id|nct_id|intervention_type|name|description
47916872|NCT01172717|DRUG|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
47916873|NCT06458816|DEVICE|Non-Invasive Knee Joint Distraction|Non-invasive Distraction device
47916874|NCT06458816|PROCEDURE|Manual Joint Distraction|no device. manual distraction.
47916875|NCT04172818|BEHAVIORAL|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
47916876|NCT01460043|DRUG|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
47916877|NCT01460043|DRUG|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
48268548|NCT05284201|DEVICE|LIFT System|The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
48268549|NCT00002085|DRUG|Azithromycin|
47916878|NCT01572987|DEVICE|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
47916879|NCT01572987|DEVICE|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
47916880|NCT03794830|OTHER|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
47916881|NCT03794830|OTHER|electrotheraphy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
47916882|NCT05173116|OTHER|Medical Outcomes Study Short Form 36 (SF 36)|completion of questionnaire quality of life SF 36 (inclusion, Month 3, Month 6).
47916883|NCT05173116|OTHER|observationnal study|data collection
47916884|NCT02889029|DEVICE|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
47916885|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
48620090|NCT02756897|DRUG|Ibrutinib|Given PO
47916886|NCT00687375|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
47916887|NCT03345290|DEVICE|PET with a cerebral step|Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography
47916888|NCT03345290|DEVICE|Central blood pressure measurement|Central blood pressure measurement
47916889|NCT03345290|OTHER|Neurocognitive tests|Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
47916890|NCT00494247|DEVICE|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
48620091|NCT02756897|OTHER|Laboratory Biomarker Analysis|Correlative studies
47916891|NCT04230135|DEVICE|Hap-pas-Hapi|Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
47916892|NCT04463459|DRUG|Vitamin C, Vitamin E|Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
47916893|NCT06164990|OTHER|PEKK framework|PEKK (Pekkton) framework in mandibular implant-supported complete fixed dental prostheses with All-on-four treatment concept
47916894|NCT04780919|DEVICE|BTL-6000 FSWT|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300.
47916895|NCT04780919|DEVICE|BTL-6000 FSWT with sham applicator|Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300 - applied with modified applicator which does not allow wave transmission.
47916896|NCT02069860|DEVICE|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.
47916897|NCT04801056|DRUG|TB006|TB006 monoclonal antibody
47916898|NCT04801056|OTHER|Placebo|Placebo i.v. infusion
47916899|NCT02460601|DRUG|Qizhiweitong granule|
48268550|NCT00457340|DRUG|Atorvastatin 80mg|
48268551|NCT00697957|BEHAVIORAL|Exercise|Progressive impact exercise
47916900|NCT03263949|OTHER|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
47916901|NCT05431270|DRUG|PT199|PT199 is an anti-CD73 mAb with a differentiated mechanism of action. PT199 is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment, rendering anti-tumor immune cells to be more responsive to checkpoint immunotherapies, such as PD-1/PD-L1 inhibitors. PT199 fully inhibits both soluble and membrane-bound CD73
47916902|NCT05431270|DRUG|Tislelizumab|Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.
47916903|NCT02507167|DIETARY_SUPPLEMENT|mixed meal|250 ml Fortimel compact (chocolate)
47916904|NCT02507167|DRUG|Rifampin|oral rifampin administration (600 mg EREMFAT®)
47916905|NCT01962363|DRUG|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
47916906|NCT02980913|DEVICE|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
47916907|NCT02980913|DEVICE|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
47916908|NCT00644085|DRUG|aspirin|oral administration of aspirin 100 mg
47916909|NCT00644085|DRUG|placebo|oral administration of placebo
47916910|NCT04013061|OTHER|Pluridisciplinary consultation|Pharmacist-anesthesiologist team will be present during the anesthetic consultation
47916911|NCT06371001|OTHER|disease|Helicobacter Pylori Infection In Chonic Kidney Diseased Patien
47916912|NCT06396104|OTHER|Mobilisation with movement|The physiotherapist places the medial edge of the thumb of one hand on the upper facet joint of the relevant segment, then applies superior-anterior slide to the facet joint by providing support with the thumb of the other hand. The 'gliding' movement is maintained while the patient actively performs the unilateral neck rotation movement and maintains it for a few seconds at the end of the movement. If joint movement is painful, attempts are made on the other facet joint of the same segment or on the spinous process. If this attempt does not immediately improve the patient's active joint motion, Mulligan Sustained Natural Apophyseal Glides (SNAG) will be applied to the upper part of the left zygapophysial joint, and in case of failure again, application will be made through the superior spinous process of the relevant segment. Painless joint movement will be applied in 6 repetitions and 3 sets.
47916913|NCT06396104|OTHER|Sham mobilisation|While the patients are sitting in a chair with a supported back, the spinal segment where pain is felt in neck joint movements will be determined. Without applying a sliding movement to this segment over the facet joint, only sensory input will be given and the patient will be asked to continue the active rotation movement and wait a few seconds at the end of the movement. The application will be completed as 6 repetitions and 3 sets.
47916914|NCT02928263|OTHER|Non-Interventional|Other
48092256|NCT01268059|DRUG|Carboplatin|Carboplatin (carboplatin area under the plasma concentration-time curve \[AUC\] of 6 milligram per milliliter into minute \[mg/mL\*min\] administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
48092257|NCT01268059|DRUG|Paclitaxel|Paclitaxel 200 milligram per square meter (mg/m\^2) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal.
48298804|NCT01892254|DRUG|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
48298805|NCT01892254|DRUG|Placebo|Placebo (to metformin)
48443501|NCT01794039|DRUG|Dexamethasone|Given PO
48620092|NCT02756897|DRUG|Venetoclax|Given PO
48620093|NCT04580680|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|At each participating center, EBP treatments with commercial membranes will be delivered in accordance with local practice and local levels of expertise. Enrolled patients will not receive additional treatments other than those routinely administered in ICUs. Nonetheless, all parameters settings for EBP treatments will be recorded in the web-based registry and analyzed a posteriori to reveal potential correlations with patient outcomes.
48268552|NCT03346174|OTHER|AAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
48268553|NCT03346174|OTHER|BAAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
48268554|NCT05807009|OTHER|core exercise|the patients will receive seven exercises performed in crook lying and side lying position on exercise mats. Cushions were used to allow the participants to be comfortable in all positions. The exercises in the crook lying position were core activation with breathing, single-leg lift with knees bent, single-leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight.
48268555|NCT05807009|OTHER|traditional therapy|the patients will receive : an active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching
48268556|NCT00594217|DRUG|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
48268557|NCT00594217|OTHER|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
48268558|NCT03135405|BEHAVIORAL|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
48268559|NCT03135405|BEHAVIORAL|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
48268560|NCT03135405|BEHAVIORAL|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
48268561|NCT04274296|DEVICE|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
48268562|NCT00008190|BIOLOGICAL|aldesleukin|
48268563|NCT00008190|BIOLOGICAL|filgrastim|
48268564|NCT00008190|DRUG|busulfan|
47916915|NCT05149521|OTHER|None - this is a consensus group study to develop an intervention|None - this is a consensus group study to develop an intervention
48620094|NCT02869035|DRUG|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
48620095|NCT02869035|DRUG|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
47916916|NCT06225869|BEHAVIORAL|Assessments in ON and OFF levodopa state|Neurological assessment, neuropsychological assessment, and fMRI in ON and OFF levodopa state
47951129|NCT02572609|DRUG|Ambroxol hydrochloride soft pastille|
47951130|NCT02572609|DRUG|Mucosolvan ® adult syrup|
48268565|NCT00008190|DRUG|cyclophosphamide|
48268566|NCT00008190|DRUG|etoposide|
48268567|NCT00008190|DRUG|melphalan|
48268568|NCT00008190|PROCEDURE|peripheral blood stem cell transplantation|
48268569|NCT04119570|BEHAVIORAL|CKD Report Card|The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
48620096|NCT00412620|DRUG|ABT-925|
48620097|NCT00412620|DRUG|Placebo|
47916917|NCT03647852|DRUG|Methylprednisolone|1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
47916918|NCT03647852|DRUG|IVIG|1. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
47916919|NCT03647852|DRUG|other basic supportive treatment|"1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d"
47916920|NCT06279208|BIOLOGICAL|Blood sample|Recovery of plasma from the bottom of a blood collection tube.
48268570|NCT00649454|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
48268571|NCT00649454|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
48268572|NCT03082560|DIAGNOSTIC_TEST|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
48268573|NCT04957186|OTHER|Collection of postoperative information|The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.
47916921|NCT00139477|DRUG|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
47916922|NCT00139477|BEHAVIORAL|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
47951131|NCT03111966|OTHER|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
47951132|NCT00014261|BIOLOGICAL|PEG-interferon alfa-2b|
47951133|NCT00014261|DRUG|temozolomide|
47951134|NCT01948037|OTHER|hydrotherapy|30-minutes/per day,for 4weeks
47951135|NCT01948037|OTHER|hydrotherapy|30-minutes/per day;4weeks
48268574|NCT04957186|OTHER|Analysis of postoperative information collected from patients|All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
48268575|NCT05290363|OTHER|Blood sampling|A 51 mL blood sample will be collected during the study
48443502|NCT01794039|DRUG|Lenalidomide|Given PO
48443503|NCT01794039|DRUG|Pomalidomide|Given PO
47916923|NCT00139477|BEHAVIORAL|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
47916924|NCT02669485|DRUG|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
47916925|NCT02669485|DEVICE|Fluorescence imaging|
47916926|NCT02149667|DEVICE|total hip arthroplasty implant|
47916927|NCT00022646|DRUG|gemcitabine hydrochloride|
47916928|NCT00022646|DRUG|pemetrexed disodium|
47916929|NCT01767142|DEVICE|The Zeltiq System with Modified Belt Applicator|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
48268576|NCT05290363|OTHER|synovial aspiration|If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
47916930|NCT05220475|DEVICE|fully covered self-expandable metal stent with an anchoring external plastic stent|Extrahepatic malignant biliary obstruction treated with fully covered self-expandable metal stent with an anchoring plastic stent
47916931|NCT05220475|DEVICE|uncovered self-expandable metal stent|Extrahepatic malignant biliary obstruction treated with uncovered self-expandable metal stent without an anchoring plastic stent
47916932|NCT06225479|BEHAVIORAL|Exercise|"An individualized 12-week exercise intervention that will follow American College of Sports Medicine guidelines to ensure a gradual safe increase in frequency and intensity. The exercise goals for participants in the intervention arm are to increase minutes/week of aerobic exercise, build strength and muscle mass, and improve flexibility, core strength, and balance progressively over the course of 12 weeks. The participants are prescribed 3 sessions of aerobic exercise lasting 45-75 minutes each, including warm up and cool down; 2 resistance training sessions per week, and at least 3 flexibility and balance sessions per week.~Intervention arm receives the following: Control arm Successful Aging newsletter plus additional educational materials related to exercise, heart rate monitor and resistance bands, and two 90-minute sessions and ten 30-minute phone sessions over 12 weeks with an exercise coach (the first two sessions include a resistance training session)."
48268577|NCT00887458|DRUG|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
47916933|NCT06225479|OTHER|Calls and Newsletter|"A 12-week remote health education program developed by the study team to provide a control for the exercise intervention. Participants in this arm will receive a summary of the American College of Sports Medicine guidelines (self-directed and time-based), a twice-monthly Successful Aging newsletter with suggestions for health diet, stress reduction, and social engagement, and twice-monthly phone calls to reinforce and discuss topics in the newsletter and to review adverse events and change in medications."
47916934|NCT05737199|DRUG|MK-3475 (pembrolizumab)|MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
47916935|NCT03228329|OTHER|fluid boluses|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
47916936|NCT02778113|DRUG|Nasal Glucagon|Administered intranasally.
47916937|NCT02778113|DRUG|Glucagon|Administered SC.
47916938|NCT05253391|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
47916939|NCT03047824|DEVICE|Intravascular continuous monitoring|Bedside usual insulin therapy guided by continuous glucose monitoring
47916940|NCT03047824|OTHER|Standard of care|Bedside usual insulin therapy guided by intemittent glucose monitoring
47916941|NCT03374319|PROCEDURE|Modified amputation procedure|A stair-step (BKA) or fishmouth (AKA) incision will be made. Tibial and fibular or femoral osteotomies will be performed. Segments of the tibialis anterior (TA), peroneus longus (PL), lateral gastrocnemius (LG) and tibialis posterior (TP) muscles will be isolated, as well as the quadriceps (Q) and hamstring (H) groups in the AKA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. The distal tibial and peroneal nerves will be redirected to skin patches in the distal or proximal thigh. Coaptation of the TA/LG, PL/TP and Q/H muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
48620098|NCT04948918|PROCEDURE|Anatomically optimized distal renal denervation|Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
47916942|NCT06342778|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study after meals
47916943|NCT06342778|DRUG|Diclectin|A single dose of R or T drug in each of 2 periods of the study after meals
47916944|NCT05594745|DRUG|Lifitegrast Ophthalmic|eyedrop
47916945|NCT05594745|DRUG|Systane Free|eyedrop
47916946|NCT05594745|DEVICE|Lipiflow|thermal pulsation
47916947|NCT02365480|DRUG|Berberine Chloride|Given PO
47916948|NCT02365480|OTHER|Laboratory Biomarker Analysis|Correlative studies
48620099|NCT03780192|DEVICE|Inspiron Sirolimus Eluting Stent|Bifurcation treatment using provisional stent technique
48620100|NCT04884568|DEVICE|Exufiber|Wound dressed with Exufiber for up to 21 days.
47916949|NCT02365480|OTHER|Placebo Administration|Given PO
47916950|NCT03156387|PROCEDURE|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
47916951|NCT03156387|PROCEDURE|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
48268578|NCT00887458|DRUG|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
48268579|NCT06499922|PROCEDURE|SURGICAL EXCISION|surgical excision of low grade glioma
48268580|NCT02472847|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
48268581|NCT02472847|DRUG|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
48268582|NCT00263263|DEVICE|sirolimus-eluting stent|
48268583|NCT00263263|DEVICE|bare metal stent|
48268584|NCT01327755|DIETARY_SUPPLEMENT|Selenium|Selenium yeast containing selenomethionine 200 mcg per day for 2 years
48268585|NCT01327755|OTHER|Placebo|Same number of pills, frequency, and duration as selenium intervention.
48268586|NCT05633615|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
48268587|NCT05633615|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
47916952|NCT03479333|DEVICE|Short implant|Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
47916953|NCT03479333|DEVICE|Standard implant with sinus lift|First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
47916954|NCT05483218|DEVICE|Nocturnal wrist orthosis wearing|Nocturnal wearing of one of the 2 wrist orthosis kind
47916955|NCT04744090|DRUG|Roflumilast|"1. Roflumilast 500 mcg daily for up to 28 days~2. Total follow up time will be 28 days.~3. Proinflammatory parameters will be assessed at baseline, day 7, day 14, and at the end of treatment.~4. Roflumilast will be combined with standard of care for ARDS.~5. During hospitalization, clinical and laboratory data will be recorded daily in the medical history of the patient and in data collection table of the study.~6. During hospitalization, adverse drug reaction will be monitored clinically and by laboratory tests.~7. In case of an adverse effect or a need to discontinue the treatment, roflumilast should be suspended."
47916956|NCT04744090|DRUG|Placebo|Placebo (identical to roflumilast dosage form) will be used for placebo-comparator group.
47916957|NCT06092918|RADIATION|EXTERNAL RADIOTHERAPY|EXTERNAL RADIOTHERAPY
48268588|NCT05633615|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
47916958|NCT06027645|BEHAVIORAL|Crawling stimulation with a mini-skateboard (i.e. the crawliskate)|Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
48268589|NCT05633615|DRUG|Cyclophosphamide|Given IV
47916959|NCT00602758|BEHAVIORAL|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
47916960|NCT00602758|BEHAVIORAL|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
47916961|NCT02815722|DRUG|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
47916962|NCT02815722|DRUG|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
47916963|NCT02185924|DRUG|Parecoxib|
47916964|NCT02185924|DRUG|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
47916965|NCT02185924|DRUG|N/S 0.9%|
47916966|NCT01137201|PROCEDURE|Suturing of mesenteric defects|
47916967|NCT02290743|OTHER|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
47916968|NCT05433285|BIOLOGICAL|COVID-19 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
47916969|NCT05433285|BIOLOGICAL|Active Comparator|Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus
47916970|NCT02567058|DEVICE|Ultrasound exam|"Ultrasound exam with :~* 2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~* 1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~* 1 succession of 3 measures for group III"
47916971|NCT02567058|BEHAVIORAL|IPAQ questionnaire|IPAQ questionnaire
47916972|NCT04377347|OTHER|Time|Exposure is the time from patients call the Emergency Medical Coordination Center to they are admitted to a neurosurgiocal department.
47916973|NCT01600170|DRUG|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
47916974|NCT01600170|DRUG|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
47916975|NCT03053206|DRUG|ADE Protocol|"ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
47916976|NCT05575323|OTHER|Same-day SBRT and spinal surgery|SBRT and surgical stabilization with or without decompression within 24 hours
47916977|NCT05575323|OTHER|Standard of care|Surgical stabilization with or without decompression followed by cRT or SBRT as soon as the wound is healed sufficiently
47916978|NCT04204551|BEHAVIORAL|high-intensity interval training (HIIT)|Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 \[rpm\], but preferably at 80-90 \[rpm\] (fast phase of interval) and 2-minutes cycling at ≤ 60 \[rpm\] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, \[bpm\]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
47916979|NCT04204551|BEHAVIORAL|conventional physical therapy|Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
47916980|NCT00122551|PROCEDURE|Intermittent antiretroviral therapy|
48268590|NCT05633615|DRUG|Fludarabine|Given IV
48268591|NCT05633615|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
48268592|NCT05633615|BIOLOGICAL|Mosunetuzumab|Given IV
47916981|NCT03364270|DRUG|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with \[F-18\] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
47916982|NCT03163797|DIAGNOSTIC_TEST|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
47916983|NCT02794675|DRUG|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
47916984|NCT02206971|OTHER|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
47916985|NCT02252744|OTHER|No intervention|
47916986|NCT01454778|DRUG|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon\* Popliteal: 1.8 mg/inflation of balloon\* Tibial: 1.4 mg/inflation of balloon\*~* not to exceed 10mg total dose"
47916987|NCT00696917|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
47916988|NCT00696917|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
47916989|NCT00037089|DRUG|UFT (Tegafur/Uracil)|
47916990|NCT03479164|OTHER|Ultra Low-Dose CT|Ultra Low-Dose CT
48478732|NCT01028911|DRUG|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
48620101|NCT04012645|PROCEDURE|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
47916991|NCT00254189|DRUG|Levonorgestrel|
47916992|NCT00254189|DRUG|Ethinyl Estradiol|
47916993|NCT05072067|PROCEDURE|the sleeve gastroplasty with the endoscopic system Overstich SX|the sleeve gastroplasty with the endoscopic system Overstich SX
47916994|NCT03672890|OTHER|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening \& evaluation, and stroke education in patients admitted with stroke.
47916995|NCT00753246|DRUG|nimotuzumab|monoclonal antibody
47916996|NCT05555420|DEVICE|SRP+Laser|Non-surgical periodontal therapy in combination with Laser
47916997|NCT00632788|OTHER|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
47916998|NCT05424289|DEVICE|videolaryngoscope|Videolaryngoscope is a high-resolution micro camera mounted on the tip of a curved blade connected to small portable digital monitor improves the view of the vocal cords
47916999|NCT02980861|PROCEDURE|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
47917000|NCT02980861|PROCEDURE|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
47917001|NCT01057589|DRUG|Pemetrexed|"Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity"
47917002|NCT01057589|DRUG|Cetuximab|"Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity"
47917003|NCT01057589|DRUG|Cisplatin|Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
47917004|NCT01057589|DIETARY_SUPPLEMENT|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
47917005|NCT01057589|DIETARY_SUPPLEMENT|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
47951136|NCT01864941|PROCEDURE|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
47951137|NCT01864941|DEVICE|Catheter venography with balloon venoplasty and balloon|
48092258|NCT01268059|DRUG|MEDI-575|MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575.
48620102|NCT04012645|PROCEDURE|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
47917006|NCT01915303|DRUG|Pasireotide with or without cabergoline|The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
47917007|NCT03159793|BEHAVIORAL|Live Modelling Technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
47917008|NCT03159793|BEHAVIORAL|Filmed Modelling technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
47917009|NCT04696614|BEHAVIORAL|exercise|intervention groups provided different sequential modality of exercise
47917010|NCT01670305|PROCEDURE|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
47917011|NCT01670305|PROCEDURE|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
47917012|NCT01670305|PROCEDURE|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
47917013|NCT01670305|PROCEDURE|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
47917014|NCT01670305|PROCEDURE|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
47917015|NCT04248283|DEVICE|Adjustable Continence Therapy for Women (ACT)|Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
47917016|NCT02642315|DRUG|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
47917017|NCT04909073|DRUG|Afatinib|Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.
47917018|NCT03229694|DRUG|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
47917019|NCT03229694|DRUG|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
47917020|NCT05344196|BEHAVIORAL|Modified EAET for prediabetes|Attempts to reduce stress and improve health behavior by engaging in emotional awareness and expression leading to changes in interpersonal relationships and health behavior
47917021|NCT02657785|DRUG|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
47917022|NCT00348881|BIOLOGICAL|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
47917023|NCT00348881|BIOLOGICAL|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
47917024|NCT00348881|BIOLOGICAL|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
47917025|NCT03558568|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
47917026|NCT02922478|RADIATION|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
48092259|NCT06403644|DEVICE|NovoTHOR XL Photobiomodulation Full Body Light Bed|Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of \~30 mW/cm\^2.
48268593|NCT05633615|OTHER|Patient Observation|Undergo observation
47917027|NCT02922478|PROCEDURE|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
47917028|NCT02922478|RADIATION|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
47917029|NCT02922478|PROCEDURE|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
47917030|NCT01755000|PROCEDURE|USCOM scan|
47917031|NCT01755000|PROCEDURE|Fluid Bolus|
47917032|NCT02078856|DRUG|A3384|
47917033|NCT00669123|DRUG|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
47917034|NCT00669123|DRUG|Placebo|
47917035|NCT03195309|DRUG|Ropivacaine|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
47917036|NCT03195309|DRUG|Fentanyl|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
47917037|NCT05690867|OTHER|Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes|group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery
48620103|NCT00034632|DRUG|Posaconazole oral suspension|
47917038|NCT05690867|OTHER|Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes|group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
47917039|NCT05906290|OTHER|Multigenerational eHealth Intervention for Grandparents and Grandchildren|Participants in this group will use an online program for 30-45 minutes per week over the course of 2 weeks delivered via smartphone, focusing on increasing physical activity.
47917040|NCT04424953|DEVICE|McGrath videolaryngoscope|A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords
47917041|NCT04424953|DEVICE|Direct laryngoscope|Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
47917042|NCT02101710|DRUG|Elantan SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
47917043|NCT02101710|DRUG|Imdur SR 60 mg|"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"
47914044|NCT05261698|OTHER|Home-based Exercise Manual|in the experimental group we will provide moist heating pads along with TENS on the neck for 10 minutes and then neck isometrics and strengthening exercises shall be performed. Patients in the experimental group will also receive a home-based exercise manual.
47917044|NCT05507112|DRUG|PD-1 inhibitor|Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
47917045|NCT05507112|DRUG|Capecitabine|Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
47917046|NCT05507112|RADIATION|Long-course radiation therapy|45-50 Gy/day, 5 days a week for a total of 5 weeks.
47917047|NCT05647603|OTHER|data collection|Information about contraception
47917048|NCT00773539|PROCEDURE|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
47917049|NCT00773539|PROCEDURE|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
47917050|NCT00773539|PROCEDURE|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
47917051|NCT00837317|DIETARY_SUPPLEMENT|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
47917052|NCT01032889|DRUG|Deoxycholic acid injection|
47917053|NCT01032889|DRUG|Placebo|Phosphate buffered saline placebo for injection
47917054|NCT00795587|DRUG|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
47917055|NCT02551796|PROCEDURE|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
48092260|NCT06403644|DEVICE|ARRC LED Photobiomodulation Full Body Light Bed|High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of \~75 mW/cm\^2.
48268594|NCT05633615|DRUG|Polatuzumab Vedotin|Given IV
48268595|NCT05633615|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
48620104|NCT03729284|DRUG|Cymbalta Capsules|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
48620105|NCT03729284|DRUG|Duloxetine Hydrochloride Capsules|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
47917056|NCT02551796|PROCEDURE|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
47917057|NCT02551796|PROCEDURE|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
47917058|NCT02937324|DEVICE|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
47917059|NCT02937324|OTHER|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
47917060|NCT00747734|DRUG|MNRP1685A|Escalating intravenous dose
47917061|NCT04536103|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in healthy patients and patients with ACL injury.
47917062|NCT04599413|OTHER|SURVEY|Pain survey on pianists
47917063|NCT00540410|DRUG|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
47917064|NCT00540410|DRUG|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
47917065|NCT00004567|DRUG|Mycophenolate Mofetil|
47917066|NCT01388985|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
47917067|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by on-body injector|PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection
47917068|NCT05194579|COMBINATION_PRODUCT|PF-06881894 by prefilled syringe|PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection
47917069|NCT05611333|BEHAVIORAL|Physician-Led Remote Exercise Program Intervention|The physician-led remote exercise program intervention consists of three 45-minute walking classes on Zoom per week for 4 weeks.
48092261|NCT01149603|DEVICE|HeartMate II Ventricular Assist Device|The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
48620106|NCT02859116|PROCEDURE|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
48092262|NCT03379415|DEVICE|Footwear|Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
48092263|NCT03379415|PROCEDURE|Gait analysis|Gait analysis will be done during several different tasks wear the footwear
48092264|NCT03496961|BEHAVIORAL|Yan Nian Jiu Zhuan Fa|Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
48620107|NCT04593602|BEHAVIORAL|Early Mobilization|Nurse-driven early mobilization activities twice daily
48620108|NCT04593602|BEHAVIORAL|Usual Mobility Care|Usual mobility care involves following physician orders for mobilization (i.e., bedrest, mobilization to chair with meals, physiotherapy consultation and care) as per local practice.
48620109|NCT04539704|DEVICE|magnet and sham|In same subject some areas will have magnet and others will have sham
48092265|NCT06549894|PROCEDURE|Performing endoscopic examinations|Performing endoscopic examinations in the conventional framework of patient follow-up. No patient data is collected. The physician performing the act is the subject of the study.
47917070|NCT05172583|BEHAVIORAL|Control|The control groups will receive the nursing interventions that are performed daily in the adult ICU. These are orientation in time, space, and place, accompaniment of the family for two hours in the morning and two hours in the afternoon, physical therapy once a day according to the patient's condition, medication with conscious sedation, and progressive reduction analgesics. opioids and benzodiazepines.
47951138|NCT03295500|RADIATION|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
48092266|NCT03871998|OTHER|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
48268596|NCT05633615|BIOLOGICAL|Tisagenlecleucel|Given IV
48298806|NCT05231876|OTHER|Recording of pathology-related information on the Wilson Register|Age, gender, date of diagnosis, clinical symptoms, ethnic charateristics and family tree will be collected and recorded on the Wilson Register during routine clinical care
47951139|NCT00002078|DRUG|Interferon alfa-n3|
47951140|NCT06244017|DEVICE|EEG spectrogram|In the experimental group, the general anesthesia is guided by using the EEG spectrogram.
47917071|NCT05172583|BEHAVIORAL|Interventions to reduce delirium based on DSM and scientific evidence|The interventions are designed from the structure of the Dynamic Symptoms Model (DSM), taking into account the antecedents of delirium, physiological such as the medical condition of mechanical ventilation and pain, and drug treatment with sedatives and analgesics; the psychological, social, and spiritual antecedents with stimulation in the values, life experience, personality and spirituality, and the environmental antecedents with an adaptation of the physical conditions of the ICU. In addition, previous experience with identification and care of concomitant symptoms such as fear, confusion, restlessness, loneliness, and discomfort, and with the measurement and classification of the trajectory of delirium when it occurs, will also be considered. The interventions follow the scientific evidence, mainly from the ABCDEF bundle. All interventions are non-pharmacological.
48637401|NCT05702619|DIAGNOSTIC_TEST|Prostate MRI scans|Patients within Arm 2 will be offered the option to undergo additional MR imaging of the pelvis in addition to any standard of care imaging acquired. In patients who agree to undergo additional scans, MRI scans will be performed on 2 occasions prior to the radical prostatectomy. MRI scans will be acquired on either the MR sim diagnostic scanner, on the MR Linac scanner or on both.
47917072|NCT00463567|DRUG|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
47917073|NCT00463567|DRUG|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
48092267|NCT05168371|BEHAVIORAL|Cognitive-Behavioural Therapy - Online (CBT-O)|"Face-to-face CBT was adapted for web-based self-directed therapy. CBT-O was found to be feasible and usable (Stephenson et al., 2021; Zippan et al., 2020).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to CBT; 2) The cognitive model and thought records; 3) Unhelpful thinking patterns; 4) Cognitive restructuring; 5) Behavioral experiments; 6) Self-touch and sensate focus; 7) Sensate focus with your partner; and 8) Maintaining (and extending) your gains."
47917074|NCT00463567|DRUG|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
48268597|NCT02096094|PROCEDURE|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
48268598|NCT02096094|PROCEDURE|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
48268599|NCT02096094|PROCEDURE|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
48268600|NCT05593848|PROCEDURE|Intratissue Percutaneous Electrolysis|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle
48268601|NCT05593848|PROCEDURE|Dry Needling|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
48268602|NCT02274688|BEHAVIORAL|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
48268603|NCT04937010|PROCEDURE|Occipital nerve stimulator implant|Implantation of occipital nerve stimulator and different stimulation parameters
48268604|NCT05087615|DRUG|Metoclopramide|This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
48268605|NCT05087615|DRUG|Ondansetron|This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
47917075|NCT00463567|DRUG|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
47917076|NCT00463567|DRUG|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
47917077|NCT01526824|DIETARY_SUPPLEMENT|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
47917078|NCT00401232|PROCEDURE|Blood Collection|Blood Collection
47917079|NCT03113890|GENETIC|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
47917080|NCT03113890|GENETIC|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
47951141|NCT06244017|DEVICE|Bispectral index|In the control group, the general anesthesia is guided by using the bispectral index
47917081|NCT03113890|OTHER|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
48268606|NCT05087615|DRUG|Metoclopramide and Ondanteron|This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
48268607|NCT05087615|DRUG|Granisetron|This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
47917082|NCT01410357|BEHAVIORAL|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
47917083|NCT02395432|DEVICE|orotracheal intubation|
47917084|NCT00702715|DRUG|sugammadex|"Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC."
48298807|NCT00195559|DRUG|Levonorgestrel/Ethinyl Estradiol|
48268608|NCT03419858|BEHAVIORAL|Mindfulness Meditation|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.
48268609|NCT03419858|BEHAVIORAL|Placebo Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
48268610|NCT03419858|BEHAVIORAL|Slow-Breathing|Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
47917085|NCT00575146|DIETARY_SUPPLEMENT|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
47914045|NCT05261698|OTHER|Conventional PT|In this group patients will receive routine physical therapy including hot pack for 10 minutes, stretching, strengthening exercise and TENS at the end of each session.
47917086|NCT00946985|DRUG|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
47917087|NCT00946985|DRUG|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
47917088|NCT02672527|DRUG|Trabectedin|
47917089|NCT02672527|DRUG|Dexamethasone|
47917090|NCT02427997|BEHAVIORAL|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
47917091|NCT02427997|BEHAVIORAL|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
47917092|NCT06520085|OTHER|interactive mHealth application for patients undergoing RSA|Patients will receive interactive information via an mHealth application tailored to their needs and progress during the rehabilitation period after RSA.
48268611|NCT03419858|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
48268612|NCT03419858|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
48268613|NCT04457960|DRUG|JNJ-66525433|Participants will receive JNJ-66525433 oral capsules.
48268614|NCT04457960|DRUG|Placebo|Participants will receive matching placebo oral capsules.
48268615|NCT04793399|DRUG|Bosutinib 400 MG Monotherapy|One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
48268616|NCT04793399|DRUG|Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection|12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
48268617|NCT02950792|DEVICE|ViewRay MRI|ViewRay Magnetic Resonance Imaging
48268618|NCT02950792|RADIATION|Stereotactic Body Radiation Therapy Boost|In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors \< 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors \< 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) \< 20 Gy with V20 \< 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
48268619|NCT04217265|DRUG|Letrozole then misoprostol|total dose 5 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
48268620|NCT04217265|DRUG|placebo then misoprostol|placebo tablets for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
48268621|NCT03393026|DRUG|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
48268622|NCT02377895|DRUG|Nasapaque Nasal Solution|
48268623|NCT02377895|DRUG|Placebo Saline Nasal Solution|
48268624|NCT01286857|DEVICE|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
47917093|NCT06392399|DEVICE|cooled radiofrequency ,|In Cooled RF, after placement of the introducer needle, the 18 gauge internally cooled RF electrode is used for 90 seconds at a temperature of 60°C.
47917094|NCT06392399|DEVICE|conventional radiofrequency|In conventional RF group lesion will be performed at 80°C for 120 seconds.
47917095|NCT06392399|DEVICE|neurolysis of ganglion|In neurolytic block, Once the position of the needle tip confirmed, 4 - 6 mL of 8% phenol in saline will be injected followed by 1 mL of saline to avoid the deposition of phenol within the intervertebral disc material.
47917096|NCT04103580|BEHAVIORAL|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
47917097|NCT03771170|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
47917098|NCT03771170|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
47917099|NCT03407716|DRUG|American Ginseng|Given PO
48268625|NCT00361738|DRUG|AVE2268|
48268626|NCT04495699|OTHER|None - observational|If the patient elects to have their stone treated, it will be treated in the usual most clinically appropriate fashion (Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy). All types of treatment will be analyzed together.
48268627|NCT04942886|DRUG|Entecavir|The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.
47917100|NCT03407716|OTHER|Laboratory Biomarker Analysis|Correlative studies
47917101|NCT03407716|OTHER|Placebo|Given PO
48268628|NCT05357378|DEVICE|Hip Innovation Technology Reverse Hip Replacement System|Implantation of the Investigational Device is performed using standard surgical procedures for THA, as described in the Instructions for Use (IFU). The control hip systems will be implanted in accordance with their respective IFU, which are also in line with standard surgical approaches for THA.
48298808|NCT05032053|DRUG|Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
47914046|NCT06516523|PROCEDURE|PEMF and Control/Sham|Use o PEMF on test implants (treatment of peri-implantitis and bone formation) Use of PEMF on experimental implants (Bone-to-implant contact)
47914047|NCT06516523|DEVICE|PEMF and without PEMF|Use o PEMF on test implants (treatment of peri-implantitis and bone formation)
48298809|NCT06077630|OTHER|No intervention|There is no intervention, observational study
47917102|NCT03407716|OTHER|Questionnaire Administration|Correlative studies
47951142|NCT03048916|OTHER|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
48298810|NCT06392984|DIAGNOSTIC_TEST|Pectus deformity study form|Pectus deformity study form consisting of clinical and radiological measurements of participants aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
47914048|NCT01757249|DRUG|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
47914049|NCT01883076|BIOLOGICAL|autologous cell-based delivery|"autologous cells (derived from self)"
47914050|NCT02879201|PROCEDURE|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
48620110|NCT06340659|BEHAVIORAL|HbAEx|Participants will have a 1-week (3 session) on-boarding period where study interventionists will deliver all necessary equipment (bike, pulse oximeters, etc.) to the participants' home, review the AEx program and prescription, and supervise the first 3 sessions to ensure participant understanding and fidelity of the AEx program. Thereafter, the remaining 33 sessions will be conducted by the participant without the direct supervision (asynchronous telerehabilitation) of the study interventionists. Subjects will cycle on recumbent stationary cycles at moderate-vigorous intensity individualized as 50-70% of heart rate reserve (HRR) and/or 11-14 on Borg Category Ratio-15 Rating of Perceived Exertion (RPE) Scale, for 30-50 minutes per session. Following the completion of each session, during the check-in meeting with the participant, the study interventionist will gather information from the participant (including HR and RPE) for dose quantification.
48478733|NCT01028911|DRUG|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
48478734|NCT02568709|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
48092268|NCT05168371|BEHAVIORAL|Mindfulness-Based Therapy - Online (MBT-O)|"The content of MBT-O was adapted from an efficacious face-to-face mindfulness intervention for women with Sexual Interest/Arousal Disorder (Brotto et al., 2021; Paterson et al., 2017). MBT-O was found to be feasible and usable (Brotto et al., under review).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to mindfulness; 2) Increasing awareness of physical sensations in the body; 3) Exploring movement and body image; 4) Awareness of sexual thoughts and beliefs; 5) Working with aversion, self-touch; 6) Exploring sexual sensations, knowing limits; 7) Integrating the partner into mindful touching; and 8) Maintaining (and extending) your gains."
48092269|NCT03672760|DEVICE|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
48092270|NCT03672760|DEVICE|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
48092271|NCT03672760|DEVICE|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
48478735|NCT02568709|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
48478736|NCT04632524|DRUG|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
48478737|NCT02668042|BIOLOGICAL|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
47917103|NCT03662581|BEHAVIORAL|Mindfulness Group Program|"The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~1. Foster peer-to-peer learning and support when it comes to coping with life challenges~2. Combat isolation~3. Increase efficiency, quality, and timeliness of care"
47917104|NCT02460237|PROCEDURE|Disease Screening|Complete HPV self-test
47914051|NCT04473469|DEVICE|Medtronic Interstim II Model 3058 Neurostimulator|Patients will undergo stimulation of the pudendal nerve. All stimulation parameters used will be within the normal hard-coded limits of the implantable pulse generator (IPG).
47917105|NCT02460237|OTHER|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
48268629|NCT05357378|DEVICE|Already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.|"Control Arm subjects will receive one of the already-marketed semi-constrained uncemented hip systems using a metal-on-XLPE or ceramic-on-XLPE bearing combination.~* DePuy Synthes Corail® Total Hip System in combination with Pinnacle® Complete Acetabular Hip System.~* Zimmer Biomet Taperloc® Complete Hip System in combination with G7® Acetabular System.~* Stryker Accolade® II femoral stem in combination with Stryker Trident® II acetabular cup.~* Smith \& Nephew Anthology® Total Hip System in combination with R3® Acetabular System."
48268630|NCT01213030|DRUG|[F-18] FMISO|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
48268631|NCT01213030|DRUG|[F-18] HX4|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
47917106|NCT02460237|OTHER|Informational Intervention|Receive standard instructions and information sheet
47917107|NCT02460237|OTHER|Laboratory Biomarker Analysis|Correlative studies
47917108|NCT02460237|OTHER|Survey Administration|Ancillary studies
47917109|NCT01710137|DRUG|Varenicline|
47917110|NCT01710137|DRUG|Placebo|
47917111|NCT01710137|BEHAVIORAL|Smoking Cessation Counseling|
48268632|NCT04548557|BIOLOGICAL|intravenous immunoglobulin therapy|It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
48268633|NCT01649336|DRUG|MEK162, MEK inhibitor; oral|multiple dose, escalating
48268634|NCT01649336|DRUG|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
48268635|NCT04687319|BIOLOGICAL|bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme
48268636|NCT00553462|DRUG|carboplatin|
47917112|NCT05755061|BEHAVIORAL|GEMS Plus|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that exceed the published physical activity guidelines for adults with MS
48268637|NCT00553462|DRUG|erlotinib hydrochloride|
48268638|NCT00553462|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
48268639|NCT00553462|RADIATION|radiation therapy|
48268640|NCT00241332|DRUG|fentanyl|
48268641|NCT01431183|BEHAVIORAL|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
47917113|NCT05755061|BEHAVIORAL|GEMS|12-months of home-based walking exercise that occurs 3-5 days per week. The program will progress up to intensities that meet the published physical activity guidelines for adults with MS
48268642|NCT02361645|DRUG|Ketorolac 0.5% eyedrops|
48268643|NCT02361645|DRUG|Indomethacin 0.5% eyedrops|
48268644|NCT02361645|DRUG|Bromfenac 0.09% eyedrops|
48268645|NCT02361645|DRUG|Nepafenac 0.1% eyedrops|
48268646|NCT05140148|DRUG|Amantadine|Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
48268647|NCT05140148|DRUG|Placebo|placebo pills
48268648|NCT00734084|DEVICE|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
48268649|NCT01232699|BEHAVIORAL|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
48268650|NCT01232699|BEHAVIORAL|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
47917114|NCT00959725|DRUG|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
47917115|NCT05403216|OTHER|no intervention|
47917116|NCT04535453|BIOLOGICAL|Ad26.COV2.S|All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
47917117|NCT04535453|OTHER|Placebo|Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
47917118|NCT03211052|DRUG|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
47917119|NCT03211052|PROCEDURE|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
47917120|NCT01499706|BEHAVIORAL|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
48268651|NCT01232699|BEHAVIORAL|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
48268652|NCT01245647|DRUG|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
48268653|NCT01245647|OTHER|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
48268654|NCT01032148|DRUG|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
47914052|NCT02428725|OTHER|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
47917121|NCT01499706|BEHAVIORAL|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
47917122|NCT06319950|DRUG|Furmonertinib|Furmonertinib, 160mg po qd
47917123|NCT06319950|DRUG|Osimertinib|Osimertinib，80mg po qd
47917124|NCT05842356|BEHAVIORAL|Communication Technique 2|A new communication technique.
47917125|NCT00488553|BEHAVIORAL|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
47917126|NCT00001272|DRUG|taxol|
47917127|NCT03391739|BIOLOGICAL|CART-19 cells|CART-19 cells treat
47917128|NCT05113238|PROCEDURE|Assisted gamete activation|compare two different assisted gamete activation protocols to improve ICSI outcome
47917129|NCT01318005|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
47917130|NCT01318005|DRUG|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
47917131|NCT01318005|DRUG|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
48268655|NCT00372879|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800IU bid
48268656|NCT05140057|COMBINATION_PRODUCT|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
48268657|NCT00589641|BEHAVIORAL|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
48268658|NCT00589641|BEHAVIORAL|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
48268659|NCT04724161|DIAGNOSTIC_TEST|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
48268660|NCT01220414|DRUG|Naltrexone, then placebo|50 mg of naltrexone
47917132|NCT03307655|OTHER|Control (fertile semen donors)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
48268661|NCT01220414|DRUG|Placebo, then Naltrexone|sugar pill
47917133|NCT03307655|OTHER|Patients (subfertile men)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
47917134|NCT00617799|BIOLOGICAL|aldesleukin|
48268662|NCT00537433|OTHER|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
48268663|NCT02563600|BEHAVIORAL|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
48268664|NCT02563600|BEHAVIORAL|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
48268665|NCT03624738|PROCEDURE|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
48268666|NCT03281642|OTHER|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
48268667|NCT00570648|DRUG|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
47917135|NCT00617799|GENETIC|gene expression analysis|
47917136|NCT00617799|GENETIC|mutation analysis|
47917137|NCT00617799|OTHER|flow cytometry|
47917138|NCT02637830|OTHER|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
47917139|NCT02637830|OTHER|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
47917140|NCT02637830|OTHER|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
47917141|NCT01525225|DRUG|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
48268668|NCT03782454|DIAGNOSTIC_TEST|Blood sampling|Blood samples taken every third hour during the first 48 hours of intensive care
48268669|NCT03863314|DEVICE|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
48268670|NCT03863314|OTHER|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
48268671|NCT00976144|DRUG|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
47917142|NCT01525225|DRUG|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
47917143|NCT01525225|DRUG|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
48268672|NCT03844867|DIETARY_SUPPLEMENT|Filippo Cea and Carmel|"Subjects will be given a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly.~Motility test: Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds)."
48268673|NCT01163786|DRUG|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
48268674|NCT03329378|DRUG|Docetaxel|Docetaxel 75mg/m2 IV, day 1
48268675|NCT03329378|DRUG|Carboplatin|Carboplatin AUC 6 IV, day 1
48268676|NCT03329378|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1
48268677|NCT03329378|DRUG|Pertuzumab|Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1
48268678|NCT03329378|DRUG|Pegfilgrastim|Pegfilgrastim 6mg SC, day 2 Cycled as per arm
48268679|NCT03329378|DRUG|Trastuzumab|Trastuzumab 6mg/kg every 21 days to complete 1 year
48268680|NCT03329378|DRUG|Paclitaxel|Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
48268681|NCT03329378|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 IV day 1
48268682|NCT03329378|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 IV day 1
48268683|NCT03329378|DRUG|Paclitaxel|80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15
48268684|NCT02790866|BEHAVIORAL|LuCaS Decision Aid|Web-based Lung Cancer Screening Decision Aid
48268685|NCT02790866|BEHAVIORAL|NCI Website|NCI Website on Lung Cancer Screening
48268686|NCT02521155|BEHAVIORAL|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
48268687|NCT00951821|BEHAVIORAL|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
48268688|NCT00951821|BEHAVIORAL|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
48268689|NCT02867007|DRUG|KHK2455|oral dosing
48268690|NCT02867007|DRUG|Mogamulizumab|i.v. administration
48268691|NCT05504200|OTHER|Bladder and Pelvic Floor Muscle Training|The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
48268692|NCT04822532|GENETIC|GSTA1 genotyping|Diplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene
48268693|NCT02557425|OTHER|No intervention in PROTECT|
48268694|NCT04361201|PROCEDURE|Ligament plastic surgery|Ligament plastic surgery of ankle under arthroscopy for recurrent instable ankle reason and failure of medical treatment.
48268695|NCT04361201|DIAGNOSTIC_TEST|RMI and ultrasound|RMI examination at 3 months on operated ankle, and 3 CT scan examinations with elastography module will be performed at planned timeframes.
48268696|NCT03136107|OTHER|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
47917144|NCT01525225|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
48268697|NCT03136107|OTHER|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
48268698|NCT06265142|PROCEDURE|Bladder catheterization|Participant will undergo the standard bladder catheterization for urine collection
48268699|NCT06265142|PROCEDURE|clean catch urine via bladder massage technique|Participant will undergo clean catch urine via bladder massage technique
48268700|NCT01097629|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
48268701|NCT01097629|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
48478738|NCT03558620|PROCEDURE|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
47917145|NCT01525225|DRUG|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
47917146|NCT01182844|DIETARY_SUPPLEMENT|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
48268702|NCT01097629|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
48268703|NCT01237860|DEVICE|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
48268704|NCT03655834|DRUG|Pemetrexed|patients will be administered a microdose with subsequent pharmacokinetic assessment.
48268705|NCT04922866|OTHER|no intervention|no intervention
48268706|NCT01425385|OTHER|Near infrared spectroscopy monitoring|This is an observational study without interventions
48268707|NCT01425385|OTHER|Autoregulation monitoring|There are no interventions in this observational study
48268708|NCT01382160|BIOLOGICAL|adalimumab|40 mg every two weeks, by subcutaneous way
48268709|NCT05617287|DIETARY_SUPPLEMENT|Semaine Menopause Supplement|Synergistic Dietary Supplement
48268710|NCT03547557|DEVICE|Exablate 2000 strappable system|
48268711|NCT05184907|BEHAVIORAL|Remote Motivational Enhancement (RME) Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing within 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
48268712|NCT05184907|OTHER|Information Only|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
48268713|NCT00211614|DRUG|Lansoprazole|
48268714|NCT05210595|DRUG|Clopidogrel 75 mg|75 mg/day as maintenance dose.
48268715|NCT05210595|DRUG|Ticagrelor 60mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
48268716|NCT05210595|DRUG|Ticagrelor 45 mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
48268717|NCT05456425|DRUG|CBT-001|CBT-001 eye drop
48268718|NCT05456425|DRUG|Vehicle|Formulation without drug
48268719|NCT00938730|DRUG|YM150|oral
48268720|NCT00938730|DRUG|Warfarin|oral
48268721|NCT02886299|DRUG|Fenofibrate|
48268722|NCT02886299|DRUG|Simvastatin|
48268723|NCT04009928|DEVICE|Active stimulation of the medial forebrain bundle or subcallosal cingulate|Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate
48268724|NCT04009928|DEVICE|Sham stimulation|Sham stimulation for 2 weeks (Cross-over design)
48268725|NCT02616913|OTHER|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
48268726|NCT02616913|OTHER|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
48268727|NCT02616913|OTHER|Placebo|Each subject consumes placebo in one of 3 treatment periods
48268728|NCT04977206|OTHER|Mutual Goal-Setting Education|Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
48478739|NCT02846883|BIOLOGICAL|1 million MSCs/kg|Intravenous infusion of 1 million allogeneic MSCs/kg.
48478740|NCT02846883|BIOLOGICAL|3 million MSCs/kg|Intravenous infusion of 3 million allogeneic MSCs/kg
47917147|NCT00946153|DRUG|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
48478741|NCT02846883|DRUG|Placebo|Intravenous infusion of Plasmalyte A (placebo)
47917148|NCT05498415|BEHAVIORAL|Education|Participants will receive standard of care education information on physical activity, sedentary behavior, and sleep via a mobile app for 8 weeks.
47917149|NCT05498415|BEHAVIORAL|Health coaching|Participants will meet with a health coach weekly for 8 weeks
48268729|NCT05719584|OTHER|hypopressive exercises|patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
47917150|NCT05498415|BEHAVIORAL|Activity Monitor|Participants will receive a Fitbit activity monitor to support goal setting and self monitoring of behaviors.
48268730|NCT05719584|OTHER|pelvic floor muscle training|patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
47917151|NCT06089551|DRUG|SmofKabiven|Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
47917152|NCT02509117|DRUG|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
47917153|NCT02509117|DRUG|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
47917154|NCT02509117|DRUG|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
47917155|NCT02509117|DRUG|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
47917156|NCT02509117|DRUG|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
47917157|NCT02509117|DRUG|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
48268731|NCT04915287|DRUG|Avatrombopag maleate|"1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure"
48268732|NCT04915287|BIOLOGICAL|Platelet transfusion|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: platelet transfusion if needed
48268733|NCT04915287|DRUG|Medicine|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
48268734|NCT00923429|PROCEDURE|Stay-active care|No other treatment than the stay-active care
48268735|NCT00923429|PROCEDURE|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
48268736|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
48268737|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
48268738|NCT05877131|DRUG|Levobupivacaine|To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
47917158|NCT00652106|DRUG|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
47917159|NCT00652106|DRUG|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
47917160|NCT00652106|DRUG|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
47917161|NCT00653939|DRUG|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
47917162|NCT00653939|DRUG|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
47917163|NCT00653939|DRUG|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
47917164|NCT00653939|DRUG|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
47917165|NCT03171753|DIAGNOSTIC_TEST|questionnaire|questionnarie will be performed before the application of headphone and after their removal.
47917166|NCT03171753|DIAGNOSTIC_TEST|laboratory test|laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
47917167|NCT03171753|DIAGNOSTIC_TEST|cardiac monitoring|the cardiac monitoring will be performed through study period
47917168|NCT03171753|DIAGNOSTIC_TEST|skin resistance|the skin resistance monitoring will be performed through study period
48268739|NCT05877131|DRUG|Ropivacaine|To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
48268740|NCT01944085|DRUG|Acetaminophen|Syrup
48268741|NCT01944085|DRUG|Ibuprofen|Syrup
48268742|NCT01944085|OTHER|Vitamin C|Syrup
47917169|NCT03171753|DEVICE|Music listening|Listening prerecorded music through an individual headset for 30 min
48268743|NCT05885581|OTHER|Arm A Grow Well|"1. the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~2. the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~3. the feasibility of collecting infant anthropometric data."
48268744|NCT05885581|OTHER|Arm B Healthy Steps|Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
48268745|NCT05198713|DEVICE|New hearing aid|Participants will complete testing while using a novel hearing aid which has been fit to compensate for their hearing loss.
47917170|NCT03171753|DEVICE|No sound|No sound through an individual headset for 30 min
47917171|NCT00581880|BEHAVIORAL|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
47917172|NCT04367909|DRUG|Nimotuzumab|Nimotuzumab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
47917173|NCT04367909|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
48268746|NCT00454779|DRUG|Cisplatin|chemotherapy arm
48268747|NCT00454779|DRUG|Panitumumab|experimental arm
48268748|NCT00454779|DRUG|Docetaxel|chemotherapy arm
48268749|NCT00454779|DRUG|Cisplatin|experimental arm
48268750|NCT00454779|DRUG|Docetaxel|experimental arm
48268751|NCT05977907|DRUG|Pembrolizumab|Pembrolizumab is an investigational drug in this study
48268752|NCT05977907|DRUG|IO102-103|IO102-103 is an investigational drug in this study.
48268753|NCT01555229|DEVICE|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
48268754|NCT01555229|DEVICE|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
48268755|NCT02572284|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
48268756|NCT02572284|PROCEDURE|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
48268757|NCT02572284|OTHER|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
48268758|NCT04639323|DIAGNOSTIC_TEST|Endoscopic ruler|"Endoscopic ruler for varices in portal hypertension~Product uses: measuring the diameter of the veins under the endoscopy for the assessment of the risk of variceal haemorrhage in patients with portal hypertension~Black and white measuring rule is highly recognizable under the endoscopy~The width of each cell is 1 mm, and the measuring range is 0-10 mm~With smooth edge, safe and reliable"
48268759|NCT02009878|DRUG|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
48268760|NCT00501475|DRUG|NAC Bicarbonate|
48268761|NCT00656890|BIOLOGICAL|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
47914053|NCT03482960|DRUG|Hyperpolarized Xenon gas|"Hyperpolarized Xenon gas~* Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~* Administration: By mouthpiece attached to a single use Tedlar bag.~* Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~* Frequency: 10-minute interval between doses."
47917174|NCT04367909|DRUG|Carboplatin|Carboplatin AUC 5 will be administered intravenously on Day 1 of each 21-day cycle.
48268762|NCT00656890|BIOLOGICAL|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
48268763|NCT03496753|DEVICE|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
48268764|NCT03160014|DRUG|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
48268765|NCT05322408|DRUG|HCW9218|HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
48268766|NCT02820467|DEVICE|fluorescence angiography|Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
48268767|NCT00679458|DRUG|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
48268768|NCT00679458|DRUG|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
48268769|NCT00237133|DRUG|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
48268770|NCT06011135|OTHER|No intervention|No intervention - qualitative study only using semi-structured interview
48268771|NCT03658226|BEHAVIORAL|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
48268772|NCT02682680|DRUG|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
48268773|NCT02682680|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
48268774|NCT00891826|DIETARY_SUPPLEMENT|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
48268775|NCT00891826|DIETARY_SUPPLEMENT|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
47917175|NCT03665025|OTHER|immediate implant using mixed allograft and xenograft|immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
48268776|NCT04051957|DRUG|Isosorbide Mononitrate|The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
48268777|NCT04051957|DRUG|Placebo oral tablet|Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
47917176|NCT02181725|BEHAVIORAL|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
47917177|NCT02181725|BEHAVIORAL|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
48268778|NCT05740774|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.
48268779|NCT03896295|DRUG|M281|M281 injection administered as intravenous infusion
48268780|NCT05152940|DRUG|Ertugliflozin|Treatment with Ertugliflozin 5 mg oral once per day for one month
48268781|NCT05152940|DRUG|Placebo|Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
48268782|NCT01900002|OTHER|Laboratory Biomarker Analysis|Correlative studies
48268783|NCT01900002|OTHER|Quality-of-Life Assessment|Ancillary studies
48268784|NCT01900002|DRUG|Sorafenib|Given PO
48268785|NCT01900002|DRUG|Sorafenib Tosylate|Given PO
48268786|NCT01900002|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
48268787|NCT06280547|OTHER|Oral health education|Oral Health Education Program performed in the school.
48268788|NCT01075347|OTHER|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
48268789|NCT01075347|OTHER|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
48268790|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
48268791|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
48268792|NCT05728788|DRUG|Antitumor drugs|Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
48268793|NCT02471157|OTHER|Observation|
47917178|NCT06250361|OTHER|Questionnaire completion|A questionnaire will be completed by the participant and their gastroenterologist. Estimated completion time is 30 minutes for the patient, 10 minutes for the gastroenterologist.
47917179|NCT00933556|DIETARY_SUPPLEMENT|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
47917180|NCT00933556|DIETARY_SUPPLEMENT|sugar pill (placebo)|placebo identical to the active product will be given
48268794|NCT05651945|OTHER|Cardiac rehabilitation program|The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
47917181|NCT05171062|DRUG|bexmarilimab (FP-1305)|standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
47917182|NCT05171062|DRUG|Pembrolizumab|Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
48268795|NCT04707638|OTHER|No intervention used|No intervention used
48268796|NCT01662648|DRUG|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
48268797|NCT04536220|DIAGNOSTIC_TEST|Endoscopic Ultrasound (EUS), Fine Needle Aspiration|Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
48268798|NCT01630525|OTHER|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
48268799|NCT01630525|OTHER|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
48268800|NCT01630525|OTHER|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
48268801|NCT03286972|DEVICE|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
48268802|NCT01302873|DRUG|BGG492A|
48268803|NCT01302873|DRUG|BGG492A|
48268804|NCT05888350|DRUG|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
48268805|NCT05888350|DRUG|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
48268806|NCT06499818|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
48268807|NCT06499818|PROCEDURE|STABLE-AF|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during Atrial Fibrillation
47917183|NCT01123551|DRUG|nebulized morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
48268808|NCT06499818|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
47917184|NCT01123551|DRUG|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).
48268809|NCT02896530|OTHER|No intervention. Description study|
48268810|NCT06462014|DRUG|Relugolix|relugolix
48268811|NCT00256295|DRUG|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
48268812|NCT00256295|DRUG|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
48268813|NCT02365623|DRUG|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4\*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
48268814|NCT02365623|DRUG|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
48268815|NCT01332448|DRUG|Orlistat 120|Orlistat 120mg tid
48268816|NCT01332448|DRUG|Orlistat 60|Orlistat 60mg tid
48268817|NCT00818259|DRUG|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
48268818|NCT00818259|DRUG|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
48268819|NCT00818259|DRUG|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
48268820|NCT00818259|DRUG|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
48268821|NCT00818259|DRUG|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
48268822|NCT01144585|PROCEDURE|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
48268823|NCT01144585|PROCEDURE|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
48268824|NCT00895830|DRUG|APD405|IV
48268825|NCT00895830|DRUG|Placebo|IV
47917185|NCT05971576|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
47917186|NCT02305810|DRUG|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
48268826|NCT04792502|DRUG|Mosunetuzumab|Administered subcutaneously by injection beginning with 5 mg and increasing to 45 mg.
48268827|NCT04792502|DRUG|Lenalidomide|Patients in the augmentation cohort will be dosed continuously, 10 mg orally once daily, with or without food.
48268828|NCT04188730|DRUG|Lofexidine (granules for reconstitution)|All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.
48268829|NCT04188730|DRUG|LUCEMYRA (lofexidine) tablets|All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
47917187|NCT05785819|DRUG|VLX-1005|VLX-1005, a 12-LOX enzyme inhibitor
47917188|NCT05785819|DRUG|Placebo|Placebo matching VLX-1005
47917189|NCT05739084|RADIATION|pre-operative radiation|As per standard of care and institutional guidelines
47917190|NCT05739084|PROCEDURE|Standard surgery after rpreoprative radiation|As per standard of care and institutional guidelines
47917191|NCT00566384|DRUG|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
48268830|NCT02554929|BEHAVIORAL|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
48268831|NCT02554929|BEHAVIORAL|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
48268832|NCT02229734|RADIATION|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
48268833|NCT02229734|DRUG|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
48268834|NCT02898480|PROCEDURE|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
48268835|NCT04218409|DRUG|OxyCODONE 5 mg Oral Tablet|Oral oxycodone 5 mg orally
48268836|NCT04218409|DRUG|Oxytocin nasal spray|Intranasal oxytocin administration (48 IU)
48268837|NCT04218409|OTHER|Placebo Oxycodone|Oxycodone 0 mg orally
48268838|NCT04218409|OTHER|Placebo oxytocin|Intranasal placebo administration
48268839|NCT04218409|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oral oxycodone 2.5 mg orally
48268840|NCT06048185|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
48268841|NCT01436721|DEVICE|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
48268842|NCT01339442|DRUG|BKM120|
48268843|NCT01339442|DRUG|Fulvestrant|
48268844|NCT01339442|PROCEDURE|biopsy|Correlative studies
48268845|NCT01451645|DRUG|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
48268846|NCT01451645|DRUG|placebo|daily placebo dosing for 16 weeks
48268847|NCT01451645|DRUG|allopurinol|background therapy
48268848|NCT00381407|BEHAVIORAL|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
48268849|NCT00381407|BEHAVIORAL|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
48268850|NCT02168686|GENETIC|ADVM-043|Gene transfer vector administration
48268851|NCT01818726|DRUG|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
48268852|NCT01818726|DRUG|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
48268853|NCT01818726|DRUG|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
48268854|NCT04207476|DEVICE|EMF|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
48268855|NCT04207476|DEVICE|Placebo|No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
48268856|NCT04918563|DRUG|Nitroglycerin|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
48268857|NCT04918563|DRUG|Acetylcholine|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
48268858|NCT02769598|DEVICE|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
48268859|NCT05378009|BEHAVIORAL|relaxation and physical activity|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
48268860|NCT05378009|BEHAVIORAL|relaxation|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
48268861|NCT05883098|PROCEDURE|Wound debridement|The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.
48268862|NCT05883098|DEVICE|Wound closure matrix application|After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
48268863|NCT00135460|DRUG|nucleoside analogue sparing HAART regimen|
48268864|NCT06504277|PROCEDURE|Low Pressure Penumoperitoneum|Maintained Pneumoperitoneum with low pressure of 10 mm Hg
48268865|NCT06504277|OTHER|Standard Pressure Group (No intervention- active comparator)|Maintained Pneumoperitoneum at standard pressure of 15 mm Hg
48268866|NCT01901835|PROCEDURE|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
48268867|NCT01901835|OTHER|survey administration|Ancillary studies
48268868|NCT01901835|PROCEDURE|quality-of-life assessment|Ancillary studies
48478742|NCT01593072|DRUG|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
48478743|NCT01593072|OTHER|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
48478744|NCT04417049|DRUG|Pentoxifylline 400 MG|All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
48478745|NCT06311669|PROCEDURE|iliac vein stenting|patients will undergo left common iliac vein stenting according to diameter measurements using balloon-mounted stents.
48478746|NCT06311669|PROCEDURE|pelvic vein embolization|embolization of pelvic veins by injection of left ovarian vein or parauterine veins pelvic escape points using sandwich technique of detachable or pushable coils and polidocanol 3 %.
48478747|NCT02501551|DRUG|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
48268869|NCT05770986|OTHER|Group A|the patient must attain the goal repetitions (and holds when required) at one level before progressing to the next level. The principal investigator will provide extensive education to the patient while progressing through the program. Three resistance bands will be used through the exercise progression; yellow band (low resistance), green band (moderate resistance) to blue band (high resistance). The patient will progress to more advanced level if he/she can sustain the position with high resistance band (blue) for one minute with three isometric holds of each exercise on each limb. three sets for 10 repetitions will be performed) Phases 1-3 of the program are focused on GMax activation. Phases 4- 5 are focused on GMax strength, and the final three phases emphasize functional applications of the GMax during ballistic tasks.
48268870|NCT05770986|OTHER|Group B|Flexibility exercises of the back muscles: knee to chest stretch, bridging, stretching exercises for hip flexors, piriformis, adductors and hamstring will be performed, with a hold of position for 30 s and with repetitions (3-5 times). Static stretches will be held for 30 seconds to induce changes in flexibility and will be repeated for three sets. Three sessions of stretching per week will be performed b. Prone resisted hip extension 10 repetitions for two sets. c. Hot pack: for 10 minutes. d. TENS: The electrodes will be placed over the area of most severe pain for 15 minutes.
48268871|NCT02104284|PROCEDURE|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
48268872|NCT01255774|DRUG|ranibizumab|An open-label, study of intravitreally administered ranibizumab
48268873|NCT04828863|BEHAVIORAL|Neurocognitive testing|Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
48268874|NCT04225325|COMBINATION_PRODUCT|SYMTUZA|DESCOVY+REZOLSTA
48268875|NCT04225325|COMBINATION_PRODUCT|DESCOVY+DOLUTEGRAVIR|DESCOVY+DOLUTEGRAVIR
48268876|NCT04225325|COMBINATION_PRODUCT|SYMTUZA+DOLUTEGRAVIR|DESCOVY+REZOLSTA+DTG
48268877|NCT05114083|OTHER|symptom assessment|symptom assessment
48268878|NCT02567448|OTHER|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
48268879|NCT00093613|DRUG|sorafenib tosylate|Given PO
48268880|NCT00093613|OTHER|pharmacological study|Correlative studies
48268881|NCT01385020|DRUG|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
48268882|NCT00001676|DRUG|SQ Fludarabine|
48268883|NCT01437787|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
48268884|NCT01437787|DRUG|Placebo|"Pharmaceutical form:capsule~Route of administration: oral"
48268885|NCT02548702|BEHAVIORAL|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
48268886|NCT05088408|DIETARY_SUPPLEMENT|Resource® Energy Apricot|"Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
47917192|NCT00566384|DRUG|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
47917193|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
47917194|NCT00119678|DRUG|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
47917195|NCT00119678|DRUG|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
47917196|NCT00119678|DRUG|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
47917197|NCT05613062|DRUG|Modified Huang-Lian-Jie-Du Decoction (MHLJDD)|Chinese medicine granules for 12 weeks twice daily
47917198|NCT05613062|DRUG|Placebo|Placebo granules for 12 weeks twice daily
47917199|NCT06252324|OTHER|Prime taper implant + cover screw|tissue level implant placement with the addition of a cover screw
47917200|NCT06252324|OTHER|Prime taper implant + healing screw|bone level implant placement with the addition of a healing screw
47951143|NCT03048916|OTHER|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
48268887|NCT05088408|OTHER|Bowel preparation as usual.|"Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
48268888|NCT06351033|DIETARY_SUPPLEMENT|High ozonide (HOO) ozonated oil|ozonated oil with high ozonides (HOO) administered orally (os) in gastro-resistant capsules
48268889|NCT04674566|DRUG|COR-101|Administered intravenously (IV) single dose
48268890|NCT04674566|DRUG|Placebo|Administered intravenously (IV) single dose
48268891|NCT02204631|OTHER|Head and Neck Educational Handbook|
48268892|NCT02492945|DRUG|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
48268893|NCT02492945|DRUG|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
48268894|NCT00850746|DRUG|YM443|Oral
48268895|NCT00850746|DRUG|Placebo|Oral
48268896|NCT00850746|DRUG|Moxifloxacin|Oral
48268897|NCT02152345|DRUG|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
48268898|NCT02152345|DRUG|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
48268899|NCT02152345|DRUG|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
48268900|NCT02152345|DRUG|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
48268901|NCT02152345|DRUG|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
48268902|NCT02152345|PROCEDURE|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
48268903|NCT00142948|DRUG|Naltrexone|naltrexone
48268904|NCT00142948|DRUG|Placebo|placebo
47917201|NCT02697149|RADIATION|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
47917202|NCT02697149|RADIATION|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
47917203|NCT03800940|PROCEDURE|Fistulography and trans-drain occlusion|"1. Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~2. Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed."
47917204|NCT03800940|PROCEDURE|Fistulography|Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
47917205|NCT00165815|DRUG|ARICEPT|
48268905|NCT04061135|PROCEDURE|Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
48268906|NCT04619394|OTHER|Aquatic exercise - own monitors program|"Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes."
48268907|NCT04619394|OTHER|Aquatic exercise - AIPAP program|"Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes."
48268908|NCT01716481|OTHER|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
48268909|NCT01091636|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
48268910|NCT03359135|OTHER|Rehabilitation|Rehabilitation during 4 weeks
48268911|NCT03359135|DEVICE|Compression Garment|Rehabilitation associated to wearing CG during 4 weeks
48268912|NCT03700099|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
48268913|NCT03700099|DRUG|Enzalutamide|Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
48268914|NCT04120155|PROCEDURE|Dissection of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the dissection group, we will dissect the inferior pulmonary ligament during the surgery.
48268915|NCT04120155|PROCEDURE|Preservation of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the preservation group, we will preserve the inferior pulmonay ligament during the surgery.
48268916|NCT06549361|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
48268917|NCT05812664|OTHER|enteral feeding|The amount of enteral nutrition that should be given daily was calculated by the nutritionist using the Harris-Benedict formula. Formula at room temperature was given with a nasogastric foley catheter and a feeding pump. The position of the nasogastric Foley catheter in the stomach was confirmed by the PAAC graph when it was first inserted, and by listening before each feeding. Feeding was done in a position with the head at 30 degrees.
48268918|NCT05812664|PROCEDURE|blood glucose measurements|Blood glucose values were measured in all groups at 06:00, 12:00, 18:00 and 24:00, 4 times a day for 7 days. The sample was taken from the patient's cannula and examined in the biochemistry lab. The targeted range in the measurements was accepted as 70-180 mg/dl.
48268919|NCT05812664|PROCEDURE|Evaluation of feeding intolerance with gastric residue|gastric residue assessment; 30 minutes after the feeding was stopped, the N/G tube was drained and the amount coming 30 minutes later was evaluated. Residue positive was defined as the return of more than half of the amount of formula in the last cycle. The same was continued without increasing the amount given. If the incoming amount was less than half, the residue was evaluated as negative and the formula was continued by increasing the predetermined amount.
48268920|NCT00848744|DRUG|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
48268921|NCT00848744|DRUG|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
48268922|NCT00318292|DRUG|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
47917206|NCT03010488|BEHAVIORAL|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
48268923|NCT00318292|DRUG|Placebo|20 ml normal saline injection.
48268924|NCT00006247|DRUG|semaxanib|
47917207|NCT03010488|BEHAVIORAL|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
47917208|NCT03010488|DEVICE|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
48268925|NCT02404987|OTHER|Nutritional Supplement|
48268926|NCT03387787|DEVICE|GlucoTab|"The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days."
48268927|NCT03387787|DRUG|Insulin Degludec|During the study, patients will be treated with basal Insulin degludec
48478748|NCT02112279|BIOLOGICAL|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy~1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
48268928|NCT05472389|OTHER|Video-electroencephalography|All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
48268929|NCT05472389|OTHER|Blood Samples|Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children \< 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
47917209|NCT02428283|DRUG|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
48268930|NCT04208425|BEHAVIORAL|Project Personality|"The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise)."
48268931|NCT04208425|BEHAVIORAL|Sharing Feelings Intervention|The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
47917210|NCT02428283|DRUG|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
47917211|NCT02428283|DRUG|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
47917212|NCT02879006|DRUG|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
47917213|NCT02879006|DRUG|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
47917214|NCT02879006|DRUG|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
48268932|NCT01501591|DRUG|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
48268933|NCT01501591|OTHER|Placebo|Matching placebo once on two different days, 72 hours apart.
48268934|NCT01501591|DRUG|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
47917215|NCT02879006|DRUG|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
47917216|NCT06096571|DRUG|Aterixen|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
47917217|NCT05741554|OTHER|Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.|Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery
47917218|NCT01523847|DRUG|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
47917219|NCT01866085|PROCEDURE|AdVance® sling procedure|
47917220|NCT01866085|PROCEDURE|ARGUS Sling procedure|
47917221|NCT00409370|DEVICE|SOMA safe enclosure|
47951144|NCT04862377|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
48268935|NCT02934009|DEVICE|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
47917222|NCT01701050|OTHER|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
47917223|NCT04437121|OTHER|Online Survey about Dietary and Lifestyle Habits|"An online survey was conducted in a random sample of families. Parents self-reported their child's and their own dietary and lifestyle habits, as well as information about their sociodemographic status.~The survey consisted of 70 questions in 3 sections."
48268936|NCT00667576|DRUG|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
48268937|NCT00667576|DRUG|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
48268938|NCT04591054|DEVICE|Extended Vision IOL|Vivity IOL implantation following cataract extraction
47917224|NCT01828151|DEVICE|Noninvasive ventilation mask|
47917225|NCT01158170|RADIATION|Prophylactic cranial irradiation|25GY/10fraction
47917226|NCT01158170|DRUG|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
47917227|NCT05366868|DRUG|Imeglimin|Imeglimin 1000 mg orally twice daily in the morning and evening (2000 mg daily).
47917228|NCT05366868|DRUG|Metformin|Metformin 500 mg orally twice daily in the morning and evening (1000 mg daily). However, until 2 weeks after the start of treatment, 250 mg should be administered orally twice daily in the morning and evening. Thereafter, after 4, 8, or 12 weeks, the dose may be increased up to 750 mg twice daily (1500 mg daily) if the physician determines that the hypoglycemic effect is inadequate.
47917229|NCT05366868|DRUG|Vildagliptin|Vildagliptin 50 mg orally twice daily in the morning and evening (100 mg daily).
47917230|NCT03156296|DRUG|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
47917231|NCT03156296|DRUG|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
47917232|NCT02508818|OTHER|Parabolic flight|
47917233|NCT02508818|OTHER|Cardiovascular measurements|
47917234|NCT04655794|DRUG|3HP|all patients taking 3HP under directly observed preventive therapy (DOPT) program
47917235|NCT02120183|BEHAVIORAL|Psycho-educational support group therapy|"Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)"
47917236|NCT06017037|DRUG|Citalopram 20mg|Citalopram 20mg tablets, encapsulated to aid blinding. To take per oral once daily for 7-9 days
47917237|NCT06017037|DRUG|Placebo|Lactose monohydrate tablets encapsulated to aid blinding. To take per oral once daily for 7-9 days
47917238|NCT01137604|DRUG|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
47917239|NCT01137604|DRUG|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
47917240|NCT03200886|DEVICE|Sinovial H-L|Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
48268939|NCT04591054|DEVICE|Neutral Aspheric Monofocal IOL|enVista IOL implantation following cataract extraction
48268940|NCT04244370|DEVICE|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
48268941|NCT03643913|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).
47917241|NCT03200886|DRUG|Triamcinolone Acetonide|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
47917242|NCT00482989|BIOLOGICAL|MEDI 545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
47917243|NCT00482989|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
47917244|NCT01483417|PROCEDURE|Single incision Laparoscopic hysterectomy|SILS port
47917245|NCT01483417|PROCEDURE|Conventional laparoscopic hysterectomy|3-4 conventional ports
47917246|NCT05437497|DRUG|Remimazolam Injection|The experimental group was sedated with remimazolam
47917247|NCT05437497|DRUG|Propofol Injection|The control group was sedated with propofol
47917248|NCT01311167|DRUG|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
48268942|NCT03643913|PROCEDURE|Moderate neuromuscular block|Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).
48268943|NCT03643913|DRUG|Neuromuscular Blocking Agents and reversing agents|Deep neuromuscular block versus moderate neuromuscular block.
47917249|NCT01311167|DRUG|Placebo|Daily administration of 2 mg of placebo for 4 days
47917250|NCT01068964|DRUG|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
47917251|NCT01068964|DRUG|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
47917252|NCT04788368|PROCEDURE|Surgical resection|Surgical resection with either of the above mentioned techniques
47917253|NCT00146848|DEVICE|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
47917254|NCT02771496|OTHER|Other: observational only- no intervention|Other: observational only- no intervention
48268944|NCT05974280|DRUG|Alofisel|Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
47917255|NCT00271505|DRUG|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
47917256|NCT00271505|DRUG|Carboplatin|AUC 6 IV every 3 weeks
47917257|NCT00271505|DRUG|Docetaxel|75 mg/m2 IV every 3 weeks
47917258|NCT02482038|DEVICE|geko|neuromuscular electrostimulator
47917259|NCT00132548|DRUG|Pyrimethamine/sulfadoxine|
48268945|NCT05974280|DRUG|Fat stem cell|mesenchymal stem cells from adipose (fat) tissue injection
47917260|NCT00132548|DRUG|Amodiaquine|
47917261|NCT00132548|DRUG|Artesunate|
48620111|NCT06340659|BEHAVIORAL|HbExergame|Participants will cycle as described in the HbAEx protocol while engaging in cognitive training for the duration of cycling. Cognitive training will include 20 levels of difficulty with 8-10 task scenarios in the context of three virtual worlds (environments. In each of the environments, the participant must follow directions and navigate to a destination where the scenario (cognitive task) will be performed. The game will inform the participant of the assigned task and, automatically, determine and inform the participant of the fastest route from the starting point to the scenario destination where the task will be performed. The participant will be required to remember the assigned task, follow the directions and navigate to the destination, and then remember what action is required to complete the task. A scenario-specific cognitive task will be triggered once the destination has been reached. The cycling and cognitive tasks will be completed throughout the sessions.
48620112|NCT02682121|DRUG|Metformin|Metformin 850 mg twice daily
48620113|NCT02682121|DRUG|Placebo|Placebo twice daily
47917262|NCT06244290|DRUG|Colgate SNF|toothpaste
47917263|NCT06244290|DRUG|Sensodyne Extra Whitening|toothpaste
47917264|NCT06244290|DRUG|Colgate Fluoride (CDC)|toothpaste
47917265|NCT03063034|OTHER|PD21864AA|A king size menthol cigarette.
47917266|NCT03063034|OTHER|PD21864AB|A king size menthol cigarette.
47917267|NCT05867329|DRUG|Cyclosporine Injection (IV)|"Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers."
47917268|NCT05867329|DRUG|Cyclosporine Oral Product|"Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician."
47917269|NCT05867329|DRUG|Upadacitinib Extended Release Oral Tablet|"This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital."
48268946|NCT05285137|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
48268947|NCT05285137|DRUG|Saline placebo|Sterile normal saline for injection
48620114|NCT03994159|DEVICE|"Use of the PARO emotional robot"|PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
48620115|NCT04120779|DEVICE|The EMPOWER-SUSTAIN e-Health Self-Management Intervention|Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
48268948|NCT03563300|OTHER|Wheat flour|Wheat flour will be administered once daily for 7 days
47917270|NCT05867329|DRUG|Intravenous Methylprednisolone|Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
47917271|NCT05867329|DRUG|Prednisone Oral Product|Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
48268949|NCT03563300|OTHER|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
48268950|NCT01052857|PROCEDURE|acupuncture|acupuncture application
48268951|NCT02834949|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
47917272|NCT06078943|DEVICE|method comparison|to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
47917273|NCT03211572|DRUG|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
48268952|NCT02834949|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
48268953|NCT02834949|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
48268954|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
48268955|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
48268956|NCT04573673|DEVICE|PTNS de verum|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.
48268957|NCT04573673|DEVICE|PTNS placebo|The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current
48268958|NCT00003378|DRUG|carboplatin|
48268959|NCT00003378|DRUG|gemcitabine hydrochloride|
48268960|NCT00003378|DRUG|paclitaxel|
48268961|NCT04363333|DIAGNOSTIC_TEST|Home Sleep Apnea Testing or In-hospital Polysomnography|Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
47917274|NCT03672097|DRUG|Prasugrel|Prasugrel, oral tablets, containing 3.75 mg per tablet
47917275|NCT04074161|DRUG|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
47917276|NCT04074161|DRUG|Placebo (semaglutide)|Administered once weekly for 68 weeks
47917277|NCT04074161|DRUG|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
48268962|NCT05628922|DRUG|Toripalimab|"Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months."
48268963|NCT05628922|OTHER|Induction chemotherapy and concurrent chemoradiation|"Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles."
47917278|NCT04074161|DRUG|Placebo (liraglutide)|Administered once daily for 68 weeks
47917279|NCT03869008|DEVICE|gammaCore Sapphire|"gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation."
47917280|NCT03869008|DEVICE|Sham Device|The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
47917281|NCT06282133|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|"Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought."
47917282|NCT01771341|DEVICE|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
47917283|NCT01771341|DEVICE|MAQUET SERVOi ventilator|Pressure Support
48268964|NCT01468311|PROCEDURE|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
48268965|NCT01468311|DRUG|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
47917284|NCT04554121|BEHAVIORAL|Brain Basics|"Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday.~life."
47917285|NCT04554121|BEHAVIORAL|Brain Training|Computer-based exercises targeting impairments in cognitive domains (processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday life.
47917286|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
48268966|NCT01468311|RADIATION|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
48268967|NCT01468311|RADIATION|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
48268968|NCT02932956|GENETIC|GAP T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
48268969|NCT02932956|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
48268970|NCT02932956|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
48620116|NCT02043067|OTHER|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
48620117|NCT00690651|PROCEDURE|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
48620118|NCT00690651|PROCEDURE|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
47917287|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
48268971|NCT03371563|DRUG|Antibiotics|Patients were treated with antibiotics for Lyme disease.
48268972|NCT03371563|OTHER|no intervention|controls were not given antibiotics
47917288|NCT01114399|DIETARY_SUPPLEMENT|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
47917289|NCT00605787|DRUG|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
47917290|NCT00000771|DRUG|Paromomycin sulfate|
47917291|NCT02019485|DRUG|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
47917292|NCT02019485|DRUG|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
47917293|NCT02238067|DRUG|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
47917294|NCT02238067|OTHER|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
47917295|NCT01675167|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
47917296|NCT01675167|DRUG|Placebo|Matching Placebo Buccal Film twice daily
47917297|NCT05971706|DEVICE|Ozone therapy using a device (Ozone DTA Ozone Generator, Denta Tec Dental AS, Norway)|Ozone therapy procedures will be performed immediately after non-surgical periodontal treatment and three times (every third day) within one week using a device equipped with a periodontal tip according to equipment producer recommendations. The periodontal tip will be halted 1 mm short of the pocket depth. Ozone will be applied only to the pockets; which depth is equal to or greater than 5 mm. Ozone application time to the pockets will be 30 seconds at a fixed concentration of 2,100 ppm (80% oxygen) through a connected handpiece.
47917298|NCT05971706|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment consists of oral hygiene instructions, full mouth supragingival scaling using hand instruments, ultrasonic devices, polishing, and subgingival debridement under local anesthesia with sharp Gracey and Universal curettes and ultrasonic instruments in a single appointment.
48620119|NCT02550210|DEVICE|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
47917299|NCT03934099|DRUG|LC350189 formulated capsule|Xanthine Oxidase Inhibitor
47917300|NCT03934099|DRUG|Placebo|Matching placebo
48620120|NCT05528848|DRUG|Carfentanil, C-11|Investigational radiotracer to be injected by IV as s a bolus during both study PET/CT scans.
47917301|NCT02481453|DRUG|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
48268973|NCT01912625|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
48268974|NCT01912625|DRUG|Carboplatin|Given IV
47917302|NCT02481453|DRUG|Placebo|Comparator: placebo
47917303|NCT02567604|BEHAVIORAL|Focus Groups|at least three focus groups lasting approximately one hour
48268975|NCT01912625|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
48268976|NCT01912625|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48268977|NCT01912625|OTHER|Laboratory Biomarker Analysis|Correlative studies
48268978|NCT01912625|DRUG|Paclitaxel|Given IV
48268979|NCT01912625|OTHER|Pharmacological Study|Correlative studies
48268980|NCT01912625|DRUG|Trametinib|Given PO
48268981|NCT05332119|DEVICE|VR glasses|Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.
48268982|NCT05332119|OTHER|Control group|Patients will not receive distraction during chest drain removal
48268983|NCT03263559|PROCEDURE|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
48268984|NCT03263559|DRUG|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
48268985|NCT03263559|DRUG|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
48268986|NCT03263559|DRUG|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
48268987|NCT03263559|DRUG|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
48268988|NCT03263559|DRUG|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
48268989|NCT03263559|RADIATION|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
48268990|NCT03263559|DRUG|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
48268991|NCT05574179|DRUG|Dexmedetomidine injection|Inj precedex 200mcg in 1ml given in stat doses
48268992|NCT05574179|DRUG|Midazolam|Inj.midazolam 5mg/5ml given in stat doses
48620121|NCT05528848|DRUG|Naloxone|Non-selective opioid antagonist injected by IV parenterally during the second study PET/CT scan only.
48620122|NCT05528848|DRUG|Loperamide Hydrochloride|Loperamide is an FDA- approved, over-the-counter drug for the control and symptomatic relief of acute or chronic diarrhea given orally prior to the optional HC third PET/CT scan only.
48620123|NCT03007940|OTHER|Coach Site Visit|The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
48620124|NCT03007940|OTHER|Walk-through|Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
47917304|NCT02884505|DEVICE|Pupillometry|Measures pupillary dynamics in darkness and light conditions
47917305|NCT02884505|BEHAVIORAL|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
47917306|NCT02884505|OTHER|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
47917307|NCT02884505|BEHAVIORAL|Hypersomnia Severity Index|Self-report measure of hypersomnolence
48268993|NCT06322719|DEVICE|Hyperangulated blade videolaryngoscope|For patients assigned to the Hyperangulated videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
48268994|NCT06322719|DEVICE|Macintosh blade videolaryngoscope|For patients assigned to the Macintosh videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
48268995|NCT05195541|DRUG|CU-20401|Subcutaneous injection in the subcutaneous fat area，0.2ml
47917308|NCT03225508|DIAGNOSTIC_TEST|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
47917309|NCT03225508|DIAGNOSTIC_TEST|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
47917310|NCT03225508|DIAGNOSTIC_TEST|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
48268996|NCT01813994|DRUG|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
47917311|NCT00578760|DRUG|aspirin|325mg ASA OD for the duration of the cisplatin
48268997|NCT01813994|DRUG|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
47917312|NCT00578760|DRUG|placebo|OD for course of cisplatin chemotherapy
47917313|NCT04452110|DIAGNOSTIC_TEST|Ultrasonography|Temporomandibular joint diseases of ultrasonography its effectiveness and reliability in diagnosis disadvantages in MR and other imaging methods be ruled out.
47917314|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counseling A|Krill powder capsules
48268998|NCT03257189|DEVICE|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
47917315|NCT03112083|DIETARY_SUPPLEMENT|Nutritional counselling B|Placebo capsules
47917316|NCT02055638|DRUG|SRX246|capsules
48268999|NCT03257189|DEVICE|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
47917317|NCT02055638|DRUG|Placebo|
47917318|NCT01491984|DEVICE|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
47917319|NCT01491984|DEVICE|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
47917320|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu low dose|The contents of 4 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
47917321|NCT05343767|DIETARY_SUPPLEMENT|Natural Wellness Low-Glu high dose|The contents of 5 capsules of NW Low-Glu were equally distributed and inserted into 6 capsules size 0, and administered in 3 daily doses
47917322|NCT05343767|OTHER|Metformin|A total dose of 2000 mg was administered per day.
47917323|NCT03891238|DRUG|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
47917324|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - single dose
47917325|NCT01074593|BIOLOGICAL|Interferon beta-1a|12.000UI - Single dose
47917326|NCT02234518|OTHER|High quantity fiber|The intervention type is food product
47917327|NCT02234518|OTHER|Low quantity fiber|The intervention type is food product
47917328|NCT02234518|OTHER|Placebo|
47917329|NCT01379144|DRUG|latanoprost 75 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
47917330|NCT01379144|DRUG|latanoprost 100 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
47917331|NCT01379144|DRUG|latanoprost 125 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
47917332|NCT01379144|DRUG|latanoprost 50 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
47917333|NCT05744843|BEHAVIORAL|exercise|cardiovascular and lower limb strengthening exercise programme
47917334|NCT05744843|PROCEDURE|Deep venous stenting|Planned surgical intervention
47917335|NCT05827198|OTHER|Low-sugar candies compared to regular sugar candies|Acute intake
47917336|NCT00625430|BIOLOGICAL|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
47917337|NCT00811486|DRUG|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
47917338|NCT05065411|DRUG|Enobosarm & Abemaciclib Combo|Subjects will receive a combo of Enobosarm \& Abemaciclib
47917339|NCT05065411|DRUG|non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant|Non-steroidal AI, a steroidal AI (exemestane with or without everolimus), OR fulvestrant
47917340|NCT04347187|DRUG|Anticoagulants|oral anticoagulants, dual or triple antithrombotic theraphy
47917341|NCT01305590|OTHER|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
47917342|NCT02036970|DRUG|Bardoxolone methyl|
47917343|NCT02036970|DRUG|Placebo|
47917344|NCT02282241|DRUG|Melatonin|
47917345|NCT02282241|OTHER|Placebo|
47917346|NCT06337019|OTHER|Cohort observational|Cohort observational
47917347|NCT04090372|DEVICE|evaluation of pre-op planning using Traumacad|The study will be compare pre-op planning with standard condition or with TraumaCad
47917348|NCT00904033|DRUG|Calcitriol|Calcitriol tablet taken once per week.
47917349|NCT00904033|BEHAVIORAL|Exercise|Exercise consisting of progressive walking and resistance band training
47917350|NCT00904033|DIETARY_SUPPLEMENT|Multivitamin|
47917351|NCT01702493|DRUG|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
47917352|NCT01702493|DRUG|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
48269000|NCT03257189|DEVICE|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
48269001|NCT03257189|OTHER|Activity classification|Visual annotation of subject posture and other activities used for reference
48269002|NCT06226363|DRUG|LNF1901 Monoclonal Antibody Injection|LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
47917353|NCT01702493|DRUG|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
47917354|NCT01702493|DRUG|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
47917355|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
47917356|NCT01702493|DRUG|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
47917357|NCT05262829|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|MSCs treatment by intestinal submucosal injection/MSCs treatment by intravenous drip + MSCs treatment by intestinal submucosal injection
47917358|NCT04264624|DEVICE|Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
47917359|NCT04264624|DEVICE|Airflow and Erythritol powder and ultrasonic debridement|Airflow combined with Erythritol powder will be used as an adjunct therapy
47917360|NCT02983929|PROCEDURE|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
47917361|NCT04095429|BEHAVIORAL|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
47917362|NCT04095429|BEHAVIORAL|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
47917363|NCT00759564|DRUG|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
47917364|NCT00554489|BEHAVIORAL|exercise intervention|participation in physical activity intervention program weeks 2 through 5
47917365|NCT03764293|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
48478749|NCT06617494|OTHER|Pain modulation testing|During the visit, noxious heat stimuli will be applied bilaterally to the face and distant body sites as part of conditioned pain modulation (CPM) testing. The test stimuli will be individually tailored to be moderately painful, while the conditioning stimulus will vary in intensity: moderately painful, non-painful, and sham heat. Participants will also record daily TMD pain intensity ratings for seven days before and after the visit.
47917366|NCT03764293|DRUG|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
47917367|NCT03764293|DRUG|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
47917368|NCT05742308|BEHAVIORAL|Laughter yoga|Laughter yoga program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. The sessions included a combination of different laughter exercises. The last step, which included yoga nidra took 5 minutes.
47917369|NCT01075308|DRUG|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
47917370|NCT04228159|DEVICE|Balance Tutor Biofeedback Rehabilitation System|Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery
47917371|NCT04228159|OTHER|Balance and strengthening exercise|exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
47917372|NCT03716154|RADIATION|Diode laser|Diode laser 810nm, 2W, 20sec, 20 HZ
47917373|NCT05448885|DRUG|Tislelizumab|Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
47917374|NCT05974059|DRUG|Oxaliplatin|Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;
47917375|NCT05974059|DRUG|Capecitabine|Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；
47917376|NCT05974059|DRUG|Cadonilimab|Cadonilimab 10 mg/kg, d1, Q3W
47917377|NCT02161900|OTHER|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
47917378|NCT00942097|DRUG|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
47917379|NCT00942097|DRUG|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
47917380|NCT05783557|DRUG|Clevidipine Butyrate Injectable Emulsion|intravenous injection
47917381|NCT05783557|DRUG|Cleviprex®|intravenous injection
47917382|NCT02619383|DEVICE|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
47917383|NCT04643717|OTHER|Electronic pupillometer analysis|Electronic pupillometer analysis
47917384|NCT03727724|DRUG|Afatinib|Tablet
47917385|NCT03727724|DRUG|Cetuximab|Injection
47917386|NCT02415036|DEVICE|Delcath Hepatic Delivery System|
47917387|NCT02415036|DRUG|Melphalan|
47917388|NCT04653597|PROCEDURE|Close monitoring|surveillance every 30 minutes of blood pressure, SpO2, respiratory rate, heart rate and GCS until the patient recovers a GCS\>8 or responds adequately to a simple order
47917389|NCT04653597|PROCEDURE|Endotracheal intubation|invasive airway management in order to avoid risk of pulmonary aspiration
47917390|NCT00967954|DRUG|antiandrogen therapy|
47917391|NCT00967954|DRUG|releasing hormone agonist therapy|
47917392|NCT00967954|GENETIC|DNA analysis|
47917393|NCT00967954|GENETIC|RNA analysis|
47917394|NCT00967954|GENETIC|comparative genomic hybridization|
47917395|NCT00967954|GENETIC|gene expression analysis|
47917396|NCT00967954|OTHER|laboratory biomarker analysis|
47917397|NCT00967954|PROCEDURE|diffusion-weighted magnetic resonance imaging|
47917398|NCT00967954|PROCEDURE|magnetic resonance spectroscopic imaging|
47917399|NCT02130791|BEHAVIORAL|Sleep|
47917400|NCT04162561|BEHAVIORAL|Patients with documented IHD|Assessment of patients' quality of life with the use of the Seattle Angina Questionnaire (SAQ), blood pressure levels (using the Korotkoff method, blood pressure is measured 3 times with 1-minute intervals on the hand with the higher blood pressure levels while sitting calm after a 5-minutes rest), laboratory methods (lipids, glycosylated hemoglobin levels), patients' adherence to treatment (original questionnaire), quality of patients' therapy taken at the time of visit, necessity of invasive coronary revascularization procedures (during all visits).
48269003|NCT02500693|BIOLOGICAL|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
48269004|NCT04660188|OTHER|Multidisciplinary collaborative care arm|Study participants will be cared for by a team of healthcare professionals; an oncologist, a PCP and a pharmacist navigator.
47917401|NCT02064413|DEVICE|ESS310 (BAY1454032)|
48269005|NCT03033745|DRUG|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
48269006|NCT01891071|PROCEDURE|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
47917402|NCT02773953|DEVICE|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
47917403|NCT02773953|DEVICE|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
47917404|NCT04194385|PROCEDURE|Upper trunk block|Block will be applied to supraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine .
47917405|NCT04194385|PROCEDURE|Costoclavicular block|Block will be applied to infraclavicular zone by 20 ml % 0.25 bupivacaine with 5 mcg/ml epinephrine.
47917406|NCT04194385|PROCEDURE|Diaphragmatic function assessment|Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.
47917407|NCT04194385|PROCEDURE|Cervical plexus blockade|Block will be applied at thyroid cartilage level via 10 ml % 0.25 bupivacaine.
47917408|NCT03114540|DRUG|GBT440|Oral
47951145|NCT04862377|DRUG|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
47951146|NCT06681688|DRUG|Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}|Eyes in the Study Arm will be treated with the following intraoperative interventions: Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%, intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10mgs/mL).
48269007|NCT02211261|BIOLOGICAL|PF-06293620|subcutaneous, single dose 0.3 mg/kg
47917409|NCT01760785|DRUG|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
47917410|NCT01760785|DRUG|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
47917411|NCT00945295|DRUG|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
47917412|NCT00945295|OTHER|Rehabilitation Therapy|Rehabilitation therapy
47917413|NCT02806583|OTHER|structured support groups|Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
48269008|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
48269009|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
48269010|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
48269011|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 3 mg/kg
47917414|NCT00260962|DRUG|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
47917415|NCT00260962|BEHAVIORAL|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
47917416|NCT02428478|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
47917417|NCT02428478|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
47917418|NCT02649751|DRUG|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
47917419|NCT02649751|DRUG|Placebo|The placebo treatment is lactose capsule.
48269012|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
48269013|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 6 mg/kg
48269014|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
48269015|NCT02211261|BIOLOGICAL|PF-06293620|Intravenous infusion single dose 1 mg/kg
48269016|NCT02211261|BIOLOGICAL|Placebo|Intravenous infusion normal saline single dose
48269017|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
48269018|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
48269019|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
48269020|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
48269021|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
47917420|NCT03828071|PROCEDURE|Autologous hematopoietic stem cell transplantation|"Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \< 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition."
47917421|NCT05977244|OTHER|HGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
47917422|NCT05977244|OTHER|LGI+palm olein|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
47917423|NCT05977244|OTHER|HGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
47917424|NCT05977244|OTHER|LGI+soy bean oil|A 5-hour postprandial feeding intervention with 1-weeks washout in between. Blood samples will be collected at 0 hour (baseline) and up to 5 hours after consumption of test meal.
47917425|NCT05081297|OTHER|Qigong|Qigong as a traditional chinese medicine technique, composed of several types of exercises: Baduanjin, taijiquan, yijinjing, baojiangong.
47917426|NCT01146587|DEVICE|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
47917427|NCT01146587|DEVICE|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
47917428|NCT01146587|OTHER|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
47917429|NCT01839669|DEVICE|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
47917430|NCT01839669|PROCEDURE|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
48269022|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
48269023|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
48269024|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
47917431|NCT01839669|DEVICE|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
47917432|NCT02366884|DRUG|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
47917433|NCT02366884|DRUG|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
47917434|NCT02366884|DRUG|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
47917435|NCT01731938|BIOLOGICAL|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
47917436|NCT01731938|DEVICE|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
47917437|NCT06083922|DRUG|Cyclophosphamide|Days 1, 8 and 15, Cycles 1-8
47917438|NCT06083922|DRUG|Bortezomib|Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
47917439|NCT06083922|DRUG|Dexamethasone|Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
47917440|NCT06083922|DRUG|Daratumumab|Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
47917441|NCT00272662|DRUG|peginesatide|
47917442|NCT02219867|DRUG|Ketamine|Drug (including placebo)
47917443|NCT05189041|OTHER|Aneurysmal pulsation in functional MRI|Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm
47917444|NCT01326338|DRUG|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
47917445|NCT02328378|PROCEDURE|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
47917446|NCT01446783|DRUG|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
47917447|NCT01446783|DRUG|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
47917448|NCT02780128|PROCEDURE|Biopsy|Needle or incisional tumor biopsy
48269025|NCT05801237|DRUG|PE0116&PE0105|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor
48269026|NCT00716469|DRUG|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
48269027|NCT02620904|DRUG|Mifepristone|
48269028|NCT02620904|DRUG|placebo|
48269029|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
48269030|NCT04959331|DRUG|Nitrofurantoin|Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
48269031|NCT04959331|DRUG|Pivmecillinam|Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
48269032|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g one sachet, taken orally, for one day
48269033|NCT00968422|DRUG|ABT-384|3 escalating doses will be administered daily for 21 days
48269034|NCT00968422|DRUG|Matching placebo to ABT-384|Doses will be administered daily for 21 days
48269035|NCT05409287|PROCEDURE|Immediate Implant Loading|A single implant crown will be mounted on the implant immediately after implant placement
47917449|NCT02780128|GENETIC|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
47917450|NCT02780128|PROCEDURE|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
47917451|NCT02780128|PROCEDURE|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
48269036|NCT05409287|PROCEDURE|Early Implant Loading|A single implant crown will be mounted on the implant 4 weeks after implant placement.
47917452|NCT02780128|OTHER|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
47917453|NCT02780128|OTHER|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
47917454|NCT02780128|OTHER|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
47917455|NCT02780128|OTHER|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
48269037|NCT05904392|OTHER|Music|Music played prior to injection
47917456|NCT02780128|BEHAVIORAL|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
47917457|NCT02780128|OTHER|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
47917458|NCT02780128|OTHER|Echocardiogram|The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
47917459|NCT02780128|DRUG|Ribociclib|Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
47917460|NCT02780128|DRUG|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
47917461|NCT00003590|DRUG|hydroxyurea|20 mg/kg/day PO
47917462|NCT05731349|OTHER|2018 Surviving Sepsis Campaign Hour-1 Bundle|"1. Measure lactate~2. Obtain blood cultures before administering antibiotics~3. Administer broad-spectrum antibiotics based on local guidelines~4. Begin fluid resuscitation with up to 30 mL/kg crystalloid for hypotension or lactate level ≥ 4 mmol/L.~5. Apply vasopressors if hypotensive during or after fluid resuscitation to maintain the MAP ≥ 65 mm Hg"
47917463|NCT04388462|OTHER|Finite element analysis|Biomechanical study to describe micromotion
47917464|NCT01316198|DIETARY_SUPPLEMENT|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
48269038|NCT05809141|DIAGNOSTIC_TEST|thromboelastography|Thromboelastography (TEG), a whole blood viscoelastic test. TEG detects the clotting time, clotting kinetics and clot stability to more comprehensively evaluate haemostatic status by several parameters, mainly including reactive time (R), kinetic time (K), angle (α), maximum amplitude (MA) and lysis-30 .
48269039|NCT06194357|OTHER|Mindfulness-based Health Qigong Intervention|Participants are introduced the practice of the most essential skills, particularly mindfulness, the basic movements of Qigong and the use of the resources package. Following the initial session, participants will kick off 8 bi-weekly online sessions of Mindfulness-based interventions approximately two hours each via the Mobile App. Afterwards, participants will be asked to practice Qigong for 30 minutes per day with five days weekly for another 8 weeks. Follow-up sessions will be conducted by an experienced coach via the Mobile App. After the first 16-week intervention, booster sessions will be provided every 3 months to revise the interventions and follow-up assessments will be completed every 6 months for 2 years.
48620125|NCT03007940|OTHER|Learning Sessions|The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
47917465|NCT01316198|DIETARY_SUPPLEMENT|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
47917466|NCT06531928|OTHER|chest tube withdrawal|The Effect of Chest Tube Withdrawal on Patients' Anxiety Levels in Thoracic Surgery Cases Performed with Video-Assisted Thoracoscopic Surgery
47917467|NCT00644891|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
47917468|NCT00644891|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
47917469|NCT03425253|DRUG|BELKYRA®|BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
47917470|NCT03425253|DEVICE|Juvéderm® VOLUMA™ with Lidocaine|Juvéderm® VOLUMA™ with Lidocaine VOLUMA™ was injected along the mandibular border.
47917471|NCT02106819|BEHAVIORAL|Testing of emotional communication ability|Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
47917472|NCT02106819|PROCEDURE|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
47917473|NCT00845793|BEHAVIORAL|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
47917474|NCT00423202|DRUG|ambrisentan|
47917475|NCT05168111|DIAGNOSTIC_TEST|Detect the serum sample|Detect the serum sample
47917476|NCT00561548|PROCEDURE|rectosigmoïdal biopsies|rectosigmoïdal biopsies
47917477|NCT03162367|BIOLOGICAL|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
47917478|NCT03162367|DRUG|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
47917479|NCT03387878|DEVICE|Intermittent Catheter|Intermittent urinary catheter for bladder drainage
47917480|NCT02870478|DRUG|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
47917481|NCT02897570|DIETARY_SUPPLEMENT|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
47917482|NCT02897570|DIETARY_SUPPLEMENT|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
47917483|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
48269040|NCT05281263|BIOLOGICAL|CPI-RSV-F Vaccine (BLB-201)|see arm/group description
48269041|NCT05586126|DRUG|Sevoflurane|sevoflurane inhalation
48269042|NCT04858893|DIAGNOSTIC_TEST|CoMDA associated with Neural Net 91 classificator|
48269043|NCT00995254|BEHAVIORAL|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
48269044|NCT05818670|DRUG|Tamsulosin|long term follow up
48269045|NCT05818670|DRUG|Tadalafil|long term follow up
48269046|NCT02431416|DRUG|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
48269047|NCT02431416|DRUG|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
48269048|NCT00141947|DRUG|bexarotene (Targretin)|
47917484|NCT02897570|DIETARY_SUPPLEMENT|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
47917485|NCT02897570|DEVICE|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
47917486|NCT02897570|DEVICE|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
47917487|NCT06333119|DIAGNOSTIC_TEST|modified rankin scale|"Modified Rankin Scale: The functional status of individuals with stroke is determined by this scale.~Modified Ashworth Scale: It allows determining the severity of spasticity. Tinetti Balance and Gait Scale: This scale helps determine the risk of falling by evaluating balance and gait.~Danish Prostatic Symptom Score: It allows to evaluate the storage and urinary functions of the bladder."
47917488|NCT00131053|DRUG|Methotrexate|
47917489|NCT00131053|DRUG|Prednisolone|
47917490|NCT00131053|DRUG|Dexamethasone|
47917491|NCT00131053|DRUG|Vincristine|
48269049|NCT00059202|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
48269050|NCT00059202|DRUG|Placebo|Placebo for Urso
48269051|NCT00748748|BIOLOGICAL|Culturelle|10\^10 Lactobacillus rhamnosus GG per capsule
48269052|NCT01629615|DRUG|BKM120|BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
48269053|NCT06126640|DRUG|SHR-A1811|Lyophilized powder injection, 100mg / bottle, intravenous drip
48269054|NCT06126640|DRUG|Trastuzumab Emtansine|Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
48269055|NCT04168294|DRUG|Propofol|patients in sedation group will be intravenous injected propofol in bolus
47917492|NCT00131053|DRUG|Pirarubicin|
47917493|NCT00131053|DRUG|Cyclophosphamide|
47917494|NCT00131053|DRUG|L-asparaginase|
47917495|NCT00131053|DRUG|Cytarabine|
47917496|NCT00131053|DRUG|Hydrocortisone|
48269056|NCT04168294|DEVICE|endoscopy|endoscopy system
48269057|NCT02972320|DRUG|temozolomide|temozolomide maintain therapeutic
48269058|NCT02651090|DRUG|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
48269059|NCT05869006|BEHAVIORAL|Designed SIA Instrument Supported Interpersonal Relations-Based Group Practice|Group Practice
47917497|NCT00131053|DRUG|Mercaptopurine|
47917498|NCT00763698|DEVICE|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
47917499|NCT01550848|DRUG|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
48269060|NCT05869006|BEHAVIORAL|Placebo group practice|The placebo control group application was carried out simultaneously with the intervention group application, and the group application without active curative content was applied.
48269061|NCT02631707|OTHER|High protein diet|The intervention diet is higher in protein than the control diet.
48269062|NCT01418495|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48269063|NCT01418495|OTHER|Pharmacological Study|Correlative studies
48269064|NCT06387680|OTHER|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial
48269065|NCT00635973|DRUG|Gefitinib (Iressa)|Iressa
48092272|NCT06613646|PROCEDURE|Ultrasound-guided injection of the subacromial bursa and pectoralis minor|"Patients will first receive an ultrasound-guided injection of the subacromial bursa. After the subacromial bursa injection, patients will be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the Numeric Rating Scale (NRS), and passive range of motion will be measured.~Following the subacromial bursa injection, patients will receive an ultrasound-guided injection of the pectoralis minor muscle. After the pectoralis minor muscle injection, patients will again be monitored for 1 hour, after which the level of relief in their complaints will be assessed using the NRS, and passive range of motion will be measured."
48092273|NCT06613646|DRUG|Lidocaine (drug)|5 mL of 2% lidocaine will be used as a local anesthetic for the subacromial bursa injection, and 4 mL of 2% lidocaine will be used for the pectoralis minor muscle injection.
48092274|NCT02850627|DRUG|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
48269066|NCT03409874|OTHER|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
48269067|NCT03409874|OTHER|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
48269068|NCT03409874|OTHER|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
47917500|NCT03986593|DEVICE|cryoablation|cryoablation of bone metastases by cone beam-CT image-guidance
48092275|NCT02850627|DRUG|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
48269069|NCT03409874|DRUG|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
48269070|NCT03409874|OTHER|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
48269071|NCT00323999|PROCEDURE|Hysteroscopic resection of fibroids, polyps and endometrium.|
48269072|NCT00130338|DRUG|Rivastigmine|
48269073|NCT00392028|DRUG|ertapenem|
48269074|NCT03110055|DRUG|Grazoprevir/Elbasvir|anti-viral treatment for HCV
48269075|NCT03110055|OTHER|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
48269076|NCT03110055|PROCEDURE|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
48269077|NCT04120558|OTHER|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
47917501|NCT00466141|BEHAVIORAL|Increased Exercise for weight loss maintenance|
47917502|NCT00466141|BEHAVIORAL|Daily Self-weighing for weight loss maintenance|
47917503|NCT00466141|BEHAVIORAL|Education for weight loss maintenance|
47917505|NCT03867370|DRUG|Toripalimab (JS001 )|Given IV
47917506|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
47917507|NCT03867370|DRUG|Toripalimab (JS001 ) Lenvatinib|Given IV 4 mg capsules
47917508|NCT04527900|DRUG|carboplatin and paclitaxel|carboplatin and paclitaxel 5-6 cycles (dosage per standard of care according to treating oncologist)
47917509|NCT04527900|RADIATION|pelvic IMPT (Intensity Modulated Proton Therapy)|whole pelvis will receive a total dose of 4500 cGy in 25 fractions to 5040 cGy in 28 fractions
47917510|NCT02410889|OTHER|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
47917511|NCT04359901|BIOLOGICAL|SARILUMAB|Single dose of 400 mg subcutaneous sarilumab
47917512|NCT00684060|BIOLOGICAL|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
47917513|NCT00684060|BIOLOGICAL|Placebo|One time infusion of 30 ml of HSA (5%)
47917514|NCT03386916|PROCEDURE|CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer|
48269078|NCT04120558|OTHER|Functional mobility tests and questionnaires|"Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
47917515|NCT05350696|DRUG|Erector Spinae plane block (plain pubivicaine)|"The erector spinae block is achieved by injecting the local anesthetic solution (with possible adjuvants) between the erector spinae muscles (iliocostalis, longissimus, spinalis/ from lateral to medial) and the transverse process .~The technique is performed under ultrasound guidance."
47917516|NCT05350696|DRUG|Intravenous morphine group|patients will receive 0.1 mg /kg of intravenous morphine diluted to 10 ml volume using saline at the end of the operation.
48269079|NCT05533749|DEVICE|GILL eHealth|The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
47917517|NCT02637349|BEHAVIORAL|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
47917518|NCT02637349|BEHAVIORAL|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
48269080|NCT05038137|BEHAVIORAL|Time restricted feeding|Participants will eat all food during a self selected 8 hour eating window prior to 8:00 PM.
48269081|NCT05038137|BEHAVIORAL|Control|Participants will have a daily eating period equal to or greater than 12 hours.
47917519|NCT03297905|BEHAVIORAL|Complementary and Integrative Therapies|Intervention time period is 3 - 6 weeks.
47917520|NCT03297905|BEHAVIORAL|Standard Rehabilitative Care|Intervention time period is 3 - 6 weeks.
47917521|NCT01896791|PROCEDURE|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation : the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
47917522|NCT01896791|PROCEDURE|Sham Stimulation|Sham Stimulation- appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
47917523|NCT04105491|DEVICE|IInvisalign® Aligners|Clear aligner orthodontic treatment
48269082|NCT01940484|DRUG|Methoxy polyethylene glycol epoetin beta|
47917524|NCT00504972|DRUG|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
47951147|NCT06681688|DRUG|Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}|"On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)"
47951148|NCT00729287|DIETARY_SUPPLEMENT|selenium|Given orally
48269083|NCT00124345|DEVICE|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
48620126|NCT03007940|OTHER|Coaching|A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
47951149|NCT00729287|OTHER|placebo|Given orally
48092276|NCT04093128|OTHER|herbal tea intervention|herbal tea intervention for 7 weeks
48269084|NCT00055380|PROCEDURE|Oral cytobrushing|
48269085|NCT03841422|PROCEDURE|video-assisted nasal self-packing|video-assisted nasal self-packing
47917525|NCT05368701|BEHAVIORAL|Volitional Help Sheet for self-harm|"The volitional help sheet (VHS) is a brief psychosocial intervention that significantly reduces thoughts and acts of self-harm in adults admitted to hospital following an initial episode of self-harm. It is based on IF-THEN statements that help people link critical situations to alternative appropriate responses. An example is: If I feel the urge to self-harm when I want to get relief from a terrible state of mind, then I will do something else instead of self-harming. IF-THEN statements are intended to act as automatic coping responses, especially in cases where people may feel the urge to self-harm.~The VHS has previously been successful in reducing self-harm in people recently admitted to hospital for self-harm. Recent data have also demonstrated that a web-based version of the VHS was acceptable among a large representative sample of UK adults with self-harm experiences. However, it is yet to be known whether this intervention is effective and acceptable among adolescents."
48269086|NCT03624257|DEVICE|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
47917526|NCT03181256|PROCEDURE|Biospecimen Collection|Undergo collection of sputum
47917527|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of nasal epithelium
47917528|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of buccal epithelium
48092277|NCT02814760|OTHER|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~* Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~* Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
48269087|NCT03624257|PROCEDURE|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
48269088|NCT06032221|DEVICE|Thermidas Vista Telehealth App|Thermal camera with telemedicine app
48269089|NCT00700804|BEHAVIORAL|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
48092278|NCT01304147|DRUG|Ketamine|A single dose of intranasal ketamine up to 50 mg
48092279|NCT01304147|DRUG|placebo|Single dose of saline intranasal
48092280|NCT02785055|PROCEDURE|Thoracic Epidural Placement|Thoracic Epidural Placement
48092281|NCT02785055|DRUG|Bupivacaine 0.05%|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
48092282|NCT02785055|DRUG|Hydromorphone 0.01mg/mL|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
48092283|NCT04108338|OTHER|Trial setting|Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
48092284|NCT00350181|DRUG|Sirolimus|Immunosuppressant beginning day -3 with 12 mg oral loading dose, 4 mg/day orally for adults
48092285|NCT00350181|DRUG|MMF|Immunosuppressant given through IV on day 0 at 15 mg/kg twice daily ≥ 2hr after the completion for the donor cell infusion
48269090|NCT00700804|BEHAVIORAL|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
47917529|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of blood
47917530|NCT03181256|PROCEDURE|Biospecimen collection|Undergo collection of urine
47917531|NCT03181256|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
47917532|NCT03181256|PROCEDURE|Computed Tomography (CT)|Undergo chest CT
47917533|NCT03181256|OTHER|Laboratory Biomarker|Correlative studies
48269091|NCT00988247|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
48269092|NCT00988247|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
48092286|NCT00350181|DRUG|BCNU|15 mg/kg, IV
48092287|NCT00350181|DRUG|VP-16|60 mg/kg, IV
48092288|NCT00350181|DRUG|CY|For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
48092289|NCT00350181|DRUG|FTBI|1320 cGy delivered in 11 120 cGy fractions over 4 day
48092290|NCT00350181|DRUG|BU|BU 1 mg/kg every 6hr x 4 doses, IV
48092291|NCT02684084|DRUG|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
48092292|NCT02684084|DRUG|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
48092293|NCT06319144|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
48092294|NCT06319144|OTHER|0.9% Normal Saline|Patients in the control group were infused intravenously with 0.9% Normal Saline (500 ml/h) in the PACU.
48092295|NCT00123799|PROCEDURE|Positron Emission Tomography Imaging|
48092296|NCT05630495|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
48092297|NCT04002362|DRUG|Triamcinolone Acetonide|An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) will be administered deep in the gluteal muscle by a trained registered nurse.
48092298|NCT03432533|DRUG|romosozumab HCP administration with PFS|210 mg romosozumab SC QM by HCP administration with 2 PFS
48092299|NCT03432533|DEVICE|romosozumab self-administration with AI/Pen|210 mg romosozumab SC QM by self-administration with 2 AI/Pens
48092300|NCT02948543|BIOLOGICAL|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
47917534|NCT03265652|DEVICE|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
48092301|NCT02948543|DRUG|Mitomycin (MM)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
48092302|NCT00971009|BEHAVIORAL|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
48092303|NCT00971009|BEHAVIORAL|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
48092304|NCT05669833|DRUG|Guselkumab|Guselkumab (GUS) subcutaneous injection
48092305|NCT05669833|DRUG|Golimumab|Golimumab (GOL) subcutaneous injection
48092306|NCT05064514|DEVICE|Transcatheter Tricuspid Valved Stent Graft|All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
48092307|NCT05209542|PROCEDURE|Hysterosalpingo-Foam Ultrasonography|"* Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection"
48092308|NCT05209542|PROCEDURE|Laparoscopy|• Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
48092309|NCT00232076|DRUG|ciclosporin|
48092310|NCT05974826|BEHAVIORAL|the SI! Program for Secondary Schools (NCT03504059)|The SI! Program is implemented from 1st to 4th grade of Secondary Schools. A total of 12 hours of classroom intervention per academic year, organized through three educational units, and with active and participative methodologies, and complementary intervention in the family setting, at school and on teachers.
47951150|NCT04378907|OTHER|ECIG Lab Session, 30 watts|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
47951151|NCT06557252|BEHAVIORAL|PDCA training|Improve diagnostic rate
47951152|NCT01347229|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
48092311|NCT05974826|BEHAVIORAL|the Fifty-Fifty Program (NCT02367963)|"1. Training stage: the focus is on improving individual health, through workshops (given in person by experts), and on the challenges of changing habits supervised and supported by the SHE Foundation~2. Peer-to-peer support group sessions: It is designed to make the subjects participate actively in their healthcare. Along the sessions subjects propose assumable health goals. Participants will be able to view videos with key messages from the workshops to continue the sustainability of the changes made, and the development of new ones. Peer-to-peer support group sessions have two phases: a) leaders will receive support from the Foundation; b) participants will become agents of change with the people around them, and also in their municipality with specific actions to promote health. The role of Foundation's will only be to monitor and resolve possible doubts."
47917535|NCT03265652|DEVICE|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
47917536|NCT04098484|OTHER|Control Trial|Participants will abstain from exercise throughout a 3-month period
48092312|NCT03389581|BEHAVIORAL|awareness and anxiety|before operation awareness and anxiety will recorded with STAIX-I score
48092313|NCT03929731|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Intravenous injection of dye-indocyanine green
48092314|NCT00331162|DRUG|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
48092315|NCT00331162|DRUG|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr \< 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature \> 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
47917537|NCT04098484|OTHER|Exercise Trial|Participants will execute a 3-month exercise training program
47917538|NCT02237222|OTHER|Gait rehabilitation|
48092316|NCT02692235|DIETARY_SUPPLEMENT|carnitine|1500 mg/d l-carnitine-l-tartrate
48269093|NCT01755663|DRUG|Ivabradine and Metoprolol|
47917539|NCT04830813|DRUG|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
47917540|NCT04830813|DRUG|Placebo|Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
47917541|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (A&B)|An app-based, evidence-based positive psychology intervention focusing on two modules: (A) Awareness \& Positivity and (B) Meaning and Accomplishment
47917542|NCT06148454|BEHAVIORAL|App-based Positive Psychology Intervention (C&D)|An app-based, evidence-based positive psychology intervention focusing on two modules: (C) Rapport \& Conflict Management and (D) Compassion \& Leadership
47917543|NCT05583578|DEVICE|Home-based mobility testing and active tDCS|"A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was"
48092317|NCT02692235|DIETARY_SUPPLEMENT|placebo|isonitrogenous
48092318|NCT01218503|BEHAVIORAL|CHOICES - obese|Standard group behavioral weight loss treatment
48092319|NCT04968782|OTHER|Patients with acute appendicitis|No intervention, single survey
48269094|NCT05535647|DRUG|Regorafenib and HAIC|Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
48269095|NCT05535647|DRUG|FOLFOX|Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
48269096|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
48269097|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
48269098|NCT01731002|DRUG|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
48269099|NCT00918944|OTHER|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~* A data entry tool for capturing asthma control data~* Standardized documentation templates to facilitate severity classification~* Order sets to facilitate ordering controller medications~* An asthma care plan that can be supplied to families"
48269100|NCT00918944|OTHER|Intervention|"Three alerts and two reminders will be programmed:~* Alert providers to enter asthma severity classification if none is on file~* Alert providers to prescribe controller medications for persistent asthma if none on file~* Alert providers to complete an asthma care plan if none on file~* Remind providers to review the asthma care plan if it is already on file by providing a link to the form~* Remind providers that educational content is available on-line by providing a web link"
48092320|NCT04655313|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
48092321|NCT02783482|BIOLOGICAL|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
48092322|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
48092323|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
48092324|NCT03647319|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
48092325|NCT01607970|DRUG|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
48269101|NCT03543085|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
47917544|NCT05583578|DEVICE|Sham tDCS|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
47917545|NCT00852839|DRUG|Placebo|Placebo to match oromucosal formulation of 552-02
47917546|NCT00852839|DRUG|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
47917547|NCT01590758|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
47917548|NCT01590758|DRUG|Topical placebo cream|14 days of treatment
47917549|NCT01590758|OTHER|Standard wound care|14 days of treatment
48269102|NCT04598490|DEVICE|Space closure into old extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket
48269103|NCT04598490|DEVICE|Space closure into recent extraction space|Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
48269104|NCT04905667|DRUG|GB221|6 mg/kg, single dose, intravenous infusion, 90-100 min
48269105|NCT04905667|DRUG|Herceptin|6 mg/kg, single dose, intravenous infusion, 90-100 min
47917550|NCT01047605|DRUG|Neurapas balance|6 tablets single dose
47917551|NCT01047605|DRUG|Pascoflair 425 mg|3 tablets , single dose
47917552|NCT01047605|DRUG|P-Tabletten weiß|3 tablets, single dose
47917553|NCT02105662|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
47917554|NCT05630963|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
48092326|NCT01077245|DRUG|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
48092327|NCT01077245|DRUG|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
48092328|NCT00825474|OTHER|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
48092329|NCT05429255|BEHAVIORAL|Aerobic Exercise|Bicycle training
48092330|NCT05429255|BEHAVIORAL|Exergame Training|Nintendo Wii
48092331|NCT02318485|BIOLOGICAL|Limbal epithelial stem cell graft|
48269106|NCT04500704|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
48269107|NCT04500704|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
48092332|NCT05381038|DEVICE|QPOP|QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
48092333|NCT05381038|DEVICE|CURATE.AI|"CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months."
47917555|NCT05630963|DRUG|PET radiotracer|"A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels."
48092334|NCT05381038|DRUG|Azacitidine + docetaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
47917556|NCT03872778|DRUG|[177Lu]-NeoB|\[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion
47917557|NCT03872778|DRUG|[68Ga]-NeoB|\[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation
48092335|NCT05381038|DRUG|Azacitidine + paclitaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
48092336|NCT05381038|DRUG|Azacitidine + irinotecan|"Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days."
48092337|NCT01955382|DRUG|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
48092338|NCT01955382|DRUG|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
48092339|NCT01955382|DRUG|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
48092340|NCT05475223|DIAGNOSTIC_TEST|End Tidal Carbon Monoxide Value|A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
48092341|NCT02860923|DRUG|Exenatide|
48092342|NCT02860923|DRUG|Placebo|
48269108|NCT05612919|OTHER|Red blood cell from umbilical cord blood|"Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of \<106/mm3.~Product validation is currently under development."
48269109|NCT05612919|OTHER|Red blood cell from adult donor|"Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise."
48269110|NCT04282005|PROCEDURE|Metabolic/Bariatric surgery|Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
48269111|NCT04282005|OTHER|Lifestyle and Diet|Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
48269112|NCT02254915|DEVICE|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
48269113|NCT02254915|DRUG|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
48092343|NCT04643353|DEVICE|Non-ablative vaginal Erbium YAG laser treatment|Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia) with SMOOTH mode setting, which enables non-ablative, thermal-only operation. The parameters are selected based on extensive preclinical and clinical studies.
48092344|NCT04643353|OTHER|PFE|PFE will be prescribed as it is already implemented in clinical practice (i.e. up to 2x 9 sessions with a pelvic floor physiotherapist of choice). Type of physiotherapy, number of completed sessions and duration of therapy will be recorded.
48092345|NCT06235879|OTHER|Control Group (Interscalene brachial plexus block)|"Patients will receive ultrasound guided interscalene brachial plexus block after induction of general anesthesia.~Scanning with SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) will be started just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle.~the transducer will be moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles at the level of the sixth cervical vertebra deep to the sternocleidomastoid muscle.~The needle will be then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction.~After negative aspiration and assurance that high resistance to injection is absent, 0.25% bupivacaine hydrochloride will be injected in a 5-ml increment below the lower root, between the 3 roots, and above the upper root.(Total amount is 15 ml of 0.25% bupivacaine hydrochloride)."
48092346|NCT06235879|PROCEDURE|Pericapsular nerve group (PENG) block|"Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia.~Using SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) ,A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head.~After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle can't be advanced further.~The needle tip will be placed between the deltoid muscle and subscapularis tendon, after a careful aspiration, 15 ml of 0.25% bupivacaine hydrochloride will be injected."
48269114|NCT03713190|COMBINATION_PRODUCT|Empagliflozin|Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
48269115|NCT03713190|DRUG|Placebo|A substance without specific pharmacology principles
48269116|NCT04947527|DRUG|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
48269117|NCT04947527|DRUG|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
48269118|NCT02529033|DEVICE|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
48269119|NCT01727089|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
48269120|NCT01727089|BIOLOGICAL|Bevacizumab|Given IV
47917558|NCT03872778|DRUG|LCZ696|dose strength 49/51 mg, film-coated tablets for oral use
47917559|NCT03966339|DRUG|Growth hormone|GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
47917560|NCT04491604|BIOLOGICAL|Topical Beremagene Geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
48269121|NCT01727089|OTHER|Laboratory Biomarker Analysis|Correlative studies
47917561|NCT04491604|OTHER|Placebo|Matching masked inactive topical gel
48269122|NCT01727089|OTHER|Pharmacological Study|Correlative studies
48269123|NCT04625777|BEHAVIORAL|Mindfulness Based Stress Reduction|"Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion."
48620127|NCT03007940|OTHER|Business as Usual|Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
48620128|NCT00757653|DEVICE|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
48620129|NCT00757653|DEVICE|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
47917562|NCT01620320|OTHER|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
47917563|NCT06190197|DRUG|Prophylactic antibiotics postoperatively.|Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
47917564|NCT00163254|DRUG|abciximab|
47917565|NCT00163254|DEVICE|stent and drug eluting stent|
47917566|NCT02782156|OTHER|Process evaluation|Adherence to screening and action algorithm
48269124|NCT04625777|BEHAVIORAL|Daily Examen spiritual practice|"The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~1. Become aware of God's presence;~2. Give thanks to God for everything in your life;~3. Review the events of the day guided by the Holy Spirit;~4. Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~5. Look toward tomorrow - what one thing should you do? Listen to what God is telling you."
47917567|NCT04357223|DRUG|extract from Angelica archangelica leaf|A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily
48092347|NCT05548530|PROCEDURE|Stereotactic intracranial hematoma puncture|Check the CT scan of the patient's brain, find out the largest hematoma level of the patient, measure the coordinates of the puncture center, locate and mark the skull surface according to the coordinates obtained from the measurement, select the puncture point under the stereotaxic instrument, and mainly avoid important blood vessels , nerves and functional areas. Use an electric drill to drill the puncture needle into the center of the hematoma, and slowly aspirate the hematoma from the side hole until the suction stops when there is resistance. The residual hematoma in CT and the location of the drainage tube were determined, and the position of the puncture needle was adjusted for the situation of brain CT. After the operation, according to the re-examination of cranial CT, urokinase was injected into the hematoma cavity through the drainage tube to dissolve the residual hematoma, and the operation process strictly followed aseptic operation.
47917568|NCT04357223|DRUG|Placebo|Placebo
47917569|NCT01649089|PROCEDURE|Conization|Undergo cone biopsy
47917570|NCT01649089|OTHER|Quality-of-Life Assessment|Ancillary studies
48092348|NCT05548530|PROCEDURE|decompressive craniectomy|Prior to the procedure, all patients obtained endotracheal intubation under general anesthesia following the informed consent provided by their family members. Upon identifying the hematoma's location through CT imaging, the surgeon made a linear or horseshoe-shaped incision on the scalp and subsequently opened the dura mater after creating a bone flap. The hematoma was punctured using a brain needle, allowing for effective decompression. The cerebral cortex was incised along the cerebral gyri, facilitating the separation of brain tissue to eliminate residual hematoma. Once hemostasis was ensured within the operative area, a silicone drainage tube was inserted, and the cranial bone flap was restored to its original position. In cases of severe brain edema or cerebral herniation, bone flap decompression was performed.
48620130|NCT00757653|DEVICE|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
48620131|NCT04120818|PROCEDURE|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
48620132|NCT04120818|PROCEDURE|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
48620133|NCT01415674|DRUG|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
48620134|NCT00536614|GENETIC|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
47917571|NCT01649089|OTHER|Questionnaire Administration|Ancillary studies
47917572|NCT01649089|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy
47917573|NCT01649089|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
47917574|NCT01640392|BEHAVIORAL|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
47917575|NCT04655937|OTHER|Acceptance and Commitment Therapy|9 x two hour remote sessions (50 minutes activity + 20 minute break + 50 minutes activity). Acceptance and Commitment Therapy (ACT) is a third wave transdiagnostic cognitive-behavioural therapy that supports clients to adjust to current experiences and 'commit' to behaviours that are congruent with their personal values, in order to promote psychological well-being and prevent future mental health crisis. ACT uses a variety of experiential techniques to support this process including: mindfulness practices; exercises to identify personal values; commitment to goals for valued living.
47917576|NCT00856232|BIOLOGICAL|Medical Air|Compressed medical air
48620135|NCT00497510|PROCEDURE|Chiropractic manipulation|
48620136|NCT05920226|DEVICE|pacemakers implantation and assessment of cardiac function and cardiac fibrosis|"150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia)."
47917577|NCT00856232|BIOLOGICAL|Oxygen|Medical Oxygen
47917578|NCT05466201|DRUG|Eltrombopag 25 MG Oral Tablet|Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.
48269125|NCT04625777|BEHAVIORAL|Stress inoculation combination|This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
48269126|NCT01961479|BEHAVIORAL|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
48269127|NCT01961479|OTHER|Waiting list|During the waiting period, participants receive no treatment.
47917579|NCT05466201|DRUG|Supportive care|Patients receive transfusion of blood products, including platelets and red blood cells.
47917580|NCT04231370|DRUG|Sintilimab|Sintilimab, 200mg, iv day1
47917581|NCT04231370|DRUG|Lenalidomide|25mg/d oral d1-14
47917582|NCT04009564|DIETARY_SUPPLEMENT|Date coffee|45 g of date seeds coffee in 280 ml of water
48269128|NCT03120169|OTHER|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
48620137|NCT05920226|DIAGNOSTIC_TEST|assessment of cardiac function and cardiac fibrosis|The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
48620138|NCT00831844|BIOLOGICAL|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
48269129|NCT03120169|OTHER|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
48269130|NCT06005168|DRUG|Cefazolin for Injection|2 grams or 3 grams based on standard of care or morphomic-based decision
48269131|NCT04742335|OTHER|Survey|Survey will be applied to the participants.
48269132|NCT03554044|DRUG|Anastrozole|Given PO
47917583|NCT04009564|DIETARY_SUPPLEMENT|Normal coffee|6 g of normal coffee in 280ml of water
47917584|NCT04009564|DIETARY_SUPPLEMENT|Placebo|water, food colouring and coffee flavouring
47917585|NCT00194649|DRUG|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
47917586|NCT01368328|DIETARY_SUPPLEMENT|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
47917587|NCT04043741|OTHER|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
47917588|NCT04043741|OTHER|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
47917589|NCT00618228|DRUG|Balsalazide|
47917590|NCT00077129|DRUG|carboplatin|
47917591|NCT00077129|DRUG|paclitaxel|
47917592|NCT01443624|DRUG|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
47917593|NCT04291404|DEVICE|Virtual Reality Distraction|Distraction therapy using a Virtual Reality (VR) device
47917594|NCT01801228|DRUG|Eplerenone|
47917595|NCT03710603|DRUG|Daratumumab|Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months \& after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.
48269133|NCT03554044|DRUG|Exemestane|Given PO
47917596|NCT03710603|DRUG|velcade|Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
47917597|NCT03710603|DRUG|Lenalidomide|Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
47917598|NCT03710603|DRUG|dexamethasone|Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
47917599|NCT01588470|DRUG|pioglitazone|45 mg per day for 6 months
48269134|NCT03554044|DRUG|Fulvestrant|Given IM
48269135|NCT03554044|DRUG|Letrozole|Given PO
48269136|NCT03554044|DRUG|Paclitaxel|Given IV
48269137|NCT03554044|BIOLOGICAL|Talimogene Laherparepvec|Given IT
48269138|NCT03554044|DRUG|Tamoxifen|Given PO
48269139|NCT03554044|DRUG|Nab paclitaxel|Given IV
48269140|NCT03554044|DRUG|Gemcitabine|Given IV
48269141|NCT03554044|DRUG|Carboplatin|Given IV
47917600|NCT03658096|DEVICE|pressure monitor ultrasound system|Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
47917601|NCT04872140|DIETARY_SUPPLEMENT|Low phytate pea powder|Exercise performance with low phytate pea powder
47917602|NCT04872140|DIETARY_SUPPLEMENT|Regular pea powder|Exercise performance with regular pea powder
47917603|NCT04872140|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Exercise performance with placebo (maltodextrin)
47917604|NCT04193644|BEHAVIORAL|Mindfulness and Self-Compassion focussed exercises during walking training|Mindfulness and Self-Compassion focussed exercises during walking training with moderate intensity
47917605|NCT04193644|BEHAVIORAL|Walking training|Walking training with moderate intensity
47917606|NCT04708249|DIETARY_SUPPLEMENT|D-chiroinositol|Supplementation with 600 mg of D-chiroinositol, two-times daily on an empty stomach, for 30 days.
47917607|NCT04387240|DRUG|Artemisinin / Artesunate|testing the drug capabilities in reducing the shedding and causing the testing for covid 19 to become negative
47917608|NCT04387240|OTHER|placebo|placebo or sham drug will be given to the second arm
47917609|NCT02113137|DRUG|group 1: drug: chlorine dioxide|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
47917610|NCT02113137|DEVICE|group 2: device: small tooth brush for tongue cleaning|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
47917611|NCT04516785|DIAGNOSTIC_TEST|FIT and VOC|Stool sample (FIT) analysed for blood in faeces and urine sample (VOC) analysed for the presence of volatile organic compounds
47917612|NCT01645943|PROCEDURE|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
47917613|NCT01278940|BIOLOGICAL|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
47917614|NCT01278940|PROCEDURE|IL-2|IL-2 were administrated by intranodal injection
47917615|NCT05519592|DRUG|Ropivacaine injection|Intramuscular ropivacaine injection (gluteus maximus and rectus femoris)
47917616|NCT05519592|DRUG|Sodium Chloride Injection|Intramuscular sodium chloride injection (gluteus maximus and rectus femoris)
47917617|NCT00579384|DRUG|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
47917618|NCT00579384|DRUG|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
47917619|NCT02675673|PROCEDURE|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
47917620|NCT02675673|PROCEDURE|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
47917621|NCT03083990|BIOLOGICAL|IBI305(Bevacizumab Biosimilar)|3mg/kg, infusion in 90minutes
47917622|NCT03083990|DRUG|Avastin(Bevacizumab)|3mg/kg, infusion in 90minutes
47917623|NCT02215980|DRUG|Lenalidomide|
47917624|NCT02215980|DRUG|Dexamethasone|
47917625|NCT05909488|BIOLOGICAL|1.5 x 10^6 UC-MSC + CM|1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
47917626|NCT05909488|BIOLOGICAL|5 x 10^6 UC-MSC + CM|5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)
47917627|NCT04655170|DRUG|Revefenacin (YUPELRI) & Formoterol (Perforomist)|Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
47917628|NCT04655170|DRUG|Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)|Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)
47917629|NCT01118000|PROCEDURE|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
48092349|NCT05548530|PROCEDURE|Neuroendoscopic|The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
47917630|NCT02194374|PROCEDURE|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
47917631|NCT02194374|DRUG|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
47917632|NCT02194374|DRUG|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
47917633|NCT02194374|DRUG|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4."
47917634|NCT02194374|DRUG|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
48092350|NCT05373719|OTHER|No intervention; observational|No intervention; observational
48269142|NCT04553107|BEHAVIORAL|Deprescribing Intervention|An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.
47917635|NCT06144580|OTHER|Community Health and Wellbeing Worker|Each CHWW will be deployed to cover 120 households in defined geographies ('villages') in North and South Westminster. LSOAs in the bottom 20% deprivation have been identified as priority areas for the CHWWs to be deployed. All households in the villages allocated to receive the intervention will be approached by the CHWW allocated to that village, irrespective of demographic characteristics and previous needs. CHWWs will visit all households each month, building a longitudinal relationship with each household so that problems arising from one month to the next can be captured in good time.
47917636|NCT00337675|DRUG|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
47917637|NCT00337675|DRUG|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
47917638|NCT00337675|DRUG|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
47917639|NCT06329193|OTHER|Mid-Season Camp Period Loading|The daily gym included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), crunches, sit-ups, reverse sit-ups, prone bridge, side bridge, bench press, mini squat (with body weight and/or ancillary equipment), lunge (with body weight and/or ancillary equipment), leg extension, leg curl, leg press, calf raises (with body weight and/or ancillary equipment), and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities). The field-based exercises included warm-up protocol (dynamic stretching of the major muscle groups of the upper and lower extremities and jogging), dynamic balance (with different balance trainer such as Both Sides Utilized \[BOSU\], trampoline), tactical training, passing, dribbling, and shooting practice, agility and speed practice, and cool-down protocol (dynamic stretching of the major muscle groups of the upper and lower extremities)
47917640|NCT04264897|DRUG|Metformin|"Metformin (Hunter Pharmacy) following a ramp up dosing protocol with a targeted dose of 1500 mg/day for 12 weeks."
48269143|NCT04553107|BEHAVIORAL|Usual Care|The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
48269144|NCT06173999|DRUG|SHR2554/CHOP|SHR2554 with CHOP
47917641|NCT04264897|DRUG|Placebo oral tablet|Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
47917642|NCT02047721|BEHAVIORAL|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
47917643|NCT02047721|BEHAVIORAL|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by \~2000 kcal/week.
47917644|NCT00985699|GENETIC|polymorphism analysis|
47917645|NCT00985699|OTHER|laboratory biomarker analysis|
47917646|NCT00985699|OTHER|pharmacogenomic studies|
47917647|NCT03790033|DRUG|Ucha-Shinki-Hwan|"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g"
47917648|NCT03790033|DRUG|Placebo|placebo granule
47917649|NCT03723967|DRUG|Durvalumab with Carboplatin/Paclitaxel|Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
47917650|NCT03976648|DRUG|GLPG1690|film-coated tablets of GLPG1690 to be administered orally
47917651|NCT01919281|BEHAVIORAL|strength training|
47917652|NCT01919281|BEHAVIORAL|interval training|
48269145|NCT06173999|DRUG|SHR2554/CHOEP|SHR2554 with CHOEP
47917653|NCT03438071|OTHER|Videoconferencing|Daily videoconference updates using Skype between parents of preterm infants hospitalized in NICU and the nurse taking care of their child, lasting 5 to 10 minutes, to check with her for the daily news and then see their child through the camera.
47917654|NCT02686723|OTHER|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
47917655|NCT02925338|OTHER|QOL questionaire|Health assessment questionnaire disability index for rheumatoid polyarthritis questionnaire
47917656|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
47917657|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
47917658|NCT03081936|DIETARY_SUPPLEMENT|Oral consumption of breast milk|Daily oral consumption of breast milk
47917659|NCT04346355|DRUG|Tocilizumab|In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours
48620139|NCT00831844|OTHER|laboratory biomarker analysis|Correlative studies
47917660|NCT01504646|DIETARY_SUPPLEMENT|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
47917661|NCT01504646|DIETARY_SUPPLEMENT|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
47917662|NCT01638182|DIETARY_SUPPLEMENT|Placebo|27 participants received for three months 1 placebo capsule per day
47917663|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
47917664|NCT01638182|DIETARY_SUPPLEMENT|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
48620140|NCT05417113|DRUG|Liposomal bupivacaine|liposomal bupivacaine
48620141|NCT05417113|DRUG|Bupivacaine|bupivacaine 0.25% in ESP blocks
48620142|NCT02485769|DRUG|PF-06650833|Suspension
48269146|NCT03710447|OTHER|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
48269147|NCT03710447|OTHER|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
48620143|NCT02485769|DRUG|Placebo|Suspension
47917665|NCT04461067|DIAGNOSTIC_TEST|ultrasonography|Ultrasonography of the stomach is performed to measure the diameter of the antrum
47917666|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 8 mg BID
47917667|NCT00505076|DRUG|MK-0777|MK-0777 GEM, 3 mg BID
47917668|NCT00505076|DRUG|placebo|2 tablets placebo BID
47917669|NCT04114617|OTHER|Starch-thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
47917670|NCT04114617|OTHER|Xanthan-gum thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
47917671|NCT04114617|COMBINATION_PRODUCT|Barium concentration|Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
47917672|NCT04276909|COMBINATION_PRODUCT|LUM Imaging System|LUM015 will be administered at the beginning of surgery. All subjects will have intraoperative imaging using the LUM imaging device.
48620144|NCT02485769|DRUG|PF-06650833|Tablet (Modified Release)
48620145|NCT02485769|DRUG|Placebo|Tablet (Modified Release)
48620146|NCT01369550|OTHER|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
48620147|NCT01369550|OTHER|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
47917673|NCT02177071|DRUG|INFLIXIMAB|
47917674|NCT02177071|DRUG|AZATHIOPRINE|
47917675|NCT02177071|DRUG|MERCAPTOPURINE|
47917676|NCT02177071|DRUG|Methotrexate|
47917677|NCT03963271|DIAGNOSTIC_TEST|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
47917678|NCT03702881|DEVICE|Bonded Spurs associated with posterior build-ups|Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
47917679|NCT03702881|DEVICE|Conventional bonded spurs|Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
47917680|NCT06287177|DRUG|Inclisiran|Injection
47917681|NCT02200809|DEVICE|MR-guided focal laser ablation|
47917682|NCT01763008|DRUG|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
47917683|NCT02396472|BEHAVIORAL|Order by time and topic|
47917684|NCT02396472|BEHAVIORAL|Order by information relevance|
47917685|NCT02396472|BEHAVIORAL|Order by social relationship|
47917686|NCT02396472|BEHAVIORAL|Order by help giving|
47917687|NCT02396472|BEHAVIORAL|Order by self-disclosure|
47917688|NCT03424941|DEVICE|FFR-guided PCI and TAVI|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
47917689|NCT03424941|DEVICE|CABG and SAVR|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
47917690|NCT01159431|DEVICE|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
47917691|NCT04599764|OTHER|HD-tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak direct currents.The respective excitability alterations-enhancement by anodal and reduction by cathodal tDCS-can last for over an hour after the end of stimulation.
47917692|NCT04599764|OTHER|computer-based cognitive training|Computer-based cognitive training (CCT) is a potentially important tool for individuals at risk of dementia. Cognitive training in healthy older adults and those at risk of dementia has been linked to benefits in cognitive functioning.
47917693|NCT03071250|PROCEDURE|Total knee or Hip Arthroplasty|Patients who received either a total knee or hip arthroplasty will be identified
47917694|NCT03956238|BEHAVIORAL|Alcohol intoxication|Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
47917695|NCT03956238|BEHAVIORAL|Objectification|Women assigned to objectifying gazes condition or eye contact control condition
48269148|NCT03710447|OTHER|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
47917696|NCT05483829|BEHAVIORAL|Adhera® Fatigue for Long COVID program|"Adhera® for the Long COVID program, which includes an application and a smartwatch, supported by digital health solution based on emotional and behavioral change techniques. Patient Adaptative Self-Management Content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 4 weeks to detect biometric and psychometric (patient-reported outcomes) information."
47917697|NCT04215497|OTHER|PSSE|"Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours.~Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home."
47917698|NCT00003497|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
47917699|NCT00924859|OTHER|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
48269149|NCT03710447|OTHER|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
48269150|NCT02363075|DRUG|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
48269151|NCT02363075|DRUG|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
48269152|NCT00893516|BIOLOGICAL|CHOP + CD4|
47917700|NCT01208753|DRUG|GLPG0555|two different aqueous formulations
47917701|NCT01208753|DRUG|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
47917702|NCT01208753|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
47917703|NCT00474279|DRUG|Orally active growth hormone secretagogue (MK-677)|
47917704|NCT00457106|DRUG|Paroxetine|
48269153|NCT00893516|DRUG|CHOP|
48269154|NCT00250692|DRUG|Nitrous Oxide|
48269155|NCT03089788|OTHER|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
48269156|NCT03089788|OTHER|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
48269157|NCT04886271|DRUG|HX009|Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
48269158|NCT03389945|PROCEDURE|25G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
48269159|NCT03389945|PROCEDURE|27G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
48269160|NCT01200784|DRUG|Nicotinamide|dosage
48269161|NCT06075823|DEVICE|TEER|transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation
48269162|NCT06075823|OTHER|Optimal Medical Therapy|optimal heart failure management of ATTR-CM
48620148|NCT01369550|OTHER|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
47917705|NCT00457106|DRUG|Risperidone|
47917706|NCT05960721|DRUG|Rivaroxaban 15mg|QD
47917707|NCT05960721|DRUG|Aspirin 100mg|QD
47917708|NCT05960721|DRUG|Clopidogrel 75mg|QD
47917709|NCT05960721|DRUG|Rivaroxaban 10mg|QD
48269163|NCT01726088|DRUG|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
48269164|NCT01736904|DRUG|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
48269165|NCT01736904|DRUG|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
48269166|NCT00397332|DRUG|Alefacept|IM Alefacept
48269167|NCT00441792|DRUG|Etomidate|Etomidate at induction dose based on weight
48269168|NCT00441792|DRUG|midazolam|Midazolam at induction dose based on weight
48269169|NCT01973309|DRUG|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
48269170|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
48269171|NCT01047202|BIOLOGICAL|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
48620149|NCT04831398|DIETARY_SUPPLEMENT|melatonin|A 5mg dose of melatonin spay will be delivered sublingually.
48620150|NCT04831398|OTHER|Placebo|10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray
48620151|NCT01796522|DRUG|progesterone 200 mg / day vaginally|
48620152|NCT01796522|DRUG|nifedipine (60 mg / day orally)|
48620153|NCT03319888|DEVICE|CPAP|continuous positive pressure in the airway
47917710|NCT05960721|DRUG|Rivaroxaban 2.5mg|B.I.D
47917711|NCT05952128|DRUG|Fluzoparib+ Dalpiciclib|"Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-3162~Drug Dalpiciclib 100mg/125mg/150mg PO qd, administered only from day1 to day 21 every cycle until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.~Other names: SHR-6390"
48269172|NCT01047202|BIOLOGICAL|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
48269173|NCT04957381|BEHAVIORAL|Group exercises|Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
47917712|NCT01051154|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
47917713|NCT01051154|DIETARY_SUPPLEMENT|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
47917714|NCT02604160|DRUG|LY3113593|Administered by slow intravenous (IV) infusion.
47917715|NCT02604160|DRUG|Placebo|Administered by slow intravenous (IV) infusion.
47917716|NCT03679507|PROCEDURE|Low Intensity Ultrasound Therapy|Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
47917717|NCT03679507|OTHER|Enhancing CBD oil penetration into joints by sonophresis|High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
47917718|NCT02249000|DEVICE|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
47917719|NCT06344897|OTHER|Kinesio taping|After appendicitis surgery, children will receive Kinesio taping in addition to the standard pain management applied in the clinic.
47917720|NCT05301478|DEVICE|standard of care insole|standard of care diabetic insole
47917721|NCT05301478|DEVICE|3D Printed Insole - pressure based|3D Printed Insole - pressure based
47917722|NCT05301478|DEVICE|3D Printed Insole - FEA|3D Printed Insole - FEA
47917723|NCT06165315|BEHAVIORAL|Parenting program|Villages in the intervention group will receive the parenting program. The parenting program consists of 20 total sessions, whereby groups will meet twice a month for 10 months.
47917724|NCT04855084|OTHER|Monolithic FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
47917725|NCT04855084|OTHER|Monolithic FDPs: after adjustment|After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.
47917726|NCT04855084|OTHER|Metal fused porcelain FDPs: before adjustment|Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
48269174|NCT06303661|DEVICE|Non-ablative Radiofrequency|There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C. When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.
48269175|NCT06303661|DEVICE|Low-intensity Shock Wave Therapy|The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis. The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
48269176|NCT05831982|OTHER|Person-centered strength training and nutrition intervention|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
48269177|NCT05831982|OTHER|Standard training|Training as usual when discharged with a rehabilitation plan.
48269178|NCT03227367|OTHER|other : PRF|mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
48269179|NCT05518604|BEHAVIORAL|Counseling with goal of modifying eating behaviors|Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol
48269180|NCT00138086|DRUG|Zevalin plus BEAM|
48269181|NCT04313556|PROCEDURE|Lateral patellar release|Arthroscopic lateral patellar reticular release
48269182|NCT01231165|DRUG|Amiloride|5mg/daily for 12th months
48269183|NCT01231165|DRUG|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
48269184|NCT00140764|DRUG|Metronidazole gel versus placebo gel|
48269185|NCT04650633|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
48269186|NCT05039060|DIETARY_SUPPLEMENT|Modified MAC diet (3-weeks)|"* Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis"
48269187|NCT02808104|DRUG|mazindol|
48269188|NCT06395493|PROCEDURE|Pilates Group|In this study, the participants in the Pilates group will undergo 2 sessions per week, for 12 consecutive weeks.
48269189|NCT06395493|PROCEDURE|Exercise Group|In this study, the participants in the Exercise group will undergo 2 sessions per week, for 12 consecutive weeks.
48620154|NCT03319888|OTHER|conservative treatment|conservative treatment group with lifestyle modifications
48620155|NCT03618277|PROCEDURE|Biopsy|Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
48269190|NCT06395493|PROCEDURE|Control Group|The participants in the control group, are those who either opt not to do the exercises or are on the waiting list for physiotherapy intervention. Therefore, they will not undergo any intervention for 12 consecutive weeks.
48269191|NCT00891995|DEVICE|Closed loop|Closed loop therapy for up to 4 to 6 days
47917727|NCT04855084|OTHER|Metal fused porcelain FDPs: after adjustment|After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.
48269192|NCT00891995|DEVICE|Home glucose monitoring|Standard diabetes management using a home glucose meter.
48269193|NCT00891995|DEVICE|Insulin pump|Insulin pump use for 2 years
48269194|NCT00891995|DEVICE|Continuous glucose monitor|Continuous glucose monitor use for 2 years
48269195|NCT06109194|OTHER|Joint mobilization|Grade III manual joint mobilization as standard-of-care physical therapy intervention
48269196|NCT04869241|DIAGNOSTIC_TEST|surface EMG|Carrying backpacks forward or backward
48269197|NCT05590520|PROCEDURE|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
48269198|NCT05590520|DRUG|GTN OINTMENT|0.2%GTN applied on anal canal.
48269199|NCT05772897|BEHAVIORAL|Circle of Security Parenting program|The Circle of Security Parenting (COSP) program is an 8- week group parenting course that was designed using decades of attachment research to foster a secure attachment by teaching parents to read and respond to infant cues, and to recognize the interplay between their own psychological and emotional experiences and the emotional regulation of their infants. The COSP program provides parents with relationship tools and techniques for understanding their children's needs in new ways that provide lasting security for the child and more satisfaction for the parent. There are two major themes in the program: 1) teaching parents how to read their children's behavior and use it as a guide for meeting their needs and 2) helping parents to understand how their own early attachment relationships have influenced them as a person, and how those influences show up in their parenting and impact their ability to help regulate their child and respond to their needs.
48269200|NCT01270334|OTHER|PH meassurment|meassuring ph USING PROBE
48269201|NCT00889044|DRUG|clopidogrel by chewing|600 mg clopidogrel by chewing
48269202|NCT00889044|DRUG|Placebo|Placebo p.o
48269203|NCT06415370|BEHAVIORAL|Home Delivered Healthy Meals Plus Social Interactions|"In-person delivery of HDHM with friendly visits and also Student Companion calls at least one time weekly.~Friendly visits last approximately 5-10 minutes and include brief wellness check questions such as, How are you doing today? Did you try \[HDHM recipe\] yesterday- how did it taste? Any suggestions for future flavors? What are some of the things you plan to do in the next few days? Is there anything else you want to share with me?~Student Companions call participants at least one time weekly to provide telephone reassurance- i.e., checking on the participant's well-being. These calls may also include referrals to appropriate resources such as NCCARE 360 (statewide network that connects individuals with complex health and social needs, to community resources and service)~Facilitators of the Friendly Visits and Student Companion calls will use an online system to facilitate the sharing of information that would benefit the participants."
48269204|NCT03450928|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~1. Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~2. Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~3. Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~4. After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
48269205|NCT05124223|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
48269206|NCT02567526|BEHAVIORAL|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
48269207|NCT02789813|DRUG|Valproic Acid|Once oral administration of 500mg before exposure therapy.
48269208|NCT02789813|DRUG|Placebo|Once oral administration of 500mg before exposure therapy.
48269209|NCT02789813|BEHAVIORAL|Fear reactivation|Fear reactivation before exposure therapy.
48269210|NCT02789813|BEHAVIORAL|No fear reactivation|No fear reactivation before exposure therapy.
48269211|NCT04406870|DRUG|Sirolimus Oral Product|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
48620156|NCT06082232|DRUG|Dexmedetomidine|Under strict aseptic conditions, a lumbar puncture will be performed with selective technique in sitting position at L2-3 or L3-4 interspaces with midline approach using a 25-G Quincke's needle. After achieving the free flow of cerebrospinal fluid, the study drug will be injected into the subarachnoid space, immediately after injection the patient will be asked for supine position.
48620157|NCT06082232|DRUG|Midazolam|1 mg midazolam intrathecal administration
48620158|NCT06082232|DRUG|Bupivacain|20 mg bupivacaine intrathecal administration
48620159|NCT05586737|DRUG|Rituximab|1 gram rituximab twice with two weeks interval
48620160|NCT02452190|DRUG|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
47917728|NCT04548869|DRUG|CDX-0159|Administered intravenously
47917729|NCT04331743|DRUG|Liposome-entrapped Mitoxantrone Hydrochloride Injection|Intravenous infusion
48620161|NCT02452190|DRUG|Placebo|Matching Placebo
48620162|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
47917730|NCT00984113|DRUG|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
48269212|NCT04406870|DRUG|propranolol|Patients with IHHE wil be treated with propranolol (1 mg / kg , twice a day, after meals), and then evaluation will be performed after 3 months (changes of the tumor size measured by ultrasound examination, and changes of tumor volume measured by abdominal enhancement CT).It will be admitted into the group once the tumor volume shrinks \<30%.Then propanolol combined with sirolimus will be given. Propranolol will be given at 1mg/kg,twice a day and sirolimus will be given at 0.8mg/m²(body surface area), twice a day. Recording and doing assessment of tumor size, adverse effects as well as complicated symptoms.
47917731|NCT00012597|PROCEDURE|Web-based telemedicine system for assessment of status of pressure ulcers|
48269213|NCT05503290|BEHAVIORAL|Lullaby Project|Our proposed intervention is the randomized participation of pregnant individuals with epilepsy in the Lullaby Project coordinated by a musical institution in Toronto. The Lullaby Project is an initiative first created by Carnegie Hall's Weill Music Institute. In this program, pregnant women and/or new mothers are paired with professional musicians to compose and write personal lullabies for their child(ren). Since its inception in 2011, the project has expanded globally and have helped numerous families write original lullabies for their newborns. The Lullaby intervention is unlike traditional music therapy as patients are actively participating in the creative song-writing process, not singularly in passive listening. Through sessions, participants will be given an opportunity to share experiences, experiment with musical arrangements, write lyrics, and receive positive feedback from the musician.
48269214|NCT04447885|DEVICE|weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
48269215|NCT00408863|DRUG|tibolone|tibolone 2.5 mg/day
48269216|NCT00408863|DRUG|placebo|
48269217|NCT02749214|OTHER|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
48269218|NCT02749214|OTHER|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
47917732|NCT01652469|DRUG|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
47917733|NCT01652469|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
47917734|NCT01933568|RADIATION|SABR|combined CFRT and SABR with concurrent cisplatin
47917735|NCT01933568|DRUG|Cisplatin|combined CFRT and SABR with concurrent cisplatin
47917736|NCT06326983|DRUG|Dexmedetomidine|Dexmedetomidine (1mcg/kg bolus given intravenously at induction of anesthesia
48269219|NCT02803333|OTHER|No Intervention|No intervention
48269220|NCT02613208|DRUG|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
48269221|NCT02613208|DRUG|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
47917737|NCT06326983|DRUG|Acetaminophen|Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).
48269222|NCT05014477|PROCEDURE|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
47917738|NCT06326983|DRUG|Ketorolac|Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
47917739|NCT06326983|DRUG|Morphine|Morphine (0.1mg/kg given intravenously at induction of anesthesia)
48620163|NCT00917696|PROCEDURE|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
48269223|NCT05888974|DIAGNOSTIC_TEST|Cardiac ultrasonography|During the inclusion visit, the patient will receive 3 cardiac ultrasonography. The first one will be performed at the time of the initiation of the 500mL vascular filling (T0), without delaying and the second one after the end of the filling (Tfin). These first two ultrasound are part of standard practice. A third will be performed 20 minutes after the end of the vascular filling (Tfin+20).
48269224|NCT05173584|DRUG|Levalbuterol|Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
48269225|NCT05173584|DRUG|Albuterol|Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
48269226|NCT05769660|DRUG|BEY1107|Administer twice daily, PO, 4-week continuous dose.
48269227|NCT05769660|COMBINATION_PRODUCT|Temozolomide|Administer once daily, PO, 5-day continuous dose, followed by 23-day rest period.
48620164|NCT00430365|DRUG|lenalidomide|oral drug
47917740|NCT04913870|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers treatment for 2 years.
47917741|NCT04913870|OTHER|Placebo|Placebo administration for 2 years.
47917742|NCT03779490|DEVICE|Transcatheter Tricuspid Valve Repair|Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR
47917743|NCT02113254|OTHER|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
47917744|NCT03334786|DRUG|FLX-787-ODT|Oral Disintegrating Tablet
47917745|NCT00171834|DRUG|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
47917746|NCT00036842|DRUG|arsenic trioxide|
47917747|NCT02683603|DRUG|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
48620165|NCT00430365|DRUG|placebo|oral placebo
48620166|NCT00234741|DRUG|STA-5326 mesylate|
48620167|NCT02213536|RADIATION|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
48620168|NCT02826096|BEHAVIORAL|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
47917748|NCT02683603|DRUG|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
48269228|NCT01814787|OTHER|CHICA Type 2 Diabetes Module|Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI \> 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
48269229|NCT02713451|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
48620169|NCT02865291|DEVICE|ForConti device|
47917749|NCT02683603|DRUG|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
47917750|NCT02683603|DRUG|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
47917751|NCT02683603|DRUG|AS colistin and imipenem|IV imipenem 1 g three times per day.
47917752|NCT02683603|DRUG|IV colistin and imipenem|IV imipenem 1 g three times per day
47917753|NCT03391245|DIAGNOSTIC_TEST|3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique|Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
47917754|NCT05011201|DEVICE|Dual Joint Visual Feedback without Scoring|Participants will walk on the treadmill while given instantaneous anterior and posterior foot position and immediate scoring information using the DJVF interface. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
48620170|NCT05190432|DIETARY_SUPPLEMENT|Taxifolin|A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
48620171|NCT05190432|DIETARY_SUPPLEMENT|Ergothioneine|An amino acid found in mushrooms, oats and some bean varieties.
48620172|NCT05190432|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose.
47917755|NCT05011201|DEVICE|Dual Joint Visual Feedback with Scoring|Participants will walk on the treadmill using the same DJFB with additional visual cumulative scoring on their performance. A pediatric physical therapist will provide (1) verbal encouragement and redirection of attention to the task as needed (2) verbal cueing to assist if difficulty in interpreting the feedback and appropriate modification is noted.
47917756|NCT00268255|DRUG|gefitinib|
47917757|NCT00268255|PROCEDURE|adjuvant therapy|
47917758|NCT00268255|PROCEDURE|enzyme inhibitor therapy|
47917759|NCT00268255|PROCEDURE|neoadjuvant therapy|
47917760|NCT00268255|PROCEDURE|protein tyrosine kinase inhibitor therapy|
48620173|NCT02702544|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
47917761|NCT00268255|PROCEDURE|radiation therapy|
47917762|NCT00268255|PROCEDURE|radiosensitization|
48269230|NCT02108925|DRUG|Oxygen|supplementary oxygen during exercise
48269231|NCT02182349|DRUG|BI 201335 NA soft gelatin capsule|
48269232|NCT02182349|DRUG|[14C]-BI 201335 NA radiolabelled drug|
48269233|NCT05980884|DIETARY_SUPPLEMENT|L-carnitine|Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days.
48269234|NCT03073746|OTHER|Health Search|
48269235|NCT03073746|OTHER|Standard Search|
47917763|NCT00591318|DRUG|ceftriaxone|2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
47917764|NCT00591318|DRUG|Normal Saline|50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
47917765|NCT01110642|DRUG|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
47917766|NCT03569345|DRUG|AFXl-assisted ingenol mebutate delivery|"Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30."
48269236|NCT00003632|BIOLOGICAL|filgrastim|
47917767|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion|Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.
47917768|NCT03337490|DRUG|Ivermectin 0.5% Topical Application Lotion [SKLICE]|Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.
47917769|NCT03337490|DRUG|Placebo 0% Lotion|Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
47917770|NCT03493217|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
48269237|NCT00003632|DRUG|carmustine|
48620174|NCT02702544|DEVICE|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
48620175|NCT06305013|OTHER|Pulseless electrical activity recognition|The ability of nurses to recognize the pulseless electrical activity in the questionnaire (electronic survey)
47917771|NCT05274893|DRUG|SYHX2011 and Abraxane®|IV infusion, 260 mg/m\^2
48443504|NCT04862572|OTHER|MRI scanning|"In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure."
48443505|NCT02778451|OTHER|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
47917774|NCT04380272|DIAGNOSTIC_TEST|The ROC analysis|The Brodsky clinical stage and ultrasonographic data of the participants will be matched, and the diagnostic value of the submental US in the classification of tonsil hypertrophy as non-obstructive and obstructive will be evaluated. A ROC analysis will be used to determine the optimal cut-off value.
48269238|NCT00003632|DRUG|cytarabine|
48269239|NCT00003632|DRUG|etoposide|
48269240|NCT00003632|DRUG|melphalan|
48269241|NCT00003632|DRUG|methotrexate|
48269242|NCT00003632|PROCEDURE|peripheral blood stem cell transplantation|
48269243|NCT03464669|OTHER|Prenatal education|Observational study : natural distribution of participants between groups
48269244|NCT02921451|DEVICE|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
48269245|NCT02733029|DRUG|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
48269246|NCT02733029|DEVICE|contrast enhanced ultrasonography|Injection of intravenous ultrasound contrast
48269247|NCT01261819|DEVICE|cystoscopy|
48269248|NCT02538302|DRUG|Minirin|Minirin 5 to 10 mg daily for 6 months
48269249|NCT02538302|DRUG|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
48269250|NCT03972072|OTHER|Pre-defined MR-linac based IGRT and plan adaptation protocol|daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6
48269251|NCT03972072|DIAGNOSTIC_TEST|salivary flow measurements|baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
48269252|NCT05038527|DEVICE|ABM/P-15 bone graft|RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
48269253|NCT01658267|OTHER|nutritional supplement|2 servings per day
48269254|NCT00358813|DRUG|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
48269255|NCT02368548|OTHER|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
47917775|NCT04814199|OTHER|Algorithm|Patients will have a printed algorithm to follow while they are in labour with an epidural for pain management.
47917776|NCT03637088|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
48269256|NCT02368548|OTHER|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
48269257|NCT02908516|DRUG|Tranexamic Acid|2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
48269258|NCT02908516|DRUG|Placebo|2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
48269259|NCT03463070|DRUG|rectal misoprostol 600mg|70 women who received 600 mg misoprostol postoperatively at operating theatre
48269260|NCT01135732|PROCEDURE|brush cytology|brush cytology during ERCP
48269261|NCT03780829|BEHAVIORAL|hypoxia|intermittent cycles of normoxia-hypoxia
48269262|NCT03780829|BEHAVIORAL|sham hypoxia|intermittent cycles of sham hypoxia
47917777|NCT03637088|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
48269263|NCT03780829|DRUG|D-cycloserine|NMDA agonist treatment
48269264|NCT03780829|DRUG|sham-NMDA agonist|sham-NMDA agonist treatment
48269265|NCT03780829|BEHAVIORAL|exercise training|bimanual massed practice training
48269266|NCT00332956|BIOLOGICAL|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
48269267|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
47917778|NCT00530816|DRUG|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
48269268|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
47917779|NCT06357676|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47917780|NCT06357676|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48269269|NCT00332956|BIOLOGICAL|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
48269270|NCT00018954|DRUG|asparaginase|
47917781|NCT06357676|PROCEDURE|Computed Tomography|Undergo CT scan or FDG PET/CT
48269271|NCT00018954|DRUG|cyclophosphamide|
48269272|NCT00018954|DRUG|cytarabine|
48269273|NCT00018954|DRUG|daunorubicin hydrochloride|
47917782|NCT06357676|PROCEDURE|Echocardiography|Undergo echocardiography
47917783|NCT06357676|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET/CT
47917784|NCT06357676|BIOLOGICAL|Glofitamab|Given IV
47917785|NCT06357676|DRUG|Ibrutinib|Given PO
47917786|NCT06357676|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47917787|NCT06357676|BIOLOGICAL|Obinutuzumab|Given IV
47917788|NCT03742466|DRUG|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
47917789|NCT03742466|DRUG|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
47917790|NCT04655651|OTHER|No intervention|There is no intervention for both groups.
47917791|NCT05003297|OTHER|hemogram inflammatory parameters|Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR)
47917792|NCT02565784|DEVICE|Restylane|Facial tissue augmentation
47917793|NCT02565784|DEVICE|Perlane|Facial tissue augmentation
47917794|NCT03975244|BEHAVIORAL|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
47917795|NCT00251043|BEHAVIORAL|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
47917796|NCT00251043|BEHAVIORAL|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
47917797|NCT03590964|PROCEDURE|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
47917798|NCT03590964|PROCEDURE|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
48269274|NCT00018954|DRUG|doxorubicin hydrochloride|
48269275|NCT00018954|DRUG|etoposide|
48269276|NCT00018954|DRUG|ifosfamide|
48269277|NCT00018954|DRUG|mercaptopurine|
48269278|NCT00018954|DRUG|methotrexate|
48269279|NCT00018954|DRUG|prednisone|
48269280|NCT00018954|DRUG|vincristine sulfate|
48269281|NCT00018954|PROCEDURE|conventional surgery|
48269282|NCT00018954|RADIATION|radiation therapy|
48269283|NCT00936988|DRUG|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
48269284|NCT02039739|DEVICE|Orsiro™ Drug Eluting Stent group|
48269285|NCT04058522|OTHER|Rotator cuff rehabilitation classes|
48269286|NCT04058522|OTHER|Individual Physiotherapy|
48269287|NCT04058522|DRUG|Triamcinolone Injection|Subacromial Injection 40mg/1ml
48269288|NCT03688217|BEHAVIORAL|Philani Intervention Model+MOVIE (PIM+M)|The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
48443506|NCT01688934|DRUG|V116517 50-mg tablets|Taken orally twice daily
47917799|NCT03499535|BEHAVIORAL|Radon & Smoking Synergistic|Participants viewed health information detailing the risks of developing lung cancer from exposure to radon gas, smoking, and their synergistic effects. This intervention represents the type of information most commonly presented in radon risk communications.
47917800|NCT03499535|BEHAVIORAL|Radon Only|Participants viewed health information detailing the risks of developing lung cancer from radon exposure. No information about the risks for developing lung cancer associated with smoking or its synergistic effect with radon exposure are included.
47917801|NCT03499535|BEHAVIORAL|Radon and Smoking Isolated|Participants viewed health information detailing the risks of developing lung cancer from radon exposure and smoking. No information describing the synergistic effects of smoking and radon exposure on lung cancer risk are included.
47917802|NCT03499535|BEHAVIORAL|EPA|Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
47917803|NCT03499535|BEHAVIORAL|Idaho|Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
47917804|NCT05726084|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
47917805|NCT05726084|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
47917806|NCT03595995|BIOLOGICAL|UB-621|Monoclonal antibody by SC injection
47917807|NCT03595995|OTHER|Placebo|The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
47917808|NCT00995293|DRUG|DOCETAXEL|Intravenous
47917809|NCT00995293|DRUG|CISPLATIN|Intravenous
47917810|NCT00995293|DRUG|5-FLUOROURACIL|Intravenous
47917811|NCT02230917|DRUG|Sotatercept|
47917812|NCT02230917|DRUG|Placebo|
47917813|NCT06341985|RADIATION|Exclusive radiotherapy|Curative radiotherapy treatment using 3D conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
47917814|NCT06462092|DRUG|Sacituzumab Govitecan|Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
47917815|NCT06462092|DRUG|Pemetrexed|Pemetrexed intrathecal chemotherapy is administered by intracerebroventricular or lumbar puncture. Pemetrexed intrathecal chemotherapy is divided into induction, consolidation and maintenance phases. Induction therapy was first performed with a single dose of 15 mg twice a week for 2 weeks for a total of 4 doses. This was followed by consolidation therapy, 1 time per week for 4 consecutive weeks for a total of 4 times.
47917816|NCT05118880|OTHER|Peer Bullying Counseling Program based on the Interpersonal Relationship Model|"The content of the program was created by the researcher in line with the issues that peer bullying children need support based on their bullying-related characteristics in the light of the relevant literature. Education topics prepared in this framework; 'Empathy', 'Peer Bullying', 'Anger Management' and 'Happy Friendship Relationships' were determined. The main nursing problem of the research is peer bullying. The main purpose of the Peer Bullying Counseling Program is to improve the empathy skills of the bullying child, to enable them to gain the right perspective towards bullying, to develop anger control, and to help them establish happy friendships. The content of the Peer Bullying Counseling Program; drawing, brainstorming, empathy demonstration, white paper activity, educational matching game, peer bullying demonstration, case studies, educational emotion puzzle game, anger control information video were applied using educational techniques."
47917817|NCT02933450|DRUG|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
47917819|NCT02408757|PROCEDURE|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
47917820|NCT01589991|DRUG|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
47917821|NCT04625517|PROCEDURE|Digital Mammography|Digital Mammography enhanced with an iodinated contrast agent
47917822|NCT04625517|DRUG|Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml|Injection of low osmolar contrast material during the digital mammography exam
47917823|NCT02560025|DRUG|Alisertib|
47917824|NCT02560025|DRUG|Cytarabine|
47917825|NCT02560025|DRUG|Idarubicin|
47917826|NCT02560025|DRUG|Daunorubicin|Can be used in place of idarubicin
47917827|NCT03795246|PROCEDURE|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
47917828|NCT03795246|BIOLOGICAL|Biological Test|"Blood test:~* FSH, LH, E2 and AMH~* 4 tubes of 7 mL"
47917829|NCT03795246|PROCEDURE|Pelvic Ultrasound|Antral Follicles Count
47917830|NCT03443583|OTHER|Immediate Dentin Sealing or Delayed Dentin Sealing|The main difference between the IDS and DDS technique lies in the fact that in IDS, a thin layer of bonding resin is applied immediately after tooth preparation and prior to impression taking, whereas in DDS this layer is applied immediately before cementation of the restoration.
47917831|NCT00349115|DRUG|Thalidomide|
47917832|NCT01658306|PROCEDURE|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
47917833|NCT01658306|PROCEDURE|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
48269289|NCT03688217|BEHAVIORAL|Philani Intervention Model (PIM)|The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
48269290|NCT00815958|PROCEDURE|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
48269291|NCT00815958|PROCEDURE|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
48269292|NCT00664248|DRUG|IDP-110|Topical application for 12 weeks
48269293|NCT00664248|DRUG|Clindamycin|Topical application for 12 weeks
48269294|NCT00664248|DRUG|Benzoyl peroxide|Topical application for 12 weeks
47917834|NCT00964210|DRUG|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
47917835|NCT04338061|DRUG|Evobrutinib|Evobrutinib twice daily (BID) in DBTP.
48269295|NCT00664248|DRUG|Vehicle|Topical application for 12 weeks
48269296|NCT05175170|BEHAVIORAL|Decision-aid|The decision aid consists of domains related to human reproduction, fertility, and fertility preservation. The domains address priority learning objectives in each domain to increase knowledge on the impact of gender-affirming medical interventions on fertility and fertility preservation options.
48269297|NCT00958672|OTHER|Endoscopic capsule|Endoscopic capsule
48269298|NCT00237679|BEHAVIORAL|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
48269299|NCT00237679|BEHAVIORAL|Unstimulated|No current is generated.
48269300|NCT04665557|BEHAVIORAL|Dove Confident Me Indonesia Single Session|"Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform."
48269301|NCT06267963|DRUG|Oral [14C]PF-07220060|A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.
48269302|NCT06267963|DRUG|Oral PF-07220060|A single oral dose of PF-07220060, will be administered as a liquid formulation in Cohort 2.
48269303|NCT06267963|DRUG|IV [14C] PF-07220060|A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
48269304|NCT03030963|OTHER|Equal ratio ventilation(ERV)|Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation
48620176|NCT02347787|BEHAVIORAL|IMPaCT|"The IMPaCT intervention has three stages:~1. Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~2. Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~3. Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
47917836|NCT04338061|DRUG|Placebo (match to Teriflunomide)|Placebo match to Teriflunomide once daily in DBTP.
47917837|NCT04338061|DRUG|Teriflunomide|Teriflunomide once daily in DBTP.
47917838|NCT04338061|DRUG|Placebo (match to Evobrutinib)|Placebo match to Evobrutinib BID in DBTP.
48269305|NCT03030963|OTHER|"I:E Ratio 1:2"|Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
48620177|NCT02347787|OTHER|Usual care|
48620178|NCT03755466|DRUG|"Baricitinib, olumiant®"|To examine the effects of baricitinib in RA patients
48620179|NCT03755466|DRUG|"Biologics"|To examine the effects of biologics in RA patients
48620180|NCT03755466|DRUG|Tofacitinib 5 MG [Xeljanz]|To examine the effects of tofacitinib in RA patients
47917839|NCT02523144|DRUG|Chloral Hydrate|70mg/kg chloral hydrate
47917840|NCT02523144|DRUG|Dexmedetomidine|2mcg/kg
47917841|NCT02523144|DRUG|Dexmedetomidine|3mcg/kg
47917842|NCT02523144|DRUG|Placebo|Flavored placebo syrup
47917843|NCT06315790|DRUG|Botulinum toxin A|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
47917844|NCT06315790|OTHER|Isotonic saline|Subcutaneously injections are given unilaterally in the face at predefined injection sites.
48269306|NCT02840851|DEVICE|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
48269307|NCT02840851|DEVICE|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
48269308|NCT00788905|DEVICE|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
48269309|NCT02381379|DRUG|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
48269310|NCT02949128|BIOLOGICAL|Ravulizumab|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to \< 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to \< 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
48269311|NCT02218229|DEVICE|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
47917845|NCT03456310|DIAGNOSTIC_TEST|transperineal ultrasound|"trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation."
47917846|NCT04608903|DIETARY_SUPPLEMENT|L-sulforaphane 1%|Administration of 4g L-sulforaphane per day, for 2 months
48269312|NCT05255380|BEHAVIORAL|Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day|The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
48269313|NCT05255380|BEHAVIORAL|Mindful awareness and reporting of current thoughts and feelings, 2 times/day|Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
48269314|NCT01920802|DRUG|olanzapine|5mg BID up to 4 weeks
48269315|NCT01920802|DRUG|iloperidone|6 mg BID up to 4 weeks
48269316|NCT01920802|DRUG|Placebo|BID up to 4 weeks
48269317|NCT05275569|PROCEDURE|True acupuncture + standard antiemetic treatment|"Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy."
48269318|NCT05275569|PROCEDURE|Sham acupuncture + standard antiemetic treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group)."
47917847|NCT04608903|DIETARY_SUPPLEMENT|Placebo Group|Administration of 4g corn starch colored with chlorophyll, per day, for 2 months
48269319|NCT00454207|DRUG|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
48269320|NCT04140214|DRUG|Hypertonic saline|Nebulized hypertonic saline solution (6%)
48269321|NCT04140214|DRUG|Carbocysteine 750 MG|Carbocisteine tablet
48269322|NCT02555163|DEVICE|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
47917848|NCT03747666|PROCEDURE|2.0 single locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.
47917849|NCT02212184|OTHER|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
48620181|NCT02818803|OTHER|Propolis|
48620182|NCT02818803|DRUG|Miconazole|
47917850|NCT02212184|OTHER|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
47917851|NCT00792493|DRUG|ORM-12741|Alternating panel multiple dose escalation
47917852|NCT02176252|DRUG|AZD1722|
47917853|NCT02176252|DRUG|Placebo|
47917854|NCT04133129|BEHAVIORAL|Low Volume-High Intensity Interval Training|On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
47917855|NCT04133129|BEHAVIORAL|Moderate Intensity Continuous Training|On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
47917856|NCT05963737|PROCEDURE|PS setting strategy in pressure-support ventilated patients|Use PMI guide PS setting in pressure-supported ventilated patients and keep PMI within the target range (0-2cmH2O).
48269323|NCT02555163|DEVICE|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
47917857|NCT01214395|DRUG|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
48269324|NCT02921386|DRUG|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
48269325|NCT01374061|DEVICE|Classical intubation|Classical intubation
47917858|NCT01613846|DRUG|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
48269326|NCT01374061|DEVICE|GLIDESCOPE|GLIDESCOPE intubation
47917859|NCT01613846|DRUG|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
47917860|NCT02405338|BIOLOGICAL|WT1/PRAME vaccination|
48269327|NCT02787772|PROCEDURE|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
47917861|NCT02766582|DRUG|Pembrolizumab|IV every 21 days at 200 mg
47917862|NCT02766582|DRUG|Carboplatin|IV every 21 days
48269328|NCT01578031|DEVICE|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
48269329|NCT01578031|OTHER|Usual Care|Usual care.
47917863|NCT02766582|DRUG|Paclitaxel|IV infusion (80mg/m2) every 7 days for 6 cycles
47917864|NCT01787721|PROCEDURE|Ankle manipulation|
47917865|NCT01787721|OTHER|Sham manipulation|
47917866|NCT04028544|DRUG|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
48269330|NCT06005584|DEVICE|Spinal Cord Stimulation - High Frequency SCS|"High Frequency-SCS consists of delivering electrical stimulation at frequencies equal to or greater than 1kHz.~This intervention will last up to 6 weeks."
48269331|NCT06005584|DEVICE|Spinal Cord Stimulation - Burst SCS|"Burst SCS consists of closely spaced, high frequency stimuli delivered to the spinal cord.~This intervention will last up to 6 weeks."
48269332|NCT06005584|DEVICE|Spinal Cord Stimulation - Sham SCS|This intervention will last up to 6 weeks.
48269333|NCT03595696|OTHER|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
48269334|NCT00657384|DRUG|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
48269335|NCT00657384|DRUG|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
48269336|NCT00531960|DRUG|Erlotinib|150 mg, PO, daily
47917867|NCT04028544|DRUG|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
47917868|NCT02497742|OTHER|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
47917869|NCT00357279|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
48269337|NCT00531960|DRUG|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
48269338|NCT00531960|DRUG|Standard platinum-based chemotherapy|At the discretion of the investigator
48269339|NCT01561651|OTHER|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
48620183|NCT03246945|BEHAVIORAL|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
48620184|NCT00025142|DRUG|FOLFOX regimen|
48620185|NCT00025142|DRUG|fluorouracil|
47917870|NCT00357279|DRUG|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
47917871|NCT05040503|BIOLOGICAL|Blood sampling at inclusion|"Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion"
47917872|NCT05040503|BIOLOGICAL|Blood sampling at 24 hours|Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)
47917873|NCT05040503|OTHER|Data collection|clinical and biological medical data for patients and general health data for healthy volunteers
47917874|NCT04382014|DIETARY_SUPPLEMENT|MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
47951153|NCT03796533|DRUG|Posaconazole|"* PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision."
48620186|NCT00025142|DRUG|gefitinib|
48620187|NCT00025142|DRUG|leucovorin calcium|
48620188|NCT00025142|DRUG|oxaliplatin|
48620189|NCT04861181|BIOLOGICAL|Pharmacokinetics, Dosage of Niraparib|The biological samples collected during the NIRAPK study will be blood only. The complete biological work-up will be processed in the same way as the usual routine care procedure. Serum niraparib will be measured over 3 courses just prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
48620190|NCT04293536|OTHER|Cases study|Patients with a retained device or almost
48620191|NCT05330975|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48620192|NCT05330975|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
47917875|NCT01783704|DIETARY_SUPPLEMENT|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
47917876|NCT01783704|BEHAVIORAL|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
47917877|NCT01783704|BEHAVIORAL|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
48269340|NCT03931304|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
48269341|NCT05210504|DRUG|L-Lysine|5g L-lysine in 50ml water, administered orally
48269342|NCT05210504|DRUG|Normal Saline|Normal (0.9%) Saline
47917878|NCT01256632|DRUG|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
47917879|NCT00795119|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
47917880|NCT04119830|BIOLOGICAL|Pembrolizumab|Given IV
48269343|NCT03765593|PROCEDURE|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
47917881|NCT04119830|OTHER|Questionnaire Administration|Ancillary studies
47917882|NCT04119830|DRUG|Rintatolimod|Given IV
47917883|NCT05867498|BEHAVIORAL|Concurrent exercise|Strength component (circuit-based exercise) and aerobic component (based on musicalized and outdoor activities).
47917884|NCT05867498|BEHAVIORAL|Aerobic exercise|Low-to-moderate-intensity continuous training and interval training based on musicalized and outdoor activities.
47917885|NCT03536117|BIOLOGICAL|MTBVAC|Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes
47917886|NCT03536117|BIOLOGICAL|BCG|Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.
47917887|NCT02401425|DRUG|Letrozole|
47917888|NCT02401425|DRUG|Misoprostol|
47917889|NCT02401425|OTHER|Placebo|
47917890|NCT02863536|DEVICE|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
47917891|NCT02641340|DRUG|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
48269347|NCT00789633|DRUG|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
48269348|NCT00789633|DRUG|Placebo|Matching placebo given orally twice daily
48269349|NCT00789633|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
48269350|NCT00490542|DRUG|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
48269351|NCT00490542|DRUG|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
48443507|NCT01688934|DRUG|V116517 30-mg tablets|Taken orally twice daily
47917892|NCT02641340|DRUG|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
47917893|NCT05828537|DEVICE|endotracheal tube|pediatric extubation
47917894|NCT00125606|PROCEDURE|conditioning for allogeneic HSCT|
48269352|NCT00584233|DEVICE|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
47917895|NCT04122651|PROCEDURE|'Off the shelf' toric lens|'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
47917896|NCT04122651|PROCEDURE|Tailored Toric lens|Fully targeted toric intraocular lens correction for corneal astigmatism
47917897|NCT02735135|DEVICE|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
47917898|NCT02735135|DEVICE|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
47917899|NCT02735135|DEVICE|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
47917900|NCT02735135|DEVICE|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
47917901|NCT06308705|DIAGNOSTIC_TEST|InBios Strongy Detect TM IgG ELISA|The InBios Strongy Detect TM IgG ELISA detects specific IgG antibodies to Strongyloides recombinant antigens NIE and SsIR in serum. It consists of an enzymatically amplified sandwich-type immunoassay. Positive and negative control samples are provided in the kit. The test will be run and interpreted according to the manufacturer's instruction. The results are expressed as OD and nOD. Clinical interpretation of the results will be done by analysis of the Receiver Operating Characteristics (ROC) curve generated using data from confirmed positive and confirmed negative samples.
47917902|NCT00262938|BEHAVIORAL|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
47917903|NCT00262938|OTHER|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
47917904|NCT00262938|OTHER|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
47917905|NCT00262938|OTHER|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
47917906|NCT00262938|PROCEDURE|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
47917907|NCT04665089|DRUG|Erythromycin|"Before each intervention (either at inclusion: day 0) and after the end of 5 days of erythromycin or placebo (day 6), the following dosages will be performed:~* Pro-inflammatory cytokine (TNF alpha)~* Anti-inflammatory cytokine (IL-10)~* Procalcitonin (PCT) Then, analysis of the variations in the TNF/ IL-10 ratio, the blood count, CRP and PCT parameters (between Day 0 and Day 6)"
47917908|NCT05813808|DIAGNOSTIC_TEST|ultra-low-dose computed tomography|7 ultra-low-dose computed tomography imaging
47917909|NCT05364359|DIETARY_SUPPLEMENT|Taste-test|Patients will receive a dietary counseling based on a simple taste-test
47917910|NCT05364359|OTHER|Standard care|Patients will receive a dietary counseling based on a standard dietary counseling for the patient group
47917911|NCT00993226|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
47917912|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
48620193|NCT05330975|BIOLOGICAL|Afluria® Quadrivalent|single-dose, pre-filled syringe for injection
47917913|NCT00993226|DRUG|Bupivacaine HCl Treatment 1c|40 ml
48620194|NCT05330975|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
47917914|NCT00993226|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
47917915|NCT00993226|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
47917916|NCT00993226|DRUG|Bupivacaine HCl Treatment 2c|40 ml
47951154|NCT06556966|DRUG|LY03020|LY03020 for one single dose
47951155|NCT06556966|DRUG|Placebo|Placebo for one single dose
48269353|NCT00584233|DEVICE|MRI|Breast MRI
48269354|NCT00544869|DRUG|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
48269355|NCT03871686|BEHAVIORAL|Brief Internet-based Behavioral Activation Intervention|A brief Internet-based behavioral activation intervention consisting of 4 sessions.
48443508|NCT01688934|DRUG|Naproxen 500-mg capsules|Taken orally twice daily
47917917|NCT03690635|PROCEDURE|VISTA (vestibular incision subperiosteal tunnel acess)|"A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity."
47917918|NCT02840617|DRUG|Indocyanine Green (ICG)|
47917919|NCT01531855|OTHER|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
47917920|NCT02999438|DEVICE|Actigraph to check activity levels at home|
47917921|NCT06523829|OTHER|GROUP GIVEN VIDEO TRAINING|Video-based training was given to this group.
47917922|NCT00732719|DEVICE|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
47917923|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
47917924|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
48269356|NCT01425099|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
47917925|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
47917926|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
47917927|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
48269357|NCT01425099|DRUG|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
48269358|NCT00434135|DRUG|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
48443509|NCT01688934|DRUG|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
47917928|NCT00732719|DEVICE|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
48269359|NCT01677247|DRUG|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
47917929|NCT04721587|DEVICE|Virtual Reality|"The patients of the VR Group will be subjected to the same hysteroscopy technique as the Standard of Care Group, but additionally a VR device will be applied where a distraction VR environment (Underwater Game) will be reproduced during the exploration"
47917930|NCT06092281|BEHAVIORAL|Questionnaire|"Patients after ESD need to complete a questionnaire on compliance-related education before discharge. The questionnaire includes the following information:~1. General information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)~2. Awareness of follow-up examinations (e.g., knowledge about the timing of the first follow-up, the process of follow-up examinations, related educational issues about follow-up, etc.)~3. Awareness of the disease (self-perceived tumor is benign or malignant, whether lifestyle changes are required, etc.)"
47917931|NCT06092281|BEHAVIORAL|Questionnaire without compliance-related education|Patients after ESD need to complete a questionnaire without compliance-related education before discharge. The questionnaire includes only general information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)
47917932|NCT03079102|DRUG|Nitric Oxide|An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
47917933|NCT03079102|DRUG|Nitrogen|Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
48269360|NCT01677247|DRUG|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
47917934|NCT04723264|BEHAVIORAL|Food protocols|"Participants will engage in several activities (i.e. offering a variety of foods and age appropriate games, etc.) regarding eating behaviors.~Participants will be asked to videotape interactions using a secure system. An alternative option may be provided if this videotaping is not acceptable."
47917935|NCT01579851|DRUG|Sugammadex|"sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations"
47917936|NCT04749511|BEHAVIORAL|Extrambulatory digital PROMs detection|The aim of the study is to investigate the validity of an alternative method of evaluating PROMs in which the questionnaire will be administered to the patient digitally (Google Forms) in an out-of-patient setting.
47917937|NCT00824733|DRUG|Trastuzumab|IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
47917938|NCT00824733|DRUG|PF03512676|Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
47917939|NCT00824733|OTHER|Correlative Studies|Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
47917940|NCT01037764|PROCEDURE|alloHCT|"\[ alloHCT arm \] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg\*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg\* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg\*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
47917941|NCT02535390|BEHAVIORAL|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
47917942|NCT02535390|BEHAVIORAL|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
47917943|NCT03567343|DIETARY_SUPPLEMENT|Proprietary Spearmint Extract Blend|Water extracted spearmint extract and green tea blend
47917944|NCT03567343|OTHER|Control|Placebo
47917945|NCT00190151|DRUG|ciprofloxacin|
48269361|NCT00211107|DRUG|Dapoxetine|
48443510|NCT06192095|DEVICE|Skin barrier film|Preventive use of skin barrier film after insertion of a vascular indwelling catheter before covering with transparent dressing +/- gauze
47917946|NCT03495778|OTHER|Test Granola|50.5 Test Granola
47917947|NCT03495778|OTHER|Control Granola|54.3 Control Granola
47951156|NCT01852305|OTHER|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI\>30) or moderate sleep apnea (AHI\>15 to \<30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI\>5 to \<15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
48443511|NCT01381653|OTHER|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
47917948|NCT02333617|OTHER|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point \[No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)\]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
48269362|NCT05850936|DRUG|Assigned Interventions: IOP-lowering eye drops|"IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the first choice for treatment.~1. If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added; If the IOP reduction of 10% is then not achieved at 1 month after adding Brinzolamide 1%, Alphagan 0.2% or Alphagan-P 0.15% eye drops will be added.~2. If an individual is allergic to Xalacom or feels uncomfortable, the eye drops will be switched to Azarga eye drops (combination drops, fixed Brinzolamide with Timolol); If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added.~3. The effect of IOP lowering would be assessed every week after applying each medication until the target IOP was achieved and follow up the schedule time. If an IOP reduction of 10% is then not achieved, the individual will be excluded from the study."
48269363|NCT06249750|DRUG|Immunotherapy|Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
48269364|NCT06249750|DRUG|Targeted therapy|Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.
47917949|NCT02333617|OTHER|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
48269365|NCT06249750|DEVICE|Hyperthermia|"Thermal stimulation is a rapidly developing physiotherapeutic tool, which is playing an increasingly important role in the field of comprehensive tumor therapy due to its unique low adverse effects and high compatibility. A large number of clinical studies have shown that the addition of heat stress to multimodal tumor therapy does not significantly increase toxicity and side effects, and the combination of heat stress with other therapies can have the effect of 1+1\>2. ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h."
48269366|NCT01894126|BEHAVIORAL|Two-way SMS Dialogue|
47917950|NCT02333617|OTHER|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
48269367|NCT01894126|BEHAVIORAL|One-way SMS Messaging|
47917951|NCT02333617|OTHER|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
47917952|NCT01651806|DRUG|Tranexamic Acid standard dose|Uniform 1 gram dosing
47917953|NCT01651806|DRUG|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
47917954|NCT01651806|DRUG|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
47917955|NCT01651806|DRUG|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
47917956|NCT01461109|DRUG|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
47917957|NCT03502551|DRUG|Ketamine|Ketamine infusion (0.5 mg/kg) over 40 minutes.
47917958|NCT02310334|OTHER|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
47917959|NCT02310334|OTHER|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
47917960|NCT06157788|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging and clinical assessment|"* fMRI task: In the active condition, video cues were utilized (lasting 10s) depicting everyday activities that trigger shoulder apprehension. Control videos were created to match the previous content, except for the absence of cues inducing shoulder apprehension. Following each video, a visual analog scale appeared for a duration of 2.5s, and participant were asked to rate the level of perceived apprehension, using an MRI-compatible response box. The rating scale consisted of nine steps, ranging from no apprehension to high apprehension. After providing their rating, participants had a rest period during which a fixation cross was displayed visually for 17.5s. Apprehension and control videos were shown in a pseudo-randomized fashion.~* General Linear Model Analysis of Task-Related Activation~* TICA Analysis of Functional Connectivity~* White Matter TBSS of DTI Data~* Voxel-based morphometry analysis of T1 images"
48269368|NCT04770519|GENETIC|whole genome sequencing or whole exome sequencing|Whole genome sequencing or whole exome sequencing will be performed for all enrolled participants.
48269369|NCT01928628|DRUG|Lercanidipine 10mg|
48269370|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg|
48269371|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg|
47917961|NCT03868644|BEHAVIORAL|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
47917962|NCT03868644|BEHAVIORAL|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
47917963|NCT02120040|OTHER|evaluation of anxiety with psychosocial scales|
47917964|NCT03849391|DIETARY_SUPPLEMENT|Skate group|This group takes 500 mg/day Skate Skin extract for 12 weeks
47917965|NCT03849391|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks
47917966|NCT02933684|DRUG|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
47917967|NCT02933684|BEHAVIORAL|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
47917968|NCT02933684|DRUG|Placebo|Administered in pill form.
47917969|NCT01868542|DRUG|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
47917970|NCT03603678|DRUG|BAY2253651|100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
47917971|NCT03603678|DRUG|Placebo|Matching Placebo dosing
47917972|NCT04125953|DEVICE|Andullation|Andullation is a horizontal vibration technique with stochastically modulated vibrations, build-in in a mattress.
47917973|NCT04125953|OTHER|Placebo|Placebo Andullation
47917974|NCT04865133|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47917975|NCT04865133|OTHER|Electronic Health Record Review|Medical record reviewed
47917976|NCT03876392|DIAGNOSTIC_TEST|magnetic resonance imaging|Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
47917977|NCT01433289|DRUG|Polyphenon E|There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
47917978|NCT01433289|DRUG|Placebo|
47917979|NCT02150538|DEVICE|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
47917980|NCT02150538|DEVICE|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
47917981|NCT00833664|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
47917982|NCT00833664|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
47917983|NCT02756806|DEVICE|Picosecond Q-switched laser|Each subject will receive laser treatments with Enlighten laser
47917984|NCT06060938|OTHER|Risk stratified arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every 1-4 years according to the risk-group)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)~* Provide a blood sample for analysis of 313 common genetic variants associated with risk of breast cancer (baseline)~* Receive a screening schedule recommendation."
47917985|NCT06060938|OTHER|Control arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every second year)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)"
47917986|NCT03614052|DRUG|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
47917987|NCT03614052|DRUG|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
47917988|NCT03761862|PROCEDURE|Neural Therapy|Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
47917989|NCT01627730|OTHER|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
47917990|NCT04599530|DEVICE|Talaris Demonstrator|The Talaris Demonstrator will be evaluated during daily activities and compared to the current prosthesis
47917991|NCT00239252|DRUG|Interferon alfacon-1|
47917992|NCT04950296|OTHER|Group I: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
47917993|NCT04950296|OTHER|Group II: L. plantarum UALp-05TM,|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
47917994|NCT04950296|OTHER|Microcrystalline cellulose|One capsule to be taken orally before lunch with a glass of water. In case the dose is missed, advise participant to take before dinner.
47917995|NCT04710472|DEVICE|Mentora App|"Participants will be invited to register their treatment side effects, symptoms, daily activities and exercise and QoL on a health app designed for this purpose.~The Mentora Health App includes a tool based on PRO-CTCAE™, a patient-reported outcome measurement system developed by the National Cancer Institute, version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria."
47917996|NCT03757390|DRUG|Exforge® tab 5/160mg, Crestor® tab 10mg|co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
47917997|NCT03757390|DRUG|CJ-30060 5/160/10mg|Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
48269372|NCT01928628|DRUG|Lercanidipin 10mg Placebo|
48269373|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg Placebo|
48269374|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg Placebo|
47917998|NCT04659811|DRUG|Pembrolizumab|200mg given intravenously (IV) on day 1 (to -1) of radiation and then every 3 weeks until progression or unacceptable toxicity
47917999|NCT04659811|PROCEDURE|Stereotactic Radiosurgery|Given in (a) single session treatment with margin dose of 15-20 Gy to the target for a maximum target volume of 8 cc or (b) five consecutive business days treatment to total dose of 25-30 Gy to the target for a maximum target volume of 20 cc when the target volume exceeds 8 cc or the target is in proximity to critical structures
47918000|NCT01204008|PROCEDURE|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
47918001|NCT01204008|PROCEDURE|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
47918002|NCT06517030|PROCEDURE|Tooth Extraction|After local anaesthesia, a buccal split-full-split-thickness envelope flap will be elevated, and the tooth will be extracted a-traumatically.
47918003|NCT06517030|PROCEDURE|Immediate Implant Placement|After providing that the extraction socket will meet the inclusion criteria, an implant will be immediately inserted with 1 mm of its transmucosal portion positioned under the interproximal bone crest.
47918004|NCT06517030|PROCEDURE|Socket reconstruction with DBBB+HA|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral with hyaluronic acid (DBBM+HA).
47918005|NCT06517030|PROCEDURE|Socket reconstruction with DBBB|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral (DBBM).
47918006|NCT06517030|PROCEDURE|CTG placement|Once the appropriate healing abutments will be installed, a CTG will be utilized as a barrier membrane. Then, the buccal flap will be coronally advanced and will be adapted to the healing abutment.
47918007|NCT06143930|OTHER|strengthening ex with BFR training|Therapeutic strengthening training with blood flow restriction of trained limb.
47918008|NCT06143930|OTHER|strengthening ex|Therapeutic strengthening training program for lower extremities.
47918009|NCT00600977|DRUG|Doxorubicine|9mg/m² J1 J4 2 COURSES
47918010|NCT00600977|DRUG|Doxorubicine pegylated|40 MG/M² J1 2 courses
47918011|NCT01105546|DRUG|recombinant activated factor VII|90 µg/kg/day i.v.
47918012|NCT01105546|DRUG|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
47918013|NCT05249478|PROCEDURE|bupivacaine and fentanyl|bupivacaine and fentanyl will be infused through the catheter
47918014|NCT06259656|DIAGNOSTIC_TEST|COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)|Maternal blood and cord blood were collected to test for COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)
47918015|NCT05622760|OTHER|Audiovisual information|The information provided to this group is in audiovisual format. This information is what has been designed with the aim of reducing the level of anxiety of patients who participate in cervical cancer screening.
47918016|NCT05622760|OTHER|Written information|The information provided to this group is in written format. This information is what is distributed to patients in the midwife's consultation and is available on the website of the health organization (Osakidetza)
47918017|NCT02230670|DRUG|IDN-6556|25 mg BID
48092351|NCT01653743|DRUG|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
48269375|NCT04497519|DRUG|inhaled hydroxychloroquine|ascending dose of iHCQ
48269376|NCT00435734|BEHAVIORAL|obesity intervention|
48269377|NCT04551014|DEVICE|Use of EverLift|Use of EverLift for submucosal injection prior to polypectomy
48269378|NCT04551014|DEVICE|Without use of EverLift|Without use of EverLift for submucosal injection prior to polypectomy
48269379|NCT03860948|DRUG|Savolitinib Test Preparation|Test preparation (T): dry granulation savolitinib tablets.
47918018|NCT02230670|DRUG|Placebo|
47918019|NCT01717599|DRUG|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
47918020|NCT01717599|DRUG|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
47918021|NCT05908565|BEHAVIORAL|Demographic Matching|At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
47918022|NCT05908565|BEHAVIORAL|Supervision Intensity|Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
47918023|NCT02447237|OTHER|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
48269380|NCT03860948|DRUG|Savolitinib Reference Preparation|Reference preparation (R): wet granulation savolitinib tablets.
48269381|NCT01857609|DRUG|Metformin|
48269382|NCT01857609|DRUG|Metformin and Pantoprazole|
48269383|NCT01857609|DRUG|Metformin and Rabeprazole|
48269384|NCT03669315|DEVICE|Transcranial Magnetic stimulation|Neuromodulation tool
48443512|NCT04625153|BIOLOGICAL|RC18 160mg|RC18 160mg is injected subcutaneously once a week for 48 times.
47918024|NCT05202340|OTHER|No intervention|No intervention
47918025|NCT05500144|OTHER|Not applicable- no intervention administered|Not applicable- no intervention administered
47918026|NCT01453062|DRUG|Arzerra|Treatment with Arzerra
47918027|NCT04314297|DRUG|Anlotinib In Combination With Durvalumab|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
47918028|NCT03367468|OTHER|Exercise|Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
47918029|NCT03367468|OTHER|Mobilization|Antero-posterior gliding, talocrural traction, metatarsal mobilization
47918030|NCT06118788|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
47918031|NCT01801267|PROCEDURE|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
47918032|NCT01801267|PROCEDURE|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
47918033|NCT06426589|OTHER|Resistence training and mediterranean diet|"Resistance training. Subjects assigned to the experimental group participated in resistance program twice a week (on Tuesdays and Thursdays) for a period of 12 weeks, totaling 24 sessions of 60 minutes each. Each session during this time was divided into three clearly differentiated parts: i) 5-minute warm-up comprised of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise.~Mediterranean Diet. In addition to the resistance intervention, the experimental group received a Mediterranean diet protocol based on the study by Ismail et al. \[34\] with the following meal plan: i) carbohydrates constituted 50% of daily intake; ii) fats repre-sented 35%; and iii) proteins accounted for 15%."
47918034|NCT01693978|BEHAVIORAL|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007)."
47918035|NCT01693978|BEHAVIORAL|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
48269385|NCT02022449|BEHAVIORAL|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
48269386|NCT05947240|OTHER|aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist.
48269387|NCT05947240|OTHER|active alternating movements for the upper limbs|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
48269388|NCT06202573|PROCEDURE|rhinoplasty|patients who have a step counter and we do not motivate them to walk
48269389|NCT05779709|OTHER|exercise|Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
48620195|NCT01767415|DRUG|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
47918036|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical creatine|
47918037|NCT03006861|DIETARY_SUPPLEMENT|3.5 mL/d topical placebo|
47918038|NCT03006861|DIETARY_SUPPLEMENT|21 g/d Oral creatine|
47918039|NCT03006861|DIETARY_SUPPLEMENT|21 g/d oral placebo|
47918040|NCT00123669|DRUG|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
47918041|NCT01821976|PROCEDURE|Ertl Procedure|
48269390|NCT05779709|OTHER|Urotherapy|Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
47918042|NCT01821976|PROCEDURE|Burgess Procedure|
47918043|NCT00040560|DRUG|111In-DAC|
47918044|NCT00040560|PROCEDURE|Diagnostic|
47918045|NCT04211675|BIOLOGICAL|Natural Killer Cells|NK cells dose 1x 108 cells/ kg on day 8 of each cycle
47918046|NCT04211675|DRUG|Temozolomide|Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
47918047|NCT04211675|DRUG|Irinotecan|Irinotecan 50mg/m2/dose IV daily on Days 1-5
47918048|NCT04211675|DRUG|Dinutuximab|Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
47918049|NCT04211675|DRUG|Sargramostim|Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
47918050|NCT03887702|OTHER|Best Practice|Receive best practice
47918051|NCT03887702|DRUG|Entecavir|Given PO
47918052|NCT03887702|DRUG|Tenofovir Alafenamide|Given PO
47918053|NCT03887702|DRUG|Tenofovir Disoproxil Fumarate|Given PO
47918054|NCT02059291|DRUG|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
47918055|NCT02059291|DRUG|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
47918056|NCT01279941|BEHAVIORAL|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
47918057|NCT03776006|PROCEDURE|Transperineal Laser Ablation|Transperineal Laser Ablation of the Prostate
48443513|NCT04625153|BIOLOGICAL|RC18 240mg|RC18 240mg is injected subcutaneously once a week for 48 times.
48620196|NCT03653741|DRUG|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
48620197|NCT05152784|DEVICE|Octaray catheter|A high density diagnostic catheter used for substrate and activation mapping.
48443514|NCT05764980|BEHAVIORAL|visual function evaluation|visual function evaluation
48620198|NCT05152784|DEVICE|Standard of care|VT ablation guided by substrate-mapping alone.
48269391|NCT00650858|DRUG|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
48269392|NCT03295214|DRUG|Acetaminophen|Acetaminophen given for pain relief
48269393|NCT02484469|DEVICE|The Virtual Human Project|Virtual Human educational videos about leprosy
48092352|NCT01653743|DRUG|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \>=18 mm; not more than 3 follicles each with a mean diameter of \>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
48269394|NCT04696640|BEHAVIORAL|Remote Patient Monitoring|Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
48092353|NCT01653743|DRUG|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
48092354|NCT06118619|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
48092355|NCT06613620|OTHER|Standard Treatment|"All participants will receive 4 weeks of intervention with a frequency of 3 times/week i.e. 10minutes of hot pack followed by post facilitation stretching and strengthening protocol.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
48092356|NCT06613620|OTHER|Visual and auditory feedback on SEMG biofeedback unit|Patients will receive SEMG biofeedback assisted post facilitation stretching and strengthening. Patients will receive 50-80%of their maximum voluntary contraction as per the biofeedback and gradually the contraction time will be increased.
48092357|NCT06613620|OTHER|Electrical muscle stimulation|Electrical muscle stimulation will be provided in addition to visual and auditory feedback by the SEMG biofeedback unit to the weak muscles until the patients achieve the desired level of contractions.
48269395|NCT06411093|COMBINATION_PRODUCT|Kinesiology tape wrapping|Place Kinesiology tape between the nail plate and the inflamed periungual granulation tissue in addition to conventional treatment for 3 months
48269396|NCT06411093|DRUG|Conventional treatment including silver nitrate cauterization|Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
48269397|NCT00885079|DRUG|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
48620199|NCT03917888|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
48269398|NCT00885079|DRUG|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
48269399|NCT00947531|DRUG|Cerebrolysin|
48269400|NCT00947531|DRUG|0.9% Saline Solution|
48443515|NCT02223585|OTHER|Animal-based protein diet|
48443516|NCT02223585|OTHER|Vegan-based protein diet|
48620200|NCT01965873|DIETARY_SUPPLEMENT|Enteral nutrition|Same as arm description
48092358|NCT03770377|DEVICE|Intermittent Perturbation to Continuous Perturbation|Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
48092359|NCT03770377|DEVICE|Continuous Perturbation to Intermittent Perturbation|Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
48092360|NCT04460443|DRUG|sofosbuvir|Sofosbuvir once daily
48092361|NCT04460443|DRUG|Sofosbuvir ledipsavir|Sofosbuvir ledipsavir once daily
48092362|NCT04460443|DRUG|Daclatasvir|Daklatasuvir tablets
48092363|NCT00522184|PROCEDURE|intra-articular injection of etanercept|
48092364|NCT00522184|PROCEDURE|intra-articular injection of steroid|
48092365|NCT02851810|BEHAVIORAL|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
48092366|NCT02851810|BEHAVIORAL|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
48092367|NCT02851810|BEHAVIORAL|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
48092368|NCT02851810|BEHAVIORAL|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
48092369|NCT02851810|BEHAVIORAL|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
47918058|NCT01170533|DRUG|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
48092370|NCT06233630|DRUG|Control Test - spinal anesthesia|No peripheral nerve block Only spinal anesthesia
48092371|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution ESPB|ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral
47918059|NCT02937402|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
48092372|NCT06233630|DRUG|Ropivacaine 0.2% Injectable Solution iPACK+ACB|ultrasound guided iPACK block + Adductor Canal Block
48092373|NCT00875147|DRUG|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
48092374|NCT02836145|OTHER|Differentiation of hiPSCs to skeletal muscle progenitors|
48092375|NCT06614413|OTHER|Neurodevelopment and behaviour assesment 2 years old|Mothers: Monthly visits guided or not by nutritionist (intervention vs control group) will consist in food questionnaires and 3-day food diary collection during pregnancy. Every three months during lactation. Children: From one year of age onwards, the KIDMED questionnaire will be administered quarterly Neurodevelopment and behavior assessment 18-24 months of age
48092376|NCT03781960|DRUG|Abemaciclib|Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
48092377|NCT03781960|DRUG|Nivolumab|Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
48092378|NCT04463043|DEVICE|SelfBACK app|The selfBACK is an evidence-based and data-driven decision support system (DSS) to support self-management of low back and neck pain delivered via a smartphone app. The selfBACK app provides individually tailored self-management plans to participants on a weekly basis by matching the participant's health information with targeted educational messages, physical activity advices and exercise recommendations via the DSS.
48269401|NCT04788420|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
48092379|NCT04463043|OTHER|e-Help webpage|The e-Help is an evidence-based web-based resource to support self-management of low back and neck pain. The e-Help webpage provides evidence-based self-management content equivalent to the selfBACK including educational messages, physical activity and exercise recommendations. Instructions on how to compose exercise programs will be given to participants, however no tailored self-management support will be offered in this solution.
48092380|NCT04463043|OTHER|Usual care|Usual care refers to seeking care or receiving treatments or help as usual.
48092381|NCT06401850|OTHER|Education Group|The intervention provided to the training group focuses on improving skills to cope with polycystic ovary syndrome. This intervention includes topics such as encouraging healthy lifestyle habits, raising awareness about nutrition and exercise, teaching stress management techniques, and offering strategies to support hormonal balance. It provides participants with the tools they need to understand and manage symptoms that impact their lives. It also provides a supportive environment, encouraging participants to share their experiences with each other and receive support. This intervention aims to improve individuals' overall quality of life while strengthening their ability to manage their own health and well-being.
48092382|NCT06401850|OTHER|Control Group|No intervention was made to the control group. This group did not receive additional training or support to cope with polycystic ovary syndrome. In this way, the effects of the control group on lifestyle, symptom management and overall quality of life were evaluated in comparison with the training group. This approach focuses on determining the direct effects of the intervention, while allowing to observe the natural course of the control group, and the results help to provide a clear assessment of the effectiveness of the intervention.
48092383|NCT03675204|OTHER|No intervention|No intervention
48092384|NCT04038281|OTHER|Sensory tests|Fat, bitter taste sensitivity and food preference measurement
48092385|NCT04514042|PROCEDURE|Peroral endoscopic myotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as peroral endoscopic myotomy. All the procedures will be documented with photographs or videorecordings.
47918060|NCT02937402|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
48269402|NCT05709808|OTHER|Kinesio-taping|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance
48269403|NCT05709808|OTHER|exercises|A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
48269404|NCT05709808|OTHER|mixed kinesiotape plus exercises|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance. A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
48269405|NCT00384020|DRUG|Paroxetine (Seroxat)|
48269406|NCT00384020|DRUG|Escitalopram (Lexapro)|
48269407|NCT03038308|DRUG|Ropinirole|0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
48269408|NCT02553694|OTHER|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
48269409|NCT02553694|OTHER|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
47918061|NCT01810614|OTHER|ADPKD Diet|Diet specifically designed for people with ADPKD
47918062|NCT00718653|DIETARY_SUPPLEMENT|Lutein|Lutein (12 mg/d)
47918063|NCT00718653|DIETARY_SUPPLEMENT|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
48269410|NCT02553694|OTHER|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
48269411|NCT02553694|OTHER|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
48269412|NCT04285333|PROCEDURE|fascia iliaca block|ultrasound guided block with 20 mL lidocaine 1.5%
48269413|NCT04285333|PROCEDURE|percapsular nerve group block|ultrasound guided block with 20 mL lidocaine 1.5%
48269414|NCT02266173|DRUG|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
48269415|NCT02229422|DRUG|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~* On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~* On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~* On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~* On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
48269416|NCT02351232|DRUG|Liraglutide|
48092386|NCT04514042|PROCEDURE|Flexible endoscopic septotomy|Patients will be hospitalized for 24 hours before procedure or at the day of procedure (depending on preference of each center). Procedures will be performed always using carbon dioxide insufflation and whenever possible under general anesthesia with endotracheal intubation by anesthesiologist recommendations. The procedure will begin after general endoscopic evaluation of the Zenker's diverticulum and esophagus. An incision of the bridge between the Zenker's diverticulum and the esophagus will be done using procedure as flexible endoscopy septotomy. All the procedures will be documented with photographs or videorecordings.
48092387|NCT05408650|OTHER|Aromatherapy Massage|"The PI will dilute pure lavender essential oil (Lavandula angustifolia) with almond oil at a dilution rate of 2.5% and apply it to the hands and feet of the patient.~* The massage technique including effleurage, petrissage, friction and lymphatic drainage on hands and feet will be adapted from Salvo, (2015) and Youssef and Hassan, (2017).~* The massage will be applied to the patient's hands and feet while the patient in semi-fowler's position."
48092388|NCT05404113|OTHER|sustained natural apophyseal glide|Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
48092389|NCT05404113|OTHER|deep friction massage|Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
48092390|NCT02889042|OTHER|MRI and biological assessment|performing a MRI and a biological assessment
48092391|NCT05646511|RADIATION|SCRT|5x5 Gy: 25 Gy
48092392|NCT05646511|DRUG|CAPOX|Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
48092393|NCT05646511|DRUG|CAPOXIRI|Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks, if the initial dose of irinotecan 150 mg/m²/day is tolerated, the dose can be increased to 200 mg/m²/day from the second cycle
48092394|NCT01442168|DRUG|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
48092395|NCT01442168|DRUG|atovaquone/proquanil|malanil according to label
40220860|NCT06051994|DEVICE|AI-guided VA ablation|Ablation of ventricular arrhythmia as guided by the ablation index, using Carto 3 electroanatomic mapping system, QDOT Micro ablation catheter, and multipolar mapping catheters (Optrell, Decanav)
48092396|NCT05908448|DEVICE|13 CGM (continuous glucose monitor)|The I3 CGM consists of three main components: a Sensor Pack (Applicator-Sensor assembly), a Transmitter Pack (with Bluetooth Low Energy (BLE)) and a mobile application (I3 CGM App). The user can view their glucose data on the I3 CGM App running on a compatible mobile device.
48092397|NCT06581874|OTHER|Clinical assessment by emergency psychiatrist|After a clinical assessment by the emergency department psychiatrist which does not lead to hospitalization, the patient will be given a psychiatric interview and sent home.
48269417|NCT02351232|DRUG|Placebo|
48269418|NCT00935389|DRUG|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
48269419|NCT02327260|BEHAVIORAL|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
48269420|NCT02327260|BEHAVIORAL|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
48269421|NCT04902365|OTHER|neurofeedback|(based on real-time functional magnetic resonance signals)
48269422|NCT06386848|DRUG|Botulinum toxin|Botulinum toxin doses injected in dystonia
48269423|NCT01233206|DRUG|Metformin|Metformin pre-treatment and co-administration
48269424|NCT01233206|DRUG|Placebo administration|Placebo pre-treatment and co-administration
47918064|NCT04167878|DEVICE|3D printed biodegradable cervical fusion cage|ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
48092398|NCT06581874|OTHER|Psychiatric consultation booked through Med@Psy platform|The patient will be seen within 48 hours after the consultation with his or her general practitioner by a psychiatrist taking part in the study.
48092399|NCT01077661|DRUG|Nebivolol|patients administrated Nebivolol according to the prescribing information
48092400|NCT04879355|DEVICE|Spinal needle (25G)|Fine needle aspiration from thyroid nodules using a 25G spinal needle.
48092401|NCT04879355|DEVICE|Conventional fine needle (25G)|Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
48092402|NCT03864731|DEVICE|Bone conduction device (ADHEAR)|adhesive bone conduction device
48092403|NCT04236986|DRUG|Lipopolysaccharide|LPS will be administered intravenously (1.0ng/kg; IV)
48092404|NCT02099539|BIOLOGICAL|N-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
48092405|NCT01540435|DRUG|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
48092406|NCT05750511|DIAGNOSTIC_TEST|molecular tissue analysis|
48092407|NCT05104762|DEVICE|plasmapheresis device|Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)
48092408|NCT05104762|DRUG|Intravenous immunoglobulin|group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.
48092409|NCT05997979|DRUG|Capsaicin 8% patch|Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
48092410|NCT05997979|DEVICE|Hydrocolloid dressing|Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
48092411|NCT02271594|BEHAVIORAL|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
48092412|NCT02271594|BEHAVIORAL|Standard education on injection technique|Usual and customary education and training normally provided injecting patients at the center
48092413|NCT04813211|PROCEDURE|mobile artificial cervical vertebrae replacement|"1. Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines."
48092414|NCT04813211|PROCEDURE|anterior cervical corpectomy and fusion|"1. Position: The patient is in a supine position with the neck hyperextended.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws."
48092415|NCT05590910|OTHER|Music|Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
48092416|NCT02193633|DRUG|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
48092417|NCT02193633|DRUG|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
48269425|NCT00505947|DRUG|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
48269426|NCT00505947|DRUG|placebo|placebo 5 mg/Kg body weight by intravenous infusion
48269427|NCT05792514|OTHER|stong,stamp,pyms|STRONG(screening tool for risk of nutritional status and growth) STAMP(screening tool assessment of malnutrition in pediatrics) PYMS
48269428|NCT01098890|DRUG|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
48269429|NCT01098890|DRUG|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
48269430|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
47918065|NCT04167878|DEVICE|PEEK cage|ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
47918066|NCT05025319|RADIATION|X-ray image|Bedside x-ray at intensive unit.
48269431|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
47918067|NCT03000439|DRUG|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
47918068|NCT03000439|DRUG|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
47918069|NCT03365843|DEVICE|Montage bone putty|Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.
47918070|NCT03365843|OTHER|Conventional Sternal Closure|Closure of sternum with standard wire cerclage.
47918071|NCT05647161|DEVICE|BAX602|Consists of the spray agent, spray set, and spraying device (regulator). Dissolves a polyethylene glycol (PEG) derivative with an N-hydroxysuccinimide group at the end (COH102) and a PEG derivative with a thiol group (COH206) as an anti-adhesion agent, which is sprayed on the surgical surface to reduce the degree, frequency, and extent of organ adhesions after surgery.
47918072|NCT05647161|DEVICE|No Intervention|Control Group
47918073|NCT06123234|DIETARY_SUPPLEMENT|Verum|Food supplement in single-dose vials
47918074|NCT06123234|OTHER|Placebo|Food supplement in single-dose vials
47918075|NCT04691414|GENETIC|NGS|next-generation sequencing on preexisting samples
47918076|NCT00152100|PROCEDURE|Stem cell transplant|
47918077|NCT00152100|DRUG|Filgrastim, Alemtuzumab|
47918078|NCT00152100|DEVICE|Miltenyi CliniMACS|
47918079|NCT01057641|PROCEDURE|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
47918080|NCT01057641|OTHER|physiotherapy|physiotherapy
47918081|NCT01103024|BIOLOGICAL|AIN457|
47918082|NCT01103024|BIOLOGICAL|AIN457|
47918083|NCT01103024|BIOLOGICAL|AIN457|
47918084|NCT01103024|BIOLOGICAL|Placebo|
47918085|NCT03219970|DRUG|Osimertinib|80mg oral daily
47918086|NCT01039129|PROCEDURE|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
47918087|NCT01039129|PROCEDURE|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
47918088|NCT01039129|PROCEDURE|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
47918089|NCT01827423|DEVICE|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
47918090|NCT03294564|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
47918091|NCT03294564|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
47918092|NCT03609606|DRUG|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
47918093|NCT03609606|DRUG|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
47918094|NCT03609606|DRUG|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
47918095|NCT03029988|DRUG|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
47918096|NCT03029988|PROCEDURE|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
47918097|NCT02452788|OTHER|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
47918098|NCT02204475|DRUG|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
47918099|NCT02204475|DRUG|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
47918100|NCT02204475|DRUG|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
47918101|NCT02204475|DRUG|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
47918102|NCT06386016|OTHER|artificial intelligence-based stethoscope|artificial intelligence-based stethoscope
47918103|NCT04264481|PROCEDURE|Adductor Canal Block|Ultrasound guided perineural injection of 5cc bupivacaine, 5cc lidocaine and 10 cc Normal saline
47918104|NCT04264481|PROCEDURE|Intra-Articular Steroid and Lignocaine Injection|Intra-articular injection of 40mg triamcinolone and 1-2 cc of lidocaine
47918105|NCT00263289|PROCEDURE|preprocedural fasting|
47918106|NCT02535156|DRUG|Risperidone|1 mg Risperidone
47918107|NCT02535156|DRUG|Placebo|Lactose Placebo
47918108|NCT04409860|RADIATION|CCRT|Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
48269432|NCT06548139|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
48269433|NCT06548139|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
48269434|NCT05646108|DEVICE|Endovascular treatment|Endovascular treatment
48269435|NCT05191160|OTHER|Soy Milk|250 mL, single-serve shelf-stable pack (Alpro Soya) 100 Kcal, 8g of soy protein
47918109|NCT04409860|DRUG|Paclitaxel, Cisplatin|The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
47918110|NCT01337037|DEVICE|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
47918111|NCT01337037|PROCEDURE|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
47918112|NCT01337037|PROCEDURE|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
47918113|NCT01337037|PROCEDURE|Open lobectomy|standard lobectomy procedure by thoracotomy approach
47918114|NCT03800420|DRUG|BBT-401-1S first and then Placebo|Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.
47918115|NCT03800420|DRUG|Placebo first and then BBT-401-1S|Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
47918116|NCT03297411|PROCEDURE|Brief Temporoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
47918117|NCT03297411|PROCEDURE|Ultrabrief Temporoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
47918118|NCT03297411|PROCEDURE|Brief Frontoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
47918119|NCT03297411|PROCEDURE|Ultrabrief Frontoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
47918120|NCT01155011|BEHAVIORAL|Physical Activity|"MIPARC will focus on 3 physical activity goals:~1. increasing walking behavior through gradually increasing step goals~2. increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~3. reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
47918121|NCT01155011|BEHAVIORAL|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
47918122|NCT01155011|BEHAVIORAL|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~1. health check~2. step goal check~3. barrier identification~4. problem solving~5. specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
47918123|NCT01155011|BEHAVIORAL|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
48269436|NCT05191160|OTHER|Cow's Milk|250 mL, single-serve shelf-stable pack (Organic Meadows) 130 Kcal, 8g of casein/whey protein
48269437|NCT05191160|OTHER|Sugar Sweetened Beverages|355 mL, single-serve cans 130-140 Kcal, 0g of protein
48269438|NCT00623571|OTHER|Treatment of elderly patients in a GMW|
48269439|NCT00623571|OTHER|Treatment of elderly patients in GHHS|
48269440|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)"
48443517|NCT00716690|PROCEDURE|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
47918124|NCT01155011|BEHAVIORAL|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
47918125|NCT01155011|BEHAVIORAL|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
47918126|NCT01155011|BEHAVIORAL|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
48092418|NCT02824289|BEHAVIORAL|Sun Safe Workplaces Program|The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
47918127|NCT01155011|BEHAVIORAL|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
47918128|NCT01155011|BEHAVIORAL|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
47918129|NCT01155011|BEHAVIORAL|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
48092419|NCT02824289|BEHAVIORAL|Attention Control|Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
48092420|NCT01981161|PROCEDURE|biological samples and clinical data|
48092421|NCT01364220|DRUG|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
48092422|NCT01364220|OTHER|Placebo tablet|Placebo tablet, once daily, for 14 days
47918130|NCT04343924|OTHER|Scuba diving activities|The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.
47918131|NCT04343924|OTHER|Virtual reality activities|The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
48092423|NCT05929937|DRUG|Opioids|Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)
47918132|NCT03233321|OTHER|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
47918133|NCT03233321|OTHER|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
47918134|NCT03545425|PROCEDURE|Biofluid samplings|Blood and Urine
47918135|NCT01952808|BEHAVIORAL|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
47918136|NCT01952808|BEHAVIORAL|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
48092424|NCT05929937|OTHER|No opioids|Standard of care, patients will not receive a prescription for opioids.
48092425|NCT01262495|OTHER|cryopreservation|cryopreservation of testicular tissue
48092426|NCT03519321|DEVICE|MID-C|The MID-C system is being connected to the spine via standard unilateral posterior approach. Pedicle screws above and below the main curve are being used to attach the device to the selected vertebra.
48092427|NCT05210894|BIOLOGICAL|Anti-IL8|
48092428|NCT00151008|DRUG|Bexarotene/NBUVB vs placebo NBUVB|
48092429|NCT04629248|DRUG|Obinutuzumab|Open Label: An intravenous (IV) infusion of 1000 milligram (mg) of obinutuzumab will be administered at Week 0, Week 2, Week 24, and Week 26. Participants who relapse during the open-label treatment period may be eligible for further treatment.
48092430|NCT04629248|DRUG|Tacrolimus|Open Label: Participants will receive tacrolimus at a starting oral dose (PO) of 0.05 mg/kilogram (kg) (participant dry weight) per day divided into two equal doses given at 12-hour intervals, titrated to serum trough level 5-7 Nanograms per millilitre (ng/mL). Optimized tacrolimus dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks. Participants who relapse during the open-label treatment period will have their dose of tacrolimus tapered over 8 weeks and may be eligible for further treatment.
48092431|NCT04629248|DRUG|Methylprednisolone|Premedication: Methylprednisolone 80 mg IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
48092432|NCT04629248|DRUG|Acetaminophen|Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
48443518|NCT03781739|DRUG|MANP|single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
47918137|NCT06531785|DEVICE|chest ultrasound|Lung ultrasound to early diagnose ILD among rheumatoid arthritis patients
47918138|NCT06137040|DRUG|Magnesium Sulfate within the first hour|"The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~\>40 kg: 2000 mg"
48092433|NCT04629248|DRUG|Diphenhydramine|Premedication: Diphenhydramine (50 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
47918139|NCT06137040|OTHER|No Magnesium sulfate within the first hour|The control group will not receive IV magnesium sulfate within the first hour of treatment.
47918140|NCT02492607|OTHER|Standard treatment|"wide local excision only or wide local excision and radiotherapy or mastectomy.~+/- hormonal therapy"
47918141|NCT02492607|DEVICE|digital mammography|annual mammography
47918142|NCT02492607|RADIATION|radiotherapy|according local policy
47918143|NCT03745885|DRUG|Supaglutide injection|Administered SC in the Supaglutide arms.
47918144|NCT03745885|DRUG|Placebo|Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
47918145|NCT06528405|DRUG|dapagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
47918146|NCT06528405|OTHER|Other anti-diabetic drug or no anti-diabetic drug|"Other anti-diabetic drug or no anti-diabetic drug for 90 days during the acute kidney disease period.~Other anti-diabetic drug includes metformin, sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitor, insulin, α-glucosidase inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonist."
47918147|NCT06528405|DRUG|empagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
47918148|NCT06528405|DRUG|canagliflozin|Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
47918149|NCT03287518|DIETARY_SUPPLEMENT|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
47918150|NCT03287518|DIETARY_SUPPLEMENT|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
47918151|NCT01511120|DRUG|Tetraspan|
47918152|NCT01511120|DRUG|acetated Ringer's solution|
47918153|NCT03753945|DIAGNOSTIC_TEST|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
47918154|NCT04939142|COMBINATION_PRODUCT|SVd (Selinexor+Bortezomib+dexamethasone)|Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
47918155|NCT04939142|COMBINATION_PRODUCT|Vd (Bortezomib+dexamethasone)|Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])
47918156|NCT01713101|DRUG|Early intravenous tranexamic acid administration|Initial history taking and physical examination --\> enrollment --\> 1g bolus over 10 minutes followed slow infusion over 8 hours.
47918157|NCT01713101|DRUG|placebo|
47918158|NCT06275542|DEVICE|Train of four monitoring device intraoperative|Only group B will receive reversal strategy based on the presence of TOF monitoring device prior to extubation. If they meet the criteria, patients will then be extubated.
47918159|NCT06275542|DRUG|Neostigmine|For subjects in Group A, the first researcher calculated the time of the last administration of the muscle relaxant and the subject's spontaneous breathing efforts. Neostigmine was administered based on the reversal protocol. For subjects in the TOF monitoring group (Group B), the first researcher attached the TOF monitoring device. After it was attached and turned on, TOF stimulation was provided without calibration, with a stimulation intensity of 50 mA. Measurements were taken in a 12-second cycle mode. Neostigmine was administered according to the measured TOF value at the start of skin/muscle closure as the protocol.
47918160|NCT06275542|PROCEDURE|Air chalenge prior to extubation|After surgery was completed and the TOF ratio was ≥ 0.90, the TOF device was removed, and extubation was performed in Group B. In Group A, after a minimum of 15 minutes following reversal, patients received only ambient air without supplemental O2. Extubation was performed if the patient could maintain an SpO2 \> 95% for a minimum of 3 minutes. If within 15 minutes after reversal the patient did not meet the extubation criteria, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed. If there was suspicion of opioid-induced hypoventilation, naloxone was administered at 0.4-0.8 mcg intravenously.If the patient was unable to maintain oxygen saturation for the 3-minute duration, oxygen supplementation was reinstated, the degree of blockade was reassessed, and a repeat dose of neostigmine and atropine was administered as needed.
47918161|NCT06275542|DEVICE|Train of Four monitoring device in recovery room|Upon arrival in the recovery room, all subjects were fitted with SpO2, EKG, NIBP monitors, and the TOF monitoring device. TOF values were measured by a second researcher who was unaware of the type of intervention. Measurements were taken twice sequential
47918162|NCT05790278|OTHER|Survey|Completion of a Purpose in Life Survey
47918163|NCT00749112|DRUG|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
47918164|NCT02678559|OTHER|tee measurement|
47918165|NCT02678559|OTHER|flotrac measurement|
47918166|NCT02678559|OTHER|clearsight measurement|
48092434|NCT04706247|OTHER|thoracic combined spinal epidural anesthesia|A combined spinal-epidural anesthesia set will be used for the block. Using the loss of resistance to saline technique, an 18 G Tuohy needle will be advanced to the T2-3 vertebral interspace with the mid-line approach. After confirming the epidural space, a 26 G pencil point spinal needle will be inserted slowly through the Tuohy needle to puncture the dura. After free flow of cerebrospinal fluid will be observed, local anesthetic wil be injected into the subarachnoid space over 15 secs. Then, an epidural catheter will be inserted into the epidural space.
48092435|NCT06085807|OTHER|Survey|Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
47951157|NCT01852305|DEVICE|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI\>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
47918167|NCT00006409|BEHAVIORAL|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
48092436|NCT03098264|PROCEDURE|Simultaneous surgery|Simultaneous surgery in complicated hepatolithiasis
48092437|NCT03098264|PROCEDURE|staged surgery|staged surgery in complicated hepatolithiasis
48269441|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules"
47918168|NCT03010644|OTHER|n/a - observational study|n/a - observational study
47918169|NCT02340871|GENETIC|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
47918170|NCT00047645|DRUG|Interferon-gamma 1b|200 mcg, SQ, 3x per week
47918171|NCT04730661|DIAGNOSTIC_TEST|Sit to stand test|"The sit to stand test (or STST) is a test consisting of performing as many sit-to-stand tests as possible in one minute, from a chair without armrests.~We note before and during this test, the SpO2 (pulsed oxygen saturation) (rest value and minimum value during exercise), heart rate (HR), dyspnea on the modified Borg scale as well as the number of chair lifts performed. completely and minimum SpO2 during the recovery phase.~The possible results from this one-minute test are as follows:~* If SpO2 \<90% or appearance of signs of respiratory distress: Immediate stop of the test and hospitalization~* SpO2 \<90% or decrease in SpO2 ≥ 4% during the test or during the recovery period: Hospitalization~* SpO2 ≥90% and no decrease in SpO2 ≥ 4% during the test or during the recovery period which will be 3 minutes maximum: discharge."
47918172|NCT04072406|OTHER|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
47918173|NCT04072406|OTHER|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
47918174|NCT02663544|OTHER|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
47918175|NCT02663544|OTHER|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
47918176|NCT02663544|OTHER|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
47918177|NCT02943304|OTHER|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
47918178|NCT01008423|DRUG|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
47918179|NCT01008423|DRUG|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
47918180|NCT06297772|DRUG|Decitabine|decitabine 20mg/m2 per day for consecutive 5 days
47918181|NCT06297772|DRUG|Fludarabine Injection|fludarabine 30mg/m2 per day for consecutive 5 days
47918182|NCT06297772|DRUG|Busulfan Injection|Busulfan 3.2mg/kg per day for consecutive 4 days
47918183|NCT02591498|BEHAVIORAL|Computerized cognitive training|
47918184|NCT02323607|DRUG|Pacritinib|Given PO
47918185|NCT02323607|DRUG|Cytarabine|Given IV
47918186|NCT02323607|DRUG|Daunorubicin Hydrochloride|Given IV
47918187|NCT02323607|DRUG|Decitabine|Given IV
47918188|NCT02323607|OTHER|Laboratory Biomarker Analysis|Correlative studies
47918189|NCT02323607|OTHER|Pharmacological Study|Correlative studies
47918190|NCT03113136|BEHAVIORAL|Low wattage E cigarette device|The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
47918191|NCT03113136|BEHAVIORAL|High wattage E cigarette device|The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
47918192|NCT03113136|BEHAVIORAL|Usual brand cigarette|The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
47918193|NCT00448643|RADIATION|Vaginal Brachytherapy|High-Dose Rate \[HDR\] or Low-Dose Rate \[LDR\], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
47918194|NCT00448643|DRUG|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
47918195|NCT00448643|RADIATION|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated \[2-Levels\]; 6 -8 hours after administration of Cisplatin chemotherapy
47918196|NCT02273596|DRUG|ALXN1840|Individualized oral doses of ALXN1840.
47918197|NCT03854994|BIOLOGICAL|Anti-CD19 CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
48092439|NCT03366272|DRUG|Nivolumab|eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
48092440|NCT03366272|DRUG|Rituximab|eight cycles of R-GemOx in 2-wk intervals
48092441|NCT03366272|DRUG|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
48092442|NCT03366272|DEVICE|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
48092443|NCT02967666|RADIATION|FDG ligand|
48092444|NCT02967666|RADIATION|DOTANOC ligand|
48269442|NCT00728221|DIETARY_SUPPLEMENT|Cornstarch|Placebo
48443519|NCT05707676|DRUG|LB4330|LB4330
47918198|NCT01788215|DRUG|doxycycline|200mg/day in divided doses of 100mg twice daily
47918199|NCT01788215|OTHER|Sugar Pill|1 pill twice a day
47918200|NCT00878761|BIOLOGICAL|STX-100|SC, single dose followed by multiple dose
47918201|NCT00973817|BIOLOGICAL|ELAD plus standard of care treatment|Use of ELAD plus standard of care
47918202|NCT00973817|OTHER|Standard of care|Standard of care in the treatment of AOCH will be administered
47918203|NCT06027957|BIOLOGICAL|anti-CD19 CAR T-cells|"For Biological: CD19 CAR T-cells~* Dose: 1-2.10e6 cells/kg of weight~* Route: intravenous infusion~For Chemotherapy Drug:~* Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3.~* Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3.~* Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after."
47918204|NCT05715112|PROCEDURE|Graded Motor Imagery|GMI consisting of education, sensory integration of the foot using contact, flooring samples, immersion, and two point discrimination.
47918205|NCT03309033|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47918206|NCT03309033|OTHER|Questionnaire Administration|Complete questionnaire
47918207|NCT05546580|DRUG|Iadademstat|iadademstat oral solution
48092445|NCT06613503|DEVICE|AI-supporter|rticipants in the experimental group will use the AI-supporter, an intelligent excretion management robot. This device utilizes AI-driven visual recognition technology to automatically detect urine and feces, followed by a cleaning and drying process. When the AI-supporter detects excretion, it activates an automated sequence that washes, dries, and sanitizes the perineal area without requiring the caregiver to remove the diaper. The AI-supporter also records relevant data, such as the time, frequency, and weight of excretion, for further analysis. This intervention is designed to reduce the incidence of urinary tract infections (UTIs) and incontinence-associated dermatitis (IAD), as well as lessen the workload for caregivers
47918208|NCT05546580|DRUG|Gilteritinib Oral Tablet|120 mg Gilteritinib
47918209|NCT05680441|OTHER|Peirodontal clinical measurements and gingival crevicular fluid sampling|The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
47918210|NCT04313140|DIAGNOSTIC_TEST|Diagnostic test|"The intervention occurs only one time (for 2h30), the MRI examination is divided as follow:~* Cinicial MRI (50 minutes)~* Research MRI (Phosphorus Spectroscopy, Sodium Imaging)"
47918211|NCT05553301|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5407|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
47918212|NCT05553301|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
47918213|NCT05553301|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
47918214|NCT05553301|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
47918215|NCT00000303|DRUG|Baclofen|
47918216|NCT00667108|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
47918217|NCT00667108|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
47918218|NCT00667108|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
47918219|NCT02445794|DRUG|Low dose cohort|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
47918220|NCT02445794|DRUG|High dose cohort|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
48092446|NCT05972616|BIOLOGICAL|Natural Matrix Protein (NMP)|human bone allograft
48443520|NCT00252720|DRUG|candesartan|32 mg oral tablet
47918221|NCT00246740|DRUG|Periostat|In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
47918222|NCT00246740|DRUG|Placebo Oral Tablet|In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
47918223|NCT04825470|PROCEDURE|Liver Transplantation|Liver Transplantation
47918224|NCT00881868|DRUG|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
47918225|NCT00881868|DRUG|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
47918226|NCT00741845|DRUG|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
47918227|NCT03189524|DRUG|Zanubrutinib|Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.
47918228|NCT02992197|BIOLOGICAL|Rotarix, dose 1|Rotarix, dose 1
47918229|NCT02992197|BIOLOGICAL|Rotarix, dose 2|Rotarix, dose 2
47918230|NCT02992197|DRUG|Placebo (for Rotarix dose 2)|Sterile water to provide volume equivalent as a second dose of Rotarix
47918231|NCT03890666|DRUG|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices:~* Device 1: Albuterol eMDPI~* Device 2: Albuterol eMDPI Patient-facing smart device application (App)~* Device 3: DHP Cloud solution)~* Device 4: Provider-facing dashboard (dashboard)"
47918232|NCT03890666|DRUG|albuterol|Standard of care albuterol-administering rescue inhaler
47951158|NCT05024773|DRUG|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
47918233|NCT05488496|BEHAVIORAL|Nature-based social intervention (NBSI)|"The nature-based social prescribing is a multicomponent complex intervention applied by health or social care professionals as facilitators after a specific training.~It comprises: a psychosocial component and nature-based activities.~The psychosocial component is adapted from the group dynamic of Circle of Friends methodology focused on loneliness (Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Barcelona and the target population of adults living in urban socio-economic vulnerable areas.~Nature-based activities are chosen by group participants through a co-created menu comprising all local resources in the area related to nature.~Specifically, participants start with an individual one-to-one session and then they meet once a week for two hours 10 weeks. Each week, participants decide the nature-based activity they wish to conduct."
47918234|NCT05488496|BEHAVIORAL|Usual care + menu with nature-based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
47918235|NCT02513927|DRUG|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
48092447|NCT05623202|BEHAVIORAL|Multi-level behavior-change intervention to strengthen food- and diet-related capital to promote food security and diet quality among low-income Hispanic/Latino adults|The behavior-change intervention with low-income Hispanic/Latino adults will mobilize existing sources of human, material, social, and cultural capital at the individual, household, social, and community level, and will include a nutrition education component and a food access component.
47918236|NCT02513927|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
47918237|NCT05231213|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
47918238|NCT05231213|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
47918239|NCT03664596|DIETARY_SUPPLEMENT|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
47918240|NCT03664596|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
47918241|NCT04640662|BIOLOGICAL|Platelet-Rich Plasma|Single-injection of 2 ml PRP into the lesion under ultrasound-guided
47918242|NCT04640662|BIOLOGICAL|Prolotherapy|Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
47918243|NCT02338570|DRUG|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
47918244|NCT05901753|DEVICE|Laryseal pro supra glottic device|The laryseal pro SP will be advanced at a forward angle aiming for the back of the tongue and soft palate. Then the colored connector will be pushed by index finger till feeling resistance . Device insertion will be considered successful by observing bilateral chest wall movement as well as a stable square-wave capnogram trace
47918245|NCT05901753|DEVICE|Laryngeal Mask Airway- Proseal™|The cuff will be inflated with air and the cuff's pressure will be adjusted to 70 mmHg using a cuff pressure manometer. the device will be lubricated well on both sides, head and neck were placed in neutral position, the proximal firmer part of the device will be compressed between the thumb and two fingers and advanced toward hard and soft palate, the tab will be pulled slightly if needed to increase curvature of the device for better fitting, the device will be advanced till resistance felt.
47918246|NCT02642055|BEHAVIORAL|Neuro+ Attention Training|Attention training program with Neuro+ software
47918247|NCT02642055|OTHER|Treatment as Usual|Continuation of current ADHD treatment
47918248|NCT05950646|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.01 ml/ kg/h (0.02 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
47918249|NCT05950646|DRUG|Esketamine|Esketamine will be infused at a rate of 0.01 ml/ kg/h (5 μg/kg/h) from 8 pm in the night before surgery until 8 am in the third morning after surgery.
47918250|NCT05950646|DRUG|Normal saline|Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
47918251|NCT01672177|BEHAVIORAL|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
47918252|NCT01458093|OTHER|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
47918253|NCT03481179|DEVICE|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
47918254|NCT03481179|OTHER|Physical therapy|The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
48092448|NCT04976036|DRUG|Nintedanib|150 mg oral nintedanib soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
48269443|NCT00728221|DIETARY_SUPPLEMENT|Korean Red Ginseng (Panax Ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules"
47918255|NCT03074019|DIETARY_SUPPLEMENT|Xylooligosaccacharide|XOS95 powder
47918256|NCT03074019|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder
47918257|NCT03395236|COMBINATION_PRODUCT|"StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon"|"The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency."
47918258|NCT03089385|OTHER|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
47918259|NCT02303132|OTHER|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
47918260|NCT04050280|DRUG|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)|"Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days."
47918261|NCT01804738|OTHER|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
47918262|NCT01804738|OTHER|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
47918263|NCT00781885|DRUG|Beraprost sodium modified release|Tablets 60mcg
47918264|NCT01136785|DEVICE|active CPAP Therapy|7 days of active CPAP therapy
47918265|NCT01136785|DEVICE|sham CPAP therapy|7 days of sham CPAP therapy
48092449|NCT04976036|DRUG|Placebo|150 mg oral placebo soft caps, once a day for 2 weeks and twice a day for 10 weeks (12 hours interval)
48092450|NCT03563781|PROCEDURE|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
47918266|NCT04709627|DEVICE|enFlow IV Fluid and Blood Warming System|The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
47918267|NCT02654717|DRUG|DFD-07 Cream|
47918268|NCT02654717|DRUG|Placebo Cream|
47918269|NCT04958460|DRUG|Placebo|Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
47918270|NCT04958460|OTHER|BF688|Administrated 1 pack each morning and evening (5×109 CFUs per day)
47918271|NCT02473146|DRUG|Gemtuzumab ozogamicin (GO)|
47918272|NCT05693961|DEVICE|CART-I plus|CART-I noninvasively measures the oxygen saturation of blood in a local area by screening the bloodstream through the user's finger using PPG signals
47918273|NCT06365970|DRUG|Niraparib|An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
47918274|NCT06365970|DRUG|Dostarlimab|An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
48269444|NCT03315351|PROCEDURE|Brachytherapy|"Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan"
48269445|NCT03315351|OTHER|PET-scan|"The patient will undergo 2 PET-scan during the clinical trial:~* the first one is additional to the brachytherapy~* the second one is realized 4 months after the brachytherapy"
47918275|NCT01523275|DRUG|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
47918276|NCT01523275|OTHER|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
47918277|NCT03568656|DRUG|CCS1477|Capsules, oral
47918278|NCT03568656|DRUG|Abiraterone acetate|Abiraterone acetate 500mg tablets plus prednisone/prednisolone
47918279|NCT03568656|DRUG|Enzalutamide|Enzalutamide 40mg capsules/tablets
47918280|NCT03568656|DRUG|Darolutamide|300mg tablets
47918281|NCT03568656|DRUG|Olaparib|150mg tablets
47918282|NCT03568656|DRUG|Atezolizumab|840mg/14ml concentrate for solution for infusion vials
47918283|NCT03687944|OTHER|Validity and reliability|Test-retest method and concurrent validity
48269446|NCT05610371|DRUG|Lidocaine|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
47918284|NCT05235490|OTHER|Non intervention|"Data study with inclusion of patients and retrospective clinical data collection, combining :~* Proofreading by radiologist of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading by iBiopsy® of the CT scan performed (within 2 months prior to surgical intervention)~* Proofreading of tumor sample slides by pathologists~* Patients follow-up (imaging, clinical)~* Recurrence-free survival"
47918285|NCT05981053|DIETARY_SUPPLEMENT|Wine enriched with Resveratrol|Wine enriched with Resveratrol
47918286|NCT03288142|OTHER|Hypertension Coaching Application and Home Monitor|The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
47951159|NCT05755165|BEHAVIORAL|Depression|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery
48092451|NCT01230034|DRUG|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
48092452|NCT01230034|DRUG|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
47951160|NCT05755165|BEHAVIORAL|Depression, adjusted|\~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor
47951161|NCT05755165|BEHAVIORAL|Control|\~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
48092453|NCT04844099|DRUG|Dihydroartemisinin Piperaquine|Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
47918287|NCT03288142|OTHER|Control: Tracking Application and Home Monitor|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
47918288|NCT02079272|OTHER|Helical tomotherapy for breast cancer|"1. At baseline, before helical tomotherapy is performed, for each included woman will have:~   * measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, ..., microparticles and miRNA)~  * cardiologic examination including echocardiography for measurement of strain and strain rate~  * a CT coronary angiogram for measurement of coronary plaque indexes~2. Helical tomotherapy will be performed for all women included in the cohort.~3. At the end of tomotherapy, follow-up will include:~   * measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~  * cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~  * A CT coronary angiogram 24 months after radiotherapy"
47918289|NCT06218498|DEVICE|ablative fractional 2940-nm Er: YAG laser|Ablative fractional 2940-nm Er: YAG laser (Dermablate MCL31, Asclepion Laser Technologies, Germany), the following parameters were used: model of N25%, energy density of 20-30J/cm2, pulse time of 300μs and one to two passes.
47918290|NCT06218498|DEVICE|non-ablative fractional 1565nm|Non-ablative fractional 1565nm (Lumenis, M22): Resur Fx len, energy of 30-35J/cm2, density of 200spot/cm2, overlap ≤10%.
48092454|NCT02749708|DRUG|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
48092455|NCT01668485|PROCEDURE|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg-1·min-1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
47918291|NCT06218498|DRUG|5% Minoxidil|topical 5% minoxidil, 1 ml, twice daily
47918292|NCT01690676|DIETARY_SUPPLEMENT|Epicatechin|
48092456|NCT01156415|DRUG|AGO178|
47918293|NCT01690676|DIETARY_SUPPLEMENT|Microcrystalline cellulose|
47918294|NCT00492713|OTHER|dark chocolate|dark chocolate
47918295|NCT00492713|OTHER|Milk chocolate 1|Milk chocolate 1
47918296|NCT00492713|OTHER|Milk chocolate 2|Milk chocolate 2
47918297|NCT01917253|DEVICE|Standard Device for peripheral vein cannulation|
47918298|NCT01917253|DEVICE|Long Catheters for peripheral vein cannulation|
48620201|NCT02340325|DRUG|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
47918299|NCT01566084|DRUG|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
47918300|NCT01566084|OTHER|placebo|Placebo tablets are administered to maintain the low sodium condition.
47918301|NCT02013258|DRUG|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
48092457|NCT01156415|DRUG|AGO178|
48092458|NCT06310122|DEVICE|Extracorporeal shockwave therapy|"Devices used to improve foot function pain and gait pattern~Patients will be placed in prone position, therapist locate the point of maximum tenderness. treatment area will be prepared with coupling gel to minimize the loss of shockwave therapy at the interface between applicator tip and skin. Each patient will receive 2000 impulses ,3 bar energy,15mm depth applicator at frequency (10 HZ) per session / week for 4 weeks"
48092459|NCT06310122|DEVICE|ultrasound|"Devices used to improve foot function pain and gait pattern~Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks"
48092460|NCT01600703|DRUG|Sitagliptin|Sitagliptin, 100mg, oral, single dose
47918302|NCT02013258|OTHER|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
48092461|NCT01600703|DRUG|Placebo|Placebo, oral, single dose
48269447|NCT05610371|DRUG|Saline|The control group underwent hysteroscopy using a saline distension medium.
47918303|NCT03671850|BIOLOGICAL|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
47918304|NCT03671850|OTHER|Placebo|Peripheral blood mononuclear cell, PBMC
47918305|NCT06320756|BEHAVIORAL|Wysa in Hindi|Wysa in Hindi is a blended digital mental health intervention
47918306|NCT06320756|BEHAVIORAL|Individual and group sessions on topics like motivation, coping, wellbeing|Individual and group sessions on wellbeing, coping, and motivation with the diabetes educator team
47918307|NCT00575484|DRUG|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
47918308|NCT00575484|DRUG|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
47918309|NCT03843008|DIETARY_SUPPLEMENT|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
48269448|NCT02268461|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
48269449|NCT02268461|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
47918310|NCT03745599|DRUG|Diclofenac|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
47918311|NCT03745599|DRUG|Flurbiprofen|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
47918312|NCT03745599|DRUG|Benzydamine|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
47918313|NCT04527393|DRUG|Individualized oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients with positive results of fentanyl test receive oral morphine 100μg/kg per dose, while patients with negative results receive oral morphine 500μg/kg per dose."
47918314|NCT04527393|DRUG|Conventional oral morphine|"Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients receive oral morphine 200μg/kg per dose."
47918315|NCT06126198|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS induces local electrical currents in the stimulated neurons and has been shown to induce long-term inhibition or excitation of groups of neurons in treated cortical areas
47918316|NCT06116513|DEVICE|S53P4 bioactive glass granules|During revision surgery, all infectious material would be removed and subsequently the posterior wall of the external ear canal would be reconstructed and the mastoid would be obliterated using S53P4 bioactive glass.
47918317|NCT04849559|DRUG|Tradipitant|Tradipitant Capsule
47918318|NCT04849559|DRUG|Placebo|Placebo Capsule
47918319|NCT03928977|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|fMRI sequences done with motor paradigm (right and left arm), followed by resting state acquisition
47918320|NCT06131099|OTHER|Dohsa hou exercises|Dohsa hou is a type of psychomotor therapy that helps improve psychological problems by using bodily movements, sensation and relaxation experience.
47918321|NCT06131099|OTHER|Standard treatment protocal|Standard treatment including soft tissue massage therapy, task specific training interventions, bicycle training and aerobic exercises.
47918322|NCT06412614|OTHER|disease phenotype|evaluation of SSc phenotypes
47918323|NCT00796991|DRUG|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
47918324|NCT00796991|DRUG|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
47918325|NCT00796991|DRUG|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
47918326|NCT00796991|DRUG|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
47918327|NCT06076967|BEHAVIORAL|Mindfulness Awareness Practices for ADHD (adapted)|The Mindful Awareness Practices (MAPs) for ADHD program is an 8-week, group-based mindfulness program for adults with ADHD.
47918328|NCT06076967|BEHAVIORAL|Services-As-Usual|Services-As-Usual includes the standard support services provided by universities
47918329|NCT04135287|DRUG|GLP-1 receptor agonist|The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
47918330|NCT04340271|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave (Fig. 2). ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
48269450|NCT01864785|PROCEDURE|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
48269451|NCT01864785|PROCEDURE|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
48269452|NCT03981432|BEHAVIORAL|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48269453|NCT03981432|BEHAVIORAL|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48269454|NCT03981432|BEHAVIORAL|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
47918331|NCT04340271|OTHER|conventional occupational therapy|Standard accupational therapy consist of range of motion exercise, strengthening exercises, and activities of daily living exercises
47918332|NCT04229134|BEHAVIORAL|Project CONNECT|Home based pain self-management intervention using peer reinforcement to promote engagement and skill uptake
47918333|NCT00543959|DRUG|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
47918334|NCT00543959|DRUG|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
47918335|NCT00543959|DRUG|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
47918336|NCT01934270|OTHER|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
47918337|NCT01716416|DRUG|Pazopanib|
47918338|NCT01716416|DRUG|Cetuximab|
47918339|NCT03049241|OTHER|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
48269455|NCT00196417|DRUG|Standard heparin (UFH) versus certoparin (LMWH)|
47918340|NCT01234935|DRUG|dasatinib|Given orally
47918341|NCT01234935|DRUG|gemcitabine hydrochloride|Given IV
47918342|NCT01234935|OTHER|laboratory biomarker analysis|Correlative studies
47918343|NCT01234935|GENETIC|mutation analysis|Correlative studies
47918344|NCT01234935|GENETIC|nucleic acid sequencing|Correlative studies
47918345|NCT01234935|OTHER|immunohistochemistry staining method|Correlative studies
47918346|NCT02467426|DRUG|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
47918347|NCT01779518|DRUG|Sofosbuvir|
47918348|NCT01779518|DRUG|Ribavirin|
47918349|NCT01779518|DRUG|Pegylated Interferon|
47918350|NCT02547363|DRUG|LEO 43204 gel|
47918351|NCT02547363|DRUG|Vehicle gel|
47918352|NCT02942459|OTHER|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
47918353|NCT02942459|OTHER|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
47918354|NCT03696459|DRUG|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
47918355|NCT03696459|DRUG|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
47918356|NCT03696459|DRUG|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
47918357|NCT03696459|DRUG|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
47918358|NCT03696459|DRUG|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
47918359|NCT03696459|DRUG|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
47918360|NCT03696459|DRUG|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
47918361|NCT01996761|DRUG|porcine brain peptide (Cerebrolysin)|
47918362|NCT01996761|DRUG|Placebo|
47918363|NCT00612105|DRUG|Retigabine|150mg/day up to 900mg/day
48092462|NCT00670540|OTHER|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
48092463|NCT06045806|BIOLOGICAL|idecabtagene vicleucel|Specified dose on specified days
47918364|NCT00612105|DRUG|Placebo|daily
47918365|NCT05650918|BIOLOGICAL|MesoPher|autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)
47918366|NCT05650918|BIOLOGICAL|Mitazalimab|agonistic human monoclonal (IgG1) antibody targeting CD40
47918367|NCT00742833|DRUG|KUC-7483|
47918368|NCT00742833|DRUG|Placebo|
47918369|NCT00054340|BIOLOGICAL|anti-thymocyte globulin|
47918370|NCT00054340|DRUG|busulfan|
47918371|NCT00054340|DRUG|cyclophosphamide|
47918372|NCT00054340|DRUG|cyclosporine|
47918373|NCT00054340|DRUG|methotrexate|
47918374|NCT00054340|PROCEDURE|allogeneic bone marrow transplantation|
47918375|NCT00054340|PROCEDURE|peripheral blood stem cell transplantation|
47918376|NCT02267993|DRUG|recombinant human thrombopoietin|Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
47918377|NCT04796090|OTHER|Clinical assessment|FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.
47918378|NCT05499299|BEHAVIORAL|Google ads|Individuals who googled COVID-19 information in Hong Kong were randomized to see one of the seven ads and, if they clicked on the ads, the corresponding vaccine message on our website
47918379|NCT05862506|BEHAVIORAL|Daily Mile|The intervention consisted of walking, jogging or running for \~ 15 min (\~ one mile) of exercise at a pace self-selected by each individual child, outside the school buildings during recess time, three times a week during 10 weeks. Children were instructed to maintain active for the full 15 min and, if necessary, to stop for resting only occasionally.
48092464|NCT06045806|DRUG|Lenalidomide|Specified dose on specified days
48269456|NCT02680782|DRUG|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
48269457|NCT00000855|DRUG|Zidovudine|
48269458|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
48269459|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L.casei|Intake of yoghurt during 4 weeks
47918380|NCT03736772|DRUG|LY3090106|Administered SC
47918381|NCT03736772|DRUG|Placebo|Administered SC
47918382|NCT03386838|BIOLOGICAL|Nivolumab|Specified dose on specified days
47918383|NCT03386838|DRUG|BMS-986205|Administered 100mg orally once daily for a maximum of 104 weeks
47918384|NCT03386838|BIOLOGICAL|Cetuximab|400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
48269460|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
47918385|NCT03386838|DRUG|Cisplatin|Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
47918386|NCT03386838|DRUG|Carboplatin|Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
47918387|NCT03386838|DRUG|Fluorouracil|1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
47918388|NCT05887596|OTHER|Patient education|The education given to the intervention group included preoperative preparation, operating room environment, breathing exercises, cough exercises, etc. to be performed after surgery, non-pharmacological methods related to pain management (cold application, positioning, distraction), and pharmacological methods related to pain management.
47918389|NCT05167695|BEHAVIORAL|Habit-based Sleep Health Intervention|A novel low-cost approach derived by leveraging the science of habit formation
47918390|NCT05167695|BEHAVIORAL|Text messaging intervention|In addition to the Habit-based Sleep Health Intervention, the participants will also receive the text messaging intervention.
47918391|NCT02160899|DRUG|ISIS-APO(a)Rx|ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
47918392|NCT02160899|DRUG|Placebo|Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
47918393|NCT04741126|OTHER|Manually assisted cough technique|Manually assisted cough technique will be given for four weeks. 10 to 12 repetitions of manually assisted cough technique with rest will be given in one minute 3 to 4 time of repetition in a 1 set. The result of the peak cough flow meter and incentive spirometer will be check pre and post only.3 sets will be given in one session and 2-time session will be recommended per day. The session will be given three days in a week. The Result of the Peak Cough flow meter and incentive spirometer will be check pre and post only.
47918394|NCT02356900|PROCEDURE|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
47918395|NCT02356900|PROCEDURE|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
47918396|NCT02356900|DRUG|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
48092465|NCT06045806|DRUG|Fludarabine|Specified dose on specified days
48092466|NCT06045806|DRUG|Cyclophosphamide|Specified dose on specified days
48092467|NCT04920214|DIAGNOSTIC_TEST|SonoVue|CEUS examination was performed and corresponding image information of liver lesions was obtained.
48092468|NCT01324882|DEVICE|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
48092469|NCT01324882|DEVICE|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
48092470|NCT04173845|DRUG|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
48269461|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Yoghurt with L. plantarum strain
48269462|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
48269463|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt|Intake of yoghurt during 4 weeks
48443521|NCT04457674|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi)|CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
47918397|NCT03298971|OTHER|Questionnaires|Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
47918398|NCT00000991|DRUG|Pentamidine isethionate|
47918399|NCT00000991|DRUG|Sulfamethoxazole-Trimethoprim|
47918400|NCT00000991|DRUG|Dapsone|
48269464|NCT04880122|DIAGNOSTIC_TEST|Dried blood spot and venous blood collection|A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
47918401|NCT00000991|DRUG|Zidovudine|
48269465|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
47918402|NCT02575027|RADIATION|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
47918403|NCT02575027|OTHER|Questionnaire Administration|Ancillary studies
47918404|NCT02575027|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
47918405|NCT00444561|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC administration
47918406|NCT00367367|PROCEDURE|Hysteroscopy and Curettage|
47918407|NCT03316495|BEHAVIORAL|PAMPHLET|EXPOSURE TO PAMPHLETS
47918408|NCT01795170|DIETARY_SUPPLEMENT|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) \[23,24\], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
47918409|NCT01795170|DRUG|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
47918410|NCT03816540|DEVICE|HRV and respiratory coherence biofeedback|Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
47918411|NCT01131013|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
47918412|NCT01131013|DRUG|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
47918413|NCT01131013|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
47918414|NCT00732446|DRUG|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
47918415|NCT00732446|DRUG|Moxifloxacin|moxifloxacin 0,5% qid and
47918416|NCT00732446|DRUG|Dexamethasone|dexamethasone 0,1% qid
47918417|NCT00103350|DRUG|TG100-115|
47918418|NCT02784639|OTHER|Plasma Analysis of circulating cell free DNA|
47918419|NCT02784639|OTHER|Tumor tissue analysis of circulating cell free DNA|
48269466|NCT02274285|BIOLOGICAL|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
48269467|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
47918420|NCT02921334|PROCEDURE|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
47918421|NCT02267876|DEVICE|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
47918422|NCT02267876|PROCEDURE|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
48269468|NCT03951636|PROCEDURE|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
47918423|NCT01874769|OTHER|Blood collection|"* 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~* 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~* 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
47918424|NCT01874769|OTHER|Skin biopsies|"* A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~* During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
47918425|NCT02888678|BEHAVIORAL|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
47918426|NCT02888678|BEHAVIORAL|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
47918427|NCT02720354|OTHER|[11C]-DMDPA|
47918428|NCT00263185|DIETARY_SUPPLEMENT|Vitamin D|
47918429|NCT00263185|DIETARY_SUPPLEMENT|Calcium carbonate|
47918430|NCT00263185|DRUG|Vitamin D|
47918431|NCT00263185|OTHER|Placebo|
47918432|NCT02084251|DRUG|PB-119|
48269469|NCT03951636|PROCEDURE|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
47918433|NCT00796978|BIOLOGICAL|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
47918434|NCT00796978|OTHER|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
47918435|NCT00796978|PROCEDURE|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
48269470|NCT03951636|PROCEDURE|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
48269471|NCT00002948|BIOLOGICAL|filgrastim|
48269472|NCT00002948|DRUG|topotecan hydrochloride|
48269473|NCT00002948|PROCEDURE|bone marrow ablation with stem cell support|
48269474|NCT00002948|PROCEDURE|peripheral blood stem cell transplantation|
48269475|NCT01474694|OTHER|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
48269476|NCT00905957|PROCEDURE|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
48269477|NCT00905957|PROCEDURE|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
48269478|NCT01822002|PROCEDURE|Canalith repositioning maneuver|
48269479|NCT05123235|BEHAVIORAL|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
48269480|NCT00004433|DRUG|pergolide|
48269481|NCT04629560|DRUG|Miracle Fruit|one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
48269482|NCT06287879|DIAGNOSTIC_TEST|Dry eye examination|"1. Lacrimal river height~2. tear break-up time~3. tear-film lipid layer thickness~4. meibomian glands two-dimensional digital infrared images"
48269483|NCT02664155|DRUG|Apixaban|Direct Oral Anticoagulant
48269484|NCT02664155|DRUG|Rivaroxaban|Direct Oral Anticoagulant
48269485|NCT02664155|DRUG|Heparin|Standard Of Care
48269486|NCT02664155|DRUG|VKA|Standard Of Care
48269487|NCT00341614|BEHAVIORAL|3-month Exercise Training and Diet Education|
48269488|NCT01707030|OTHER|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
48269489|NCT01707030|OTHER|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
48269490|NCT03543683|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
47918436|NCT00796978|PROCEDURE|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
47918437|NCT03893695|DRUG|GT90001 and Nivolumab|Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
47918438|NCT02368561|DRUG|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
48269491|NCT03543683|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
48269492|NCT02978482|DRUG|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
48269493|NCT02978482|DRUG|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
48269494|NCT03690310|BIOLOGICAL|Anti-CD19 CAR NK Cells|Anti-CD19 CAR NK Cells injection
48269495|NCT06228612|DEVICE|vacuum therapy|vacuum therapy :all patients were informed about initial suction sensation and possible appearance of bruising at the application site. Basic vacuum therapy equipment (cangexia, China) was utilized including a manual suction pump, plastic cups of 40 mm diameter with rolled edge, and anti-septic tools.
48269496|NCT06228612|DEVICE|maxillary stabilization splint (MSS)|maxillary stabilization splint (MSS): was constructed for each patient from hard, heat-cured clear acrylic resin and fitted to the maxillary teeth. On the mounted master casts, the vertical dimension was adjusted to provide 3 mm of vertical space between the closest opposing cusps of the maxillary and mandibular teeth.
48269497|NCT06228612|DEVICE|vacuum therapy VT and maxillary stabilization splint (MSS)|vacuum therapy VT and maxillary stabilization splint (MSS): both Basic vacuum therapy and maxillary stabilization splint :Procedures were the same as in group I and II.
47918439|NCT04075253|BEHAVIORAL|VO2 peak testing|Exercise on treadmill starts with \~4km/h at 0% inclination before inclination is increased to 4% and speed kept unchanged. Inclination will then be increased with two percent approximately after each minute until exhaustion.
47918440|NCT02030899|PROCEDURE|Cage fusion|Randomized selection of surgery type
47918441|NCT02030899|PROCEDURE|Plate fusion|Randomized selection of surgery type
47918442|NCT02249897|DRUG|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
48269498|NCT04689230|PROCEDURE|upper eyelid blepharoplasty|upper eyelid blepharoplasty
48269499|NCT04075435|DRUG|high CBD/low THC sublingual solution|Hemp derived solution to be administered sublingually twice daily.
47918443|NCT04626401|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
47918444|NCT02561767|OTHER|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
47918445|NCT02561767|OTHER|Saline|Saline as placebo of MSCs
47918446|NCT02561767|DRUG|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
47918447|NCT02561767|DRUG|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
47918448|NCT03287206|BIOLOGICAL|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
47918449|NCT03287206|BIOLOGICAL|blood samples from parents|secondary controls for children's analyses
47918450|NCT02873494|DEVICE|PHYSIOFLOW - PF05 Lab1TM|
47918451|NCT00296296|DRUG|Cyclosporin|Dose adjustment to pre-established targets
48269500|NCT06091644|DEVICE|AirAngel® 3D printed videolaryngoscope|This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
47918452|NCT00296296|DRUG|Tacrolimus|Dose adjustment to pre-established targets
47918453|NCT00296296|BEHAVIORAL|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
47918454|NCT03708783|PROCEDURE|laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection|For patients with locally advanced upper or middle third gastric cancer, laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection is performed.
47918455|NCT04986956|DIETARY_SUPPLEMENT|Whole coffee cherry extract|200mg WCCE
47918456|NCT04986956|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to WCCE
47918457|NCT01948856|DRUG|J022X ST|"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
47918458|NCT01948856|DRUG|Placebo|"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"
47918459|NCT03229642|DEVICE|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
47918460|NCT03229642|DEVICE|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
48092471|NCT04173845|DRUG|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
48269501|NCT01086436|BIOLOGICAL|Rotarix ™|Oral, single dose
48269502|NCT01086436|BIOLOGICAL|Placebo|Oral, single dose
48269503|NCT04439955|DRUG|CBD|300 mg CBD
47918461|NCT00474305|BEHAVIORAL|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
47918462|NCT03844204|DEVICE|Thermal servo-controlled system|All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
47918463|NCT00002069|DRUG|Ditiocarb sodium|
47918464|NCT00332735|DRUG|spinal administration of articaine|
47918465|NCT00332735|DRUG|spinal administration of bupivacaine|
47918466|NCT05068882|DIETARY_SUPPLEMENT|Immunonutrition|Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
47918467|NCT05068882|DIETARY_SUPPLEMENT|High-protein nutrition|Oral nutrition with high-protein content
47918468|NCT05068882|DIETARY_SUPPLEMENT|Standard nutrition|Oral nutrition with standard ingredients
47918469|NCT02466659|DEVICE|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
47918470|NCT00000722|DRUG|Pentamidine isethionate|
47918471|NCT00004042|BIOLOGICAL|monoclonal antibody F19|
47918472|NCT00004042|RADIATION|iodine I 131 monoclonal antibody F19|
47918473|NCT00097656|OTHER|multi-center, randomized, controled periodontal therapy|periodontal therapy
47918474|NCT02902484|DRUG|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
47918475|NCT03543072|DRUG|Bisphosphonates|a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
48092472|NCT03661970|OTHER|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
48092473|NCT00367237|DRUG|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
48269504|NCT02575209|OTHER|GENDER|
48269505|NCT00927563|DRUG|Tolcapone|pill, 100-300mg/day for 8 weeks
48269506|NCT05891067|BEHAVIORAL|SterkWerk|Classroom-based intervention program
47918476|NCT03222882|PROCEDURE|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
47918477|NCT01945918|BEHAVIORAL|Self-management support education|Same as Arm Description
47918478|NCT01945918|BEHAVIORAL|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
47918479|NCT01945918|BEHAVIORAL|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
47918480|NCT05268510|DRUG|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
47918481|NCT05268510|DRUG|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
47918482|NCT05268510|DRUG|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
47918483|NCT05268510|DRUG|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
47918484|NCT01338454|DRUG|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
47918485|NCT04363788|PROCEDURE|double gloves|The study was based on dying gloves used during resuscitation. The gloves were secured with disposable hermetically sealed pouches and described by one of the EMS team members - each time after resuscitation was completed.
47918486|NCT06212037|DIAGNOSTIC_TEST|Point of Care Ultrasound|Point of Care Ultrasound will be performed on all subjects and their laryngeal air column width difference will be calculated. The patients will be followed after extubation and the presence/absence of post extubation stridor will be recorded.
47918487|NCT03629314|OTHER|Educational pamphlet arm|Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
47918488|NCT05460091|DEVICE|PTech Device|High-frequency vibration device used on regular basis in orthodontics
47918489|NCT05460091|DEVICE|PTech Sham Device|sham device (does not vibrate)
47918490|NCT00999193|PROCEDURE|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
48092474|NCT00367237|DRUG|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
48269507|NCT05891067|BEHAVIORAL|Treatment-as-usual|Active control group
48269508|NCT01029730|DRUG|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
48269509|NCT01029730|DRUG|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
48269510|NCT01029730|DRUG|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
47918491|NCT00999193|PROCEDURE|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
47918492|NCT00999193|OTHER|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
47918493|NCT02682862|DRUG|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
47918494|NCT02682862|DRUG|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
47918495|NCT00380042|DEVICE|Cortical Stimulation|Cortical stimulation of prefrontal cortex
47918496|NCT00380042|DEVICE|Sham|Sham stimulation
47918497|NCT02686008|DRUG|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
47918498|NCT05061056|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
47918499|NCT05061056|OTHER|Russian current 20%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
47918500|NCT05061056|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
47918501|NCT05061056|OTHER|Aussie current 20%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
47918502|NCT05157828|OTHER|No intervention|No intervention
47918503|NCT02402998|DRUG|Eltrombopag|Eltrombopag 50 mg/daily.
47918504|NCT06455046|DRUG|AK104|PD-1/CTLA-4 bispecific antibody
47918505|NCT06455046|DRUG|Recombinant Human Adenovirus 5 Injection|Recombinant Human Adenovirus 5 Injection
47918506|NCT06144099|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
47918507|NCT06144099|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
47918508|NCT01596062|DRUG|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
48092475|NCT06614257|DRUG|LG-TAP block with local anesthetic|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
48092476|NCT06614257|PROCEDURE|Port site infiltration|Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
48269511|NCT00000690|DRUG|Dextran sulfate|
47918509|NCT01596062|DRUG|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
47918510|NCT01596062|DRUG|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
47918511|NCT01596062|DRUG|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
47918512|NCT01596062|DRUG|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
47918513|NCT06019442|BEHAVIORAL|Brief alcohol intervention (Health4Her-Automated)|"Embedded within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive a brief alcohol intervention. The brief alcohol intervention will comprise information and behaviour-change content regarding alcohol consumption, including: messaging around alcohol risks/harms (with a focus on alcohol use and breast cancer risk), positive-framed messaging on the health benefits of reducing alcohol intake, and alcohol harm-reduction / behaviour change strategies (e.g. drink counting, goal setting, behaviour substitution, problem solving).~Post-session information will be provided via email (i.e. electronic brochure summarising brief alcohol intervention content)."
47918514|NCT06019442|BEHAVIORAL|Lifestyle health promotion|"Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight)."
47918515|NCT03285022|PROCEDURE|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
47918516|NCT04188444|BIOLOGICAL|Blood test|20 ml of blood, three times
47918517|NCT00347620|DEVICE|spectacles|
47918518|NCT00347620|PROCEDURE|Cataract Surgery|
47918519|NCT04590846|BEHAVIORAL|Constipation Health Education Intervention Course|"The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them."
47918520|NCT04590846|BEHAVIORAL|General Health Course|General courses about health issues according to the curriculum of each primary school.
47918521|NCT01626937|OTHER|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
47918522|NCT01626937|OTHER|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
47918523|NCT03870594|DIAGNOSTIC_TEST|glycated hemoglobin|hemoglobin A1c level in blood
47918524|NCT00863213|PROCEDURE|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
47918525|NCT00863213|DRUG|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
47918526|NCT02856152|DRUG|GDC-0276 capsule|Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.
47918527|NCT02856152|DRUG|GDC-0276 tablets|Three 90 mg GDC-0276 tablets administered orally.
48092477|NCT06614257|DRUG|LG-TAP block with saline solution|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
48092478|NCT04990882|OTHER|Interpretation of FAPI-PET/CT scans|Each observer's Group will be asked to review FAPI-PET/CT scans of patients with representative cancer types.
48092479|NCT03521921|DEVICE|Mitraclip|Edge-to edge mitral valve repair
48092480|NCT02283645|DRUG|3 % minoxidil lotion|
48092481|NCT02283645|DRUG|Placebo|
48092482|NCT05211531|OTHER|Measuring number of post-operative steps|Measuring the number of post-operative steps that inpatients take.
48092483|NCT02886988|DRUG|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
48092484|NCT02886988|DRUG|normal saline|0.1mlof normal saline will be injected with a 30G needle.
48092485|NCT04893798|COMBINATION_PRODUCT|Sayana Press|Sayana Press is a drug-device combination and is considered a medical product in the EU.
47918528|NCT03645434|DRUG|AZD8871|Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
48269512|NCT05866198|DIAGNOSTIC_TEST|Actigraph CP Insight Watch|"CP Insight Watch (Actigraph, Pensacola, FL) is usually worn on the wrist. The watch captures and records continuous high-resolution raw acceleration data to provide objective, real-world physical activity, mobility, and sleep measures, in near real time. That data is then processed by ActiLife software into what is called Epoch data (i.e. turning it into activity counts so that things such as moderate vigorous physical activity can be found). The device also passively scores every minute of recorded data as Sleep or Wake based on the amount of activity taking place."
47918529|NCT03645434|DRUG|Anoro® Ellipta®|Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
47918530|NCT03792828|DRUG|Duloxetine HCl 30mg|In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.
47918531|NCT04408560|DRUG|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)|Rhus toxicodendron 9 CH + Ruta graveolens 5 CH
47918532|NCT04408560|OTHER|paracetamol (drug analgesic class1)|paracetamol (drug analgesic class1)
47918533|NCT02852187|DEVICE|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
47918534|NCT02852187|DEVICE|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
47918535|NCT06449196|DRUG|Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via bolus dosing.
47918536|NCT06449196|DRUG|: Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via fractionated dosing
47918537|NCT03646643|PROCEDURE|Standard Atrial fibrillation ablation|The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
47918538|NCT03646643|PROCEDURE|Coronary sinus to left atrium connection elimination|Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
47918539|NCT05437705|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
47918540|NCT00049985|DRUG|Darbepoetin Alfa|
47918541|NCT05677685|DEVICE|VISUPRIME|twice daily
47918542|NCT05677685|DEVICE|Placebo|twice daily
47918543|NCT00344487|DRUG|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
47918544|NCT02385422|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
47918545|NCT02385422|DRUG|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
47918546|NCT05099367|DIAGNOSTIC_TEST|Microdialysis, current induced vasodilation|"CIV will be applied over all microdialysis fibers: one perfused with saline, one perfused with a preferential COX-1 blocker; and one perfused with a preferential COX-2 blocker.~CIV will be applied over all fibers in the following conditions: one perfused with saline, one perfused with fluconazole and L-NMMA, and the last one perfused with lidocaine.Dialysate collection will be performed after each CIV: dermal PGI2 metabolite (6-ketoPGF1α) and other COX-dependent prostanoids or metabolite (e.g. 11-dehydroTXB2) will be collected in the dialysate fluid and quantified. One hour after the last condition, treprostinil will be perfused over all fibers."
48092486|NCT01281761|DRUG|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- \[C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min\] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV \[over 90min\] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
47918547|NCT05099367|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy will be proposed. It will be performed on the internal superior calf (medial gastrocnemius), at a reasonable distance from the foot
47918548|NCT05099367|DIAGNOSTIC_TEST|peri-ulcerated skin biopsy|Non-ulcerated skin from the peri-wound area will be collected. These patient will not undergo all the procedures included in this protocol.
47918549|NCT02899572|PROCEDURE|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
47918550|NCT03463005|OTHER|Royal jelly|The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
47918551|NCT03463005|PROCEDURE|IUI|Subjects in IUI group received 75 units of FSH from the second day of the cycle.
47918552|NCT05847985|DEVICE|transcranial direct current stimulation (tDCS)|tDCS using electric currents to modulate underlying neurons
48092487|NCT01105494|DRUG|epoetin beta [NeoRecormon]|As prescribed by physician
47918553|NCT06455969|DRUG|Goserelin 3.6 MG|Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.
47918554|NCT06455969|OTHER|Multi-Stressor Training|A 4-week physical training program that mimics military training.
47918555|NCT06455969|DRUG|Testosterone gel (AndroGel 5g)|Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).
47918556|NCT06455969|DRUG|Testosterone gel (AndroGel 1.25g)|Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).
47918557|NCT06455969|DRUG|Estradiol / Levonorgestrel Transdermal System [Climara Pro]|Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.
47918558|NCT06455969|DRUG|Placebo Patch|Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.
47918559|NCT00201552|DRUG|Statin|
47918560|NCT05776095|PROCEDURE|Cataract surgery|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
47918561|NCT05776095|DEVICE|Eyedeal® Model PX65AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
47918562|NCT01339520|BEHAVIORAL|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
48269513|NCT04947644|PROCEDURE|Thoracic epidural analgesia|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
47918563|NCT01339520|BEHAVIORAL|Control|Standard of care for diabetes subjects
48298811|NCT06392984|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. Investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second) (Liter-L), FEV1 (%predicted), FVC (Forced Vital Capacity) (Liter-L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
47918564|NCT01758536|DRUG|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
47918565|NCT03666533|OTHER|Active transcranial Direct Current Stimulation|Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
47918566|NCT03666533|OTHER|Sham transcranial Direct Current Stimulation|Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
47918567|NCT00641511|DRUG|SYN117 (nepicastat)|120 mg per day
47918568|NCT00641511|DRUG|Placebo comparator|once per day placebo capsules
47918569|NCT02416622|BIOLOGICAL|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
47918570|NCT02611596|DRUG|Ranolazine|24 weeks of the assigned medication
47918571|NCT02611596|DRUG|Placebo|Placebo for 24 weeks
47918572|NCT04193618|PROCEDURE|Conservative surgery for placenta accretta|Uterine devasculrization and transverse compressing sutures before placental delivery
47918573|NCT03701035|BEHAVIORAL|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if \< 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
47918574|NCT03701035|BEHAVIORAL|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait \& balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
47918575|NCT02102204|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
47918576|NCT05761717|DRUG|Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection|Subcutaneous Injection
47918577|NCT00004845|DRUG|Rofecoxib|
47918578|NCT00004845|DRUG|Naproxen|
47918579|NCT00115583|DRUG|Drug Infusion (BQ-123)|
48092488|NCT01613118|DRUG|RE-021 (Sparsentan)|Oral, once-daily
48092489|NCT01613118|DRUG|Irbesartan|Oral, once-daily
47918580|NCT00799214|DRUG|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
47918581|NCT00799214|DRUG|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
47918582|NCT00799214|DRUG|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
47918583|NCT02998957|DEVICE|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
47918584|NCT02998957|DEVICE|Sham AcuTENS|Portable TENS electrostimulation device with no electrical output
47918585|NCT00995059|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
47918586|NCT00995059|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
47918587|NCT00995059|DRUG|bortezomib|Given IV
47918588|NCT00995059|DRUG|melphalan|Given IV
47918589|NCT00995059|DRUG|anti-thymocyte globulin|Given IV
47918590|NCT00995059|DRUG|sirolimus|Given orally
47918591|NCT00995059|DRUG|tacrolimus|Given oral or IV
47918592|NCT00995059|RADIATION|total-body irradiation|Undergo total-body irradiation
47918593|NCT05348278|DRUG|Urea cream|apply 10% urea cream at both hands and feet twice daily
47918594|NCT04986436|DRUG|HS-10360|Single or multiple dose(s) of HS-10360
47918595|NCT04986436|DRUG|Placebo|Single or multiple dose(s) of Placebo
47918596|NCT03400605|OTHER|Infant feeding questionnaire|Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
47918597|NCT04023734|BEHAVIORAL|Reminders, habit-based strategies and/or involvement of family member|"Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit."
47918598|NCT04023734|BEHAVIORAL|Counselling to increase knowledge|The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
47918599|NCT04023734|BEHAVIORAL|Counselling to increase motivation|The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
47918600|NCT04023734|BEHAVIORAL|Explore/address other drug related problems|The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
47918601|NCT04023734|BEHAVIORAL|Usual care based on the Indonesian guideline|Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
47918602|NCT05343728|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography was done by using TEG 5000 Hemostasis Analyzer (Haemonetics Corp., USA)
47918603|NCT05343728|DIAGNOSTIC_TEST|Standard coagulation profile laboratory examination|Standard coagulation profile laboratory examination (platelets, PT/APTT, fibrinogen, and D-dimer) was performed by using Sysmex® CS-2500 and 5100 (Sysmex Corp., Japan)
47918604|NCT00433602|OTHER|clinical observation|
47918605|NCT00433602|PROCEDURE|management of therapy complications|
47918606|NCT00433602|PROCEDURE|ultrasound imaging|
47918607|NCT01325337|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
47918608|NCT01325337|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
47918609|NCT01325337|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
47918610|NCT01325337|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
47918611|NCT01325337|DRUG|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
47918612|NCT03919097|OTHER|Medical Data extraction|Data extraction from the patient's Medical Files
47918613|NCT05519540|DRUG|Xevinapant (Debio 1143)|All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
47918614|NCT00796523|BEHAVIORAL|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
47918615|NCT00796523|BEHAVIORAL|control videotape|a videotape with general newborn care instructions
47918616|NCT01932437|BIOLOGICAL|ETI-204|monoclonal antibody
47918617|NCT01932437|OTHER|Placebo|Placebo for ETI-204
47918618|NCT05176171|PROCEDURE|Photorefractive Keratectomy with Corneal Cross-Linking|To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
47918619|NCT02859584|BIOLOGICAL|Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|
47918620|NCT05706051|OTHER|posturography|posturography will be performed when diagnosis of ARHL, in need of hearing aid fitting, is done and after information and written approval from patient. Posturography is performed later when hearing aid fitting and 3months after hearing aid use
48092490|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
47918621|NCT04806555|DIAGNOSTIC_TEST|Compression ultrasound examination|After successful revascularisation for acute ischemia and clinical suspicion of acute compartment syndrome, compression ultrasound (CU) will be performed in OR followed by standard intra-compartmental measurement. Two physicians will perform two subsequent measurements of the affected limb after revascularisation. The unaffected limb will be examined once to obtain baseline elasticity ratio values. All CU examinations will be documented in PACS (picture archiving and communication system) and evaluated after ICP measurement, and if necessary, fasciotomy is performed.
47918622|NCT04295824|DIAGNOSTIC_TEST|Skin imaging and Skin biopsy|"Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed."
48269514|NCT04947644|PROCEDURE|Ultrasound guided continuous erector spinae plane block|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
48269515|NCT02777528|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
47918623|NCT04135586|OTHER|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
47918624|NCT04135586|OTHER|Control|Yoga + educational program
47918625|NCT04012164|BIOLOGICAL|blood sampling|5ml blood sampling
47918626|NCT04012164|BIOLOGICAL|stool collection|self stool collection (2g)
47918627|NCT04012164|OTHER|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
47918628|NCT04012164|OTHER|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
48269516|NCT02777528|PROCEDURE|Revascularization Procedure|Revascularization procedure of the great vessel
48269517|NCT01929135|DRUG|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
47918629|NCT03300596|BEHAVIORAL|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
47918630|NCT03300596|BEHAVIORAL|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
47918631|NCT05155189|BIOLOGICAL|C-CAR031|Targeting GPC3 armored CART cell injection (C-CAR031)
47918632|NCT05155189|DRUG|Lenvatinib|Tyrosine kinase inhibitors
47918633|NCT05155189|DRUG|PD-1(L1) monoclonal antibody|Immune checkpoint inhibitors, ICIs
47918634|NCT00006118|DRUG|cisplatin|
47918635|NCT00006118|DRUG|gemcitabine hydrochloride|
48269518|NCT01929135|DRUG|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
47918636|NCT00006118|DRUG|paclitaxel|
47918637|NCT04997356|BEHAVIORAL|Hostile Bias Modification Training|Volunteers will complete a novel computer-based hostile bias modification training where they are instructed to respond to word fragments (words with missing letters) based on whether the word fragments can be completed to form aggressive or positive/neutral words. They will refrain from making words that can only form aggressive words.
47918638|NCT04997356|BEHAVIORAL|Other training|Volunteers will complete a computer-based task where they are instructed to respond to word fragments (words with missing letters) regardless of whether the fragments can make hostile or ambiguous words.
47918639|NCT00232791|DEVICE|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
47918640|NCT00232791|DEVICE|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
47951162|NCT06074861|PROCEDURE|Fasting-mimicking diet + non-surgical periodontal therapy|Test group will receive a full-mouth non-surgical periodontal therapy (also named professional mechanical plaque removal-PMPR) and, in the same day (starting at morning), a fasting-mimicking diet (FMD) will be started (for a cycle of 5 days). Other two cycles of FMD will be followed at 45- and 85- days after treatment, respectively.
48092491|NCT01488110|DEVICE|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
48269519|NCT06068972|DEVICE|MolecuLight|Point-of-care fluorescence imaging of high bacterial loads
48269520|NCT01494363|DRUG|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
47918641|NCT02957214|OTHER|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
47918642|NCT06135298|PROCEDURE|OSTEOSYNTHESIS|Routine procedure for anesthesia and infection prophylaxis according to written instructions will be followed in every patient. The patient will be operated supine with the fractured leg positioned in traction table. The hip region is scrubbed and dressed in sterile drapes. Using standard technique, a nail is inserted into the intramedullary canal after fracture reduction. To insert the helical blade in the femoral neck, 2.0 mm diameter guide wire is first placed in the femoral neck, checking the fluoroscopic AP and lateral views. The canal is opened using a 10 mm drill bit and the length of helical blade is measured. After the pilot hole is created for the helical blade placement, the hollow helical blade will be inserted to its end position with gentle blows with a hammer.
47918643|NCT06135298|DRUG|Zoledronic acid|Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 5 mg (as per clinical protocol) will be injected intravenously 5 days after surgery, during hospitalization.
47918644|NCT06135298|DEVICE|CERAMENT BONE VOID FILLER (BVF)|In addition to the standard surgical procedure, in the study group, after creating the canal with 10 mm drill bit and partly insertion of the helical blade, the synthetic bone void filler CaS/HA will be injected. The helical blade will be inserted partially with gentle blows with a hammer, 2.5 cm from its final intended position. The injectable CaS/HA biomaterial will be mixed as per the manufacturer guidelines and the paste will be transferred into an injection syringe. At t = 2.5 min from the start of mixing, 2-3 mL of BVF paste will be injected by a CE marked Introducer Needle connected to the injection syringe, through the hollow helical blade. Finally, the helical blade will be inserted to its end position with gentle blows with a hammer. Remaining material approximately 2 mL still being moldable will be manually deposited in the trochanteric fracture void.
48092492|NCT02963597|DEVICE|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
48092493|NCT02963597|OTHER|Standard Medical Therapy|Standard medical therapy according to current guidelines.
48092494|NCT05792046|DEVICE|Visual field|test for detecting loss in visual function
48092495|NCT02466126|BEHAVIORAL|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
48092496|NCT04478747|PROCEDURE|TVM|Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)
48092497|NCT04478747|PROCEDURE|Colposacropexy|Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
48092498|NCT00536666|DRUG|Iron oligosaccharide|
48092499|NCT01792609|PROCEDURE|Maximum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
48092500|NCT01792609|PROCEDURE|Minimum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
48092501|NCT00116870|DRUG|lovastatin|
48092502|NCT02646046|BEHAVIORAL|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
48092503|NCT02646046|BEHAVIORAL|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
48092504|NCT04055753|DRUG|Doxil|Doxil 50 mg/m2, as per institutional standard
48092505|NCT04055753|DRUG|Doxorubicin|Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
48092506|NCT04528355|DRUG|data collection|Study subjects will receive alemtuzumab, melphalan, thiotepa, fludarabine and hydroxyurea-based, reduced-intensity conditioning regimen in accordance with clinical practice at UPMC Children's Hospital of Pittsburgh at the discretion of the treating physician. Medical data will be abstracted from subject's medical charts once the patient signs the informed consent.
48092507|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
48269521|NCT01494363|DRUG|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
48269522|NCT01494363|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
48269523|NCT01494363|DRUG|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
48443522|NCT04457674|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
48092508|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - CHEST & FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~3. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
48092509|NCT02651558|DEVICE|Experimental: OBPM 2015-MD-0022 - FINGER|"At the onset of general anesthesia:~1. continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~2. continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
48092510|NCT03344289|DIAGNOSTIC_TEST|Colonoscopy|Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
47918645|NCT06438510|PROCEDURE|Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG)|All endoscopic procedures will be performed with the patient in the supine position, under general anesthesia, with endotracheal intubation, in CO2 using a flexible endoscopic suturing system (OverStitchTM; Apollo Endosurgery, Austin, TX, USA) connected to a dual-channel endoscope (GIF-2TH180 or GIF-2TH160; Olympus, Center Valley, PA, USA ). The HybridAPC with submucosal injection and APC will be delivered by ErbeJet®2. ESG will be obtained by placing full-thickness sutures in the body gastric wall, from the angulus to the gastric fundus. Biopsy tissue will be collected from the gastric fundus and the samples will be fixed for histopathologic examination. In the next step HybridAPC to the gastric mucosa of the fundus is applied.
47918646|NCT02492932|DEVICE|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
48092511|NCT04011384|BEHAVIORAL|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
48092512|NCT04895306|DRUG|Testosterone Cypionate|Weekly intramuscular administration of testosterone at a dose of 3 mg
48092513|NCT04895306|DRUG|Placebo|Weekly intramuscular administration of Placebo
47918647|NCT04165421|BEHAVIORAL|Family intervention group|Education and Family conversations
47918648|NCT04333745|OTHER|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
47918649|NCT04333745|DIETARY_SUPPLEMENT|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
47918650|NCT04469998|DRUG|AXR-270 Low Dose|AXR-270 Topical Eyelid Cream
48092514|NCT02338609|DRUG|Everolimus|At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
48092515|NCT01495780|BEHAVIORAL|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
47918651|NCT04469998|DRUG|AXR-270 High Dose|AXR-270 Topical Eyelid Cream
47918652|NCT04469998|DRUG|AXR-270 Vehicle|AXR-270 Topical Eyelid Cream Vehicle
47918653|NCT03495856|BEHAVIORAL|Mindfulness Training For Chronic Pain|4-week group Mindfulness training program for adults with chronic pain
48092516|NCT00249483|DRUG|Venlafaxine|Venlafaxiine 300mg/day
47918654|NCT00577616|PROCEDURE|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
47918655|NCT04371588|OTHER|No Response to Train of Four Stimulation|No response is observed during Train of Four stimulation monitoring during surgery
48092517|NCT00249483|DRUG|Placebo|Placebo
48092518|NCT00591747|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
48092519|NCT00591747|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
48092520|NCT03717311|OTHER|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
48443523|NCT04032782|DRUG|HM15136|10 mg/mL as protein in prefilled syringes
48443524|NCT04032782|DRUG|Placebo of HM15136|Placebo in prefilled syringes
47918656|NCT04371588|OTHER|1-2 Response to Train of Four Stimulation|1 to 2 response is observed during Train of Four stimulation monitoring during surgery
47918657|NCT02163603|PROCEDURE|Pelvic osteotomy|
47918658|NCT03515317|BEHAVIORAL|LoRETA Z-score NF|LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
47951163|NCT03959254|PROCEDURE|Physiotherapy post-surgical protocol for femoroacetabular impingement|"The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise."
48092521|NCT01125202|BEHAVIORAL|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
47918659|NCT03515317|BEHAVIORAL|theta/beta NF|The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
47918660|NCT01667419|DRUG|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
48092522|NCT01125202|BEHAVIORAL|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
48092523|NCT03293862|DEVICE|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
48092524|NCT03293862|PROCEDURE|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
48092525|NCT03293862|DEVICE|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
47918661|NCT01667419|DRUG|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
47918662|NCT06044051|OTHER|Blood sample|An additionnal volume of blood will be collected at inclusion and at each follow-up visit
47918663|NCT06044051|OTHER|Expectoration|Expectoration will be collected at inclusion and at each follow-up visit
47918664|NCT06044051|OTHER|Nasopharyngeal swab|A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
47918665|NCT03736902|OTHER|Qualitative semi structured interview|One-to-one semi structured interviews, guided by the Physical Activity for people with a Disability Framework (van der Ploeg et al, 2004) which is a model for understanding the different factors that influence whether people with a disability engage in physical activity. Participants that agree to take part in the study, will be offered an interview either in a private clinic room at the hospital, at their home (if they live within a 40-mile radius of the hospital) or via a web-based video link. The interviews are expected to last one hour and will be conducted by the primary researcher.
47918666|NCT06460740|OTHER|4-7-8 breathing technique|Treatment will be given 18 exercise sessions per month (four to five times per week). The patient at first will be directed to sit or lie down, in which manner they feel sense of comfort. Then they are asked to exhale completely through mouth emptying their lungs. Then closing their lips and inhaling silently through nose while counting on the count of 4 seconds, holding their breath for a count of 7 seconds and exhale slowly through semi-closed lips making a Whoosh sound for a count of 8 seconds. Inhale, hold breath, and exhale ratio of 4:7:8. In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling.
47918667|NCT06460740|OTHER|Stationary Cycling|In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling
48092526|NCT00819234|DRUG|Placebo|placebo pramlintide and placebo metreleptin twice daily
48092527|NCT00819234|DRUG|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
48092528|NCT05753293|OTHER|breathing exercise|"Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles"
48092529|NCT01700530|DRUG|Statin|Statins (40mg/day)for 12 weeks
48620202|NCT02340325|DRUG|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
48620203|NCT01257438|DEVICE|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
48620204|NCT01257438|DEVICE|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
48092530|NCT01700530|OTHER|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
48092531|NCT01700530|OTHER|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
48092532|NCT01938664|DRUG|Candesartan with CBT|8 mg, po (by mouth)
48092533|NCT01938664|OTHER|Placebo with CBT|
48092534|NCT05945082|OTHER|biopsy|biopsy of a colorectal cancer site
48092535|NCT03589924|PROCEDURE|Immediate IBBR+TiLoop®Bra|Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
48092536|NCT03589924|PROCEDURE|Immediate-delayed IBBR+TiLoop®Bra|Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
48443525|NCT05719922|OTHER|Resistance Training|Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
48620205|NCT05441904|DRUG|PXL770|A single dose of 500 and 750 mg was administered to each subject.
48620206|NCT00265278|DRUG|Modafinil|
48620207|NCT02650583|OTHER|Educational Intervention|Receive Enhancing Connections Program
47918668|NCT02867644|OTHER|standard care|Patients coming for preoperative breast assessment will have standard care.
48092537|NCT06140693|OTHER|Continuous exercise at an intensity below the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 80% of the intensity at the ventilatory threshold
48092538|NCT06140693|OTHER|Continuous exercise at an intensity at the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 100% of the intensity at the ventilatory threshold
48092539|NCT06140693|OTHER|Continuous exercise at an intensity above the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 110% of the intensity at the ventilatory threshold
48092540|NCT06140693|OTHER|Sprint interval training|22 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by four 30-s 'all-out' sprints, each with a 4-min recovery intervals at 25 W
47918669|NCT02867644|OTHER|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
47918670|NCT00166413|DRUG|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
47918671|NCT04947852|DEVICE|Investigation Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
47918672|NCT04947852|DEVICE|Comparator Mask|Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff
47918673|NCT03941704|DIETARY_SUPPLEMENT|Pulse-based diet|Low Glycemic Index
48092541|NCT06140693|OTHER|Reduced-exertion high-intensity interval training|10 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by two 20-s 'all-out' sprints, with a 3-min and a 4-min recovery interval at 25 W after the first and second sprint respectively
48092542|NCT01141140|BEHAVIORAL|Healthy|Favourable nutritional characteristics.
48092543|NCT01141140|BEHAVIORAL|Diet|Benefits of an ingredient/nutrient for weight management
48092544|NCT01141140|BEHAVIORAL|Unhealthy|Hedonic characteristics and less healthy ingredients.
47918674|NCT03941704|DIETARY_SUPPLEMENT|Regular diet|Moderate Glycemic Index
47918675|NCT01149668|DRUG|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
48092545|NCT02876146|DRUG|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
48092546|NCT04530344|DRUG|ruxolitinib|ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
48092547|NCT04530344|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
47918676|NCT04581707|DEVICE|Kyphoplasty Single Balloon Catheter Allevo|Vertebral compression fractures treated with Kyphoplasty Single Balloon Catheter Allevo (Joline®) and BonOs® Inject bone cement
48092548|NCT03556826|BEHAVIORAL|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
48620208|NCT02650583|OTHER|Questionnaire Administration|Ancillary studies
47918677|NCT04581707|DEVICE|Quattroplasty Double Balloon Catheter Stop'n GO|Vertebral compression fractures treated with Stop'n GO double balloon kyphoplasty system (Joline®) and BonOs® Inject bone cement
48620209|NCT01402726|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
47918678|NCT00197548|DIETARY_SUPPLEMENT|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
47918679|NCT00197548|DIETARY_SUPPLEMENT|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
47918680|NCT00512057|DRUG|allopurinol|allopurinol 300mg twice a day
47918681|NCT00512057|DRUG|placebo|placebo
48092549|NCT03063307|PROCEDURE|Atraumatic Restorative Treatment|
48092550|NCT03063307|OTHER|Silver Diamine Fluoride|
48269524|NCT03504826|DEVICE|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
47918682|NCT02292069|DRUG|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
47918683|NCT04516954|BIOLOGICAL|Convalescent COVID 19 Plasma|A total of 500 ml of convalescent COVID 19 plasma will be transfused intravenously per subject
47918684|NCT00572130|GENETIC|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
47918685|NCT00572130|GENETIC|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
47918686|NCT04122469|RADIATION|Stereotactic Body Radiotherapy|The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
47918687|NCT00233454|DRUG|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
48092551|NCT05350436|BEHAVIORAL|Balance Conditions|"Balance Conditions: (\~ 5 minutes in total)~* Balance Condition 1 (Feet 20cm apart)~* Balance Condition 2 (Feet together)~* Balance Condition 3 (Tandem stance)~Initial measurements of balance conditions serve two purposes: it generates a postural control baseline for us without the attribution of singing conditions, furthermore it allows us to separately measure long-term singing experience's effect on postural control, by assessing tasks differing in difficulty level. Balance conditions will be randomised to prevent a learning effect."
48269525|NCT01054079|OTHER|laboratory biomarker analysis|Correlative study
47918688|NCT00798278|DRUG|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
47918689|NCT00798278|PROCEDURE|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
47918690|NCT02408159|DRUG|Varicella Zoster Vaccine|
47918691|NCT02408159|DRUG|Placebo|
47918692|NCT04520529|OTHER|Biologic Samples|"* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.~* an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.~* In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research."
47918693|NCT01629446|DRUG|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
47918694|NCT02646371|BIOLOGICAL|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
48092552|NCT05350436|BEHAVIORAL|Singing|"Singing Conditions: (\~ 15 minutes)~* Warmup - including jaw and breathing exercises~* Singing Condition 1 (Spoken Happy Birthday - Traditional Tempo)~* Singing Condition 2 (Sung Happy Birthday - Traditional Tempo~* Singing Condition 3 (Spoken Happy Birthday - Fast Tempo)~* Singing Condition 4 (Sung Happy Birthday - Fast Tempo)~* Singing Condition 5 (Spoken Happy Birthday - Slow Tempo)~* Singing Condition 6 (Sung Happy Birthday - Slow Tempo)~Link to singing instructional video:~https://www.dropbox.com/s/tro58i6vx6i6w3a/Singing%20Balance%20Exercise%20Video.mp4?dl=0~Time stamps for the video:~* Warmup (including jaw exercises and breathing exercises) - beginning at 2:55 until 6:06~* Happy Birthday protocol - beginning at 15:26 until 20:21"
48269526|NCT01054079|PROCEDURE|quality-of-life assessment|Ancillary study
48269527|NCT01054079|OTHER|questionnaire administration|Ancillary study
48620210|NCT01459159|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
47918695|NCT02646371|BIOLOGICAL|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
47918696|NCT05506241|DEVICE|Dynavision D2|Use of the Dynavision will be comprised of six 3-minute or nine 2-minute sessions with 30 seconds to one-minute rest in between. All Dynavision sessions require clients to scan the 4' by 4' vertical board and hit the lit targets one at a time. Participants will be able to depress targets with their left or right hand, in standing or sitting.
48620211|NCT02078167|OTHER|nutraceutical combination (red yeast rice, policosanols and berberine)|
48443526|NCT03203876|BIOLOGICAL|Lirilumab|Specified dose on specified days
47918698|NCT00523445|DRUG|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
47918699|NCT00523445|DRUG|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
47918700|NCT02713074|DRUG|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
47918701|NCT02713074|DRUG|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
47918702|NCT05094778|PROCEDURE|a single-portal palm approach|a single-portal palm approach that passes superficially to palmar aponeurosis, and cut the full transverse carpal ligament.
47918703|NCT02551042|DRUG|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
47918704|NCT02551042|DRUG|0.9% sodium chloride|IV infusion
47918705|NCT02668471|PROCEDURE|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
47918706|NCT02668471|PROCEDURE|traditional method|Radial artery catheters will be placed by the palpation technique only.
47918707|NCT01412489|DEVICE|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
47918708|NCT04726540|OTHER|Patient Satisfaction|Patients were then asked to grade their overdentures/dentures on a visual analog scale and written questionnaire to evaluate their overall satisfaction.
47918709|NCT00150917|BEHAVIORAL|Supportive-Expressive Group Therapy|
47918710|NCT05682222|DRUG|EDP1815|EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.
47918711|NCT05682222|DRUG|EDP2939|EDP2939 is a pharmaceutical preparation of extracellular vesicles.
47918712|NCT05682222|DRUG|Placebo oral capsule|Placebo.
47918713|NCT00155675|DRUG|GUSUIBU|
47918714|NCT06055543|DIETARY_SUPPLEMENT|Fortimel|2 bottles/day of the high energy ONS
47918715|NCT05915156|OTHER|Post-acute home physiotherapy program|This health services research assessed the effects of a post-acute home physiotherapy program that was designed to provide physical rehabilitation services to older adults recently discharged from acute or post-acute care. Under this program, every patient was attended by a physiotherapy technologist within 48 hours of being discharged and received home physiotherapy for a minimum of three days per week for a maximum of eight weeks.
47951164|NCT04473092|DEVICE|TMVR|Patients who undergo TMVR for MR at the PI´s site
48092553|NCT01939860|OTHER|Written and verbal patient education on hypertension and its treatment|
48269528|NCT01054079|DRUG|cinacalcet hydrochloride|Given PO
48269529|NCT00880360|DRUG|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
48269530|NCT02155933|OTHER|Blood sampling|Blood sampling for later hormone measurements
48092554|NCT00594932|DRUG|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
48092555|NCT00594932|OTHER|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant). During the fourth month mycophenolate mofetil will be given in ascending doses to 3 gms/day (or less if tolerance issues arise) and continues until the end of the study at 6 months."
48092556|NCT05322161|BEHAVIORAL|yoga classes|"There will be 6 total yoga classes (one introduced per week for a 6 week period). Each yoga session will be divided into three components, which will vary in duration based on a curriculum designed specifically with the post-partum state of mothers in mind:~1. Yoga postures (Asana) = low impact gentle postures meant to be done individually~2. Breathing techniques (Pranayama) = deliberate modifications of breath such as rapid diaphragmatic breathing, slow/deep breathing, alternate nostril breathing, breath holding~3. Meditation (Dhyana) = guided meditation"
48092557|NCT01853917|OTHER|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
48269531|NCT01958645|DRUG|MEDI8111|MEDI8111 lyophilisate for solution for infusion
48092558|NCT04990674|BEHAVIORAL|REMOTION|REMOTION is an internet-based program focusing on emotion regulation and aimed at reducing patient symptom severity and improving emotion regulation. It consists of six modules and the structure is based on the extended process model of emotion regulation by Gross (2015). The intervention is currently being studied in an outpatient psychotherapy setting (Bielinski et al., 2020).
47918716|NCT04633044|DIETARY_SUPPLEMENT|Betaine|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
47918717|NCT04633044|DIETARY_SUPPLEMENT|Placebo|The intervention with supplement will start during the first 48h after birth and will last for 12 weeks
48092559|NCT04990674|BEHAVIORAL|TAU|Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).
48092560|NCT01334541|BEHAVIORAL|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~1. Risk Assessment~2. Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~3. Clinical Follow-Up Protocol"
48269532|NCT01958645|OTHER|Placebo|Placebo for MEDI8111 saline solution for infusion
48092561|NCT01273701|BEHAVIORAL|Psychosocial intervention|"The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1."
47918718|NCT00651079|DRUG|GSK1247303|
48269533|NCT04415424|BIOLOGICAL|4CMenB vaccine|A four-component meningococcal B vaccine
48269534|NCT04415424|OTHER|Placebo|0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
48269535|NCT02969902|DEVICE|Buzzy® device|
48269536|NCT02969902|DEVICE|Hand-held computer|
48269537|NCT01886521|PROCEDURE|Lumbar drain|
48269538|NCT01886521|PROCEDURE|Ventricular drain|
48269539|NCT05770128|PROCEDURE|laparoscope|subserosal manipulation of gallbladder with laparoscope .
48269540|NCT00927641|DRUG|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
48269541|NCT00927641|OTHER|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
47918719|NCT01074385|BEHAVIORAL|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
47918720|NCT03810872|DRUG|Afatinib|Open label
47918721|NCT03810872|DRUG|Paclitaxel|Paclitaxel
47918722|NCT04900740|DEVICE|Catheter fixation with surgical stitch|The catheter will be fixed using the standard procedure - surgical stitch.
47918723|NCT04900740|DEVICE|Catheter fixation with glue (cyanoacrylate tissue glue Secure PortIV)|The catheter will be fixed using the experimental procedure - novel surgical glue.
48269542|NCT04320524|DEVICE|Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention|3 weeks
48269543|NCT01289015|DRUG|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
48269544|NCT01289015|DRUG|Placebo|Topical; applied once daily for two weeks
48269545|NCT02909621|DIETARY_SUPPLEMENT|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
48269546|NCT02909621|OTHER|PLACEBO|
48269547|NCT06318208|DIAGNOSTIC_TEST|lung function testing|lung function testing including LCI, FEV1, FVC, DLCO
48269548|NCT01811511|DIETARY_SUPPLEMENT|Chungkookjang|
48269549|NCT01811511|DIETARY_SUPPLEMENT|Placebo|
48269550|NCT00797693|DRUG|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
48269551|NCT05331911|DRUG|Propofol|total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
48620212|NCT05855941|DIAGNOSTIC_TEST|FDG-PET/CT and FDG-PET/MRI|Intravenous injection of FDG 3 MBq/kg. Intravenous injection of Dotarem 279.3 mg/ml, 0.2 ml/kg.
47918724|NCT03598517|RADIATION|high dose chemoradiotherapy|"Radiation therapy: 60 Gy at 2 Gy/Fx/d over 6 weeks, immediately followed by 28.8 Gy in 24 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 88.8 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy is planned 6 weeks after high dose chemoradiation."
48269552|NCT05331911|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
47918725|NCT03835832|OTHER|The participants do not receive any intervention for this study|The participants do not receive any intervention for this study
48269553|NCT04786067|DRUG|Belatacept|Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
48092562|NCT01273701|BEHAVIORAL|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
48269554|NCT03897751|DEVICE|ABT12 Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
47918726|NCT01039103|DRUG|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
47918727|NCT01039103|DRUG|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
47918728|NCT00152269|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
47918729|NCT00152269|DRUG|Asoprisnil|25mg Tablet, oral Daily for 12 months
48620213|NCT01414296|DRUG|PSMA ADC|PSMA ADC administered IV
47918730|NCT00152269|DRUG|Placebo|Placebo, Tablet, oral Daily for 12 months
48269555|NCT03897751|DEVICE|COMPLETE Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
48269556|NCT03897751|DEVICE|Sensitive Eyes® Rewetting Drops|For use as needed during the study.
48269557|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
48269558|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
48269559|NCT05398614|BIOLOGICAL|SENL101|Patients will be treated with CD7 CAR-T cells
48620214|NCT05850507|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
48620215|NCT05850507|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells) .
47918731|NCT06138093|DEVICE|Sealing device|Intratracheal tracheostomy sealing
47918732|NCT06138093|DEVICE|No device|Open tracheostomy wound
47918733|NCT03303508|DIAGNOSTIC_TEST|anti-ds DNA|venous blood samples
47918734|NCT04291170|OTHER|QDASH|completing the tasks on the QDASH: open jar, wash wall, carry shopping bag, wash back, cut food, hammer wood
47918735|NCT04291170|OTHER|KOOSJR|completing tasks on the KOOSJR: pivot, straighten, go up/down stairs, stand upright, rise from sitting, bend over
47918736|NCT00299611|DRUG|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
47918737|NCT00299611|DRUG|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
47918738|NCT00299611|DRUG|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
47918739|NCT04790565|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
48092563|NCT00164593|BEHAVIORAL|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
48092564|NCT05510687|DEVICE|Glasses to correct presbyopia|Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
48092565|NCT04795141|DRUG|ABY-035|ABY-035 Solution for injection
48269560|NCT01745757|DRUG|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
48269561|NCT01745757|DRUG|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
48269562|NCT02662790|OTHER|Doppler|
48269563|NCT02720757|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
48269564|NCT00903279|DRUG|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
48269565|NCT00903279|DRUG|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
48620216|NCT02744456|DRUG|Losartan|An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
48620217|NCT02744456|DRUG|Amlodipine|A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
48620218|NCT02744456|DRUG|Hydrochlorothiazide|A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
48269566|NCT05261854|DEVICE|Pressure biofeedback|Deep cervical flexor training by using preesure biofeedback will be given 5 days a week for 6 week Conventional exercise for deep cervical muscle training will be given 5 days a week for 6 weeks
48269567|NCT05261854|OTHER|Conventional exercises for deep cervical muscle training|Conventional exercise for deep cervical muscle training will be given 4 days a week for 6 weeks
48269568|NCT01911858|DEVICE|Askina Calgitrol Paste|
48269569|NCT00784667|DRUG|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
48269570|NCT00784667|DRUG|Erlotinib|100mg orally daily continuously
48620219|NCT01719328|BEHAVIORAL|Vinyasa yoga|
48092566|NCT04795141|DRUG|Placebo|Normal Saline for injection
47918740|NCT02532699|DIETARY_SUPPLEMENT|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
47918741|NCT02532699|DIETARY_SUPPLEMENT|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
47918742|NCT00257270|DRUG|gabapentin|
47918743|NCT05865041|DRUG|Farudodstat|Farudodstat tablets administered orally
47918744|NCT05865041|DRUG|Placebo|Placebo tablets administered orally
47918745|NCT01467219|PROCEDURE|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
47918746|NCT01467219|PROCEDURE|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
47918747|NCT01467219|PROCEDURE|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
47918748|NCT01467219|RADIATION|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
47918749|NCT01368562|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
47918750|NCT00644007|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
48092567|NCT00273676|PROCEDURE|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
47918751|NCT00644007|DRUG|SK3530|SK3530 100 mg
47918752|NCT04708236|DRUG|ORTD-1 low dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
47918753|NCT04708236|DRUG|ORTD-1 mid dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
47918754|NCT04708236|DRUG|ORTD-1 high dose|ORTD-1 will be administered intravenously once daily for 5 consecutive days.
47918755|NCT04708236|OTHER|Vehicle control|Vehicle Control will be administered intravenously once daily for 5 consecutive days.
47918756|NCT05236699|COMBINATION_PRODUCT|DEB-TACE combined with Surufatinib and Camrelizumab|"1. All patients will be treated with standard DEB-TACE on the first day (D1).~2. After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~3. Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~4. The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study."
48092568|NCT00660374|DRUG|insulin NPH|"Soft-treat-to-target dose titration scheme, injection s.c."
48092569|NCT00660374|DRUG|EX1000|"Soft-treat-to-target dose titration scheme, injection s.c."
47918757|NCT00809302|DRUG|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
47918758|NCT05103852|PROCEDURE|Cardiac MRI|vigilant patient installed in the MRI with compatible ECG electrodes for synchronization and monitoring, blood pressure cuff for monitoring, cardiac antenna. Sterile drape over the femoral region, femoral local anesthesia, femoral venipuncture, Swan Ganz probe venous navigation (CE marking, MRI compatible at 1.5T) with balloon inflated with 2 cc of gadolinium, navigation under real time SSFP cine sequence.
48092570|NCT01944982|BIOLOGICAL|Expanded haploidentical natural killer cells (NKAEs)|
47918759|NCT04093024|DRUG|Nintedanib|Capsule
47918760|NCT04093024|DRUG|Placebo|Capsule
48092571|NCT02742909|DRUG|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
48092572|NCT02742909|DRUG|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
48092573|NCT01904357|DRUG|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and \< 50 kg will receive the 1g dose.
48092574|NCT01904357|DRUG|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
48092575|NCT06327113|DRUG|CeFAZolin Injectable Solution|One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
48092576|NCT06275880|OTHER|Intra-articular infiltration of PVP Collagen|Intra-articular collagen injection plus physiotherapy program
48092577|NCT06275880|OTHER|Rehabilitation|Patients who received conservative treatment through rehabilitation with a home program for one month
48092578|NCT05396495|DEVICE|NeurolyserXR|Using the NeurolyserXR to non-invasively ablate the posterior sacral branches enervating the sacroiliac joint
48092579|NCT03791177|OTHER|Music Therapy|"Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy"
48092580|NCT01642186|DRUG|everolimus|
48092581|NCT01642186|DRUG|letrozole plus leuprolide|
48092582|NCT01642186|DRUG|combination of everolimus, letrozole and leuprolide|
48092583|NCT04805151|OTHER|No intervention|No intervention
47918761|NCT05760690|PROCEDURE|Retro-Auricular Single-Site Endoscopic Thyroidectomy|The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.
47918762|NCT05760690|PROCEDURE|Transoral Endoscopic Thyroidectomy Vestibular Approach|The patient was placed in a supine position with slight neck extension under nasotracheal intubation. The mouth was garbled with povidone iodine before surgery. Three laparoscopic ports (a 10- to 15-mm port at midline and two 5-mm ports at the lateral junction between the canine and first premolar teeth)were inserted under the lower lip at the oral vestibular area.The strap muscleswere separated in the midline to expose the thyroid and trachea. The recurrent laryngeal nerve (RLN) was identified at the insertion to the larynx, then followed downandparallel tothe trachea inferiorly.
47918763|NCT05760690|PROCEDURE|Transareola Endoscopic Thyroidectomy|The patient was in supine position. Incision was made inside the right areola and a 10mm puncture device was placed, subcutaneous separation rod was used to separate the space, and a 30° endoscope was introduced, puncture device was placed in a 5mm incision on the left areola, ultrasonic knife free flap was used, subcutaneous separation space was placed in the upper sternal segment, and a 5mm puncture device was placed outside the right areola. The anterior cervical flap was further dissociated to establish a space. The median cervical line was cut to cut off the isthmus of the thyroid, and the tracheal fascia ligament of the thyroid was separated and the nerve was exposed to protect the nerves. Then remove the lobe of thyroid and central lymph nodes
47918764|NCT03630770|DRUG|Medium-Chain Triglyceride (MCT) Oil|Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
48092584|NCT06202937|BEHAVIORAL|Mother Baby Yoga|Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level
48092585|NCT06202937|OTHER|No intervention:control|the control group received the usual care
47918765|NCT03196609|BIOLOGICAL|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
47918766|NCT02411864|OTHER|different low b-values distribution|
47918767|NCT01958489|DRUG|Evacetrapib|Administered orally
47918768|NCT01958489|DRUG|Pravastatin|Administered orally
47918769|NCT00133003|DRUG|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight
48269571|NCT03298009|DRUG|Canagliflozin 100mg|2-week intervention
47918770|NCT00133003|DRUG|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
48092586|NCT04992442|DRUG|TAK-935 Oral Tablet|TAK-935 tablet
48092587|NCT04992442|DRUG|[14C]TAK-935 IV Infusion|\[14C\]TAK-935 IV infusion
48092588|NCT04992442|DRUG|[14C]TAK-935 Oral Solution|\[14C\]TAK-935 oral solution
48269572|NCT03298009|DRUG|Placebo oral capsule|2-week intervention
48269573|NCT03298009|RADIATION|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
48269574|NCT03841552|DEVICE|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
47918771|NCT03216434|DIAGNOSTIC_TEST|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
47918772|NCT03684369|DEVICE|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
47918773|NCT06443645|DRUG|Anthracycline|as standard of care
48092589|NCT04515784|BEHAVIORAL|Safety Aid Reduction Treatment for PTSD|START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).
48269575|NCT03841552|OTHER|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
47918774|NCT02967341|OTHER|Ciprofloxacin administration|Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
47918775|NCT06259006|DRUG|Dexamethasone Oral|4mg capsules taken orally in three divided doses to a total daily dose of 20mg/m2 (maximum dose 24mg/day) for three days
47918776|NCT06259006|DRUG|Placebo|Matching capsules taken orally three times daily for three days
47918777|NCT03013309|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health and prevent/manage obesity
48092590|NCT06477939|DRUG|Administration of L-TC|"Administration of L-TC (300 mg) as an IV perfusion, before each radiotion session~Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
48092591|NCT06477939|OTHER|Radiotherapy plus Temozolomide|"Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days."
48092592|NCT06356259|DRUG|IRX-010|Administered IV
48092593|NCT06356259|DRUG|Placebo|Administered IV
47918778|NCT03013309|OTHER|Treatment as usual|Treatment as usual
47918779|NCT05369182|DIAGNOSTIC_TEST|Invasive physiologic assessment|"All coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters.~In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed."
47918780|NCT05369182|DIAGNOSTIC_TEST|Intravascular imaging|By the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS \[Boston Scientific, Natick, Massachusetts, USA\] or OCT \[Abbott Vascular\], St. Paul, MN, USA\]).
47918781|NCT03595228|BIOLOGICAL|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
47918782|NCT00173641|PROCEDURE|blood drawing|
47918783|NCT03859947|DEVICE|Heated humidiﬁed high-flow nasal cannula|Non-invasive ventilation with a nasal cannula
47918784|NCT01814709|DRUG|GDC-0032|Oral doses of GDC-0032
47918785|NCT01814709|DRUG|Itraconazole|Oral doses of Itraconazole
47918786|NCT01814709|DRUG|Rifampin|Oral doses of Rifampin
47918787|NCT05652088|PROCEDURE|Colonoscopy|Colonoscopy is a procedure where an instrument called colonoscope is inserted through the rectum to look at the entire internal surface of the intestine. Participants will be placed on a stretcher on the left side. A colonoscope will be advanced into the colon and into the terminal ileum. The entire procedure should take approximately 40 minutes
47918788|NCT01748240|DRUG|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
47918789|NCT01612923|OTHER|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
47918790|NCT02090842|DIETARY_SUPPLEMENT|Ca-caseinate|
47918791|NCT02090842|DIETARY_SUPPLEMENT|Maltodextrin|
47918792|NCT02090842|DIETARY_SUPPLEMENT|Whey protein isolate|
47918793|NCT04513626|DRUG|DORAVIRINE 100 MG [Pifeltro]|Immediate switch
47918794|NCT01117909|OTHER|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
47918795|NCT01117909|OTHER|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
47918796|NCT04494568|DEVICE|HIFU treatment|HIFU Treatment of rectal endometriosis
47918797|NCT00460291|DEVICE|Implantation of the ProVena vein graft during bypass surgery|
47918798|NCT03948945|RADIATION|Profile HaloTM Mixed Fractional Laser|Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
47918799|NCT00093249|DRUG|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
47918800|NCT00093249|DRUG|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
47918801|NCT05048511|BIOLOGICAL|vitamin D estimation|Serum samples to estimate vitamin D status were collected on the sixth day of stimulation
47918802|NCT01181986|DRUG|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
47918803|NCT01181986|DRUG|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
47918804|NCT01181986|DRUG|Placebo SC|Placebo sc BID/10days
47918805|NCT01181986|DRUG|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
47918806|NCT01181986|DRUG|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
48443527|NCT03203876|BIOLOGICAL|Nivolumab|Specified dose on specified days
47918807|NCT01301898|DRUG|GC1111_0.5mg/kg|
47918808|NCT01301898|DRUG|GC1111_1.0mg/kg|
47918809|NCT01301898|DRUG|Elaprase_0.5mg/kg|
47918810|NCT05401942|OTHER|Tele-monitoring through mobile application|Tele-monitoring of Patient reported outcomes
47918811|NCT00199719|DRUG|Ribavirine|
47918812|NCT03615040|DRUG|MSTT1041A|"MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2."
47918813|NCT03615040|DRUG|Placebo|Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
47918814|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 30μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.
47918815|NCT04760743|BIOLOGICAL|NBP2001 adjuvanted with alum (RBD 50μg/dose)|Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.
47918816|NCT04760743|OTHER|Normal Saline|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
47918817|NCT03833193|RADIATION|Hypofractionated radiotherapy|Radiation: Hypofractionated radiotherapy at 3Gy/f
47918818|NCT05155891|DEVICE|Embosphere Microspheres|The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.
47918819|NCT05155891|PROCEDURE|HoLEP Procedure|The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
47918820|NCT03697889|DRUG|Naproxen sodium (test product)|Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
47918821|NCT03697889|DRUG|Naproxen sodium (reference product)|Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
47918822|NCT00440791|DEVICE|PillCam Colon capsule endoscopy|
48269576|NCT01983644|DEVICE|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
48269577|NCT01983644|DEVICE|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
48269578|NCT04291144|RADIATION|PET-CT using FEOBV|We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
47918823|NCT03718091|DRUG|M6620|M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
47918824|NCT05260918|OTHER|Float-REST|Participants will utilize sensory deprivation tanks.
47918825|NCT05260918|OTHER|Nappod|Participants will utilize nappod.
47918826|NCT03409887|PROCEDURE|Intraorifice barrier of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
47918827|NCT03409887|PROCEDURE|Base of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
47918828|NCT03409887|PROCEDURE|Direct composite restoration|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
48092594|NCT03269396|PROCEDURE|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
48269579|NCT04291144|RADIATION|MRI-scan|All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.
48269580|NCT04291144|DIAGNOSTIC_TEST|Cognitive assessment|Full neuropsychometric examination including tests in 5 cognitive domains.
48269581|NCT04291144|DIAGNOSTIC_TEST|Clinical assessment|Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.
48269582|NCT01030692|DRUG|Placebo|The placebo groups will receive the same dosage throughout the study.
48269583|NCT01030692|DRUG|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
48443528|NCT03203876|BIOLOGICAL|Ipilimumab|Specified dose on specified days
47918829|NCT03288051|OTHER|Fluid management|Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
48269584|NCT01030692|DRUG|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
47918830|NCT03288051|DRUG|Norepinephrine|Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
48269585|NCT01030692|DRUG|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
47918831|NCT03288051|DRUG|Dobutamine|Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
47918832|NCT04193072|BEHAVIORAL|Assessment of imagery ability|Movement imagery, kinesthetic imagery, and visual imagery ability assessed.
47918833|NCT05429736|BEHAVIORAL|Motor Skill Training (MST)|During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
48269586|NCT01030692|DRUG|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
47918834|NCT05429736|DEVICE|Transcutaneous Spinal Stimulation (TSS)|TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
47918835|NCT04030156|PROCEDURE|tonsillectomy|Tonsillectomy was performed under general anesthesia using cold dissection method.
47918836|NCT02903459|OTHER|Transversal Study so there is no intervention|
47918837|NCT01806701|BEHAVIORAL|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
47918838|NCT00817596|DEVICE|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
47918839|NCT06196671|DRUG|H101|H101 15x10\^11vp intratumorally injection starts at day 1.
47918840|NCT06196671|DRUG|Camrelizumab|Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.
47918841|NCT05606029|PROCEDURE|Cholecystectomy, extended cholecystectomy|Cholecystectomy and histopathological evaluation
47918842|NCT01622309|DIETARY_SUPPLEMENT|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
47918843|NCT01622309|OTHER|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
47918844|NCT04305067|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
47918845|NCT06365762|DRUG|EDTA Ophthalmic Solution 2.6%|
47918846|NCT06365762|DRUG|EDTA Ophthalmic Solution 1.3%|
47918847|NCT06365762|DRUG|Saline Solution (Placebo)|
47918848|NCT05212818|DRUG|TF0023|Techfields Inc. is developing TF0023, a new investigational prodrug, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19 and other viruses.
47918849|NCT03264729|OTHER|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
48269587|NCT01988389|DIETARY_SUPPLEMENT|whole apples (WA)|
48269588|NCT01988389|DIETARY_SUPPLEMENT|apple juice (AJ)|
48269589|NCT01730248|DRUG|INC424|5 mg tablets administered orally twice daily
48269590|NCT01730248|DRUG|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
48269591|NCT01629407|OTHER|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
48269592|NCT04582760|OTHER|early mobilization|In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
48269593|NCT02384811|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
48269594|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
48269595|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
48269596|NCT05123560|OTHER|Anonymous online questionnaire|A QR code qill be provided to access the online questionnaire
47918850|NCT03264729|OTHER|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.~If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
48269597|NCT00536172|DRUG|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
48269598|NCT00536172|DRUG|Placebo|Placebo distribution matches the active medication.
48269599|NCT01824979|DEVICE|CPAP mask ( Pilairo)|
48269600|NCT01824979|PROCEDURE|Other CPAP mask|
48269601|NCT00712374|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
48269602|NCT02268162|PROCEDURE|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
47918851|NCT03264729|OTHER|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
48269603|NCT01124565|DRUG|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
48269604|NCT01214044|DRUG|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
47918852|NCT03135119|BEHAVIORAL|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
48269605|NCT02908100|DRUG|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
48269606|NCT02908100|DRUG|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
48269607|NCT05320575|DRUG|Zanubrutinib|The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
48269608|NCT01111266|DEVICE|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
48269609|NCT06111989|BEHAVIORAL|Neuropsychological testing|The neuropsychological assessment will involve paper and pencil tests, computerized tests (such as reaction time measurements) and a driving simulator.
48269610|NCT06111989|BEHAVIORAL|On road test|The driving instructor will guide the participant on a standard route, and will evaluate the performance using standard criteria that will focus mainly on traffic safety.
48269611|NCT02838173|PROCEDURE|serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)|
48269612|NCT02838173|PROCEDURE|tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)|
48269613|NCT02838173|PROCEDURE|serratus plane bloc : placebo|
48269614|NCT02838173|PROCEDURE|tissue infiltration : placebo|
48269615|NCT02356809|DRUG|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
48269616|NCT04391725|PROCEDURE|Periapical surgery with guided tissue regeneration|periapical surgery will be done followed by placement of mixture of iPRF and type 1 collagen granules
48269617|NCT04391725|PROCEDURE|Periapical surgery without anyguided tissue regeneration|periapical surgery will be done followed by flap closure
48269618|NCT03585140|OTHER|Normal diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
48269619|NCT03585140|OTHER|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
48269620|NCT03585140|DRUG|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
48269621|NCT03585140|DRUG|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
48269622|NCT04939688|RADIATION|Conventional dose AND ultra low-dose CT scanning in the search for cranial lesions|As well as undergoing the usual, conventional radiation dose CT scan, these patients will also undergo ultra low-dose CT scanning in the search for cranial lesions.
48269623|NCT04067765|BEHAVIORAL|Alcohol cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor)
48269624|NCT04067765|BEHAVIORAL|Neutral cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of neutral beverages (water).
48269625|NCT04082208|DEVICE|High Flow nasal cannula|Administration of high flow nasal cannula during ERCP procedure
48269626|NCT04082208|DEVICE|Low Flow nasal cannula|Administration of low flow nasal cannula during ERCP procedure: standard care
48269627|NCT02850419|DRUG|ThermoDox (Thermally Sensitive Liposomal Doxorubicin)|A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
48269628|NCT02850419|RADIATION|Radiation Therapy|A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
48269629|NCT02850419|DEVICE|Superficial Hyperthermia|Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
48269630|NCT03047499|DRUG|Botulinum toxin type A|Botulinum toxin type-A injection
48269631|NCT04157387|OTHER|Cyriax inferior capsular stretching + Manual Therapy|Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
48269632|NCT04157387|OTHER|Manual therapy|"Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)"
48269633|NCT00145444|DRUG|olanzapine|
48269634|NCT00145444|DRUG|ziprasidone|
48269635|NCT03871478|DRUG|Lidocaine|See Arm Description
48269636|NCT03871478|DRUG|Bupivacaine|See Arm Description
48269637|NCT03871478|DRUG|Lidocaine and Bupivacaine|See Arm Description
48269638|NCT05073055|PROCEDURE|İnguinal Hernia Repair|After hemodynamic stability, the patient was placed in the lateral position and infiltration anesthesia with 2% lidocaine was applied. Following aseptic preparation of the skin and probe, a medium-frequency curvey USG transducer was first placed in the midline to visualize the transverse projection of the first lumbar (L1) vertebra, then moved 2.5 cm laterally in the parasagittal plane, after imaging the transverse process, in-plane spreading was injected. Hydrodissection was achieved on the TP of L1 by using a 5 cm, 21G peripheral nerve block needle just below the erector spina muscle with real-time imaging of the substance. Afterwards, a unilateral injection of 15 ml at T12 and L1 levels was applied to each segment with the needle directed at two different angles from the same insertion point.
48269639|NCT02002143|BEHAVIORAL|Group Appointments|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
48269640|NCT02002143|BEHAVIORAL|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
48269641|NCT04317755|BEHAVIORAL|AdhaFULL body image comics|The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
48269642|NCT03135912|DRUG|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
47918853|NCT03135119|BEHAVIORAL|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
47918854|NCT06128265|BEHAVIORAL|Sleep Extension|Extending time in bed by 2 hours (going to bed earlier and/or waking up later)
47918855|NCT06128265|BEHAVIORAL|Sleep Regularity|Consistent bedtimes (within 30min)
47918856|NCT01284491|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
47918857|NCT01284491|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
47918858|NCT03758300|OTHER|Radiofrequency|See previous page
47918859|NCT02322853|DRUG|Tamoxifen|hormonotherapy
47918860|NCT02322853|DRUG|Ralimetinib (LY2228820 dimesylate)|
47918861|NCT02809222|OTHER|Samples|Blood samples
47918862|NCT02809222|OTHER|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
47918863|NCT04458480|COMBINATION_PRODUCT|Fast Inpatient Rehabilitation|Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
47918864|NCT01903980|OTHER|No intervention. It is a retrospective study|No intervention. It is a retrospective study
47918865|NCT02909608|OTHER|No interventions / observations only|This is an observational study only
47918866|NCT00003472|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
48620220|NCT00997529|DRUG|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 \& 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction \& immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression \& do not have signs of GVHD, will receive a DLI
48620221|NCT02442128|DRUG|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
47918867|NCT02613026|DRUG|Pirarubicin|
47918868|NCT02613026|DRUG|Docetaxel|
47918869|NCT02613026|DRUG|Cyclophosphamide|
47918870|NCT00985777|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
47918871|NCT02365233|DRUG|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
47918872|NCT02365233|DRUG|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
47918873|NCT02365233|DRUG|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
47918874|NCT00001012|DRUG|AL 721|
47918875|NCT06514989|DIETARY_SUPPLEMENT|Low-residue full nutrition formula podwer|The day before the colonoscopy, subjects were given a low-residue full nutrition formula podwer instead of a traditional self-prepared low-residue diet. Subjects were given 6 packs (60g/pack) pre-packaged FNFP and asked to use the FNFP according to individual needs. The 2 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 1 liter taken 3-5 hours before the colonoscopy.
47918876|NCT06514989|DIETARY_SUPPLEMENT|Self-prepared low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liter taken 4-6 hours before the colonoscopy.
47918877|NCT05254847|DRUG|Capecitabine combined with lenvatinib and tislelizumab|Capecitabine combined with lenvatinib and tislelizumab
47918878|NCT05468047|DRUG|Ketamine hydrochloride injection|Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
47918879|NCT02543749|BIOLOGICAL|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
47918880|NCT05114642|DEVICE|Skeletal Class III Malocclusion Treatment with Face Mask Group|Expanding the maxilla, which is narrower than the mandible in the transverse dimension, using a rapid maxillary expansion device and protraction of the maxilla, which is located behind in the sagittal dimension, forward using the face-mask appliance.
47918881|NCT01639729|DRUG|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
47918882|NCT01639729|DRUG|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
47918883|NCT01639729|DRUG|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
47918884|NCT01639729|DRUG|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
47918885|NCT00756535|PROCEDURE|Exercise training|Group-based exercise training 5 days a week during hospitalization
47918886|NCT00756535|PROCEDURE|usual treatment and rehabilitation|usual treatment and rehabilitation
47918887|NCT02891070|DRUG|FS VH S/D 500 s-apr|
47918888|NCT02891070|DEVICE|DuraSeal Dural Sealant|
47918889|NCT06514807|DRUG|Ropeginterferon alfa-2b (BESREMi®)|Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
47918890|NCT00374829|BEHAVIORAL|An IT-based patient follow-up and reminder system|
47918891|NCT01363349|DRUG|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
47918892|NCT01363349|DRUG|Risperidone|
48269643|NCT03135912|DRUG|Placebo|Dosage method of SESC 01, without active ingredients.
47918893|NCT00300547|PROCEDURE|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
48269644|NCT03135912|DRUG|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
47918894|NCT03711240|DRUG|bevacizumab|5mg/kg iv day 1 every 2 weeks
47918895|NCT03711240|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
47918896|NCT03711240|DRUG|Irinotecan|150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
47918897|NCT03711240|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
47918898|NCT03711240|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
48269645|NCT02817672|BEHAVIORAL|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
48269646|NCT02817672|BEHAVIORAL|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
47918899|NCT06297278|BEHAVIORAL|Moderate Intensity Exercise|Participants randomized to the active (moderate intensity) exercise condition will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as participants staying within a zone of 60-80% AAMHR with the target being to attain and maintain 70-75% AAMHR while briskly walking and/or jogging depending on current fitness status, is reached for a total of 30 min.
48092595|NCT06615115|OTHER|Exercise|All participants will perform a total body stretching exercise for 10 minutes, followed by 10 minutes of obstacle course navigation, 10 minutes of balance training (including tandem walking, balance board exercises, single-leg balance, and two-legged reaching exercises), and will conclude with 10 minutes of strength training exercises.
48092596|NCT00748969|DRUG|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
48092597|NCT06204666|DIETARY_SUPPLEMENT|High Dose Hemp Fiber Bar|High dose hemp fiber bar with other ingredients
48092598|NCT06204666|DIETARY_SUPPLEMENT|Low Dose Hemp Fiber Bar|Low dose hemp fiber bar with other ingredients
48092599|NCT06204666|DIETARY_SUPPLEMENT|Placebo|Placebo bar with other ingredients
48092600|NCT01293461|DRUG|CBX129801|Subcutaneous injection
48092601|NCT01293461|DRUG|Placebo|Subcutaneous injection
48620222|NCT02442128|DRUG|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
47918900|NCT06272903|DRUG|20% benzocaine, topical anesthetic|"Indicated as a topical anesthetic for use on oral mucosa prior to local anesthetic injections, scaling and prophylaxis. Also useful to relieve discomfort associated with taking impressions and intra- oral radiographs.~The benzocaine topical anesthetic will be applied according to standard clinical practice, aiming to provide local anesthesia to the treatment site and minimize discomfort during the procedure (placing elastomeric orthodontic separators)."
47918901|NCT06272903|OTHER|Children's Toothpaste|Strawberry-flavored children's toothpaste available in Dubai, UAE.
47918902|NCT02537795|DEVICE|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
48092602|NCT02718469|BIOLOGICAL|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
48092603|NCT02718469|BIOLOGICAL|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
48092604|NCT02718469|BIOLOGICAL|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
48269647|NCT03057366|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
48269648|NCT03057366|DRUG|[14C]-Pevonedistat|\[14C\]-Pevonedistat intravenous infusion.
48269649|NCT03057366|DRUG|Docetaxel|Docetaxel intravenous infusion.
48620223|NCT04558528|DIAGNOSTIC_TEST|Novel in vitro diagnostics and medical applications|Novel in vitro diagnostics and medical applications
47918903|NCT02537795|PROCEDURE|anterior capsulotomy|
48269650|NCT03057366|DRUG|Carboplatin|Carboplatin intravenous infusion.
48269651|NCT03057366|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
48269652|NCT00122135|OTHER|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
48269653|NCT00245947|DRUG|ERB-041|
48269654|NCT03665038|DRUG|Brexanolone|Administered as IV infusion.
48443529|NCT01364493|DRUG|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
48443530|NCT03205241|DIETARY_SUPPLEMENT|n-3 PUFA|n-3 PUFA capsules containing EPA and DHA
48443531|NCT03205241|DIETARY_SUPPLEMENT|Placebo|Olive oil capsules
47918904|NCT03900325|DRUG|Nimacimab|2.5 mg/kg
48092605|NCT02718469|BIOLOGICAL|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
47918905|NCT03900325|DRUG|Placebo|0.9% sodium chloride
47918906|NCT01054833|PROCEDURE|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
47918907|NCT06010043|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
47918908|NCT06010043|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
47918909|NCT03730402|DRUG|Bupivacaine|utilizing local anesthetic to perform a regional block under laparoscopic guidance
47918910|NCT03730402|DRUG|Exparel 266 milligram Per 20 ML Injection|utilizing local anesthetic to perform a regional block under laparoscopic guidance
47918911|NCT03730402|DRUG|Saline|placebo injection of saline
47918912|NCT02083861|DEVICE|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
47918913|NCT03028454|DIETARY_SUPPLEMENT|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
47918914|NCT03028454|DIETARY_SUPPLEMENT|Placebo|Capsules containing rice flour powder.
47918915|NCT00120757|DRUG|Alendronate|
47918916|NCT04504409|OTHER|Rehabilitation|Training
47918917|NCT01368224|DIETARY_SUPPLEMENT|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|"1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route."
47918918|NCT01184950|OTHER|Trainer Curriculum|
47918919|NCT06049901|DRUG|Nitazoxanide|Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
47918920|NCT06073483|DEVICE|Toumai Endoscopic surgery System|5G remote gastrectomy on subjects using the Toumai endoscopic surgery system
47918921|NCT05877742|OTHER|AA group|Participants will individually receive a 5-minute AA education delivered verbally at his/her respective clinic by a trained nursing student interventionist in addition to the usual scheduled follow-ups and activities at clinics.
47918922|NCT05877742|OTHER|Control group|To mimic the time and attention spent, the control group will individually receive a 5-minute seminar delivered by an RA.
47918923|NCT00137878|DRUG|TNFerade™|
47918924|NCT04228029|DEVICE|Carboxytherapy|Carbon dioxide (CO2) gas in injection form
47918925|NCT04228029|DRUG|Intralesional Steroid Injection|triamcinolone acetonide 8 mg/mL
47918926|NCT04130269|OTHER|No intervention|Questionnaires, lab-run
47918927|NCT02198001|DRUG|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10"
47918928|NCT02198001|PROCEDURE|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
47918929|NCT03497351|DRUG|Nicardipine|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
47918930|NCT03497351|DRUG|Urapidil|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
47918931|NCT04027075|BEHAVIORAL|Qlarity app users|Use of the Qlarity app involves completing 12 modules and 12 practice sessions over 30 days.
47918932|NCT02441296|OTHER|Formula with lactose|
47918933|NCT02441296|OTHER|Formula with maltodextrins|
47918934|NCT04316819|OTHER|Packed Promise Demonstration Benefits|Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
47918935|NCT01485172|DRUG|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
47918936|NCT01485172|DRUG|placebo monotherapy|placebo as monotherapy in Parkinson's disease
48620224|NCT01402856|OTHER|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long \& utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, \& interactive games simulating distracted driving.
48620225|NCT00017160|DRUG|doxorubicin|
48620226|NCT00017160|DRUG|filgrastim|
47918937|NCT02193906|OTHER|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
47918938|NCT02193906|OTHER|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
47918939|NCT04344964|OTHER|None - NA|Observational study
47918940|NCT05382949|OTHER|SilverBills Financial and Legal Tech Tool for Caregivers|All subjects will be receiving the Silverbills financial and legal tech tool and a pre-post analysis will be conducted.
47918941|NCT02152280|DRUG|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
47918942|NCT02152280|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
48092606|NCT04122924|OTHER|Abdominal muscle training|The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
48269655|NCT04815837|BEHAVIORAL|Intervention|"1. Viewing a video promoting Human Papillomavirus (HPV) vaccination: participants will watch a 5-minute online video promoting MSM's uptake of HPV vaccination. In the video, a peer MSM discussed about the risk of contracting HPV and having anal cancers among MSM, severe consequences of HPV-related diseases, as well as the benefits of HPV vaccination. He also demonstrated the procedures of taking up HPV vaccination in the collaborative private clinics, which portrayed caring, privacy guaranteed, and non-judgmental environment.~2. Receiving the discount coupons: each participant will be given a discount coupon. By using the coupon, one can enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborating private clinic.~3. Visiting the project webpage: Participants can assess the project webpage by scanning the QR code on the discount coupon.~4. Follow-up reminders: participants received five reminders at Month 1, 2, 4, 6, \& 8."
48269656|NCT04866290|DEVICE|HepaSphere Microspheres|
48269657|NCT00389025|DRUG|Olopatadine (generic name)|
48269658|NCT01111305|DRUG|Reslizumab|
48269659|NCT01111305|DRUG|Diethylcarbamazine|
48269660|NCT01111305|OTHER|Placebo|
48269661|NCT03924401|DRUG|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
47918943|NCT00701662|BIOLOGICAL|Vivaglobin|
47918944|NCT06123351|DEVICE|Denneroll cervical traction orthodontic|traction for 3 to 15 minutes once daily
47918945|NCT06123351|OTHER|stretching and strengthening exercises|strengthening exercises with 10 repetitions twice per day 3 times per week stretching exercises with hold for 20 to 30 seconds 3 repetitions daily
47918946|NCT06123351|DEVICE|Vacuum-formed soft occlusal splint|2 mm thick elastic rubber sheets
47918947|NCT02549599|BEHAVIORAL|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
47918948|NCT02549599|BEHAVIORAL|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
47918949|NCT02549599|OTHER|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
47918950|NCT04988360|DEVICE|HMD: Immersive VR|"Participants with dementia will view 360-degree films using a commercially-available Virtual Reality head mounted display (HMD) that has built-in speakers. While wearing the HMD, participants with dementia will be able to visually explore the virtual environments by turning their head to face different directions. Caregivers-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the HMD through the screen mirroring function."
48092607|NCT04524104|BEHAVIORAL|Lumen Treatment|the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
48269662|NCT03969875|DEVICE|Interscalene catheter|rescue catheters attached to a PCA pump
48269663|NCT03969875|DRUG|Liposomal bupivacaine|10 cc
48269664|NCT03969875|DRUG|Dexamethasone|1 cc of 4mg
48269665|NCT03969875|DRUG|Bupivacaine|0.5% bupivacaine
48269666|NCT00563147|DRUG|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
48269667|NCT03952338|OTHER|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
48269668|NCT03952338|OTHER|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
48620227|NCT00017160|DRUG|ifosfamide|
48269669|NCT04415398|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
48092608|NCT00565318|DRUG|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
47918951|NCT04988360|DEVICE|Tablet: Non-immersive VR|Participants with dementia will view 360-degree films on a commercially-available tablet that has built-in speakers. Participants with dementia will be able to visually explore the virtual environment using the touch screen (dragging the view around with one's finger). Caregiver-participants will take part in the VR experience concurrently by viewing the tablet while sitting or standing beside the participant with dementia.
47918952|NCT01087736|DRUG|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
47918953|NCT01087736|OTHER|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
47918954|NCT00646854|DRUG|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
47918955|NCT00646854|DRUG|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
47918956|NCT03961009|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
48269670|NCT02908399|DEVICE|FLIR ONE|
48269671|NCT02295722|DRUG|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
47918957|NCT05573269|DIETARY_SUPPLEMENT|FOPE (fish oil + pine extract)|During the experiment period the participants will receive a capsule of pine bark extract (Oligopin® 100mg) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
48620228|NCT00017160|PROCEDURE|biological response modifier therapy|
47918958|NCT05573269|OTHER|FO (fish oil +placebo)|During the experiment period the participants will receive a capsule of placebo (maltodextrin + magnesium stearate) and a capsule of fish oil (EPA 350mg + DHA 250mg) a day. Blood collecting (biomedical parameters and antioxidative status) and cognitive function evaluation will be examined at the 0, 12, 24th week. Body composition, 24-hour dietary recall and blood pressure measurement will be measured at 0, 4, 8, 12, 16, 20, 24th week.
47918959|NCT01440257|DRUG|Placebo|Placebo capsules once daily
47918960|NCT01440257|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
47918961|NCT00920010|OTHER|biologic sample preservation procedure|
47918962|NCT01775397|DRUG|Fidaxomicin|capsule
47918963|NCT01775397|DRUG|Vancomycin|capsule
47918964|NCT01775397|DRUG|Placebo|Capsule
47918965|NCT04384081|DRUG|BI 456906|Solution for injection
47918966|NCT04384081|DRUG|Placebo|Solution for injection
47918967|NCT00476008|DRUG|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
47918968|NCT00476008|DRUG|Placebo|One tablet placebo morning and evening (BID) for 12 months
47918969|NCT05571319|DRUG|Metformin Extended Release Oral Tablet|Glucophage XR 500 mg
47918970|NCT03500445|DRUG|Daratumumab|"Daratumumab (16 mg/kg) will be administered as an IV infusion:~* Cycle 1-2: 16 mg/kg weekly~* Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~* Cycles 9-24: 16 mg/kg IV infusion Day 1"
47918971|NCT03500445|DRUG|Carfilzomib|"Carfilzomib will be given as an IV infusion over 30 minutes:~* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~* Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~* Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16"
47918972|NCT03500445|DRUG|Lenalidomide|"Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21"
48092609|NCT00565318|DRUG|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
48092610|NCT00233129|BEHAVIORAL|Top Down|Six months
48092611|NCT00233129|OTHER|cognitive rehabilitation day treatment program|six months
48092612|NCT00601640|DRUG|Diclofenac Na gel|Given topically twice daily on days 1-90
48092613|NCT00601640|DRUG|Eflornithine HCL ointment|Given topically twice daily on days 1-90
48092614|NCT04697784|DEVICE|TREO Abdominal Stent-Graft System|The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.
48269672|NCT02295722|DRUG|Melphalan|200 mg/m2
48269673|NCT02295722|OTHER|ASCT|Day 0 - Stem cell infusion
48269674|NCT02337803|BEHAVIORAL|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
48620229|NCT00017160|PROCEDURE|brachytherapy|
48620230|NCT00017160|PROCEDURE|chemotherapy|
48620231|NCT00017160|PROCEDURE|colony-stimulating factor therapy|
48269675|NCT02337803|BEHAVIORAL|Usual Care|Will continue daily physical activity and complete surveys online
48269676|NCT01097772|DEVICE|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
48269677|NCT06206096|DRUG|oxaliplatin+capecitabine+bevacizumab+PD-1 antibody|oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.
48269678|NCT04577040|DRUG|Tadalafil 5mg|Drugs
47918973|NCT03500445|DRUG|Dexamethasone|"Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~* Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~* Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1"
48269679|NCT03285932|RADIATION|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
48269680|NCT03285932|RADIATION|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
48269681|NCT03335540|BIOLOGICAL|Nivolumab|Specified dose on specified day
48269682|NCT03335540|BIOLOGICAL|Relatlimab|Specified dose on specified day
48269683|NCT03335540|BIOLOGICAL|Cabiralizumab|Specified dose on specified day
48269684|NCT03335540|BIOLOGICAL|Ipilimumab|Specified dose on specified day
48269685|NCT03335540|DRUG|IDO1 Inhibitor|Specified dose on specified day
48269686|NCT03335540|RADIATION|Radiation Therapy|Specified dose on specified day
48269687|NCT02168595|DRUG|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
48269688|NCT02168595|DRUG|Placebo|
48269689|NCT05323422|PROCEDURE|intravenous Ketamine induction|preoperatively ketamine wll administer in group 1-3
48269690|NCT06501703|OTHER|Instruments|instruments used as different techniques in final irrigation after root canal preparation
48269691|NCT00843908|DEVICE|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
47918974|NCT00271284|DRUG|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
48620232|NCT00017160|PROCEDURE|conventional surgery|
47918975|NCT00271284|DRUG|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
47918976|NCT02763683|RADIATION|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
47918977|NCT00294619|DRUG|growth hormone|subcutaneous injection, once-weekly
47918978|NCT06088472|BIOLOGICAL|TIL injection|Autologous tumor infiltrating lymphocyte injection
47918979|NCT06148324|BEHAVIORAL|MENTOR Program|"MENTOR is an online wellness program covering 11 wellness modules: Exercise; Nutrition; Mindfulness; Spiritual Practice; Self-Care; Arts \& Leisure; Rest \& Relaxation; Outdoors in Nature; Relationships; Core Values; and Contribution to Others.~The 8-week cycle comprises 40 hours of online group-based instruction and discussion, meeting up to five times per week."
48269692|NCT00843908|DEVICE|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
48269693|NCT04870437|OTHER|Extracorporeal phototherapy|The principle of ECP is to collect mononucleated cells from the blood by centrifugation. After purification, the mononucleated cells are incubated ex-vivo with a photo-activatable DNA intercalating agent (8-methoxypsoralen, UVADEX®), then re-injected to the patient.
48269694|NCT03603769|DIETARY_SUPPLEMENT|Food supplement capsules containing Salmon-Polar Lipids|Postprandial decreased Platelet activation/aggregation in subjects, after the food supplement capsule consumption
48269695|NCT03603769|DIETARY_SUPPLEMENT|Placebo food supplement capsule|Postprandial unaffected platelet activation/aggregation in subjects, after the food supplement capsule consumption
48269696|NCT03482869|DIAGNOSTIC_TEST|walking ability|Included patients will perform a 6 min walk test
48269697|NCT01307033|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
48269698|NCT01307033|DRUG|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
48269699|NCT01307033|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
48269700|NCT01307033|DRUG|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
48269701|NCT00771472|DRUG|vorinostat|Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
48269702|NCT05152381|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48269703|NCT04865965|PROCEDURE|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
48620233|NCT00017160|PROCEDURE|cytokine therapy|
48620234|NCT00017160|PROCEDURE|intraoperative radiotherapy|
47918980|NCT04193696|DRUG|Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma|The treatment will be started within 1 week after being admitted into the trial. IMRT or SBRT are adopted , and dose of radiation: Dt-PGTV=40Gy/10fractions,Dt-PGTV=30Gy/10fractions,Dt-PGTV=20Gy/10fractions ,and so on.200mg/ of Carelizumab for injection will be given intravenously every 3 weeks for 5 times since the first day of radiotherapy until disease progression, or intolerable toxicity.
47918981|NCT05526040|DIETARY_SUPPLEMENT|Immunonutrient-enriched oral nutrition supplementation|"Individualized dietary assessment and counselling with additional high energy, high protein, immunonutrient-enriched oral nutrition supplement; taken 3 servings per day, from 1 week prior to cancer treatment and continued throughout the cancer treatment.~Oral Impact® is an oral nutrition supplement product enriched with arginine (3.3g/sachet), omega-3 fatty acids (0.8g/sachet) and nucleotides (0.3g/sachet). The immunonutrient-enriched formula is also a complete and balanced formula, and is gluten free. The osmolality of the formula is 620 mOsm/kg water."
48269704|NCT05436548|OTHER|Supervisor-employee frequent check-ins to identify and address work stressors|Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
48269705|NCT05436548|OTHER|Usual practice waitlist controls|If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
48269706|NCT01400256|DRUG|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
48269707|NCT02111564|DRUG|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
48269708|NCT02111564|DRUG|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
48269709|NCT02111564|DRUG|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
48269710|NCT00963950|PROCEDURE|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
48269711|NCT00963950|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
48269712|NCT05448625|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
48269713|NCT04187235|PROCEDURE|Laparascopic repair of parastomal hernia|Laparascopic repair of parastomal hernia
48269714|NCT04480281|DRUG|Lidocaine Iv|Patients in the Lidocaine group received a bolus of lidocaine 1% 1.5mg/kg at the induction of general anesthesia followed by a continuous infusion of lidocaine 1% 2mg/kg/h just before surgical incision and continued until 24h after the surgery
48269715|NCT04480281|DRUG|Normal Saline|Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
47918982|NCT05526040|DIETARY_SUPPLEMENT|Standard medical nutrition therapy|Individualized dietary assessment and counselling and standard nutrition supplementation via oral nutrition supplementation or enteral nutrition as necessary.
48269716|NCT06541431|OTHER|Abdominal Drainage Fluid Collection|Abdominal drainage fluid will be collected daily from the subjects until they are discharged from the hospital, or their abdominal/pelvic drain is removed, as determined by the treating surgeon.
47918983|NCT06292611|DEVICE|Battery operated toothbrush|Device on extrinsic stain removal efficacy
47918984|NCT06292611|DEVICE|Manual toothbrush|Device on extrinsic stain removal efficacy
47918985|NCT00196092|DEVICE|Roll-in|Proctored entry.
48269717|NCT06366243|DRUG|Emraclidine|Oral tablet
48269718|NCT06366243|DRUG|Esomeprazole|Oral delayed-release capsule
48269719|NCT01356381|DRUG|Vildagliptin|Dosage 50mg b.i.d.
48269720|NCT01356381|DRUG|Placebo|50mg bid
48269721|NCT05333094|OTHER|Brackets|"Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)"
48269722|NCT02784093|DRUG|Gastrograﬁn|
48269723|NCT02784093|PROCEDURE|enemas|
47918986|NCT00196092|DEVICE|Surgical|Surgery
47918987|NCT00196092|DEVICE|Standard Risk|Standard Endovascular repair
47918988|NCT00196092|DEVICE|High Risk|High Risk Endovascular repair.
47918989|NCT00196092|DEVICE|Compassionate Use|Endovascular repair for compassionate use patients.
47918990|NCT00196092|DEVICE|Treatment for females|Endovascular repair in female patients
48269724|NCT03045003|BEHAVIORAL|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
48620235|NCT00017160|PROCEDURE|radiation therapy|
48620236|NCT00017160|PROCEDURE|surgery|
48620237|NCT05571813|DRUG|CKD-341|A single dose of 1tablets under fasting condition
47918991|NCT00196092|DEVICE|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
47918992|NCT00196092|DEVICE|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
47918993|NCT00852488|PROCEDURE|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
47918994|NCT01352403|PROCEDURE|Roux-en-Y gastric bypass|
47918995|NCT01352403|BEHAVIORAL|Psychotherapy-enhanced lifestyle intervention|
47918996|NCT06035224|DRUG|AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally|AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
47918997|NCT04166799|DEVICE|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
47918998|NCT05039021|DEVICE|HARMONIC 1100 Shears|HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
47918999|NCT05034822|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
47919000|NCT02082756|DRUG|Bifidobacterium viable pharmaceutics|
47919001|NCT02082756|DRUG|Berberine Hydrochloride|
47919002|NCT02199717|DEVICE|Accelerometer|
48092615|NCT02409160|PROCEDURE|Standard Roux-en-Y gastric bypass|
47919003|NCT01313741|DEVICE|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
47919004|NCT03007251|OTHER|"Eurythmy Therapy Movement R"|
47919005|NCT03007251|OTHER|"Eurythmy Therapy Movement L"|
47919006|NCT03007251|OTHER|"Eurythmy Therapy Movement B"|
47919007|NCT03007251|OTHER|Normal movements during walking or standing|
47919008|NCT03725241|DIETARY_SUPPLEMENT|Glutathione Supplement|1000 mg/day Glutathione
47919009|NCT03725241|DIETARY_SUPPLEMENT|Placebo Supplement|Crystalline cellulose
47919010|NCT06205680|DEVICE|NAA for topical anaesthesia of the nasal cavity|NAA for topical anaesthesia of the nasal cavity
48092616|NCT05499585|OTHER|Whole Dairy|2 1/2 servings of whole dairy per day
48092617|NCT00000195|DRUG|Naltrexone|
48092618|NCT02948946|PROCEDURE|NETest|5 mL of blood will be drawn from participants for testing.
48092619|NCT02725203|BEHAVIORAL|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
48092620|NCT00002374|DRUG|Ritonavir|
48092621|NCT00002374|DRUG|Nelfinavir mesylate|
48092622|NCT00002374|DRUG|Saquinavir|
48092623|NCT00002374|DRUG|Stavudine|
48092624|NCT05315804|OTHER|MINSD and amelogenins|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, amelogenins in gel will be applied to the intraosseous periodontal pockets using a sterile syringe with plasticized needle.
48092625|NCT05315804|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
48092626|NCT05108051|DRUG|ZSP1273|ZSP1273 tablets 600mg administered orally once daily
48092627|NCT05108051|DRUG|Oseltamivir|Oseltamivir 75mg administered orally twice daily
48092628|NCT03795974|BIOLOGICAL|MNC|Hematopoietic stem cells derived from allogenic umbilical cord
48092629|NCT03795974|BIOLOGICAL|MSC|Mesenchymal cells derived from allogenic umbilical cord
48092630|NCT03795974|PROCEDURE|Control|control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
48092631|NCT03176134|DRUG|Tedizolid phosphate|Tedizolid phosphate IV solution or oral suspension
48092632|NCT03176134|DRUG|Comparator|Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
48092633|NCT00839228|DRUG|Perhexiline|100mg o bd for 3 months
48092634|NCT00839228|DRUG|Placebo|Placebo one tablet bd for 3 months
48092635|NCT04308616|OTHER|Blood samples|Blood samples
48092636|NCT06481501|BEHAVIORAL|ONE Mindfulness-Oriented Recovery Enhancement|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
48620238|NCT04131803|DRUG|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
48620239|NCT04131803|DRUG|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
47919011|NCT01402102|DIETARY_SUPPLEMENT|Aged garlic powder|Aged garlic powder(6.0g/day)
47919012|NCT01402102|DIETARY_SUPPLEMENT|Placebo powder|Placebo powder(6.0g/day)
47919013|NCT00000679|DRUG|Zidovudine|
47919014|NCT00000679|DRUG|Zalcitabine|
47919015|NCT05998889|BEHAVIORAL|Experimental group|Education, Graded Pain Exposure Exercises and Graded Motor Imagery. One supervision a week/9 weeks + exercises at home + encourage returning relevant activities despite pain
47919016|NCT05998889|BEHAVIORAL|Control group|Graded Motor Imagery following the GRaMI protocol, One supervision a week/9 weeks + exercises at home, activities encourage but pain contingency.
48092637|NCT03526120|OTHER|Pistachio|Dailly 44 g unsalted pistachios snack for 12 weeks
48092638|NCT01911221|BIOLOGICAL|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
48092639|NCT00147654|DRUG|Tolterodine ER 4 mg QD|
48092640|NCT00147654|DRUG|Tamsulosin 0.4 mg QD|
48620240|NCT00357162|DRUG|belinostat|Given IV
48269725|NCT02477345|DRUG|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
47919017|NCT02753257|OTHER|Non-Interventional|Non-Interventional
48269726|NCT04138160|OTHER|5:2 Intermittent energy restriction|Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.
48269727|NCT04138160|OTHER|Continuous energy restriction|20% energy restriction each day relative to the energy requirement.
48269728|NCT02594644|DEVICE|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
48269729|NCT02594644|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
48269730|NCT02594644|RADIATION|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
48269731|NCT02797119|DRUG|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
48106699|NCT06301035|DEVICE|Standard(symmetric) High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
48269732|NCT02797119|DRUG|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
48269733|NCT02797119|DRUG|Saline Solution (TA0)|
48269734|NCT05388747|DRUG|Cefuroxime|Population pharmacokinetics, effectiveness, and safety of cefuroxime
48269735|NCT03489733|OTHER|Hydrolyzed Formula|Infant formula with extensively hydrolyzed proteins and pre- and probiotics.
48269736|NCT03489733|OTHER|Control formula|Infant formula with intact proteins and pre- and probiotics.
48269737|NCT03642145|DRUG|Deflazacort|Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
48269738|NCT01722513|DRUG|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
48269739|NCT00000573|PROCEDURE|enteral nutrition|
47919018|NCT03976804|OTHER|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
47919019|NCT03976804|OTHER|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
47919020|NCT03976804|OTHER|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
47919021|NCT02529553|DRUG|LY3076226|Administered IV
47919022|NCT00708487|OTHER|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
47919023|NCT03300102|OTHER|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
48269740|NCT04275713|DRUG|Metformin|Metformin is an oral antidiabetic drug
47919024|NCT04036370|PROCEDURE|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
48269741|NCT04275713|DRUG|Cisplatin|Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
47919025|NCT04036370|OTHER|Control group|Standard pain follow up and monitorization will be performed.
47919026|NCT06405308|PROCEDURE|R-NOSES group|robotic natural orifice specimen extraction surgery
47919027|NCT06405308|PROCEDURE|R-TSES group|robotic transabdominal specimen extraction surgery
48269742|NCT04704622|DRUG|Ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
48269743|NCT04704622|DRUG|Midazolam|midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
48269744|NCT04704622|DRUG|Dexmedetomidine|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
48269745|NCT05231083|DEVICE|Genital Nerves Stimulation|Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
48269746|NCT01466244|BIOLOGICAL|cetuximab|
48269747|NCT01466244|DRUG|cisplatin|
48269748|NCT01466244|GENETIC|gene expression analysis|
48269749|NCT01466244|GENETIC|microarray analysis|
48269750|NCT01466244|OTHER|immunohistochemistry staining method|
48269751|NCT01466244|OTHER|laboratory biomarker analysis|
48269752|NCT01832740|DEVICE|brain stimulation|oscillating direct current brain stimulation
48269753|NCT01832740|DEVICE|SHAM|no stimulation
47919028|NCT02997306|PROCEDURE|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
48269754|NCT01176916|DRUG|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
48269755|NCT04622345|DRUG|VSJ-110|ophthalmic solution
48269756|NCT04622345|DRUG|Placebo|ophthalmic solution
48269757|NCT02538172|OTHER|T-Track® CMV assay|
48269758|NCT04351139|OTHER|modification of the planned therapeutic management|to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
48269759|NCT04305015|DEVICE|NOL Guided Analgesia|NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends
48269760|NCT04305015|OTHER|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
48269761|NCT00989989|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
48269762|NCT00989989|PROCEDURE|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
48269763|NCT00989989|DRUG|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
48269764|NCT00989989|PROCEDURE|Sham laser photocoagulation|Sham laser treatment administered at day 1.
48269765|NCT01958957|DRUG|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
48269766|NCT00603135|DRUG|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
48269767|NCT03880500|OTHER|Spinal Manipulative Therapy|The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
48269768|NCT01865331|DRUG|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
48269769|NCT01865331|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
48269770|NCT01865331|DRUG|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
48269771|NCT01508741|DIETARY_SUPPLEMENT|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
48269772|NCT01508741|DIETARY_SUPPLEMENT|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
48269773|NCT05032950|DRUG|Midazolam|Midazolam administered as a single dose on Day 1
48269774|NCT05032950|DRUG|PF-07321332/ritonavir + Midazolam|"PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5"
48269775|NCT05032950|DRUG|Ritonavir + Midazolam|"Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5"
48269776|NCT02144779|BEHAVIORAL|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
48269777|NCT02144779|BEHAVIORAL|Usual Care|usual hospital care, not assigned to palliative care team
48269778|NCT05682014|BEHAVIORAL|Mindful Breastfeeding Program|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
48269779|NCT00723684|OTHER|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
48269780|NCT00723684|OTHER|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
48269781|NCT01631669|DRUG|Celecoxib|200 mg Q 12 hours orally
48269782|NCT00374803|DRUG|Mycophenolic Acid (Myfortic)|"* Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."
48269783|NCT03646448|BEHAVIORAL|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
48269784|NCT00899093|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48269785|NCT00899093|OTHER|Laboratory Biomarker Analysis|Correlative studies
48092641|NCT05205460|DEVICE|Home-based telehealth exercise training program|A home-based exercise mobile app will be offered combined with the heart rate sensing clothes to each participant in the group of home-based telehealth exercise training program. The mobile app provides auto-feedback of heart rate at each exercise training session through the heart rate sensing clothes and alarm function identifying individuals' appropriate exercise intensity (target heart rate) during their exercise based on their exercise prescription calculated and set up inside the app. After completing each exercise training session, the record of training time and heart rate response is simultaneously uploaded to the cloud system of the medical center through the heart rate sensing clothes. The experienced and well-trained nurse checked the cloud system data to monitor participants' adherence to exercise training. In addition, online communication is enabled using LINE software, which provided a platform for patients and researchers to interact with each other through messaging.
48092642|NCT05205460|BEHAVIORAL|Education and self-exercise|The participants will receive a exercise prescription suggestion. Then, they will maintain their routine outpatient follow-up per month and usual lifestyles with weekly reminders.
48092643|NCT02335021|DIETARY_SUPPLEMENT|Sucralose|2 packets per 12 fl oz
48092644|NCT02335021|DIETARY_SUPPLEMENT|Sucrose|equisweet to sucralose
48092645|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
48092646|NCT02335021|DIETARY_SUPPLEMENT|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
48092647|NCT01556841|BIOLOGICAL|TroVax®|"Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
48092648|NCT01556841|BIOLOGICAL|Placebo|"Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only."
48092649|NCT03241498|OTHER|Medicines optimisation|
48092650|NCT02618629|DRUG|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
48092651|NCT04730947|DRUG|Dapagliflozin|10 mg orally once a day
48092652|NCT04730947|DRUG|Placebo|Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
48092653|NCT04950543|BEHAVIORAL|Meditation|An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
48092654|NCT01260974|DRUG|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
48092655|NCT00431509|PROCEDURE|conventional vs. navigated total knee arthroplasty|
48092656|NCT01824446|DRUG|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
48092657|NCT01746394|BEHAVIORAL|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
48092658|NCT01746394|BEHAVIORAL|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
48092659|NCT05157334|DEVICE|Non-invasive auricular electrical transcutaneous vagus nerve stimulation|"A NEMOS ® stimulator (Cerbomed, Erlangen, Germany) is used for transcutaneous auricular vagus nerve stimulation. This is a handheld battery driven stimulator which stimulates conca in the outer ear. It stimulates in a serie of small electrical impulses with a pulse width at 250 us and a frequency at 25 Hz for 30 minutes in a cycle for 30 seconds on and 30 seconds off to avoid habituation. It is previously indicated that a stimulation intensity at 0,5 mA, 1 mA or 1,5 mA does not cause a significant chance in HRV, thus 0,5 mA is used in this study."
48092660|NCT05157334|OTHER|Deep breathing|The participant is first verbally introduced to the breathing exercises, and then to the visually cue (animation), which the participant have to follow throughout the session.
48092661|NCT05489705|DRUG|Mavacamten|As per product label
48092662|NCT05489705|DRUG|Non-mavacamten symptomatic oHCM therapy|Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
48092663|NCT02117115|RADIATION|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
48092664|NCT02117115|DRUG|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
48092665|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Angiography（ FE-MRA）；Coronary/Renal /Lower artery Arteriography|When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.
48269786|NCT05431296|DEVICE|Dexcom ONE Continuous Glucose Monitoring System|The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
47919029|NCT02997306|PROCEDURE|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
48269787|NCT02321592|DRUG|AFM13|
48269788|NCT02617238|OTHER|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~1. In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~2. In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
47919030|NCT03137069|DRUG|GDC-0853|GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.
47919031|NCT03137069|DRUG|Placebo|Matching Placebo will be administered orally, as per the dosing schedules described above.
48269789|NCT04727541|DRUG|Bintrafusp alfa|Neoadjuvant therapy with bintrafusp alfa
47919032|NCT00125528|DRUG|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
47919033|NCT00125528|DRUG|placebo|placebo bid
48269790|NCT02468648|DRUG|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
48269791|NCT02468648|DRUG|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
47919034|NCT05949502|DRUG|Beautifil II LS (Low-Shrinkage)|low shrinkage bioactive material Giomer
47919035|NCT05949502|DRUG|3M Filtek Z250 XT Universal|Universal Nano-hybrid composite
47919036|NCT00470834|DRUG|dutasteride|0.5mg dutasteride (Investigation Product)
47919037|NCT00470834|DRUG|placebo|making placebo
48269792|NCT00168350|DRUG|memantine|
48269793|NCT01703000|DEVICE|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
48269794|NCT05495347|OTHER|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
48269795|NCT00145990|DRUG|methacholine|
48269796|NCT00145990|DEVICE|KoKo Digidoser|
48269797|NCT00145990|DEVICE|Rosethal Dosimeter|
48269798|NCT01405092|DEVICE|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
48269799|NCT01405092|DEVICE|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
48269800|NCT00388050|BEHAVIORAL|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
48269801|NCT00388050|BEHAVIORAL|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
48269802|NCT04805086|BIOLOGICAL|MON002|Autologous monocytes
48269803|NCT00313924|DRUG|DETRUSITOL|
47919038|NCT00470834|DRUG|bicalutamide|50 mg Casodex or generic equivalent
47919039|NCT04600271|DRUG|Crystalloid Solutions|exposure
47919040|NCT04600271|DRUG|Colloid Blood Volume Expanders|exposure
47919041|NCT04600271|OTHER|blood replacement|exposure
47919042|NCT04600271|DRUG|Diuretic|exposure
47919043|NCT04600271|DRUG|noradrenaline|exposure
47919044|NCT04600271|DRUG|Non-Steroidal Anti-Inflammatory Analgesics|exposure
47919045|NCT05861817|DEVICE|Laser theapy|participants were randomized into either the LLLT group or sham treatment group by a computer-generated random number. The participants were treated using LLLT (904nm and 2.5 J/ sinus). treatment was delivered for one month
47919046|NCT01909011|DEVICE|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
47919047|NCT01909011|DEVICE|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
48269804|NCT06127589|BEHAVIORAL|Brief cessation advice (AWARD)|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
48269805|NCT06127589|DRUG|Nicotine Replacement Therapy (NRT)|1-week sampling of Nicotine Replacement Therapy (NRT) will be provided to support quit attempt. Full pharmacological treatment (12-week) will be available if needed.
48269806|NCT06127589|BEHAVIORAL|Instant messaging Support (IM)|Chat-based mHealth personalized psychosocial and behavioural counselling (smoking cessation and SHS exposure reduction messages will be derived from previously tested interventional studies) using baseline children health and biofeedback data to support quitting throughout the intervention period of 3 months.
48269807|NCT06127589|BEHAVIORAL|Financial Incentive (FI)|A financial incentive (vouchers) of HK$ 500 will be provided for biochemically validated smoking abstinence at 3- and 6-month follow-up. Considering a possibly low engagement rate of the smokers in mHealth-based support (17% in our previous trial, non-engagement mostly due to busy work), additional HK$ 200 will be provided for participants who actively engaged in the mHealth counselling (defined by have discussed quitting process for \>2 times) at 3-month follow-up.
47919048|NCT06471283|OTHER|physical activity|Exercising physical activity during dialysis
48269808|NCT06127589|BEHAVIORAL|Self-help smoking cessation booklet|A well-designed self-help booklet will be provided to guide and provide detailed information on smoking cessation. The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
48269809|NCT06127589|BEHAVIORAL|Environmental assessment derived intervention|"In a selected subgroup of 50 families with an additional signed consents, four home visits will be done to: 1. Setup an indoor air quality (IAQ) monitor to collect 24hr air quality data (2 weeks), 2. Collect the monitor for data retrieval, 3. Setup the monitor at 6 months follow-up (2 weeks), 4. Collect the monitor for data retrieval.~Environmental assessment derived intervention, including results interpretation and health advice, will be provided via phone calls for the 50 families within 1 week after the data collection."
48269810|NCT05093101|OTHER|case series review of clinical data|Extraction of pre-surgical and chemotherapy blood test laboratory data and clinical and instrumental data related to patient history from digitized medical records and analysis
48269811|NCT04737473|DRUG|Opiod Free Anesthesia|The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
48269812|NCT03089307|DEVICE|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
47919049|NCT03310489|BEHAVIORAL|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
48269813|NCT03170752|BEHAVIORAL|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
48269814|NCT05717348|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
48269815|NCT05242770|OTHER|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
48269816|NCT05242770|OTHER|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
48269817|NCT05242770|OTHER|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
48269818|NCT05242770|OTHER|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
48269819|NCT05242770|OTHER|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
48269820|NCT02652039|OTHER|Questionnaires|Questionnaires
48269821|NCT00830921|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
48269822|NCT05145621|DRUG|Fingolimod 0.5 mg capsules- Test drug|An oral dose of the assigned formulation (3 capsules) will be administered in the morning to subjects with about 240 mL of water at ambient temperature according to the randomization scheme.
48269823|NCT06042673|DIETARY_SUPPLEMENT|Pomegranate seed oil|10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
48269824|NCT06042673|DIETARY_SUPPLEMENT|Mixed vegetable oil|50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
48269825|NCT01661790|DRUG|Bevacizumab|Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
48269826|NCT01661790|DRUG|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
48269827|NCT00080197|DRUG|E7070|
48269828|NCT01457183|DEVICE|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
48269829|NCT05926427|DRUG|Orelabrutinib|150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
48269830|NCT05926427|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
48269831|NCT05926427|DRUG|Chemotherapy|Not specified, recommended regimen according to histopathologic type
48269832|NCT02070107|OTHER|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
47919050|NCT03310489|BEHAVIORAL|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
47919051|NCT03565328|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
47919052|NCT02715440|DRUG|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
47919053|NCT00200356|DRUG|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
47919054|NCT00200356|DRUG|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
48269833|NCT01324284|DRUG|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
48269834|NCT06325501|DRUG|Misoprostol 200mcg Tab|receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery
48269835|NCT06325501|DRUG|Oxytocin|after the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
48269836|NCT02970929|DRUG|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
47919055|NCT00109603|DRUG|Tenofovir disoproxil fumarate|
47919056|NCT01170247|DRUG|Ketamine|Intranasal Ketamine (100 mg/mL)
48269837|NCT04505683|DRUG|Benapenem|Benapenem for IV injection administered as a 1-gram IV infusion
48269838|NCT04505683|DRUG|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion
47919057|NCT01170247|DRUG|Ketamine|Intramuscular Ketamine
48269839|NCT02109159|OTHER|A short online video with emotional content|
47919058|NCT03445949|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
48269840|NCT02109159|OTHER|A short online video with less emotional content|
47919059|NCT03445949|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
47919060|NCT03445949|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
47919061|NCT03445949|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
48269841|NCT02653950|PROCEDURE|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
48269842|NCT02653950|PROCEDURE|Traditional septoplasty|septoplasty under direct vision
47919062|NCT03448484|DIETARY_SUPPLEMENT|Intervention (integrated package)|"Provided to all intervention households:~* Soap (for daily hand washing)~* Chlorine solution (for daily drinking water treatment)~* 8 birds of chicken (child consumes 1 egg/day)~* Vegetable seeds (red onion, indigenous managu and sukuma)~* Monthly trainings to all farmers on nutrition and WASH~* Micronutrient powder (MixMe, 1g sachet every third day)~* Oral rehydration solution (ORS) + zinc (to be used to treat acute diarrhoea: 20 mg zinc tablets; ORS sachets (10.3 g/sachet))~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group."
47919063|NCT03448484|OTHER|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. The control intervention is the same for study 1 and study 2. This agriculture-focused package consists of:~* Agricultural training (every 2 weeks on average) for all~* Free to enrol for the following products on credit:~  * Compost boosters~ * Cook stoves~ * Seeds (onions, maize, indigenous greens, beans)~ * Maize storage bags~ * Drying tarps~ * Trees~ * Solar lights~ * Fertilizer~ * Actellic dust (insecticide)~ * Re-usable sanitary pads"
47919064|NCT01600534|BEHAVIORAL|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
47919065|NCT00170378|DRUG|Enoxaparin|
47919066|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
47919067|NCT01947855|DRUG|Empagliflozin|Empagliflozin low dose
47919068|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
48269843|NCT03426176|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
48269844|NCT03426176|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
48269845|NCT03426176|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
48269846|NCT03426176|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
48269847|NCT01130922|DRUG|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
48269848|NCT01130922|DRUG|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
48269849|NCT01495494|DEVICE|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
47919069|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin low dose
47919070|NCT01947855|DRUG|Empagliflozin|Empagliflozin high dose tablet once daily
47919071|NCT01947855|DRUG|Placebo|Placebo tablet matching Empagliflozin high dose
47919072|NCT02609867|DEVICE|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
47919073|NCT02009540|DRUG|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
48092666|NCT06136806|DIAGNOSTIC_TEST|Ferumoxytol Enhanced Magnetic Resonance Venography（ FE-MRV）, Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.|When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.
48269850|NCT01495494|DEVICE|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
48269851|NCT00496392|DRUG|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
48269852|NCT01431092|DRUG|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
48269853|NCT01431092|DRUG|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
48269854|NCT02498873|BEHAVIORAL|Linear Periodization|Linear Intensity Periodization Running
48269855|NCT02498873|BEHAVIORAL|Non Linear Periodization|Non Linear Periodization Running
48269856|NCT01917786|DEVICE|ECG|
48269857|NCT02914509|DRUG|Travoprost|
48269858|NCT02914509|OTHER|Placebo Vehicle|
48269859|NCT04019262|RADIATION|Radiation Therapy|Radiation
48269860|NCT04019262|DRUG|Temozolomide Oral Product|Oral Temozolomide (150mg/m\^2 or 75 mg/m\^2)
47919074|NCT02009540|DRUG|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
47919075|NCT03599232|OTHER|Formative objective structured clinical examination (OSCE)|
47919076|NCT00807560|BEHAVIORAL|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
48269861|NCT02669979|OTHER|Intervention|Professional oral care
47919077|NCT00807560|BEHAVIORAL|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
48269862|NCT02903004|DRUG|Trabectedin|
48269863|NCT02903004|DRUG|Pegylated Liposomal Doxorubicin|
48269864|NCT02903004|DRUG|Topotecan|
48269865|NCT02903004|DRUG|Gemcitabine|
48269866|NCT02903004|DRUG|Weekly Paclitaxel|
47919078|NCT04803240|DEVICE|Thealoz Duo|Non applicable
48269867|NCT02903004|DRUG|Carboplatin|
48269868|NCT00924157|DIETARY_SUPPLEMENT|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
47919079|NCT04657666|DRUG|Nabiximols|oromucosal spray
47919080|NCT04657666|DRUG|Placebo|oromucosal spray
47919081|NCT00914108|BEHAVIORAL|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
47919082|NCT00530387|DRUG|19 organic sunscreen filters and 5 topical NSAIDs|
47919083|NCT03288233|DIAGNOSTIC_TEST|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
47919084|NCT00961909|DRUG|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
47919085|NCT00961909|DRUG|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
48092667|NCT02863159|DEVICE|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
48269869|NCT00924157|OTHER|Placebo|Matching placebo capsules
48269870|NCT00482716|BIOLOGICAL|epoetin alfa|
48269871|NCT00482716|BIOLOGICAL|epoetin beta|
48269872|NCT00482716|DIETARY_SUPPLEMENT|iron dextran complex|
48269873|NCT00482716|DIETARY_SUPPLEMENT|iron sucrose injection|
48269874|NCT02265484|DRUG|Lactulose+Rifaximin +Bromocriptine|
48269875|NCT04765605|DEVICE|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
48269876|NCT02718859|BIOLOGICAL|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
48269877|NCT02718859|PROCEDURE|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
48269878|NCT06454708|DRUG|Clascoterone Cream 1%|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
48269879|NCT05753956|DRUG|5 Methoxy N,N Dimethyltryptamine|GH002 administered via i.v. bolus injection(s)
47919086|NCT00961909|DRUG|metformin|stable dose
47919087|NCT00961909|DRUG|placebo|sc once weekly for 4 weeks
47919088|NCT04793022|DRUG|TIVA with Propofol|Total intravenous anesthesia with propofol
47919089|NCT04793022|DRUG|Inhaled Anesthesia|General anesthesia given with inhaled anesthetics
47919090|NCT05019118|OTHER|Experimental milk|UNICLA milk naturally enriched in selenium and omega-3.
48269880|NCT05753956|DRUG|Placebo|GH002 placebo administered via i.v. bolus injection
48269881|NCT04831060|PROCEDURE|Periodontal treatment|"For Cases :~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~* Non-surgical periodontal treatment~* At 3 months = periodontal reevaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* If periodontal pockets greater than 5mm and bleeding persist: periodontal surgery and gingival explant sampling~* At 3 months post-surgery = periodontal re-evaluation; Periodontal bacteria, gingival fluid and unstimulated saliva collection~* Maintenance~For Controls:~* Inclusion; Periodontal bacteria, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~* Plastic or pre-prosthetic surgery = gingival explant sampling~* Healing control at 15 days"
48269882|NCT05190952|DRUG|Bupivacaine|Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
48269883|NCT05190952|DRUG|Ketamine|In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
48269884|NCT05190952|DRUG|Dexamethasone|In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
48269885|NCT05606237|DEVICE|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
48269886|NCT01338467|DEVICE|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
48269887|NCT03665363|OTHER|SCOPE|SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
48269888|NCT03665363|OTHER|Self-study|Active control consisting of directed self-studies on internet.
48269889|NCT04206878|DIAGNOSTIC_TEST|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
48269890|NCT00313573|PROCEDURE|management of therapy complications|
48269891|NCT00313573|PROCEDURE|pain therapy|
48269892|NCT00313573|PROCEDURE|psychosocial assessment and care|
48269893|NCT00313573|PROCEDURE|quality-of-life assessment|
47919091|NCT05019118|OTHER|Experimental yogur|UNICLA yogur naturally enriched in selenium and omega-3.
48269894|NCT02780076|OTHER|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
48269895|NCT01187992|DRUG|Atorvastatin|80 mg/day
48269896|NCT03926676|OTHER|grandio blocks|nano hybrid composite blocks
48269897|NCT03926676|OTHER|emax|ceramic blocks
48269898|NCT00859755|DRUG|ARRY-403, glucokinase activator; oral|single dose, escalating
48269899|NCT00859755|DRUG|Placebo; oral|matching placebo
48269900|NCT03540186|DIETARY_SUPPLEMENT|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
48269901|NCT03540186|PROCEDURE|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
48269902|NCT00680836|DRUG|Placebo|orally two times per day for 14 days
48269903|NCT00680836|DRUG|Rifaximin|550 mg orally two times per day for 14 days
48269904|NCT02495922|DRUG|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
48269905|NCT02495922|DRUG|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
48269906|NCT02495922|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
48269907|NCT02495922|DRUG|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
48269908|NCT00638937|DRUG|saracatinib|Given PO
48269909|NCT03883074|DEVICE|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
48269910|NCT03883074|DEVICE|Placebo|tablets with the same aspect of the active device
48269911|NCT04996355|OTHER|comprehensive treatment after MDT discussion|"The comprehensive treatment plan was determined through MDT discussion, which was completed by the Department of Gastrointestinal Surgery, Peking University People's Hospital.~The following regimens will be tested with organoids-on-a-chip：~1. 5-FU~2. Oxaliplatin~3. Irinotecan~4. 5-FU+ Oxaliplatin~5. 5-FU+ Irinotecan~6. 5-FU+ Oxaliplatin+ Irinotecan~7. 5-FU+Cetuximab~8. Cetuximab~9. Regorafenib"
48269912|NCT01061931|PROCEDURE|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
48269913|NCT04887571|OTHER|No Intervention - Observational Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
48269914|NCT02034045|OTHER|Community Paramedicine|
48269915|NCT02034045|OTHER|Usual Care|
48269916|NCT01099969|DEVICE|Glidescope videolaryngoscope|
48269917|NCT01099969|DEVICE|McGrath videolaryngoscope|
47914054|NCT03482960|DRUG|PFP|"* Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
47919092|NCT05019118|OTHER|Experimental fresh cheese|UNICLA fresh cheese naturally enriched in selenium and omega-3.
47919093|NCT05019118|OTHER|Placebo milk|Conventional milk
47919094|NCT05019118|OTHER|Placebo yogur|Conventional yogur
47919095|NCT05019118|OTHER|Placebo fresh cheese|Conventional fresh cheese
47919096|NCT04285281|DRUG|Gabapentin oral capsules|Oral capsule pharmaceutical treatment.
48269918|NCT01099969|DEVICE|Non-styletted Endotrol endotracheal tube (ETT)|
48269919|NCT01099969|DEVICE|Regular endotracheal tube (ETT) with Gliderite stylet|
47919097|NCT06132815|DEVICE|Laser troughing|Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line
48269920|NCT05830383|BEHAVIORAL|PDCA circular management|"PDCA circular management means PlanDoCheckAction four steps"
47919098|NCT06132815|OTHER|Retraction cord and astringent|Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan
48269921|NCT05798052|BEHAVIORAL|Psychological stressors added to simulated clinical scenarios.|In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).
48269922|NCT00437216|DRUG|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
48269923|NCT00437216|DRUG|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
48269924|NCT04586829|OTHER|Diet|\<50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.
48269925|NCT06089044|DRUG|Dalbavancin Injection|Dalbavancin as long-term suppressive therapy.
48269926|NCT03223571|OTHER|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
48269927|NCT04461821|DIAGNOSTIC_TEST|Real-time SESI-MS breath analysis|Participants will be asked to refrain from eating, drinking, chewing gum use or brushing their teeth at least 1 hour before the measurements will be performed. Room temperature and lighting will be set at the same level for all measurements. Participants will exhale through a disposable mouthpiece into a commercially available SESI source (FIT S.L., Spain). While performing full exhalations, the subjects will keep the pressure through the sampling line at a fixed value monitored by a digital manometer. Breath prints will be collected in real-time recording multiple replicates (typically six in positive and negative ion mode). The whole procedure is absolutely non-invasive and is usually accomplished without any effort in around 15 min per subject.
48269928|NCT04461821|DIAGNOSTIC_TEST|Off-line breath analysis|In young children below the age of 4 not capable of completing the on-line exhalation maneuvers, or in cases when the patient needs cannot approach the mass spectrometer, the sample will be collected off-line. They will be asked to exhale into a bag that will be transported to the lab and deflated into the mass spectrometer for analysis. Exhaled breath of patients under anesthesia will also collected using available ventilation system in the operation theatre.
48269929|NCT04461821|DIAGNOSTIC_TEST|Blood analysis|Blood analysis done in patients who undergo regular blood sampling needed for clinical routine laboratory controls. This includes i) children and adolescents receiving medications which require TDM ii) patients with acute diseases such as TD1 and pneumonia and iii) patients with chronic diseases such as asthma bronchiale. For those patients where a blood sample is drawn during the clinical routine, an additional blood sample consisting of only several blood drops will be collected using the same blood sampling line. No additional venous puncture for research purpose will be done.
48269930|NCT04461821|DIAGNOSTIC_TEST|Saliva analysis|During the diagnostic and therapeutic work-up of T1D patients, saliva samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
48269931|NCT04461821|DIAGNOSTIC_TEST|Urine analysis|During the diagnostic and therapeutic work-up of T1D patients, urine samples are collected during the clinical routine. For those patients, additional samples will be obtained by clinically trained investigators.
48269932|NCT02772757|BEHAVIORAL|standard hearing aid fitting|standard hearing aid, face-to-face fitting
48269933|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using average RECDs
48269934|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using measured RECDs
48269935|NCT01693445|DRUG|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
47914055|NCT02327663|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
47914056|NCT04724824|DEVICE|Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
47914057|NCT04724824|DEVICE|Sham Brain-Computer Interface|Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
47914058|NCT03372902|DEVICE|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
47914059|NCT03372902|DEVICE|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
48269936|NCT05607628|COMBINATION_PRODUCT|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
48269937|NCT05607628|COMBINATION_PRODUCT|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
48269938|NCT05375279|PROCEDURE|Lip Salivary Gland Biopsy|Obtaining few salivary glands from the partipants' lip that will be studied using the Congo Red staining method.
48269939|NCT05100537|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
48269940|NCT05100537|OTHER|continuing a routine life|No intervention will be made in the control group.
48269941|NCT04226313|DIAGNOSTIC_TEST|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
48269942|NCT04226313|DIAGNOSTIC_TEST|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
48269943|NCT05571683|OTHER|oxygen support|40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
48269944|NCT02939131|BEHAVIORAL|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
48269945|NCT02939131|BEHAVIORAL|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
48269946|NCT05211778|BEHAVIORAL|Digital Education Group|Multimedia education provided to the intervention group via a digital tablet
47919099|NCT06132815|OTHER|Cordless retraction paste with astringent|The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.
47919100|NCT06132815|OTHER|Cordless retraction paste without astringent|The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
47919101|NCT03572205|DIETARY_SUPPLEMENT|LA|The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
48269947|NCT05546619|DRUG|HIPEC+tislelizumab + targeted therapy|Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
48269948|NCT04541914|DIAGNOSTIC_TEST|5-gene classification model|Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
48269949|NCT04224935|PROCEDURE|Leukocyte Platelet rich fibrin membrane|the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
48269950|NCT06426940|OTHER|anesthesia-related critical events|anesthesia-related critical events
48269951|NCT05708742|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
47919102|NCT03572205|DIETARY_SUPPLEMENT|ALA|The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
47919103|NCT05962567|OTHER|Non surgical periodontal therapy|scaling and subgingival debridement
47919104|NCT03449524|DRUG|75mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
47919105|NCT03449524|DRUG|150mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
47919106|NCT03449524|OTHER|Placebo|Placebo
47919107|NCT01380821|RADIATION|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
47919108|NCT01324141|DRUG|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
47919109|NCT01324141|DRUG|5-Fluorouracil|5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
47919110|NCT01324141|DRUG|Mitomycin-C|Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
47919111|NCT01324141|PROCEDURE|Radiation Therapy|Radiation therapy (RT) will be delivered to a total dose of 50-54 Gray (Gy) based on tumor characteristics.
48269952|NCT05708742|DRUG|Bupivacaine Hydrochloride|The ESP block group underwent US-guided ESP block at L4 vertebrae level with 20 ml of bupivacaine 0.25%.
48269953|NCT05708742|DRUG|saline solution|The control group underwent the same procedure but had a sham injection (20 ml of saline).
48269954|NCT05708742|DEVICE|Needle|A 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) was inserted in the cranial-caudal direction towards the TP in-plane with the US transducer until the needle touched the TP crossing all three muscles.
48269955|NCT04091893|BEHAVIORAL|Usual care/wait list|Individuals in this group can continue with their usual care (but receive no museum-based intervention)
48269956|NCT04091893|BEHAVIORAL|Art Rx|Individuals in this group participate in a specialized tour of an art museum
48269957|NCT04091893|BEHAVIORAL|Artful Meditation|Individuals in this group participate in a meditation and art appreciation program at an art museum
48269958|NCT02485080|DRUG|Simeprevir|
48269959|NCT02485080|DRUG|Sofosbuvir|
48269960|NCT02509559|DRUG|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
48269961|NCT02509559|DRUG|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
48269962|NCT02509559|DEVICE|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
48269963|NCT02509559|DEVICE|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
48269964|NCT02509559|DEVICE|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
48269965|NCT02509559|DEVICE|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
48269966|NCT02509559|DEVICE|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
48269967|NCT02509559|PROCEDURE|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
48269968|NCT01736956|PROCEDURE|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
48269969|NCT04992702|BEHAVIORAL|Animated Video|Animated video to improve learning and motivation
48269970|NCT02116621|BEHAVIORAL|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
48092668|NCT02652130|BIOLOGICAL|Remestemcel-L|No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
48269971|NCT02116621|DEVICE|smartphone|
48269972|NCT05050760|DRUG|Camrelizumab|Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
48269973|NCT05050760|DRUG|DCF|DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
48269974|NCT06296121|DRUG|BCD-264|IV, 16 mg/kg
48269975|NCT06296121|DRUG|Darzalex|IV, 16 mg/kg
48269976|NCT00826735|BEHAVIORAL|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
48269977|NCT05706935|DIAGNOSTIC_TEST|MeMed BV® test|The MeMed BV® test is an automated semiquantitative immunoassay that measures three nonmicrobial (host) proteins (TRAIL, IP-10, and CRP) in serum samples and is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection.
48269978|NCT03325179|OTHER|Thread-embedding Therapy|
48269979|NCT05670626|PROCEDURE|Refractive Surgery|Phakic implantable contact lens ( ICL)
48092669|NCT01113229|DRUG|Misoprostol|two misoprostol tablets taken orally (400µg)
48269980|NCT00842933|DRUG|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
48269981|NCT00842933|DRUG|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
48269982|NCT04633590|BEHAVIORAL|Home-based exergaming|Participants will undertake one of two 6-week training interventions. In both groups participants will be asked to train 3 times per week (18 sessions total), during which adherence to the training will be measured. To monitor adherence to training and training load (exercise completion, exercise duration and heart rate achieved during workouts) throughout the 6 weeks participants will be given a heart rate monitor.
47914060|NCT03372902|OTHER|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
48092670|NCT02543450|OTHER|Cardiovascular and task-oriented training|
48092671|NCT02543450|OTHER|Upper limb strength training program|
48269983|NCT06359184|OTHER|yoga|1 hour yoga practice 2 days a week for 8 weeks
48269984|NCT06359184|OTHER|control|no intervention for 8 weeks
48269985|NCT06151652|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
48269986|NCT06151652|DRUG|Placebo|placebo
48269987|NCT02522767|DRUG|Mesalamine|
48269988|NCT02522767|DRUG|Placebo|
48269989|NCT04311658|DRUG|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
48269990|NCT04311658|DRUG|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
48269991|NCT05202626|DIAGNOSTIC_TEST|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.
48269992|NCT01907386|OTHER|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
48269993|NCT01714986|BEHAVIORAL|Affect School|
48269994|NCT01714986|BEHAVIORAL|Body Awareness Therapy|
48269995|NCT03110588|DRUG|PACE with Cabazitaxel (15 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
48269996|NCT03110588|DRUG|PACE with Cabazitaxel (20 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
48269997|NCT05438667|BIOLOGICAL|TCR-T therapy|"1.Preprocessing strategy：~1. Cyclophosphamide: 500mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~2. Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3 - 5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 14 days (24 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed ."
48269998|NCT02043925|DRUG|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
48269999|NCT00974415|PROCEDURE|CO2|CO2 treatment delivered to randomized flank at each study visit
48270000|NCT00974415|PROCEDURE|Sham|Sham treatment to other flank at each study visit
48270001|NCT05957887|DRUG|Dapagliflozin|Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
48270002|NCT02382133|DEVICE|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
48270003|NCT06076668|DRUG|Dexmedetomidine|Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
48270004|NCT06076668|DRUG|Melatonin 3 MG|Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
48270005|NCT06076668|DRUG|Saline|Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
48270006|NCT00217919|BEHAVIORAL|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
48270007|NCT01295060|DRUG|Octreotide|84 mg Octreotide Implant
48270008|NCT06260514|DRUG|APR-1051|WEE1 Inhibitor
48270009|NCT03454373|BEHAVIORAL|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
48270010|NCT02310048|DRUG|MT-1303-FormA|
48270011|NCT02310048|DRUG|MT-1303-FormB|
48270012|NCT01859377|DRUG|V0498 - A mg|Single oromucosal administration
48270013|NCT01859377|DRUG|Ibuprofen|Single oral administration
48270014|NCT03556215|DEVICE|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
48270015|NCT03556215|PROCEDURE|Myringotomy|Myringotomy will be performed using a standard procedure.
48092672|NCT02743663|PROCEDURE|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
48092673|NCT02743663|PROCEDURE|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
48092674|NCT02743663|PROCEDURE|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach \~2%. Each test in duplicate and average is calculated.
48092675|NCT02743663|PROCEDURE|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
48092676|NCT02743663|PROCEDURE|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
48092677|NCT02743663|DRUG|salbutamol|Given during bronchodilator response.
48092678|NCT02743663|PROCEDURE|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
48092679|NCT02743663|PROCEDURE|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
48092680|NCT02743663|PROCEDURE|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
48092681|NCT02743663|PROCEDURE|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
48092682|NCT02222415|DIETARY_SUPPLEMENT|Exercise + Protein drink|
48092683|NCT00766857|DRUG|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
48092684|NCT00766857|DRUG|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
48092685|NCT04523181|DRUG|Antroquinonol|double-blind for antroquinonol and Placebo with same out-look and same frequency.
48092686|NCT04523181|OTHER|Placebo|Capsule without active compound
48092687|NCT06239974|DRUG|Vericiguat|Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group
48092688|NCT06239974|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|All patients will have stress CMR examinations at recruitment and at the end of trial.
48092689|NCT04159506|BEHAVIORAL|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
48092690|NCT06300398|DRUG|IAMA-6|IAMA-6 liquid suspension
48092691|NCT06300398|DRUG|Placebo|Placebo-to-match IAMA-6 liquid suspension
48092692|NCT02114827|BEHAVIORAL|Video|23-minute video
48092693|NCT02114827|BEHAVIORAL|FAQ Sheet|
48092694|NCT06167252|OTHER|Exploration of a database|extraction of data
48092695|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task A|Participants will engage in a modified version of the Iowa Gambling Task with visual stimuli that are aligned with the Pé-de-Meia program's requirements. Advantageous cards will display images that are congruent with the program's criteria, while disadvantageous cards will feature images that are contrary to the Pé-de-Meia program's requirements.
48092696|NCT06344455|BEHAVIORAL|Iowa Gambling Task|The participants will play the unmodified Iowa Gambling Task.
48092697|NCT06344455|BEHAVIORAL|School Retention and Completion Incentive Savings via Modified Iowa Gambling Task B|"The participants will play the modified IGT (Iowa Gambling Task). For the disadvantageous cards, images that align with the requirements of the Pé-de-Meia program will be presented, while for the advantageous cards, images that contradict the criteria of the Pé-de-Meia program will be shown."
48092698|NCT00479947|DRUG|Probiotics (Natural product)|
48092699|NCT00479947|DRUG|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
48092700|NCT00578227|BIOLOGICAL|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
48092701|NCT00578227|BIOLOGICAL|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
48092702|NCT00740272|PROCEDURE|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
48092703|NCT00740272|PROCEDURE|Pacemaker implantation|regular pacemaker implantation
48092704|NCT01556243|PROCEDURE|therapeutic conventional surgery|
48092705|NCT01556243|RADIATION|whole breast irradiation|
48092706|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 10000 IU|Tablet of 5000 IU of vitamin D3 given twice daily
48092707|NCT05126602|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Tablet of 1000 IU of vitamin D3 given once daily
48092708|NCT01447797|DRUG|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
48092709|NCT04816682|DRUG|Silymarin|Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
48092710|NCT04394819|OTHER|electromyography-triggered electrical stimulation|All treatments were planned as 2 sessions per week, for a total of 10 sessions for 5 weeks. For EMG-trigger-ES application, dual-channel Nu-Tek® brand, Maxi plus 2 Model EMG-trigger-BF-ES Device in our clinic was planned to be used. With EMG-triggered-ES application, while the patient is in a sitting position, shoulder adduction, and the elbow is 90 degrees of flexion and pronation, the patient will extend to the ball of 5 cm in diameter, which is placed as far as the distance between the acromion and the 3rd toe, and then the finger-wrist active extension will be stimulated and then It was planned to apply the ball to be grasped. One of the two 5x5 cm superficial square electrodes of the device was planned to be placed on the extensor carpi radialis and extensor digitorum Communis and the other 2 cm distal.
48106700|NCT05880732|DRUG|Magnesium Sulfate|Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
48270016|NCT06020794|BEHAVIORAL|Exercise|quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
48270017|NCT06020794|BIOLOGICAL|LP-PRP|The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
48270018|NCT03480802|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
48270019|NCT03480802|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
48270020|NCT03480802|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
48270021|NCT05136625|DRUG|Sphenopalatine ganglion block|A cotton swab soaked in levobupivacaine 7,5% in inserted into the nose to block sphenopalatine ganglion, with the classic technique previously described
48270022|NCT05136625|DRUG|Standard Preparation|Troncular scalp blockade. Local site infiltration
48270023|NCT01236456|DRUG|Cyclophosphamide|
48270024|NCT04234737|BEHAVIORAL|Hypnotherapy|Hypnotherapy
48270025|NCT00126165|PROCEDURE|radiotherapy|
48270026|NCT02649257|PROCEDURE|cataract surgery|
48270027|NCT02649257|DEVICE|intraocular lens (MC 6125 AS)|
48270028|NCT02649257|DEVICE|capsular tension ring (CTR 13/11)|
48270029|NCT05587751|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test to measure lung function
48270030|NCT05587751|DIAGNOSTIC_TEST|Plethysmography|Pulmonary function test to measure lung volume
48270031|NCT05744427|DRUG|JSKN003|JSKN003 should be given on the first day of administration every 3 weeks by intravenous drip.
48270032|NCT00189462|DRUG|Montelukast|
48270033|NCT00189462|DRUG|Placebo|
48270034|NCT06293924|DIAGNOSTIC_TEST|Pericardiocentesis|"Enrolled patients will not undergo any invasive investigations outside of normal clinical practice. Patients with acute pericarditis and non-inflammatory pericardial effusion will undergo pericardiocentesis for diagnostic or therapeutic purposes.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
48270035|NCT06293924|DIAGNOSTIC_TEST|Pericardiotomy|"During any type of cardiac surgery involving pericardiotomy, 4 ml of pericardial fluid will be collected and analyzed upon opening the pericardial sac of enrolled patients.~Four ml of pericardial fluid will be collected: 2 ml for biochemical analysis in lithium heparin or serum-gel separator-associated tubes, and 2 ml for cellular analysis in K3 EDTA tubes."
48270036|NCT06293924|DIAGNOSTIC_TEST|Cytofluorometry and Gene expression analysis|"A 30 ml sample of peripheral venous blood in K3 EDTA tubes will be collected by enrolled patients who participating in the translational substudy and stored with pericardial fluid samples.~Pericardial fluid cells by lineage and expression of inflammatory cytokines will be characterized through cytofluorometry and expression profile analysis of transcribed RNAs. Cytokine concentrations in peripheral blood and pericardial fluid will be analyzed by molecular assay. Peripheral blood mononucleated cells (PBMCs) and pericardial fluid cells will be cultured in vitro and exposed to the main therapies used during pericarditis, to verify the effects on gene expression and inflammatory molecules."
48106701|NCT05880732|DRUG|normal saline isotonic solution|only 250 ml of normal saline isotonic solution 30 minutes before induction,
48270037|NCT00483327|DRUG|Megestrol Acetate|
48270038|NCT00085280|DRUG|erlotinib hydrochloride|Given orally
48270039|NCT00085280|OTHER|laboratory biomarker analysis|Correlative studies
48270040|NCT02077933|DRUG|alpelisib|"alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.~In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.~In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.~In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.~In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily."
48270041|NCT02077933|DRUG|everolimus|"everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.~In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation."
48270042|NCT02077933|DRUG|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
48106702|NCT05241119|PROCEDURE|SLNB|undergo fluorescence SLNB.
48106703|NCT05241119|PROCEDURE|pALND|undergo low axillary lymph node dissection with ICBN as the boundary
48106704|NCT05241119|PROCEDURE|ALND|undergo ALND
48270043|NCT00934102|DEVICE|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
48270044|NCT00934102|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
47919112|NCT03263702|DEVICE|Computational Mapping Algorithm|This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
47919113|NCT06180187|DEVICE|Electrical mallet|elevation of the Schneiderian membrane of maxillary sinus using electrical mallet and place bone graft material to augment the residual alveolar ridge and then place dental implant .
47919114|NCT06180187|DEVICE|Osseo-densification burs|elevation of the Schneiderian membrane of maxillary sinus using osseodensification burs and place bone graft material to augment the residual alveolar ridge and then place dental implant .
47919115|NCT03739034|BEHAVIORAL|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
47919116|NCT01702636|DRUG|Tranexamic Acid|
47919117|NCT01702636|DRUG|Placebo|
47919118|NCT02820948|DRUG|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
47919119|NCT04591678|DRUG|nusinersen|SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
48092711|NCT02729324|DRUG|Medical Radiation Protectants (FORRAD®)|Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
48092712|NCT02729324|DRUG|Trolamine (Biafine)|Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
48092713|NCT05559099|DRUG|Tecovirimat Oral Capsule|"200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
48092714|NCT05559099|DRUG|Placebo|Capsules to match tecovirimat
48092715|NCT02518906|BEHAVIORAL|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
48092716|NCT02518906|BEHAVIORAL|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
48092717|NCT01250951|DRUG|Deferasirox|
48092718|NCT00457080|DEVICE|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
48092719|NCT01141179|DRUG|LEO 27847|2 mL (0.1 mg) dose of oral solution
48092720|NCT05814640|DRUG|Fluoxetine|Commonly used oral antipsychotics intervention therapy.
48092721|NCT05814640|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
48092722|NCT05814640|DRUG|Vortioxetine|Commonly used oral antipsychotics intervention therapy.
48092723|NCT05814640|DRUG|Duloxetine|Commonly used oral antipsychotics intervention therapy.
48092724|NCT05814640|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
48092725|NCT05814640|DRUG|Lithium Carbonate|Commonly used oral antipsychotics intervention therapy.
48092726|NCT05814640|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
48092727|NCT05814640|BEHAVIORAL|GCBT|Commonly used intervention therapy of psychotherapy.
48092728|NCT03516149|OTHER|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
48092729|NCT05586217|OTHER|INCENTIVE SPIROMETRY|"* Sit up and hold the device.~* Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~* Breathe out (exhale) normally.~* Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~* Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~* Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~* If you breathe in too fast, the ball will shoot to the top.~* If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale."
48092730|NCT05586217|OTHER|Active cycle of breathing|"Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways"
48092731|NCT02442414|DRUG|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
48092732|NCT06092710|DIAGNOSTIC_TEST|neuro-sensorial subjective evaluation of the airways collapsibility|verbal and manual guidance of subjects from a therapist to experiment the subjective perception of the air flow through their airways and airways collapsibility
48092733|NCT02609555|PROCEDURE|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
48092734|NCT04021043|DRUG|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Given IV
48092735|NCT04021043|BIOLOGICAL|Ipilimumab|Given IV
48092736|NCT04021043|BIOLOGICAL|Nivolumab|Given IV
48092737|NCT04021043|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48092738|NCT04333836|DEVICE|Removable Clear Aligners|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction."
48092739|NCT04847648|PROCEDURE|Air-polishing|Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
48092740|NCT04847648|PROCEDURE|Mechanical decontamination|Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
48092741|NCT02249481|PROCEDURE|Adductor Canal catheter delivering 0.0625% L- Bupivacaine|Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
48092742|NCT02249481|PROCEDURE|Femoral nerve catheter delivering 0.0625% L- Bupivacaine|Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
48092743|NCT00108784|BEHAVIORAL|Reduced-energy-density diet|
48092744|NCT02821312|DRUG|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
48092745|NCT02821312|DRUG|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
48092746|NCT03935828|DRUG|Oral versus topical antibioitics|Previously described in two arms
48092747|NCT00427973|DRUG|cediranib maleate|Given orally
48106705|NCT00768651|DRUG|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
48106706|NCT00768651|DRUG|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
47919120|NCT03234569|PROCEDURE|sonoHSG|This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
47919121|NCT05813041|DEVICE|BioCaptis|The BioCaptis is a medical device intended to capture cell-free DNA from peripheral blood for use in liquid biopsy. When used as a cartridge filter during an apheresis procedure in which plasma is passed through the device, the BioCaptis binds cfDNA which can be eluted, concentrated, and used as an input for cancer diagnostic tests.
47919122|NCT03903315|OTHER|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
47919123|NCT02238184|DRUG|Atrovent®|
47919124|NCT02238184|DRUG|Ventilat®|
47919125|NCT01269242|DRUG|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
47919126|NCT01269242|DRUG|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
47919127|NCT01269242|DRUG|placebo|bindarit-matching placebo tablets for 6 months.
47919128|NCT04242641|BEHAVIORAL|WW|WW is a structured lifestyle modification, weight-loss programme involving a programme for healthy eating, physical activity and positive mindset and support via attendance at local WW workshops and digital tools.
47919129|NCT03248791|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
47919130|NCT03248791|DRUG|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
47919131|NCT03248791|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
47919132|NCT05379010|PROCEDURE|Endodontic Microsurgery|Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.
47919133|NCT03835793|DIAGNOSTIC_TEST|CAC-score|Testing for possible unfavourable health effects of early surgical menopause
48092748|NCT00427973|OTHER|laboratory biomarker analysis|Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R\&D Systems.
48092749|NCT00427973|PROCEDURE|computed tomography|computed tomography (CT) every 8 weeks to evaluate response and progression.
48092750|NCT00427973|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
48092751|NCT00427973|OTHER|pharmacological study|Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
48092752|NCT00142064|BEHAVIORAL|observed levels of pain|
48092753|NCT00412516|BIOLOGICAL|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
48092754|NCT01974921|DEVICE|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
48092755|NCT06191536|OTHER|Pilates|
48092756|NCT06191536|OTHER|Pelvic floor exercises|
47919134|NCT04448028|DRUG|Placebo|Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.
47919135|NCT04448028|DRUG|Esomeprazole 20mg|Patients with a pre-existing PPI therapy stop their prior PPI medication and have it replaced with esomeprazole 20mg/day for 360 days.
48092757|NCT04034238|DRUG|LMB-100|Arms 1 and 2: Administered intravenous (IV) as an approximate 30-minute infusion of each 21-day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.
47919136|NCT03142685|DEVICE|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
48092758|NCT04034238|DRUG|Tofacitinib|Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.
48092759|NCT04034238|DEVICE|Mesothelin Expression|Test for mesothelin expression in tumor tissues for study eligibility
47919137|NCT05189821|PROCEDURE|Radiofrequency Ablation|Ultrasound guided radiofrequency ablation
47919138|NCT06193109|OTHER||the patients with sepsis and septic shock were performed echocardiography for detecting right ventricular systolic function
47919139|NCT00561626|DIETARY_SUPPLEMENT|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
47919140|NCT00561626|DIETARY_SUPPLEMENT|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
47919141|NCT03482934|DEVICE|sphygmomanometer|device used for measurement of brachial blood pressure
47919142|NCT03482934|DEVICE|mobilogragh|device used for measurement of central blood pressure
47919143|NCT03482934|DIAGNOSTIC_TEST|ECG|Electrocardiogram
47919144|NCT03482934|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
47919145|NCT03542032|OTHER|i-gel placement maneuvers|the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) In the classic maneuver , the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place.
47919146|NCT03133884|OTHER|acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
47919147|NCT03133884|OTHER|superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
47919148|NCT04259918|PROCEDURE|Alveolar recruitment maneuver|Applying 30 or 60 cmH2O of alveolar recruitment maneuver 5 times every 5 min at the end of bariatric surgery
47919149|NCT01640834|DRUG|LY2409021|Administered orally
47919150|NCT01640834|DRUG|Placebo|Administered orally
47919151|NCT01640834|DRUG|Glucagon|Administered via intramuscular injection
47919152|NCT00822549|DRUG|intravenous morphine titration|intravenous morphine titration
47919153|NCT06149247|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
47919154|NCT06149247|DRUG|Mechlorethamine Topical Gel|Valchlor is an FDA-approved drug for the treatment of CTCL.
47919155|NCT00528554|PROCEDURE|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
47919156|NCT00528554|PROCEDURE|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
47919157|NCT06469801|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO. Patients will undergo imaging within 24 hours of ECMO initiation/cannulation. Patients that remain on ECMO will have repeat imaging at 72-120 hours of ECMO therapy and again weekly for the duration of their ECMO course.
47919158|NCT04466579|OTHER|BIS monitor|BIS monitor is used to control and monitor the depth of general anesthesia.
48092760|NCT06614205|DIAGNOSTIC_TEST|tumoral dosimetry by scintigraphy|The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment
47919159|NCT04466579|OTHER|Standard care|Standard anesthesiology care according to the protocol of the study
47919160|NCT02270944|BIOLOGICAL|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
47919161|NCT02270944|BIOLOGICAL|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
47919162|NCT00616499|DRUG|gefitinib|
47919163|NCT00616499|PROCEDURE|neoadjuvant therapy|
47919164|NCT00616499|PROCEDURE|therapeutic conventional surgery|
47919165|NCT05086029|DIAGNOSTIC_TEST|Superb Microvascular Imaging|Superb microvascular imaging (SMI) is a new ultrasound technology that can diferen-tiate blood flow signals from artifacts by using a new algorithm.
47919166|NCT00692536|BEHAVIORAL|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
47919167|NCT00692536|BEHAVIORAL|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
47919168|NCT00690144|DEVICE|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
47919169|NCT05083858|OTHER|Classical Physiotherapy Program + Cervical Stabilization Exercises|First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.
47919170|NCT05083858|OTHER|Classical Physiotherapy Program + Oculomotor Exercises|Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.
48092761|NCT05687890|DRUG|Placebo of SC0062|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
47919171|NCT05083858|OTHER|Classical Physiotherapy Program|"Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done."
47919172|NCT01977872|BEHAVIORAL|A worksite activity-diet intervention|
47919173|NCT00693082|DIETARY_SUPPLEMENT|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
47919174|NCT04085900|BIOLOGICAL|Blood and saliva|Collect blood and saliva samples from participants
47919175|NCT04085900|DIAGNOSTIC_TEST|P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA|Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
47919176|NCT04085900|DIAGNOSTIC_TEST|Fiberoptic endoscopy and biopsy|Screening participants will refer to fiberoptic endoscopy and biospy
47919177|NCT00921518|DRUG|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
47919178|NCT00921518|DRUG|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
47919179|NCT02052713|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
47919180|NCT02052713|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
47919181|NCT04227028|BIOLOGICAL|Bevacizumab|Given IV
47919182|NCT04227028|DRUG|Brigatinib|Given PO
47919183|NCT02471326|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
47919184|NCT02606201|OTHER|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
47919185|NCT03246997|OTHER|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
47919186|NCT03246997|OTHER|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
47919187|NCT06153719|OTHER|12-weeks combined exercise intervention|This 12-week combined exercise intervention will consist of 3 supervised exercise classes per week, each one lasting 50 minutes. It will involve both aerobic and resistance training in order to follow the UK's physical activity recommendations
47919188|NCT01437475|BIOLOGICAL|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
47919189|NCT01802164|DEVICE|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
47919190|NCT00286598|BEHAVIORAL|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
48620241|NCT01141309|DRUG|sorafenib with everolimus|"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles \*Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
47919191|NCT04680182|PROCEDURE|Suction drain|Suction drain either kept for three weeks or gradually pulled out.
47919192|NCT05433844|DRUG|Reference Drug or Test Drug|"Test Drug: single administration of JW0301 Reference Drug: single administration of C2105~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
47919193|NCT04243382|BIOLOGICAL|Autologous umbilical cord blood|Single infusion of autologous umbilical cord blood cells
47919194|NCT04243382|BIOLOGICAL|Placebo|Placebo
48620242|NCT01056276|DRUG|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
47919196|NCT00947960|DRUG|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
47919197|NCT00947960|OTHER|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
48620243|NCT01056276|DRUG|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
48620244|NCT01056276|DRUG|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
48620245|NCT00097968|DRUG|everolimus|
48620246|NCT01869309|DRUG|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
48620247|NCT01869309|DRUG|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
47919198|NCT04798651|BIOLOGICAL|blood sample|28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
47919199|NCT04798651|BIOLOGICAL|cerebro-spinal fluid|1 ml of cerebro-spinal fluid
47919200|NCT06367712|DRUG|Letrozole tablets|To determine if the usage of All interventions are effective for simple induction of ovulation in polycystic ovarian syndrome in infertile couples.
48092762|NCT05687890|DRUG|SC0062 low dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
48270045|NCT00934102|DEVICE|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
48092763|NCT05687890|DRUG|SC0062 medium dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
48270046|NCT01362582|DRUG|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
48270047|NCT05695326|BEHAVIORAL|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
48270048|NCT00457574|DRUG|GMX1777|
48270049|NCT00291720|DRUG|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
48270050|NCT00291720|DRUG|Placebo|matching placebo
48270051|NCT01852084|DEVICE|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
48270052|NCT01852084|DEVICE|enVista control lens|Spherical Control lens
48270053|NCT03320655|OTHER|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
48270054|NCT03320655|OTHER|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
48270055|NCT00005979|DRUG|FOLFIRI regimen|
48270056|NCT00005979|DRUG|fluorouracil|
48270057|NCT00005979|DRUG|irinotecan hydrochloride|
48270058|NCT00005979|DRUG|leucovorin calcium|
48270059|NCT03015103|DEVICE|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
48270060|NCT02005120|DRUG|Bevacizumab|Intrapleural administration of bevacizumab
48270061|NCT02005120|DRUG|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
48270062|NCT04336163|DEVICE|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
48270063|NCT05658224|BEHAVIORAL|Education on effects of Exercise-induced hypoalgesia from exercise|Educational session with participants
48270064|NCT00804687|OTHER|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
48620248|NCT03094728|DIAGNOSTIC_TEST|HLA cross matching|"HLA Typing and Mismatch~Cross matching (total and autocross):~Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result."
47919201|NCT04215302|DEVICE|laryngeal mask|the size of laryngeal mask given to the patient was based on patient's weight measurement
48092764|NCT05687890|DRUG|SC0062 high dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
48092765|NCT03732274|DRUG|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
48092766|NCT00716664|OTHER|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
48092767|NCT00716664|OTHER|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
48092768|NCT06346145|PROCEDURE|Bariatric surgery|Type of surgery assigned by surgeon in consultation with patient
48092769|NCT06346145|PROCEDURE|Standard care|Standard care can consist of dietary intervention, physiotherapy or drug treatment in accordance to the care given in the region of Sweden where the patient resides.
48092770|NCT06485297|OTHER|questionnary|questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)
48092771|NCT01913756|DIETARY_SUPPLEMENT|Gamalost (Norwegian traditional cheese)|
48092772|NCT01913756|DIETARY_SUPPLEMENT|Gouda-type cheese|
48092773|NCT00205530|BEHAVIORAL|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
48092774|NCT03276364|DIAGNOSTIC_TEST|Ultrasound|Point-of-care ultrasound examination by pulmonary and critical care fellow
48092775|NCT02512146|PROCEDURE|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
48092776|NCT03617874|OTHER|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
47919202|NCT04966663|DRUG|Nivolumab|Antineoplastic agent
47919203|NCT04966663|DRUG|Pemetrexed|Antineoplastic agent
47919204|NCT04966663|DRUG|Gemcitabine|Antineoplastic agent
47919205|NCT04966663|DRUG|Cisplatin|Antineoplastic agent
47919206|NCT04966663|DRUG|Carboplatin|Antineoplastic agent
48092777|NCT03617874|OTHER|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
48092778|NCT00865956|BEHAVIORAL|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
48092779|NCT00865956|OTHER|Case management|Nurse case manager assigned to participant
48092780|NCT02338622|DRUG|olaparib|olaparib BD
48092781|NCT02338622|DRUG|AZD5363|AZD5363 BD
48092782|NCT00301379|OTHER|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
48092783|NCT06614868|BEHAVIORAL|Acceptance and Commitment Therapy|Up to 16 session of unstructured counseling therapy informed by Acceptance and Commitment Therapy tradition.
48270065|NCT00804687|DRUG|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
48092784|NCT04316455|OTHER|Integrative Yoga Therapy|Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
48092785|NCT01419847|DRUG|Ciclopirox|
48092786|NCT01419847|DRUG|Placebo|
48092787|NCT05162768|DRUG|Elamipretide|60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks
47919207|NCT04966663|PROCEDURE|ctDNA blood test|Blood will be collected for ctDNA testing
48092788|NCT05162768|DRUG|Placebo|Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
48092789|NCT00716079|OTHER|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
48270066|NCT00804687|DRUG|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
48270067|NCT03599700|DIAGNOSTIC_TEST|myeloproliferative neoplasms|BLOOD SAMPLING
48270068|NCT04953871|DRUG|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
48270069|NCT03618641|DRUG|CMP-001|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
48270070|NCT03618641|BIOLOGICAL|Nivolumab|A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
48270071|NCT03201055|DEVICE|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
48270072|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection before vitrectomy
48270073|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection after vitrectomy
48270074|NCT04799561|BEHAVIORAL|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
48270075|NCT00770848|DRUG|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
48270076|NCT00770848|DRUG|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
48270077|NCT00770848|DRUG|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
48270078|NCT00770848|DRUG|Placebo|Placebo
48270079|NCT00770848|DRUG|Prednisone|5 mg orally BID
48270080|NCT04390867|DEVICE|TOPS1 DBS|TOPS1 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
48270081|NCT04390867|DEVICE|TOPS2 DBS|TOPS2 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
48270082|NCT04390867|DEVICE|TOPS3 DBS|TOPS3 is an investigational novel pattern of stimulation that is programmed non-invasively into an already implanted DBS system
48270083|NCT04390867|DEVICE|Standard DBS|Standard is the pattern of stimulation that is usually delivered clinically by a DBS system
48270084|NCT04159883|OTHER|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
47919208|NCT03050229|DRUG|Empagliflozin|Empagliflozin 10mg/day once daily before or after breakfast
47919209|NCT03050229|DRUG|Placebo|Placebo once daily before or after breakfast
48106707|NCT04155151|OTHER|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
48106708|NCT01215019|DRUG|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
48092790|NCT04422925|PROCEDURE|Living Donor Hepatectomy|On living donor hepatectomy (preoperative), the first following day of surgery, 3rd day, and 7th day, blood will be taken for the measurement of S100β, NSE, and GFAP levels in the postoperative period. The plasma of the blood taken will be separated and stored at -800C. Values will be measured by the ELISA method. During the hospitalization, the delirium status of the patients will be evaluated with the delirium evaluation scale (Delirium Rating Scale-Revised - 98 Turkish version). Functional and cognitive information and other results will be collected at each follow-up point.
48092791|NCT05423080|DRUG|Bolus injection of remimazolam|Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.
48092792|NCT05423080|DRUG|Infusion of remimazolam|Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
48106709|NCT01215019|DRUG|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
48106710|NCT00939042|PROCEDURE|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
48106711|NCT00939042|PROCEDURE|BMNC therapy|Injection of BMNC after common PCI
48106712|NCT00377455|DRUG|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
48106713|NCT00377455|DRUG|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
48106714|NCT04381494|DEVICE|Multiparametric Mobile Technology|Using a spirometer, an armband, and a tablet to collect data.
47919210|NCT01237899|DRUG|LY2623091|Administered orally.
48092793|NCT03541811|DIAGNOSTIC_TEST|3-d gait examination (level walking)|"Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured."
48092794|NCT03541811|DIAGNOSTIC_TEST|Anthropometrics and body composition assessment|Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
47919211|NCT01237899|DRUG|Placebo|Administered orally.
47919212|NCT01237899|DRUG|Eplerenone|Administered orally.
47919213|NCT00363545|BIOLOGICAL|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
47919214|NCT00363545|BIOLOGICAL|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
47919215|NCT00407056|DRUG|Difluprednate Ophthalmic Emulsion|
47919216|NCT02648256|OTHER|Polymerase Chain Reaction on Oropharyngeal rinse|
48092795|NCT03541811|DIAGNOSTIC_TEST|Biomarkers|"Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method)."
48106715|NCT05255718|DIETARY_SUPPLEMENT|Aronia juice|Once daily dose of 100 mL of aronia juice
48106716|NCT05255718|OTHER|Placebo|Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
48106717|NCT02045719|DRUG|uncaria tomentosa (cat´s claw)|
48106718|NCT01958099|BEHAVIORAL|Education|
48620249|NCT04166331|DRUG|Placebos|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
47919217|NCT02874144|DRUG|AZ compound|40 mg three times daily po for 12 weeks
47919218|NCT02874144|OTHER|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
47919219|NCT02874144|DRUG|Intranasal corticosteroid|QD Nasal Spray
47919220|NCT02874144|DRUG|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
47919221|NCT05905978|PROCEDURE|Corneal donors predisposed by CXL|Corneal donors predisposed by CXL and DALK procedure was conducted in patients
47919222|NCT05905978|PROCEDURE|Corneal donors stored in corneal storage media|Corneal donors stored in corneal storage media and DALK procedure was conducted in patients
47919223|NCT02802917|DRUG|SPF 50 Y49 091 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
47919224|NCT02802917|DRUG|SPF 50 X15 158 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
47919225|NCT02802917|DRUG|SPF 50 X15 160 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
47919226|NCT02802917|DRUG|SPF 50 X57 162 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
47919227|NCT02802917|OTHER|J & J baby shampoo, X46 046 (control)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
47919228|NCT05867771|DRUG|PM1022|PM1022 Injection
47919229|NCT03258528|BEHAVIORAL|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
47919230|NCT05953233|OTHER|Active classroom HEPA cleaner|Commercially available portable HEPA cleaner
47919231|NCT05953233|OTHER|Sham classroom HEPA cleaner|Commercially available portable HEPA cleaner with filtration device removed
47919232|NCT05037435|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Group 1 (20 participants) - received the pentavalent live vaccine to prevent rotavirus infection Single-use orally 2.5 ml (1 dose).
47919233|NCT05037435|OTHER|Placebo|Group 2 (20 participants ) - received placebo orally once of 2.5 ml (1 dose).
47919234|NCT01282580|DIETARY_SUPPLEMENT|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
47919235|NCT01282580|OTHER|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
47919236|NCT06278818|BEHAVIORAL|Cognitive Telerehabilitation|Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.
47919237|NCT06278818|OTHER|Control Condition|This activity is commonly used as a control condition to test the effectiveness of innovative rehabilitative treatments.
47919238|NCT00386919|PROCEDURE|CyberKnife|
47919239|NCT05430633|PROCEDURE|Appendectomy|Appendectomy - laparoscopic or open
47919240|NCT05917678|OTHER|Repositioning Therapy|Caregivers will be instructed how to increase tummy time activities and reshape their infant's heads using at-home methods to direct their attention to the non-preferred side.
47919241|NCT05917678|DEVICE|Cranial Remolding Orthosis|A custom cranial remolding orthosis (FDA Class II device) will be made to fit affected infants. this should be worn 23 hours per day and the Orthotist needs to be seen regularly for adjustments until the head shape is resolved.
47919242|NCT00637949|DEVICE|lumiracoxib|400 mg once daily, oral over 6 weeks
48092796|NCT03541811|DIAGNOSTIC_TEST|Clinical examination|Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
48092797|NCT03541811|DIAGNOSTIC_TEST|Habitual physical activity tracking (accelerometer based)|Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.
47919243|NCT00637949|DRUG|rofecoxib|25 mg, oral, daily over 6 weeks
47919244|NCT05878262|DRUG|ibuprofen suppository|After the induction of anesthesia was performed, the nurse delivered the ibuprofen suppository at the dose of 5-10 mg/Kg for the pre-emptive analgesia group children.
47919245|NCT03122951|DIAGNOSTIC_TEST|ovulation test use|Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
47919246|NCT01695759|DRUG|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
48092798|NCT01444066|PROCEDURE|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
48092799|NCT06365554|DEVICE|Remedy Robot|A trained Neurointerventionalist will operate the Remedy Robot from a computer-based user interface in a room adjacent to the patient. An entire cerebral angiogram or cerebral embolization will be performed, excluding insertion and removal of the femoral sheath.
48092800|NCT06460467|DEVICE|scintigraphy of 177Lu-DOTATATE|The medical device under study is a hybrid wide-field CZT solid-state camera, the VERITON-CT ™ camera.
48092801|NCT00112723|DRUG|alvocidib|Given IV
48092802|NCT02398825|DRUG|Ponatinib|Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to \> 1%. Dose adjustments for toxicity are detailed in the protocol.
48092803|NCT02049437|DRUG|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
48092804|NCT02049437|DRUG|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
48092805|NCT02931149|DRUG|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
48092806|NCT00846781|DRUG|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
48092807|NCT06614517|OTHER|Birdwatching Intervention|Description: Participants will attend three birdwatching sessions, where they will enjoy direct contact with nature in selected environments such as forests and farms. These outings will be guided by an expert, who will also introduce participants to the use of binoculars and tools for identifying the birds observed during the excursions. During the outings, participants will learn the body scan technique, which will help them focus on physical sensations without making judgments. This exercise will encourage them to pay attention to details such as muscle tension, temperature, or surface contact, allowing them to be more present and connected to their surroundings during the birdwatching sessions. In addition to the in-person outings, participants will receive digital materials via WhatsApp to complement the intervention.Birdwatching Intervention
48092808|NCT03794778|DRUG|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
48092809|NCT03794778|DRUG|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
48092810|NCT03794778|DRUG|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
48092811|NCT06443047|DEVICE|TTS suturing system|The use of TTS suturing system could allow a quick, complete endoscopic closure of colonic post-ESD defects, providing relevant clinical and medico-economic benefits.
48092812|NCT05910931|DRUG|ICG angiography|"* A first injection with the patient asleep before starting the intervention to visualize the vascular anatomy of each patient and assess the pedicles and incisions.~* A second bolus after breast resection to assess the viability of skin flaps and glandular pedicles.~* A third injection to obtain an angiography after implant placement and wound closure.~For angiography, the SPY System with the SPY-Q software will be used."
48092813|NCT03730298|DIETARY_SUPPLEMENT|American Ginseng|cpr
48092814|NCT03730298|OTHER|Placebo|cpr
48092815|NCT04765202|PROCEDURE|AG Tx|The control treatment is meshed autograft applied to a FT burn area
48092816|NCT04765202|BIOLOGICAL|SOMA Tx|The experimental treatment is more widely meshed autograft than the AG Tx site applied to a FT burn area and covered with SOMA
48092817|NCT01147770|DRUG|progesterone|duration
48092818|NCT05090423|OTHER|balance training alone|"The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
48092819|NCT05090423|OTHER|balance training and neurodynamic intervention for the common peroneal nerve|"The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller."
48092820|NCT06009783|OTHER|ChatGPT Language Model|ChatGPT Language Model - ability to converse with the model and ask questions regarding vasectomies
48092821|NCT06479460|DIAGNOSTIC_TEST|ctDNA-MRD|This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.
48092822|NCT01348854|DEVICE|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
48092823|NCT03681340|OTHER|Hydroxyapatite toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
48092824|NCT03681340|OTHER|Fluoridated toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
48092825|NCT03882463|DEVICE|Continuous glucose monitoring with the stop insulin pump function|"Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology."
48092826|NCT05254509|OTHER|Occupational Therapy|Occupational therapy helps individuals with chronic pain to participate in daily activities in an adaptive way. The subjects will be provided with customized plans and objectives to address their self-care, vocational, and leisure goals. This includes education, home exercises, stress management, home safety, energy conservation, and work simplification - all of which promote a safe return to daily activities.
48270085|NCT04159883|OTHER|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account."
48620250|NCT04166331|DRUG|Dobutamine|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
47919247|NCT01695759|DRUG|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
47919248|NCT02720172|BEHAVIORAL|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
47919249|NCT02720172|OTHER|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
47919250|NCT01931371|PROCEDURE|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
47919251|NCT01931371|PROCEDURE|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
47919252|NCT02145650|OTHER|No Intervention|There is no intervention administered in this study.
47919253|NCT00838032|DRUG|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
48092827|NCT05254509|OTHER|Occupational Therapy +Virtual Reality|The occupational therapy +VR utilizes the regular therapy sessions along with providing a Virtual reality headset to relieve pain. After each VR session, there will be a debriefing from the therapist.
48092828|NCT05541419|DRUG|Budesonide Nasal|The patient performed a lavage once daily with 2mg dilute budesonide. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
48092829|NCT05541419|DRUG|Placebos|Composed of 1% glycerin diluted in water. The maximum clinical treatment consists of intramuscular injection of Dispropan® in intramuscular injectable suspension and busonid in nasal spray, two sprays of 50mcg in each nostril.
48092830|NCT02777983|BEHAVIORAL|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
48092831|NCT05341544|DEVICE|Parasym device|The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.
48092832|NCT05341544|DEVICE|Sham device|Sham device
47919254|NCT00838032|DRUG|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
48092833|NCT05812794|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Participants will come for 5 sequential days of 2 hour long occupational therapy sessions augmented by tDCS for the first 20 minutes of the session. At arrival, the stimulation safety sheet will be completed by the occupational therapist.The saline soaked electrodes will be placed on the study subjects head and connected to the Soterix 1x1 Limited Total Energy (LTE) enabled tDCS device. Current output through the device will be sham stimulation on day 1 , followed by steady increases to a maximum of 1milliampere (mA) in patients aged 5-12 years old, and 1.5 mA in patients aged 13-19 years old, per the study design flow sheet at the end of this protocol. Blood pressure, pulse rate, and peg-board scores will be recorded as indicated on the stimulation safety sheet during each session.A repeat assessment will be done by the occupational therapist one week post therapy completion.There will be a repeat assessment visit 3 months post intervention."
48092834|NCT06413615|DRUG|FDA022-BB05|Monoclonal antibody-drug conjugate for injection
48092835|NCT03270111|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
48092836|NCT03270111|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
48092837|NCT03270111|BEHAVIORAL|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
48092838|NCT03270111|BEHAVIORAL|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
48092839|NCT06217731|COMBINATION_PRODUCT|Laser+clonazepam|treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril 0.25mg once every 24 hours for a month
48270086|NCT00331006|DRUG|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
48620251|NCT02467244|DRUG|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
48092840|NCT06217731|DEVICE|Laser Sham|INACTIVE Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
48092841|NCT06217731|DEVICE|Laser|Active Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
48092842|NCT06217731|DRUG|Clonazepam|Rivotril 0.25mg once every 24 hours for a month
48092843|NCT00562393|OTHER|Nutritional|Overfeeding high fat diet for 28 days
48092844|NCT01340833|DRUG|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK2118436, starting 1.75 hours after the oral dose
48092845|NCT04619368|OTHER|Follow up calls|The follow-up will consist in phone call with an intensive care doctor. These visits would be the opportunity to screen the complications after intensive-care with, find solutions to cure them or decrease their impact on patient's life to improve quality of life and prevent the post-traumatic syndrome disorder PTSD. A review would be sent to the patients' General Practitioners at the end of each visit.
48092846|NCT05515796|DRUG|Terelizumab (aka Tislelizumab)|q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
48092847|NCT05515796|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
48620252|NCT05608863|OTHER|Lifestyle - group sessions|The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting.
48620253|NCT05608863|OTHER|Lifestyle - individual coaching|The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting.
48092848|NCT05515796|DRUG|Trastuzumab|q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
48092849|NCT05515796|RADIATION|Radiotherapy|25 Gy/5 fractions
48092850|NCT02028975|OTHER|Measure the threshold of detection for linoleic acid|
48092851|NCT02028975|OTHER|Oral stimulation tests|
48092852|NCT02028975|OTHER|Venous blood samples|
48092853|NCT02028975|OTHER|Samples for genetic studies (ancillary study)|
48092854|NCT04836195|DRUG|PCLX-001|To ensure maximal safety in this first-in-human trial, the starting dose level was chosen to be 20 mg daily on a 28-day cycle.
48092855|NCT06298630|OTHER|Assessments|Safety and efficacy assessments
48092856|NCT05585762|OTHER|Ketone ester|75 mL chocolate flavored beverage containing 25 g of ketone ester. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
48092857|NCT05585762|OTHER|Non-ketone placebo|75 mL chocolate flavored beverage containing 25 g of non-ketogenic fat. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
48620254|NCT02305147|OTHER|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
48092858|NCT03382743|DRUG|Endocervical Lidocaine spray|5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
48092859|NCT00599677|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
48092860|NCT00599677|DRUG|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
48092861|NCT04272151|BIOLOGICAL|BCMA CAR-T cells|A single infusion of BCMA CAR-T cells will be administered intravenously.
48092862|NCT05239702|BIOLOGICAL|CD7 CAR T-cells|Each subject receive CD7 CAR T-cells by intravenous infusion
48092863|NCT02912039|DEVICE|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
48092864|NCT02912039|DEVICE|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
48092865|NCT05192512|DRUG|TQB2928 injection|TQB2928 injection is a CD47 Blocker.
48092866|NCT05929651|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection
48092867|NCT05895773|DRUG|Povidone-Iodine|Povidone Iodine 0.5% plus glycyrrhizin acid 2.5 mg/ml as a nasal and an oropharyngeal spray (mint flavored) will be applied 4 times per day.
48092868|NCT05895773|DRUG|Saline spray|Normal saline 0.9% as a nasal and oropharyngeal spray (Mint flavored) will be applied 4 times per day.
48092869|NCT01878695|DRUG|IV/oral n-acetylcysteine|
48092870|NCT04865562|DRUG|testosterone propionate|1mg/0.1mL solution, to be administered intranasally
47919255|NCT03060122|DEVICE|NIN|The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
47919256|NCT03060122|DEVICE|Sham CES|The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
48092871|NCT04865562|DRUG|0.5% cholorbutanol, saline|125 mg 0.5% cholorbutanol, 50mg saline
48092872|NCT00892229|DRUG|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
48092873|NCT00892229|DRUG|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
48092874|NCT01227356|DRUG|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
48092875|NCT04776213|DRUG|Mavenclad®|This low interventional extension study involves the follow up of participants in the parent study. The participants were followed up for an additional 2 year period (until 4 years after initial administration of Mavenclad® tablets), during which the participants were not treated with Mavenclad®, as per European Medicines Agency (EMA) label of Mavenclad®.
48092876|NCT02239185|PROCEDURE|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
48092877|NCT02239185|PROCEDURE|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
48092878|NCT06614023|PROCEDURE|coronary artery bypass grafting|surgical coronary revascularization
48092879|NCT03064503|BIOLOGICAL|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
48092880|NCT03064503|DEVICE|MRI|MRI will be performed to measure interstitial fibrosis
48092881|NCT03064503|BIOLOGICAL|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
48092882|NCT00592748|RADIATION|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
48092883|NCT05236543|DRUG|AZD4831|Subjects will receive single oral dose only on Day 1 and Day 11.
48092884|NCT05236543|DRUG|Itraconazole|Subjects will receive Itraconazole orally on Days 8 followed by dosing from Day 9 to Day 17.
48092885|NCT00191685|DRUG|duloxetine|
48092886|NCT04438785|DEVICE|The intervention consists of myofunctional therapy (MT) using the AirwayGym app.|Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
48092887|NCT06170489|BIOLOGICAL|JS004 in combination with Toripalimab|Participants will receive JS004 in combination with Toripalimab (200 mg/240 mg) by intravenous (IV) infusion on Day 1, then every three weeks (Q3W), for up to 35 infusions.
48092888|NCT06170489|DRUG|Bendamustine or gemcitabine|Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
47919257|NCT03060122|DEVICE|CES|Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
48092889|NCT05805059|DEVICE|Control Contact Lens (stenfilcon A)|one week wear
48092890|NCT05805059|DEVICE|Test Contact Lens (senofilcon A)|one week of wear
48092891|NCT00138164|BIOLOGICAL|denileukin diftitox|
48092892|NCT01779375|DRUG|Metformin|
48092893|NCT01779375|DRUG|Glargine|
48092894|NCT01588704|DRUG|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
48620255|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra|
48620256|NCT02895737|DEVICE|TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems|
48092895|NCT02923895|OTHER|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
48092896|NCT02923895|OTHER|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
48092897|NCT01391156|DRUG|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
48092898|NCT01391156|DRUG|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
48092899|NCT04497311|DIAGNOSTIC_TEST|Thoraxic computed tomography|Diagnostic lung CT.
48092900|NCT03924245|DRUG|Entinostat|Given by mouth
48092901|NCT03924245|DRUG|Olaparib|Given by mouth
48092902|NCT03084861|DRUG|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
48092903|NCT03084861|DRUG|Conventional treatment|"1. Artificial tears: Lubristil ®~2. Therapeutic Contact lens: Air Optix Night\&Day"
48092904|NCT00795132|DRUG|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
48092905|NCT00795132|DRUG|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
48092906|NCT00795132|DRUG|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
48270087|NCT03957967|OTHER|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
48270088|NCT05449457|OTHER|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
47919258|NCT04384133|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
48620257|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
48620258|NCT02895737|DEVICE|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems|
47919259|NCT04384133|DIAGNOSTIC_TEST|Spirometric pulmonary function test|In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
47919260|NCT04384133|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
47919261|NCT04384133|DIAGNOSTIC_TEST|Thorax Computed Tomography|Computed tomography is a radiological examination.
47919262|NCT04384133|DIAGNOSTIC_TEST|Chest X Ray|Chest X ray is a radiological examination.
47919263|NCT04384133|DIAGNOSTIC_TEST|Blood eosinophil level|A tube of blood will be drawn from the participant.
47919264|NCT04384133|OTHER|CAT|It consists of 8 questions.
47919265|NCT04384133|OTHER|mMRC|It is the scale used to measure the severity of shortness of breath.
47919266|NCT00256672|DEVICE|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
47919267|NCT02343549|DEVICE|NovoTTF100A|
47919268|NCT02343549|DRUG|Bevacizumab|
47919269|NCT02343549|DRUG|Temozolomide|
47919270|NCT01361204|DIETARY_SUPPLEMENT|Theanine|Taking 4 tablets of theanine two times daily for 16 days
47919271|NCT01846767|OTHER|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton \& Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
47919272|NCT01548833|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
47919273|NCT01548833|DEVICE|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
47919274|NCT01548833|DEVICE|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
48620259|NCT03645447|DIAGNOSTIC_TEST|Taste test|A pseudo-randomised series of taste solutions are presented to the participant for identification as sugar or water, in order to establish their taste threshold.
47919275|NCT01148992|DRUG|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
47919276|NCT01148992|DRUG|Placebo|0mg
47919277|NCT06522594|DRUG|Esmolol|A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
48092907|NCT00795132|DRUG|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
47919278|NCT02995824|OTHER|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) \[lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)\] \[Group 1\] versus other ART regimens including boosted PI or NNRTIs \[Group 2\] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
47919279|NCT05622253|COMBINATION_PRODUCT|Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser|Selected patients will be treated with low-dose oral isotretinoin (10mg/day) over a period of sessions and six sessions of 1064 ND- YAG laser (Deka motous AY) using 150 J/cm2, 20-25 milliseconds pulse duration, and 5 mm spot size, at 2 weeks' interval.
47919280|NCT00597597|DRUG|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
48106719|NCT00678795|DRUG|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
47919281|NCT01250145|DRUG|LY333334|Transdermal patch
47919282|NCT01250145|DRUG|Placebo|Transdermal patch
47919283|NCT02082340|BEHAVIORAL|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
47919284|NCT02082340|OTHER|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
47919285|NCT02082340|OTHER|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
47919286|NCT02082340|BEHAVIORAL|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
47919287|NCT02082340|BEHAVIORAL|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
47919288|NCT03968133|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
47919289|NCT03968133|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
47919290|NCT04832269|OTHER|Exposure to methylprednisolone during pregnancy|Exposure to methylprednisolone during pregnancy in the context of an MS relapse therapy
47919291|NCT02855918|OTHER|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :~* A clinical assessment by psychiatrist~* Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits...~* A neuropsychological assessment for the evaluations of cognitive performances~* A routine blood sampling to the realization of a standard blood test~* A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
47919292|NCT04442035|BEHAVIORAL|5-element music therapy|participants were treated by TCM five-phase music therapy for not less than 30 minutes per day, and group music therapy was performed every three weeks. In addition, the therapeutic schedule is composed of treatment time (1pm-2pm, 9pm-11pm), frequency treatment (two times a day), intervention (10-15 minutes in the afternoon, 30 minutes in the evening) and content (individuals: dialectical selection of music; groups: community singing, every three weeks).
47919293|NCT06284824|DEVICE|Stryker Triathlon with MAKO Robotic-Arm|Implant is the Stryker Triathlon total knee arthroplasty and the robotic device is the MAKO robotic-arm
47919294|NCT06284824|DEVICE|DePuy Attune with VELYS Robotic-Assistance|Implant is the DePuy Attune total knee arthroplasty and the robotic device is the VELYS robotic-assistance
47919295|NCT05194423|DEVICE|Tricuspid Valve Replacement System via jugular vein|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system via jugular vein.
47919296|NCT00005642|DRUG|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
47919297|NCT03089164|DIAGNOSTIC_TEST|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
47919298|NCT03467685|DEVICE|Vibratory Anesthetic Device (VAD)|This is a handheld \~10cm long tool, battery operated, which provides vibration at a rate of \~150 Hz
47919299|NCT00625664|DRUG|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
47919300|NCT00625664|DRUG|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
47919301|NCT00625664|DRUG|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
48270089|NCT02629731|DEVICE|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
47919302|NCT00597896|DRUG|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
47919303|NCT04398095|RADIATION|Hypofractionated radiotherapy|Resectable or marginally resectable tumors: preoperative hypofractionated 12x 3 Gy radiotherapy (4 days in a week, three weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.
47919304|NCT04398095|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
47919305|NCT04398095|RADIATION|Hypofractionated radiotherapy with boost|"Non-resectable/inoperable tumors: definitive hypofractionated 12x 3 Gy radiotherapy prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with simultaneous integrated boost 3.5 Gy per fraction prescribed on boost planned target volume (tumor volume + setup/error margin), 4 days in a week, three weeks.~Radiotherapy with daily image guidance with cone beam-CT or kV-portal position verification."
47919306|NCT00697138|DRUG|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
47919307|NCT05879094|OTHER|Morton extension|A Morton extension with a height of 5 mm was insert from the proximal area of the first metatarsal head to the base of the proximal phalanx of the Hallux of the subjects' bare feet using a paper bandage. The material, shape, size, and thickness of the Morton Extension were the same.
47919308|NCT03374852|DRUG|CPI-613|500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
47919309|NCT03374852|DRUG|mFOLFIRNOX|mFOLFIRNOX (given immediately after CPI-613 administration):
47919310|NCT01739062|GENETIC|Genetic risk assessment|
47919311|NCT03034551|BEHAVIORAL|Financial Incentive, Mobile Phone App, and Cellular Scale|Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
47919312|NCT05883241|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
47919313|NCT05883241|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn during treatment via SAM patch.
47919314|NCT05311878|DEVICE|EEG-based perceptual training|Electroencephalography (EEG) signals will be recorded from subjects as they perform rotation-based perceptual tasks. The neural correlates of conscious perception of rotations will be processed and decoded in real-time using machine learning algorithms to provide feedback. Subjects are instructed to assume a mental state/find a strategy to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
47919315|NCT05311878|DEVICE|Behavior based perceptual training|Subjects complete the rotation-based perceptual tasks, and ground truth visual feedback is provided indicating whether subjects have spotted the rotations correctly. Subjects are instructed to spot as many rotation as possible to maximise the accuracy of feedback. In total, each subject will complete 5 sessions of perceptual training with this intervention.
47919316|NCT00732407|DRUG|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
47919317|NCT00732407|DRUG|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
47919318|NCT00544700|BIOLOGICAL|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
47919319|NCT00544700|OTHER|no maintenance|No treatment until progression
47919320|NCT02501187|PROCEDURE|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
47919321|NCT02501187|PROCEDURE|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
47919322|NCT02501187|PROCEDURE|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
47919323|NCT01743859|DRUG|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
47919324|NCT01743859|DRUG|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
47919325|NCT01743859|OTHER|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
47919326|NCT03284892|BEHAVIORAL|SOC program|A once-daily, 7-day SOC program, including oral-motor exercise, sensory stimulation and lubrication, and safe-swallowing education.
47919327|NCT04185285|DEVICE|Percutaneous coronary intervention, stents|
47919328|NCT03539549|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
47919329|NCT00323011|DRUG|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
47919330|NCT05615025|DRUG|Sevoflurane|Anesthesia will be maintained by sevoflurane.
47919331|NCT05615025|DRUG|Propofol|Anesthesia will be maintained by propofol.
47919332|NCT01676636|DRUG|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
47919333|NCT01676636|DRUG|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
48270090|NCT06083584|OTHER|RNA sequencing|RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample
47919334|NCT01676636|DRUG|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
47919335|NCT01676636|DRUG|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
47919336|NCT01168219|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
47919337|NCT01168219|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
47919338|NCT01168219|DRUG|Azacitidine|Given SC or IV
47919339|NCT01168219|DRUG|Busulfan|Given IV
47919340|NCT01168219|DRUG|Fludarabine Phosphate|Given IV
47919341|NCT01168219|OTHER|Laboratory Biomarker Analysis|Correlative studies
47919342|NCT01168219|DRUG|Methotrexate|Given IV
47919343|NCT01168219|OTHER|Pharmacological Study|Correlative studies
47919344|NCT01168219|DRUG|Tacrolimus|Given PO or IV
47919345|NCT02372227|DRUG|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
47919346|NCT03347370|DRUG|SC Peginterferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
47919347|NCT03347370|DRUG|SC interferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).
47919348|NCT03347370|DRUG|SC interferon beta-1b|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
47919349|NCT04189185|PROCEDURE|Suture fixation|The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
47919350|NCT01819532|PROCEDURE|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
47919351|NCT01819532|PROCEDURE|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
47919352|NCT04027478|DIETARY_SUPPLEMENT|FMD|fasting mimicking diet
47919353|NCT02972567|DIETARY_SUPPLEMENT|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
47919354|NCT02972567|DIETARY_SUPPLEMENT|Control|Maltodextrin
47919355|NCT03816709|DEVICE|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
47919356|NCT03133741|OTHER|GIP-A|GIP-A (GIP receptor antagonist)
47919357|NCT03133741|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
47919358|NCT03133741|OTHER|Placebo|Saline (9mg/mL)
47919359|NCT03133741|OTHER|GIP-A + Exendin[9-39]|GIP receptor antagonist + GLP-1 receptor antagonist
47919360|NCT04795336|DRUG|Melatonin 5 mg|Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
47919361|NCT04795336|OTHER|Placebo|The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
47919362|NCT02160041|DRUG|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
47919363|NCT03354507|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate. See arms.
47919364|NCT03157700|BEHAVIORAL|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
47919365|NCT01209182|DEVICE|Testing a new device (LS BioPath TOUCH) on excised tissue|Measurements are obtained with test device on excised tissue.
47919366|NCT05424770|OTHER|Education with crossword|Afterwards, crossword activities prepared by the researcher will be implemented and students will be actively involved in the process. The researcher will also include a collaborative learning environment where students can exchange information with each other. After the completion of each puzzle, the researcher will make the necessary checks and corrections.
47919367|NCT02888496|DRUG|tocilizumab|3 monthly IV infusions in PMR patients
47919368|NCT00536497|DRUG|GW842166X|
47919369|NCT02200198|OTHER|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
47919370|NCT02200198|OTHER|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
47919371|NCT02200198|OTHER|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
47919372|NCT02037555|BIOLOGICAL|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
47919373|NCT02037555|OTHER|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
47919374|NCT06311877|DIETARY_SUPPLEMENT|mBerry|mBerry tablets (.4 grams), which contain protein within the miracle berry called miraculin.
47919375|NCT06311877|OTHER|No intervention|The control group will not received intervention.
47919376|NCT01536392|DRUG|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
47919377|NCT01536392|DRUG|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
47919378|NCT01536392|BEHAVIORAL|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
47919379|NCT01536392|BEHAVIORAL|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
47919380|NCT04316832|BEHAVIORAL|Mindfulness based cognitive training|The mindfulness based cognitive training will include three short mindfulness exercises: a) a breathing exercise, b) a body scan exercise, and c) a mindfulness attention exercise.
47919381|NCT04316832|OTHER|Control exercise|Participants will listen to the first chapter of the audiobook The Hobbit, JRR Tolkien.
47919382|NCT04385693|PROCEDURE|Pulpotomy|Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
47919383|NCT04385693|PROCEDURE|Extraction and placement of space maintainer|If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
47919384|NCT03632954|DEVICE|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
47919385|NCT05532293|DRUG|MSP008-22|MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
47919386|NCT05532293|OTHER|Placebo|Placebo tablets identical in appearance, taste and smell to the tablets of MSP008-22
47919387|NCT00003076|DRUG|eflornithine|
47919388|NCT03183154|OTHER|no intervention|no intervention
47919389|NCT02102711|DIETARY_SUPPLEMENT|Vitamin A oral drops|
47919390|NCT06348290|DRUG|JMKX001899|Oral
47919391|NCT06348290|DRUG|Itraconazole|Oral
47919392|NCT06348290|DRUG|Midazolam|Oral
47919393|NCT06348290|DRUG|Rifampin|Oral
47919394|NCT06348290|DRUG|dextromethorphan|Oral
47919395|NCT06348290|DRUG|Rosuvastatin|Oral
47919396|NCT06348290|DRUG|digoxin|Oral
47919397|NCT00246545|BEHAVIORAL|exercise|
47919398|NCT03303664|OTHER|IMPROVE Protocol|Comprehensive pain management protocol
47919399|NCT02223702|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
48270091|NCT01099228|OTHER|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
48270092|NCT01099228|OTHER|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
47919400|NCT02223702|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
47919401|NCT02223702|DRUG|Moxifloxacin|400 mg, once in a day for 7 days.
47919402|NCT04480970|DEVICE|Nasogastric tube placement|All patients enrolled in the study will have a nasogastric tube placed for gastric decompression.
47919403|NCT06332872|DRUG|Oral Ivermectin|Oral formulation (3mg tablet) Dosage: 2 single doses of 200 mcg/kg given 7 days apart
47919404|NCT06332872|DRUG|4% dimenticone liquid gel|topical formulation (liquid gel) only 1 application
47919405|NCT05549921|BIOLOGICAL|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)|NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
47919406|NCT04326426|DRUG|Tradipitant|Neurokinin-1 antagonist
47919407|NCT04326426|DRUG|Placebo|Matching placebo
47919408|NCT03523598|OTHER|Placebo gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
47919409|NCT03523598|OTHER|Placebo Gel + Potassium Nitrate Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
48270093|NCT01936220|BEHAVIORAL|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
47919410|NCT03523598|OTHER|Potassium Nitrate Gel + Normal Toothpaste|"* 15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin.~* A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
47919411|NCT04972045|DRUG|CuminUP60®|4 capsules, 400 mg / capsule
47919412|NCT04972045|DRUG|Curcumin capsules|4 capsules, 400 mg / capsule
47919413|NCT04455490|OTHER|Self-control|We compared relevant scores of patients before and after surgery
47919414|NCT01900210|BEHAVIORAL|WaySafe|
47919415|NCT04599634|DRUG|Obinutuzumab|Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
47919416|NCT04599634|DRUG|Venetoclax|For FL patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL, MCL or CLL patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
47919417|NCT04599634|DRUG|Magrolimab|Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.
47919418|NCT02527044|PROCEDURE|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
47919419|NCT01896206|DEVICE|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
47919420|NCT02005861|PROCEDURE|bone marrow cells transplantation on collagen scaffold|"120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.~After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant."
47919421|NCT01886599|DRUG|Asunaprevir|
47919422|NCT00485797|DRUG|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
47919423|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
47919424|NCT01484886|OTHER|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
47919425|NCT03390114|BEHAVIORAL|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
47919426|NCT06044597|DEVICE|SyncAV function on|CRT-D with SyncAV plus activated
47919427|NCT05653388|OTHER|Plasma Collection|Patients will provide tissue and blood samples. No medical intervention will be completed for study purposes
47919428|NCT05822765|DRUG|Epinephrine concentration of 1:1000000|Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
47919429|NCT05822765|DRUG|Epinephrine concentration of 1:500000|Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
48270094|NCT01936220|BEHAVIORAL|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
47919430|NCT02720042|DEVICE|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
47919431|NCT06141356|DRUG|[18F]Florbetazine ([18F]92)|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer \[18F\]Florbetazine and will undergo a PET/CT scan.
48620260|NCT00857389|DRUG|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
47919432|NCT06141356|DRUG|[11C]PIB|Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer \[11C\]PIB and will undergo a PET/CT scan.
47919433|NCT01980485|BEHAVIORAL|Lung Age feedback and exhaled carbon monoxide|"In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation."
47919434|NCT01980485|BEHAVIORAL|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
48620261|NCT00857389|DRUG|Clofarabine|40 mg/m\^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
47919435|NCT04341428|DRUG|DWP14012 20 mg|DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
47919436|NCT04341428|DRUG|DWP14012 20 mg placebo|DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
47919437|NCT04341428|DRUG|Lansoprazole 15 mg|Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
47919438|NCT04341428|DRUG|Lansoprazole 15 mg Placebo|Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
47919439|NCT04042090|DEVICE|Reducept, virtual reality|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on a VR goggles. It consists of an education module and three games.
47919440|NCT02141737|DRUG|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
47919441|NCT02141737|DRUG|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
47919442|NCT02141737|DRUG|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
47919443|NCT02141737|DRUG|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
47919444|NCT02141737|DRUG|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
48092908|NCT00795132|DRUG|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
47919445|NCT02141737|DRUG|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
47919446|NCT04039009|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification system|The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
47919447|NCT01138917|DEVICE|ReCell and Split-thickness skin graft|The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.
47919448|NCT00655174|DRUG|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
47919449|NCT00655174|DRUG|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
47919450|NCT00655174|DRUG|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
47919451|NCT02487017|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
47919452|NCT02487017|BIOLOGICAL|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
47919453|NCT00079365|DRUG|fluorouracil|
48270095|NCT01936220|BEHAVIORAL|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
48270096|NCT02299960|DEVICE|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
47919454|NCT00079365|DRUG|gemcitabine hydrochloride|
48092909|NCT01562743|DRUG|SPM 962|Tansdermal patch
47919455|NCT00079365|RADIATION|brachytherapy|
47919456|NCT00079365|RADIATION|phosphorus P32|
47919457|NCT00079365|RADIATION|radiation therapy|
47919458|NCT03085914|DRUG|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
47919459|NCT03085914|DRUG|Pembrolizumab|Pembrolizumab
47919460|NCT03085914|DRUG|Oxaliplatin|Oxaliplatin
47919461|NCT03085914|DRUG|Leucovorin|Leucovorin
47919462|NCT03085914|DRUG|5-Fluorouracil|5-Fluorouracil
47919463|NCT03085914|DRUG|Gemcitabine|Gemcitabine
47919464|NCT03085914|DRUG|nab-Paclitaxel|nab-Paclitaxel
47919465|NCT03085914|DRUG|Carboplatin|Carboplatin
48092910|NCT00790062|DRUG|Oxytocin|See arms
48092911|NCT02724267|BIOLOGICAL|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
47919466|NCT03085914|DRUG|Paclitaxel|Paclitaxel
47919467|NCT03085914|DRUG|Pemetrexed|Pemetrexed
47919468|NCT03085914|DRUG|Cyclophosphamide|Cyclophosphamide
47919469|NCT03085914|DRUG|Carboplatin|Carboplatin
47919470|NCT03085914|DRUG|Cisplatin|Cisplatin
47919471|NCT03085914|DRUG|5-Fluorouracil|5-FU
47919472|NCT03085914|DRUG|Investigator's choice of platinum agent|Investigator's choice of platinum agent: carboplatin or cisplatin
47919473|NCT00369291|BIOLOGICAL|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
47919474|NCT00369291|BIOLOGICAL|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
47919475|NCT02576145|BIOLOGICAL|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
48092912|NCT01085487|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
48092913|NCT01085487|DRUG|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
48092914|NCT01085487|DRUG|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
48106720|NCT00678795|DRUG|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
47919476|NCT02576145|DRUG|Daclizumab|The fifth dose (1 milligram per kilogram \[mg/kg\]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
47919477|NCT02576145|BIOLOGICAL|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
47919478|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing stretching
47919479|NCT00550641|OTHER|physical therapy|physical therapy in warm pool performing Ai Chi
47919480|NCT04020861|DEVICE|Active PBM|To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
47919481|NCT04020861|DEVICE|Active TENS|To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
47919482|NCT04020861|DEVICE|Placebo PBM|In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
47919483|NCT04020861|DEVICE|Placebo TENS|To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
47919484|NCT01783756|DRUG|lapatinib ditosylate|Given PO
47919485|NCT01783756|DRUG|everolimus|Given PO
47919486|NCT01783756|DRUG|capecitabine|Given PO
47919487|NCT01783756|OTHER|laboratory biomarker analysis|Correlative studies
47919488|NCT04617496|BEHAVIORAL|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features
47919489|NCT04617496|BEHAVIORAL|Health education|Provision of general information about a variety of topics
47919490|NCT03117452|BEHAVIORAL|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
47919491|NCT05067218|DEVICE|buzzy device|bee shaped with wings could be frozen.
48106721|NCT04884737|OTHER|Mepilex Border Flex® (MBF) dressing|A new dressing technology (Mepilex Border Flex® (MBF)) provides increased conformability of the dressing to the skin with the ability of the dressing to move in all directions (e.g., 360-degree flexibility) with even slight body movements. Limited data exists on use of silicone foam dressings with all direction flexibility during prone surgical procedures.
47919492|NCT05067218|OTHER|Conventinal anasthesia|normal technique of injection
47919493|NCT06408753|PROCEDURE|sterotatic body radiotherapy|checkpoint inhibitors with or without sterotatic body radiotherapy
47919494|NCT03332680|BIOLOGICAL|EmbryoGlue® (laboratory culture medium)|Embryos placed in this medium prior to transfer
47919495|NCT03332680|BIOLOGICAL|Standard control medium|Embryos placed in this medium prior to transfer
47919496|NCT04145219|BIOLOGICAL|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
47919497|NCT04145219|OTHER|Placebo|For daily administration (1 tablet per day)
47919498|NCT03785223|DRUG|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
47919499|NCT03785223|DRUG|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
47919500|NCT01155128|BEHAVIORAL|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
47919501|NCT00133549|DRUG|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
47919502|NCT00133549|BIOLOGICAL|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
48106722|NCT02459899|DRUG|Placebo|Placebo, once daily, before the first meal of the day
47919503|NCT00133549|BIOLOGICAL|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
47919504|NCT00361933|DRUG|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
47919505|NCT03050411|DRUG|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
47919506|NCT03050411|DRUG|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
47919507|NCT03653559|BEHAVIORAL|Home meals|"Adult participants with overweight or obesity are asked to consume home meals during 12 weeks."
47919508|NCT03653559|BEHAVIORAL|Healthy meals|"Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks."
47919509|NCT03921645|DRUG|aerosol antibiotics|use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
47919510|NCT04500262|DEVICE|Open-tip pulsed needle biopsy (NeoNavia Biopsy System)|Ultrasound-guided biopsy using 14G open-tip pulsed biopsy needle
47919511|NCT04500262|DEVICE|Core needle biopsy (CNB)|Ultrasound-guided biopsy using standard of care core needle biopsy
47919512|NCT01876004|DRUG|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
47919513|NCT01876004|DRUG|Placebo|Prescribed Placebo IM (intramuscularly), single dose
47919514|NCT04207541|BEHAVIORAL|Brief motivational interview|Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
47919515|NCT03389048|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
47919516|NCT03389048|DIAGNOSTIC_TEST|SLR|With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
47919517|NCT00453414|DRUG|Iloprost Inhalation Solution (Ventavis)|
47919518|NCT04529486|OTHER|Kinesio taping|Before applying the tape, it was checked whether the children were allergic. Tape was first started from the distal part of the fingers and taped with 0% tension with Kinesio Taping Functional Correction Technique. Another I tape was applied from palmar area of the hand to spina scapula for supination of the forearm and external rotation of the shoulder with %0 tension to make functional correction (Figure 2). Kinesio Taping Functional Correction method is suggested to be done with 75% of tension but for children, we applied it with 0% tension to minimize the shear effects to the skin4. Kinesio Tex Light Touch Plus tape was used for taping application (Kinesio Co., USA).
47919519|NCT05318742|PROCEDURE|laser|Endolaser photocoagulation during PPV
47919520|NCT02103153|DEVICE|Picosure Laser System|
47919521|NCT02737891|DRUG|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
47919522|NCT02737891|DRUG|Placebo|
47919523|NCT03522623|OTHER|Non-interventional study|Non-interventional study
47919524|NCT02499133|OTHER|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
47919525|NCT05984550|DRUG|NMN|"NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide. Its structure can be divided into α and β Two isomers, of which only β- NMN is a naturally occurring form with biological activity.~In human body, NMN is the precursor of NAD+(Nicotinamide adenine dinucleotide, also known as coenzyme I), and its function is mainly reflected through NAD+."
47919526|NCT06317545|OTHER|Mulligan Taping|Mulligan taping involves the application of tape to the lateral aspect of the elbow to offload stress during movement of the extensor tendons.
47919527|NCT02806141|DRUG|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
47919528|NCT02806141|DRUG|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
48106723|NCT02459899|DRUG|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
47919529|NCT01784822|DEVICE|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
47919530|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
47919531|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
47919532|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
47919533|NCT01788358|DRUG|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
47919534|NCT01583829|BEHAVIORAL|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
47919535|NCT01583829|BEHAVIORAL|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
47919536|NCT01583829|OTHER|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
47919537|NCT04181814|DEVICE|Ultrasound|Use ultrasound to assess gastric contents in diabetic patients before anesthesia
47919538|NCT03423199|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
48106724|NCT02899286|BIOLOGICAL|PEG-BCT-100|PEGylated recombinant human arginase
47919539|NCT03423199|DRUG|Placebo|Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
47919540|NCT03423199|DRUG|Tamoxifen|Tamoxifen, 20mg, orally once daily (continuously)
47919541|NCT03423199|DRUG|Goserelin|For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
47919542|NCT05358613|BEHAVIORAL|My Choices|"The My Choices program is an harm reduction program to modify substance use habits. It is based on the Miller \& Rollnick Motivational interviewing as well as Deci and Ryan's Self-determination theory and Bandura's social learning theory.~It is presented as a guide, divided in 6 phases. In every phase, participants will find, in the guide, some auto-observation exercises about their alcohol use habits and other aspects about their quality of life, reflexions and information about alcohol. The participants are also invited to note the number of standard units of alcohol they use on every occasion."
47919543|NCT04900532|DIETARY_SUPPLEMENT|Tocotrienol rich fraction|Supplementation with a Vitamin E compound.
47919544|NCT04900532|DIETARY_SUPPLEMENT|Placebo|Administration of placebo containing 0,96mg of tocotrienol and 1,76mg of tocopherol twice a day for three months.
47919545|NCT02158429|OTHER|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
47919546|NCT06247189|OTHER|ICOPE Monitoring|"At inclusion set up of the ICOPE monitor program on the patient's device and evaluation (all steps) of ICOPE Monitor program.~Monthly, re-evaluation of the patient (Step 1 and others if necessary ) according to the ICOPE Monitor program"
47919547|NCT01386866|DRUG|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of \[14C\]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
47919548|NCT03485300|DIAGNOSTIC_TEST|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
47919549|NCT03485300|BEHAVIORAL|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
47919550|NCT03485300|DRUG|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
47919551|NCT02894697|DEVICE|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
47919552|NCT02894697|DEVICE|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
47919553|NCT02720029|DEVICE|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
47919554|NCT05339776|BEHAVIORAL|Hand Lateralization Test|Before hand lateralization test, participants will be evaluated. Both groups (Amputees and Control) will complete hand lateralization test for at least 10 days. The test will be sent each day on an online system. Participants' performances will be recorded via online system. After hand lateralization test, participants will be evaluated.
48092915|NCT03186807|DIAGNOSTIC_TEST|ultrasonographic scan of fetal brain|"1. Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~   specific measurements as follow:~2. Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~3. Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~4. Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
48092916|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
48270097|NCT02299960|DEVICE|NICOM|Non-invasive measurement of cardiac output
48270098|NCT04664348|OTHER|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
47919555|NCT04228133|BEHAVIORAL|Attention Control Training (ACT)|A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.
47919556|NCT04228133|BEHAVIORAL|Attention Bias Modification (ABM)|A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.
47919557|NCT02291653|DEVICE|McGrath|video-laryngoscopy
47919558|NCT02291653|DEVICE|MIL|direct-laryngoscopy
47919559|NCT06047119|PROCEDURE|Blood pressure|Blood pressure targets during general anesthesia and 2 hours after
47919560|NCT06047119|PROCEDURE|Positive end expiratory pressure|Positive end expiratory pressure during general anesthesia
47919561|NCT06047119|PROCEDURE|Tidal volume|Tidal volume during general anesthesia
47919562|NCT06047119|PROCEDURE|Fraction of inspired oxygen|Fraction of inspired oxygen during general anesthesia and 2 hours after
47919563|NCT04525885|DRUG|Gefapixant 45 mg twice daily (BID)|Gefapixant 45 mg tablet to be administered orally BID
47919564|NCT04525885|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
47919565|NCT04525885|DRUG|Placebo|Placebo tablet administered orally BID
47919566|NCT04525885|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet to be administered orally BID
47919567|NCT04571671|OTHER|Collect retrospectively data|Analyse the incidence of Mullerian anomalies in these populations
47919568|NCT00381576|BEHAVIORAL|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
47919569|NCT01389661|BIOLOGICAL|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
47919570|NCT02468245|BEHAVIORAL|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
47919571|NCT02468245|BEHAVIORAL|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
47919572|NCT05297981|PROCEDURE|Erector spinae plane block|The patient will be placed in lateral decubitus position. A high frequency linear probe of a transportable Fuji M-Turbo ultrasound system will be placed on the spinous process at T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the inplane technique,then 0.5 ml/kg of 0.25% bupivacaine will be injected between the muscle and transverse process. The same procedure will be performed bilaterally.
47919573|NCT05297981|PROCEDURE|Quadratus lumborum block|The patient will be placed in the lateral decubitus position. A low frequency curved probe of a transportable Fuji M-Turbo ultrasound system will be placed horizontally in the anterior axillary line midway between the subcostal margin and the iliac crest to identify the triple abdominal muscle layers.A 22-G, 80-mm needle echogenic needle will be inserted in plane relative to the US probe, into the posterior aspect of the QL muscle (between QL and erector spinae muscle); this is known as QLB type 2. Then, 0.5 ml/kg of 0.25% bupivacaine will be injected behind the muscle as a bolus dose. The block will be performed bilaterally.
48092917|NCT01536262|DEVICE|Respimat|Respimat inhaler
48092918|NCT01536262|DRUG|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
48092919|NCT01536262|DRUG|Olodaterol|Olodaterol once daily inhalation
47919574|NCT03542396|BEHAVIORAL|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
47919575|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
47919576|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
47919577|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
47919578|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
47919579|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
47919580|NCT00548652|DRUG|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
47919581|NCT00548652|BEHAVIORAL|medical crisis councelling|group counselling sessions
47919582|NCT00548652|BEHAVIORAL|MOVE|is a VA based multidesciplinary weight loss intervention
48092920|NCT01536262|DEVICE|Respimat|Respimat inhaler
48092921|NCT01536262|DEVICE|Respimat|Respimat inhaler
48092922|NCT00432159|DEVICE|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
48092923|NCT00432159|DEVICE|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
48092924|NCT04414722|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
48092925|NCT04414722|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
48092926|NCT04414722|OTHER|Control Yogurt|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
48106725|NCT03172533|DRUG|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
48106726|NCT03172533|DRUG|Placebo oral capsule|placebo
48106727|NCT05453864|BEHAVIORAL|CMAP Plus TFCBT|This will include 8 individual sessions of CMAP Plus TFCBT delivered by a trained therapist over a period of 12 weeks. Each session will last between 45 to 60 minutes.
48092927|NCT04010175|BEHAVIORAL|Control - Cognitive training in a practitioner's office one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.
48092928|NCT04010175|BEHAVIORAL|Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).
48092929|NCT04010175|BEHAVIORAL|Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
48092930|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
48092931|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine tongue diagnosis.
48092932|NCT03937271|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pulse diagnosis.
48092933|NCT03937271|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
48092934|NCT03937271|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
48092935|NCT06232161|DEVICE|Red-light therapy device|Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.
48092936|NCT06232161|DEVICE|Spectacles|Single focus spectacles, that is to say, wearing glasseses with minus power lens
48092937|NCT06527105|DEVICE|Eye masks and ear plugs|Eye masks and ear plugs given during sleeping time in Icu After cardiac surgery
48092938|NCT01827228|OTHER|Assays|May vary across sites
47919583|NCT05391789|DRUG|Ulinastatin|Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days
48092939|NCT01827228|OTHER|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
48092940|NCT01827228|OTHER|Social network and venue tracing|This is described in Arms 1 and 2
48092941|NCT01827228|OTHER|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
48092942|NCT01827228|OTHER|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
47919584|NCT05391789|DRUG|Placebo|Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
48092943|NCT01827228|BEHAVIORAL|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
48092944|NCT00414414|DRUG|Prednisone|
48092945|NCT00414414|DRUG|placebo|placebo
48092946|NCT04937075|OTHER|No intervention|No intervention
48092947|NCT03840070|DEVICE|Potenfill|Maximum: 22ml
48092948|NCT01575145|BEHAVIORAL|Quitline facilitation intervention|brief quitline facilitation intervention
48092949|NCT01575145|BEHAVIORAL|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
48092950|NCT02752152|BEHAVIORAL|Computer-assisted counseling|The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
48092951|NCT02752152|BEHAVIORAL|On-demand counseling|The counselor only invites the participants to ask questions about HIV and other STIs.
48620262|NCT00857389|DRUG|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
48620263|NCT00857389|PROCEDURE|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
48620264|NCT00857389|DRUG|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
47919585|NCT00975897|BIOLOGICAL|bevacizumab|
47919586|NCT00975897|BIOLOGICAL|cetuximab|
47919587|NCT00975897|DRUG|fluorouracil|
47919588|NCT00975897|DRUG|irinotecan hydrochloride|
47919589|NCT00975897|DRUG|leucovorin calcium|
47919590|NCT00975897|DRUG|oxaliplatin|
47919591|NCT00975897|GENETIC|RNA analysis|
47919592|NCT00975897|GENETIC|cytogenetic analysis|
47919593|NCT00975897|GENETIC|fluorescence in situ hybridization|
48092952|NCT02752152|BEHAVIORAL|Standard counseling|The counselor gives face-to-face general information/education
48092953|NCT02752152|BEHAVIORAL|Appointment + reminder|Has an appointment and receive reminders for further testing
48092954|NCT02752152|BEHAVIORAL|Reminder|Only receive reminders for further testing
47919594|NCT00975897|GENETIC|gene expression analysis|
47919595|NCT00975897|GENETIC|mutation analysis|
47919596|NCT00975897|GENETIC|protein expression analysis|
47919597|NCT00975897|OTHER|diagnostic laboratory biomarker analysis|
47919598|NCT00975897|OTHER|immunohistochemistry staining method|
47919599|NCT00975897|OTHER|questionnaire administration|
47919600|NCT00975897|PROCEDURE|cognitive assessment|
48092955|NCT02752152|BEHAVIORAL|No appointment and no reminder|No appointment and no reminders for further testing
48092956|NCT06314425|PROCEDURE|Immediate dental implants placements on fresh sockets after tooth extraction|Zirconia dental implants (SDS®, Swiss Dental Solution, Kreuzlingen, Switzerland) are to be placed within the fresh extraction sockets. The immediate implants are placed using a minimally invasive technique without vertical releasing incisions. Implant placements are performed following the SDS osteotomy protocol after sulcus marginal and crestal incision or flapless surgery. The same surgeon places implants for all patients. Infected sites are debrided using piezo surgery touch.
48092957|NCT02453529|DRUG|WCK 4873|Oral tablets
48092958|NCT00797225|DRUG|Leuprorelin Acetate Depot|Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
48092959|NCT00797225|DRUG|Elagolix|Elagolix tablets administered orally
47919601|NCT00123253|DRUG|TH9507|
48092960|NCT00797225|DRUG|Placebo to Elagolix|Placebo tablet administered orally
47919602|NCT01227135|DRUG|hydroxychloroquine|
47919603|NCT01227135|DRUG|imatinib mesylate|
47919604|NCT01227135|GENETIC|cytogenetic analysis|
47919605|NCT01227135|GENETIC|polymerase chain reaction|
47919606|NCT01227135|OTHER|laboratory biomarker analysis|
47919607|NCT01227135|OTHER|pharmacological study|
47919608|NCT01081418|BEHAVIORAL|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
48092961|NCT00797225|DRUG|Placebo to Leuprorelin Acetate|Saline solution administered as an intramuscular injection
48443532|NCT04106830|DRUG|Intravenous steroid|This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
47919609|NCT02914002|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
47919610|NCT00420043|DRUG|imatinib|
47919611|NCT02215941|DRUG|TV-45070|TV-45070 8% ointment
47919612|NCT02215941|DRUG|Placebo|Placebo
47919613|NCT02558647|BEHAVIORAL|CBT for insomnia (CBT-I)|CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
47919614|NCT02558647|BEHAVIORAL|Psycho-Education about Sleep (PE)|PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
47919615|NCT05996913|OTHER|Imagery rescripting|The current project aims to explore the feasibility of intervention featuring imagery rescripting (ImRs) and grounding in the management of somatic flashbacks amongst this population. ImRs was developed as a method to help activate a traumatic memory, bring corrective information into the memory, create a more favourable outcome to the memory and to support the participant to discover and express inhibited trauma-related emotional responses (Arntz \& Weertman, 1999).
48092962|NCT05630339|DIETARY_SUPPLEMENT|Magnesium chloride|Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
48092963|NCT05630339|DIETARY_SUPPLEMENT|Vitamin D|Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
48092964|NCT05630339|DIETARY_SUPPLEMENT|Inert placebo|Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.
48092965|NCT01253200|DEVICE|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
48092966|NCT01253200|DEVICE|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
48092967|NCT03691584|DRUG|TP-6076|The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
48092968|NCT03691584|PROCEDURE|Bronchoalveolar lavage|Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
48443533|NCT01854047|DRUG|Dupilumab|Solution for injection, Subcutaneous injection
48443534|NCT01854047|DRUG|placebo|Solution for injection, Subcutaneous injection
47919616|NCT05413434|OTHER|exercise|high-intensity interval training will be performed on the treadmill.
47919617|NCT05413434|DEVICE|inspiratory muscle training|Respiratory muscle strength exercise will be performed with the respiratory muscle strengthening device 'POWERbreathe Classic Light Resistance'.
47919618|NCT01656356|BIOLOGICAL|Avian Flu Vaccine|
47919619|NCT01656356|BIOLOGICAL|Placebo|
47919620|NCT01609829|PROCEDURE|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
47919621|NCT04740138|BEHAVIORAL|Dialectical Behavioral Therapy Skills + Parent Training|"The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression."
47919622|NCT00740610|DRUG|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
47919623|NCT00740610|DRUG|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
47919624|NCT04123691|DEVICE|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
48298812|NCT06392984|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity-TLC) (millimeter-mm)) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
47919625|NCT03801031|DRUG|Lidocaine Topical|Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
47919626|NCT03801031|DRUG|Placebo|Placebo solution intervention used to validate the effects of the lidocaine solution usage.
47919627|NCT05654077|BIOLOGICAL|CAR-T Cell Injection|intravenously once, and the dose group was 3.0 × 10\^6cells/kg、9.0 × 10\^6cells/kg、1.5 × 10\^7cells/kg。
47919628|NCT05654077|DRUG|Fludarabine|Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
47919629|NCT05654077|DRUG|cyclophosphamide|250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
47919630|NCT02437110|DRUG|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
47919631|NCT02437110|DRUG|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.
47919632|NCT02437110|DRUG|Dolutegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.
47919633|NCT02437110|DRUG|Tenofovir alafenamide (TAF)|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.
47919634|NCT00375206|BIOLOGICAL|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
47919635|NCT04271618|OTHER|TheraTogs Orthotic Undergarment|Strapping undergarment made from a lightweight, breathable fabric that is velcro sensitive. It consists of sleeveless vest (tank-Top), two shorts (Hipster) each with two thigh cuffs and limb cuffs
47919636|NCT03060161|BEHAVIORAL|Health in the right measure|Nutritional monitoring and individual guidance on regular physical exercise.
47919637|NCT03425474|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
47919638|NCT03425474|DRUG|Propofol|Initial dose plus supplemental doses as necessary
47919639|NCT05704569|DIAGNOSTIC_TEST|measurement of multiple biomarkers|All patients were tested for glucose and cholesterol levels. The capillary blood glucose level was measured by an electrochemical method using an Accu-Chek Active by AkkuChek blood glucose meter. The DM was considered to be verified when there were criteria which the World Health Organization (WHO) set in 2001: glucose concentration in whole blood is \>6.1 mmol/l, and glucose concentration is \>11.1 mmol/l in random measurement. Plasma for the study was obtained via the standard phlebotomy technique from ethylenediaminetetraacetic acid (EDTA) anticoagulants. Plasma was aliquoted into cryovials and got frozen quickly. The samples were stored in a low-temperature refrigerator (-70°C) until the study commencement (up to 3 months). All biomarkers were measured by magnetic bead-based multiplex immunofluorescence assay through the Xmap technology using the Milliplex map Human CVD Magnetic Bead Panel 1 (Millipore)
47919640|NCT05330247|OTHER|Carbohydrate-reduced high-protein (CRHP) Diet|Macronutrient intake of 30 percentage of energy from carbohydrate, 30 percentage of energy from protein and 40 percentage of energy from fat.
47919641|NCT05330247|OTHER|Conventional diabetes (CD) Diet|Macronutrient intake of 50 percentage of energy from carbohydrate, 17 percentage of energy from protein and 33 percentage of energy from fat.
47919642|NCT05213819|OTHER|Carpal Tunnel Syndrome|
48092969|NCT02697721|BEHAVIORAL|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
48092970|NCT02697721|OTHER|Control with delayed intervention|Control with delayed intervention
48092971|NCT01755286|DRUG|OTO-201|Single intra-operative injection
47919643|NCT04606680|DEVICE|Heat application at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required."
47919644|NCT04606680|DEVICE|Medicated plaster at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
48092972|NCT01755286|DRUG|Placebo|Single intratympanic injection
48092973|NCT01755286|DRUG|Sham|Simulated single intratympanic injection
47919645|NCT04606680|DEVICE|Herb-partitioned moxibustion at acupoints|"1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard\[18\]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group."
47919646|NCT02931669|OTHER|Qualitative Descriptive Study|
47919647|NCT05805618|BIOLOGICAL|Recombinant Norovirus Hexavalent Vaccine|To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17
47919648|NCT05805618|OTHER|Matching Placebo|matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002
47919649|NCT06153303|BEHAVIORAL|Acceptance and commitment therapy|The participants will go through an active internet-based ACT treatment focused on education about endometriosis and chronic pain, value-based exposure for avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 2 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
47919650|NCT01407380|DRUG|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
47919651|NCT03196492|OTHER|No intervention|No intervention
47919652|NCT02796417|BEHAVIORAL|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
47919653|NCT02796417|BEHAVIORAL|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
47919654|NCT05184829|OTHER|selective lymph node dissection|selective lymph node dissection
47919655|NCT05184829|OTHER|Systemic Lymph Node Dissection|Systemic Lymph Node Dissection
47919656|NCT03625843|BEHAVIORAL|Mindfulness exercises|
48092974|NCT02641210|PROCEDURE|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
48092975|NCT02641210|DRUG|Albendazole|All participants took Albendazole 400 mg before the intervention.
48092976|NCT05805306|BEHAVIORAL|Entre Herman@s|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a PrEP Conversation followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
48092977|NCT05805306|BEHAVIORAL|Vaccines for Health|The intervention unfolds as follows: (Week 1) the research team, Latino MSM, \& sibling will all engage in a Health Conversation about vaccines for COVID, Hep A/B, or MPOX, followed by an individual Sibling Training for siblings to learn communication strategies for promoting health behaviors; (Week 2) we will send siblings reminders and a link to motivational interviewing techniques; (Week 3) we will conduct brief Follow-ups with siblings to determine if their brother changed his behavior; (Week 4) we will send a reminder to Latino MSM that they will have a follow-up the following week; (Week 5) we will conduct 30-day Follow-up with Latino MSM to determine if there was uptake of the new behavior change; (Week 7) same as week 5 above; (Week 10) send siblings information on motivational interviewing; (Week 12) final follow-up for both Latino MSM and siblings.
48298813|NCT01461031|DRUG|nefopam|nefopam infusion for postoperative 24 hours
47919657|NCT00522236|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~* A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~* A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~* B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
47919658|NCT05494411|DRUG|Mitomycin for pyelocalyceal solution|
47919659|NCT04786834|PROCEDURE|Vesico urethral anastomosis on chicken model|Performance of a vesico urethral anastomosis on a chicken model with Da Vinci robotic system
47919660|NCT01451437|DRUG|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
47919661|NCT02870933|BIOLOGICAL|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
47919662|NCT00682578|DRUG|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
47919663|NCT00682578|DRUG|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
47919664|NCT01198613|BIOLOGICAL|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
47919665|NCT01198613|BIOLOGICAL|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
47919666|NCT04941170|DRUG|Bupivacain|Ultrasound-guided oblique subcostal transversus abdominis plane block will be performed in the supine position under strict aseptic precautions. placing a linear high-frequency ultrasound probe obliquely near the costal margin and xiphoid process On confirming the placement of the needle in the correct target space, 1 mL of 0.25% bupivacaine will be injected to hydro-dissect the fascia layer between the RA and TA. After confirming the separation of the transversus abdominis fascia plane, the remaining 19 mL of 0.25% bupivacaine will be administered, advancing the needle infero-laterally parallel to the subcostal margin. A similar procedure will be performed on the contralateral side of the abdomen with an injection of another 20 mL of 0.25% bupivacaine.
47919667|NCT04941170|DRUG|Bupivacaine|Ultrasound-guided erector spinae plane block will be performed in the sitting position. T7 spinous process will be located To perform the block. The tip of the T7 transverse process will be then identified using the ultrasound probe that is placed in a transverse orientation The ultrasound transducer will then be placed in a longitudinal orientation 2-3 cm lateral to the midline in a longitudinal orientation to identify the hyperechoic line of the transverse process with its associated acoustic shadow. After local anaesthetic infiltration, the block needle will be inserted in a craniocaudal direction until contact will be achieved with the T 7 transverse process where the tip will lay in the inter-fascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle to confirm the proper needle position. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally.
47919668|NCT06247956|DRUG|SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Oxaliplatin: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
47919669|NCT06247956|DRUG|Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|Adebrelimab: Specified dose on specified days. Oxaliplatin Injection: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
48092978|NCT04668781|PROCEDURE|Analgesia via epidural catheter|Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
48092979|NCT04668781|PROCEDURE|Analgesia via wound catheter|Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.
48620265|NCT00857389|DRUG|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
48092980|NCT03923608|DIAGNOSTIC_TEST|Maximal muscle strength Test|1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
47919670|NCT00621062|PROCEDURE|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
47919671|NCT00621062|PROCEDURE|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
47919672|NCT00621062|PROCEDURE|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
47919673|NCT00621062|PROCEDURE|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
47919674|NCT04661579|BIOLOGICAL|Malaria Vaccine RTS,S/AS01E|RTS,S/AS01E vaccine 0.5 mL, containing 25 μg protein comprising circumsporozoite protein (CS) and hepatitis B surface antigen (RTS,S), 25 μg monophosphoryl lipid (AMPL), 25 μg Quillaja saponaria 21 (QS21) in a liposomal formulation) for the first two immunizations. One-fifth dose RTS,S/AS01E vaccine was used for the third immunization.
48092981|NCT03923608|DIAGNOSTIC_TEST|Exhaustion test|Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
47919675|NCT04661579|BIOLOGICAL|Abhayrab rabies vaccine|Abhayrab rabies vaccine, 0.5 mL, contains 2.5 IU rabies antigen.
47919676|NCT04661579|DRUG|Dihydroartemisinin-piperaquine (DHA/Pip)|"Dihydroartemisinin (120 mg or 160 mg based on weight) and piperaquine tetraphosphate (960 mg or 1280 mg based on weight) mg) administered once a day for 3 days.~DHA/Pip is a long acting anti-malarial used to clear asexual stage and young gametocyte parasites."
47919677|NCT04661579|DRUG|Artemether / Lumefantrine|"Artemether (80 mg) and lumefantrine (480 mg) administered twice a day for 3 days.~Coartem is a short-acting artemisinin combination therapy used to provide clearance of blood stage parasites in order to establish a clean baseline for determination of vaccine efficacy."
47919678|NCT04661579|DRUG|Primaquine|One dose of 15 mg primaquine. Low dose primaquine (LD PQ) is used to clear mature gametocytes of P. falciparum.
47919679|NCT06113679|DEVICE|RDX-19|RD-X19 device with a 5 minute, 32 J/cm2 dose, 2X/day, 7 days. Each treatment at least 6 hours apart.
47919680|NCT00587496|DRUG|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
47919681|NCT00587496|DRUG|placebo|lactose placebo capsule, six per day for 30 days
47919682|NCT00587496|DRUG|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
47919683|NCT02917018|DRUG|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
47919684|NCT06007898|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
47919685|NCT05089851|PROCEDURE|Onabotulinumtoxin A|Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)
47919686|NCT05089851|COMBINATION_PRODUCT|Facial Cleanser|Facial Cleanser to be used by participants twice daily
47919687|NCT05089851|COMBINATION_PRODUCT|Facial Moisturizer|Bland moisturizer to be used by study participants after serum twice daily.
47919688|NCT05089851|COMBINATION_PRODUCT|Sunscreen|Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
47919689|NCT05683171|DRUG|Rituximab|Given by IV (vein)
47919690|NCT05683171|DRUG|Lenalidomide|Given by PO
47919691|NCT05683171|DRUG|Valemetostat|Given by PO
47919692|NCT00183417|BEHAVIORAL|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
48092982|NCT04484688|DRUG|perindopril-bisoprolol|outpatients with permanent atrial fibrillation and with preserved ejection fraction
48092983|NCT06183047|DIAGNOSTIC_TEST|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).|early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
48092984|NCT04120337|DEVICE|RemovAid device + lidocaine patch|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
47919693|NCT00183417|BEHAVIORAL|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
47919694|NCT00183417|BEHAVIORAL|Bibliotherapy|Participants will be given a book on how to increase their mood.
47919695|NCT01071018|DRUG|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
47919696|NCT01071018|DRUG|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
47919697|NCT01267357|OTHER|no intervention|
47919698|NCT05515185|DRUG|KT095 CAR-T injection|Clearance of lymphocytes
47919699|NCT03232333|DEVICE|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
47919700|NCT02689921|DRUG|Exemestane|Aromatase inhibitor
47919701|NCT02689921|DRUG|Letrozole|Aromatase inhibitor
47919702|NCT02689921|DRUG|Anastrozole|Aromatase inhibitor
47919703|NCT02689921|DRUG|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
47919704|NCT02689921|DRUG|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
47919705|NCT02689921|DRUG|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
47919706|NCT04769700|BEHAVIORAL|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.
48092985|NCT04120337|PROCEDURE|Standard technique + lidocaine injection|Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
48092986|NCT04120337|DEVICE|RemovAid device + lidocaine injection|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
47919707|NCT04769700|BEHAVIORAL|Breast Feeding Adherence|This will be addressed according to the breastfeeding initiation practices according to the WHO.
48092987|NCT01439425|BEHAVIORAL|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
48092988|NCT00814853|DEVICE|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
47919708|NCT04769700|BEHAVIORAL|Fear of Covid-19 Scale|The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.
48092989|NCT04942054|DRUG|Part 1|Dose escalation cohort
47919709|NCT05316935|DRUG|GnRHa|Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks , and the maximum using courses will be 6.
47919710|NCT05316935|DRUG|Letrozole 2.5mg|2.5mg po qd and no more than 24 weeks
47919711|NCT05316935|DRUG|Diane-35|Periodic use. Patients will receive one pill po qd for 21 days, and next period should be started after 7 days.
47919712|NCT05316935|DRUG|MET|500mg po tid
48092990|NCT04942054|DRUG|Part 2|Pharmacodyanamic (PD) dose exploration cohorts
47919713|NCT00296205|DRUG|Cyclophosphamide|
47919714|NCT00040300|DRUG|Racivir|
47919715|NCT00000144|PROCEDURE|Argon Laser Treatment|
47919716|NCT02133703|BEHAVIORAL|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
47919717|NCT02133703|BEHAVIORAL|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
47919718|NCT02133703|BEHAVIORAL|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
47919719|NCT02133703|BEHAVIORAL|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
47919720|NCT02133703|BEHAVIORAL|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
47919721|NCT02087007|DRUG|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
47919722|NCT02087007|DRUG|placebo|100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
47919723|NCT04007354|OTHER|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
47919724|NCT02706990|DEVICE|Physica KR|Kinematic retaining total knee implant
47919725|NCT02706990|DEVICE|Physica PS|Posterior stabilized total knee implant
47919726|NCT03956537|DEVICE|NEO Pedicle Screw System™|The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.
47919727|NCT03956537|DEVICE|Neo Cage System™|Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
47919728|NCT05067309|DRUG|Letrozole 2.5mg|Missed abortion received letrozole then misoprostol
48092991|NCT04942054|DRUG|Part 3|Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
48092992|NCT05306444|DRUG|CLN-418|Intravenous (IV) administration
47919729|NCT01334619|PROCEDURE|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
47919730|NCT05448443|DRUG|AD981|Oral administration of AD981 in the morning and before sleep for 14 days
47919731|NCT05448443|OTHER|Placebo|Oral administration of placebo in the morning and before sleep for 14 days
47919732|NCT04124679|OTHER|Transcutaneous Electrical Acupoint Stimulation|patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
47919733|NCT00406562|BIOLOGICAL|Boostrix|
47919734|NCT00160667|DRUG|Placebo|Daily oral dose of two equal intakes.
47919735|NCT00160667|DRUG|Brivaracetam|Daily oral dose of two equal intakes.
47919736|NCT01043939|OTHER|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
47919737|NCT01043939|OTHER|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
48092993|NCT03679702|DEVICE|Viveve System|Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
48092994|NCT02519556|DRUG|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
47919738|NCT00795678|DRUG|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
47919739|NCT00795678|DRUG|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
48092995|NCT02519556|DRUG|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
48092996|NCT02595307|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
47919740|NCT00795678|DRUG|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
48092997|NCT02528955|RADIATION|A: De-Intensification RT primary tumor region|"A:~* Reduction of radiation dose in the primary tumor region to 56 Gy,~* Elective Radiotherapy of both neck sides"
47919741|NCT00795678|DRUG|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
47919742|NCT00795678|DRUG|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
47919743|NCT00795678|DRUG|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
47919744|NCT00795678|DRUG|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
48092998|NCT02528955|RADIATION|B: De-Intensification RT contralateral lymph nodes|"B:~* No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
48092999|NCT02528955|RADIATION|C. De-Intensification RT primary tumor region AND contralateral lymph nodes|"C:~* Reduction of radiation dose in the primary tumor region to 56 Gy, AND~* Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
48093000|NCT04626921|DRUG|CNM-Au8|30 mg of CNM-Au8
48093001|NCT02401529|DRUG|IV dexamethasone|0.15 mg/kg
48093002|NCT02401529|DRUG|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
48093003|NCT02401529|DRUG|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
48093004|NCT02401529|DRUG|IV saline|IV saline
48093005|NCT06271356|BEHAVIORAL|BC-Navigate|BC-Navigate is a website/application to help guide women through care delivery during breast cancer treatment.
48093006|NCT05465694|PROCEDURE|2-minute-time interval of per oral 24% sucrose|Experiment began with a five-minute observation period of all outcome measures while infant was resting in an incubator. Later, attendant nurse gave 1 ml of 24% sucrose solution on neonate's tongue. In the 2-two minute-time interval prior to heel lance intervention, following two minutes of waiting period, heel lance procedure was applied to infant's foot. In no time interval of sucrose given immediately prior to heel lance intervention, attendant nurse performed heel lance procedure immediately after giving 1 ml of 24% sucrose solution sucrose on tongue. Infant's facial actions and heart rate, and oxygen saturation were recorded by using two video cameras. Recording was carried out by a nurse during whole procedure. After collecting data, researcher watched videos separately and scored them by using PIPP-R. Measurement of study outcome relied on data collection strategies: Neonatal close-up video recording of infant facial actions, pulse oximeter, observation for adverse events.
48093007|NCT05465694|PROCEDURE|no time interval of per oral 24% sucrose|no time interval of per oral 24% sucrose
48093008|NCT05707182|DRUG|18F-rhPSMA-7.3|18F-rhPSMA-7.3 PET/MR
48093009|NCT00249223|DRUG|Risperidone Long acting injectable|
48093010|NCT04704960|OTHER|Diagnostic Test: liquid biopsy|detection of tumor DNA alteration in cf-DNA
48093011|NCT06560840|OTHER|dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
48093012|NCT01890161|DRUG|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
48093013|NCT01890161|DRUG|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
48093014|NCT00557505|DRUG|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
48093015|NCT05145556|DEVICE|Videolarygoscopy|In a randomised order we evaluate the first pass success rate of the tracheal tube into the trachea.
48093016|NCT05145556|DEVICE|conventional laryngoscopy|In a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
48093017|NCT00237367|DRUG|rabeprazole and pantoprazole|
48093018|NCT04217421|DRUG|Allopurinol|Allopurinol powder for solution for infusion (PFI) 20 mg/kg body weight per administration will be administered early postnatally (within 45 minutes and 12 hours after the first dose), preoperatively (12 hours before surgery), intraoperatively (during surgery) and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Allopurinol PFI will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
48093019|NCT04217421|DRUG|Mannitol|Mannitol powder for solution (PFI) placebo will be administered early postnatally (within 45 minutes and 12 hours after birth), preoperatively (12 hours before surgery), intraoperatively (during surgery), and postoperatively (24 hours after surgery) to the neonate in case of a prenatal CCHD diagnosis. Mannitol PFI-placebo will be administered only pre-, intra- and postoperatively to the neonate in case of a postnatal CCHD diagnosis.
48093020|NCT06020417|DEVICE|O-ARM (Medtronic, Inc, Louisville, CO)|scanner that allows imaging of screws intraoperatively
48093021|NCT06020417|PROCEDURE|Conventional corrective surgery for arthrodesis|Conventional procedure without neuronavigation guide
48093022|NCT03090217|BEHAVIORAL|Pelvic Physiotherapy|1) daily pelvic floor muscle training (PFMT).
48620266|NCT00857389|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
47919745|NCT00795678|DRUG|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
48093023|NCT03090217|BEHAVIORAL|Standard care (SC)|1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
47919746|NCT05118659|PROCEDURE|sustained natural apophyseal glides|It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each
47919747|NCT05118659|PROCEDURE|SHAM SNAG|Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
48093024|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
48093025|NCT03392532|DEVICE|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
48093026|NCT02775617|DRUG|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
48093027|NCT02775617|DRUG|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
48093028|NCT02775617|DRUG|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
48093029|NCT05434442|OTHER|simulation model training|"Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator."
48093030|NCT05434442|OTHER|mobile app training|"An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher."
48093031|NCT05434442|OTHER|control group|Clinical routine training will be given to caregivers in this group.
47919748|NCT01675544|PROCEDURE|Electrocardiogram|EKG voltage changes between admission and discharge
47919749|NCT01675544|PROCEDURE|Six minute walk test|
47919750|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.01%|Topical sterile ophthalmic solution
47919751|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
47919752|NCT03844945|DRUG|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
47919753|NCT03844945|OTHER|Netarsudil Ophthalmic Solution Placebo|Topical sterile ophthalmic solution
47919754|NCT02319629|DRUG|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
47919755|NCT02319629|DRUG|Placebo|
47919756|NCT04586842|BEHAVIORAL|Community-based Occupational Therapy|Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.
48093032|NCT02643771|PROCEDURE|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
48093033|NCT06343441|DEVICE|intraoral scan|intraoral scanning of the edentulous arch and scan body
48093034|NCT06343441|DEVICE|open tray impression|conventional method of impression making with silicone rubber material
48093035|NCT01023178|DRUG|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
48093036|NCT01023178|DRUG|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
48093037|NCT01023178|DRUG|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
48093038|NCT01023178|DRUG|Progesterone, micronized|Given starting at 18 months
48298814|NCT01461031|DRUG|normal saline (control)|normal saline infusion for postoperative 24 hours
47919757|NCT04586842|BEHAVIORAL|Standard community-based intervention|Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
47919758|NCT02370108|DEVICE|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
47919759|NCT03632408|DRUG|Zopiclone|Oral, single dose, 7.5 mg
47919760|NCT03632408|BEHAVIORAL|hangover|as per subjects choice to consume alcohol
47919761|NCT03632408|DRUG|Placebo oral capsule|oral
47919762|NCT00992589|DRUG|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
47919763|NCT00992589|DRUG|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
47919764|NCT00992589|DRUG|Placebo|Matching placebo capsules once daily in the morning.
48106728|NCT05395949|DRUG|conservative treatment|Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
47919765|NCT00832624|DRUG|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
47919766|NCT06160934|BEHAVIORAL|T1D Parent Check-in|The Type 1 Diabetes (T1D) Parent Check-in is an innovative, 3-session, T1D-specific intervention for parents of newly diagnosed children and adolescents that can be delivered via telehealth. The T1D Parent Check-in is an adaptation of The Parent Check-In, a brief, prevention-based parenting intervention developed by Grolnick, Levitt, Caruso, \& Lerner (2021). The T1D Parent Check-in is designed to promote parenting skills on dimensions of autonomy support, structure and involvement that facilitate children's adjustment and motivation, and integrates skills from cognitive-behavioral therapy, customized to be highly relevant to families with a child 6-12 months from new diagnosis of T1D. The intervention is intended to promote diabetes-related resilience and positive psychological and medical outcomes among families of children with T1D.
47919767|NCT01981551|DRUG|PF-03084014|Treatment with the selective small-molecule \>=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
47919768|NCT01018810|DRUG|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
47919769|NCT01018810|DRUG|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
47919770|NCT01018810|DRUG|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
47919771|NCT01018810|DRUG|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
47919772|NCT04450381|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
47919773|NCT00912184|DEVICE|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
48106729|NCT04089618|BEHAVIORAL|MBLM|Complex 8 week Mind-Body program.
47919774|NCT00912184|DEVICE|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
47919775|NCT02871037|DRUG|PF-05221304|Single or repeated, escalating dose of PF-05221304
47919776|NCT02871037|OTHER|Placebo|single or repeated dose of placebo
47919777|NCT04854447|DEVICE|Single-Vision Spectacles|Spectacle correction for myopia treatment
47919778|NCT03207763|DEVICE|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
47919779|NCT03207763|DEVICE|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
47919780|NCT01630993|OTHER|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
47919781|NCT05377801|BEHAVIORAL|Multi-dimensional fall prevention intervention program for 12 weeks|The intervention group of this study is a multi-dimensional intervention conducted by nursing students over a 12-week period, consisting of four parts: individualized balance and strength training, vision screening, drug evaluation, home risk assessment and home repair and transformation. These components were carried out through a combination of personal home visits and telephone interviews.
47919782|NCT06119750|DEVICE|NS Solution|This will be administered via skin patch.
47919783|NCT06119750|OTHER|Normal Saline|This will be administered via skin patch.
47919784|NCT06119750|OTHER|SLS|This will be administered via skin patch.
47919785|NCT05857475|DEVICE|CPAP therapy|Continous positive airway pressure therapy
47919786|NCT05857475|OTHER|Control|No CPAP
47919787|NCT03084783|DRUG|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
47919788|NCT02147119|PROCEDURE|Coronary angiography|
47919789|NCT03007641|BEHAVIORAL|Didactic session|This session will include an overview of the approach to and management of older MBC patients through a case-based presentation.
47919790|NCT03007641|BEHAVIORAL|Comprehensive Geriatric Assessment|The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.
47919791|NCT04459208|DEVICE|Manta|plug-based vascular closure
47919792|NCT04459208|DEVICE|ProGlide|suture-based vascular closure
48270099|NCT04664348|OTHER|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
47919793|NCT06248580|DIAGNOSTIC_TEST|Anti Delta|Anti Delta by ELISA
47919794|NCT01089517|DRUG|E10030 plus Lucentis|once a month intravitreal injection
47919795|NCT01089517|DRUG|Lucentis|10 mg/mL intravitreal injection monthly
47919796|NCT01873612|PROCEDURE|Hypoxic ventilatory response|
47919797|NCT01873612|PROCEDURE|Hypercapnic ventilatory response|
47919798|NCT04049877|OTHER|None - Observational study|None - Observational study
47919799|NCT00439738|DRUG|HCTZ + Amlodipine|"* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules~* 5 mg amlodipine capsules~* 10 mg amlodipine capsules"
47919800|NCT00439738|DRUG|Valsartan/HCTZ|"* 160 mg film-coated valsartan tablets~* 320 mg film-coated valsartan tablets~* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules"
47919801|NCT05246085|DIAGNOSTIC_TEST|Cortisol level|Cortisol levels will be checked in both groups to screen for adrenal insufficiency.
47919802|NCT02697344|DRUG|Dexamethasone|Given PO
47919803|NCT02697344|OTHER|Laboratory Biomarker Analysis|Correlative studies
47919804|NCT02697344|DRUG|Lenalidomide|Given PO
47919805|NCT02697344|OTHER|Pharmacological Study|Correlative studies
47919806|NCT02697344|DRUG|R-(-)-Gossypol Acetic Acid|Given PO
47919807|NCT00219895|DRUG|Ibuprofen|
47919808|NCT03635658|PROCEDURE|titanium mesh|the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
47919809|NCT03635658|PROCEDURE|collagen membrane (Sausage technique)|the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
47919810|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.5%
47919811|NCT00891540|DRUG|Ropivacaine|Ropivacaine 0.2%
47919812|NCT00891540|DRUG|placebo|Isotonic NaCl
47919813|NCT05172934|DRUG|intra-arterial tenecteplase|intra-arterial drug administered after mechanical thrombectomy
47919814|NCT03278704|OTHER|RE only|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
47919815|NCT03278704|OTHER|RE + HIIT|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
48443535|NCT01854047|DRUG|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
48443536|NCT01854047|DRUG|Salbutamol/albuterol|Oral inhalation as needed
48443537|NCT01854047|DRUG|Levosalbutamol/levalbuterol|Oral inhalation as needed
48620267|NCT00857389|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
47919822|NCT02711267|DRUG|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
47919823|NCT02711267|DRUG|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
47919824|NCT02711267|DRUG|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
47919825|NCT02711267|DRUG|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
47919826|NCT02711267|DRUG|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
47919827|NCT02711267|PROCEDURE|OFM|Sampling method for interstitial fluid
47919828|NCT02711267|DEVICE|OFM Probe|Sampling probe used during OFM
47919829|NCT02711267|DEVICE|OFM Pump|Pump used to operate OFM probes
47919830|NCT03718780|OTHER|simultaneous determination of PaCO2 and PtCO2|"Patients in intensive care, equipped, for their routine clinical management, with an arterial catheter blood line, will have a simultaneous determination of PaCO2 and PtCO2:~* 1) at rest; 2 arterial CO2/PtCO2 determinations will be carried out, 10 minutes apart~* 2) During the muscular exercise part of their routine rehabilitation program (whatever it might be, limbs active mobilization, walking, etc...) : several arterial /PtCO2 samples will be collected during the first minutes of their muscular routine: 30 sec, 1 minute, 1 ½ minute, 2, 2 ½ , 3, 4, 5 minutes, 10 minutes (end of exercise). This will generate several couples of blood/transcutaneous CO2 determinations"
47919831|NCT03718780|OTHER|Hyperventilation test|Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest (0), then 30 sec post beginning of hyperventilation (breathing with accelerated frequency e.g. 30/min), 1 minute, 1 ½ minute 2, 2 ½ , 3, , 4, 5 minutes; recovery of this hyperventilation will be followed, for 5 minutes, with the PtCO2, during 3 minutes
48270100|NCT05029050|DRUG|Dexmedetomidine|Continous intravenous infusion
48270101|NCT05029050|DRUG|Clonidine|Continous intravenous infusion
48270102|NCT05029050|DRUG|Natriumchlorid|Continous intravenous infusion NaCl
48270103|NCT03499431|DEVICE|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
47919832|NCT03718780|OTHER|Exercise test|an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
47919833|NCT02964013|BIOLOGICAL|vibostolimab|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
47919834|NCT02964013|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
47919835|NCT02964013|DRUG|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
47919836|NCT02964013|DRUG|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
47919837|NCT02964013|BIOLOGICAL|pembrolizumab/vibostolimab coformulation|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
47919838|NCT02964013|DRUG|cisplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
47919839|NCT02964013|DRUG|etoposide|Administered as an IV infusion on Days 1-3 of 21-day infusion Cycles 1-4
47919840|NCT03268655|DIETARY_SUPPLEMENT|Ginger extract|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
47919841|NCT03268655|OTHER|Placebo|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
47919842|NCT03419585|DEVICE|Intervention systematic light exposure|30 minutes of intervention systematic light exposure daily
47919843|NCT03419585|DEVICE|Comparison systematic light exposure|30 minutes of comparison systematic light exposure daily
47919844|NCT01410916|DRUG|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
47919845|NCT03329014|DRUG|Remimazolam|For induction and maintenance of sedation
47919846|NCT03329014|DRUG|Placebo|Control arm
47919847|NCT05722444|OTHER|Nighttime Feminine Product|"During nights while menstruating:~* Standardized nighttime feminine product + typical nighttime behaviors to prevent leak~* Standardized nighttime feminine product + refraining from nighttime behaviors to prevent leak"
47919848|NCT03069105|OTHER|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
47919849|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
47919850|NCT03830892|OTHER|E-cigarette Lab Session 15 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
47919851|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
47919852|NCT03830892|OTHER|E-cigarette Lab Session 30 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
47919853|NCT03830892|OTHER|Own Brand Session - E-cigarette|E-cigarette paired with own brand liquid and preferred power
47919854|NCT03830892|OTHER|Own Brand Session - E-cigarette/Cigarette|Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
47919855|NCT06415500|DRUG|NK042|NK042 intraperitoneal infusion on Days 0,7 and 14.
47919856|NCT00490529|BIOLOGICAL|CpG-MCL vaccine|CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
47919857|NCT00490529|BIOLOGICAL|PF-3512676|PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
47919858|NCT00490529|PROCEDURE|Vaccine-primed T-cells|Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
47919859|NCT00490529|PROCEDURE|Autologous hematopoietic stem cell transplant (HSCT)|Regular medical procedure
47919860|NCT00490529|DRUG|Rituximab|375 mg/m² by infusion
47919861|NCT00490529|DRUG|Standard induction chemotherapy|Patient-specific, regular medical care treatment as determined by treating oncologist
47919862|NCT00490529|DRUG|Cyclophosphamide|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
47919863|NCT00490529|DRUG|Filgrastim|Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
47919864|NCT02340351|DEVICE|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
47919865|NCT02340351|PROCEDURE|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
47919866|NCT01831583|DEVICE|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
47919867|NCT01831583|DEVICE|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
47919868|NCT00582075|DRUG|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
47919869|NCT05680532|DIETARY_SUPPLEMENT|Black raspberry|Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.
47919870|NCT05680532|OTHER|Placebo|Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
47919871|NCT05147233|DRUG|Dexamethasone|Dexamethasone
47919872|NCT05147233|DRUG|Vehicle Placebo|Placebo comparator
47919873|NCT03472170|DIETARY_SUPPLEMENT|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
47919874|NCT03472170|OTHER|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
47919875|NCT04708457|OTHER|VV-ECMO|Early use of VV-ECMO in SARI patients.
47919876|NCT00329524|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
47919877|NCT00228176|DRUG|Rimonabant|Tablet, oral administration
47919878|NCT00228176|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
47919879|NCT05632588|OTHER|Observational study|Observational surveillance study
47919880|NCT01552421|PROCEDURE|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
47919881|NCT05664568|DRUG|Cephalexin|Participants in intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
47919882|NCT05664568|DRUG|Amoxicillin-Clavulanate 500 Mg-125 Mg Oral Tablet|Participants in the intervention group will receive a combination of cephalexin and amoxicillin-clavulanate for the first 2 weeks of TB treatment
47919883|NCT05664568|OTHER|Standard of care treatment of tuberculosis|The control group will be given standard of care treatment of tuberculosis consisting of rifampicin, isoniazid, pyrazinamide and ethambutol
47919884|NCT01423188|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
47919885|NCT01423188|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
47919886|NCT05777291|DEVICE|Activity watch monitoring|Patients will be using activity devices during the study period
47919887|NCT05777291|DEVICE|Sleep mattress monitoring|Patients will be using sleep mattress during the study period
47919888|NCT05777291|BEHAVIORAL|Physical activity counseling|Physical activity counseling in accordance to the Swedish model
47919889|NCT00918931|DRUG|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
47919890|NCT03930264|DRUG|Azathioprine 50Mg Tab|tablet
47919891|NCT03930264|DRUG|Azathioprine 10mg/mL oral suspension|oral suspension
48270104|NCT02208960|DEVICE|Neonatal Kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~7. Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
47919892|NCT02350764|DRUG|nivolumab|
47919893|NCT02350764|DRUG|pilimumab|
47919894|NCT04995458|PROCEDURE|composite-ceramic|To assess the clinical performance of composite-ceramic crowns
47919895|NCT04995458|PROCEDURE|Monolithic zirconia|To assess the clinical performance of monolithic z¡irconia crowns
47919896|NCT00536445|DEVICE|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
47919897|NCT01142804|BEHAVIORAL|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
47919898|NCT05631964|DRUG|BL-M07D1|Administration by intravenous infusion
47919899|NCT02935283|PROCEDURE|MRI|MRI, fMRI, 1H MRS, DTI
47919900|NCT02935283|BEHAVIORAL|Behavioral|Battery of executive function tasks
47919901|NCT00662467|DRUG|aspirin + clopidogrel|Dual therapy
47919902|NCT00662467|DRUG|aspirin + clopidogrel + warfarin|Triple therapy
47919903|NCT05300438|DRUG|TSN084|Oral tablets
47919904|NCT04363541|DEVICE|Electric pad for human external pain therapy|An electric pad for local heat production will be put on the back of the patient for two hours
47919905|NCT04321135|BEHAVIORAL|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
47919906|NCT04321135|BEHAVIORAL|Self-Guided Lifestyle Program (Control Arm)|In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
47919907|NCT03458013|BEHAVIORAL|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
47919908|NCT01292824|DRUG|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
47919909|NCT06429553|PROCEDURE|Minimally invasive hematoma aspiration drainage combined with urokinase injection|Minimally invasive hematoma aspiration drainage combined with urokinase injection
47919910|NCT00902044|GENETIC|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
47919911|NCT00902044|DRUG|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes"
47919912|NCT00902044|DRUG|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes"
47919913|NCT00902044|GENETIC|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
47919914|NCT05547204|OTHER|Beverage|Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.
47919915|NCT00811096|DRUG|Tinidazole|2gms, p.o. q.d. for 5 days
47919916|NCT00811096|DRUG|chloroquine|
47919917|NCT01812278|BEHAVIORAL|ACT|
47919918|NCT01812278|BEHAVIORAL|CBT|
47919919|NCT03370172|DRUG|BAX 888|Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.
47919920|NCT05148195|DRUG|Envofolimab|300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
48270105|NCT02208960|BEHAVIORAL|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~1. Eye contact and talking to children~2. Responsive feeding and caregiving~3. Singing songs, including those with gentle touch"
48270106|NCT05539014|OTHER|Data collection|Prospectif data collection
48270107|NCT01442181|PROCEDURE|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
48270108|NCT01442181|OTHER|Medical therapy|Patients are treated with rhythm and rate control medications.
48270109|NCT05019937|BEHAVIORAL|Educational meeting|The investigators will hold a full-day educational meeting. The meeting will include educating 4-5 representatives of each school, and school-district representatives about the guideline and the advantages of adhering to the guideline.
48270110|NCT05019937|BEHAVIORAL|Implementation team|The school-principal forms an implementation team that is responsible for implementing the guideline within their school. The team members (n=4-5) reflect on the implementation progress, make, and refine plans according to Plan-Do-Study-Act, share lessons learned and support each other.
48270111|NCT05019937|BEHAVIORAL|Workshops|"The investigators will hold 5 workshops. Workshops will include providing in-depth knowledge and skills on the guideline recommendations. During each workshop one of the guideline recommendations will be presented and discussed.~Moreover, the concept of Plan-Do-Study-Act will be introduced and how it can be used to implement the guideline recommendation(s). During each workshop, the implementation team will share with the group their developed PLAN and barriers and facilitators that have influenced the execution of the PLAN."
48270112|NCT05019937|BEHAVIORAL|Plan-Do-Study-Act improvement cycles|The implementation team will implement the guideline in a cyclical manner by using Plan-Do-Study-Act. First a Plan is specified during the workshop by using SMART-goals, next the change is carried out between workshops (Do), the implementation team analyses whether it went well and what needs to be improved (Study), changes are made (Act) and finally the next cycle is planned.
48270113|NCT05019937|BEHAVIORAL|Internal facilitator|Each municipality assigns one or more internal facilitators, for example HR-strategist. The internal facilitator will meet their local implementation teams during the educational meeting and workshops. Further meeting can be scheduled based on the needs of each implementation team. The internal facilitator will create a supportive environment within which knowledge is exchanged, barriers to implementation identified, and processes or solutions to overcome those barriers developed, applied, and refined. Moreover, the internal facilitator will establish ongoing audit and feedback processes.
47919921|NCT05148195|DRUG|BD0801|2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
47919922|NCT05148195|DRUG|Docetaxel|75mg/m2，Q3W
47919923|NCT05148195|DRUG|Irinotecan|180 mg/m2，Q2W
47919924|NCT05148195|DRUG|Leucovorin calcium|400mg/m2，Q2W
47919925|NCT05148195|DRUG|5-Fluorouridine|2400 mg/m2，Q2W
47919926|NCT02878798|DRUG|topiramate|Oral topiramate at a target dose of 50mg twice daily.
47919927|NCT02878798|OTHER|Placebo|overencapsulated placebo of identical color, shape and packaging to topiramate
47919928|NCT05086614|DRUG|Thymosin Alpha1|Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
47919929|NCT02771613|OTHER|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
47919930|NCT02771613|OTHER|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
47919931|NCT00571168|DRUG|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
47919932|NCT00571168|DRUG|Placebo|Placebo capsules on day 1-4
47919933|NCT05807165|RADIATION|Hypofractionated Stereotactic Radiotherapy (HF-SRT)|The administered dose-fractionation schemes range between 30 and 35 Gy delivered within two weeks with a dose per fractionation ranging from 6 to 7 Gy.
47919934|NCT05807165|RADIATION|Hippocampus-Sparing Whole-Brain Radiotherapy (HS-WBRT) plus memantine|"* The prescribed dose is 30 Gy delivered in 12 fractions for therapeutic or adjuvant WBRT.~* The prescription of memantine for finally twice-daily dosing will be prescribed as follows:~  * During the first 3 weeks concurrent with the delivery of hippocampus-sparing WBRT, 5-mg morning dose will be initially prescribed \[Week 1 -3\]~ * 5-mg twice a day in the following week \[Week 4\]~ * A morning dose of 10 mg and an evening dose of 5 mg in the following week \[Week 5\]~ * 10-mg twice a day for the subsequent weeks up to Week 24 \[Week 6 - 24\]"
47919935|NCT01227018|DRUG|STA-9090|Given IV
47919936|NCT01227018|RADIATION|Radiologic imaging|radiologic modalities used to evaluate response to treatment
47919937|NCT01227018|PROCEDURE|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
47919938|NCT02855541|DEVICE|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
47919939|NCT02205840|DRUG|SI-614|1 drop in each eye
47919940|NCT02205840|DRUG|Vehicle|1 drop in each eye
47919941|NCT01017913|OTHER|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
47919942|NCT01017913|OTHER|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
47919943|NCT00777153|DRUG|Cediranib|30 mg/day, oral, until progression
47919944|NCT00777153|DRUG|Cediranib|20 mg/day, oral, until progression
47919945|NCT00777153|DRUG|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
47919946|NCT00777153|DRUG|Placebo Cediranib|Oral, until progression
47919947|NCT03472846|DRUG|Prolia, 60 Mg/mL Subcutaneous Solution|antiresorptive treatment with Prolia
47919948|NCT03472846|DRUG|Teriparatide|osteoanabolic treatment with Forsteo
47919949|NCT00874939|DRUG|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
47919950|NCT00874939|DRUG|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
47919951|NCT00874939|DRUG|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
47919952|NCT00874939|DRUG|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
47919953|NCT00874939|DRUG|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
47919954|NCT00764764|PROCEDURE|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
47919955|NCT00764764|PROCEDURE|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
47919956|NCT06349889|DRUG|Adebrelimab|"Drug: Adebrelimab Adebrelimab 20mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.~Other Names:~PD-L1 antibody~Drug: Gemcitabine Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Other Names:~GEM~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation~Other Names:~DDP~Radiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.~Other Names:~IMRT"
47919957|NCT04609007|BEHAVIORAL|Cognitive behavioral therapy (CBT)|A brief 4 sessions online CBT program with therapist support.
47919958|NCT04609007|BEHAVIORAL|Regular help-line telephone counselling|A single session of telephone counselling with a help-line counsellor
47919959|NCT05750199|OTHER|Immunotherapy Special Training Course (ISTC)|16 weeks and includes 8 hours of digital media training and 2 days of workshop training.
47919960|NCT05750199|OTHER|Advanced Oncology Nurse Training Course (AONTC)|4 weeks and includes 8 days of Advanced Oncology Nurse Training Course
47919961|NCT06428071|OTHER|standard physical therapy|All Patients in the three groups will receive supervised systematic exercise therapy that was performed effectively in previous work. This program consisted of lower limb static, dynamic, and flexibility exer¬cises that targeted the quadriceps, hamstrings, and gluteus muscles; and core strength training for 20 minutes per day. This program will be applied 3 times per week for 6 weeks to all the participants
47919962|NCT06428071|OTHER|knee Decompression|continuous mechanical decompression using 20% of the body weight as a traction force for 15 minutes.
47919963|NCT06428071|OTHER|hot pack|hot pack over the treated knee joint will be applied for 20 minutes. this application will be performed while the patient is receiving the decompression session
47919964|NCT04360382|OTHER|ERACS|Pregnant women scheduled for cesarean section will be subjected to preoperative, intra-operative and postoperative nurse care aiming at early recovery.
47919965|NCT04360382|OTHER|Regular care|Usual care for all cases subjected to cesarean section at our hospital.
47919966|NCT04884464|DEVICE|Hyaluronic acid-based gel|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
47919967|NCT04884464|DRUG|Chlorhexidine Gluconate|Dosage: application of an even coat of 1mm thickness Frequency: 3 times/day (after main meals) Duration: 2 weeks
47919968|NCT01686997|PROCEDURE|Roux-en-Y Gastric Bypass|
47919969|NCT04950478|OTHER|Virtual Reality|5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
47919970|NCT02990624|RADIATION|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
47919971|NCT04174404|OTHER|ICory-Circumcision|The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.
47919972|NCT04174404|OTHER|Routine care|The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
47919973|NCT03680118|DEVICE|autogenous rings with GBR and autogenous graft with ti-mesh|"* Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~* Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~* Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~* The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
47919974|NCT00927914|DRUG|Ranirestat|Ranirestat 40 mg tablets
47919975|NCT00927914|DRUG|Placebo|Placebo tablets
47919976|NCT01559740|DRUG|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
47919977|NCT01615276|DEVICE|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
47919978|NCT01615276|DEVICE|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
47919979|NCT00545272|DRUG|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
47919980|NCT00545272|DRUG|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
47919981|NCT00545272|DRUG|placebo to indacaterol|Placebo TWISTHALER® device
47919982|NCT00545272|DRUG|placebo to formoterol|Placebo AEROLIZER® device
47919983|NCT00545272|DRUG|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
47919984|NCT03236155|DRUG|opioid pain pills|patient will receive their pain pill prescription
47919985|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP)|"Patients will follow TAU and LMP. This program will consist of 6 weekly group sessions (lasting 90 minutes each) led by an experienced psychologist and complemented by PowerPoint presentations. The content is the following:~1. Presentation of the project and psychoeducation on depression.~2. Behavior activation.~3. Sleep hygiene habits and careful exposure to sunlight.~4. Physical activity.~5. Adherence to the Mediterranean diet.~6. Summary of previous sessions with practical final suggestions."
47919986|NCT03951350|BEHAVIORAL|Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)|Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).
48093039|NCT01824082|DRUG|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
48093040|NCT01766518|DRUG|Mycophenolate mofetil|MY-REPT capsule 500\~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
48093041|NCT01258361|PROCEDURE|echocardiography|Echocardiography is performed for all patients
48093042|NCT02793882|DRUG|18F-Fluorocholine PET/CT|
48093043|NCT02888795|DRUG|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
48093044|NCT02452229|OTHER|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
47919987|NCT01490489|OTHER|blood sample and doppler Ultrasound of uterine arteries|"* 36 ml of blood samples (serum and plasma) will be collected~* After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
48093045|NCT00378872|DRUG|IV Tranexamic acid 10mg/kg pt body weight|
48093046|NCT00378872|DRUG|Quixil topical sealant|
48093047|NCT04895787|BEHAVIORAL|Gait + aerobic exercise|Following skill-based gait training, the participants in the AEX group will engage in 20 minutes of moderate to high intensity aerobic exercise on a recumbent bicycle. The participants will first perform a brief warm-up, followed by 20 minutes of moderate to high intensity aerobic exercise pedaling at 60-80 rpm with a target heart rate range between 60-70% of heart rate reserve (HRR). Given the potential of having autonomic dysfunction in this population, it has been suggested that a RPE scale between 14-17 is appropriate.
48443538|NCT01138540|OTHER|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
48443539|NCT02023853|PROCEDURE|ultrasonic|
48443540|NCT02023853|PROCEDURE|erythritol|
47919988|NCT04241900|BEHAVIORAL|Shuttle run test|At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
47919989|NCT00448318|PROCEDURE|Music Therapy|
47919990|NCT03855826|DRUG|Nifekalant hydrochloride|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
47919991|NCT03855826|DRUG|Amiodarone|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
47919992|NCT00612807|BEHAVIORAL|Weekly marital therapy|Weekly marital therapy for 6 months.
47919993|NCT00612807|DRUG|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
47919994|NCT02594020|PROCEDURE|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
47919995|NCT02594020|PROCEDURE|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
47919996|NCT02594020|PROCEDURE|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
47919997|NCT01715441|DRUG|Sorafenib and irinotecan combination|
47919998|NCT01715441|DRUG|Sorafenib monotherapy|
47919999|NCT01715441|DRUG|Irinotecan monotherapy|
47920000|NCT04952155|DRUG|IL-2|The administration period was divided into 6 courses. 6 cycles of IL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks, followed by a 2-week break in treatment. The adminstration course was 24 weeks.. The 24-week follow-up period was followed after the treatment.
47920001|NCT00776919|DRUG|clindamycin / benzoyl peroxide gel|Once a day application to the face
47920002|NCT00776919|DRUG|clindamycin gel|Once a day application to the face
47920003|NCT00776919|DRUG|BPO gel|Once a day application to the face
47920004|NCT00776919|DRUG|vehicle gel|Once a day application to the face
47920005|NCT00196846|DRUG|Goserelin|
47920006|NCT03616808|OTHER|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
47920007|NCT02023333|DRUG|Regorafenib|All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
47920008|NCT03227783|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
47920009|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
48093048|NCT04895787|BEHAVIORAL|Gait + resistance exercises|Following skill-based gait training, the participants in the REX group will engage in resistance training, which will target major muscle groups important for daily activities. The resistance training will be provided with free weights or therabands at an intensity of 8-12 repetition maximum (RM). Each muscle group should be trained with 8-12 repetitions ranging from 1 to 3 sets with resting intervals provided between each set. The target RPE scale will be set between 14-17, and the training load will be progressively increased as the participants improved.
48443541|NCT02023853|DRUG|metronidazole gel|
47920010|NCT00747357|DEVICE|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
47920011|NCT01947413|OTHER|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
47920012|NCT01947413|OTHER|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
47920013|NCT01947413|OTHER|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
47920014|NCT04664764|DRUG|Degludec|Basal insulin comparison
47920015|NCT04664764|DRUG|Glargine|Basal insulin comparison
47920016|NCT04664764|DRUG|NPH insulin|Basal insulin comparison
47920017|NCT04704947|DRUG|nonselective beta blocker|nonselective beta blocker
47920018|NCT04704947|DRUG|cardio-selective beta blocker group|cardio-selective beta blocker group
47920019|NCT04704947|DRUG|alendronate sodium|alendronate sodium
47920020|NCT02091557|DRUG|GnRH-analogue|
47920021|NCT04911985|DEVICE|Measurement of the Cardiac Output/ Cardiac Index|Semiinvasive Measurement of the Cardiac Output/ Cardiac Index with the Pulsion device
47920022|NCT05439785|DEVICE|Dental floss/Interdental brush|Initially plaque disclosing tablets were used to disclose plaque and plaque and bleeding scores will be recoded. After mechanical plaque debrided, instructions regarding the allocated interdental device given to the patient along with motivation to continue practicing good oral hygiene. After six weeks patients were recalled for reevaluation
47920023|NCT01429025|BIOLOGICAL|rituximab|IV
47920024|NCT01429025|DRUG|bendamustine|IV
47920025|NCT01429025|DRUG|lenalidomide|PO
47920026|NCT03805659|DEVICE|HD-tDCS|High-Dose transcranial Direct Current Stimulation
47920027|NCT03805659|DEVICE|Sham|Sham sessions (no electric current)
47920028|NCT04327193|PROCEDURE|Titrated PEEP based on driving pressure|Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.
47920029|NCT04327193|PROCEDURE|Conventional PEEP|Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
47920030|NCT00336830|BEHAVIORAL|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
48093049|NCT04895787|BEHAVIORAL|Gait + conventional physical therapy|Following skill-based gait training, the participants in the CPT group will receive conventional physical therapy, which may include stretching exercise, balance training, or practice over-ground walking based on the participant's need.
48093050|NCT04895787|BEHAVIORAL|Gait + rest|Following skill-based gait training, the participants will sit and rest on a chair.
48093051|NCT03291275|OTHER|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
48093052|NCT01305824|DRUG|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
48093053|NCT01305824|DRUG|Placebo|Placebo administered at the time of AVF creation.
48093054|NCT01305824|DRUG|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
48093055|NCT03245164|OTHER|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
48093056|NCT03245164|OTHER|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
48093057|NCT00589862|DRUG|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
48093058|NCT01799954|BIOLOGICAL|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
48093059|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
48093060|NCT01799954|BIOLOGICAL|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
47920031|NCT00336830|BEHAVIORAL|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
48093061|NCT01799954|BIOLOGICAL|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
48093062|NCT01799954|BIOLOGICAL|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
48093063|NCT01799954|BIOLOGICAL|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
48093064|NCT04517591|BEHAVIORAL|The Take a STAND for health|A 4-month parallel-group randomised controlled trial will be performed, in which patients post-bariatric surgery will be assessed at baseline pre-surgery (PRE-BAR), 3 months after surgery and pre-intervention (PRE-INT) and 4 months after intervention (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.
48620268|NCT00857389|DRUG|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
48093065|NCT04228770|BEHAVIORAL|Meeting with pharmacist|Meeting with pharmacist to support drug management following their routine surgery.
48093066|NCT00423774|BEHAVIORAL|Problem-Solving Education|
48093067|NCT02359058|DRUG|Ramucirumab|Administered IV
48093068|NCT02359058|DRUG|Capecitabine|Administered orally
48093069|NCT02359058|DRUG|Cisplatin|Administered IV
48093070|NCT02359058|DRUG|S-1|Administered orally
48093071|NCT02359058|DRUG|Oxaliplatin|Administered IV
48093072|NCT03818997|DRUG|DKN-01|Patient will receive DKN-01 300 mg IV every 2 weeks
48093073|NCT03818997|DRUG|Atezolizumab|Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
48093074|NCT03818997|DRUG|Paclitaxel|Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD
48093075|NCT05625399|DRUG|Nivolumab + Relatlimab|Specified dose on specified days
48093076|NCT05625399|DRUG|rHuPH20|Specified dose on specified days
48093077|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
48093078|NCT03905135|DRUG|rhIL-15|Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
48093079|NCT03905135|BIOLOGICAL|Avelumab|Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
48093080|NCT06044961|RADIATION|CT scan|All pre-operative CT scan collected
48093081|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
48093082|NCT01121874|PROCEDURE|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
48093083|NCT01121874|PROCEDURE|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
48620269|NCT00857389|DRUG|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
48093084|NCT01084122|DRUG|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
48093085|NCT04679584|OTHER|Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings|Oberservatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care
48093086|NCT05756439|DRUG|Intravenous Sedatives with or Without Analgesia|Participants having dental surgery with conscious intravenous sedation
48093087|NCT05756439|DRUG|No IV sedation|Participants having dental surgery without conscious intravenous sedation
48093088|NCT03635177|PROCEDURE|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
48093089|NCT01452490|DEVICE|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
48093090|NCT03771235|BEHAVIORAL|Mindfulness-based Intervention for Tics|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
48093091|NCT03771235|BEHAVIORAL|Tic Information and Coping Strategies|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
48093092|NCT00279422|DRUG|visilizumab|
48093093|NCT00279422|DRUG|visilizumab|
47920032|NCT01430169|BIOLOGICAL|AA4500|Two injections of AA4500 0.58 mg 24 hours apart
48270114|NCT03501927|DIAGNOSTIC_TEST|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~* Left ventricular systolic function~* Left ventricular diastolic function~* Right ventricular systolic function~* Right ventricular pressure overload~* Biventricular sizes~* Pathology of the mitral- and aortic valves~* Pericardial fluid~* Gross fluid status~* Pleural effusion"
48270115|NCT00618748|DRUG|Olanzapine|5-20 mg/day, oral, daily
48270116|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
48270117|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
47920033|NCT01761162|DEVICE|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
47920034|NCT01761162|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
47920035|NCT03087617|DEVICE|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
47920036|NCT03087617|BEHAVIORAL|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
47920037|NCT03087617|OTHER|Usual Care|Usual Care for Lung Cancer Screening patients.
47920038|NCT06085456|DIAGNOSTIC_TEST|Hematologic features|Hematologic features including blood routine tests, blood biochemical indicators, and tumor markers before surgery
47920039|NCT01224951|DRUG|Beclomethasone|400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
48093094|NCT00461448|DIETARY_SUPPLEMENT|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
48093095|NCT00783692|DRUG|vedolizumab|Vedolizumab for intravenous infusion
48093096|NCT00783692|OTHER|Placebo|Placebo intravenous infusion
48093097|NCT04895345|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48093098|NCT04895345|RADIATION|Intensity modulated radiotherapy|Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
48093099|NCT06615024|DIAGNOSTIC_TEST|G6pd enzyme sickling test|Measuring the enzyme level of G6PD and presence of Hbs
48093100|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and sickling test|Measuring enzyme level of G6PD and level of HbS
48093101|NCT06615024|DIAGNOSTIC_TEST|G6PD enzyme and HPLC|Measuring G6PD enzyme level in neonates and measuring level of HbS
48093102|NCT02214251|DEVICE|PK-16CH EXG system|
48093103|NCT04274179|OTHER|Modified Atkins Diet|Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
48093104|NCT04274179|DRUG|Absence epilepsy medications|At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
48093105|NCT04887272|OTHER|Supervised Exercise Training Protocol|EXT: Supervised EXT will include a progressive individualized program that combines aerobic and resistance protocols. Volume progression will begin with 3-days of supervised training sessions/wk and will increase by 1 session/wk to a maximum of 5-days/wk. Each EXT session will include 30 minutes of aerobic training (15 minutes cycling; 15 minutes treadmill walking/running/elliptical) and 30 minutes of resistance training (specifics below). Considering individual fatigue will be a concern, therefore similar to exercise training standards in COPD, the duration of rest periods may be extended (\~1-3 min) as needed, however, all exercise durations will be completed within a 1.5-hour time slot. On days that EXT and IMET interventions overlap, the training and IMET will be spread out over a 2-hour session as opposed to the 1.5-hour time slot.
48270118|NCT01774422|DEVICE|Extracorporeal CO2 removal device|
48270119|NCT05011487|DRUG|Osimertinib|80mg/qd oral for 60 days
48270120|NCT05011487|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
48270121|NCT05011487|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
48270122|NCT01390792|DRUG|Zanamivir hydrate|
48093106|NCT04887272|OTHER|Inspiratory Muscle and Exercise Training|Inspiratory Muscle Training (IMT): All IMT sessions will be performed similar to EXT, with the exception of having 2-3-sessions of at-home IMT training depending on where in the exercise progression the individual is (i.e., Week1 vs week 6). On the days that IMT and exercise training overlap, all training will be spread out over a 2-hour session with periods of IMT training occurring at the beginning, middle and end of the session. Each week will include a measure of Maximal Inspiratory Pressure (MIP) and a Test of Inspiratory Respiratory Endurance (TIRE). The intensity of the IMT will be 50% of the weekly MIP, thus progressive increases in IMT threshold intensity will remain at 50% of the weekly MIP. In contrast, the TIRE protocol will assess respiratory endurance based on the relative baseline intensity. Thus TIRE testing will begin at a MIP intensity of 50% (weeks 1-2), and then progressing to 65% (weeks 3-4), and 80% (weeks 5-6).
48093107|NCT04749693|DEVICE|DBLG1 System|Use of DBLG1 System in real life condition
48093108|NCT02334943|BIOLOGICAL|Blood test|Blood test
48093109|NCT01641276|DEVICE|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
48093110|NCT00297765|DRUG|Tacrolimus, Prograf®|
48093111|NCT03504449|OTHER|neoadjuvant chemoradiotherapy|
47920040|NCT03457064|BEHAVIORAL|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
48093112|NCT04296162|DRUG|Vinorelbine|Vinorelbine chemotherapy (oral)
48093113|NCT04296162|DRUG|Capecitabine|Capecitabine chemotherapy (oral)
48093114|NCT04296162|DRUG|Trastuzumab|Trastuzumab target therapy
48093115|NCT00002111|DRUG|Saquinavir|
48093116|NCT02060253|DRUG|ganetespib|Given IV
47920041|NCT01567839|PROCEDURE|Mandibular buccal Infiltration injection|
48093117|NCT02060253|DRUG|paclitaxel|Given IV
48093118|NCT02060253|BIOLOGICAL|trastuzumab|Given IV
48093119|NCT02060253|BIOLOGICAL|pertuzumab|Given IV
48093120|NCT00563277|PROCEDURE|combined pterygium and cataract operation|
48093121|NCT00563277|PROCEDURE|pterygium excision followed by cataract operation|
48093122|NCT04531683|OTHER|electroacupuncture|same as described in experimental arm.
48093123|NCT04531683|OTHER|sham electroacupuncture|same as described in sham comparator.
48093124|NCT04531683|BEHAVIORAL|life style counselling|life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
47920042|NCT00422864|DRUG|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
48093125|NCT01055782|DEVICE|Endoguide|Use of endoguide to facilitate completion of endoscopy
47920043|NCT00422864|DRUG|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
47920044|NCT00422864|DRUG|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
47920045|NCT00422864|PROCEDURE|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
48093126|NCT05300555|DRUG|Rivaroxaban 20 MG Oral Tablet|After randomization, the patient will start medication (rivaroxaban 20mg per day or 15mg per day if eGFR between 30 and 50ml/min/1,73m²) within 24 hours. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
48093127|NCT05300555|DRUG|Warfarin|After randomization, the patient will start medication within 24 hours. Bridge with heparin or enoxaparin is recommended. The INR target is between 2,0 and 3,0. The medication will be prescribed up to 30 days after hospital discharge and if there is no clinical, electrocardiographic and Holter evidence of AF, the medication will be discontinued
48093128|NCT01929993|PROCEDURE|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
48093129|NCT01929993|PROCEDURE|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
48093130|NCT04100356|OTHER|Exercise|Exercise program - indoor bicycle interval exercise, duration 60 min 3x week
48093131|NCT04100356|OTHER|Normal Diet|Normal diet recommended by the health authorities
48093132|NCT04100356|OTHER|LCHF Diet|LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
48093133|NCT00889564|DEVICE|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
48093134|NCT01237392|DEVICE|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
48093135|NCT05052411|OTHER|App usage assessments and analytics|All participants will be given a brief overview of the purpose of the study followed by a survey on participant characteristics and barriers to accessing HIV testing and PrEP uptake and P/SUD support services. The participant will be observed downloading the JomPrEP app and instructed with a brief tutorial on the onboarding process. The participant will be told to keep the app for 1 month and encouraged to use all app components. At 30 days, the participant will complete a post-survey, to which the Systems Usability Scale will be added. App analytics will also be collected (e.g., the number of logins). Participants will be asked to provide feedback on functionality, performance, and errors encountered, motivation to use the app, overall experiences using the app, feedback for further refinement, and subjective impact of the app on HIV prevention.
47920046|NCT06531434|COMBINATION_PRODUCT|"Docetaxel, Cisplatin, fluorouracil, Radiation"|Induction chemotherapy with Docetaxel, Cisplatin, and fluorouracil for 4 to 8 cycles, followed by concurrent chemoradiotherapy with Cisplatin and Radiation 30.6-40 Gy.
47920047|NCT03647813|RADIATION|Photobiomodulation|Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
48093136|NCT04840147|DEVICE|JointRep®|JointRep® is a medical device based on a thermogel polymer (Chitosan) for the treatment of chondral lesions, which consists of an injectable aqueous composition that forms a solid and sticky hydrogel in situ within cartilage defect(s). JointRep® is composed of an injectable thermo-gelling aqueous composition. It is used in conjunction with a Bone Marrow Stimulation type of procedure like Microfracture.
48093137|NCT04840147|PROCEDURE|Microfracture|Microfracture is a bone marrow stimulation type of procedure where after debridement of the damaged chondral tissue within the lesion, obtention of stable vertical margins and curettage of the entire calcified layer, multiple holes are created with a variety of instruments (awls, picks, microdills, nanofracture) to establish a communication with the subchondral bone to create a blood clot to elicit the natural healing process
47920048|NCT03647813|RADIATION|Placebo|The same laser protocol was followed but with the device switched off.
47920049|NCT04364984|DRUG|Angiotensin converting enzyme inhibitor|routine drug intake
48093138|NCT00336921|DRUG|Alfuzosin|Once daily
48093139|NCT00336921|DRUG|Placebo|Once daily
48093140|NCT00502281|DRUG|highly purified urinary FSH|
47920050|NCT04364984|DRUG|Angiotensin Receptor Blockers|routine drug intake
47920051|NCT04364984|DRUG|Direct renin inhibitor|routine drug intake
47920052|NCT02042716|OTHER|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
47920053|NCT06109818|DRUG|ICP-488 Tablets|ICP-488 will be administered as tablet
47920054|NCT06109818|DRUG|ICP-488 Placebo|ICP-488 Placebo will be administered as tablet
47920055|NCT03799302|BEHAVIORAL|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
47920056|NCT03840434|DIAGNOSTIC_TEST|MyotonPRO|Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
47920057|NCT02984930|DRUG|Administration of study drug (esomeprazole, mosapride)|Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
48093141|NCT00502281|BEHAVIORAL|timed intercourses, intrauterine insemination|
48093142|NCT04071340|DEVICE|non-contrast MSCT|non-contrast multi-slice computed tomography
48093143|NCT04071340|DEVICE|Abdominal ultrasonography|Abdominal ultrasonography
47920058|NCT02984930|DRUG|Administration of study drug (esomeprazole, placebo tablet)|Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
48093144|NCT04071340|DIAGNOSTIC_TEST|Urine analysis|Urine analysis
48093145|NCT04071340|DIAGNOSTIC_TEST|Urine culture|Urine culture
48093146|NCT04651738|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177
48093147|NCT03818061|DRUG|Atezolizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
48093148|NCT03818061|DRUG|Bevacizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
48093149|NCT03020355|PROCEDURE|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
48093150|NCT03020355|PROCEDURE|not Placental Blood Drainage|In the control group, the clamped cord will not released.
48093151|NCT05235061|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PTE is an adaptation of the HOBSCOTCH program for people with a traumatic brain injury and post-traumatic epilepsy that incorporates education about TBI, PTE, and cognition into the education module.
48093152|NCT05235061|BEHAVIORAL|HOBSCOTCH-PTE for Caregivers|Select components of the HOBSCOTCH-PTE program delivered to caregivers consist of session 1 of the HOBSCOTCH-PTE (virtual) program (education module), guidance and instructions on utilizing quick relaxation, and session 8 of the HOBSCOTCH-PTE program (program wrap-up and maintenance planning).
47920059|NCT02984930|PROCEDURE|upper endoscopy, scintigraphy|After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
47920060|NCT02730780|DIETARY_SUPPLEMENT|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.
47920061|NCT02730780|DIETARY_SUPPLEMENT|High-Salt Diet|The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
47920062|NCT00783484|DRUG|PF-03716539|PF-03716539 10 mg oral solution, single dose
47920063|NCT00783484|DRUG|PF-03716539|PF-03716539 25 mg oral solution, single dose
47920064|NCT00783484|DRUG|PF-03716539|PF-03716539 3 mg oral solution, single dose
47920065|NCT00783484|OTHER|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
47920066|NCT00783484|DRUG|PF-03716539|PF-03716539 100 mg oral solution, single dose
47920067|NCT00783484|DRUG|PF-03716539|PF-03716539 200 mg oral solution, single dose
47920068|NCT00783484|DRUG|PF-03716539|PF-03716539 50 mg oral solution, single dose
47920069|NCT00783484|OTHER|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
47920070|NCT00783484|DRUG|Midazolam|Midazolam 1 mg IV, single dose
47920071|NCT00783484|DRUG|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
47920072|NCT00783484|DRUG|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
47920073|NCT00783484|DRUG|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
48093153|NCT02390297|GENETIC|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
48093154|NCT04018664|DRUG|Nalbuphine HCl solution|nalbuphine solution administered at various strengths
48093155|NCT04018664|DRUG|Placebo solution|Placebo
48093156|NCT03106961|DEVICE|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
48093157|NCT03680014|DIAGNOSTIC_TEST|CUSH|Machine learning assisted remote monitoring/ telehealth platform to predict and prevent falls
48093158|NCT00501241|DRUG|ATI-7505|Tablet,placebo, BID
48093159|NCT00501241|DRUG|ATI-7505|ATI-7505 20 mg BID for 4 weeks
47920074|NCT00783484|DRUG|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
48093160|NCT00501241|DRUG|ATI-7505|tablet, 40 mg, BID, $ weeks
48093161|NCT00501241|DRUG|ATI-7505|80 mg ATI-7505, BID for 4 weeks
48093162|NCT00501241|DRUG|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
48093163|NCT00733460|DRUG|BFPET|
47920075|NCT00783484|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
48093164|NCT01796093|DRUG|Digoxin and ivabradine|No more details
48093165|NCT00304811|DRUG|Vancomycin|
48093166|NCT00304811|DRUG|Vancomycin plus Gentamicin|
48093167|NCT00304811|DRUG|Vancomycin plus Rifampin|
48093168|NCT00304811|DRUG|Vancomycin plus Gentamicin plus Rifampin|
48093169|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
48093170|NCT00884611|DEVICE|Predictive Low Glucose Suspend Algorithm OFF|
48093171|NCT02301234|DRUG|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
48093172|NCT02301234|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
48093173|NCT02301234|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
48093174|NCT02301234|DRUG|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
48093175|NCT02301234|DRUG|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
48093176|NCT04459832|PROCEDURE|stretch hamstring|Stretching of the hamstring muscles was performed by the primary researcher. A straight-leg-raising technique was used for this stretch because we believe that it is commonly used in the clinical setting for elderly people. All subjects were supine lying as flat as possible
48093177|NCT06313723|OTHER|Prenatal education management delivered via podcast|Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure
48093178|NCT04478175|OTHER|multidisciplinary assessment and intervention|early multidisciplinary assessment and intervention in addition to usual patient care
48093179|NCT01065272|DRUG|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
48093180|NCT01065272|DRUG|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
48093181|NCT02679768|BEHAVIORAL|Circadian Reinforcement Therapy|Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.
47920076|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
47920077|NCT00783484|DRUG|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
48093182|NCT02679768|BEHAVIORAL|Standard treatment|Standard treatment plus electronical monitoring
48093183|NCT05675306|BEHAVIORAL|Dynamic Temporal and Tactile Cueing Treatment|"DTTC is a dynamic, motor-based treatment approach designed for children with severe CAS. This approach is based on Integral Stimulation (Edeal \& Gildersleeve-Neumann, 2011; Maas \& Farinella, 2012; Maas et al., 2019; Strand \& Debertine, 2000; Strand \& Skinder, 1999), in which the clinician instructs the child to listen to me, watch me, and do what I do and systematically taxes and supports the speech motor system to facilitate system-wide change in speech output (Strand, 2020)."
48093184|NCT06163482|OTHER|Mixed meal|Each individual will ingest 5 mL/kg of Boost energy drink.
48093185|NCT00255021|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
48093186|NCT05092932|OTHER|Normal Foot Force|LoadSol Insoles will be inserted into the participants shoes. The device measures the pressure distribution on the bottom of the foot. Participants will then be asked to walk normally, use crutches, use a walker, and use a wheeled knee scooter. The pressure placed throughout the foot will be analyzed and compared under different conditions. This testing will take approximately 10 minutes.
48093187|NCT06224075|BEHAVIORAL|Task-specific training|"Participants in the intervention group will receive the treatment established for the control group and nursing care based on task-specific training. The intervention was designed with the aim of improving inhaler management in COPD patients. The content of the tasks will be adapted to the different types of devices present in the patient's therapeutic regimen, mainly pressurized cartridge and dry powder devices.~In order to carry out the intervention, several tasks related to education, assessment and/or training will be established with the aim of improving the ability to use the prescribed inhalers. The tasks have been classified into 3 blocks: technique execution, device cleaning and medication administration."
48093188|NCT06224075|OTHER|Usual care|All patients will receive standard treatment during their hospital stay (medical and pharmacological care). This treatment will include steroids, antibiotics, inhaled bronchodilators and oxygen therapy. In addition, during hospitalization they may receive diuretics, anticoagulants and cardiovascular treatments if necessary.
48093189|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
47920078|NCT00783484|DRUG|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
48270123|NCT00773279|DEVICE|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
48270124|NCT00773279|DEVICE|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
48093190|NCT00350532|DRUG|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
47920079|NCT00875693|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
47920080|NCT04909983|DEVICE|DPLX-PT1|A polymer skin patch for occlusional therapy
47920081|NCT04909983|OTHER|Control arm|Standard of care
47920082|NCT00749047|DRUG|Pioglitazone|15-45 mg/day
48093191|NCT01456663|DRUG|AFQ056|
47920083|NCT04981613|DRUG|Kunxian capsule|Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
47920084|NCT06288464|DIETARY_SUPPLEMENT|Soluble Fibre|Patients will be assigned to stoma feeding by the Colorectal Surgeon, which will be managed by the stoma nurses for the duration, approximately 4 weeks, of feeding. For the final 7-14 days (minimum 7 days) of feeding, 10g of soluble fibre will be added to 100ml of Ensure™ (or equivalent liquid nutrient feed) before instillation into the stoma on a daily basis. The soluble fibre will be provided in 10g portions and should be added to the newly-opened bottle of ensure and shaken to mix well.
47920085|NCT03537300|BEHAVIORAL|DCF muscles training using pressure biofeedback in addition to conventional exercises|DCF muscles training using pressure biofeedback in addition to conventional exercises
47920086|NCT03537300|BEHAVIORAL|conventional exercises|conventional exercises
47920087|NCT04650867|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of the bowel wall (terminal ileum, ascending caecum/colon, transverse colon, descending colon, and sigmoid colon).
47920088|NCT04478344|OTHER|Ultrasound guided hydrodissection of superior cluneal nerve|Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
48093192|NCT01649726|PROCEDURE|Apnea test - control|
48093193|NCT01649726|PROCEDURE|Apnea test - CPAP|
48093194|NCT03197311|OTHER|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
48270125|NCT05315609|BEHAVIORAL|VR Meditation|This 4-week VR program will use the Oculus Pro-Quest 2 headsets for the 15-minute seated VR meditation twice per week for a total of 8 sessions over the 4 weeks.
48270126|NCT04285775|DEVICE|Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)|A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
47920089|NCT01643421|OTHER|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
48093195|NCT03992638|PROCEDURE|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
47920090|NCT04306796|DEVICE|3D printed splints|3D printed made to measure splints
47920091|NCT04306796|DEVICE|Thermoplastic splints|thermoplastic splints individually adjusted by occupational therapists
48093196|NCT03992638|PROCEDURE|CAF|Completing root coverage by coronally advanced flap technique alone
48093197|NCT05387928|DRUG|KL340399 injection|KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
48093198|NCT01855308|PROCEDURE|Single site robotic chole|Cholecystectomy
48270127|NCT03585855|OTHER|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
47920092|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25ug + spacer|
47920093|NCT00536913|DRUG|Budesonide/formoterol pMDI 40/2.25 ug|
48093199|NCT01855308|DEVICE|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
48093200|NCT03805958|PROCEDURE|realtime ultrasonography|Applying realtime ultrasound during the combined anesthesia
48093201|NCT03805958|PROCEDURE|prescan ultrasonography|Applying realtime ultrasound before the combined anesthesia
48093202|NCT00361998|DRUG|NITROFURANTOIN MACROCRYSTALS|
48093203|NCT01238029|DRUG|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
47920094|NCT01311024|BIOLOGICAL|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
47920095|NCT01311024|BIOLOGICAL|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
47920096|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
47920097|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
48093204|NCT02698462|OTHER|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
48093205|NCT04623723|OTHER|PS (DS-016A, EMS® Piezon, Switzerland) scaler tips. )|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using PS (DS-016A, EMS® Piezon, Switzerland) scaler tips
48093206|NCT04623723|OTHER|Conventional (FS-407, EMS® Piezon, Switzerland)|Supragingival scaling with a portable ultrasonic scaler device (EMS®) with Piezon, Switzerland using Conventional (FS-407, EMS® Piezon, Switzerland)
48093207|NCT01154686|BEHAVIORAL|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
48093208|NCT01444976|DRUG|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
47920098|NCT02968537|BEHAVIORAL|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
48093209|NCT01444976|BEHAVIORAL|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
48093210|NCT01444976|DRUG|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
48093211|NCT01454362|DRUG|Nicotine|Inhalation of nicotine.
48093212|NCT00913432|DRUG|masitinib|3 mg/kg/day oral route
48093213|NCT00913432|DRUG|masitinib|masitinib 6 mg/kg/day oral route
48093214|NCT06391203|PROCEDURE|Long-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 7 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
48093215|NCT06391203|PROCEDURE|Short-term Drainage|After drilling or puncture, the drainage catheter is indwelling continuously and keeps to drainage for 2 days. Keep incision sterility, record the daily fluid drainage flow, and perform biochemical and bacterial culture identification tests for CSF regularly. Removing drainage catheter when the allocated time is reached. If there is still unabsorbed effusion after the allocated time is reached, the catheter placement time is extended and the relevant information is recorded.
48093216|NCT02679651|OTHER|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
48093217|NCT02679651|OTHER|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
48093218|NCT02679651|OTHER|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
48093219|NCT02788656|DEVICE|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
47920099|NCT02968537|BEHAVIORAL|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
47920100|NCT02968537|BEHAVIORAL|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
47920101|NCT02968537|BEHAVIORAL|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
48093220|NCT02788656|DRUG|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
47920102|NCT05707039|OTHER|Open kinetic chain exercises|In open chain exercises extremities are free to move and there is no weight bearing.
47920103|NCT05707039|OTHER|Closed kinetic chain exercises|In closed kinetic chain exercises extremities are fixed and weight bearing is done.
47920104|NCT02767297|DRUG|FDL169|
48093221|NCT02788656|DRUG|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
48093222|NCT02788656|DRUG|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
48093223|NCT06438757|DRUG|JYB1904|Participants will receive JYB1904 every 8 weeks for 24 weeks.
47920105|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of lower mean BP
47920106|NCT04339244|OTHER|RALRP under lower mean BP|RALRP under regulation of highly normal mean BP
47920107|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 1|Description in the arm description
47920108|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 2|Description in the arm description
48093224|NCT06438757|DRUG|Omalizumab|Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
47920109|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 3|Description in the arm description
47920110|NCT05424640|DIETARY_SUPPLEMENT|Dietary fiber 4|Description in the arm description
48093225|NCT06613594|OTHER|Conventional physical therapy|Patients will receive hot pack, Broom stick ROM exercises, Codman and strengthening exercises. A total of 10 sessions, 5 sessions per week for 2 consecutive weeks.
48093226|NCT06613594|OTHER|Kaltenborn traction mobilization|kaltenborn direction non specific traction mobilization for (1 minute), 3 sets of 10 reps with 1 minute rest in between will be given.
48093227|NCT06613594|OTHER|Kaltenborn translatoric glides|Kaltenborn direction specific linear tranlatoric glides, rhtymic 5reps of each glide, such anterior glide for extension and external rotation, caudal glide for abduction,post glide for flexion and internal roation,these3 sets of painless glides will performed with 10 reps,rest of 1 minutes between these sets.
48093228|NCT02091063|DRUG|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
47920111|NCT05204693|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
47920112|NCT05204693|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
47920113|NCT02760498|DRUG|cemiplimab|
47920114|NCT02730013|BEHAVIORAL|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
47920115|NCT02384915|DRUG|prilocaine|
47920116|NCT02384915|DRUG|mepivacaine|
47920117|NCT02384915|PROCEDURE|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
47920118|NCT02384915|PROCEDURE|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
47920119|NCT02384915|DEVICE|Sonoplex, Pajunk|
47920120|NCT00922727|BIOLOGICAL|L. reuteri|The oil drops contains 10\^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10\^8 CFU/ 5 drops and less than 8 x 10\^8 CFU/ 5 drops.
48093229|NCT05191797|DRUG|Bomedemstat|Given PO
48093230|NCT05191797|BIOLOGICAL|Atezolizumab|Given IV
48093231|NCT05799560|OTHER|THERAPEUTIC TOUCH|Therapeutic touch will be done. It will be applied twice a week for two weeks, each application for 20 minutes.
47920121|NCT00922727|BIOLOGICAL|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops.
47920122|NCT01541397|DRUG|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
47920123|NCT05983081|PROCEDURE|Injection Treatment|Physical Therapy
48093232|NCT05799560|OTHER|REİKİ|It will be applied twice a week for two weeks, each application for 20 minutes.
48093233|NCT00004870|BIOLOGICAL|oblimersen sodium|
48093234|NCT00004870|DRUG|irinotecan hydrochloride|
48093235|NCT05682261|DIETARY_SUPPLEMENT|UNIMMAP-MMS|The study participants in this arm will receive the United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) containing 15 micronutrients including 30 mg of iron and 400 µg of folic acid.
47920124|NCT00748852|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
47920125|NCT04135170|COMBINATION_PRODUCT|ALBC vs plain bone cement|The patients undergoing full-cemented primary total knee arthroplasty are allocated to either ALBC or plain bone cement and compare the effectiveness of ALBC use vs pain bone cement bone cement without antibiotic) with respect to revision due to PJI one year after primary TKA surgery.
47920126|NCT04636983|DRUG|BV100|Rifabutin IV
48270128|NCT04297358|DRUG|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
47920127|NCT04636983|DRUG|Placebo|Saline
47920128|NCT04499313|DRUG|Dexamethasone|Injectable solution
47920129|NCT04499313|DRUG|Methylprednisolone|Injectable solution
47920130|NCT02237534|DRUG|Lanthanum carbonate|
47920131|NCT02237534|DRUG|Calcium Carbonate|
47920132|NCT03241147|DRUG|Lu AF35700|Single dose, 10 mg film coated tablet
47920133|NCT03725228|DRUG|Magnesium Sulfate|Magnesium Sulfate 15mg/kg/h
47920134|NCT03725228|DRUG|Lidocaine|Lidocaine 1,5mg/kg/h
47920135|NCT03390842|DRUG|TRC101|Oral suspension
47920136|NCT03390842|DRUG|Placebo|Oral suspension
47920137|NCT00827138|DRUG|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
47920138|NCT06529978|DEVICE|CoreMap EP Mapping System Mapping|Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.
47920139|NCT06529978|DEVICE|CoreMap EP Mapping System Map-Guided Ablation|Initial development and evaluation of a map-guided tailored ablation strategy.
47920140|NCT00381290|BEHAVIORAL|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
47920141|NCT00381290|BEHAVIORAL|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
47920142|NCT04566887|DRUG|Acalabrutinib|Administered as 100mg tablets.
47920143|NCT04566887|DRUG|R-CHOP chemotherapy|R-CHOP chemotherapy
47920144|NCT00171522|DRUG|Tegaserod and Polyethylene Glycol 3350|
47920145|NCT05668988|DRUG|DZD9008|orally, 300 mg, once daily until a treatment discontinuation criterion is met.
47920146|NCT05668988|DRUG|Pemetrexed+carboplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
47920147|NCT04502940|DIAGNOSTIC_TEST|Flow Cytometric analysis|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
48093236|NCT05682261|DIETARY_SUPPLEMENT|IFA|The study participants in this arm will receive iron-folic acid supplements with 30 mg of iron and 400 µg of folic acid.
48093237|NCT05682261|OTHER|Placebo|The study participants in this arm will receive placebo made of sugar (lactose anhydrous).
48270129|NCT05726357|PROCEDURE|vital pulp therapy|removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp
48298815|NCT00818142|BEHAVIORAL|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
47920148|NCT01486082|OTHER|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
47920149|NCT04120311|DRUG|Episcleral Dexamethasone|Sustained Release Episcleral Dexamethasone
47920150|NCT00773838|DRUG|Vorinostat|Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.
47920151|NCT00773838|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
47920152|NCT00773838|DRUG|Dexamethasone|Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
47920153|NCT01701388|DEVICE|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
47920154|NCT01978938|DRUG|Eravacycline|
47920155|NCT01978938|DRUG|Levofloxacin|
47920156|NCT01024309|PROCEDURE|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
47920157|NCT01024309|PROCEDURE|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
47920158|NCT04013685|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
47920159|NCT02227940|DRUG|Ceritinib|Given PO
47920160|NCT02227940|DRUG|Cisplatin|Given IV
47920161|NCT02227940|DRUG|Gemcitabine Hydrochloride|Given IV
47920162|NCT02227940|OTHER|Laboratory Biomarker Analysis|Correlative studies
47920163|NCT02227940|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
47920164|NCT02227940|OTHER|Pharmacological Study|Correlative studies
47920165|NCT03798678|DRUG|Carfilzomib|Given IV
47920166|NCT03798678|DRUG|Dexamethasone|Given PO
47920167|NCT03798678|DRUG|Telaglenastat Hydrochloride|Given PO
47920168|NCT00921167|DRUG|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks
47920169|NCT00156936|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
47920170|NCT00156936|DRUG|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
47920171|NCT01124864|DRUG|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
47920172|NCT00670943|OTHER|Platelet function testing|
47920173|NCT03310060|DRUG|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
47920174|NCT03310060|DRUG|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
47920175|NCT03336593|BIOLOGICAL|Quadrivalent Influenza Vaccine|1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
47920176|NCT03336593|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
47920177|NCT05768022|OTHER|Cura Kensio-tapping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length.
47920178|NCT05768022|OTHER|placebo|placebo taping
47920179|NCT05339867|BEHAVIORAL|Prevent Maternal Mortality using Mobile technology (PM3)|"PM3: The app will include:~1. integrated self-management and tailored health messaging feature~2. support center based on social support gaps which will also provide a centralized place for identifying healthcare providers and facilities~3. multimedia resource kit comprised of videos, current events, news feeds, podcasts, and support groups related to women's postpartum health and community resources~4. a feature that will update women on maternal and reproductive health policies that impact women."
47920180|NCT05283512|OTHER|Preventive treatment with IV-hydration|IV hydration with isotonic 0.9% NaCl
48620270|NCT02382302|DEVICE|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
47920181|NCT05283512|OTHER|Preventive treatment with oral hydration|Oral hydration with regular bottled water
47920182|NCT03692819|DRUG|Placebo Oral Tablet|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
47920183|NCT03692819|DRUG|Amoxicillin 500 Mg|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
47920184|NCT03692819|DRUG|Lactobacillus reuteri Oral Drops|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
47920185|NCT00529607|DRUG|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
47920186|NCT00529607|PROCEDURE|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
47920187|NCT00529607|PROCEDURE|cardiac MRI|before discharge and after 6 months
47920188|NCT00529607|PROCEDURE|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
47920189|NCT00294086|DRUG|valsartan 160 mg|
47920190|NCT00294086|DRUG|valsartan 160 mg BID|
47920191|NCT00927004|DRUG|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
47920192|NCT00927004|DRUG|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
47920193|NCT05730803|OTHER|dietary intervention|During the iodine balance period of pregnant women, seaweed was added to lunch on the 4-6 days of the experiment, and the iodine content was about 200 μg.
47920194|NCT00252252|DEVICE|VPAP non-invasive ventilator|
47920195|NCT00252252|DEVICE|AutoVPAP non-invasive ventilator|
47920196|NCT01078818|DRUG|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h"
48620271|NCT00870142|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
47920197|NCT01078818|DRUG|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
47920198|NCT01078818|DRUG|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
47920199|NCT01906996|PROCEDURE|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
47920200|NCT01906996|PROCEDURE|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
47920201|NCT05352633|DRUG|Intensive BP Arm|Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals: Angiotension converting enzyme (ACE)-inhibitors;Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
47920202|NCT05352633|DRUG|Standard BP Arm|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
47920203|NCT00689117|DRUG|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
47920204|NCT00689117|DRUG|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
47920205|NCT00689117|DRUG|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
47920206|NCT00689117|DRUG|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
47920207|NCT02883257|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
47920208|NCT00756912|DRUG|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
47920209|NCT03278067|OTHER|Enhanced vaccine safety surveillance|Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
47920210|NCT05382442|DRUG|AK112|AK112 via intravenous (IV) infusion until disease progression or unacceptable toxicity
47920211|NCT05382442|DRUG|AK117|AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity
47920212|NCT05382442|DRUG|Oxaliplatin|Oxaliplatin via IV infusion
47920213|NCT05382442|DRUG|Capecitabine|Capecitabine via oral,The total daily dose was 2000mg/sqm, Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
47920214|NCT05382442|DRUG|Irinotecan|Irinotecan via IV infusion
47920215|NCT05382442|DRUG|Leucovorin|Leucovorin via IV infusion
48620272|NCT00870142|DRUG|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
47920216|NCT05382442|DRUG|5-fluorouracil|5-fluorouracil via IV infusion
47920217|NCT03608358|DRUG|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
47920218|NCT03608358|DRUG|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
47920219|NCT03608358|DRUG|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
47920220|NCT03608358|DRUG|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
47920221|NCT03608358|DRUG|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
47920222|NCT03608358|DRUG|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
47920223|NCT03464292|DRUG|Capsaicin Patch 8% or 0.1% Capsaicin Cream|0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
47920224|NCT03464292|OTHER|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin.
47920225|NCT02756429|OTHER|blood samples|Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
47920226|NCT01464281|DRUG|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
47920227|NCT04636216|BEHAVIORAL|COPE parent training|Weekly 1.5 hour parent training meetings for eight weeks
47920228|NCT05916599|DEVICE|ultrasound|a device which is used in intensive care units,
47920229|NCT04903743|DRUG|bupivacaine|group B received 28ml of 0.25% bupivacaine and 2ml normal saline
47920230|NCT04903743|DRUG|magnesium sulfate|group BM received 28 ml of 0.25% bupivacaine and 2 ml magnesium sulfate 10%.
47920231|NCT05473078|OTHER|online anonymous exploratory study|online self-administered questionnary
47920232|NCT01300013|DRUG|Placebo|48-hour infusion of placebo
47920233|NCT01300013|DRUG|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
47920234|NCT05253261|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|CBCT scans (Green X, Vatech, Hwaseong, Korea) are carried out prior to cystostomies. The scanning conditions are constant at 200 µm isotropic voxel size with 360° rotation, 94 kV tube voltage, 7.2 mA tube current and 9 s exposure time with a 15 × 8 cm field of view field of view (FOV).
47920235|NCT05253261|PROCEDURE|tooth removal and cystostomy|Surgical interventions are carried out in local anaesthesia. If it is deemed that a tooth or teeth included in the odontogenic cyst is of hopeless prognosis, it is removed at the time of cystostomy procedure. During cystostomy a bony window is created to accessthe cyst. The lining of the cyst is opened to accomodate the tube of the decompression appliance. A sample from the lining of the cyst is sent for histologic evaluation to confirm the diagnosis of odontogenic cyst.
47920236|NCT05253261|PROCEDURE|Decompression|The decompression appliances is delivered in the same sitting as the cystostomy. Patients are instructed on how to wear and clean their decompression device and are recalled for clinical examinations.
47920237|NCT05253261|DIAGNOSTIC_TEST|Postoperative Cone Beam Computed Tomography (CBCT) scan|Postoperative CBCT examination is performed six months into the decompression period using the same scanning conditions as those used for the preoperative CBCT scan.
47920238|NCT05253261|PROCEDURE|Cyst Enucleation|Following the decompression period enucleation of the remaining cyst is carried out in local anaesthesia.
48620273|NCT00097435|DRUG|Albuferon|
48620274|NCT00097435|DRUG|Ribavirin|
47920239|NCT03433612|OTHER|Classic Intercristal Line Technique|"Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
47920240|NCT03433612|OTHER|Novel SAIL Technique|"Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
47920241|NCT01112449|OTHER|Placebo|no active medication
47920242|NCT01112449|DIETARY_SUPPLEMENT|selenomethionine|200 µg/day of selenomethionine (SM)
47920243|NCT01112449|DIETARY_SUPPLEMENT|low dose selenized-yeast|200 µg/day of SY
47920244|NCT01112449|DIETARY_SUPPLEMENT|high dose selenized-yeast|285 µg/day of SY
47920245|NCT01681355|OTHER|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
47920246|NCT05146947|DEVICE|near infrared spectroscopy|near infrared spectroscopy monitoring on kidney after reperfusion
47920247|NCT00006233|BIOLOGICAL|therapeutic allogeneic lymphocytes|
47920248|NCT00006233|DRUG|cyclosporine|
47920249|NCT00006233|DRUG|fludarabine phosphate|
47920250|NCT00006233|DRUG|mycophenolate mofetil|
47920251|NCT00006233|PROCEDURE|peripheral blood stem cell transplantation|
47920252|NCT00006233|RADIATION|radiation therapy|
47920253|NCT04489069|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging (sturctural MRI, fMRI resting state and task related, DTI)
48620275|NCT02867852|DRUG|Abiraterone acetate|Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 \[CYP17\]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
47920254|NCT04489069|DIAGNOSTIC_TEST|Clinical and Neuropsychological evaluations|Clinical interviews and neuropsychological tests (paper/pencil and computer based)
47920255|NCT04489069|DIAGNOSTIC_TEST|Drawing DNA sample|Saliva sample
47920256|NCT00486811|DRUG|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
47920257|NCT00486811|DRUG|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
47920258|NCT00486811|DRUG|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
47920259|NCT01809639|DRUG|Progesterone|
47920260|NCT01809639|DRUG|Placebo|Standard placebo
47920261|NCT05237089|OTHER|Electroacupuncture|Regular acupuncture will be applied at the main and the additional acupoints with 0.25mm\*40mm or 0.30mm\*75mm needles. The main acupoints include Shangwan (CV13), Zhongwan (CV12), Jianli (CV11), Xiawan (CV10), bilateral Quchi (LI11), Hegu (LI4), Liangmen (ST21), Tianshu (ST25), Daheng (SP15), Fujie (SP14), Shuidao (ST28), Zusanli (ST36), Fenglong (ST40), Wailing (ST26), Guilai (ST29). Additional acupoints include bilateral Shangjuxu (ST37) and Neiting (ST44), bilateral Yinlingquan (SP9) and Shuifen (CV9), Qihai (CV6) and Guanyuan (CV4). Acupuncturists will use all main acupoints and choose the combined acupoints based on the patients' patterns during each treatment session. The EA apparatus will be connected to the needles at the bilateral ST21, ST25, SP15, using continuous wave type, frequency at 3 Hz, and intensity of 4-5 mA based on the endurance of each patient. Needles will be retained for 30 minutes before removal.
47920262|NCT05237089|OTHER|Sham acupuncture|Patients will receive superficial acupuncture treatment at the same main acupoints as EA group with 0.22\*0.25mm needles. The electroacupuncture apparatus will connected to the needles at the bilateral Liangmen (ST21), Tianshu (ST25), Daheng (SP15) without current output. Needles will be retained for 30 minutes before removal. The treatment will be given 3 times a week in week 1-12, 2 times a week in week 13-20, and once a week in week 21-24, totaling 56 sessions of real or sham acupuncture.
48620276|NCT02565251|DEVICE|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
47920263|NCT05237089|OTHER|Health education|The health management brochure will be distributed to all patients in the trial after enrollment, and health education will be arranged online or offline at week 4, 8, 12, 16, 20 and 24 for about 60 minutes, including lifestyle, diet and physical activity. According to the specific situation of each patient, healthier individual lifestyle and behavior will be recommended to all patients, but there will be no strict restrictions on the diet or physical activity.
47920264|NCT05771883|DRUG|IMM0306|IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα. The Fc segment of the recombinant protein in IMM0306 is IgG1 and has been modified by ADCC-enhanced genetic engineering.
47920265|NCT05771883|DRUG|Lenalidomide capsule|Chemical name 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidin-2,6-dione, molecular formula C 13H 13 N 3 O 3, is an anti-tumor drug developed by Celgene Biopharmaceutical Company in the United States, with multiple effects such as anti-tumor, immunomodulatory and anti-angiogenesis
47920266|NCT00502411|DRUG|Doxorubicin|17.5 mg/m\^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
47920267|NCT00502411|RADIATION|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
47920268|NCT02671513|DRUG|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
47920269|NCT00095940|DRUG|lapatinib ditosylate|Given orally
47920270|NCT00095940|PROCEDURE|therapeutic conventional surgery|Undergo surgery
47920271|NCT00095940|OTHER|laboratory biomarker analysis|Correlative studies
47920272|NCT00095940|OTHER|pharmacological study|Correlative studies
47920273|NCT00095940|PROCEDURE|positron emission tomography|Correlative studies
47920274|NCT00095940|PROCEDURE|magnetic resonance imaging|Correlative studies
48620277|NCT02565251|DEVICE|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
47920275|NCT00892801|DRUG|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
47920276|NCT00892801|RADIATION|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
47920277|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C gummy|vitamin C
47920278|NCT03562988|DIETARY_SUPPLEMENT|Vitamin C tablet|vitamin C
47920279|NCT01930578|OTHER|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
47920280|NCT01930578|OTHER|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
47920281|NCT01930578|OTHER|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
47920282|NCT00094484|DRUG|Cinacalcet HCl|
47920283|NCT00149318|OTHER|Biochemical analyses.|Biochemical analyses.
47920284|NCT00000485|DRUG|diuretics|
47920285|NCT00000485|DRUG|antihypertensive agents|
47920286|NCT01787162|OTHER|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
47920287|NCT02919358|OTHER|Music|
47920288|NCT02919358|OTHER|No music.|This is the control group.
47920289|NCT02873949|BIOLOGICAL|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
47920290|NCT02873949|BIOLOGICAL|Saliva samples (1ml)|
47920291|NCT02873949|OTHER|Etiologic treatment|education on oral hygiene, scaling and root planing
47920292|NCT02873949|OTHER|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
48620278|NCT02565251|DEVICE|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
47920293|NCT00783198|BIOLOGICAL|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
47920294|NCT00783198|BIOLOGICAL|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
47920295|NCT00783198|BIOLOGICAL|Placebo|matching placebo sublingual tablets administered once daily
47920296|NCT01318824|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
47920297|NCT01318824|PROCEDURE|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
47920298|NCT03618355|DRUG|eRapa (encapsulated rapamycin)|"The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels."
47920299|NCT02766140|DRUG|SHR1020 plus Docetaxel|SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
47920300|NCT02766140|DRUG|Placebo plus Docetaxel|Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
47920301|NCT06092944|PROCEDURE|Catheterization|Before the operation,the patient was placed in the left lateral position.The catheter（soft tip epidural catheter 20-gauge-100 cm） was placed at the rhomboid-intercostal plane under ultrasound guidance at the T5-T6 level, followed by ultrasound-guided catheter placed in the anterior serrated muscle plane at the T7-9 level。
47920302|NCT06092944|PROCEDURE|Single nerve block|Before the operation,40milliliters of 0.3% ropivacaine was injected into the rhomboid-intercostal fascia plane and anterior serrated muscle plane respectively under the guidance of ultrasound.
47920303|NCT06092944|PROCEDURE|Continuous nerve block|After surgery,local anesthetics were injected continuously through catheters.Local anesthetic formula:Ropivacaine 300mg + normal saline, prepared into 150milliliters liquid, background dose 2milliliters/h.
47920304|NCT06092944|PROCEDURE|PCIA|After surgery, the patient was given controlled intravenous analgesia. Analgesic pump drug formula:Sufentanil 50ug+ Dezocine 20mg+ Granisetron 10mg+150milliliters saline, continuous dose of 2milliliters/h intravenous pump, single injection dose of 2milliliters, locking time of 20 min
47920305|NCT05404672|OTHER|Aerobic Training|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control. In addition to this Aerobic Training (cycling, treadmill) will also be practiced for 30 minutes constituting 5 days/ week. Initial training would avoid upright position. Mild-to-moderate-intensity endurance training, progressing from semi-recumbent to upright position plus strength training will be practiced.
47920306|NCT05404672|OTHER|Conventional Treatment|Progressive breathing retraining exercises for a period of 4 weeks, for 15 minutes twice daily. As patients progressed to the seated posture, the controlled pause technique (exercise) will be introduced. 4 times a day followed by a sustained period of breathing control.
47920307|NCT03220451|PROCEDURE|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
47920308|NCT05829785|DEVICE|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vascular occlusion test
47920309|NCT05200234|DRUG|Nattokinase|Nattokinase + standard treatment
47920310|NCT05200234|DRUG|Placebo|Placebo+ standard treatment
47920311|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Vero cells）|The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
47920312|NCT03873740|BIOLOGICAL|EV71 inactived vaccine（Human diploid cells）|The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
47920313|NCT01295879|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
47920314|NCT04955600|OTHER|Implementation Study|Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
47920315|NCT04484571|DEVICE|Neuroexsos elbow module|The treatment group will be further divided into two levels (sub-groups), based on pathological severity: Level 1 corresponds to an FM score equal or below 28, and Level 2 with FM greater than 28. The two sub-groups will receive different combinations of robotically assisted passive mobilization (PM) and active mobilization (AM) treatment modalities, according to their differing clinical needs
47920316|NCT05539300|DIAGNOSTIC_TEST|PSMA-PET/CT response evaluation|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront enzalutamide therapy
47920317|NCT02674204|DRUG|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
48298816|NCT05517759|OTHER|Educational program|The sessions were delivered in form of face to face, group disscussion, brainstorming and smart cards. The educational package covered all aspect of knowledge regarding VAP such as definitions, risk factors m cause, manifestation, diagnostic criteria, and nursing care to prevent VAP. A PowerPoint and information pamphlet were used to display the material.
47920318|NCT02674204|DRUG|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
47920319|NCT01206322|DRUG|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
47920320|NCT01206322|DRUG|Placebo|The acute effects of intranasal sterile saline.
47920321|NCT05412602|PROCEDURE|full spine corrective protocol|36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
47920322|NCT04185116|DEVICE|3D Optic System (Olympus VISERA Elite II 3D)|"Use of the 3D Optic System Olympus VISERA Elite II 3D"
47920323|NCT01832584|DIETARY_SUPPLEMENT|RGC|
47920324|NCT01832584|DIETARY_SUPPLEMENT|Placebo|
47920325|NCT05646017|DEVICE|Intermittenly scanned continuous glucose monitoring|Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre)
47920326|NCT02060916|DRUG|PAZ320|Single-center pilot study, open label dose escalation design
47920327|NCT05825157|DEVICE|BioBridge|Fibralign BioBridge is a thread-like, multi-lumen scaffold consisting of highly aligned collagen fibrils, optimized to encourage the endothelial cell attachment,alignment and migration that are prerequisites to new vessel formation. BioBridge is a device made from highly purified, medical-grade porcine collagen.
47920328|NCT06393556|OTHER|Virtual reality experience|An immersive VR experience, delivered using a VR head-mounted display, of the real-world environment at the hospital, featuring the pre-operative admission suite, pre-anesthetic bay, operating theatre, postoperative recovery room, and medical staff.
47920329|NCT05254977|DRUG|Standard Preparation|Any kind of intervention received to reduce adverse effects
47920330|NCT06238102|OTHER|pure tone audiometry|measuring hearing impairment to select patients with hearing loss to evaluate who can this hearing impairment affects their quality of life
47920331|NCT06420609|OTHER|Go-TAD|The participants will receive a medical visit that will include the 4 open-ended questions comprising the Go-TAD intervention
47920332|NCT01980589|DRUG|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
47920333|NCT01980589|DRUG|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
47920334|NCT01980589|DRUG|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
47920335|NCT00614770|PROCEDURE|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
47920336|NCT00614770|PROCEDURE|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
47920337|NCT00614770|PROCEDURE|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
47920338|NCT01624246|DRUG|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
47920339|NCT01754402|DRUG|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
47920340|NCT01754402|DRUG|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
47920341|NCT01754402|DRUG|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
47920342|NCT04495205|BIOLOGICAL|PRF under non-eugenol containing periodontal pack|Platelet Rich Fibrin under non-eugenol containing periodontal pack
48298817|NCT01595256|BEHAVIORAL|muscular strength|12-week moderate intensity walking program
48298818|NCT00734409|DEVICE|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
48298819|NCT02314208|DRUG|Xenbilox|
47920343|NCT04495205|OTHER|Non-eugenol containing periodontal pack|Non-eugenol containing periodontal pack after gingival depigmentation
47920344|NCT03011944|OTHER|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
47920345|NCT04034667|OTHER|No intervention|No intervention
47920346|NCT05604378|PROCEDURE|Gastrectomy|All patients in our study underwent gastrectomy.
47920347|NCT01014910|OTHER|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
47920348|NCT01014910|DEVICE|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
47920349|NCT02881567|DRUG|Daclizumab|High yield formulation
47920350|NCT00116298|DRUG|stavudine, efavirenz, lamivudine|
47920351|NCT05089422|PROCEDURE|Squint surgery|Lateral rectus recession and /or medial rectus resection
47920352|NCT01386970|DRUG|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
47920353|NCT00585598|OTHER|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
47920354|NCT01533740|DRUG|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
47920355|NCT00824837|OTHER|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
47920356|NCT00824837|OTHER|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
47920357|NCT02029300|OTHER|Fiberoptic Intubation through the nasal route|
47920358|NCT02029300|OTHER|Fiberoptic intubation through the oral route|
47920359|NCT02716012|DRUG|MTL-CEBPA|Intravenous administration
47920360|NCT02716012|DRUG|Sorafenib 200mg|Sorafenib tablets
47920361|NCT03571698|DEVICE|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
47920362|NCT02760225|DRUG|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
48093238|NCT05376579|OTHER|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
47920363|NCT02760225|DEVICE|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
47920364|NCT03891797|OTHER|Cognitive Processing Therapy|Group-based psychotherapy.
47920365|NCT05040113|DRUG|CBP-307|CBP-307 capsules oral administration
47920366|NCT04671446|DIAGNOSTIC_TEST|Autoantibody ELISA|Serum will be tested for novel autoantibodies against eosinophil proteins by ELISA, such as those previously identified as of importance (e.g. eosinophil-peroxidase, EPX) and also novel candidate proteins specific to eosinophils (including ARFIP1, BCL2A1, PPCDC, SLC12A6 etc) as identified by FANTOM5 geneset analysis.
47920367|NCT01033149|DRUG|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
47920368|NCT04580641|OTHER|Questionnaire|A self-administered questionnaire will be completed by each study subject
47920369|NCT01714791|OTHER|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
47920370|NCT01714791|OTHER|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~* Structural High Velocity Low Amplitude-techniques.~* Muscle Energy Techniques.~* General osteopathic mobilisations.~* Functional techniques (Sutherland-, Jones-techniques,...) including inhibition techniques.~* Fascia techniques.~* Soft tissue- and connective tissue techniques.~* Neurovisceral and neurolymphatic reflex techniques.~* Fluidal techniques (lymphatic manipulative techniques,...).~* Visceral manipulations.~* Neurocranial and viscerocranial techniques."
48298820|NCT02314208|DIETARY_SUPPLEMENT|Resveratrol|
48298821|NCT02314208|DRUG|Tahor|
47920371|NCT05787600|DRUG|Perhyal rinse|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
47920372|NCT05787600|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
47920373|NCT05787600|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
47920374|NCT01146457|DRUG|Morphine|Active dosage
48093239|NCT05627765|BEHAVIORAL|Standard treatment (ST) arm|Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
47920375|NCT01146457|DRUG|Saline|Saline Control
48093240|NCT05627765|OTHER|Integrated Intervention (II) arm|Participants will receive brief advice on alcohol use based on the FRAMES model, which is a well-established and effective brief intervention for drinking.
47920376|NCT02433509|OTHER|HUCB monocyte cells|"1. The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million \~ 500 million will used.~2. 20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
48093241|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose|administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
47920377|NCT01349049|DRUG|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
48093242|NCT00810303|DRUG|Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)
48093243|NCT00810303|DRUG|Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
48093244|NCT00810303|DRUG|Sustiva (efavirenz) single dose|administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
47920378|NCT01349049|DRUG|PLX3397|The drug product is available in capsule form, to be taken orally.
48093245|NCT06614816|BIOLOGICAL|Oka strain varicella attenuated live vaccine|lyophilized powder, subcutaneous injection
48093246|NCT06376890|DIETARY_SUPPLEMENT|Red chili peppers|2.4 grams/day of powdered red chili pepper
48093247|NCT06376890|DIETARY_SUPPLEMENT|Green Chili Pepper|2.4 grams/day of powdered green chili peppers
48093248|NCT06376890|DIETARY_SUPPLEMENT|Placebo|2.4 grams of a metabolically equivalent placebo
48093249|NCT06421974|PROCEDURE|DaVinci si or xi system|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
47920379|NCT03774056|DRUG|HC-1119|oral
47920380|NCT05772585|OTHER|Blood collection|Blood collection (1 to 4 times for each patient) in order to perform metabolomic analyses of the plasmatic fingerprints of patients with hepatic encephalopathy
47920381|NCT05638919|DRUG|Oral Antiviral|Nirmatrelvir plus ritonavir or molnupiravir
47920382|NCT02114658|DRUG|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
47920383|NCT01543581|DRUG|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
47920384|NCT01543581|DRUG|Placebo|
47920385|NCT00920803|DRUG|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
47920386|NCT00920803|DRUG|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
47920387|NCT00287417|DEVICE|echography|
47920388|NCT00287417|OTHER|blood sample|
48093250|NCT06421974|PROCEDURE|laparoscopic radical resection|In this study, subjects were randomly divided into an experimental group (robot-assisted radical resection of right colon cancer group, referred to as robotic surgery group) and a control group (laparoscopic radical resection of right colon cancer group, referred to as laparoscopic surgery group).
48093251|NCT06309043|DRUG|recombinant anti-EGFR human/murine chimeric monoclonal antibody injection|a single dose，250 mg/m2
48093252|NCT01570777|PROCEDURE|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
48298822|NCT04822363|DRUG|Aspirin|Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
47920389|NCT06105905|BEHAVIORAL|"Healthy futures (Futuros Saludables)"|The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and 2 sessions for parent/guardian(s). Feedback on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Participants will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. After the delivery of the intervention, facilitators will take field notes and complete a debriefing questionnaire to assess practicality and fidelity. Parent/guardians will complete a 5 minute pre- and post- intervention survey. Teens will complete a 15 minute survey pre-intervention, immediately post-intervention, three-month, six-month, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors.
47920390|NCT01104532|DRUG|ASP1941|oral tablet
47920391|NCT01104532|DRUG|sitagliptin|oral tablet
47920392|NCT03817086|BEHAVIORAL|Hand coordination and mental practice|"20 chronic (\>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group)."
47920393|NCT03817086|BEHAVIORAL|Hand coordination and action observation|In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
47920394|NCT04635800|DRUG|MHU650|MHU650 powder for solution for injection
47920395|NCT01798160|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
47920396|NCT01798160|PROCEDURE|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
47920397|NCT05887583|BEHAVIORAL|The Rising New York Road Runners program|The Rising New York Road Runners program provides lesson plans covering fundamental movement skills that are intended to build competence, confidence, and motivation to be physically activity. Family engagement materials (emails, text messages, videos, social media) complement school materials to communicate what children are learning at school related to physical activity and what activities families can do at home together to reinforce these concepts.
48093253|NCT01570777|PROCEDURE|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
48093254|NCT06303986|DEVICE|Neomonki|The Neomonki is a monitoring kit for hospital use in neonates with Neonatal Abstinence Syndrome (NAS).
48093255|NCT04440228|BEHAVIORAL|TeamSTEPPS|"TeamSTEPPS is an evidence-based approach for teams that can be adapted for school mental health.~Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS), has been widely disseminated in health care settings with promising outcomes. TeamSTEPPS is designed to build competencies in the areas of leadership, situation monitoring, mutual support, and communication and has been associated with improvements in teamwork and communication as well as patient outcomes, such as decreased seclusion in psychiatric hospitals."
48093256|NCT00002956|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
48093257|NCT05169567|DRUG|Abemaciclib|Administered orally.
47920398|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~1. Check head and cannula position~2. Increase mean arterial pressure~3. Increase pump flow~4. Increase systemic oxygenation~5. Increase PaCO2 \> 45~6. Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~7. Consider PRBC transfusion for Hct \< 21%"
48093258|NCT05169567|DRUG|Fulvestrant|Administered IM.
48093259|NCT05169567|DRUG|Placebo|Administered orally.
48093260|NCT00252993|DRUG|DDP225|
48093261|NCT03666429|DEVICE|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
48093262|NCT03666429|DEVICE|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
48093263|NCT02978456|DEVICE|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus \~10% of distal reference vessel diameter).
48093264|NCT02978456|DEVICE|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
48093265|NCT02493790|OTHER|Cognitive and motor performances|
48093266|NCT03454243|DRUG|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
47920399|NCT01149148|DEVICE|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
47920400|NCT02587182|DEVICE|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
48298823|NCT04822363|DRUG|Clopidogrel|Arms C and E
48443542|NCT05065866|DRUG|BMS-986345|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
47920401|NCT01061255|OTHER|Evaluation of the stress|"Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).~Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.~Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender."
47920402|NCT05981781|PROCEDURE|ultrasound guided peng block in paediatric hip surgery|"On the supine position, under strict aseptic technique, a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed in the transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral artery, and femoral nerve. The probe will be then rotated, and aligned with the pubic ramus to visualize the AIIS, iliopubic eminence (IPE), femoral artery, psoas muscle, and the superior pubic ramus.~Under direct visualization, a needle will be advanced in-plane, lateral to medial between the psoas tendon and pubic ramus until the needle contacts the IPE. The needle will be slightly withdrawn, and following negative aspiration, 0.5 ml/kg of bupivacaine 0.25% will be injected."
47920403|NCT05981781|PROCEDURE|ultrasound guided caudal epidural block in paediatric hip surgery|On lateral decubitus position, under strict aseptic technique, the sacral hiatus will be visualized at the level of the sacral cornua by employing a linear, high-frequency transducer (5-13 MHz) of a Sonosite (M-Turbo; Sonosite Inc, Bothell, W, USA) portable US machine will be placed transversely at the midline to obtain a transverse view of the two cornua, sacrococcygeal ligament, sacral bone, and sacral hiatus. At this level, the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and subsequently placed between the two cornua. A needle will be advanced toward the upper third of the sacrococcygeal ligament. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament. (17) At this level, after confirming absence of blood or cerebrospinal fluid on aspiration, bupivacaine 0.25% (0.5 mL/kg) will be injected over 1 minute while observing an ultrasound longitudinal image.
47920404|NCT01251536|DRUG|Dose escalation of cetuximab|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
47920405|NCT01251536|DRUG|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
47920406|NCT00526916|DRUG|[C-11]PBR28|
47920407|NCT03550521|BEHAVIORAL|Mindfulness|Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
47920408|NCT03438370|OTHER|Three monthly ART supply at CAGs|Sites where three monthly ART supply will be provided at outreaches
47920409|NCT03438370|OTHER|Six monthly ART supply at outreaches|Sites where six monthly ART will supply will be provided at outreaches
47920410|NCT01853488|RADIATION|DXA|Osteodensitometry
47920411|NCT01853488|RADIATION|pQCT|Osteodensitometry
47920412|NCT03087799|BEHAVIORAL|Brief Behavioral Treatment for Sleep|The BBT arm will consist of 2 in-person treatment visits and 2 telephone check-in visits. Treatment will involve psychoeducation about sleep hygiene and stimulus control as well as sleep schedule modification and sleep restriction. The treatment manual is attached for clarification. This manual is used solely to guide clinical decision making and will not be provided to participants.
47920413|NCT05030285|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
47920414|NCT05229497|DRUG|AK112|IV infusion,Specified dose on specified days
47920415|NCT05229497|DRUG|AK117|IV infusion,Specified dose on specified days
47920416|NCT05229497|DRUG|Carboplatin|IV infusion,Specified dose on specified days
47920417|NCT05229497|DRUG|Cisplatin|IV infusion,Specified dose on specified days
47920418|NCT05229497|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
48093267|NCT03326479|DIAGNOSTIC_TEST|Caris Molecular Intelligence Profile|A comprehensive biomarker testing
48093268|NCT02295475|DRUG|Apixaban|
48093269|NCT02295475|DRUG|Warfarin|
48093270|NCT06340243|RADIATION|radiotherapy|radiotherapy
48093271|NCT01582243|DRUG|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
48093272|NCT03683355|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
48093273|NCT06508099|DRUG|Vitamin A|300 000 IU single dose orally
48093274|NCT06508099|DRUG|Vitamin D3|100 000 IU single dose orally
48093275|NCT00917189|BEHAVIORAL|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
48093276|NCT00955461|PROCEDURE|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
48093277|NCT00955461|PROCEDURE|Fractionated Laser treatment|
48093278|NCT03685747|DRUG|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
48093279|NCT00767715|DRUG|olanzapine|physician determined dose, oral, daily, 5 months
48093280|NCT00767715|DRUG|haloperidol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
48093281|NCT00767715|DRUG|zuclopentixol|physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months
48093282|NCT04709731|DRUG|Ponatinib 15mg QD|Ponatinib 15 mg tablet, taken orally once daily
47920419|NCT02712047|DRUG|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
47920420|NCT02712047|DRUG|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
47920421|NCT02712047|DRUG|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
47920422|NCT00645437|DRUG|Levofloxacin|
47920423|NCT02864862|DEVICE|Immediate implant|
47920424|NCT02864862|BIOLOGICAL|SCTG|
47920425|NCT02864862|BIOLOGICAL|ADM|
48093283|NCT04709731|DRUG|Ponatinib 30mg QD|Ponatinib 30 mg tablet, taken orally once daily
48093284|NCT01369355|DRUG|Placebo SC|Placebo will be administered subcutaneously.
48093285|NCT01369355|DRUG|Placebo IV|Placebo will be administered as a single Intravenous infusion at week 0.
47920426|NCT03118661|OTHER|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
47920427|NCT03118661|PROCEDURE|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
48093286|NCT01369355|DRUG|Ustekinumab 90 mg SC q8w|Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
48093287|NCT01369355|DRUG|Ustekinumab 130 mg IV|Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
47920428|NCT03528499|OTHER|Scapular Movement Training|Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.
48093288|NCT01369355|DRUG|Ustekinumab 90 mg SC q12w|Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
47920429|NCT03528499|OTHER|General Exercises|Strengthening and stretching exercises.
47920430|NCT01737593|DRUG|Acetaminophen|
47920431|NCT06491368|PROCEDURE|Cesarean Delivery|A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.
47920432|NCT02659748|DIETARY_SUPPLEMENT|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
47920433|NCT02659748|DIETARY_SUPPLEMENT|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
47920434|NCT01789398|DRUG|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
47920435|NCT00245167|PROCEDURE|Tracheal Aspirate Fluid|
47920436|NCT05006742|PROCEDURE|CB study arm|Included patients are randomized to receive cryobiopsy
47920437|NCT05006742|PROCEDURE|FB-CB study arm|Included patients are randomized to receive forceps biopsy and cryobiopsy within the same session
47920438|NCT04170972|OTHER|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
47920439|NCT03904056|PROCEDURE|ISQ-RP|"Patients were treated with single-spot targeted retinal photocoagulation directed toward areas of retinal nonperfusion detected by fluorescein angiography. In this group, laser treatment was performed in two sessions (week 0 and 2), with a shot duration of 100 ms, but spots were placed 1/2 burn apart and power modulated in order to generate moderately white spots on the retina.~Retinal photocoagulation was performed with single-spot full-scatter PRP using Purepoint green diode laser (Alcon, Fortworth, Texas) with an Ocular Mainster PRP 165 lens with a dynamic field of view of 180 degrees, and a 200 micron spot size (which produces a 392 micron spot size on the retina). Intravitreal injection of 0.5 mg (0.05 ml) ranibizumab (Lucentis®) (IVR) were performed 180 minutes after the first laser session (week 0) by a single retina specialist."
47920440|NCT03904056|PROCEDURE|ETDRS-PRP group|Panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab
47920441|NCT01250444|OTHER|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
47920442|NCT00146484|DRUG|Twice Daily versus Three Times Daily Insulin Injections|
47920443|NCT01860729|DRUG|Anacetrapib|
47920444|NCT01860729|DRUG|Placebo|
48093289|NCT03298087|PROCEDURE|radical prostatectomy|surgical removal of the prostate
48093290|NCT03298087|RADIATION|stereotactic body radiotherapy|Highly targeted radiation
48093291|NCT03298087|DRUG|Leuprolide|Lowers serum testosterone
48093292|NCT03298087|DRUG|apalutamide|antiandrogen
48093293|NCT03298087|DRUG|abiraterone|Inhibits androgen synthesis
48093294|NCT05983692|DEVICE|Magnesium based wire|Mg wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft
48093295|NCT02928939|OTHER|drug-drug or drug-disease interaction|
48093296|NCT00003311|BIOLOGICAL|filgrastim|
48093297|NCT00003311|DRUG|cyclophosphamide|
48093298|NCT00003311|DRUG|cytarabine|
48093299|NCT00003311|DRUG|dexamethasone|
48093300|NCT00003311|DRUG|doxorubicin hydrochloride|
48093301|NCT00003311|DRUG|methotrexate|
48093302|NCT00003311|DRUG|vincristine sulfate|
48093304|NCT00420472|DRUG|mycophenolate mofetil [CellCept]|
47920445|NCT03917407|DRUG|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
47920446|NCT03917407|DRUG|DUR-928 (Severe AH)|"Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study."
48093305|NCT06310239|OTHER|Collection of biologic samples and data|"* collection of skin flora samples via swabs~* data collection regarding subject's medications See Detailed Description in Study Description section above for more details"
48093306|NCT05341167|DEVICE|HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
47920447|NCT01394640|BIOLOGICAL|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
47920448|NCT04183361|DIAGNOSTIC_TEST|ABR and salivary cortisone testing|"Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold."
47920449|NCT03353233|DRUG|Ropivacaine|Local anesthetic (numbing drug)
47920450|NCT03353233|PROCEDURE|Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
47920451|NCT03353233|DRUG|Saline|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
47920452|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
47920453|NCT04153708|BEHAVIORAL|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
47920454|NCT05827471|DIAGNOSTIC_TEST|Diagnosis of colon cancer|Clinical diagnosis results
48093307|NCT05341167|DRUG|Vasoactive Agent|Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
48093308|NCT04880070|DEVICE|Shockwave Treatment|Self-controlled, single-arm group using the Shockwave device.
48093309|NCT05166343|DRUG|Epinephrine Injection|Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
48093310|NCT05331495|DEVICE|Intraoperative Hemoperfusion|During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
48093311|NCT06577857|DEVICE|Inferonasal Minimally Invasive Micro Sclerostomy|The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
47920455|NCT05279573|DIETARY_SUPPLEMENT|Omega-3 and/or botanical ingredient|Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
48093312|NCT05210140|DRUG|Escitalopram|"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is commercially known as ELORYQA®, Elicea®, Escital®,PRAMES® or Lata® in Serbia. The recommended dose for Major depressive disorder is 10mg/day. Based on the individual response, dose can be adjusted and the maximum dose is 20 mg/day; 5 mg/day dose is also available. Escitalopram is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia) and Panic disorder (with or without agoraphobia) by Medicines and Medical Devices Agency of Serbia.~In known CYP2C19 poor metabolizers, initial dose should be 5mg/day during first 2 weeks, and based on the individual response it can be increased up to maximum of 10 mg of escitalopram per day, according to the guidelines of Medicines and Medical Devices Agency of Serbia."
48093313|NCT05833360|DEVICE|Exai oncRNA blood test|A phlebotomist will collect approximately 40 ml (about 2-3 tablespoons) of blood from the subjects after consent. The Exai oncRNA blood test will be run on the blood samples.
48093314|NCT04550039|DEVICE|Body-weight-supported treadmill|Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
47920456|NCT05279573|OTHER|Control product consumption|Product with identical characteristics to the experimental product. Consumption for 60 days. Subjects should consume two capsules in the morning and two capsules in the afternoon.
47920457|NCT05650411|DEVICE|LMCA PCI with Biofreedom Ultra drug-coated stent (Biosensors International, Switzerland)|Successful LMCA PCI with ≥1 BioFreedom Ultra polymer-free drug-coated stent (Biosensors International, Switzerland).
47920458|NCT05650411|DRUG|P2Y12 inhibitor-based SAPT after short DAPT|Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years. Aspirin stopped after LMCA or at latest at hospital discharge.
48093315|NCT04550039|DEVICE|Ekso Bionics EksoNR exoskeleton|Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
47920459|NCT05650411|DRUG|Conventional DAPT|6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
47920460|NCT06097390|DRUG|Semaglutide|Oral administration
48093316|NCT00855192|BEHAVIORAL|mindful meditation|interpersonal and psycho-educational
48093317|NCT00855192|BEHAVIORAL|interpersonal therapy|psycho-educational
48093318|NCT00874796|DRUG|GS-9450|Taken as one capsule by mouth once daily
48093319|NCT00874796|DRUG|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
47920461|NCT04193462|OTHER|Post-partum depression- Dyadic psychotherapy-|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity. Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant. During the whole therapy-trial, the therapist will also use cognitive-behavioral approach to address the mother's perception of her infant and of herself as a mother.
47920462|NCT04193462|OTHER|Post-partum depression- Psycho-educational therapy|Mothers will receive a therapy in their homes for 8 weeks, 1.5 hours for each session by a therapist arriving at their home. Each session will address a different developmental aspects of the baby (feeding, movement, social-emotional development etc.). Therapist will ask the mother about her baby, will give information about developmental needs and expectations and will help mother to enrich child's development and deal will potential problems
47920463|NCT03348436|PROCEDURE|radiofrequency ablation|
47920464|NCT05990595|DIETARY_SUPPLEMENT|Adlay with white rice|We will investigate the lipid- and glucose-lowering effects of Adlay rice in comparison to white rice through a randomized cross-over trial.
47920465|NCT05990595|DIETARY_SUPPLEMENT|white rice|white rice
47920466|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
48093320|NCT00000764|DRUG|Isotretinoin|
48093321|NCT00000764|DRUG|Interferon alfa-2a|
47920467|NCT01433250|DRUG|AIN457|(10mg/kg i.v.).
47920468|NCT02360683|OTHER|patients with Parkinson's disease|
47920469|NCT04683601|OTHER|Thoracoscopic esophagectomy in left decubitus|Making surgical field at thoracoscopic esophagectomy in left decubitus
47920470|NCT01998568|OTHER|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
48093322|NCT00353145|DRUG|Gemcitabine (Gemox)|1000 mg/m\^2, infused at 10 mg/m\^2/min on Day 1 repeated every 14 days (one cycle).
48093323|NCT00353145|DRUG|Oxaliplatin|100 mg/m\^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
48093324|NCT00353145|BEHAVIORAL|Questionnaire|Quality of Life Surveys
48093325|NCT01878890|DRUG|Efavirenz 600mg|Efavirenz 600 mg (oral daily intake)
48093326|NCT01878890|DRUG|Efavirenz 1200 mg|Efavirenz 1200mg (oral daily intake)
47920471|NCT03878433|DRUG|Glisodin|500 mg/day between 12 weeks
47920472|NCT03878433|OTHER|placebo|Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
47920473|NCT03127332|OTHER|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
48093327|NCT01878890|DRUG|Efavirenz 1800 mg|Efavirenz 1800mg (oral daily intake)
48093328|NCT01878890|DRUG|Efavirenz 2200 mg|Efavirenz 2200mg (oral daily intake)
48093329|NCT05948098|BEHAVIORAL|Facilitated Tucking Position|a sub-form of method of nesting the baby and the procedure of bringing the body to middle or even close position by holding the upper and lower extremities of the baby in flexion with hands
48093330|NCT05948098|BEHAVIORAL|Gentle Human Touch|It is a form of healing touch
48093331|NCT05406986|OTHER|care bundle application|The patients in the experimental group will be given care according to the current care bundle for 14 days
48093332|NCT01251614|BIOLOGICAL|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
48093333|NCT01251614|DRUG|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
48093334|NCT01251614|BIOLOGICAL|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
48093335|NCT01251614|DRUG|Placebo to Methotrexate|Orally once a week
48093336|NCT01461356|PROCEDURE|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
48093337|NCT01461356|PROCEDURE|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
48093338|NCT00789061|DRUG|Proton pump inhibitor|One dosage/day/year
47920474|NCT04356261|BEHAVIORAL|Gamified Personalized Normative Feedback|Each week, all players will answer 3 questions of interest about first-year students' attitudes and behaviors (e.g., drinking, partying, exercising, studying, dorm life, etc.) generated by the student players. They will also guess how the typical same-sex student at their University answered the same questions and wager points on how close to the correct answer (group norm) each of their guesses is. Further, they will rate (e.g., thumbs up/thumbs down) the reported behaviors of other players and, then, submit and vote on questions for subsequent rounds. At the end of each week, players will receive enhanced personalized normative feedback feedback on two of the three questions, and receive feedback on how other students rated the answer they reported (preferred-sex injunctive norms).
47920475|NCT05020015|BIOLOGICAL|TAK-007|TAK-007 intravenous injection.
47920476|NCT05020015|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide as per standard of care.
48093339|NCT05864768|DIETARY_SUPPLEMENT|Vegan/vegetarian diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
48106730|NCT04041999|BEHAVIORAL|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
48270130|NCT04134494|DEVICE|Ablative Fractional 2940 nm Laser|"* Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~* Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~* Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚."
48270131|NCT02538484|DRUG|Letrozole|Aromatase inhibitor
47920477|NCT03124667|BEHAVIORAL|Games|The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
47920478|NCT03124667|BEHAVIORAL|Videos|The video training will emphasize health and educational information.
47920479|NCT03900689|OTHER|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
47920480|NCT03900689|OTHER|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
47920481|NCT02660138|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
47920482|NCT02660138|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
47920483|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
47920484|NCT02660138|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
47920485|NCT01258569|DRUG|Entereg|Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
47920486|NCT01258569|DRUG|Entereg|oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
47920487|NCT01258569|DRUG|placebo|12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
47920488|NCT02323100|DRUG|Ravicti low dose|8 am, 4pm and midnight
47920489|NCT02323100|DRUG|Ravicti high dose|8 am, 4pm and midnight
47920490|NCT02323100|DRUG|Placebo|8 am, 4pm and midnight
47920491|NCT06071429|DEVICE|MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold|CLTI patients treated with MAGNITUDE BRS
47920492|NCT06071429|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|CLTI patients treated with PTA
47920493|NCT00994344|DRUG|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
47920494|NCT00994344|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
47920495|NCT03618589|DRUG|Pregabalin|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
47920496|NCT03618589|DRUG|Opioid|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
47920497|NCT06020872|OTHER|Health literacy program|Health literacy program was the health education related to healthy plate.
47920498|NCT06286254|DRUG|Cycloferone|Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
48093340|NCT05864768|DIETARY_SUPPLEMENT|Omnivorous diet|"At baseline, following the compilation of a periodontal chart in which pocket probing depth (PPD) and FMPS and FMBS were recorded, patients with pathological probing depths \>3mm associated with periodontitis were excluded. Healthy patients underwent a prophylaxis session and oral hygiene instructions with brushing and flossing. A mouthwash based on chlorhexifdine 0.20% to be used twice a day was prescribed.~At 15 days from the baseline (T0) the periodontal chart was compiled again and the parameters relating to PD, FMP, FMBS and the Eastman Interdental Bleeding Index (EIBI) were collected. Patients with FMBS and FMPS values \>20% were excluded.~From time T0 all patients were asked to suspend the interdental hygiene maneuvers by interrupting the use of dental floss and abandoning the use of mouthwash. All patients were recalled weekly, for a total of 4 times (T1, T2, T3, T4) in which parameters related to FMBS, FMPS and EIBI were recorded."
48106731|NCT03368833|DIAGNOSTIC_TEST|Electrocardiogram|12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
47920499|NCT02346773|DIETARY_SUPPLEMENT|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
47920500|NCT02346773|OTHER|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
47920501|NCT03530709|OTHER|videoconferencing|Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
47920502|NCT00983008|BEHAVIORAL|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
47920503|NCT02862340|GENETIC|Genetic test|
47920504|NCT02192333|PROCEDURE|Management of Therapy Complications|Receive survivorship care
47920505|NCT02192333|OTHER|Quality-of-Life Assessment|Ancillary studies
47920506|NCT02192333|OTHER|Questionnaire Administration|Ancillary studies
47920507|NCT02192333|BEHAVIORAL|Telephone-Based Intervention|Receive phone-based booster intervention
47920508|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy with Splenectomy|
47920509|NCT01875198|PROCEDURE|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
47920510|NCT03896256|DRUG|ketamine infusion|Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
47920511|NCT04866745|DEVICE|Magnetotherapy plus exercise|The VARIMAG-4E magnetotherapy device will be used. It is a pulsed radiofrequency energy device. The device has a voltage of 220V, 4 amps of intensity, 50 Hz of frequency and a maximum power of 100 Gauss. For the active treatment application, the patient will be in supine position and will introduce both knees in the 50 cm coil in case of bilateral knee osteoarthritis. In the case of unilateral knee osteoarthritis, the affected knee will be introduced in the 30cm coil. The duration of the treatment will be 20 minutes, the frequency administered will be 50 Hz and a power of 100 Gauss.
47920512|NCT04866745|DEVICE|Microwave plus exercise|The application of deep heating therapy will be with the patient in a sitting position. The VARITRON 250-EP microwave device will be used with a frequency of 2450 MHz and a maximum output power of 250W. In the case of unilateral knee osteoarthritis, the circular applicator with a diameter of 170mm will be placed approximately 15 cm from the knee. The duration of the session will be 20 minutes, 10 minutes over the internal face and 10 minutes over the external face of the knee. In the case of bilateral knee osteoarthritis, the large lumbar applicator will be placed approximately 15 cm from the anterosuperior face of both knees for 20 minutes. The patient will have to perceive a moderate heat sensation.
47920513|NCT04866745|DEVICE|Sham Magnetotherapy plus exercise|The protocol and device will be the same in the active/placebo treatment. The sham device does not emit an electromagnetic field. The energy from the active device is not felt by the user, and the active device cannot be distinguished in any way from the placebo device.
47920514|NCT05302453|OTHER|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), which is among the body-mind approaches, is also frequently used in the rehabilitation of patients with psychiatric disorders, pain, and chronic musculoskeletal system problems.
47920515|NCT01317550|DRUG|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
47920516|NCT01317550|OTHER|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
47920517|NCT01317550|DRUG|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
47920518|NCT01317550|BEHAVIORAL|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
47920519|NCT00464880|DRUG|Aliskiren|
47920520|NCT05297318|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
47920521|NCT05297318|OTHER|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
47920522|NCT04663490|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
47920523|NCT01376518|PROCEDURE|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
47920524|NCT04549402|OTHER|Mirror Therapy group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
47920525|NCT04549402|OTHER|Video group|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, on time. The intervention will last 4 weeks, with a periodicity of 7 weekly sessions. In total there will be 28 sessions lasting between 15 and 45 minutes depending on the number of joints affected.
47920526|NCT06150118|BEHAVIORAL|CBT+VR (Cognitive behavioral therapy and virtual reality)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
47920527|NCT06150118|BEHAVIORAL|VR (Virtual reality)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
47920528|NCT06150118|BEHAVIORAL|CBT (Cognitive behavioral therapy)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
47920529|NCT06150118|BEHAVIORAL|Control|The investigators are testing whether the placebo control protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
47920530|NCT01736761|DRUG|Darunavir, Ritonavir and Rilpivirine|
47920531|NCT05667077|DRUG|Amantadine|The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks
47920532|NCT00335179|DRUG|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
47920533|NCT00335179|DRUG|Vehicle cream|Vehicle cream in 250 mg
47920534|NCT03712085|OTHER|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
47920535|NCT03712085|OTHER|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
47920536|NCT02183740|BEHAVIORAL|Multifaceted educational program|
47920537|NCT06063603|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
47920538|NCT06063603|BEHAVIORAL|Cancer Pain Management|Receive pain clinic referral
47920539|NCT06063603|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
47920540|NCT06063603|PROCEDURE|Discussion|Participate in focus group
47920541|NCT06063603|OTHER|Educational Intervention|Receive self-guided pain management education materials
47920542|NCT06063603|OTHER|Exercise|Participate in exercise
47920543|NCT06063603|OTHER|Interview|Complete interview
47920544|NCT06063603|PROCEDURE|Massage Therapy|Receive massage
47920545|NCT06063603|BEHAVIORAL|Mindfulness Relaxation|Practice mindfulness
47920546|NCT06063603|PROCEDURE|Pain Therapy|Receive pain treatment/medicine
47920547|NCT06063603|OTHER|Palliative Therapy|Receive palliative care referral
47920548|NCT06063603|BEHAVIORAL|Patient Navigation|Undergo visits with PCM and CHW for pain management
47920549|NCT06063603|OTHER|Referral|Receive pain management referrals
47920550|NCT06063603|PROCEDURE|Spiritual Therapy|Receive spiritual support
47920551|NCT06063603|PROCEDURE|Spiritual Care Referral|Receive spiritual care referral
48270132|NCT02538484|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 free fatty acid
47920552|NCT06063603|OTHER|Survey Administration|Ancillary studies
47920553|NCT04671732|PROCEDURE|Fenestrated endovascular aortic aneurysm repair|Fenestrated endovascular aortic aneurysm repair consists in excluding a juxtrenal or suprarenal aneurysm by deploying a covered stent (stent graft) in the aorta so as to created sealing zones on both sides of the aneurysm. Since the proximal sealing is located in the visceral segment of the aorta, fenestrations are created to maintain blod flow in renal and visceral arteries. These fenestrations are custom made for each patient. Brindging covered stents are deployed between each fenestration and corresponding target arteries in order to insure sealing of the system.
47920554|NCT04671732|PROCEDURE|open repair of abdominal aortic aneurysm.|Open repair of abdominal aortic aneurysms consists in cross-clamping the aorta on both sides of the aneurysm and replace the diseased segment by a prosthetic graft.
47920555|NCT00763503|DRUG|CD 2027|3µg/g Oily Spray
47920556|NCT03353740|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
47920557|NCT05468073|DRUG|Proleukin|Sub-cutaneous injections of Interleukin-2 (PROLEUKIN ®) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks
47920558|NCT05468073|DRUG|Placebo|Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
47920559|NCT03400267|DRUG|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
47920560|NCT03400267|DRUG|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
47920561|NCT00853216|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
47920562|NCT00853216|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
47920563|NCT02619539|PROCEDURE|plasma fibrinogen measurement|plasma fibrinogen measurement
47920564|NCT02027090|DRUG|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
47920565|NCT02027090|DRUG|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
47920566|NCT04628455|DEVICE|Inversion and snaring|"Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B \[midway between umbilicus and symphysis pubis\] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's \[Point C\] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port."
47920567|NCT03035474|OTHER|Digital Engagement|Patient engagement to improve self-management/medication adherence
47920568|NCT03035474|OTHER|Direct Engagement|Health system engagement to improve local QI programs
47920569|NCT02610504|DEVICE|Durolane|single injection of 3ml
47920570|NCT04620213|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
47920571|NCT04620213|OTHER|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
47920572|NCT00926029|DRUG|Fluoride|Brush twice daily
47920573|NCT00926029|DRUG|Triclosan, fluoride|Brush twice daily
47920574|NCT00926029|OTHER|Metal salt|Brush twice daily
47920575|NCT04646434|PROCEDURE|Electroencephalography|Undergo EEG
47920576|NCT04646434|PROCEDURE|Electromyography|Undergo EMG
47920577|NCT04646434|OTHER|Questionnaire Administration|Complete questionnaire
47920578|NCT04646434|PROCEDURE|Urodynamics (UDS)|Undergo UDS
47920579|NCT02553356|DRUG|PT2385|
47920580|NCT03808259|DRUG|(S)-ketamine Oral Thin Film|(S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
47920581|NCT03808259|DRUG|(S)-ketamine IV Infusion|(S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
47920582|NCT03808259|DRUG|Placebo|Participants will receive matching placebo.
47920583|NCT00766350|DRUG|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
47920584|NCT00766350|DRUG|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
47920585|NCT05197660|PROCEDURE|surgical procedures|number of hospital stays
47920586|NCT02935426|DEVICE|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
47920587|NCT02935426|DEVICE|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
47920588|NCT03881761|BIOLOGICAL|CD19/CD20 bispecific CAR-T cells|collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
47920589|NCT04379128|OTHER|Attentional tasks|a neuropsychological assessment of attentional task, executive task and interview is proposed to patients or normal control
47920590|NCT01256294|DRUG|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
47920591|NCT01256294|DRUG|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
47920592|NCT06275633|DRUG|Levodopa|Medicine response
47920593|NCT03890042|DRUG|Dienogest group|VISANNE 2MG Tablet once daily
47920594|NCT03890042|DRUG|Gestodene-Ethinyl Estradiol|Gynera tablet once daily
47920595|NCT03890042|RADIATION|Ultrasound|ultrasound assessment of uterine volume
47920596|NCT03890042|OTHER|visual analogue scale|visual analogue scale for assessment of pain
47920597|NCT02094768|DIETARY_SUPPLEMENT|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
47920598|NCT02094768|DIETARY_SUPPLEMENT|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
47920599|NCT05641389|OTHER|Monitoring|Participants will be monitored for alcohol use.
47920600|NCT00678756|DRUG|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
47920601|NCT00678756|RADIATION|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
47920602|NCT00943449|DRUG|4SC-201|oral administration
47920603|NCT00943449|DRUG|Sorafenib|oral administration
47920604|NCT04432727|DEVICE|Flexitouch Plus with Cellular Connectivity (FT-CC)|Daily use of FT-CC
47920605|NCT02706964|DEVICE|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
47920606|NCT02706964|DEVICE|Magnetic resonance imaging|A brain MRI will be performed.
47920607|NCT02706964|DEVICE|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
47920608|NCT05356156|PROCEDURE|Closure of the mesenteric defects|The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.
47920609|NCT05356156|PROCEDURE|Non-closure of the mesenteric defects|The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
47920610|NCT00680641|DRUG|Simvastatin|40mg of Simvastatin once daily
47920611|NCT00680641|DRUG|Placebo|40mg of placebo once daily
47920612|NCT03249662|PROCEDURE|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
47920613|NCT03249662|DRUG|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
47920614|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
47920615|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
47920616|NCT01473680|OTHER|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
47920617|NCT06277843|DEVICE|Thermal Jacket|In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention (Thermal Jacket) as a supplement of Kangaroo Mother Care (KMC).
47920618|NCT04865367|OTHER|Exposure to culture media|Exposure to culture media
47920619|NCT05984069|OTHER|observational prospective data collection|Collection of data from medical records.
47920620|NCT02470988|BEHAVIORAL|Cognitive Behavioural Analysis System of Psychotherapy|
47920621|NCT02470988|BEHAVIORAL|CBASP Without DPI|
47920622|NCT03897439|DRUG|Nicotine patch|Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
47920623|NCT03897439|DRUG|Varenicline Tartrate|VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
47920624|NCT03897439|DRUG|Bupropion|BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
47920625|NCT02553252|OTHER|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
47920626|NCT00266786|DRUG|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
47920627|NCT00266786|DRUG|Intranasal Placebo|Intranasal Placebo
47920628|NCT05216744|DRUG|Ceftriaxone 1000mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
47920629|NCT05216744|DRUG|Cefixime 800mg + doxycycline 100 mg|Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
47920630|NCT01395524|DRUG|NKTR-118|12.5 mg oral tablet once daily
48093341|NCT05357196|DRUG|PT-112|"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."
48093342|NCT06613451|OTHER|Mobile Application|Mobile Application Use on the Intravenous, Intramuscular and Subcutaneous Drug Administration
48093343|NCT06552234|DRUG|Repotrectinib|Repotrectinib 160 mg BID, until progression or unacceptable toxicity
48093344|NCT05638659|BEHAVIORAL|Computerized dual-task balance and home program|Portable force plate with aluminum top plate for measuring ground reaction forces, moments and the center of pressure in biomechanics. Through software to collect data from the force plates, converts the trials into useful information and plots the results. The force plates and charge amplifiers are fully remote controlled by software thus making the system extremely flexible and easy to use.
47920631|NCT01395524|DRUG|NKTR-118|25 mg oral tablet once daily
47920632|NCT01395524|DRUG|Placebo|Oral tablet intake once daily
47920633|NCT00600119|DRUG|placebo|placebo, oral, once daily (QD)
47920634|NCT00600119|DRUG|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
48093345|NCT05638659|BEHAVIORAL|Medical consultation and traditional balance training|Participants were assigned to read the health education flier and were assessed directly.
48093346|NCT06606613|PROCEDURE|Intraurethral injection|"Procedure: Intraurethral injection~Patients are positioned in the lithotomy position during the procedure. General and/or local anesthesia is administered depending on the investigator\&amp;amp;#39;s preference. An applicator developed for intraurethral injection will be used. This device comprises a holder that is placed into and fixates the urethra (i.e., it distends the urethral circumference, thus smoothing out the longitudinal folds), allowing the use of four syringes to inject cross-linked hyaluronic acid/dextranomer at approximately the 2, 4, 8, and 10 o'clock positions.~Drug: Cross-linked hyaluronic acid/dextranomer"
48093347|NCT06606613|PROCEDURE|Mid-urethral sling|"Procedure: Starting with the dorsal lithotomy position, a foley catheter is inserted to the urethra. Starting with 1-1.5 cm below the urethral meatus, a 1.5-2 cm vertical incision is made. Following the dissection of anterior vaginal mucosa, pubocervical fascia should be dissected sharply .~Dissection is continued laterally to the ischiopubic ramus. Starting downwards from the tendinous insertion of the adductor longus muscle at the level of clitoris, a 1cm incision is made close to the bone. The needle is placed in to the incision and passed medially through the obturator membrane. It has to be considered that the needle is passed very close to the bone in order not to damage the obturator vessel-nerve bundle. With the guidance of the opposite hand's index finger in the vaginal incision the tip of the needle has to be palpated afterwards passing with a 45-degree angle rotation. The next manoeuvre is passing the tip of the needle beside the urethra through the vaginal incision ."
48093348|NCT00984074|PROCEDURE|blood-oxygen-level-dependent functional magnetic resonance imaging|
47920635|NCT04802122|DRUG|Sevoflurane inhalant product|Sevoflurane 8% / O2 100% with the vital capacity breathing method (vital capacity induction, VCI) will be used for induction to anesthesia and facilitate endotracheal intubation.
48093349|NCT00984074|PROCEDURE|diffusion tensor imaging|
48093350|NCT00984074|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
47920636|NCT04802122|DRUG|Propofol Fresenius|Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% will be for induction to anesthesia and facilitate endotracheal intubation. .
48093351|NCT00984074|PROCEDURE|functional magnetic resonance imaging|
48093352|NCT00984074|RADIATION|intensity-modulated radiation therapy|
48093353|NCT00984074|RADIATION|radiation therapy treatment planning/simulation|
48093354|NCT00088465|DRUG|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
48093355|NCT06060418|OTHER|aromtherapy|aromatherapy with essential oil is being used as a non-pharmacological nursing intervention within the health care setting. This approach aims to manage the patient's discomfort and alleviate the symptoms of postoperative nausea and vomiting. One of the most beneficial oils is Lavender Essential Oil (LEO), which is used to treat a variety of digestive issues.
48093356|NCT06613945|PROCEDURE|ERCP biliary drainage|bilateral metallic stents insertion will be attempted through ERCP to secure biliary drainage
47920637|NCT05414357|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging at rest and in activation with attentional task|"Participants complete 3 successive assessments (T1: baseline, T2: at 6 months, T3: after galvanic vestibular stimulation). Assessments include:~* Functional and Anatomic Magnetic Resonance Imaging at rest and in activation (only at T1 and T2).~* Biological and physiological measurements~* Spatial memory task~* Cognitive battery~* Questionnaires (sleep, quality of life)"
48093357|NCT06613945|PROCEDURE|Combined ERCP and EUS-HGS biliary drainage|unilateral metallic stent will be inserted on right side by ERCP and a hepaticogastrostomy transmural stent will be inserted on left side by EUS to secure biliary drainage.
48093358|NCT05133167|PROCEDURE|Balloon Tamponade or B-Lynch|In group A, balloon tamponade (using Foley catheter 28 Fr) was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by measuring the amount of blood collected in Foley balloon tamponade bag, in milliliters. In group B, B lynch suture was used intra-operatively to prevent post-partum hemorrhage. Post-operative blood loss within first 24 hours was estimated by the weight difference of the pads before and after patient use (1-gram weight difference = 1 ml blood volume lost). Mean blood loss within first 24 hours post procedure, was compared in both the groups for outcome measurement.
48093359|NCT04908163|BEHAVIORAL|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
48093360|NCT04908163|BEHAVIORAL|Mediterranean diet-based culinary intervention|The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
48093361|NCT02919085|PROCEDURE|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
48093362|NCT02443792|PROCEDURE|Unicirc with tissue adhesive|As above
48093363|NCT02443792|PROCEDURE|Open Surgical|As above
48093364|NCT05149144|DIAGNOSTIC_TEST|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
48093365|NCT05149144|BEHAVIORAL|audio signal dataset creation and validation; machine learning analysis, empirical evaluations|The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
48093366|NCT06391177|DRUG|Vonoprazan|Oral tablet.
48106732|NCT01967186|PROCEDURE|Intraportal islet transplantation|
48106733|NCT01967186|PROCEDURE|Intramuscular islet transplantation|
48106734|NCT01967186|PROCEDURE|Intramuscular transpl with stemcells|
48106735|NCT01967186|PROCEDURE|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
47920638|NCT01180218|PROCEDURE|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
47920639|NCT01180218|PROCEDURE|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
47920640|NCT05634993|OTHER|Assessment|Assessment of disability level and trunk control
48106736|NCT00756743|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
48106737|NCT00756743|DRUG|Placebo|Placebo capsules q12 hours for 10 days
47920641|NCT04195971|DIAGNOSTIC_TEST|Liver CT|Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
48620279|NCT02827539|DEVICE|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
47914061|NCT03372902|PROCEDURE|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
47920642|NCT02495038|DRUG|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
47920643|NCT02495038|DRUG|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
47920644|NCT05122702|DRUG|modified Shenling Baizhu San|modified Shenling Baizhu San granules, twice daily for 12 weeks.
47920645|NCT05122702|OTHER|Placebo|Placebo granules, twice daily for 12 weeks.
47920646|NCT02382484|DEVICE|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
47920647|NCT03373903|OTHER|Placebo|oral
47920648|NCT03373903|DRUG|BEZ235|oral
47920649|NCT03373903|DRUG|BEZ235 plus everolimus (RAD001)|Oral
47920650|NCT02891928|DEVICE|Rocker sole shoes|Measure of walk testing Measure of standing position
47920651|NCT02891928|DEVICE|Normal shoes|Measure of walk testing Measure of standing position
47920652|NCT00030459|DRUG|cisplatin|
47920653|NCT00030459|DRUG|mitomycin C|
47920654|NCT00030459|DRUG|vinblastine sulfate|
47920655|NCT00030459|DRUG|vinorelbine tartrate|
47920656|NCT00835562|PROCEDURE|Non-surgical management|Non-surgical management (physiotherapy and self-training)
47920657|NCT00835562|PROCEDURE|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
47920658|NCT00835562|PROCEDURE|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
47920659|NCT04921813|OTHER|3 dimensional scoliosis exercise|Schroth exercises
47920660|NCT04921813|OTHER|Balance Exercise|Balance-coordination exercises
47920661|NCT04921813|OTHER|Brace treatment|Brace usage
47920662|NCT00223782|BEHAVIORAL|Gait Training with Feedback|
47920663|NCT00223782|BEHAVIORAL|Gait Training with no feedback|
47920664|NCT03027791|BEHAVIORAL|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
47920665|NCT03027791|BEHAVIORAL|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
47920666|NCT04162782|PROCEDURE|obstetric and gynaecological surgeries|surgeries for gynecologic and obstetric diseases
47920667|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin I
47920668|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula with Inulin II
47920669|NCT01515644|OTHER|Powder based infant formula|Powder based infant formula without Inulin
47920670|NCT05251402|BEHAVIORAL|Group A - Patient Education|"If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.~* In months 1-3, you will attend 3 individual and 8 group sessions. Individual sessions will last \~15 minutes and the first one will be in-person. Group sessions will last \~30 minutes and the first 2 of the 8 will be in person. You and your coach will determine if you may attend the remaining individual and group sessions remotely instead, via Zoom or phone. The purpose of these sessions is to provide you with general information about respiratory health topics, including recommendations for asthma care, inhaler use, and lung health.~* In months 4-12, you will complete 11 phone check-ins for \~10 minutes each. The purpose of these phone calls is to provide you with ongoing support and discuss health topics of your choice."
47914062|NCT03372902|BEHAVIORAL|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
47914063|NCT03877328|OTHER|BiotechCoachForAll|A group of thirty subjects diagnosed with heart failure (HF) of any etiology undergo an experimental procedure in the following order: resting-state (eyes-closed), passively viewing thirty two agents which are grouped with respect to different appearance characteristics and passively viewing combinations of virtual agents. During the experiment, brain activity, heart rate, skin conductance, temperature and eye-gaze biosignals are collected by means of electroencephalography, Empatica E4 and Gazepoint. Subsequently, a prospective cohort study is performed in a subgroup of ten participants which undergo a three additive stage procedure. Stage 1, a wearable monitoring device (Wavelet Health) is given in order to provide objective information on the patient's activity. Stage 2, the FitForAll physical exercise program is introduced. Stage 3, introduces the coaching aspects, where personalized recommendations and suggestions are delivered through home surfaces' projection.
47914064|NCT02469870|BEHAVIORAL|Autism Parent Trainer (APT)|Experimental condition
47914065|NCT02469870|BEHAVIORAL|Teaching Routines (Control)|Content comparison group.
47914066|NCT04787536|PROCEDURE|Non-cardiac surgery|Non-cardiac surgery excluding cranial neurosurgery
47914067|NCT03323281|OTHER|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
48093367|NCT01043731|PROCEDURE|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
48093368|NCT02831400|BEHAVIORAL|Walking test|Walking test to increase cardiac output, maximum 12 minutes
48093369|NCT02831400|BEHAVIORAL|Standard Meal|After the walking test, volunteers eat a standard warm meal
48093370|NCT00710164|DRUG|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
48093371|NCT00710164|DRUG|Placebo|14 days of Placebo
47920671|NCT05251402|BEHAVIORAL|Group B - Patient Education with Nutrition Counseling|"If you are assigned to this group, you will receive the same patient education as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.~* In months 1-3, the duration of the sessions will increase to \~30 minutes each for the 3 individual sessions and to \~60 minutes each for the 8 group sessions. This is because in addition to providing the same information on asthma and health as in Group A, your health coach will also counsel you on how to follow the DASH diet by adopting effective behavior change techniques such as goal setting, self-monitoring, and problem solving.~* In months 4-12, your health coach will review your progress, provide you with personalized feedback, assist you in problem solving as you continue to work towards the DASH dietary goals, and help you maintain the changes you have made over the long term."
47920672|NCT00576329|DRUG|Ketorolac|Topical use before surgery
48093372|NCT03233165|PROCEDURE|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
48093373|NCT03233165|PROCEDURE|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
48093374|NCT05913323|DEVICE|Rapid Expiratory Occlusion Monitor (REOM)|Device for which Health Canada approval (ITA Authorization) has been obtained for use in the present study.
48093375|NCT05913323|DIAGNOSTIC_TEST|Standard oscillometry|tremoflo device-100, Thorasys Thoracic Medical Systems Inc., Montreal, Canada
48093376|NCT05913323|DIAGNOSTIC_TEST|Standard pulmonary function test|Standard-of-care respiratory test.
48093377|NCT02424344|DRUG|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
47920673|NCT00527891|PROCEDURE|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
47920674|NCT03986372|BIOLOGICAL|Platlet-rich plasma|Multiple Platlet-rich plasma injection.
47920675|NCT02613273|BEHAVIORAL|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
48093378|NCT02424344|DRUG|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
48093379|NCT06522867|OTHER|Intraocular pressure measure|The intraocular pressure of the subjects using either the Goldmann applanation tonometer, Icare or Accupen. The order of the measure is randomized.
48093380|NCT00287638|DEVICE|CPAP|Continuous positive pressure device with a time clock
48093381|NCT00287638|DEVICE|placebo|no CPAP
47914068|NCT02140593|DRUG|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
47920676|NCT02613273|BEHAVIORAL|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
47920677|NCT06166121|OTHER|ShenJu|One package per time, twice a day, 90 days of treatment
47920678|NCT06166121|OTHER|Placebo|One package per time, twice a day, 90 days of treatment (the placebo was basically the same as ShenJu in terms of appearance, shape, color, taste, etc.)
47920679|NCT03012126|BEHAVIORAL|Healthy Weight Clinic|
47920680|NCT03012126|BEHAVIORAL|Healthy Weight and Your Child|
48093382|NCT05652608|BEHAVIORAL|Immune Strength|Multi-week wellness program provided by the Cleveland Clinic
48093383|NCT06614361|BEHAVIORAL|Health education on COVID and flu vaccination|1 session (30 min) with a health educator on vaccination
48093384|NCT06614361|BEHAVIORAL|Nurse-led shared decision-making|1 session and FU calls with a trained nurse
48093385|NCT06614361|BEHAVIORAL|Text messages|Health \&amp; wellness interactive text message (TM) intervention (12 weeks, 2 texts/week)
48093386|NCT06614361|BEHAVIORAL|Lottery prize for vaccination|Modest lottery prize for COVID vaccination
48093387|NCT06614361|BEHAVIORAL|Peer navigation|Peer navigation (4 months duration, contact as needed).
48093388|NCT00354029|DRUG|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
48093389|NCT00354029|DRUG|Placebo|isotonic saline
48093390|NCT05714553|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
48093391|NCT05714553|DRUG|Leucovorin|Intravenous infusion
48093392|NCT05714553|DRUG|Pembrolizumab|Intravenous infusion
48093393|NCT05714553|DRUG|Docetaxel|Intravenous infusion
48093394|NCT02190838|DRUG|Metformin|per os 850 mg BID
48093395|NCT02190838|DRUG|Melatonin|per os 3 mg daily
48093396|NCT02190838|DRUG|Dacarbazine|IV 1 hour 1000 mg/m\^2 once in 28 days
48093397|NCT06321159|OTHER|mobile application|mobile application for diet, exercises and medication adherence
47920681|NCT02634190|OTHER|Thinprep® LBC|liquid based cytology
48093398|NCT05452629|BEHAVIORAL|Mindfulness induction (MI)|In the MI condition, participants were guided to focus on present experiences regarding the thoughts, emotions and sensations through the three classic mindfulness exercises (i.e., focused breathing, meditation, and body scanning). The duration of MI was 30-minutes.
48093399|NCT05452629|BEHAVIORAL|Relaxation (RI)|In the RI condition, participants were guided to relax each muscle group following the audio for 30-minutes.
48093400|NCT02288858|DIETARY_SUPPLEMENT|Viviscal Oral Supplement Tablets|Tablet (512 mg)
48093401|NCT00000772|DRUG|Ribavirin|
48093402|NCT00000772|DRUG|Didanosine|
48093403|NCT00256139|DRUG|Raptiva|
48093404|NCT06439862|OTHER|Children with PUV|Male children aged 6 to 17 years old treated for PUV in their first year of life between 2006 and 2018 in Lyon, and managed in the Femme-Mère-Enfant Hospital in Lyon
48093405|NCT01577043|DRUG|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
48093406|NCT01577043|OTHER|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
48093407|NCT00375856|DEVICE|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
48093408|NCT06613607|OTHER|Core Strengthening|"Strengthening protocol will comprise of following three phases:~Warm up phase Following exercise would be performed in warm up; Scissor skier, Criss cross crunches, , Hip circles, Bent over twist.~Strengthening:~Abdominal bracing Bracing with heel slides Bracing with leg lifts Bracing with bridging Quadruped alternate arm and leg lifts with bracing Side support with knees flexed Cool down phase: Following exercise would be performed for cood down: Child's pose, Cat cow stretch, Lower back stretch, Obliques stretch"
48093409|NCT03256682|BEHAVIORAL|Stress management counseling|stress management counseling based on CBT and relaxation
48093410|NCT01151254|DRUG|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
48093411|NCT01151254|OTHER|Propofol|Propofol for sedation in the CVICU
48093412|NCT05238779|OTHER|Standard of care including palliative care|Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
48093413|NCT05753709|PROCEDURE|Hand sewn end-to-end anastomosis|Hand sewn end-to-end anastomosis (EE) Holding sutures were taken through a seromuscular bite with PDS (Polydiaxonone) 3-0 or Silk 2-0 RB (Round Bodied needle), one each at the mesenteric and antimesenteric ends of the stoma. A posterior layer of Lembert sutures was taken first. The first bite was taken at the anti-mesenteric end and a knot was applied. A Connell stitch was applied at the corner and then the posterior layer was closed using an inverting interlocking continuous stitch till the mesenteric end. Another Connell stitch was applied here to secure the corner and the suture was continued on to the anterior layer which was then closed in a similar manner using a continuous interlocking stitch. The final bite crossed the initial knot and the final knot was applied. An anterior layer of Lembert sutures was taken to reinforce the anastomotic line.
47920682|NCT02634190|OTHER|APTIMA® HPV Assay|in vitro diagnostic test
47920683|NCT02634190|OTHER|HR HC2® HPV DNA|in vitro diagnostic test
48093414|NCT05753709|PROCEDURE|Hand sewn side-to-side anastomosis|Hand sewn side-to-side anastomosis (HSSA) Each end of the stoma was closed using either a single layer of inverting interlocking continuous sutures with PDS 3-0 or Silk 2-0 RB, or a Linear Stapling device. The two closed stumps were then brought adjacent to each other in an anti-peristaltic arrangement. A posterior layer of Lembert sutures was applied using Silk 2-0 RB. The bowel wall was incised using electrocautery close to the suture line. The incision was lengthened up to a width of at least 5-6 cm. The posterior and anterior layer was now closed using the same technique as in HS using PDS 3-0. An anterior layer of Lembert sutures was applied. The mesenteric defect was then closed using a superficial interrupted layer of Silk 2-0 RB.
48093415|NCT05753709|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis or Functional End-to-end anastomosis (SSSA/FEEA) The two limbs of a Linear Cutter SR55 are placed into the proximal and distal bowel loops of the stoma, facing as far away from the mesenteric border as possible and then fired. If both lumens are of similar size, traction sutures are applied with Silk 2-0 RB at the anterior and posterior termination ends of the staple line. The two ends are pulled away from each other, and a Linear Cutter SR75 is applied just below the edge of the bowel and fired. However, in case of an ileo-colostomy, after the first linear cutter SR55 is fired, the two suture lines are approximated in such a way that they do not get apposed but rather lie adjacent to each other. The lumen is then clamped in SR75 which is then fired.
48093416|NCT06507254|DIETARY_SUPPLEMENT|Polyphenol Supplement|Dietary supplement taken twice daily for 12 months.
48093417|NCT06507254|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary supplement taken twice daily for 12 months.
48093418|NCT06370351|COMBINATION_PRODUCT|SENS-501 administration|Administration of SENS-501 with a dedicated administration system
48093419|NCT04859556|DEVICE|Alcon 25Gauge, 10,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
47914069|NCT02140593|DRUG|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
47914070|NCT04655352|DIETARY_SUPPLEMENT|Bacillus subtilis MB40|1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
47914071|NCT03815318|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
47914072|NCT00283335|DRUG|gemfibrozil|
47914073|NCT00283335|OTHER|Placebo|Matching placebo tablets taken once per day
47914074|NCT01426841|RADIATION|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
47914075|NCT00567398|DRUG|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
47914076|NCT00567398|DRUG|Physioneal|Physioneal 40 or Physioneal 35
48093420|NCT04859556|DEVICE|Alcon 25Gauge, 5,000 cuts per minute Ultravit cutter|a proprietary Vitrector from Alcon for the use on the Constellation system
48093421|NCT03647475|COMBINATION_PRODUCT|Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT|To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
48093422|NCT00836810|DRUG|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
48093423|NCT00836810|DRUG|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
48093424|NCT03907397|BIOLOGICAL|Peanut Protein|up to 3 level teaspoons peanut butter or equivalent (approximately 3400 mg)
48093425|NCT02843022|BEHAVIORAL|standardized electronic messages|supportive and educational short messages
48093426|NCT02843022|BEHAVIORAL|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
48093427|NCT02843022|BEHAVIORAL|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
47920684|NCT02634190|OTHER|Colposcopy|Colposcopy
47920685|NCT03647189|DEVICE|Hybrid Fractional Laser|Hybrid Fractional Laser
48093428|NCT06614075|BEHAVIORAL|Questionnaire and anthropometric measurement|Questionnaire including sociodemographic characteristics, lifestyle habits, body weight, height, dietary assessment and diabetes risk; Anthropometric measurement including waist circumference
48093429|NCT00254475|DRUG|simvastatin|
48093430|NCT00254475|DRUG|valsartan|
48093431|NCT00419068|DRUG|Cholecalciferol|
48093432|NCT00419068|DRUG|Migliol Placebo Oil|
48093433|NCT02806895|DRUG|JZP-110|
48093434|NCT02806895|DRUG|Placebo|
48093435|NCT03888911|DIETARY_SUPPLEMENT|High dose IQP-LU-104 (5120mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
48093436|NCT03888911|DIETARY_SUPPLEMENT|Low dose IQP-LU-104 (2560mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
48093437|NCT03888911|DIETARY_SUPPLEMENT|Placebo|1 sachet to be taken 2 times daily orally, together with 2 main meals
48093438|NCT04491617|OTHER|Standard opioid prescribing|Patients are routinely prescribed opioid medications in addition to non-opioids.
48093439|NCT04491617|OTHER|Restrictive opioid prescribing|Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.
47920686|NCT01123993|DEVICE|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
48093440|NCT00715286|OTHER|timing of surgery|Surgery is followed by chemotherapy
47920687|NCT06518590|DEVICE|Cycle|Kettler upright bike Giro P:
48093441|NCT00715286|OTHER|timing of surgery|Chemotherapy is followed by surgery
48093442|NCT05693662|BEHAVIORAL|Session 1|"* Ensuring group interaction, allowing parents to meet each other,~* Providing information in line with the Awareness-Based Self-Compassion Training Booklet for Parents of Children with Autism Spectrum Disorder prepared as training material,"
48093443|NCT05693662|BEHAVIORAL|Session 2|"* Making explanations about the contents of the training sessions to be held with parents,~* Teaching proper breathing techniques,~* Visual demonstration and application of relaxation techniques"
47920688|NCT03322319|PROCEDURE|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
47920689|NCT05874167|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 after an overnight fast~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin after an overnight fast"
47920690|NCT04880902|PROCEDURE|sleeve gastrectomy|Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
47920691|NCT01550653|DRUG|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
47920692|NCT01550653|DRUG|Placebo|
47920693|NCT06151509|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48093444|NCT05693662|BEHAVIORAL|Session 3|"* Breathing break with kindness application,~* Thinking and evaluating how threat, impulse and soothing systems develop in individuals' own lives,~* Safe place application,~* Applying kindness meditation,"
48093445|NCT05693662|BEHAVIORAL|Session 4|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with resistance,~* Kindness meditation: a do-gooder application,~* A hand on the heart application,~* A compassionate companion application,"
48093446|NCT05693662|BEHAVIORAL|Session 5|"* Breathing break with kindness application,~* The practice of establishing a compassionate relationship with desire,~* Guided meditation to discover the inner pattern practice,~* Kindness meditation: a good friend application,"
48620280|NCT02827539|DEVICE|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
47920694|NCT06151509|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48093447|NCT05693662|BEHAVIORAL|Session 6|"* Pretending practice regarding parents' awareness,~* An expanded version of the practices carried out in previous sessions to raise awareness, the internalizing compassion practice,~* Kindness meditation: a neutral person, kindness towards your body and walking with kindness practices, which are based on mindfulness practices and increase body awareness and mindful movement,"
48093448|NCT05693662|BEHAVIORAL|Session 7|"* A compassionate letter application, which is carried out by asking parents to think about a situation they have encountered recently or some time ago that still causes distress,~* Kindness meditation: the 'difficult' person, compassion and breathing: yourself and compassionate breathing: others practices,~* Researching how parents can cope with difficulties and implementing a compassionate breath break without words,"
48093449|NCT05693662|BEHAVIORAL|Session 8|"* Revisiting the good application to enable parents to experience the five senses in a pleasant way,~* Practices of self-forgiveness, asking for forgiveness, forgiving others, gratitude, which can be a way of mending the cracks in parents' relationships with themselves and others,~* Expanding the practice into kindness meditation: groups and all beings,"
48093450|NCT05693662|BEHAVIORAL|Session 9|"* The practice of allowing parents to choose a day in their lives for a few minutes to pause mindfully,~* A breather for wise and compassionate action practice,~* Calmness meditation application,~* Sharing the joy meditation application,"
47920695|NCT01212380|DRUG|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
47920696|NCT01212380|OTHER|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
48093451|NCT05693662|BEHAVIORAL|Session 10|"* Evaluating the entire education by telling parents about the practices they can use where help is needed to develop compassion towards self-healing skills,~* River of Life application, which evaluates awareness in depth,~* Saying goodbye."
48093452|NCT06042387|GENETIC|Blood or saliva sample collection|Blood or saliva sample \& clinical data collection
47914077|NCT00567398|DRUG|Extraneal|Extraneal - 7.5% Icodextrin
47914078|NCT00567398|DRUG|Nutrineal|Nutrineal - 1.1% Amino Acids
47914079|NCT03803241|DRUG|CD133+ infusion|Infusion of cells cd133+
47914080|NCT03803241|OTHER|portal vein embolization|portal vein embolization
47914081|NCT04716296|DRUG|Ketamine|Ketamine will be given for the second stage of the DBS surgery.
47914082|NCT04716296|DRUG|Saline|Saline will be given for the second stage of the DBS surgery.
47914083|NCT03205449|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)|The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
47914084|NCT03205449|OTHER|Parenting Effectiveness Service|Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. \[12\].
47914085|NCT00853632|DEVICE|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
47914086|NCT05625555|DRUG|Ketamine|IV Ketamine infusion 0.5mg/kg over 40 minutes
47914087|NCT05625555|DRUG|Midazolam|IV Midazolam infusion 30μg/kg over 40 minutes
47914088|NCT05681143|OTHER|Crisis Prevention Arm|The crisis prevention program involves a 3-session model. Each session lasts up to 60 minutes. They take place via telehealth with a licensed clinical therapist. Sessions involve case formulation, provision of prevention strategies, connecting with professional and lay resources, what to do if a crisis occurs, and strategies to prevent the re-occurrence of a crisis, should one occur. Each session involves use of checklists, a community resource guide, and homework. Implementation is standardized using two different manuals, one for the parent and the other for the provider.
47914089|NCT05681143|OTHER|Control|The control condition will involve sending families the Autism Speaks Challenging Behavior Toolkit. It offers a complimentary set of recommendations. It is freely available and can be found here: https://www.autismspeaks.org/tool-kit/challenging-behaviors-tool-kit. There is no interaction with the clinician in the controlcondition. After the study observation period, we will provide them with the crisis manual (for parents) used in the active treatment arm.
47914090|NCT01214733|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
47914091|NCT05354362|COMBINATION_PRODUCT|ATG-010 and ATG-008|Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
47914092|NCT02331277|DRUG|BI 655064|subcutaneous injection
47914093|NCT02331277|DRUG|Placebo|Placebo
47914094|NCT00597324|PROCEDURE|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
47914095|NCT00241189|DRUG|rapamycin|
47914096|NCT00241189|DRUG|methotrexate|
47914097|NCT05359991|OTHER|Exercise|Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
48093453|NCT04671628|BEHAVIORAL|Relaxing music|Participants will be asked to listen to relaxing music for 30 minutes each day. They will allowed to choose between several playlists based on their preference.
48093454|NCT05064761|DEVICE|Sculptra new dilution|Treatment to improve appearance of cellulite.
48093455|NCT04524442|DRUG|arginine/lysine|1000 milliliters (mL) administered at a constant rate of 250 mL per hour
48093456|NCT02994706|PROCEDURE|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
48093457|NCT02994706|OTHER|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
48093458|NCT00624104|DIETARY_SUPPLEMENT|Food (fat free meal)|Fat free meal (40% of REE)
48093459|NCT01542619|BIOLOGICAL|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
48093460|NCT01542619|BIOLOGICAL|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
48093461|NCT03505645|PROCEDURE|Periarticular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~1. Medial femoral condyle periosteum~2. Medial gutter~3. Lateral femoral condyle periosteum~4. Lateral gutter~5. Posteromedial capsule~6. Posterolateral capsule"
48093462|NCT03505645|PROCEDURE|Intra-articular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule."
48093463|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
48093464|NCT03341026|OTHER|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
48093465|NCT03738358|DIETARY_SUPPLEMENT|Trehalose|80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g
48093466|NCT03738358|OTHER|Placebo|80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g
48093467|NCT00415155|DRUG|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
48093468|NCT00684502|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
48093469|NCT00684502|DRUG|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
48093470|NCT00998816|DRUG|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
48093471|NCT03106376|OTHER|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
48093472|NCT03106376|OTHER|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
48093473|NCT04376476|BIOLOGICAL|Blood sample|blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
48093474|NCT04376476|BIOLOGICAL|Low or upper respiratory tract sample|"Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0"
48093475|NCT04376476|BIOLOGICAL|Stool collection or fecal swab|"The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0"
48093476|NCT04376476|OTHER|phone call|phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
48093477|NCT00239161|DRUG|Levofloxacin|
48093478|NCT06340789|DRUG|Sodium Benzoate 2gram/day|the add-on sodium benzoate with conventional pharmacological treatment
48093479|NCT06340789|DRUG|Placebo|the add-on placebo with conventional pharmacological treatment
48093480|NCT02906683|DRUG|TAS-303|Oral administration for 8 weeks, once daily.
48093481|NCT02906683|DRUG|Placebo|Oral administration for 8 weeks, once daily.
48093482|NCT03990025|DIAGNOSTIC_TEST|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
48093483|NCT03990025|DIAGNOSTIC_TEST|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
48270133|NCT04158063|BEHAVIORAL|Dual Task Training|"In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~* Titrated digit span backwards~* Auditory vigilance with alphabets~* Subtracting by 7~Motor tasks:~* Walking at self-selected speed~* Walking while carrying a cup of water~* Walking while stepping over obstacles~* Walking crisscross"
48093484|NCT05780047|DIAGNOSTIC_TEST|Mail-in Urine Test for EDCs|Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
47920697|NCT01212380|OTHER|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
48093485|NCT06296251|OTHER|Placebo treatment|Microcrystaline cellulose (MCC)
48093486|NCT06296251|DIETARY_SUPPLEMENT|Plant derived phenolics|Dietary supplement containing plant derived phenolics
48093487|NCT06613958|BEHAVIORAL|Physical activity timing|The investigators will compare our interventions to a 14-day period of sedentary behavior, during which the participant will refrain from any moderate to vigorous exercise. Next, participants will participate in two interventions consisting each of a 14-day physical activity regimen. The active morning and active evening interventions are equal in content. Both groups will be instructed to refrain from any moderate to vigorous exercise for the rest of the day. Per intervention, a total of eight Vitality Club training session comprising of a combination of aerobic endurance training and resistance exercise training will be given by a trained sports coach or physical therapist specialized in geriatric physical therapy. During the weekends, participants will be asked to perform a 'relative rest' session with some light activity during the training time window of the intervention arm.
48093488|NCT02926300|BIOLOGICAL|stem cells|IV infusion
48093489|NCT04535375|DIAGNOSTIC_TEST|Doppler Ultrasound of venous cerebral circulation|No additional ultrasound examinations, specifically for the purpose of this study, will be performed. Instead, with each routine ultrasound examination, additional images on top of the routine frames will be collected. Those images will document the velocity and flow in the internal cerebral veins bilaterally using the standard Color Doppler tech-nique. Taking these additional images will prolong the time of ultrasound examination only minimally (with a few minutes).
48093490|NCT05892575|BEHAVIORAL|improving quality of life, coping with urinary incontinence and kegel exercise training|Face-to-face training will be given to the elderly in the experimental group for a total of 5 weeks, once a week day (60 minutes). In the 4th week, reminder messages will be started over the phone. The 4th week kegel exercise chart and nutrition list will be given. In the 5th week, kegel exercise dance will be watched. Sending reminder messages from the phone will continue for 3 months.
48093491|NCT04978077|OTHER|Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)|After a night fast participants will drink the test meal
48093492|NCT04602364|OTHER|Noninterventional|Not applicable; Noninterventional study
48093493|NCT06268210|DRUG|Lazertinib+Pemetrexed+Carboplatin|Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)
48093494|NCT06268210|DRUG|Lazertinib|Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
47920698|NCT01212380|OTHER|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
47920699|NCT01212380|OTHER|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
47920700|NCT03658876|DRUG|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
47920701|NCT03658876|DRUG|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
48093495|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
48093496|NCT00730418|DRUG|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
48093497|NCT00620581|DRUG|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
48093498|NCT01021878|OTHER|icodextrin|glucose sparing dialysis solution
48093499|NCT01021878|OTHER|Dianeal|glucose based dialysis solution
48093500|NCT00812630|DRUG|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
48093501|NCT02320253|BEHAVIORAL|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
48270134|NCT04158063|OTHER|Single Mobility Training|standard routine training
48270135|NCT05316714|PROCEDURE|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
48270136|NCT03709927|DRUG|ZTI-01|6g IV fosfomycin
48270137|NCT03709927|DRUG|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
47920702|NCT00496600|DRUG|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
48093502|NCT02320253|BEHAVIORAL|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
48093503|NCT02320253|BEHAVIORAL|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
48093504|NCT06528769|DRUG|all-trans retinoic acid|Given orally
48093505|NCT06528769|DRUG|Cemiplimab|Given intravenously (IV)
48093506|NCT06528769|PROCEDURE|Computed Tomography|Undergo CT
48093507|NCT06528769|PROCEDURE|Magnetic resonance imaging|Undergo MRI
48093508|NCT03222284|DEVICE|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
48093509|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide|
48093510|NCT01788020|DRUG|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
47920703|NCT00496600|DRUG|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
47920704|NCT03405233|PROCEDURE|Double vein cuffed ePTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around both ends of PTFE Graft
47920705|NCT03405233|PROCEDURE|single vein cuffed eTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around the venous end of PTFE Graft
47920706|NCT03405233|PROCEDURE|ePTFE graft without any cuff|anastmosis between arterial and venous side usinf non cuffed ePTFE graft
47920707|NCT05330715|OTHER|Management|Comparison if different strategies to manage acute emergencies in the pre-hospital setting.
47920708|NCT03629275|COMBINATION_PRODUCT|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
47920709|NCT03629275|DRUG|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
47920710|NCT01381562|DRUG|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
47920711|NCT01381562|DRUG|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
47920712|NCT01381562|OTHER|Placebo|saline placebo
48093511|NCT01658488|OTHER|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
48093512|NCT01658488|OTHER|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
48093513|NCT01924481|DIETARY_SUPPLEMENT|High Caffeine|
48093514|NCT01924481|DIETARY_SUPPLEMENT|Low caffeine|
48093515|NCT01924481|DIETARY_SUPPLEMENT|High theobromine|
48093516|NCT01924481|DIETARY_SUPPLEMENT|low theobromine|
48093517|NCT01924481|DIETARY_SUPPLEMENT|No theobromine|
48093518|NCT06384053|COMBINATION_PRODUCT|Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined|The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.
48093519|NCT06384053|RADIATION|Radiotherapy (RT)|Radiotherapy is applied.
48093520|NCT05860543|DIAGNOSTIC_TEST|C2i-WGS-MRD Test|The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA
48270138|NCT03709927|OTHER|Placebo IV|IV Placebo (0.9% Normal Saline)
48270139|NCT01207830|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
48270140|NCT05845359|DRUG|Methadone|One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
47920713|NCT06146231|DEVICE|Motiva Flora® Tissue Expander|"This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant.~Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication.~To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study."
48093521|NCT00918190|DRUG|Placebo|Saline
48093522|NCT00918190|DRUG|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
48093523|NCT00918190|DRUG|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
48093524|NCT01697761|OTHER|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
48093525|NCT01697761|OTHER|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
48093526|NCT01144117|DRUG|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
48093527|NCT01783457|OTHER|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
48270141|NCT02273245|RADIATION|Thoracic aortogram CT|With and without contrast dye
47914098|NCT00771953|DRUG|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
47914099|NCT00771953|DRUG|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
47920714|NCT06266793|DEVICE|Holmium Laser|Assigned to be treated using the Lumenis Pulse 120H Moses 2.0 Holmium Laser.
47920715|NCT06266793|DEVICE|Thulium Laser|Assigned to be treated using the Olympus Soltive Thulium SuperPulsed Fiber Laser
47920716|NCT05692336|OTHER|vestibular training|balance training in the form of vestibular training
47920717|NCT05692336|OTHER|dual task training|balance training in the form of dual task training
47920718|NCT05737615|DIAGNOSTIC_TEST|PET Scan|Participants will be imaged up to 4 time points post-injection to allow for biodistribution and dosimetry determination
47920719|NCT05737615|DRUG|hu5B1-TCO|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
47920720|NCT05737615|DRUG|64Cu-Tz-SarAr|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
47920721|NCT05737615|DIAGNOSTIC_TEST|Pharmacokinetics|All participants receiving 64Cu-Tz-SarAr will have serial blood samples drawn.
48093528|NCT01783457|OTHER|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
48093529|NCT05237193|DIAGNOSTIC_TEST|The level of CIN|The extracted DNA from bile will be analyzed by UCAD to determine the level of CIN. And the patient will be followed for up to 2 years.
48093530|NCT05121870|BIOLOGICAL|UC-MSCs|3 does of UC-MSCs(6.0×10E7cells per time) intravenously at week 0, week 4, week 8.
48093531|NCT05121870|BIOLOGICAL|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo intravenously at week 0, week 4, week 8.
48093532|NCT06452394|DRUG|Doxycyclin|Belongs to the class of tetracyclines. It has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. Its mechanism of action lies in the binding to the 30S ribosomal subunit
48093533|NCT01245413|DEVICE|SenSura|Adhesive to stoma bag
48093534|NCT01245413|DEVICE|Athena|Adhesive to stoma bag
48093535|NCT03533855|DIAGNOSTIC_TEST|CS plus FRFSE|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
48093536|NCT04172987|DRUG|Tirzepatide|Administered SC
48093537|NCT04172987|DRUG|EE/NGM|Combination oral contraceptive administered orally
47914100|NCT00771953|DRUG|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
47914101|NCT03622918|DRUG|colistin and rifampin combination therapy|Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
47914102|NCT03622918|DRUG|colistin monotherapy|. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
47920722|NCT00168792|DRUG|Tenecteplase|
47920723|NCT00168792|PROCEDURE|PCI|
47920724|NCT04086498|OTHER|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
47920725|NCT04086498|OTHER|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
48093538|NCT05824221|DEVICE|rTMS|Non invasive brain stimulation in Cocaine Use Disorder
48093539|NCT02383550|OTHER|Observational Cognitive assessments|Observational
48093540|NCT00186810|DRUG|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
48093541|NCT00186810|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
48270142|NCT03339492|DEVICE|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
48270143|NCT03892837|PROCEDURE|PRP|PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
48270144|NCT03892837|PROCEDURE|Conventional treatment for benign airway stenosis|Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
48270145|NCT02380755|DRUG|Clomiphene Citrate|50 mg orally daily during 12 weeks
48270146|NCT02380755|DRUG|Placebo|1 pill orally daily during 12 weeks
48270147|NCT04684654|BIOLOGICAL|BMS-986325|Specified dose on specified days
47920726|NCT04086498|OTHER|KD|The group received a plan for a low carbohydrate ketogenic diet
48093542|NCT05878353|PROCEDURE|Decontamination of the pocket with local doxycycline|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage. Local doxycycline was administered according to the manufacturer's instruction. Briefly, the plastic needle of the syringe will be inserted into the sulcus and the product will be progressively released in the periodontal pocket up to the gingival margin. The syringe will be then removed and a cotton pellet used to compact the gel into the sulcus. Patients will be then instructed not to floss or use interdental brushes in that area for the following 10 days.
48093543|NCT05878353|PROCEDURE|Decontamination of the pocket with mechanical instrumentation|Gentle debridement will be performed under local anesthesia (mepivacain 2% 1:1000) for a time of 5 minutes by mean of ultrasonic devices by the same experienced clinician. Great attention will be made to avoid marginal and interproximal soft tissue damage.
48093544|NCT06390553|DEVICE|Task-Oriented Virtual Reality Application with Crowd Simulation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
48093545|NCT06390553|PROCEDURE|Conventional Parkinson Rehabilitation|Patients will be treated 4 days a week for 8 weeks in accordance with their assigned group.
48093546|NCT02651103|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
48093547|NCT05708417|BEHAVIORAL|Lifestyle Intervention|"The intervention in SDOI has the predominantly focus on each individual reflection and realisation and is built upon ACT' six core processes: 1) Acceptance, 2) Cognitive defusion 3) Being present, 4) Self as context, 5) Values, and 6) Committed action.~The program is based on up to 13 times attendance within the 12 months intervention period."
48093548|NCT05708417|OTHER|Placebo|No lifestyle intervention within the study, only test/datacollection
48093549|NCT05504694|DRUG|Ofatumumab|"The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion."
48093550|NCT06615336|BEHAVIORAL|Intensive Sleep retraining|Intensive Sleep Retraining treatment consisted of 42 sleep onset trials over a 21-hour sleep deprivation period
47920727|NCT04849702|PROCEDURE|No intervention was compared|No intervention was compared
48093551|NCT06615336|BEHAVIORAL|Total Sleep Deprivation|Total Sleep Deprivation treatment consisted of an equivalent 21-hour sleep deprivation period without sleep onset trials
47920728|NCT05620121|PROCEDURE|Surgery for Incisional hernias|Laparoscopic and laparoscopic abdominal wall repair for Incisional Hernia with/without prosthetic material in urgent/emergent settings, with/without direct closure of the defect (IPOM and IPOM +).
47920729|NCT04960839|RADIATION|Prophylactic contralateral breast irradiation|The whole contralateral breast will be irradiated once daily, 5 days a week, for 5-6 weeks, using 1.8-2 Gy/fx to a total dose of 45-50 Gy.
47920730|NCT04764474|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
47920731|NCT02091505|DRUG|Ranibizumab|
47920732|NCT03462511|BEHAVIORAL|HABIT Intervention|Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
47920733|NCT03462511|OTHER|Standard of Care|Standard of care used to treat patients with SCD
48093552|NCT04467463|PROCEDURE|peripheral nerve block by 0.25% levobupivacaine|SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
48093553|NCT00253214|DRUG|galantamine hydrobromide|
48093554|NCT01784913|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
47920734|NCT03462511|OTHER|Education materials|Education materials provided to all patients enrolled in the trial
47920735|NCT02338882|DEVICE|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
47920736|NCT02338882|DEVICE|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
47920737|NCT05380479|DRUG|Mirtazapine|mirtazaine15 mg tablet daily for 8 weeks.
47920738|NCT05380479|DRUG|Megestrol Acetate|megestrol acetate 160 mg tablet daily for 8 weeks.
47920739|NCT00489125|OTHER|physiologic testing|physical testing of range of motion, grip strength etc.
47920740|NCT02069275|OTHER|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
47920741|NCT02069275|OTHER|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
47920742|NCT01018784|DRUG|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
47920743|NCT05887778|DRUG|Sodium Chloride 0.9% Inj|administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block
47920744|NCT05887778|DRUG|0,1mg/kg Dexamethasone|administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
47920745|NCT05887778|DRUG|0,2mg/kg Dexamethasone|administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
47920746|NCT01640431|OTHER|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
47920747|NCT05160142|BEHAVIORAL|DICE|10-week culinary and nutrition education program for children with type I diabetes
47920748|NCT02748382|OTHER|higher chloride crystalloid|Normal saline
48093555|NCT00264589|BEHAVIORAL|8 weeks individualized training program|no drugs added
48093556|NCT00219921|DRUG|Intrathecal morphine at surgery, 0.1mg and placebo|
48093557|NCT00219921|DRUG|Patient Controlled Analgesia with iv morphine and placebo|
48093558|NCT00219921|DRUG|intrathecal morphine AND patient controlled analgesia with iv morphine|
47920749|NCT02748382|OTHER|higher chloride albumin|5% Octalbin
48093559|NCT04602962|PROCEDURE|fertility preservation, several methods|fertility preservation using assisted reproductive techniques or not
48093560|NCT04007887|OTHER|Adult education program|A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
47920750|NCT02748382|OTHER|lower chloride crystalloid|Ringers Lactate
47920751|NCT02748382|OTHER|lower chloride albumin|5% Plasbumin
47920752|NCT03595618|DRUG|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
48093561|NCT00508885|DRUG|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
48093562|NCT00508885|DRUG|Placebo|Placebo
48093563|NCT00117611|DRUG|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
48093564|NCT05759221|PROCEDURE|Bronchoscopy with airway biopsy|Forceps biopsy of peripheral airways under direct endoscopic visualisation.
48093565|NCT00318513|DRUG|Bevacizumab|
47920753|NCT03595618|DRUG|Placebo|Film-coated tablets of matching placebo for oral use.
48093566|NCT05039736|DRUG|Cabozantinib|Given by PO
48093567|NCT05039736|DRUG|Nivolumab|Given by IV
48093568|NCT02582203|DRUG|Ceftaroline|
48093569|NCT02582203|DRUG|Vancomycin|
48270148|NCT04684654|OTHER|Placebo for BMS-986325|Specified dose on specified days
48270149|NCT03679325|DIETARY_SUPPLEMENT|vitamine D|a dose once a week
47920754|NCT02128685|DRUG|Dydrogesterone|
47920755|NCT02128685|DRUG|Placebo|
48270150|NCT03679325|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
48270151|NCT01262625|DEVICE|CCTA|Complete diagnostic CCTA per protocol specifications.
48093570|NCT04758507|BIOLOGICAL|donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
48093571|NCT04758507|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
48093572|NCT06615674|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
48093573|NCT00244361|DRUG|rituximab|
48093574|NCT04768790|OTHER|multidisciplinary program|multimodal exercises to improve, through gradual exposure, cervical mobility, postural control and strengthening of the cervical muscles; stabilization techniques for the deep neck muscles; task-oriented exercises maintaining the activation of the deep spinal muscle. Under the supervision of a psychologist, the subjects will also be involved in cognitive-behavioral therapy aimed at modifying the fear of movement (kinesiophobia) and the maladaptive behavior of the disease. Ergonomic consultancy.
48093575|NCT04768790|OTHER|General program|exercises for muscle strengthening, regional stretching and spinal mobilization. Ergonomic consultancy.
48093576|NCT03034382|DRUG|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
48093577|NCT03034382|DRUG|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
48093578|NCT03034382|DRUG|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
48093579|NCT03034382|DRUG|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
47920756|NCT01523977|DRUG|Everolimus|Orally, daily days 1-32 per assigned dose level
47920757|NCT01523977|DRUG|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
47920758|NCT01523977|DRUG|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
47920759|NCT01523977|DRUG|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
47920760|NCT01523977|DRUG|Doxorubicin|30 mg/m2 IV on days 4 and 5
47920761|NCT01523977|DRUG|Dexrazoxane|300 mg/m2 IV on days 4 and 5
47920762|NCT01331252|OTHER|semi-recumbent|Patient rests in a semi-recumbent body position
47920763|NCT01331252|OTHER|supine|Patient rests in a supine position
47920764|NCT05397704|DEVICE|brain pulse oximeter|brain oxygen monitoring during hypoxia
47920765|NCT02690571|OTHER|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
47920766|NCT04935645|BEHAVIORAL|Progressive Muscle Relaxation|PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
47920767|NCT01121809|DRUG|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
48093580|NCT00224133|DRUG|Silodosin|8 mg daily
48093581|NCT05299086|DRUG|Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)|The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
48106738|NCT03037502|BEHAVIORAL|Tailor Made: Solutions for your health (A su Medida: Soluciones para su salud)|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 80 African American and 40 Latino men; to compare changes in chronic disease risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 3-months.
48106739|NCT04067960|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
48106740|NCT04067960|OTHER|Genetic Testing|Undergo pharmacogenomics testing
48270152|NCT01262625|DEVICE|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
48093582|NCT05119933|DRUG|YL-15293|After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
48093583|NCT06384430|DIAGNOSTIC_TEST|Shoulder functional tests and ultrasound|On the day of the study, demographic data will be collected from patients with a clinical diagnosis of impingement and who agree to participate in the study, then DASH and Constant Murley scores will be calculated and subacromial bursa thickness, supraspinatus tendon thickness, acromiohumeral distance, supraspinatus tendon thickness/acromiohumeral distance ratio will be calculated on ultrasound.
48093584|NCT01979055|BEHAVIORAL|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
47920768|NCT01121809|DRUG|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
47920769|NCT03817047|BEHAVIORAL|Physical education|"Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary."
48093585|NCT01979055|BEHAVIORAL|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
47920770|NCT03817047|BEHAVIORAL|Physical active learning|The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
47920771|NCT03817047|BEHAVIORAL|Physical activity|"Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus."
47920772|NCT03817047|BEHAVIORAL|Be happy|The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
47920773|NCT03456882|DRUG|RNS60|normal saline plus oxigen in nanobubble
47920774|NCT00382642|DRUG|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
48093586|NCT03716167|DEVICE|Summus Laser|infrared laser treatment
47920775|NCT00382642|DRUG|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
47920776|NCT04124497|DRUG|Daratumumab|"* Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1."
48093587|NCT03716167|DEVICE|Summus Laser Sham|non-infrared light
48093588|NCT04257279|PROCEDURE|ExcelsiusGPS™|The ExcelsiusGPS™ is a Robotic Positioning System that includes a computer controlled robotic arm, hardware, and software that enables real time surgical navigation and robotic guidance using radiological patient images (pre-operative CT, intra-operative CT and fluoroscopy), using a dynamic reference base and positioning camera.
48093589|NCT06481930|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|The enrolled patients underwent fluorescence photoelectric cervical lesion image detection, followed by colposcopy and biopsy to obtain histopathological results. The results of fluorescence photoelectric image detection were compared with histopathological results, and at the same time compared with HPV and TCT results at the time of enrollment.
48093590|NCT00198874|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
48093591|NCT00198874|OTHER|Education|Drug education curriculum was delivered to participants assigned to this condition.
48093592|NCT04574245|PROCEDURE|Gastrectomy; Hepatectomy|
48093593|NCT01606189|DRUG|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
48093594|NCT01606189|DRUG|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
48093595|NCT01606189|DRUG|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
47920777|NCT04124497|DRUG|Pomalidomide|4 mg once daily on days 1-21
47920778|NCT04124497|DRUG|Dexamethasone|Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22
47920779|NCT02595645|GENETIC|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
47920780|NCT04602234|DIAGNOSTIC_TEST|Lung ultrasonography|Investigators performed lung ultrasonography on patients
48093597|NCT06569953|DRUG|Liposomal bupivacaine|Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).
48093598|NCT06569953|DRUG|Bupivacaine Hydrochloride|Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)
48093599|NCT04516811|BIOLOGICAL|COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.
48093600|NCT04516811|BIOLOGICAL|Standard of care (SOC) plus placebo|A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
48093601|NCT00843362|DRUG|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
48093602|NCT00843362|DRUG|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
48093603|NCT01759121|RADIATION|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
48093604|NCT01759121|RADIATION|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
48093605|NCT03356015|DRUG|4L Polyethylene Glycol|4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
48093606|NCT03356015|DRUG|3L Polyethylene Glycol|3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
48093607|NCT05415930|OTHER|Psychosocial assistance|Firs evaluation at Acceptess-T locals by a health mediator specialised in transidentity : advice for administrative procedures (health insurance, residency permit, housing, etc.) management of others social issues Orientation to Acceptess-T sexual health space for medical evaluation Orientation to Acceptess-T mental health space if needed : special focus on sexual health and gender related issues
48093608|NCT05415930|OTHER|Medical care|Sexual health clinics at Acceptess-T health space First STI risk evaluation: HIV, HCV, HBV, syphilis TROD realisation Spanish speaking Infectious Diseases (ID) specialist (from ID Department of Bichat hospital) first evaluation Proposition of PrEP if indicated Orientation for hospital follow-up in dedicate PrEP clinics Prescription and follow-up of a feminazing hormonal therapy if needed
48093609|NCT05415930|OTHER|Legal-Administrative Assistance|Legal counselling, provided by a sex worker union representative Access to FAST (fond action social trans) which give an economic help to TW in high precarity situations
48093610|NCT05415930|OTHER|Focus Group|"A group of 10-15 TW, identified through convenience sampling, along with the Acceptess-T Health Space multidisciplinary team will be invited to participate in an Human Centered Design (HCD) project.~The project will be led by a team of anthropologists and sociologists and exchanges will be recorded and fully transcribed and analysed by a person competent in qualitative methodology.~The objective will be to co-create tailored solutions that meet the needs of TW and are viable to implement within the health system, so TW can be better managed The solutions ideated will work synergistically towards improving TW PrEP access and adherence and health system retention.This is an adaptative program : if new solutions to face PrEP barriers are created during the study follow-up, new mesures will be added to the intervention."
48093611|NCT05695989|DEVICE|Dual Robotic Arm Accessory (DRAA)|Dual Robotic Arm Accessory (DRAA)
48093612|NCT02487290|DEVICE|Aneufix ACP-T5|The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
48093613|NCT01144949|DRUG|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
47920781|NCT04453943|DEVICE|Exoskeleton Walking - with or without FES|The study involves validation of computer algorithms to estimate and control walking movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Walking movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
48093614|NCT01144949|DRUG|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
48093615|NCT04028492|DRUG|Tradipitant|BID
48093616|NCT04028492|DRUG|Placebo|BID
48093617|NCT04028492|DRUG|Open Label Tradipitant|BID
48093618|NCT02768805|BIOLOGICAL|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
48093619|NCT02768805|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
48093620|NCT02768805|BIOLOGICAL|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
48093621|NCT03655483|DRUG|GLS-010|Full-human anti-pd-1 monoclonal antibodies
48106741|NCT04067960|OTHER|Quality-of-Life Assessment|Ancillary studies
48270153|NCT04206826|DEVICE|PREDELFI|It's a natural film which contains a concentrated alpha-GOS (alpha-galacto-oligosaccharide) soy extract, a milk protein concentrate containing caseins and whey proteins and vegetable glycerin
48106742|NCT04067960|OTHER|Questionnaire Administration|Ancillary studies
48106743|NCT01942083|DRUG|OPB-111077|
48106744|NCT03318536|DRUG|Granisetron Hydrochloride|Patients received Granisetron.
48270154|NCT04206826|DEVICE|CONTROL|It's a natural film which is devoided of active ingredient. It contains sodium alginate; vegetable glycerin, caramel, beta carotene and water.
48270155|NCT05665179|BEHAVIORAL|Removing Barriers to Recovery|Experimental patients are provided no-cost legal services in-person at addiction treatment centers using an online platform
48270156|NCT06313437|DRUG|Revumenib|Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.
48270157|NCT06313437|DRUG|Midostaurin|Kinase inhibitor, capsule taken orally per protocol.
48106745|NCT03318536|DRUG|No Granisetron|Patients who did not receive Granisetron.
48106746|NCT05493124|DRUG|Manpixiao|A traditional Chinese medicine composition
48106747|NCT05493124|DRUG|Active comparator|Other drugs that may have therapeutic effects
48106748|NCT00010946|PROCEDURE|Acupuncture|
48093622|NCT03830775|PROCEDURE|Platelet-rich plasma (PRP)|"PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)"
48093623|NCT05989737|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
47920782|NCT04453943|DEVICE|Exoskeleton Sitting to Standing - with or without FES|The study involves validation of computer algorithms to estimate and control sitting/standing movements. The Rifton E-Pacer motorized walker, arm crutches, parallel bars, or a conventional walker may be used in order to assist donning and doffing of the exoskeleton system, standing, and walking for all subjects, at any time during experimentation. Sitting/Standing movements will be elicited by the hybrid walking platform that combines a powered exoskeleton and an FES system. The powered exoskeleton can provide joint actuation at the hip and knee joints of a participant. The FES system can stimulate the quadriceps, hamstrings muscle, glutes, and ankle muscles.
48093624|NCT04163666|BEHAVIORAL|Mirror therapy|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
47920783|NCT05734417|DIETARY_SUPPLEMENT|Probiotic|Oral administration of Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day for 4-weeks
48093625|NCT04163666|BEHAVIORAL|Cognitive therapeutic exercise|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
48093626|NCT00002784|BIOLOGICAL|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
48093627|NCT00002784|DRUG|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
48093628|NCT00002784|DRUG|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
48093629|NCT00002784|DRUG|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
48093630|NCT00002784|DRUG|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
47920784|NCT05734417|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
47920785|NCT02067975|DRUG|Tryptophan|
47920786|NCT02067975|DRUG|Placebo|
47920787|NCT00538083|OTHER|Chocolate|74 grams of single dose solid dark chocolate versus placebo
47920788|NCT00538083|OTHER|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
47920789|NCT00538083|OTHER|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, \& placebo given for six weeks
48093631|NCT00002784|DRUG|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
48093632|NCT00002784|DRUG|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
48093633|NCT00002784|DRUG|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
48093634|NCT00002784|DRUG|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
48270158|NCT06313437|DRUG|Cytarabine|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
47920790|NCT05900440|OTHER|Ultrasound with Artificial Inteligence Engabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
47920791|NCT05900440|OTHER|Ultrasound without Artificial Intelligence Enabled|Participants shall be randomized 1:1 to receive personal access to a handheld ultrasound device with artificial intelligence vs a device with no artificial intelligence. The groups shall not cross over in which intervention they received.
47920792|NCT05738590|PROCEDURE|muscle biopsy|true cut needle biopsy
47920793|NCT04909476|PROCEDURE|Endotracheal intubation|Airways management in COVID 19 patients pneumonia
48093635|NCT00002784|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
48093636|NCT00002784|RADIATION|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
48270159|NCT06313437|DRUG|Daunorubicin|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
48270160|NCT01446809|DRUG|Doxorubicin Hydrochloride|Given IV
48093637|NCT00002784|RADIATION|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
48093638|NCT04559308|DRUG|Metformin|first-line anti-diabetic drug
48270161|NCT01446809|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
48270162|NCT01446809|DRUG|Ifosfamide|Given IV
48270163|NCT01446809|OTHER|Laboratory Biomarker Analysis|Correlative studies
48270164|NCT01446809|DRUG|Pazopanib Hydrochloride|Given PO
48270165|NCT01446809|OTHER|Pharmacological Study|Correlative studies
48270166|NCT01446809|OTHER|Placebo|Given PO
48093639|NCT04559308|DRUG|Chemotherapy|First line neoadjuvant chemotherapy protocol
48093640|NCT04370093|DRUG|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
48093641|NCT04370093|BEHAVIORAL|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
48093642|NCT04370093|OTHER|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
48093643|NCT05612776|OTHER|HIIT|HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.
48093644|NCT05612776|OTHER|HRV|The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
48093645|NCT04818320|DRUG|Favipiravir|Day 1: 1800mg BD, day 2-5: 800mg BD
48093646|NCT00001061|DRUG|Sevirumab|
48093647|NCT00001061|DRUG|Foscarnet sodium|
47920794|NCT06065098|BEHAVIORAL|Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.
47920795|NCT03970044|DRUG|Exenatide 2 MG|Glucagon-like peptide-1 receptor
47920796|NCT03970044|DRUG|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
47920797|NCT02828670|BIOLOGICAL|blood sample|
47920798|NCT02828670|PROCEDURE|spleen sample|
48093648|NCT00001061|DRUG|Ganciclovir|
47920799|NCT04642157|OTHER|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~* A systematic initial contact with an ELIOS web-clinician~* Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~* The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
47920800|NCT04642157|OTHER|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~* The General Practitioner (GP)~* The closest medico-psychologic center (CMP)~* The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
47920801|NCT04405466|PROCEDURE|Blood sampling|Blood samples
47920802|NCT04405466|PROCEDURE|Throat swab|Throat swab
48093649|NCT04285996|PROCEDURE|PET Scan|
48093650|NCT03768544|BEHAVIORAL|Self-help guided by a lay provider|Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
48093651|NCT03768544|BEHAVIORAL|Waiting list where participants wait for delayed treatment|Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.
48093652|NCT00335556|DRUG|Doxorubicin Hydrochloride|Given IV
48093653|NCT00335556|DRUG|Irinotecan Hydrochloride|Given IV
48093654|NCT00335556|PROCEDURE|Conventional Surgery|Patients undergo resection
48093655|NCT00335556|DRUG|Cyclophosphamide|Given IV
48093656|NCT00335556|DRUG|Etoposide|Given IV
47920803|NCT05929573|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin|Neutrophil Gelatinase-Associated Lipocalin, which can be measured from serum or urine, can detect acute kidney failure that may occur after surgery in the early stages.
48093657|NCT00335556|DRUG|Carboplatin|Given IV
48093658|NCT00335556|BIOLOGICAL|Dactinomycin|Given IV
48093659|NCT00335556|DRUG|Vincristine Sulfate|Given IV
48093660|NCT00335556|RADIATION|Radiation Therapy|Undergo radiotherapy
48093661|NCT00335556|OTHER|Laboratory Biomarker Analysis|Correlative studies
48093662|NCT00000746|BIOLOGICAL|rgp120/HIV-1 SF-2|
48093663|NCT00000746|BIOLOGICAL|Env 2-3|
48093664|NCT00000746|BIOLOGICAL|HIVAC-1e|
48093665|NCT00000746|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
48093666|NCT04827875|DRUG|AIV001|Intradermal
48093667|NCT05718219|DRUG|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
48093668|NCT05718219|DRUG|SIM0348|Several dose levels will be evaluated for SIM0348 administered as a single agent . SIM0348 will be given via IV infusion on Day 1,Day 8,Day 15,Day 22 of each cycle (28-day or depending on study cohort and phase) until disease progression or loss of clinical benefit.
48093669|NCT02138916|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
48093670|NCT02138916|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
48093671|NCT02138916|DRUG|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
48093672|NCT02658721|DRUG|Lidocaine|
48093673|NCT02658721|DRUG|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
48093674|NCT02658721|DRUG|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
48093675|NCT02658721|DRUG|Fentanyl|If the patient had a VAS score of \>4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
48093676|NCT02658721|DRUG|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR \<50/min), 0.5 mg intravenous atropine was administered."
48093677|NCT02658721|DRUG|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
48093678|NCT02658721|DRUG|Diclofenac sodium|The patients with a VAS score of \>4 were administered with 75 mg diclofenac sodium via intramuscular route.
48093679|NCT02658721|DRUG|Ephedrine|In the event of hypotension (systolic arterial pressure \<90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
48093680|NCT02658721|DRUG|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
48093681|NCT04975581|BIOLOGICAL|Allograft Patch|Rotator Cuff repair with Allograft Patch (Graftjacket Now)
48093682|NCT03279198|BEHAVIORAL|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
48093683|NCT03279198|BEHAVIORAL|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
48093684|NCT03279198|BEHAVIORAL|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
48093685|NCT03279198|BEHAVIORAL|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
48093686|NCT05168969|OTHER|Questionnaire|The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
48093687|NCT04746820|OTHER|single-center prospective pilot study|"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP"
48093688|NCT00020189|DRUG|acetylsalicylic acid|
47920804|NCT05929573|DIAGNOSTIC_TEST|Renal Doppler Resistive Index|Renal Doppler Resistive Index (RDRI) is a non-invasive index believed to reflect renal vascular perfusion. RDRI measurement is a repeatable, inexpensive, and easy-to-apply technique. RDRI has been found to be associated with AKI in conditions such as renal dysfunction, hypertension, and post-traumatic hemorrhagic shock. Furthermore, due to the impact on renal perfusion in patients undergoing major surgery, RDRI, which reflects renal vascular resistance, can serve as an indicator of kidney perfusion.
47920805|NCT02886403|OTHER|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
47920806|NCT02886403|OTHER|New adhesive strip|A newly developed adhesive strip
48093689|NCT00020189|DRUG|alvocidib|
48270167|NCT01446809|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48093690|NCT00020189|DRUG|clopidogrel bisulfate|
48093691|NCT04925050|DRUG|VB0004|Each study part (A,B and C) will be completed sequentially or with partial overlapping. Safety and PK data through at least day 8 from a subsequent cohort will be reviewed by the SMC prior to dosing the fed period of FE cohort. Safety data will be assessed by SMC after completing each cohorts in MAD healthy volunteers and MAD mild Hypertension patients.
48093692|NCT04925050|OTHER|Matching Placebo for VB0004|Matching Placebo
48093693|NCT04848909|RADIATION|stereotactic body radiotherapy (SBRT)|Stereotactic body or external-beam radiation therapy (SBRT) is a method of delivery of radiation in precision manner to the prostate bed in this study. The SBRT dose prescription will be 3000 cGy in 5 fractions to the prostate bed and 2500 cGy in 5 fractions to the pelvic nodes if elective nodal irradiation (ENI) is used, delivered every other business day.
48093694|NCT01615809|DRUG|AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
48093695|NCT02286856|BEHAVIORAL|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
48093696|NCT00550732|DRUG|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
48093697|NCT03367364|BEHAVIORAL|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
48093698|NCT03367364|BEHAVIORAL|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
47920807|NCT02113397|DRUG|TOBI™ Podhaler™ 112 mg inhaled twice daily|
47920808|NCT02113397|DRUG|Colistimethate 75 mg inhaled two times daily|
47920809|NCT04176484|OTHER|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
47920810|NCT00798759|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
48093699|NCT06343155|OTHER|Therapeutic Group|Pelvic tilt exercise:Participant will be supine position on the floor with your knees bent. Flatten your back against the floor by tightening your abdominal muscles and bending your pelvis up slightly. Lumbar flexion(single knee to chest): Participants will be supine position with knees bent and feet flat on the floor. The right knee will be brought closer to your chest and held with the hands. Lumbar flexion(double knee to chest) : Participants will be supine position with both legs flat on the floor. One hip and knee will be bent first to the chest, then the other to the chest. The knees will be grasped with the hands. Straight Leg Raise: Participants will be supine position with hips and legs comfortably on the floor. By contracting the quadriceps muscle the straight leg will be fixed. Inhaling slowly, the straight leg will be lifted six inches off the floor. Spine twist: Participants will turn their hips and knees to one side as much as possible in a supine position.
48093700|NCT06343155|OTHER|Rocabado's Group|Rest position of tongue: Making a 'clucking' sound positions the tongue against the hard palate in the correct resting position for appropriate nasal and diaphragmatic breathing. Once the activity is practiced, the patient is to attempt to maintain appropriate tongue / jaw resting position throughout normal activity. Shoulder retraction:Sitting up nice and tall, squeeze your shoulder blades back and together. Stabilized head posture:Place your hands behind your hand with fingers interlocked.Gently bring head forward with gentle overpressure from hands.Axial extension of the neck: Sitting up nice and bring your chin backward as if trying to make a double chin. Rotation control of temporomandibular joint: Place tongue at the roof of your mouth just behind your front teeth and place fist underneath chin. Gently open mouth into fist and hold for a few seconds. Rhythmic stabilization:Patients apply resistance to opening, closing, and lateral deviation with the jaw in a resting position.
48093701|NCT00000989|DRUG|Zidovudine|
48093702|NCT00000989|DRUG|Sargramostim|
48093703|NCT00000989|DRUG|Ganciclovir|
48093704|NCT03722303|OTHER|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
48093705|NCT03722303|DRUG|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
48093706|NCT03477110|DRUG|Temozolomide|Given PO
48093707|NCT03477110|RADIATION|Radiation Therapy|Undergo radiation therapy
47920811|NCT00798759|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
47920812|NCT04908943|BEHAVIORAL|RENEW|RENEW is a 12-week, peer-led, web-based program to help people with scleroderma learn skills that can be used to manage disease symptoms and improve well-being.
47920813|NCT00618345|DRUG|everolimus|
47920814|NCT00618345|GENETIC|DNA analysis|
47920815|NCT00618345|GENETIC|protein analysis|
47920816|NCT00618345|GENETIC|western blotting|
47920817|NCT00618345|OTHER|flow cytometry|
47920818|NCT00618345|OTHER|laboratory biomarker analysis|
47920819|NCT00618345|PROCEDURE|biopsy|
47920820|NCT00859027|DRUG|risedronate|35 mg/week by mouth
47920821|NCT00859027|DRUG|Placebo risedronate oral tablet|One tablet by mouth every week as directed
47920822|NCT00119093|PROCEDURE|Laboratory and clinical monitoring regimens|
47920823|NCT03835416|DIETARY_SUPPLEMENT|Foods rich in high quality protein|Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
47920824|NCT01801345|OTHER|Fatigued|
47920825|NCT01801345|OTHER|Rested|
47920826|NCT03811236|OTHER|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
47920827|NCT02381483|OTHER|Cold exposure|
47920828|NCT06163378|DEVICE|Rubato Life App|An algorithmically enhanced personalized music-based intervention
48093708|NCT03477110|DEVICE|NovoTTF-200A Device|Undergo tumor treatment fields therapy using NovoTTF-200A device
48093709|NCT03477110|PROCEDURE|Tumor Treating Fields Therapy|Undergo tumor treatment fields therapy using NovoTTF-200A device
48093710|NCT04934462|PROCEDURE|physiotherapy|Six months physiotherapy aimed at hip stability.
48093711|NCT04934462|PROCEDURE|arthroscopy|Arthroscopic plication of hip joint capsule.
48093712|NCT03613584|DRUG|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
48093713|NCT03613584|DRUG|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
48093714|NCT00406809|DRUG|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
48093715|NCT00268411|DRUG|gemcitabine hydrochloride|
48093716|NCT00268411|DRUG|oxaliplatin|
48093717|NCT06038071|OTHER|nutrition, IYCF, WASH education|nutrition, IYCF, WASH education
48093718|NCT06038071|OTHER|scheduled anthropometric screening|anthropometric screening by health care workers at 1, 3, and 6 months
48093719|NCT06038071|OTHER|family MUAC|family MUAC training for the primary caregiver present at the time of recovery
48093720|NCT01902901|GENETIC|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
48093721|NCT01902901|GENETIC|Carrier status testing|Carrier status testing
48093722|NCT06004167|RADIATION|Adaptive Bridging Radiation Therapy (ABRT)|Radiation Therapy
48093723|NCT04267094|DEVICE|Iterative reconstruction at reduced radiation dose|Evaluating Agatston coronary calcium score using reduced dose acquisitions reconstructed using iterative reconstruction
47920829|NCT02317744|DRUG|Naltrexone and bupropion combination|
47920830|NCT02317744|OTHER|Pill Placebo|
47920831|NCT02135003|OTHER|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
48093724|NCT03238729|BEHAVIORAL|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
48093725|NCT03238729|BEHAVIORAL|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
48093726|NCT01842243|PROCEDURE|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
48093727|NCT01842243|PROCEDURE|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
47920832|NCT03158662|OTHER|Survey|Survey Study
47920833|NCT03339154|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
47920834|NCT00967824|OTHER|informational intervention|
47920835|NCT00967824|OTHER|questionnaire administration|
47920836|NCT00967824|OTHER|survey administration|
48093728|NCT01842243|DEVICE|Pacemaker|MR conditional Pacemaker implanted in all study patients
48093729|NCT05429021|DRUG|IMM-BCP-01|Single dose of IMM-BCP-01
48093730|NCT05429021|DRUG|Placebo|Placebo matching single dose of IMM-BCP-01
48093731|NCT03411811|OTHER|Usual Care|Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
48093732|NCT03411811|PROCEDURE|Dextrose|Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
48093733|NCT03123640|OTHER|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
48093734|NCT06465576|DRUG|Solifenacin|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
48093735|NCT06465576|DRUG|Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
48093736|NCT06465576|DRUG|Solifenacin + Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
48093737|NCT02896608|DEVICE|measure of neuronal excitability|
48093738|NCT02981134|PROCEDURE|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
48093739|NCT00244257|BIOLOGICAL|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
48093740|NCT00244257|BIOLOGICAL|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
48093741|NCT00244257|BIOLOGICAL|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
48093742|NCT00244257|BIOLOGICAL|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
48093743|NCT00244257|BIOLOGICAL|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
48093744|NCT05417997|DIETARY_SUPPLEMENT|Kunamin®|Grape juice, seed, stem and rice extracts supplement containing KH good healthy cells (proteins)
48093745|NCT05417997|DRUG|Favipiravir|Antiviral medication used to treat influenza
48093746|NCT05417997|DRUG|Enoxaparin|Anticoagulant medication
48093747|NCT05417997|DRUG|Lansoprazole|Treat stomach ulcers, a damaged esophagus, gastroesophageal reflux disease (GERD), and high levels of stomach acid.
48093748|NCT05417997|DRUG|Paracetamol|Analgesic to treat minor aches and pains, and fever reducer.
47920837|NCT01008241|BEHAVIORAL|Paper questionnaire|Participants will complete a paper and pencil questionnaire that measures 4 domains of interest (advanced care planning; end of life care; hospice care and death and dying) as well as demographic factors (age, marital status, education etc.)
47920838|NCT04783558|BEHAVIORAL|Mobile-based NAS Caregiving Tool|The information and skills training in the adapted NAS caregiving tool will be largely based on elements of Eat Sleep Console. Therefore, the NAS mobile tool intervention will incorporate non-intrusive caregiving skills and strategies that encompass providing a low stimulating environment (e.g., dimmed light and low noise), swaddling, continuous comfort and contact with caregiver, skin-to-skin contact, frequent breastfeeding/feeding, as well as novel components identified in the key informant interviews (e.g., preparing for stigma during delivery, CPS involvement, etc.).
47920839|NCT01342237|DRUG|HDCT 1(TTC), HDCT2(MEC)|"1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
47920840|NCT03081156|DRUG|Glycopyrrolate / Formoterol|Exercise Tolerance
47920841|NCT01437306|DRUG|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
48093749|NCT05417997|DRUG|Ceftriaxone/ Clarithromycin|Inhibits the production of pneumolysin
48093750|NCT05417997|DRUG|Methylprednisolone|Treat inflammation, severe allergies, flares of chronic illnesses
48093751|NCT04201015|DEVICE|Heart rate optimisation using force frequency data|Programming heart rate rise according to the force frequency relationship
48093752|NCT00451698|DRUG|acyanotic erythropoietin|Single dose IV push
48093753|NCT00451698|DRUG|acyanotic placebo|Single dose IV push
48093754|NCT01528124|DRUG|LY3025876|Given as a subcutaneous injection
48093755|NCT01528124|DRUG|Placebo|Given as a subcutaneous injection
48093756|NCT06562725|OTHER|specific ventilator settings|The special ventilator settings used in the intervention group - aimed at reducing airway pressure - include inspiratory flow \<25 L/min, tidal volume = 5m L/Kg, inspiratory time = 1 sec, respiratory frequency \<20 c/min, PEEP = 5 cmH2O, and FiO2 = 100%
48093757|NCT02219594|DEVICE|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
48093758|NCT01547104|DRUG|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
48093759|NCT01547104|DRUG|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
48093760|NCT02437851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
48093761|NCT04107649|BEHAVIORAL|Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives|As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 6-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $95 in bonus rewards.
48093762|NCT04107649|BEHAVIORAL|Wrist based activity tracker wear|Activity tracking data will be collected on a weekly basis. Participants who receive this intervention are eligible to be entered into a lottery to win one of two $25 rewards for every week they wear their wrist-based activity tracker \>10 hours for \>4/7 days a week, beginning 6-weeks after surgery.
48093763|NCT04107649|OTHER|Basic Study Activities|Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), having check-in calls with study staff weekly from weeks 1-13 after surgery and every other week for weeks 14-31, completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will be eligible to receive up to $235 for completing these activities over the course of two years.
48270168|NCT03868943|DRUG|Soliramfetol|Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
47920842|NCT02604901|BEHAVIORAL|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR\*S (BI). BI was considered an active intervention method.
47920843|NCT02604901|BEHAVIORAL|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
47920844|NCT04475042|DRUG|Dapagliflozin|10mg od
47920845|NCT04475042|DRUG|Placebo|Placebo
48270169|NCT02813122|DEVICE|x-ray|x-ray for the detection of leaks and bleeding
48093764|NCT04907448|OTHER|Physical Therapy|"The IsoK-ST group received their usual physical therapy program for 45 minutes, three times a week for eight successive weeks, which comprised advanced balance training, weight-bearing exercises, gait training, postural and flexibility exercises, and strength training exercises.~Additionally, the IsoK-ST group received an IsoK-ST program, thrice/week for eight successive weeks.~The control group received the usual physical rehabilitation program only for 45 minutes, three times a week for eight successive weeks."
48093765|NCT05037994|PROCEDURE|Ultrasound Guided Continuous Suprascapular Nerve Block With methyl prednisolone and marcaine|"The high frequency linear ultrasound transducer (Sonosite 6-13 MHz) in a transverse orientation will be placed over the scapular Spine.~Moving the transducer cephalad the suprascapular fossa will be identified. 18 gauge touhy needle will be inserted in plane after subcutaneous local anesthesia infiltration with 1 ml lidocaine 2% Real-time imaging will be used to direct injection of 2 ml lidocaine 2% to test perineural spread of injectate after confirmation of the position of tip of needle injection of 40mg methyl prednisolone diluted in 5 ml bupivacaine 0.5% will be done through the needle to anesthetize the nerve and create space for catheter insertion. After catheter insertion another 2 ml lidocaine 2% will be injected through the catheter to confirm position perineural in the scapular notch. Lastly Catheter will be fixed via skin tunnel and secured with skin sutures and adhesive tap."
48093766|NCT00490555|DRUG|Testosterone gel|Testosterone gel 10 g
48093767|NCT00490555|DRUG|Dutasteride|dutasteride 0.5 mg orally
47920846|NCT06531551|OTHER|The group to which Acupressure will be applied in each fraction|Acupressure application protocol will be started after patient information. This process is planned to take 30 minutes.Before the application, approximately 20 seconds of warming and rubbing without direct pressure on the acupressure points will be performed to reduce tissue sensitivity and prepare the points for acupressure. Subsequently, the researcher will apply pressure with the thumb on the predetermined acupressure points, considering the individual's pain threshold, with 10 seconds of pressure followed by two seconds of relaxation without lifting the finger, in consecutive presses following the rhythm of breathing. A digital clock (belonging to the researcher) will be used to determine the duration of the acupressure application.
47920847|NCT05471154|DEVICE|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
47920848|NCT04248621|DRUG|Leuprorelin|LHRH agonist
47920849|NCT04248621|DRUG|Goserelin|LHRH agonist
48093768|NCT00490555|DRUG|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
47920850|NCT04248621|DRUG|Triptorelin|LHRH agonist
47920851|NCT04248621|DRUG|Degarelix|LHRH antagonist
48093769|NCT00490555|OTHER|Placebo Testosterone gel|Place gel applied daily for 12 weeks
48093770|NCT00490555|OTHER|Placebo dutasteride|placebo pill for 12 weeks
48093771|NCT00490555|OTHER|Placebo DMPA|placebo DMPA injection Once
47920852|NCT04248621|DRUG|Bicalutamide|Antiandrogen
47920853|NCT04248621|DRUG|Flutamide|Antiandrogen
47920854|NCT04248621|DRUG|Maximum androgen blockade|Combination therapy with LHRH agonist and antiandrogen
47920855|NCT00450125|OTHER|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
48093772|NCT03569813|BEHAVIORAL|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit has components for self-collection of urine, rectal and pharyngeal swabs, microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up (FU) visits will be done on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of emtricitabine triphosphate (FTC-TP).~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly FU visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Study Clinicians will review Lab and survey results and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as needed."
48093773|NCT03569813|OTHER|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, emtricitabine triphosphate (FTC-TP).
48093774|NCT00185484|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
48093775|NCT03337750|BEHAVIORAL|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
48093776|NCT01471262|PROCEDURE|Right hepatectomy|Right liver resection
48093777|NCT01471262|PROCEDURE|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
48093778|NCT00866216|DRUG|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
48093779|NCT00866216|DRUG|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
47920856|NCT00450125|OTHER|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
47920857|NCT02284425|DRUG|REGN1193|
47920858|NCT02284425|DRUG|Placebo|
47920859|NCT00553722|DRUG|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
47920860|NCT00553722|DRUG|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
48093780|NCT04636710|PROCEDURE|Lymphoscintigraphy|An imaging procedure using an injected radioactive substance or dye to identify lymph drainage A doctor reviews the images to identify the sentinel lymph nodes based on where the dye goes to first.
48093781|NCT03033732|DRUG|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
48093782|NCT03033732|DRUG|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
48093783|NCT03017456|BEHAVIORAL|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
48093784|NCT02114008|OTHER|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
48093785|NCT03888365|DRUG|Treprostinil|Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
48093786|NCT03888365|DRUG|Non-Treprostinil PAH Medications|Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
48093787|NCT00910884|OTHER|laboratory biomarker analysis|No supplements are given
48093788|NCT00910884|PROCEDURE|therapeutic dietary intervention|Given orally daily for 12 months
48093789|NCT04314661|BIOLOGICAL|Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|After Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
48093790|NCT04314661|BIOLOGICAL|Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|After Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
48093791|NCT04314661|BIOLOGICAL|Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Without Arthroscopy intervention, patient recieve 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, two weeks afterward, patient receive 2 cc Secretome, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
48093792|NCT04314661|BIOLOGICAL|Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Without Arthroscopy intervention, patient recieve 2 cc Secretome, two weeks afterward patient receive 10 million Allogeneic Umbilical Cord Mesenchymal Stem Cells in 2 cc NaCl, and four weeks later, patient receive another 2 cc Secretome. All intervention will be done via Intra-articular.
48093793|NCT02123966|DRUG|Sirolimus|
48093794|NCT05287932|BEHAVIORAL|Brief physical activity intervention|See arm/group descriptions
48093795|NCT06070597|DRUG|Iclepertin|Iclepertin
48093796|NCT06070597|DRUG|Iclepertin Placebo|Placebo to Iclepertin
48093797|NCT06070597|DRUG|Moxifloxacin|Moxifloxacin
48093798|NCT06070597|DRUG|Moxifloxacin Placebo|Placebo Moxifloxacin
48093799|NCT04892303|COMBINATION_PRODUCT|Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)|To safely administer a minimum cumulative dose of external beam radiation to up 3 index tumors per patient, supplemented radiation dose delivered by radioactive iodine (RAI)
48093800|NCT03589482|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
48093801|NCT03589482|OTHER|ExPRESS-derived PEEP level|The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
48093802|NCT05040243|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
48093803|NCT05040243|OTHER|placebo acupoint application|"The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group."
48093804|NCT02673008|BIOLOGICAL|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
48093805|NCT00002556|DRUG|vincristine sulfate|Given IV
48093806|NCT00002556|DRUG|carmustine|Given IV
48093807|NCT00002556|DRUG|melphalan|Given PO
48093808|NCT00002556|DRUG|cyclophosphamide|Given IV
48093809|NCT00002556|DRUG|prednisone|Given PO
48093810|NCT00002556|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
48093811|NCT00002556|OTHER|laboratory biomarker analysis|Correlative studies
48093812|NCT00410384|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
48093813|NCT00410384|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
48093814|NCT00410384|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
48093815|NCT03708068|OTHER|Early exclusive enteral nutrition|Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
48093816|NCT06036030|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
48093817|NCT06036030|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
48093818|NCT06036030|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
48093819|NCT06036030|OTHER|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
48093820|NCT04906382|PROCEDURE|Biopsy|Undergo biopsy
48093821|NCT04906382|DRUG|Carboplatin|Given IV
48093822|NCT04906382|DRUG|Paclitaxel|Given IV
48093823|NCT04906382|BIOLOGICAL|Tislelizumab|Given IV
48093824|NCT00003802|DRUG|pyrazoloacridine|
48093825|NCT03946202|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
48093826|NCT02535338|DRUG|Erlotinib Hydrochloride|Given PO
48093827|NCT02535338|OTHER|Laboratory Biomarker Analysis|Correlative studies
48093828|NCT02535338|DRUG|Onalespib Lactate|Given IV
48093829|NCT02535338|OTHER|Pharmacological Study|Correlative studies
48093830|NCT03605186|OTHER|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
48093831|NCT03605186|OTHER|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
48093832|NCT03423901|OTHER|Blood sampling|Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
48093833|NCT02274246|DRUG|gadobutrol|Gadobutrol administration in healthy volunteers
48093834|NCT05079217|BIOLOGICAL|High-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48093835|NCT05079217|BIOLOGICAL|Medium-dosage SARS-CoV-2 vaccine|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48093836|NCT02304653|OTHER|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
48093837|NCT04639206|BEHAVIORAL|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
48093838|NCT00221130|PROCEDURE|surgical operation of cell transplantation|
48093839|NCT03349190|DRUG|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
48093840|NCT03717545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor~2. conditioning regimen: FLU/CY/anti-CD25 moAb"
48093841|NCT06071104|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
48093842|NCT06071104|DEVICE|UNITY VCS|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY Cataract FMS Pack, and UNITY Anterior Vitrectomy Kit
48093843|NCT05326373|DRUG|Stannous fluoride|brush twice daily with stannous fluoride toothpaste for 8 weeks
48093844|NCT04682574|DRUG|Vitamin C|mega dose is given to the selected critically ill patients
48093845|NCT03676556|DRUG|Lidocaine|Two sterile gauzes will be dampen with the content of the syringe (20ml lidocaine 0.5%) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
48093846|NCT03676556|DRUG|Saline Solution|Two sterile gauzes will be dampen with the content of the syringe (20ml saline serum) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
48093847|NCT02883543|DRUG|icotinib|Icotinib is orally administered three times per day.
48093848|NCT02883543|DRUG|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
48093849|NCT02883543|RADIATION|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
48093850|NCT02723656|BEHAVIORAL|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
48093851|NCT02723656|BEHAVIORAL|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
48093852|NCT04808869|OTHER|Exercise|Cycling 3 times a week for 15 minutes at 70 rpm using blood flow restriction cuffs at different occlusions.
48093853|NCT03437798|OTHER|Disease status|Women who reported periodontal disease diagnosis/condition
48106749|NCT05237219|PROCEDURE|Passive heating|Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
48270170|NCT05158855|DIETARY_SUPPLEMENT|Bacillus subtilis spore extract|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
48270171|NCT03776656|DRUG|Allopurinol|Daily oral administration
47920861|NCT00907179|DRUG|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
47920862|NCT00907179|DRUG|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
47920863|NCT00512629|DRUG|Omegaven|Omegaven is a fish based intravenous fat emulsion
47920864|NCT00512629|DRUG|Intralipid|Intralipid is a plant based intravenous fat emulsion
47920865|NCT03892278|BEHAVIORAL|Water-based aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.
47920866|NCT03892278|BEHAVIORAL|Water-based aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
47920867|NCT03892278|BEHAVIORAL|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
47920868|NCT05674097|OTHER|no intervention|no intervention
47920869|NCT04107389|BEHAVIORAL|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
47920870|NCT04107389|BEHAVIORAL|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
47920871|NCT06111118|DEVICE|ThermaCare HeatWraps|ThermaCare HeatWraps application
47920872|NCT06129617|DEVICE|Hemodialysis|5 treatments with hemodialysis on day 1, 2, 3, 5 and 7
47920873|NCT06129617|DEVICE|ADVOS|5 treatments with ADVOS on day 1, 2, 3, 5 and 7
47920874|NCT02010151|OTHER|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
47920875|NCT04120298|BEHAVIORAL|Supervised exercise|An individualised exercise programme supervised by a trained instructor
47920876|NCT06311318|PROCEDURE|lower eyelid massage|The massage technique was executed with the patient in a fully open-eyed state, maintaining an upward gaze. The lateral aspect of the distal phalanx of the index finger was employed, exerting pressure on the lower eyelid to bring its margin into contact with the upper eyelid margin for a duration of 10 seconds per repetition. This procedure comprised 10 repetitions per set, administered once hourly, spanning 10 hours daily. The massage instruction was provided either by the authors or plastic surgery residents.
47920877|NCT05802953|OTHER|Physical assessments|Physical assessments include the presence of joint sounds (yes/no), Fonseca Anamnestic Questionnaire, tenderness/pressure pain threshold rating, muscle strengths assessments, temporomandibular joint and cervical region range of motion measurements, and pain.
47920878|NCT05802953|OTHER|Questionnaire|General Health Questionnaire-28 and SF-36 will be apply.
47920879|NCT05912790|DEVICE|eyeTube|Implantation of a drainage device in the eye, in combination with the eyeWatch implant
47920880|NCT00886847|PROCEDURE|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
47920881|NCT03068091|DEVICE|Chest CT|Inspiration and expiration chest CT
47920882|NCT03068091|DIAGNOSTIC_TEST|Pulmonary Function Testing|Measure lung function
48270172|NCT05085509|PROCEDURE|US guidance and MB staining|Ultrasound guidance and methylene blue staining
48270173|NCT05328570|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
47920883|NCT01774656|DRUG|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
47920884|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (ZCB00) vs. an enhanced monofocal IOL (ICB00)
48093854|NCT04259762|BEHAVIORAL|Breast, Colorectal, and Cervical Cancer Screening Interventions|Adult men and women will receive age- and gender-specific interventions. Women age 50-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 50-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The 4-week interventions, delivered once a week, will consist of educational sessions that discuss cancer-specific information (i.e., breast, colorectal, and cervical cancer): breast (colorectal, cervical) cancer myths and facts, risk factors and symptoms, screening, and review/action plan. The educational sessions will be complemented by cancer-specific small media (brochure).
48093855|NCT00503074|BEHAVIORAL|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
48093856|NCT00503074|BEHAVIORAL|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
48093857|NCT03605329|OTHER|to explore the severity of NAC in case of OSAS|"After overnight polysomnography, cardiovascular autonomic neuropathy will be evaluated by different methods: study of HRV, cardiovascular autonomic reflex test (Ewing), measurements of urinary levels of catecholamines and measurements of sweat gland dysfunction using Sudoscan.~The severity of CAN will be evaluated in T1D patients with moderate to severe OSAS (apnea hypopnea index (IAH) ≥15 / hour) compared to T1D patients with IAH \<15 / hour."
47920885|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Sensar 1 AAB00) vs. an enhanced monofocal IOL (ICB00)
48093858|NCT02307123|PROCEDURE|Intubation|HEMS physician prehospital intubation
48093859|NCT06250439|OTHER|ECMO-Flow variations|"The protocol unfolds in 5 steps as follows, each step lasting between 10 and 15 minutes to allow for the patient's hemodynamic adaptation. At each step, invasive and non-invasive hemodynamic evaluation is performed.~1. The 1st step is called 100% flow: it involves recording the patient's hemodynamic measurements at the baseline, i.e., at 100% of their ECMO-VA flow, previously set by the clinician entirely independently of the study.~2. The 2nd step is called 125% flow: the patient's ECMO-VA flow is increased to 125% of the initial flow.~3. The 3rd step is called 150% flow: the patient's ECMO-VA flow is increased to 150% of the initial flow.~4. The 4th step is called 175% flow: the patient's ECMO-VA flow is increased to 175% of the initial flow.~5. The 5th and final step is called 200% flow: the patient's ECMO-VA flow is increased to 200% of the initial flow."
48093860|NCT03836664|DRUG|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
48093861|NCT03836664|DRUG|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
47920886|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (Vivinex XY1) vs. an enhanced monofocal IOL (Vivinex impress)
47920887|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Vivinex impress) in both eyes
48093862|NCT05741411|OTHER|RPM-assisted specialist access|Participants will be prompted to report current symptoms and activity once a day via remote patient monitoring chat technology for up to 28 days following injury. Patients with either escalating or plateauing symptoms will be flagged, with an electronic alert sent via the electronic health record to a nurse navigator. The nurse navigator will have access to the symptom data and facilitate scheduling an in person or telehealth specialist visit as indicated. Symptoms will continue to be monitored through the 28-day acute study period with additional clinical visits occurring according to clinical need.
48093863|NCT01388543|DRUG|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
47920888|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (EnVista) vs. an enhanced monofocal IOL (LuxSmart)
47920889|NCT05822089|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of an enhanced monofocal IOL (Acrysof IQ Vivity) in both eyes if irregular astigmatism is observed
47920890|NCT06001359|OTHER|No intervention|No intervention
48093864|NCT02350361|DRUG|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
48093865|NCT02350361|DRUG|Placebo|Placebo
48093866|NCT03310463|DRUG|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
48093867|NCT05883800|RADIATION|On-couch adaptive radiotherapy|A new treatment plan, guided by volumetric images, is created at each treatment session
48093868|NCT03610633|DRUG|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
47920891|NCT00554281|DEVICE|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
47920892|NCT01277003|DEVICE|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
47920893|NCT01277003|DEVICE|TENS|tow therapeutic points, each for 15 minutes
48093869|NCT03610633|DRUG|Placebo|Saline solution.
47920894|NCT03635450|BIOLOGICAL|Infusion of hCT-MSC|Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
48093870|NCT04848896|DEVICE|CORI Robotics|Total knee arthroplasty (TKA) treated with CORI Robotics System.
48093871|NCT04848896|PROCEDURE|Conventional Procedure|Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
47920895|NCT05972057|PROCEDURE|cardiac surgery|All cardiac surgery patients who met the inclusion criteria were included in the cardiac surgery department of Renji Hospital.
47920896|NCT02161692|DRUG|Cyclophosphamide|
47920897|NCT02161692|DRUG|Etoposide|
47920898|NCT02161692|DRUG|Cisplatin|
48093872|NCT01275053|DRUG|leptin|0.01mg/kg
47920899|NCT02161692|DRUG|Bleomycin|
47920900|NCT02161692|DRUG|Carboplatin|High dose carboplatin
47920901|NCT03399396|BEHAVIORAL|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
47920902|NCT02864654|PROCEDURE|ADRC injection|10 mL of autologous ADRC suspension will be injected intramuscularly
47920903|NCT02864654|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
47920904|NCT02864654|PROCEDURE|Liposuction|
47920905|NCT03905044|OTHER|eyes with congenital cataracts|observation
47920906|NCT05697185|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
47920907|NCT04402255|OTHER|pilates exercise|The key elements of Pilates during supine, prone, side-lying and standing positions will be taught. These key elements are: breathing (diaphragmatic), focusing (neutral position), rib cage placement, shoulder placement, head and neck placement (neutral position). Then, Pilates based 'mat' exercises will be performed by the physiotherapist in the clinic for 8 weeks, 2 days / week, 16 sessions. Each session will be programmed to be 45 minutes. During all exercises, including warm-up and cooling, patients will be asked to provide key elements and protect them during movements. Depending on the condition of the patients, the exercises will be advanced from easy to difficult.
47920908|NCT02150434|DEVICE|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
47920909|NCT02150434|DRUG|Compressed air|compressed air delivered at a fixed flow of 2 L/min
47920910|NCT02150434|DRUG|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
47920911|NCT06057961|OTHER|Art Therapy|8 meetings in 1 year
47920912|NCT00266058|DRUG|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
47920913|NCT03505840|DIAGNOSTIC_TEST|Ultrasound with Doppler and 3D technology|ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
47920914|NCT04052178|DEVICE|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
47920915|NCT04052178|DEVICE|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
47920916|NCT04052178|DIETARY_SUPPLEMENT|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
47920917|NCT03218800|COMBINATION_PRODUCT|Ertapenem|"Dose: 1g per day if creatinine clearance \> 30mL/min or 500 mg per day if creatinine clearance \< 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
47920918|NCT06286189|DRUG|Placebo oral tablet|Placebo capsule taken 30 min before sleep
47920919|NCT06286189|DRUG|Trazodone Hydrochloride|Trazodone 100 mg 30 min before sleep
47920920|NCT01811056|DRUG|Mifepristone|Mifepristone use outside of the center
48093873|NCT04327596|PROCEDURE|RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter|Ablation of AF is standard of care in the management of patients with paroxysmal or persistent AF. The most common triggers initiating AF arise from pulmonary veins (PV) and successful electrical isolation of PV's can significantly reduce the burden of AF. Therefore, the main objective in patients undergoing ablation of AF is to achieve PV isolation.
48093874|NCT02931162|OTHER|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
48093875|NCT02931162|OTHER|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
48093876|NCT01730417|DRUG|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
48093877|NCT06139211|BIOLOGICAL|JS015|JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
48093878|NCT06139211|BIOLOGICAL|Toripalimab|Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.
48093879|NCT06139211|BIOLOGICAL|Paclitaxel|Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.
48093880|NCT06139211|DRUG|Irinotecan|Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
48093881|NCT06139211|DRUG|Capecitabine|Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
48093882|NCT06139211|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
48093883|NCT06139211|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
48093884|NCT06139211|DRUG|Fluorouracil|Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
48093885|NCT06139211|DRUG|Leucovorin|Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
47920921|NCT02093052|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
48093886|NCT06139211|DRUG|Gemcitabine|Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
48093887|NCT06139211|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
47920922|NCT02093052|BEHAVIORAL|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
47920923|NCT02894502|BEHAVIORAL|Motivational interviewing|The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
48093888|NCT03553095|PROCEDURE|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
48093889|NCT06475677|DEVICE|OrthoCor Advanced System|The OrthoCor Advanced System is a portable battery-operated non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) plus heat therapy for general use pain relief. It utilizes a wrap that positions the device over painful areas and joint motion tracking recorded by a smart device application to monitor recovery metrics and therapy compliance.
48093890|NCT05177081|DEVICE|Preemptive management using home BIA monitoring system|Patients check their body composition and fluid using Home BIA system. Investigators analyze patients' body congestion status and send patient's edema status and direction of extra-diuretics usage to enrolled patients every one week.
48093891|NCT02785601|DRUG|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
48093892|NCT04581590|OTHER|Cognitive training|Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
47920924|NCT00593476|OTHER|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
47920925|NCT00593476|OTHER|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
48093893|NCT03677947|BEHAVIORAL|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
48093894|NCT03677947|OTHER|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
48093895|NCT05640128|OTHER|Aldosterone in HPLC-MS/MS|Aldosterone in HPLC-MS/MS
47920928|NCT05786742|RADIATION|grade and compare reported side effects between groups|"Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment."
47920929|NCT03007810|DRUG|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
47920930|NCT03007810|DRUG|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
48093896|NCT05392426|DEVICE|Left Ventricular Global Longitudinal Strain|Left Ventricular Global Longitudinal Strain is collected from Speckle tracking imaging (STI) technique of echocardiography. This index is tested before and after the surgery.
47920931|NCT03624010|DRUG|Levosimendan 2.5 mg/ml Injectable Solution|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
47920932|NCT00915499|DEVICE|VPAP Adapt SV|Comparison of ASV and CPAP modes
47920933|NCT02292914|PROCEDURE|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
48093897|NCT05392426|DEVICE|EF CO SV EDV ESV|Ejection fraction、cardiac output、stroke volume、end diastolic volume、end systolic volume. These indexes are collected before and after the surgery, using traditional echocardiography.
48093898|NCT06379360|DRUG|Hypomethylating agent, Azacitidine or Decitabine|All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.
48093899|NCT01642264|BEHAVIORAL|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
48093900|NCT03957980|OTHER|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
47920934|NCT02292914|PROCEDURE|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
47920935|NCT00792571|DRUG|Beraprost Sodium Modified Release|
47920936|NCT01795768|DRUG|AZD 4547|
47920937|NCT03826784|COMBINATION_PRODUCT|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
47920938|NCT04204876|DIAGNOSTIC_TEST|Magnet Resonance Imaging (MRI)|MRI with and without Gadolinium contrast agent for the following vessels: thoracic aorta (ascending, arch, descending arch, left and right common carotic, subclavian, and vertebral artery)
47920939|NCT04204876|DIAGNOSTIC_TEST|PET/CT analysis|Standard value uptake measurement (SUV) based on quantitative score normalized to liver (SUV vessel max/liver mean) at the following vessel regions: Carotid artery: common, internal, external; Subclavian artery; Axillary artery; Vertebral artery; Thoracic Aorta; Abdominal Aorta; Common femoral artery; Deep femoral artery; Popliteal artery
47920940|NCT03663660|OTHER|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
47920941|NCT00163917|DEVICE|Virtual reality relaxation|
47920942|NCT00250146|BEHAVIORAL|Gluten (behaviour)|
47920943|NCT03094507|DRUG|Tivicay|50 mg once daily
47920944|NCT03094507|DRUG|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
47920945|NCT02776618|PROCEDURE|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
47920946|NCT03836001|DRUG|Serlopitant Tablet|Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.
47920947|NCT03836001|DRUG|Placebo Oral Tablet|The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
48093901|NCT01070056|BEHAVIORAL|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
48093902|NCT01070056|BEHAVIORAL|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
48093903|NCT03860246|DIAGNOSTIC_TEST|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
47920948|NCT00181597|DRUG|Trilostane|Taken orally once a day for three days then twice daily thereafter.
47920949|NCT00181597|DRUG|Hydrocortisone|Taken orally with trilostane.
47920950|NCT00132977|DEVICE|Cardiac Resynchronization Therapy|
47920951|NCT02384798|OTHER|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
47920952|NCT02384798|OTHER|interval training|interval training
47920953|NCT04782206|PROCEDURE|superior hypogastric plexus block|superior hypogastric plexus chemical neurolysis
47920954|NCT04782206|PROCEDURE|pulsed radiofrequency at S3 root plus superior hypogastric plexus block|pulsed radiofrequency neuromodulation at S3 root plus superior hypogastric plexus chemical neurolysis
47920955|NCT04781933|DIETARY_SUPPLEMENT|Treatment with Combo|Treatment with Combo
47920956|NCT04781933|OTHER|Treatment with placebo|Treatment with placebo
47920957|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
47920958|NCT01589653|DRUG|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
47920959|NCT02380768|DEVICE|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
48093904|NCT05550974|DEVICE|Minimally Invasive Surgery|gynecological, urologic, thoracic, plastic and reconstructive and ENT etc. endoscopic and laparoscopic surgical procedures
48093905|NCT03673202|DIAGNOSTIC_TEST|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
48093906|NCT00948844|DEVICE|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
48093907|NCT05035836|DRUG|Zanidatamab|Given IV
48093908|NCT05035836|DRUG|Letrozole|Given by PO
48093909|NCT05035836|DRUG|Tamoxifen|Given by PO
48093910|NCT04569214|DRUG|PAZ320|Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
47920960|NCT02380768|DEVICE|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
48093911|NCT04569214|OTHER|Placebo|Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
48093912|NCT06486779|OTHER|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
47920961|NCT06426706|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Before the induction of general anesthesia, under aseptic conditions, serratus posterior superior intercostal plane block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
47920962|NCT06426706|PROCEDURE|Paravertebral Block|Before the induction of general anesthesia, under aseptic conditions, paravertebral block will be performed with a single dose of 30 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
47920963|NCT02704390|DRUG|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
47920964|NCT00458770|PROCEDURE|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
47920965|NCT02206789|DRUG|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
47920966|NCT02206789|DRUG|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
47920967|NCT04578821|OTHER|Educational intervention|Educational intervention
47920968|NCT00635258|DRUG|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
47920969|NCT00635258|DRUG|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
47920970|NCT04951661|DEVICE|Virtual Reality|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
48093913|NCT02060097|DIETARY_SUPPLEMENT|Cocoa flavanol beverage|
48093914|NCT02060097|DIETARY_SUPPLEMENT|Placebo beverage|
48093915|NCT04282746|DRUG|JNJ-54135419|Single dose of JNJ-54135419 oral solution will be administered sublingually.
48093916|NCT05843500|OTHER|Survey|Patients who received medical, surgical or interventional treatment for chronic thromboembolic pulmonary hypertension will be followed and given quality of life questionnaires.
48093917|NCT06165679|DRUG|Prilocaine|The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl
48093918|NCT06165679|DRUG|Bupivacaine|The patients will receive a single injection of spinal anesthesia using Bupivacaine plus fentanyl
48093919|NCT03185429|BIOLOGICAL|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.
48093920|NCT03185429|DRUG|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
48093921|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
48093922|NCT01013675|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
48093923|NCT06433193|DEVICE|PAK HD Sorbent Therapy|"Study Period 1:~Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment.~Study Period 2:~Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful."
48093924|NCT02089451|DRUG|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
48093925|NCT02583074|PROCEDURE|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
48093926|NCT02583074|PROCEDURE|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
47920971|NCT03248349|DRUG|Pharmacokinetics|"* Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~* Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~* Whole blood is stored for DNA analysis~* Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis"
47920972|NCT03179202|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain."
47920973|NCT00123643|DRUG|rosiglitazone|
47920974|NCT00123643|DRUG|glyburide|
47920975|NCT05466370|BIOLOGICAL|Transfusion of Allogeneic Blood|Transfusion of Allogeneic Blood
47920976|NCT04679415|DRUG|hzVSF-v13|Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
48093927|NCT00765661|DRUG|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"
48093928|NCT00765661|DRUG|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
47920977|NCT04679415|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
48093929|NCT03243760|DRUG|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
48093930|NCT03243760|DRUG|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
48093931|NCT03243760|DRUG|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
48093932|NCT06486935|DEVICE|IoT sensors|The proposed assistive Activities of Daily Living (ADL) monitoring system consists of ambient infrared sensors embedded seamlessly into the living environment, and a visualization app. Multimodality sensors with wireless data transmission capability will be installed at different locations (e.g. bedroom, kitchen, toilet, bathroom, living room, etc.) to monitor and detect the activities performed by individual elderly, such as cooking, sleeping, going to the bathroom, going out of the apartment or potential wandering, bathroom falls, etc. In addition, a micro-bend fiber optic pressure sensor mat will be placed unobtrusively below the bed mattress to measure the elderly's heart and respiratory rates during sleep. This mat helps provide information on the quality of sleep and sleep-wake rhythms of the elderly with sleep disorders. The collected data will then be transferred through a secured gateway with Raspberry Pi to a dedicated server for data processing and analysis.
47920978|NCT00846950|DRUG|dexchlorpheniramine, lorazepam|
47920979|NCT06179342|DIAGNOSTIC_TEST|Multiple-Breath-Washout|One additional diagnostic test is performed using the Multiple-Breath-Washout technology
47920980|NCT04493892|BEHAVIORAL|Educational Intervention|Deliver an educational intervention on harmful chemical exposures, such as phthalates, found in hair care products, developed by the research team using empirical evidence with key informant feedback. The intervention will cover phthalates 1) Exposure through HCPs 2) Potential adverse health outcomes for the mother and child 3) Ways to reduce exposure
47920981|NCT04164511|DIETARY_SUPPLEMENT|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
47920982|NCT02747472|DRUG|GIP-A|GIP receptor antagonist
47920983|NCT02747472|DRUG|GIP(1-42)|GIP receptor agonist
47920984|NCT02747472|OTHER|Saline|Placebo
47920985|NCT03361683|DEVICE|High-flow nasal oxygen|Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
47920986|NCT03361683|DEVICE|Venturi mask|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
47920987|NCT04622943|BEHAVIORAL|firearms safety|interactive and engaging website with videos and educational games to teach children firearms, hunting and shooting safety
47920988|NCT04622943|BEHAVIORAL|nutrition|interactive and engaging website with videos and educational games to teach children about nutrition and exercise
47920989|NCT00495898|DEVICE|CYPHER sirolimus-eluting stent|drug-eluting stent
47920990|NCT00495898|DEVICE|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
47920991|NCT00042471|DRUG|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
47920992|NCT01764139|PROCEDURE|Blood sampling|
47920993|NCT03034239|DIETARY_SUPPLEMENT|Protein supplementation|+ insect protein
48093933|NCT06486935|OTHER|Traditional/Manual elderly monitoring|Traditional elderly care without the use of IoT sensors.
48093934|NCT00519779|DIETARY_SUPPLEMENT|omega-3 supplementation|2.5 g/day omega-3
48093935|NCT00519779|DIETARY_SUPPLEMENT|Oral omega-3 fish oil placebo|to match experimental dosage
48093936|NCT05507697|BIOLOGICAL|HUC-MSCs|5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
48093937|NCT05507697|BIOLOGICAL|Lipoic Acid|Lipoic Acid Injection，600 mg/d for 15 consecutive days
48093938|NCT02823743|DRUG|Aspirin|Daily medication
48093939|NCT02823743|DRUG|Placebo|Daily intake
48093940|NCT06132321|BEHAVIORAL|Quality of life questionnaires|Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
47920994|NCT03034239|OTHER|Resistance training|Resistance exercise
48093941|NCT02883504|PROCEDURE|Echo-Doppler examination and left heart catheterization|
48093942|NCT04699799|OTHER|Present odors to participants while recording brain activity|Present odors to participants while recording brain activity
48093943|NCT06395363|PROCEDURE|fixation method|The fixation methods were either involved trans-articular fixation through the acromioclavicular joint, supplemented with an additional cerclage wire tension band for enhanced stability. Or, creating a tunnel in the sub-acromial space posterior to the acromioclavicular joint and inserting the hook into this tunnel.
48093944|NCT03494699|BEHAVIORAL|Multidisciplinary prevention|group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking \& alcohol cessation monitoring and feedback
48093945|NCT04968587|PROCEDURE|Sustained Low-Efficiency Dialysis|All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
48093946|NCT02735265|BEHAVIORAL|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
48093947|NCT02735265|BEHAVIORAL|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
48093948|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Zirconia Implant|Orbital floor reconstruction with Patient Specific Zirconia Implant will be done
48093949|NCT06369129|PROCEDURE|Orbital floor reconstruction with Patient Specific Titanium Implant|Orbital floor reconstruction with Patient Specific Titanium Implant will be done
47920995|NCT02284841|DEVICE|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
48093950|NCT06480487|BEHAVIORAL|Feedback provided face to face|Feedback will be provided face-to-face.
48093951|NCT06480487|BEHAVIORAL|Feedback provided by electronic mail|Feedback will be provided by electronic mail.
48093952|NCT06480487|BEHAVIORAL|Feedback provided by researchers|Feedback will be provided by researchers.
48093953|NCT06480487|BEHAVIORAL|Feedback provided by authoritative bodies|Feedback will be provided by authoritative bodies.
48093954|NCT06480487|BEHAVIORAL|Feedback provided with peer comparision|Feedback will be provided with peer comparison.
48093955|NCT06480487|BEHAVIORAL|Feedback provided without peer comparision|Feedback will be provided without peer comparision.
48093956|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
48093957|NCT03115775|DIETARY_SUPPLEMENT|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
48093958|NCT03115775|DIETARY_SUPPLEMENT|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
48093959|NCT03115775|OTHER|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
48093960|NCT02124460|BEHAVIORAL|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
48093961|NCT05761067|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
47920996|NCT00367783|DRUG|CP-741,952|
47920997|NCT03894007|DRUG|Docetaxel|75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
47920998|NCT03894007|DRUG|Carboplatin|AUC 6 iv, day 1 every third week, 4 courses preoperatively.
47920999|NCT03894007|DRUG|Trastuzumab|600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
47921000|NCT03894007|DRUG|Pertuzumab|840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
47921001|NCT03894007|DRUG|Epirubicin|90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
47921002|NCT03894007|DRUG|Cyclophosphamide|600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
47921003|NCT03894007|DRUG|Atezolizumab|840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
47921004|NCT03894007|DRUG|Trastuzumab emtansine|3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
47921005|NCT03894007|DRUG|Paclitaxel|80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
47921006|NCT05176132|OTHER|Life style intervention (dietician+ physiotherapist)|Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
48093962|NCT05460130|BEHAVIORAL|Simplified Hepatitis C Virus (HCV) Treatment Protocol|A simplified, low-barrier, locally contextualized, HCV treatment protocol delivered by trained front-line health care providers (primary care physicians and mid-level providers) serving hard-to-reach-populations.
48093963|NCT01133613|DRUG|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
48093964|NCT01841840|OTHER|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
48093965|NCT01841840|OTHER|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
47921007|NCT05176132|OTHER|Self management|Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
47921008|NCT05176132|OTHER|No intervention|Control groups (BMI 20-25 and BMI 25-30)
47921009|NCT03598114|BEHAVIORAL|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
48093966|NCT01970943|OTHER|Placebo|Placebo will be compared to No Intervention.
48093967|NCT03746275|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
47921010|NCT00081094|PROCEDURE|18F-Fluorodeoxyglucose-PET (FDG-PET)|
47921011|NCT00081094|PROCEDURE|11Carbon-Acetate-PET|
47921012|NCT01542424|DRUG|biphasic insulin aspart 30|Prescribed at the discretion of the physician
47921013|NCT01542424|DRUG|insulin detemir|Prescribed at the discretion of the physician
48093968|NCT03746275|DRUG|Acetylsalicylic acid|75 - 100 mg once daily according to local label
48093969|NCT04380844|OTHER|Beprevent|10 will become part of the intervention group. At first, they are given a series of questionnaires, later (1 day later) we stay at their home to install the Beprevent device, which will remain in their home for a period of two weeks, to finish and once the device of your home, we will proceed to pass the same questionnaires as at the beginning of the test, in order to compare results.
47921014|NCT05227092|DEVICE|3D OPTIMIZED WMN MPRAGE|"* At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~* At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set."
48093970|NCT00552734|DEVICE|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
47921015|NCT05902650|DIAGNOSTIC_TEST|imaging|imaging
48093971|NCT04318444|DRUG|Hydroxychloroquine|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
48093972|NCT04318444|DRUG|Placebo oral tablet|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.
48093973|NCT06102343|DEVICE|Alma Harmony|Acne scars treatment using non-ablative ER:Glass 1540 nm laser module.
48093974|NCT04541225|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
48093975|NCT05831046|OTHER|ED management software|Patients utilize software after being screened, but prior to being re-evaluated by physician
48093976|NCT01822158|OTHER|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
48093977|NCT02527850|DEVICE|B-cure laser|
48093978|NCT06613399|PROCEDURE|MTI-TME|Multi-Technology Tntegrated Total Mesorectal Excision，MTI-TME
48093979|NCT06613399|PROCEDURE|C-TME|Conventional Total Mesorectal Excision，C-TME
48093980|NCT02977143|PROCEDURE|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
48093981|NCT05346692|OTHER|Survey Administration|Complete Survey
48093982|NCT05346692|OTHER|Interview|Complete Interview
48093983|NCT05346692|OTHER|Text Message-Based Navigation Intervention|Complete mindfulness intervention
48093984|NCT05346692|OTHER|Interview|Complete interview
48093985|NCT00986271|PROCEDURE|EVLI was determinated by PiCCO plus system.|
48106750|NCT05237219|PROCEDURE|Thermoneutral|Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
48106751|NCT05046132|DRUG|Setmelanotide|Administered once daily via SC injection.
48106752|NCT05046132|DRUG|Moxifloxacin|Moxifloxacin capsules via oral administration.
48106753|NCT05046132|DRUG|Oral Placebo|Placebo capsules via oral administration.
48106754|NCT05046132|DRUG|SC Placebo|Placebo via SC injection.
47921016|NCT03278054|OTHER|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
47921017|NCT03278054|OTHER|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
48093986|NCT06615609|BEHAVIORAL|Smart family doctor|"Based on health managers, participants were additionally provided Smart family doctor, which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the \&amp;#34;Smart family doctor\&amp;#34;."
48093987|NCT06615609|BEHAVIORAL|Health manager|Participants will received 2-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice. The research team will provide participants with one smart band, requiring them to wear the band daily to collect health data during the 6-month study period.
48093988|NCT01394770|DRUG|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
48093989|NCT04252820|DEVICE|WarmTouch total body blanket, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room
48093990|NCT05242458|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
48093991|NCT00897767|OTHER|biologic sample preservation procedure|
48093992|NCT01492309|DEVICE|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
48093993|NCT01492309|DEVICE|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
48093994|NCT02942056|DRUG|Cinnamon|Cinnamon tablets to treat type 2 DM
48093995|NCT02942056|DRUG|placebo|placebo
48093996|NCT02288715|OTHER|no interventions|
48093997|NCT03131141|DRUG|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
48093998|NCT01106287|DRUG|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
48093999|NCT01106287|DRUG|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
48094000|NCT04107519|BEHAVIORAL|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
48094001|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
48094002|NCT00531479|DRUG|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
48094003|NCT00531479|DRUG|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
48094004|NCT05310084|BIOLOGICAL|BNT162b2|Intramuscular injection
48094005|NCT05310084|OTHER|Placebo|Saline intramuscular injection
48094006|NCT05310084|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV intramuscular injection
47921018|NCT03278054|OTHER|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
48094007|NCT05169281|OTHER|Medication Disposal Packet|The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (\~$1.50/ mailed packet) and scalable.
48094008|NCT03371108|BIOLOGICAL|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
48094009|NCT03371108|BIOLOGICAL|Lantus®|Route of administration: subcutaneous injection
48094010|NCT06612554|DIETARY_SUPPLEMENT|zinc acetate|Participants in Control group. They will continue the SoC + 3 tablets of placebo and participants in Zinc supplementation group. Tablets will be separated 12h (just in case the ART is based in Integrase Inhibitors (INSTI)) during supplementation for 16 weeks with 3 tablets of zinc (83mg Zinc acetate/tablet).
48106755|NCT05907850|DRUG|Riboflavin|Commercially available source of riboflavin capsules
48094011|NCT06612554|OTHER|Placebo|participants in Control group. They will continue the SoC + 3 tablets of placebo. 3 tablets separated 12h from ART during 16 weeks
48094012|NCT02087033|DIETARY_SUPPLEMENT|ritmonutra|2 tablets a day by mouth for 4 weeks
48094013|NCT02087033|DIETARY_SUPPLEMENT|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
48094014|NCT03597308|DRUG|5mg of Oxycodone every 6 hours as needed for pain|5mg of Oxycodone every 6 hours as needed for pain
48094015|NCT03597308|DRUG|600mg of Ibuprofen every 6 hours as needed for pain|600mg of Ibuprofen every 6 hours as needed for pain
48094016|NCT03597308|DRUG|500mg of Acetaminophen every 6 hours as needed for pain|500mg of Acetaminophen every 6 hours as needed for pain
48094017|NCT06100939|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
48094018|NCT06100939|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
48094019|NCT03236233|DRUG|PC786 - Single doses|Safety and tolerability of single doses
48094020|NCT03236233|DRUG|Placebo - Single doses|Safety and tolerability of single doses
48094021|NCT03236233|DRUG|PC786 - Repeat doses|Safety and tolerability of repeat doses
48094022|NCT03236233|DRUG|Placebo - Repeat doses|Safety and tolerability of repeat doses
48094023|NCT00819910|DRUG|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
48094024|NCT00819910|DRUG|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
48094025|NCT00819910|DRUG|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
48094026|NCT00819910|DRUG|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
48094027|NCT06456931|BEHAVIORAL|Traditional Buddhist mindfulness|Details are provided in the arm/group descriptions.
48094028|NCT06456931|BEHAVIORAL|secular mindfulness based cognitive therapy|Details are provided in the arm/group descriptions.
48094029|NCT06492603|DEVICE|Ultrasonography|Ultrasound is an assessment device that uses high-energy sound waves to look at either superficial tissues like linea alba and/or organs inside the body. The sound waves make echoes that form pictures of the tissues and organs on a computer screen (sonogram).
48094030|NCT06492603|DEVICE|The MyotonPRO Device|The MyotonPro is a portable device for measuring biomechanical and viscoelastic properties in superficial soft tissues
48094031|NCT06204185|DRUG|Metformin|Locally delivered Metformin gel in the treatment of periodontitis patients
48094032|NCT06204185|DRUG|Placebo|Placebo gel consist of drug without the active component.
48094033|NCT03342079|DRUG|Local Anesthetics,Topical|topical anesthetic
48094034|NCT03342079|DRUG|Placebos|placebo topical anesthetic
48094035|NCT06615466|RADIATION|Partial Breast Irradiation|26Gy/5.2Gy/5f
48094036|NCT01051778|DRUG|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
48094037|NCT01051778|DRUG|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
48094038|NCT00984178|OTHER|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
48094039|NCT00984178|OTHER|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
48094040|NCT03700255|PROCEDURE|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
48094041|NCT02121704|DEVICE|Magnetic Endoscope Imaging (Scope Guide)|
48094042|NCT04215913|OTHER|The investigators will extract total protein, DNA and RNA from PSC patients.|The investigators will extract total protein, DNA and RNA from PSC patients.
48094043|NCT06153888|PROCEDURE|Ultrafiltration rate|Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
48094044|NCT06479564|OTHER|free weight training and machine training|20 participants will be in control group who will only perform free weight and machine training
48094045|NCT06479564|OTHER|Aerobic Exercises|20 participants will be in experimental group giving them aerobic exercise training protocol along with free weight and machine training
48094046|NCT01380119|BIOLOGICAL|V7|experimental arm
48094047|NCT01380119|OTHER|placebo|placebo pill
48094048|NCT05058794|OTHER|Blood flow Restriction/Resistance Training|During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
48094049|NCT05058794|OTHER|Conventional Therapy Group|Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
48094050|NCT04939428|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules taken by mouth.
48094051|NCT04939428|DRUG|Placebo|Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
48094052|NCT05247840|DIAGNOSTIC_TEST|uroflowmetry|Uroflowmetry will be performed using a uroflow-cystometer (UroDoc Frytech) which determines Qmax, Qave and TQmax. Voided volume (in mL), voiding time (in sec), average and maximum urinary flow rate (Qave and Qmax in mL/sec), and time to maximum urinary flow (TQmax in sec) will be measured; urine flow acceleration (Qacc in mL/sec2) will be calculated. Qmax and Qave are defined according to the International Children's Continence Society. Voided volume will be measured by the uroflow-cystometer device; boys void in a standing, girls in a sitting position. Postvoid bladder diameter (mm) will be measured by ultrasonography and converted to bladder residual volume (mL). The device will be calibrated according to the prescribed instructions for use by a skilled technician. The examinations will take approximately 10 minutes.
48094053|NCT05247840|DIAGNOSTIC_TEST|Cardiovascular autonomic dysfunction test proposed by Ewing et al.|CAD will be assessed by five reproducible and standardized cardiovascular reflex tests described by Ewing et al. Three of the five tests assess parasympathetic function: heart rate response to deep breathing, to standing, and the Valsalva maneuver. Two tests evaluate sympathetic function which are blood pressure responses from lying to standing and at sustained handgrip. Each of these five tests is assigned a score of 0 for normal, 0.5 for borderline, and 1 for abnormal results. The sum of these 5 scores - which is the Ewing score - is used to assess severity of CAD. Patients having Ewing score ≥ 2 form the CAD + group, and patients who have less than 2 form the CAD - group.
48094054|NCT05247840|DIAGNOSTIC_TEST|peripheral nerve conduction test|Peripheral neuropathy will be evaluated by nerve conduction test. The device measures motor conduction in the lower extremities. It operates at two dedicated frequencies in order to perform a thick myelin sheath cordless fibre (5Hz) and thin myelinated nerve fibre (2000Hz) examination. The device will be calibrated according to the prescribed instructions for use by a skilled technician.
48094055|NCT04737590|DEVICE|Bioactive glass|Comparison of bioactive glass to allogenic bone in pediatric bone cysts
48094056|NCT05963776|DEVICE|spirometry|pulmonary function tests using spirometry
48094057|NCT00009685|DRUG|VRC4302|
48094058|NCT05245656|DRUG|RB/RBAC alternating|"Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4"
48094059|NCT05245656|DRUG|RB|"Every 4 weeks for 6 cycles~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2"
47921019|NCT04653467|DRUG|GLPG4399 oral suspension|GLPG4399 for oral administration
47921020|NCT04653467|DRUG|GLPG4399 capsules|GLPG4399 for oral administration
47921021|NCT04653467|DRUG|Placebo|Placebo oral suspension
47921022|NCT02812498|OTHER|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
47921023|NCT02812498|OTHER|Standard|Group of patients followed in a traditional way
47921024|NCT01996839|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
47921025|NCT01996839|DRUG|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
48094060|NCT04670575|PROCEDURE|Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL|Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
48094061|NCT04547543|OTHER|Videoconsultation|Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status
48094062|NCT06613425|COMBINATION_PRODUCT|Combined platelets|1 therapeutic dose combined platelet contained no less than 2.5 ×10\^11 platelets as a quality standard.
48094063|NCT03400098|DRUG|Inotersen|Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
48094064|NCT04096313|DIAGNOSTIC_TEST|HbA1c, Lipids, UACR|compare diagnostic tests to reference methods
47921026|NCT01996839|DRUG|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
47921027|NCT01996839|DRUG|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
47921028|NCT04408222|OTHER|Awake proning|Prone positioning of awake, as tolerated, for up to 24 hours daily.
47921029|NCT00932828|DRUG|Peanut oral immunotherapy|Defatted peanut in flour form to be used as treatment for peanut allergy
47921030|NCT04939350|OTHER|questionnaire|patients will complete a vaccination questionnaire
47921031|NCT04812847|DIAGNOSTIC_TEST|Identification of MDR characteristics|Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
48094065|NCT03668067|DEVICE|2WIN photoscreener|conventional infrared off-axis photoscreener
48094066|NCT06341374|BIOLOGICAL|Influvac Tetra|All participants will take influenza vaccine (Influvac Tetra, Abbott Biologicals, IL, USA) and the trained immune response will be evaluated.
48094067|NCT04643743|DEVICE|Endarterectomy|Endarterectomy is a surgical procedure to remove the atheromatous plaque material, or blockage, in the lining of an artery constricted by the buildup of deposits. It is carried out by separating the plaque from the arterial wall.
48094068|NCT04912557|OTHER|postoperative pain assess|numerical pain scale and Metameric levels of cold insensitivity
48094069|NCT04141163|DRUG|Metformin|Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
48094070|NCT04141163|DRUG|Placebo oral tablet|No therapeutic effect
48094071|NCT06478199|DIAGNOSTIC_TEST|semen analysis|lab invesigation
48094072|NCT05993208|DIAGNOSTIC_TEST|optical coherence tomography,multifocal electroretinogram. VA measurment|retinal photography
48094073|NCT01853358|BIOLOGICAL|NK Cell infusion|"* level 1: 1 x 10e6 NK cells /kg;~* level 2: 5 x 10e6 NK cells /kg;~* level 3: \> 5.10e6 and ≤ 5.10e7 cellules NK/kg"
48094074|NCT04155853|PROCEDURE|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
48094075|NCT04155853|PROCEDURE|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
48094076|NCT04252937|DRUG|Adrecizumab|HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
48094077|NCT02485964|OTHER|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
47921032|NCT04004871|DRUG|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
47921033|NCT04004871|RADIATION|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
47921034|NCT04944108|PROCEDURE|LISA approach|Participants will be randomized to administer surfactant in a preterm manikin by using the LISA approach (thin catheter) or the INSURE approach (tracheal tube)
47921035|NCT04944108|PROCEDURE|Insure approach|Participants will be randomized to administer surfactant in a preterm manikin by using the INSURE approach (tracheal tube)
47921036|NCT01199367|DRUG|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
48094078|NCT02600429|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
48094079|NCT02600429|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
48094080|NCT05190185|BIOLOGICAL|TAA06 injection|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.
48094081|NCT06480422|OTHER|Segmental breathing technique|To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly. Blow patient's nose and huff, cough to clear your upper airways to mucus. This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath. Hold the breath for three seconds. With some gentle force exhale all the air out of your lungs. Repeat three times. Do not cough untill after the third breath. Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, 20 and 45 minutes.
48094082|NCT06480422|OTHER|autogenic drainage|"To begin an autogenic drainage sit in a relaxed seated position with neck extended slightly.Blow ptient's nose and huff, cough to clear your upper airways to mucus.This technique has three phases. Moving mucus from small airways (Unsticking), Moving mucus from small airways to medium sized airways(Collecting), Moving mucus from medium sized airways to large airways(Evacuation) Take in a deep breath.Hold the breath for three seconds.With some gentle force exhale all the air out of your lungs. Repeat three times.Do not cough untill after the third breath.~Repeat sessions 3 times in a week for 4 almost weeks. Repeat the cycle untill you have cleared your lungs as much as possible, which should take between 20 and 45 minutes."
48094083|NCT03937687|DRUG|Caffeine+TeaCrine+Dynamine|combination of caffeine, TeaCrine, and Dynamine
48094084|NCT03937687|DRUG|Placebo|Placebo
48094085|NCT03937687|DRUG|Caffeine|Caffeine
48094086|NCT04591899|DEVICE|CAD/CAM splints|"Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D."
48094087|NCT00082485|DRUG|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
48094088|NCT00082485|OTHER|Placebo|Placebo
48094089|NCT04398459|DRUG|Ibrutinib|Each recruited subject will accept Ibrutinib treatment.
48094090|NCT00852228|DRUG|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
48094091|NCT00852228|DRUG|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
48094092|NCT00852228|DRUG|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
48094093|NCT04485780|BIOLOGICAL|botulinum toxin type A|In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
48094094|NCT04068597|DRUG|CCS1477|Oral capsule
47921037|NCT05466864|DEVICE|Belun Sleep platform|BSP(Belun Technology Company Limited) is a novel wearable system using a neural network algorithm that consists of a patented wearable device (Belun Ring), a charging cradle, and cloud-based software. The Belun Ring, an FDA-cleared pulse oximeter, acquires signals from the radialis indicis artery of the proximal index finger. The Belun Ring total sleep time can be derived from features extracted from accelerometer, SpO2, and PPG signals, whereas Belun Ring AHI can be derived from Ring-TST and features extracted from HRV and SpO2 changes. The BSP proprietary OSA detection algorithm was using neural network. BSP performance can be improved by training the algorithm through continual data collection. To our knowledge, BSP is the only validated sleep platform using a medical-grade wearable pulse oximeter, actigraphy, and artificial intelligence algorithm that has the capability to identify sleep stages, detect OSA events, and monitor autonomic nervous system activity changes during sleep.
47921038|NCT01661842|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
47921039|NCT01661842|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
47921040|NCT03695770|OTHER|kit for self-diagnosis and self-treatment|distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
48094095|NCT04068597|DRUG|Pomalidomide|oral capsule
48094096|NCT04068597|DRUG|Dexamethasone|oral tablet
48094097|NCT04068597|DRUG|Azacitidine|Powder suspension for Injection
48094098|NCT04068597|DRUG|Venetoclax|Oral tablet
48094099|NCT01416909|OTHER|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
48094100|NCT01416909|OTHER|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
48094101|NCT01416909|OTHER|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
48094102|NCT00696904|DRUG|ABT-333|Capsule, see arms for intervention description
48094103|NCT00696904|DRUG|Placebo|Capsule, see arms for intervention description
48094104|NCT00372970|DRUG|Botulinum toxin A|200 U given by injection into the pylorus.
48094105|NCT00372970|DRUG|Placebo|saline injection into pylorus.
48094106|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
48094107|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
48094108|NCT02109679|DRUG|BI 187004|multiple doses BI 187004 given as tablets
47921041|NCT02575547|DRUG|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
48094109|NCT02109679|DRUG|metformin|multiple doses metformin given as tablet
48094110|NCT03582137|DRUG|Cannabidiol|Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
48094111|NCT03582137|OTHER|Placebo|Subjects randomized to this arm will receive Placebo
48094112|NCT04544540|OTHER|Units of transfusion|Participants will either receive 1-unit or 2-unit red blood cell outpatient transfusions
48094113|NCT01813955|DRUG|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
48094114|NCT01895257|DEVICE|HAI-90Y radioembolization (SIR-spheres injection)|"Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~1. Hepatic Angiogram~2. Liver-Lung Break-Through Nuclear Scan"
48106756|NCT05907850|DRUG|Placebo|Placebo capsule compounded to be similar in appearance to the active intervention
48106757|NCT04095403|OTHER|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
48106758|NCT04095403|OTHER|passive cooling|Supine rest.
48094115|NCT01895257|DRUG|systemic chemotherapy LV5FU2|"Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure."
48094116|NCT03214887|BIOLOGICAL|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
48094117|NCT00248612|DRUG|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
48094118|NCT00248612|BEHAVIORAL|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
48094119|NCT00248612|OTHER|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
48094120|NCT00248612|OTHER|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
47921042|NCT03255083|DRUG|DS-1205c|DS-1205c 200 mg capsule
47921043|NCT03255083|DRUG|Osimertinib|Osimertinib 80 mg tablet
48094121|NCT06501118|OTHER|Education|"1. Standardized materials to discuss the rationale and procedural aspects of the intervention, including details on the specific oxygen target-related modifications to the mechanical ventilation order-set prior to starting the intervention phase.~2. Virtual respiratory therapist (vRT) - directed real-time feedback on adherence to the SpO2 target range as a part of the mechanical ventilation order-set embedded in UCHealth EHR (EPIC)."
48094122|NCT00478556|DRUG|Omnipaque|Oral CT contrast
48094123|NCT00478556|DRUG|Gastroview|Oral CT contrast
48094124|NCT03353272|BEHAVIORAL|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
47921044|NCT03661567|RADIATION|chest radiation|split-course chest radiation
48094125|NCT06396390|DRUG|Progestin|In this regimen, Dydrogesterone (Duphaston©; 10mg; Deva Holding, Tekirdag/Turkiye) 3x1 PO will be started on day 2 of menstrual cycle and will be continued until the trigger day. The patient's dosage will be tailored based on their BMI, AMH value, and the number of follicles observed during the ultrasound examination on the 2nd day of the menstrual cycle. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
48094126|NCT06396390|DRUG|GnRH antagonist|In this regimen, Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day. For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH, Kiel/Germany) 2 amp SC will be used. All oocytes picked-up will be frozen.
48094127|NCT05805345|DEVICE|Delefilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
48094128|NCT05805345|DEVICE|Lehfilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
48094129|NCT05805345|DEVICE|Lotrafilcon B toric soft contact lens|Commercially available silicone hydrogel contact lens
48094130|NCT05805345|DEVICE|Verofilcon A toric soft contact lens|Commercially available silicone hydrogel contact lens
48094131|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
48094132|NCT01408680|DIETARY_SUPPLEMENT|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
48094133|NCT01408680|DIETARY_SUPPLEMENT|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
48094134|NCT05191901|OTHER|Stress Ball|Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
48094135|NCT02802020|DEVICE|Pancreatic fully-covered self-expanding metal stent (FCSEMS)|The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
48094136|NCT01409174|DRUG|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I."
47921045|NCT03661567|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
47921046|NCT03661567|DRUG|Methylprednisolone|Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
47921047|NCT03554694|DIETARY_SUPPLEMENT|Prebiotics|Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
47921048|NCT03554694|DIETARY_SUPPLEMENT|Maltodextrin (placebo)|Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
47921049|NCT05844475|PROCEDURE|Conventional Free Gingival Graft Approach (FGG)|Conventional Free Gingival Graft Approach involving palatal soft tissue harvesting
47921050|NCT05844475|PROCEDURE|Buccal Strip Graft with a collagen matrix (bSG + CM)|A small strip of keratinized gingiva is harvested from the buccal gingiva of a site showing abundant keratinized gingiva, and combined with a xenogeneic collagen matrix
47921051|NCT01605630|BEHAVIORAL|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
47921052|NCT01605630|BEHAVIORAL|Control|standard of care
48094137|NCT01409174|DRUG|Temozolomide|200 mg/m\^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
48094138|NCT01409174|DRUG|Cisplatin|25 mg/m\^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
48094139|NCT01409174|DRUG|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
48094140|NCT01409174|DRUG|Interleukin-2|9 million IU/m\^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
48094141|NCT00832780|RADIATION|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
48094142|NCT03829280|BEHAVIORAL|Cognitive Adaptation Training|Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior
48094143|NCT03829280|BEHAVIORAL|Community Treatment|Medication follow-up and case management as provided in usual community care in the setting
48094144|NCT05922436|DRUG|QLG2071|intravenous injection
48094145|NCT05922436|DRUG|Cleviprex®|intravenous injection
48094146|NCT02639962|RADIATION|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
48094147|NCT05471726|BEHAVIORAL|Prospective audit-and-feedback|The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
48094148|NCT06420167|DRUG|Dapagliflozin|10mg orally once daily
47921053|NCT05867589|DRUG|68Ga/18F-FAPI-04|Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
47921054|NCT02250729|OTHER|intradermal pholcodine allergy test in cases|
48094149|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation with Volume Guarantee (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P and high-frequency tidal volume (VThf).
48094150|NCT05592431|DEVICE|High Frequency Oscillatory Ventilation (SLE6000;SLE)|ventilator settings will be recorded such as: inspiratory: expiratory ratio (I:E), fractionated inspired oxygen (FiO2), mean airway pressure (MAP), frequency (HZ), delta P
48094151|NCT00558753|DRUG|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
48094152|NCT00558753|DRUG|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
48094153|NCT04344990|PROCEDURE|Epidural analgesia - Group E|Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
48094154|NCT04344990|PROCEDURE|Femoral blockade - Group F|Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
48094155|NCT04344990|PROCEDURE|Intraarticular infusion - Group I|Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
48094156|NCT00000816|DRUG|Sulfamethoxazole-Trimethoprim|
48094157|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
48094158|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
48094159|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
48094160|NCT01169519|DRUG|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
48094161|NCT00483912|DEVICE|Molecular adsorbent recirculating system|
47921055|NCT02250729|OTHER|Blood sampling|
47921056|NCT01986556|DRUG|Lesinurad 400 mg (Site 1)|
47921057|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot A)|
47921058|NCT01986556|DRUG|Lesinurad 400 mg (Site 2, Lot B)|
47921059|NCT00966875|BIOLOGICAL|LY2439821|Subcutaneous
47921060|NCT00966875|DRUG|Placebo|Subcutaneous
47921061|NCT03033550|BEHAVIORAL|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
47921062|NCT03039946|DEVICE|Closed-Loop GDFT|Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
48094162|NCT02760862|DRUG|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
48094163|NCT02760862|DRUG|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
48094164|NCT04864561|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart
48094165|NCT04864561|BIOLOGICAL|AZD1222|2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.
48094166|NCT04864561|BIOLOGICAL|VLA2001 - adolescent part|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
48094167|NCT04864561|BIOLOGICAL|Placebo|2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
48094168|NCT02215798|DRUG|Cymbalta|
48094169|NCT00071643|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
47921063|NCT03039946|OTHER|Restrictive Fluid Therapy|Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
47921064|NCT04247542|DRUG|Ibezapolstat|Investigational antibacterial agent
47921065|NCT04247542|DRUG|Vancomycin|Active comparator
47921066|NCT04028271|DEVICE|Comfort-in injection system|local anesthesia during dental treatment
47921067|NCT04028271|OTHER|conventional injection with dental needle|for local anesthesia during dental treatment
47921068|NCT05744245|OTHER|Swallow Strength and Skill Training|Practice swallowing exercises with biofeedback and strength and skill targets
48094170|NCT00071643|DRUG|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
48094171|NCT00071643|OTHER|Placebo|Participants will receive a placebo pill.
48094172|NCT02860091|DRUG|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
48094173|NCT05051397|BIOLOGICAL|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
48094174|NCT05051397|BIOLOGICAL|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
48094175|NCT00715806|DEVICE|Open MRI scanner.|Imaging in an Open MRI scanner.
48094176|NCT00715806|DEVICE|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
48094177|NCT01664234|OTHER|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
48094178|NCT01664234|OTHER|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
48094179|NCT03583437|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
48094180|NCT00230451|PROCEDURE|Radiation|
48094181|NCT00230451|DRUG|Paclitaxel|
48270174|NCT02611401|BEHAVIORAL|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
47921069|NCT03084380|BIOLOGICAL|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
47921070|NCT03084380|DRUG|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
47921071|NCT03084380|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
47921072|NCT03687463|DRUG|Decitabine|Decitabine for injection
47921073|NCT00003745|DRUG|topotecan hydrochloride|
47921074|NCT04368078|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle. Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, oral at least 38 days of each 6 weeks cycle, day 2.~Number of cycle: until progression or unacceptable toxicity events develop"
48094182|NCT00230451|DRUG|Cisplatin|
48094183|NCT00230451|DRUG|5-Fluorouracil|
48094184|NCT03042793|BIOLOGICAL|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
48094185|NCT01763736|BEHAVIORAL|Music|playlist per patient preference
48094186|NCT06201065|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48094187|NCT06201065|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
48094188|NCT06201065|DRUG|Toripalimab|240 mg iv.drip Q3W
48094189|NCT06201065|DRUG|oxaliplatin , fluorouracil, and leucovorin|FOLFOX-HAIC
48094190|NCT01627236|DRUG|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
48094191|NCT05000190|DIETARY_SUPPLEMENT|Active capsule|1 capsule daily for 28 days
48094192|NCT05000190|OTHER|Placebo capsule|1 capsule daily for 28 days
48094193|NCT01598025|RADIATION|total-body irradiation (TBI)|
48094194|NCT01598025|DRUG|thiotepa|
48094195|NCT01598025|DRUG|fludarabine phosphate|
48094196|NCT01598025|DRUG|melphalan|
48094197|NCT01598025|BIOLOGICAL|anti-thymocyte globulin|
48094198|NCT01598025|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48094199|NCT01598025|BIOLOGICAL|peripheral blood stem cell transplantation|
48094200|NCT01598025|OTHER|laboratory biomarker analysis|
48094201|NCT05356026|OTHER|Online postpartum follow-up|The women in the experimental group were administered three follow-ups (education/consultancy) in line with the timing and content in the T.R. Ministry of Health Postpartum Care Management Guide (2014). The follow-ups were performed using the Zoom® program, which enabled video talk.
48094202|NCT05841784|BEHAVIORAL|MBCT-T|MBCT-T is an 8-week group-based program that combines training in mindfulness and cognitive-behavioral therapy to reduce psychological distress and negative emotions. Each weekly 1-hour session will consist of a check-in, discussion, teaching, mindfulness or cognitive behavioral practice or exercise, inquiry by the facilitator, and summary of the at-home practice.
48094203|NCT05841784|BEHAVIORAL|Booster Mindfulness Sessions|Following the standard 8-week MBCT-T program, participants in certain arms will receive monthly MBCT-T booster sessions for 4 months of follow up. Each booster session will be 1 hour long. The sessions will include a concise review and summary of the main MBCT-T sessions.
48094204|NCT05841784|BEHAVIORAL|Website Support|Participants in certain arms will receive continuous intervention support via the use of an online study website. The website will provide quick access to intervention materials and support to encourage participants to complete the at-home practice and apply the content of the MBCT-T program to real life situations.
48094205|NCT05475470|PROCEDURE|finger-blade technique|laparoscopic access technique for group a
48094206|NCT05475470|PROCEDURE|Hasson's technique|laparoscopic access technique for group b
48094207|NCT05475470|PROCEDURE|veress needle technique|laparoscopic access technique for group c
48094208|NCT04902742|PROCEDURE|Fluoroscopy-guided ganglion impar block|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Being most commonly used technic, transsacrococcygeal technique, a 22-gauge, 1.5-inch spinal needle is advanced through the sacrococcygeal disk and positioned carefully anterior to the sacrococcygeal junction. Injection of contrast results in a classical comma sign. A mixture of steroid and local anesthetic is given.
48094209|NCT04902742|PROCEDURE|Fluoroscopy-guided caudal epidural steroid injection|Fluoroscopy guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. An 18-gauge epidural needle (Tuohy) is advanced at an angle of 45° to the skin until a 'give-way' sensation is felt and position of the needle is confirmed by lateral and anteroposterior fluoroscopic images. Then 5 ml of iohexol solution is injected through it to confirm the position. A properly placed needle would produce a classical 'inverted fern tree' appearance in anteroposterior view after dye injection or a 'filling defect'. The needle is introduced up to S3 level for proper spread of the drug. A mixture of steroid and local anesthetics is given.
48094210|NCT06085950|DEVICE|Transcranial Ultrasonic Stimulation prototype|Transcranial Ultrasonic Stimulation prototype delivers personalized low-intensity ultrasound stimulation
48094211|NCT05203055|DRUG|Peginterferon alpha-2b|180μg/w
48094212|NCT05203055|DRUG|Nucleotide Analog|Etecavir 0.5mg qd or Tenofovir 300mg qd
48094213|NCT05203055|DRUG|pulse peginterferon alpha-2b|180μg/w for 8 consecutive weeks and cessation for 4 weeks
48094214|NCT02261415|DRUG|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
48094215|NCT02261415|DRUG|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
48094216|NCT05979194|BEHAVIORAL|Labor Care Guide|Identifying information and labor characteristics at admission, supportive care, care of the baby, care of the woman, labor progress, medication, and shared decision-making
48094217|NCT03107702|DIAGNOSTIC_TEST|melatonin|the relationship between melatonin level and analgesia requirement.
48094218|NCT04305912|DEVICE|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses.
48094219|NCT04305912|DEVICE|verofilcon A|Subjects will be randomized to wear verofilcon A daily disposable lenses.
48094220|NCT00462943|DRUG|Omacetaxine mepesuccinate|"Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
48094221|NCT02060279|OTHER|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
48094222|NCT02060279|OTHER|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
48094223|NCT04159155|RADIATION|External Beam Radiation|Radiation therapy given outside the patient to a particular part of the body.
48094224|NCT04159155|DRUG|Niraparib|Oral drug
48094225|NCT04159155|RADIATION|Vaginal high-dose rate brachytherapy|Internal radiation to the vagina
48094226|NCT04159155|OTHER|Observation - no drugs|Observation
48094227|NCT03115346|OTHER|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
48094228|NCT02883322|OTHER|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
48094229|NCT02263885|DEVICE|ExAblate Transcranial System|Transcranial MRgFUS
48094230|NCT00174720|DRUG|Ciclesonide (XRP1526)|
48094231|NCT02947711|DRUG|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
47921075|NCT02366091|DRUG|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
48094232|NCT02947711|DRUG|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
48094233|NCT05213403|DIAGNOSTIC_TEST|Evaluation with new scoring system|"Evaluate whether patients who have received surgery in line with the developed scoring system have a better aesthetic and oncological outcomes"
48094234|NCT02005666|DRUG|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
48094235|NCT02005666|DRUG|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
48094236|NCT02005666|DRUG|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
48094237|NCT03000712|BIOLOGICAL|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml drug: saline solution
48094238|NCT01930279|OTHER|Blood withdrawal|Blood withdrawal
47921076|NCT02366091|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
47921077|NCT02366091|DRUG|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
47921078|NCT02265159|PROCEDURE|Focal Therapy Using High Intensity Focused Ultrasound|
47921079|NCT05082597|DEVICE|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
48094239|NCT03528954|DRUG|Propofol|Those who received intravenous propofol
48094240|NCT01886469|DRUG|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
48094241|NCT01886469|DRUG|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
48094242|NCT01886469|DRUG|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
48094243|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
48094244|NCT00990756|DRUG|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
48094245|NCT00577629|DRUG|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
48094246|NCT00577629|DRUG|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
48094247|NCT00577629|DRUG|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
48094248|NCT00577629|DRUG|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
48094249|NCT00577629|DRUG|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
48094250|NCT00577629|DRUG|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
48094251|NCT03023059|DRUG|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
48094252|NCT04759339|DRUG|AG-920|AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
47921080|NCT02998632|PROCEDURE|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
47921081|NCT02998632|PROCEDURE|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
48094253|NCT04609293|COMBINATION_PRODUCT|camrelizumab+apatinib+hyperfractionated radiotherapy|Immunotherapy, anti-angiogenesis targeted therapy combined with hyperfractionated radiotherapy
48094254|NCT02516579|DRUG|Siklos|
48094255|NCT00823589|OTHER|Blood test and clinical test|Blood test and clinical test
47921082|NCT04232332|DRUG|Recombinant human nerve growth factor injection,experimental|Intramuscular injection once on the first day according to dose requirements
48094256|NCT00180440|DEVICE|ICD|all models of Guidant/Bsc ICD's
48094257|NCT03936062|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
48094258|NCT03936062|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
48094259|NCT03575962|DRUG|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
48270175|NCT02611401|BEHAVIORAL|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
48094260|NCT03575962|DRUG|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
48094261|NCT02560103|OTHER|Transmeridian travel across multiple time zones|
48094262|NCT04656470|DRUG|Dexmedetomidine|Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.
48106759|NCT00872417|DRUG|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
48106760|NCT00872417|DRUG|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
48094263|NCT03022266|BEHAVIORAL|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
48094264|NCT04955795|BEHAVIORAL|Alcohol Brief Intervention (BI)|The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
48094265|NCT04955795|BEHAVIORAL|Common Elements Treatment Approach (CETA) via Telemedicine|CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
48094266|NCT01644773|DRUG|Crizotinib|"Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
48094267|NCT01644773|DRUG|Dasatinib|"Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
48094268|NCT00073957|BIOLOGICAL|rituximab|
48094269|NCT00073957|DRUG|cytarabine|to be used for CNS prophylaxis
48094270|NCT00073957|DRUG|liposomal cytarabine|to be used as CNS prophylaxis
48094271|NCT00073957|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48094272|NCT03906747|OTHER|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
48094273|NCT03906747|OTHER|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~1. Proportion of patients who fits criteria of EOL who died within 48 hours;~2. Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~3. Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~4. Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
48094274|NCT03301922|BEHAVIORAL|Metacognitive therapy and work-focused interventions|Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
48094275|NCT03301922|OTHER|Waiting list|Waiting list
48094276|NCT01079598|DEVICE|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
48094277|NCT01648283|DRUG|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
48094278|NCT01648283|DRUG|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
48094279|NCT02983214|DRUG|Clopidogrel|
47921083|NCT04232332|DRUG|Recombinant human nerve growth factor injection,single dose|Intramuscular injection once on the first day according to dose requirements
47921084|NCT04232332|DRUG|Recombinant human nerve growth factor injection,multiple dose|Intramuscular injection once daily for 7 days according to dose requirements
47921085|NCT00294762|DRUG|Tarceva|oral tablet
47921086|NCT00294762|DRUG|carboplatin|IV
47921087|NCT00294762|DRUG|paclitaxel|IV
48094280|NCT02983214|DRUG|Cilostazol|
47921088|NCT00744302|DRUG|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
47921089|NCT02459288|DRUG|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
47921090|NCT02459288|DRUG|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
47921091|NCT01809093|BIOLOGICAL|Blood draw|3-4 tablespoons of blood will be drawn, one time.
48094281|NCT03912103|OTHER|Interdisciplinary Deprescribing and Medication Optimization Intervention|as current
48094282|NCT06452407|OTHER|Implementation of elleFA smartphone application|Participants will download the elleFA application on their smartphone. Through this application, the user will be prompted to complete a short modified Biberoglu and Behrman (B\&B) questionnaire and a longer EHP-30 questionnaire monthly, for a period of 6 months. Optionally, patients may complete an additional weekly summary of their mental health symptoms, pain localization, and other symptoms. Also optionally, they may record any daily symptoms, separated into categories from lifestyle to physical pain, objectified through a 6-point Likert scale.
48094283|NCT03770624|DRUG|QL-007 tablet|QL-007 will be administered orally daily over the 28 days under fasted state.
48094284|NCT03770624|DRUG|TDF|TDF will be administered orally daily over the 28 days e.
48094285|NCT03742843|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
48094286|NCT00240643|DRUG|SB424323|
47921092|NCT01604356|PROCEDURE|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device \[Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L\] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
47921093|NCT05207722|BIOLOGICAL|CYNK-101|CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).
48094287|NCT03406429|DEVICE|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
48094288|NCT03406429|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
48094289|NCT03057561|DRUG|Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)|Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
48094290|NCT03057561|DRUG|Cardiac MRI with contrast agent, Gadovist|Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
48094291|NCT05515367|DRUG|Desidustat|Oral tablet
48094292|NCT04293991|DEVICE|High Flow Nasal Cannula|Evaluate the use of HFNC in prevention of intubation in immunocompromised patients adimitted to icu.
48094293|NCT04293991|DEVICE|Non Invasive Ventilation|Evaluate the use of HFNC in prevention of intubation in immunocompromised patient admitted to icu.
48094294|NCT05057754|BEHAVIORAL|Cooling|Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
48094295|NCT05057754|BEHAVIORAL|Heating|A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
47921094|NCT05207722|DRUG|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
47921095|NCT05207722|DRUG|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
47921096|NCT05207722|DRUG|Recombinant Human Interleukin-2|6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
47921097|NCT05207722|DRUG|Cyclophosphamide|Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
47921098|NCT05207722|DRUG|Fludarabine|Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
47921099|NCT05207722|DRUG|Mesna|MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
47921100|NCT04110652|OTHER|pulmonary rehabilitation program|"The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly."
47921101|NCT05331859|DRUG|Insulin|Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.
48094296|NCT05057754|BEHAVIORAL|Exercising|Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
48094297|NCT05057754|BEHAVIORAL|Typing|All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
47921102|NCT05331859|DRUG|autologous serum (AS)|Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.
48094298|NCT05057754|BEHAVIORAL|Using a mouse|"Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software."
48094299|NCT05057754|BEHAVIORAL|Cooking|Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
48094300|NCT03677024|PROCEDURE|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
47921103|NCT05331859|DRUG|conventional|Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.
48094301|NCT00188240|DRUG|Pegasys; Copegus.|
47921104|NCT04772677|BEHAVIORAL|BEAM Mental Health and Parenting Program|The BEAM program is a novel mobile app-based therapeutic intervention that incorporates key parenting concepts and Unified Protocol (UP) therapy modules with clinician-facilitated peer social support and connection. The primary aim of the program is to improve symptoms of depression and promote a positive parent-child relationship. There are three main components of the program: 1) the UP content, which will target maternal mental health symptomology, 2) the parenting skills training content, which is designed to correspond to the UP modules and promote maternal responsivity to children's emotions, and 3) a closed online community forum to encourage social support and connection between participants of the program.
47921105|NCT03002090|DIETARY_SUPPLEMENT|Iron trained|"1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
47921106|NCT03002090|DIETARY_SUPPLEMENT|Iron Untrained|1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
47921107|NCT03002090|DIETARY_SUPPLEMENT|BZKL Trained|"1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~2. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
47921108|NCT03002090|DIETARY_SUPPLEMENT|BZKL Untrained|1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
48094302|NCT02742051|DRUG|Everolimus|Neoadjuvant endocrine therapy
48094303|NCT02742051|DRUG|Letrozole|Neoadjuvant endocrine therapy
48094304|NCT02742051|DRUG|Fluorouracil|Neoadjuvant chemotherapy
47921109|NCT03002090|DIETARY_SUPPLEMENT|Placebo Trained|1. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
47921110|NCT03002090|DIETARY_SUPPLEMENT|Placebo Untrained|No intervention
48094305|NCT02742051|DRUG|Epirubicin|Neoadjuvant chemotherapy
48094306|NCT02742051|DRUG|Cyclophosphamide|Neoadjuvant chemotherapy
48094307|NCT05800821|PROCEDURE|Carotid revascularization|Carotid revascularization
48094308|NCT00438906|PROCEDURE|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
47921111|NCT03954340|DEVICE|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
48094309|NCT00438906|DRUG|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
48094310|NCT06614283|BEHAVIORAL|Diabetes self management @ click|A mobile application tailored for patients with Type 2 diabetes, aiming to enhance their self-management practices will be used for the intervention arm. The app includes features such as medication tracking, appointment scheduling, patient data storage, advice for treatment and follow-ups, health education and promotion, and real-time health monitoring.
48094311|NCT00442663|DEVICE|Transcervical Foley Catheter|
48094312|NCT00442663|DEVICE|Transcervical Foley Catheter with an EASI|
48094313|NCT05125861|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
48106761|NCT01638884|BEHAVIORAL|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
48106762|NCT01638884|OTHER|Structural MRI|to compare differences between each populations
48106763|NCT01638884|OTHER|Functional MRI|to compare differences between each populations
48094314|NCT05125861|PROCEDURE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mmHg. All patients underwent dynamic cerebral autoregulation on days 1-2 and 7-10 after onset, and intravenous blood was collected by a nurse and stored in the laboratory 0-6 hours after thrombolysis and 24 hours after thrombolysis.
48094315|NCT02680769|DIETARY_SUPPLEMENT|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
47921112|NCT02190565|DIETARY_SUPPLEMENT|Food supplement|Randomized double-blind, placebo-controlled
48094316|NCT02680769|OTHER|Placebo|This group will take a placebo
48094317|NCT03880656|BIOLOGICAL|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
47921113|NCT04129437|DRUG|Ibuprofen|Weight based ibuprofen dosing
47921114|NCT04129437|PROCEDURE|Osteopathic manipulative treatment|Low velocity osteopathic manipulative treatment
47921115|NCT05941871|OTHER|Dietary intervention - intervention group|"Low-calorie diet for 4 months with a different daily energy distribution according to the chronotype:~* Morning chronotype: 50% of kcal administered before lunch and 15% in the second part of the day (specifically: 40% at breakfast, 10% in the morning snack, 35% at lunch, 5% at afternoon snack and 10% at dinner)~* Evening chronotype: 15% of kcal given before lunch and 50% in the second half of the day (specifically: 10% of kcal at breakfast, 5% in the morning snack, 35% at lunch, 10% at snack time and 40% at dinner)"
47921116|NCT05941871|OTHER|Dietary intervention - control group|Group that will follow a low-calorie diet with a standard daily energy distribution (20% of kcal at breakfast, 10% in the morning snack, 35% at lunch, 10% at afternoon snack and 25% at dinner) for 4 months
47921117|NCT01529775|DEVICE|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
47921118|NCT01529775|DEVICE|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
47921119|NCT02659774|BEHAVIORAL|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
47921120|NCT02659774|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
47921121|NCT02659774|BEHAVIORAL|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
47921122|NCT02659774|BEHAVIORAL|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
47921123|NCT02659774|BEHAVIORAL|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
47921124|NCT02659774|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
47921125|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - low|
47921126|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - medium|
48094318|NCT02379364|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
48094319|NCT01587833|DRUG|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
47921127|NCT02264145|DRUG|Ethanolic Solution From HFA134a-MDI - high|
47921128|NCT02264145|DRUG|Ethanolic Solution From Respimat®|
47921129|NCT03618290|DIAGNOSTIC_TEST|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
47921130|NCT05437302|DEVICE|prism spectacle|a prism is dispensed in prescription glasses
47921131|NCT01064375|BIOLOGICAL|tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
47921132|NCT01064375|DEVICE|Derma Vax (electroporation device)|Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
47921133|NCT01064375|BIOLOGICAL|GM-CSF|GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
48094320|NCT05087238|BEHAVIORAL|CBT|Cognitive Behavior Therapy for PVC-specific anxiety education, in-vivo exposure, interoceptive exposure, behavioral activation, relapse prevention
48094321|NCT05127395|OTHER|To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.|The study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.
47921134|NCT01064375|DRUG|Cyclophosphamide|One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
47921135|NCT03338322|DEVICE|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
47921136|NCT03338322|DEVICE|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
47921137|NCT00349050|DEVICE|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
48094322|NCT01220674|OTHER|cognitive testing|computer-based cognitive assessment
48094323|NCT04529057|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
48094324|NCT02309840|BEHAVIORAL|choice architecture|"1. Place vegetables at the beginning of the lunch line.~2. Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~3. Promote fruits and vegetables with prominently displayed signage and images.~4. Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
48094325|NCT02309840|OTHER|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
47921138|NCT00349050|PROCEDURE|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
47921139|NCT04430595|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells
47921140|NCT05529095|DRUG|Apomorphine Sublingual Film|Sublingual Apomorphine initial dose 10 mg, titrated depending on symptomatic response.
47921141|NCT05529095|DRUG|Placebo|Placebo (sugar pill)
47921142|NCT00630383|BIOLOGICAL|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
47921143|NCT00630383|OTHER|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
47921144|NCT04268823|DRUG|QBW251|Capsule 300mg
47921145|NCT04268823|DRUG|Placebo|Capsule 300mg
48094326|NCT01695343|BIOLOGICAL|KB001-A|
47921146|NCT03540550|OTHER|Diet based on inulin-rich vegetables|During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
47921147|NCT03241030|DRUG|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
48443543|NCT05065866|DRUG|Duvelisib|"Patients will be treated at the following dose levels:~Duvelisib BMS-986345 Dose Level 15 mg twice daily 100mg daily -1 25 mg twice daily 100mg daily 1 50 mg twice daily 100mg daily 2 75 mg twice daily 100mg daily 3 75 mg twice daily 200mg daily 4 75 mg twice daily 300mg daily 5~After the first two cycles of treatment, the dose of Duvelisib will be dropped to 25 mg twice daily irrespective of the starting dose level unless the patient is at dose level -1 then they will stay on that dose level after the initial 2 cycles"
47921148|NCT03241030|OTHER|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
47921149|NCT03241030|DRUG|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
47921150|NCT03241030|DRUG|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
47921151|NCT00888199|DEVICE|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
47921152|NCT01906944|DRUG|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
47921153|NCT01906944|DRUG|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
47921154|NCT03712371|DRUG|Chitosan|The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
47921155|NCT05919836|PROCEDURE|Laparoscopic assisted hernia|Percutaneous assisted laparoscopic hernia
47921156|NCT05919836|PROCEDURE|Laparoscopic hernia by purse string closure|Laparoscopic purse string closure of hernial sac
47921157|NCT05919836|PROCEDURE|Total laparoscopic dissection of hernial sac|Total laparoscopic dissection of hernial sac
47921158|NCT06153680|DEVICE|Insoles|"Device : Insoles~At Day 0, the patient received the insoles and adapted them to his shoes.~The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.~The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14."
47921159|NCT04339842|OTHER|Assessment of Dietary Changes in Adults in the Quarantine|The online survey will help to collect demographic data from the volunteers. Personal information and contact details, such as email, will not be asked. The survey will include questions about any increase or decrease in the consumption of main meals, snacks and fluid intake. If the participants of the study have observed changes in their dietary pattern since the beginning of the quarantine, details of these changes, such as an increase in the amount of main meal consumption, will be questioned.
47921160|NCT01203644|DRUG|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
47921161|NCT01203644|DRUG|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
47921162|NCT00432549|DRUG|Almotriptan|
47921163|NCT00432549|DRUG|Topiramate|
47921164|NCT03149744|DEVICE|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
47921165|NCT04136847|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
48094327|NCT01695343|DRUG|Placebo Comparator|
48106764|NCT01638884|OTHER|Virtual reality / Memory assessment|to compare differences between each populations
48106765|NCT04534712|DIAGNOSTIC_TEST|LYMPHOCYTE MONOCYTE RATIO|Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
48094328|NCT02987829|DRUG|TRC253|TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.
48094329|NCT05727059|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
48094330|NCT04607252|DRUG|Metformin plus Megestrol acetate|metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
48094331|NCT04607252|DRUG|Megestrol Acetate|megestrol acetate 160mg per day, oral
48094332|NCT06276595|BEHAVIORAL|Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS)|The TODOS program consists of 11 weekly sessions conducted with girls ages 8-11 and their female caregivers. Five of the 11 sessions will be taught to small groups, and 6 of the Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room.
48094333|NCT06276595|BEHAVIORAL|Control condition - 3 Monthly Group Activities in the Community|The control condition consists of 3 group sessions delivered monthly for three months. The first group session will occur at a community center and will consist of a meal and ice breaker activities. The second group session will consist of going to a movie at the local movie theatre The third group session will consist of going bowling at the local bowling alley.
48094334|NCT01702038|DRUG|Rituximab|1000 mg administered intravenously
48094335|NCT06613815|OTHER|radiofrequency of the geniculate nerves|radiofrequency of the geniculate nerveswith a scopy-guided technique versus the ultrasound-guided technique
48094336|NCT04413279|PROCEDURE|LipiFlow Thermal Pulsation|To manage patients with dry eye disease secondary to MGD
48094337|NCT04413279|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation|to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
48094338|NCT03118752|BEHAVIORAL|Collaborative Care|The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
48094339|NCT00362752|DRUG|Norfloxacin|400 mg po bid
48094340|NCT00362752|DRUG|Placebo|Placebo 400 mg po bid
48094341|NCT06021990|DRUG|Clopidogrel Bisulfate 75Mg Tab|Severe COPD patients who meet eligibility criteria will be given Clopidogrel Bisulfate 75 mg Tablet daily, along with standard of care treatment till the completion of the study duration or any side effects that warrants stoppage of the drug
48094342|NCT05568719|DIAGNOSTIC_TEST|Testing of hepatic AAV Vector integration|Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
48094343|NCT05971641|OTHER|progressive relaxation exercise|Patients who undergo total knee replacement surgery in the experimental group will be taught progressive relaxation exercises. The exercise will last for 30 minutes and will be applied twice a day. Patients will wear a smart wristband. Patient Information Form, Numeric Rating Scale, Richard Campbell Sleep Quality Survey, and Postoperative Recovery Index Scale will be administered. The scales will be filled out for 5 days and will take approximately 10-15 minutes.
48094344|NCT02232763|DRUG|Losartan|12 weeks of losartan or placebo with crossover to the other
48094345|NCT02232763|DRUG|Placebo|12 weeks of losartan or placebo with crossover to the other
48094346|NCT00079937|DRUG|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
48094347|NCT00079937|DRUG|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
48094348|NCT00079937|DRUG|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
48094349|NCT06613568|DEVICE|Moda-flx Hemodialysis System™|The Moda-flx Hemodialysis System™ is a portable hemodialysis system
48094350|NCT06614140|BIOLOGICAL|Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors|"This intervention involves a personalized neoantigen peptide vaccine composed of peptides containing tumor-specific mutations, such as SNVs, indels, and frameshift mutations. Neoantigens are selected based on criteria that enhance expression and immunogenicity.~The vaccine is administered alongside Poly-ICLC, a TLR3 agonist, to enhance immune activation. After the initial vaccine doses, checkpoint inhibitors (e.g., anti-PD-1 or anti-PD-L1) are introduced once neoantigen-specific T-cell responses are detected, preventing immune exhaustion and sustaining a strong immune response.~During the follow-up phase, both checkpoint inhibitors and Poly-ICLC are continued to maintain immune activity and ensure a lasting anti-tumor effect."
48094351|NCT03670381|OTHER|Psychiatric diagnosis|
48094352|NCT05763251|OTHER|therapy duration|the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
48094353|NCT06087068|DRUG|Thyroxine|The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)
48094354|NCT01008748|DRUG|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke \>10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
48094355|NCT01008748|BEHAVIORAL|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
48443544|NCT02304211|DRUG|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
47921166|NCT00109590|DRUG|Didanosine, enteric-coated|once daily
47921167|NCT00109590|DRUG|Lopinavir/ritonavir|twice daily
47921168|NCT00109590|DRUG|Nevirapine|single-dose at the onset of labor
48094356|NCT01008748|BEHAVIORAL|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
48094357|NCT01008748|BEHAVIORAL|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
48094358|NCT02938390|PROCEDURE|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
48094359|NCT06231082|PROCEDURE|Group one - percutaneous (P)|Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
48094360|NCT06231082|PROCEDURE|Group two - EUS FNB (E)|"EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the wet suction technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the blood patch technique."
48094361|NCT00288769|DRUG|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
48094362|NCT02275936|DRUG|N91115|S Nitrosoglutathione Reductase Inhibitor
48094363|NCT01517022|DRUG|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
48094364|NCT02782988|OTHER|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
48094365|NCT03614130|DEVICE|LID011121 contact lens|Investigational silicone hydrogel contact lens
48094366|NCT03614130|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
48094367|NCT03796689|DEVICE|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
48094368|NCT03796689|DEVICE|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
48094369|NCT06479980|BEHAVIORAL|Single Session Narrative Therapy|Single-session narrative psychotherapy intervention is an evidence-based strategy on a stepped care continuum that can assist patients in accessing care when they most need it and can lead to the most effective utilization of scarce resources. It offers a transdiagnostic, strengths, solution-oriented, and non-pathologizing intervention to address patients' behavioral health needs.
48094370|NCT02656940|DIETARY_SUPPLEMENT|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
47921169|NCT00109590|DRUG|Zidovudine|twice daily
48094371|NCT02656940|DIETARY_SUPPLEMENT|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
48094372|NCT02656940|DIETARY_SUPPLEMENT|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
48094373|NCT00809874|DIETARY_SUPPLEMENT|Casein|
48094374|NCT00809874|DIETARY_SUPPLEMENT|Whey Isolate|
48094375|NCT00809874|DIETARY_SUPPLEMENT|Whey Hydrolysate|
47921170|NCT06243562|OTHER|combined exercises and progressive muscle relaxation group|Participants in the intervention group will receive a combined exercise program that will last 45-60 minutes, 3 days a week for 8 weeks, and progressive muscle relaxation training that will last 10-15 minutes, under the supervision of a therapist.
47921171|NCT06243562|OTHER|combined exercises group|Patients in the control group will perform a combined exercise consisting of aerobic, strengthening and stretching exercises, which will last 45-60 minutes, 3 days a week for 8 weeks, under the supervision of a physiotherapist. At the end of the combined exercise program, they will rest in the relaxation position for 10-15 minutes each session.
47921172|NCT04572152|BIOLOGICAL|AK119|Subjects will receive AK119 by intravenous administration.
47921173|NCT04572152|BIOLOGICAL|AK104|On the same day subjects will receive AK104 by intravenous administration.
47921174|NCT04787419|OTHER|placebo|saccharum lactis
47921175|NCT04787419|COMBINATION_PRODUCT|probiotics|Lactobacillus acidophilus, Bifidobacterium longum, Strepococcus thermophilus
47921176|NCT03557840|DRUG|temocillin|Drug dosing and blood sampling as per the protocol
47921177|NCT01988701|OTHER|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
48094376|NCT00809874|DIETARY_SUPPLEMENT|Alphalact-Albumin|
48094377|NCT03815916|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
48094378|NCT03383211|OTHER|RNAseq|Transcriptome profiling of peripheral blood using RNA sequencing technology
48094379|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
48094380|NCT01496196|DRUG|tranexamic acid|500 mg/5 ml 3-4 times a day
48094381|NCT06434428|DRUG|dexmedetomidine (IV)|Administration of IV dexmedetomidine
48094382|NCT06434428|DRUG|dexmedetomidine (IN)|Administration of IN dexmedetomidine
48094383|NCT04854486|OTHER|GSE and Xylitol|Participants are given the experimental treatment to be used for 7 days.
48094384|NCT04854486|DRUG|Control Placebo|Saline
48094385|NCT05798104|BEHAVIORAL|Collaborative nurse-pharmacist counseling|At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
48094386|NCT00266097|DRUG|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
47921178|NCT01307644|BEHAVIORAL|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
47921179|NCT01307644|BEHAVIORAL|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
48094387|NCT00266097|DRUG|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
48094388|NCT00266097|DRUG|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
48094389|NCT00266097|RADIATION|radiation therapy|5040 cGy, every week, up to 6 weeks
48094390|NCT00266097|DRUG|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
48094391|NCT00266097|DRUG|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
48094392|NCT00602160|DRUG|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
48094393|NCT00686621|DRUG|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
48094394|NCT03037060|OTHER|[11C]-(+)-PHNO PET scan|PET scan
48094395|NCT03037060|OTHER|Alcohol Self-Administration|Session for assessing motivation for consuming alcohol.
48094396|NCT03037060|OTHER|Craving Task|Cue exposure paradigm
48094397|NCT03037060|OTHER|MRI scan|MRI scan scan to analyze the PET data will be administered.
48094398|NCT03037060|OTHER|Neuropsychological Assessment|Cognitive questionnaires administered over course of study.
48094399|NCT01374490|DRUG|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
48094400|NCT02882503|DEVICE|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
48094401|NCT03765697|DRUG|Lidocaine 5% medicated plaster|Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).
48094402|NCT00429702|DRUG|Decadron®|Given IV
48094403|NCT00429702|DRUG|Benadryl®|Given IV
48094404|NCT00429702|DRUG|Ativan®|Given IV
48094405|NCT00429702|DRUG|ondansetron hydrochloride|Given IV
48094406|NCT06417905|OTHER|Supervised exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
48094407|NCT06417905|OTHER|video based exercises|strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
48094408|NCT04717882|DEVICE|CDSS-OPTIMED|The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.
48094409|NCT00555581|DRUG|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
48094410|NCT02347917|DRUG|BBI608|480 mg orally twice daily (960 mg total daily dose)
48094411|NCT02347917|DRUG|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
48094412|NCT02347917|DRUG|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
48094413|NCT04028674|DEVICE|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
48094414|NCT06611644|OTHER|Erector Spinae Plane Block|Patients in this group will receive an Erector Spinae Plane (ESP) block in addition to standard postoperative care. The ESP block will be performed under ultrasound guidance. A needle will be advanced in-plane or out-of-plane, targeting the lateral aspect of the T6 transverse process. Local anesthetic (20 to 30 ml) will be injected into the fascial plane between the erector spinae muscle and the transverse process. This block is intended to provide postoperative analgesia by blocking the transmission of pain through the thoracic spinal nerves.
48094415|NCT06611644|OTHER|SPSIPB blcok|Patients in this group will receive a Serratus Posterior Superior Intercostal Plane (SPSIP) block along with standard postoperative care. The SPSIP block will be performed under ultrasound guidance, where the needle is advanced between the second and third ribs towards the medial aspect of the scapula. Local anesthetic 20 to 30 ml) will be injected into the fascial plane between the serratus posterior superior muscle and the intercostal muscles after confirming needle placement with hydrodissection using 1-2 ml of saline. This block is intended to provide broad analgesia across the upper thoracic dermatomes, from C3 to T7, to control postoperative pain.
48094416|NCT06611644|OTHER|Control|Patients in the control group will receive standard postoperative pain management without any regional block intervention. This will include the administration of systemic analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics will be administered as needed based on the patient's pain level. Pain management will be conducted according to the standard protocol followed for breast surgery patients.
48094417|NCT06613997|DRUG|Albendazole 400mg|Albendazole 400mg per days for 21 consecutive days
48094418|NCT06613997|DRUG|Placebo|Placebo for 21 consecutive days
48094419|NCT05207787|DRUG|HS-10365|Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
48094420|NCT01838551|DRUG|Levoketoconazole|Levoketoconazole is the 2S,4R- enantiomer derived from racemic ketoconazole
48094421|NCT00828945|DEVICE|Lipid Self Test|Self test for lipid levels, twice during study period
48094422|NCT03766919|DEVICE|Implant of the INVICTA lead|The implant or the attempt to implant an INVICTA lead
48094423|NCT06610357|OTHER|Group 1|42 diparetic children with cerebral palsy were included in the study. The Modified Ashworth Scale (MAS), the Children's Functional Independence Measure (WeeFIM)-Mobility section and the Gross Motor Function Measure-88 (GMFM-88) were applied before and after SDR surgery.
48094424|NCT03049696|BEHAVIORAL|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
48094425|NCT00288964|DEVICE|Hattler Respiratory Assist Catheter|
48094426|NCT04438915|BEHAVIORAL|Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery|The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
48094427|NCT00006221|DRUG|ixabepilone|
48094428|NCT03425292|DRUG|Temozolomide|concomitant and 5-day adjuvant temozolomide
48094429|NCT03425292|RADIATION|conformal brain radiation therapy|standard radiation therapy for newly diagnosed glioblastoma
48094430|NCT03425292|DRUG|Nivolumab|nivolumab 240 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
48094431|NCT03425292|DRUG|Ipilimumab|ipilimumab 1 mg/kg IV every 6 weeks (or every 8 weeks when nivolumab is administered every 4 weeks) for a maximum of 4 doses
48094432|NCT03425292|DRUG|Bevacizumab|bevacizumab 5 mg/kg IV every 2 weeks (up to 10 mg/kg at treating physician's discretion)
48094433|NCT03425292|DRUG|5-day Temozolomide|150 mg/m\^2 oral, once daily on Days 1-5 of each 28-day cycle (stepwise titration every cycle up to 200 mg/m\^2 permitted)
48094434|NCT03425292|DRUG|5-day Temozolomide|100 mg/m\^2 oral, once daily on Days 2-6 of each 6 week course (stepwise titration every cycle up to 200 mg/m\^2 permitted)
48094435|NCT03425292|DRUG|Lomustine|100 mg/m\^2 oral, on Day 1 of each 6 week course
48094436|NCT03425292|DRUG|Nivolumab monotherapy|nivolumab 300 mg IV every 2 weeks for the first 28-day cycle, then option to modify to 480 mg IV every 4 weeks
48094437|NCT06268925|OTHER|Exercises|number of exercises will be guided to do through zoom
48094438|NCT04616482|BEHAVIORAL|Digital therapeutic carbohydrate restriction (TCR) program|A 12-week, personalized, online program to teach and coach patients about therapeutic carbohydrate restriction as for obesity and/or T2D (or risk of T2D). The program is intended to enhance the usual clinical care provided for patients.
48094439|NCT00320866|DEVICE|syringe driver|
48094440|NCT04248764|OTHER|Foam roller application|Following the fatigue protocol, foam roller application will be applied to the quadriceps femoris muscle for five minutes in the prone position.
48094441|NCT04248764|OTHER|Massage application|Following the fatigue protocol, sports massage will be applied to the quadriceps femoris muscle for five minutes.
48094442|NCT02831153|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
48094443|NCT02042443|DRUG|Capecitabine|Given PO
48094444|NCT02042443|DRUG|Fluorouracil|Given IV
48094445|NCT02042443|OTHER|Laboratory Biomarker Analysis|Correlative studies
48094446|NCT02042443|DRUG|Leucovorin Calcium|Given IV
48094447|NCT02042443|DRUG|Trametinib|Given PO
48094448|NCT05311475|DRUG|Mometasone|Mometasone furoate nasal spray (50 mcg per actuation)
48094449|NCT05311475|DRUG|Azelastine|Azelastine hydrochloride nasal spray (140 mcg per actuation)
48094450|NCT05311475|DRUG|Placebo|Placebo nasal spray
48094451|NCT03545490|DIETARY_SUPPLEMENT|Early nutritional intervention|Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
48094452|NCT02470104|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
48094453|NCT06169241|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
48094454|NCT06169241|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
48094455|NCT02461238|OTHER|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
48094456|NCT02461238|OTHER|Nutrition education|Nutrition education workshops taught by a dietician
48094457|NCT00498186|DRUG|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
48094458|NCT02029053|DEVICE|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
48094459|NCT02292394|BEHAVIORAL|Multicomponent Cognitive Behavioral Telephone Intervention|
48094460|NCT02292394|BEHAVIORAL|Telephone Intervention Pleasant Activities|
48094461|NCT02477943|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
48094462|NCT02477943|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
48094463|NCT05044130|DIETARY_SUPPLEMENT|High-fat mixed-meal tolerance test (HF-MMTT)|The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)
48094464|NCT00920374|BIOLOGICAL|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
48094465|NCT05685758|OTHER|FTP-based therapeutic mobile-app|Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
48094466|NCT06081855|DIAGNOSTIC_TEST|CT|Measuring aortic root diameter by CT
48094467|NCT06614634|OTHER|Remotely supervised exercise at home or outdoors|Aerobic and strengthening exercise program at home/outdoors at least three days a week for four weeks using a Polar H9 heart rate monitor and elastic band.
48094468|NCT06614634|OTHER|Hospital-based exercise program|The aerobic and strengthening exercise program three days a week for four weeks under supervision in our cardiopulmonary rehabilitation unit.
48094469|NCT06614634|BEHAVIORAL|Cardiovascular risk modification|Psychosocial support for physical activity counselling, heart-healthy diet, referral for smoking cessation and stress management.
48094470|NCT06614634|OTHER|Phone calls with reinforcement feedback|Calls once a week that include symptom inquiries and encouraging feedback on exercise logs.
48094471|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.
48094472|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.
48094473|NCT04880213|DRUG|M5049|Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
48094474|NCT04651179|OTHER|observation|not applicable, observational study
47921180|NCT01307644|BEHAVIORAL|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
47921181|NCT00064064|DRUG|gemcitabine hydrochloride|
48094475|NCT01796665|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
48094476|NCT01796665|DRUG|Acanya Gel|
48094477|NCT01796665|DRUG|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
48094478|NCT02846818|PROCEDURE|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
48094479|NCT05435963|BEHAVIORAL|Pulmonary rehabilitation (PR)|A typical PR program will include exercise training, disease-specific and self-management strategies education, and will last 6 - 8 weeks
48094480|NCT00623246|BEHAVIORAL|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
48094481|NCT00623246|BEHAVIORAL|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
48094482|NCT02755922|BIOLOGICAL|Application of autologous mesenchymal stem cells|within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
48094483|NCT04990687|DEVICE|gammaCore™|"Implantable VNS (iVNS), the electrical stimulation of the nervous system to modulate or modify function, has been FDA approved in the United States since the late 1990s. Implantable VNS therapy has been approved for use in epilepsy and depression.~When treating major depression with implanted VNS, the widely held belief is that chronic stimulation is required for therapeutic effect. In trials of implantable VNS in major depression, more patients respond at 12 months than at 3 months. Once depressed patients respond to VNS, the effects have been demonstrated to continue for up to five years with continued stimulation. This finding suggests that VNS gradually changes brain function through neuroplasticity."
48094484|NCT00151619|DRUG|Amlodipine|
48094485|NCT03452111|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
48094486|NCT03701464|PROCEDURE|Endoscopic naso-gallbladder drainage|Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.
48094487|NCT03701464|PROCEDURE|Percutaneous gallbladder drainage|Percutaneous transhepatic technique insert drainage tube into gallbladder
48094488|NCT05262972|OTHER|Conservatory treatment|Personalized plantar orthosis
48094489|NCT05262972|OTHER|Innovate treatment|Personalized plantar orthosis + percutaneous electrolysis
48094490|NCT00448864|DRUG|Ecallantide|
48094491|NCT00448864|DRUG|Placebo|
48094492|NCT01452672|RADIATION|Radiotherapy|RT 40 Gy in 15 fractions
48094493|NCT01452672|RADIATION|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
48094494|NCT00868205|DIETARY_SUPPLEMENT|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
48094495|NCT02135783|PROCEDURE|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
48094496|NCT02135783|PROCEDURE|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
48094497|NCT02491411|DRUG|Dexamethasone|Given PO
48094498|NCT02491411|DRUG|Enzalutamide|Given PO
48094499|NCT02491411|OTHER|Laboratory Biomarker Analysis|Correlative studies
48094500|NCT02491411|OTHER|Quality-of-Life Assessment|Ancillary studies
48094501|NCT02429609|DEVICE|Moorfields Acuity Chart|
47921182|NCT00064064|DRUG|triapine|
48094502|NCT01962064|BEHAVIORAL|Cognitive assessment|
48094503|NCT01962064|OTHER|Brain imaging examination MRI|
48094504|NCT01363479|DRUG|Oral palonosetron|
48094505|NCT01363479|DRUG|I.V. palonosetron|
48094506|NCT01363479|DRUG|Dexamethasone|
48094507|NCT06423781|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
48094508|NCT04323995|OTHER|Sprint Interval Training|Sprint interval training of 2 weeks and more.
48094509|NCT03530280|DRUG|pregabalin (lyrica)|preoperative pregabalin and the postoperative sham block will perform.
48094510|NCT03530280|DRUG|Placebo oral tablet|The preoperative placebo oral tablet and the postoperative sham block will perform.
48094511|NCT03530280|DRUG|adductor canal block including bupivacaine|The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
48094512|NCT02386371|PROCEDURE|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
48094513|NCT02386371|RADIATION|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
48094514|NCT05577962|DRUG|T group|OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation, an experienced anesthesiologist guided by ultrasound performed bilateral superficial cervical plexus block with 0.5% ropivacaine and injected 3-4ml at two points respectively; During the operation, sevoflurane (MAC1.0 - 1.4) was used to maintain the depth of anesthesia
48094515|NCT02758262|DEVICE|Noninvasive brain stimulation|
48094516|NCT00081809|DRUG|autologous human tumor-derived HSPPC-96|
48094517|NCT00321477|DRUG|GW679769 oral tablets|
48094518|NCT00927342|OTHER|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
48094519|NCT00927342|OTHER|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
48094520|NCT00852475|DIETARY_SUPPLEMENT|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
48094521|NCT00852475|DIETARY_SUPPLEMENT|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
48094522|NCT00515138|DRUG|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
48094523|NCT04892810|PROCEDURE|Percutaneous ablation|Hepatic Percutaneous Ablation with radiofrequency or microwave
48094524|NCT02201030|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
48094525|NCT02201030|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
48094526|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
48094527|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
48094528|NCT00875628|DRUG|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
48094529|NCT03288350|DRUG|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
48094530|NCT04689698|DIAGNOSTIC_TEST|Thomayer test|Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
48094531|NCT00658411|DRUG|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
48094532|NCT00818025|BEHAVIORAL|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
47921183|NCT05389852|DRUG|Dexmedetomidine|After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg
48094533|NCT05565742|DRUG|LY3819469|Administered SC
48094534|NCT05565742|DRUG|Placebo|Administered SC
48094535|NCT04202575|PROCEDURE|Tube clamping|Clamping of the tube between the additional and standard venous reservoir
48094536|NCT01649102|DEVICE|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~* Palindroom~* Hemoglide Bard"
48094537|NCT02763020|OTHER|Fruit extracts high in polyphenols|
48094538|NCT02763020|OTHER|placebo|
48094539|NCT05226481|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|Trauma-focused cognitive-behavioral therapy (TF-CBT) is an evidence-based method for the treatment of posttraumatic stress among youth.
48094540|NCT00507637|DRUG|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
48094541|NCT01660295|DRUG|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
48094542|NCT01660295|DRUG|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
48094543|NCT01660295|DRUG|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
48094544|NCT01660295|DRUG|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
48094545|NCT01941264|OTHER|community based screening and treatment|Already described in intervention arm description.
47921184|NCT01233232|DRUG|Placebo|Oral dose bid
48094546|NCT03748160|OTHER|Letter|Intervention consists of two different types of postal letters reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers
48094547|NCT06008067|RADIATION|tricuspid annular plane systolic excursion (TAPSE)|Echocardiography
48094548|NCT06382142|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
48443545|NCT03313622|BEHAVIORAL|Beads Task|Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
47921185|NCT01233232|DRUG|AZD5069 50mg|Oral dose bid
47921186|NCT01233232|DRUG|AZD5069 80mg|Oral dose bid
48094549|NCT06382142|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
48094550|NCT06382142|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
48094551|NCT06382142|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
48094552|NCT06382142|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
48094553|NCT04071080|DRUG|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
48094554|NCT04071080|DRUG|Placebo|500mL Gatorade
48094555|NCT04451733|PROCEDURE|Endotracheal intubation|Perform the endotracheal intubation during CPR
48094556|NCT04500821|DEVICE|Activator LFD-2100|LipiFlow treatment with the Activators LFD-2100 will be performed on both eyes with MGD
48094557|NCT05476822|DIAGNOSTIC_TEST|Obtain antibody titers|Obtain blood samples for antibody titers at the time of enrollment, at three months, six months and nine months post vaccine booster (+/- ten days).
48094558|NCT04531540|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.
48094559|NCT00672256|BEHAVIORAL|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
48094560|NCT00647140|OTHER|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
48094561|NCT06614231|DRUG|Tislelizumab Combined With Chemotherapy|Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy
48094562|NCT01495507|PROCEDURE|MPFL- Reconstruction|
48094563|NCT05874791|BEHAVIORAL|Goal Management training|metacognitive group intervention
48094564|NCT02634008|DRUG|Paritaprevir/ritonavir/ombitasvir|
48094565|NCT02634008|DRUG|Dasabuvir|
48094566|NCT02634008|DRUG|Ribavirin|
48094567|NCT02634008|DRUG|Glecaprevir/pibrentasvir|
48094568|NCT06429410|DIETARY_SUPPLEMENT|fortified formula milk powder|Fortified formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, β-hydroxy-β-methylbutyrate, and sodium hyaluronate per day orally for 24 weeks.
48094569|NCT06429410|DIETARY_SUPPLEMENT|formula milk powder|Formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, and sodium hyaluronate per day orally for 24 weeks.
48094570|NCT06429410|DIETARY_SUPPLEMENT|regular milk powder|Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
48094571|NCT06613464|DIAGNOSTIC_TEST|diagnosis confirmation|The patients diagnoses will be confirmed though imaging methods like computed tomography chest x-ray and anamnesis
48094572|NCT03229798|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
48094573|NCT03229798|COMBINATION_PRODUCT|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
48094574|NCT04978363|DEVICE|BOOT|A walking boot is a common type of brace/boot that restricts ankle and foot movement.
48094575|NCT04978363|DEVICE|HFC|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands.
48094576|NCT04978363|DEVICE|SAC|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries.
48094577|NCT04978363|DEVICE|HFC+BOOT|The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
48094578|NCT04978363|DEVICE|SAC+BOOT|Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
48094579|NCT05318014|DIETARY_SUPPLEMENT|Intervention group|dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
48094580|NCT05318014|OTHER|Regular nutrition education|dietitian regular nutrition educataion which was following a low protein diet
48094581|NCT03486340|PROCEDURE|Cardiologic assessment|Aggressive ischemic risk factor management
47921187|NCT06394167|DRUG|VX-993|Solution for IV administration.
48094582|NCT05426265|DEVICE|MEL-T01|A 12 week intervention with MEL-T01.
48094583|NCT05426265|DEVICE|MEL-S01|A 12 week intervention with MEL-S01.
48094584|NCT03453632|DRUG|Botulinic toxin|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot"
48094585|NCT03453632|DRUG|Placebo|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot"
48094586|NCT06426654|DRUG|sintiliman plus LDRT|"All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles."
48094587|NCT03136276|OTHER|IPS Empress CAD|standard etchable glass ceramics
48094588|NCT03136276|OTHER|polished Celtra Duo|new glass ceramic material
48094589|NCT01979978|OTHER|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
48094590|NCT02078830|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
48094591|NCT02078830|DEVICE|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
48094592|NCT02492594|OTHER|Peripheral blood sampling|"Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~* at the start of neutropenic fever~* after 24 hours~* after 48 hours~* before the start of antimycotic therapy, if pertinent~* at the end of antimycotic therapy, if pertinent"
48094593|NCT01368120|DEVICE|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
48094594|NCT01368120|DEVICE|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
48094595|NCT01368120|DEVICE|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
48094596|NCT05924893|DRUG|Naltrexone Hydrochloride|naltrexone film
48094597|NCT05924893|DRUG|Carboxy methyl cellulose|Carboxy methyl cellulose drops
48094598|NCT05266261|DRUG|Ibandronate Oral Tablet|150 mg of ibandronate + 24,000 IU of cholecalciferol
47921188|NCT06394167|DRUG|Placebo|Solution for IV administration.
47921189|NCT03741387|OTHER|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
47921190|NCT03741387|OTHER|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
48094599|NCT05008341|DRUG|Solriamfetol 150 mg Oral Tablet|Single-dose 150 mg tablet orally administered.
48094600|NCT02782182|DRUG|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
48094601|NCT02112929|DRUG|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
48094602|NCT05282459|DRUG|Enasidenib mesylat dose escalation|Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
48094603|NCT01040663|OTHER|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
48094604|NCT06096129|PROCEDURE|Spy PTC|Percutaneous transhepatic cholangioscopy with SpyGlass DS system
48094605|NCT04874610|DRUG|Methylprednisolone|Administration of methylprednisolone Prescribed per Standard of care
48094606|NCT06614985|DRUG|Telitacicept|Subcutaneous injection of 160 mg is administered once a week.
48094607|NCT06614985|DRUG|Prednisone|Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.
48094608|NCT06614985|DRUG|Cyclophosphamide|An intravenous injection of 0.4 g is administered twice a month.
48094609|NCT05843565|DEVICE|Cobalt video laryngoscope blade|Non-standard hyperangulated Cobalt video laryngoscope blade
48094610|NCT05843565|DEVICE|Miller video laryngoscope blade|Standard Miller video laryngoscope blade
48094611|NCT04476043|DRUG|INCB054707|Oral; Tablet
48094612|NCT04476043|DRUG|Placebo|Oral; Tablet
48094613|NCT00774111|DRUG|GSK1349572|GSK1349572 50 mg in combination with Etravirine
48094614|NCT02022462|BEHAVIORAL|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
48094615|NCT05238597|DRUG|A197 Ophthalmic Solution|A197 Ophthalmic Solution
48094616|NCT05238597|DRUG|A197 Vehicle Control|A197 Vehicle Control
48094617|NCT05238597|DRUG|Active Comparator|Active Comparator
48094618|NCT00196911|PROCEDURE|Implantation of stimulation electrodes in the STN|
48094619|NCT06555419|DRUG|Nusinersen|Administered as specified in the treatment arm.
48094620|NCT06555419|DEVICE|ThecaFlex DRx System|Implantated as specified in the treatment arm.
48094621|NCT06614166|OTHER|SBD111 Probiotic Medical Food|Medical food comprised of probiotics and prebiotic fibers
48094622|NCT06614166|OTHER|SBD121 Probiotic Medical Food|Probiotic medical food comprised of three lactic acid bacteria and one bacillus
48094623|NCT05489887|DRUG|Naxitamab|Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
48094624|NCT05489887|DRUG|Ceritinib|Ceritinib is an inhibitor that selectively targets the ALK tyrosine kinase
48094625|NCT00462553|DRUG|sunitinib malate|Given orally
48094626|NCT00462553|DRUG|gemcitabine hydrochloride|Given IV
48094627|NCT04332276|DRUG|A-dopamine|"During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days."
48094628|NCT04332276|DRUG|optimized oral treatment|The patient will received his usual dopaminergic treatment.
47921191|NCT05056584|BIOLOGICAL|Glucagon infusion|One hour glucagon-clamp followed by one hour of blood sampling
48094629|NCT05617339|BEHAVIORAL|I am (internet approach to migraine)|I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
48094630|NCT02763553|DIETARY_SUPPLEMENT|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
48094631|NCT02763553|DIETARY_SUPPLEMENT|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
48094632|NCT01031693|DEVICE|Transcranial Magnetic Stimulation|daily sessions for 5 days
48106766|NCT02175043|PROCEDURE|atrial electrogram and liner ablation|"1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
48106767|NCT04416971|PROCEDURE|AVF puncture|For patients with mature/immature AVF on HD initiation, AVF puncture will be conducted.
48106768|NCT00570869|OTHER|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
48094633|NCT06360718|BEHAVIORAL|"Who is Luke Eemia? Storybook"|"Parents in this group will receive the Who is Luke Eemia? storybook, and will receive guidance from the child life specialist on how to utilize the storybook with their school-aged child. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey and (3) Storybook Assessment survey to review the parent's impression of the storybook intervention tool (at the time of discharge, or about 1 week following the child life intervention), and the (4) Parenting Stress Index -4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later)."
48094634|NCT01460992|PROCEDURE|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
48094635|NCT03570255|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
48094636|NCT03177187|DRUG|AZD5069|10mg and 40mg plain, beige, film-coated tablets packaged in bottles
48094637|NCT03177187|DRUG|Enzalutamide 40 MG|Enzalutamide is presented in 40mg white to off white capsules or tablets. The capsules/tablets are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules/tablets. Each carton contains 4 wallets (112 soft capsules/tablets). Or tablets in bottles (120 per bottle).
48094638|NCT00748254|PROCEDURE|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
48094639|NCT00748254|PROCEDURE|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
48094640|NCT03720340|DRUG|Recombinant Human Interleukin-11|Recombinant Human Interleukin-11 was administed through respiratory tract.
48094641|NCT03720340|DRUG|Saline|saline was administed through respiratory tract
48094642|NCT06330402|OTHER|Hypertonic saline injection|0.25 mL injection with hypertonic saline (7%) to the infrapatellar fat pad.
48094643|NCT06330402|OTHER|Isotonic saline injection|Control injection with 0.25 mL isotonic saline (0.9%) to the infrapatellar fat pad.
48443546|NCT03313622|BEHAVIORAL|PROVOC Tasks|Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
48094645|NCT06086808|OTHER|Resistance Training|A resistance training program will be used as a progressive, high-intensity protocol. The training stimulus will be provided using free weights. The exercises will consist of bench presses, biceps curls, triceps extensions, Latissimus Dorsi pull-down exercises, hamstring curls, and calf raises. The intensity of the training stimulus will be at a working range of 6 to 8 repetitions (2 sets). The training stimulus will subsequently be increased using the 7-RM (repetition maximum) method when 2 sets of 6 to 8 repetitions are completed with proper form and without discomfort. Other key strength exercises will include mini-squats, mini-lunges, and lunge walks. The number of sets completed and the load lifted for each exercise will be recorded for each participant in every class.
48094646|NCT06086808|OTHER|General Fitness and Toning|The general fitness and toning program will consist of stretching exercises, range-of-motion exercises, basic core-strengthening exercises, balance exercises, and relaxation techniques. Key balance exercises will include tandem stand, tandem walking, and single leg stance (eyes opened and closed). No additional loading (e.g., hand weights or resistance bands) will be applied to any of the exercises. This group will serve to control for confounding variables such as physical training received by traveling to the training centers, social interaction, and changes in life style secondary to study participation.
48094647|NCT01268566|DRUG|MEDI-575|MEDI-575 as an IV infusion.
48094648|NCT06251908|OTHER|Rewritalize|"REWR is conceptualised as a hybrid between an art group and a group therapy intervention. It is structured as a progressive participatory art group program led by a conductor-tandem: the primary conductor, a professional writer with extensive teaching experience, is supplemented by a co-conductor with clinical expertise who participates in the group activities together with the other participants. The conductor-tandem secure high artistic standards while also ensuring psychological safety. A close collaboration between the two is necessary and both participate in a 30-hour preparatory course and are supervised during the course of the intervention.~The writing course consists in 15 sessions of 3 hours per session. At each session participants are introduced to literary texts that work as prompts for the writing exercises, which last 5-15 min. After each text is read out loud, the participants engage in a reflective discussion about the text."
48094649|NCT06251908|OTHER|Standard mental health care|"F-ACT is a community-based treatment model that provides multidisciplinary, flexible, and assertive outpatient treatment to patients with severe mental illness. OPUS is a nationally implemented 2-year-long early intervention for people with first-episode psychosis. OPUS is a multidisciplinary assertive community treatment model and offer psychoeducation, social skills training, relapse prevention and family involvement, including possibility for treatment participation in psychoeducational multifamily groups.~In F-ACT and OPUS a primary staff member is in regular contact with the patient and responsible for coordinating the treatment elements. The treatment is individual and contingent upon patients' needs."
48094650|NCT05004779|PROCEDURE|human stem cell conditioned media was applied after non-ablative laser therapy|After laser treatment on hypertrophic scars, human stem cell media was applied to one side
48094651|NCT05004779|PROCEDURE|normal saline was applied after non ablative laser therapy|physiological saline was applied to the other side.
48094652|NCT00004643|DRUG|cytarabine|
48094653|NCT03506490|OTHER|Aerobic exercises|The training session lasted 45 minutes and was composed of running exercises.
48094654|NCT03950908|OTHER|Single bite biopsy technique|During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
48094655|NCT03950908|OTHER|Double bite biopsy technique|During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
48094656|NCT04135924|OTHER|Rehabilitation|physical exercise and respiratory muscle training
48094657|NCT03454932|OTHER|Blood sampling|
48094658|NCT04893564|BIOLOGICAL|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
48094659|NCT04893564|BIOLOGICAL|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
48094660|NCT00824785|DRUG|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
48094661|NCT00824785|DRUG|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
47921192|NCT05056584|BIOLOGICAL|Primed tracer infusion|Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
47921193|NCT00074698|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm description.
48094662|NCT02739568|DRUG|Pitolisant (BF2.649)|
48094663|NCT02739568|DRUG|Placebo|
48094664|NCT05113589|DEVICE|PBM TREATMENT|Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
47921194|NCT05289518|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.
48094665|NCT05113589|DEVICE|PLACEBO PBM|The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
48094666|NCT04708821|DRUG|Dexamethasone ophthalmic insert 0.4Mg|Dextenza 0.4Mg Ophthalmic Insert
47921195|NCT05289518|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
47921196|NCT05664412|DEVICE|at-home tACS using Starstim-Home tES|We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
48094667|NCT04708821|DRUG|0.2% loteprednol etabonate ophthalmic suspension|0.2% loteprednol etabonate ophthalmic suspension
48094668|NCT04708821|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|olopatadine hydrochloride ophthalmic solution 0.7%
48094669|NCT02562014|OTHER|Glucose|75g glucose
48094670|NCT02562014|OTHER|Inulin|75g glucose plus 24g inulin
48094671|NCT02562014|OTHER|Resistant Starch|75g glucose plus 28.2g resistant starch
48094672|NCT02759198|DRUG|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
48094673|NCT02759198|DRUG|Celecoxib|Drug: Celecoxib 200mg
48094674|NCT02759198|DRUG|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
48094675|NCT04167891|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
48094676|NCT01805323|DRUG|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
48094677|NCT02321358|BEHAVIORAL|Two-time implementation intention|Will be given intervention and booster at six weeks
48094678|NCT02321358|BEHAVIORAL|One-time implementation intention|Will only be given the intervention once
48094679|NCT02321358|BEHAVIORAL|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
48094680|NCT02321358|BEHAVIORAL|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
48094681|NCT04280029|DEVICE|SELUTION SLR™ DEB|The SELUTION Sustained Limus Release (SLR)™ drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal coronary angioplasty (PTCA) balloon catheter coated with a drug (Sirolimus).
48094682|NCT04280029|DEVICE|Control|POBA or FDA-approved -limus DES
48094683|NCT05504343|DEVICE|"Intensity SL Intraocular Lens"|Cataract surgery and intraocular lens implantation
48094684|NCT00870350|BIOLOGICAL|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
48094685|NCT00870350|BIOLOGICAL|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
48094686|NCT04638387|DIETARY_SUPPLEMENT|PB125|Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
48094687|NCT04638387|DIETARY_SUPPLEMENT|Placebo|Placebo comparator to P125
48094688|NCT01571089|BEHAVIORAL|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
47921197|NCT05815875|COMBINATION_PRODUCT|STEADI Program|The investigators will conduct STEADI Algorithm for Falls Prevention educational sessions for healthcare providers in the neurosurgery unit, including doctors, nurses, physical therapists, and pharmacists. All healthcare providers in the neurosurgery unit will be invited to attend the educational sessions. Their participation will be voluntary and no obligations will be made, though. Healthcare providers will be invited to attend one 2-hour educational session. In each session, The investigators will have between 8-10 healthcare providers. The educational sessions will be delivered in the classroom available in the neurosurgery unit to facilitate the healthcare providers' access. PowerPoint presentations, videos, quizzes, case studies, and in-class discussions will be used to deliver learning content during the educational sessions. Healthcare providers will then be asked to apply the STEADI interventions on a group of patients.
47921198|NCT05815875|OTHER|Routine care|The control group participants will receive routine care. Routine care involves only assessing for falls using Morse Falls Scale (MFS). MFS assesses a patient's fall risk upon admission, following a change in status, and at discharge or transfer to a new setting.
47921199|NCT04876300|OTHER|No intervention|All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study will take place.
47921200|NCT04347668|OTHER|Virtual Reality|VR requires the user to use a multi-projected in their own room using BroomX to generate realistic images, sounds and other sensations that simulate a user's physical presence in a virtual or imaginary environment
47921201|NCT04347668|OTHER|Usual Care|meals, engagement in scheduled and non-scheduled programs such as exercise, and activities, groups. Residents are supported in their activities of daily living, and social engagement. Specific interventions based on resident needs are supported in a Dementia capable environment.
47921202|NCT05653453|DEVICE|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months.~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months."
47921203|NCT05653453|DRUG|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
47921204|NCT05371808|OTHER|EQ-5D-5L Instrument|This instrument is a measure of health status for use in evaluating health and healthcare.
47921205|NCT05371808|OTHER|Work Productivity and Daily Activity Impairment (WPAI) survey|The questionnaire includes three open-ended questions that determines: 1) hours absent from work due to health problems; 2) hours absent from work due to other reasons; and (3) hours actually worked over the past 30 days. Additional questions ask about the impact of health problems on work productivity and daily activities and are scored along a vertical visual analog scale. The WPAI provides estimates on absenteeism, presenteeism, global measures of lost productivity (absenteeism+presenteeism) and daily activity impairment (impaired ability to perform non-work activities including work around the house, child care, exercise, studying, and leisure activities)
47921206|NCT05371808|OTHER|Resource Utilization Form (SMRC)|Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
47921207|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
47921208|NCT02462642|OTHER|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
48094689|NCT06239662|BEHAVIORAL|Therapeutic Group|The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.
48094690|NCT06239662|BEHAVIORAL|Usual care|The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
48094691|NCT05355805|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
48094692|NCT05355805|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
48094693|NCT03342924|OTHER|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
48094694|NCT05395208|BEHAVIORAL|Therapeutic touch group accompanied by white noise|During the intravenous catheter intervention, approximately 15-20 minutes of white noise was applied with therapeutic touch.
48094695|NCT01192295|DRUG|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
48094696|NCT02248454|DRUG|Lispro|Increasing insulin doses
48094697|NCT04639947|DEVICE|EyeCheck|EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
48094698|NCT04639947|DEVICE|Traditional Tonometer (Goldmann and Tonopen)|Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
47921209|NCT02462642|DIETARY_SUPPLEMENT|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
47921210|NCT02462642|OTHER|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
47921211|NCT00638638|DRUG|Abciximab|"* Abciximab: 0.25 mg/Kg bolus~* Abciximab placebo bolus~* Abciximab infusion 10 µg/Kg/min"
47921212|NCT00638638|DRUG|Abciximab placebo|"* Abciximab placebo Bolus~* Abciximab: 0.25 mg/Kg bolus~* Abciximab infusion 10 µg/Kg/min"
47921213|NCT01067092|BEHAVIORAL|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
47921214|NCT01067092|BEHAVIORAL|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
47921215|NCT03554343|DIAGNOSTIC_TEST|test for SMN1 exon 7 deletion|Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
47921216|NCT02941172|OTHER|Cold exposure|Controlled cold exposure is performed before and during PET scan
47921217|NCT02941172|OTHER|[18F]FMPEP-d2|PET radiotracer used in imaging
48094699|NCT00083421|DRUG|ONO-2506PO|
48094700|NCT02540941|OTHER|non|
47921218|NCT02941172|OTHER|[18F]FDG|PET radiotracer used in imaging
48094701|NCT01685580|DEVICE|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
48094702|NCT02365298|DEVICE|etafilcon A|etafilcon A soft contact lens
48094703|NCT02365298|DEVICE|nelfilcon A|nelfilcon A
47921219|NCT04145440|DRUG|MOR202|Patients will receive 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing will occur weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
48094704|NCT06277817|OTHER|expiratory rib cage compression|Expiratory rib cage compression: The hands are placed on the lower third of the rib cage. During expiration, the end and sides of the patients' rib cage are gradually compressed with the hands.At the end of expiration, compression is released from the thorax to allow patients to take a free inspiration. After each compression, the patient is allowed to perform 3 breathing cycles.Expiratory rib cage compression is applied for 5 minutes.
48094705|NCT06277817|OTHER|percussion vibration|Percussion :Percussion is performed 3-5 times on each area from a height of approximately 10 cm with the domed hand. . It starts from the right and left lower lobes and goes up.Vibration:The hand is firmly/strongly placed on the application area. The arm and shoulder are stretched and the fingers are gently vibrated or shaken gently. While the patient is exhaling, vibration is performed 3-5 times in each area, starting from the right and left lower lobes.
47921220|NCT04142177|OTHER|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
47921221|NCT04142177|PROCEDURE|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
47951165|NCT03316365|OTHER|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
48094706|NCT05033067|BEHAVIORAL|P3BC|The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
48094707|NCT01972139|DEVICE|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
48094708|NCT01972139|OTHER|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
47921222|NCT04142177|OTHER|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
47921223|NCT04142177|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
47921224|NCT04142177|PROCEDURE|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
48094709|NCT01972139|DEVICE|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
48094710|NCT05298670|DRUG|MetFORMIN 1000 Mg Oral Tablet|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
47921225|NCT04142177|PROCEDURE|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
47921226|NCT04109508|DRUG|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
47921227|NCT03820700|BEHAVIORAL|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
47921228|NCT03820700|BEHAVIORAL|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
47921229|NCT03820700|BEHAVIORAL|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
47921230|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
47921231|NCT01640574|DRUG|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
47921232|NCT01640574|DRUG|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
47921233|NCT01640574|DRUG|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
47921234|NCT05520892|DRUG|intravenous immunoglobulin|To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia
47921235|NCT05486624|OTHER|Reiki|Reiki, one of the complementary treatments, was applied by touching the chakra areas of the body by hand.
48094711|NCT05298670|DRUG|Interferon beta-1a|Disease Modifying Therapies (DMTs)
48094712|NCT03628079|DRUG|ReposMBZ|Capsules 50mg, 100mg, 200mg
48094713|NCT03412838|PROCEDURE|graft surgery|A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
48094714|NCT02955862|OTHER|Vietnam Cryptococcal Retention in Care Study (CRICS)|"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.~Other Names:~• Fluconazole"
48094715|NCT00041262|DRUG|cisplatin|
48094716|NCT00041262|DRUG|epirubicin hydrochloride|
48094717|NCT00041262|DRUG|fluorouracil|
48094718|NCT00041262|PROCEDURE|conventional surgery|
48094719|NCT00041262|PROCEDURE|neoadjuvant therapy|
48094720|NCT01833065|DRUG|Elobixibat 10 mg/day|Elobixibat 10 mg/day
48094721|NCT01833065|DRUG|Elobixibat 5 mg/day|Elobixibat 5 mg/day
48094722|NCT01833065|DRUG|Placebo|Placebo
48094723|NCT04502927|PROCEDURE|Passive extension mobilization of the hand and wrist joints|"The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization."
47921236|NCT02605291|OTHER|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
48094724|NCT04550650|OTHER|Training groupe|Using virtual training
48094725|NCT04550650|OTHER|PNF|PNF technique was used
47921237|NCT02605291|OTHER|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
47921238|NCT02605291|OTHER|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
47921239|NCT02605291|OTHER|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
47921240|NCT02605291|OTHER|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
48094726|NCT04550650|OTHER|Spinning grp|They only worked with spinning bikes.
48094727|NCT04550650|OTHER|Balance|Balance development was done
48094728|NCT04223362|OTHER|Community-based physical activity programme|After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
48094729|NCT04223362|OTHER|Pulmonary Rehabilitation|Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
47921241|NCT00905645|DEVICE|Silimed Gel-Filled Mammary Implant|
47921242|NCT00250198|DRUG|STA-5326|
47921243|NCT05289401|OTHER|ultrasound guided blocks|Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
47921244|NCT02801266|BEHAVIORAL|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
47921245|NCT06427135|BEHAVIORAL|Exercise interventions|Rehabilitation physician or rehabilitation therapist, to engage in physical exercise or patients, according to the medical examination data (including exercise test and physical strength test), according to their health, physical strength, and cardiovascular function status, with the form of a prescription for the type of exercise, intensity of exercise, exercise time and frequency of exercise, to put forward the precautions to be taken during exercise.
47921246|NCT03977740|OTHER|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
47921247|NCT03977740|OTHER|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
48094730|NCT04127344|BEHAVIORAL|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
48094731|NCT02513433|DRUG|Bupivacaine|Local anesthetic
48094732|NCT02513433|DRUG|Levobupivacaine|Local anesthetic
47921248|NCT00877123|DRUG|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
47921249|NCT00877123|DRUG|Placebo|similar placebo once a month for three consecutive months
47921250|NCT01860183|DRUG|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
48094733|NCT02513433|DRUG|Ropivacaine|Local anesthetic
47921251|NCT04420936|BEHAVIORAL|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
47921252|NCT04420936|BEHAVIORAL|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
47951166|NCT05763212|OTHER|Reverse Walking+Baseline treatment|Reverse Walking+Baseline treatment
47951167|NCT05763212|OTHER|Whole Body Vibration + Reverse Walking+Baseline treatment|Whole Body Vibration + Reverse Walking+Baseline treatment
47951168|NCT01270854|OTHER|Plasmalyte A|Intravenous fluid
47951169|NCT01270854|OTHER|Normal Saline|Intravenous fluid
48094734|NCT05310721|BEHAVIORAL|Early time-restricted eating|Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
48094735|NCT05310721|BEHAVIORAL|Late time-restricted eating|Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
48106769|NCT04680260|OTHER|Standard of care|Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
48094736|NCT05310721|BEHAVIORAL|Self-selected time-restricted eating|Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
48094737|NCT05549024|DRUG|68Ga-RM26-RGD|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
47921253|NCT04395053|DRUG|SHR1459|"TR group:~The first period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h.~RT group:~The first period，the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h; 7 days washout； The second period，the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h."
47921254|NCT00637702|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
47921255|NCT05554562|OTHER|Adductor strength assessment|Adductor strength will be evaluated with HHD (handheld dynamometer) and forceplates (Forceframe), both injured leg and healthy will be assess in order to compare both limbs
48094738|NCT05549024|DRUG|18F-FDG|18F-FDG injection
47921256|NCT03035487|DEVICE|Ultrasound guided prostate exam using SOC ultrasound system|
47921257|NCT03035487|DEVICE|mpMRI guided prostate examination using PI-RADS v2|mpMRI guided prostate examination using standard of care MRI system
48094739|NCT05549024|DRUG|68Ga-RM26|Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
48094740|NCT05549024|DRUG|68Ga-RGD|Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
47921258|NCT03035487|DEVICE|High-resolution micro-ultrasound guided prostate biopsy|
47921259|NCT01328405|DEVICE|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
48094741|NCT00547976|DRUG|[C-11]PBR28|
48094742|NCT04762342|OTHER|Power training|"First a brief warm up on a stationary bike and uni-lateral knee raises is completed.~Power training: Involves exercises performed with fast/explosive muscle contraction during the concentric phase, and slow/controlled (approximately 2-3 s) muscle contraction during the eccentric phase.~Functional- and balance exercises are included from week 9-24.~Progression:~Week 1-4: 3 sets of 12 repetitions at a load of 14 repetitions maximum (RM) with focus on introducing resistance exercise and familiarizing participants with exercises.~Week 5-8: 3 sets of 12 repetitions at a load of 14 RM the power training component.~Week 9-16: 3 sets of 10 repetitions at a load of 12 RM. Week 17-24: 3 sets of 8 repetitions at a load of 10 RM~Strengthening exercises:~* Bilateral leg-press~* Bilateral plantar flexion~* Bilateral knee extension~* Unilateral banded dorsal flexion~* Bilateral lying leg curl~* Back extension~* Shoulder press~* Seated row~* Chest press~* Lat pull-down"
48094743|NCT00871429|OTHER|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
48094744|NCT06614088|DIAGNOSTIC_TEST|serum calprotectin|A blood sample is collected at time of admission to detect serum level of calprotectin
48094745|NCT06221774|DRUG|TT-00420 + Toripalimab|TT-00420 tablets in combination with Toripalimab injection
47921260|NCT02895126|BEHAVIORAL|"Appui Parental program"|
47921261|NCT02895126|BEHAVIORAL|Regular parental support|
48094746|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2 and 4 months
48094747|NCT00189020|BIOLOGICAL|PCV7|PCV7 at age 2, 4 and 11 months
48094748|NCT06629766|DEVICE|Microfluidic sperm separation device|An aliquot of 850ul will be used for the Zymot sperm selection device. The sperm processing via Zymot will be per manufacturer's guidelines
48094749|NCT06629766|OTHER|Density grade centrifugation|5ul of the ejaculated sample will be assessed for DGC via Makler assessment. If the sample for DGC is adequate per lab standard operating procedures, then routine DGC sperm preparation and embryologist sperm selection for the ICSI procedure will occur.
48094750|NCT02708862|DEVICE|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
48094751|NCT06525246|DRUG|ONO-7475|Specified dose, once daily
48094752|NCT06525246|DRUG|Osimertinib Mesylate|Specified dose, once daily
48094753|NCT05437471|DRUG|GNRH Analoge, Duphaston, Letrozole|GNRH Analoge, Duphaston, Letrozole
47921262|NCT02482818|DRUG|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
47921263|NCT02482818|DRUG|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
47921264|NCT00985920|DRUG|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
47921265|NCT00985920|DRUG|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
47921266|NCT03399201|PROCEDURE|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
47921267|NCT03399201|PROCEDURE|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
47921268|NCT03399201|DIAGNOSTIC_TEST|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
47921269|NCT06426524|PROCEDURE|IGF-1 Gel|After degranulation of the defect, IGF-1 gel mixed with Hydroxyapatite graft will be placed in the defect.
47921270|NCT06426524|PROCEDURE|Hydroxyapatite|After degranulation of the defect, Hydroxyapatite graft will be placed in the defect.
47921271|NCT03920644|DRUG|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
47921272|NCT03920644|DRUG|Scopolamine|IND, up to 6 administration of intranasal gel.
47921273|NCT03920644|DRUG|Placebo Patch|Placebo Patch, 1 patch behind the ear.
47921274|NCT03920644|DRUG|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
47921275|NCT03452748|DEVICE|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
47921276|NCT04976582|DEVICE|dry needle|modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.
47921277|NCT04583059|OTHER|Taping|A hard-preventive Zinc oxide tape was used in this study. Taping procedure consists of three separate steps: First step involved application of the anchor tape, which achieved by applying the tape circumferentially just above the malleolar level at the lo
47921278|NCT05087992|DRUG|BI 905711|BI 905711
47921279|NCT05087992|DRUG|FOLFIRI|FOLFIRI
47921280|NCT05087992|DRUG|Bevacizumab|Bevacizumab
47921281|NCT05795998|OTHER|Adaptation of the Sabotage in Romantic Relationships Scale into Turkish and its validity and reliability analyzes|Approval was obtained from the local ethics committee before starting the study. Permission was obtained from Racquel PEEL, who developed the scale. The scale was administered to 495 participants and they were informed about the study by a specialist psychiatrist. Language validity, construct validity and reliability analyzes of the scale were performed. The findings were discussed in the light of the literature.
47921282|NCT04101838|DRUG|Fluzone|inactivated seasonal influenza vaccine
48094754|NCT05928182|BEHAVIORAL|El Faro Treatment Intervention|"Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\]."
48094755|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
48094756|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
48094757|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
48094758|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
48094759|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
48094760|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
48094761|NCT00703482|DRUG|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
48094762|NCT01390857|DRUG|Valaciclovir|
48094763|NCT04056156|BEHAVIORAL|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
48094764|NCT04056156|BEHAVIORAL|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
48094765|NCT03417843|DEVICE|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
48094766|NCT06488599|RADIATION|Peri-apical radiographs on the implants|Peri-apical radiographs on the implants supporting the prosthesis
48094767|NCT03193346|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
48094768|NCT03193346|DRUG|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® \[Sodium chloride 0.9 mg\] IM injections in head/neck areas.
48094769|NCT03932617|DEVICE|end tidal carbon dioxide by capnography|"Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states."
48094770|NCT00126113|BEHAVIORAL|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
48094771|NCT00126113|BEHAVIORAL|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
48094772|NCT06193330|PROCEDURE|antibiotic-coated plate|A plate for fixing long bone fractures is coated with antibiotics cement prepared in theatre
48094773|NCT06193330|PROCEDURE|external fixator|external fixators are applied to participants with severe long bone fractures
47921283|NCT04101838|DRUG|Flucelvax|inactivated seasonal influenza vaccine
47921284|NCT04101838|DRUG|Fluzone High-Dose|inactivated seasonal influenza vaccine
47921285|NCT04101838|DRUG|Fluad|inactivated seasonal influenza vaccine
47921286|NCT04279106|PROCEDURE|0.05%chlorhexidine mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
47921287|NCT04279106|PROCEDURE|0.05% sodium fluoride mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
47921288|NCT04279106|PROCEDURE|alcohol free essential oils mouthwash|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
48094774|NCT05186454|DRUG|Morphine Sulfate|analgesia
47921289|NCT04279106|PROCEDURE|Placebo|All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
47921290|NCT05274295|DEVICE|Diabetic leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
47921291|NCT02834754|DRUG|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
47951170|NCT06621719|PROCEDURE|Alveolar Cleft Reconstruction|Alveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group
48094775|NCT05186454|DRUG|Bupivacaine|Analgesia
48094776|NCT05186454|DRUG|dexamethasone, morphine, midazolam|1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
48094777|NCT03743012|OTHER|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
48094778|NCT03743012|OTHER|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
48094779|NCT04268264|PROCEDURE|Incremental haemodialysis|twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
48094780|NCT04268264|PROCEDURE|Conventional haemodialysis|three times weekly 4-hour long haemodialysis sessions from the start
48094781|NCT06463171|DRUG|Almonertinib|"Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off."
48094782|NCT05378581|DEVICE|Virtual reality mask|virtual reality mask Deepsen® with age-appropriate software Birdy®
48094783|NCT05378581|OTHER|control arm|usual process
48106770|NCT04680260|OTHER|Circulating tumor DNA guided treatment approach|Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
47951171|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
48094784|NCT06441773|PROCEDURE|Respiratory Rehabilitation|"An initial assessment is conducted upon admission to personalize the program. This includes:~Clinical examination Spirometry Maximum Inspiratory Pressure (PImax) measurement Multidimensional Dyspnea Profile questionnaire at end of TM6 Exercise Functional Testing Measurement of quadriceps strength and endurance Blood gases Educational interview and shared educational assessment London Chest Activity of Daily Living (LCADL) Tobacco and/or dietary consultation~The respiratory rehabilitation program, performed twice a week, includes:~Exercise training on an ergocycle and treadmill (30 minutes at ventilatory threshold for the ergocycle; 30 minutes at 60-80% walking speed for the treadmill; or dyspnea rated 4-6 on the Borg scale after endurance exercise) Quadriceps muscle strengthening Therapeutic education program Group gymnastics Smoking cessation assistance Socio-psychological and nutritional support"
48094785|NCT02107001|PROCEDURE|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
48094786|NCT05978609|DRUG|Candonilimab|Candonilimab 10mg/kg, Ivgtt，Q3W，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
48094787|NCT05978609|DRUG|Cisplatin|Cisplatin，25mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
48094788|NCT05978609|DRUG|Gemcitabine|gemcitabine 1000mg/m2，Ivgtt，Dosing on days 1 and 8，Every 21 days is a cycle, administered on the first day of each cycle, and used continuously；
48094789|NCT01879904|PROCEDURE|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
48094790|NCT00967369|DRUG|Bortezomib|Given IV
48094791|NCT00967369|DRUG|Carboplatin|Given IV
48094792|NCT00967369|DRUG|Etoposide|Given IV
48094793|NCT00967369|DRUG|Ifosfamide|Given IV
48094794|NCT03246672|BEHAVIORAL|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
48094795|NCT05167747|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal"
48094796|NCT05167747|OTHER|Placebo|Oral administration: 2 tablets/day at evening meal
48094797|NCT01642940|DRUG|Prasugrel|Prasugrel 10mg/day
48094798|NCT01642940|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
48094799|NCT00932919|BEHAVIORAL|Thought field therapy|5 sessions with Thought field therapy
48094800|NCT00932919|BEHAVIORAL|Cognitive therapy|12 sessions of Cognitive therapy
48094801|NCT00932919|BEHAVIORAL|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
48094802|NCT00961805|BEHAVIORAL|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
48094803|NCT00961805|OTHER|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
48094804|NCT05553561|PROCEDURE|IPRL device|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
48094805|NCT05553561|PROCEDURE|pharmacological therapy & Eyelid hygiene|traditional methods of MGD treatment as Eyelid hygiene, topical preservative free lubricant, topical \& systemic antibiotics \& anti-inflammatory agent
48094806|NCT01597518|DRUG|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
48094807|NCT01597518|DRUG|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
48094808|NCT01149135|DEVICE|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
48094809|NCT01149135|DEVICE|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
48094810|NCT00607035|DRUG|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
48094811|NCT00607035|DRUG|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
48094812|NCT00232011|DRUG|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
48094813|NCT03390556|OTHER|Nurse-delivered education|"The nurse will:~1. Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~2. Give caregivers information about asthma management written at or below 6th grade reading levels.~3. Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~4. Demonstrate MDI/spacer technique with teach-back.~5. Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~6. Ask patients to make a 1 month follow-up appointment for asthma care."
48094814|NCT01650337|OTHER|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
48094815|NCT03768245|BEHAVIORAL|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
48094816|NCT03768245|DIETARY_SUPPLEMENT|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
48094817|NCT00507611|PROCEDURE|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
48094818|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
48094819|NCT03424928|DRUG|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
48094820|NCT04654351|DRUG|TAK-667|TAK-667 single SC administration
48094821|NCT06121570|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
48094822|NCT06121570|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
48094823|NCT06121570|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
48094824|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
48094825|NCT06121570|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
48094826|NCT06121570|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
48094827|NCT06121570|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|Participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
48094828|NCT06121570|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
48094829|NCT06121570|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
48094830|NCT03422510|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
48094831|NCT06614569|DRUG|AXO-AAV-GM2|Participants who received AXO-AAV-GM2 will be tracked in long term follow up
48094832|NCT05544136|DIAGNOSTIC_TEST|18F-FMISO PET/CT scan|18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start
47921292|NCT02834754|DRUG|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
47921293|NCT01507064|DRUG|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
47951172|NCT04037046|BEHAVIORAL|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
48094833|NCT05544136|RADIATION|Chemoradiation therapy|"* 18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~* 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes."
48094834|NCT05544136|DRUG|Carboplatin|The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
48094835|NCT05767073|BEHAVIORAL|Lifestyle InterVEntion (LIVE)|"The lifestyle intervention Coaching on Lifestyle (CooL) (van Rinsum 2018)),formed the basis of LIVE and was adapted to specific dysfunctional elements in depressed patients regarding motivation and self-management.~The focus is on reducing depressive symptoms, enhancing the quality of life and possibly achieving weight loss.~The lifestyle intervention lasts six months, with 13 weekly 1.5 to 2 hour group sessions and five 45 to 60 -minute individual sessions with at least one person from the patient's support network of friends or family (preferably sharing the same household). All sessions end with individual homework exercises, and each session starts with a 10 to 15-minute positive psychology intervention (PPI) and 5 to 15 minutes of physical activity. These sessions are followed by two booster sessions after about two and six months. Groups consist of 4-8 people."
48094836|NCT02125513|DRUG|carboplatin and paclitaxel followed by surgery|
48094837|NCT03206294|OTHER|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
48094838|NCT02953275|DRUG|vedolizumab|standard of care
48094839|NCT02953275|DRUG|Pentoxifylline|added to vedolizumab
48094840|NCT02953275|DRUG|placebo|added to vedolizumab
48094841|NCT02813499|OTHER|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
48094842|NCT03381430|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
47921294|NCT01507064|PROCEDURE|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
47921295|NCT02779322|PROCEDURE|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
48094843|NCT04140058|DRUG|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
48094844|NCT04140058|DRUG|Normal saline|Placebo of 10 mL normal saline was administered.
48094845|NCT03203161|PROCEDURE|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
48094846|NCT05373901|DRUG|Dinutuximab Beta|Dinutuximab beta was administered intravenously at a dosage of 10 milligrams/ meters squared (mg/m2) per day for 10 consecutive days
48094847|NCT05373901|DRUG|13-cis-Retinoic Acid|13-cis-Retinoic Acid was administered orally at a daily total dose of 160 mg/m2, divided into approximately two equal doses given twice daily for 14 days following the conclusion of dinutuximab beta infusion.
48094848|NCT01102361|PROCEDURE|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
48094849|NCT03559361|DIETARY_SUPPLEMENT|EPA-rich|6 months omega 3 supplementation
47921296|NCT02779322|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
47921297|NCT01558128|DRUG|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
47921298|NCT01558128|PROCEDURE|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
47921299|NCT05350956|DRUG|TPO-RA (Herombopag)|During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
47921300|NCT05350956|DRUG|TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)|During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
47921301|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by SpO2|Titration of fraction of inspired oxygen (FiO2) guided by SpO2
47921302|NCT04211246|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2|Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2
47951173|NCT04037046|BEHAVIORAL|Screening HCV at primary care center|DBS for HCV screening at primary care center
47951174|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine.
48094850|NCT03559361|DIETARY_SUPPLEMENT|DHA-rich|6 months omega 3 supplementation
48094851|NCT03559361|DIETARY_SUPPLEMENT|Olive oil Placebo|6 months placebo supplementation
48094852|NCT01941316|DRUG|Carfilzomib|20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
48094853|NCT01941316|DRUG|Irinotecan|125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
48094854|NCT00312312|BIOLOGICAL|Specific immunotherapy|
48094855|NCT05328505|RADIATION|Image-guided Radiotherapy|de-escalation radiotherapy to elective volumes + simultaneous integrated boost to PSMA avid lesions delivered in 20 fractions +/- ADT (clinical decision). The elective prostate bed and pelvic lymph node regions will receive 45 Gy. The PSMA-avid lymph node(s) will receive an SIB to 55-60 Gy and/or the PSMA-avid lesion in the prostate bed will receive an SIB to 60 Gy. Pelvic nodal treatment and ADT use will be left to the discretion of the treating physician.
48094856|NCT00092560|DRUG|MK0653, ezetimibe|
48094857|NCT00092560|DRUG|Comparator: fenofibrate monotherapy|
48094858|NCT05518110|DRUG|Trametinib|2mg of Trametinib (orally) daily.
47951175|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
47951176|NCT06681805|DRUG|Placebo + Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine.
47951177|NCT06681805|DRUG|Placebo+ Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
48094859|NCT05518110|DRUG|Hydroxychloroquine|1200mg of Hydroxychloroquine (orally; 600mg twice a day (BID)) daily.
48094860|NCT01565538|DRUG|Erlotinib|150 mg Given orally
48094861|NCT01565538|DRUG|Pemetrexed|500mg/m2 Given IV
48094862|NCT05077631|DRUG|ACD856|Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.
48094863|NCT05077631|DRUG|Placebo|Placebo oral solution
48094864|NCT05077631|DRUG|ACD856 (fed cohort)|Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
48094865|NCT05343013|DRUG|TAS-102|GIven by PO
47921303|NCT06173700|BEHAVIORAL|web-based group problem solving and coping training|"The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide."
47921304|NCT04269083|OTHER|BIRC3|BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
47921305|NCT01051518|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
47921306|NCT03634241|BIOLOGICAL|Pembrolizumab|Given IV
48094866|NCT01576315|DRUG|Itraconazole/voriconazole|The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
47921307|NCT03634241|OTHER|Quality-of-Life Assessment|Ancillary studies
47921308|NCT03634241|PROCEDURE|Computed Tomography|Undergo CT
47921309|NCT03634241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47921310|NCT03319745|BIOLOGICAL|Pembrolizumab|Given IV
47921311|NCT01539044|DRUG|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
47921312|NCT01539044|DRUG|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
47921314|NCT06089096|DIAGNOSTIC_TEST|Home Sleep Apnea test (HSAT)|Patient will received HSAT at baseline
47921315|NCT04308967|OTHER|balance exercises|Three-stage progressive balance exercises will be applied.
47921316|NCT05278351|DRUG|Tislelizumab Combined With Cetuximab and Irinotecan|Tislelizumab (an anti-PD-1 monoclonal antibody) Cetuximab (monoclonal antibody against EGFR) Irinotecan
47921317|NCT05278351|DRUG|Third-line regimens|Trifluridinetipiracil or Regorafenib or Fruquintinib
48094867|NCT06601907|BEHAVIORAL|alivis|alivis is an interactive online program for independent use by users with Borderline Personality Disorder. It focuses on recognized treatment elements from Dialectical Behavior Therapy, Schema Therapy, Acceptance and Commitment Therapy, and Mindfulness Self-Compassion Therapy.
47921318|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
47921319|NCT01642615|DRUG|Dexlansoprazole|Dexlansoprazole capsules
47921320|NCT01642615|DRUG|Placebo|Dexlansoprazole placebo-matching capsules
47921321|NCT06327724|DRUG|Belimumab|Start of new treatment due to active disease
47921322|NCT00458029|BEHAVIORAL|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
47921323|NCT00060359|DRUG|Carboplatin|Given IV
47921324|NCT00060359|DRUG|Paclitaxel Poliglumex|Given IV
47921325|NCT00060359|OTHER|Pharmacological Study|Correlative studies
47921326|NCT03931135|DRUG|IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section|"The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped"
48094868|NCT04669613|OTHER|CUDI|Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
47921327|NCT03180619|DRUG|TAF|Tablet administered orally once daily
47921328|NCT00190255|PROCEDURE|CY2PC9 genotyping|CY2PC9 genotyping
47921329|NCT01293071|OTHER|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
47921330|NCT00668993|BEHAVIORAL|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
47921331|NCT02269540|DRUG|Sertraline|selective serotonin reuptake inhibitor
47921332|NCT02269540|DRUG|Citalopram|selective serotonin reuptake inhibitor
47921333|NCT02269540|DRUG|N-acetylcysteine (NAC)|natural health product
47921334|NCT02269540|DRUG|Existing depression medication treatment|Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
47921335|NCT02520089|PROCEDURE|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
47921336|NCT02520089|PROCEDURE|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
47921337|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
47921338|NCT02058823|DRUG|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
47921339|NCT02058823|DRUG|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
47921340|NCT02058823|DRUG|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
48094869|NCT04216303|DIAGNOSTIC_TEST|hemoglobin A1c|The hemoglobin A1c test (A1c) screens for, helps diagnose, and monitors diabetes and prediabetes.
48094870|NCT05305911|DRUG|SGLT-2 inhibitors|SGLT2 inhibitor once daily for six months
47921341|NCT01261780|DEVICE|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
47921342|NCT01261780|DRUG|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
47921343|NCT00229424|DRUG|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
47921344|NCT00229424|DRUG|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
48094871|NCT05305911|DRUG|Placebo|Placebo once daily for six months
48094872|NCT06418906|OTHER|Self-reported questionnaires|After participants agree to participate in this study, they will first fill out the set of questionnaires once. After two weeks, the research team will send them reminders to fill out the same set of questionnaires again.
47921345|NCT00229424|OTHER|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
47921346|NCT01578850|DRUG|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
47921347|NCT01578850|DRUG|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
47921348|NCT03517345|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
47921349|NCT03517345|DIETARY_SUPPLEMENT|Control|The only yogurt consumed as 200 g/d without prebiotic.
47921350|NCT01781468|DRUG|armodafinil 150 mg|given orally
47921351|NCT01781468|OTHER|Placebo|given orally
47921352|NCT01781468|DRUG|armodafinil 250 mg|given orally
47921353|NCT00264459|BIOLOGICAL|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
47921354|NCT00264459|OTHER|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
48094873|NCT00512824|DIETARY_SUPPLEMENT|low calcium milk of 180 ml|twice daily for 24 weeks
48094874|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml|twice daily for 24 weeks
48094875|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
48094876|NCT00512824|DIETARY_SUPPLEMENT|regular milk of 180 ml + probiotics|twice daily for 24 weeks
48094877|NCT06080958|DEVICE|NPWT|the NPWT dressing applied to fasciocutaneous flap
47921355|NCT04796181|DEVICE|Neteera 130H|The Neteera 130H will used to perform measurements in proximity to study participants.
47921356|NCT01916291|DRUG|Propess insertion group|
47921357|NCT00909207|BEHAVIORAL|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
47921358|NCT04752644|BIOLOGICAL|MVA-mBN294B|MVA-BN-RSV (nominal titre 5 x10\*8 Inf.U per 0.5 mL) as intramuscular injections. Liquid frozen suspension, single dose of 0.5ml.
47921359|NCT04752644|DRUG|Placebo|TBS (Placebo) as intramuscular injections (0.5ml)
48094878|NCT06080958|OTHER|Conventional dressing|Conventional dressing ( topical care ) applied to fasciocutaneous flap
48094879|NCT06371482|DRUG|Durvalumab|Durvalumab is an immunoglobulin G (IgG) 1-κsubtype monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 in T cells and CD80 (B7.1) in immune cells (ics). Durvalumab is developed by Astrazeneca /MedImmune for the treatment of cancer. Durvalumab is designed to reduce the cytotoxicity of antibody-dependent cells and complement dependent cytotoxicity. In vitro studies have demonstrated that Durvalumab can antagonize the inhibition of PD-L1 in human primary T cells, causing them to resume proliferation and release interferon gamma (IFNγ). To date, more than 1,800 patients have been treated with valiuzumab as a single agent or in combination with other cancer agents as part of ongoing studies. Durvalumab: 10mg/Kg, intravenously, starting at week 7 every 3 weeks for at least 1 year, or until progression, intolerance, or spontaneous withdrawal of the patient.
48094880|NCT06371482|DRUG|Chemotherapy drug of EP regimen|"Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks."
47921360|NCT05363254|OTHER|Marlboro Gold Box|A combustible cigarette
47921361|NCT05363254|OTHER|Newport Box|A combustible cigarette
47921362|NCT05363254|OTHER|Non-combusted cigarette variant 42001401|A menthol flavor variant of a non-combusted cigarette (42001401)
47921363|NCT05363254|OTHER|Non-combusted cigarette variant 42001399|A menthol flavor variant of a non-combusted cigarette (42001399)
47921364|NCT05363254|OTHER|Non-combusted cigarette variant 40007386|A menthol flavor variant of a non-combusted cigarette (40007386)
47921365|NCT05363254|OTHER|Non-combusted cigarette variant 42001402|A non-menthol flavor variant of a non-combusted cigarette (42001402)
47921366|NCT03068351|DRUG|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram \[mg/kg\] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
48094881|NCT06371482|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
48094882|NCT01663610|BEHAVIORAL|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
48094883|NCT04198961|OTHER|opioid prescribing|Individualized taper and safety recommendations will be communicated to prescribers via an electronic medical record encrypted message.
48094884|NCT05576662|DRUG|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours
47921367|NCT03068351|BIOLOGICAL|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
47921368|NCT02208687|BEHAVIORAL|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
47921369|NCT02208687|OTHER|Control group|Usual care
47921370|NCT02206178|DRUG|N-acetylcysteine combination with acetaminophen|
47921371|NCT02206178|DRUG|Placebo|
47921372|NCT00910299|DRUG|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
47921373|NCT00910299|DRUG|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
47921374|NCT03208582|DRUG|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
47921375|NCT03208582|DIETARY_SUPPLEMENT|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
48094885|NCT05576662|DRUG|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours
47921376|NCT02970240|PROCEDURE|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
47921377|NCT03363113|DRUG|Botulinum Toxins|Injection of botulinum toxin in the muscles affected by oromandibular dystonia
47921378|NCT03663400|DIAGNOSTIC_TEST|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
47921379|NCT05251389|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation of an ICI responding or Fecal microbiota transplantation from an ICI non-responding donor, in combination with ICI.
48094886|NCT05576662|DRUG|Ritonavir|One 100 mg capsule taken by mouth every 12 hours
47921380|NCT00308464|DRUG|PHA-794428|
48094887|NCT04364880|DEVICE|TBS|Theta-burst stimulation (TBS) is a novel repetitive transcranial magnetic stimulation (rTMS)
48094888|NCT04364880|DEVICE|Sham|The sham-TBS coil produced a similar sound without a magnetic pulse.
47921381|NCT00437008|DRUG|Benfotiamine 1050mg, 3 days|
47921382|NCT00437008|BEHAVIORAL|high-AGE vs. low-AGE meal|
47921383|NCT03717272|DRUG|AEF0117|AEF0117 capsules
47921384|NCT03717272|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
47921385|NCT00771862|PROCEDURE|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
47921386|NCT01028300|DEVICE|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
47921387|NCT01258322|DRUG|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
47921388|NCT04904224|DEVICE|Panintestinal video capsule endoscopy|Performing a video capsule endoscopy using the Pill Cam Crohn's capsule from Medtronic
48094889|NCT05991505|OTHER|Physical exercise|Multimodal exercises twice a week
47921389|NCT04904224|DEVICE|Colonoscopy|Performing a standard colonoscopy using the colonoscope available in the study center
47921390|NCT02499445|DRUG|Remifentanil|administering remifentanil for anesthesia maintenance
47921391|NCT02499445|DRUG|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
47921392|NCT02499445|DRUG|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
47921393|NCT02499445|DRUG|propofol|administering propofol for anesthesia maintenance
47921394|NCT02499445|DRUG|sufentanil|administering sufentanil for anesthesia maintenance
47921395|NCT00319072|BEHAVIORAL|TalkToYourDoc(sm) hormone therapy module|
47921396|NCT03599375|BIOLOGICAL|CD19-targeted CART cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.This is a second generation CRAT.
47921397|NCT03728283|PROCEDURE|implant placement in combination with connective tissue grafting|A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
47921398|NCT03728283|OTHER|Implant placement|Implants were placed following teh manufacturer's instructions
48094890|NCT01663337|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
48094891|NCT01663337|BEHAVIORAL|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
48094892|NCT02734368|DRUG|Hyperpolarized Helium-3|
48094893|NCT02998827|DRUG|Thalidomide|
48094894|NCT02998827|DRUG|infliximab, azathioprine|other treatment include infliximab, azathioprine
48094895|NCT02998827|OTHER|enteral nutrition|
48094896|NCT04181801|PROCEDURE|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
48094897|NCT02506426|PROCEDURE|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
48094898|NCT02506426|PROCEDURE|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
48094899|NCT00196170|PROCEDURE|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
48094900|NCT00196170|PROCEDURE|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
48094901|NCT00196170|PROCEDURE|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
47921400|NCT05180396|OTHER|Questionnaires|Application of a study based questionnaire described in the protocol
47921401|NCT00095147|DRUG|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
48094902|NCT00196170|PROCEDURE|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
47921402|NCT00095147|DRUG|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
47921403|NCT00095147|DRUG|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
47921404|NCT00095147|DRUG|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
47921405|NCT00095147|DRUG|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
47921406|NCT00514748|PROCEDURE|DIEP|flap survival, operation time, flap complications, donor site morbidity.
47921407|NCT00514748|PROCEDURE|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
47921408|NCT03276455|GENETIC|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
47921409|NCT03002467|OTHER|PESI score|
47921410|NCT00311584|DRUG|irinotecan hydrochloride|Given IV
47921411|NCT00311584|DRUG|temozolomide|Given IV
47921412|NCT05307198|DRUG|Oxaliplatin|"Drug: Oxaliplatin Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.~The dose of oxaliplatin used for rectal artery infusion was uncertain because there were no previous study. We design this study with Oxaliplatin 85mg/㎡for rectal artery infusion chemotherapy in Day 1 every 3 weeks and repeat for 2 cycles, based on intravenous chemotherapy regimens recommended by NCCN（mFolfox6）.If there were severe side effects caused by oxaliplatin observed within first 5 patients, we would decreasing the dose of oxaliplatin depending on the multidisciplinary discussion of researchers.~We acknowledged that our study did not determine the most appropriate dosage of oxaliplatin used for artery infusion, but rather performed a novel therapeutic method for microsatellite stable locally advanced rectal cancer."
47921413|NCT05307198|PROCEDURE|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
47921414|NCT05307198|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy in Day 1 to Day 14 every 3 weeks and repeat for 4 cycles.
47921415|NCT05307198|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD1 antibody 200mg/m2 in Day 2 after Rectal Artery Infusion Chemotherapy. Repeat every 3 weeks for 2 cycles.
47921416|NCT04276324|OTHER|Resistance training|Ten weeks of resistance training
47921417|NCT04276324|OTHER|Testing sessions|Testing sessions
47921418|NCT03772288|DRUG|TAK-659|Tablets.
47921419|NCT03772288|DRUG|NKTR-214|Intravenous infusion.
47921420|NCT02835040|OTHER|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
47921421|NCT02835040|OTHER|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
47921422|NCT01460511|DRUG|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
47921423|NCT01460511|DRUG|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
48094903|NCT03574909|DRUG|Aspirin|Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
47921424|NCT04206241|DIAGNOSTIC_TEST|Point of care early infant diagnosis (POC EID)|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
47921425|NCT05711758|PROCEDURE|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
47921426|NCT02791568|PROCEDURE|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
47921427|NCT02791568|PROCEDURE|MRI Scan|MR imaging will take approximately 30 minutes.
47951178|NCT06680193|BEHAVIORAL|Processing of Positive Memories Technique|"PPMT was administered weekly as a 4-session protocol. In session 1, participants receive psychoeducation on PTSD symptoms, an overview of PPMT, and are assessed for psychological symptoms. Sessions 1-4 involve the detailed processing of a salient positive autobiographical memory to elicit values, affect, strengths, and thoughts related to that positive memory. Homework assignments include listening to an audio recording of that memory, completing a values, affect, strengths, and thoughts log, and engaging in a behavioral activity. In session 4, the therapist also reviews psychological symptoms and addresses termination."
48094904|NCT03574909|DRUG|Placebos|Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
47921428|NCT02791568|DRUG|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
48094905|NCT01688544|DRUG|Ilaprazole|Ilaprazole 10 mg for 7 days
48094906|NCT04284748|OTHER|Plyometric exercise with blood flow restriction|"Blood flow restriction training is an exercise protocol based on the method of limiting blood flow with external pressure by pneumatic tourniquet from the proximal of the muscle to be strengthened. Blood flow restriction (Occlusion) during pliometric exercises for 8 weeks, a pneumatic tourniquet (Kaatsu Master) proximal to the thigh will be applied to each patient within a safe pressure range. The pressure to be applied to the patient will be calculated with the following formula described in the literature.~Pressure = 0.5 x (systolic blood pressure) + 2 x (thigh circumference) + 5 Application will be done for a maximum of 15 minutes, then rest for 10-15 minutes and other exercises will continue.~Plyometric training with blood flow restriction. Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)"
47921429|NCT01685398|DRUG|0.5% timolol maleate eye drop|
47921430|NCT01685398|DRUG|Normal saline|
47921431|NCT05724693|DRUG|Bemnifosbuvir (BEM)|Day 1: A single dose of BEM will be administered
47921432|NCT04136782|DRUG|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
47921433|NCT04136782|DRUG|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
47921434|NCT05473650|DIAGNOSTIC_TEST|CBC.with with differential Peripheral smear|determine spectrum of hematological disorders in childern with pancytopenia
47921435|NCT00333944|DRUG|Pralidoxime(drug)|
47921436|NCT05702346|BEHAVIORAL|Enhance Physical Activity (EPA)|EPA is eight weeks with four weekly, hour-long parts: virtual group exercises, virtual group discussions, individual PA participation, and individual phone check-ins.
47921437|NCT03234283|DEVICE|IRRIS InfraRed - Red Intubation System|IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
47921438|NCT00313781|DRUG|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
47921439|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
47921440|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
47921441|NCT00313781|DRUG|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
47921442|NCT00313781|DRUG|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
47921443|NCT05545280|DRUG|Neostigmine with glycopyrrolate|Administration by intravenous infusion
47921444|NCT05545280|DRUG|Sugammadex|Administration by intravenous infusion
47921445|NCT02870322|BEHAVIORAL|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
48094907|NCT04284748|OTHER|Plyometric exercise|Plyometric training Jump in functional squat system (30+15+15+15= 75 rep) Lunge jump (30 rep) Side jump (30 rep) Box jump (15 rep) Exercises to be added after 4 weeks; Square jump (15 rep) One leg hop (15 rep)
48094908|NCT04284748|OTHER|Routine physiotherapy program|Anterior and lateral plan exercise (3x10 rep) Open kinetic quadriceps and hamstring strengthening exercise (3x10 rep) Lunge exercises on different ground (3x10 rep) Single leg squat exercise on different ground (3x10 rep) Anterior and lateral walking exercise in a squatting position with an exercise band (40 step) Balance and proprioceptive exercises
48094909|NCT00315965|DRUG|Nitric oxide, Carbon monoxide, Helium|
48094910|NCT00471211|DRUG|PBT2|
48094911|NCT01572077|RADIATION|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
48106771|NCT01233713|PROCEDURE|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
47921446|NCT02870322|BEHAVIORAL|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
48094912|NCT04374877|DRUG|CHS-388|CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
47921447|NCT03730792|BEHAVIORAL|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
47921448|NCT05239429|BEHAVIORAL|Transcendental Meditation Technique|Participants receive one-on-one training on how to use Transcendental Meditation technique which is then practiced twice daily for approximately 20 minutes.
47921449|NCT02581150|PROCEDURE|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
47921450|NCT02619916|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
48094913|NCT04374877|DRUG|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
47921451|NCT02619916|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
48094914|NCT04374877|DRUG|Toripalimab|Toripalimab by IV infusion
48094915|NCT05395143|DRUG|Zinc sulfate|Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
48094916|NCT05395143|DRUG|Placebo|Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
48094917|NCT04216160|OTHER|ACN cream (YUN)|Application of the facial cream ACN (YUN) twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
48094918|NCT04216160|OTHER|Placebo cream (YUN)|Application of the facial placebo cream twice a day, for 8 weeks +/- 2 days. Assessment before product use (T0), after 2, 4 and 8 weeks +/- 2 days of product use (T2w, T4w and T8w, respectively) and after 4 weeks +/- 2 days without product use (T12w).
48094919|NCT00694811|BEHAVIORAL|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
48094920|NCT02162940|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
48094921|NCT02162940|OTHER|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
48094922|NCT01060566|DRUG|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
47921452|NCT05366504|COMBINATION_PRODUCT|LiST + PRP intracorporeal injection|12 LiST sessions (2 sessions per week) plus PRP (2 intracorporeal injections 3 weeks apart, after the 1st and the 7th LiST sessions) ( 30 patients).
47921453|NCT05366504|COMBINATION_PRODUCT|LiST + Placebo(normal saline intracorporeal injection)|All subjects of this group will receive 12 sessions (V3-V14) of LiST with session frequency 2/week and 2 normal saline injections with 3 weeks treatment interval (V3 and V9), 10 ml of normal saline will be injected at each session.
48094923|NCT01060566|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
48094924|NCT04463082|PROCEDURE|Intravenous administration of fluids|Intravenous administration of fluids (20ml/kg, but the maximum volume will be limited up to 500ml) within 60 minutes.
48094925|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
48094926|NCT00893217|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
48094927|NCT05607966|DEVICE|ORIGIN® CR devices|It is planned to include consecutive eligible subjects which will be treated with the ORIGIN® CR devices.
48094928|NCT02911272|DEVICE|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
48094929|NCT02911272|DRUG|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
48094930|NCT02911272|PROCEDURE|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
48094931|NCT02911272|DEVICE|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
48094932|NCT01235585|DRUG|Placebo|Oral doses, once a day for 52 weeks
48094933|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
48094934|NCT01235585|DRUG|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
48094935|NCT02539758|OTHER|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
48094936|NCT02539758|DEVICE|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
48094937|NCT02539758|DEVICE|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
48106772|NCT01233713|PROCEDURE|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
48106773|NCT02266641|BEHAVIORAL|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
47921454|NCT05563870|PROCEDURE|Endoluminal radiofrequency ablation|Endoluminal Radiofrequency ablation (RFA) of the entire stricture length will be performed using the Habib probe. A current of 7W will be delivered for 90s intervals at a time. If multiple ablation sessions are needed in order to ablate the entire stricture lenght, there will be an overlap of ablated areas in order to ensure proper stricture treatment. Dilation of the stricture prior to RFA delivery will be performed if required. After RFA treatment, biliary drainage of all hepatic territories will be ensured.
48094938|NCT04213846|BEHAVIORAL|Experimental: Mobile Alcohol Expectancy Intervention|Participants randomized to the intervention condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
48094939|NCT05360732|DRUG|FOLFIRINOX|Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
48094940|NCT05675631|OTHER|Suspension training|This group will perform training using suspension devices.
48094941|NCT05675631|OTHER|Strength training|This group will perform training using weights and elastic bands.
48094942|NCT05247853|PROCEDURE|Blood collection|Blood collection at enrollment visit
48094943|NCT05247853|PROCEDURE|Oral, cervicovaginal and anal specimen collection|Oral, cervicovaginal and anal specimen collection at enrollment and follow-up visits
48094944|NCT05247853|PROCEDURE|Anoscopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent anal HPV16/18+ in WLWH
48094945|NCT05247853|PROCEDURE|Colposcopy & Biopsy of Acetowhite Lesions|Used for management in follow-up visits of persistent type-specific high-risk HPV cervicovaginal HPV
48094946|NCT05247853|PROCEDURE|Ablative Treatment|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy
48094947|NCT05247853|PROCEDURE|LEEP (Loop Electrosurgical Excision Procedure)|Use for management in follow-up visits of persistent cervicovaginal HPV 16/18+ in WLWH, as identified in colposcopy and biopsy that ablation ineligible
48094948|NCT06121115|DRUG|Norepinephrine|Norepinephrine administered in midline catheter according to clinical routine
48094949|NCT00362193|BEHAVIORAL|Telephonic diabetes care|
48094950|NCT06263829|OTHER|Use of Tappt App|Use of Tappt, a novel digital medication companion solution
48094951|NCT03013842|DEVICE|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
48094952|NCT02552277|BIOLOGICAL|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
48094953|NCT02552277|DRUG|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
48094954|NCT06336746|DEVICE|Esophageal Doppler|Esophageal Doppler: measuring cardiac performance. INVOS: measuring regional saturation of the brain.
48094955|NCT02135393|DIETARY_SUPPLEMENT|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
48094956|NCT04437108|PROCEDURE|Li-SWT (suprapubic approach)|The patient will be asked to lie in flat dorsal position. A commercially used gel for sonography will be applied to the suprapubic region. The applicator will be placed on suprapubic region with two fingers apart from the symphysis pubis tilting to 45°. Shock waves will be directed to 3 different sites; the midline (over the bladder dome) and 3 cm right and left to the midline (over bilateral bladder walls). The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
48094957|NCT04437108|PROCEDURE|Li-SWT (perineal approach)|The patient will be asked to lie in lithotomy position. A commercially used gel for sonography will be applied to the perineum. The applicator will be placed on perineal region. Shock waves will be directed to 3 different sites: the midline and 2 cm above and below the midline. The patient will receive 3000 shocks (1000 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
48094958|NCT04437108|PROCEDURE|Li-SWT (combined approach)|The patient will receive 3000 shocks; 1500 shocks through suprapubic approach (500 shocks per site) and another 1500 shocks through perineal approach (500 shocks per site) with energy flux density of 0.12 mJ/mm² and frequency of 4 Hz.
48094959|NCT04437108|PROCEDURE|Sham treatment|The same technique of Li-SWT will be used but the applicator of the shock wave device will be turned off.
48094960|NCT04437108|DRUG|Solifenacin|The patients will be treated by antimuscarinics (solifenacin) which are considered as the conventional treatment of storage symptoms after prostatectomy.
48094961|NCT00753987|DRUG|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
48094962|NCT03623646|DRUG|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
48094963|NCT03623646|DRUG|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
48094964|NCT02803294|PROCEDURE|transcatheter aortic valve replacement|
48094965|NCT06500572|OTHER|Landmark Guided Intercostobrachial Nerve Block|In addition to the supraclavicular plexus block, the intercostobrachial nerve block block will be performed without ultrasound guidance and based on the traditional method using superficial anatomy and nerve pathway by subcutaneous injection of 20 mL of bupivacaine 0.25% at the site of the pulse.
48106774|NCT02266641|DIETARY_SUPPLEMENT|multivitamin supplement|
47921455|NCT05563870|PROCEDURE|Endoscopic biliary stenting|Endoscopic biliary stenting will be performed via ERCP using multiple plastic stents, in order to ensure propper drainage of all accessed hepatic territories.
47921456|NCT03743077|BEHAVIORAL|Exercise training including inspiratory muscle training|Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
47921457|NCT05364333|PROCEDURE|Remote ischemic preconditioning|For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time
47921458|NCT01757158|RADIATION|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
47921459|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
47921460|NCT02559492|DRUG|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
47921461|NCT02559492|DRUG|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
47921462|NCT02559492|DRUG|INCB050465|INCB050465 tablets will be administered orally once daily.
47921463|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus collagen|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
48094966|NCT06500572|OTHER|Ultrasound Guided Intercostobrachial Nerve Block|The patient's head will be turned to the opposite side while the patient is in the supine position and the shoulder to be treated will be elevated 5- 10 cm. The high-frequency linear ultrasound probe (12-4 MHz) and the region to be treated will be prepared in sterile conditions and placed transversely across the external jugular vein at 3-4 cm above the clavicle. Between the anterior and middle scalene muscles, the imaging of the brachial plexus showed three to five hypoechoic circles. The entry will be in-plane technique using an 80-mm block needle from lateral to medial. After confirming the needle insertion site with 2 mL saline solution, a 20 mL bupivacaine 0.25% will be administered.
47921464|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus maltodextrin|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
47921465|NCT00236704|DRUG|topiramate|
48094967|NCT06500572|OTHER|Serratus Plane Block|The patient will be placed in the lateral decubitus position with the area to be treated on the upper side. The high-frequency linear ultrasound probe and the region to be treated will be sterilized. The ultrasound probe will be placed on the anterior line at the level of fourth and fifth ribs. Images of the muscle's latissimus dorsi and serratus anterior, the ribs, and the pleura will be obtained. Subsequently, with the in-plane technique, an 80-mm block needle will be advanced between the latissimus dorsi and the serratus muscles planes in a caudal to the cranial direction. There is no blood or air in aspiration. After confirming the location of the needle with 2 mL of saline solution, (20 mL of bupivacaine 0.25%) will be administered between the two muscles.
47921466|NCT04260139|PROCEDURE|Calculation of metric variables on the colectomy specimens.|"Calculation of metric variables on the colectomy specimens including Lengths as mm~1. Proximal colon,~2. Ileum in cases with right hemicolectomy only,~3. Proximal border,~4. Tumor,~5. Distal border,~6. Total specimen,~7. Vascular pedicle, the longitudinal distance between the nearest bowel wall and the end of ligated major vascular pedicle depending on the tumor's localization, 2. Colonic mesenteric area as mm2."
47921467|NCT03144609|PROCEDURE|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
48094968|NCT05969561|PROCEDURE|ultrasound-guided femoral nerve block|The local analgesia is injected and infiltrated around the femoral nerve under ultrasound guidance.
48094969|NCT05969561|DRUG|Intravenous or intramuscular pain medication|Intravenous or intramuscular pain medication is given for patients with hip fracture.
48094970|NCT02538640|OTHER|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
48094971|NCT02538640|OTHER|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
48094972|NCT05205447|DRUG|LY3410738|Oral LY3410738
48094973|NCT05205447|DRUG|Itraconazole|Oral Itraconazole
48094974|NCT05205447|DRUG|Carbamazepine|Oral Carbamazepine
48094975|NCT06378879|DRUG|Propofol 100 MG in 10 ML Injection|Sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes), any involuntary patient movement, quality of sedation (VAS) and adverse events
47921468|NCT03144609|PROCEDURE|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
47921469|NCT03144609|PROCEDURE|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
47921470|NCT06017999|DRUG|XG005 tablet|Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
47921471|NCT06017999|DRUG|Placebo tablet|Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
47921472|NCT04696887|BEHAVIORAL|Tele Tai Chi Intervention for Persons Aging with Long-Term Mobility Disabilities|• 8-week Tele Tai Chi intervention, participants will use a tablet or computer to join a small-group, online class (1hr, twice weekly) from home; during each session, participants will exercise as a group along with the pre-recorded video lessons and have the opportunity for social interaction (via video chat) before and after class.
47921473|NCT05807568|OTHER|NCAEM EM-SART Pre-Screen|Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
47921474|NCT03086187|DEVICE|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
47921475|NCT02908542|GENETIC|genetic analysis with massively parallel sequencing|
48094976|NCT06585540|DRUG|Amisulpride IV Prevention|Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia
47921476|NCT04987359|BEHAVIORAL|Multimodal Lifestyle Program|The multimodal lifestyle program will utilize intensive behavioral therapy with structured exercise training and nutritional counseling.
47921477|NCT01350193|DEVICE|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
47921478|NCT01350193|OTHER|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
47921479|NCT00361413|DRUG|Alefacept (AMEVIVE®)|Alefacept
47921480|NCT00361413|DRUG|control group|these patients will receive the same treatment as group A, without alefacept
47921481|NCT02907190|OTHER|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
47921482|NCT02907190|OTHER|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
47921483|NCT02414529|DRUG|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
47921484|NCT02414529|DRUG|Placebo|
47921485|NCT01836978|OTHER|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
48094977|NCT06585540|DRUG|Amisulpride IV Treatment|Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.
48094978|NCT06585540|DRUG|Placebo Preventative|Patients in this arm will receive placebo (Normal Saline) while under general anesthesia
48094979|NCT06585540|DRUG|Placebo Treatment|Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
47921486|NCT04554056|DRUG|MW05|Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection
47921487|NCT04554056|DRUG|PEG-rhG-CSF|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
47921488|NCT00508781|BEHAVIORAL|Multiphoton laser image in cutaneous pathology|
47921489|NCT05194371|RADIATION|definitive radiotherapy or definitive chemoradiotherapy|A total dose of radiation therapy should be more than 50Gy
47921490|NCT02997241|BIOLOGICAL|OncoCare|Personalized monitoring
47921491|NCT02997241|DRUG|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
47921492|NCT04084119|OTHER|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
47921493|NCT04084119|OTHER|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
47921494|NCT03152006|OTHER|ACT|Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
47921495|NCT00447070|DRUG|ATAZANAVIR|
47921496|NCT01883453|DEVICE|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
47921497|NCT01883453|DEVICE|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
47921498|NCT04497883|DRUG|Maribavir (400 mg)|Non-Hispanic, Caucasian group and Japanese descent group participants will receive 400 mg maribavir tablets orally once on Day 1 during treatment period 1.
47921499|NCT04497883|DRUG|Maribavir (200 mg)|Japanese descent group participants will receive 200 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
48094980|NCT06613828|BEHAVIORAL|Mnemonic-Based Educational Training for Stroke Symptom Recognition|"This is a Culturally Adapted Mnemonic-Based Educational Strategies for Rapid Stroke Symptom Recognition in the Spanish-Speaking Population.~It uses five distinct mnemonic strategies (RAPIDO, CORRE, DALE, CAMALEON, ICTUS 911), each specifically tailored for a Spanish-speaking audience.~Aims to improve the recognition of early cerebrovascular disease symptoms, differentiating it from other clinical studies that might focus on different health conditions or target populations.~Emphasizes its focus on rapid action by educating participants about stroke symptoms and the importance of contacting emergency services (911)."
48094981|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
48094982|NCT01631903|DRUG|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
48094983|NCT01631903|DRUG|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
48094984|NCT01631903|DRUG|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
48094985|NCT01631903|DRUG|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
48094986|NCT05798728|PROCEDURE|Outpatient transcervical foley balloon|These participants will receive a 16-French Foley catheter which will be placed by a physician present in the clinic. The balloon will be inflated with 40 mL of sterile water, and the catheter will then be gently withdrawn so that the balloon applies pressure against the internal os. The catheter will then be taped to the inner thigh.
47921500|NCT04497883|DRUG|Maribavir (800 mg)|Japanese descent group participants will receive 800 mg maribavir tablets orally once on Day 1 during treatment period 2 or 3.
47921501|NCT04585061|DRUG|Lidocaine Hydrochloride|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle
47921502|NCT04585061|DEVICE|Virtual reality device (Harga Miniso Vr Glass 3d terbaru)|"Virtual reality device (Harga Miniso Vr Glass 3d terbaru) is placed on the face of the patient, playing a video of Tom and Jerry cartoon.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized"
47921503|NCT04585061|DIETARY_SUPPLEMENT|Xylitol|Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized while xylitol tablet putted under tongue
47921504|NCT01929941|DRUG|INCB047986|Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
47921505|NCT01929941|DRUG|INCB047986|INCB047986 tablets administered orally at the protocol specified dose and frequency
47921506|NCT01929941|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
47921507|NCT01929941|DRUG|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
47921508|NCT03117439|OTHER|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
47921509|NCT02942940|DEVICE|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
47921510|NCT02942940|OTHER|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
47921511|NCT01741402|DEVICE|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
48094987|NCT05798728|PROCEDURE|Inpatient Vaginal Misoprostol|These participants will receive 25 micrograms of Misoprostol (100- microgram tablet cut into fourths by the hospital pharmacist) inserted vaginally into the posterior fornix every 4 hours and repeated up to a maximum of six doses per our standard hospital protocol.
47921512|NCT01741402|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
47921513|NCT05731011|OTHER|antioxidative stress|blood interventions
47921514|NCT05731011|DEVICE|electrotherapy|hotpack,Tens, ultrasound
47921515|NCT03140059|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
47921516|NCT03140059|PROCEDURE|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
47921517|NCT04369261|DRUG|Synovian®|Synovian® Inj.
47921518|NCT03453788|DEVICE|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
47921519|NCT04614402|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
47921520|NCT04614402|DEVICE|Edwards PASCAL Precision Transcatheter Valve Repair System|The Edwards PASCAL Precision Valve Repair System is indicated for the percutaneous reconstruction of an insufficient tricuspid valve.
47921521|NCT04446390|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
47921522|NCT04446390|OTHER|colgate cavity protection|fluoride toothpaste as a part of a caries preventive regimen
47921523|NCT00275132|DRUG|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
47921524|NCT00275132|DRUG|Matched placebo|Matched placebo PO daily
47921525|NCT05266729|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
48094988|NCT06471218|DRUG|SHR-1918; SHR-1918 Placebo|SHR-1918/SHR-1918 Placebo,two administration
48094989|NCT01719289|BEHAVIORAL|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
47921526|NCT05266729|DRUG|Placebo|Phosphate buffered saline placebo for injection
48094990|NCT00508443|RADIATION|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
48094991|NCT03351829|GENETIC|Gene-modified autologous stem cells|1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances
48094992|NCT05032235|DRUG|Fluzoparib|Normal Renal Function:A single oral dose of Fluzoparib will be administered.
48094993|NCT05032235|DRUG|Fluzoparib|Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.
48094994|NCT05032235|DRUG|Fluzoparib|Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.
48094995|NCT04401722|PROCEDURE|PANCREATICODUDENECTOMY|dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
48094996|NCT05708820|BEHAVIORAL|Online education programme|Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
48094997|NCT05708820|BEHAVIORAL|Standard education programme|Face-to-face educacion programme in a group session
48094998|NCT00006265|DRUG|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
48094999|NCT00006265|BIOLOGICAL|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)
48095000|NCT02794116|PROCEDURE|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
48095001|NCT02794116|PROCEDURE|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
48095002|NCT02214459|BEHAVIORAL|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
47921527|NCT04734678|DRUG|Tocilizumab|400 mg IV only once
47921528|NCT04734678|DRUG|Infliximab|5 mg/kg/day IV for 2 doses 12-24 hours
48095003|NCT02579512|OTHER|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
48095004|NCT06180356|DRUG|Niraparib oral tablets|Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
47921529|NCT04370340|DEVICE|BabySlide|Application of BabySlide during vacuum-assisted births for perineal protection
47921530|NCT05086211|OTHER|proprioceptive neuromuscular facilitation|"Each session including three proprioceptive neuromuscular facilitation techniques:~Balance training exercises,participants will be treated for 20 minutes with PNF techniques that included;Rhythmic initiation, slow reversal techniques practiced with D1 and D2 pattern in lower limb,repeated contraction and Resisted PNF.The Technique will be performed for 3 days per week in same order on all subjects."
48095005|NCT04910347|DRUG|Nivolumab|"Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs."
48095006|NCT02196012|BEHAVIORAL|Intervention group|
48095007|NCT02196012|BEHAVIORAL|attention control condition|
47921531|NCT05086211|OTHER|pertubation based balance training|Each session will include a 5-10min warm-up,voluntary tasks intended to induce internal perturbations,voluntary tasks combined with external perturbations and a 5-10mins cool down.The technique will be performed for 2 sets of 10 repetitions on all subjects
47921532|NCT03478293|DEVICE|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
47921533|NCT01644747|DEVICE|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
47921534|NCT04772833|OTHER|Autopsy|The subjects deceased will undergo an autopsy to analyze the histopathological, ultrastructural and microbiological findings, related to the COVID-19 disease.
47921535|NCT01131819|DEVICE|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
48095008|NCT03142789|DRUG|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
48095009|NCT03142789|DRUG|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
48095010|NCT03142789|DRUG|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
48095011|NCT03142789|DRUG|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
48095012|NCT03318120|BEHAVIORAL|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
48095013|NCT06058637|DEVICE|Eye screening|Nurse-assisted eye-screening will take place with the Easee app, which is implemented on the tablet or laptop of the community nurse. The nurse's smartphone will function as a remote control by which he/she submits input to a computer screen that displays the test. If the participant can do the test by him or herself, the nurse will merely supervise to ensure correct application. Standard audio instructions guide the nurse and participant through the test. The test will start with triage questions, which are used to set up a correct referral. During the test, both eyes are tested consecutively, covering one eye at a time. The participant will wear his/her spectacles, if present. The participant is presented a sequence of optotypes (i.e. tumbling-E and triangle-circle optotypes) that the participant must correctly identify, in addition to various grate sizes, both near and at a distance. The Amsler grid test is performed to detect any macular problems.
48095014|NCT01026662|PROCEDURE|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
48095015|NCT01026662|DEVICE|eMatrixCO2|
48095016|NCT03756194|DEVICE|Socially-assistive Pepper robot with a CARESSES cultural competence solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way."
48095017|NCT03756194|DEVICE|Socially-assistive control Pepper robot with an alternative CARESSES solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way."
48095018|NCT03207425|DRUG|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
48095019|NCT01123161|DEVICE|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
48095020|NCT01123161|DRUG|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
48095021|NCT02476643|OTHER|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
48095022|NCT05975320|DRUG|Warfarin|Patients receiving oral anticoagulants will be followed up for 6 months to detect occurrence of any major bleeding events include (spontaneous epistaxis , spontaneous bleeding per gums , hematemesis , bleeding per rectum , intracranial hemorrhage and internal hemorrhage ). Then, incidence of bleeding events using both (HAS-BLED) \& (ORBIT) SCORES will be calculated and compared for all cases .
48095023|NCT05030376|DIETARY_SUPPLEMENT|intraileal infusion|intraileal glucose or intraileal saline infusion
48095024|NCT00315627|DRUG|Islet transplantation|Islet transplantation
48095025|NCT02400190|OTHER|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
48095026|NCT05388916|OTHER|Cosentyx|Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.
48095027|NCT06613932|PROCEDURE|pulpotomy|removal of the coronal pulp tissue and preservation of the radicular portion to ensure continuation of growth and vitality of tooth structure
48270176|NCT01276184|BEHAVIORAL|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s).
47921536|NCT06329284|DIAGNOSTIC_TEST|ELISA|ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
47921537|NCT05224167|DRUG|Melatonin 5 MG Sublingual Tablet|Melatonin 5 mg 12 hours and 2 hours prior to surgery
47921538|NCT05224167|DRUG|Hydroxyzine|Hydroxyzine 1mg/kg 12 hours and 2 hours prior to surgery
47921539|NCT02807415|DRUG|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
47921540|NCT04471285|PROCEDURE|acupuncture|acupuncture
47921541|NCT04471285|PROCEDURE|Sham acupuncture|Sham acupuncture
47921542|NCT03713905|DRUG|GLS-010|Recombinant Human Anti-PD-1 Monoclonal Antibody
48095028|NCT01879878|DIETARY_SUPPLEMENT|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
48095029|NCT01879878|DIETARY_SUPPLEMENT|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
48095030|NCT05978661|DRUG|FKC288|Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
48095031|NCT02518243|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
48095032|NCT01313598|DRUG|GLPG0187|continuous IV infusion
48095033|NCT06044649|BEHAVIORAL|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain.
48095034|NCT06044649|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
48095035|NCT06044649|BEHAVIORAL|Emotional Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
48095036|NCT06044649|OTHER|Treatment as Usual|Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
48095037|NCT00747279|OTHER|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
48095038|NCT00747279|DRUG|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
48095039|NCT06217029|OTHER|physiotherapy and maxillary traction|"1. Mobility exercises~2. Ultrasound or electric stimulation~3. Application of equipment, such as braces, slings and taping~4. Registered massage therapy~5. Trigger point and myofascial release"
48095040|NCT02601703|DRUG|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
48095041|NCT02601703|DRUG|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
48095042|NCT02601703|DRUG|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
48095043|NCT05136742|OTHER|aerobic exercise and diet program|It is an interventional study in which 60 women estimated to enrol according to random allocation and assigned into two groups equal. The study group will receive aerobic exercises in addition to diet recommendations while the control group will receive diet recommendations. the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercise on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks .insulin resistance will be measured by HOMA -IR index and sex hormones (estridol ,testosterone. sex hormone binding globin ) pre and post intervention and use zung self-rating depression scale to assess depression
48095044|NCT05136742|OTHER|diet program|balanced restricted diet
48095045|NCT06552689|DEVICE|Sutra Hemi-valve Transcatheter Mitral Valve Replacement (TMVR) System|Trans-septal Sutra Hemi-valve TMVR System to treat mitral regurgitation
48095046|NCT03176745|DIAGNOSTIC_TEST|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
48095047|NCT06615323|BEHAVIORAL|Polyphonic Lullaby Group|After discharge, mothers will be asked to play the Dandini Dandini Dastana lullaby by vocal artist Mircan Kaya, which they downloaded from the YouTube application, and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by switching the phone to airplane mode just before sleep. In the event of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the polyphonic lullaby volume will be gradually reduced. The polyphonic lullaby will be played at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effects of confounding factors, mothers in the polyphonic lullaby group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the study.
48095048|NCT06615323|OTHER|Pish Pish Sound Group|After discharge, mothers will be asked to turn on the Piş Piş sound downloaded from the YouTube application and listen to it from a distance of one meter (away from the baby's head to minimize radioactive effects) and by turning the phone to airplane mode just before sleep. In case of active sleep (signs of sleep transition such as slowing down muscle movements and closing eyes), the piş piş sound will be gradually reduced. The polyphonic lullaby played will be at a volume level of 55 decibels for the first 5 minutes after falling asleep, then reduced to 25 decibels and then turned off. In order to reduce the effect of confounding factors, mothers in the piş piş sound group who use another assistive method (breastfeeding/rocking to sleep) to put their babies to sleep will be excluded from the scope of the research.
48270177|NCT00652184|DRUG|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
48270178|NCT00652184|DRUG|placebo|placebo cream and placebo valaciclovir
48270179|NCT00652184|DRUG|valaciclovir|active valaciclovir
47921543|NCT04891640|OTHER|Standard TNFi Therapy|Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.
48095049|NCT05061862|DEVICE|cardiac implantable electronic devices (CIEDs)|Subjects will be implanted with various cardiac implantable electronic devices and followed according to their standard of care. Medical imaging will be collected at various stages of the implant procedure and/or non-invasive diagnostic collection at follow-up visits, as applicable.
48095050|NCT02335268|DRUG|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
48095051|NCT03270020|DRUG|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
48095052|NCT04424485|PROCEDURE|Total thyroidectomy (TT)|Standard TT procedure for thyroid carcinoma, for both groups
48095053|NCT04424485|PROCEDURE|Central lymph node dissection (CLND)|Standard CLND for thyroid carcinoma, for both groups
48095054|NCT04424485|DIAGNOSTIC_TEST|Sentinel lymph node (SLN) bopsy|Intrathyroidal injection of ICG for SL biopsy, for only experimental group
48095055|NCT04424485|DIAGNOSTIC_TEST|Identification of parathyroid glands (PGs)|Near-infrared (NIR) fluorescence visualization of PGs, for only experimental group
48095056|NCT02638298|DEVICE|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
47921544|NCT04891640|OTHER|TNFi fixed longer dosing intervals|"Participants randomly assigned to this arm will increase the time between TNFi medication doses.~* Adalimumab- from every 2 to 3 weeks~* Certolizumab- from every 2 to 4 weeks~* Etanercept- from every 1 to 2 weeks~* Golimumab- from every 4 to 6 weeks~* Infliximab- from baseline to baseline + 2 weeks"
47921545|NCT04891640|OTHER|Stop TNFi treatment|Participants randomly assigned to this arm will stop TNFi medication.
47921546|NCT00078169|BEHAVIORAL|Behavior Therapy|
47921547|NCT04605991|DRUG|LY900014|Administered SC
47921548|NCT04605991|DRUG|Insulin Glargine|Administered SC
48095057|NCT02638298|OTHER|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
48095058|NCT00699933|OTHER|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
47921549|NCT04316403|PROCEDURE|Er:YAG laser|This application was made before the onset of canine retraction in one side of the mouth
47921550|NCT03176537|DRUG|Testosterone gel|Androgel (50mg testosterone), gel, daily
48095059|NCT06232525|PROCEDURE|transobturator tape operation (TOT)|TOT surgery: With an 18 French Foley urinary catheter, the sling passes through the skin in the groin, the obturator foramen, the back of the adductor longus tendon, and the midurethral vaginal incision; extends 1 cm below the midpoint of the urethra, the tape is held in place without sutures by its interface with the patient's tissue. After the mesh is placed, the incision in the suburethral midline is closed.
48095060|NCT06232525|PROCEDURE|urethral ligament plication|Urethral ligament plication: With an 18 French Foley urinary catheter, a vertical incision of approximately 3 cm is made in the anterior-lateral wall sulcus of the vagina on the right and left lines, 2 cm laterally from the midline, with the urethral meatus remaining in the midline, and external urethral ligaments on both sides inferolateral to the urethra, sutured in the midline by using 2-0 or 3-0 polyester sutures on both sides separately. The incised anterior vaginal tissue is closed one by one with 2-0 rapid Vicryl.
48095061|NCT00945477|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
48095062|NCT06317025|DIAGNOSTIC_TEST|Multi-modal Intelligent Anesthesia Monitoring System|To evaluate the sensitivity and specificity of self-developed anesthesia monitoring systems in diagnosing the depth of anesthesia (too deep or too shallow)
48095063|NCT02856529|OTHER|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
48095064|NCT02856529|OTHER|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
48095065|NCT01965080|DRUG|Exemestane|One tablet Exemestane 25 mg daily
48095066|NCT03897998|DRUG|Naloxone|"4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
47921551|NCT03176537|DRUG|Placebos|Placebo, gel, daily
47921552|NCT02070198|DRUG|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
47921553|NCT02070198|DRUG|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
47921554|NCT02070198|DRUG|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
47921555|NCT00338182|DRUG|AZD1152 part A|48-hour continuous intravenous infusion
47921556|NCT00338182|DRUG|AZD1152 part B|2-hour intravenous infusion
47921557|NCT05282602|OTHER|baseline physical therapy treatment along with Wii Fit based exercises|Group A performed Wii Fit based exercises for 6 weeks. Group A will be treated with Wii Fit based exercises (40 mins session, 3 days/week, Penguin slide, soccer heading, tilt table, tightrope walking)
47951179|NCT04992910|DEVICE|Functional electrical stimulation through medical device|"The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks."
47951180|NCT04992910|OTHER|Standard therapy|Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
48095067|NCT03897998|OTHER|Saline|"Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
47921558|NCT05282602|OTHER|Proprioceptive exercises|Group B will be treated with Proprioceptive training (40 min session, 3 days/week, toe walking, heel walking, cross-body leg swings right and left sides, partial squat, ). In both groups pre and post-test measurements of Balance and Fall of risk will be assessed through Berg Balance scale, STAR excursion, Modified Fall Efficacy scale, and Timed Up and Go (TUG). Evaluation will be done before session start and at the end of 6th Week.
47921559|NCT05831683|OTHER|Introduction of Standard Operating Procedure regarding lung protective ventilation during general anaesthesia.|The Standard Operating Procedure document will be introduced. The SOP document will cover the theoretical background, definition, and recommendations/criteria of LPV. The SOP document will reflect the most recent LPV guidelines.
47921560|NCT06282458|DRUG|Enobosarm|Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
47921561|NCT06282458|DRUG|Semaglutide|Semaglutide for Chronic Weight Management
47921562|NCT01425463|DRUG|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
48095068|NCT04018729|DEVICE|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
47921563|NCT01425463|DRUG|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
47921564|NCT01425463|OTHER|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
47921565|NCT01425463|OTHER|Placebo to Polyferose|Administered orally with water.
48095069|NCT04018729|BIOLOGICAL|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
47921566|NCT05174182|OTHER|A novel treatment approach|A novel treatment approach, as described before.
47921567|NCT05174182|OTHER|Usual care|Usual care, as described before.
47921568|NCT04526821|DRUG|Bovine Lactoferrin|Bovine Lactoferrin 600mg daily for 12 weeks (3 chewable tablets of 100mg , twice a day), for 12 weeks plus personal portection provided from the hospital.
47921569|NCT04526821|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 600mg daily for 12 weeks (3 chewable tablets of 100mg, twice a day), for 12 weeks plus personal portection provided from the hospital.
47921570|NCT03085849|DRUG|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
47921571|NCT03085849|DRUG|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
48095070|NCT03463811|DIAGNOSTIC_TEST|Lactate concentration in vaginal fluid|Lactate concentration in vaginal fluid
48095071|NCT04123002|OTHER|Miswak chewing sticks|Chewing stick are routinely used by this population
48095072|NCT03519451|OTHER|Internet-Based Intervention|Given KickAsh smartphone mobile application
48095073|NCT03519451|OTHER|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
48095074|NCT03519451|OTHER|Questionnaire Administration|Ancillary studies
48095075|NCT06614556|OTHER|Resistance Training|Participants in the training groups performed bilateral hand grip resistance training three times per week for four weeks using a specialized hand-grip kit provided to them. Participants were provided with pictures and instructions for each exercise upon completion of the initial testing (PRE) session. They were asked to perform 12 training sessions (approximately 30-45 mins) over the 4 weeks according to their schedule. Each participant was asked to keep a training log to assist with accountability. Those assigned to the control groups were asked to maintain their normal daily activities throughout the four weeks.
48095076|NCT03634189|DRUG|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
48095077|NCT05450302|OTHER|PURE EP (Observational Study)|This is an observational study. No interventions involved in this study.
48095078|NCT00797862|DRUG|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
48095079|NCT00797862|DRUG|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
47921572|NCT03085849|DRUG|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
47921573|NCT03581461|BEHAVIORAL|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
47921574|NCT05834387|PROCEDURE|EICU Transfer Routine Care|EICU Transfer Routine Care
47921575|NCT05834387|PROCEDURE|Implementing interventions based on a 'health care-family-environment' linkage|"Nursing interventions in the experimental group The interventions were based on the health care-family-environment linkage"
47921576|NCT03800017|BIOLOGICAL|Hyperoxia|Participants breathe 60% oxygen during exercise
47921577|NCT05288907|DRUG|Lidocaine Ointment|Composite over-the-counter lidocaine ointment administered twice daily for 2 weeks.
47921578|NCT00950820|DRUG|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
48095080|NCT00797862|DRUG|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
48095081|NCT04730180|DEVICE|Transcranial Magnetic Simulation|Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.
48095082|NCT04730180|DEVICE|Mixed reality neuronavigation|Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
48095083|NCT03678753|DRUG|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.
48095084|NCT03678753|DRUG|Placebo|Matching Placebo
48095085|NCT00651677|PROCEDURE|HAL proctectomy|Hand-assisted laparoscopic proctectomy
48095086|NCT00651677|PROCEDURE|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
47921579|NCT00950820|DRUG|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
48095087|NCT00651677|PROCEDURE|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
48095088|NCT00651677|PROCEDURE|SL Proctectomy|Straight laparoscopic proctectomy
48095089|NCT02013232|DRUG|Aripiprazole|
48095090|NCT01618331|BEHAVIORAL|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
48095091|NCT01618331|DIETARY_SUPPLEMENT|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
48095092|NCT05243056|OTHER|Best Practice|Receive enhanced usual care
48095093|NCT05243056|OTHER|Educational Intervention|Receive Y-AMBIENT
48095094|NCT05243056|OTHER|Quality-of-Life Assessment|Ancillary studies
48095095|NCT05243056|OTHER|Questionnaire Administration|Ancillary studies
48095096|NCT02179918|DRUG|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
48095097|NCT02179918|DRUG|MK-3475|2 mg/kg q3wks, IV
47921580|NCT05006300|OTHER|Topialyse Baume Barrière|Evaluation of the efficacy of the cosmetic product SVR TOPIALYSE Baume Barrière on the reduction of topical corticosteroid consumption in children from 3 months to 17 years old presenting mild to moderate atopic dermatitis after 28 and 56 days of use, at one or two apllications /day.
47921581|NCT03360864|OTHER|Education program|Patient will participate to a education program.
48095098|NCT03378479|DRUG|SOC +Posaconazole 18 MG/ML (milligram/milliliter)|.2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days (total 7 days)
48095099|NCT03378479|OTHER|standard of care (SOC)|treatment for influenza pneumonia at the investigators discretion
48095100|NCT06631417|DRUG|BI 1291583|formulation 1
48095101|NCT06631417|DRUG|BI 1291583|formulation 2
48095102|NCT06631417|DRUG|BI 1291583|formulation 3
48095103|NCT01675830|DEVICE|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
47921582|NCT03972891|OTHER|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~* no therapeutic intervention during the break~* no language-specific specific exercises~* language-specific strategies in everyday life can be applied, e.g. modeling techniques"
48095104|NCT00450502|DRUG|Batracylin|
48095105|NCT03554187|DEVICE|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
48095106|NCT03554187|BIOLOGICAL|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
48095107|NCT03554187|GENETIC|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
48095108|NCT03554187|BIOLOGICAL|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
47951181|NCT06680557|BEHAVIORAL|Aerobic and resistance exercises|"* Aerobic exercise session: A 30-minutes of brisk walking exercise on an indoor track without speed walking or running .~* Resistant exercise session: A 30-minutes of resistance exercise using rubber bands including warm-up and cool-down periods. Rubber band exercises are composed of seven exercises: squat, leg extension, pull apart, seated row, standing biceps curl, overhead press and lateral raise. Each exercise consists of three sets of 10 repetitions with 1 minute rest between each exercise set."
48095109|NCT03554187|DEVICE|Halitosis measure|With appropriate device : halimeter
48095110|NCT03679130|BEHAVIORAL|Structured supervised exercise training|EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
48095111|NCT03679130|BEHAVIORAL|Motivational counseling supported by health technology|MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
48095112|NCT02819193|OTHER|raw mother's own milk|Infants receive mother's own milk before day 7.
48095113|NCT03351309|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy (CBT)|Four session telephone CBT protocol.
47951182|NCT00110903|DRUG|Etanercept Liquid|
48095114|NCT04609540|DRUG|Trastuzumab|Dual anti-HER2 therapy
48095115|NCT05490043|DRUG|ATG-101|ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
48095116|NCT05847764|DRUG|RC48+Tislelizumab+carboplatin|RC48+PD-1/PD-L1 inhibitor+chemo in treatment-naive patients harboring HER2 alterations
48095117|NCT05847764|DRUG|RC48+Furmonertinib, 1L|RC48+Furmonertinib in treatment-naive patients harboring EGFR mutations as well as HER2 alterations
48095118|NCT05847764|DRUG|RC48+Furmonertinib, 2L+|RC48+Furmonertinib in patients who failed at least one line of standard treatment and harboring HER2 alterations
48095119|NCT05706662|PROCEDURE|inguinal hernia repair with mesh|inguinal hernia repair with mesh
48095120|NCT01498874|DRUG|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
48095121|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
48095122|NCT01498874|DRUG|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
48270180|NCT02337387|BIOLOGICAL|Blosozumab|Administered SC
48270181|NCT02337387|OTHER|Placebo|Administered SC
48095123|NCT05897788|BEHAVIORAL|Text Message Check-ins|Patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything AND patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week.
48095124|NCT05897788|BEHAVIORAL|Contingency Management|Patients will receive incentives for engagement with treatment. Participant will receive compensation for filling their buprenorphine scripts at discharge and attending their follow-up care appointments.
48095125|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 1|Medium dose, approximately 10\^4.5 TCID50/mL
48095126|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 2|High dose, approximately 10\^5.5 TCID50/mL
48095127|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 3|TBD, depending on outcome of Part A
48095128|NCT03566680|DEVICE|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
48095129|NCT01518257|BIOLOGICAL|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
48095130|NCT01518257|DRUG|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
48095131|NCT04389255|OTHER|Star Excursion Balance Test|The Star Excursion Balance Test (SEBT) is a dynamic test that requires strength, flexibility, and proprioception. It is a measure of dynamic balance that provides a significant challenge to athletes and physically active individuals. The test can be used to assess physical performance, but can also be used to screen deficits in dynamic postural control due to musculoskeletal injuries (e.g. chronic ankle instability), to identify athletes at greater risk for lower extremity injury, as well as during the rehabilitation of orthopeadic injuries in healthy active adults.\[
48095132|NCT04389255|DEVICE|Balance Master device|The Balance Master (Neurocom International, Inc Clackamas,) device is a computerized posturography device. The device consists of a fixed support surface consisting of a force table and individuals, a variety of ground elements and a computer screen that will provide visual feedback and conduct test protocols. Posturography tests a person's ability to integrate visual, vestibular and somatosensory inputs and suppress inappropriate sensory information. Thus, it can quantitatively score the person's balance and examine balance problems in detail with the tests it contains. There are various protocols that evaluate balance differently in Balance Master (BMc). Limits of Stability Test (LOS) and Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) were used in the BMc.
48095133|NCT00916006|DRUG|PEP005 Gel|0.015%, three day treatment
48095134|NCT00916006|DRUG|Vehicle gel|Vehicle gel, three day treatment
48095135|NCT02427737|BEHAVIORAL|Comfort Talk® Training|Personnel of MRI units is trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This entails 16 hrs classroom work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
48095136|NCT05793099|OTHER|Effect of aqueous propolis gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
48095137|NCT05793099|OTHER|Effect of placebo gums in salivary and dental plaque pH in children|"The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured."
48095138|NCT01094171|BIOLOGICAL|Poliorix TM|Intramuscular administration, 3 doses
48095139|NCT01094171|BIOLOGICAL|Infanrix TM|Intramuscular administration, 3 doses
48095140|NCT05635266|DIAGNOSTIC_TEST|Specimen sample|The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys.
48095141|NCT06162819|DRUG|Amitriptyline|Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
48095142|NCT06162819|DRUG|Flunarizine 5mg|Flunarizine will be used for prophylaxis of migraine,
48095143|NCT02408562|OTHER|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
48095144|NCT02408562|OTHER|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
48095145|NCT06433505|DRUG|BMS-986365|Specified dose on specified days
48095146|NCT06433505|DRUG|[14C] BMS-986365|Specified dose on specified days.
48095147|NCT06433505|DRUG|[14C] BMS-986409 + BMS-986410|Specified dose on specified days
48095148|NCT06433505|DRUG|[14C] BMS-986410 + BMS-986409|Specified dose on specified days
48095149|NCT04763317|GENETIC|Prostate cancer risk gene panel|A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
48095150|NCT00237341|DRUG|fentanyl|
48270182|NCT05941104|OTHER|frailty|Frailty is a group of common clinical syndromes in the elderly, characterized by systematic, dynamic and reversible, the core of which is the decline of physiological reserves and the destruction of self-balance.
48095151|NCT05376488|OTHER|One meal|One meal given to assess impact on ammonia levels serially
48095152|NCT02058914|DIETARY_SUPPLEMENT|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
48095153|NCT02058914|DIETARY_SUPPLEMENT|High Glucose sweetened beverage|HG-sweetened beverage
48095154|NCT04500743|DRUG|Dienogest|Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
48095155|NCT04500743|DRUG|leuprorelin acetate|Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
48095156|NCT03547999|DRUG|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
48095157|NCT03547999|BIOLOGICAL|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
47921583|NCT02738788|OTHER|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
47921584|NCT00065429|DRUG|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
48095158|NCT03547999|BIOLOGICAL|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
48095159|NCT03547999|DRUG|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
48095160|NCT01273558|DRUG|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
48095161|NCT03364816|PROCEDURE|TDR|total artificial disc replacement
48095162|NCT00690469|OTHER|Laboratory Biomarker Analysis|Correlative studies
48095163|NCT00690469|OTHER|Questionnaire Administration|Ancillary studies
48095164|NCT04830514|OTHER|Recommended Dietary Allowance of Protein|0.8 g/kg/day protein intake
48095165|NCT04830514|OTHER|Habitual protein intake|1.0 g/kg/day protein intake
48095166|NCT04830514|OTHER|Optimal Protein Intake|1.5 g/kg/day protein intake
48095167|NCT06116266|OTHER|Education and support for primary care providers (PCPS)|All PCPs in the EUC and Co-Care arms receive brief education on SUD treatment, including medications for OUD and AUD and contingency management for StUD, and recognizing and counteracting stigma while caring for patients with SUD.
48095168|NCT06116266|OTHER|Nurse Care Manager (NCM) visits|A full-time clinic-embedded nurse care manager who works with patients and their PCPs to facilitate and support patient engagement in evidence-based treatment for polysubstance use and management of associated health conditions
48095169|NCT06116266|OTHER|Addiction specialist consultant|An addiction specialist consultant who supports the nurse care manager and PCP in formulating and adjusting treatment plans
48095170|NCT06116266|OTHER|Health coaching sessions|Health coaches who use motivational interviewing and cognitive behavioral therapy to motivate and support patients in behavior change to reduce polysubstance use-related harms. Patients may receive up to 12 health coaching sessions in total. The sessions will occur via phone and/or HIPAA compliant video chat software.
48095171|NCT06116266|OTHER|Patient educational materials|Patient participants receive an educational pamphlet addressing overdose prevention, information about accessing naloxone, and local SUD treatment options.
48095172|NCT06631573|OTHER|fixed all-on-four prosthesis reinforced with PEEK framework.|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with PEEK framework.
48095173|NCT06631573|OTHER|Fixed all-on-four prosthesis reinforced with Co-Cr framework|Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with Co-Cr framework
48095174|NCT02391909|BIOLOGICAL|Vivotif|
48095175|NCT05424198|PROCEDURE|Cervical Medial Branch Radiofrequency Ablation|The skin and superficial tissues will be anesthetized at each site with 1-2 mL of lidocaine. Prior to the ablation up to 2 mL of lidocaine may be used at each site to ensure adequate pain control during the ablation. Once in position, a radiofrequency ablation lesion will be made using a 30 second ramp-up time to a maximum temperature of 80 °C, followed by an additional 90 seconds at maximum temperature.
48095176|NCT00157053|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
48095177|NCT06033300|BIOLOGICAL|blood sample|blood sample
48095178|NCT05784155|DRUG|Test Drug(JW0302) or Reference Drug(C2206)|"Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration"
48270183|NCT03229720|DEVICE|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
47921585|NCT03165604|OTHER|standard information|The participates will be given a standard information regarding the water drink before physical activity
47921586|NCT03165604|OTHER|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
47921587|NCT00566202|DRUG|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
48095179|NCT02858934|RADIATION|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
48095180|NCT05611580|BEHAVIORAL|Chronic Disease Risk Reduction|The intervention involves education information about chronic diseases and way to reduce risk for developing chronic diseases and/or decrease worsening of existing conditions.
48095181|NCT01872611|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|
48095182|NCT01872611|OTHER|Vehicle|Inactive ingredients used as placebo comparator
48095183|NCT01872611|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
48095184|NCT06297980|OTHER|Personalized modifications to treatment to address menstrual cycle effects on glycemia|The study physician will examine glucose patterns measured using continuous glucose monitoring over a 3 month observational period to identify hypo- or hyperglycemia related to menstrual cycle phase or exercise, and will provide changes to insulin basal or bolus rates, carbohydrate ratios, post-exercise food intake or use of sleep mode on automated insulin delivery systems.
48095185|NCT05483907|DRUG|BBT-877|BBT-877 24 weeks + Follow-up 4 weeks
48095186|NCT05483907|DRUG|Placebo|Placebo 24 weeks + Follow-up 4 weeks
48095187|NCT00444574|DRUG|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
48095188|NCT00444574|DRUG|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
48095189|NCT00444574|DRUG|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
48095190|NCT04209881|OTHER|ovarian reserve for Ankylosing spondylitis and control groups|"Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded."
48095191|NCT00276328|DRUG|Diosmectite (Smecta®)|
48095192|NCT05284422|PROCEDURE|Traditional Peripheral venous catheter insertion|Insertion of a short catheter in a peripheral vein with the help of visualization palpation
48095193|NCT05284422|PROCEDURE|Ultrasound-guided insertion of a peripheral venous catheter|Insertion of a short catheter in a peripheral vein with the help of an ultrasound device
48095194|NCT06426082|BEHAVIORAL|Thermoneutral condition|Participants will be exposed 2 hours/day at 32ºC for 5 days/week
48095195|NCT06426082|BEHAVIORAL|Cold condition|Participants will be exposed 2 hours/day at 18ºC for 5 days/week
48095196|NCT06426082|BEHAVIORAL|Aerobic exercise condition|Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
48095197|NCT06426082|DRUG|Salbutamol|Participants will take salbutamol 12 mg/day. 7 days week
48095198|NCT05372003|DRUG|Dupilumab|dupilumab injections will be prescribed and managed by dermatology as standard of care
48095199|NCT05372003|OTHER|Photo therapy|light therapy will be prescribed and managed by dermatology as standard of care
48095200|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
48095201|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
48095202|NCT01238497|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
48095203|NCT06040645|OTHER|APP Co-management|"To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated."
48095204|NCT06040645|OTHER|E-consult|"In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics)."
48095205|NCT00077883|DRUG|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
48095206|NCT02905513|BEHAVIORAL|Contraceptive app instant messages|
48095207|NCT02905513|OTHER|Mobile phone app|
48095208|NCT00273455|DRUG|bimatoprost 0.03%|
48095209|NCT00273455|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
48095210|NCT00273455|DRUG|placebo|
48095211|NCT04470817|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil
48095212|NCT02635659|OTHER|Encapsulated nutrients|
48095213|NCT02635659|OTHER|Placebo|
48095214|NCT05370989|OTHER|Technology-Based Parent School Program|The program will be continued for 10 weeks in the intervention group and will be included five web-based modules, five online group interactions after each module, and consultation throughout the program and the follow-up period.
48095215|NCT05370989|OTHER|ongoing treatment|Health service of the control group will ongoing.
48095216|NCT06392360|DIETARY_SUPPLEMENT|Betaine|White betaine powder
48095217|NCT06392360|DIETARY_SUPPLEMENT|Placebo|White placebo powder
48095218|NCT03310528|BEHAVIORAL|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
48095219|NCT03310528|PROCEDURE|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
48095220|NCT01616719|DEVICE|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
48095221|NCT01928940|DRUG|dabrafenib|150 mg twice daily
48095222|NCT01928940|DRUG|trametinib|2 mg once daily
47921588|NCT00566202|DRUG|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
47921589|NCT00566202|DRUG|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
47921590|NCT02801019|OTHER|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
47921591|NCT02801019|OTHER|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
47921592|NCT00892840|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
47921593|NCT00892840|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
47921594|NCT03069729|OTHER|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
47921595|NCT00130975|DRUG|Candesartan|
47921596|NCT05605938|DRUG|Tenoten for children|Oral administration
47921597|NCT05605938|DRUG|Placebo|Oral administration
47921598|NCT01175083|BIOLOGICAL|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
47921599|NCT01175083|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
47921600|NCT01175083|BIOLOGICAL|Polio Sabin|4 oral doses
47921601|NCT05411575|DRUG|Plerixafor 20 MG/ML [Mozobil]|Plerixafor (Mozobil®) continuous intravenous infusion for 7 days
47921602|NCT05411575|OTHER|Placebo|Placebo continuous intravenous infusion for 7 days
48095223|NCT01141660|DEVICE|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
48095224|NCT01141660|DEVICE|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
48095225|NCT06613698|DRUG|GSK4532990|GSK4532990 will be administered
48095226|NCT06613698|DRUG|Placebo|Placebo will be administered
47921603|NCT00086268|DRUG|zoledronic acid|
47921604|NCT00086268|DRUG|Taxotere|
47921605|NCT00086268|DRUG|Carboplatin|
47921606|NCT01077921|DRUG|Propranolol|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
47921607|NCT01077921|DRUG|Placebo|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
47921608|NCT01127789|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
47951183|NCT01899664|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
47951184|NCT05496998|DEVICE|Medtronic Intrepid™ TMVR TF System|Patients with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC will have a Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR Transfemoral System
48095227|NCT06081361|DRUG|Bedaquiline|Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week
48095228|NCT06081361|DRUG|Delamanid|Oral, 100mg bid
48095229|NCT06081361|DRUG|Contezolid|Oral, 800mg bid
48095230|NCT06081361|DRUG|Levofloxacin|Oral, 400mg qd for weight \<50kg, 600-750mg qd for weight ≥50kg
48095231|NCT06081361|DRUG|Moxifloxacin|Oral, 400mg qd
48095232|NCT06081361|DRUG|Clofazimine|Oral, 100mg qd
48095233|NCT06081361|DRUG|Linezolid|Oral, 600mg qd
48095234|NCT06081361|DRUG|Cycloserine|Oral, 250mg bid
48095235|NCT06081361|DRUG|Prothionamide|Oral, 600mg qd for weight \<50kg, 600-800mg qd for weight ≥50kg
48095236|NCT06081361|DRUG|Pyrazinamide|Oral, 1500mg qd for weight \<50kg, 1750mg qd for weight ≥50kg
48095237|NCT06081361|DRUG|Para-Aminosalicylic Acid|8000mg qd for weight \<50kg, 10000mg qd for weight ≥50kg
48095238|NCT06081361|DRUG|Ethambutol|750mg qd for weight \<50kg, 1000mg qd for weight ≥50kg
48095239|NCT05893966|RADIATION|Whole breast irradiation +/- tumor bed boost|Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)
48095240|NCT03530553|OTHER|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
48095241|NCT05992909|PROCEDURE|Lymphovenous bypass procedure|Participants will return to the clinic 14 days, 6 months, 12 months, 18 months, and 24 months after your surgery for measurements of your legs to see if there are changes over time
48095242|NCT02655692|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
48095243|NCT02655692|DRUG|Placebo/Saline|This is a saline placebo/non-active solution.
48095244|NCT04215744|BEHAVIORAL|Ice water immersion|Ice water immersion of the left hands
48095245|NCT01189955|PROCEDURE|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
48095246|NCT01189955|PROCEDURE|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
48095247|NCT02286661|PROCEDURE|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
48095248|NCT02286661|PROCEDURE|Casting (short arm)|
48095249|NCT03281564|OTHER|Quality of life after Essure® removal|Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
48095250|NCT04393103|DRUG|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~* Group A (Control Group) : Follow Up of 30 patients.~* Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
48095251|NCT04393103|DRUG|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
48095252|NCT06180798|PROCEDURE|cold snare endoscopic mucosal resection (C-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used .~submucosal injection of saline mixed with methylene blue will be used (no epinephrine) followed by resection using snare without using electrocautery in C-EMR group.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.~Bleeding will be assessed for 2 mins to decide upon requirement of immediate hemostatic methods in the form of clipping or electrocoagulation."
48095253|NCT06180798|PROCEDURE|Hot snare endoscopic mucosal resection (H-EMR)|"All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.~The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.submucosal injection of saline mixed with methylene blue will be used.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.~After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps."
47951185|NCT05928260|DEVICE|Medtronic Guardian Connect Sensor 3|This is a real-time CGMS which transmits all the blood glucose readings into the application downloaded in a device continuously and also gives alarms and alerts to the person.
48095254|NCT05218603|DRUG|Bortezomib|Maintenance: Administration as per routine clinical practice.
48095255|NCT05218603|DRUG|Daratumumab|Maintenance: Administration as per routine clinical practice.
48095256|NCT00910702|DEVICE|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
48095257|NCT03898687|DEVICE|SLN Biopsy with Magtrace®/Sentimag®|Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
48095258|NCT04901728|BEHAVIORAL|Cultural Domain Analysis|80 and up to a maximum of 120 participants
48095259|NCT04901728|BEHAVIORAL|Focus Group Discussion|At least 18 and up to a maximum of 60 participants
48095260|NCT04901728|BEHAVIORAL|In-depth interview|At least 18 and up to a maximum of 36 participants
48095261|NCT00119587|DRUG|darbepoetin alfa|
48095262|NCT06529120|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia with Cognitive-Behavioral Symptom Coping Skills|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
48095263|NCT02846415|BEHAVIORAL|Play Intervention for Dementia|"1. 8 weekly session, 45-75 minutes each~2. Play with toys~3. Sessions will be facilitated by a play specialist, trained play assistants, and centre staff."
48095264|NCT03591289|DRUG|NMB with rocuronium bromide|Moderate versus deep neuromuscular block Not a device study
48095265|NCT02392156|BIOLOGICAL|rFVIIIFc|As described in the treatment arm
48095266|NCT02392156|BIOLOGICAL|rFIXFc|As described in the treatment arm
48095267|NCT02392156|DRUG|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
48095268|NCT02392156|DRUG|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
48095269|NCT03208556|BIOLOGICAL|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10\^5 /kg，1×10\^6 /kg，3×10\^6 /kg，and 6×10\^6 CAR T cells/kg"
48095270|NCT03208556|DRUG|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
48095271|NCT00542022|DRUG|MK0812 / Duration of Treatment: 12 Weeks|
48095272|NCT00542022|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
48095273|NCT05628662|DEVICE|Automated Insulin Delivery System (SAFE-AP)|Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.
47921609|NCT05666050|BEHAVIORAL|Mobile health intervention|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.
47921610|NCT00288899|OTHER|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
47921611|NCT00288899|OTHER|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
48095274|NCT00450892|DRUG|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
48095275|NCT00450892|DRUG|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
48095276|NCT00450892|DRUG|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
48095277|NCT06323408|DIAGNOSTIC_TEST|Tissue, blood, cerebrospinal-spinal fluid|Processing, analysis
48095278|NCT04497584|DRUG|Afatinib + Prednisone|Afatinib (40mg) will be taken by mouth daily starting on Cycle 1, Day -7. Prednisone (40mg) will be taken by mouth daily starting on Cycle 1, Day 1.
48095279|NCT01729871|DRUG|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
48095280|NCT01729871|DRUG|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
48095281|NCT04699448|OTHER|Nutritional intervention.|Diets designed for body weight loss, based on different macronutrient content.
48095282|NCT01021644|BEHAVIORAL|aerobic exercise-training|3 times per week for 6 months
48095283|NCT01021644|BEHAVIORAL|stretch exercise|3 times per week for 6 months
48095284|NCT06570551|DEVICE|i3 CGM(continuous glucose monitor)|The i3 CGM consists of a Sensor Pack (including probe, iCGM-S3), a Transmitter Pack (iCGM-t3), and an application (iCGM-APP (released version: V02)).application (i3 CGM App). The user can view their glucose data on the i3 CGM App running on a compatible mobile device.
48095285|NCT05557422|DIAGNOSTIC_TEST|BD OneFlow LST, and B-CLPD T1 to T4 Assays|a panel of fluorochrome-conjugated antibodies for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric™ flow cytometer with BD FACSuite™ Clinical application.
48095286|NCT00561574|DRUG|Esmirtazapine|One tablet daily
48095287|NCT05005169|DIAGNOSTIC_TEST|SGB PCR|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
48095288|NCT05005169|DIAGNOSTIC_TEST|SGB culture|"This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent."
48095289|NCT04107337|OTHER|Vocal work session with straw exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath in the straw ; (1 minute) Phonation in the straw ; (2 minutes) Make a siren in the straw ; (4 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
47921612|NCT03010371|BEHAVIORAL|Positive Psychotherapy|Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).
47951186|NCT05928260|DEVICE|Abott Freestyle Libre Sensor|This system is an is-CGMS in which the participant gets his blood glucose only when the device is scanned.
47951187|NCT05928260|OTHER|Self blood Glucose monitoring by a glucometer|In this all patients will check their blood glucose using a needle prick and glucometer at pre-specified intervals.
48095290|NCT04107337|OTHER|Vocal work session with open mouth exercises|"* Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~* Vocal exercises during 10 minutes : (1 minute) Checking the posture ; (1 minute) Control of the management of breath on a \[f\] with open mouth ; (1 minute) Phonation on the vowel \[a\] with open mouth ; (2 minutes) Make a siren on the vowel \[a\] with open mouth ; (4 minutes) Vocalizations on the vowel \[a\] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 10-minutes voice assessment focusing on aerodynamic parameters."
48095291|NCT04000893|OTHER|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
48095292|NCT05062590|OTHER|Recommendations|Ressources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP
48095293|NCT03968237|DRUG|Buprenorphine/Naloxone|Controlled substances
48095294|NCT01061905|BEHAVIORAL|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
48095295|NCT01061905|BEHAVIORAL|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
48095296|NCT01061905|BEHAVIORAL|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
48095297|NCT06392256|PROCEDURE|Non surgical therapy|Non-surgical submarginal instrumentation using titanium curettes with saline irrigation will be done once in the treatment session.
48095298|NCT06392256|PROCEDURE|Free gingival Grafting|In the PM-NS-FGG group, soft tissue augmentation using a free gingival graft will be performed.
48095299|NCT06629025|DIAGNOSTIC_TEST|High-resolution impedance manometry|High-resolution impedance manometry (HRIM) can calculate the bolus motion parameters and the ratio of complete esophageal transit
48095300|NCT02547805|DRUG|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
48095301|NCT02547805|DRUG|Placebo|Placebo 5 capsules PO TID with meals
48095302|NCT03793855|BEHAVIORAL|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
48095303|NCT03793855|BEHAVIORAL|Dietary Prescription|Dietary prescription according to guidelines.
48095304|NCT04071522|OTHER|no intervention|no intervention
48095305|NCT06614946|BEHAVIORAL|Electronic Safety Plan (ESP)|Participants will receive an electronic safety plan in the ED. ESP focuses on developing a personalized coping plan to manage suicidal thoughts and urges.
48095306|NCT06614946|BEHAVIORAL|Text support|Those in the text-based support program will receive up to 2 texts per day for a month with varying levels of tailoring, based on ESP and dynamic personalized feedback.
48095307|NCT01143077|DRUG|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
48095308|NCT01702896|DRUG|Interleukin-2|Interleukin-2
48095309|NCT05566405|PROCEDURE|General Anaesthesia|All patients in the general anaesthesia group will be premedicated with intravenously administered (iv) midazolam (2mg) and fentanyl (100 mcg). Induction will be performed using intravenous propofol (2.5-3mg/kg) and lidocaine (40mg); dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg will also be administered. After successful tracheal intubation, total intravenous anaesthesia will be maintained by administering propofol (0.05 mg/kg/sec iv) and remifentanil (0.2 mcg/kg/sec iv). Pain management will be achieved by paracetamol (1g iv) and tramadol (100mg iv) whereas muscle relaxation by vecuronium (0.6 mg/kg iv).
48095310|NCT05566405|PROCEDURE|Combined (Epidural and Spinal) Anaesthesia|Combined (epidural and spinal) anaesthesia will be performed using an epidural 18G needle and a spinal 27G needle, in the L2-L3 or L3-L4 interspace. Induction will be carried out by spinal intrathecal administration of levobupivacaine (2.6-3ml of 0.5%) and mild sedation by midazolam (5mg iv in bolus). All patients will be administered dexamethasone 8mg, metoclopramide 10mg and omeprazole 40mg iv. Maintenance will be performed 75 minutes after induction and obtained using an epidural administration of levobupivacaine (4-5ml of 0.5%).
48095311|NCT05566405|PROCEDURE|Open Retropubic Radical Prostatectomy|All patients will undergo a nerve-sparing open retropubic radical prostatectomy
48095312|NCT05610696|OTHER|Low impact immersion|Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
48095313|NCT05610696|OTHER|Conventional aquatic physiotherapy|include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
48270184|NCT04323371|DIAGNOSTIC_TEST|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
47951188|NCT03550885|OTHER|High taurine and saturated fat diet|This is a 3-week (21 day) isocaloric Western-type diet with all meals, snacks, beverages and condiments provided.
47951189|NCT03550885|OTHER|Low in taurine and saturated fat diet|This is a 3-week (21 day) isocaloric largely plant-based diet with all meals, snacks, beverages and condiments provided.
48095314|NCT05610696|OTHER|High intensity aquatic physiotherapy|In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
48095315|NCT06615180|BEHAVIORAL|Transcultural Nursing Course (new curriculum)|"Multinational Collaboration: Developed with input from institutions across five countries, ensuring a broad, international perspective on transcultural nursing.~Comprehensive Theoretical Framework: Integrates multiple cultural competence models (Purnell, Campinha-Bacote, Papadopoulos) with Leininger's Culture Care Theory, offering a thorough approach.~Extensive Practical Training: Includes 17 hours of hands-on experience, featuring hospital visits and interactions with healthcare professionals.~Interactive Learning Methods: Combines role-playing, reflective essays, and cultural activities (e.g., traditional clothing, dances) for dynamic, multimodal education.~Peer Education: Incorporates peer education and evaluation, enhancing collaborative learning and critical thinking.~Standardized Materials: Educational materials and teaching methods are standardized across institutions to ensure consistency and quality in instruction."
48095316|NCT03478579|OTHER|observational|No intervention, it is observational study
48095317|NCT01462019|DEVICE|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
48095318|NCT04261712|DRUG|Paltusotine|Paltusotine, once daily by mouth
48095319|NCT01019577|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
48095320|NCT03437668|DRUG|WSE|WSE tablets
48095321|NCT03437668|DRUG|Placebo Oral Tablet|Placebo tablet
48095322|NCT02949271|OTHER|Programmed Intermittent Epidural Bolus|
48095323|NCT02949271|OTHER|Continuous Epidural Infusion|
48095324|NCT02949271|DRUG|Ropivacaine|
48095325|NCT02949271|DRUG|Fentanyl|
48095326|NCT06466668|DIAGNOSTIC_TEST|Sleep study|All subjects will undergo a polysomnography at home
48095327|NCT06466668|DIAGNOSTIC_TEST|stress-related biomarkers and microbiome composition will be assessed using saliva samples|stress and stress-related inflammatory biomarkers will be tested using saliva sample
48095328|NCT06466668|DIAGNOSTIC_TEST|Audiological tests|Pure tone audiometry, Uncomfortable Loudness Levels, Distortion-Product Otoacoustic Emissions, tablet test for hyperacusis, tablet test for hearing screening
48095329|NCT06435572|OTHER|Suction|Each patient will be evaluated as both the experimental and control group. In the study, open suction applied to the patient will be evaluated as control, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be done as open suction, and the second suction will be done as closed suction.
48095330|NCT03980756|DRUG|AD-206 20mg|1 tablet administered before the breakfast during 7 days
48095331|NCT03980756|DRUG|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
48095332|NCT03980756|DRUG|AD-206 40mg|1 tablet administered before the breakfast during 7 days
48095333|NCT03980756|DRUG|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
48095334|NCT04940390|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
48095335|NCT04940390|DRUG|Placebo|Placebo for STS101
48095336|NCT04793139|DRUG|Camrelizumab|Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
48095337|NCT04960280|DEVICE|©VoqX stethoscope|Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
48095338|NCT04087772|BEHAVIORAL|Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
48095339|NCT04087772|BEHAVIORAL|Racial/Ethnic Discrimination Interventions (RED)|Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
48270185|NCT06310993|OTHER|Exercise|Exercise programme is the intervention for this study
48270186|NCT05782829|DIETARY_SUPPLEMENT|L-tyrosine supplementation|L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
48270187|NCT05782829|DIETARY_SUPPLEMENT|Placebo supplementation|Placebo supplementation before surgery for inguinal hernia under general anaesthesia
47921613|NCT03010371|BEHAVIORAL|Positive Online Psychotherapy|The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.
48095340|NCT01963026|OTHER|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module \[17\] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. \[17\]. Intervention B will be called 'ToCUEST variability' in the present project.
48095341|NCT01963026|OTHER|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
48095342|NCT04485741|DEVICE|RESP|The RESP device will be placed on the patient for periodic recording of auscultory sound.
48095343|NCT06446674|PROCEDURE|mini monaka|mini monaka,perforated plugs
48095344|NCT02862704|BIOLOGICAL|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
48095345|NCT01789203|DRUG|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
48095346|NCT01789203|DRUG|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
48095347|NCT02530151|DRUG|Morphine with clonidine|see arm description
47921614|NCT03010371|BEHAVIORAL|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) is based on the Cognitive Behavioral Stress Management (Antoni, 2003) and the training program derived from it, Breast Cancer Stress Management and Relaxation Training (B-SMART) by Antoni Michael (2003). In its Spanish version, it is a 10-session therapy aimed to reduce cancer-related emotional distress, facilitating adjustment to illness and greater quality of life. Stress management and relaxation techniques help patients to identify their own stress responses and learn alternative ways of thinking and acting in response to the demands they perceive as highly stressful."
47921615|NCT00539968|DRUG|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID"
47921616|NCT01848041|DRUG|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
48095348|NCT02530151|OTHER|Normal saline|see arm description
48095349|NCT06530667|DEVICE|broadband collaborative pulse ablation|Via CT guided, patients with malignant pulmonary nodules would be treated by broadband collaborative pulse ablation
48095350|NCT02636413|DRUG|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
48095351|NCT02636413|DIETARY_SUPPLEMENT|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
48095352|NCT04879134|DRUG|Apomorphine Injectable Solution|"Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo"
48095353|NCT04879134|DRUG|Placebo|"0.9% saline placebo injection~Other Names:~• Saline"
48095354|NCT06174896|PROCEDURE|Group 1|The LMA Proseal will be inserted directly by hand, without the use of any laryngoscope, as recommended in the instruction manual. The cuff will be gently guided along the hard palate where it is pushed into the hypopharynx and increased resistance is felt, and the cuff will be placed towards the hypopharynx.
48095355|NCT06174896|PROCEDURE|Group 2|Appropriately sized laryngoscope blade will be used and after the location of the epiglottis is determined, the tongue and epiglottis will be lifted forward. Then, LMA Proseal will be placed at the point where resistance is felt at a level where the proximal edge of the mask can be seen.
48095356|NCT06174896|PROCEDURE|Group 3|After the video laryngoscope is placed with an appropriately sized blade, the location of the epiglottis and vocal cords will be determined and the LMA Proseal will be placed at the point where slight resistance is encountered after the epiglottis is lifted. proximal aspect of LMA
47921617|NCT01848041|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
47921618|NCT04355585|DRUG|Colchicine Tablets|1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
47921619|NCT04355585|DRUG|Placebo oral tablet|Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)
47921620|NCT02649348|BEHAVIORAL|pre-operative prehabilitation|To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
48095357|NCT03940469|DRUG|Saline|2 ml normal saline
48095358|NCT03940469|DRUG|Dexamethasone Injection|8 mg dexamethasone
48095359|NCT03940469|DRUG|Dexmedetomidine Hydrochloride|100 microgram dexmedetomidine
48095360|NCT04773002|OTHER|Different anesthesia methods|Total intravenous anesthesia (TIVA)and volatile anesthesia
48270188|NCT00629395|BEHAVIORAL|Captain's Log Computer Program|12 Computer Program
48270189|NCT04111614|DRUG|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
48270190|NCT04111614|DRUG|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
48270192|NCT01439438|DRUG|Topiramate coated tablet|Test formulation
48270193|NCT01439438|DRUG|Topamax® coated tablet|Reference formulation
48270194|NCT01656525|DRUG|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
48095361|NCT06629532|OTHER|medical management, surgical interventions, and rehabilitative strategies|By leveraging a wide array of treatment data - including medical management, surgical interventions, and rehabilitative strategies - the RESEARCH registry intends to provide a granular view of current treatment landscapes and their direct impact on patient recovery and quality of life.
48095362|NCT01027871|DRUG|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
48095363|NCT01027871|DRUG|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
48095364|NCT04160585|OTHER|There is no intervention.|There is no intervention.
48095365|NCT05726864|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
48095366|NCT06459661|OTHER|Diet|Intake of unrefined, intact plant foods
48095367|NCT02999217|DRUG|Iron isomaltoside|"Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
48095368|NCT02999217|DRUG|Saline|"Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
48095369|NCT02973919|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, \& Renssen, 1999; de Jongh, Holmshaw, Carswell, \& van Wijk, 2011; Lapsekili \& Yelboga, 2014; Muris, Merckelbach, van Haaften, \& Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
48095370|NCT02973919|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger \& Pauli, 2011).
48095371|NCT03239210|DRUG|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
48095372|NCT03239210|DRUG|Placebo|placebo equivalent
48095373|NCT04663399|OTHER|Prospective patient|The immuno-inflammatory and thrombo-inflammatory profiles will be evaluated at inclusion, and at 24 hours +/- 12 hours of the reperfusion treatment.
48095374|NCT02360345|DRUG|ONX-0801|
48095375|NCT03956199|PROCEDURE|pulpotomy|removal of the pulp from pulp chamber
48095376|NCT03956199|PROCEDURE|Root canal treatment|Removal of at the entire content of the root canal system and root canal obturation
47951190|NCT04354961|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
47951191|NCT04569656|DRUG|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
47951192|NCT06117397|OTHER|Text Messaging Intervention|A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
47951193|NCT03303014|DEVICE|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
48095377|NCT00800371|PROCEDURE|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
48095378|NCT05671705|DIAGNOSTIC_TEST|DEXA Scan|Fu of diagnostic tests
48095379|NCT02871765|OTHER|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
48095380|NCT06565390|DEVICE|Babies in the Owlet monitor group|The Owlet group will be given an Owlet OSS 3.0 monitor to wear when sleeping. The Owlet alarms if the baby has a very low heart rate or very low oxygen levels. In addition, caregivers in the Owlet group with a smart phone and Wi-Fi access will be able to use an application to monitor the baby's vital signs and sleep state.
48095381|NCT05137912|BIOLOGICAL|Immunotherapy|"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."
48095382|NCT02507310|OTHER|thermostat|ambient temperature as modified by thermostat
48095383|NCT05210842|OTHER|Endoscopy|The procedures are performed using a flexible therapeutic linear array echoendoscope.
48095384|NCT03783455|PROCEDURE|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
48095385|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
48095386|NCT03783455|PROCEDURE|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
48095387|NCT03783455|PROCEDURE|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
47921621|NCT06505772|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine ) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~For example, it begins with an infusion of 4 ml over 10 minutes and then continues the infusion, depending on the weight of the child, at a rate of 1.6 ml/kg/hour.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
47921622|NCT06505772|DRUG|Normal saline|"Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study."
47921623|NCT01643785|DRUG|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
47921624|NCT05081791|BEHAVIORAL|Exercise Training|12-week exercise training program including a combination of endurance and resistance training for 45 minutes, twice a week.
47921625|NCT04321447|OTHER|Clinical practice guideline for prevention and management of extravasation injury|Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
47921626|NCT06242353|DIAGNOSTIC_TEST|Coagulopathy parameters|"Standard coagulation tests: APT (Activated Partial Thromboplastin Time), PT/INR (Prothrombin Time Test), Protein-C, Protein-S, Fibrinogen, Antithrombin, D-dimers.~Global haemostasis assays: CAT (Calibrated Automated Thrombogram), OHP (Overall Haemostatic Potential), Fibrin clot turbidity assay, microparticle detection by flow cytometry, scanning electron microscopy.~Protein expression profile (mass spectroscopy)~Ultrasound of catheterised neck veins to detect clots"
48095388|NCT03783455|PROCEDURE|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
48095389|NCT04315220|OTHER|Corestability training|"Level -1: Mat exercises~Abdominal muscle contraction,bridging,cat stretch,single limb circle and superman.:~Level- 2: Swiss Ball Exercises Abdominal contraction,bridging and squats."
48095390|NCT04315220|OTHER|No Intervention|No Intervention
48095391|NCT01174550|PROCEDURE|Coronary Angiography|Use of standard equipment for usual-care testing
48095392|NCT01174550|PROCEDURE|Stress Echocardiogram|Use of standard equipment for usual-care testing
48095393|NCT01174550|PROCEDURE|Nuclear Stress Test|Use of standard equipment for usual-care testing
48095394|NCT01174550|PROCEDURE|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
48095395|NCT02023944|OTHER|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
48095398|NCT01304706|DRUG|Fluocinolone Acetonide|0.2 μg/day
48095399|NCT04349384|PROCEDURE|Colorectal resection|Colon or rectal resection for colorectal adenocarcinoma
48095400|NCT01899209|PROCEDURE|STARR|
48270195|NCT01656525|DRUG|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
48095401|NCT01899209|PROCEDURE|Laparoscopic Ventral Rectopexy|
48095402|NCT06628193|DEVICE|Low intensity focused ultrasound|low-intensity focused ultrasound for neuromodulation applied to the head.
48095403|NCT06628193|DEVICE|Sham (No Treatment)|Sham LIFU application
48095404|NCT05066451|OTHER|%5 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
48095405|NCT05066451|OTHER|%15 dextrose prolotherapy|"Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week.~Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact."
48095406|NCT01688973|DRUG|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
48270196|NCT01656525|DRUG|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
48270197|NCT01656525|DRUG|Placebo|subcutaneous doses every 4 weeks for 24 weeks
48270198|NCT05477186|BIOLOGICAL|CV0501 (3 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
47921627|NCT03537469|DEVICE|CTU Mega 20 real device|The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
48095407|NCT01688973|OTHER|Laboratory Biomarker Analysis|Correlative studies
48095408|NCT01688973|DRUG|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
47921628|NCT03537469|DEVICE|CTU Mega 20 sham device|A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
47921629|NCT04561726|OTHER|Connective Tissue Manipulation|Connective tissue manipulation is a soft tissue manipulative technique and also a reflex therapy which is characterized by localised and specific strokes performed in where the fascia is superficial or palpable. A shear force is created between the skin-underlying fascia or dermis-hypodermis and angulatory force is applied to the collagen fibers to produce reflex and mechanical effects.
47921630|NCT04561726|OTHER|Exercise|The purpose of the given home exercises is to increase motor ability in activities such as standing, walking and posture, to increase muscle strength and also to elongate muscles. Exercises progressed day by day according to the adaptation of the motor system and muscle strength to the exercises.
48095409|NCT05909943|DRUG|Ruxolitinib|Treatment with ruxolitinib will be initiated in an initial dose regimen of 5-10 mg twice daily. Two months later, the dose of ruxolitinib will be increased to 10-15 mg twice daily.
48095410|NCT06028048|BEHAVIORAL|PLACES|"The PLACES intervention is based on eight IPS principles, ensuring competitive employment, client choice, service integration, personalized benefits counseling, rapid job search, systematic development, and individualized support.~Coaches: Certified IPS coaches receive training from Phrenos IPS knowledge center and Re-turn. Ongoing support includes video lectures, clarifications with researchers, and biannual collective sessions. Coaches, regionally specialized, implement interventions autonomously.~Intervention Phases:~1. Intake and Assessment: Participants meet IPS coaches within three days to discuss goals, procedures, and responsibilities, continuing until objectives are met.~2. Acquisition and Application: Coaches assist job search and placement, aiming for employment within 30 days.~3. Placement and Support: Coaches offer personalized support, adapting to needs, scheduling meetings based on preferences.~The intervention ends at 12 months or when goals are achieved."
47921631|NCT04650451|BIOLOGICAL|chimeric antigen receptor (CAR) T cell therapy|HER2-targeted dual-switch CAR-T cells
47921632|NCT02086032|DRUG|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
47921633|NCT02086032|DRUG|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
47921634|NCT02086032|DRUG|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
47921635|NCT02358291|PROCEDURE|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
47921636|NCT02358291|PROCEDURE|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
47921637|NCT02358291|PROCEDURE|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
47921638|NCT06466018|DIAGNOSTIC_TEST|Schirmer test paper|"This paper is centrifuged and your tears are collected then frozen before analysis. We collect the fat from your tears by scraping the edge of your lower eyelid with small sterile tweezers. All surgical waste will be collected during eye surgeries only if you must have them.~During each ocular surgical procedure, the vitreous, subretinal fluids and/or aqueous humor will eventually be recovered when required by the procedure. The rest of the blood samples, not used during diagnostic analyses, will be kept for later analyses.~Tears will be collected using a non-invasive and painless method that takes around ten minutes. The tissues (connectiva, cornea, retina, epi-retinal membrane) which must have been removed when required by the surgical procedure will also be preserved."
47921639|NCT01757990|DIETARY_SUPPLEMENT|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
47921640|NCT04696211|OTHER|Music-with-movement exercise|A music-with-movement exercise programme to reduce chronic pain in older adults.
47921641|NCT04303728|DIAGNOSTIC_TEST|Muscle ultrasound|The muscle thickness and muscle quality will be assessed on ultrasound
47921642|NCT01889745|DRUG|HX-1171|Anti-oxidatant, Anti-inflamation
47921643|NCT04643145|PROCEDURE|Flexible ureteroscopy for renal calculi less than 20 mm|Patients with renal calculi less than 20 mm will be managed by flexible ureteroscopy. at the end of the procedure, they will be randomized to receive either temporary ureteral catheter for 2 days or indweeling double J stent for 2-4 weeks
48095411|NCT00250224|DEVICE|Radiotherapy stent|
48095412|NCT00917254|DRUG|YM150|oral
48095413|NCT00917254|DRUG|Placebo|oral
48095414|NCT00917254|DRUG|Enoxaparin|injection
48095415|NCT05567159|DRUG|Donanemab|Administered IV.
48095416|NCT05545462|DRUG|Doxycyclin|THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA
48095417|NCT05545462|OTHER|COMMON SALT|THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
47921644|NCT02797002|OTHER|Assessment|
47921645|NCT00955305|BIOLOGICAL|Bevacizumab|Given IV
47921646|NCT00955305|DRUG|Carboplatin|Given IV
47921647|NCT00955305|BIOLOGICAL|Cixutumumab|Given IV
48095418|NCT05397808|OTHER|Pilates Training|The group that received pilates training.
48095419|NCT05397808|OTHER|breathing and relaxation exercises|The group who received breathing and relaxation exercises with a home program.
48095420|NCT00964717|PROCEDURE|real chiropractic|real chiropractic manipulation
48095421|NCT00964717|PROCEDURE|Sham Chiropractic|Placebo stimulation using 'activator' thumper
47921648|NCT00955305|DRUG|Paclitaxel|Given IV
48095422|NCT03687385|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
47921649|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
47921650|NCT00732940|DRUG|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
47921651|NCT03754439|BEHAVIORAL|Physiological changes to noise and vibration exposure|Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
48095423|NCT03687385|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
48095424|NCT02941146|DEVICE|The ZELTIQ System|The CoolSculpting System will be used to perform the treatments with the CoolAdvantage family of applicators.
48095425|NCT00003891|DRUG|lurtotecan liposome|
47921652|NCT03032380|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
48095426|NCT03165383|DRUG|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
47921653|NCT03032380|DRUG|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
47921654|NCT03032380|DRUG|Linezolid|600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
47921655|NCT02255435|DRUG|Omaveloxolone Capsules, 2.5 mg|
47921656|NCT02255435|DRUG|Omaveloxolone Capsules, 5 mg|
47921657|NCT02255435|DRUG|Omaveloxolone Capsules, 10 mg|
47921658|NCT02255435|DRUG|Placebo|
47921659|NCT02255435|DRUG|Omaveloxolone Capsules, 20 mg|
48095427|NCT03165383|DRUG|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
47921660|NCT02255435|DRUG|Omaveloxolone Capsules, 40 mg|
47921661|NCT02255435|DRUG|Omaveloxolone Capsules, 80 mg|
47921662|NCT02255435|DRUG|Omaveloxolone Capsules, 160 mg|
47921663|NCT02255435|DRUG|Omaveloxolone Capsules, 300 mg|
47921664|NCT02255435|DRUG|Omaveloxolone Capsules, 150 mg|
47921665|NCT02949479|BEHAVIORAL|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
47921666|NCT01617226|DRUG|Azacitidine|Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
47921667|NCT01617226|DRUG|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
47921668|NCT03209128|RADIATION|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
47921669|NCT04308200|OTHER|CO-OP approach|"There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies."
47921670|NCT04308200|OTHER|NDT|All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
48095428|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
48095429|NCT00438425|DIETARY_SUPPLEMENT|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
48095430|NCT00438425|DIETARY_SUPPLEMENT|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
47921671|NCT04178278|DIAGNOSTIC_TEST|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
48095431|NCT05166174|PROCEDURE|Transvaginal ultrasound in the third trimester pregnancy|Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
48095432|NCT06083714|OTHER|Scapular Stabilization Exercises|Home-based scapular stabilization exercises (Inferior Glide, Low Row, Scapular Clock, Wall Push Up, Wall Slide and Squat Robbery) will be performed once or twice a day, 3 sets x 20 repetitions, 3 days a week for 8 weeks.
48095433|NCT06083714|OTHER|Schroth Exercises|It will be implemented face to face, 3 days a week, each session lasting approximately 45 minutes and in 8-week programs.
48095434|NCT01113515|DRUG|Esmolol hydrochloride|
47921672|NCT04178278|DIAGNOSTIC_TEST|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
47921673|NCT04178278|DIAGNOSTIC_TEST|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
48095435|NCT01113515|DRUG|Esmolol hydrochloride|
47921674|NCT02938715|OTHER|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
47921675|NCT01762137|PROCEDURE|Flow Diversion|Endovascular flow diverter placement
47921676|NCT01762137|PROCEDURE|Coiling|Endovascular coil placement
47921677|NCT03350269|OTHER|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
47921678|NCT05606471|DRUG|Semaglutide Pen Injector [Ozempic]|Glucagon-like peptide 1 (GLP-1) receptor agonist
47921679|NCT05606471|DIETARY_SUPPLEMENT|Very-low Calorie Diet|Total meal replacement with a limit of 800 kilocalories per day
48095436|NCT01113515|DRUG|Esmolol hydrochloride|
48095437|NCT01113515|DRUG|Placebo gel|
47921680|NCT04267900|DRUG|99mTc-HPArk2|99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
47921681|NCT05960292|PROCEDURE|Laparoscopic and Vaginal Hysterectomy|To make a comparison between the Vaginal Vault complications after Hysterectomy
47921682|NCT03041129|DIAGNOSTIC_TEST|oral glucose tolerance test|6 hours OGTT
47921683|NCT03041129|DIAGNOSTIC_TEST|MRI of liver|MRI of the liver and use of DIXON method
47921684|NCT04359381|OTHER|kinesiotaping application|kinesiotaping was applied once the menstrual pain begins (one day before menstruation) for periods of 4 to 5 days until the pain disappears and then removed it. Kinesiotaping was used for 3 successive menstruations.
47921685|NCT04359381|OTHER|Pilate exercises program|Each girl in group (B) was engaged in a supervised pilate exercises program for 30 minutes per session for 3 days/week for 12 weeks except days of menstruation. Participants would be oriented to wear comfortable clothes .
48095438|NCT05441280|DRUG|pimavanserin|pimavanserin 34mg PO at bedtime
48095439|NCT05441280|OTHER|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
47921686|NCT02583217|DRUG|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
47921687|NCT02583217|DRUG|remifentanyl|
47921688|NCT02583217|DRUG|propofol|
47921689|NCT02583217|DEVICE|laryngeal mask|
47921690|NCT01494493|DEVICE|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
47921691|NCT01494493|PROCEDURE|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
47921692|NCT00224185|PROCEDURE|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
47921693|NCT00224185|PROCEDURE|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
48095440|NCT05832723|DEVICE|650 nm low-level red-light|Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
48095441|NCT06103461|PROCEDURE|Autologous fat grafting|Autologous fat grafted at contour defects with pigmentary changes
48095442|NCT03079375|OTHER|basic intervention|medication review
48095443|NCT03079375|OTHER|extended intervention|medication review, medication interview before discharge and follow-up
48095444|NCT04488653|DIETARY_SUPPLEMENT|Oligopin®|French Maritime Pine Bark Extract - 100mg/day
48095445|NCT04488653|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48095446|NCT05823987|DRUG|H101|a modified human recombinant type 5 adenovirus with genetic modifications
48095447|NCT05823987|DRUG|Tislelizumab|a PD-1 immune check inhibitor
48095448|NCT05823987|DRUG|Lenvatinib|Lenvatinib capsules
48095449|NCT02828930|DRUG|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
47921694|NCT00224185|PROCEDURE|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
47921695|NCT05668390|DRUG|STALORAL® Birch 300 IR|2 treatment periods will consist of 2 steps: an escalation phase, where the treatment dose will gradually increase, followed by a maintenance phase.
48095450|NCT02828930|DRUG|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
48095451|NCT02828930|DRUG|[13C]-radiolabeled Idasanutlin|\[13C\]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
48095452|NCT02828930|DRUG|[14C]-radiolabeled Idasanutlin|\[14C\]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
48095453|NCT05756426|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
47921696|NCT04954651|BIOLOGICAL|Approved vaccines against Sars-Cov2|Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
47921697|NCT05781880|OTHER|Oxygen 100%|NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)
47921698|NCT00842907|DRUG|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
48095454|NCT02724878|DRUG|Bevacizumab|
47921699|NCT00842907|DRUG|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
47921700|NCT04453553|DIAGNOSTIC_TEST|Q16 testing|Nasal swab tested on a rapid near patient device
48095455|NCT02724878|DRUG|Atezolizumab|
48095456|NCT00991744|DRUG|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
48095457|NCT00991744|DRUG|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
48095458|NCT01151033|DEVICE|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
48095459|NCT03863717|OTHER|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
48095460|NCT03863717|OTHER|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
48095461|NCT04785183|DIETARY_SUPPLEMENT|Melatonin drops|Melatonin oral administration
47921701|NCT04453553|DIAGNOSTIC_TEST|Nasopharyngeal swab and main laboratory|Standard of care testing
47921702|NCT04408378|OTHER|observation of covid 19 pneumonia|We try to reveal the fact,covid-19 pneumonia prognosis can be estimated by using MPV/PLT ratio
47921703|NCT06120270|DEVICE|CeraFlex PFO Closure System|The Lifetech CeraFlex™ PFO occluder device is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
47921704|NCT04988191|DRUG|Toripalimab|"Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.~Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles."
47921705|NCT04988191|DRUG|Bevacizumab|Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.
47921706|NCT04988191|DRUG|Irinotecan|Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.
47921707|NCT04911192|PROCEDURE|mechanical fragmentation|patients who will be treated with catheter-directed mechanical fragmentation under fluoroscopy guidance. This group will include patients with absolute contraindication for fibrinolytic therapy
47951194|NCT01024231|DRUG|BMS-936558 (MDX1106-04)|
47951195|NCT01024231|DRUG|Ipilimumab|
48095462|NCT04785183|OTHER|Placebo|Oral 5% glucose
48095463|NCT00477412|DRUG|Bortezomib|Given IV
48095464|NCT00477412|DRUG|Cyclophosphamide|Given IV
48095465|NCT00477412|DRUG|Cytarabine|Given IV
48095466|NCT00477412|DRUG|Dexamethasone|Given PO or IV
48095467|NCT00477412|DRUG|Doxorubicin|Given IV
48095468|NCT00477412|DRUG|Methotrexate|Given IV
48095469|NCT00477412|BIOLOGICAL|Rituximab|Given IV
48095470|NCT00477412|DRUG|Vincristine|Given IV
48095471|NCT01743729|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5.0%
48095472|NCT01743729|DRUG|Placebo|Placebo for Lifitegrast Ophthalmic Solution 5.0%
48095473|NCT00991276|DRUG|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
48095474|NCT00991276|DRUG|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
48095475|NCT00991276|DRUG|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
48095476|NCT05920577|OTHER|exergames and resistance training|"In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software Nintendo Switch Sports will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training."
48095477|NCT05920577|OTHER|Resistance training|The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.
47921708|NCT04911192|PROCEDURE|In Situ thrombolysis|Group (C) will include the patients who will be treated with bed side administration of low dose of local thrombolytic therapy (In Situ) via a trans-Jugular Swan-Ganz pulmonary artery catheter. with guidance of the pressure waveforms obtained from SGC (Swan-Ganz catheter) and echocardiography guidance for ideal Catheter placement. This group will include the patients with relative contraindications for systemic thrombolysis, contraindications for contrasted administration (patients with renal impairment) and also patients with contraindications for radiation exposure (pregnant women).
47921709|NCT05518318|DRUG|GLS-010|Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W
47921710|NCT05518318|DRUG|Chemotherapy of Investigator's choice|Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
47921711|NCT01310205|DRUG|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
47921712|NCT06362733|BEHAVIORAL|Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth|This is a 12-week intervention program (1 hour/week) of treatment to target insistence on sameness in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of combination of parent-training and child-focused intervention.
48095478|NCT02008864|DRUG|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
48095479|NCT02008864|DRUG|Placebo|Placebo tablet/ 2 times per day
48095480|NCT01997840|DRUG|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
48095481|NCT03178201|DRUG|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
48095482|NCT00028132|DRUG|Tenofovir|
47921713|NCT00361634|DRUG|Etanercept|
47921714|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
47921715|NCT01192802|DRUG|albendazole|single 1 tablet of 400 mg of albendazole
47921716|NCT01192802|DRUG|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
47921717|NCT04754945|DRUG|Bortezomib|Given SC
47921718|NCT04754945|DRUG|Cyclophosphamide|Given IV or PO
47921719|NCT04754945|DRUG|Dexamethasone|Given IV or PO
47921720|NCT04754945|BIOLOGICAL|Isatuximab|Given IV
47921721|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
47921722|NCT03246386|DRUG|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
47921723|NCT03071757|DRUG|ABBV-368|Intravenous infusion
47921724|NCT03071757|DRUG|ABBV-181|Intravenous infusion
48095483|NCT03299491|OTHER|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
48095484|NCT03299491|OTHER|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
48095485|NCT01560143|DRUG|Tigecycline|100 mg IV as a single infusion over 30 minutes
47921725|NCT02335814|DRUG|FLX925|
47921726|NCT06321380|BEHAVIORAL|Complex span task|"The intervention consists in a computerized working memory task. This task follows the design of a complex span task, involving alternation between memorization and processing steps.~For each trial, participants have to memorize French words. These words are sequentially displayed on the screen. Between each word, participants perform a processing task consisting in a spatial location task: They have to determine if a shape is at the top or at the bottom of the screen. After each processing episode, participants have a free time (i.e., available time to maintain information in WM). At the end of each trial, participants perform an orally immediate recall. This experimental task involves several conditions in order to manipulate the opportunities for the spontaneous use of refreshing and elaborative strategies."
48095486|NCT01066260|DIETARY_SUPPLEMENT|Probiotic formulation|Twice a day for 24 days
48095487|NCT01066260|OTHER|Placebo|Twice a day for 24 days
48095488|NCT01234194|DRUG|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
48095489|NCT01234194|DRUG|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
48095490|NCT06388421|OTHER|Prospective study assessments|Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.
48095491|NCT03293667|OTHER|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
48270199|NCT05477186|BIOLOGICAL|CV0501 (6 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
48270200|NCT05477186|BIOLOGICAL|CV0501 (12 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
47921727|NCT06321380|DIAGNOSTIC_TEST|Clinical neuropsychological assessment|"As part of routine care, participants in the patient group undergo a standardized clinical neuropsychological assessment that evaluates several cognitive functions. The investigators hypothesize correlations between working memory performance during the experimental task and the results of neuropsychological tests. Thus, the investigators consider the results to several French versions of neuropsychological tests:~* MMSE (Mini-Mental State Examination)~* Digit Span Backward subtest (WAIS-IV)~* Stroop Test~* Trail Making Test (TMT)~* Rappel Libre - Rappel Indicé à 16 items or GERIA-12~* Category fluences~* Instrumental Activities of Daily Living and ADL ."
47921728|NCT06321380|DIAGNOSTIC_TEST|Clinical neurospychological assessement|"Participants in the control group undergo 2 tests clinical that evaluate cognitive functioning.~The investigators consider the results to French versions of these neuropsychological tests:~* MMSE (Mini-Mental State Examination; )~* Digit Span Backward subtest (WAIS-IV)"
47921729|NCT03101553|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
47921730|NCT03101553|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
47921731|NCT05192447|BEHAVIORAL|Exercise treatment|Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.
47921732|NCT00995033|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
47921733|NCT00995033|BIOLOGICAL|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
47921734|NCT00995033|DRUG|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
47921735|NCT02809040|OTHER|Electrocardiogram/Echocardiography|"Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart."
47921736|NCT02809040|OTHER|Portable digital auscultation|"Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation"
47921737|NCT02711917|DRUG|MAC 0.5|0.5 MAC Sevoflurane
47921738|NCT02711917|DRUG|MAC 0.75|0.75 MAC Sevoflurane
47921739|NCT02711917|DRUG|MAC 1.0|1.0 MAC Sevoflurane
47921740|NCT02711917|DRUG|Propofol|Propofol consumption
47921741|NCT02711917|DRUG|Etomidate|Etomidate consumption
47921742|NCT02711917|DRUG|Rocuronium|Consumption of Rocuronium
47921743|NCT03209739|OTHER|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
47921744|NCT01478048|BIOLOGICAL|Elotuzumab|Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 \& 2: Days 1, 8 \& 15; Cycles 3-8: Days 1 \& 11; Cycle 9+: Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
47921745|NCT01478048|DRUG|Bortezomib|Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
47921746|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1\& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
47921747|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
47921748|NCT01478048|DRUG|Dexamethasone|Solution; IV; 8 mg; (Cycles 1\& 2: Days 1, 8, 15; Cycles 3-8: Days 1 \&11; Cycles 9+; Days 1 \& 15); Until subject meets criteria for discontinuation of study drug
48095492|NCT05045872|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
47921749|NCT01478048|DRUG|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
47921750|NCT05972525|BEHAVIORAL|Shared decision-making supported by an in-consultation PtDA to patients with severe osteoarthritis in their hip or knee|The intervention group has been involved in the development process of the PtDA. After receiving a training course in SDM and the use of a PtDA, the surgeons will practice SDM supported by an in-consultation PtDA during the consultations with the participant.
47921751|NCT02410343|DRUG|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
48095493|NCT04188288|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
47921752|NCT02410343|DRUG|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
47921753|NCT05900206|DRUG|Trastuzumab deruxtecan|Experimental drug. Provided in 100mg vials. IV infusion.
47921754|NCT05900206|DRUG|Docetaxel|Active comparator. IV infusion.
47921755|NCT05900206|DRUG|Paclitaxel|Active comparator. IV infusion.
47921756|NCT05900206|DRUG|Carboplatin|Active comparator. IV infusion.
48095494|NCT04188288|DEVICE|Control feedback|Participants provided with control type of feedback (for example, in the form of a line graph) and will be instructed to try to make the line go up or down.
48095495|NCT04188288|DEVICE|fMRI|fMRI will be used to assess brain activity
47921757|NCT05900206|DRUG|Trastuzumab|Active comparator. IV infusion.
47921758|NCT05900206|DRUG|Pertuzumab|Active comparator. IV infusion.
47921759|NCT05900206|DRUG|Ribociclib|Experimental drug. Tablets.
47921760|NCT05900206|DRUG|Letrozole|Experimental drug. Tablets.
48095496|NCT03995043|BEHAVIORAL|Education|Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.
48095497|NCT03995043|BEHAVIORAL|Personal Support|Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.
47921761|NCT05900206|DRUG|Epirubicin|Active comparator. IV infusion.
47921762|NCT05900206|DRUG|Cyclophosphamide|Active comparator. IV infusion.
47921763|NCT00906737|DEVICE|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
47921764|NCT00906737|OTHER|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
47921765|NCT04382989|DEVICE|Analysis of human milk composition by mid-infrared spectrophotometry|"Analysis of human milk macronutrient content was performed by mid-infrared spectrophotometry using a Miris Human Milk Analyser.~An immune-enzymatic ELISA assays were used to estimate lysozyme and lactoferrin concentrations in human milk."
47921766|NCT01452100|DRUG|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
47921767|NCT01452100|OTHER|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
47921768|NCT04229732|DEVICE|ClearMateTM|Passive isocapnic hyperventilation breathing circuit.
47921769|NCT03206281|DIAGNOSTIC_TEST|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
47921770|NCT05611294|DEVICE|Topography Guided LASIK Surgery|LASIK surgery, using corneal topography data in treatment profile, to correct myopia or myopia with astigmatism refractive error.
47921771|NCT05611294|DEVICE|Small Incision Lenticule Extraction Surgery|Corneal lenticule formation using a femtosecond laser, with subsequent lenticule extraction, to correct myopia or myopia with astigmatism refractive error.
47921772|NCT01395290|DRUG|cholecalciferol|20.000 IU per week, oral
47921773|NCT04862221|DRUG|High-dose methylprednisolone|Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
47921774|NCT04862221|DRUG|Equine anti-thymocyte globulin|Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
47921775|NCT04862221|DRUG|Prednisolone|"Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
47921776|NCT04862221|DRUG|Placebo for prednisolone|"Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue"
48095498|NCT03995043|BEHAVIORAL|Access to contraception|Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
48095499|NCT03570749|DRUG|Baricitinib|Administered orally.
48095500|NCT03570749|DRUG|Placebo|Administered orally.
48095501|NCT02321540|DRUG|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
48095502|NCT02458846|OTHER|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
47921777|NCT04862221|DRUG|Placebo for infusions|Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
47921778|NCT04862221|DRUG|Diphenhydramine|Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
47921779|NCT04862221|DRUG|Methylprednisolone|Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
47921780|NCT05315895|OTHER|natural aging process|To observe the relationship between new cases of diseases and health status of people exposed to different factors such as life style, alcohol consumption, eating habits, etc.
47921781|NCT06317129|DEVICE|Endoscopic gastric restriction and biliodigestive diversion|The BariTon™ is endoscopically implanted.
47921782|NCT01143701|OTHER|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
47921783|NCT02885571|DEVICE|SomnoDent Flex with DentiTrac|
47921784|NCT03476005|BEHAVIORAL|proficiency based progression training|proficiency based progression training supported by technology enhanced learning
47921785|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
47921786|NCT05166837|DRUG|Placebo|Intravenous injection
47921787|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
47921788|NCT05166837|DRUG|Placebo|Intravenous injection
47921789|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
47921790|NCT05166837|DRUG|Placebo|Intravenous injection
47921791|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
48095503|NCT02458846|OTHER|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
47921792|NCT05166837|DRUG|Placebo|Intravenous injection
47921793|NCT05166837|DRUG|STSA-1002 injection|Intravenous injection
47921794|NCT05166837|DRUG|Placebo|Intravenous injection
48443547|NCT04570215|OTHER|Gotcha! Therapy application|"Gotcha! will provide an app-based therapy for people with dementia who have difficulty naming people they know well.~The therapy element works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. This DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item."
48443548|NCT04570215|OTHER|Gotcha Therapy application: Maintenance|Gotcha! Maintenance therapy is identical to Gotcha! but takes place over a longer period of time in an attenuated form.
48443549|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
47921795|NCT00665808|DRUG|insulin detemir|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
47921796|NCT00665808|DRUG|isophane human insulin|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
48443550|NCT00989274|BIOLOGICAL|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
47921797|NCT03301116|BEHAVIORAL|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
47921798|NCT03301116|BEHAVIORAL|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
47921799|NCT00930137|OTHER|isocaloric for week diet|"Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
47921800|NCT02438475|DEVICE|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
47921801|NCT02438475|OTHER|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
47921802|NCT03353337|BEHAVIORAL|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
47921803|NCT03353337|BEHAVIORAL|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
47921804|NCT05382767|DRUG|CKDB-501A|Muscle Spasticity
47921805|NCT05382767|DRUG|Botox®|Muscle Spasticity
47921806|NCT03141294|PROCEDURE|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
47921807|NCT00949494|DEVICE|Synvisc|intra-articular, 3 weekly injections
47921808|NCT03444480|DRUG|Remimazolam Tosylate|Initial dose plus supplemental doses
47921809|NCT02773784|OTHER|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
47921810|NCT05504239|DRUG|Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet|To be orally administered once daily
47921811|NCT05504239|DRUG|Teneligliptin Placebo Oral Tablet|To be orally administered once daily
47921812|NCT05791383|DEVICE|transcutaneous auricular neurostimulation|All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
47921813|NCT02717832|DRUG|hyperinsulinemic-euglycemic clamp|
47921814|NCT04211220|OTHER|A decision support software|Insulin pump Continuous glucose monitoring
47921815|NCT01571544|DEVICE|Thermal suit|Thermal suit
47921816|NCT01571544|OTHER|Conventional clothing|Conventional clothing
47921817|NCT05207345|OTHER|Interventional programme|"90-minute session divided into:~* 45 minutes of core stability treatment~* 45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training)."
47921818|NCT05207345|OTHER|General exercise programme|90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
47921819|NCT02983279|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo caloric restriction diet
47921820|NCT02983279|OTHER|Counseling|Undergo counselor-led dietary counseling
47921821|NCT02983279|PROCEDURE|Therapeutic|Undergo standard of care surgery
47921822|NCT04500561|DRUG|YY-20394|Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
47921823|NCT00002671|DRUG|aminocamptothecin|
47921824|NCT03543787|COMBINATION_PRODUCT|Health IT and Peer Support Intervention|"Health IT will support referral system by establishing 1) communication between healthcare providers and peer navigators 2) decision support for clinician to facilitate appropriate referrals 3) tracking of referred patients real-time 4) dashboards to monitor key evaluation metrics.~Peer Support intervention: peer navigators at each level of the referral network will ensure 1) referral adherence by link clinicians and patients 2) health system navigation 3) psychosocial support: leverage their shared disease experience to help patients overcome barriers to health seeking behaviour."
47921825|NCT00096356|DIETARY_SUPPLEMENT|CoQ10 & Vitamin E|
47921826|NCT00096356|DIETARY_SUPPLEMENT|Placebo & Vitamin E|
48095504|NCT02458846|DEVICE|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
47921827|NCT00036608|DRUG|Entecavir|
47921828|NCT03843671|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy
48095505|NCT02458846|OTHER|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near \& far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
48443551|NCT00989274|BIOLOGICAL|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
47921829|NCT03843671|DEVICE|Hyperbaric chamber|Hyperbaric chamber
47921830|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
47921831|NCT00883519|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
47921832|NCT03406741|BEHAVIORAL|psychometric evaluation|Wechsler type composite scales (WISC)
47921833|NCT03406741|BEHAVIORAL|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
47921834|NCT05636800|DEVICE|Swift System|"Localized microwave energy applied to the distinct AK lesion. Each subject will receive treatment for a maximum of 2 visits (4-week interval between treatment).~For AK lesions assessed as Thin AK (Olsen Grades 1 and 2): Set at 3W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions). There will be approximately 20 seconds between each repeat dose.~For AK lesions assessed as Thick AK (Olsen Grade 3): Set at 4W and apply locally for up to a 3 second burst and adjust the dose and duration. Repeat on the same AK lesion as is tolerable for the subject (3 repetitions).~As the AK lesions may be larger than 3mm in diameter, the dose administered to one AK lesion may require overlapping applications with the applicator tip. Ensure there is approximately 20 seconds between each repeat dose administered"
47921835|NCT01929499|BIOLOGICAL|cytokine-induced killer cells|
47921836|NCT01398917|PROCEDURE|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
47921837|NCT01398917|PROCEDURE|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
47921838|NCT05881070|BEHAVIORAL|Mobile-health self management|Mobile-health self management
47921839|NCT00108108|DRUG|HCD122|
47921840|NCT02073344|PROCEDURE|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
47921841|NCT02073344|OTHER|no intervention|no renal replacement therapy
47921842|NCT04354597|DRUG|HCQ & AZ|Subjects will receive weekly HCQ 400mg PO and AZ PO 500mg X 3 Days; weekly for 16 weeks.
47921843|NCT05913037|DRUG|Test group (Group A): FCN-159 8 mg, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
47921844|NCT05913037|DRUG|Control group (Group B): Placebo, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
47921845|NCT05811234|DRUG|CAL/BDP PAD Cream|As provided in real-world clinical practice.
47921846|NCT05120557|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
47921847|NCT03147157|OTHER|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
47921848|NCT05975398|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
47921849|NCT05975398|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
47921850|NCT01250496|DRUG|Aminophylline|75 mg of intravenous aminophylline
47921851|NCT01250496|DRUG|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
47921852|NCT03060551|PROCEDURE|SVF injection|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
47921853|NCT02765009|DRUG|diuretics|Used to reduce fluid overload as evidenced by weight gain
47921854|NCT02765009|DRUG|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
47921855|NCT02765009|OTHER|fluid restriction|Used to reduce fluid overload
47921856|NCT02765009|DEVICE|renal replacement|Used to reduce fluid overload in patients with renal replacement
47921857|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
47921858|NCT00726843|OTHER|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
47921859|NCT03909594|DRUG|Bupivacaine|Bupivacaine
48095506|NCT04438811|OTHER|delivery of the spinal anesthetic by a trained medical officer|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
48270201|NCT05477186|BIOLOGICAL|CV0501 (25 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
47921860|NCT03909594|DRUG|Ketamine|Ketamine
47921861|NCT01463007|RADIATION|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
47921862|NCT01463007|OTHER|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
47921863|NCT04140760|OTHER|Symprove|A liquid probiotic
47921864|NCT04140760|OTHER|Symprove placebo product|An inert placebo
47921865|NCT01696682|PROCEDURE|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
47921866|NCT01696682|PROCEDURE|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
47921867|NCT05949034|DEVICE|JUUL E-Cigarette Device|We will use the commercially available and popular JUUL e-cigarette device and e-cigarette solutions.
47921868|NCT06376903|OTHER|Pilates exercise - pelvic floor exercise - home advices|"Group (A) (Study group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform program of pilates exercises, 3 sessions/week (30 minutes a session ) for 12 weeks in addition to Kegel exercises (15min/three times per week/ for 12 weeks) and home care advices.~• Group (B) (Controlled group): It will be consisted of thirty postmenopausal women suffering from mild and moderate stress urinary incontinence, will perform kegel exercises (15min/three times per week/ for 12 weeks) and home care advices as in group (A)."
47921869|NCT03219775|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)\*~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~  * since June 5, 2019, the treatment in all four boost cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)"
47921870|NCT01717053|DRUG|Abiraterone acetate|1000 mg orally once a day for 6 months.
47921871|NCT01717053|DRUG|Androgen deprivation|LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
47921872|NCT01717053|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
47921873|NCT01717053|DRUG|Prednisone|5 mg tablet once daily for 6 months.
47921874|NCT05864092|OTHER|Virtual Reality Goggles|We will offer patients virtual reality goggles with guided meditation software in addition to standard medical therapy (NSAID and opioid).
47921875|NCT04508218|DIETARY_SUPPLEMENT|whey protein supplementation powder (Inkospor X-TREME; France)|Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening
47921876|NCT04508218|OTHER|Exercise training program|After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.
47921877|NCT04508218|OTHER|traditional burn care|ROM exercises, stretching, ADL activities and scar management
47921878|NCT00176956|PROCEDURE|Skin Biopsy|Skin biopsy.
47921879|NCT06043544|DEVICE|Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe|Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
47921880|NCT06043544|DRUG|Corticosteroid injection|Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
47921881|NCT05731050|DRUG|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
47921882|NCT04850508|DEVICE|Mapping and ablation with the Advisor HD Grid catheter|"After confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side.~If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed."
47921883|NCT04583137|DRUG|Lidocain|Layngeal direct fiberoptic examination transnasaly
47921884|NCT04590833|BEHAVIORAL|Supervised walking on a treadmill|Each participant will be provided with an individualized target heart rate zone based on his/her age. Heart rate during exercise will be measured using a finger pulse oximeter. Following baseline measures, participants will receive instructions on how to use a finger pulse oximeter by a student. For participants who are not physically fit or are just engaging in regular exercise, they will be advised to start walking on a treadmill at a comfortable pace for 5 to 10 minutes at one time.46 Exercise duration and intensity will be progressed from week 3 to week 5, until participants will walk at 40-59% of heart rate reserve based on their age, which will be maintained throughout the study.
47921885|NCT04590833|BEHAVIORAL|Supervised stretching exercise|Following baseline measures, a student will demonstrate the use of a pulse oximeter and stretching movements to these participants. Starting on week 3, participants will do the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise. Stretching will target all major muscle-tendon groups including shoulder, chest, neck, truck, lower back, hips, and legs. It will also involve a slow and constant motion that accounts for any physical limitations and physician-specified precautions
47921886|NCT06391632|DIAGNOSTIC_TEST|Revised Cardiac Risk Index|The Revised Cardiac Risk Index (RCRI) attempts to estimate the likelihood of cardiac complications during hospitalization in patients undergoing noncardiac surgery.The Frailty Index is a commonly used tool in clinical practice to assess the degree of frailty in patients.The Quality of Recovery-15 scale (QoR-15) is an easy-to-use score for assessing the quality of post-operative recovery.
47921887|NCT01096628|OTHER|Chiropractic + Exercise|"Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.~Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise."
47951196|NCT06681844|OTHER|Tooth Shape assessed using an intraoral scanner one after avulsion|"* Tooth Shape assessed using an intraoral scanner one after avulsion and stored as StereoLithography (STL) file~* Age, gender, reason of avulsion, type of tooth taken from the database and stored in a google sheet"
48095507|NCT04438811|OTHER|delivery of spinal anesthetic by a consultant anesthetist|The delivery of spinal anesthesia by the trained medical officers in 3 rural Indian hospitals will be compared to those delivered by consultant anesthetists in the same hospitals in a non-inferiority analysis.
48095508|NCT03129035|PROCEDURE|Cesarean hystrectomy|Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
48095509|NCT03129035|PROCEDURE|Internal iliac artery ligation|The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
48095510|NCT00051974|DRUG|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
48270202|NCT05477186|BIOLOGICAL|CV0501 (50 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
48270203|NCT05477186|BIOLOGICAL|CV0501 (75 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
47921888|NCT01096628|OTHER|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
47921889|NCT06156709|PROCEDURE|Group I: Lower Volume with Higher Anaesthetic Concentration|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
47921890|NCT06156709|PROCEDURE|Group II: Higher Volume with LowerAnaesthetic Concentration|20 ml of a solution containing 0,0625% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 10 ml may be administered
47921891|NCT01302145|DRUG|ASP1941|Tablet
47921892|NCT01302145|DRUG|Metformin|Tablet
48095511|NCT05182437|RADIATION|LINAC-based Stereotactic Radiotherapy|Target definition: the target volume is defined as the epileptogenic zone (EZ) on all (non) invasive examinations (e.g. 3, 7 Tesla MRI or Stereo-EEG) of the presurgical path. Planning target volume (PTV) = GTV. A single fraction SRT with a prescribed isotoxic dose of 24 Gy to the 100% surrounding isodose. Dose is depending on the proximity and maximum tolerable dose to the radiosensitive organs at risk and EZ volume resulting in a V12\<= 10 cc reducing the risk on radionecrosis.
48095512|NCT05507203|DRUG|ABX464|Administered once daily in the morning with food
48095513|NCT05507203|DRUG|Placebo|Administered once daily in the morning with food
48095514|NCT06054737|PROCEDURE|SPA THERAPY|"Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~* 10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~* 20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~* Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes"
48095515|NCT03677726|BEHAVIORAL|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
48095516|NCT03677726|OTHER|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
48095517|NCT00854139|DRUG|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
48095518|NCT00854139|PROCEDURE|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
48095519|NCT00854139|RADIATION|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
48270204|NCT05477186|BIOLOGICAL|CV0501 (100 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
48270205|NCT05477186|BIOLOGICAL|CV0501 (150 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
47921893|NCT01302145|DRUG|Placebo|Tablet
47921894|NCT03526588|BIOLOGICAL|Autologous umbilical cord blood|6×10\^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
47921895|NCT02325869|DEVICE|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
47921896|NCT04083625|DRUG|carbetocin 100 mcg|a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.
47921897|NCT04083625|DRUG|placebo|a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
47951197|NCT05078242|DEVICE|EaseVRx|Participants will experience 7 sessions of the EaseVRx device for chronic pain.
47951198|NCT04636151|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
47951199|NCT03561961|RADIATION|Moderate Hypo-fractionation|66-68Gy in 25#
47951200|NCT03561961|RADIATION|Extreme Hypo-fractionation|35-36.25 Gy in 5#
48095520|NCT00854139|PROCEDURE|Bone marrow transplant from a related donor|• Donor bone marrow (\> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is \> 60 seconds, the protamine treatment shall be repeated
47921898|NCT05367258|OTHER|Patients satisfaction after medical and surgical treatment for umbilical endometriosis|It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.
47921899|NCT03225040|DRUG|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
47921900|NCT02280798|PROCEDURE|Endometrial Biopsy|4 endometrial biopsy
47921901|NCT04825730|DRUG|JOINTSTEM|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
48095521|NCT02746900|PROCEDURE|Cervical cerclage|McDonald cervical cerclage
47921902|NCT02296372|DEVICE|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
47921903|NCT03736915|PROCEDURE|Injection using 1 cc of NaCl 0.9%|The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
48095522|NCT06614530|DEVICE|Chilipad Docker Pro|The Chilipad Dock Pro is an advanced sleep system designed to optimize sleep by dynamically adjusting the bed\&#39;s surface temperature. It consists of a mesh mattress pad and a Dock Pro control unit that circulates water through the pad, allowing users to customize the temperature between 55°F and 115°F. The system offers both single and dual control, making it ideal for individual or shared use. Equipped with AI-driven features, the Dock Pro can monitor sleep patterns and environmental factors to make real-time adjustments, ensuring optimal sleep conditions throughout the night. This intelligent temperature management system is enhanced when paired with the optional Sleepme Tracker, creating a personalized sleep experience.
47921904|NCT03736915|OTHER|Patient Preference Question|Patient is asked at the end of each injection which injection they prefer
47921905|NCT03736915|OTHER|Questionnaires|Patient is asked to answer questionairres at the end of each injection
48095523|NCT02286440|OTHER|AssureRx GeneSight genotyping results|
47921906|NCT01245569|DRUG|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
47921907|NCT01245569|DRUG|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
47921908|NCT03225859|BEHAVIORAL|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
47921909|NCT00926315|DRUG|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
47921910|NCT00926315|DRUG|Calcitriol|calcitriol 0.25 mcg PO bid
47921911|NCT00588068|OTHER|Tumor and Marrow Markers|Tumor and Marrow Markers
47921912|NCT03675854|DRUG|Cefazolin|3 weeks
47921913|NCT02130102|DEVICE|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
47921914|NCT00575393|DRUG|gold sodium thiomalate|
47921915|NCT00575393|GENETIC|gene expression analysis|
47921916|NCT00575393|OTHER|fluorine F 18 fluorothymidine|
47921917|NCT00575393|OTHER|mass spectrometry|
47921918|NCT00575393|OTHER|pharmacological study|
47921919|NCT01510457|DRUG|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
47921920|NCT01510457|DRUG|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
47921921|NCT05612932|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
47921922|NCT05612932|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
47921923|NCT04136119|OTHER|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
47951201|NCT01982565|DEVICE|NOx dressing|The NOx dressing should be changed at least every 2 days.
48095524|NCT02286440|OTHER|Treatment as usual|
48095525|NCT05860881|DRUG|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
48095526|NCT05860881|OTHER|Placebo|Cream containing only the base, or vehicle.
48095527|NCT05826548|BEHAVIORAL|Telerehabilitation group|Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
48095528|NCT05826548|BEHAVIORAL|Conventioanl treatment group|Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
48095529|NCT02420587|DRUG|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
48095530|NCT02420587|BEHAVIORAL|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
47921924|NCT02618213|DEVICE|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
48095531|NCT04374318|DRUG|Dexmedetomidine|INTRATHECAL AND INTRAVENOUS
48095532|NCT02655653|DRUG|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
48095533|NCT02655653|DRUG|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
47921925|NCT02618213|DEVICE|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
47921926|NCT06031389|DRUG|Henagliflozin|On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.
47921927|NCT06031389|DRUG|Placebo|On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
48095534|NCT04399707|DEVICE|Transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
48095535|NCT04399707|DEVICE|Placebo transcutaneous electrical nerve stimulation (TENS) unit|Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
48095536|NCT00003543|BIOLOGICAL|monoclonal antibody A33|
47921928|NCT03137264|DRUG|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
47921929|NCT02414256|OTHER|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
48095537|NCT00003543|DRUG|carmustine|
47921930|NCT02766556|DRUG|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
47921931|NCT02766556|PROCEDURE|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
48095538|NCT00003543|DRUG|fluorouracil|
48095539|NCT00003543|DRUG|streptozocin|
48095540|NCT00003543|DRUG|vincristine sulfate|
48095541|NCT04373135|BEHAVIORAL|Brief educational video|A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
48270206|NCT05477186|BIOLOGICAL|CV0501 (200 μg)|Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
47921932|NCT02766556|DRUG|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
47921933|NCT02252341|DIETARY_SUPPLEMENT|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
48095542|NCT05367674|BEHAVIORAL|Summer Harvest Adventure|Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
48095543|NCT05367674|BEHAVIORAL|My Summer Plate (MSP)|My Summer Plate (MSP)
48095544|NCT02459964|DRUG|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
48095545|NCT02459964|DRUG|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
48095546|NCT02459964|BEHAVIORAL|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
48095547|NCT00248287|DRUG|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
48270207|NCT02148367|DRUG|Erythropoietin|"This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
48270208|NCT02050412|OTHER|Cat fur scratch test|
48270209|NCT03842995|BEHAVIORAL|Genetic Counselor|Standard of Care
47921934|NCT05002244|DRUG|CTL0801 (Azilsartan)|CTL0801 (Azilsartan), single dose, daily, repeated oral administration
48270210|NCT03842995|BEHAVIORAL|Trained Healthcare Provider|Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
47921935|NCT05002244|DRUG|CTL0802 (Rosuvastatin)|CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
48270211|NCT02863198|DEVICE|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
48270212|NCT03012581|DRUG|Nivolumab|Treatment
48270213|NCT06094101|BIOLOGICAL|Peptide vaccine IPX|"Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
48270214|NCT02186184|DEVICE|Orthokeratology|
48270215|NCT02186184|DEVICE|Spectacle|
47921936|NCT05002244|DRUG|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)|CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration
47921937|NCT04796064|OTHER|low-intensity aerobic training|"A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes."
47921938|NCT04608539|DRUG|Ferric Derisomaltose|Single-dose intravenous infusion, 20 mg/kg body weight, postoperative day 1
47921939|NCT04608539|DRUG|Ferrous sulfate|Oral therapy, 100 mg twice daily, from postoperative day 4 until 4-week follow-up
47921940|NCT04608539|DRUG|normal saline|Single-dose infusion (placebo), postoperative day 1
47921941|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
47921942|NCT01054547|DRUG|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
47921943|NCT06356480|BIOLOGICAL|1% Acetic acid dressing|1% acetic acid dressing in chronic diabetic foot and wounds to see early epithelialization and later on graft application.
48270216|NCT04892563|PROCEDURE|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
48270217|NCT04892563|DRUG|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
47921944|NCT03708887|DRUG|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year
48270218|NCT04201743|DRUG|Acellular amniotic membrane derived allograft injection (NuDYN)|Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
47921945|NCT03708887|DRUG|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
47921946|NCT03708887|DRUG|Control drug|Matching placebo capsules,3 g/d by mouth for 1 year
47921947|NCT02631993|RADIATION|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320-400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2-1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3-5 times each week.
48270219|NCT01260558|DEVICE|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
48270220|NCT01260558|DEVICE|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
48270221|NCT05448014|BEHAVIORAL|Compassion focused group therapy online|Seven sessions of therapist-led online compassion-focused therapy in groups of 4-8 adolescents with mild to moderate symptoms of distress, anxiety, or depression. Trained therapists administer the CFT program in face-to-face meetings.
48270222|NCT05949307|DEVICE|acupuncture|acupuncture
47921948|NCT04274998|DRUG|[18F]NOS|Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
47951202|NCT01982565|OTHER|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
48270223|NCT05949307|DEVICE|laser acupuncture|laser acupuncture
48270224|NCT05949307|DEVICE|Sham-laser acupuncture|Sham-laser acupuncture
48270225|NCT05777733|DRUG|n-acetylcystine|Single daily oral administration of N_acetylcystein on dose 10mg /kg/day
48270226|NCT02427113|OTHER|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
48270227|NCT02427113|OTHER|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
48270228|NCT00836550|BEHAVIORAL|Video|The participants saw a 6 minute video
48270229|NCT00836550|BEHAVIORAL|in-person HIV pre-test counseling|
48270230|NCT05105386|DEVICE|SynAir-Child|Monitor the indoor pollutants and their effect on children well being
48270231|NCT06206889|OTHER|NAS|NAS Turkish language validation will be carried out. NAS and CNSI scores will be recorded during the shifts of nurses serving patients in Level 3 intensive care units by the nurse in charge and another independent evaluator, and the correlation between the two scores will be investigated.
47921949|NCT04274998|DRUG|[11C]PBR28|Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
48270232|NCT06174350|BEHAVIORAL|Cognitive behavioral therapy|Earthquake is a process that affects the lives of many people. It is very important to evaluate the psychological state of individuals after the earthquake and take appropriate action. When studies conducted after the earthquake were examined, no study was found that evaluated the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes. For this reason, this thesis was conducted to evaluate the effect of cognitive behavioral therapy on ruminative thoughts and cognitive distortions in individuals exposed to earthquakes.
48270233|NCT06174350|OTHER|Placebo|Intervention Description not
47921950|NCT00643084|PROCEDURE|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
48270234|NCT00940004|BIOLOGICAL|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
48270235|NCT05429879|OTHER|Preferred Music Arm|Patients will choose their preferred music to be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
48270236|NCT05429879|OTHER|Classical Music Arm|A standardized playlist of copyright free classical music will be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
48270237|NCT01041248|DRUG|Tocilizumab|8mg/kg every 2 weeks i.v.
48270238|NCT06526780|PROCEDURE|Bronchscopy|Bronchscopy in critical ill children with airway diseases
48270239|NCT03023904|BIOLOGICAL|Nivolumab|Given IV
47921951|NCT00643084|PROCEDURE|standard bowel preparation|standard bowel preparation
47921952|NCT05884164|PROCEDURE|Thoracic erector spinae plane block|After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance
48270240|NCT03023904|OTHER|Laboratory Biomarker Analysis|Correlative studies
47921953|NCT05884164|PROCEDURE|Thoracic paravertebral plane block|After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
47921954|NCT00700167|BIOLOGICAL|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
48270241|NCT03151486|DRUG|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
48270242|NCT03151486|DRUG|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
48270243|NCT03151486|DRUG|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
48270244|NCT03151486|DRUG|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
48270245|NCT03151486|DRUG|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
48270246|NCT03151486|DRUG|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
48270247|NCT03151486|DRUG|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
48270248|NCT03151486|DRUG|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
48270249|NCT03151486|DRUG|Placebo|Participants will receive matching placebo in all cohorts.
47921955|NCT02385656|DRUG|Modafinil|200mg of modafinil daily for 4 weeks
47921956|NCT05659160|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
48270250|NCT02550158|PROCEDURE|Educational program EDU-MICI|
48270251|NCT01133145|PROCEDURE|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
48270252|NCT03183544|COMBINATION_PRODUCT|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
48270253|NCT02484027|DRUG|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
47921957|NCT00504946|DRUG|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose"
47921958|NCT00504946|DRUG|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
47921959|NCT00504946|DRUG|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose"
47921960|NCT00504946|DRUG|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children \> 14 years old received 10mg oral tablet once daily at bedtime
47921961|NCT00504946|DRUG|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
47921962|NCT03343353|OTHER|LED (Light Emission Diode)|LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
47921963|NCT02809716|OTHER|Biomarker Analysis|Correlative studies
48270254|NCT00000257|DRUG|0% N2O and 10% N2O|
47921964|NCT02809716|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
47921965|NCT03927378|DRUG|S-ketamine|S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
47921966|NCT03927378|DRUG|Placebo|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
47921967|NCT02678494|OTHER|Neurofeedback training|
47921968|NCT04136015|DRUG|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
48270255|NCT00000257|DRUG|0% N2O and 20% N2O|
48270256|NCT00000257|DRUG|0% N2O and 30% N2O|
47921969|NCT02212600|OTHER|Observational|observational cohort of proximal humerus fractures
47921970|NCT01139008|DRUG|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
48270257|NCT00000257|DRUG|0% N2O and 40% N2O|
47921971|NCT01139008|DRUG|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
47921972|NCT00974584|DRUG|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\\n\\n\\n\\n\\n\\n
47921973|NCT00974584|DRUG|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
47921974|NCT00974584|DRUG|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter\*minute (mg/mL\*min).\\n
47921975|NCT00974584|DRUG|cisplatin|Cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of every 3-week cycle.\\n
48270258|NCT03311256|DIAGNOSTIC_TEST|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
48270259|NCT04350333|BEHAVIORAL|CBT-I|Strategies and techniques of Cognitive behavioral therapy for insomnia adapted for pregnant women: stimulus control; sleep hygiene; sleep restriction; cognitive control etc.
48270260|NCT04350333|BEHAVIORAL|Assertive communication training|Intervention based on improving assertive communication and regulating emotions.
48270261|NCT04917770|DRUG|Sintilimab in combination with Multimodality Radiotherapy|Participants will be treated with sintilimab in combination with multimodality radiotherapy
48270262|NCT00286052|DRUG|Low Dose Naloxone|
47921976|NCT00974584|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of every 3-week cycle.\\n\\n
47921977|NCT00974584|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 IV on Day 1 of every 3-week cycle.
47921978|NCT02156271|DRUG|ramelteon|
47921979|NCT02156271|DRUG|placebo|
47921980|NCT01499368|DRUG|Lafutidine|Lafutidine 20mg/day
47921981|NCT01499368|DRUG|Famotidine|Famotidine 40mg/day
47921982|NCT01499368|DRUG|Omeprazole|Omeprazole 20mg/day
47921983|NCT02547961|BIOLOGICAL|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
47921984|NCT04494100|PROCEDURE|TRONC|injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
47921985|NCT04494100|PROCEDURE|WALANT|infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
47921986|NCT04494100|PROCEDURE|Tourniquet|inflation pressure 75 to 100 mmHg above systolic blood pressure.
47921987|NCT04494100|DRUG|Ropivacaine|troncular blocks with Ropivacaine 3.75 mg/ml
47921988|NCT04494100|DRUG|Lidocaine + Epinephrine|WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
48270263|NCT04325477|DEVICE|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
48270264|NCT00372892|DRUG|Rituximab|375mg/m2 per week for 4 consecutive weeks
48270265|NCT00372892|DRUG|Placebo|Saline IV placebo once per week for 4 consecutive weeks
48270266|NCT03013465|OTHER|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
48270267|NCT03013465|OTHER|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
48270268|NCT01871792|DRUG|Pitavastatin|
48270269|NCT01871792|DRUG|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
48270270|NCT04323930|DEVICE|eyeWatch|The eyeWatch system will be implanted as per the manufacturer's instruction, and trabeculectomy will be performed using mitomycin C as per standard surgical protocols.
48270271|NCT02412280|OTHER|retrospecive observational|
47921989|NCT02224248|BEHAVIORAL|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
48270272|NCT01250821|DRUG|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
48270273|NCT00697996|DRUG|Rituximab for transplant rejection|
48270274|NCT00382967|PROCEDURE|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
48270275|NCT03313960|DRUG|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
47921990|NCT02224248|BEHAVIORAL|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
47921991|NCT00718588|DRUG|MTRX1011A|Subcutaneous and intravenous single and repeating dose
48270276|NCT03313960|OTHER|"One Drop | Premium"|"Participants in this group will receive One Drop \| Premium (i.e., One Drop \| Experts in-app CDE coaching with the One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months)."
47921992|NCT06431867|OTHER|Guidelines for primary care management of osteoporosis|All usual care of osteoporosis in primary care
48270277|NCT01015508|OTHER|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
48270278|NCT01015508|OTHER|Weight maintenance|10 months
48270279|NCT02958943|BEHAVIORAL|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
48270280|NCT02876978|GENETIC|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
48270281|NCT02876978|DRUG|Fludarabine|30 mg/m\^2/day x 4 days
48270282|NCT02876978|DRUG|Cyclophosphamide|500 mg/m\^2/day x 2 days
48270283|NCT00749333|DRUG|AZD8566|solution. Specific dose will be selected by the safety review committee
48095548|NCT00248287|DRUG|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
48095549|NCT02688361|DRUG|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
48095550|NCT02688361|DRUG|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
48095551|NCT04927052|DEVICE|Revanesse Shape + with Lidocaine|Revanesse Shape + with Lidocaine. Participants had 1 cheek treated with Revanesse Shape + with Lidocaine
48095552|NCT04927052|DEVICE|Juvederm Voluma with Lidocaine.|Juvederm Voluma with Lidocaine. Participants had 1 cheek treated with Juvederm Voluma with Lidocaine
48095553|NCT03031639|PROCEDURE|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
48095554|NCT02998489|OTHER|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
48095555|NCT02998489|OTHER|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
48095556|NCT06546449|DRUG|LH-001|LH-001 will be administered oral
48095557|NCT06546449|DRUG|Placebo|Placebo will be administered oral
48270284|NCT00749333|DRUG|Placebo|Single 10ml oral solution.
48270285|NCT00686556|DRUG|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
48270286|NCT00686556|DRUG|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
48270287|NCT00686556|DRUG|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
48270288|NCT00686556|DRUG|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients \<40 kg, 3 gm/day for patients \>40 kg.
48270289|NCT00686556|RADIATION|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
48270290|NCT00686556|PROCEDURE|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
48095558|NCT05247489|DRUG|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied twice a day (BID).
48270291|NCT00686556|BIOLOGICAL|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10\^9/L for 3 consecutive days.
48270292|NCT00686556|BIOLOGICAL|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
48270293|NCT01743573|OTHER|yoga|
48270294|NCT03409822|DEVICE|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
48270295|NCT01622426|DIETARY_SUPPLEMENT|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
48270296|NCT01622426|DIETARY_SUPPLEMENT|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
47921993|NCT05056428|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
47921994|NCT04202042|OTHER|Psychological first aid|PFA responders (peer support workers) are trained to deliver 8 core actions: contact and engagement, safety and comfort, stabilization, information gathering, practical assistance, connection with social supports, information on coping, and linkage with collaborative services
47921995|NCT04202042|OTHER|Usual organisational intervention|Emergency intervention by workplace psychologist and limited therapeutic sessions with employee aid program
48270297|NCT01990157|DRUG|TAB08|Weekly intravenous administration in escalating doses.
47921996|NCT04143308|OTHER|Simultaneous training of walking and cognitive group|"Device:~1. SWATCH system (App \& controller)~2. Wearable technology Fitness wristband \& APP"
48270298|NCT00516594|PROCEDURE|Diet with polyfructans and viscous fibers or soy protein|
48270299|NCT04768582|DIAGNOSTIC_TEST|P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay|The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
48270300|NCT03097380|DRUG|AZD2115|AZD2115
47921997|NCT04143308|OTHER|Cognitive training group|"Device:~1. SWATCH system (App)~2. Wearable technology Fitness wristband \& APP"
47921998|NCT04143308|OTHER|Treatment as usual group|Keep treatment as usual
48270301|NCT03097380|DRUG|SPIRIVA|Tiotropium
47921999|NCT04871191|DRUG|Rituximab|375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
47922000|NCT04871191|DRUG|Tocilizumab|Subcutaneous injection of 162 mg per week
48270302|NCT03097380|RADIATION|[11C]AZ13754366|Radioligand
48270303|NCT04329026|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
48270304|NCT04329026|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
48270305|NCT01126580|DRUG|Metformin|
48270306|NCT01126580|DRUG|LY2189265|
48270307|NCT01126580|DRUG|Placebo (oral)|
48270308|NCT01126580|DRUG|Placebo (subcutaneous)|
48270309|NCT05936762|DEVICE|Neoial HC|Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
48270310|NCT05863715|BEHAVIORAL|Visual Search Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
48270311|NCT05750992|PROCEDURE|surgical TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
48270312|NCT05750992|PROCEDURE|US guided TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
48270313|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP|
48270314|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FePP + Stabilizer|
47922001|NCT04871191|DRUG|Abatacept|Subcutaneous injection of 125 mg per week
47922002|NCT00951613|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
48270315|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4|
48270316|NCT02327299|DIETARY_SUPPLEMENT|Bouillon fortified with FeSO4 + Stabilizer|
48270317|NCT00355264|DRUG|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
48443552|NCT01543217|OTHER|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
48443553|NCT01543217|OTHER|Ususal care|Routine respiratory care.
48270318|NCT01516827|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
47922003|NCT01457352|DRUG|SPARC0921|
48270319|NCT01365156|PROCEDURE|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
48270320|NCT01365156|RADIATION|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
47922004|NCT01457352|DRUG|Placebo0921|
47922005|NCT06392373|DIETARY_SUPPLEMENT|CHO+PRO|0.9 g CHO/kg/hr + 0.3 g PRO/kg/hr
47922006|NCT06392373|DIETARY_SUPPLEMENT|CHO|1.2 g CHO/kg/hr
47922007|NCT06058208|BEHAVIORAL|Olfactory stimulation|Olfactory stimulation: Mothers will be made to smell their babies' odor.
47922008|NCT06058208|BEHAVIORAL|Visual stimulation|Mothers will be shown video images of their babies.
47922009|NCT02900989|BEHAVIORAL|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
47922010|NCT01410344|DRUG|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m\^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~* Days -6 to -2: Flu (30 mg/m\^2/day, total dose of 150 mg/m\^2)~* Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m\^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m\^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
47922011|NCT01410344|DRUG|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m\^2, Melphalan total dose: less than or equal to 150 mg/m\^2. Recommended regimen:~* Days -5 to -2: Flu (30mg/m\^2/day, total dose of 120 mg/m\^2)~* Day -1: Mel (140mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
47922012|NCT01410344|DRUG|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m\^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~* Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m\^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively)~* Days -5 to -2: Flu (30 mg/m\^2/day, total dose of 120 mg/m\^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
47922013|NCT01410344|DRUG|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~* Days -7 to -4: TBI (total dose of 1200-1420 cGy)~* Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
47922014|NCT01812447|DEVICE|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
47922015|NCT01812447|OTHER|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
47922016|NCT02679963|DRUG|Olaparib|
47922017|NCT02679963|DRUG|Placebo|
47922018|NCT04251676|OTHER|Observational study|Observational study
47922019|NCT05022667|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
47922020|NCT06130683|OTHER|Single-cell sequencing|Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.
47922021|NCT02395172|DRUG|Avelumab|Participants received 10 milligrams per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
47922022|NCT02395172|DRUG|Docetaxel|Participants received 75 mg per square meter (m\^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or Investigational Medicinal Product (IMP) as defined in the study protocol was fulfilled.
47922023|NCT06393335|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
47922024|NCT04220476|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
47922025|NCT04220476|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
47922026|NCT04220476|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
47922027|NCT06437444|BEHAVIORAL|The implementation strategy to encourage the adoption of the Care Pathway|"1. Dissemination of the most novel aspects of the agreed Care Pathway via corporate mail.~2. Audit \& Feedback (A\&F) data reports, sent every two weeks, to each paediatrician on the rate of prescription of bronchodilators administered with a spacer chamber, together with the rates of the other indicators established in the pathway, in their health centre and in the rest of the centres in the participating health areas.~3. Interactive training sessions, in which epidemiological data and data on the health, economic and social impact of asthma attacks were presented, together with data on other indicators associated with the care pathway, and key messages on current treatment recommendations based on the latest clinical practice.~4. Distribution of reminder posters in paediatrics consultations, PEDs and health centers."
47922028|NCT02642497|DRUG|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
47922029|NCT02642497|DRUG|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
47922030|NCT02642497|DRUG|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
47922031|NCT03371888|BIOLOGICAL|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
47922032|NCT03371888|BIOLOGICAL|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
47922033|NCT03496779|DRUG|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
47922034|NCT03496779|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
48443554|NCT01887548|OTHER|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
48443555|NCT03239314|DRUG|Saline Solution|Injected in the adductor canal
48443556|NCT03239314|DRUG|Dexamethasone|Injected in the adductor canal
47922035|NCT03496779|DRUG|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
47922036|NCT03496779|PROCEDURE|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
47922037|NCT04284462|OTHER|Flavored carbonated soft drink (CSD)|1-2 cans/day (330 ml per can)
47922038|NCT02184572|BIOLOGICAL|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
47922039|NCT02184572|BIOLOGICAL|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
47922040|NCT02184572|BIOLOGICAL|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
47922041|NCT02184572|BIOLOGICAL|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
47922042|NCT02184572|BIOLOGICAL|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
47922043|NCT01606215|DRUG|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
47922044|NCT01606215|DRUG|Placebo|Placebo
47922045|NCT04546828|DRUG|Gemcitabine, Cisplatin, and Nab-Paclitaxe|"* Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:~* Gemcitabine 800 mg/m2 in 500ml over 30 minute IV infusion on days 1 and 8 repeated every 21 days ."
47922046|NCT04085939|OTHER|Online survey|Anonymous survey using the online survey tool, JotForm
47922047|NCT02415842|OTHER|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
47922048|NCT06531967|OTHER|No intervention|No intervention
47922049|NCT02750020|OTHER|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
47922050|NCT01671579|PROCEDURE|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
48443557|NCT01354418|DRUG|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
48443558|NCT01354418|DRUG|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
48443559|NCT03133637|DRUG|ceftriaxone|Eligible infants will receive ceftriaxone as standard of care for sepsis
48443560|NCT00937898|DIETARY_SUPPLEMENT|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
48443561|NCT00937898|DIETARY_SUPPLEMENT|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
47922051|NCT01671579|PROCEDURE|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
47922052|NCT02909387|BEHAVIORAL|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
47922053|NCT05901844|DIAGNOSTIC_TEST|Paraffin pathological diagnosis|Perform two diagnostic methods on the same sample
47922054|NCT00187603|BEHAVIORAL|tobacco cessation program|
47922055|NCT05090319|DIAGNOSTIC_TEST|complete blood count|Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.
47922056|NCT01956344|BEHAVIORAL|Cognitive Behavioral Therapy|Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
47922057|NCT01414348|BEHAVIORAL|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
47922058|NCT01414348|BEHAVIORAL|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
47922059|NCT01009372|BEHAVIORAL|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
47922060|NCT01816945|BEHAVIORAL|MOMBA web-based application|Web-based, interactive, social network application.
47922061|NCT01835509|BEHAVIORAL|Intervention, Camp plus reunions|
47922062|NCT03314571|OTHER|analgesia for labor|A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
47922063|NCT01764191|OTHER|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
47922064|NCT00543244|DRUG|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: \< 75 kg 1000 mg/day, \>=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
47922065|NCT02321670|PROCEDURE|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
47922066|NCT02321670|PROCEDURE|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
47922067|NCT00575341|DRUG|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
47922068|NCT00575341|DRUG|placebo|placebo, oral, once daily
47922069|NCT00510653|DRUG|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
47922070|NCT01794338|DEVICE|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
47922071|NCT01794338|DEVICE|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
47922072|NCT05170867|DIETARY_SUPPLEMENT|Hafnia alvei HA4597™|One capsule of probiotic supplement, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the dietary supplement contain 5x107 CFU of Hafnia alvei HA4597™, 5 mg of zinc and 20 μg of chromium.
47922073|NCT05170867|OTHER|Placebo|One capsule of placebo, twice a day, to be taken with water, during each breakfast and lunch (approx. 5 minutes after starting eating), for 90 days. Two capsules of the placebo contain 5 mg of zinc and 20 μg of chromium.
47922074|NCT01989468|BIOLOGICAL|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
47922075|NCT01989468|BIOLOGICAL|Placebo|Secukinumab placebo provided in 1 mL autoinjector
47922076|NCT02285036|BIOLOGICAL|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
47922077|NCT02285036|BIOLOGICAL|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
47922078|NCT02816827|DIETARY_SUPPLEMENT|AG-01|Product to increase mental alertness
47922079|NCT02816827|DIETARY_SUPPLEMENT|AG-05|Product to increase mental alertness
47922080|NCT02816827|DIETARY_SUPPLEMENT|AG-06|Product to increase mental alertness
47922081|NCT02816827|DIETARY_SUPPLEMENT|AG-07|Product to increase mental alertness
47922082|NCT03541915|DRUG|Mg (magnesium sulfate)|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
47922083|NCT03541915|DRUG|Control (saline)|The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
47922084|NCT02329340|BEHAVIORAL|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
47922085|NCT02329340|BEHAVIORAL|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
47922086|NCT02600819|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
47922087|NCT02600819|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
47922088|NCT01643772|DRUG|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
47922089|NCT05539989|BIOLOGICAL|VPM1002 Vaccine|0.1 mL (2-8x10\^5 CFU)
47922090|NCT05539989|BIOLOGICAL|BCG Vaccine|0.1mL (0.075 Mycobacterium bovis)
47922091|NCT05539989|DRUG|Placebo|0.1 mL (sodium chloride for injection 0.9%)
47922092|NCT00511940|DRUG|acamprosate|999 mg/day - 2997 mg/day, oral
47922093|NCT00511940|OTHER|placebo|oral, placebo
47922094|NCT00464971|DRUG|estradiol, 25 mcg|
47922095|NCT01049009|DRUG|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
47922096|NCT01049009|DRUG|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
47922097|NCT00005815|DRUG|temozolomide|
47922098|NCT00005815|DRUG|thalidomide|
47922099|NCT02338232|DRUG|Telmisartan|
47922100|NCT02511223|DRUG|OLAPARIB|Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
47922101|NCT00935155|PROCEDURE|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
47922102|NCT00935155|PROCEDURE|exercises|Coordination, mobilizing, endurance, strength
47922103|NCT00167492|DRUG|Myfortic|720 mg by mouth every 12 hours
47922104|NCT00740935|BIOLOGICAL|Rotateq vaccine|"Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose."
47922105|NCT02453815|PROCEDURE|non-cardiac surgery|all surgical procedures except cardiac
47922106|NCT02453815|OTHER|arterial catheter|arterial catheter
47922107|NCT05907941|DEVICE|ciNPT|Following closure of the abdominal donor site, the closed incision will be dressed with the ciNPT system \[V.A.C.ULTA™ Negative Pressure Wound Therapy System (KCI, USA)\] applied by the operating surgeon in a sterile fashion (Figure 2). The ciNPT device will be set at -125mmHg of continuous negative pressure for a period of 7 days or until patient discharge from hospital. Removal of the ciNPT dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied to the abdominal incision unless clinically indicated secondary to dehiscence.
47922108|NCT05907941|OTHER|Conventional Tape Dressings|Following closure of the abdominal donor site, the closed abdominal incision will be dressed with 1-inch Micropore™ Surgical Tape (3M, USA) with an alcohol swab applied to the tape for additional adhesion, by the operating surgeon in a sterile fashion. This dressing will remain in-situ for up to 7 days or until patient discharge from hospital. Removal of the traditional tape dressing will be performed by the surgical team at the time of discharge. Following removal, no additional dressings will be applied unless clinically indicated secondary to dehiscence.
47922109|NCT05907941|PROCEDURE|DIEP Breast Reconstruction|All patients enrolled in the study will undergo DIEP breast reconstruction and have their abdominal incision sutured according to routine clinical practice. At the Hamilton sites, we will use 3-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 4-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 5-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure. At the London sites, we will use 2-0 VICRYL ® suture (Ethicon, USA) for deep fascia closure, 3-0 MONOCRYL® suture (Ethicon, USA) for deep dermal closure, and 4-0 MONOCRYL® suture (Ethicon, USA) for subcuticular closure.
47922110|NCT04175990|DRUG|Dydrogesterone Pill|started from day 1 of menses till trigger day
47922111|NCT03488511|OTHER|FoodforCare at home|Six small protein rich meals that will be delivered twice a week for 3 weeks.
47922112|NCT05446337|OTHER|Open-Ended Semi-Structured Interview|Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
47922113|NCT04332861|OTHER|Initial clinical and laboratory evaluation|"Initial evaluation, prior to administration of any antibiotics if possible, includes history, physical exam, and labs including:~* Urinalysis~* Urine culture~* Blood cultures~* Complete blood count with differential~* Comprehensive metabolic panel~* Lactate~* Procalcitonin~* Other inflammatory markers"
48270321|NCT05435820|DEVICE|Near-infrared Transcranial Laser Therapy|The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
48270322|NCT02530645|BEHAVIORAL|OnTrack|
48443562|NCT02632344|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
47922114|NCT03860818|OTHER|Health services delivery|Technology-enabled pharmacist intervention
47922115|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
47922116|NCT00941629|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
47922117|NCT03698344|OTHER|Biodiesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
47922118|NCT00749710|PROCEDURE|clopidogrel|ORIF - surgical treatment
47922119|NCT00749710|PROCEDURE|no antiaggregant therapy|ORIF - surgical treatment
47922120|NCT03268421|BEHAVIORAL|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
47922121|NCT03268421|BEHAVIORAL|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
47922122|NCT03268421|BEHAVIORAL|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
48270323|NCT02530645|BEHAVIORAL|Treatment as Usual|
48270324|NCT02530645|BEHAVIORAL|Brief Motivational Interviewing|
48270325|NCT02670603|DRUG|EVONAIL® solution|
48270326|NCT00151892|DRUG|SPD476|2.4 g/day Once Daily (QD)
48270327|NCT00151892|DRUG|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
48270328|NCT02371850|DRUG|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
48270329|NCT06428214|DEVICE|Restylane Shaype|Injection
47922123|NCT04253054|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
47922124|NCT04253054|OTHER|Aging related health problems|Aging related health problems
47922125|NCT05942781|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.
47922126|NCT05942781|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
47922127|NCT00327821|BEHAVIORAL|calorie controlled diet|
47922128|NCT03219658|BEHAVIORAL|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
47922129|NCT03316911|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
47922130|NCT00076453|DEVICE|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
47922131|NCT00076453|DEVICE|Standard orthotic shoe inserts|Neutral orthotic inserts
47922132|NCT06518434|DRUG|Medical Cannabis|Medical cannabis oil three times daily
48270330|NCT06428214|DEVICE|Restylane Defyne|Injection
47922133|NCT01022398|DRUG|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
47922134|NCT04668027|DIAGNOSTIC_TEST|impulse oscillation（IOS）|The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
47922135|NCT04668027|DIAGNOSTIC_TEST|bronchial provocation test(BPT)|Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
47922136|NCT04668027|DIAGNOSTIC_TEST|bronchial dilation test(BDT)|The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
47922137|NCT05246865|DRUG|oral androgen challenge with dehydroepiandrosterone (DHEA)|The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
47922138|NCT00118456|DRUG|AEE788|
47922139|NCT01336400|OTHER|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
47922140|NCT02968056|PROCEDURE|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
47922141|NCT04750616|DRUG|Niacinamide|Niacinamide 3 grams on the day of surgery and post-surgical days one and two
47922142|NCT04750616|DRUG|Placebo|Matched placebo on the day of surgery and post-surgical days one and two
47922143|NCT05761795|DRUG|IVMED 85|Eye drop
47922144|NCT05761795|DRUG|Placebo|Placebo eye drop
47922145|NCT04806867|OTHER|SePaRIC-Covid19 cohort|All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
47922146|NCT03820440|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
47922147|NCT03820440|DIAGNOSTIC_TEST|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
47922148|NCT02551510|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique
47922149|NCT02551510|DEVICE|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n-Butyl-2-Cyanoacrylate Monomer)
47922150|NCT06297785|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8 sessions), will be given online in a group setting.The hypnosis treatment is administered by a nurse specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment is based on the North Carolina protocol. Patients will assess gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
48270331|NCT06428214|DEVICE|Restylane Lyft lidocaine|Injection
48270332|NCT00546364|DRUG|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
48443563|NCT03620591|DRUG|Lidocaine|Intraoperative administration of lidocaine
47922151|NCT06171841|OTHER|low-intensity resistance training|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions performed twice a week for 6 weeks.
47922152|NCT06171841|OTHER|high-intensity resistance training|4 sets of 10 repetitions of leg press exercise at 70-80% one-repetition maximum (weeks 1-3: 70%, weeks 4-6: 80%) in normoxic conditions performed twice a week for 6 weeks.
47922153|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normoxic conditions with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
47922154|NCT06171841|OTHER|low-intensity resistance training in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in hypoxia conditions (3500 meters above sea) performed twice a week for 6 weeks.
48270333|NCT00546364|DRUG|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
48270334|NCT00546364|DRUG|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
48270335|NCT01989221|DRUG|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
48270336|NCT04375306|PROCEDURE|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
48270337|NCT04375306|PROCEDURE|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
47922155|NCT06171841|OTHER|low-intensity resistance training combined with blood flow restriction in hypoxia condition|4 sets of 30/15/15/15 repetitions of leg press exercise with a load of 20-30% of one-repetition maximum (weeks 1-3: 20%, weeks 4-6: 30%) in normobaric hypoxia conditions (3500 meters above sea) with lower-limbs blood flow restriction (80% total occlusion pressure) performed twice a week for 6 weeks.
47922156|NCT02631473|DRUG|50mg NANO-efavirenz|OD
47922157|NCT02631473|DRUG|400mg NANO-Lopinavir|BID
47922158|NCT02631473|DRUG|200mg NANO-Lopinavir|BID
47922159|NCT02631473|DRUG|100mg Ritonavir|BID
47922160|NCT02631473|DRUG|300mg NANO-Efavirenz|OD
47922161|NCT02631473|DRUG|600mg Sustiva|OD
47922162|NCT02631473|DRUG|200mg NANO-Efavirenz|OD
47922163|NCT02631473|DRUG|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
47922164|NCT02631473|DRUG|+/- 200mg NANO-Lopinavir|BID
47922165|NCT02631473|DRUG|+/- 200mg ritonavir NORVIR|BID
47922166|NCT02631473|DRUG|400mg Sustiva|
47922167|NCT04264832|OTHER|Clinical data collection|"Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life ."
47922168|NCT00675467|BEHAVIORAL|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
47922169|NCT00675467|BEHAVIORAL|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
47922170|NCT00551928|DRUG|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
47922171|NCT00551928|DRUG|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
48270338|NCT01148173|DRUG|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
48270339|NCT03011645|DRUG|Ziprasidone|Given by mouth, single dose of 60 mg.
47922172|NCT00551928|DRUG|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
47922173|NCT00551928|DRUG|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
47922174|NCT05919706|BEHAVIORAL|Patient Education with Game-Based Mobile Technology and Motivational Interviewing|Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
48095559|NCT05247489|DEVICE|NB-UVB phototherapy|NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit
48270340|NCT03011645|DRUG|Lorcaserin|Given by mouth, single dose of 20 mg.
48270341|NCT03011645|DRUG|Placebo Oral Tablet|Given by mouth, single dose.
48443564|NCT03620591|DRUG|Placebo|Intraoperative administration of normal saline
48443565|NCT03514017|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
48443566|NCT03514017|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
48443567|NCT01644058|PROCEDURE|Immediate loading|
48443568|NCT06373185|PROCEDURE|Ultrasound-guided sacral erector spinae plane block|Patients were received ultrasound-guided sacral erector spinae plane block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
47922175|NCT01689493|BEHAVIORAL|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
47922176|NCT04938297|DRUG|Rituximab, Lenalidomide, Zanubrutinib|Induction therapy: Rituximab 375 mg / m2, day 1, Zanubrutinib 160 mg bid, orally, Lenalidomide 25mg QD, orally on day 1-21, 28 days as a course of treatment, 8 courses of treatment.
47922177|NCT04938297|DRUG|Lenalidomide, Zanubrutinib|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) or Zanubrutinib 160 mg bid. Continuously use for 2 years or until disease progression
47922178|NCT04938297|DRUG|Lenalidomide|Maintenance therapy: Lenalidomide: 25mg qd (adjusted according to hectogram condition) . Continuously use for 2 years or until disease progression
47922179|NCT02345564|DEVICE|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
47922180|NCT05286645|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
47922181|NCT05286645|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
47922182|NCT06073145|DEVICE|conventional transcranial Doppler probe and wearable ultrasound patch.|Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
47922183|NCT00629967|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
47922184|NCT00629967|DRUG|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
48270342|NCT00834015|OTHER|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
47922185|NCT00835029|DRUG|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
47922186|NCT00835029|DRUG|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
47922187|NCT04320758|OTHER|conventional preparation design|chamfer finish line
47922188|NCT04320758|OTHER|biologically oriented preparation technique|shoulder less preparation design
47922189|NCT03159260|DEVICE|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
47922190|NCT03159260|OTHER|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
47922191|NCT05402605|PROCEDURE|ICSI with AOA|"Step 1: All post-ICSI oocytes will be added in the medium drop in AOA dish, these oocytes will be placed in the incubator at 37oC, 6% CO2, and 5% O2 for 20 minutes.~Step 2: After 20 minutes, calcium ionophore stock (Sigma-Aldrich - USA) will be diluted into 10µM drops in AOA dish.~Step 3: After 10 minutes of incubation, all post-ICSI oocytes will be moved to the AOA drop, then this dish will be put back in the incubator for 10 minutes.~Step 4: After 10 minutes, all the oocytes in drop AOA will be moved to another drop for rinsing and then put back in the incubator for 20 minutes.~Step 5: After 20 minutes, the oocytes will be moved into drop AOA and then put back in the incubator for 10 minutes.~Step 6: After 10 minutes, all post-ICSI oocytes will be added in the medium drop, then divided into drops with maximum 3 oocytes per drop for culturing. After that, the culture dish will be put in the K-system G185 incubator at 37oC, 6% CO2, and 5% O2"
48270343|NCT02984800|OTHER|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
48270344|NCT02984800|OTHER|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
47922192|NCT05402605|PROCEDURE|ICSI without AOA|Conventional ICSI procedure will be performed without the application of AOA.
47922193|NCT02711241|DRUG|Dipyrone|1 gram by slow IV infusion
47922194|NCT02711241|DRUG|Papaverine|80 mg by slow intravenous infusion
47922195|NCT05272345|PROCEDURE|sexual therapy|In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month.
47922196|NCT03936231|OTHER|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
47922197|NCT03153384|PROCEDURE|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
47922198|NCT02862756|OTHER|diffusion-weighted MRI and clinical examination|
47922199|NCT04185597|OTHER|HFP Intervention: Delivered by Community Farmers|Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services
47922200|NCT04185597|OTHER|HFP Intervention: Delivered by agricultural Retailers|HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services
47922201|NCT04185597|OTHER|Control|Current Standard of Practice
47922202|NCT01056302|PROCEDURE|Surgical repair of mandibular fractures|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated surgical outcome using the proposed software tool.
48270345|NCT02984800|OTHER|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
48270346|NCT02029742|BEHAVIORAL|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
48270347|NCT02029742|BEHAVIORAL|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
48270348|NCT03598907|OTHER|Fresh frozen plasma|Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
48443569|NCT06373185|PROCEDURE|Ultrasound-guided caudal block|Patients were received ultrasound-guided caudal block, 1ml/kg %0.25 bupivacaine (max 20 ml), for postoperative pain management
47922203|NCT05977738|DRUG|Pitavastatin calcium|Daily Pitavastatin administration
47922204|NCT01297777|DRUG|Imatinib Mesylate|"* In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~* In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
47922205|NCT06086197|DRUG|Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin|"Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator."
47922206|NCT02102659|GENETIC|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
47922207|NCT02102659|GENETIC|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
47922208|NCT02906982|OTHER|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
47922209|NCT02906982|OTHER|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
47922210|NCT04040322|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
47922211|NCT04040322|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
47922212|NCT04129151|DRUG|Palbociclib|Oral, per protocol pre determined dosage, once a day for 21 days
48270349|NCT04194060|COMBINATION_PRODUCT|Enhanced Recovery after Surgery group|"* Tracheal intubation and with General anesthesia~* Short acting anesthetic agents,avoid opioid agents~* Omental patch repair with placement of sub hepatic drain~* Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~* Post operative nausea and vomiting prophylaxis.~* Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~* Initiation of feeding-Oral sips on day 1, step up day 2 onward~* Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~* Removal of urinary catheter-after weaning from the effect of general anesthesia.~* Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~* Avoid opiod analgesics."
47922213|NCT04129151|DRUG|Ganitumab|-Intravenous, per protocol predetermined dosage, twice per cycle
47922214|NCT00114790|RADIATION|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
47922215|NCT03534479|DRUG|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
47922216|NCT03968640|DIETARY_SUPPLEMENT|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
47922217|NCT03968640|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
47922218|NCT00717236|DRUG|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
47922219|NCT00717236|OTHER|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
47922220|NCT01030640|OTHER|placebo|single dose of the drug formulation
48270350|NCT04194060|COMBINATION_PRODUCT|Conventional|"Tracheal intubation~* Short acting anesthetic agents, avoid opiod anesthesia agents.~* Omental patch repair along with sub hepatic drain placement.~* Post operative nausea and vomiting prophylaxis.~* Ambulation-as per patients' own request.~* Initiation of oral feed- after passage of 1st flatus.~* Nasogastric tube removal-output \<300ml/day with resolution of ileus.~* Removal of urinary catheter- when patient sits on bed side/ambulate.~* Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~* Patient will receive opiod analgesics."
47922221|NCT01030640|BIOLOGICAL|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
47922222|NCT00883688|DRUG|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
47922223|NCT00883688|DRUG|Lapatinib|Pills of 700 mg/m\^2/dose given orally 2 times each day.
48095560|NCT02741479|OTHER|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
48095561|NCT00003195|BIOLOGICAL|recombinant interferon alfa|
48095562|NCT00003195|DRUG|busulfan|
48270351|NCT02423096|DRUG|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
47922224|NCT03014999|DEVICE|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
47922225|NCT03014999|DEVICE|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
47922226|NCT03014999|DEVICE|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
47922227|NCT01700387|DRUG|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
47922228|NCT01700387|DRUG|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
47922229|NCT01700387|DRUG|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
47922230|NCT03820739|OTHER|Follow-up|No investigational vaccine will be administered during this study
47922231|NCT03820739|OTHER|Blood sample collection|Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
47922232|NCT06250335|OTHER|Prebiotic Food-Enriched Diet|Given by PO
47922233|NCT06250335|DRUG|Ipilimumab|Given by IV
47922234|NCT06250335|DRUG|Nivolumab|Given by IV
47922235|NCT03118908|DIETARY_SUPPLEMENT|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
47922236|NCT03118908|DIETARY_SUPPLEMENT|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
47922237|NCT03118908|DIETARY_SUPPLEMENT|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
47922238|NCT03908489|PROCEDURE|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
47922239|NCT03908489|PROCEDURE|vital pulpotomy using mta|mta vital pulpotomy
47922240|NCT05330884|BIOLOGICAL|BCG vaccine|0.1ml BCg vaccine to be given intradermally
47922241|NCT05330884|DRUG|Oral Chemoprophylaxis|Oral chemoprophylaxis will be standard of care - either 6 months of Isoniazid or 3 months of weekly Isoniazid and Rifapentine
47922242|NCT04598191|DRUG|Iloprost|"Participants in Iloprost group will be administered aerosolized 20 μg iloprost in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
47922243|NCT04598191|DRUG|Control (Normal saline)|"Participants in Control group will be administered aerosolized 5 ml of normal saline in 15 min through a nebulizer connected to the inspiratory limb of the respiratory system when the internal mammary artery harvesting is done."
48270352|NCT03898635|DRUG|Linezolid|To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
48270353|NCT03807531|DEVICE|Temporary Spur Stent System|Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
48270354|NCT00208637|BEHAVIORAL|moderate carbohydrate, high protein diet (MCHP)|
48270355|NCT00208637|BEHAVIORAL|high carbohydrate-high fibre (HCHF) diet|
48095563|NCT00003195|PROCEDURE|allogeneic bone marrow transplantation|
48270356|NCT03155646|DRUG|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
48270357|NCT03155646|DRUG|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
48270358|NCT03155646|DRUG|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
48270359|NCT04675047|OTHER|no intervention for healthy control|observational study - no intervention
48270360|NCT00540891|DRUG|ALFUZOSIN|
48270361|NCT04760184|OTHER|Autologous stem cell transplantation|The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
47922244|NCT00628043|DRUG|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
47922245|NCT00628043|DRUG|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
47922246|NCT01733303|BEHAVIORAL|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
47922247|NCT05324904|DRUG|Vitamin D|"- Vitamin D~* The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~* Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts \> 10 mm need multiple injections at different sites)~* Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions"
47922248|NCT05324904|DRUG|acyclovir|"-Acyclovir~* Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~* After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~* Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions"
47922249|NCT02656225|DRUG|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
47922250|NCT02656225|DRUG|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
47922251|NCT06481280|DIETARY_SUPPLEMENT|Test Formula|Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.
47922252|NCT06481280|DIETARY_SUPPLEMENT|Placebo Formula|Infants will receive a placebo formula during the DBPCFC to compare against the test formula.
47922253|NCT01757145|DRUG|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count \< 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count \>50,000/microliter will be reached again)."
47922254|NCT02081066|OTHER|cardiovascular risk factors|
47922255|NCT00446680|DRUG|Mannitol|400mg BD for 6 months followed by a 6 month open label period
47922256|NCT00446680|DRUG|placebo|placebo BD for 6 months
47922257|NCT00178776|BEHAVIORAL|Transtheoretical Model Group Therapy|
47922258|NCT00178776|BEHAVIORAL|Education & Advice|
47922259|NCT01677429|DEVICE|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
47922260|NCT01677429|DEVICE|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
48270362|NCT01880307|DRUG|Azathioprine|
48270363|NCT01880307|DRUG|Infliximab|
47922261|NCT01677429|BEHAVIORAL|Cognitive Behavioral Therapy|For the treatment of panic disorder
47922262|NCT00491088|DEVICE|CPAP|CPAP for 12 weeks
47922263|NCT01717833|PROCEDURE|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
47922264|NCT01717833|PROCEDURE|Sham|Sham sessions of neuromuscular electrical stimulation
47922265|NCT05873166|OTHER|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point|Bilateral pressure release in Flexor Brevis Digitorum in subjects with latent trigger point
47922266|NCT05873166|OTHER|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
47922267|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
47922268|NCT01502215|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
47922269|NCT03680846|DEVICE|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
47922270|NCT03680846|OTHER|CMM|Conventional Medical Management
47922271|NCT02208063|DRUG|Telavancin|
47922272|NCT02208063|DRUG|Vancomycin|
47922273|NCT02208063|DRUG|Daptomycin|
47922274|NCT02208063|DRUG|Synthetic penicillin|
47922275|NCT02208063|DRUG|Cefazolin|
47922276|NCT02449746|BIOLOGICAL|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
48095564|NCT00003195|PROCEDURE|peripheral blood stem cell transplantation|
48095565|NCT00003195|RADIATION|radiation therapy|
48270364|NCT01880307|DRUG|Prednisolon|
48270365|NCT00522067|BIOLOGICAL|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
48270366|NCT01884792|OTHER|Sitting OGTT|
48270367|NCT01884792|OTHER|Standing OGTT|
47922277|NCT02449746|BIOLOGICAL|Intravenous immunoglobulin|"Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
48270368|NCT01884792|OTHER|Sitting CGM|
47922278|NCT03449784|OTHER|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
47922279|NCT00027833|BIOLOGICAL|ALVAC-CEA-B7.1 vaccine|
47922280|NCT00027833|BIOLOGICAL|tetanus toxoid|
47922281|NCT00027833|DRUG|FOLFIRI regimen|
47922282|NCT00027833|DRUG|fluorouracil|
47922283|NCT00027833|DRUG|irinotecan hydrochloride|
48270369|NCT01884792|OTHER|Standing CGM|
48270370|NCT05238376|BEHAVIORAL|Exercise training|12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
48270371|NCT05046756|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
47922284|NCT00027833|DRUG|leucovorin calcium|
47922285|NCT01431638|DRUG|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
47922286|NCT04531709|OTHER|Comprehensive Score for financial toxicity (COST)|Measure indirect and direct health care cost that burden patients and their loved ones.
47922287|NCT04531709|OTHER|Functional Assessment of Cancer Therapy: General (FACT-G)|General quality of life instrument
47922288|NCT04531709|OTHER|EORTC QLQ C-30|Assess quality of life in cancer patients
47922289|NCT04531709|OTHER|EORTC QLQ-TC26.|To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.
47922290|NCT00546598|DEVICE|Total hip replacement/arthroplasty|Hip replacement
48270372|NCT05559307|DRUG|Xingnaojing injection|Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
48270373|NCT01749384|BIOLOGICAL|Bevacizumab|Given IV
48270374|NCT01749384|OTHER|Laboratory Biomarker Analysis|Correlative studies
48270375|NCT01749384|OTHER|Pharmacological Study|Correlative studies
48270376|NCT01749384|DRUG|Tivantinib|Given PO
48270377|NCT00783016|DRUG|Morphine|
48270378|NCT06069661|DEVICE|Aortic Stenosis|F2 Filter and Delivery system to cover the 3 great cerebral vessels
48270379|NCT02992574|RADIATION|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
47922291|NCT05705635|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
47922292|NCT05705635|DRUG|Taxotere|Taxotere, by intravenous infusion, every 3 weeks.
48270380|NCT00124280|DRUG|RAD001|
47922293|NCT05596383|DIETARY_SUPPLEMENT|Vitamin D 5000 IU|Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
47922294|NCT05596383|DIETARY_SUPPLEMENT|Placebo|Placebo
47922295|NCT06472076|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
47922296|NCT06472076|BIOLOGICAL|Belrestotug|Belrestotug will be administered.
47922297|NCT06472076|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
47922298|NCT06472076|DRUG|Placebo|Placebo will be administered.
47922299|NCT02117128|DRUG|Tranexamic acid|
47922300|NCT00934648|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
47922301|NCT00934648|DRUG|methotrexate|10-25mg weekly
47922302|NCT01779791|DRUG|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
48270381|NCT01690845|DEVICE|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
48270382|NCT00260585|PROCEDURE|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
48270383|NCT00260585|PROCEDURE|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
48270384|NCT00260585|PROCEDURE|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
48270385|NCT00260585|PROCEDURE|Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies|Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.
48270386|NCT06123312|DIAGNOSTIC_TEST|Tri-modality biopsy|When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
48270387|NCT03457961|DRUG|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
47922303|NCT02754700|OTHER|Neuromuscular Training|Standardized, comprehensive neuromuscular training
47922304|NCT02754700|OTHER|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
47922305|NCT02754700|OTHER|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
47922306|NCT06515795|OTHER|Isometric exercise|In each arm, participants will execute an isometric exercise, in which they will perform 4 repetitions of 2 minutes.
47922307|NCT06351384|DEVICE|miRNA detection test|miRNA sequencing based on Next-Generation Sequencing (NGS) technology
47922308|NCT05966337|PROCEDURE|CPAP|Use of non-invasive ventilation in patients in group 2 with CPAP.
47922309|NCT05966337|PROCEDURE|BIPAP|Use of non-invasive ventilation in patients in group 3 with BIPAP.
47922310|NCT05966337|PROCEDURE|Usual care in phisicaltherapy|Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol
47922311|NCT05846607|DIETARY_SUPPLEMENT|Intervention oral supplement|The oral supplement used as intervention for the study will be DongzheSutang(DAISY FSMP,Jiangsu,China). The formula contains only carbohydrate:12.5g in 100ml of product(glucose syrup and maltodextrin)，with a caloric density of 16.32kcal/g.
47922312|NCT00107484|DRUG|ferumoxtran-10|
48270388|NCT05833802|OTHER|virtual anti-cancer drug|the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
48270389|NCT02151344|BIOLOGICAL|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
48270390|NCT02151344|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
47922313|NCT00107484|PROCEDURE|magnetic resonance imaging|
47922314|NCT00107484|PROCEDURE|sentinel lymph node biopsy|
47922315|NCT04134546|PROCEDURE|CBD exoloration|Early versus late intervention after biliary tract injury post cholecystectomy
47922316|NCT02586441|DEVICE|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
47922317|NCT02586441|DRUG|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
47922318|NCT02586441|DRUG|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
47922319|NCT00444678|DRUG|Cetuximab|500 mg/m2, IV every two weeks
47922320|NCT00444678|DRUG|Oxaliplatin|85 mg/m2, IV, q 2 weeks
48270392|NCT05396209|PROCEDURE|Hydrated Amniotic Membrane Plug|Using Hydrated Amniotic Membrane plug with vitrectomy to try to close refractory macular hole
47922321|NCT00444678|DRUG|Capecitabine|2500 mg, po bid x 7 days every two weeks
47922322|NCT00200343|DRUG|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
47922323|NCT00200343|DRUG|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
47922324|NCT00200343|DRUG|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
48095566|NCT04697069|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
48095567|NCT04697069|BIOLOGICAL|Placebo|Placebo
47922325|NCT00401687|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
47922326|NCT01809587|DEVICE|IQP-PO-101|
47922327|NCT00988650|OTHER|isocaloric diet|
47922328|NCT00988650|OTHER|free living conditions|
47922329|NCT03935568|DRUG|PU-AD|3 cohorts receiving a single oral dose of PU-AD at one time.
47922330|NCT03935568|DRUG|Placebo|3 cohorts receiving a single oral dose of Placebo at one time
47922331|NCT03935568|DRUG|Placebo|2 cohorts receiving multiple oral dose of Placebo at one time
47922332|NCT03935568|DRUG|PU-AD|2 cohorts receiving multiple oral dose of PU-AD at one time
47922333|NCT04843683|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
47922334|NCT01893034|PROCEDURE|Arthroscopic treatment of femoroacetabular impingement|
47922335|NCT01893034|OTHER|Physiotherapy and activity modification|
48270393|NCT05396209|PROCEDURE|ILM filling|The ILM filling technique - Rossi et al show that ILM filling technique was more efficacious in closing full-thickness macular holes larger than 630μm, in which the free ILM after peeling is plug into the area of the macular hole
48270394|NCT05396209|PROCEDURE|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
47922336|NCT06079229|OTHER|Phone call|The only follow-up visit provided for in the protocol was a telephone contact 3 to 30 months after the patient's surgery. The rest of the data required for the study were obtained from the patient's medical records, collected in the course of routine practice.
47922337|NCT01666340|OTHER|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
47922338|NCT01666340|OTHER|Exercise intervention|High intensity exercise
47922339|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
47922340|NCT00127270|DRUG|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
47922341|NCT00127270|BEHAVIORAL|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
47922342|NCT05457621|OTHER|Effaclar serum|Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.
48095568|NCT04348370|BIOLOGICAL|BCG Vaccine|BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.
47922343|NCT02184052|DRUG|Meloxicam|7.5 mg or 15 mg
47922344|NCT02846298|BIOLOGICAL|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
47922345|NCT00901732|DEVICE|Caphosol|Oral Mouth Rinse
47922346|NCT05035602|OTHER|Physical activity assessment|Physical activity patterns will be obtained from google location history, using an Android phone
47922347|NCT00375401|DRUG|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
47922348|NCT00375401|DRUG|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
48095569|NCT04348370|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.
48095570|NCT06631001|OTHER|Abdominal Massage|Abdominal massage will be administered twice a day for 15 minutes over three days. This intervention aims to evaluate its effects on defecation frequency, gastric residual volume, and abdominal distension.
48095571|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (250 mg/kg)|250 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
48270395|NCT03103893|DRUG|Rapamycin|topical formulation
47922349|NCT00375401|DRUG|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
47922350|NCT00866229|DRUG|Rosuvastatin|10 mg per day for 12 weeks
47922351|NCT00866229|DRUG|Simvastatin|20 mg per day
47922352|NCT02215018|DRUG|BI 44370 TA solution|
47922353|NCT02215018|DRUG|BI 44370 TA tablet|
47922354|NCT02215018|DRUG|Placebo solution|
47922355|NCT02215018|DRUG|Placebo tablet|
47922356|NCT02262208|OTHER|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
47922357|NCT02262208|OTHER|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
47922358|NCT02262208|DEVICE|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
47922359|NCT02735824|PROCEDURE|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
47922360|NCT02735824|PROCEDURE|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
47922361|NCT02735824|PROCEDURE|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
47922362|NCT05673798|OTHER|initial chemotherapy response|Initial chemotherapy response is the first imaging examination of SCLC patient after starting chemotherapy
48270396|NCT01552057|DRUG|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
48270397|NCT01552057|DRUG|Placebo|Placebo taken orally once every day for 15 weeks
47922363|NCT02372734|OTHER|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
47922364|NCT06445452|BEHAVIORAL|Direct SNAP-Ed|Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
47922365|NCT06349759|DRUG|phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist|Once daily dosing
47922366|NCT06349759|DRUG|Placebo|Once daily dosing
47922367|NCT00734747|DEVICE|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
47922368|NCT03851172|DRUG|Ketorolac Ophthalmic|Preoperative administration of Ketorolac 0.5% eye drops
48270398|NCT00003141|BIOLOGICAL|filgrastim|Given IV
48270399|NCT00003141|DRUG|carboplatin|Given IV
48270400|NCT00003141|DRUG|cisplatin|Given IV
48270401|NCT00003141|DRUG|cyclophosphamide|Given IV
47922369|NCT03851172|DRUG|Nepafenac Ophthalmic|Preoperative administration of Nepafenac 1 mg eye drops
47922370|NCT03851172|DRUG|Cyclopentolate Ophthalmic|Preoperative administration of Cyclopentolate eye drops
47922371|NCT01236547|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
47922372|NCT01236547|DRUG|Paclitaxel|Given IV
47922373|NCT01236547|DRUG|Pazopanib Hydrochloride|Given PO
47922374|NCT01236547|OTHER|Placebo Administration|Given PO
47922375|NCT00659347|DRUG|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
47922376|NCT00659347|DRUG|Placebo|Capsules,25 mg,BID,6weeks
48095572|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (500 mg/kg)|500 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
47922377|NCT04882345|DRUG|Almonertinib|"Almonertinib is a class 1 new drug,the third-generation small molecule EGFR TKI, which can irreversibly and highly selectively inhibit EGFR sensitive mutations (such as exon 19 deletion and L858R mutation) and T790M resistance mutations.~Patients meeting the criteria for inclusion and exclusion were included in the Almonertinib treatment group and received 110 mg of Almonertinib orally once a day."
47922378|NCT02509234|DRUG|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
48270402|NCT00003141|DRUG|etoposide|Given IV
47922379|NCT02710955|DIETARY_SUPPLEMENT|Thickened infant formula|
47922380|NCT05638789|PROCEDURE|endoscopic sphincterotomy (EST) versus EST plus endoscopic papillary large balloon dilatation (EPLBD)|EST alone vs EST plus EPLBD in removing common bile duct stone
48095573|NCT06630312|DIETARY_SUPPLEMENT|Alpha galactosidase|Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.
48270403|NCT00003141|DRUG|thiotepa|Given IV
48270404|NCT00003141|DRUG|vincristine sulfate|Given IV
48270405|NCT00003141|PROCEDURE|conventional surgery|
48270406|NCT00003141|PROCEDURE|peripheral blood stem cell transplantation|
48270407|NCT04413955|DEVICE|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
48270408|NCT02837679|OTHER|Geriatric Follow up|
48270409|NCT00281814|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
48270410|NCT05203250|RADIATION|Heavy-ion therapy (hadrontherapy)|Only data available from routine clinical practice at the National Center for Oncological Hadrontherapy (CNAO), based Pavia, will be collected. Intervention is not assigned.
47922381|NCT00847509|DRUG|[F-18]FLT|The individual doses of \[F-18\]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
47922382|NCT03030846|OTHER|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
47922383|NCT03030846|OTHER|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
47922384|NCT05165693|OTHER|Experimental Formula|Diabetes-specific study formula
47922385|NCT05165693|OTHER|Test Meal|Instant oatmeal
47922386|NCT01185353|DRUG|LY3009104|Administered orally
47922387|NCT01185353|DRUG|Placebo|Administered orally
47922388|NCT01185353|DRUG|Methotrexate|Administered orally as background therapy
47922389|NCT00779259|DRUG|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
47922390|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
47922391|NCT00779259|DRUG|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
47922392|NCT00779259|DRUG|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
47922393|NCT02785796|OTHER|CV4|
48270411|NCT03228563|OTHER|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5\*10\^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
47922394|NCT02785796|OTHER|SHAM TECHNIQUE|
47922395|NCT00421941|PROCEDURE|Tube feeding|
47922396|NCT02251964|DRUG|Rituximab|2 times 1000mg dose at 14 days interval treatment
47922397|NCT02251964|RADIATION|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
47922398|NCT06530433|DEVICE|CPRCard + TCPR Link App and Web|Application that allows responder to perform CPR with two-way audio communication and one-way video streaming to SCDF Dispatcher
48095574|NCT06630312|DIETARY_SUPPLEMENT|Placebo|Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.
48095575|NCT05492890|DEVICE|Dexcom G6|Continuous glucose monitoring
48095576|NCT05878743|BEHAVIORAL|Safety Planning a recovery-orientated mental health risk management intervention|Developing the skills to manage risks associated with mental health difficulties in ways which increase personal recovery for individuals.
48095577|NCT03771326|BIOLOGICAL|Kisspeptin-10|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
48443570|NCT05277363|OTHER|None (Observational study)|No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
47922399|NCT06530433|DEVICE|CPRCard Only|Control arm with standard care of procedure that Bystander using CPRCard only
48095578|NCT05260840|OTHER|Evaluation study - provision of an online questionnaire|Evaluation study - provision of an online questionnaire
48443571|NCT00307697|PROCEDURE|receipt of copy of psychiatic assessment letter|
47922400|NCT00062231|DRUG|amoxicillin-clavulanate potassium|
47922401|NCT00062231|DRUG|ciprofloxacin|
47922402|NCT00062231|DRUG|moxifloxacin hydrochloride|
47922403|NCT00062231|PROCEDURE|management of therapy complications|
47922404|NCT05576545|DEVICE|The Breast Cancer Self-Care App|The Breast Cancer Self-Care App includes several parts- introduction to breast cancer, types of treatment, side effects care, nutrition, relaxation videos, insurance, medical news and recording side effects, etc. The researcher assisted in installing the App on the patient's mobile phone, entered the personal account, and asked the patient to fill in questionnaires. Patients were given individual health education task in the Breast Cancer Self-Care App every week according to the type of chemotherapy drugs. After four weeks, they filled in questionnaires again.
47922405|NCT02373085|OTHER|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
47922406|NCT00097149|PROCEDURE|Systematic pediatric care|
47922407|NCT05716672|DRUG|Lazertinib|Lazertinib 240mg(3tablets, 80mg/1tablet), once a day(QD), oral(PO), until disease progression or unacceptable toxicity
47922408|NCT05223153|DIAGNOSTIC_TEST|Optical Coherence tomography angiography|Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
47922409|NCT03673397|BEHAVIORAL|Aerobic exercise, bicycle ergometer|Exercise performed below individual anaerobic threshold for 30 minutes
47922410|NCT00946140|PROCEDURE|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
47922411|NCT00935246|DRUG|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
47922412|NCT02890641|GENETIC|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)|Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
47922413|NCT05288062|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate/biopsy
47922414|NCT05288062|DRUG|Dexamethasone|Given orally
47922415|NCT05288062|DRUG|Lenalidomide|Given orally
47922416|NCT05288062|DRUG|Pomalidomide|Given orally
47922417|NCT05090800|DRUG|Definity contrast during ultrasound|Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
47922418|NCT04371302|DIAGNOSTIC_TEST|Questionnaire|Assessment of demographics, burnout, depression and self-perceived medical errors
47922419|NCT00228215|BEHAVIORAL|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
47922420|NCT04986358|OTHER|Follow up at 2 years|The patients will have a follow-up to carry out 2 years after their intervention in addition to their traditional care
47922421|NCT00895102|DRUG|ABT-333 Tablet|See Arm Description for more information.
47922422|NCT00895102|DRUG|Placebo|See Arm Description for more information.
47922423|NCT00895102|DRUG|ABT-333 Capsule|See arm description for more information
47922424|NCT03035877|BEHAVIORAL|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
47922425|NCT03035877|BEHAVIORAL|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
47922426|NCT01004276|OTHER|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
47922427|NCT00921895|DEVICE|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
47922428|NCT01964768|OTHER|Skin prick-test|
47922429|NCT02325843|OTHER|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
48270412|NCT04760002|DEVICE|NightOwl|The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
48270413|NCT00732173|BEHAVIORAL|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
47922430|NCT00486655|PROCEDURE|NOTES-Assisted Cholecystectomy|
47922431|NCT00043342|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
47922432|NCT03924557|DIAGNOSTIC_TEST|Genotype-guided Supportive Care|In this arm, supportive care will be administered based on the results of the genotype test.
48270414|NCT00732173|BEHAVIORAL|exercise intervention|Undergo SUCCEED lifestyle intervention
48270415|NCT00732173|OTHER|counseling intervention|Undergo SUCCEED lifestyle intervention
48270416|NCT00732173|OTHER|educational intervention|Receive information
48270417|NCT00732173|OTHER|survey administration|Undergo SUCCEED lifestyle intervention
47922433|NCT01395784|DRUG|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
47922434|NCT00121043|DEVICE|SimpleJectTM|
47922435|NCT00121043|DRUG|Kineret® (Anakinra)|
47922436|NCT04440605|PROCEDURE|Preoperative staging--D2 gastrectomy--Postoperative staging|Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
47922437|NCT01689194|DRUG|genexolPM + cisplatin|
47922438|NCT06409156|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|With the OSTAP block, local anesthetic is injected into the fascial plane between the posterior rectus sheath and the transversus abdominis muscle beneath the subcostal margin.
47922439|NCT06409156|PROCEDURE|External Oblique Intercostal Fascial Plane block|With the EOIF block, local anesthetic targets the terminal part of the thoracoabdominal nerves pass behind the costal cartilage and continue anteriorly in the plane between the internal oblique and transversus abdominis muscle, before piercing the rectus abdominis sheath as anterior cutaneous branches supplying the skin of the midabdomen.
47922440|NCT02537288|DRUG|Fedovapagon|
47922441|NCT02537288|DRUG|Moxifloxacin|
47922442|NCT02537288|DRUG|Placebo (for fedovapagon)|
47922443|NCT00004005|DRUG|fluorouracil|
47922444|NCT00004005|DRUG|irinotecan hydrochloride|
47922445|NCT00004005|DRUG|leucovorin calcium|
47922446|NCT00004005|PROCEDURE|conventional surgery|
47922447|NCT00004005|RADIATION|radiation therapy|
47922448|NCT03568188|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
47922449|NCT03568188|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
47922450|NCT03568188|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
47922451|NCT03568188|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
47922452|NCT03568188|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
47922453|NCT03568188|BIOLOGICAL|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
47922454|NCT03568188|BIOLOGICAL|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
47922455|NCT01489813|DRUG|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
47922456|NCT01489813|DRUG|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
47922457|NCT06095271|DIAGNOSTIC_TEST|serum Neurofilament Filament Light chain (sNfL) monitoring|the intervention consist of a blood draw and providing the sNfL information to the treating physician
47922458|NCT01944280|OTHER|massage|
47922459|NCT01788813|DRUG|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
47922460|NCT01788813|DRUG|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
47922461|NCT02081885|PROCEDURE|Tricalcium Phosphate / Chitosan|
47922462|NCT02081885|PROCEDURE|Autologous Graft|
47922463|NCT00257257|DRUG|Rimonabant (SR141716)|
48270418|NCT03043144|OTHER|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
48270419|NCT03043144|OTHER|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
47922464|NCT02594995|DRUG|NBP|
47922465|NCT04610281|DEVICE|Inner Garden|"Care actions adapted to the intensity of the states of agitation (The child can be removed from the group while remaining in the same room on a chair with a caregiver. If the problems are too serious, the child can be accompanied to a soothing room where the carer will take care of him/her individually. In units equipped with Inner Garden, the child can use it under semi- supervision of nurses.)"
48270420|NCT03043144|OTHER|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
48270421|NCT03043144|OTHER|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
47922466|NCT03406091|DRUG|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
47922467|NCT03619057|OTHER|General anesthesia with laryngeal mask i-gel|General anesthesia with laryngeal mask i-gel
47922468|NCT05843786|DRUG|Interferon gamma|Daily subcutaneous administration of Interferon gamma during 5 days
47922469|NCT05843786|DRUG|Placebo|Placebo during 5 days
47922470|NCT01534858|DEVICE|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
47922471|NCT04158843|PROCEDURE|Radical resection|Radical resection is performed, and the cutting edge is negative.
47922472|NCT04158843|RADIATION|Radical radiotherapy|Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
47922473|NCT04158843|OTHER|Palliative treatment|Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
47922474|NCT00775047|OTHER|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
48270422|NCT03043144|OTHER|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
47922475|NCT00775047|OTHER|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
47922476|NCT06530979|DEVICE|Tailored nutritional education program utilizing Saudi-sign language supplied by Saudi-sign language interpreter|The program will be implemented in an experimental group composed of profoundly impaired hearing adults (91 Decibels and above). The experimental group will receive nutrition group counselling via photos, and models, and Saudi-sign language interpreter, including awareness of food groups and their nutrients, choose healthy and balanced items from supermarkets, restaurants or coffee shop menus-traffic lights on nutrition labelling and health problems or diseases related to diet and weight management
48270423|NCT03043144|OTHER|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
48270424|NCT02840136|DRUG|Piperacillin-tazobactam combination product|
48270425|NCT02840136|DRUG|Meropenem|
48270426|NCT02840136|DRUG|Ceftazidime|
48270427|NCT05596266|BIOLOGICAL|CD5 CAR-T|CD5 CAR-T will be administered by I.V. infusion.
48270428|NCT05700266|DRUG|Rivaroxaban|Rivaroxaban (2.5mg orally twice a day for 90 days)
47922477|NCT04226768|OTHER|"Enhanced Haematology Palliative Care (Fast-track) Group"|Early and proactive multidisciplinary care
47922478|NCT04226768|OTHER|Conventional Care|Conventional care and referral as indicated
47922479|NCT03998839|OTHER|Community distribution of Sulfadoxine-pyrimethamine (SP)|Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
47922480|NCT05423860|OTHER|no interventions will be performed (observational)|Not applicable. (no interventions will be performed with this observational study
47922481|NCT02141477|DRUG|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
47922482|NCT02141477|DRUG|Decitabine|"Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
47922483|NCT06277453|OTHER|surgery|radical gastric cancer surgery (R0) and D2 lymph node dissection
47922484|NCT04294056|DRUG|Ciprofol|First-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg Second-stage: 0.4mg/kg, 0.6 mg/kg, 0.8 mg/kg
47922485|NCT04294056|DRUG|Propofol|First-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg Second-stage: 2.0mg/kg, 3.0 mg/kg, 4.0 mg/kg
47922486|NCT02893579|BEHAVIORAL|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
47922487|NCT02893579|BEHAVIORAL|Delayed SR intervention|Activity tracking only for the first month
47922488|NCT06313788|OTHER|Possession of a customized placebo analgesic band-aid prior to vaccination or injection|Participants will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference. They will be displayed band-aids with different cartoon images (such as Luffy, minions etc) from which they can freely choose their favorite one . They will be asked to sign their name on the band-aid. This is to establish their sense of ownership. Lastly, with the assistance of the parent, they will be encouraged to anticipate and describe how the owned band-aid is important to them and can help them cope with the forthcoming pain from injection.
47922489|NCT03079713|DEVICE|Handheld vibrator triggered during intravitreal injection for wet ARMD|A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
47922490|NCT03079713|DEVICE|Normal eye esthesiometry with and without vibration|Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
47922491|NCT03079713|DEVICE|Handheld vibrator not triggered during intravitreal injection for wet ARMD|Control group undergoing standard intravitreal injection without triggering of the vibrator.
47922492|NCT01160419|DRUG|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
47922493|NCT01160419|DRUG|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
47922494|NCT01160419|DRUG|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
47922495|NCT01160419|DRUG|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
47922496|NCT04735640|BEHAVIORAL|nurse-led teleconsultation|Patients assigned to this group will receive personalized dietary and physical activity advice during 9 months. Behavioural goals and action plans will be developed in a stepwise manner in accordance with baseline levels of nutritional and physical activity adherence to recommendations.
47922497|NCT04735640|BEHAVIORAL|SMS|Patients assigned to this group will receive a total of 150 text messages (4 to 5 messages per week during weekdays) throughout the intervention period (9 months). The content of the text messages includes advice on diet and exercise.
47922498|NCT04270279|DRUG|Xueshuanxinmaining tablet|A kind of Chinese patent medicine
47922499|NCT04270279|DRUG|Xueshuanxinmaining placebo|The simulant of Xueshuanxinmaining tablet
47922500|NCT04270279|DRUG|Nitroglycerin tablets|Be used when angina attack
47922501|NCT00107640|BEHAVIORAL|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
47922502|NCT04157673|BEHAVIORAL|Episodic Future Thinking|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week, 8-week or 10-week baseline period.
47922503|NCT03689309|PROCEDURE|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
47922504|NCT00874926|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
47922505|NCT06316310|OTHER|acupoint thread embedding|Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen. Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle. The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand. Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
47922506|NCT00848562|DRUG|Nicorandil|Oral administration of nicorandil (15 mg/day)
48095579|NCT00421902|PROCEDURE|Acupuncture|Patients will be have acupuncture (with electro stimulation)
48270429|NCT05700266|DRUG|Clopidogrel|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)
48095580|NCT03421444|OTHER|No intervention|No intervention
48095581|NCT05171933|BEHAVIORAL|Survey|This study is based on a survey made on COVID-19
48270430|NCT05700266|DRUG|Aspirin|Aspirin (100mg once a day for 1 year)
47922507|NCT05747040|DIAGNOSTIC_TEST|monitoring|"The intervention consists of 48-h monitoring by using two types of monitoring: an objective monitoring, through a class IIa wearable medical device recording four physiological signals, and a subjective monitoring through a questionnaire developed with Microsoft Forms that can be compiled with a smartphone. The monitoring will be conducted during a motor neurorehabilitation treatment, 24 hours before and 24 hours after the treatment at the participant's home. Besides this monitoring, stratification questionnaires will be administered to each participant to be stratified in one of the three categories (absence of pain, nociceptive pain, or neuropathic pain) based on the following timeline:~t0: baseline t1: pre-treatment t2: post-treatment t3: follow-up"
47922508|NCT02970682|DRUG|SFX-01|Stabilised Sulforaphane
47922509|NCT02970682|DRUG|Fulvestrant|Fulvestrant
48443572|NCT00845715|OTHER|Early motion|Early referral to physical therapy for range of motion (2 days post)
47922510|NCT02970682|DRUG|Tamoxifen|Tamoxifen
47922511|NCT02970682|DRUG|Aromatase Inhibitors|
47922512|NCT06335745|BEHAVIORAL|PediCARE Intervention|A household material hardship intervention with monthly, direct provision of groceries and transportation. Resources will be centrally administered by the Dana-Farber Cancer Institute study team.
47922513|NCT00660686|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
47922514|NCT00660686|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
47922515|NCT04816968|DRUG|Cefepime|Cefepime from 3 to 6 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
47922516|NCT04816968|DRUG|Piperacillin/tazobactam|Piperacillin/Tazobactam 18 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
47922517|NCT04816968|DRUG|Meropenem|Meropenem 3 gr, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
47922518|NCT04816968|DRUG|Vancomycin|Vancomycin 30 mg/kg, based on patient's clinical status, reduced dose based on organ function and physician discretion, in 100cc saline solution in elastomer, perfused in 24 hours.
48443573|NCT00845715|OTHER|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
47922519|NCT04565808|PROCEDURE|primary percutaneous coronary intervention|Primary Percutaneous Coronary Intervention (PPCI), also known as angioplasty or coronary angioplasty, is a procedure used to diagnose and treat the narrowed coronary arteries of the heart.
47922520|NCT02123914|OTHER|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
47922521|NCT02123914|OTHER|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
47922522|NCT02123914|OTHER|No exercise|"Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
47922523|NCT02874170|OTHER|Spectroscopy magnetic resonance of phosphorus 31|
47922524|NCT05996302|BEHAVIORAL|Relocation to sea level|Relocation to sea level by bus and stay for 2 days
47922525|NCT01696162|OTHER|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
47922526|NCT01696162|OTHER|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
47922527|NCT01696162|OTHER|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
47922528|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric vein|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
48270431|NCT05700266|OTHER|Risk Factor Management in both arms|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed
48270432|NCT00945919|DRUG|Oxymorphone ER|Rapid Opioid rotation/titration
48443574|NCT00772161|DRUG|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
48443575|NCT00124618|BIOLOGICAL|cetuximab|
48443576|NCT00124618|RADIATION|radiation therapy|
48443577|NCT03804983|DEVICE|Hybrid Closed Loop (HCL)|Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
48443578|NCT03804983|DEVICE|Control-IQ with MyTDI|Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
48443579|NCT02146105|OTHER|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
47922529|NCT02746224|PROCEDURE|Initially dissection of inferior mesenteric artery|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
48443580|NCT05732207|PROCEDURE|cerebellar transcranial direct current stimulation|TDCS is a safe and non-invasive technique for modulating cortical excitability and behavior. TDCS, delivered via surface electrodes, induces an intracerebral current flow sufficient to achieve changes in cortical excitability. Anodal stimulation up-regulates cortical excitability, while cathodal stimulation decreases excitability.
47922530|NCT02746224|PROCEDURE|Latero-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
47922531|NCT02746224|PROCEDURE|Termino-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
47922532|NCT04903314|DRUG|Xcopri|Xcopri will be administered orally not to exceed 400mg/day adult equivalent
47922533|NCT03525964|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
47922534|NCT03525964|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
47922535|NCT03525964|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
47922536|NCT02489422|OTHER|Laboratory Biomarker Analysis|Correlative studies
47922537|NCT02489422|OTHER|Questionnaire Administration|Ancillary studies
47922538|NCT02489422|OTHER|Daily Survey Administration|Ancillary studies
47922539|NCT02489422|BEHAVIORAL|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
47922540|NCT02489422|BEHAVIORAL|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
47922541|NCT02489422|OTHER|Actigraphy Assessment|Ancillary studies
47922542|NCT05157802|BEHAVIORAL|Physical activity coaching|Physical activity coaching over 5 sessions
47922543|NCT01768429|BEHAVIORAL|Fatty fish|
47922544|NCT01768429|BEHAVIORAL|Lean Fish|
47922545|NCT01768429|BEHAVIORAL|Alpha-linolenic acid|
47922546|NCT01768429|BEHAVIORAL|Control|
47922547|NCT02560506|DEVICE|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
47922548|NCT06174142|DEVICE|High-Frequency ESWT|Participants will receive extracorporeal shock wave therapy at a frequency of 15 Hz and intensity/pressure level 3, with a total of 1800 impulses per session. This intervention will be conducted once per week for six weeks, alongside a standard physical therapy regimen
47922549|NCT06174142|DEVICE|Low-Frequency ESWT Group|"Participants will be treated with extracorporeal shock wave therapy at a frequency of 10 Hz and intensity/pressure level 4, also with a total of 1800 impulses per session. This protocol will be delivered weekly for six sessions, accompanied by standardized physical therapy exercises."
47922550|NCT06174142|DEVICE|Sham ESWT Control Group|"Participants in this control group will undergo a sham ESWT procedure that mimics the treatment experience without actual therapeutic effects, ensuring the blinding of participants. This sham therapy will be scheduled once a week for six weeks, in conjunction with the same physical therapy program as the other groups."
47922551|NCT03126344|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
47922552|NCT03126344|DEVICE|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
47922553|NCT03126344|DEVICE|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
47922554|NCT05469698|BEHAVIORAL|Tobacco Treatment Research Program Standard Care|Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.
47922555|NCT06299488|OTHER|Sip2Sleep: Montmorency Cherry and Apocynum Venetum|See arm description
47922556|NCT06194045|DIETARY_SUPPLEMENT|LC-MUFA oil|2 x 1 g capsules containing marine oil from North Atlantic fish
47922557|NCT06194045|DIETARY_SUPPLEMENT|Placebo|2 x 1 g capsules containing corn oil
48095582|NCT06055556|PROCEDURE|Partial Heart Transplantation|"Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue."
48095583|NCT06055556|OTHER|Freshly procured valve|Fresh donor graft semilunar heart valve.
47922558|NCT05668611|OTHER|Primary Training Phase|A four-day training program taken over the course of two weekends will include materials on RHD and RHD echocardiographic screening using focused artificial intelligence navigational guided echocardiographic acquisition to identify patients who are screen positive or screen negative for RHD. The echo protocol will be limited to the parasternal long axis-view (2D and color Doppler) focusing on mitral and aortic valve morphology and function and a single 2D apical 4 chamber view for auto EF. The curriculum package will include online modules, instructor delivered PowerPoint presentations, and hands on practice on volunteers with and without RHD.
47922559|NCT05668611|OTHER|Primary Assessment Phase|A pre- and post-training test on RHD knowledge and diagnosis will be administered. A rapid competency assessment, including obtaining imaging on volunteers with or without RHD and an online test with pre-recorded cases of RHD, LV dysfunction and Pericardial effusions, will be utilized at the end of the 4-day training sessions. Trainees will be monitored by trained study personnel and at the end of the practicum training, the expert users will blindly review and assess the quality of each study using the standardized scale and competency scorecard provided below. Additionally, they will be asked to pass the knowledge quiz (80% or better). If competency is not achieved, an additional weekend of training can be added.
48270433|NCT01756274|DEVICE|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
48270434|NCT01756274|DEVICE|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
48270435|NCT01756274|DEVICE|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
48270436|NCT03729882|PROCEDURE|EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. A prophylaxis gallbladder drainage will be done using a 3.8 mm working-channel linear-array therapeutic echoendoscope (EG3870UTK;Pentax, Hamburg, Germany) attached to an ultrasound console (Avius Hitachi, Tokyo, Japan) within a transgastric and/or transduodenal approaches to the gallbladder puncture followed by placement of a lumen apposing stent (LAMS) (AXIOS; Xlumena Inc, CA, USA) with a 10 mm luminal diameter and a dumbbell-shaped flanges to bring together the 2 walls in apposition. These feature of the Axios decrease the risk for bile leak, stent migration, and stent occlusion.
47922560|NCT05668611|OTHER|Primary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
47922561|NCT05668611|OTHER|Secondary Training Phase|Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
47922562|NCT05668611|OTHER|Secondary Assessment Phase|The secondarily trained nurses will be assessed and certified by the nurse trainer.
47922563|NCT05668611|OTHER|Secondary Screening Phase|"Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks."
47922564|NCT00264758|DEVICE|Conventional hemodialysis|Three times per week in-center hemodialysis
48270437|NCT03729882|PROCEDURE|Non EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage
48270438|NCT02698098|DRUG|Methadone|
48270439|NCT05974982|BIOLOGICAL|PRP|PRP is a volume of autologous plasma that has a platelet concentration above baseline i.e., five times more than normal platelet counts. PRP enhances wound healing by promoting the healing process by seven growth factors present in it. They are platelet derived growth factor (αα, αβ, αβ), fibroblast growth factor, vascular endothelial growth factor, epidermal growth factor, transforming growth factor.
48270440|NCT05974982|OTHER|Conventional therapy|Conventional therapy
48270441|NCT02325544|BEHAVIORAL|Cognitive Behavioral Therapy|"12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.~Standardised medical as described in other intervention."
48270442|NCT02325544|BEHAVIORAL|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
48270443|NCT02798926|DEVICE|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
48270444|NCT03038646|DRUG|MIN-101|
47922565|NCT00264758|DEVICE|Frequent hemodialysis|Six times per week in-center hemodialysis
47922566|NCT00183729|DRUG|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
47922567|NCT00183729|OTHER|Placebo|Placebo distribution is planned to mimic the active drug.
47922568|NCT03264118|PROCEDURE|Scaling and root planing|Furcation treatment by scaling and root planing
47922569|NCT03264118|DRUG|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
48270445|NCT05028621|DIAGNOSTIC_TEST|Genetic testing|Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.
48270446|NCT03761329|PROCEDURE|mini-Bier's block with lidocaine 0.5% 25ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.
47922570|NCT04444856|DRUG|Eptacog alfa (activated)|The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
47922571|NCT04444856|OTHER|Standard of care|The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.
47922572|NCT00724711|DRUG|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
47922573|NCT00724711|DRUG|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
47922574|NCT02149849|PROCEDURE|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
47922575|NCT04873232|BIOLOGICAL|Engensis|Injections with Engensis in study VMDN-003-2
48270447|NCT03761329|PROCEDURE|Conventional Bier's block with lidocaine 0.5% 40ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
48270448|NCT03980366|DEVICE|Electroconvulsive Therapy (ECT)|Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
48270449|NCT03998657|DEVICE|Exablate Prostate Treatment|The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
48270450|NCT05312008|DRUG|Intranasal oxytocin|Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
48270451|NCT05312008|DRUG|Intranasal placebo|Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
48270452|NCT05995392|DRUG|Topical spironolactone ophthalmic solution, 0.005 mg/cc|Used four times a day in both eyes for 4 weeks.
48270453|NCT05995392|DRUG|Placebo|Used four times a day in both eyes for 4 weeks.
48270454|NCT02519660|DRUG|Lidocaine/Tetracaine patch|
48270455|NCT02519660|DRUG|Lidocaine/Prilocaine cream|
48270456|NCT03029832|DRUG|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
48270457|NCT03029832|DRUG|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
48270458|NCT02615457|DRUG|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
48270459|NCT06290440|OTHER|Telepharmacy-led counselling|The counselling process will be delivered as follows: (1) researchers assist patients in signing up and using the telepharmacy application; (2) researchers send the counselling information from the telepharmacy application to the patient's account (the information will be provided as leaflets and 3-5-minute videos to improve the accessibility); (3) the integrated chatbot system forwards any additional questions or concerns of the patients to the counselling pharmacists; and (4) the pharmacists directly address the patient's questions or concerns through phone calls within the shortest possible timeframe.
48270460|NCT06290440|OTHER|Pharmacist-led counselling|Pharmacists will counsel the patients on how to use their OAC. Each counselling section will take approximately 7-15 minutes, depending on the patient's questions or concerns. The counselling contents have already been compiled and validated by NDGD Hospital to ensure rationale and simplicity for every patient. Counselling pharmacists have received specialised training in drug information and patient communication so intervention delivery will be consistent across different pharmacists.
48270461|NCT01073579|DRUG|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
48270462|NCT00687791|DEVICE|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
48270463|NCT04578002|OTHER|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
48270464|NCT01779284|DRUG|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
47922576|NCT04873232|OTHER|Placebo|Injections with Placebo in study VMDN-003-2
47922577|NCT05514808|OTHER|Nutrition education modules|Nutrition education modules on sports nutrition and dietary supplements over a period of 4 weeks (1 module/week)
48095584|NCT02391662|DRUG|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle
48270465|NCT01779284|DRUG|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
47922578|NCT00755209|DRUG|tranexamic acid|Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
47922579|NCT06405945|GENETIC|PCR and sequence|sequence the mutatation SNPs
47922580|NCT00483756|DRUG|Cyclosporine|Standard of care
48095585|NCT02391662|DRUG|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
48095586|NCT01594060|DRUG|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
48095587|NCT01594060|DRUG|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
48095588|NCT00788424|DRUG|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
48095589|NCT01532050|DEVICE|Mandibular Advancement Device ( MAD)|
48095590|NCT04706013|DRUG|Pyridoxal Phosphate|Oral tablets 50 mg
48095591|NCT05892289|PROCEDURE|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
47922581|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
47922582|NCT00483756|DRUG|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
48270466|NCT01444300|DRUG|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
48270467|NCT01444300|DRUG|Placebo|placebo pill, bid for 12 weeks
48270468|NCT00138697|DRUG|IVIG-L|
48270469|NCT03804671|DRUG|BI 730357|Oral dose
48270470|NCT03804671|DRUG|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
48270471|NCT00000584|DRUG|immunoglobulins|
48270472|NCT00348621|PROCEDURE|Visual impairment intervention program|enhanced access to eye care services
47922583|NCT01242813|DRUG|ACZ885|
47922584|NCT03596749|DRUG|Sevelamer Carbonate|Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
47922585|NCT01466257|BIOLOGICAL|cetuximab|
47922586|NCT01466257|DRUG|cisplatin|
48270473|NCT02063035|DRUG|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
48270474|NCT02063035|DRUG|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
48270475|NCT02731742|BIOLOGICAL|MK-1966|MK-1966 administered as an intravenous (IV) infusion
47922587|NCT01466257|GENETIC|DNA analysis|
47922588|NCT01466257|GENETIC|gene expression analysis|
47922589|NCT01466257|GENETIC|mutation analysis|
47922590|NCT01466257|OTHER|laboratory biomarker analysis|
47922591|NCT04039100|OTHER|Family Caregiver Ambassador Support|Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
47922592|NCT02226445|OTHER|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
47922593|NCT00304213|DRUG|Testosterone|
48270476|NCT02731742|DRUG|SD-101|SD-101 administered as an intratumoral (IT) injection
48270477|NCT05764486|DEVICE|Hitachi's Heavy Ion Beam Therapy System HyBEAT|treating patients with solid tumor
48270478|NCT02870725|BEHAVIORAL|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
48270479|NCT03619629|OTHER|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
48270480|NCT03619629|OTHER|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
48270481|NCT03619629|OTHER|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
48270482|NCT03619629|OTHER|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
48270483|NCT05430269|OTHER|Faecal bacteriotherapy (FBT)|Enema of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors.
48270484|NCT05430269|OTHER|standard-of-care protocolised treatment of postantibiotic diarhea|standard-of-care protocolised treatment of postantibiotic diarhea
47922594|NCT02743611|BIOLOGICAL|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
47922595|NCT02743611|DRUG|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
48270485|NCT05617521|DEVICE|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
48270486|NCT05617521|DEVICE|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
48270487|NCT01007214|PROCEDURE|Prostatectomy|Elective prostatectomy
48270488|NCT03311971|DEVICE|Virtual reality glasses|Patients will be treated with virtual glasses
48270489|NCT03311971|DEVICE|No VR glasses|Patients will not use VR glasses
48270490|NCT00793351|PROCEDURE|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~* Enrollment - Pre-RIST treatment - RIST~* 4 cycles of conventional chemotherapy will be given prior to RIST.~* Surgery will be done whenever possible prior to RIST.~* Local radiotherapy will be applied whenever possible prior to RIST.~* topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~* Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
48270491|NCT04819906|DRUG|Estetrol 20 mg|One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
48270492|NCT04819906|DRUG|Estetrol 100 mg|Five estetrol monohydrate (E4) 20 mg tablets orally once
48270493|NCT04819906|DRUG|Placebo|Five placebo tablets orally once
48270494|NCT04819906|DRUG|Moxifloxacin 400 mg|One moxifloxacin 400 mg tablet orally once (open-label)
48270495|NCT02157454|OTHER|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
48270496|NCT00004160|DRUG|cisplatin|
48270497|NCT00004160|DRUG|gemcitabine hydrochloride|
48270498|NCT00004160|DRUG|paclitaxel|
48270499|NCT00004160|RADIATION|radiation therapy|
48270500|NCT01763164|DRUG|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
48270501|NCT01763164|DRUG|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
48270502|NCT02475889|PROCEDURE|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
48270503|NCT02475889|PROCEDURE|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
48270504|NCT05589792|DRUG|Placebo oral capsule|Placebo before sleep for 3 nights before the study (inclusive)
48270505|NCT05589792|DRUG|Acetazolamide|Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
48270506|NCT00004493|DRUG|sodium dichloroacetate|
48270507|NCT00242294|DRUG|Roflumilast|
48270508|NCT04524845|DEVICE|Unloading brace|"Participants underwent one session of gait analysis. The experimental protocol was divided in four conditions, the control condition without brace (NO), and then three conditions with the different braces tested in a randomized order.~For each condition, the participant was fitted with the brace by the same experimenter and equipped with 19/20 retro-reflective markers (without/with brace) on the pelvis and the investigated leg for motion analysis. After a short recording in a fixed standing position (static trial), each participant carried out at least three barefoot walking trials of a few meters long at a self-selected pace. The walking trial was validated if a complete gait cycle occurred on the two 90cm x 90 cm force plates recording the ground reaction forces. After each condition, the participant had to assess knee pain."
48270509|NCT04524845|DEVICE|Rebel Reliever (RR)|Rebel Reliever (RR) (Thuasne, Levallois Perret, France)
48270510|NCT04524845|DEVICE|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France)
47922596|NCT03886545|OTHER|Assessment of physical and functional capacities|Comparaison of physical and functional capacities between caregivers with work-related musculoskeletal disorders of the shoulder healthy subjects matched in age and gender;
47922597|NCT04334577|BIOLOGICAL|live attenuated zoster vaccine|subcutaneous injection
47922598|NCT04334577|BIOLOGICAL|placebo|subcutaneous injection
47922599|NCT02630901|DRUG|PRX003|
48270511|NCT05679206|DIAGNOSTIC_TEST|Echocardiography images|"Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~* Left ventricular ejection fraction,~* Left ventricular mass index,~* Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~* Tricuspid annular plane systolic excursion,~* Left atrial volume index,~* Right ventricle to right atrium (RV/RA) gradient"
48270512|NCT05679206|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring|Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)
48270513|NCT05200260|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
48270514|NCT05200260|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
48270515|NCT05200260|DRUG|PARP inhibitor|For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
47922600|NCT02630901|OTHER|Placebo|
47922601|NCT01136187|PROCEDURE|Access site in primary PCI|
47922602|NCT03943537|DRUG|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
47922603|NCT04375657|COMBINATION_PRODUCT|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
47922604|NCT04375657|COMBINATION_PRODUCT|Active Control|Metformin and DHEA
48270516|NCT04025593|DRUG|Cyclophosphamide|750mg/m2 day 1
48270517|NCT04025593|DRUG|Rituximab|375mg/m2 day 0
48270518|NCT04025593|DRUG|Doxorubicin|50mg/m2 day 1
48270519|NCT04025593|DRUG|Vincristine|1.4mg/m2, max 2mg day 1
47922605|NCT00864695|OTHER|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
47922609|NCT00678678|DEVICE|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
47922610|NCT00678678|DEVICE|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
48270520|NCT04025593|DRUG|Prednisone|60mg/m2, max 100mg day 1-5
48270521|NCT04025593|DRUG|Ibrutinib|420mg/day qd
48270522|NCT04025593|DRUG|Lenalidomide|25mg day1-10
48270523|NCT04025593|DRUG|chidamide|20mg day 1,4,8,11
47922611|NCT01875679|OTHER|Comprehensive Surgical Coaching|
47922612|NCT01875679|OTHER|Conventional Surgical Training|Surgical training as per participant's residency program
47922613|NCT00366067|DRUG|Phenytoin|
47922614|NCT01699867|DEVICE|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
47922615|NCT02736890|DRUG|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
47922616|NCT02736890|DRUG|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
47922617|NCT00301184|BIOLOGICAL|pGA2/JS7 DNA|DNA Vaccine
47922618|NCT00301184|BIOLOGICAL|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
47922619|NCT03827915|DEVICE|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
47922620|NCT00213993|DRUG|antiperspirant|antiperspirant topically once daily to one foot
47922621|NCT00536393|DRUG|Doxorubicin|
47922622|NCT00536393|DRUG|Doxorubicin pegylated|
47922623|NCT04753424|PROCEDURE|Surgical technique|Description of novel surgical technique using autologous semitendinosus graft as meniscus transplant.
47922624|NCT03069521|DEVICE|EndoArt® Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
47922625|NCT03826368|DIETARY_SUPPLEMENT|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
47922626|NCT00960726|DRUG|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
47922627|NCT00117052|DRUG|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
47922628|NCT05271500|DEVICE|laser acupuncture|gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks
47922629|NCT04989153|DIAGNOSTIC_TEST|pepsinogen|serum pepsinogen diagnosed gastric cancer and precanceous lesion
47922630|NCT04066712|DRUG|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
47922631|NCT04655196|OTHER|SOLUS-D + weekly feedback by a coach|internet-based self-help
47922632|NCT04655196|OTHER|SOLUS-D + weekly automated messages|internet-based self-help
47922633|NCT01317459|BEHAVIORAL|Guided self-determination|Group counselling
47922634|NCT01066390|BIOLOGICAL|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
47922635|NCT01849744|DRUG|VS-4718|
47922636|NCT00608569|DRUG|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
47922637|NCT00608569|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
47922638|NCT00608569|DRUG|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
47922639|NCT00608569|DRUG|Zidovudine|300-mg tablet taken orally twice daily
47922640|NCT00608569|DRUG|Emtricitabine|200-mg tablet taken orally once daily
47922641|NCT04914260|OTHER|Questionnaire|The participants will have to fill in an on-line questionnaire regarding quality of life, their level of knowledge of the rehabilitation through sport program and their level of satisfaction toward this program.
47922642|NCT04320030|DRUG|[18F]-DPA-714 PET/CT scan|Pretherapeutic \[18F\]-DPA-714 PET/CT scan
47922643|NCT02303392|DRUG|Selinexor|Given PO
47922644|NCT02303392|DRUG|Ibrutinib|Given PO
47922645|NCT02303392|OTHER|Pharmacological Study|Correlative studies
47922646|NCT02303392|OTHER|Laboratory Biomarker Analysis|Correlative studies
47922647|NCT06394882|BEHAVIORAL|Family-Centered Healthy Lifestyle Program (FamCe-HLP)|A multidisciplinary-led healthy lifestyle program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The program will run on scheduled days using one of the center's offices for the IBT and the center's seminar room for the MBT.
47922648|NCT05592860|DEVICE|Mobile application|participants in intervention group will use smart phone application and update glucose level and investigator will adjust the insulin accordingly
47922649|NCT05592860|BEHAVIORAL|Daily Diary|participants will use daily diary to record glucose level
47922650|NCT02108015|PROCEDURE|Brain Imaging (PET)|
47922651|NCT02108015|PROCEDURE|Aterial Line|
47922652|NCT02108015|PROCEDURE|Blood Sampling|
47922653|NCT02116530|DRUG|Olanzapine|oral
47922654|NCT02116530|DRUG|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
47922655|NCT02116530|DRUG|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
48270524|NCT04025593|DRUG|decitabine|decitabine 10mg/m2 day-5 to day-1
48270525|NCT06461910|DRUG|Anti-PD-1 Combined with Thymosin and SOX|Anti-PD-1 Combined with Thymosin and SOX in Neoadjuvant Treatment of cStage IIII Gastric or Esophagogastric Junctional Adenocarcinoma
48443581|NCT05548647|BEHAVIORAL|Behavioral Treatment|All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh \< 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
48443582|NCT05548647|DRUG|Placebo|An inactive saline solution administered via subcutaneous injection
47922656|NCT02116530|OTHER|Placebo|oral
47922657|NCT05354453|DRUG|BI 1839100|BI 1839100
47922658|NCT05354453|DRUG|Placebo|Placebo
47922659|NCT05354453|DRUG|allyl isothiocyanate (AITC)|allyl isothiocyanate (AITC)
47922660|NCT02526030|DRUG|Aripiprazole|
47922661|NCT02526030|DRUG|Quetiapine|
47922662|NCT02526030|DRUG|Ziprasidone|
47922663|NCT01557634|PROCEDURE|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
47922664|NCT01232803|DRUG|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
47922665|NCT01232803|DRUG|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
47922666|NCT01232803|DRUG|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
47922667|NCT04732013|OTHER|No clinical intervention is planned; study is observational|No intervention
47922668|NCT04431674|DRUG|Definity Suspension for Injection|MRI-guided ultrasound-stimulated microbubble-treatment
47922669|NCT05307913|OTHER|EIT-guided PEEP|PEEP setting according to EIT
47922670|NCT05307913|OTHER|Table-guided PEEP|PEEP setting according to the lower PEEP/FiO2 table
47922671|NCT02398006|OTHER|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
47922672|NCT02398006|OTHER|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
47922673|NCT03031002|BEHAVIORAL|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
47922674|NCT04143178|OTHER|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
48443583|NCT05548647|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
47922675|NCT04143178|OTHER|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
47922676|NCT05195060|DRUG|casirivimab with imdevimab|Monoclonal antibody
47922677|NCT05195060|DRUG|sotrovimab|Monoclonal antibody
47922678|NCT05195060|DRUG|molnupiravir|antiviral agent
47922679|NCT01934647|DRUG|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
47922680|NCT05509868|DRUG|PBK_L1704 0.35mg|The subject will receive PBK_L1704 0.35mg/ml by PCA
47922681|NCT05509868|DRUG|PBK_L1704 0.5mg|The subject will receive PBK_L1704 0.5mg/ml by PCA
47922682|NCT05509868|DRUG|Placebo|The subject will receive placebo by PCA
47922683|NCT03720652|BEHAVIORAL|8-Week Mindful Self-Compassion (MSC)|"The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~* Discovering Mindful Self-Compassion~* Practicing Mindfulness~* Practicing Lovingkindness~* Discovering your Compassionate Voice~* Living Deeply~* Meeting Difficult Emotions~* Exploring Challenging Relationships~* Embracing Your Life"
48270526|NCT04436276|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
48270527|NCT04436276|BIOLOGICAL|Placebo|Participants will receive Placebo.
48270528|NCT01817790|DRUG|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
48270529|NCT01817790|DRUG|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
48270530|NCT03992144|DRUG|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
48270531|NCT03992144|DRUG|metronidazole 400mg|400mg of metronidazole an hour before extraction
48270532|NCT03992144|DRUG|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
47922684|NCT03720652|BEHAVIORAL|6-Week Mindful Self-Compassion (MSC)|"The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~* What is Self-Compassion~* Practicing Self-Compassion~* Discovering your Compassionate Voice~* Self-Compassion and Resilience~* Self-Compassion and Burnout~* Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff."
47922685|NCT01191567|PROCEDURE|VAC treatment|wound treatment with VAC-therapy
47922686|NCT01191567|PROCEDURE|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
48270533|NCT05651971|BEHAVIORAL|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
47922687|NCT05506228|OTHER|No intervention|
47922688|NCT03253341|BEHAVIORAL|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
47922689|NCT03253341|BEHAVIORAL|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
47922690|NCT03642132|DRUG|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
47922691|NCT03642132|DRUG|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
47922692|NCT03642132|DRUG|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
48270534|NCT03132402|DIAGNOSTIC_TEST|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
48270535|NCT05202145|DRUG|ALXN2050|Oral tablet.
48270536|NCT05202145|DRUG|Cyclosporine|Oral capsule.
47922693|NCT04732390|PROCEDURE|erector spinae block with bupivacaine|Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5
48270537|NCT05202145|DRUG|Tacrolimus|Oral capsule.
47922694|NCT04732390|PROCEDURE|erector spinae block with bupivacaine and magnesium sulphate|Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5.
48270538|NCT05202145|DRUG|MMF|Oral tablet.
48270539|NCT03611439|DIETARY_SUPPLEMENT|ReBuilder|8-component botanical dietary supplement
48270540|NCT03611439|DIETARY_SUPPLEMENT|Placebo|Inactive Placebo Capsule
47922695|NCT04623853|DEVICE|Variable Stiffness AFO|The Dynamic AFO is able to adjust in stiffness depending on activity.
47922696|NCT04953988|PROCEDURE|Robotic TKA|Robotic TKA
47922697|NCT04953988|PROCEDURE|Manual operation|Manual operation
47922698|NCT01853618|DRUG|Tremelimumab|3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
47922699|NCT01853618|PROCEDURE|RFA|Performed on Day 36
47922700|NCT01853618|PROCEDURE|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
47922701|NCT01853618|PROCEDURE|Cryoablation|Performed on Day 36
47922702|NCT05094518|BEHAVIORAL|Mobile phone reminders|Appointment reminders in the form of push notifications will be sent through HERA app.
47922703|NCT00970385|DRUG|CHOP21|"CHOP regimen:~* cyclophosphamide 750 mg/m2 intravenously (IV) day 1~* doxorubicin 50 mg/m2 IV day 1~* vincristine 1,4 mg/m2 (maximum 2 mg) day 1~* prednisone 100 mg/m2/D from D1 to D5."
48270541|NCT00389584|DRUG|irinotecan hydrochloride|
48270542|NCT00389584|PROCEDURE|cognitive assessment|
48270543|NCT00389584|PROCEDURE|management of therapy complications|
48270544|NCT00389584|RADIATION|radiation therapy|
48270545|NCT01934569|DRUG|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
48270546|NCT04957459|OTHER|No intervention|No intervention
48270547|NCT04239326|DIAGNOSTIC_TEST|targeted Next Generation Sequencing (tNGS)|The index tests used in this trial will include up to three end-to-end, targeted next generation sequencing (tNGS) solutions for diagnosis of DR-TB. Each solution will include all of the equipment, reagents, and software necessary for handling the entire sequencing workflow, including DNA extraction from processed sputum samples (i.e. sediment), library preparation, sequencing, and data analysis/interpretation for clinical result reporting.
48270548|NCT00159094|DRUG|Doxil and Vinorelbine|
48270549|NCT05861505|DRUG|Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)|"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
48270550|NCT05861505|OTHER|Repeat local treatment|"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
48270551|NCT01639326|DRUG|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
48270552|NCT01639326|DRUG|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
47922704|NCT00970385|DRUG|VIP/ABVD|"VIP regimen:~* etoposide 100 mg/m2/D IV from D1 to D3~* ifosfamide 1000 mg/m2/D from D1 to D5~* cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~* doxorubicin50 mg/m2/D on D1 and D14~* bleomycin 10 mg/m2/D~* vinblastine 10 mg/m2/D~* dacarbazine 375 mg/m2/D"
47922705|NCT00970385|RADIATION|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
47922706|NCT03610529|DEVICE|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
47922707|NCT03610529|DEVICE|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
48270553|NCT04566367|DIAGNOSTIC_TEST|blue laser imaging|The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
48270554|NCT01786317|DEVICE|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
47922708|NCT03496714|BEHAVIORAL|Psychoeducation on trauma reactions|The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
47922709|NCT03496714|BEHAVIORAL|Psychoeducation on safety behaviors|The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
47922710|NCT03512457|BEHAVIORAL|Minimal Intervention|Women view an educational poster in changing room, and they receive a brochure.
47922711|NCT03512457|BEHAVIORAL|Intensive Intervention|Women view an educational poster in changing room, and they receive a brochure.
47922712|NCT01481532|DRUG|Crotoxin|Intra patient dose escalation
47922713|NCT02975232|BEHAVIORAL|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
47922714|NCT02975232|BEHAVIORAL|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
47922715|NCT05453149|BEHAVIORAL|Integrated Physical Activity and Behavioural Change Intervention|"Physical Activity (PA) Component: A group-based PA program geared to the level of injury and mobility delivered through web conferencing software. Participants select at three sessions weekly over 10 weeks. Sessions include 45 mins of exercise (i.e boxercise; aerobics; yoga) and 15 mins of social interaction with the group.~Behavioural Change Component: Participants will also receive synchronous 1:1 sessions (approximately 20 mins/week) with a trained clinician on behavioural strategies to initiate and maintain engagement in PA over the 10-week period. Content of the sessions includes: providing information on PA and the self-management of impairments and related symptoms; evaluating barriers to engagement (e.g. fear of injury); and behavioural strategies."
47922716|NCT05867979|DIAGNOSTIC_TEST|Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes|The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.
47922717|NCT05262062|OTHER|Strain Counter Strain Technique|"When general or local pain began to diminish, upper trapezius , levator scapulae and SCM was placed in a position of ease and was held for approximately 20 to 30 seconds.~2. Moderate digital pressure was applied to the identified MTrP as participants rated their level of pain on a scale ranging from 1 to 10.~3. Ease was defined as the point at which a reduction in pain of at least 70% was achieved.~4. Once the position of ease was identified, it was held for 20 to 30 seconds."
47922718|NCT05262062|OTHER|Muscle Energy Technique,|"After the ease position was maintained for 20 to 30sec an isometric contraction focused on the muscle fibers around the MTrP was performed.~2. Each isometric contraction was held for 7 to 10 sec and was followed by a soft-tissue stretch for 15 seconds and then relax for 30 seconds. Each stretch was held for 30 seconds, and it was repeated 3 times during the treatment session.~3. Treatment was performed on the 3 most painful areas between the upper border of the upper trapezius muscle, the SCM, the levator scapulae, and the SC muscle."
47922719|NCT05262062|OTHER|Integrated Neuromuscular Inhibition Technique|"1. Group c will receive Combination of exercise (strain counter strain , muscle energy \& ischemic compression. In ischemic compression patient will receive compression,~2. After MTrPs identification,~3. Ischemic compression was applied in an intermittent manner for up to 2 minutes for each MTrP.~4. The pincer grasp (for the trapezius muscle and SCM) or direct digital pressure (for the levator scapulae and SC muscle) was used with the patients in either the supine position or sitting upright"
47922720|NCT05484544|DIAGNOSTIC_TEST|High sensitivity troponin T|Collection of hs-cTnT samples
47922721|NCT01346995|OTHER|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
48270555|NCT02975830|RADIATION|Three dimensional CT based images|Right bronchial angle, left bronchial angle
48270556|NCT00445302|DRUG|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
48270557|NCT00002969|DRUG|paclitaxel|
48270558|NCT02736903|BEHAVIORAL|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
48443584|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains|"The pathologists assess pyloric or pseudopyloric metaplasia. Pyloric or pseudopyloric metaplasia of corpus is defined as the presence of torturous deep glands in a pseudo-pylori pattern with focal or complete loss of parietal cells. The score of pyloric or pseudopyloric metaplasia of the corpus mucosa is ranging from 0 to 3. Score 0 is no loss of parietal cells with normal fundus gland patterns. Score 1 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia with few forming pylorus-like glands. Score 2 presents focal loss of parietal cells and scattered patterns of pyloric or pseudopyloric metaplasia mixed with \>= 4 pylorus-like glands. Score 3 was clusters of pylorus-like glands; the metaplasia involves \> 60% of mucosa and extends to the lower third of mucosa."
47922722|NCT01346995|OTHER|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
47922723|NCT00712400|DRUG|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
47922724|NCT00712400|DRUG|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
47922725|NCT01782391|DEVICE|Stimulation|
48270559|NCT02736903|BEHAVIORAL|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
47922726|NCT01782391|DEVICE|SHAM|no stimulation
47922727|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
47922728|NCT00388583|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
47922729|NCT06533995|DEVICE|Visuprime|Visuprime is a medical device (class IIa sterile) with ophtalmic indication, consisting on a 10 ml multidose bottle
47922730|NCT06533995|OTHER|Placebo|placebo eyedrop isotonic buffered saline solution
47922731|NCT00435253|BIOLOGICAL|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
47922732|NCT00199043|DRUG|Allopurinol|
47922733|NCT00199043|DRUG|Rasburicase|
47922734|NCT05482750|OTHER|Resistance training in the fasted state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
47922735|NCT05482750|OTHER|Resistance training in the fed state|On the first day of evaluations, the subjects will perform the basal metabolic rate (BMR) analysis, as well as familiarization with the neuromuscular tests. After the preliminary tests, the volunteers will perform the pre-intervention procedures. Assessments of body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be performed. In addition, instruments related to dietary control and physical activity level will be applied. Subsequently, in a randomized manner, participants will be allocated to one of two different interventions. During the intervention (8 weeks), the adherence to the standard diet will be verified, as well as body composition, muscle thickness and quality, maximum dynamic strength and maximum power will be reassessed. After the 12 weeks of intervention, the volunteers will perform the evaluations referring to the post-intervention moment, following the same steps of the pre-intervention collections.
47922736|NCT03393247|DRUG|infliximab and azathioprine combination at week 0|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
47922737|NCT03393247|DRUG|infliximab and azathioprine combination at week 14|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
48270560|NCT00166348|BEHAVIORAL|Cognitive Group Therapy|
48270561|NCT04887402|DRUG|Clomiphene Citrate|"All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles \>10mm, follow up till ovulation"
48270562|NCT01568203|DRUG|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
48270563|NCT01568203|DRUG|Placebo|Matching placebo control for AMG 579 at each dose level
48270564|NCT02159027|DRUG|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
48270565|NCT02159027|DRUG|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
48270566|NCT01232478|BEHAVIORAL|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
48270567|NCT05548088|BIOLOGICAL|LILRB4 STAR-T cells|Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg。
48270568|NCT00289913|BIOLOGICAL|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
47922738|NCT03504046|DEVICE|Artificial Pancreas App|The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
47922739|NCT04197310|DRUG|Nivolumab|240mg, intravenously, Day 1 and 15 of a 28 day cycle
47922740|NCT04197310|DRUG|Cabozantinib|40mg, orally, Daily for a 28 day cycle
47922741|NCT00511394|DRUG|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
47922742|NCT00511394|DRUG|Normal Saline|Infusion of 100 mL of Normal Saline
47922743|NCT04175847|DRUG|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
47922744|NCT06533761|DRUG|Eganelisib|eganelisib will be administered as monotherapy
47922745|NCT06533761|DRUG|Eganelisib in combination with cytarabine|eganelisib will be administered in combination with cytarabine
47922746|NCT03868527|OTHER|Data collection|Data collection for biostatistical analysis about hematological diseases
48270569|NCT00289913|BIOLOGICAL|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
47922747|NCT03601884|BEHAVIORAL|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication \& Metabolic Monitoring, Collaborative \& Strategies, Change enhancement, Visioning \& Goal Setting and Maintain Well-being.
47922748|NCT03601884|OTHER|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
47922749|NCT00285389|DRUG|Adriblastin|
48270570|NCT00289913|BIOLOGICAL|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
47922750|NCT00285389|DRUG|dexamethasone|
47922751|NCT00285389|DRUG|Chlorambucil|
47922752|NCT00285389|DRUG|rituximab|
48270571|NCT04901156|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
48270572|NCT04901156|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
48270573|NCT04901156|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
48270574|NCT04390087|OTHER|Exercise|Upper-body rowing performed while participants are sitting in their own wheelchair.
48270575|NCT03706573|DRUG|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
48270576|NCT05859035|DEVICE|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
48270577|NCT05901467|DRUG|kisspeptin 112-121|One IV bolus of kisspeptin 112-121
48270578|NCT05901467|DRUG|GnRH|One IV bolus of gonadotropin-releasing hormone
47922753|NCT00285389|DRUG|cyclophosphamide|
47922754|NCT00285389|DRUG|alkeran|
47922755|NCT00285389|PROCEDURE|Total body irradiation (8Gy/4fr)|
47922756|NCT00285389|DRUG|vincristine|0,4 mg/day day 1 to day 4
47922757|NCT01688206|BIOLOGICAL|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
47922758|NCT01688206|BIOLOGICAL|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
47922759|NCT04540510|DEVICE|OPEP therapy|Oscillatory Positive Expiratory Pressure therapy
47922760|NCT04540510|OTHER|Standard care|Standard pneumonia care
47922761|NCT01311284|DEVICE|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
47922762|NCT01311284|DEVICE|Macintosh laryngoscope|intubate with the macintosh laryngoscope
47922763|NCT01311284|DEVICE|McGrath|Intubate with McGrath device
47922764|NCT01311284|DEVICE|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
47922765|NCT06293976|OTHER|Changes in the ventilator respiratory rate and tidal volume|"With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.~If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,"
47922766|NCT05346822|PROCEDURE|integrated rehabilitation (the collaborative patient education)|Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
47922767|NCT01505764|DRUG|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
47922768|NCT01505764|DRUG|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
47922769|NCT04352972|DEVICE|Tele-monitored home exercise program|Tele-monitoring home exercise program used in the home with monitoring by physiotherapists.
47922770|NCT04352972|OTHER|Hospital-based rehabilitation program|Participants will receive a maximum of 8 sessions over 10 weeks with the option of two additional sessions. Participants will receive exercises, patient education, manual therapy and other modalities that were prescribed and progressed at the project physiotherapist's discretion. Participants will also receive a set of home exercises and they will be instructed to exercise on days when not attending rehabilitation.
47922771|NCT03159962|DEVICE|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
47922772|NCT03159962|DEVICE|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
47922773|NCT06478381|DRUG|L218CAR19|L218CAR19 is intravenously administered at three dose levels.
47922774|NCT01697280|BEHAVIORAL|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~1. Vaccines can save a child's life~2. Children who are immunized on time are less likely to become ill~3. Unimmunized children can become disabled for life~4. Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
47922775|NCT01697280|OTHER|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
47922776|NCT01697280|OTHER|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
47922777|NCT01105065|DRUG|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
47922778|NCT00781573|DRUG|Clopidogrel|Clopidogrel, 75 mg QD, for one year
47922779|NCT00514852|DRUG|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
47922780|NCT00514852|DRUG|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
47922781|NCT02263352|DRUG|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
47922782|NCT02263352|DEVICE|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
47922783|NCT00004040|BIOLOGICAL|recombinant interferon alfa|
47922784|NCT00004040|BIOLOGICAL|rituximab|
47922785|NCT04473742|BIOLOGICAL|Blood collection|4 EDTA tubes for 24 mL blood collection
47922786|NCT04473742|BIOLOGICAL|Blood sample|2 drying tubes for 12 mL blood collection
47922787|NCT04473742|BIOLOGICAL|Blood sample|1 drying tube for 6 mL blood collection
47922788|NCT03223168|DEVICE|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
47922789|NCT04263584|DRUG|Copanlisib|Copanlisib vials 60 mg
47922790|NCT04263584|DRUG|R-CHOP Chemotherapy|Immunochemotherapy
47922791|NCT02559700|BEHAVIORAL|Brain training programme|An online package of brain training programmes
47922792|NCT01374100|BEHAVIORAL|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
47922793|NCT01374100|BEHAVIORAL|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
47922794|NCT01865552|BIOLOGICAL|SB4|SC administration
47922795|NCT01865552|BIOLOGICAL|EU sourced Enbrel|SC administration
47922796|NCT01865552|BIOLOGICAL|US sourced Enbrel|SC administration
47922797|NCT02683590|DEVICE|Ceramic Implant|The replacement of the sternum by a ceramic implant
47922798|NCT02522624|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
47922799|NCT00742664|BEHAVIORAL|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
47922800|NCT00742664|BEHAVIORAL|Wait-list control|The subject will not receive active treatment during this interval.
47922801|NCT03541395|DRUG|GnRH antagonist|
47922802|NCT01719744|DRUG|ENMD-2076|
47922803|NCT03414892|DRUG|Globalagliatin Hydrochloride|once daily, oral
47922804|NCT03414892|DRUG|Placebo|once daily, oral
47922805|NCT02117557|PROCEDURE|Single incision laparoscopic surgery|
47922806|NCT02117557|PROCEDURE|Conventional laparoscopic surgery|
47922807|NCT00499616|DRUG|carboplatin|Given IV
47922808|NCT00499616|DRUG|cyclophosphamide|Given IV
47922809|NCT00499616|DRUG|doxorubicin hydrochloride|Given IV
47922810|NCT00499616|DRUG|etoposide|Given orally
47922811|NCT00499616|DRUG|topotecan hydrochloride|Given IV
47922812|NCT00499616|DRUG|Isotretinoin|Given orally
47922813|NCT00499616|PROCEDURE|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
48270579|NCT01277640|DRUG|dapivirine|"* dosage form: gel 0.05%~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
48270580|NCT01277640|DRUG|matched placebo|"* dosage form: gel, no api~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
48270581|NCT01277640|DRUG|universal placebo|"* dosage form: gel, HEC-based~* dosage: 2.5g~* frequency: once daily~* duration: 7 days"
47922814|NCT00499616|DRUG|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
47922815|NCT02922699|DRUG|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
47922816|NCT02922699|DRUG|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
47922817|NCT03574181|OTHER|Smartwatch to measure Blood Alcohol Level (BAL)|Subjects will wear a wristwatch with a sensor that measures blood alcohol level during a 1-hour period of consuming alcohol followed by a 5 hour observation period.
47922818|NCT05439213|DRUG|Adrenaline 0,33 Mg/mL Solution for Injection|adrenaline dosage
47922819|NCT05439213|DRUG|Adrenaline 1 Mg/mL Solution for Injection|adrenaline dosage
47922820|NCT01630278|DRUG|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
47922821|NCT01630278|DRUG|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
47922822|NCT02043899|DRUG|[124I]meta-Iodobenzylguanidine|Single intravenous administration of \[124I\]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq \[124I\]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
47922823|NCT03260049|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy
47922824|NCT02872506|DRUG|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
47922825|NCT02872506|PROCEDURE|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
47922826|NCT04672382|DRUG|Morphine|During the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm) located 3 cm apart. Two areas will be treated with an intradermal injection of morphine (0.05 ml, 0.1 mg/ml), and two areas with an intradermal injection of isotonic saline.
48270582|NCT01597102|OTHER|No interventions|No intervention is planned in this study
47922827|NCT05311644|OTHER|Telephone survey|All participants are interviewed by telephone, and are asked to answer a survey.
47922828|NCT03470675|DRUG|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
47922829|NCT03470675|DRUG|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
47922830|NCT03470675|DRUG|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
47922831|NCT00662298|DRUG|prednisolone|40mg of prednisolone once a day for 14 days
47922832|NCT03584581|DIETARY_SUPPLEMENT|Olive polyphenols|The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
48270583|NCT04248205|DRUG|Ketamine|Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
48270584|NCT00883883|DRUG|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
48270585|NCT00883883|DRUG|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
48270586|NCT03472508|DRUG|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
48270587|NCT03472508|DRUG|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
48270588|NCT03472508|DRUG|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
48270589|NCT00427362|DRUG|Adalimumab|
47922833|NCT03584581|DIETARY_SUPPLEMENT|Control|Placebo
47922834|NCT03602560|DRUG|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
47922835|NCT03602560|DRUG|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
47922836|NCT03602560|DRUG|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
47922837|NCT04381039|DEVICE|Insole|3D printing insole (Nylon), 3D printing insole (TPU), CNC machine insole (EVA), shoe only
47922838|NCT00038389|DRUG|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
47922839|NCT00052624|BIOLOGICAL|transferrin-CRM107|
47922840|NCT05202964|OTHER|Tolerance and adherence to oral antibiotics in patients managed for BJI|"Adherence and tolerance will be measured 6 weeks (S6) and 3 months (M3) after the surgery.~The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire) Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.~Patients will respond to a questionnaire about the tolerance on the consultation at S6 and M3."
47922841|NCT05662800|DIAGNOSTIC_TEST|Assessment of peanut, tree nuts and sesame allergy|"Children will undergo skin prick testing with the following allergens: commercial extracts for peanut, hazelnut, almond, cashew, pistachio, walnut, macadamia, sesame, Timothy grass, and birch pollen; positive and negative control; peanut butter and tahini (sesame) paste.~Specific IgE levels will be quantified to all the above-listed tree nuts, peanuts, sesame seed and peanut components (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, Ara h 9).~Children will undertake cumulative or incremental oral food challenge with peanut, sesame and tree nuts, depending on the risk assessment based on patient's medical history and results of diagnostic tests."
47922842|NCT02878187|DEVICE|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
47922843|NCT06138860|OTHER|strain counter strain technique|It will be done in accordance with the technique principles in which the therapist will locate trigger point, and then find a position of comfort or mobile point (at least a 70% decrease in tenderness),monitored the tender point, holding the position o f comfort for 90 seconds, It will be conducted three times per session, for twelve sessions three times per week every other day over the course of a month.
47922844|NCT06138860|OTHER|physical therapy exercises|"Physical therapy exercises for twelve sessions, three times a week, over the course of a month.~Exercises will include:~stretching exercises for the hamstring, calf muscles, and back muscles.~strengthening exercises for back muscles and abdominal muscles."
47922845|NCT06220760|DIAGNOSTIC_TEST|Ultrasound|The use of US to calculate placenta accreta index
47922846|NCT02817529|DEVICE|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
47922847|NCT02817529|DEVICE|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
47922848|NCT06466408|DIETARY_SUPPLEMENT|Supplementation Protocol|After the pre-test, the enzyme group consumed 30 mL of vegetable and fruit enzymes (The contents include needle-leaf cherries, cherries, apples, cranberries, blackberries, black currants, blueberries, beets, broccoli, cabbage, carrots, Concord grapes, cranberries, elderberries, kale, oranges, peaches, papayas, parsley, pineapples, raspberries, red currants, spinach, and tomatoes, etc.)(Enzyme Village, Chiayi, Taiwan) mixed with 150 mL of water twice a day (at breakfast and dinner) for 14 consecutive days. The placebo group followed the same protocol but consumed malt syrup (Amazon, USA) instead until the end of the study. Participants returned to the laboratory each morning to receive the daily supplement, which was administered on-site. Following supplementation, participants reported their dinner intake to the researchers, ensuring compliance with the prescribed supplementation regimen.
47922849|NCT06466408|DIAGNOSTIC_TEST|Blood Lactate Test|The blood lactate was measured at five time points: before exercise, after the fourth and eighth bouts of exercise, and at 5 and 10 minutes after exercise. The blood lactate were analyzed using a Biosen Cline blood analysis system (EKF-diagnostic, Germany). Capillary blood samples of 10 μL were collected and added to red blood cell lysis reagent and stored at low temperature until analyzed. Prior to analysis, instrument standardization and test calibration were performed, and the coefficient of variation was determined to be ≤1.5%. The detection range for blood lactate was 0.5-40 mM
48095592|NCT05777057|DIAGNOSTIC_TEST|Diagnodent|using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
48095593|NCT05893043|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral capsules.
48095594|NCT05893043|OTHER|Placebo|Participants will receive matching placebo oral capsules.
48095595|NCT00002589|BIOLOGICAL|aldesleukin|
48095596|NCT00002589|BIOLOGICAL|muromonab-CD3|
48095597|NCT00002589|BIOLOGICAL|therapeutic autologous lymphocytes|
47922850|NCT06466408|DIAGNOSTIC_TEST|Training Impulse|In this study, the exercise load was represented by the TRIMP \[32\], which is calculated as the product of exercise intensity and duration. To accommodate the convenience of the experiment, two different TRIMP calculation methods were used, including % HRmax (objective) and RPE (subjective). At the end of each exercise bout (8 bouts in total) and during the recovery period before the next bout (7 bouts in total), participants were asked to report their RPE, and their heart rate was recorded. This process was repeated 8 times.
47922851|NCT06466408|DIAGNOSTIC_TEST|Exergaming HIIE Test|The sensor system utilized two Nintendo controllers: one mounted on the exercise ring and the other secured to the participant's thigh to enhance gameplay interaction. Through the Ring-Con, participants engaged in diverse physical activities such as weightlifting, yoga, and aerobic exercises. The fitness ring sensor accurately captures and integrates players' movements into the game. The gameplay involves unlocking levels and engaging in fitness challenges that are achieved through actual physical activities. It offers a wide range of exercise routines targeting various muscle groups and provides engaging gaming challenges. The exercise protocol included eight sets of 20-second high-effort exercises, interspersed with 30-second rest intervals, totaling 370 seconds of active exercise time. Specifically, the fitness game mode used was the Adventure Mode in 'Ring Fit Adventure,' comprising exercises targeting the pectoralis major, latissimus dorsi, deltoids, and quadriceps muscles.
47922852|NCT04829084|BEHAVIORAL|Pre-post educational intervention|To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway
47922853|NCT00605956|DRUG|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
47922854|NCT00605956|DRUG|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
47922855|NCT00605956|DRUG|Blank Patch|Blank Patch
47922856|NCT02029378|DRUG|Eculizumab|
47922857|NCT03679520|OTHER|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~1. Introduction, life-change of becoming a parent and co-parenting~2. Early parenthood~3. Breastfeeding, caring for the baby and early parenthood~4. and 5 Labour, birth and postnatal care"
47922858|NCT03679520|OTHER|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~1. (or 1 and 2) Labour, birth and postnatal care~2. or 3 Breastfeeding, caring for the baby and early parenthood"
47922859|NCT01870934|DEVICE|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
47922860|NCT01724554|DRUG|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
47922861|NCT01757340|BEHAVIORAL|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
47922862|NCT01757340|BEHAVIORAL|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
47922863|NCT01700309|BEHAVIORAL|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
47922864|NCT02651909|OTHER|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
47922865|NCT02219802|PROCEDURE|Treatment according arm|
47922866|NCT02524483|BEHAVIORAL|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
47922867|NCT02524483|BEHAVIORAL|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
48270590|NCT00892580|DRUG|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
47922868|NCT04644315|DRUG|Alectinib|Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death.
47922869|NCT04441190|BEHAVIORAL|Digital Action Observation Therapy (Digital AOT)|The participants will be asked to observe videos and then practice what the participants observed.
47922870|NCT04441190|BEHAVIORAL|Digital Mirror Therapy (Digital MT)|The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.
47922871|NCT04441190|BEHAVIORAL|Conventional Occupational Therapy|The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
47922872|NCT04554836|DRUG|Cetuximab|Patients in Arm A will receive FOLFIRI +cetuximab.
48270591|NCT03684135|OTHER|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
47922873|NCT04554836|OTHER|FOLFIRI|Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
47922874|NCT06212258|PROCEDURE|Abdominal Laparascopy|pneumoperitoneum
47922875|NCT01771809|DRUG|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
47922876|NCT01771809|DRUG|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
47922877|NCT05594862|DEVICE|Lipogems|Micro-fragmented adipose tissue infiltration
48270592|NCT06362967|COMBINATION_PRODUCT|Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG|For allogeneic haematopoietic stem cell transplantation patients with high titers of anti-HLA antibodies present in the body, a desensitisation regimen of immunosorbent or plasma exchange combined with rituximab and high-dose IVIG is used prior to transplantation.
47922878|NCT03847441|DRUG|Calcipotriol|Calcipotriol ointment (0.005%)
47922879|NCT03847441|DEVICE|Narrow Band UVB|NB-UVB (311nm) phototherapy
47922880|NCT03847441|DIAGNOSTIC_TEST|vitamin D3 level|vitamin D3 (ng/ml)
47922881|NCT04297722|OTHER|Dairy products|Dairy consumption including total dairy, full-fat dairy, low-fat dairy, total milk, full-fat milk, low-fat milk, total yogurt, full-fat yogurt, low-fat yogurt, total cheese, hard cheese and fresh cheese
47922882|NCT00165802|DRUG|E7974|Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
48270593|NCT03628027|DEVICE|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
48270594|NCT00351364|DRUG|Montelukast Sodium|100 mg P.O. One time only
48443585|NCT05238181|DIAGNOSTIC_TEST|Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains|"Mouse anti-human TFF2 monoclonal antibody (R\&D Systems) is used to stain gastric corpus tissues to assess the presence and degree of SPEM. The score of TFF2 staining of the corpus mucosa is ranging from 0 to 3. Score 0 is not stained. Score 1 is a scattered pattern of TFF staining between parietal cells; the staining is limited in the middle third of the mucosa. Score 2 is TFF2-expressing cells distributed over both the middle and lower third of the glands. Score 3 is torturous gastric oxyntic glands with a diffuse expression of TFF2 into the whole glands over both the middle and lower third of the glands of the mucosa."
48443586|NCT05238181|DIAGNOSTIC_TEST|The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)|"We take five gastric mucosal biopsies in each patient under gastroscopy, including two from the antrum (at the lesser and greater curvature, 2 cm within the pylorus, respectively), two from the corpus (at the lesser curvature of the lower corpus and the greater curvature of the middle corpus, respectively), and one from the lesser curvature of the high corpus.~The pathologists assess the gastric pathology according to the updated Sydney system. Accordingly, the histological findings are translated into CGI, the Operative Link for Gastritis Assessment (OLGA), and the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) stages."
48443587|NCT06220097|DRUG|Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells|Bridging therapies from enrollment before CD19 CAR-T infusion. A treatment regimen containing mitoxantrone hydrochloride liposome injection, including but not limited to the following recommended regimens: R-MINE regimen (rituximab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) G-MINE regimen (obinutuzumab + ifosfamide + mitoxantrone hydrochloride liposome + etoposide) MAE regimen (mitoxantrone liposome hydrochloride + cytarabine + etoposide) . The recommended dose of mitoxantrone liposome hydrochloride is not limited. For patients who achieve SD or better after one cycle of bridging treatment, it is up to the investigator to decide whether to receive CAR-T therapy. Fludarabine-based lymphodepletion chemotherapy was followed by CD19 CAR-T cells (relma-cel, axi-cel or humanized CAR19). Relma-cel and axi-cel will be infused according to the instructions. CART19 infusion is conducted at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
48443588|NCT05091645|OTHER|GFI|Two trained raters who will be blinded and will have no access to each other's evaluation, will administer the GFI questionnaire within 24 hours of patients' hospital admission.
48443589|NCT05066217|DRUG|Clemizole HCl|Double-Blind Randomized
48443590|NCT05066217|DRUG|Placebo to match EPX-100|Double-Blind Randomized
48443591|NCT04776330|BIOLOGICAL|BCMA targeted prime CAR-T cells|BCMA targeted prime CAR-T cell therapy
48443592|NCT02851771|OTHER|Nasopharyngeal Swab|
47922883|NCT02811874|BEHAVIORAL|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
48443593|NCT01771263|DEVICE|iControl-RP|
48443594|NCT06559514|BEHAVIORAL|Group-based multi-component psychoeducational inventions (GMC-PEIs)|The participants were randomly assigned to either the experimental group, using a computer-generated list of random numbers.
48443595|NCT00670761|DRUG|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
48443596|NCT00670761|PROCEDURE|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
48443597|NCT05277779|DIAGNOSTIC_TEST|cardiac magnetic resonance(CMR)|CMR was performed to assess myocardial tissue characteristics in the study population
47922884|NCT02811874|BEHAVIORAL|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
47922885|NCT05884749|BEHAVIORAL|Peer to Community (P2C) Model|The P2C model is an outreach model including peer support, occupational therapy and social work aimed at facilitating community integration through relationship building and meaningful activity engagement for individuals living with concurrent disorders following homelessness.
47922886|NCT05884749|BEHAVIORAL|Care as Usual (UC)|Participants in this group will receive care available typically in the community
48095598|NCT00002589|PROCEDURE|adjuvant therapy|
48270595|NCT05888896|OTHER|methyldopa tablets 250mg|patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks
47922887|NCT03007004|DRUG|Botulinum toxin type B (2500 units / vial)|BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.
47922888|NCT03007004|DRUG|Physiological saline|Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
47922889|NCT01604993|OTHER|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
47922890|NCT01604993|OTHER|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
47922891|NCT02495571|OTHER|Cough Assessment in ALS Patients|"1. Volitional Cough assessment by spirometer:~   a) Peak Cough Espiratory Flow (PCEF)~2. Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)"
47922892|NCT00168129|PROCEDURE|Helical tomotherapy|
48270596|NCT05888896|OTHER|methyldopa tablets 250mg + foot reflexology|patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
47922893|NCT00611754|DRUG|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
47922894|NCT01588418|DRUG|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
48270597|NCT06253416|OTHER|Exercise|a home exercise program consist of stretching and strengthening exercises , 5 repetitions of each exercise three days a week for 12 weeks
48270598|NCT06253416|OTHER|Control|exercise freely and without supervision with their daily routine
48270599|NCT04899635|OTHER|In-vitro contractile fatigue protocol|Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
48270600|NCT01352481|OTHER|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
48270601|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI structured group CBT|ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
48270602|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI study-specific workbook|A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
48270603|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI YouTube videos|YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
47922895|NCT01588418|DRUG|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
47922896|NCT04475198|DRUG|ST-2427|Investigational drug
47922897|NCT04475198|DRUG|Placebo|5% Dextrose Injection
47922898|NCT06233669|OTHER|Analysis of Burnout|No intervention used.
47922899|NCT04150367|DRUG|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
47922900|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
47922901|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
47922902|NCT04150367|DRUG|Rifampicin|Participants will get the dosage according to the instruction for use.
47922903|NCT04150367|DRUG|Isoniazid|. Participants will get the dosage according to the instruction for use.
47922904|NCT04150367|DRUG|Ethambutol|Participants will get the dosage according to the instruction for use.
47922905|NCT02885467|PROCEDURE|Total knee arthroplasty with Saphenous nerve burial|
47922906|NCT02885467|PROCEDURE|Standard total knee arthroplasty|
47922907|NCT04096378|BEHAVIORAL|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
47922908|NCT04096378|BEHAVIORAL|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
48270604|NCT05567523|DRUG|Dexmedetomidine|In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.
47922909|NCT04010578|DIETARY_SUPPLEMENT|MK-7 and vitamin D3|Patients will receive 400 micro-grams of Menaquinone-7 and 80 micro-grams of vitamin D3 per day.
47922910|NCT04010578|OTHER|Placebo|Patients will receive a placebo each day.
47922911|NCT04596436|OTHER|no intervention|no intervention
47922912|NCT05132803|DRUG|HPV 16 TA-CIN|No dose escalation or reduction
47922913|NCT02507037|DIETARY_SUPPLEMENT|gum+PEG|chew sugarless gum
47922914|NCT02507037|DRUG|polyethylene glycol|2L PEG
47922915|NCT03763565|BIOLOGICAL|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
47922916|NCT03763565|OTHER|Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
47922917|NCT00248963|DRUG|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
47922918|NCT03471624|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
47922919|NCT01087788|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
47922920|NCT01087788|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
47922921|NCT01087788|OTHER|Placebo|Matching Placebo to CZP injection.
47922922|NCT05178368|PROCEDURE|Surgical/ Transcatheter aortic valve replacement|The choice of intervention will be made by the local clinical team. The timing of intervention will be determined by randomisation as part of the main EASY/EVOLVED trials
47922923|NCT05045989|BEHAVIORAL|Residence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)|SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.
47922924|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
47922925|NCT04586387|DEVICE|intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle|repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
47922926|NCT03560518|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
47922927|NCT03560518|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration)
47922928|NCT01248104|DRUG|Tranexamic Acid|Infusion during cardiac surgery
47922929|NCT01248104|DRUG|Aminocaproic Acid|Infusion during cardiac surgery
48270605|NCT05567523|DRUG|Normal saline|normal saline
47922930|NCT05973721|BIOLOGICAL|phage|The treatment group was given one phage each time, once a day for two weeks
47922931|NCT06139627|OTHER|Best Practice|Receive usual care
47922932|NCT06139627|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
47922933|NCT06139627|OTHER|Communication Intervention|Receive GA assessment summary and assessment-based recommendations
47922934|NCT06139627|OTHER|Comprehensive Geriatric Assessment|Complete GA
47922935|NCT06139627|OTHER|Electronic Health Record Review|Ancillary studies
47922936|NCT06139627|OTHER|Survey Administration|Ancillary studies
47922937|NCT02757638|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
47922938|NCT03320824|DEVICE|New Dermal Filler|hyaluronic acid
47922939|NCT03320824|DEVICE|Device: FDA Approved Dermal Filler|hyaluronic acid
47922940|NCT02051933|DRUG|Botulinum toxin type A|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
47922941|NCT02051933|DRUG|sodium chloride|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
48270606|NCT05567523|DRUG|Midazolam|midazolam
48270607|NCT04856137|DRUG|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
48270608|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade the Flexor Hallucis|
48270609|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade adductor of the thumb.|
48270610|NCT03823391|DRUG|ABBV-3373|ABBV-3373 is administered as intravenous (IV) infusion
48270611|NCT03823391|DRUG|Placebo for ABBV-3373|Placebo for ABBV-3373 is administered as IV infusion
48270612|NCT03823391|DRUG|Adalimumab|Adalimumab is administered as subcutaneous (SC) injection
48443598|NCT05812781|DRUG|VTX2735|Dose A
47922942|NCT02587377|OTHER|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
47922943|NCT00243646|RADIATION|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
47922944|NCT00243646|DRUG|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
47922945|NCT00243646|DRUG|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
48270613|NCT03823391|DRUG|Placebo for adalimumab|Placebo for adalimumab is administered as subcutaneous (SC) injection
47922946|NCT01879644|BEHAVIORAL|NF|
47922947|NCT01879644|BEHAVIORAL|SM|
47922948|NCT01879644|BEHAVIORAL|PE|
47922949|NCT01879644|BEHAVIORAL|SU|
47922950|NCT02857348|BEHAVIORAL|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
47922951|NCT02857348|BEHAVIORAL|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
47922952|NCT04277806|BEHAVIORAL|New Oral feeding process|From the beginning of 32 weeks, try oral feeding once a day, suck pacifier for 10 minutes before feeding. When she/he can finish 50% of the amount of one meal in consecutive two days, and there is no adverse events happened, then we will try oral feeding twice a day. In the same way, in the oral feeding she/he can finish 50% of this meal in consecutive two days, there is no adverse events happened, then we will try three oral feedings three times a day. We wil continue the process until the infant can be fully oral fed by herself/himself.
47922953|NCT04330729|DRUG|Acetylsalicylic acid|Se arm description
47922954|NCT02205489|DRUG|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
47922955|NCT02205489|DRUG|cetirizine|Pharmaceutical form:tablet Route of administration: oral
47922956|NCT02205489|DRUG|ranitidine|Pharmaceutical form:tablet Route of administration: oral
47922957|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
47922958|NCT02205489|DRUG|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
47922959|NCT02205489|DRUG|aciclovir|Pharmaceutical form:tablet Route of administration: oral
47922960|NCT02205489|DRUG|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
47922961|NCT02205489|DRUG|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
47922962|NCT02205489|DRUG|paracetamol|Pharmaceutical form:tablet Route of administration: oral
47922963|NCT03743935|OTHER|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
47922964|NCT00386542|BIOLOGICAL|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
48270614|NCT05876403|OTHER|Conventional|The participants of controlled group will be given the treatment protocol after baseline measurements controlled breathing techniques (3session per week 10mins for 6 weeks) \& Aerobic exercise(3 session per week for 6 weeks) with 10sec hold into 10reps.outcome measures will be recorded through a digital spirometer \& measurement of 6MWT \& chest expansion.
48270615|NCT05876403|OTHER|PNF|The participants of experimental group will be given the Intervention protocol after baseline measurements. Additionally these 30 participants will also receive PNF technique exercises consisting of Thoracic Vertebral pressure, Anterior Basal stretch, and Intercostal stretch for 20-25 minutes in 3 sessions per week, and outcomes Measures will be recorded through a digital spirometer and measurements of 6 minutes walk test and chest Expansion.
48270616|NCT01247311|DIETARY_SUPPLEMENT|Dietary supplement|Placebo given orally 3xweek for six months
48270617|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
48443599|NCT05812781|DRUG|VTX2735|Dose B
47922965|NCT00386542|DEVICE|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
47922966|NCT03553992|BEHAVIORAL|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
47922967|NCT03553992|BEHAVIORAL|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
47922968|NCT05923216|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
47922969|NCT05923216|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
47922970|NCT01158001|BEHAVIORAL|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
47922971|NCT00899353|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
47922972|NCT05237206|BIOLOGICAL|SUPLEXA|PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.
47922973|NCT04727021|DRUG|20 mg tablet rivaroxaban|Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
47922974|NCT04727021|DRUG|20 mg rivaroxaban, granules for oral suspension|Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
47922975|NCT00770575|DRUG|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
47922976|NCT00770575|DRUG|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
47922977|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
48270618|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
47922978|NCT02160132|DRUG|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
47922979|NCT02886208|BEHAVIORAL|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
47922980|NCT00606905|BIOLOGICAL|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
47922981|NCT00606905|OTHER|normal saline|equivalent volume of normal saline
47922982|NCT00167778|DEVICE|Transverse plane rotation adaptor pylon|Potential future practice
47922983|NCT00167778|DEVICE|Rigid pylon|Current clinical practice
47922984|NCT00613912|OTHER|Magnetic Resonance Imaging|"* Morphological sequences~* Arterial Spin Labelling (Perfusion)~* Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
47922985|NCT06434987|PROCEDURE|Retrograde Inferior Vena Cava Perfusion|Retrograde inferior vena cava (RIVP) involves perfusing oxygenated blood into the inferior vena cava, which then flows towards the viscera, abdominal organs and lower extremities. By maintaining perfusion to these regions during cardiopulmonary bypass (CPB) and induced hypothermia, Retrograde inferior vena cava (RIVP) helps mitigate the risk of ischemic injury to the abdominal organs. Following the initiation of total cardiopulmonary bypass, the body temperature will be gradually lowered to achieve deep-moderate hypothermia ( 24-38°C). This procedure will involve the combination of selective antegrade cerebral perfusion and retrograde inferior vena cava perfusion. Antegrade perfusion will be maintained at a flow rate of 5-7mL/min/kg, while retrograde perfusion will be regulated to sustain the required pumm pressure and blood flow.
47922986|NCT06434987|PROCEDURE|Antegrade cerebral perfusion|After mild to moderate hypothermia is achieved, a cannula will be inserted into the right axillary artery, brachiocephalic or innominate artery to provide continuous flow to the brain. A flow rate of 5-7mL/min/kg will be maintained.
47922987|NCT00574236|DRUG|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
47922988|NCT05729867|PROCEDURE|Endoscpic biliary drainage using fully covered metal stent|"After selective cannulation of the bile duct, cholangiography is obtained using contrast agent.~A guide wire is passed through the stricture, and then fully-covered metal stent is inserted under fluoroscopy guidance during ERCP."
47922989|NCT02730793|DRUG|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
48270619|NCT00758784|DRUG|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
48270620|NCT00891202|DRUG|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
48443600|NCT04030845|PROCEDURE|breast reconstruction|The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
48443601|NCT04030845|PROCEDURE|oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
48443602|NCT01193712|PROCEDURE|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
48443603|NCT06263972|DEVICE|Direct Stimulation Prefrontal Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to prefrontal cortex for 3 weeks.
47922990|NCT02730793|DRUG|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
47922991|NCT02730793|DRUG|Nasal Placebo|Placebo (nasal saline twice per day)
47922992|NCT04381182|DEVICE|Apollo Wearable Device|Participants wear Apollo device which generates vibration frequencies on skin and can be controlled by the user
47922993|NCT06173180|DEVICE|TOT|In the Transobturator Tape-TOT operation, the anterior vaginal wall is incised 2 cm sagittal 1.5 cm below the urethra in the dorsal lithotomy position and the paraurethral areas are separated by sharp and blunt dissection and the ischiopubic bone is reached with the finger. The skin is incised so as to remain 1 cm lateral to the ischiopubic ramus on the line passing through the clitoris, and the synthetic tape is placed from outside to inside with special inclined trocars, passing under the urethra close to the medial part of the obturator foramen. Cystoscopy is not performed during the procedure. The vagen mucosa is sutured and the procedure is terminated by inserting a urethral foley catheter. The urethral catheter is removed on postoperative day 1 after the investigator evaluates the patient.
47922994|NCT06173180|DEVICE|VACS-D|The VACS-Minifiks procedure is a vaginal application of a natural tissue repair procedure whose efficacy has been proven in the abdominal route. The second difference is that the procedure is performed through a single incision instead of the three incisions used in the Transobturator Tape-TOT operation. Thus, the same goal will be achieved in a less invasive way without placing an artificial permanent implant. There is no difference in parameters such as anesthesia, operation time, and discharge time.
47922995|NCT03856281|DEVICE|Intermittent Pneumatic Compression|Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period
47922996|NCT02956590|DRUG|Pitavastatin|Statin
47922997|NCT02956590|DRUG|Placebo|Placebo
47922998|NCT02277561|PROCEDURE|diffusion tensor imaging|Undergo VB-DTI
47922999|NCT02277561|RADIATION|whole-brain radiation therapy|Undergo WBRT
47923000|NCT02277561|RADIATION|stereotactic radiosurgery|Undergo SRS
47923001|NCT02277561|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
47923002|NCT02277561|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
47923009|NCT00093405|DRUG|tanespimycin|
47923010|NCT04109885|DRUG|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
48298824|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
47923011|NCT04109885|DRUG|prochlorperazine and diphenhydramine.(Standard Treatment)|Intravenous administration of prochlorperazine and diphenhydramine.
47923012|NCT04169932|BIOLOGICAL|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 \^ 6 cells/kg,2 × 10 \^ 6 cells/kg,4 × 10 \^ 6 cells/kg,8 × 10 \^ 6 cells/kg).
47923013|NCT03417713|DEVICE|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
47923014|NCT06280742|RADIATION|PET-MRI with [18F]-DPA-714|PET-MRI with \[18F\]-DPA-714
47923015|NCT02204124|DEVICE|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
47923016|NCT02204124|DEVICE|Standard of care scissors, ligatures, clips, and sutures|
47923017|NCT01323855|DRUG|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
47923018|NCT05049317|PROCEDURE|Laparoscopic FTME surgery|Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
47923019|NCT04863183|BIOLOGICAL|CELLISTEM-OA|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
47923020|NCT04863183|DRUG|Triamcinolone acetonide|The intra-articular puncture will be performed by an orthopedic doctor specializing in knee and hip treatments. The procedure will be carried out using sterile technique, after cooling the skin with local ice.
47923021|NCT05600777|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
47923022|NCT05600777|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
47923023|NCT03663556|OTHER|Infant-feeding|Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
47923024|NCT00711178|PROCEDURE|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
47923025|NCT02568891|DIETARY_SUPPLEMENT|Probiotic|multispecies probiotic
47923026|NCT02568891|DIETARY_SUPPLEMENT|Placebo|matrix
47923027|NCT01270802|DRUG|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
47923028|NCT01270802|DRUG|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
47923029|NCT01270802|DRUG|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
47923030|NCT01337102|PROCEDURE|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
47923031|NCT01337102|PROCEDURE|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
47923032|NCT06298942|PROCEDURE|natural band|to use the round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy
47923033|NCT06298942|PROCEDURE|silicone band|to use synesthetic band with sleeve gastrectomy
47923034|NCT00451503|DEVICE|Middle Ear Implant|surgery
47923035|NCT02926521|DEVICE|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
47923036|NCT02926521|DEVICE|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
47923037|NCT03354143|DRUG|Standard Care|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
47923038|NCT03354143|DRUG|Intensive Treatment|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
47923039|NCT04810689|DRUG|Xuanfei Baidu Granules|Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
47923040|NCT04810689|OTHER|Placebo|Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
47923041|NCT00145977|DRUG|Alendronate|alendronate 70 mg once weekly
48270621|NCT00891202|DRUG|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
48270622|NCT02357511|DEVICE|Study Monitor used|
48270623|NCT00143325|DRUG|varenicline (CP-526,555)|
48270624|NCT02542176|OTHER|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
48270625|NCT02542176|OTHER|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
47923042|NCT00145977|DIETARY_SUPPLEMENT|Calcium Citrate|600 mg of calcium citrate
47923043|NCT00145977|DIETARY_SUPPLEMENT|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
47923044|NCT04756336|DRUG|LTX-109 gel, 3% w/w|The drug is applied to affected lesions according to treatment regimen
47923045|NCT05922800|DEVICE|Electro Press Needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
47923046|NCT05922800|DRUG|Gamma-Oryzanol|The patients in this group were given orally gamma-oryzanol tablets 20mg each time, three times a day, for 6 months.
47923047|NCT01049542|DRUG|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
47923048|NCT02856360|OTHER|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
47923049|NCT02856360|OTHER|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
47923050|NCT04221776|OTHER|Group toilet training in daycare|During the training, children wore underpants, were informed about potty training, were encouraged to drink often and were asked regularly if they felt the need to void. Tutors looked for elimination signals in the child and quickly responded by putting the child on the potty when he/she expressed the need to void or to defecate. Children were positively rewarded. Parents received a leaflet containing practical tips concerning TT and their child's successes of the past two days. They were asked to continue TT at home during the following weekend and longer if necessary. Daycare workers were asked to pay more attention on the TT during the following days and weeks to ensure the effect of the intervention.
48270626|NCT01873755|BEHAVIORAL|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
48270627|NCT04991831|DEVICE|Unilateral thalamotomy|Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.
47923051|NCT04221776|OTHER|Individual toilet training at home|Parents were encouraged to start TT their child, because they were considered as being ready to initiate TT. Children did not receive any intervention, but parents were asked to start TT in their own manner. Parents were allowed to search for information on methods of TT with their relatives, internet, books,...
47923052|NCT05738681|DRUG|N acetyl cysteine|N acetyl cysteine 1,200 mg/day for 8 weeks in NAC group
47923053|NCT03267485|DEVICE|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
47923054|NCT02082938|DEVICE|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
48270628|NCT03314506|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
47923055|NCT06193122|DEVICE|Ultrasound imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
47923056|NCT02432352|BEHAVIORAL|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
47923057|NCT00518960|DRUG|ProAlgaZyme|
47923058|NCT04195542|OTHER|Questionnaire|questionnaire assessing knowledge of the need to take vitamin B9 supplementation in women in the periconceptional period and the reasons why this supplementation is carried out or not
47923059|NCT00978757|DRUG|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
47923060|NCT00978757|OTHER|Placebo|saline solution
47923061|NCT00097981|DRUG|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
47923062|NCT00097981|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
47923063|NCT00097981|DRUG|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
47923064|NCT01937429|DEVICE|Colonoscopy with blue Indigo Carmin®|
47923065|NCT01937429|DEVICE|Standard colonoscopy with insufflation of air|
48443604|NCT06263972|DEVICE|Shame cortex stimulation|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with shame low current electrical stimulation to cortex for 3 weeks.
48443605|NCT06263972|DEVICE|Direct Stimulation to Motor Cortex|The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation to Motor cortex for 3 weeks.
47923066|NCT00483132|DRUG|interferon alpha 2a|
47923067|NCT03439683|OTHER|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
47923068|NCT03834558|OTHER|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
47923069|NCT00305929|DRUG|Treatment with Tookad VTP|
47923070|NCT00305929|DRUG|Treatment with Tookad VTP|Tookad 2 mg/kg
47923071|NCT00305929|DRUG|Treatment with Tookad VTP|2 mg/kg
48095599|NCT06135831|OTHER|Functional olive paste|Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.
48270629|NCT02257047|DIETARY_SUPPLEMENT|Tea|
48095600|NCT06135831|OTHER|Calciovitmag (CDCaMg)|Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
48270630|NCT02257047|DIETARY_SUPPLEMENT|RYR|red yeast rice
48270631|NCT01812902|PROCEDURE|Radical Prostatectomy|
48270632|NCT03404778|DEVICE|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
48270633|NCT01967290|DEVICE|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
48443606|NCT06263972|BEHAVIORAL|erobic physical activity|Aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment),
48443607|NCT01003054|DRUG|Busulfan|130 mg/m\^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
47923072|NCT02379130|BEHAVIORAL|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
47923073|NCT02379130|BEHAVIORAL|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
48270634|NCT01967290|DEVICE|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
48270635|NCT01245088|DRUG|chondroitin sulfate|400 mg orally three times daily for 8 weeks
48270636|NCT01586845|DRUG|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
48270637|NCT01586845|DRUG|tacrolimus|tacrolimus as per labeled dose
48270638|NCT03411395|DIETARY_SUPPLEMENT|5AA+CrPic Water|Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
48270639|NCT03411395|OTHER|Placebo drink|Placebo water with carbonation and aroma
48270640|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
48270641|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)|Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
48270642|NCT01496157|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
48270643|NCT03521947|DIAGNOSTIC_TEST|Complete blood picture|Iaboratory investigation
48270644|NCT00403260|DRUG|Pyronaridine - artesunate|once a day for 3 days
47923074|NCT04830098|OTHER|Spinal stabilization exercises|It will be given stabilization exercises for a total of 18 sessions, 3 times a week for 6 weeks, each session for 45 minutes.
47923075|NCT04830098|OTHER|Chiropractic manipulation|It will be applied high-speed low-amplitude (HVLA) chiropractic manipulation for a total of 6 sessions, once a week for 6 weeks.
47923076|NCT00645450|DRUG|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
47923077|NCT00645450|DRUG|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
47923078|NCT01601600|DRUG|BYM338|BYM338
48270645|NCT00403260|DRUG|Mefloquine plus artesunate|once a day for 3 days
48270646|NCT05293730|BEHAVIORAL|eFRIEND|eFRIEND is a 6-month CWH-led intervention. All CHW will be part of the research team to ensure successful recruitment and interaction with patients, and all CHW will be certified and have participated in the North Carolina Community Health Worker Standardized Core Competency Training.
47923079|NCT01601600|DRUG|Placebo|BYM338 Placebo
47923080|NCT06353022|DRUG|Teclistamab|Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
47923081|NCT06353022|DRUG|Talquetamab|Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses
48270647|NCT05293730|OTHER|Usual Care|Routine treatment in primary care
48270648|NCT00320970|DRUG|Candesartan|
48270649|NCT06412692|OTHER|The Motivational Interviewing Technique|Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
48270650|NCT03846245|OTHER|No intervention|No intervention
47923082|NCT06353022|DRUG|Lenalidomide|"Induction therapy with lenalidomide:~Lenalidomide 25 mg/day oral from Day 1 to Day 21.~Maintenance therapy lenalidomide (administered orally) for finite duration."
48270651|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
48270652|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
48270653|NCT03268356|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure Kit|A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
48270654|NCT04032340|OTHER|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
48270655|NCT02844790|DRUG|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
48270656|NCT01592994|BEHAVIORAL|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
48270657|NCT00363831|DRUG|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
48270658|NCT02210663|DRUG|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
48270659|NCT00755079|DRUG|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
48270660|NCT00755079|DRUG|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
48270661|NCT03538769|OTHER|electronic alert and clinical decision support system|Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
48270662|NCT05647330|DRUG|Hydroxychloroquine Combined With Gemcitabine|Hydroxychloroquine combined with chemotherapy
48270663|NCT00054132|BIOLOGICAL|Bevacizumab|Given IV
48270664|NCT00054132|DRUG|Erlotinib Hydrochloride|Given PO
48270665|NCT00054132|OTHER|Laboratory Biomarker Analysis|Correlative studies
48270666|NCT01752023|DRUG|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
48270667|NCT01752023|DRUG|Cisplatin + Gemcitabine|Active Comparator
48270668|NCT02297789|DEVICE|Investigative Full Face Mask with Headgear|
48270669|NCT00179959|DRUG|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
48270670|NCT00179959|DRUG|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
48270671|NCT00179959|DRUG|Water|Water baths twice weekly for three months
48270672|NCT00179959|DRUG|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
48270673|NCT00827190|DRUG|ILS-920|
48270674|NCT05274126|BEHAVIORAL|Patient group/Passvers|"Passvers intervention aims at :~* helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~* supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~* Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~* encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~* promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~* allowing cooperation between health and social structures aiming at destigmatizing mental illness."
47923083|NCT06353022|DRUG|Bortezomib|Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
47923084|NCT06353022|DRUG|Daratumumab|Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
48095601|NCT06135831|OTHER|Phosporovitmag (PDCaMg)|Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily
48095602|NCT06135831|OTHER|Control|Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
48095603|NCT05380232|BEHAVIORAL|Leisure-time physical activity|Self-reported leisure-time physical activity, categorized as; zero (reference), \>0-7.49 MET-hrs/week, 7.5-14.9 MET-hrs/week, or ≥15 MET-hrs/week.
48270675|NCT05939297|OTHER|Heart Health Self-efficacy and Self-Management Scale|In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
48270676|NCT05939297|OTHER|Self-Care Management Scale in chronic diseases|For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
48270677|NCT05939297|OTHER|general self-efficacy scale|For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
48270678|NCT01016873|DEVICE|IRay|Low voltage stereotactic radiotherapy system
48270679|NCT03813030|PROCEDURE|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
48270680|NCT03813030|DRUG|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
48270681|NCT03813030|DRUG|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
48270682|NCT03813030|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
48270683|NCT03813030|DEVICE|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
48270684|NCT03813030|PROCEDURE|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
48270685|NCT03813030|PROCEDURE|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
48270686|NCT05133830|DRUG|Obeticholic acid|OCA will be administered
48270687|NCT05133830|DRUG|Linerixibat|Linerixibat will be administered
48270688|NCT05345470|OTHER|140 calories per 30 gram test meal|Food
48270689|NCT05585749|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
48270690|NCT00005724|BEHAVIORAL|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
48270691|NCT00005724|OTHER|Minimal Intervention Group|Dietary Information pamphlets.
48443608|NCT01003054|DRUG|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
48270692|NCT00005724|BEHAVIORAL|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
48270693|NCT06549803|DEVICE|skin bond|"In the skin bond group, fascia closure is performed for incision sites of 10 mm or more, and skin bond is sufficiently applied after subcuticular suture.~For incision sites less than 10 mm, subcuticular closure is performed without closing the fascia, and then skin bond is applied."
48270694|NCT06549803|DEVICE|skin stapler|"In the skin stapler group, fascia closure is performed on incision sites larger than 10 mm, and the skin is closed at 2-3 mm intervals using a stapler.~For incision sites less than 10 mm, skin closure is performed using a skin stapler without closing the fascia."
48270695|NCT00511043|DRUG|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
48270696|NCT03696472|PROCEDURE|robotic assisted surgery|robotic assisted surgery was benefit to operation
48270697|NCT03696472|PROCEDURE|laparoscopic|conventional laparoscopic surgery
48270698|NCT06042374|OTHER|Progressive Core Stabilization Training|The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions. A session consisted of warm-up, core stabilization (30-40 min.), and cool-down exercises. During the training period, exercise volume, degree of difficulty, additional weight, and level of instability (contralateral limb movements and reduction of the support surface, etc.) for each exercise were incrementally increased in four steps.
48270699|NCT06042374|OTHER|Standard Core Strengthening Exercises|The athletes included in the CG performed only Standard Core Strengthening Exercises which is the first phase of the Progressive Core Stabilization Training on fixed surfaces (i.e. without pads and balls, with a flat floor and a bench) for 3 days/week and totally 9-week.
48270700|NCT00955058|DRUG|OCP|Daily For 3 months
48270701|NCT00003400|BIOLOGICAL|filgrastim|
48270702|NCT00003400|DRUG|carmustine|
48270703|NCT00003400|DRUG|cisplatin|
48270704|NCT00003400|DRUG|melphalan|
48270705|NCT00003400|DRUG|vinorelbine tartrate|
48270706|NCT00003400|PROCEDURE|peripheral blood stem cell transplantation|
48270707|NCT01511757|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
48270708|NCT01511757|DRUG|Fluconazole|fluconazole 200 mg
48270709|NCT03030287|DRUG|OMP-305B83|intravenous (in the vein) infusion
48270710|NCT03030287|DRUG|Paclitaxel|administered intravenously
48270711|NCT03124069|DEVICE|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
48270712|NCT03215563|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
48270713|NCT03215563|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
48270714|NCT05116774|DRUG|BCX9930|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
48270715|NCT05116774|DRUG|Eculizumab|Administered by intravenous infusion per current dose regimen
48270716|NCT05116774|DRUG|Ravulizumab|Administered as intravenous infusion per current dose regimen
47923085|NCT06353022|DRUG|Dexamethasone|"Induction therapy with Dexamethasone:~cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22"
47923086|NCT03704753|DRUG|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
48270717|NCT01709331|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
48270718|NCT01709331|DRUG|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
48270719|NCT05855161|OTHER|Rebound therapy|Participants will receive exercise-based training on a trampoline
48270720|NCT05855161|OTHER|Exercises on a stable surface|Participants will receive exercise-based training on a stable surface
48270721|NCT05541783|PROCEDURE|laparoscopy-assisted distal gastrectomy Group|LADG
48270722|NCT05541783|PROCEDURE|Totally laparoscopic distal gastrectomy|TLDG
48270723|NCT04232657|DRUG|Romosozumab|39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
48270724|NCT04232657|DRUG|Denosumab|Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
48270725|NCT04232657|DRUG|Placebo|Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
48270726|NCT05389449|DRUG|Danicopan|Oral tablet
48270727|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
48270728|NCT02086331|BEHAVIORAL|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
48270729|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|
48270730|NCT04237493|DRUG|Metformin and Glimepiride (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 1.5 or 3 mg \[75% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
47923087|NCT03704753|DRUG|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
47923088|NCT00907452|DRUG|melphalan-prednisone-thalidomide|
47923089|NCT00907452|DRUG|lenalidomide-dexamethasone|
47923090|NCT01529138|DRUG|Axitinib|Combination treatment with temsirolimus and axitinib
47923091|NCT01529138|DRUG|Temsirolimus|Combination treatment with temsirolimus and axitinib
48270731|NCT04237493|DRUG|Metformin and Vildagliptin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; OD \[with Ifṭār\])"
48270732|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 9-33 units \[75% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
47923092|NCT05330104|BEHAVIORAL|Mobile Ecological Momentary Assessment|mEMA is a tool that allows for scheduled or triggered surveys to assess a participant's CIPN symptoms and/or fall risk
47923093|NCT03667898|PROCEDURE|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
47923094|NCT03667898|PROCEDURE|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
47923095|NCT06219798|DIAGNOSTIC_TEST|GFR|Exit of the study due to death, dialysis, or transplantation
47923096|NCT06532240|DRUG|Methylene Blue|Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.
47923097|NCT06532240|DRUG|Placebo|An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
48270733|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr \[75% of the pre-Ramadan doses\])"
48270734|NCT04237493|DRUG|Metformin and Glimepiride (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 2 or 4 mg \[100% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
48270735|NCT04237493|DRUG|Metformin and Vildagliptin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; BID \[with Ifṭār and with Suḥūr\]\])"
48270736|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 11-44 units \[100% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
48270737|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr \[100% of the pre-Ramadan doses\])"
47923098|NCT02642224|BEHAVIORAL|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
47923099|NCT05481476|DRUG|Surufatinib|250mg, qd, po, 21 days for a cycle
48270738|NCT00854646|DRUG|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
47923100|NCT05481476|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
48270739|NCT03345056|PROCEDURE|vitrectomy with planned foveal detachment|23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
47923101|NCT05481476|DRUG|AG|nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
47923102|NCT03800394|OTHER|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
47923103|NCT01473368|DIETARY_SUPPLEMENT|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
47923104|NCT01473368|DRUG|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
47923105|NCT04508140|PROCEDURE|Hepatic Biopsy|In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
48270740|NCT00267527|DRUG|CJC 1295|
47923106|NCT04508140|DRUG|BO-112 with Pembrolizumab|. The study treatment consists of the combination of BO-112 given intratumorally inside the liver metastasis at the dose of 1gm in 1.2 mL in combination with intravenous pembrolizumab given at the fixed dose of 200 mg. This treatment will be given every 3 weeks, with a maximum duration of 35 cycles (2 years). Of note, during the first cycle, BO-112 will be administered on D1 and D8.
47923107|NCT02172534|DRUG|Tiotropium bromide low|
48095604|NCT02783950|OTHER|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
48270741|NCT05391243|PROCEDURE|LLETZ|Large loop excision of the transformation zone
48443609|NCT01003054|DRUG|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is \>1500/mcl and platelets \>50,000 /mcl, may be titrated to maintain ANC \>1.0 and platelets \>50,000 /mcl.
48443610|NCT01003054|PROCEDURE|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
48443611|NCT04612140|PROCEDURE|Radiosurgery|The study subjects randomized in this study arm will undergo a radiosurgery procedure.
48270742|NCT03018132|OTHER|mental health screening, education and referral program|"I. Psychosocial assessments:~1. Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~2. Exercise, smoking \& substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~1. All receive a brochure entitled, Speak Up When You Are Down~2. If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~3. Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
48270743|NCT04601480|BEHAVIORAL|Choice Architecture Nudge|During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
48270744|NCT04601480|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
48270745|NCT05533060|OTHER|No intervention|patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
48270746|NCT02418130|DRUG|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
48270747|NCT02418130|DRUG|Placebo|
47923108|NCT02172534|DRUG|Tiotropium bromide medium|
47923109|NCT02172534|DRUG|Tiotropium bromide high|
47923110|NCT02172534|DRUG|Placebo|
47923111|NCT05282953|DRUG|KIO-301|KIO-301 intravitreal injection at ascending doses
48270748|NCT01774214|PROCEDURE|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
48270749|NCT01774214|PROCEDURE|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
48270750|NCT01284504|DRUG|Celecoxib|200 mg tablet oral
48270751|NCT01284504|OTHER|placebo|Placebo, tab
48443612|NCT04612140|PROCEDURE|Repeated catheter ablation|The study subjects randomized in this study arm will undergo repeated catheter ablation.
47923112|NCT04160975|BEHAVIORAL|Video about safety and effectiveness of adult seasonal flu vaccination|The investigators will show subjects videos of either Black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of Black or white actors playing the role of either a doctor or a layperson as well as different scripts.
47923113|NCT02122913|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
47923114|NCT04592718|BEHAVIORAL|Slow deep breathing plus breath counting|Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
47923115|NCT04592718|BEHAVIORAL|Normal-paced breathing plus breath counting|Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
47923116|NCT01943253|DEVICE|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
47923117|NCT01943253|DEVICE|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
47923118|NCT01600625|DRUG|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
47923119|NCT04546984|DRUG|HEC96719|Part 2：Mulltiple doses up to 10 days
48270752|NCT03275909|BEHAVIORAL|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
48270753|NCT00838357|DRUG|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
48270754|NCT05636280|OTHER|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
48270755|NCT05636280|OTHER|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
48270756|NCT06330779|OTHER|Trauma-adapted yoga|"Trauma-adapted-yoga (TAY) classes The classes, which span eight weeks with a once-a-week frequency, each last approximately 45-50 minutes. These small group classes are structured in a semi-circle arrangement to create a sense of security and empowerment for the participants. The teaching approach is trauma-sensitive, characterized by its inviting nature, provision of choices when facing challenges (A-B choices), and direction toward tangible physical sensations to enhance interoceptive awareness. Each yoga session follows a structured sequence of activities designed to promote participants' well-being and physiological awareness.~Online TAY classes After eight weeks, adolescents in the yoga group can continue their practice online. Exclusive to previous in-person participants, they'll receive a link for recorded classes and they will have the possibility to contact their health care contact any time."
48270757|NCT03824301|DEVICE|Volume controlled ventilation|Changing modes of ventilation during cardiopulmonary bypass
48270758|NCT03824301|DEVICE|Pressure controlled ventilation|Applying pressure controlled ventilation during cardiopulmonary bypass Period
48270759|NCT04561232|BEHAVIORAL|Prone and Upright Locomotor Training|"During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve."
48270760|NCT02021409|DRUG|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
48270761|NCT02021409|BIOLOGICAL|Darbepoetin alfa|
48270762|NCT05427578|OTHER|fNIRS measurement|measurement using functional near-infrared spectroscopy
48270763|NCT06395844|DRUG|METR-NK cell(Metabolic Remodeling Nature Killer Cells)|The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
48270764|NCT06259799|BEHAVIORAL|Smart Water Bottle|Participants in the intervention group will receive a bottle which measures participant fluid consumption. The bottle will be set to recommend 2.5L for male participants and 2.0L for female participants, consistent with fluid intake recommendations from the European Food Safety Authority for each sex. Participants will be prompted by the bottle (bottle will light up) when they are behind on fluid intake recommendations. Participants will use a validated urine color chart, 9 point Likert scale for thirst, and measure nude body mass on their own each morning. Participants will be informed that higher values for nude body mass and thirst, and lower values for nude body mass each morning may indicate they are less hydrated day-to-day.
48270765|NCT05595538|BIOLOGICAL|Multiple doses of anti-SARS-CoV-2 Convalescent Plasma|SARS-CoV-2 Convalescent Plasma(1-2 units; \~300-600 mL with the presence of IgG anti-SARS-CoV-2.
48270766|NCT00643630|DEVICE|Tetrix|Twice daily topical application
47923120|NCT02101164|BIOLOGICAL|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
48270767|NCT00643630|DEVICE|Tetrix|Twice daily topical application
48270768|NCT00715130|BEHAVIORAL|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
48270769|NCT03227874|DIETARY_SUPPLEMENT|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
48270770|NCT03227874|DIETARY_SUPPLEMENT|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
48270771|NCT00977470|DRUG|Erlotinib|150 mg taken orally once daily
48270772|NCT00977470|DRUG|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
48270773|NCT03381456|OTHER|LICI|Paired pulse TMS to measure LICI and late cortical disinhibition
48270774|NCT02920060|DRUG|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
48270775|NCT02920060|DRUG|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
47923121|NCT02101164|DRUG|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
47923122|NCT04510428|DRUG|Ocular Surface Immune Globulin (OSIG)|Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
47923123|NCT04510428|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
47923124|NCT01713933|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
47923125|NCT00839176|DRUG|RX-10100|Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks
48095605|NCT00611637|BIOLOGICAL|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
48270776|NCT00961987|OTHER|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
48270777|NCT00961987|OTHER|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
48270778|NCT03638492|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
48270779|NCT03638492|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
48270780|NCT00970606|DRUG|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
48270781|NCT00970606|DRUG|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
48270782|NCT01184690|PROCEDURE|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
48270783|NCT01184690|PROCEDURE|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
48106775|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes."
48270784|NCT06166628|PROCEDURE|Geniculate artery embolization|Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.
48270785|NCT06166628|PROCEDURE|Genicular nerve phenol nerve ablation|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.
48270786|NCT06166628|PROCEDURE|Skin infiltration of 2cc of 0.25% bupivacaine at the knee|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
48270787|NCT01254669|BEHAVIORAL|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
48270788|NCT04210271|BEHAVIORAL|Buddy self-testing condition|
48270789|NCT04210271|BEHAVIORAL|Control self-screening condition|
48270790|NCT03316352|PROCEDURE|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
48270791|NCT03316352|PROCEDURE|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
48270792|NCT03316352|DEVICE|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
48270793|NCT03316352|DRUG|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
48270794|NCT01869348|BEHAVIORAL|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
48270795|NCT00670826|DEVICE|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand \& forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
48270796|NCT00670826|DEVICE|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
48270797|NCT00127751|BEHAVIORAL|Enhance health lifestyle changes and medication compliance|
48270798|NCT03283085|DRUG|25 mg Ontamalimab|Ontamalimab SC solution for injection
48270799|NCT03283085|DRUG|75 mg Ontamalimab|Ontamalimab SC solution for injection
48270800|NCT00000479|DRUG|Aspirin|Participants will receive 100 mg of aspirin every other day.
48270801|NCT00000479|DRUG|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
48270802|NCT00000479|BEHAVIORAL|Placebo|Participants will receive placebo.
48270803|NCT05466643|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
48270804|NCT05466643|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
48270805|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel|
48270806|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel (Reference)|
48270807|NCT02525549|DRUG|Placebo gel|
48270808|NCT03312192|DEVICE|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
48443613|NCT04658745|DEVICE|Intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients, by using a butterfly shape coil.
48270809|NCT03312192|DEVICE|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
48270810|NCT03283631|BIOLOGICAL|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
48270811|NCT02153099|DRUG|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
48270812|NCT02153099|DRUG|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
48270813|NCT02799862|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
48270814|NCT02799862|DRUG|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
48270815|NCT00705978|DRUG|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
48270816|NCT00705978|DRUG|Placebo|placebo
48270817|NCT05146141|OTHER|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
48270818|NCT01275014|DRUG|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
48270819|NCT01275014|DRUG|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
48270820|NCT03835741|DEVICE|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
48270821|NCT03835741|OTHER|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
48270822|NCT02118792|DRUG|AN2728 Topical Ointment, 2%|
48270823|NCT02118792|DRUG|Matching vehicle control|
48270824|NCT05237895|DIAGNOSTIC_TEST|Serum Endocan Levels|Detection of Serum Endocan Levels and detection of possible diagnostic association with gestational diabetes
48443614|NCT04658745|BEHAVIORAL|Mirror Therapy|Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to synchronize with the non-affected hand (illusion on the mirror). The movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
48270825|NCT02338102|OTHER|Saline mixture|premeasured salt packets mixed with distilled water
48270826|NCT00222027|PROCEDURE|Collection of treatment-stratefying prognostic factors|
48270827|NCT01440335|DRUG|Oral R,R'-Fenoterol|
48270828|NCT01440335|DRUG|Oral Racemic Fenoterol|
48270829|NCT03062657|DEVICE|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
48270830|NCT00442403|DRUG|chloroquine|
48270831|NCT00442403|DRUG|dehydroepiandrosterone sulphate|
48270832|NCT01524991|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)
48270833|NCT01524991|DRUG|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
48270834|NCT01524991|DRUG|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
48270835|NCT02174718|DIETARY_SUPPLEMENT|Transdermal D Patch|
48270836|NCT02174718|DIETARY_SUPPLEMENT|Oral vitamin D3|
48270837|NCT02174718|DIETARY_SUPPLEMENT|Placebo patch|
48270838|NCT02174718|DIETARY_SUPPLEMENT|Oral placebo|
48270839|NCT02770521|DRUG|Treprostinil|Administered SC.
48270840|NCT02770521|DRUG|Placebo|Administered SC.
48270841|NCT02770521|DRUG|LY900014|Administered SC.
48270842|NCT02770521|DRUG|Insulin Lispro|Administered SC.
48270843|NCT05366283|BIOLOGICAL|sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
48270844|NCT05855304|OTHER|manual therapy|The leg length was measured while the subjects were lying on their stomachs. Then, by grasping the lateral malleolus, the knees are bent 90 degrees and changes in leg length were observed, the positions of the SI joints were noted. Afterwards, the person
48270845|NCT05855304|OTHER|Kinesiology taping|As part of the tape (kinesio tex brand) kinesio protocol used in this study, the starting position of the kinesio tape is the site of lumbar spine flexion. Kinesio tape was applied transversely to the bilateral sacroiliac joint area as a long I-shaped piece of tape with 80% tension and no tension was applied to the ends of the tape. Another short tape will be adhered to the SI joint with 80% tension at a right angle to the hip, and no tension is applied to the ends of the tape.
48270846|NCT03604731|DEVICE|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
48270847|NCT03072602|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
48270848|NCT03072602|OTHER|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
48270849|NCT04106154|BEHAVIORAL|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
48270850|NCT04810702|OTHER|no intervention|no intervention
48270851|NCT05762926|OTHER|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
48443615|NCT04658745|DEVICE|Sham intermittent theta burst stimulation|iTBS (20 trains of ten bursts at eight-second intervals, 600 stimuli, 200-second per session) will be delivered to the ipsilesional hemisphere in stroke patients. However, a sham coil will be used, which is not associated with any stimulation effect on the brain.
47923126|NCT02872844|DEVICE|ICS AirCal3|Each patient will undergo a 30-minute heat stress to one ear. For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers. An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic. The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes. The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
47923127|NCT06022471|PROCEDURE|Stapes surgery|Stapedectomy operation
47923128|NCT05111015|DEVICE|Concomitant Open Heart Surgical Ablation Procedures|AtriCure's Concomitant Open Heart Surgical Ablation Devices used for the treatment of Atrial Fibrillation.
47923129|NCT05111015|DEVICE|Hybrid (Convergent) Ablation Procedures|AtriCure's Hybrid (Convergent) Ablation Devices used for the treatment of Atrial Fibrillation.
47923130|NCT05111015|DEVICE|AtriCure LAA Exclusion Procedures|AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the treatment of Atrial Fibrillation.
47923131|NCT01528267|OTHER|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
47923132|NCT01528267|OTHER|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
47923133|NCT04301310|DRUG|BMS-986235 (Treatment A)|Specified dose on specified days
47923134|NCT04301310|DRUG|Rifampin (Treatment B)|Specified dose on specified days
47923135|NCT00274833|DRUG|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
47923136|NCT00274833|DRUG|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
47923137|NCT00274833|RADIATION|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
47923138|NCT06414785|OTHER|analysis of samples of periprosthetic capsules taken during breast implant change procedure|characteristics of inflammation and the importance of silicone exposure (intact implant, implant rupture in serum or silicone) at the genomic molecular level, by analyzing the level of expression of genes related to the extracellular matrix and inflammation within a periprosthetic capsule fragment
47923139|NCT00846183|PROCEDURE|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
47923140|NCT00004913|DRUG|cisplatin|
47923141|NCT00004913|DRUG|docetaxel|
47923142|NCT00004913|DRUG|fluorouracil|
47923143|NCT00004913|DRUG|leucovorin calcium|
47923144|NCT03950921|BEHAVIORAL|Patient Safety Display|Digital display of catheter and pressure injury information in patient hospital room
47923145|NCT01298908|PROCEDURE|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
47923146|NCT01298908|PROCEDURE|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
47923147|NCT01298908|PROCEDURE|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
47923148|NCT03271645|BEHAVIORAL|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
47923149|NCT03271645|BEHAVIORAL|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
47923150|NCT03271645|BEHAVIORAL|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
48270852|NCT02146339|OTHER|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
47923151|NCT03271645|BEHAVIORAL|Face-to-face counselling|Face-to-face counselling
48270853|NCT02146339|OTHER|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
47923152|NCT00202475|PROCEDURE|eythrocytapheresis|machinal collection of erythrocytes
47923153|NCT00202475|PROCEDURE|whole blood collection|collection of whole blood
47923154|NCT05317780|DRUG|rAAV9-CB6-AspA|This study is an open label, expanded access trial of a simultaneous, single intravenous (IV) and intracerebroventricular (ICV) administration of rAAV9-CB6-AspA in a child with Canavan disease. The subject will also receive an immunosuppression protocol to prevent reaction to ASPA and vector capsids.
47923155|NCT02819232|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
47923156|NCT01542567|DRUG|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
47923157|NCT01542567|DRUG|Placebo|Placebo suppositories
47923158|NCT04797624|PROCEDURE|Gastric cancer surgery|Appropriate gastric cancer surgery types for the convenient patients
47923159|NCT00305461|DRUG|Ciclesonide|Effect of Ciclesonide on Quality of Life
47923160|NCT01037192|DRUG|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
47923161|NCT01037192|DRUG|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
47923162|NCT01252667|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
47923163|NCT01252667|DRUG|Clofarabine|Given IV
47923164|NCT01252667|DRUG|Cyclosporine|Given PO
47923165|NCT01252667|OTHER|Laboratory Biomarker Analysis|Correlative studies
48270854|NCT02146339|OTHER|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
47923166|NCT01252667|DRUG|Mycophenolate Mofetil|Given PO
47923167|NCT01252667|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
47923168|NCT01252667|OTHER|Pharmacological Study|Optional correlative studies
47923169|NCT01252667|RADIATION|Total-Body Irradiation|Undergo TBI
47923170|NCT05561205|DEVICE|rTMS|repetitive transcranial magnetic stimulation
48270855|NCT02146339|OTHER|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
48270856|NCT02146339|OTHER|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
48270857|NCT02146339|OTHER|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
47923171|NCT05561205|DRUG|methylphenidate|methylphenidate
47923172|NCT03289624|BEHAVIORAL|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG \& PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, \& ending with a review of material, addressing questions, \& previewing the next session. Sessions titles are: Communication \& Health Education; Care Values; Care Preferences; Family, Friends, \& Community Resources; Taking care of yourself-taking care of each other; \& Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values \& preferences are supported when decisions have to be in the future."
47923173|NCT04363151|OTHER|No intervention.|
48270858|NCT03346330|DRUG|TRK-750|TRK-750 capsule
47923174|NCT04347603|PROCEDURE|TAVR|Femoral percutaneous aortic prosthesis (TAVR)
47923175|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
47923176|NCT01547559|DRUG|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
47923177|NCT01547559|DRUG|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
47923178|NCT01547559|DRUG|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
47923179|NCT01547559|DRUG|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
47923180|NCT03238170|DEVICE|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
47923181|NCT05423223|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
47923182|NCT05423223|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
47923183|NCT04578652|DRUG|Metformin 850 mg oral tablet bid|MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
47923184|NCT04578652|DIETARY_SUPPLEMENT|Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.|The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
47951203|NCT06056674|BEHAVIORAL|U-PEACE Intervention|"This program will involve about 13 group sessions, with each group session lasting approximately 40-50 minutes. The program session will be held about 2 times a week during the school day (e.g., lunch time) if the group meets in person, or at a pre-scheduled time every week if the group meets online via Zoom.~Participants will learn how to better understand emotional experiences and use this understanding to embrace agency in challenging situations. Participants will develop skills to better deal with emotions by increasing awareness of what is happening in different settings and choose how to respond. Skill-building exercises may include mindfulness practices, flexible thinking, behavioral activation, problem-solving, and exposure activities."
47923185|NCT03020940|DRUG|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
47923186|NCT04104126|OTHER|Standard of Care Physical Therapy|Will receive standard of care physical therapy
47923187|NCT04104126|OTHER|Blood flow restriction|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.
47923188|NCT04206280|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
47923189|NCT04206280|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
47923190|NCT02081755|DRUG|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
47923191|NCT02081755|DRUG|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
47923192|NCT02081755|DRUG|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 12 months
47923193|NCT02081755|DRUG|CellCept|CellCept: 500 mg to 1500 mg BID for 12 months
47923194|NCT02081755|DRUG|Imuran|0.5 mg/kg to 2 mg/kg QD for 12 months
47923195|NCT01332799|DRUG|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
47923196|NCT01332799|OTHER|Placebo|Sugar pill administered orally for 3 years.
47923197|NCT03531632|BIOLOGICAL|MGD007 + MGA012|MGD007 and MGA012 are administered by IV infusion.
47923198|NCT05212545|DIETARY_SUPPLEMENT|Placebo|maltodextrin taken daily for 4 weeks with water
47923199|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement taken daily for 4 weeks with water
47923200|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic combination|prebiotic oligosaccharides mixture taken daily for 4 weeks with water
47923201|NCT05212545|DIETARY_SUPPLEMENT|Prebiotic oligosaccharides|Prebiotic oligosaccharides taken daily for 4 weeks with water
47923202|NCT02603666|DEVICE|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
47923203|NCT00238602|PROCEDURE|Stereotactic radiosurgery|
47923204|NCT03561688|DEVICE|Foot orthotics|Insoles for shoes
47923205|NCT03561688|DEVICE|Standard insole|Sham foot orthotic
47923206|NCT03160794|DIAGNOSTIC_TEST|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, \[18F\]DCFPyL
47923207|NCT03160794|RADIATION|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using \[18F\]DCFPyL PET/MRI
47923208|NCT04552145|PROCEDURE|surgery|standard decompression surgery
47923209|NCT04552145|BEHAVIORAL|Physiotherapy|3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
47923210|NCT05693012|DIAGNOSTIC_TEST|cfDNA methylation assessment|An exploratory study to establish the early detection and prognosis models of multiple myeloma patients in China based on plasma cf DNA methylation assessment
47923211|NCT01683097|OTHER|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
47923212|NCT04015375|DRUG|Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
47923213|NCT04015375|DRUG|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical gel
47923214|NCT04015375|OTHER|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
47923215|NCT00666484|DRUG|cyclophosphamide|
47923216|NCT00666484|DRUG|doxorubicin hydrochloride|
47923217|NCT00666484|DRUG|etoposide|
47923218|NCT00666484|DRUG|prednisolone|
47923219|NCT00666484|DRUG|procarbazine hydrochloride|
47923220|NCT00666484|DRUG|vincristine sulfate|
47923221|NCT00666484|RADIATION|radiation therapy|
47923222|NCT05282745|OTHER|Follow-up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
47923223|NCT04287543|DRUG|Melatonin|25 mg of melatonin gel at noon and 25 mg of melatonin gel 30 minutes before sleeping for 12 months
47923224|NCT04287543|DRUG|Placebos|25 mg of placebo gel at noon and 25 mg of placebo gel 30 minutes before sleeping for 12 months
47923225|NCT05061043|OTHER|Routine physical therapy treatment|Control group will receive the routine physical therapy treatment that will include EMS, Infrared and Intermittent stretching of facial muscles for 36 sessions on alternate days, each session comprise 30 minutes for 5 days a week
47923226|NCT05061043|OTHER|Routine physical therapy along with orofacial therapy|Experimental group will receive routine physical therapy along with orofacial therapy (36 sessions on alternate days, each session comprise 45 minutes)
47923227|NCT00689260|DEVICE|easypod|Subjects is aware that the device records injection information that can be viewed by user
47923228|NCT00689260|DEVICE|easypod|Subjects is not aware that the device records injection information that can be viewed by user
47923229|NCT01785862|DRUG|Ibuprofen 25 mg|Lozenge, Oromucosal administration
47923230|NCT01785862|DRUG|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
47923231|NCT01128764|BEHAVIORAL|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
47923232|NCT01128764|BEHAVIORAL|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
48270859|NCT03346330|DRUG|Placebo|Placebo capsule
47923233|NCT00322972|DRUG|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
47923234|NCT00436540|DRUG|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
47923235|NCT00436540|DRUG|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
47923236|NCT03213171|BEHAVIORAL|Reception staff providing handout.|Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
47923237|NCT03213171|BEHAVIORAL|Mobile Tablet (e.g. iPad)|Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
47923238|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Myo-inositol
47923239|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|N-Acetyl-Cysteine
47923240|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Folic Acid
48270860|NCT05490706|BEHAVIORAL|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
48270861|NCT05490706|BEHAVIORAL|Walking|Performing a 30 minute minute walk after dinner at home
47923241|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Selenium
47923242|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-arginine
47923243|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|L-carnitine
47923244|NCT03726450|DIETARY_SUPPLEMENT|Andrositol Plus|Vitamin E
47923245|NCT06374043|DRUG|Dapagliflozin 10mg Tab|Oral administration
47923246|NCT06374043|DRUG|Placebo|Oral administration
47923247|NCT06374043|DEVICE|Withings BPM Connect|"CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 28 days. Three consecutive measurements are taken."
47923248|NCT06374043|DEVICE|Withings Body+|"CE marked and clinically validated advanced Wi-Fi smart scale.~Body weight will be measured by the participants once daily on 40 days."
47923249|NCT06374043|DIAGNOSTIC_TEST|Hem-Col Capillary Blood Collection Device|Capillary blood samples will be obtained using a BD Microtainer® Contact-Activated Lancet (Franklin Lakes, New Jersey, USA) once daily on 22 days. These blood samples will be collected into Hem-Col® tubes (Hem-Col, Labonovum, Limmen, the Netherlands), specifically designed for collection of capillary blood acquired through a finger prick. The Hem-Col microtube is equipped with an anticoagulant and a preservation buffer, enhancing the stability of analytes in whole blood. These Hem-Col tubes have the dimensions of standard blood collection tubes and are constructed from polyethylene, featuring a pierceable cap made of thermoplastic elastomers. Each tube incorporates a liquid barrier, with the inner part preventing the loss of Hem-Col preservation fluid and the outer part serving as a scoop for collecting blood from a finger prick. The Hem-Col lithium heparin tubes will be utilized for the analysis of creatinine, CRP, lipid profile, HbA1c, uric acid, glucose and NT-proBNP.
47923250|NCT06374043|DEVICE|MEMS (Medication Electronic Monitoring System) Cap|Medication will be provided in standard medicine bottles with the MEMS® (Medication Electronic Monitoring System) Cap (AARDEX Ltd, Union City, CA, USA), which is a customizable medication package which records and stores up to 4,000 dosing events. The cap fits on standard medicine bottles and with integrated microcircuits, the child-resistant MEMS® Cap records the date and time whenever a patient opens a vial. The stored information can be transferred at any time through the MEMS® Reader to the adherence software for immediate analysis and interpretation.
47923251|NCT06374043|BEHAVIORAL|Questionnaire: participants' perspectives toward remote data collection|Self-made questionnaires consisting of 6 multiple choice questions and 2 open questions will be used to assess patient experience and satisfaction to guide and inform future trials and use in clinical practice.
47923252|NCT03940768|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
47923253|NCT03940768|DIETARY_SUPPLEMENT|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
47923254|NCT00985036|PROCEDURE|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
47923255|NCT01608022|DRUG|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
47923256|NCT06272227|DRUG|alfacalcidol|Subjects assigned to arm 1 take two doses of alfacalcidol once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
47923257|NCT06272227|DRUG|placebo|Subjects assigned to arm 2 take two doses of placebo once a day for a total of 52 weeks from the day after baseline visit 2 to the day before the end of the test (visit 4).
47923258|NCT06272227|DRUG|Denosumab|denosumab
48270862|NCT00000733|DRUG|Ribavirin|
48270863|NCT06031077|PROCEDURE|cardiac catheterization|An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.
48270864|NCT03856944|DEVICE|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
47923259|NCT04831632|DIAGNOSTIC_TEST|quantitative and qualitative iFOBTs|They will have their qualitative and quantitative iFOBTs done within the week prior to the VCC study completion. The reading of both of them will be done in Hospital El Cruce's laboratory. The result of the qualitative iFOBT will have two valid expressions: positive or negative.The result of the quantitative iFOBT will be expressed as µg from hemoglobin per gram of fecal matter through the use of automatized equipment for laboratory analysis.
47923260|NCT00170534|BEHAVIORAL|Behavior|
47923261|NCT01221285|BIOLOGICAL|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
47923262|NCT05033405|BEHAVIORAL|NEURO-LINGUISTIC PROGRAMMING (NLP)|● One session (20-minute long) of NLP application was performed. The NLP techniques that were employed were representational systems and submodality. In this technique, the sensory, auditory, and kinesthetic feelings of the individual are learned. These emotions are modified by imagining. The NLP application was carried out by a researcher who has a certificate in this field
47923263|NCT06148844|OTHER|interactive robot group|Intervention group will receive one day pre-operative preparation intervention applied by researcher. Preparation will be 30-40 minutes long
47923264|NCT00313183|DRUG|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
47923265|NCT02672696|DEVICE|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
47923266|NCT00979667|DRUG|Oseltamivir|75 mg twice daily for 5 days
47923267|NCT00979667|DRUG|Zanamivir|10 mg twice daily for 5 days
48270865|NCT04576312|DRUG|UNI911 inhalation 1% and intranasal spray 1%|Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
47923268|NCT00979667|DRUG|Placebo of Oseltamivir|twice daily for 5 days
47923269|NCT00533793|PROCEDURE|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
47923270|NCT01239732|DRUG|Paclitaxel|175 mg/m\^2 on Day 1 every 3 weeks or at a dose of 80 mg/m\^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
47923271|NCT01239732|DRUG|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
47923272|NCT01239732|DRUG|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
47923273|NCT03162913|DIETARY_SUPPLEMENT|Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
47923274|NCT03162913|OTHER|Placebo|12g red, strawberry-flavored powder, twice daily with water, for 90 days
47923275|NCT03717870|PROCEDURE|Laparoscopic enucleation of ovarian endometrioma.|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
47923276|NCT03717870|PROCEDURE|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
47923277|NCT03717870|PROCEDURE|Assisted Reproductive Technology (ART)|Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
47923278|NCT00601042|OTHER|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
47923279|NCT00601042|OTHER|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
47923280|NCT05863000|OTHER|Online questionnaire/survey|Participants are expected to answer a short survey based on their overall experiences with their own health. No participants will therefore be followed for more than the duration of time it takes a subject to answer the questionnaire (approx 15 minutes). Randomly selected volunteers of around 30 respondents will afterwards be invited to participate in a qualitative interview with the intend to elaborate their questionnaire responds.
47923281|NCT00726401|DRUG|COLD-fX|200mg BID for 4 weeks
47923282|NCT00726401|DRUG|Placebo|200mg BID for 4 weeks
47923283|NCT04441580|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a FIT-positive screening population.
47923284|NCT00439816|BEHAVIORAL|Group Visits|
47923285|NCT01862692|BEHAVIORAL|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
47923286|NCT01862692|BEHAVIORAL|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
47923287|NCT06248047|PROCEDURE|uretheroplasty|4. When the bulb and bulbar urethra are exposed and before further dissection, the bulbar arteries are located using a directional doppler ultrasound stethoscope and a decision is made to sacrifice the artery with the lowest doppler signal to preserve the contralateral best artery. The bulbar urethra is then mobilized, circumferentially dissected and separated distally from the corpus cavernosum up to the penoscrotal angle to gain sufficient length for a tension-free end-to-end anastomosis without detachment of the bulb from the perineal body. If the dissection is not sufficient to bridge the gap,inter-corporal septal separation or even an inferior pubectomy are performed. The scarred tissue is removed completely, the proximal urethral segment is exposed as usual with spatulation of the healthy urethral ends and end-to-end anastomosis of the urethra over a silicon catheter is performed. No dissection is performed contralaterally at the bulb to preserve the artery of that side.
47923288|NCT00505778|DRUG|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
47923289|NCT00505778|DRUG|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
47923290|NCT04155242|DIAGNOSTIC_TEST|Cytosponge test|The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
47923291|NCT04155242|DIAGNOSTIC_TEST|Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation|Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
47923292|NCT04155242|DIAGNOSTIC_TEST|Oesophagogastroduodenoscopy|"* Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~* NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~* Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~* Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands \<3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies."
47923293|NCT02642744|OTHER|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
47923294|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid|2.8mg
47923295|NCT01210040|DIETARY_SUPPLEMENT|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
47923296|NCT05427617|DRUG|Control group|Physician chosen treatment
47923297|NCT05427617|DRUG|Case group|Druggable ctDNA alterations-guided therapy
47923298|NCT01042041|DRUG|sorafenib tosylate|Given orally
47923299|NCT01042041|DRUG|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
47923300|NCT01042041|DRUG|cisplatin|Given via transarterial/hepatic chemoembolization
47923301|NCT01042041|DRUG|mitomycin C|Given via transarterial/hepatic chemoembolization
47923302|NCT01042041|PROCEDURE|transarterial chemoembolization|
47923303|NCT01042041|PROCEDURE|hepatic artery embolization|
47923304|NCT00391209|DRUG|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
47923305|NCT00391209|DRUG|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
47923306|NCT05948865|DRUG|CPO301|Administered by intravenous injection
47923307|NCT05041608|PROCEDURE|Endoscopic Surgery|These procedures include: POEM (Peroral Endoscopic Myotomy) for Achalasia, G-POEM (Gastric Peroral Endoscopic Myotomy) for gastric outlet obstruction, Z-POEM (Peroral endoscopic myotomy for Zenker's Diverticulum), EMR (Endoscopic Mucosal Resection), ESD (Endoscopic submucosal dissection), STER (Submucosal tunneling endoscopic resection), NOTES (Natural Orifice Translumenal Endoscopic Surgery), TIF (Transoral Incisionless Fundoplication), Endoscopic Fistula Closure, Endoscopic Suturing, Capsule Endoscopy and EFTR (Endoscopic full-thickness resection).
47923308|NCT02434588|DEVICE|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
47923309|NCT00564057|DRUG|candesartan|tablet 8-16 mg once daily, one year
47923310|NCT00564057|DRUG|lercanidipine|tablets 10-20 mg once daily, one year
47923311|NCT00680394|DRUG|mifepristone|200 mg mifepristone
47923312|NCT00680394|DRUG|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
47923313|NCT00680394|DRUG|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
47923314|NCT01046435|PROCEDURE|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
47923315|NCT01046435|PROCEDURE|Two placebos|Two placebos 3 times a day for 7 days
47923316|NCT00385190|DRUG|HCV-796|
47923317|NCT05813223|DRUG|Gefapixant|Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
47923318|NCT02122068|BEHAVIORAL|Mentalizing Imagery Therapy|4 week long meditation and mindfulness intervention
47923319|NCT02122068|BEHAVIORAL|Relaxation cd|
47923320|NCT05948384|OTHER|PNF|For the PNF intervention, we applied a lower extremity hip extension-abduction-internal rotation with knee extension pattern, together with the rhythmic initiation of a repeated stretch and a combination of isotonic techniques. By this we'll target rectus femoris, medial gastrocnemius, lateral gastrocnemius, biceps femoris and semitendinosus musculature of the patient. The session will be given in 2 sets of 5 repetitions with rest of 45 seconds
47923321|NCT02364336|DRUG|Peginterferon alfa-2a|
47923322|NCT01646333|BEHAVIORAL|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
47923323|NCT01646333|BEHAVIORAL|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
47923324|NCT01755026|DRUG|cefazolin|2 gram dose for pre-operative prophylaxis
47923325|NCT01755026|DRUG|cefazolin|4 gram dose for pre-operative prophylaxis
47923326|NCT02936661|DRUG|Tranexamic Acid|
47923327|NCT02936661|DRUG|Placebo|
47923328|NCT02220088|PROCEDURE|TAI of FOLFOX|Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
47923329|NCT02220088|DRUG|Sorafenib|Accept sorafenib.
47923330|NCT00913458|DRUG|etanercept|
47923331|NCT02439359|DRUG|CF-301|Dose escalation
47923332|NCT02439359|DRUG|Placebo|
47923333|NCT02379689|DRUG|Injectable placental tissue extract called BioDGenesis (Active Product)|
47923334|NCT02379689|DRUG|Placebo|
47923335|NCT05250544|OTHER|control group|For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
47923336|NCT00129844|DRUG|Motexafin Gadolinium|
47923337|NCT03124927|DEVICE|DCI pulse oximeter sensor|
47923338|NCT01450852|BEHAVIORAL|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
47923339|NCT01610999|DRUG|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
47923340|NCT04605705|COMBINATION_PRODUCT|Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.|Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
47923341|NCT02489929|OTHER|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
47923342|NCT02489929|DRUG|azacytidine|
47923343|NCT06032013|OTHER|Cardiac rehabilitation program (PROMs)|"The program is multidisciplinary with the following components:~* Medical assessment~* Physical training and counselling on physical activity~* Identification and control of risk factors~* Nutritional assessment and counselling~* Psychological assessment and intervention~* Education and information"
47923344|NCT03762096|DIETARY_SUPPLEMENT|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
47923345|NCT03762096|DIETARY_SUPPLEMENT|Placebo|Placebo
47923346|NCT03291093|DRUG|18F-Flutemetamol PET/MRI|All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
47923347|NCT02595632|OTHER|No intervention|
47923348|NCT03181646|DRUG|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
47923349|NCT06529926|OTHER|Observational|Only classical physiotherapy application for 4 weeks.
47923350|NCT06529926|OTHER|IASTM Technique Application|IASTM application for 2 sessions per week with classical physiotherapy for 4 weeks.
47923351|NCT04466709|OTHER|none intervention type|This is an observational study, no intervention
47923352|NCT03148691|DRUG|A-101|Topical Solution
47923353|NCT02691871|DRUG|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
47923354|NCT02691871|DRUG|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
47923355|NCT02691871|DRUG|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
47923356|NCT05414734|DRUG|HHT120|Capsule, oral administration
47923357|NCT05414734|DRUG|Placebo|Capsule, oral administration
47923358|NCT04242667|BEHAVIORAL|e-Health (web-based) disclosure portal|Patient uses secure web-based portal to access genetic research results
47923359|NCT04242667|BEHAVIORAL|Provider mediated disclosure|Patient has disclosure of genetic research result by a provider (genetic counselor)
47923360|NCT03310307|DRUG|Vit D|50,000 IU
47923361|NCT03310307|OTHER|Placebo|
47923362|NCT05621525|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
47923363|NCT00124046|PROCEDURE|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
47923364|NCT00124046|PROCEDURE|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
47923365|NCT03597204|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
47923366|NCT03733990|BIOLOGICAL|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
47923367|NCT01343641|DRUG|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.
47923368|NCT01343641|DRUG|Placebo|Inactive Pill used as a comparator
47923369|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 1 and 15
47923370|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 1 and 15
47923371|NCT03535727|DRUG|Capecitabine|PO twice daily (BID); Days 1-7, 15-21
47923372|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 1 and 15
47923373|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 1 and 15
47923374|NCT03535727|DRUG|Nab-paclitaxel|IV over 30 minutes; Days 4 and 11
47923375|NCT03535727|DRUG|Gemcitabine|IV over 30 minutes; Days 4 and 11
47923376|NCT03535727|DRUG|Capecitabine|PO BID; Days 1- 14
47923377|NCT03535727|DRUG|Cisplatin|IV over 60 minutes; Days 4 and 11
47923378|NCT03535727|DRUG|Irinotecan|IV over 30 minutes; Days 4 and 11
47923379|NCT00947440|DRUG|ABT-072|See arm description for more information
47923380|NCT03129399|DEVICE|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
47923381|NCT03129399|DEVICE|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
47923382|NCT04314791|DEVICE|Ultrasound evaluation, with grayscale and color Doppler imaging|In pregnant women with previous CS and anterior low-lying or placenta previa, the following three sonographic criteria were assessed: (i) the smallest myometrial thickness in the sagittal plane; (ii) presence of placental lacunae and its grade from 0-3; (iii) bridging vessels using color Doppler. The PAI score (up to 9) was calculated for every patient as described by Rac et al.2015.
47923383|NCT02527577|DRUG|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
47923384|NCT02527577|DRUG|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
47923385|NCT04067570|RADIATION|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
47923386|NCT02465554|PROCEDURE|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
47923387|NCT00154089|DRUG|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
47923388|NCT05990218|DEVICE|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
47923389|NCT05990218|DEVICE|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
47923390|NCT05258188|OTHER|Instrument-assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization is used for a mechanical benefit for the therapist providing deeper approach and braces remodeling of connective tissues through dissolution of extravagant fibrosis, while provoking repair and reconstructing forwarded by the recruitment of fibroblast.
47923391|NCT05258188|OTHER|Compressive Myofascial Release Technique|Compressive Myofascial Release Technique is a technique of soft tissue stretching that uses compression and sustained myofascial stretches to create a releasing force in the targeted area
47923392|NCT02429180|OTHER|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
47923393|NCT00027872|DRUG|tipifarnib|Given orally
47923394|NCT00027872|OTHER|laboratory biomarker analysis|Correlative studies
47923395|NCT04257188|PROCEDURE|minimally invasive vitrectomy under subtenon anaesthesia|The safety and feasibility in terms of tolerance and pain sensation during the surgery as well as the possible perception of light and colour sensations in minimally invasive vitrectomy under sub-tenon anesthesia shall be investigated.
47923396|NCT03135418|DEVICE|Intervention|"Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
47923397|NCT03135418|DEVICE|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
47923398|NCT01699347|DRUG|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
47923399|NCT00000776|DRUG|Flucytosine|
47923400|NCT00000776|DRUG|Fluconazole|
47923401|NCT00000776|DRUG|Amphotericin B|
47923402|NCT00000776|DRUG|Dexamethasone|
47923403|NCT03014232|PROCEDURE|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
47923404|NCT03014232|PROCEDURE|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
47923405|NCT03059355|BIOLOGICAL|UCMSCs|Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
47923406|NCT03059355|BIOLOGICAL|BMMSCs|Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
47923407|NCT03059355|OTHER|Placebo|a single administration of placebo delivered via peripheral intravenous infusion.
47923408|NCT00443963|DRUG|Esomeprazole Magnesium|PPI compared to H2RA
48270866|NCT04576312|DRUG|Placebo|The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
47923409|NCT06121245|OTHER|Proton Pump inhibitor|A proton pump inhibitor will be used as a tool to study the effect of pH changes in the stomach lumen on the release of somatostatin (evaluated by measurements of somatostatin and pro-somatostatin 1-64)
47923410|NCT06121245|OTHER|Placebo|Placebo capsule
47923411|NCT06089785|DEVICE|elastography|evaluation of degree of spleen stiffness in liver cell failure patient by elastography.
47923412|NCT04424277|OTHER|diaphragm ultrasound|respiratory loading
47923413|NCT05676918|BEHAVIORAL|Positive Psychology Intervention|PPI includes 2 modules: hedonic well-being and eudaimonic well-being.
47923414|NCT05676918|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 3 modules: behavioral activation, cognitive restructuring, and interpersonal skills.
47923415|NCT00000682|DRUG|Zidovudine|
47923416|NCT00000682|DRUG|Zalcitabine|
47923417|NCT05728099|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations coupled with SpiroGym app. per training session .
47923418|NCT05728099|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations per training session. Participants will be given the practice log to track training adherence.
47923419|NCT04330313|PROCEDURE|Traction|Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
47923420|NCT04330313|PROCEDURE|Laser therapy|Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
47923421|NCT04330313|PROCEDURE|Hot pack|The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
47923422|NCT04330313|PROCEDURE|Stretching|Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
48270867|NCT00529737|PROCEDURE|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
47923423|NCT04064125|DRUG|FMX-101|
47923424|NCT04414735|OTHER|Extracorporeal Photopheresis|Infusion of autologous cellular products exposed to ultraviolet light (UV), in the presence of a photosensitizer. The cellular product is obtained through leucopheresis and its subsequent exposure to 8-methoxypsoralen (8-MOP) and irradiation with UV-A light.
47923425|NCT02036151|DRUG|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
48270868|NCT00529737|PROCEDURE|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
48270869|NCT01208389|BIOLOGICAL|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
48270870|NCT01417754|DRUG|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
48443616|NCT04658745|BEHAVIORAL|Sham mirror Therapy|In sham mirror therapy, the mirror will be covered. Participants will practice the movements with the non-affected hand and try moving the affected arm at the same time to move the non-affected hand. The participants cannot receive mirror visual feedback of the paretic upper extremity movement during the therapy. Same as mirror therapy, the movement practice will involve 5 table-top tasks and the participant will be instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session, lasting for 20 minutes.
47923426|NCT02036151|DRUG|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
47923427|NCT03980353|OTHER|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
47923428|NCT01957670|DEVICE|Lacrima medical Prototypes|
47923429|NCT03675009|OTHER|Educational Programming|Green Cleaning educational programming to day care staff.
47923430|NCT01627834|DRUG|Ropinirole|
47923431|NCT04380064|PROCEDURE|ILM Peeling|ILM peeling performed during primary PPV for PDR
47923432|NCT04380064|PROCEDURE|No ILM Peeling|ILM peeling not performed during primary PPV for PDR
48270871|NCT06126991|DRUG|Cetirizine|Oral administration of cetirizine at 10mg once daily will be used.
48270872|NCT06126991|DRUG|Midazolam and Fentanyl|Midazolam 50mg + fentanyl 300ug micro pump push will be used with a starting dose of 5ml/hour, adjusted according to the patient's level of sedation. The patient's RASS score will be maintained between -1-0 and the drug will be suspended with a blood pressure below 90/60mmHg.
47923433|NCT03546868|DRUG|[18F]FSPG|Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
47923434|NCT03279289|DRUG|Aflibercept|4 mg/kg administered intravenous infusion on day 1
47923435|NCT03279289|DRUG|Irinotecan|180 mg/m2 intravenous infusion
47923436|NCT03279289|DRUG|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
47923437|NCT03279289|DRUG|5Fluorouracil|400 mg/m2 intravenous bolus
47923438|NCT03279289|DRUG|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
47923439|NCT02844062|BIOLOGICAL|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
47923440|NCT02844062|DRUG|cyclophosphamide|250 mg/m\^2 d1-3
47923441|NCT02844062|DRUG|Fludarabine|25mg/m\^2 d1-3
47923442|NCT01037894|PROCEDURE|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
47923443|NCT01037894|PROCEDURE|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
47923444|NCT04705493|OTHER|fluid resuscitation with crystalloid|give two-volume of fluids initial 250ml then another 250 ml
47923445|NCT05504967|DRUG|Oradexon|With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
47923446|NCT05504967|DRUG|Ropivacaine|With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
47923447|NCT05504967|DRUG|Saline solution|With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
47923448|NCT05371847|OTHER|assessment for upper limb dysfunction|clinical assessments and questionnaires
48270873|NCT03049449|BIOLOGICAL|Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
47923449|NCT05371847|OTHER|retest assessment|For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.
47923450|NCT03373331|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
47923451|NCT03373331|BEHAVIORAL|Placebo Control Exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
47923452|NCT04511377|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to rotator cuff repair post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 6 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 6 to 12 weeks post surgery."
47923453|NCT04511377|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
47923454|NCT02850471|DEVICE|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
47923455|NCT03337919|DRUG|Nivolumab|Up to 8 cycles of nivolumab
47923456|NCT06126250|DEVICE|Power sonic toothbrush|Subjects will brush twice daily for 30 seconds using a fluoride toothpaste.
47923457|NCT06126250|DEVICE|Manual toothbrush|Subjects will brush twice daily for 2 minutes using a fluoride toothpaste.
48443617|NCT05728541|DRUG|SYH2043|Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
47923458|NCT02630043|DRUG|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
47923459|NCT02630043|DRUG|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
47923460|NCT04032509|OTHER|2 x 5 mL blood sample|2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
47923461|NCT06227182|DIAGNOSTIC_TEST|Muscle ultrasound with surface electromyography and dynamometry|The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
47923462|NCT06227182|DIAGNOSTIC_TEST|MRI scan|In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
47923463|NCT00147368|DRUG|intravenous (IV) arginine|
47923464|NCT01870076|BEHAVIORAL|Healing Touch|
47923465|NCT01870076|BEHAVIORAL|Healing Touch, Sham|
47923466|NCT01870076|BEHAVIORAL|Control, Presence|
47923467|NCT05451485|DIAGNOSTIC_TEST|Blood speckle tracking|Blood speckle tracking measurements will be acquired of the carotid artery and superficial femoral artery
48270874|NCT03049449|DRUG|Cyclophosphamide|300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
47923468|NCT05451485|DIAGNOSTIC_TEST|Ultrasound particle Imaging Velocimetry|Ultrasound particle imaging velocimetry will be acquired of the carotid artery and superficial femoral artery
47923469|NCT05451485|DIAGNOSTIC_TEST|4D flow MRI|4D flow MRI will be acquired of the carotid artery and superficial femoral artery
47923470|NCT05451485|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements will be acquired of the carotid artery and superficial femoral artery
47923471|NCT02133300|OTHER|electrical stimulation|
47923472|NCT02463890|OTHER|Training|
47923473|NCT02463890|OTHER|Control|
47923474|NCT01425580|DRUG|liraglutide|1.8 mg s.c. (QD)
47923475|NCT01425580|DRUG|glimepiride|4 mg p.o. (QD)
47923476|NCT01425580|DRUG|Metformin|500 mg p.o. (BID)
47923477|NCT01765959|OTHER|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
47923478|NCT01765959|OTHER|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
47923479|NCT02921464|OTHER|none - registry clinic followup only|
47923480|NCT04504851|DRUG|Rosuvastatin 10mg|10mg of Rosuvastatin in the Intensive Phase of Therapy (8 weeks)
47923481|NCT04504851|DRUG|Rifampicin|Rifampicin 10mg/kg
47923482|NCT04504851|DRUG|Isoniazid|Isoniazid 5mg/kg
47923483|NCT04504851|DRUG|Pyrazinamide|Pyrazinamide 25mg/kg
47923484|NCT04504851|DRUG|Ethambutol|Ethambutol 15mg/kg
47923485|NCT05070780|DEVICE|Robot-assisted examination|evaluation of muscle tone with Robot-assisted perturbation
47923486|NCT03560700|DIETARY_SUPPLEMENT|lactobacillus probiotic strain|Approved Dietary supplement
47923487|NCT03560700|OTHER|placebo|placebo comparator
47923488|NCT04031209|DEVICE|G7 Acetabular System|All patients will receive G7 Acetabular System
48270875|NCT03049449|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
48443618|NCT04613258|DIETARY_SUPPLEMENT|SCAR Porridge|The treatment group was given SCAR porridge supplementation in the form of a soft porridge (a mixture of 50 g dry powder porridge added to 200 mL of hot water) along with nutritional counseling. The control group only received nutritional counseling and no SCAR porridge supplementation. A 50 g portion of SCAR porridge was provided once a day for 14 days. The SCAR porridge was monitored and administered by a researcher once a week to inquire about adherence to the supplementation consumption and perceived side effects. All research subjects went through a clearance period of one week and were requested not to consume any supplements.
47923489|NCT02879331|PROCEDURE|10 coils in upper lobes|
47923490|NCT02879331|PROCEDURE|15 coils in upper and lower lobes|
47923491|NCT02879331|PROCEDURE|cycloergometry|
47923492|NCT05254145|DIAGNOSTIC_TEST|Next Generation Sequencing|During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
47923493|NCT04870697|BEHAVIORAL|ACT intervention|"The components of ACT intervention will include six processes to foster parental PF according to the ACT framework.~Session one - Generate creative hopelessness and build acceptance. The objective is to help parents know about the ACT intervention and realize the experiential avoidance or emotional control strategies do not work, finally turn attention to more useful strategies.~Session two - Create space for your thought. The objective is to help parents create a distance from their thoughts and facilitate parents' ability of not being trapped by thoughts.~Session three - Focus on here and now. The objectives to facilitate parents' experiences of observing self and contact with the present moment but not trapped in the past or future.~Session four - Commit actions in line with the value. The objectives to help parents identify their inner value and take value-based actions even facing the challenges in current difficulties of their children with cancer."
47923494|NCT04870697|OTHER|Usual care|Usual care in this study setting includes providing general information, education, psychological support, and consultation.
47923495|NCT05129033|DRUG|Prednisone tablet|Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.
47923496|NCT05129033|DRUG|itraconazole|Anti-fungal medication to reduce fugal load.
47923497|NCT05129033|BIOLOGICAL|Omalizumab|Anti-IgE monoclonal antibody, used for high IgE allergic disease.
47923498|NCT01788436|BEHAVIORAL|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
47923499|NCT01788436|BEHAVIORAL|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
47951204|NCT06056674|BEHAVIORAL|SAU|Participants in this group will continue to receive standard of care within their school clinic.
48270876|NCT01083667|DRUG|Pyrimethamine|Open Label, dose escalating,
48270877|NCT00054847|PROCEDURE|saphenous vein graft|Saphenous vein harvested from the arm is used as a conduit for CABG.
48270878|NCT00054847|PROCEDURE|radial artery graft|Radial artery harvested from the arm is used as a conduit for CABG.
47923500|NCT03860558|OTHER|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
47923501|NCT03860558|OTHER|No Intervention|Participants will not undergo an intervention.
47923502|NCT00003897|BIOLOGICAL|gp100 antigen|
47923503|NCT00003897|BIOLOGICAL|sargramostim|
47923504|NCT03478865|DRUG|Vitamin A palmitate|Provide vitamin A to participants with pre/post assessments of vision.
47923505|NCT03347292|DRUG|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
48443619|NCT04613258|OTHER|Counseling|21 subjects in the control group (C) who only received dietary counseling
47923506|NCT03347292|DRUG|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
47923507|NCT05657574|DRUG|D377|oral, once daily, 8 weeks
47923508|NCT05657574|DRUG|CKD-331|oral, once daily, 8 weeks
47923509|NCT05657574|DRUG|D086|oral, once daily, 8 weeks
47923510|NCT05657574|DRUG|Placebo (for D377)|oral, once daily, 8 weeks
47923511|NCT05657574|DRUG|Placebo (for CKD-331)|oral, once daily, 8 weeks
47923512|NCT05657574|DRUG|Placebo (for D086)|oral, once daily, 8 weeks
47923513|NCT00627575|DRUG|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
47923514|NCT00627575|DRUG|atorvastatin|Atorvastatin will available as 40 mg tablets.
47923515|NCT00627575|DRUG|phenytoin|Phenytoin will available as 100 mg capsules.
47923516|NCT04042246|BEHAVIORAL|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
47923517|NCT03838094|BIOLOGICAL|Biodentine|it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
47923518|NCT03838094|BIOLOGICAL|MTA|MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
47923519|NCT03412565|DRUG|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
47923520|NCT03412565|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
47923521|NCT03412565|DRUG|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
47923522|NCT03412565|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
47923523|NCT03412565|DRUG|Melphalan|Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
47923524|NCT03412565|DRUG|Prednisone|Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
48443620|NCT00610363|BIOLOGICAL|Rilonacept|Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
48443621|NCT00610363|OTHER|Placebo (for Rilonacept)|Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
47923525|NCT03412565|DRUG|Carfilzomib|Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
47923526|NCT01291485|BEHAVIORAL|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
47923527|NCT02403466|BEHAVIORAL|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
47923528|NCT04734197|DRUG|SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|combination of a topical immunosuppressant and a topical corticosteroid solution
47923529|NCT04734197|DRUG|Mycophenolic Acid 0.1%|topical immunosuppressant
47923530|NCT04734197|DRUG|Mycophenolic Acid 0.3%|topical immunosuppressant
47923531|NCT04734197|DRUG|Betamethasone Sodium Phosphate 0.01%|topical corticosteroid solution
47923532|NCT04734197|DRUG|Placebo Comparator: Vehicle|topical vehicle solution
47923533|NCT04734197|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|topical ophthalmic emulsion
47923534|NCT04734197|DRUG|Lifitegrast 5% Ophthalmic Solution|topical ophthalmic solution
47923535|NCT06491901|OTHER|PS was given according to lung ultrasound score|If the lung ultrasound confirms RDS and LUS is more than 8, a full dose of PS will be promptly administered at 200 mg/kg (Poractant Alfa, Curosurf®). If the lung ultrasound does not indicate RDS or if LUS is 8 or less, clinical monitoring will continue. Should the clinical criteria for NRDS be met, a full dose of PS will be administered at 200 mg/kg (Poractant Alfa, Curosurf®). In terms of the administration method, less-invasive surfactant administration (LISA) will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube.
47923536|NCT06491901|OTHER|PS was given according to clinical criteria|In cases where clinical diagnosis confirms NRDS, PS will be administered at a dosage of 200 mg/kg (Poractant Alfa, Curosurf®). LISA will be employed for infants in a non-invasive ventilation state, while those in an invasive ventilation state will receive PS via endotracheal tube. If clinical manifestations do not meet the diagnosis of NRDS, PS will not be administered.
47923537|NCT01975857|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
47923538|NCT01975857|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
47923539|NCT05094310|DEVICE|Acupuncture|Patients with breast cancer who experienced fatigue were measured by the Brief Fatigue Inventory(BFI) scale and other Fatigue related questionnaire. Breast cancer patients diagnosed with cancer related fatigue are included in our clinical study，and those patients will receive acupuncture treatment. The position of acupuncture refers to the principle of acupuncture treatment of traditional Chinese medicine. According to ICD-10-CD code R53.0, the diagnosis of CRF is determined by the experience of diminished energy or other physical and psychological symptoms every day or almost every day for two consecutive weeks in the past month. We collected patients' blood to detect fatigue related SNP.
47923540|NCT05659537|DRUG|Dulaglutide|Administered SC
47923541|NCT05867641|BEHAVIORAL|Immersive VR Therapy in Head-Mounted Device (HMD)|"Caregivers will be trained to administer VR\&R therapy to their loved ones with dementia, in their private home/residence. Participants with dementia will view immersive VR experiences using a commercially-available VR head-mounted device for up to 30 minutes a time, approximately every other day (or as desired), for three weeks. The caregiver will use the custom VR\&R web-based application on their personal device (laptop, tablet, or mobile phone) to select and monitor what their loved one sees in VR.~Staying nearby to monitor for safety and assistance, the caregiver may choose to use the time when their loved one is engaged to take some respite time for themselves (e.g., make a cup of coffee, have an uninterrupted phone call)."
47923542|NCT02044107|BEHAVIORAL|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc \& ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc \& antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
47923543|NCT06110832|BEHAVIORAL|Mindfulness-based Meditation and Yoga program|In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
47923544|NCT00851162|BIOLOGICAL|Trinity multipotent stem cells|Enough to fill voids which vary in size
47923545|NCT00851162|BIOLOGICAL|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
47923546|NCT00210158|PROCEDURE|Nitrous oxyde|
47923547|NCT01128621|DRUG|GSK1292263|Tablet
47923548|NCT01128621|DRUG|GSK1292263 matching placebo|Tablet
47923549|NCT01128621|DRUG|Sitagliptin|Tablet
47923550|NCT01912313|PROCEDURE|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
47923551|NCT02123251|BEHAVIORAL|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
47923552|NCT01239992|DRUG|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
47923553|NCT04458324|DRUG|Buspirone Hydrochloride|Subjects take 30 mg buspirone HCl twice a day for 6 months.
47923554|NCT04458324|DRUG|Buspirone placebo|Subjects take a placebo tablet twice a day for 6 months.
47923555|NCT04458324|DEVICE|Noninvasive Ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
47923556|NCT04458324|DEVICE|Sham Non-invasive ventilation (NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
47923557|NCT04458324|OTHER|Functional Electrical Stimulation Row Training (FESRT)|Subjects participate in a supervised exercise training program 2-3 times/week for 6 months using an adapted indoor rower and FES.
47923558|NCT06172985|OTHER|No intervention|Due to observational study
47923559|NCT02929498|DRUG|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
47923560|NCT02929498|DRUG|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
47923561|NCT06199583|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound shear-wave elastography
47923562|NCT05293899|DIAGNOSTIC_TEST|exome sequencing approach|Depending on the primary results in the proteomic and the metabolic profiling, this pilot study will search for genetic associations, using an exome sequencing approach to individuals. The findings will be compared to individuals without depression, and to relatives of depressed patients who suffer from autoimmune diseases.
47923563|NCT04769180|OTHER|Evaluation of extraintestinal manifestations|The researchers evaluated the prevalence and kind of extraintestinal symptoms in NCWS patients and the possible relationship between the clinical, serological, genetic and histological characteristics of the NCWS patients and the number and kind of extraintestinal manifestations, using, as control groups, CD and IBS patients.
47923564|NCT01455909|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
47923565|NCT01455909|DRUG|sitagliptin|sitagliptin oral 100 mg/day
47923566|NCT03995329|OTHER|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
47923567|NCT01552798|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
47923568|NCT01552798|DRUG|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
47923569|NCT01552798|DRUG|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
48106776|NCT00662324|BEHAVIORAL|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes."
47923570|NCT02654964|DRUG|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
47923571|NCT02076425|BEHAVIORAL|PCIT-ED|
47923572|NCT02788279|DRUG|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
47923573|NCT02788279|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
47923574|NCT02788279|DRUG|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
47923575|NCT04579887|OTHER|Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations|Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
47923576|NCT05904301|OTHER|Usual medical management of patients, additional blood and stool samples for biobanking|"For all systemic diseases the following data will be collected:~Clinical examination, Laboratory data, Current medications, Constitution of biobanking.~For each disease:~Pathology specific Activity score, Global subjective disease activity by patient and by physician."
47923577|NCT04605367|DEVICE|Transcranial stimulation|For both tasks, the training modalities are the same. After the pre-test, this group will physically repeat the correct sequence as many times as possible, during 12 blocks of 30s. After this training, they will perform the post-test. And immediately after the post-test, they will receive the real anodal stimulation. The intensity of the current will gradually increase for 30s until it reaches 1mA, will remain constant for 15min, then will gradually decrease for 30s until 0mA is reached. The current density during stimulation will be 0.04 mA/cm². For the manual task the anode will be centered above C4 (according to the international 10-20 EEG system) that is located near the hand area of M1. The cathode will be placed on the supraorbital region ipsilateral to the trained hand (Fp1). For the body task, the anode will be placed in the center of the cortex (Cz) and the cathode will be placed at the medial supraorbital region (Fpz).
47923578|NCT02577887|DEVICE|Patients implanted with a St. Jude Medical pacemakers|
48270879|NCT05568771|OTHER|Core Exercises Assisted Injury Prevention Training Program|After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
47923579|NCT04865926|OTHER|Scapular and Neck Proprioceptive Neuromuscular Facilitation exercises|The researcher will perform a total of 12 sessions of scapular and neck pnf exercises for 4 weeks. The participants will apply PNF exercises using rhythmic initiation, rhythmic stabilization and cobination techniques of isotonics. Patterns of anterior elevation, posterior depression, anterior depression, posterior elevation will be used in scapular exercises. Upper cervical flexion, lower cervical flexion, rotation and lateral flexion patterns will be used in neck pnf exercises.
47923580|NCT04865926|OTHER|McKenzie and Kendall exercises|Kendall and Mckenzie exercises will be given to the participants as a home workout. The self-stretch exercise methods are as followed: Placing both hands on the shoulders and pushing out the chest, placing one hand over the shoulder and grasp the elbow of the turned hand, with the other hand over the head and slowly pull it inward, throwback the head until it has reached the fully stretched point, look straight ahead and slowly turn the head horizontally until the maximum value is reached, throwback the head, and turn it until it has reached the fully stretched point, lower the head turn it until it has reached the maximal point. Stretching pectoralis muscle, strengthening shoulder retraction, strengthening the deep cervical flexors, strengthening the deep cervical flexors.
47923581|NCT00760799|PROCEDURE|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
47923582|NCT03251131|OTHER|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
47923583|NCT05471713|OTHER|Autonomic dysfunction|Autonomic dysfunction
47923584|NCT02150694|PROCEDURE|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
48270880|NCT01044563|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
48270881|NCT01044563|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
47923585|NCT02150694|PROCEDURE|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
47923586|NCT02150694|OTHER|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
47923587|NCT02150694|OTHER|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
47923588|NCT03845439|OTHER|Lumbar puncture|Lumbar puncture
47923589|NCT05536128|DRUG|Olaparib|Olaparib tablet 300 mg taken orally twice daily Olaparib 500 mg on Days 1, 15, 29, and every 4 weeks thereafter The treatment will continue till disease progression or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met.
48270882|NCT03352245|BEHAVIORAL|Prescribed Activity|Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
47923590|NCT05536128|DRUG|Fulvestrant|Fulvestrant 500 mg on Days 1, 15, 29, and every 4 weeks thereafter
47923591|NCT04838717|DRUG|BPG|intramuscular injection of 2.4 million units
47923592|NCT04838717|DRUG|Doxycycline|Oral: at a dose of 100 mg bid for 14 days
47923593|NCT02480946|DRUG|MBS2320|As described in the arm descriptions
47923594|NCT02480946|DRUG|Placebo|As described in the arm descriptions
47923595|NCT02480946|DRUG|Methotrexate|Background therapy as described in the arm descriptions
47923596|NCT00179491|BEHAVIORAL|Intercessory Prayer|14 days of intercessory prayer from 3 sites
47923597|NCT01331421|DRUG|exemestane|25 mg tablet
47923598|NCT01595022|DRUG|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
47923599|NCT01595022|DRUG|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
47923600|NCT01595022|DRUG|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
47923601|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
47923602|NCT00588861|DEVICE|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
47923603|NCT01883856|DEVICE|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
47923604|NCT01883856|DEVICE|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
47923605|NCT04884451|BEHAVIORAL|Lifestyle modification|Diet and physical activity modification and behavioral approach
47923606|NCT03201081|OTHER|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
47923607|NCT04363190|DIAGNOSTIC_TEST|Cytogenetic analysis|"1. FISH study using the UroVysion kit in interphase peripheral lymphocytes, that allows the study of numerical aberrations for chromosomes 3, 7 and 17 and locus 9p21.~2. G banding study to analyse the whole karyotype study regarding both numerical and structural aberrations during metaphase.~3. Sister chromatid exchanges (SCE) analysis with bromodeoxyuridine (BrdU) staining for the whole karyotype during metaphase: analizing the proportion of SCE per metaphase (NSM)."
47923608|NCT04195776|DRUG|Tenofovir Douche|660 mg TFV in 125 mL hypo-osmolar solution
47923609|NCT02433431|BEHAVIORAL|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
47923610|NCT02433431|BEHAVIORAL|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
47923611|NCT02433431|BEHAVIORAL|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
47923612|NCT04049409|DRUG|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
47923613|NCT04049409|DRUG|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
47923614|NCT02980809|DRUG|Apatinib|
47923615|NCT02980809|DRUG|Topotecan|
47923616|NCT04062903|BEHAVIORAL|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
47923617|NCT04062903|BEHAVIORAL|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
47923618|NCT04618510|DEVICE|SEED 1-dayPure EDOF soft contact lens|Centre-distance contact lens with peripheral add power working on extended depth of focus principle to control myopia
47923619|NCT04618510|DEVICE|Single Vision Spectacles|These are the type of glasses that correct vision for a single distance
47923620|NCT00562315|DRUG|FACBC|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
47923621|NCT00562315|OTHER|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
47923622|NCT03911102|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
47923623|NCT00088556|DRUG|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
47923624|NCT00088556|DRUG|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
47923625|NCT00088556|DRUG|paclitaxel|200 mg/m² Once every 3 weeks
48270883|NCT01393977|PROCEDURE|rehabilitation of limb function|only receive rehabilitation of limb function
48270884|NCT01393977|PROCEDURE|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
48270885|NCT05206448|DRUG|Letrozole|Letrozole tablet
47923626|NCT02649829|BIOLOGICAL|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:~1. four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~2. four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
47923627|NCT00291213|DRUG|levetiracetam|
47923628|NCT00291213|DRUG|placebo|
47923629|NCT04048278|DRUG|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
47923630|NCT04048278|DRUG|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
47923631|NCT00537615|DRUG|PD 0332334|
47923632|NCT06450119|OTHER|walking training|The walking training alone group would receive walking training for 60 minutes twice weekly for twelve weeks.
47923633|NCT06450119|OTHER|cognition training|The cognition training alone group would receive cognition training for 60 minutes twice weekly for twelve weeks.
47923634|NCT02880956|DRUG|ABBV-8E12|ABBV-8E12 solution for IV infusion
47923635|NCT02880956|DRUG|placebo for ABBV-8E12|placebo solution for intravenous (IV) infusion
47923636|NCT01830400|DRUG|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
47923637|NCT05814302|DRUG|Paracetamol|Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)
47923638|NCT02991989|BEHAVIORAL|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
47923639|NCT02991989|DIETARY_SUPPLEMENT|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
47923640|NCT05788848|BEHAVIORAL|VRCT|The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home.
47923641|NCT00647569|PROCEDURE|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
47923642|NCT00647569|PROCEDURE|Conventional facial closure|The abdominal facia is closed with with continuous running suture
47923643|NCT02303418|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
47923644|NCT02303418|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
47923645|NCT03948477|DRUG|Pantoprazole 40mg|Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
47923646|NCT03948477|DRUG|Placebo|Matched placebo
47923647|NCT05738343|OTHER|dieta mediterranea|nutritional education or Mediterranean food scheme
47923648|NCT00181636|DRUG|Galantamine-CR|
47923649|NCT06085976|DRUG|Octreotide|"A loading dose of 100 mcgr of octreotide will be administered in the intervention group, diluted in 100 ml of SSF to be passed in 30 minutes.~Subsequently, it will be administered in continuous perfusion at 25 mcgr/h in the intervention group.~The drug can be administered through a peripheral or central venous line at the choice of the anesthesiologist, since the drug has a density that allows its administration by both routes."
48443622|NCT03909620|DIAGNOSTIC_TEST|Low-dose computed tomography of chest|Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
47923650|NCT06085976|OTHER|Placebo|In the case of the control group, 100 ml of SSF will be administered to be passed in half an hour and then an perfusion of SSF.
47923651|NCT03370705|DRUG|Sulodexide|Sulodexide 250 ULS twice daily per oral route
47923652|NCT03370705|DRUG|Statin|Statin 20mg once daily per oral route,
47923653|NCT03370705|DRUG|Antiplatelet Agents|Antiplatelet therapy 75mg once daily per oral route
47923654|NCT03370705|DRUG|ACE inhibitor|ACE inhibitor 20mg once daily per oral route
47923655|NCT02882750|OTHER|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
47923656|NCT02882750|OTHER|PS Q18|Patients Satisfaction Questionnaire
47923657|NCT02882750|OTHER|Decision Self-Efficacy Scale|Questionnaire
47923658|NCT02458937|OTHER|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
48443623|NCT05428943|DRUG|OPT101|15-mer peptide derived from the sequence of mouse CD154.
47923659|NCT02458937|OTHER|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
47923660|NCT02458937|OTHER|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
47923661|NCT03896893|OTHER|Skin antisepsis|1% aqueous chlorhexidine gluconate
47923662|NCT03896893|OTHER|Emollient|Aquaphor skin cream
47923663|NCT00853970|DRUG|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
47923664|NCT00853970|DRUG|Placebo Comparator|sterile ophthalmic solution
47923665|NCT00147550|DRUG|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
47923666|NCT03005184|DRUG|Valsartan 80 mg bid|oral medication during run-in and washout period
47923667|NCT03005184|DRUG|Enalapril 10 mg bid|oral medication
47923668|NCT03005184|DRUG|Sacubitril-Valsartan 200 mg bid|oral medication
47923669|NCT03005184|DRUG|Icatibant|intravenous medication
47923670|NCT03005184|DRUG|Placebo|intravenous medication
47923671|NCT03594942|DIAGNOSTIC_TEST|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
47923672|NCT06405971|DRUG|Metformin|Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
47923673|NCT02024178|PROCEDURE|Ultrasound Imaging|
47923674|NCT03870958|PROCEDURE|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
47923675|NCT03870958|PROCEDURE|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
47923676|NCT06476054|PROCEDURE|Optimal timing for laparoscopic cholecystectomy|To compare early and late cholecystectomy after cholecystostomy.
47923677|NCT02663934|BEHAVIORAL|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
47923678|NCT02663934|BEHAVIORAL|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
47923679|NCT01324518|DRUG|ORM-12741|60mg twice a day
47923680|NCT01324518|DRUG|ORM-12741|200mg twice a day
47923681|NCT01324518|DRUG|Placebo for ORM-12741|Placebo twice a day
47923682|NCT04966858|OTHER|Individualized Caloric Refeeding (ICR)|Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
47923683|NCT04966858|OTHER|Higher Calorie Refeeding (HCR)|Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
47923684|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
47923685|NCT02585661|DIETARY_SUPPLEMENT|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
47923686|NCT03387488|DEVICE|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
48270886|NCT05206448|DRUG|Clomiphene Citrate|Clomiphene Citrate tablet
47923687|NCT04500847|DRUG|Emtriva Capsule|200mg daily oral dose
47923688|NCT04500847|DRUG|Placebo|200mg daily oral dose
47923689|NCT02828215|DEVICE|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
47923690|NCT06505733|BEHAVIORAL|postnatal attendant training|"Intervention Group: Training and counselling will be provided to the puerperant and companions before discharge in a quiet and stimulus-free environment using the Companion Training Guide. Research data will be collected three times: pre-test data, after the training and on the tenth day."
47923691|NCT02858817|DRUG|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
48270887|NCT01349647|BIOLOGICAL|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
47923692|NCT02858817|BIOLOGICAL|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
47923693|NCT02858817|OTHER|NaCl 0,9%|0.9% NaCl solution for injection
47923694|NCT02122783|DEVICE|ADR™ brace resistance|
47923695|NCT02122783|DEVICE|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
47923696|NCT00862797|OTHER|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
47923697|NCT06134011|OTHER|Without any intervention|There were no special interventions for the two groups.
47923698|NCT02268929|DEVICE|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
47923699|NCT02268929|DEVICE|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
47923700|NCT04479371|DRUG|Liposomal bupivacaine|Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
47923701|NCT04479371|DRUG|Bupivacaine|Standard bupivacaine
47923702|NCT05859737|BEHAVIORAL|Disaster Preparedness Education Program|The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
47923703|NCT05859737|OTHER|Disaster and Emergency Management Presidency Education|Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
47923704|NCT03259620|DRUG|CLS006|Furosemide Topical Gel
47923705|NCT03259620|DRUG|CLS006 Vehicle|Vehicle Topical Gel
47923706|NCT04235413|BEHAVIORAL|Real-Time Incentives Group|The use of a novel computer program with a mobile phone interface to provide real-time financial incentives at the point of purchase for discounts on fruit and vegetables in low-income families. This intervention will be applied to subjects randomized to the intervention arm. They will receive 50% off eligible fruits and vegetable products at the point of purchase, up to $10 a week for 6 months. Maximum amount they can receive is $260 in discounts over the 6 month period.
47923707|NCT05066542|BEHAVIORAL|NDPP + Basketball (BB)|DPP Hoops: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches along with virtual fitness sessions and in-person basketball sessions. During Months 1-4, participants will attend a 60-minute virtually facilitated session of the NDPP curriculum, followed by a 30- minute virtual fitness session. During that same week, participants will meet in person, for a 90-minute BB session. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks and there will no longer be a 30-minute online fitness session succeeding the session. During this same four-month period, 60-minute, in-person BB sessions will be held weekly. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session and biweekly 60-minute in-person BB sessions. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
47923708|NCT05066542|BEHAVIORAL|NDPP Standard of Care SOC|DPP: Participants in this arm will participate in the traditional NDPP program delivered virtually by certified NDPP coaches. During Months 1-4 participants will attend a 60-minute virtually facilitated session of the NDPP curriculum. During Months 5-8, virtual NDPP curriculum sessions will be held every two weeks. During Months 9-12, participants will attend a monthly 60-minute NDPP curriculum session. Participants will submit a weekly weight report during the 12 month participation and will complete the ASA 24 hour food recall every 90 days.
47923709|NCT01097031|OTHER|Infusion Intermittent|
47923710|NCT04203277|OTHER|IVY|a combination of practice education and quality improvement interventions
48270888|NCT01349647|BIOLOGICAL|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
48270889|NCT01552681|BIOLOGICAL|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
48270890|NCT01552681|OTHER|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
48270891|NCT00691665|DRUG|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
47923711|NCT05918471|DIETARY_SUPPLEMENT|Very Low Energy Diet with Liquid Supplementation|"The preoperative VLED protocol will utilize Optifast 900, a commercially available weight loss product sold by Nestlé Health Sciences. Optifast 900 is designed as a high-protein, low-carbohydrate, and low-fat meal replacement with complete micronutrient composition. Instructions for use are as follows:~1. Consume 4 Optifast 900 packets each day~2. Take 1 sachet of Optifast 900 once in the morning (AM), once at noon, once in the early evening (PM #1), and once later in the evening (PM #2) for three-weeks.~3. Mix 1 sachet with at least 300 mL (1 1⁄4 cups) of cold water. Shake well or blend in a blender."
47923712|NCT04682119|DRUG|LY3526318|Administered orally.
47923713|NCT04682119|DRUG|Placebo|Administered orally.
47923714|NCT03543488|DIAGNOSTIC_TEST|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
47923715|NCT04451213|DIAGNOSTIC_TEST|MRI head|MRI head
47923716|NCT05152225|DIAGNOSTIC_TEST|Brain MRI|Brain MRI performed routinely in patients with EI
48270892|NCT00691665|DRUG|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
48270893|NCT03718364|PROCEDURE|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
48270894|NCT01576640|DRUG|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
47923717|NCT05152225|DIAGNOSTIC_TEST|digital subtraction angiography (DSA)|Digital Subtraction Angiography (DSA) performed routinely in patients with EI
48270895|NCT01576640|DRUG|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
48270896|NCT01576640|OTHER|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
47923718|NCT00307320|BEHAVIORAL|Relaxation Training|Relaxation techniques training
47923719|NCT03167281|COMBINATION_PRODUCT|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
47923720|NCT04486300|PROCEDURE|Pneumatic reduction and Laparotomy|Pneumatic reduction is the main intervention for suitable cases and If failed a laparotomy exploration and surgical reduction is done to save life
47923721|NCT04220593|OTHER|tDCS associated with Tcog|2mA-intensity aETCC will be applied to the left dorsolateral prefrontal cortex (CPFDL) region for 20 min, three times a week (every other day) over a one-month period, totaling 12 sessions. In each session activities aimed at stimulating cognition will be applied over the 20 minutes.
47923722|NCT00472680|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
47923723|NCT00472680|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
47923724|NCT00472680|BEHAVIORAL|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
47923725|NCT05158400|RADIATION|Ultrasound|Ultrasound examination on the hand
47923726|NCT04915950|DRUG|Temanogrel|Participants will receive a single oral dose of temanogrel during the treatment visit.
47923727|NCT04915950|DRUG|Placebo|Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.
47923728|NCT01230177|DRUG|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
47923729|NCT02991664|OTHER|Equia Forte|Glass ionomer restorative system
47923730|NCT02991664|OTHER|G-aenial Posterior|Micro hybrid composite resin
48270897|NCT02476318|DEVICE|ArterX Vascular Sealant|
48270898|NCT01583478|BIOLOGICAL|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
47923731|NCT05698875|OTHER|High glycaemic load breakfast meal|Breakfast meal
47923732|NCT05698875|OTHER|High glycaemic load breakfast meal with additional 10g protein|Breakfast meal
47923733|NCT05698875|OTHER|Medium glycaemic load breakfast meal|Breakfast meal
47923734|NCT01561196|PROCEDURE|arterial catheterisation|arterial catheterisation in Arterial Radialis
48270899|NCT05650021|DEVICE|SpaceOAR Vue|CBCT images acquired during the first five fractions of radiotherapy
48270900|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
48270901|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
48270902|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
48270903|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
48270904|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
48270905|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
48270906|NCT02413203|DRUG|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
48270907|NCT02413203|DRUG|Placebo|Blood and urine collections before and 3 hours after placebo administration.
48270908|NCT05112796|PROCEDURE|Class I extractions sites received immediate implants using the Vestibular Socket Therapy|A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
47923735|NCT00270842|BEHAVIORAL|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
47923736|NCT00270842|BEHAVIORAL|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
47923737|NCT00270842|BEHAVIORAL|Education Control group|This control group participated in 10 weeks of general health education classes.
47923738|NCT05901389|DRUG|Lidocaine|After the thoracoscopic surgery, lidocaine will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
47923739|NCT05901389|DRUG|normal saline|After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
47923740|NCT02081859|DEVICE|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
47923741|NCT02081859|OTHER|Conventional Criteria|
47923742|NCT01414920|DRUG|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
47923743|NCT01414920|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
47923744|NCT01414920|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
47923745|NCT01414920|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
47923746|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
47923747|NCT01414920|DRUG|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
47923748|NCT05488756|OTHER|Group 1|Physical therapy agents and isometric exercise training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and isometric training 3 times a week for 4 weeks by the physical therapist.
47923749|NCT05488756|OTHER|Group 2|Physical therapy agents and deep cervical flexor muscle training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and muscle training 3 times a week for 4 weeks by the physical therapist. Training of the craniocervical flexor muscles is going to be focused on the deep flexor muscles such as longus capitis and longus colli muscles, making neck flexion, not the head.
47923750|NCT05488756|OTHER|Group 3|Physical therapy agents and core stabilization training will be applied to the patients. These will be administered a combination of transcutaneous electrical nerve stimulation, ultrasound, a hot pack, and stabilization training 3 times a week for 4 weeks by the physical therapist. These exercises will be performed for 10 repetitions with 10 seconds of contraction and 5 seconds of relaxation.
47923751|NCT06138730|BEHAVIORAL|Appa Complete|Weekly mentorship meetings \& guided CBT videos. Participants assigned to Appa Complete will have unlimited access to the Appa website and materials described in Appa Lite, along with weekly mentorship meetings with a trained and supervised near-peer mentor with whom they have been matched. Matching is based on preference for mentor gender, racial/ethnic minority status, and LGBTQ status and is designed to increase the sense of identification with the mentor and peer-mentor alliance. Virtual meetings begin with a review and discussion of the video and other materials for the week. Mentors ask about how clients are incorporating their CBT learnings into their life, share ways they have used the focal skills in their own lives, illustrate skills use in popular culture, and provide problem solving strategies. Each week has a specific prompt to ensure that clients are applying the concepts and skills they are learning and can talk about any questions or reflections with their mentors.
47923752|NCT06138730|BEHAVIORAL|Appa Lite|Unguided EBP videos and materials. Participants assigned to the Appa Lite condition will have unlimited access to the Appa website, including short form CBT-based videos and materials such as an emotions wheel pdf and thoughts, feelings, and behavior worksheets. The website is structured so that the materials are presented in a developmentally appropriate manner consistent with evidence-based principles in a 12-week format, beginning with general psychoeducation to define mental health, proceeding to introducing CBT and basic CBT skills such as identifying thoughts, feelings, and behaviors, layering on applying specific CBT skills, and ending with reflective journal exercises. Client progress through the materials will be completely unguided.
47923753|NCT00620932|BEHAVIORAL|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
47923754|NCT03428919|PROCEDURE|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
47923755|NCT03428919|PROCEDURE|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
47923756|NCT00894959|BIOLOGICAL|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
47923757|NCT00894959|BIOLOGICAL|Heparin sodium APP|Heparin sodium APP 5.000 USP
47923758|NCT00870584|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
47923759|NCT00870584|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
47923760|NCT00401180|DRUG|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
47923761|NCT00401180|DRUG|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
47923762|NCT02565134|DRUG|PAC-14028 cream 0.1%|Topical application
47923763|NCT02565134|DRUG|PAC-14028 cream 0.3%|Topical application
47923764|NCT02565134|DRUG|PAC-14028 cream 1.0%|Topical application
48270909|NCT05112796|PROCEDURE|class I extractions sites received immediate implants using the Partial Extraction Therapy|the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
48270910|NCT04345419|DRUG|Remdesivir|Remdesivir as antiviral drug
48270911|NCT04345419|OTHER|Standard of care treatment|Standard of care treatment
48270912|NCT03233932|DRUG|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
48270913|NCT03233932|DRUG|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
48270914|NCT05121415|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
48270915|NCT01904799|OTHER|Cognitive Assessment test|
48270916|NCT03280251|DRUG|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
48270917|NCT03280251|DRUG|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
47923765|NCT02565134|DRUG|PAC-14028 cream vehicle|Topical application
47923766|NCT00727441|BIOLOGICAL|GVAX pancreatic cancer vaccine|Given intradermally
47923767|NCT00727441|DRUG|cyclophosphamide|Given IV (Arm B), given orally (Arm C)
47923768|NCT03579602|DRUG|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
47923769|NCT03579602|DEVICE|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
47923770|NCT01797406|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
47923771|NCT01797406|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
47923772|NCT03381794|PROCEDURE|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
47923773|NCT06192394|OTHER|Chewing Gum|Patients will be asked to chew xylitol gum for 20 minutes every 2 hours (17.00-19.00, 19.00-21.00, 21.00-23.00) after drinking the X-M Diet syrup prescribed the day before the colonoscopy procedure. After the enema is given on the day of the colonoscopy, they will be asked to chew gum for 20 minutes every 2 hours until one hour before the scheduled procedure time. Xylitol is a naturally occurring five-carbon sugar alcohol (C5H12O5) found in fruits and vegetables such as plums, strawberries, cauliflower, and pumpkin. It is similar in taste to sucrose but contains 40% fewer calories than other carbohydrates (1 gram of xylitol = 2.4 calories). Xylitol has positive effects on dental health and may also have beneficial impacts on other systems such as immunity, respiratory, and digestive systems. Since xylitol is not digested by human enzymes, it has a laxative effect. In the study, sugar-free gum with xylitol will be used.
47923774|NCT06192394|OTHER|Walking Exercise|Patients will be given a pedometer to count their steps and will be asked to walk at least 3000 steps before the colonoscopy procedure.
47923775|NCT06192394|OTHER|Control|Patients will undergo standard bowel preparation determined by the hospital.
47923776|NCT03032302|DIETARY_SUPPLEMENT|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
47923777|NCT03032302|DIETARY_SUPPLEMENT|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
47923778|NCT02366364|DRUG|Placebo|Single oral administration of placebo consumption on Day 1
47923779|NCT02366364|DRUG|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
47923780|NCT02366364|DRUG|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
47923781|NCT02366364|DRUG|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
47923782|NCT00428584|DRUG|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
47923783|NCT00428584|DRUG|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
47923784|NCT05893953|DEVICE|immediately feedback device|Sitting in a standard chair with immediate feedback device
47923785|NCT05893953|DEVICE|Unstable chair|sitting in an unstable chair
47923786|NCT05893953|OTHER|Standard chair|Sitting in a standard chair
47923787|NCT04081259|DRUG|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
47923788|NCT00522925|DRUG|PS433540|200mg capsule, once daily for 28 days
47923789|NCT00522925|DRUG|placebo|placebo capsule, once daily for 28 days
47923790|NCT00522925|DRUG|PS433540|500mg capsule, once daily for 28 days
48270918|NCT03280251|OTHER|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
48270919|NCT03280251|OTHER|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
48270920|NCT01256541|DRUG|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
48270921|NCT05976256|OTHER|Kinesio taping|Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.
47923791|NCT04754217|DEVICE|VAVGJ|Replacement of the aortic valve and ascending aorta
48270922|NCT05976256|OTHER|sham tape (leukotape classic)|leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape
48270923|NCT05976256|OTHER|standard treatment|standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
48270924|NCT04608214|DRUG|Alisporivir|Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
48270925|NCT04608214|OTHER|Standard of care (SOC)|Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
48270926|NCT01551693|DRUG|STA-9090|
47923792|NCT04754217|DEVICE|CAVGJ|Replacement of the aortic valve and ascending aorta
47923793|NCT04567901|OTHER|Death|Mortality group
47923794|NCT04567901|OTHER|Survive|Survival group
47923795|NCT00197158|BIOLOGICAL|Hepatitis B vaccine|
47923796|NCT06341790|OTHER|jowar based products|jowar based products like jowar flakes, jowar aata, jowar vermicelli is given to the intervention group
47923797|NCT01287182|DRUG|Ateronon|Ateronon daily for 3 months
47923798|NCT01375855|PROCEDURE|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
47923799|NCT01447667|PROCEDURE|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
47923800|NCT03005210|DRUG|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
47923801|NCT03005210|DRUG|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
47923802|NCT03005210|DRUG|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
47923803|NCT03101111|BIOLOGICAL|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
47923804|NCT03101111|BIOLOGICAL|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
47923805|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
47923806|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
47923807|NCT04552678|BEHAVIORAL|Healthy Eating, Active Play, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
47923808|NCT04552678|BEHAVIORAL|Healthy Eating + Active Play|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
47923809|NCT04552678|BEHAVIORAL|Healthy Eating, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
48270927|NCT05773677|DIETARY_SUPPLEMENT|Specific Diet|"A specific diet will be developed for each patient, which will also take into account any food allergies or intolerances.~Each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same."
48270928|NCT04676854|DEVICE|PRIMA Bionic Vision System|Implantation of PRIMA, Vision training, follow up
48270929|NCT02965378|DRUG|Docetaxel|Given IV
48270930|NCT02965378|DRUG|FGFR Inhibitor AZD4547|Given PO
48270931|NCT02965378|OTHER|Laboratory Biomarker Analysis|Correlative studies
48270932|NCT01858233|BEHAVIORAL|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
48270933|NCT02349126|DRUG|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
48270934|NCT02224131|DRUG|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
48270935|NCT02224131|DRUG|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
48270936|NCT01005160|DRUG|Metformin|CKD-501 0.5mg, metformin 1000mg
48270937|NCT01005160|DRUG|CKD-501|CKD-501 0.5mg, metformin 1000mg
48270938|NCT01854346|BEHAVIORAL|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
48270939|NCT01219556|DRUG|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
48270940|NCT01371461|DRUG|Paroxetine|
48270941|NCT02891421|BEHAVIORAL|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
48270942|NCT02891421|OTHER|Standard Care|Standard Care: Participants received standard care
48270943|NCT00909155|DRUG|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
48270944|NCT00909155|DRUG|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
48270945|NCT03037281|DIAGNOSTIC_TEST|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
48443624|NCT02286154|DRUG|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
48443625|NCT04949334|DEVICE|Dofin Breathing Strength Builder|"If the patient's condition is stable, respiratory muscle training will be performed under Dofin Breathing Strength Builder 7 days after stroke. The patient will receive respiratory muscle training by repetition of 30 times, two courses per day, x 7 days, for three weeks.~The initial load was set at 30% of the participants' maximal baseline strength and increased weekly at intervals of 2 cmH2O."
48443626|NCT04480762|DRUG|SHR-1703|SHR-1703
48270946|NCT01552902|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
48270947|NCT01552902|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
48270948|NCT01552902|DRUG|Placebo|Daily oral dosing in the AM for 6 weeks
48443627|NCT04480762|DRUG|Placebo|Placebo of the SHR-1703
48443628|NCT02714062|DRUG|Placebo|po once daily
48443629|NCT02714062|DRUG|VI-0521 Mid Dose|po once daily
48443630|NCT02714062|DRUG|VI-0521 Top Dose|po once daily
48443631|NCT02079194|DRUG|P2Y12 antagonist monotherapy|
48443632|NCT02079194|DRUG|aspirin plus P2Y12 antagonist|
48270949|NCT04801407|PROCEDURE|percutaneous radiofrequency trigeminal rhizotomy|percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
48270950|NCT04801407|PROCEDURE|Microvascular decompression of the trigeminal nerve|Microvascular decompression is a procedure that decompress the nerve from vascular conflict
48270951|NCT05183919|OTHER|Digital Treatment|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
48270952|NCT03288298|DRUG|luteolin|flavonoid natural extract
48270953|NCT03288298|DRUG|nano-luteolin|nanoparticles of luteolin
48270954|NCT00267735|BEHAVIORAL|Use of Computerized Decision Aid on Childbirth|
48270955|NCT02058732|OTHER|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
48270956|NCT04674462|BIOLOGICAL|CpG-adjuvanted HBV Vaccine|Subjects receiving CpG-adjuvanted HBV vaccine will require two doses at 0 and 1 month after initiation. The second dose will be considered the same as the one month time point following the first dose.
48270957|NCT04674462|BIOLOGICAL|Traditional HBV Vaccine|Subjects receiving traditional HBV vaccine series will require three doses at 0, 1, and 6 months after initiation. The second dose will be considered the same as the one month time point following the first dose.
48270958|NCT00240760|DRUG|Memantine Hydrochloride|
48270959|NCT01286493|BIOLOGICAL|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
48270960|NCT04613986|DEVICE|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
48270961|NCT05389488|DEVICE|OsciPulse system|The OsciPulse system is a pneumatic compression system designed to provide intermittent compression to the limbs to augment venous blood flow.
48270962|NCT05389488|DEVICE|Flowtron ACS900|The Arjo Flowtron ACS900 intermittent pneumatic compression system provides compression the calf to augment venous blood flow.
48443633|NCT04807439|DEVICE|SYNERGY XLV (Megatron) Coronary Stent System|The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries \>3.50 mm to \<5.00 mm in diameter in lesions \<28 mm in length.
48443634|NCT01082926|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given intratumorally
48443635|NCT01082926|BIOLOGICAL|aldesleukin|Given intratumorally
48443636|NCT01082926|OTHER|laboratory biomarker analysis|Optional correlative studies
48443637|NCT01082926|PROCEDURE|positron emission tomography|Optional correlative studies
48443638|NCT05661097|PROCEDURE|Suture mode|Patients in the small hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture by hernia hook needle.Patients in the large hernia ring group received continuous suture with barbed wire according to simple random method Closure mode, intermittent full layer suture with hernia hook needle, continuous suture with barbed wire+hernia Intermittent full layer crochet suture.
48443639|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
48443640|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
48443641|NCT01515592|DRUG|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
48443642|NCT01515592|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
48443643|NCT03197285|OTHER|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~1. To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~2. To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~3. Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
48270963|NCT02440334|DRUG|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
48270964|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 1-12
48270965|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 13-24
48270966|NCT01587989|DRUG|placebo|methotrexate placebo orally weekly, Weeks 13-24
48270967|NCT01587989|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
48443644|NCT03197285|OTHER|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
48443645|NCT04395586|OTHER|Culture|Culture
48270968|NCT01554787|DRUG|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
48270969|NCT01554787|OTHER|Placebo|at a rate of 2.8g three times per day
48270970|NCT06199167|BEHAVIORAL|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.
48270971|NCT06199167|BEHAVIORAL|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
48270972|NCT05868421|BEHAVIORAL|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
48270973|NCT05868421|BEHAVIORAL|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
48270974|NCT05868421|BEHAVIORAL|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
48270975|NCT01324830|DRUG|day 1 to day 5|low to high dose
48270976|NCT01324830|DRUG|day 1 to day 14|low to high dose
48270977|NCT05739773|OTHER|five-element music therapy|music therapy
48270978|NCT05675449|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
48270979|NCT05675449|DRUG|Carfilzomib|proteasome inhibitor
48270980|NCT05675449|DRUG|Maplirpacept|CD47-SIRP alpha-directed
48270981|NCT01743833|OTHER|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
48270982|NCT01743833|OTHER|Scapular High Velocity, Low Amplitude Thrust Maneuver|
48270983|NCT03170830|DIAGNOSTIC_TEST|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
48270984|NCT03204149|DEVICE|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
48270985|NCT03204149|DEVICE|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used."
48270986|NCT04211129|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
48270987|NCT04211129|OTHER|Sham acupuncture|Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
48270988|NCT01554657|OTHER|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
48443646|NCT05602103|DRUG|use of anticancer drugs in monotherapy or in combination therapy|Cases of cancer therapy-related cardiac dysfunction associated with anticancer drugs will be identify and describe
48443647|NCT00934050|DRUG|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
48443648|NCT03904563|DRUG|Bevacizumab|Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.
48443649|NCT03904563|RADIATION|chest radiation|split-course chest radiation
48443650|NCT03904563|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
48443651|NCT03173547|DRUG|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
48443652|NCT03173547|DRUG|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
48270989|NCT01554657|OTHER|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
48270990|NCT02334150|DRUG|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
48270991|NCT02532348|OTHER|Blood samples|Blood samples
48270992|NCT05601245|OTHER|High voltage pulsed current|The treatment session duration is 45 minutes (Reverse the polarity after the first 22 minutes)
48443653|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
48270993|NCT05601245|OTHER|Microcurrent therapy|The treatment session duration is 40 minutes.
48270994|NCT04897490|OTHER|Evaluation of first line treatment with ATO/ATRA outcome|Evaluation of first line treatment with ATO/ATRA outcome (o event free survival and overall survival and toxicity) in adult patients with APL.
48443654|NCT00652418|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
48270995|NCT00331760|DRUG|cisplatin|
48270996|NCT00331760|RADIATION|intensity-modulated radiation therapy|
48270997|NCT04617808|OTHER|Questionnaire|"The regulatory scheme applied to all investigative centers is as follows:~* Call from Center 15 by a major patient for secondary headache no traumatic. (i.e. not having been the victim of a head trauma during the 48 hours preceding the call)~* Detection of the pattern of non-traumatic headache, by the regulatory assistant medical with registration of the word cephareg in the medical regulation software in order to alert the regulator about the possible inclusion of the patient~* If possible, patient information on the collection of their data for research and possibility of opposing~* Filling of a medical questionnaire by the regulating doctor~* Weekly collection of medical questionnaires by investigating doctors"
48270998|NCT01597063|DEVICE|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
48443655|NCT00066001|DRUG|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
48443656|NCT03592953|OTHER|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
48443657|NCT03859089|OTHER|Medical Cannabis|N/A - Observational Cohort Study
48270999|NCT00434967|DRUG|Candesartan cilexetil|32 mg oral tablet
48271000|NCT00434967|DRUG|Hydrochlorothiazide|25 mg oral tablet
48443658|NCT05595590|DRUG|Tislelizumab|Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)
48443659|NCT05595590|RADIATION|Pulse radiation|66-70Gy/33-35Fx, 2Gy/Fx.
48271001|NCT00434967|DRUG|Candesartan/HCT 32/25 mg|
48271002|NCT00189644|PROCEDURE|6 FEC 100|
48443660|NCT05289674|DIETARY_SUPPLEMENT|High Calorie Formula|The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia
48443661|NCT05900934|OTHER|Myofascial Releasing Group|Using a subjective 7/10 target numeric rating scale rating (0 representing no discomfort and 10 representing maximum discomfort), the intensity of foam roller application can be determined. This intensity defines an application intensity that is mildly painful for the participant and appropriate according to previous literature.
48443662|NCT05900934|OTHER|Sham Myofascial Releasing Group|The severity of the application is not felt at all according to the numerical rating scale of 0/10.
48443663|NCT03128762|BIOLOGICAL|ILC2 levels in blood|The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
48443664|NCT01344707|DRUG|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
48443665|NCT03192930|OTHER|Hyperbaric exposure|Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
48443666|NCT00743964|DRUG|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
47923810|NCT04552678|BEHAVIORAL|Healthy Eating + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
48271003|NCT00189644|PROCEDURE|4 FEC 100 followed by 4 Taxol|
48271004|NCT05121402|DRUG|TLL018|a TYK2/JAK1 inhibitor
48271005|NCT05121402|OTHER|Placebo|a TLL018 Placebo
48271006|NCT00456690|OTHER|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
48271007|NCT06304324|DRUG|0.9% Sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
48271008|NCT06304324|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
48271009|NCT06304324|DRUG|0.05ug/kg Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
48271010|NCT01105390|BIOLOGICAL|rilotumumab|Given IV
48271011|NCT01105390|DRUG|cisplatin|Given IV
48271012|NCT01105390|DRUG|pemetrexed disodium|Given IV
48443667|NCT00743964|DRUG|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
48271013|NCT01105390|OTHER|laboratory biomarker analysis|Correlative studies
48271014|NCT04459845|BEHAVIORAL|Parent Child Interaction Therapy|Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
48271015|NCT04459845|BEHAVIORAL|Child Parent Psychotherapy|Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
48271016|NCT00094614|DRUG|Atropine|
47923811|NCT04552678|BEHAVIORAL|Healthy Eating + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
47923812|NCT04552678|BEHAVIORAL|Healthy Eating Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Healthy Eating curriculum. Parents will receive access to web-based resources on food literacy.
47923813|NCT04552678|BEHAVIORAL|Active Play, Self-Regulation, Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
47923814|NCT04552678|BEHAVIORAL|Active Play + Self-Regulation|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
47923815|NCT04552678|BEHAVIORAL|Active Play + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
47923816|NCT04552678|BEHAVIORAL|Active Play Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
47923817|NCT04552678|BEHAVIORAL|Self-Regulation + Parent Education|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
47923818|NCT04552678|BEHAVIORAL|Self-Regulation Only|In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
47923819|NCT04552678|BEHAVIORAL|Food Literacy + Parent Education|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
48271017|NCT05430620|DRUG|Oxygen|Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
48271018|NCT06435702|DRUG|Darolutamide in addition to androgen deprivation therapy|Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
48443668|NCT03055637|PROCEDURE|Furlow double opposing z-plasty|\* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
48443669|NCT03055637|PROCEDURE|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
47923820|NCT04552678|BEHAVIORAL|Food Literacy Only|Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
47923821|NCT04240795|DIETARY_SUPPLEMENT|Low lubricity (LL) hydrogels containing fibre-based beads|The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
47923822|NCT02490345|DRUG|gabapentin|gabapentin usage as adjunctive treatment for pain control
47923823|NCT02490345|DRUG|Placebo|Identical placebo
47923824|NCT05122598|DRUG|COT|The COT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
47923825|NCT05122598|DRUG|Sham|Sham COT uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks.
47923826|NCT03104660|DEVICE|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
47923827|NCT00186953|DRUG|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
47923828|NCT00272714|DRUG|Afimoxifene (0.057%) in hydroalcoholic gel|
47923829|NCT01264601|BIOLOGICAL|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
47923830|NCT00794898|BIOLOGICAL|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
47923831|NCT04704362|BEHAVIORAL|Ensuring Quality in Psychological Support|Trainees are evaluated with the Enhancing Assessment of Common Therapeutic factors structured role play tool and the results are shared with trainers and/or supervisors to modify training based on strengths and weakness on the competency scores.
47923832|NCT04704362|BEHAVIORAL|Standard Training and Supervision|Trainees are trained using a manual for non-specialist-delivered psychological interventions.
47923833|NCT01528202|DIETARY_SUPPLEMENT|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
47923834|NCT01528202|DIETARY_SUPPLEMENT|Fruit juice cordial|fruit flavoured juice concentrate
47923835|NCT02721394|BEHAVIORAL|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
47923836|NCT00314002|DEVICE|Mechanical Thrombectomy|
47923837|NCT00129909|DRUG|fixed dose combination therapy|
47923838|NCT05456282|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
47923839|NCT05456282|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
47923840|NCT00300430|DRUG|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
47923841|NCT00300430|DRUG|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
47923842|NCT00300430|DRUG|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
47923843|NCT04796870|OTHER|Online Brain and Balance Training Program|The intent of the intervention is to encompass cardiovascular conditioning, cognitive performance and balance performance improvements. To promote cardiovascular conditioning the exercises are structured to keep the participant in motion while maintaining an elevated heart rate using techniques such as squats, marching and upper extremity movements. The video provides adaptations to increase or decrease the challenge based on subject ability. To promote cognitive performance, participants will be asked to complete simple and complex cognitive tasks, such as arithmetic, spatial memory recall and attention while completing the physical exercises. To promote balance performance, the videos include single limb stance and weight shifting tasks. Videos are presented in a progressively challenging manner for all domains.
47923844|NCT00300742|DRUG|Topiramate|Topiramate up to 300 mg per day.
47923845|NCT00947505|DEVICE|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
47923846|NCT00947505|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
47923847|NCT03834649|PROCEDURE|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
47923848|NCT03834649|PROCEDURE|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
48095606|NCT06559228|OTHER|ConnectedNest|Among those receiving ConnectedNest, participants will receive a secure message to register and download ConnectedNest's patient app, EmpowerNest. They will be directed to complete a set of modules at the baseline through ConnectedNest: demographics, SDoH needs (e.g., social support, transportation, housing) and quality-of-life. They will receive basic training on the functionality and services available within the app (e.g., how to indicate a need, connect with community services). They will be directed to use the app to identify and connect with needed social and community services for 90 days.
48271019|NCT06435702|DRUG|androgen deprivation therapy only|The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
47923849|NCT01489241|PROCEDURE|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
47923850|NCT03798119|DRUG|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
47923851|NCT02536404|DRUG|Etrasimod|
47923852|NCT02536404|DRUG|Placebo|
47923853|NCT02142387|OTHER|BLS CPR program with dispatcher assisted CPR simulation|the training program more focuses on cooperation with a dispatcher, from recognition to perform DA-CPR and hands-on practice.
47923854|NCT02551991|DRUG|nal-IRI|
47923855|NCT02551991|DRUG|5 fluorouracil|
47923856|NCT02551991|DRUG|Leucovorin|
47923857|NCT02551991|DRUG|Oxaliplatin|
47923858|NCT02967757|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
47923859|NCT00601952|BEHAVIORAL|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
47923860|NCT00601952|BEHAVIORAL|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
47923861|NCT04837326|OTHER|Heel Lance Blood Sampling in Facilitated Tucking Position|
47923862|NCT04837326|OTHER|Heel Lance Blood Sampling When the Infant is Embraced by the Mother|
47923863|NCT04837326|OTHER|Heel Lance Blood Sampling Using White Noise|
47923864|NCT05111288|DEVICE|Pulsed electromagnetic field therapy (PEMF)|Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
47923865|NCT05111288|DEVICE|Inactive Pulsed electromagnetic field therapy (PEMF)|PEMF device that turns on but does not provide any electromagnetic stimulation
47923866|NCT04036292|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
47923867|NCT04036292|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
47923868|NCT00220922|PROCEDURE|Alcohol Wipes vs. No Alcohol Wipes|
47923869|NCT03708393|DEVICE|Imagio (IUS+OA)|The Imagio ultrasound and opto-acoustic images to be reviewed as part of the reader study
47923870|NCT03708393|DEVICE|Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of the reader study
47923871|NCT03708393|DEVICE|Mammography|Mammography images as available per standard of care
47923872|NCT02126345|DEVICE|MASTER SL femoral stem and DELTA TT acetabular cup|
47923873|NCT02412813|DEVICE|LEGION OXINIUM|Investigational Group
47923874|NCT02412813|DEVICE|LEGION Cobalt Chrome|Control Group
47923875|NCT03351205|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
47923876|NCT03351205|PROCEDURE|dried biological amnion graft|"Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane"
47923877|NCT03351205|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
47923878|NCT02494063|PROCEDURE|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
47923879|NCT02494063|PROCEDURE|At least unilateral systematic pelvic lymph node dissection|
47923880|NCT01265264|DRUG|ulodesine|Oral dose administered daily for 84 days.
47923881|NCT01265264|DRUG|Placebo|Oral dose administered daily for 84 days.
47923882|NCT05412589|DRUG|mFOLFOX7+Camrelizumab+Apatinib|"Drug: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Drug: Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle. Drug: Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Drug: Camrelizumab 200mg infusion on D1 for every 21 days Drug: Apatinib 250mg，po，qd for every 21 days"
47923883|NCT05128708|PROCEDURE|combined medial and caudal approach right hemicolectomy open and laparoscopic|resection of right colon cancer by this radical approach
47923884|NCT02074891|DRUG|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
47923885|NCT03373227|DRUG|Envarsus|Patients will take once daily Envarsus
47923886|NCT06023836|DEVICE|ESWT|Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position
47923887|NCT06023836|PROCEDURE|Dry needling|Dry needling with Seirin branded 0.6\*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
47923888|NCT02728427|DEVICE|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
47923889|NCT02728427|DEVICE|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
47923890|NCT03276169|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
47923891|NCT03276169|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
47923892|NCT03276169|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
47923893|NCT05986201|DEVICE|TachoSil®|TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
47923894|NCT03467100|DRUG|XEN901|Capsule filled with XEN901
47923895|NCT03467100|DRUG|Inert Ingredients Oral Product|Placebo capsule
47923896|NCT00067938|DRUG|lamotrigine|Lamotrigine
47923897|NCT02588001|DRUG|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
47923898|NCT06024512|DEVICE|Burn|This study is being done to collect pictures of burns using an investigational device called the Spectral MD Deep View Snapshot Handheld (DV-H), similar to a camera. The data collected will be used to assess the performance of the DV-H device, and to determine the device's ability to differentiate healing versus non-healing burn tissue. This device, if approved, is expected to give caregivers a better understanding of what parts of burn wounds will likely not heal on their own and as a tool used by the military in the field. This current study involves the collection of images over the course of your clinical treatment and follow-up according to your routine standard of care. The device will not be used to diagnose or prescribe treatment for your burn.
47923899|NCT05873127|BEHAVIORAL|web-based guided self-help Enhanced Cognitive Behavioral therapy|The subjects would learn and practice CBT-E course through the online learning platform for 12 times, and were required to complete the course once a week.
47923900|NCT05873127|BEHAVIORAL|online Enhanced Cognitive Behavioral therapy|A closed structured group would be established by online video conference for group CBT-E therapy. Each group would receive 12 group sessions, once a week for 120 minutes each time. Each group would be led by two CBT therapists, all of whom are nationally registered psychotherapists with systematic professional training.
47923901|NCT03320551|BEHAVIORAL|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
47923902|NCT00796445|DRUG|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
47923903|NCT00796445|DRUG|Placebo|IM solution, a course of 13 injections administered over 27 months
47923904|NCT03472547|DRUG|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
47923905|NCT04772326|OTHER|Questionnaire|Questionnaire
47923906|NCT04725357|DRUG|Meloxicam 15 mg|Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery
47923907|NCT04725357|PROCEDURE|Preoperative Interscalene Nerve Block|Preoperatively participants will standardly receive an interscalene nerve block
47923908|NCT04725357|PROCEDURE|arthroscopic labral repair|participant will have their standard surgical procedure done
47923909|NCT01901796|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
47923910|NCT04040491|DRUG|PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Gemcitabine is a cytosine nucleoside derivative, its main metabolite incorporates into DNA in cells and mainly acts on G1 / S phase.
47923911|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
47923912|NCT00308581|BIOLOGICAL|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
47923913|NCT00308581|OTHER|Placebo|placebo administered 4-weekly in Active 1
47923914|NCT04712240|DEVICE|Respiration rate monitor|A portable continuously monitoring respiration rate monitor will be fitted to each participant. The respiration rate monitor is housed within a comfortable chest strap that be secured to the participant for the duration of the surgical procedure
47923915|NCT05279391|DRUG|Dexamethasone|Dexamethasone 6-8 mg once daily
47923916|NCT05279391|DRUG|Low molecular weight heparin|Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
47923917|NCT05279391|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.
47923918|NCT05279391|DRUG|Tocilizumab|IV administration of Tocilizumab as a single dose of 8mg/kg
47923919|NCT05279391|DRUG|Baricitinib|4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
47923920|NCT05279391|DRUG|Dornase Alfa Inhalant Product|Inh. 2,500 U/twice daily, for up to 14 days.
47923921|NCT04476173|DRUG|Methoxyflurane - Penthrox|ACS patients who received inhaled methoxyflurane as analgesic treatment
47923922|NCT04476173|DRUG|Morphine|ACS patients who received intravenous morphine as analgesic treatment
47923923|NCT01811264|BEHAVIORAL|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
47923924|NCT05423353|DEVICE|Paraffin Bath Therapy|Device named 'Fizyowax 1300' (Fizyomed, Turkey).
47923925|NCT05423353|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
47923926|NCT00977847|OTHER|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
47923927|NCT03666156|OTHER|No intervention|No Intervention
47923928|NCT06419530|OTHER|Probiotic formula capsule|The subjects take 4 capsules a day for 84 days.
47923929|NCT06419530|OTHER|placebo capsule|The subjects take 4 capsules a day for 84 days.
47923930|NCT06419530|OTHER|FMT capsule|The subjects take 4 capsules a day for 84 days.
47923931|NCT04176172|DRUG|Varenicline|Participants will receive open-label varenicline for 12 weeks.
47923932|NCT04176172|DRUG|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
47923933|NCT04176172|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
47923934|NCT04176172|BEHAVIORAL|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
47923935|NCT05563038|DEVICE|Scrambler Therapy|"Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system."
47923936|NCT05563038|DRUG|Standard Medication Management|Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
47923937|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.1).
47923938|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 200 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
47923939|NCT04604132|DRUG|Derazantinib-paclitaxel-ramucirumab combination|"Derazantinib was administered orally at a dose of 300 mg once daily in combination with paclitaxel and ramucirumab.~Paclitaxel was administered intravenously at a dose of 80 mg/m² on days 1, 8, and 15 of a 28-day cycle in combination with ramucirumab.~Ramucirumab was administered intravenously at a dose of 8 mg/kg every 2 weeks in combination with paclitaxel."
47923940|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 200 mg twice daily as monotherapy in the Substudy 1 (Cohort 1.3).
47923941|NCT04604132|DRUG|Derazantinib|Derazantinib was administered orally at a dose of 300 mg once daily as monotherapy in the Substudy 1 (Cohort 1.2).
47923942|NCT05525078|BEHAVIORAL|e-cigarette|Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
47923943|NCT05525078|OTHER|Nicotine patch, Nicotine lozenge|Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
47923944|NCT03686267|OTHER|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
47923945|NCT03686267|OTHER|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
47923946|NCT03686267|OTHER|titanium abutment with no color masking|color masking methods are avoided in this arm
47923947|NCT04267601|DRUG|Anagliptin|Anagliptin treatment for 24weeks
48095607|NCT06559228|OTHER|Standard of care|The participants assigned to the control arm will be asked to complete a baseline survey with the same information as the ConnectedNest arm, except their survey will be administered through REDCap.
48443670|NCT04509648|RADIATION|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral chest wall or whole breast and regional lymph regions and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast
48443671|NCT03579095|DIETARY_SUPPLEMENT|Cereboost|200mg Cereboost and Maltodextrin capsules
48443672|NCT03579095|DIETARY_SUPPLEMENT|Placebo|200mg Maltodextrin capsules
47923948|NCT03355547|OTHER|questionnaire about the severity of their symptoms of upper respiratory tract infection|Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
47923949|NCT03700684|BEHAVIORAL|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
47923950|NCT03700684|DEVICE|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
48271020|NCT06075381|COMBINATION_PRODUCT|Pulmonary Expansion Device (PED)|The Pulmonary Expansion Device constitutes an innovative instrumental technique for lung expansion, designed for use in patients with or without an artificial airway. This device is attached to the artificial airway, the oronasal mask, or the patient's mouth. It enables voluntary control through a system of one-way valves that restrict the air's escape from the lungs to the outside. This creates an environment conducive to retaining air within the lungs, thereby increasing intrapulmonary pressure. Additionally, it reduces the risk of pulmonary complications associated with conventional management, employing a strategy free from exogenous application of positive pressure to the airway. This approach doesn't necessitate expensive equipment or electrical power.
48271021|NCT06075381|PROCEDURE|Conventional management|The conventional management includes: Adequate postoperative pain control, global postural reeducation, reeducation of breathing pattern, airway hygiene, early mobilization, respiratory and scapular waist exercises, and in patients with evidence of lung atelectasis or mild persistent hypoxemia, conventional management will involve the use of intermittent positive pressure ventilation in the airway.
48271022|NCT04512833|RADIATION|Cyberknife stereotactic body radiation therapy|A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.
48271023|NCT00619957|DRUG|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
47923951|NCT03700684|BEHAVIORAL|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
48271024|NCT00619957|DRUG|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
47923952|NCT03776370|PROCEDURE|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
47923953|NCT03776370|PROCEDURE|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
47923954|NCT02015221|DEVICE|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
47923955|NCT02015221|DEVICE|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
47923956|NCT00732836|DRUG|HAI Abraxane|Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
47923957|NCT00732836|PROCEDURE|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
48271025|NCT03837184|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
47923958|NCT00732836|DRUG|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
48271026|NCT05105763|OTHER|Sequential switched feedback training on the knee and the hip (Condition A)|Condition A will include four 6-mins training blocks: 2-mins knee joint feedback-on, 2-mins hip joint feedback-on, and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
48271027|NCT05105763|OTHER|Feedback training on the knee alone (Condition B)|Condition B will include four 6-mins training blocks: 4-mins knee joint feedback-on and 2-mins feedback-off. Training with feedback on will occur as follows: The subject will walk on the treadmill and try to achieve the target hip and/or knee flexion pattern shown on the feedback interface. Training with feedback off will occur as follows: The subject will walk on the treadmill and try to maintain the pattern without any form of visual or verbal feedback.
48271028|NCT04749394|DRUG|Camrelizumab, PD-1 monoclonal antibody|Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
48271029|NCT04749394|DRUG|Apatinib, VEGFR2 antibody|Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
47923959|NCT00523367|PROCEDURE|24 hour pH testing|24 hour pH testing will be used to screen patients
47923960|NCT05908006|DEVICE|Velacur|Imaging Procedures Comparison
47923961|NCT04119271|OTHER|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
47923962|NCT04271644|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cell therapy
47923963|NCT03377140|DIETARY_SUPPLEMENT|Hesperidin|2 capsuls
47923964|NCT03377140|OTHER|control|2 capsuls
48095608|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG and L-PRF|immediate implant placement using ATBG as a graft material, with L-PRF
48271030|NCT01879410|DRUG|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
48271031|NCT01879410|DRUG|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
47923965|NCT05637060|DRUG|Test Drug|One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
48271032|NCT01879410|DRUG|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
48271033|NCT01879410|DRUG|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
48271034|NCT03883269|DRUG|Erythromycin 4% topical gel formulation|Erythromycin 4% topical gel formulation, BID, 4 weeks
48271035|NCT03883269|DRUG|Clindamycin 1% topical lotion formulation|Clindamycin 1% topical lotion formulation, BID, 4 weeks
48271036|NCT03883269|DRUG|70% topical ethanol solution|70% topical ethanol solution, BID, 4 weeks
48271037|NCT01894672|DRUG|LGX818|
48271038|NCT00468897|DRUG|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
48271039|NCT03557567|DIAGNOSTIC_TEST|NGS molecular screening|
48271040|NCT01321489|DRUG|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
48271041|NCT01321489|DRUG|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
48271042|NCT00420511|DRUG|Sitagliptin|sitagliptin 100 mg once a day
47923966|NCT05637060|DRUG|Reference Drug|One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
48271043|NCT00420511|DRUG|Placebo|placebo once a day
48271044|NCT00420511|DRUG|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
48271045|NCT02834910|OTHER|collection of bacterial sample|
48271046|NCT02159807|DRUG|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
47923967|NCT04896970|OTHER|Concert|A musical show in a closed hall, lasting for about 2 hours, in respects of safety measure (masks, hydroalcoholic gel, etc...) with approximately 200 participants.
48271047|NCT02159807|DRUG|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
48271048|NCT04850729|OTHER|non-intervention|non-intervention
47923968|NCT03320876|DRUG|filgotinib|one filgotinib oral tablet once daily.
47923969|NCT02923024|BEHAVIORAL|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
47923970|NCT05076864|OTHER|No intervention|No intervention
47923971|NCT02785770|DRUG|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
47923972|NCT02785770|DRUG|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
48271049|NCT01505894|DRUG|BI 409306|Film-coated tablet
48271050|NCT01505894|DRUG|Placebo|Film-coated tablet
47923973|NCT02785770|DRUG|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
47923974|NCT00539175|DEVICE|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
47923975|NCT00539175|DEVICE|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
47923976|NCT02821663|BEHAVIORAL|vocal intervention|10 x 60 min. sessions of vocal intervention
48095609|NCT04795102|COMBINATION_PRODUCT|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without L-PRF
48095610|NCT03880422|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet plan
48095611|NCT03880422|OTHER|Educational Intervention|Attend educational meeting
48271051|NCT00527449|DRUG|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
48271052|NCT02510079|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
48271053|NCT01902940|OTHER|Natural History|Assessment of natural history in IBM and CCFDN
48271054|NCT05064657|PROCEDURE|Bubble blowing method|"The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process."
48271055|NCT04864587|DIAGNOSTIC_TEST|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
48271056|NCT02781792|DRUG|Temozolomide|-Given standard of care
47923977|NCT00400803|DRUG|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
48271057|NCT02781792|OTHER|Functional Assessment of Cancer Therapy - Brain|"* 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
48271058|NCT02781792|OTHER|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
47923978|NCT01725659|OTHER|Motor Learning|training of the hemiplegic upper limb with motor learning
48271059|NCT04937504|BEHAVIORAL|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
47923979|NCT01725659|OTHER|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
47923980|NCT01725659|OTHER|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
47923981|NCT02191215|DRUG|Nevirapine (Viramune®)|
47923982|NCT03608150|DEVICE|Luminopia One|Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
47923983|NCT03608150|DEVICE|Refractive Correction|Standard of care refractive correction (ex. spectacles)
47923984|NCT06013813|PROCEDURE|Radial Artery approach on percutaneous coronary intervention (PCI)|"* Randomized patients with a right patent radial artery.~* The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~* Technique and devices (introducer and compression devices) are the same in both approaches."
47923985|NCT03310762|OTHER|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
47923986|NCT03310762|OTHER|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
47923987|NCT02431260|DRUG|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
47923988|NCT04805489|OTHER|Mask|"The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks."
47923989|NCT01007630|DRUG|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
47923990|NCT01007630|DRUG|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
47923991|NCT01491438|PROCEDURE|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
47923992|NCT01491438|PROCEDURE|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
48443673|NCT05971420|OTHER|VR activity-based|VR games activities were chosen for simulated cognitive-motor training in the VR group. The VR training modules for this study included fire drill, walking exercise, balancing game activities and community shopping practices. These training modules involved dual task components; the participant was expected to train up his/her physical and cognitive motor performances in an 8-week VR activity-based program. VR group participants received 2-sessions per week, 16 training sessions in total.
48443674|NCT05971420|OTHER|Exercise-based (Baduanjin)|The exercise group used a traditional Chinese Qigong Baduanjin exercise incorporating with a fall prevention education strategy.
48271060|NCT04937504|BEHAVIORAL|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
48443675|NCT02453386|DRUG|tozadenant|
48443676|NCT02453386|DRUG|placebo|
48443677|NCT02350621|PROCEDURE|ACDF|
48443678|NCT02350621|PROCEDURE|minimal invasive Posterior Cervical Foraminotomy|
48443679|NCT01079585|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
48443680|NCT04841317|COMBINATION_PRODUCT|Mobile technology intervention|Home blood pressure cuff used by patients twice a week, with blood pressures transmitted to providers remotely
48443681|NCT01481363|BEHAVIORAL|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
47923993|NCT01253707|DRUG|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
47923994|NCT06156293|BEHAVIORAL|Cognitive behavioral prevention program for insomnia (CBP-I)|CBP-I will be provided to participants once their districts are exposed.
47923995|NCT06251401|BEHAVIORAL|In-person supervised cardiac rehabilitation|In-person CR consists of weekly group-based supervised exercise training at Women's College Hospital, supplemented with home-based exercise training, with the goal of reaching Canadian Physical Activity Guidelines of 150 minutes a week of moderate-intensity exercise per week. Exercise prescriptions are individualized at baseline by the cardiac rehabilitation team. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
47923996|NCT06251401|BEHAVIORAL|Virtual cardiac rehabilitation|Virtual CR consists of once-weekly telephone or video conferencing-based follow-ups (according to participant preference and access to internet/smart device) by one of the cardiac rehab providers. Similar to the in-person program, the virtual program also encourages participants to set goals to achieve 150 minutes a week of moderate-intensity exercise. The exercise prescription is individualized to each participant's ability and can vary in number of sessions per week and duration of each exercise session, as per the cardiac rehab provider's discretion. Unlike the in-person program, all these sessions are completed at home in an unsupervised manner. Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
48443682|NCT01481363|BEHAVIORAL|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
47923997|NCT03570463|BEHAVIORAL|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
47923998|NCT02777320|DRUG|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
47923999|NCT02777320|DRUG|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
47924000|NCT05286879|BEHAVIORAL|Patient Navigator|Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
47924001|NCT05286879|BEHAVIORAL|Mobile Health Unit|Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
47924002|NCT01256190|BIOLOGICAL|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
47924003|NCT01256190|DEVICE|Gelatin sponge|absorbable gelatin sponge for topical use
47924004|NCT02910505|DEVICE|enLighten Laser|Laser for tattoo removal
47924005|NCT03740893|DRUG|AZD6738|"PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle."
47924006|NCT03740893|DRUG|Olaparib|"PART 1: Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2: 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle."
47924007|NCT03740893|DRUG|Durvalumab|"PART 1: Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2: 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle."
47924008|NCT05736029|OTHER|blood, stool and tissue samples collection|blood, stool and tissue samples collection before and during the treatment, as applicable
47924009|NCT01932879|OTHER|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
47924010|NCT01932879|OTHER|Jello|
47924011|NCT00083252|DRUG|talabostat (PT-100) tablets|
47924012|NCT00083252|DRUG|cisplatin|
48095612|NCT03880422|BEHAVIORAL|Exercise Intervention|Complete exercise program
48271065|NCT03262376|DIETARY_SUPPLEMENT|Minerals + Vitamins|A mineral and vitamin tablet
48271066|NCT03262376|DIETARY_SUPPLEMENT|Botanical A|Botanical extract administered in capsule form
48271067|NCT03262376|DIETARY_SUPPLEMENT|Botanical B|Botanical extract administered in capsule form
48271068|NCT03262376|OTHER|Placebo|Cellulose crystalline tablet
48271069|NCT03478618|DRUG|Lactated Ringer|"Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups"
48271070|NCT02773966|RADIATION|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
48271071|NCT02773966|RADIATION|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
47924013|NCT02376959|BEHAVIORAL|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
47924014|NCT01062178|DRUG|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
47924015|NCT02931708|OTHER|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
47924016|NCT04357288|OTHER|Patient Decision Aid|The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
47924017|NCT04357288|OTHER|Encounter Decision Aid|The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
47924018|NCT03494491|DIETARY_SUPPLEMENT|Chitin-glucan|Second test day (D2), subjects will received 4.5g of chitine-glucan
47924019|NCT03494491|DIETARY_SUPPLEMENT|Maltodextrin|First test day (D0), subjects will received 4.5g of maltodextrin.
47924020|NCT04148144|OTHER|No intervention included|No intervention included
47924021|NCT00930748|DEVICE|MR imaging with endorectal coil|MR imaging with endorectal coil
47924022|NCT00930748|DEVICE|MRI with endo-rectal coil|MRI with endo-rectal coil
47924023|NCT06470568|BEHAVIORAL|Progressive Resistance exercise training|"The training sessions will begin with a 5-minute warm-up on a cycle ergometer and global movements involving the upper limbs. Following this, participants will perform one additional warm-up set, followed by four regular sets on both the leg press and leg extension machines. Upper body exercises will then be conducted on the chest press, pull-up, and horizontal rowing machines, with each exercise comprising 2 sets.~To conclude each session, there will be a 5-minute cooldown period involving global muscle stretching exercises. During the initial 6-week period, the workload will progressively increase from 60% to 80% of 1RM (10 repetitions per set). Subsequently, the 1RM will be reassessed to adjust workloads (maintaining 60%-80%) for the subsequent 6-week period. Compliance for per-protocol analysis will require participants to complete at least 80% of the training sessions (i.e., a minimum of 29 out of 36 sessions)."
47924024|NCT00448396|DRUG|Patupilone|
47924025|NCT04887376|DEVICE|Mirror frame|Combined Mirror and NMES therapy
47924026|NCT04887376|DEVICE|Control|Only NMES therapy
47924027|NCT02660840|DRUG|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
47924028|NCT02660840|DRUG|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
48271072|NCT01770327|BEHAVIORAL|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
47924029|NCT02660840|DRUG|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
47924030|NCT02660840|DRUG|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
47924031|NCT02660840|DRUG|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
47924032|NCT02660840|DRUG|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
47924033|NCT00935090|DEVICE|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
48095613|NCT03880422|OTHER|Quality-of-Life Assessment|Ancillary studies
48271073|NCT01961544|DRUG|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
48271074|NCT03474055|BIOLOGICAL|Liquid Rotavirus Vaccine|Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
48271075|NCT00191373|DRUG|Gemcitabine|
48271076|NCT00191373|DRUG|Trastuzumab|
47924034|NCT01024621|DEVICE|Endomicroscope|Pentax EC3870K, Tokyo, Japan
47924035|NCT01024621|DEVICE|Standard endoscopy|Pentax EG-2931 gastroscope
47924036|NCT03968939|DRUG|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
48095614|NCT03880422|OTHER|Survey Administration|Ancillary studies
48095615|NCT04768062|DRUG|Viltolarsen|Received during weekly intravenous infusions
48443683|NCT03818841|DEVICE|High-flow nasal cannula device|Patients will be randomly allocated to this treatment
47924037|NCT03968939|DIETARY_SUPPLEMENT|Melatonin|Oral Melatonin, 3 mg
47924038|NCT03968939|BEHAVIORAL|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
47924039|NCT03253562|DRUG|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
47924040|NCT03253562|DRUG|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
47924041|NCT05673174|DIAGNOSTIC_TEST|Non-Invasive Estimation of Left Ventricular Diastolic Pressure|Modified blood pressure cuff used to detect arterial waveforms used for the estimation of LVDP
47924042|NCT03418103|DEVICE|Thermal imaging analysis of participant position in a hospital bed|The SAFE sensor system will use thermal imaging to detect and identify a participant's position relative to the edges of the hospital bed. If a dangerous position is identified, an alarm notification will be sent to the ward staff to allow them to take pre-emptive action to prevent the participant's situation from evolving into a fall event.
47924043|NCT05294913|BEHAVIORAL|Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention|This intervention will ask students to identify socio-culturally integrated academic or personal goals, so that students may be able to better strategize obstacle-overcoming to attain their future academic aspirations and modulate negative emotions or environments and associated physiological responses.
47924044|NCT05294913|BEHAVIORAL|Placebo|The placebo control group will receive a 5- to 10-minute online goal-setting video tutorial and confirm that they have completed it by filling out an online check-list.
47924045|NCT03649308|DEVICE|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
47924046|NCT03649308|PROCEDURE|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
47924047|NCT02971033|DRUG|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
47924048|NCT02971033|DRUG|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
48443684|NCT03818841|DEVICE|Non-rebreathing oxygen mask group|Patients will be randomly allocated to this treatment
47924049|NCT02971033|DRUG|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
47924050|NCT00091325|DIETARY_SUPPLEMENT|defined green tea catechin extract|
47924051|NCT00345332|DRUG|Botox|Injected
47924052|NCT00345332|DRUG|Placebo|Injected
47924053|NCT01385397|OTHER|Preceptorship and virtual community|
47924054|NCT05055492|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
47924055|NCT05947292|PROCEDURE|Ultrasound-Guided Fascia Iliaca Compartment Nerve Block|Patient's who receive this intervention will have an ultrasound-guided fascia iliaca compartment nerve block performed in the Emergency Department.
47924056|NCT04685239|DEVICE|dual mobility cup|The use of a Sunfit dual mobility cup
47924057|NCT04685239|DEVICE|unipolar cup|The use of a TMT cup
47924058|NCT03021161|DRUG|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
47924059|NCT03021161|OTHER|Placebo Oral Capsule|Capsule containing no probiotic
47924060|NCT05365945|OTHER|NDT Bobath therapy|Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The duration of the treatment session for each patient in both groups was 120 minutes.
47924061|NCT05365945|OTHER|The classic exercises.|"They underwent classical neurological rehabilitation. such as passive exercises, but also an approximation. In addition, the patients performed self-assisted exercises on a manual rotor, and in order to relieve the directly affected limb, the patients exercised in a suspension system. As the physiotherapy progressed, the patients performed active exercises, and then active exercises with resistance, e.g. using the Thera Band. Patients also exercised their balance with the use of large gymnastic balls or sensor pads. A large part of the physiotherapy was locomotion training and gait re-education.~The duration of the treatment session for each patient in both groups was 120 minutes."
47924062|NCT03995251|DRUG|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
47924063|NCT03995251|DRUG|Standard Medical Treatment|Standard Medical Treatment
47924064|NCT03995251|OTHER|Exercise|Exercise
48443685|NCT03520517|DRUG|BHV-0223|BHV-0223, 40 mg BID
48443686|NCT01747694|BEHAVIORAL|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
47924065|NCT00812760|DRUG|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
47924066|NCT03839043|BEHAVIORAL|Brief behavioral intervention|"Quit for a bit- \*advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence\* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems\*reduction of these risks if able to quit for a bit\*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure."
48095616|NCT02783105|OTHER|Musical intervention|
48095617|NCT02783105|OTHER|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
48443687|NCT02316015|DIETARY_SUPPLEMENT|Infatrini® or Infatrini Peptisorb®|
48271077|NCT02452502|DEVICE|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
48271078|NCT05195528|DRUG|Vonoprazan|Orally via capsule
48271079|NCT05195528|DRUG|Placebo|Orally via capsule
48271080|NCT02459379|RADIATION|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
48271081|NCT01091961|PROCEDURE|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
48271082|NCT04265664|BEHAVIORAL|Telerehabilitation|Participants in the telerehabilitation program will receive a graded exercise and self-management intervention. This program will be delivered in a ≤2:1 participant:therapist ratio. Each participant grouping will receive two 60-90 minutes telerehabilitation sessions per week for 4 weeks focusing on lower extremity recovery (total 8-12 hours), with a therapist trained in the use of technology for the provision of rehabilitation. Participants will also be asked to complete at least one additional independent self-managed exercise session each week. This independent exercise session will include selected exercises from the telerehabilitation sessions that will be safe to perform without therapist oversight, and jointly agreed upon by the participant and therapist.
48271083|NCT04529655|DEVICE|Capillary Refill Assessment|Device to quantify capillary refill time
48271084|NCT02416869|PROCEDURE|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
48271085|NCT02416869|PROCEDURE|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
48271086|NCT02416869|DRUG|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
48271087|NCT02416869|DRUG|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
48271088|NCT02416869|PROCEDURE|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
48271089|NCT02416869|PROCEDURE|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
48443688|NCT01314391|GENETIC|mutation analysis|
47951205|NCT06097338|PROCEDURE|bariatric surgery (BS)|bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths
48271090|NCT00404092|DRUG|caspofungin|i.v.
48271091|NCT04706884|DEVICE|Near infrared spectroscopy|The rSO2 (cerebral oxygen satutation) was continuously monitored by NIRS (Near infrared spectroscopy) with a sensor positioned on the forehead of the patient
48271092|NCT04798287|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
48271093|NCT04798287|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
48271094|NCT03153839|BEHAVIORAL|Aquatic physical activity in babies|"A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again."
48271095|NCT01851538|OTHER|Observational study; no intervention.|
48271096|NCT02038348|DEVICE|PET with 18F-FDOPA|
48443689|NCT01314391|GENETIC|polymerase chain reaction|
48443690|NCT01314391|OTHER|laboratory biomarker analysis|
48443691|NCT03663179|DEVICE|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (\~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
48620281|NCT01407419|OTHER|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
48271097|NCT03971721|DEVICE|Wave 4.3|The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
48271098|NCT02073487|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
48271099|NCT02073487|DRUG|Trastuzumab|anti-Her2 monoclonal antibody
48271100|NCT02073487|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
48271101|NCT02073487|DRUG|Abraxane|albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
48271102|NCT02073487|DRUG|Paclitaxel|chemotherapy - microtubule inhibitor
48271103|NCT02073487|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
48271104|NCT03712826|DRUG|Anti-TNF Drug|Crohn patient with antiTNF treatment
48271105|NCT03712826|DRUG|Ustekinumab|Crohn disease with ustekinumab treatment
48443692|NCT03663179|DEVICE|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
48443693|NCT03517085|GENETIC|DTX401|DTX401 administered as a single peripheral intravenous (IV) infusion
48271106|NCT02536287|PROCEDURE|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
48271107|NCT02536287|PROCEDURE|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1\*1 \*1 mm,and placed into the subcutaneous of the forearm.
48271108|NCT05359107|BEHAVIORAL|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
48271109|NCT05359107|BEHAVIORAL|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
48443694|NCT03517085|DRUG|steroid regimen|prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
48271110|NCT03913663|OTHER|vestibuloocular training|using vestibulo ocular training program for training neglect patient
48271111|NCT03913663|OTHER|regular exercise training for hemiplegic patients|Traditional gait training program.
47924067|NCT03839043|OTHER|SMS Program|"Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes."
48271112|NCT00065026|BEHAVIORAL|Physical activity opportunities for low-income women|
48271113|NCT01402245|BIOLOGICAL|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
48271114|NCT01402245|BIOLOGICAL|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
47951206|NCT06681142|OTHER|Pharmacy-Physiotherapy Intervention|"Pharmacists will provide comprehensive 1:1 patient care, including a complete patient assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide patient education, including further written materials.~Participants will be offered either individual or group physiotherapy sessions at the a private clinic."
48271115|NCT03935516|OTHER|Cast|The use of plaster and/or fiberglass for casting of subject arm.
48271116|NCT02060422|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
48271117|NCT02060422|BEHAVIORAL|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
48271118|NCT03235687|DIAGNOSTIC_TEST|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
48271119|NCT03216382|BEHAVIORAL|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
48271120|NCT03216382|BEHAVIORAL|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
48095618|NCT02944903|OTHER|Audit|Questionnair
48271121|NCT05527457|DRUG|BAY2586116|160 μg BAY2586116 nasal spray application
48271122|NCT05527457|DRUG|Placebo|Placebo (saline) nasal spray application
48271123|NCT06224114|DEVICE|Coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a coloured-light torch to the study eye.
48271124|NCT06224114|DEVICE|Different coloured-light torch|Participant administered, at-home, 3-minute daily morning application (between 8 - 10am) of a different coloured-light torch to the study eye.
48271125|NCT03885778|DRUG|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
48443695|NCT02247752|OTHER|inactive carrier|"Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology."
48443696|NCT05551273|DRUG|Selgantolimod|1.5 mg tablet
48443697|NCT05551273|DRUG|Placebo|Matching placebo tablet
48271126|NCT06334367|DRUG|CD25 treatment|CD25 prophylaxis
48271127|NCT06334367|DRUG|low-dose ATG|HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.
48271128|NCT01708057|DRUG|AZD8683|AZD8683 administered via inhalation
48271129|NCT01708057|DRUG|Placebo|Placebo administered via inhalation
48271130|NCT01708057|DRUG|Tiotropium|Tiotropium administered via inhalation
47924068|NCT03160313|BEHAVIORAL|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
47924069|NCT03160313|BEHAVIORAL|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
48271131|NCT01050114|DRUG|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
47924070|NCT00164476|BEHAVIORAL|Preventive Services Prevention Kit|
47924071|NCT00164476|BEHAVIORAL|peer mentors (control group)|
47924072|NCT03499964|DEVICE|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
47924073|NCT03499964|DEVICE|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
47924074|NCT00456443|PROCEDURE|Historical records|
47924075|NCT04401020|DRUG|SAR442257|Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
47924076|NCT00583713|DRUG|BLI-800|BLI-800 oral solution (two doses)
47924077|NCT02333864|DEVICE|POGO® BGMS|SMBG
47924078|NCT01911910|BEHAVIORAL|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
47924079|NCT05303662|DIAGNOSTIC_TEST|Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs|Pooled throat/nose sample and a rectal sample is taken prior to the ERCP
47924080|NCT05303662|DIAGNOSTIC_TEST|MDRO-testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's
47924081|NCT05303662|DIAGNOSTIC_TEST|Microbiome through rectal swab|An rectal swab is collected for microbiome purposes
47924082|NCT05303662|DIAGNOSTIC_TEST|Microbiome testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis
47924083|NCT03457441|OTHER|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
47924084|NCT03457441|DEVICE|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
47924085|NCT03961698|DRUG|IPI-549 (eganelisib)|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
47924086|NCT03961698|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
47924087|NCT03961698|DRUG|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
47924088|NCT03961698|DRUG|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
47924089|NCT05342480|OTHER|EMDR and PE combined treatment|Daily program monday to friday with daily PE and EMDR sessions, physical activity between sessions, in vivo exposure treament and psychoeducational groups. Daily rotation of both EMDR and PE therapists. Multidisiplinary team attached to each pati
47924090|NCT02181270|OTHER|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes
48271132|NCT01050114|DRUG|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
48271133|NCT04779502|OTHER|oregawash|mouthwash containing oregano essential oil
48271134|NCT04779502|OTHER|corsodyl|0.2% chlorhexidine mouthwash
48271135|NCT04779502|OTHER|placebo|distilled water
47924091|NCT02181270|OTHER|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
47924092|NCT05173545|DRUG|Mitoxantrone Hydrochloride Liposome Injection|"Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes."
48271136|NCT01130129|OTHER|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
47924093|NCT05143788|PROCEDURE|Awake craniotomy|The awake neurosurgical procedure performed on the brain is to provide a real-time neurological functions monitoring in order to preserve the functions of brain to the greatest extent.
47924094|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation therapy|Transcranial Direct Current Stimulation with two saline-soaked electrodes (5cm x 7cm) is applied by our occupational therapist. The anode is placed on the ipsilesional primary motor cortex (C3/C4). The cathode is placed on the contralesional shoulder. The current is 1.5 milliampere and lasts 20 minutes.
47924095|NCT04944680|BEHAVIORAL|Motor imagery therapy|Stroke patients are asked to watch a video about the upper extremity movement. The video lasts 20 minutes. The contents are as follows: the patients are asked to relax the muscles for the first 2 minutes; the action refers to shoulder flexion and extension, elbow flexion and extension, forearm pronation and supination, wrist flexion and extension, finger flexion and extension, and corresponding daily functional activities for 16min; the patients are asked to relax their mind and body for the last 2 minutes.
47924096|NCT04944680|BEHAVIORAL|Transcranial Direct Current Stimulation and motor imagery therapy|The treatment parameters are the same as the above. It should be emphasized that the participants sit and perform the motor imagery task while receiving Transcranial Direct Current Stimulation.
47924097|NCT00000481|BEHAVIORAL|diet, fat-restricted|
47924098|NCT05426499|DRUG|Patients requiring cefotaxime treatment|Dosage according to SmPC
47924099|NCT05426499|DRUG|Patients requiring meropenem treatment|Dosage according to SmPC
47924100|NCT05426499|DRUG|Patients requiring fluconazole treatment|Dosage according to SmPC
47924101|NCT05426499|DRUG|Patients requiring isavuconazole treatment|Dosage according to SmPC
47924102|NCT05426499|DRUG|Patients requiring anidulafungin treatment|Dosage according to SmPC
47924103|NCT01253811|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
48271137|NCT00199004|DRUG|Cyclophosphamide|
48271138|NCT00199004|DRUG|Dexamethasone / Prednisolone|
48271139|NCT00199004|DRUG|Vincristine|
48271140|NCT00199004|DRUG|Daunorubicin|
47924104|NCT00046800|DRUG|OSI-211 (Liposomal Lurtotecan)|
47924105|NCT02068898|DRUG|XS003|
47924106|NCT02068898|DRUG|Tasigna|
47924107|NCT01561898|DRUG|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
47924108|NCT05289167|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on Day +3 and +4
47924109|NCT05289167|DRUG|Abatacept|"Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28"
47924110|NCT05289167|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
47924111|NCT03355469|DRUG|Low Intensity Exercise + Metformin|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.
47924112|NCT03355469|DRUG|High Intensity Exercise + Metformin|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.
47924113|NCT03355469|DRUG|Low Intensity Exercise + Placebo|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
47924114|NCT03355469|DRUG|High Intensity Exercise + Placebo|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
48271141|NCT00199004|DRUG|Asparaginase|
48271142|NCT00199004|DRUG|Methotrexate|
47924115|NCT04367051|DRUG|Withdrawal of Spironolactone|Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
47924116|NCT04367051|DRUG|Continuation of spironolactone|Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
47924117|NCT00323817|DRUG|Z-338|
47924118|NCT03545971|DRUG|IBI310|IBI310 is anti CTLA-4 antibody
47924119|NCT03545971|DRUG|Sintilimab|PD-1 monoclonal antibody
48271143|NCT00199004|DRUG|Cytarabine|
48271144|NCT00199004|DRUG|Mercaptopurine|
48271145|NCT00199004|DRUG|G-CSF|
47924120|NCT02979860|BEHAVIORAL|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
47924121|NCT02979860|BEHAVIORAL|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
47924122|NCT02979860|BEHAVIORAL|Sleep timing|Sleep timing: bed time kept consistent
47924123|NCT01597167|DIETARY_SUPPLEMENT|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
47924124|NCT05852041|PROCEDURE|Biopsy of Prostate|Undergo MRI/PET prostate biopsy
47924125|NCT05852041|GENETIC|Decipher Prostate Cancer Test|Undergo decipher
47924126|NCT05852041|OTHER|Flotufolastat F-18 Gallium|Given IV
47924127|NCT05852041|PROCEDURE|Magnetic Resonance Imaging|Undergo PET-MRI
48271146|NCT00199004|DRUG|Vindesine|
48271147|NCT00199004|DRUG|VP16|
48271148|NCT00199004|DRUG|Adriamycin|
48271149|NCT00199004|DRUG|Thioguanine|
48271150|NCT00199004|DRUG|VM26|
48271151|NCT00199004|DRUG|Rituximab|
48271152|NCT00199004|PROCEDURE|CNS irradiation|
48271153|NCT00199004|PROCEDURE|Mediastinal irradiation (if residual TU)|
48271154|NCT00199004|PROCEDURE|Stem cell transplantation|
48271155|NCT05671276|DRUG|aspirin and clopidogrel|DAPT (until 6 months) + ASA
48271156|NCT05671276|DRUG|Rivaroxaban|half-dose NOAC
48443698|NCT03368508|BEHAVIORAL|Simulating video|A 360-degree simulating video showing physiotherapy assessment in lumbar area
47924128|NCT05852041|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
48271157|NCT06190457|OTHER|intrathecal rituximab|All children were treated with a modified NHL-BFM95 regimen for children NHL with the addition of rituximab, both intravenous and intrathecal, and rituximab intrathecal infusion is scheduled to be used simultaneously with rituximab intravenous drip. rituximab intrathecal doses are 10 mg, 15 mg, and 20 mg in increments every 3 weeks. rituximab intrathecal injection does not use methotrexate or/and cytarabine intrathecaline chemotherapy.
48271158|NCT03569202|DEVICE|Piiloset Trehalose Emulsion Eye Drops|Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily
47924129|NCT05852041|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
47924130|NCT05852041|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
47924131|NCT04529356|DEVICE|Transcranial magnetic stimulation|By using different frequency of TMS, the device can generate different effects. For low frequency, such as 1HZ, it mainly generates inhibition on the brain cortex; while high frequency (usually higher than 10HZ) can generate stimulation effects. The later one could be used to treat different central nervous disease.
47924132|NCT04529356|DRUG|Acetaminophen|Acetaminophen is used as the painkiller to alleviate patients' headache before and during the clinical trial. In order to decrease the medication bias, we required these patients to only use acetaminophen instead of other non-steroid anti-inflammatory drugs. In the meantime, participants are requested to recorder the frequency and dosage of acetaminophen they used during the treatment course.
47924133|NCT02216110|PROCEDURE|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
47924134|NCT00205920|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
47924135|NCT00393510|DRUG|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
47924136|NCT00393510|DRUG|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
47924137|NCT03625908|DEVICE|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
47924138|NCT03625908|DEVICE|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
47924139|NCT04800770|DIAGNOSTIC_TEST|4C mortality score|4C mortality score and phosphate levels
47924140|NCT02825797|DRUG|3BNC117|Intravenous infusion of 3BNC117
47924141|NCT02825797|DRUG|10-1074|Intravenous infusion of 10-1074
47924142|NCT02825797|OTHER|Analytical treatment interruption|Analytical treatment interruption
47924143|NCT02825797|DRUG|Placebo|Intravenous infusion of placebo (sterile saline)
47924144|NCT04837352|OTHER|Study of the role of sociocognitive factors|Questionnaires
47924145|NCT03337828|OTHER|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
47924146|NCT03337828|OTHER|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
47924147|NCT06385067|DEVICE|Biolimus Coated Coronary Artery Balloon Dilation Catheter|Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
47924148|NCT01215929|DRUG|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
47924149|NCT01215929|DRUG|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
47924150|NCT02782858|DRUG|GNbAC1|Monthly IV repeated dose
48271159|NCT03569202|DEVICE|Control Eye Drops|Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
48271160|NCT06220006|PROCEDURE|Pulmonary vein isolation|Catheter ablation
48271161|NCT00000191|DRUG|Carbamazepine|
48271162|NCT02582996|DRUG|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
47924151|NCT02782858|DRUG|Placebo|Monthly IV repeated dose
47924152|NCT01922401|OTHER|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
47924153|NCT02576184|DEVICE|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
47924154|NCT02576184|DEVICE|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
47924155|NCT04772638|BEHAVIORAL|PLAY|This intervention focuses on promoting physical activity in preschoolers and the adults (parents and teachers) in their lives. It consists of 1) Teacher training 2) Activity trackers for children, teachers and parents and 3) text messaging with content and individualized goal setting.
47924156|NCT04772638|OTHER|Wait list control|not an active intervention
47924157|NCT06493292|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
47951207|NCT04215250|OTHER|andropulous method|Counts the CVC depth using specific equation
47924158|NCT05315908|OTHER|Community outreach method|The method includes automated call and text messaging to increase testing for COVID-19
47924159|NCT02524600|DEVICE|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
48271163|NCT02582996|DRUG|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
48271164|NCT06369714|DRUG|Concerta|Methylphenidate Hydrochloride Extended-Release Tablets with the following specifications: 18mg dosage, oral administration, once a day for a duration of 8 weeks.
48271165|NCT06369714|DEVICE|Digital therapeutics|30 sessions of digital therapeutics, each lasting 30 minutes, will be conducted with a frequency of once every 1-2 days over an 8-week period.
48271166|NCT00797420|DRUG|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
48271167|NCT00797420|DRUG|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
48271168|NCT02755402|DEVICE|Xpert HCV Viral load|HCV viral load testing
48271169|NCT02755402|DEVICE|Transient elastography|Evaluation of liver fibrosis
48271170|NCT02224235|DRUG|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
48271171|NCT02224235|DEVICE|Resolute Integrity DES|Resolute Integrity DES
48271172|NCT02224235|DEVICE|COBRA PzF|
48271173|NCT02224235|DRUG|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
48271174|NCT00430144|DRUG|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
48271175|NCT02421250|DEVICE|Radical-7 Noninvasive Hgb Monitor|
48443699|NCT03368508|BEHAVIORAL|Conventional video|A conventional video showing physiotherapy assessment in lumbar area
48443700|NCT03098394|DEVICE|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
48443701|NCT03098394|DEVICE|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
48443702|NCT01939756|DEVICE|Intravesical baobab oil|Intravesical baobab oil
48443703|NCT02210182|DRUG|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
48443704|NCT02210182|OTHER|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
48443705|NCT00931697|DRUG|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
47924160|NCT02524600|DEVICE|scintigraphic imaging|
47924161|NCT00602199|DRUG|ABT-510|
47924162|NCT00602199|OTHER|immunoenzyme technique|
47924163|NCT00602199|OTHER|immunohistochemistry staining method|
47924164|NCT00602199|OTHER|laboratory biomarker analysis|
47924165|NCT00602199|OTHER|pharmacological study|
47924166|NCT00602199|PROCEDURE|biopsy|
47924167|NCT04822805|DRUG|Anlotinib hydrochloride|Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
47924168|NCT05145270|DIETARY_SUPPLEMENT|Escitalopram+Sulforaphane|Escitalopram(No-specified) 10-20mg/d, once per day; Sulforaphane(ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.). 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day .
47924169|NCT05145270|DEVICE|Escitalopram+rTMS|Escitalopram(No-specified) 10-20mg/d, once per day; rTMS: rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day.
47924170|NCT05145270|DRUG|Escitalopram|Escitalopram(No-specified) 10-20mg/d, once per day.
48271176|NCT03160729|DRUG|Dexamethasone|pre-operative, single-shot injection
48271177|NCT00410176|BEHAVIORAL|sanitation and personal hygiene|
48271178|NCT01107444|DRUG|Docetaxel|Administered intravenously
48271179|NCT01107444|DRUG|LY2181308|Administered intravenously
48271180|NCT03981159|OTHER|Physical training|Physical training for three months, twice per week (60 minutes per session).
48271181|NCT06108102|OTHER|Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)|Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
48271182|NCT06077084|OTHER|Physiotherapy|"4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum"
48271183|NCT04580147|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
48271184|NCT04580147|OTHER|Sham control|Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
48271185|NCT05027386|DRUG|Apatinib, Irinotecan, Temozolomide|The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.
48443706|NCT00931697|DRUG|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
48443707|NCT00931697|DRUG|Placebo|Over-encapsulated placebo to maintain blinding
48443708|NCT00828919|DRUG|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
48443709|NCT00828919|DRUG|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
47924171|NCT01564056|DRUG|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
47924172|NCT01564056|DRUG|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
47924173|NCT01302132|DRUG|ASP1941|Oral solution
47924174|NCT01037088|DRUG|Mild dose cannabis|3.53% THC by weight
47924175|NCT01037088|DRUG|Low dose cannabis|1.29% THC by weight
47924176|NCT01037088|DRUG|Cannabis|0.00% THC by weight
47924177|NCT03866395|DRUG|Ivabradine|Ivabradine 5 mg twice a day
47924178|NCT00000590|DRUG|immunoglobulins|
47924179|NCT00019994|BIOLOGICAL|MART-1 antigen|
47924180|NCT00019994|BIOLOGICAL|aldesleukin|
47924181|NCT00019994|BIOLOGICAL|gp100 antigen|
47924182|NCT00019994|BIOLOGICAL|incomplete Freund's adjuvant|
47924183|NCT04582123|PROCEDURE|crossed pin configuration|comparison of two crossed pin fixation methods
47924184|NCT02607748|OTHER|18F-NaF PET and coronary CTA imaging|
47924185|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.
47924186|NCT05933109|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
47924187|NCT05373056|BEHAVIORAL|Scapular program|the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.
47924188|NCT05373056|BEHAVIORAL|Conventional program|They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
47924189|NCT00948220|DRUG|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
47924190|NCT04641338|DRUG|Fixed dose combination Dipyrone and Codeine|Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
47924191|NCT04641338|DRUG|Dipyrone|use of 1000 mg dipyrone every 6 hours if necessary.
47924192|NCT04641338|DRUG|Codeine|30 mg codeine every 6 hours if necessary.
47924193|NCT04226170|DRUG|DAS-001|ondansetron + pyridostigmine
47924194|NCT04125251|BEHAVIORAL|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
47924195|NCT04193514|OTHER|Acceptance and Commitment Therapy|The intervention is a 7-day self-guided acceptance-based intervention using a published Acceptance and Commitment Therapy self-help work book. This therapy is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of depression, anxiety and/or stress. The therapy includes two components: (a) educating patients about the exacerbation of stress and negative affect through rigid attempts at experiential avoidance, and (b) introducing acceptance and the willingness to experience pregnancy-related sensations and cognitions as an alternative to experiential control, through the practice of intentional and non-judgmental paying attention to one's thoughts, feelings, images and bodily sensations (including aversive symptoms) and learning to see thoughts as an ongoing process distinct from self rather than merely an event with literal meaning.
47924196|NCT00899496|OTHER|immunological diagnostic method|
47924197|NCT00899496|OTHER|physiologic testing|
47924198|NCT00422084|DRUG|Pyronaridine artesunate|Oral PA (180:60mg tablets) once a day plus AL-placebo (twice a day) for 3 consecutive days (Day 0, 1, and 2)
47924199|NCT00422084|DRUG|Coartem® (artemether lumefantrine)|AL (20:120mg tablets) twice a day plus PA-placebo (once a day) for 3 consecutive days (Day 0, 1, and 2)
47924200|NCT04924439|OTHER|foot reflexology|Foot reflexology was applied to the experimental group for 40 minutes once a week for postpartum 8 weeks. The control group was only watched.
47924201|NCT02338908|OTHER|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
47924202|NCT02338908|OTHER|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
47924203|NCT05985460|DEVICE|Intervention: motion-sensor video game|The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
47951208|NCT04215250|DEVICE|ECG|Using ECG to monitor the insertion of the CVC
47924204|NCT05985460|DEVICE|Placebo: mobile APP game (without motion-sensoring)|The placebo arm is a 1-2 mins mobile app game, which allows 1-4 participants to play together with a duration of 1-2 minutes. It aims to increase participants' family and personal well-being by increasing the interaction of family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
47924205|NCT05903209|DEVICE|Chang Gung Pneumothorax Detection Software|"The Chang Gung Pneumothorax Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pneumothorax. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pneumothorax.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
47924206|NCT01491113|DRUG|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
47924207|NCT01491113|DRUG|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
47924208|NCT04610957|DRUG|Rosafem (FEMININE FORMULA)|Rosafem is the only phytoestrogen product with the convenient dose which provides significant improvement of menopausal related symptoms premenstrual syndrome symptoms
47924209|NCT01806662|DRUG|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
48271186|NCT00245271|DRUG|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
48271187|NCT00245271|DRUG|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
48271188|NCT06370416|DRUG|Trilaciclib|After pathological diagnosis of NSCLC, 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
48271189|NCT04997239|BIOLOGICAL|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
48095619|NCT03429309|DRUG|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
48095620|NCT00764179|OTHER|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
48271190|NCT04997239|BIOLOGICAL|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
48095621|NCT00764179|OTHER|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
48095622|NCT04045119|OTHER|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
48095623|NCT01218828|OTHER|LVEDP -Based hydration strategy|
48095624|NCT01218828|OTHER|Standard hydration|
48095625|NCT04234243|PROCEDURE|cytoreduction and HIPEC|cytoreduction CCR 0-1, and HIPEC close technique
48095626|NCT00004645|PROCEDURE|Plasma exchange|
48095627|NCT03315221|OTHER|Test product|HMF with added lipids - Intervention group
48095628|NCT03315221|OTHER|Control product|Commercially available HMF (without lipids) - control group
48095629|NCT01567059|DRUG|tosedostat|Given PO
48095630|NCT01567059|DRUG|cytarabine|Given IV
48095631|NCT01567059|DRUG|decitabine|Given IV
48095632|NCT06562608|DRUG|Anticholinergic Deprescription|per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
48095633|NCT06562608|DRUG|No Anticholinergic Deprescription|In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
48271191|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
48271192|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
47924210|NCT01806662|OTHER|Placebo|Injection of placebo
47924211|NCT00770380|BEHAVIORAL|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
47924212|NCT00770380|OTHER|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
47924213|NCT02031328|RADIATION|Stereotactic Ablative Radiation|
47924214|NCT00864916|DRUG|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
48095634|NCT03433274|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
48095635|NCT03433274|DEVICE|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
48095636|NCT04517851|BIOLOGICAL|Elotuzumab|Given IV
48271193|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
48271194|NCT00793793|DRUG|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
48271195|NCT00793793|DRUG|Placebo|
48271196|NCT05446493|DRUG|Tadalafil 5mg|"* Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months.~* Penile color Doppler ultrasound examination before and after treatment"
48271197|NCT04095455|PROCEDURE|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
48443710|NCT02563561|DRUG|Apaziquone|One dose of apaziquone administered by intravesical administration
47924215|NCT00864916|DRUG|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
47924216|NCT00864916|DRUG|Placebo|Participants will receive placebo three times per day for 48 weeks.
48271198|NCT04095455|DRUG|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
47924217|NCT05120921|OTHER|Osteopathic Manual Treatment|includes touch, joint manipulations, stretching and massage
48271199|NCT04095455|DRUG|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
48095637|NCT04517851|OTHER|Questionnaire Administration|Ancillary studies
48095638|NCT00070954|DRUG|ginkgo biloba|EgB 761
48095639|NCT00070954|OTHER|matched placebo|Inactive look-alike placebo
48095640|NCT00082719|BIOLOGICAL|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
48095641|NCT00539903|BEHAVIORAL|Physical activity (PA) and immigrants|
48271200|NCT00274391|DRUG|7% NaCl|
48271201|NCT00274391|DRUG|Amiloride HCl|
48095642|NCT03968887|OTHER|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
48095643|NCT01049139|BEHAVIORAL|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
48095644|NCT01049139|BEHAVIORAL|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
48095645|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
47924218|NCT05120921|OTHER|Self-management|Providing rehabilitative exercises to patients to do at home
47924219|NCT05120921|OTHER|Reassurance|Reassuring patients on their symptoms, diagnosis and prognosis.
47924220|NCT05120921|OTHER|Biopsychosocial management|Giving a central place to the patient in the decision-making to help them to get back to valued activities.
48095646|NCT01096056|BIOLOGICAL|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
48095647|NCT01096056|BIOLOGICAL|Fluarix|Intramuscular administration, 1 dose
48095648|NCT05536427|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
48095649|NCT05120869|BEHAVIORAL|Tailored HPV Education and Professional Skills Intervention Group|The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
48095650|NCT05120869|BEHAVIORAL|General HPV Education and Communication Skills Control Group|The general provider education intervention will involve audio and visual content and will be delivered in the English language.
48095651|NCT03415022|BEHAVIORAL|computer-based treatment|30 minute sessions of free viewing of faces and listening to music
48095652|NCT01671475|DEVICE|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
48095653|NCT03381391|BEHAVIORAL|Personalized Feedback Intervention|The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
47924221|NCT00488709|DRUG|Topotecan|
48095654|NCT00410995|DRUG|Naproxen|
48095655|NCT04470726|DRUG|AIV001|Intradermal/intratumoral
48095656|NCT00968331|DRUG|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
47924222|NCT00488709|DRUG|Fludarabine|
47924223|NCT00488709|DRUG|Cytarabine|
47924224|NCT05681559|BEHAVIORAL|Medi for All|Please see description of Medi for All arm
47924225|NCT05681559|DIETARY_SUPPLEMENT|Standard Fiber Supplementation|Please see description of Fiber Supplementation arm
47951209|NCT04747639|OTHER|500 ml glucose-depleted apple juice|
47951210|NCT04747639|OTHER|500 ml conventional apple juice|
47951211|NCT04747639|OTHER|250 ml glucose-depleted apple juice|
47951212|NCT04747639|OTHER|250 ml conventional apple juice|
47951213|NCT01016353|DEVICE|NPWT|ABThera Open Abdomen Negative Pressure Therapy System
47951214|NCT01016353|DEVICE|BVPT|Barker's Vacuum Packing Technique
48095657|NCT04221035|DRUG|Vincristine|1.5 mg/m2 (max dose 2 mg)
48095658|NCT04221035|DRUG|Carboplatin|750 mg/m2
48095659|NCT04221035|DRUG|Etoposide|175 mg/m2
48095660|NCT04221035|DRUG|Vindesine|3 mg/m2/day (max dose 6 mg)
48095661|NCT04221035|DRUG|Dacarbazine|200 mg/m2/day
48095662|NCT04221035|DRUG|Ifosfamide|1500 mg/m2/day
48095663|NCT04221035|DRUG|Doxorubicin|30 mg/m2/dose
48271202|NCT04967131|OTHER|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
48271203|NCT01775748|OTHER|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
48095664|NCT04221035|DRUG|Busulfan|\< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
48095665|NCT04221035|DRUG|Melphalan|140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
47924226|NCT01816451|OTHER|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
47924227|NCT03001271|DRUG|Angiotensin 1-7|
48095666|NCT04221035|DRUG|Thiotepa|300 mg/m2/day over 2 hours
48095667|NCT04221035|RADIATION|Radiotherapy|21.6 Gy 21.6 Gy + boost de 14.4 Gy
47924228|NCT03001271|OTHER|Placebo|
47924229|NCT00878436|DRUG|Panobinostat|
47924230|NCT00878436|DRUG|Bicalutamide|
47924231|NCT05613712|OTHER|Patients|Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
47924232|NCT05613712|OTHER|Referring physician|Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
47924233|NCT05580445|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
47924234|NCT05580445|DRUG|Toripalimab|Programmed Death 1(PD-1) antibody
47924235|NCT05580445|DRUG|Gemcitabine|nucleoside inhibitor
47924236|NCT04479319|DIAGNOSTIC_TEST|Thorax CT|Subjects in all arms have a Thorax CT and RT-PCR for SARS-CoV-2.
47924237|NCT05599477|DEVICE|Endoscopic sutured gastroplasty with endomina|"The endomina is is used to perform endoscopic sutured gastroplasty. Two guidewires are introduced via an upper GI endoscopy down to the duodenum. The endomina system is introduced and the endoscope is inserted and fixed to the system. Next a needle preloaded with suture is introduced into the platform. The stomach wall is grasped with a forceps and pulled back. The needle is pushed through the wall, and a first tag is released. The needle is retracted, the first plicature is released and a second plicature is made with the same needle at the opposite wall. Then the pretied knot is grasped and tightened until both plicatures are firmly apposed. The same procedure is repeated along the great curvature from the incisura to the upper body.~The procedure will include the placement of 6-9 sutures. The first suture is done at the level of the incisura, at the lower part of the greater curvature. The following stitches are placed along the body of the stomach"
47924238|NCT02282293|DRUG|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
47924239|NCT02282293|DRUG|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
47924240|NCT00370045|DRUG|Bivalirudin with and without eptifibatide|
47924241|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
47924242|NCT01062373|DIETARY_SUPPLEMENT|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
47924243|NCT05896436|BEHAVIORAL|Emotion Focused Therapy|12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
47924244|NCT04130308|OTHER|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
47924245|NCT02720107|DRUG|fingolimod|
48095668|NCT04221035|DRUG|Dinutuximab Beta|Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
48095669|NCT04221035|DRUG|Cisplatin|80 mg/m2/24h
48095670|NCT04221035|DRUG|Temozolomide 100 MG|100 mg/m²/Day
48095671|NCT04221035|DRUG|Irinotecan|50 mg/m²/jour de J0 à J4
48095672|NCT04221035|DRUG|Cyclophosphamid|Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
47924246|NCT00220779|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
47924247|NCT00220779|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|
47951215|NCT01724879|DRUG|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
47951216|NCT06681441|DRUG|QRL-101 Dose A|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
47951217|NCT06681441|DRUG|QRL-101 Dose B|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
47951218|NCT06681441|DRUG|Placebo|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
48095673|NCT00183573|BEHAVIORAL|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
48095674|NCT00183573|BEHAVIORAL|Brief Informational Intervention|15 minute informational DVD on safer sex
48095675|NCT00183573|BEHAVIORAL|Intensive Informational Intervention|4-hour, information-only intensive group workshop
48095676|NCT00183573|BEHAVIORAL|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
48095677|NCT03961256|DRUG|Exenatide SR|Exenatide SR 2 mg subcutaneous (SQ) weekly
48095678|NCT03394248|DEVICE|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
47924248|NCT02249637|PROCEDURE|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
47924249|NCT06081322|DRUG|PRRT with 177Lu-EB-FAPI|PRRT with 177Lu-Fibroblast activation protein inhibitor and modified by Evans blue
47924250|NCT04070911|OTHER|WATER|ORAL WATER
47924251|NCT04070911|OTHER|ICE APPLICATION|ICE APPLICATION
47924252|NCT04931888|BEHAVIORAL|EMPOWER|EMPOWER is an adapted social emotional learning (SEL) and wellness education initiative delivered to a community of refugee families that was developed through a pre-pilot in the New Haven Afghan refugee community in 2020. Unlike traditional school-based SEL curricula, EMPOWER partners with community organizations to provide translated and trauma-informed wellness education to family units. The program combines in-person (socially distant) and remote delivery of culturally-informed physical, emotional, and medical wellness tools adapted from evidenced-based behavioral medicine, refugee trauma and recovery, and community health research.
47924253|NCT01465685|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
47924254|NCT01465685|DRUG|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
47924255|NCT01465685|DRUG|Placebo|capsules identical to MDMA or methylphenidate
47924256|NCT04668261|OTHER|Advanced imaging investigation|MRI imaging
48271204|NCT01775748|OTHER|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
48271205|NCT03211182|BEHAVIORAL|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI\>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
47924257|NCT04307615|COMBINATION_PRODUCT|Oxygen + continuous positive airway pressure (CPAP)|Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment
47924258|NCT04307615|DRUG|Oxygen|Oxygen: 20 min treatment followed by 10 min rest and assessment
47924259|NCT04813003|OTHER|Functional Brain Imaging and neurobehavioural tasks|"Combination of 3 neurobehavioural tasks:~Task 1 consists in subjective value rating of 64 food items. Participants are asked to rate how much they would want to eat the presented food item while fMRI (functional magnetic resonance imaging ) scanning is performed.~Task 2 consists in rating of subjective nutrient factor of the same 64 food items. Participants will answer the following four categorical questions in randomized order for each item: low or high in added sugar/protein/fat and healthy or unhealthy.~Task 3 consists of a decision-making task. Participants will be presented with two food items (out of the 64 food items), and asked to choose which of the two items they prefer to consume at the end of the experiment."
47924260|NCT00456144|DRUG|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
47924261|NCT05732402|DRUG|povetacicept|Administered by subcutaneous injection every 4 weeks
48095679|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
48095680|NCT02511704|DRUG|Nicotine|Multiple dose nicotine
47924262|NCT05732402|DRUG|povetacicept|Administered by subcutaneous injection every 4 weeks
47924263|NCT00954096|DRUG|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
48095681|NCT02970461|OTHER|Gamified Group|See Gamified Group in Arms description.
48271206|NCT05554120|OTHER|Supermarket tobacco sales ban|In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
48095682|NCT02970461|OTHER|Control Group|See Control Group in Arms description.
48443711|NCT02563561|OTHER|Placebo|Matching placebo (containing 12 mg FD\&C red #40, 15 mg sodium chloride, and 10 mg mannitol was supplied in identical appearing vials) by intravesical administration.
47924264|NCT02667353|PROCEDURE|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) \< 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
47924265|NCT02667353|DRUG|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
47924266|NCT02667353|DRUG|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
48095683|NCT02797405|RADIATION|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
48095684|NCT05015972|BIOLOGICAL|CTA30X UCAR-T injection|CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
48095685|NCT03557333|COMBINATION_PRODUCT|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
48095686|NCT04341064|BEHAVIORAL|SHINE Intervention|\[see arm/group descriptions\]
48443712|NCT03104374|DRUG|Upadacitinib|Oral tablet
48443713|NCT03104374|DRUG|Placebo|Oral tablet
48620282|NCT01407419|OTHER|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
47924267|NCT04286997|DEVICE|GRAIL population|each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
48095687|NCT04294082|BEHAVIORAL|Mindfulness based intervention|"A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~* an introduction to mindfulness~* body-scan exercises~* sitting meditation~* mindful movement exercises~* individual and group reflections~* homework exercises"
48095688|NCT01569906|RADIATION|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
48095689|NCT02435901|DRUG|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
48271207|NCT03261115|PROCEDURE|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
48271208|NCT03047525|BIOLOGICAL|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
48271209|NCT00158366|BEHAVIORAL|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
48095690|NCT02435901|DRUG|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
48271210|NCT00158366|BEHAVIORAL|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
48271211|NCT00158366|BEHAVIORAL|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
48271212|NCT03006614|DRUG|NVB|
48095691|NCT02435901|DRUG|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
48271213|NCT03006614|DRUG|EPI|
48271214|NCT03006614|DRUG|DDP|
48095692|NCT02435901|DRUG|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
48095693|NCT02435901|DRUG|Mycophenolate mofetil|Immunosuppressant to prevent graft vs host disease is given on Day -1.
48095694|NCT02435901|DRUG|Tacrolimus|Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
48095695|NCT02435901|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
48271215|NCT03006614|DRUG|CAP|
48271216|NCT03006614|DRUG|GEM|
48095696|NCT00197457|PROCEDURE|serum pepsinogen|
48271217|NCT03006614|DRUG|H|
48271218|NCT03006614|DRUG|CTX|
48271219|NCT03006614|DRUG|T|
48095697|NCT00197457|PROCEDURE|urea breath test|
48095698|NCT03139175|DEVICE|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
48095699|NCT01579656|DIETARY_SUPPLEMENT|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
48095700|NCT01579656|DIETARY_SUPPLEMENT|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
48095701|NCT01579656|DIETARY_SUPPLEMENT|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
48095702|NCT01579656|DIETARY_SUPPLEMENT|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
48095703|NCT01579656|DIETARY_SUPPLEMENT|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
48095704|NCT02161510|DRUG|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
48095705|NCT02121574|DEVICE|Zero flux and ingestible thermometers|
48095706|NCT04810455|OTHER|Purrble|"The objective of this study is to evaluate the impact of having access to the Purrble intervention, compared to an active control in the form of a non-interactive plush toy, on child daily emotion regulation (primary outcome) as well as a range of secondary outcomes over a period of one month.~The investigators hypothesise that engagement with an in-situ, 'bottom-up' emotion regulation intervention which enables in-the-moment soothing for children, will lead to measurable changes in child self-regulatory behaviours over time."
47924268|NCT02586506|DRUG|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
47951219|NCT01069627|DRUG|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
47951220|NCT01069627|DRUG|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
48443714|NCT05488834|OTHER|Critical-Care Pain Observation Tool|"The Critical Care Pain Observation Tool (CPOT) was created to help assess pain in critically ill patients who were unable to self-report pain.~The CPOT instrument evaluates facial expression, body movement, muscle tension, and compliance with ventilator or vocalisation to evaluate an individual's pain. The total score ranges from 0 to 8, where 8 is the worst pain. Patients are observed for 60 seconds while resting and during nociceptive procedures such as turning or wound dressings to detect any change in behaviour that could indicate pain. Further, the patient must be observed before and at the peak of analgesia medications administered to evaluate pain treatment effectiveness."
48095707|NCT04810455|OTHER|Active control toy|The selected active control toy is the Wild Republic 8'' Hedgehog animal. The selection process was guided by: the plush toy needed to have analogous size, weight, quality of materials, and at least similar (if not higher) visual appeal. The investigators also made sure to include the design characteristics our prior work suggested were important for the narrative around the toy. These were selecting a similarly stylised animal (to enable emotion projection and feelings of care), as well as no visible mouth on the toy (to prevent setting an expectation about the toy's emotional state as a mouth would imply an emotional expression). Additionally, the investigators have adapted the one-page parent-facing descriptions of the narrative that come with Purrble also for the active control unit: as such, the active control families will receive the same general narrative-without the explicit mentions of the toy interactivity-and the same suggested activities for parents.
48095708|NCT01054430|DRUG|avanafil|200 mg avanafil tablets QD
48095709|NCT04073355|BEHAVIORAL|Physical Activity|Smartphone-delivered physical activity intervention
48095710|NCT04196985|DIAGNOSTIC_TEST|PET/MRI|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
48095711|NCT04196985|DIAGNOSTIC_TEST|PET/CT|each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
48095712|NCT02770664|DRUG|Placebo|Placebo
48095713|NCT02770664|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
48095714|NCT02770664|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
48095715|NCT02770664|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
48095716|NCT01270789|DRUG|Liraglutide|Liraglutide administered as once daily sc injection
48095717|NCT01270789|DRUG|placebo|placebo administered as once daily sc injection
48095718|NCT06037382|OTHER|Mood Triggers App|"The current intervention will deploy a smartphone application called Mood Triggers. Mood Triggers was designed to provide personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction."
48095719|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
48095720|NCT03511248|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
48095721|NCT04676802|DRUG|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
48095722|NCT04676802|DRUG|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
48095723|NCT04952272|COMBINATION_PRODUCT|CpG-ODN|CAR-T cells secreting scFv against OX40
48095724|NCT06461156|DRUG|HS-10504|HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.
48095725|NCT05471232|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
48443715|NCT04203147|BEHAVIORAL|Supportive Therapy (Control)|Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
48443716|NCT04203147|BEHAVIORAL|Home DM-BAT|Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
48095726|NCT05471232|OTHER|EHR-Based Network Model|EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
48095727|NCT05042271|DRUG|meropenem|each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
48095728|NCT02525705|BIOLOGICAL|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
48095729|NCT06121999|BEHAVIORAL|Standard of care acceptance-based behavioral weight loss program|Evidence-based, structured weight loss program for adults with co-morbid conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Published as a workbook for participants and a clinician guide, the intervention consists of twenty-five sessions or modules with accompanying worksheets. Each session covers specific acceptance-based behavioral skills to implement and build upon in subsequent sessions.
48095730|NCT06121999|BEHAVIORAL|Occupational therapy dietary and lifestyle modifications|Occupational therapy Model of Human Occupation Screening Tool (MOHOST) and Role Checklist version 3 (RCv3) assessments identify areas of need for personalizing participant implementation of the standard of care acceptance-based behavioral weight loss program. Areas of need may include physical activity limitations to be addressed in an exercise plan or social determinants of health that are barriers to dietary and lifestyle modifications. Dietary and lifestyle modifications are based on American Gastroenterology Association (AGA) recommendations published in practice guidelines for this population. Recommendations include a Mediterranean diet, improved self-management of co-morbid chronic conditions, and a total body weight loss of five to ten percent at 1 - 2 pound weekly increments.
48095731|NCT01338727|BEHAVIORAL|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
48095732|NCT02374957|DRUG|Cilostazol|100 mg twice daily for 90 days
48095733|NCT01460381|DRUG|LY2216684|
48095734|NCT01460381|DRUG|Quinidine|
48095735|NCT04179240|OTHER|audio and animated cartoon questionnaire|participants were asked to complete a questionnaire audio and animated cartoon on a platform
48271220|NCT05249049|DEVICE|e-OPRA Implant System for Transtibial Amputees|The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.
48443717|NCT02767921|OTHER|Cytology Specimen Collection Procedure|Correlative studies
47924269|NCT02586506|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
47924270|NCT04962256|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
48443718|NCT02767921|OTHER|Laboratory Biomarker Analysis|Correlative studies
47924271|NCT02445547|OTHER|UC-MSCs by peripheral intravenous infusion|
47924272|NCT02445547|DRUG|received hormone maintenance therapy|
47924273|NCT01859546|BEHAVIORAL|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
48271221|NCT00627237|BEHAVIORAL|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
48271222|NCT00627237|BEHAVIORAL|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
47924274|NCT00917644|DRUG|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
47924275|NCT00917644|GENETIC|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
47924276|NCT03096587|DEVICE|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
48271223|NCT04141176|DEVICE|Spiri+|CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
48271224|NCT05693402|PROCEDURE|opioid anesthesia|opioid-free general anesthesia vs non opioid-free general anesthesia
48443719|NCT02767921|PROCEDURE|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
48443720|NCT02767921|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
48443721|NCT02767921|PROCEDURE|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
48443722|NCT00115128|DRUG|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
48443723|NCT03841266|DIAGNOSTIC_TEST|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
48443724|NCT04666116|DIETARY_SUPPLEMENT|Dietary supplementation in patients with covid disease admitted to hospital|Dietary supplementation in patients with covid disease admitted to hospital
48443725|NCT06406608|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
47924277|NCT03096587|DEVICE|ultrasonic activated irrigation|by Satelec,Acteon, France
47924278|NCT01122056|OTHER|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
48443726|NCT06171919|OTHER|Organizational Partnerships|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs and risks of formerly incarcerated individuals living with HIV. Component 3 includes the provision of legal support.
48443727|NCT06171919|OTHER|HIV Continuum Care|Participants will be included in the pilot trial. The investigative team will work with the staff at Hope and Help Inc. to identify and recruit those out of care through reviewing electronic medical records.
48443728|NCT02288195|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
47924279|NCT00121862|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
47924280|NCT03460509|DRUG|Sugammadex|Dose-response
48443729|NCT02288195|DRUG|capecitabine|"825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B."
48443730|NCT02288195|RADIATION|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
47924281|NCT01416597|BIOLOGICAL|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
47924282|NCT04135105|OTHER|Normal hearing group|Observational
47924283|NCT05633550|DIAGNOSTIC_TEST|Flexion-extension radiographs|Participants will undergo (regular) flexion-extension radiographs.
47924284|NCT04801264|DRUG|68Ga-PSMA|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga-PSMA will be used to image lesions of adenoid cystic carcinoma by PET/CT.
47924285|NCT04801264|DRUG|1.85GBq (50 mCi) of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
47924286|NCT04184388|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 1g/day) for 12 week
47924287|NCT04184388|DIETARY_SUPPLEMENT|Placebo|once a day for 1 p.o., after breakfast(10 ml/day, Hydrolysed Red Ginseng extract for 0g/day) for 12 week
47924288|NCT00256971|PROCEDURE|meniscectomy|
47924289|NCT02470637|DRUG|SAR439065|"Pharmaceutical form:dry powder insulin~Route of administration: inhalation"
47924290|NCT02470637|DRUG|Insulin lispro|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
47924291|NCT04925856|OTHER|blood sample|"•Blood sample:~* 1 heparinized tube (4 mL) for collection of plasma and storage~* 1 heparinized tube (4 mL) for immunophenotyping,~* 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation."
47924292|NCT06481176|BEHAVIORAL|12-Week RLS Exercise Program|"Participants will complete 12 weeks of an evidence-based exercise program that has been used for people with RLS, designed for people with RLS, and was informed by exercise guidelines outlined by the American College of Sports Medicine (ACSM) and the American Heart Association, and Center for Disease Control.~The program includes three sessions per week for 12 weeks including:~* cardiovascular exercise (e.g., walking/jogging, bicycling) for 30 minutes/day on at least 3 days/week at a moderate-to-vigorous intensity~* strength training on 2 non-consecutive days/week targeting major muscle groups for approximately 30 minutes~* Stretching all major muscle groups on three or more days per week"
47924293|NCT05187273|BEHAVIORAL|Elastance Group|Fluids are given based on dynamic elastane value
47924294|NCT03224559|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
47924295|NCT06068426|DIAGNOSTIC_TEST|Transabdominal ultrasound Shear wave elastography|TUS SWE will be performed using a Canon Aplio i800 ultrasound system and a curved 1-6 MHz transducer. 2D SWE will be performed with measurement of shear wave speed in the head, body and tail of the pancreas.
47924296|NCT05373888|DEVICE|Flexima®/Softima® stoma bags|"One piece stoma bags for enterostomates available as:~* Closed (flat and convex)~* Drainable with Roll'Up (flat and convex)~* High flow with tape outlet (flat)"
47924297|NCT06158529|DEVICE|spinal cord stimulator|A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.
47924298|NCT06158529|DEVICE|high frequency spinal cord stimulation|A spinal cord stimulator is an implanted device that sends low levels and high frequency of electricity directly into the spinal cord to relieve pain.
47924299|NCT06467136|BEHAVIORAL|Sound production treatment|Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.
47924300|NCT06467136|BEHAVIORAL|Motor Imagery Practice|Practice of target items using motor imagery during home practice
47924301|NCT01997112|DRUG|Paracetamol|
47924302|NCT01997112|DRUG|Placebo oral capsule|
47924303|NCT01790243|DEVICE|Lutonix Drug Coated Balloon|Use of the Lutonix Drug Coated Balloon (DCB) for the treatment of stenosis or occlusion of the femoropopliteal arteries.
47924304|NCT01790243|DEVICE|Standard PTA Balloon|Use of Standard PTA Balloon in the treatment of stenosis or occlusion of the femoropopliteal arteries.
47924305|NCT04273880|DRUG|Methylphenidate|10mg of MPH taken an hour and a half before one of the testing sessions.
47924306|NCT04273880|DRUG|Vitamin C|90 mg of Vitamin C taken an hour and a half before the other testing session
47924307|NCT02153229|RADIATION|Photodynamic Therapy|
47924308|NCT02153229|PROCEDURE|Radical Pleurectomy|
47924309|NCT02153229|RADIATION|Chemotherapy|
47924310|NCT02153229|DRUG|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
47924311|NCT00835731|DRUG|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E
48443731|NCT02613754|BEHAVIORAL|Contingency Management|See arm description.
48443732|NCT02613754|BEHAVIORAL|Treatment as Usual|See arm description
48443733|NCT00449592|DRUG|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
47924312|NCT00835731|DEVICE|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D\&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D\&E
48443734|NCT00449592|DRUG|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
47924313|NCT00685009|DRUG|Estrogen hormone therapy|Estrogen pill daily
47924314|NCT00685009|DRUG|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
47924315|NCT00685009|DRUG|Placebo|Placebo pill daily
47924316|NCT03459391|DRUG|XC221 60 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
47924317|NCT03459391|DRUG|XC221 200 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
47924318|NCT03459391|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
47924319|NCT02213406|DIETARY_SUPPLEMENT|yogurt|Subjects will receive yogurt with varying fat concentrations
47924320|NCT02965768|DRUG|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
47924321|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG+L-PRF|Patients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material.
47924322|NCT03756493|PROCEDURE|Periodontal Surgery with OFD+ABG|Patients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material.
47924323|NCT03756493|PROCEDURE|Periodontal Surgery OFD|Patients will be treated by Open Flap Debridement without use of filling material.
47924324|NCT00003544|DRUG|irinotecan hydrochloride|
48443735|NCT02301975|DRUG|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
48443736|NCT02301975|DRUG|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
47924325|NCT00003544|PROCEDURE|surgical procedure|
48271225|NCT05359393|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
48271226|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
47924326|NCT00340574|DRUG|AMA1-C1/Alhydrogel + CpG 7909|
48271227|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
48271228|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
48271229|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
48271230|NCT05910229|OTHER|Phone call|In the experimental arm the patient will be called 3 days before the CT scan
48271231|NCT04623957|DEVICE|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
48271232|NCT00733525|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
48271233|NCT00733525|DRUG|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
48271234|NCT00733525|BEHAVIORAL|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
48271235|NCT04920136|PROCEDURE|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
48271236|NCT04920136|PROCEDURE|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
48271237|NCT02619851|BIOLOGICAL|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
48271238|NCT02619851|DEVICE|Conventional Therapy|Typical therapy conducted for burn injury patients
48271239|NCT05555004|OTHER|TEST1|Toddler milk with preconditioned L. reuteri and containing GOS
48271240|NCT05555004|OTHER|TEST 2|Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
48271241|NCT03291561|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
48443737|NCT02301975|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
47924327|NCT05510271|OTHER|White Noise|"Orhan OSMAN's song Don't Let Your Baby Cry-2 from the Kolik album was used."
47924328|NCT05510271|OTHER|Yakson Touch|In order to transfer the Ki energy to the baby, he took a deep breath and gathered the universal energy in his palms, intending the baby's well-being and healing. The researcher applied the Yakson touch by covering the abdomen and chest of the newborn with his right hand (dominant hand) while the newborn was in the supine position, and supported the baby's back and hips with his left hand.
47924329|NCT05925543|PROCEDURE|Kasai portoenterostomy operation.|Kasai portoenterostomy operation for biliary atresia patients.
47924330|NCT06123013|BEHAVIORAL|Music Assisted Relation Intervention (MARI)|A standardized 30-minute MARI intervention, personalized to the participant's music and imagery preferences. During the MARI intervention, the board certified music therapist (MT-BC) will provide live guitar accompaniment personalized to the participant's music preferences and read from a standardized script directing the participant to relax muscles of the body, practice deep breaths, and explore a relaxing place.
47951221|NCT00987545|DRUG|QAX576|QAX576 injection
47951222|NCT00987545|DRUG|QAX576 placebo|Placebo to QAX576 injection
48271242|NCT03291561|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
48271243|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
48271244|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
48443738|NCT02301975|DRUG|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
48443739|NCT02301975|DRUG|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
47924331|NCT02000908|DEVICE|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
48271245|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
48271246|NCT03862027|DEVICE|Esophageal Balloon catheter|"Pressures \[Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)\] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
48271247|NCT02647151|DRUG|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
48271248|NCT02647151|DRUG|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
47924332|NCT02000908|OTHER|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
47924333|NCT02000908|OTHER|Physiotherapy|Chiropractic massage and lymphedema treatment
47924334|NCT02783079|BEHAVIORAL|CBT|
48271249|NCT05166707|DEVICE|BIXINK OC Free|OC Free is a 6-week ERP-based intervention to deliver Exposure and Response Prevention (ERP) to reduce the anxiety from obsessive thoughts and compulsive rituals.
47924335|NCT02783079|BEHAVIORAL|MBSR|
47924336|NCT03417401|PROCEDURE|Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.|Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
48271250|NCT05246514|DRUG|Trastuzumab deruxtecan|administered as an IV infusion
48271251|NCT05790486|BEHAVIORAL|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
47924337|NCT03417401|DRUG|Intravenous Infusion|Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
47924338|NCT01876940|DEVICE|air-Q, followed by fiberoptic intubation|
47924339|NCT01876940|DEVICE|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
47924340|NCT00972140|DRUG|Formoterol|Formoterol-HFA pMDI 12µg twice daily
47924341|NCT00972140|DRUG|Formoterol|Formoterol-DPI 12 µg twice daily
47924342|NCT03354793|OTHER|Survey on first pregnancy after endometriosis diagnosis|Obstetric complications were noted
47924343|NCT03354793|OTHER|Survey on first pregnancy|Obstetric complications were noted
47924344|NCT05154305|BEHAVIORAL|multidisciplinary intervention|"* individually adjusted physical program consisting of strength and endurance training \> 3 times a week, 2 times guided by a physical therapist at the University Hospital or at a private practice, and ones a week by themselves at home recorded by an activity tracker. Follow-up is foreseen on monthly basis.~* multidisciplinary coaching (discipline depending on personal needs of patient) on a monthly basis. These coaching sessions could be in small groups or individual."
47924345|NCT02512627|BEHAVIORAL|Cognitive training|visuospatial, attention, memory, and executive abilities
47924346|NCT02512627|BEHAVIORAL|Physical exercise|endurance, balance, and mobility
47924347|NCT03273218|DEVICE|Tiger catheter|
47924348|NCT03273218|DEVICE|Judkins catheter|
47924349|NCT00118495|DRUG|Non-prescription Zestra(TM): patented formulation|
47924350|NCT04669418|DIAGNOSTIC_TEST|RNA expression signature|Whole transcriptome profiling using RNA sequencing
47924351|NCT05179343|DEVICE|Active AffeX-CT device|(Trans-cutaneous Autonomic Neurostimulation) tAN treatment will be administered using AffeX-CT device (a device based on a totally TENS unit). AffeX device comprises of a battery-operated control unit, two electrode pairs arranged on ear clips and connected to the control unit with electrical leads. The AffeX device generates an electrical signal that is used to stimulate the nerves that naturally control the output from the sympathetic nervous system.
47924352|NCT05179343|DEVICE|Sham AffeX-CT device|Sham Totally TENS device. The device is identical to the active device used in the study, but its only purpose is to act as a placebo. The ear-clip electrodes have been modified so that the electric current is not transmitted to the participant.
47924353|NCT00484744|DRUG|Acetaminophen|
47924354|NCT00484744|DRUG|Avicel (placebo)|
47924355|NCT00484744|DRUG|Ibuprofen|
47924356|NCT02624947|BIOLOGICAL|RSV F vaccine with adjuvant|
47924357|NCT02624947|BIOLOGICAL|Formulation buffer|
47924358|NCT05324644|BEHAVIORAL|Motivational interview|In the first interviews with the students; It is planned to provide information about acquaintance and research, fill in the scales in 10-15 minutes, make CO measurements, and also conduct an average of 20-40 minutes of motivational interviews in the intervention group. In the second interview in the 1st month, it is planned to summarize the first interview, fill in the scales in 3-5 minutes, make the CO measurements in 10-15 minutes or get the measurement results and apply motivational interview in the average of 20-40 minutes. In the third interview in the 3rd month, it is planned to summarize the second interview in 3-5 min, fill in the scales in 10-15 minutes, make CO measurements or get the measurement results and to apply motivational interviews for an average of 20-40 minutes. In the last interview in the 6th month, it is planned to summarize the 3rd-month interview, to apply the scales for approximately 10-15 minutes, to make CO measurements or to get the measurement results.
47924359|NCT02478567|OTHER|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
47924360|NCT02478567|OTHER|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
47924361|NCT03083444|DIAGNOSTIC_TEST|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
47924362|NCT03037645|DRUG|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
47924363|NCT01974739|DRUG|Hydrochloorthiazide|
47924364|NCT01974739|DRUG|placebo|
47924365|NCT04374227|PROCEDURE|Osteopathic Manipulative Treatment|Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
47924366|NCT03540251|OTHER|Auricular Points Sticking|"Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments."
47924367|NCT02294968|OTHER|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
47924368|NCT03997227|PROCEDURE|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
47924369|NCT05860270|DRUG|Cholecalciferol|Patients in the intervention group will receive oral cholecalciferol 4000U per day.
47924370|NCT05860270|DRUG|Placebo|Patients in the control group will receive placebo 2 capsules per day.
47924371|NCT02121665|DRUG|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
48271252|NCT05790486|BEHAVIORAL|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
47924372|NCT02121665|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
47924373|NCT00205907|BIOLOGICAL|BLVR Hydrogel|10 mL BLVR Hydrogel
48271253|NCT05790486|OTHER|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
48443740|NCT05293145|OTHER|Building Futures Program Primary Services|Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
48443741|NCT05132933|PROCEDURE|PEEP trial - Electrical Impedance Tomography|Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
47924374|NCT02779361|DIETARY_SUPPLEMENT|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*)."
47924375|NCT00681356|DRUG|4975, 15 and 5 mg|Direct instillation into the surgical site
47924376|NCT00681356|DRUG|Placebo Comparator|Direct instillation into the surgical site
47924377|NCT00681356|DRUG|4975 - 5 mg|Direct instillation into the surgical site
48443742|NCT03128723|DEVICE|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
47924378|NCT02166944|DRUG|tamoxifen 40 mg daily for one year|both arms with riluzole daily
47924379|NCT05766358|BEHAVIORAL|Intensive lifestyle change therapy|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
48443743|NCT01042665|DRUG|latanoprost 0.005%|Active comparator
48443744|NCT01042665|DRUG|Placebo|Placebo comparator
48443745|NCT02071108|DEVICE|Shockwave Lithoplasty System|
48620283|NCT01660542|DRUG|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -\> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
47924380|NCT05766358|DRUG|Tirzepatide|Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
47924381|NCT04660838|OTHER|ACB intervention|Stopping and/or switching ACB medication to an alternative
47924382|NCT05683353|OTHER|None intervention|None intervention.
47924383|NCT00761644|DRUG|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m\^2 by vein over 3 hours.
47924384|NCT00761644|DRUG|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
47924385|NCT00761644|DRUG|Temsirolimus|Days 1, 8 \& 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
47924386|NCT04634305|PROCEDURE|Total elbow arthroplasty|Total elbow arthroplasty by a single operator
47924387|NCT05411627|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once per week for three weeks.
47924388|NCT02061527|PROCEDURE|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
47924389|NCT02061527|PROCEDURE|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
47924390|NCT02061527|PROCEDURE|Reconstruction with implant|Immediate breast reconstruction with implant
47924391|NCT02061527|PROCEDURE|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
47924392|NCT02061527|PROCEDURE|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
47924393|NCT04670250|DIAGNOSTIC_TEST|non invasive markers|non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
47924394|NCT02483767|DRUG|goserelin|Gonadotropin-Releasing Hormone Agonist
47924395|NCT02483767|DRUG|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
48271254|NCT05790486|OTHER|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
48271255|NCT02247089|OTHER|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
48271256|NCT02247089|OTHER|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
48271257|NCT02604264|DEVICE|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
48271258|NCT00049387|DRUG|tipifarnib|Given PO
48271259|NCT00049387|DRUG|temozolomide|Given PO
48271260|NCT00049387|RADIATION|radiation therapy|Undergo partial brain radiation therapy
48271261|NCT02603744|BIOLOGICAL|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
47924396|NCT03328884|DRUG|Irinotecan Hydrochloride|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy."
47924397|NCT03708354|DRUG|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
47924398|NCT03708354|DRUG|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
47924399|NCT05141877|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
47924400|NCT05141877|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
47924401|NCT02512484|PROCEDURE|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
47924402|NCT02452827|OTHER|Biomechanical parameters|
47924403|NCT02452827|OTHER|MRI|MRI of cervical spine
47924404|NCT01464957|BEHAVIORAL|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
47924405|NCT00662675|DRUG|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
47924406|NCT00662675|DRUG|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
47924407|NCT02184455|BIOLOGICAL|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
47924408|NCT06304467|BEHAVIORAL|Contingency Management|Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
47924409|NCT00536211|BEHAVIORAL|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at \~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
47924410|NCT00536211|DRUG|Metformin|oral tablet, 1000 mg daily for 17 days
47924411|NCT04348968|DEVICE|Total hip arthroplasty|"The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.~In this study, the acetabular component is the Zimmer Maxera Cup, which is a monoblock construct consisting of a pre-assembled shell and liner. The ceramic liner articulates with a ceramic femoral head for a ceramic-on-ceramic large diameter head articulation. The Maxera Cup is intended for single use only and is designed for reconstruction of the hip joint for conditions described in the inclusion and exclusion section of this protocol."
47924412|NCT02858700|BIOLOGICAL|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
47924413|NCT04335305|DRUG|Tocilizumab|IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
47924414|NCT04335305|BIOLOGICAL|Pembrolizumab (MK-3475)|IV infusion over 30 minutes, 200 mg; single dose
47924415|NCT02224885|DEVICE|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
47924416|NCT04745260|DRUG|Intranasal Fentanyl Spray and Intranasal Midazolam Spray|Intranasal Fentanyl 2mcg/kg and Intranasal Midazolam 0.2mg/kg
47924417|NCT04745260|DRUG|Intranasal Midazolam Spray|Intranasal Midazolam 0.3mg/kg
47924418|NCT02113800|DRUG|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
47924419|NCT03284918|DIETARY_SUPPLEMENT|Plant stanol ester|
47924420|NCT03284918|DIETARY_SUPPLEMENT|Placebo|
47924421|NCT05232409|BIOLOGICAL|Zeaxanthin|The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
47924422|NCT05232409|COMBINATION_PRODUCT|Zeaxanthin Plus Pembrolizumab|"The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab."
47924423|NCT05607212|OTHER|Kettlebell Swing|Participants will perform two-handed kettlebell swings using the interval training protocol outlined in the study carried out by Jay et. al. (2011). The protocol calls for 30 seconds of work, followed by 30-60 seconds of rest for a total of 10 intervals. The mechanics of the kettlebell swing will follow those outlined in the study carried out by McGill et. al. (2012). All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability. The weight is higher than previous and similar study by Brandon et al to ensure measurable differences between experimental and comparison groups.
47924424|NCT05607212|OTHER|Isometric Hold|Participants will perform an isometric hold of a kettlebell for 30 seconds followed by 30 seconds of rest for a total of 10 intervals. Participants will mimic initial kettlebell swing position by standing shoulder width apart with their back straight, and hips and knees flexed. Participants will be cued to squeeze their glutes and look straight ahead while they hold the weight for the 30 second interval. All male participants will perform the intervention with a 16kg kettlebell and all female participants will perform the intervention with a 12kg kettlebell to assure reliability.
47924425|NCT05607212|OTHER|Control|Control group: participants will be educated on the benefit of a kettlebell swing.
47924426|NCT05536388|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
47924427|NCT01156064|DEVICE|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
47924428|NCT01156064|DEVICE|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
47924429|NCT03897140|DIAGNOSTIC_TEST|Diagnostic Test: Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
47924430|NCT06294210|DEVICE|Mobile app and wrist-worn monitor|A mobile app was developed based on students feedback about their wellbeing needs gathered in a previous study through focus groups, surveys and design activities. This app includes features for students to track wellbeing habits, enter goals, access evidence-based resources related to their wellbeing topics of interest, and see heart rate variability summary metrics. These metrics will stream via bluetooth from the wrist-worn wearable device that has been developed at the Royal College of Surgeons in Ireland. This device includes a PPG sensor, charging port, and light indicator. There is no screen, so all data will be displayed through the mobile app.
47924431|NCT05714644|OTHER|FIT kit Screening Test|FIT kit mailed to the patient's home
47924432|NCT05714644|OTHER|Cologuard Screening Test|Cologuard test mailed to the patient's home
47924433|NCT00825253|DRUG|biphasic insulin aspart 30|
47924434|NCT00825253|DRUG|biphasic human insulin 30|
47924435|NCT00042341|DRUG|clofarabine (IV formulation)|
48271262|NCT04897867|DEVICE|CoolSculpting® Elite System with CoolSculpting® Elite applicators|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
47924436|NCT01303224|DRUG|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
47924437|NCT01303224|DRUG|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
47924438|NCT01303224|DRUG|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
47924439|NCT01303224|DRUG|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
47924440|NCT04023838|PROCEDURE|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
47924441|NCT04892368|OTHER|Home-based supervised exercise program|Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
47924442|NCT04123951|OTHER|Home-based Exercise|Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
47924443|NCT01587768|DRUG|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
47924444|NCT00324298|BIOLOGICAL|bleomycin sulfate|
47924445|NCT00324298|DRUG|cisplatin|
47924446|NCT00324298|DRUG|etoposide|
47924447|NCT00324298|PROCEDURE|management of therapy complications|
47924448|NCT05857553|OTHER|Unconditional Cash Transfer|Unconditional monthly transfer of $500 to household
47924449|NCT05857553|OTHER|No Direct Cash Transfer|No intervention
47924450|NCT02694757|DEVICE|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
47924451|NCT02482831|PROCEDURE|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
47924452|NCT01030081|DRUG|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
47924453|NCT01030081|DRUG|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
47924454|NCT01012674|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
47924455|NCT01012674|OTHER|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
47924456|NCT00811642|DRUG|Posaconazole|400mg BID oral suspension for 12 weeks
47924457|NCT06102330|OTHER|HomeVENT decision support tool|Web-based decision support tool that describes diverse family experiences with making decisions about pediatric chronic home ventilation
47924458|NCT04427826|DRUG|Morphine hydrochloride|A single open-label injection of morphine (T0) at the dose closest to that defined by the model (estimation by Bayesian method) from among the following 4 doses: 0.02; 0.04; 0.07 and 0.1mg/kg will be adminestred to the patients.
47924459|NCT00950885|BIOLOGICAL|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
47924460|NCT00950885|BIOLOGICAL|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
47924461|NCT00950885|BIOLOGICAL|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
47924462|NCT02176746|BIOLOGICAL|cancer stem cell vaccine|
47924463|NCT00282347|DRUG|Rituximab|Rituximab was provided as a sterile solution for injection.
48443746|NCT03999684|DRUG|Tretinoin|ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
47924464|NCT00282347|DRUG|Placebo|Placebo was provided as a sterile solution for injection.
47924465|NCT00282347|DRUG|Mycophenolate mofetil|
47924466|NCT00282347|DRUG|Methylprednisolone|
47924467|NCT00282347|DRUG|Diphenhydramine|
47924468|NCT00282347|DRUG|Acetaminophen|
47924469|NCT00282347|DRUG|Prednisone|
47924470|NCT03337672|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
47924471|NCT03337672|DRUG|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
47924472|NCT06095648|OTHER|Dose of platelet transfusion|Intervention is using a lower (5ml/kg) compared to usual (15ml/kg) dose of platelets for transfusion in non-bleeding babies born at or before 32 weeks in NICU
47924473|NCT03163602|DRUG|Control group|Access flap and debridement
47924474|NCT03163602|DEVICE|Test group|Regenerative treatment
47924475|NCT03802058|DRUG|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
47924476|NCT03802058|DRUG|Carboplatin|Carboplatin AUC=2 for Injection weekly
47924477|NCT03802058|RADIATION|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
47924478|NCT05788289|DRUG|Tafasitamab|Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
47924479|NCT05788289|DRUG|Lenalidomide|Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
47924480|NCT05605951|OTHER|non-interventional study|observational study
47924481|NCT00567255|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
47924482|NCT00567255|DRUG|Placebo|
48271263|NCT04389177|DRUG|Pembrolizumab Injection [Keytruda]|"Neoadjuvant period:preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks.~Da Vinci robot radical surgery: Before surgery, head/abdomen/chest CT scan, type B ultrasonic, upper gastrointestinal contrast, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 4-6 weeks after last neoadjuvant treatment finished.~Adjuvant period: Adjuvant treatment with pembrolizumab 200mg every 3 weeks (6 cycles) should be performed within 3-6 weeks after surgery if the surgical pathology result is not pCR. abdomen/chest CT scan will be performed every 3 month after surgery."
48443747|NCT01352091|DRUG|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
48443748|NCT01352091|DRUG|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
48271264|NCT02310373|OTHER|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
48271265|NCT04600167|DRUG|Isoniazid and Rifapentine (INH-RPT)|Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
48443749|NCT04437303|DRUG|Continuation of oral anticoagulants|Oral anticoagulant treatment will not be interrupted before the procedure.
47924483|NCT00567255|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
47924484|NCT00274092|DRUG|tiotropium inhalation capsules (18 mcg once daily)|
47924485|NCT00274092|DRUG|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
47924486|NCT06093074|BEHAVIORAL|self-management program after traumatic injuries|The self-management support (SMS) program is manualized and will include eight weekly 2.5-hour sessions in groups of 5-7 participants. This feasibility trial will assess both face-to-face delivered program and a tele-health program via electronic devices. The tele-health intervention will be delivered with the same SMS content, frequency, and in-group mode.
47924487|NCT03348189|OTHER|Pulse Oximeter|Pulse Oximeter
47924488|NCT06131476|DRUG|Blink® Tears eye drops|Control Drops
47924489|NCT06131476|DRUG|Investigational lipid eye drops|Test Drops
47924490|NCT05952752|OTHER|giving dexemedetomidine 12 microgram Iv dripping|Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg
47924491|NCT05952752|OTHER|Dexamethsone IV|4 mg IV dexamethasone
47924492|NCT02083549|OTHER|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
47924493|NCT05402371|DRUG|Rencofilstat|Rencofilstat soft gel capsule
47924494|NCT05402371|DRUG|Placebo|placebo soft gel capsule
47924495|NCT01698307|OTHER|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
47924496|NCT01698307|OTHER|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
47924497|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Frozen section|Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
48271266|NCT04600167|DRUG|Placebo|Participants in the control group will receive placebo once weekly for 12 weeks
48271267|NCT00220220|DRUG|olmesartan medoxomil|
48271268|NCT00220220|DRUG|amlodipine|
48271269|NCT03283202|DRUG|Avadomide (CC-122)|Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
48271270|NCT03283202|DRUG|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
48271271|NCT03283202|DRUG|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
48271272|NCT03283202|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
48271273|NCT03283202|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
48271274|NCT04244344|OTHER|fall prevention measures|High fall risk signage, information sheet, High fall risk bracelet, verbal instructions
48271275|NCT00516919|DRUG|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
48271276|NCT00516919|BEHAVIORAL|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
48443750|NCT04437303|DRUG|Interruption of oral anticoagulants|"Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician."
47924498|NCT03837522|DIAGNOSTIC_TEST|Procurement Biopsy: Permanent section|Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
47924499|NCT04333303|OTHER|Implementation of a complex regional Advance Care Planning program|"Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book \[SGB\] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management."
47924500|NCT02721953|DIETARY_SUPPLEMENT|Butyrate|Butyrate
47924501|NCT02721953|OTHER|Placebo|Placebo
47924502|NCT05024292|PROCEDURE|rapid local ischemic postconditioning (RL-IPostC)|with 5 circules of balloon inflations in the ipsilateral internal carotid artery, each circulation includes inflation lasting 15 seconds followed by 15 seconds of deflation
47924503|NCT00353860|DEVICE|SOLEX 300i Stem Cell Selection|
47924504|NCT00947791|DRUG|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
47924505|NCT00947791|DRUG|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
47924506|NCT05921045|OTHER|modification of clinical approach in clinical practice at time 0|evaluation of modification in clinical approach after training
47924507|NCT05921045|OTHER|modification of clinical approach in clinical practice at 6 months|evaluation of modification in clinical approach after retraining
47924508|NCT03940183|DRUG|Trelagliptin Succinate|the experimental group will use trelagliptin succinate 100 mg for 24weeks
47924509|NCT03940183|DRUG|Placebo Oral Tablet|the placebo Comparator groups use placebo oral tablet for 24weeks
47924510|NCT01317108|DRUG|CMF Chemotherapy|
47924511|NCT00413985|DRUG|Nutrient-enriched human milk|
47924512|NCT00815555|OTHER|There is no intervention - this is an observational study|
47924513|NCT05705089|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
48443751|NCT00362596|DRUG|acyclovir|
48443752|NCT03531294|DRUG|Aflibercept Injection|intravitreal 2mg aflibercept injection
47924514|NCT05705089|DRUG|Warfarin|Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
47924515|NCT00317291|PROCEDURE|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
47924516|NCT00317291|OTHER|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
47924517|NCT03815578|OTHER|Clinical examination|"* Number of painful joints,~* Number of swollen joints,~* Patient Global assessment VAS (0 - 100)~* and Physician Global assessment VAS (0 - 100)"
47924518|NCT03815578|OTHER|Pain assessment|"* Pressure Pain Thresholds (PPTs),~* Mechanical Temporal Summation (MTS)~* and Diffuse Noxious Inhibitory Control (DNIC)"
47924519|NCT03815578|OTHER|blood sample|18 ml whole blood for ELISA analysis and miRNAs detection
48443753|NCT05262985|DRUG|Durvalumab|In patients with advanced treatment naive LCNEC, treatment with Durvalumab+ Cisplatin/Carboplatin+Etoposide
48443754|NCT00045422|BIOLOGICAL|recombinant interferon alfa|
48443755|NCT00045422|DRUG|imatinib mesylate|
48443756|NCT00061321|DRUG|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
47924520|NCT03815578|OTHER|Patient Reported Outcomes|"* Health Assessment Questionnaire (HAQ),~* Rheumatoid Arthritis Impact of Disease score (RAID),~* Daily joint pain intensity VAS (0-100),~* Hospital Anxiety and Depression scale~* and Coping Strategy Questionnaire."
47924521|NCT05908643|DRUG|pTTL|pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
47924522|NCT03063047|OTHER|PD21871AA|A 100s size menthol cigarette.
47924523|NCT03063047|OTHER|PD21872AA|A 100s size menthol cigarette.
47924524|NCT02490969|PROCEDURE|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
47924525|NCT02907840|DEVICE|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
47924526|NCT00933218|DIETARY_SUPPLEMENT|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
47924527|NCT00933218|DIETARY_SUPPLEMENT|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
47924528|NCT05176457|OTHER|communication tool PICT'REA|"The pictograms communication tool PICT'REA will be available to patients with invasive ventilation systems preventing them from speaking"
47924529|NCT02776748|DRUG|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
47924530|NCT01436617|OTHER|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
47924531|NCT05806489|OTHER|Intermittent Fasting|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 6 hours (while fasting for the remaining 18 hours). Diet plans were matched for energy and macronutrients.
47924532|NCT05806489|OTHER|Control Diet|Participants received a 3-day individualized diet plan consisting of 3 meals per day. Meals needed to be consumed during 12 hours (while fasting for the remaining 12 hours). Diet plans were matched for energy and macronutrients.
47924533|NCT04955678|DRUG|Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes|ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.
47924534|NCT04955678|DRUG|Placebo|Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.
47924535|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
47924536|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
47924537|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
47924538|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
47924539|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
47924540|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
47924541|NCT01264575|DRUG|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
47924542|NCT01264575|DRUG|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
47924543|NCT01264575|DRUG|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
47924544|NCT01264575|DRUG|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
47924545|NCT01264575|DRUG|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
47924546|NCT01264575|DRUG|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
47924547|NCT05566483|BEHAVIORAL|Exercise|exercise protocol
47924548|NCT04043598|DRUG|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
47924549|NCT04043598|DRUG|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
47924550|NCT05946356|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
47924551|NCT05623462|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
47924552|NCT05623462|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
47924553|NCT02868827|DRUG|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
47924554|NCT02868827|OTHER|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
47924555|NCT04208113|BEHAVIORAL|School teacher training /.b|"The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher."
48443757|NCT05358860|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
47924556|NCT06082973|DEVICE|Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.
47924557|NCT06082973|DEVICE|Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control|Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
47924558|NCT00853996|DRUG|acolbifene hydrochloride|Given orally
47924559|NCT05028361|BIOLOGICAL|mRNA COVID-19|ACIP-CDC recommended vaccine
47924560|NCT05028361|BIOLOGICAL|IIV4|ACIP recommended vaccine
47924561|NCT05028361|OTHER|Placebo (saline)|Saline Control
47924562|NCT03841747|DRUG|Pembrolizumab|200 mg Pembrolizumab IV Q3W.
48271277|NCT03707457|DRUG|Nivolumab|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
47924563|NCT03841747|DRUG|Paclitaxel|80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
47924564|NCT05324761|DRUG|Pregabalin 75mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
47924565|NCT05324761|DRUG|Gabapentin 300mg|Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
47924566|NCT04113369|DEVICE|TENS|30 minutes of conventional antalgic TENS to non-paretic forearm
47924567|NCT04113369|PROCEDURE|Conventional rehabilitation|40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
47924568|NCT04113369|DEVICE|EMS|20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
47924569|NCT00307008|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection
47924570|NCT00103233|BIOLOGICAL|trastuzumab|
47924571|NCT00103233|DRUG|vinorelbine tartrate|
47924572|NCT04915378|OTHER|hypoxia altitude simulation test (HAST) at 760m|Normobaric hypoxia at a FiO2 of 15.1% will be generated by the Everest Summit II altitude generator (Hypoxico Altitude Training Systems, Bickenbach, Germany) and delivered to the patients face via tubes and a tightly fitted mask. Patients will be seated comfortably in a chair and fitted with a full-face mask equipped with a one-way valve. After a baseline period of quiet rest of 5-10 min with ambient air breathing and installation of equipment, patients will breath the hypoxic air mixture via a tightly fitted facial mask. They will be monitored with a finger-tip pulseoximetry to continuously assess SpO2 and heart rate. After at least 15' and steady-state values of the SpO2 (±1%) for at least 5' arterial blood gases will be drawn from a radial artery and immediately analyzed (RapidPoint 500, Siemens, Zürich, Switzerland).
47924573|NCT04915378|PROCEDURE|High Altitude (3100m)|High Altitude (3100m) exposure for 2 days
47924574|NCT00752440|OTHER|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
47924575|NCT03349398|PROCEDURE|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
47924576|NCT03349398|PROCEDURE|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
47924577|NCT05322044|BEHAVIORAL|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
47924578|NCT00545870|DRUG|bevacizumab|intravitreal application
47924579|NCT00545870|DRUG|Ranibizumab|intravitreal application
47924580|NCT00959400|DRUG|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
47924581|NCT02397018|BIOLOGICAL|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10\^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
47924582|NCT05991544|BEHAVIORAL|Training and Follow-up According to the Neuman Systems Model|Neuman Systems Model (NSM) it presents a holistic approach to patients by including physiological, spiritual, sociocultural and five major developmental variables
47924583|NCT01578824|OTHER|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
47924584|NCT01495312|DEVICE|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
47924585|NCT00295386|BEHAVIORAL|Cognitive behavior therapy (CBT)|
47924586|NCT00295386|DRUG|Zopiclone|
48271278|NCT03707457|DRUG|Anti-GITR Monoclonal Antibody MK-4166|Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
48271279|NCT03707457|DRUG|IDO1 inhibitor INCB024360|Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
47924587|NCT02188901|OTHER|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) \[GE healthcare\]
47924588|NCT05111301|DEVICE|Control-IQ technology 1.5|"All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor.~Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level."
47924589|NCT01371279|DEVICE|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
47924590|NCT06027632|OTHER|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
47924591|NCT06027632|OTHER|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
48271280|NCT03707457|DRUG|Ipilimumab|Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
48271281|NCT01783067|OTHER|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
47924592|NCT05633030|PROCEDURE|using UAS during flexible ureteroscopy and using PCN during flexible ureteroscopy|under general anesthesia and given appropriate antibiotic cover. a clssic flexible ureteroscopy procedure is done and appropriately sized UAS was then inserted over the wire and positioned just distal to the PUJ or below upper ureteric stone under fluoroscopic guidance. We then perform a flexible ureteroscopy using Olympus URF-V2 (8.5 Fr) flexible ureteroscope to inspect the proximal ureter if there is upper ureteric stone, renal pelvis, and calyces for the presence of stones. Irrigation with 0.9% saline solution via a pressure-infusing system. Next, Holmium laser lithotripsy with a holmium:YAG laser \[20 W; Lumenis (UK) Ltd., Elstree, UK\] using a 272 micron laser fiber (Lumenis, Inc.) is carried out and/or stone extraction with a basket device, in the other group we add inserted trans papillary in the lower calyx of the kidney by an expert intervention radiologist
47924593|NCT00715143|DEVICE|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
47924594|NCT05365685|BEHAVIORAL|Low energy turnover|"Low Energy Turnover. The adolescents with ingest low energy intake at lunch and breakfast and will not perform physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~Moderate Energy Turnover. The adolescents with ingest moderate energy intake at lunch and breakfast and will perform one 45 minutes physical exercise during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.~High Energy Turnover. The adolescents with ingest high energy intake at lunch and breakfast and will perform two 45-minute physical exercises during the day. The will will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals."
48271282|NCT01783067|OTHER|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
48271283|NCT02663895|DRUG|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
47924595|NCT00392145|DRUG|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
47924596|NCT00392145|DRUG|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
47924597|NCT00408941|DRUG|Propofol|
47924598|NCT00408941|DRUG|Prilocaine|
47924599|NCT03005873|DRUG|TLC599 LD group|Single dose via intra-articular injection
47924600|NCT03005873|DRUG|Normal Saline|Single dose via intra-articular injection
47924601|NCT03005873|DRUG|TLC599 HD group|Single dose via intra-articular injection
47924602|NCT00205270|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
48271284|NCT01938157|PROCEDURE|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
48271285|NCT02868203|DEVICE|OCT|OCT after stent implantation
47924603|NCT00705744|DRUG|Lactic acid (Dermacyd Femina)|
47924604|NCT05107752|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
47924605|NCT05107752|DRUG|Stellate Ganglion Block|SGB is a procedure that has demonstrated efficacy for the reduction of PTSD symptoms. SGB is performed using real-time ultrasonography with an in-plane technique, and consists of 7-10 mL of ropivacaine 0.5%, which is injected around and into the site of the ganglion at the level of the C4 and C6 anterior tubercle (Mulvaney, Curtis et al., 2020). Ropivacaine is a long-acting amide local anesthetic agent and a pure S-enantiomer with a high pKa and relatively low solubility. Patients are not sedated during the procedure. Successful sympathetic blockade is confirmed by the presence of Horner's syndrome, which is characterized by constriction of the pupil (miosis) and drooping of the upper eyelid (ptosis). If Horner's syndrome is not observed within 20 minutes of the first injection, the right-sided SGB is repeated one hour later using the same technique. If Horner's syndrome is not confirmed after the second injection, no additional injections are provided.
47924606|NCT06269939|BEHAVIORAL|STEM|Memory technique training
47924607|NCT02923921|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus FOLFOX
47924608|NCT02923921|DRUG|FOLFOX|FOLFOX Alone
47924609|NCT02384642|BEHAVIORAL|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
48271286|NCT02868203|DEVICE|eLuting stent|
48271287|NCT03182738|BEHAVIORAL|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
48271288|NCT03182738|BEHAVIORAL|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
48271289|NCT03623789|DRUG|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
48271290|NCT03623789|DRUG|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
48271291|NCT03623789|DRUG|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
48271292|NCT03566940|BIOLOGICAL|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
48271293|NCT03566940|BIOLOGICAL|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
48443758|NCT00436163|DRUG|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
47924610|NCT02384642|BEHAVIORAL|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
47924611|NCT03027544|RADIATION|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles."
47924612|NCT02879487|DEVICE|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
48271294|NCT03379519|BEHAVIORAL|Multi-domain Attention Training (MAT)|The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
47924613|NCT00093444|DRUG|lyso-thermosensitive liposomal doxorubicin|
47924614|NCT00093444|PROCEDURE|radiofrequency ablation|
47924615|NCT05873907|DRUG|AMG 592|Administered as SC injection
48443759|NCT02671526|OTHER|Computerized plasticity-based adaptive cognitive training|
48443760|NCT00448591|DRUG|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
47924616|NCT05873907|OTHER|Placebo|Administered as SC injection
47924617|NCT03254108|DRUG|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
47924618|NCT03254108|DRUG|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
47924619|NCT03254108|DRUG|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
47924620|NCT03254108|DRUG|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
47924621|NCT03254108|DRUG|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
47924622|NCT03664349|DEVICE|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
47924623|NCT05396716|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
47924624|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
47924625|NCT02258776|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
47924626|NCT02258776|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1/day for 12 weeks.
47924627|NCT01723644|OTHER|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
48271295|NCT03379519|BEHAVIORAL|Passive information activities (PIA)|The active control group (Passive information activities) training content included reading online e-books and playing online games.
48443761|NCT00448591|DRUG|Taxane-based chemotherapy|As prescribed
48443762|NCT03036085|DRUG|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
47924628|NCT01723644|OTHER|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
47924629|NCT02675556|DRUG|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
47924630|NCT02675556|DRUG|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
47924631|NCT02588404|DRUG|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
47924632|NCT00435045|DRUG|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
47924633|NCT00435045|DRUG|atorvastatin|atorvastatin + placebo
48443763|NCT03036085|DRUG|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
48443764|NCT03036085|DRUG|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
48443765|NCT03036085|DRUG|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
47924634|NCT06316999|DIAGNOSTIC_TEST|Intestinal Ultrasound|Transabdominal and trans perineal ultrasound of the pouch
47924635|NCT04583722|DIETARY_SUPPLEMENT|AX-olive oil-PP emulsion|single dose and plasma samples
47924636|NCT03829423|DIAGNOSTIC_TEST|Breast MRI interpretation|Analysis and interpretation of breast MRI sequences by a specially developed breast MRI interpretation algorithm
47924637|NCT03929094|DRUG|Paclitaxel for Injection（Albumin Bound）|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
47924638|NCT03929094|DRUG|Gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
47924639|NCT02247648|DRUG|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
47924640|NCT02247648|DRUG|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
47924641|NCT02775019|DIETARY_SUPPLEMENT|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
47924642|NCT02775019|DIETARY_SUPPLEMENT|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
47924643|NCT00439049|DRUG|modafinil|400 mg daily
47924644|NCT00439049|DRUG|d-amphetamine|60mg daily
47924645|NCT00439049|DRUG|L-Dopa|800/200mg daily
47924646|NCT00439049|DRUG|Naltrexone|50mg daily
47924647|NCT03219710|DRUG|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
47924648|NCT03219710|DRUG|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
47924649|NCT03219710|DRUG|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO
48443766|NCT04985019|PROCEDURE|Arm I (Prepectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
47924650|NCT03219710|DRUG|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
47924651|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
48443767|NCT04985019|OTHER|Arm II (Subpectoral)|Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
48443768|NCT06561737|OTHER|Video|For the students in the experimental group, the application was first demonstrated on a model by the course instructor, after which each student was required to perform the application individually. While the students were performing the application, someone not part of the research team recorded them on their phones. During the application, two researchers independently assessed the student's skills using the application checklist. Afterward, the students were asked to watch their videos and evaluate themselves over a 15-day period. After 15 days, the students were called back and asked to perform the same application again. At this stage, the researchers once again evaluated the students independently.
48443769|NCT01859858|DIETARY_SUPPLEMENT|curcumin|
48443770|NCT01859858|DRUG|Irinotecan|
48443771|NCT05803603|BEHAVIORAL|Stipend and Social Work Supports|Same as arm description
48443772|NCT02880761|PROCEDURE|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
47924652|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Kindeva)|single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
47924653|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes
47924654|NCT04936984|COMBINATION_PRODUCT|abaloparatide-sMTS (Patheon)|single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes
47924655|NCT02324634|DEVICE|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
47924656|NCT05880290|PROCEDURE|gynaecological examination in lateral decubitus|Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful
47924657|NCT00653432|DEVICE|Monovisc®|Intra-articular injection
47924658|NCT00653432|OTHER|Saline|0.9% Sterile Saline
48443773|NCT00834522|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
47924659|NCT04693052|OTHER|No interventions|This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
47924660|NCT04592952|DRUG|Calcitonin Gene-Related Peptide|Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
47924661|NCT04592952|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
47924662|NCT05614856|DEVICE|EVAR off-label use|Normally a femoral access was used, although a brachial approach can be useful for crossing total occlusions. For TASC B and C lesions, predilatation of the iliac lesions is advisable, while for TASC D it is mandatory. In case of total aortic occlusions, the procedure demands that recanalization of the distal aorta occurs as close as possible to the bifurcation.. The key technique is to recanalize from one common iliac artery into the opposing snaring the wire to create a femoral-femoral crossover. The femoral-femoral wire is then replaced with a MPA catheter; the SurePass wire attached to the contralateral limb is then passed through the catheter. The sheath can be placed within 5 cm of the aortic bifurcation, and the AFX can be delivered through the common iliac and aortic occlusion. Predilatation were performed with bilateral 6-8 mm x 150 mm balloons and or progressive dilatators.
47924663|NCT00106509|DRUG|tolevamer potassium-sodium (GT267-004)|
47924664|NCT00436501|DRUG|docetaxel|25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
47924665|NCT00436501|BIOLOGICAL|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
47924666|NCT00436501|OTHER|laboratory biomarker analysis|Correlative studies
47924667|NCT00436501|OTHER|pharmacological study|Correlative studies
47924668|NCT03683732|BEHAVIORAL|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
47924669|NCT01871480|DRUG|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
47924670|NCT01871480|DRUG|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
47924671|NCT03497598|DRUG|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
47924672|NCT03497598|DRUG|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
47924673|NCT01598142|PROCEDURE|Team 1|experienced endoscopist with a experienced assistant
48443774|NCT00834522|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
48443775|NCT02284087|DEVICE|PAS|
48443776|NCT00850174|DRUG|Oxcarbazepine|600 mg Tablet
47924674|NCT01598142|PROCEDURE|Team 2|same experienced endoscopist with a new trained assistant
47924675|NCT00400036|BEHAVIORAL|Cod protein NCEP-diet|
47924676|NCT05014737|OTHER|no intervention|this is an abservational study and no intervention will be involved
47924677|NCT02775929|DRUG|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
48443777|NCT00850174|DRUG|Trileptal®|600 mg Tablet
47924678|NCT02775929|DRUG|ART|ART for HIV-1 infected partners
47924679|NCT05453734|PROCEDURE|Progressive Muscle Relaxation Exercises|Before data collection, one of the researchers received training and certification from a psychotherapist specialist in this field to be able to apply the PMR exercises. The guidelines on the PMR exercises were prepared in line with the literature and training received by the researcher. In the guidelines, the person is asked to be in a comfortable place and position, to reach the face by following the large muscle groups gradually, starting from the feet, to tense the muscles in each step, and then to release them. It is necessary to take a deep breath after each muscle group, to stop for a while, and release it slowly
47924680|NCT05391178|OTHER|Lumiton yarn sleeve|Sleeve made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
48443778|NCT02959580|DRUG|Hydrocortisone Butyrate|topical use
48443779|NCT02959580|PROCEDURE|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
48443780|NCT02296008|DEVICE|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded."
47924681|NCT05391178|OTHER|Lumiton yarn hat|Hat made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
47924682|NCT05391178|OTHER|Lumiton yarn shirt|Shirt made from patented technology embedded in synthetic yarns that harnesses the sun's energy and generates red and near-infrared light - elevating apparel
47924683|NCT03810729|DIAGNOSTIC_TEST|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
47924684|NCT03810729|DIAGNOSTIC_TEST|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
47924685|NCT02105753|DEVICE|1210nm Diode Laser treatments|
47924686|NCT01588756|DRUG|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
47924687|NCT01588756|DRUG|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
48443781|NCT02514941|DRUG|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
48443782|NCT02514941|DRUG|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
48443783|NCT02514941|DRUG|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
47924688|NCT00004082|DRUG|carboplatin|
47924689|NCT00004082|DRUG|docetaxel|
47924690|NCT00004082|DRUG|gemcitabine hydrochloride|
47924691|NCT03685890|DRUG|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
47924692|NCT03685890|PROCEDURE|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
47951223|NCT01595633|DRUG|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
48443784|NCT02514941|PROCEDURE|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
48443785|NCT02514941|PROCEDURE|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
48443786|NCT02514941|PROCEDURE|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
48443787|NCT03682263|BEHAVIORAL|Full Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, care management services, and Medication Management Support provided by a Nurse Care Coordinator (NCC).
47924693|NCT06492499|PROCEDURE|Zero-Fluoroscopy Radiofrequency Catheter Ablation|Patients undergo zero-fluoroscopy RFCA for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) or inferior vena cava (IVC) approach. The procedure is performed under conscious sedation and local infiltration anesthesia. A large-tip electrode catheter is used for mapping and ablation, guided by the EnSite NavX system, with ablation parameters set at 40 W power and 50°C temperature.
47924694|NCT00035113|DRUG|epothilone b|
47924695|NCT02331095|DRUG|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
47924696|NCT02331095|DRUG|Anticoagulation Therapy|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
47924697|NCT00321126|DRUG|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
47924698|NCT00102778|DRUG|GW873140|
47924699|NCT00102778|DRUG|Kaletra (lopinavir/ritonavir)|
47924700|NCT00008450|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
47924701|NCT00008450|DRUG|Cyclosporine|Given PO or IV
47924702|NCT00008450|OTHER|Laboratory Biomarker Analysis|Correlative studies
47924703|NCT00008450|DRUG|Mycophenolate Mofetil|Given PO or IV
47924704|NCT00008450|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
47924705|NCT00008450|RADIATION|Total-Body Irradiation|Undergo TBI
47924706|NCT05188157|OTHER|mirror therapy|The patients in IG will receive exercise program before mirror theraphy. The patient will continue to do the exercises in front of the mirror for the remaining 20 minutes of the exercise. While doing the exercise with the healthy side in front of the mirror, the patient will try to do the same movement with the shoulder diagnosed with impingement syndrome on the other side of the mirror. The patient will try to do the movement correctly with the reflection in the mirror.
47924707|NCT05188157|OTHER|conventional physiotherapy|The conventional physiotherapy program included, wand exercises for shoulder abduction, flexion, hyperextension and internal and external rotation, Codman exercises and isometric and resistive exercises of the shoulder girdle. The exercise program is performed under the supervision of an experienced physiotherapist. The isometric exercises will be used during the painful period, and the resistance exercises will be added after the pain began to relieve.under the supervision of a physician in the first 30 minutes of their exercise.
47924708|NCT04792242|DEVICE|cv line insertion|Svo2 and central venous pressure measurements
47924709|NCT04792242|DEVICE|Urinary catheter insertion|urine output measurement
47924710|NCT04792242|DEVICE|Arterial line|Arterial blood gases measurment
47924711|NCT02664623|PROCEDURE|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
47924712|NCT02664623|PROCEDURE|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
47924713|NCT01024725|OTHER|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
47924714|NCT00275821|DRUG|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
47924715|NCT00275821|DRUG|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
47924716|NCT00275821|DRUG|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
47924717|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
47924718|NCT03174002|DRUG|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
47924719|NCT01633593|DRUG|Donepezil|5 mg PO a day, during 2 weeks
47924720|NCT00254267|DRUG|AMG 706|AMG 706 125mg, oral, once a day
47924721|NCT02030431|DEVICE|Dynaloc|
47924722|NCT02030431|DEVICE|Cancellous screws|
47924723|NCT02593136|DIETARY_SUPPLEMENT|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
47924724|NCT02593136|OTHER|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
47951224|NCT06680518|OTHER|tourniquet|peroperation tourniquet
47951225|NCT06680518|OTHER|No tourniquet|no tourniquet during surgery
47951226|NCT03637023|BEHAVIORAL|Virtual Reality|Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
48443788|NCT03682263|BEHAVIORAL|Basic Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, and care management services.
48443789|NCT02431000|PROCEDURE|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
47924725|NCT04175119|DEVICE|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
47924726|NCT01697410|DRUG|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
47924727|NCT01697410|DRUG|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
47924728|NCT00885820|DRUG|Tacrolimus|Oral
47924729|NCT00885820|DRUG|MMF|Oral
47924730|NCT00885820|DRUG|Corticosteroids (Prednisone)|Oral
47924731|NCT00618098|BIOLOGICAL|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
47924732|NCT00618098|BIOLOGICAL|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
47924733|NCT02079818|DEVICE|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
47924734|NCT04231552|DRUG|Camrelizumab|Radiotherapy with CAPOX+ Camrelizumab following surgical therapy Radiation: 25 Gy/5 fractions CAPOX (2 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine:Dose of 2000mg/m2,14days, q3w Camrelizumab (2 cycles): 200mg on day 1 of each cycle, q3w Surgical therapy: the resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
47924735|NCT05614934|DRUG|standard Clarithromycin triple therapy|Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days
47924736|NCT05614934|DRUG|Vonoprazan triple therapy|Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days
47924737|NCT05614934|DRUG|Vonoprazan dual therapy|Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days
47924738|NCT05304780|BEHAVIORAL|needs-tailored nurse-led recovery program|The needs-tailored nurse-led recovery program were divided into five major stages of care, which were build partnership, conduct integrated needs assessment, set needs-based recovery goals and provide empowerment-oriented care, conduct continuous monitoring of goals, and conduct effectiveness evaluations.
47924739|NCT03365388|DRUG|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
47924740|NCT03365388|DRUG|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
47924741|NCT05109455|DIETARY_SUPPLEMENT|MANOSAR®|MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
48443790|NCT04813081|PROCEDURE|Free Gingival Graft|In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
47924742|NCT05109455|DIETARY_SUPPLEMENT|Proanthocyanidins|The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
47924743|NCT00540618|DRUG|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
47924744|NCT00540618|OTHER|Placebo|
47924745|NCT00540618|DRUG|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
47924746|NCT00540618|DRUG|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
47924747|NCT06431971|DRUG|Talineuren|Talineuren infusion weekly
47924748|NCT06431971|DRUG|Placebo|Placebo infusion weekly
47951227|NCT03637023|BEHAVIORAL|Exercise Therapy|The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
48443791|NCT03656783|DRUG|Biktarvy|Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
48443792|NCT01107093|DRUG|CDB-2914 (ulipristal acetate)|single oral dose of 30 mg
48443793|NCT01107093|DRUG|Placebo|single oral dose
48271296|NCT06203301|BEHAVIORAL|resistance exercise and walking|"After receiving the cases, they were divided into 4 groups by random allocation:~1. Control group: No exercise intervention measures are performed, and the patients carry out their daily lives according to their past living habits.~2. Resistance exercise group: Resistance exercise training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. The patients are given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. Afterwards, the patient is asked to regularly perform resistance exercise on his own for at least 1 year.~3. Walking group: Walking training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. They should walk continuously for 15 minutes at least twice a day and continue walking at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walk"
48271297|NCT05265767|BIOLOGICAL|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.
48271298|NCT05840614|BEHAVIORAL|The remote family support program|"Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT."
48443794|NCT00485394|DRUG|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
48443795|NCT00485394|DRUG|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
48443796|NCT00485394|DRUG|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
48443797|NCT01845298|DRUG|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
48443798|NCT00410774|BIOLOGICAL|bevacizumab|
48271299|NCT06192979|DRUG|Daratumumab|"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."
48271300|NCT06192979|DRUG|Bortezomib|All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
47924749|NCT03970356|OTHER|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
47924750|NCT00910507|BEHAVIORAL|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
47951228|NCT06680544|DRUG|Voriconazole high dose|Oral voriconazole 200mg once a day for a maximum of 28 days
47951229|NCT06680544|DRUG|Voriconazole low dose|Oral voriconazole 200mg twice a day for a maximum of 28 days
48271301|NCT06192979|DRUG|Dexamethasone|All patients received 20-40 mg oral or intravenous dexamethasone
48271302|NCT06192979|DRUG|Venetoclax|All patients received venetoclax 400mg daily.
48271303|NCT00929240|DRUG|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
48271304|NCT00929240|DRUG|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
48271305|NCT05768373|DEVICE|3M™ Clinpro™ Fluoride Aqueous Solution|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
48271306|NCT05768373|DEVICE|3M™ Vanish™|Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.
48271307|NCT06211855|DIAGNOSTIC_TEST|doppler assesment|In all cases, the measurement, including UA PI and MCA PI, was measured with a 6-4 MHz convex transabdominal probe. All measurements were made by an obstetrician (Ş.D.) with 28 years of experience. Doppler measurements were collected from the proximal third of the MCA and the free-floating segment of the umbilical cord, ensuring that the angle of insonation was as close to zero as feasible and that fetal movements were absent
48271308|NCT03281785|OTHER|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
48271309|NCT03281785|OTHER|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
48271310|NCT03281785|OTHER|Pressure support mode (PS)|Pressure support mode (PS)
48271311|NCT03882424|BIOLOGICAL|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
48443799|NCT00410774|DRUG|gemcitabine hydrochloride|
47924751|NCT00910507|BEHAVIORAL|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
47924752|NCT01606917|OTHER|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
47924753|NCT04276558|DRUG|Udonitrectag|Eye drop solution in single dose unit.
47924754|NCT04276558|OTHER|Vehicle|Eye drop solution with no active substance in single dose unit.
47924755|NCT00266864|DRUG|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
47924756|NCT02400164|DEVICE|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
47924757|NCT03112954|DRUG|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
47924758|NCT03112954|DRUG|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
47924759|NCT05401058|DRUG|Droperidol Injection|About 30min before the end of operation, Droperidol 1.25mg/0.5ml will be administered by intravenous injection.
47924760|NCT05401058|DRUG|Saline|About 30min before the end of operation, Normal saline 0.5ml will be administered by intravenous injection.
47924761|NCT05052931|DRUG|Nab-paclitaxel combined with oxaliplatin and S-1|Nab-paclitaxel 100mg/m\^2, D1, Q3W; oxaliplatin 85 mg/m\^2, D1, Q3W; S-1 60 mg/m\^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.
47924762|NCT04097951|DRUG|Combinations|Montelukast and Bepotastine Combination
47924763|NCT06333600|DRUG|Topical minoxidil|Therapeutic intervention
47924764|NCT06333600|DRUG|Topical Vitamin D|Therapeutic intervention
47924765|NCT06333600|DRUG|Saline spray|placebo
47924766|NCT00796926|DRUG|Systane Ultra eyedrops|Four times a day
47924767|NCT00796926|DRUG|Refresh eye drops|Four times a day
47924768|NCT03162900|DRUG|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
47924769|NCT03162900|DRUG|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
47924770|NCT03162900|DRUG|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
47924771|NCT03162900|OTHER|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
48271312|NCT03882424|BIOLOGICAL|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
47924772|NCT02885116|DEVICE|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
47924773|NCT02885116|DEVICE|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
47924774|NCT06531980|OTHER|Modi|"The Modi course, an eight-week mobile application intervention for adolescents with anxiety symptoms, is based on cognitive therapy. Guided by a rule-based chatbot named Anna, users navigate through predefined options and responses, learning about anxiety and recording their challenges. The app includes animated videos, illustrations, and audio files to enhance engagement. Modi consists of six chapters, with a focus on psychoeducation, the cognitive triangle, and exposure exercises. Participants receive guidance from two Modi therapists who provide weekly support via messages and scheduled phone calls, ensuring personalized assistance and addressing any issues throughout the course."
48271313|NCT03882424|BIOLOGICAL|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
47924775|NCT06531980|OTHER|Treatment as usual|Participants receive usual treatment at their local Child and Family Services. This treatment, known as Treatment as Usual (TAU), is not standardized but reflects the care they would receive in regular practice. It aligns with national clinical guidelines and includes individual therapy, parental counseling, and assessments. Typically, the treatment is provided by a therapist trained in cognitive behavioral therapy (CBT) or a psychologist
47924776|NCT02972385|PROCEDURE|Mouthwash sample|A one time mouthwash sample will be performed.
47924777|NCT02972385|PROCEDURE|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
47924778|NCT02730195|DRUG|Pioglitazone|Given PO
47924779|NCT02730195|DRUG|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
48443800|NCT00410774|PROCEDURE|adjuvant therapy|
47924780|NCT02842034|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
47924781|NCT06165458|OTHER|6% hydrogen peroxide gel + violet LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED
47924782|NCT06165458|OTHER|6% hydrogen peroxide gel + blue LED|Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED
47924783|NCT06165458|OTHER|35% hydrogen peroxide gel + violet LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED
47924784|NCT06165458|OTHER|35% hydrogen peroxide gel + blue LED|Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
47924785|NCT00329901|BIOLOGICAL|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
47924786|NCT00329901|BIOLOGICAL|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
47924787|NCT00329901|BIOLOGICAL|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
47924788|NCT03330392|DIETARY_SUPPLEMENT|AGP|take two tablets per day (500 mg/day) for 8 weeks
47924789|NCT03330392|DIETARY_SUPPLEMENT|Placebo|take two tablets per day (500 mg/day) for 8 weeks
47924790|NCT05101200|OTHER|High Dose Neural Mobilization Technique|Patients in This Group will receive the high dose neural mobilization along with hot pack, strengthening exercises, Neural mobilization technique (slump, sciatic). Participants in the NMG will be asked to actively perform knee extension, ankle dorsiflexion, and head extension in a slumped posture (body and neck semi flexion) followed by simultaneous ankle plantar flexion together with knee and head flexion, Hot pack for 15 minutes, Strengthening exercises of muscles with 10 /8sets. Strengthening exercises of quadriceps with10 rep/8sets, Static stretching exercise for hamstring muscle with 10 rep/8sets, Group A will be given session of 40 min/day, 2 days/week for 4 weeks.
47924791|NCT05101200|OTHER|Low Dose Neural Mobilization Technique|Patients in this Group will receive the same treatment as group A but with less intensity and low dosage. Hot pack: 15 minutes, Strengthening exercises of muscles with 10 rep/4sets, Static stretching exercise for hamstring muscle with 10 rep/4sets. Group B will be given session of 40min/day, 2 days/week for 4weeks.
47924792|NCT00445237|DEVICE|H1 and H2 deep TMS coils|
47924793|NCT01967498|DRUG|Montelukast|
47924794|NCT05631002|DIAGNOSTIC_TEST|Chemical shift encoding-based water-fat MRI|Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method
47924795|NCT00995566|DRUG|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
47924796|NCT00201162|DIETARY_SUPPLEMENT|Soy|Dietary supplement of isolated soy protein containing isoflavones
47924797|NCT00201162|DIETARY_SUPPLEMENT|Placebo|dietary supplement casein placebo
47924798|NCT06299410|DRUG|ITI-1284 10 mg|ITI-1284 tablet
47924799|NCT06299410|DRUG|ITI-1284 20 mg|ITI-1284 tablet
47924800|NCT03923244|DIAGNOSTIC_TEST|OSDI survey|"Normal patient consultation schedule for cataract surgery with:~* Preoperative appointment scheduled for the patient~* Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~* Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~* An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~* Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
47924801|NCT00227708|DRUG|docetaxel|
47924802|NCT00227708|PROCEDURE|quality-of-life assessment|
47924803|NCT05228379|PROCEDURE|Small Bowel Capsule Endosocopy|A wireless capsule is ingested by the patient. It moves passively along with the peristaltic movements to capture images of the small intestine. The images are processed and recorded by data recorder worn on a belt. The recorded images are downloaded and analyzed by the computer software.
47924804|NCT01488513|DRUG|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
47924805|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
47924806|NCT01004198|DRUG|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
47924807|NCT01004198|DRUG|Ringers Lactate solution|Ringers Lactate solution for Injection
47924808|NCT01022008|DEVICE|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
47924809|NCT02603263|OTHER|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
47924810|NCT03262311|OTHER|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
47951230|NCT00547196|BIOLOGICAL|filgrastim|
47914103|NCT06020989|DRUG|Lazertinib+Pemetrexed+Carboplatin|Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.
47914104|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
47951231|NCT00547196|DRUG|Busulfan|
47951232|NCT00547196|DRUG|Cyclophosphamide|
47951233|NCT00547196|DRUG|Cyclosporine|
47951234|NCT00547196|DRUG|Fludarabine phosphate|
47951235|NCT00547196|DRUG|Melphalan|
47951236|NCT00547196|DRUG|Mycophenolate Mofetil|
47951237|NCT00547196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
47951238|NCT00547196|PROCEDURE|umbilical cord blood transplantation|
47924811|NCT02224196|OTHER|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
47924812|NCT02224196|OTHER|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
47924813|NCT02908490|DRUG|Sildenafil|Sildenafil 50 mg once daily
47924814|NCT02908490|OTHER|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
48271314|NCT06424496|OTHER|Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression|Quazi-Experimental study (pre/post design) to assess the Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression
47914105|NCT06020989|DRUG|Lazertinib|Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
47914106|NCT02709382|DRUG|Cefepime and Tazobactam combination|
47951239|NCT00547196|RADIATION|total-body irradiation|
47951240|NCT00547196|RADIATION|Fractionated total body irradiation|
48271315|NCT03630055|DRUG|Rivaroxaban 15 MG Oral Tablet [Xarelto]|Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
48271316|NCT04153084|DRUG|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
48271317|NCT04153084|DRUG|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
48443801|NCT05879471|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
47924815|NCT00639652|PROCEDURE|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
47951241|NCT00195273|DRUG|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
47914107|NCT01921595|OTHER|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
47914108|NCT01921595|OTHER|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
47914109|NCT04783090|DRUG|MT1013|bispecific peptide as a CaSR agonist and a functional OGP analogue
47914110|NCT06204835|DRUG|RD-Cy7 fluorophore|Fluorophore targeting ITGA6 that is overexpressed in HCC cells
47914111|NCT00229385|DRUG|Ziprasidone|40-80 mg BID
47914112|NCT04121663|DEVICE|Total arthroscopic rotator cuff repair|The equivalence of the two devices was compared by using control and experimental instruments during the operation
47914113|NCT05338424|OTHER|Sprint Interval Training (SIT)|Active arm-- exercise dictated by protocol
47914114|NCT02518295|OTHER|Positive control|200ml milk containing 18g lactose
47914115|NCT02518295|OTHER|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
47914116|NCT02518295|OTHER|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
47914117|NCT02518295|OTHER|Negative control|200 ml of UHT Lactose free milk
47914118|NCT03933891|PROCEDURE|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
47914119|NCT03110913|OTHER|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
47914120|NCT00539188|DRUG|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
47914121|NCT00539188|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
47914122|NCT04161248|DRUG|Venetoclax|"Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP"
47914123|NCT04161248|DRUG|Rituximab Injection|375 mg/m2 - Day 1, cycle 1.
47914124|NCT04161248|DRUG|Rituximab SC|1400 mg fixed dose - Day 1, cycle 2 and 3
47914125|NCT04161248|DRUG|Gemcitabine|1000 mg/m2 - Day 1 to day 8
47914126|NCT04161248|DRUG|Dexamethasone|40 mg daily - Day 1 to day 4
47914127|NCT04161248|DRUG|Cisplatin|75mg/m2 - Day 1
47914128|NCT04161248|DRUG|Glofitamab|Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP
47914129|NCT04161248|DRUG|Tafasitamab|Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
47914130|NCT02906605|DRUG|JNJ-809|JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.
47914131|NCT02906605|DRUG|Apalutamide|Apalutamide 240 mg orally daily.
47914132|NCT04228380|OTHER|No intervention|No intervention
47914133|NCT05584319|DRUG|Empagliflozin 10 Mg|subjects in Empagliflozin group takes Empagliflozin 10mg per day
47914134|NCT01986699|PROCEDURE|Laparoscopic Assisted Polypectomy|
47914135|NCT04129281|PROCEDURE|Surgery|Surgery acconding to clinical practice
47914136|NCT03283514|OTHER|Complete denture|questionnaire
47914137|NCT02433951|OTHER|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
47914138|NCT00102583|DRUG|Subconjunctival Cyclosporine Implant|
47914139|NCT02453204|BEHAVIORAL|Sitting|
47914140|NCT02453204|BEHAVIORAL|Standing|
47914141|NCT02453204|BEHAVIORAL|Walking|
47914142|NCT00262054|DRUG|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
47914143|NCT00262054|DRUG|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
47914144|NCT00885222|DEVICE|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
47914145|NCT01641419|DRUG|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
47924816|NCT00639652|PROCEDURE|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
47924817|NCT03359018|DRUG|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
47924818|NCT03359018|DRUG|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
47924819|NCT03463200|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
47924820|NCT03463200|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
47924821|NCT03463200|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
47924822|NCT02521896|DEVICE|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
47924823|NCT06251531|OTHER|Goal-Directed Therapist-Guided Play-Based Intervention (GD-TG-PBI)|The GD-TG-PBI used play to improve performance in targeted functional activities. The program was planned by a physiotherapist with 25 years' experience and an occupational therapist with six years' experience in play. The sessions were based on motor-learning principles supporting cortical plasticity. Individual-specific goals were transformed into play activities that increase occupational participation with regard to the child's abilities, needs, and learning potential. A top-down approach based on direct gamification was adapted without dividing it into components, instead of a component-based, bottom-up approach. Thus, a structured play program was created and an individual-specific intervention was applied in line with the occupational goals and detailed motor evaluations. Positive, active experiences facilitated the adaptation of the learned skills to daily life.
47914146|NCT01641419|DRUG|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
47914147|NCT01641419|DRUG|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
47914148|NCT05395936|OTHER|Myocardial Probe Temperature Screen|The myocardial probe is a needle that measures temperatures. The skin site for introducing the myocardial probe will be small enough that participants will not notice that temperatures have been collected. If participants have multiple operations, temperatures may be collected at each operation.
47914149|NCT05395936|OTHER|Data Collection|Study team members will collect medical history and other information to potentially understand the safety and success of breast surgery better to allow investigators to identify variables, or changes to help understand investigators roles in potential complications in breast surgery.
47914150|NCT06159426|OTHER|Vojta Therapy|"The subject will be placed on a stretcher with the torso uncovered. Once the adhesive electrodes have been placed in the different recording areas on the anterior part of the trunk, a recording of the activity at rest will begin, two minutes of stimulation (digital pressure), one minute of rest, two minutes of stimulation in the contralateral side and, finally, one minute of rest.~The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg."
47914151|NCT00019201|OTHER|cytology specimen collection procedure|
47914152|NCT00019201|OTHER|immunohistochemistry staining method|
47914153|NCT00019201|OTHER|sputum cytology|
47914154|NCT00019201|PROCEDURE|bronchoscopic and lung imaging studies|
47914155|NCT00019201|PROCEDURE|bronchoscopy|
47914156|NCT00019201|PROCEDURE|comparison of screening methods|
47914157|NCT00019201|PROCEDURE|endoscopic biopsy|
47914158|NCT03651024|DEVICE|ED surgery|The surgical implant for ED treatment
47914159|NCT00710541|DEVICE|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
47914160|NCT02413151|BEHAVIORAL|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
47914161|NCT02413151|DEVICE|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
47914162|NCT06464783|OTHER|Comprehensive Corrective Exercise Program|"Week 1st to 2nd: Corrective exercises +Core strengthening (2 sets 10 reps). Stretchings (30 sec hold, 3 reps).~Week 3rd to 5th: Corrective exercises +Core strengthening (3 sets 15 reps). Stretchings (30 sec hold, 3 reps).~Week 5th to 8th: Corrective exercises +Core strengthening (3 sets 20 reps). Stretchings (30 sec hold, 3 reps)."
47914163|NCT06464783|OTHER|Thoracic Exercise Program|"Week 1st to 2nd: Thoracic extension (2 sets 10 reps). Mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps).~Week 3rd to 5th: Thoracic extension (2 sets 15 reps). T W Y I thoracic exercise in prone (2 sets 15 reps). Self-mobilization (60 seconds 2 reps). Stretching (30 sec hold and 3 reps)~Week 5th to 8th. Thoracic extension (3 sets 20 reps). T W Y I thoracic exercise in prone position (3 sets 20 reps). Self-mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps)"
47914164|NCT04508088|DIAGNOSTIC_TEST|Coronal T1 weighted spin echo images|Coronal T1 weighted spin echo images will be obtained through the knee with a field of view of 16cm to include distal femoral and proximal tibial metaphyses.
47924824|NCT03255629|DRUG|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
47924825|NCT03255629|DEVICE|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
47924826|NCT01949467|DRUG|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
47924827|NCT00427115|BEHAVIORAL|Multimodal exercise and psychosocial program|
47924828|NCT03619967|DEVICE|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
47924829|NCT04763681|BEHAVIORAL|Couple HOPES Guided, Internet-Delivered, Self-Help Intervention|Couple HOPES is a guided self-help intervention for individuals with PTSD and their partners based on Cognitive-Behavioral Conjoint Therapy for PTSD (Monson \& Fredman, 2012). This intervention consists of text and video-based content across seven intervention modules and phone and online-based coaching sessions with a paraprofessional. Participants are able to complete these modules in their own home or private location of their choosing. The primary outcomes are PTSD symptoms, relationship satisfaction, and the mental health and wellbeing of partners of those with PTSD.
47924830|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
47924831|NCT03034603|DIETARY_SUPPLEMENT|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
47924832|NCT04457622|OTHER|Auditory perception tasks in healthy participants|"The participants complete auditory perception tasks while EEG, and MEG record brain signals (primary outcome measure). The tasks acquire behavioral responses with button presses (secondary outcome measure).~All analyses are intra-subject (no analyses are between-subject)."
47924833|NCT03635411|DIETARY_SUPPLEMENT|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
47924834|NCT03635411|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Basis supplement.
47924835|NCT03141996|OTHER|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
47924836|NCT03141996|OTHER|Standard of Care|Standard of care treatment
47924837|NCT01936090|DRUG|Bortezomib|Given IV
47924838|NCT01936090|RADIATION|Total-Body Irradiation|Undergo TBI
47924839|NCT01936090|DRUG|Melphalan|Given IV
47924840|NCT01936090|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
47924841|NCT01936090|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
47924842|NCT01936090|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
47924843|NCT01936090|OTHER|Laboratory Biomarker Analysis|Correlative studies
47924844|NCT03963167|DRUG|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
47924845|NCT01490801|GENETIC|DNA analysis|
47924846|NCT01490801|GENETIC|RNA analysis|
47924847|NCT01490801|GENETIC|cytogenetic analysis|
47924848|NCT01490801|GENETIC|in situ hybridization|
47924849|NCT01490801|GENETIC|mutation analysis|
47924850|NCT01490801|GENETIC|polymerase chain reaction|
47924851|NCT01490801|GENETIC|western blotting|
47924852|NCT01490801|OTHER|flow cytometry|
47924853|NCT01490801|OTHER|immunohistochemistry staining method|
47924854|NCT01490801|OTHER|medical chart review|
47924855|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
47924856|NCT03777462|DRUG|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
47924857|NCT03777462|DRUG|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
47924858|NCT01397734|DRUG|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
47924859|NCT03195400|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
47924860|NCT03195400|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
47924861|NCT03195400|DIAGNOSTIC_TEST|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
47924862|NCT03195400|DIAGNOSTIC_TEST|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
47924863|NCT05874570|DRUG|Esomeprazole|Proton pump inhibitor
47924864|NCT05874570|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
47924865|NCT05874570|DRUG|Tetracycline|Antibiotics for H. pylori eradication
47924866|NCT05874570|DRUG|Doxycycline|Antibiotics for H. pylori eradication
47924867|NCT05874570|DRUG|Metronidazole|Antibiotics for H. pylori eradication
47951242|NCT00195273|DRUG|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
47951243|NCT00195273|DRUG|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
47924868|NCT06531889|OTHER|classical physiotherapy program|Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)
47924869|NCT06531889|OTHER|Core Stabilization Exercises|The interventions of the core exercise were applied when the patient lay on his/her back with his/her knees at flexion. The number of repeats for each exercise was five, and these exercises were done 3 times a week for 6 weeks with the same physiotherapist. The further steps in the exercises were extended according to the activation duration of the core muscles, and this extension was elongated 5 s
47924870|NCT00710125|DRUG|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
47924871|NCT05427877|DEVICE|Heating device (Heatwave Technology)|Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.
47924872|NCT03168958|DRUG|Methadone|Methadone will be provided at induction of anesthesia
47924873|NCT03168958|DRUG|Saline|Saline will be administered at induction of anesthesia
48271318|NCT04153084|DRUG|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~* From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~* From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~* Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
48271319|NCT06055257|DRUG|modified PENTOCLO (mPENTOCLO)|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added."
48271320|NCT06055257|DRUG|sham mPENTOCLO|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo)."
48271321|NCT04093596|GENETIC|ALLO-715|ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
48271322|NCT04093596|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
48271323|NCT04093596|DRUG|Fludarabine|Chemotherapy for lymphodepletion
48271324|NCT04093596|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
48271325|NCT04093596|DRUG|Nirogacestat|a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
47924874|NCT02491944|DRUG|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
48271326|NCT00682058|OTHER|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
47924875|NCT02491944|DRUG|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of \[14C\] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
48271327|NCT05352685|DRUG|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
47924876|NCT03140215|DEVICE|laryngeal mask insertion (Baska)|
47924877|NCT03140215|DEVICE|laryngeal mask insertion (I-gel )|
47924878|NCT06411171|DRUG|Pembrolizumab plus chemotherapy (FLOT)|The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone
47924879|NCT00189774|DRUG|nateglinide|
47924880|NCT02447224|DRUG|1 gm IV ertapenem at enrollment|
47924881|NCT02447224|DRUG|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
47924882|NCT02447224|PROCEDURE|Appendectomy|
47924883|NCT04740905|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
48271328|NCT03414957|DIAGNOSTIC_TEST|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
47924884|NCT04740905|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
48271329|NCT02393209|DRUG|Docetaxel|Docetaxel intravenous infusion
48271330|NCT02393209|DRUG|TAK-117|TAK-117 Tablets
48271331|NCT04088448|DRUG|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
48271332|NCT04088448|DRUG|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
48271333|NCT00470821|DRUG|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
48271334|NCT00470821|DRUG|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
48271335|NCT06322082|DEVICE|The DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL AG)|"The LiESWT was applied to Pilates and Shock Wave group and Shock Wave group with 0.25 mJ/mm2 of intensity, 3000 pulses of shock, and 3 pulses/s of frequency, applicator was placed on the suprapubic skin area one session in the week for twelve weeks, totaling 12 sessions.~Pilates exercises were performed to Pilates and Shock Wave group and Pilates group. The sessions of Pilates were applied twice a week for twelve weeks, totaling 24 sessions. The 50 min Pilates sessions were divided into three phases: warm-up, strengthening, and stretching. They also received written orientations to perform three exercises and two of the Pilates session at home every day - Conventional pelvic floor exercises performed for all groups include Kegel exercise, squats, bridging, and squeeze and release exercises. These exercises were performed 3 times per day, lasting for 12 consecutive weeks"
48271336|NCT05302635|OTHER|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
48271337|NCT02965157|BIOLOGICAL|CART20|
48271338|NCT05662514|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis BLa80|"Test product contain 3 × 109 colony-forming units \[CFU\] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days."
48271339|NCT05662514|OTHER|Placebo|To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
48271340|NCT06030427|BEHAVIORAL|Behavioral Dietary Intervention|Participate in weight management program
48271341|NCT06030427|OTHER|Educational Intervention|Receive patient education handouts
48271342|NCT06030427|OTHER|Health Promotion and Education|View behavioral educational PowerPoint presentation
48271343|NCT06030427|OTHER|Internet-Based Intervention|Complete virtual behavioral weight management with an integrated mindfulness component program
48271344|NCT06030427|OTHER|Interview|Ancillary studies
48271345|NCT06030427|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
48271346|NCT06030427|BEHAVIORAL|Mindfulness Relaxation|Complete mindfulness components
47924885|NCT04740905|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
48271347|NCT06030427|OTHER|Physical Performance Testing|Ancillary studies
48271348|NCT06030427|OTHER|Questionnaire Administration|Ancillary studies
48271349|NCT00624221|PROCEDURE|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
48271350|NCT01722461|DEVICE|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
48271351|NCT01722461|DEVICE|Sham treatment|Ulthera System delivering no ultrasound energy
48271352|NCT01384292|DRUG|NKTR-118|12.5 mg oral tablet once daily
48271353|NCT01384292|DRUG|NKTR-118|25 mg oral tablet once daily
48271354|NCT01384292|DRUG|Placebo|Oral treatment
48271355|NCT04315467|DRUG|SGM-101|A one-time infusion of SGM-101
48271356|NCT04315467|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
48271357|NCT00870337|DRUG|everolimus|
48271358|NCT06100783|DEVICE|Depot-medroxy Progesterone Acetate Injectable Contraceptives|Depot-medroxy progesterone acetate injectable contraceptives
48271359|NCT05264220|BEHAVIORAL|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
48271360|NCT02953041|DRUG|Glycopyrronium|long-acting muscarinic antagonist
48271361|NCT02953041|DRUG|Indacaterol|ultra long-acting beta agonist
48271362|NCT03700047|DEVICE|GAL1704|new dermal filler
48271363|NCT03700047|DEVICE|Juvederm Voluma|hyaluronic acid
48271364|NCT02862769|DRUG|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
48271365|NCT02862769|DRUG|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
48271366|NCT00460980|BEHAVIORAL|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
48271367|NCT03820245|DIETARY_SUPPLEMENT|Bixin|Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
48271368|NCT03820245|DIETARY_SUPPLEMENT|Norbixin|Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
48271369|NCT03820245|DIETARY_SUPPLEMENT|Lycopene|Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
48271370|NCT03820245|DIETARY_SUPPLEMENT|Placebo|Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
47924886|NCT04055428|DRUG|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
48271371|NCT02007551|BEHAVIORAL|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
48271372|NCT02224898|BEHAVIORAL|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
48271373|NCT03352401|OTHER|Ultrasouund assessment of gastric contents|A qualitative and quantitative ultrasound evaluationof the stomach will be performed when the patient arrives in the pre-anesthesia room. The examination will be held in the right lateral decubitus with a low frequency convex ultrasound probe.
47924887|NCT04055428|DRUG|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
48271374|NCT01624194|DRUG|Oxytocin nasal spray|24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.
48271375|NCT01624194|DRUG|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
48271376|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
48271377|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
48271378|NCT04626414|DRUG|Ferric maltol capsule|single dose of 30 mg capsule
48271379|NCT04626414|DRUG|Ferric maltol suspension|single dose of 30mg (5ml) oral suspension
48271380|NCT01766947|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
48271381|NCT00929955|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
48271382|NCT00929955|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
48271383|NCT00929955|DRUG|Placebo|Placebo added to TAU
47924888|NCT04055428|OTHER|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
47924889|NCT04055428|DIETARY_SUPPLEMENT|Standardized Meals|Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
47924890|NCT04055428|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
47924891|NCT05898529|DIAGNOSTIC_TEST|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
48271384|NCT02835885|DEVICE|Digitmer High Voltage Stimulator model DS7A TENS unit|
48271385|NCT00004987|DRUG|Dextrin 2-sulfate|
48271386|NCT01299727|BIOLOGICAL|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
48271387|NCT01299727|BIOLOGICAL|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
48271388|NCT01299727|BIOLOGICAL|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
48271389|NCT00191854|DRUG|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
48271390|NCT00191854|DRUG|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
47924892|NCT03714269|OTHER|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
47924893|NCT03714269|OTHER|measurement evaluated with an 2D ultrasound|"* simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~* recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
48271391|NCT00191854|DRUG|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
48271392|NCT00191854|DRUG|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
48271393|NCT06325514|DIAGNOSTIC_TEST|Artificial intelligence based program|the AI based program is based on image analysis
48271394|NCT03266679|OTHER|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
48271395|NCT05774327|OTHER|Foam Roller|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
48271396|NCT05774327|OTHER|Foot Core Exercises|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
48271397|NCT03700957|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
47924894|NCT03714269|OTHER|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
47924895|NCT00075192|DRUG|CP-675,206 and leuprolide acetate and bicalutamide|
47924896|NCT00075192|DRUG|leuprolide acetate and bicalutamide|
47951244|NCT00195273|DRUG|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
47951245|NCT00195273|DRUG|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
47951246|NCT05678582|DIAGNOSTIC_TEST|Liver biopsy|liver biopsy were taken then evaluated by histopathological examination
47951247|NCT02380027|DEVICE|MRI|This will be a multi-parametric MRI of the prostate
48271398|NCT03700957|OTHER|placebo|placebo
47924897|NCT02057328|DRUG|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
47924898|NCT02057328|DRUG|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
48271399|NCT02775032|BEHAVIORAL|Advance care planning conversations between patients and their GP|
48271400|NCT03354689|RADIATION|Scintigraphy|Scintigraphy
48271401|NCT01354132|DRUG|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
48271402|NCT01354132|DRUG|Placebo|Placebo tablets are placed in water or juice in the AM and PM
48271403|NCT00887861|DRUG|Investigational new drug, company code: BGG492|
48271404|NCT00887861|DRUG|Placebo|
48271405|NCT04371367|BIOLOGICAL|avdoralimab|intravenous administration of avdoralimab
48271406|NCT04371367|OTHER|Placebo|intravenous administration of placebo
48271407|NCT01214486|DRUG|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
48271408|NCT05530057|DRUG|Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle and SB3 8 mg/kg I.V. over 90 minutes on day 1 of cycle 1 . Thereafter, SB3 6 mg/kg will be infused over 30 minutes on day 1 of each subsequent 21-day cycle until progression or unacceptable toxicity.~* Dose reductions for eribulin, but not for SB3, is permitted.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed for eribulin before consideration of study treatment discontinuation. Eribulin could be continued as monotherapy if trastuzumab-similar was discontinued, and vice-versa."
48271409|NCT05530057|DRUG|Eribulin Mesylate|"* Patients will receive eribulin mesylate 1.4 mg/m2 administered I.V. with infusion over 2 to 5 minutes on days 1 and 8 of each 21-day cycle until progression or unacceptable toxicity.~* Two dose reductions (1.1, 0.7 mg/m2) are allowed before consideration of study treatment discontinuation."
48271410|NCT04574726|OTHER|static balance|30-second right and left unipodal static balance test
48271411|NCT04574726|OTHER|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point"
48271412|NCT04049019|DIAGNOSTIC_TEST|Urine collection through a collecting device (Uridome®) for maximum 1 week|"The child will collect:~* Urine at bedtime before a wet and a dry night.~* Urine during a wet night through a collecting device.~* First morning voided volume following both a wet and a dry night."
47924899|NCT00215176|DRUG|modafinil|
47924900|NCT05418309|DRUG|Tislelizumab Nab paclitaxel|Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles;Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
47924901|NCT03746288|DRUG|CAN008|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
47924902|NCT02687867|DRUG|Dabigatran (Pradaxa)|As prescribed by treating physicians
47924903|NCT02687867|DRUG|Vitamin K antagonist|As prescribed by treating physicians
47924904|NCT00830908|DEVICE|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
47924905|NCT04099394|BEHAVIORAL|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
47924906|NCT04099394|BEHAVIORAL|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
47924907|NCT04415242|OTHER|positioning|different positioning prior surgery
47924908|NCT04903470|DRUG|Bisacodyl|Biscodyl a stimulant laxative is expected to stimulate rectal contraction and enhance expulsion of Fecobionics
48271413|NCT04049019|DIAGNOSTIC_TEST|Urine collection|"The child will collect:~* Urine at bedtime.~* First morning voided volume"
48271414|NCT03706586|PROCEDURE|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
48443802|NCT00486863|DRUG|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
47924909|NCT04903470|DRUG|Atropin|Atropin is an anticholinergic drug that is expected to inhibit rectal contractions and make defecation more difficult.
47924910|NCT02185976|OTHER|cartoon|5 different cartoons which will be recorded on a tablet PC.
47924911|NCT04811534|BEHAVIORAL|Interview|Mixed exploratory study, mixing a mainly qualitative study (semi-directed interviews) with a descriptive observational study (short self-questionnaire of the interviewees).
47924912|NCT05830617|DEVICE|real tACS|The effect of transcranial alternating current stimulation (tACS) will be investigated in WP3. Patients will undergo standard intensive rehabilitation plus gamma tACS for two weeks.
47924913|NCT05830617|DEVICE|sham tACS|In WP3, patients will undergo standard intensive rehabilitation plus sham tACS for two weeks.
47924914|NCT00586092|DRUG|bevacizumab, ABT-510|"* Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID\*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days\*~* Stage 2 (RPTD) ABT-510: X mg SC BID\*\*, bevacizumab: Y mg/kg IV every 14 days\*\*~  * Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~    * \*Both agents begin on Day 1 of Cycle 1.~      * \*\*At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
47924915|NCT05630391|DEVICE|High-Fidelity Simulation Manikin|A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
47924916|NCT05630391|OTHER|Education|Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
47924917|NCT06194578|OTHER|Sterile Saline|Sterile saline will be administered subcutaneously.
47924918|NCT05648669|DRUG|Elagolix|200 mg tablet
47924919|NCT05648669|DRUG|Elagolix placebo|Elagolix-matched Placebo tablet
47924920|NCT01659801|DEVICE|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
47924921|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
47924922|NCT05330910|PROCEDURE|Laparoscopic sleeve gastrectomy arm|Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
47924923|NCT03977311|DEVICE|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
47924924|NCT03977311|RADIATION|Radiation therapy|-Standard of Care
47924925|NCT00195208|DRUG|Pantoprazole for approximately 9 weeks|
47924926|NCT05099094|GENETIC|BD311|Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
48271415|NCT03706586|PROCEDURE|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
48271416|NCT00379951|DRUG|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
47924927|NCT02578719|DRUG|bupivacaine|marcaine %0.5 20 ml flacon
47924928|NCT02578719|DRUG|saline|%0.9 sodium chloride
47924929|NCT02735889|OTHER|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
47924930|NCT02735889|OTHER|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
47924931|NCT02735889|OTHER|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
47924932|NCT05970354|DRUG|EMLA Cream|Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)
47924933|NCT05970354|DRUG|VersaPro Cream Base for Compounding|Placebo
47924934|NCT04094415|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
47951248|NCT02380027|PROCEDURE|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
47951249|NCT02380027|PROCEDURE|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
48271417|NCT01422005|OTHER|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
48271418|NCT01422005|OTHER|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
48443803|NCT00486863|OTHER|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
48443804|NCT01139047|DRUG|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
48443805|NCT01139047|DRUG|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
47924935|NCT01090583|OTHER|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
47924936|NCT02763943|BEHAVIORAL|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
47924937|NCT01151943|OTHER|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
47924938|NCT01151943|OTHER|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
47924939|NCT04933370|OTHER|Stimulation parameters|Different device stimulation parameters
47924940|NCT05337020|OTHER|Survey|Each patient will be asked to fill in the questionnaire to assess their vision on telemedicine
47924941|NCT00166556|DRUG|Campath-1H and Tacrolimus|
47924942|NCT02604537|DRUG|betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
47924943|NCT02604537|DRUG|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
47924944|NCT06076291|DRUG|SG1827|PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
47924945|NCT05278598|PROCEDURE|Erector Spinae Plane Block|"After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides."
47924946|NCT05278598|PROCEDURE|Thoracic Paravertebral Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
47924947|NCT05278598|PROCEDURE|Quadratus Lumborum Plane Block|"After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides."
47924948|NCT02524613|OTHER|Pelvis CT scan|
47924949|NCT02745145|DRUG|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
48271419|NCT02103140|BEHAVIORAL|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
48271420|NCT02103140|BEHAVIORAL|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
47924950|NCT02745145|DRUG|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
48271421|NCT03228121|PROCEDURE|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
48271422|NCT03228121|PROCEDURE|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
48271423|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
48271424|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
47924951|NCT02745145|DRUG|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
47924952|NCT03877640|DEVICE|BTL EMSELLA|High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
47924953|NCT05662670|DRUG|WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
47924954|NCT05046327|DRUG|Avatrombopag 20 mg Oral Tablet|Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
47924955|NCT05014633|OTHER|EI skills training|EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
47924956|NCT05145218|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
47924957|NCT05145218|DRUG|Paclitaxel injection|Paclitaxel is a novel anti-microtubule agent.
47924958|NCT05145218|DRUG|TQB2450 injection|TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
47924959|NCT00003388|BIOLOGICAL|filgrastim|
47924960|NCT00003388|DRUG|cyclophosphamide|
47924961|NCT00003388|DRUG|cytarabine|
47924962|NCT00003388|DRUG|methotrexate|
47924963|NCT00003388|DRUG|pegylated liposomal doxorubicin hydrochloride|
47924964|NCT00003388|DRUG|prednisone|
47924965|NCT00003388|DRUG|vincristine sulfate|
47924966|NCT00003388|RADIATION|radiation therapy|
47924967|NCT06225908|PROCEDURE|Serratus posterior superior intercostal plane block|application of local anestesic under serratus posterior superior muscle at the level of second costa
47924968|NCT06398743|DEVICE|MRD|ctDNA MRD test
47924969|NCT04740645|OTHER|NOCDURNA Cohort|Non intervention
47924970|NCT04740645|OTHER|LUTS Cohort|Non intervention
47924971|NCT03769610|OTHER|Inpatient Foley catheter|
47924972|NCT03769610|OTHER|Outpatient Foley catheter|
47924973|NCT01520428|BEHAVIORAL|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
47924974|NCT06069440|OTHER|Swimming Fatigue Task|Swim freestyle at a steady, controlled pace until mechanical failure (i.e., inability to maintain the predetermined speed) is reached.
47924975|NCT02621840|BEHAVIORAL|Mandatory On-Site Pre-Admission Testing|
47924976|NCT03936452|DRUG|Sintilimab|Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
47924977|NCT02966054|BEHAVIORAL|Digital Health Physical Activity Intervention Group|Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
47924978|NCT00129662|BEHAVIORAL|Pictorial action plan|
47924979|NCT03445156|BEHAVIORAL|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
47924980|NCT03445156|BEHAVIORAL|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
47924981|NCT01718340|DRUG|Metformin|metformin tablet 500mg three time per day
47924982|NCT00494767|DRUG|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
47924983|NCT00494767|DRUG|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
47924984|NCT00494767|DRUG|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
47924985|NCT00494767|DRUG|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
47924986|NCT03519542|DRUG|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
47924987|NCT00239135|DRUG|PEP005|
47924988|NCT05784285|BEHAVIORAL|Engagement in a 8-week community-based activity program|Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
47924989|NCT03982134|DRUG|PDR001|PDR001 is a humanized IgG4 antibody
47924990|NCT03982134|DRUG|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
47924991|NCT01348477|PROCEDURE|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
47924992|NCT05299983|OTHER|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
47924993|NCT05299983|OTHER|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
47924994|NCT05723471|OTHER|Adaptative Physical Activity|12 weeks of a collaborative program of customized, adaptative and supervised physical activity by sports instructor
47924995|NCT00662532|DRUG|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
47924996|NCT03505398|PROCEDURE|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
47924997|NCT03505398|PROCEDURE|visual acuity|using ETDRS scales
47924998|NCT03505398|PROCEDURE|automated visual field|recording visual attention based on central or peripheral visual information
47924999|NCT03505398|PROCEDURE|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
47925000|NCT05139511|DEVICE|Study group|The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
47925001|NCT05139511|OTHER|Control group|Same procedure but without energy
47925002|NCT05634447|DRUG|Drug: CKD-391, QD, PO|Drug: CKD-331, D337 QD, PO
47925003|NCT04057716|BEHAVIORAL|Sleep restriction|Participants will be asked to restrict their time in bed to 8 hours each night for one week.
47925004|NCT04057716|BEHAVIORAL|Sleep extension|Participants will be asked to extend their time in bed to 11 hours each night for one week.
47925005|NCT01793870|DRUG|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
47925006|NCT01793870|DRUG|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
47925007|NCT01793870|DRUG|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
47925008|NCT06389656|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies, paired with behavioral strategies for weight management.
47925009|NCT06389656|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception, through challenging weight-related stereotypes, self-compassion, reducing self-criticism, and coping with weight stigma.
47925010|NCT00936728|OTHER|therapeutic nutritional supplementation|Given orally
47925011|NCT00936728|DIETARY_SUPPLEMENT|white wine|Given orally
48271425|NCT04936321|BEHAVIORAL|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
48271426|NCT03024216|DRUG|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
48271427|NCT03024216|DRUG|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
47925012|NCT00936728|OTHER|questionnaire administration|Ancillary studies
47925013|NCT03729271|DRUG|Rifaximin|Rifaximin will be given during weeks 2-4
47925014|NCT03729271|DEVICE|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
47925015|NCT00000496|DRUG|aspirin|
47925016|NCT00000496|DRUG|dipyridamole|
47925017|NCT04176653|DRUG|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
47925018|NCT01870323|BEHAVIORAL|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
47925019|NCT01870323|BEHAVIORAL|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
47925020|NCT03927482|BEHAVIORAL|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
47925021|NCT03927482|BEHAVIORAL|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
47925022|NCT03140358|DRUG|Atropine sulfate 0.01%|Atropine 0.01%
47925023|NCT03140358|DRUG|Placebo|placebo
47925024|NCT03861026|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
47925025|NCT00495040|RADIATION|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
47925026|NCT05165498|PROCEDURE|Real-time ultrasound guidance for thoracic epidural catheter placement.|With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.
48095736|NCT02596906|DEVICE|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.
47925027|NCT03196388|DRUG|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is \>95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
47925028|NCT01650870|DRUG|Crystalline Lactulose|
47925029|NCT00061412|BEHAVIORAL|Comprehensive program to improve reading and writing skills|
47925030|NCT03507114|BEHAVIORAL|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings \& vignettes of participants experiences of the therapy.
47925031|NCT00648050|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
47925032|NCT00648050|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
47925033|NCT01479283|DRUG|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
47925034|NCT01479283|DRUG|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if \< 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
47925035|NCT03970980|OTHER|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
47925036|NCT03927560|PROCEDURE|Robotic Assisted Percutaneous Coronary Intervention|Robotic Assisted Percutaneous Coronary Intervention
47925037|NCT04209985|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to five phone calls from a health coach
47925038|NCT00561977|BEHAVIORAL|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
47925039|NCT00561977|BEHAVIORAL|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
47925040|NCT00561977|BEHAVIORAL|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
47925041|NCT04385329|OTHER|Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.
47925042|NCT04385329|OTHER|Shock wave therapy on plantar fascia only|Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
47925043|NCT03470727|DEVICE|Citrate dialysate|Change form acetate to citrate dialysate
47925044|NCT04532580|DEVICE|Diagnosis of fracture on X-Ray Radiographs|Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
47925045|NCT02256397|OTHER|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
47925046|NCT02256397|OTHER|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~* If between 2 and 5 years old--\> will receive Home-centered comprehensive care with the propeller~* 5 and above--\> will receive home-centered comprehensive care with propeller and PIKO"
47925047|NCT05095532|BIOLOGICAL|Bone marrow-derived mesenchymal stem cells|MSC transplantation
47925048|NCT05095532|OTHER|Placebo|Standard of Care
47925049|NCT01217307|DRUG|Metformin|Metformin 500mg twice daily during 4 months
47925050|NCT01217307|DRUG|Placebo|Placebo twice daily during 4 months
47925051|NCT03137745|OTHER|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
47925052|NCT03513341|OTHER|No intervention|No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
47925053|NCT01724619|DRUG|[F-18] fluorinated dihydrotestosterone (FDHT)|
47925054|NCT01116778|BIOLOGICAL|eN-Lac®|One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po
47925055|NCT01116778|OTHER|Placebo|One placebo capsule, once daily, po
47925056|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
48271428|NCT05573802|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.
47925057|NCT02300636|OTHER|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
47925058|NCT02300636|OTHER|Training|Standard ACL rehabilitation
48271429|NCT05573802|DRUG|Lenalidomide|Lenalidomide will be administered per os.
47925059|NCT01332461|DRUG|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
47925060|NCT01332461|DRUG|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
47925061|NCT01917656|DRUG|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
47925062|NCT01917656|DRUG|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
47925063|NCT01917656|DRUG|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
47925064|NCT04144127|BEHAVIORAL|Soccer|"* Soccer drills and other fitness routines (two 1-hour sessions per week)~* In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure."
47925065|NCT00870103|DRUG|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
47925066|NCT03741478|DRUG|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~1. Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~2. Cognitive arm - 5mg on Day 0, 10mg on Day 1"
47925067|NCT03741478|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
47925068|NCT03741478|DRUG|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
47925069|NCT03741478|OTHER|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
47925070|NCT03947476|DEVICE|thoracic band|Thoracic band fixation
47925071|NCT05293392|BEHAVIORAL|Culturally-Tailored COVID-19 Vaccine Uptake Intervention|This is a multi-component intervention to increase COVID-19 vaccine uptake among youth that was co-created with community partners and refined with qualitative feedback from Black and Latino youth and parents. The intervention consists of culturally-tailored educational materials to increase awareness about the COVID-19 vaccine, culturally-sensitive communication strategies employed by pediatric primary care providers and community health workers, and strategies to facilitate and standardize access to the COVID-19 vaccine in the primary care clinic.
47925072|NCT05293392|BEHAVIORAL|Standard Care|Standard care includes routine offer of the COVID-19 vaccine and counseling about the COVID-19 vaccine by pediatric primary care providers.
47925073|NCT03812237|OTHER|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
47925074|NCT05464953|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
47925075|NCT05464953|DRUG|Formulated Triamcinolone|Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate
47925076|NCT02011139|BEHAVIORAL|Cognitive-behavioral group therapy|
47925077|NCT02207946|DRUG|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
48271430|NCT05573802|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
48271431|NCT05573802|DRUG|Nirogacestat|Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.
48271432|NCT04421326|OTHER|Analysis of the clot|Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
48271433|NCT03514589|DRUG|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
48271434|NCT03514589|DRUG|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
48271435|NCT05836298|OTHER|Non-surgical periodontal treatment|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
47925078|NCT02207946|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
47925079|NCT00023699|DRUG|gefitinib|
47925080|NCT00724321|DRUG|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
47925081|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
47925082|NCT01209104|DRUG|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
47925083|NCT02776202|DRUG|Fludarabine monophosphate|"The HSCT preparative regimen will consist of~* Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~* Fludarabine: 35 mg/m2/day IV on Days -8 through -4~* Melphalan: 140 mg/m2 IV on Day -3~* Rest on Day -2 and -1~* Day 0 is the day of transplant~* GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
47925084|NCT05526300|DEVICE|Intelligent Hypertension Management System|The intelligent hypertension management system is used to remotely detect the blood pressure of hypertensive patients
47925085|NCT05526300|OTHER|The standard care|The standard care
47925086|NCT00273533|DRUG|Ramipril|
47925087|NCT04844710|COMBINATION_PRODUCT|acupuncture and standard care|manual acupuncture in acupoint LI4, LI11, ST36 every 2 days for 6 times standard care
47925088|NCT04844710|DRUG|standard care|standard care only
48095737|NCT02596906|DEVICE|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
47925089|NCT06025136|OTHER|Using a gel pillow|Within the scope of the study, gel pillows with a cold surface were used in the patients in the study group. It is produced by combining the obtained special liquid with elastic material with NASA approved molecule exchange technology and is made of OEKO-TEX CLASS 1 certified material.Thanks to the gel material on the pillow surface, the surface temperature is reduced from 37°C to 24°C in about 10 seconds. It gives a feeling of coolness with its thermal conductivity feature.
47925090|NCT06096610|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
47925091|NCT02805504|DRUG|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
47925092|NCT02805504|DRUG|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
47925093|NCT00002280|DRUG|Didanosine|
47925094|NCT04244305|OTHER|Exercise Therapy|Endurance training in the form of treadmill/cycle-ergometry
47925095|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
47925096|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)|A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.
47925097|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
47925098|NCT05661084|DEVICE|Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)|Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
47925099|NCT02724540|DEVICE|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
47925100|NCT02724540|COMBINATION_PRODUCT|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
47925101|NCT02724540|COMBINATION_PRODUCT|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
47925102|NCT03763513|DEVICE|ESWT|Extracorporeal Shock Wave Therapy=ESWT
47925103|NCT03763513|OTHER|Kinesiotaping Application|Kinesiotaping=KT (CT)
47925104|NCT06261281|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
47925105|NCT06261281|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
47925106|NCT06261281|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
47925107|NCT02423967|BIOLOGICAL|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
47925108|NCT02423967|BIOLOGICAL|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
47925109|NCT03596541|DEVICE|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
47925110|NCT05798468|OTHER|Augmented reality|The intervention will be carried out in the Physiotherapy Degree of the Universities of Malaga and Cadiz. It will consist of the use of software and a platform that works with augmented reality. Previously a study of the demographic variable of the population that conforms the study will be carried out. During the intervention, teaching will be carried out with the support and enhancement of the use of augmented reality through Zapworks and Aumentaty. A study and analysis of the variables of the qualifications and usability of the study population will be carried out. For the qualification variable, the academic performance of the students will be taken into account and for the usability variable, the System Usability Scale will be used. Subsequently, an analysis and interpretation will be carried out to assess the correlation between both variables.
47925111|NCT05798468|OTHER|Control group|Traditional education will be carried out
47925112|NCT05808634|DRUG|BA3182|Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
47925113|NCT04475705|DRUG|propofol|intravenous propofol using Target Controlled Infusion 'Paedfusor' model 2-5 as the main anaesthetic to achieve Bispectral Index 40-60
48271436|NCT04939857|DRUG|Trimetazidine|The experimental group will be treated with trimetazidine, and the control group will not be intervened
47925114|NCT04475705|DRUG|sevoflurane|sevoflurane at Minimal Alveolar Concentration 0.7-1.3 as the main anaesthetic to achieve Bispectral Index 40-60.
47925115|NCT06174168|OTHER|Modified Frailty Index -11|MFI-11: the parameter included in the score is history of congestive heart failure, presence of diabetes mellitus, history of chronic obstructive pulmonary disease or pneumonia, functional health status/dependence, history of hypertension, history of myocardial infarction, cardiac problems, cognitive impairment, history of transient ischemic attack or cerebrovascular accident, history of peripheral vascular disease is questioned. Patients will be monitored according to standard non-operating room anesthesia procedures.
47925116|NCT00206232|DRUG|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
47925117|NCT00146432|PROCEDURE|Immunoadsorption of LPS, IL-6 and C5a|
47925118|NCT04316975|OTHER|Study Driven Procurement of Biopsies|Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
47925119|NCT05095012|OTHER|Pediatric Acute Care Concussion Clinical Pathway|MD assessment will be partially standardized to assess for patients at higher risk of becoming persistently symptomatic. These patients scoring as 'high risk' will be referred to one of three specialty clinics. High risk is defined as scoring 9 or higher out of 12 on the 5P score.
47925120|NCT01989208|OTHER|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
47925121|NCT01989208|OTHER|Placebo|200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
47925122|NCT05254743|DRUG|Pirtobrutinib|Administered orally.
47925123|NCT05254743|DRUG|Ibrutinib|Administered orally.
47925124|NCT00814216|DRUG|QAV680|
47925125|NCT00814216|DRUG|Matching placebo for QAV680|
47925126|NCT00814216|DRUG|Fluticasone Propionate|
47925127|NCT05775523|DRUG|No intervention|No intervention
48271437|NCT05220592|BEHAVIORAL|Internet-based recovery training program|The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
48271438|NCT04085887|DRUG|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
48271439|NCT04085887|DEVICE|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
48271440|NCT04085887|DEVICE|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
48271441|NCT04085887|DEVICE|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
48271442|NCT02867397|DRUG|Teysuno (S1) in combination with epirubicin and oxaliplatin|
48271443|NCT03777449|RADIATION|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
48271444|NCT00368706|DRUG|solifenacin succinate|Oral
48271445|NCT00368706|DRUG|tolterodine|oral
48271446|NCT06030934|DRUG|envafolimab and lenvatinib combined with paclitaxel-albumin|envafolimab: 200mg d1,15 s.c. Q4W; lenvatinib: 8mg (\<60kg) or 12mg (≥60kg) p.o. Q.d.; paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
47925128|NCT02108678|BEHAVIORAL|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
47925129|NCT02108678|BEHAVIORAL|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
47925130|NCT05037578|BEHAVIORAL|Project Grace|A multilevel church-based intervention to encourage cognitive screens and brain health.
47925131|NCT02236351|DEVICE|Pinch Patch/ flat Patch|
47925132|NCT03317301|DRUG|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
47925133|NCT03317301|DRUG|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
47925134|NCT01049945|DRUG|bendamustine hydrochloride|Given IV
47925135|NCT01049945|DRUG|lenalidomide|Given orally
47925136|NCT01049945|DRUG|dexamethasone|Given orally or IV
47925137|NCT01779817|BEHAVIORAL|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
47925138|NCT03279393|DRUG|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
47925139|NCT05520164|OTHER|Listening the maternal heart sound during the invasive interventions|Heart sounds of the newborns' own mothers were recorded on the voice recorder with the help of a hand doppler device. This sound was listened by the newborns in the experimental group during the heel blood procedure.
47925140|NCT03489746|OTHER|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
47925141|NCT03489746|OTHER|Standard care|Normal clinically indicated inhaled therapy
47925142|NCT01888432|DRUG|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
47925143|NCT01888432|DRUG|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
47925144|NCT00665314|DRUG|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
47925145|NCT00665314|DRUG|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
47925146|NCT06289205|DRUG|Methotrexate|Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
47925147|NCT03933995|OTHER|no Intervention|no Intervention
47925148|NCT05832775|BIOLOGICAL|MRx0029|Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
47925149|NCT05832775|BIOLOGICAL|MRx0005|Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
47925150|NCT04422340|OTHER|Group1|"* Comorbidities (CIRS-G scale),~* Functional status of the patient with~  * Clinical frailty scale (1 month before infection)~ * ADL score (1 month before infection)~* Biological data~  * Blood group~ * TP, D-dimers, CRP, creatinine level at the patient's entry, triglyceridemia, fibrinogen, ferritin~ * Parameters derived from the platelet formula count on D1 of the start of intensive care (lymphocytes, neutrophils, platelets, average platelet volume, red blood cell distribution index), SYSMEX data (IG: Immature granulocytes; HFLC: high fluorescent lymphocyte count)~* Resuscitation outcomes~  * LDH rate at the start of intensive care~ * PaO2 / FiO2 ratio at the start of intensive care~ * IGSII / SASPII score (simplified acute physiology score) on D1 of the start of intensive care~ * SOFA score (sepsis-related organ failure assessment): a posteriori estimate based on IGSII / SASPII~ * Delay between the appearance of the first signs of infection and admission to intensive care"
47925151|NCT05240443|PROCEDURE|Bariatric Surgery + Medical Management of CKD.|The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
47925152|NCT05240443|OTHER|Medical Management for CKD|Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
47925153|NCT06481462|PROCEDURE|Intrathecal Morphine (ITM)|morphine 100 mcg + 12.5 mg bupivacaine + 10 mcg fentanyl
47925154|NCT06481462|PROCEDURE|Quadratus Lumborum II (QLB-II) Block|12.5 mg bupivacaine + 20 mcg fentanyl bilateral QLB block (posterior tip 2) 25 cc 0.25% bupivacaine
47925155|NCT05378698|DRUG|Application of Tralokinumab|2 Arms 20 patients 5 healthy controls
47925156|NCT00559494|DRUG|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
47925157|NCT00559494|DRUG|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
47925158|NCT00559494|PROCEDURE|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
47925159|NCT00559494|PROCEDURE|SCPP control|maintenance of Mean arterial pressure of \>65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
47925160|NCT02603965|RADIATION|Copper Cu 64 TP3805|Given IV
47925161|NCT02603965|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
47925162|NCT02603965|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
47925163|NCT02603965|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
47925164|NCT02603965|OTHER|Laboratory Biomarker Analysis|Correlative studies
47925165|NCT02168387|DEVICE|continuous high frequency oscillator (CHFO)|
47925166|NCT02168387|DRUG|Acetylcysteine|
47925167|NCT02168387|DRUG|dornase alfa|
47925168|NCT00470509|DRUG|Adalimumab|2 subcutaneous injections on day 0 and 7
47925169|NCT00470509|DRUG|Placebos|2 subcutaneous injections on day 0 and 7
47925170|NCT06154278|DRUG|Imdusiran (AB-729)|60mg subcutaneously, every 8 weeks, for a total of 4 doses
47925171|NCT06084975|PROCEDURE|Splenic vessels preservation|preservation the splenic vessels
47925172|NCT00770146|DRUG|Mipomersen sodium|200 mg/mL
47925173|NCT00770146|DRUG|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
47925174|NCT04267224|DRUG|Ticagrelor 90mg|Ticagrelor is a direct-acting inhibitor of the platelet P2Y12 receptor with a rapid antiplatelet effect. It has been shown to reduce the rate of major cardiovascular events among patients with acute coronary syndromes, as compared with Clopidogrel, and has the potential to improve coronary reperfusion and the prognosis for patients with STEMI treated with primary PCI.
47925175|NCT06192810|PROCEDURE|Laparoscopic/open adrenalectomy|
47925176|NCT02162407|DRUG|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
47925177|NCT02162407|DRUG|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
47925178|NCT00966914|DRUG|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
47925179|NCT00966914|DRUG|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
47925180|NCT03513107|OTHER|ospeoporosis score|"* Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass \& Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein \& Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~* Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
47925181|NCT04634045|BEHAVIORAL|Web Based Treatment|The literature regarding the efficacy of web-based platforms for behavioral weight management interventions in pediatric populations continues to grow. Considering the continued increase in technology and internet use among youth, web-based interventions have the potential to serve as a more cost-effective and personalized approach to pediatric behavioral weight management. Extant research supports this consideration. More research that compares web-based vs. traditional delivery of acceptance-based pediatric behavioral weight management interventions is necessary to understand the utility of this platform as well as which aspects are most effective.
47925182|NCT00329446|DRUG|Quetiapine Fumarate|
47925183|NCT00329446|DRUG|Escitalopram oxylate|
47925184|NCT02156245|OTHER|conventional rehabilitation program (including concentric cycle ergometer)|
47925185|NCT02156245|OTHER|cycling included into a conventional rehabilitation program|
47925186|NCT00204438|DRUG|0.15mg desogestrel /0.03mg ethinyl estradiol|
47925187|NCT00178503|DRUG|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
47925188|NCT00178503|DRUG|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
47925189|NCT00178503|OTHER|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
47925190|NCT03062254|DRUG|radium-223 dichloride|6 doses of Radium-223
47925191|NCT04573023|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
47925192|NCT04573023|DRUG|Idursulfase|IV infusion
48271447|NCT02031094|OTHER|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
48271448|NCT03881709|BEHAVIORAL|Using an E-Book|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
48271449|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
47925193|NCT04573023|DRUG|JR-141 or Idursulfase|"The subjects who have achieved the pre-specified criteria\* are able to change the drug.~\*If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141.~If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase."
47925194|NCT03254576|OTHER|Functional MRI|
47925195|NCT00182481|PROCEDURE|Induced sputum cell counts|
47925196|NCT00182481|DRUG|inhaled corticosteroids and other asthma drugs|
48095738|NCT02594176|DEVICE|FLEXISEQ®|applicable gel
48095739|NCT02594176|DEVICE|Placebo|applicable gel
48095740|NCT04191161|DEVICE|Wearing the rigid brace|Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
48271450|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
48271451|NCT02690909|DEVICE|Redy™ Renal Denervation System|Renal Denervation System
48271452|NCT02502864|DRUG|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m\^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
48271453|NCT02502864|DRUG|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
48271454|NCT02502864|OTHER|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
48271455|NCT00746174|DRUG|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
48271456|NCT00746174|DRUG|Placebo|Placebo 1 tablet PO daily for 16 weeks
48271457|NCT03258892|OTHER|Educational Intervention|Receive STG
48271458|NCT03258892|OTHER|Quality-of-Life Assessment|Ancillary studies
48271459|NCT03258892|OTHER|Survey Administration|Ancillary studies
48271460|NCT02633540|RADIATION|IMRT Radiation|Radiation to Larynx
48271461|NCT00974220|DRUG|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
47925197|NCT05446831|DRUG|Baricitinib|Oral baricitinib was given at a dose of 4 mg daily. The decision to initiate rescue therapy was made after assessment of the extent of bleeding, patient preferences, lifestyle and activity, the complications of specific therapies, comorbidities that predisposed patients to bleeding and the tolerance of side effects. If a platelet count over 300,000/μL was observed for two consecutive tests at least 2 weeks apart, baricitinib treatment was interrupted.
47925198|NCT01247298|COMBINATION_PRODUCT|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
48271462|NCT00974220|DRUG|normal saline (placebo)|single dose, 0.9% saline solution
48271463|NCT03347149|DEVICE|Alarm Advisor Software|Providing advice on alarm limits as part of routine medical care
48271464|NCT01976806|DRUG|Aspirin|
48271465|NCT01976806|DRUG|Docosahexaenoic acid|
48271466|NCT01976806|DRUG|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
48271467|NCT06154967|RADIATION|tereotactic body radiotherapy|In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
48271468|NCT03033329|DRUG|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
48271469|NCT03033329|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
48271470|NCT03033329|DRUG|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
48271471|NCT03033329|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
48271472|NCT03033329|DRUG|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
47925199|NCT01873521|PROCEDURE|Non invasive ventilation|
47925200|NCT02081248|OTHER|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
47925201|NCT02081248|OTHER|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
47925202|NCT01734889|DRUG|Nitisinone|Oral suspension
47925203|NCT00924040|DRUG|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
47925204|NCT04783688|OTHER|Full Face Snorkel Mask (FFSM)|A mask used for snorkeling that covers the entire face, as opposed to a conventional snorkel, which is held in the mouth only.
47925205|NCT01800461|OTHER|OPC-Stroke|Occupational therapy coaching intervention
47925206|NCT01800461|OTHER|Usual care|Usual community care
47925207|NCT03874429|DEVICE|T2259|Sodium Hyaluronate and Trehalose
47925208|NCT03874429|DEVICE|Vismed multi|HA
47925209|NCT02929043|OTHER|air puffs|
47925210|NCT00000939|DRUG|Hydroxyurea|
47925211|NCT00000939|DRUG|Efavirenz|
47925212|NCT00000939|DRUG|Stavudine|
47925213|NCT00000939|DRUG|Didanosine|
47925214|NCT05331417|DIAGNOSTIC_TEST|Patients with herpes-simplex infection requiring bronchoscopy|Due to the observational design of the study, no study-specific interventions are performed. The indication for bronchoscopy is determined by the responsible ICU physicians. Except for the above mentioned laboratory analyses, the treatment of the patients is completely guided by the responsible ICU physicians.
47925215|NCT05383001|DRUG|combination regimen tremelimumab /durvalumab|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Durvalumab 1500 mg fixed dose plus tremelimumab 300 mg fixed bolus dose~Maintenance Therapy:~Durvalumab 1500 mg fixed dose Q4W up to 12 cycles within the study"
47925216|NCT05383001|DRUG|platinum-based chemotherapy (SoC)|"Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel, nab-paclitaxel, vinorelbine or gemcitabine~Combination treatment:~Continuation of second-line chemotherapy with 2-4 further cycles (Q3W) platinum-based combination therapy.~Maintenance Therapy:~Optional continued maintenance therapy with pemetrexed according to marketing authorization will be allowed for a maximum of 13 cycles."
47925217|NCT01029405|DRUG|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
47925218|NCT01029405|DRUG|Placebo|Ointment B Vehicle applied once or twice daily
47925219|NCT01193296|DRUG|Vildagliptin|
47925220|NCT01193296|DRUG|Sitagliptin|
47925221|NCT02285062|DRUG|lenalidomide|
47925222|NCT02285062|DRUG|Placebo|
47925223|NCT02285062|DRUG|Rituximab|
47925224|NCT02285062|DRUG|Cyclophosphamide|
48271473|NCT00454493|DRUG|Omacor (omega-3-acid ethyl esters)|
48271474|NCT05943730|DEVICE|Seismofit|The Seismofit device uses seismocardiography to estimate peak oxygen consumption from a resting measurement. This study will assess its validity against the gold standard measure of peak oxygen consumption, cardiopulmonary exercise test, conducted as part of standard care.
48271475|NCT02203149|DRUG|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
48271476|NCT02203149|DRUG|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
48271477|NCT02203149|DRUG|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
48271478|NCT02203149|DRUG|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
48271479|NCT03452267|DRUG|Metformin|oral, 850 mg twice daily
48271480|NCT03452267|DRUG|Pioglitazone|oral, 45 mg daily
48271481|NCT03452267|DRUG|Placebo|oral, once daily
47925225|NCT02285062|DRUG|Doxorubicin|
47925226|NCT02285062|DRUG|prednisone|
47925227|NCT02285062|DRUG|vincristine|
47925228|NCT00571584|DRUG|activated recombinant human factor VII|
47925229|NCT03190733|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
47925230|NCT04676256|PROCEDURE|Early vitrectomy|Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
47925231|NCT04665869|BEHAVIORAL|Combined balance and brisk walking training|6-months of combined balance and brisk walking training
47925232|NCT04665869|BEHAVIORAL|Flexibility and strengthening exercise|6-months of flexibility and strengthening exercise
47925233|NCT00633542|DRUG|thalidomide|100 mg/day orally until progression or severe toxicity
47925234|NCT00633542|DRUG|interferon alpha|3 MU 3 times a week until progression or severe toxicity
47925235|NCT02307253|DEVICE|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
47925236|NCT00691119|BEHAVIORAL|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
47925237|NCT00691119|OTHER|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
47925238|NCT05027360|DRUG|SNP - Sodium Nitroprusside|The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.
48271482|NCT01279057|DRUG|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
48271483|NCT01279057|DRUG|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
47925239|NCT04113590|PROCEDURE|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
47925240|NCT05425316|BEHAVIORAL|Home Recordings|If patients are willing to download the Winterlight application to their personal iOS devices this will be done at study visit 1. The application will send a notification to the patient once per month, requesting that they perform a paragraph reading task, a picture description task, and an animal naming task.
47925241|NCT05425316|BEHAVIORAL|In-patient Recordings|If patients are admitted to UM hospital for suspected or confirmed OHE, with patient assent, physician study staff will assist the patient in recording a paragraph reading task, a picture description task, and an animal naming task.
47925242|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Regular Appointment|Staff will call patients in anticipation of in-person regular visits to set up a same-day study visit. Patients will record the three speech tasks at this time.
47925243|NCT05425316|BEHAVIORAL|Same-Day Study Visit - Procedure|Staff will call patients in anticipation of in-person procedure visits to set up a same-day study visit, prior to procedure if sedation is planned. Patients will record the three speech tasks at this time.
47925244|NCT05425316|BEHAVIORAL|Phone Call Follow-up Visits|Non-physician study staff will call the patients every 3 months and, using a phone script, will ask them survey questions about their hepatic health.
47925245|NCT05596097|DRUG|Zanubrutinib|Zanubrutinib, 180mg, bid, p.o., d1-28; Treatment cycles every 28 days
47925246|NCT00458224|BEHAVIORAL|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
47925247|NCT05874206|DEVICE|Cratos™ Stent Graft|Cratos™ Stent Graft TEVAR procedure for the treatment of aortic lesions.
47925248|NCT04516395|OTHER|Combined antibiotic regimens|Combined antibiotic combinations defined as the optimal antibiotic combination regimens which are created from in vitro study and the application of PK/PD.
47925249|NCT04516395|OTHER|Standard antibiotic regimens|Standard antibiotic regimens defined as the antibiotic regimens which are generally given to the patients following to the hospital protocol.
47925250|NCT00319267|DRUG|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
47925251|NCT00590928|DRUG|esomeprazole|40mg once daily
47925252|NCT00590928|DRUG|ranitidine|50mg every h hours
47925253|NCT06435065|DRUG|Biodentine|DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE
47925254|NCT06435065|DRUG|Mineral Tri-Oxide Aggregate|DIRECT PULP CAPPINGWILL BE DONE USING MTA
47925255|NCT06435065|DRUG|THERACAL LC|DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC
47925256|NCT06435065|DRUG|TRISTRONTIUM ALUMINATE|DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
47925257|NCT00875134|OTHER|Verbal prompt|Patient hears a voice recording
47925258|NCT00875134|OTHER|Skin Stimulus|Patient receives either a skin stimulus
47925259|NCT00228982|DRUG|Ceftobiprole medocaril|
47925260|NCT00228982|DRUG|Vancomycin|
47925261|NCT00321646|DRUG|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
47925262|NCT00321646|DRUG|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
47925263|NCT03337789|DIETARY_SUPPLEMENT|Polygonatum sibiricum|Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
47925264|NCT03337789|DIETARY_SUPPLEMENT|Placebo|Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
47925265|NCT00225264|DRUG|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
47925266|NCT00225264|DRUG|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
48271484|NCT01279057|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
48271485|NCT06353672|DEVICE|Robotic liver resection|Liver resection using Da Vinci robotic system
48271486|NCT00000927|DRUG|BufferGel|
48271487|NCT05510960|OTHER|Video game & Robotic surgery simulator success|"A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills."
48271488|NCT03148730|DEVICE|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
47925267|NCT05624333|OTHER|Vegan diet (intervention)|The intervention diet will be a fully controlled vegan diet that will be consumed for a duration of 10 days. No animal-based food products will be included in the diet.
48443806|NCT04507711|DRUG|0 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
47925268|NCT05624333|OTHER|Omnivorous diet (control)|The control diet will be an a priori composed controlled omnivorous diet with a duration of 10 days. The omnivorous diet and the vegan diet will be isocaloric and isonitrogenous.
47925269|NCT02065388|BEHAVIORAL|Standard of care dosing for warfarin|
47925270|NCT02065388|GENETIC|Genotype-guided dosingTaiwan algorithm for warfarin|
47925271|NCT02065388|GENETIC|Genotype-guided dosing IWPC algorithm for warfarin|
47925272|NCT05735210|DEVICE|Polso™ Watch blood pressure measurement compared to a reference blood pressure measurement|The referenced blood pressure measurements are taken by dual auscultators.
47925273|NCT01642628|OTHER|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
47925274|NCT04705844|DRUG|Adalimumab|adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)
47925275|NCT04705844|DRUG|Placebo|placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)
47925276|NCT03189056|DIAGNOSTIC_TEST|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
47925277|NCT03189056|BIOLOGICAL|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
47925278|NCT03189056|PROCEDURE|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
47925279|NCT03045224|DEVICE|PTA, balloon angioplasty, stent|
47925280|NCT04097587|BEHAVIORAL|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
47925281|NCT04097587|OTHER|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
47925282|NCT01700439|DEVICE|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
47925283|NCT02811523|DRUG|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
47925284|NCT05885178|PROCEDURE|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
47925285|NCT04618627|OTHER|lung ultrasound|Role of lung ultrasonography in prediction of the seveity and the need for surfactant administration in neonates with respiratory distress syndrome.
47925286|NCT02358356|DRUG|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
47925287|NCT02358356|DRUG|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
47925288|NCT02358356|DRUG|Temozolomide|temozolomide 75mg/m2 b.i.d.
47925289|NCT00333346|DRUG|Administration of tramadol intravenously|
47925290|NCT04838808|DRUG|Rivaroxaban 2.5 MG [Xarelto]|Rivaroxaban 2.5mg twice daily for 90-days
47925291|NCT04838808|DRUG|Placebo|Placebo tablet twice daily for 90-days
48095741|NCT02473120|BIOLOGICAL|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
47925292|NCT05185206|DEVICE|Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
48271489|NCT01323907|DRUG|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
47925293|NCT05185206|DEVICE|Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).|"Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm)."
47925294|NCT02248675|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
48443807|NCT04507711|DRUG|1 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
47925295|NCT02248675|OTHER|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
47925296|NCT04182464|OTHER|Sucralose|Food additive used to replace sugar providing a sweet taste without calories
47925297|NCT04182464|OTHER|Placebo|Cornstarch without significant physiological effects
47925298|NCT00081510|DRUG|Lonafarnib|
47925299|NCT00081510|DRUG|Placebo|
47925300|NCT00081510|DRUG|anastrozole|
47925301|NCT05617313|DRUG|Pembrolizumab|200 mg intravenously on Day 1 of cycle.
47925302|NCT05617313|DRUG|GT103|10mg/kg taken intravenously on Day 1 of cycle.
47925303|NCT02935751|OTHER|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
47925304|NCT02989987|BEHAVIORAL|Narrative Exposure Therapy|
47925305|NCT02989987|BEHAVIORAL|Social Support|A local counselors provides social support on demand.
47925306|NCT00650481|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
47925307|NCT00650481|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
47925308|NCT00603642|DRUG|Placebo|Subcutaneously administered, once a week, for 12 weeks
47925309|NCT00603642|DRUG|AMG 531|Subcutaneously administered, once a week, for 12 weeks
47925310|NCT00708084|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
47925311|NCT00708084|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
47925312|NCT04365101|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
47925313|NCT00649597|DRUG|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
47925314|NCT00649597|DRUG|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
47925315|NCT01456624|DRUG|Megace|800mg
47925316|NCT01456624|DRUG|DW-ES(B)|625mg
47925317|NCT00746200|PROCEDURE|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
47925318|NCT00746200|PROCEDURE|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
47925319|NCT03051620|DRUG|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
47925320|NCT03207438|DRUG|Quetiapine 50 MG Extended Release Oral Tablet|OD
47925321|NCT03207438|DRUG|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
47925322|NCT03207438|DRUG|Placebos|Placebo
47925323|NCT00793273|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
47925324|NCT05917431|COMBINATION_PRODUCT|SBRT plus tislelizumab and regorafenib|Participants will receive SBRT plus tislelizumab and regorafenib concurrently
47925325|NCT00021372|DRUG|estramustine phosphate sodium|
47925326|NCT00021372|DRUG|paclitaxel|
47925327|NCT02226133|DEVICE|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
47925328|NCT01155167|DRUG|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
47925329|NCT01155167|OTHER|Placebo|Placebo
47925330|NCT04204070|PROCEDURE|Accuro|A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
47925331|NCT04204070|PROCEDURE|APAD|APAD
47925332|NCT06119243|DEVICE|Vivior|The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
47925333|NCT00125125|DRUG|Fluvastatin|
47925334|NCT02753088|DRUG|BCD-063|
47925335|NCT02753088|DRUG|Copaxone-Teva|
47925336|NCT02753088|DRUG|Placebo|
47925337|NCT01406405|PROCEDURE|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
47925338|NCT00353756|DRUG|C326, IL-6 Inhibitory Avimer protein|
47925339|NCT06284629|DEVICE|Neptune|Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can self-report symptoms, view their motor data and get medication reminders, and a physician portal, where the treating physician can view the objective motor data and patient-reported outcomes prior to a clinical visit.
47925340|NCT06284629|OTHER|Standard clinical care|Treatment and management according to standard clinical care
47925341|NCT05265780|PROCEDURE|kinesiotape|an elastic adhesive tape
47925342|NCT05265780|PROCEDURE|sham taping|a sham taping without the tension
47925343|NCT01233518|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
47925344|NCT00045981|DRUG|ALT-711|
48271490|NCT03825913|BEHAVIORAL|Exercise Intervention|"Training sessions will include a split routine based on the day of the week.~* Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~* Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention."
48443808|NCT04507711|DRUG|10 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
47925345|NCT03029884|DEVICE|Open-Loop DBS|Conventional brain stimulation that is tonically providing stimulation, without feedback
47925346|NCT03029884|DEVICE|Sham Stimulation|No Active Stimulation
47925347|NCT03029884|DEVICE|Closed-Loop DBS|Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
47925348|NCT01943357|BEHAVIORAL|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
47925349|NCT00984620|DRUG|BI 201335|BI 201335
47925350|NCT00984620|DRUG|BI 201335|BI 201335
47925351|NCT00984620|DRUG|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
47925352|NCT00984620|DRUG|Ribavirin (RBV)|Ribavirin (RBV)
47925353|NCT01449942|BIOLOGICAL|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
47925354|NCT01449942|OTHER|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
47925355|NCT00030004|PROCEDURE|spinal manipulation|
47925356|NCT00030004|DRUG|midazolam|
47925357|NCT01402427|DRUG|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
47925358|NCT01402427|DRUG|Placebo|Intraarterial administration of 10 mL saline.
47925359|NCT06305884|PROCEDURE|Bioelectric Impedance Analysis|Undergo BI
47925360|NCT06305884|OTHER|Exercise|Pedal an exercise bike
47925361|NCT06305884|PROCEDURE|Photoplethysmography|Undergo PPG
47925362|NCT06305884|BEHAVIORAL|Questionnaire Administration|Ancillary studies
47925363|NCT00986284|DRUG|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
47925364|NCT05895526|PROCEDURE|Self etch dentin adhesive, Fluoride varnish|After an informed consent, in one group 5% sodium fluoride varnish will be applied in affected area, while the other group will receive self etch dentin adhesive.
47925365|NCT00255424|DRUG|ferumoxytol or oral iron|
47925366|NCT03911687|BEHAVIORAL|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
47925367|NCT03520127|DEVICE|Intact Breast Lesion Excision System (BLES)|Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
47925368|NCT03077087|DEVICE|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
47925369|NCT01513200|DRUG|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
47925370|NCT01513200|DRUG|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
47925371|NCT01513200|DRUG|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
47925372|NCT05146102|OTHER|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
47925373|NCT03079544|COMBINATION_PRODUCT|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
47925374|NCT04690439|DEVICE|Photobiomodulation therapy (PBMT)|The MLS M6 laser from ASA will be used to apply the laser therapy.
47925375|NCT04690439|PROCEDURE|Manual Lymphatic drainage|Patients will receive twice weekly MLT executed by trained physiotherapist
47925376|NCT02615626|PROCEDURE|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
47925377|NCT03997292|DRUG|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
47925378|NCT03997292|DRUG|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
47925379|NCT02045030|DRUG|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
47925380|NCT05471583|OTHER|Main group|no intervention; observational only
47925381|NCT00371553|DRUG|SU011248 (Sunitinib)|
47925382|NCT06506591|DRUG|WD-890|Administered P.O.
47925383|NCT06506591|DRUG|WD-890 Tablets Placebo|Administered P.O.
47925384|NCT03105466|PROCEDURE|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
47925385|NCT03105466|DEVICE|Acellular Porcine Cornea|
47925386|NCT03105466|DRUG|Tacrolimus eye drops|
47925387|NCT03105466|DRUG|Tobradex eyedrops|
47925388|NCT05870982|BEHAVIORAL|Early TRE|Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
47925389|NCT05870982|BEHAVIORAL|Late TRE|Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
47925390|NCT05870982|BEHAVIORAL|DCR|Participants will be instructed to reduce caloric intake by 25%.
48271491|NCT03825913|BEHAVIORAL|Wellness Intervention|In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
48271492|NCT06055634|GENETIC|genotyping of SIRT1 in chronic obstructive patients|genotyping of SIRT1 in chronic obstructive patients
47925391|NCT04355728|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
47925392|NCT04355728|OTHER|Vehicle + Heparin along with best supportive care|Best supportive care treatment per the treating hospital protocol.
47925393|NCT00858572|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
47925394|NCT01397097|DRUG|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
47925395|NCT01397097|DRUG|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
47925396|NCT01836276|DRUG|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
47925397|NCT04044144|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
47925398|NCT05542745|DEVICE|palatal and buccal retraction|comparison
47925399|NCT01680198|DRUG|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
47925400|NCT01680198|DRUG|placebo|
47925401|NCT00725842|BIOLOGICAL|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
47925402|NCT00725842|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
47925403|NCT00832832|OTHER|Eyelid closure|Eyelid will be closed after eye drop instillation
47925404|NCT00832832|OTHER|No intervention will be assigned|No intervention will be assigned to this arm
47925405|NCT00865423|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
47925406|NCT00865423|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
48271493|NCT03812406|PROCEDURE|French Abulatory Cesrean Section|A cesarean section performed according to the FAUCS technique
47925407|NCT00663949|DRUG|Captopril|25 mg captopril tablet q8h
47925408|NCT00663949|DRUG|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
47925409|NCT04232969|DRUG|Exenatide extended release 2mg (Bydureon)|Subcutaneous Injection
47925410|NCT04379492|DRUG|Hydroxychloroquine|Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.
47925411|NCT04379492|OTHER|Placebo|Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
47925412|NCT04023929|PROCEDURE|Cord blood sampling|A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
48271494|NCT03812406|PROCEDURE|Misgav-Ladach|A cesarean section performed according to the Misgav Ladach technique
47925413|NCT00125346|DRUG|Tobramycin Inhalation Powder|
47925414|NCT04541277|DRUG|Tislelizumab|Tislelizumab combined with DNA demethylation agent +/- CAG regimen
47925415|NCT00125398|DRUG|AQUAVAN (fospropofol disodium; GPI 15715 )|
47925416|NCT01012648|DRUG|Fluid resuscitation|Volume resuscitation
47925417|NCT01012648|DRUG|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
47925418|NCT03640780|OTHER|observation|The surgical ages and other information between two groups were compared.
47925419|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
47925420|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
47925421|NCT00782470|BEHAVIORAL|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
47925422|NCT00001068|DRUG|Lamivudine|
47925423|NCT04717206|OTHER|Plyomtric training to male badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
47925424|NCT04717206|OTHER|Plyomtric training to female badmninton players|"Plyometric training has been proven to be effective and effecient in developing strength and speed.~plyometric training includes different types hops,jumping,drills."
47925425|NCT05767567|BEHAVIORAL|Brief Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
47925426|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 1|
47925427|NCT01229917|OTHER|Fruit juice with Lactobacillus rhamnosus GG, version 2|
47925428|NCT01229917|OTHER|Standard fruit juice|
47925429|NCT01606657|PROCEDURE|Irrigation|The patient will receive irrigation as a part of their wound care
47925430|NCT01606657|OTHER|No Irrigation|The patient will not receive irrigation as part of their wound care
47925431|NCT03453372|DEVICE|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
47925432|NCT03453372|OTHER|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
47925433|NCT02816567|DRUG|propofol|
47925434|NCT02816567|DRUG|NMBA - cisatracurium|
47925435|NCT02816567|DRUG|placebo - isotonic saline serum|
47925436|NCT02816567|DRUG|sufentanil|
47925437|NCT02816567|PROCEDURE|laparoscopic surgery|
48271495|NCT00888355|DRUG|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
48271496|NCT00888355|DRUG|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
48271497|NCT01880411|BIOLOGICAL|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
48443809|NCT04507711|DRUG|100 ul of palonosetron|Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
47925438|NCT04805879|BIOLOGICAL|FMT oral Capsules|Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool donated by a healthy indvidual that was screened to have no mental health issues or chronic or contagious doseases. Each capsule will contain 0.67 ml of pelleted intestinal microbes. Therefore it is considered that the 20 capsules are equivalent to 100 grams of stool
47925439|NCT04805879|BIOLOGICAL|Placebo Capsules|Placebo Capsules that will look and weigh the same as the FMT oral capsules.
47925440|NCT02789319|DEVICE|Blood Glucose Meter Systems|
48271498|NCT06185855|OTHER|Retrospective Ultrasonographic Data Analysis|The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.
48271499|NCT04171609|BEHAVIORAL|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
48271500|NCT01070329|DRUG|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
48271501|NCT01070329|DRUG|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
48271502|NCT02342834|DIETARY_SUPPLEMENT|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
48271503|NCT02605525|BIOLOGICAL|SM101|Human soluble recombinant Fcγ Receptor IIB
48271504|NCT02605525|OTHER|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
48271505|NCT05808257|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
48271506|NCT05808257|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
48271507|NCT00692367|BEHAVIORAL|Physical Activity|1. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
48271508|NCT00167258|BEHAVIORAL|Voucher Reinforcement|
48271509|NCT00167258|BEHAVIORAL|Extra Counseling Services|
48271510|NCT00167258|BEHAVIORAL|Voucher Reinforcement + Extra Counseling Services|
47925441|NCT00170690|DRUG|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
47925442|NCT00170690|DRUG|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
47925443|NCT05222672|OTHER|His Bundle Pacing|Pacing of the His bundle
47925444|NCT04580810|BEHAVIORAL|CBT4CBT in the Black Church|Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
47925445|NCT04678687|PROCEDURE|Liver, lung, heart and kidney biopsy|Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.
47925446|NCT01073501|DRUG|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
47925447|NCT01073501|DRUG|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
47925448|NCT02968862|OTHER|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
47925449|NCT02612831|PROCEDURE|Early bariatric surgery|
48271511|NCT01244256|DRUG|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
48271512|NCT01244256|DRUG|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
48271513|NCT03135366|BEHAVIORAL|Keheala|
48271514|NCT03135366|OTHER|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
47925450|NCT02612831|PROCEDURE|Delayed bariatric surgery|
47925451|NCT03459690|BEHAVIORAL|Meditation|Isha Kriya meditation is simple meditation practice which can be easily learned by employing online guided tools. Isha Kriya meditation requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. Isha Kriya does not incorporate a spiritual or religious focus.
48271515|NCT02704598|DRUG|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
48271516|NCT02704598|DRUG|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
48271517|NCT03467178|DRUG|Decitabine|Nucleic Acid Synthesis Inhibitor
47925452|NCT03459690|DEVICE|Enobio 32- EEG machine|This study utilizes the Enobio 32 EEG device made by Neuroelectrics (an FDA-cleared 24-bit EEG data reader which is a wearable wireless device) to analyze EEG changes after subjects have undergone meditation. This study does not evaluate the Enobio device, and the IRB of record approved an Investigational Device Exemption for this study.
47925453|NCT05304936|DRUG|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
47925454|NCT03351101|DEVICE|Senofilcon C|Senofilcon C Contact Lens
47925455|NCT03351101|DEVICE|Samfilcon A|Samfilcon A Contact Lens
47925456|NCT03206164|OTHER|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
47925457|NCT05015413|DEVICE|Shockwave|Shock wave master 500 Germany
47925458|NCT01375075|DRUG|LY2484595|Administered orally
47925459|NCT01375075|DRUG|Placebo|Administered orally
47925460|NCT01375075|DRUG|Atorvastatin|Administered orally
47925461|NCT00740376|DEVICE|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
47925462|NCT00740376|DEVICE|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
47925463|NCT01467687|DRUG|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
47925464|NCT04612608|PROCEDURE|upright bed|moving the bed into an upright position
47925465|NCT01622634|BEHAVIORAL|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
47925466|NCT01622634|OTHER|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
48271518|NCT03467178|DRUG|Carboplatin|Chemotherapy medication
48271519|NCT03467178|DRUG|Pegylated Liposomal Doxorubicin|Chemotherapy medication
48271520|NCT03467178|DRUG|Gemcitabine|Chemotherapy medication
48271521|NCT03467178|DRUG|Paclitaxel|Chemotherapy medication
48271522|NCT06528600|DEVICE|Hymovis ONE|Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
48271523|NCT06528600|DEVICE|Monovisc|Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
48271524|NCT02145962|DEVICE|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
47925467|NCT01622634|OTHER|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
47925468|NCT03775538|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
47925469|NCT03775538|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
47925470|NCT00890045|DEVICE|HeRO Vascular Access Device|HeRO Vascular Access Device
47925471|NCT00890045|DEVICE|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
47925472|NCT05481957|DRUG|Vortioxetine|5-10mg for 16 weeks
47925473|NCT05481957|DRUG|valprote|500\~1000mg for 16 weeks
47925474|NCT01781273|OTHER|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
47925475|NCT01781273|OTHER|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
47925476|NCT02437123|BEHAVIORAL|The Cedar Project mHealth intervention|
48271525|NCT02145962|DEVICE|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
48271526|NCT01082484|DRUG|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
48271527|NCT01082484|DRUG|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
48271528|NCT01082484|DRUG|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
47925477|NCT04224688|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
47925478|NCT04224688|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
48095742|NCT06055595|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
47925479|NCT05944328|OTHER|systematic and structured review of patient pharmacotherapeutic treatment plans|"The intervention consisted of a systematic and structured review of patient pharmacotherapeutic treatment plans to identify problems or situations of risk related to pharmacological treatments and to propose changes or improvements to optimise them. phases:~Individualised review of pharmacological treatment plans to detect drug-related problems:~Indication, Appropriateness, Effectiveness, Safety When a drug-related problem was detected according to the above criteria, the pharmacist proposed an adjustment to the pharmacotherapeutic plan. The proposals could include: discontinuation of the drug, change of drug, change to a therapeutic equivalent, initiation of treatment, change of dosage, change of frequency or intensified monitoring.~The proposals made by the pharmacist were assessed and agreed upon by a committee comprising the doctors responsible and the pharmacist. Thereafter, the consensual proposals for change were discussed with the patient."
47925480|NCT02799251|OTHER|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
47925481|NCT00000724|DRUG|Trimetrexate glucuronate|
47925482|NCT00000724|DRUG|Leucovorin calcium|
47925483|NCT06191211|BEHAVIORAL|Motivational Interviewing, AIMS|Motivational interviewing (MI). MI is an approach to patient engagement which promotes a collaborative conversation style for strengthening a person's own motivation and commitment to change. With MI, the doctor facilitates patient exploration of potential reasons for behaviour change in the context of what is important to the patient, rather than the physician directly telling the patient what to do. MI has been found more effective than other approaches to patient engagement and health behaviour change and can be effectively taught to primary care providers.
47925484|NCT06191211|BEHAVIORAL|Facility engagement|A letter to the facility from the local health officials; a meeting with the facility manager and health staff to formally announce that we would like providers to encourage COVID-19 vaccinations; deploying a tracking sheet for vaccinations.
47925485|NCT03452475|DRUG|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
47925486|NCT03452475|DRUG|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
47925487|NCT03452475|DRUG|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
47925488|NCT05550207|DRUG|AXS-07 (meloxicam-rizatriptan)|AXS-07 tablets, taken orally for the acute treatment of migraine
47925489|NCT00565929|DRUG|Placebo|Sterile saline (0.9%).
47925490|NCT00565929|BIOLOGICAL|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.
47925491|NCT05676775|OTHER|No intervenetion|Observational inception cohort, with remote follow-up via participants and data record linkage
47925492|NCT06491966|OTHER|observation|data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.
47925493|NCT04503733|DRUG|Q4W GMA301 IV injections (300 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
47925494|NCT04503733|DRUG|Q4W GMA301 IV injections (600 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
47925495|NCT04503733|DRUG|Q4W GMA301 IV injections (1000 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
47925496|NCT04503733|DRUG|Q4W GMA301 IV injections (1800 mg)|Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
47925497|NCT04503733|OTHER|Q4W placebo IV injections|Placebo is indistinguishable from GMA301.
47925498|NCT04685174|DEVICE|Invos Model 5100C Cerebral/Somatic Oximeter|To measure the correlation between post arterial and venous anastomoses (reperfusion) NIRS values of transplanted kidney and post-transplant graft failure as manifested in initiation of renal replacement therapy post transplant
47925499|NCT00981942|DRUG|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
47925500|NCT00957125|DRUG|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
47925501|NCT00957125|DRUG|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
47925502|NCT00957125|DRUG|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
47925503|NCT05662709|PROCEDURE|Tooth extraction|Tooth extraction in the most atraumatic way
47925504|NCT05662709|PROCEDURE|Alveolar ridge preservation with L-PRF|Blood will be drawn from the patient, centrifugued and leukocyte and platelet-rich fibrin (L-PRF) will be obtained. L-PRF plugs and membranes will be prepared and placed in the socket after extraction
47925505|NCT06530472|OTHER|Monitoring|At baseline, 3, 6 and 12 months, people will undergo to both a psychological and cardiological assessment.
47925506|NCT01446614|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
47925507|NCT03679442|DRUG|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
47925508|NCT05667415|DRUG|disulfiram and cisplatin|on the first day of treatment, patients were given intravenous drip of 80mg/m2 cisplatin, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg disulfiram orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of disulfiram can be re-evaluated during the treatment, and the lowest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 3 weeks as a cycle.
47925509|NCT05667415|DRUG|cisplatin|on the first day of treatment, patients were given 80mg/m2 cisplatin intravenously, and 21 days was a course of treatment, lasting for 6 courses.
47925510|NCT04662970|DEVICE|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
47925511|NCT02395302|DEVICE|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
47925512|NCT03430453|PROCEDURE|Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
47925513|NCT00131924|BIOLOGICAL|esterified estrogens|
47925514|NCT00717704|DRUG|ixabepilone|by vein once every 3 weeks
47925515|NCT00717704|DRUG|Dasatinib|by mouth once daily
47925516|NCT03367247|BEHAVIORAL|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
47925517|NCT03367247|OTHER|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
47925518|NCT04774458|PROCEDURE|Fluoroscopic-guided cervical epidural access|After identifying the target level of the cervical spine under a fluoroscopy-guided anteroposterior image, an 18-Tuohy needle is inserted through a paramedian approach after local infiltration with 1% lidocaine. When feeling a strong resistance through the needle by a ligamentum flavum, the image intensifier is rotated to 50 degrees contralateral oblique (CLO) direction. After then, the needle is advanced to just before the ventral interlaminar line in CLO view. It is subsequently advanced further until it is in the epidural space using a LOR-to-air technique. Correct epidural access is confirmed by the injection of contrast medium. After identifying epidural space in AP and CLO view without abnormal dispersion of contrast,(vascular uptake, intrathecal spreads, etc.), a 3-4ml mixture of 0.5% lidocaine with dexamethasone 5mg is injected.
47925519|NCT02557477|DIETARY_SUPPLEMENT|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
47925520|NCT02557477|DIETARY_SUPPLEMENT|Placebo|Three placebo capsules twice daily
47925521|NCT01857596|DRUG|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
47925522|NCT00603486|DEVICE|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
47925523|NCT04118452|BEHAVIORAL|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
47925524|NCT05671809|OTHER|NCRT with surgery, or NCT with surgery, or surgery|The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.
47925525|NCT02674854|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop daily in the evening (PM) in both eyes (OU)
47925526|NCT02674854|DRUG|Netarsudil (AR-13324) ophthalmic solution 0.02%|1 drop daily in the evening (PM) in both eyes (OU)
47925527|NCT02674854|DRUG|Latanoprost ophthalmic solution 0.005%|1 drop daily in the evening (PM) in both eyes (OU)
47925528|NCT04825197|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
47925529|NCT01555385|DIETARY_SUPPLEMENT|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
47925530|NCT03469869|OTHER|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
47925531|NCT01671527|PROCEDURE|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
47925532|NCT00534313|DRUG|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
47925533|NCT00534313|DRUG|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
47925534|NCT02178839|DIETARY_SUPPLEMENT|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
47925535|NCT02178839|DIETARY_SUPPLEMENT|Maltodextrin|8.5 g/d Maltodextrin
47925536|NCT05429775|DRUG|Budesonide|single dose of 2 mg oral suspension formulation administered orally under fasting conditions
47925537|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
47925538|NCT00164944|PROCEDURE|Colonoscopy|To determine the adenomas during colonoscopy
47925539|NCT03849573|BEHAVIORAL|"OncoTool Intervention (MBSR + HT education)"|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
47925540|NCT03849573|BEHAVIORAL|"Oncotool Control (health +HT education)"|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
47925541|NCT00318942|DRUG|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
47925542|NCT00318942|DRUG|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
48271529|NCT04052841|PROCEDURE|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
47925543|NCT00318942|DRUG|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
47925544|NCT00318942|DRUG|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
47925545|NCT06088602|PROCEDURE|Cryoneurolysis|Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.
47925546|NCT06088602|PROCEDURE|Sham|The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
47925547|NCT00005862|DRUG|semaxanib|
47925548|NCT02730143|OTHER|Altitude exposure|Altitude exposure
48271530|NCT04052841|PROCEDURE|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
47925549|NCT02335671|PROCEDURE|Intra-operative Magnetic Resonance Imaging (MRI)|
47925550|NCT02335671|OTHER|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
47925551|NCT04924413|DRUG|Tislelizumab|PD-1 positive lymphocytes are isolated from peripheral blood and amplified for transfusion
47925552|NCT06221657|DRUG|Vemlidy|1 tablet once a day, oral administration
47925553|NCT06221657|DRUG|Virreal|1 tablet once a day, oral administration
47925554|NCT01820260|DRUG|Ingenol mebutate gel|
47925555|NCT01820260|DRUG|placebo|
48271531|NCT04052841|PROCEDURE|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
48271532|NCT00855439|DRUG|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
48271533|NCT00855439|DRUG|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
47925556|NCT06363305|DIETARY_SUPPLEMENT|Dietary capsules|Daily doses of dietary capsaicin or placebo in capsule form
47925557|NCT01409343|DRUG|TrasGEX™|Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
47925558|NCT04133922|DRUG|GLP-1|glucagon-like peptide 1
47925559|NCT04133922|DRUG|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
47925560|NCT04133922|DRUG|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
47925561|NCT06339476|DIAGNOSTIC_TEST|Serum ADMA, MDA and M30 levels mesurment|Blood samples collected from patienst, only 7 mL
47925562|NCT04145843|PROCEDURE|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
47925563|NCT02057588|PROCEDURE|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
47925564|NCT02767362|DRUG|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
47925565|NCT04064008|DEVICE|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
47925566|NCT04905498|BEHAVIORAL|Commercial Advertising Literacy Training|"Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy."
47925567|NCT04905498|BEHAVIORAL|Control|Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
47925568|NCT02396160|DIETARY_SUPPLEMENT|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
47925569|NCT02396160|OTHER|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
47925570|NCT05772988|DIETARY_SUPPLEMENT|Beta-alanine|Beta-alanine
47925571|NCT05772988|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
47925572|NCT04571528|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.
47925573|NCT04571528|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
47925574|NCT04571528|BEHAVIORAL|TAU + Physiotherapy part of VIRTUAL FIBROWALK|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
47925575|NCT03505931|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
47925576|NCT02195414|DEVICE|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
47925577|NCT05979545|DIAGNOSTIC_TEST|Rapid Diagnostics|Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
47925578|NCT00802815|DRUG|Etanercept|50 milligrams subcutaneously every week
47925579|NCT06272175|OTHER|Open Kinetic Chain Activity|PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.
47925580|NCT06272175|OTHER|Closed Kinetic Chain Activity|Weight-bearing on the hemiplegic hand with extended elbow in standing position
47925581|NCT01642875|OTHER|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
47925582|NCT01642875|OTHER|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
47925583|NCT02747979|OTHER|hemodialysis only|hemodialysis treatment only
47925584|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
47925585|NCT02747979|OTHER|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
47925586|NCT02762773|PROCEDURE|non-dissection of inferior rectus sheath|Non-dissection of inferior rectus sheath
47925587|NCT02762773|PROCEDURE|control|Dissection of inferior and superior aspect of the rectus sheath
47925588|NCT03199755|DRUG|ACT|Current approved drug for treating malaria
47925589|NCT03199755|DRUG|DLA1|Experimental drug treatment, single dose.
47925590|NCT03199755|DRUG|DLA2|Experimental drug treatment, doubled the dose of DLA1.
47925591|NCT00851968|PROCEDURE|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
47925592|NCT00851968|PROCEDURE|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
47925593|NCT00851968|PROCEDURE|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
47925594|NCT06329128|OTHER|Experimental: Study Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary.~In the manual therapy group, in addition to the above treatment, manual therapy will be given 3 days a week. The content of the manual therapy program is as follows;~* Patellofemoral joint superior-inferior mobilization~* Medial-lateral mobilization with active knee flexion~* Tibiofemoral joint ventral (anterior-posterior) mobilization~* Tibiofemoral traction mobilization"
48271534|NCT04802473|PROCEDURE|Mucogingival surgery|In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
48271535|NCT02237690|DRUG|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
47925595|NCT06329128|OTHER|Active Comparator: Control Group|"A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary."
47925596|NCT01027806|DRUG|Montelukast|1 pill per day for 4 months
47925597|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein concentrate|Protein concentrate treatment
47925598|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean protein isolate|Protein isolate treatment
47925599|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean starch|Starch treatment
47925600|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with added faba bean flour|Flour treatment
47925601|NCT02658591|DIETARY_SUPPLEMENT|Crackers/pasta with no faba bean fraction|Control treatment
47925602|NCT04248725|BEHAVIORAL|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
47925603|NCT05480345|DIAGNOSTIC_TEST|Impedance cardiography|Transthoracic impedance cardiography recorded with ICG monitor (niccomoTM; Medis, Ilmenau, Germany): electrodes attached to both sides of the patient's neck (4 electrodes in total) and along the midaxillary line of the left and right sides of the chest (4 electrodes in total), employing the xyphoid process as a reference line.
47925604|NCT04473235|BEHAVIORAL|Literacy training|Teaching adults how to read and write using the analytical and phonemic method
47925605|NCT04473235|BEHAVIORAL|Non-Literacy training|Attending classes in geography, history, sciences, without receiving the specific training in literacy
47925606|NCT01374035|OTHER|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
47925607|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Day 1 in SAD stage
47925608|NCT05308940|DRUG|TB001|once-daily subcutaneous injection, on Days 1-7 in MAD stage
47925609|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Day 1 in SAD stage
47925610|NCT05308940|DRUG|Placebo|once-daily subcutaneous injection, on Days 1-7 in MAD stage
47925611|NCT02819908|DRUG|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
47925612|NCT02819908|DRUG|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
47925613|NCT04108117|PROCEDURE|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
47925614|NCT03636841|DEVICE|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
47925615|NCT00799851|DEVICE|Variceal band ligation|
47925616|NCT00799851|DRUG|cyanoacrylate injection|cyanoacrylate injection
47925617|NCT02878057|DRUG|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
47925618|NCT04914013|OTHER|no intervention|no intervention
47925619|NCT03495583|OTHER|Early introduction|Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
47925620|NCT04803682|BEHAVIORAL|Preventive Intervention|Participate in ASPIRE and mentorship program
47925621|NCT04803682|BEHAVIORAL|Questionnaire Administration|Ancillary studies (pre and post questionnaire)
47925622|NCT03452449|PROCEDURE|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
47925623|NCT05503745|OTHER|CBT-F+MIT|The aim is to develop healthier strategies for managing negative thoughts and feelings antecedent to ED and for engaging patients in social interactions that meet their relational basic wishes. They will thus understand that perfectionism and the need for control they experience through ED are coping strategies developed within interpersonal patterns of interaction with significant others, where low self-esteem and emotive dysregulation play a central role. MIT aims to improve individuals' capacity to make sense of their own affect and cognitions and become aware of being driven by maladaptive, rigid and biased schemas about self and others, to form a richer understanding of the mind of the others and use this knowledge to react in more adaptive ways to social difficulties or evolutionary selected wishes. MIT also enables individuals to reflect on how these schemas may act as triggers for ED behavior and to develop more effective coping strategies in face of interpersonal stressors.
47925624|NCT05503745|OTHER|CBT-E|In the first Stage, the treatment will be focused on achieving a shared understanding of the patient's eating disorder and the related maintenance factors. In this phase the patient will be helped to regulate and stabilize his eating habits and so to address his weight concerns. In the second stage, progress made is reviewed in detail. In the third stage, the sessions will be focused on the central processes that are maintaining the psychopathology of the patient's eating disorder. In particular, this involves in addressing concerns about weight and body shape, cognitive and caloric dietary restriction, events and emotions that affect nutrition. In phase three and four clinical perfection, low global self-esteem, intolerance of emotions and interpersonal difficulties are also addressed. Towards the end of the third stage and during the fourth stage, procedures will be also implemented to minimize the risk of short- and long-term relapse.
47925625|NCT04514783|DEVICE|Debridement with Debritom+ micro water jet device|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~* Debridement using Debritom+ micro water jet technology~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
47925626|NCT04514783|OTHER|Debridement with|"Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Debridement using scalpel and curette~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)"
47925627|NCT03137667|OTHER|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
47925628|NCT02645838|BEHAVIORAL|Motivational interviewing|1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
47925629|NCT05270447|OTHER|Massage and patient education|"Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off."
47925630|NCT05270447|BEHAVIORAL|Routine care and advising|Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
47925631|NCT01055873|BIOLOGICAL|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
47925632|NCT06080672|OTHER|Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)|All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
47925633|NCT03753581|DEVICE|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
48271536|NCT05358132|DEVICE|Pneumowave Device placement and data capture|"Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,"
47925634|NCT03753581|DEVICE|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
47925635|NCT01149954|DRUG|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
47925636|NCT04851093|DRUG|TCM granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks."
47925637|NCT04851093|DRUG|TCM placebo granule plus conventional drug|"All patients will receive conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.~Placebo Yiqiwenfei granule for qi deficiency and internal cold fluid syndrome.~Placebo Fuzhengqinghua granule for qi and yin deficiency and unclean phlegm heat syndrome.~Placebo Fuzhengzaohua granule for lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome.~TCM placebo granule (Jiangyin Tian Jiang Pharmaceutical Co.,Ltd, 10g/packet) will be administered twice daily for 8 weeks.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The placebo granule consists of dextrin, bitter and 5% of the TCM granule."
47925638|NCT03127982|BEHAVIORAL|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
47925639|NCT01661582|OTHER|CT/PET Myocardial Perfusion Imaging using O-15 water|
47925640|NCT01661582|OTHER|Coronary blood flow measured by doppler echocardiography|
47925641|NCT04647981|OTHER|Xpert® Bladder Cancer Monitor Test|The urine sample is analyzed with the Xpert® Bladder Cancer Monitor test.
47925642|NCT02858544|OTHER|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
47925643|NCT02858544|OTHER|ImPACT|Patient- completed computerized neurocognitive test battery
47925644|NCT04617431|BEHAVIORAL|Mobile health application and social media|"The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps."
47925645|NCT04811300|OTHER|There is no intervention|There is no intervention
47925646|NCT03706924|DRUG|VM-1500FDC|A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
47925647|NCT03706924|DRUG|Elpida®|Elpida®, capsules, elsulfavirine 20 mg
47925648|NCT03706924|DRUG|Truvada®|Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
47925649|NCT04896450|PROCEDURE|Guided tissue regeneration (GTR)|GTR is handled with the utilization of a coronally advanced flap, followed by a thorough debridement of the denudated root surface and the intrabony component. Regenerative materials are resorbable collagen membrane (BioGide, Geistlich Phara AG, Wolhusen, Switzerland) and deproteinized bovine bone mineral (BioOss, Geistlich Phara AG), finally surgery is finished with multilayer suturing technique.
47925650|NCT04896450|DEVICE|Orthodontic tooth movement (OTM)|An early initialization of the tooth movement with the help of a multibond fixed orthodontic device utilizing low level of continuous orthodontic forces.
47925651|NCT05407740|OTHER|no intervention study|no intervention study
48271537|NCT04061083|DEVICE|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
48271538|NCT04061083|DEVICE|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
47925652|NCT02836639|DRUG|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
47925653|NCT02836639|DRUG|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
47925654|NCT02836639|DRUG|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
47925655|NCT04074876|DEVICE|Pulmonary echography|"Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~* 0: normal pattern (A-lines)~* 1: multiple B lines (at least 3 for field), well defined.~* 2: B lines coalescent~* 3: consolidation of any dimension"
47925656|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).
48271539|NCT03843047|DRUG|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
48271540|NCT03843047|DRUG|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
48271541|NCT03843047|DRUG|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
47925657|NCT01429337|DRUG|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
47925658|NCT00289029|DRUG|Iopamidol 370 mgI/mL|
47925659|NCT06255678|DIAGNOSTIC_TEST|Angiography-based vessel fractional flow reserve (vFFR) calculation|vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
47925660|NCT02058745|BEHAVIORAL|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
47925661|NCT02058745|BEHAVIORAL|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
47925662|NCT02058745|BEHAVIORAL|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
47925663|NCT00571402|BEHAVIORAL|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
47925664|NCT00571402|BEHAVIORAL|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
47925665|NCT02672020|BIOLOGICAL|omics identity card|
47925666|NCT04613778|PROCEDURE|Laser acupuncture|Laser acupuncture is a low-level laser technique with no invasive procedure
47925667|NCT00773045|OTHER|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
47925668|NCT02228616|DRUG|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
47925669|NCT02228616|DRUG|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
48271542|NCT03843047|DRUG|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
47925670|NCT02228616|DRUG|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
48271544|NCT04568850|DIAGNOSTIC_TEST|Plasma IgG levels|Plasma IgG levels of subjects who tested reactive for IgG SARS CoV-2 antibodies will be monitored every month for 4 months for IgG levels
48271545|NCT05560737|BEHAVIORAL|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~* Automated digital counselling resources (educational pages, videos, tools, and trackers)~* Chatrooms available 24/7~* Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
47925671|NCT00329849|BIOLOGICAL|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
47925672|NCT00329849|BIOLOGICAL|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
47925673|NCT00045942|DRUG|Itraconazole|Itraconazole was commercially available.
47925674|NCT00045942|DRUG|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
47925675|NCT04083729|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
47925676|NCT01917877|DRUG|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
47925677|NCT01917877|DRUG|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
47925678|NCT03448874|DEVICE|Seal-G MIST System|Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
47925679|NCT01129583|DRUG|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
48271546|NCT02300493|BEHAVIORAL|Experimental|Asked to weigh themselves
48271547|NCT06461598|DRUG|Chemotherapy|All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
47925680|NCT01129583|DRUG|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
47951250|NCT03875768|BEHAVIORAL|Tracking plus coaching|Participants will track their nutrition intake every day for six months using a study app and receive tailored feedback via text message based on their nutritional intake and adherence to the DASH dietary pattern. If necessary, they will receive responsive coaching from a Nourish registered dietitian in order to increase adherence to the DASH dietary pattern and their engagement with the intervention.
47951251|NCT03402113|DRUG|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
47925681|NCT05516563|OTHER|EDucation and eXercise intervention|"The exercise programme includes 3 key streams:~1. Low-load isometric abduction~2. Functional loading~3. Abductor loading: Graduated abductor loading, designed to improve load tolerance by applying progressively higher loads across the abductor muscles. Daily exercise will be completed three days a week at a 'hard' to 'very hard' level, alternating with three 'light' days and one rest day. The clinic day will constitute one of the 'hard' days.~Education will be delivered via a 20 minute video which focusses on understanding and managing lateral hip pain ( ie pain associated with gluteal tendinopathy). Education will also be tailored to each patient on attendance with the physiotherapist at the 6 clinic visits"
47925682|NCT01343901|DRUG|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
47925683|NCT02412514|BIOLOGICAL|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
47925684|NCT02412514|BIOLOGICAL|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
47925685|NCT02412514|BIOLOGICAL|IPV|IPV administered at 6 weeks of age
47925686|NCT00435500|DRUG|Fluoride varnish|
47925687|NCT00425178|DRUG|FGF-1|
47925688|NCT05410756|DIAGNOSTIC_TEST|Assessment of Voice Quality and Function|An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
47925689|NCT02589600|DRUG|Zoledronic acid|Annual intravenous 5.0 mg
47925690|NCT02589600|DIETARY_SUPPLEMENT|vitamin D|800 IU daily
48106777|NCT00662324|BEHAVIORAL|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes."
48271548|NCT02818699|DIETARY_SUPPLEMENT|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
47925691|NCT02589600|DIETARY_SUPPLEMENT|calcium|approximately 1200 mg (dietary and supplement)
47925692|NCT02589600|OTHER|Saline|Annual intravenous saline placebo
47925693|NCT00977457|GENETIC|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
47925694|NCT00977457|GENETIC|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
47925695|NCT00977457|GENETIC|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
47925696|NCT00977457|GENETIC|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
47925697|NCT00977457|GENETIC|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
48271549|NCT02818699|DIETARY_SUPPLEMENT|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
47925698|NCT00977457|OTHER|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
47925699|NCT00977457|PROCEDURE|therapeutic conventional surgery|
47925700|NCT03707275|DEVICE|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
47925701|NCT03707275|OTHER|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
48271550|NCT06050135|OTHER|Roadmap to Parenthood|web-based decision support
48271551|NCT06050135|OTHER|Informational Booklet|web-based informational booklet about young adult cancer survivorship
47925702|NCT00407680|DRUG|Intensive therapy Valsartan,Fluvastatin|
47925703|NCT02078076|DEVICE|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
47925704|NCT02086643|PROCEDURE|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
47925705|NCT02518464|DRUG|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
47925706|NCT05299853|OTHER|Robot assisted arm training|Patients will receive 30 minutes of robot-assisted arm training and 30 minutes of conventional arm rehabilitation training. Patients will undergo 30 sessions of combined therapy (robotic+conventional) for a total of 6 weeks (5 sessions/week).
48271552|NCT03595202|DRUG|TS-143|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
48271553|NCT03595202|DRUG|Placebo|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
48271554|NCT06418178|DRUG|Midomafetamine|One to five MDMA-assisted therapy sessions, each followed by three non-drug psychotherapy sessions (see behavioral intervention below)
48271555|NCT06418178|BEHAVIORAL|Psychotherapy|Standardized psychotherapy performed by therapy team
48271556|NCT04539093|OTHER|Exposure of interest - Use of left ventricular assist device (LVAD)|Mechanical circulatory support devices such as left ventricular assist device is used as a treatment option for patients with end-stage heart failure.
48271557|NCT04030078|OTHER|Survey|Questionnaire-based survey
48271558|NCT04214652|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
48271559|NCT04214652|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
48271560|NCT05266404|DRUG|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
48271561|NCT05266404|DRUG|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
48271562|NCT05266404|DRUG|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
48271563|NCT04472728|DRUG|BIO101|BIO101 capsules
48271564|NCT04472728|DRUG|Placebo|placebo capsules
48271565|NCT02857218|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
48271566|NCT02857218|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
47925707|NCT05299853|OTHER|Conventional rehabilitation|Patients will receive 30 sessions of conventional arm training (60 minutes/day) for a total of 6 weeks (5 sessions/week).
47925708|NCT04605614|RADIATION|Copper Cu 64-DOTA-pembrolizumab|Given IV
48271567|NCT02077790|DEVICE|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
48271568|NCT02235649|BEHAVIORAL|Social Cognition therapy ( Psychological Therapy)|
48271569|NCT00699179|DRUG|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
48271570|NCT06278688|DIETARY_SUPPLEMENT|Precision probiotics|The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
48271571|NCT00312455|DRUG|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
48271572|NCT00312455|DRUG|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
48271573|NCT00312455|DRUG|Placebo|5 capsules/day
48271574|NCT01485614|DRUG|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
48271575|NCT01485614|DRUG|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
48271576|NCT01485614|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
48271577|NCT01485614|DRUG|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
48271578|NCT01485614|DRUG|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
48271579|NCT01485614|BIOLOGICAL|Glycemic Rescue 2|Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
48271580|NCT02906254|OTHER|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
48271581|NCT02906254|OTHER|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
48271582|NCT04741373|DIETARY_SUPPLEMENT|oral nutritional supplements|oral nutritional supplements, 400-600kcal/day;
48271583|NCT04741373|BEHAVIORAL|rehabilitation exercise|Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
48271584|NCT04741373|OTHER|health education|Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
48271585|NCT06088927|DEVICE|Conduction system pacing|Conduction system pacing (His Bundle Pacing or Left Bundle Branch Area Pacing)
48271586|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
47925709|NCT04605614|BIOLOGICAL|Pembrolizumab|Given IV
47925710|NCT04605614|PROCEDURE|Positron Emission Tomography|Undergo PET
47951252|NCT03402113|DRUG|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
48271587|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
48271588|NCT04769791|DEVICE|intracuff pressure measurement|intracuff pressure is measured by a pressure manometer
48271589|NCT01077765|DEVICE|Eutrophill|Polyacrylamide Hydrogel
48271590|NCT03526289|BIOLOGICAL|GIP1-42 infusion|5-hour GIP1-42 infusion (time point 0-300 minutes)
48271591|NCT03526289|OTHER|Saline|5-hour infusion of saline (placebo) (time point 0-300 minutes)
48271592|NCT02913313|DRUG|BMS-986207|Specified dose on specified days
48271593|NCT02913313|BIOLOGICAL|Nivolumab|Specified dose on specified days
48271594|NCT02913313|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48271595|NCT02673229|DRUG|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
48271596|NCT02673229|DRUG|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
48271597|NCT00260520|DRUG|Dalteparin|
48271598|NCT01903265|DRUG|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
48271599|NCT01903265|DRUG|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
47925711|NCT03841578|DIETARY_SUPPLEMENT|Healthy|25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
47925712|NCT06148649|DRUG|HEC88473, Placebo, Dulaglutide|T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
47925713|NCT01369329|DRUG|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
47925714|NCT01369329|DRUG|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight \> 55 kg and \<= 85 kg), and 520 mg (weight \> 85 kg).
47925715|NCT01369329|DRUG|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
47925716|NCT01101308|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
47925717|NCT01101308|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
47925718|NCT04559711|OTHER|Strengthening coverage and quality of nutrition services during ANC|Intervention clusters will receive inputs both at facility level and community level. The supply side inputs will include efforts for improving facility readiness, quality of nutrition services during ANC, multiple micronutrient supplementation(MMS) and strengthening monitoring and supervision for ANC. On the other hand, community mobilization interventions will be carried out for demand creation. All public health facilities providing ANC services in the intervention area will be included; Union Health \& Family Welfare Center, Community Clinic and Satellite Clinic.
47925719|NCT02823444|OTHER|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
47925720|NCT01214057|DRUG|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
47925721|NCT01214057|DRUG|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
48271600|NCT02858427|BEHAVIORAL|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
47925722|NCT06092229|DIAGNOSTIC_TEST|Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
47925723|NCT06092229|DIAGNOSTIC_TEST|Ultrasonography with TACA approach|identification of the cricothyroid membrane, using ULTRASONOGRAPHY with TACA approach , a procedure used to prepare for front of neck airway access
47925724|NCT04857229|DEVICE|Histolog Scanner|Confocal Microscope
47925725|NCT01306578|DRUG|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
47925726|NCT01306578|PROCEDURE|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
47925727|NCT03416062|DRUG|Remaxol®|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
47925728|NCT03416062|DRUG|Ringer's Solution|Solution for intravenous infusion, 400 or 800 ml
47925729|NCT02051699|PROCEDURE|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
47925730|NCT04992858|DRUG|CT053PTSA|CT053PTSA will be administered orally once a day
47925731|NCT01410617|PROCEDURE|hemodialysis|3 sessions hemodialysis before CABG
47925732|NCT04241978|OTHER|Patient Decision Aid (PtDA)|Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
47925733|NCT04241978|OTHER|Brochure with general information about osteoarthritis|Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
48271601|NCT02858427|BEHAVIORAL|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
47951253|NCT02090075|DRUG|apixaban|5 po or 2.5 po bid.
48271602|NCT02858427|BEHAVIORAL|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
48271603|NCT02858427|BEHAVIORAL|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
48271604|NCT00024427|DRUG|fluorouracil|High dose 5-FU
48271605|NCT00024427|DRUG|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
48271606|NCT00024427|DRUG|triacetyluridine|6 grams (12 tablets)
48271607|NCT05332860|PROCEDURE|Congenital Cardiovascular Surgery|Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
48271608|NCT03499730|DRUG|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
48095743|NCT04550156|PROCEDURE|Colorectal Bundle|"1. Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~2. Preoperative showering with an antiseptic agent~3. Administer preoperative antibiotic prophylaxis~4. Hair removal in the operative field with clippers~5. Peri-, intra-, and postoperative warming to maintain body temperature~6. Peri- and intraoperative glucose control~7. Usage of a wound protection device~8. Change of gloves and instruments after anastomosis~9. Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures"
48095744|NCT04448743|OTHER|Blood sample|20 Ml blood sample
48095745|NCT01986374|DRUG|HCG is introduced|must have good blastocysts
48095746|NCT06061484|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|Standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
48095747|NCT06061484|DRUG|Amoxicillin|Standard weight-based dosing per Ehtiopian national guidelines
48095748|NCT00691158|DRUG|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
48095749|NCT00691158|DRUG|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
48095750|NCT00691158|DRUG|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
48095751|NCT00691158|DRUG|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
47925734|NCT00299468|BEHAVIORAL|Patient Activation Measure Intervention Package|
48095752|NCT05153174|DRUG|Sulforaphane|This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.
48095753|NCT03922243|OTHER|retrospective|Retrospective study to assess treatment done by dental students
48095754|NCT03771885|DRUG|BI 705564|Film-coated Tablet
48095755|NCT03771885|DRUG|Placebo|Film-coated Tablet
48095756|NCT01773122|DRUG|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
48095757|NCT01773122|DRUG|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
48095758|NCT01773122|DRUG|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
48095759|NCT01773122|DRUG|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
48095760|NCT06458738|DEVICE|Printable denture base material|The newly developed printable denture base material will be used for the production of dentures.
48271609|NCT00709202|DRUG|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
48271610|NCT00709202|DRUG|Placebo Oral Tablet|
48095761|NCT00253240|PROCEDURE|Screening|
48095762|NCT00253240|PROCEDURE|Management|
48095763|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
48095764|NCT02322216|DRUG|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
47925735|NCT01909791|PROCEDURE|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
47951254|NCT02090075|DRUG|warfarin|
47951255|NCT03061383|OTHER|8% Arginine based toothpaste|toothpaste
48095765|NCT02322216|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
48095766|NCT00713934|BIOLOGICAL|CD133|portal vein infusion of CD133+ cells
48095767|NCT00713934|BIOLOGICAL|BM-MNC|portal vein infusion of BM-MNC
48095768|NCT05223413|DEVICE|RIPC|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.
48095769|NCT05223413|DEVICE|Simulated RIPC (Sham)|The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.
48095770|NCT00785772|DRUG|Gabapentin|100-200mg once a day
48095771|NCT00785772|DRUG|Gabapentin|200-500mg once a day
48095772|NCT00785772|DRUG|Gabapentin|400-1000mg (200-500 mg twice a day)
48095773|NCT06196528|DEVICE|WristArt implant|implantation of the WristArt implant
48095774|NCT03916380|DIETARY_SUPPLEMENT|Grapefruit Juice|Single 8 ounce administration of oral grapefruit juice
48095775|NCT03047590|BEHAVIORAL|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
48095776|NCT03047590|BEHAVIORAL|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
47925736|NCT01909791|DRUG|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
47925737|NCT01909791|PROCEDURE|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
47925738|NCT01909791|DRUG|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
47925739|NCT02248558|BEHAVIORAL|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
47925740|NCT02248558|BEHAVIORAL|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
47925741|NCT02890108|DIETARY_SUPPLEMENT|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
47925742|NCT02890108|DIETARY_SUPPLEMENT|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
47925743|NCT03372759|PROCEDURE|airtamponade|airtamponade is applicated in the study group air
47925744|NCT03372759|PROCEDURE|saline|saline is left in the study Group saline
47925745|NCT05639244|BEHAVIORAL|Time restricted eating (TRE)|Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.
47925746|NCT05639244|BEHAVIORAL|Regular diet|Participants have to consume their regular diet within an unrestricted time period for 2 weeks
47925747|NCT03830723|DRUG|Follitropin delta|Study medication doses during all 3 insemination will be personalized using a suggested algorithm
48095777|NCT03047590|BEHAVIORAL|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
48095778|NCT02735915|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
48095779|NCT06614686|DRUG|U87 autologous CAR T-cell|Treatment with U87 chimeric antigen receptor T-cell infusion.
48271611|NCT05110079|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening."
47925748|NCT02631382|PROCEDURE|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
47925749|NCT04045418|DEVICE|Laser doppler|"A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively."
47925750|NCT00557817|DRUG|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to \> 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases \< 13 g/dL. If the Hb decreases to \< 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
47925751|NCT00557817|DRUG|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin \> 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS \> 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation \< 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
47925752|NCT03996369|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
47925753|NCT03996369|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
47925754|NCT05562401|DEVICE|Coconut Water|Coconut water is the clear fluid inside the coconut, has natural electrolytes such as potassium, sodium and manganese.
47925755|NCT05562401|DRUG|Sport Drink|A type to sport drink is isotonic drink. Is an industrialized drink that containing water, carbohydrates, and 4-8% electrolytes.
47925756|NCT04468529|DRUG|Recombinant human Neuregulin for injection|10 hours per day i.v. drip for the first 10 days (0.6ug/kg/day)
47925757|NCT04468529|DRUG|Placebo|10 hours per day i.v. drip for the first 10 days (0ug/kg/day)
47925758|NCT01075633|PROCEDURE|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
47925759|NCT01075633|PROCEDURE|Colonoscopy with sedation|Colonoscopy with sedation
48095780|NCT00395811|PROCEDURE|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
48095781|NCT03201809|DEVICE|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
48271612|NCT02507804|OTHER|Patient diary PROMs|
48271613|NCT02507804|OTHER|Counselling|
48271614|NCT06018701|DEVICE|"A dental device made of zirconia. This is a new invention and does not exist generically. The given generic name of the invention (dental device) is Dantya Nikhan."|Dental device is surgically placed and cemented with PMMA bone cement on edentulous region.
47925760|NCT05337904|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
47925761|NCT05337904|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
47925762|NCT00347256|DRUG|cisplatin|
47925763|NCT00347256|PROCEDURE|targeted radiation therapy|
48271615|NCT02666326|PROCEDURE|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is \<9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is \<14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
48271616|NCT00315861|DRUG|pemetrexed|
47925764|NCT00347256|PROCEDURE|tumor resection|
48095782|NCT03201809|DRUG|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
47925765|NCT03609593|DRUG|Bendamustine|Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
48095783|NCT01720043|DRUG|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
48095784|NCT02317705|DRUG|OTL38|
48095785|NCT02317705|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
48095786|NCT02317705|PROCEDURE|Laparotomy|primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
48095787|NCT00472147|PROCEDURE|shock efficacy|
48095788|NCT03286725|BEHAVIORAL|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
48095789|NCT02920398|DRUG|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
48271617|NCT00315861|DRUG|topotecan|
47925766|NCT03609593|DRUG|Venetoclax|"Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration."
47925767|NCT03609593|DRUG|Rituximab|For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
47925768|NCT02192424|DRUG|Metformin alone|
47925769|NCT02192424|DRUG|Metformin + Intermittent Insulin Therapy|
47925770|NCT06013215|OTHER|Cochlear implant (Oticon) stimulation parameter optimization|The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
47925771|NCT03438721|BEHAVIORAL|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
47925772|NCT03438721|BEHAVIORAL|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
48095790|NCT01922570|DIETARY_SUPPLEMENT|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
48095791|NCT01343654|BEHAVIORAL|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
48095792|NCT01343654|BEHAVIORAL|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
48095793|NCT05684003|OTHER|Neuromuscular exercise based injury-prevention program|Neuromuscular exercise based injury-prevention program
48106778|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
47925773|NCT02444000|DRUG|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
47925774|NCT02444000|DRUG|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
47925775|NCT00884767|DRUG|FOLFOX regimen|
47925776|NCT00884767|DRUG|fluorouracil|
47925777|NCT00884767|DRUG|leucovorin calcium|
47925778|NCT00884767|DRUG|oxaliplatin|
47925779|NCT00884767|GENETIC|gene expression analysis|
47925780|NCT00884767|GENETIC|protein expression analysis|
47925781|NCT00884767|GENETIC|proteomic profiling|
47925782|NCT00884767|OTHER|laboratory biomarker analysis|
47925783|NCT00884767|OTHER|pharmacogenomic studies|
48106779|NCT02135341|DRUG|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
48106780|NCT06294704|OTHER|bariatric surgery|Having undergone bariatric surgery and on a closed-loop insulin pump after bariatric surgery
48106781|NCT02047851|OTHER|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
48106782|NCT03441360|DRUG|Eribulin mesylate|Intravenous infusion
48106783|NCT05273281|PROCEDURE|Transabdominal plane block|Peripheral nerve block
47925784|NCT02224118|DRUG|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
47925785|NCT02224118|DRUG|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
47925786|NCT02224118|DRUG|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
47925787|NCT02224118|DRUG|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
47925788|NCT02224118|DRUG|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
47925789|NCT01388556|BEHAVIORAL|Tango dancing|Twice weekly tango dance classes
47925790|NCT02700334|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
47925791|NCT02700334|DRUG|Placebo|one per day before breakfast during 12 weeks.
47925792|NCT04607798|DEVICE|Radiofrequency and pulsed electro-magnetic fields treatment|Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.
47925793|NCT03721029|DEVICE|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
47925794|NCT03721029|PROCEDURE|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
47925795|NCT03294577|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
47925796|NCT03294577|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
47925797|NCT03294577|OTHER|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
47925798|NCT03294577|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
47925799|NCT04585009|DRUG|GSK3923868|GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
47925800|NCT04585009|DRUG|Matching placebo|Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
47925801|NCT04585009|DEVICE|Monodose RS01|Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
47925802|NCT04555967|DEVICE|SAPIEN 3 Ultra System|Transcatheter aortic valve implantation
47925803|NCT00562900|PROCEDURE|robotic assisted cholecystectomy|robotic assisted cholecystectomy
47925804|NCT00562900|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
47925805|NCT04399460|OTHER|Dairy-based commercially available food products|Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses
47925806|NCT04399460|OTHER|Restrictive Eating|Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein
47925807|NCT03489954|OTHER|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
47925808|NCT00182585|PROCEDURE|computer-based HIV, STD & Hepatitis Education|
47925809|NCT00182585|PROCEDURE|educator-delivered HIV, STD and Hepatitis education|
47925810|NCT04620798|BEHAVIORAL|Immediate vs. delayed provision of antibody test results|The primary experiment will be assessing whether provision of the antibody test results leads to behavior change with respect to personal protective behaviors. To that end, we will randomize all participants to a trial arm that immediately receive results (within 24 hours) or a trial arm with a delayed provision of results (after 4 weeks).
47925811|NCT02337231|DIETARY_SUPPLEMENT|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
47925812|NCT03138993|BEHAVIORAL|Patient decision aid|Web-based patient decision aid plus a paper workbook.
47925813|NCT03138993|BEHAVIORAL|General sleep education|Web-based information about sleep plus a paper workbook
47925814|NCT01708096|DIETARY_SUPPLEMENT|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
47925815|NCT01708096|DIETARY_SUPPLEMENT|Normal diet|normal diet 2 weeks before gastric by-pass
47925816|NCT05212129|DEVICE|Percutaneous vagal nerve stimulation (pVNS) device|Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).
47951256|NCT03061383|OTHER|8% strontium acetate based toothpaste|toothpaste
47951257|NCT03061383|OTHER|placebo|toothpaste
48271618|NCT02620020|DRUG|Fasinumab|Participants received fasinumab SC or IV, Q4W or Q8W.
47951258|NCT05076396|DRUG|PM14|PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
48106784|NCT05273281|PROCEDURE|Quadratus lumborum block|Peripheral nerve block
48271619|NCT02620020|DRUG|placebo|Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
47925817|NCT05212129|OTHER|Acoustic vagal nerve stimulation (aVNS) treatment|All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.
47925818|NCT01887054|DEVICE|Tower of Hanoi|
47925819|NCT01887054|OTHER|Placebo group - non use of Tower of Hanoi|
47925820|NCT03838809|DEVICE|surface electromyography-biofeedback|Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
47925821|NCT00052442|DRUG|pralatrexate|
47925822|NCT02230488|OTHER|Intensive Diabetes Case Management|"A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~--------------------------------------------------------------------------------"
47925823|NCT03605602|OTHER|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
47925824|NCT01382147|DRUG|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
47925825|NCT04111562|PROCEDURE|Cranioplasty|Bone grafts
47925826|NCT01282970|DRUG|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
47925827|NCT01282970|DRUG|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
47925828|NCT00002289|DRUG|Thymopentin|
47925829|NCT00473122|PROCEDURE|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
47925830|NCT03310333|DRUG|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
47925831|NCT03310333|DEVICE|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
47925832|NCT04717830|DRUG|Gamezumab|solution for infusion
47925833|NCT00154323|DRUG|Oxcarbazepine|
47925834|NCT00002501|BIOLOGICAL|filgrastim|
47925835|NCT00002501|DRUG|cyclophosphamide|
47925836|NCT06210360|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14 day cycle
47925837|NCT06210360|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14 day cycle
47925838|NCT06210360|DRUG|5-FU|2400 mg/m² continuous IV infusion in 46 h
47925839|NCT06210360|DRUG|LV|400 mg/m² on Day 1 of a 14 day cycle
47925840|NCT02929654|DEVICE|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
48106785|NCT05824377|OTHER|Continuous Feeds|Continuous feeds will be delivered via an indwelling nasogastric/orogastric tube with a continuous infusion pump.
47925841|NCT02929654|DEVICE|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
47925842|NCT02929654|DEVICE|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
47925843|NCT00710762|DRUG|BIBF1120|
47925844|NCT00710762|DRUG|Placebo|
47925845|NCT03356704|OTHER|no intervention|Observational study
47925846|NCT02642549|BEHAVIORAL|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
47925847|NCT04571983|OTHER|Blood Eosinophil counts - comparing historical with stable state|Comparing historical blood eosinophil counts over 24 months to stable state eosinophil count.
47925848|NCT05955573|DIAGNOSTIC_TEST|xray|radiological description
47925849|NCT05449015|DRUG|1% atropine|Daily application can be used for mydriasis and refraction examination Weekly long-term application can be used to control myopia
47925850|NCT00973297|OTHER|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
48106786|NCT05824377|OTHER|Intermittent Bolus Feeds|Intermittent bolus feedings will be given by gravity every 3 hours over 15- 30 minutes.
47925851|NCT02962843|BEHAVIORAL|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 \& 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills \& Problem Solving.
47925852|NCT00828100|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
47925853|NCT00828100|DEVICE|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A \& B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
47925854|NCT05424432|DRUG|Neoadjuvant Chemotherapy|Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
47925855|NCT05424432|DRUG|Neoadjuvant Toripalimab|Toripalimab 240mg every 3 weeks for two cycles (D2,D23)
47925856|NCT05424432|RADIATION|Short Course Neoadjuvant Radiotherapy|30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
47925857|NCT03515954|PROCEDURE|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
47925858|NCT01120782|DEVICE|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
47925859|NCT01120782|DEVICE|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
47925860|NCT02524834|PROCEDURE|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
47925861|NCT02524834|DEVICE|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
47925862|NCT00969982|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
47925863|NCT00969982|DRUG|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
47925864|NCT04075812|DEVICE|Neuromuscular Stimulator|
47925865|NCT04751214|PROCEDURE|APPENDICECTOMY|
47925866|NCT00545285|PROCEDURE|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
47925867|NCT04311593|DIAGNOSTIC_TEST|CD4, CD19, CD38, CD56 and CD11b|measuring CD markers by flowcytometry
47925868|NCT03115281|DEVICE|PCI|PCI
47925869|NCT00561860|DEVICE|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
47925870|NCT03796520|DIAGNOSTIC_TEST|EpiPick simplified seizure classification algorithm|"EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age \> 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain."
47925871|NCT02762227|DEVICE|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
47925872|NCT02762227|DEVICE|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
47925873|NCT02762227|PROCEDURE|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
47925874|NCT03985878|DRUG|Eteplirsen|Eteplirsen IV infusion once weekly.
47925875|NCT04641689|DEVICE|Desk Only|Provision of height-adjustable desk
47925876|NCT04641689|BEHAVIORAL|Program Only|Online modules will promote goal setting, self-monitoring, habit formation, social support, barrier identification, and environmental modifications
47925877|NCT01517360|DRUG|Oxytocin|Oxytocin 40 IU, intranasal inhalation
47925878|NCT01517360|OTHER|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
48095794|NCT06416280|OTHER|Assessment of the TRiP(cast) score|"In patients presenting to the emergency department with trauma to a lower limb, the TRiP(cast) score is assessed in accordance with the recommendations. If the patient does not object. The attending physician will then be asked to fill in his implicit assessment of the risk of venous thromboembolism on a paper CRF and then to complete his assessment of the TRiP(cast) score. He will then be free to decide whether or not to anticoagulate the patient.~At the same time, a doctor not involved in the patient's care will assess the TRiP(cast) score and record it on a paper CRF. The second doctor's assessment will be independent and will have no impact on the patient's management.~The CRFs will then be analysed and stored. Data will be anonymised during data collection and each patient will be assigned an anonymity number."
48095795|NCT06378372|BEHAVIORAL|Music therapy based on piano learning|The intervention will consist of pianistic training. Patients will receive piano classes adapted to their competence designed to achieve motor, sensory and behavioral control.
48095796|NCT03458780|DRUG|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
48271620|NCT04113967|OTHER|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
48271621|NCT00005630|BIOLOGICAL|ras peptide cancer vaccine|
48271622|NCT00005630|BIOLOGICAL|sargramostim|
47925879|NCT01517360|BEHAVIORAL|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
47925880|NCT04404218|DIETARY_SUPPLEMENT|Açaí palm berry extract - natural product|Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.
47925881|NCT04404218|OTHER|Placebo|Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.
47925882|NCT00613067|DRUG|escitalopram|"* Start with escitalopram 10mg~* According to patient's symptoms, stay on 10mg or increase up to 20mg~* Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~* Length of washout period will be at least 2 weeks for any psychotropic drugs"
47925883|NCT06328478|DEVICE|Observational prospective study.|Observational prospective study
47925884|NCT00918996|PROCEDURE|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
47925885|NCT04982003|OTHER|exercise|10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
47925886|NCT05711446|OTHER|Double Voiding|Participant will be instructed to void twice.
47925887|NCT05711446|OTHER|Regular Voiding|Participant will void as usual
47925890|NCT02834845|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
47925891|NCT02834845|DRUG|Desflurane|Desflurane %6-8 for general anesthesia maintenance
47925892|NCT02292901|DEVICE|Macintosh laryngoscope|
47925893|NCT02292901|DEVICE|McGrath Mac videolaryngoscope|
47925894|NCT00390026|DRUG|Bevacizumab (Avastin)|
47925895|NCT00390026|DRUG|Verteporfin photodynamic therapy (PDT)|
47925896|NCT03681223|DEVICE|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
47925897|NCT03681223|DEVICE|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
47925898|NCT03681223|PROCEDURE|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
47925899|NCT03681223|PROCEDURE|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
47925900|NCT05253001|DEVICE|smartphone|Use the mobile chatbot approach for intervention groups to improve prenatal education.
47925901|NCT00753740|DRUG|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
47925902|NCT00753740|DRUG|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
48106787|NCT03145337|BIOLOGICAL|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
48271623|NCT00448292|DRUG|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
48271624|NCT00448292|DRUG|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
47925903|NCT00753740|DRUG|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
47925904|NCT01512667|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
47925905|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
47925906|NCT00479271|BEHAVIORAL|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
47925907|NCT04424329|DIETARY_SUPPLEMENT|Fibers and probiotics|A blend of fibers and seven probiotics
47925908|NCT02428127|DIETARY_SUPPLEMENT|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
47925909|NCT02428127|DIETARY_SUPPLEMENT|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
47925910|NCT02428127|OTHER|Water|lukewarm water
47925911|NCT02242591|DRUG|Ropivacaine 7,5 mg/ml|
47925912|NCT02242591|DRUG|Saline|
47925913|NCT04407572|OTHER|Serum zinc, vitamin d vitamin b12 levels .|Serum zinc, vitamin d vitamin b12 levels of 45 patients will be measured and evaluated together with the information of the patients.
47925914|NCT00493857|DRUG|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
47925915|NCT00493857|DRUG|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
47925916|NCT01210417|OTHER|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
47925917|NCT00769327|DRUG|imatinib mesylate|
47925918|NCT00769327|DRUG|nilotinib|
47925919|NCT00769327|GENETIC|cytogenetic analysis|
47925920|NCT00769327|GENETIC|fluorescence in situ hybridization|
47925921|NCT00769327|GENETIC|microarray analysis|
47925922|NCT00769327|GENETIC|mutation analysis|
47925923|NCT00769327|GENETIC|polymerase chain reaction|
47925924|NCT00769327|GENETIC|polymorphism analysis|
47925925|NCT00769327|OTHER|laboratory biomarker analysis|
47925926|NCT03852680|PROCEDURE|aneurysm clipping|treatment of wide necked intracranial aneurysms using different modalities as open surgery by clipping or endovascular techniques as coiling and flow diversion
47925927|NCT00471614|DRUG|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
47925928|NCT03842982|DRUG|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
47925929|NCT00520585|DRUG|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
47925930|NCT01491594|DRUG|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
47925931|NCT00680719|BEHAVIORAL|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
47925932|NCT00680719|BEHAVIORAL|IBFT|Integrated Behavioral and Family Therapy (IBFT).
47925933|NCT05059288|DEVICE|Investigational Non Invasive Ventilation Mask|Oronasal non invasive ventilation mask
47925934|NCT04504058|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
47925935|NCT04493528|COMBINATION_PRODUCT|Meso-Jet, 2% lidocaine(xylocaine)|Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.
47925936|NCT04493528|COMBINATION_PRODUCT|Needle,2% lidocaine(xylocaine)|Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
47925937|NCT04628377|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
47925940|NCT01286961|DRUG|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
47925941|NCT00811213|DEVICE|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
47925942|NCT00811213|DEVICE|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
47925943|NCT05661747|DEVICE|Vivos Grow/Vivos Way Device|Children already using the device will be monitored to determined whether it improves symptoms of SDB
47925944|NCT00642889|DRUG|Safinamide|
47925945|NCT00642889|DRUG|Safinamide|
48271625|NCT00388947|DEVICE|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
48271626|NCT02358811|DEVICE|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~* Before any examination, the manipulator will check the absence of contraindication to MRI.~* During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~* Throughout the examination, a physician will always be present."
48271627|NCT02358811|BEHAVIORAL|Cognitive assessment|"This cognitive assessment will include the following executive tests :~* test of Stroop~* left Trail Making Test A and B~* verbal fluence test~* test of memory of figures direct and inverse in order~* completion of matrices~* Paced Auditory Serial Addition Test (PASAT)"
48271628|NCT03141944|OTHER|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
48271629|NCT01970176|DRUG|Tadalafil|Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is \>95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.
48271630|NCT01970176|DRUG|Placebo|Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is \>95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is\> 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is \> 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.
48271631|NCT00582894|DRUG|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
48271632|NCT01246206|DRUG|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
48271633|NCT06376721|DRUG|Linperlisib|Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.
48271634|NCT06376721|DRUG|Camrelizumab|Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.
48271635|NCT06376721|DRUG|Pegaspargase|"Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle.~Camrelizumab for Injection should not be applied on the same day as Dexamethasonee."
48271636|NCT06376721|DRUG|Dexamethasone|Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
48271637|NCT02512458|DRUG|Cabazitaxel|
48271638|NCT04217395|BEHAVIORAL|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, \& Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
48271639|NCT05858190|PROCEDURE|Parallel Assignment|intervention group: treated with drug eluting balloon（paclitaxel-coated balloon； Orchid, Acotec Scientific Holdings Limited, Beijing, China)； control group :treated with plain old balloon
48271640|NCT05827796|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
48271641|NCT05827796|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
48271642|NCT05827796|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
48271643|NCT05827796|DRUG|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
48271644|NCT00578123|BEHAVIORAL|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
47925946|NCT00642889|DRUG|Placebo|
47925947|NCT00330161|DRUG|vorinostat|Given orally
47925948|NCT00330161|OTHER|laboratory biomarker analysis|Correlative studies
47925949|NCT02878356|BEHAVIORAL|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
48106788|NCT03145337|BIOLOGICAL|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
48271645|NCT01012908|DIETARY_SUPPLEMENT|Norzyme - Bergamo|2 - 8 tablets per day.
48271646|NCT01012908|DIETARY_SUPPLEMENT|Creon|2 - 8 tablets pet day
48271647|NCT02002702|DRUG|Serelaxin|Intravenous infusion
48271648|NCT02002702|DRUG|Placebo|Placebo
47925950|NCT02878356|BEHAVIORAL|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
47925951|NCT02878356|BEHAVIORAL|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
47925952|NCT02682979|OTHER|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
47925953|NCT05824143|DRUG|Darigabat|Oral tablet
47925954|NCT05824143|DRUG|Carbamazepine|Oral tablets
47925955|NCT04204980|DRUG|Daratumumab dose escalation|- Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
47925956|NCT04204980|DRUG|Daratumumab full dose|- Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
47925957|NCT00129311|DRUG|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
47925958|NCT00129311|DRUG|Placebo|
47925959|NCT04503187|BEHAVIORAL|Visuomotor leg reaching task|Similar to a hand reaching task in which participants were asked to reach to a tea-cup, in a visuomotor leg reaching task, participants will be seated and given real-time visual feedback about their leg movements via a cursor display on a computer screen. The task is to control a foot mouse/marker attached to the foot and move the cursor from a start location to the target displayed on a wall screen. Three different targets, equidistant from the start location at top, top-left, and top-right screen positions, will be used for leg reaching. In each trial, one of three targets will be randomly presented and subjects will be instructed to make forward, or rightward, or leftward foot reaches to guide the cursor to one of the targets. Throughout the entire experiment, subjects are blocked from viewing leg movements by a cardboard.
47925960|NCT01426542|DRUG|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
47925961|NCT01426542|OTHER|No medication, but routine heart surgery|No medication, but routine heart surgery
47925962|NCT05577520|PROCEDURE|Sinus floor augmentation|
47925963|NCT00357760|BIOLOGICAL|VEGF Trap|Given IV
47925964|NCT02490020|BIOLOGICAL|mesenchymal stem cell|
47925965|NCT02778360|DEVICE|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics."
47925966|NCT02778360|DRUG|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
47925967|NCT01180179|DRUG|Lansoprazole|30mg once daily
47925968|NCT01180179|DRUG|Famotidine|40mg once daily
47925969|NCT00128323|DRUG|Gentian violet 1% solution|
47925970|NCT00128323|DRUG|Gentian violet 0.00165% solution|
47925971|NCT00128323|DRUG|Nystatin solution|
47925972|NCT04673279|DIAGNOSTIC_TEST|serology|An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
47925973|NCT00523263|DEVICE|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
47925974|NCT00523263|DEVICE|Human umbilical vein femoro-popliteal bypass|
47925975|NCT04967040|PROCEDURE|medial plantar artery flap|Medial plantar artery flap is a fasciocutaneous island flap raised from the non-weightbearing instep of the plantar foot. The dominant vascular pedicle of the flap consists of the medial plantar artery and venae comitantes
47925976|NCT04967040|PROCEDURE|Distally based sural artery flap|Distally based sural artery flap is a fascio-cutaneous island flap taken from the posterior aspect of the middle third of the leg and fed by the lower peroneal septo-cutaneous perforators in reverse fashion. Its vascular basis is the close association between the median superficial sural artery and peroneal artery perforators
47925977|NCT00679445|DEVICE|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
47925978|NCT01892384|DRUG|Placebo|matching placebo
47925979|NCT01892384|DRUG|BI 409306|BI 409306
47925980|NCT02243462|DEVICE|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
47925981|NCT02243462|OTHER|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
48271649|NCT02078349|DRUG|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
48271650|NCT00424398|DRUG|Bepreve|sterile ophthalmic solution
48271651|NCT00424398|DRUG|Placebo|sterile ophthalmic solution
48271652|NCT00424398|DRUG|Bepotastine Besilate|sterile ophthalmic solution
48271653|NCT05758090|PROCEDURE|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score \> 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score \< 50 indicates inadequate narcotic and narcotic should be given.
47925982|NCT00660881|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
47925983|NCT04879147|DIAGNOSTIC_TEST|Evalution of thyroid function|Determination of TSH, free T4, free T3, SPINA-GT, SPINA-GD and Jostel's TSH index
47925984|NCT00755300|PROCEDURE|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
47925985|NCT03229343|OTHER|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
47925986|NCT02847676|PROCEDURE|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
47925987|NCT02727231|DEVICE|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
47925988|NCT02727231|DEVICE|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
47925989|NCT03844711|OTHER|Transcutaneous electrical diaphragmatic stimulation (TEDS)|"* Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~* Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue."
47925990|NCT03844711|OTHER|Inspiratory Muscle Training (IMT)|- Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
47925991|NCT03844711|OTHER|Conventional physiotherapy|- Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
47925992|NCT03994029|DIETARY_SUPPLEMENT|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
47925993|NCT04598256|PROCEDURE|Endoscopic procedure|Esophagogastroscopy and colonoscopy
47925994|NCT05370183|PROCEDURE|Hyperambulatory tenotomy|Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia
47925995|NCT05370183|PROCEDURE|Operating room tenotomy|Operating room tenotomy is performed according standard practice, with general anesthesia.
47925996|NCT00934843|DRUG|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
47925997|NCT00934843|DRUG|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
47925998|NCT01788410|PROCEDURE|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
47925999|NCT01788410|DEVICE|MRI Seednet Cryotherapy System (Galil Medical)|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
47926000|NCT04121078|DRUG|TAK-906|TAK-906 capsule.
47926001|NCT04121078|DRUG|Rifampin|Rifampin infusion.
47926002|NCT03561532|OTHER|Fecal microbiota transplantation (FMT)|FMT administered into the cecum of the patient in colonoscopy.
47926003|NCT03561532|OTHER|Placebo|Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
48106789|NCT06229717|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
47926004|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (\~710mL) daily for three weeks, along with their habitual diets.
47926005|NCT04118257|DIETARY_SUPPLEMENT|Sugary beverage: Soda|Participants consumed soda (\~710mL) daily for three weeks, along with their habitual diets.
47926006|NCT04118257|DIETARY_SUPPLEMENT|Control: Water|Participants consumed water (\~710mL) daily for three weeks, along with their habitual diets.
47926007|NCT03468569|OTHER|Functional Movement Screen|
47926008|NCT01886027|BEHAVIORAL|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
47926009|NCT01886027|BEHAVIORAL|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
47926010|NCT03740984|OTHER|Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.|During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
47926011|NCT03430076|PROCEDURE|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
47926012|NCT03430076|DEVICE|Propaten®|Propaten®
47926013|NCT03430076|DEVICE|Crude PTFE|Crude PTFE
47926014|NCT03283605|RADIATION|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
47926015|NCT03283605|DRUG|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
47926016|NCT03283605|DRUG|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
47926017|NCT02815826|OTHER|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
47926018|NCT02815826|OTHER|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
47926019|NCT02143050|DRUG|Dabrafenib|
47926020|NCT02143050|DRUG|Trametinib|
47926021|NCT02143050|DRUG|Metformin|
47926022|NCT00315757|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
47926023|NCT00315757|BIOLOGICAL|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
47926024|NCT00315757|DRUG|Bortezomib|1.3 mg/m\^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
47926025|NCT04839575|DRUG|Latiglutenase|Administered orally (daily)
47926026|NCT04839575|DRUG|Placebo|Administered orally (daily)
48271654|NCT05758090|PROCEDURE|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
48271655|NCT01798914|DRUG|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
47926027|NCT00709579|DRUG|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
47926028|NCT00709579|DRUG|Placebo|placebo
48271656|NCT02281890|OTHER|Proven sepsis|Exposure is proven sepsis
48271657|NCT01290887|DRUG|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
48271658|NCT01466842|PROCEDURE|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
48271659|NCT05641701|DEVICE|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
48271660|NCT05641701|DEVICE|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
48271661|NCT01272583|DRUG|Sitagliptin|100 mg once daily for six weeks
48271662|NCT01272583|DRUG|Placebo|placebo, once daily for six weeks
47926029|NCT03229174|DRUG|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
47926030|NCT03229174|DRUG|Placebo|Placebo (sugar pill)
47926031|NCT06151080|DRUG|Lenalidomide combined with G-CHOP (LO CHOP)|Lenalidomide combined with G-CHOP to treat newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL)
47926032|NCT02245425|OTHER|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
47926033|NCT02245425|OTHER|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
47926034|NCT01337999|OTHER|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
47951259|NCT03688009|BEHAVIORAL|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
47951260|NCT03688009|BEHAVIORAL|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
47951261|NCT02554942|DRUG|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
48271663|NCT06381193|DIETARY_SUPPLEMENT|Probiotic|oral, daily
48271664|NCT06381193|DIETARY_SUPPLEMENT|Prebiotic|oral, daily
48271665|NCT06381193|DIETARY_SUPPLEMENT|Probiotic + Prebiotic|oral, daily
48271666|NCT06381193|DIETARY_SUPPLEMENT|Placebo|oral, daily
48271667|NCT00211003|DRUG|doripenem|
48271668|NCT03093402|DRUG|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
48271669|NCT03093402|DRUG|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
47926035|NCT05956444|OTHER|Neurodevelopmental Therapy (NDT)|In the treatment program; vestibular and proprioceptive training on the balance board; dynamic balance training in sitting with eyes open and closed, kneeling upright and standing; balance exercises in front of the mirror; standing on one leg with eyes open and closed to increase proprioceptive input; vestibular and proprioceptive training on exercise balls of the appropriate size; balance training on the trampoline; footpad sensory stimulation with different materials; weight-bearing training in sitting, crawling, kneeling and standing positions; functional reaching and throwing-holding exercises in different positions; multitasking pieces of training; gait exercises in various ways and training for climbing and descending stairs appropriate to the child's situation (assisted, unaided, symmetrical, reciprocal) took place.
47926036|NCT05956444|OTHER|Conventional Physiotherapy|Classical physiotherapy applications for balance.
47926037|NCT02817399|DEVICE|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
47926038|NCT02817399|DEVICE|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
47926039|NCT02817399|PROCEDURE|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
47926040|NCT04910308|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
47926041|NCT01122264|DRUG|Tadalafil|Administered orally for 24 weeks.
47926042|NCT01122264|DRUG|Sildenafil Citrate|Administered orally for 24 weeks.
48095797|NCT04483882|DEVICE|Tactile Labels for Drug identity and dose frequency|The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
48095798|NCT01668342|BEHAVIORAL|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
47926043|NCT01378546|DRUG|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
47926044|NCT00348608|DRUG|iodixanol|
47926045|NCT05779371|BEHAVIORAL|Integrated-based Laughing Qigong Program|The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
47926046|NCT06370715|DRUG|Insulin Lispro-aabc|Administered SC
47926047|NCT06370715|DRUG|Insulin Glargine|Administered SC
47926048|NCT00349700|PROCEDURE|Compression: 2 weeks four layer bandages, then stockings|
47926049|NCT00349700|PROCEDURE|debridement|
47926050|NCT00349700|PROCEDURE|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
47926051|NCT04600011|OTHER|Physical and occupational therapy (PT/OT)|"Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk."
48095799|NCT05866510|DRUG|Utidelone and anlotinib|"Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days."
47926052|NCT04600011|OTHER|Home Safety Evaluation (HSE)|The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
47926053|NCT04105478|PROCEDURE|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
47926054|NCT04564300|PROCEDURE|Training|Both groups will perform a standardized training protocol
47926055|NCT02279407|DRUG|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
47926056|NCT02279407|DRUG|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
47926057|NCT02279407|DRUG|Dapagliflozin|10 mg administered as 10 mg tablet
47926058|NCT02279407|DRUG|Placebo|Placebo matching to dapagliflozin 10 mg
47926059|NCT05680116|DEVICE|MYOVOLT (MyovoltTM, Myovolt Limited, Christchurch, New Zealand ) wearable vibration therapy device|Patients will wear Myovolt shoulder device twice a week and each session will continue 30minutes. This therapy will apply during the radiotherapy process. The device will be applied on the bare skin of the shoulder area. The first 10 minutes of the 30 minutes will be intermittent vibration, the other 20 minutes will be done in the sinusoidal vibration program. Both programs will be in the range of 20-100 Hz.
47926060|NCT05680116|OTHER|Home based exercise|Patients will do home based exercise during the radiotherapy process. 5 days a week. 2 sessions a day, each exercise will be 10x2 repetitions
47926061|NCT04043624|DRUG|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
47926062|NCT04043624|DRUG|Saline|IV bolus of saline, followed by continuous infusion of saline
47951262|NCT04592107|DIAGNOSTIC_TEST|eGFR|estimated glomerular filtration rate
47951263|NCT00211484|DRUG|Anecortave Acetate|
47951264|NCT03038451|DRUG|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
47926063|NCT04944056|OTHER|conventional physiotherapy|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
47926064|NCT04944056|OTHER|compression mobilization|"* Ultrasound therapy 3-4 minutes.~* Tibiofemoral AP and PA glides 1 set x10reps x 3 sets.~* Patellar glides 1 set x 5 reps x 3 sets.~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Compression mobilization 1 set x 10 reps x 3sets.~Home plan:~* Quads isometrics 1 set x 10 reps.~* Hams self stretching 1 sets x 10 reps.~* Active range of motion."
47926065|NCT02047344|DRUG|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
47926066|NCT06427083|DRUG|Envlo Tablet|Enavogliflozin 0.3mg
48095800|NCT04994262|OTHER|Menthol Lozenge|"In the study, Oka Menthol, a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.~Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant."
48095801|NCT01174329|DEVICE|"Automatic neuro-electrostimulation by Saliwell Crown"|"Continuous stimulation of the lingual nerve by Saliwell Crown"
48095802|NCT01174329|DEVICE|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"On-demand stimulation of the lingual nerveby Saliwell Crown"
48095803|NCT00303849|DRUG|Carboplatin|Given IA
48095804|NCT00303849|DRUG|Etoposide|Given IV
47926067|NCT06427083|DRUG|Envolomet SR Tablet|Enavogliflozin 0.3mg/Metformin1,000mg
47926068|NCT03033147|DRUG|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment
47926069|NCT03033147|DRUG|Oral placebo|placebo 30 minutes before root canal treatment
48095805|NCT00303849|DRUG|Etoposide Phosphate|Given IV
48095806|NCT00303849|OTHER|Laboratory Biomarker Analysis|Correlative studies
48095807|NCT00303849|DRUG|Mannitol|Given IA
47926070|NCT01837576|DRUG|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
47926071|NCT00646932|DRUG|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
47926072|NCT00646932|DRUG|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
47926073|NCT00646932|DRUG|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
47926074|NCT00646932|DRUG|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
47926075|NCT03156647|DIAGNOSTIC_TEST|Level of alpha-synuclein|Test of levels of total and ratio total:oligomeric in saliva
47926076|NCT01466829|DRUG|Parathyroid hormone|100 microgram daily. S.c
47926077|NCT01466829|DRUG|Placebo|Placebo; saline injection.
47926078|NCT01845623|DRUG|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
47926079|NCT01845623|DRUG|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
47926080|NCT01845623|OTHER|Placebo Concept 1|Placebo administered via the Concept 1 device.
47926081|NCT01845623|OTHER|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
47926082|NCT01794195|BEHAVIORAL|Diffusion tensor imaging and fibres tracking|
47926083|NCT03772002|DIAGNOSTIC_TEST|HCV screening|HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
47926084|NCT02154828|BEHAVIORAL|Integrative practices|
48095808|NCT00303849|DRUG|Melphalan|Given IA
48095809|NCT00303849|OTHER|Quality-of-Life Assessment|Ancillary studies
48095810|NCT00303849|DRUG|Sodium Thiosulfate|Given IV
48095811|NCT03658941|PROCEDURE|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
48095812|NCT03658941|PROCEDURE|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
48095813|NCT06614829|DEVICE|Stratafix Suture|Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.
48095814|NCT06614829|DEVICE|DERMABOND PRINEO|"DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days.~Dermabond Prineo system will be applied to the skin for skin closure."
48095815|NCT05916885|OTHER|short-intensity modified CIMT and conventional therapy|an experimental group receiving short-intensity modified CIMT and conventional therapy
48095816|NCT05916885|OTHER|conventional therapy alone|a control group receiving conventional therapy alone.
48095817|NCT03199885|DRUG|Atezolizumab|Given IV
48095818|NCT03199885|PROCEDURE|Biopsy|Undergo biopsy
48095819|NCT03199885|PROCEDURE|Bone Scan|Undergo bone scan
48095820|NCT03199885|PROCEDURE|Computed Tomography|Undergo CT scan
48095821|NCT03199885|DRUG|Docetaxel|Given IV
48095822|NCT03199885|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48095823|NCT03199885|DRUG|Paclitaxel|Given IV
48095824|NCT03199885|BIOLOGICAL|Pertuzumab|Given IV
48095825|NCT03199885|OTHER|Placebo Administration|Given IV
48095826|NCT03199885|OTHER|Quality-of-Life Assessment|Ancillary studies
48095827|NCT03199885|BIOLOGICAL|Trastuzumab|Given IV
47926085|NCT00745589|DRUG|sevelamer hydrochloride|First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
47926086|NCT03853824|OTHER|Increased postoperative surveillance|Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
47926087|NCT03853824|OTHER|Usual postoperative care|Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
47926088|NCT04631094|OTHER|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
47926089|NCT04631094|OTHER|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
47926090|NCT04631094|OTHER|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
47926091|NCT04631094|OTHER|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
47926092|NCT04656899|BEHAVIORAL|Reminders messages to improve adherence.|"If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose."
47926093|NCT01900912|OTHER|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
47926094|NCT00627952|DRUG|amlodipine 10 mg|amlodipine 10 mg once daily
47926095|NCT00627952|DRUG|manidipine 20 mg|manidipine 20 mg once daily
47926096|NCT00627952|DRUG|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
47926097|NCT00627952|DRUG|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
47926098|NCT00513825|DRUG|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
47926099|NCT03538171|DRUG|Entinostat|Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.
47926100|NCT03538171|DRUG|Placebo|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
47926101|NCT03538171|DRUG|Exemestane|Exemestane PO once daily on day 1-28.
47926102|NCT05796830|OTHER|Puzzle application|Five expert opinions will be taken for the puzzle application to be applied after the surgery, and the application and difficulty level of the puzzle will be decided.
47926103|NCT00745849|DRUG|esomeprazole|40mg by mouth twice daily
47926104|NCT00745849|DRUG|placebo|
47926105|NCT03786627|OTHER|Combined NMES and motor control|This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
47926106|NCT03786627|OTHER|Motor control and placebo NMES|This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
47926107|NCT04316910|DRUG|General anesthetic|General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
48095828|NCT01994161|PROCEDURE|intracranial stenting|"all the participants in this group will be performed with intracranial stenting~--------------------------------------------------------------------------------"
47926108|NCT02275884|DIETARY_SUPPLEMENT|Dark chocolate (85% cocoa)|
47926109|NCT02275884|DIETARY_SUPPLEMENT|White chocolate (0% cocoa)|
47926110|NCT00322985|DRUG|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
47926111|NCT04008927|DIAGNOSTIC_TEST|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
47926112|NCT04008927|DIAGNOSTIC_TEST|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL). In addition a measure of the liver stiffness will be performed.
47926113|NCT04008927|DRUG|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
47926114|NCT02361476|DRUG|Clonidine|Injection - during surgery
47926115|NCT02361476|DRUG|Placebo|Injection - during surgery
47926116|NCT06455267|DIETARY_SUPPLEMENT|Now Foods L-Ornithine Capsules|L-ornithine is an amino acid that helps the liver clear toxic ammonia and plays an important role in liver protection and treatment of hepatic encephalopathy. Now Foods L-ornithine capsules are an ornithine supplement containing 500mg of L-ornithine per capsule. Patients in the L-ornithine supplementation group take ornithine capsules orally twice a day, three capsules each time, for 8 weeks.
47926117|NCT01470989|DRUG|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
47926118|NCT01470989|DRUG|Triamcinolone acetonide 40 mg|Participants received 40 mg intramuscular (IM)
47926119|NCT02486341|DRUG|Insulin|Continuous glucose monitoring system over 120-hour period.
47926120|NCT01718418|OTHER|test meal|
47926121|NCT01718418|OTHER|reference|
47926122|NCT00790309|PROCEDURE|Weight loss surgery|Weight loss surgery
47926123|NCT00790309|PROCEDURE|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
47926124|NCT05953441|OTHER|AI-powered doctor|AI-powered virtual doctor
47926125|NCT05953441|OTHER|Human-controlled doctor avatar|Virtual doctor avatar controlled by the medical student.
47926126|NCT03540719|PROCEDURE|Osteosynthesis|Osteosynthesis of posterior tibial plateau fracture with a posterior tibial plateau plate
47926127|NCT02278523|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
47926128|NCT02342418|DRUG|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
48271670|NCT04232826|BIOLOGICAL|single dose of CNCT19|"Dose A: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
48271671|NCT00188578|PROCEDURE|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
47926129|NCT06476639|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound monitoring|Participants in the Interventional Group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, participants will receive a groin node ultrasound every 2 months and a clinical examination every 3 months, for a follow up period of 12 months. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
47926130|NCT03209674|PROCEDURE|Cardiothoracic surgery|Cardiac or thoracic procedure
47926131|NCT05845697|OTHER|Trigger point dry needling|Filiform needle that pierces the skin and is inserted into an identified trigger point in the muscle
47926132|NCT05845697|OTHER|Sham dry needling|A validated sham dry needle that is blunted on the end and does not pierce the skin
47926133|NCT04326101|OTHER|Transmission of adherence records|Electronic transmission of patient adherence records by pharmacists into medical EHR (Electronic Health Records)
47926134|NCT03343418|DRUG|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
48271672|NCT00079378|DRUG|decitabine|Given IV
48271673|NCT00079378|DRUG|valproic acid|Given orally
48271674|NCT00079378|OTHER|pharmacological study|Correlative studies
48271675|NCT00079378|OTHER|laboratory biomarker analysis|Correlative studies
48271676|NCT00323284|DEVICE|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
47926135|NCT03343418|DRUG|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
48271677|NCT00323284|PROCEDURE|Cataract surgery only|Cataract surgery only
48271678|NCT00252330|DRUG|SR58611A|
48271679|NCT04668508|DRUG|Anlotinib|concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
48271680|NCT01618760|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
48271681|NCT01618760|DRUG|Risperidone|1 mg tablet once a day
48271682|NCT00675025|DRUG|Donepezil hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
48271683|NCT02198833|BIOLOGICAL|Urine Culture|Obtain urine culture every third day
48271684|NCT02198833|DEVICE|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
48271685|NCT02198833|DEVICE|Scanning Electron Microscopy|Houston Site Only
47926136|NCT01418508|BEHAVIORAL|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
47926137|NCT01418508|BEHAVIORAL|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
47926138|NCT00619320|BEHAVIORAL|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
47926139|NCT04156542|BEHAVIORAL|Basic School Lunchroom Nudges|"The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and \[School Mascot\] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers."
47926140|NCT01135563|DRUG|Vinblastine and Sirolimus|"Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough"
47926141|NCT02600871|DRUG|Provodine|
48271686|NCT02198833|PROCEDURE|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
48271687|NCT02198833|PROCEDURE|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
48271688|NCT03529409|BEHAVIORAL|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
48271689|NCT06547957|DRUG|EOS301984|Multiple doses of EOS301984
48271690|NCT06547957|DRUG|Anti-PD-1 monoclonal antibody|Multiple doses of EOS301984 in combination with Anti-PD-1
48271691|NCT00342368|PROCEDURE|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
48271692|NCT00714779|DRUG|Fluoxetine|20-40 mg / day orally
48271693|NCT00714779|BEHAVIORAL|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
48271694|NCT03160560|DRUG|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
47926142|NCT02600871|PROCEDURE|Incision and Drainage|
47926143|NCT04933643|OTHER||
47926144|NCT02876250|DRUG|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
47926145|NCT02876250|DRUG|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
47926146|NCT03263650|DRUG|Cabazitaxel|25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
47926147|NCT03263650|DRUG|Carboplatin|AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
47926148|NCT03263650|DRUG|Prednisone 5Mg|5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
48095829|NCT06487364|OTHER|Rehabilitation|A routine physical therapy program prescribed by a specialist physician and physiotherapist will be applied.
48271695|NCT03160560|DRUG|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
48271696|NCT03160560|OTHER|Placebo|Subjects in Placebo group will receive Placebo Rinse.
48271697|NCT06281392|DEVICE|CADe system|Colonoscopy assisted by an artificial intelligence system (CADe).
48271698|NCT06281392|DEVICE|NBI|Virtual colonoscopy assisted by NBI
48271699|NCT03980340|BEHAVIORAL|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
48271700|NCT03980340|BEHAVIORAL|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
48271701|NCT00533962|DRUG|Anterior Juxtascleral Depot of Anecortave Acetate|
48271702|NCT02533089|OTHER|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
48271703|NCT06141083|DIETARY_SUPPLEMENT|TCI188 Probiotic|take two tablets per day
48271704|NCT06141083|DIETARY_SUPPLEMENT|Placebo|take two tablets per day
48271705|NCT03623074|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
48271706|NCT03623074|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
48271707|NCT00474240|DRUG|Atorvastatin 20 mg|
48271708|NCT00474240|DRUG|AEGR-733 5 mg|
48271709|NCT00474240|DRUG|AEGR-733 10 mg|
48271710|NCT00474240|DRUG|Placebo|
48271711|NCT00474240|DRUG|AEGR-733 5 mg + atorvastatin 20 mg|
48271712|NCT00474240|DRUG|AEGR-733 10 mg + atorvastatin 20 mg|
48271713|NCT02113787|PROCEDURE|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
48271714|NCT02506738|DEVICE|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
48271715|NCT01105637|BEHAVIORAL|Augmented Exercise Program|12 week (3 x per week) exercise prescription
48271716|NCT03105739|OTHER|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
48271717|NCT03242954|OTHER|Autonomous minor consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
48271718|NCT03242954|OTHER|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
48271719|NCT03242954|OTHER|Parental permission required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
47926149|NCT03263650|DRUG|Olaparib|Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
47926150|NCT05795634|BEHAVIORAL|Trier Social Stress Test|Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
47926151|NCT00281658|DRUG|Lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
47926152|NCT00281658|DRUG|Paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
48271720|NCT00299988|DRUG|Intravenous Immunoglobulin|
48271721|NCT00299988|OTHER|Placebo|
47926153|NCT00281658|DRUG|Placebo|Paclitaxel Matching Placebo
47926154|NCT05744440|DRUG|allogenic NK cells|The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10\^7/kg, 5x10\^7/kg) after chemotherapy with azacitidine
47926155|NCT04882969|DEVICE|Fractionated Thulium laser|LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
47926156|NCT04062136|COMBINATION_PRODUCT|stem cell transplantation|Transplantation of umbilical cord mesenchymal stem cells
47926157|NCT01175681|PROCEDURE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
47926158|NCT00108875|BIOLOGICAL|Survivin peptide vaccine|
47926159|NCT05168501|OTHER|Rebreathing procedure|Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
47926160|NCT04769999|BEHAVIORAL|Simple cognitive task|A brief memory reminder cue followed by playing the computer game Tetris for 25 minutes using mental rotation instructions. Option for subsequent booster sessions (self-administered/researcher-assisted).
47926161|NCT02025153|OTHER|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
47926162|NCT00879008|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
47926163|NCT02614521|OTHER|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
47926164|NCT04090775|DRUG|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
47926165|NCT04090775|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
48271722|NCT00455117|DRUG|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
48271723|NCT05611073|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
48271724|NCT05611073|DIAGNOSTIC_TEST|Biometric Data Collection|Measurement of biometric data will be obtained from the Zeiss IOL Master 700, Atlas 9000, and the iTrace.
48271725|NCT05611073|OTHER|Patient Questionnaire|Patients will complete a Patient Questionnaire to determine their level of spectacle independence and visual acuity satisfaction.
48271726|NCT02393911|DIETARY_SUPPLEMENT|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
48271727|NCT01227967|DRUG|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
48271728|NCT01227967|DRUG|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
48271729|NCT04726332|DRUG|XL102|oral doses of XL102
48271730|NCT04726332|DRUG|Fulvestrant|fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.
48271731|NCT04726332|DRUG|Abiraterone|abiraterone 1000 mg administered orally once daily.
48271732|NCT04726332|DRUG|Prednisone|prednisone 5 mg administered orally twice daily.
48271733|NCT00961961|DRUG|Lithium / Fluoxetine|Individualized Daily Dosage
48271734|NCT00961961|DRUG|Lithium / Placebo|Individualized Daily Dosage
48271735|NCT01486576|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
48271736|NCT01486576|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
48271737|NCT04796519|PROCEDURE|Total knee arthroplasty|Surgical procedure
48271738|NCT05852639|DEVICE|Ultrasound|Routine obstetric ultrasound will be done at term (at 37 weeks gestation): to confirm gestational age, assess fetal weight and amniotic fluid index and to exclude fetal anomalies.Doppler study and cerebroplacental ratio assessment will be done at 37 weeks gestation and repeated every two weeks
48271739|NCT00669617|DRUG|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
48271740|NCT00669617|DRUG|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
47926166|NCT04090775|DRUG|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
47926167|NCT04090775|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
47926168|NCT04951167|DRUG|Norepinephrine|in the form of infusion
47926169|NCT04951167|DRUG|Norepinephrine|in the form of bolus
47926170|NCT05628259|BEHAVIORAL|Tele-Nursing based Motivational Interviewing|A motivational interview (MI) program based on the telenursing approach was applied to the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
47926171|NCT05873660|OTHER|No treatment given|No treatment given
47926172|NCT02917057|DRUG|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
47926173|NCT02917057|DRUG|basal insulin|basal insulin tretament in the customary clinical care in USA
47926174|NCT05133960|OTHER|Questionnaire assessment|Validity and reliability of the Turkish Version of the Activity Diversity Questionnaire
47926175|NCT01666847|PROCEDURE|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
47926176|NCT04335214|OTHER|one to one interview|one to one interviews with older people from moroccon origin in Belgium
47926177|NCT01612845|PROCEDURE|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
47926178|NCT01612845|BIOLOGICAL|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
47926179|NCT05395793|OTHER|Support Group|Support Group with moderator
47926180|NCT05461378|DRUG|Evusheld|Participants who have received or plan to receive Evusheld.
47926181|NCT01453582|DRUG|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
47926182|NCT01453582|DRUG|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
47926183|NCT03865888|DRUG|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
47926184|NCT03865888|DRUG|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
47926185|NCT03073551|OTHER|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
47926186|NCT02895425|OTHER|Registry (No intervention)|
47926187|NCT02024152|DRUG|JDP-205 IV high dose|
47926188|NCT02024152|DRUG|JDP-205 IV low dose|
47926189|NCT02024152|DRUG|JDP-205 IM|
47926190|NCT02024152|DRUG|Control: Zyrtec|
47926191|NCT04918056|DIAGNOSTIC_TEST|Hematological Analysis and Genetical Analysis|"Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA).~Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay."
47926192|NCT05277337|BIOLOGICAL|Alluzience|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
47926193|NCT05277337|BIOLOGICAL|powder BoNT-A (BOTOX/Vistabel)|Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
47926194|NCT05872854|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment
47926195|NCT05872854|OTHER|Visible Light|After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.
47926196|NCT01546272|DEVICE|Insorb resorbable staples|Subcutanous suture using resorbable staples
47926197|NCT01546272|DEVICE|Monocryl resorbable wire|Subcutanous suture using resorbable wire
47951265|NCT02020187|OTHER|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
48271741|NCT00669617|DRUG|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
48271742|NCT00669617|DRUG|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
48271743|NCT00669617|DRUG|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
47926198|NCT06190054|DEVICE|MERAMIRT|"MERAMIRT®, a class IIa medical device, is indicated for hydration and lubrication of the ocular surface under conditions of eye disorders caused by environmental, visual and mechanical stress, also due to asthenopia and accommodation effort. The main component of MERAMIRT® are Hydroxypropyl-methylcellulose (HPMC 0.3%) and Inositol (0.1%).~HPMC has the property of moisturizing and lubricating the eye. Inositol is used with an antioxidant role"
47926199|NCT04865523|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
47926200|NCT03591770|BIOLOGICAL|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
47926201|NCT03633240|OTHER|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
47926202|NCT04427332|OTHER|Investigation of smell and taste disorders|The study consists of an epidemiological investigation by means of a prospective observational study with the aim of investigating the demographic and clinical factors related to the sense of smell and taste in patients with Sars Cov 2 infection.
47926203|NCT01167387|DIETARY_SUPPLEMENT|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
47926204|NCT01167387|OTHER|water|The control group will receive plain water with the same volume and timing of treatment.
47926205|NCT01220544|BIOLOGICAL|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain \> 8 x 10e6 CD34+ cells/kg and \< 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
48271744|NCT00669617|DRUG|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
47926206|NCT02793648|DRUG|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
47926207|NCT02793648|DRUG|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
47926208|NCT02793648|DRUG|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
47926209|NCT03556488|DIAGNOSTIC_TEST|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
47926210|NCT03149367|PROCEDURE|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
47926211|NCT03149367|PROCEDURE|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
47926212|NCT02508558|OTHER|motion perception and locomotor operation performance measurements|
47926213|NCT02508558|OTHER|parabolic flight|
47926214|NCT03355482|DRUG|Methylprednisolone|160mg IM at baseline
47926215|NCT03355482|DRUG|Placebos|IM saline injection at baseline
47926216|NCT06119958|DRUG|DWC202313|Experimental Drug 1
47926217|NCT06119958|DRUG|DWC202314|Experimental Drug 2
47926218|NCT06394362|OTHER|Bispectral index monitor|Bispectral Index (BIS), that was introduced in 1992, is a tool that monitors the depth level of hypnosis through data processing of an electroencephalogram using computer algorithm and presented in the form of processed EEG. Utilizing BIS as a monitoring tool has shown effectiveness in reducing recovery time, prevent awareness, and bring down the amount of anesthesia agent however, as of now, it has not been incorporated into the 2020 American Society of Anesthesiologists (ASA) standard procedure on anesthesia monitoring. aims to comparing the deep hypnotic time duration on two group of geriatric patients which undergoes general anesthesia with BIS monitoring compared to standard monitoring.
47926219|NCT03395119|DRUG|Ozone|After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
47926220|NCT03395119|DIETARY_SUPPLEMENT|Fish Oil|3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver \>60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
47926221|NCT03395119|DIETARY_SUPPLEMENT|Olive Oil|3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
47926222|NCT02867553|DRUG|rituximab|
47926223|NCT02867553|RADIATION|Multi-fields radiotherapy|
48271745|NCT04452890|DIAGNOSTIC_TEST|Sonourethrography|Ultrasound of the urethra.
48271746|NCT02312804|DRUG|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
48271747|NCT02312804|DRUG|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
47926224|NCT00366093|DRUG|Eszopiclone|eszopiclone 3 mg
47926225|NCT00366093|DRUG|Placebo|placebo tablet
47926226|NCT04163289|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
47926227|NCT00316108|DEVICE|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
47926228|NCT00167869|BEHAVIORAL|dairy peptides|
47926229|NCT01237483|DRUG|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
47926230|NCT02108340|PROCEDURE|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
47926231|NCT00321581|DRUG|Cediranib, AZD2171, RECENTIN|
47926232|NCT03038477|DRUG|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
47926233|NCT04458688|OTHER|Observation of Ocrelizumab as Treatment in RRMS Patients|It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.
47926234|NCT06299254|OTHER|Placebo-Natural History|"Half of the participants will receive a placebo (i.e., motivational/verbal) cue before and after an experimental session in which they will perform several lifts.~Half of the participants will receive no placebo before and after an experimental session in which they will perform several lifts."
47926235|NCT02901327|PROCEDURE|Lumbar Stabilisation Exercise|"McGill protocol starting with:~1. 'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~2. 'curl-up' exercise 10 repetitions with 7 seconds hold each~3. 'side-bridge' exercise 10 repetitions with 7 seconds hold each~4. 'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
47926236|NCT02901327|PROCEDURE|treadmill walk exercise|"Bruce protocol~This include:~1. '5 minutes warm up' at zero degree inclination.~2. '20 minutes active exercise with increasing speed and inclination'~3. '5 minutes cool down'"
47926237|NCT02299518|DRUG|mitoxantrone hydrochloride|Given IV
47926238|NCT02299518|DRUG|etoposide|Given IV and PO
47926239|NCT02299518|DRUG|cytarabine|Given IV
47926240|NCT02299518|DRUG|selinexor|Given PO
47926241|NCT02299518|OTHER|laboratory biomarker analysis|Correlative studies
47926242|NCT02299518|OTHER|pharmacological study|Correlative studies
47926243|NCT00368290|DRUG|Modafinil|300mg a day for 8 weeks
47926244|NCT00368290|DRUG|placebo|placebo pills for 8 weeks
47926245|NCT00368290|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
47926246|NCT02320201|DEVICE|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
47926247|NCT01873469|RADIATION|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
47926248|NCT01779219|DEVICE|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
47926249|NCT01779219|DEVICE|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
47926250|NCT03265223|DRUG|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
47926251|NCT04568824|OTHER|GraphoLearn reading intervention|This is an Edtech reading intervention
47926252|NCT04568824|OTHER|Vektor math control intervention|This is an Edtech math/cognition intervention
47926253|NCT05905744|DIAGNOSTIC_TEST|cholangioscopy|cholangioscopy examination and forceps biopsy, followed by brush biopsy from ERCP
47926254|NCT05342038|DEVICE|T-02|Stent retriever
47926255|NCT04293744|DEVICE|Colloid priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
47926256|NCT04293744|DEVICE|Standard priming solution for ECC circuit|Prospective, multi-center, double-blinded, randomized, controlled clinical trial
47926257|NCT01819818|DRUG|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
47926258|NCT00515424|DRUG|RKI983|
47926259|NCT03907839|OTHER|clinical trials|examined two type of training on cognitive parameters for COPD patients
47926260|NCT02243423|PROCEDURE|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
47926261|NCT02243423|PROCEDURE|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
47926262|NCT03759808|BEHAVIORAL|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
47951266|NCT06157918|DRUG|SYHA1813 oral solution (2.0g:25mg)|SYHA1813 oral solution, 25mg, oral
47951267|NCT06157918|DRUG|SYHA1813 oral solution (20ml:200mg)|SYHA1813 oral solution, 25mg, oral
47951268|NCT02280538|DEVICE|Intra-Articular Hyaluronic Acid|
47926263|NCT02386189|BEHAVIORAL|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
47926264|NCT01643031|DRUG|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
47926265|NCT01643031|DRUG|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
47926266|NCT03231683|DRUG|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
47926267|NCT03231683|DRUG|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
47926268|NCT03231683|DRUG|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
47926269|NCT03231683|DRUG|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
47926270|NCT04319497|DEVICE|Subjective refraction|Subjective refraction measurements will be performed by two testers for all the patients included
47926271|NCT04319497|DEVICE|Autorefraction|Five autorefraction measurements will be performed for all the patients included
47926272|NCT04319497|DEVICE|Wavefront aberrometry|Five wavefront measurements will be performed for all the patients included
47926273|NCT02830438|DEVICE|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
47926274|NCT05323825|DIETARY_SUPPLEMENT|Probiotic|Fermented milk product containing a probiotic
47926275|NCT05323825|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
47926276|NCT03697135|BEHAVIORAL|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
47926277|NCT05145738|BEHAVIORAL|C-Raven with avatar|Computer delivered intervention with the investigators' avatar; with linkage to community health worker.
47926278|NCT05145738|BEHAVIORAL|C-Raven without avatar|Computer delivered intervention without the investigators' avatar; with linkage to community health worker.
47926279|NCT04835831|OTHER|adapted physical activity + Dietetic advice|adapted physical activity during 24 weeks
47926280|NCT01594801|DEVICE|InsuPad|Use of the InsuPad for at least 3 times a day.
47926281|NCT06273137|BEHAVIORAL|Positive affect treatment|PAT includes 15 weekly, 1-hour sessions. The treatment is composed of three modules targeting behaviors (Sessions 1-7), cognitions (Sessions 8 -10), and compassion (Sessions 11-14), with skills being reinforced in a cumulative manner in subsequent sessions. The final session in the original treatment (Session 15) addressed relapse prevention, which will be adapted to focus on further reinforcing and generalizing learned skills. The treatment includes guided activities that target different aspects of positive affectivity such as reward approach-motivation, reward learning, and reward attainment.
47926282|NCT02289716|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
47926283|NCT02289716|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
47926284|NCT02289716|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
47926285|NCT05083780|DRUG|Chlorphenesin Carbamate, Hydroxychloroquine|In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
47926286|NCT04658940|DEVICE|AcQBlate® Force Sensing Ablation System|Percutaneous catheter ablation of the cavotricuspid isthmus
47926287|NCT02793622|DRUG|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
47926288|NCT02793622|DRUG|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
47926289|NCT00362180|DRUG|mipomersen|200 mg subcutaneous injections
48271748|NCT02312804|DRUG|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
47926290|NCT00362180|DRUG|Placebo|subcutaneous injections
47926291|NCT01092832|DRUG|voriconazole|"Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
47951269|NCT02280538|DEVICE|Placebo|
48271749|NCT02737865|DRUG|Sonazoid|Sonazoid: Commercially available contrast material for ultrasonography
48271750|NCT02737865|DEVICE|Superb-Microvascular imaging|Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
48271751|NCT00295269|DRUG|Mythylprednisolone|
47926292|NCT02635932|DEVICE|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
47926293|NCT02635932|DEVICE|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
47926294|NCT06005129|BEHAVIORAL|Personality-Based Therapy|Participants will be randomized to a 2- or 4-week assessment-only baseline period. After the baseline period, participants will receive the personality-based treatment module corresponding to their highest clinical elevation (i.e., neuroticism, \[low\] conscientiousness, \[low\] agreeableness). Treatment will consist of six weekly 50-60-minute sessions. After the 6-week intervention period, participants will complete a 4-week follow-up period to determine the sustainability of effects observed
47926295|NCT01255748|RADIATION|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
47926296|NCT02870023|OTHER|Balance training|
47926297|NCT02870023|OTHER|Strength training|
47926298|NCT01203852|DRUG|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
47926299|NCT01203852|DRUG|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
48095830|NCT05753852|DRUG|Tauroursodeoxycholic Acid|Tauroursodeoxycholic acid (TUDCA) 250 mg capsules Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal Mode of administration: orally Duration: 18 months
47926300|NCT00766753|BIOLOGICAL|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
47926301|NCT00766753|BIOLOGICAL|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
47926302|NCT00766753|BIOLOGICAL|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
47926303|NCT04698096|OTHER|Biological sample collection|Collection of faeces, urine, saliva, and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
47926304|NCT04698096|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
47926305|NCT04698096|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
47926306|NCT05088473|OTHER|Biological collection|Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
47926307|NCT04036123|OTHER|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
47926308|NCT00551304|DEVICE|Ardian Catheter|
47926309|NCT05377697|OTHER|Dry lavender flower scent|Participants in the experimental group will be informed about the effects of lavender scent on sleep and lavender sachets will be given. They will be informed that they should put these lavender sachets in their pillows every day and sleep with a lavender sachet for the next month, and that they should not make any changes in their rooms or beds other than the lavender sachet.
47951270|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) automatic oxygen flow titration|Automatic adjustment of oxygen flow titration through the FreeO2 device. The monitor allows continuous monitoring and recording of SpO2 and Heart rate
48095831|NCT02142439|BEHAVIORAL|Strength training|Three times per week with strength training
48095832|NCT04740255|DEVICE|Straberi Epistamp|The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
48095833|NCT04700007|DRUG|Capsaicin|A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.
48095834|NCT04700007|DRUG|Diphenhydramine|Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.
48095835|NCT04700007|DRUG|Morphine Chloride|Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.
48095836|NCT04700007|DRUG|Isotonic saline|injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
48095837|NCT04700007|DRUG|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
47926310|NCT03234140|GENETIC|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
47926311|NCT03234140|GENETIC|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
47926312|NCT05661188|DRUG|Atezolizumab plus Tiraglolumab|All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
47926313|NCT04285840|OTHER|Venous ACT|Matched/paired venous ACT samples will be drawn at the same time as arterial ACT samples to compare the results agreement between venous and arterial ACTs. Subjects undergoing atrial fibrillation ablations will continue to have Heparin dosed on the arterial ACT sample results only per the standard of care. Heparin will not be administered based on venous ACT levels obtained during this study.
47926314|NCT05579951|PROCEDURE|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
47926315|NCT05579951|PROCEDURE|Conventional|Total knee replacement with conventional instrumentation
47926316|NCT05579951|DEVICE|Patient specific instrumentation|Medacta GMK Sphere MyKnee Patient specific Instrumentation
47926317|NCT05448820|DRUG|YH001|Anti-CTLA4 antibody
47926318|NCT05448820|DRUG|Envafolimab|Anti-PD-L1 antibody
47926319|NCT05448820|DRUG|Doxorubicin|Anthracycline
47926320|NCT02270996|OTHER|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
47926321|NCT01204723|DRUG|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
48271752|NCT05312957|OTHER|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
47926322|NCT01204723|DRUG|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
47926323|NCT01246817|DRUG|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
48271753|NCT06257914|DIAGNOSTIC_TEST|Catquest-9SF|Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
48271754|NCT00943995|DRUG|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
48271755|NCT05986942|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
48271756|NCT05986942|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
48271757|NCT04522869|BIOLOGICAL|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
48271758|NCT01746433|OTHER|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
47926324|NCT00260364|DRUG|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
47926325|NCT00260364|DRUG|Capecitabine orally days 1 -21|
48271759|NCT06340217|OTHER|washed microbiota transplantation|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive two doses of WMT for DGP.
47926326|NCT00260364|DRUG|Erlotinib 100 mg orally days 1-28|
47926327|NCT00260364|DRUG|Bevacizumab 5 mg/kg intravenously every 2 weeks|
47926328|NCT05229861|BEHAVIORAL|HIIT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants will perform five high-intensity intervals (95% HRpeak) at high pedalling rates of 80-100 rpm for 90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20W, 60-70rpm) aimed to return to 60% HRpeak (approximately 1-1.5 min). The duration of a HIIT sessions is approximately 25 minutes.
47926329|NCT05229861|BEHAVIORAL|MCT|Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Participants perform continuous bicycle ergometry at moderate intensity (60% HRpeak) and 60-70 rpm for the duration of 30 minutes.
47926330|NCT03565367|OTHER|Gadolinium|gadolinium enhanced MRI
47926331|NCT03565367|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
47926332|NCT03565367|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47926333|NCT03565367|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
47926334|NCT06276738|DIAGNOSTIC_TEST|LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
47926335|NCT00680238|DRUG|Human derived FSH|Customized for each patient
47926336|NCT02545543|BIOLOGICAL|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
48095838|NCT00831597|DRUG|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
48095839|NCT00831597|DRUG|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
47926337|NCT02545543|BIOLOGICAL|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
47926338|NCT00213694|DRUG|docetaxel and celecoxib|
47926339|NCT02087267|PROCEDURE|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
47926340|NCT05622747|OTHER|Passive heating|1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C)
47926341|NCT04518189|DRUG|lidocaine patch|lidocaine patch applied 3 hours before the procedure
47926342|NCT04518189|DRUG|Sham patch|Sham patch applied 3 hours before the procedure
47926343|NCT00385476|BEHAVIORAL|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
47926344|NCT00254579|DRUG|CP-675,206|15 mg/kg Q12W dosing regimen
47926345|NCT05062434|OTHER|Academic detailing and audit and feedback intervention|An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
47926346|NCT05292547|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.
47926347|NCT00427401|DRUG|PF-00915275|
47926348|NCT03473548|DEVICE|Portable sleep monitor|Type III at home portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis
48271760|NCT06340217|OTHER|placebo|A carrier fluid with matching volume and consistent appearance to the infusion of washed microbiota.
48271761|NCT06047704|OTHER|No intervention|No intervention
48271762|NCT05059990|OTHER|Low Intensity Aerobic Exercises Group|Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session
48271763|NCT05059990|OTHER|Active Exercises Group|Intervention Upper and lower limb ROM \& stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
48271764|NCT04484350|DRUG|Labetalol|10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
48271765|NCT04484350|DRUG|Hydralazine|10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
48271766|NCT04484350|DRUG|Enalapril|1.25 - 2.5 mg IV bolus and then q6h PRN.
48271767|NCT02511977|OTHER|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
47926349|NCT03473548|OTHER|In-laboratory Polysomnography|Polysomnography testing will determine the sleep stages, apnea hypopnea index (AHI), blood saturation oxygen nadir (SPO2 nadir), and average blood oxygen saturation. A McGill Oximetry Score will also be calculated for the in-laboratory PSG.
47926350|NCT04518995|DRUG|CTP-543 matching placebo|Administered as tablets.
47926351|NCT04518995|DRUG|CTP-543|Administered as tablets.
47926352|NCT04518995|DRUG|CTP-543|Administered as tablets.
47926353|NCT02930980|DEVICE|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
47926354|NCT02451371|DEVICE|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
47926355|NCT01057875|OTHER|caffeine|Starbuck's Grande Pike Roast coffee
47926356|NCT01057875|OTHER|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
47926357|NCT01479426|DIETARY_SUPPLEMENT|EFLA400|EFLA400(960mg/day)for 12 weeks
47926358|NCT01479426|DIETARY_SUPPLEMENT|Placebo|Placebo(960mg/day) for 12 weeks
47926359|NCT04643600|DRUG|L-Arginine, 500 Mg Oral Capsule|The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
47926360|NCT05397782|DEVICE|BioNourish, a component of Flourish HEC|BioNourish, one of three parts of the Flourish HEC system, is a vaginal moisturizing gel - a Class II medical device with FDA 510k clearance obtained in 2020.
47926361|NCT02653703|OTHER|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
47926362|NCT02653703|OTHER|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
47926363|NCT00634738|PROCEDURE|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
47926364|NCT06343857|DIAGNOSTIC_TEST|self-assessment questionnaire|Completion of the anatomical site-specific self-assessment questionnaire.
47926365|NCT05403398|DIETARY_SUPPLEMENT|B. subtilis CU1|2 billion CFUs daily, for 4 weeks
47926366|NCT01268579|DRUG|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
48095840|NCT01112072|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
47926367|NCT01198522|DRUG|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
47926368|NCT02065427|BEHAVIORAL|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
47926369|NCT00002339|DRUG|Fluconazole|
47926370|NCT04563832|OTHER|Standardized respiratory management program|Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years
47926371|NCT04563832|OTHER|CoughAssist|self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)
47926372|NCT03483064|OTHER|Interferential current|interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
47926373|NCT02042820|OTHER|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
47926374|NCT05595759|OTHER|Violence against women education supported by creative drama|Violence against women supported by creative drama training will be applied to male patients diagnosed with addiction every day for 5 days.
47926375|NCT05595759|OTHER|Routine service operation|No additional training will be applied to the control group and SAMBA trainings in the service operation will be applied.
47926376|NCT03386045|RADIATION|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
47926377|NCT03386045|RADIATION|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach\|) and one third will get the standard treatment (60 Gy in 20 treatments)"
48095841|NCT00331214|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
47926378|NCT01238627|DRUG|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
47926379|NCT01238627|DRUG|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
47926380|NCT02480036|RADIATION|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
47926381|NCT02480036|DEVICE|Intrabeam®|
47926382|NCT05922670|BEHAVIORAL|The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth|BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
47926383|NCT00917293|DRUG|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
47926384|NCT00917293|DRUG|Placebo|Placebo 2 pills, po bid.
47926385|NCT03207373|DIAGNOSTIC_TEST|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
47926386|NCT05084729|DEVICE|Imagio OA/US|Imagio optoacoustic
47926387|NCT00958438|DRUG|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
48095842|NCT00331214|DRUG|placebo patch|placebo patch replaced every 3-4 days for 6 months
47926388|NCT00958438|DRUG|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
47926389|NCT00958438|DRUG|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
47926390|NCT04869501|DRUG|TJ004309|Antibody to CD73
47926391|NCT04869501|DRUG|Atezolizumab|Humanized monoclonal antibody to PD-L1
48095843|NCT01928511|DRUG|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
48095844|NCT01928511|DRUG|Nucleos(t)ide analogue therapy|
47926392|NCT04375319|DEVICE|OCT|OCT can provide clear in vivo imaging and evaluate the vascular repair after stent implantation by measuring the optical echo of near-infrared light reflection
47926393|NCT03946722|DRUG|GnRH analogue downregulation|"Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to one week of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm."
47926394|NCT03946722|OTHER|Participant questionnaire|Participant will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again two months after completion of treatment.
47926395|NCT04832100|DRUG|Pregabalin 150mg, imipramine 25mg|Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
47926396|NCT06403488|DRUG|Letrozole 2.5mg|specific aromatase inhibitor
47926397|NCT02437227|DRUG|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
47926398|NCT00839033|DEVICE|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
47926399|NCT00839033|DEVICE|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
47926400|NCT04352426|OTHER|Exercise Test|Tests were conducted to evaluate exercise capacity.
47926401|NCT05228847|DIETARY_SUPPLEMENT|Human milk-derived HMF|Fortification with human milk-derived product
47926402|NCT05228847|DIETARY_SUPPLEMENT|bovine milk-derived HMF|bovine milk-derived HMF
47926403|NCT02843997|GENETIC|Endophenotype and sequencing|Draw an endophenotype and genetic study
47926404|NCT00535288|DRUG|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
47926405|NCT00535288|DRUG|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
47926406|NCT03739242|DIETARY_SUPPLEMENT|Nutraceutical combination|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
47926407|NCT03739242|OTHER|Placebo|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
47926408|NCT00709709|PROCEDURE|multislice coronary scan|multislice coronary scan
47926409|NCT02914028|PROCEDURE|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
47926410|NCT02914028|DRUG|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
47926411|NCT00130247|DRUG|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
47926412|NCT00130247|DRUG|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
47926413|NCT00130247|DRUG|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
47926414|NCT00130247|DRUG|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
47926415|NCT01109732|OTHER|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
47926416|NCT03648866|OTHER|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
47926417|NCT00395343|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
47926418|NCT00395343|DRUG|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
47926419|NCT02996058|DRUG|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
47926420|NCT02996058|DRUG|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
47926421|NCT01819285|PROCEDURE|Immediate Orchiectomy or depot LHRH|
47926422|NCT01819285|PROCEDURE|Delayed Orchiectomy or depot LHRH|
47926423|NCT06081088|OTHER|Graded Motor Imagery (GMI) training|"GMI consists of three basic components:~1. Left / Right Discrimination training (Lateralization training): For lateralization training, patients will be trained by asking them to distinguish between right and left with images taken at various angles and positions in the RecogniseTM (NOI-Australia) applications (shoulder and hand sections) (In weeks 1 and 2).~2. Motor Imagery (Explicit Motor Imagery): At this stage, the participant will be asked to imagine doing various functional activities (brushing teeth, combing hair, etc.) in the position they feel most comfortable in and in a quiet environment (In weeks 2 and 3).~3. Mirror Therapy (providing visual feedback through a mirror): In this phase, active ROM exercises and progressive resistance exercises with simultaneous movement of the affected and unaffected extremities will be applied using a standard size posture mirror (In weeks 3-6).~This program will be applied for 6 weeks (3 sessions per week)."
47926424|NCT06081088|OTHER|Conventional Physiotherapy|Conventional physiotherapy program includes passive, active-assistive (wand exercises) and active ROM exercises for shoulder joint, passive / active posterior and anterior capsule stretching exercises, superior-inferior, mediolateral and distraction techniques for scapular mobilization exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, static and dynamic stabilization exercises for proprioception exercises. To reduce the pain that may occur after exercises, cold application and Transcutaneous Electrical Nerve Stimulation (TENS) will be applied to benefit from their analgesic effects. Cold application will be applied around the shoulder using a coldpack (gel pack) cold therapy for 15 minutes. Conventional TENS application around shoulder will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes for 15 minutes.This program will be applied for 6 weeks (3 sessions per week).
47926425|NCT06081088|OTHER|Home Exercise Program|The home exercises program includes shoulder jonit active ROM exercises, active posterior and anterior shoulder capsule stretching exercises, shoulder flexion, abduction, internal and external rotation muscles strengthening exercises, shoulder proprioception exercises, and cold therapy. This program will be applied for 6 weeks (3 sessions per week).
47926426|NCT04017195|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
48271768|NCT04644848|DIAGNOSTIC_TEST|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~* Round shape.~* Cortical thickness \> 3 mm~* Eccentric cortical thickness.~* Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
48271769|NCT04644848|PROCEDURE|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
48271770|NCT04644848|DIAGNOSTIC_TEST|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
48271771|NCT04644848|PROCEDURE|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
48271772|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
48271773|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
48271774|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
48271775|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
48271776|NCT00814385|BIOLOGICAL|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
48271777|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
48271778|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
48271779|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
48271780|NCT00814385|BIOLOGICAL|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
48271781|NCT01997151|BEHAVIORAL|Healthy Pregnancy: Step by Step|
48271782|NCT00838591|DRUG|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
48271783|NCT00838591|DRUG|Placebo|
48271784|NCT06164769|PROCEDURE|blocking both the abdominal trunk and superior mesenteric artery in the pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
48271785|NCT03162848|BEHAVIORAL|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
48271786|NCT00105872|BEHAVIORAL|Cognitive-Behavioral Therapy|
48271787|NCT00989599|OTHER|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
48271788|NCT00989599|OTHER|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
48271789|NCT01100489|RADIATION|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
48271790|NCT01100489|OTHER|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
47926427|NCT04017195|DRUG|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
47951271|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) manual oxygen flow titration|Manual oxygen flow titration performed by the healthcare provider in charge of the patient (nurse, physician). For this group, the FreeO2 device will only monitor and record SpO2 and heart rate.
48271791|NCT01100489|PROCEDURE|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins \< 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
48271792|NCT00004054|DRUG|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
47926428|NCT00866008|DRUG|Ovarian stimulation|"1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
47926429|NCT06390072|BEHAVIORAL|Self-Hypnosis|Participants listened to an 8-minute audio-guided self-hypnosis related to improving their physical performance
47926430|NCT06390072|BEHAVIORAL|Ankle Education|Participants listened to an 8-minute video on ankle sprain diagnosis, prognosis, and treatment
47926431|NCT00711516|DRUG|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
47926432|NCT00711516|DRUG|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
47926433|NCT05568940|DRUG|Tibolone 2.5 Mg Oral Tablet|Tibolone oral therapy for 2-3 months: All participants will take a Tibolone 2.5 mg tablet orally daily, at the same time each day, following a scheduled, luteal-phase injection of leuprolide acetate 11.25mg intramuscular (IM).
47926434|NCT00729846|DRUG|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
47926435|NCT00729846|DEVICE|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].
47926436|NCT00729846|DEVICE|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
47926437|NCT03758755|DEVICE|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once the exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
47926438|NCT03758755|OTHER|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
47926439|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 26 to 52
47926440|NCT03381833|DRUG|LJPC-401|subcutaneous injection, up to 20 mg per week from week 1 to 52
47926441|NCT01984762|PROCEDURE|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
47926442|NCT01984762|PROCEDURE|sleeve gastrectomy|SG = sleeve gastrectomy
47926443|NCT04022733|DRUG|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
47926444|NCT04022733|DRUG|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
47926445|NCT06270758|DIAGNOSTIC_TEST|CT scan at the femur|Additional CT scan which is not part of the standard clinical path
47926446|NCT04950868|DRUG|Quetiapine|They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
47926447|NCT00456664|GENETIC|IE gene|
47926448|NCT00771589|DEVICE|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
47926449|NCT02866955|DRUG|Estramustine|140mg/4 caps/day
47926450|NCT02866955|DRUG|Tamoxifen|20mg/day
47926451|NCT03254459|DRUG|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
47926452|NCT03254459|DRUG|Morphine|4 mg Intravenous Injection
47926453|NCT03254459|DRUG|Oxycodone Hydrochloride|10 mg tablet
47926454|NCT03254459|DRUG|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
47926455|NCT01525992|BEHAVIORAL|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
47926456|NCT01525992|OTHER|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
47926457|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
47926458|NCT01213576|DRUG|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
48271793|NCT00004054|DRUG|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
48271794|NCT00004054|DRUG|etoposide|50 mg/m\^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
47926459|NCT01213576|DRUG|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
47926460|NCT01213576|DRUG|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
47951272|NCT04863547|OTHER|Data collection|Data collection
48271795|NCT00004054|DRUG|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
48271796|NCT00004054|DRUG|paclitaxel|135 mg/m\^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
48271797|NCT00004054|DRUG|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
48271798|NCT00004054|RADIATION|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
47926461|NCT04708171|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
47926462|NCT04708171|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
47926463|NCT04708171|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
47926464|NCT03676101|BIOLOGICAL|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
48271799|NCT00004054|DRUG|warfarin|To keep international normalized ratio (INR) \> 1.5 and \< 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
48271800|NCT06348121|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study had last 84 days, and each patient will make 4 visits (d0, d28, d56, d84).
48271801|NCT02239172|BIOLOGICAL|PA83-FhCMB|
48271802|NCT05244239|DRUG|Lurbinectedin|Given IV
48271803|NCT05244239|RADIATION|Palliative Radiation Therapy|Undergo RT
48271804|NCT05829681|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive a 5-day course of 10x daily rTMS, with sessions delivered hourly. Each session will deliver up to 1800 pulses of theta-burst stimulation per target.
47926465|NCT03676101|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
48271805|NCT02480530|BEHAVIORAL|Individual Feedback|Patient gets feedback reports on adherence weekly.
48271806|NCT02480530|BEHAVIORAL|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
48271807|NCT04485455|DEVICE|iTBS Device/Motor Threshold Coil|Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.
47926466|NCT01496937|DRUG|GLPG0974|
47926467|NCT01496937|DRUG|GLPG0974|
47926468|NCT06361342|BEHAVIORAL|General decrease in smartphone use|Subjects will decrease their time on smartphone in general.
47926469|NCT06361342|BEHAVIORAL|Avoiding Social Media Apps|Subjects will avoid use of social media apps on the smartphone which includes Twitter, Facebook, Tik Tok, Instagram, and Pinterest.
47926470|NCT00998244|OTHER|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
48271808|NCT04485455|DEVICE|iTBS Device/Treatment Coil|iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
48271809|NCT00503256|BEHAVIORAL|Questionnaire|Questionnaires each taking 60 minutes to complete.
48271810|NCT01860560|DEVICE|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
48271811|NCT01860560|DEVICE|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
47926471|NCT03643536|OTHER|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
47926472|NCT01067924|BEHAVIORAL|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
47926473|NCT05349201|OTHER|KYMRIAH|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
47926474|NCT05349201|OTHER|YESCARTA|Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
47926475|NCT02299401|DRUG|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
47926476|NCT02299401|DEVICE|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
47926477|NCT00108368|DRUG|Risperidone|
47926478|NCT00108368|DRUG|Olanzapine|
47926479|NCT06240364|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
47926480|NCT06240364|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 84 days.
47926481|NCT04269382|DEVICE|Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements|Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
47926482|NCT02306031|DRUG|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
47926483|NCT02306031|DRUG|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
47926484|NCT00233909|DRUG|Zosuquidar|
47926485|NCT00233909|DRUG|gemtuzumab ozogamicin|
47926486|NCT03513445|DRUG|Morphine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
47926487|NCT03513445|DRUG|Epinephrine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
48271812|NCT03240406|OTHER|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
47926488|NCT03513445|DRUG|naropin|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
47926489|NCT01402336|DRUG|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
47926490|NCT01402336|DRUG|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
47926491|NCT02898285|BEHAVIORAL|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
47926492|NCT02898285|BEHAVIORAL|Individual sport condition|Participants will choose from a list of individual sports.
47926493|NCT02898285|BEHAVIORAL|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
47926494|NCT03154229|OTHER|Smartphone-based decision-support|WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
47926495|NCT03154229|OTHER|Paper-based decision-support|WHO guidelines presented on paper
47926496|NCT03154229|OTHER|Pre-Assessment of practices|Observation of baseline clinical practice.
47926497|NCT04124744|OTHER|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
47926498|NCT04124744|OTHER|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
47926499|NCT03441217|DRUG|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
47926500|NCT03441217|DRUG|Saline Solution|Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
47926501|NCT00855270|DRUG|Placebo|IV saline will be used as placebo for control
47926502|NCT00855270|DRUG|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
48271813|NCT03240406|OTHER|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
48271814|NCT03227809|BEHAVIORAL|Handbook condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
47926503|NCT04196387|DIAGNOSTIC_TEST|urine culture|urine culture and antibiotic susceptibility test
47926504|NCT00002952|BIOLOGICAL|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
47926505|NCT00002952|BIOLOGICAL|recombinant MAGE-3.1 antigen|
47926506|NCT00002952|BIOLOGICAL|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
47926507|NCT00477841|PROCEDURE|Esophageal stent placement|
47926508|NCT00477841|PROCEDURE|dysphagia scores|
47926509|NCT00477841|PROCEDURE|complications of therapy|
47926510|NCT00477841|PROCEDURE|survival time of therapy|
47926511|NCT00588159|DRUG|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
47926512|NCT00588159|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
47926513|NCT02845219|DRUG|semaglutide|Oral administration once daily alone or together with oral contraceptive.
47926514|NCT02845219|DRUG|SNAC|Oral administration once daily together with oral contraceptive.
48271815|NCT03227809|BEHAVIORAL|Handbook plus condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
47926515|NCT02845219|DRUG|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
47926516|NCT00917215|DEVICE|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
47926517|NCT00317278|OTHER|massage therapy|massage therapy to stable preterm infants
47926518|NCT00317278|OTHER|Sham|Sham (placebo) provided to the control group
47926519|NCT00736515|DRUG|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
47926520|NCT00736515|DRUG|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
47926521|NCT04810780|DEVICE|DUO Extended Set|to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
47926522|NCT06103331|OTHER|Invasive Fungal disease surveillance|Management of invasive fungal infection according to pathogen identification and susceptibility report.
47926523|NCT00178529|BEHAVIORAL|Psychoeducation, Counseling and Skill Training|
47926524|NCT01648556|OTHER|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
47926525|NCT04635605|DRUG|Methylene Blue|Treatment Group. Methylene Blue 100 mg capsules, twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
47926526|NCT04635605|DRUG|Control Test|Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
48271816|NCT06166550|BEHAVIORAL|Parent's Emotional Intelligence Network|A two-day in-person training session will be arranged for the participating parents at least one week apart. The psychologists will conduct the training session on emotional intelligence. A training of the trainer manual will be developed to train the psychologists. The training session will include a power point presentation and certain group and individual activities to practice emotional intelligence. The participants will also be given a diary and a mobile app in order to practice emotional intelligence at home.
47926527|NCT01710540|OTHER|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
48271817|NCT06166550|DEVICE|Diary|A diary will be developed that contain different practice materials regarding emotional intelligence. It will be a personal diary given to the participants to take to home.
48271818|NCT06166550|DEVICE|Mobile App|It will be a mobile app, developed based on the concept of emotional intelligence. It will contain different videos, audios, and texts related to emotional intelligence. It will also provide a communication platform where users can communicate through texts and upload documents.
48271819|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
47926528|NCT01710540|OTHER|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
47926529|NCT02171910|DRUG|Doxapram|
48271820|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
48271821|NCT01431287|DRUG|tiotropium|low dose or high dose
48271822|NCT01431287|DRUG|tiotropium|low dose or high dose
48271823|NCT01431287|DRUG|olodaterol|one dose only
47926530|NCT02171910|DRUG|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
47926531|NCT04395950|DRUG|PF-05221304|PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)
47926532|NCT04395950|DRUG|Placebo|Placebo two tablets daily in the morning for 6 weeks
47926533|NCT01100476|DEVICE|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
47926534|NCT02718170|PROCEDURE|Buried Intramedullary K-wire Fixation|
47926535|NCT02718170|PROCEDURE|Plate and Screw Fixation|
47926536|NCT04550377|DRUG|Cannabidiol|The drug product to be used in this study is an oral formulation of CBD
47926537|NCT04550377|DRUG|Placebo|non-active medication
47926538|NCT01362010|DRUG|Topical Minocycline Foam FXFM244|Topically applied once a day.
48271824|NCT01431287|DEVICE|Respimat|Respimat inhaler
48271825|NCT01633957|OTHER|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
48271826|NCT01633957|OTHER|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
47926539|NCT01947062|DRUG|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
47926540|NCT01947062|DRUG|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
47926541|NCT00402233|DRUG|Pramipexole|
47926542|NCT00402233|DRUG|Placebo|
47926543|NCT05974462|DRUG|Methylprednisolone 125 MG|125 mg daily for 3 days diluted in saline solution 250 mL
48271827|NCT01905475|DRUG|POL6326|
48271828|NCT01905475|DRUG|Placebo|
48271829|NCT00877344|PROCEDURE|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
48271830|NCT00877344|PROCEDURE|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
48271831|NCT05853471|DRUG|[18F]MC225|All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.
48271832|NCT00006227|DRUG|Paclitaxel|Given IV
47926544|NCT05974462|OTHER|IV saline solution 0.9%|Saline solution 0.9% 250 mL
48271833|NCT01483677|OTHER|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
48271834|NCT01483677|OTHER|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
47926545|NCT02719561|BEHAVIORAL|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
47926546|NCT06226532|DRUG|lidocaine spray|Group SL: Spray 10% lidocaine for 4 puffs at the endotracheal tube cuff, also prepare for spray at the laryngeal inlet for 4 puffs (total approximately 1.5mg/kg)
47926547|NCT06226532|DRUG|Intravenous Lidocaine|2% lidocaine 1.5 mg/kg IV will be given 2 minutes after cisatracurium injection (3 minutes prior intubation).
47926548|NCT03706547|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
47926549|NCT03706547|DRUG|Fludarabine|30mg/m2/d
47926550|NCT03706547|DRUG|Cyclophosphamide|300mg/m2/d
47926551|NCT04891393|DIETARY_SUPPLEMENT|Coffee|"Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)"
47926552|NCT04891393|DIETARY_SUPPLEMENT|Decaffeinated coffee|"Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)"
47926553|NCT00007059|DRUG|mycophenolate mofetil|
47926554|NCT02527200|DRUG|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
47926555|NCT02527200|DRUG|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
47926556|NCT06154577|DIAGNOSTIC_TEST|Ultrasonography|Assessment of tongue morphology and posterior airway space using ultrasonography (AmCAD-UO, CE mark NB1639)
47926557|NCT05049083|DRUG|New Process SHR2554 tablet、Former Process SHR2554 tablet|New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
47926558|NCT05049083|DRUG|Former Process SHR2554 tablet、New Process SHR2554 tablet|Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
47926559|NCT02744950|PROCEDURE|Pulley stitches|
47926560|NCT02744950|PROCEDURE|Intermediate Repair|
47926561|NCT04329624|DRUG|Levosimendan|Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL. Levosimendan injection is a clear, yellow to orange solution. Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.
47926562|NCT04329624|DRUG|Placebo|"Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL.~Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose."
48271835|NCT00963326|OTHER|laboratory biomarker analysis|
48271836|NCT01540643|DEVICE|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
48271837|NCT01147497|DRUG|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
48271838|NCT01147497|DRUG|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
48271839|NCT05995444|DRUG|Epetraborole and matching placebo|Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
48271840|NCT05995444|DRUG|Epetraborole|Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
48271841|NCT05995444|DRUG|Placebo|Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
48271842|NCT05995444|DRUG|Moxifloxacin|Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
48271843|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) lower dose formulation vaccine|1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
47926563|NCT03680235|OTHER|Informational Intervention|Receive standard information about breastfeeding and pregnancy
47926564|NCT03680235|OTHER|Informational Intervention|Receive information about breastfeeding and cancer
47926565|NCT03680235|OTHER|Interview|Participate in focus groups
47926566|NCT03680235|OTHER|Survey Administration|Ancillary studies
47926567|NCT03789409|DIETARY_SUPPLEMENT|Intermittent Fasting|The aforementioned intermittent fasting in arm/group descriptions.
47926568|NCT05828641|PROCEDURE|Supination-flexion maneuver|In the Supination-flexion group, the forearm will be supinated first, followed by full flexion of the elbow joint (Supination-flexion maneuver).
47926569|NCT05828641|PROCEDURE|Hyperpronation maneuver|In the hyperpronation group, the forearm will be pronated with the child's palm facing down (hyperpronation maneuver).
47926570|NCT06530186|DEVICE|LiviWell Postcoital Vaginal Insert|subjects will use Livi within minutes of completion of sex, and will remove study device in under an hour.
47926571|NCT03956719|DRUG|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
47926572|NCT03956719|PROCEDURE|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
48271844|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) higher dose formulation vaccine|2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
47926573|NCT01428947|PROCEDURE|Arterial approach|Randomization to right radial or femoral approach
47926574|NCT05981976|BIOLOGICAL|Abatacept|Specified dose on specified days
48271845|NCT03636906|BIOLOGICAL|GSK's multicomponent meningococcal B vaccine|3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
48271846|NCT03636906|BIOLOGICAL|Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine|3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
48271847|NCT03636906|BIOLOGICAL|GSK's pneumococcal polysaccharide conjugate vaccine|3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
48271848|NCT03636906|BIOLOGICAL|GSK's meningococcal group A, C, W-135 and Y conjugate vaccine|2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
48271849|NCT03636906|DRUG|Placebo|1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
48271850|NCT03190187|OTHER|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
48271851|NCT03190187|OTHER|Sham manipulation|Patients will receive simulated spinal manipulation without force application
48271852|NCT04925960|DRUG|Epalrestat|Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG.
48271853|NCT04925960|DRUG|Placebo|The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
48271854|NCT01755832|PROCEDURE|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
47926575|NCT02859805|OTHER|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
47926576|NCT00347373|DRUG|Tonalin Conjugated linoleic acid (dietary supplement)|
47926577|NCT02823639|PROCEDURE|Transcranial direct current stimulation|
47926578|NCT03526380|BEHAVIORAL|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
48271855|NCT05527990|DEVICE|Multimodal PO|Mixed methods diagnostic accuracy and implementation of multimodal PO
47926579|NCT00430131|PROCEDURE|Cognitive Orientation to Occupational Performance|
47926580|NCT00430131|PROCEDURE|Contemporary Treatment Approach|
47926581|NCT02535572|DEVICE|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
47926582|NCT02535572|DEVICE|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
47926583|NCT06449365|DEVICE|midazolam by nasal atomizer|midazolam
47926584|NCT06449365|DRUG|intravenous midazolam|midazolam
47926585|NCT03206788|DRUG|Losartan|25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
47926586|NCT03206788|DRUG|placebo|Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
47926587|NCT03131427|DRUG|Standard of care|Standard of care according to the updated national and/or international guidelines
47926588|NCT01222156|PROCEDURE|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
47926589|NCT01222156|DEVICE|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
47926590|NCT02685059|DRUG|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
47926591|NCT02685059|DRUG|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
47926592|NCT02685059|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
47926593|NCT02685059|DRUG|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
47926594|NCT02685059|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
47926595|NCT05262348|DEVICE|adaptive DBS delivered through AlphaDBS IPG System|"The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive real-time fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable."
47926596|NCT05262348|DEVICE|conventional DBS delivered through AlphaDBS IPG System|The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
47926597|NCT01129024|DRUG|Lusutrombopag|tablet
47926598|NCT04549207|DRUG|Bone modifying agent|Use of bone modifying agent
47926599|NCT00355836|BEHAVIORAL|Mental Imagery|
48271856|NCT04972877|OTHER|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25\*40/50 mm) will be inserted into a depth of 15\~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
47926600|NCT05014061|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 6 hours
47926601|NCT04169971|OTHER|Music|Played through headphones during the operation under spinal anaesthesia
47926602|NCT03154892|PROCEDURE|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
47926603|NCT03154892|PROCEDURE|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
47926604|NCT01014923|BEHAVIORAL|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
47926605|NCT00960583|OTHER|Exercise program|24 group exercise sessions during 12 weeks
47926606|NCT00960583|OTHER|Routine follow-up|Advice to stay active
47926607|NCT06492837|DRUG|Mosunetuzumab in combination with Zanubrutinib|Combinations of Mosunetuzumab and Zanubrutinib as salvage strategy in patients with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
47926608|NCT05366400|DIAGNOSTIC_TEST|ECHO|Conventional routine tests and ECHO will be assessed. Biomarkers will be measured using ELISA The functional capacity was assessed by the COPD assessment test (CAT) questionnaire.
47926609|NCT00128505|DRUG|Mifepristone|
47926610|NCT01518738|BEHAVIORAL|breath attention training|4 week training
47926611|NCT01518738|BEHAVIORAL|working memory attention training|4 week training
47926612|NCT05973149|DRUG|QLH12016|according to the scheme description
47926613|NCT02257762|DIETARY_SUPPLEMENT|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
47926614|NCT02257762|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
47926615|NCT02257762|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet.
47926616|NCT04698577|BEHAVIORAL|Attention Training|The training was delivered face-to-face in groups of three participants. Participants were involved in a game of table tennis with two players and one spectator. The roles were rotated every 5 minutes so that each participant experienced 10 minutes of play and 5 minutes of observation. The game was played as normal with one point awarded to the player for every score achieved. All 3 players were asked to keep the score of the game in their minds during each 5-minute round. Participants had two objectives 1) to play and win the game and 2) to silently keep the score of the game. The researcher watched the game and accurately kept score, using a notepad. At the end of every 5-minute round, the researcher paused play and asked each child to write down the score they were holding in their mind. The researcher then revealed the true score, asked participants to swap roles and commence another round.
47926617|NCT04698577|BEHAVIORAL|Active Control|The control group was the same as the training group except for the core training mechanism; children were not required to mentally keep score. The researcher kept score by continually calling out the updated score as each point was won. The observing child was simply told to wait his/her turn.
47926618|NCT00492063|BIOLOGICAL|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
47926619|NCT00492063|BIOLOGICAL|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
47926620|NCT03857347|OTHER|Psychoeducation Group for FND|he intervention is a psychoeducation based group.
47926621|NCT00353470|BEHAVIORAL|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
47926622|NCT00353470|BEHAVIORAL|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
47926623|NCT00353470|BEHAVIORAL|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
47926624|NCT00532675|DRUG|LBH589|PAN 5 mg and PAN 20 mg capsules
47926625|NCT00532675|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 5mg or 25 mg
47926626|NCT04743570|DRUG|Placebo treatment|Active drug/placebo is given for the first 5 days of admission.
47926627|NCT04743570|DRUG|Methylnaltrexone treatment|Active drug/placebo is given for the first 5 days of admission.
47926628|NCT00412373|DRUG|Placebo|for 6 weeks
47926629|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
47926630|NCT00412373|DRUG|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
47926631|NCT04678076|DRUG|Ketoprofen Lysine|A single oral dose of test product - ketoprofen 25 mg/5 ml oral gel stick pack - will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
47926632|NCT04678076|DRUG|Ketoprofen Oral Product|A single oral dose of reference product as a single dose of half of a bipartite sachet of OKi® 80 mg granules for oral solution will be administered to healthy male and female volunteers under fed conditions in two consecutive study periods with a wash-out interval of at least 7 days between the two administrations.
47926633|NCT03665818|DEVICE|oral appliance treatment|mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
47926634|NCT00948467|DRUG|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
47926635|NCT03269162|DRUG|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
47926636|NCT03269162|DRUG|Docetaxel|75mg/m2,ivgtt 30mins, d1
47926637|NCT03269162|DRUG|Pemetrexed|500mg/m2, ivgtt 30mins, d1
47926638|NCT03269162|DRUG|Cisplatin|75mg/m2, ivgtt \>2h, d1
47926639|NCT04215757|PROCEDURE|peripheral nerve block|peripheral nerve blocks with low dose lignocaine in acute radiculopathy
47926640|NCT02400411|OTHER|Wheat bread|
47926641|NCT02400411|OTHER|margarine|
47926642|NCT02400411|OTHER|ham|
47926643|NCT02400411|OTHER|soup|
47926644|NCT02400411|OTHER|rye bread|
47926645|NCT03601234|PROCEDURE|laparoscopic and endoscopic cooperative surgery|compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery
47926646|NCT03601234|PROCEDURE|laparoscopic surgery|the traditional surgery
47926647|NCT04591860|DEVICE|Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet|Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.
47926648|NCT00985829|RADIATION|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
47926649|NCT01621815|BEHAVIORAL|Video Game|Playing various video games: RPG, Race, FPS, Strategy
47926650|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.|The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
47926651|NCT05579067|PROCEDURE|ACL Reconstruction using an autograph of Hamstrings muscle tendons.|The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
47926652|NCT02604329|DEVICE|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~* Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~* Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
47926653|NCT06005324|DRUG|Paclitaxel|Given as part of induction chemotherapy.
47926654|NCT06005324|DRUG|Carboplatin|Given as part of induction chemotherapy.
47926655|NCT06005324|DRUG|Cetuximab|Given as part of induction chemotherapy.
48095845|NCT03270930|PROCEDURE|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
47926656|NCT06005324|RADIATION|Standard Dose Radiation|Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.
48095846|NCT02735187|DEVICE|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
48095847|NCT02735187|DRUG|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
47926657|NCT06005324|RADIATION|Low Dose Radiation|Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.
47926658|NCT06005324|DRUG|Cisplatin|Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
47926659|NCT06005324|DRUG|TFHX Regimen|Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
47926660|NCT00028145|BEHAVIORAL|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
47926661|NCT01444092|DRUG|Entocort|Entocort capsules, oral
47926662|NCT03841084|DRUG|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
47926663|NCT04087330|OTHER|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
47926664|NCT04087330|OTHER|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
48620284|NCT04345224|OTHER|Dynamic tape|A kinesiology tape will be applied to the lateral hip of the affected side to facilitate the gluteus medius muscle activation while the participant is lying down. The first third of one I-strip will begin at the posterior iliac crest without tension to provide an anchor that will not cross the target tissue. The participant will actively flex the adducted hip to allow for the application of the middle third of the tape with approximately 50 percent tension (able to visualize the wave pattern in the tape). Subsequently, with the leg in the original position, the remainder of the tape will be applied without tension, ending approximately at the greater trochanter. Afterward, the second I-strip will be applied in the same manner starting at the anterior iliac crest.
47926665|NCT00286559|DRUG|SonoVue|
47926666|NCT00286559|DRUG|Optison|
47926667|NCT06448416|PROCEDURE|UBE|Patients with HDL were treated with UBE
47926668|NCT06306872|DRUG|Sequence A ABSK-011|Subjects in sequence A will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
47926669|NCT06306872|DRUG|Sequence B ABSK-011|Subjects in sequence A will receive 200 mg(100 mg capsule \*2) Oral administration of ABSK-011 old formulation at the first day of cycle 1 (C1D1), followed by a washout period of at least 4 days.Subjects will receive 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) Oral administration of ABSK-011 new formulation at the first day of cycle 2 (C2D1).
47926670|NCT06333197|PROCEDURE|ORIF through transparotid approach|The Retromandibular Transparotid approach is a surgical method used to access structures in the parotid gland region by making an incision behind the mandible.
47926671|NCT06333197|PROCEDURE|ORIF through retroparotid approach|The Retromandibular Retroparotid approach, also known as the Modified Blair Incision, is a surgical technique used to access structures within the parotid gland region by creating an incision behind the mandible and extending it into the parotid region.
47926672|NCT02739178|OTHER|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
48095848|NCT04730336|DEVICE|Tixel|Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
47926673|NCT00692354|DRUG|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
47926674|NCT02650921|DEVICE|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
47926675|NCT01143389|DRUG|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
47926676|NCT01143389|DEVICE|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
47926677|NCT01246908|DRUG|Placebo|Placebo administered twice per day for six weeks.
47926678|NCT01246908|DRUG|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
47926679|NCT03010436|DRUG|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
47926680|NCT03240744|BIOLOGICAL|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
47926681|NCT03978143|DRUG|Treatment A|Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
47926682|NCT03978143|DRUG|Treatment B|A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
47926683|NCT03978143|DRUG|Treatment C|A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
47926684|NCT03978143|DRUG|Treatment D|A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
47926685|NCT03978143|DRUG|Treatment E|250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
47926686|NCT03978143|DRUG|Treatment F|250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
47926687|NCT03978143|DRUG|Treatment G|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
47926688|NCT03978143|DRUG|Treatment H|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
47926689|NCT06449937|PROCEDURE|Radical local Surgery|Radical local resection of liver metastases ( hepatectomy, ablation )
47926690|NCT06449937|DRUG|Systemic therapy|Chemotherapy, targeted drug therapy, immunotherapy treatment.
48271857|NCT04972877|OTHER|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18\*25 mm) will be inserted superficially to a depth of \< 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
48271858|NCT00166387|PROCEDURE|Blood draw|A single blood draw.
47926691|NCT06449937|OTHER|Interventional therapy|Transcatheter arterial chemoembolization (TACE) Hepatic arterial infusion chemotherapy (HAIC)
47926692|NCT02622997|OTHER|Cervico-vaginal self-sample taken with first flocked swab|Cervico-vaginal self-sample taken with first flocked swab
47926693|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a second flocked swab|Cervico-vaginal self-sample taken with a second flocked swab
47926694|NCT02622997|OTHER|Cervico-vaginal self-sample taken with a HerSwab device|Cervico-vaginal self-sample taken with a HerSwab device
48271859|NCT03044392|OTHER|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
48271860|NCT00135629|BIOLOGICAL|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).
48271861|NCT00135629|OTHER|Placebo Injection|Placebo Injection
47926695|NCT04268602|OTHER|local anesthetic injection|1% lidocaine
48271862|NCT00135629|PROCEDURE|Venepuncture: 100ml blood sample taken on 12 separate visits|Venepuncture: 100ml blood sample taken on 12 separate visits
48271863|NCT02673255|BIOLOGICAL|Tetanus and Diphtheria (Td) Vaccine|
48271864|NCT03670030|DRUG|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
47926696|NCT05252260|PROCEDURE|Diode Laser|Vestibuloplasty surgery was performed via diode laser. Laser irradiation was performed in continuous wave mode, using a 980 nm diode laser with a power of 1.5W, 600 μm optical fiber.
47926697|NCT05252260|PROCEDURE|Conventional Surgery|A local anesthetic was administered bilaterally to the mental area and waited for 5 min for diffusion of the solution. Then, a horizontal incision was prepared at the mucogingival junction with a scalpel blade no. 15c. All the muscle fibers over the periosteum were resected carefully. Following, the mucosal flap was sutured to the depth of the vestibule sulcus with 4-0 polypropylene suture material, once every 4 mm, from a total of 5 regions.
47926698|NCT05252260|OTHER|Low level laser therapy (LLLT)|Vestibuloplasty surgery was performed via diode laser. Following, LLLT was applied in continuous wave mode for 1 minute without contacting the tissue, using a phototherapy probe (power output, 0.5W; total energy of 6 J / cm²) at a distance of 1-2 mm from the tissue. LLLT was repeated immediately after the surgery, on the 1st, 3rd and 7th days
47926699|NCT05473585|OTHER|very low nicotine content cigarettes|Investigational combusted cigarettes with very low nicotine content
47926700|NCT05473585|OTHER|normal nicotine content cigarettes|Investigational combusted cigarettes with normal nicotine content
47926701|NCT05473585|OTHER|Study e-cigarette|E-cigarette provided by study
47926702|NCT06453057|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
47926703|NCT04179409|DRUG|Amondys 45|This drug is used to target skipping of exon 45 of the dystrophin gene.
47926704|NCT04179409|DRUG|Exondys 51|This drug is used to target skipping of exon 51 of the dystrophin gene.
47926705|NCT04179409|DRUG|Vyondys 53|This drug is used to target skipping of exon 53 of the dystrophin gene.
47926706|NCT03835728|DRUG|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
47926707|NCT03835728|DRUG|Saline|This will be the matching placebo used in the study.
47926708|NCT03483129|BEHAVIORAL|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
47926709|NCT00970775|DRUG|AZD2423|oral solution, single dose
48271865|NCT05946967|OTHER|Biofeedback with TENS|Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve
48271866|NCT05946967|OTHER|Biofeedback only|Constipation patients will be given biofeedback treatment only
47926710|NCT00970775|DRUG|Placebo|oral solution,single dose
47926711|NCT00217464|DRUG|fulvestrant|intramuscularly
47951273|NCT05578248|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Non-invasive imaging technology that produces three-dimensional detailed anatomical images
47951274|NCT05578248|PROCEDURE|ACL reconstruction|Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
48271867|NCT03624647|DEVICE|Power toothbrush|Experimental power toothbrush
48271868|NCT03624647|DEVICE|Manual toothbrush|Marketed manual toothbrush
48271869|NCT01042444|DEVICE|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
48271870|NCT01424592|DEVICE|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
48271871|NCT00055640|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
47926712|NCT00459056|DRUG|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
47926713|NCT00459056|DRUG|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
47926714|NCT05038345|PROCEDURE|Pull through surgery|The principal purpose of pull through surgery for Hirschsprung disease is to remove aganglionic bowel and reconstruct the intestinal tract by connecting the normally innervated bowel just above the anus so that normal sphincter function is preserved.
47926715|NCT05714319|OTHER|Data collection|"Variables collected will include:~* demographics (sex, age)~* comorbidities (type 2 diabetes mellitus, familiar history of CAD, smoke habit, dyslipidaemia, hypertension, history of CAD)~* echocardiographic (left ventricle ejection fraction at admission, the presence and grade of diastolic dysfunction, and the presence and grade of any valvulopathies)~* angiographic data (presence of non-obstructive CAD (any coronary lesion \<50% diameter stenosis), the presence of myocardial bridge and, if this latter is present, its localization and length)~* laboratory measurements (hematologic variables (haemoglobin and white blood cells), creatinine, high sensitivity cardiac troponin I (hs-cTnI), and C-reactive protein (CRP) at the time of admission)~* medical therapy at admission~* response to intracoronary provocative test with ACh."
47926716|NCT05714319|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACCE in the past months will be investigated and collected.
47926717|NCT05164107|DEVICE|Globe Mapping and Pulsed Field Ablation System (Globe PF System)|During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.
47926718|NCT02787239|DRUG|HLX01|
47926719|NCT02787239|DRUG|Rituximab|
47926720|NCT02787239|DRUG|CHOP|
47926721|NCT04599179|DEVICE|self-expandable metal stent|self-expandable metal stent endoscopic positioning
47926722|NCT03469778|DEVICE|Robotic Therapy|Robotic Therapy
47926723|NCT05779384|OTHER|It was an observational study|data collected concerning the incidence of exacerbations
47926724|NCT01908881|BEHAVIORAL|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
47926725|NCT01908881|BEHAVIORAL|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
47926726|NCT03885167|OTHER|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
47926727|NCT05997394|OTHER|A prayer concert will be held for the participants.|Participants who are in the experimental group will be given a prayer audience.
47926728|NCT04672954|DRUG|Placebo|Placebo matching to 10 mg BI 474121 administered as uncoated tablets with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1: randomised, placebo-controlled, single-blind.
47926729|NCT04672954|DRUG|2.5 milligram (mg) BI 474121|2.5 mg BI 474121 administered as uncoated tablets (1 x 2.5 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
47926730|NCT04672954|DRUG|10 milligram (mg) BI 474121|10 mg BI 474121 administered as uncoated tablets (1 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 3 of the study: randomised, open-label.
47926731|NCT04672954|DRUG|20 milligram (mg) BI 474121|20 mg BI 474121 administered as uncoated tablets (2 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 1 of the study: randomised, placebo-controlled, single-blind.
47926732|NCT04672954|DRUG|40 milligram (mg) BI 474121|40 mg BI 474121 administered as uncoated tablets (4 x 10 mg) with 240 milliliter of water after subjects fasted overnight for at least 10 hours. This arm was part of Part 2 of the study: non-randomised, open-label.
47926733|NCT04367571|OTHER|Osteopathic Manipulative treatment (OMT)|"OMT techniques were focused on correcting the dysfunctions found before each OMT session and included myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field.~OMT group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
47951275|NCT01050543|DRUG|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
47951276|NCT01050543|DRUG|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
47951277|NCT05939570|OTHER|Interview|Prospective, semi-structured, qualitative interview.
48271872|NCT00055640|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
47926734|NCT04367571|OTHER|Manual Placebo (MP)|"The MP treatment consists of passive touch without joint mobilization in a protocolled order. The practictioners will be standing next to the bed, they'll touch lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they'll touch for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest for 5 minutes each.~MP group will receive a total of 4 sessions, one time each week for 4 weeks. Each session will last 40 minutes. It will be required by the patients to modify their bowels habits. The subjects will be evaluated right at baseline (T0), after one month (T1) after four sessions (T2) and after 1 month after the treatment (T3)."
47926735|NCT01847131|DRUG|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
47926736|NCT01847131|DRUG|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
47926737|NCT02694432|BEHAVIORAL|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
47926738|NCT02694432|BEHAVIORAL|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
47926739|NCT06311799|BEHAVIORAL|WIC Referral|Clinical team will refer study participants to WIC
47926740|NCT06311799|BEHAVIORAL|RDN Referral|Clinical team will refer study participants to a RDN
47926741|NCT02977182|OTHER|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
47926742|NCT06065111|OTHER|study tendon damage in osteogenesis imperfecta patients|"* To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease.~* To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease."
47926743|NCT03935113|OTHER|Kinesio taping|In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
47926744|NCT05477472|DRUG|St John's Wort|daily intake of CERES St John's Wort mother tincture. Dose according to the treating physician.
47926745|NCT06029517|OTHER|Education Intervention|Receive Indigneous SIPin intervention
47926746|NCT06029517|OTHER|Interview|Complete interviews
47926747|NCT06029517|PROCEDURE|Discussion|Attend focus groups
47926748|NCT06053710|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
48271873|NCT00055640|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
48620285|NCT04345224|OTHER|Rigid tape|The rigid tape will be applied in a standing position. The first tape will be applied from the greater trochanter to the anterior iliac crest. The second from the greater trochanter to the posterior iliac crest. Both tapes are applied with the muscle mass lifted towards the iliac crest.
47926749|NCT04976270|DRUG|GLPG3667|GLPG3667 capsules
47926750|NCT04976270|DRUG|Placebo|Matching placebo capsules
47926751|NCT00910624|DRUG|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
47926752|NCT00910624|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
47926753|NCT00910624|DRUG|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
47926754|NCT02677311|PROCEDURE|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
47926755|NCT02677311|PROCEDURE|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
47926756|NCT04176601|BEHAVIORAL|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
47926757|NCT02666157|DRUG|Dabigatran etexilate|this drug is administered twice per day for the entire study period
47926758|NCT02666157|DRUG|Rivaroxaban|this drug is administered once per day for the entire study period
47926759|NCT02666157|DRUG|Apixaban|this drug is administered twice per day for the entire study period
48271874|NCT00055640|DRUG|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
47926760|NCT06000267|PROCEDURE|Intubation|All the patients will be ventilated with face mask and intubated before elective surgery
47926761|NCT02907476|BEHAVIORAL|Iyengar Yoga|
48620286|NCT04345224|OTHER|Sham tape|The control group (sham tape application) will receive a single strip of a Kinesio tape across the lateral affected hip without tension in the tape or muscle stretch.
47926762|NCT02907476|BEHAVIORAL|Walking|
47926763|NCT00415298|DRUG|DACH polymer platinate AP5346|
47926764|NCT00415298|DRUG|oxaliplatin|
47926765|NCT00415298|GENETIC|gene expression analysis|
47926766|NCT00415298|OTHER|immunohistochemistry staining method|
47926767|NCT00415298|OTHER|pharmacological study|
47926768|NCT00415298|PROCEDURE|biopsy|
47926769|NCT05291169|DEVICE|Omeza® OCM™|"Omeza® OCM™ is a wound care matrix comprised of coldwater fish peptides (device) and cod liver oil (drug).~OCM™is supplied in a sterile single use vial."
47926770|NCT04034797|OTHER|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
47926771|NCT04034797|OTHER|No photo|Usual management without photography teletransmission
47926772|NCT00736047|BIOLOGICAL|NIC002|
47926773|NCT00736047|BIOLOGICAL|Placebo|
47926774|NCT05315011|OTHER|Whole-body cryotherapy|"The term cryotherapy refers to the process of chilling the body for medicinal purposes. WBC is carried out in a dedicated temperature and humidity controlled cryogenic chamber, which includes a brief exposure to extremely cold air. To avoid frostbite, only a few layers of clothes will be worn during the exposure. To avoid skin burns and necrosis, each participant must first remove their sweat before entering the cryochamber and a surgical mask is also worn to prevent moist air from being exhaled. Subjects will move their fingers and legs in the cryochamber and avoid holding their breath. The exposure time will be 4 minutes and 30 seconds in -85°C."
47926775|NCT05315011|OTHER|Placebo cryotherapy|The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
47926776|NCT06334406|OTHER|Biological samples|"Blood samples will be collected at baseline, after the diagnostic TURBT, and D15 after the end of treatment in each cohort.~Tumor tissues will be collected at baseline for three patients."
47926777|NCT02101697|BEHAVIORAL|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
47926778|NCT03879343|OTHER|Known diagnosis of attention deficit / hyperactivity disorder|Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
48271875|NCT00055640|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
47926779|NCT04486898|OTHER|Music group|Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
47926780|NCT02969408|DRUG|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
48271876|NCT00055640|GENETIC|microarray analysis|genetic testing
48271877|NCT00806221|DRUG|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
47926781|NCT05530018|BEHAVIORAL|Brief contact intervention|The brief contact intervention (BCI) will send out text messages to the participants. The text messages will include caring messages, reminders of appointments, and a link to a web page. The web page is anticipated to include safety planning, volitional helpsheet, and resources information. The text messages are anticipated to send out to the participants on a weekly base for 6 weeks in a row, and then change to monthly reminders. The monthly reminders are anticipated to include caring messages, reminders of appointments, and invitations to encourage the participants to click the previous web links again. The monthly reminders are anticipated to send out to the participants three times in a row. In the final reminder, the participants will be told that this intervention is going to end. In total, the participants will receive 9 texts within 5 months.
47926782|NCT05063071|DRUG|Tenofovir Alafenamide 25 MG|After orthotopic liver transplant, all patients will receive Tenofovir Alafenamide monotherapy without HBIG for HBV Prophylaxis.
47926783|NCT01716962|OTHER|Infusion of 6% tetrastarch for a total of 500 ml|
47926784|NCT02241889|DEVICE|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
47926785|NCT02241889|DEVICE|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
47926786|NCT03597646|DEVICE|Kinesio Tape|
47926787|NCT03597646|DEVICE|Threshold Inspiratory Muscle Trainer|
48271878|NCT00917436|DRUG|Thiocolchicoside|
48271879|NCT02463461|DEVICE|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
48271880|NCT02463461|DEVICE|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
48271881|NCT02463461|DEVICE|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
48443810|NCT01668602|DEVICE|Fast Walking with Fast Functional Electrical Stimulation (FES) Training|Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.
48443811|NCT01668602|OTHER|Fast Walking|Fast walking training sessions will be similar to FastFES in duration, dosage, structure but no FES will be provided.
48443812|NCT05546138|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
47926788|NCT06066229|OTHER|Questionnaire- Delphi method|Identify important evaluation criteria for lung transplant patients by rating each criterion
47926789|NCT01055652|DRUG|Dapagliflozin|10mg, oral, once daily
47926790|NCT00277082|DRUG|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
48271882|NCT02463461|DEVICE|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
48271883|NCT02463461|DEVICE|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
48443813|NCT05546138|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
48443814|NCT05546138|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
48443815|NCT05546138|DIAGNOSTIC_TEST|Corneal confocal Microscopy|Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density
47926791|NCT05120063|DEVICE|SPS monoblock stem, Symbios|hip prosthesis
47926792|NCT05120063|DEVICE|Quadra-H, Medacta|hip prosthesis
47926793|NCT05120063|PROCEDURE|3D planning of THR|primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)
47926794|NCT05120063|PROCEDURE|2D planning of THR|primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
47926795|NCT00918008|GENETIC|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
48443816|NCT05546138|DIAGNOSTIC_TEST|MRI|Functional and structural MRI pictures of peripheral nerves and CNS
47926796|NCT00156156|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
47926797|NCT00156156|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
47926798|NCT03657771|OTHER|DED|DED: Diet eliminating dairy
47926799|NCT03657771|OTHER|FREE|FREE: Diet eliminating dairy and food additives
47926800|NCT05885308|BEHAVIORAL|Otago|Group training is compared with training performed at participants' homes, using an online film
47926801|NCT04551313|BEHAVIORAL|social skill group|We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
47926802|NCT05069701|DIAGNOSTIC_TEST|SVV test|SVV test will be done with virtual reality glasses.
47926803|NCT00849316|DRUG|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
47926804|NCT00555308|OTHER|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
47926805|NCT00053898|DRUG|anastrozole|1 mg/day and placebo for 5 years
47926806|NCT00053898|DRUG|tamoxifen citrate|20 mg/day and placebo for 5 years
47926807|NCT00053898|RADIATION|Radiation Therapy|Adjuvant radiation therapy
47926808|NCT05599568|OTHER|Exercise|Either concentric or excentric exercise
47926809|NCT05292898|BIOLOGICAL|LCAR-AIO Cells|LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
48271884|NCT00950170|PROCEDURE|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
47926810|NCT05787990|DIAGNOSTIC_TEST|Diabetes Microvascular Complication Tests|Continuous glucose monitoring using Freestyle Libre Pro, Foot examination with monofilament and neurothesiometer, HbA1c and Urine Microalbumin Creatinine Ratio, Corneal confocal microscopy, Fundal photography, Optical coherence tomography, Optical cohere
47926811|NCT04978519|PROCEDURE|Cryotherapy|Cryotherapy is administered by using perineal needles, placed under ultrasound guidance to freeze the target tissue.
47926812|NCT03894722|PROCEDURE|Control|During the third molar extraction the saline solution will be used in the control group.
47926813|NCT03894722|PROCEDURE|0.5% concentration of PVP-I|During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
47926814|NCT03894722|PROCEDURE|1 % concentration of PVP-I|During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
47926815|NCT03894722|PROCEDURE|3 % concentration of PVP-I|During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
47926816|NCT03458598|PROCEDURE|Rectus sheath block|Rectus sheath block under ultrasound
47926817|NCT03458598|PROCEDURE|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
47926818|NCT03458598|DRUG|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
47926819|NCT03458598|PROCEDURE|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
47926820|NCT05424783|OTHER|Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate|The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
47926821|NCT06361381|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|"Both concha will be swabbed with an alcohol wipe before applying a thin layer of conductive gel. An ear clip electrode will be placed in the concha of both ears.~A frequency of 25 Hz will be applied with a pulse duration of 200 µs. Every 5 minutes, the subject will be asked if the intensity can be increased, decreased or remain the same to maintain the same level of intensity. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm."
47926822|NCT06361381|DEVICE|Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS)|For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. Participants will also receive active TENS, 100 Hz, 200 µsec on forearm.
47926823|NCT06361381|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS will be applied on subject's forearm at a strong but comfortable intensity
48271885|NCT03783949|DRUG|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
48443817|NCT05546138|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of Sural nerve
47926824|NCT05186415|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|The patient will receive the weight-based dose of Lumason of 0.03 mL/kg per injection, not to exceed 2.4 mL per injection per the FDA and manufacturer recommendations.
47926825|NCT05055245|OTHER|cycles|Patients are grouped according to the number of IVF/ICSI cycles.
47926826|NCT01165762|DRUG|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
47926827|NCT02848443|DRUG|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
47926828|NCT02848443|DRUG|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
47926829|NCT02848443|DRUG|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
47926830|NCT02848443|DRUG|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
47926831|NCT00754221|DRUG|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
47926832|NCT05428878|DIAGNOSTIC_TEST|ANS Watch|"1. ANS Watch will be used to record the pulse waves~2. Constitution questionnaire will be used to measure the constitution type"
48271886|NCT03783949|DRUG|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
48271887|NCT03783949|DRUG|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
48271888|NCT03783949|DRUG|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
48271889|NCT03783949|DRUG|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)
47926833|NCT00649545|BIOLOGICAL|adalimumab|40 mg every other week
47926834|NCT05555173|DEVICE|Buzzy|Buzzy is a small vibrating bee with ice-pack wings.
48271890|NCT06500663|OTHER|haemodialysis|haemodialysis effect on thyroid function
48271891|NCT01957956|OTHER|Laboratory Biomarker Analysis|Correlative studies
48271892|NCT01957956|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
48271893|NCT01957956|DRUG|Temozolomide|Given PO
48271894|NCT05690659|OTHER|device and exercise|cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
47926835|NCT05212857|DRUG|Leuprolide acetate|Given subcutaneously or as an injection
47926836|NCT05212857|DRUG|Goserelin acetate|Given subcutaneously or as an injection
47926837|NCT05212857|DRUG|Triptorelin acetate|Given subcutaneously or as an injection
47926838|NCT05212857|DRUG|Degarelix acetate|Given subcutaneously or as an injection
47926839|NCT05212857|DRUG|Abiraterone acetate|Given orally
48271895|NCT03878485|DEVICE|MRIdian Linac System from ViewRay|"* 0.35T MRI combined with a linear accelerator~* This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
48443818|NCT05546138|OTHER|Composite scores and questionnaires|Composite scores and questionnaires
47926840|NCT05212857|DRUG|Apalutamide|Given orally
47926841|NCT05212857|DRUG|Enzalutamide|Given orally
47926842|NCT05212857|PROCEDURE|Local treatment for primary lesion|Radical prostatectomy to remove prostate primary lesion
47926843|NCT05212857|RADIATION|Radiotherapy for primary lesion|Radical radiotherapy for primary lesion
47926844|NCT05212857|RADIATION|Radiotherapy for metastatic lesion|Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
47926845|NCT04954248|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
47926846|NCT03661476|BEHAVIORAL|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
47926847|NCT04523727|DRUG|ferric citrate|oral tablets
47951278|NCT03824184|PROCEDURE|manipulation of endometrium|Manipulation of endometrium with saline
48271896|NCT03878485|RADIATION|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
48271897|NCT01482702|BEHAVIORAL|weight loss intervention|Behavioral weight loss intervention
48271898|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
48271899|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
48271900|NCT06410014|OTHER|No intervention is performed|The study is observational
48271901|NCT03244358|DRUG|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
48271902|NCT03649919|OTHER||Patients receive routine diagnostic and treatment medications.
48271903|NCT02747485|DEVICE|Cardiac MRI|
48271904|NCT02747485|BIOLOGICAL|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
48271905|NCT02747485|PROCEDURE|myocardial biopsy|
47926848|NCT02217774|DEVICE|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
47926849|NCT04874051|DEVICE|Experimental Group|The experimental treatment will be provided by means of the OAK system. This device consists of 1 cabinet with 2 independent balance boards, 2 monitors (one for the physiotherapist and one for the patient) and 3 wireless IMUs (one for the left lower limb, one for the right lower limb and one for the trunk). The 2 balance boards provide body weight transfer exercises, while the wireless motion sensors provide one leg stance exercises or trunk exercises in a virtual environment.
47926850|NCT04874051|OTHER|Control Group|The Control Group will perform conventional balance exercises similar to the exercises provided with the OAK system.
47926851|NCT04958395|DIAGNOSTIC_TEST|FFR and d-FFR|Measure FFR and d-FFR
47926852|NCT03670420|OTHER|Medical honey|The investigators use Medihoney®, a medical honey released by the DermaSciences.
47926853|NCT02004288|DIETARY_SUPPLEMENT|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
48271906|NCT02747485|GENETIC|blood samples|extract DNA to look for genomic mutations associated with the disease.
47926854|NCT02051075|BIOLOGICAL|PXN sperm treatment|immotile sperm activation with PXN
47926855|NCT02051075|BIOLOGICAL|Sperm activation with PXN and oocyte activation|
47926856|NCT00329056|DRUG|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
47926857|NCT03253419|OTHER|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
47926858|NCT01903252|DRUG|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
47926859|NCT01903252|DRUG|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
48271907|NCT01903941|BEHAVIORAL|Aerobic Exercise|
48443819|NCT05992220|RADIATION|Atezolizumab plus bevacizumab, combined EBRT to vascular invasion|"The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites."
47926860|NCT03421769|PROCEDURE|EA and AMLK|A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
47926861|NCT03421769|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
47926862|NCT00729469|DRUG|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
47926863|NCT00729469|DRUG|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
47926864|NCT02899078|DRUG|Ibrutinib|Given PO
47926865|NCT02899078|DRUG|Nivolumab|Given IV
47926866|NCT00331110|DEVICE|Laterally-Wedged Insole with Ankle Strapping|
47926867|NCT00331110|DEVICE|Laterally-Weged Insole|
47926868|NCT04896801|RADIATION|MR-guided RT|The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy \< 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
47926869|NCT02587611|OTHER|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
47926870|NCT02587611|OTHER|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg \[13C\]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
47926871|NCT03028337|RADIATION|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
47926872|NCT03028337|BEHAVIORAL|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
47926873|NCT05260541|DRUG|60 mg PRAX-114 or 40 mg PRAX-114|Once daily oral treatment for 4 weeks
47926874|NCT05260541|DRUG|Placebo|Once daily oral treatment for 4 weeks
48271908|NCT01903941|BEHAVIORAL|Only Counseling|
48271909|NCT02848937|DEVICE|Bath with citrate|bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
48271910|NCT02848937|DEVICE|Bath with citrate and Ca_eq|bath with citrate and Ca_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
48271911|NCT02586714|OTHER|No intervention|Observation only
48271912|NCT02794337|RADIATION|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
47926875|NCT05260541|DRUG|40 mg PRAX-114|Once daily oral treatment for 8 weeks
47926876|NCT04290728|DEVICE|Apnea with high-flow nasal cannula|Application of oxygenation with high-flow nasal cannula with a rate of 2L/kg/min
47926877|NCT04290728|OTHER|Apnea|Apnea without any application of oxygenation
47926878|NCT05484687|DRUG|Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation|Administer 1.5 mg/kg lidocaine
47926879|NCT03873675|DIAGNOSTIC_TEST|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
48271913|NCT02794337|PROCEDURE|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
48271914|NCT02794337|DRUG|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
48443820|NCT05992220|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab q3w
48443821|NCT00003630|DRUG|arsenic trioxide|
48443822|NCT02259283|DEVICE|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
48443823|NCT01203332|BEHAVIORAL|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
48271915|NCT00127127|DRUG|vorinostat|vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
48443824|NCT02252120|DEVICE|Supreme|
48443825|NCT02252120|DEVICE|Laryngeal Tube|
48443826|NCT00054626|DRUG|cisplatin|
48443827|NCT00054626|DRUG|gemcitabine hydrochloride|
48443828|NCT00054626|PROCEDURE|adjuvant therapy|
48443829|NCT06133439|BEHAVIORAL|Colorectal Screen rates with implementation of evidence-based intervention|Mailed FIT kits, Cologuard, and diagnostic colonoscopies.
47926880|NCT02027129|OTHER|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
47926881|NCT06125470|BEHAVIORAL|Uptake of quality Reproductive health and Family planning products, information and Services|Strengthening capacity of health facilities and outreach to deliver quality reproductive and family planning services and address demand side barriers to the uptake of the services
47926882|NCT06125470|BEHAVIORAL|Capacity building of facility based and community based healthcare providers (public and private sector) on FP /SRH|"Training sessions on FP / SRH including FP Methods - LARC, PPIUD - Task Sharing \& Shifting for facility based healthcare providers at provincial level for Master Trainers with trickle down sessions at district level.~Training on Sayana Press, ECP, Balance Counselling Strategy and Life Skills Based Education for community-based healthcare providers including LHWs at district level."
47926883|NCT06125470|BEHAVIORAL|Adolescent Engagement|Identification of adolescent-friendly spaces through community based platforms including LHW health houses for girls and village health committees for boys with context-appropriate arrangements for LSBE and SRH counselling.
47926884|NCT06125470|BEHAVIORAL|Renovation and Refurbishment of selected healthcare facilities|Identification and improvement/ renovation of public and private healthcare facilities to strengthen the quality, provision and delivery of FP/SRH services, especially counselling, to catchment population
47926885|NCT06125470|BEHAVIORAL|Use of Data for Effective Decision-making|Improvement in data recording at the source level with reporting at existing platforms i.e. DHIS and LHW-MIS and use of this data for local decision making
47926886|NCT06125470|BEHAVIORAL|Procurement of FP/SRH medical supplies and equipment|Provision of commodities / supplies for shortest-time possible in facilities having stock-outs
47926887|NCT02723487|DRUG|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
47926888|NCT02723487|DRUG|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
47926889|NCT05273502|BEHAVIORAL|Citizen Science intervention|Intervention generated by a participatory research process (co-creation) in the elderly population living in rural areas to co-create solutions to improve their lifestyles, quality of life and health.
48271916|NCT01642212|DRUG|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
48271917|NCT01642212|DRUG|Placebo|
48271918|NCT00773487|OTHER|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
48271919|NCT03870841|DRUG|PC945|PC945, nebulized
48271920|NCT01071187|DRUG|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
48271921|NCT01071187|DRUG|Placebo|Placebo
48443830|NCT01434147|DRUG|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
48443831|NCT00549718|DRUG|Lurasidone HCl|Once daily
48443832|NCT03568838|DRUG|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
48443833|NCT03092466|PROCEDURE|femoral nerve catheter|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
48443834|NCT03092466|DRUG|femoral group|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
48271922|NCT03611699|DRUG|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
48271923|NCT03611699|DRUG|Placebo|Placebo inhaler
48271924|NCT01349309|BEHAVIORAL|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
48443835|NCT03092466|DRUG|control group|infusion of saline solution (15ml) in femoral catheter
48271925|NCT00508729|DRUG|Qingyi granules|
48271926|NCT03711227|DIAGNOSTIC_TEST|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
48271927|NCT06214988|PROCEDURE|selective approach defunctioning stoma|With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
48271928|NCT00670007|BIOLOGICAL|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
48271929|NCT00138021|DEVICE|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk \& Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
48271930|NCT02493647|BEHAVIORAL|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
48271931|NCT00727207|DRUG|everolimus|
48271932|NCT05637255|DRUG|SYL1801|1 drop in the eligible eye
48271933|NCT05406908|BIOLOGICAL|tozinameran|Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
48271934|NCT05387356|OTHER|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 \<150 despite a PEEP \>10 cmH2O.
48271935|NCT04920240|BEHAVIORAL|cleaning and disinfection mode for surfaces with high frequency contact|According to the results of the survey on the status of high frequency contact surface, the corresponding frequency and method of cleaning and disinfection are determined. Set up a multidisciplinary quality control team.
48271936|NCT04920240|BEHAVIORAL|Routine procedure|clean the high frequency contact surface like other surfaces
48271937|NCT00030784|DRUG|ifosfamide|
48443836|NCT03645681|DEVICE|InnAVasc arteriovenous graft surgical implant|An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
48443837|NCT01038947|BIOLOGICAL|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
48443838|NCT02559063|BEHAVIORAL|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
47926890|NCT05772351|DRUG|micronized flavonoid fraction|"Patients of the experimental group received Detralex® 1000 mg QD for 15 days before the operation, 3000 mg starting from day 1 after the surgery for 4 days, then 2000 mg for the next 3 days and 1000 mg till day 30 after surgery.~Under spinal anesthesia appropriate surgical intervention was performed. After the surgery, the patient was given a questionnaire and a scale for assessing pain at rest and during defecation within the first 2 weeks after surgery. During the hospital stay, the nurse filled out a section on the drugs used; after discharge, the patient filled out this section for 7 days after the surgery. After 30 days, the side effects section was filled out, and the quality of life was assessed on days 7 and 30. Also, the patients indicated in a separate column on which day after the surgery they were able to return to normal living or go to work."
48443839|NCT02559063|BEHAVIORAL|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
48443840|NCT05458635|PROCEDURE|Right heart catheter|Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
48271938|NCT00030784|DRUG|pegylated liposomal doxorubicin hydrochloride|
48271939|NCT06172556|PROCEDURE|Endovascular coiling, Surgical clipping, Mix|Endovascular coiling, Surgical clipping, Mix
48271940|NCT00891514|BEHAVIORAL|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
48271941|NCT00891514|BEHAVIORAL|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
48271942|NCT03157531|DEVICE|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
48443841|NCT00095108|DRUG|Recombinant Human Interleukin-21|
48443842|NCT01239017|BIOLOGICAL|REGN475|
48443843|NCT01239017|OTHER|Placebo|
48443844|NCT04813354|DEVICE|ELLIPTA|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
48443845|NCT04813354|DEVICE|BREEZHALER|"* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 1~* ELLIPTA followed by BREEZHALER/ Preference Questionnaire version 2~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 1~* BREEZHALER followed by ELLIPTA/ Preference Questionnaire version 2"
47926891|NCT02880696|BEHAVIORAL|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
47926892|NCT02880696|BEHAVIORAL|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
47926893|NCT02880696|DEVICE|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
47926894|NCT00253708|PROCEDURE|management of therapy complications|
47926895|NCT00253708|PROCEDURE|massage therapy|
47926896|NCT00253708|PROCEDURE|pain therapy|
47926897|NCT00253708|PROCEDURE|psychosocial assessment and care|
48271943|NCT05489081|BEHAVIORAL|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
48271944|NCT00682656|DRUG|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
48271945|NCT00682656|DRUG|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
48271946|NCT03710421|PROCEDURE|CS1-CAR T Therapy|Undergo CS1-CAR T therapy
48271947|NCT03710421|DRUG|Cyclophosphamide|Given IV
48271948|NCT03710421|DRUG|Fludarabine|Given IV
48271949|NCT03710421|PROCEDURE|Leukapheresis|Undergo leukapheresis
48271950|NCT00270608|PROCEDURE|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
48443846|NCT04417933|DEVICE|Tumor Electric Fields Treatment System|Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
48443847|NCT00128791|DRUG|Nitroprusside|
47926898|NCT00253708|PROCEDURE|quality-of-life assessment|
47926899|NCT04058171|DIAGNOSTIC_TEST|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
47926900|NCT05053932|OTHER|blood collection|blood collection
47926901|NCT00906971|OTHER|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
47926902|NCT05163015|OTHER|Data collection|Description: quality of life assessment
47926903|NCT00171470|DRUG|Tegaserod|
47926904|NCT06472986|OTHER|Activity-based therapy and transcutaneous spinal cord stimulation|Activity Based Therapy (ABT) is a method of neuro-rehabilitation that incorporates a high intensity, long duration and effortful engagement from the individual receiving therapy, to garner improvements in sensory and motor function. The ABT constitutes 4 types of exercises including: cardio-fitness, resistance, postural/weightbearing and functional exercises. TransCutaneous Spinal Cord Stimulation (TCSCS) stimulates spinal networks in the cervical region to neuro-modulate the descending motor commands/motor intentions from the brain, which control the muscles. In tCSCS, electrical stimulation is delivered at a frequency of 30-50Hz at 500-1000µs between C3-C7. 12 sessions of ABT (4 weeks), followed by 28 sessions of ABT-TCSCS (7 weeks). Each session will last 1 hour and delivered 3 times per week.
47926905|NCT06356428|OTHER|Physcian Attitudes toward Cardiac Rehabilitation and Referral Scale-Revised (PACRR-R)|The PACRR comprises 20 items and 1 open ended item to assess physicians' attitudes and beliefs about CR and referral (includes instructions for scale completion to respondents). Response options were 1 = strongly disagree, 2 = agree, 3 = neutral, 4 = agree, and 5 = strongly agree. Five (5) items are reverse-scored to mitigate acquiescence bias (denoted with \*), such that higher scores reflect more positive atti- tudes toward CR and referral. A mean score is computed for the total (where at least 80% of items were completed; i.e., 15/19) scale and subscales.
47926906|NCT05986084|DRUG|Cabotegravir Injection [Apretude]|Injection
47926907|NCT03048136|DRUG|Nivolumab|Specified dose on specified days
47926908|NCT03048136|DRUG|Ipilimumab|Specified dose on specified days
47926909|NCT05391191|DEVICE|MitrAssist TRISKELE® transcatheter aortic valve system|Patients were treated with MitrAssist TRISKELE® transcatheter aortic valve system
47926910|NCT00443196|PROCEDURE|MiCK Assay|Physician determined treatment
47926911|NCT00545129|DRUG|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
47926912|NCT00545129|DRUG|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
47951279|NCT06257485|DIAGNOSTIC_TEST|99mTc-pyrophosphate Single Photon Emission Computed Tomography|All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
48271951|NCT00270608|PROCEDURE|MRI of the spine and the right knee|a single time 45 minutes procedure
48271952|NCT00270608|PROCEDURE|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
48271953|NCT05651347|OTHER|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
48271954|NCT05651347|DRUG|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
48271955|NCT04756414|BEHAVIORAL|Exposure based face-to-face Cognitive Behavior Group Therapy|See under detailed description
48443848|NCT06349967|DRUG|Nab-paclitaxel Combined With Cadonilimab (AK104)|Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;
48443849|NCT02570009|BEHAVIORAL|TEAMS (Talking about Eating, Activity, Mutual Support)|
47926913|NCT03454009|BEHAVIORAL|Multimodal hygiene intervention|hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
47926914|NCT01615497|BEHAVIORAL|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
47926915|NCT01615497|BEHAVIORAL|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
47926916|NCT01615497|BEHAVIORAL|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
48443850|NCT02570009|BEHAVIORAL|Need Support Training|
47926917|NCT00813943|DRUG|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
47926918|NCT00813943|DRUG|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
47926919|NCT00813943|DRUG|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m\^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
47926920|NCT00813943|RADIATION|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
47926921|NCT01675089|DRUG|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
47926922|NCT05558501|OTHER|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
47926923|NCT05558501|OTHER|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
47926924|NCT00232869|DEVICE|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
47926925|NCT00232869|DEVICE|bare-metal stent|SMART™ bare-metal stent
47926926|NCT01785173|PROCEDURE|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
47926927|NCT01785173|PROCEDURE|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
47926928|NCT02925416|DRUG|Oritavancin|Administered intravenously
47926929|NCT02925416|DRUG|Placebo (D5W)|Administered intravenously
47926930|NCT03528902|DRUG|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
47926931|NCT03528902|DRUG|Placebo Oral Tablet|Placebo
47926932|NCT04392700|DRUG|Tenofovir disoproxil fumarate 300mg|Take the medicine once a day ，300mg/d
47926933|NCT04392700|DRUG|Entecavir 0.5 mg|Take the medicine once a day，0.5 mg/d
47926934|NCT06401629|DIAGNOSTIC_TEST|NPRP criteria|Under the NPRP criterion, the plasma glucose level at each time point (TP1, TP2, and TP3) is multiplied by its weight (Doi et al. 2022), and the sum of these products yields the unified Doi's Weighted Average Glucose (dwAG) value for each woman. The dwAG is then categorized into four groups: a dwAG of 6.8 or lower, \>6.8 to ≤7.5, \>7.5 to ≤8.6, and above 8.6 mmol/L, indicating normal gestational glycemia (NGG), impaired gestational glycemia (IGG), gestational diabetes mellitus (GDM), and high-risk gestational diabetes mellitus (hGDM), respectively (Doi et al. 2022).
47926935|NCT06401629|DIAGNOSTIC_TEST|IADPSG criteria|The IADPSG criteria define GDM as any one of the three-time points above specific thresholds: the time point prior to glucose ingestion (TP1) is considered abnormal when the fasting plasma glucose (FPG) value is ≥ 5.1 mmol/L, the 1-hour time-point after glucose ingestion (TP2) is considered abnormal when the value is ≥ 10 mmol/L, and the 2-hour time-point after glucose ingestion (TP3) is considered abnormal when the Post-Load Plasma Glucose levels are ≥ 8.5 mmol/L (Metzger et al. 2010). Put simply, meeting any one of these cut-offs results in a GDM diagnosis, regardless of whether the other time points show normal values or not (Metzger et al. 2010).
48443851|NCT03793972|OTHER|Triage with referral to primary care|During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
48443852|NCT03793972|OTHER|Usual care|During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
48443853|NCT06180460|BEHAVIORAL|CALM|The CALM intervention is a supportive-expressive therapy that is administered by CALM trained clinicians in a particular style.
47926936|NCT04985396|DRUG|Platelet Rich Plasma (PRP) group|Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
47926937|NCT00073853|PROCEDURE|Autologous Incubated Macrophages (cell therapy)|
47926938|NCT03508791|OTHER|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
47926939|NCT03508791|OTHER|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
47926940|NCT03508791|OTHER|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
47926941|NCT05045937|DRUG|Ivermectin|Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
47926942|NCT02489916|DRUG|CM4307|CM4307 300mg bid, each 4 week cycle
47926943|NCT05205473|PROCEDURE|Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
47926944|NCT05205473|PROCEDURE|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
47926945|NCT03893890|BIOLOGICAL|Previously Treated with EN3835|No treatment to be administered - Observational only
47926946|NCT06215768|DRUG|Dexmedetomidine and Midazolam|"This will be a prospective, double-blind, randomized controlled study conducted between October 2023and June 2024 .~Patients aged( 2_12) years, American Society of Anesthesiologists class (ASA) I or II, scheduled for tonsillectomy with and without adenoidectomy will be randomized to receive intravenous dexmedetomidine 0.5 μg/kg Or intravenous midazolam 0.1 mg /kg(Group A) or (Group B) over 10 minutes after induction of anesthesia. The primary outcome is the incidence of ED within 30 minutes after extubation. Other outcomes are the incidence of pain, extubation time, post-anesthesia care unit (PACU) length of stay after extubation, adverse events, and the incidence of negative postoperative behavioral changes (NPOBCs)."
47926947|NCT06492655|DRUG|CKD-383(Fed)|After maintaining NPO for at least 10 hours before a high-fat meal, take a high-fat meal within 20 minutes on each medication day, and take CKD-383 two tablets orally with 150 mL of water at room temperature.
47926948|NCT06492655|DRUG|CKD-383(Fasted)|After maintaining NPO for at least 10 hours before dosing, and take CKD-383 two tablets orally with 150 mL of room temperature water with 30g of sugar added on each dosing day.
47926949|NCT02585570|DRUG|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
47926950|NCT02642588|DIETARY_SUPPLEMENT|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
47926951|NCT02556164|PROCEDURE|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
47926952|NCT02556164|OTHER|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
47926953|NCT03751657|DRUG|Insulin icodec|Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
47926954|NCT03751657|DRUG|Placebo (insulin 287)|Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
47926955|NCT03751657|DRUG|Metformin|Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
47926956|NCT03751657|DRUG|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
47926957|NCT03751657|DRUG|Insulin glargine|Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
47926958|NCT03751657|DRUG|Placebo (insulin glargine)|Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
47926959|NCT02973373|DEVICE|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
47926960|NCT02973373|OTHER|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
47926961|NCT01456767|DIETARY_SUPPLEMENT|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
47926962|NCT01624311|OTHER|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
47926963|NCT01624311|OTHER|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
47926964|NCT00400296|DRUG|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
47926965|NCT02358317|BEHAVIORAL|Video Game Motor Training|
47926966|NCT02358317|BEHAVIORAL|Sedentary Video Game Training|
47926967|NCT00084890|DRUG|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
47926968|NCT00084890|DRUG|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
47926969|NCT03452527|BIOLOGICAL|ICON-1|ICON-1 0.6 mg by intravitreal injection
47926970|NCT03452527|BIOLOGICAL|aflibercept|aflibercept 2 mg by intravitreal injection
47926971|NCT05094973|DEVICE|Carriere Motion Appliance®|To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
47926972|NCT01193257|DRUG|Orteronel|Orteronel tablets
47926973|NCT01193257|DRUG|Prednisone|Prednisone tablets
47926974|NCT01193257|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
48271956|NCT03084133|BEHAVIORAL|Therapeutic Education Strategy|"In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002)."
47926975|NCT00952380|DRUG|dalteparin|dalteparin subcutaneous injection
48271957|NCT01941589|DRUG|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
47926976|NCT06139042|DIAGNOSTIC_TEST|Blood drawing|The participants had their blood drawn.
48271958|NCT01941589|DRUG|corticosteroids only|IV corticosteroids only
47926977|NCT03302364|DRUG|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
47926978|NCT02174588|DRUG|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
47926979|NCT02174588|DRUG|propofol|propofol are used for sedation drug
47926980|NCT03090048|DRUG|Vitamin A|Vitamin A 2-3 % concentration
47926981|NCT03090048|DRUG|Azithromycin|azithromycin monohydrate
47926982|NCT00373438|PROCEDURE|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
47926983|NCT00593242|BIOLOGICAL|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
47926984|NCT00593242|OTHER|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
47926985|NCT03615508|DRUG|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
48271959|NCT06068582|BEHAVIORAL|Strenghtening the brain|Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
48271960|NCT06068582|BEHAVIORAL|Strengthening the mind|Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
48271961|NCT06195202|DRUG|AIs|Patients with AIs
48271962|NCT06195202|DRUG|OFS+AIs|Patients with OFS+AIs
48271963|NCT06195202|DRUG|FUL|Patients with FUL
48271964|NCT05444712|PROCEDURE|Chemotherapy + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
48443854|NCT06180460|BEHAVIORAL|Treatment as usual|Treatment as usual includes a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.
48443855|NCT04638452|BEHAVIORAL|Video & movements recording|Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
48443856|NCT04638452|BEHAVIORAL|Questionnaires|Passing self and hetero questionnaires of emotion felt and perceived.
48443857|NCT04472156|PROCEDURE|Transfer of mosaic embryo|Subjects will transfer a mosaic embryo transferred to their uterus
47926986|NCT04328207|OTHER|No Financial Incentive|Standard of care eye health education
47926987|NCT04328207|BEHAVIORAL|Financial Incentive|Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
47926988|NCT00407381|DRUG|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
47926989|NCT00407381|PROCEDURE|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
47926990|NCT02622906|DRUG|Pasireotide|60 mg per month of the Pasireotide during 6 months
47926991|NCT02622906|DRUG|Placebo|Vehicule injection per month during 6 months
47926992|NCT04443595|PROCEDURE|Dual-scopic pancreatic necrosectomy（DPN）|Treatment of Acute Severe Pancreatitis with DPN
47926993|NCT03896347|OTHER|ViBone®|Viable bone allograft
47926994|NCT03896347|OTHER|Demineralized Bone Matrix|Demineralized Bone Matrix
47926995|NCT03896347|OTHER|Bone Morphogenetic Protein|Bone Morphogenetic Protein
47926996|NCT03554811|DEVICE|Functional electrical stimulation assisted supine cycling (FESC)|A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.
47926997|NCT03554811|OTHER|Conventional early exercise and mobility interventions|These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
47926998|NCT03250364|DEVICE|Multilayer bandage|See arm/group descriptions
47926999|NCT03250364|DEVICE|Double compression bandage|See arm/group descriptions
47927000|NCT03250364|DEVICE|Cohesive bandage|See arm/group descriptions
47927001|NCT03250364|DEVICE|Adhesive compression bandage|See arm/group descriptions
47927002|NCT03250364|DEVICE|Kinesiotaping bandage|See arm/group descriptions
47927003|NCT03250364|OTHER|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
47927004|NCT03250364|OTHER|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
47927005|NCT03250364|BEHAVIORAL|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
47927006|NCT05048069|DRUG|Mucosta®SR Tablets 150mg(Rebamipide)|adult patients with gastric mucosal lesions (erosion, bleeding, redness, and edema) of acute gastritis or acute exacerbation of chronic gastritis prescribed with Mucosta®SR Tab. according to the medical considerations of the investigator.
47927007|NCT05610189|DRUG|Tavapadon|Oral tablets
47927008|NCT01566214|BEHAVIORAL|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
47927009|NCT00000477|DRUG|lovastatin|
47927010|NCT00164697|BEHAVIORAL|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
48271965|NCT05444712|PROCEDURE|Chemotherapy + ASCT + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
48271966|NCT01335971|DRUG|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
48271967|NCT01335971|DIETARY_SUPPLEMENT|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
48271968|NCT01335971|OTHER|Placebo|Microcrystalline cellulose once daily by mouth
48271969|NCT02149225|DRUG|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
48443858|NCT01513174|DRUG|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
48443859|NCT01513174|DRUG|Olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
48443860|NCT00953498|DRUG|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
48443861|NCT00953498|DRUG|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
48271970|NCT02149225|DRUG|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
48271971|NCT02472457|OTHER|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
48271972|NCT02472457|OTHER|Free Diet|This diet contains no restrictions.
48271973|NCT05547945|BEHAVIORAL|Health Promotion Program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
48271974|NCT05547945|BEHAVIORAL|Control group|The control group received as usual care.
48271975|NCT00292084|DRUG|Celgosivir|
48271976|NCT02138734|BIOLOGICAL|BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )|"BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, 18, 24,30 and 36 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included."
48271977|NCT02138734|BIOLOGICAL|BCG( 50mg/Instillation)|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
48271978|NCT06300801|DIAGNOSTIC_TEST|Is the preoperative c-reactive protein/albumin ratio successful in predicting postoperative pancreatic fistula in patients undergoing pancreatoduodenectomy?|In this study, predicting pancreatic fistula before surgery will reduce postoperative complications and mortality.
48443862|NCT01061021|BEHAVIORAL|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
48443863|NCT01061021|BEHAVIORAL|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
48443864|NCT02252250|PROCEDURE|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
47927011|NCT01638442|DRUG|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
47927012|NCT01638442|DRUG|CHR-2797|"Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------"
47927013|NCT03768557|DRUG|Minocycline|Minocycline (200mg)
47927014|NCT03768557|OTHER|placebo|Lactose (400mg)
47927015|NCT06072898|DRUG|Psilocybin|Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.
47927016|NCT06072898|OTHER|Microcrystalline cellulose|MCC (excipient), 25mg PO.
47927017|NCT06072898|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy in the form of reassurance, integration, and de-escalatory techniques (if needed). Facilitating rapport and a positive environment.
47927018|NCT05373069|PROCEDURE|Mechanical ischemic preconditioning of diep-type flap|"Mechanical ischemic preconditioning: Performing series of reperfusion ischemia on the flap pedicle, before cold ischemia of the flap (flap harvesting before vascular mechanical anastomoses at the recipient site)~* 10 min of clamping with single-use microvascular forceps~* 10 min declamping~* 10 min of tightening with pliers~* 10 min declamping Either preconditioning for 40 minutes, simulating 2 cycles of ischemia reperfusion prior to flap harvesting and cold ischemia before revascularization."
47927019|NCT02359175|DRUG|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
47927020|NCT02359175|DRUG|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
47927021|NCT02359175|DRUG|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
47927022|NCT02359175|DRUG|Oral Paracetamol|Paracetamol to be given orally
47927023|NCT02359175|DRUG|Oral NSAID|NSAID to be given orally
47927024|NCT02359175|DRUG|Oral opioids|Opioids to be given orally
47927025|NCT02359175|DRUG|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
47927026|NCT02635646|OTHER|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:~1. nutritional counseling,~2. physical activity counseling,~3. psychological counseling,~4. metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
47927027|NCT02635646|OTHER|individual approach|"individual approach that includes:~1. nutritional and physical activity counseling in individual appointments,~2. metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
47927028|NCT01976039|OTHER|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
47927029|NCT01106417|BIOLOGICAL|NeoFuse|Single Dose NeoFuse Surgical Implantation
48271979|NCT01646359|DEVICE|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
48271980|NCT01646359|DEVICE|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
47927030|NCT01106417|DEVICE|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
47927031|NCT06504745|OTHER|Peer education|experimental group
47927032|NCT06504745|OTHER|control group|instruction training
47927033|NCT02656680|BEHAVIORAL|Continuous Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.
47927034|NCT02656680|BEHAVIORAL|Closed Enrollment|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
47927035|NCT03364829|DRUG|Indacaterol/Glycopyrronium|
47927036|NCT01863589|DRUG|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
47927037|NCT04963842|BEHAVIORAL|Use of bio-plastic food packaging material and avoidance of plastic food packaging material|The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
47927038|NCT00383474|DRUG|Bortezomib|Given IV
47927039|NCT00383474|OTHER|Laboratory Biomarker Analysis|Correlative studies
47927040|NCT00383474|DRUG|Tipifarnib|Given orally
48106790|NCT06229717|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
48271981|NCT02251912|DRUG|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
48271982|NCT02251912|DRUG|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
48271983|NCT06329050|DRUG|Losartan|Administration of Losartan tablets(50 mg)
48271984|NCT06329050|DRUG|Placebo|Administration of Placebo tablets
47927041|NCT03645343|DEVICE|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
47927042|NCT03645343|DEVICE|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
47927043|NCT04732000|DRUG|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
47927044|NCT04732000|OTHER|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
47927045|NCT01715597|DRUG|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
47927046|NCT01715597|DRUG|Normal saline|normal saline 500ml IV
47927047|NCT02173262|DRUG|G-CSF|
47927048|NCT02173262|DRUG|Ciprofloxacin|
47927049|NCT05382000|DIAGNOSTIC_TEST|Advanced triage tool for Gynecology and Obstetrics emergencies based on artificial intelligence algorithms.|"After the conventional triage, a second independent doctor will make the suit with the Mediktor Hospital tool.. In less than 3 minutes and with an average of 14 questions, Mediktor performs an interrogation very similar to what an emergency doctor would do. The professional version allows the health professional to modify the course of the questions in the middle of the evaluation, if he considers it necessary to go deeper into some aspect of the anamnesis. The system allows you to see in real time the diseases that Mediktor considers possible during the evaluation.~At the end of the triage process, Mediktor offers the level of urgency and a list of possible diagnoses based on the signs and symptoms answered. The professional can change the level of urgency if he considers it beneficial for the patient.~Once the two triages (Conventional and Mediktor) have been carried out, the patient will be seen according to the care protocols of the center."
47927050|NCT03893253|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
47927051|NCT03893253|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
47927052|NCT02452931|DRUG|Leuprolide Acetate 45 mg|Subcutaneous injection
47927053|NCT03134456|DRUG|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
47927054|NCT02539056|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
47927055|NCT06394934|BEHAVIORAL|Healthscan App|Participants will use the Healthscan mobile application to monitor and record their daily blood pressure at home. The app allows participants to enter their BP measurements, which are then used to calculate blood pressure variability (BPV). The app's use is intended as a non-invasive, practical tool for patient self-management and longitudinal health monitoring in hypertensive individuals.
47927056|NCT06354556|DRUG|HRS-1893 tablet|HRS-1893 tablet single dose
47927057|NCT06354556|DRUG|Verapamil tablet|Verapamil tablet 80 mg tid
47927058|NCT06044766|PROCEDURE|Surgical exatrction of impacted lower third molars|Surgical exatrction of impacted lower third molars to verify the form of the root
47927059|NCT00385164|PROCEDURE|PET/CT scan for RT planning|
47927060|NCT00357591|DEVICE|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
47927061|NCT00813540|BEHAVIORAL|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
47927062|NCT00813540|OTHER|Usual Care|Usual Care
47927063|NCT03430713|PROCEDURE|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
47927064|NCT05421884|BEHAVIORAL|5 Love Languages|Emotional support will be given through utilizing the patient/partners specific Love Language (physical touch, words of affirmation, gifts, quality time, and acts of service).
47927065|NCT05934669|DRUG|Intranasal Midazolam|Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
47927066|NCT05934669|DRUG|Intranasal Dexmedetomidine|See above
47927067|NCT05934669|DRUG|Intranasal Ketamine|See above
47927068|NCT04250077|BEHAVIORAL|Community Reinforcement And Family Training (CRAFT)|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
48271985|NCT02155400|DEVICE|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
48271986|NCT02155400|DEVICE|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
48271987|NCT03775707|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48271988|NCT03775707|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
47927069|NCT04250077|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
47927070|NCT03317327|DRUG|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
47927071|NCT03317327|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
47927072|NCT03689907|OTHER|Chimerism Evaluation|Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
47927073|NCT04240080|DEVICE|Accuvein® Veinfinder|Near-infrared light reflection utilized by healthcare providers to see superficial veins under the skin.
47927074|NCT00000803|DRUG|Delavirdine mesylate|
47927075|NCT00000803|DRUG|Zidovudine|
47927076|NCT00000803|DRUG|Didanosine|
47927077|NCT05181280|OTHER|Intervention Group|"Exposure session will consist of 15 social media ideal body message posts."
47927078|NCT05181280|OTHER|Control Group|Exposure will consist of 15 social media posts on infant feeding tips.
47927079|NCT03196700|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
47927080|NCT01782001|DIETARY_SUPPLEMENT|vitamin A|vitamin A with placebo
47927081|NCT01782001|DIETARY_SUPPLEMENT|vitamin A and zinc|combination of vitamin A and zinc supplements
47927082|NCT02050178|DRUG|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
47927083|NCT06034990|OTHER|10-min online survey|This is a cross-sectional study. The data are collected by a 10-min online survey administered to included physicians which will be distributed via online channels such as such as official website or Facebook pages of Society of intensive care or Society of nephrology of corresponding countries.
47927084|NCT05457582|DRUG|Placebo plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
47927085|NCT05457582|DRUG|PCSK 9 Inhibitor plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
47927086|NCT00528970|DRUG|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
47927087|NCT00528970|DRUG|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
47927088|NCT03655002|DRUG|Cyclophosphamide|Given IV
47927089|NCT03655002|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
47927090|NCT03655002|BIOLOGICAL|Nivolumab|Given IV
47927091|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
48443865|NCT02252250|PROCEDURE|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
47927092|NCT02683746|DRUG|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
47927093|NCT02683746|DRUG|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
47927094|NCT02683746|DRUG|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
47927095|NCT01115192|PROCEDURE|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
47927096|NCT01115192|PROCEDURE|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
48443866|NCT02778815|OTHER|Kindness for Mums|
48271989|NCT02626676|OTHER|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
47927097|NCT00389402|DRUG|saquinavir/ritonavir|
47927098|NCT00389402|DRUG|atazanavir/ritonavir|
47927099|NCT01403948|DRUG|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
47927100|NCT02700633|DEVICE|Pacemaker|
47927101|NCT01791959|DIETARY_SUPPLEMENT|synbiotic|2 symbiotics capsules per day for 28 weeks
47927102|NCT01791959|OTHER|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
47927103|NCT02837081|OTHER|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
47927104|NCT02837081|OTHER|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
48271990|NCT02382094|DRUG|Bicalutamide|
48443867|NCT02513056|OTHER|MRI|MRI
48443868|NCT02813018|PROCEDURE|0.2 ml/kg of 0.2% ropivacaine|In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
48443869|NCT02813018|PROCEDURE|0.2mg/kg of Normal Saline|In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
48443870|NCT01817985|DRUG|GS-5816|
47927105|NCT01135667|DRUG|clopidogrel|clopidogrel 150 mg once daily for 30 days
47927106|NCT01135667|DRUG|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
47927107|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection|Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
47927108|NCT05047445|BIOLOGICAL|COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection|Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).
47927109|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants|Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
47927110|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants|Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29
47927111|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants|A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
47927112|NCT05047445|BIOLOGICAL|COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants|A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
47927113|NCT02572739|DEVICE|PICCO|measurements based on thermodilution
47927114|NCT02572739|DEVICE|NICCOMO|measurements based on impedance
47927115|NCT01254942|OTHER|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
47927116|NCT01254942|OTHER|Usual Care|
47927117|NCT02111278|OTHER|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
47927118|NCT02111278|OTHER|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
47927119|NCT02111278|OTHER|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
48095849|NCT06240039|OTHER|Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon|"The experimental days consist of four study days:~1. Assessment of liver fat and visceral fat by magnetic resonance imaging (MRI; 6-point Dixon) (study day A)~2. Somatostatin infusion (4 hours) plus amino acid infusion (45 minutes) (study day B)~3. Saline infusion (4 hours) plus amino acid infusion (45 minutes) (study day C)~4. Somatostatin infusion (4 hours) plus saline infusion (45 minutes) (study day D)~The subjects will participate in the experimental days (study day B to D) in randomized order on three different days. For study day B to D, at timepoint t = -75, subjects will receive either; a 240-minute intravenous infusion of a somatostatin analogue (at 200 ng/kg/min (infusion rate will not exceed 1000 µg/hour) or saline. After 75 minutes (timepoint t = 0), the subjects will receive a 45-minute intravenous infusion of amino acids or saline at 3.885 ml/kg/hour.~In total, blood will be sampled 11 times over a period of 6 hours and 15 minutes."
48095850|NCT04204564|DEVICE|pactlitaxel PAD device|Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
48095851|NCT03523910|DEVICE|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
48095852|NCT05665855|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid ketone monoester supplement.
48095853|NCT05665855|OTHER|Placebo|A liquid placebo that is taste-matched to the ketone monoester supplement.
48095854|NCT06480409|OTHER|VR Mindfulness and Stress Reduction Program|"Intervention Procedure:~Duration and Frequency: Participants will engage in 15-minute VR relaxation sessions, held five times a week over a period of one month.~VR Content: The VR sessions will feature high-quality 360° videos with therapeutic audio, including guided relaxation, calming music, and nature sounds.~Physiological Monitoring: Throughout the sessions, participants' physiological responses will be monitored using Polar H-10 sensors to measure heart rate variability (HRV), providing data on autonomic nervous system activity.~Psychological Assessment: Participants will complete the Perceived Stress Scale (PSS-10) before and after the intervention to evaluate changes in stress levels.~Cybersickness Monitoring: The occurrence of any adverse effects, such as cybersickness, will be monitored and recorded."
48095855|NCT05879666|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
48443871|NCT03810950|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
48095856|NCT06199687|OTHER|Use of Virtual Reality|Use of Virtual Reality after After Thyroid-Parathyroid Surgery
47927120|NCT02204761|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
47927121|NCT00538785|BIOLOGICAL|Motavizumab|15 mg/kg IM administered at monthly intervals
47927122|NCT00538785|BIOLOGICAL|Palivizumab|15 mg/kg IM administered at monthly intervals
47927123|NCT01634256|DIETARY_SUPPLEMENT|Placebo|Placebo(3.0g/day)
47927124|NCT01634256|DIETARY_SUPPLEMENT|Fermented turmeric|Fermented turmeric(3.0g/day)
47927125|NCT04391985|DRUG|SOF plus (OBV/PTV/r) plus RBV|They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
47927126|NCT05347147|DRUG|Presendin|Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
47927127|NCT05347147|DRUG|Placebo|Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
48095857|NCT02043717|DIETARY_SUPPLEMENT|Vitamin D|"Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism \[Internet\]. 2012 May \[cited 2012 Oct 31\];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505"
48095858|NCT02838316|DRUG|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
48095859|NCT02018666|DEVICE|NAVA endotracheal tube|
48095860|NCT04357418|OTHER|it is a survey|this interview can be carried out face to face or remotely.
48095861|NCT01501929|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
48095862|NCT01501929|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
48095863|NCT01501929|PROCEDURE|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
48095864|NCT01501929|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
48095865|NCT01501929|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
48095866|NCT00867347|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
48095867|NCT00867347|RADIATION|radiation therapy|Patients undergo radiotherapy
48095868|NCT01126840|BEHAVIORAL|Telephone Interview|The phone interview should take 30-45 minutes to complete.
48095869|NCT01126840|BEHAVIORAL|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
48095870|NCT02126397|PROCEDURE|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
47927128|NCT06047951|PROCEDURE|Stereotactic RadioSurgery (SRS)|"All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~* The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~* Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~* Only one aneurysm will be treated per patient~* The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~* A prescription dose of 25 Gy at the margin of the target will be used~* The maximal dose on optic pathways will be kept below 10 Gy~* The brainstem 12-Gy volume will be kept below 1cc"
48095871|NCT02126397|PROCEDURE|polyps resection with bipolar electrode|
48095872|NCT01195675|DRUG|BI 10773 (low)|single oral dose
47927129|NCT05680805|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day in 3 divided dose for 24 weeks
47927130|NCT00668356|DRUG|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
47927131|NCT00668356|DRUG|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
48095873|NCT01195675|DRUG|Moxifloxacin|single oral dose
47927132|NCT00176189|DEVICE|All ceramic FPDs|
47927133|NCT04444830|DRUG|Sprix|Intranasal Ketorolac - used as directed for an appropriate, previously established indication
48095874|NCT01195675|DRUG|BI 10773 Placebo|2 times single dose
48095875|NCT01195675|DRUG|BI 10773 (high)|single oral dose
48095876|NCT05428436|DRUG|BI 1015550 ICF|BI 1015550 intended Commercial Formulation (iCF)
48095877|NCT05428436|DRUG|BI 1015550 TF2|BI 1015550 trial formulation 2 (TF2)
48095878|NCT04372992|OTHER|Timing of stoma closure|Defining the best timing of stoma closure in relation to adjuvant therapy compliance
48095879|NCT01214902|DEVICE|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
48095880|NCT01214902|BEHAVIORAL|play|play which encourages the use of the hemiplegic hand
48095881|NCT05875207|BEHAVIORAL|Mindfulness based practice|Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.
48095882|NCT05875207|BEHAVIORAL|Control/Standard Physical Therapy|Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
48095883|NCT04684342|DIAGNOSTIC_TEST|Routine Laboratory investigations|"1. Complete blood picture~2. Liver function test and prothrombine time \& concentration.~3. Blood urea and creatinine~4. Blood glucose, serum Na and K~5. CRP and ESR~6. Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers"
48095884|NCT00406289|PROCEDURE|18F-FDG-PET radiotherapy|
48095885|NCT06486974|DRUG|NaF|Group 1 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
48095886|NCT06486974|DRUG|Na MFP|Group 2 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
48095887|NCT03408314|OTHER|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
48095888|NCT03408314|OTHER|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
48095889|NCT04465071|DRUG|AEONTM Repair and AEONTM Protect Plus lubricating eye drops|AEONTM Repair and AEONTM Protect Plus lubricating eye drops
48095890|NCT02576418|OTHER|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
48095891|NCT06582563|DIAGNOSTIC_TEST|Whole Blood Clotting Time|Comparator
48095892|NCT06358638|DRUG|Daratumumab|Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
48095893|NCT06358638|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
48095894|NCT06358638|DRUG|Sirolimus|Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
48095895|NCT06358638|RADIATION|Total Body Irradiation|Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.
48095896|NCT05198453|BIOLOGICAL|vaccination|patients who received COVID-19 vaccine
48095897|NCT03392662|DEVICE|Hemopatch|Patients received product at the discretion of their surgeon.
48095898|NCT00150566|DRUG|Lanthanum carbonate|
48095899|NCT00246298|DRUG|epoetin alfa|
48095900|NCT06076343|BEHAVIORAL|DBT skills-training and Family Connections interventions|"DBT skills-training program includes four modules: 1. Mindufulness, 2. Distress Tolerance, 3. Emotion Regulation, 4. Interpersonal effectiveness.~FC program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills."
48095901|NCT01147549|DRUG|[C14]AZD9668|Oral Solution 60 mg Single Dose
48095902|NCT03293264|BEHAVIORAL|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
48095903|NCT06048341|PROCEDURE|Sono-guided injection|After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
48095904|NCT06048341|DRUG|Ropivacaine injection|After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
48095905|NCT06048341|DRUG|Saline injection|After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
48095906|NCT03720015|BEHAVIORAL|Physical exercise|Physical exercise controlled program supervised by an accredited exercise specialist
48095907|NCT03720015|DIETARY_SUPPLEMENT|Nutritional management|Nutritional management controlled by a PhD clinical and sport nutrition specialist
48095908|NCT02689375|DEVICE|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
48095909|NCT01656304|BIOLOGICAL|bevacizumab|Given IV
48095910|NCT01656304|OTHER|laboratory biomarker analysis|Correlative studies
48095911|NCT00926393|DRUG|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
47927134|NCT04248959|BEHAVIORAL|Multimodal prehabilitation|"Multimodal Prehabilitation~* Aerobic exercise~  * Home-based, high-intensity interval training (HIIT), 2 days/week~ * Home-based, moderate-intensity continuous training (MICT), 2-3 days/week~* Resistance exercise~  * Home-based, moderate-intensity resistance training, 2-3 d/wk, all major muscle groups (working around tumour-related deficits), 8-10 exercises, 12-15 repetitions, resistance bands and body weight based~* Nutrition~  * Protein intake 1.2-1.5 g/kg body weight/day in compliance with European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines~* Stress management~  * Daily mindfulness practice, 20 min/session, guided by audio file created at Mount Sinai Hospital"
48095912|NCT00926393|DRUG|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
48095913|NCT05905289|OTHER|observational study|no intervention as it is an observational study
48095914|NCT05564988|OTHER|Preconditionning|"Remote ischemic conditioning will be induced using a Tourniquet cuff applied to the patient's non-dominant arm. The device used will be an Ulrich Kariba machine. A strip of absorbent cotton will be applied to the arm and the tension cuff will be placed over it in a standard way. The systolic pressure and the application time will be set manually.~Ischemia will be obtained after inflating the cuff to a pressure of 200 mmHg (or a pressure at least 50 mmHg above the patient's systolic pressure). After a five-minute period, the cuff will be deflated and the arm allowed to reperfuse for five minutes. These maneuvers will be repeated until 3 cycles of ischemia- reperfusion have been completed once a day. Patients will experiment with this procedure for at least 5 days."
48095915|NCT01720719|DRUG|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
48095916|NCT01720719|DRUG|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
48095917|NCT01763047|DEVICE|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
48095918|NCT01763047|DEVICE|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
48095919|NCT05515094|BEHAVIORAL|Empowerment Counseling Intervention|The intervention entails case managers conducting first-line support (i.e., a brief psychosocial support session), and a safety and health assessment, adapted from current case management content and the Safe and Sound intervention.
48095920|NCT01282775|BEHAVIORAL|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
48095921|NCT01282775|BEHAVIORAL|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
48095922|NCT03085017|DEVICE|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
48095923|NCT03085017|DEVICE|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
48095924|NCT02731521|DEVICE|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
48095925|NCT02731521|DEVICE|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
48095926|NCT00049114|DRUG|doxorubicin hydrochloride|
48095927|NCT00049114|DRUG|cyclophosphamide|Given IV
48095928|NCT00049114|DRUG|tipifarnib|Given orally
48095929|NCT00049114|BIOLOGICAL|filgrastim|Given subcutaneously
48095930|NCT00049114|PROCEDURE|therapeutic conventional surgery|Undergo complete resection
48095931|NCT00049114|OTHER|laboratory biomarker analysis|Correlative studies
48095932|NCT04846101|OTHER|OMNISHADE|Anterior dental cavities (Class III, Class IV) will be restored with an omnishade composite material
48095933|NCT04846101|OTHER|MULTISHADE|Anterior dental cavities (Class III, Class IV) will be restored with conventional multishade composite material.
48095934|NCT04846101|DIAGNOSTIC_TEST|Instrumental Shade Analysis|Assessment will be performed by single operator using spectrophotometer (EASYSHADE) to detect color difference between tooth and restoration
48095935|NCT04846101|OTHER|Visual Shade Analysis|Visual assessment will be performed by two calibrated specialists to evaluate shade matching between the tooth and restoration
48095936|NCT04846101|OTHER|Patient satisfaction|Patient satisfaction of the final shade match will be assessed on a visual analogue scale
48095937|NCT00517478|PROCEDURE|Blood Sample|
48095938|NCT06055712|DRUG|Cefazolin|Intravenous dose(s).
47927135|NCT01762020|DEVICE|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
47927136|NCT01762020|DRUG|Standard Preparation|standard creams
47927137|NCT00510965|DRUG|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
47927138|NCT05035810|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
47927139|NCT05035810|DRUG|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
48095939|NCT06055712|DRUG|Cephalexin|Five days oral.
48095940|NCT02197689|DEVICE|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
48095941|NCT01571921|DIETARY_SUPPLEMENT|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
48095942|NCT06187870|OTHER|Collection of biological data|Biological samples will be collected from the patient at the time of their access to the Hospital
48095943|NCT02206685|DRUG|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
48095944|NCT02206685|DRUG|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
48095945|NCT03610477|DIETARY_SUPPLEMENT|Medium chain triglycerides|Gel capsules, each containing 1 gram
47927140|NCT05035810|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
47927141|NCT05035810|DRUG|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
48095946|NCT03610477|DIETARY_SUPPLEMENT|Long chain triglycerides|Gel capsules, each containing 1 gram
48271991|NCT03690154|DRUG|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
48095947|NCT05144217|DRUG|Placebo|1 capsule per day of placebo
48095948|NCT05144217|DRUG|2x 140 mg per day|2 capsule per day of silimarit
48095949|NCT05144217|DRUG|3x 280 mg per day|3 capsule per day of silimarit
48095950|NCT05144217|DRUG|1x 1120 mg|8 capsule per day of silimarit
48095951|NCT04210856|OTHER|Contemplative landscape exposure|landscapes classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to non-contemplative ones.
48095952|NCT02519179|BEHAVIORAL|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
48095953|NCT02519179|BEHAVIORAL|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
48095954|NCT06250855|DEVICE|Mini Toric IOL|Adults (males and females) ≥18 years with cataract and pre-existing corneal astigmatism who have undergone monocular or binocular Mini Toric Ready implantation after cataract surgery in which the cataract lens was removed by phacoemulsification, with circular capsulorhexis, leaving the posterior capsule intact.
47927142|NCT02233478|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice alone
47927143|NCT02233478|DIETARY_SUPPLEMENT|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
48095955|NCT05451108|DEVICE|PCL Pectus Scaffold implantation and autologous fat grafting|A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
48095956|NCT02553382|DIETARY_SUPPLEMENT|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
48095957|NCT02553382|DIETARY_SUPPLEMENT|Positive Control|Oat bran blend and wheat bran capsules
48095958|NCT05852366|DRUG|Toothpaste Preparation|Dentifrice for management of dentinal hypersensitivity
48095959|NCT01365338|DRUG|Placebo|Administered as specified in the treatment arm
48095960|NCT01365338|DRUG|PF-04958242|Administered as specified in the treatment arm
48095961|NCT06472089|BEHAVIORAL|BMT-CARE|Therapist-delivered psychosocial intervention comprised of 6 sessions
47927144|NCT02233478|DIETARY_SUPPLEMENT|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
47927145|NCT02226679|DEVICE|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
48095962|NCT06472089|BEHAVIORAL|Usual Care|Meeting a transplant social worker prior to HCT and as needed for extra visits
48095963|NCT06427603|BEHAVIORAL|physical activity|workshops and mobile apps: break sedentary behavior by activity breaks
48095964|NCT03458897|DIAGNOSTIC_TEST|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
48095965|NCT05464589|OTHER|Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract."
48271992|NCT05360550|DRUG|LSP-5415|pregnancy prevention
48443872|NCT03810950|BEHAVIORAL|Reading Newspaper|Participants read newspaper
48443873|NCT03810950|BEHAVIORAL|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
47927146|NCT00134420|DRUG|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
47927147|NCT00134420|PROCEDURE|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
47927148|NCT00134420|PROCEDURE|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
47927149|NCT00134420|PROCEDURE|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
47927150|NCT00591110|BEHAVIORAL|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
47927151|NCT00591110|BEHAVIORAL|Social-contact control|Participants receive an engaging informational session on a non-health related topic
47927152|NCT00408044|PROCEDURE|cardiac surgery with sternotomy|
48095966|NCT05464589|OTHER|Pelvic floor muscles strengthening|"Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening."
48095967|NCT00279474|BEHAVIORAL|cognitive-behavior groups|
48095968|NCT05180045|BEHAVIORAL|LINKED-BP Program|The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.
48271993|NCT05722964|DRUG|SHR-1906|Intravenous injection
47927153|NCT04630574|OTHER|Speech evaluation with the clinical evaluation of dysarthria|A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
47927154|NCT04630574|OTHER|complete assessment of the MonPaGe computerized protocol|The application records directly and anonymously stores speech productions made by the patient.
47927155|NCT04140227|DRUG|NOV03|100% Perfluorohexyloctane
47927156|NCT00403169|DRUG|lenalidomide|drug
47927157|NCT04136444|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
48095969|NCT04866407|OTHER|Mentha x piperita|2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.
47927158|NCT05266573|OTHER|Exercise Group|The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
48095970|NCT04866407|OTHER|Eucalyptus globulus|2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
48095971|NCT00155610|DEVICE|intravesical current perception test|
48095972|NCT02516774|DRUG|Adalimumab|
48095973|NCT04835584|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
48095974|NCT04835584|DRUG|Dasatinib|Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
48095975|NCT04835584|DRUG|Nilotinib|Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
48095976|NCT05288101|DIETARY_SUPPLEMENT|Proteinex and Enterex DBT Victus Laboratories|The supplement was provided five days per week. Three days a week, the supplement was given at the beginning of the HD session and the patients were instructed to consume it slowly during the next 3 hours. The remaining two days, the supplement was consumed at home and instructed to be consumed between meals. The ONS consisted of one can of polymeric formula (Enterex DBT, Victus Laboratories) and 5.6 g of a protein powder supplement (Proteinex, Victus Laboratories). The final mixture provided 240 kcal, 17 g protein, 8.1 g lipids, 25 g carbohydrates, 4 g dietary fiber, 201 mg sodium, 490 mg calcium, 356 mg phosphorus and 371 mg potassium
48095977|NCT05288101|PROCEDURE|Dry weight adjustment through BIVA|Those participants with post-dialysis vectors located within the 50 or 75% ellipses, were considered to be in dry weight, so they did not require any fluid removal adjustment. However, participants with vectors outside the 75% ellipse were considered overhydrated or dehydrated and dry weight was adjusted. In these patients, if the vectors fell outside the 75% ellipse but within the 95%, above or below the major axis, the established dry weight was adjusted by 0.5 Kg. If the vectors fell outside the 95% ellipse, the weight was adjusted by 1.0 Kg.
48443874|NCT04107675|DRUG|Liposomal Cyclosporine A|Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
47927159|NCT02916121|DIETARY_SUPPLEMENT|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
47927160|NCT02916121|OTHER|Placebo|placebo
48095978|NCT03669042|DEVICE|PhotoFix|PhotoFix Patch Implantation
48095979|NCT01203553|PROCEDURE|Abdominal surgery|Intraoperative mesh implantation
48095980|NCT05290766|PROCEDURE|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
48271994|NCT05722964|DRUG|SHR-1906|Intravenous injection
48271995|NCT05722964|DRUG|Placebo|Placebo，Intravenous injection
48271996|NCT05689619|DIETARY_SUPPLEMENT|Silibinin|Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
48271997|NCT05689619|OTHER|Placebo|Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
48443875|NCT04107675|DRUG|Liposomal Placebo|Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
48443876|NCT01583127|BEHAVIORAL|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
48443877|NCT02443961|BIOLOGICAL|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
47927161|NCT01986777|DRUG|lisdexamfetamine|
47927162|NCT01986777|DRUG|Placebo|The placebo capsules will be filled with lactose.
47927163|NCT01770444|OTHER|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~1. Prospective gating~2. Range: dedicated imaging (below carina to heart base)"
47927164|NCT01770444|OTHER|Conventional cardiac CT protocol|"Conventional CCTA protocol~1. Retrospective gating with tube current modulation~2. Range: dedicated imaging (below carina to heart base)"
48095981|NCT05290766|PROCEDURE|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
48095982|NCT05290766|DEVICE|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
48095983|NCT03686683|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with recombinant fusion protein composed PAP linked to GM-CSF (PA2024), a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
48095984|NCT02775435|BIOLOGICAL|Pembrolizumab|IV infusion
48095985|NCT02775435|DRUG|Paclitaxel|IV infusion
48095986|NCT02775435|DRUG|Nab-paclitaxel|IV infusion
48095987|NCT02775435|DRUG|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
48095988|NCT02775435|DRUG|Saline placebo for pembrolizumab|IV infusion
48095989|NCT06554652|PROCEDURE|Lymph node tracer navigated selective neck dissection|Selective lateral lymph node dissection (after injection of tracer, lymph nodes in compartment III-IV are dissected; if there is dyed lymph node in compartment IIA, then IIA is dissected).
48095990|NCT06554652|PROCEDURE|Modified neck dissection|Lymph nodes in compartment IIA, IIB, III, IV, VB are dissected.
48095991|NCT06051162|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
48095992|NCT06613776|DRUG|Amoxicillin|4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
48095993|NCT06613776|DRUG|Placebo|4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
48271998|NCT01412853|OTHER|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
48271999|NCT00899340|GENETIC|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
47927165|NCT04280770|PROCEDURE|23 PARS PLANA VITRECTOMY|We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
47927166|NCT04671472|DRUG|NPC-09|The drug will be administered by the oral route with the same manner
47927167|NCT04671472|DRUG|NPC-09 placebo|The drug will be administered by the oral route with the same manner
47927168|NCT02769897|BEHAVIORAL|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
47927169|NCT02610101|OTHER|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
47927170|NCT02610101|OTHER|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
47927171|NCT02610101|OTHER|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
47927172|NCT03954678|BEHAVIORAL|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
47927173|NCT03954678|DIETARY_SUPPLEMENT|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
47927174|NCT00320957|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
48095994|NCT06615297|DIAGNOSTIC_TEST|ultrasonographic evaluation|facial nerve thickness (right/left), depressor labi inferior, depressor anguli oris, buccinator and risorius muscles will be evaluated.
48095995|NCT03416218|BEHAVIORAL|Prognosis|Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
48095996|NCT02851147|DEVICE|SL-D301|Slit Lamp
48095997|NCT02851147|DEVICE|DC-4|Digital Camera Attachment
48095998|NCT02851147|DEVICE|SL-3G|Slit Lamp
48095999|NCT04945694|OTHER|Ultrasound-guided bilateral pecto-intercostal fascial block|- PATIENT IN SUPINE POSITION, SKIN WILL BE DISINFECTED, A HIGH-FREQUENCY LINEAR PROBE WILL BE PLACED PARALLEL TO LONGITUDINAL AXIS OF STERNUM ON LATERAL BORDER AND SCANNED LATERALLY TO IDENTIFY 4TH AND 5TH COSTAL CARTILAGE. THE PECTORALIS MAJOR MUSCLE (PMM), INTERNAL INTERCOSTAL MUSCLE (IIM), TRANSVERSUS THORACIS MUSCLE (TTM), RIBS, AND PLEURA WILL BE IDENTIFIED. COLOR DOPPLER ULTRASONOGRAPHY WILL BE USED TO DETERMINE PERFORATING BRANCHES OF INTERNAL THORACIC ARTERY, WHICH TRAVEL ANTERIORLY THROUGH THE ANTERIOR CHEST WALL, PIERCING THE INTERCOSTAL MUSCLE AND PMM. A 22G NEEDLE WILL BE INSERTED IN PLANE WITH PROBE, IN CAUDAL-TO-CRANIAL DIRECTION UNTIL THE TIP IS POSITIONED IN INTER- FASCIAL PLANE BETWEEN THE PMM AND IIM. NORMAL SALINE WILL BE USED TO DETERMINE CORRECT PLACEMENT OF NEEDLE TIP IN INTER-FASCIAL PLANE, AS SHOWN BY SEPARATION OF FASCIAL LAYERS THEN LOCAL ANESTHETIC WILL BE INJECTED
48096000|NCT04945694|DRUG|Intravenous fentanyl|In this group, patients will receive only incremental doses of intravenous fentanyl
48096001|NCT04945694|DRUG|Propofol|Propofol anesthesia
48272000|NCT00899340|GENETIC|microarray analysis|microarray analysis
48272001|NCT00899340|GENETIC|protein expression analysis|protein expression analysis
48272002|NCT00899340|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
48096002|NCT04945694|DRUG|Sevoflurane|Sevoflurane anesthesia
48096003|NCT04945694|DRUG|Atracurium|Intravenous atracurium
48096004|NCT04945694|DEVICE|ultrasound|ultrasound-guided block
48096005|NCT02887378|DEVICE|hot clamps|reusable hot biopsy forceps
48096006|NCT02887378|DEVICE|normal clamps|
48096007|NCT04701502|DIETARY_SUPPLEMENT|Viusid|"Patients received daily doses of 30 ml of Viusid every 8 hours plus standard care for COVID-19. Viusid is administered orally.~Treatment duration: 21 days"
48096008|NCT04701502|DIETARY_SUPPLEMENT|Asbrip|"Patients received daily doses of 10 ml of Asbrip every 8 hours plus standard care for COVID-19. Asbrip is administered orally.~Treatment duration: 21 days"
48096009|NCT04701502|DRUG|Standard Care|Standard care for COVID-19
48096010|NCT04878380|DEVICE|Fitbit|A consumer sleep tracker will be used to monitor sleep patterns throughout the study
48096011|NCT04878380|BEHAVIORAL|Sleep education tips|Sleep tips will be provided before the intervention phase
48096012|NCT04878380|BEHAVIORAL|Goal-setting|During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
48096013|NCT02757885|PROCEDURE|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.
48096014|NCT02757885|DRUG|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing \>125% ideal body weight.
48096015|NCT02757885|DRUG|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing \>125% ideal body weight.
48096016|NCT02757885|DRUG|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing \> 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
48096017|NCT02757885|DRUG|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
48096018|NCT02757885|OTHER|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
47927175|NCT05704127|OTHER|Intelligent Moxibustion Robot|The intelligent moxibustion robot holds the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
47927176|NCT05704127|OTHER|Artificial moxibustion|The people hold the thunder fire moxibustion stick and conducts suspension moxibustion treatment on the points BL23, BL25, DU3 and pain points for 10 minutes in each group, a total of 40 minutes. BL23 and BL25 have one acupuncture point on each side of the spine, and the straight line reciprocating moxibustion technique is adopted. DU3, a single point, adopts the whirling moxibustion technique. Pain points,according to the number of pain points, choose straight reciprocating moxibustion or rotary moxibustion.
48096019|NCT02757885|RADIATION|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
48096020|NCT06321172|DEVICE|FES Bike|Six months of FES-cycling trainings twice a week is performed for each pilot. Each session includes at most 30 minutes of stimulation. At the beginning of the training period, a conditioning phase is performed until the pilot reaches pedalling autonomy. This period is also used to define the stimulation parameters (minimum and maximum values of current intensity and pulse width), reference cadence and gear, specific for the ability of each pilot. Then the training period starts and is performed indoor, setting the resistance of the smart trainer at 10% for all the participants. The sessions are organized as follows: a 3-minute warmup followed by four sets of 6 minutes of pedalling and a 3-minute cool down.
48096021|NCT02377206|OTHER|ADAS-Cog evaluation|\[18F\]DPA-714 PET imaging
48096022|NCT02095704|DRUG|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
48096023|NCT02095704|DRUG|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
48096024|NCT01111890|DRUG|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
48096025|NCT01111890|DRUG|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
48096026|NCT03127345|DRUG|Omegaven|Intravenous omega 3 fatty acid administration
48096027|NCT03127345|DRUG|Intralipid|Standard of care
48096028|NCT04327037|BIOLOGICAL|Expanded Haploidentical Natural Killer cells|One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells
48096029|NCT04327037|DRUG|IL-2|6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.
48096030|NCT06629623|OTHER|No intervention|No intervention
48096031|NCT04135495|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
48096032|NCT04135495|DRUG|Ivacaftor|CFTR potentiator
48096033|NCT00800124|PROCEDURE|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
48096034|NCT01739556|DRUG|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
48096035|NCT04571073|PROCEDURE|Fascial Distortion Model|"Using physical exam and manual manipulation skills informed by the FDM, he identified and treated locations of presumed fascial distortion about the plantar area of the foot; distortions could include any of the six reported fascial anomalies in the FDM: continuum distortions, trigger bands, herniated trigger points, folding distortions, cylinder distortions, and tectonic fixations. Each distortion is associated with a recommended reparative manipulation. The purported mechanism of action is that the distortion-specific manipulation restores normal fascial homogeneity."
48096036|NCT06615362|PROCEDURE|preparation of dentin membrane from hopeless tooth for Guided Bone Regeneration in Immediate Implant|tooth extraction , preparation of dentin membrane ,immediate implantation ,Xenogeneic bone graft material, application of dentin derived barrier membrane
48096037|NCT06615362|PROCEDURE|Collagen Membrane for Guided Bone Regeneration in Immediate Implant|like group one but with application of collagen membrane
48096038|NCT04094012|DRUG|isoniazid and rifapentine|This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
48096039|NCT02943382|OTHER|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
48096040|NCT00666120|OTHER|Enfamil LIPIL with iron|cow's milk based infant formula
48096041|NCT00666120|OTHER|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
48096042|NCT06250075|DIETARY_SUPPLEMENT|Formulation with probiotics|Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
48096043|NCT06250075|OTHER|Non-intervention for Clinical Outcomes -G5|only observation of clinical outcomes in the postoperative period
48096044|NCT00647413|BEHAVIORAL|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
48096045|NCT05366387|DEVICE|intrapulmonary percussive ventilation|Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.
48096046|NCT05366387|RADIATION|delivery of 99mTc-DTPA aerosol|A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
48096047|NCT03097211|DRUG|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
48096048|NCT03097211|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
48096049|NCT03097211|DRUG|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
48096050|NCT03097211|DRUG|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
48096051|NCT05557019|DEVICE|Booster Balloon Catheter|The Booster balloon therapy (i.e. partial occlusion of the CS lumen with a subsequent backward pressure elevation without obstructing the CS blood flow) will start immediately after a successful PCI of the culprit coronary lesion in the LAD, with TIMI-II flow restoration. The Booster balloon therapy will then be continued for up to 90 min, but not less than 60 min.
48096052|NCT01649427|DRUG|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
48096053|NCT01649427|DRUG|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
48272003|NCT00899340|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
48272004|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
48096054|NCT03810885|OTHER|Bread with reduced salt content|Bread with gradually lowered salt content
48096055|NCT03810885|BEHAVIORAL|Dietary advice|Participants will receive information on how to lower salt and increase potassium intake
48096056|NCT03810885|OTHER|Bread with standard salt content|Bread with normal salt content
48096057|NCT05487586|DRUG|ceftazidime avibactam group|Non-Interventional Study
48096058|NCT05801042|DIETARY_SUPPLEMENT|Maltodextrin|Placebo product
48096059|NCT05801042|DIETARY_SUPPLEMENT|Encapsulated Lactocaseibacillus rhamnosus|Probiotic product
48096060|NCT05801042|DIETARY_SUPPLEMENT|Non-encapsulated Lactocaseibacillus rhamnosus|Probiotic product
48096061|NCT00004209|DRUG|cisplatin|
48096062|NCT00004209|DRUG|mitomycin C|
48096063|NCT00004209|DRUG|vinblastine sulfate|
48096064|NCT05717335|DRUG|TachoSil|Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
48096065|NCT00846209|OTHER|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
48096066|NCT00875641|OTHER|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
48272005|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
48272006|NCT00800215|DRUG|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
48272007|NCT00800215|DRUG|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
48272008|NCT03144648|OTHER|lifestyle|Observational study
48272009|NCT06052956|DRUG|Methylene Blue|Administration of 0.1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
48096067|NCT00188929|PROCEDURE|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
48096068|NCT03161522|DRUG|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
47927177|NCT04411381|OTHER|Telemedicine|Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
47927178|NCT01252693|DRUG|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
47927179|NCT01252693|DRUG|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
47927180|NCT04683731|BEHAVIORAL|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
47927181|NCT04683731|BEHAVIORAL|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
47927182|NCT04683731|BEHAVIORAL|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
47927183|NCT04683731|BEHAVIORAL|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the EHR within 24 hours of their visit with the enrolled patient.
47927184|NCT04796987|DIAGNOSTIC_TEST|Convolutional Neural Network|Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
47927185|NCT05725759|BEHAVIORAL|Rehabilitation|Particapants currently receiving tofersen treatment will be referred to outpatient physical and/or occupational therapy.
47927186|NCT05581901|DRUG|Methadone (Dose1)|Dose: 0.10mg/kg
47927187|NCT05581901|DRUG|Methadone (Dose 2)|Dose: 0.15mg/kg
47927188|NCT05581901|DRUG|Methadone (Dose 3)|Dose 0.20mg/kg
47927189|NCT03571945|DEVICE|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
47927190|NCT03571945|DEVICE|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
47927191|NCT02889744|DEVICE|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
47927192|NCT00533754|PROCEDURE|drawing blood|
47927193|NCT03865797|OTHER|Experimental|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.
47927194|NCT03865797|OTHER|Control active|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
47927195|NCT06074731|DIAGNOSTIC_TEST|SS-OCT system Plex Elite 9000|We will use a commercially available SS-OCT system (Plex Elite 9000; Carl Zeiss Meditec).
47927196|NCT01300533|DRUG|BIND-014|
47927197|NCT06058988|DRUG|Trastuzumab deruxtecan|All participants will receive T-DXd prior to indicated brain tumor resection/biopsy
47927198|NCT06131762|OTHER|Active release technique|This include active release technique for 4 weeks
47927199|NCT06131762|OTHER|Positional release technique|This include positional release technique for 4 weeks
47927200|NCT00409175|DRUG|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
47927201|NCT00409175|DRUG|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
47927202|NCT03040570|PROCEDURE|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
47927203|NCT03040570|PROCEDURE|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining \>94%.
48096069|NCT03161522|DRUG|Chemotherapy|Receive induction chemotherapy
48096070|NCT03161522|PROCEDURE|Conventional Surgery|Undergo surgery
48096071|NCT03161522|DRUG|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
48096072|NCT03161522|RADIATION|Radiation Therapy|Undergo RT
48096073|NCT04582175|PROCEDURE|angioplasty|angioplasty of all non-culprit lesions
48096074|NCT03985579|OTHER|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
48096075|NCT04731714|DEVICE|Rhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at 12 Hz, at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
48096076|NCT04731714|DEVICE|Arrhythmic median nerve stimulation|Square-wave 200 µs pulses triggered by computer at random intervals with a mean rate of 12 Hz (as described in Morera Maiquez et al., 2020), at the threshold for thumb movement (expected \~2-15mA), applied to surface electrodes over the median nerve at the right wrist (conductive gel, 30 mm apart center-to-center, anode distal). This is a non-significant risk device study.
48096077|NCT02116387|OTHER|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
48096078|NCT02116387|DEVICE|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
48096079|NCT04029740|BEHAVIORAL|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert \& Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
48096080|NCT04029740|OTHER|No intervention|Healthy controls will not receive any intervention.
48096081|NCT01110174|DIAGNOSTIC_TEST|HD PET/CT|imaging
48096082|NCT06170060|OTHER|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a surgical procedure widely used in the treatment of obesity. It's a bariatric procedure, meaning its primary aim is to induce weight loss, and it has gained popularity due to its effectiveness and relatively low complication rates compared to other bariatric surgeries.
48096083|NCT02392338|PROCEDURE|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
48096084|NCT01793740|BEHAVIORAL|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
48096085|NCT02812966|DEVICE|Lutonix|Drug Coated Balloons
48096086|NCT02812966|DEVICE|IN.PACT|Drug Coated Balloons
47927204|NCT03381534|DEVICE|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
47927205|NCT03381534|DEVICE|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
47927206|NCT04865874|OTHER|PPV-GDT|fluid-therapy based on PPV monitoring
48096087|NCT04656236|BIOLOGICAL|3-hydroxybutyrate|3-hydroxybutyrate is a metabolite, produced in the human body.
48096088|NCT05536466|PROCEDURE|bariatric surgery|bariatric surgery
48096089|NCT01112735|BIOLOGICAL|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
48272010|NCT06052956|DRUG|Lipid Emulsion|The abscess cavity will be filled with sterile 0.1% lipid emulsion solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
48272011|NCT06052956|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
47927207|NCT04865874|OTHER|Zero-balance|fluid-therapy based on urinary output balance
48096090|NCT01112735|PROCEDURE|Standard of care|Standard of care
48096091|NCT04672460|DRUG|TALZENNA capsule|Current commercial talazoparib formulation 1 mg once daily given under fasting condition
48096092|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
48096093|NCT04672460|DRUG|Talazoparib soft gel capsule|Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
48272012|NCT06052956|DEVICE|Laser Illumination (pre-defined dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set such that the fluence rate at the abscess wall due to ballistic photons is 20 mW/cm2.
47927208|NCT01954927|DRUG|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
48096094|NCT05063331|PROCEDURE|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
48096095|NCT05063331|PROCEDURE|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
48096096|NCT04017884|COMBINATION_PRODUCT|Remin Pro Forte|a combination of chemicals with natural products cream .
48096097|NCT04017884|COMBINATION_PRODUCT|Remin Pro|a combination of chemicals
48096098|NCT06613438|DEVICE|eGERD device|"The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.~For optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user."
48096099|NCT06613438|DEVICE|eGERD_Sham|The eGERD_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD_Sham is identical to the eGERD device.
48096100|NCT04308447|DEVICE|AbleLite|The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
47927209|NCT01954927|DRUG|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
47927210|NCT04582825|OTHER|N/A - Observational Study|N/A - Observational Study
48096101|NCT04750629|DEVICE|POC CoviDx™ Rapid Antigen Test|All patients will have a nasal swab for CoviDx™ Rapid Antigen testing
48096102|NCT03813056|DRUG|Glanatec|Rho kinase Inhibitor
48096103|NCT03813056|DRUG|Optive, Ophthalmic Solution|artificial tears (placebo)
47927211|NCT00791973|DRUG|fluticasone furoate|2 puffs in each nostril once daily for 1 week
47927212|NCT00791973|DRUG|Placebo|2 puffs in each nostril once daily for 1 week
47927213|NCT03657303|DEVICE|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
48096104|NCT03813056|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
48096105|NCT00031291|DRUG|Anthrax Immune Globulin|
48096106|NCT02550054|DRUG|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
48096107|NCT02550054|DRUG|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
48096108|NCT03885037|DRUG|Infliximab [infliximab biosimilar 3]|\<Rheumatoid arthritis\> The usual dose is 3 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
48096109|NCT02122848|DEVICE|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
48096110|NCT06614777|PROCEDURE|skin biopsies and blood extraction|"Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area."
48096111|NCT05540990|DEVICE|Robot assisted gait training|15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).
48096112|NCT05540990|OTHER|Conventional physiotherapy|individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
48096113|NCT04986982|DRUG|Opicapone 50 mg|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI) (L-dopa/DDCI).
48096114|NCT04986982|OTHER|Matching placebo|Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
48096115|NCT05392764|DRUG|Empagliflozin 10 MG|once-daily oral empagliflozin 10 mg
48096116|NCT05392764|DRUG|Placebo|Placebo matching empagliflozin 10 mg
48096117|NCT01268761|DRUG|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
48096118|NCT01268761|DRUG|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
48096119|NCT05488782|BEHAVIORAL|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
48096120|NCT05488782|OTHER|Waitlist|After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
48096121|NCT04925180|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|As prescribed by the treating physician
48096122|NCT00188409|PROCEDURE|CT scan|
48096123|NCT03485729|DRUG|ONC201|ONC201
48096124|NCT02250144|DEVICE|Foot orthoses|
48096125|NCT05000775|DIETARY_SUPPLEMENT|G-Niib|G-NiiB®, a patent-protected microbiome immunity formula, composed of naturally occurring food-grade bacteria approved by health authorities, has been developed by a group of CUHK gastroenterology experts.
48096126|NCT05000775|DIETARY_SUPPLEMENT|Placebo|Placebo
48096127|NCT03971357|DRUG|Netarsudil|netarsudil opthalmic solution 0.02%
48096128|NCT03971357|DRUG|Placebo|Placebo eye drops
47927214|NCT06161896|DIAGNOSTIC_TEST|Stool samples|Analysis of microbiome, mutations, alterations in body composition and lifestyle
47927215|NCT03518476|BEHAVIORAL|intensive multi-disciplinary education program on tobacco treatment for pharmacists|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
47927216|NCT03518476|OTHER|Control arm|Participants in control arm will receive a non-tobacco related training or educational session
47927217|NCT00177047|PROCEDURE|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
47927218|NCT00177047|DRUG|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
47927219|NCT00177047|DRUG|Melphalan|Administered intravenously 200 mg/m\^2
47927220|NCT00177047|BIOLOGICAL|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
47927221|NCT05349253|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
47927222|NCT05349253|DIETARY_SUPPLEMENT|Placebo|One intake in total
47927223|NCT00940667|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
47927224|NCT00940667|DRUG|Amlodipine|amlodipine 5mg q.d.
47927225|NCT05690256|BEHAVIORAL|Resilience Clinic|A psychoeducational caregiver-child intervention based in primary care, designed to mitigate toxic stress and promote child resilience. Participants engage in 6 weekly visits in primary care using an interactive curriculum based in the evidence-based Circle of Security Parenting along with mindfulness principles.
47927226|NCT05690256|BEHAVIORAL|Enhanced primary care|In addition to usual pediatric primary care, enhanced primary care (the control condition for this study) provides navigational services to link to community resources based on screening for unmet social needs (e.g., food insecurity, housing, financial strain).
47927227|NCT03848299|OTHER|Experimental: Single Arm|"All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants."
47927228|NCT01875224|DRUG|Belatacept|
47927229|NCT01875224|DRUG|Tacrolimus|Standard administration of tacrolimus
47927230|NCT06044311|DRUG|Vactosertib|200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
47927231|NCT06044311|DRUG|Standard of Care Chemotherapy|Neoadjuvant chemotherapy treatment as per standard of care.
47927232|NCT06044311|RADIATION|Concurrent Radiation|Neoadjuvant radiation treatment as per standard of care.
47927233|NCT02266953|BEHAVIORAL|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
47927234|NCT02266953|BEHAVIORAL|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
47927235|NCT02436980|DRUG|Tramadol|GROUP T
47927236|NCT02436980|DRUG|Midazolam|GROUP M
47927237|NCT01005121|DRUG|colchicine|2mg, per-os, once daily for six months
47927238|NCT04034953|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
47927239|NCT04034953|DIAGNOSTIC_TEST|Prostate-Specific Antigen Test|PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
47927240|NCT04034953|DIAGNOSTIC_TEST|Mammogram|Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
47927241|NCT01515020|DRUG|vancomycin monotherapy|intravenous therapy by vancomycin
48096129|NCT06001684|BIOLOGICAL|IBR854 Cell Injection|The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
48096130|NCT01441778|DRUG|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
48096131|NCT01441778|DRUG|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
48096132|NCT02518893|OTHER|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
48096133|NCT02518893|OTHER|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
48096134|NCT04036240|OTHER|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
48096135|NCT03983343|DEVICE|exofin®|Perineal skin will be closed by adhesive glue - exofin® (Octyl-2-cyanoacrylate).
48096136|NCT00038792|DRUG|Recombinant Human Keratinocyte Growth Factor|
48096137|NCT05526508|DEVICE|Rebound exercise|Exercise training on the rebounder/ mini-trampoline with stability handles attached
48096138|NCT03465111|DRUG|ACTH (adrenocorticotropic hormone) gel|The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
48096139|NCT02891369|OTHER|No intervention. Descriptive study|
48096140|NCT03453385|BEHAVIORAL|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
48096141|NCT05835050|DIAGNOSTIC_TEST|serum interleukin 10 level|b. Serum levels of IL-10 were measured using a quantitative enzyme-linked immunosorbent assay (ELISA)
48096142|NCT00684970|DRUG|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
48096143|NCT02096003|DRUG|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
47927242|NCT01515020|DRUG|daptomycin monotherapy|intravenous therapy by daptomycin
47927243|NCT04469829|DRUG|Secukinumab|standard doses of secukinumab for psoriasis
47927244|NCT04469829|DRUG|Methotrexate|Methotrexate 15 mg/week
47927245|NCT03650946|DIAGNOSTIC_TEST|Ga-68 PSMA PET|Ga-68 PSMA PET
47927246|NCT03699969|RADIATION|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
47927247|NCT03257709|PROCEDURE|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
47927248|NCT03257709|PROCEDURE|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
47927249|NCT02825290|DRUG|Choriogonadotropin alfa|
48096144|NCT02096003|DRUG|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
48096145|NCT05588674|DIETARY_SUPPLEMENT|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
48096146|NCT05588674|OTHER|Placebo Capsule|8.5 week supplementation period. One capsule daily.
48096147|NCT03034733|DRUG|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
48096148|NCT03034733|DRUG|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
48096149|NCT01126021|BEHAVIORAL|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
48096150|NCT01126021|BEHAVIORAL|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
48096151|NCT03364959|OTHER|Corticosteroids inhalation|Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
48096152|NCT03364959|OTHER|Corticosteroids inhalation|Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
48096153|NCT05727956|PROCEDURE|Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.
48096154|NCT03061955|BIOLOGICAL|influenza vaccination|administration of influenza vaccination
48096155|NCT01084161|DRUG|N1539|5 mg IV once per day
48096156|NCT01084161|DRUG|N1539|7.5 mg IV once per day
48096157|NCT01084161|DRUG|N1539|15 mg IV once per day
48096158|NCT01084161|DRUG|N1539|30 mg IV once per day
48096159|NCT01084161|DRUG|placebo|IV placebo once per day
48096160|NCT01084161|DRUG|Morphine|morphine 10-15 mg IV once per day
48096161|NCT01084161|DRUG|N1539|60 mg IV once per day
48096162|NCT05838560|DRUG|Dasatinib + quercetin|dasatinib 100mg / quercetin 1250mg The intervention will involve the participant taking both dasatinib and quercetin combined.
48096163|NCT04311203|BEHAVIORAL|Mental Health First Aid|The intervention has 3 parts:1.Two-day MHFA training provided by MHFA England. A manualised programme designed to provide individuals with: an in-depth understanding of mental health and the factors that can affect wellbeing, practical skills to spot triggers and signs of mental health issues, confidence to step in, reassure and support a person in distress, enhanced interpersonal skills such as non-judgemental listening, knowledge to help someone recover their health by guiding them to further support - whether that's self-help resources, through their employer, the NHS, or a mix. 2.Raising awareness of the presence of MHFA in the organisation. 3.The application of MHFA to participants in the workplace using the manualised five-stage approach, ALGEE: Approach the person, assess and assist with any crisis; Listen and communicate non-judgementally; Give support and information; Encourage the person to get appropriate professional help and Encourage them to seek other forms of support.
48096164|NCT01571778|BEHAVIORAL|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
48096165|NCT05561855|BEHAVIORAL|lifestyle intervention|"During the 3-month lifestyle intervention period, the participants need to complete the weight monitoring, behavioral goal recording, diet and exercise recording, online course learning by using the WeChat official account module of Weight Loss and Glucose Control.They will receive corresponding feedback and integral rewards every week, and receive monthly follow-ups to complete health education, goal review, motivational interview as well as collecting medication changes and blood glucose monitoring data."
47927250|NCT02825290|DRUG|Triptorelin acetate|
47927251|NCT03381729|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
47927252|NCT00663247|DEVICE|Mesalazine|3 grams daily for 3 months
47927253|NCT00663247|DRUG|Placebo|3 grams daily for 3 months
48096166|NCT04991857|OTHER|T-FAME-HF|16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits
48096167|NCT04991857|OTHER|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by the team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
48096168|NCT06355817|DEVICE|Vibration|Vibration Assist Device, held to the forehead
48096169|NCT06355817|OTHER|Tapping|Tapping on the forehead
48096170|NCT05981456|OTHER|patient safety competency|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the competence levels of the students.
48096171|NCT05981456|OTHER|satisfaction with the training method|Investigation of the effect of patient safety education given with the flipped education model and traditional education model on the satisfaction levels of the students from the education methods.
48096172|NCT04863105|DRUG|Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)|"Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
48096173|NCT02939001|DEVICE|iris recognition scanner|
48096174|NCT06116019|RADIATION|Online adaptive radiation therapy|Daily cone-beam CT based online adaptive radiation therapy
48096175|NCT01684046|DEVICE|Opti-Free® PureMoist® MPDS|
48096176|NCT01684046|DEVICE|RevitaLens MPDS|
48096177|NCT01684046|DEVICE|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
48096178|NCT05583240|DRUG|Essences and Essential Oils|Participants will received Essential Oils through a nasal stick during 4 weeks.
48096179|NCT02648529|PROCEDURE|MRI|"Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)"
48096180|NCT02648529|PROCEDURE|functional MRI (fMRI)|"fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
48096181|NCT02648529|BEHAVIORAL|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
48096182|NCT05154916|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
48096183|NCT01106703|DIETARY_SUPPLEMENT|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
48096184|NCT01106703|OTHER|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
48096185|NCT02890693|BEHAVIORAL|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
48096186|NCT05650333|DRUG|Ritlecitinib 20 mg|orally administered, Ritlecitinib 20 mg once daily (QD)
48096187|NCT04986917|DEVICE|Hernia repair surgery using the Su2ura® approximation device|. The hernia defect will be measured and the Su2ura® approximation device will then be used to close the defect, placing stainless steel implantable anchors threaded on a Polyethylene braided surgical suture.
48096188|NCT04986917|DIAGNOSTIC_TEST|Physical Examination|All subjects will undergo a standard physical examination by an authorized physician. The physician's evaluation will include diagnosis and documentation of any significant clinical abnormalities or diseases.
48096189|NCT04986917|DIAGNOSTIC_TEST|Vital Signs|Vital signs include blood pressure, pulse, temperature, body weight and height, body mass index (BMI).
48096190|NCT04986917|DIAGNOSTIC_TEST|Blood Tests|"All subjects will undergo Hematology and Biochemistry blood tests. Blood Hematology test will include a complete CBC. Blood Biochemistry test will include the following measures: Sodium (Na), Potassium (K), Chloride (Cl), Creatinine, Glucose, Urea, Albumin, Calcium total, Alkaline Phosphatase (ALP), ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Uric Acid, CRP, and Lipid Profile (including Total Cholesterol, HDL, LDL, Triglycerides).~5 ml of blood (equals to 1 spoon) will be taken for each test."
48096191|NCT04986917|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test will be performed during the screening visit (for WOCBP).
48096192|NCT04986917|DIAGNOSTIC_TEST|Abdominal Ultrasound imaging|All subjects will undergo an abdominal ultrasound (US) imaging at 12 Months visit. The US will be performed to verify an absence of hernia recurrence.
48096193|NCT04986917|OTHER|EuraHS-QoL|patients will be asked to fill a questionnaire assessing patient-reported satisfaction and function. questionnaire score range: 0-180; higher score indicates higher pain and discomfort
48096194|NCT04986917|OTHER|Visual Analouge Scale (VAS)|A validated, subjective measure measuring acute and chronic pain. questionnaire score range: 0-10; higher score indicates higher pain level.
48096195|NCT04986917|DIAGNOSTIC_TEST|Clinical evaluation for hernia recurrence and clinical bulging|"The procedure includes:~1. Clinical examination to determine the presence of hernia recurrence and clinical bulging, in an inconclusive physical exam a radiological imaging will be performed such as US or CT.~2. SAE's and SADE's evaluation of the seroma.~3. Taking a photograph of the surgery area without disclosing the subject's identity."
48272013|NCT06052956|DEVICE|Optical Spectroscopy Measurement|The same sterile optical fiber used for treatment will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity, polarized white light will be delivered by a tungsten halogen lamp by the fiber, and captured by the same fiber. Light that has been de-polarized by interaction with tissue will be detected by a spectrometer and analyzed to extract tissue optical properties. Upon completion of these measurements, the fiber optic will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
47927254|NCT02066987|BEHAVIORAL|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
47927255|NCT02066987|BEHAVIORAL|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
48096196|NCT03083522|DRUG|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48096197|NCT03083522|DRUG|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48096198|NCT04034121|DEVICE|DESolve Cx drug eluting coronary scaffold system|percutaneous coronary intervention
48272014|NCT06052956|DEVICE|Laser Illumination (patient-specific dose)|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The optical power will be set to deliver a fluence rate of 20 mW/cm2 in 95% of the abscess wall, based upon abscess morphology and optical spectroscopy results.
48272015|NCT06052956|PROCEDURE|Standard of care abscess drainage|Following standard practice, a drainage catheter will be placed in the abscess cavity and used to aspirate purulent fluid.
47927256|NCT02066987|BEHAVIORAL|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
47927257|NCT03539809|DIETARY_SUPPLEMENT|L-Amino Acids|6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
48272016|NCT00631631|DRUG|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
48272017|NCT06164405|DEVICE|arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration
48272018|NCT03425708|DRUG|20mg Febuxostat|Participants take 20mg febuxostat pill once a day for at least six months.
48272019|NCT03425708|DRUG|40mg Febuxostat|Participants take 40mg febuxostat pill once a day for at least six months.
48272020|NCT01956214|OTHER|FES Exercise|receive FES while exercising
48272021|NCT01956214|OTHER|Mock FES Exercise|participants will receive Mock FES
48272022|NCT00611247|DRUG|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
48272023|NCT01727960|BEHAVIORAL|Education and posture correction|a lecture concerning the fine posture for health and exercises
48096199|NCT04362319|DIAGNOSTIC_TEST|Questionnaire forms|Assessment of demographics, burnout, depression and self-perceived medical errors
48096200|NCT06614348|DRUG|Prednisolone acetate eye drop group|Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
48096201|NCT06614348|DRUG|Sodium hyaluronate eye drops|Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
48272024|NCT05462379|PROCEDURE|Ovarian graft|Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.
47927258|NCT02270853|DEVICE|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
47927259|NCT00497042|DEVICE|Self Adjusting File|
47927260|NCT03044600|OTHER|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
48096202|NCT01400100|DRUG|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
48096203|NCT01400100|DRUG|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
47927261|NCT03044600|OTHER|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
48096204|NCT03106025|DEVICE|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
48272025|NCT06160401|DRUG|Singletine|Singletine orally administered
48272026|NCT06160401|DRUG|Placebo|Placebo orally administered
48272027|NCT02591264|OTHER|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
48272028|NCT01269164|PROCEDURE|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
48272029|NCT05202457|PROCEDURE|Elective surgery|Patient undergoing elective or urgent surgery
48272030|NCT04755374|OTHER|Discharged ≤ 21 days|Discharged from palliative care unit in equal less than 21 days
48096205|NCT03106025|OTHER|Ophthalmology Assessment|Number of subjects with retinal detachment per formal ophthalmology assessment. This assessment is a composite measurement which includes the following chief complain, primary impression, right visual acuity, left visual, acuity, ultrasound diagnosis, diagnosis changed, ophthalmology diagnosis.
48096206|NCT05779722|DEVICE|Vapor barrier|Vapor barrier
48096207|NCT02117869|OTHER|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
48096208|NCT02117869|OTHER|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
48096209|NCT02117869|OTHER|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
47927262|NCT01449643|DEVICE|Threshold|
47927263|NCT01449643|DEVICE|Sham Threshold|
48096210|NCT04164628|OTHER|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
48096211|NCT04501224|DRUG|Tenofovir alafenamide fumarate|Patients would take tenofovir alafenamide fumarate, 25mg，once per day
48096212|NCT04501224|DRUG|Entecavir or Tenofovir disoproxil fumarate|Patients would take entecavir 0.5 mg once per day, or tenofovir disoproxil fumarate 300 mg once per day
48096213|NCT06625151|BEHAVIORAL|Perfectionism and Coping Processes Model - Explanatory Feedback Intervention (PCPM-EFI)|The PCPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and coping processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in perceived criticism, self-blame, perceived control, avoidant coping, and event stress are connected to increases negative affect; (b) how changes in perceived social support, positive reinterpretation, perceived control, avoidant coping, and problem-focused coping are linked to increases in positive affect; (c) how self-critical perfectionism and maladaptive stress and coping tendencies explain enduring mood problems; (d) how healthy striving, adaptive appraisal, and coping tendencies can identify personal strengths; and, most important, (e) what the person needs to do to manage and improve his or her mood.
48096214|NCT06625151|BEHAVIORAL|Perfectionism and Emotion Regulation Processes Model - Explanatory Feedback Intervention (PERPM-EFI)|The PERPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and emotion regulation processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in event stress, mindfulness, self-compassion, experiential avoidance, and rumination are connected to increases in negative affect, (b) how changes in event stress, mindfulness, reappraisal, self-compassion, and experiential avoidance are linked to increases in positive affect, (c) how self-critical perfectionism and maladaptive stress and emotion regulation tendencies explain enduring mood problems, (d) how healthy striving, adaptive appraisal, and emotion regulation tendencies can identify personal strengths, and, most important, (e) what the person needs to do to manage and improve his or her mood.
48096215|NCT05854628|PROCEDURE|skin biopsy|Skin biopsies will be obtained at different time points.
48272031|NCT04755374|OTHER|Prolonged discharge|Discharged from palliative care unit in longer than 21 days
47927264|NCT03134079|OTHER|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
47927265|NCT03134079|OTHER|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
47927266|NCT03134079|OTHER|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
47927267|NCT05507359|OTHER|clove gel|4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
47927268|NCT05507359|OTHER|Benzocaine gel|20% Benzocaine gel (Opahl gel)
47927269|NCT04585971|DIAGNOSTIC_TEST|Signal intensity gradient|"Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
47927270|NCT06036004|DRUG|Intranasal OXT|"Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment."
47927271|NCT06036004|OTHER|Placebo nasal spray|"The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment."
48096216|NCT01231282|OTHER|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
48096217|NCT01385865|DIETARY_SUPPLEMENT|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
48096218|NCT01385865|DIETARY_SUPPLEMENT|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
47927272|NCT04002518|DEVICE|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
47927273|NCT04869748|OTHER|Perfetti method|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Participants received a 15-minute session of Perfetti method on affected elbow flexor.~* Participants were asked to concentrate on the position of their elbows.~* Protocol has 4 steps of training starting from 2 positions; full flexion and full extension 3 positions; full flexion, elbow flexion 90 degree and full extension 4 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 45-60 degree and full extension 5 positions; full flexion, elbow flexion 110-140 degree, elbow flexion 90 degree, elbow flexion 45-60 degree and full extension of elbow.~* After therapist passively moved elbow joint to a position, participant guessed the position of his/her elbow. If the answers were correct consecutively for 10 times, the therapist increased the number of positions according to the protocol."
47927274|NCT04869748|OTHER|passive stretching|"* Participant was blindfolded, while lying flat in a quiet and comfortable room.~* Each participant received gentle passive stretching of elbow flexor and maintained in full elbow extension position for 15 minutes."
47927275|NCT02454361|DRUG|KBP-7072|KBP-7072
47927276|NCT02454361|DRUG|Placebo|Placebo
47927277|NCT00938886|DRUG|Naltrexone|Daily 50 mg naltrexone
47927278|NCT00938886|DRUG|Placebo|Matched naltrexone placebo
47927279|NCT01943474|DEVICE|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
47927280|NCT01943474|DEVICE|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
47927281|NCT05153889|OTHER|Hospitalized in Intensive care unit|Patient hospitalized in Intensive care unit with ECG monitoring
47927282|NCT05153889|OTHER|Hospitalized in General cardiology ward|Patient hospitalized in General cardiology ward without ECG monitoring. patients randomized in this group will not be hospitalized in intensive care unit unless an event require intensive care unit monitoring.
47927283|NCT05171725|DIAGNOSTIC_TEST|EEG,PSG|concurrent overnight sleep study with full electroencephalography (in-lab or at home)
47927284|NCT05171725|DIAGNOSTIC_TEST|biosample collection (blood and CSF)|blood or CSF collection for analyses of neurodegenerative, inflammatory, and, per condition, genetic information
47927285|NCT05171725|DIAGNOSTIC_TEST|neuropsychological testing|paper and pencil, as well as tablet based cognitive testing
47927286|NCT05171725|DIAGNOSTIC_TEST|actigraphy|week long actigraphy assessment with concurrent sleep diary acquisition
47927287|NCT05171725|DIAGNOSTIC_TEST|clinician assessment|standard clinical assessment by an expert clinician in the respective field of brain disorders
47927288|NCT03511898|DRUG|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
47927289|NCT03511898|DRUG|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
47927290|NCT03511898|DRUG|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
47927291|NCT01566812|BEHAVIORAL|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
47927292|NCT01566812|BEHAVIORAL|Usual care|Usual care applied in the hospital
47927293|NCT04313647|BIOLOGICAL|1X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
47927294|NCT04313647|BIOLOGICAL|2X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
47927295|NCT04313647|BIOLOGICAL|4X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
47927296|NCT04313647|BIOLOGICAL|6X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
47927297|NCT04313647|BIOLOGICAL|8X level of MSCs-Exo|Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
47927298|NCT02052765|DEVICE|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
47927299|NCT02965092|GENETIC|Second generation CAR-T cells|
47927300|NCT02955251|DRUG|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
47927301|NCT02955251|DRUG|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
47927302|NCT04158193|OTHER|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
47927303|NCT04158193|OTHER|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
48096219|NCT06613906|DEVICE|Healsea Children nasal spray|dosage: 1 puff in each nostril twice daily during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days
48096220|NCT04805346|DEVICE|autoRIC®|With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
48096221|NCT02501629|DRUG|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
48096222|NCT02501629|DRUG|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
47927304|NCT00882570|DRUG|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
47927305|NCT00882570|DRUG|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
48096223|NCT02501629|DRUG|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
48096224|NCT02501629|DRUG|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
48096225|NCT00369135|PROCEDURE|combined intervention|
48096226|NCT00241644|BIOLOGICAL|Rotarix™|Two or Three doses, oral administration
48096227|NCT00241644|BIOLOGICAL|Placebo|One or three doses, oral administration.
48096228|NCT00521716|DEVICE|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
48096229|NCT00521716|DEVICE|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
48096230|NCT05951595|DRUG|Artemether-Lumefantrine-Amodiaquine (ALAQ)|A new fixed-dose combination containing artemether, lumefantrine and amodiaquine (ALAQ) will be used in the trial. Each paediatric (dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine, 40 mg amodiaquine. Adult (hard) tablets will contain either 50 mg or 60 mg of artemether, 300 or 360 mg of lumefantrine and 100 or 120 mg of amodiaquine. The treatments will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine, 22.5-45 mg/kg of amodiaquine).
48096231|NCT05951595|DRUG|Artemether-Lumefantrine (AL)|A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).
48096232|NCT05951595|DRUG|Artesunate-Amodiaquine (ASAQ)|ASAQ will also be administered as a fixed dose combination. The tablets will contain 25 mg of artesunate and 67.5 mg of amodiaquine in the paediatric formulation and 100 mg artesunate, 270 mg amodiaquine in the adult formulation. The dosing will be administered once a day for 3 days at H0, H24 and H48 according to the schedule currently recommended by the WHO.
48096233|NCT01772719|DRUG|Simvastatin and zoledronic acid|"1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
48096234|NCT00409864|PROCEDURE|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
48096235|NCT01949584|DEVICE|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
47927306|NCT06237192|DRUG|blinatumomab for B-ALL, venetoclax for T-ALL|MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
47927307|NCT05409560|OTHER|Swimming participants in the 6-hour cold water swim|The 6-hour cold water swim was the qualifying swim for the English Channel swim during the Channel Swim Camp Dinard 2021 and participants were the swimmers registered for the 6-hour cold water swim who volunteered to participate in this study
47927308|NCT06433856|OTHER|Cold Water Immersion|Cold water immersion consists in 12 min standing in 10 °C water
47927309|NCT06433856|DEVICE|Percussive Massage Therapy|Percussive massage therapy is performed with a massage gun on the thigh muscles for 12 min
47927310|NCT00184171|DRUG|Budesonide|Budesonide 9 mg
47927311|NCT00184171|DRUG|Bismuth|Bismuth mixture
47927312|NCT00184171|DRUG|Fiber|Fiber for control
47927313|NCT05319873|DRUG|Carboplatin|Given IV
47927314|NCT05319873|DRUG|Docetaxel|Given IV
47927315|NCT05319873|DRUG|Fulvestrant|Given SC
47927316|NCT05319873|BIOLOGICAL|Pertuzumab|Given IV
47927317|NCT05319873|OTHER|Quality-of-Life Assessment|Ancillary Studies
47927318|NCT05319873|DRUG|Ribociclib|Given PO
47927319|NCT05319873|BIOLOGICAL|Trastuzumab|Given IV
47927320|NCT05319873|DRUG|Tucatinib|Given PO
47927321|NCT04668612|DEVICE|Dual-bolus|Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
47927322|NCT04668612|DEVICE|Standard bolus|Standard boluses for all meals
47927323|NCT01223443|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
47927324|NCT02921061|DRUG|Cladribine|Given IV
47927325|NCT02921061|DRUG|Cytarabine|Given IV
47927326|NCT02921061|DRUG|Decitabine|Given IV
47927327|NCT02921061|BIOLOGICAL|Filgrastim|Given SC
47927328|NCT02921061|OTHER|Laboratory Biomarker Analysis|Correlative studies
47927329|NCT02921061|DRUG|Mitoxantrone Hydrochloride|Given IV
47927330|NCT06367218|DRUG|opioid based strategy|Induction and maintenance of anesthesia with opioids
47927331|NCT06367218|DRUG|opioid-free strategy|Esketamine was used for induction and maintenance of anesthesia
47927332|NCT06367218|PROCEDURE|Laryngeal mask airway; Preserved spontaneous breathing|The patient used a laryngeal mask to maintain spontaneous breathing
47927333|NCT06367218|PROCEDURE|Double lumen tracheal tube; Mechanical ventilation|The patient was mechanically ventilated using a double-lumen tracheal catheter
47927334|NCT02734901|DIETARY_SUPPLEMENT|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
48096236|NCT05181306|PROCEDURE|Robotic-assisted Total Gastrectomy with D2 Lymphadenectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
48096237|NCT05181306|PROCEDURE|Laparoscopic-assisted Total Gastrectomy with D2 Lymphadenectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and excluding T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
48096238|NCT03837925|DRUG|Atorvastatin 40mg Tablet|Patient participation for 6 weeks of treatment
48096239|NCT03837925|DRUG|Placebo comparator|Patient participation for 6 weeks of treatment
48096240|NCT03853733|RADIATION|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
48096241|NCT02807753|OTHER|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
48096242|NCT02807753|OTHER|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
48096243|NCT00323089|PROCEDURE|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
48096244|NCT01261065|DRUG|carvedilol|Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.
48096245|NCT06021574|DRUG|VDJ001|a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
48096246|NCT06021574|DRUG|Placebo|Placebo
48096247|NCT03431779|PROCEDURE|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
48096248|NCT03431779|PROCEDURE|Surgical excision|Excision of painful areas
48272032|NCT01734876|BEHAVIORAL|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
47927335|NCT02734901|DIETARY_SUPPLEMENT|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
47927336|NCT02734901|DIETARY_SUPPLEMENT|Placebo|1x daily intake of 600 mL raspberry deprived supplement
47927337|NCT00645255|DRUG|placebo|placebo one capsule daily
47927338|NCT00645255|DRUG|sibutramine or placebo|one capsule daily
47927339|NCT00813969|BIOLOGICAL|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
47927340|NCT01579812|DRUG|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
48096249|NCT01526603|DRUG|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
48096250|NCT01526603|BIOLOGICAL|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
48096251|NCT01526603|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) \> 2000/μL for 3 consecutive days.
48096252|NCT01526603|RADIATION|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring \>1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
48272033|NCT01734876|BEHAVIORAL|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
48272034|NCT01348737|DRUG|AZD3839|Single Oral Dose
48272035|NCT01348737|DRUG|AZD3839 Placebo|Single Oral Dose
48272036|NCT04474327|DRUG|Montelukast Sodium|Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
48272037|NCT00981526|DRUG|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
48272038|NCT00981526|DRUG|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
48272039|NCT00981526|DRUG|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
48272040|NCT00981526|DRUG|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
48096253|NCT01526603|DRUG|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients \>12 kg isotretinoin (accutane) should be administered at 160 mg/m\^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
48096254|NCT01526603|DRUG|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
48096255|NCT01526603|DRUG|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
48096256|NCT02086708|DEVICE|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
48096257|NCT03824652|OTHER|walnuts|2 ounces of walnuts daily for 4-10 weeks
47927341|NCT01120067|BEHAVIORAL|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
48096258|NCT03824652|OTHER|usual diet|Subject continues usual diet
48096259|NCT03824652|OTHER|phone counseling with dietitian|Weekly calls with dietitian
48096260|NCT03383887|DRUG|Placebo oral capsule|Placebo before sleep
48096261|NCT03383887|DRUG|DAW1033D oral capsule|DAW1033D before sleep
48096262|NCT00530374|DIETARY_SUPPLEMENT|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
47927342|NCT01120067|BEHAVIORAL|Treatment as Usual|Treatment as Usual.
48096263|NCT00530374|DIETARY_SUPPLEMENT|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
48096264|NCT06622499|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
48096265|NCT04074954|PROCEDURE|Cataract surgery|Patients will receive cataract surgery
48096266|NCT06421831|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
48096267|NCT03874975|DRUG|oral vitamin D|vitamin D and UVB versus UVB alone in psoriatic patients and evaluate patients by PASI score before and after treatment and measure serum vitamin D before and after treatment
48096268|NCT05989048|DRUG|Zavegepant|The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
48096269|NCT05989048|DRUG|Placebo|Single dose of matching placebo taken within Treatment Phase.
48096270|NCT01176799|DRUG|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
47927343|NCT01722695|OTHER|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
48096271|NCT01176799|DRUG|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
48096272|NCT02616367|DRUG|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
47927344|NCT00881543|DRUG|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
47927345|NCT04942197|OTHER|use pregnancy management application|Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
47927346|NCT05520710|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
47927347|NCT05520710|OTHER|Education|Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
47927348|NCT00506532|DRUG|Surfactant (calfactant)|
48096273|NCT02616367|DRUG|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
48096274|NCT02157714|DRUG|PRX002|
48096275|NCT02157714|OTHER|Placebo|
48096276|NCT04756401|DRUG|Carfilzomib|Given IV
48096277|NCT04756401|BIOLOGICAL|Daratumumab|Given IV
48096278|NCT04756401|DRUG|Dexamethasone|Given PO
48096279|NCT04756401|OTHER|Quality-of-Life Assessment|Ancillary studies
48096280|NCT04756401|DRUG|Selinexor|Given PO
47927349|NCT02919384|OTHER|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
48096281|NCT02417311|OTHER|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
48272041|NCT04416022|DIAGNOSTIC_TEST|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
48096282|NCT04358861|PROCEDURE|Nonsurgical Root canal therapy|After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
48096283|NCT04358861|DEVICE|Dental operating microscope|Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
48096284|NCT03001362|RADIATION|Radical external beam radiotherapy|pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
48096285|NCT02303769|DRUG|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
48096286|NCT02303769|DRUG|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
48096287|NCT03323840|OTHER|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
48096288|NCT06342258|DRUG|Ultradent Ultra Seal XT Plus|Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
48096289|NCT02620189|DRUG|Anti-TNF Biologics Therapy|
48096290|NCT00589732|DRUG|Valsartan|Valsartan 160mg per day
48096291|NCT03361592|PROCEDURE|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
48272042|NCT05451719|DRUG|Fruquintinib Plus Capecitabine|Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
48272043|NCT05451719|DRUG|Capecitabine|Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
47927350|NCT06138223|OTHER|Exercise intervention|During 12 weeks, patients will visit twice a week a trained oncology physiotherapist for one hour per session. This training includes supervised aerobic and resistance exercises to increase aerobic condition and muscle resistance, based on their own fitness level as assessed at baseline. Additionally, physiotherapists will educate participants on how to increase their daily activity. To this end, all participants will receive an activity tracker to monitor their daily activities.
47927351|NCT06138223|OTHER|Nutrition intervention|Once every two weeks patients in the intervention group will receive a nutritional assessment and intervention by a trained dietician for optimization of their nutritional intake to improve their nutritional status, following the ESPEN guideline on nutrition in cancer patients and the national guidelines of the National Nutritionists Oncology Working Group (NNOWG; in Dutch: Landelijke Werkgroep Diëtisten Oncologie, LWDO). Moreover, an amount of 15-25 grams of protein within 1-2 hours after exercise will be advised, to prevent muscle protein breakdown and enhance muscle protein synthesis.
47927352|NCT02647450|OTHER|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
47927353|NCT05828810|DRUG|surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution|"Patients will be randomized to receive surgical antiseptic skin preparation with either chlorhexidine or iodine-based solution.~Specifically, the first treatment arm will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The second treatment arm will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation."
47927354|NCT03588962|BIOLOGICAL|In-stent restenosis|Patch tests for the metals applicated in each of the patients
47927355|NCT04152993|DEVICE|NeuroPace® RNS® System|In this intervention, patients suffering from PTSD undergo a surgical procedure to implant the responsive neurostimulation device (RNS, NeuroPace). This procedure involves the placement of a depth lead bilaterally in the amygdala and hippocampus following a trans-occipital trajectory. The two leads are then connected to a pulse generator fixated to the skull. RNS is able to detect specific signals from the target and to respond with a programmed electrical stimulation. One month after the implantation of the system, the patients will undergo 3 tasks: a fear conditioning task, the international affective picture system and the subsequent memory recall paradigm. These tasks will yield electrophysiological biomarkers of arousal and re-experiencing. We will then program RNS to detect and respond to those biomarkers. The patients will be followed longitudinally for improvement and evidence of target engagement as seen on cerebral metabolism and global electroencephalography.
47927356|NCT00928590|DRUG|Travoprost/Timolol Maleate Fixed Combination solution|
47927357|NCT05094544|RADIATION|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
48272044|NCT03514082|DEVICE|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
48272045|NCT03640884|DRUG|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
48272046|NCT03589001|OTHER|Activity modification|Activity modification, exercises and gradual return to sport
48272047|NCT04658069|OTHER|no specific interventions|no specific interventions
48272048|NCT00347815|DRUG|Buprenorphine|
48272049|NCT00898092|GENETIC|microarray analysis|
48272050|NCT00898092|GENETIC|molecular genetic technique|
48272051|NCT00898092|GENETIC|mutation analysis|
48096292|NCT03361592|PROCEDURE|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
48096293|NCT03329833|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
48096294|NCT03329833|BEHAVIORAL|Web-based application|Web-based application participants will be asked to log activity at least on a daily basis.
48096295|NCT01217580|DRUG|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
47927358|NCT01341392|DRUG|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
47927359|NCT01341392|DRUG|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
48096296|NCT01217580|DRUG|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
48096297|NCT06470204|DRUG|Ropivacaine|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2ml 0.9% NaCl)
48096298|NCT06470204|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2mg Dexamethasone)
48096299|NCT02892409|DRUG|Clarithromycin|Clarithromycin tablets
48096300|NCT02892409|DRUG|Amoxicillin|Amoxicillin capsules
48096301|NCT02892409|DRUG|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
47927360|NCT01341392|DRUG|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
47927361|NCT04922047|DRUG|tislelizumab and BCG|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks in first year and continue to second year based on physician choose. BCG 120 mg induction therapy administered via intravesical instillation (once weekly for 6 weeks). BCG induction therapy is followed by maintenance therapy (once weekly for 3 weeks at months 3, 6, 12, 18, 24m).
47927362|NCT02692651|DRUG|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
48272052|NCT00898092|GENETIC|polymerase chain reaction|
47927363|NCT02692651|DRUG|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
48096302|NCT02892409|DRUG|Lansoprazole|Lansoprazole capsules
48096303|NCT02892409|DRUG|TAK-438|TAK-438 tablets
47927364|NCT03070743|PROCEDURE|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
47927365|NCT03339297|DRUG|Defibrotide|6.25 mg/kg via 2-hour IV infusion every 6 hours
47927366|NCT03339297|DRUG|Standard of Care|Administered according to local institutional guidelines, physician preference, and patient need.
47927367|NCT06224751|DIAGNOSTIC_TEST|Near logMAR letter acuity|Comparison of gold standard printed tests and computerised versions
47927368|NCT06224751|DIAGNOSTIC_TEST|Near LogMAR word acuity|Comparison of gold standard printed tests and computerised versions
48096304|NCT05974839|OTHER|Ocrelizumab|Non-interventional
48096305|NCT04559932|OTHER|Tracheostomy Training Course|A standardized competency-based education tracheostomy module has been developed by the investigator group in collaboration with Respiratory Medicine, Complex Care, Respiratory Therapy, Nursing Education, Family Advisory Network and the Learning Institute at SickKids. Instructional methods for the full module are based on principles of adult learning and evidence from the procedure education literature and include the use of interactive, small-group teaching, hands-on simulation-based learning stations with relevant equipment as well as a formal assessment of knowledge and skills using simulation. Pre-learning packages are sent to course attendees at the time of registration to facilitate higher level discussions on the day of the course. While investigators have rigorously developed the curriculum and evaluation measures, the course outcomes remain unknown.
47927369|NCT06224751|DIAGNOSTIC_TEST|Red Green Stereoacuity|Comparison of gold standard printed tests and computerised versions
47927370|NCT06224751|DIAGNOSTIC_TEST|Auckland Optotype/Auckland Vanishing Optotypes|Comparison of gold standard printed tests and computerised versions
47927371|NCT06224751|DIAGNOSTIC_TEST|Vanishing Optotype Sloan Letters|Comparison of gold standard printed tests and computerised versions
47927372|NCT06224751|DIAGNOSTIC_TEST|Letter Contrast Sensitivity|Comparison of gold standard printed tests and computerised versions
48096306|NCT04056221|OTHER|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
47927373|NCT06224751|DIAGNOSTIC_TEST|Low Contrast Letter Acuity|Comparison of gold standard printed tests and computerised versions
47927374|NCT01931215|OTHER|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
48096307|NCT04056221|OTHER|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
48272053|NCT00898092|GENETIC|reverse transcriptase-polymerase chain reaction|
48272054|NCT00898092|OTHER|diagnostic laboratory biomarker analysis|
48272055|NCT05307458|DRUG|Buprenorphine/naloxone|Participants will receive gradually increasing doses of buprenorphine while tapering down on their methadone dose.
48096308|NCT04660084|DIAGNOSTIC_TEST|Ultra-rapid molecular point-of-care testing|"Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is \<2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs."
48096309|NCT03597321|BIOLOGICAL|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
47927375|NCT01931215|OTHER|TAP-block with ropivacaine and clonidine|
47927376|NCT06009185|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
47927377|NCT03442868|DEVICE|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
47927378|NCT05537870|BEHAVIORAL|cancer nurse navigator care|oncology case manager care combined with cancer nurse navigator care
48096310|NCT02312440|DRUG|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
48096311|NCT02312440|DRUG|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
48096312|NCT02312440|DRUG|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
48096313|NCT04506190|PROCEDURE|Revisional bariatric surgery|Subjects who undergo revisional bariatric surgery
48096314|NCT00611065|DEVICE|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
48096315|NCT01495637|DRUG|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
48443878|NCT04802694|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart. Water-based barrier tape will be applied to the area every time the plaster will be changed and current skin condition score will be noted to the chart."
47927379|NCT05537870|BEHAVIORAL|case manager care|case manager care (usual care)
47927380|NCT03104816|DRUG|Acetaminophen IV Soln 10 MG/ML|
47927381|NCT03104816|DRUG|Acetaminophen|
48096316|NCT06416085|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
48096317|NCT00099918|DRUG|vildagliptin|
48096318|NCT05334082|OTHER|FIFA 11+|15 progressive exercise drills for training preparation (warm-up)
48096319|NCT05091762|BEHAVIORAL|exercise|Upper limb resistance training with blood flow obstruction
48096320|NCT03529864|OTHER|Exercise Therapy|
48096321|NCT05822440|DRUG|PF-07817883|Single oral dose (period 1) or co-administered with itraconazole (period 2)
47927382|NCT03104816|DRUG|Hydromorphone|
47927383|NCT03821662|BEHAVIORAL|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
47927384|NCT00817128|PROCEDURE|PEPT|Pain Exposure Physical Therapy
47927385|NCT00817128|PROCEDURE|CBO standard|Standard therapy as defined in CBO guideline 2006
47927386|NCT05476484|DRUG|SQ SLIT-tablet|SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet
47927387|NCT04503915|PROCEDURE|different estrogen supplementation modes|The different estrogen supplementation modes are randomized into two groups.
47927388|NCT02483533|DRUG|LIPO-202|
47927389|NCT02483533|DRUG|Placebo|
47927390|NCT02390791|OTHER|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
47927391|NCT02390791|OTHER|treatment as usual standard portal|Standard version of myADHDportal.com web software
47927392|NCT02392533|OTHER|Education|Education
47927393|NCT01686802|DRUG|oral morphine|
47927394|NCT01686802|DRUG|Ibuprofen|
47927395|NCT02470715|GENETIC|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
48096322|NCT05822440|DRUG|Itraconazole|Interacting drug which will be given for 7 days in period 2
48096323|NCT03614234|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
48096324|NCT05960162|DIAGNOSTIC_TEST|90K|Blood test
48272056|NCT05014854|DEVICE|Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.|Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
48443879|NCT04802694|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale . Since the hydrocolloid barrier tape can stay on the skin for 7 days and be transparent, the assessment of skin condition will be realized for 7 days and noted down to the chart."
47927396|NCT05201456|DEVICE|LithoVue Elite System|The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
47927397|NCT06163677|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
47927398|NCT03127098|BIOLOGICAL|ETBX-011|ETBX-011 immunization was administered by subcutaneous (SC) injection.
47927399|NCT03127098|BIOLOGICAL|ALT-803|ALT-803 was administered by SC injection.
47927400|NCT01975324|DRUG|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
47927401|NCT01975324|DRUG|Placebo|placebo (sugar pill) twice a day for two weeks
47927402|NCT03315091|DRUG|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
47927403|NCT03315091|DRUG|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
47927404|NCT02915874|BEHAVIORAL|Acceptance and Commitment Therapy|
47927405|NCT03748615|DEVICE|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
47927406|NCT02248688|DEVICE|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
47927407|NCT02248688|PROCEDURE|Left Gastric Artery Embolization|
47927408|NCT04445389|DRUG|GX-19|DNA vaccine expressing SARS-CoV-2 S-protein antigen
47927409|NCT04445389|DRUG|Saline|Saline
47927410|NCT04567732|COMBINATION_PRODUCT|injection of Filtered Autologous Adipose Tissue|Single injection of Filtered Autologous Adipose Tissue
47927411|NCT04567732|DRUG|Placebo|Single injection of Placebo
47927412|NCT04585503|DEVICE|Electrode implantation|The intervention consist in implanting 6 electrodes in subdural or intra cortical position and monitor the central nervous system activity. This monitoring will be additional to the usual monitoring.
47927413|NCT00100334|DRUG|PPI-1019 (APAN)|
47927414|NCT00189410|DRUG|Pegylated Liposomal Doxorubicin and Carboplatin|
47927415|NCT05955976|OTHER|BIOPSY|biopsy
47927416|NCT05702749|PROCEDURE|Microsurgical resection of VS|Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
47927417|NCT05702749|RADIATION|Stereotactic radiosurgery|Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
47927418|NCT05702749|OTHER|PREHAB|A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
47927419|NCT01100957|PROCEDURE|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
48096325|NCT04144985|OTHER|Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.|Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
48272057|NCT04213404|DRUG|Ribociclib|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
48272058|NCT04213404|DRUG|Spartalizumab|Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
47927420|NCT05023369|DRUG|Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)|Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
47927421|NCT05616689|OTHER|Bundled hyperpolypharmacy|Bundled hyperpolypharmacy playbook to be used by pharmacist, with physician approval, in shared decision making with participant,
47927422|NCT04996472|BEHAVIORAL|Sensitivity to phonological rules: Adults|Assess whether adults are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon.
47927423|NCT04996472|BEHAVIORAL|Sensitivity to semantic category cues: Adults|Assess whether adults show improved learning of OR or family resemblance rules when a semantic category cue is used.
47927424|NCT05532423|DRUG|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
47927425|NCT05532423|DRUG|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
47927426|NCT00164970|DIETARY_SUPPLEMENT|Vitamin B12|
47927427|NCT00164970|DIETARY_SUPPLEMENT|folate|
47927428|NCT04320641|OTHER|ACUPRESSURE|Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
47927429|NCT03387111|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
47927430|NCT03387111|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
47927431|NCT03387111|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
47927432|NCT03387111|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
47927433|NCT03387111|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
47927434|NCT03387111|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
47927435|NCT03387111|BIOLOGICAL|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
47927436|NCT03387111|BIOLOGICAL|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
47927437|NCT03387111|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
47927438|NCT03387111|DRUG|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
47927439|NCT03387111|DRUG|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
47927440|NCT03387111|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
47927441|NCT03387111|DRUG|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
47927442|NCT03387111|DRUG|Cisplatin|cis-diamminedichloroplatinum(II)
47927443|NCT03387111|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
47927444|NCT03387111|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
47927445|NCT03387111|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
47927446|NCT03387111|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
47927447|NCT03387111|DRUG|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
47927448|NCT03387111|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
47927449|NCT03387111|BIOLOGICAL|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
47927450|NCT05869357|OTHER|cream containing 2.5% sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
47927451|NCT05869357|OTHER|cream containing 5%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
47927452|NCT05869357|OTHER|cream containing 10%sericin and 2%turmeric|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
47927453|NCT05869357|OTHER|cream base|Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
47927454|NCT02920853|BEHAVIORAL|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
47927455|NCT02920853|BEHAVIORAL|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
47927456|NCT02434471|DEVICE|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~1. Respiratory-triggered T1w DISCO LAVA precontrast~2. Respiratory-triggered T1w DISCO LAVA in the portal venous phase~3. Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
47927457|NCT04774211|DIAGNOSTIC_TEST|SOS-PD|Validation of SOS-PD bedside assessments comparing the Danish SOS-PD scale with a Child Psychiatrist using DSM-V as the reference standard
47927458|NCT05961345|OTHER|experimental group|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
47927459|NCT04929717|OTHER|Breastfeeding education and counseling|Breastfeeding education was applied for four weeks.
47927460|NCT04929717|OTHER|Routine postpartum breastfeeding training included in the hospital procedure|The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
48443880|NCT04802694|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart."
48443881|NCT03429712|DEVICE|Dual-source multi-detector computed tomography (DSSE)|Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
47927461|NCT00737399|BEHAVIORAL|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
47927462|NCT06457672|DIAGNOSTIC_TEST|Group I|Complete Crown technique of superimposition
47927463|NCT06457672|DIAGNOSTIC_TEST|Group II|Gold standard technique of superimposition
47927464|NCT02820532|DEVICE|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
47927465|NCT06114524|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied for 15 min before the procedure.
47927466|NCT03446144|DRUG|IONIS-FB-Lrx|Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
47927467|NCT03446144|DRUG|Placebo (sterline saline 0.9%)|Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
47927468|NCT01604278|DRUG|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
47927469|NCT01604278|DRUG|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
47927470|NCT00657410|DRUG|dexamethasone|
47927471|NCT00657410|DRUG|prednisone|
47927472|NCT00657410|PROCEDURE|quality-of-life assessment|
47927473|NCT04093063|OTHER|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
47927474|NCT05268627|DRUG|Liraglutide|endoscopy
47927475|NCT00672204|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
47927476|NCT00672204|DRUG|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
47927477|NCT00672204|DRUG|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
47927478|NCT00672204|DRUG|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
47927479|NCT05504772|GENETIC|Whole Genome Sequencing|Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
47927480|NCT05504772|GENETIC|RNA seq|Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
47927481|NCT05504772|GENETIC|DNA Methylation|Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
47927482|NCT05504772|GENETIC|Targeted Panel Sequencing|"Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type"
47927483|NCT05504772|GENETIC|High Throughput Sequencing (in vitro)|High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \<30%) and selected tumor types.
47927484|NCT05504772|GENETIC|Patient Derived Xenograft (PDX)(in vivo)|In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
48443882|NCT00040391|DRUG|Investigational drug|
48443883|NCT00040391|DRUG|Irinotecan|
48443884|NCT00040391|DRUG|5-fluorouracil|
48443885|NCT00040391|DRUG|Leucovorin|
48443886|NCT04598828|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
47927485|NCT05504772|OTHER|Liquid Biopsy|Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
47927486|NCT02688322|DRUG|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
47927487|NCT04012489|PROCEDURE|Breath Stacking|Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
48443887|NCT00367861|DRUG|interruption of Glivec®|interruption of Glivec®
48443888|NCT00019591|BIOLOGICAL|aldesleukin|
48443889|NCT00019591|BIOLOGICAL|ras peptide cancer vaccine|
48443890|NCT00019591|PROCEDURE|adjuvant therapy|
48443891|NCT00387686|DRUG|rhBMP-2/CPM|
48443892|NCT00387686|DRUG|rhBMP-2/CPM|
48443893|NCT00387686|DRUG|rhBMP-2/CPM|
47927488|NCT04012489|PROCEDURE|Air Stacking|The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
48443894|NCT00387686|DRUG|rhBMP-2/CPM|
48443895|NCT02601560|BIOLOGICAL|MEDI6012|Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
48443896|NCT02601560|BIOLOGICAL|Placebo SC|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
47927489|NCT00547001|DRUG|Estradiol|1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
47927490|NCT03391193|BIOLOGICAL|Multi-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
47927491|NCT03391193|BIOLOGICAL|Single-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
47927492|NCT01119937|DRUG|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
47927493|NCT01119937|DRUG|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
47927494|NCT05938049|DEVICE|IVC ultrasound & Carotid doppler|"bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as (\[PV max- PV min\]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment"
47927495|NCT03999775|DIETARY_SUPPLEMENT|Calcium, vitamin D and bioactive collagen peptides supplement|
47927496|NCT03999775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|
47927497|NCT04195191|OTHER|ANM|communication intervention
47927498|NCT04195191|OTHER|Placebo|regular assistance in community pharmacies
47927499|NCT04623125|BEHAVIORAL|Spaced Retrieval Practice|Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
47927500|NCT05615935|OTHER|Experiential HIV Testing|The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
47927501|NCT05320744|PROCEDURE|surgical extraction of impacted lower third molar|surgical removal of impacted third molar under local anesthesia.
47927502|NCT01076127|BEHAVIORAL|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
47927503|NCT01076127|BEHAVIORAL|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
47927504|NCT00941434|DIETARY_SUPPLEMENT|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
47927505|NCT04316702|DEVICE|Hyperbaric oxygen therapy (HBOT) treatment|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
47927506|NCT04316702|DRUG|Cymbalta / Lyrica - Drug treatment|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
47927507|NCT03282331|PROCEDURE|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
47927508|NCT03282331|PROCEDURE|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
47927509|NCT03282331|PROCEDURE|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
47927510|NCT02747303|PROCEDURE|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
47927511|NCT04948931|OTHER|Lavender aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
47927512|NCT04948931|OTHER|Rosemary aromatherapy|The application will be once a day, every day for four weeks. Each session will take five minutes.
48096326|NCT01894347|OTHER|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
48096327|NCT05931484|DRUG|Gemfibrozil|Oral Solution
48443897|NCT02601560|BIOLOGICAL|Placebo IV|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
48443898|NCT00002062|DRUG|Spiramycin|
47927513|NCT04948931|OTHER|Control|The application will be once a day, every day for four weeks. Each session will take five minutes.
47927514|NCT04278274|PROCEDURE|artificial intelligence prediction system|The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
47927515|NCT04278274|PROCEDURE|the radiologists|The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
47927516|NCT04106414|DRUG|Nivolumab|Nivolumab 480 mg every 4 weeks.
47927517|NCT04106414|DRUG|BMS- 986205|BMS-986205 100 mg every 4 weeks.
47927518|NCT06059131|OTHER|KeenMind|320 mg/d (2 capsules/d) during 3 months
48096328|NCT05931484|DRUG|Placebo|Daily dose of Placebo
48443899|NCT03474757|OTHER|Data Collection|Data will be extracted from July 2009 to the last available database extraction
48443900|NCT05824325|DRUG|SHR-A1811|HER2 ADC
48443901|NCT05824325|DRUG|TROP2 ADC|TROP2 ADC
48096329|NCT02474511|OTHER|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
47927519|NCT06059131|OTHER|Placebo|320 mg/d (2 capsules/d) during 3 months
48096330|NCT03867864|DEVICE|Necklace with essential oil for the first 4 weeks|The necklaces contain essential oil.
48096331|NCT03867864|DEVICE|Necklace without essential oil for the first 4 weeks|The necklaces do not contain essential oil.
48096332|NCT03867864|OTHER|Washout|Washout (do not wear the necklace) for one week for two groups, then two groups cross-over.
48096333|NCT03867864|DEVICE|Necklace with essential oil for last 4 weeks|The necklaces contain essential oil.
48096334|NCT03867864|DEVICE|Necklace without essential oil for last 4 weeks|The necklaces do not contain essential oil.
48096335|NCT06376019|PROCEDURE|solitary Implant loading with ball attachment|ball attachment will be attached to the dental implant on the day of implant placement
48272059|NCT03591900|DEVICE|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
48272060|NCT04122287|DRUG|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
48272061|NCT04122287|DRUG|tinidazole|tinidazole-tetracycline-containing quadruple regimens
48443902|NCT00958451|DRUG|Paricalcitol|"1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
48443903|NCT00958451|DRUG|Ergocalciferol|"1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
48443904|NCT00015626|DRUG|Metformin|
48443905|NCT00015626|PROCEDURE|skin biopsy|
47927520|NCT02639858|DRUG|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
47927521|NCT01945710|DRUG|Eribulin-LF|
47927522|NCT03553966|PROCEDURE|Prophylactic|Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
48096336|NCT06376019|PROCEDURE|splinted Implant loading with intra oral welding|Titanium bar will be welded to the dental implant on the day of implant placement
48096337|NCT06376019|PROCEDURE|complete denture|Mucosa supported conventional complete denture will be fabricated without supporting implants
48096338|NCT06556004|BIOLOGICAL|TRIMELVAX|The safety of this immunotherapeutic compound will be tested in patients with advanced melanoma and will secondarily evaluate the induced immune response.
48096339|NCT04983888|DRUG|Obinutuzumab|1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
48096340|NCT02333851|DRUG|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
48096341|NCT02333851|DRUG|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
48096342|NCT05037656|BEHAVIORAL|School-based curriculum|Participants will be randomized, at the school level, to receive either the e-cigarette/tobacco/areca nut use prevention curriculum or the standard of care (i.e., control). The curriculum will be implemented using 5 intensive in-class lessons over the span of 6 weeks. All sessions of the curriculum follow the same basic format: a) an introduction and/or review of the past lesson, b) a cultural wall activity, c) a video, d) 1-2 interactive activities, and e) a wrap-up activity. Lessons are designed such as to help improve knowledge about drugs and correct cognitive misperceptions and to train on skills to resist normative social influence. Participants will complete identical survey questionnaires for assessments at 3 time-points: pretest (baseline, before implementing the intervention), immediate posttest (following the end of the intervention), and six-month follow-up. The surveys will be administered in the classroom, during regular school hours.
48443906|NCT00015626|BEHAVIORAL|diet and exercise|
48443907|NCT00015626|DRUG|pioglitazone|
48443908|NCT00015626|DRUG|rosiglitazone|
47927523|NCT03553966|PROCEDURE|Cleaning teeth|Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
48096343|NCT05536284|DRUG|Bisoprolol Fumarate Tablets|Antihypertensive drug used for acute coronary syndrome patients
48096344|NCT01032850|DRUG|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
48443909|NCT02937415|PROCEDURE|Breath carbon monoxide|Breath carbon monoxide measurement.
48443910|NCT02937415|PROCEDURE|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
48443911|NCT02937415|PROCEDURE|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
48443912|NCT01067183|BEHAVIORAL|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
48096345|NCT00000568|BEHAVIORAL|smoking cessation|
48096346|NCT00000568|DRUG|ipratropium|
48096347|NCT02028884|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
48096348|NCT02028884|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
48096349|NCT02028884|DRUG|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
48096350|NCT02943655|DRUG|combined contraceptive pills (microcept)|oral combined contraceptive once daily
48096351|NCT02943655|DRUG|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
48096352|NCT02943655|DRUG|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
47927524|NCT03553966|DEVICE|Restorative dentistry|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
48096353|NCT04069546|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
48096354|NCT04091672|PROCEDURE|Control Intervention (Conventional Autograft)|Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)
48096355|NCT04091672|DEVICE|Investigational Intervention (RECELL + more widely meshed autograft)|More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
48096356|NCT02272517|DRUG|Vortioxetine 10-20 mg|
47927525|NCT00956098|DRUG|oltipraz|60mg bid 90mg qd
47927526|NCT00956098|DRUG|placebo|
47927527|NCT02739633|DRUG|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
47927528|NCT02739633|DRUG|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
47927529|NCT04057989|DRUG|ketamine|
47927530|NCT03635671|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
47927531|NCT02020720|PROCEDURE|Biopsy|Undergo image-guided biopsy
47927532|NCT02020720|PROCEDURE|Computed Tomography|Undergo 18F-DOPA-PET/CT
47927533|NCT02020720|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
47927534|NCT02020720|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
47927535|NCT02020720|OTHER|Laboratory Biomarker Analysis|Correlative studies
47927536|NCT02020720|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
47927537|NCT02020720|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
47927538|NCT02020720|PROCEDURE|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
47927539|NCT04998136|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
47927540|NCT04998136|DRUG|Placebo (semaglutide 2.4 mg)|Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
47927541|NCT00057980|DRUG|celecoxib|
47927542|NCT00057980|DRUG|epirubicin hydrochloride|
47927543|NCT00469170|DEVICE|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
47927544|NCT04850781|BEHAVIORAL|Bi-weekly frozen meal home delivery|All participants randomized to this arm will receive 10 frozen meals that are mailed to their home every two weeks from a MOW vendor, TRIO foods.
47927545|NCT04850781|BEHAVIORAL|Daily home meal delivery|All participants randomized to this arm will receive meals delivered to their home multiple times per week from a MOW program employee/volunteer with a wellness check and socialization.
47927546|NCT01673347|BIOLOGICAL|Meniscal Allograft|Meniscal allograft
47927547|NCT01534182|DRUG|Fingolimod|0.5 mg orally once a day
47927548|NCT01534182|DRUG|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
48096357|NCT02272517|DRUG|Escitalopram 10-20 mg|
48096358|NCT04917757|DIAGNOSTIC_TEST|1mg Dexamethasone test|For each patient a 1mg dexamethasone test has been performed.
48096359|NCT03374046|PROCEDURE|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
48096360|NCT05608967|DEVICE|PREHapp|Prehabilitation programme through the PREHapp platform
48106791|NCT06229717|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
48272062|NCT00944827|DIETARY_SUPPLEMENT|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
47927549|NCT01534182|DRUG|Glatiramer acetate (GA)|20 mg subcutaneously once a day
47927550|NCT04636853|BIOLOGICAL|Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)|"A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control."
47927551|NCT01829243|DRUG|Milnacipran|
47927552|NCT01829243|DRUG|Placebo|
48096361|NCT06244108|OTHER|Occupational therapy home program|"After evaluating the children, an occupational therapy home intervention program will be developed for each child. The program will be monitored through telephone and computer interviews, as well as video, photo, and audio recordings. The interventions in this study were selected based on successful occupational therapy home programs for children with disabilities. The program consists of five steps.~Step 1 is to establish collaborative relationships with parents. Step 2 is to determine the most appropriate goals for the child and their family. Step 3 involves selecting the most suitable therapeutic activities to achieve these goals. Step 4 is to educate and support parents in performing these therapeutic activities. Finally, Step 5 involves measuring the results and providing feedback."
48096362|NCT00603447|DRUG|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
48096363|NCT00603447|DRUG|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
48096364|NCT00603447|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
48096365|NCT00192153|BIOLOGICAL|CAIV-T or TIV|
48096366|NCT06366074|DEVICE|Watch-TEA group|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
48096367|NCT06366074|DEVICE|Tethered TEA device|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
48096368|NCT03638219|OTHER|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.|Data collection, follow up and bioscore calculation at the end of study
48096369|NCT03349684|DRUG|Acarbose|Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
48096370|NCT03349684|DRUG|Metformin|500 mg 3 times daily, oral, with the first mouthful of main meal
48096371|NCT03349684|DRUG|Placebo|Acarbose matching placebo, oral
48096372|NCT04376164|RADIATION|low level laser therapy|mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5J/cm2energy density, for 10 seconds at 10 points (0.2 J/point) on facial and lingual aspects. This protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months
48096373|NCT00192192|BIOLOGICAL|CAIV-T|
48096374|NCT02397889|DRUG|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
48096375|NCT02397889|DRUG|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
47927553|NCT00455832|PROCEDURE|peginterferon alpha and ribavirin|sperm collection
48096376|NCT01007708|DRUG|IDP-108|Topical application once a day for 48 weeks
48096377|NCT01007708|DRUG|Vehicle|Topical application once a day for 48 weeks
48096378|NCT00418847|DRUG|miglustat|Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA \> 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
48096379|NCT00779571|BEHAVIORAL|Crispbread|8 week low calorie diet
48096380|NCT03455413|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
48096381|NCT06630819|OTHER|1.8 ml of 4% Articaine|Buccal infiltration of 1.8 ml of 4% Articaine
48096382|NCT06630819|OTHER|3.6 ml of 4% Articaine|Buccal infiltration of 3.6 ml of 4% Articaine.
48272063|NCT00944827|DIETARY_SUPPLEMENT|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
48272064|NCT01196442|OTHER|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
48096383|NCT03881254|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
48096384|NCT03881254|OTHER|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
48096385|NCT03881254|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
48272065|NCT01196442|OTHER|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
48272066|NCT01973855|DRUG|Western Medicine|Physical cooling,Hydrocortisone
47927554|NCT05507788|DEVICE|Wheelchair air cushion|Reaching tasks during each of the seating conditions decribed in the Arms section.
48096386|NCT03881254|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
48106792|NCT06229717|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
48272067|NCT01973855|DRUG|TCM and Western Medicine|Third Infectious diseases soup recipe
48272068|NCT04590456|OTHER|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
48272069|NCT00937222|DIETARY_SUPPLEMENT|Peanuts and peanut butter|Peanuts and peanut butter
48272070|NCT00067756|DRUG|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
48272071|NCT02162849|DRUG|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
48272072|NCT02162849|DRUG|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
47927555|NCT00697580|BEHAVIORAL|Nutrition|Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
47927556|NCT00697580|BEHAVIORAL|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
47927557|NCT00697580|BEHAVIORAL|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
47927558|NCT03859830|DEVICE|Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
47927559|NCT03859830|DEVICE|AK200 Ultra S, extracorporeal circulation conduct of blood purification|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
47927560|NCT04762901|DRUG|Niraparib|Oral tablet
47927561|NCT04762901|DRUG|Doxorubicin|IV
47927562|NCT04762901|DRUG|Cyclophosphamide|IV
47927563|NCT04762901|DRUG|Paclitaxel|IV
47927564|NCT04762901|DRUG|Pegfilgrastim|Injection
47927565|NCT04762901|DRUG|Carboplatin|IV
47927566|NCT02802046|RADIATION|Computed tomographic angiography of coronary artery|
47927567|NCT00450385|DRUG|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
47927568|NCT00450385|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
47927569|NCT00450385|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
47927570|NCT00450385|DRUG|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
47927571|NCT00450385|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
47927572|NCT03907618|DIAGNOSTIC_TEST|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
47927573|NCT04384367|DRUG|Rizatriptan 10 mg + Naproxen 550mg|oral - single dose
47927574|NCT04384367|DRUG|Maxalt 10Mg Tablet|oral - single dose
47927575|NCT04384367|DRUG|Flanax 550mg|oral - single dose
47927576|NCT04384367|DRUG|Placebo oral tablet|oral - single dose
47927577|NCT02426489|DEVICE|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
47927578|NCT02972476|DRUG|Budesonide & formoterol fumarate and Aclidinium bromide|
47927579|NCT02972476|DRUG|Fluticasone 500 & salmeterol and Aclidinium bromide|
47927580|NCT02972476|DRUG|Fluticasone 250 & salmeterol and Aclidinium bromide|
47927581|NCT02972476|DRUG|Aclidinium bromide & formoterol fumarate|
48272073|NCT02162849|DRUG|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
48272074|NCT02162849|DRUG|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
47927582|NCT04825353|PROCEDURE|Endoscopic compbined guided PCNL|patient undergo stone removal by ECIRS
47927583|NCT04825353|PROCEDURE|Standard PCNL|patient undergo SPCNL
47927584|NCT00288743|DRUG|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
47927585|NCT00639743|DRUG|placebo ( group B)|placebo ( group B)
47927586|NCT00639743|DRUG|tenecteplase (group A)|tenecteplase (group A)
47927587|NCT06516835|OTHER|Enteral fluid|GNAK will be administered to the gastrointestinal tract with EN in the same volume.
47927588|NCT06516835|OTHER|Intravenous fluid|Undiluted EN will be given to the gastrointestinal tract. GNAK, in the same volume, will be administered intravenously.
47927589|NCT01743001|DRUG|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
47927590|NCT01743001|DRUG|Placebo|Macitentan-matching placebo oral tablet once daily
47927591|NCT03515291|BIOLOGICAL|iMP cells|Immunomodulatory progenitor cells
47927592|NCT03515291|OTHER|Control injection|Cell suspension solution
47927593|NCT03363022|DRUG|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
47927594|NCT03363022|OTHER|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
47927595|NCT03363022|OTHER|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
47927596|NCT01162798|OTHER|infant formula|test infant formula fed to infants until 6 months corrected gestational age
47927597|NCT01162798|OTHER|control infant formula|commercially available infant formula
47927598|NCT02644681|PROCEDURE|Aortic Aneurysm, Thoracic surgery|
47927599|NCT02671916|BEHAVIORAL|questionnaire|Investigation on all study patients, no Intervention, no groups
47927600|NCT06092047|BIOLOGICAL|UTAA09 cells for infusion|Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.
47927601|NCT06092047|DRUG|Fludarabine|30 mg/m\^2/day×4 days
47927602|NCT06092047|DRUG|Cyclophosphamide|1000 mg/m\^2/day×3 days
47927603|NCT00933413|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
48443913|NCT05313217|DIAGNOSTIC_TEST|Knee extension angle|"Knee Extension Angle (KEA):~* This test will be administered with an ankle-foot orthosis (AFO) maintaining the participants ankle in neutral.~* The participant will lie supine on the examination table with the contralateral lower extremity (LE) stabilized on the support surface using a mobilization strap.~* The hip of the lower being examined will be flexed to 90 degrees.~* The participant will then actively straighten their lower leg while maintaining upper leg in same position~* Once the participant feels they are at maximal knee extension (patient instructed to straighten leg as far as what is comfortable), the angle will be measured with iPhone Inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
48443914|NCT05313217|DIAGNOSTIC_TEST|Straight Leg Raise|"Straight Leg Raise (SLR):~* Position the participant in supine on the plinth with knees extended and L LE strapped to the plinth~* The participant will keep the AFO donned on the R distal ankle to keep the ankle in neutral position.~* A researcher will passively lift the participant's right leg moving at a slow but consistent pace of approximately 15 degrees per second, while keeping it straight until a significant resistance is detected or the participant reports a production of symptoms, whichever occurs first.~* Measurement of the SLR angle will be assessed with iPhone inclinometer.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
48443915|NCT05313217|DIAGNOSTIC_TEST|Slump Test|"Slump Test Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant will sequentially flex trunk, look down at the floor~* Participant will extend R knee until symptoms are felt. Measure of angle with iPhone inclinometer placed at superior aspect of medial malleolus~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
48443916|NCT05313217|DIAGNOSTIC_TEST|Extended slump test|"Extended Slump Procedure:~* Participant will be instructed to sit upright with their legs over the edge of table~* AFO remains on R leg~* Participant is asked to arch their lower back into maximal extension in sitting, stabilized to research bench to maintain hyper-lordosis posture.~* The participant is asked first flex cervical spine, then to extend their knee until it reaches full ROM or symptoms are felt that limit ROM.~* Knee extension ROM is assessed with iPhone inclinometer at superior aspect of medial malleolus.~* Participant asked to report any symptoms they are feeling and where (recorded for qualitative analysis)"
48443917|NCT01123694|OTHER|Survey Study|Survey regarding quality of life
48443918|NCT03368287|DEVICE|Fitbit One, the activity tracker|Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
48443919|NCT00314990|DRUG|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
48443920|NCT01759277|DRUG|Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve block and postoperative ropivacaine 0.2% infusion
48443921|NCT01759277|DRUG|Experimental: Adductor Canal perineural local anesthetic infusion|The control group will receive an adductor canal nerve block and postoperative ropivacaine 0.2% infusion
48443922|NCT06456918|PROCEDURE|Quality of Recovery 15 questionnaire|return to daily life after surgery according to the patient's baseline or social norms
48443923|NCT00002053|DRUG|Pentamidine isethionate|
48443924|NCT00848653|DEVICE|CRT device|market approved CRT device
48443925|NCT03142165|DRUG|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
48443926|NCT03142165|OTHER|Placebo|Placebo
48443927|NCT03142165|DRUG|Diphenhydramine|50 mg intravenous administration
48443928|NCT03142165|DRUG|Famotidine|20 mg intravenous administration
48443929|NCT03323008|OTHER|Prototype|Usability testing and System Usability Scale
48443930|NCT00350753|DRUG|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
48443931|NCT05051462|BEHAVIORAL|Family / systemic constellation therapy|Family / systemic constellation therapy is a short-term group counseling intervention aiming to help clients better understand and resolve their conflicts within their personal systems, which in turn might lead to a decrease in psychopathological or functional somatic symptoms. The personal system addressed is most often the family but other inter- or intrapersonal systems (e.g., ego parts, victim-perpetrator dyads) can also be the target of the intervention.
48443932|NCT02004197|DRUG|Quadruple Allopathic therapy|
48443933|NCT02004197|DRUG|Pylorex plus|
48443934|NCT04518631|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
48443935|NCT05057702|OTHER|Specialized Tumor Board Treatment Plan|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
48443936|NCT04374773|DRUG|Dronabinol|2.5 mg PO administered once prior to and once after 1 week of hormone therapy
48443937|NCT05810753|BEHAVIORAL|SPOONful|Participants will be asked to consume two ONS daily, in addition to their regular diet, for three weeks. Participants will be asked to consume one ONS with their breakfast, and one with lunch.
48443938|NCT04727398|DEVICE|Wide-field optical coherence tomography (Optovue®)|Merged 4 images for wide-filed OCT-based PVD classification, 2 vertical line images and 2 horizontal line images
48443939|NCT00298350|DRUG|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
47927604|NCT01585519|DIETARY_SUPPLEMENT|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
47927605|NCT01966432|BEHAVIORAL|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
47927606|NCT01966432|BEHAVIORAL|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
48443940|NCT00828698|OTHER|No intervention|
48272075|NCT02162849|BEHAVIORAL|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
48272076|NCT02162849|BEHAVIORAL|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
48272077|NCT02162849|OTHER|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
48443941|NCT03521765|OTHER|Cancer education|Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation (about 30 minutes) and after each follow-up visit to the clinic (about 15-20 minutes); the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. For the first OT consultation, in the first 15 minutes, the occupational therapist educated the participants based on the CRC education handbook chapter by chapter. The next 15 minutes, the occupational therapist interacted with the participants and provided them customized lifestyle suggestions. For the each following (second and third) consultations, occupational therapists interacted with the participants and provided customized suggestions based on the participants' lifestyle at home.
48443942|NCT05832411|DEVICE|Endoangle|there is additional information presented to endoscopists:（1）the virtual stomach model monitoring；（2）time;（3）scoring.
48443943|NCT01846585|BEHAVIORAL|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
47927607|NCT04440423|DRUG|Clotiazepam 5 mg Test Product Coated Tablets|Investigational Medicinal Product
47927608|NCT04440423|DRUG|Clotiazepam 5 mg Reference Product Coated Tablets|Rize (Trademark)
47927609|NCT05541887|OTHER|Muscadine Wine Polyphenol|dealcoholized muscadine wine with alcohol content \<0.5% with addition of 50ppm of sodium metabisulfite for preservation
47927610|NCT05541887|OTHER|Placebo|this placebo beverage is formulated with matching sugar and organic acid content to the muscadine wine polyphenol. Food coloring is added to match the color of the intervention. 50ppm of sodium metabisulfite for preservation
47927611|NCT03660670|BEHAVIORAL|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
47927612|NCT03660670|BEHAVIORAL|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
47927613|NCT02316509|DRUG|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
47927614|NCT04592484|BIOLOGICAL|CDK-002|CDK-002 administered intratumorally
47927615|NCT02296138|DRUG|olodaterol|fixed dose combination
47927616|NCT02296138|DRUG|tiotropium|fixed dose combination
47927617|NCT02296138|DRUG|tiotropium|
47927618|NCT05541588|PROCEDURE|peripheral nerve block|ultrasound guided nerve block
47927619|NCT02513147|DRUG|Dolutegravir|
47927620|NCT02513147|DRUG|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
47927621|NCT02513147|DRUG|2 NRTI|
47927622|NCT02513147|DRUG|2 NRTI|
47927623|NCT03802214|DRUG|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
47927624|NCT00276042|DRUG|Faropenem Medoxomil|
47927625|NCT00617669|DRUG|Docetaxel|intravenous infusion given every three weeks
47927626|NCT00617669|DRUG|ZD4054|10 mg oral once daily dose
47927627|NCT00617669|DRUG|Placebo|placebo oral tablet once daily
48272078|NCT02162849|OTHER|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
48443944|NCT01846585|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
47927628|NCT06094062|OTHER|App-based treatment support|The intervention includes a smartphone app that patients will download on their smartphones. Medication intake, symptom course and well-being will be tracked over treatment duration. If symptoms worsen, the pharmacist will contact the patients and counsel them based on their adherence and well-being data. Patients who still have symptoms after the 30 days of treatment will receive a final counseling by the pharmacy, and if necessary will be forwarded to the treating physician.
47927629|NCT02842554|OTHER|EPT|
47927630|NCT02842554|DRUG|Drug Placebo Administration|
47927631|NCT02842554|OTHER|C|No Intervention
47927632|NCT04249232|DRUG|Abaloparatide 80 micrograms per Pen dose|prefilled injector pen to deliver 80 micrograms daily subcutaneously
47927633|NCT04249232|DRUG|Placebo prefilled injector pen|prefilled injector pen to deliver inactive solution daily subcutaneously
47927634|NCT06243523|BEHAVIORAL|The stress management psychoeducation program based on Neuman's Systems Model|The stress management psychoeducation program will be implemented in six sessions with individual interviews lasting approximately 45-60 minutes, three times a week for the spouses of patients in intensive care. The first session includes the meeting and introduction of the psychoeducation program. The second session includes the adaptation process to the intensive care unit. The third, fourth and fifth sessions include methods of coping with stress. The sixth session includes evaluation and termination of the psychoeducational program. Quantitative data of the research will be collected with the pre-action and post-action Psychological Distress Scale and the Stress Coping Styles Scale. Qualitative data of the research will be collected through semi-structured individual in-depth interviews conducted after the action.
47927635|NCT00102401|BEHAVIORAL|Internet-based Dyspnea Self-Management Program|
47927636|NCT00102401|BEHAVIORAL|Face-to-face Dyspnea Self-Management Program|
47927637|NCT03547115|DRUG|voruciclib monotherapy|Voruciclib will be administered orally
47927638|NCT03547115|DRUG|voruciclib and venetoclax|Voruciclib and Venetoclax will be administered orally
48096387|NCT03959709|PROCEDURE|immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
48096388|NCT03959709|PROCEDURE|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
48096389|NCT02744079|BEHAVIORAL|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
48096390|NCT02744079|BEHAVIORAL|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
48096391|NCT03446508|DEVICE|Active frontal|1) active HD-tDCS will be administered
48096392|NCT03446508|DEVICE|Active parietal|2) active HD-tDCS will be administered
48096393|NCT03446508|DEVICE|Sham|3) sham HD-tDCS - no current
48096394|NCT03683472|BEHAVIORAL|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
48096395|NCT06268418|OTHER|Artificial intelligence|Segmentation
48096396|NCT03518983|DEVICE|Dornier Aries2 device|The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
48096397|NCT03518983|DEVICE|Dornier Aries2 device (sham probe)|The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
48096398|NCT01794377|BEHAVIORAL|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:~* 30 sec at 120% of Vo2max,~* 1 min at 50% of Vo2max,~* 15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,~* 1 min at 50% of Vo2max.~The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
47927639|NCT05930015|BEHAVIORAL|Music intervention only|Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks
47927640|NCT05930015|BEHAVIORAL|Sports games intervention only|Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks
48096399|NCT01794377|BEHAVIORAL|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
48272079|NCT03839108|OTHER|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
48272080|NCT03839108|DRUG|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
48272081|NCT00777179|DRUG|Vandetanib|Tablet, oral, daily
47927641|NCT05930015|BEHAVIORAL|Music and sports games intervention|Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
48272082|NCT00777179|DRUG|Placebo|Placebo
48272083|NCT03180892|OTHER|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
48443945|NCT00283764|DRUG|Xalatan|
48096400|NCT05592613|DEVICE|Next-generation Reader and ID-Cap System|The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
48096401|NCT05592613|DRUG|Truvada for pre-exposure prophylaxis (PrEP)|Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
48096402|NCT05592613|DRUG|Biktarvy for antiretroviral therapy (ART)|Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
48096403|NCT04356066|DIAGNOSTIC_TEST|serum cxcl10 by ELISA|serum sample
48096404|NCT06022848|PROCEDURE|occipital nerve stimulator|Quantitative sensory testing
48096405|NCT06340347|DRUG|Osivelotor|"a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367"
48096406|NCT05968508|DRUG|BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)|A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
48096407|NCT00689156|DRUG|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
48096408|NCT00689156|DRUG|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
48096409|NCT06016556|DRUG|nirmatrelvir, ritonavir|single cohort
48096410|NCT04108910|DIAGNOSTIC_TEST|Guidance UTI|
48096411|NCT05971381|DEVICE|RECELL® Autologous Cell Harvesting Device|The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
48096412|NCT00736749|PROCEDURE|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
48096413|NCT00736749|OTHER|Questionnaire Administration|"Complete patient response form, Health Status Update Form (called the Keep in Touch form), and Quality of Life Questionnaire (PROMIS)"
48096414|NCT06554964|PROCEDURE|performing chromotubation during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube|Performing chromotubation )injection of blue dye to the fallopian tube via cevical catheter) during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube
48096415|NCT04391309|BIOLOGICAL|anti-CD14|4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV)
48096416|NCT04391309|OTHER|Placebo|Placebo administered intravenously on Days 1-4
48096417|NCT04391309|DRUG|remdesivir|Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5.
48096418|NCT06614244|PROCEDURE|Oral immunotherapy (OIT)|OIT in DOPA group will be implemented as follows. Both the first micro-dose of the offending food and the subsequent micro-increments will be administered at home. Any interruptions and resumptions of OIT, due to intercurrent events (e.g. infections), will be managed via email with or without medical visit via video call. Patients will be provided with ondansetron (sublingual film) and instructions for its use. An explanatory letter will also be provided in case of need for emergency room access.
48096419|NCT06614244|DIETARY_SUPPLEMENT|Culprit food elimination diet|The Diet group consists of a population of children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet of the incriminated food.
48096420|NCT06454292|DRUG|Oliceridine Fumarate|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and a starting dose of 6ug/kg/h of oliceridine fumarate was continuously pumped, and the time of oliceridine fumarate initiation was recorded as T0. Subjects were assessed for sedation using the RASS score, and for analgesia using the CPOT score. Waiting for the original sedative-analgesic drug to elute until CPOT ≥ 3 and RASS \> 0. Adjust the infusion rate of oliceridine fumarate according to the CPOT score (recommended to be adjusted by 2ug/kg/h, the range of adjustment is 2-20 ug /kg/h, and the maximum infusion rate is not more than 20 ug /kg/h) until the analgesic score of the subject is CPOT\<3. The interval between two trial drug rate adjustments should be ≧5 min, and a CPOT score should be performed before each drug adjustment.
48096421|NCT06454292|DRUG|Remifentanil|After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
48096422|NCT06089629|PROCEDURE|Lingual frenuloplasty|Surgical release of ankyloglossia with suture reorientation of the wound to improve lingual mobility, done under local or general anesthesia
48272084|NCT03805126|BEHAVIORAL|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
48272085|NCT03805126|BEHAVIORAL|Usual Care|Usual care includes consultation with a social worker and a community health worker.
48272086|NCT01068444|DRUG|Pioglitazone|"1. Name: GLITOS（Pioglitazone）~2. Dosage form: Tablets~3. Dose(s): 30mg~4. Dosing schedule: QD~5. Duration: 6 months"
48096423|NCT05489224|BIOLOGICAL|CT-P47|CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
48096424|NCT05489224|BIOLOGICAL|EU-approved RoActemra|EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
48272087|NCT01068444|DRUG|placebo|placebo 30 mg/d for 6 months
48443946|NCT02080663|PROCEDURE|Proximal row carpectomy|
48096425|NCT00052962|PROCEDURE|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
48096426|NCT00052962|PROCEDURE|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m\^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m\^2 and paclitaxel 125 mg/m\^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m\^2 on day 1 only, leucovorin 200 mg/M\^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m\^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
48096427|NCT06631768|OTHER|Casual labor subsidy|Eligible participants will be offered a voucher that can be redeemed for a set number of days of agricultural labor from casual laborers hired by local One Acre Fund offices. Casual laborers receive standard training in line with the trainings currently offered by the organization to participating farmers.
48096428|NCT03298932|PROCEDURE|Aortic valve surgery|Aortic valve surgery
48096429|NCT04432974|DEVICE|Automatic closed-loop anesthesia|Total intravenous anesthesia performed with the ACTIVA automatic control system
48096430|NCT06631274|BEHAVIORAL|counseling|The intervention (IVY; Intervention for Victimized Youth) is an 8 week group counseling intervention delivered in a virtual environment.
48096431|NCT00000106|DEVICE|Whole body hyperthermia unit|
48443947|NCT01971060|DEVICE|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
48443948|NCT01307124|DRUG|kaletra|"The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW \>35-50 kg 400/100 mg 300/75 mg"
48443949|NCT06029686|DEVICE|Stanford Glove|The vibrotactile device sends weak non-painful pattern type vibratory stimulus to the fingertips and is non-invasive. Some patient may experience dyskinesia which can me medicated with a decrease in Parkinson's medication
48443950|NCT00210587|DRUG|epoetin alfa|
48443951|NCT04960163|OTHER|No intervention|No intervention
48443952|NCT02412852|DRUG|Sodium nitrite|Sustained release formulation of sodium nitrite
48443953|NCT02412852|DRUG|Placebo|Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
48443954|NCT01820793|DRUG|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
48443955|NCT02627235|BEHAVIORAL|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
48443956|NCT02627235|BEHAVIORAL|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
47927642|NCT04371874|DRUG|Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin|The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
47927643|NCT02787486|OTHER|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
47927644|NCT04517279|BEHAVIORAL|Invest in My Recovery Bank|The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.
47927645|NCT04517279|BEHAVIORAL|Usual Care Peer Services|Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
47927646|NCT05269121|BIOLOGICAL|Phage Therapy|Patient will undergo a DAIR procedure. After the DAIR, phage therapy will be administered in conjunction with antibiotic treatment.
47927647|NCT03271983|DRUG|Metronidazole gel 1|RLD gel
47927648|NCT03271983|DRUG|Metronidazole gel 2|generic gel
47927649|NCT03271983|DRUG|Metronidazole cream|generic cream
47927650|NCT03938753|DEVICE|Audéo M90-T|Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
47927651|NCT03093584|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
48096432|NCT00868231|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
48096433|NCT00868231|DRUG|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
48096434|NCT00868231|DRUG|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
48443957|NCT03501147|OTHER|Resistance training|15 minutes of resistance training during work every day
48096435|NCT04782999|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.
47927652|NCT03093584|BEHAVIORAL|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
48096436|NCT04782999|DIAGNOSTIC_TEST|Hyperglycemic clamp with infusion of saline, GLP-1 or GIP|"Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min)."
48096437|NCT06080711|OTHER|AI assistance|Participants will be informed of the diagnostic probabilities for each of ten differential diagnoses according to the AI tool
48096438|NCT06554483|OTHER|Exercise|supportive reliable exercise programs
48443958|NCT04726163|DEVICE|Continuous blind glucose measurement device (Free style Pro)|A continuous blind glucose measurement device (Free style Pro) will be set up on the first day and throughout the entire hospital stay
48096439|NCT04045470|DEVICE|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
48096440|NCT04045470|OTHER|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
48096441|NCT04045470|OTHER|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
48096442|NCT00072475|DRUG|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
48096443|NCT05653089|PROCEDURE|Choice and adjustment of the wheelchair according to the patient's needs|"After a personalized analysis of the patient and his needs, the occupational therapists define the equipment necessary for the good positioning of the patient:~* Choice and adjustments of the wheelchair~* Choice and adjustments of the wheelchair/patient interface"
48096444|NCT04298840|DIETARY_SUPPLEMENT|Creatine Monohydrate Supplementation|Participants in the creatine monohydrate supplementation arm will consume 5 grams per day of creatine monohydrate.
48096445|NCT04298840|DIETARY_SUPPLEMENT|Placebo Supplementation|Participants in the placebo supplementation arm will consume 5 grams per day of maltodextrin placebo.
48096446|NCT06629610|BEHAVIORAL|DAiLY|The 2-year intervention includes three components, all supported by social media. Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in HBWs. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods to community members. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals. Fitbits will be used as a motivational tool for participants to track their progress.
48096447|NCT00903045|DRUG|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
48096448|NCT00903045|DRUG|Placebo|Identical placebo twice a day
48096449|NCT02518711|BEHAVIORAL|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
48096450|NCT02929108|BEHAVIORAL|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
48096451|NCT02929108|BEHAVIORAL|ACCESS|"Intervention will have two components.~1. Participants will be enrolled in a Secret Facebook group for social support and education~2. Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
48443959|NCT00270777|DRUG|adrenaline, promethazine, hydrocortisone|
48443960|NCT01891461|DRUG|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
48443961|NCT01631383|DRUG|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
48443962|NCT01631383|DRUG|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
47927653|NCT03466593|OTHER|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
48096452|NCT02223793|BEHAVIORAL|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
48096453|NCT02223793|BEHAVIORAL|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
47927654|NCT03466593|OTHER|Routine care|Preoperative information
47927655|NCT03466593|OTHER|Extra early mobilization|Mobilization the day of surgery
47927656|NCT03466593|OTHER|Standard mobilization|Mobilization the day after surgery
48096454|NCT02223793|BEHAVIORAL|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
48096455|NCT05966519|DEVICE|Total Knee Replacement (TKR)|Damaged cartilage of knee due to degenerative disease is replaced with metallic and plastic protheses
48096456|NCT00946192|DRUG|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
48096457|NCT00946192|DRUG|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
48096458|NCT00946192|DIETARY_SUPPLEMENT|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
48096459|NCT02949648|DEVICE|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
48096460|NCT03995810|DIETARY_SUPPLEMENT|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
48096461|NCT04015986|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
48096462|NCT04015986|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
48096463|NCT06189742|BIOLOGICAL|Tezepelumab|Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).
48096464|NCT04295538|DRUG|Elezanumab|Solution for infusion; Intravenous (IV)
48096465|NCT04295538|DRUG|Placebo|Solution for infusion; Intravenous (IV)
48096466|NCT04461106|OTHER|Social Marketing Campaign|aims to raise awareness about the benefits of eggs - 'why eggs': increasing the value of eggs from a consumer perspective and encourage consumption of eggs by children (\<5yrs) and pregnant/lactating women
48096467|NCT06393400|DRUG|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation with 100 g of healthy donor stool in 36-40 oral capsules once~Other Names:~* FMT~* Stool Transplant~* Poop Transplant"
48096468|NCT06393400|DRUG|PEG3350|"Polyethylene Glycol 3350 17 g oral dissolved in 4 litres of water consumed the evening before FMT.~Other Names:~* PEG3350~* RestoraLAX~* MiraLAX"
48096469|NCT06393400|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Gemzar"
48096470|NCT06393400|DRUG|nab-Paclitaxel|"nab-Paclitaxel 125 mg/m2/day IV on Days 1, 8, and 15 of each 28-day cycle.~Other Names:~- Abraxane"
48096471|NCT04001504|BIOLOGICAL|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
48096472|NCT04001504|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
48096473|NCT01744691|DRUG|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
48096474|NCT01500551|DRUG|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet \[mg BID\] or solution \[ml BID\]) 5 - \< 7 kg (2 mg or 2 ml) 7 - \< 10 kg (2.5 mg or 2.5 ml) 10 - \<15 kg (3 mg or 3 ml) 15 - \<25 kg (3.5 mg or 3.5 ml) 25 - \<40 kg (4 mg or 4 ml) \>=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing \<40 kg. Oral tablets (5 mg) will be used for subjects weighing \>=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
48096475|NCT01500551|DRUG|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
48096476|NCT03955419|DIETARY_SUPPLEMENT|NO-NPO (Daesang WelLife Co., Ltd., Korea)|800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
48096477|NCT02090309|DRUG|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
48096478|NCT02090309|DRUG|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
48096479|NCT03607799|BEHAVIORAL|Dietary Intervention|Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.
48096480|NCT03607799|BEHAVIORAL|Control|Control group participants will be provided with PDFs, website links to encourage healthy eating, physical activity, and other lifestyle factors during pregnancy. They will also receive weekly text messages aimed at increasing walking.
48443963|NCT06219044|PROCEDURE|laparoscopic endometrioma laser vaporization|laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy
48443964|NCT05213156|DRUG|Oxatrex|0.3% ofloxacin eye drops in single doses
48443965|NCT02296177|BEHAVIORAL|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
48096481|NCT06300840|DEVICE|BalanceBelt|The vibrotactile belt (i.e., Elitac BalanceBelt®) supports patients with severe balance disorders by substituting the missing balance information with vibrations (haptic feedback).
48096482|NCT06290089|OTHER|Enterotoxigenic E. coli (ETEC) strain|Challenge strain
48443966|NCT04511910|PROCEDURE|Early Laparoscopic Cholecystectomy|
48443967|NCT01762605|OTHER|Supportive Care|
48443968|NCT01762605|PROCEDURE|Cast|
48096483|NCT02077738|DEVICE|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
48096484|NCT04162509|OTHER|AR app|Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
48096485|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks.
48096486|NCT03303105|DRUG|TEV-48125|TEV-48125 will be administered subcutaneously once every 12 weeks.
48443969|NCT01794715|PROCEDURE|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
48443970|NCT03202238|OTHER|Conventional|Conventional venepuncture without use of any venepuncture assistive device.
47927657|NCT03066973|BEHAVIORAL|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
47927658|NCT01197443|BEHAVIORAL|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
47927659|NCT01197443|BEHAVIORAL|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
47927660|NCT05090176|OTHER|povidone-soaked suture|suture soak with povidone solution for 3 mins
47927661|NCT05090176|OTHER|ordinary suture|suture no need to soak with povidone solution
47927662|NCT06055738|DRUG|Zimberelimab|240mg,d1,iv,Q21D
47927663|NCT06055738|DRUG|Albumin-bound Paclitaxel|260mg/m2,d1,iv,Q21D
47927664|NCT06055738|DRUG|Cisplatin|75mg/m2,d1,iv,Q21D
47927665|NCT06046742|BIOLOGICAL|M1-c6v1|Intravenous drip administration
47927666|NCT00965965|BEHAVIORAL|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
47927667|NCT00965965|BEHAVIORAL|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
47927668|NCT00222131|DRUG|Esomeprazole|Esomeprazole 40 mg QD
47927669|NCT00222131|OTHER|Placebo|Placebo
47927670|NCT00344890|PROCEDURE|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
47927671|NCT05633303|OTHER|Substrate guided ablation|Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.
47927672|NCT06421129|PROCEDURE|anal fistula surgery|anal fistula surgery consists of;Fistulotomy and Fistulotomy with seton placement
47927673|NCT04622800|OTHER|Exercise, proprioceptive neuromuscular fasilition (PNF) techniques|PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
47927674|NCT03338959|BIOLOGICAL|Pembrolizumab|Given IV
47927675|NCT03338959|RADIATION|Radiation Therapy|Undergo radiation therapy
47927676|NCT03320525|DIETARY_SUPPLEMENT|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
47927677|NCT00005866|DRUG|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
47927678|NCT00005866|DRUG|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
47927679|NCT00005866|DRUG|cyclosporine|both arms per published schedule
47927680|NCT00005866|DRUG|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
47927681|NCT00005866|PROCEDURE|allogeneic bone marrow transplantation|day 0
47927682|NCT00005866|RADIATION|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
47927683|NCT04821362|DEVICE|Ultrasound group|In the ultrasound group, the nurses will insert the cannulas to the peripheral veins as horizontally and longitudinally with the linear probe.
47927684|NCT04821362|DEVICE|Near Infrared Device Group|In the near infrared device group, the nurses will insert the cannulas to the peripheral veins with AccuVein AV 400.
47927685|NCT05712486|OTHER|High force hip Lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.
47927686|NCT05712486|OTHER|Placebo force hip lateral distraction|Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.
47927687|NCT05800431|DEVICE|Non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
48096487|NCT02157493|BEHAVIORAL|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
47927688|NCT03970408|PROCEDURE|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
47927689|NCT01073046|DEVICE|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
48096488|NCT02157493|BEHAVIORAL|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
48096489|NCT04056104|DIAGNOSTIC_TEST|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
48096490|NCT04841486|OTHER|Data collection|evaluation of women's stress
48096491|NCT03542708|PROCEDURE|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. The patient will be under IV sedation. Record of which ovary was injected will be kept in the online research database and not in the clinical chart.
48096492|NCT00372216|DRUG|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
48272088|NCT04513470|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
48096493|NCT05139056|BIOLOGICAL|Neural Stem Cells-expressing CRAd-S-pk7|Given intracerebrally
47927690|NCT05806827|DIAGNOSTIC_TEST|Virological screening|The preoperative viral screening protocol will start with a self-assessment questionnaire that will be provided to all the enrolled patients, where they will be asked to indicate previously SARS-CoV-2, HPV, EBV, CMV infections. Collection of peripheral blood mononuclear cells (PBMCs) from blood samples and serum specimens for the virological screening (HPV, EBV, CMV, SARS-CoV-2). Preoperative MoCA assessment, follow-up 5 days, 3 months and 6 months after the surgery.
47927691|NCT04505501|DRUG|N-803|N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
48096494|NCT05139056|PROCEDURE|Resection|Undergo surgical resection
48272089|NCT00786045|OTHER|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
48272090|NCT05684380|DRUG|MAZ-101association|Experimental drug
48272091|NCT05684380|DRUG|DYMISTA®|Active comparator
47927692|NCT02956902|OTHER|Clinician supported smartphone application intervention|
47927693|NCT05627778|DRUG|68Ga-PSMA-11|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-11. Tracer doses of 68Ga- PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
48096495|NCT03251651|DRUG|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
48096496|NCT03251651|DRUG|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
48096497|NCT05085184|DRUG|administration of UI018|Test
48096498|NCT05085184|DRUG|co-administration of UIC201806 and UIC201602|Reference
48096499|NCT00903721|DRUG|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
48096500|NCT00119743|BIOLOGICAL|undecavalent pneumococcal-protein D conjugate vaccine|
48096501|NCT01501630|DEVICE|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
48096502|NCT05618301|DRUG|Motixafortide|Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
48096503|NCT05618301|DRUG|Natalizumab|Natalizumab will be administered as an IV infusion at a flat dose of 300 mg
48096504|NCT05618301|PROCEDURE|Leukapheresis|Leukapheresis consisting of a 1 Blood Volume procedure
48096505|NCT05038124|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
48096506|NCT01244100|DRUG|PL2200 fasted|Fasted state
47927694|NCT05627778|DRUG|68Ga-P15-041|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-P15-041. Tracer doses of 68Ga- 15-041 will be used to image lesions of prostate cancer by PET/CT.
48096507|NCT01244100|DRUG|PL2200 fed|Fed state
48096508|NCT00361309|DRUG|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
48096509|NCT02952261|DEVICE|template-guided localization|Based on CT data, digital model of the navigational template was created using CAD software and imported to 3D printer. The navigational template serves as a guider to the localizer in lung nodule localization.
48096510|NCT02952261|OTHER|CT-guided localization|Percutaneous lung nodule localization was conducted under the real-time guidance of CT scan. This is the conventional method of transthoracic lung nodule localization.
48096511|NCT00508690|DRUG|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
48096512|NCT00508690|DRUG|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
48096513|NCT01801319|DEVICE|Libra Deep Brain Stimulation System|
48096514|NCT00512408|DRUG|testosterone|
48272092|NCT04929990|BEHAVIORAL|Respiratory muscle training|Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
48272093|NCT03746561|DIAGNOSTIC_TEST|deep learning|detect and classify spinal stenosis by deep learning
48272094|NCT01484964|DRUG|ASP015K|oral
47927695|NCT02665403|OTHER|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
47927696|NCT02665403|OTHER|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
48096515|NCT03645356|DEVICE|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
48096516|NCT03645356|DEVICE|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
48096517|NCT02537899|DRUG|NeuroAiD|
48096518|NCT01809379|DRUG|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
48096519|NCT02549443|DIETARY_SUPPLEMENT|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
48096520|NCT05202379|DRUG|CC-42344|CC-42344 capsules
48096521|NCT05202379|DRUG|Placebo|Placebo capsules
48096522|NCT01178242|PROCEDURE|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
48096523|NCT06631196|PROCEDURE|Jacobson's PMRT|each child in the intervention group will perform five sessions of Jacobson's PMRT. Each session lasted for 15-20 minutes under the supervision of the researcher.
48096524|NCT00389519|DRUG|ramipril|once a day oral ramipril capsules given for 4 weeks
48096525|NCT00389519|DRUG|placebo|once a day oral placebo capsule for 4 weeks
48096526|NCT00003429|PROCEDURE|biopsy|
48096527|NCT00003429|PROCEDURE|computed tomography|
48096528|NCT00003429|PROCEDURE|positron emission tomography|
48096529|NCT00003429|RADIATION|fludeoxyglucose F 18|
48096530|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
48096531|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
48096532|NCT00175435|BIOLOGICAL|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
48272095|NCT05851469|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
48443971|NCT03202238|DEVICE|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
48443972|NCT03202238|DEVICE|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
48096533|NCT04337489|DEVICE|SensiumVitals wearable sensor|A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.
48096534|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
48096535|NCT00567164|DRUG|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
48096536|NCT00567164|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
48096537|NCT03983161|DRUG|Fedratinib|Fedratinib
48096538|NCT06163521|OTHER|Education|A training consisting of 8 sessions of 40 minutes each will be applied to the children. One session will be done every week. The training will consist of activities including information, discussion and role-playing about children with special needs. The training topics consist of; Children with Special Needs Empathy Differences, Respect for Differences Contact Activity Awareness Benevolence Social Acceptance and Behaviour What can we do?
48096539|NCT02573740|DRUG|ABT-957|
48096540|NCT02573740|OTHER|Placebo|
48272096|NCT01750255|OTHER|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
48443973|NCT02514122|DRUG|Ketamine|Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
48443974|NCT02514122|DRUG|Saline|Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
48620287|NCT02497014|DEVICE|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
47927697|NCT03861494|BEHAVIORAL|Enhanced Stroke Education|In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.
47927698|NCT03861494|BEHAVIORAL|Usual Stroke Education|The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
47927699|NCT04623424|DIAGNOSTIC_TEST|intestinal microbiota|Stoll samples will be tested for different bacteria
47927700|NCT01578512|BEHAVIORAL|Face-to-Face|Face-to-Face behavioral weight loss
47927701|NCT01578512|BEHAVIORAL|Web-based|Web-based behavioral weight loss
47927702|NCT01578512|BEHAVIORAL|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
47927703|NCT02728713|PROCEDURE|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
47927704|NCT02728713|PROCEDURE|Sham/Placebo|A laying on of hands with no actual treatment being performed.
47927705|NCT06090292|DEVICE|Real TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).
47927706|NCT06090292|DEVICE|Real FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
47927707|NCT06090292|DEVICE|Sham TUS|2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.
47927708|NCT06090292|DEVICE|Sham FES|"Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs."
47927709|NCT01650129|DRUG|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
47927710|NCT01650129|DRUG|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
47927711|NCT06312696|OTHER|SMT|"SMT will be provided by a licensed chiropractor with at least 5 years' experience.~Treatment will last 15 to 20 minutes each and include a brief history and examination of the cervical spine. SMT will consist of low velocity, variable amplitude spinal mobilization to the cervical spine - Maitland grades 3 or 4. Spinal segments will be determined by the chiropractor using manual palpation and the patients' response to care. Drop-table or instrument-assisted SMT will not be allowed."
47927712|NCT06312696|OTHER|Light Massage|Light Massage will be provided as a pseudo-sham intervention to control for time, attention, and touch by a licensed chiropractor with at least 5 years' experience to control for touch and is intended to be delivered gentler and shorter than recommended for therapeutic massage.
47927713|NCT05282056|DIAGNOSTIC_TEST|CAD analysis|CAD shows the radiologist automatically delineated areas of potential COVID-19 affection, together with an overall lung affection percentage.
48096541|NCT04619459|OTHER|Kangaroo Mother Care (KMC)|Kangaroo mother care is a method of care of infants. The method involves infants being carried, usually by the mother, with skin-to-skin contact. Kangaroo mother care (KMC). early after delivery have better success at breastfeeding and achieve this success sooner. In this method The newborns' diapers were tied, their caps put on and then they were positioned on their mother's naked chest for KMC. The KMC session was continued for 3 hours.
48096542|NCT01271270|DRUG|Palomid 529|
48096543|NCT03005249|PROCEDURE|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
48096544|NCT03005249|OTHER|the control group|The patients will be assigned to the control group for cerebral palsy.
48096545|NCT01821911|BIOLOGICAL|Zagreb2-1-1|Injection on day 0、7、21
48096546|NCT01821911|BIOLOGICAL|Essen|Injection on day 0、3、7、14、28
48096547|NCT03904719|DRUG|CM082 plus JS001|CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
48096548|NCT04003428|DEVICE|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
48096549|NCT01394809|BEHAVIORAL|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
48096550|NCT05729373|DRUG|SEP-363856|once daily tablet
48096551|NCT05729373|DRUG|Placebo|once daily tablet
48096552|NCT04079712|DRUG|Cabozantinib S-malate|Given PO
48096553|NCT04079712|BIOLOGICAL|Ipilimumab|Given IV
48096554|NCT04079712|BIOLOGICAL|Nivolumab|Given IV
48096555|NCT03952481|DRUG|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
48096556|NCT00751790|DRUG|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
48096557|NCT05556356|DRUG|Acetaminophen|pre-operative acetaminophen (1000mg)
48096558|NCT05556356|OTHER|Placebo: Multivitamin|pre-operative Multivitamin
48096559|NCT04384770|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
48096560|NCT04384770|RADIATION|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
48096561|NCT04384770|OTHER|Questionnaire Administration|Ancillary studies
48272097|NCT01750255|OTHER|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
48272098|NCT02917460|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
48096562|NCT04531514|OTHER|Sensitivity to phonological rules & referents OR: Toddlers|Assess whether the inclusion of a semantic reference decreases OR phonological rule learning
48272099|NCT02674945|DEVICE|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
48443975|NCT01547377|DIETARY_SUPPLEMENT|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
48443976|NCT01547377|OTHER|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
48096563|NCT04531514|OTHER|Sensitivity to phonological rules & referents FR: Toddlers|Assess whether the inclusion of a semantic reference increases FR phonological rule learning
48096564|NCT02256969|DRUG|Blephamide|
48096565|NCT02256969|DRUG|GenTeal PM Night-Time|
48096566|NCT02256969|PROCEDURE|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
48272100|NCT02932267|DRUG|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
48272101|NCT04901572|DIAGNOSTIC_TEST|QISI device|QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
48272102|NCT03619213|DRUG|Dapagliflozin|10 mg tablets given once daily, per oral use.
48096567|NCT02256969|PROCEDURE|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
48096568|NCT05165290|DRUG|Latanoprost ophthalmic solution, 0.005%|Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
48096569|NCT05165290|DRUG|TC-002 latanoprost ophthalmic solution, 0.005%|TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.
48096570|NCT00291707|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
48096571|NCT00291707|DRUG|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if \>6000 cGy to be delivered)
48096572|NCT00291707|PROCEDURE|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
48096573|NCT06133972|DRUG|Placebo|Placebo s.c. monthly
48096574|NCT06133972|DRUG|Ianalumab|Ianalumab s.c. monthly Ianalumab s.c. quarterly
48096575|NCT04927598|DEVICE|plasmapheresis|patients of Gullian Barrie syndrome undergo plasmapharesis
48096576|NCT01605968|DEVICE|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
48096577|NCT01605968|DEVICE|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
48096578|NCT06614972|DEVICE|Balloon-expandable drug-eluting stent|Balloon-expandable drug-eluting stent (BDES) is the device comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
48096579|NCT02388555|PROCEDURE|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
48096580|NCT04893135|OTHER|pratice physical activity|treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%
48096581|NCT01253824|DRUG|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
48096582|NCT01253824|DRUG|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
48096583|NCT06056154|DEVICE|LIO ASQELIO TM monofocal QLIO130C|Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
48096584|NCT05335681|BEHAVIORAL|WARM SHOWER APPLICATION|Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
48096585|NCT04171661|BIOLOGICAL|SASS|SASS applied on chronic skin wounds as skin graft
48096586|NCT06055907|DIAGNOSTIC_TEST|Serum anti-Xa activity|4 hours after third dose of dalteparin, serum anti-Xa activity is measured
48096587|NCT02661646|DEVICE|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
48096588|NCT03484182|BEHAVIORAL|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
48096589|NCT03484182|BEHAVIORAL|Standard Home Exercise Program|Standard paper-based home exercise program
48096590|NCT03767764|DIAGNOSTIC_TEST|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
48096591|NCT02900365|PROCEDURE|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
48096592|NCT02900365|PROCEDURE|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
48096593|NCT06368180|DEVICE|Robotic assisted gait training|is a robotic treadmill training system that uses body weight support to suspend patients by attaching their legs to robotic legs that help them walk
48096594|NCT06368180|DEVICE|Body weight supported treadmill training|The Biodex Unweighting System was used to support the child's body weight, by an adjustable harness placed, over the treadmill.
48272103|NCT03619213|DRUG|Placebo|Placebo matching dapagliflozin 10 mg
48443977|NCT06295211|OTHER|observational|observational
48096595|NCT06550115|BEHAVIORAL|Time-restricted eating|Night shift workers will participate in 4 weeks of fasting during the biological nighttime while remaining awake during overnight work shifts.
48096596|NCT06550115|BEHAVIORAL|Control eating|Night shift workers will participate in 4 weeks of Control eating across the daytime and nighttime hours while remaining awake during overnight work shifts.
48096597|NCT03374072|BEHAVIORAL|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adults with their autistic sibling and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with autistic adults. The program will involve a series individual and joint sessions with siblings and autistic adults using Zoom.
48096598|NCT03374072|BEHAVIORAL|Information Only Condition|Siblings will be provided with online information about services for adults with ASD and future planning.
48096599|NCT02824003|DRUG|ISIS-GCGRRx|once weekly dosing for 13 weeks
48096600|NCT02824003|DRUG|Placebo|once weekly dosing for 13 weeks
48096601|NCT04172844|DRUG|Azacitidine|75mg/m\^2 Days 1-7 given IV
48096602|NCT04172844|DRUG|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
48096603|NCT04172844|DRUG|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
48096604|NCT00535197|BIOLOGICAL|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
48096605|NCT04375644|OTHER|Questionnaires on psychological quality of life|Assessement of evolution of the psychological quality of life of health professionals during the confinement period linked to the COVID-19 pandemic by two questionnaires (one during the confinement period and the second one month after the end of the confinement period)
48096606|NCT02956499|DRUG|APX001 single dose 1|
48096607|NCT02956499|DRUG|APX001 single dose 2|
48096608|NCT02956499|DRUG|APX001 single dose 3|
48096609|NCT02956499|DRUG|APX001 single dose 4|
48096610|NCT02956499|DRUG|APX001 single dose 5|
48096611|NCT02956499|DRUG|APX001 single dose 6|
48096612|NCT02956499|DRUG|APX001 multiple dose 1|
48096613|NCT02956499|DRUG|APX001 multiple dose 2|
48096614|NCT02956499|DRUG|APX001 multiple dose 3|
48096615|NCT02956499|DRUG|APX001 multiple dose 4|
48096616|NCT02956499|DRUG|Matching Placebo|
48096617|NCT02552550|PROCEDURE|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
48096618|NCT00287573|DEVICE|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
48096619|NCT00287573|PROCEDURE|Brachytherapy (beta source)|Brachytherapy (beta source)
48096620|NCT03861728|DEVICE|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
48096621|NCT03861728|OTHER|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
48096622|NCT04921761|PROCEDURE|Conventional epidural|In this group, a 20-gauge multi-orifice catheter was threaded through the cephalic-directed tip of the epidural needle 5 cm into the epidural space.
48096623|NCT04921761|PROCEDURE|Dural puncture epidural|In this group, the dura was punctured by 25G Whitacre needle. After confirmation of CSF flow, the needle was removed and the epidural catheter was threaded.
48096624|NCT02211768|PROCEDURE|MRI, FDG-PET/CT scans|Standard of care to be obtained as part of the study
48096625|NCT02211768|DRUG|[18F]-FLT-PET/CT scans|FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
48096626|NCT02892799|OTHER|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
48096627|NCT02892799|OTHER|Standard of Care|
48272104|NCT00542191|DRUG|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
48096628|NCT00699738|BEHAVIORAL|Breastfeeding|Breastfeeding
48096629|NCT00699738|BEHAVIORAL|Bottlefeeding|Bottlefeeding
48096630|NCT06488170|DRUG|Tildrakizumab|As provided in real world clinical practice.
48272105|NCT00542191|PROCEDURE|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
48272106|NCT00542191|RADIATION|Radiotherapy|Standard of care RADIATION THERAPY as indicated
48096631|NCT02999282|DEVICE|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
48096632|NCT02999282|DEVICE|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
48096633|NCT05974943|OTHER|Problem Solving And Decision Making Education|"The Problem-Solving and Decision-Making Training Program, which was based on developing problem-solving and decision-making skills of nurse managers in the experimental group (n=30), was prepared. 2 faculty members and the researcher organized the training program consisting of four modules and 16 hours.~In the content of the Training Program; the definition of the concept of problem-solving and decision-making, the process of problem-solving and decision-making and decision-making models, the impact of decision-making on employee, patient and organizational outcomes, and the importance of managers' roles in decision-making, the importance of the role of nurse managers in decision making, the impact of managerial decisions on patient care outcomes, the impact of managerial decisions on nurse outcomes, the impact of administrative decisions on organizational results/performance, problem-solving, and decision-making techniques and case studies."
48096634|NCT05014724|DRUG|Rozanolixizumab|Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.
48096635|NCT06494748|OTHER|Follow up Decision|"0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit"
48096636|NCT00363285|BIOLOGICAL|gonadotrophin releasing hormone|
48096637|NCT00363285|DRUG|cyproterone acetate|
48096638|NCT00363285|PROCEDURE|quality-of-life assessment|
48096639|NCT00317655|DRUG|Glucosamine sulphate|
48096640|NCT00317655|DRUG|Ginger|
48096641|NCT00317655|DRUG|Ginger-Avocado-Soya|
48096642|NCT00317655|DRUG|Ginger-ibuprofen|
48096643|NCT01621581|GENETIC|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
48096644|NCT05982600|DIAGNOSTIC_TEST|Single Assessor Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.
48096645|NCT05982600|DIAGNOSTIC_TEST|2 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.
48096646|NCT05982600|DIAGNOSTIC_TEST|3 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
48443978|NCT02991378|BEHAVIORAL|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
48443979|NCT05467111|OTHER|Acute Exercise|Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
48443980|NCT05316428|DRUG|TPN171H tablet plus alcohol|10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
48443981|NCT05316428|OTHER|alcohol|0.5 g/kg alcohol
48096647|NCT05982600|DIAGNOSTIC_TEST|5 people Teledermatological triage (TDT)|The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
48096648|NCT02805387|DIETARY_SUPPLEMENT|Treatment|Bicarbonate was ingested
48096649|NCT06628856|OTHER|Quality of life|The study proposes a 3-time longitudinal design, with evaluations at baseline, 2.5 months, and 5 months, to measure the impact of an intervention on terminally ill patients and their families, focusing on health status, quality of life, and emotional well-being.
48096650|NCT02728245|DRUG|Dienogest|Dienogest 2mg po qd
48096651|NCT02728245|DRUG|Placebo drug|Placebo 1 table po qd
48096652|NCT02728245|PROCEDURE|Surgery|conservative surgery without intent to oophorectomy
48096653|NCT00557843|DRUG|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
48096654|NCT00557843|DRUG|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
48096655|NCT06631820|DIETARY_SUPPLEMENT|Epicatechin extract|In the experimental phase, patients will take 50 mg of (-)- Epicatechin twice a day for 8 weeks (total dose 100mg/day). The nutraceutical will be supplied as monodose sachets from Aayam Therapeutics.Study participants will mix the sachet powder with juice (10-20mL) in the morning 15 minutes before breakfast and in the evening 15 minutes before sleeping or 1h after dinner.
48096656|NCT06292182|DEVICE|Near-infrared light|daily application of near-infrared light
48096657|NCT01554592|DRUG|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
48096658|NCT01554592|DRUG|Statin therapy|Participants will continue on stable statin therapy.
48096659|NCT04379986|DEVICE|Senbiosys|The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
48096660|NCT04569578|OTHER|Policy|"The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~1. A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~2. At least 10 minutes teacher-led active play per day~3. A minimum of 1 weekly outdoor excursion~4. Meet the children outdoors when they arrive at preschool and/or picked up by their parents~5. Only use screen tablets and computers for educational teaching purposes~6. Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires"
48096661|NCT05998590|DIETARY_SUPPLEMENT|High protein supplement|The participants received a 60g protein bolus each evening prior to sleep from week 3 to week 12 of training.
48096662|NCT05998590|DIETARY_SUPPLEMENT|Moderate protein supplement|The participants received a 20g protein bolus each evening prior to sleep from week 3 to week 12 of training.
48096663|NCT05998590|DIETARY_SUPPLEMENT|Carbohydrate placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep from week 3 to week 12 of training.
48096664|NCT05998590|OTHER|Control: No supplementation|The participants did not receive any supplementation but instead acted as a control group doing BT only
48096665|NCT05718297|DRUG|Brigatinib|"Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them."
48096666|NCT05718297|DRUG|Durvalumab|Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
48096667|NCT00004886|DRUG|docetaxel|
48096668|NCT00004886|DRUG|dofequidar fumarate|
48443982|NCT05316428|DRUG|TPN171H tablet|10 mg TPN171H tablet QD
47927714|NCT01484288|DEVICE|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
47927715|NCT02058524|BIOLOGICAL|fecal microbiota transplantation|
48096669|NCT05244447|OTHER|Primary Services|Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 6 weeks. Participants also receive life coaching and ongoing job readiness support.
48096670|NCT04936217|OTHER|Data collection|For each patient, the following data will be collected and analyzed: age at operation, sex, Body Mass Index (BMI), ASA score, ASIA score, type of bladder dysfunction assessed by urodynamic evaluation, urinary abnormalities assessed by morphological examination (ultrasound and / or computed tomography) and cystoscopy, creatinine clearance, operative indications, initial mictional mode, surgical assembly, immediate and later complications.
48096671|NCT04936217|OTHER|Interview using a validated questionnaire|A telephone survey will be conducted by means of a questionnaire in order to evaluate the patient's quality of life.
48096672|NCT00353067|DRUG|veliflapon (DG-031)|
48096673|NCT00354094|DRUG|[S,S]-Reboxetine|
48096674|NCT03120676|DRUG|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
48096675|NCT02544282|DRUG|Levobupivacaine|Pecs II Block
48096676|NCT02544282|DRUG|NaCl 0.9%|Placebo Pecs II block
48096677|NCT02544282|DRUG|Sevoflurane|General Anesthesia
48096678|NCT02544282|DRUG|Propofol|General Anesthesia
48096679|NCT02544282|DRUG|Sufentanil|General Anesthesia
48096680|NCT02544282|DRUG|Atracurium|General Anesthesia
48096681|NCT02544282|DRUG|Paracetamol|Pain Relief
48096682|NCT02544282|DRUG|Tramadol|Pain Relief
48096683|NCT02544282|DRUG|Piritramide|Pain Relief
48443983|NCT00193245|DRUG|Topotecan|
48443984|NCT00193245|DRUG|Docetaxel|
48096684|NCT05964257|DRUG|Botulinum toxin type A|Botulinum toxin type A(HU-014) will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
48096685|NCT05964257|DRUG|normal Saline|Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
48096686|NCT05846711|DIAGNOSTIC_TEST|BPPV diagnostic|Supine Roll Test and Dix-Hallpike Test
48096687|NCT05846711|DEVICE|TRV chair|Mechanical rotational chair
48096688|NCT05846711|DEVICE|VNG goggles|Goggles for video nystagmography
48096689|NCT05846711|DEVICE|IMU sensor|A sensor that measures triaxial acceleration and triaxial angular velocity.
48096690|NCT05846711|PROCEDURE|Manual BPPV diagnostics|Bedside BPPV diagnostics
48096691|NCT06632145|OTHER|Cog Fun Ageing intervention|Cog Fun Ageing is a group-based occupation-centered intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 14 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
48096692|NCT05349877|BEHAVIORAL|Expressive writing|Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.
48096693|NCT05349877|BEHAVIORAL|Self-affirmation|Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.
48096694|NCT05349877|BEHAVIORAL|Placebo|Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.
48096695|NCT05295082|PROCEDURE|guided trephination-based drilling protocol|the implant site preparation in this group will be done by guided trephination protocol which uses the surgical guide to trephine the implant site then remove the guide and continue the drilling in a freehand manner
48096696|NCT05295082|PROCEDURE|guided Conventional drilling-based protocol|the implant site preparation in this group will be done by a guided conventional drilling protocol which uses the surgical guide to guide the sequential drills up to the final drill
48096697|NCT01737008|DRUG|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
48096698|NCT01737008|RADIATION|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
48096699|NCT01737008|DRUG|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
48096700|NCT05766098|GENETIC|Genotyping|Characterization of genetic profile of tumor tissues
48096701|NCT01645111|DRUG|Clevidipine|
48096702|NCT04653714|PROCEDURE|Scaling and root planing|Patients with periodontitis in the test group will be treated by conventional non-surgical root debridement and in the control group by low-intensive supragingival plaque removal with mechanical brush and professional tooth paste only.
48272107|NCT05450614|OTHER|Thrive app|The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.
48096703|NCT04653714|DEVICE|Probiotic lozenges|Patients with gingivitis in the test group will be treated with supragingival debridement and with probiotic lozenges with strains of Lactobacillus brevis and Lactobacillus plantarum once a day for 3 months and in the control group by low-intensive supragingival plaque removal, as a placebo treatment, and placebo probiotics lozenges.
48096704|NCT00441675|PROCEDURE|Symptom Score|Symptom Score
48096705|NCT00441675|PROCEDURE|Symptom Score and PD20|Symptom Score and PD20
48096706|NCT03683862|OTHER|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
48096707|NCT01501214|DRUG|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
48096708|NCT01501214|DRUG|Normal saline|Normal saline given
48096709|NCT06339905|PROCEDURE|Sonic Activation with EndoActivator|sonic activation
48096710|NCT06339905|PROCEDURE|Control Needle Irrigation|control group
48096711|NCT02800161|DRUG|Trehalose|Trehalose 70g/die
48096712|NCT02800161|DRUG|Maltose|Maltose 70g/die
48096713|NCT01134575|DRUG|CMC-544 (Inotuzumab Ozogamycin)|"First patients \> 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
48096714|NCT01134575|DRUG|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m\^2 IV (by vein) over 2-6 hours every 3-4 weeks.
48096715|NCT05792540|DRUG|Fluoxetine 20 mg|Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
48096716|NCT05792540|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
48096717|NCT05792540|DRUG|Atorvastatin 80mg|Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
48096718|NCT06370325|PROCEDURE|VPOD Wireless Tens Unit|The VPOD unit will deliver NMES to participants in the Intervention Group.
48096719|NCT06370325|PROCEDURE|Physical Therapy|Physical therapy as per standard of care.
48096720|NCT06370325|DEVICE|Biodex|Used to assess strength, endurance, power, and range of motion.
48096721|NCT04215341|BEHAVIORAL|Physiotherapy|A course of breathing retraining delivered by a physiotherapist and practiced by the participant at home.
48096722|NCT06122935|DEVICE|Aurora Xi New Nomogram Software 2.0|Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.
48096723|NCT06122935|DEVICE|Aurora Xi Currently Approved Software 1.3|Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System
48096724|NCT03843892|DRUG|OFEV|twice daily
48096725|NCT02611427|BEHAVIORAL|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
48096726|NCT02611427|BEHAVIORAL|Education|The education group will receive information about safe physical activity.
48096727|NCT01710150|PROCEDURE|CTI ablation alone|
48096728|NCT01710150|PROCEDURE|CTI ablation and Pulmonary vein isolation (PVI)|
48096729|NCT05707052|OTHER|Neck-Trunk Stabilization Exercises and conventional physical therapy|Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
48096730|NCT05707052|OTHER|Bobath Therapy and conventional physical therapy|Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
48096731|NCT02131740|OTHER|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest \& eye rubbing for a further 1 minute.
48096732|NCT02131740|OTHER|No eye rubbing|This eye will not be rubbed
48096733|NCT02064751|DEVICE|CRT with MultiPoint Pacing|
48096734|NCT02064751|PROCEDURE|Hemodynamic measurements for CRT device programming|
48096735|NCT04139694|DIETARY_SUPPLEMENT|Food plan with cinnamon supplementation|cinnamon twice daily plus follow Cardiometabolic diet
48096736|NCT04139694|BEHAVIORAL|Food plan without cinnamon supplementation|Cardiometabolic diet only
47927716|NCT03693560|DRUG|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
48096737|NCT01014338|DRUG|Fosinopril|10mg od
48096738|NCT01014338|OTHER|lactose|placebo
48096739|NCT00106808|DRUG|Muraglitazar|
48096740|NCT00106808|DRUG|Pioglitazone|
48096741|NCT05189457|DRUG|Luteinizing Hormone Releasing Hormone|During the first strike, LHRH will be administered for 12 to 18 weeks. During the second strike, participants will receive 4 cycles of LHRH
47927717|NCT03693560|DRUG|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
47927718|NCT03693560|DRUG|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
48096742|NCT05189457|DRUG|New Hormonal Agent|During the first strike, if Abiraterone is chosen 1000mg of Abiraterone will be taken orally. If Enzalutamide is used, 160 mg will be taken orally every 24 hours.
48096743|NCT05189457|DRUG|Docetaxel|"During the second strike, participants will receive 4 cycles of Docetaxel at 75mg/m2 given intravenously at day 1 of ever 21 days. For participants with positive prostate biopsy or detectable PSA, the second strike will receive 2 additional cycles of docetaxel."
48096744|NCT05189457|DRUG|Tislelizumab|During the second strike, participants will receive 6 doses of Tislelizumab at 200 mg, given intravenously once every 3 weeks.
48096745|NCT06295796|DRUG|MK-8527|Oral Capsule
48096746|NCT05247216|DRUG|Hemay007 800 mg QD group|daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
48096747|NCT05247216|DRUG|Hemay007 1200 mg QD group|daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
48096748|NCT05247216|DRUG|Hemay007 600 mg QD group|daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
48096749|NCT05247216|DRUG|Hemay007 placebo group|daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
48096750|NCT02778308|DRUG|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
48096751|NCT05702203|OTHER|Creative Music Therapy|Creative Music Therapy 3x20 minutes per week during admission, at least 10 session during admission, after discharge once every other week until 6 months of age.
48096752|NCT03092440|OTHER|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
48096753|NCT06447142|OTHER|Open kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, open kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
48096754|NCT06447142|OTHER|Closed kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, closed kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
48096755|NCT03398135|DRUG|risankizumab|subcutaneous (SC) injection
48096756|NCT03398135|DRUG|placebo for risankizumab|subcutaneous (SC) injection
48096757|NCT00285558|BEHAVIORAL|CBT with peer-enhanced activities|
48096758|NCT00285558|BEHAVIORAL|CBT with supervised aerobic exercise|
48096759|NCT05560828|OTHER|Zio XT service|There will be no intervention. Standard of care at participating NHS organizations will not be affected.
48096760|NCT02664220|DRUG|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
48096761|NCT02664220|PROCEDURE|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
48096762|NCT01843465|OTHER|Maneuvers for documenting the disconnection|
48096763|NCT00024466|BIOLOGICAL|GVAX|
48096764|NCT00024466|PROCEDURE|Autologous transplant|
48096765|NCT06628739|DRUG|Imatinib|The long-term maintenance dose of every patient was determined by the physician based on the guidelines and the patients' individual conditions such as adverse reactions.
48096766|NCT04045366|OTHER|Sample collection|Plasma and BAL sample collection
48096767|NCT02074566|OTHER|Cryoballoon ablation|PVI using cryoballoon
48096768|NCT01585181|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
48096769|NCT01585181|BIOLOGICAL|Placebo|Approx 2 grams of lactose reconstituted in water
48096770|NCT01693094|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
47927719|NCT03616223|DRUG|FX-322|Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate
48096771|NCT05123638|DEVICE|Virtual reality cycling exercise|Daily voluntary cycling for up to 30 minutes with the virtual reality technology
48096772|NCT05123638|BEHAVIORAL|Unsupervised stationary cycling exercise|Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
47927720|NCT03616223|DRUG|Placebo|Intratympanic injection
47927721|NCT02226744|BEHAVIORAL|Focused Breathing|
48096773|NCT06453356|DRUG|Zavegepant 10mg|intransal spray 10mg
47927722|NCT04223492|DIAGNOSTIC_TEST|Liquid biopsy|A blood sample containing circulating tumor DNA and circulating tumor cells.
47927723|NCT04223492|DIAGNOSTIC_TEST|Multi-parametric MRI|Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
47927724|NCT01962038|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
47927725|NCT01962038|BEHAVIORAL|Stretching Exercises|Gym and home based stretching exercises
47927726|NCT01962038|BEHAVIORAL|Cognitive Training|Group-based cognitive training
47927727|NCT02032043|DRUG|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
47927728|NCT04966910|BEHAVIORAL|Stay Connected|Stay Connected is a menu-driven set of strategies to combat loneliness, anxiety and depression in older adults based on behavioral activation principles.
48096774|NCT05541757|DRUG|In vitro heparin|In vitro heparin and in vitro LMWH
48096775|NCT06218186|DEVICE|Medical Device: Wesper Lab Home Sleep Test|Wesper Lab is a medical device that is used for the diagnosis of sleep apnea. Wesper lab is composed of two flexible biosensors that adhere to the abdomen and thorax with medical grade adhesive. A FDA approved pulse oximeter is worn on a finger.
48096776|NCT00483262|DRUG|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
48096777|NCT00483262|DRUG|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
48096778|NCT02253186|DEVICE|Auto-Adjustable MOBIDERM Armsleeve|
48096779|NCT02256787|DRUG|BILB 1941 ZW - single rising dose part|
48096780|NCT02256787|DRUG|Placebo|
48096781|NCT02256787|DRUG|BILB 1941 ZW - solution|
48096782|NCT02256787|DRUG|BILB 1941 ZW - tablet|
48096783|NCT02256787|OTHER|standardized breakfast|
48096784|NCT02283255|OTHER|Aerobic Exercise Training|Supervised aerobic and light muscle resistance exercise training
48096785|NCT02283255|OTHER|Inspiratory Muscle Training|Inspiratory muscle training with POWERbreathe device
48096786|NCT02283255|OTHER|No Exercise Training|Usual care
47927729|NCT04966910|BEHAVIORAL|Treatment as usual|Regular check-ins, resource/referral provision
47927730|NCT03015480|BEHAVIORAL|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
47927731|NCT04951323|DRUG|anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)|Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
47927732|NCT02387476|DEVICE|FRESCA mask first night|FRESCA nasal mask first night
47927733|NCT02387476|DEVICE|CPAP Mask first night|CPAP Nasal Mask first night
47927734|NCT01431209|OTHER|Laboratory Biomarker Analysis|Correlative studies
47927735|NCT01431209|DRUG|Ruxolitinib Phosphate|Given PO
47927736|NCT04544215|BIOLOGICAL|Dosage 1 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (8.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
47927737|NCT04544215|BIOLOGICAL|Dosage 2 of MPCs-derived exosomes|7 times aerosol inhalation of MPCs-derived exosomes (16.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
47927738|NCT04544215|BIOLOGICAL|No MPCs-derived exosomes|No aerosol inhalation of MPCs-derived exosomes
47927739|NCT06029257|DRUG|Tildrakizumab|As provided in real-world clinical practice.
47927740|NCT01116856|OTHER|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
47927741|NCT04657107|DRUG|S-ketamine|K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;
47927742|NCT04657107|OTHER|normal saline|Saline group: pregnant women received saline, intravenous drip
47927743|NCT04657107|DRUG|S-ketamine|K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
47927744|NCT04718545|PROCEDURE|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
47927745|NCT05343468|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
47927746|NCT01993836|DRUG|Total intravenous anesthesia with propofol|
47927747|NCT01993836|DRUG|General anesthesia with isoflurane|
47927748|NCT03278119|DIAGNOSTIC_TEST|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
47927749|NCT05459090|OTHER|ex-vivo study|ex-vivo experiments in tissue slices obtained from biopsies
47927750|NCT01088607|DRUG|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
47927751|NCT01982968|PROCEDURE|Surgery|Full fundoplication surgery for the treatment of abnormal GER
47927752|NCT05194566|DEVICE|tACS|Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
47927753|NCT06286709|BIOLOGICAL|Faecal Microbiota Transplant|FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
47927754|NCT06286709|OTHER|FMT Placebo|FMT Placebo is 50mL aliquots containing 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v. FMT Placebo for administration via colonoscopy will be made up of 250mL (5 aliquots). FMT Placebo for administration via enema will be made up of 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
48096787|NCT05708261|BEHAVIORAL|MR Intervention|Grounded in Social Cognitive Theory, the intervention delivers five 2-hour sessions with 3 post-session group check-in's to develop skills in partnership communication, HIV disclosure and prevention. The intervention utilizes self-assessments on skills learned and then action plan for these developed and then finalized in the last session.
47927755|NCT01030666|DRUG|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
48272108|NCT05450614|BEHAVIORAL|TCCG|In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
48272109|NCT06229392|BIOLOGICAL|Fluzone Quadrivalent|Successive cohorts of participants (3 participants per tumor type per cohort) will each be started on a fixed dose of the influenza vaccine. For the first cohort, patients will receive Fluzone Quadrivalent - (Sanofi Pasteur) - 60mcg/0.5mL (standard dose IT flu shot, or dose level 0) intratumorally on day -6 +/- 1 day and day 0 or 1. For the second cohort, patients will receive Fluzone High-Dose Quadrivalent - (Sanofi Pasteur) - 240mcg/0.7mL (high dose IT flu shot, or dose level 1) intratumorally on day -6 +/- 1 day and day 0 or 1. has context menu
47927756|NCT01030666|DRUG|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
47927757|NCT01030666|PROCEDURE|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
47927758|NCT01030666|BIOLOGICAL|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
47927759|NCT01030666|DRUG|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
47927760|NCT01030666|DRUG|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
47927761|NCT01030666|DRUG|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
47927762|NCT02061319|BEHAVIORAL|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
47927763|NCT00819793|DEVICE|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
47927764|NCT05179174|GENETIC|blood sample examination|droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
47927765|NCT01046409|OTHER|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
47927766|NCT00463021|DRUG|Hectorol (doxercalciferol capsules)|
47927767|NCT00463021|DRUG|Zemplar (paricalcitol injection)|
47927768|NCT00748020|PROCEDURE|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
47927769|NCT00748020|PROCEDURE|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
47927770|NCT01503671|DRUG|Atorvastatin|Atorvastatin 40 mg/day
47927771|NCT01890720|DEVICE|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
47927772|NCT01890720|OTHER|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
48096788|NCT05708261|OTHER|Be Well Attention Match|Attention match control arm providing one-way SMS of general health content delivered once per week during the first 5 weeks after enrollment.
48096789|NCT01120275|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
48096790|NCT01120275|OTHER|laboratory biomarker analysis|Correlative studies
48272110|NCT02750202|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
48272111|NCT02750202|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
48272112|NCT06151392|DRUG|Probiotic Formula|probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
48272113|NCT06151392|DRUG|Zinc|Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
48096791|NCT05120440|OTHER|Breakfast omission|Breakfast omission will consist of not eating breakfast on the morning of afternoon resistance training performance assessment.
48096792|NCT05120440|OTHER|Breakfast consumption|Breakfast consumption will consist of eating a standardized breakfast on the morning of afternoon resistance training performance assessment.
48096793|NCT00274989|DRUG|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
48096794|NCT00274989|BIOLOGICAL|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
48096795|NCT04355637|DRUG|Inhaled budesonide|adding budesonide to standard of care for pneumonia in COVID19 positive patients
48096796|NCT05798208|DIAGNOSTIC_TEST|blood pressure measurement|Taking blood pressure with automated arm sphygmomanometer and pressure higher than 140/90 was considered abnormal
48096797|NCT05588791|DIAGNOSTIC_TEST|whole-body computed tomography|whole-body computed tomography prescription in the emergency department : an identification tool for low risk patients
48096798|NCT02862327|DRUG|intravenous dexamethasone|intravenous injection of dexamethasone
48096799|NCT02862327|DRUG|intravenous placebo|intravenous injection of placebo
48096800|NCT02862327|DRUG|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
48096801|NCT02862327|OTHER|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
48096802|NCT04415112|BEHAVIORAL|Mediterranean Diet|A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.
48443985|NCT04058080|OTHER|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
48443986|NCT04058080|OTHER|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
47927773|NCT01642732|OTHER|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
47927774|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF glucosamine salt|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt
47927775|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 1|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1
47927776|NCT05699473|DIETARY_SUPPLEMENT|5-MTHF calcium salt 2|Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
47927777|NCT06458218|COMBINATION_PRODUCT|Multi-component Interventions|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, EmoEase, for individuals with mental health issues among high-risk COPD population(very familiar with intelligent mobile phone);~3. NicQuit, digital health intervention to smokers;~4. Health education to smokers and individuals with mental health issues;~5. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~6. To actively include individuals whose blood pressure and glucose are higher than the normal value into the National Essential Public Health Service in China;~7. A CBT-based health education to the BMI abnormal;~8. Pay-for-performance incentives to medical workers."
47927778|NCT05617495|OTHER|Mindfulness + fMRI Neurofeedback|Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
47927779|NCT06471387|BEHAVIORAL|Flexiquit Smoking Cessation Intervention|Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.
47927780|NCT05967039|OTHER|Physiotherapy|Physiotherapy in respiratory rehabilitation
47927781|NCT03287271|DRUG|VS-6063|"Phase 1:~* First 3 patient cohort: VS-6063 200 mg PO twice daily~* IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
48096803|NCT04415112|BEHAVIORAL|Low Fat Diet|These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
48096804|NCT02799056|DEVICE|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines at the eighth intercostal space in the mid-axillary line. The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
48096805|NCT06127563|OTHER|creation of a clinical pathway to increase vaccination coverage in frail patients|creation of a clinical pathway to increase vaccination coverage for frail patients, integrating hospital and local health units through an automated algorithm
48272114|NCT02948361|OTHER|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
48272115|NCT01526525|DRUG|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
48272116|NCT01526525|DRUG|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
48272117|NCT01526525|DRUG|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
48272118|NCT01526525|DRUG|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
48272119|NCT01526525|PROCEDURE|sedation|If the patient had sedation score \>2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
48443987|NCT00871247|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
48443988|NCT00871247|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
47927782|NCT03287271|DRUG|Paclitaxel|"Phase 1:~* First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
47927783|NCT03287271|DRUG|Carboplatin|"Phase 1:~* First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~* IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
47927784|NCT00936689|PROCEDURE|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
47927785|NCT00936689|PROCEDURE|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
47927786|NCT05062954|DIETARY_SUPPLEMENT|Polyphenol-rich cranberry extract supplement standardized in proanthocyanidins|Participants will be randomly assigned to the consumption of one capsule of Polyphenol-rich cranberry extract standardized in PACs.
47927787|NCT05062954|DIETARY_SUPPLEMENT|Placebo supplement|Participants will be randomly assigned to the consumption of one capsule of placebo per day for 56 consecutive days.
47927788|NCT01823588|BEHAVIORAL|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
47927789|NCT02905396|DEVICE|Spinal cord stimulation|implantation of spinal cord stimulator
47927790|NCT05763745|DIAGNOSTIC_TEST|Point of Care Ultrasound|Use Point of Care Ultrasound to evaluate the gastric content/bleed prior to upper endoscopy
47927791|NCT01147627|DRUG|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
47927792|NCT01147627|DRUG|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
47927793|NCT01147627|DRUG|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
47927794|NCT02980952|OTHER|High-fat overfeeding|
47927795|NCT02980952|OTHER|Forearm immobilization|
47927796|NCT02535780|PROCEDURE|Transcranial magnetic stimulation|TMS
47927797|NCT02535780|PROCEDURE|Transcranial direct current stimulation|tDCS
48096806|NCT01580943|DRUG|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
48096807|NCT01580943|DRUG|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
48096808|NCT04127539|BEHAVIORAL|Strong & Steady exercise program|The community-based group exercise program S\&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S\&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S\&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
48096809|NCT02704481|DRUG|Mifepristone|200mg oral mifepristone
48096810|NCT02704481|DRUG|Misoprostol|800mcg buccal misoprostol
48096811|NCT02704481|DRUG|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
48096812|NCT02704481|DRUG|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
48096813|NCT04589611|DRUG|amobarbital/Gel-One (one dose)|One dose of amobarbital/Gel-One during the initial surgical intervention
48096814|NCT04589611|DRUG|Placebo (single dose)|One dose of placebo during the initial surgical intervention
48096815|NCT04589611|DRUG|amobarbital/Gel-One (two doses)|One dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
48096816|NCT04589611|DRUG|Placebo (two doses)|One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
48096817|NCT04393896|BEHAVIORAL|WeChat-based integrative family intervention (WIFI)|The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
48096818|NCT01895140|DEVICE|Renal denervation device|
48096819|NCT06055621|DRUG|Dasatinib|Daily orally administration of DASATINIB
48096820|NCT02622230|DRUG|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
48096821|NCT02622230|DRUG|Placebo|Placebo to match with experimental groups
48096822|NCT05166161|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
48443989|NCT02504138|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
48443990|NCT02504138|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
48443991|NCT00060697|BEHAVIORAL|Adolescent sexual activity education for mothers|
48096823|NCT00928200|DRUG|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
48096824|NCT00928200|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
48096825|NCT00928200|DRUG|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
48096826|NCT00928200|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
48096827|NCT00928200|DRUG|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
48096828|NCT00928200|DRUG|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
48096829|NCT00928200|DRUG|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
48096830|NCT00928200|DRUG|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
48096831|NCT00723294|PROCEDURE|cryosurgery|
48096832|NCT00723294|PROCEDURE|therapeutic conventional surgery|
48272120|NCT01526525|PROCEDURE|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
48096833|NCT02162238|DEVICE|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
48096834|NCT03920163|OTHER|Enhanced Recovery Measures|Perioperative measures
48096835|NCT05764824|DIETARY_SUPPLEMENT|Blueberry powder|20 g per day of blueberry powder
48096836|NCT05764824|OTHER|Controlled and matched powder|20 g per day
48096837|NCT02851030|BEHAVIORAL|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
48096838|NCT05404230|DIETARY_SUPPLEMENT|Fish oil|Fish oil containing poly unsaturated fatty acids.
48096839|NCT05404230|DIETARY_SUPPLEMENT|Corn oil|Corn oil
48096840|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
48096841|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
47927798|NCT03661879|DRUG|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
47927799|NCT03661879|DRUG|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
47927800|NCT01144299|BIOLOGICAL|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
47927801|NCT00170001|DRUG|Nexium|40 mg bid dosing
47927802|NCT00170001|DRUG|Sugar Pill|40 mg BID
47927803|NCT01690897|BEHAVIORAL|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
47927804|NCT01690897|BEHAVIORAL|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
47927805|NCT01357850|DRUG|GSK716155|GSK716155
47927806|NCT01357850|DRUG|Placebo|Placebo
48096842|NCT02240875|BIOLOGICAL|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
48096843|NCT02240875|BIOLOGICAL|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
48096844|NCT02240875|BIOLOGICAL|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
48096845|NCT02240875|BIOLOGICAL|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
48096846|NCT04722276|OTHER|positive end expiratory pressure|7cmH2O of positive end expiratory pressure with fraction of inspired oxygen 80% applied during induction of anesthesia
48096847|NCT04722276|OTHER|fraction of inspired oxygen 80%|fraction of inspired oxygen 80% applied during induction of anesthesia
48096848|NCT01257503|DRUG|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
48096849|NCT01257503|DRUG|placebo|liquid made to look like the active homeopathic remedy
48096850|NCT04974489|BEHAVIORAL|Emotion-based messages about the harm of VLNC|Participants in this arm will receive 3 emotion-based messages about the harm of VLNC during the survey data collection.
48096851|NCT04974489|BEHAVIORAL|Continued-harm-framed messages about the harm of VLNC|Participants in this arm will receive 3 continued-harm-framed messages about the harm of VLNC during the survey data collection.
48096852|NCT04974489|BEHAVIORAL|Myth-refuting messages about the harm of VLNC|Participants in this arm will receive 3 myth-refuting messages messages about the harm of VLNC during the survey data collection.
48096853|NCT04974489|BEHAVIORAL|Control messages about littering|Participants in this arm will receive 3 control messages about littering during the survey data collection.
48096854|NCT03947164|OTHER|biopsy|"For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination."
48096855|NCT04676399|DRUG|Hydrochlorothiazide 12.5mg|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days.
48096856|NCT04676399|DRUG|Placebo|2 pills/day (1 pill every morning and 1 pill every evening) for 14 days
48096857|NCT00421915|DRUG|Enbrel (etanercept)|
48096858|NCT00504920|BEHAVIORAL|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
48096859|NCT00575978|DRUG|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
48096860|NCT04281264|BEHAVIORAL|Passive Hypoxia|During 30 minutes of session, the participants will perform an intellectual activity while they will be exposed to normobaric hypoxic conditions in a hypoxic chamber (CAT 310, Lousiville, Colorado). They will inspire oxygen fraction (FiO2) set to 16.1% (0.16)
48096861|NCT04281264|BEHAVIORAL|Normoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
48096862|NCT04281264|BEHAVIORAL|Hypoxia Circuit Training with Elastic Bands|"Each training sessions will consist of a circuit training with elastic bands, where different muscle groups will be involved (pectoral, shoulders, back, arms, thighs, legs and abdominals). Duration of the session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles at the end of the sessions. Main section of the sessions will be a circuit that will be composed by 3 sets of 12-15 repetitions of nine different exercises.~Subjects will inspire FiO2 of 21.0% (0.21)"
48096863|NCT04281264|BEHAVIORAL|Normoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performed on platform.~Subjects will inspire FiO2 of 21.0% (0.21)"
48272121|NCT01526525|DRUG|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
47927807|NCT01802918|DRUG|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
47927808|NCT01802918|DRUG|Placebo|Visually matching GSK2838232
47927809|NCT01802918|DRUG|Ritonavir|100mg tablets once daily for 12 days
47927810|NCT03551925|BEHAVIORAL|Treatment as Usual Plus Occupational Therapy|The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).
47927811|NCT03551925|BEHAVIORAL|Treatment as Usual|A clinical pharmacist counsels participants on proper medication adherence.
47927812|NCT02073383|PROCEDURE|Axillary brachial plexus block|
47927813|NCT01239719|DRUG|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
47927814|NCT01239719|DRUG|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
48272122|NCT01526525|DRUG|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
48272123|NCT03486392|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
48272124|NCT03486392|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
48272125|NCT03486392|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
48272126|NCT03486392|DRUG|Liraglutide|Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
48272127|NCT03486392|DRUG|Placebo|Participants will receive matching placebo SC once-weekly until Week 26.
48272128|NCT02736747|OTHER|Cryotherapy|
48272129|NCT02736747|OTHER|Placebo|
48272130|NCT01907620|OTHER|blood sample|
47927815|NCT03498053|BEHAVIORAL|Marlboro|Participants smoke Marlboro during the first experimental day, ad libitum.
47927816|NCT03498053|BEHAVIORAL|Marlboro Prime|Participants smoke Marlboro Prime during the second experimental day, ad libitum.
47927817|NCT03498053|BEHAVIORAL|Marlboro Prime (ventilation holes taped)|Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
47927818|NCT01263912|DIETARY_SUPPLEMENT|LCPUFA Supplement|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
47927819|NCT01263912|DIETARY_SUPPLEMENT|Placebo|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
47927820|NCT00655915|OTHER|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
47927821|NCT00837733|PROCEDURE|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
47927822|NCT00837733|PROCEDURE|Endometrial Biopsy|Biopsy catheter
47927823|NCT01410851|OTHER|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
48096864|NCT04281264|BEHAVIORAL|Hypoxia Vibration|"The subjects will perform dynamic and static vibration exercise provide by a commercially available device (Galileo 2000, Novotec GmbH, Pforzheim, Alemania). The duration of the WBV session will be about 30 minutes, which will include 10 minutes warm-up consisting of slight movements, and 5 minutes of static stretching for the muscles.~Repetitions of 30 seconds with a frequency of 18.5 Hz will be performed. The rest interval will be 60 seconds between 4 repetitions during weeks 1-12 and 45 seconds between 5 repetitions during weeks 12-24. The vertical amplitude of WBV was set at 2.5 mm. Four stance will be performance on the platform.~Participants will inspire a fraction of inspired oxygen (FiO2) of 16.1% (0.16)"
48096865|NCT06384131|DRUG|ABI-4334|10 mg or 50 mg tablets for oral administration
48096866|NCT06384131|DRUG|Placebo|10 mg or 50 mg tablets for oral administration
48096867|NCT06547645|OTHER|Sub-Acute Rehab at Home|Patients randomized to the intervention group will receive skilled nursing and rehabilitative care at home upon discharge from the hospital, or when eligible for skilled-nursing facility care when requiring a step up in services at home. Home care will be delivered and overseen by a multidisciplinary clinical team, which will develop individualized care plans based on diagnosis, specific rehabilitation objectives, and broader goals of care.
48096868|NCT06619639|BEHAVIORAL|Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context.
48096869|NCT02494830|DRUG|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
48096870|NCT05882318|DEVICE|eCoin Peripheral Neurostimulator System|The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
48096871|NCT01385280|BIOLOGICAL|therapeutic estradiol|Given orally (PO)
48096872|NCT01385280|DRUG|exemestane|Given PO
48096873|NCT01385280|OTHER|laboratory biomarker analysis|Correlative studies
48096874|NCT01385280|OTHER|enzyme-linked immunosorbent assay|Correlative studies
48096875|NCT03034252|PROCEDURE|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
48096876|NCT01674569|DRUG|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
48096877|NCT01674569|DRUG|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
48096878|NCT06575959|DRUG|Enlicitide|Oral tablet
48096879|NCT05068037|OTHER|ACUPUNCTURE|standard acupuncture TCM (analgesia, vomiting)
48096880|NCT05068037|OTHER|ANTIEMETICS|NO ACUPUNCTURE, WITH ANTIEMETICS
48096881|NCT05068037|OTHER|NOTHING|NO ACUPUNCTURE, NO ANTIEMETICS
48096882|NCT04463264|DRUG|Nitazoxanide|NTX (500 mg every 6 hours for 14 days) orally with food (P.O.).
48272131|NCT00166790|DRUG|chemotherapy agents|
48272132|NCT00166790|PROCEDURE|suction curettage|
48096883|NCT04463264|DRUG|Placebo|Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
48096884|NCT04360941|DRUG|Palbociclib|Highly selective oral inhibitor of CDK4 and CDK6.
48096885|NCT04360941|DRUG|Avelumab|Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
48096886|NCT04406779|DEVICE|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies|thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
48096887|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 150mg|leaves of the mango food plant
48096888|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 300mg|leaves of the mango food plant
48096889|NCT05580146|DIETARY_SUPPLEMENT|Zynamite® 15% 600mg|leaves of the mango food plant
48096890|NCT05580146|DIETARY_SUPPLEMENT|Placebo|Sunflower oil matched for appearance
48096891|NCT01468324|DRUG|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
48096892|NCT05641896|DRUG|[18F]FAPI-74 PET/CT|\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
48096893|NCT02050594|DRUG|Ipilimumab|
48096894|NCT01456780|DRUG|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
48096895|NCT01456780|DRUG|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
48096896|NCT01456780|DRUG|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
48106793|NCT06229717|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21- item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
48272133|NCT03341884|DRUG|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
48272134|NCT01756456|DRUG|rhNGF 10 μg/ml|rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
48272135|NCT01756456|DRUG|rhNGF 20 μg/ml|one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
48272136|NCT01756456|OTHER|vehicle|ophthalmic solution of the same composition as the test product without rhNGF
48272137|NCT05887999|DRUG|LY3532226|Administered subcutaneously (SC).
48272138|NCT05887999|DRUG|Placebo|Administered SC.
48272139|NCT05821270|OTHER|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
48096897|NCT06548477|DRUG|Human albumin|Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
48096898|NCT04541641|PROCEDURE|New Reverse Drilling technique|a new technique of dental implant drilling that promote osseodensification by rotating the drills anti-clockwise rather than clockwise to promote bone condensation rather than bone cutting
48096899|NCT04541641|PROCEDURE|osteotome technique|a technique for dental implant placement by using the osteotome to condense the bone and create an osteotome rather than cutting the bone
48096900|NCT01101919|DRUG|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
48096901|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by \[(3× birth weight (Kg) + 9)/2+1)\]
48096902|NCT02939690|DEVICE|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
48096903|NCT02939690|DEVICE|Ultrasound|
48096904|NCT03265873|OTHER|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
48096905|NCT00073970|DRUG|celecoxib|400mg, given twice daily
48096906|NCT02298374|OTHER|Homecare reablement|
48096907|NCT02298374|OTHER|usual care|
48096908|NCT02387346|DEVICE|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
48096909|NCT02387346|DEVICE|Magstim Rapid 2 Sham Stimulation|
48096910|NCT04789850|DRUG|Itacitinib|200 mg oral for 360 days
48096911|NCT04789850|DRUG|Placebo|200 mg oral for 360 days
48096912|NCT03571243|OTHER|no intervention|observational study
48096913|NCT03491956|DEVICE|DFPP|Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
48096914|NCT00990678|DRUG|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
48096915|NCT00990678|DRUG|Vitamin D|tablets, vitamin D3, 30 microgram daily
48096916|NCT00990678|DRUG|Calcium|tablets, 400 mg calcium, 3 times daily
48096917|NCT00221351|PROCEDURE|CRP point of care testing|
48096918|NCT03244566|DIAGNOSTIC_TEST|positron emission tomography|patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
48096919|NCT06631131|DEVICE|Distalization with clear aligners supported by Class II elastics|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. ). In group 1, with the beginning of the movement of the upper first molars, Class II intermaxillary elastics were used from precision cuts of the upper canines to the buttons on the lower first molars for supporting distalization movement.
48096920|NCT06631131|DEVICE|Distalization with clear aligners supported by miniscrew|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. In group 2, IZC miniscrews were inserted in the IZC region between the upper molars in both sides before first molar movement started. The same intramaxillary elastics were used from precision cuts of the upper canines to the IZC miniscrew for supporting distalization movement.
48096921|NCT05493722|OTHER|PS and OS stimulation order 1|PS, OS, OS
48096922|NCT05493722|OTHER|PS and OS stimulation order 2|OS, PS, OS
48096923|NCT05493722|OTHER|PS and OS stimulation order 3|OS, OS, PS
48096924|NCT02901821|GENETIC|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
48096925|NCT05274789|DRUG|Dexmedetomidine|Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
48096926|NCT05274789|OTHER|Saline|Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
48096927|NCT01619943|OTHER|no intervention|clinical follow up
48096928|NCT01619943|OTHER|no intervention|no intervention
48096929|NCT06162351|DRUG|PLX038|"Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death."
48096930|NCT03688828|DRUG|Saccharomyces boulardii|500mg bid
48096931|NCT03688828|DRUG|Esomeprazole|20mg bid
48096932|NCT03688828|DRUG|Amoxicillin|1.0g bid
48096933|NCT03688828|DRUG|Clarithromycin|0.5g bid
48096934|NCT03688828|DRUG|Bismuth potassium citrate|0.22g bid
48096935|NCT06631547|DRUG|Progesterone|Hormonal treatment
48096936|NCT06631547|DRUG|The usual head trauma care|the basic treatment
48096937|NCT06631781|OTHER|GOLD-Cog+|6 weeks of combined cognitive intervention (GOLD-Cog+),which includes participation in 9, one hour long Cognitive-Orientation to Occupational Performance(CO-OP)-based group sessions and 24 individual and independent 30-minute computerized cognitive training (CCT) program using the Effectivate platform (Israeli-based CCT developed for older adults. Available in both Hebrew and English).
48096938|NCT03664661|DRUG|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
48096939|NCT06631963|BEHAVIORAL|Emotional Awareness and Expression Therapy|Emotional Awareness and Expression Therapy (EAET) is a form of psychotherapy designed to help individuals identify, process, and express emotions that may be linked to physical symptoms or chronic pain. It emphasizes the role of unresolved emotional experiences, such as trauma or interpersonal conflicts, in contributing to physical distress. Through EAET, patients learn to connect their emotions to their physical symptoms, express those emotions in a healthier way, and ultimately reduce both emotional and physical suffering. This therapy has been shown to be effective in treating conditions such as chronic pain, irritable bowel syndrome, and fibromyalgia.
48096940|NCT01382810|DRUG|Altaire Gel forming solution|Three times a day for two months
48096941|NCT01382810|DRUG|Refresh Tears|Three times a day for two months
48096942|NCT04241796|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
48096943|NCT05305040|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
48096944|NCT05305040|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
48096945|NCT01605331|DRUG|sustained-release recombinant human GH (SR-rhGH)|
48096946|NCT02837380|DRUG|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
48096947|NCT02837380|DRUG|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
48096948|NCT04291521|DRUG|Ketamine|Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
48096949|NCT04291521|DRUG|Etomidate|Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
48096950|NCT04291521|DRUG|Propofol|Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
48272140|NCT05918380|BEHAVIORAL|PAL2|"Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
48096951|NCT01139697|OTHER|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
48096952|NCT01735929|PROCEDURE|Neck Liposuction and Ultrasound Treatment|
48096953|NCT01735929|PROCEDURE|Sham Treatment|
48096954|NCT06510686|OTHER|İnspiratory muscle training|exercises to strengthen inspiratory muscles
48096955|NCT06510686|OTHER|Core training|exercises to strengthen inspiratory and core muscles
48096956|NCT05001828|DRUG|ADI-PEG 20|ADI-PEG 20 in combination with venetoclax and azacitidine
48096957|NCT04053829|DEVICE|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
48106794|NCT05987540|DEVICE|Non-invasive brainstem stimulation|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device.
48272141|NCT05918380|OTHER|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
48272142|NCT00180973|DRUG|Hydroxyurea|
48096958|NCT04053829|OTHER|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 8 week programme.
48096959|NCT00256308|DRUG|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
48096960|NCT00256308|PROCEDURE|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
48096961|NCT02527889|OTHER|Exercise training|8-week resistive exercise training
48096962|NCT06548009|DIAGNOSTIC_TEST|Metabolomics and other blood samples|Blood samples taken with the objective of identifying a diagnostic test
48096963|NCT02377531|OTHER|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
48272143|NCT03541421|OTHER|Patient involvement in administration of drugs|The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
48620288|NCT02497014|DEVICE|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
48620289|NCT03669679|PROCEDURE|Breast reduction|breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
48620290|NCT01767220|PROCEDURE|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
48620291|NCT01767220|PROCEDURE|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
48620292|NCT03236389|DEVICE|Q Collar|measuring changes in brain during MRI while wearing the Q collar
48620293|NCT02184156|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
48620294|NCT02184156|DRUG|4 mL injection of Placebo|
48620295|NCT01413802|PROCEDURE|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
48620296|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with crushing|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
48096964|NCT02377531|OTHER|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
48096965|NCT05006690|OTHER|Clinical Pilates-Based Exercise Training|Clinical Pilates-Based exercise training based on spinal stabilization aim at controlling the position of the trunk over the pelvis to provide optimal energy production and energy transfer to distal segments and involve the cocontraction of muscles, which may restore stability to the spine.
48096966|NCT04600180|PROCEDURE|sigmoidoscopies and and venous blood sampling|Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
48272144|NCT00750984|PROCEDURE|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
48620297|NCT00639093|BEHAVIORAL|psychoeducational / motivational combined with control|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
48620298|NCT04256408|DEVICE|Bronchoscopic transparenchymal interlobar fissure closure using Aeriseal|Transbronchial or transparenchymal injection of AeriSeal into the interlobar collateral ventilation channels region to convert CV-positive lobes into CV-negative lobes.
48620299|NCT01926535|PROCEDURE|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
48620300|NCT01926535|DEVICE|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
48096967|NCT05446389|DEVICE|Pacifier Activated Lullaby ®|Pacifier Activated Lullaby (PAL®) is a medical device that encourages and reinforces the development of non-nutritive sucking (NNS) of premature infants. This is accomplished by giving positive feedback in the form of music/mother's voice as an auditory input in direct response to effective sucking.
48096968|NCT05203172|DRUG|Binimetinib only treatment|Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Parent Studies C4211001 and C4211003 with water irrespective of food, continuously, starting on Day 1.
48096969|NCT05203172|DRUG|Encorafenib only Treatment|Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
48096970|NCT05203172|DRUG|Encorafenib & Binimetinib Treatment|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
48096971|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Ribociclib|Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binimetinib tablets BID. The study drugs will be administered as a flat-fixed dose, and not by body weight or body surface area.
48096972|NCT05203172|DRUG|Treatment of Encorafenib & Binimetinib & Cetuximab|Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.
48096973|NCT04135144|OTHER|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
48096974|NCT04135144|OTHER|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
48096975|NCT05512390|DRUG|ABBV-319|Intravenous (IV); Infusion
48096976|NCT04012606|DRUG|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
48096977|NCT00364598|DRUG|Anginera, a human tissue replacement therapy|
48096978|NCT06629376|DRUG|Pegylated Recombinant Candida Utilis Uricase for Injection|According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
48096979|NCT03315403|DIAGNOSTIC_TEST|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
48096980|NCT05724550|DRUG|Sugammadex|"* Sugammadex(100mg/mL), 2mg/kg~* After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery."
48096981|NCT05724550|DRUG|Neostigmine|"* Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~* After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery."
48096982|NCT00802919|DRUG|Varenicline|Varenicline 1-2 mg/day
48096983|NCT00802919|DRUG|Placebo for varenicline|Placebo
48096984|NCT04054661|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
48096985|NCT04054661|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
48096986|NCT04054661|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
48272145|NCT00750984|PROCEDURE|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
48096987|NCT00207129|DRUG|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
48096988|NCT00207129|DRUG|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
48096989|NCT00002563|PROCEDURE|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
48096990|NCT00002563|PROCEDURE|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
48096991|NCT01982019|BEHAVIORAL|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
48272146|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
48272147|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
48272148|NCT02436941|RADIATION|Proton or Photon|
48272149|NCT05848934|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
48272150|NCT05848934|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
48272151|NCT02667184|DIETARY_SUPPLEMENT|Low FODMAP Oral Nutrition Supplement|
48272152|NCT01705015|BEHAVIORAL|direct feedback about exercise|
48272153|NCT01705015|BEHAVIORAL|PLacebo|UCFit plus encouraged exercise
48096992|NCT06079593|PROCEDURE|Gasless Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane flap and ophthalmic viscosurgical device covering
48272154|NCT02197377|DEVICE|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
48272155|NCT02197377|DEVICE|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
48272156|NCT01916278|DEVICE|Emervel Lips Lidocaine|
48272157|NCT01916278|DEVICE|Juvéderma Volbella with Lidocaine|
47927824|NCT06022289|DRUG|Pemigatinib|Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
47927825|NCT02122601|DRUG|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
47927826|NCT03255070|DRUG|ARX788|An antibody drug conjugate
47927827|NCT05855876|PROCEDURE|subanesthetic ketamine infusions and bilateral cervical sympathetic blocks|Combined protocol of subanesthetic ketamine infusions and bilateral cervical sympathetic blocks
47927828|NCT03725462|DEVICE|Cardioskin|Subjects have a monitoring with cardioskin and comparator
47927829|NCT03725462|DEVICE|Neuronaute|Subjects have a monitoring with Neuronaute and comparator
47927830|NCT02507960|DEVICE|The Gamma Pod|Immobilization of breast during radiation.
47927831|NCT02507960|DEVICE|CT simulation|See arm description
47927832|NCT05008978|OTHER|Test 1|25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min
47927833|NCT05008978|OTHER|Test 2|25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
47927834|NCT05008978|OTHER|Test 3|25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
47927835|NCT05008978|OTHER|Test 4|25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
47927836|NCT05008978|OTHER|Test 5|25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
47927837|NCT03455790|DIAGNOSTIC_TEST|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
47927838|NCT01613170|DRUG|Toviaz|Toviaz 4mg daily
47927839|NCT01613170|DRUG|Premarin|Premarin cream 1 g per vagina twice weekly
47927840|NCT01613170|DRUG|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
47927841|NCT00222716|BEHAVIORAL|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
47927842|NCT00022347|DRUG|canfosfamide hydrochloride|
47927843|NCT04308733|DEVICE|Anodal tDCS|patients will be stimulated over the contralateral pharyngeal motor cortex with anodal tDCS (2mA, 20 minutes) for 4 consecutive days
48272158|NCT01166048|DRUG|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
48272159|NCT01166048|DRUG|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
48272160|NCT02954380|DEVICE|Zio|long term continuous monitoring
48272161|NCT01727258|DEVICE|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
48272162|NCT01727258|DRUG|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
47927844|NCT00198887|PROCEDURE|Operations research|
47927845|NCT03480464|BEHAVIORAL|App-technology to increase physical activity|The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
47927846|NCT01761032|DEVICE|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
47927847|NCT00411580|BIOLOGICAL|CAD106|
47927848|NCT00411580|DRUG|Placebo|
47927849|NCT05314764|DRUG|Cefiderocol|Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
47927850|NCT02299778|DIETARY_SUPPLEMENT|13C6-p-aminobenzoic acid|
47927851|NCT00945906|BIOLOGICAL|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
48096993|NCT06079593|PROCEDURE|Standard Macular hole surgery|Pars plana vitrectomy to treat full thickness macular hole, with internal limiting membrane peel, and C2F6 tamponade
48096994|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Test Drug|Investigational Medicinal Product
48096995|NCT05158192|DRUG|Diosmin/Hesperidin (90/10) 500 mg Reference Product|Daflon (Trademark)
48096996|NCT00151996|DRUG|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
48096997|NCT00151996|DRUG|Amphetamine + SPD503|
48272163|NCT01727258|DRUG|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
48096998|NCT04630652|DRUG|Risankizumab-Rzaa|Risankizumab at a dose of 150 mg with injections administered at baseline, week 4 and week 16 following FDA-approved dosage and time periods
48096999|NCT04630652|PROCEDURE|Punch biopsies of the skin at baseline visit|Two 6 mm punch biopsies of the skin at baseline visit
48097000|NCT04630652|PROCEDURE|Punch biopsies of the skin at week 28 visit|One 6 mm punch biopsy of the skin at week 28 visit
48097001|NCT05506930|DRUG|Intrathecal Morphine|One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
48097002|NCT05506930|DRUG|Quadratus lumborum block|The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
48097003|NCT04090320|DEVICE|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
48097004|NCT06322342|DRUG|RVP-001|MRI contrast agent
48097005|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - fast release|
48097006|NCT00233792|DEVICE|sirolimus coated Bx VELOCITY stent - slow release|
48097007|NCT00005581|DRUG|cyclophosphamide|
48097008|NCT00005581|DRUG|epirubicin hydrochloride|
48097009|NCT00005581|DRUG|fluorouracil|
48097010|NCT00005581|DRUG|paclitaxel|
48097011|NCT02933320|BIOLOGICAL|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
48097012|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab escalation phase|An investigation of combination treatment of BI-1206 with rituximab.
48097013|NCT02933320|BIOLOGICAL|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the RP2D.
48097014|NCT02933320|BIOLOGICAL|Combination of BI-1206 with rituximab expansion phase|BI-1206 in combination with rituximab at the RP2D.
48097015|NCT03985709|OTHER|Probiotic product|Probiotic (Lactobacillus casei) once daily taken by 3 months.
48097016|NCT01784380|DRUG|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
48097017|NCT01619254|BEHAVIORAL|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
48097018|NCT04857944|BEHAVIORAL|IDEA program (Improving depressive symptoms through personalised exercise and activation)|The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.
48097019|NCT04857944|DEVICE|IDEApp|An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.
48097020|NCT06123117|PROCEDURE|single transversus abdominis laparoscopy-guided plane block|please see arm/group descriptions
48097021|NCT06123117|PROCEDURE|local trocar site ropivacaine infiltration|please see arm/group descriptions
48097022|NCT04496674|DRUG|CC-1 and Toczilizumab|Adminsitration of CC-1 and Toczilizumab
48097023|NCT05407220|DRUG|HCP1904-1|take it once per period
48097024|NCT05407220|DRUG|HCP1904-3|take it once per period
48097025|NCT05626543|BEHAVIORAL|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs|Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs will be used combinedly. CBT will be constructed based on the CBT model of Beck, (2021) and mindfulness practice will be implemented based on the MBSR program developed by Williams et. al. (2011).
48097026|NCT00823979|DRUG|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
48097027|NCT00823979|DRUG|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
48097028|NCT00823979|DRUG|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
48097029|NCT05710744|BEHAVIORAL|Shared decision making tip sheet|Physicians will view tip sheets containing best practices for shared decision making with diverse families.
48097030|NCT02109393|OTHER|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
48097031|NCT02109393|OTHER|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
48097032|NCT02915809|BIOLOGICAL|GC3110B vaccine|0.5mL, Intramuscular
48097033|NCT02915809|BIOLOGICAL|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
48097034|NCT02040844|DRUG|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
48097035|NCT02040844|DRUG|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
48097036|NCT02040844|DRUG|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
48097037|NCT01436409|OTHER|echography|echography during labor
48097038|NCT05929807|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
48097039|NCT01300858|DRUG|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
48097040|NCT00583843|PROCEDURE|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
48097041|NCT06288919|OTHER|Erythritol prophylactic powders|erythritol with particle size of \~14 µm will be used for 5 seconds (AIRFLOW® PLUS EMS)
48097042|NCT06288919|OTHER|Ultrasonic scaler with peek inserts|ultrasonic scaler, a piezoelectric handpiece with peek inserts (Mini Piezon EMS; PI, EMS) will be used.
48097043|NCT05417204|BEHAVIORAL|Abdominothoracic biofeedback|A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
48097044|NCT05683301|DRUG|Amlodipine + Perindopril|Single pill combination of dual antihypertensive agent
48097045|NCT05683301|DRUG|Perindopril + Indapamide|Single pill combination of dual antihypertensive agent
48097046|NCT05683301|DRUG|Amlodipine + Indapamide|Single pill combination of dual antihypertensive agent
48097047|NCT05468658|OTHER|Designing the birthing unit according to the philosophy of Feng Shui|"1. The cabinets will be painted using salmon and pastel green.~2. It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~3. Live nature videos and sounds will be projected onto the wall.~4. Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~5. Natural plants will be placed.~6. Lighting will be used.~7. Bed linen will be designed according to the Feng Shui.~8. Wooden bell will be used.~9. Turtle, elephant and Wu Lou objects will be placed.~10. The Bagua mirror will be placed.~11. Crystals will be placed.~12. Natural stones will be placed.~13. The fountain will be placed in the east compass direction of the unit.~14. Straw bamboo separator will be used."
48097048|NCT06622148|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
48097049|NCT06622148|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
48097050|NCT01683695|DRUG|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
48097051|NCT01683695|DRUG|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
48097052|NCT02799212|DRUG|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
48097053|NCT02799212|DRUG|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
48097056|NCT02647749|DEVICE|Cardioinsight® mapping system|
48097057|NCT02647749|OTHER|Conventional method without non-invasive mapping|
48097058|NCT00598013|DRUG|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
48097059|NCT02727621|DRUG|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
48097060|NCT02727621|DRUG|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
48097061|NCT03688854|DIETARY_SUPPLEMENT|SCFA mixture|Intracolonic administration
48097062|NCT04601311|BEHAVIORAL|Guided self-determination|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....~The goal is registered.~Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2.~A relative may take part in one session completing an analogue reflection sheet as preparation.~Participants continue usual care."
48272164|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
48272165|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
48272166|NCT01106547|DRUG|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
48272167|NCT01106547|DRUG|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
48097063|NCT04601311|BEHAVIORAL|Personal support in goal-pursuing|"Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'....~The goal is registered.~Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session.~Participants continue usual care."
48097064|NCT06628999|OTHER|Visual Training|16-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness
48097065|NCT06628999|OTHER|Control Group|16-week of active lifestyle based on healthy habits
48097066|NCT06628999|OTHER|Visual Training-detraining|8-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness, followed by 8 week with no specific training protocol
48097067|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
48097068|NCT01051882|BIOLOGICAL|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
48097069|NCT02027935|BIOLOGICAL|Aldesleukin|Given SC
48097070|NCT02027935|BIOLOGICAL|Autologous CD8+ Melanoma Specific T Cells|Given IV
48097071|NCT02027935|DRUG|Cyclophosphamide|Given IV
48097072|NCT02027935|BIOLOGICAL|Ipilimumab|Given IV
48097073|NCT02027935|OTHER|Laboratory Biomarker Analysis|Correlative studies
48097074|NCT01264718|BEHAVIORAL|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
48097075|NCT00108524|BEHAVIORAL|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
48097076|NCT00108524|DRUG|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
48097077|NCT00108524|BEHAVIORAL|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
48097078|NCT03829332|BIOLOGICAL|Pembrolizumab|IV infusion
48097079|NCT03829332|DRUG|Lenvatinib|oral capsule
48097080|NCT03829332|DRUG|Placebo for lenvatinib|oral capsule
48097081|NCT03014687|DRUG|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
48097082|NCT03014687|DRUG|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
48097083|NCT01487564|DRUG|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
48097084|NCT04746859|OTHER|Prevention Visit|Patients will have a one-on-one, approximately one-hour long visit with a specially trained Prevention Practitioner. During this visit, they will discuss the patient's health history, their risks for developing chronic diseases, including cancer, and possible steps they can take to reduce those risks. The Prevention Practitioner will also assist the patient to develop and articulate specific goals the patient would like to work on to reduce their risk of chronic diseases.
48097085|NCT04746859|BEHAVIORAL|Peer health coaching|Patients will be invited to register with the software platform used to facilitate peer health coaching. Once they have registered, they will be matched to a peer health coach who will connect with the patient to initiate the process. The coach will work collaboratively with the patient to help her follow through on a step-wise, personalized plan to achieve health goals that were developed with their prevention practitioner. The coach's approach will be informed by principles of brief action planning and motivational interviewing. Coaches will also provide social support, help to navigate to relevant information and community resources, and advise about options for self-monitoring. Coaching will occur over 12-16 sessions via phone calls, text messages, video calls and/or in-person meetings as desired/convenient and in accordance with local public health guidelines.
48097086|NCT05060185|DEVICE|the Flow Diverter|Those who meet the inclusion criteria but do not meet the exclusion criteria will be enrolled through the electronic central registration system. The investigator log in to the central registration system, fill in the subject information and submit it who enroll in the study. The investigator complete the surgery and conduct relevant evaluation according to the protocol.
48097087|NCT02205931|OTHER|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
48272168|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - high intensity interval training (HIIT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 4x4-min high intensity aerobic intervals at a rating of perceived exertion 15-17 (hard to very hard), interspersed by a 3-min active recovery at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (4-min) and cool-down (3-min) at a light intensity.
48272169|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - moderate intensity continuous training (MICT)|During cardiac rehabilitation (12-weeks, 3 sessions/week), exercise training will comprise of 34-min of continuous aerobic exercise at a rating of perceived exertion 11-13 (fairly light to somewhat hard). Warm-up (3-min) and cool-down (3-min) at a light intensity.
48097088|NCT02205931|DRUG|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
48097089|NCT00319943|PROCEDURE|Computer-based training for Mild Cognitive Impairment (MCI)|
48097090|NCT06628596|DIETARY_SUPPLEMENT|Paraxanthine 200mg and 300mg|Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
48097091|NCT02683824|DIAGNOSTIC_TEST|Computed Tomography|Undergo CT scan
48097092|NCT02683824|OTHER|Laboratory Biomarker Analysis|Correlative studies
48097093|NCT02683824|DIAGNOSTIC_TEST|PET/MRI scan|Undergo PET/MRI scan
48097094|NCT02683824|DRUG|[18F]FP-R01-MG-F2|radioactive tracer
48097095|NCT06184789|DIAGNOSTIC_TEST|Echocardiographic assessment|Echocardiographic and hemodynamics assessment of Mitraclip results
48097096|NCT06631677|DRUG|Dupilumab|Administered per protocol
48097097|NCT02248142|DRUG|Pramipexole|
48097098|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample every 6 months for 1 year which is not part of health routine care
48097099|NCT06230562|BIOLOGICAL|Blood sample|The intervention is to take a blood sample at baseline.
48097100|NCT03074851|DIETARY_SUPPLEMENT|low sodium salt|To give free low sodium salt intervention for 2 months
48097101|NCT03074851|OTHER|informational intervention|to give reporter informational intervention.
48097102|NCT04745702|COMBINATION_PRODUCT|Low Calorie Meals Rich in Plant Components|Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
48097103|NCT04745702|COMBINATION_PRODUCT|Low Calorie Balanced Meals|Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
48097104|NCT06629285|PROCEDURE|Continuous compression cryotherapy|Using continuous compression cryotherapy around knee after anterior cruciate ligament reconstruction for 3 postoperative days
48097105|NCT06629285|PROCEDURE|Conventional ice treatment|Using icepack around knee after anterior cruciate ligament reconstruction for 3 postoperative days
48097106|NCT06630962|OTHER|Financial Navigation Program|"A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa.~Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies."
48097107|NCT02959151|DRUG|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
48097108|NCT01359137|BEHAVIORAL|Probation as usual|Routine probation with do deferred jail condition.
48097109|NCT01359137|BEHAVIORAL|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
48097110|NCT01359137|BEHAVIORAL|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
48272170|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - control|Participants will receive exercise advice in line with usual hospital discharge procedures. This involves exercise physiologists providing verbal and written information on achieving the national physical activity guidelines (150min/week of moderate intensity exercise) 60 and range of movement exercises for surgical patients with sternotomy. However, no structured or supervised exercise training program or other contact with participants will be provided after hospital discharge, to reflect the usual care process for patients that decline cardiac rehabilitation.
48272171|NCT05012878|BEHAVIORAL|Cardiac rehabilitation - observational|During cardiac rehabilitation (12-weeks), program frequency and exercise training protocol will align with clinical care decisions and/or patient choice rather than random assignment.
48272172|NCT00412477|BIOLOGICAL|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
48097111|NCT03988387|BEHAVIORAL|Peer Support (PS)|Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
48272173|NCT05159414|DEVICE|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
48272174|NCT06255873|DIETARY_SUPPLEMENT|L- Carnitine|L-carnitine was taken after feeds in the form of tablets or dissolved tablets in a dose of 50 mg/kg/day, with maximum dose of 2 g/day.
48272175|NCT06255873|OTHER|ketogenic diet|ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
48272176|NCT01724957|PROCEDURE|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
48097112|NCT03988387|BEHAVIORAL|Reminder and Resource Transfer (RRT)|"Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points."
48097113|NCT03988387|DRUG|daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]|All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
48097114|NCT02454907|OTHER|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
48097115|NCT05914558|DIAGNOSTIC_TEST|Clinical appointment|One clinical interview and examination to confirm the diagnosis of trigeminal neuralgia and temporomandibular disorder.
48097116|NCT01834235|DRUG|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
48097117|NCT01834235|DRUG|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
48097118|NCT01834235|DRUG|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
48097119|NCT03226730|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
48097120|NCT03226730|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
48443992|NCT03968172|BEHAVIORAL|EBBC programme|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~1. Diagnosis and disease progression~2. Support in disease processing~3. Techniques for coping with stress and depressive symptoms as well as developing positive emotions~4. Optimisation of dietary behaviour~5. Optimisation of physical activity behaviour~6. Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
48097122|NCT06095310|BEHAVIORAL|New computer vision methods|Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)
48097123|NCT02465359|DRUG|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
48097128|NCT00058058|PROCEDURE|MRI|Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
48272177|NCT02586805|DRUG|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
48097129|NCT03433261|DIETARY_SUPPLEMENT|Ketogenic Diet|Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
48097130|NCT04809402|OTHER|remote monitoring after cataract surgery|remote monitoring after cataract surgery
48097131|NCT03397160|BEHAVIORAL|Decision Support Intervention (DSI)|"A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps)."
48097132|NCT03645174|DEVICE|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
48097133|NCT03645174|DEVICE|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
48272178|NCT02586805|DRUG|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
48097134|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
48097135|NCT03038256|DRUG|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
48097136|NCT05203913|DRUG|Nivolumab|The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
48097137|NCT05203913|DRUG|Nab paclitaxel|The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
48097138|NCT05203913|DRUG|Cisplatin|The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
48097139|NCT05203913|RADIATION|Radiotherapy|Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
48097140|NCT04816526|BIOLOGICAL|Descartes 08|Car T-cells
48097141|NCT00612001|BIOLOGICAL|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
48097142|NCT02292043|DRUG|HTEA|HTEA
48097143|NCT06140849|DIAGNOSTIC_TEST|artificial intelligence model|artificial intelligence model of anterior open bite diagnosis
48097144|NCT04888455|DIAGNOSTIC_TEST|Quantitative sensory testing (QST)|Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).
48097145|NCT03827187|OTHER|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
48097146|NCT02766504|DEVICE|airway ultrasound|airway assessment using ultrasound
48097147|NCT03748732|PROCEDURE|sclerectomy|scleral flap
48097148|NCT01121783|OTHER|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
48272179|NCT02586805|DRUG|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
48272180|NCT02586805|DRUG|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
47914165|NCT04508088|DIAGNOSTIC_TEST|Spin-lattice relaxation (T1)|Spin-lattice relaxation (T1) relaxometry acquisition consisting of seven fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
48097149|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
48097150|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
48097151|NCT01121783|DIETARY_SUPPLEMENT|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
48272181|NCT02718378|DRUG|estetrol|
48272182|NCT02718378|DRUG|placebo|
48272183|NCT04544722|BEHAVIORAL|Jianfei Kangfu Cao|The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.
48272184|NCT04544722|BEHAVIORAL|lung rehabilitation training|The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.
48272185|NCT05042726|DEVICE|cTBS First|Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 33.2s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.
48272186|NCT05042726|DEVICE|Pseudo-stimulation First|The transcranial magnetic stimulator operating system has a built-in control group option, in which the stimulation parameters are set consistent with the research group, which can realize the operation of only sound without stimulation.
48097152|NCT05478122|DEVICE|Trachospray for awake videolaryngoscopy|Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device
48097153|NCT02467491|DEVICE|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
48097154|NCT01723670|DRUG|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
48097155|NCT01723670|DRUG|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
48097156|NCT01723670|DRUG|Placebo|oral tablet,once a day for 24 months
48097157|NCT05903807|DRUG|68Ga-FAPi-46|Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
48097158|NCT01885364|DRUG|Normal saline|intravenous injection with normal saline before injection of propofol
48097159|NCT01885364|DRUG|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
48097160|NCT01885364|DRUG|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
48097161|NCT01885364|DRUG|propofol|intravenous injection after pretreatment
48097162|NCT06629259|DRUG|Guanfacine Extended Release (XR)|3mg tablet once daily
48097163|NCT06629259|DRUG|Placebo|placebo tablet once daily
48097164|NCT03812159|DEVICE|iCSPlan|"The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed."
48097165|NCT03612115|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
48097166|NCT04213222|DRUG|Bevacizumab|bevacizumab combined with chemotherapy
48097167|NCT02214108|OTHER|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
48097168|NCT00742573|DRUG|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
48097169|NCT00742573|BEHAVIORAL|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
48097170|NCT05249179|OTHER|Pacifier|Preterm infants in Groups 2 and 3 will suck a pacifier 3 times a day (09:00, 12:00, 15:00) for 3 minutes before feeding and then they will be fed with the O/G feeding tube.
48097171|NCT05249179|OTHER|Oral stimulation|Infants in groups 1 and 3 will receive a prefeeding oral stimulation program once a day, 15 to 30 minutes before a tube feeding. Oral stimulation programs will be delivered by trained nurses or pediatric physical therapies. Nurses will be trained to deliver the stimulation program to the infants, by a member from the pediatric physical therapies medical staff, before the beginning of the study. Based on Backman's principles, the pre-feeding oral stimulation program consisted of a 12-minute stimulation program that included stroking the cheeks, lips, gums, and tongue.
48097172|NCT01090609|DEVICE|Stent implantation|Stent implantation
48097173|NCT06041087|BEHAVIORAL|High-Intensity Exercise|A single bout of high-intensity exercise (cycling intervals, resistance exercise, plyometrics) per trial.
48097174|NCT06041087|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50g consumed immediately after exercise and 1h after exercise.
48097175|NCT06041087|DIETARY_SUPPLEMENT|Skim Milk|500ml consumed immediately after exercise and 1h after exercise.
48272187|NCT04364204|OTHER|Kangaroo Mother Care and BEMPU bracelet|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C, signaling hypothermia and prompting caregiver to provide thermal care.
48097176|NCT06041087|DIETARY_SUPPLEMENT|Greek yogurt|200g consumed immediately after exercise and 1h after exercise.
48097177|NCT06041087|DIETARY_SUPPLEMENT|Water|500ml consumed immediately after exercise and 1h after exercise.
48097178|NCT05784935|DEVICE|Real time AI detection model|Bowel preparation will be conducted according to usual local practices. During colonoscopy, the colonoscope will be first advanced to the cecum in all patients as confirmed by identification of the appendicular orifice and ileocecal valve or by intubation of the ileum, as per the standard of care by experienced endoscopists. During the insertion, no action will be taken. After cecal intubation is performed, the colonoscope will be slowly withdrawn to the splenic flexure by the primary endoscopists. Real time AI detection model will be activated with the output displayed in real time on a separate monitor and will be only viewed by an independent investigator, who is an experienced endoscopists (or a person trained in polyp recognition). The primary endoscopists will be blinded to the AI real time detection result
48097179|NCT05009446|PROCEDURE|endoscopic surgery|endoscopic surgery or endoscope-assisted surgery open surgery
48097180|NCT05009446|RADIATION|intensity-modulated radiation therapy or volume of rotating intensity-modulated radiotherapy or Proton or heavy ion radiation therapy|radiotherapy was administrated before surgery
48097181|NCT05009446|DRUG|Chemotherapy drug|Chemotherapy was administrated before surgery. Chemotherapy may also be administrated after surgery in selected cases.
48097182|NCT02004613|DRUG|Dexmedetomidine|Dexmedetomidine
48097183|NCT02004613|DRUG|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
48097184|NCT00398502|DRUG|MOA-728|
48272188|NCT04364204|OTHER|Kangaroo Mother Care|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. This is the current standard of care for low birthweight/preterm infants.
48097185|NCT05100966|OTHER|FitJoints Multi-modal Intervention|"Exercise: The study physiotherapist will prescribe an exercise program tailored to the participant's individual ability and preference with functional movements to mimic activities of daily living.~Nutritional consultation and protein supplement: The site research assistant will coach participants to improve their nutrition, determine their daily protein target, and provide educational tools on how to achieve their target. Protein supplements will be provided to participants.~Vitamin D: Participants will be provided with vitamin D3 (1000 IU) tablets to reduce the risk of falls and to preserve muscle strength and functional ability. They will be instructed to take one tablet daily for the duration of the intervention period.~Medication optimization: The study pharmacist will conduct a medication review and provide, if required, recommendations for medication optimization."
48097186|NCT05402891|DRUG|Lithium Carbonate|Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
48097187|NCT03667248|DEVICE|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
48097188|NCT00090272|DRUG|MK0826, ertapenem sodium|
48097189|NCT00090272|DRUG|Comparator: cefotetan|
48097190|NCT00635817|DRUG|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
48097191|NCT00635817|DRUG|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
48097192|NCT03564626|OTHER|Health-IT +/- Scheduled Follow Up|"* Training patient and caregiver on Patient Buddy and EncephalApp~* Counseling regarding readmission~* Daily contact through app~* Standard of care counseling regarding readmission and discharge instructions~* Follow up phone calls at Week 1 and Week 3~* In-person follow up visits at Week 2 and Week 4"
48097193|NCT05243992|OTHER|CTS-PAD device imaging|Participants in the CTS-PAD Study will undergo a conventional ABI (cABI) evaluation, followed by the non-contact imaging evaluation with the CTS-PAD device. The supplemental CTS-PAD testing will add approximately ten (10) minutes to the overall evaluation time.
48097194|NCT04068545|DEVICE|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
48097195|NCT03261661|BEHAVIORAL|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
48097196|NCT03261661|BEHAVIORAL|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
48097197|NCT03261661|BEHAVIORAL|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
48097198|NCT03261661|BEHAVIORAL|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
48097199|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
48097200|NCT00196365|DRUG|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
48097201|NCT05320913|PROCEDURE|Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
48097202|NCT05320913|PROCEDURE|isolated periarticular multimodal drug injection (PMDI)|periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
48097203|NCT05692401|BEHAVIORAL|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
48097204|NCT00388011|DRUG|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
48097205|NCT00388011|DRUG|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
48097206|NCT00388011|DRUG|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
48097207|NCT00388011|DRUG|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
48272189|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
48097208|NCT00388011|DRUG|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
48097209|NCT00388011|DRUG|Intranasal placebo|Intranasal placebo
48097210|NCT01005992|PROCEDURE|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
48620301|NCT04256499|PROCEDURE|Acute water load test|The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
48097211|NCT01005992|PROCEDURE|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
48620302|NCT06425614|PROCEDURE|Autotransfusion|"ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center."
48097212|NCT05426291|OTHER|BIOMARKER LEVELS IS IT POSSIBLE TO PREDICT ACUTE RENAL DAMAGE IN THE PREOP PERIOD?|In open heart surgery, it will be followed whether acute kidney injury will develop by looking at the biomarkers in the preoperative period.
48097213|NCT02148809|RADIATION|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
48097214|NCT05167253|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
48097215|NCT05052983|DRUG|Nemolizumab|Participants received either 1 \[30 milligram (mg)\] or 2 (2\*30 mg) subcutaneous (SC) injection(s) of nemolizumab every 4 weeks (Q4W) for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by interactive response technology (IRT).
48097216|NCT05052983|DRUG|Placebo|Participants received either 1 (30 mg) or 2 (2\*30 mg) SC injection(s) of placebo every 4 weeks for a period of 24 weeks (with last injection at Week 20). Participants received the same dosage (1 or 2 SC injections) as received in the lead-in LTE study RD.06.SPR.202699, as assigned by IRT.
48097217|NCT00690456|DRUG|Rimonabant|Tablet, oral administration
48097218|NCT00690456|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
48097219|NCT00690456|DRUG|Metformin|Metformin continued at stable dose as background therapy
48097220|NCT01645852|DIETARY_SUPPLEMENT|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
48097221|NCT04859777|DRUG|MPT-0118|MPT-0118 is an inhibitor of MALT1 protease
48097222|NCT04859777|DRUG|MPT-0118 + pembrolizumab|MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
48097223|NCT04239339|DRUG|Escitalopram 20 mg|20mg daily for approximately 3 weeks.
48097224|NCT04239339|DRUG|Placebo|Placebo daily for approximately 3 weeks.
48097225|NCT03111095|OTHER|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
48097226|NCT06268028|BEHAVIORAL|Training|Discharge training
48097227|NCT05527483|DRUG|[68Ga]PSMA|Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging
48097228|NCT05527483|DRUG|Flourine-18 [F-18] Sodium Fluoride (NaF)|Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
48097229|NCT05527483|DIAGNOSTIC_TEST|PET/CT|Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT
48272190|NCT03866187|BIOLOGICAL|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
48272191|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
48097230|NCT03531905|DRUG|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
48097231|NCT03531905|DRUG|Ezetimibe 10 mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
48097232|NCT03531905|DRUG|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
48097233|NCT03531905|DRUG|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
48097234|NCT05121207|DEVICE|Terahertz scanning|Short scans using Terahertz device
48097235|NCT05629598|BIOLOGICAL|Recombinant human erythropoietin injection|The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
48097236|NCT05629598|BIOLOGICAL|Human erythropoietin injection|Refer to the product instructions
48097237|NCT00697892|DRUG|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
48097238|NCT00697892|DRUG|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
48097239|NCT00697892|DRUG|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
48097240|NCT05491161|OTHER|Longitudinal study|Longitudinal study following infant development from birth to 1 year of age
48097241|NCT05868226|DRUG|ALX148|CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
48097242|NCT05868226|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
48097243|NCT05868226|DRUG|Zanidatamab|Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
48097244|NCT05868226|DRUG|Tucatinib|Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
48097245|NCT01371201|DRUG|Sunitinib|sunitinib 37.5 mg per day
48097246|NCT01371201|DRUG|Placebo|Placebo 37.5 mg per day
48097247|NCT01969890|DRUG|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
48097248|NCT03882489|DRUG|Isobaric 2-chloroprocaine|The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
48097249|NCT04590989|OTHER|Personalized Nutrition Plan|"* Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~* Personalized behavioral change program via electronic push notifications by ONMI"
48097250|NCT04590989|OTHER|Non-Personalized Nutrition Plan|"* Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~* Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization)."
48097251|NCT01037933|OTHER|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
48097252|NCT01037933|OTHER|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
48097253|NCT04954430|DIAGNOSTIC_TEST|pupillometer|The dynamic changes of PLR were measured using the PLR-3000 pupillometer (NeurOptics, CA, USA), a hand-held portable device. Determination of PLR with automated pupillometry can be performed with a rubber cup covering the measured eye and the subject's hand covering the non-measured eye. A flash of visible white light with a duration of 0.8 sec and a pulse intensity of 50 µW is delivered to induce a pupillary reflex, and repeated video images at more than 30 frames/sec are stored for 6.65 sec. The device provided the examiner with maximum and minimum pupil size (Init and End), constriction percentage (%PLR), latency (LAT), constriction and dilation velocity (CV and DV), and T75.
48097254|NCT01750957|DRUG|Placebo|orally daily, 12 weeks
48097255|NCT01750957|DRUG|RO4917523|Dose A orally daily, 12 weeks
48097256|NCT01750957|DRUG|RO4917523|Dose B orally daily, 12 weeks
48097257|NCT02575391|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
48097258|NCT04660370|DRUG|CKD-348|QD, PO
48097259|NCT04660370|DRUG|CKD-828, D097, D337|QD, PO
48097260|NCT04751747|PROCEDURE|Computed Tomography|Undergo CT simulation
48097261|NCT04751747|OTHER|Contrast Agent|Given IV
48097262|NCT05587140|DEVICE|Acupuncture like TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: 3/10 painful sensation with muscle contraction , time: 30 minutes
48097263|NCT05587140|DEVICE|Conventional TENS|Frequency: 100 Hz, pulse duration: 200 μs, intensity: strong but comfortable tingling sensation , time: 30 minutes
48097264|NCT05587140|DEVICE|Sham TENS|Frequency: 4 Hz, pulse duration: 200 μs, intensity: tingling sensation, time: turn on the electricity for 15 seconds, then turn off the machine for 30 minutes
48097265|NCT02017106|PROCEDURE|Endovenous Laser ablation and concomitant phlebectomies|
48272192|NCT03866187|BIOLOGICAL|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
48272193|NCT03866187|BIOLOGICAL|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
48272194|NCT03866187|BIOLOGICAL|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
48620303|NCT03710811|DRUG|Insulin|Continuous Subcutaneous Insulin Infusion
48097266|NCT02017106|PROCEDURE|Endovenous Laser ablation and sequential phlebectomies|
48097267|NCT05962385|DEVICE|Brain state while receiving TMS|Brain state whilst receiving TMS - cognitive control or perceptual. Repeated measures design, so all participants receive the same procedures.
48097268|NCT00507208|DEVICE|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
48097269|NCT00507208|OTHER|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
48097270|NCT03163862|PROCEDURE|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
48097271|NCT03163862|DRUG|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
48097272|NCT03163862|DRUG|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
48097273|NCT06630507|BEHAVIORAL|Educational module|1 hour pre-recorded educational module created by Dr. Sharma.
48097274|NCT00003743|BIOLOGICAL|aldesleukin|
48097275|NCT06630793|RADIATION|IMPT (Intensity Modulated Proton Therapy)|Proton therapy is a form of radiation treatment in which high doses can be delivered within the tumour while relatively sparing the surrounding normal tissues. This may help further reduce the side-effects of radiation treatment observed with IMRT.
48097276|NCT06630793|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|The standard management of carcinoma of the anal canal is radiotherapy using the IMRT technique along with concurrent chemotherapy. The use of IMRT has reduced the treatment-related side-effects as compared to older radiation techniques. However, further reducing these side effects poses a major challenge.
48097277|NCT02462655|OTHER|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
48097278|NCT02462655|OTHER|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
48097279|NCT05579080|DEVICE|noninvasive ventilation|The medical records whose patients used some type of non-invasive ventilatory device and devices that promote oxygen supplementation will be analyzed.
48097280|NCT06290544|OTHER|Standard of care plus additional examinations|The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies
48272195|NCT03866187|DRUG|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
48443993|NCT03968172|BEHAVIORAL|Control group programme|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~1. Disease progression~2. Invisible symptoms of multiple sclerosis~3. Symptomatic therapy~4. Immunotherapy decision support~5. Coping strategies~6. Autonomy~7. Fatigue~8. Quality of life~9. Physical activity~10. Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
48443994|NCT01746485|DRUG|UT-15C|
48443995|NCT05952986|DRUG|FB825 or Placebo in subcutaneous route|FB825 or placebo solution for SC injection
48443996|NCT05952986|DRUG|FB825 in intravenous route|FB825 solution for IV infusion
48443997|NCT03289845|DEVICE|BHX implant (Bone anchored hearing system)|Bone anchored hearing system for hearing rehabilitation
48097281|NCT04797533|DEVICE|The Body Information Management Systems (BIMS)|"The Body Information Management Systems (BIMS) are advanced biological sensors which monitor human behaviour, activity and basic vital signs. There is a combination of four separate ultra-sensitive weighing scales attached to each of the individual legs of a hospital bed measuring:~* Micro-changes in weight distribution~* Activity/sleep pattern~In addition to the bed-based system, there will be a wrist worn wearable (Samsung fit gear) that will monitor participants when they are both in and out of bed. These are about the size of a small watch, light weight, water resistant, and will be worn 24/7 by participants. These measure:~* Movement and sleep~* Heart rate"
48097282|NCT06628479|OTHER|interleukin, enzyme, hormone|Relaxin, MMP-2 and IL-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples
48097283|NCT05629091|DEVICE|FibDex|Nanofibrillar cellulose wound dressing
48097284|NCT05629091|DEVICE|Epicite hydro|Wound dressing
48097285|NCT05629091|DEVICE|Epiprotect|Wound dressing
48097286|NCT03404609|DEVICE|MagPro X100 by MagVenture|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
48097287|NCT04007302|OTHER|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
48097288|NCT04007302|OTHER|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
48097289|NCT04007302|OTHER|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
48097290|NCT05358730|OTHER|Standard Exercise|Glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises were performed under the supervision of a physiotherapist two days per week for six weeks at the clinical setting (Celik and Kaya Mutlu, 2016).
48097291|NCT05358730|OTHER|Instrument Assisted Soft Tissue Mobilization (IASTM)|IASTM treatment was applied to the posterior-anterior-middle deltoid, latissimus dorsi, teres major, teres minor, supraspinatus and infraspinatus muscle fibers, superficial and deep fascia. IASTM was applied in parallel and vertical direction to the muscle fibers treated with the instrument at a 45° angle, each technique (SWEEP, BRUSH (straight short steps) techniques) for 20 seconds (Ikeda, Otsuka, Kawanishi, and Kawakami, 2019). It was performed two days per week for six weeks.
48097292|NCT05358730|OTHER|Home Exercise|"Hme exercise program consisted of glenohumeral exercises, scapulothoracic exercises, stretching exercises and mobilization exercises.~It was asked to perform two days per week for six weeks."
48097293|NCT05824351|DEVICE|Tanzanian beeswax-pine resin|Thin ring of adhesive in the form of a Tanzanian beeswax-pine resin formula.
48097294|NCT05824351|DEVICE|Domestic beeswax-pine resin|Thin ring of adhesive in the form of a domestic beeswax-pine resin formula.
48097295|NCT05824351|DEVICE|Hollister's AdaptTM Barrier Rings|Thin ring of adhesive in the form of Hollister's AdaptTM Barrier Rings.
48097296|NCT00306683|DRUG|DIAZOXIDE|
48106795|NCT03939819|DEVICE|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
48443998|NCT01207986|RADIATION|Low dose computed tomography (CT)|
48097297|NCT04798521|OTHER|Tele-HCV|Patients will be prescribed HCV medication treatment for 4 weeks at a time. The study pharmacist will check in with the participant by telephone or telemedicine visit at week 0, week 4, and end of treatment to 1) determine general medication tolerance, 2) assess quality of adherence and 3) dispense medications. Peers will assist participants in keeping telehealth appointments and navigating medication pick up or storage. HCV labs will be repeated at 12 weeks post end of treatment and results will be relayed to the participant in the SVR12 follow up visit with the research assistant, along with follow up surveys. Those successfully achieving SVR12 will be counseled on ongoing harm reduction methods. Those showing persistent HCV viremia at 12 weeks post treatment will be referred to community-based HCV treatment providers for treatment re-initiation.
48097298|NCT04798521|OTHER|Community Linkage to Care|Following study inclusion and enrollment, research staff will refer the participant to a local community health clinic to engage in hepatitis C care and seek treatment. Peers will assist patients to engage with local primary care and health plan resources and will receive an information sheet on optional clinics to attend and questions to ask their provider.
48097299|NCT00021112|DRUG|cisplatin|
48097300|NCT00021112|DRUG|etoposide|
48097301|NCT00021112|PROCEDURE|conventional surgery|
48097302|NCT00021112|RADIATION|radiation therapy|
48097303|NCT01366196|DRUG|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
48097304|NCT01366196|DRUG|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
48097305|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
48097306|NCT04133363|PROCEDURE|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
48097307|NCT04133363|PROCEDURE|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
48097308|NCT01989442|DEVICE|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
48097309|NCT01989442|DEVICE|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
48097310|NCT02606734|DEVICE|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
48097311|NCT04617600|DRUG|MTA|Survival rate using MTA in cariously exposed vital primary molars
48097312|NCT04617600|DRUG|TheraCal PT|Survival rate using TheraCal PT in cariously exposed vital primary molars
48097313|NCT04832646|PROCEDURE|atrial fibrillation ablation|persistent atrial fibrillation ablation with both AF and sinus rhythm map available
48097314|NCT06630988|OTHER|Failure rates|Describe the management failure rate for hand infections, including panariasis, phlegmons and arthritis.
48097315|NCT02978521|OTHER|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
48097316|NCT05926050|DIETARY_SUPPLEMENT|Treatment (CopaPrime+ (USANA Health Sciences)|Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
48620304|NCT04294823|DIAGNOSTIC_TEST|Helicobacter Pylori Diagnostic|"Helicobacter Test INFAI with standard test Meal (1g citric acid as test meal and 75 mg C\^13 urea)~+ The C\^13 UBT with the new test (REFEX). All patients will take Nexium mups (40 mg) orally once daily 30 min before breakfast from day 1 to 28."
48097317|NCT05926050|OTHER|Placebo|Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
48097318|NCT03781804|DRUG|OPN-375|OPN-375, BID
48097319|NCT01535430|DIAGNOSTIC_TEST|Brain mapping|Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
48097320|NCT00542386|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
48097321|NCT00542386|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
48097322|NCT04831580|DEVICE|da Vinci|Minimally invasive robotic-assisted radical or simple hysterectomy
48097323|NCT04831580|OTHER|open surgery|open radical or simple hysterectomy
48097324|NCT04654936|BEHAVIORAL|MIND diet|12 week MIND diet study: Participants access a website that is theory driven using the Behaviour Change Wheel to help motivate and promote MIND diet adherence. Participants are to consume MIND diet foods daily and meet MIND diet weekly recommendations
48097325|NCT04654936|BEHAVIORAL|MIND diet with no support|Participants are to consume MIND diet food recommendations over a 12 week period with no support except for a self-monitoring resource and MIND diet guidelines
48443999|NCT01979861|DEVICE|AEGEA Vapor System(TM)|vapor endometrial ablation
48620305|NCT04294823|DEVICE|Vital signs measurments|No description;
48620306|NCT04294823|DIAGNOSTIC_TEST|endoscopy|Upper endoscopy where 6 biopsy samples will be obtained . Two biopsies will be taken from antrum and corpus for histology. The biopsies will be stained with Haematoxylin \& Eosin and Giemsa stains, and gastritis wilt be scored using the Updated Sydney System 12,13 Two biopsies will be taken from antrum and corpus for rapid urease test (RUT) and two biopsies will be taken from antrum and corpus for culture. All biopsy samples will be analysed in the local laboratory of the centre.
48097326|NCT01723436|OTHER|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
48620307|NCT04294823|DRUG|Nexium Pill|patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
48097327|NCT03296371|PROCEDURE|Biospecimen Collection|Undergo saliva or buccal mucosa collection
48097328|NCT03296371|OTHER|Laboratory Biomarker Analysis|Correlative studies
48097329|NCT03296371|OTHER|Questionnaire Administration|Ancillary studies
48097330|NCT01769391|DRUG|Necitumumab|Administered IV
48097331|NCT01769391|DRUG|Paclitaxel|Administered IV
48097332|NCT01769391|DRUG|Carboplatin|Administered IV
48097333|NCT04473950|DRUG|Naloxone Hydrochloride|An intramuscular (IM) injection of naloxone will be given.
48097334|NCT04473950|DRUG|Placebo|An IM injection of 0.9% normal saline will be given.
48097335|NCT02703129|OTHER|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
48097336|NCT05819190|DEVICE|Healsea Rescue*|Subjects will be administered with Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
48097337|NCT05819190|DEVICE|Placebo|Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
48097338|NCT03054220|DRUG|Dextromethorphan 5 MG|
48097339|NCT03054220|DRUG|Tramadol 10 mg|
48097340|NCT03054220|DRUG|Duloxetine 60mg|
48097341|NCT03054220|DRUG|Paroxetine 20 mg|
48097342|NCT06630468|OTHER|Task-oriented occupational therapy (TOOT)|The task-oriented occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
48097343|NCT06630468|OTHER|Control group|Routine upper-extremity-based occupational therapy intervention was applied to individuals in the TOOT group in the form of 30-minute sessions, 5 consecutive days a week, over 4 weeks.
48097344|NCT03722433|DRUG|Vigiis 101-LAB and sequential therapy|Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
48272196|NCT04460755|OTHER|Control group|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
47914166|NCT04508088|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at echo times of 20, 30, 40, and 50 ms using 32 signal averages per echo time with a TR of 2.5 s (total scan time = 5.4 minutes). Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
48097345|NCT03722433|DRUG|Placebo and sequential therapy|Placebo without Vigiis 101-LAB component
48097346|NCT02714829|DEVICE|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
48097347|NCT02714829|DEVICE|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
48097348|NCT02516176|BEHAVIORAL|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
48097349|NCT04059562|COMBINATION_PRODUCT|Combination of Lonsurf® and Irinotecan|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan~* Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~* Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
48097350|NCT04363762|BEHAVIORAL|Internet-based multimodal pain program|A guided internet-based multimodal pain program for chronic TMD pain
48097351|NCT04363762|DEVICE|Occlusal splint|Occlusal splint, standard
48097352|NCT06518499|PROCEDURE|Pilonidal sinus surgery|Bascom's Pit-Pick procedure, Primary Closure, Karydakis procedure
48097353|NCT03901729|DRUG|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
48097354|NCT03901729|OTHER|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
48097355|NCT03901729|DRUG|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
48097356|NCT03901729|OTHER|Placebo Furosemide|Tablet; Once daily in the morning; Oral
48097357|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
48097358|NCT00349908|DEVICE|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
48097359|NCT06629818|DRUG|Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)|qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12
48097360|NCT06629818|DRUG|Venetoclax|400mg po qd for 1 year
48097361|NCT06629818|DRUG|Dexamethasone|Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
48097362|NCT05097573|DEVICE|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, stretch marks, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 4 treatments approximately 4 weeks apart.
48097363|NCT04384146|RADIATION|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
48097364|NCT04384146|BEHAVIORAL|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
48097365|NCT04417712|DEVICE|KONAR-MF™ VSD Occluder|All patients will be implanted with a KONAR-MF™ VSD Occluder in accordance with the instructions for use (IFU).
48097366|NCT03368001|BEHAVIORAL|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
48097367|NCT03368001|BEHAVIORAL|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
48097368|NCT02543216|DIETARY_SUPPLEMENT|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
48097369|NCT04183166|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
48097370|NCT05751200|OTHER|No Intervention.|No Intervention.
48097371|NCT02266810|DEVICE|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
48097372|NCT02266810|PROCEDURE|Sinus Surgery alone|Sinus surgery only, without implant placement
48097373|NCT02266810|DEVICE|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
48097374|NCT00182416|DEVICE|pacemaker|
48097375|NCT02814266|OTHER|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
48097376|NCT02814266|OTHER|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
48097377|NCT03450876|OTHER|Non-Interventional|Non-Interventional
48097378|NCT00953485|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
48097379|NCT02844764|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Day 7, 14 and 30 \[PRP\]
48097380|NCT03043066|PROCEDURE|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
48097381|NCT03043066|DRUG|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
48097382|NCT04252066|DRUG|migalastat|This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
48097383|NCT02888613|PROCEDURE|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
48097384|NCT02888613|PROCEDURE|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
48097385|NCT06629064|BEHAVIORAL|Working Memory Training|Computer-administered working memory training program. WMT is a modified working memory capacity task designed to train working memory functioning. WMT is designed to contain high interference across trials and is adaptive to performance. As participants improve working memory, the task becomes more difficult.
48097386|NCT06629064|OTHER|Sham Training|The Sham condition requires participants to complete a similar computer task for the same length of time. The Sham Training is a modified working memory capacity task designed to place less demands on working memory.
48097387|NCT05730764|DIAGNOSTIC_TEST|Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making|With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
48620308|NCT02617095|DEVICE|T2762|One drop in each eye 3 to 6 times daily
48620309|NCT02617095|DEVICE|Optive|One drop in each eye 3 to 6 times daily
48097388|NCT05730764|DIAGNOSTIC_TEST|Clinicians follow a routine protocol|Treatment is performed by the clinician according to the usual protocol.
48097389|NCT05365529|BEHAVIORAL|Time-Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
48097390|NCT05365529|BEHAVIORAL|Standard of Care|Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
48097391|NCT01474538|DRUG|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
48097392|NCT01474538|DRUG|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
48097393|NCT00668174|BEHAVIORAL|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
48097394|NCT06098027|DRUG|[14C]CS0159|Single oral administration of 4mg \[14C\]CS0159
48097395|NCT02775981|DRUG|RX0041-002|
48097396|NCT00124826|DRUG|Insulin|
48097397|NCT02588482|DEVICE|high-density electroencephalography|Auditory stimulations during electroencephalography recording
48097398|NCT02588482|DEVICE|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
48097399|NCT02781584|DRUG|SEL|Administered orally once daily
48097400|NCT02781584|DRUG|FIR|Administered orally once daily
48097401|NCT02781584|DRUG|CILO|Administered orally once daily
48097402|NCT02781584|DRUG|FENO|Administered orally once daily
48097403|NCT02781584|DRUG|VAS|Administered orally two times daily
48097404|NCT03032796|BEHAVIORAL|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
48097405|NCT03032796|BEHAVIORAL|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
48097406|NCT03032796|BEHAVIORAL|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
48097407|NCT03032796|BEHAVIORAL|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
48097408|NCT06434857|PROCEDURE|Strength training in older adults with mild or non existent cognitive impairment|Strength training program applied to strength training group
48097409|NCT06434857|PROCEDURE|Multimodal excercise in older adults with mild or non existent cognitive impairment|Multimodal exercise program applied to multimodal exercise group
48097410|NCT02028130|PROCEDURE|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
48097411|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly
48097412|NCT01816113|BIOLOGICAL|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly
48097413|NCT01816113|BIOLOGICAL|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
48097414|NCT01816113|BIOLOGICAL|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
48097415|NCT03721016|DRUG|MT10109L|MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
48097416|NCT03721016|DRUG|Placebo|Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
48272197|NCT04460755|OTHER|Whitening toothpaste 1|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
48272198|NCT04460755|OTHER|Whitening toothpaste 2|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
48272199|NCT04460755|OTHER|Whitening toothpaste 3|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
48097417|NCT04215978|DRUG|BGB-A445|Administered as specified in the treatment arm
48097418|NCT04215978|DRUG|tislelizumab|Administered as specified in the treatment arm
48097419|NCT05582616|DEVICE|Transcranial Direct Current Stimulation|See treatment arm description
48097420|NCT05582616|DEVICE|Sham Transcranial Direct Current Stimulation|See sham comparator arm description
48272200|NCT04460755|OTHER|Whitening toothpaste 4|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
48272201|NCT04460755|OTHER|Whitening toothpaste 5|"A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study."
48097421|NCT06337110|DRUG|Lu AF28996|Oral solution containing radiolabelled \[14C\]-Lu AF28996.
48272202|NCT04141371|DRUG|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
48272203|NCT04141371|DRUG|physiological serum|daily saline infusion over 3 hours during the vasospasm period
48097422|NCT05520827|DRUG|BI 1584862|BI 1584862
48097423|NCT05520827|DRUG|Placebo|Placebo
48097424|NCT00420589|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
48097425|NCT00420589|DRUG|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
48097426|NCT05095428|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
48097427|NCT05095428|BEHAVIORAL|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
48097428|NCT06434051|OTHER|Traditional Chinese cervical manipulation|The CMP will first palpate the transverse processes of C1 and C2. The transverse process with apparent tenderness will be regarded as the pain side. The right side will be the painful side for the following example). During the manipulation, the CMP will use his left hand to support the lower jaw and passively rotate the neck to the left side by 70-75 degrees (or to the maximum angle without discomfort). The physician's right-hand fingers will support the left-side transverse processes of C1 and C2, and the thumb and thenar muscle will be placed on the spinous process and occipital area. While maintaining a passive left neck rotation, the physician will increase the rotation angle by 5-10 degrees with both hands under a sudden pulling force. The above procedure will be repeated on the right side (pain side).
48097429|NCT06434051|OTHER|Sham manipulation|The posture and position of the participant and the practitioner and the procedure are the same as the CCM technique. The right side will be regarded as the pain side once again. When performing the sham technique, the CMP uses the left hand to support the lower jaw position and passively rotates the neck to the left side by 70-75 degrees or to the maximum angle. The right hand presses the upper inner corner of the right scapula. While maintaining the passive left rotation of the neck, the right hand slowly exerts force downwards and outwards on the inner side of the scapula. The left hand only maintains the left rotation of the neck without any pulling force. After completion, repeat the above actions on the right side. After the technique is completed, participants can get up after resting for 5-10 minutes.
48097430|NCT06629480|DRUG|Bictegravir|The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. A randomized open clinical trial was developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC.
48097431|NCT04836793|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
48097432|NCT03613103|DEVICE|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
48097433|NCT03613103|DEVICE|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
48097434|NCT06220045|COMBINATION_PRODUCT|Polyvinylidene fluoride mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh."
48097435|NCT06220045|COMBINATION_PRODUCT|Prophylactic polypropylene mesh|"Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh."
48097436|NCT03425539|DRUG|Lucerastat|Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.
48097437|NCT03425539|DRUG|Placebo|Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
48097438|NCT06630208|OTHER|Myofascial release|The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.
48097439|NCT06630208|OTHER|Breathing exercises|Following the 3 phases of myofascial release, breathing exercises will be done for patients.
48272204|NCT02893345|BEHAVIORAL|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
48272205|NCT02893345|OTHER|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
48272206|NCT04847388|DRUG|Substance like alcohol, marijuana, etc.|Cohort study
48272207|NCT02195492|DRUG|Synvisc®|
48272208|NCT00739284|DEVICE|nephrostomy tube and ureteral stent|
48272209|NCT02154399|DRUG|EF5|Given IV
48272210|NCT02154399|OTHER|Laboratory Biomarker Analysis|Correlative studies
48272211|NCT02154399|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
48272212|NCT02154399|OTHER|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
48272213|NCT03967821|OTHER|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
48272214|NCT00746499|DRUG|Raltegravir|400mg raltegravir BID x 7 days
48272215|NCT03032783|RADIATION|Total-Body Irradiation|Undergo Total Body Irradiation
48272216|NCT03032783|PROCEDURE|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
48272217|NCT03032783|DRUG|Cyclophosphamide|Given IV
48272218|NCT03032783|DRUG|Tacrolimus|Given IV
48272219|NCT03032783|DRUG|Mycophenolate Mofetil|Given IV
48272220|NCT03032783|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
48097440|NCT06630208|DRUG|Pharmacological treatment|Patients will take pharmacological treatment prescribed by the cardiologist.
48097441|NCT00000456|DRUG|naltrexone (Revia)|
48097442|NCT00000456|BEHAVIORAL|cognitive behavior therapy|
48097443|NCT00000456|BEHAVIORAL|motivational enhancement therapy|
48097444|NCT06616688|OTHER|Organoid-guided treatment|After specimen removal as per clinical practice and pathological examination, a small piece of tumor tissue will be sent to the Axo-Glial Interaction Unit and cultured to build up organoid cultures
48097445|NCT04581837|DIAGNOSTIC_TEST|2D-speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography (2D-STE) allows for an angle-independent evaluation of myocardial strain, and provides comprehensive information on LV myocardial contractility. Thus, 2DSTE is superior in detecting subtle deteriorations of contractility. we will take 2D speckle tracking views for LV and RV strain (4ch, 2ch, 3ch, RV modified view).
48272221|NCT00826813|DEVICE|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
48272222|NCT02771834|OTHER|Biomechanical analysis|
48272223|NCT02771834|OTHER|Kiphosis analysis|
48272224|NCT02771834|OTHER|Vitamin D level|
48272225|NCT04488237|DRUG|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
48272226|NCT05594784|DRUG|Olverembatinib|a third-generation TKI
48272227|NCT05594784|DRUG|Venetoclax|a selective inhibitor of B-cell lymphoma 2 (Bcl-2)
48272228|NCT05594784|DRUG|prednisone|Glucocorticoids
48272229|NCT05594784|DRUG|Vincristine|Anti-tumor alkaloids
48272230|NCT00834054|PROCEDURE|Double-lung transplantation|Double-lung transplanted patients
48097446|NCT00119899|PROCEDURE|FDG-PET scan|
48097447|NCT04330443|PROCEDURE|Surfactant therapy|To study if lung ultrasound allows an earlier surfactant therapy (within the first 2 hours of life) compare to FiO2 and Chest X Ray
48097448|NCT04599114|BEHAVIORAL|VIRTUES|VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
48097449|NCT03172208|BIOLOGICAL|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
48272231|NCT01286584|DRUG|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
48272232|NCT01286584|DRUG|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
48272233|NCT03420534|DRUG|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
48272234|NCT03420534|DRUG|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
48272235|NCT03420534|DIETARY_SUPPLEMENT|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
48272236|NCT03420534|DIETARY_SUPPLEMENT|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
48272237|NCT01268293|DRUG|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
48272238|NCT02140255|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
48272239|NCT02140255|DRUG|Nevirapine (NVP)|Administered orally. Dosed according to study step/participant's age/participant's weight.
48097450|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
48272240|NCT02140255|DRUG|Lopinavir/Ritonavir (LPV/r)|Administered orally. Dosed according to study step and participant's age.
48272241|NCT02140255|DRUG|Raltegravir (RAL)|Administered orally. Dosed according to study step and participant's age.
48272242|NCT02140255|DRUG|VRC01|40 mg/kg administered subcutaneously.
48272243|NCT02140255|DRUG|DTG|Administered orally. Dosed according to participant's weight.
48272244|NCT02140255|DRUG|VRC07-523LS|40 mg/kg administered subcutaneously.
48272245|NCT01239407|BEHAVIORAL|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
48272246|NCT01219842|PROCEDURE|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
48272247|NCT01219842|OTHER|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
48272248|NCT05136833|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
48272249|NCT05136833|BIOLOGICAL|Placebo|Normal saline will be used as a placebo.
48272250|NCT06148961|PROCEDURE|botox prior to modified lip repostioning|"botox injection prior to surgical intervention by 5 to 10 days A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
48272251|NCT00923637|DRUG|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
48097451|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
48097452|NCT03172208|BIOLOGICAL|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
48097453|NCT03172208|OTHER|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
48097454|NCT03172208|OTHER|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
48097455|NCT03172208|OTHER|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
48097456|NCT06631118|PROCEDURE|pericapsular nerve group block for group A,low dose intravenous Propofol [0.7mg/kg] over 30 seconds for group B|Patients in group A will receive ultrasound guided pericapsular nerve group block (PENG) while patients in group B will receive low dose intravenous Propofol0.7mg/kg\] over 30 seconds followed by spinal anesthesia in both groups
48097457|NCT03666741|DEVICE|AVR with or without CABG|Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™
48097458|NCT06629805|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
48097459|NCT06629805|DIETARY_SUPPLEMENT|Placebo|Placebo 1,000 mg/day for 12 weeks
48272252|NCT03607721|DEVICE|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
48272253|NCT04003610|DRUG|Pemigatinib|13.5 mg once a day orally
48272254|NCT04003610|DRUG|Pembrolizumab|200 mg Q3W intravenously
48272255|NCT04003610|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
48272256|NCT04003610|DRUG|Carboplatin|Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
48097460|NCT02896894|OTHER|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
48620310|NCT05443854|DRUG|Aminoglycosides intervention|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation."
48097461|NCT05895929|DRUG|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
48097462|NCT06083480|DRUG|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
48097463|NCT06083480|DRUG|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
48097464|NCT04046523|DEVICE|Video ophthalmoscope|Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
48097465|NCT02690103|DRUG|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
48097466|NCT02690103|DIETARY_SUPPLEMENT|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
48272257|NCT01838044|DRUG|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
48272258|NCT01838044|DRUG|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
48272259|NCT02498210|OTHER|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
48272260|NCT01413958|DRUG|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
48272261|NCT01413958|DRUG|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
48097467|NCT02690103|DRUG|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
48097468|NCT01124162|DRUG|Losartan|100 mg Tablet
48097469|NCT01124162|DRUG|Cozaar®|100 mg Tablet
48097470|NCT01106729|DIETARY_SUPPLEMENT|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
48097471|NCT04927975|DRUG|Upadacitinib|Oral tablets
48097472|NCT04927975|DRUG|Placebo|Oral tablets
48097473|NCT03302156|DRUG|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
48097474|NCT01484106|OTHER|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
48097475|NCT01484106|OTHER|Standard of Care|Standard of Care
48097476|NCT02260739|OTHER|Blood samples|
48272262|NCT01413958|DRUG|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
48272263|NCT00321165|DRUG|taurolidine|
48272264|NCT00247104|DRUG|Cranberries - Vaccinium macrocarpon|
48272265|NCT04417257|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
48097477|NCT05688280|DRUG|1.0% IP-001 for Injection|4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
48097478|NCT06288152|DRUG|Sodium Thiosulfate|0.15 mL administered
48097479|NCT06177795|BEHAVIORAL|Post-visit patient text messaging|Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
48097480|NCT06177795|BEHAVIORAL|Default pended order|A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
48097481|NCT06177795|BEHAVIORAL|High risk bidirectional post-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit. This intervention will query the patient about common questions or concerns about breast cancer screening. The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
48106796|NCT03939819|DEVICE|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
48272266|NCT04417257|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
48620311|NCT05443854|BEHAVIORAL|Lack of protective isolation intervention|"Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated"
48097482|NCT04820582|OTHER|Delphi Questionnaire|Evaluation of a list of PROMs and CROMs specific for endometriosis (previously selected from a litterature review) on a Likert scale of 1 to 9 for their relevance and feasibility
48097483|NCT02466295|OTHER|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
48097484|NCT02466295|OTHER|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
48097485|NCT02393898|DRUG|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
48097486|NCT02393898|DRUG|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
48097487|NCT02393898|DRUG|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
48097488|NCT00470795|OTHER|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
48097489|NCT00470795|PROCEDURE|placebo/sham acupuncture|acupuncture at sham points without skin penetration
48097490|NCT04679363|OTHER|Active release technique|ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
48097491|NCT04679363|OTHER|Post isometric relaxation|PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
48097492|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (EnzySystem HemA version A - whole blood)|Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.
48097493|NCT06357572|DIAGNOSTIC_TEST|Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)|Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.
48097494|NCT06357572|DIAGNOSTIC_TEST|Additional coagulation tests|"Plasma samples are frozen for later coagulation testing. The following tests are performed:~Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay"
48097495|NCT06281717|DEVICE|Fetal Endotracheal Occlusion (FETO)|The FETO insertion procedure will be performed between gestational age 27 weeks 0 days and 29 weeks and 6 days. The Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus using the Delivery Microcatheter (BALTACCI-BDPE100). The fetal tracheal balloon will be removed between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
48097496|NCT02870270|OTHER|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
48097497|NCT03137914|BIOLOGICAL|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
48097498|NCT03137914|PROCEDURE|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
48097499|NCT01119950|DRUG|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
48097500|NCT01119950|DRUG|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
48097501|NCT01119950|DRUG|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
48097502|NCT01119950|DRUG|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
48097503|NCT01119950|DRUG|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
48097504|NCT01119950|DRUG|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
48097505|NCT01119950|DRUG|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
48097506|NCT01119950|DRUG|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
48097507|NCT02324114|DEVICE|Hsp90|Detect plasma Hsp90α concentration
48097508|NCT04815824|BEHAVIORAL|Exercise Mode|Stationary cycling or treadmill walking
48272267|NCT00856310|BIOLOGICAL|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
48272268|NCT06277973|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention is based on EMDR therapy for PTSD treatment. Participants will answer demographic questions, choose a primary distress source and watch a therapist-guided video (male or female, based on participant choice) that will instruct them through the 'Butterfly Hug' method (tapping alternately on both sides of the body) while hearing positive statements from the therapists on the chosen distress source. Before and after each video participants will rate their distress level on a scale between 0 and 10 and they can view up to 8 videos per session. The system will monitor distress levels, and if it detects a sustained deterioration, it will end the intervention. At the end of the intervention, participants will be given information about possible reactions to it and how to deal with them, they will be encouraged to use the technique whenever necessary, and they will be informed of relevant support lines that they can contact if needed.
48272269|NCT00688909|DRUG|letrozole|2.5 mg daily by mouth for 6 months
48272270|NCT05763602|DRUG|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
48272271|NCT04068857|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
48272272|NCT00562809|DRUG|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
48272273|NCT03494647|DEVICE|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
48272274|NCT03494647|DEVICE|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
48272275|NCT00914381|BEHAVIORAL|Behavioral therapy|
48272276|NCT05881382|DRUG|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
48272277|NCT05881382|DRUG|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
48272278|NCT04876547|PROCEDURE|appendectomy|appendectomy performance
48272279|NCT00709826|DRUG|gemcitabine|Gemcitabine: per package insert.
48272280|NCT00709826|DRUG|placebo|placebo: 100 mg tablets, 400 mg/day
48272281|NCT00709826|DRUG|Erlotinib|Erlotinib - per package insert.
48272282|NCT00709826|DRUG|apricoxib|apricoxib: 100mg tablets, given orally
48272283|NCT05415748|DRUG|Tamsulosin|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
48272284|NCT05415748|DRUG|Placebo|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
48272285|NCT01586988|BEHAVIORAL|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
48272286|NCT05163704|DRUG|Dexmedetomidine|Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
48272287|NCT04134650|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
48272288|NCT04134650|DRUG|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
48272289|NCT05759884|DRUG|Anti-VEGF|Intravitreous injection of anti-VEGF drugs
48272290|NCT05759884|RADIATION|subthreshold micropulse laser|577nm micropulse laser photocoagulation therapy
48272291|NCT02109081|DRUG|Dexamethasone|
48272292|NCT02109081|DRUG|Placebo|
48272293|NCT04409678|BEHAVIORAL|activity|physical activity
48272294|NCT03773302|DRUG|BGJ398|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
48272295|NCT03773302|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
48272296|NCT03773302|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
48272297|NCT03716479|OTHER|Low Fiber|20 g of acacia gum will be added to orange juice
48272298|NCT03716479|OTHER|High Fiber|40 g of acacia gum will be added to orange juice
48272299|NCT03716479|OTHER|Placebo/Control|No acacia gum will be added to orange juice.
48272300|NCT01906749|DRUG|Colchicine|0.5mg once daily orally
48272301|NCT01906749|DRUG|Placebo|
48272302|NCT00298714|DRUG|Losartan|
48272303|NCT00820326|DRUG|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
48272304|NCT00820326|DRUG|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
48272305|NCT00003417|DRUG|carmustine|
48272306|NCT00003417|RADIATION|radiation therapy|
48272307|NCT01712347|DRUG|Bevacizumab|Bevacizumab will be administered as per approved label.
48272308|NCT01712347|DRUG|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
48272309|NCT03052647|DEVICE|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
48272310|NCT03052647|DEVICE|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
48272311|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
48272312|NCT03303989|DRUG|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
48272313|NCT03303989|DRUG|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
48272314|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
48272315|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
48272316|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
48272317|NCT03679403|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
48097509|NCT02949817|DEVICE|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
48097510|NCT02949817|OTHER|Conventional OT group|2. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
48097511|NCT06628492|DEVICE|stainless steel printed surgical guide|the patient will wear the stainless steel surgical guide for the insertion of one implant
48097512|NCT06628492|DEVICE|resin printed surgical guide|the patient will wear the resin surgical guide for insertion of adjacent another implant implant
48097513|NCT02908464|DEVICE|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
48097514|NCT03247348|BEHAVIORAL|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
48097515|NCT06206473|OTHER|mEEG assessment|mEEG assessment (V1) will be performed at the patient's bed within 72 hours of the diagnosis of delirium. The mEEG recording, which lasts approximately 2 hours, will be performed by one of the investigators with expertise in electrophysiological acquisition. This non-invasive assessment consists of placing an EEG net on the scalp of the participants and earphones through which the auditory stimuli will be delivered.
48097516|NCT05584124|DEVICE|High frequency repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
48097517|NCT05584124|DEVICE|Sham repetitive transcranial magnetic stimulation|MAGSTIM Super Rapid2 Plus
48097518|NCT06617689|OTHER|Various levels of patient education|"The three interventions:~GROUP BASED TEACHING In groups of 8-12 patients, 30 minutes of standardised teaching is given. The teaching focuses in particular on the changes in diet and the impact this has on oral pH, enamel erosion and caries; recommended oral hygiene; and good drinking habits.~WEBSITE Website providing recommendations for oral hygiene and drinking habits, as well as in depth information on the topic.~DENTAL HYGIENE SAMPLES These are samples relevant for maintaining proper oral hygiene, distributed free, together with a description of how to use them."
48097519|NCT04910269|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
48097520|NCT04910269|OTHER|Placebo|Infusion of 35 milliliters standard isotonic saline
48097521|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
48097522|NCT04570761|DEVICE|Dreem headband|acoustic stimulation
48097523|NCT04651361|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
48620312|NCT05443854|OTHER|No systematic aminoglycosides intervention - standard arm|"Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides."
48620313|NCT05443854|OTHER|Protective isolation intervention - standard arm|"Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~1. High-efficiency air filtration \[filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better\]~2. Geographical isolation in an individual room~3. Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care"
48620314|NCT02632214|OTHER|fMRI measure|
48097524|NCT04651361|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
48097525|NCT06631651|PROCEDURE|Brachioradialis release|During distal radius fracture surgery (open reduction+internal fixation) partial brachioradialis release from the insertion of brachioradialis muscle was performed in order to perform reduction of fracture
48097526|NCT06631651|PROCEDURE|Brachioradialis not released|During distal radius fracture surgery (open reduction+internal fixation) brachioradialis release was not performed.
48097527|NCT02258295|DRUG|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
48097528|NCT02258295|DRUG|Saline|Saline
48097529|NCT06398223|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA): Surgical procedure to remove the plaque buildup in the carotid artery.
48097530|NCT06398223|PROCEDURE|Carotid artery stenting|Carotid artery stenting: Treatment of the stenosis with a stent. The plaque in the artery wall is not removed but the narrowing is dilated.
48097531|NCT05658562|DRUG|MT-2111|i.v. infusion
48097532|NCT00049517|BIOLOGICAL|sargramostim|Given IV or as an injection
48097533|NCT00049517|DRUG|busulfan|Given IV
48097534|NCT00049517|DRUG|cyclophosphamide|Given IV
48097535|NCT00049517|DRUG|cytarabine|Given as a continuous infusion
48097536|NCT00049517|DRUG|gemtuzumab ozogamicin (GO)|Given IV
48097537|NCT00049517|DRUG|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
48097538|NCT00049517|PROCEDURE|Autologous HCT|Autologous hematopoietic cell transplantation
48097539|NCT00049517|PROCEDURE|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
48097540|NCT05795829|DEVICE|disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument|Disposable intravascular ultrasound ablation catheters (used with an ultrasound ablation instrument) can use ultrasound energy to block sympathetic activity in the renal arteries.
48097541|NCT06629597|DRUG|YL201|YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.
48097542|NCT06629597|DRUG|Docetaxel|Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.
48097543|NCT06629597|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
48097544|NCT06629597|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
48097545|NCT00782041|DRUG|Oxaliplatin|85 mg/m²
48097546|NCT00782041|DRUG|5-FluoroUracil|2,000 mg/m²
48097547|NCT00782041|DRUG|Folinic acid|20 mg/m²
48097548|NCT04109690|DRUG|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
48097549|NCT01131247|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
48097550|NCT06388447|BIOLOGICAL|Umbilical cord-mesenchymal stem cells|One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
48097551|NCT05903066|PROCEDURE|Magnetic Resonance Enterography (MRE)|MRE performed as part of the standard of care follow up of the patient, the exam will be recorded for the study and analysed by central readers.
48620315|NCT01020422|PROCEDURE|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
48097554|NCT02111343|OTHER|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
48097555|NCT06406933|DRUG|Carbomer Gel/Jelly|The drug is for dry eye syndrome by providing temporary relief from discomfort and irritation.
48097556|NCT06433895|OTHER|Manual Therapy|Manual Therapy
48272318|NCT03804541|DRUG|Ensartinib|A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
48097557|NCT06433895|OTHER|Exercise|Isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation
48097558|NCT04679935|BIOLOGICAL|Brolucizumab|Intravitreal injection
48097559|NCT02755363|OTHER|osteopathic manual therapy|"* suboccipital decompression - atlanto-occipital joint relaxation technique.~* deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~* thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~* stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
48097560|NCT02755363|OTHER|control group|"* manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~* manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
48097561|NCT04094064|DEVICE|Continuous Glucose Monitor|Use of a continuous glucose monitor during study period.
48097562|NCT06306365|BEHAVIORAL|Modern board game-based learning|Modern board game-based learning involves using contemporary board games as educational tools. It emphasizes active participation, critical thinking, and social interaction among participants. By integrating strategic thinking and problem-solving within a game context, this approach aims to enhance learning experiences in an engaging and enjoyable manner. In this study, board games have been selected to target and engage executive functions.
48097563|NCT03617107|OTHER|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
48097564|NCT05478863|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants.
48097565|NCT05478863|DRUG|Oral THC|THC will be orally self-administered by study participants.
48097566|NCT05478863|DRUG|Oral CBD|CBD will be orally self-administered by study participants.
48097567|NCT05478863|DRUG|Oral Caffeine|Caffeine will be orally self-administered by study participants.
48097568|NCT00290706|DRUG|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
48097569|NCT00290706|DRUG|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
48097570|NCT03615001|DEVICE|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
48097571|NCT04455048|OTHER|Cervicothoracic thrust manipulation|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. Thrust manipulation will be applied at the end of exhale.
48097572|NCT04455048|OTHER|Cervicothoracic thrust manipulation sham|The patient will be positioned in a supine position with arms crossed over over the trunk and holding the shoulders. The therapist will place a stabilizing hand over transverse process of T1 in pistol grip and contacted patients elbow with sternum and patient will be asked do a hip bridge while taking a deep breath than exhale. A soft compression will be applied at the end of exhale without a thrust.
48097573|NCT00002620|DRUG|carmustine|
48097574|NCT00002620|DRUG|chemotherapy|
48097575|NCT00002620|DRUG|mitolactol|
48097576|NCT00002620|RADIATION|low-LET cobalt-60 gamma ray therapy|
48620316|NCT00583544|DRUG|TC-2216|Multiple ascending dose groups will be explored.
48097577|NCT00002620|RADIATION|low-LET photon therapy|
48097578|NCT00553215|PROCEDURE|quality-of-life assessment|
48097579|NCT00553215|PROCEDURE|questionnaire administration|
48097580|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 1|Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland
48097581|NCT05926765|GENETIC|AAV2-hAQP1 Concentration 2|Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland
48097582|NCT05926765|OTHER|Placebo|Administration of diluent via Stensen's duct to each parotid gland
48097583|NCT05380531|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
48097584|NCT06628427|DIAGNOSTIC_TEST|MoCA Test|MoCA (Montreal Cognitive Assessment or The MoCA Test) was validated as a highly sensitive tool for early detection of mild cognitive impairment (MCI) in hundreds of peer-reviewed studies since 2000. MoCA has been widely adopted in clinical settings and used in academic and non-academic research around the world. The sensitivity of MoCA for detecting MCI is 90%, compared to 18% for the MMSE. Prospective participants meeting the eligibility criteria, as determined by the Montreal Cognitive Assessment (MoCA) test, will be invited to the Brain- Computer Interface (BCI) laboratory at the Kroto Research Centre on the University of Sheffield north campus to participate in the study.
48097585|NCT06628427|DEVICE|Random Dot Motion (RDM) task|Random Dot Motion task (RDM) has been widely used in research on spatial attention, and decision-making ability, etc., and its results (accuracy and reaction time) can be used as indicators to detect spatial attention. During the assessment, participants were required to monitor a series of dots in constant random motion on the screen. The dots sometimes moved coherently together to the left or right, and participants were required to press the left mouse button when they perceived them moving to the left and the right mouse button when they observed them moving to the right. We are going to use the motion coherence level of 50%. The higher the coherence level, the greater the number of dots moving together, and the combination of the moving direction and coherence level of the dots appear randomly during the task.
48097586|NCT06628427|DEVICE|P300-BCI task without feedback|Two different speller matrix sizes: 3×3 and 5×5, two inter-stimulus intervals (ISIs): 117ms (i.e., commonly used ISI for healthy adults) and 175ms (i.e., 50% longer than the widely used ISI) and two spelling words (QUICK and JUMP) are designed in this experiment to explore the calibration accuracy of these eight parameter combinations in the young and old groups and obtain the best parameter combination. The matrix contains letters and digits, and the target letters will be displayed below the matrix letter by letter. When the speller runs, the rows and columns in the matrix will flash 15 times each randomly. Each flash will last for 55ms, and the subsequent ISI will last for different times according to different parameter designs. Participants only need to focus on the target letter and silently count the number it flashes, as flashing target letters can generate P300 if well attended.
48097587|NCT00282438|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
48272319|NCT02866864|OTHER|Animal allergy +|Allergic symptom occurs when subject contact animal
48620317|NCT01101100|DRUG|AMG 827|210 mg SC or 140 mg SC
48097588|NCT00282438|BIOLOGICAL|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
48097589|NCT06083233|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and cerebrospinal fluid sampling (sample 1 in measurement)
48097590|NCT06083233|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
48097591|NCT06083233|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
48097592|NCT06083233|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of cerebrospinal fluid (5 days, 1 month a 2 months after surgery)
48097593|NCT06083233|PROCEDURE|Blood sampling #1|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours prior surgery
48272320|NCT02866864|OTHER|Animal allergy -|Allergic symptom does not occur when subject contact animal
48097594|NCT06083233|PROCEDURE|Blood sampling #2|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 24 hours after surgery
48097595|NCT06083233|PROCEDURE|Blood sampling #3|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 5 days after surgery
48097596|NCT06083233|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of biomarkers (NfL, NfH, NSE, S100, Tau, beta-amyloid) from standardized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
48097597|NCT06500286|DRUG|Marciane|Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
48097598|NCT06500286|DRUG|Marcaine|Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
48097599|NCT02180113|DEVICE|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
48097600|NCT04928872|COMBINATION_PRODUCT|Predefined meal|Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
48097601|NCT06410508|OTHER|Just Do You|"As described in further detail previously, the experimental intervention is a brief psychotherapeutic intervention informed by principles of CBT and motivational interviewing that is co-delivered by a mental health clinician and peer support worker. This intervention will be a version of the initial intervention delivered in the Just Do You trial by Munson et al.(2022), adapted for increased suitability with our clinical population."
48097602|NCT05886751|OTHER|Black Doctor Screening Video|Participants will view an online video with a Black doctor speaking about prostate cancer screening.
48097603|NCT05886751|OTHER|White Doctor Screening Video|Participants will view an online video with a White doctor speaking about prostate cancer screening.
48097604|NCT05886751|OTHER|Black Patient Screening Video|Participants will view an online video with a Black patient speaking about prostate cancer screening.
48097605|NCT05886751|OTHER|White Patient Screening Video|Participants will view an online video with a White patient speaking about prostate cancer screening.
48097606|NCT05886751|OTHER|Black Doctor Clinical Trials Video|Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
48272321|NCT02935972|DRUG|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
48272322|NCT02935972|DRUG|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
48097607|NCT05886751|OTHER|White Doctor Clinical Trials Video|Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
48097608|NCT05886751|OTHER|Black Patient Clinical Trials Video|Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
48097609|NCT05886751|OTHER|White Patient Clinical Trials Video|Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
48097610|NCT01588015|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given SC
48097611|NCT01588015|OTHER|laboratory biomarker analysis|Correlative studies
48097612|NCT00849147|BIOLOGICAL|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~* Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
48097613|NCT00849147|BIOLOGICAL|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~* Cy: 50 mg/kg IV on Days 3 and 4~* Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~* Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~* Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm\^3 for 3 consecutive days"
48097614|NCT06629493|BEHAVIORAL|Fitbit Versa 3|Fitbit Versa 3 is a commercially available activity tracker
48097615|NCT06629493|BEHAVIORAL|In-patient alcohol use disorder treatment|In-patient alcohol use disorder treatment, including group therapy, counseling, and occupational activities
48272323|NCT02935972|DRUG|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
48272324|NCT02930174|DEVICE|noninvasive positive pressure ventilation|Application of various levels of positive pressure
48272325|NCT04453735|DRUG|Atorvastatin mylan 40 Mg Oral Tablet|Oral tablet on regular prescription
48272326|NCT00548548|DRUG|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
48097616|NCT06356207|DIAGNOSTIC_TEST|Tilt Table Test|The main goal of the study is to evaluate the time elapsed between the T-LOC during Video Tilt Table Testing and the asystole at the ECG using a national registry and to assess its predictive value in patients undergoing invasive treatment. The hypothesis is that a vasodepressive component could lessen the effect of pacing in a patient, leading to cerebral hypoperfusion and syncope despite maintaining a stable rhythm.
48097617|NCT03947112|BEHAVIORAL|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
48097618|NCT06629467|BEHAVIORAL|Cognitive-behavioral therapy for smoking cessation|Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.
48097619|NCT06629467|BEHAVIORAL|Personalized PA plan|The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
48097620|NCT06629467|DEVICE|Fitbit Versa 3|Wearable activity tracker with the functionalities of a watch function, including time, date, calendar, and weather (connection to the internet is required). Physical activity monitoring (steps per day, active minutes per day, plants climbed, heart rate monitoring, time, intensity, caloric expenditure, and exercise type of exercise session), sleep monitoring (sleep time, sleep phases time, sleep quality), stress levels managing and guided breathing application are the main health-related functionalities.
48097621|NCT02929303|DRUG|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
48097622|NCT03441048|BIOLOGICAL|Lintuzumab-Ac-225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.
48097623|NCT03441048|DRUG|Cladribine|Cladribine is a purine antimetabolite.
48097624|NCT03441048|DRUG|Cytarabine|Cytarabine is an antineoplastic anti-metabolite.
48097625|NCT03441048|DRUG|Mitoxantrone|Mitoxantrone is an anthracenedione antineoplastic agent.
48097626|NCT03441048|DRUG|G-CSF|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
48097627|NCT05722652|BEHAVIORAL|CONFIDENCE|"This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination"
48097628|NCT02219906|DIETARY_SUPPLEMENT|Resveratrol|1000mg tid
48097629|NCT02219906|DIETARY_SUPPLEMENT|Placebo|1000mg tid placebo
48097630|NCT01182870|DRUG|choleclaciferol|800-6000 IU cholecalciferol per day
48097631|NCT03712293|DEVICE|BBB Disruption with Chemotherapy Arm|The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
48097632|NCT04322656|DEVICE|Lipiflow treatment|Patients will be treated on one eye with Lipiflow
48097633|NCT04143646|BEHAVIORAL|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
48097634|NCT02697799|BEHAVIORAL|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
48097635|NCT02697799|BEHAVIORAL|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
48097636|NCT03492632|OTHER|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
48097637|NCT01306669|BIOLOGICAL|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
48097638|NCT01306669|BIOLOGICAL|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
48097639|NCT06417489|DRUG|Combination therapy|Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.
48097640|NCT06417489|DRUG|Sequential treatment group|Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
48097641|NCT00841282|PROCEDURE|Colonoscopy for colorectal cancer screening|
48097642|NCT00841282|PROCEDURE|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
48272327|NCT00548548|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
48097643|NCT00841282|PROCEDURE|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
48097644|NCT03799341|BEHAVIORAL|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
48097645|NCT03799341|BEHAVIORAL|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
48097646|NCT06557785|BIOLOGICAL|CH505M5 N197D mRNA-gp160|To be administered intramuscularly as a split dose
48097647|NCT06557785|BIOLOGICAL|CH505 TF mRNA-gp160|To be administered intramuscularly as a split dose
48097648|NCT04457141|COMBINATION_PRODUCT|Effect of pelvic floor for the use of minimalist shoes versus shod in woman.|Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
48097649|NCT01301664|OTHER|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
48097650|NCT02469064|OTHER|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
48097651|NCT02469064|OTHER|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
48272328|NCT00548548|DRUG|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
48097652|NCT04893980|DRUG|Recombinant human interleukin-2 (rhIL-2)|During Day 0-14, patients in this group will receive treatment with antihistamines at the same dosage as pre-recruitment, together with a low-dose recombinant human Interleukin-2 (rhIL-2) at a dosage of 1 million international units every other day by intramuscular injection (rhIL-2, 1 MIU, im, Qod). During Day 15-28, the injections of rhIL-2 will be continued at the same dosage and the dose of antihistamines may be adjusted according to the control of symptoms.
48097653|NCT04893980|DRUG|Control group|During Day 0-14, patients in the control group receive treatment with only antihistamines at the same dosage as pre-recruitment, but no injection of rhIL-2. During Day 15-28, treatment with low dose recombinant human Interleukin-2 (rhIL-2), i.e., 1 million international units every other day by subcutaneous or intramuscular injection (rhIL-2, 1MIU, im, Qod), will be added.
48272329|NCT00548548|DRUG|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
48272330|NCT00548548|DRUG|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
48272331|NCT04133077|BIOLOGICAL|blood samples collection|Serology and genetic analyses will be performed in patients blood samples
48272332|NCT01762514|DRUG|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
48272333|NCT01762514|DRUG|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
48272334|NCT06096025|DRUG|pneumoniae bacteremia therapy|To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
47914167|NCT04508088|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). We will also evaluate molecular gene signatures from the blood samples that correlate with the previously described bone imaging phenotypes. At that point, the information will be used to develop a CyTOF panel to evaluate differences in immune cellular populations between CD patients with normal versus low BMD, and matched controls.
48097658|NCT02174211|DRUG|Ranibizumab|Intravitreal injection of ranibizumab
48097659|NCT02174211|DRUG|Aflibercept|Intravitreal injection of aflibercept
48097660|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
48097661|NCT02071511|PROCEDURE|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
48097662|NCT06429618|DIETARY_SUPPLEMENT|Low carbonhydrate diet|Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same dietitian. Whether the patients adhere to the diet and which components the prescribed diet consists of is recorded in detail. After 3 months of standard application, the patient is examined again by the gynecologist and obstetrician at the PCOS clinic.
48097663|NCT03274102|BIOLOGICAL|Concomitant administration of EV71 vaccine with EPI vaccines|"1. The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
48097664|NCT03274102|BIOLOGICAL|Single injection of EPI vaccine|"1. The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~2. The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
48097665|NCT03274102|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
48097666|NCT02334306|BIOLOGICAL|AMG 557/MEDI5872|Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
48097667|NCT02334306|OTHER|Placebo|The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
48272335|NCT05408611|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
48097668|NCT05256381|DRUG|Nanrilkefusp Alfa|Subcutaneous (SC) injection.
48097669|NCT05256381|DRUG|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
48097670|NCT04570644|DRUG|ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)|"Drug : ALZT-OP1a~1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~ALZT-OP1b anti-inflammatory~Device: Dry Powder Inhaler The inhaler will be used to deliver ALZT-OP1a via oral inhalation for dosing on study."
48097671|NCT00776711|DRUG|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
48097672|NCT00776711|DRUG|VRC-AViDNA036-00-VP|
48097673|NCT02817633|DRUG|TSR-022|TSR-022 will be administered.
48097674|NCT02817633|DRUG|Nivolumab|Nivolumab will be administered.
48097675|NCT02817633|DRUG|TSR-042|TSR-042 will be administered.
48097676|NCT02817633|DRUG|TSR-033|TSR-033 will be administered.
48097677|NCT02817633|DRUG|Docetaxel|Docetaxel will be administered.
47914168|NCT05746455|BEHAVIORAL|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
47914169|NCT03382340|DRUG|Imx-110|a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
48097678|NCT02817633|DRUG|Pemetrexed|Pemetrexed will be administered.
48097679|NCT02817633|DRUG|Cisplatin|Cisplatin will be administered.
48097680|NCT02817633|DRUG|Carboplatin|Carboplatin will be administered.
48097681|NCT00010881|DRUG|antioxidants|
48097682|NCT00010881|BEHAVIORAL|stress reduction|
48097683|NCT02924454|DRUG|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
48097684|NCT02924454|DRUG|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
48097685|NCT02924454|DRUG|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
48097686|NCT02924454|DRUG|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
48097687|NCT02157402|BEHAVIORAL|Social marketing activities and pop-up events to promote healthy lifestyles|
48097688|NCT05857293|DEVICE|Catheter-guided PDA stent implantation|PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation. It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
48097689|NCT06629194|DIAGNOSTIC_TEST|interferon gamma releasing assay (IGRA)|All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.
48272336|NCT05408611|OTHER|Placebo acupressure|Placebo acupressure is manual pressure applied to unreal acupressure points.
47914170|NCT03561467|OTHER|Observational|Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy
48097690|NCT01076218|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
48097691|NCT03976609|PROCEDURE|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
48097692|NCT00102414|DRUG|Gemcitabine|
48097693|NCT05114109|DRUG|Isatuximab Injection|Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
48272337|NCT02153502|DRUG|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
48272338|NCT02153502|DRUG|Placebo|Placebo capsules administered twice a day over a 10-week period
48272339|NCT03649152|DRUG|Propagermanium|Immediate release capsule
48097694|NCT06107517|OTHER|DREAMS-OT|"Patients will receive the DREAMS-OT protocol 3 times per day, 20 minutes per therapy session.~Intervention frequency will be confirmed with a feasibility trial. If not feasible to maintain 3 times per day, the intervention will still be maintained at the same intensity of 1 hour per day, with a graded approach."
48097695|NCT01805856|DRUG|PIPC piperacillin sodium|
48097696|NCT01805856|DRUG|CEZ, cefazolin sodium|
48097697|NCT01323660|DRUG|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
48097698|NCT01323660|DRUG|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
48097699|NCT01323660|DRUG|GSK573719 125|125mcg QID
48272340|NCT03649152|DRUG|Placebo|Placebo capsule
47914171|NCT01319552|PROCEDURE|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
48097700|NCT01323660|DRUG|GSK573719 62.5|62.5mcg QID
48097701|NCT01323660|DRUG|GW642444 25|25mcg QID
48097702|NCT01323660|DEVICE|placebo|Comparator QID
48097703|NCT05470374|PROCEDURE|Intraoperative sonography|ultrasound scanning of brain to search tumor remnants
48272341|NCT00100048|DRUG|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
48272342|NCT00100048|DRUG|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
48272343|NCT00100048|DRUG|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
48272344|NCT00100048|DRUG|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
48272345|NCT00100048|DRUG|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
48272346|NCT00100048|DRUG|Placebo monotherapy|Placebo to MK0518 twice daily
48272347|NCT02066792|DRUG|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
48272348|NCT02066792|DRUG|Placebo|Sugar pill
48272349|NCT02066792|BEHAVIORAL|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
48272350|NCT05904626|DRUG|ELGN-2112|To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
48272351|NCT05904626|DRUG|Placebo|A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
48272352|NCT05375084|DRUG|BBP-398 with nivolumab|BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
48272353|NCT00825604|PROCEDURE|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
48272354|NCT02185378|PROCEDURE|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
48272355|NCT02185378|PROCEDURE|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
47914172|NCT01319552|PROCEDURE|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
48097704|NCT03243656|DRUG|Eltrombopag|An oral thrombopoietin receptor agonist
48097705|NCT05738538|DRUG|ziftomenib|
48097706|NCT03681730|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
48097707|NCT05482386|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
48097708|NCT05623995|DRUG|PCSK9 inhibitor|Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..
48097709|NCT05623995|DRUG|Statin|Guideline recommended statin therapy.
48097710|NCT05019781|OTHER|Therapeutic tape|Tape was applied to sternocleidomastoid, upper trapezius, deltoid, flexor palmaris longus muscles as suggested by Kase et al. (Kase, Wallis, Kase, \& Association, 2003). The tape was applied to the left side of the participants while sitting position because the violin is traditionally played by placing it on the left shoulder, balancing the neck using the left hand, and bowing with the right arm.
48097711|NCT05019781|OTHER|Placebo tape|The placebo tape was applied transverse to the muscle groups in two levels (a point of 10 cm above to wrist and elbow) with no tension when the participants were sitting position with the shoulder flexed at 90°, and the elbow flexed at 90°.
48097712|NCT02693626|BEHAVIORAL|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
48097713|NCT02693626|BEHAVIORAL|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
48097714|NCT02889822|DRUG|Alprostadil Liposomes for Injection|"1. Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~2. Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
48272356|NCT03527576|DRUG|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
48097715|NCT04074499|OTHER|No intervention|There is no intervention.
48097716|NCT00263679|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus and pertussis|
48097717|NCT00017277|BIOLOGICAL|epoetin alfa|
48097718|NCT00017277|RADIATION|radiation therapy|
48097719|NCT06125678|DIAGNOSTIC_TEST|Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography|First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
48097720|NCT03736785|DRUG|LY3209590|Administered SC
48097721|NCT03736785|DRUG|Insulin Degludec|Administered SC
48097722|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
48097723|NCT01240356|DEVICE|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
48097724|NCT06629870|DEVICE|virtual reality|patients who received distraction using virtual reality glasses
48097725|NCT06629870|OTHER|control group|no any anxiety-reducing application
48097726|NCT06629870|OTHER|hypnotherapy|patients receiving hypnotherapy
48097727|NCT06629870|OTHER|mindfulness|patients who underwent mindfulness-based meditation
48097728|NCT03988062|DEVICE|TrelliX Embolic Coil System|Embolic coil with shape memory polymer
48097729|NCT01414166|DRUG|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
48097730|NCT01414166|DRUG|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
48097731|NCT04898803|OTHER|conventional DGVS training|see above
48097732|NCT04898803|OTHER|extended simulator training|see above
48097733|NCT03353584|OTHER|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
48097734|NCT00803426|PROCEDURE|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
48097735|NCT05831280|BEHAVIORAL|Laughter Yoga|"* Warm-up exercises (5 minutes),~* Deep breathing exercises (5 minutes),~* Childlike playfulness (5 minutes),~* Laughter exercises (15 minutes)."
48097736|NCT03192085|DIAGNOSTIC_TEST|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
48272357|NCT03527576|DRUG|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
48272358|NCT01860937|PROCEDURE|leukapheresis or collection of PBMCs|
48097737|NCT03192085|DIAGNOSTIC_TEST|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
48097738|NCT02541643|DRUG|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~* H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~* H2 blocker: ranitidine (50mg IV) or equivalent~* acetaminophen (650-1000mg PO)"
48097739|NCT03893591|DIAGNOSTIC_TEST|Anti Xa levels|one Blood sample
48097740|NCT06141057|BIOLOGICAL|Matrix M with RH5.1|50 µg of Matrix-M adjuvant with RH5.1 at different doses on days 0 and 28.
48097741|NCT04208737|PROCEDURE|recruitment maneuver|30 cmH2O pressure 15 seconds
48097742|NCT06053931|BEHAVIORAL|white noise music|"Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw\&t=6478s)."
48097743|NCT06053931|BEHAVIORAL|lullaby music|"Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)"
48097744|NCT00093795|DRUG|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
48097745|NCT00093795|DRUG|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
48097746|NCT00093795|DRUG|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
48097747|NCT00093795|DRUG|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
48097748|NCT00093795|DRUG|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
48097749|NCT03717987|DRUG|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
48272359|NCT01860937|DRUG|cyclophosphamide based chemotherapy regimens|
48272360|NCT01860937|BIOLOGICAL|modified T cells|
48272361|NCT04409704|DEVICE|Repetitive Transcranial Magnetic Stimulation|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
48272362|NCT02688517|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
48272363|NCT02688517|OTHER|Laboratory Biomarker Analysis|Correlative studies
48097750|NCT03717987|DIETARY_SUPPLEMENT|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
48097751|NCT05616221|BIOLOGICAL|AP-PA02|Bacteriophage administered via inhalation
48097752|NCT05616221|OTHER|Placebo|Inactive Placebo administered via inhalation
48097753|NCT03523091|DRUG|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
48097754|NCT03238482|DRUG|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
48097755|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
48097756|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
48097757|NCT03238482|DRUG|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
48272364|NCT04850183|BEHAVIORAL|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
48272365|NCT02548065|OTHER|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
48272366|NCT02548065|OTHER|Placebo|Bath with Thermal tap water
48097758|NCT03804411|DRUG|Automatic system guided treatment|Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide
48097759|NCT03804411|DRUG|Standard treatment|"Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide"
48097760|NCT02710968|DEVICE|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
48097761|NCT05903027|DRUG|Rimegepant 75 MG Disintegrating Oral Tablet|Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
48097762|NCT03539159|OTHER|Allogeneic conventional sized serum eye drops|allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
48272367|NCT00083161|DRUG|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
48272368|NCT00083161|DRUG|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
48444000|NCT06450145|DRUG|interferon α-2b|Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to follow-up occurred. Tumor assessments were performed every 4 to 6 weeks (as determined by the investigator) during trial treatment. Those who achieved CR/PR/PD/ withdrawal were then returned to standard treatment (treatment regimen was determined by the clinician), and those who completed the combination treatment period of the trial entered the survival follow-up period.
47914173|NCT02549924|DRUG|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
47914174|NCT02549924|DRUG|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
48097763|NCT03539159|OTHER|Allogeneic micro sized serum eye drops|Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
48097764|NCT05515770|DRUG|Cabotegravir Injection|Long action cabotegravir injection
48097765|NCT06314256|BIOLOGICAL|Injection|İnterdental papilla will be injected by i-PRF.
48097766|NCT06314256|DRUG|Injection|Interdental papilla will be injected by Tesoyal PureSense Glabal Action HA gel.
48097767|NCT00318968|DRUG|Esomeprazole|
48097768|NCT05165238|BEHAVIORAL|Impact of four week coaching program on dietary habits|A registered dietitian will provide dietary coaching via online groups to participants.
48097769|NCT01805362|OTHER|Randomization that determine the time of treatment|
48097770|NCT06398899|DRUG|Group S: sugammadex injection|Reversal agent: sugammadex no TOF (train-of-four) response, Sugammadex 4 mg/kg TOF count is ≥ 1, Sugammadex 2 mg/kg
48272369|NCT00083161|DRUG|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
48272370|NCT01290627|DEVICE|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
48272371|NCT01290627|DEVICE|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
48272372|NCT05787847|BEHAVIORAL|Incentives for Abstinence|Participants in the incentives for abstinence condition will have the opportunity to earn financial incentives for abstaining from stimulant use.
48272373|NCT05787847|BEHAVIORAL|Health Education|The Health Education condition is based on a previous intervention used as a control in a number of other studies. Sessions consist of an educational program addressing a variety of health, wellness, and lifestyle topics adapted from a previously implemented wellness manual.
48272374|NCT06481137|DIAGNOSTIC_TEST|Electrophysiological study (EP study)|Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.
48272375|NCT06481137|DIAGNOSTIC_TEST|ePatch (extended Holter Monitoring)|Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI
48272376|NCT00730340|PROCEDURE|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
48272377|NCT00730340|PROCEDURE|Tonsillectomy with open fossa|SOP for a tonsillectomy.
48272378|NCT02347631|DEVICE|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
48272379|NCT02347631|DEVICE|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
48272380|NCT05030714|DIAGNOSTIC_TEST|Visual Field Testing|Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test
48272381|NCT02933918|OTHER|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
48272382|NCT02507479|DRUG|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
48272383|NCT06055166|DRUG|Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))|Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
48272384|NCT00200265|BEHAVIORAL|diet|diet
48272385|NCT00395967|DRUG|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
48272386|NCT03775837|DIETARY_SUPPLEMENT|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
48272387|NCT03775837|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
48272388|NCT00612599|DRUG|biphasic insulin aspart|
48272389|NCT06154902|DRUG|Idecabtagene vicleucel|According to approved product label in France
48272390|NCT06154902|OTHER|Not treated|Eligible for idecabtagene vicleucel treatment but not treated
48272391|NCT04764942|DRUG|Carfilzomib|Given IV
48272392|NCT04764942|DRUG|Dexamethasone|Given PO
48272393|NCT04764942|DRUG|Pomalidomide|Given PO
48272394|NCT04764942|OTHER|Quality-of-Life Assessment|Ancillary studies
48272395|NCT04764942|OTHER|Questionnaire Administration|Ancillary studies
48272396|NCT04764942|DRUG|Selinexor|Given PO
48272397|NCT04764942|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
48272398|NCT04764942|PROCEDURE|Computed Tomography|Undergo PET/CT
48272399|NCT04764942|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48272400|NCT04764942|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48272401|NCT04764942|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48272402|NCT04764942|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48272403|NCT03471026|DIAGNOSTIC_TEST|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
48272404|NCT02181933|DRUG|Nevirapine|
48272405|NCT02181933|DRUG|Zidovudine (ZDV)|
48272406|NCT02181933|DRUG|Lamivudine (3TC)|
48272407|NCT02853760|BEHAVIORAL|walking|
48272408|NCT02853760|DEVICE|Treadmill|
48272409|NCT06037356|DEVICE|Prostatic Urethral Lift|Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel
48272410|NCT06037356|PROCEDURE|TURP|Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
48272411|NCT01711242|DRUG|Capecitabine|
48272412|NCT01711242|DRUG|Oxaliplatin|
48272413|NCT01711242|RADIATION|Radiotherapy|
48272414|NCT01180803|DEVICE|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
48272415|NCT01180803|DEVICE|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
48272416|NCT00095563|DRUG|lapatinib ditosylate|Given orally
48272417|NCT00095563|OTHER|laboratory biomarker analysis|Correlative studies
48272418|NCT00102089|BIOLOGICAL|VRC-HIVADV014-00-VP booster|
48272419|NCT00102089|DRUG|VRC-HIVADV014-00-VP|
48272420|NCT00558935|DIETARY_SUPPLEMENT|Red Wine|20g alcohol daily/red wine for 4 weeks
48272421|NCT03437447|DRUG|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
48272422|NCT03437447|DRUG|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
48272423|NCT01070420|OTHER|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
48272424|NCT01070420|OTHER|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
48272425|NCT03695029|DRUG|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
48272426|NCT03782337|BEHAVIORAL|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
48272427|NCT00738816|OTHER|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
48272428|NCT02221609|OTHER|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
48272429|NCT02221609|OTHER|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
48272430|NCT05071131|DIETARY_SUPPLEMENT|Inulin|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
48272431|NCT05071131|DIETARY_SUPPLEMENT|Placebo|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
48272432|NCT06549075|OTHER|Therapeutic support|The modular intervention consists of three modules, including Dignity Therapy, CALM Therapy and Mindfulness-based training. According to the patient's preferences, the patient will be allocated to one of the three interventions, which will be conducted by trained therapists within two sessions.
48272433|NCT06549075|OTHER|Standard Specialized Palliative Consultation Service|According to needs standard specialized palliative care will include support of symptom control, shared decision making/ advance care planning, network planning and support of relatives.
48272434|NCT00275431|DRUG|AT-101|Oral
48272435|NCT01023789|DEVICE|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
48272436|NCT05494307|DRUG|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
48272437|NCT05494307|DRUG|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
48272438|NCT04096534|PROCEDURE|Normotonic partial nephrectomy|partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg
48272439|NCT04096534|PROCEDURE|Hypotonic partial nephrectomy|partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
48272440|NCT05487794|DRUG|Testosterone Cypionate 100 MG/ML|Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).
48272441|NCT02759042|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
48272442|NCT00661583|DRUG|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
48272443|NCT00661583|DRUG|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
48272444|NCT00661583|DRUG|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
48272445|NCT05698290|OTHER|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
48272446|NCT04820751|DRUG|Cyproheptadine Hydrochloride 4 MG|Cyproheptadine associated to standard care
48272447|NCT01067820|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
48272448|NCT01067820|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
48444001|NCT03789994|BEHAVIORAL|Affective touch|The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.
47914175|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
48272449|NCT04873492|OTHER|Biological sample collection|Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
48272450|NCT00888667|OTHER|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
48272451|NCT03455673|DIAGNOSTIC_TEST|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (\> 270 ng/ml) = 1"
48272452|NCT05847478|OTHER|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
48272453|NCT05847478|BEHAVIORAL|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
48272454|NCT05847478|BEHAVIORAL|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
48272455|NCT06021249|PROCEDURE|Traditional ventilation strategies|"1. Tidal volume：10ml/kg predicted body weight（PBW）；~2. 0 cm H2O positive end expiratory pressure（PEEP）；~3. negative pressure extubation"
48272456|NCT06021249|PROCEDURE|Traditional lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. Ventilator-controlled recruitment manoeuvre；~4. CPAP；~5. negative pressure extubation"
48272457|NCT06021249|PROCEDURE|Innovative lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. positive pressure extubation；~4. postoperative breathing training"
48272458|NCT06021249|PROCEDURE|Lung-protective ventilation|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；"
48272459|NCT06021249|PROCEDURE|negative pressure extubation|The suction tube is inserted into the endotracheal tube, continuous negative pressure suction, and at the same time that the balloon is completely deflated, the suction tube, dental pad and endotracheal intubation are pulled out at the same time, and then the patient is instructed to cough independently and remove sputum.
48444002|NCT03789994|OTHER|Fine motor exercise|Fine motor exercises that are commonly used for rehabilitation.
48444003|NCT00742547|OTHER|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
48097771|NCT06398899|DRUG|Group N: neostigmine/glycopyrrolate|Reversal agent: glycopyrrolate and neostigmine. TOF 2-3, neostigmine 50 µg/kg; TOF 4, neostigmine 20-40 µg/kg For all patients, glycopyrrolate 0.4 mg is co-administered with neostigmine.
48097772|NCT00449657|DRUG|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
48097773|NCT00449657|PROCEDURE|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
48097774|NCT00449657|DRUG|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 \& 9
48097775|NCT00449657|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 \& 9
48097776|NCT06231628|PROCEDURE|Percutaneous cementoplasty|"Percutaneous image guided cementoplasty will be performed as follows:~Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely"
48097777|NCT04340245|OTHER|NA (Observational)|No interventions will be carried out. Comparisons will be made between patients whose cancer has progressed over the course of one year and patients whose cancer hasn't.
48097778|NCT01501435|DRUG|CJ-30039|single dose
48097779|NCT01501435|DRUG|fenofibric acid|single dose
48097780|NCT02887261|DEVICE|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
48097781|NCT02887261|DEVICE|Conventional Port|not for power injection for contrast media.
48097782|NCT04536077|DRUG|CDX-301|The drug will be supplied free of charge by Celldex
48097783|NCT04536077|DRUG|CDX-1140|The drug will be supplied free of charge by Celldex
48097784|NCT04536077|PROCEDURE|Research blood draw|At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
48097785|NCT06460363|DEVICE|Transcranial alternating current stimulation (TACS)|Transcranial alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes.
48097786|NCT06460363|DEVICE|Sham TACS|Sham treatment with few seconds of actual electrical current and same electrode configuration
48097787|NCT00359619|BIOLOGICAL|CervarixTM|Subjects were administered three doses of HPV vaccine
48097788|NCT00359619|BIOLOGICAL|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
48272460|NCT06021249|PROCEDURE|positive pressure extubation|The adjustable pressure limiting（APL）was adjusted to 30cm H2O, and after the patient breathed spontaneously until the peak airway pressure reached 30cm H2O, and after maintaining this level for 10s, the balloon was quickly cut off to remove the endotracheal tube, so that the patient had an autonomous coughing action, and then the oral sputum was removed.
48272461|NCT06021249|PROCEDURE|postoperative breathing training|Inhale deeply through the nose, hold the breath for 5s, and then slowly spit out the breath through the mouth, cycle 5-6 times, and inflate the balloon. The above steps need to be performed 15 times within 24 hours after surgery.
48272462|NCT03320499|PROCEDURE|echo doppler at the bed|we practise the echo doppler at the patient 's bed
48272463|NCT03320499|PROCEDURE|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
48272464|NCT04123821|DEVICE|Nasopharyngeal airway|A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
48272465|NCT01975103|PROCEDURE|Topcon Endpoint Management|
48272466|NCT02719340|PROCEDURE|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
48272467|NCT00450944|BIOLOGICAL|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
48272468|NCT02507349|BEHAVIORAL|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
48272469|NCT02507349|BEHAVIORAL|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
48272470|NCT00308451|DRUG|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
48272471|NCT04236544|BEHAVIORAL|PExMS and DECIMS-Wiki|The intervention consists of an information provision on immunotherapies as a combination of factual and experiential information. PExMS is a multimedia website providing patient experiences with MS in everyday life and with therapies illustrated by video, audio and text files of 48 persons with multiple sclerosis. The development of the intervention followed largely recommendation for standardised qualitative research provided by international DIPEx (Database of Individual Patients' Experience of illness) association, which use standardised qualitative research methods to provide 'balanced' information from original interview data. Data for the website was generated in a qualitative interview study with relapsing remitting multiple sclerosis patients across Germany. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies.
48272472|NCT04236544|BEHAVIORAL|DECIMS-Wiki|The active comparator is DECIMS-Wiki, which is an evidence-based online information platform. It is considered to be excellent factual information about immunotherapies for multiple sclerosis.
48272473|NCT06355882|PROCEDURE|Anesthetic infiltration|Application of local dental anesthesia with two cartridges (3,6 mL) for dental procedures (tooth extraction or periodontal treatment) in patients with low cardiac output syndrome.
48272474|NCT05740150|DEVICE|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
48272475|NCT05740150|DEVICE|Heparin lock (heparin 100 IU/mL)|The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
48272476|NCT03831087|DIAGNOSTIC_TEST|TAVR-CMR|CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
48272477|NCT03831087|DIAGNOSTIC_TEST|TAVR-CT|CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
48272478|NCT03396289|OTHER|Conventional physiotherapy including balance exercises|Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
48272479|NCT03396289|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
48272480|NCT02959814|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
48272481|NCT01524380|DRUG|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
48272482|NCT01524380|DRUG|Placebo|twice a day, 10 weeks
48272483|NCT05136274|DRUG|Medical treatment|The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
48272484|NCT01106924|OTHER|Probiotic|daily probiotic consumption
48272485|NCT01106924|OTHER|Placebo|daily placebo consumption
48272486|NCT03501979|DRUG|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
48272487|NCT03501979|DRUG|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
48272488|NCT03501979|DRUG|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
48272489|NCT06013774|DEVICE|IXSI|Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
48272490|NCT00967265|BEHAVIORAL|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
48272491|NCT00967265|OTHER|Usual care|Usual care
48272492|NCT03757884|BEHAVIORAL|Mindfulness breathing exercise|Spire monitor instructed mindfulness breathing
48272493|NCT03757884|BEHAVIORAL|Diagnostic Checklist|Checklist reminder for diagnosis
48272494|NCT03757884|BEHAVIORAL|Noise cancelling headphones|Noise cancelling headphones
48272495|NCT03757884|BEHAVIORAL|Privacy tablescreen|Privacy Tablescreen
48272496|NCT03757884|BEHAVIORAL|Diagnostic assistance application|Diagnostic assistance application
48272497|NCT03631576|BIOLOGICAL|CD123/CLL1 CAR-T Cells|CD123/CLL1 CAR-T Cell Therapy
48272498|NCT00240435|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
48272499|NCT00240435|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
48272500|NCT01009528|DEVICE|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
48272501|NCT03219164|DRUG|AZLI|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
48272502|NCT03219164|DRUG|Placebo|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
48272503|NCT04550182|PROCEDURE|Positioning schedule|"The Braden scale will be collected every morning. Patients' care will be friction and repositioning applied at a frequency defined by the Braden scale:~6 ≥ Braden ≤ 8: alternate positioning every 2 hours 9 ≥Braden ≤ 13: alternate positioning every 4 hours 14 ≥ Braden ≤ 17: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 6 hours.~18 ≥Braden ≤ 23: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 12 hours.~Positioning will alternate semi-lateral decubitus at 30, semi-Fowler 30° -30°, half-sitting position 45° with elevation of the lower limbs.~A medical prescription as part of the daily reassessed care will ensure the absence of absolute contraindication to the mobilization or contraindication to certain positions.Friction will be performed during repositioning."
48272504|NCT05935384|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
48272505|NCT02844465|DEVICE|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
48272506|NCT02590029|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
48097789|NCT04146818|BEHAVIORAL|Adapted Tango Dancing|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.
48097790|NCT04146818|BEHAVIORAL|Control|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
48097791|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
48097792|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
48097793|NCT04040543|DIETARY_SUPPLEMENT|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
48272507|NCT02590029|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
48272508|NCT02590029|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
48272509|NCT00430755|DEVICE|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
48272510|NCT00430755|PROCEDURE|physician taken history|Convential history taking by physicians
48097794|NCT02055482|DRUG|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
48272511|NCT00430755|OTHER|Computer-assisted history taking|
48272512|NCT03358914|OTHER|No intervention|Completion of surveys
48272513|NCT01562028|DRUG|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
48272514|NCT01562028|DRUG|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
48097795|NCT02055482|BIOLOGICAL|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
48097796|NCT04011033|BIOLOGICAL|iNKT cells|5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
48097797|NCT04011033|DRUG|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
48272515|NCT00807950|DRUG|Simvastatin|
48272516|NCT04894955|DEVICE|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
48272517|NCT00002884|DRUG|chemotherapy|
48272518|NCT00002884|DRUG|cisplatin|
48097798|NCT04011033|PROCEDURE|TAE/TACE|TAE/TACE will be conducted to all patients at 0th week and 4th week.
48097799|NCT00009958|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
48097800|NCT00009958|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
48097801|NCT00009958|BIOLOGICAL|sargramostim|Given SC
48097802|NCT00009958|OTHER|laboratory biomarker analysis|Correlative studies
48097803|NCT02341989|DRUG|Bleomycin Etoposide and Cisplatin|
48097804|NCT02341989|DRUG|Carboplatin|
48272519|NCT00002884|DRUG|fluorouracil|
48272520|NCT00002884|RADIATION|brachytherapy|
48272521|NCT00002884|RADIATION|radiation therapy|
48272522|NCT02303925|DEVICE|NESTER COILS|
48272523|NCT03931018|OTHER|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
48272524|NCT02495948|DEVICE|Lotrafilcon B contact lenses|
48272525|NCT02495948|DEVICE|Samfilcon A contact lenses|
48272526|NCT02495948|DEVICE|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
48272527|NCT02495948|DEVICE|Saline solution|Used for rinsing contact lenses, as needed
48272528|NCT04653519|DEVICE|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
48272529|NCT00452725|DRUG|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
48272530|NCT03894345|DRUG|Prazosin|Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
48272531|NCT05213247|DEVICE|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
48272532|NCT01995929|PROCEDURE|transnasal functional endoscopy|
48272533|NCT04480619|DIAGNOSTIC_TEST|Ga-68-PEG-Αvβ3-IAC|Clinical management and diagnosis of angiogenic Breast Cancer.
48272534|NCT04223609|DRUG|Oxycodone|5 mg tablet
48272535|NCT04223609|DRUG|Placebo|Oxycodone-matched placebo tablet
48272536|NCT04223609|DEVICE|EyeLink 1000 Plus|Non-invasive video-based eye tracking system
48272537|NCT04223609|DIAGNOSTIC_TEST|Oculo-Cognitive Addition test (OCAT)|Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
48097805|NCT03828695|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
48097806|NCT00361621|DRUG|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
48097807|NCT00361621|DRUG|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
48097808|NCT00361621|DRUG|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
48097809|NCT00361621|DRUG|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
48097810|NCT00361621|DRUG|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
48272538|NCT04223609|DEVICE|VT3mini - Eye Tracking Technology for OEMs|Non-invasive eye-tracking device
48272539|NCT00423826|DRUG|Busulfan|3 mg/kg intravenously over 3 hours
48097811|NCT00361621|DRUG|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
48272540|NCT00423826|DRUG|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
48272541|NCT00423826|DRUG|Fludarabine phosphate|25 mg/M2/day IV
48097812|NCT00361621|RADIATION|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
48097813|NCT00403208|PROCEDURE|Analgesia based sedation in ICU patients|
48097814|NCT03547505|PROCEDURE|R-Pilot®|Glide path preparation using R-Pilot® in reciprocating manner.
48097815|NCT03547505|PROCEDURE|ProGlider®|Glide path preparation using ProGlider® in a rotating manner.
48097816|NCT03547505|PROCEDURE|Manual preparation|Glide path preparation using manual K-files numbered from 08 to 15.
48272542|NCT00423826|DRUG|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
48272543|NCT00423826|DRUG|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
48272544|NCT00423826|PROCEDURE|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
48272545|NCT00423826|PROCEDURE|umbilical cord blood transplantation|10 days post drug intervention
48272546|NCT00423826|RADIATION|total-body irradiation|10 days post drug intervention
48272547|NCT06002464|PROCEDURE|Acupuncture|Patient will have session of 30 minutes of acupuncture every day during 3 days
48272548|NCT06002464|PROCEDURE|Bilateral ESP catheter|Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
48272549|NCT03973476|OTHER|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
48272550|NCT03185546|OTHER|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
48272551|NCT03185546|OTHER|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
48272552|NCT03185546|OTHER|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
48272553|NCT03185546|OTHER|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
48272554|NCT03185546|OTHER|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
48272555|NCT03185546|OTHER|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
48272556|NCT01769937|DRUG|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
48272557|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
48272558|NCT01062360|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
48272559|NCT01062360|DRUG|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
48272560|NCT01062360|DRUG|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
48272561|NCT01946178|DEVICE|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
48272562|NCT00057707|DRUG|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
48272563|NCT00057707|PROCEDURE|Functional MRI|
48272564|NCT00057707|PROCEDURE|Neuropsychological Testing|
48272565|NCT00404521|DRUG|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
48272566|NCT03588741|DRUG|Turoctocog alfa|"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."
48272567|NCT04752761|BEHAVIORAL|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
48272568|NCT03018548|OTHER|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
48272569|NCT03809897|DRUG|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
48272570|NCT03809897|DRUG|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
48272571|NCT03599180|DEVICE|microdialysis|Use microdialysis skill to collect dialyzate at sensitization acupoints
48272572|NCT02150031|DRUG|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
48272573|NCT02150031|DRUG|1% Chlorhexidine|subgingival irrigation
48272574|NCT02150031|DRUG|1% Chlorhexidine|supragingival irrigation
48272575|NCT02150031|PROCEDURE|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
48272576|NCT02150031|DRUG|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
48272577|NCT02150031|PROCEDURE|Tooth extraction|dental extraction
48272578|NCT02439580|DIETARY_SUPPLEMENT|Annona muricata extract|ethanol-soluble fraction of water extract
48272579|NCT02439580|DIETARY_SUPPLEMENT|Placebo|maltose
48272580|NCT01989130|DEVICE|Roche AMPLICOR CT/NG|
48272581|NCT01989130|DEVICE|Cepheid Xpert CT/NG Test|
48272582|NCT02835430|PROCEDURE|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
48272583|NCT02835430|PROCEDURE|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
48272584|NCT04024592|DEVICE|Biodex System 4|Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
48272585|NCT00828464|DRUG|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
48272586|NCT03983499|BEHAVIORAL|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
48272587|NCT05900804|OTHER|Training Prepared in Line with the Fracture Liaison Service Model|The Effect of Education Prepared in Line with Fracture Liaison Service Model on Patients' Frailty Level, Care Dependency and Fear of Movement in Hip Surgery Patients
48272588|NCT03867630|PROCEDURE|Transforaminal Block|Epidural block via neural foramen of lumbar spine
48272589|NCT04287621|DRUG|DUPIXENT®|There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
48272590|NCT03288948|OTHER|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
48272591|NCT01572155|PROCEDURE|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
48272592|NCT01572155|PROCEDURE|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
48272593|NCT03835091|OTHER|BRASS score|Brainstem response on neurologic examination
48272594|NCT04748263|OTHER|No intervention. Only survey and normal use of eye-tracking|"The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE."
48272595|NCT01290926|DRUG|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
48272596|NCT05616143|DEVICE|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
48272597|NCT04975802|OTHER|Placebo|10 oz (296 ml) cherry flavored still beverage
48272598|NCT04975802|DIETARY_SUPPLEMENT|Coffeeberry|10 oz (296 ml) cherry flavored still beverage
48272599|NCT04975802|DIETARY_SUPPLEMENT|Caffeine|10 oz (296 ml) cherry flavored still beverage
48272600|NCT06054217|DRUG|Vehicle of TP-03|The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
48272601|NCT01908595|DRUG|M518101|
48272602|NCT00868790|DRUG|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
48272603|NCT00868790|DRUG|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
48272604|NCT00868790|DRUG|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
48272605|NCT00868790|DRUG|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
48272606|NCT00199979|DRUG|Nevirapine|
48272607|NCT03990870|OTHER|dCBGT + WASABI|Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).
48272608|NCT03990870|OTHER|dCBGT Only|Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
48272609|NCT05311384|BEHAVIORAL|Keys Constraint-induced Movement Therapy protocol|All participants will receive the Keys CI Therapy protocol over an 8-week intervention period. Specific CI therapy strategies will be delivered, including: 1) supervised movement training will be carried out for 1 hour for 4 days/week for the first 4 weeks, 2 days/week for weeks 5 and 6, and 1 day/week for weeks 7 and 8; 2) participants will use the restraint mitt on their less-affected UE for most of their waking hours for an 8 week period; 3) transfer package methods will be modified to accommodate the longer time period between clinic visits; and 4) participants will be asked to independently perform additional movement training for 30 minutes each day at home.
48272610|NCT06418620|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
48272611|NCT01267955|OTHER|Laboratory Biomarker Analysis|Correlative studies
48272612|NCT01267955|OTHER|Pharmacogenomic Study|Correlative studies
48272613|NCT01267955|DRUG|Vismodegib|Given PO
48272614|NCT01596257|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
48272615|NCT01596257|DEVICE|CliniMACS|
48272616|NCT01337349|DRUG|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
48272617|NCT01337349|DRUG|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
48272618|NCT04402047|OTHER|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
48272619|NCT04402047|DRUG|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
48272620|NCT00120003|DRUG|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
48272621|NCT00120003|DRUG|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
48272622|NCT03906682|BEHAVIORAL|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
48272623|NCT03906682|BEHAVIORAL|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
48272624|NCT06443658|OTHER|Hypertonic saline|Patients from intervention group will inhale hypertonic saline solution 5 minutes before performing the morning ELTGOL technique
48272625|NCT06443658|DRUG|Isotonic saline|Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique
48272626|NCT06443658|OTHER|ELTGOL|Patients from control group will perform the ELTGOL technique twice-daily
48272627|NCT01151683|DIETARY_SUPPLEMENT|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
48272628|NCT01151683|DIETARY_SUPPLEMENT|placebo|Two capsules of placebo per oral twice a day
48272629|NCT04082221|OTHER|no intervention|no intervention
48272630|NCT01427309|BIOLOGICAL|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
48272631|NCT01427309|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
48272632|NCT02076165|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
48106797|NCT03990220|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
48272633|NCT02076165|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
48272634|NCT04139083|PROCEDURE|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
48272635|NCT04139083|PROCEDURE|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
48272636|NCT04349137|DEVICE|HD-tACS|non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
48272637|NCT04349137|DEVICE|sham HD-tACS|sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
48272638|NCT02514759|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
48272639|NCT00242918|DRUG|docetaxel|
48272640|NCT00242918|DRUG|ZD1839|
48272641|NCT01596179|BEHAVIORAL|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
48272642|NCT01596179|BEHAVIORAL|Internet access|a netbook computer with internet access is provided to participants on the control arm.
48272643|NCT00348166|DRUG|cyclopentolate|
48272644|NCT01785355|OTHER|Dental treatment|"1. The preliminary stage deals with:~   * assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~  * education of the patient regarding correct oral hygiene habits;~2. Phase I Therapy:~   * plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~  * evaluation of response to the treatment~3. Phase II Therapy - surgical phase:~   * extraction of hopeless teeth~  * evaluation of the surgical results.~4. Maintenance phase:~   * periodic reevaluation of plaque and calculus and of periodontal conditions."
48272645|NCT01571479|PROCEDURE|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
48272646|NCT00235521|DRUG|aerosolized iloprost|
48272647|NCT02497001|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler \[MDI\])
48272648|NCT02497001|DRUG|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
48272649|NCT02497001|DRUG|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
48272650|NCT02497001|DRUG|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
48272651|NCT01185847|DRUG|RO5083945|intravenously, until disease progression
48272652|NCT01185847|DRUG|cisplatin|standard treatment, up to 6 cycles
48272653|NCT01185847|DRUG|gemcitabine|standard treatment, up to 6 cycles
48272654|NCT01185847|DRUG|pemetrexed|standard treatment, up to 6 cycles
48272655|NCT04737148|OTHER|Mortality scores|Revised Baux, BOBI and FLAMES scores
48272656|NCT00799526|PROCEDURE|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
48272657|NCT00799526|PROCEDURE|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
48272658|NCT01051089|BEHAVIORAL|Lifestyle modification|Exercise and diet education
48272659|NCT04607395|RADIATION|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
48272660|NCT01658514|DRUG|Met DR|metformin delayed-release tablets
48272661|NCT01658514|DRUG|Met XR|metformin extended-release tablets
48097817|NCT06357143|OTHER|REMOVE|"INITIAL STAGE:~* Aim: Recover mobility~* Exercises: Passive therapy, isometric exercises focused on middle deltoid.~* Goal: 80º passive flexion, 45º abduction, 5 N of abduction force STRENGTHENING STAGE~* Aim: Enhance scapulohumeral rhythm and strength rotator cura~* Exercises: Active-assisted therapy, isotonic exercises between 45-90º of forward flexión and abduction with dumbbells and isometric exercises focused on internal and external rotation.~* Goal: 100º passive flexion, 90º lateral abduction, 10 N of abduction force INTENSIVE STAGE~* Aim: Improve motor control and increase cross-sectional muscular área~* Exercises: Rowe with resistance band, wall push ups, lateral elevation with dumbbles, active external and internal rotation.~* Goal: 15 N of abduction force FUNCTIONAL STAGE~* Aim: Develope daily life activities~* Exercises: Overhead tasks, rowe with Kettlebell, internal and external rotations with resistance bands~* Goal: 20 N of abduction force"
48097818|NCT06357143|OTHER|CONTROL|Patients will undergo standard care which consists of an initial consultation with the physiotherapist to receive some recommendations about exercises, progression and health education
48097819|NCT04286022|OTHER|Speed Loss 20% Strength Training|Strength training based on the control of speed loss in execution.
48097820|NCT04286022|OTHER|Reduced Rest Time Strength Training|Strength training based on a protocol that includes reduced rest times between sets.
48097821|NCT04895579|DRUG|Durvalumab|Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.
48097822|NCT04895579|DRUG|Copanlisib|Copanlisib will be delivered at various doses (30-60mg/kg) via IV infusion at days 1 and 15 every 28 days.
48097823|NCT03942822|DIETARY_SUPPLEMENT|Milled chia seeds|8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
48097824|NCT05975294|DRUG|amixture 0.125% bupivicaine with fentanyl|ultrasound guided continuous erector spinae plane block with abolus 0.3ml /kg of amixture 0.125% bupivicaine with fentanyl of 2 mic per ml then Infusion of 0.1 ml /kg/hr of the same mixture.
48097825|NCT05975294|DRUG|100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset|PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
48097826|NCT00142766|BEHAVIORAL|Nurse Implemented Goal-Directed Comfort Algorithm|See description
48097827|NCT00912587|DRUG|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
48097828|NCT02793609|OTHER|Intervention is to let patient to go home.|Intervention is to let patient to go home.
48097829|NCT02793609|OTHER|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
48097830|NCT00870259|DIETARY_SUPPLEMENT|Optifast VLCD|Meal replacement, three times daily for 8 weeks
48097831|NCT04443153|DEVICE|Personalized Feedback|Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.
48097832|NCT04443153|DEVICE|Decision Support System|CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges
48272662|NCT01658514|DRUG|Placebo|
48272663|NCT04126824|DRUG|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
48272664|NCT04126824|DRUG|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
48272665|NCT04126824|OTHER|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
48272666|NCT00318435|DEVICE|Stent or stent-graft deployment|
48272667|NCT02310399|DEVICE|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
48272668|NCT01085188|BEHAVIORAL|ACC|Weekly community based behavioral counseling and case management
48272669|NCT01085188|BEHAVIORAL|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
48272670|NCT01085188|BEHAVIORAL|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
48272671|NCT01587066|DRUG|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
48272672|NCT01587066|DRUG|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
48272673|NCT00313274|DRUG|Clevudine|
48272674|NCT01538056|DEVICE|Fenestrated Endovascular Graft|Modified endovascular graft with fenestrations to allow for blood flow to vital visceral vessels such as the renal arteries and SMA (Superior Mesenteric Artery).
48272675|NCT04819321|DEVICE|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
48272676|NCT03168867|BEHAVIORAL|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
48272677|NCT00282126|DIETARY_SUPPLEMENT|Potassium citrate|kcitrate
48272678|NCT02744976|DRUG|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
48272679|NCT02744976|BEHAVIORAL|Lifestyle recommendations|Standard lifestyle recommendations
48272680|NCT03592979|DEVICE|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
48272681|NCT03592979|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
48272682|NCT01742429|DRUG|Proton pump inhibitor|
48272683|NCT01742429|DRUG|Bismuth subsalicylate|
48272684|NCT01742429|DRUG|Metronidazole|antibiotic
48272685|NCT01742429|DRUG|Tetracycline|antibiotic
48272686|NCT01742429|DRUG|Amoxicillin|antibiotic
48272687|NCT01742429|DRUG|Levofloxacin|antibiotic
48272688|NCT05769231|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Chatbot|Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.
48272689|NCT06391645|DRUG|Nerve Growth Factor|intravenously injection
48272690|NCT04532788|PROCEDURE|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
48272691|NCT04532788|PROCEDURE|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
48272692|NCT01608425|PROCEDURE|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
48272693|NCT04355988|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
48272694|NCT04671836|DRUG|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
48272695|NCT04671836|DRUG|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
48272696|NCT05825690|OTHER|Retrospective evaluation of specific brain MRI features|"Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
48272697|NCT00472693|DRUG|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
48272698|NCT01646099|BEHAVIORAL|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
48272699|NCT03050164|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
48272700|NCT03050164|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
48272701|NCT02803957|DEVICE|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
48272702|NCT02803957|DEVICE|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
48272703|NCT03079440|DRUG|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
48272704|NCT02379325|BEHAVIORAL|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
48272705|NCT02379325|BEHAVIORAL|pamphlets material|Given pamphlets material on smoking and complication
48272706|NCT02296060|PROCEDURE|6 minutes walking test|
48272707|NCT05340504|DRUG|N-Acetyl cysteine|Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
48272708|NCT05340504|DRUG|Placebo|Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
48272709|NCT03906253|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
48272710|NCT05522426|DEVICE|SyntrFuge System|Microsized Adipose Tissue
48272711|NCT02964637|OTHER|Observational Study|
48272712|NCT02690701|DRUG|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
48272713|NCT02690701|BIOLOGICAL|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
48272714|NCT03085784|DRUG|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
48272715|NCT02948439|OTHER|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
48272716|NCT01889602|DRUG|Lorazepam|Lorazepam: 2mg, po, 1x
48272717|NCT01889602|OTHER|Placebo|Non-active placebo, po, 1x
48272718|NCT01889602|DRUG|Topiramate 100mg|Topiramate: 100 mg, po, 1x
48272719|NCT01889602|DRUG|Topiramate 150mg|Topiramate: 150 mg, po, 1x
48272720|NCT01889602|DRUG|Topiramate 200mg|Topiramate: 200 mg, po, 1x
48272721|NCT06546033|OTHER|application of different types of diet|application of different types of diet
48272722|NCT06490861|DEVICE|Paragit|Sleeve to quantify symptoms
48272723|NCT02926807|OTHER|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
48272724|NCT02926807|OTHER|MDCT|a MDCT to calculate the Agatston score
48272725|NCT02926807|OTHER|biopsy and blood collection|biopsy and blood collection to assess biomarkers
48272726|NCT00864240|DRUG|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
48272727|NCT05963503|OTHER|Assessments|Health literacy Anxiety and depression Physical activity Adherence to airway clearance techniques
48097833|NCT04443153|DEVICE|Sensor Augmented Mode|A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.
48272728|NCT00358657|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
48272729|NCT00358657|DRUG|Cyclophosphamide|Given IV
48272730|NCT00358657|DRUG|Fludarabine Phosphate|Given IV
48272731|NCT00358657|OTHER|Laboratory Biomarker Analysis|Correlative studies
48272732|NCT00358657|DRUG|Mycophenolate Mofetil|Given PO
48097834|NCT00643838|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
48097835|NCT05032755|OTHER|SPECTRUM NRC 102/103 investigational cigarettes|Very low nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
48097836|NCT05032755|OTHER|SPECTRUM NRC 600/601 investigational cigarettes|Normal nicotine content (nonmenthol/menthol) SPECTRUM investigational cigarettes
48097837|NCT03022903|PROCEDURE|Aminolevulinic Acid (ALA)|Photosensitizing
48097838|NCT00651885|DRUG|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
48097839|NCT00651885|DRUG|Placebo|Placebo
48097840|NCT03232268|BIOLOGICAL|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
48097841|NCT04440943|DRUG|CDX-527|CDX-527 is administered by infusion every 2 weeks
48097842|NCT03578731|DEVICE|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~* Interview during regular consultation with doctor~* Web-App for gathering doctors data~* Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~* Well-being through a patient rating on a visual analog scale~* Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
48097843|NCT00476203|BEHAVIORAL|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
48097844|NCT00476203|OTHER|Delayed yoga classes|Delayed yoga classes (after 6 months) offered \[wait list control group\]
48097845|NCT02828605|DEVICE|Virtual Interactive Platform (VIP) Transplant|
48097846|NCT05037851|DRUG|Opelconazole|Nebulizer suspension
48097847|NCT05037851|DRUG|Standard of Care|Standard of Care
48097848|NCT06615310|OTHER|ultrasonograpic evaluotion|The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.
48097849|NCT04724369|DRUG|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
48097850|NCT01953809|DRUG|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
48097851|NCT01953809|DRUG|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
48097852|NCT01953809|DRUG|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
48097853|NCT01953809|DRUG|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
48272733|NCT00358657|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
48272734|NCT00358657|DRUG|Sirolimus|Given PO
48272735|NCT00358657|DRUG|Tacrolimus|Given IV or PO
48272736|NCT00358657|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
48272737|NCT05960565|DRUG|Glucagon|A micro-dose of glucagon is added exactly at the same site as insulin is injected.
48272738|NCT02952976|DEVICE|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
48272739|NCT02952976|DEVICE|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
48272740|NCT05590572|DRUG|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
48272741|NCT05590572|DRUG|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
48272742|NCT05590572|DRUG|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
48272743|NCT01224548|OTHER|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
48272744|NCT01224548|OTHER|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
48272745|NCT03216460|DEVICE|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
48272746|NCT01765894|OTHER|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
48272747|NCT00003414|BIOLOGICAL|aldesleukin|
48272748|NCT00003414|BIOLOGICAL|recombinant interferon gamma|
48272749|NCT00003414|DRUG|busulfan|
48272750|NCT00003414|DRUG|cyclophosphamide|
48272751|NCT00003414|DRUG|cyclosporine|
48272752|NCT00003414|PROCEDURE|peripheral blood stem cell transplantation|
48272753|NCT00003414|RADIATION|radiation therapy|
48272754|NCT01459978|OTHER|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
48272755|NCT02577263|OTHER|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
48272756|NCT01453881|DEVICE|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
48272757|NCT01453881|DEVICE|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
48272758|NCT00348140|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
48272759|NCT00348140|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
48272760|NCT00348140|OTHER|Placebo|Placebo
48272761|NCT03146286|DIETARY_SUPPLEMENT|Saturated fat|Palm stearin
48272762|NCT03146286|DIETARY_SUPPLEMENT|Placebo|Water
48272763|NCT03146286|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil, Omega 3 PUFA
48272764|NCT03670459|OTHER|Cawthorne Cooksey exercises|Eye movements and head movements
48272765|NCT03670459|OTHER|Vestibular habituation exercises|Move from a sitting position to flat on the back
48272766|NCT03670459|OTHER|Balance exercises|Weight Shift Forward and Back
48272767|NCT01965249|DEVICE|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
48272768|NCT01965249|DEVICE|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
48272769|NCT04116099|OTHER|Conservative care|May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
48272770|NCT04116099|DEVICE|Flexitouch Plus|Flexitouch Plus treatment.
48272771|NCT02278913|DRUG|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
48272772|NCT02278913|DRUG|Human Insulin|NPH twice a day + Regular insulin before meals
48097854|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
48097855|NCT03109015|DRUG|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
48097856|NCT03241888|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
48272773|NCT02562547|DEVICE|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
48097857|NCT03241888|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
48097858|NCT06631911|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Emotional Awareness and Expression Therapy (EAET) is a manualized, short-term psychodynamic therapy that, in this instance, is delivered in a group format.~The core of Emotional Awareness and Expression Therapy (EAET) involves helping individuals identify, understand, and express their emotions in a therapeutic setting. The therapy emphasizes the connection between unprocessed emotions and physical symptoms, encouraging participants to explore the emotional underpinnings of their distress. Through guided discussions, psychoeducation, and expressive exercises, participants learn to recognize patterns of emotional avoidance, develop self-compassion, and improve interpersonal communication. This process aims to reduce somatic symptoms and enhance overall emotional well-being by fostering a greater awareness of emotional experiences."
48097859|NCT05161403|DRUG|Hyaluronic acid|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
48097860|NCT05161403|DIETARY_SUPPLEMENT|honey|"Wound healing is still a clinical challenge especially in patients who undergo several tooth extractions under general anesthesia or those undergoing major surgeries or those with systemic conditions that disrupt the wound healing process.~Use of this natural substance is a simple and cost-effective technique and is easily tolerated by children."
48097861|NCT02274402|BIOLOGICAL|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
48097862|NCT04454567|DRUG|ABI-H0731|Participants will receive ABI-H0731 tablets orally once daily
48097863|NCT04454567|DRUG|Placebo|Participants will receive placebo to ABI-H0731 tablets orally once daily
48097864|NCT04454567|DRUG|NrtI|Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
48272774|NCT01695421|PROCEDURE|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
48272775|NCT01695421|PROCEDURE|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
48272776|NCT01695421|PROCEDURE|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
48272777|NCT01695421|PROCEDURE|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
48272778|NCT05789992|DRUG|Propofol|Propofol (Random:3-5ug/ml)
48272779|NCT05789992|DRUG|Low Remifentanil|Remifentanil (Random:0-3ug/ml)
48272780|NCT05789992|DRUG|Heigh Remifentanil|Remifentanil (Random:3-5ug/ml)
48272781|NCT05789992|PROCEDURE|Intubation|Endotracheal intubation before surgery
48272782|NCT05789992|PROCEDURE|tetanic electrical stimulation|tetanic electrical stimulation before surgery
48272783|NCT05302323|OTHER|Disposable Drape|Disposable surgical drapes, consisting of 6 pieces, were used as a set during surgery
48272784|NCT05302323|OTHER|Reusable Drape|Reusable surgical drapes, consisting of 6 pieces, were used as a set during surgery
48272785|NCT05299658|DRUG|CNMAu8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
48272786|NCT03135249|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
48097865|NCT06200402|DRUG|Antibiotic loaded|This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement
48097866|NCT06200402|OTHER|Placebo|Placebo
48097867|NCT01168401|BIOLOGICAL|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
48097868|NCT01168401|BIOLOGICAL|Saline|Two doses 28 days apart
48097869|NCT00869570|DRUG|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
48097870|NCT00869570|DRUG|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
48097871|NCT00869570|RADIATION|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
48097872|NCT00705991|PROCEDURE|ROTEM|
48097873|NCT06629948|DEVICE|x ray|whole spine x ray posterioanterior and lateral views
48097874|NCT06629948|DIAGNOSTIC_TEST|the cranio-cervical flexion test|measure of deep neck flexors muscles endurance
48097875|NCT02721511|DRUG|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
48097876|NCT01893320|DRUG|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
48097877|NCT01893320|DRUG|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
48097878|NCT05755035|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
48097879|NCT05755035|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
48272787|NCT04175145|OTHER|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
48272788|NCT05850078|OTHER|FB101|Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
48620318|NCT01665027|PROCEDURE|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
48097880|NCT04371926|DRUG|Hydroxychloroquine Sulfate|"Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks"
48097881|NCT05730205|DRUG|Nexplanon 68 MG Drug Implant|Progestin contraceptive device
48097882|NCT03601143|OTHER|Blood samples prior to a new line of AR-targeted therapy|Blood will be drawn at baseline prior to a new line of AR-targeted therapy.
48097883|NCT05593185|BIOLOGICAL|Galinpepimut-S|
48097884|NCT03352388|DIETARY_SUPPLEMENT|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
48097885|NCT04962100|OTHER|Analysis of capacitation-associated tyrosine phosphorylation in human sperm by flow cytometry|"After the assessment of the macroscopic and microscopic characteristics of the sample, we will wash the sample and process it using three layers of density gradients.~In the case of samples for diagnostic analysis, the remaining volume will be incubated in at 37ºC, and 0.1-0.2 ml aliquots will be taken from the end of the processing at t0 (just before introducing the sample in the incubator), at t1 (after one hour of incubation) and at t3 (after 3 hours of incubation). Additionally, a sample will be taken after washing, prior to processing the sample with the density gradients. In the case of samples processed for insemination, an additional aliquot will be taken at the exact moment in which the insemination is carried out and the elapsed incubation time will be noted.~The evaluation of the capacitation will be carried out by analyzing the state of phosphorylation of tyrosines by flow cytometry."
48097886|NCT06158958|DRUG|ABBV-303|Intravenous (IV) Infusion
48272789|NCT02298114|DEVICE|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
48272790|NCT02298114|OTHER|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
48272791|NCT03181113|DRUG|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
48272792|NCT03181113|DRUG|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
48272793|NCT02130414|DRUG|Sandimmun® IV|2 mg/kg IV
48272794|NCT02130414|DRUG|CyCol® capsules|37.5 mg CyCol® capsules
48272795|NCT03560973|DRUG|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
48272796|NCT03560973|DRUG|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
48272797|NCT02312973|DRUG|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
48272798|NCT02312973|DRUG|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
48272799|NCT05896007|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
48272800|NCT05896007|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
48272801|NCT05896007|DRUG|Methotrexate|3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
48272802|NCT05896007|DRUG|Temozolomide|150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
48620319|NCT01665027|PROCEDURE|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
48097887|NCT06158958|DRUG|Budigalimab|IV Infusion
48097888|NCT03569683|PROCEDURE|External bevel gingivectomy|External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
48097889|NCT03569683|DEVICE|Diode laser Biostimulation|After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
48097890|NCT03569683|OTHER|Hyaluronic acid (Gengigel) topical application.|After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
48097891|NCT03569683|OTHER|Herbal gel (Hiora SG) topical application|After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
48272803|NCT00630045|DRUG|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
48272804|NCT00630045|PROCEDURE|resection of liver metastasis|surgery with the aim of R0 resection
48272805|NCT03494556|OTHER|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
48272806|NCT01316042|DRUG|sugar pill|2 pills per day for 12 months
48272807|NCT01316042|DRUG|Metformin, glucophage|2 212.5mg pills/day for 12 months
48272808|NCT05981066|DRUG|Neoantigen vaccine, I.M injection|Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
48272809|NCT04992988|DRUG|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
48272810|NCT00462787|BIOLOGICAL|filgrastim|
48272811|NCT00462787|DRUG|clofarabine|
48272812|NCT00462787|DRUG|dexamethasone|
48272813|NCT00462787|DRUG|thiotepa|
48272814|NCT00462787|DRUG|topotecan hydrochloride|
48620320|NCT00836108|BEHAVIORAL|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
48620321|NCT03268863|DEVICE|Virtual Reality|Google Cardboard virtual reality headset
48620322|NCT03268863|OTHER|Cold Pressor|A cold ice water bath for use in pain/discomfort simulation
48620323|NCT04000724|BEHAVIORAL|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
48097892|NCT00931229|DRUG|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
48097893|NCT01178515|OTHER|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
48097894|NCT01178515|OTHER|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
48097895|NCT01178515|OTHER|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
48097896|NCT03580967|DRUG|Vortioxetine|Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
48097897|NCT05532813|DRUG|Treatment taken|Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
48097898|NCT05692258|OTHER|Acupuncture|"Acupuncture is a kind of therapy used to treat diseases, in which a needle (usually a millimeter needle) is inserted into a patient's skin or tissue at a certain Angle to stimulate a specific part of the body (acupoint).~Disposable sterile acupuncture filiform needle (0.30mm×25mm、0.30mm×40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011."
48097899|NCT04584021|DEVICE|Xiaomi MiBand3|Recording of sleep, activity and heart rate data to study their association with stress.
48097900|NCT04584021|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be filled by the participants at the beginning of the study with the following personal data: age, gender, marital status, residential environment, cohabitation unit, educational level, socio-economic level, contract, working hours, overtime or not, number of overtime hours in a day, overtime frequency and perceived stress level
48097901|NCT04584021|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be filled by the participants at the beginning, mid-term and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
48097902|NCT04584021|OTHER|Pittsburgh Sleep Quality Index (PSQI)|Questionnaire to be filled by the participants whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning, mid-term, and completion of the study.
48097903|NCT04584021|OTHER|State-Trait Anxiety Inventory (STAI)|Questionnaire to be filled by the participants which measures the anxiety level. To be given at the beginning, mid-term and completion of the study.
48097904|NCT04584021|OTHER|Perceived Stress Scale-10 (PSS-10)|Questionnaire to be filled by the participants which measures the stress level. To be given at the beginning, mid-term and completion of the study.
48097905|NCT04584021|OTHER|Stress questionnaire|Questionnaire designed by a work stress psychologist professional from the research group which is focused on stress and daily functioning. This questionnaire was given for the participants to fill. It is composed by 3 daily items and 4 weekly items.
48097906|NCT06381674|OTHER|Vestibular therapy for mTBI augmented with audio and visual real-time biofeedback|During physical therapy sessions participants will wear sensors on their head, chest, waist, and feet for real-time instrumented audio and visual biofeedback on quality of therapeutic exercise.
48272815|NCT00462787|DRUG|vinorelbine tartrate|
48272816|NCT06246773|BEHAVIORAL|Positive Parenting Program|During the first week, women will receive one session of Recovering from Intimate partner violence through Strengths and Empowerment (RISE) and from week 2 they will receive RISE and PALS simultaneously. Participants will receive four to six components of RISE - education on health effects of violence, improving coping and self-care, enhancing social support, and addressing sexual violence, increase safety planning, and assist in making difficult decisions. During each of the PALS sessions, parents will receive instruction on four responsive parenting constructs: contingent responsiveness, warm sensitivity (responses include high levels of affection and understanding of child states), maintaining vs. redirecting attention to objects and topics of conversation, and verbal scaffolding .In addition to direct instruction, parents will video-record themselves interacting with their child and engage in self-reflection of their own parenting behavior.
48272817|NCT06246773|BEHAVIORAL|Usual Care|Participants will receive services available to them at the shelter or housing facility
48272818|NCT01639430|OTHER|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
48272819|NCT04856592|DEVICE|Boston Scientific Vici® Venous Stent System|The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires
48272820|NCT04856592|DEVICE|Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)|The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.
48272821|NCT01053429|DRUG|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
48272822|NCT04142645|DEVICE|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~1. an ICT platform:~   * automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~  * a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~  * an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~2. a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
48272823|NCT04148092|DRUG|ripretinib|orally administered solid dosage form
48272824|NCT05373550|BEHAVIORAL|Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.|Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
48272825|NCT05112731|DIAGNOSTIC_TEST|BAFF and MGO|measurement of BAFF and MGO levels before reperfusion and after 3 months
48272826|NCT05468970|OTHER|NO Intervention|NO Intervention
48272827|NCT01455974|OTHER|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
48272828|NCT01530139|BEHAVIORAL|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
48272829|NCT01530139|BEHAVIORAL|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
48272830|NCT01530139|BEHAVIORAL|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
48272831|NCT01530139|BEHAVIORAL|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
48272832|NCT05507957|DIAGNOSTIC_TEST|direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment|-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
48272833|NCT00375544|DEVICE|Low level light therapy|
48272834|NCT00357773|DRUG|Azithromycin (T1225)|
48272835|NCT03667001|DRUG|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
48272836|NCT03667001|DRUG|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
48097907|NCT06381674|OTHER|Vestibular therapy for mTBI|During physical therapy sessions participants will go through vestibular therapeutic exercise WITHOUT audio and visual real-time biofeedback.
48097908|NCT03134235|OTHER|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
48097909|NCT05873556|BEHAVIORAL|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
48097910|NCT03684733|DIAGNOSTIC_TEST|MRI|Clinical MRI breast screening examination
48272837|NCT03048955|DEVICE|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
48272838|NCT03048955|PROCEDURE|Direct decompression Surgery|A surgical procedure - the control
48272839|NCT00862251|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
48272840|NCT00862251|DRUG|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
48272841|NCT00862251|DRUG|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
48272842|NCT00862251|DRUG|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
48097911|NCT05753917|DEVICE|Piezo-surgery insert OR Conventional Drills|piezo-surgery: Group A (piezoelectric device with IM1, IM2, IM2-3, or IM3 piezo-inserts according to the manufacturer's protocol (Piezosurgery, Mectron Medical Technology, Carasco, Italy) Conventional drill: Group B (conventional drills according to the manufacturer's protocol (Premium, Sweden \& Martina, Due Carrare, Padova, Italy)
48272843|NCT03785054|DRUG|HTL0014242|HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
48272844|NCT03785054|DRUG|Placebo oral capsule|Placebo treatment
48097912|NCT06627738|RADIATION|Cyberknife irradiation|Additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in inoperable patients with locally advanced non-small cell lung carcinoma
48272845|NCT00002285|DRUG|Zidovudine|
48272846|NCT05447702|DRUG|Camrelizumab|Intravenous (IV) infusion
48272847|NCT05447702|DRUG|Apatinib|po.
48272848|NCT05447702|DRUG|Nab-paclitaxel|IV infusion.
48272849|NCT05447702|DRUG|Epirubicin|IV infusion.
48272850|NCT05447702|DRUG|Cyclophosphamide|IV infusion.
48272851|NCT04790227|DEVICE|MRI|MRI
48272852|NCT02000609|DRUG|CHF 1535 NEXThaler 800/48|
48272853|NCT02000609|DRUG|CHF 1535 NEXThaler 200/12|
48272854|NCT02000609|DRUG|CHF 1535 NEXThaler PLACEBO|
48272855|NCT02000609|DRUG|CHF 1535 pMDI 200/12|
48272856|NCT02000609|DRUG|CHF1535 pMDI 800/48|
48272857|NCT02222402|BEHAVIORAL|INTRA-DIALYTIC EXERCISE TRAINING|
48272858|NCT04076826|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
48272859|NCT04076826|DRUG|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
48097913|NCT05521867|DEVICE|Endoscopic balloon dilation|EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.
48272860|NCT04076826|DIAGNOSTIC_TEST|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
48272861|NCT02768376|DRUG|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
48272862|NCT02768376|DRUG|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
48272863|NCT06261411|DIAGNOSTIC_TEST|Lung Ultrasound|Diagnostic ultrasound of pulmonary tissues such as pleura, plural spaces, and parenchyma.
48272864|NCT02598830|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
48272865|NCT02598830|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
48272866|NCT00206167|DRUG|Budesonide/formoterol pMDI|
48272867|NCT00206167|DRUG|Formoterol Turbuhaler|
48272868|NCT00600171|DRUG|GW642444M|GW642444M
48272869|NCT00600171|DRUG|Placebo|Placebo mulit-dose dry powder inhaler
48272870|NCT01614964|DRUG|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
48272871|NCT01614964|DRUG|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
48272872|NCT03844009|OTHER|Computer integrated debriefing|At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
48272873|NCT03720314|OTHER|NA observational study|observational study
48272874|NCT04427254|DRUG|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
48272875|NCT03172689|DEVICE|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
48272876|NCT05987748|BEHAVIORAL|Exercise training|Mixed exercise training containing strength and endurance elements carried out under supervision
48272877|NCT04921215|BEHAVIORAL|Morning bright light|All participants will receive phase advancing morning bright light.
48272878|NCT00972699|BEHAVIORAL|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
48272879|NCT05946590|PROCEDURE|Frenotomy|Frenotomy in which clipping/incised of the lingual frenulum releases the tongue-tie performed by a health care professional
48272880|NCT00473876|DRUG|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
48272881|NCT00473876|DRUG|Matched Placebo (Capsules)|Similar dosing regime as active comparator
48272882|NCT03936387|DRUG|Ropivacaine|Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
48272883|NCT02408692|DRUG|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.
47914176|NCT03961438|BIOLOGICAL|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
48272884|NCT02408692|DRUG|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
48272885|NCT01976949|BEHAVIORAL|online social-networking intervention|
48272886|NCT00412256|DRUG|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
48272887|NCT00206726|DRUG|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
48272888|NCT01815645|BEHAVIORAL|ST+CM|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
48272889|NCT01815645|BEHAVIORAL|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
48272890|NCT04257331|BEHAVIORAL|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
48272891|NCT03478241|DEVICE|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
48272892|NCT03478241|DEVICE|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
48272893|NCT03478241|DEVICE|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
48272894|NCT03666351|DRUG|Amlodipine 5mg|Amlodipine 5 mg
48272895|NCT03666351|DRUG|Losartan|Losartan Potassium 50 mg
48272896|NCT03666351|DRUG|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
48272897|NCT03666351|DRUG|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
48272898|NCT03666351|DRUG|current treatment|treatment is done by maintaining the current treatment
48272899|NCT01328457|DRUG|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
48272900|NCT04026984|DRUG|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
48272901|NCT04026984|DRUG|Placebo|Matching Placebo tablets
48620324|NCT04000724|BEHAVIORAL|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
48272902|NCT04426305|OTHER|community health worker support|usual care by professional primary care providers + emotional support by trained community health worker
48272903|NCT04426305|OTHER|care as usual|care as usual is provided by professional primary care provider
48272904|NCT03717376|OTHER|Self-questionnaire YSQ-S3 (Young Schema Questionnaire)|All participants will fill the YSQ-S3 at home and send it back to the main investigator.
48272905|NCT03996772|DRUG|Apixaban Oral Tablet|Factor Xa Inhibitor
48272906|NCT03996772|DRUG|Dabigatran|Direct Thrombin Inhibitor
48272907|NCT03996772|DRUG|Edoxaban Tablets|Factor Xa Inhibitor
48272908|NCT03996772|DRUG|Rivaroxaban|Factor Xa Inhibitor
48272909|NCT04122599|DRUG|Melatonin|Melatonin for prevent post stroke delirium
48272910|NCT05035121|DIETARY_SUPPLEMENT|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
48272911|NCT05035121|DIETARY_SUPPLEMENT|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
48272912|NCT05035121|BEHAVIORAL|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
48272913|NCT00191672|DRUG|Gemcitabine|
48272914|NCT00191672|DRUG|Paclitaxel|
48272915|NCT00191672|DRUG|Docetaxel|
48272916|NCT03772327|DEVICE|"Adheretech smart bottle"|"A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message."
48272917|NCT03772327|BEHAVIORAL|Routine adherence counseling|Participants will be provided with routine adherence counseling
48272918|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)|Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
48272919|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel|Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
48272920|NCT01193686|OTHER|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
48272921|NCT03567902|DEVICE|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
48272922|NCT03567902|DEVICE|Direct laryngoscope intubation|Direct laryngoscope intubation
48272923|NCT04310644|OTHER|No intervention planned, but all patients get our standart treatment|Patients are selected from clinical Routine and get our standart Treatment based on their disease
48272924|NCT03388593|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
48272925|NCT03388593|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
48272926|NCT00393419|BEHAVIORAL|Comprehensive pharmacy care program|
48272927|NCT06299189|BEHAVIORAL|MinADHD|Guided self-help, 7 modules Interventions
48272928|NCT05943080|DRUG|PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.
48272929|NCT05943080|DRUG|IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
48272930|NCT05943080|DRUG|ACB ( 0.25% marcaine + %0.9 saline)|It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
48272931|NCT01804231|OTHER|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
48272932|NCT00787436|DRUG|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
48272933|NCT05675007|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
48272934|NCT05675007|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
48272935|NCT01278576|DRUG|BOTOX-A®|200 units, single treatment only
48272936|NCT01412229|DRUG|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
48272937|NCT01412229|DRUG|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
48272938|NCT01412229|DRUG|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
48272939|NCT04314050|DRUG|Tramadol|tramadol and paracetamol will perform
48272940|NCT04314050|DRUG|Dexmedetomidine|dexmedetomidine and paracetamol will perform
48272941|NCT04314050|OTHER|control|paracetamol will perform
48272942|NCT04273074|RADIATION|sonographic assessment|preoperative sonographic assessment to airway
48272943|NCT03624816|DEVICE|Restylane Defyne|hyaluronic acid dermal filler gel
48272944|NCT04426695|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
48272945|NCT04426695|DRUG|Placebo|Placebo IV Single Dose
48272946|NCT00215930|DRUG|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
48272947|NCT00215930|DRUG|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
48272948|NCT00215930|DRUG|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
48272949|NCT00215930|DRUG|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
48272950|NCT01007526|OTHER|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
48272951|NCT04216173|OTHER|Acupuncture|Acupuncture weekly for 12 consecutive weeks. Acupuncture protocol consists of both scalp and body acupuncture points.
48272952|NCT03453892|DRUG|Nivolumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
48272953|NCT03453892|DRUG|Pembrolizumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
48272954|NCT03453892|RADIATION|Radiotherapy|The normal clinical treatment-plan of the underlying disease remains unchanged.
48272955|NCT03453892|DRUG|Ipilimumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
48272956|NCT01938287|DEVICE|SENSIMED Triggerfish|
47927852|NCT06363266|BEHAVIORAL|TEMPO|"Stage 1 interventions (week 1-12): After 12 weeks, response will be determined. At recruitment, at least one member of the dyad must report anxiety symptoms defined as a Hospital Anxiety and Depression Scale (HADS)-Anxiety subscale score \> 6. After Stage 1, for the dyad to be TEMPO Responder, both members' anxiety scores on the HADS-Anxiety must be \< 6 or decreased by at least 2 points. If both members of the dyad had anxiety symptoms at recruitment, then both must meet a response criterion. As soon as one dyad member does not meet the response criterion, the dyad is TEMPO non-responder.~Stage 2 interventions (week 14-25): TEMPO responders continue with TEMPO. Non-responders will be re-randomized to: a) more time with TEMPO or b) add non-health care professional guidance (8 x 20-minute telephone calls). Guides' training will include TEMPO review, their role and the manual. Semi-structured exit interview will gather guides' experiences."
48272957|NCT02964598|BEHAVIORAL|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
48272958|NCT02964598|BEHAVIORAL|Sleep coaching|A new personalized program, duration 4-6 weeks
48272959|NCT02964598|DEVICE|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
48272960|NCT02964598|OTHER|Control|Minimal information on sleep timing and advancing the sleep rhythm
48272961|NCT02964598|OTHER|Psychoeducation|An extensive information platform in the internet created for this purpose
48272962|NCT04274439|OTHER|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
48272963|NCT04274439|OTHER|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
48272964|NCT05642377|DRUG|HGR4113|Once-daily oral administration
48272965|NCT05642377|DRUG|Placebo|Once-daily oral administration
48272966|NCT05642377|DRUG|HGR4113|Twice-daily oral administration
48272967|NCT05642377|DRUG|Placebo|Twice-daily oral administration
48272968|NCT01371630|BIOLOGICAL|Blinatumomab|Given CIVI
48272969|NCT01371630|DRUG|Cyclophosphamide|Given IV
48272970|NCT01371630|DRUG|Cytarabine|Given IT and IV
48272971|NCT01371630|DRUG|Dexamethasone|Given IV or PO
48272972|NCT01371630|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
48272973|NCT01371630|OTHER|Laboratory Biomarker Analysis|Correlative studies
48272974|NCT01371630|DRUG|Mercaptopurine|Given PO
48272975|NCT01371630|DRUG|Methotrexate|Given IT, IV, and PO
48272976|NCT01371630|DRUG|Prednisone|Given PO
48272977|NCT01371630|BIOLOGICAL|Rituximab|Given IV
48272978|NCT01371630|DRUG|Vincristine|Given IV
48272979|NCT05434884|PROCEDURE|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
48272980|NCT05434884|PROCEDURE|endocrown restorations|endocrown restorations
48272981|NCT00330707|DRUG|Bacillus Calmette Guerin and interferon alpha|
48272982|NCT06200350|OTHER|Experimental group|Tailored training based on the profile of each participant.
48272983|NCT06200350|OTHER|Control group|They will continue with the traditional training.
48272984|NCT01628926|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
48272985|NCT01628926|DRUG|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
48272986|NCT01628926|DRUG|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
48272987|NCT04405219|OTHER|The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain|Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
48272988|NCT04187092|OTHER|KneeBright Group|"The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions."
48272989|NCT04187092|OTHER|Standard Rehabilitation group|Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
48620325|NCT04000724|BEHAVIORAL|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
48272990|NCT04000477|DEVICE|Cytobrush|the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
47927853|NCT06363266|OTHER|Active Monitoring dyads' anxiety|"Stage 1 interventions (week 1-12): Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices).~Stage 2 interventions (week 14-25): Dyads not responding to active monitoring will be stepped up to TEMPO; responders to active monitoring will only be invited to complete the follow-up measures."
48272991|NCT04000477|DEVICE|Kevorkian curette|the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
48272992|NCT04338490|DEVICE|Feedback mannequim|The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
48272993|NCT02407535|DEVICE|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
48272994|NCT01832961|DEVICE|Flutter valve exercises|30 minutes of flutter exercises
48272995|NCT01832961|DEVICE|Flutter Sham exercises|30 minutes of flutter-sham exercises
48272996|NCT01832961|DEVICE|Flutter and bronchodilator exercises|Flutter + bronchodilator exercises with an interval of 3 to 5 days
48272997|NCT02471690|DRUG|Oritavancin|IV - Single dose 1200 mg Oritavancin
47927854|NCT04565327|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV prior to imaging
48272998|NCT02471690|DRUG|Dextrose|D5W 5% in Water
48272999|NCT02734173|DRUG|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
48273000|NCT03068715|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
48273001|NCT03068715|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
48273002|NCT03068715|DEVICE|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
48273003|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Bicruciate retaining|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
48273004|NCT04334304|PROCEDURE|Robot-assisted Total Knee Arthroplasty|A total knee arthroplasty will be performed with robot-assistance (NAVIO).
48273005|NCT04334304|PROCEDURE|Total Knee Prosthesis - type Posterior Stabilized|A total knee arthroplasty will be performed with a bicruciate retaining implant (Journey II, XR). The control group will consist out of patients receiving a posterior stabilized implant (Journey II, BCS).
48273006|NCT04184687|PROCEDURE|Nanofractures|anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
48273007|NCT04184687|PROCEDURE|no treatment cartilaginous lesions|patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
48273008|NCT02375867|DRUG|prednisolone|Oral administration of 1 mg/Kg/day
48273009|NCT02375867|DRUG|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
47927855|NCT04565327|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
47927856|NCT00720447|BIOLOGICAL|alemtuzumab|
47927857|NCT00720447|BIOLOGICAL|donor lymphocytes|
47927858|NCT00720447|DRUG|carmustine|
47927859|NCT00720447|DRUG|cytarabine|
47927860|NCT00720447|DRUG|etoposide|
47927861|NCT00720447|DRUG|melphalan|
47927862|NCT00720447|PROCEDURE|allogeneic bone marrow transplantation|
48273010|NCT01917123|DRUG|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
48273011|NCT01124825|DEVICE|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
48273012|NCT01124825|DEVICE|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
48273013|NCT01707992|DRUG|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
48273014|NCT01707992|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
48273015|NCT02051907|DEVICE|KAM1403 Gel|
48273016|NCT02051907|DEVICE|aloevera gel|
48273017|NCT05726214|OTHER|Exercise|"The face-to-face multicomponent program entailed:~* Strength training of upper and lower limbs. Familiarization phase included 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets lasted 1-3 minutes.~* Balance exercises included proprioception, agility and weight transfer exercises. Difficulty progressively increased by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~* Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~The Vivifrail exercise wheel corresponding to each participant was given according to their functional level type."
48620326|NCT02927626|DRUG|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
48620327|NCT02927626|DRUG|Routine medical care|Routine medical care
48620328|NCT00820534|DRUG|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
48273018|NCT05726214|OTHER|Recommendations for active lifestyle|After the baseline assessments, all participants received individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants were encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations were transmitted verbally and through written material.
48273019|NCT04447053|DRUG|Belimumab Injection [Benlysta]|Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
48273020|NCT01665937|DRUG|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
48273021|NCT04508907|DRUG|Mavyret|Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
48273022|NCT02254343|DEVICE|proximal robot-assisted therapy|
48273023|NCT02254343|DEVICE|distal robot-assisted therapy|
48273024|NCT02254343|BEHAVIORAL|individualized intensive therapy|
48273025|NCT04507009|DEVICE|Ozone|topical gaseous ozone application
48273026|NCT04507009|OTHER|CGF|concentrated growth factor (CGF) application
48273027|NCT04507009|OTHER|Traditional treatment|Alvogyl application
48273028|NCT03912584|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
48273029|NCT03912584|DEVICE|P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
48273030|NCT03502512|OTHER|Questionnaire Administration|Ancillary studies
48273031|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
48273032|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
48273033|NCT01470677|DRUG|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
48273034|NCT06502561|DRUG|Aramchol meglumine|Aramchol meglumine is a salt form of Aramchol free acid
48273035|NCT06502561|DRUG|Aramchol free acid|Aramchol free acid is a fatty acid-bile acid conjugate
48273036|NCT04005794|BEHAVIORAL|VR social skills training|Social skills game that we developed in the R21 phase will be used across 10 sessions of training in the lab. Each session is about 1 hour long. Participants come to the lab twice a week for 5 weeks.
48273037|NCT04005794|BEHAVIORAL|Cognitive training|Commercially available cognitive training program will be used to control for the time spent in the lab and associated social interactions as well as the total exposure to computerized games.
48273038|NCT00997516|PROCEDURE|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
48273039|NCT00997516|PROCEDURE|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
48273040|NCT00728065|DIETARY_SUPPLEMENT|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
48273041|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
48273042|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
48273043|NCT00728065|DIETARY_SUPPLEMENT|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
48273044|NCT00728065|DIETARY_SUPPLEMENT|Rice milk|Rice milk containing 50g of available carbohydrates
48273045|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
48273046|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
48273047|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
48273048|NCT03892421|DRUG|Rituximab|Rituximab 375 mg/m²
47927863|NCT00720447|PROCEDURE|peripheral blood stem cell transplantation|
48273049|NCT03892421|DRUG|Carboplatin|Carboplatin AUC5
48273050|NCT03892421|DRUG|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
48273051|NCT03892421|DRUG|Dexamethasone|Dexamethasone 40 mg
48273052|NCT03892421|DRUG|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
48273053|NCT05253456|PROCEDURE|Derma -Dartos Flap for second layer closure|usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
48273054|NCT06330909|RADIATION|Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT|"technique: IMRT/IGRT/SBRT~The HypoFocal-SBRT study combines ultra-hypofractionated RT / stereotactic body RT (reduction of treatment time) with a focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts."
48273055|NCT06330909|RADIATION|Radiotherapy (RT) Arm B - IMRT/IGRT|"technique: IMRT/IGRT~Moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide."
48273056|NCT05051956|DRUG|Palbociclib 125mg and Ribociclib 600 mg|Administration of Palbociclib or Ribociclib
48273057|NCT02047669|BEHAVIORAL|Biopsychosocial|
48273058|NCT02047669|BEHAVIORAL|Reference|
48273059|NCT00006417|PROCEDURE|Stem cell transplantation|
48273060|NCT05875545|OTHER|Breathing Exercises|Diaphragmatic breathing exercises with a physiotherapist for 8 weeks, two days a week
48273061|NCT05875545|OTHER|Pelvic Floor Exercises|Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
48273062|NCT03995719|OTHER|Preoperative education|65 patients were instructed to a preoperative stoma-education program
48273063|NCT03995719|OTHER|Postoperative education|73 patients, receiving the same information in postoperative period.
48273064|NCT02928952|BEHAVIORAL|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
48273065|NCT04023084|DRUG|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
48273066|NCT04568837|DRUG|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
48273067|NCT02804360|DEVICE|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
48273068|NCT00092508|DRUG|OPC-6535|
48273069|NCT00092508|DRUG|Asacol®|
48273070|NCT02937805|DEVICE|Moisturizing vaginal and vulvar sea buckthorn oil cream|
48273071|NCT02937805|DEVICE|Moisturizing vaginal and vulvar cream|
48273072|NCT00643240|RADIATION|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
48273073|NCT00643240|RADIATION|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
48273074|NCT03189979|BEHAVIORAL|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
48273075|NCT03099733|OTHER|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
48273076|NCT04492904|OTHER|Home-use Test and Follow-up Questionnaire|Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
48273077|NCT03691714|DRUG|Durvalumab|Two hour infusion
48273078|NCT03691714|DRUG|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
48273079|NCT04101175|PROCEDURE|Evaluation of the procedure of abortion|Observational study using questionnaires
48273080|NCT03244059|BIOLOGICAL|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
48273081|NCT03244059|DRUG|Placebo|An identically appearing placebo infusion.
48273082|NCT02034487|OTHER|retrospective data collection|
48273083|NCT06373874|BEHAVIORAL|Heel blood collection in a newborn simulation model|"The person who will take heel blood in the newborn simulation model can prepare the materials.~Firstly, the blood sample can fill in all the information on the filter paper. Knows where the baby's face should be. It can determine the area where a heel blood sample can be taken.It can gently warm the heel area for a few minutes. The area can be cleaned with alcoholic preparation (cotton/swab, etc.). He can squeeze the heel with his thumb and index finger in front. The other 3 fingers can be rubbed at the back. May stroke the heel three times. The heel can be pierced once with a lancet at a suitable location. He can relax his hand. He can wipe away the first drop of blood. It can create a large thick drop of blood to be collected on filter paper. It can make the drop fill the entire ring on the filter paper with one touch. After the procedure is completed, the heel can be pressed."
48273084|NCT01700829|DRUG|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
48097914|NCT05521867|DEVICE|Endoscopic stricturotomy with or without stricturoplasty|Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
48097915|NCT00272610|DRUG|0.4% Retinol Cream|
48097916|NCT02718443|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
48097917|NCT01387490|BEHAVIORAL|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
48273085|NCT01700829|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
48273086|NCT04610476|DRUG|Prednisolone|Prednisolone oral 1-5 mg/day
48273087|NCT04610476|DRUG|Sulfasalazine|Sulfasalazine oral 2 x 1000 mg/day
48273088|NCT04610476|DRUG|Leflunomide|Leflunomide oral 20 mg/day
48273089|NCT04610476|DRUG|Methotrexate|Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
48273090|NCT04610476|DRUG|Tofacitinib|Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
48273091|NCT04610476|DRUG|Apremilast|Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
48273092|NCT04610476|DRUG|Etanercept|Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
48273093|NCT04610476|DRUG|Adalimumab|Adalimumab s.c. 40 mg every 2 weeks
48273094|NCT04610476|DRUG|Infliximab|Infliximab i.v. 5 mg/kg BW every 8 weeks
48273095|NCT04610476|DRUG|Certolizumab pegol|Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks
48273096|NCT04610476|DRUG|Golimumab|Golimumab s.c. 1x 50 mg every 4 weeks
48273097|NCT04610476|DRUG|Abatacept|Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
48273098|NCT04610476|DRUG|Secukinumab|Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
48273099|NCT04610476|DRUG|Ixekizumab|Ixekizumab s.c. 1x 80 mg every 4 weeks
48273100|NCT04610476|DRUG|Ustekinumab|Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
48273101|NCT00004826|DRUG|clozapine|
48273102|NCT03838484|DRUG|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
48273103|NCT03838484|DRUG|Placebo patch|Placebo skin patch will be applied to the skin.
48273104|NCT02823457|BEHAVIORAL|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
48273105|NCT06302257|DRUG|Chlorprocaine|we aim to examine whether selective nociceptive analgesia can be obtained in epidural analgesia for women in labor by using a combination of lidocaine (opens TPRV-1 and TPRA-1 channels) and chlorprocaine (polarized local anesthetic)
48273106|NCT06302257|DRUG|Lidocaine|Study participants will receive lidocaine alone
48273107|NCT06302257|DRUG|Lidocaine-chlorprocaine combination|study participants randomized to this study arm will receive a a 50:50 mixture of both drugs - where all drugs are administered in concentrations based on their ED50 doses, together with epidural opioids (fentanyl)
48273108|NCT05685940|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
48273109|NCT05685940|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
48273110|NCT00766792|PROCEDURE|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
48273111|NCT00766792|PROCEDURE|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
48273112|NCT01748799|DRUG|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
48273113|NCT01748799|DRUG|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
48273114|NCT01480739|DRUG|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
48273115|NCT01480739|DRUG|100 mg Placebo|Twice daily for 7 days
48273116|NCT03606382|DIAGNOSTIC_TEST|HostDx Fever Test|HostDx Fever test to distinguish between viral and bacterial infections
48273117|NCT03606382|DIAGNOSTIC_TEST|HostDx Sepsis Test|HostDx Fever test to determine the severity of a presented, suspected infection.
48273118|NCT03872492|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~* My daily survey~* My evaluation~* My cognition~* My emotions~* My voice~Data will also be collected passively."
48273119|NCT01110187|DRUG|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
48273120|NCT01110187|DRUG|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
48273121|NCT02048345|DRUG|Suspension Fasted State|
48273122|NCT02048345|DRUG|Suspension Fed State|
48273123|NCT02048345|DRUG|Solution Fasted State|
48273124|NCT02048345|DRUG|Solution Fed State|
48273125|NCT05692960|OTHER|Hypnotic Relaxation Intervention (HRI)|HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)
48273126|NCT05692960|DEVICE|Vulvovaginal Atrophy (VVA)|VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
48273127|NCT02316834|OTHER|Laboratory Biomarker Analysis|Correlative studies
48273128|NCT02316834|DRUG|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
48273129|NCT01136551|DRUG|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
48273130|NCT03543813|DRUG|CX-2029|CX-2029 Monotherapy
48273131|NCT05020561|BEHAVIORAL|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
48273132|NCT05020561|BEHAVIORAL|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
48273133|NCT01517880|DRUG|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
48273134|NCT01517880|DRUG|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
48273135|NCT04297943|DEVICE|Orthosis fabrication|see summary
48273136|NCT04297943|DEVICE|Thermal Sensor Monitoring of Orthosis Use|see summary
48273137|NCT04297943|DIAGNOSTIC_TEST|4D CT Scan|see summary
48273138|NCT06127329|PROCEDURE|BAI combine with DEB-BACE|"1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
48620329|NCT00820534|DRUG|Placebo|Placebo every 2 hous during waking hours for 96 hours
48273139|NCT05367102|BEHAVIORAL|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
48273140|NCT06140771|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48273141|NCT06140771|DRUG|1.15% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48273142|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48273143|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48273144|NCT04141657|OTHER|Pharmacogenetic test|Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
48273145|NCT02446587|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
48273146|NCT00078364|PROCEDURE|MRI|
48273147|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
48273148|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
48273149|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex|In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).
48273150|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location|In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1.
48273151|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location|In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.
48273152|NCT01487421|DRUG|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
48273153|NCT01487421|DRUG|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
48273154|NCT02345798|PROCEDURE|Standard Follow-Up Care|Undergo usual care
48273155|NCT02345798|OTHER|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
48273156|NCT02345798|OTHER|Educational Intervention|Undergo video-assisted intervention
48273157|NCT02345798|OTHER|Quality-of-Life Assessment|Undergo quality of life assessment
48097918|NCT01387490|OTHER|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
48273158|NCT02345798|OTHER|Questionnaire Administration|Undergo questionnaire administration
48273159|NCT00620061|DRUG|Lubiprostone 24|24 mcg capsules for oral administration
48273160|NCT02308644|DRUG|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
48273161|NCT00544934|DRUG|GLY-230|125, 250 0r 375 mg bid for 14 days
48273162|NCT00544934|OTHER|Placebo|No drug administered
48273163|NCT00717730|DIETARY_SUPPLEMENT|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
47927864|NCT04821505|BEHAVIORAL|Health Education|didactic classroom instruction on improving ones lifestyle through healthier diet, exercise and control of substance use.
47927865|NCT04821505|BEHAVIORAL|Transcendental Meditation|TM is described as simple technique practiced 20 minutes twice a day for deep rest and relaxation.
47927866|NCT02230969|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
47927867|NCT03769376|DEVICE|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
48097919|NCT05880238|BEHAVIORAL|Intervention group|The intervention consisted of a total of 3 modules, 20 sessions. These modules are: Module A: I explore my inner and outer world Module B: I am learning self-editing methods C module: discovering self-editing In these modules, students were trained to use sensorimotor strategies for self-regulation. The intervention program was carried out in one-hour sessions, twice a week, for a total of 10 weeks.
48097920|NCT05880238|OTHER|Control group|The control group will continue their education according to the preschool education curriculum.
48273164|NCT00717730|DIETARY_SUPPLEMENT|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
48273165|NCT00717730|DIETARY_SUPPLEMENT|Placebo|Placebo with no active ingredients
48273166|NCT00717730|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
48273167|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
48273168|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
48273169|NCT02527356|BEHAVIORAL|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
48273170|NCT03424161|DEVICE|Secret RF|Subjects will receive treatment with the Secret RF device
48273171|NCT04103866|DEVICE|Juvederm Voluma|Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
48273172|NCT04175470|DRUG|Bevacizumab|10 mg/kg intravenously every three weeks
48273173|NCT04175470|DIETARY_SUPPLEMENT|Tocotrienol|Capsules, 300 mg orally three times daily
48273174|NCT05303129|BIOLOGICAL|Blood sampling|Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
48273175|NCT01206881|DRUG|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
48273176|NCT06091345|DRUG|Midodrine|• Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10%
48273177|NCT06091345|BIOLOGICAL|albumin|• Albumin infusion 1g/kg/day (max 20g) every two weeks (if pre-infusion serum albumin is \< 3.5 gm/dl
48273178|NCT06091345|OTHER|Standard Medical Treatment|Standard Medical Treatment
48273179|NCT05173129|DIAGNOSTIC_TEST|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
48273180|NCT02232256|DRUG|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
48273181|NCT01045954|DRUG|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
48273182|NCT02065544|BEHAVIORAL|behavioral weight loss and exercise|Weight loss and exercise counseling
48273183|NCT00277758|BIOLOGICAL|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
48273184|NCT00277758|DRUG|Ribavirin|Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (\> 85 kg)
48273185|NCT00277758|BIOLOGICAL|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
48273186|NCT00277758|BIOLOGICAL|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
48273187|NCT00277758|DRUG|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight \<65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight \>85 kg.
48273188|NCT04006184|OTHER|Chart review|Retrospective review of medical records at a single site with six physicians
48273189|NCT02427048|BEHAVIORAL|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
48273190|NCT04547322|OTHER|VR application group|During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
48273191|NCT00450580|DRUG|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
48273192|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device|Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).
48273193|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device (Sham)|Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
48273194|NCT02947919|BEHAVIORAL|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
47927868|NCT03769376|DEVICE|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
48097921|NCT01551615|DRUG|Metformin 1000 mg|2 x 500 mg oral tablets
48097922|NCT01551615|DRUG|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
47927869|NCT00990418|DRUG|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
48273195|NCT01931046|DRUG|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
48273196|NCT04749212|DIAGNOSTIC_TEST|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
48273197|NCT02800174|DEVICE|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
48273198|NCT02800174|DRUG|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
48273199|NCT05072444|DRUG|QPX7728|beta lactamase inhibitor
48273200|NCT05072444|DRUG|QPX2014|antibiotic
48273201|NCT04770766|OTHER|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
48273202|NCT00999830|DRUG|IPH2101|One infusion of IPH2101 every 4 weeks
48273203|NCT00806104|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
48273204|NCT00806104|DIETARY_SUPPLEMENT|Maltodextrins|Dietary supplementation for 4 weeks
48273205|NCT03242655|BEHAVIORAL|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
48273206|NCT00841451|DRUG|Lovaza (Fish Oils)|Double blinded placebo controlled
48273207|NCT04184817|OTHER|Collection of clinical data registered in Easily software|Collection of clinical data registered in Easily software
48273208|NCT03737656|DRUG|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
48273209|NCT03452839|DRUG|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
48273210|NCT03403400|BEHAVIORAL|VRWP Group|The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
48273211|NCT03403400|BEHAVIORAL|VRW Group|The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
48273212|NCT04730518|BEHAVIORAL|Yoga-based group therapy|see above
48273213|NCT00036335|DRUG|Duloxetine Hydrochloride|
48273214|NCT01241500|DRUG|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
48273215|NCT01419132|DRUG|Furosemide|125-250 mg furosemide bid
48273216|NCT01419132|DRUG|Furosemide|125-250 mf furosemide bid
48273217|NCT05572476|DRUG|Association of lurbinectedin and durvalumab|"A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks."
48273218|NCT05572476|DRUG|Association of carboplatin and etoposide|"Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks"
48273219|NCT02479789|DRUG|Lidocaine|
48273220|NCT02479789|DRUG|Placebo|
48273221|NCT02397473|DRUG|Galcanezumab|Administered SC
48273222|NCT02397473|DRUG|Placebo|Administered SC
48273223|NCT02432547|DRUG|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
48273224|NCT02432547|PROCEDURE|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
48273225|NCT00588367|DEVICE|Mayo Interactive Breath Hold Monitor|Biofeedback device
48273226|NCT04744974|BEHAVIORAL|Diet intervention|Participants will be given dietician counseling on their assigned diet
48273227|NCT00120614|BEHAVIORAL|Premature infant behavior and development information|
48273228|NCT00120614|BEHAVIORAL|Parental activities to support premature infant information|
48273229|NCT02005055|PROCEDURE|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
48273230|NCT02595242|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
48273231|NCT02595242|DRUG|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
48273232|NCT02595242|DRUG|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
48273233|NCT02913248|PROCEDURE|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
48273234|NCT01413386|DEVICE|biliary stent|palliative treatment for malignant patients
48273235|NCT02668614|DEVICE|WR-22 model microwave sensor|
48273236|NCT03851692|OTHER|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
48273237|NCT00073840|DRUG|levalbuterol|"* Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID"
48273238|NCT04902235|DRUG|Experimental: CRH administration|CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
48097923|NCT04057456|OTHER|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
48273239|NCT04902235|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
48273240|NCT01781949|OTHER|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
48273241|NCT01781949|OTHER|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
48273242|NCT01781949|OTHER|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
48273243|NCT00755820|BEHAVIORAL|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
48273244|NCT00755820|BEHAVIORAL|Exposure Therapy + Placebo|Exposure therapy with placebo medication
48273245|NCT00755820|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy
48273246|NCT01511484|BEHAVIORAL|Information-only|"Selected pages from the British National Health Service (NHS) information booklets \[5 A Day, Just Eat More (fruit \& veg); pages i, ii, 12-15, 20 \& 21\] and \[5 A Day, Just Eat More (fruit \& veg): What's it all about?; pages i-ii)\] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
48444004|NCT02778321|DEVICE|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~* Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~* Data on the CI:~* Monitoring Results scope ICU Neurovascular.~* Presence palpitations~* Treatment influencing the rate (beta-blockers or antiarrhythmic)~* Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
47927870|NCT02506985|DRUG|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
47927871|NCT02506985|DRUG|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
47927872|NCT01827683|OTHER|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
47927873|NCT04399746|DRUG|Ivermectin|6mg once daily in day 0,1,7 and 8
47927874|NCT04399746|DRUG|Azithromycin|500mg once daily for 4 days
48273247|NCT01511484|BEHAVIORAL|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
48273248|NCT01511484|BEHAVIORAL|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
48273249|NCT03821584|OTHER|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest
48273250|NCT00152633|DRUG|Losartan|
48273251|NCT00152633|DRUG|Metoprolol|
48273252|NCT00152633|DRUG|Losartan|Treatment with Losartan
48273253|NCT05228366|OTHER|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
48273254|NCT05228366|OTHER|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
48273255|NCT05228366|OTHER|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
48273256|NCT02071238|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
48273257|NCT02071238|BEHAVIORAL|Group Consultation|Informed consent discussion in group-format
48273258|NCT05530096|DIAGNOSTIC_TEST|Standard of care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy
48273259|NCT04492566|DEVICE|Automated Insulin Delivery|"Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
48273260|NCT02305563|DRUG|BMS-936564|
48273261|NCT02305563|DRUG|Cytarabine|
48444005|NCT00656305|DEVICE|ExAblate MRfFUS|MR guided focused ultrasound.
48444006|NCT00656305|DEVICE|Sham|sham comparator
47927875|NCT04399746|DRUG|Cholecalciferol|400 IU twice daily for 30 days
48097924|NCT04057456|OTHER|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
48097925|NCT04057456|DRUG|Nabilone Capsules|Capsules will be 0.5mg nabilone. Participants will undergo a 5-week titration period by taking 1 (0.5mg) nabilone capsule per day for a three-day period. The dose will be increased on a fixed schedule by 1 (0.5mg) capsule every three days to a maximum of 8 capsules/day (4mg). Dosage will be maintained if higher doses are not tolerated or if sufficient relief is obtained (at least a 2-point change on the NRS). Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period.
48097926|NCT04057456|OTHER|Placebo capsules|Placebo capsules contain no active ingredient. Participants on placebo capsules will undergo the same 5-week titration period and intervention period as those on active treatment.
48097927|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Pain Intensity 3a|PROMIS Scale v2.0 - Pain Intensity 3a is a 3-question short form in which patients rate their worst, average, and current level of pain during the past 7 days.
48097928|NCT06627582|BEHAVIORAL|PROMIS 29+2|PROMIS 29+2 (PROMIS-Preference, PROPr) is a compilation of item banks to assess pain intensity
48097929|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Nociceptive Pain Quality 5a|5-question short form that identifies patients who have experienced nociceptive pain during the past 7 days
48097930|NCT06627582|BEHAVIORAL|PROMIS Scale v2.0 - Neuropathic Pain Quality 5a|5-question short form that identifies patients who have experienced neuropathic pain during the past 7 days
48097931|NCT02662192|OTHER|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
48097932|NCT02662192|OTHER|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
48097933|NCT06630117|BIOLOGICAL|V330|Intramuscular injection
48097934|NCT06630117|BIOLOGICAL|Placebo|Intramuscular injection
48097935|NCT04587791|DRUG|400mg Cannabidiol|Participants will receive 400mg
48097936|NCT04587791|DRUG|800mg Cannabidiol|Participants will receive 800mg
48097937|NCT04587791|DRUG|1200mg Cannabidiol|Participants will receive 1200mg
48097938|NCT04587791|DRUG|Saline|Participants will receive saline
48097939|NCT04984876|DRUG|ligelizumab|Subcutaneous injection once every 4 weeks
48097940|NCT04984876|DRUG|Placebo|Subcutaneous injection once every 4 weeks
48273262|NCT04348851|BEHAVIORAL|Caregiver problem-solving|Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
48273263|NCT04348851|BEHAVIORAL|Attention Control|The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
48273264|NCT00642642|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
48273265|NCT00642642|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
48273266|NCT02633176|DRUG|Cetuximab|400 mg/m\^2 intravenously on day 1,then 250 mg/m\^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m\^2 intravenously every week concurrent with radiotherapy.
48273267|NCT02633176|DRUG|Cisplatin|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.
48273268|NCT02633176|DRUG|Docetaxel|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
48273269|NCT02633176|DRUG|Capecitabine|1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
48273270|NCT02633176|RADIATION|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
48273271|NCT04256967|OTHER|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
48273272|NCT02991599|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
48273273|NCT02991599|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
48273274|NCT00542711|DRUG|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
48273275|NCT03972631|BEHAVIORAL|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
48273276|NCT03972631|BEHAVIORAL|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
48273277|NCT03972631|BEHAVIORAL|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
48273278|NCT03269981|RADIATION|Whole breast irradiation|Radiotherapy to the whole breast alone.
48273279|NCT03269981|RADIATION|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
48273280|NCT01841892|BEHAVIORAL|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
48273281|NCT05390216|PROCEDURE|Partial capsule decortication|The anterior wall of the capsule was removed during the operation.
48273282|NCT01583426|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
48273283|NCT01583426|DRUG|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
48273284|NCT02351102|DRUG|Valacyclovir|
48444007|NCT01992991|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
48444008|NCT04935411|OTHER|nAMD|patients diagnosed with Neovascular Age-Related Macular Degeneration
48097941|NCT03363256|BEHAVIORAL|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
48097942|NCT03363256|BEHAVIORAL|TAU|Standard outpatient addiction treatment
48097943|NCT00186680|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
48273285|NCT02351102|DRUG|Placebo|
48273286|NCT05655403|BEHAVIORAL|Step training program|The program will consist of 3 phases: (1) getting familiar, (2) increasing complexity, and (3) consolidating skills. In Phase 1, the participants will be asked to use one foot to step on single-colored stepping panels located in a specific region of the plastic mat (e.g., upper quadrant). In Phase 2, the exercise will progress by introducing the following 4 cognitively challenging stepping tasks. After finishing the 4 stepping tasks in Phase 2, the exercises will progress to Phase 3, which will consolidate the participants' stepping and cognitive skills. The following 4 additional stepping tasks will be introduced. The instructor will tailor the exercises for each participant, based on their training performance.
48273287|NCT01998542|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
48273288|NCT01998542|BIOLOGICAL|CRCL|autologous tumor-derived chaperone protein mixture
48273289|NCT01998542|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
48273290|NCT01717534|DIETARY_SUPPLEMENT|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
48273291|NCT02437136|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACs)
48273292|NCT02437136|DRUG|pembrolizumab|A selective humanized monoclonal antibody (mAb)
48273293|NCT01664793|BEHAVIORAL|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
48273294|NCT01535235|DRUG|Lisinopril|Lisinopril 20mg QD x 24 weeks
48273295|NCT01535235|DRUG|Placebo|Placebo QD x24wks
48273296|NCT01420510|DRUG|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
48273297|NCT01420510|DRUG|Placebo vaginal gel|Application of a placebo vaginal gel
48444009|NCT01618097|BEHAVIORAL|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
48444010|NCT01618097|BEHAVIORAL|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
48273298|NCT02280850|DRUG|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
48273299|NCT02280850|DRUG|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
48273300|NCT02280850|DRUG|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
48273301|NCT02774993|DRUG|Doxycycline|
48273302|NCT02774993|DRUG|placebo|
48273303|NCT00211406|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
48097944|NCT02817373|OTHER|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
48097945|NCT06629974|BEHAVIORAL|Parental empowerment program|"The empowerment program consisted of two parts: the empowerment training program for parents and motivational interviews.~The empowerment training program was prepared to enable parents to carry out the care process more effectively in areas where parents have difficulties caring for their children with autism. Within the scope of the empowerment training program, parents were trained on the importance of play and communication, problems and management in the field of nutrition, sleep problems and management, safety and protection from accidents, and problems and management in the field of self-care.~Ten days after the empowerment training program, two face-to-face motivational interviews were conducted with each participant in the intervention group. Each participant had a one-week break between the first and second motivational interviews. Each motivational interview session lasted approximately 25-30 minutes."
48097946|NCT04138628|DRUG|Atezolizumab|The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
48097947|NCT03693443|BEHAVIORAL|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
48097948|NCT01982643|DRUG|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
48097949|NCT02678052|DRUG|Vedolizumab|Vedolizumab exposure
48097950|NCT02678052|BIOLOGICAL|Other Biological Agent|Other Biological Agent exposure
48097951|NCT03441984|DRUG|Treatment A|TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
48097952|NCT03441984|DRUG|Treatment B|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
48097953|NCT03441984|DRUG|Treatment C|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
48097954|NCT03441984|DRUG|Treatment D|"DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth."
48097955|NCT03441984|DRUG|Treatment E|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
48097956|NCT03441984|DRUG|Treatment F|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
48097957|NCT06554444|PROCEDURE|Dental Implant Surgery|Dental implants will be placed in edentulous areas.
48273304|NCT02344576|BEHAVIORAL|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
48273305|NCT03377920|DEVICE|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"* pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~* 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
48273306|NCT04969055|OTHER|Not|Not
48273307|NCT02627040|DEVICE|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
48273308|NCT02627040|DEVICE|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
48273309|NCT00254566|OTHER|Moxifloxacin Placebo|1 capsule once daily for 5 days
48273310|NCT00254566|DRUG|Moxifloxacin|1 X 400mg capsule once daily for 5 days
48273311|NCT00254566|OTHER|Azithromycin SR Placebo|single dose, oral.
48273312|NCT00254566|DRUG|Azithromycin SR|single dose 2.0 g oral
48273313|NCT05257512|DRUG|SY-3505|The third-generation ALK TKI
48273314|NCT02662478|PROCEDURE|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
48273315|NCT01922921|BIOLOGICAL|HER-2/neu Intracellular Domain Protein|Given ID
47927876|NCT03964558|DRUG|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
47927877|NCT02310087|DIETARY_SUPPLEMENT|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
48273316|NCT01922921|OTHER|Laboratory Biomarker Analysis|Correlative studies
48273317|NCT01922921|BIOLOGICAL|Pertuzumab|Given per standard of care
48273318|NCT01922921|OTHER|Placebo|Given PO
48273319|NCT01922921|BIOLOGICAL|Polysaccharide-K|Given PO
48273320|NCT01922921|BIOLOGICAL|Trastuzumab|Given per standard of care
48273321|NCT04143633|OTHER|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
48273322|NCT04143633|OTHER|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
48273323|NCT04249882|DRUG|Placebo|Matched to active medication
48273324|NCT04249882|DRUG|Naltrexone|50 mg once a day
48273325|NCT04249882|DRUG|Varenicline|1 mg twice a day
48273326|NCT03964584|OTHER|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
48273327|NCT05679414|DIAGNOSTIC_TEST|RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes|Venous blood sample
48273328|NCT02906800|DRUG|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
48273329|NCT03462251|COMBINATION_PRODUCT|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
48273330|NCT03462251|COMBINATION_PRODUCT|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
47927878|NCT02310087|OTHER|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
48273331|NCT03575026|BEHAVIORAL|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
48273332|NCT03575026|BEHAVIORAL|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
48273333|NCT00421876|BEHAVIORAL|multifactorial continued educational - behavioural programme|
48273334|NCT01780792|OTHER|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
48273335|NCT00192374|BIOLOGICAL|CAIV-T, Liquid|
48273336|NCT00295945|DRUG|fentanyl citrate|
48273337|NCT00295945|DRUG|hydromorphone hydrochloride|
48273338|NCT00295945|DRUG|ropivacaine hydrochloride|
48273339|NCT06310148|COMBINATION_PRODUCT|The Chronic Disease Co-Care (CDCC) Pilot Scheme|Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
48273340|NCT04301427|OTHER|Bone mineral density|Bone mineral density will be measured twice in all included patients.
48273341|NCT00006449|DRUG|naltrexone (Revia)|
48273342|NCT00006449|BEHAVIORAL|broad spectrum treatment|
48273343|NCT00006449|BEHAVIORAL|motivational enhancement therapy|
48273344|NCT00708370|OTHER|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
48273345|NCT00708370|OTHER|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
47927879|NCT00274924|BIOLOGICAL|filgrastim|Given subcutaneously or intravenous bolus.
48273346|NCT01284803|BEHAVIORAL|an educational intervention|To elaborate an educational program for the management of depression in primary care
48273347|NCT06247969|DEVICE|endotracheal tube|Endotracheal Tube (ETT) is a flexible plastic tube that is inserted through the mouth or nose into the trachea to establish an artificial airway.
48273348|NCT05357456|BEHAVIORAL|Cognitive function assessment; functional magnetic resonance imaging|cognitive function measurement
47927880|NCT00274924|BIOLOGICAL|rituximab|Given IV
47927881|NCT00274924|DRUG|carboplatin|Given IV
47927882|NCT00274924|DRUG|cyclophosphamide|Given IV
47927883|NCT00274924|DRUG|doxorubicin hydrochloride|Given IV
48273349|NCT05357456|PROCEDURE|laparoscopic adrenal surgery|Only a subgroup of the autonomous cortisol secretion patients will have the laparoscopic adrenal surgery
48273350|NCT01364805|DRUG|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
48273351|NCT01364805|DRUG|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
47927884|NCT00274924|DRUG|etoposide|Given IV
47927885|NCT00274924|DRUG|ifosfamide|Given IV
47927886|NCT00274924|DRUG|prednisone|Taken orally
47927887|NCT00274924|DRUG|vincristine|Given IV
47927888|NCT00775203|DRUG|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
47927889|NCT00775203|DRUG|Placebo|
47927890|NCT04842032|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
48273352|NCT01984515|BEHAVIORAL|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
48273353|NCT04790591|PROCEDURE|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
48273354|NCT02550899|PROCEDURE|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
48273355|NCT02550899|PROCEDURE|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
48273356|NCT02550899|PROCEDURE|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
48273357|NCT01769105|DEVICE|Lipiflow|Patients receive a single Lipiflow-treatment
48273358|NCT01769105|BEHAVIORAL|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
48273359|NCT02236689|PROCEDURE|Non operative|no surgical intervention
48273360|NCT02236689|PROCEDURE|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
48273361|NCT05501626|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
48273362|NCT05501626|DEVICE|Sham Theta Burst Stimulation (TBS)|Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
48273363|NCT05383924|PROCEDURE|postplacental IUD insertion|"patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD."
48273364|NCT05383924|PROCEDURE|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
48273365|NCT00899652|GENETIC|Southern blotting|
48273366|NCT00899652|GENETIC|chromosomal translocation analysis|
48273367|NCT00899652|GENETIC|cytogenetic analysis|
48273368|NCT00899652|GENETIC|gene rearrangement analysis|
48273369|NCT00899652|GENETIC|mutation analysis|
48273370|NCT05243849|DEVICE|Optical Coherence Tomography Angiography|Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
48273371|NCT01910792|DEVICE|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
48273372|NCT04812561|DIETARY_SUPPLEMENT|Bronch™|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
48273373|NCT04812561|DIETARY_SUPPLEMENT|placebo|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
48273374|NCT01284790|DEVICE|Cochlear implants|
48273375|NCT01672957|DRUG|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
48273376|NCT01672957|DRUG|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
48273377|NCT05148026|DRUG|Unfractionated heparin + RCA first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH
48273378|NCT05148026|DRUG|Unfractionated heparin first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
48273379|NCT05641883|COMBINATION_PRODUCT|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
48273380|NCT02949830|DRUG|Givosiran|Givosiran by subcutaneous (SC) injection.
48273381|NCT02886702|DRUG|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
48273382|NCT02886702|DRUG|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
48273383|NCT02886702|DRUG|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
48273384|NCT02557087|DRUG|Hyoscine|
48273385|NCT02557087|DRUG|Pethidine|
48273386|NCT03884465|DRUG|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
48444011|NCT03091335|OTHER|Music-listening|Patients listen to music on headphones
47927891|NCT02186301|DRUG|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
48273387|NCT03562494|BIOLOGICAL|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
48273388|NCT03562494|OTHER|Sham (Placebo) Surgery|Bilateral partial burr/twist holes without dura penetration
48273389|NCT03168516|DEVICE|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)|Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
48273390|NCT01964404|DRUG|Marijuana|Smoked plant with THC
48273391|NCT01964404|DRUG|Dronabinol|Capsule with THC
48273392|NCT01964404|DRUG|Placebo|Capsule with no active ingredient
48273393|NCT05953636|DIETARY_SUPPLEMENT|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session)|oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) given in group A (predialytic: 1 hour before the start of the session), in group B (intradialytic: 2 hours after the start of the session ), in group C (interdialytic: in non-dialysis days )
48273394|NCT01575613|DRUG|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
48273395|NCT01575613|BIOLOGICAL|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
48273396|NCT01575613|BIOLOGICAL|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
48273397|NCT01575613|BIOLOGICAL|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
48273398|NCT00000981|DRUG|Fiacitabine|
48273399|NCT00506857|DRUG|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
48273400|NCT00506857|DRUG|Fludarabine|30 mg/m\^2 by vein daily x 4 days.
48273401|NCT05205590|OTHER|Non|Non
48273402|NCT05859087|BEHAVIORAL|Counseling|Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.
48273403|NCT05859087|BEHAVIORAL|Flyer|Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
48273404|NCT01392183|DRUG|Pazopanib|800 mg by mouth daily in 4 week study cycle.
48273405|NCT01392183|DRUG|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
48273406|NCT01392183|BEHAVIORAL|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
48273407|NCT01392183|DRUG|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
48273408|NCT01285349|BEHAVIORAL|Couple HIV/STI prevention intervention|
48273409|NCT01285349|BEHAVIORAL|Couple-based HIV/STI prevention|
48273410|NCT01285349|BEHAVIORAL|Individual HIV/STI prevention|
48273411|NCT01285349|BEHAVIORAL|Couple Wellness Promotion|
48273412|NCT00190060|DRUG|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
48273413|NCT00190060|DRUG|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
48273414|NCT02953717|RADIATION|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
48273415|NCT02953717|RADIATION|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
48273416|NCT01961115|DRUG|Epacadostat|Given PO
48273417|NCT01961115|BIOLOGICAL|MELITAC 12.1 Peptide Vaccine|Given ID/SC
48273418|NCT03787914|PROCEDURE|Mobile Outreach Approach|TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
48273419|NCT02304926|DRUG|Simvastatin|simvastatin (40 mg/day) for 4 weeks
48273420|NCT02304926|DRUG|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
48273421|NCT02304926|DRUG|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
48273422|NCT01993888|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|
48273423|NCT01993888|OTHER|Standard of Care (SoC)|
48273424|NCT00808444|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
48273425|NCT00808444|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
48273426|NCT00808444|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
48273427|NCT00808444|BIOLOGICAL|Rotarix|Oral, 2 doses
48273428|NCT06078657|DRUG|IBI110+Sintilimab|"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."
48273429|NCT01486420|PROCEDURE|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
48273430|NCT01486420|PROCEDURE|Open surgery|Open A1-pulley release
48273431|NCT00006131|DRUG|Valacyclovir|
48273432|NCT05192343|DEVICE|Virtual Reality and nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
48273433|NCT05192343|OTHER|nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
48273434|NCT05238584|PROCEDURE|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at \>2 cm from the gastroepiploic arcade.
48273435|NCT01746251|DRUG|Afatinib|
48273436|NCT01834404|DRUG|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
48273437|NCT01834404|DRUG|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
48273438|NCT01652924|DEVICE|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
48273439|NCT01652924|DEVICE|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
48273440|NCT05804799|DIAGNOSTIC_TEST|Contrast-enhanced liver CT scan|"The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
48273441|NCT04011202|BEHAVIORAL|Virtual reality gaming program (VR-gaming program)|Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
48273442|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
48273443|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
48273444|NCT05003557|OTHER|Questionnaire administration|"3 different questionnaires are going to be administered to each participant,~* concerning the current health situation~* the SF 36~* the IPQ-R questionnaire"
48273445|NCT06160102|OTHER|Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities|"Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation."
48273446|NCT04566484|DRUG|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
48273447|NCT04566484|DRUG|Normal Saline|Normal saline is the placebo
48273448|NCT06130332|DRUG|PD-1 with chemotherapy|"Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
48273449|NCT06130332|PROCEDURE|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
48273450|NCT04453774|DEVICE|Covidfree@home|Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
48273451|NCT00003729|DRUG|cytarabine|
48273452|NCT00003729|DRUG|fludarabine phosphate|
48273453|NCT00003729|DRUG|idarubicin|
48273454|NCT06220695|BEHAVIORAL|Dietary intervention|The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
48273455|NCT00002309|DRUG|Azithromycin|
48273456|NCT06248957|COMBINATION_PRODUCT|Immunomodulation|Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation
48273457|NCT00255073|DRUG|baclofen|
48444012|NCT01237691|BEHAVIORAL|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
47927892|NCT02186301|DRUG|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
48273458|NCT03462095|PROCEDURE|Autologous HSCT|After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
48273459|NCT00206921|DEVICE|Pulsed dye laser|
48273460|NCT00206921|DEVICE|Intense pulsed light|
48273461|NCT03648918|OTHER|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
48273462|NCT02505529|OTHER|Resistance Exercise Training|Behavioral interventions of resistance exercise
48273463|NCT02505529|OTHER|Mental Imagery|Behavioral intervention of mental imagery
48273464|NCT01541293|DRUG|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
48273465|NCT01541293|DRUG|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
48273466|NCT06134297|DEVICE|Cycle ergometer|The Aerobic Exercise Group will perform a cycle ergometer for 15 consecutive minutes with a load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age). Peripheral oxygen saturation will be controlled and, upon a sustained drop (\> 2 minutes after load reduction) below 90%, the session will be interrupted. The subjective feeling of tiredness in the legs and shortness of breath will be constantly monitored and if values equal to or greater than 8 (0-10) occur, the exercise will be stopped.
48273467|NCT06134297|DEVICE|Strength Training - elastic band and shin guards|The Anaerobic Exercise Group will perform muscular strength training using maximum strength, where the contraction time should not exceed 20 seconds. For the upper limbs, the overload used will be through the use of an elastic band, with guidance for the patient to perform the shoulder external rotation exercise, elbow flexion exercises and open row rowing exercise. For the lower limbs, bridge movements, lunges and sit-up exercises will be performed with a maximum of 15 repetitions, and overload with ankle weights or dumbbells can be used in addition to body weight. The muscle contraction should lead the patient to a state of muscular fatigue and if the objective is not achieved, the exercise will be adapted to require greater strength from the patient so that he or she can reach maximum strength.
48273468|NCT06134297|DEVICE|Cycle ergometer, elastic band and shin guards|Mixed Exercise Group will perform the exercises by alternating between aerobic and anaerobic overload, in a 1:1 ratio until the end of the physical rehabilitation program, following exactly the same protocols described previously (alternating one session of the aerobic protocol and in the following session the anaerobic protocol).
48273469|NCT06368726|DEVICE|tDCS or Transcranial Direct Current Stimulation|We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days
48273470|NCT06368726|DRUG|Risperidone|Risperidone Risperidone according to child's weighs
48273471|NCT05774821|PROCEDURE|Tricuspid valve surgery|Surgical repair or valve prosthesis implant to treath the regurgitation of the tricuspid valve
48273472|NCT02867631|BEHAVIORAL|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
48273473|NCT02773329|OTHER|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
48273474|NCT02773329|OTHER|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
48273475|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract|
48273476|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin|
48273477|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract placebo|
48273478|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin placebo|
48273479|NCT05424393|DRUG|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
48273480|NCT05424393|DRUG|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
48273481|NCT00971126|DRUG|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
48273482|NCT01580930|BEHAVIORAL|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
48273483|NCT01580930|BEHAVIORAL|sedentary time reduction|participants provided with strategies to decrease sitting
48273484|NCT01580930|BEHAVIORAL|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
48273485|NCT04002167|BEHAVIORAL|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
48273486|NCT04002167|BEHAVIORAL|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
48273487|NCT04354428|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
48273488|NCT04354428|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy
48273489|NCT04354428|DRUG|Azithromycin|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
48273490|NCT04354428|DRUG|Folic Acid|Eligible participants in a household will receive folic acid and an additional intervention drug
48273491|NCT04354428|DRUG|Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]|Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
48273492|NCT02125214|DEVICE|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
48273493|NCT02770157|DRUG|DA-3002|
48273494|NCT02770157|DRUG|Genotropin®|
48273495|NCT01499290|DRUG|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
48273496|NCT01499290|DRUG|Metronidazole|500 mg of Metronidazole
48273497|NCT01499290|DRUG|Meropenem|1 gram of Meropenem
48273498|NCT00275561|DRUG|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
48273499|NCT00275561|DRUG|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
48273500|NCT03651843|OTHER|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
48273501|NCT05401747|OTHER|Healthy lifestyle|Nutrition consultation and teaching: A registered dietitian has the responsibility of teaching and explaining the diet. Plan: One meeting per 12 weeks. The exercise program is based on the Physical Activity Guidelines Advisory Committee and American Heart Association guideline and a modified version of Dose-Responses to Exercise Training study protocol for older adults summarized our weekly plans in detail. Plan: 2 meetings per week. Cognitive enhancement: Participants can select any of the following activities:methods requiring mental activities, physical activity, and social activity, enjoying music and our weekly dance classes (Waltz).
48273502|NCT02747524|OTHER|Vita Mamba peanut butter paste|
48273503|NCT01023984|PROCEDURE|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
48273504|NCT01023984|PROCEDURE|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
48273505|NCT01150487|PROCEDURE|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
48273506|NCT01150487|PROCEDURE|lymph node collection|An Iliac lymph node collection.
48273507|NCT03908944|DRUG|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
48273508|NCT03908944|DRUG|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
48273509|NCT00157833|DRUG|Artekin / Coartemther|
48273510|NCT03921996|PROCEDURE|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
48273511|NCT03921996|PROCEDURE|Radical prostatectomy (RP) only|Radical prostatectomy
48273512|NCT02953808|DRUG|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
48273513|NCT02953808|DRUG|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
48273514|NCT04647110|DRUG|crizotinib|as provided in real world practice
48273515|NCT04647110|DRUG|alectinib|as provided in real world practice
48273516|NCT04647110|DRUG|brigatinib|as provided in real world practice
48273517|NCT04647110|DRUG|ceritinib|as provided in real world practice
48273518|NCT04647110|DRUG|lorlatinib|as provided in real world practice
48273519|NCT04003129|OTHER|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
48273520|NCT05797714|DRUG|Tenofovir Amibufenamide（TMF）|TMF, 25mg QD, from baseline to 144 weeks
48273521|NCT03119012|DRUG|Clopidogrel|75mg/day
48273522|NCT03119012|DRUG|Ticagrelor|120mg/day
48273523|NCT03119012|DRUG|Aspirin|100mg/day
48273524|NCT02493348|DEVICE|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
48273525|NCT04673097|OTHER|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
48273526|NCT04673097|OTHER|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
48273527|NCT00284830|DEVICE|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
48444013|NCT01237691|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
48444014|NCT03655535|DRUG|BTI320|Non-systemic galactomannan complex polysaccharide
48444015|NCT03655535|OTHER|Placebo|Placebo
48273528|NCT03625531|OTHER|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
48273529|NCT03625531|DRUG|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
48273530|NCT03625531|DRUG|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
48273531|NCT03561402|DRUG|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
48273532|NCT06057311|OTHER|Hippotherapy|The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
48273533|NCT06057311|OTHER|Equine-Assisted Activities Therapy|The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
48273534|NCT06057311|OTHER|Control|The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
48273535|NCT06321692|OTHER|Evaluation of blood levels of biomarkers of cardiac damage|Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
48273536|NCT01097928|PROCEDURE|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
48273537|NCT02910427|OTHER|Regular salt|Participants eat a regular salt diet.
48273538|NCT02910427|OTHER|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
48273539|NCT02910427|OTHER|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
48273540|NCT01111604|BIOLOGICAL|Ramucirumab|8 mg/kg IV Q2W
48273541|NCT01111604|BIOLOGICAL|Icrucumab|15 mg/kg IV Q2W
48273542|NCT01111604|DRUG|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
48273543|NCT04410874|BIOLOGICAL|Imvamune|Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
48273544|NCT05432531|DRUG|Anti JAK1,2|Induction of remission of active lupus nephritis
48273545|NCT05432531|DRUG|Cyclophosphamid|Induction of remission of active lupus nephritis
48273546|NCT03367871|DRUG|Pembrolizumab|IV
48273547|NCT03367871|DRUG|Paclitaxel|Administered intravenously (IV) on day 1
48273548|NCT03367871|DRUG|Cisplatin|Administered intravenously (IV) on day 1
48273549|NCT03367871|DRUG|Carboplatin|Administered intravenously (IV) on day 1
48273550|NCT03367871|DRUG|Bevacizumab|Administered intravenously (IV) on day 1
48273551|NCT06354933|DIAGNOSTIC_TEST|Neurological Soft Signs|Neurological Soft Signs score according to the Heidelberg Manual
48273552|NCT03448640|DRUG|Drug used in the examination of premature infants.|to investigate side effects of eye drops used
48273553|NCT04772248|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
48273554|NCT04772248|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
48273555|NCT02126059|BEHAVIORAL|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5."
48273556|NCT02126059|BEHAVIORAL|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5."
48273557|NCT02126059|BEHAVIORAL|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
48273558|NCT03746691|DRUG|Citalopram HCl|Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
48273559|NCT03746691|DRUG|Placebos|Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
48273560|NCT03733652|DRUG|Interferon Alfa 2a|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
48273561|NCT01349140|DRUG|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
48273562|NCT04386889|OTHER|Vasculitis In SLE|20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
48273563|NCT00930202|DRUG|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
48273564|NCT04911621|BIOLOGICAL|Dendritic cell vaccination + temozolomide-based chemoradiation|"1. Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~2. Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~3. Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle."
48273565|NCT04911621|BIOLOGICAL|Dendritic cell vaccination +- conventional next-line treatment|"1. Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~2. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~3. Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~4. (Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition."
48273566|NCT06023667|BEHAVIORAL|SMART-IBD|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
48273567|NCT01919892|DRUG|Lithium|
48273568|NCT04156321|DIETARY_SUPPLEMENT|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
48273569|NCT04378166|DEVICE|Smart glass|Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
48273570|NCT04923594|DRUG|mazindol extended release|Dosed orally, once daily for up to 3 weeks
48273571|NCT04923594|DRUG|Placebo|Dosed orally, once daily for up to 4 weeks.
48273572|NCT06444438|DIAGNOSTIC_TEST|subarachnoid hemorrhage|CT presented subarachnoid hemorrhage
48273573|NCT00723957|DRUG|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
48273574|NCT00723957|DRUG|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m\^2
48273575|NCT00723957|DRUG|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
48273576|NCT04720703|BEHAVIORAL|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
48273577|NCT04720703|BEHAVIORAL|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
48273578|NCT02063555|BIOLOGICAL|DAR-901|
48273579|NCT02063555|BIOLOGICAL|BCG|
48273580|NCT02063555|BIOLOGICAL|Sterile saline|
48273581|NCT01495143|PROCEDURE|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
48273582|NCT01442298|PROCEDURE|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
48273583|NCT01442298|PROCEDURE|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
48273584|NCT03530514|DRUG|REGN4461|REGN4461
48273585|NCT03530514|DRUG|Placebo|Placebo-matching REGN4461
48273586|NCT01032629|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily
48273587|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
48273588|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
48273589|NCT05821361|DRUG|HAIC+Cadonilimab+Bevacizumab|Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
48273590|NCT01019564|DEVICE|Complete Easy Rub Formula MPS|Multi-purpose solution
48273591|NCT01019564|DEVICE|Aquify MPS|Multi-purpose solution
48273592|NCT05865184|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
48273593|NCT03683602|OTHER|PNF group|PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
48273594|NCT03683602|OTHER|manual therapy group|"Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain."
48273595|NCT04581720|DEVICE|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 \~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
48273596|NCT05146908|BIOLOGICAL|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
48273597|NCT05146908|OTHER|Echography|"In 3 steps:~* before initiation of enteral nutrition~* 4h after initiation of enteral nutrition~* After 24 hours of enteral nutrition"
48273598|NCT05146908|OTHER|Data collection|"At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~* echographic parameters at H0, H4 and H24~* venous congestion parameters~* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~* the occurrence or not of the primary endpoint (and time to occurrence).~* symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~* organ failure and replacement over the period, and mortality.~* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study."
48273599|NCT00925600|BIOLOGICAL|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
48273600|NCT00925600|BIOLOGICAL|Placebo|Prefilled syringe for subcutaneous (SC) injection
48273601|NCT06544109|DRUG|venetoclax|patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
48273602|NCT03871894|OTHER|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
48273603|NCT03871894|OTHER|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
48273604|NCT03377647|BEHAVIORAL|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
48273605|NCT03377647|BEHAVIORAL|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
48273606|NCT06117189|OTHER|Questionnaire|Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
48273607|NCT04698876|PROCEDURE|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
48273608|NCT04698876|PROCEDURE|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
48273609|NCT04698876|PROCEDURE|Blood pressure|Blood pressure measurement for 24 h
48273610|NCT01305499|DRUG|Entinostat days 3, 10|Given orally on days 3, 10
48273611|NCT01305499|DRUG|5AC|
48273612|NCT01305499|DRUG|Entinostat days 10,17|Given orally on days 10, 17
48273613|NCT00480857|DRUG|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
48273614|NCT03152942|DRUG|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
48273615|NCT03152942|DRUG|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
48273616|NCT01872455|DIETARY_SUPPLEMENT|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
48273617|NCT01872455|DIETARY_SUPPLEMENT|Usual diet|Usual diet of the patients
48273618|NCT00452803|DRUG|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
48273619|NCT00452803|DRUG|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
48273620|NCT00452803|RADIATION|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
48273621|NCT00840827|DRUG|lenalidomide|Lenalidomide 10mg po daily
48273622|NCT00840827|DRUG|cyclosporine A|CSA 250mg orally twice daily
48273623|NCT01776125|OTHER|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
48273624|NCT00003200|DRUG|Taxotere|
48273625|NCT00003200|RADIATION|Radiation therapy|
48273626|NCT05317767|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
48273627|NCT05317767|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
48273628|NCT00032084|BEHAVIORAL|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
48273629|NCT00032084|DRUG|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
48273630|NCT00032084|DRUG|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
48273631|NCT00032084|PROCEDURE|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
48273632|NCT01128387|DRUG|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
48273633|NCT04418921|BEHAVIORAL|Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality|The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
48273634|NCT04418921|BEHAVIORAL|Traditional self-regulation program|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
48273635|NCT01053910|DRUG|Ramipril|tablet of Ramipril once daily
48273636|NCT03796403|OTHER|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
48273637|NCT01409928|DEVICE|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
48273638|NCT04301414|DRUG|BMS-986218 and Degarelix|BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy plus degarelix 240mg subcutaneous (SQ) x1 dose 2 weeks prior to radical prostatectomy.
48273639|NCT04301414|DRUG|Degarelix|Degarelix 240mg SQ x1 dose 2 weeks prior to radical prostatectomy
48273640|NCT04752202|BEHAVIORAL|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
48273641|NCT04752202|BEHAVIORAL|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
48273642|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
48273643|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
48273644|NCT02786901|DRUG|Vehicle Gel|Gel
48273645|NCT02406846|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
48273646|NCT02406846|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
48273647|NCT01226290|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
48273648|NCT03009604|DRUG|Simethicone|Simethicone 40mg oral tablets
48273649|NCT03009604|DRUG|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
48273650|NCT00931164|DRUG|Sodium Oxybate|dosage is by weight
48273651|NCT04004052|OTHER|Ultrasound guided injection|
48273652|NCT04004052|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
48273653|NCT04004052|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
48273654|NCT01487369|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
48273655|NCT00859859|DEVICE|Vagus Nerve Stimulation|"1. Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~2. Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
48273656|NCT04108429|BEHAVIORAL|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
48273657|NCT04920773|OTHER|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
48273658|NCT04920773|OTHER|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
48273659|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
48273660|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
48273661|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
48273662|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
48273663|NCT02847884|BIOLOGICAL|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
48273664|NCT00705237|PROCEDURE|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
48273665|NCT03322358|OTHER|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
48273666|NCT03322358|DEVICE|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
48273667|NCT03322358|OTHER|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
48273668|NCT00522392|DRUG|bortezomib|Given IV
48273669|NCT00522392|DRUG|lenalidomide|Given PO
48273670|NCT00522392|DRUG|dexamethasone|Given PO
48273671|NCT02093611|DIETARY_SUPPLEMENT|Placebo|
48273672|NCT02093611|DIETARY_SUPPLEMENT|ATP|400 mg of ATP
48273673|NCT03311672|DRUG|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
48273674|NCT03311672|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
48273675|NCT03311672|RADIATION|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
48273676|NCT00666744|OTHER|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
48273677|NCT04879797|OTHER|Implementation of Maternal Safety Bundles|In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
48273678|NCT04879797|OTHER|Doula Services|Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
48273679|NCT00446914|BEHAVIORAL|Systems Change (High Blood Pressure Strategy)|
48273680|NCT05920213|DRUG|Polyethylene Glycols|280g/ 24 hours for 5 days
48273681|NCT05920213|DRUG|Lactulose oral solution|60-120 ml per day for 5 days
48273682|NCT05920213|DRUG|L-ornithine L-aspartate|30g/24 hours in 3 divided doses for 5 days
48273683|NCT05897814|OTHER|Location of the epidural analgesia catheter|Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
48273684|NCT00615537|PROCEDURE|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
48273685|NCT03886844|DIETARY_SUPPLEMENT|Human milk fortifier based on human milk (Prolacta)|Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight \<10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
48273686|NCT02661594|DRUG|APD421 5 mg|Therapeutic dose of amisulpride
48273687|NCT02661594|DRUG|APD421 40 mg|Supra-therapeutic dose of amisulpride
48273688|NCT02661594|DRUG|Moxifloxacin|Positive control for assay sensitivity
48273689|NCT02661594|DRUG|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
48273690|NCT03751267|PROCEDURE|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
48273691|NCT05170360|DIAGNOSTIC_TEST|Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:|"1. Assessment of smoking exposure:~   Serum cotinine will be measured by using serum cotinine ELISA kits~2. Assessment of heavy metal exposure:~   Lead and cadmium will be measured using Graphite Tube Atomizer.~3. Assessment of organophosphorus exposure:~   By measuring pseudocholinesterase level by spectrophotometer~4. Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR"
48273692|NCT04489654|BIOLOGICAL|deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)|deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
48273693|NCT00308724|BEHAVIORAL|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
48273694|NCT00308724|BEHAVIORAL|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
48273695|NCT04879615|DRUG|Alteplase|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
47927893|NCT05557825|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 830 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy
48273696|NCT01929083|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
48273697|NCT01929083|DRUG|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
48273698|NCT01929083|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
48273699|NCT03437421|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|"* Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
48273700|NCT03345186|OTHER|nurse led plus standard of care|structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
48273701|NCT02144272|DRUG|LY3114062 SC|LY3114062 administered SC.
48273702|NCT02144272|DRUG|Placebo|Placebo administered SC.
48273703|NCT02144272|DRUG|LY3114062 IV|LY3114062 administered IV.
48273704|NCT01499173|BEHAVIORAL|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
48273705|NCT02815215|PROCEDURE|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
48273706|NCT02815215|PROCEDURE|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
48273707|NCT05337618|DIAGNOSTIC_TEST|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
48273708|NCT05337618|COMBINATION_PRODUCT|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
48273709|NCT06295055|PROCEDURE|Ridge augmentation with semi-rigid shell barrier system|The semi-rigid shell, fixed to the outside cortex by tacks, acts as a bone wall. Bone particles are placed in the gap and covered with the semi-resorbable covering membrane, serving as a barrier membrane.
47927894|NCT04674540|OTHER|No Intervention|No Intervention
48273710|NCT03941002|DIAGNOSTIC_TEST|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
48273711|NCT03770403|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
48273712|NCT00562380|BIOLOGICAL|ganitumab|
48273713|NCT00562380|OTHER|laboratory biomarker analysis|
48273714|NCT00562380|OTHER|pharmacological study|
47927895|NCT00927940|DEVICE|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
47927896|NCT03986931|OTHER|Experimental: Pharmacist-Bidirectional Texting Group|The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
48273715|NCT00562380|PROCEDURE|biopsy|
48273716|NCT01954823|DEVICE|e-diary|"The e-diary can collect data on:~* Medical data: information on diseases, treatments and attending physicians~* Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~* Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~* Reports: textual and graphical reports of the data in the diary can be created"
48273717|NCT01147614|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
48273718|NCT01147614|BEHAVIORAL|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
48273719|NCT00747487|DRUG|Idebenone|Idebenone 900 mg/day
48273720|NCT00747487|DRUG|Placebo|Placebo
47927897|NCT03986931|OTHER|Active Comparator: Control Group|This group will receive bidirectional texting, but no pharmacist monitoring.
48273721|NCT01526356|DRUG|Placebo|Study cream is applied nightly to the affected areas on the face.
48273722|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
48273723|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
48273724|NCT01157117|BIOLOGICAL|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
48273725|NCT01157117|BIOLOGICAL|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
48273726|NCT01157117|DRUG|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
48273727|NCT02266550|DRUG|[14C] BILL 284 BS|
48273728|NCT00873002|DRUG|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
48273729|NCT00873002|DRUG|sorafenib tosylate|400 mg PO BID
48273730|NCT05585255|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.
48273731|NCT03931174|BEHAVIORAL|Addiction Technology Transfer Center (ATTC) Training Strategy|Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
48273732|NCT03931174|BEHAVIORAL|Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy|Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
48273733|NCT01653730|DEVICE|Eclipse 3 portable oxygen concentrator|
48273734|NCT01653730|DEVICE|EverGo portable oxygen concentrator|
48273735|NCT01653730|DEVICE|iGo portable oxygen concentrator|
48273736|NCT01859403|GENETIC|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
48273737|NCT01859403|GENETIC|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
48273738|NCT01883037|OTHER|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
48273739|NCT02415790|DRUG|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
48273740|NCT02415790|DRUG|E2027 matching placebo|E2027 matching placebo capsule will be administered.
48273741|NCT04762030|DRUG|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
48273742|NCT00131807|PROCEDURE|Blood Pressure Measurement|
48273743|NCT00131807|PROCEDURE|Questionnaire|
48273744|NCT03202693|DRUG|PA-824|
48273745|NCT00365989|DEVICE|ExAblate Enhanced Sonication|
48273746|NCT02519114|PROCEDURE|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
48273747|NCT01238120|DRUG|Ibuprofen|200 mg BID and 8 hours apart
48273748|NCT01238120|BEHAVIORAL|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
48273749|NCT01238120|DRUG|Placebo|200mg BID and 8 hours apart
48273750|NCT04020744|OTHER|real-time fMRI based neurofeedback from the hippocampus|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
48273751|NCT04020744|OTHER|real-time fMRI based neurofeedback from another brain area|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
48273752|NCT03376633|BEHAVIORAL|Working on Womanhood (WOW)|A trauma-informed group counseling and clinical mentoring intervention for young women
48273753|NCT02467998|DEVICE|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
48273754|NCT00433888|DRUG|R744|100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
48273755|NCT00433888|DRUG|R744|150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
48273756|NCT01309737|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
48273757|NCT01309737|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
48273758|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
48273759|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
48273760|NCT00519870|DRUG|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
48273761|NCT00519870|DRUG|losartan|II: losartan
47927898|NCT03991546|BEHAVIORAL|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
48273762|NCT00519870|DRUG|Nifedipine, losartan|I: nifedipine II: losartan
48273763|NCT06438328|DIAGNOSTIC_TEST|Left/ Right affected arm|Therapeutic exercises: eccentric and concentric exercises and wrist isometrics 10 repetitions of 3 sets with 10 seconds interval
48273764|NCT06438328|OTHER|Grip strength|assessed by using modified sphygmomanometer in which it first inflated to 100 mmHg with closed valve. The pressure was reduced to 20mmHg and the resisted wrist extension performed at baseline and at the 4th week.
48273765|NCT04828824|DRUG|Ethinyl Estradiol / Norgestimate Oral Tablet|Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
48273766|NCT00195130|BEHAVIORAL|There are no interventions in this study|
48273767|NCT00000148|PROCEDURE|Argon Laser Trabeculoplasty|
48273768|NCT00000148|PROCEDURE|Trabeculectomy|
48273769|NCT01136239|DRUG|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
48273770|NCT01136239|DRUG|Placebo|Placebo (600mg twice daily)
48273771|NCT04841226|DEVICE|Long-term indwelling Foley catheter|Foley Catheter inserted for up to 28-days
48273772|NCT00340431|DRUG|MSP1(42)-FVO & MSP1(42)-3D7|
48273773|NCT03184844|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
48273774|NCT05843214|OTHER|Non-invasive neuromonitoring evaluation (transcranial doppler, optic nerve envelope diameter and quantitative pupillometry)|4 days Post-operation follow-up. Data will be gathered before the surgery and at regular times after the surgery until day 4
48273775|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
48273776|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PG)|5.0 grams of PGX
48273777|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX|7.5 grams of PGX
48273778|NCT00801814|DIETARY_SUPPLEMENT|Control|0g of PGX
48273779|NCT00801814|DIETARY_SUPPLEMENT|Second Control|0g of PGX
48273780|NCT03529656|BEHAVIORAL|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
48273781|NCT04082104|DIAGNOSTIC_TEST|Stuttering Severity Instument version 3|Riley's Stuttering Severity Instrument is used for the objective assessment of severity and in other examinations of stuttered speech. Current versions of the instrument measures three parameters: 1) stuttering frequency; 2) duration of selected stutters; 3) observed physical concomitants.
48273782|NCT03744455|BIOLOGICAL|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
48273783|NCT06252116|DRUG|Pregabalin group|Pregabalin group
48273784|NCT06252116|DRUG|Duloxetine group|Duloxetine group
48273785|NCT02335502|DEVICE|Implantation with the commercially available Axium neurostimulator|
48273786|NCT01330901|DRUG|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
48273787|NCT03067090|DEVICE|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
48273788|NCT02319902|DEVICE|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
48273789|NCT02319902|DEVICE|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
48273790|NCT06314724|BIOLOGICAL|Varicella Vaccine|lyophilized powder,subcutaneous injection
48273791|NCT06314724|BIOLOGICAL|Varivax|lyophilized powder,subcutaneous injection
48273792|NCT03979976|DRUG|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
48273793|NCT01349348|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
48273794|NCT01349348|DRUG|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
48273795|NCT01349348|DRUG|placebo|tablet, 7.5/15mg , Qd, 7days.
48273796|NCT05731921|BEHAVIORAL|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
48273797|NCT06314087|OTHER|Placebo + conventional treatment including radiotherapy|Placebo + conventional treatment including radiotherapy
48273798|NCT06314087|COMBINATION_PRODUCT|Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine|The peptide vaccine treatment will take 5 months as a treatment course until the treatment suspension event as stipulated in the plan occurred.
48273799|NCT04171739|DRUG|Itraconazole oral solution|200 mg once daily on Days 6 to 15
48273800|NCT04171739|DRUG|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
48273801|NCT04171739|DRUG|Olorofim|Single oral dose on Days 1 and 11
48273802|NCT03065179|DRUG|Nivolumab/Ipilimumab|IV immunotherapy
48273803|NCT03065179|RADIATION|SBRT|SBRT will be delivered in conjunction with immunotherapy
48273804|NCT04894799|OTHER|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
48273805|NCT04894799|OTHER|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
48273806|NCT00570245|DRUG|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
48273807|NCT00570245|DRUG|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
48273808|NCT05759299|PROCEDURE|Tracheal intubation|Advanced airway management with tracheal intubation performed after induction with hypnotic and/or opioid drugs and laryngoscopy
48273809|NCT03254173|DRUG|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
48273810|NCT03254173|DRUG|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
48273811|NCT06030180|DEVICE|EsoGuard|EsoGuard is a set of genetic assays and algorithms for the assessment of specific methylation patterns of DNA encoding the genes vimentin (VIM) and cyclin A1 (CCNA1)
48273812|NCT04899583|DEVICE|Sirolimus Coated Balloon Catheter|a Sirolimus Coated Balloon Catheter designed and produced by Acotec
48273813|NCT04899583|DEVICE|a Paclitaxel Coated Balloon Catheter|a Paclitaxel Coated Balloon Catheter(trade name:Bingo)
48273814|NCT02029976|BEHAVIORAL|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
48273815|NCT02029976|BEHAVIORAL|Mailed monthly newsletters|Newsletters
48273816|NCT00872222|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
48273817|NCT02609581|DRUG|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
48273818|NCT02087332|DRUG|Prolonged release Torasemide (Britomar)|
48273819|NCT02087332|DRUG|Torasemide (Diuver)|
48273820|NCT05749835|OTHER|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
48273821|NCT05749835|OTHER|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\\her head is cradled between your body and your right forearm (when you stand at his\\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
48273822|NCT01381094|DRUG|AKB-6548|oral dose administered once daily for 42 days
48273823|NCT01381094|DRUG|Placebo|oral Placebo administered once daily for 42 days
48273824|NCT02162888|DRUG|Test Product (Bendamustine)|
48273825|NCT05502497|OTHER|Observational|No application will be made to the control group.
48273826|NCT05502497|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
48273827|NCT00052390|BIOLOGICAL|bevacizumab|
48273828|NCT00052390|DRUG|doxorubicin hydrochloride|
48273829|NCT02151513|DEVICE|Intrathecal Pump Placement|
48273830|NCT05841940|DRUG|[14C]HLX208|Carbon-14 labeled HLX208
48273831|NCT06331091|OTHER|Home exercise|Home exercise are done at home without the supervision of a specialist.
47927899|NCT06208956|DRUG|Dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy.
47927900|NCT06208956|DRUG|Propofol|Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reach 3. During the whole process, propofol is given intermittently to maintain Ramsay score 3 to 4. If body movement happen, propofol 10mg will be administrated every time.
48273832|NCT06331091|OTHER|Manual therapy|Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.
48273833|NCT06331091|DEVICE|Neuromuscular electrical stimulation|"Home exercise are done at home without the supervision of a specialist. Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.~Neuromuscular electrical stimulation is the application of electrical current to the muscle through special electrodes in order to increase muscle strength.~Supervised exercise is done under the supervision of a physiotherapist."
48273834|NCT06331091|OTHER|Supervised exercise|Supervised exercise is done under the supervision of a physiotherapist.
48273835|NCT04928183|OTHER|Carbon monoxide rebreathe|Carbon monoxide exposure to increase blood (Carboxyhemoglobin) COHb safely to \~10%
48273836|NCT04928183|DRUG|Sodium Nitroprusside|Bolus Sodium Nitroprusside (SNP) injection for endothelium-independent vasodilation measure
48273837|NCT04928183|DRUG|Phenylephrine Hydrochloride|Bolus Phenylephrine injection for observe α1-mediated vasoconstriction during mild exercise
48273838|NCT01930786|DRUG|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
48273839|NCT00595231|DRUG|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
48273840|NCT00595231|DRUG|Placebo|0 mg tablets
48273841|NCT04796402|BIOLOGICAL|Bamlanivimab|700 mg/20mL IV over at least one hour OD
48273842|NCT04796402|OTHER|Standard of Care|Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
48273843|NCT06400992|DEVICE|Cochlear implant processor Sky CITM M90 (CI-5295)|"The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
48273844|NCT06400992|DEVICE|Hearing Aid, including sound processor Phonak: Sky Link M90|"The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine.~The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
48273845|NCT06400992|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target. The speech will be presented from the front, noise from 180°. Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
48273846|NCT06400992|BEHAVIORAL|Audiologist Fitting Questionnaire|After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
48273847|NCT06400992|BEHAVIORAL|Patient Satisfaction Questionnaire|The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use. The audiologist will go over the instructions for filling out the questionnaire at inclusion. Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
48273848|NCT06400992|BEHAVIORAL|AutoSens Feedback Discussion Form|6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
48273849|NCT00382148|DRUG|omalizumab|SC repeating dose
48273850|NCT04030000|DRUG|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
48273851|NCT04030000|RADIATION|Pelvic radiation therapy|EBRT and vaginal brachytherapy
48273852|NCT04818515|DRUG|Atogepant|Oral; Tablet
48273853|NCT04818515|DRUG|Ubrogepant|Oral; Tablet
48273854|NCT03471325|PROCEDURE|Plaque disclosed with air flow|air polishing with prior plaque disclosing
48273855|NCT03471325|PROCEDURE|Plaque disclosed with rubber cup|rubber cup polishing with prior plaque disclosing
48273856|NCT03471325|PROCEDURE|Non plaque disclosed air flow|air polishing with no prior plaque disclosing
48273857|NCT03471325|PROCEDURE|Non plaque disclosed rubber cup|rubber cup polishing with no prior plaque disclosing
48273858|NCT00864760|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
48273859|NCT00864760|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
48273860|NCT02848755|DEVICE|Cranial ultrasonography|
48273861|NCT06217393|DRUG|Itopride Hydrochloride 150 mg extended release tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
48273862|NCT06217393|DRUG|Itopride Hydrochloride 50 mg film coated tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
48273863|NCT02505256|OTHER|No intervention|
48273864|NCT01142414|BIOLOGICAL|panitumumab|
48273865|NCT01142414|DRUG|cisplatin|
48273866|NCT01142414|DRUG|fluorouracil|
48273867|NCT01142414|OTHER|laboratory biomarker analysis|
47927901|NCT01765478|DRUG|HM71224 single ascending dose|
47927902|NCT01765478|DRUG|HM71224 food effect|
48273868|NCT01142414|PROCEDURE|adjuvant therapy|
48273869|NCT01142414|PROCEDURE|quality-of-life assessment|
48273870|NCT01142414|RADIATION|3-dimensional conformal radiation therapy|
48273871|NCT01142414|RADIATION|intensity-modulated radiation therapy|
48273872|NCT02581995|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
48273873|NCT01559103|BIOLOGICAL|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
48273874|NCT01559103|BIOLOGICAL|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
48273875|NCT03359902|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
48273876|NCT03359902|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
48273877|NCT00442598|DRUG|Glufosfamide|
48273878|NCT00103012|DRUG|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
48273879|NCT00103012|DRUG|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
48273880|NCT00103012|DRUG|Panax ginseng|Panax ginseng 500 mg twice daily
48273881|NCT02750059|DRUG|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
48273882|NCT02750059|DRUG|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
48273883|NCT04268719|DIAGNOSTIC_TEST|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
48273884|NCT01676831|DRUG|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
48273885|NCT01676831|DRUG|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
48273886|NCT03148210|DRUG|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
48273887|NCT03148210|BEHAVIORAL|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
48273888|NCT03148210|BEHAVIORAL|Participant Education|Standardized education for asthma or COPD disease
48273889|NCT04013126|DIAGNOSTIC_TEST|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
48273890|NCT02992002|OTHER|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
48273891|NCT02357420|DRUG|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
48273892|NCT02357420|DRUG|Placebo|Placebo given subcutaneously for 12 weeks.
48273893|NCT06072014|OTHER|Virtual reality|A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
48273894|NCT02299193|BEHAVIORAL|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
48273895|NCT02299193|BEHAVIORAL|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
48273896|NCT05699148|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Triple combination therapy is licensed in the UK for prescription to paediatric patients aged 6 to 11 years. ETI will be started as part of routine clinical care.
48273897|NCT03975192|DEVICE|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
48273898|NCT03545464|DRUG|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
48273899|NCT03545464|DRUG|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
48273900|NCT03545464|DRUG|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
48273901|NCT05463081|DEVICE|Laser treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
48273902|NCT05463081|DIAGNOSTIC_TEST|Blood test|Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
48273903|NCT05463081|DIAGNOSTIC_TEST|Clinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
48273904|NCT05463081|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
48273905|NCT05463081|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
47927903|NCT01765478|DRUG|HM71224 Multiple ascending dose|
48097958|NCT05634213|DRUG|normal saline|Once the patient is placed on cardiopulmonary bypass, the product will be injected into the left atrial wall using a 27 gauge needle as 4 injections of 200 μL each. Two will be placed in the atrial appendage. The remaining 2 injections will be placed equidistant on the anterior atrial free wall. Each injection will be performed just under the surface of the atrial epicardium over 30 seconds. The needle will stay in place for 10 seconds after the injection to limit back flow from the site of injection.
47927904|NCT06004492|BEHAVIORAL|blended learning program|8 hours of workshops and four months of practical learning on technology platforms
47927905|NCT03467009|BEHAVIORAL|iPACT Intervention|Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.
48097959|NCT02463162|OTHER|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
48273906|NCT05463081|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
48273907|NCT05463081|OTHER|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
48273908|NCT05463081|OTHER|The Short Form Health Survey|The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
48273909|NCT05463081|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
48273910|NCT05463081|DIAGNOSTIC_TEST|Vital signs determination|Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
48273911|NCT05463081|DIAGNOSTIC_TEST|pH of vagina determination|Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
48273912|NCT05463081|DIAGNOSTIC_TEST|Physical parameters determination|Physical parameters determination (body weight, age, height, body mass index).
48273913|NCT00585234|OTHER|Digital Photography|Digital Photography
48273914|NCT05410990|DIAGNOSTIC_TEST|eosinophil and other hematological parameters|
48273915|NCT05962008|DIETARY_SUPPLEMENT|DHAPS® product|Take 4 capsules per day after breakfast with warm water.
48273916|NCT05962008|DIETARY_SUPPLEMENT|BioPS® product|Take 4 capsules per day after breakfast with warm water.
48273917|NCT05962008|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules per day after breakfast with warm water.
48273918|NCT03772912|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
48273919|NCT04736823|DRUG|AK112|IV infusion
48273920|NCT04736823|DRUG|Pemetrexed|IV infusion
48273921|NCT04736823|DRUG|Paclitaxel|IV infusion
48273922|NCT04736823|DRUG|Carboplatin|IV infusion
48273923|NCT04736823|DRUG|Docetaxel|IV infusion
48273924|NCT05996484|DRUG|Toripalimab|Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.
48273925|NCT05996484|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.
48273926|NCT05996484|DRUG|Albumin paclitaxel|Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.
48273927|NCT05996484|DRUG|Cisplatin|Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.
48273928|NCT05527002|OTHER|Satisfaction of patients after medical and surgical treatment for thoracic endometriosis|"It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.~The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.~If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study."
48273929|NCT01133340|RADIATION|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
48273930|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
48273931|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
48273932|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
48273933|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
48273934|NCT05872048|DEVICE|periodontal distractor|custom made device from hyrex screw
47927906|NCT03467009|OTHER|Control: Enhanced Usual Care (EUC)|EUC group participants will receive standardized information on cyberbullying.
48273935|NCT06016478|DIETARY_SUPPLEMENT|L-citrulline|4 weeks of L-citrulline (6 g/day) in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
48273936|NCT06016478|DIETARY_SUPPLEMENT|Placebo|4 weeks of microcrystalline cellulose in 8 capsules. Supplementation will be ingested daily, half of the doses in the morning and half at night.
48273937|NCT02489214|DRUG|donafenib tosilate tablets|200mg bid
48273938|NCT02595034|DRUG|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
48273939|NCT02595034|DRUG|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
48273940|NCT02595034|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
48273941|NCT05519631|OTHER|electroencephalogram|The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
48273942|NCT01396369|DRUG|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
48273943|NCT01396369|DRUG|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
48273944|NCT02318758|DRUG|UT-15C|sustained release oral treprostinil
48273945|NCT02318758|OTHER|ethanol|Absolut 100 vodka
48273946|NCT01211912|DRUG|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
48273947|NCT01211912|DRUG|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
48273948|NCT05329116|DRUG|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
48273949|NCT05329116|BIOLOGICAL|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
48273952|NCT00793767|DRUG|erythropoietin|bolus of 400 IU/kg
48273953|NCT00793767|DRUG|placebo (saline)|i.v
48273954|NCT04312087|PROCEDURE|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
48273955|NCT04312087|PROCEDURE|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
48273956|NCT04312087|PROCEDURE|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
48273957|NCT01714466|DRUG|NER1006|
48273958|NCT01714466|DRUG|MOVIPREP|
48273959|NCT04326530|DEVICE|Pneumopipe® (European patent 12425057.2, Rome, Italy)|Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.
48273960|NCT04326530|OTHER|Other assessments|"* Spirometry, both at the baseline and at the last visit.~* 24-hour urine collection, both at the baseline and at the last visit."
48273961|NCT00037648|DRUG|Anakinra|anakinra
48273962|NCT00037648|DRUG|Placebo|placebo
48273963|NCT02100384|PROCEDURE|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
48273964|NCT02313740|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
48273965|NCT02318784|DRUG|Carfilzomib|
48273966|NCT03314285|OTHER|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
48273967|NCT05932719|OTHER|COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.|"The following items will be collected~* Diagnostic date~* Diagnostic stage~* Date of surgery~* Date of surgery appointment~* First antineoplastic treatment date~* Last antineoplastic treatment date~* Number of treatment cycles recommanded by MDTM"
48273968|NCT06484335|BIOLOGICAL|VRC07-523LS|VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site
48273969|NCT06484335|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.
48273970|NCT06484335|BIOLOGICAL|ChAdOx1.tHIVconsv1|ChAdOx1.tHIVconsv1 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv1.
48273971|NCT06484335|BIOLOGICAL|ChAdOx1.HIVconsv62|ChAdOx1.HIVconsv62 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv62.
48273972|NCT06484335|BIOLOGICAL|MVA.tHIVconsv4|MVA.tHIVconsv4 is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated tHIVconsv4.
48273973|NCT06484335|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine.
48273974|NCT06484335|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic
48273975|NCT06484335|OTHER|Placebo|Normal saline (0.9% sodium chloride for injection) will be used as a placebo.
48273976|NCT05593029|DRUG|SEP-363856|Tablet
48273977|NCT05593029|OTHER|Placebo|Placebo
48273978|NCT02633449|BEHAVIORAL|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
48273979|NCT02633449|DEVICE|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
48273980|NCT02633449|DEVICE|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
48273981|NCT00737529|DRUG|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
48273982|NCT01201213|DRUG|local anaesthetic injection|Single bolus of drug for pain relief in early labour
48273983|NCT01689038|DRUG|F17464|Single dose
48273984|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - M1/DLPFC|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of M1 then rTMS of DLPFC.
48273985|NCT06129890|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - DLPFC/M1|Repetitive transcranial magnetic stimulation (rTMS) is a treatment technique involving the induction of an electrical current on the surface of the cortex by applying a magnetic field to the scalp. This field is generated using a stimulation loop controlled by a robotic arm linked to a neuronavigation system. rTMS of DLPFC then rTMS of M1.
48273986|NCT02608632|DEVICE|Renal denervation guided by HFS|
48273987|NCT02608632|DEVICE|Renal denervation as standard procedure|
48273988|NCT05501925|DEVICE|GlideSheath Slender® and conventional arterial sheath|Using the GlideSheath Slender® with the outside diameter 2.46mm
48273989|NCT05501925|DEVICE|Conventional arterial sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II )
48273990|NCT02836561|OTHER|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
48273991|NCT03443167|BEHAVIORAL|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
48273992|NCT03443167|BEHAVIORAL|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
48273993|NCT05407987|DRUG|Ferric derisomaltose|Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight \<50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight \>50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.
48273994|NCT05407987|DRUG|Placebo|Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
48273995|NCT05350787|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
48273996|NCT00386841|DRUG|Escitalopram|Escitalopram 10 mg p.o. per day
48273997|NCT00386841|DRUG|Placebo|Placebo
48273998|NCT03192904|DEVICE|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
48273999|NCT03192904|DEVICE|Stapling Device|Stapling Device, including linear stapler and curved stapler.
48274000|NCT01400932|DRUG|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
48274001|NCT01400932|DRUG|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
48274002|NCT00217633|PROCEDURE|Conventional Surgery|
48274003|NCT00756548|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
48274004|NCT00756548|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
48274005|NCT04401267|DRUG|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
48274006|NCT04401267|DRUG|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
48274007|NCT04401267|OTHER|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
48274008|NCT04401267|OTHER|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
48274009|NCT00932516|BEHAVIORAL|South Beach Diet™ with South Beach Diet™ Products|
48274010|NCT00932516|BEHAVIORAL|South Beach Diet™|
48274011|NCT00932516|BEHAVIORAL|Calorie restricted diet with South Beach Diet™ Products|
48274012|NCT00932516|BEHAVIORAL|Calorie Restricted Diet|
47927907|NCT03467009|BEHAVIORAL|iPACT Intervention- app|Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
47927908|NCT01970904|DRUG|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
47927909|NCT01970904|DRUG|Ribavirin|Ribavirin tablets of various strengths for oral administration
47927910|NCT01970904|DRUG|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
48274013|NCT04209231|OTHER|1.25(OH)2D3|
48274014|NCT04209231|OTHER|25(OH)D|
48274015|NCT00753389|OTHER|None (anesthesia)|anesthesia
48274016|NCT00701493|DRUG|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
48274017|NCT01461681|PROCEDURE|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
47927911|NCT00918060|DRUG|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
48274018|NCT00452712|PROCEDURE|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
48274019|NCT00024232|BIOLOGICAL|monoclonal antibody huJ591|
48274020|NCT05046028|DIETARY_SUPPLEMENT|Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet|ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
48274021|NCT05046028|DIETARY_SUPPLEMENT|ONS without a sensor component and taste + standard diet|Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
48274022|NCT05046028|DIETARY_SUPPLEMENT|Standard diet|Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
48274023|NCT03109431|BEHAVIORAL|Level 1|"Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
48274024|NCT03109431|BEHAVIORAL|Level 2|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
48274025|NCT03109431|BEHAVIORAL|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
48274026|NCT00360347|DRUG|C.E.R.A.|
48274027|NCT06468358|DRUG|LB1410|anti-PD-1/TIM3 bispecific antibody
48274028|NCT06468358|DRUG|LB4330|anti-claudin18.2/IL-10 fusion protein
48274029|NCT00324103|DRUG|Structured Treatment Interruptions|
48274030|NCT01390545|DRUG|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
48274031|NCT04106388|BEHAVIORAL|Virtual Behavioral Health Integration|The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
48274032|NCT00167674|DRUG|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
48274033|NCT00167674|DRUG|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
48274034|NCT02131857|BEHAVIORAL|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
48274035|NCT01694043|OTHER|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
48274036|NCT01694043|OTHER|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
48274037|NCT01851967|OTHER|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
48274038|NCT03437603|DRUG|Eltrombopag|Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
47927912|NCT02685475|DRUG|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
47927913|NCT06252077|DIETARY_SUPPLEMENT|very low ketogenic diet|1 month of active phase of very low ketogenic diet
47927914|NCT06200025|OTHER|Cue-based speech therapy in virtual reality|Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.
48274039|NCT05459376|OTHER|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
48274040|NCT05338008|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
48274041|NCT04727671|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
48274042|NCT04727671|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
48274043|NCT04727671|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
48274044|NCT04727671|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
48274045|NCT02075801|OTHER|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
48274046|NCT02075801|OTHER|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment."
48274047|NCT06129630|PROCEDURE|Conventional occupational therapy sessions.|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
48274048|NCT06129630|PROCEDURE|Conventional occupational therapy sessions + Nintendo Switch|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
48274049|NCT01553149|DRUG|Lenalidomide|Given PO
48274050|NCT01553149|OTHER|Pharmacological Study|Correlative studies
48274051|NCT04217369|DEVICE|Diabits Predictions|Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
48274052|NCT00006187|DRUG|Investigational drug|
48274053|NCT06146894|PROCEDURE|Single obturation technique (Bioceramic Sealer)|Root canal will be obturated using single cone technique using Bioceramic Sealer
48274054|NCT06146894|PROCEDURE|lateral condensation technique (Bioceramic Sealer)|Root canal will be obturated using lateral condensation technique using Bioceramic Sealer
48274055|NCT06146894|PROCEDURE|Warm Vertical condensation technique (Bioceramic Sealer)|Root canal will be obturated using vertical condensation technique using Bioceramic Sealer
48274056|NCT06146894|PROCEDURE|lateral condensation technique (AH Plus Sealer)|Root canal will be obturated using lateral condensation technique using AH plus Sealer
48274057|NCT06146894|PROCEDURE|Warm Vertical condensation technique (AH plus Sealer)|Root canal will be obturated using vertical condensation technique using AH plus Sealer
48274058|NCT03855501|OTHER|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
48274059|NCT03855501|OTHER|Calcium hydroxide|Apexification treatment was done with calcium hydroxide
48274060|NCT03152292|OTHER|Real-world, non-interventional|N/A - non-interventional
48274061|NCT01048346|BEHAVIORAL|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
48274062|NCT05294029|OTHER|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
48274063|NCT01369121|DRUG|XERECEPT|BID dosing, subcutaneous for 1 year
48274064|NCT03403192|DEVICE|EZ-Blocker|"The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation."
48274065|NCT03403192|DEVICE|DLT|A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
48274066|NCT04387097|DRUG|remifentanil|postoperative drip-infusion of remifentanil
48274067|NCT02006771|OTHER|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
48274068|NCT02006771|OTHER|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
48274069|NCT02006771|OTHER|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
48274070|NCT02006771|OTHER|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
48274071|NCT04572009|OTHER|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
48274072|NCT04572009|OTHER|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
48274073|NCT03137979|BIOLOGICAL|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
48274074|NCT03137979|BIOLOGICAL|Collagen scaffolds|Patients in this group were given collagen scaffolds.
48274075|NCT03137979|PROCEDURE|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
48274076|NCT01054066|BEHAVIORAL|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
48274077|NCT05951283|DEVICE|Hybrid Closed Loop Insulin Pump|As above
48274078|NCT05207475|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
48274079|NCT00067210|DEVICE|Head and Neck Cooling System|
48274080|NCT03996447|DRUG|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
48274081|NCT03996447|DRUG|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
48274082|NCT05079789|DRUG|Amiloride|Treatment with amiloride, start dose 5 mg
48274083|NCT05079789|DRUG|Furosemide|Treatment with furosemide, start dose 40 mg
48274084|NCT00699192|DRUG|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
48274085|NCT00699192|DRUG|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
48274086|NCT00699192|DRUG|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
48274087|NCT00699192|DRUG|Placebo|1 capsule placebo to match valsartan orally once daily
48274088|NCT02184637|DRUG|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
48274089|NCT02184637|DRUG|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
48274090|NCT02184637|DRUG|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
48274091|NCT06427551|DRUG|Ropivacaine|The local anesthetic was dosed on the patient's weight (50-59kg: 120mg, 60-61kg: 140mg, 70-79kg: 160mg, ≥80kg: 180mg)
48274092|NCT04089956|OTHER|No interventation|A retrospective cohort Observational study with no intervention
48274093|NCT02227576|DRUG|Romiplostim|
48274094|NCT02610309|BEHAVIORAL|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
47927915|NCT06200025|OTHER|Cue-based speech therapy|Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
48097960|NCT03460353|DRUG|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
48097961|NCT04244591|DRUG|methylprednisolone therapy|Methylprednisolone 40 mg q12h for 5 days
48274095|NCT00367211|DRUG|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
48274096|NCT00367211|DRUG|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
48274097|NCT00265655|DRUG|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
48274098|NCT00000943|BIOLOGICAL|Tetanus Toxoid Vaccine|
48274099|NCT00000943|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
48274100|NCT00000943|BIOLOGICAL|HIV-1 Immunogen|
48274101|NCT00000943|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
48274102|NCT05095506|OTHER|eHealth Intervention|The intervention platform is interactive, and uses multimedia-assisted components. The system uses three SCI-QOL computer-adaptive tests (CATs) to assess depression, anxiety, and resilience; cut scores are used to tailor multi-media content that specifically addresses users' emotional health concerns.
48274103|NCT05095506|OTHER|Active Control Condition|The active control condition is a static site that displays symptom assessments followed by one educational video each week. These videos, which play in a predetermined order, provide education about managing physical health in individuals with SCI.
48274104|NCT02036320|DEVICE|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
48274105|NCT01429571|OTHER|No intervention|No intervention
48274106|NCT04931836|BEHAVIORAL|Physical Activity Intervention|Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
48274107|NCT04686422|DEVICE|Tetric PowerFill|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
48274108|NCT04120688|DEVICE|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
48274109|NCT03017209|DIETARY_SUPPLEMENT|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
48097962|NCT04244591|OTHER|Standard care|Standard care
47927916|NCT02602756|RADIATION|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
48097963|NCT04648046|DRUG|Cyclophosphamide|Non-ablative conditioning with cyclophosphamide.
48097964|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, low dose|A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.
48097965|NCT04648046|BIOLOGICAL|LVgp120duoCAR-T cells, high dose|A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.
48097966|NCT04648046|OTHER|Analytic Treatment Interruption|HIV antiretroviral therapy medications will be paused.
48097967|NCT03518541|PROCEDURE|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
48097968|NCT05739123|DRUG|Relugolix-Containing Product|Any relugolix-containing therapy
48097969|NCT04290429|DRUG|Teduglutide|Treatment of patients with SR-GI-GVHD with teduglutide
48097970|NCT01027286|DEVICE|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
48097971|NCT06629454|DEVICE|Adherence to digital incentive spirometer in the postop period after major chest surgery.|Major chest surgery can lead to respiratory compromise and traditional breathing exercises are not supervised or monitored. The primary objective of this study is to evaluate the effect of a multifeatured digital IS and integrated phone app on patient adherence to incentive spirometry. Together the device and app will include the following functions: an auditory and haptic reminder cue, visual and auditory cues to guide exercise completion, exercise gamification, and data tracking and visualization features.
48097972|NCT06369090|DEVICE|Electrical impedance tomography (EIT)|Non-invasive, radiation-free bedside lung monitoring using small alternating currents with no known side effects.
48097973|NCT04586192|OTHER|Common Elements Toolbox- Adult version (COMET-A)|COMET includes four different modules that teach participants exercises designed to improve mental health and well-being. Participants are asked to complete exercises focused on behavioral activation, cognitive restructuring, gratitude and self-compassion. At the end of the intervention, participants are sent templates that they can you to complete the exercises on, and are encouraged to continue practicing their exercises in their daily life.
48097974|NCT04586192|OTHER|Self-awareness Control|A control condition in which participants learn about self-awareness through writing about memories, writing a short argumentative essay, and noticing objects in their surroundings.
48097975|NCT03585361|BEHAVIORAL|Health centers provide PPFP counseling and services|Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
48097976|NCT03585361|BEHAVIORAL|HEWs provide PPFP counseling and services|HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
48097977|NCT03585361|BEHAVIORAL|Volunteers (Development Army) promote PPFP|HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
48097978|NCT03585361|BEHAVIORAL|Health centers conduct data reviews|Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
48097979|NCT03585361|BEHAVIORAL|HEWs and volunteers track PPFP|HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
48097980|NCT03729804|DRUG|Carfilzomib|"Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24."
48097981|NCT03729804|DRUG|Lenalidomide|"Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24."
48097982|NCT03729804|DRUG|Dexamethasone|"Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24."
48097983|NCT03729804|DRUG|Bortezomib|Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
48097984|NCT05518201|BIOLOGICAL|Placebo among 18-45 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
48097985|NCT05518201|BIOLOGICAL|Placebo among 9-17 yrs|Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).
48097986|NCT02350595|OTHER|Lean fish|
48097987|NCT02350595|OTHER|Fatty fish|
47927917|NCT02702297|OTHER|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
47927918|NCT05736575|GENETIC|BDNF analysis (Elisa KIT)|Analysis of peripheral BDNF will be performed
48097988|NCT06480656|PROCEDURE|Rehabilitation with eccentric cycling exercise|Instead of normal cycling, patients will exercise on the eccentric bike.
48097989|NCT06480656|PROCEDURE|normal rehabilitation|Normal rehabilitation will be conducted
48097990|NCT03078920|DEVICE|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
48097991|NCT05985915|DRUG|Ianalumab (VAY736)|VAY736 300 mg /2 mL, PFS, Solution for injection for subcutaneous use
48097992|NCT05985915|OTHER|Placebo|Placebo 0 mg/2 mL, PFS, Solution for injection for subcutaneous Use
48097993|NCT00462969|PROCEDURE|Sonohysterography|Sonohysterography
48274110|NCT03017209|DIETARY_SUPPLEMENT|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
48274111|NCT03017209|OTHER|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
48274112|NCT02343692|PROCEDURE|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
48274113|NCT03185689|BEHAVIORAL|Effectiveness of an intensified DSME in T2D adult patients|
48274114|NCT04970667|DRUG|Flupentixol melitracen tablets|Patients were treated with Flupentixol and melitracen tablets for 12 weeks
48274115|NCT01883505|DRUG|Levodopa and carbidopa|Subcutaneous continuous administration
48274116|NCT01883505|DRUG|Placebo|Subcutaneous continuous administration
48274117|NCT03633279|DRUG|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
48274118|NCT03633279|DRUG|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
48274119|NCT02508155|BIOLOGICAL|MEDI7352 for IV infusion|MEDI7352 for IV infusion
48274120|NCT02508155|BIOLOGICAL|Placebo for IV infusion|IV Placebo infusion
48274121|NCT02508155|BIOLOGICAL|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
48274122|NCT02508155|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
48274123|NCT04285320|DRUG|Intravesical antibiotic instillation|"Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water"
48274124|NCT04285320|DRUG|Antibiotic oral suppressive therapy|"In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)"
48274125|NCT06120257|PROCEDURE|lithotripsy using Flexible ureteroscope|using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
48274126|NCT06120257|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
48274127|NCT06120257|PROCEDURE|holmium laser lithotripsy using Karl® Storz MIP set|using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
48274128|NCT02684305|DRUG|Administration of Propess|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
48444016|NCT03057210|OTHER|Stress Protocol|Participants will be submitted to an exercise protocol consisting of a jumping program and a maximum short cycle test (ALMEIDAetal). The jumping program consists of 10 sets of 10 jumps with one minute interval between sets. The participants will then perform the Wingate Anaerobic Test protocol, which will be performed on a Biotec 2100 cycle ergometer (Cefise, Nova Odessa, Brazil). A 5-minute warm-up will be carried out where the participant will pedal at a speed of 60 to 90 rpm with a fixed load of 1.0 kg and perform sprints in the 2nd and 4th minute and the test itself, which consists of a maximum of pedals In 30 seconds with a stipulated load of 0.075 kP · kg-1 of the participant's body mass.
48097994|NCT00005106|DRUG|Lamivudine/Zidovudine|
47927919|NCT00509262|DRUG|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
47927920|NCT00509262|DRUG|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
48097995|NCT00005106|DRUG|Abacavir sulfate|
48097996|NCT00005106|DRUG|Nelfinavir mesylate|
48097997|NCT00005106|DRUG|Lamivudine|
47927921|NCT00509262|DRUG|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
48097998|NCT00005106|DRUG|Stavudine|
48097999|NCT02062827|BIOLOGICAL|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
48098000|NCT06073171|BIOLOGICAL|Blood sample|7.5 mL will be sampled on EDTA tube for each patient
48098001|NCT06073171|BIOLOGICAL|Cutaneous biopsy|4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
48274129|NCT02684305|DEVICE|balloon|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
48274130|NCT02684305|DRUG|Intravenous oxytocin infusion|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
48274131|NCT02643095|DEVICE|scleral contact lens|Scleral contact lens
48274132|NCT04711837|DRUG|HSK3486|HSK3486 for induction of general anesthesia.
48274133|NCT04711837|DRUG|Propofol|Propofol for induction of general anesthesia.
48274134|NCT00700856|DRUG|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
48274135|NCT00700856|DRUG|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
48274136|NCT00895063|BEHAVIORAL|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
48274137|NCT03648164|OTHER|CHAT-CS Survey|Students will complete a computer-based survey
48274138|NCT05028803|DRUG|sodium phenylbutyrate|same as arm/group
48274139|NCT02692625|DIETARY_SUPPLEMENT|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
48274140|NCT02692625|DIETARY_SUPPLEMENT|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
48274141|NCT06331624|DRUG|Tazarotene (GRI-0621)|Oral 4.5mg soft gel capsule
48274142|NCT06331624|DRUG|Placebo|Oral 4.5mg soft gel capsule
48274143|NCT04397484|DRUG|0.5% Levobupivacaine|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
48274144|NCT04397484|DRUG|2% Xylocaine with adrenaline 1:200,000|The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
48274145|NCT01133964|DIETARY_SUPPLEMENT|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
48274146|NCT03386084|DEVICE|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
47927922|NCT00509262|DRUG|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
48098002|NCT06073171|GENETIC|High troughput sequencing of human's exome|Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
48098003|NCT02041676|PROCEDURE|Chest physiotherapy|
48098004|NCT02041676|PROCEDURE|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
48274147|NCT00869297|OTHER|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
48274148|NCT00869297|OTHER|Control|Fluids titrated at discretion of anesthesiologist.
48274149|NCT01825902|DRUG|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
48274150|NCT01825902|RADIATION|fludeoxyglucose F 18|Undergo 18F-FDG PET
48274151|NCT01825902|PROCEDURE|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
48098005|NCT05701462|DIAGNOSTIC_TEST|biopsy under sonographic gidance|pleural biopsy under sonographic guidance
48274152|NCT01825902|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
48274153|NCT01825902|OTHER|laboratory biomarker analysis|Correlative studies
48274154|NCT04724148|DRUG|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1\~2 mg/kg fentanyl.
48274155|NCT04222283|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
48274156|NCT04152382|DRUG|LY3462817 - IV|Administered IV
48274157|NCT04152382|DRUG|LY3462817 - SC|Administered SC
48274158|NCT04152382|DRUG|Placebo - IV|Administered IV
48274159|NCT04152382|DRUG|Placebo - SC|Administered SC
48274160|NCT04152382|DRUG|LY3509754|Administered orally.
48274161|NCT04152382|DRUG|Placebo|Administered orally.
48274162|NCT04268030|OTHER|collection of LFPs|collection of local field potentials (LFPs) at rest and during hand opening and closing
48274163|NCT04561349|OTHER|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
48274164|NCT04561349|OTHER|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
48274165|NCT03371355|DRUG|Placebo|Placebo (Matched with ISIS 703802)
48274166|NCT03371355|DRUG|ISIS 703802 40 mg|ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
48274167|NCT03371355|DRUG|ISIS 703802 80 mg|ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
48274168|NCT03371355|DRUG|ISIS 703802 20 mg|ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
48274169|NCT01590342|DRUG|Diclofenac|Diclofenac 75 mg, two doses
48274170|NCT01590342|DRUG|Placebo|Placebo, two doses
48274171|NCT05206461|OTHER|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
48274172|NCT03078062|DRUG|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
48274173|NCT03078062|DRUG|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
48274174|NCT01454076|DRUG|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
48274175|NCT01454076|DRUG|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
48274176|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
48274177|NCT01454076|DRUG|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
48274178|NCT01454076|DRUG|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
48274179|NCT01454076|DRUG|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
47927923|NCT01482390|DRUG|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than \[\<\] 75 kg) or 1200 mg (for participants weighing greater than or equal to \[\>=\] 75 kg) orally for 24 or 48 weeks.
48274180|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
48274181|NCT03849326|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
48274182|NCT03849326|BIOLOGICAL|blood test|complete blood count and cytokine concentration
48274183|NCT03849326|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
48274184|NCT03849326|DEVICE|actigraphy|assessment of sleep quality
47927924|NCT01482390|DRUG|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
47927925|NCT01482390|DRUG|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
47927926|NCT01482390|DRUG|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
48274185|NCT03849326|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging (optional)"
48274186|NCT03198143|DRUG|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
48274187|NCT03198143|DRUG|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
48274188|NCT01169779|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48274189|NCT01169779|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
47927927|NCT01482390|DRUG|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
48274190|NCT01169779|DEVICE|Pen auto-injector|
48274191|NCT01169779|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
48274192|NCT01169779|DRUG|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
48274193|NCT06450665|BEHAVIORAL|VR Social Avoidance Intervention|The intervention is based on cognitive-behavioral approach with a virtual coach acting as the therapist. It will be designed in tandem with input from Hong Kong users to ensure the scenario can resonate with them. By testing beliefs that inhibit confidence in a safe and controlled environment, participants will complete tasks with increasing difficulty in three VR scenarios and learn that they can cope in situations that they previously avoid.
48274194|NCT03812510|DRUG|A-101|hydrogen peroxide topical solution 45%
48274195|NCT02246972|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
48274196|NCT04974788|OTHER|Low Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
48274197|NCT04974788|OTHER|Medium Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
48274198|NCT04974788|OTHER|High Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
48274199|NCT04371796|DRUG|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
48098006|NCT05348577|DRUG|capivasertib|"320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment."
48098007|NCT05348577|DRUG|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
48098008|NCT05348577|OTHER|placebo|matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
48098009|NCT05348577|DRUG|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
48098010|NCT00459264|DRUG|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
48098011|NCT00459264|DRUG|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
48098012|NCT03521323|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
48098013|NCT03521323|DRUG|Placebos|Placebos: Saline，Sham operation
48098014|NCT01809964|BIOLOGICAL|ANT-1401|
48098015|NCT01809964|BIOLOGICAL|Vehicle|
48098016|NCT03888820|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
48098017|NCT03888820|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
48098018|NCT00001421|DRUG|methimazole|
48098019|NCT00925730|DRUG|Pimecrolimus|
48098020|NCT06489171|PROCEDURE|Received laparoscopic-assisted vaginal radical trachelectomy|"The LAVRT procedure began with laparoscopic pelvic lymphadenectomy, and all lymph nodes were removed for frozen pathological analysis. The laparoscopic-assisted vaginal radical trachelectomy procedure was continued only if the nodes were negative. The pararectal pouch was revealed, and the uterine arteries were divided from their origin to the internal iliac artery. The ureters were freed from the posterior leaf of the broad ligament down to the level where they entered the ureteral tunnel and then displaced laterally. The uterosacral ligaments, cardinal ligaments, and parametrial portions were then divided and dissected. The section of the procedure was performed laparoscopically. The vaginal epithelium was circumferentially incised approximately 3 cm distal to the endocervix. Frozen section analysis confirmed no cancer involvement at the endocervical or vaginal margin. The vaginal mucosa was sutured to the cervical stump to form a new cervical os."
48098021|NCT03203798|PROCEDURE|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
48274200|NCT04420130|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks
48274201|NCT04420130|DRUG|Chemotherapy|The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
48274202|NCT04420130|PROCEDURE|Ablation|First give pancreatic cancer patients with liver metastases to ablation of liver metastases
48274203|NCT01851837|OTHER|Exercise time|Continuous training, Interval training
48274204|NCT00501228|DRUG|Filgrastim|5 mg/kg ID Once Daily x 1 Week
48274205|NCT05513443|PROCEDURE|Irreversible electroporation, IRE|IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.
48274206|NCT05513443|PROCEDURE|Radical prostatectomy|Radical prostatectomy
48274207|NCT05513443|RADIATION|Radiation therapy|Radiation therapy for prostate cancer
48274208|NCT05313438|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
48274209|NCT02882256|OTHER|Video discharge instructions|Discharge instructions provided in video form
48274210|NCT01767402|BIOLOGICAL|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
48274211|NCT01767402|BIOLOGICAL|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
48274212|NCT01767402|BIOLOGICAL|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
48274213|NCT03204630|DIETARY_SUPPLEMENT|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
48274214|NCT03204630|DIETARY_SUPPLEMENT|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
48274215|NCT03204630|OTHER|Control|Standard infant formula
48274216|NCT03793400|DRUG|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
48274217|NCT00998439|DEVICE|SeQuent® Please|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
48274218|NCT00998439|DEVICE|SeQuent® II|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
48274219|NCT03968419|DRUG|Canakinumab|200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks
48274220|NCT03968419|DRUG|Pembrolizumab|200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
48274221|NCT04477226|DIAGNOSTIC_TEST|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
48274222|NCT00001303|DRUG|Reference Endotoxin|
48274223|NCT00001303|DRUG|Inhaled Nitric Oxide|
48274224|NCT03674021|OTHER|Chest Pain Choice visual aid|The Chest Pain Choice (CPC) decision aid is a visual aid that was developed to facilitate shared decision-making between physicians and patients who present to the emergency department with chest pain. The visual aid includes a brief description of what tests have been done thus far to assess the patient's risk of MACE, a graphic representation of the risk as calculated based on the HEART score, as well as the evaluation options available. The visual aid has been modified from its original form for the local context in terms of viable options for further evaluation.
48274225|NCT01701622|DRUG|febuxostat|"If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
48274226|NCT00863551|DRUG|Trospium Chloride|Extended release, 60 mg, oral daily
48274227|NCT00018902|DRUG|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
48274228|NCT00018902|DRUG|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
48274229|NCT00018902|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
48274230|NCT00018902|DRUG|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
48274231|NCT03088969|OTHER|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
48274232|NCT05195788|BEHAVIORAL|Cardiac rehabilitation|The cardiac rehabilitation program is based on 3/week exercise training's sessions including aerobic and muscle building exercises. All exercises are individualized, supervised by a certified kinesiologist at the research center, and in line with the latest recommendations for physical activity in individuals with congenital heart disease. Participants are encouraged to do a minimum of 1 supervised session per week at the research center and may, with the agreement of the cardiologist and the kinesiologist, do the other training sessions at home (hybrid program). The characteristics of the activities are recorded with a heart rate sensor. Each session lasts a maximum of 60 minutes in total and includes approximately 30 minutes of aerobic exercise, and approximately 20 minutes of muscle strengthening exercises, with 5 to 10 minutes of warm-up and cool-down.
48274233|NCT06545227|DEVICE|continuous blood glucose monitoring in a subset of women (n=25) in the early monitoring group.|To continuously monitor blood glucose from baseline to 28 weeks to determine if if there is hyperglycaemia in a subset of women (n=25)
48274234|NCT06545227|OTHER|Collection of urine, maternal blood at baseline and 28 weeks in a subset of women (n=25)|To study maternal metabolome
48274235|NCT06545227|OTHER|Collection of umbilical cord blood, placental samples and cord tissue in a subset of women (n=25)|To study mesenchymal stem cell differentiation, change in fetal epigenetic and placental signalling pathways.
48274236|NCT06545227|OTHER|Maternal and neonatal outcome data collection for all women in the study|Data for maternal and neonatal outcomes will be collected
48274237|NCT01096914|PROCEDURE|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
48274238|NCT01096914|PROCEDURE|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
48274239|NCT02055625|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
48274240|NCT02894229|BEHAVIORAL|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
48274241|NCT02894229|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
48274242|NCT03431233|DIETARY_SUPPLEMENT|Protein-enriched bar, commercial cereal bar, or water|Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
48274243|NCT04523740|DRUG|Placebo|Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
48274244|NCT04523740|DRUG|Paracetamol|Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
48274245|NCT05650034|RADIATION|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H\&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H\&N SCCs ( pN0 or by PETCT).
48274246|NCT02229773|DRUG|BIBB 1464 MS low dose|
48274247|NCT02229773|DRUG|Placebo|
48274248|NCT02229773|DRUG|Pravastatin|
48274249|NCT02229773|DRUG|BIBB 1464 MS medium dose|
48274250|NCT02229773|DRUG|BIBB 1464 MS high dose|
48274251|NCT00004396|DRUG|heme arginate|
48274252|NCT00004396|DRUG|tin mesoporphyrin|
48274253|NCT01296048|DEVICE|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
48274254|NCT03156803|BEHAVIORAL|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
48274255|NCT00271388|DEVICE|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
48274256|NCT02678429|DEVICE|Change DBS programming|Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
48274257|NCT02905734|DRUG|Nicotine patch|Single administration of an active treatment (nicotine patch)
48274258|NCT02905734|OTHER|placebo patch|Single administration of a placebo treatment
48274259|NCT02204904|GENETIC|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
48274260|NCT00719199|DRUG|IMO-2055|SC weekly injections
48274261|NCT00719199|DRUG|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
48274262|NCT00719199|DRUG|FOLFIRI|Given day 1 of each cycle
48274263|NCT00864734|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
48274264|NCT00864734|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
48274265|NCT05395221|OTHER|Guided Mediation Virtual Reality App|Guided Meditation Virtual Reality App uses over 40 lush environments with 30 hours of guided meditations on Anxiety, Depression, Maternity, Resilience, Sleep, or Zen and 200 relaxing audio tracks using Virtual reality.
48274266|NCT04874857|OTHER|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
48274267|NCT04874857|OTHER|Baby oil|Massage application
48274268|NCT00972465|DRUG|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
48274269|NCT01871883|PROCEDURE|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
48274270|NCT01871883|PROCEDURE|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
48274271|NCT01781455|DRUG|BBI503|
48274272|NCT06110650|DRUG|Surufatinib|Surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
48274273|NCT03850821|BEHAVIORAL|Connect Social Mechanisms Intervention|"The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day."
48274274|NCT02368470|DRUG|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
48274275|NCT02368470|DRUG|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
48274276|NCT02626728|PROCEDURE|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
48274277|NCT00302393|DRUG|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
48274278|NCT00302393|DRUG|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
48274279|NCT00539019|OTHER|calories measured 5x following wound healing|measure REE at various time points postburn
48274280|NCT00008385|OTHER|placebo|Given orally
48274281|NCT00008385|DRUG|selenium|Given orally
48274282|NCT05984446|DEVICE|real-rTMS|Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
48274283|NCT05984446|DEVICE|sham-rTMS|The sham condition will match the real-rTMS protocol, but a sham coil will be used.
48274284|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
48274285|NCT02890719|DRUG|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
48274286|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
47927928|NCT00949767|DRUG|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
47927929|NCT00949767|DRUG|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
48274287|NCT02890719|DRUG|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
48274288|NCT02890719|DRUG|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
48274289|NCT01113151|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
48274290|NCT01113151|OTHER|Placebo|3 placebo tablets daily for 12 weeks
48274291|NCT05335889|DEVICE|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
48274292|NCT05335889|DEVICE|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
48274293|NCT00496366|DRUG|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
48274294|NCT00496366|DRUG|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
48274295|NCT01918254|DRUG|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
48274296|NCT01918254|DRUG|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
48274297|NCT01918254|DRUG|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
48274298|NCT03415165|DRUG|green tea buccal tablet|buccal tablet for 8 hrs 3 times aday
48274299|NCT03415165|DRUG|Corticosteroids Topical|kenacort in orabase 4 times aday
48274300|NCT03215784|DIETARY_SUPPLEMENT|Fish Oil|
48274301|NCT03215784|DIETARY_SUPPLEMENT|Probiotic|
48274302|NCT03215784|DIETARY_SUPPLEMENT|Placebo|
48274303|NCT05148884|DRUG|NLX-112|NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
48274304|NCT05148884|DRUG|Placebo|Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
48274305|NCT01061281|DEVICE|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
48274306|NCT01061281|DEVICE|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
48274307|NCT05516329|DRUG|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.
48274308|NCT03112811|DEVICE|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
48274309|NCT03112811|DEVICE|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
48274310|NCT02569034|OTHER|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
48274311|NCT02569034|OTHER|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
48274312|NCT01206569|DRUG|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
48274313|NCT00541983|DRUG|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
48274314|NCT00541983|DRUG|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
48274315|NCT02871479|DRUG|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
48274316|NCT02871479|DRUG|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
48274317|NCT02871479|DRUG|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
48274318|NCT02844127|PROCEDURE|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
48274319|NCT01055509|BEHAVIORAL|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
48274320|NCT04366999|PROCEDURE|SG|SG involved a vertical gastric resection beginning 4-6 cm from the pylorus and ending 1-2 cm from the His angle, using linear staplers with the guidance of a 36 French intragastric bougie.
48274321|NCT04366999|PROCEDURE|RYGB|RYGB entails the creation of a 15-30 mL (approximate) gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb.
48274322|NCT04366999|PROCEDURE|OAGB|OAGB entails the creation of a long gastric tube by beginning 2 cm below the angular incisure starting from the lesser curvature side and then divided vertically upward by linear cutting staplers as calibrated with a 36 French bougie, followed by the creation of a single gastrojejunal anastomosis with an afferent biliopancreatic limb of 200 cm.
48274323|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.
48274324|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta after determining the safe zones of clamping|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
48274325|NCT05786157|OTHER|Alcohol Administration|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
48274326|NCT00879450|OTHER|Booklet|booklet given to parents for home exercises
48274327|NCT02016014|DEVICE|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
48274328|NCT02016014|BEHAVIORAL|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
48274329|NCT04116021|OTHER|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
48274330|NCT04116021|OTHER|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
48274331|NCT03732547|DRUG|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
48274332|NCT03732547|DRUG|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
48274333|NCT01808560|DEVICE|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
48274334|NCT01808560|DEVICE|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
48274335|NCT05931783|PROCEDURE|skeletonized harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in skeletonized technique. Thereby, only the artery itself is harvested.
48274336|NCT05931783|PROCEDURE|pedicled harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in pedicled technique. Thereby, the artery will be harvested together with the accompanying veins, the endothoracic fascia and fatty tissue in order to create an 1-2 cm broad pedicle.
48274337|NCT05462184|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
48274338|NCT05462184|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|
48274339|NCT03971188|PROCEDURE|Trapeziectomy with Internal Brace|Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
48106798|NCT03423394|BEHAVIORAL|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
48274340|NCT05925608|COMBINATION_PRODUCT|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)
48274341|NCT05383690|DEVICE|LED bright light treatment device|Subjects will be instructed to use the bright light treatment device, as early as possible, for 30 minutes each morning. These devices will be equipped with monitoring electronics that will enable us to download their daily degree of use. Participants will also be provided with yellow-tinted blue light blocking glasses and will be instructed to wear them starting 2 hours before bedtime if they are viewing LED or liquid-crystal display screens.
48274342|NCT03252782|DEVICE|Herbst Appliance|Acrylic Splint Herbst Appliance
48274343|NCT03252782|DEVICE|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
48274344|NCT00058461|DRUG|ifosfamide|Given IV
48274345|NCT00058461|DRUG|etoposide|Given IV
48274346|NCT00058461|BIOLOGICAL|rituximab|Given IV
48274347|NCT00058461|DRUG|carboplatin|Given IV
48274348|NCT00058461|BIOLOGICAL|filgrastim|Given SC
48274349|NCT00058461|DRUG|methotrexate|Given IT
48274350|NCT00058461|DRUG|cytarabine|Given IT
48274351|NCT00058461|OTHER|laboratory biomarker analysis|Correlative studies
48274352|NCT01136395|DRUG|Rituximab|375mg/m2 4 weeks before ABOi LD transplantation
48274353|NCT01136395|PROCEDURE|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
48274354|NCT01136395|PROCEDURE|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
48274355|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)|The COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)was manufactured by Sinovac Research\& Development Co., Ltd.1200SOU inactivated SARS-CoV-2 Omicron strain in 0.5ml of aluminium hydroxide solution per injection.
48274356|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
48274357|NCT01321047|DRUG|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age \> 70 or ASA class III-IV)
48274358|NCT01321047|DRUG|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
48274359|NCT00704470|OTHER|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
48274360|NCT00704470|OTHER|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
48274361|NCT01271140|DRUG|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
48274362|NCT04782167|BEHAVIORAL|BRACE|"Balance training,Static balance:~1. Romberg with eye open \& eye close \[30 sec repeat 3 times\]~2. Tandem standing with eye open then with eye close. Right foot front first, then left foot front \[10 Sec repeat 3 times\]~3. Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~1. Sit to stand: 5 repetition~2. Functional reach test: forward, sideways \& cross reach, practice 1 min for each~3. TUG test: with distance of 10 feet \& time 10 sec. practice 2 min Cognitive exercises~1) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words"
48274363|NCT04782167|BEHAVIORAL|Propirioceptive training|1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
48274364|NCT06546865|DEVICE|22F Sheath Size|Participants in this group will have the 22F sheath size used in their procedure.
48274365|NCT06546865|DEVICE|26F Sheath Size|Participants in this group will have the 26F sheath size used in their procedure.
48274366|NCT02964156|OTHER|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
48274367|NCT02964156|OTHER|No intervention|No intervention
48274368|NCT04807959|OTHER|20Lighter anti-obesity program|A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
48274369|NCT04514263|OTHER|OHIP-14 Administration|All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy
48274370|NCT04514263|OTHER|VNS Administration|All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
48274371|NCT05191043|OTHER|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
48274372|NCT05191043|OTHER|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
48274373|NCT04321811|OTHER|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
48274374|NCT04025632|DRUG|zilucoplan|Daily subcutaneous (SC) inection
48274375|NCT04025632|OTHER|Placebo|Daily subcutaneous (SC) inection
48274376|NCT06005454|DIETARY_SUPPLEMENT|Fish oil (Omega)|We will use a dietary supplement source of omega 3 fatty acids from the available syrup ( each 5 ml contain 640 mg of high DHA Fish oil) so we will give it in a dose 2.7 ml twice daily for children between 1 and 3 years and 3.5 ml twice daily for children between 4 and 5 years.
48274377|NCT01856114|DRUG|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
48274378|NCT01856114|OTHER|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
48274379|NCT01856114|BEHAVIORAL|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
48274380|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
48274381|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
48274382|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
48098022|NCT03203798|PROCEDURE|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
48098023|NCT03771898|DRUG|SHP611|Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
48274383|NCT05646810|DIAGNOSTIC_TEST|Lidocaine (10 mg/ml)|Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
48274384|NCT05646810|DIAGNOSTIC_TEST|Isotonic saline|Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
48274385|NCT00502840|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
48274386|NCT03680937|OTHER|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
48274387|NCT03680937|OTHER|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
48274388|NCT01402219|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
48274389|NCT01402219|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
48274390|NCT04265066|DIAGNOSTIC_TEST|microcirculation|measurement of microcirculation
48274391|NCT04804891|BIOLOGICAL|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
48274392|NCT04852640|PROCEDURE|Active Rehabilitation Program (ARP)|The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.
48274393|NCT04852640|PROCEDURE|Nonspecific Passive Intervention (NPI)|The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
48274394|NCT04737044|OTHER|Study 1: MRBS|MRBS as added sugar based on their habitual diet
48274395|NCT04737044|OTHER|Study 2: White sugar & education module|White sugar for daily usage (\<10% daily energy intake)
48274396|NCT04737044|OTHER|Study 2: MRBS & education module|MRBS for daily usage (\<10% daily energy intake)
48274397|NCT02844907|DRUG|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
48274398|NCT02844907|DRUG|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
48274399|NCT02844907|OTHER|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
48274400|NCT03224286|DEVICE|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
48274401|NCT00123084|BEHAVIORAL|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
48274402|NCT00123084|BEHAVIORAL|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
48274403|NCT00712348|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
48274404|NCT02210338|DEVICE|Karl Storz C-MAC|
48274405|NCT02210338|DEVICE|Bonfils Intubation Fibrescope|
48274406|NCT06299943|OTHER|Biofeedback gait training by biomechanical target parameter|The patient walks using a treadmill at a comfortable speed until he gets tired. The patient is instructed that when performing a virtual task (in a virtual environment on the screen), his walking will be harmonized (without informing him on what parameter). If it fails to cope, then the zones of permissible changes (on the information columns) will expand, and the virtual task will signal its incomplete completion.
48274407|NCT03631927|OTHER|Observation|Observation
48274408|NCT05597787|BEHAVIORAL|HIV Connect|online education and clinical skills
48274409|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention|education and clinical skills
48274410|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention and Stigma Reduction|education, clinical skills and contact
48274411|NCT05559879|DRUG|Cabo + Dostarlimab|Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
48274412|NCT05246540|OTHER|Data collection|Data collection
48274413|NCT05564767|DIETARY_SUPPLEMENT|B. adolescentis Bif-038|B. adolescentis Bif-038 (probiotic capsule) delivered orally once daily at a minimum of 5 billion CFU/day
48274414|NCT05564767|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12® (probiotic capsule) delivered orally once daily at a minimum of 1 billion CFU/day
48274415|NCT05564767|DIETARY_SUPPLEMENT|Placebo|Placebo capsule delivered orally once daily
48274416|NCT01006343|OTHER|Higher Protein (HP)|
47927930|NCT00949767|DRUG|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
48274417|NCT01006343|OTHER|Lower Protein (LP)|
48274418|NCT04223245|BEHAVIORAL|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
48274419|NCT04223245|BEHAVIORAL|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
48274420|NCT00521781|DRUG|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
48274421|NCT00521781|DRUG|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
48274422|NCT00521781|DRUG|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
48274423|NCT03471455|DRUG|Isotretinoin|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
48274424|NCT03471455|DRUG|Terbinafine|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
48274425|NCT03471455|DRUG|Itraconazole 200 mg|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
48274426|NCT02226666|DRUG|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
48274427|NCT02226666|DRUG|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
48274428|NCT01708031|OTHER|physiological signals|
48274429|NCT04004949|OTHER|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores \& scapular balance angle test (SBA).
48274430|NCT04351412|OTHER|Gluma|Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
48274431|NCT04351412|OTHER|fluoride varnish|fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
48274432|NCT04351412|OTHER|Tetric N-Bond self-etch adhesive|Tetric N-Bond self-etch adhesive is one step dental adhesive and is also claimed to relief dentine hypersensitivity due to blockage of dentinal tubules. It was applied according to the manufacturer's instructions, in a thick layer, for at least 30 seconds, using a light brushing motion. Then, it was dried with a steady stream of air for 3 seconds and light-cured for 10 seconds. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
48274433|NCT02983604|DRUG|GS-5829|Tablet(s) administered orally once daily
48274434|NCT02983604|DRUG|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
48274435|NCT02983604|DRUG|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
48274436|NCT05873712|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48274437|NCT05873712|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
48274438|NCT05873712|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
48274439|NCT05873712|DRUG|Cyclophosphamide|Given IV
48274440|NCT05873712|DRUG|Fludarabine|Given IV
48274441|NCT05873712|PROCEDURE|Leukapheresis|Given IV
48274442|NCT05873712|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
48274443|NCT05873712|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
48274444|NCT05873712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48274445|NCT05873712|DRUG|Zanubrutinib|Given PO
48274446|NCT00883493|DRUG|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
48274447|NCT00883493|DRUG|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
48274448|NCT05383235|OTHER|ROUTINE CARE|1. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient
48274449|NCT05383235|DEVICE|Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task|"2. RUN-IN PERIOD :~* Eligibility criteria will be assessed during the multidisciplinary meeting;~* Study presentation, delivery of the information note and consent form; 3. STUDY:~* Collection of consent form;~* Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~* Neuropsychological evaluation (TOM-15);~* Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~* Debriefing."
48274450|NCT02968355|OTHER|Observational study|Observational study
48274451|NCT05678803|OTHER|xrays and CT|A dedicated sheet will be used to record patients' data including all demographic data, detailed analysis of the mechanism of injury, time of injury, time and details of surgery (if any), neurological status on admission and all radiological findings. All patients will undergo plain X-rays and CT imaging. Patients with suspected discoligamentous injuries and/or neurological deficits will also be assessed by MRI.
48274452|NCT04187027|DEVICE|pulsed electromagnetic field therapy device|magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
48274453|NCT06273995|OTHER|Behavioral Activation|All participants will undergo behavioral activation treatment for 8-10 weeks
48274454|NCT06121128|PROCEDURE|Inspiratory Muscle Training (IMT)|"The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week."
48274455|NCT06121128|PROCEDURE|Normal Breathing|No IMT performed
47927931|NCT00949767|DRUG|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
48274456|NCT05764369|BEHAVIORAL|Parenting Wisely Residential Treatment (PWRT)|PWRT experimental intervention
47927932|NCT00949767|DRUG|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
48274457|NCT05764369|BEHAVIORAL|TAU|The TAU condition is the standard of care offered to parents in RT settings.
48274458|NCT02850302|OTHER|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
48274459|NCT02850302|OTHER|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
48274460|NCT05684640|DRUG|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
48274461|NCT05684640|DRUG|Placebo|Tablets, Oral, 0mg, BID
48274462|NCT02874911|OTHER|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
48274463|NCT01743430|OTHER|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
48274464|NCT05962125|OTHER|periodic alveolar recruitment maneuvers|A stepwise increment of tidal volume was used for each ARM.
48274465|NCT05962125|OTHER|positive end-expiratory pressure|a PEEP of 6 to 8 cm H2O
48274466|NCT04058587|DRUG|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
48274467|NCT01413893|DRUG|linifanib|QD daily
48274468|NCT04654312|DRUG|Hydrochlorothiazide|Please see arm descriptions
48274469|NCT04654312|DRUG|Placebo|Please see arm descriptions
48274470|NCT01361256|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
48274471|NCT01361256|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
48274472|NCT03677674|OTHER|Dehydration|Participants will be dehydrated (2% of their body weight) using sauna.
48274473|NCT01548261|PROCEDURE|Donating oral mucosal cells|Donating oral mucosal cells
48274474|NCT05658757|OTHER|Regular sweetened commercial foods|"This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do."
48274475|NCT05658757|OTHER|Allulose sweetened commercial foods|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
48274476|NCT05658757|OTHER|Whole and minimally processed and sweetened foods|"Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines."
48274477|NCT03339804|OTHER|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
48274478|NCT03778489|OTHER|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
48274479|NCT04531267|DIETARY_SUPPLEMENT|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
48274480|NCT05812391|PROCEDURE|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
48274481|NCT05812391|PROCEDURE|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
48274482|NCT01249235|PROCEDURE|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
48274483|NCT03485989|OTHER|Hazelnuts|Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
48274484|NCT00006430|BIOLOGICAL|Autologous dendritic cells transfected with amplified tumor RNA|
48274485|NCT05369819|DRUG|Midazolam|. Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room
48274486|NCT05369819|DRUG|Saline|Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room
48274487|NCT00850252|DEVICE|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
48274488|NCT06124989|DIAGNOSTIC_TEST|MINERVA Machine Learning model|The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
48274489|NCT00716976|DRUG|sodium thiosulfate|Given IV
48274490|NCT00716976|PROCEDURE|examination|Patients undergo audiological assessments periodically
48274491|NCT02960282|PROCEDURE|Biospecimen Collection|Undergo collection of fecal specimens
48274492|NCT02960282|OTHER|Laboratory Biomarker Analysis|Correlative studies
48274493|NCT06160050|BEHAVIORAL|Breakthrough Parenting Curriculum: Transforming trauma across generations|The BPC (Breakthrough Parent Curriculum): Navigating Trauma Across Generations is a 10 module course adapted from the NCTSN training called Caring for Children Who Have Experienced Trauma: A Workshop for Resource Parents (RPC). The BPC is specifically designed for parents who have been involved with (or are at risk for being involved with)the child welfare system. The course provides information about the impact of trauma on the development, attachment, emotions and behaviors of children while holding space for parents to learn together about concrete strategies for managing daily and ongoing challenges and enhancing their relationships with their children. All while acknowledging the challenges of parenting a child who has experienced trauma, while having experienced your own trauma.
48274494|NCT01113320|DRUG|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
48274495|NCT01113320|DRUG|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
48274496|NCT04531384|DEVICE|robot-assisted rehabilitation intelligent treatment|robot-assisted rehabilitation psychotherapy
48274497|NCT04531384|OTHER|standard psychotherapy treatment|standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
48274498|NCT04304456|OTHER|Treatment|Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
48274499|NCT04294485|BEHAVIORAL|Physical therapy|Electrostimulation combined with exercise
48274500|NCT04514614|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of arthritis by PET/CT.
48274501|NCT03614936|OTHER|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
48274502|NCT03614936|OTHER|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~* the socio-cultural evaluation scale,~* the ADL autonomy questionnaire,~* assessment of locomotor disorders,~* nutritional assessment,~* the MMSE Cognitive Function Evaluation Questionnaire,~* the GDS-4 mood rating scale,~* the comorbidity assessment test (Charlson Index)"
48274503|NCT03622281|OTHER|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
48274504|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 1|The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
48274505|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 2|The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
48274506|NCT03934645|OTHER|Early prediction model for delirium in ICU patients|The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
48274507|NCT02631720|PROCEDURE|Blood Draw|
48274508|NCT02631720|PROCEDURE|Bronchoscopy|
48274509|NCT06258642|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, Q2W, iv
48274510|NCT06258642|DRUG|Anlotinib|12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.
48274511|NCT00619502|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
48274512|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
48274513|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
48274514|NCT04401657|DIAGNOSTIC_TEST|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
48274515|NCT01953952|PROCEDURE|therapeutic conventional surgery|Undergo transoral eHNS
48274516|NCT01953952|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48274517|NCT01953952|DRUG|cisplatin|Given IV
48274518|NCT01953952|PROCEDURE|quality-of-life assessment|Ancillary studies
48274519|NCT01953952|OTHER|laboratory biomarker analysis|Correlative studies
48274520|NCT06001567|DRUG|Avatrombopag|Avatrombopag (platelet count \[PLT\] \<40×10\^9/L, 60mg P.O. QD; PLT of 40-75×10\^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10\^9/L, the treatment will be discontinued.
48274521|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
48274522|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
48274523|NCT01849926|DRUG|Ibuprofen|
48274524|NCT01849926|DRUG|Mecillinam|
48274525|NCT01865292|DRUG|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
48274526|NCT01865292|DRUG|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
48274527|NCT00439855|DRUG|Enoxaparin i.v.|
48274528|NCT00439855|DRUG|unfractionated heparin|
48274529|NCT03823664|DIAGNOSTIC_TEST|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
48274530|NCT03502330|DRUG|APX005M|APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
48274531|NCT03502330|DRUG|Cabiralizumab|Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
48274532|NCT03502330|DRUG|Nivolumab|Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
48274533|NCT03778437|PROCEDURE|subclavian vein catheterization|Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
48274534|NCT03778437|PROCEDURE|landmark techniques|The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
48274535|NCT03778437|PROCEDURE|Ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
48274536|NCT01710930|OTHER|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
48274537|NCT05288582|DEVICE|NovaTears|Over-the-counter eye drop
48274538|NCT03762304|OTHER|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
48274539|NCT02162862|BEHAVIORAL|Behavioral Counseling|
48274540|NCT02162862|DRUG|bupropion-SR|
48274541|NCT04827641|OTHER|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
48274542|NCT04201379|OTHER|quality of life assesment|The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once
48274543|NCT01835184|DRUG|cabozantinib-s-malate|Given PO
48274544|NCT01835184|DRUG|vemurafenib|Given PO
48274545|NCT01835184|OTHER|laboratory biomarker analysis|Correlative studies
48274546|NCT01835184|OTHER|pharmacological study|Correlative studies
48274547|NCT05229939|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
48274548|NCT05431244|DRUG|Antiviral treatment in combination with low-dose gemcitabine|-maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
48274549|NCT01972321|OTHER|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:~1. Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~2. Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~3. Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
47927933|NCT00949767|DRUG|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
48274550|NCT01972321|BEHAVIORAL|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
48274551|NCT01972321|OTHER|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
48274552|NCT06033729|DRUG|Remifentanil TCI|REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
48274553|NCT06033729|DRUG|Midazolam injection|Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
48274554|NCT06033729|DRUG|Fentanyl|Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
48274555|NCT06033729|DRUG|Propofol|Bolus adminitration of propofol until a Ramsey score 2-3 was reached
48274556|NCT05264350|DEVICE|Sialic acid nasal spray|The nasal spray will be self administered twice daily for 8 weeks.
48274557|NCT05264350|DEVICE|Isotonic Saline Nasal Spray|The nasal spray will be self administered twice daily for 8 weeks.
48274558|NCT05104944|RADIATION|Serial MRIs|Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
48274559|NCT04952623|OTHER|Rotator Cuff Related Shoulder Pain E-Learning Program|The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
48274560|NCT02321969|DIETARY_SUPPLEMENT|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate \[EGCG\]).
48274561|NCT05304364|COMBINATION_PRODUCT|Combination Product: Naltrexone|Naltrexone Implant
48274562|NCT04947475|BEHAVIORAL|SBIRT|First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
48274563|NCT02285400|PROCEDURE|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
48274564|NCT05533567|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
48274565|NCT05533567|DRUG|Propofol|The control group was sedated with propofol.
48274566|NCT01784796|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
48274567|NCT01784796|BEHAVIORAL|Health Education Program|8 week Health Education Program
48274568|NCT00531193|DRUG|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
48274569|NCT00531193|OTHER|[11C]SCH442416|11C\]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. \[11C\]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
48274570|NCT01907165|DRUG|Temozolomide|
48274571|NCT01907165|DRUG|Disulfiram|
48274572|NCT01907165|DIETARY_SUPPLEMENT|Copper gluconate|
48274573|NCT02185521|OTHER|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
48274574|NCT00981994|BEHAVIORAL|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
48274575|NCT03709563|DIETARY_SUPPLEMENT|Oral Nutraceutical Supplement|Standardized Botanicals. Take 4 capsules by mouth daily with a meal
48274576|NCT03709563|DIETARY_SUPPLEMENT|Placebo|Placebo. Take 4 capsules by mouth daily with a meal
48274577|NCT04558697|DRUG|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
48274578|NCT04558697|DRUG|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
48274579|NCT04558697|DRUG|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
48274580|NCT04558697|DRUG|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
48274581|NCT03798288|BEHAVIORAL|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
48274582|NCT03798288|OTHER|Usual care|Participants will receive usual care
48274583|NCT00415220|PROCEDURE|Spinal Manipulation, Microdiscectomy|
48274584|NCT05756192|OTHER|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
48274585|NCT01447394|BIOLOGICAL|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
48274586|NCT01447394|BIOLOGICAL|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
48274587|NCT01447394|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
48274588|NCT05397314|DIETARY_SUPPLEMENT|Punalpin|
48274589|NCT05397314|OTHER|Placebo|
48274590|NCT01322906|OTHER|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
48274591|NCT01322906|OTHER|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
48274592|NCT01322906|OTHER|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
48274593|NCT03625388|DRUG|Dasatinib|Film coated tablet contains dasatinib monohydrate
48274594|NCT04790942|DRUG|berberine hydrochloride|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
48274595|NCT04790942|BEHAVIORAL|lifestyle intervention group|The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
48274596|NCT03240900|DEVICE|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
48274597|NCT03240900|PROCEDURE|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
48274598|NCT02536248|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
47927934|NCT00949767|DRUG|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
48274599|NCT02536248|DRUG|Placebo|Placebo for 6 weeks
48274600|NCT01906437|DEVICE|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
48274601|NCT01341457|DRUG|LY2603618|Administered intravenously
48274602|NCT01341457|DRUG|Gemcitabine|Administered intravenously
48274603|NCT00212407|BIOLOGICAL|Umbilical Cord Blood Transplantation|
47927935|NCT00949767|DRUG|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
48274604|NCT04826900|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
48274605|NCT04826900|OTHER|Robotic therapy (RT)|A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
48274606|NCT04826900|OTHER|Robotic mirror therapy (RMT)|Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
48274607|NCT04826900|OTHER|Functional task training|After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
48274608|NCT01982591|OTHER|laboratory biomarker analysis|Correlative studies
48274609|NCT01982591|OTHER|questionnaire administration|Ancillary studies
48274610|NCT01035190|DRUG|Budesonide|Inhalation, 200 µg/puff
48274611|NCT00376961|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 for cycles 1-6.
48274612|NCT00376961|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
48274613|NCT00376961|DRUG|cyclophosphamide|750 mg/m\^2 on day 1 of cycles 1-6.
48274614|NCT00376961|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 1 of cycles 1-6.
48274615|NCT00376961|DRUG|prednisone|100 mg on days 1-5 of cycles 1-6.
48274616|NCT00376961|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 1 of cycles 1-6.
48274617|NCT01147926|DRUG|Placebo|Placebo matched to Prucalopride tablet orally once daily.
48274618|NCT01147926|DRUG|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
48274619|NCT01009307|GENETIC|polymorphism analysis|
48274620|NCT01009307|OTHER|laboratory biomarker analysis|
48274621|NCT01009307|OTHER|medical chart review|
48274622|NCT04597476|DIETARY_SUPPLEMENT|Fucoidan|Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
48274623|NCT04597476|OTHER|Placebo( Potato starch)|Potato starch 4.4gram
48274624|NCT01557790|RADIATION|Proton Radiation Therapy|
48274625|NCT05957705|PROCEDURE|Maxilar Sinus augmentation|The patients will be submitted to bilateral sinus augmentation using two different techniques to provide enough bone tissue for dental implants placement.
48274626|NCT05957705|PROCEDURE|Dental implant placement using guided surgery|After 4 months of sinus augmentation, patients will be prepared to receive dental implants for oral rehabilitation. Performed by guided surgery the implants will be placed at the best location for the rehabilitation and at the place were the sinus lighting were performed.
48274627|NCT04968444|OTHER|Physiotherapy|"Physiotherapy helps to restore movement and function when someone is affected by injury, illness or disability. It can also help to reduce your risk of injury or illness in the future.~This can take the form of~* advice and education~* manual therapy~* exercise prescription~* relaxation"
48274628|NCT04968444|OTHER|Back Pain Workshop|Back workshop is an intervention protocol consisting of an educational program and skills acquisition program, including physical exercises. The session is supervised by a specialist physiotherapist.
48274629|NCT03522129|DRUG|CT1812|Active Study Drug
48274630|NCT03522129|DRUG|Placebo|Non-active study drug
48274631|NCT02158559|DRUG|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
48274632|NCT02158559|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
48274633|NCT04003714|DEVICE|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
48274634|NCT04003714|DEVICE|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
48274635|NCT05257122|DRUG|Fruquintinib|Fruquintinib 5mg qd, d1-21, q28d
48274636|NCT04742673|DRUG|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
48274637|NCT04742673|DRUG|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
48274638|NCT01511731|DRUG|Famotidine|Famotidine Tablets 40 mg
48274639|NCT01511731|DRUG|Pepcid|40mg tablets
48274640|NCT02370121|DRUG|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
48274641|NCT02370121|DRUG|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
48274642|NCT05451420|DRUG|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
48274643|NCT06110052|OTHER|prospective follow up|compare preoperative and postoperative visual analog scale VAS of maximum perceived pain in ladies with OMAs
48274644|NCT00898547|OTHER|immunoenzyme technique|
48274645|NCT00898547|OTHER|laboratory biomarker analysis|
48274646|NCT04022486|OTHER|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
48274647|NCT01357213|DRUG|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
48274648|NCT01357213|OTHER|Placebo|Normal saline 100 ml
48274649|NCT02619422|OTHER|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
48274650|NCT04513691|DIAGNOSTIC_TEST|EOS Calculator|Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
48274651|NCT06428890|DIETARY_SUPPLEMENT|Grape Seed Extract|dietary supplements that rich in polyphenolic compounds
48274652|NCT06428890|DIETARY_SUPPLEMENT|Placebo|Starch
48274653|NCT03177161|OTHER|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
48274654|NCT04120922|OTHER|calcium carbonate|See arm description
48274655|NCT04120922|OTHER|sevelamer carbonate|See arm description
48274656|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 200 J/cm\^2.
48274657|NCT05736406|COMBINATION_PRODUCT|5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2|5-ALA HCl, 20 mg/kg, is orally administered 4-6 hours before the surgery. Then after resection of tumor tissue is judged maximal, the intraoperative PDT procedure is initiated at 400 J/cm\^2.
48274658|NCT02440750|PROCEDURE|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
48274659|NCT02440750|DRUG|Dienogest|21 days administration of dienogest 2 mg/die
48274660|NCT02440750|DRUG|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
48274661|NCT06179901|PROCEDURE|Integrative Korean Medicine Treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine, cupping, moxibustion.
48274662|NCT06179901|PROCEDURE|lower limb motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.
48274663|NCT00591734|DRUG|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
48274664|NCT00591734|DRUG|Everolimus|10 mg by mouth daily
48274665|NCT00579813|DRUG|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
48274666|NCT01261403|BIOLOGICAL|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
48274667|NCT01261403|DRUG|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
48274668|NCT05239845|DIETARY_SUPPLEMENT|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
48274669|NCT05239845|OTHER|Control|Maltodextrin
48274670|NCT02976155|OTHER|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
48274671|NCT00203684|DRUG|Flunisolide-HFA|
48274672|NCT00609622|DRUG|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
48274673|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
48274674|NCT00609622|DRUG|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
48274675|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
48274676|NCT05340972|DIAGNOSTIC_TEST|MEESSI score|The score aimed to predict the AHF patient's future in the month following management for ED
48274677|NCT04529291|OTHER|Group with walking disorder|During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
48274678|NCT04529291|OTHER|Group without walking disorder|"During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team."
48274679|NCT05015309|DRUG|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
48274680|NCT02487875|OTHER|rehabilitation|
48274681|NCT00716716|DRUG|rFIXFc|As specified in the treatment arm
48274682|NCT04711096|PROCEDURE|Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.|After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
48274683|NCT03036878|OTHER|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
48274684|NCT03545139|BIOLOGICAL|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
48274685|NCT03545139|BIOLOGICAL|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
48274686|NCT05422092|DRUG|Canagliflozin|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
48274687|NCT05422092|DRUG|Pioglitazone|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
48274688|NCT02553837|BIOLOGICAL|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
48274689|NCT01893749|BEHAVIORAL|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
48274690|NCT04749030|OTHER|Faecal microbiota transplantation (FMT) capsules|The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).
48274691|NCT04749030|OTHER|Placebo capsules|The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
48274692|NCT06138145|OTHER|Video|Different videos were shown for Arms B and C. No Video was shown for Group A or D.
48274693|NCT06138145|BEHAVIORAL|Survey|Survey about participant's demographics, information source trust, and clinical trials knowledge. Also includes question about whether the participant is interested in enrolling in the Pediatric Trials Notification System.
48274694|NCT02006576|DRUG|600 mg ibuprofen three times daily for 48 weeks|
48274695|NCT02006576|OTHER|Placebo three times daily|
48274696|NCT05394415|DRUG|Tislelizumab|The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.
48274697|NCT05394415|DRUG|Paclitaxel|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
48274698|NCT05394415|DRUG|Carboplatin|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
48274699|NCT05394415|RADIATION|Radiotherapy|Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
48274700|NCT04313725|DEVICE|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
48274701|NCT04313725|OTHER|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
47927936|NCT02689102|DEVICE|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
48274702|NCT03580330|OTHER|mHealth intervention|Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
48274703|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
48274704|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
48274705|NCT01878630|DEVICE|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~* weighing scale (Seca 861 with bluetooth, seca gmbh \& co. kg.)~* blood pressure device (UA767PBT with bluetooth, A\&D Ltd.)~* ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~* patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~* help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~- electronic patient record (eHealth connect 2.0, T-Systems International)"
48274706|NCT01878630|OTHER|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
48274707|NCT05096299|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
48274708|NCT05174091|OTHER|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
48274709|NCT06064760|BEHAVIORAL|Psychoeducational Workshop on Personal Strengths and Emotional Competences to Improve the Psychological Wellbeing and Quality of Life of Grandparents Caring for Their Grandchildren|"The intervention is a psychoeducational group workshop (6-8 participants). It includes 5 sessions of, approximately, 90 minutes. In addition, 3 months after the end of the workshop, a follow-up call will be organized with the participants. Due to the Covid-19 pandemic, the workshop will be held online.~The sessions are:~* Session 1: Defining my role as grandparent.~* Session 2: Deepening my relationships.~* Session 3: Growing as grandparent.~* Session 4: Discovering my emotional world.~* Session 5: Caring for others and caring for myself."
48274710|NCT02563301|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
48274711|NCT04203901|BIOLOGICAL|CMN-001|Autologous Dendritic Cell Therapy
48274712|NCT04203901|BIOLOGICAL|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
48274713|NCT04203901|DRUG|Lenvatinib+Everolimus|TKI+mTOR inhibitors
48274714|NCT03374280|DRUG|pemetrexed/cisplatin intercalating gefitinib|
48274715|NCT03374280|DRUG|pemetrexed/cisplatin|
48274716|NCT06251011|BEHAVIORAL|Exercise training|"1. Physical therapy training via video call~2. An advise and a leaflet for cardiopulmonary rehabilitation"
48274717|NCT03081689|DRUG|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
48274718|NCT03081689|DRUG|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
48274719|NCT03081689|DRUG|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
48274720|NCT03792048|PROCEDURE|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
48274721|NCT06416501|OTHER|Mode of detection|Mode of detection
48274722|NCT02005822|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
48274723|NCT01822561|DRUG|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
48274724|NCT03326934|DIETARY_SUPPLEMENT|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
48274725|NCT03326934|DIETARY_SUPPLEMENT|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
48274726|NCT02682836|BEHAVIORAL|Walk with Ease|
48274727|NCT00924703|DRUG|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
48274728|NCT02221089|DRUG|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
48274729|NCT02221089|DIETARY_SUPPLEMENT|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
48274730|NCT02221089|OTHER|Placebo|Placebo capsules identical in appearance to Retaron capsules
47927937|NCT04631991|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
47927938|NCT00720018|DRUG|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
48274731|NCT05491759|DRUG|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
48274732|NCT05491759|DRUG|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
48274733|NCT05491759|DRUG|Product 3 - Standard Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
48274734|NCT05495048|PROCEDURE|NOSES VIIIA|totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction
48274735|NCT05495048|PROCEDURE|laparoscopic surgery with mini-laparotomy|laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
48274736|NCT01191814|PROCEDURE|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
48274737|NCT01191814|PROCEDURE|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
48274738|NCT01849757|OTHER|prime crystalloid|used for priming the CPB circuit
48274739|NCT01849757|OTHER|Human Albumin|Used as a constituent for priming the CPB circuit
48274740|NCT01849757|OTHER|Voluven|Used as a constituent for priming the CPB circuit
48274741|NCT05212025|DRUG|Adavosertib|Taken Orally
48274742|NCT05212025|DRUG|Gemcitabine|Intravenous Infusion
48274743|NCT00582517|DEVICE|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
48274744|NCT00582517|PROCEDURE|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
48274745|NCT05548036|DEVICE|OPEP|OPEP (Aerobika (tm)
48274746|NCT03982550|BEHAVIORAL|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
48274747|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
48274748|NCT06142084|DIETARY_SUPPLEMENT|Oat Protein, high bioavailability|Participants will consume a protein meal consisting of heated oat protein concentrate (amount based on body weight, 0.3g of protein/kg bodyweight).
48274749|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, low bioavailability|Participants will consume a protein meal consisting of cooked whole yellow peas (amount based on body weight, 0.3g of protein/kg bodyweight).
48274750|NCT06142084|DIETARY_SUPPLEMENT|Pea Protein, high bioavailability|Participants will consume a protein meal consisting of heated pea protein isolate (amount based on body weight, 0.3g of protein/kg bodyweight).
48274751|NCT06142084|DIETARY_SUPPLEMENT|Protein-free meal|Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
48274752|NCT01114789|OTHER|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
48274753|NCT05765903|OTHER|Standard of Care|"* Diagnosis education.~* Follow-appointment scheduling assistance.~* Offer resources in the community.~* Offer weekly follow-up calls for one month.~* Social Determinants of Health (SDoH) assessment."
48274754|NCT05765903|OTHER|Enhanced Care|"* Additional educational training using computer tablet devices, such as iPads.~* Focus on readmission risk.~* Set-up Home Health Services (HHS), Mobile Integrated Healthcare (MIH) or Resources, Education and Access to Community Health (REACH)."
48274755|NCT03399383|OTHER|Patient education|Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
48274756|NCT06222944|DRUG|Anlotinib|Anlotinib: 12mg PO, QD, D1-14, Q3W;
48274757|NCT06222944|DRUG|TQB2450|TQB2450: 1200 mg, IV, D1, Q3W
48274758|NCT06222944|DRUG|Albumin-Bound Paclitaxel|125mg/m2 IV D1,8，Q3W
48274759|NCT03234335|OTHER|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
48274760|NCT00014092|BIOLOGICAL|aldesleukin|
48274761|NCT00014092|BIOLOGICAL|recombinant interferon alfa|
48274762|NCT00014092|BIOLOGICAL|sargramostim|
48274763|NCT00014092|DRUG|temozolomide|
48274764|NCT01636492|DRUG|bitopertin|Single oral dose
48274765|NCT01636492|DRUG|placebo|Single oral dose
48274766|NCT03124459|DRUG|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
48274767|NCT03124459|DRUG|Placebo|Recombinant fusion protein or buffer solution
48274768|NCT00235105|DRUG|Adalimumab 40 mg sc every other week|
48274769|NCT02811744|DRUG|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
48274770|NCT02730156|OTHER|Altitude exposure|Altitude exposure
48274771|NCT03190525|OTHER|Quality of life questionnaires|QLQ-C30
48274772|NCT00432809|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
48274773|NCT00432809|PROCEDURE|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
48274774|NCT00022074|DRUG|gabapentin|
48274775|NCT00022074|PROCEDURE|quality-of-life assessment|
48274776|NCT05381506|DRUG|Orelabrutinib and Gemox|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"
48274777|NCT06330129|DEVICE|CTT Pegasus|The intervention aims to assess the construct validity of trunk flexor, extensor, and rotator muscle strength using the CTT PEGASUS isometric dynamometer (Leipzig, Germany). This involves correlating muscle strength measured isometrically with its physiological determinants: MRI-based anatomical cross-sectional area (CSA) in the lumbar region and muscle activation measured via surface electromyography (EMG) of spine and trunk muscles. Additionally, the intervention will assess the test-retest reliability of isometric strength of trunk flexors, extensors, and rotators.
48274778|NCT03248921|PROCEDURE|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
48274779|NCT02763956|DEVICE|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
48274780|NCT02763956|OTHER|Placebo|Intradiscal saline injection
48274781|NCT06487013|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
48274782|NCT06487013|OTHER|Sham MRgHIFU treatment|Sham MRgHIFU treatment
48274783|NCT05657769|DEVICE|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
48274784|NCT05657769|DEVICE|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
48274785|NCT01510327|DEVICE|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
48274786|NCT01510327|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
48274787|NCT01510327|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
48274788|NCT00420030|DRUG|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
48274789|NCT04545957|DEVICE|MRI Simulator|Radiation mapping to define the target for radiation.acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data.
48274790|NCT04545957|RADIATION|Radiation Therapy|In Phase I, radiation will be institutional standard per disease site. In Phase II, either radiation according to MR-based dose painting or adjusted RT. These adjusted doses and/or RT will vary per disease site and will be pre-specified in the subprotocols.
48274791|NCT01517035|PROCEDURE|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
48274792|NCT01621932|PROCEDURE|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
48274793|NCT01621932|PROCEDURE|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
48274794|NCT06218927|OTHER|QoL monitoring|QoL questionnaire
48274795|NCT01262183|DRUG|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
48274796|NCT01262183|DRUG|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
48274797|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
48274798|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
48274799|NCT05929534|DEVICE|active intermittent Theta Burst Stimulation|Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
48274800|NCT05929534|DEVICE|sham intermittent Theta Burst Stimulation|Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
48274801|NCT02829879|DRUG|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
48274802|NCT02829879|DRUG|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
48274803|NCT01812642|DRUG|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
48274804|NCT01812642|OTHER|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
48274805|NCT05518461|DEVICE|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
48274806|NCT03601871|DRUG|Thalidomide|Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
48274807|NCT03601871|DRUG|Dexamethasone|Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
48274808|NCT03601871|DRUG|5-HT3 antagonists|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
48274809|NCT03757039|DEVICE|Multifocal soft contact lenses|Commercially available contact lenses
48274810|NCT03757039|OTHER|Progressive addition lens spectacles|Per subject's habitual prescription
48274811|NCT01705691|DRUG|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
48274812|NCT01705691|DRUG|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
48274813|NCT01705691|DRUG|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
48274814|NCT01705691|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
48274815|NCT01380054|BEHAVIORAL|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
48274816|NCT05527951|OTHER|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
48274817|NCT05527951|OTHER|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
48274818|NCT02996812|DRUG|Exendin (9-39)|
48274819|NCT01236391|DRUG|PCI-32765|560 mg daily
48274820|NCT02971592|DEVICE|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
48274821|NCT02971592|OTHER|Mock Device|reception of device that does not apply the electromagnetic field
48274822|NCT01780233|DRUG|Fentanyl 400 µg sublingual spray|
48274823|NCT01780233|DRUG|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
48274824|NCT01780233|DRUG|Fentanyl citrate injection 100 µg intravenously|
48274825|NCT01780233|DRUG|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
48274826|NCT02296411|DRUG|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
48274827|NCT02296411|DRUG|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
48274828|NCT05619965|DRUG|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
48274829|NCT05619965|DEVICE|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
48274830|NCT05619965|DEVICE|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
48274831|NCT00702143|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
48274832|NCT03206801|PROCEDURE|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
48274833|NCT04313946|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
48274834|NCT02292823|DEVICE|MGuard™ Prime Embolic Protection Stent System|
48274835|NCT03369795|DRUG|Methotrexate|Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
48274836|NCT03369795|OTHER|Placebo Arm|Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
48274837|NCT03406533|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
48274838|NCT03406533|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
48274839|NCT03406533|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
48274840|NCT03406533|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
48274841|NCT03406533|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
48274842|NCT00646659|BIOLOGICAL|cetuximab|
48274843|NCT00646659|DRUG|carboplatin|
48274844|NCT00646659|DRUG|cisplatin|
48274845|NCT00646659|DRUG|docetaxel|
48274846|NCT00646659|DRUG|fluorouracil|
48274847|NCT00646659|GENETIC|fluorescence in situ hybridization|
48274848|NCT00646659|GENETIC|molecular genetic technique|
48274849|NCT00646659|GENETIC|reverse transcriptase-polymerase chain reaction|
48274850|NCT00646659|OTHER|immunoenzyme technique|
48274851|NCT00646659|OTHER|immunohistochemistry staining method|
48274852|NCT00646659|OTHER|laboratory biomarker analysis|
48274853|NCT00646659|PROCEDURE|biopsy|
48274854|NCT00646659|RADIATION|3-dimensional conformal radiation therapy|
48274855|NCT00646659|RADIATION|intensity-modulated radiation therapy|
48274856|NCT00754156|DEVICE|ABRA Abdominal Closure System|ABRA Abdominal Closure System
48274857|NCT00754156|DEVICE|V.A.C. Therapy|V.A.C. Therapy Alone
48274858|NCT00754156|DEVICE|KCI ABThera|KCI ABThera
48274859|NCT03646084|OTHER|Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program|To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.
48274860|NCT03646084|OTHER|Rehabilitation program|Rehabilitation program current clinical practice
48274861|NCT01533727|DRUG|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
48274862|NCT01533727|DRUG|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
48274863|NCT00878124|DIETARY_SUPPLEMENT|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
48274864|NCT00878124|OTHER|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
48274865|NCT06642545|DRUG|Disitamab Vedotin|Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
48274866|NCT06642545|DRUG|RC148|20mg/kg, intravenous infusion, once every 2 weeks
48274867|NCT06642545|DRUG|Albumin-bound Paclitaxone|125 mg/m2,intravenous infusion, D1-8, every 3 weeks
48274868|NCT06642545|DRUG|Toripalimab|240mg,intravenous infusion, once every 3 weeks
48274869|NCT01016626|DRUG|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~* 500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
48274870|NCT01016626|DRUG|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~* 250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
48274871|NCT03251326|DRUG|Nabilone|Nabilone capsules (4 mg)
48274872|NCT03251326|DRUG|Cannabis|Cigarettes (0.0 and 5.6% THC)
48274873|NCT03251326|DRUG|Propranolol|Propranolol capsules (40mg)
48274874|NCT03251326|DRUG|Placebo|Placebo capsules
48274875|NCT02922387|DRUG|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
48274876|NCT02922387|BEHAVIORAL|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
48274877|NCT06413004|OTHER|Elimination and re-introduction of CLE or COLAP positive food item(s)|Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)
48274878|NCT05029557|BEHAVIORAL|Education and telephone follow ups based on the Chronic Care Model|The effects of Chronic Care Model-based education and telephone follow-up given to patients with COPD on self-efficacy and patient-reported outcomes.
48274879|NCT00956930|RADIATION|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
48274880|NCT00956930|DRUG|Doxorubicin|75mg fixed dose
48274881|NCT04525703|BEHAVIORAL|Pathways for Parents after Incarceration|The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
48274882|NCT02377102|PROCEDURE|Physical Therapy|12 weeks of supervised physical therapy.
48274883|NCT05591989|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
48274884|NCT00891735|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
48274885|NCT04899479|DRUG|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
48274886|NCT04899479|OTHER|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
48274887|NCT02486861|OTHER|optical coherence tomography|
48274888|NCT05034640|PROCEDURE|Conventional multiport thoracoscopic surgery|Use 2 or more incisions for multiple instrument entry during the surgery and chest tube placement at the end of the operation.
48274889|NCT05034640|PROCEDURE|Single port site thoracoscopic surgery|Using only 1 incision for multiple instrument entry during the surgery and chest tube placement at the end of the operation. Single port - GelPOINT Mini® port (Applied Medical, Rancho Santa Margarita, California, USA)
48274890|NCT03767257|DRUG|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
48274891|NCT06351202|OTHER|Abdominal massage|An abdominal massage for premature babies lasts 10 minutes. Our abdominal massage techniques is described in our protocole and will be adapted according to the term of the child.
48274892|NCT05309447|OTHER|data collection|The study entails the collection of clinical, functional, radiological, and biomechanical data.
48274893|NCT00456703|OTHER|intraoperative fluid management|fluid restriction
48274894|NCT00456703|OTHER|fluid restriction|restriction of fluids
48274895|NCT03211390|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
48274896|NCT03211390|DIAGNOSTIC_TEST|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
48274897|NCT01243268|DRUG|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
48274898|NCT00486486|DRUG|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
48274899|NCT00486486|DRUG|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
48274900|NCT05963763|BEHAVIORAL|Career Navigator Coaching|"The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs."
48274901|NCT05230498|DEVICE|anatomy-based fitting then default fitting|Cochlear implant with anatomy-based fitting then default fitting
48274902|NCT05230498|DEVICE|default fitting then anatomy-based fitting|Cochlear implant with anatomy-based fitting then default fitting
48274903|NCT06147024|OTHER|historical control|Received a conventional preoperative assessment
48274904|NCT06147024|OTHER|3D printed lesion model|Received 3D printed lesion models for preoperative planning
48274905|NCT01523483|DRUG|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
48274906|NCT01523483|DRUG|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
48274907|NCT05426200|BEHAVIORAL|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
48274908|NCT01278290|DIAGNOSTIC_TEST|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
48274909|NCT01278290|DIAGNOSTIC_TEST|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
48274910|NCT04523662|DRUG|Camrelizumab Apatinib Mesylas|This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
48274911|NCT03099681|OTHER|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
48274912|NCT01604746|BIOLOGICAL|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
48274913|NCT04574843|PROCEDURE|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
48274914|NCT02095301|OTHER|Herbal Beverage|
48274915|NCT00832819|DRUG|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
48274916|NCT00832819|DRUG|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
48274917|NCT00832819|DRUG|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
48274918|NCT00832819|DRUG|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
48274919|NCT04213651|OTHER|No intervention|There is no intervention for this study
48274920|NCT02033356|PROCEDURE|Adductor canal block with lidocaine 1%|US-guided adductor canal block
48274921|NCT02033356|DRUG|Lidocaine|
48274922|NCT02190734|OTHER|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
48274923|NCT02190734|OTHER|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
48274924|NCT02190734|OTHER|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
48274925|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
48274926|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
48274927|NCT04586491|COMBINATION_PRODUCT|Oral care protocol|Oral care protocol
48274928|NCT03758586|OTHER|Computerized spatial skill training|The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.
48274929|NCT03758586|OTHER|Watching a presentation regarding robotic surgery|Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
48274930|NCT01393093|PROCEDURE|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
48274931|NCT06488300|DRUG|Ribavirin|"Oral ribavirin 400 to 1000mg three times a day for 5 days. Each tablet contains 200mg, The total daily dosage in adults is weight dependent as outlined below;~* 40-59.9kg = 1200mg/day~* 60-79.9kg = 1800mg/day~* 80-99.9kg = 2400mg/day~* ≥100kg = 3000mg/day"
48274932|NCT06488300|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5 days
48274933|NCT06488300|DRUG|Favipiravir|Oral favipiravir 1800mg BD on Day 0, and 800mg BD for a further 4 days
48274934|NCT00294151|PROCEDURE|Vertebroplasty|
48274935|NCT01755169|DRUG|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
48274936|NCT01755169|DRUG|Placebo|
48274937|NCT02335684|OTHER|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
48274938|NCT02335684|OTHER|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
48274939|NCT02800460|PROCEDURE|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
48274940|NCT05792826|OTHER|BSZY Cream|The patients receive BSZY Cream twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
48274941|NCT05792826|OTHER|emulsion matrix|The patients receive emusion matrix twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
48274942|NCT01845545|OTHER|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
48274943|NCT01245673|BIOLOGICAL|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
48274944|NCT01245673|OTHER|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion \~day 2 post-transplant. The target number of costimulated T-cells for infusion will be \~ 5 x 10e10 T-cells total in 100-500 mL total volume.
48274945|NCT01245673|DRUG|Revlamid® (Lenalidomide)|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
48274946|NCT01245673|BIOLOGICAL|MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF \[+ coinjection of 2mg of Hiltonol®(Poly-ICLC)\]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
48274947|NCT04636905|OTHER|Questionnaires|Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
48274948|NCT02132442|DIETARY_SUPPLEMENT|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
48274949|NCT04328506|DRUG|CM082 tablet (test product)|Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
48274950|NCT04328506|DRUG|CM082 tablet (reference product)|Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
48274951|NCT01530243|DRUG|Placebo|same as tolterodine and terazosin dose
48274952|NCT01530243|DRUG|Terazosine|2 mg BID
48274953|NCT01530243|DRUG|Tolterodine|2 mg daily
48274954|NCT01530243|DRUG|Tolterodine + Terazosin|2mg daily and 2mg BID
48274955|NCT03305640|PROCEDURE|acetabular fracture surgery|acetabular fracture surgery
48274956|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 pm
48274957|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 am
48274958|NCT00227201|BEHAVIORAL|Self-affirmation intervention|
48274959|NCT01796002|DRUG|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
48274960|NCT01796002|DRUG|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
48274961|NCT05704114|DRUG|Tazarotene 0.045% Lotion|Daily topical use of tazarotene for 16 weeks.
48274962|NCT05397236|DRUG|Bupivacaine- Magnesium|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
48274963|NCT05397236|DRUG|Bupivacaine dexamethasone|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
48274964|NCT05397236|DRUG|Bupivacaine saline|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
48274965|NCT04766866|DIAGNOSTIC_TEST|sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation|A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
48274966|NCT01271686|DRUG|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
48274967|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic retrosigmoid minimally invasive vestibular neurectomy
48274968|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic tenotomy of middle ear muscles
48274969|NCT03670576|PROCEDURE|Optional Bronchoscopy|Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
48274970|NCT03670576|OTHER|Quality of Life Questionnaires|MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
48274971|NCT03670576|OTHER|Blood Samples for Biomarkers|a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
48274972|NCT03670576|OTHER|Home Hand Held Spirometry|Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
48274973|NCT01536301|DRUG|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
48274974|NCT01536301|DRUG|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
48274975|NCT06428903|DRUG|ADC189 tablet|ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)
48274976|NCT06428903|DRUG|ADC189 granules|ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)
48274977|NCT06428903|DRUG|ADC189 180mg|ADC189 tablet, 180 mg, single oral dose. (Part 2 study)
48274978|NCT04824378|OTHER|No Intervention.|No Intervention.Only learn ICG image features of different label groups
48274979|NCT01848275|DEVICE|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
48274980|NCT01848275|DEVICE|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
48274981|NCT03793439|DRUG|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
48274982|NCT03793439|DIAGNOSTIC_TEST|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
48274983|NCT03793439|GENETIC|RNA Sequencing|RNA sequencing test at baseline and week 16
48274984|NCT03793439|DIAGNOSTIC_TEST|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
48274985|NCT03793439|DRUG|Corticosteroid|Taper corticosteroids starting at week 4
48274986|NCT03793439|DRUG|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
48274987|NCT01955616|DRUG|RM-131|
48274988|NCT01955616|DRUG|Placebo|
48274989|NCT00928070|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg
48274990|NCT00928070|DRUG|Placebo|Placebo sham 4 mg and 8 mg
48274991|NCT01417676|RADIATION|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
48274994|NCT00682630|DRUG|pyronaridine artesunate clinical trial reference tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
48274995|NCT00682630|DRUG|pyronaridine artesunate to-be-marketed tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
48274996|NCT02764541|DRUG|Letrozole|
48274997|NCT02764541|DRUG|Tamoxifen|
48274998|NCT02764541|DRUG|Palbociclib|
48274999|NCT02764541|DRUG|Endocrine Therapy|
48275000|NCT04343950|BEHAVIORAL|SMS reminders to enhance colorectal cancer screening|"Cluster randomization instead of individual randomization will be used. The cluster will be invitation week.~Individuals assigned to the experimental arm with a wrong phone number will get a reminder letter (protocol analysis)."
48275001|NCT04343950|BEHAVIORAL|SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|"Cluster randomization instead of individual randomization will be used. The cluster will be invitation week.~Individuals with a wrong phone number assigned to the experimental arm will not get any reminder (protocol analysis)."
48275002|NCT04343950|BEHAVIORAL|Invitation by SMS to previous participants in breast cancer screening:|Individual randomization. Women assigned to the experimental arm and with a wrong phone number will get an invitation letter (protocol analysis).
48275003|NCT01253733|BEHAVIORAL|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
48275004|NCT03008187|DRUG|SEL24/MEN1703|SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
48275005|NCT04769557|DRUG|paracetamol|tablet paracetamol 500 mg
48275006|NCT04769557|DRUG|Placebo|placebo
48275007|NCT03669978|PROCEDURE|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
48275008|NCT01231412|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
48275009|NCT01231412|DRUG|Cyclosporine|Given PO or IV
48275010|NCT01231412|DRUG|Fludarabine Phosphate|Given IV
48275011|NCT01231412|DRUG|Mycophenolate Mofetil|Given PO
48275012|NCT01231412|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
48275013|NCT01231412|DRUG|Sirolimus|Given PO
48275014|NCT01231412|RADIATION|Total-Body Irradiation|Undergo TBI
48275015|NCT01154608|DRUG|Creon|
48275016|NCT01154608|OTHER|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
48444017|NCT03057210|OTHER|Massage Protocol|"the present protocol will have a total of 12 minutes duration, being six minutes in the anterior region of the thigh (three minutes for each limb) and six minutes in the posterior region of the trunk.~Surface and deep sliding techniques will be used, the latter being presented in two intensities, moderate or intense, gradually increased. The massage will be performed towards the muscle fibers, from distal to proximal and following the lymphatic flow. In addition to the standardization of the intensity of the massage performed by the physiotherapist, in order to avoid causing discomfort and possible variations in the application of the technique, participants should report their level of comfort from a scale that considers the technique light, moderate or Intense, corresponding respectively to surface slip, Deep Slip 1 and Deep Slip 2."
48275017|NCT03294993|DEVICE|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
48275018|NCT06222892|DRUG|Camlipixant|Camlipixant will be administered.
48275019|NCT05599958|DIAGNOSTIC_TEST|sweat chloride test|assessing chloride (Cl-) concentration in sweat of the patient
48275020|NCT05599958|GENETIC|genetic testing|detection of CFTR mutation
48275021|NCT03446495|DRUG|Trabectedin + PLD|Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
48275022|NCT00610636|PROCEDURE|Hepatic resection|Hepatic resection
48275023|NCT06379334|DIAGNOSTIC_TEST|Urine test|Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
48275024|NCT02658448|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
48275025|NCT04890873|DRUG|ERX1000|ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
48275026|NCT04890873|DRUG|Placebo|A suspension containing magnesium hydroxide carbonate in polysorbate
48275027|NCT00643383|DRUG|Combination drug (Acetaminophen + Tramadol)|
48275028|NCT00643383|DRUG|Placebo|
48275029|NCT04502615|OTHER|Sand|sand surface
48275030|NCT04502615|OTHER|artificial grass|grass surface
48275031|NCT04502615|OTHER|firm ground|firm surface
48275032|NCT06657196|OTHER|No Intervention: Observational Cohort|No intervention.
48275033|NCT01323296|OTHER|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
48275034|NCT00340470|BEHAVIORAL|Driver Education|
48275035|NCT01129947|DRUG|DHEA|DHEA 25 mg tid
48275036|NCT05119387|OTHER|Observation|Observation of genetic characteristics
48275037|NCT00426673|DRUG|Brivaracetam (ucb34714)|
48275038|NCT01895530|DIETARY_SUPPLEMENT|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
48275039|NCT04107038|PROCEDURE|General Endotracheal Anesthesia|Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
48275040|NCT04107038|PROCEDURE|Monitored anesthesia care|Participants receive monitored anesthesia care for their procedure.
48275041|NCT03011125|DRUG|dexlansoprazole injection|
48275042|NCT03011125|OTHER|placebo|
48275043|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
48275044|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
48275045|NCT04077333|PROCEDURE|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
48275046|NCT02286388|PROCEDURE|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
48275047|NCT02286388|PROCEDURE|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
48275048|NCT02286388|DEVICE|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
48275049|NCT02286388|DEVICE|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
48275050|NCT00849017|BIOLOGICAL|albiglutide|albiglutide weekly injection
48275051|NCT00849017|BIOLOGICAL|albiglutide uptitration|albiglutide uptitration at week 12
48275052|NCT00849017|BIOLOGICAL|placebo|matching albiglutide placebo weekly injection
48275053|NCT05232734|DRUG|Caffeine Citrate 20 MG/ML Oral Solution|Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
48275054|NCT02547727|BIOLOGICAL|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
48275055|NCT03496701|DEVICE|Test lens|contact lens
48275056|NCT03496701|DEVICE|control lens|contact lens
48275057|NCT01200433|DRUG|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
48275058|NCT01200433|DRUG|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
48275059|NCT00003060|BIOLOGICAL|filgrastim|
48275060|NCT00003060|DRUG|busulfan|
48275061|NCT00003060|DRUG|cyclophosphamide|
48275062|NCT00003060|DRUG|cyclosporine|
48275063|NCT00003060|DRUG|methotrexate|
48275064|NCT00003060|PROCEDURE|allogeneic bone marrow transplantation|
48275065|NCT03476044|DRUG|Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
48275066|NCT03476044|DRUG|Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
48275067|NCT05054855|BEHAVIORAL|: Cognitive Support Technology (CST)|"Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012)."
48444018|NCT02111694|BEHAVIORAL|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
48275068|NCT01097044|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
48275069|NCT01097044|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
48275070|NCT02625402|BEHAVIORAL|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
48444019|NCT04739384|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg followed by Ticagrelor 60 mg
48275071|NCT02625402|BEHAVIORAL|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
48275072|NCT00433238|BEHAVIORAL|Participants will be screened for depression and cognitive impairment, then receive screening results.|
48275073|NCT00202592|DRUG|Perindopril|
48275074|NCT03987750|DRUG|Safinamide Methanesulfonate 150mg|150 mg (free base)
48275075|NCT03987750|DRUG|Safinamide Methanesulfonate 100mg|100 mg (free base)
48275076|NCT03987750|DRUG|Safinamide Methanesulfonate matching placebo|placebo
48275077|NCT06151925|DEVICE|Laminaria|mechanical method for induction of labor
48275078|NCT06151925|DRUG|Vaginal prostaglandin|Vaginal prostaglandin for ripening
48275079|NCT02773797|DRUG|IN-DEX 1.0 mcg/kg, intranasal saline|
48275080|NCT02773797|DRUG|IN-DEX 1.5 mcg/kg, intranasal saline|
48275081|NCT02773797|DRUG|Placebo - Saline|
48275082|NCT00116025|DRUG|Human acylated ghrelin|
48275083|NCT05233358|PROCEDURE|Hepatic Artery Infusion Chemotherapy|HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
48275084|NCT05233358|PROCEDURE|Transarterial Chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
48275085|NCT05233358|DRUG|Regorafenib|Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
48275086|NCT05233358|DRUG|Immune Checkpoint Inhibitors|Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
48275087|NCT04343651|DRUG|Placebo|Placebo
48275088|NCT04343651|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
48275089|NCT04080206|DRUG|188-0551 Spray|Applied topically twice daily for two weeks
48275090|NCT04080206|DRUG|RLD|Applied topically twice daily for two weeks
48275091|NCT01790490|DRUG|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
48275092|NCT01790490|DRUG|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
48275093|NCT01790490|DRUG|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
48275094|NCT06329934|BEHAVIORAL|Establishment of a hierarchical monitoring and management team|To be specific, the head nurse served as the team leader to conduct comprehensive macro supervision; moreover, there were 3 responsible team leaders and 6 responsible nurses, all of whom had rich clinical nursing experience and solid theoretical knowledge of pressure injury. Consequently, a joint-action mechanism of the head nurse - responsible team leader - responsible nurses was developed to facilitate the unification of the training of nursing content, precautions, etc.
48275095|NCT06329934|BEHAVIORAL|Assessment of pressure injury|Based on the postoperative coma of patients, the Braden assessment scale was applied to effectively evaluate patients from six dimensions of sensory perception, moisture, activity mode, mobility, nutrition, friction, and shear. The total score was 23 points. Patients scoring 13\~14 points were evaluated by Braden once per week; and those scoring ≤12 points were evaluated at a frequency of 3d/ time.
48275096|NCT06329934|BEHAVIORAL|Communication|Through intensive face-to-face communication with family members, timely information on the surgical effect, mechanism of pressure injury, preventive measures, and clinical manifestations through intuitive methods such as PPT and video, family members were taught with basic knowledge of pressure injury, and guided to inform medical staff in a timely manner when patients had symptoms of pressure ulcer. Simultaneously, by case sharing and positive suggestions, family members were supported to alleviate their concerns and improve their coordination with treatment
48275097|NCT06329934|BEHAVIORAL|Intervention for pressure ulcer|For patients with a Braden score of \>14 points, attention should be paid to keeping skin dry and clean, regularly changing bed sheets and bedding (once per day). Patients with Braden score of 13-14 points should be provided with sponge mattresses, increased times of turning over once per 2 hours, and soft pillows or foam dressings at the site of occipital protuberance to relieve pressure and prevent pressure injury. For patients with Braden score ≤12 points, medical staff should repeatedly emphasize to their families the harm of pressure injury to postoperative recovery.
48275098|NCT06329934|BEHAVIORAL|Rehabilitation training|After regaining consciousness with stable vital signs, patients received rehabilitation training following the principle of association of activity and inertia in a regular order. Patients were guided to perform upper limb movements, joint flexion, lower limb flexion and extension, as well as daily training such as washing face, rinsing mouth, and dressing at a frequency of 3\~4 times/d. Moreover, patients were advised to minimize violent behaviors such as laughing and talking loudly
48275099|NCT06329934|BEHAVIORAL|introduction of the current patient's condition to family members|timely introduction of the current patient's condition to family members to alleviate their concerns
48275100|NCT06329934|BEHAVIORAL|maintaining appropriate temperature and humidity in the ward|maintaining appropriate temperature (20 ℃\~22 ℃) and humidity (60.0%\~70.0%) in the ward
48275101|NCT06329934|BEHAVIORAL|careful observation of vital signs in patients|careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients
48275102|NCT04409847|DIAGNOSTIC_TEST|ABPM|24 hour ambulatory blood pressure monitoring
48275103|NCT04409847|DIAGNOSTIC_TEST|ECG|Electrocardiogram
48275104|NCT04409847|DIAGNOSTIC_TEST|FMD|Flow mediated dilatation
48275105|NCT04409847|DIAGNOSTIC_TEST|PWV|Pulse wave velocity
48275106|NCT04409847|DIAGNOSTIC_TEST|Rarefaction|nailbed capillaroscopy
48275107|NCT04908995|DRUG|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
48275108|NCT04908995|OTHER|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
48275109|NCT04278794|OTHER|Transitional Care Stroke Intervention (TCSI)|"Core components:~1. Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~2. Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~3. Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~4. Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention."
48275110|NCT03745924|DRUG|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
48275111|NCT03975998|PROCEDURE|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
48275112|NCT00507325|PROCEDURE|Blood Sample|Blood samples will be collected.
48275113|NCT00507325|PROCEDURE|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
48275114|NCT00001087|DRUG|Ritonavir|
48275115|NCT00001087|DRUG|Nelfinavir mesylate|
48275116|NCT00001087|DRUG|Efavirenz|
48275117|NCT00001087|DRUG|Levocarnitine|
48275118|NCT00001087|DRUG|Adefovir dipivoxil|
48275119|NCT00001087|DRUG|Saquinavir|
48275120|NCT00001087|DRUG|Lamivudine|
48275121|NCT00001087|DRUG|Stavudine|
48275122|NCT00001087|DRUG|Zidovudine|
48275123|NCT00001087|DRUG|Zalcitabine|
48275124|NCT00001087|DRUG|Didanosine|
48275125|NCT02779205|PROCEDURE|adipose tissue sample|adipose tissue sample
48275126|NCT04268134|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
48275127|NCT03133767|DRUG|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
48275128|NCT03133767|DRUG|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
48275129|NCT03205579|OTHER|Video group|Using video for educate cancer pain patients
48275130|NCT03205579|OTHER|conventional group|Face to face cancer pain education by trained nurse
48275131|NCT01642355|BEHAVIORAL|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
48275132|NCT01642355|BEHAVIORAL|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
48275133|NCT02684071|DRUG|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
48275134|NCT02684071|DRUG|topotecan|To be administered in conjunction with methotrexate
48275135|NCT02684071|DRUG|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
48275136|NCT00619008|OTHER|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
48275137|NCT00619008|OTHER|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
48275138|NCT00619008|OTHER|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
48275139|NCT05850741|DEVICE|Cardiokit|The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
48275140|NCT00112476|DRUG|bryostatin 1|Given IV
48275141|NCT00112476|DRUG|temsirolimus|Given IV
48275142|NCT05379751|PROCEDURE|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
48444020|NCT04739384|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg followed by Ticagrelor 90 mg
48444021|NCT00101647|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
48444022|NCT00112463|DRUG|romidepsin|DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
48275143|NCT06358014|DRUG|Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs|In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
48275144|NCT06358014|DRUG|SSRIs|This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
48275145|NCT04917926|BEHAVIORAL|Financial and social incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target. Regarding social incentives, participants will be placed in teams of six, receiving feedback of their physical activity performance, rankings within their groups, and positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
48275146|NCT04917926|BEHAVIORAL|Financial incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.
48275147|NCT02757547|DEVICE|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
48275148|NCT02757547|DEVICE|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
48275149|NCT01602731|DEVICE|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
48275150|NCT00535340|DRUG|SR58611A|
48275151|NCT00000402|DRUG|Calcium|
48275152|NCT05617560|OTHER|Telemedical care|Telemedical care will be provided to all participants after stationary hospital stay. This care will be in form of telephone consultations and / or videocall consultations with a medical physician. Depending on the individual medical history and the planned aftercare and procedure of the participants it will comprise of one or more such telephone consultations.
48275153|NCT02812199|DEVICE|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
48275154|NCT02812199|DRUG|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
48275155|NCT02812199|PROCEDURE|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
48275156|NCT00239850|BEHAVIORAL|lifestyle changes|
48275157|NCT01477021|DRUG|cyclophosphamide|Given IV
48275158|NCT01477021|BIOLOGICAL|NY-ESO-1-specific T cells|Given IV
48275159|NCT01477021|OTHER|laboratory biomarker analysis|Correlative studies
48275160|NCT04795479|DRUG|Relacorilant|Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
48275161|NCT04795479|DRUG|Placebo to relacorilant|Placebo to relacorilant capsule by mouth once daily
48275162|NCT04795479|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet by mouth
48275163|NCT03827161|DIETARY_SUPPLEMENT|Glucosamine|Given PO
48275164|NCT03827161|OTHER|Placebo|Given PO
48275165|NCT05149638|DIAGNOSTIC_TEST|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
48275166|NCT06070428|OTHER|PAC provision at hospital discharge|Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
48275167|NCT06070428|OTHER|Control non-intervention; PAC without filter|Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
48275168|NCT03766243|BEHAVIORAL|Brochure and DVD plus nursing training|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website."
48444023|NCT06400355|DRUG|Mannitol|in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery
48444024|NCT06400355|DRUG|Ringer's Lactate|similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
48275169|NCT03766243|BEHAVIORAL|Brochure and DVD only|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD."
48275170|NCT05581030|DRUG|Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)|"Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient."
48275171|NCT05581030|DRUG|Calaspargase Pegol|Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.
48275172|NCT05581030|DRUG|Rituximab|Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL.
48275173|NCT02091180|DRUG|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
48275174|NCT02091180|DRUG|Control|Saline infusion
48275175|NCT01800188|PROCEDURE|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
48275176|NCT01800188|PROCEDURE|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
48275177|NCT01800188|PROCEDURE|Meal test|A 3 hour standardized liquid meal test without dialysis
48275178|NCT04519944|DRUG|Edoxaban|This is an observational, prospective study; no treatment will be administered.
48275179|NCT00004165|BIOLOGICAL|filgrastim|
48275180|NCT00004165|DRUG|melphalan|
48275181|NCT00004165|PROCEDURE|peripheral blood stem cell transplantation|
48275182|NCT00594477|RADIATION|IMRT|
48275183|NCT04399382|DRUG|Biologics|The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.
48275184|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every week|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48275185|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48275186|NCT02598414|PROCEDURE|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
48275187|NCT02598414|PROCEDURE|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
48275188|NCT02598414|DEVICE|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
48275189|NCT03478384|BEHAVIORAL|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
48275190|NCT01724892|DRUG|Dexamethasone|
48275191|NCT01724892|DRUG|Loteprednol etabonate|
48275192|NCT00947648|OTHER|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
48275193|NCT00947648|OTHER|Cooked Foods|Diet containing only cooked foods.
48275194|NCT01486862|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
48275195|NCT01276288|DRUG|BI 10773|multiple oral doses
48275196|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
48275197|NCT01276288|DRUG|torasemide|multiple oral doses
48275198|NCT01276288|DRUG|BI 10773|multiple oral doses
48275199|NCT01276288|DRUG|torasemide|multiple oral doses
48275200|NCT01276288|DRUG|BI 10773|multiple oral doses
48275201|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
48275202|NCT04320836|PROCEDURE|Cervical epidural steroid injection|Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
48275203|NCT05499520|OTHER|Culturally Tailored Anti-Smoking Messages|Anti-smoking messages will be administered online via a Qualtrics survey.
48275204|NCT00925847|DRUG|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
48275205|NCT04781075|OTHER|Pain Scale|Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)
48275206|NCT04781075|DRUG|Exparel Injectable Product|Given at the beginning of the surgery for post-operative pain management
48275207|NCT04781075|DRUG|Bupivacaine Injection|Given at the beginning of the surgery for post-operative pain management
48275208|NCT01934504|PROCEDURE|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
48275209|NCT02500537|DEVICE|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
48275210|NCT02537041|PROCEDURE|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
48275211|NCT02537041|PROCEDURE|MRI|
48275212|NCT04319848|OTHER|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
48275213|NCT01627418|BEHAVIORAL|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
48275214|NCT01627418|BEHAVIORAL|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
48275215|NCT00135057|DRUG|insulin glulisine|
48275216|NCT00135057|DRUG|insulin glargine|
48275217|NCT01049776|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
48275218|NCT00815646|DRUG|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
48275219|NCT00887952|PROCEDURE|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
48275220|NCT00887952|PROCEDURE|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
48275221|NCT05147675|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48275222|NCT00212043|DRUG|carboplatin and gemcitabine|
48275223|NCT03760588|DRUG|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
48275224|NCT03576144|DRUG|BI 1265162|Multiple rising inhaled doses
48275225|NCT03576144|DRUG|Placebo|Multiple rising inhaled doses
48275226|NCT04335487|BEHAVIORAL|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
48275227|NCT04335487|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
48275228|NCT04130815|DRUG|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
48275229|NCT03125603|OTHER|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
48275230|NCT04493047|BEHAVIORAL|Mobile health (mHealth) for pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.
48275231|NCT03106233|PROCEDURE|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
48275232|NCT03537040|OTHER|Method of Levels|Talking Therapy
48275233|NCT01573312|DRUG|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
48275234|NCT01573312|BIOLOGICAL|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
48275235|NCT03669705|PROCEDURE|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
48275236|NCT03931655|DIAGNOSTIC_TEST|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
48275237|NCT02673333|DRUG|Pembrolizumab|
48275238|NCT04792229|OTHER|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
48275239|NCT03791632|OTHER|classical lecture style presentation|classical lecture style presentation
48275240|NCT03791632|OTHER|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
48275241|NCT03791632|OTHER|digital media intervention|digital media intervention
48275242|NCT04480151|OTHER|standard of care|retrospective study: standard of care
48275243|NCT00575861|DRUG|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
48275244|NCT05589142|BEHAVIORAL|Time Restricted Eating|Eating calories only during a specific feeding window.
48275245|NCT01508455|DRUG|Dexmedetomidine|
48275246|NCT01508455|DRUG|Midazolam|
48275247|NCT01508455|DRUG|Fentanyl|
48275248|NCT01508455|DRUG|Morphine|
48275249|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
48275250|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
48275251|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
48275252|NCT00733902|BIOLOGICAL|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
48275253|NCT05657184|DRUG|REGEND001|Transplantation of REGEND001 for dose escalation.
48275254|NCT04372095|PROCEDURE|oral smears|oral smears
48275255|NCT02658461|DRUG|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
48275256|NCT01823809|DEVICE|adenosine stress Cardiac Magnetic Resonance Imaging|
48275257|NCT00706628|DRUG|BIBF 1120|
48275258|NCT00706628|DRUG|BIBW 2992|
48275259|NCT00706628|DRUG|Sequential BIBF 1120 + BIBW 2992|
48275260|NCT02018692|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
48275261|NCT02018692|DIETARY_SUPPLEMENT|Placebo:Starch|Starch powder
48275262|NCT02476487|PROCEDURE|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
48275263|NCT05241158|BEHAVIORAL|Counselling with visual aid|patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure
48275264|NCT05241158|BEHAVIORAL|Counselling|Patients counselled about the procedure, complications and the post-procedure recovery phase
48275265|NCT06486831|OTHER|Squeeze the stress ball.|The child and parents will be taken to the procedure room for the casting procedure. The plastering process in children takes an average of 10-15 minutes. In the experimental group, the stress ball selected by the child will be started 1-2 minutes before the casting process and will be watched for an average of 10 minutes. If the procedure is prolonged, the time for squeezing and playing with the stress ball will be extended.
48275266|NCT00940277|BEHAVIORAL|Group Counseling|Group counseling
48275267|NCT01935895|BEHAVIORAL|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
48275268|NCT01734148|BEHAVIORAL|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
48275269|NCT05349955|OTHER|Intensive guideline algorithm implementation|Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg， LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
48275270|NCT05349955|OTHER|Conventional guideline algorithm implementation|The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
48275271|NCT00476099|DRUG|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
48275272|NCT00476099|DRUG|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
48275273|NCT00476099|DRUG|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
48275274|NCT05940675|BEHAVIORAL|Food and Nutrition|A key element is that children receive a free of charge healthy do-it-yourself school lunch 4 days per week. The meals adhere to the Nordic Nutrition Recommendations and the Danish Food-Based Dietary Guidelines with focus on fish, wholegrains, fruits and vegetables and drinking water as well as stimulation of children's food literacy. Other intervention components involve the after school clubs, local retail stores and the parents.
48275275|NCT05940675|BEHAVIORAL|Physical Activity (FitFirst)|To ensure that all children reach the recommended 3x30 minutes of vigorous activity per week, we will implement three weekly 40-minute sessions in the school curriculum. These sessions will be carried out throughout the study period and will encompass modified and varied sporting activities and games, which promote motivation, physical literacy, active involvement of all children, and high training intensity.
48444025|NCT01083719|PROCEDURE|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
48444026|NCT00738049|DRUG|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
48275276|NCT05940675|BEHAVIORAL|Sleep and screen media|The aim of this component is to promote healthy sleep and screen media behaviours. Sleep and screen media recommendations will be presented for parents at three parent workshops and in electronic infographics. Teachers/pedagogues will facilitate small assignments on screen media and sleep practices with children during school time. Children will talk about and reflect upon screen media and sleep practices in their family, based on assignments and material from e.g., Medierådet (The Danish Media Council). The results of the children's assignments will be presented to their parents at later workshops. This is done to integrate the children's perspective in the parent workshops, especially in relation to screen media habits.
48275277|NCT05940675|BEHAVIORAL|Community capacity building|Community capacity building in selected local communities. To promote healthier eating, children and families need to be supported within their local community by food environments that make the healthy choice the easy choice and not a challenge in their everyday life. To promote physical activity, the children will be invited to participate in activities in the local sports clubs including camps in the holidays.
48275278|NCT00136864|PROCEDURE|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
48275279|NCT05699655|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
48275280|NCT05699655|DRUG|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
48275281|NCT05699655|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
48275282|NCT05699655|DRUG|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
48275283|NCT01498133|PROCEDURE|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
48275284|NCT01973257|PROCEDURE|imaging diagnostics|
48275285|NCT02469129|DRUG|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
48275286|NCT04149314|OTHER|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
48275287|NCT03688386|BEHAVIORAL|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
48275288|NCT03688386|BEHAVIORAL|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
48275289|NCT03688386|BEHAVIORAL|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
48275290|NCT03688386|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
48275291|NCT03688386|BEHAVIORAL|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
48275292|NCT05653375|OTHER|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
48275293|NCT05653375|OTHER|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
48275294|NCT03502187|BEHAVIORAL|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about \~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
48275295|NCT03502187|DEVICE|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back \& abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
48444027|NCT06017713|BEHAVIORAL|tDCS + symptoms provocation|The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
48275296|NCT03502187|BEHAVIORAL|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
48275297|NCT03689218|DIETARY_SUPPLEMENT|Maamta (Nutritious Food Supplement)|Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
48275298|NCT03689218|DIETARY_SUPPLEMENT|Wawamum (Lipid-Based Nutrient Supplement)|Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
48275299|NCT00569257|DRUG|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
48275300|NCT00854269|PROCEDURE|surgery|cervical biopsy or specimen of hysterectomy
48275301|NCT00398112|DRUG|sunitinib malate|Given orally
48275302|NCT00398112|OTHER|pharmacological study|Correlative studies
48275303|NCT00398112|OTHER|laboratory biomarker analysis|Correlative studies
48275304|NCT06322758|OTHER|Tidal volume customization in the acute respiratory distress syndrome|During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
48275305|NCT03777514|DRUG|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
48275306|NCT03777514|DRUG|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
48275307|NCT03777514|OTHER|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
48275308|NCT03777514|OTHER|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
48275309|NCT04695509|DRUG|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
48275310|NCT04695509|DRUG|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
48275311|NCT02783560|BEHAVIORAL|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
48275312|NCT02783560|BEHAVIORAL|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
48275313|NCT03781557|DIETARY_SUPPLEMENT|Docosahexaenoic acid|High-concentrated DHA
48275314|NCT03781557|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|High-concentrated EPA
48275315|NCT03781557|DIETARY_SUPPLEMENT|Olive oil|Olive Oil softgels
48275316|NCT03377634|BEHAVIORAL|MORPH|Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
48275317|NCT02916277|BIOLOGICAL|endocan|to look series Endocan level for 5 days in intubated patients
48275318|NCT06195228|DRUG|dabrafenib plus trametinib with or without PD-1 antibody|advanced thyroid cancer patients who harbor BRAF V600E mutation
48275319|NCT06195228|DRUG|entrectinib or larotrectinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor NTRK mutation
48275320|NCT06195228|DRUG|pralsetinib or selpercatinib with or without anti-PD-1 antibdoy|advanced thyroid cancer patients who harbor RET fusion or medullary thyroid carcinoma patients who habor RET mutation.
48275321|NCT06195228|DRUG|anlotinib or anlotinib plus anti-PD-1 antibody|For patients with medullary carcinoma, if there is no RET gene mutation or RET gene mutation is unknown
48275322|NCT06195228|DRUG|lenvatinib plus anti-PD-1 antibody|Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
48275323|NCT06195228|DRUG|Other Targets: precise treatment based on the target|Advanced thyroid cancer patients who had other treatment targets not included above
48275324|NCT01106001|DRUG|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
48275325|NCT01106001|DRUG|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
48275326|NCT02314793|DRUG|ASP2205|oral
48275327|NCT02314793|DRUG|Placebo|oral
48275328|NCT05011396|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
48275329|NCT05011396|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
48275330|NCT01085682|BEHAVIORAL|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
48275331|NCT01085682|BEHAVIORAL|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
48275332|NCT00345605|DRUG|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
48275333|NCT00345605|DRUG|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
48275334|NCT04508387|PROCEDURE|Group HH (heated-humidified)|Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
48275335|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
48275336|NCT01121289|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
48275337|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
48275338|NCT01121289|DRUG|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
48275339|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
48275340|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
48275341|NCT00631878|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
48275342|NCT05946343|DIAGNOSTIC_TEST|Surface Electromyography (sEMG) Assessment|Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.
48275343|NCT05994170|RADIATION|Reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)
48275344|NCT05994170|RADIATION|Non-reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)
48275345|NCT04217343|DIAGNOSTIC_TEST|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
48275346|NCT02395549|DRUG|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
48275347|NCT02395549|DRUG|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
48275348|NCT02395549|DRUG|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
48275349|NCT02395549|DRUG|Vehicle Control Gel|
48275350|NCT05448118|DIAGNOSTIC_TEST|Virtual POC Toxicology Test|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
48275351|NCT05300087|DRUG|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
48275352|NCT05300087|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
48275353|NCT05596214|COMBINATION_PRODUCT|Curcumin-Berberine (coptis)|dietary supplement
48275354|NCT05596214|COMBINATION_PRODUCT|Placebo|Placebo
48275355|NCT05148871|BIOLOGICAL|Spikogen/Covax-19|Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant
48275359|NCT00246168|DRUG|tramadol hydrochloride + acetaminophen|
48275360|NCT01587950|DRUG|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
48275361|NCT01587950|DRUG|Placebo|Sterile Water
48275362|NCT03542994|OTHER|EDP1066|EDP1066 is an orally administered monoclonal microbial
48275363|NCT03542994|DRUG|Placebo oral capsule|placebo
48275364|NCT00486902|DRUG|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
48275365|NCT00486902|DRUG|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
48275366|NCT00906438|DIETARY_SUPPLEMENT|2006-RD-05|300 mg daily, once a day for 28 consecutive days
48275367|NCT00906438|DIETARY_SUPPLEMENT|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
48275368|NCT02323022|DRUG|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
48275369|NCT02323022|DRUG|IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
48275370|NCT01300104|BEHAVIORAL|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None."
48275371|NCT01300104|BEHAVIORAL|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
48275372|NCT01300104|BEHAVIORAL|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
48275373|NCT03083717|DIAGNOSTIC_TEST|Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)|2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
48275374|NCT03939234|COMBINATION_PRODUCT|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
48275375|NCT04033289|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
48275376|NCT02562625|DRUG|Pembrolizumab|Powder solution for infusion
48275377|NCT02562625|RADIATION|Radiotherapy|24Gy
48275378|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
48275379|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
48275380|NCT03718247|OTHER|Modified Atkins diet|High fat low carbohydrate diet.
48275381|NCT00004479|DRUG|midodrine|
48275382|NCT04178148|OTHER|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
48275383|NCT02747784|BEHAVIORAL|Cognitive training program RehaCom®|Cognitive training program RehaCom®
48275384|NCT03884686|OTHER|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
48275385|NCT00670787|DRUG|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
48275386|NCT05381402|OTHER|Questionnaire|Questionnaire to assess the impact of COVID 19 on psoriasis patients
48275387|NCT03981601|DRUG|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
48275388|NCT03981601|PROCEDURE|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
48275389|NCT04598542|DRUG|Lorecivivint (LOR)|0.07 mg
48275390|NCT04598542|DRUG|Triamcinolone acetonide (TA)|40 mg
48275391|NCT02531815|BIOLOGICAL|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
48275392|NCT02531815|DRUG|Placebo|Placebo for PF-06741086, single dose
48275393|NCT03609255|BEHAVIORAL|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
48275394|NCT03609255|BEHAVIORAL|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
48275395|NCT03609255|BEHAVIORAL|Control|An educational handout for sedentary behavior and weekly neutral topic videos
48275396|NCT04080011|DEVICE|NP-PWD|Application of NP-PWD device.
48275397|NCT04898634|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
48275398|NCT00640094|DRUG|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
48275399|NCT03541473|DIETARY_SUPPLEMENT|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
48275400|NCT03541473|DIETARY_SUPPLEMENT|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
48275401|NCT05798988|BEHAVIORAL|Neurophysiology-based exercise program|Neurophysiology-based exercise program combines physiotherapy exercises and neuro-physiology principles with focus on foot and core functional stabilisation and balance training.
48275402|NCT02822456|PROCEDURE|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
48275403|NCT02832050|BEHAVIORAL|Play therapy|See previous description of play therapy intervention arm.
48275404|NCT02832050|BEHAVIORAL|Standard of care|See previous description of comparator arm.
48275405|NCT05696938|DIETARY_SUPPLEMENT|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
48275406|NCT05696938|DIETARY_SUPPLEMENT|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
48275407|NCT06363162|DIAGNOSTIC_TEST|Immunohistochemistry or genetic test|Perform two diagnostic methods on the same sample
48275408|NCT03866200|DRUG|resveratrol|125 mg/day or 5 ml once per day for 90 days
48275409|NCT03866200|DRUG|Placebo|5 ml once per day for 90 days
48275410|NCT01625806|DRUG|RO4602522|Single oral dose
48275411|NCT01625806|DRUG|ketoconazole|Multiple oral doses
48275412|NCT02049502|BIOLOGICAL|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
48275413|NCT02049502|PROCEDURE|sigmoidoscopy|
48275414|NCT04045067|PROCEDURE|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
48275415|NCT04045067|PROCEDURE|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
48275416|NCT00737139|PROCEDURE|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
48275417|NCT00737139|PROCEDURE|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
48275418|NCT05005884|DRUG|Oral intake of medication|Prescription of oral phenolics 250 mg two times daily
48275419|NCT05005884|DRUG|Placebo|Prescription of oral phenolics 250 mg two times daily
48275420|NCT04490889|DIAGNOSTIC_TEST|NiPGT-A|NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
48275421|NCT05779748|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
48275422|NCT01841632|DRUG|MultiStem|
48275423|NCT05623566|DEVICE|Picterus Jaundice Pro|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
48275424|NCT01850615|DRUG|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
48275425|NCT01850615|DRUG|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
48275426|NCT03010540|DRUG|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
48275427|NCT03010540|DRUG|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
48275428|NCT01228747|DRUG|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
48275429|NCT01228747|DRUG|Placebo|Matching oral placebo tablets twice daily for 28 weeks
48275430|NCT01293617|OTHER|Blackberries|300 g blackberries daily for 5 days
48275431|NCT01293617|OTHER|Gelatin|300 g gelatin per day for 5 days
48275432|NCT02544555|PROCEDURE|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
48275433|NCT02544555|PROCEDURE|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
48275434|NCT01676038|PROCEDURE|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
48275435|NCT01676038|PROCEDURE|Conventional Total Knee Arthroplasty|Conventional technique.
48275436|NCT06075303|BEHAVIORAL|Modified Cycles|
48275437|NCT05592340|BEHAVIORAL|Exposure to calorie information|Calories for all foods and beverages
48275438|NCT05592340|BEHAVIORAL|Exposure to carbon footprint information|Carbon footprint labels for all foods and beverages
48275439|NCT02824484|BEHAVIORAL|GWDP|"In each writing session participants are asked to:~1. Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~2. Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~3. Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
48275440|NCT02824484|BEHAVIORAL|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
48275441|NCT02518555|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
48620330|NCT03770819|PROCEDURE|Photodynamic therapy|"Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam."
48620331|NCT05542641|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|real versus sham rTMS
48275442|NCT02518555|DRUG|Ibrutinib|Given PO
48275443|NCT02518555|OTHER|Laboratory Biomarker Analysis|Correlative studies
48275444|NCT02518555|OTHER|Pharmacological Study|Correlative studies
48275445|NCT02518555|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
48275446|NCT02518555|OTHER|Quality-of-Life Assessment|Ancillary studies
48275447|NCT02518555|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
48275448|NCT01306760|DRUG|Ketamine|Ketamine used as the anaesthetic during ECT.
48275449|NCT01306760|DRUG|Propofol|The standard anaesthetic used for ECT.
48275450|NCT00428402|BEHAVIORAL|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
48275451|NCT04587115|DRUG|Risperidone|Risperidone 1mg to be used in combination with other drugs
48275452|NCT04587115|DRUG|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
48275453|NCT04587115|DRUG|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
48275454|NCT06657625|OTHER|Sepsis Performance Improvement Program|Training/awareness for medical and paramedical staff; creation of informational posters; development of an institutional pathway in the emergency department; creation of a protocol ; establishment of a sepsis team with a dedicated contact number.
48275455|NCT01846455|DRUG|2.0mg Buprenorphine/0.5mg Naloxone|Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
48275456|NCT01846455|DRUG|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
48275457|NCT03501862|BEHAVIORAL|Mindfulness-based cognitive therapy (psychosis)|A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
48275458|NCT03501862|BEHAVIORAL|Psychoeducation (psychosis)|A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
48275459|NCT02986178|BIOLOGICAL|PVSRIPO|A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)
48275460|NCT03851510|DEVICE|Vector ventilator|The Vector ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with the primary cause being COPD. This device is not intended for life support. It may be used to screened for the presence and abolishment of expiratory flow limitation. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments. The vector ventilator will titrate and treat EFL using non-invasive ventilatory support.
48275461|NCT03851510|DEVICE|Resmon Pro|The Resmon Pro uses the forced oscillation technique (FOT) which is a noninvasive method to measure the mechanical properties of the lung and airways during tidal breathing. In addition to measuring total impedance (resistance and reactance), the Resmon Pro can measure expiratory flow limitation which is a key index of respiratory obstruction
48275462|NCT01274221|DRUG|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
48275463|NCT01274221|OTHER|Placebo|1 capsule per day for one week of the double-blind crossover phase
48275464|NCT04059744|DEVICE|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
48275465|NCT03819075|DEVICE|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
48275466|NCT03819075|OTHER|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
48275467|NCT02781974|OTHER|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
48275468|NCT01137214|DEVICE|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
48275469|NCT00500266|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
48275470|NCT04614818|OTHER|Non-intervention research|Non-intervention research
48275471|NCT00748657|BIOLOGICAL|Bevacizumab|Given IV
48275472|NCT00748657|OTHER|Laboratory Biomarker Analysis|Correlative studies
48275473|NCT00564993|DRUG|Dobutamin|10\&20 µg/kg/min
48275474|NCT00349128|DRUG|fenofibrate and metformin combination (drug)|
48275475|NCT04782791|DRUG|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA\<1.25 m2, 40mg; 1.25\<BSA\<1.50 m2, 50mg; BSA\>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
48275476|NCT04782791|DRUG|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
48620332|NCT04200300|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
48275477|NCT04782791|PROCEDURE|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
48275478|NCT06544239|BEHAVIORAL|Virtual reality basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
48275479|NCT06544239|BEHAVIORAL|Traditional basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
48275480|NCT05103150|DIAGNOSTIC_TEST|High-definition white light endoscopy (HD-WLE)|"Evaluation of the duodenal mucosa with HD-WLE (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.~There were used the following standard endoscopic findings were: a) scalloping or dented aspect of the duodenal folds; b) submucosal vascular pattern; c) mosaicism or micronodular look of the mucosa; d) grooves and fissurations of the mucosa."
48275481|NCT05103150|DIAGNOSTIC_TEST|HD-WLE plus I-Scan optical enhancement (OE) virtual chromoendoscopy with High-definition optical magnification (HD-OM)|"Evaluation of the duodenal mucosa through upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves using a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode one and mode two without HD-OM to obtain an overview of the duodenal surface and identify any changes in the mucosa, then HD-OM will be implemented.~There were used OE criteria as previously validated by Cammarota et al: brightness, Ave/peak, blue, red, surface, contrast, and tone enhancement."
48275482|NCT00316823|GENETIC|gene expression analysis|
48275483|NCT00316823|GENETIC|polymerase chain reaction|
48275484|NCT00316823|GENETIC|reverse transcriptase-polymerase chain reaction|
48275485|NCT00316823|OTHER|diagnostic laboratory biomarker analysis|
48275486|NCT00316823|OTHER|immunohistochemistry staining method|
48275487|NCT00316823|PROCEDURE|needle biopsy|
48275488|NCT03514914|BEHAVIORAL|The CHARM2 Intervention|CHARM2 intervention will involve gender, culture \& contextually-tailored family planning and gender equity counseling.
48275489|NCT06544278|DIETARY_SUPPLEMENT|probiotic product|During the experiment, subjects take one sachet probiotic product daily. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
48275490|NCT06544278|DIETARY_SUPPLEMENT|Maltodextrin|During the experiment, subjects take one sachet maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
48275491|NCT02770807|DRUG|EryDex Low dose DSP|EDS-EP dose range of \~5-10 mg DSP/infusion
48275492|NCT02770807|DRUG|EryDex High dose DSP|EDS-EP dose range of \~14-22 mg DSP/infusion
48275493|NCT02770807|DRUG|Pooled Placebo|EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
48275494|NCT06156527|DRUG|Lazertinib|Lazertinib 240mg, QD, daily
48275495|NCT06156527|DRUG|Bevacizumab Injectable Product|Bevacizumab: 15mg/kg IV every 3 weeks
48275496|NCT00745108|DRUG|tibolone|oral 1.25 mg tablet, once daily, for 2 years
48275497|NCT00745108|DRUG|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
48275498|NCT00745108|DRUG|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
48275499|NCT03917121|DEVICE|Jet injector|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using Madajet XL injector as per the manufacturer's instructions.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
48275500|NCT03917121|DEVICE|Needle attached dental syringe|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using standard needle-attached syringe in a classical local infiltration.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
48275501|NCT01449890|BEHAVIORAL|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
48275502|NCT05289960|OTHER|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
48275503|NCT01212445|DRUG|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
48275504|NCT04698928|DEVICE|Theta burst stimulation|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
48275505|NCT03192579|DRUG|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
48275506|NCT03192579|DRUG|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
48275507|NCT03663257|DEVICE|AneurysmFlow|AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
48275508|NCT01202461|PROCEDURE|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.~IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
48275509|NCT06301360|BEHAVIORAL|Internet based Emotional Awareness and Expression Therapy (I-EAET)|"In I-EAET with therapist support, the therapist and participants communicate asynchronous using written messages. The therapist gives feedback each week on home-work assignments and is available on demand for support.~In I-EAET without therapist support, the participants works with home-work assignments on their own and only have technical support."
48275510|NCT00002113|DRUG|Flucytosine|
48275511|NCT00002113|DRUG|Fluconazole|
48275512|NCT01559909|DEVICE|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
48275513|NCT03656913|DIAGNOSTIC_TEST|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
48275514|NCT05983640|OTHER|Video|Just in time training video on hands only CPR
48275515|NCT05983640|OTHER|AHA course|AHA Heartsaver CPR course
48275516|NCT05548478|PROCEDURE|Transepithelial PRK/MMC|transepithelial photorefractive keratectomy (PRK) and mitomycin C addition
48275517|NCT05548478|PROCEDURE|Alcohol-Assisted PRK/MMC|photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
48275518|NCT03752125|DIETARY_SUPPLEMENT|Flavonoid, caffeine|2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
48275519|NCT03752125|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules before breakfast, 2 capsules before lunch
48275520|NCT06085183|OTHER|Saline Injection 0.9%|Placebo
48275521|NCT06085183|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
48275522|NCT05395676|DEVICE|Exergame home training programme|Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
48275523|NCT02529527|BEHAVIORAL|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
48275524|NCT01468649|DEVICE|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
48275525|NCT05068856|DRUG|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
48275526|NCT00337233|PROCEDURE|yoga therapy|10 week yoga class
48275527|NCT01504932|DIETARY_SUPPLEMENT|BRB Lozenge|ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
48275528|NCT01504932|OTHER|Survey Administration|Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
48275529|NCT01504932|OTHER|Laboratory Biomarker Analysis|Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
48275530|NCT01504932|OTHER|pharmacological study|Correlative studies
48275531|NCT03661684|DRUG|Prednisone|40 mg po q day of Prednisone for 3 days
48275532|NCT00469079|DRUG|Nicotine gum and lozenge|Nicotine replacement
48275533|NCT00469079|OTHER|Taboka|smokeless tobacco product
48275534|NCT00469079|OTHER|Camel Snus|smokeless tobacco product
48275535|NCT05555550|DRUG|18F-Fluciclovine|18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
48275536|NCT00820430|OTHER|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
48275537|NCT04444245|PROCEDURE|lipoaspiration harvest tSVF|Use of disposable, sterile microcannula lipoharvest to acquire tSVF
48275538|NCT04444245|PROCEDURE|Platelet Rich Plasma|Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)
48275539|NCT04444245|PROCEDURE|Endovaginal Ultrasound|Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally
48275540|NCT04444245|DEVICE|Cellular Isolation cSVF|Digestion of tSVF with Liberase, isolation \& concentration of cSVF in Centricyte 1000
48275541|NCT04444245|DRUG|Normal Saline (NS) .9% 10 mL Injection|10 cc Sterile Normal Saline for Injection
48275542|NCT04444245|DEVICE|emulsification tSVF|Harvested tSVF emulsification with sterile, disposable Nanofat screen device
48275543|NCT01551745|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
48275544|NCT01551745|DRUG|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
48275545|NCT01472484|OTHER|586/8x87 white|2 x 50 g
48275546|NCT01472484|OTHER|586/8x87 brown|2 x 50 g
48275547|NCT01472484|OTHER|BAT 881|2 x 50 g
48275548|NCT01472484|OTHER|586/8|2 x 50 g
48275549|NCT00757315|DEVICE|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
48275550|NCT00757315|DRUG|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
48275551|NCT01682005|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
48275552|NCT04814264|BIOLOGICAL|Red blood cells|All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
48275553|NCT03933943|DRUG|LY3361237|Administered SC
48275554|NCT03933943|DRUG|Placebo|Administered SC
48275555|NCT03415555|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
48275556|NCT03415555|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
48620333|NCT03860753|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
48098024|NCT04157166|DIAGNOSTIC_TEST|to record a whole body 3D of 25 minutes in camera VERITON-CT ™|The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
48275557|NCT03415555|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
48275558|NCT03415555|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
48275559|NCT01172067|DEVICE|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
48275560|NCT01172067|DEVICE|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
48275561|NCT02429999|DRUG|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
48620334|NCT03860753|DRUG|Placebo|Pill capsules will look same as that of active drug.
48620335|NCT01314729|DEVICE|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
48106799|NCT03423394|BEHAVIORAL|Treatment as Usual|TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
48106800|NCT00927667|PROCEDURE|No Drug|Patients have received primary FVIII prophylaxis (started \< 2 years of age)
48106801|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - \< 6 years of age)
48106802|NCT00927667|PROCEDURE|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - \< 12 years of age)
48106803|NCT00927667|PROCEDURE|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
48106804|NCT00927667|PROCEDURE|No Drug|Patients have received on-demand therapy
48106805|NCT03273348|PROCEDURE|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
48106806|NCT02572141|DRUG|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
48106807|NCT02572141|DRUG|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
48106808|NCT03857334|BIOLOGICAL|Injection of autologous platelet rich plasma|
48106809|NCT03857334|DRUG|Injection of cortivazol : Altim®|Corticosteroids
48106810|NCT06031194|OTHER|Non-Interventional Study|Non-interventional study
48275562|NCT02429999|DRUG|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
48275563|NCT02747914|DEVICE|Transcranial magnetic stimulation|TMS 1Hz under the motor zone of cortex.
48275564|NCT02747914|OTHER|Conventional exercise|Exercise will be administrated in a conventional way.
48275565|NCT00379327|PROCEDURE|Acupuncture|Acupuncture administered in last three weeks of pregnancy
48275566|NCT00379327|DEVICE|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
48620336|NCT01314729|DEVICE|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
48275567|NCT03195894|DEVICE|TripleA|
48275568|NCT00904787|DRUG|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
48275569|NCT03330327|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
48275570|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
48275571|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
48275572|NCT04239846|DRUG|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
48275573|NCT04239846|OTHER|Placebo Gel|Placebo Gel, BID
48275574|NCT05796479|DRUG|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
48275575|NCT05796479|DRUG|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
48275576|NCT01773655|OTHER|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
48275577|NCT03990129|DRUG|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
48275578|NCT02536586|DRUG|LY3023414|LY3023414 administered orally.
48275579|NCT04271761|OTHER|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
48275580|NCT05043584|DEVICE|Fluobeam LX, Fluoptics, Grenoble, France|See arm description
48275581|NCT00997971|OTHER|Modilac Rose 1|Infant formula used for non-breastfed children
48275582|NCT03756792|BEHAVIORAL|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
48620337|NCT05946733|PROCEDURE|Group A|After induction of general anesthesia, oblique subcostal TAP blocks will be done(14) under the guidance of Sonosite ,superficial probe ,14-15 MHz ultrasound transducer
48620338|NCT05946733|PROCEDURE|Group B|After induction of general anesthesia, bilateral lateral TAP block will be performed (15) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz)
48275583|NCT03756792|BEHAVIORAL|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
48275584|NCT03859284|OTHER|flowable resin composite|gold standard
48275585|NCT03859284|OTHER|self adhering flowable|moist bonding self adhering flowable composite
48275586|NCT03859284|OTHER|self adhering flowable with adhesive|moist bonding self adhering flowable composite with the aid of an adhesive system.
48275587|NCT06246383|DIETARY_SUPPLEMENT|Q Actin|cucumber extract
48275588|NCT00787111|DRUG|Fluoxetine (prozac)|Formulation: ODT
48275589|NCT05922202|OTHER|Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months|At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
48106811|NCT01038349|OTHER|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
48275590|NCT01445171|DEVICE|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
48275591|NCT00686816|DIETARY_SUPPLEMENT|Low calorie diet|low calorie diet
48275592|NCT00686816|DIETARY_SUPPLEMENT|Olestra|low calorie Olestra diet
48275593|NCT05230147|PROCEDURE|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
48275594|NCT05230147|PROCEDURE|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
48275595|NCT02104063|PROCEDURE|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
48275596|NCT02241473|OTHER|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
48275597|NCT00693706|BIOLOGICAL|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
48275598|NCT00693706|BIOLOGICAL|Fluarix|IM injection on Day 0
48275599|NCT01151137|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
48275600|NCT01151137|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
48275601|NCT02760251|DRUG|romiplostim|
48275602|NCT03698201|OTHER|Non-interventional|Translational, observational study
48275603|NCT01795651|PROCEDURE|identification of take-home message of lecture|
48275604|NCT00332202|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
48275605|NCT00332202|DRUG|placebo|oral, daily
48275606|NCT01898156|DRUG|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
48275607|NCT04007159|OTHER|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square \[mL/cm\^2\] of serum in an individual cell of patch)
48275608|NCT04007159|OTHER|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of lotion in an individual cell of patch)
48275609|NCT04007159|OTHER|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of cream in an individual cell of patch)
48275610|NCT04007159|OTHER|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of normal saline in an individual cell of patch)
48275611|NCT02412865|BEHAVIORAL|Quit4Baby|
48275612|NCT02412865|BEHAVIORAL|Text4Baby|
48275613|NCT00456313|DRUG|FLIXOTIDE and SERETIDE|comparator
48275614|NCT00851903|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
48275615|NCT00851903|DRUG|Sitagliptin|Oral administration. 100mg film-coated tablets.
48275616|NCT00851903|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
48275617|NCT06296563|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion for 2 times.
48275618|NCT06296563|DRUG|Adebrelimab|Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.
48275619|NCT06296563|DRUG|Apatinib|Apatinib 250mg, po, qd,q3w,up to one year of use at most.
48275620|NCT05258461|OTHER|use of a smartphone app for adverse event management|At their enrollment, patients will receive detailed introduction and adequate assistance on the use of the smartphone app. The smartphone app will offer proper advice for adverse event management based on calculated results by artificial intelligence on the innovative app, which was developed by YL et al. It was specifically intended for risk prediction, early prevention, as well as management of symptoms and concerns during adjuvant chemotherapy in the treatment of breast cancer. The app consisted of 4 modules: (1) Module 1: clinical data collection. (2) Module 2: risk evaluation for 12 common adverse events during breast cancer chemotherapy. (3) Module 3: personalized prophylaxis based on predicted risks of adverse events. (4) Module 4: Q\&A platform.
48275621|NCT05258461|OTHER|conventional adverse event management|Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
48275622|NCT03669523|DRUG|Denosumab-nivolumab combination|"* Denosumab: 120 mg every 4 weeks subcutaneously~* Nivolumab: 240mg intravenously on day 1 every 2 weeks"
48275623|NCT06213428|BIOLOGICAL|Progressive Perfect Probiotic|Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.
48275624|NCT06213428|OTHER|Placebo|Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
48275625|NCT04680117|OTHER|Blood collection|"Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
48275626|NCT04680117|OTHER|Saliva sample|Saliva sample by subject at J0
48275627|NCT04680117|OTHER|Nasal|Nasal brushing by subject at J0
48275628|NCT01145560|DRUG|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
48275629|NCT01145560|DRUG|Placebo|Placebo
48275630|NCT06543628|DRUG|Tadalafil 5mg|Participants will take tadalafil once daily at a dose of 5 mg for 6 months.
48275631|NCT06543628|DEVICE|LIPUS (Low Intensity Pulsed Ultrasound)|Participants will receive LIPUS treatment applied twice a week for 4 weeks, with the cycle repeated after a 4-week interval without treatment.
48275632|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
48275633|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
48275634|NCT01411787|BEHAVIORAL|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
48275635|NCT05961748|OTHER|Multi-disciplinary assessment|Multi-disciplinary assessment
48275636|NCT03095092|DRUG|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
48275637|NCT06441708|OTHER|No intervention|No intervention on patient
48275638|NCT03742778|BEHAVIORAL|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
48275639|NCT03742778|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
48275640|NCT05728814|DRUG|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
48275641|NCT01855256|DRUG|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
48275642|NCT01855256|DRUG|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
48275643|NCT03056443|DEVICE|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
48275644|NCT04646148|BEHAVIORAL|Yoga classes|All participants are invited to attend weekly yoga classes.
48275645|NCT00393718|DRUG|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
48275646|NCT00393718|DRUG|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
48275647|NCT00393718|DRUG|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
48275648|NCT00393718|DRUG|placebo|glibenclamide placebo. Given orally once or twice daily.
48275649|NCT04743050|DRUG|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
48275650|NCT04743050|DIAGNOSTIC_TEST|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
48275651|NCT02601573|DRUG|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
48275652|NCT02601573|DRUG|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
48620339|NCT05946733|OTHER|Group C|the analgesia will be maintained using a morphine patient-controlled analgesia (PCA) device set to give 1.5 mg bolus administration of morphine without a basic rate and 15 min lock-out time. The total amount of morphine administration will be recorded for the subsequent 24 h
48620340|NCT02649933|DEVICE|Watch PAT 200|screening of OSA with Watch PAT 200
48275653|NCT02601573|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
48275654|NCT02601573|DRUG|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
48275655|NCT04909606|OTHER|nurse-led prevention program|"Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~1. A video explaining corticosteroids related adverse events and adequate preventive measures~2. An individual interview with the trained nurse~3. A consultation with a dietetician~4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures"
48275656|NCT04909606|OTHER|Current care|Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
48275657|NCT06054529|PROCEDURE|Surgical removal of the GBM tumor|Surgical removal of the GBM tumor
48275658|NCT06054529|OTHER|d4-NAM infusion|Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.
48275659|NCT05346107|DRUG|pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage|The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
48275660|NCT04474730|DEVICE|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
48275661|NCT04474730|OTHER|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
48275662|NCT05168930|DRUG|Venetoclax|C4-15
48275663|NCT05168930|DRUG|Zanubrutinib|C1-15
48620341|NCT01685554|DEVICE|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
48620342|NCT01685554|DEVICE|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
48620343|NCT01501097|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
48620344|NCT01995383|OTHER|LS followed by NS diet condition|LS diet period followed by NS diet period
48275664|NCT06190587|DIETARY_SUPPLEMENT|Goji Berry|As a functional food goji berry contains 19 amino acids, 21 minerals, a wide range of carotenoids (β-Carotene, Neoxanthin, Cryptoxanthin, Zeaxanthin), polysaccharides, flavonoids, phytosterols, vitamin A, C and E.
48275665|NCT04522492|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.
48275666|NCT04522492|OTHER|Quality of life promotion|2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
48275667|NCT06340919|DEVICE|Sudden Sound Reduction Setting|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
48275668|NCT00431392|DRUG|Phenylephrine|
48275669|NCT00431392|DRUG|NG-Monomethyl-L-Arginine|
48275670|NCT00431392|DRUG|Propanolol|
48275671|NCT00431392|DRUG|Atropine|
48275672|NCT01305447|BEHAVIORAL|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
48275673|NCT01305447|BEHAVIORAL|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
48275674|NCT01305447|BEHAVIORAL|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
48275675|NCT00608855|OTHER|questionnaire administration|
48275676|NCT00608855|PROCEDURE|cryosurgery|
48275677|NCT00608855|PROCEDURE|pain therapy|
48275678|NCT00608855|PROCEDURE|quality-of-life assessment|
48275679|NCT04640727|PROCEDURE|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
48275680|NCT04640727|PROCEDURE|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
48275681|NCT03409549|RADIATION|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
48275682|NCT02441361|OTHER|Exercise training|Exercise training will comprise aerobic and strength exercises
48275683|NCT00686543|DRUG|Posaconazole|Posaconazole will be used for prophylaxis
48275684|NCT00138762|DRUG|torcetrapib/atorvastatin|
48275685|NCT00138762|DRUG|atorvastatin|
48275686|NCT00138762|DRUG|placebo|
48275687|NCT04537611|DIAGNOSTIC_TEST|dHb contrast and gadolinium contrast imaging|see arm description
48275688|NCT04980131|DEVICE|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
48275689|NCT04980131|DEVICE|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
48275690|NCT02340650|DEVICE|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
48275691|NCT00559091|DRUG|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
48275692|NCT00628186|DEVICE|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
48275693|NCT00628186|DEVICE|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
48275694|NCT05093127|DEVICE|Carotid Artery Stenting|R-OneTM system is a tool available to physicians for performing CAS without changing the treatment of the pathology. R-OneTM system is designed to remotely deliver and manipulate guidewires and stent/balloon devices during Carotid Artery Stenting. The system is composed of the R-OneTM robotic platform used in combination with two accessories, the Mobile radioprotection screen and a sterile and single-use R-OneTM consumable kit. The physician, seated at the remote radio-protected control station, manipulates guidewires and/or balloon/stent catheters using joysticks on the Command unit.
48275695|NCT02571348|PROCEDURE|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
48620345|NCT01995383|OTHER|NS followed by LS diet condition|NS diet period followed by LS diet period
48620346|NCT01995383|DRUG|Placebo|Single oral administrations
48620347|NCT01995383|DRUG|Placebo|2 single oral administrations
48275696|NCT05011084|DEVICE|Game Ready Cryotherapy with Compression Group|Instead of using the traditional ice-pack cryotherapy (without compression), patients randomized into this group will use the Game Ready device, which uses cryotherapy with compression, during their post-operative treatment care.
48275697|NCT05011084|OTHER|Control Cryotherapy Group|Patients randomized to the control group will use the standard of care, which is using traditional cryotherapy (i.e., an ice pack without compression)
48275698|NCT00108329|BEHAVIORAL|Weight Loss|
48275699|NCT00960271|PROCEDURE|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
48275700|NCT02746510|GENETIC|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
48275701|NCT01422330|DRUG|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
48275702|NCT02792868|OTHER|24 h urines analyses|patient collects urines during 24h
48275703|NCT00260208|DRUG|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
48275704|NCT00260208|DRUG|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
48275705|NCT05551130|OTHER|Restoration|Restorations completed with these materials.
48275706|NCT02618369|DEVICE|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
48275707|NCT00316264|BIOLOGICAL|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
48275708|NCT00316264|BIOLOGICAL|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
48275709|NCT00316264|BIOLOGICAL|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
48275710|NCT06393283|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
48275711|NCT04186611|OTHER|early occupational therapy|"The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit."
48275712|NCT02292849|BEHAVIORAL|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
48275713|NCT02292849|OTHER|Standard Mental Health Referral|Standard mental health referral to a community agency
48275714|NCT03440944|DEVICE|Ultrasound Guided Peripheral IV Catheter|Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
48275715|NCT03440944|DEVICE|Midline Catheter|Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
48275716|NCT02080052|DEVICE|Robot-assisted prostate biopsy|
48275717|NCT04376450|PROCEDURE|Experimental- Nonincised papillae surgical approach|"The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot."
48275718|NCT04376450|PROCEDURE|Active comparator- Entire papilla preservation technique|The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
48275719|NCT02392260|DEVICE|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
48275720|NCT05020379|PROCEDURE|Perioperative and postoperative multimodal analgesia|"Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.~The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day."
48275721|NCT05020379|PROCEDURE|ESP Block|Patients in the ESPB group will be placed in a sitting position. A convex probe ultrasound transducer will be placed in a longitudinal parasagittal orientation approximately 3 cm lateral to the spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep face of the erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.
48620348|NCT01995383|DRUG|RO6836191|Orally administered, single ascending doses
48620349|NCT01995383|DRUG|RO6836191|2 single oral doses
48620350|NCT01995383|DRUG|RO6836191|Intravenous administration
48275722|NCT03719235|OTHER|CBCT|ultra-low dose CBCT
48275723|NCT03893045|DRUG|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
48275724|NCT03893045|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
48275725|NCT05124626|PROCEDURE|MIRPE with two bars|Minimally invasive repair of pectus excavatum utilizing two metallic bars
48275726|NCT05124626|PROCEDURE|MIRPE with one bar|Minimally invasive repair of pectus excavatum utilizing one metallic bar
48275727|NCT00000979|DRUG|Zidovudine|
48275728|NCT00000979|DRUG|Didanosine|
48275729|NCT04460430|DRUG|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
48275730|NCT03046420|OTHER|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
48275731|NCT04081805|PROCEDURE|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
48275732|NCT04081805|PROCEDURE|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
48275733|NCT04081805|DRUG|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
48275734|NCT04331041|DEVICE|Adaptive stereotactic body radiation therapy|"* Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions"
48275735|NCT04331041|DRUG|Defactinib|-Oral drug 400 mg twice a day
48275736|NCT04331041|PROCEDURE|Tumor biopsy|-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)
48275737|NCT04331041|PROCEDURE|Research blood draw|-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
48275738|NCT05961228|OTHER|exercise|"Three different posture with and without correction according to the Schroth method"
48275739|NCT03751332|DRUG|Tacrolimus|Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
48275740|NCT01368796|BIOLOGICAL|Agriflu|0.5mL dose IM vaccination
48098025|NCT02637271|OTHER|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
48275741|NCT01368796|BIOLOGICAL|Fluad|0.5mL dose of vaccine given IM
48275742|NCT01368796|BIOLOGICAL|Intanza|0.5mL dose vaccine given IM
48275743|NCT01368796|BIOLOGICAL|Vaxigrip|0.5mL dose vaccine given IM
48275744|NCT05480969|OTHER|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
48275745|NCT01412879|BIOLOGICAL|rituximab|Given IV
47927939|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
48098026|NCT02637271|OTHER|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
48275746|NCT01412879|DRUG|bendamustine hydrochloride|Given IV
48275747|NCT01412879|DRUG|cyclophosphamide|Given IV
48275748|NCT01412879|DRUG|cytarabine|Given IV
48275749|NCT01412879|DRUG|dexamethasone|Given PO or IV
48275750|NCT01412879|DRUG|doxorubicin hydrochloride|Given IV
48275751|NCT01412879|DRUG|leucovorin calcium|Given PO or IV
48275752|NCT01412879|DRUG|methotrexate|Given IV
48275753|NCT01412879|DRUG|vincristine sulfate|Given IV
48275754|NCT05907707|DEVICE|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
48275755|NCT05907707|DEVICE|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
48275756|NCT05907707|DEVICE|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
48275757|NCT05907707|DEVICE|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
48275758|NCT03617731|DRUG|Lenalidomide|25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
48275759|NCT03617731|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
48275760|NCT03617731|DRUG|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
48275761|NCT03617731|DRUG|Isatuximab|10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
48275762|NCT04048512|PROCEDURE|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
48275763|NCT04048512|PROCEDURE|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
48275764|NCT04274322|OTHER|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
48275765|NCT05015101|OTHER|Cohort observation|Cohort observation
48275766|NCT04295590|BEHAVIORAL|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
48275767|NCT04295590|BEHAVIORAL|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
48275768|NCT06445374|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
48275769|NCT06159478|DRUG|Binimetinib 15 MG|Binimetinib 45mg is orally administered twice daily.
48275770|NCT03900780|PROCEDURE|PGT-A|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
48275771|NCT03900780|PROCEDURE|Control|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
48275772|NCT02300649|DRUG|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
48444028|NCT03744481|OTHER|Questionaire|"Evaluation of psychomotor development in children with mild EAI without indication of therapeutic hypothermia.~Precise analysis of the type (motor, sensory, language, epilepsy) and the severity of sequelae by sending a questionnaire to parents.~Investigation of early, clinical and paraclinical prognostic factors of good or bad neurodevelopmental outcome.~Evaluation of the height-weight growth and the cranial perimeter"
48275773|NCT02300649|DRUG|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
48275774|NCT03759158|DRUG|N-Acetyl Cysteine|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
48275775|NCT03759158|DRUG|Placebo Oral Tablet|Placebo Oral Tablet twice daily.
48275776|NCT05634902|BEHAVIORAL|CME Educational Intervention|The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.
48275777|NCT05634902|BEHAVIORAL|Study Developed Educational Materials for Patients|Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
48275778|NCT00391599|PROCEDURE|enema|
48275779|NCT04241029|DIETARY_SUPPLEMENT|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12\*10\^9 cfu/day) for eight weeks.
48275780|NCT04681261|OTHER|this study is not an intervention study|this study is not an intervention study
48275781|NCT03295825|DIAGNOSTIC_TEST|Biomarker|Measument of heparin-binding protein in the serum of patients
48275782|NCT03506932|DIETARY_SUPPLEMENT|Untreated|Bread made with 20% yellow pea flour that was untreated.
48275783|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
48275784|NCT03506932|DIETARY_SUPPLEMENT|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
48275785|NCT03506932|DIETARY_SUPPLEMENT|Wheat|Bread made with 100% wheat
48275786|NCT06217328|DEVICE|Revi System Treatment|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable
48275787|NCT06217328|DEVICE|Revi System - Delayed Activation|The Revi System is an implantable neuromodulation device placed in the ankle region that is activated by a battery-operated rechargeable external wearable. The system will be implanted but it will not be turned on until 4 months post implant procedure.
48444029|NCT02659150|DRUG|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
48444030|NCT01348789|DEVICE|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
48275788|NCT03848819|DEVICE|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
48275789|NCT01002781|DRUG|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
48275790|NCT01023282|DRUG|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
48275791|NCT01023282|DRUG|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
48275792|NCT03492593|OTHER|lycopene|A tomato oleoresin containing lycopene
48275793|NCT03492593|OTHER|beta-carotene|13C beta-carotene
48275794|NCT03492593|OTHER|control|emulsified liquid meal alone
48275795|NCT05653895|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
48275796|NCT05653895|DRUG|Metformin|Metformin
48275797|NCT05653895|COMBINATION_PRODUCT|Acetyl-L-Carnitin, L Arginine, Co-Q10|Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
48275798|NCT06423248|DIETARY_SUPPLEMENT|Culinary spices|Powdered culinary spices
48275799|NCT03026738|PROCEDURE|Laparoscopic anterior mesh rectopexy|fixation of the rectum anteriorly using laparosopy and polypropylene mesh
48275800|NCT03026738|PROCEDURE|Laparoscopic posterior mesh rectopexy|fixation of the rectum posteriorly using laparosopy and polypropylene mesh
48275801|NCT03026738|DEVICE|polypropylene mesh|A strip of polypropylene mesh will be introduced and sutured.
48275802|NCT03461055|OTHER|Lavender|Lavender aromatherapy
48275803|NCT03461055|OTHER|Water|Water
48275804|NCT02748343|DEVICE|allograft bone|Use of the allograft bone to treat the bone defect in patients
48275805|NCT02748343|DEVICE|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
48275806|NCT05971797|BEHAVIORAL|REBT|During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.
48275807|NCT04125537|BEHAVIORAL|IHI Breakthrough Collaborative Model|Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
48275808|NCT00550160|DRUG|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
48275809|NCT04800380|OTHER|Edpuzzle interactive videos|The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
48275810|NCT03932526|DRUG|Vinorelbine + placebo|Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
48275811|NCT03932526|DRUG|Vinorelbine + Apatinib|Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
48275812|NCT04026568|DRUG|4-Aminopyridine|Single drug test for nerve continuity
48275813|NCT04026568|DRUG|Placebo oral tablet|Placebo arm
48275814|NCT05320939|DRUG|Mepolizumab 100 MG|30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
48275815|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
48275816|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
48275817|NCT01062477|BIOLOGICAL|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
48275818|NCT01360125|GENETIC|proteomic profiling|
48275819|NCT01360125|OTHER|flow cytometry|
48275820|NCT01360125|OTHER|laboratory biomarker analysis|
48275821|NCT03035760|DRUG|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
48275822|NCT03404648|DRUG|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
48275823|NCT03404648|DRUG|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
48275824|NCT03404648|DEVICE|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
48275825|NCT02921425|BEHAVIORAL|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
48275826|NCT04210726|DRUG|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
48275827|NCT04210726|OTHER|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
48275828|NCT04092842|DEVICE|Silicone prosthesis|Silicone prosthesis
48275829|NCT04092842|PROCEDURE|Usual practice|Usual surgery
48275830|NCT00943683|DRUG|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
48275831|NCT00943683|DRUG|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
48275832|NCT04172090|OTHER|Control|Normal physical activity and standard energy intake
48275833|NCT04172090|OTHER|SIT+E|Reduced physical activity and standard energy intake
48275834|NCT04172090|OTHER|SIT=E|Reduced physical activity and reduced energy intake
48275835|NCT00359892|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
48275836|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
48275837|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
48275838|NCT05150132|DEVICE|Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
48275839|NCT03561727|PROCEDURE|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
48275840|NCT03561727|PROCEDURE|Layered closure technique|he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
48275841|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
48275842|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
48275843|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
48275844|NCT00971308|DRUG|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
48275845|NCT00971308|DRUG|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
48275846|NCT03651076|DEVICE|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
48275847|NCT04959123|OTHER|pharmacokinetic analysis|Non-compartmental descriptive pharmacokinetic analysis (i.e. without the need for mathematical modelling), with determination of the pharmacokinetic parameters of interest either directly from the experimental points (Cmax, Tmax), or from simple mathematical equations (calculation of the area under the curve (AUC) by the trapezoidal method, calculation of the terminal slope of elimination)
48275848|NCT01106755|DEVICE|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
48275849|NCT01106755|DEVICE|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
48275850|NCT00221364|DRUG|Mass treatment with oral azithromycin to an entire village|
48444031|NCT05451069|DIAGNOSTIC_TEST|Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells|"1. Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~2. Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry."
48275851|NCT02457234|BEHAVIORAL|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
48275852|NCT05213871|OTHER|Instrument-assisted soft tissue mobilization|For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.
48275853|NCT05213871|OTHER|Myofascial release therapy|Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.
48275854|NCT05213871|OTHER|Postural correction exercises (PCE)|Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
48275855|NCT03140319|BIOLOGICAL|Fibroblast|Transplantation of 20 million cell by three injection
48275856|NCT03140319|BIOLOGICAL|Placebo|Injection of Placebo
48275857|NCT06119880|DRUG|Pancreatin Enteric-coated Capsules|pancreatic enzyme replacement therapy
48275858|NCT06119880|OTHER|Routine treatment plan|Routine treatment plan without PERT
48275859|NCT05707572|DRUG|methylprednisolone|a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
48275860|NCT05707572|PROCEDURE|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
48275861|NCT04261530|BEHAVIORAL|Self-hypnosis/self-care|
48275862|NCT04261530|BEHAVIORAL|Music/self-care|
48275863|NCT04261530|BEHAVIORAL|Self-care|
48275864|NCT04261530|BEHAVIORAL|Psycho-education|
48275865|NCT06158243|OTHER|Sono-anatomical Study|The arm is abducted (90°), externally rotated, with the forearm flexed over the arm (90°). A linear ultrasound probe (8-15 MHz) is placed in front of the humeral head, in a sagittal plane. Location begins at axillary level, vessels, nerves and humerus are identified, and the probe is moved medially to reach and identify the humeral head.
48275866|NCT04057209|RADIATION|Single Vocal Cord Irradiation (SVCI)|The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of \<107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
48275867|NCT04057209|PROCEDURE|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|"The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin."
48275868|NCT02945657|DRUG|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
48275869|NCT05408689|DEVICE|T1 TENS|The subjects in Group A will received TENS (Burst mode, 9 pulses per burst, pulse frequency =160Hz, burst frequency=2Hz, intensity was set to trigger visible muscular twitches). Two 2 x 3 cm electrodes was attached on T1 level with 2 cm from the spine. Previous study has shown that it was effective to improve the cognitive function in subjects with Alzheimer's disease.
48275870|NCT05408689|DEVICE|Concha TENS|The subjects in Group B will received TENS (25Hz, 0.5mA) on the concha of left outer ear. The electrical stimulation was generated by the portable neurostimulator (Nemos®, Cerbomed, Erlangen, Germany) and was delivered by a titanium electrodes positioning on top of a silicon earplug. Previous study has shown that it was effective to improve the Accelerate extinction memory formation and retention in healthy young adults.
48275871|NCT05408689|DEVICE|Control|The subjects in Group C will receive 30 min sham electrical stimulation on T1 by a placebo-TENS device. The Placebo-TENS was applied by an apparently identical TENS unit. The unit's power indicator light was illuminated, but the unit's electrical circuit had been manually disconnected inside. In order to shape the common mindset, all subjects (except those in the Control group) were informed that they might or might not feel an electrical current, as different stimulation parameters were being applied.
48275872|NCT05760716|OTHER|practicing prone position|Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
48275873|NCT03284190|PROCEDURE|Surgery|Surgery
48275874|NCT01969266|DRUG|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
48275875|NCT01969266|DRUG|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
48275876|NCT04439786|DRUG|placebo|the control group will be given the same volume of saline.
48275877|NCT04439786|DRUG|lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
48275878|NCT05971849|DRUG|kisspeptin 112-121|IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin
48275879|NCT01677845|RADIATION|Radiation|"Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions."
48275880|NCT04379752|DEVICE|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
48275881|NCT05192187|OTHER|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~* perceived harmfulness of activities (selection of PHODA-SeV)~* cognitions about lifting and pain~* reasons for avoidance behaviour (lifting)~Standardised questionnaires include~* NRS for pain~* TSK-11~* FABQ~* RMDQ"
48275882|NCT00212329|PROCEDURE|T Cell Proliferation and Autoreactivity Assays|
48275883|NCT00212329|PROCEDURE|Cellular Immunoblot Assays|
48275884|NCT00212329|PROCEDURE|Tetramer Studies|
48275885|NCT00212329|PROCEDURE|Cytokine ELISPOT|
48275886|NCT04848493|BIOLOGICAL|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
48275887|NCT05629039|BEHAVIORAL|Volitional Help Sheets|The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
48275888|NCT03741361|OTHER|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
48275889|NCT05207761|DRUG|D565|Q.D. in both eye
48275890|NCT05207761|DRUG|D930|T.I.D in both eye
48275891|NCT02938182|DRUG|clopidogrel|clopidogrel troche 75 mg daily for three months
48444032|NCT00667212|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
48444033|NCT00667212|BEHAVIORAL|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
48275892|NCT05543590|DRUG|Plasmapheresis|5 sessions of plasma exchanges
48275893|NCT05543590|OTHER|Blood collection|Blood collection to assess biological markers at baseline, M3 and M12
48275894|NCT05543590|OTHER|Stool samples|Stool samples will be collected from participants at baseline,M3 and M12
48275895|NCT05543590|OTHER|PET scan|PET scan at baseline and M6
48444034|NCT06324838|PROCEDURE|Standard laparoscopic ileocecal resection|Participants will undergo standard mesocolic sparing resection.
48444035|NCT06324838|PROCEDURE|Extended laparoscopic ileocecal resection|Extended mesocolic resection to assess its impact on reducing recurrence at the anastomotic site.
48444036|NCT00873639|DRUG|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
48444037|NCT00873639|DRUG|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
48444038|NCT03295474|OTHER|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.~Patients are taught to use the system during the first session of aerobic training.~During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).~At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).~The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.~The study takes off on the session during which the patients are autonomous in using the telehealthcare system.~If patients are not autonomous on the fifth session, the study also takes off."
48275896|NCT05543590|OTHER|Cycle ergometer stress test|Cycle ergometer stress test at M6
48275897|NCT05543590|OTHER|Questionnaires at baseline|Questionnaires at baseline, M3 and M6
47927940|NCT01855373|DIETARY_SUPPLEMENT|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
48275898|NCT05543590|OTHER|Medical consultations|Medical consultations
48275899|NCT00623831|BIOLOGICAL|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
48275900|NCT00389207|DRUG|nevirapine bid|nevirapine twice daily
48275901|NCT00389207|DRUG|nevirapine qd|nevirapine once daily
48275902|NCT00389207|DRUG|atazanavir|atazanavir once daily
48275903|NCT05591781|DEVICE|high frequency chest wall oscillation with vest system|Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.
48275904|NCT05591781|DEVICE|Lung flute (OPEP)|. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
48275905|NCT00128687|BEHAVIORAL|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
48275906|NCT04792866|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D FLAIR versus Coronal T2-WI MRI in detecting Optic Neuritis
48275907|NCT05827159|DRUG|Naltrexone Pill|In the MAUD component, some participants will receive oral Naltrexone in the ED.
48275908|NCT05827159|DRUG|Naltrexone Injection|In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.
48275909|NCT05827159|BEHAVIORAL|Brief Negotiation Interview|Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
48275910|NCT05827159|DRUG|Gabapentin Pill|In the MAUD component, ancillary treatment with gabapentin will be provided.
48275911|NCT00928811|DRUG|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
48275912|NCT00928811|DRUG|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
48275913|NCT04035876|DRUG|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
48275914|NCT04666207|DIAGNOSTIC_TEST|PCR|RT-PCR for SARS-CoV-2
48275915|NCT00216034|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
48275916|NCT00216034|DRUG|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
48275917|NCT02193789|PROCEDURE|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
48275918|NCT02193789|DEVICE|Covered Self-expandable Metallic Stents|
48275919|NCT05255003|BIOLOGICAL|Enoxaparin|"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
48275920|NCT05255003|BIOLOGICAL|Dalteparin|"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation"
48275921|NCT05255003|BIOLOGICAL|Tinzaparin|"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
48275922|NCT02717156|PROCEDURE|Computed Tomography|Correlative studies
48275923|NCT02717156|OTHER|Laboratory Biomarker Analysis|Correlative studies
48275924|NCT02717156|BIOLOGICAL|Pembrolizumab|Given IV
48275925|NCT02717156|PROCEDURE|Positron Emission Tomography|Correlative studies
48275926|NCT02717156|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
48275927|NCT02752828|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48275928|NCT02752828|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48275929|NCT02752828|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
48275930|NCT01994187|PROCEDURE|Carotid endarterectomy|
48275931|NCT01994187|PROCEDURE|carotid angioplasty|
48275932|NCT06015490|OTHER|Conditioned Stimulus: Sucrose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
48275933|NCT06015490|OTHER|Conditioned Stimulus: Glucose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of glucose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
48275934|NCT06015490|OTHER|Conditioned Stimulus: Fructose (aim 1)|Participants will consume flavored beverage solutions containing 110 calories of fructose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
48275935|NCT06015490|OTHER|Conditioned Stimulus: Sucrose (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
48275936|NCT06015490|OTHER|Conditioned Stimulus: High Fructose Corn Syrup (aim 2)|Participants will consume flavored beverage solutions containing 110 calories of high fructose corn syrup in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
48275937|NCT06015490|OTHER|Conditioned Stimulus: Sucrose + Non-nutritive Sweetener (aim 2)|Participants will consume flavored beverage solutions containing a non-nutritive sweetener and 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurements inside a metabolic chamber over a 2-hour period. The other 5 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
48275938|NCT02872103|DRUG|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
48275939|NCT02872103|DRUG|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
48275940|NCT00001757|DRUG|Voriconazole|
48275941|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
48275942|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
48275943|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
48275944|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
48275945|NCT00809133|DRUG|BIBW2992|MTD dose of part A
48275946|NCT00809133|DRUG|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
48275947|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
48275948|NCT00809133|DRUG|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
48275949|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
48444039|NCT04470115|OTHER|General anesthesia|Patients will receive general endotracheal anesthesia with typical drugs used (propofol, fentanyl, sevoflurane). the exact dose of the drug will be on the discretion of anesthesia provider, according to good clinical practice.
48275950|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
48275951|NCT04816240|DRUG|Midodrine|5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90)
48275952|NCT04816240|BIOLOGICAL|Albumin|80grams/week for 2 weeks followed by 40gram/week
48275953|NCT04816240|OTHER|Standard Medical Treatment|Standard Medical Treatment
48275954|NCT04816240|OTHER|Placebo|Placebo
48275955|NCT03011229|DEVICE|Pro Core Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
48275956|NCT03011229|DEVICE|medtronic Sharkcore Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
48275957|NCT05563493|OTHER|Treatment group, Chair-Based Exercise Training|"The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized."
48275958|NCT05563493|OTHER|Control group, Breathing exercise|Breathing exercise will be applied to the patients every day they are hospitalized.
48275959|NCT06484166|OTHER|Fullerene cream|Patients are instructed to apply a thin layer of the Fullerene cream third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
48275960|NCT06484166|DRUG|Trolamine (Biafine)|Patients are instructed to apply a thin layer of the Trolamine (Biafine) third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
48275961|NCT00543179|DRUG|Somatuline (Lanreotide Autogel®)|
48275962|NCT01225341|DRUG|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
48275963|NCT01225341|OTHER|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
48275964|NCT00268814|DRUG|Diacetylmorphine|Diacetylmorphine (i.v.), daily
48275965|NCT00268814|BEHAVIORAL|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
48275966|NCT00268814|DRUG|Methadone|Methadone (p.o.), daily
48275967|NCT00268814|BEHAVIORAL|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
48275968|NCT04139122|DRUG|SJP-0132|SJP-0132 is administered as an eye drop
48275969|NCT04139122|DRUG|Placebo|Placebo is administered as an eye drop
48275970|NCT05422976|DEVICE|EVI-01|High molecular weight Hyaluronic Acid
48275971|NCT05305482|DEVICE|Drug-coated stent|The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.
48275972|NCT05305482|DEVICE|Drug-eluting stent|The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.
48275973|NCT05303454|BEHAVIORAL|Cartoons|cartoons were found to be effective in reducing children's pain and fear levels.
48275974|NCT05303454|BEHAVIORAL|musical-moving toys|musical-moving toys were found to be effective in reducing children's pain and fear levels.
48275975|NCT03911622|DEVICE|MRI|medical device that is used as an imaging tool for soft tissues
48275976|NCT01307423|DRUG|Apremilast 20mg|Apremilast 20mg twice daily, orally
48275977|NCT01307423|DRUG|Apremilast 30mg|Apremilast 30mg twice daily, orally
48275978|NCT01307423|DRUG|Placebo|Placebo
48275979|NCT02862691|DRUG|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
48275980|NCT02862691|DRUG|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
48275981|NCT00603239|DRUG|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
48275982|NCT00603239|DRUG|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
48275983|NCT00843570|DRUG|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
48275984|NCT05122130|DRUG|Melatonin|The donor site will be dressed with melatonin loaded gelatin sponge
48444040|NCT04470115|OTHER|Regional anesthesia- femoral and lateral femoral cutaneous nerve blocks|The femoral nerve (FN) is identified with ultrasound. The needle is inserted in-plane, from lateral to medial. We administer 15 to 17ml of local anesthetic (0.5 to 0.75% ropivacaine). After good anesthetic spread on FN we identify lateral femoral cutaneous nerve (LFCN) in its expected location 2-3 cm below inguinal ligament, laterally to sartorius muscle and inject usually 4 to 5 ml of local anesthetic. Oxygen 2-3 l/min is given via face mask to maintain Sp02 and the block is followed by sedation. Sedation is achieved with boluses of propofol to enable procedure and maintain patient in comfort. We aim to keep the depth of sedation at Ramsay sedation scale of 4. Whether it is possible we use loud verbal stimulus, if it is not we use gently glabella tap to assess depth of sedation. Patient is breathing spontaneously during the whole surgery. After surgical field is prepared, surgeon infiltrates expected entry points of intramedullary nail system with 0,5% lidocaine.
48444041|NCT00000541|BEHAVIORAL|dietary supplements|
48275985|NCT05122130|DRUG|Carbopol|The donor site will be dressed with carbopol loaded gelatin sponge (placebo).
48275986|NCT02103686|DRUG|Lyrica|
48275987|NCT02103686|DRUG|Experimental drug|sustained release formulation of pregabalin
48275988|NCT02103686|DIETARY_SUPPLEMENT|High fat meal|
48275989|NCT02103686|DIETARY_SUPPLEMENT|fasted|
48275990|NCT05243888|DIAGNOSTIC_TEST|self-sampling|eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter
48275991|NCT04947293|OTHER|Physical activity|Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
48275992|NCT00749190|DRUG|BI 10773|
48275993|NCT00749190|DRUG|placebo|
48275994|NCT00749190|DRUG|sitagliptin|
48275995|NCT03241446|DRUG|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
48275996|NCT04219436|PROCEDURE|esthetic crown leghthening|two different suturing technique used for flap closure after esthetic crown lengthening
48275997|NCT02828176|PROCEDURE|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
48275998|NCT02828176|PROCEDURE|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
48275999|NCT02828176|PROCEDURE|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
48276000|NCT02828176|PROCEDURE|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
48276001|NCT01036399|DRUG|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
48276002|NCT04753125|BEHAVIORAL|follow-up by telephone|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
48276003|NCT04753125|BEHAVIORAL|follow-up via a game in a smartphone app|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
48276004|NCT04753125|BEHAVIORAL|conventional follow-up by a health professional|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
48276005|NCT00833092|DIETARY_SUPPLEMENT|Sugar Pill|Sugar pill supplementation for 9 weeks
48276006|NCT00833092|DIETARY_SUPPLEMENT|magnesium|300 milligrams daily for 8 weeks
48276007|NCT03325764|OTHER|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
48276008|NCT01364987|DRUG|ASP015K|oral
48276009|NCT01364987|DRUG|Mycophenolate Mofetil|oral
48276010|NCT03803527|PROCEDURE|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
48276011|NCT04919915|DEVICE|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
48276012|NCT00781365|OTHER|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
48276013|NCT04965519|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
48276014|NCT05448079|OTHER|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
48276015|NCT04621903|OTHER|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
48276016|NCT06063473|DRUG|Trifarotene Cream 0.005%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
48276017|NCT06063473|DRUG|Placebo|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
48276018|NCT06063473|DRUG|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
48276019|NCT01696357|DEVICE|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
48276020|NCT02722044|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
48276021|NCT02722044|DEVICE|Autoinjector|Subcutaneous administration
48276022|NCT04325503|DRUG|carbidopa|carbidopa and carbidopa-levodopa standard treatment
48276023|NCT05987215|COMBINATION_PRODUCT|Radiologic diagnosis|Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis
48276024|NCT05987215|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis
48276025|NCT03632642|DRUG|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
48276026|NCT03632642|DRUG|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
48276027|NCT02489539|DEVICE|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
48276028|NCT02600299|BEHAVIORAL|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
48276029|NCT02600299|BEHAVIORAL|Usual Care|Usual Care
48276030|NCT01237951|DRUG|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
48276031|NCT01237951|DRUG|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
48276032|NCT01237951|DRUG|Gemcitabine|1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
48276033|NCT01237951|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
48444042|NCT00000541|DRUG|vitamin C|
48444043|NCT00000541|DRUG|vitamin E|
48444044|NCT00000541|DRUG|beta-carotene|
48444045|NCT00000541|DRUG|folic acid/Vitamin B6/Vitamin B12|
48276034|NCT01237951|DRUG|Melphalan|60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
48276035|NCT01237951|PROCEDURE|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
48276036|NCT01237951|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
48276037|NCT02956811|DRUG|Dapagliflozin|SGLT2 inhibitor
48276038|NCT02956811|DRUG|Placebo|Matching Placebo
48276039|NCT03642561|DEVICE|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
48444046|NCT04044261|PROCEDURE|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
48444047|NCT04093505|DRUG|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
48276040|NCT03642561|DEVICE|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
48276041|NCT02226341|DRUG|CellCept|"For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
48276042|NCT02226341|DRUG|ACTHar gel|"Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response."
48276043|NCT00019955|PROCEDURE|laparoscopic surgery|
48276044|NCT00019955|PROCEDURE|radiofrequency ablation|
48276045|NCT00019955|PROCEDURE|thermal ablation therapy|
48276046|NCT01977287|DEVICE|Functional Electrical Stimulation|
48276047|NCT01977287|DEVICE|Ankle Foot Orthosis|
48276048|NCT01311778|DRUG|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
48276049|NCT01311778|DRUG|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
48276050|NCT03511365|BIOLOGICAL|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
48276051|NCT05740241|OTHER|Elderly|A group of participants with physical activity (protocolized)
48276052|NCT05122325|DEVICE|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
48276053|NCT05122325|DEVICE|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
48276054|NCT05122325|DEVICE|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
48276055|NCT04278911|DIAGNOSTIC_TEST|MMSE and MoCA|This is an observational study. All the patients evaluate with MMSE (Mini-mental State Examination) and MoCA (Montreal Cognitive Assessment), and investigate the incidence and characteristics of cognitive and MACE
48276056|NCT04964011|OTHER|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
48276057|NCT06044324|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
48276058|NCT00165009|DEVICE|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
48276059|NCT05601700|DRUG|Letrozole tablets|ATC: L02BG04
48276060|NCT05601700|DRUG|carboplatin AUC 5 and paclitaxel 175 mg/m2|ATC: L01XA02 and ATC: L01CD01 respectively
48276061|NCT02830802|OTHER|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
48276062|NCT02830802|OTHER|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash."
48276063|NCT06329479|BEHAVIORAL|Cognitive behavioural therapy for Insomnia (CBT-I)|A psychoeducational and evidence-based skills and strategies course for insomnia delivered online over four lessons through ThisWayUp. This will be completed during an 8-week feasibility trial.
48276064|NCT06329479|DEVICE|Bright Light Therapy|Daily bright light therapy for 30 minutes on waking delivered using the Lumie-L light box during an 8-week feasibility trial.
48276065|NCT06329479|BEHAVIORAL|Individualised activity plan|An individualised activity plan is created at baseline and adjusted weekly aiming to increased daytime physical activity and reduce sedentary behaviours. The activity plan takes into consideration personal interests, perceived barriers to activity and develops an activity plan using Specific Measureable Achievable Realistic and Timely (SMART) goals. This will take place during an 8-week feasibility trial.
48276066|NCT06329479|OTHER|Clincial review|Two clinical reviews will take place during an 8-week feasibility trial and consider uncontrolled symptoms, medication and blood test abnormalities which may impact on rest and physical activity levels
48276067|NCT02583984|PROCEDURE|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
48444048|NCT04093505|DRUG|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
48276068|NCT02583984|PROCEDURE|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
48276069|NCT00224666|DEVICE|Cortex stimulation|
48276070|NCT00087438|RADIATION|stereotactic body radiation therapy|
48276071|NCT01026584|DRUG|Aripiprazole|6 week prospective study
48276072|NCT05303740|DRUG|Anlotinib|This is an observational study.
48276073|NCT03213665|DRUG|Tazemetostat|Given PO
48276074|NCT01287104|BIOLOGICAL|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
48276075|NCT01287104|BIOLOGICAL|Stem Cell Infusion|Transplant Day 0: \>4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) \>5000/microliters x2
48276076|NCT05816603|DEVICE|Real Soterix Mini-CT tDCS stimulator|Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.
48276077|NCT05816603|DEVICE|Sham Soterix Mini-CT tDCS stimulator|Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
48276078|NCT01348230|OTHER|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
48276079|NCT05485207|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
48276080|NCT01206907|DRUG|oxymorphone IR|oxymorphone IR liquid
48276081|NCT01737814|DRUG|Saline|
48276082|NCT01737814|DRUG|MST-188|
48276083|NCT01990261|DRUG|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
48276084|NCT05991024|BEHAVIORAL|the incisional hernia recurrent|Recurrence after repair was the main outcome
48276085|NCT03180814|OTHER|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
48276086|NCT01678976|DRUG|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
48276087|NCT01678976|DRUG|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
48276088|NCT02485717|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
48276089|NCT02485717|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
48276090|NCT04333082|OTHER|Data collection|"collection of patient data~Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients"
48276091|NCT04651634|DRUG|MIT-001 plus CCRT|MIT-001 IV-infusion plus CCRT
48276092|NCT04924127|DIAGNOSTIC_TEST|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
48276093|NCT02395991|DRUG|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
48276094|NCT02395991|OTHER|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
48444049|NCT04093505|DRUG|Glasdegib|Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27
48444050|NCT04093505|DRUG|Placebo Oral Tablet|Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27
48444051|NCT03153540|DEVICE|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
48276095|NCT02069691|DEVICE|virtual reality-cycling training system|
48276096|NCT06227403|BEHAVIORAL|Leadership, Engagement, and youth Activism Program with Mindfulness|The Leadership, Engagement, and youth Activism Program with Mindfulness intervention (LEAP-M) was designed and co-created with youth to improve youth wellbeing by enhancing civic engagement and leadership opportunities and by developing mindfulness in day-to-day life. LEAP-M seeks to foster these improvements in youth of color as a strategy to combat structural racism encountered at school- and neighborhood-levels and to increase youth mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
48276097|NCT06227403|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential transition skills and digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
48276098|NCT03276741|DIETARY_SUPPLEMENT|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
48444052|NCT03153540|DEVICE|Sham iTBS|Sham intervention
48444053|NCT06422845|DEVICE|Dissolve AV Peripheral Scoring Drug-coated Balloon|Subjects in the test group are treated with Dissolve AV Peripheral Scoring Drug-coated Balloon
48444054|NCT05854186|BEHAVIORAL|Telehealth solution: video conferencing|Telehealth solution: video conferencing
48444055|NCT00731978|PROCEDURE|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
48276099|NCT04970329|DRUG|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
48276100|NCT02022826|DEVICE|SmartPill Monitoring System|
48444056|NCT02596100|DRUG|Betrixaban|
48276101|NCT03396328|BEHAVIORAL|conventional low salt education|conventional low salt education
48276102|NCT03396328|BEHAVIORAL|Intensive low salt dietary education by smartphone application|Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
48276103|NCT00666562|DIETARY_SUPPLEMENT|Defined Green Tea Catechin Extract|Given orally
48276104|NCT00666562|OTHER|Laboratory Biomarker Analysis|Correlative studies
48276105|NCT00666562|OTHER|Pharmacological Study|Correlative studies
48276106|NCT00666562|DRUG|Placebo|Given orally
48276107|NCT00666562|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48276108|NCT05114772|DIAGNOSTIC_TEST|Measuring Serum bio-markers|ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
48276109|NCT02772783|OTHER|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.
48276110|NCT02772783|OTHER|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.
48276111|NCT02772783|DRUG|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
48276112|NCT02772783|DRUG|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
48276113|NCT00130871|DRUG|levosimendan|
48276114|NCT02415309|DRUG|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
48276115|NCT02415309|DRUG|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
48276116|NCT02415309|OTHER|Placebo|40 patients will randomly receive a placebo/sugar pill
48276117|NCT03780998|DRUG|Life7|Life7 will used on the perianal skin with finger tips
48276118|NCT06051630|DRUG|Lidocaine intravenous|Perioperative lidocaine intravenous administration
48276119|NCT06051630|DRUG|Serum saline intravenous|Perioperative serum saline intravenous administration
48276120|NCT02899169|DRUG|Realgar-Indigo naturalis formula|
48276121|NCT02899169|DRUG|all-trans retinoic acid|
48276122|NCT02899169|DRUG|Arsenic trioxide|
48098027|NCT04274751|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation
48276123|NCT02899169|DRUG|Hydroxyurea|
48276124|NCT02732067|OTHER|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
48276125|NCT02419027|DIETARY_SUPPLEMENT|GI Flora|
48276126|NCT02419027|DIETARY_SUPPLEMENT|Placebo|
48276127|NCT05338229|DEVICE|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
48276128|NCT02515513|PROCEDURE|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
48276129|NCT02735213|DEVICE|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
48276130|NCT02735213|DEVICE|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.
48276131|NCT05710432|OTHER|Quasi-Isometric Neck Flexion|Patients will be asked to minimally lift their head from the pillow generating a quasi-isometric neck contraction (2 sets of 6-10 flexions).
48276132|NCT05710432|OTHER|Inspiratory Muscle Training|"Patients will be asked to complete 2 sets of 6-10 breaths through a POWERbreathe device, which applies a variable resistance provided by an electronically controlled valve (variable flow resistive load).~During each IMT and neck flexion maneuver ultrasound measurements will be performed (measurements of the diaphragm, sternocleidomastoid, parasternal intercostal, internal oblique \[IO\], external oblique \[EO\], transversus abdominis \[TrA\] and rectus abdominis \[RA\] will be taken) and, during the entire period, sEMG monitoring of the target muscles (diaphragm, sternocleidomastoid, parasternal intercostal and EO) will be continued."
48276133|NCT04567563|DEVICE|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
48276134|NCT04285060|DEVICE|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
48276135|NCT04550026|OTHER|HTP inhalation|Sham inhalation for 30 minutes
48276136|NCT02832089|DRUG|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
48276137|NCT03200951|DRUG|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
48276138|NCT03200951|DRUG|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
48276139|NCT01021566|DEVICE|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
48276140|NCT01021566|DRUG|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
48276141|NCT00323661|DEVICE|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
48276142|NCT00323661|DEVICE|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
48276143|NCT04272593|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
48276144|NCT05723887|BEHAVIORAL|Attachment-Based Intervention Program|Attachment-Based Intervention Program
48276145|NCT01488006|DEVICE|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
48276146|NCT01305512|DRUG|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
48276147|NCT03445702|DRUG|Metformin|Metformin 1000mg once
48276148|NCT03445702|DRUG|Placebo|Sugar pill manufactured to mimic metformin 1000mg
48276149|NCT02421861|BEHAVIORAL|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
48276150|NCT02421861|OTHER|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.
48276151|NCT03048630|BEHAVIORAL|Education|Owner-to-Worker training about reducing chemical exposures in nail salons
48276152|NCT02113202|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
48276153|NCT02113202|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
48276154|NCT02543242|DEVICE|InToneTM (InControl Medical, LLC) - Medical Device|
48276155|NCT00866099|OTHER|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
48276156|NCT02168582|BEHAVIORAL|physiotherapy as usual in primary care|
48276157|NCT02115308|DRUG|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
48276158|NCT04658602|PROCEDURE|Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)|Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
48276159|NCT00167479|DRUG|risperidone (Risperdal)|
48276160|NCT06273969|OTHER|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol is designed to target the somatic dysfunction associated with TOS. The somatic dysfunction associated with TOS include muscular hypertonicity of the anterior and middle scalene muscles, hypertonicity of the pectoralis muscles, and tension in the fascia of the supraclavicular area between the clavicle and first rib. The OMT protocol will consist of the following four techniques:~Direct Thoracic Inlet Myofascial Release (TIMFR) - Reduce tension at the thoracic inlet fascia located between the thoracic outlet and the cervical spine.~Direct Muscle Energy for the Scalene Muscles -Reduce tension within the scalene muscle group~Direct Muscle Energy for the Pectoralis Muscles - Reduce tension within the pectoralis muscle group~Supraclavicular Fascial Release - Reduce fascial tension within the supraclavicular fossa"
48276161|NCT03127449|DRUG|Alflutinib|patients take Alflutinib orally once per day at different dose
48276162|NCT02970695|DEVICE|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
48276163|NCT02970695|DEVICE|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
48276164|NCT04668560|BEHAVIORAL|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
48276165|NCT06541444|DRUG|NK520|The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
48276166|NCT00119340|DRUG|cyclosporine|
48276167|NCT00119340|DRUG|fludarabine phosphate|
48276168|NCT00119340|DRUG|mycophenolate mofetil|
48276169|NCT00119340|PROCEDURE|peripheral blood stem cell transplantation|
48276170|NCT00119340|RADIATION|radiation therapy|
48276171|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
48276172|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
48276173|NCT03122626|BEHAVIORAL|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
48276174|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
48276175|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
48276176|NCT04324853|DIAGNOSTIC_TEST|Microscopy ( Urine filtration), UCAA test, qPCR,|Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.
48276177|NCT04324853|DIAGNOSTIC_TEST|Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,|Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
48276178|NCT03499509|OTHER|Low Glycemic Diet|"Low Glycemic (LG) diet: The LG diet will be made up of foods that do not stimulate insulin secretion. The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., High-Protein SlimFast). Dinner will be a frozen entrée (e.g., Atkins, Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be nuts, berries, and full-fat dairy products (one serving per day), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
48276179|NCT03499509|OTHER|High Glycemic Diet|"High Glycemic (HG) diet: The HG diet will conform to United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/). The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., SlimFast). Dinner will be a frozen entrée (e.g., Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be fruit, fat-free dairy products, and low-fat bars (e.g., Optifast), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
48276180|NCT02272192|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
48276181|NCT02272192|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
48444057|NCT03914183|DEVICE|mCPN Intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened"
48444058|NCT03914183|DEVICE|Control|Use of standard of care insulin pen needle
48444059|NCT03351244|DRUG|BI 409306|28 week treatment period
48444060|NCT03351244|DRUG|Placebo|28 week treatment period
48444061|NCT02848924|OTHER|No intervention|
48444062|NCT02310386|DEVICE|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
48444063|NCT01313780|DRUG|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
48444064|NCT01313780|DRUG|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
48276182|NCT05606939|DEVICE|intestinal ultrasound|"All patients will be evaluated using intestinal ultrasound with special emphasis on intestinal wall thickness as well as stratification and Visualization of the vascularization of the bowel using color Doppler sonography also visualization of motility.~Findings of intestinal ultrasound will be compared regrading colonoscopic findings"
48276183|NCT02995434|DEVICE|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/"
48276184|NCT02995434|OTHER|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
48276185|NCT00333996|DRUG|Dexamethasone|
48276186|NCT00880750|DRUG|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
48276187|NCT00880750|DRUG|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
48276188|NCT01668368|OTHER|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
48276189|NCT06316479|DEVICE|PTMC Dermal Filler|A total of 120 subjects will receive treatment with PTMC Dermal Filler. The volume of filler injected will vary depending on the severity of the nasolabial fold. Injections will be administered by the investigator at the beginning of the study, with the injection technique, plane, and volume recorded. Touch-up treatments are permitted at the 1-month follow-up visit, if necessary.
48276190|NCT06226402|DRUG|Hypertonic saline 3% nebulizer|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
48276191|NCT06226402|DRUG|Intravenous hypertonic saline 3%|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
48276192|NCT02566720|DRUG|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
48276193|NCT02566720|PROCEDURE|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
48276194|NCT01361711|BIOLOGICAL|alemtuzumab|Given SC
48276195|NCT01361711|BIOLOGICAL|ofatumumab|Given IV
48276196|NCT01361711|PROCEDURE|biopsy|Correlative studies
48276197|NCT01815957|DRUG|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
48276198|NCT04584177|BEHAVIORAL|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
48276199|NCT04584177|BEHAVIORAL|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
48276200|NCT05003115|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
48276201|NCT05838326|DEVICE|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
48276202|NCT05838326|DEVICE|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed."
48276203|NCT04836949|DEVICE|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
48276204|NCT04836949|DEVICE|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
48276205|NCT01419509|GENETIC|DNA methylation analysis|
48276206|NCT01419509|GENETIC|microarray analysis|
48276207|NCT01419509|GENETIC|polymerase chain reaction|
48276208|NCT01419509|OTHER|laboratory biomarker analysis|
48276209|NCT00002025|DRUG|Ganciclovir|
48276210|NCT01983891|OTHER|Cooking course|6-week nutrition education and cooking course
48276211|NCT05381831|DRUG|NatestoTM|Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
48276212|NCT03216993|OTHER|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
48276213|NCT03216993|OTHER|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
48276214|NCT00673595|DRUG|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
48276215|NCT00673595|DRUG|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
48276216|NCT02041962|BEHAVIORAL|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
48276217|NCT02041962|OTHER|Educational Control|
48276218|NCT04910984|BEHAVIORAL|Chatbot messages|Automated personalized messages containing HIV testing-related information, motivation and skills
48276219|NCT04910984|BEHAVIORAL|Attention-matched educational materials|Attention-matched educational materials manually sent by our research assistant. These educational materials will be retrieved from CDC and WHO websites and curated into short articles (\<200 words) and pictures. All educational materials will be screened by HIV experts from University of Malaya to ensure accuracy before being sent to participants.
48276220|NCT06067854|PROCEDURE|the standard procedure - without regional anaesthesia|the standard procedure - without regional anaesthesia
48276221|NCT06067854|PROCEDURE|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
48276222|NCT04839861|BEHAVIORAL|Mightier Family Games|Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.
48276223|NCT04839861|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own."
48098028|NCT02938650|DRUG|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
48098029|NCT05925712|DEVICE|AeroFit Seal-In Liner / Socket|Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
48098030|NCT05925712|DEVICE|Seal-In Silicone Liner|Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
48098031|NCT05837676|BEHAVIORAL|Problem Solving Training for Concussion|PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
48276224|NCT06408844|BEHAVIORAL|Physical activity behavior change program implemented with 5A model|"According to the 5A model, the personal action plan includes the following items:~1. List specific goals by behavioral period~2. List obstacles and strategies to address them~3. Determine follow-up plan~4. Sharing the plan with the child and family In accordance with this plan, it is aimed to increase physical activity behavior in the classroom and during online meetings for 8 weeks. Additionally, after the training, motivational reminders will be held at regular intervals until the 28th week."
48276225|NCT00046722|DRUG|Smoked Marijuana|
48276226|NCT05407792|DRUG|Staphylococcus and Neisseria Tablets|0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
48444065|NCT03992222|DEVICE|Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows|administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
47927941|NCT01855373|DIETARY_SUPPLEMENT|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
48098032|NCT05837676|OTHER|Treatment as usual|Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
48098033|NCT01700569|DRUG|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
48276227|NCT05407792|OTHER|On-demand treatment|At the time of enrollment, patients with acute exacerbation of bronchiectasis were given routine treatment. For patients with stable bronchiectasis at the time of enrollment, they are treated as needed (that is, according to the needs of the disease, receive corresponding treatment).
48276228|NCT04073550|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
48276229|NCT04073550|DRUG|Placebos|Anlotinib blank analog capsule.
48276230|NCT04073550|DRUG|Topotecan|A topoisomerase I inhibitor.
48276231|NCT00465257|DRUG|artesunate + amodiaquine|
48276232|NCT00331305|BEHAVIORAL|Supervised Exercise|
48276233|NCT00331305|BEHAVIORAL|Home-Based Exercise|
48276234|NCT00331305|DRUG|Sertraline (Zoloft)|
48276235|NCT00331305|DRUG|Placebo Pill|
48276236|NCT01216774|OTHER|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
48276237|NCT05588427|DIETARY_SUPPLEMENT|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
48276238|NCT05588427|DIETARY_SUPPLEMENT|Placebo|Water, 5% sucralose (w/w), octaacetate (1 mM)
48276239|NCT01503216|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
48276240|NCT01503216|DIETARY_SUPPLEMENT|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
48276241|NCT01503216|DIETARY_SUPPLEMENT|Placebo|Placebo
48276242|NCT03429868|DEVICE|integrated PET/MRI|"The participants receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan."
48276243|NCT02575430|OTHER|No treatment: retrospective chart review|
48276244|NCT01451593|DRUG|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
48276245|NCT01451593|DRUG|Placebo|placebo identical in appearance to active IMP (phenytoin)
48276246|NCT03146364|DEVICE|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
48276247|NCT01205009|DRUG|Ovitrelle|One dose of Ovitrelle 250 mcg
48276248|NCT00435422|PROCEDURE|Stroke volume optimization|Stroke volume optimization
48276249|NCT00158184|DRUG|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
48276250|NCT00158184|DRUG|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
48276251|NCT00158184|DRUG|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
48620351|NCT04892160|OTHER|Guided Imagery|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will play an audio recording of an underwater guided imagery during one of these procedures: port access, dressing changes, and IV sticks. Guided imagery is an intervention that relies on a patient's imagination to create a sensory experience that utilizes mental images, sounds, smells, tastes, and touch. The guided imagery script used in this study describes an underwater scene and is meant to closely mimic the VR condition with the exception that it will be non-immersive. It will last approximately 15 minutes but can be played again if the procedure lasts longer than 15 minutes. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
48276252|NCT00710645|DEVICE|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
48276253|NCT02207114|OTHER|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
48276254|NCT03993015|OTHER|Help to diagnosis software|Help to diagnosis software
48276255|NCT00907075|BEHAVIORAL|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
48276256|NCT00907075|BEHAVIORAL|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
48276257|NCT02683369|DIETARY_SUPPLEMENT|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~* 15 mg of Vitamin C~* 400 mcg of Folate~* 30 mcg Vitamin of B-12~* 26 mg of Iron~* 125 mg of Beet Root"
48276258|NCT04047888|OTHER|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
48276259|NCT04047888|OTHER|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
48276260|NCT05318521|DRUG|Placebo|The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
48444066|NCT03197415|OTHER|Platelet-rich plasma|intradiscal injection of plasma-rich platelet
48276261|NCT05318521|DRUG|Ibuprofen modified release tablet 800 mg|Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
48276262|NCT03041311|DRUG|Trilaciclib|Trilaciclib IV
48276263|NCT03041311|DRUG|Placebo|Placebo IV
48276264|NCT03041311|DRUG|Carboplatin|Carboplatin IV
48276265|NCT03041311|DRUG|Etoposide|Etoposide IV
48276266|NCT03041311|DRUG|Atezolizumab|Atezolizumab IV
48276267|NCT06074003|OTHER|Seated Rest (Non-exercise control)|Sitting for 30 minutes
48276268|NCT06074003|OTHER|High-intensity interval exercise|Performing a single session of high-intensity interval exercise on a cycle ergometer
48276269|NCT06432738|DRUG|ZL-82|This group of subjects take ZL-82
48276270|NCT06432738|DRUG|ZL-82 placebo|This group of subjects take ZL-82 placebo
48276271|NCT03115996|DRUG|REGN3918|Intravenous (IV) or Subcutaneous (SC)
48276272|NCT03115996|DRUG|Placebo|Matching Placebo
48276273|NCT03973450|OTHER|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
48276274|NCT01993472|DRUG|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
48276275|NCT01993472|DRUG|Capecitabine|
48276276|NCT01994083|DRUG|Placebo|Administered orally
48276277|NCT01994083|DRUG|IX-01|Administered orally
48276278|NCT03614572|BEHAVIORAL|Group MI|refer to the arm description
48276279|NCT03584763|DIAGNOSTIC_TEST|Umbilical artery Doppler|Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
48276280|NCT02867306|DRUG|ASP1707|Oral
48276281|NCT02867306|DRUG|methotrexate (MTX)|Oral
48276282|NCT05328050|OTHER|Registry|observational, data collection
48276283|NCT05805514|OTHER|Animal source of food and psychosocial stimulation|209 mother-child pair will receive the animal source of food and psychosocial stimulation for 12 months. Child will be recruited within 6-12 months.
48276284|NCT05805514|OTHER|Animal source of food|209 mother-child pair will receive the animal source of food for 12 months. Child will be recruited within 6-12 months.
48276285|NCT05805514|OTHER|Control|209 mother-child pair will receive the control package for 12 months. Child will be recruited within 6-12 months.
48276286|NCT01569633|DRUG|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
48276287|NCT01569633|DRUG|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
48276288|NCT01569633|DRUG|placebo|The dose of sugar water is 1 ml per 8 hours.
48276289|NCT04626063|DRUG|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
48276290|NCT04626063|DRUG|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
48276291|NCT04626063|DRUG|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
48276292|NCT04506112|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention (TranS-C), adapted for cardiac rehabilitation|Participants will complete the TranS-C intervention as adapted for cardiac rehabilitation. TranS-C is a behavioral intervention that is rooted in basic sleep and circadian science and draws from empirically-supported treatments including Cognitive Behavioral Therapy for Insomnia (CBT-I), Interpersonal and Social Rhythm Therapy (IPSRT), chronotherapy, and light therapy. It was designed to promote sleep health across a range of sleep problems. Participants in this group will also continue to receive care as usual, cardiac/sleep-related or otherwise.
48276293|NCT05215184|DEVICE|Zeto WR19 EEG Recording|15 minutes of EEG recording to be obtained from eligible participants
48276294|NCT02786069|DRUG|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
48276295|NCT05791058|PROCEDURE|ultrasound guided pericapsular nerve group shoulder block|The patient's arm is placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 20 cc of 0.25% bupivacaine hydrochloride with 4mg dexamesathone will be injected
48276296|NCT05791058|PROCEDURE|ultrasound guided suprascapular and axillary nerve block|The patient will be positioned in a semi-recumbent position with the operating arm on the contralateral shoulder. The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected below the supraspinatous fascia then the posterior surface of the humerus will be visualised in the short axis view. So, the AN and posterior circumflex artery will be visualised longitudinally. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected into space
48276297|NCT05791058|OTHER|general anesthesia without nerve block|this group will receive general anesthesia without nerve block
48276298|NCT03973814|DEVICE|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
48276299|NCT01761734|BEHAVIORAL|text message|
48276300|NCT02318095|DRUG|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
48276301|NCT02318095|RADIATION|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
48276302|NCT02318095|OTHER|Sugical resection|Surgical resection of the pancreas post radiation therapy
48276303|NCT02318095|DRUG|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
48276304|NCT06124079|OTHER|OPY interactive messaging service|3 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The three versions differ in the motivational techniques interspersed throughout the OPY experience.
48276305|NCT06124079|OTHER|Standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
48276306|NCT02970773|DRUG|Rivaroxaban Oral Tablet|oral application of Xarelto
48276307|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
48276308|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
48276309|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
48276310|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
48276311|NCT03696329|DRUG|Tetrabenazine Tablets 25 mg|
48276312|NCT02521129|DEVICE|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
48276313|NCT03900195|OTHER|BottlePEP|Positive expiratory device with a bottle
48276314|NCT01116050|DRUG|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
48276315|NCT01116050|DRUG|Placebo|5 tablets in opque introducer
48276316|NCT06228157|BEHAVIORAL|Routine therapy|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
48276317|NCT06228157|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48276318|NCT01577862|DRUG|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
48276319|NCT01577862|DRUG|Rifampicin|600 mg every 12 hours intravenously
48276320|NCT05803941|DRUG|AAA617|Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent clinical interventional Novartis sponsored clinical trials.
48276321|NCT03903757|OTHER|DNA methylome and total RNA sequencing|Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
48276322|NCT00759603|DRUG|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
48276323|NCT00759603|DRUG|Rituximab|Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
48276324|NCT01778244|DRUG|metformin|1000mg/day for 24 weeks
48276325|NCT02160457|OTHER|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~1. Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~2. Impairment-Focused Interpretation~3. Recommendation for interdisciplinary interventions~4. Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
48276326|NCT05529654|DEVICE|Impella 5.5 with SmartAssist|For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
48276327|NCT02670876|BEHAVIORAL|Anti-bullying intervention|"The title of each session were as follows :~1. Introduction of intervention and setting rules, building rapport~2. Understanding school bullying (The definition of school bullying and proper coping strategies)~3. Empathy of others ( Practice of understanding victims of school bullying)~4. Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~5. Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~6. Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~7. Communication skills enhancement~8. Increasing self esteem"
48276328|NCT03055026|DRUG|Rivaroxaban|Tablets
48276329|NCT03055026|DRUG|Placebo|Tablets
48276330|NCT06192576|DRUG|Olipudase alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
48276331|NCT03602092|OTHER|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
48276332|NCT02495337|OTHER|Tissue Collection|
48276333|NCT02644408|DRUG|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
48276334|NCT02644408|RADIATION|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
48276335|NCT02644408|OTHER|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
48276336|NCT00957541|DEVICE|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
48276337|NCT01443013|OTHER|Renal Transplant|urinary sample at month 3, 6 and 12
48276338|NCT04840121|DIAGNOSTIC_TEST|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.
48276339|NCT06657703|DRUG|HC022|Administered as specified in the treatment arm
48276340|NCT06657703|DRUG|Placebo|Administered as specified in the treatment arm
48276341|NCT02988856|DEVICE|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
48276342|NCT06053021|DRUG|aspirin, clopidogrel, cilostazol, and dipyridamole|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
48276343|NCT05057364|OTHER|Heart Smart Virtual Self-Management Group|The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
48276344|NCT02461017|OTHER|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
48276345|NCT02461017|OTHER|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
48276346|NCT02013544|DRUG|Placebo|
48276347|NCT02013544|DRUG|Prasterone (DHEA)|
48276348|NCT06192121|OTHER|Web Based Education|In this research, a reminder message will be sent 3 times a week along with web-based training.
48276349|NCT02976415|OTHER|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
48276350|NCT03519048|PROCEDURE|Nasofibroscopy|every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
48276351|NCT03519048|OTHER|Low Dose Chest CTscan|every year in patients with tobacco consumption history of \> 20 pack-year
48276352|NCT03519048|OTHER|injected CT-scan|the first performed 12 months after inclusion
48276353|NCT03519048|OTHER|whole body PET-CT|annual whole body PET-CT (the first at 6 months after inclusion)
48276354|NCT03519048|PROCEDURE|Lugol upper gastrointestinal endoscopy|the first performed 12 months after inclusion
48276355|NCT03519048|PROCEDURE|Biopsy|In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
48276356|NCT05664620|DIAGNOSTIC_TEST|Risk Stratification Tool|Patients will be allocated to three groups (Low,medium and high risk) by using the Risk Stratification Tool, and High risk patients will receive multidisciplinary treatment assigned to them by a physician
48276357|NCT03182439|DEVICE|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
48276358|NCT03182439|DEVICE|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
47927942|NCT01855373|OTHER|Placebo|Placebo: 2 capsules twice daily on an empty stomach
48276359|NCT03182439|DEVICE|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
48276360|NCT03182439|DEVICE|Apple Watch|Apple Watch Heart Rate Monitoring Device
48276361|NCT04178655|DRUG|Tranexamic acid injection|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
48276362|NCT04178655|DRUG|PLACEBO|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
48276363|NCT04378777|PROCEDURE|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study \[GWAS\]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
48276364|NCT04378777|PROCEDURE|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
48276365|NCT00260221|BEHAVIORAL|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
48276366|NCT00227058|DRUG|Orotic acid and Glutathione-(Nutritional Supplements)|
47927943|NCT02872220|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
47927944|NCT02872220|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
48098034|NCT01700569|DRUG|folinic acid at pharmacological dose is the escalated drug|
48276367|NCT01322815|DRUG|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
48276368|NCT01322815|DRUG|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
48276369|NCT06227832|DRUG|KP-001|KP-001
48276370|NCT06227832|DRUG|Metformin|oral dose of 850 mg Metformin
48276371|NCT06227832|DRUG|Midazolam|oral dose of 2 mg Midazolam
48276372|NCT06227832|DRUG|Clarithromycin|oral doses of 1000 mg Clarithromycin
48276373|NCT03879291|OTHER|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
48276374|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
48276375|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
48276376|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
48276377|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
48276378|NCT02639351|BIOLOGICAL|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
48276379|NCT03751293|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg
48276380|NCT06656156|OTHER|Proprioceptive neuromuscular facilitation technique|"Experimental group was given proprioceptive neuromuscular facilitation technique (PNF) along with conventional treatment.~PNF will be applied on iliopsoas and hamstring muscles, 3 repetitions/session with a break of 2 minutes/repetition (10 second isometric Contraction then 10 second stretch)~Treatment contains total 12 sessions (3 times/week for 4 consecutive weeks)"
48276381|NCT06656156|OTHER|Conventional treatment|"Conventional treatment contains tens and hotpack.~Tens Will be applied for 20 minutes and hotpack for 10 minutes~Total 12 sessions (3 times/week for 4 consecutive weeks)"
48276382|NCT02510807|OTHER|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
48276383|NCT05334329|BIOLOGICAL|Antineoplastic Immune Cell|Given COH06 IV
48276384|NCT05334329|BIOLOGICAL|Atezolizumab|Given IV
48276385|NCT05334329|PROCEDURE|Biospecimen Collection|Correlative studies
48276386|NCT05334329|DRUG|Cyclophosphamide|Given IV
48276387|NCT05334329|DRUG|Fludarabine|Given IV
48276388|NCT00790517|BEHAVIORAL|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
48276389|NCT02052102|RADIATION|Radiation therapy|
48276390|NCT01892488|DRUG|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
48276391|NCT01892488|DRUG|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
47927945|NCT02872220|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
48276392|NCT00341328|BIOLOGICAL|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
48276393|NCT05330026|COMBINATION_PRODUCT|Diaphragm´s study during yoga breathing|Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
48276394|NCT02341612|OTHER|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
48276395|NCT02341612|OTHER|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
48276396|NCT02341612|OTHER|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
48276397|NCT02341612|OTHER|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
48276398|NCT02341612|OTHER|passive recovery|The control group was exposed to treatment after the EIMD protocol.
48276399|NCT01964248|DRUG|Placebo|Placebo cream applied 2 hours before blood sample
48276400|NCT01964248|DRUG|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
48276401|NCT00024687|DRUG|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
48276402|NCT04233125|PROCEDURE|Core Decompression|Core Decompression
48276403|NCT04233125|PROCEDURE|PMMA augmentation|Polymethylmethacrylate (PMMA) augmentation
48444067|NCT02110953|COMBINATION_PRODUCT|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
48444068|NCT02110953|PROCEDURE|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
48276404|NCT02537678|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
48276405|NCT02537678|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
48276406|NCT00743795|DRUG|placebo|oral BID
48276407|NCT00743795|DRUG|GS-9190|40 mg oral BID
48276408|NCT00743795|DRUG|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
48276409|NCT00743795|DRUG|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
48276410|NCT01870544|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
48276411|NCT01870544|DIETARY_SUPPLEMENT|Placebo|placebo will be administered daily for 44 days
48276412|NCT00078130|DRUG|Buprenorphine/naloxone|
48276413|NCT00138216|DRUG|irinotecan hydrochloride|
48276414|NCT00138216|DRUG|temozolomide|
48276415|NCT00138216|DRUG|vincristine sulfate|
48276416|NCT06543771|DIAGNOSTIC_TEST|Safety Test ABO and ABTest Card®|Pre transfusional control with the Safety Test ABO device (reference device) and the ABTest Card® device (comparator).
48276417|NCT00507247|DRUG|Daptomycin|6mg/kg/day IV for at least 10 days.
48276418|NCT05523934|DRUG|Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.
48276419|NCT04196114|DEVICE|STIMO-2 device implantation|Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
48276420|NCT02185391|PROCEDURE|Audience Response System|patients use during oral presentations an audience response system
48276421|NCT02185391|BEHAVIORAL|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
48276422|NCT05484193|DRUG|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
48276423|NCT05484193|DRUG|Progesterone|vaginal progesterone for luteal phase support
48276424|NCT00908284|BEHAVIORAL|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
48276425|NCT00908284|BEHAVIORAL|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
48276426|NCT05690321|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
48276427|NCT05690321|DRUG|Placebo|Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
48276428|NCT01083108|OTHER|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
48276429|NCT01083108|OTHER|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
48276430|NCT03114449|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
48276431|NCT03114449|DEVICE|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
48098035|NCT01700569|RADIATION|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
48276432|NCT06227130|BEHAVIORAL|MindYou|A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
48276433|NCT01644877|DRUG|DAS181 dry powder, formulation F02|
48276434|NCT01644877|DRUG|Lactose Placebo|
48276435|NCT02698189|DRUG|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
48276436|NCT05704985|BIOLOGICAL|DK210 (EGFR)|Solution for SC administration
48276437|NCT05704985|RADIATION|Radiation therapy|Short regimen radiation therapy (10 fractions or less)
48276438|NCT05704985|BIOLOGICAL|Immune checkpoint blockers|IV administration of approved PD1 blocker
48276439|NCT05704985|DRUG|Chemotherapy|Single agent or combination of not more than two
48276440|NCT04811092|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
48276441|NCT04811092|OTHER|Placebo|Placebo
48276442|NCT05011591|OTHER|Swimming economy|Detailed in arm's section
48276443|NCT03705390|DRUG|ILB|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
48276444|NCT06199466|DRUG|Gemcitabine|Given by IV
48276445|NCT06199466|DRUG|Nab-paclitaxel|Given by IV
48276446|NCT06199466|DRUG|YL-13027|Given by PO
48276447|NCT02586480|DEVICE|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
48276448|NCT06166836|DRUG|D1553|D1553 orally taken，600mg twice a day
48276449|NCT06166836|DRUG|IN10018（Ifebemtinib）|IN10018 orally taken once daily at approximately the same time each day
48276450|NCT04222829|PROCEDURE|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
48276451|NCT04963829|BIOLOGICAL|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
48276452|NCT04963829|BIOLOGICAL|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
48276453|NCT04963829|BIOLOGICAL|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
48276454|NCT04957563|BEHAVIORAL|olfactory rehabilitation|treatment for improve olfactory function
48276455|NCT05823142|BEHAVIORAL|CB Sleep|The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (\<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
48276456|NCT02780791|OTHER|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
48276457|NCT02780791|OTHER|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
48276458|NCT01800721|BEHAVIORAL|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
48276459|NCT01800721|BEHAVIORAL|SNAP Control|Behavioral: SNAP control 7 group sessions
48276460|NCT04012749|BEHAVIORAL|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
48276461|NCT04012749|BEHAVIORAL|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
48276462|NCT04012749|BEHAVIORAL|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
48276463|NCT05354960|OTHER|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
48276464|NCT02912663|DRUG|Verapamil and Magnesium Sulfate|Single dose strategy will be used
48276465|NCT02912663|OTHER|Placebo|Single matching dosing strategy will be used
48276466|NCT02649101|DRUG|Thalidomide|Thalidomide tablet 100mg qn po.
48276467|NCT02649101|DRUG|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
48276468|NCT01935219|BEHAVIORAL|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
48276469|NCT01935219|BEHAVIORAL|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
48276470|NCT01935219|BEHAVIORAL|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
48276471|NCT00129025|PROCEDURE|Hypofractionated radiotherapy|
48276472|NCT06488677|BEHAVIORAL|Lifestyle changes (diet and physical activity)|Nurse-led telephone personalized dietary and PA advice
48276473|NCT05564338|DRUG|Sitravatinib|Administered orally
48276474|NCT05564338|DRUG|Tislelizumab|Administered intravenously
48276475|NCT05564338|DRUG|sitravatinib-matching placebo|administered orally
48276476|NCT05564338|DRUG|tislelizumab-matching placebo|administered intravenously
48276477|NCT04469569|BEHAVIORAL|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
48276478|NCT00352703|DRUG|Kepivance (Palifermin)|
48276479|NCT04934826|DIETARY_SUPPLEMENT|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
48276480|NCT04934826|DIETARY_SUPPLEMENT|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
48276481|NCT04233489|BEHAVIORAL|Family Nurture Intervention (FNI)|"FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU)."
48276482|NCT01805648|DRUG|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
48276483|NCT01838135|DEVICE|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
48276484|NCT06095830|DIAGNOSTIC_TEST|Complete blood count|Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome
48276485|NCT00634231|BIOLOGICAL|AdV-tk|
48276486|NCT00634231|DRUG|valacyclovir|
48276487|NCT00634231|RADIATION|Radiation|
48276488|NCT05241249|DRUG|Bethanechol|Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.
48276489|NCT05241249|DRUG|Gemcitabine|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2
48276490|NCT05241249|DRUG|nab-paclitaxel|Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
48276491|NCT06028620|BEHAVIORAL|Trauma Focused-Cognitive Behavior Therapy|TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
48276492|NCT05052489|OTHER|registy|Children with diarrhea were registered in the hospital. Baseline information of the children was recorded and followed up to observe the distribution of disease types, clinical manifestations, treatment plans and clinical outcomes
48276493|NCT00422279|DEVICE|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
48276494|NCT04392193|RADIATION|Proton Particle Therapy|Proton therapy will be delivered in a single fraction using the Probeat-V system
48276495|NCT02714179|DRUG|Paracetamol was given intravenously in both group at different times|
48276496|NCT00624234|BEHAVIORAL|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
48276497|NCT00624234|BEHAVIORAL|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
48276498|NCT05680558|DRUG|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
48276499|NCT05680558|DEVICE|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
48276500|NCT00096161|DRUG|Cyclosporine|Given PO
48276501|NCT00096161|DRUG|Mycophenolate Mofetil|Given PO
48276502|NCT00096161|DRUG|Pentostatin|Given IV
48276503|NCT00096161|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
48276504|NCT03388814|DRUG|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
48276505|NCT03388814|DRUG|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
48276506|NCT01974817|BIOLOGICAL|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
48276507|NCT02151825|DIETARY_SUPPLEMENT|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
48276508|NCT02151825|OTHER|Placebo|3 capsules of Maltodextrin per day
47927946|NCT02872220|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
47927947|NCT00000375|DRUG|Nortriptyline-lithium (NOR-Li)|
48276509|NCT00662961|PROCEDURE|Periosteum|Periosteum fixation
48276510|NCT00662961|PROCEDURE|Bone|Bone tunnel fixation
48444069|NCT02139839|OTHER|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
48276511|NCT03939013|DIAGNOSTIC_TEST|Xpert HCV VL|Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
48276512|NCT04730895|DRUG|Oral 13 cis retinoic acid|Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
48276513|NCT04730895|DRUG|Aerosolized 13 cis retinoic acid|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
48276514|NCT04730895|COMBINATION_PRODUCT|13 cis retinoic acid doses orally in combination with spike protein based vaccine|Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
48276515|NCT04730895|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
48276516|NCT04730895|BIOLOGICAL|Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
48276517|NCT00220363|DRUG|SPM 907|
48098036|NCT00515086|DRUG|Everolimus|Tablets taken once a day with a full glass of water.
48276518|NCT04034017|OTHER|no intervention|descriptive study, no intervention
48276519|NCT03304522|DRUG|VX-150|Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
48276520|NCT03304522|DRUG|Placebo|Participants received placebo matched to VX-150 for 6 weeks.
48276521|NCT04029376|DRUG|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
48276522|NCT04987281|PROCEDURE|Computed Tomography|Undergo CT
48276523|NCT04987281|DRUG|Indocyanine Green Solution|Given via injection
48276524|NCT04987281|DEVICE|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
48276525|NCT02850848|DRUG|Entigin Film Coated Tablet 0.5mg|
48276526|NCT02850848|DRUG|(Baraclude 0.5mg Tablets|
48276527|NCT03495492|DEVICE|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
48276528|NCT03495492|DIETARY_SUPPLEMENT|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
48276529|NCT04360265|OTHER|No Investigational Product|No investigational product will be administered in this follow-up trial.
48276530|NCT04360265|DRUG|Adjuvant Immunosuppression (IS) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IS therapy.
48276531|NCT05490992|OTHER|Behavioral Skills Training In-person|"Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person."
48276532|NCT00645086|DRUG|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
48276533|NCT00645086|DRUG|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
48276534|NCT00927485|DRUG|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
48276535|NCT00927485|OTHER|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
48276536|NCT00927485|OTHER|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
48276537|NCT00927485|OTHER|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
47927948|NCT00000375|PROCEDURE|Bilateral electroconvulsive therapy (ECT)|
48276538|NCT00927485|OTHER|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
48276539|NCT02760290|PROCEDURE|Extraperitoneal cesarean section|
47927949|NCT00000375|DRUG|Continuation therapy|
48276540|NCT02760290|PROCEDURE|Intraperitoneal cesarean section|
48276541|NCT00002462|BIOLOGICAL|bleomycin sulfate|
48276542|NCT00002462|DRUG|doxorubicin hydrochloride|
48276543|NCT00002462|DRUG|mechlorethamine hydrochloride|
48276544|NCT00002462|DRUG|prednisone|
48276545|NCT00002462|DRUG|procarbazine hydrochloride|
48276546|NCT00002462|DRUG|vinblastine sulfate|
48276547|NCT00002462|DRUG|vincristine sulfate|
48276548|NCT00002462|RADIATION|low-LET cobalt-60 gamma ray therapy|
48276549|NCT00002462|RADIATION|low-LET photon therapy|
48276550|NCT00002462|RADIATION|radiation therapy|
48276551|NCT06202248|DEVICE|Experimental: DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
48276552|NCT04022746|PROCEDURE|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
48276553|NCT04022746|PROCEDURE|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
48276554|NCT05421000|PROCEDURE|WALANT|Wide awake local anesthesia without tourniquet for distal radius fracture surgery
48276555|NCT05421000|PROCEDURE|Locoregional anesthesia and tourniquet|Locoregional anesthesia and tourniquet for distal radius fracture surgery
48276556|NCT05519215|DEVICE|ECHELON 3000 Stapler|There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
48276557|NCT04680650|DRUG|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
48276558|NCT04680650|DRUG|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
48276559|NCT03569267|DRUG|OLX10010|A cell penetrating asymmetric siRNA (cp asiRNA)
48276560|NCT03569267|DRUG|Placebo|Placebo
48276561|NCT03394638|OTHER|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
48276562|NCT03394638|OTHER|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
48276563|NCT03394638|PROCEDURE|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
48276564|NCT02016287|OTHER|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
48276565|NCT04995094|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
48276566|NCT04995094|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein. Pembrolizumab will be administered at 200 mg IV Q3W for 9 weeks.
48276567|NCT02243501|BEHAVIORAL|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
48276570|NCT00185861|DRUG|Arsenic Trioxide|
48276571|NCT00185861|PROCEDURE|Stereotactic radiosurgery|
48276572|NCT06333340|DRUG|Oxytocin|Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.
48276573|NCT06333340|DRUG|Carbetocin|Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.
48276574|NCT06656338|OTHER|Higher HEI-2020 diet followed by lower HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
48276575|NCT06656338|OTHER|Lower HEI-2020 diet followed by higher HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
48276576|NCT00006120|DRUG|docetaxel|
48276577|NCT00006120|DRUG|paclitaxel|
48276578|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
48276579|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
48276580|NCT00333216|OTHER|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
48276581|NCT01684462|BIOLOGICAL|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4\~8h, commencing within 12 hours of stroke onset
48276582|NCT01684462|DRUG|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
48276583|NCT05589818|DRUG|Pembrolizumab|Patients will be treated with the standard dose of pembrolizumab for the first 12 weeks of the study. After week 12 assessments, patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV. Patients will be offered this schedule, also an FDA-approved option, at the discretion of the treating physician, based on tolerability of the q3week regimen and clinician assessment of need for closer follow up intervals. Pembrolizumab will be continued until disease progression, unacceptable toxicity, withdrawal of consent, or death.
48276584|NCT04552470|DRUG|Placebo|3 matching placebo tablets taken twice a day (BID)
48276585|NCT04552470|DRUG|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
48276586|NCT03422484|OTHER|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
48276587|NCT03572088|DRUG|Terlipressin|Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
48276588|NCT03572088|DRUG|normal saline|Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
48098037|NCT00515086|PROCEDURE|Surgery|Salvage surgical resection
48276589|NCT00435552|PROCEDURE|Ease-It Spray|
48276590|NCT03993717|BIOLOGICAL|SHINGRIX|A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
48098038|NCT04920890|DEVICE|Radiofrequency therapy with manual therapy|Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
48098039|NCT04920890|DEVICE|Placebo without radiofrequency.|The device will be used without turning on the patient, thus administering a placebo treatment.
48098040|NCT04920890|OTHER|Manual therapy.|Common manual therapy administered for said pathology by traditional physiotherapy.
48098041|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: ropivacaine|The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
48276591|NCT00976755|DRUG|everolimus|"Everolimus:~10mg daily"
48276592|NCT05548686|OTHER|adapted physical activity|3 sessions of adapted physical activity per week during 12 weeks for each patient
48276593|NCT04739839|OTHER|survey questionnaire|Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
48276594|NCT05218811|DEVICE|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
48276595|NCT02901171|BEHAVIORAL|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
48276596|NCT02901171|BEHAVIORAL|ACT group treatment|
48276597|NCT02901171|BEHAVIORAL|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
48276598|NCT05267821|DRUG|Anakinra|See information in arm/group descriptions
48276599|NCT05267821|DRUG|Placebo|See information in arm/group descriptions
48276600|NCT00365755|DRUG|carboplatin|
48276601|NCT00365755|DRUG|cisplatin|
48276602|NCT00365755|DRUG|cyclophosphamide|
48276603|NCT00365755|DRUG|etoposide|
48276604|NCT00365755|DRUG|melphalan|
48276605|NCT00365755|DRUG|vincristine sulfate|
48276606|NCT00365755|PROCEDURE|autologous bone marrow transplantation|
48276607|NCT00365755|PROCEDURE|conventional surgery|
48276608|NCT00104871|DRUG|Bortezomib|Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
48276609|NCT00061711|DRUG|Hormone Replacement Therapy|
48276610|NCT00061711|DRUG|Cimicifuga racemosa (Black Cohosh)|
48276611|NCT00061711|DRUG|Multibotanical phytoestrogen formula|
48276612|NCT05192603|DIETARY_SUPPLEMENT|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
48276613|NCT04097548|BEHAVIORAL|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
48276614|NCT03763786|DRUG|Cetrorelix Acetate|Used a standard
48276615|NCT02304003|OTHER|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
48276616|NCT02304003|OTHER|Standard Care|Standard follow up in primary care.
48276617|NCT05825248|OTHER|Fine and gross motor treatment only|occupational therapy intervention involving general fine and gross motor activities
48276618|NCT05825248|OTHER|Reflex integration + fine and gross motor treatment|occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
48276619|NCT03124043|OTHER|Livongo for Diabetes program|See description in arm/group description.
48276620|NCT06318884|DRUG|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
48276621|NCT03006653|BEHAVIORAL|Assessment only|Mobile ecological assessment only.
48276622|NCT04774003|DRUG|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
48276623|NCT04774003|DRUG|Placebo|Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
48276624|NCT04774003|DRUG|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
48276625|NCT04684199|DIETARY_SUPPLEMENT|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
48276626|NCT04684199|DIETARY_SUPPLEMENT|Placebo|
48276627|NCT02344810|DRUG|c-Met inhibitor AMG 337|Given PO
47927950|NCT00000375|BEHAVIORAL|Continuation ECT|
48276628|NCT02344810|OTHER|placebo|Given PO
48276629|NCT02344810|DRUG|oxaliplatin|Given IV
48276630|NCT02344810|DRUG|leucovorin calcium|Given IV
48276631|NCT02344810|DRUG|fluorouracil|Given IV
48276632|NCT02344810|OTHER|pharmacological study|Correlative studies
48276633|NCT02344810|OTHER|laboratory biomarker analysis|Correlative studies
48276634|NCT04267640|BIOLOGICAL|AMG0001|AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly
48276635|NCT04267640|BIOLOGICAL|Placebo|Matching placebo
48276636|NCT02314806|DRUG|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
48276637|NCT02314806|DRUG|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
48276638|NCT02314806|DRUG|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
48276639|NCT05972512|OTHER|Placebo|Mode of usage: Two times a day Route of administration: Oral
48276640|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardized biotin|Mode of usage: Two times a day Route of administration: Oral
48276641|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardised biotin with silica|Mode of usage: Two times a day Route of administration: Oral
48276642|NCT04159090|DIAGNOSTIC_TEST|F18-PSMA|Patients with moderate or high risk of prostate cancer
48276643|NCT03561233|DRUG|Omeprazole 20mg|omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
48276644|NCT03704337|DIETARY_SUPPLEMENT|Commercially Available Food Bar|Active
48276645|NCT03704337|DIETARY_SUPPLEMENT|Placebo|Placebo
48276646|NCT05736263|BEHAVIORAL|Moderate intensity exercise|moderate intensity aerobic exercise trial
48276647|NCT05736263|BEHAVIORAL|High intensity interval exercise|High intensity interval exercise trial
48276648|NCT05736263|BEHAVIORAL|Combined exercise|Combined aerobic and resistance exercise trial
48276649|NCT05736263|BEHAVIORAL|Resistance exercise|Resistance exercise trial
48276650|NCT01597947|DRUG|ACHN-975|Intravenous single dose
48276651|NCT01597947|DRUG|placebo|Intravenous single dose
48276652|NCT02612909|BIOLOGICAL|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
48276653|NCT02612909|BIOLOGICAL|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
48276654|NCT01284881|DEVICE|MRA|daily wear overnight
48276655|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
48276656|NCT05877144|OTHER|Medical Device Usage and Evaluation|Receive LiSWT
48276657|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
48276658|NCT05877144|OTHER|Survey Administration|Ancillary studies
48276659|NCT05877144|PROCEDURE|Nerve-Sparing Prostatectomy|Undergo nerve-sparing prostatectomy per standard of care
48276660|NCT05877144|PROCEDURE|Sham Intervention|Receive sham LiSWT
48276661|NCT05877144|PROCEDURE|Duplex Ultrasound|Undergo DDUS
48276662|NCT05877144|OTHER|Survey Administration|Ancillary studies
48276663|NCT04321161|DRUG|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
48276664|NCT04144621|PROCEDURE|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
48276665|NCT04733820|DRUG|Adjuvant chemotherapy|Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
48276666|NCT05532397|DRUG|QPOP category 1|combination regimens with published data in the setting of gliomas
48276667|NCT05532397|DRUG|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
48276668|NCT00499109|DRUG|Docetaxel|"GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days"
48276669|NCT00499109|DRUG|Vinorelbine|DV Group: 35 mg/m\^2 on days 1 and 15
48276670|NCT00499109|DRUG|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
48276671|NCT00499109|DRUG|Gemcitabine|"GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
48276672|NCT06343090|DRUG|CD19 CAR T-cell|Murine-derived CD19 CAR T cells
48276673|NCT06343090|DRUG|CD22 CAR T cells|humanized CD22 CAR T cells
48276674|NCT06343090|PROCEDURE|hematopoietic stem-cell transplantation|allo-HSCT
48276675|NCT00648401|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
48276676|NCT00648401|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
48276677|NCT05806242|OTHER|Italian Validation of the Italian Elderly Mobility Scale (EMS-I)|Two physiotherapists independently evaluate the same enrolled patient with the Italian Elderly Mobility Scale (EMS-I) and Barthel Index
47927951|NCT00043329|DRUG|Actimmune Registry|as administered by physician
48276678|NCT05152186|DRUG|Topical Solution|Topical administration
48276679|NCT05152186|DRUG|Topical Foam|Topical administration
48276680|NCT05152186|OTHER|Topical|Topical administration
48276681|NCT03064464|OTHER|None Intervention|It is observational study, no interventios to any of the three study arms
48276682|NCT02331576|DRUG|rocaine|
48276683|NCT02331576|DRUG|Fentanyl|
48276684|NCT00175981|DRUG|sildenafil, fluvoxamine|
48276685|NCT01661322|DRUG|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
48276686|NCT00125047|BIOLOGICAL|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
48276687|NCT00125047|BIOLOGICAL|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
48444070|NCT02139839|DRUG|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
48444071|NCT03183986|DEVICE|Phototherapy|Phototherapy for 24 hours.
48444072|NCT05269901|GENETIC|SLC7A11, GPX4, P53|Obtained patients or healthy controls peripheral blood , used Western blot and Rt-qPCR to investigate the possible difference between two groups
48444073|NCT05586490|DEVICE|Multifunctional RehabilitationDevice (MRD)|Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
48276688|NCT03430310|OTHER|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
48276689|NCT03430310|OTHER|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
48276690|NCT00667706|PROCEDURE|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
48276691|NCT00667706|PROCEDURE|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of \<50, and \>50, respectively.
48276692|NCT03291314|DRUG|Axitinib|1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].
48276693|NCT03291314|DRUG|Avelumab|2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
48276694|NCT04917783|BEHAVIORAL|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
48276695|NCT04917783|BEHAVIORAL|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
48276696|NCT00914693|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
48276697|NCT04378426|DRUG|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
48276698|NCT04378426|DRUG|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
48276699|NCT04378426|DRUG|Nitrogen|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
48276700|NCT04378426|DRUG|Oxygen|inhaled gas
48276701|NCT04378426|DRUG|Saline|Placebo infusion
48276702|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
48276703|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
48276704|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
48276705|NCT00844493|BIOLOGICAL|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
48276706|NCT04256928|PROCEDURE|Preoperative electrical clipping|Body hair in the operative field will be clipped with an electrical clipper by hospital personnel during preparation to planned surgery.
48276707|NCT03420976|DIETARY_SUPPLEMENT|Novel Supplement Based Therapy|"Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term"
48276708|NCT00470496|DRUG|HPPH|Given IV
48276709|NCT00470496|DRUG|photodynamic therapy|Undergo laser light exposure
48276710|NCT00470496|PROCEDURE|conventional surgery|Undergo surgery
48276711|NCT02601144|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
48276712|NCT03677193|BEHAVIORAL|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min \* 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
48276713|NCT04268888|DRUG|Nivolumab and TACE/TAE|Immunotherapy and TACE/TAE
47927952|NCT04272112|COMBINATION_PRODUCT|IPS e.max CAD, Ivoclar Vivadent|Type: monolithic lithium-disilicate glass ceramic
47927953|NCT04272112|COMBINATION_PRODUCT|BruxZir, Glidewell|Type: high translucent zirconia
48276714|NCT04268888|PROCEDURE|TACE/TAE|TACE/TAE (as per local practice)
48276715|NCT04203914|DRUG|Empagliflozin Tablets|Add-on 25mg once daily
48276716|NCT04275427|DEVICE|LA-400 laser acupuncture|low level laser
48276717|NCT02547623|DRUG|Dexamethasone|depot intracameral
48276718|NCT02547623|DRUG|Prednisolone|Prednisolone eye drops 1%
48276719|NCT05807308|BEHAVIORAL|Technology-based cognitive and artistic therapeutic activities|Therapeutic and artistic activities within the program (drawing, mandala, etc.). The program will be implemented in 6 sessions in two weeks. At the beginning and end of the program, children's anxiety and spiritual well-being levels will be evaluated.
48276720|NCT06079216|BEHAVIORAL|Volunteer Led Making Connections Thru Music|Volunteer led Group music therapy-based intervention
48276721|NCT06079216|BEHAVIORAL|Staff Led Making Connections Thru Music|Staff led Group music therapy-based intervention
48276722|NCT06656403|DRUG|0.1% sodium hyaluronate|After baseline measurement, 0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
48276723|NCT01725139|DRUG|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
48276724|NCT01725139|DRUG|Placebo|Matching placebo will be available
48276725|NCT00080847|BIOLOGICAL|oblimersen sodium|Given IV
48276726|NCT00080847|BIOLOGICAL|rituximab|Given IV
48276727|NCT00080847|DRUG|cyclophosphamide|Given IV
48276728|NCT00080847|DRUG|doxorubicin hydrochloride|Given IV
48276729|NCT00080847|DRUG|vincristine sulfate|Given IV
48276730|NCT00080847|DRUG|prednisone|Given orally
48276731|NCT00080847|OTHER|laboratory biomarker analysis|Correlative studies
48276732|NCT04851184|DEVICE|Gaze stabilization Exercises using Virtual Reality Device|Participants will utilize a wireless virtual reality headset to perform their gaze stabilization exercises to better control the background and visual field as well as collect data related to speed, excursion, and duration of head movements.
48276733|NCT04851184|BEHAVIORAL|Gaze stabilization non-instrumented|Participants will perform gaze stabilization exercises in a non-instrumented manner. Subjects are instructed to focus on a letter on a piece of paper held at arm's length. They are instructed to move their head back and forth as quickly as they can while keeping the letter in focus. The total duration of the exercise (from 10 - 240 seconds) and background complexity (simple to complex moving) are increased gradually according to patient symptoms.
48276734|NCT06657040|OTHER|MUSIC|The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first). MusicCare has been widely tested in several countries and there are a large number of publications in anesthesiology, ICU, cardiology and neurology, among other specialties, demonstrating its safety and efficacy69,70. Patients who were hospitalized for more than 48 hours, that is, who received a minimum of 4 intervention periods, will be considered as patients with effective intervention. Patients with less time will be evaluated in the form of intention to treat.
48276735|NCT00962715|BIOLOGICAL|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
48276736|NCT00962715|DRUG|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
48276737|NCT00962715|DRUG|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
48276738|NCT05617170|OTHER|Rehabilitation|"50 case of acute cerebrovascular stroke patients will subject to implanted early rehabilitation programme based on telemedicine if avilable .~50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques ."
48276739|NCT00978302|DRUG|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
48276740|NCT00978302|DRUG|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
48276741|NCT00978302|DRUG|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
48276742|NCT00978302|DRUG|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
48276743|NCT00978302|DRUG|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
48276744|NCT00978302|DRUG|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
47927954|NCT04272112|COMBINATION_PRODUCT|BruxZir*, Glidewell|Type: high translucent zirconia with a mini-veneer of porcelain
48276745|NCT00978302|DRUG|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
48276746|NCT03381443|OTHER|different assessments|coded survey about NTS and assessment
48276747|NCT05621356|OTHER|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
48276748|NCT01475734|BIOLOGICAL|albiglutide|subcutaneous injection
48276749|NCT01475734|BIOLOGICAL|placebo|subcutaneous injection
48276750|NCT05759052|BEHAVIORAL|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
48276751|NCT00362973|OTHER|laboratory biomarker analysis|
48276752|NCT00362973|PROCEDURE|needle biopsy|
48276753|NCT00362973|PROCEDURE|positron emission tomography|
48276754|NCT00362973|PROCEDURE|radionuclide imaging|
48276755|NCT00362973|RADIATION|fludeoxyglucose F 18|
48276756|NCT00289640|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
48276757|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
48276758|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
48276759|NCT00926926|DRUG|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
48276760|NCT00926926|DRUG|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
48276761|NCT05655117|OTHER|AI based eye screening|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
48276762|NCT05811065|DEVICE|OPTIVF dosage|Opt-IVF dosage
48276763|NCT05811065|DEVICE|traditional drug treament|Traditional drug treatment
48276764|NCT02498821|DEVICE|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
48276765|NCT02498821|DEVICE|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
48276766|NCT02498821|PROCEDURE|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
48276767|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily"
48276768|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
48276769|NCT00902837|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
48098042|NCT05824338|DRUG|Spinal anesthesia for lumbar surgery: bupivacaine|The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
48098043|NCT05824338|DRUG|General anesthesia for lumbar surgery|Patient will be intubated and ventilated under general anesthesia.
48276770|NCT00902837|DRUG|oxycodone prolonged release tablet|
48276771|NCT00902837|DRUG|oxycodone naloxone tablet|
48276772|NCT01203488|DRUG|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
48276773|NCT01203488|OTHER|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
48276774|NCT06349629|DEVICE|3D printed WE43 magnesium alloy|This 3D printed WE43 magnesium alloy has porous structure and suitable mechanical strength, can be stable in the bone support, and gradually degrade to promote bone healing.
48098044|NCT06433037|DIETARY_SUPPLEMENT|Chicory inulin|Chicory inulin (12g/day) divided over two dosages (6g per dose)
48098045|NCT06433037|DIETARY_SUPPLEMENT|Resistant dextrin|Resistant dextrin (14g/day) divided over two dosages (7g per dose)
48098046|NCT06433037|DIETARY_SUPPLEMENT|Seaweed polysaccharide|Seaweed polysaccharide (1g/day) divided over two dosages (0.5g per dose). Additionally contains 7g/day of placebo as a volumetric and isocaloric filler.
48098047|NCT06433037|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (7g/day) will be provided in two divided doses (3.5g per dose)
48098048|NCT04157842|PROCEDURE|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
48098049|NCT04157842|PROCEDURE|total hip replacement with no osteotomy|just total hip replacement
48276775|NCT03593915|COMBINATION_PRODUCT|Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine|"PHASE 1b:~Decitabine administered as an intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion (hybrid dosing) Once the maximum dose of alvocidib administered via hybrid dosing has been determined, 2 cohorts of patients will receive azacitidine followed by alvocidib administered as an IV infusion. Azacitidine may be administered as either an IV bolus over 10 to 40 minutes or as a subcutaneous (SC) injection on either a 7 day or 5-2 2 schedule. Regardless of which azacitidine schedule or route of administration is used, alvocidib will be given on Day 10 as a 30-to-60 minute IVI~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design using the RP2D of alvocidib administered as a 30-to-60 minute IV infusion determined in the Ph1b study to explore efficacy of alvocidib when administered in sequence after azacitidine."
48276776|NCT00817271|DRUG|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
48276777|NCT00817271|DRUG|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
48276778|NCT04396587|DRUG|Sufentanil|Sufentanil(0.1μg/kg) was administered before anesthesia induction.
48276779|NCT04396587|DRUG|Hydromorphone|Hydromorphone(20μg/kg)was administered before anesthesia induction.
48276780|NCT04396587|DRUG|Oxycodone|Oxycodone(60μg/kg) was administered before anesthesia induction.
48276781|NCT04396587|DRUG|normal Saline|normal saline 10ml
48276782|NCT03058744|DRUG|IDP-118 Lotion|Lotion
48276783|NCT03058744|DRUG|HP Monad Lotion|Lotion
48276784|NCT03058744|DRUG|Ultravate Cream|Cream
48276785|NCT03058744|DRUG|Tazorac Cream|Cream
48276786|NCT05037929|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W.
48276787|NCT05037929|DRUG|Placebo|Participants will receive SC placebo Q2W.
48276788|NCT03106532|DRUG|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
48276789|NCT03106532|DRUG|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
48276790|NCT03106532|DRUG|Placebo ophthalmic solution|3 drops daily, 28 days
48276791|NCT05738915|DIAGNOSTIC_TEST|CRP/Albumin ratio in IBD|Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.
48276792|NCT00749203|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
48276793|NCT00749203|DRUG|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
48276794|NCT00928330|DRUG|GDC-0941|Oral repeating dose
48276795|NCT00928330|DRUG|Trastuzumab|Intravenous repeating dose
48276796|NCT00928330|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
48276797|NCT02197325|DEVICE|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
48276798|NCT04177303|DRUG|Metformin|Participants will be randomized to metformin 2000 mg
48276799|NCT04177303|DRUG|Placebo|Participants will be randomized to placebo
48276800|NCT00518349|DEVICE|Passive bending function|Colonoscope with a passive bending function
48276801|NCT00518349|DEVICE|No passive bending function|Examination using standard colonoscope without passive bending function
48276802|NCT01446211|DRUG|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
48276803|NCT01446211|DRUG|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
48276804|NCT00778830|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
48276805|NCT00778830|DRUG|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
48276806|NCT00778830|DRUG|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
48276807|NCT03094130|OTHER|News items with spin|Interpretation of news items with spin
48276808|NCT03094130|OTHER|News items without spin|Interpretation of news items without spin
48276809|NCT03521791|DRUG|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
48276810|NCT03521791|OTHER|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
48276811|NCT00828451|BIOLOGICAL|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
48276812|NCT02102750|DRUG|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
48276813|NCT04407715|PROCEDURE|The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater|The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
48276814|NCT05564559|OTHER|multifamily group psychoeducation|The intervention involves 8 weeks of multifamily psychoeducation for families. Duration of sessions: 75 minutes on average Context: First session: psychoeducation on substance-abuse disorders; second session; effects of addiction on the family; third session; illness management; fourth session; supporting recovery; fifth session; improving stress coping skills/stress management; sixth session; developing problem-solving skills; seventh session; strengthening the family; eighth session; working with stigma Preferred approach: face-to-face, multi-family Approach: Psychoeducation
48276815|NCT06231017|DRUG|Adebrelimab + Cetuximab+ Chemotherapy|Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
48276816|NCT03890809|DRUG|BMS-986165|Oral administration
48276817|NCT05413330|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.
48276818|NCT03333473|BEHAVIORAL|PPFP Clinical and Counseling Skills|Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
48276819|NCT03333473|BEHAVIORAL|Facility-Level Leadership Management and Governance Training|The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
48276820|NCT04911387|DEVICE|Intraocular pressure measurments|Intraocular pressure measurements with iCare Home by participants (patients, volunteers) and healthcare staff as well as intraocular pressure measurements with GAT by participants different healthcare staff.
48276821|NCT04145466|BEHAVIORAL|High-fat diet|"The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
48276822|NCT04145466|BEHAVIORAL|High-carbohydrate diet|"The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
47927955|NCT05315869|PROCEDURE|Appendectomy|Surgical procedure for removal of the appendix
48276823|NCT06476808|DRUG|BMS-986463|Specified dose on specified days
48276824|NCT04525729|DRUG|Rituximab|To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
48276825|NCT04525729|DRUG|RAS 2410|To evaluate the efficacy and safety of RASi in patients with IgAN.
48276826|NCT00596544|BEHAVIORAL|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
48276827|NCT00596544|BEHAVIORAL|questionnaires|Those women who have a FSFI score \> 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
48276828|NCT06574633|BEHAVIORAL|In-person therapy|Participants will be referred to in-person therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
48276829|NCT06574633|BEHAVIORAL|Telehealth therapy|Participants will be referred to telehealth therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
48276830|NCT02707770|OTHER|Pulmonary Rehabilitation|
48276831|NCT05766722|DEVICE|DORA AI|Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
48276832|NCT00712101|DRUG|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
48276833|NCT00712101|DRUG|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
48276834|NCT04672083|DRUG|CPT31|CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
48276835|NCT04672083|DRUG|Placebo|matching placebo
48276836|NCT04290637|OTHER|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
48276837|NCT04290637|OTHER|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
48276838|NCT05269576|OTHER|Clinical practice|Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.
48276839|NCT05269576|OTHER|Clinical simulation|Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
48276840|NCT06217679|OTHER|Control Oral Glucose Tolerance Test|control oral glucose tolerance test
48276841|NCT06217679|OTHER|Mixed Exercise|exercise performed in randomized order
48276842|NCT00940706|DEVICE|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
48276843|NCT00940706|OTHER|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
48276844|NCT00940706|BEHAVIORAL|Monitoring physical activity|Activity monitoring with accelerometers
48276845|NCT00538642|DRUG|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
48276846|NCT05752448|BEHAVIORAL|POSTCare Survivorship transition process|Survivorship coaching intervention
48276847|NCT04548076|OTHER|Block group|Control group
48276848|NCT02902094|DEVICE|Drug eluting balloons|
48276849|NCT02902094|DEVICE|Non drug eluting balloons|
48276850|NCT05024006|DRUG|Remdesivir|Two intravenous loading doses, then daily infusion for 10 days
48276851|NCT05024006|DRUG|Hydroxychloroquine|Two oral loading doses, then orally twice daily for 10 days
48444074|NCT05586490|DEVICE|existing standard rehabilitation device|existing standard rehabilitation device to be used for in-home comparison testing for aim 3
47927956|NCT01328444|DRUG|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
48276852|NCT05024006|DRUG|Lopinavir / Ritonavir|Orally twice daily for 14 days
48276853|NCT05024006|DRUG|Interferon beta-1a|Daily injection for 6 days
48276854|NCT05024006|DRUG|Acalabrutinib|Orally twice daily for 10 days
48276855|NCT03590860|DRUG|LY3322207|Administered by SC injection
48276856|NCT03590860|DRUG|Placebo|Administered by SC injection
48276857|NCT01057277|DRUG|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
48276858|NCT01128985|DRUG|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
48276859|NCT01128985|DRUG|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
48276860|NCT01128985|DRUG|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
48276861|NCT01128985|DRUG|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
48276862|NCT06152887|DEVICE|Sooma Oy (tDCS), Helsinki, Finland|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
48276863|NCT06152887|DEVICE|Sooma Oy (Sham), Helsinki, Finland|For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
48276864|NCT03619915|DIAGNOSTIC_TEST|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
48276865|NCT03619915|OTHER|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
48276866|NCT05090956|OTHER|mri|
48276867|NCT01739426|DEVICE|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
48276868|NCT04751721|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
48276869|NCT00419796|DRUG|Lumiracoxib|
48276870|NCT06399315|DRUG|ZE46-0134 or placebo|The patients will receive ZE46-0134 or placebo
48276871|NCT06399315|DRUG|Rabeprazole, 20mg oral|Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered
48276872|NCT00768222|DEVICE|silk suture|skin closure
48276873|NCT00768222|DEVICE|VICRYL* Plus suture|skin closure
48276874|NCT04644718|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
48276875|NCT03228368|DRUG|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
48276876|NCT04078750|BEHAVIORAL|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
48276877|NCT05891171|DRUG|AB598|Administered as specified in the treatment arm
48276878|NCT05891171|DRUG|Zimberelimab|Administered as specified in the treatment arm
48276879|NCT05891171|DRUG|Carboplatin|Administered as specified in the treatment arm
48276880|NCT05891171|DRUG|Pemetrexed|Administered as specified in the treatment arm
48276881|NCT05891171|DRUG|Fluorouracil|Administered as specified in the treatment arm
48276882|NCT05891171|DRUG|Leucovorin|Administered as specified in the treatment arm
48276883|NCT05891171|DRUG|Oxaliplatin|Administered as specified in the treatment arm
48276884|NCT02229201|DRUG|Propofol|4-6 mg/kg/h during anaesthesia
48276885|NCT02229201|DRUG|Sevoflurane|0.8 MAC
48276886|NCT03389243|DRUG|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
48276887|NCT03389243|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
48444075|NCT02478047|DRUG|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
48276888|NCT03389243|DRUG|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
48276889|NCT03060421|DEVICE|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
48276890|NCT03386708|PROCEDURE|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
48276891|NCT03386708|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2 \* 10\^7 cells (2ml)
48276892|NCT02065089|OTHER|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
48276893|NCT05435521|BEHAVIORAL|Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)|"Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation."
47927957|NCT01328444|DRUG|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
48276894|NCT05435521|OTHER|Body composition|Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device
48276895|NCT05435521|OTHER|Musculoskeletal and visceral Ultrasound|Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
48276896|NCT05641649|DRUG|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
48276897|NCT03339141|PROCEDURE|Intubation position|The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
48276898|NCT00764725|DRUG|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
48276899|NCT00764725|BIOLOGICAL|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
48276900|NCT06326944|PROCEDURE|Ultrasound- guided Fascia Transversalis plane block|Ultrasound probe will be placed in a transverse orientation above the iliac crest; and the external oblique, internal oblique (IO), and transversus abdominis TA muscles will be identified and traced posteriorly until first the TA muscle and then the IO muscle tapered into their common aponeurosis, adjacent to the quadratus lumborum muscle. The tip of a 22-gauge 80-mm block needle will be positioned just deep to the TA muscle and its aponeurosis at the point where the TA is tapered off. 0.4 ml/kg bupivacaine 0.25% will be injected into the plane between the TA and underlying transversalis fascia
48276901|NCT06326944|PROCEDURE|Ultrasound-guided Transversus abdominus plane block|the probe will be placed transversely in the mid-axillary line between the iliac crest and the costal margin at the level of the umbilicus. The external oblique, internal oblique and transversus abdominis muscles and their fascias will be visualized. A 22 gauge, 80 mm needle will be introduced anteriorly and in the plane of the ultrasound probe, and on entering the plane between IO and TA, 2 ml of 0.9% saline will be injected to verify the correct position of the needle. Following negative aspiration, 0.4 ml/kg of bupivacaine 0.25% will be injected.
48276902|NCT06326944|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
48276903|NCT06326944|DRUG|Pethidine|Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.
48276904|NCT06326944|DRUG|Acetaminophen|patients will be given paracetamol (15 mg /kg/8 hrs ).
48276905|NCT02617914|PROCEDURE|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
48276906|NCT03502122|OTHER|VR rehabilitation for motor function|rehabilitation for motor function
48276907|NCT02363179|BEHAVIORAL|Live preferential music|Live preferential music will be performed for patients in the emergency department.
48276908|NCT00960076|DRUG|Saxagliptin|5mg oral tablet once daily
48276909|NCT00960076|DRUG|Metformin XR|500mg oral tablet once daily
48276910|NCT00960076|DRUG|Metformin XR|750mg, 2 tablets once daily
48276911|NCT06464211|BEHAVIORAL|Cognitive Behavioral Model-Based Family Counseling Program|A Cognitive Behavioral Model-Based Family Counseling Program is a therapeutic approach that focuses on identifying and changing negative thought patterns and behaviors within the family unit, using principles of cognitive-behavioral therapy to improve communication, resolve conflicts, and enhance overall family functioning.
48444076|NCT02478047|OTHER|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
47927958|NCT01328444|DRUG|GSK 573719 125|125mcg
48276912|NCT04791384|DRUG|Abemaciclib|taken orally
48276913|NCT04791384|DRUG|Elacestrant|taken orally
48276914|NCT06135792|OTHER|Arginine|See arm description
48276915|NCT06135792|OTHER|Placebo|See arm description
48276916|NCT02210780|DRUG|Dupilumab|Administered via subcutaneous injection.
48276917|NCT02210780|DRUG|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
48276918|NCT03282032|OTHER|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
48276919|NCT00559338|DRUG|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
48276920|NCT00559338|DRUG|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
48276921|NCT00626873|DRUG|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
48276922|NCT00626873|OTHER|medical chart review|
48276923|NCT04436302|DEVICE|Exergame device|motor-cognitive training
48276924|NCT00886990|DRUG|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
48276925|NCT00886990|DRUG|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
48276926|NCT01883141|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
48276927|NCT01276821|DRUG|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
48276928|NCT01276821|DRUG|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
48276929|NCT05014178|DIAGNOSTIC_TEST|Sodium-23 MRI|Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
48276930|NCT00441688|DRUG|GI265235|
48276931|NCT03343821|OTHER|Balance and daily life questionnaire|Patients complete questionnaire
48276932|NCT03845530|DIAGNOSTIC_TEST|Blood Test|Blood test taken and sent for laboratory analysis
48276933|NCT04874272|OTHER|Chaplain led post-code debrief|an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
48276934|NCT00193830|PROCEDURE|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
48276935|NCT02249741|DRUG|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
48276936|NCT03057444|DIETARY_SUPPLEMENT|SymbioIntest|The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
48276937|NCT01523821|DRUG|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
48276938|NCT03728088|OTHER|Rating scales concerning non-technical attributes|
48276939|NCT03505268|BEHAVIORAL|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
48276940|NCT05046288|OTHER|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
48276941|NCT00457405|DRUG|dipyridamole|dipyridamole 200mg twice daily
48276942|NCT00882414|DRUG|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
48276943|NCT00882414|DRUG|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
48276944|NCT00743704|OTHER|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
48276945|NCT03375385|DRUG|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
48276946|NCT03939208|BEHAVIORAL|BRISC|
48276947|NCT03939208|BEHAVIORAL|SAU|
48276948|NCT01389245|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
48276949|NCT03184948|DEVICE|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
48276950|NCT05511038|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Injection, 2mg (equivalent to 50 µL solution for injection)
48276951|NCT02520479|DRUG|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
48276952|NCT02520479|RADIATION|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
48276953|NCT02520479|DRUG|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
48276954|NCT04475328|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
48276955|NCT04475328|DRUG|Placebo of AngongNiuhuang pill|This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
48276956|NCT04475328|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke
48276957|NCT00004255|BIOLOGICAL|anti-thymocyte globulin|
48276958|NCT00004255|BIOLOGICAL|filgrastim|
48276959|NCT00004255|DRUG|cyclophosphamide|
48276960|NCT00004255|DRUG|fludarabine phosphate|
48276961|NCT00004255|DRUG|methylprednisolone|
48276962|NCT00004255|DRUG|tacrolimus|
48276963|NCT00004255|PROCEDURE|allogeneic bone marrow transplantation|
48276964|NCT00004255|PROCEDURE|in vitro-treated bone marrow transplantation|
48276965|NCT00004255|RADIATION|radiation therapy|
48276966|NCT05418764|OTHER|Miyamodel Training|standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
48276967|NCT02655484|DEVICE|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
48276968|NCT02267486|OTHER|Standard therapy of Alzheimer Dementia (AD)|
48276969|NCT02267486|OTHER|Observation|
48276970|NCT06656143|OTHER|Traditional Physical therapy|"The exercise program included the strengthening of the deep cervical flexor and shoulder retractor muscles and also stretching of the pectoralis and cervical extensor muscles.~(3 sets of 12 repetitions) Strengthening Deep Cervical Flexors Lying chin tuck Lying chin tuck with head lift. Strengthening Shoulder Retractors Standing shoulder pull back with elastic Shoulder pull back with weight Stretch Cervical Extensors Chin drop Stretch Pectoralis Muscle Bilateral Pectoral stretch"
48276971|NCT06656143|OTHER|Diaphragmatic Myofascial Release|To release the diaphragm, the patient was positioned in the supine position. The therapist stood at the head of the patient. The therapist made manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist was gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist deepened hand contacts towards the inner costal margins Exercise Program (3 sets of 12 reps) Strengthening deep cervical flexors Strengthening shoulder retractors Stretching Cervical Extensors Stretching Pectoralis Muscle
48276972|NCT04567784|DRUG|Cannabidiol (CBD)|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
48276973|NCT04567784|DRUG|Placebo|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
48276974|NCT05990803|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
48276975|NCT05990803|DRUG|SI-B003|SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
48276976|NCT00384579|DRUG|Botulinum toxin B|Botulinum Toxin B
48276977|NCT00384579|DRUG|Placebo|Placebo
48276978|NCT00123929|DRUG|docetaxel|100 mg/m2 every 3 weeks times 4
48276979|NCT00123929|DRUG|doxorubicin|75 mg/m2 every 3 weeks times 4
48276980|NCT05662592|DEVICE|Broadband Light|Broadband Light device will be used for treatment of pigmented skin lesions
48276981|NCT05252689|OTHER|monolithic zirconia single posterior crowns with deep chamfer finish line|deep chamfer of 1 mm average thickness for cervical finish line, a convergence angle of 6-12° on each side and up to 20° total, in some studies, is acceptable and occlusal reduction of 1,5-2 mm
48276982|NCT05252689|OTHER|monolithic zirconia single posterior crowns with vertical finish line|using special round-ended 2 degrees tapered diamond burs a non-working tip (batt bur). It has coronal diameter of 1.2 mm, apical diameter of 0.7 mm, and non- cutting end of 1 mm, which reduces or avoids damage to the connective attachment and allows a tooth-guided preparation procedure
48276983|NCT01120639|DRUG|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
48276984|NCT01120639|PROCEDURE|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
48276985|NCT04352920|OTHER|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
48276986|NCT00246259|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
48276987|NCT00246259|DRUG|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
48276988|NCT03945279|DRUG|BIIB100|Administered as specified in the treatment arm.
48276989|NCT03945279|DRUG|Placebo|Administered as specified in the treatment arm.
48276990|NCT00541307|DEVICE|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
48276991|NCT01355289|DRUG|Avatrombopag|
48276992|NCT01355289|DRUG|Placebo|
48276993|NCT01355289|DRUG|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
48276994|NCT01355289|DRUG|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
48276995|NCT01355289|DRUG|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
48276996|NCT01027689|DRUG|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
48276997|NCT01027689|DRUG|alprazolam test sublingual tablet|1 mg tablet, single dose
48276998|NCT02054702|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
48276999|NCT02054702|DRUG|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
48277000|NCT04728204|BEHAVIORAL|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
48277001|NCT04109599|BEHAVIORAL|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
48277002|NCT04109599|BEHAVIORAL|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
48277003|NCT04109599|BEHAVIORAL|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
48277004|NCT03501056|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
48277005|NCT03501056|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
48277006|NCT02219230|DEVICE|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
48277007|NCT02219230|DEVICE|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
48277008|NCT02219230|DEVICE|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
48277009|NCT02948166|PROCEDURE|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
48277010|NCT02948166|PROCEDURE|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
48277011|NCT06653855|OTHER|Dry Static Cupping|A myofascial decompression cupping set with a precision pressure pump will be used to perform dry static cupping to the adductor and hamstring muscle groups of the affected limb, using a negative pressure of 300mmHg for eight minutes each.
48277012|NCT06653855|OTHER|Placebo cupping|The same protocol will be used as stated for the Dry static cupping intervention, with the only difference being that the cup will be pumped to 50mmHg instead of 300mmHg.
48277013|NCT06653855|OTHER|Standard physical therapy treatment|"Treatment will consist of typical physical therapy interventions performed for patients with spasticity of the lower extremity after stroke. These may include, but not be limited to:~* Balance exercise~* Therapeutic exercise~* Neuromuscular/muscular coordination exercise~* Manual (hands on) therapy~* Gait training~The treating physical therapist is left with the autonomy of the standard physical therapy treatment (within the above stated groups of interventions) because patients with the diagnosis of stroke do not all present with the same type or level of impairment. Furthermore co-morbidities (e.g., hypertension) and/or functional level (wheelchair bound vs. independent ambulator) may necessitate different treatment strategies. Therefore, while the general categories of treatment will remain the same across all study patients, it is expected that the treating physical therapist provides patient-specific interventions."
48277014|NCT00005104|DRUG|clomiphene citrate|
48277015|NCT00005104|DRUG|metformin|
48277016|NCT03542682|DEVICE|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
48277017|NCT03542682|DEVICE|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
48277018|NCT04365374|DEVICE|Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)|GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile
48277019|NCT04365374|RADIATION|Stereotactic Radiation Therapy|External Beam Radiation Therapy
48277020|NCT04574999|DRUG|Estriol|Gel for vaginal application
48277021|NCT04574999|OTHER|Placebo|Gel for vaginal application
48277022|NCT05983393|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed
48277023|NCT05983393|PROCEDURE|Control|Erector spinae plane block was not applied.
48277024|NCT01128712|DRUG|Pregabalin|150 mg /day
48277025|NCT01128712|DRUG|Pregabalin|450 mg/day
48277026|NCT04846114|PROCEDURE|Dental implant surgery|
48277027|NCT03904680|DRUG|Methotrexate|Methotrexate 2.5 mg tablet
48277028|NCT03904680|DRUG|Vitamin D|Vitamin D 200,000 IU ampules
48277029|NCT03116880|PROCEDURE|Endovascular aortic repair|Endovascular aortic repair
48277030|NCT04402502|DEVICE|Ultrasound Imaging|The participant will go to the Rheumatology clinic (St. Joseph's Hospital) and have 3D hand ultrasound performed on their hands.
48277031|NCT03888625|PROCEDURE|Conventional ILM Peeling|peeling with complete removal of the internal limiting membrane (ILM)
48277032|NCT03888625|PROCEDURE|Inverted ILM Peeling|the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
48277033|NCT05987761|BEHAVIORAL|PRT for Adolescents|Clinician-led 70-minute PRT sessions targeting social skills once per week at Stanford.
48277034|NCT03370757|OTHER|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
48277035|NCT03370757|OTHER|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
48277036|NCT00628355|DRUG|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
48277037|NCT00628355|PROCEDURE|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
48277038|NCT05225155|DRUG|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
48277039|NCT04294888|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
48277040|NCT00446303|DRUG|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
48277041|NCT04515355|BEHAVIORAL|Ready for MS|Receive 'ready for MS' programme in addition to standard care.
48277042|NCT03422822|DRUG|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
48277043|NCT03422822|DRUG|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
48277044|NCT03422822|DRUG|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
48277045|NCT03422822|DRUG|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
48277046|NCT03422822|DRUG|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
48277047|NCT03422822|DRUG|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
48277048|NCT05679882|OTHER|Masking Sounds|Masking sounds will be played from outdoor speakers.
48277049|NCT05679882|OTHER|No Masking Sounds|No masking sounds will be played from outdoor speakers.
48277050|NCT04239417|OTHER|Graduated abdominal strengthening exercises|"1. Exercise mat and inflatable Swiss ball~2. Wall bar, wedges, elastic tubing"
48277051|NCT04239417|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
48277052|NCT04239417|COMBINATION_PRODUCT|Graduated abdominal strengthening exercises and the Russian current stimulation|Combination between The Russian current and abdominal exercises
48277053|NCT01564706|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
48277054|NCT02226965|DRUG|PNT2258|
48277055|NCT05735054|PROCEDURE|endoscopic thyroidectomy|the patients who underwent endoscopic transaxillary thyroidectomy
48277056|NCT03004560|PROCEDURE|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
48277057|NCT03004560|PROCEDURE|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
48277058|NCT02970617|OTHER|Memory Intervention|Ring bell after final radiation treatment
48277059|NCT02970617|OTHER|Questionnaire Administration|Ancillary studies
48277060|NCT02970617|RADIATION|Radiation therapy|Radiation therapy with or without chemotherapy
48277061|NCT00032929|DRUG|Selegiline|
48277062|NCT06651411|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|"The intervention is a chatbot-based stress management intervention developed by the World Health Organization (WHO). It consists of 10 sessions, which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Thought Challenging (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained e-helpers contact participants to support them individually weekly.~The effect of the intervention will be compared against a control group that receives basic psychoeducation. The intervention is provided in Lithuanian."
48277063|NCT06651411|BEHAVIORAL|Basic psychoeducation|Basic psychoeducation includes basic information on stress management.
48277064|NCT00432237|DRUG|MK0974 50 mg|
48277065|NCT00432237|DRUG|MK0974 150 mg|
48277066|NCT00432237|DRUG|MK0974 300 mg|
48277067|NCT00432237|DRUG|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
48277068|NCT04727515|DRUG|fentanyl 2µg/kg intravenously and maintained with isoflurane|Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
48277069|NCT04727515|PROCEDURE|Axillary nerve Block|Axillary block will be performed using ultrasound technique. Patients will receive an axillary block under ultrasound guidance using a linear 5-12 MHz probe.
48277070|NCT00679887|PROCEDURE|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
48277071|NCT05240144|OTHER|IHG|Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
48277072|NCT05240144|OTHER|Aerobic exercises|Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
48277073|NCT05240144|OTHER|Sham IHG|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
48277074|NCT05204563|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
48277075|NCT05204563|DRUG|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
48277076|NCT00870688|DRUG|sodium valproate|valproate sustained release minitablets, once daily.
48277077|NCT04210479|PROCEDURE|Filled-bladder|Urinary bladder filling with 300 ml diluted methylene blue
48277078|NCT04210479|PROCEDURE|non filled-bladder|Pull up the empty (non-filled) urinary bladder using Allis forceps
48277079|NCT06061445|COMBINATION_PRODUCT|Radiotherapy combined with TKI and Anti-PD-1 Antibody|After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
48277080|NCT03041727|OTHER|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
48277081|NCT03041727|OTHER|Standard exercises protocol|Stretching and strengthening exercises
48277082|NCT04471896|DEVICE|Joovv Mini|Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
48277083|NCT03069911|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
48277084|NCT03069911|BIOLOGICAL|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
48277085|NCT03715465|DRUG|Melatonin 0.5 MG|Melatonin tablet
48277086|NCT03715465|OTHER|Dim Light Melatonin Onset (salivary)|Test to determine the time of melatonin onset in saliva under dim light conditions
48277087|NCT01933087|BEHAVIORAL|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
48277088|NCT04154098|DEVICE|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
48277089|NCT04154098|PROCEDURE|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
48277090|NCT04154098|OTHER|No assistance|Participants are elevating their arm without being assisted
48277091|NCT04154098|OTHER|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
48277092|NCT02497703|DEVICE|Knee robot|
48277093|NCT00797121|PROCEDURE|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
48277094|NCT03182530|DEVICE|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
48277095|NCT03182530|DEVICE|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
48277096|NCT03182530|DEVICE|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
48277097|NCT04340050|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
48277098|NCT00510705|OTHER|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
48277099|NCT00510705|OTHER|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
48444077|NCT02478047|OTHER|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
48277100|NCT00510705|OTHER|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
48277101|NCT01217502|BEHAVIORAL|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
48277102|NCT01217502|BEHAVIORAL|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
48277103|NCT04547257|DEVICE|Seraph 100|Bloodfiltration with Seraph 100
48277104|NCT04713943|DIETARY_SUPPLEMENT|>Your< Iron Syrup|Once daily dose of \>Your\< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
48277105|NCT04713943|OTHER|Placebo|Once daily dose of placebo syrup for 12 weeks
48277106|NCT00002586|DRUG|13-cis retinoic acid|
48277107|NCT00002586|DIETARY_SUPPLEMENT|Tocopherol|
48277108|NCT05674448|BIOLOGICAL|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
48277109|NCT05674448|BIOLOGICAL|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
48277110|NCT06338644|DRUG|Palbociclib|3 weeks on, 1 week off
48277111|NCT00707356|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
48277112|NCT03884075|DRUG|Semaglutide|Semaglutide injection once weekly
47927959|NCT01328444|DRUG|GSK 573719 62.5|62.5mcg
47927960|NCT01328444|DRUG|GW642444 25|25mcg
48277113|NCT04716322|BEHAVIORAL|Adapted Physical Activity|A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
48277114|NCT05831085|PROCEDURE|State-of-the-Art Percutaneous Coronary Intervention|supported by intracoronary imaging (e.g., intravascular ultrasound \[IVUS\] or optical coherence tomography \[OCT\]), intracoronary physiology (e.g., fractional flow reserve \[FFR\] or instantaneous wave-free ratio \[iFR\]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy \[GDMT\] with advanced cardiovascular and anti-diabetic medications \[e.g., a sodium-glucose cotransporter \[SGLT\]-2 inhibitors\]) in patients with type 2 diabetes and three-vessel coronary artery disease (CAD) (not involving left main)
48277115|NCT05831085|PROCEDURE|standard CABG|Coronary-Artery Bypass Grafting
48277116|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
48277117|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
48277118|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
48277119|NCT01283737|DEVICE|DBX Putty|OCD of the knee will be treated with DBX Putty
48277120|NCT01283737|PROCEDURE|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
48277121|NCT05637268|DRUG|Camrelizumab|Camrelizumab 200mg iv q2w
48277122|NCT05637268|DRUG|Paclitaxel|150mg/m² iv d1 q2w
48277123|NCT05637268|DRUG|Cisplatin|50 mg/m² iv d2 q2w
48277124|NCT05491122|BEHAVIORAL|Increasing or decreasing daily total fluid intake|1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
48277125|NCT01802281|PROCEDURE|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
48277126|NCT01802281|PROCEDURE|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
48277127|NCT04426630|OTHER|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
48277128|NCT06143878|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
48277129|NCT06143878|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
48277130|NCT06143878|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
48277131|NCT06143878|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
48277132|NCT00812669|BIOLOGICAL|pegfilgrastim|
48277133|NCT00812669|BIOLOGICAL|rituximab|
48277134|NCT00812669|DRUG|cyclophosphamide|
48277135|NCT00812669|DRUG|fludarabine phosphate|
48277136|NCT00812669|GENETIC|cytogenetic analysis|
48444078|NCT02478047|OTHER|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
48444079|NCT02157623|DRUG|Levulan|Levulan application followed by Red or Blue light PDT
48444080|NCT02157623|OTHER|Red Light PDT|Aktilite™ (red lamp) after Levulan application on lesions
48444081|NCT02157623|OTHER|Blue Light PDT|Blu-U® (blue lamp) after Levulan application on lesions
48444082|NCT00283608|GENETIC|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
48277137|NCT00812669|GENETIC|fluorescence in situ hybridization|
48277138|NCT00812669|GENETIC|gene expression analysis|
48277139|NCT00812669|GENETIC|mutation analysis|
48277140|NCT00812669|GENETIC|protein expression analysis|
48277141|NCT00812669|OTHER|flow cytometry|
48277142|NCT00812669|OTHER|laboratory biomarker analysis|
48277143|NCT05211167|DRUG|Human Erythropoiesis Injection (CHO cell)|Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
48277144|NCT05211167|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
48277145|NCT01811914|OTHER|intraoperative TTE|
48277146|NCT02149641|RADIATION|Intensity modulated radiotherapy with chemotherapy|
48277147|NCT05715216|DRUG|Nivolumab|Given by IV (vein)
48277148|NCT05715216|DRUG|Etigilimab|Given by IV (vein)
48277149|NCT01916395|DRUG|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
48444083|NCT00283608|OTHER|high performance liquid chromatography|analysis of plasma concentrations of drugs
48444084|NCT00283608|OTHER|measurements by DXA|determine bone mineral density (BMD)
48444085|NCT00283608|OTHER|questionnaire administration|determine attitude changes
48277150|NCT04151108|OTHER|Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
48277151|NCT04151108|OTHER|Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
48277152|NCT03467620|DRUG|Cannabidiol|Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
48277153|NCT03467620|DRUG|Placebo oral capsule|Administration of one oral placebo capsule daily for a duration of 12 weeks
48277154|NCT02154646|DRUG|LY2157299|Administered orally
48277155|NCT02154646|DRUG|Gemcitabine|Administered IV
48277156|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD|Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
48277157|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses|Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
48277158|NCT05177055|OTHER|6-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
48277159|NCT01588821|DRUG|Cabozantinib|60 mg daily by mouth
48277160|NCT01380899|PROCEDURE|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
48277161|NCT01939379|DRUG|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
48277162|NCT01939379|DRUG|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
48277163|NCT03046251|DRUG|Natalizumab|
48277164|NCT04919629|BIOLOGICAL|Bevacizumab|Given IV
48277165|NCT04919629|PROCEDURE|Biopsy|Undergo tumor biopsy
48277166|NCT04919629|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48277167|NCT04919629|DRUG|Pegcetacoplan|Given IV and SC
48277168|NCT04919629|BIOLOGICAL|Pembrolizumab|Given IV
48444086|NCT01038817|DRUG|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
48444087|NCT05230563|DEVICE|Ti-LUNG|"Participating clinicians will perform two image interpretations on all cases. One period the clinicians only will perform lung nodule detection on chest CT images, and the other period will perform lung nodule detection on chest CT images with the aid of Taihao lung CT decision support system. In each interpretation, all lung nodule is marked by each radiologist. This test collects chest computerized tomography cases for computer analysis, and evaluates whether the TaiHao lung CT decision support system helps doctors make more accurate diagnoses."
48277169|NCT04919629|OTHER|Questionnaire Administration|Ancillary studies
48277170|NCT01830530|DRUG|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
48277171|NCT01830530|DRUG|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
48277172|NCT01830530|DRUG|placebo|two tablets daily in the morning
48277173|NCT02570373|DRUG|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
48277174|NCT00206973|PROCEDURE|mannitol test|
48277175|NCT06642753|BIOLOGICAL|immediate implant with buccal plate augmentation using sticky bone|"* Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the pouch ."
48277176|NCT06642753|BIOLOGICAL|immediate implant with sticky bone as a filling material in the jumping gap|"Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the jumping gap."
48277177|NCT00751413|DRUG|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
48277178|NCT06372977|DIAGNOSTIC_TEST|kappa index|CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb
48277179|NCT05602428|DRUG|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
48277180|NCT05602428|DRUG|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
48277181|NCT05602428|DRUG|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
48277182|NCT04271267|OTHER|No Intervention|
48277183|NCT01936038|OTHER|CPAP|CPAP
48277184|NCT01936038|PROCEDURE|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
48277185|NCT06168409|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~• 2 mg per tablet."
48277186|NCT06168409|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
48277187|NCT04792294|DEVICE|Extracorporeal photopheresis|ECP can be used as second-line treatment in patients unresponsive to azithromycin. ECP has been firstly developed for treatment of cutaneous T cell lymphomas and later used in a variety of other indications including solid organ transplantation. The process starts with leukapheresis, followed by incubation of the isolated cells with 8-methoxypsoralen (8-MOP) and subsequent activation of 8-MOP with ultraviolet A radiation. At the end, the cells are reinfused into the patient. 8-MOP is a biologically inert substance, but in the presence of UVA light it cross-links DNA by forming covalent bonds with pyrimidine bases and causes apoptosis.
48277188|NCT01967043|DRUG|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
48277189|NCT00646295|DEVICE|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
48277190|NCT04125680|BEHAVIORAL|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
48277191|NCT03783195|OTHER|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
48277192|NCT05779085|OTHER|Dermocosmetic|Use of daily cleanser to treat facial acne
48277193|NCT02386774|DEVICE|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
48277194|NCT02386774|DEVICE|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine"
48277195|NCT02386774|PROCEDURE|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
48277196|NCT02426814|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
48277197|NCT02426814|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
48277198|NCT04880811|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 21 day cycle.
48277199|NCT04880811|DRUG|Toripalimab|Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
48277200|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Oblique Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Oblique liners according to the approved indications and compatible device.
48277201|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Offset Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Offset liners according to the approved indications and compatible device.
48277202|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
48277203|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
48277204|NCT01395238|BEHAVIORAL|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
48277205|NCT03193268|OTHER|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
48277206|NCT03193268|OTHER|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
48277207|NCT01629303|PROCEDURE|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
48277208|NCT05275114|DEVICE|tDCS stimulation with hand task|30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
48277209|NCT05275114|DEVICE|sham tDCS stimulation with hand task|30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
48277210|NCT02830165|OTHER|Laboratory Biomarker Analysis|Correlative studies
48277211|NCT02830165|OTHER|Quality-of-Life Assessment|Ancillary studies
48277212|NCT02830165|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48277214|NCT00811252|DRUG|Placebo|capsules; daily; orally
48277215|NCT00811252|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
48277216|NCT00811252|DRUG|Duloxetine|encapsulated tablets; daily; orally
48277217|NCT03637049|DRUG|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
47927961|NCT01328444|DRUG|Plb|Comparator
48277218|NCT00619229|DRUG|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
48277219|NCT00619229|OTHER|Placebo|Placebo/d i.v. for 15 days
48277220|NCT04046861|DIETARY_SUPPLEMENT|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
48277221|NCT04046861|OTHER|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
48277222|NCT04290182|BIOLOGICAL|MSC-KI-PL-204|Autologous MSC product
48277223|NCT04725682|DRUG|Tacrolimus|a single dose of 1 mg capsule per period
48277224|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
48277225|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
48277226|NCT00030082|DRUG|isolated perfusion|
48277227|NCT00030082|DRUG|melphalan|
48277228|NCT06487052|COMBINATION_PRODUCT|Standard Catheter-Directed Low Dose Thrombolysis|Using femoral or jugular vein access the mechanical blood clots fragmentation by PigTail 6F catheter circular rotational movements. For unilateral thromboembolism, the PigTail catheter is positioned in the obstructed branch of the pulmonary artery, 1 mg of alteplase is injected as a bolus, followed by a micro-jet injection of 1 mg/hour. For bilateral thromboembolism, the PigTail catheter is positioned in the pulmonary trunk with a bolus of 2 mg alteplase followed by an infusion of 2 mg/hour. The total duration of infusion will be 9 hours, the total dose of alteplase will be 10 mg for unilateral lesions and 20 mg for bilateral lesions. During the alteplase infusion, unfractionated heparin is continued with a target activated partial thromboplastin time (aPTT) of 50 to 60 seconds. After completion of the procedure, UFH therapy is continued for 24 hours, followed by a change to oral anticoagulants.
48277229|NCT06487052|DRUG|Standard Anticoagulation|Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed
48277230|NCT05040191|OTHER|Traditional Education(control)|The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.
48277231|NCT05040191|OTHER|Haptic interactive virtual reality simulation training|Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.
48277232|NCT05040191|OTHER|Haptic interactive computer-based simulation training|"Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill."
48277233|NCT05742321|GENETIC|Genotyping|Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
48277234|NCT05742321|DIAGNOSTIC_TEST|Histology|Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
48277235|NCT05742321|OTHER|Collection of data|Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
48277236|NCT04453111|BIOLOGICAL|Placenta-derived MMSCs|Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
48277237|NCT04453111|BIOLOGICAL|Bone marrow-derived MMSCs|Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
48277238|NCT04453111|DRUG|Hyalgan 20 mg in 2 ML Prefilled Syringe|Hyaluronic Acid 20 mg
48277239|NCT00935883|DRUG|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
48277240|NCT00935883|DRUG|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
48277241|NCT01416129|DEVICE|Standard of care socket|Amputees' preferred socket.
48277242|NCT01416129|DEVICE|Prosthetic brimless socket|Study socket
48277243|NCT04845217|DRUG|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
48277244|NCT04845217|DRUG|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
48277245|NCT01713634|OTHER|Preflight|4-d controlled diet sessions will occur twice before flight.
48277246|NCT01713634|OTHER|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
48277247|NCT05871203|OTHER|Gene sequencing|Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery
48277248|NCT04825548|OTHER|No intervention|Examination of patients with previous DVT
48277249|NCT04746586|OTHER|Circulating MiRNA indentification|Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
48277250|NCT00352248|PROCEDURE|Tongue Acupuncture (Procedure)|
48277251|NCT01147809|DRUG|Eltrombopag olamine|thrombopoietin receptor agonist
48277252|NCT01147809|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
48277253|NCT03578679|DRUG|Ivermectin Oral Product|treatment of pediculosis (head lice)
48277254|NCT00270894|DRUG|epirubicin|epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
48277255|NCT00270894|DRUG|cyclophosphamide|cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
48277256|NCT00270894|DRUG|docetaxel|docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
48277257|NCT00270894|DRUG|trastuzumab|trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
48277258|NCT02047006|DRUG|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
48277259|NCT01912755|DRUG|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
48277260|NCT01912755|DRUG|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
48277261|NCT01296906|BEHAVIORAL|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
48277262|NCT01296906|BEHAVIORAL|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
48277263|NCT03906266|DIAGNOSTIC_TEST|NRS 2002, nutric, SGA and adductor pollicis|NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
48277264|NCT01869335|DEVICE|radiography|
48277265|NCT01869335|DEVICE|MRI (magnetic resonance imaging)|
48277266|NCT03634982|DRUG|RMC-4630|RMC-4630 for oral administration
48277267|NCT02585557|OTHER|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
48277268|NCT06016816|PROCEDURE|Bilateral endoscopic sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
48277269|NCT06016816|PROCEDURE|placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
48277270|NCT05550532|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
48277271|NCT05550532|OTHER|Placebo|Placebo tablet will be administered orally.
48277272|NCT03151889|DEVICE|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
48277273|NCT00477087|DRUG|Mitoxantrone|Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.
48098050|NCT04837495|PROCEDURE|right stellate ganglion block|The skin should be anaesthetised with lidocaine 2%. Using a lateral approach and in-plane imaging, a blunt regional anaesthesia needle should be advanced deep to the carotid sheath towards the longus colli muscle. Following careful aspiration, inject 10 ml lidocaine 2% that will result in expansion of the fascia of the longus colli. Confirmation of the SGB success can be detected by warming of left upper limb and left Horner's syndrome.
48098051|NCT05996133|DRUG|Bupivacain|30 mL of 0.25% bupivacaine
48098052|NCT05996133|DRUG|Dexamethasone|0.5 mL (5 mg) preservative-free dexamethasone
48277274|NCT00477087|DRUG|GM-CSF|GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
48277275|NCT00837187|DRUG|Intravenous dexmedetomidine|100 ug
48277276|NCT00837187|DRUG|Intranasal dexmedetomidine|100 ug
48277277|NCT00749606|BEHAVIORAL|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
48277278|NCT00749606|BEHAVIORAL|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
48277279|NCT04954482|OTHER|No Intervention|This is an observation study, with no intervention
48277280|NCT05841030|OTHER|No Intervention|There is no interventional treatment administered to the participants as a part of this study.
48277281|NCT02974244|DRUG|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
48277282|NCT02974244|DRUG|basal insulin|basal insulin treatment in the customary clinical care in USA
48277283|NCT06657183|DEVICE|Alio Smart Patch™|"Alio Smart Patch is a non-invasive wearable biosensor that combines a unique, multi-sensor, wearable device with a provided- based portal to track sequentially the participant's physiologic, hematologic and electrolyte data. It works in conjunction with a home hub data relay system and an end-to-end cloud software data path. The system has been developed to enable home monitoring for multiple key metrics by healthcare provider caring for participants.~Enhanced Care Management (ECM) is a comprehensive, system-centric approach crafted to bridge the latent gaps in traditional care paradigms. ECM provides an exhaustive review of a participant's medical history and their personalized social needs, addressing both in a cohesive, participant-focused strategy.~This intervention couples Quantify Remote Care's Enhanced Care Management with the Alio Smart Patch technology."
48277284|NCT00049348|BIOLOGICAL|epoetin alfa|
48277285|NCT00049348|BIOLOGICAL|filgrastim|
48277286|NCT00049348|DRUG|cisplatin|
48277287|NCT00049348|DRUG|fluorouracil|
48277288|NCT00049348|DRUG|gemcitabine hydrochloride|
48444088|NCT03959683|DEVICE|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
47927962|NCT04095585|GENETIC|chromosomal microarray analysis (CMA) and whole exome sequencing (WES)|"The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)"
48277289|NCT00049348|PROCEDURE|adjuvant therapy|
48444089|NCT03959683|DEVICE|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
48444090|NCT06322420|BEHAVIORAL|Behavioural Activation (BA)|"Behavioural activation treatment delivered in this single arm study. Individual treatment given to all participants in 12 sessions over 11 weeks. All treatment components have been introduced by session 8 that defines minimum amount of treatment in the trial (i.e. 8 session completed).~Behavioral Activation is a psychological treatment for depression focused on gradually re-engaging people with sources of reinforcement and reward in their environment by re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours."
48277290|NCT00049348|PROCEDURE|conventional surgery|
48277291|NCT00049348|PROCEDURE|neoadjuvant therapy|
48277292|NCT00049348|RADIATION|radiation therapy|
48277293|NCT02908906|DRUG|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
48277294|NCT01497171|PROCEDURE|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
48277295|NCT01497171|PROCEDURE|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
48277296|NCT03582111|OTHER|Study of medical records|Study of medical records
48277297|NCT00701987|DRUG|ALS-357|Topical application of ALS-357
48277298|NCT05779891|OTHER|Mulligan Traction Straight Leg Raise Technique|The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.
48277299|NCT05779891|OTHER|Slump Stretching|The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
48277300|NCT00188188|DRUG|quinipril|
48277301|NCT05456750|DEVICE|Intravascular laser irradiation of blood|Low intensity intravenous laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
48277302|NCT03663452|BEHAVIORAL|Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)|TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
47927963|NCT03095196|DEVICE|Multipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
48098053|NCT05996133|DRUG|Epinephrine|0.1 mL epinephrine 1:400,000.
48277303|NCT03663452|BEHAVIORAL|Prolonged exposure training|Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
48277304|NCT05314673|DRUG|Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery."
48277305|NCT05314673|PROCEDURE|pterygium surgery without adjunctive therapy|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture"
48277306|NCT03758560|OTHER|Pre-operative Nepali version of pain catastrophizing scale (PCS) questionnaire|Patients will be asked to complete the scores based Nepali version of pain catastrophizing scale (PCS) questionnaire preoperatively
48277307|NCT06491043|OTHER|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells
48277308|NCT06387056|DRUG|Rezvilutamide|240mg by mouth once a day for 24 weeks.
48277309|NCT06387056|DRUG|Goserelin Microspheres for Injection|3.6mg by intramuscular injection once 4 weeks for 24 weeks.
48277310|NCT06387056|DRUG|Docetaxel|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
48277311|NCT06387056|DRUG|Pamiparib|60mg by mouth twice a day for 20 weeks.
48277312|NCT06387056|DRUG|Cisplatin|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
48277313|NCT06387056|DRUG|Tislelizumab|200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
48277314|NCT00874380|OTHER|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
48444091|NCT01555645|BEHAVIORAL|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
48098054|NCT05996133|DRUG|Normal saline|3 mL normal saline
48098055|NCT05481411|DRUG|Olpasiran|Subcutaneous injection
48098056|NCT04991259|PROCEDURE|Continuous Renal Replacement Therapy (CRRT)|Continuous renal replacement therapy will be administered as continuous venovenous hemodiafiltration (CVVHDF) using Prisma and Prismaflex (Gambro) devices, with blood flows ranging from 150-180 mL/hr and target effluent rates of 20 - 25 mL/kg/hr. Anticoagulation was not used during dialysis. CRRT would be continued until resolution of cerebral edema and in decrease in ammonia levels below 150 ug/dl or in those who develop adverse effects of therapy.
48277315|NCT06447506|DRUG|GSK1070806|Participants will receive GSK1070806.
48277316|NCT01082276|DRUG|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
48277317|NCT02119520|DRUG|Platelet rich fibrin +Atorvastatin|
48098057|NCT04991259|OTHER|Standard Medical Treatment|In the L- ICU, patients will be managed by a multidisciplinary team. Intubation and ventilation will be undertaken for standard indications in addition to the development of grade 3 encephalopathy or evidence of cerebral edema on CT-scan. Fluid management will be done with crystalloids, with the use of colloids (5% albumin) in patients with severe hypoalbuminemia (serum albumin less than 2.5gm/dl). Norepinephrine will be the primary vasopressor used to target a mean arterial pressure of 65-70 mm of Hg. with adjunctive use of intravenous low dose hydrocortisone and vasopressin in patients not responsive to initial therapy.
48098058|NCT05698940|PROCEDURE|Infundibultomy|Infundibultomy on one side of patient
48277318|NCT02119520|DRUG|Platelet rich fibrin|
48277319|NCT02119520|PROCEDURE|open flap debridement|
48277320|NCT02866344|PROCEDURE|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
48277321|NCT02866344|PROCEDURE|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
48277322|NCT00511303|DRUG|STI571|
48277323|NCT03533166|OTHER|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
48277324|NCT03533166|OTHER|Placebo|Placebo mouth rinse
48277325|NCT05376917|DEVICE|Zeiss CT Asphina / Zeiss CT Asphina|Monovision with refractive target of -1.50D on the dominated eye
48277326|NCT05376917|DEVICE|Zeiss AT Lara/ Zeiss AT Lisa Tri|Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)
48277327|NCT05376917|DEVICE|Zeiss CT Asphina/ Zeiss AT Lara|Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)
48277328|NCT05376917|DEVICE|Zeiss AT Lara / Zeiss AT Lara|Micromonovision with refractive target of -0.75D on the non-dominant eye
48277329|NCT04927273|OTHER|Survey|Surveyed neurological and orthopedic surgeons
48277330|NCT03306654|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
48277331|NCT06654557|OTHER|Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
48277332|NCT06654557|OTHER|0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
48277333|NCT06654557|OTHER|0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
48277334|NCT06654557|OTHER|1% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
48277335|NCT06654557|OTHER|6% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
48277336|NCT06654557|OTHER|6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
48277337|NCT06654557|OTHER|6% carbohydrate electrolyte solution with glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
48277338|NCT01495988|DRUG|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
48277339|NCT01495988|DRUG|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
48277340|NCT01495988|DRUG|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
48277341|NCT05102565|BEHAVIORAL|sleep education program|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
48277342|NCT01122355|DRUG|lipid modification|1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
48277343|NCT05439031|RADIATION|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
48277344|NCT05974306|DEVICE|implantable loop recorder|Implantation of an implantable loop recorder
48277345|NCT01238003|OTHER|Interpretation of blood test results|Interpretation of blood test results
48277346|NCT00572884|OTHER|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
48277347|NCT05405829|OTHER|Health education|theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
48277348|NCT01253603|DRUG|QAW039 capsules once daily for 28 days|
48277349|NCT01253603|DRUG|Placebo to QAW039 capsules once daily for 28 days|
48277350|NCT01253603|DRUG|Fluticasone propionate inhaler twice daily for 28 days|
48277351|NCT01950819|BIOLOGICAL|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
48277352|NCT01950819|DRUG|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
48277353|NCT01950819|DRUG|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
48277354|NCT01950819|DRUG|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
48277355|NCT05605756|DRUG|OnabotulinumtoxinA 145 UNT [Botox]|"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
48277356|NCT00289822|DRUG|intracoronary infusion of progenitor cells|
48277357|NCT04994925|OTHER|Control ready meal|Supermarket brand lasagne ready meal
48277358|NCT04994925|OTHER|Test ready meal|The Slimming World lasagne ready meal
48277359|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
48277360|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
48277361|NCT04918121|DRUG|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
48277362|NCT02503605|DRUG|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
48277363|NCT02503605|DRUG|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
48277364|NCT02209506|DRUG|MLN3126|MLN3126 tablets
48277365|NCT02209506|DRUG|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
48277366|NCT00780403|DRUG|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
47927964|NCT03095196|DEVICE|Bipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
48444092|NCT04140877|DEVICE|Visu|An experimental (test) virtual reality display
48277367|NCT00780403|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
48277368|NCT00195650|BIOLOGICAL|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
48277369|NCT01207466|DEVICE|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
48277370|NCT01207466|DEVICE|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
48277371|NCT00881660|DEVICE|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
48277372|NCT00460382|DRUG|raltegravir potassium|400 mg twice a day
48277373|NCT00460382|DRUG|darunavir/ritonavir|2 pills of 300 mg twice a day
48277374|NCT00460382|DRUG|etravirine|2 pills of 100 mg twice a day
48277375|NCT00460382|DRUG|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
48277376|NCT03906825|DIETARY_SUPPLEMENT|CEAG|Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA
48277377|NCT03906825|DIETARY_SUPPLEMENT|placebo|placebo
48277378|NCT03156036|DRUG|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
48277379|NCT01479608|PROCEDURE|Liver transplantation and liver resection|
48277380|NCT03885297|DRUG|Saxenda|Obesity pharmacotherapy
48277381|NCT03885297|OTHER|Lifestyle modification|Tier 3 NHS weight management
48277382|NCT03885297|DIAGNOSTIC_TEST|Metabolomics|Small molecule intermediates and products of metabolism
48444093|NCT04605861|DRUG|Liraglutide|Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
47927965|NCT03095196|DRUG|HF drugs|full medical therapy to treat HF symptoms and its progression.
47927966|NCT01715129|DRUG|Triptorelin Pamoate 11.25mg|
48277383|NCT03885297|DIAGNOSTIC_TEST|miRNA|Small non-coding RNA molecules
48277384|NCT04626622|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
48277385|NCT04626622|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
48277386|NCT03913754|OTHER|Psycho-social consequences of lupus erythematosus|It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
48277387|NCT02078479|PROCEDURE|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
48277388|NCT02078479|PROCEDURE|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
48277389|NCT01496664|PROCEDURE|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
48277390|NCT02113657|DRUG|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
48277391|NCT04250584|DEVICE|iSlpr™|mandibular advancement device
48277392|NCT04250584|DEVICE|SomnoDent® Classic|mandibular advancement device
48277393|NCT04836039|OTHER|A questionnaire and scales.|Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
48277394|NCT01771783|DRUG|ACEI-ARB-RI|
48277395|NCT01771783|DRUG|ARB-RI-ACEI|
48277396|NCT01771783|DRUG|RI-ACEI-ARB|
48277397|NCT06523803|DRUG|ZW171|Administered per protocol requirements
48277398|NCT04800315|DRUG|CC-93538|Specified dosages on specified days
48277399|NCT04800315|OTHER|Placebo|Specified dosages on specified days
48277400|NCT05809973|DIAGNOSTIC_TEST|VISA tool|Validation of VISA
48444094|NCT04605861|DRUG|Placebo|Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
48444095|NCT04737486|DRUG|AV-001|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
47927967|NCT02006095|OTHER|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
47927968|NCT02006095|BEHAVIORAL|Neuropsychological testing|
47927969|NCT01407653|PROCEDURE|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
47927970|NCT01407653|PROCEDURE|Usual care|Classical care
47927971|NCT02788162|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
48277403|NCT01179529|DRUG|Omalizumab (Xolair®)|
48277404|NCT01724281|OTHER|No intervention, only follow up|
48277405|NCT00150189|BEHAVIORAL|Sucrose|
48277406|NCT05474092|DEVICE|Aeson Total Artificial Heart|Heart Replacement Therapy
48277407|NCT03617705|DEVICE|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
48277408|NCT03617705|DEVICE|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
48277409|NCT03617705|DEVICE|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
48277410|NCT02912364|DRUG|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
48277411|NCT02912364|DRUG|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
48277412|NCT00056199|DRUG|EYE001|
48277413|NCT04994756|PROCEDURE|Stroke/Thrombectomy/Aneurysm-specific surgical procedures|Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.
48277414|NCT00378118|OTHER|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
48277415|NCT00378118|OTHER|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
48277416|NCT00278525|DRUG|standard of care|standard of care medication will be given
48444096|NCT04737486|OTHER|Placebo|D-PBS
47927972|NCT02336126|BEHAVIORAL|Biopsychological intervention|
47927973|NCT03796845|OTHER|No limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
47927974|NCT00574964|OTHER|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
47927975|NCT00158132|DRUG|Propranolol|Propranolol 100mg/day in 3 divided doses
47927976|NCT00158132|DRUG|Amantadine|Amantadine 100mg three times daily
47927977|NCT00158132|DRUG|Placebo|Placebo pills
48098059|NCT05695573|DIAGNOSTIC_TEST|ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile|Use the ACR to divide diabetic patients to 3groups not normoalbuminuria, microalbuminuria, macroalbuminuria to evaluate the urinary uromodulin level and its exosomal umod mRNA as a potential biomarker of Diabetic nephropathy diagnosis
48098060|NCT02730767|BEHAVIORAL|partially supervised exercise intervention|
48277417|NCT00278525|PROCEDURE|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
48277418|NCT01542307|BIOLOGICAL|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
48277419|NCT01542307|BIOLOGICAL|Room air|Placebo
48277420|NCT04085432|OTHER|Self administered questionnaire and Clinical evaluation|Self administered questionnaire and clinical evaluation
48277421|NCT03869814|OTHER|Blood Draw|Blood Draw
48277422|NCT04284293|BIOLOGICAL|CNS10-NPC implantation|All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
48277423|NCT04239209|BEHAVIORAL|Indirect - other patients|Video depicting an indirect response focusing on a comparison to other patients.
48277424|NCT04239209|BEHAVIORAL|Indirect - physiology|Video of an indirect response focusing on the physiology of the patient.
48277425|NCT04239209|BEHAVIORAL|Redirection|Video of a redirection towards discussing the patient's values and possible future decisions.
48277426|NCT04239209|BEHAVIORAL|Direct communication|Video of a direct response.
48277427|NCT04931602|DIAGNOSTIC_TEST|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
48277428|NCT03217851|DIAGNOSTIC_TEST|Blood Collection|blood smear and/or rapid diagnostic
48277429|NCT03217851|DIAGNOSTIC_TEST|Dried Blood Spot|Dried Blood Spot on filter paper
48277430|NCT05937477|OTHER|Fitbit smartwatch|Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
48277431|NCT00635102|DRUG|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
48277432|NCT00635102|DRUG|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
48277433|NCT00635102|DRUG|Placebo D-Cycloserine PO and Glycine IV|
48277434|NCT00635102|DRUG|D-Cycloserine PO and placebo Glycine IV|
48277435|NCT04982133|DIETARY_SUPPLEMENT|Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment|"At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk."
48444097|NCT03272373|DEVICE|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
48277436|NCT06131710|OTHER|Isolated Strengthening Exercises|Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.
48277437|NCT06131710|OTHER|Combined Strengthening Exercises|Combined strengthening exercises for Patellofemoral Pain Syndrome (PFPS) typically include a mix of quadriceps strengthening exercises, hip strengthening exercises, and core stability exercises. The goal is to address muscle imbalances and improve the overall stability of the knee joint.
48277438|NCT02279511|DRUG|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
48444098|NCT03272373|DEVICE|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
48444099|NCT02775045|OTHER|Observation Period|8 week observational period
48444100|NCT01928147|DRUG|PPI-383|
48444101|NCT01928147|DRUG|Placebo|
48444102|NCT03810118|DIAGNOSTIC_TEST|fluid challenge|4 ml/kg fluid challenge infused over in either 10 or 20 minutes
48444103|NCT01473953|DRUG|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
48444104|NCT01473953|DRUG|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
48444105|NCT03644147|DRUG|Acetaminophen|Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
48444106|NCT03877692|DRUG|Experimental dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
48444107|NCT03877692|OTHER|Standard dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
48444108|NCT04377009|DEVICE|Sleep Healthy Using the Internet (SHUTi)|Cognitive behavioral therapy delivered via internet-guided program customized for military service members
48444109|NCT04377009|OTHER|Education Control Program|Online portal designed to inform participants about healthy lifestyle activities and general insomnia information
48444110|NCT06110377|PROCEDURE|MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE)|After the anesthetic block, dutasteride will be injected using syringes and needles into the area of alopecia.
48444111|NCT06110377|PROCEDURE|MMP (INJECTIONS WITH A TATTOO MACHINE)|After the anesthetic block, dutasteride will be injected through needling performed by a tattoo machine in the area of alopecia.
48444112|NCT05430776|RADIATION|Photobimodulation|laser therapy application
48444113|NCT03522363|OTHER|Streptococcus dentisani CECT7746|Treatment will be applied topically as an adhesive gel with a dental splint
48444114|NCT03644264|DRUG|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
48098061|NCT06631378|PROCEDURE|Transverse groin incision|The transverse incision is made parallel to the inguinal ligament either superiorly or inferiorly to the skin crease directly over the femoral artery. The subcutaneous tissue is dissected in the transverse direction till Scarpaes fascia after which the dissection is performed in the longitudinal direction along the line of the vessels. The lymphatic vessels are spared as much as possible. Any damaged lymph vessels are closed with surgical clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage. In case of difficulty with proper access to the femoral arteries, the incision can be extended either medially, laterally, or vertically.
48098062|NCT06631378|PROCEDURE|Longitudinal incision|The longitudinal incision is made directly over the femoral artery from the inguinal ligament. The subcutaneous tissue is dissected along the line of the vessel sparing the lymphatic vessels as much as possible. Any damaged lymph vessels are closed with clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage.
48098063|NCT01224678|DIETARY_SUPPLEMENT|vitamin D|Given orally
48277439|NCT02279511|DRUG|PLACEBO|Infusion of 500 mL of saline solution. (IV)
48277440|NCT04992416|PROCEDURE|immediate implant placement with ATBG and SMV|immediate implant placement using ATBG as a graft material, with SMV
48277441|NCT04992416|PROCEDURE|immediate implant placement with ATBG|immediate implant placement using ATBG as a graft material without SMV
48444115|NCT03644264|DRUG|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
48444116|NCT05536739|DEVICE|Robotic hip exoskeleton|The intervention is an experimental robotic hip exoskeleton that has been previously developed by the team. It is used to improve walking gait performance.
48444117|NCT02670772|DRUG|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
48444118|NCT02670772|DRUG|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
48444119|NCT01998295|DRUG|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
48444120|NCT00005591|BIOLOGICAL|cetuximab|
48444121|NCT00005591|DRUG|gemcitabine hydrochloride|
48277442|NCT05988814|DRUG|FOLFIRINOX treatment|"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression"
48444122|NCT01599728|DRUG|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min \[15, 50 and 150 ng/min\] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) \[to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively\] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
48444123|NCT06554405|OTHER|Unilateral Intervention|Treatment plan will be applied to the symptomatic side.
48444124|NCT06554405|OTHER|Bilateral Intervention|Treatment plan will be applied to the symptomatic and nonsymptomatic sides.
48277443|NCT02406755|OTHER|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
48277444|NCT02406755|OTHER|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
48277445|NCT02406755|OTHER|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
48277446|NCT05626088|OTHER|No Intervention|This is a non-interventional study.
48277447|NCT03463772|PROCEDURE|standard IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
48277448|NCT03463772|DRUG|In vitro maturation|Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
48277449|NCT04337437|DRUG|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
48277450|NCT04337437|DRUG|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
48277451|NCT02338843|DRUG|LJPC-501|Treatment arm
48277452|NCT02338843|DRUG|Placebo|PBO
48444125|NCT01858493|BEHAVIORAL|Continence promotion group education workshop|Interactive group education workshop promoting continence
48444126|NCT01858493|BEHAVIORAL|Sham health lecture|Interactive group education workshop about general health
48444127|NCT01224535|DIETARY_SUPPLEMENT|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
48444128|NCT02737046|DRUG|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1\*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
48277453|NCT01552434|BIOLOGICAL|Bevacizumab|Given IV
48277454|NCT01552434|BIOLOGICAL|Cetuximab|Given IV
48277455|NCT01552434|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48277456|NCT01552434|OTHER|Pharmacological Study|Optional correlative studies
48444129|NCT02737046|DRUG|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
48444130|NCT02737046|DRUG|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
48098064|NCT01224678|OTHER|placebo|Given orally
48098065|NCT01565928|DRUG|MDV3100|4 x 40 mg capsules, orally, once per day
48277457|NCT01552434|DRUG|Temsirolimus|Given IV
48277458|NCT01552434|DRUG|Valproic Acid|Given PO
48444131|NCT02737046|DRUG|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
48444132|NCT05250843|PROCEDURE|TACE/HAIC|Within 1-3 days of lenvatinib and sintilimab, start Transarterial chemobolization treatment or FOLFOX-based chemotherapy infusion,after three months,patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection.
48444133|NCT05250843|DRUG|Lenvatinib|Participants received lenvatinib capsules 8mg for patients weight \<60kg, or 12mg for patients weight more than 60Kg.
48444134|NCT05250843|DRUG|Sintilimab|Sintilimab Injection will be administered every three weeks (200mg) until surgery or disease progression.
48444135|NCT05250843|PROCEDURE|liver resection|liver resection is feasible after evaluation by the liver cancer surgery expert group
48444136|NCT02124135|BEHAVIORAL|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
48444137|NCT02067624|OTHER|Thai massage|
48444138|NCT03168633|BEHAVIORAL|web-based DM2 information pages|"Each email will include information on one of the following topics:~1. The importance of physical activity~2. Correct nutrition~3. The importance of adhering to medication regimens.~Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).~The information will be provided by different approaches: medical research results, practical tips, patient testimonies...."
48277459|NCT01059448|DRUG|AMG 827|AMG 827 210 mg
48444139|NCT03117296|OTHER|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
48444140|NCT03117296|OTHER|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
48444141|NCT03117296|OTHER|OT post procedure|PT and OT Daily until goals met or patient discharge.
48444142|NCT03117296|OTHER|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
48444143|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
48444144|NCT00961207|DRUG|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
48444145|NCT06458491|DEVICE|Evolution of urinary symptoms|Evolution of urinary symptoms 3 months after the start of use of the TENSI+ device
48444146|NCT03283722|DEVICE|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
48277460|NCT02934607|DRUG|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
48277461|NCT02934607|DRUG|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
48277462|NCT04579549|DEVICE|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
48277463|NCT03534037|DRUG|Febuxostat 40 mg|Febuxostat 40 mg orally per day plus dietary control only
48444147|NCT05294094|BEHAVIORAL|blended learning|The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.
48444148|NCT05294094|BEHAVIORAL|teaching format as usual|The teaching format as usual represents the usual teaching of clinical diagnostic knowledge and the ability to conduct structured clinical interviews. Also in this intervention students also have the opportunity to discuss the course content with a teacher, practice their interviewing skills with other students and conduct a structured interview with an actor simulating a patient.
48444149|NCT06400147|BEHAVIORAL|Strategy Training|This intervention will use an adapted form of strategy training for people with neglect.
48444150|NCT06400147|BEHAVIORAL|Attention Control|This intervention will use a reflective listening protocol.
48444151|NCT00941811|DRUG|Imiquimod|Local Imiquimod three times weekly for 16 weeks
48444152|NCT03600467|DRUG|SEVI-D (Seviteronel in combination with dexamthasone)|"Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study."
48444153|NCT03968601|OTHER|Mitral regurgitation surgery such as mitral valve replacement or repair|Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
48444154|NCT04530656|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
47927978|NCT00948584|OTHER|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
48098066|NCT00005890|DRUG|corticotropin|
48098067|NCT05091593|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional.
48277464|NCT03534037|DRUG|Benzbromarone 50mg|Benzbromarone 50mg orally per day plus dietary control only
48277465|NCT03534037|OTHER|Control|Dietary control only
48277466|NCT00642330|DRUG|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
48277467|NCT00642330|DRUG|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
48277468|NCT00486603|DRUG|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
48277469|NCT00486603|DRUG|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
48277470|NCT00486603|OTHER|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
48277471|NCT00486603|RADIATION|Radiation|Radiation during the first six weeks of treatment Monday-Friday
48277472|NCT01118910|DRUG|Vusion|Vusion will be applied to areas of intertrigo
48277473|NCT01963494|BEHAVIORAL|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
48277474|NCT01963494|BEHAVIORAL|Individual planning intervention|Target persons form action plans on their own.
48277475|NCT01963494|BEHAVIORAL|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
48444155|NCT04530656|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
48444156|NCT04530656|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
48277476|NCT02291211|DRUG|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
48277477|NCT06004804|BEHAVIORAL|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
48277478|NCT06004804|BEHAVIORAL|Mindfulness Meditation|Seeks to help individuals achieve present moment awareness, self-compassion, and acceptance of chronic pain. It will use techniques such as the body scan, grounding, mindful breathing, mindful walking, loving kindness, and compassionate breathing.
48444157|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Two doses of placebo (0.5ml) at the schedule of day 0, 28
48444158|NCT04530656|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 28（high-dose group）|Two doses of placebo (1.0ml) at the schedule of day 0, 28
48444159|NCT04530656|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）|Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
48444160|NCT05643573|DRUG|Asundexian (BAY2433334)|Once a day
48444161|NCT05643573|DRUG|Apixaban|5 mg or 2.5 mg, twice a day, according to product label.
48444162|NCT05643573|DRUG|Asundexian matching placebo|Placebo to asundexian, once a day
48444163|NCT05643573|DRUG|Apixaban matching placebo|Placebo to apixaban, twice a day
48444164|NCT05114447|OTHER|Routine medical care|"Eligible subjects will be contacted from physicians, by telephone or directly when they attend the clinical centre for control visits. Once the patients have provided their signed informed consent, they will have to fill in the clinical form and to perform routine functional/clinical tests.~Subjects will be investigated at baseline (T0), at 6-month follow-up (T6) and at 12-month follow-up (T12).~All the possible variations that could occur in the patients' disease status and disease management, according to the routine medical care, will be registered and taken into account in the RISER study.~RISER study is not a clinical trial, but it is an observational study without any specific drug administration by the investigators. Participants will receive interventions, which can include medical products, such as drugs or devices, or procedures, as part of their routine medical care but they will not be assigned to specific interventions by the investigator as in a clinical trial."
48444165|NCT05114447|OTHER|Telephone interview|"Eligible subjects will be contacted by telephone from trained personnel of the Research Unit. Once the signed informed consent is obtained by each enrolled subject, they will be invited to answer the phone questionnaire.~Subjects will be investigated at baseline (T0) and at 12-month follow-up (T12). Subjects fitting the epidemiological definition of severe/uncontrolled asthma will be invited at the Pisa clinical centre to have routine clinical/functional tests.~Each subject performing baseline clinical/functional tests at the Pisa clinical centre will be clinically and functionally re-assessed"
48444166|NCT00239863|DRUG|FTY720|
48444167|NCT00798954|DEVICE|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
48444168|NCT00798954|DEVICE|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
48444169|NCT04111263|DIETARY_SUPPLEMENT|FP|Fiber and polyphenol blend
48444170|NCT04111263|DIETARY_SUPPLEMENT|Placebo|Matched placebo
48444171|NCT04111263|OTHER|High altitude|Simulated high altitude in altitude chamber using hypobaric hypoxia
48444172|NCT04111263|OTHER|Sea level|Sea level environment in altitude chamber
48444173|NCT00229281|BEHAVIORAL|Group therapy|
48444174|NCT06381128|RADIATION|Cardiac CT|Computed tomography angiography
48444175|NCT04413266|DIETARY_SUPPLEMENT|Curcumin supplementation|The patients will receive 3 capsules per day containing 500mg of curcumin for 4 weeks
48098068|NCT05091593|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
48277479|NCT06004804|BEHAVIORAL|Cognitive Behavioral Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
48277480|NCT00002283|DRUG|Trimethoprim|
48277481|NCT00002283|DRUG|Sulfamethoxazole|
48277482|NCT00002283|DRUG|Dapsone|
48277483|NCT05163665|PROCEDURE|Closure type|Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
48277484|NCT02388295|DRUG|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
48444176|NCT02365012|DRUG|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
48444177|NCT01244620|DRUG|sitaxentan|sitaxsentan 100 mg QD for 6 days
48444178|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
48444179|NCT01244620|DRUG|sitaxsentan|sitaxsentan 100 mg QD for 6 days
48444180|NCT01244620|DRUG|tadalafil|tadalafil 40 mg QD for 6 days
48444181|NCT01244620|DRUG|sitaxsentan|sitaxentan 100 mg QD for 6 days
48444182|NCT01244620|DRUG|sildenafil|sildenafil 20 mg TID for 6 days
48444183|NCT02664961|DRUG|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
48444184|NCT02664961|DRUG|Bevacizumab|Bevacizumab will be dosed every two weeks.
48444185|NCT04550585|OTHER|Education: Session 1 - Basics of type 1 management|"In a group education session, a diabetes educator provides educational session 1 - Basics of type 1 management.~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
48098069|NCT06466473|DRUG|Phenytoin (Ascoli)|Phenytoin 50mg chewable tablets
48444186|NCT04550585|OTHER|Session 2 - Carbohydrate counting|"In a group education session, a diabetes educator provides educational session 2 - Carbohydrate counting~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
48444187|NCT04550585|OTHER|Education: Session 3 - Insulin self- adjustment|"In a group education session, a diabetes educator provides educational session 3 - Insulin self- adjustment~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
48444188|NCT04550585|OTHER|Education: Session 4 - Sick day rules and physical activity dose adjustments|"In a group education session, a diabetes educator provides educational session 4 - Sick day rules and physical activity dose adjustments~Accompanying educational guide:~How Can I Manage My Type 1 Diabetes Better?"
48444189|NCT04550585|OTHER|Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users)|"In a group education session, a diabetes educator provides educational session 5 - Starting the insulin pen (for pen users) or pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump? Is the Insulin Pen Right for Me?"
48444190|NCT04550585|OTHER|Education: Session 6 - Trouble shooting the pump (for pump users)|"In a group education session, a diabetes educator provides educational session 6 - Trouble shooting the pump (for pump users)~Accompanying educational guide:~Is the Insulin Pump Right for Me? How Do I Use an Insulin Pump?"
48444191|NCT04691895|OTHER|SARS-CoV2 infection|Confirmed COVID19 cases The definitions of COVID19 state are according to the WHO document released in March 2020. A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.
48444192|NCT04142918|OTHER|Immunostaining|Immunostaining of oral mucosa/gingiva samples
48444193|NCT03292328|OTHER|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
48444194|NCT03292328|OTHER|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
48444195|NCT02731534|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
48444196|NCT02731534|DRUG|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
48444197|NCT04011410|DRUG|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
48444198|NCT04414917|DRUG|Twin block|Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
48444199|NCT04414917|DEVICE|iPill dispenser|An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
48444200|NCT00001135|DRUG|Nevirapine|
48444201|NCT04750707|DRUG|Hydroxyurea|The study intervention will be daily oral Hydroxyurea given in single doses starting at approximately 20mg/kg/day and escalated to a maximum 30mg/kg/day depending on clinical need and according to standard guidelines.
48444202|NCT03767361|BIOLOGICAL|packed red blood cells transfusion|packed red blood cells transfusion
48444203|NCT03595917|DRUG|ABL001|•ABL001 is administered daily per 28 day cycle
48444204|NCT03595917|DRUG|Dasatinib|Fixed doses oral once a day per 28 day cycle
48444205|NCT03595917|DRUG|Prednisone|Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
48444206|NCT03595917|DRUG|Blinatumomab|By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
48444207|NCT02783352|PROCEDURE|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
48444208|NCT02783352|PROCEDURE|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
48444209|NCT03838263|DRUG|Nivolumab|2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.
48444210|NCT03838263|RADIATION|Chemoradiation|Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
48098070|NCT06466473|DRUG|Phenytoin (Vega Baja)|Phenytoin 50mg chewable tablets
48444211|NCT02368639|DEVICE|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher \& Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
48444212|NCT05331261|PROCEDURE|Total knee replacanent surgery|Breath exercises
48444213|NCT02503527|OTHER|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
48098071|NCT04776486|DRUG|Iohexol|"Intravenous injection of 5 ml of iohexol (Omnipaque) to calculate the glomerular filtration rate (area under the curve).~Blood samples (2 ml) and urine (2 ml minimum) are to be collected for the determination of iohexol clearance at the following time points: pre-dose, 5 minutes, and 1, 2, 3, 4, 5, 6 hours post dose."
48277485|NCT02388295|DRUG|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
48277486|NCT02599402|DRUG|Nivolumab|
48444214|NCT02503527|OTHER|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
48444215|NCT01593007|OTHER|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
48444216|NCT01593007|OTHER|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
48444217|NCT01197248|PROCEDURE|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
48444218|NCT01197248|PROCEDURE|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
48444219|NCT05820360|BEHAVIORAL|CoMBI-SMI|The first step is analysis of the behavioral problem because the core need is insufficiently compensated by the current environment or counteracted by the behavior of people within that environment. Step 2 is to choose the right core need based on this analysis. CoMBI-SMI describes the patient's self-image, the image of others, the triggering events and the problematic behavior of the patient based on personality disorders as classified by the Diagnostical and Statistical Manual of Mental Disorders. Step 3 is to choose the nursing intervention that is easily deployable so that Healthcare providers can identify the underlying core need and reduce the behavioral problems and burden on the healthcare providers. The fourth and final step is to draw up a CoMBI plan. The CoMBI-SMI is a cyclical process where it is important that the entire team is aligned with the patient's behavioral approach. Interventions are carried out by the entire team and evaluated after an agreed period of time.
48444220|NCT03114891|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. In this study, we used administered theta burst TMS stimulation.
48444221|NCT03114891|BEHAVIORAL|Task|Subject completes a working memory task (Letter Nback) between the two rounds of theta burst stimulation.
48444222|NCT03114891|PROCEDURE|fMRI-guided TMS target|Administration of TMS to individualized targeting from the participant's fMRI scans. Our preliminary data suggest this target region is particularly effective at influencing the sgACC.
48444223|NCT04166630|DEVICE|Clinical Electrical Stimulator|Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
48444224|NCT00872092|OTHER|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
48098072|NCT02540213|DEVICE|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
48277487|NCT02599402|DRUG|Ipilimumab|
48277488|NCT00000769|DRUG|Interleukin-4|
48277489|NCT00785577|DRUG|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
48277490|NCT00785577|DRUG|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
48277491|NCT00785577|DRUG|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
48444225|NCT02723981|DEVICE|COMBO-Stent|The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
48444226|NCT02723981|DRUG|Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
48444227|NCT02723981|DEVICE|Any drug eluting stent oder bare metal sent|Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
48444228|NCT02723981|DRUG|ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
48444229|NCT00275600|DRUG|Vitamin E, Evening Oil of Primrose, and Placebo|
48444230|NCT04548141|OTHER|Questionnaire|Scoring of the IPAQ is performed according to references. Scoring of the SAPHIR has been submitted for copyright protection (involves a series of 23 additions)
48444231|NCT04231422|COMBINATION_PRODUCT|Platelet-rich plasma|12mL of platelet-rich plasma injected into cavernosal bodies bilaterally
48444232|NCT00152685|DRUG|human serum albumin|
48444233|NCT05593991|OTHER|Elevated heels|"Each subject will undergo the following evaluations:~1. neutral barefoot position;~2. neutral barefoot position (re-test);~3. 3 cm rise of both heels, made with plastic spacer;~4. 7 cm rise of both heels, made with plastic spacer."
48277492|NCT00785577|DRUG|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
48277493|NCT00785577|DRUG|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
48277494|NCT00777543|OTHER|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
48444234|NCT00813592|DRUG|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
47927979|NCT00608946|DIETARY_SUPPLEMENT|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
47927980|NCT00608946|DIETARY_SUPPLEMENT|placebo|placebo
48277495|NCT00777543|DIETARY_SUPPLEMENT|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
48277496|NCT00777543|DIETARY_SUPPLEMENT|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
48277497|NCT02043886|DRUG|Acarbose|Acarbose 50 mg by mouth given during Meal Test
48277498|NCT02043886|DRUG|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
48277499|NCT06178068|DEVICE|Comparison of bronchodilator effectiveness of nebulizer therapy devices|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
48277500|NCT01962779|OTHER|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
48277501|NCT02183714|DRUG|Songha Night ®|
48277502|NCT02183714|DRUG|Placebo|
48277503|NCT01908348|DIETARY_SUPPLEMENT|Erythritol|
48277504|NCT01999738|DRUG|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
48277505|NCT01129752|OTHER|No intervention|there is no intervention for this study
48277506|NCT01543321|DRUG|Tetrabenazine|"Treatment with tetrabenazine consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
48277507|NCT01543321|DRUG|Placebo|"Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
48277508|NCT01438645|DEVICE|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
48277509|NCT03822884|DRUG|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
48277510|NCT00294125|DRUG|Flavocoxid|Daily flavocoxid for 12 weeks
48277511|NCT00294125|DRUG|Placebo|Daily placebo for 12 weeks
48277512|NCT03714126|DEVICE|Cordio Medical|Recording to an app, no interference to the regular care
48277513|NCT01668277|DRUG|7.2% NaCl|
48277514|NCT01668277|DRUG|0.9% NaCl|
48277515|NCT02380131|DRUG|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
48277516|NCT02380131|DRUG|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
48277517|NCT00277537|DRUG|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
48277518|NCT00277537|DRUG|placebo|BD for 12 weeks
48277519|NCT00814931|DRUG|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
48277520|NCT00814931|DRUG|Placebo|matching oral liquid suspension placebo twice a day for 8 days
48277521|NCT04404335|DIAGNOSTIC_TEST|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
48277522|NCT05600127|DRUG|Avelumab|3 cycles of avelumab (800mg, every 2 weeks)
48277523|NCT00474916|DRUG|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
48277524|NCT00474916|DRUG|Placebo|Normal Saline given as dose escalation for placebo
48277525|NCT00825370|DRUG|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
48277526|NCT00825370|DRUG|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
48277527|NCT02205450|DRUG|Recombinant Somatropin|
48277528|NCT06657144|DRUG|CHS-114|Sterile solution for infusion
48277529|NCT06657144|DRUG|Toripalimab|Sterile solution for infusion
48277530|NCT01961531|DEVICE|Accuboost APBI|28Gy delivered in 5 daily fractions
47927981|NCT02571907|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
47927982|NCT02571907|DEVICE|Atrium iCAST™|Implantation of Atrium iCAST
48444235|NCT03738605|DEVICE|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
48444236|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
48444237|NCT01537640|BIOLOGICAL|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
48444238|NCT05477784|OTHER|Educational Intervention|Receive EC-PC program
48444239|NCT05477784|OTHER|Informational Intervention|Receive education booklet
48444240|NCT05477784|OTHER|Questionnaire Administration|Ancillary studies
48444241|NCT00965874|DRUG|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
48444242|NCT00965874|DRUG|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
48444243|NCT00965874|DRUG|Placebos|serum salin
48444244|NCT06030752|DRUG|Washed Microbiota Transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
48444245|NCT05345990|DRUG|Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)|"Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day"
48444246|NCT06128668|BEHAVIORAL|Yoga|Yoga will be applied
48444247|NCT02960594|BIOLOGICAL|INO-1400|
48444248|NCT02960594|BIOLOGICAL|INO-9012|
48444249|NCT02960594|BIOLOGICAL|INO-1401|
48444250|NCT05365932|DEVICE|Intra auricular device (IAD)|The Intra Auricular Device (IADs) are a pair of inconspicuous, custom fit auricular prosthetic devices.The ear inserts are manufactured using computer-aided design/computer-aided manufacturing (CAD/CAM) technology and are made from a liquid, photo-reactive acrylate (EShell 300), used in hearing aid shells and otoplastics for the last 10 years. They are designed to be placed into the outer third of the ear canals, and they have a small retraction post used to facilitate removal . A red or blue dot, respectively, indicates the right and the left side. The device do not interfere with hearing or speech
48444251|NCT05394935|OTHER|High-Intensity Exercise|Acute, low-volume HIIT 12x (1min:1min) Working intensity: \>85% heart rate reserve Resting intensity: Active rest
48444252|NCT05394935|OTHER|Moderate-Intensity Exercise|Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve
48444253|NCT03567668|PROCEDURE|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
48444254|NCT05648721|OTHER|Datos mobile health application|The mobile Health application will send women reminders to perform glucose tests and test results will be sent to the clinic personnel for evaluation. The clinic personnel will receive an alert if a woman does not send glucose charts or when there is an abnormality in the test results. In addition, women will be able to communicate with the clinic's personnel via chat, messages, phone calls, and video.
48444255|NCT05648721|OTHER|Regular follow-up|Regular follow-up according to the local clinic protocol
48444256|NCT01833182|OTHER|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
48444257|NCT01833182|OTHER|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
48444258|NCT02443220|DEVICE|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
48444259|NCT02443220|DEVICE|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
48444260|NCT02443220|DEVICE|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
48444261|NCT04988763|OTHER|Opinions about tele-rehabilitation for consulting a clients with neurological impairments|Opinions about telerehabilitation for consultation purpose
48444262|NCT01638520|DRUG|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
48444263|NCT01638520|DRUG|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
48444264|NCT03135743|OTHER|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
48444265|NCT05209347|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
48444266|NCT00852462|BEHAVIORAL|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
48444267|NCT05601674|OTHER|: Conventional flow Anesthesia|During the initial wash-in period 2 L/min Fresh gas flow will be used.
48444268|NCT05601674|OTHER|Low Flow Anesthesia|Fresh gas flow rate will be 0.5 L/min throughout the procedure.
48444269|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe assistance|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
48444270|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, no leave-in-situ|All detected polyps regardless of size and optical diagnosis will be resected and sent to pathology.
48444271|NCT06041945|DEVICE|Standard, high-definition colonoscopy with the use of CADe/CADx assistance, leave-in-situ|Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.
48478750|NCT06433635|DRUG|Cariprazine|"1. Cariprazine monotherapy outperformed placebo in improving depressive symptoms in most large randomized control trials (RCT). Pooled data showed higher remission rates (30.2%) with cariprazine (1.5 mg and 3 mg/day) compared to placebo (20.9%). Its efficacy extends to bipolar I depression, including mixed features and anxiety.~2. Common adverse effects include nausea (8%) and akathisia (7%). Somnolence and sedation were slightly more common with cariprazine than placebo.~3. Results from a large RCT evaluating cariprazine for bipolar disorder maintenance treatment (NCT03573297) are awaited. An open-label trial reported reduced manic symptoms over 16 weeks.~4. Cariprazine is a D3-preferring partial agonist for D3 and D2 receptors. It antagonizes 5-HT2A and 5-HT2B receptors and partially agonizes 5-HT1A receptors. Affinity for 5-HT1C and histamine 1 receptors is low to moderate."
47927983|NCT02571907|DEVICE|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
48098073|NCT00857480|DRUG|NRL972|Single intravenous administration of 2 mg NRL972
48098074|NCT00857480|DRUG|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
48098075|NCT00857480|DRUG|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
48098076|NCT01760044|DEVICE|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
48098077|NCT00124956|DRUG|Doxorubicin|
48098078|NCT06631690|OTHER|Isokinetic and functional balance tests|Isokinetic and functional balance tests
48098079|NCT00586274|PROCEDURE|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
48277531|NCT01865734|OTHER|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
48277532|NCT01865734|OTHER|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
48277533|NCT06427447|COMBINATION_PRODUCT|Adjuvant chemoradiotherapy|Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)
48277534|NCT06427447|DRUG|Adjuvant chemotherapy|Chemotherapy (gemcitabine plus capecitabine)
48277539|NCT04628507|OTHER|Spent media collection|Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
48277540|NCT06421636|DRUG|REGN7999|Administered subcutaneous (SC)
48277541|NCT06421636|DRUG|Placebo|Administered SC
48277542|NCT06292013|DRUG|Lepodisiran Sodium|Administered SC
48277543|NCT06292013|DRUG|Placebo|Administered SC
48277544|NCT01383031|PROCEDURE|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
48277545|NCT01383031|PROCEDURE|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
48277546|NCT05219695|PROCEDURE|Harmonic motion imaging guided focused ultrasound (HMIgFUS)|"Harmonic motion imaging guided focused ultrasound (HMIgFUS) is a combined treatment and imaging method, in which focused ultrasound (FUS) is used to thermally ablate tissue and harmonic motion imaging (HMI) is used for FUS guidance and monitoring. FUS applies high intensity focused ultrasound waves at its specified target to heat the tissue over a specified duration, causing cell death at the target area. HMI is an elasticity imaging technique which induces dynamic tissue vibrations at the target for tissue elasticity characterization.~One of the inclusion criteria for this study is that participants must be scheduled for surgical excision of their breast tumor. In this study, HMIgFUS will be applied to anesthetized participants immediately prior to their scheduled surgery. HMI imaging will also be performed immediately prior to and after HMIgFUS application."
48277547|NCT01734343|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
48277548|NCT01734343|DEVICE|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
48277549|NCT00287742|DRUG|risperidone|
48277550|NCT02154750|DEVICE|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
48277551|NCT02154750|DEVICE|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
48277552|NCT01649700|BIOLOGICAL|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
48444272|NCT04839276|COMBINATION_PRODUCT|Injection Laryngoplasty with Platelet-rich Fibrin and Autologous Fat|Injection Laryngoplasty with a combination of Platelet-rich Fibrin (PRF) and Autologous Fat. The PRF was made by taking 10 mL of peripheral blood from a healthy donor. Blood is then put inside the tube from the Regen lab kit. The tube was centrifuged with a force of 1,500 g (3000 rpm) for 5 minutes producing platelet-rich plasma (PRP). 4 mL of the aforementioned PRP was transferred to a 10 mL test tube, 1 M CaCl2 was added with a micropipette until final concentration of 25 mM was, reached producing PRF. Autologous fat harvested from the patient's abdomen was then mixed with the PRF solution to create the filler for injection laryngoplasty procedures. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
48444273|NCT04839276|PROCEDURE|Injection Laryngoplasty with Autologous Fat|Injection Laryngoplasty with autologous microlobular fat harvested from the patient's abdominal fat. Lidocaine was infiltrated under the umbilicus and then an incision was made in the area followed by fat removal using scissors. The fat was cleaned with 0.9% NaCl solution and then sheared into microlobular form. The injection procedures are done by placing the patient in a sniffing position followed by intraoral Kleinsasser laryngoscope insertion through the uvula, posterior pharyngeal wall, and epiglottis until the vocal cords are visible. Injection of the filler is then done to the paralyzed vocal cords.
48444274|NCT06223763|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.
48444275|NCT06223763|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.
48444276|NCT06223763|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
48444277|NCT06133725|PROCEDURE|erector spinae plane block|The experimental group received ultrasound-guided erector spinae plane block, and bilateral erector spinae plane block was performed at T7 segment with 20ml 0.375% ropivacaine on each side.While the control group received ultrasound-guided transversus abdominis plane block combined with rectus sheath block, which will be performed under the costal margin with 10ml 0.375% ropivacaine for bilateral transversus abdominis plane block and 10ml 0.375% ropivacaine for bilateral rectus sheath block.
48444278|NCT02955641|DRUG|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
48444279|NCT02955641|DRUG|Nepafenac 0.1%|four drops a day for four days after LPI treatment
48444280|NCT02955641|DRUG|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
48444281|NCT00992147|DRUG|Adipocell|autologous cultured adipocytes (ANTG-adip)
48444282|NCT02334644|DIETARY_SUPPLEMENT|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
48444283|NCT02334644|DIETARY_SUPPLEMENT|Placebo|2 sachets/day x 12 weeks
48444284|NCT04097483|BEHAVIORAL|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
48444285|NCT05499572|DEVICE|Inhalation maneuver with placebo Inbrija and placebo Cyclops|Patients perform the inhalation maneuvers with placebo inhalers (Inbrija and Cyclops) during a Parkinson's off episode.
48444286|NCT05349435|DRUG|Fezagepras|Investigational drug
48444287|NCT05349435|DRUG|Sodium phenylbutyrate|Investigational drug
48444288|NCT00609674|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
48444289|NCT00609674|DRUG|Placebo|Placebo
48444290|NCT00707161|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
48444291|NCT00707161|DRUG|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
48444292|NCT00707161|PROCEDURE|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
48444293|NCT00752973|DRUG|MALG (malathion) Treatment|MALG applied for 30 minutes
48444294|NCT00817219|DRUG|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
48444295|NCT02875769|PROCEDURE|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
48444296|NCT02875769|DRUG|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
48444297|NCT02875769|DRUG|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
48444298|NCT02875769|OTHER|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
48444299|NCT02875769|OTHER|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
48277553|NCT05407623|BEHAVIORAL|PAX Good Behavior Game|"PAX GBG is packaged into ten specific tools that the teachers are trained to introduce in in their classroom management practice. The program introduces verbal and visual cues that facilitate prosocial and attentive behaviors One of the core elements of the program is the PAX-game, meaning that the children - while focusing on ordinary school tasks like math - get to play a game in teams where each team tries to make as few classroom rules infractions as possible during a certain period of time. The teams that succeed in achieving predetermined goals get a reward (often a fun and desirable activity) that serves as a reinforcer of prosocial and task-oriented behaviors.~Supervision is performed individually with each teacher and included that the PAX-trainer observes a lecture given by the teacher before each supervision session."
48444300|NCT06144385|BIOLOGICAL|CAR-GPC3 T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 . During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
48444301|NCT03925532|BIOLOGICAL|Denosumab|Given SC
48444302|NCT01151930|DRUG|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
48444303|NCT04552418|DRUG|Potato starch|Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
48444304|NCT02822326|BIOLOGICAL|CD19-CAR-T2 Cells|
48444305|NCT01745120|GENETIC|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
48444306|NCT04233385|OTHER|Myofascial Massage|The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.
48444307|NCT04233385|OTHER|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
48444308|NCT00488800|BIOLOGICAL|pneumococcal conjugate vaccine|
48444309|NCT00993122|DRUG|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
48444310|NCT05445739|BEHAVIORAL|The effect of an online exercise course on the increase of elders' regular exercise intention|The intervention of an online exercise course which 2 days a week for 4 weeks to increase the elders' regular exercise intention.
48444311|NCT02255097|BIOLOGICAL|pembrolizumab|
48444312|NCT01638377|DRUG|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
48444313|NCT01638377|DRUG|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
48444314|NCT06250309|DIETARY_SUPPLEMENT|Dietary assignment|A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.
48444315|NCT05177991|DRUG|Liposomal Bupivacaine|20cc of Liposomal Bupivacaine for TAP block
47927984|NCT02896322|RADIATION|Partial breast irradiation with cyberknife|
48444316|NCT05177991|DRUG|Bupivacaine|20cc of Bupivacaine for TAP block
48444317|NCT01882647|DRUG|000-0551 Lotion|
47927985|NCT05792657|BEHAVIORAL|High dosage in-person exercise coaching|High dosage (one hour each week) of in-person exercise coaching by an exercise professional.
48444318|NCT01882647|DRUG|Vehicle Lotion|
48444319|NCT01879345|DRUG|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
48444320|NCT01879345|DRUG|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
47927986|NCT05792657|BEHAVIORAL|Medium dosage in-person exercise coaching.|Medium dosage (one hour every other week) of in-person exercise coaching by an exercise professional.
48444321|NCT01879345|DRUG|Placebo|placebo tablets
48444322|NCT05479487|DRUG|Fluzoparib+Apatinib|Fluzoparib 100mg bid+ Apatinib 375mg qd
48444323|NCT05479487|DRUG|Fluzoparib Monotherapy|Fluzoparib 150mg bid
48444324|NCT02430272|DRUG|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
48277554|NCT05407623|BEHAVIORAL|Count on Me!|"Count on me! is set in adventure game where the child has an avatar that travels thru different worlds/platforms by using their mathematical skills. The child starts of in the home of the avatar, in a house like environment, where the child discovers a magical map that brings the child into a different world called Numberia. During the adventures in Numberia the child learns that it has certain skills, called the mathemagical powers, that will be used to liberate Numberia from the evil Prince Claw that has captured all the beautiful things (e.g., the birds that used to sing in the forest).~Count on me! was developed within a behavior analytic framework using a nonlinear programming process."
48277555|NCT05407623|BEHAVIORAL|Collegial Learning Community|"Collegial learning community is a feasible way of professional learning for teachers according to the five cyclical steps. The teachers go through the first step that is to assess the skill or knowledge gaps for students, using various data sources (for example testing, grades, surveys, student interviews). The second step is to reflect upon what skills the teacher needs to acquire in order to help the students to meet the goals. The third step is to deepen the professional knowledge and skills. The fourth step is engaging the students in the new practice, and in the fifth step to evaluate the impact the new practice has had on student outcomes.~In Collegial learning community teachers take help from their peers in each of these steps in a structured way. For example, way of deepening tacit or procedural knowledge (in step two) is to visit a colleague during class and make observations on their classroom practice."
48277556|NCT01995890|DRUG|nepafenac|
48277557|NCT01244737|DRUG|[18F] FLT|\[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
48277558|NCT03420560|BEHAVIORAL|warmer temperature|Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
48277559|NCT00297414|OTHER|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
48277560|NCT02979756|PROCEDURE|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
48277561|NCT02586857|DRUG|ACP-196|Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
48277562|NCT06154629|DIETARY_SUPPLEMENT|Botanical ingredient|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
48277563|NCT06154629|DIETARY_SUPPLEMENT|Control group|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
48277564|NCT00116454|DRUG|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
48277565|NCT02806401|DEVICE|landmark|
48277566|NCT02806401|DEVICE|US_Ax|
48277567|NCT01574534|DEVICE|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
48277568|NCT01574534|DEVICE|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
48277569|NCT02602509|DRUG|Celecoxib|
48277570|NCT02602509|DRUG|Rifampicin|
48277571|NCT02602509|DRUG|Pyrazinamide|
48277572|NCT00853983|DRUG|[14C] AZD0530|Solution, Oral, once
48277573|NCT03007264|DEVICE|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
48277574|NCT04117750|DIETARY_SUPPLEMENT|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
48277575|NCT04511702|BIOLOGICAL|Pegloticase with MTX|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
48277576|NCT05426148|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®|The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
48277577|NCT01392833|DRUG|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
48277578|NCT01392833|DRUG|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
48277579|NCT01392833|DRUG|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
48277580|NCT05300048|DRUG|Serabelisib|serabelisib administered orally
48277581|NCT05300048|OTHER|Insulin Suppressing Diet|3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
48277582|NCT05300048|DRUG|Nab paclitaxel|nab-paclitaxel administered intravenously weekly
48277583|NCT00000851|DRUG|Stavudine|
48277584|NCT00000851|DRUG|Didanosine|
48277585|NCT01982825|BEHAVIORAL|Online intervention arm|See online intervention arm
48277586|NCT01982825|BEHAVIORAL|Online control arm|See online control arm
48277587|NCT06504381|GENETIC|DB107-RRV|Given intracranially (IC) during resection and intravenously (IV) immediately following
48277588|NCT06504381|GENETIC|DB107-FC|Given orally (PO)
48277589|NCT06504381|RADIATION|Radiation Therapy (RT)|Undergo RT
48277590|NCT06504381|DRUG|Temozolomide|Given PO
48277591|NCT06504381|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo standard of care MRI
48277592|NCT06504381|PROCEDURE|Surgical resection|Undergo non-investigational tumor resection
48277593|NCT00003558|DRUG|carboplatin|
48277594|NCT00003558|DRUG|etoposide|
48277595|NCT00003558|DRUG|fluorouracil|
48277596|NCT00003558|DRUG|leucovorin calcium|
48277597|NCT00003558|DRUG|paclitaxel|
48444325|NCT03171545|BEHAVIORAL|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
48098080|NCT00586274|DRUG|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m\^2
48277598|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
48277599|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
48277600|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
48277601|NCT01888094|OTHER|Ultrasound-guided cannulation and examination|
48277602|NCT00269763|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
48277603|NCT02318056|OTHER|Aquacel® Ag Burn Glove|burn dressing
48277604|NCT02318056|OTHER|Mepilex® Transfer Ag|burn dressing
48277605|NCT02318056|DRUG|antibiotic|antibiotic burn dressing
48277609|NCT00988390|BEHAVIORAL|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
48277610|NCT02339948|RADIATION|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
48277611|NCT06247826|PROCEDURE|Blood sampling|Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.
48277612|NCT01058603|OTHER|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
48277613|NCT01058603|OTHER|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
48277614|NCT04857021|DIETARY_SUPPLEMENT|GABA|oral administration of GABA capsule once daily before sleep
48277615|NCT04857021|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo capsule once daily before sleep
48277616|NCT02494141|DRUG|Curcumin|Dietary Supplement
48277617|NCT02494141|OTHER|Placebo|
48277618|NCT04626830|OTHER|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
48277619|NCT04937699|DRUG|Standard-DAPT of Ticagrelor plus aspirin|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
48277620|NCT04937699|DRUG|Sequential monotherapy of Ticagrelor and clopidogrel|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
48277621|NCT06559839|OTHER|Vestibulocortical Stimulation|50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.
48277622|NCT05655585|OTHER|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
48277623|NCT05655585|OTHER|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
48277624|NCT01929070|DRUG|HCP1007|
48277625|NCT01929070|DRUG|Omarco and Crestor|
48277626|NCT03582358|OTHER|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
48277627|NCT01264939|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
48277628|NCT01264939|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
48277629|NCT01264939|DRUG|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
48277630|NCT01264939|DRUG|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
48277631|NCT04176861|DEVICE|home-based Brainwave Entrainment Technology|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
48277632|NCT01717638|BIOLOGICAL|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
48277633|NCT01717638|BIOLOGICAL|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
48277634|NCT06602141|PROCEDURE|Muscle Biopsy|This procedure is used to sample muscle cells from the leg Vastus Lateralis (thigh) muscle.
48277635|NCT06602141|PROCEDURE|Adipose Biopsy|This procedure is used to sample fat tissue from the abdomen (belly).
48277636|NCT06602141|OTHER|Glucose Clamp|In this test, we will measure the effect of insulin by giving you insulin and glucose (sugar) intravenously through an IV line in your arm.
48277637|NCT06602141|OTHER|Accelerometer|The tri-axial accelerometer measure activity and uses those values to estimate the number of calories burned based on your height, weight, age, and gender. The monitor also evaluates physical effort and the body's response to different activities.
48277638|NCT06602141|OTHER|Endurance Exercise|Visit the study site 3 times a week to engage in endurance exercise training for approximately 12 weeks. Each session will last approximately 75 minutes, and exercise group can choose to use either a stationary bike or a treadmill to complete the training.
48444326|NCT03171545|BEHAVIORAL|Provider Education|Staff in clinics assigned to this group will receive team training and a checklist.
48444327|NCT03680248|DIETARY_SUPPLEMENT|Fat|Subjects will consume dairy cream (150 g of fat) at time 0 hours.
48444328|NCT03680248|DIETARY_SUPPLEMENT|Fasting|Subjects will fast throughout the experiment.
48277639|NCT06602141|OTHER|Physical activity/ dietary habits|Visit the study site bi-weekly to get weight measurements and speak to the study team about weight maintenance and participant physical activity/dietary habits.
48277640|NCT06602141|OTHER|Heavy Water Labeling Period|Participants in both control groups will be required to drink heavy water, which is ordinary water that is enriched with deuterium (stable, non-radioactive isotope) and called deuterium-labeled water, for 12 weeks.
48444329|NCT03680248|DIETARY_SUPPLEMENT|Fat+Glucose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.
48444330|NCT03680248|DIETARY_SUPPLEMENT|Glucose|Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.
48277641|NCT00234949|DRUG|cefdinir|
48277642|NCT00234949|DRUG|cephalexin|
48277643|NCT02867696|OTHER|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
48277644|NCT02867696|BEHAVIORAL|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
48277645|NCT04132050|DRUG|R788|Oral administration
48277646|NCT04132050|DRUG|Placebo|Oral administration
48277647|NCT04568330|OTHER|best support care|Best support care
48277648|NCT04568330|OTHER|moisture cream|BSC plus moisture cream
48277649|NCT04568330|OTHER|10% urea-based cream|BSC plus 10% urea-based cream.
48277650|NCT02945982|DRUG|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
48277651|NCT02945982|DRUG|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
48277652|NCT01634373|DRUG|Torrent's Quetiapine Fumarate Tablets|
48277653|NCT00592683|DRUG|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
48277654|NCT00592683|DIETARY_SUPPLEMENT|fish oil|1600mg (4 capsules) daily for 12 weeks
48277655|NCT00592683|DRUG|Placebo|Placebo
48277656|NCT04920409|OTHER|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which \< 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
48277657|NCT04920409|OTHER|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
48277658|NCT03441126|OTHER|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
48277659|NCT06367322|DRUG|Statin|"The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy."
48277660|NCT02747082|PROCEDURE|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
48277661|NCT02042066|DEVICE|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
48277662|NCT06249529|DEVICE|Airway Bypass|Bypass stent(s) are implanted to allow air trapped in the parenchyma to escape
48277663|NCT01159262|DRUG|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
48277664|NCT01159262|DRUG|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
48277665|NCT01159262|DRUG|Dexmedetomidine|
48277666|NCT02158078|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
48277667|NCT01104220|OTHER|Weight loss|Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight
48277668|NCT03747445|PROCEDURE|Roux-en-Y gastric bypass|laparoscopic surgical procedure
48277669|NCT06454864|BEHAVIORAL|Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
48277670|NCT06454864|BEHAVIORAL|Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
48277671|NCT06454864|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching.
48277672|NCT01993979|DRUG|Chemotherapy|
48277673|NCT01993979|OTHER|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
48277674|NCT01883570|OTHER|training in visual search strategy|
48277675|NCT01883570|OTHER|access to a library of chest x-rays without search strategy|
48277676|NCT01914679|DEVICE|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
48277677|NCT04102150|DRUG|Valemetostat Tosylate|Once a day, 200 mg, oral administration
48277678|NCT02820961|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDAC)
48277679|NCT02820961|DRUG|exemestane|Aromatase inhibitor
48277680|NCT02590393|COMBINATION_PRODUCT|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
48277681|NCT05316896|OTHER|Internal Perturbation|"* Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~* In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* Step forward and backward with right and left foot alternately~* Take a step back and step back alternately with right and left foot~* Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~* First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~* Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait."
48277682|NCT05316896|OTHER|Eksternal Perturbation|"* Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~* Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~* Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~* Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~* Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~* Holding the ball thrown by physiotherapist~* Kicking a ball thrown by physiotherapist~* Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards."
48277683|NCT03920969|BEHAVIORAL|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
48277684|NCT03332069|DEVICE|Modulated electro-hyperthermia|Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
48277685|NCT03332069|RADIATION|External beam radiation|
48277686|NCT03332069|DRUG|Cisplatin|
48277687|NCT03332069|RADIATION|Brachytherapy|High Dose Rate
48277688|NCT06487156|DRUG|Nivolumab + ipilimumab|As per product label
48277689|NCT00430807|DRUG|hydroxychloroquine/placebo|
48277690|NCT00622193|DRUG|anamorelin HCl|50 mg tablet
48277691|NCT00622193|DRUG|anamorelin HCl|100 mg tablet
48277692|NCT00622193|DRUG|placebo|placebo tablet
48277693|NCT03111030|BEHAVIORAL|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~1. An assessment of motivated the participant is to be physically active~2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~   B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~3. Progress and barriers will be reassessed and discussed."
48277694|NCT03707184|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48277695|NCT03707184|DRUG|Fluciclovine F18|Given IV
48277696|NCT03707184|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48277697|NCT01717248|DRUG|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
48277698|NCT03360812|OTHER|Online training resource|Please see information included in the description of the intervention group.
48277699|NCT04629729|DRUG|FT819|Experimental Interventional Therapy
48277700|NCT04629729|DRUG|Cyclophosphamide|Lympho-conditioning agent
48277701|NCT04629729|DRUG|Fludarabine|Lympho-conditioning agent
47927987|NCT05792657|BEHAVIORAL|Low dosage in-person exercise coaching|Low dosage (one hour every month) of in-person exercise coaching by an exercise professional
48277702|NCT04629729|DRUG|IL-2|Biologic response modifier
48277703|NCT04629729|DRUG|Bendamustine|Lympho-conditioning agent
48277704|NCT05296967|BEHAVIORAL|chewing|patients are asked to chew chewing gum X 3/ day
48277705|NCT05347615|PROCEDURE|IOL Implantation:EDOF lens|A EDOF lens is implanted in the dominant eye
48277706|NCT05347615|PROCEDURE|IOL Implantation: Monofocal lens|A monofocal lens is implanted in the non dominant eye.
48277707|NCT06657248|DEVICE|univation® XF Pro|Primary medial unicompartmental knee arthroplasty
48277708|NCT03724448|DRUG|aleozen|treatment with herbal medicine
48277709|NCT03724448|DRUG|Placebo Oral Tablet|No aleozen treatment
48277710|NCT02210156|DIETARY_SUPPLEMENT|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
48277711|NCT02210156|OTHER|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
48098081|NCT00586274|BIOLOGICAL|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are \> 1000/ul.~Dose level -1 (1 x 10\^3 T cells/Kg); Dose level 1 (1 x 10\^4 T cells/Kg); Dose level 2 (1 x 10\^5 T cells/Kg); Dose level 3 (1 x 10\^6 T cells/Kg); Dose level 4 (5 x 10\^6 T cells/Kg)"
48277712|NCT04398732|DRUG|Enbrel|As provided in real world practice
48277713|NCT05372809|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
48277714|NCT05372809|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen-alginate primary wound dressing~* Local offloading with felt pad for wounds on weight bearing surfaces~* Foam~* Multi-layer compression dressing~* Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations"
48277715|NCT05668221|BEHAVIORAL|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
48277716|NCT04490629|DEVICE|Lyoplant Onlay|Lyoplant Onlay is a kind of latest artificial Dura Mater
48277717|NCT04490629|DEVICE|DURAFORM|DURAFORM is a kind of conventional artificial Dura Mater
48277718|NCT01149200|DRUG|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
48277719|NCT01149200|DRUG|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
48277720|NCT06172101|OTHER|Free fat flap|Free fat flap In Recurrent neurogenic thoracic outlet syndrome Surgical Treatment
48444331|NCT03680248|DIETARY_SUPPLEMENT|Fat+Fructose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.
48444332|NCT03680248|DIETARY_SUPPLEMENT|Fructose|Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
48444333|NCT02373397|DEVICE|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
48444334|NCT02373397|DEVICE|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
48444335|NCT01244022|PROCEDURE|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
48444336|NCT03141398|DIAGNOSTIC_TEST|Continuous Glucose Monitoring (CGM)|Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
48444337|NCT03141398|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test (OGTT)|Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.
48444338|NCT03141398|DIAGNOSTIC_TEST|T2* MRI of the Pancreas|MRI \[Magnetic resonance imaging\] of the pancreas which is safe and takes around 30 minutes.
48444339|NCT04065867|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
48444340|NCT04082858|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
48444341|NCT04082858|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
48098082|NCT00586274|BIOLOGICAL|Campath 1h|10 mg iv over 4 hours day-8 through day-6
48098083|NCT00586274|BIOLOGICAL|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
48444342|NCT03113422|DRUG|Induction Venetoclax|"1 cycle = 28 days.~* Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~* Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~* Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine."
48444343|NCT03113422|DRUG|Maintenance Venetoclax|Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
48444344|NCT04461379|BIOLOGICAL|BCG vaccine|A single dose BCG vaccine intradermally (deltoid region of the right arm) 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis . (Tokio 172 strain)
48444345|NCT04461379|OTHER|Placebo|A single dose intradermally ((deltoid region of the right arm) 0.1 ml of NaCl 0.9% solution
48444346|NCT03977272|DRUG|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
48444347|NCT03977272|DRUG|Chemotherapy|modified-FOLFIRINOX
48444348|NCT00112190|DRUG|Itopride Hydrochloride|100 mg tid
48098084|NCT02024308|DRUG|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
48277721|NCT01968941|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
48098085|NCT02024308|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
48277722|NCT01968941|RADIATION|Conventional Radiotherapy (CRT)|
48277723|NCT06464107|DEVICE|PadKit™ from Preprogen|"The interlabial pad is classified as a Class 1 device by the FDA and the device is exempt from requiring a 510(k) approval.~The interlabial pad is worn for 4-6 consecutive hours and collects cells shed from the cervix and uterine cavity. The pad is then removed and placed in the smaller, inner tube that contains the transport solution. After replacing the lid securely, it is then carefully placed back inside the larger outer tube with the outer lid secured and returned to the original box. The entire box is placed in the polybag and mailed back to the lab for analysis."
48277724|NCT00003803|DRUG|cisplatin|
48277725|NCT00003803|DRUG|gemcitabine hydrochloride|
48277726|NCT00003803|RADIATION|radiation therapy|
48277727|NCT05525663|BEHAVIORAL|Rehabilitation Intervention|progressive, multi-domain rehabilitation and exercise training intervention
48277728|NCT03539432|DRUG|Gemfibrozil 600 MG|Gemfibrozil capsules (600 mg) taken twice per day
48277729|NCT03539432|DRUG|Placebo oral capsule|Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
48277730|NCT04755556|OTHER|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
48277731|NCT04755556|OTHER|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
48277732|NCT00296322|DRUG|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
48277733|NCT05792202|PROCEDURE|microfracture procedure|double raw repair combined with microfracture procedure which promotes tendon healing by releasing growth factors
48277734|NCT05792202|PROCEDURE|only double raw repair|the double raw repair was used to repair the tendon tear
48277735|NCT05747989|PROCEDURE|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
48277736|NCT05747989|PROCEDURE|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
48277737|NCT05374486|DEVICE|NeuroExo co-robot neurorehabilitation system|In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
48277738|NCT05356793|DRUG|SCH-1|Novel anti-infective eyedrop
48277739|NCT05356793|DRUG|Placebo|SCH-1 vehicle minus active components eyedrop
48277740|NCT05284695|PROCEDURE|Bariatric surgery|Patients undergoing elective bariatric surgery
48277741|NCT06112587|BEHAVIORAL|strength training|A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
48277742|NCT06657690|DRUG|Irinotecan liposome|Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.
48444349|NCT00112190|DRUG|itopride|100 mg three times daily
48444350|NCT03468764|PROCEDURE|Vigileo monitoring during lung recruitment maneuver|"Standard monitoring parameters, invasive blood pressure and hemodynamic values (SVV and CO, through Vigileo device) will be monitored. With the patient in a supine position and as SVV reaches a value of 12-15%, a LRM is performed, consisting in the application of 30 cm H2O continuous positive airway pressure for 30 seconds.~The alterations in the above mentioned parameters will be registered before and after the maneuver.~The same procedure will be performed after a 8 ml/kg crystalloids fluid challenge, as soon as SVV reaches the value of 10%."
48444351|NCT02538523|DEVICE|Erchonia FX-635|The Erchonia FX-635 is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
48444352|NCT02538523|DEVICE|Placebo Laser|The Placebo Laser is applied to the lower back and hips area for 20 minutes per treatment administration, 8 times across 4 weeks, 2 times per week.
48444353|NCT02745054|OTHER|mgt of bleeding concerns/complications of oral anticoagulants|observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only
48444354|NCT05497362|DEVICE|Real tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.
48444355|NCT05497362|DEVICE|Sham tDCS|2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
48444356|NCT00706186|DRUG|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
48444357|NCT01096433|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
48444358|NCT02527382|PROCEDURE|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
48444359|NCT01165086|OTHER|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
48444360|NCT04775745|DRUG|LP-168|For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.
48444361|NCT04775745|DRUG|LP-168|For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
48444362|NCT05902702|OTHER|Nebulized isotonic saline|The intervention will constitute nebulized isotonic saline.
48444363|NCT05902702|OTHER|Nasal irrigation with isotonic saline|The intervention will constitute isotonic saline administered as nasal drops.
48444364|NCT03187158|DIAGNOSTIC_TEST|Forced Oscillation Technique|F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
48444365|NCT02197481|PROCEDURE|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
48444366|NCT02197481|DEVICE|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
48444367|NCT04582019|DEVICE|stent extraction|stent extraction using magnetic retriever or flexible cystoscope
48444368|NCT06196281|OTHER|wooble board proprioceptive training|this includes wooble board proprioceptive training twice a day for four weeks
48444369|NCT06196281|OTHER|multi-station proprioceptive training|this includes multi-station proprioceptive training twice a day for four weeks
48444370|NCT01982981|OTHER|water provision|perception behavioral change at the beginning and at the end of the intervention
48444371|NCT01982981|OTHER|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
48444372|NCT02874677|OTHER|Effort reeducation program|personalized reeducation program at a load level preceding hyperventilation
48444373|NCT02593357|DEVICE|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
48444374|NCT05615454|DEVICE|bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).|The experimental group (receive the BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
48444375|NCT05615454|DEVICE|placebo BEMER|Comparison group (receive placebo BEMER therapy) for five sessions/week for three weeks. Plus, pelvic floor exercise.
48444376|NCT02115347|DRUG|Ertugliflozin 15 mg|Tablet
48098086|NCT04792099|PROCEDURE|Continuous positive airway pressure|After study entry, CPAP will be provided via mask or binasal prongs in order to have a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery. A PEEP of 5 will be used for uniformity.
48277743|NCT06657690|DRUG|S-1|S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).
48444377|NCT03284476|OTHER|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
48444378|NCT01767363|OTHER|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
48444379|NCT01767363|OTHER|Alpha-blockers|Use of alpha-blockers over the study period.
48444380|NCT05514860|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
47927988|NCT03409978|DEVICE|in-Motion app|mobile phone application for recording fidgety movements at home
47927989|NCT02735499|DRUG|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
48444381|NCT05514860|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
48444382|NCT00056667|BEHAVIORAL|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
48444383|NCT00056667|BEHAVIORAL|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
48444384|NCT00056667|OTHER|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
48444385|NCT00359281|DRUG|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
48444386|NCT00359281|DRUG|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
48444387|NCT00359281|DRUG|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
48444388|NCT00359281|DRUG|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
48444389|NCT00359281|DRUG|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
48444390|NCT00359281|DRUG|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
48444391|NCT01083784|DRUG|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
48444392|NCT01083784|DRUG|Control group|Control group
48444393|NCT03575403|DRUG|Alcohol|In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
48444394|NCT03575403|DRUG|Placebos|Subjects will receive placebo capsules.
48444395|NCT03575403|DRUG|Duloxetine|Subjects will receive duloxetine capsules.
48444396|NCT03575403|DRUG|Methylphenidate|Subjects will receive methylphenidate capsules.
48444397|NCT05107323|BEHAVIORAL|Compassionate Mind Training for Teachers|Compassionate Mind Training for Teachers is a biopsychosocial evidence-based approach that aims to foster compassion, affect regulation, prosocial qualities and wellbeing in teachers.
48444398|NCT03184389|BEHAVIORAL|Prompt to use smartphone apps for stress management|Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
48620352|NCT04892160|OTHER|Virtual Reality|Upon completion of study paperwork and 3-5 minutes prior to the nurse entering the room, study personnel will assist the patient in beginning the VR intervention during one of these procedures: port access, dressing changes, and IV sticks. The VR intervention consists of interactive audio and visual underwater experience. The VR software offers both passive and active gameplay over the course of 15 minutes, which can be repeated. In the passive experience, the software moves patients through an ocean filled with sea creatures and allows them to look around and observe the underwater scene. In the active experience, patients launch balls at the fish. Patients will be encouraged but not required to actively participate; staff will record whether the patient participates in the active portion of the VR program. Study personnel will remain in the room to record the time of the procedure, staff number, time in the room, and complete an observational measure of distress.
48620353|NCT03422185|OTHER|No intervention|No intervention
48620354|NCT00117819|DRUG|[123I]ß CIT and SPECT imaging|To assess \[123I\]ß CIT and SPECT imaging
47927990|NCT02104037|PROCEDURE|Lumbar puncture|
48444399|NCT01990391|DIETARY_SUPPLEMENT|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
48444400|NCT01990391|DIETARY_SUPPLEMENT|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
48444401|NCT00859105|DRUG|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
48620355|NCT01063907|DRUG|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
48620356|NCT01063907|DRUG|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
48620357|NCT03829384|BIOLOGICAL|mRNA-1944|mRNA encoding Chikungunya antibody
48620358|NCT03829384|OTHER|Placebo|Saline
48620359|NCT00025467|DRUG|thalidomide|Given orally
48620360|NCT00025467|OTHER|laboratory biomarker analysis|Correlative studies
48444402|NCT00859105|DRUG|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
48444403|NCT00859105|DRUG|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
48444404|NCT00859105|DRUG|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
48444405|NCT06406491|DEVICE|active microprocessor-controlled knee|Active microprocessor-controlled knees are motorized prosthesis, actively supporting the users while walking, getting up, and climbing stairs.
48277744|NCT02421198|BEHAVIORAL|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
48277745|NCT02355301|PROCEDURE|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
48277746|NCT03538028|BIOLOGICAL|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
48277747|NCT02109237|PROCEDURE|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
48277748|NCT01725880|OTHER|Observation|
48277749|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg
48277750|NCT02319369|DRUG|AZA|AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
48277751|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
48277752|NCT02987855|PROCEDURE|Lipoaspiration|Closed syringe harvesting subdermal fat
48277753|NCT02987855|PROCEDURE|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
48277754|NCT02987855|PROCEDURE|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
48277755|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 1|"The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix."
48277756|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 2|Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
48277759|NCT03965143|DEVICE|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
48277760|NCT04928014|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
48277761|NCT03475225|DRUG|Cholecalciferol|Cholecalciferol delivery
48277762|NCT03475225|DRUG|Placebo Oral|manufactured to mimic Cholecalciferol
48277763|NCT04996693|DIAGNOSTIC_TEST|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
48277764|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
48277765|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
48277766|NCT06382090|OTHER|Laughter yoga|This practice, which includes deep breathing exercises and laughter exercises, takes approximately 45 minutes. The sessions will be conducted by the principal investigator.
48277767|NCT02261441|OTHER|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
48277768|NCT00346827|DRUG|Apomorphine Nasal Powder|
48444406|NCT00550758|DRUG|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
48620361|NCT03617887|OTHER|Experimental group|"Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group."
48277769|NCT02452333|PROCEDURE|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
48277770|NCT02452333|PROCEDURE|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
48277771|NCT02452333|OTHER|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
48277772|NCT02452333|OTHER|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
48444407|NCT00550758|DEVICE|spirometry|spirometry
48444408|NCT06002230|DRUG|Homeopathic medicines|Globules were administered orally..
48620362|NCT03617887|OTHER|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
48277773|NCT04207398|PROCEDURE|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
48277774|NCT04207398|OTHER|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
48277775|NCT01381081|BIOLOGICAL|platelet-rich plasma|a single intra-articular injection
48277776|NCT01381081|DRUG|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
48277777|NCT01936740|PROCEDURE|cataract surgery|
48444409|NCT00185458|DRUG|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
48444410|NCT01004341|BEHAVIORAL|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
48444411|NCT04042285|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period.
48444412|NCT04042285|OTHER|Standard Wound Care|dressing changes, negative pressure wound therapy, offloading footwear, debridement, glycaemic control and antibiotics as necessary
48444413|NCT02502474|OTHER|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
48444414|NCT03121443|OTHER|Perfusion index|supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
48444415|NCT04425928|PROCEDURE|occupational therapy based activity training programs|Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
48444416|NCT04425928|PROCEDURE|Physiotherapy based exercise training programs|Cawthorne-cooksey exercises were performed at vestibular rehabilitation
48444417|NCT05879653|DRUG|MK-3475|During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.
48444418|NCT05879653|DRUG|ASG-22CE|During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.
48444419|NCT05879653|PROCEDURE|maximal TURBT|All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
48444420|NCT05879653|RADIATION|Radiation therapy|Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
48444421|NCT05038293|DEVICE|Automated mouthpiece-based toothbrush|One-time use during study visit.
48444422|NCT05038293|DEVICE|Manual toothbrush|One-time use during study visit.
48444423|NCT02649179|DRUG|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
48444424|NCT02649179|DRUG|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
48444425|NCT01350557|OTHER|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
48444426|NCT01350557|OTHER|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
48444427|NCT02664103|DRUG|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
48444428|NCT01190865|BIOLOGICAL|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
48444429|NCT05408169|BEHAVIORAL|Suggested deadline for return of screening test|"A screening invitation letter modified to state, highlighted in yellow: Please return your kit within \[X\] weeks (by \[DD.MM.YYYY\]) or as soon as possible."
48277778|NCT01591330|DRUG|LY2140023 Reference form|80-mg tablet administered orally
48277779|NCT01591330|DRUG|LY2140023 Test-Low|80-mg tablet administered orally
48277780|NCT01591330|DRUG|LY2140023 Test-Medium|80-mg tablet administered orally
48277781|NCT01591330|DRUG|LY2140023 Test-High|80-mg tablet administered orally
48277782|NCT05240261|DRUG|Quetiapine|Quetiapine 25 mg / day
47927991|NCT03654573|DEVICE|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
48444430|NCT05408169|BEHAVIORAL|Planning sheet|A planning tool presented on a separate single sheet of paper inserted into the screening invitation envelope. The colour illustrated tool prompts participants to identify concerns they have with using the bowel screening kit and to link them to a tip to help them overcome this concern.
48444431|NCT06359938|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
48444432|NCT06359938|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
48444433|NCT01846923|BIOLOGICAL|PCV13|
48444434|NCT04715893|DEVICE|Ostomy belt|Stealth ostomy belt continuous for eight weeks
48444435|NCT01209793|BIOLOGICAL|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
48444436|NCT00312897|DRUG|Omega-3 Fatty Acids|10 wk treatment period
48444437|NCT00312897|DRUG|corn oil|placebo comparator
48444438|NCT04914611|OTHER|No intervention|No intervention
48444439|NCT03222557|PROCEDURE|Electroacupuncture|Refer to arm description
48444440|NCT03222557|PROCEDURE|Sham Acupuncture|Refer to arm description
48098087|NCT04792099|PROCEDURE|Nasal Cannula|After study entry, flow will be set to 0.5 L/kg with 1L maximum while on NC during the study period to reduce the risk of inadvertent PEEP with higher flows. Initial FiO2 can be titrated to achieve target saturations, and may be increased up to 100% while on NC.
47927992|NCT03660137|DEVICE|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
47927993|NCT01306929|DRUG|pridopidine|45mg bid
48098088|NCT05954169|DRUG|SHR4640|SHR4640 single-dose
47927994|NCT06518850|DRUG|Rifaximin|Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
48098089|NCT03618095|DEVICE|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
48098090|NCT01392755|DRUG|danoprevir|oral doses of danoprevir
48098091|NCT01392755|DRUG|omeprazole|oral doses of omeprazole
48098092|NCT01392755|DRUG|ranitidine|oral dose of ranitidine
48098093|NCT01392755|DRUG|ritonavir|oral doses of ritonavir
48098094|NCT05133362|DEVICE|Gait training with EksoNR|Participants will receive forward gait training with EksoNR
48444441|NCT03222557|DEVICE|Electroacupuncture|Refer to arm description
48444442|NCT03222557|DEVICE|Sham Acupuncture|Refer to arm description
48444443|NCT03199547|DRUG|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
48444444|NCT03199547|DRUG|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
48444445|NCT02447874|DRUG|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~* Loading dose: 200 mg/kg once~* Continuous IV: 300 mg/kg/24 hours"
48444446|NCT02447874|DRUG|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
48444447|NCT02447874|DRUG|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
48444448|NCT00002764|BIOLOGICAL|filgrastim|
48444449|NCT00002764|DRUG|doxorubicin hydrochloride|
48444450|NCT00002764|DRUG|ifosfamide|
48444451|NCT00002764|PROCEDURE|conventional surgery|
48444452|NCT04510545|DIAGNOSTIC_TEST|Endobrain, Computer Aided Diagnosis (CAD)|Artificial intelligence
48444453|NCT01185691|DEVICE|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
48444454|NCT03682341|GENETIC|endometriosis|patients with or without ovarian endometriosis
48444455|NCT05663411|DRUG|SHR6508|SHR6508
48444456|NCT05663411|DRUG|SHR6508|SHR6508
48444457|NCT05663411|DRUG|Cinacalcet|Cinacalcet
48444458|NCT05665686|DEVICE|Relaxation training with device|Relaxation training will be applied with the device.
48444459|NCT05665686|OTHER|Home Exercise|An exercise application including home exercise programs will be performed for six weeks.
48444460|NCT05792072|DEVICE|rTMS|High-frequency rTMS
48444461|NCT05792072|DEVICE|Sham rTMS|sham rTMS
48620363|NCT05625464|OTHER|SCTP|Real-time automated monitoring of the electronic medical record to identify suspected sepsis patients without completion of sepsis bundle measures within 1-hour of the completion deadline and generated reminder pages. Clinicians responsible for patients randomized to the intervention receive reminder pages whereas no pages are sent for control arm patients.
48444462|NCT01922180|RADIATION|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
48444463|NCT02892253|DEVICE|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
48444464|NCT01291121|PROCEDURE|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
48444465|NCT03944330|DIETARY_SUPPLEMENT|standard hospital diet|patients were provided standard hospital diet that provided 25-30 kcal/kg/day
48444466|NCT04188197|OTHER|JUUL|Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
48444467|NCT05819918|DRUG|Calcifediol|Subjects hospitalized with COVID-19 treated with calcifediol
48444468|NCT05819918|DRUG|Best available therapy|Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
48444469|NCT04433611|DRUG|2% lidocaine|"intrauterine infusion of 2% lidocaine (Rafa laboratories, Israel) just prior to HyFoSy~The VAS consisted of a 10 cm line ranging from 0 to 10 (anchored by 0=no pain and 10=very severe pain). Patients were asked to mark the number that represented their perceived level of pain. Based on the VAS scores, the pain level ratings were classified as: mild (rated 1-3), moderate (4-6) or severe (7-10)."
48444470|NCT04433611|DRUG|0.9 % normal saline|intrauterine infusion of 0.9 % normal saline
48444471|NCT04886973|OTHER|Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.|Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
48444472|NCT00440453|OTHER|Nutritional therapy|Nutritional therapy by dietician
48444473|NCT01046474|BEHAVIORAL|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
48620364|NCT01048424|DEVICE|RESPeRATE|"RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate."
48277783|NCT06327230|PROCEDURE|Thoracic Epidural Analgesia|Thoracic epidural analgesia is performed by a standardized anesthesia team. Patients are positioned in the lateral decubitus position, and routine disinfection is performed. The puncture site is selected at the T7-T9 level. When encountering sudden disappearance of resistance and appearance of negative pressure during needle advancement, it is determined that the needle has entered the epidural space. After confirming needle tip placement in the epidural space with a test dose, an epidural catheter is inserted approximately 3-5cm cephalad and securely fixed in place. The test dose consists of 3 mL of 1% lidocaine injection solution, administered to observe the level of anesthesia, confirming the effectiveness and safety of the epidural anesthesia. Subsequently, a maintenance regimen of 0.15% ropivacaine 250mL with 2.5mg of hydroma.
48277784|NCT03240926|DEVICE|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
48277785|NCT00222105|DRUG|Doxil|Doxil 40 mg/m2 IV day 1
48277786|NCT00222105|DRUG|Thalidomide|50-100 mg day 1-28
48277787|NCT00222105|DRUG|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
48277788|NCT03065829|BEHAVIORAL|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
48277789|NCT03065829|BEHAVIORAL|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
48277790|NCT05437887|DIETARY_SUPPLEMENT|Fucoidan|All patients consumed fucoidan.
48277791|NCT01814657|DRUG|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
48277792|NCT01814657|DRUG|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
48277793|NCT04721353|DRUG|Prazosin Hydrochloride|prazosin hydrochloride oral 1-25 mg/day
48277794|NCT03515187|DRUG|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
48277795|NCT03515187|DRUG|0.1% sodium bromide solution|one to two drops in eye, twice per day
48277796|NCT03515187|OTHER|Meibomian gland massage|Physiotherapy
48277797|NCT03515187|OTHER|Placebo|Vehicle
48444474|NCT05673317|OTHER|"Breastfeeding at AU Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
48444475|NCT06223893|DEVICE|CirrhoCare management system|"This is a UKCA-marked, digital-therapeutic system consisting of:~* clinical-grade, cirrhosis monitoring sensors and a smartphone app,~* a clinical team-facing, decision-facilitating dashboard, and~* CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: \~Wellue BP monitor, \~Wellue weighing scale \~Bluetooth thermometer.~The CirrhoCare management system also includes:~* The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~* The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring."
48444476|NCT02365454|DEVICE|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
48444477|NCT02977260|OTHER|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
48444478|NCT02977260|OTHER|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
48444479|NCT02977260|OTHER|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
48444480|NCT02977260|OTHER|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
48444481|NCT00961168|OTHER|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
48444482|NCT00961168|OTHER|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
48444483|NCT01967485|OTHER|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
48444484|NCT01967485|OTHER|Treatment as usual|Children will receive stimulant treatment for ADHD.
48444485|NCT04258917|DEVICE|Study withdrawn|Study withdrawn
48444486|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 1
48444487|NCT01613040|DRUG|Moxifloxacin|Single oral dose on Day 11
48444488|NCT01613040|DRUG|RO4917838|Multiple daily low doses of RO4917838 for 10 days
48444489|NCT01613040|DRUG|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
48444490|NCT01613040|DRUG|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
48620365|NCT01048424|OTHER|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
48098095|NCT05133362|PROCEDURE|Backward gait training with EksoNR|Participants will receive backward gait training with EksoNR
48444491|NCT05375604|DRUG|CDK-004|ASO-STAT6 exosome administered Intravenously
48444492|NCT03430830|DRUG|Ravidasvir 50mg|50mg, Tablet
48444493|NCT03430830|DRUG|Ravidasvir 200mg|200mg, Tablet
48444494|NCT04309981|BIOLOGICAL|Adult differentiated autologous T-cells with anti-BCMA specificity|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
48444495|NCT04678882|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
48444496|NCT04678882|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
48444497|NCT05088343|DRUG|Rosuvastatin|Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.
48444498|NCT05088343|DRUG|Hetrombopag|7.5 mg hetrombopag was administered on Day 6 to Day 11.
48444499|NCT00000661|DRUG|Oxazepam|
48444500|NCT00000661|DRUG|Zidovudine|
48444501|NCT03011294|DEVICE|Continuous positive airway pressure (CPAP)|Standard treatment for sleep apnea
48444502|NCT03011294|DEVICE|Nasal strip|Placebo
48444503|NCT01853657|OTHER|Virological monitoring|
48444504|NCT03393208|DRUG|Test GIR|Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
48098096|NCT06617169|DRUG|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.
48098097|NCT05851417|DEVICE|Fast Field-Cycling (FFC) imaging|FFC scan
48444505|NCT03393208|DRUG|Reference GIR|Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
48444506|NCT04449315|OTHER|Young Living Lavender Essential Oil|For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
48444507|NCT00268905|DRUG|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m\^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
48444508|NCT00268905|DRUG|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
48444509|NCT00268905|DRUG|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
48444510|NCT00950989|DRUG|Brodalumab|3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
48444511|NCT00950989|DRUG|Placebo|3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10
48444512|NCT00950989|DRUG|Methotrexate|Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.
48444513|NCT00950989|DIETARY_SUPPLEMENT|folic acid|at least 5 mg per week
48277798|NCT00889096|DRUG|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
48277799|NCT00889096|DRUG|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
48444514|NCT02618577|DRUG|Edoxaban|"Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
48444515|NCT02618577|DRUG|ASA|ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripherial or coronary artery disease, a prior myocardial infarction, or a prior stroke.
48444516|NCT04741620|OTHER|Capsaicin 10microM (TRPV1 natural agonist)|10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
48444517|NCT04741620|OTHER|Piperine 150microM (TRPV1 & TRPA1 natural agonist)|10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
48444518|NCT04741620|OTHER|Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)|10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
48444519|NCT04741620|OTHER|Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)|10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
48444520|NCT04741620|OTHER|Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)|10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
48444521|NCT04741620|OTHER|Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)|10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
48444522|NCT00059306|DRUG|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
48444523|NCT00059306|DRUG|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
48444524|NCT00059306|OTHER|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
48444525|NCT00059306|OTHER|placebo|an inactive substance
48444526|NCT02803398|OTHER|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann \& Rauscher).
48444527|NCT04342559|OTHER|Belamy (vaginal moisturizer)|"The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~* Do not change genital / vaginal hygiene habits;~* Not having sexual intercourse in the 48 hours (2 days) before the research visits;~* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~* Do not perform gynecological / intimate showers during the study period"
48444528|NCT02467205|OTHER|pedometer supported walking and education|"A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.~The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support)."
48444529|NCT05917925|DIETARY_SUPPLEMENT|COLLAGEN (COL)|The collagen-based supplement will be ingested every day for 12 weeks at the same time.
48444530|NCT05917925|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested every day for 12 weeks at the same time.
48444531|NCT04395677|DRUG|AB-106|"Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients~Stage 2: 600mg QD"
48444532|NCT01281891|DRUG|LIA|Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
48444533|NCT01281891|DRUG|I/T morphine|Morphine special 0.1 mg injected intrathecally
48444534|NCT05729529|OTHER|Lipoid acid gel|Topic lipoid acid gel used with topic oral gel used on tongue
48444535|NCT05729529|DRUG|Placebo|Placebo oral gel used on tongue
48444536|NCT00501488|DRUG|rosiglitazone|
48444537|NCT02344732|DRUG|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
48444538|NCT02344732|DRUG|Homatropine 2% eye drops thrice daily|
48444539|NCT02344732|DRUG|Oxygen gas|
48444540|NCT05381220|OTHER|early mobilization|Patients will receive early mobilization measures within 24 to 48 hours after the onset of stroke.
48444541|NCT03408691|DIETARY_SUPPLEMENT|Fresh fermented dairy drink containing probiotic strain|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.
48444542|NCT03408691|OTHER|Acidified dairy drink without ferment|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
48444543|NCT01878344|DRUG|NAC|
48444544|NCT01878344|DRUG|Saline|
48444545|NCT00657332|PROCEDURE|blood sample draw|
48444546|NCT00657332|PROCEDURE|urine sample|
48444547|NCT04189146|BEHAVIORAL|Inner Engineering Intervention|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
48444548|NCT01702987|DIETARY_SUPPLEMENT|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
48444549|NCT01702987|DIETARY_SUPPLEMENT|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
48444550|NCT01702987|DRUG|statin|statin was given for 1 month to 21 patients
48444551|NCT02069080|DRUG|64-Cu-plerixafor|"Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion."
48444552|NCT04005677|DIAGNOSTIC_TEST|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.|The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
48444553|NCT04106193|OTHER|Blended Facilitation|Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
48277800|NCT03537664|PROCEDURE|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
48277801|NCT03537664|PROCEDURE|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
48444554|NCT04106193|OTHER|Implementation as usual|Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
48444555|NCT04106193|OTHER|Toolkit|All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
48444556|NCT04542356|DRUG|PEG-rhG-CSF|During the concurrent chemoradiotherapy, a single subcutaneous injection of 6 mg PEG-rhG-CSF was given to the patient 2 hours after radiotherapy on the first day after the end of chemotherapy. Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
48444557|NCT04542356|DRUG|rhG-CSF|Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during radiotherapy, rhG-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.
48444558|NCT02514876|DEVICE|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
48277802|NCT06052748|DRUG|AD-223A|PO, Once daily(QD), 8weeks
48277803|NCT06052748|DRUG|AD-223B|PO, Once daily(QD), 8weeks
48277804|NCT06052748|DRUG|AD-223C|PO, Once daily(QD), 8weeks
48277805|NCT06052748|DRUG|AD-223A Placebo|PO, Once daily(QD), 8weeks
48444559|NCT01816490|DRUG|Intravenous Silibinin (iSIL)|
48277806|NCT06052748|DRUG|AD-223B Placebo|PO, Once daily(QD), 8weeks
48277807|NCT06052748|DRUG|AD-223C Placebo|PO, Once daily(QD), 8weeks
48444560|NCT06241963|DEVICE|Active Comparator: Unilateral real High definition transcranial direct current stimulation|Improvement of cortical excitability, unilateral stimulation was effective, and no side effects were observed
48444561|NCT06241963|DEVICE|Active Comparator: Bilateral real High definition transcranial direct current stimulation|Improved cortical excitability, the effect was more obvious than unilateral stimulation, the effect lasted longer, and no side effects were observed
48444562|NCT06241963|DEVICE|Sham Comparator: Sham High definition transcranial direct current stimulation|The sham stimulation is mainly used for blank control, control variables, and exclude the interference of other factors
48444563|NCT05815745|DEVICE|Pacemaker - Physiological pacing|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
48444564|NCT05815745|DEVICE|Pacemaker - Right Ventricular pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
48444565|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
48444566|NCT01149473|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
48444567|NCT03677492|OTHER|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
48444568|NCT06413186|DRUG|Uteratonic administration|Administer IV 10 IU oxytocin
48444569|NCT06413186|OTHER|cord clamping|delayed cord clamping
48444570|NCT06413186|OTHER|delivery of the placenta|Applying controlled core traction
48444571|NCT01931722|DIETARY_SUPPLEMENT|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
48277808|NCT06196411|BEHAVIORAL|Task-oriented Training|Task-oriented training will be applied to study group 5 days a week, for a total of 6 weeks, in addition to Bobath training. Task-oriented training will consist of performing the lying, sitting, standing and walking exercises by performing tasks for specific goals. Exercises will be perform by accomplishing tasks such as touching the ball with the upper or lower extremities, reaching for the ball, crossing various tracks to move blocks from one place to another, walking through obstacles or climbing stairs.
48277809|NCT06196411|BEHAVIORAL|Bobath Training|Bobath Concept includes sensory, perceptual and adaptive exercises aimed at improving function through mobilisation, weight-bearing, practicing more normal movement patterns and performing more efficient, less effortful tasks.
48277810|NCT05787704|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
48277811|NCT01552343|DRUG|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
48277812|NCT01552343|DRUG|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
48444572|NCT01931722|BEHAVIORAL|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
48444573|NCT03227302|PROCEDURE|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
48444574|NCT03227302|PROCEDURE|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
48444575|NCT03227302|PROCEDURE|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
48444576|NCT02020915|PROCEDURE|lateral sphincterotomy|
48444577|NCT02020915|PROCEDURE|ultrasound guided lateral sphincterotomy|
48444578|NCT02431494|DEVICE|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
48277813|NCT02295202|DEVICE|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
48277814|NCT02295202|DEVICE|Nasal strips|
48277815|NCT03728049|DIAGNOSTIC_TEST|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
48277816|NCT03728049|OTHER|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
48277817|NCT06036875|OTHER|Non-Interventional Study|Non-interventional study
48277818|NCT04028037|PROCEDURE|FTPGT treated patients|"The recipient bed will be prepared according to Langer\&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured."
48444579|NCT02431494|DEVICE|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
48444580|NCT02431494|DEVICE|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
48444581|NCT03702218|DRUG|Direct Acting Antivirals|"Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30"
48444582|NCT02152397|BEHAVIORAL|Therapist-led brief intervention (TBI)|
48444583|NCT06560580|DRUG|3% Diquafosol Sodium Eye Drops|Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.
48444584|NCT05069961|PROCEDURE|ESPB|Ropivacaine is injected near the nerves in the back
48444585|NCT05069961|PROCEDURE|TEA|Bupivacaine is injected into the space around the spinal cord.
48444586|NCT03202277|BEHAVIORAL|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
48444587|NCT03202277|BEHAVIORAL|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
48444588|NCT03951363|BEHAVIORAL|interactive Obesity Treatment Approach (iOTA)|The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
48444589|NCT03714685|DRUG|Firibastat|Firibastat (QGC001) 500 mg
48444590|NCT00949585|OTHER|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
48444591|NCT03023150|OTHER|Ischemic Preconditioning|
48444592|NCT03023150|OTHER|Sham|
48444593|NCT01805583|OTHER|Acceptance and Commitment Therapy (ACT)|
48444594|NCT01805583|OTHER|workplace intervention (WPI)|
48444595|NCT00276926|DRUG|STI571|
48444596|NCT01465581|PROCEDURE|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
48444597|NCT04043377|DRUG|injection of 68Ga-DOTATATE|PET after injection of 68Ga-DOTATATE 2 MBq/kg (Max. 200 MBq); intra-venous; single injection, at M0 followed by a coronary CTA to localize the signal in coronary arteries Consultation and low-dose cardiac CT for coronary calcium scoring performed at M12 and M24 after inclusion.
48444598|NCT00731744|PROCEDURE|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
48444599|NCT02935517|BIOLOGICAL|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
48444600|NCT00371722|PROCEDURE|Appendectomy|
48444601|NCT03944447|DRUG|Cannabis, Medical|Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
48444602|NCT03944447|DEVICE|RYAH-Medtech Inhaler|Our research study will involve incorporation of RYAH-Medtech company's devices into our protocols. They have an inhaler and a transdermal patch for both hemp-derived CBD and cannabis. RYAH has developed an integrated phone app for tracking product use and patient response. They are currently involved in clinical trials in Europe. OMNI Medical will integrate the partner with RYAH device for several reasons. Primary goals will involve using their integrated smart phone app to collect and secure large quantities of data. Secondary goals will include FDA approval as a medical device. The specific cannabis strain will be tracked using scannable QR codes programed into the smart phone app. This will allow us to track patient feedback and capture data on usage. OMNI Medical will have patients use RYAH's products as part of and FDA Investigational Device Exemption, which requires an IRB. Use of the devices would be completely voluntary by study participants.
48444603|NCT01370317|DRUG|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
48444604|NCT01370317|DRUG|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
48444605|NCT01684774|DRUG|Bupivacaine|
48098098|NCT04315454|DRUG|Levobupivacaine|A group of patients will receive 20 ml of normal saline into the interfascial plane between rhomboids major \&erector spinae muscle bilaterally at level thoracic spine T7,10 ml each side, the other group of patients will receive 20 mg 0.25% Levobupivacaine bilaterally as above 10 mg each side.
48444606|NCT03878654|DRUG|Tauroursodeoxycholic Acid|Naturally occurirng bile acid
48444607|NCT01418586|DRUG|Torrent's Alfuzosin Extended Release Tablet|
48444608|NCT03735485|OTHER|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
48444609|NCT03735485|OTHER|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
48444610|NCT03735485|OTHER|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
48444611|NCT00006468|DRUG|FOLFOX regimen|
48444612|NCT00006468|DRUG|fluorouracil|
48444613|NCT00006468|DRUG|leucovorin calcium|
48444614|NCT00006468|DRUG|oxaliplatin|
48444615|NCT04391933|DIAGNOSTIC_TEST|MRI 3 tesla|MRI of colon cancer. Sensitivity, specificity, positivity predictive values and negative predictive values are calculated form the histopathological surgical specimen. This will be the endpoint for both CT and MRI.
48444616|NCT01677962|BIOLOGICAL|Poly-ICLC|
48444617|NCT01677962|BIOLOGICAL|dendritic cell|
48277819|NCT04028037|PROCEDURE|CAF+SCTG treated patients|According to De Sanctis \& Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
48277820|NCT04640623|DRUG|TAR-200|TAR-200 will be administered transuretherally.
48277821|NCT04640623|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
48277822|NCT00416533|DRUG|docetaxel|
48277823|NCT00416533|DRUG|doxorubicin hydrochloride|
48277824|NCT00416533|DRUG|prednisone|
48277825|NCT03467906|OTHER|In-laboratory assessment|Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
48444618|NCT05905718|OTHER|assessment|Assessments of thoracic kyphosis angle, balance performance, and gait performance.
48444619|NCT05107089|DEVICE|Ultrasound|Use of ultrasound at subclavian vein cannulation for visualization
48444620|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
48444621|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
48444622|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
48444623|NCT01581658|DRUG|BI10773|BI10773 medium dose tablet single dose
48620366|NCT05488431|DRUG|Bempedoic acid|Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in \>4300 individuals and is currently being studied in \>14,000 individuals in CLEAR Outcomes (NCT02993406).
48620367|NCT05488431|OTHER|Placebo|Placebo
48277826|NCT03947541|OTHER|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
48444624|NCT04048317|DRUG|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
48444625|NCT04048317|DRUG|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
48277827|NCT03947541|OTHER|No Bracing|Participants will not wear a brace in the study.
48277828|NCT01479972|BIOLOGICAL|VPM1002|Tuberculosis vaccine
48277829|NCT01479972|BIOLOGICAL|BCG|commercially available live vaccine BCG
48277830|NCT01767584|DRUG|Cephalexin 1g tablets|Reference product
48277831|NCT01767584|DRUG|Cephalexin 1g tablets|Test product
48277832|NCT01986530|DIETARY_SUPPLEMENT|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
48277833|NCT01986530|OTHER|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
48277834|NCT01617044|DIETARY_SUPPLEMENT|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
48277835|NCT01617044|DIETARY_SUPPLEMENT|Placebo|Placebo
48444626|NCT05703022|OTHER|Aerobic interval training|The intervention will start between 7 and 21 days after heart valve surgery. While hospitalized the participants will perform supervised aerobic interval training comprised 4x4 minute, 3 times per week. Intensity will start at 60% of maximum heart rate in the first week, around 13-14 in Borg RPE-Scale. The workload will be gradually increased as the participant tolerance improves, but not above 85% of maximum heart rate or 16-17 in Borg RPE Scale.
48444627|NCT02996591|PROCEDURE|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
48444628|NCT02996591|PROCEDURE|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
48444629|NCT02996591|DRUG|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
48444630|NCT02996591|PROCEDURE|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
48444631|NCT02996591|PROCEDURE|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
48444632|NCT04208724|OTHER|Training|Participate in the training program
48444633|NCT04208724|OTHER|Cancer Screening intervention|Receive cancer screening intervention
48444634|NCT04208724|OTHER|Survey Administration|Ancillary studies
48444635|NCT03928691|DRUG|Magnesium Sulfate|4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.
48444636|NCT00356785|BEHAVIORAL|health education|
48444637|NCT00356785|BEHAVIORAL|food supplementation|
48444638|NCT00356785|BEHAVIORAL|food supplementation combined with physical activity program|
48444639|NCT00501397|DRUG|ketoconazole|
48444640|NCT00501397|DRUG|GSK189075|
48444641|NCT03522675|DEVICE|NeoMatriX Wound MatriX Collagen Dressing|Collagen wound dressing
48444642|NCT00115960|BIOLOGICAL|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
48444643|NCT00115960|BIOLOGICAL|IL-15 DNA adjuvant|Cytokine injection
48444644|NCT00115960|BIOLOGICAL|IL-12 DNA adjuvant|Cytokine injection
48444645|NCT02760732|DEVICE|drug eluting balloon; cutting balloon|Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.
48444646|NCT02760732|DEVICE|drug eluting stent|with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
48444647|NCT00122785|DRUG|dexamethasone|
48444648|NCT05126485|DEVICE|Haptic Biofeedback from SageMotion Biofeedback System|"Haptic biofeedback units (vibrating motors) will be placed on individual body segments. The haptic biofeedback system will be configured to provide vibratory stimuli when a target minimum hip extension angle is reached during the loading response. The minimum threshold will be determined by the therapist based on the patient's current ability. Specifically, the system will target a 10-20% increase in extension angle from their current level, as identified by the therapist. A vibration stimulus will be first applied each time this minimum angle is achieved, and will continually increase in intensity in proportion to the degree with which the patient exceeds this minimum value. The stimuli will stop being applied when the extension angle drops back below the threshold. These intensity-modulated stimuli have been selected to encourage the patient to exceed the minimum threshold rather than stop extending when the stimulus is first applied"
48444649|NCT05691322|DIAGNOSTIC_TEST|transvaginal ultrasound|Transvaginal ultrasound for endometriosis diagnosis (UBESS)
48444650|NCT05691322|DIAGNOSTIC_TEST|MRI|MRI for endometriosis diagnosis (Enzian classification)
48444651|NCT04262934|DRUG|Cholecalciferol 100.000 UI administration|One oral Administration - Every month
48444652|NCT04262934|OTHER|No vitamin D administration|No vitamin D administration
48444653|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
48444654|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
48444655|NCT03733730|DEVICE|ACRYSOF IQ RESTOR +2.5 D Multifocal IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.
48444656|NCT03733730|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with IOL implantation
48444657|NCT04627467|DRUG|Chloroquine|250mg tablet (150mg base chloroquine)
48444658|NCT00545506|DEVICE|conventional bandage|
48444659|NCT00545506|DEVICE|warming bandage|
48444660|NCT06147596|OTHER|Head impact exposure|The cohort is exposed to naturalistic head impacts (heading) during voluntary participation in a soccer match. All participants are regular soccer players and are therefore not exposed to excessive head impacts compared to their regular exposure.
48620368|NCT03335527|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
48444661|NCT00286702|DEVICE|hand splint|
48444662|NCT05978557|OTHER|Biospecimen collection|Biospecimen will be collected during surgery.
48620369|NCT03335527|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
48620370|NCT04447248|DEVICE|QDSP Protocol|Computerized expert system for fetal monitoring, based on cardiotocogrpaphy
48444663|NCT01802320|DRUG|Akt Inhibitor MK2206|Given PO
48444664|NCT01802320|OTHER|Laboratory Biomarker Analysis|Correlative studies
48444665|NCT01802320|OTHER|Pharmacological Study|Correlative studies
48444666|NCT01342263|BEHAVIORAL|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
48444667|NCT05016323|DRUG|HR19042 Capsules|HR19042 Capsules
48444668|NCT05016323|DRUG|Placebo|Placebo
48444669|NCT02294253|DRUG|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
48444670|NCT02476994|DRUG|Clinolipid|
48444671|NCT02476994|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion
48444672|NCT04486339|RADIATION|Stereotactic Radiotherapy|Stereotactic radiotherapy targets on the pulmonary vein ostium aiming to achieve pulmonary vein electrial isolation
48444673|NCT06626776|PROCEDURE|lateral sinus lift with using allograft and collagen membrane|sinus floor elevation with placing allograft and collagen membrane
48444674|NCT06626776|PROCEDURE|lateral sinus lift with using exteneded platelet rich fibrin|sinus floor elevation with placing eprf
48444675|NCT00125086|DEVICE|autologous platelet gel|
48444676|NCT04053296|OTHER|Observational study|We follow up the results of patients.
48444677|NCT02350231|DRUG|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
48444678|NCT02350231|DRUG|Tonics group|Those patients will receive only tonics
48444679|NCT06317454|DIAGNOSTIC_TEST|Blood and saliva analysis|Phenotyping and genotyping characterization using blood and saliva
48444680|NCT03972683|OTHER|Handgrip Exercise Training|Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.
48444681|NCT03972683|DRUG|Acetylcholine|Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
48444682|NCT03972683|DRUG|Adenosine Triphosphate|Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.
48444683|NCT03972683|DRUG|Atropine|Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.
48444684|NCT03972683|DRUG|Phenylephrine|Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.
48444685|NCT03972683|DRUG|Sodium Nitroprusside|Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
48444686|NCT04608188|BEHAVIORAL|Summer Camp|The intervention camps will operate according to routine practice, with no assistance from the investigative team. The camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. All camp meals will adhere to the United States Department of Agriculture Summer Food Service Program nutrition guidelines. The camps employ 1 staff member for every 12 children - which is consistent with childcare regulations in the state of operation and operate daily (Mon-Fri) for 8 weeks during the summer. The camps open at 7am and close 6 pm daily.
48444687|NCT04180280|BEHAVIORAL|Behavioral self-regulation Phone counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.
48444688|NCT04180280|BEHAVIORAL|Behavioral self-regulation Office counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
48444689|NCT05654922|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
48444690|NCT05654922|OTHER|Standard of care only|Standard 3-therapy immunosuppression regimen and azithromycin
48444691|NCT01171963|BIOLOGICAL|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
48444692|NCT01171963|BIOLOGICAL|Placebo|Oral administration
48444693|NCT01171963|BIOLOGICAL|Infanrix™|Intramuscular administration
48444694|NCT01171963|BIOLOGICAL|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
48444695|NCT06451783|OTHER|Traditional Chinese medicine combined with manipulation treatment|"The specific procedure involves administering the Shengyu Decoction, which consists of the following herbs:~* Shu Di Huang 20 grams~* Bai Shao 15 grams~* Dang Gui 15 grams~* Chuan Xiong 8 grams~* Ren Shen 20 grams~* Huang Qi 18 grams One dose is taken per day, and a course of treatment consists of five weeks. Add manipulation of massage：~  * Press and grasp the affected limb three times；~    * Five-finger five-acupoint pressing method；~      * Point pressing on Zusanli (ST36) and Sanyinjiao (SP6)；~        * grasp the interior method to treat the calf three times；~          ⑤ Apply rolling technique around the knee joint；~          ⑥ Knead and straighten the standing tendon (the lateral muscle of the calf)；~          ⑦ Six-finger six-acupoint pressing method；~          ⑧ Push and pull the patella to flex and extend the knee joint；~          ⑨ Knee joint reunion and smooth dispersion method."
48444696|NCT06451783|DRUG|Celecoxib capsule|Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.
48444697|NCT04561063|DRUG|Nitazoxanide|Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)
48444698|NCT04561063|DRUG|Sofosbuvir/Daclatasvir|Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
48444699|NCT02013154|DRUG|DKN-01 150 mg|Administered by IV infusion
47927995|NCT03680456|DRUG|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
48277836|NCT04976452|OTHER|Multi-component teaching content|The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
48444700|NCT02013154|DRUG|Paclitaxel|Administered by IV infusion
48444701|NCT02013154|DRUG|Pembrolizumab|Administered by IV infusion
48444702|NCT02013154|DRUG|DKN-01 300 mg|Administered by IV infusion
48444703|NCT04018482|OTHER|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
48444704|NCT04018482|OTHER|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
48444705|NCT03848286|DRUG|KL-A167 Injection|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
48444706|NCT04131621|BIOLOGICAL|Nivolumab/Ipilimumab|Immune checkpoint inhibitor combination
48444707|NCT05137821|DEVICE|Er: YSGG laser|Er: YSGG laser decontamination of infected implant surfaces to simulate peri-implantitis therapy
48444708|NCT05137821|OTHER|no therapy|new sealed implant without any surface treatment
48444709|NCT05086003|COMBINATION_PRODUCT|Combined kidney and bone marrow transplantation|Combined kidney and bone marrow transplantation
48620371|NCT03186664|DEVICE|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
48098099|NCT02537392|DIETARY_SUPPLEMENT|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
48098100|NCT02537392|DIETARY_SUPPLEMENT|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
48098101|NCT02537392|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid.
48277837|NCT05012748|OTHER|Ketogenic diet|The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
48444710|NCT00974935|DRUG|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
48444711|NCT00974935|BIOLOGICAL|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
48444712|NCT00365534|PROCEDURE|MEI|
48444713|NCT05703932|OTHER|home-based exercises|Joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises will be applied. Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
48444714|NCT01950715|DEVICE|sacral nerve stimulation|Sacral nerve stimulation
48444715|NCT02371343|DIETARY_SUPPLEMENT|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
48444716|NCT02371343|DIETARY_SUPPLEMENT|Sunflower Oil|
48444717|NCT03574558|DEVICE|MD-Logic Switch Advisor|Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
48444718|NCT03204539|DRUG|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
48444719|NCT05228626|DRUG|COVIDEX|COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
48444720|NCT03733444|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
48444721|NCT03733444|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
47927996|NCT03680456|DRUG|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
47927997|NCT00732004|DEVICE|Silicone Hydrogel Contact Lenses|
47927998|NCT00732004|DEVICE|1x PMBH preserved MPS|
47927999|NCT00732004|DEVICE|1x Polyquad/Aldox MPS|
47928000|NCT04595994|DRUG|Selinexor|For both interventional ( Selinexor and Gencitabine) Dose-limiting toxicity (DLT) will be applied only to either of the following toxicities occurring during the first treatment cycle (days 1-21).
47928001|NCT02671162|DRUG|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
48444722|NCT03976635|DEVICE|Removable Mandibular Retractor|The appliance will be used 18 hours per day. It can only be removed for eating meals.
48444723|NCT03976635|DEVICE|Bone-anchored intermaxillary traction|The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
48444724|NCT02053454|DRUG|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
48444725|NCT02053454|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
48444726|NCT00693290|OTHER|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
48444727|NCT00612287|DRUG|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
48444728|NCT04643197|DEVICE|Barbed PDS suture (STRATAFIX Symmetric PDS Plus)|STRATAFIX Symmetric PDS Plus is a barbed suture.
48444729|NCT04643197|DEVICE|Non-barbed PDS suture (PDS Plus)|Non-barbed suture
48444730|NCT01980823|DRUG|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
48444731|NCT01980823|DRUG|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
48444732|NCT01980823|PROCEDURE|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
48444733|NCT04917328|OTHER|compression ultrasound|performing a compression ultrasound
48444734|NCT03414593|DRUG|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
48444735|NCT03428386|PROCEDURE|Gastric plication ileal bypass|laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
48444736|NCT03563274|DEVICE|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
48444737|NCT02594358|DRUG|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
48444738|NCT05886920|DRUG|D3S-002|Oral
48444739|NCT02092363|DRUG|OMP-54F28, Paclitaxel and Carboplatin|
48444740|NCT00836758|DEVICE|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
48444741|NCT01524718|RADIATION|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
48444742|NCT02624050|DRUG|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
48444743|NCT02624050|DRUG|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
48444744|NCT03810703|DRUG|Placebo oral capsule|Placebo oral capsule
48444745|NCT03810703|DRUG|d-amphetamine 10 mg oral capsule|d-amphetamine 10 mg oral capsule
48444746|NCT03810703|DRUG|d-amphetamine 20 mg oral capsule|d-amphetamine 20 mg oral capsule
48444747|NCT06311396|GENETIC|genetic model|Create a complete molecular-level description of the heterogeneous population of cells that are capable of giving rise to tumor transformation in the liver.
48444748|NCT06130436|DEVICE|Sham-Remote Ischemic Conditioning|Sham-Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.
48444749|NCT06130436|DEVICE|Remote Ischemic Conditioning Once Daily|"Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, the morning of the postoperative day 1, the morning of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.~Sham-Remote Ischemic Conditioning (at the time points of 30 min after surgery, the afternoon of the postoperative day 1, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg."
48444750|NCT06130436|DEVICE|Remote Ischemic Conditioning Twice Daily|Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.
48098102|NCT06346262|BEHAVIORAL|SMART RM|The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).
48444751|NCT00947908|BIOLOGICAL|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
48444752|NCT04825314|DEVICE|Urethral catheter|All Patients will have urethral catheterization with either Noble Metal Alloy coated catheter or Silicon Foley catheter.
48444753|NCT01868945|DIETARY_SUPPLEMENT|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
48444754|NCT01868945|DIETARY_SUPPLEMENT|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
48444755|NCT01868945|DIETARY_SUPPLEMENT|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
48444756|NCT01868945|DIETARY_SUPPLEMENT|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
48444757|NCT01188681|DRUG|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
48444758|NCT01188681|DRUG|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
48444759|NCT01188681|DRUG|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
48444760|NCT01188681|DRUG|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
48444761|NCT06515054|BEHAVIORAL|wall squat|self-learnt wall squat exercise to be conducted for totally 24 weeks
48444762|NCT06515054|BEHAVIORAL|passive stretching|time-matched passive stretching exercise to be conducted for totally 24 weeks
48444763|NCT02450682|DRUG|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
48444764|NCT02450682|DRUG|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
48444765|NCT03173235|DIAGNOSTIC_TEST|Plasma level of vitamin D|messurement of plasma level of vitamin D
48444766|NCT03230630|DIAGNOSTIC_TEST|plasma melatonin levels|
48277838|NCT04673058|PROCEDURE|Spinal Manipulation|Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
48277839|NCT04673058|PROCEDURE|Sham Manipulation|The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
48277840|NCT06292078|BEHAVIORAL|Instructional Skill-Building Learning Approach (ISLA)|The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.
48277841|NCT05995535|DRUG|LFX/PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 100mg and 25mg"
48277842|NCT05995535|DRUG|LFX/PLA-PGB|"lofexidine tablets 0.18mg tabs~pregabalin capsules 0mg"
48277843|NCT05863611|OTHER|arms|During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
48277844|NCT02504255|BIOLOGICAL|Biological samplings|Blood, urine and faecal sampling every 3 months
48277845|NCT02504255|OTHER|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
48277846|NCT04223466|PROCEDURE|Subxiphoid surgery procedure|Subxiphoid procedure for thymectomy
48277847|NCT04223466|PROCEDURE|VATS surgery procedure|VATS procedure for thymectomy
48277848|NCT02505984|DRUG|Oxytocin|Study participants will be randomized to a placebo or drug group.
48277849|NCT02505984|DRUG|Placebo|Study participants will be randomized to a placebo or drug group.
48444767|NCT02576522|RADIATION|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
48444768|NCT03525522|DEVICE|Nd:YAG Laser|Three sessions of Nd:YAG treatment every two weeks.
48444769|NCT03525522|DRUG|Topical corticosteroid Diprosone|3 months of topical corticosteroids Diprosone
48620372|NCT03186664|DRUG|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
48277850|NCT00728429|BEHAVIORAL|exercise intervention|24 week program of exercise
48277851|NCT01221857|DRUG|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
48277852|NCT02241486|DRUG|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
48277853|NCT03662295|BEHAVIORAL|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
48277854|NCT03528525|OTHER||observation
48444770|NCT06056817|DEVICE|Calyan Pacemaker|The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
48444771|NCT06461091|RADIATION|TMI|Observing the efficacy and safety of allogeneic hematopoietic stem cell transplantation in treating adult acute lymphoblastic leukemia with a conditioning regimen including total marrow irradiation (TMI) in individuals aged 16 years and older: Primary Exploratory Endpoint: Event-free survival at 1 year post allogeneic hematopoietic stem cell transplantation (EFS).
48444772|NCT01247701|DRUG|Busulfan|Busulfan dosing will be as follows: Patients \< 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \> 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
48444773|NCT01247701|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
48277855|NCT05071898|DRUG|Semaglutide Pen Injector [Ozempic]|Participants will receive subcutaneously injected semaglutide (0.25 mg/wk) for 4 weeks followed by semaglutide (0.5 mg/wk) for an additional two weeks.
48277856|NCT06399783|DRUG|Simvastatin|Group of patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months, while another group will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.
48277857|NCT06399783|DRUG|Mometasone Furoate|Patients will be treated by fractional CO2 laser for 6 sessions each will be followed immediately by topical application of Mometasone Furoate.
48277858|NCT06399783|PROCEDURE|Fractional CO2 laser|Fractional CO2 laser will be used for assisted drug delivery for both topical simvastatin and mometasone Furoate.
48277859|NCT01624584|BEHAVIORAL|Experimental treatment|six sessions of child anxiety treatment
48277860|NCT01624584|BEHAVIORAL|Traditional Treatment|six sessions of treatment consistent with current practice
48277861|NCT06295445|PROCEDURE|care cardio-pulmonary ultrasound|Evaluation of the heart and lung conditions in shocked patients using focused cardio-pulmonary ultrasound for treatment guidance and their implication on the patient's outcome
48277862|NCT06295445|OTHER|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management
48277863|NCT00216567|DRUG|topamax|
48277864|NCT03358472|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
48277865|NCT03358472|DRUG|Epacadostat|Epacadostat administered orally twice daily.
48277866|NCT03358472|DRUG|Cetuximab|Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
48444774|NCT01247701|DRUG|Fludarabine|Fludarabine will be given IV daily over 1 hour for 3 days. Dosing will be as follows: for patients ≤ 10 kg: 1.3 mg/kg; for patients \> 10 kg: 40 mg/m\^2.
48444775|NCT01247701|PROCEDURE|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
48444776|NCT01827566|OTHER|gluten|
48444777|NCT01827566|OTHER|gluten free flour|
48444778|NCT03702322|BEHAVIORAL|Voice therapy: respiratory|Abdominal voice onset
48444779|NCT03702322|BEHAVIORAL|Voice therapy: glottal closure|Pulling/pushing task
48444780|NCT03702322|BEHAVIORAL|Voice therapy: loud|Assertive task
48444781|NCT03702322|BEHAVIORAL|Voice therapy: Semiocclusion|Semi-occluded vocal tract
48277867|NCT03358472|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.
48277868|NCT03358472|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.
48277869|NCT03358472|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
48277870|NCT03135392|PROCEDURE|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
48277871|NCT03135392|PROCEDURE|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
48277872|NCT03135392|PROCEDURE|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
48277873|NCT03856957|DEVICE|Endocuff colonoscopy|Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
48277874|NCT03856957|DEVICE|control|colonoscopy without endocuff
48277875|NCT05654402|DIAGNOSTIC_TEST|Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical©) - WAKIe R3 2TC®) (PWV in cm/s)|"* Measurement of the carotid-femoral transit time (ms) (recorded on Data Warehouse Connect).~* Measurement of the distance between the carotid and femoral points with a tape measure (m).~* Calculation of the propagation speed of the wave PWV (expressed in m/s).~For all patients PWV in (m/s=) will be collected over three distinct periods:~* Before induction (awake without premedication)~* During general anesthesia or loco-regional anesthesia~* Upon awakening from general anesthesia or lifting of the loco-regional anaesthesia"
48277876|NCT03551548|DRUG|Spironolactone 25mg|25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
48277877|NCT03551548|DRUG|Placebo oral capsule|oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
48277878|NCT05641350|BEHAVIORAL|Barlow's Unified Protocol|Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.
48444782|NCT02727088|PROCEDURE|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
48444783|NCT02727088|PROCEDURE|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
48444784|NCT03022786|OTHER|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
48444785|NCT03022786|OTHER|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
48444786|NCT03022786|OTHER|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
48444787|NCT06392438|DRUG|CycloSPORINE Ophthalmic|Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
48444788|NCT06392438|PROCEDURE|Intense Pulsed Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
48444789|NCT06392438|PROCEDURE|Sham Intense Pulse Light|Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
48444790|NCT01660594|OTHER|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
48444791|NCT01724372|DRUG|Antidepressant|
48444792|NCT01724372|DRUG|Antipsychotic|
48444793|NCT00849901|DRUG|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
48444794|NCT00849901|DRUG|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
48444795|NCT00849901|DRUG|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
48444796|NCT04761861|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG tablet once daily
48444797|NCT04761861|DRUG|Placebo|Placebo one tablet daily
48444798|NCT04881435|DEVICE|Hydrogen gas therapy|Hydrogen gas therapy three times one day for 5 days
48277879|NCT03505437|OTHER|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
48277880|NCT03505437|OTHER|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
48444799|NCT04374487|DRUG|Convalescent Plasma|200 ml of ABO compatible plasma transfusion will be done to the subject randomized for the test arm therapy
48444800|NCT04374487|OTHER|Standard Care Therapy|Subjects randomized to control group will be on standard care treatment according to Institutional Protocols.
48444801|NCT04024007|DIAGNOSTIC_TEST|Citrate dosage|Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
48444802|NCT04609917|PROCEDURE|trainee invlovement|Patients underwent selective biliary cannulation with trainee involvement
48444803|NCT06062498|DRUG|elacestrant, palbociclib, abemaciclib, ribociclib|Given orally
48444804|NCT03375463|DRUG|Tirzepatide|Administered SC
48444805|NCT03375463|DRUG|Tirzepatide|Administered IV
48277881|NCT00175305|DRUG|Sandostatin LAR|
48277882|NCT02706938|OTHER|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
48277883|NCT02706938|OTHER|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
48277884|NCT06035822|OTHER|Debriefing with TeamGAINS|The IG debriefings were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool, using this tool as a debriefing script, in accordance with the objectives Clinical Simulation Scenario
48444806|NCT03375463|DRUG|Placebo|Administered SC
48444807|NCT03375463|DRUG|Tirzepatide|Administered IV
48277885|NCT04833803|BEHAVIORAL|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
48277886|NCT06383494|DEVICE|LMA supreme group|Patient in this group received LMA supreme (one of laryngeal airway management device) for airway management during general anesthesia
48444808|NCT05721586|OTHER|Self Assembling Peptide P11-4 (CURODONTTM REPAIR) + Fluoride varnish (DURAFLOR|The WSL was Acid etched with phosphoric acid gel 35-37% for 20 seconds, the tooth surface was rinsed with water and then dried afterwards application of CURODONTTM REPAIR
48444809|NCT05721586|OTHER|Fluoride varnish (DURAFLOR|A very thin coat of the DURAFLOR varnish was applied by a thin brush which was then allowed to dry for 10 seconds. The varnish hardens on contact with saliva or moisture
48444810|NCT00153530|DRUG|methotrexate|"1. chemotherapy with radiotherapy~2. chemotherapy without radiotherapy"
48444811|NCT00153530|RADIATION|radiotherapy|whole-brain irradiation
48444812|NCT01757392|BIOLOGICAL|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
48444813|NCT03772522|BEHAVIORAL|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The program was designed and carried out by dk Leadership - an established leadership and executive coaching centre in Toronto, Canada.
48444814|NCT00003659|BIOLOGICAL|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients \> 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
48444815|NCT00003659|BIOLOGICAL|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
48444816|NCT00003659|DRUG|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
48444817|NCT00003659|DRUG|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
48444818|NCT04110236|BEHAVIORAL|PriCARE|PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
48444819|NCT04110236|BEHAVIORAL|Positive Discipline Module|The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
48444820|NCT05580692|PROCEDURE|Biospecimen Collection|Biospecimen Sample Collection
48444821|NCT05205876|BEHAVIORAL|Eddii mobile application|Participants will use the Eddii mobile application in the intervention arm.
48444822|NCT05463822|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
48444823|NCT04887766|DEVICE|GS300|Gelesis300 hydrogel in gelatin capsules
48444824|NCT04887766|DEVICE|Placebo|Placebo capsules
48444825|NCT04230525|DIAGNOSTIC_TEST|non invasive whole body bioimpedence system|Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
48444826|NCT03186976|BEHAVIORAL|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4) An OMRON BP monitor will be supplied to each patient. A target SBP of \<140/80 mm/Hg will be targeted.~5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c\<6.5%"
48444827|NCT03186976|OTHER|Standard of Care|Recommendations based on current guidelines
48620373|NCT04254757|PROCEDURE|Two different treatment|One group treated by percutaneous endoscopic surgery. The another group treated by open decompression and fusion surgery
48098103|NCT06346262|DRUG|Valtoco Nasal Product|Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
48277887|NCT06383494|DEVICE|I-gel group|Patient in this group received I-gel laryngeal (one of laryngeal airway management device) for airway management during general anesthesia
48277888|NCT06383494|DEVICE|GMA-Tulip|Patient in this group received GMA-Tulip (one of laryngeal airway management device) for airway management during general anesthesia
48277889|NCT05669742|DRUG|Empagliflozin|sodium-glucose transport protein two inhibitor
48277890|NCT05669742|DRUG|olanzapine|antipsychotics
48277891|NCT03839602|RADIATION|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
48277892|NCT04255511|DEVICE|Twin Block|Functional appliance
48098104|NCT05448755|DRUG|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
48098105|NCT02293421|OTHER|Obstructive sleep apnea|
48277893|NCT04255511|DEVICE|Fixed orthodontic appliance|Braces
48277894|NCT06261879|DEVICE|Special sanitary pad|The special sanitary pad is similar to the normal sanitary pad with 0.01 agar gel only. The agar gel is an approved source of food.
48277895|NCT06583083|DRUG|Sintilimab with P-GEMOX Regimen|Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
48277896|NCT06583083|DRUG|P-GEMOX Regimen|Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
48277897|NCT04801290|PROCEDURE|TIPS insertion|Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
48277898|NCT00257634|DRUG|dexamethasone to injury site|
48444828|NCT04261894|BEHAVIORAL|OPTIMIZE|The study intervention is implementation of the OPTIMIZE perinatal care checklist with patient navigation support. The checklist will contain perinatal care components to be assessed for each participant. Specifically, the checklist will be built into the electronic health record as a secure digital record of: (1) the participant's adherence to the recommended prenatal and postpartum visit schedule, (2) the completion of procedures and processes in a participant's prenatal and postpartum standard care plan, and (3) the completion of processes to address social determinants of health, along with completion of referrals to appropriate support resources. The OPTIMIZE checklist will also include records of patient navigation review, engagement, and tracking of barrier status and resolution
48444829|NCT03950089|DEVICE|Optical Coherence Tomography Angiography (OCT-A)|Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
48444830|NCT05645367|OTHER|No intervention|This is a post-hoc analysis of a cross-sectional study.
48444831|NCT03060863|BEHAVIORAL|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
48277899|NCT03339895|OTHER|pvı-guided|pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value \<%13 and if MAP\>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value \<%13 and if MAP\>65mmHg 5 mcg efedrin intravenous bolus till MAP\>65 mmHg If PVI value \>%13 and MAP\>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value \>%13 and MAP \<65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13
48277900|NCT03339895|OTHER|traditional-guided|traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP \<65 mmHg or \<30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP\>65 mmHg no intervention
48277901|NCT01892722|DRUG|Interferon beta-1a|Administration once weekly via i.m. injections.
48277902|NCT01892722|DRUG|Fingolimod|"Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less."
48277903|NCT01892722|DRUG|Placebo capsule|Matching placebo capsule required for double-dummy masking to blind formulations.
48277904|NCT01892722|DRUG|Placebo i.m. injection|Matching placebo i.m. injection required for double-dummy masking to blind formulations.
48277905|NCT01886118|PROCEDURE|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
48277906|NCT01886118|OTHER|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
48277907|NCT01886118|OTHER|Conventional media culture|embryos are cultured in conventional media
48277908|NCT00459030|OTHER|educational intervention via internet|additional cancer screening information via password protected internet site
48277909|NCT00459030|OTHER|educational intervention mailed|
48277910|NCT00459030|OTHER|No additional educational intervention|
48277911|NCT01856101|DRUG|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
48277912|NCT02494570|DRUG|nab-Sirolimus|Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
48277913|NCT01948492|DIETARY_SUPPLEMENT|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
48277914|NCT03709992|DRUG|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
48277915|NCT03709992|DRUG|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
48277916|NCT03512236|DRUG|BC Pram Ins|Injection of BC Pram Ins
48277917|NCT03512236|DRUG|Symlin® and Humulin®|Injection of pramlintide and human insulin
48277918|NCT03512236|DRUG|Humalog®|Injection of lispro
48277919|NCT03512236|DRUG|Placebo|Injection of 0.9% NaCl
48277920|NCT02333227|DIETARY_SUPPLEMENT|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
48277921|NCT00056706|PROCEDURE|Transient deafferentation|
48277922|NCT04964869|PROCEDURE|epinephrine solution injection|epinephrine solution injection at least 1 ml to the post- sphincterotomy wound
48277923|NCT00553995|DRUG|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
48277924|NCT00553995|DRUG|Placebo|
48277925|NCT05405556|DIAGNOSTIC_TEST|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers"
48277926|NCT04701125|DEVICE|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
48444832|NCT03060863|BEHAVIORAL|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
48444833|NCT03060863|BEHAVIORAL|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
48444834|NCT03060863|BEHAVIORAL|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
48444835|NCT01566721|DRUG|Herceptin|Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
48444836|NCT00064090|DRUG|cytarabine|
48444837|NCT00064090|DRUG|triapine|
48444838|NCT00053963|DRUG|romidepsin|Given IV
48444839|NCT00498654|BIOLOGICAL|Ty800 (Salmonella typhi) Oral Vaccine|
48444840|NCT05572723|DRUG|Remifentanil 2 MG|Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.
48444841|NCT05572723|DRUG|dexmedetomidine|"Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability."
48444842|NCT05988983|OTHER|Availability of OTC contraceptive pill|Over the counter contraceptive pill
48444843|NCT01783561|DRUG|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
48444844|NCT04192162|OTHER|Mud therapy application|Aplication the mud pack therapy from 20 minutes
48444845|NCT04192162|OTHER|Sulfur water application|Aplication the sulfur water in bath from 20 minutes
48444846|NCT04192162|OTHER|Hygienic water|Exercise in hygienic water
48444847|NCT02679703|DEVICE|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
48444848|NCT02679703|DEVICE|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
48444849|NCT02679703|OTHER|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
48444850|NCT03962439|BEHAVIORAL|High-Demand Photography|The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
48444851|NCT03962439|BEHAVIORAL|Moderate-Demand Photography|The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
48444852|NCT03962439|BEHAVIORAL|At-Home Engagement|The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
48444853|NCT00209781|DRUG|Sulfadoxine-Pyrimethamine (Fansidar)|
48444854|NCT00209781|DEVICE|ITNs|
48444855|NCT00808418|DRUG|Elesclomol Sodium|Chemotherapy agent
48444856|NCT00808418|DRUG|Docetaxel|Chemotherapy agent
48098106|NCT05680012|DIETARY_SUPPLEMENT|Gluten containing snack bar|Ingest snack bars containing 3 grams of gluten every day for 6 weeks.
48098107|NCT05161702|OTHER|MAG-SPM treatment on isolated PBMC cells|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
48444857|NCT03094598|OTHER|Leaflet|The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
48444858|NCT03094598|OTHER|Brochure|The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
48444859|NCT03094598|OTHER|Booklet|The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
48444860|NCT04889014|GENETIC|Personal genomic educational testing (PGET)|PGET consisted of a panel of pharmacogenomic variants
48444861|NCT04889014|GENETIC|No personal genomic educational testing (NPGET)|Lack of pharmacogenomic testing
48444862|NCT03839121|DEVICE|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of CRT patients
48444863|NCT01393054|DRUG|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
48620374|NCT01426126|DRUG|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
48444864|NCT04320420|OTHER|Adapted Physical Activity|"The APA program is defined in 3 stages:~STEP 1: during the initial chemotherapy over 3 months~* 3 supervised APA sessions/week on site:~  * two muscle strengthening sessions, stretching, flexibility in the gym~ * a cardio session (Nordic Walking: outdoors)~* at home: exercise book if the patient wishes~STEP 2: during hospitalization for the autograft, over 1 month:~* 2 sessions/week supervised by an APA engineer + exercise book and encouragement of individual work~* If the patient wishes, he can continue the exercises carried out with the APA engineer independently~STEP 3: after the transplant~* the first 3 months:~  * 2 supervised indoor sessions/week (muscle strengthening, stretching, flexibility),~ * 1-hour cardio session/week independently~* the following 3 months: 1 indoor session per week + independent exercises at home and walking or cycling sessions"
48444865|NCT02984696|DRUG|1 mg of transdermal estradiol daily and 10mg of oral MPA|
48277927|NCT05464017|DEVICE|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
48277928|NCT00001325|DRUG|18 FDG|
48277929|NCT05888025|BEHAVIORAL|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
48277930|NCT02427282|DEVICE|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
48277931|NCT02427282|DEVICE|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
48277932|NCT03490487|DRUG|conventional antiepileptic drugs|will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
48277933|NCT03490487|DRUG|oral steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
48277934|NCT00609921|DRUG|ARQ197|treatment
48277935|NCT00948740|DRUG|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
48277936|NCT04273724|OTHER|Targeted Interventions for Impairments Identified During Geriatric Assessment|Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
48277937|NCT04996056|DRUG|TNX-1300|TNX 1300 200 mg Intravenous injection
48277938|NCT04996056|OTHER|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
48277939|NCT06214312|DIAGNOSTIC_TEST|Lung Ultrasounds|An ultrasound exam of the lungs to identify possible areas of atelectasis.
48277940|NCT04407767|BEHAVIORAL|Case Formulation plus Cognitive Processing Therapy|The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.
48277941|NCT04407767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
48444866|NCT00335348|DRUG|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
48444867|NCT00335348|DRUG|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
48444868|NCT01498172|BIOLOGICAL|MAGE-A3 ASCI|5 doses every 3 weeks
48444869|NCT01498172|BIOLOGICAL|BCG|1 intravesical dose /week for 6 weeks
48620375|NCT04150887|DRUG|Cusatuzumab|Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
48620376|NCT04150887|DRUG|Azacitidine|Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
48620377|NCT04150887|DRUG|Venetoclax|Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
48620378|NCT04649983|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
48444870|NCT02846363|OTHER|public awareness campaign|"The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~* 3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~* A leaflet on stroke will be created~* 3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~* Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~* A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~* On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently"
48444871|NCT04811794|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.
48444872|NCT04811794|OTHER|Personal history|Personal history on diagnosis, treatment, and socioeconomic factors
48444873|NCT05296304|DRUG|Bexarotene|Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
48444874|NCT05296304|RADIATION|Total Skin Electron Beam (TSEB)|At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
48444875|NCT04583657|OTHER|Eggs|Consumption of two eggs (control or test) per day during three months
48444876|NCT00244764|DRUG|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
48444877|NCT00244764|DRUG|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
48444878|NCT03749252|DRUG|P03277|A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
48444879|NCT04897321|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis. Intravenous
48444880|NCT04897321|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
48444881|NCT04897321|DRUG|MESNA|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
48444882|NCT04897321|DRUG|B7-H3 CAR T cells|The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.
48444883|NCT04690101|OTHER|none, this is an observational study|none, this is an observational study
48444884|NCT00655590|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
48444885|NCT00655590|DRUG|Sildenafil|100 mg daily dosing
48444886|NCT00655590|DRUG|Placebo|Matching placebos
48444887|NCT04766450|DRUG|Acetyl cysteine|NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
48444888|NCT03129022|PROCEDURE|epidural anaesthesia|Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
48444889|NCT02129894|DEVICE|abdominal Binder|placement of abdominal binder
48444890|NCT03607253|OTHER|repetitive heel rise activity|Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
48444891|NCT05875597|OTHER|Physical therapy exercise programme|Carrying out a programme of therapeutic physical exercise for 12 weeks, twice a week for 45 minutes.
48444892|NCT00857103|BEHAVIORAL|CHOICE|Use of Choice support system as preparation for patient consultations
48444893|NCT06537193|DIAGNOSTIC_TEST|AMRI|The study subjects will receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination will be conducted using a 3-Tesla MRI machine, and the MRI protocol consists of T2-weighted imaging,diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
48444894|NCT06537193|DIAGNOSTIC_TEST|CT|CT will be performed by obtaining dynamic phases (precontrast phase, arterial phase, portal venous phase, and delayed phase images). Subjects will receive intravenous injection of iodine contrast media. Scan coverage was from the basal lung to the iliac crest or pelvis.
48444895|NCT03232619|BIOLOGICAL|CD19 CART|Patients will get one course of CART treatment with the dose of 0.5-5\*10\~6/KgBW.
48444896|NCT05954598|DIETARY_SUPPLEMENT|probiotic|This study was designed as a randomized double-blind controlled study. The enrolled subjects were randomized into two groups: intervention group and waiting intervention group. The intervention group received 12 weeks of probiotic intervention from the start of the study, and the waiting group received 12 weeks of placebo intervention from the start of the study. At the start of the study, both groups received 12 weeks of probiotic intervention.
48444897|NCT05351892|DRUG|Elinzanetant (BAY3427080)|Soft gel capsule, oral
48444898|NCT02319824|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
48444899|NCT02319824|OTHER|Laboratory Biomarker Analysis|Correlative studies
48444900|NCT02319824|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
48444901|NCT05166148|OTHER|Session (a)|Eccentric cycling
48444902|NCT05166148|OTHER|Session (b)|High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
48444903|NCT05166148|OTHER|Session (c)|Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
48444904|NCT04549272|OTHER|No interventions|No interventions - observational study
48444905|NCT02003833|DEVICE|Poly-L-lactic acid|Sculptra injections
48444906|NCT02003833|DEVICE|Placebo comparator|saline injections
48444907|NCT03946891|DRUG|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
48444908|NCT03946891|DRUG|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
48444909|NCT02200224|OTHER|Rapid Testing|
48444910|NCT03154047|DRUG|NEOD001|humanized monoclonal antibody
48444911|NCT00673647|BEHAVIORAL|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
48444912|NCT01747135|DRUG|VTS-270|
48444913|NCT02494479|DRUG|Prurisol|50mg tablet
48444914|NCT02494479|DRUG|Placebo|Sugar pill designed to match Purisol tablet
48444915|NCT03797872|DRUG|Methotrexate|Methotrexate up to 25mg/week as tolerated po or sc
48444916|NCT03797872|DRUG|Sulfasalazine|Sulfasalazine up to 3g daily po
48444917|NCT03797872|DRUG|Leflunomide|Leflunomide 10-20mg daily po
48444918|NCT03797872|DRUG|Methylprednisolone|For IA or IM injection 20-120mg
48444919|NCT03797872|DRUG|Triamcinolone|For IA or IM injection 20-120mg
48444920|NCT00664014|DRUG|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
48444921|NCT00664014|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
48444922|NCT04354493|DEVICE|Myo-electric Gaming Interface|Non-significant risk, video game controller which maps myo-electric control signals to button presses.
48444923|NCT02849457|DRUG|Early Vigabatrin|Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
48444924|NCT02849457|DRUG|Delayed Vigabatrin (Placebo)|Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
48444925|NCT03871166|OTHER|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~\[Time Frame: 01/2007 - 12/2018\]"
48444926|NCT02479633|OTHER|Coronally advanced flap with connective tissue graft|"Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction."
48444927|NCT03565133|DIETARY_SUPPLEMENT|Quinine sham feeding quinine|Oral sham feeding with quinine
48444928|NCT03565133|DIETARY_SUPPLEMENT|Gastric quinine|A gastric capsule containing quinine
48444929|NCT03565133|DIETARY_SUPPLEMENT|Oral sham feeding placebo|Oral sham feeding with placebo (tap water)
48444930|NCT03565133|DIETARY_SUPPLEMENT|Gastric placebo|A gastric capsule containing placebo (cellulose)
48444931|NCT05598476|OTHER|5kg bag|a 5 kg bag is applied on the chest for 2 hours
48444932|NCT04180709|DEVICE|Sleepio|Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
48444933|NCT04630834|DRUG|Ibuprofen|Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
48444934|NCT04630834|DRUG|Acetaminophen|patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
48444935|NCT04630834|DRUG|Placebo|patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
48444936|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
48444937|NCT00829673|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
48444938|NCT06279338|DRUG|Azacitidine Injection|On the basis of the conventional transplantation treatment regimen, combining azacitidine injection with BUCY2 conditioning regimen (azacitidine 75 mg/m2/d for -11 days to -5 days, cytarabine 2 g/m2 q12h for -8 days to -7 days, cyclophosphamide 1.8 g/m2/d for -6 days to -5 days, busulfan 3.2 mg/kg/d for -4 days to -2 days)
48444939|NCT05640544|OTHER|Sound and light stimulation in Gamma band|"We expect to screen out the efficacy of Gamma band in the prognosis and treatment of disorders of consciousness by various frequencies of stimulation.~Optical stimulation:~A computer program is used to control the flashing frequency of LED lights for stimulation. The serial port can convert the parallel data characters of the computer CPU into a continuous serial data stream. According to the frequency designed by experiment (10Hz, 20hz, 40hz, 80hz), we modulate the flicker frequency of LED lamp. LED lamp uses T8 lamp, diameter 25.4 mm, length 620 mm, and power 20W.~Acoustic stimulation:~We use Adobe Audition CC 2022 to modulate the tones. The tones modulated to 10Hz, 20Hz, 40Hz and 80Hz are play by noise-canceling headphones to the patients."
48444940|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
48444941|NCT01639092|DRUG|Tenofovir|Tenofovir 300mg Daily Oral
48444942|NCT01639092|DRUG|Entecavir|Entecavir 1 mg daily Oral
48444943|NCT02060747|BEHAVIORAL|Coordinator-based post fracture program|
48444944|NCT05223322|BEHAVIORAL|Taking Charge during Treatment (TCT) Intervention|CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
48444945|NCT00974740|DRUG|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
48444946|NCT00974740|DRUG|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
48444947|NCT02043132|DRUG|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
48444948|NCT02043132|DRUG|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
48444949|NCT04171570|PROCEDURE|Coronary angiography and or Percutaneous coronary Intervention|Radial access punture site
48444950|NCT00485667|DRUG|SKY0402|Subects received either 300mg or 450mg
48444951|NCT00485667|DRUG|Moxifloxacin 400mg|
48444952|NCT00485667|DRUG|Placebo injection|
48444953|NCT00485667|DRUG|Placebo tablet|
48444954|NCT05318898|OTHER|Vegetal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetal protein sources
48444955|NCT05318898|OTHER|Animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
48444956|NCT00471523|DRUG|Clomiphene citrate|
48444957|NCT00471523|DRUG|Metformin|
48444958|NCT00445445|OTHER|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
48444959|NCT00445445|OTHER|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
48444960|NCT00445445|PROCEDURE|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
48444961|NCT00445445|PROCEDURE|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
48444962|NCT00445445|PROCEDURE|study of high risk factors|"* Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~* Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
47928002|NCT02671162|DRUG|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
47928003|NCT02726542|DRUG|somatropin|Norditropin (growth hormone) given by injection using a pen-device
48444963|NCT02209285|BEHAVIORAL|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
48444964|NCT01692717|DRUG|Atorvastatin|10 mg
48444965|NCT01692717|DRUG|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
48444966|NCT01692717|DRUG|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
48444967|NCT05729594|DRUG|Bimatoprost Ophthalmic|eyedrops
48444968|NCT02193061|BIOLOGICAL|Rotarix|
48444969|NCT02193061|BIOLOGICAL|RotaTeq|
48444970|NCT05806957|DEVICE|Fundus Photography|Subjects will undergo Fundus Photography using FDA approved non-mydriatic fundus cameras and mydriatic camera with OCT
48444971|NCT00739947|OTHER|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
48444972|NCT02723721|DRUG|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
48444973|NCT00139113|BIOLOGICAL|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
48444974|NCT02612298|DRUG|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
48444975|NCT02612298|DRUG|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
48444976|NCT01948414|PROCEDURE|electroencephalography|
48444977|NCT01948414|BIOLOGICAL|Blood sampling|
48444978|NCT01948414|BEHAVIORAL|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
48444979|NCT00497263|DEVICE|Niti CAR|
48444980|NCT01045681|DRUG|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
48444981|NCT06172894|DRUG|APN401|APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
48444982|NCT06007937|DRUG|Lorlatinib|Lorlatinib 100 mg orally daily
48444983|NCT06007937|DRUG|Ramucirumab|Ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose.
48444984|NCT00152646|DRUG|placebo, aspirine, clopidogrel|
48444985|NCT04371133|DIAGNOSTIC_TEST|Adropin (ng/L)|Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
48444986|NCT01686477|OTHER|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
48444987|NCT01686477|OTHER|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
48444988|NCT01686477|OTHER|Preterm Formula used when there is a shortfall in mother's own milk|
48444989|NCT01259791|DRUG|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
48444990|NCT01259791|DRUG|Placebo|Placebo
48444991|NCT01608269|DRUG|Abacavir/Lamivudine|one tablet once a day
48444992|NCT06340633|DRUG|Ebselen|Glutathione peroxidase mimetic
48444993|NCT06340633|DRUG|Placebo|Matching placebo containing excipients
48444994|NCT03265574|DRUG|Enalapril|Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
48277942|NCT04423848|OTHER|Home Hospital for Lymphoma|Remote monitoring and home-based care designed for hospitalized patients with lymphoma
48444995|NCT04490005|OTHER|pupillometry|evaluation of pupillary reflex by using the Neuroptics Pupillometer every 4 hours during ICU stay
48277943|NCT05631132|PROCEDURE|BAL + PAP|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
48277944|NCT05247411|OTHER|Educational intervention|"During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life."
48444996|NCT05206318|DRUG|Topical Cysteamine|Topical cysteamine cream applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
48444997|NCT05206318|DRUG|Topical Vehicle Control|Topical vehicle control cream without cysteamine active ingredients applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
48444998|NCT03783091|DRUG|Hydroxocobalamin|Single IV administration of Vitamin B12
48444999|NCT03783091|DRUG|Placebo|Single IV administration of saline
48445000|NCT01330576|PROCEDURE|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
48445001|NCT01330576|PROCEDURE|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
48445002|NCT04960917|BEHAVIORAL|Evaluation of ehealth literacy workshop|Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
48445003|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before conditioning|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
48445004|NCT05111223|DEVICE|Real transcranial magnetic stimulation (TMS) before devaluation test|Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
48445005|NCT05111223|DEVICE|Sham transcranial magnetic stimulation (TMS)|Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
48445006|NCT02148497|PROCEDURE|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
48445007|NCT04415515|BEHAVIORAL|RN case management|A Registered Nurse (RN) case manager makes phone contact with the member to review medications, health risks, care gaps/barriers, \& to develop a case management plan that focuses on improving medication adherence \& reconciliation, condition-based measures \& outcomes, addressing psycho-social needs, \& intensive post-admission care transition. RNs may refer the member to social workers,specialist providers, \& support programs (including to more intense case management where the primary care physician is notified that RNs may contact them to support treatment \& coordinate services).
48445008|NCT04415515|BEHAVIORAL|Community Health Worker Case Management|In selected UHC markets for defined time periods, members randomized to the treatment arm also received an enhanced version of the SCC that included in-home case management support from non-clinical Community Health Workers (CHW).
48445009|NCT04415515|BEHAVIORAL|RN Standard care coordination and disease management|RN Standard care coordination and disease management
48445010|NCT05470972|DRUG|Ethanol Injection|The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
48445011|NCT03194217|DRUG|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
48445012|NCT03194217|DRUG|Placebo|Placebo
48445013|NCT04724187|DRUG|Misoprostol|it is prostaglandin E1 .
48445014|NCT04724187|DRUG|Oxytocin|it stimulates uterine contractions
48445015|NCT04400890|DRUG|Resveratrol|Resveratrol vs placebo given for 15 days.
48445016|NCT04400890|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 100,000 IU given on day one.
48445017|NCT00308048|DRUG|Pegylated Interferon alfa 2b and ribavirin|
48445018|NCT00546988|BIOLOGICAL|allogeneic stem cell transplant|
48445019|NCT02232776|DRUG|Losartan|Dose of Losartan : 0.7mg/kg once daily.
48098108|NCT05161702|OTHER|Isolated PBMC cells without treatment.|Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.
48098109|NCT04585347|DRUG|ALZ-801 170 mg Fasting|
48098110|NCT04585347|DRUG|ALZ-801 205 mg Fasting|
48098111|NCT04585347|DRUG|ALZ-801 205 mg After Food|
48445020|NCT05641961|BEHAVIORAL|Survivorship mobile application|Mobile phone application
48445021|NCT05641961|OTHER|Questionnaires|Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
48445022|NCT04163354|PROCEDURE|5% sodium fluoride varnish (NaF)|In the NaF varnish groups, 0.25mL (one drop) of the varnish is placed in a plastic dappen dish. A disposable microbrush is used to apply the varnish onto the second primary molars included in the study and all other teeth. The child is instructed not to eat or drink after the application of varnish for at least half an hour.
48445023|NCT04163354|PROCEDURE|Glass ionomer sealant (GIS)|Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
48098112|NCT04585347|DRUG|ALZ-801 342 mg Fasting|
48098113|NCT06629428|DRUG|Ublituximab|The participants will receive 48 weeks of treatment with ublituximab.
48098114|NCT06629922|OTHER|No intervention|This is a observational study and the participants will not receive any intervention
48098115|NCT04566874|DEVICE|ALIF|Anterior Lumbar Interbody Fusion
48098116|NCT00445406|DRUG|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
48098117|NCT00445406|DRUG|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
48098118|NCT00035230|DRUG|Topiramate|
48445024|NCT02519491|OTHER|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
48445025|NCT02519491|OTHER|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
48445026|NCT02543489|DEVICE|Flex IM rod|
48445027|NCT01658774|DRUG|Albendazole|Single 400mg dose
48445028|NCT01658774|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C
48445029|NCT05234502|OTHER|Adequate and balanced healthy diet program (CHO: 45-60%, protein:10-20%, fat:20-35%)|In calculating the estimated basal metabolic rate of individuals, Mifflin-St. The Jeor Equation will be used.BMR will be multiplied by the physical activity factor of the individual and 500\*700 kcal will be subtracted from the found value and the total daily energy requirement will be obtained.
48445030|NCT05234502|OTHER|Ketogenic diet program (CHO: 6%, protein:19%, fat:75%)|A ketogenic diet will be applied to Group 1 for 12 weeks simultaneously with taxane treatment.
48445031|NCT04550013|OTHER|Heavy-Slow Resistance training|Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
48445032|NCT04550013|OTHER|Low-Load Blood Flow Restriction training|Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
48445033|NCT06407622|OTHER|Foot Reflexology|In previous studies, no study was found investigating the effect of foot reflexology on sleep quality and bowel functions in patients undergoing surgical intervention. This study is thought to be the first to evaluate the effect of foot reflexology on sleep quality and bowel functions in surgical patients. In this respect, it is a study that will contribute to the literature.
48445034|NCT00273026|DRUG|salmeterol xinafoate/fluticasone propionate|
48445035|NCT02009774|PROCEDURE|NBI Function|
48445036|NCT03703791|BIOLOGICAL|AR101|AR101 powder
48445037|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
48445038|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
48445039|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
48445040|NCT02436447|DRUG|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
48445041|NCT00100464|DRUG|Paroxetine|
48445042|NCT00100464|DRUG|5HTP|
48445043|NCT05385601|OTHER|eVOG (Mobile VideoOculoGraphy)|"* Eyes movements assessed with e-VOG (mobile application developed on an iPad, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)"
48445044|NCT01036009|OTHER|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
48445045|NCT03505463|OTHER|Blood samples|"Three blood samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
48445046|NCT03505463|OTHER|Cerebrospinal fluid sample|"Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
48445047|NCT03505463|OTHER|Clinical examination|Clinical examinations will be performed at \<72 hours, 7 days and 365 days post-injury.
48445048|NCT02856386|DIETARY_SUPPLEMENT|polyphenol supplement|8 mL once daily
48445049|NCT04206332|DRUG|VRC-MALMAB0100-00-AB|VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.
48445050|NCT04206332|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).
48445051|NCT03546283|DRUG|Placebos|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
48445052|NCT03546283|DRUG|Cattle Encephalon Glycoside and Ignotin|The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
48445053|NCT05675033|DRUG|Serplulimab and Bevacizumab injection|"Serplulimab, 4.5mg/kg, intravenous injection, D1,Q21, until the disease progressed or showed intolerable side effects.~Bevacizumab injection, 7.5mg/kg, intravenous injection, D1, Q21, until the disease progressed or showed intolerable side effects.~Platinum-based chemotherapy: pemetrexed combined with carboplatin, D1-2, Q21, a total of 4 cycles."
48445054|NCT03394547|DEVICE|Allay|pulsed shortwave therapy treatment for painful periods
48445055|NCT03394547|DEVICE|Placebo|A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
48445056|NCT01519661|DRUG|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
48445057|NCT00104481|BEHAVIORAL|cognitive behavior therapy|
48445058|NCT05669547|DEVICE|dual hormone fully closed loop (DHFCL)|dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
48445059|NCT05436860|DEVICE|liver ultrasound|"At the time of access to the emergency room, a cohort of male and female patients aged 18 or over will be consecutively recruited with green or white color coded triage.~patients who agree to participate in the study will undergo liver ultrasound. Patients who test negative on ultrasound evaluation for liver hyperechogenicity will be part of the control group."
48445060|NCT02372747|PROCEDURE|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
48445061|NCT02372747|PROCEDURE|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
48445062|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
48445063|NCT00147498|DRUG|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
48445064|NCT00147498|DRUG|CP-690,550|30 mg BID for 6 weeks
48445065|NCT00147498|OTHER|Placebo|Placebo tablets
48445066|NCT04234334|OTHER|Consume 2 eggs with spinach per day|Participants will be randomly allocated to consume either 2 eggs or 2 egg substitutes with spinach daily for 4 weeks and after a 3-week wash out, they will be allocated to the alternate treatment
48445067|NCT04234334|OTHER|Egg Subsitute with spinach per day|Egg Subsitute with spinach per day
48445068|NCT05643911|PROCEDURE|HFNC|In the HFNC group, patients will receive HFNC oxygen therapy for 20 minutes.
48445069|NCT05643911|PROCEDURE|NIV|Patients will receive NIV for 20 minutes delivered with a naso-buccal or face mask according to the patient's tolerance.
48445070|NCT02237820|DRUG|Dexamethasone|6 mg/day of Oral Dexamethasone
48445071|NCT02237820|DRUG|Prednisone|40 mg/day of Oral Prednisone
48445072|NCT05404594|BEHAVIORAL|Maternal vocal contact|"Two consecutive venipuncture (order randomly balanced) within a short period of time will be realized with and without the presence of the mother talking/singing to her VPI infant.~In this intervention group, the mother will be supported to talk or to sing to her infants during before and during the venipuncture."
48445073|NCT01279902|DRUG|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
48445074|NCT01398163|OTHER|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
48445075|NCT01398163|OTHER|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
48445076|NCT00113386|BIOLOGICAL|filgrastim|Consolidation chemotherapy
48445077|NCT00113386|BIOLOGICAL|pegfilgrastim|Consolidation chemotherapy
48445078|NCT00113386|DRUG|cisplatin|
48445079|NCT00113386|DRUG|docetaxel|
48445080|NCT00113386|PROCEDURE|adjuvant therapy|
48445081|NCT00113386|PROCEDURE|conventional surgery|
48445082|NCT00113386|PROCEDURE|neoadjuvant therapy|
48445083|NCT00113386|RADIATION|radiation therapy|
48445084|NCT04700787|DRUG|Sulopenem|sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
48445085|NCT04311320|DEVICE|Low-Resource Oxygen Blender|The device that is being evaluated is a novel low-cost, high access oxygen blender designed to be used in the World Health Organization bCPAP design. It functions by utilizing the Venturi effect, whereby a narrow jet of one fluid (i.e. oxygen) creates a suction effect and entrains surrounding ambient fluid (i.e. room air) into the jet, effectively creating a mixed solution of both fluids. The cost of materials amounts to approximately 1.40 U.S.D. The average time it takes to build a blender and incorporate it into a bCPAP circuit for a new user is approximately 16 minutes. The materials can all be found in a standard hospital, namely 3cc syringes with rubber stops and a 22 gauge hypodermic needle.
48445086|NCT03311594|DRUG|Low Alcohol|Low Alcohol Consumption
48445087|NCT03311594|DRUG|Moderate Alcohol|Moderate Alcohol Consumption
48445088|NCT03311594|DRUG|Placebo Alcohol|Placebo Alcohol Consumption
48445089|NCT03311594|OTHER|Pain Induction|10% capsaicin solution placed on forearm and heat induction
48445090|NCT03311594|OTHER|No Pain Induction|Water placed on forearm
48445091|NCT01320254|DRUG|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
48445092|NCT01320254|DRUG|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
48445093|NCT03077880|PROCEDURE|intra-operatory measurement during implant placement|mucoperiosteal flap, soft tissue thickness measurement, implant insertion
48445094|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
48445095|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
48445096|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
48445097|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
48445098|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
48445099|NCT01472848|DRUG|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
48445100|NCT06218108|DIAGNOSTIC_TEST|Taulí-T1 versus conventional classifications|All the slides of each case will be reviewed, selecting the one that contains the most invasive section, and this will be digitized to take measurements in micrometers with greater precision. To measure the degree of infiltration, the measurement of residual healthy submucosa (hrSB) will be used, which is the distance between the point of greatest infiltration and the muscularis propria. The total thickness of the submucosa in the tumor area will also be measured, taking as a reference the muscularis of the mucosa or, in its absence, the surface of the lesion, to calculate the percentage of infiltration of the submucosa. This percentage will be calculated as the inverse percentage of invasion with respect to the hrSB: (total thickness of the submucosa - hrSB / total thickness of the submucosa) x 100. The qualitative categories will be obtained: sm1 (\< 33.3%), sm2 (33.3% - 66.6%) and sm3 (\> 66.6%). Measurements will be also taken in micrometers for the conventional classifications.
48445101|NCT03829891|DRUG|Beinaglutide|"1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
48445102|NCT03829891|DRUG|glargine|"1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
48445103|NCT03191474|BEHAVIORAL|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
48445104|NCT00840099|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
48445105|NCT00840099|DRUG|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
48445106|NCT02412384|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
48445107|NCT02412384|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
48445108|NCT06310655|RADIATION|Proton SBRT|Patients will receive SBRT over 5 days, either every day or every other day, to a dose of 25-50 Gy.
48445109|NCT06278844|DEVICE|Conduction system pacing|In the conduction system pacing group, the right ventricular lead will be placed in a septal position to achieve conduction system pacing, either His bundle pacing (HBP) or left bundle branch area (LBBA) pacing. In the usual care group, the right ventricular lead will be placed in the right ventricle apex as usual.
48445110|NCT06278844|DEVICE|Right ventricular apical pacing|This is the usual care group. Patients will receive a pacemaker device with the right ventricular lead inserted in the apex and not in the septal position.
48445111|NCT03918174|DEVICE|Dart splint orthosis|The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.
48445112|NCT03918174|OTHER|Conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.
48445113|NCT04131374|BEHAVIORAL|Reminiscence Therapy|Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
48098119|NCT03986606|BIOLOGICAL|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
48445114|NCT02338583|DEVICE|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
48445115|NCT01461421|BEHAVIORAL|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
48445116|NCT01461421|BEHAVIORAL|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
48445117|NCT01461421|BEHAVIORAL|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
48445118|NCT01461421|BEHAVIORAL|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
48445119|NCT03547622|DRUG|MAT taper with galantamine|Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
48445120|NCT03547622|DRUG|MAT taper with placebo|Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
48445121|NCT06238791|OTHER|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease.|Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease and lipedema.
48098120|NCT02072005|OTHER|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
48277945|NCT01996787|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
48445122|NCT00982397|DEVICE|Protecta VR-ICD|Protecta single-chamber implantable cardioverter defibrillators.
48445123|NCT00982397|DEVICE|Protecta DR-ICD or CRT-D|Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
48445124|NCT00793832|BEHAVIORAL|supervised exercise|supervised exercise
48445125|NCT00793832|BEHAVIORAL|Diet advice|Diet Advice
48445126|NCT02216006|PROCEDURE|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
48445127|NCT02216006|PROCEDURE|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
48445128|NCT00068991|BEHAVIORAL|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
48445129|NCT00068991|BEHAVIORAL|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
48445130|NCT00068991|BEHAVIORAL|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
48445131|NCT01795872|PROCEDURE|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
48445132|NCT04512430|DRUG|Atezolizumab|"Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~* No premedication administered for atezolizumab specifically is permitted~* Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~* If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles \> 2 at the discretion of the treating physician.~* If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes."
48445133|NCT04512430|DRUG|Bevacizumab|Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
48445134|NCT04512430|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center"
48445135|NCT04512430|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo\[2,3 d\]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
48445136|NCT01771939|PROCEDURE|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
48445137|NCT01771939|PROCEDURE|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
48445138|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
48445139|NCT04019951|DIETARY_SUPPLEMENT|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
48445140|NCT04019951|DIETARY_SUPPLEMENT|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
48445141|NCT00654030|DRUG|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
48445142|NCT04138186|DEVICE|2.0g G-PUR®, oral administration|tid for 12 weeks
47928004|NCT03712709|DIAGNOSTIC_TEST|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
48445143|NCT04138186|DEVICE|Placebo, oral administration|tid for 12 weeks
48445144|NCT05841628|DEVICE|532 nm laser treatment|The port wine birthmark will be treated with the DermaV 532 nm laser.
48445145|NCT00960297|DRUG|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
48445146|NCT00960297|DRUG|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
48445147|NCT00960297|DRUG|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
48445148|NCT02944617|OTHER|Laboratory Biomarker Analysis|Correlative studies
48445149|NCT02944617|DIETARY_SUPPLEMENT|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
48445150|NCT02944617|DRUG|VEGF-TKI|Must be received as standard of care chemotherapy
48445151|NCT00312039|DRUG|Elvucitabine|Elvucitabine 10 mg QD for 14days
48445152|NCT00312039|DRUG|Lamivudine|Lamivudine 300 mg QD for 14 days
47928005|NCT03976869|DRUG|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
47928006|NCT03450330|DRUG|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
48445153|NCT04396015|DIETARY_SUPPLEMENT|Bulletproof Brain Octane|Medium chain triglyceride oil (MCT)
48445154|NCT04396015|DIETARY_SUPPLEMENT|Placebo|Placebo (olive) oil
48445155|NCT04205266|DRUG|Ferumoxytol|IV iron infusion
48445156|NCT04205266|DRUG|Ferrous Sulfate|oral iron therapy
48445157|NCT04297891|OTHER|Clinical rating scale to measure Ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
48445158|NCT04297891|OTHER|Clinical rating scale to measure spastic paraplegia disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
48445159|NCT04297891|OTHER|Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)|"The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity."
48445160|NCT04297891|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
48445161|NCT02380560|DEVICE|Ultrasonographic examination|"An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker."
48445162|NCT04263649|DEVICE|Peripherally Inserted Central Catheter|insertion of a Peripherally Inserted Central Catheter (PICC)
48445163|NCT01126203|PROCEDURE|SLT|All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
48445164|NCT01126203|PROCEDURE|ALT|All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with \~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
48445165|NCT04381130|DRUG|EF-009|"Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy"
48445166|NCT02762422|OTHER|Phlebotomy|Removal of 500 cc of blood via forearm vein
48445167|NCT04435353|DEVICE|VibroLUNG|Lungs intensive therapy
48445168|NCT00139711|DRUG|Irinotecan|
48445169|NCT00139711|DRUG|Docetaxel|
48445170|NCT03715933|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
48445171|NCT03715933|DRUG|Carboplatin|Chemotherapy
48445172|NCT03715933|DRUG|Cisplatin|Chemotherapy
48445173|NCT03715933|DRUG|Pemetrexed|Chemotherapy
48445174|NCT03715933|DRUG|5-fluorouracil|Chemotherapy
48445175|NCT03715933|DRUG|Irinotecan|Chemotherapy
48445176|NCT03715933|DRUG|Temozolomide|Chemotherapy
48445177|NCT02525211|DRUG|Ropivacaine|a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
48445178|NCT02525211|DRUG|physiological saline|a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
48445179|NCT00852020|DIETARY_SUPPLEMENT|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
48445180|NCT03575234|DRUG|Cyclophosphamide|Given IV
48445181|NCT03575234|BIOLOGICAL|IRX-2|Given SC
48445182|NCT03575234|BIOLOGICAL|Nivolumab|Given IV
48445183|NCT03575234|PROCEDURE|Surgery|Undergo surgery
47928007|NCT05491460|DRUG|Apixaban 5 MG Tab|oral intake
47928008|NCT05491460|DRUG|Dabigatran 150 MG Tab|oral intake
48445184|NCT01354860|OTHER|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
48445185|NCT01354860|OTHER|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
47928009|NCT05491460|DRUG|Edoxaban 60Mg Tab|oral intake
48445186|NCT03601819|DRUG|Pacritinib|Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
48445187|NCT05327491|DRUG|Sotorasib|Oral Tablet
48445188|NCT00836667|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
48445189|NCT00836667|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
48277946|NCT01996787|DEVICE|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
48277947|NCT04468477|DEVICE|6 Lead ECG|Patients will be assessed with the Kardiamobile device.
48277948|NCT05199584|DRUG|ENV-101 (taladegib)|tablets dosed once-daily
48277949|NCT01039207|OTHER|Laboratory Biomarker Analysis|Correlative studies
48445190|NCT06073691|BEHAVIORAL|Exercise intervention|Practice systematic and regular aerobic physical exercise (walking and running).
48445191|NCT06073691|OTHER|Placebo|Placebo
48277950|NCT01039207|BIOLOGICAL|Rilotumumab|Given IV
48277951|NCT03671122|DIAGNOSTIC_TEST|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
48277952|NCT03671122|OTHER|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
48277953|NCT03671122|PROCEDURE|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
48277954|NCT05985681|PROCEDURE|Biospecimen Collection|Undergo blood sample and vaginal swab collection
48277955|NCT05985681|BIOLOGICAL|HPV16 RG1 VLP Vaccine|Given IM
48277956|NCT05985681|OTHER|Questionnaire Administration|Ancillary studies
48277957|NCT05985681|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given via injection
48277958|NCT05985681|OTHER|Saline|Given IM
48277959|NCT04073667|BEHAVIORAL|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
48445192|NCT01160926|DRUG|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
48445193|NCT01160926|DRUG|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets"
48445194|NCT03058003|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
48445195|NCT03058003|OTHER|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
48277960|NCT00977977|DRUG|Rituximab Infusion|Drug Rituximab Infusion 2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
48445196|NCT05408884|OTHER|Social Support|"Social support phone buddy program."
48445197|NCT05408884|OTHER|Basic income|$750 per month for 12 months
48445198|NCT05190341|DRUG|Ibuprofen 800 mg oral|1 hour before HSG
48445199|NCT05190341|DRUG|Ketorolac 30mg oral|1 hour before HSG
47928010|NCT05491460|DRUG|Rivaroxaban 20 MG Tab|oral intake
48277961|NCT00977977|DRUG|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
48277962|NCT04452643|BIOLOGICAL|BACMUNE (MV130)|BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
48277963|NCT04452643|OTHER|Placebo|Placebo is a solution on sodium chloride at 0.9%
48277964|NCT04929210|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
48277965|NCT04929210|DRUG|Placebo|Matching placebo will be administered as subcutaneous injection.
48277966|NCT04261543|OTHER|High protein and early exercise|High protein is defined as protein prescription of ≥2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization
48277967|NCT04261543|OTHER|Usual Care|Usual care group has protein prescription of ≤1.2 gram/kg body weight and exercise at the discretion of attending clinicians
48277968|NCT00125034|BIOLOGICAL|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m\^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
48445200|NCT02900443|DRUG|Mycophenolate mofetil|
48445201|NCT02900443|DRUG|Azathioprine|
48445202|NCT06427161|PROCEDURE|LLLT application|The LLLT group received the laser application at 8 points, once a week, over a 2-month period, totaling 8 sessions. Each point was stimulated for 8 seconds in the soft palate, uvula, pharyngeal walls, palatine tonsils, and on the tongue base. LLLT protocol: Diode laser 810nm in continuous contact mode was used, and the radiant energy was 2J (250uw X 8 sec) for each point. Total energy was 16J (2J X 8 points) for each session.
48445203|NCT06427161|PROCEDURE|dextrose injection|25% dextrose was injected in the same 8 points; 1/2 ml for each point, total 4ml for each session. The injection was done weekly, up to 4 sessions.
48445204|NCT04671368|DIAGNOSTIC_TEST|Artificial Intelligence|The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.
48445205|NCT04671368|DIAGNOSTIC_TEST|Practicing Pathologists|The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images
48445206|NCT04671368|DIAGNOSTIC_TEST|Gold Standard|Firstly, the two expert pathologist(\>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(\>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
48445207|NCT05288881|BIOLOGICAL|ANX105|Participants will receive single-ascending doses of ANX105 administered by IV infusion.
48445208|NCT05288881|DRUG|Placebo|Participants will receive matching placebo administered by IV infusion.
48445209|NCT03305263|DRUG|Hydroxychloroquine|One tablet a day from inclusion until end of pregnancy or gestational age 28
48445210|NCT03305263|DRUG|Hydroxychloroquine placebo|One tablet a day from inclusion until end of pregnancy or gestational age 28
48445211|NCT05621694|BEHAVIORAL|Tai Chi Easy|A meditative movement practice that includes simple qigong movement/breath practices and single, repeated tai chi movements taught to generate a meditative state and flow
48445212|NCT00490594|DEVICE|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
48277969|NCT00125034|DRUG|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m\^2/day IV over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
48277970|NCT05819229|DRUG|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
48277971|NCT03384329|DRUG|Resveratrol Pill|Resveratrol 500 mg
48277972|NCT03384329|DRUG|Placebos|Placebo Pills
48277973|NCT04036825|DIETARY_SUPPLEMENT|Liquid Nutritional Supplement from Hospital Product|Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
48277974|NCT04036825|DIETARY_SUPPLEMENT|Placebo|Standard nutritional supplement is given 2 times daily as placebo for 14 days
48277975|NCT06456710|BEHAVIORAL|Conventional IBS Health Education|Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.
48277976|NCT06456710|BEHAVIORAL|Based on ACT Theory of Psychological Intervention|"On the basis of the control group, the stigma intervention program of college students with IBS based on ACT theory was implemented. The duration of intervention was 40 to 50 minutes for 6 times, once a week for 6 weeks.~Week1: established relationships; introduced the core contents of ACT, the treatment process, and the effects of application.~Week2: encouraged to express negative emotions and behaviors; made patients accept the disease.~Week3: explained the importance of coping with negative emotions; instructed to separate negative thoughts from reality through cognitive dissociation exercises.~Week4: changed the concept of self and actively accepted IBS; guided to focus on the current life and true self.~Week5: introduced the values in ACT; helped clarify the values; guided to build confidence and focused on the core values.~Week6: introduced the importance of commitment to action; developed goals and plans together; encouraged to strengthen the use of ACT."
48277977|NCT02511522|OTHER|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
48277978|NCT02511522|RADIATION|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
48277979|NCT01591005|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
48277980|NCT01591005|PROCEDURE|endarterectomy|carotid endarterectomy
48277981|NCT01591005|PROCEDURE|carotid stenting|percutaneous transluminal angioplasty and stenting
48445213|NCT02900209|OTHER|Influenza Vaccination|
48445214|NCT00910052|DEVICE|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
48445215|NCT06290284|PROCEDURE|Long Peripheral Catheter|PowerGlide Pro™ Midline Catheter
48445216|NCT06290284|PROCEDURE|Peripheral Intra-Venous Catheter|Venflon™ Pro Safety Needle Protected IntraVenous Cannula
48445217|NCT01269086|BEHAVIORAL|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
48445218|NCT04891120|DIAGNOSTIC_TEST|Treadmill test (Bruce protocol)|Treadmill test performed with and without a mask.
48445219|NCT05261945|OTHER|Routine Physical Therapy|Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.
48445220|NCT05261945|OTHER|Manual Therapy And Routine Physical Therapy|Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.
48445221|NCT05261945|OTHER|Stretching Exercises And Routine Physical Therapy|Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
48445222|NCT06420869|DIAGNOSTIC_TEST|Assessment|A postural evaluation will be conducted, including the measurement of the thoracic kyphosis angle and the assessment of sagittal head posture.A proprioception evaluation will be conducted, whereby the cervical region, trunk and ankle joint position sense and trunk and foot sensation will be evaluated for the purpose of assessing the proprioception of the spine.Turkish adaptation of the Kyphosis Specific Spine Appearance Questionnaire (KSAQ) will be employed to assess postural appearance perception. The KSAQ is a reliable and valid patient-reported outcome tool for assessing individual perception of various aspects of kyphotic deformity and appearance in young patients with kyphosis. KSAQ is a 10-item questionnaire based on a five-point Likert scale, with responses ranging from 1 to 5. The mean of the responses is used to obtain a total score for the KSAQ. The questionnaire is related to patients' perception of appearance, with higher scores indicating a worsening of the deformity.
48445223|NCT02288221|OTHER|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games"
48445224|NCT02288221|OTHER|Patient's answer without non pharmacological therapeutic|No installation at patient's home
48445225|NCT01488058|OTHER|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
48445226|NCT01488058|OTHER|Waitlist Control|Waitlist will receive iCBT at week 11
48445227|NCT04414891|DEVICE|Non invasive ventilation|"Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks.~ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)."
48445228|NCT05314647|DIETARY_SUPPLEMENT|lutein|daily dose of 5 mg lutein
48445229|NCT05314647|DIETARY_SUPPLEMENT|placebo|daily dose of 0 mg lutein
48445230|NCT04383366|DEVICE|Pentacam® (Oculus, Inc., Wetzlar, Germany)|Scheimpflug imaging
48445231|NCT04383366|DEVICE|Casia II (Tomey Germany, Nürnberg)|Anterior segment optical coherence tomography
48445232|NCT04383366|DEVICE|Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)|Anterior segment optical coherence tomography
48445233|NCT03429361|OTHER|Health by Mindstrong|Health by Mindstrong is a smartphone application that collects data on a participant's smartphone usage patterns.
48445234|NCT03782779|OTHER|Breathing program and regular exercise|This program will be supervised by a physical therapist and will include learning and performing a diaphragmatic-abdominal breathing, and incorporating the new breathing pattern to a upper and lower limbs regular exercises as well as to daily life activities.
48445235|NCT03782779|OTHER|Regular Exercise|Regular upper and lower limbs exercises supervised by a physical therapist
48445236|NCT01762579|DIETARY_SUPPLEMENT|wheat flour|wheat flour is administered three times per day for 15 days
48445237|NCT01762579|DIETARY_SUPPLEMENT|Xylose|Xylose will be administered three times per day for 15 days
48445238|NCT04073394|BEHAVIORAL|Standard Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.
48445239|NCT04073394|BEHAVIORAL|Modified Lifestyle Intervention|Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.
48445240|NCT01294787|DRUG|indacaterol and glycopyrronium bromide (QVA149)|
48445241|NCT01294787|DRUG|placebo|
48445242|NCT01294787|DRUG|tiotropium|
48445243|NCT02821247|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
48445244|NCT02527109|DRUG|Nifedipine|
48445245|NCT02193165|DRUG|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
48445246|NCT02193165|DRUG|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
48445247|NCT02193165|DRUG|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
48445248|NCT02356978|DEVICE|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
48445249|NCT02356978|DEVICE|DRAP|
48445250|NCT02625558|DRUG|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
48445251|NCT02625558|DRUG|Placebo|Placebo given three times a day
48445252|NCT03983486|OTHER|Imaging flow cytometry in multiple myeloma|Combination of immunophenotyping by flow cytometry and FISH in suspension (IS-FISH) may provide both cytogenetic and phenotypic information for a large number of cells in a single test. In this scope, a recent study demonstrated a proof of concept for IS-FISH to detect non pathological signals with the new ImageStream X technology (ISX).1
48445253|NCT02493868|DRUG|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
48445254|NCT02493868|DRUG|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
48445255|NCT02493868|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
48445256|NCT02493868|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
48277982|NCT02581709|BEHAVIORAL|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
48277983|NCT04724889|DIAGNOSTIC_TEST|blood test|Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
48277984|NCT04732663|OTHER|No Intervention|Cross-sectional study, no intervention.
48277985|NCT05391438|OTHER|Meal-timing|We propose a cross-over, proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents (ages 13-19 years), with obesity, without diabetes, to determine how timing of eating impacts glycemic response to the test meal after a 16-h fasting period. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose.
48277986|NCT06642974|OTHER|Education module on learning disabilities|Data will be collected for a period of one -year. samples will be equally distributed among experimental and control group. Socio -demographic data and knowledge and attitude of primary school teachers on learning disability will be assessed by interview method using questionnaire. Control group will receive general information on children with learning disabilities while experimental group will receive education training program. After 15 days again education program will be repeated as a reinforcement. Pre and posttest will be conducted for both the groups at one-month interval. Required data will be collected for one-year period by interview method using questionnaire. Competency assessment will be done by using checklist on identification of learning disabilities Teachers' competency for experimental group then the competency will be verified by education counselor . As a follow up of the research study, after one-month interval no of referral by each teacher will be collected to m
48277987|NCT06642974|OTHER|pamphlet on learning disability|Education pamphlets will be provided to total of 67 samples
48277988|NCT02606552|DRUG|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
48277989|NCT02606552|DRUG|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
48277990|NCT02606552|DEVICE|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
48277991|NCT05729841|OTHER|Ocean row|the Talisker Whisky Atlantic Challenge annual ocean rowing race.
48277992|NCT02262403|OTHER|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
48277993|NCT00635622|DRUG|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
48277994|NCT00635622|DRUG|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
48277995|NCT03232541|OTHER|Standard care|A) Standard antiemetic treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
48277996|NCT03232541|DEVICE|Sham acupuncture|"B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model."
48445257|NCT02493868|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
48445258|NCT02493868|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
48445259|NCT06209983|PROCEDURE|ERAS|"1. Preoperative preparation: shorten the fasting time, take a small amount of sugar water two hours before the surgery, and reduce excessive bowel preparation.~2. Intraoperative care: multi-model analgesia (mainly epidural analgesia), sleep depth monitoring, warm air blanket to avoid hypothermia.~3. Postoperative care: focus on pain relief methods (such as oral analgesics, patient-controlled epidural analgesia), early postoperative feeding (try drinking water on the first day after surgery, liquid diet on the second day, and soft diet on the third day), early removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters, and medication to prevent postoperative nausea and vomiting."
48445260|NCT06209983|PROCEDURE|Conventional care|"1. Preoperative preparation: overnight fasting preparation, bowel preparation.~2. Intraoperative care: traditional pain care (intravenous analgesics), sleep depth monitoring, warm air blanket, central venous pressure and body water monitoring indicators, traditional muscle tension relaxation treatment and the use of health insurance antagonist drugs (Neostigmine).~3. Postoperative care: patient-controlled intravenous drip for postoperative pain relief, oral feeing (rice porridge) on the postoperative day 5, and according to the progression of patient condition, step by step to removal of invasive tubes such as nasogastric tubes, intravenous catheters, and urinary catheters."
48445261|NCT04135235|DRUG|TAF|Propofol tenofovir fumarate
48445262|NCT04135235|DRUG|TDF|Dipirofurate fumarate tenofovir
48445263|NCT01208337|DRUG|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
48445264|NCT03818581|DRUG|Suvorexant|10-mg or 20-mg Suvorexant capsules
48445265|NCT03818581|OTHER|Placebo|Matching placebo capsules
48445266|NCT03949426|DRUG|KPG-818|KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
48445267|NCT06118918|BEHAVIORAL|Phase II comprehensive cardiac rehabilitation program|the program extends over 3 months after cardiac surgery. The program includes exercise, health education, and stress management. all content will be delivered to the participants through the WhatsApp application as instruction videos and short lectures. exercise will be gradually increased in terms of intensity, and duration. health education will cover topics like a healthy diet blood pressure, blood cholesterol control, smoking cessation ...etc. stress management will include relaxation therapy, breathing control, behavioral change, and other strategies to control stress. Phone call follow-ups once weekly will be made by one of the research team to evaluate the adherence and answer potential questions All interventions are guided by universal guidelines like the Australian Cardiovascular Health and Rehabilitation Association (ACRA) and American Heart Association (AHA
48445268|NCT04471363|BEHAVIORAL|Cancer-Specific Exercise education|An audio-recorded PowerPoint presentation created by the study team on the benefits of exercise for survivors, caregivers and romantic couples.
48445269|NCT00446563|DRUG|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
48445270|NCT00446563|DRUG|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
48445271|NCT00446563|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
48445272|NCT00446563|DRUG|Losartan|100 mg tablets taken orally once daily in the morning.
48445273|NCT05890261|DEVICE|Cold water-perfused cooling garment|Two types of cooling garments will be used. One is a cooling vest and the other includes cooling pants.
48445274|NCT04138368|BEHAVIORAL|dyadic psychotherapeutic intervention|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
48445275|NCT04138368|BEHAVIORAL|supportive intervention|Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
48445276|NCT02832063|BIOLOGICAL|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
48445277|NCT02832063|BIOLOGICAL|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
48445278|NCT02834663|DRUG|Lucentis|Local anesthesia with T-caine with Saline irrigation. Routine eye drap was done by potadine-cotton ball. Lucentis injected to vitreous cavity, finally dressing.
48445279|NCT00510172|DRUG|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
48445280|NCT00510172|DRUG|Placebo|NaCL 0,9%
48445281|NCT05664763|DRUG|[18F]FPEB with PET|radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
48445282|NCT05664763|BEHAVIORAL|Cannabis abstinence|Motivational enhancement and contingency management (CM) to promote and maintain cannabis abstinence after the baseline scan.
48445283|NCT02134379|DEVICE|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
48445284|NCT00207090|DRUG|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
48445285|NCT00207090|DRUG|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
48277997|NCT03232541|DEVICE|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
48277998|NCT06274593|DEVICE|OCT|Peripapillary angiography (OCT) at baseline and each year during 3 year
48445286|NCT06102213|DRUG|B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)|PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
48445287|NCT04044521|OTHER|Systems consultation|"Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 21 months.~AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit \& feedback report on their prescribing.~PF: clinics will be randomized to receive practice facilitation. Facilitators will meet with each clinic. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly.~PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing."
48445288|NCT00760630|DEVICE|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
48445289|NCT03435835|DEVICE|Control/Sham Treatment|Water at 33ºC was circulated through water-circulating trousers.
48445290|NCT03435835|DEVICE|Heat Therapy (HT)|Water at 42-43ºC was circulated through the water-circulating trousers.
48445291|NCT03805815|DEVICE|tunable crack sensor|blood pressure monitoring via crack sensor
48445292|NCT05235581|OTHER|Intervention A : virtual environment with avatar|30-second right and left unipodal static and dynamic balance test with avatar only
48445293|NCT05235581|OTHER|Intervention B : virtual environment with reinforced visual signal|30-second right and left unipodal static and dynamic balance test with reinforced visual signal only
48445294|NCT05235581|OTHER|Intervention C : virtual environment with avatar and reinforced visual signal|30-second right and left unipodal static and dynamic balance test with avatar and reinforced visual signal
48445295|NCT05235581|OTHER|Intervention D : real environment|30-second right and left unipodal static and dynamic balance test in real environment
48445296|NCT06008704|DIAGNOSTIC_TEST|Clinical assessment|The clinical assessment consists on behavioural and motor evaluations to determine the characteristics of the population
48445297|NCT06008704|DIAGNOSTIC_TEST|Pain characteristics assessment|The pain characteristics assessment will be made with a variety of scales and questionnaires which allow to identify the extent of central pain and functional impairment
48445298|NCT06008704|DIAGNOSTIC_TEST|MRI|The MRI examination allows anatomical imaging, diffusion imaging and functional imaging to measure specific markers
48445299|NCT06008704|DIAGNOSTIC_TEST|Thermotest|The thermotest is performed to assess the pain perception threshold
48445300|NCT06008704|DIAGNOSTIC_TEST|UPDRS-III Scale|The UPDRS-III scale allows to asses motor functionality of PD patients
48445301|NCT06008704|DIAGNOSTIC_TEST|[18F]-MPPF PET scan|The PET scan after injection of \[18F\]-MPPF at a dose of 200 Megabecquerel/kg +/-10% allows in vivo imaging of 5HT1A receptors
48445302|NCT04028180|OTHER|p-Menthane,3-8-diol (PMD) Topical Repellent|"p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
48445303|NCT04028180|OTHER|Picaridin Topical Repellent|"Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
48445304|NCT05584345|OTHER|Conventional Treatment|Cold pack, ultrasound, TENS, finger ladder, Codman, shoulder wheel, and Wand exercises, as well as stretching and capsule exercises, will be used in addition to conventional physiotherapy. Exercises with a wand will be performed 10 times in each direction. There will be 30 repetitions in each direction of the Codman exercises. 5 days a week, for a total of 30 sessions, the afflicted shoulder will get 6 minutes of daily US treatment, with complete contact to the shoulder area and at a right angle. All patients will receive manual stretching in the shoulder flexion, abduction, extension, external rotation, and internal rotation directions. The physiotherapist will perform these stretches 5 times in each direction, pausing for 20 seconds at the conclusion of each repeat. TENS will be applied for 20 minutes. In addition, a 15-minute cold pack application will be made to the shoulder region. The application of theraband strengthening exercises will depend on the patients' state.
48445305|NCT05584345|OTHER|Respiratory Exercises|Diaphragmatic breathing and thoracic expansion breathing exercises will be applied 5 days a week.
48445306|NCT06084494|DIAGNOSTIC_TEST|analytical determination and interpretation of heat stress using calculation of the Predicted Heat Strain and Wet Bulb Globe Temperature|The temperature inside the climatic chamber was set at 40 C and 31 C at a relative humidity of 20 % and 70 % respectively to count for a WBGT level of 28 C. The subject does walk at 5 km/h and jog at 8 km/h under these conditions for up to 70 minutes. The test includes the measurement of the height and weight of the subjects, heart rate, oxygen consumption, body weight loss (sweat evaporation), skin temperature, and core body temperature under hot environmental conditions. Subjective responses will also be recorded. WBGT was recorded after every ten minutes by heat stress meter and Bruel Kjaer.
48445307|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48445308|NCT02404701|DIETARY_SUPPLEMENT|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48445309|NCT02404701|DIETARY_SUPPLEMENT|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48445310|NCT02404701|DIETARY_SUPPLEMENT|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48277999|NCT05415410|DRUG|Apraglutide|Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.
48278000|NCT06066580|DRUG|Sevasemten|Sevasemten is administered orally once per day
48278001|NCT06109545|PROCEDURE|Laparoscopy|Patients included in this study will have diagnostic laparoscopy type WOLF done after checking all above ultrasound parameters of malignant tumor. This procedure will be done under general anathesia then a verses needle will be used at umbilicus or at palmer point if the mass is large or in cases of umbilical hernia or previous abdominal or pelvic surgery, then Fagotti criteria will be assessed
48278002|NCT01403298|BEHAVIORAL|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
48278003|NCT01403298|OTHER|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
48278004|NCT00867750|DEVICE|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
48278005|NCT00867750|DRUG|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
48278006|NCT00089557|DRUG|Capsaicin Dermal Patch|
48278007|NCT05312502|OTHER|Birth Ball|During labour, the pregnant woman was positioned using a birth ball.
48278008|NCT04240587|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|"The ITN delivers small electrical currents to the inner cavity of the nose, gently activating nerves that stimulate the body's natural tear production system. Those in the ITN active arm will receive the active tips which contain the current from the base to the nasociliary nerve. Those in the ITN sham arm will receive tips without the current."
48278009|NCT00876031|DRUG|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
48278010|NCT05013840|BEHAVIORAL|Filling in an online survey|Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
48278011|NCT03599661|OTHER|Interview|Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.
48278012|NCT03599661|OTHER|Questionnaire Administration|All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
48445311|NCT02404701|DIETARY_SUPPLEMENT|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48445312|NCT02404701|DIETARY_SUPPLEMENT|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48445313|NCT02404701|DIETARY_SUPPLEMENT|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48445314|NCT02404701|DIETARY_SUPPLEMENT|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
48445315|NCT00707408|DRUG|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
48445316|NCT00979303|DEVICE|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
48445317|NCT03500341|DEVICE|INVSENSOR00014|Noninvasive pulse oximeter sensor
48445318|NCT00804960|DRUG|Letrozole|1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
48445319|NCT00804960|DRUG|Std IVF Protocol|2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
48445320|NCT05385640|OTHER|NO intervention|NO intervention
48445321|NCT06536257|OTHER|Predictive model|Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.
48445322|NCT03405454|DRUG|durvalumab|Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression
48445323|NCT03405454|DRUG|standard chemotherapy|chemotherapy treatment will be administered as per local institutional guidelines
48445324|NCT04137575|BEHAVIORAL|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
48445325|NCT04137575|BEHAVIORAL|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
47928011|NCT03581890|OTHER|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~1. age- and sex-adjusted available income the year before surgery~2. Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~3. Urbanicity (in four officially, predefined categories)."
47928012|NCT04397770|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
47928013|NCT04397770|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
48445326|NCT04559503|OTHER|Progressive relaxation exercises|Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
48445327|NCT02354339|DIETARY_SUPPLEMENT|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
48445328|NCT02354339|OTHER|Placebo|Intervention will be administered 30 minutes before meals
48445329|NCT03832530|BEHAVIORAL|Safer conception counseling inclusive of periconception PrEP|Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 month. Maximum 19 month follow-up period (through pregnancy outcome).
48445330|NCT05270135|BEHAVIORAL|ASAP|ASAP is an intervention geared toward increasing non-stigmatized syringe sales to people who inject drugs to prevent bloodborne illnesses.
48445331|NCT02152163|DRUG|IV Ibuprofen|
47928014|NCT04397770|DRUG|Temozolomide Injection|Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
48445332|NCT02152163|DRUG|placebo|
48445333|NCT02284490|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
48445334|NCT04927091|OTHER|Integration of HIV and PWID services|Co-location of clinical services for HIV and PWID patients
48445335|NCT03448107|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
48445336|NCT03448107|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
48445337|NCT03448107|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
48445338|NCT06187363|PROCEDURE|Tubularized incised plate procedure|Tubularized incised plate urethroplasty procedure
48445339|NCT06187363|PROCEDURE|Other procedures|Other procedures than tubularized incised plate urethroplasty procedure
48445340|NCT04342650|DRUG|Chloroquine Diphosphate|150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
48445341|NCT04342650|DRUG|Placebo oral tablet|150mg placebo tablets
48445342|NCT00378547|DRUG|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
48445343|NCT00378547|DRUG|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
48098121|NCT02831114|OTHER|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
48098122|NCT05215652|OTHER|adherence monitoring package (AMoPac)|"AMoPac is a tool that consists of~* an electronic monitoring device,~* data management and data analysis,~* feedback on patient's performance,~* clinical-pharmaceutical evaluation of medication adherence,~* transmission of an adherence report."
48098123|NCT03201757|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
48098124|NCT04452955|BIOLOGICAL|PRL3-zumab|Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
48098125|NCT05468606|BIOLOGICAL|GA2|GA2 sporozoites administered by 50 mosquito bites
48445344|NCT00378547|DRUG|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
48445345|NCT01068821|OTHER|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
48445346|NCT01068821|OTHER|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
48445347|NCT02822235|OTHER|No Intervention|
48445348|NCT02503293|DEVICE|Chrono Super PID then Generic Syringe-Gammanorm|"Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
48445349|NCT02503293|DEVICE|Generic Syringe then Chrono Super PID-Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
48445350|NCT06466707|OTHER|Collection of microbiome samples|Collection of skin, oral and vaginal (if applicable) microbiome samples by means of a swab and collection of fecal material using Fecotainer collection kit.
48445351|NCT05594420|PROCEDURE|Mitral valve replacement|Mitral valve replacement through median sternotomy and minimally invasive approach
48445352|NCT00702091|DRUG|Ramipril|10 mg capsule
48445353|NCT04459585|DRUG|Dabigatran Etexilate Mesylate|Single oral 150 mg capsule dose
48445354|NCT04459585|DRUG|Quizartinib|Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
48445355|NCT06089239|OTHER|High Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
48445356|NCT06089239|OTHER|Low Intensity Coaching|External coaching is a commonly used strategy to change practice, especially for multi-site collaboratives where implementation requires customization to the site. Coaches serve as skill builders who train organizational personnel in quality improvement processes and develop proficiency in the targeted practice area (i.e., fall prevention).
48445357|NCT05514431|PROCEDURE|Epidural|Traditional epidural catheter placement
48445358|NCT05514431|PROCEDURE|Dural Puncture Epidural (DPE) technique|Epidural catheters placed via DPE technique
48098126|NCT05468606|BIOLOGICAL|BCG|0.1 mL BCG vaccine intradermally
48445359|NCT05514431|PROCEDURE|Combined Spinal-Epidural (CSE) technique|Epidural catheters placed via CSE technique
48445360|NCT06319625|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
48445361|NCT06319625|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48445362|NCT06319625|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48445363|NCT06319625|PROCEDURE|Placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48445364|NCT03090568|DRUG|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
48445365|NCT00440167|DRUG|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
48445366|NCT00440167|DRUG|Capecitabine|"Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)"
48445367|NCT00440167|DRUG|Erlotinib|Erlotinib 150 mg/d oral, daily without break
48445368|NCT04843995|PROCEDURE|Mid-urethral sling|Treatment of stress urinary incontinence with retropubic mid-urethral sling
48445369|NCT05901870|OTHER|Questionnaire administration|All study participants will be surveyed with the questionnaire, which includes such instruments as EQ-5D-3L and WG-SS, to assess their health-related quality of life, health-related behavior, and health care utilization indicators.
48445370|NCT05596279|DIAGNOSTIC_TEST|Intravascular ultrasound|Hybrid IVUS-OCT and control IVUS were performed after stenting
47928015|NCT04233918|DRUG|Evinacumab|Part A: Single IV dose Part B \& C: IV dose Q4W
47928016|NCT02815280|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
48098127|NCT05468606|BIOLOGICAL|YF-17D (fractional ID dose)|0.1 mL YF17D vaccine intradermally
48098128|NCT05468606|DRUG|Imiquimod|250mg imiquimod 5% cream topical
47928017|NCT02815280|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
48098129|NCT05468606|OTHER|Mock immunization|50 bites by uninfected mosquitoes
48098130|NCT00227981|BEHAVIORAL|Interpersonal Psychotherapy|
48098131|NCT00227981|DRUG|Fluoxetine|
48445371|NCT05596279|DIAGNOSTIC_TEST|Optical coherence tomography|Hybrid IVUS-OCT and control OCT were performed after stenting
48445372|NCT02812121|DRUG|umbilical cord blood mesenchymal stem cells|
48445373|NCT00834756|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
48445374|NCT00834756|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
48445375|NCT04158245|DRUG|18F-fluciclovine PET Scan|The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
48278013|NCT02315521|PROCEDURE|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
48445376|NCT02649621|BIOLOGICAL|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
48445377|NCT05271786|OTHER|Decannulation|retrospective evaluation of decannulation
48445378|NCT02009462|DRUG|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
48445379|NCT05333809|DRUG|Pembrolizumab|an anti-PD-1 monoclonal antibody
48278014|NCT05106361|BEHAVIORAL|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
48278015|NCT05106361|BEHAVIORAL|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
48445380|NCT05333809|DRUG|Disitamab vedotin|HER2-ADC
48445381|NCT03590808|BIOLOGICAL|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
48445382|NCT00697476|DRUG|topotecan, vorinostat|"Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal."
48445383|NCT04350359|DEVICE|Variable-dose TTNS Protocol 5 x week|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
48445384|NCT04350359|DEVICE|Fixed-dose TTNS Protocol|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
48278016|NCT03677570|DIAGNOSTIC_TEST|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
48445385|NCT04350359|DEVICE|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
48445386|NCT05631587|BEHAVIORAL|WExercise|A 10-weekly technology-based intervention delivered in a mobile application using the M-PAC framework to promote PA in post-treatment cancer survivors. Participants will be given individualised access to the app. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.
48445387|NCT05631587|BEHAVIORAL|Control|A control group receiving an information sheet for self-directed exercise.
48445388|NCT03979508|DRUG|Abemaciclib|Given PO
48445389|NCT03979508|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgical resection
48445390|NCT04935164|OTHER|Psychiatric evaluations|At different time points, several psychiatric evaluations will be performed on patients and volunteers for study purposes
48445391|NCT05604430|DEVICE|731 Series Ventilator|FDA cleared ventilator indicated for use in the management of acute or chronic respiratory failure or during resuscitation.
48445392|NCT03593512|PROCEDURE|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
48445393|NCT05748535|DEVICE|Auricular Vagus Nerve Stimulation|First of all, the application will be explained to the participants and a signed consent form for the application will be obtained from the individuals. Groups; It will be in the form of Right Ear Stimulation, Left Ear Stimulation and Bilateral Ear Stimulation group. Non-invasive auricular vagus nerve stimulation will be applied to all participants with a VAGUSTIM device, biphasic, frequency 10 Hz, pulse width 300 μs in Modulation mode, and current intensity for 20 minutes for 10 sessions, keeping the current constant at the point where the participant feels the current comfortably. Before and after each application, pulse variability (rmssd, LF/HF, pNN50, LF, HF) and blood pressure measurements will be taken from both the right index finger and left index finger. Before the first session and after the 10th session, pain level will be evaluated with the Numerical Pain Rating Scale, and disability level related to headache will be evaluated with the Headache Impact Test.
48278017|NCT03536897|RADIATION|IORT|Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
48278018|NCT05402384|DRUG|AVTX-801|"Medical grade D-galactose~dosage:2.0 g/kg/day"
48445394|NCT06471556|DRUG|IV Methylprednisolone pulses|Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /
48445395|NCT00840411|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
48445396|NCT00840411|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
48445397|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 60mg (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose 60mg (based on Part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
48445398|NCT02253420|DRUG|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
48445399|NCT02253420|DRUG|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
48445400|NCT02253420|DRUG|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
48445401|NCT03218137|DRUG|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
48445402|NCT06352138|BIOLOGICAL|Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.|comparison vs the reference product to demonstrate biological similarity
48445403|NCT06352138|BIOLOGICAL|Active comparator: European Union licenced epoetin alfa|comparison vs. the test product to demonstrate biological similarity
48445404|NCT03309774|DIAGNOSTIC_TEST|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~* Questionnaire KIDSCREEN 52~* Visual Analogue Scale (EVA)~* Neuropathic Pain 4 (DN4)~* Pain of the child Gustave Roussy (DEGR)"
48445405|NCT03309774|DIAGNOSTIC_TEST|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
48445406|NCT03309774|DIAGNOSTIC_TEST|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
48445407|NCT03309774|OTHER|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale."
48445408|NCT00741858|PROCEDURE|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
48445409|NCT00741858|PROCEDURE|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
48445410|NCT04484883|OTHER|Observational|Observational
48445411|NCT03614845|PROCEDURE|VCV|after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
48445412|NCT03614845|PROCEDURE|PCV-VG|after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
48278019|NCT05402384|DRUG|Placebo|Matching placebo
48278020|NCT00345891|BEHAVIORAL|Coping-focused counseling telephone calls|
48278021|NCT01708226|BEHAVIORAL|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
48278022|NCT05201781|DRUG|Cilta-cel|Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
48278023|NCT02913989|OTHER|Smoking habits characterization|
48445413|NCT03614845|DIAGNOSTIC_TEST|lung ultrasonography|all patients will be performed lung ultrasonography pre and postoperatively
48445414|NCT00678639|OTHER|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
48445415|NCT02729714|DRUG|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
48445416|NCT02729714|DRUG|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
48445417|NCT05275998|DRUG|TMB-365/TMB-380|Monoclonal antibodies to be given intravenously
48445418|NCT04514939|OTHER|Elevation of the legs during bed rest|Patients of Group A will will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees)
48445419|NCT02526121|PROCEDURE|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
48445420|NCT02526121|BEHAVIORAL|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
48445421|NCT01652092|DRUG|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
48445422|NCT01652092|DRUG|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
48445423|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
48278024|NCT04776850|DRUG|Bortezomib|Given IV
48278025|NCT04776850|DRUG|Busulfan|Given IV
48278026|NCT04776850|DRUG|Cyclophosphamide|Given IV
48278027|NCT04776850|DRUG|Dexamethasone|Given IV
48278028|NCT04776850|DRUG|Fludarabine Phosphate|Given IV
48278029|NCT04776850|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
48278030|NCT04776850|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
48278031|NCT04776850|DRUG|Mycophenolate Mofetil|Given IV or PO
48445424|NCT01652092|BIOLOGICAL|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg."
48445425|NCT01652092|DRUG|Fludarabine phosphate 40 mg|40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)
48445426|NCT01652092|DRUG|Melphalan|140 mg/m\^2 IV on day -3
48445427|NCT01652092|DRUG|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
48445428|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
48445429|NCT01652092|DRUG|Fludarabine phosphate 30 mg|fludarabine 30 mg/m\^2 IV on days -8 through -4
48278032|NCT04776850|PROCEDURE|Plasmapheresis|Undergo plasmapheresis
48278033|NCT04776850|BIOLOGICAL|Rituximab|Given IV
48278034|NCT04776850|DRUG|Tacrolimus|Given IV or PO
48278036|NCT01891643|DRUG|Lenalidomide|
48278037|NCT01891643|DRUG|Dexamethasone|
48278038|NCT01891643|BIOLOGICAL|Elotuzumab|
48278039|NCT00584974|DRUG|SEP-225289|0.5 mg SEP-225289
48278040|NCT00584974|DRUG|SEP-225289|2.0 mg SEP-225289
48278041|NCT00584974|DRUG|Venlafaxine|150 mg Venlafaxine
48278042|NCT00584974|DRUG|placebo|Placebo
48278043|NCT02693223|OTHER|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
48278044|NCT06372717|DRUG|APL-4098|APL-4098 is administered orally in 28-day cycles
48445430|NCT01652092|DRUG|MESNA|administered as per the standard institutional protocol.
48445431|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
48278045|NCT06372717|DRUG|Azacitidine and APL-4098|Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.
48445432|NCT00698256|DIETARY_SUPPLEMENT|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
48445433|NCT06562777|OTHER|Non-Interventional Study|Non-Interventional Study
47928018|NCT04548843|PROCEDURE|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
48278046|NCT01046812|DRUG|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
48278047|NCT00312520|DRUG|prednisolone|
48278048|NCT00312520|DRUG|methylprednisolone|
48278049|NCT02673281|OTHER|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
48278050|NCT02673281|OTHER|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
48278051|NCT02740309|BEHAVIORAL|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
48278052|NCT02740309|BEHAVIORAL|Treatment as usual|Facilitated community referral for mental health treatment
48445434|NCT00593463|DRUG|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
48445435|NCT00593463|DRUG|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
48445436|NCT00593463|DRUG|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
48445437|NCT00593463|DRUG|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
48445438|NCT00593463|DRUG|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
48445439|NCT00593463|DRUG|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
48445440|NCT00593463|DRUG|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
48445441|NCT00593463|DEVICE|Saline|Saline: I.M. injection may possibly be given
48445442|NCT00593463|DRUG|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
48445443|NCT00797160|DRUG|propofol|2mg/Kg IV in bolus before tracheal intubation
48445444|NCT00219154|DRUG|aliskiren|
48445445|NCT04876157|DIAGNOSTIC_TEST|Artificial intelligence-aimed point-of-care ultrasound image interpretation system|improve the sensitivity and specificity of the AI-aimed ultrasound interpretation system
48278053|NCT05888831|DRUG|BMS-986449|Specified dose on specified days
48278054|NCT05888831|DRUG|Nivolumab|Specified dose on specified days
48278055|NCT04724525|OTHER|soft contact lens Toric|soft contact lens toric with different axis and power that use in human's eye
48278056|NCT02122627|DRUG|Vitamin D|Colecalciferol 16.800 IU per week
48278057|NCT02122627|DRUG|Placebo|
48278058|NCT02201758|DIETARY_SUPPLEMENT|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
48278059|NCT02201758|OTHER|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
48445446|NCT02997150|DRUG|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
48445447|NCT06561035|DRUG|Opiate Sparing|Subjects will receive medications in the Opiate Sparing arm for pain control.
48445448|NCT06561035|DRUG|Opiate Based|Subjects will receive medications in the Opiate Based arm for pain control.
48445449|NCT01114048|DRUG|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"1. Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1\~28 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D 1\~4, 15-18 Repeated every 28 days~2. Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~   * Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
48445450|NCT05865769|OTHER|Balance|measuring pulmonary and vestibular functions in all subjects
48445451|NCT04543682|DRUG|0.125 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours
48445452|NCT04543682|DRUG|0.25 ng/kg/min Iloprost|Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours
48445453|NCT04543682|PROCEDURE|open reduction and internal fixation with an angular stable plate (PHILOS)|open reduction and internal fixation with an angular stable plate (PHILOS)
48445454|NCT00077077|DRUG|DJ-927|
48445455|NCT00077077|DRUG|capecitabine|
48445456|NCT06554717|DRUG|Tesamorelin|Tesamorelin SV 1.4 mg given subcutaneously daily
48445457|NCT06554717|DRUG|Placebo|Identical placebo injection given subcutaneously daily
48445458|NCT06554717|BEHAVIORAL|Exercise|Home-based semi-supervised exercise program
48445459|NCT05667649|BIOLOGICAL|RB-ADSC|Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
48445460|NCT02241863|BEHAVIORAL|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
48445461|NCT02241863|BEHAVIORAL|Routine counseling|
48445462|NCT01395563|BEHAVIORAL|strength training|strength training, high intensity, twice up to 3 times per week
48445463|NCT02056691|PROCEDURE|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
48445464|NCT02056691|PROCEDURE|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
48445465|NCT01297179|DRUG|Mirabegron|Oral
48445466|NCT01297179|DRUG|Minidril|Oral
48445467|NCT01297179|DRUG|Placebo|Oral
48445468|NCT01137539|DEVICE|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
48445469|NCT02975765|PROCEDURE|Piezosurgery|The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
48445470|NCT06561750|OTHER|Rooibos tea|Participants will be subjected to 12 g of rooibos tea per 1200 ml of freshly boiled water
48445471|NCT06561750|OTHER|Control|Participants will be subjected to 12 g per 1200 ml of freshly boiled water which is equivalent to 6 cups of tea
48445472|NCT01364532|PROCEDURE|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
48445473|NCT01364532|PROCEDURE|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
48445474|NCT01686451|DRUG|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
48445475|NCT01686451|DRUG|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
48445476|NCT05570487|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
48445477|NCT01415232|DEVICE|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
48445478|NCT04421508|COMBINATION_PRODUCT|INOpulse|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
48445479|NCT04421508|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.
48445480|NCT02603003|DRUG|JinFuKang|po.tid.30ml
48445481|NCT02603003|DRUG|Cisplatin|According to the individual patient's condition
48445482|NCT02603003|DRUG|Pemetrexed|According to the individual patient's condition
48445483|NCT03217539|DIAGNOSTIC_TEST|Imaging|
48445484|NCT02622737|OTHER|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
48445485|NCT02622737|DEVICE|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
48445486|NCT02622737|DEVICE|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
48445487|NCT04757792|OTHER|File inquiry|Data extraction out of file registry
48445488|NCT02131363|DEVICE|Ingrowing Toenail Treatment Kit|detailed in arm description
48445489|NCT03596294|DRUG|Clazosentan|Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
48445490|NCT03596294|DRUG|Rifampicin|Single i.v. dose of 600 mg rifampicin for 30 min
48445491|NCT03596294|OTHER|Saline (0.9% sodium chloride)|Single i.v infusion of 500 mL saline for 30 min
48445492|NCT03588923|DRUG|SH229|tablet, oral, 400 mg once daily for 3 days
48445493|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
48445494|NCT03588923|DRUG|SH229|tablet, oral, 600 mg once daily for 3 days
48445495|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
48445496|NCT03588923|DRUG|SH229|tablet, oral, 800 mg once daily for 3 days
48620379|NCT03021915|OTHER|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
48620380|NCT02935387|OTHER|Taper|Taper
48278060|NCT05091138|DRUG|Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
48278061|NCT05091138|DRUG|Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
48278062|NCT05198648|OTHER|Trigeminal cardiac reflex|Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
48278063|NCT05198648|OTHER|Non-trigeminal cardiac reflex|No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
48278064|NCT01276886|DRUG|antibiotic|
48278065|NCT01276886|PROCEDURE|Colonic resection with or without stoma|
48278066|NCT02013219|DRUG|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
48278067|NCT02013219|DRUG|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
48278068|NCT02013219|DRUG|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
48278069|NCT04439890|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
48278070|NCT04439890|DRUG|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
48278071|NCT04439890|DRUG|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
48278072|NCT04439890|DRUG|Placebo|Placebo
48278073|NCT01523080|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
48278074|NCT05134909|DEVICE|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
48445497|NCT03588923|DRUG|Placebos|tablet, oral, once daily for 3 days
48445498|NCT04908852|OTHER|Blood Sample Collection - Observational Study|Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.
48445499|NCT04908852|OTHER|Symptom questionnaires - Observational Study|Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
48445500|NCT04866524|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
48278075|NCT00021983|BIOLOGICAL|BL22 immunotoxin|
48278076|NCT03592459|DEVICE|Macy Catheter|Undergo placement of Macy catheter
48278077|NCT03592459|PROCEDURE|Pain Therapy|Receive opioids via Macy catheter
48278078|NCT03592459|OTHER|Questionnaire Administration|Ancillary studies
48278079|NCT03592459|OTHER|Survey Administration|Ancillary studies
48445501|NCT04866524|OTHER|Physical development and General Health|Physical development and General health examination
48445502|NCT04866524|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
48620381|NCT04841889|DIAGNOSTIC_TEST|Associated factors with decannulation|All factors potentially associated with successful tracheostomy removal will be prospectively collected: severity factors related to the ICU stay, ventilatory factors, respiratory and extra-respiratory factors. Lung and diaphragm ultrasound, swallowing, muscles and functional assessment will be performed.
48098132|NCT06134505|PROCEDURE|Use of Barrier cream group 1 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that Barrier cream 1 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
48098133|NCT06134505|PROCEDURE|Use of Barrier cream 2 in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that barrier cream 2 would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
48098134|NCT06134505|PROCEDURE|Use of olive oil in the healing of diaper dermatitis|"In this study, the infant's first-degree diaper dermatitis was determined by the doctor or midwife using the Uncomplicated Diaper Dermatitis Severity Rating Scale in Infants. After first-degree diaper dermatitis was detected in the babies and their written consent was obtained, the parents of the babies were informed about the research before application and the parent-baby identification information form was filled out. Families were provided with education based on the ABCDE model. Mothers were informed that olive oil would be used at each diaper change. Baby dermatitis was monitored face to face by the researcher on the 1st, 3rd and 5th days, and the scores were recorded on the observation form. Follow-up of those with a diaper dermatitis score of 0 was discontinued because full recovery was achieved."
48278080|NCT06327152|DRUG|Caffeine|"Infants randomized to receive caffeine will continue to receive caffeine at the current weight-based dose (which is the standard of care maintenance dose of 10-15 mg/kg/day) given every 24 hours. The weight-based dose calculated using the weight at the time of enrollment will be the weight-based dose used for the duration of the study. The dose will be weight adjusted every 7 days, starting on the day of enrollment. Caffeine will be given enterally, via nasogastric tube or by mouth.~The study drug (caffeine) will be administered for a maximum of 4 weeks. The study drug will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The study drug will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
48278081|NCT06327152|OTHER|Sterile Water Placebo|"Infants randomized to the placebo group will be given sterile water at an equivalent volume to the volume if caffeine were to be given, using the previous weight-based caffeine dose. The placebo will be given every 24 hours. The dose/volume will be weight adjusted every 7 days, starting on the day of enrollment. The placebo will be given enterally, via nasogastric tube or by mouth.~The placebo will be administered for a maximum of 4 weeks. The placebo will be discontinued after 4 weeks or when the infant reaches Step 4 of our institution's oral feeding protocol (oral feeding 6 times per day), whichever comes first. The placebo will also be discontinued if the open-label maintenance caffeine is started by the clinical team based on clinical indications."
48278082|NCT02917590|OTHER|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
48278083|NCT02917590|OTHER|Single-task obstacle crossing training|Obstacle crossing training
48278084|NCT06352177|OTHER|Noom Weight Application|This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.
48278085|NCT03465033|OTHER|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
48278086|NCT04561505|PROCEDURE|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
48278087|NCT04561505|PROCEDURE|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
48278088|NCT03664726|BEHAVIORAL|Episodic Future Thinking|Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.
48278089|NCT03664726|BEHAVIORAL|Episodic Recent Thinking|Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.
48620382|NCT03881371|DRUG|Safinamide|At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
48445503|NCT06560853|OTHER|Comprehensive School Health Programme|"Combination intervention which consists of:~* Upgrading sanitation facilities and constructing a 'health room' in the school~* Health teacher training: 5-10 teachers per school are recruited and trained for two weeks to become School Health Workers (SHWs) by Healthy Learners~* The SHWs: (1) deliver education on health and good sanitation and hygiene (2) coordinate with local clinics to deliver preventive care (e.g. school deworming and vitamin A supplementation); (3) assess sick students in the health room with a tablet-based clinical decision support system (CDSS); (4) treat sick students in the health room for some conditions (malaria, diarrhoea, schistosomiasis, pneumonia, conjunctivitis) or (5) refer to the health facility for treatment; (6) monitor absence of learners~* Referral: learners referred by SHWs are given a referral form by the SHW, which contains information about symptoms and suggested diagnosis by the CDSS. The learners are prioritised in the local clinic."
48278090|NCT03664726|BEHAVIORAL|Scarcity Narrative|Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.
48278091|NCT03664726|BEHAVIORAL|Neutral Narrative|Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
48445504|NCT06560853|OTHER|Deworming and vitamin A supplementation delivery|Schools implement the government policy of distributing deworming drugs and vitamin A supplementation to learners twice a year. Additional support from Healthy Learners ensures reliable delivery.
48445505|NCT04277390|OTHER|clinical intervention for microbial analysis and MIR155 as biomarker|Subgingival plaque was collected with sterile curette and placental tissue sample(postpartum with surgical blade with the help of gynecologist. all the samples were subjected to RTPCR for analysis of microorganisms likeTannerella forsythia(Tf), Treponema denticola(Td), Porphyromonas gingivalis(Pg), Prevotella intermedia(Pi), Fusobacterium nucleatum(Fn). Herpes Simplex Virus(HSV), Ebstein Barr Virus(EBV), Human Cytomegalovirus(HCMV). and MIR155 levels were also estimated
48445506|NCT04166734|DRUG|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
48445507|NCT04166734|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
48445508|NCT00640562|DRUG|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
48445509|NCT00640562|DRUG|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
48445510|NCT01854463|DRUG|Vitamin D3|2000IU per day
48445511|NCT01854463|DRUG|placebo|elemental calcium 200mg per day per 24 weeks
48445512|NCT01499186|OTHER|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
48445513|NCT04435847|BIOLOGICAL|HST 001|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of active treatment (HST 001).
48445514|NCT04435847|OTHER|Phosphate Buffered Saline|Participants will receive intradermal injections at 3 timepoints only: week 0, week 6 and week 12. At each of these 3 interventional visits they will receive 0.1 mL X 20 injections spaced approximately 0.8 - 1.2 cm apart from one another of placebo control (Phosphate Buffered Saline).
48445515|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
48445516|NCT00796653|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
48445517|NCT00796653|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
47928019|NCT04548843|PROCEDURE|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
47928020|NCT04548843|BIOLOGICAL|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
47928021|NCT00243607|OTHER|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
48278092|NCT03721068|BIOLOGICAL|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6
48278093|NCT03721068|DRUG|Cyclophosphamide|500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
48278094|NCT03721068|DRUG|Fludarabine|30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
48278095|NCT04673383|DRUG|SPL026|Intravenous solution
48278096|NCT04673383|DRUG|Placebo|SPL026-matched placebo
48278097|NCT00023322|DRUG|Peginterferon Alpha-2a|Treatment
48278098|NCT02119715|DRUG|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
48278099|NCT02119715|DRUG|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
48445518|NCT00796653|DRUG|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
48445519|NCT05644587|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
48445520|NCT02193971|DEVICE|BS-DES (Biostable polymer drug-eluting stent)|
48445521|NCT02193971|DEVICE|BD-DES (Biodegradable polymer drug-eluting stent)|
48445522|NCT02193971|DRUG|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
48445523|NCT01753375|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
48445524|NCT01753375|DIETARY_SUPPLEMENT|Placebo|Placebo to be given orally on weekly basis
48445525|NCT05922696|DRUG|Cholecalciferol|50.000IU weekly in Group A , or 200.000IU monthly in Group B
48445526|NCT00909610|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
47928022|NCT05551247|DRUG|Envafolimab|300mg,sc,d3,Q3W;
47928023|NCT05551247|DRUG|recombinant human endostatin (endostatin)|210mg,civ,d1-3,Q3W
47928024|NCT05433623|PROCEDURE|Surgery|It will be documented if the patient underwent surgery for their vascular issue
47928025|NCT04625296|BEHAVIORAL|Semi-directive interview|Semi-directive interview, lasting a maximum of 45 minutes
47928026|NCT04625296|BEHAVIORAL|Questionnaire : Preparedness for Caregiving Scale|Preparedness for Caregiving Scale - 8 questions
47928027|NCT03923803|DIAGNOSTIC_TEST|C- reactive protein|the measurement will be done by chemileumeniscence
47928028|NCT03923803|DIAGNOSTIC_TEST|Pro calcitonin|the measurement will be done by chemileumeniscence
48278100|NCT02119715|DRUG|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
48278101|NCT02436109|DEVICE|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
48278102|NCT05208229|DIAGNOSTIC_TEST|WB-MRI|Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
48278103|NCT03182764|OTHER|No intervention|No intervention
48278104|NCT03766425|DRUG|Aflibercept|subconjunctival injection
48278105|NCT03766425|DRUG|Mitomycin|subconjunctival injection
48278106|NCT06183008|DRUG|Intravenous immunoglobulin|Each patient will during the 30-week trial period get 3 IVIG courses (each total dose 2g/kg) for three consecutive days
48278107|NCT06183008|DRUG|Placebo|Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
48278108|NCT04114981|RADIATION|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
48278109|NCT04114981|RADIATION|Fractionated Stereotactic Radiosurgery|Undergo FSRS
48278110|NCT04114981|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
47928029|NCT00185653|PROCEDURE|Autologous followed by non-myeloablative allogeneic transplantation|
48098135|NCT03910478|DEVICE|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
48278111|NCT04114981|OTHER|Questionnaire Administration|Ancillary studies
48278112|NCT04398901|OTHER|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
48278113|NCT04963478|OTHER|exercise|exercise testing
48278114|NCT03566212|DEVICE|Conventional Syringe|local anesthesia was administered in first group using Conventional syringe
48278115|NCT03566212|DEVICE|Camouflage Syringe|local anesthesia was administered in second group using Camouflage syringe
48278116|NCT00948961|BIOLOGICAL|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
48278117|NCT00948961|BIOLOGICAL|CDX-1401|
48278118|NCT00948961|BIOLOGICAL|Resiquimod|
48278119|NCT00948961|BIOLOGICAL|poly-ICLC|
48278120|NCT02610985|DEVICE|3-D laparoscopy|3-D laparoscopy
48278121|NCT02610985|DEVICE|2-D laparoscopy|2-D laparoscopy
48278122|NCT05092607|DIAGNOSTIC_TEST|Venous and Capillary blood sampling|"Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers"
48445527|NCT00909610|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
47928030|NCT01849887|BIOLOGICAL|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
47928031|NCT01849887|DRUG|Placebo|Placebo
48098136|NCT03910478|OTHER|Standard Control Strategy|Standard of care with office-based testing.
48098137|NCT02095158|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
48098138|NCT01278693|DRUG|L-carnitine|500 mg,twice daily, 16 weeks
48098139|NCT01278693|DRUG|placebo|500 mg,twice daily, 16 weeks.
48445528|NCT04653363|OTHER|assessments|All assesments will be done by the first physiotherapist. But only 3m backward test will be done by the first and second physiotherapist in the first day and second day.
48445529|NCT03616730|DIAGNOSTIC_TEST|NICOM (non-invasive cardiac output monitor)|Transthoracic bio-reactance, or the non-invasive cardiac output measurement \[NICOMTM, Cheetah Medical Inc., Portland, OR\] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
48445530|NCT03726892|DEVICE|PCI|Coronary Intervention
48445531|NCT04289870|DEVICE|Trillium™|Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
48445532|NCT05332535|BEHAVIORAL|serious game based web application education|serious game based web application education for nursing students
48445533|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and bimanual serious games|Patients will undergo a bimanual 30-session robotic rehabilitation, using the robot ALEx RS with the bimanual configuration and the related serious games. Each session will last 45 minute. Daily sessions will be provided, five days a week.
48445534|NCT05176600|DEVICE|Robotic rehabilitation using the Arm Light Exoskeleton Rehab Station (ALEx RS) and unimanual serious games|Patients will undergo a unimanual 30-session robotic rehabilitation, using the robot ALEx RS with the unimanual configuration and the related serious games.Daily sessions will be provided, five days a week.
48445535|NCT05361330|DRUG|Shuganjieyu capsule|2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
48445536|NCT05361330|DRUG|Fluoxetine|Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
48445537|NCT00772239|DEVICE|Rotation thromboelastometry (ROTEM)|Coagulation measurement
48445538|NCT00772239|PROCEDURE|Standard coagulation managment procedure|Standard coagulation managment procedure
48445539|NCT02807545|BEHAVIORAL|Scoliosis Specific Exercises|
48445540|NCT06092450|OTHER|develop and validate a deep learning radiomics model based on preoperative enhanced CT image|develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC
48445541|NCT05672030|OTHER|Non-Interventional|No intervention.
48445542|NCT06185322|OTHER|Physical therapy program with upper cross syndrome specific exercises|Ten physical therapy sessions consisting of electrotherapy and upper cross syndrome -specific exercise program.
47928032|NCT05987488|BIOLOGICAL|ShigETEC live, attenuated, oral vaccine|"Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses."
48445543|NCT06185322|OTHER|Physical therapy program with conventional neck strengthening exercises|Ten physical therapy sessions consisting of electrotherapy and conventional neck strenthening exercises
48445544|NCT01942122|DRUG|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
48445545|NCT01942122|DRUG|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
48445546|NCT01942122|DRUG|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
48445547|NCT04383886|OTHER|stress and anxiety questionnaire|Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
48445548|NCT05287763|PROCEDURE|Palatal soft tissue graft harvesting|After local anaesthesia, a horizontal incision 2 mm apically from the gingival margin will be carried out using a #15C blade. The standardized rectangular graft with a thickness of 1.5 mm will be harvested from distal aspect of canine till first molar. The graft will be lifted and separated using tissue forceps and a blade till it is free from all sides.
48445549|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
48445550|NCT00777023|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
48445551|NCT00777023|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
48445552|NCT03411148|BEHAVIORAL|Weekly exercise sessions with physical therapist and psychologist|Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.
48445553|NCT03411148|BEHAVIORAL|Home-based exercises|Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
48445554|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
48445555|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
48445556|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|Serratus plane block realized with 20 ml of injectable solution of physiological saline
48445557|NCT03110120|DRUG|0.5% levobupivacaine injectable solution with physiological saline|local infiltration of the wound with 20 ml of injectable solution of physiological saline
48445558|NCT06561022|DRUG|Fluzoparib|Fluzoparib
48445559|NCT06561022|DRUG|Everolimus|Everolimus
47928033|NCT05987488|OTHER|Placebo|"Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart."
48445560|NCT06561022|DRUG|Fulvestrant|Fulvestrant
48445561|NCT06561022|DRUG|Abemaciclib|Abemaciclib
48445562|NCT00868413|DRUG|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
48445563|NCT00868413|DRUG|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
48445564|NCT00868413|DRUG|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
48445565|NCT06366048|DIAGNOSTIC_TEST|the different definitions of PHLF according to 50-50 criteria and ISGLS criteria|Our study respectively defined the PHLF according to the 50-50 criteria and the ISGLS criteria in literature review.
48445566|NCT02473718|OTHER|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
48445567|NCT02473718|DEVICE|Ultrasound|
48445568|NCT02329262|BEHAVIORAL|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
48445569|NCT02329262|BEHAVIORAL|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
48445570|NCT06385236|BIOLOGICAL|Dupilumab|"Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W).~Participants may self-administer injection after proper training."
48445571|NCT06385236|BIOLOGICAL|Benralizumab|"Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W).~Participants may self-administer injection after proper training."
48445572|NCT02837991|DRUG|CDX-014|
48445573|NCT01194791|DRUG|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
48445574|NCT01194791|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
48445575|NCT01194791|DRUG|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
48445576|NCT00614250|DRUG|AVE0657|capsules once a day at bedtime
48445577|NCT00614250|DRUG|placebo|capsules once a day at bedtime
48445578|NCT01577381|BIOLOGICAL|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
48445579|NCT01577381|BIOLOGICAL|Placebo|Intravenous, 11 doses, 30 minute infusion
48445580|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using modular dual mobility cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
48278123|NCT05595876|PROCEDURE|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
48278124|NCT05595876|PROCEDURE|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
48445581|NCT05181566|PROCEDURE|Total hip replacement arthroplasty using conventional acetabular cup|In a total hip replacement (also called total hip arthroplasty), the damaged bone and cartilage is removed and replaced with prosthetic components
48445582|NCT00711386|DRUG|GSK706769|50mg, 100mg, 200mg, or 400mg
48445583|NCT00711386|OTHER|Placebo|Placebo
48445584|NCT02605265|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
48445585|NCT02605265|DRUG|Capecitabine|
48445586|NCT02605265|DRUG|Irinotecan|
48445587|NCT02605265|DRUG|Oxaliplatin|
48445588|NCT05080894|DEVICE|Virtual reality|Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
48445589|NCT06558162|BEHAVIORAL|Mindfetalness|"They will be instructed to lie on their left side and focus on the fetal movements for 15 minutes every day while the foetus is awake. They will also be instructed to monitor the character, strength and frequency of fetal movements (not to count them) and to seek medical advice if they feel any change in this pattern.~After two weeks, the pregnant women will be invited back to the organisation for a follow-up interview to check whether they have performed the practice and recorded correctly. An interview will be conducted again after four weeks."
48445590|NCT06558162|BEHAVIORAL|Sadovsky|"They will be asked to continue this procedure every morning, noon or evening for one month (depending on the movements of the pregnant woman and her baby, the time will be left to the pregnant woman, but it should be at the same time every day). Since the aim of the study is to increase maternal awareness rather than to determine fetal well-being, mothers will be asked to count at least 10 movements based on the count to ten and Sadovsky method, and will be asked to record the start and completion time of the movements each time. A follow-up will be made after two weeks and a final follow-up will be made after one month"
48445591|NCT01674491|DIETARY_SUPPLEMENT|black soy peptide|black soy peptide: 4.5g/day for 8 weeks
48445592|NCT04553133|DRUG|PF-07104091 monotherapy dose escalation|PF-07104091 will be administered orally
48445593|NCT04553133|DRUG|PF-07104091 + palbociclib + fulvestrant|PF-07104091 will be administered orally in combination with palbociclib and fulvestrant
48445594|NCT04553133|DRUG|PF-07104091 + palbociclib + letrozole|PF-07104091 will be administered orally in combination with palbociclib and letrozole
48445595|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 will be administered orally
48445596|NCT04553133|DRUG|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 will be administered orally
48445597|NCT04553133|DRUG|PF-07104091 + Fulvestrant (post CDK4/6)|PF-07104091 will be administered orally in combination with fulvestrant
48445598|NCT04553133|DRUG|PF-0704091 + Fulvestrant (post CDK4/6)|PF-07104091 + fulvestrant (post 4/6) dose expansion
48445599|NCT04028440|BIOLOGICAL|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
48445600|NCT05664919|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
48445601|NCT02523963|OTHER|family work shop|"1. The family work shop has 5 courses, with 6 families in one course.~2. One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
48445602|NCT00652288|DRUG|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
48445603|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given separately
48445604|NCT00652288|DRUG|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
48445605|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given separately
48445606|NCT00652288|DRUG|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
48445607|NCT06321835|PROCEDURE|Endotracheal tube cuff pressure measurement|This is a prospective study conducted on 200 patients undergoing urological procedures in supine, prone, lateral flank and litotomy positions. After intubation (T0), the cuff pressure was checked with a cuff manometer and adjusted at 25 cmH2O as the baseline and continuously monitored. The cuff pressure was checked again before (T1) and after achieving the final position (T2) and then at 5 (T3), 10 (T4), 15 (T5), 30, 45, 60, 90, 120, 150, 180 minutes after the position, at the end of the procedure (T6) and before extubation (T7). At postoperative 2nd and 12th hours, the patients were interviewed for sore throat, hoarseness and cough.
48445608|NCT03174847|PROCEDURE|Adrenalectomy|Adrenalectomy for unilateral adrenal hyperplasia / adenoma
48445609|NCT03174847|DRUG|Mineralocorticoid Receptor Antagonists|Medical treatment with MRA / amiloride
48445610|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
48445611|NCT00647686|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
48445612|NCT04798144|DEVICE|Distilled water irrigation kept at 2.5°C degree|The use of cold distilled water for final irrigation of root canal system during root canal treatment
48445613|NCT04798144|DEVICE|Distilled water irrigation kept at room temperature|The use of distilled water kept at room temperature for final irrigation of root canal system during root canal treatment
48445614|NCT04913285|DRUG|KIN-2787|KIN-2787 will be administered orally twice daily in 28-day cycles
48445615|NCT04913285|DRUG|KIN-2787 and binimetinib|KIN-2787 and binimetinib will be administered orally twice daily in 28-day cycles
48445616|NCT00875550|DRUG|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
48445617|NCT00875550|DRUG|Midazolam|Rescue medication for sedation according to UMSS scores
48445618|NCT00875550|DRUG|Fentanyl|Rescue medication for pain based on UMSS scores
48445619|NCT00875550|DRUG|Morphine|Rescue medication for pain based on UMSS scores.
48445620|NCT06151691|OTHER|Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test|"Blood samples of participants meet the inclusion/exclusion criteria will be collected.~Pancreatic ductal adenocarcinoma minimal residual disease detection test."
48445621|NCT02598089|BIOLOGICAL|Trivalent Seasonal Influenza Vaccine|
48445622|NCT02598089|OTHER|Placebo|0.5 mL of phosphate buffered saline
48445623|NCT01097577|DRUG|pregabalin|1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
48445624|NCT01097577|DRUG|Placebo|1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
48445625|NCT05468879|DRUG|Glimepiride|Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
48445626|NCT05468879|DRUG|Amaryl®|Amaryl®
48445627|NCT01067963|BEHAVIORAL|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
48445628|NCT01067963|BEHAVIORAL|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
48445629|NCT02124122|BIOLOGICAL|Lactobacillus reuteri|Probiotic
48445630|NCT02124122|BIOLOGICAL|Placebo|Placebo
48445631|NCT01344291|DRUG|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
48445632|NCT03733314|DRUG|E6011|E6011, infusion, intravenously.
48445633|NCT03733314|DRUG|Placebo|Placebo, infusion, intravenously.
48445634|NCT06562647|DRUG|SY001|PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages
48445635|NCT03580785|GENETIC|genetic analysis|saliva is collected for DNA extraction
48445636|NCT03580785|RADIATION|panoramic radiography|panoramic radiography
48445637|NCT03580785|RADIATION|teleradiography|teleradiography
48445638|NCT03580785|RADIATION|intraoral X-rays|intraoral X-rays
48445639|NCT03580785|RADIATION|CT scan of maxillary and mandible|CT scan of maxillary and mandible
48445640|NCT01400087|DEVICE|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
48445641|NCT00633451|OTHER|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
48445642|NCT00633451|OTHER|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
48445643|NCT00118235|DRUG|cisplatin|Given IV
48445644|NCT00118235|DRUG|irinotecan hydrochloride|Given IV
48445645|NCT00118235|BIOLOGICAL|bevacizumab|Given IV
48445646|NCT00118235|OTHER|laboratory biomarker analysis|Correlative studies
48445647|NCT00979043|BEHAVIORAL|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
48445648|NCT00979043|BEHAVIORAL|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
48445649|NCT03265522|BEHAVIORAL|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
48445650|NCT03265522|BEHAVIORAL|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention)."
47928034|NCT06235255|BEHAVIORAL|Guided Imagery|The participant will complete the Guided Imagery Intervention for 21 consecutive days.
48278125|NCT02339467|OTHER|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
48445651|NCT03265522|BEHAVIORAL|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
48445652|NCT04991610|RADIATION|computed tomography|CT scans will be obtained from patients lying in a supine position using 120 kV tube voltage, 150 effective mA and 1 mm slice thickness parameters.
48445653|NCT03494894|DIAGNOSTIC_TEST|Middle meatus aspirations and sputum|Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
48445654|NCT01110122|DIETARY_SUPPLEMENT|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
48445655|NCT04383574|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (600SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
48445656|NCT04383574|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of high dosage (1200SU/0.5ml) experimental vaccine at the schedule of day 0,28,and one dose of booster immunization(the third dose) with medium dosage (1200SU/0.5ml) experimental vaccine 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.And the second booster dose (the fourth dose) 1 year after the second dose.
48445657|NCT04383574|BIOLOGICAL|Two doses of placebo at the schedule of day 0,28|The placebo was manufactured by Sinovac Research \& Development Co., Ltd., Two doses of placebo at the schedule of day 0,28,and one dose of booster immunization with placebo 1 year after primary immunization at the schedule of day 0,28 in phaseⅠand 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
48445658|NCT04383574|BIOLOGICAL|Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd..Two doses of low dosage (300SU/0.5ml)experimental vaccine at the schedule of day 0,28,and one dose of booster immunization with low dosage (300SU/0.5ml) experimental vaccine 6 months after primary immunization at the schedule of day 0,28 in phase Ⅱ.
48445659|NCT01904344|DEVICE|Sensor testing and validation|
48445660|NCT00252967|DRUG|Atorvastatin|80 mg of Atorvastatin
48445661|NCT00252967|DRUG|Placebo|
48445662|NCT03238781|DRUG|Placebo|Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
48098140|NCT06629012|PROCEDURE|Breast reconstruction with neurotization|Patients received breast reconstruction with neurotization procedure
48445663|NCT03238781|DRUG|AMG 301|AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
48445664|NCT00214097|RADIATION|Radiotherapy|Daily radiation to prescribed dose
48445665|NCT03072433|BEHAVIORAL|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
48445666|NCT03072433|BEHAVIORAL|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
48445667|NCT03181594|DEVICE|ClariFix Device|Cryoablation in the nasal passageway using the ClariFix Device
48445668|NCT03986801|OTHER|pharmaceutical interview|pharmaceutical interview at the end of hospitalization
48445669|NCT06262269|OTHER|Home-based adapted physical activity program supervised by an APA teacher via individual video conference.|Participants will follow a 12-week tele-rehabilitation programme involving high-intensity interval training (HIIT) adapted to their AIS. The programme includes three 45-minute individual sessions per week. The exercises are selected from a database designed for AIS patients. The APA teacher will systematically document the patient's presence or absence at each tele-rehabilitation session, thus assessing their adherence to the programme.
48445670|NCT06262269|OTHER|First period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet of specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
48445671|NCT06262269|OTHER|Second period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet containing specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
48445672|NCT05500703|DRUG|Dexmedetomidine Injectable Solution|continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
48445673|NCT05500703|DRUG|Sodium Chloride 0.9% Inj|the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
48445674|NCT06438224|OTHER|Extracorporeal shock wave therapy (ESWT)|Those in the ESWT group were asked to select the most hypertrophic and retracting scars for treatment. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals.
48445675|NCT06438224|OTHER|sham stimulation|the sham group was treated using an adapter that had the same shape but did not emit any energy
48445676|NCT03483194|DEVICE|Virtual Reality|Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
48445677|NCT03483194|DRUG|Kalinox|Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
48445678|NCT01551498|DIETARY_SUPPLEMENT|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
48445679|NCT01551498|DIETARY_SUPPLEMENT|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
48445680|NCT02005419|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48445681|NCT02005419|DRUG|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48445682|NCT02005419|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48445683|NCT02648074|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
48445684|NCT02648074|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
48445685|NCT03423485|DEVICE|CG-100 Intraluminal Bypass Device|Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
48445686|NCT06551090|OTHER|CAMERA (Context-Aware Multimodal Ecological Research and Assessment)|The CAMERA platform is a multimodal, hardware-software framework for measuring brain-behavior interactions in an unstructured environment and predict ecological states. CAMERA will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy. CAMERA consists of: Wristband sensors of autonomic physiologic signals, emphasizing heart rate metrics and electrodermal activity; Smartphone usage, emphasizing natural language processing of text input for linguistic features; Subject-tracking audiovisual array, emphasizing subject vocal activity; Intracranial neural recordings, emphasizing hippocampal theta power and high-frequency activity (\~70-200 Hz).
48445687|NCT04360447|DEVICE|Reformer Pilates|Reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks.
48445688|NCT04360447|OTHER|Home Exercise|A home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.
47928035|NCT06235255|BEHAVIORAL|Cognitive Power Intervention|The investigator with the subject uses the power profile generated by the PKPCT to generate goals that will positively affect functional health.
48098141|NCT06629012|PROCEDURE|Breast reconstruction without neurotization|Patients received breast reconstruction without neurotization
48445689|NCT02374385|BIOLOGICAL|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
48278126|NCT02339467|OTHER|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
48445690|NCT02374385|OTHER|Placebo|Normal saline
48445691|NCT01067833|DRUG|K201 Tablet|oral tablet, x28 days
48445692|NCT01067833|DRUG|Placebo Tablet|oral tablet, x28 days
48445693|NCT00247247|DRUG|Comtess®|
48445694|NCT02894593|OTHER|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
48445695|NCT02894593|OTHER|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
48445696|NCT02894593|OTHER|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
48445697|NCT02894593|OTHER|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
48445698|NCT03992118|BEHAVIORAL|Parent coaching|Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
48445699|NCT03796871|DEVICE|Dermapol|Use of the experimental medical device before lesion excision : skin lesion lighting (4 wavelengths) for less than 1 minute and image recording
48445700|NCT00047099|DRUG|cyclophosphamide|
48445701|NCT00047099|DRUG|docetaxel|
48445702|NCT00047099|DRUG|epirubicin hydrochloride|
48445703|NCT00047099|DRUG|fluorouracil|
48445704|NCT00047099|DRUG|goserelin acetate|
48445705|NCT00047099|DRUG|tamoxifen citrate|
48445706|NCT00047099|PROCEDURE|adjuvant therapy|
48445707|NCT00047099|RADIATION|radiation therapy|
48445708|NCT02736721|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
48445709|NCT01972386|DEVICE|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
48445710|NCT02069158|DRUG|PF-05212384|iv administrartion
48445711|NCT02069158|DRUG|Paclitaxel|iv administration
48445712|NCT02069158|DRUG|Carboplatin|iv administration
48445713|NCT02004535|PROCEDURE|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
48445714|NCT02803450|PROCEDURE|Epidural needle|Medication administration via epidural needle.
47928036|NCT06235255|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|This intervention is a combination of the Guided Imagery Intervention in tandem with the Cognitive Power Intervention
48445715|NCT02803450|PROCEDURE|Catheter Administration|Medication administration via epidural catheter.
48445716|NCT02803450|PROCEDURE|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
48445717|NCT05907733|DIAGNOSTIC_TEST|Genotyping.|5 ml biood withdrawen by venipuncture in EDTA tube DNA extraction will be done after centrifucation and used for quantatitive Real-time polymerase chain reaction.
48445718|NCT04123548|BIOLOGICAL|StrataGraft skin tissue|StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm\^2 of treatment area using no more than 20 tissues.
48445719|NCT05013463|DRUG|Hydroxychloroquine Pill|Oral Hydroxychloroquine, 200mg BID
48445720|NCT05013463|DRUG|Indapamide Pill|Oral Indapamide, 2.5 mg OD
48445721|NCT00952250|BEHAVIORAL|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
48445722|NCT00952250|BEHAVIORAL|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
48445723|NCT01278095|DRUG|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
48445724|NCT01278095|DRUG|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
48445725|NCT03708458|DRUG|indomethacin suppository|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
48445726|NCT03708458|DRUG|N-acetylcysteine (NAC)|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
48445727|NCT02618083|DEVICE|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
48445728|NCT01457300|OTHER|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
48620383|NCT03881371|OTHER|Placebo|At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
48445729|NCT03105453|OTHER|3 Sampling points|When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
48445730|NCT01535222|DRUG|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
48445731|NCT01535222|DRUG|Placebo|Commercially available NaCl
48445732|NCT06456580|BIOLOGICAL|Telitacicept|Subcutaneous injection
48445733|NCT06456580|DRUG|Placebo|Subcutaneous injection
48445734|NCT05422391|DIETARY_SUPPLEMENT|3 day caloric restriction/metabolic reset|Participants will consume \~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
48445735|NCT01677754|DRUG|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
48445736|NCT01677754|DRUG|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
48445737|NCT01677754|DRUG|Donepezil|Stable dose as background medication
48445738|NCT01677754|DRUG|Memantine|Stable dose as background medication in combination with AChEIs
48445739|NCT01677754|DRUG|Rivastigmine|Stable dose as background medication
48445740|NCT01677754|DRUG|Galantamine|Stable dose as background medication
48445741|NCT04492774|COMBINATION_PRODUCT|Goldic serum|epidural injections
48445742|NCT04492774|DRUG|Steroid injections|epidural injections
48445743|NCT04492774|PROCEDURE|Manual therapy|Veno-lymphatic drainage
48445744|NCT05539339|OTHER|Individualized intervention based on genomic alterations|Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
48445745|NCT05655845|OTHER|bowel function score(BFS) questionnaire survey|A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS\<17 ); and normal group (BFS\>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .
48445746|NCT03264352|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
48445747|NCT03264352|DRUG|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
48445748|NCT03264352|OTHER|Standard treatment by current guideline|No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
48445749|NCT04033276|DRUG|Rituximab|IV rituximab
48445750|NCT04033276|DRUG|intravenous immune globulin|iv intravenous immune globulin
48445751|NCT00819312|DRUG|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
48445752|NCT04945252|DIAGNOSTIC_TEST|Signpost caries|Identify carious lesion according to ICCMS visual criteria
48278127|NCT06621407|PROCEDURE|24 hours active subperiostal drainage|24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
48445753|NCT04212234|DEVICE|ultrasound propagation velocities, ultrasound fetal quality|"Obese pregnant women will be included before the second trimester fetal ultrasound examination.~Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.~In the control group, exam will be performed using the conventional ultrasound velocity.~An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.~The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.~All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al."
48445754|NCT06030583|OTHER|Scales and Forms|This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.
48445755|NCT05552482|OTHER|Identification of predictive factors|Evaluation of the following variables : age, sex, body mass index, Diabetes mellitus, vascular disease, hematologic disease, venous thromboembolic disease, antiplatelet or anticoagulant treatments, haemodialysis Catheter Insertion, number of comorbid conditions, Venous diameter, Arterial diameter, AVF type, AVF limb, Anasthesia group
48445756|NCT03399812|DIETARY_SUPPLEMENT|Animal protein|The animal protein intervention is a smoothie containing 40 grams of whey protein isolate.
48445757|NCT03399812|DIETARY_SUPPLEMENT|Plant protein|The animal protein intervention is a smoothie containing 40 grams of pea protein isolate.
48445758|NCT00433225|DRUG|Prednisolone Acetate|
48445759|NCT00433225|DRUG|Ketorolac 0.4%|
48445760|NCT00433225|DRUG|Gatifloxacin 0.3%|
48445761|NCT05494203|DIAGNOSTIC_TEST|questionnaire survey|All patients received lifestyle questionnaire, medical history, physical signs, auxiliary examination and laboratory examination results before treatment.
48445762|NCT02622386|DRUG|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
48445763|NCT02622386|OTHER|Placebo|Matching placebo capsule taken daily for 12 weeks.
48278128|NCT06621407|PROCEDURE|24 hours passive subdural drainage|24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
48445764|NCT01703975|OTHER|Training in pairs (Dyad training)|
48445765|NCT06102434|DRUG|Psilocybin|Five oral capsules containing 5 mg of psilocybin each
48445766|NCT00985894|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
48445767|NCT00985894|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
48445768|NCT00366925|DEVICE|Adacolumn®|
48445769|NCT03545828|DIAGNOSTIC_TEST|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
48445770|NCT05572684|DRUG|NC410|NC410 will be given intravenously (IV) every 2 weeks
48445771|NCT05572684|DRUG|pembrolizumab|Pembrolizumab 400mg will be given IV every 6 weeks.
48445772|NCT02111239|DEVICE|CTA|pelvic/abdominal CTA scan
48445773|NCT02111239|DEVICE|MRA|pelvic/abdominal MRA scan
48445774|NCT03154645|DRUG|Ibuprofen|non-steroidal anti-inflammatory drug
48445775|NCT03154645|DRUG|Acetazolamide|a diuretic
48445776|NCT01152827|DRUG|RAD001|"RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~* progression of disease~* the subject develops unacceptable toxicity~* consent to participate in the study is withdrawn"
48445777|NCT01960920|OTHER|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
48445778|NCT01960920|OTHER|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
48445779|NCT01960920|OTHER|Clean air|No pollution and no filter mask
48445780|NCT05099380|DEVICE|senofilcon A C3|TEST Lens
48445781|NCT05099380|DEVICE|senofilcon A|CONTROL Lens
48445782|NCT03974685|DRUG|99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)|Single dose
48445783|NCT05852392|OTHER|Adapted PARENT Model|PARENT is a team-based approach to care that utilizes a clinic-based community health worker as part of the WCC team to provide comprehensive and family-centered preventive care services.
48445784|NCT01013467|BEHAVIORAL|"CoCo colour coded blood pressure control"|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
48445785|NCT01093989|DIETARY_SUPPLEMENT|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
48278129|NCT06193473|BEHAVIORAL|Intervention Group: Group to which the clinical pharmacist makes recommendations|The drugs administered to patients within 24-48 hours after hospitalization were recorded. A detailed medication review will be conducted by the clinical pharmacist during the participants' hospitalization.As a result of a comprehensive evaluation, recommendations were made to doctors regarding drug-related problems and were recorded.
48445786|NCT02078791|DRUG|Botox infiltration|botox cervical infiltration in a group
48445787|NCT02078791|BEHAVIORAL|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
48445788|NCT02078791|OTHER|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
48445789|NCT03917147|PROCEDURE|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
48445790|NCT00315562|PROCEDURE|carotid endarterectomy|
48445791|NCT05914857|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin Tablets, Oral, 10mg, Once daily
48445792|NCT05914857|BEHAVIORAL|lifestyle interventions|Consisting of 30 minutes of moderate-intensity exercise every day and a reduction of 300 calories in the total diet
48445793|NCT02642653|DRUG|Lovastatin|Once per day dosing
48445794|NCT02642653|OTHER|Placebo|Once per day dosing
48445795|NCT02793245|OTHER|Questionnaire|Questionnaire on their main characteristics : age, gender, height, weight, smoking
48445796|NCT02793245|OTHER|Simplified pulmonary function test|
48445797|NCT04818892|DIAGNOSTIC_TEST|Serological Assay for SARS-CoV-2|LabCorp's Cov2Quant IgG™ assay which uses immunoassay that uses electrochemiluminescent technology (ECL) for quantitative determination of anti-receptor binding domain (RBD) IgG antibodies specific to SARS-CoV-2.
48445798|NCT05096663|DIETARY_SUPPLEMENT|Cobalamin|Given intramuscularly
48445799|NCT05096663|DRUG|Dexamethasone|Given orally (PO)
48445800|NCT05096663|DRUG|Docetaxel|Given IV
48278130|NCT00326092|DRUG|Brinzolamide/Timolol|
48278131|NCT04900402|OTHER|Survey|International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)
48445801|NCT05096663|DIETARY_SUPPLEMENT|Folic Acid|Given PO
48445802|NCT05096663|DRUG|Gemcitabine|Given IV
48278132|NCT05242887|DIAGNOSTIC_TEST|Delirium screening using 3D-CAM and UB-CAM|Patients will be evaluated with 3D-CAM and UB-CAM by a trained examiner (geriatrician, resident or neuropsychologist). On the same day, they will be given a reference diagnosis of delirium based on DSM-V criteria by another trained examiner, blind to the results of the UB-CAM and 3D-CAM.
48445803|NCT05096663|DRUG|Nogapendekin Alfa|Given SC
48445804|NCT05096663|BIOLOGICAL|Pembrolizumab|Given IV
48278133|NCT05503953|DRUG|AGSAVI|Uptitation
48278134|NCT05503953|DRUG|AGLS|Uptitration
48278135|NCT00638872|DRUG|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
48278136|NCT00638872|OTHER|0.9% NaCl|same as PDRN
48445805|NCT05096663|DRUG|Pemetrexed|Given IV
48445806|NCT05096663|BIOLOGICAL|Ramucirumab|Given IV
48445807|NCT06209320|DRUG|Lower dose atropine sulfate eye drops|administer to eyes
48445808|NCT06209320|DRUG|Low dose atropine sulfate eye drops|administer to eyes
48445809|NCT06209320|DRUG|placebo|administer to eyes
48445810|NCT00127946|PROCEDURE|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
48445811|NCT02882945|OTHER|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
48445812|NCT02882945|OTHER|Group B|200 cases of type 2 DM without complications were enrolled in the study.
48445813|NCT02882945|OTHER|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
48445814|NCT01414153|DRUG|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
48445815|NCT01414153|DRUG|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
48445816|NCT01414153|DRUG|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
48445817|NCT01414153|DRUG|sham injection|administered monthly for 4 months
48445818|NCT00988663|DRUG|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
48445819|NCT00988663|DRUG|Placebo|will give placebo that looks like memantine
48445820|NCT05122286|PROCEDURE|Bailout angioplasty|Use balloons or stents for bailout angioplasty
48445821|NCT05122286|PROCEDURE|Standard therapy|Stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters
48445822|NCT05591118|DRUG|Anticoagulant Therapy|All subjects will receive anticoagulation for a minimum of 3 months.
48445823|NCT05591118|DEVICE|Catheter-Directed Therapy|The endovascular physician can choose to use either mechanical thrombectomy (MT) using a device cleared by the FDA to treat PE or catheter-directed thrombolysis (CDL) using an infusion catheter cleared by the FDA to administer thrombolytic drugs for the treatment of PE
48445824|NCT02992366|PROCEDURE|implant placement|implant placement
48445825|NCT02435823|DEVICE|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
48445826|NCT05087745|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
47928037|NCT01584544|DRUG|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
47928038|NCT01584544|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
47928039|NCT01584544|DRUG|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
48278137|NCT02094599|DRUG|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
48278138|NCT02094599|DRUG|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
48278139|NCT02094599|DRUG|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
48278140|NCT04924426|PROCEDURE|TTC immersion|TTC immersion
47928040|NCT01584544|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
47928041|NCT01584544|DRUG|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
47928042|NCT03961477|OTHER|Interferential therapy|Exercise therapy
48098142|NCT00362843|DRUG|[15-O]water|
48098143|NCT00114803|DRUG|Calcitonin nasal spray (salmon)|
48098144|NCT05541237|DIETARY_SUPPLEMENT|Food|Food
48098145|NCT02375321|BEHAVIORAL|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
48278141|NCT02066064|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
48278142|NCT02066064|PROCEDURE|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
48278143|NCT03282747|BEHAVIORAL|no intervention|no intervention
48278144|NCT02209766|DRUG|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
48278145|NCT02209766|DRUG|Placebo|"1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
48278146|NCT06002152|DRUG|Bupivacaine|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
48278147|NCT06002152|DRUG|Placebo|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
48278148|NCT04630028|DRUG|Ustekinumab Dose Based on BSA and Body Weight|As per BSA and body weight Ustekinumab will be administered SC and IV.
48278149|NCT04630028|DRUG|Matching Placebo|Placebo will be administered subcutaneously.
48278150|NCT05047523|DRUG|ALXN1840|Administered as an oral tablet.
48278151|NCT05047523|DRUG|Standard of Care|Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
48278152|NCT01485978|DRUG|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
48278153|NCT01485978|DRUG|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
48445827|NCT03695692|BEHAVIORAL|pelvic floor exercise and connective tissue massage|Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
48445828|NCT03695692|BEHAVIORAL|pelvic floor exercise|The exercise program is performed every day for 6 weeks
48445829|NCT00836849|DRUG|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
48445830|NCT00836849|DRUG|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
48445831|NCT03057730|BIOLOGICAL|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
48445832|NCT05251155|DIAGNOSTIC_TEST|Distant best corrected visual acuity assessment|Measuring distant visual acuity on snellen's chart using two methods and results were converted to equivalent logarithm of minimum angle of resolution to compare accuracy of mobile based chart to the standard vision chart.
48445833|NCT02570477|PROCEDURE|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
48098146|NCT04883762|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Undergo FMT via colonoscopy.
48098147|NCT02327039|DRUG|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
48278154|NCT01485978|DRUG|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
48278155|NCT06234267|BEHAVIORAL|Eat, Play, Sleep|The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.
48278156|NCT05129449|DEVICE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.
48278157|NCT06334939|DEVICE|Bispectral Index Monitoring|"Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia."
48278158|NCT02479347|DRUG|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
48278159|NCT02479347|DRUG|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
48445834|NCT02570477|DRUG|Vancomycin|125mg Vancomycin four times per day
48445835|NCT01095315|OTHER|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
48445836|NCT00245063|DRUG|cediranib maleate|Given PO
48445837|NCT00245063|OTHER|laboratory biomarker analysis|Correlative studies
48445838|NCT00245063|OTHER|pharmacogenomic studies|Optional correlative studies
48445839|NCT01327391|PROCEDURE|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
48445840|NCT01327391|PROCEDURE|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
48445841|NCT00188539|PROCEDURE|Pre-treatment tumour oxygen measurements (under anesthesia)|
48445842|NCT04306783|OTHER|In-home sensor monitoring|-Installed and maintained by Foresite Healthcare
48445843|NCT03408665|RADIATION|SBRT|3 sessions at least, up to 6. Neither specifc device is imposed.
48445844|NCT00692939|BIOLOGICAL|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
48445845|NCT00692939|DRUG|Alemtuzumab|Transplant conditioning
48445846|NCT00692939|DRUG|ATG|Transplant conditioning
48445847|NCT00692939|DRUG|Melphalan|Transplant conditioning
48445848|NCT00692939|DRUG|Thiotepa|Transplant conditioning
48445849|NCT00692939|DRUG|Rituximab|Transplant conditioning
48445850|NCT00692939|DRUG|Cyclophosphamide|Mobilization
48445851|NCT00692939|DRUG|G-CSF|Mobilization
48445852|NCT00692939|DRUG|Mesna|Mobilization
48098148|NCT02327039|DRUG|Placebo|Tables of Dapagliflozin placebo
48098149|NCT06610344|DIETARY_SUPPLEMENT|R-1,3-Butanediol|R-1,3-Butanediol 35 mL
48278160|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
48278161|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
48278162|NCT02514044|DRUG|Dexedrine|10 mg immediate release of Dexedrine
48278163|NCT02514044|DEVICE|Active tDCS|1.5 mA tDCS anodal tDCS
48278164|NCT02514044|BEHAVIORAL|Speech Therapy|60 min of speech therapy
48278165|NCT02514044|DRUG|Placebo|
48278166|NCT02514044|DEVICE|Sham tDCS|
48278167|NCT00327938|DEVICE|Measuring of skin conductance|
48278168|NCT00327938|PROCEDURE|Tetanic stimuli|
48278169|NCT06653621|DRUG|Bupivacaine liposome|Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
48278170|NCT06653621|PROCEDURE|Nerve block mode : adductor block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.
48278171|NCT06653621|DRUG|Bupivacaine|Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
48278172|NCT06653621|PROCEDURE|Nerve block mode: femoral triangle block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
48278173|NCT02612870|DEVICE|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
48278174|NCT02612870|DEVICE|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
48445853|NCT02378935|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
48445854|NCT02378935|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
48445855|NCT02378935|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48445856|NCT03296722|BEHAVIORAL|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
48445857|NCT06033456|PROCEDURE|Radiofrequency stellate ganglion block using ultrasound guidance (SGB)|"Visualization of C6-C7 level will be targeted under fluoroscopic posterior-anterior (PA) guidance. Skin will be infiltrated with 1% lidocaine using a 25-gauge needle. Next, the RF needle will be inserted under a trajectory approach toward the target. Then, with ultrasound guidance, using a superficial linear ultrasound probe to guide further needle penetration so that the needle-tip will lie anterior to the longus colli muscle, the exclusion of vascular structures will be confirmed by duplex(8).~Then, 5 to 1 mL of omnipaque dye (iohexol) will be injected. Subsequently, a 100 mm length Baily RF electrode will be inserted and connected to the generator. The RF needle will be positioned alongside the stellate ganglion in the thermal RF technique. With repeated sensory and motor stimulation before RF lesioning"
48445858|NCT06033456|PROCEDURE|Radiofrequency thoracic (T2, T3) paravertebral block under fluoroscopic guidance (TPVB)|Radiofrequency sympathectomy will be performed with the patient in the prone position. Under fluoroscopic guidance, the T2, T3 vertebral bodies will be identified in an anteroposterior view. For radiofrequency sympathectomy, 10 cm curved, sharp radiofrequency insulated needle with an active tip of 10 mm, needle entry will be performed, and the final placement of the needle tip will be located at the posterior third of the vertebral body in lateral view and just lateral to the body in the anteroposterior view. Once the correct position is confirmed, 0.5 to 1 ml of Omnipaque will be injected, then a 10 cm electrode will be introduced through the RF needle. Before lesioning, a sensory and motor test stimulation is performed to verify the location.
48445859|NCT06033456|PROCEDURE|Combined radiofrequency of stellate ganglion block plus thoracic T2, T3 paravertebral block|Combination between radiofrequency of stellate ganglion block and thoracic T2, T3 paravertebral block.
48445860|NCT00276133|DRUG|Effects of atorvastatin versus probucol on small dense LDL|
48445861|NCT03187522|DEVICE|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
48445862|NCT06462066|PROCEDURE|Experimental medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Gluban Tiss® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
48278175|NCT02612870|DEVICE|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
48278176|NCT02612870|DEVICE|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
48278177|NCT02612870|DEVICE|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
48278178|NCT01246492|DIETARY_SUPPLEMENT|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
48278179|NCT00003688|BIOLOGICAL|dactinomycin|
48278180|NCT06377059|DEVICE|WARD|Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.
48278181|NCT06282692|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg|Dose : 1 dose 0.5 ml containing 5 µg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
48278182|NCT03173703|DEVICE|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
48278183|NCT03173703|PROCEDURE|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
48278184|NCT03173703|DEVICE|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
48278185|NCT03860506|DRUG|PSI-697|
48278186|NCT03860506|DRUG|Placebo|
48278187|NCT00805415|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
48278188|NCT00805415|DRUG|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
48278189|NCT06456177|DEVICE|Assessment of nociception in obstetric patients during epidural analgesia|Comparing nociception in obstetric patients during epidural analgesia, subjectively, by Visual analog scale and objectively by monitoring Nociception level Index
48278190|NCT05025943|OTHER|Diet intervention|The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.
48278191|NCT05025943|OTHER|Control group|The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
48445863|NCT06462066|PROCEDURE|Comparator medical device|Open the blister and pour the sterile single-dose bottle onto the operating table in a sterile field. Before opening the single-dose bottle verify the state of fluidity of the glue and its transparency. Open the single dose of Glubran® 2. Insert the transfer tip on the single dose, grabbing it near the neck to apply adequate pressure that allows the insertion of the tip. Gradually fill the cartridge by carefully pressing on the body of the single dose.
48445864|NCT06302114|OTHER|Assessment of overhead athletes|Assessment of medicine ball forward throw, Y balance test, Range of motion of the shoulder (internal and external rotation), strength of internal and external rotator muscles.
48445865|NCT00803153|PROCEDURE|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
48445866|NCT06066476|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
48445867|NCT03751345|BEHAVIORAL|Parenting Wisely|PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
48445868|NCT04325139|OTHER|Questionnaire|Before colonoscopy, the following information was obtained by the colonoscopists through asking patients: the characteristics of last stool, the time of drinking first dose of laxative, the time of first defecation, the time of drinking last dose of laxative. The beginning time of colonoscopy was also recorded. During withdrawal phase, the quality of bowel preparation was evaluated based on BBPS scale.
48278192|NCT06656325|DEVICE|Erchonia® FX405|"Procedure administrations with the Erchonia® FX-405 will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Erchonia FX405 takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Erchonia FX405, and a second time at the 3-month study midpoint assessment visit."
48278193|NCT06656325|DEVICE|Placebo Laser|"Procedure administration with the Placebo Laser (emitting non therapeutic light) will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Placebo Laser takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Placebo Laser, and a second time at the 3-month study midpoint assessment visit."
48278194|NCT04879329|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
47928043|NCT00245219|BEHAVIORAL|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
47928044|NCT00245219|BEHAVIORAL|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
47928045|NCT06173310|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
47928046|NCT06273371|OTHER|Damira 2000 Infant formula|100% extensive casein hydrolysate Infant formula
48278195|NCT04879329|DRUG|pembrolizumab|Given by IV on Day 1 of each 6-week cycle.
48278196|NCT03685448|DRUG|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
48278197|NCT04419103|OTHER|no intervention|Natural exposure of iodine.
48278198|NCT04007484|DEVICE|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
48278199|NCT03812809|DRUG|BPI-7711|BPI-7711: 180mg, QD, oral
48278200|NCT06638112|PROCEDURE|Brachial Plexus Block|Interscalene brachial plexus block with 0.75% ropivacaine. Intraoperative sedation with remimazolam.
48278201|NCT06638112|PROCEDURE|General Anesthesia (control group)|General anesthesia with propofol, fentanyl and rocuronium for induction, and with sevoflurane for maintenance. Brachial plexus block with 0.5% ropivacaine for intra- and postoperative analgesia.
48278202|NCT05552222|DRUG|Teclistamab|Teclistamab will be administered as SC injection.
48278203|NCT05552222|DRUG|Daratumumab|Daratumumab will be administered as SC injection.
48278204|NCT05552222|DRUG|Lenalidomide|Lenalidomide will be administered orally.
48445869|NCT05310591|DRUG|Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )|"Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks. It will include patients with MRD negative disease status.~1. Four decreasing starting times for beginning nivolumab (day 14, day 11, day 5 and day -1) will be available for testing~2. Patients will be enrolled sequentially by cohorts of 3 with escalation between cohorts based only on the limiting toxicities between infusion and D28~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
48445870|NCT05310591|DRUG|Nivolumab starting at day -1|"It will include relapsed patients. Patients included first receive a lympho-depleting chemotherapy by Fludarabine / Cyclophosphamide. tisagenlecleucel infusion should then be administered 2 to 14 days after completion of chemotherapy.~Nivolumab (Opdivo®) will be given intravenously at 3mg/kg every 2 weeks.~-nivolumab starting at day -1.~Nivolumab will be given until 12 months after tisagenlecleucel infusion in case of response."
48445871|NCT03018717|OTHER|Telemonitoring Constant|telemedicine of Constant
48445872|NCT03018717|OTHER|Standard clinical care|The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
48445873|NCT01931007|DRUG|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
48445874|NCT01931007|DRUG|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
48445875|NCT03004118|DIETARY_SUPPLEMENT|Nutridrink|Liquid meal of 200ml
48445876|NCT03004118|DEVICE|High resolution manometry probe|Catheter inserted via the nose into the stomach to measure intragastric pressure.
48445877|NCT03004118|DEVICE|perfusion catheter|Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
48445878|NCT03004118|DRUG|Placebo Oral Tablet|4 week oral intake (daily)
48445879|NCT03004118|DRUG|Ursochol oral tablet|4 week oral intake (daily) (dose of 10.5mg/kg/day)
48445880|NCT03004118|DEVICE|Duodenal fluid aspiration catheter|Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
48445881|NCT03004118|PROCEDURE|Duodenogastroscopy|Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
48445882|NCT03004118|PROCEDURE|Blood sample|Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
47928047|NCT06409793|BEHAVIORAL|mHealth|A 3-month structured exercise and PA intervention, supported by an exercise specialist, with a 3-month follow-up
48278205|NCT05552222|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously (IV).
48278206|NCT05552222|DRUG|Talquetamab|Talquetamab will be administered as SC injection.
48445883|NCT05836545|DRUG|Remimazolam|The patient with remimazolam
48445884|NCT05836545|DRUG|Midazolam|The patient with midazolam
48445885|NCT01673672|BIOLOGICAL|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
47928048|NCT04925154|BEHAVIORAL|The only intervention will be the information brochure that will be given after the first questionnaire.|The information brochure will be given to both groups at the same time at 2-3 weeks after the first consultation (patients group) or after answering the first questionnaire (physicians group).
47928049|NCT00303589|DRUG|Standard care|As prescribed
47928050|NCT00303589|DRUG|beta-lactam|750mg iv q8h
47928051|NCT00303589|DRUG|beta-lactam|1500mg iv q8h
47928052|NCT02447705|DRUG|telbivudine|telbivudine replace Lamivudine
48278207|NCT02228499|OTHER|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
48278208|NCT03926143|DRUG|BAY94-9343 (Anetumab ravtansine)|BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
47928053|NCT02104388|DRUG|SJP-0035 Ophthalmic Solution|
47928054|NCT02104388|DRUG|Vehicle of SJP-0035 Ophthalmic Solution|
47928055|NCT00626470|PROCEDURE|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
47928056|NCT05653531|OTHER|Blood sample|Liver blood tests (AST, ALT, PAL, GGT, bilirubin, PT) will be performed before each ICI injection during the first three injections and again at 6 months.
48278209|NCT04407169|OTHER|no intervention|There will be no intervention. It is only an observationnal study
48278210|NCT00083538|DRUG|Dexamethasone|
48278211|NCT00083538|DRUG|Thalidomide|
48278212|NCT00083538|DRUG|Cisplatinum|
48278213|NCT00083538|DRUG|Adriamycin|
48278214|NCT00083538|DRUG|Cyclophosphamide|
48278215|NCT00083538|DRUG|Etoposide|
48278216|NCT01715844|DIETARY_SUPPLEMENT|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
48278217|NCT02443402|DRUG|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
48445886|NCT01673672|BIOLOGICAL|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
48445887|NCT01804985|DRUG|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
48445888|NCT01804985|DRUG|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
48445889|NCT01804985|DRUG|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
48445890|NCT00927069|DRUG|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
48445891|NCT00927069|DRUG|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
48445892|NCT00905528|DRUG|Telmisartan 80 mg/d|
48445893|NCT00905528|DRUG|Ramipril 10 mg/d|
48445894|NCT01913405|BIOLOGICAL|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
48445895|NCT00301691|BEHAVIORAL|behavioral dietary intervention|
48445896|NCT00301691|OTHER|educational intervention|
48445897|NCT00301691|OTHER|preventative dietary intervention|
48445898|NCT05962463|PROCEDURE|Canal adductor blockade|The same experienced anesthesiologist has performed all blocks. Always after surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade. After the blockade, all participants were monitored in our ambulance for the next hour.
48445899|NCT05962463|PROCEDURE|Canal adductor pulsed radio-frequency therapy|The same experienced anesthesiologist has performed all PRF therapy After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. We've previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42ºC. After the treatment, all participants were monitored in our ambulance for the next hour.
48445900|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
48445901|NCT01142635|DRUG|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
48445902|NCT00313794|DRUG|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
48445903|NCT05331508|BEHAVIORAL|gender-based violence screening, first-line support (LIVES) and reproductive coercion empowerment counseling (ARCHES)|Providers will (1) introduce routine client screening for GBV, including intimate partner violence, sexual violence, and reproductive coercion using a standardized screening form, in FP and ANC services,(2) for individuals disclosing GBV, provide first-line response-empathetic counseling, including listening, inquiring about experiences sensitively, and validating experiences, helping clients develop safety plans, and providing support; (3) regardless of disclosure of GBV, provide counseling and information, education and communication (IEC) materials on IPV, including reproductive coercion, and FP options, to both FP and ANC clients.
48445904|NCT03545451|DEVICE|Videogames|Videogames
48278218|NCT02443402|DRUG|Placebo|One pill daily until discharge
48278219|NCT02443402|DRUG|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
48278220|NCT02443402|DRUG|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate \>2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is \> 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine"
48445905|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group While Lying Prone|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
48445906|NCT05623735|OTHER|Instrument Assisted Soft Tissue Mobilization Group Combined with Functional Movement|"1. Sliding movements in all directions at 30 - 60 degree angles will be made in the form of mobilizations of 45 seconds with instruments.~2. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~3. Starting with an angle of 60 degrees on the area to be treated, the movement of shifting towards an angle of 30 degrees will be made in all directions for 30 seconds.~4. The tissue will be mobilized for 30 consecutive seconds, starting from just caudal to your waist and drawing the letter J towards the cranial.~5. Sliding movements in all directions at 30 - 60 degree angles will be made with instruments in the form of mobilizations for 45 seconds.~6. Mobilizations of 45 seconds will be made with instruments along the quarter circle line in all directions at 30 - 60 degree angles.~7. 30 - 60 degree swipe movement shorter brushing style small movements will be done for 30 seconds."
48278221|NCT02443402|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
48445907|NCT05538416|PROCEDURE|Posterior Lumbar Interbody Fusion (PLIF)|Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.
48445908|NCT02186821|DRUG|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
48445909|NCT01526694|DRUG|Bendamustine|Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
48445910|NCT01526694|DRUG|Thalidomide|Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
48445911|NCT01526694|DRUG|Dexamethasone|It's a corticosteroid.
48445912|NCT04776798|OTHER|Taping|Tape applications will repeat twice per week, for 4 weeks.
48445913|NCT03803774|DRUG|Birinapant|Given IV
48445914|NCT03803774|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRRT
48445915|NCT03803774|PROCEDURE|Tumor Biopsy|Baseline and cycle 1 day 4 at week 1.
48445916|NCT03803774|DIAGNOSTIC_TEST|PET Scan|Within 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.
48445917|NCT03803774|DIAGNOSTIC_TEST|CT Scan|CT scan of the neck, chest, and upper abdomen with contrast at 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.
48445918|NCT03803774|DIAGNOSTIC_TEST|MRI Scan|MRI scan of the neck, chest, and upper abdomen with contrast at 6 weeks pre-treatment, +/- 2 weeks 3 months post radiation treatment, and +/- 4 weeks at 6, 9,12,18 and 24 months post radiation treatment.
48445919|NCT02375685|BIOLOGICAL|Gevokizumab|
48445920|NCT06485531|OTHER|Pranamaya|Pranamaya
48445921|NCT06485531|OTHER|Pursed Lips Breathing|Pursed Lips Breathing
48445922|NCT05236764|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
48445923|NCT05041127|BIOLOGICAL|Cetuximab|Given IV
48445924|NCT05041127|OTHER|Questionnaire Administration|Ancillary studies
48445925|NCT04987411|DIAGNOSTIC_TEST|Measurement of methane concentrations in exhaled breath|To measure methane concentrations, a near-infrared laser technique-based photoacoustic apparatus will be attached to the exhalation outlet of the ventilator upon arrival of severely injured patients. Exhaled methane levels will be monitored continuously during the first 72 in-hospital hours and will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission).
48445926|NCT04987411|DIAGNOSTIC_TEST|Videomicroscopy of the sublingual microcirculation|Orthogonal polarization spectral imaging technique (Cytoscan A/R, Cytometrics) will be used to visualize the microcirculation of the sublingual mucosa of the patients. The OPS technique utilizes reflected, polarized light at the wavelength of the isobestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). The diminution of sublingual microcirculation can refer to circulatory redistribution due to hemorrhage. Sublingual microcirculation of the patients will be visualized and evaluated at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
48445927|NCT04987411|DIAGNOSTIC_TEST|Blood gas and laboratory analysis|Arterial blood gas analysis and laboratory testing of venous blood are routine examinations in clinical practice. Base deficit and lactate are considered as global markers of blood loss and shock, and can be obtained rapidly with blood gas analysis. Hemoglobin and hematocrit values can correspond to the severity of blood loss, and are measured routinely both from arterial and venous blood. Sampling of arterial and venous blood for blood gas and laboratory analyses will be performed at pre-determined time points (directly upon arrival, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
48445928|NCT04987411|DIAGNOSTIC_TEST|Hemodynamic monitoring|Hemodynamic monitoring is an essential part of emergency trauma care. Non-invasive monitoring of blood pressure, heart rate and respiratory rate of patients will be started immediately upon arrival. After patients are stabilized, invasive arterial blood pressure (IABP) monitoring can be started. IABP is considered as the gold standard of blood pressure measurement in critical care as it reflects the fluctuations of blood pressure in real time. Blood pressure and heart rate values will be recorded at pre-determined time points (directly upon arrival, 6 hours post-admission, 12 hours post-admission, 24 hours post-admission, 48 hours post-admission and 72 hours post-admission) during the first 72 in-hospital hours.
48445929|NCT00828295|DRUG|palonosetron|palonosetron IV 1 mcg/kg
48445930|NCT00828295|DRUG|palonosetron|palonosetron 3mcg/kg IV
48445931|NCT02158572|DRUG|AG200-15|Transdermal contraceptive delivery system
48445932|NCT00905346|DRUG|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
48445933|NCT00905346|DRUG|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
48445934|NCT00905346|OTHER|Applesauce|Applesauce
48445935|NCT06560164|OTHER|Red Blood Cell transfusion|When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.
48445936|NCT03612232|DRUG|Cabozantinib-s-malate|oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
48445937|NCT00911235|DRUG|Fesoterodine|Single 8 mg oral dose of fesoterodine
48445938|NCT00911235|DRUG|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
48445939|NCT03040648|DEVICE|DSA|DSA was used for detection of intravascular injection
48445940|NCT03040648|DEVICE|RTF|RTF was used for detection of intravascular injection
48445941|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
48445942|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
48445943|NCT04078763|BEHAVIORAL|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
48445944|NCT04078763|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
48445945|NCT04078763|BEHAVIORAL|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
48445946|NCT01480544|OTHER|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
48445947|NCT01480544|OTHER|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
48445948|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
48445949|NCT01289691|OTHER|One Lung Ventilation|Patients in this group will be ventilated with only oxygen during one lung ventilation.
48445950|NCT06183216|BIOLOGICAL|Sinovac PCV13|0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
48445951|NCT06183216|BIOLOGICAL|PREVNAR 13|0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
48445952|NCT03792477|BIOLOGICAL|Test formulation|A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).
48445953|NCT03792477|BIOLOGICAL|Reference formulation|A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).
48445954|NCT00723710|BIOLOGICAL|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m\^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m\^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
48445955|NCT05522361|DRUG|Risdiplam|administered to participants per product label insert
48445956|NCT05108467|DIAGNOSTIC_TEST|Point of care Lactate|"StatStrip Lactate is a handheld, point-of-care (POC) meter that brings lactate testing directly to the bedside. Lactate measured with blood gas analyzers is problematic for bedside care. Blood gas analyzers require arterial samples, large sample volumes (100-200 μL), and long analysis times (up to 2.5 minutes). In addition, blood gas analyzers are complex to use, stationary, and expensive to purchase and run.~StatStrip Lactate testing is as easy as bedside glucose testing. Single-use, pre-calibrated biosensors provide the fastest turnaround time (13 seconds) from the smallest whole blood sample (0.6 μL) with excellent correlation to central laboratory reference methods."
48445957|NCT04304066|OTHER|18F-WL12 PET or 68Ga-WL12 PET|WL12, labeled with PET radio-nuclide ( Ga-68 or F-18)will be used as a molecular imaging tracer for PET/CT scanning
48445958|NCT05472311|OTHER|Thermal Ablation|Thermal ablation is based on local heating (around 100 degrees centigrade), applied for 20 to 60 seconds to destroy abnormal tissue by burning and inducing necrosis of pre-cancer and surrounding tissue. It has been used in by gynecological surgery for over 50 years, proven safe and easy to use by middle level health care providers in primary care settings.
48445959|NCT01423994|PROCEDURE|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
48098150|NCT04914676|DRUG|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
48098151|NCT04914676|DRUG|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
48445960|NCT01423994|PROCEDURE|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate \<50 bpm, High Heart Rate \>165 bpm, and Pause \> 3 seconds.
48445961|NCT02227186|OTHER|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
48445962|NCT00659763|OTHER|Exclusion diagnosis|"Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.~3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy"
48445963|NCT00659763|OTHER|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
48445964|NCT03377361|BIOLOGICAL|Nivolumab|Specified dose on specified days
48445965|NCT03377361|DRUG|Trametinib|Specified dose on specified days
48445966|NCT03377361|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48445967|NCT03377361|DRUG|Regorafenib|Specified dose on specified days
48445968|NCT03161717|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
48445969|NCT03161717|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
48445970|NCT01964053|BEHAVIORAL|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
48445971|NCT01964053|BEHAVIORAL|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
48445972|NCT03559491|DRUG|Intravitreal injection|Long term release steroid injection
48445973|NCT06293196|OTHER|acupressure|Massage acupoints and non-acupoint areas around the eyes.
48445974|NCT06293872|DEVICE|12*2 mm length miniscrew|"Prior to mini-inplant insertion the patient will instructed to rinse mouth with chlorhexidine mouthwash, then local anesthesia will be applied.~The clinical implication for miniscrew insertion in the IZ crest of adults is 14 to 16 mm above the maxillary occlusal plane and the maxillary first molar.~The self-drilling screw is directed at 90° to the occlusal plane at this point. After the initial notch in the bone is created after couple of turns to the driver, the bone screw driver direction is changed by 55°-70° toward the tooth, downward, which aid in bypassing the roots of the teeth and directing the screw to the infra-zygomatic area of the maxilla. The bone screw is screwed until only the head of the screw is visible outside the alveolar mucosa.~Follow-up: C.B.C.T will be performed after surgery to verify the implant position relative to the adjacent roots"
48445975|NCT02321098|DRUG|Loceryl NL + Cosmetic varnish|Loceryl NL + Cosmetic varnish once/week for 12 weeks
48445976|NCT02321098|DRUG|Loceryl NL 12 weeks|Loceryl NL once/week for 12 weeks
48445977|NCT02321098|DRUG|Loceryl NL 15 months|Loceryl once/week for additional 15 months
47928057|NCT02592642|BEHAVIORAL|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
48098152|NCT02289560|DEVICE|Transcranial ExAblate|Transcranial ExAblate
48098153|NCT03450109|DRUG|LY01005|One gluteal IM injection
48098154|NCT03450109|DRUG|Zoladex|One Subcutaneous injection in the abdominal wall
48445978|NCT05278507|DEVICE|Arrowga+rd Blue Advance Protection PICC Placement|The PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
48445979|NCT05278507|DEVICE|Sham Comparator PICC placement|The sham comparator PICC will be placed by a qualified healthcare professional, in accordance with institutional policies and procedures and the device's IFU.
48445980|NCT04741893|DEVICE|EndoFLIP|Use of Endoluminal Functional Lumen Imaging Probe to assess anal canal function
48445981|NCT03769025|BEHAVIORAL|Suboxone Remote Observed Dosing|The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
48445982|NCT03769025|OTHER|Suboxone Attention Control|Attention control group will send a text message daily confirming that they have taken their Suboxone dose
48445983|NCT04927663|PROCEDURE|Computed Tomography|Undergo CT imaging
48445984|NCT04927663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48445985|NCT04927663|PROCEDURE|Positron Emission Tomography|Undergo PET imaging
48445986|NCT04927663|DRUG|11C-YJH08|Given IV
48445987|NCT04927663|PROCEDURE|Optional Tumor Biopsy|Optional procedure to obtain tumor tissue
48445988|NCT00000330|DRUG|Opioid-Related Disorders|
48445989|NCT03023956|PROCEDURE|Locking plates were used for proximal humeral fractures.|
48445990|NCT04052503|BEHAVIORAL|Knowledge Broker|Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
48445991|NCT04827394|DEVICE|Neonatal warming mattress|Babies will be warmed with a standard neonatal transport warming mattress immediately after birth.
48445992|NCT04827394|DEVICE|Sterile polyethylene wrap|Babies will be wrapped in a sterile polyethylene wrap prior to arrival at the warmer.
48445993|NCT01616381|DRUG|Sildenafil|PDE-5 Inhibitor
48445994|NCT01616381|DRUG|Placebo|Placebo for sildenafil 40mg x 3 daily
48445995|NCT03902548|DRUG|[18F]P16-129|Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
48445996|NCT02482090|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
48445997|NCT02482090|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
48445998|NCT02482090|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
48445999|NCT02482090|DRUG|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
48446000|NCT05050071|DRUG|Allium Sativum|Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
48446001|NCT05050071|DEVICE|Polymerase chain reaction|Change in the bacterial load in response to different treatment procedures
48446002|NCT04030091|DRUG|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
48446003|NCT04030091|DRUG|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
48446004|NCT00469417|DRUG|Metvix® cream|
48446005|NCT00469417|PROCEDURE|Hand held liquid nitrogen spray cryotherapy|
48446006|NCT03557541|DIETARY_SUPPLEMENT|Sardine|They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
48446007|NCT03557541|DIETARY_SUPPLEMENT|Control|They received a common T2D-preventive diet
48446008|NCT04478786|OTHER|Focus group discussion|There is no intervention. This is a qualitative piece of work only.
48446009|NCT03621163|PROCEDURE|Bleaching agent ( BOOST 40%)|Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.
48446010|NCT03621163|PROCEDURE|laminate veneers(lithium-silicate)|A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
48446011|NCT01196000|PROCEDURE|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
48446012|NCT01196000|PROCEDURE|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
48446013|NCT01196000|PROCEDURE|quality-of-life assessment|Ancillary studies
48446014|NCT01196000|OTHER|questionnaire administration|Ancillary studies
48446015|NCT05318690|DEVICE|PlayGait|PlayGait is a dynamic energy storing and returning lower-limb exoskeleton.
48446016|NCT05318690|OTHER|Baseline|Baseline condition with no prescribed or intervention lower-limb devices.
48446017|NCT04195360|OTHER|Standardized mobilization procedure|5 minutes bed rest (h1), followed by 3 minutes passive leg raise (PLR), followed by 5 minutes bed rest (h2), followed by 3 minutes sitting on the egde of the bed (sit), followed by 3 minutes standing/walking on the spot (sta), followed by 5 minutes bedrest (h3)
48446018|NCT05433857|DRUG|Lacteol forte capsules|probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
48446019|NCT06427005|DRUG|Fruquintinib|Fruquintinib 5 mg daily for 14 days followed by a 7-day break
48446020|NCT06427005|DRUG|S-1|S-1 80-120 mg daily for 14 days, followed by a 7-day break
48446021|NCT06427005|DRUG|raltitrexed|raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
48446022|NCT01270594|BEHAVIORAL|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
48446023|NCT01270594|BEHAVIORAL|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
48446024|NCT00522262|BEHAVIORAL|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
48446025|NCT00226317|DRUG|Aripiprazole|
48446026|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
48446027|NCT01017926|DRUG|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
48446028|NCT06208215|DRUG|RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
48446029|NCT06208215|DRUG|RZ358 (10 mg/kg) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
48446030|NCT06208215|DRUG|RZ358 (5-10 mg/kg) + SOC|Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
48446031|NCT05571449|PROCEDURE|Open reduction and internal fixation|Internal fixation of the fracture
48446032|NCT05571449|PROCEDURE|Standard osteosynthesis planning|Plain radiograph and CT images are used
48278222|NCT02443402|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG \> 400 mg/dL; 7-9 units of insulin aspart"
48278223|NCT02149992|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
48278224|NCT02149992|DEVICE|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
48278225|NCT02149992|DEVICE|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
48278226|NCT04060615|PROCEDURE|percutaneous coronary intervention|PCI of the chronic total occlusion of the coronary artery
48278227|NCT00257036|DRUG|levofloxacin|
48278228|NCT00047567|DRUG|zonisamide|
48278229|NCT02532049|BIOLOGICAL|ChAd63 Pfs25-IMX313|
48278230|NCT02532049|BIOLOGICAL|MVA Pfs25-IMX313|
48278231|NCT02594501|DEVICE|COBRA PzF|
48278232|NCT02594501|DEVICE|Drug Eluting Stent|
48278233|NCT02898012|DRUG|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
48278234|NCT02898012|DRUG|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage \> grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
48278235|NCT05464095|DEVICE|mHealth Intervention|The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
48278236|NCT05464095|DEVICE|Usual Care|The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
48278237|NCT02983084|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
48278238|NCT05694598|GENETIC|VGR-R01|CYP4v2-coding gene delivered by AAV vector
48278239|NCT02278783|DRUG|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
48278240|NCT03059290|DEVICE|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
48278241|NCT00468234|DRUG|nicotine polacrilex|
48278242|NCT00468234|DRUG|nicotine transdermal system|
48278243|NCT00468234|DRUG|nicotine inhaler|
48278244|NCT05452603|DEVICE|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
48278245|NCT04747405|OTHER|therapy group|therapy group of maximum 8 people repeated twice
48278246|NCT00097539|BIOLOGICAL|Somatrem|
48278247|NCT00097539|BIOLOGICAL|Somatropin|
48446033|NCT05571449|PROCEDURE|3-D model osteosynthesis planning|A 3D plastic model made from CT images is used
48446034|NCT01727947|OTHER|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied \> 13% of nuclear area) in each sample will be assessed.
48446035|NCT04255420|PROCEDURE|SPG Block|A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
48446036|NCT04255420|DRUG|Standard IV Treatment|Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
48446037|NCT00601120|PROCEDURE|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
48446038|NCT06161623|BEHAVIORAL|Laughter Yoga Application|The intervention group took eight sessions of laughter yoga, that is, two sessions per week for 4 weeks. The participants in the intervention group were asked to fill in the data collection tools before the laughter yoga sessions, and after the 4th and 8th yoga sessions.
48446039|NCT04816253|DRUG|Normal saline|Normal saline irrigation and No other drug placed after extraction
48446040|NCT04816253|DRUG|Hyaluronic acid|Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
48446041|NCT04816253|DRUG|Methylprednisolone|Methylprednsolone will be injected half an hour preoperatively
48446042|NCT04816253|DRUG|Methylprednisolone and Hyaluronic acid|Methylprednisolone will be injected half an hour preoperatively and Immediately after removal of impacted tooth (hyaluronic acid) placed in extraction socket
48446043|NCT01776190|DEVICE|UVA1 radiation treatment|
48446044|NCT02136290|BEHAVIORAL|Prepackaged meals|Portion-controlled prepackaged meals
48446045|NCT02136290|BEHAVIORAL|Usual Care|Usual care dietary counseling
48446046|NCT01893008|OTHER|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable)."
48446047|NCT04760704|BIOLOGICAL|Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration|Specific T cells and specific antibodies assessment
48446048|NCT01339247|DRUG|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
48446049|NCT01339247|DRUG|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
48446050|NCT01926119|DEVICE|Transcranial Magnetic Stimulation|
48446051|NCT02849093|OTHER|Non-invasive OCT imaging|Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
48446052|NCT04086186|PROCEDURE|Liposomal Bupivacaine Peri-articular Injection|A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
48446053|NCT04086186|PROCEDURE|Adductor canal block|Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
48446054|NCT04836598|OTHER|laparoscopic cholecystectomy|A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).
48446055|NCT05332496|DRUG|PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab|PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
48446056|NCT05332496|PROCEDURE|TACE|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
48446057|NCT03038009|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
48446058|NCT02982161|DRUG|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
48446059|NCT02982161|DRUG|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
48620384|NCT02521480|DEVICE|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
48620385|NCT02521480|DEVICE|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
48620386|NCT06238726|BEHAVIORAL|Reminder|Shingrix messages via SMS, patient portal, email, and/or another modality
48446060|NCT02982161|DRUG|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
48446061|NCT02140580|DEVICE|Minimally invasive surfactant therapy|Active Comparator
48446062|NCT02140580|OTHER|Continuation on CPAP|Sham Comparator
48620387|NCT03546959|OTHER|Lycra sleeve|custom-fitted lycra sleeve extending from axilla to wrist
48446063|NCT01149590|PROCEDURE|Computer Tomography Angiography|Computed Tomography Angiography
48446064|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose, 1 day
48446065|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
48446066|NCT00878020|DRUG|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
48446067|NCT00878020|DRUG|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
48446068|NCT03347435|GENETIC|genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435|The CYP2C19\*2 (10q24.1-q24.3; rs4244285), CYP2C19\*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.
48446069|NCT03347435|OTHER|clinical algorithm|Antiplatelet therapy will be choose on the basis of clinical algorithm alone
48446070|NCT03572777|DRUG|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days.
48446071|NCT03572777|DRUG|Concomitant therapy|Clarithromycin ('Makcin') 500 mg bid for 14 days
48446072|NCT03572777|DRUG|Concomitant therapy|Metronidazole ('Medazol') 500 mg bid for 14 days
48446073|NCT03572777|DRUG|Concomitant therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
48446074|NCT03572777|DRUG|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days
48446075|NCT03572777|DRUG|Hybrid therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
48446076|NCT03572777|DRUG|Hybrid therapy|Clarithromycin ('Makcin') 500 mg bid for the last 7 days
48446077|NCT03572777|DRUG|Hybrid therapy|Metronidazole ('Medazol') 500 mg bid for the last 7 days
48446078|NCT00476281|PROCEDURE|Urinary collect|
48446079|NCT00476281|PROCEDURE|Continuous Glucose Monitoring System (CGMS)|
48098155|NCT01243801|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
48098156|NCT05837780|OTHER|Nasoalveolar molding device|comparison between using conventionally and digitally constructed nasoalveolar molding devices
48446080|NCT05010018|BEHAVIORAL|Web-based application connecting small food store owners and suppliers of healthier foods and beverages|The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
48098157|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
48098158|NCT01171924|DRUG|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
48278248|NCT01608334|DRUG|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
48278249|NCT01608334|DRUG|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
48278250|NCT05836090|BEHAVIORAL|Family Spirit Strengths (FSS)|The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).
48278251|NCT05836090|BEHAVIORAL|Family Spirit Nurture|The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
48278252|NCT04714086|DRUG|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
48278253|NCT01561287|PROCEDURE|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
48278254|NCT01561287|PROCEDURE|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
48278255|NCT02842931|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
48278256|NCT02842931|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
48278257|NCT02842931|DRUG|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
48278258|NCT02842931|DRUG|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
48446081|NCT00276848|DRUG|Fludarabine plus Cyclophosphamide|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
48446082|NCT00276848|DRUG|Fludarabine|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
48446083|NCT04414228|DEVICE|M-Entropy guidance of anesthesia depth|In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.
48446084|NCT04414228|DEVICE|ProAQT in guiding goal-directed hemodynamic therapy|If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If mean arterial pressure is \< 70 mmHg and/or cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of \< 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
48446085|NCT06000449|BEHAVIORAL|Center M|Digital mental health platform. Screening and prevention activities will be provided through the Center M platform, telehealth group mindfulness sessions, and digitally delivered home practice materials.
48446086|NCT06000449|BEHAVIORAL|Treatment as Usual|Paper screening and PD handout.
48446087|NCT03965169|PROCEDURE|Prone spinal surgery|spinal surgery in prone position under general anesthesia
48446088|NCT06238388|DRUG|HSK21542 Injection|A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
48446089|NCT05357417|DRUG|utidelone|30mg/m2 (±10%), day 1-5 every 3-week cycle
48446090|NCT05357417|DRUG|Bevacizumab|15mg/kg, day 1
48446091|NCT00520923|DRUG|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
48446092|NCT00520923|DRUG|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
48446093|NCT00520923|DRUG|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
48446094|NCT00520923|DRUG|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
48446095|NCT00520923|DRUG|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
48446096|NCT00520923|DRUG|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
48446097|NCT00520923|DRUG|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
48446098|NCT02184845|DEVICE|Implant NobelActive 3.0|
48446099|NCT03965286|DRUG|DAAs|Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
48446100|NCT01705574|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
48446101|NCT01705574|DRUG|ATV|300 mg capsule administered orally with food once daily
48446102|NCT01705574|DRUG|RTV|100 mg tablet administered orally with food once daily
48446103|NCT01705574|DRUG|FTC/TDF|200/300 mg tablet administered orally with food once daily
48446104|NCT01705574|DRUG|E/C/F/TDF Placebo|Tablet administered orally with food once daily
48446105|NCT01705574|DRUG|ATV Placebo|Tablet administered orally with food once daily
48446106|NCT01705574|DRUG|RTV Placebo|Capsule administered orally with food once daily
48278259|NCT02852525|DEVICE|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
48278260|NCT06600906|DRUG|Hyperpolarized 13C-Pyruvate|Given intravenously (IV)
48278261|NCT06600906|PROCEDURE|Computed tomography (CT)|Undergo CT imaging
48278262|NCT06600906|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
48446107|NCT01705574|DRUG|FTC/TDF Placebo|Tablet administered orally with food once daily
48446108|NCT01705574|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
48446109|NCT06022419|PROCEDURE|Lucerne Cast|Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.
48446110|NCT06022419|PROCEDURE|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
48446111|NCT02376777|OTHER|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
48446112|NCT01792726|RADIATION|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
48446113|NCT03214276|DIETARY_SUPPLEMENT|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
48446114|NCT03214276|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
48446115|NCT05880576|DEVICE|Monitoring using resonance Raman spectroscopy, pulse oximetry, blood pressure, and near-infrared spectroscopy|Infants will have monitoring three times a day with resonance Raman spectroscopy device during arch watch period. They will have continuous monitoring with pulse oximetry and near infrared spectroscopy. They will have intermittent blood pressure monitoring.
48446116|NCT02761512|DRUG|CJ-12420 50 mg QD|CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
48446117|NCT02761512|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
48446118|NCT02761512|DRUG|Lansoprazole 30 mg QD|Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
48446119|NCT00151489|DRUG|pregabalin|
48446120|NCT00151489|DRUG|placebo|
48446121|NCT02399917|DRUG|Azacitidine|Given SC or IV
48446122|NCT02399917|BIOLOGICAL|Lirilumab|Given IV
48446123|NCT02897791|BEHAVIORAL|written evaluations|answering questions about pictures and stories
48446124|NCT05669781|DRUG|Metoclopramide 10mg|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively
48446125|NCT05669781|COMBINATION_PRODUCT|Gum and metoclopramide|Intravenous metoclopramide 10mg 8hourly for the first 72hours post-operatively and one stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
48446126|NCT05669781|OTHER|Gum|One stick of sugar-free gum (over 15minutes) 8 hourly till either the first flatus or feces was passed
48446127|NCT05669781|OTHER|Control|10ml of sterile water intravenously 8hourly for the first 72hours post-operatively
48446128|NCT04834414|BIOLOGICAL|Cold Stored Platelets|Platelets stored at 1-6 degree Celsius
48446129|NCT04834414|BIOLOGICAL|Room Temperature Platelets|Platelets stored at 20-24 degrees Celsius
48446130|NCT04673201|PROCEDURE|"Viscotrabeculotomy Versus trabeculectomy with MMC"|Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
48446131|NCT04343001|DRUG|Aspirin|Aspirin 150mg
48446132|NCT04343001|DRUG|Losartan|Losartan 100mg
48278263|NCT01816503|DRUG|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
48278264|NCT04095520|PROCEDURE|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
48278265|NCT04095520|PROCEDURE|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
48278266|NCT03542838|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
48278267|NCT03542838|DRUG|Saline|Saline is a normal physiological solution
48278268|NCT01122927|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
48446133|NCT04343001|DRUG|Simvastatin|Simvastatin 80mg
48446134|NCT02409355|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
48446135|NCT02409355|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
48446136|NCT02409355|DRUG|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m\^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
48446137|NCT02409355|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 (when coadministered with carboplatin) or 1250 mg/m\^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
48446138|NCT01963728|DRUG|Insulin, Isophane|daily dosing based on fasting morning glucose levels
48278269|NCT05805501|DRUG|Tobemstomig|Participants will receive IV tobemstomig Q3W.
48278270|NCT05805501|DRUG|Tiragolumab|Participants will receive IV tiragolumab Q3W.
48278271|NCT05805501|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W.
48278272|NCT05805501|DRUG|Axitinib|Participants will receive axitinib PO BID.
48278273|NCT02886429|DRUG|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
48278274|NCT02886429|DRUG|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
48446139|NCT01963728|DRUG|insulin glargine|daily dose based on fasting morning glucose levels
48446140|NCT00407147|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
48446141|NCT02225314|BEHAVIORAL|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
48446142|NCT02225314|BEHAVIORAL|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
48446143|NCT02225314|BEHAVIORAL|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
48446144|NCT02278835|OTHER|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
48446145|NCT02278835|DEVICE|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
48446146|NCT02278835|DEVICE|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
48446147|NCT02278835|DEVICE|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
48446148|NCT05333341|BEHAVIORAL|TCM|TCM care is remotely-delivered and medium-term (up to 12 months), with the objective of improving CP and OUD/misuse symptoms primarily through medication management.
48446149|NCT05333341|BEHAVIORAL|TCM plus COPES|The COPES program will augment the effectiveness of TCM alone. COPES is a 12-week, Interactive Voice Response (IVR)-facilitated program of CBT for CP and common sequelae (depressive symptoms, sleep difficulties, low physical activity). Ongoing COPES engagement will be tracked by the COPES system. The primary components of the intervention are: 1) a self-help handbook containing the rationale and instructions for using ten pain self-management skills and their corresponding weekly skill practice goals; 2) a pedometer-facilitated walking program; 3) daily, automated IVR calls to collect pain interference, sleep quality, pedometer-measured step count, and adherence to the pain coping skill practice ratings; and 4) weekly, two to four minute pre-recorded, personalized therapist messages based on participant IVR-reported data.
48446150|NCT06118047|DRUG|Crisaborole Ointment|Crisaborole ointment to be applied twice daily.
48446151|NCT06118047|DRUG|Cetuximab|Cetuximab
48446152|NCT05652543|BIOLOGICAL|SCTV01E|Participants will be vaccinated with SCTV01E on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
48446153|NCT05652543|BIOLOGICAL|Placebo (normal saline)|Participants will be vaccinated with Placebo (normal saline) on Day 0, and safety and immunogenicity will be monitored for 180 days after vaccination.
48446154|NCT03224494|DEVICE|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
48278275|NCT01661257|DRUG|Infliximab|
48446155|NCT03224494|OTHER|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
48278276|NCT06487377|BIOLOGICAL|IX001 TCR-T cells|IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.
48446156|NCT03224494|OTHER|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
48446157|NCT06558864|PROCEDURE|Subiculum RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform Subiculum RF-TC.
48446158|NCT05004740|OTHER|Vaccinated Pregnant or Lactating persons|vaccinated lactating persons from Sinai Health System or the general public
48446159|NCT02435043|OTHER|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
48446160|NCT02435043|OTHER|standard management after stroke|standard management after stroke is individualised.
48278277|NCT05693584|OTHER|distraction|diverting the patient's attention with virtual reality glasses
48278278|NCT04738955|DRUG|Micafungin Sodium|micafungin sodium ≥ 100, \<200mg/time, once a day, intravenous drip. Low dose group
48278279|NCT06190314|DIAGNOSTIC_TEST|Measure serum vitamin b12 levels|Measure the vitamin b-12 levels in patients that are admitted for stroke of any kind
48446161|NCT05227703|DRUG|CVL-231 15 mg|CVL-231 15 mg, oral (tablet), once per day for 6 weeks
48446162|NCT05227703|DRUG|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
48446163|NCT05227703|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
48446164|NCT01507051|DRUG|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
48446165|NCT01507051|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
48446166|NCT01507051|DRUG|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
48446167|NCT01507051|DRUG|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
48446168|NCT06017635|OTHER|Exposure factors|"1. General information Name, gender, age, weight (kg), major diseases~2. Clinical data:~Non-contrast CT scan results of cranial CT on the first day of admission, serum SUR1, trpm4 and MMP-9 expression on the 1st, 4th, 7th and 14th days of admission, S100-β and NSE values on the 1st, 4th, 7th, and 14th days of admission, disturbance coefficient on the 1st, 4th, 7th, and 14th days of admission, Glasgow coma score on the 1st, 4th, 7th, and 14th days of admission, GOS-E score and Merriam-Webster Intelligence Scale score at 3 months of discharge."
48446169|NCT04766697|BEHAVIORAL|Risk-Reduction Sessions|The 8-session intervention protocol emphasizes cognitive-behavioral interventions for anger management, conflict resolution, reducing sexual risk behavior, substance use, and enhancement of couple functioning.
48278280|NCT03120143|OTHER|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
48278281|NCT03120143|OTHER|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
47928058|NCT02592642|BEHAVIORAL|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
48098159|NCT01766856|OTHER|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
48278282|NCT01941225|DRUG|Inhaled iloprost 5.0 mcg|Single administration
48278283|NCT01941225|DRUG|Placebo|Single administration
48278284|NCT03478826|OTHER|ILD|100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
48278285|NCT03478826|OTHER|Healthy|100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
48278286|NCT03478826|OTHER|Pneumonia|100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
48278287|NCT01239927|PROCEDURE|Primary sigmoid resection with end colostomy (Hartmann)|
48278288|NCT01239927|PROCEDURE|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
48278289|NCT04368754|OTHER|Questionnaire|Patients evaluated with different questionnaire.
48278290|NCT01258920|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
48278291|NCT05384561|OTHER|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
48278292|NCT01479348|DRUG|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
48278293|NCT01479348|DRUG|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m\^2, IV
48278294|NCT01479348|DRUG|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
48278295|NCT01479348|DIAGNOSTIC_TEST|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
48278296|NCT06139289|PROCEDURE|EVD placements in the OR versus the bedside.|Reducing EVD-related complications
48278297|NCT05747690|DEVICE|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
48278298|NCT02955329|DRUG|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
48278299|NCT02955329|DRUG|Cannabis|Participants will vape marijuana leaves with nicotine out of the PAX device.
48278300|NCT02955329|DEVICE|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
48278301|NCT00190775|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
48278302|NCT00190775|DRUG|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
48278303|NCT02639377|DRUG|Chlorhexidine gluconate|
48278304|NCT02639377|DRUG|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
48278305|NCT05327062|DEVICE|CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment|"The following information and data will be obtained from the routine clinical work up of the patients: Patient demographics, cardiovascular medical history, and clinical examination; 12-lead ECG; Standard echocardiography; Computed tomography angiography for visualization of atria, ventricle, and coronary sinus.~Imaging data will be transferred to the cloud-based web-platform using a dedicated software provided by study sponsor. Data processing includes evaluating the quality of the data and calculation of various anatomical and electrical parameters, and identification of the target zone as a point in the target vein closest to the latest activation zone.~LV-lead location is based on the information provided by the dedicated software followed by visual X-ray based verification of anatomically suitable/most desirable position.~The patient will undergo CRT device implantation according to local protocols."
48278306|NCT05844917|DEVICE|ultrasound|Ultrasound detection of subclinical arthritis among Patients With SLE
48278307|NCT06145230|OTHER||
48278308|NCT05453903|DRUG|Bleximenib|Participants will receive bleximenib.
48278309|NCT05453903|DRUG|Venetoclax (VEN)|Participants will receive VEN.
48278310|NCT05453903|DRUG|Azacitidine (AZA)|Participants will receive AZA.
48278311|NCT05453903|DRUG|Cytarabine|Participants will receive cytarabine
48278312|NCT05453903|DRUG|Daunorubicin or Idarubicin|Participants will receive daunorubicin or idarubicin
48278313|NCT00336102|OTHER|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
48278314|NCT00336102|PROCEDURE|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
48446170|NCT05624034|DEVICE|Electrogastrography|Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis
48446171|NCT01030133|DEVICE|Operator Role Real TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
48446172|NCT01030133|DEVICE|Receiver Role Real TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
48446173|NCT01030133|DEVICE|Operator Role Sham TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
48446174|NCT01030133|DEVICE|Receiver Role Sham TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
48446175|NCT01030133|DEVICE|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
48446176|NCT05790824|OTHER|Spa therapy|"The RH2 rheumatology treatment protocol will propose treatments that can be carried out with water from the SL5 borehole and will be composed of:~* 54 treatments among the following treatments:~  * Swimming pool, 15 minutes (code 201)~ * Bath with aerobath, 10 minutes (code 205)~ * Bath with immersion shower, 10 minutes (code 206)~ * Cataplasm in multiple local application, 10 minutes (code 408)~* 18 sessions of mobilization pool, 15 minutes (code 601)"
48446177|NCT03527017|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.
48446178|NCT03527017|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in adult IQOS users residing in Germany.
48446179|NCT03324178|BEHAVIORAL|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
48446180|NCT03324178|BEHAVIORAL|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
48446181|NCT02836821|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
48446182|NCT02836821|DRUG|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
48446183|NCT05443386|PROCEDURE|colorectal surgery|we have included several types of colorectal surgery procedures, in emergency conditions
48446184|NCT02335658|DRUG|DSP-5423P|40-80mg/day
48446185|NCT04859517|DRUG|ADG20|Single dose of ADG20
48446186|NCT04859517|DRUG|Placebo|Single dose of placebo
48446187|NCT06424457|PROCEDURE|video assisted thoracoscopy (VATS)|the investigators compare the outcomes of intervention by VATS and doing complete decortication or open surgery thoracotomy
48446188|NCT06424457|PROCEDURE|open thoracotomy|the investigators assess the outcomes of intervention by doing complete decortication through open surgery thoracotomy
48446189|NCT03700723|BIOLOGICAL|Resusix|spray-dried solvent/detergent treated plasma (blood product)
48446190|NCT03700723|BIOLOGICAL|FP24 (Frozen Plasma)|plasma frozen within 24 hours of phlebotomy
48446191|NCT06464120|OTHER|Increasing load strength training|The Smith machine was used to intervene with athletes by employing an incremental load approach.
48446192|NCT06464120|OTHER|Constant load strength training|The Smith machine was used to intervene with athletes by employing a constant load approach.
48446193|NCT00365846|DRUG|Campath-1H|
48446194|NCT01377779|DRUG|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
48446195|NCT01377779|DRUG|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
48446196|NCT01691456|DRUG|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
48446197|NCT05978726|DRUG|Dual antiplatelet therapy with aspirin and either ticagrelor or clopidogrel|Patients with acute myocardial infarction randomly received dual antiplatelet therapy with with aspirin 100mg daily and either ticagrelor 90mg twice daily or clopidogrel 75mg once daily for at least 9 months after PCI as needed.
48446198|NCT01438853|BIOLOGICAL|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
48446199|NCT01438853|DRUG|Placebo|Single intravenous dose of saline control
48446200|NCT03325387|DRUG|LY3305677|Administered SC
48446201|NCT03325387|DRUG|Placebo|Administered SC
48446202|NCT01472263|DRUG|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
48446203|NCT01472263|DRUG|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
48446204|NCT00568672|DRUG|Olanzapine|Olanzapine 5 mg / day for 6 months
48446205|NCT01906918|PROCEDURE|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
48446206|NCT04865653|DRUG|Lysergic Acid Diethylamide Base oral drinking solution|A moderate dose of 0.1 mg LSD will be administered.
48446207|NCT04865653|DRUG|Lysergic Acid Diethylamide Base solid orodispersible film|A moderate dose of 0.1 mg LSD will be administered.
48446208|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate oral drinking solution|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
48446209|NCT04865653|DRUG|Lysergic Acid Diethylamide Tartrate intravenous administration|A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).
48446210|NCT04865653|OTHER|LSD Placebo|Placebo for each formulation containing only the solvent or gel but no LSD.
48446211|NCT04512092|BEHAVIORAL|Compassionate Mind Training for Caregivers|CMT-C is a 12-session group program, each lasting about 2,5 hours, which run on a weekly basis. The program is organized across 3 modules: 1) Our mind according to a compassion-based approach (to provide insight into the evolved and socially shaped mind and the affect regulation systems); 2) Compassionate mind training (understanding and cultivating the attributes and competencies of compassion in its three flows, and addressing its fears); and 3) final session (revising key information and practices and its application to the RCH practices/routines). Its sessions have the following structure: 1) Check-in (grounding exercise, reviewing the previous session, sharing the weekly practice); 2) Exploration of the session theme (psychoeducation and experiential practices followed by group opportunities for share experiences and discussion); 3) Check-out (session summary and application to the self, youths and RCH practices, weekly practice challenge, session evaluation, session take-off).
48446212|NCT03701191|PROCEDURE|Inverted periosteal pedicle flap|The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
48446213|NCT05329025|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
48446214|NCT05278325|OTHER|Telephone intervention|Two planned phone call between clinical controls
48446215|NCT05643976|BEHAVIORAL|KardioPAC Mobile Application|"Like those in the SOC CR arm, participants assigned to the CR+KardioPAC arm will receive standard of care and attend CR as prescribed by their physician. Additionally, they will receive access to the digital app, KardioPAC, \& a BP device for home use that will record their BP readings in the app.~KardioPAC is a remote patient monitoring system that allows providers to monitor patients and send out daily reminders. It integrates with BP monitors and fitness watches to collect patient health information at home. The information is uploaded to the HIPAA-compliant server and presented on the website for providers to read. Its reminder system can be customized to meet diverse clinical needs.~Lastly, the Kura Care in-house Registered Nurse will provide 20-30 min of health coaching to intervention arm participants on a weekly or bi-weekly basis via the app. The coaching will include greetings, review of medication adherence, encouragement to exercise, and symptom management, if applicable."
48446216|NCT05643976|OTHER|Standard of Care|During the prescribed cardiac rehabilitation, the SOC CR intervention participants will receive standard of care by attending the 36-72 sessions of CR as prescribed by his/her physician and administered by the University of California San Diego Health Cardiac Rehabilitation Center.
48446217|NCT03359356|DRUG|Dupilumab|A total of 24 doses
48446218|NCT03359356|DRUG|Placebo|A total of 24 doses
48446219|NCT03084250|DRUG|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
48446220|NCT03084250|DRUG|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
48446221|NCT06139588|DEVICE|acellular dermal matrix implant for breast reconstruction|acellular dermal matrix implant in implant-based breast reconstruction in patients receiving radiotherapy
48446222|NCT03913559|DRUG|Inotuzumab ozogamicin|dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
48446223|NCT03913559|DRUG|Methotrexate|Intrathecal (IT) therapy
48446224|NCT03913559|DRUG|Hydrocortisone|Intrathecal (IT) therapy
48446225|NCT03913559|DRUG|Cytarabine|Intrathecal (IT) therapy
48446226|NCT03913559|DRUG|Diphenhydramine|1 mg/kg (max 50 mg) IV
48446227|NCT03913559|DRUG|Acetaminophen|10 mg/kg (max 650 mg) PO x 1
48446228|NCT03913559|DRUG|Methylprednisolone|1 mg/kg IV x 1
48446229|NCT00731783|DRUG|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
48446230|NCT00731783|DRUG|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
48446231|NCT00731783|BEHAVIORAL|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~* Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~* Use liquid(pour or pump) soaps instead of bar soaps.~* Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~* Do not share personal care items such as razors and brushes.~* Wash all sheets and towels in hot water. Wash sheets every week.~* Use towels and wash cloths only once before washing and do not share."
48446232|NCT00820586|PROCEDURE|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
48446233|NCT01521533|DRUG|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):~* 3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
48098160|NCT04417556|DIAGNOSTIC_TEST|Sleep measurement|Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
48446234|NCT04473807|DRUG|Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation|The hypothesis to be tested is that the intravenous loading regimen followed by oral sotalol administration 4 hours after the conclusion of the IV infusion (every 12 hours thereafter) will result in sotalol peak concentrations at the end of IV loading dose (IV to oral loading) which are comparable to the steady state and maximum QTc seen on Day 3 after the last in-hospital oral dose.
48446235|NCT06370377|OTHER|the Egyptian code of ethical practice|Nurses' adherence to the Egyptian code of ethical practice
48620388|NCT03546959|OTHER|Rehabilitation|Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy
48446236|NCT02088931|BIOLOGICAL|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease \<50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
48446237|NCT02922777|DRUG|BGB324|75 mg/m2 every 21 days
48446238|NCT02922777|DRUG|Docetaxel|75 mg/m2 given IV every 21 days
48278315|NCT00336102|PROCEDURE|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
48446239|NCT02109263|PROCEDURE|saccharose versus breast-feeding|saccharose versus breast-feeding
48446240|NCT04774705|OTHER|SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )|A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.
48446241|NCT04774705|OTHER|Placebo group|For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
48446242|NCT00836576|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
48446243|NCT00836576|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
48446244|NCT01568762|DRUG|VAK694|Intravenous infusion
48446245|NCT01568762|DRUG|VAK694 placebo|Intravenous infusion
48098161|NCT02054247|DEVICE|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
48278316|NCT05152212|BIOLOGICAL|LVGN7409|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
48278317|NCT06092970|DRUG|RBT-1|Intravenous administration
48278318|NCT06092970|DRUG|Placebo|Intravenous administration
48278319|NCT02730559|OTHER|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
48278320|NCT04585685|BEHAVIORAL|Cognitive Processing Therapy|A 12-session cognitive behavioral therapy for posttraumatic stress disorder
48278321|NCT04585685|BEHAVIORAL|Self-Compassion Therapy|A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
48278322|NCT00110305|DRUG|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
48278323|NCT00110305|DRUG|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
48446246|NCT01568762|DRUG|QAX576|Intravenous infusion
48446247|NCT01568762|DRUG|QAX576 placebo|Intravenous infusion
48446248|NCT00082147|PROCEDURE|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
48446249|NCT00834067|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
48446250|NCT00834067|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
48446251|NCT03315247|BEHAVIORAL|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
48446252|NCT00682461|DRUG|Nicotine|Marketed nicotine replacement therapy formulation
48446253|NCT00682461|DRUG|Nicotine|Nicotine prototype
48446254|NCT01838681|DRUG|Placebo|Once daily, tablets, orally
48446255|NCT01838681|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
48446256|NCT01838681|DRUG|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
48446257|NCT01694212|DRUG|Perioperative Diclofenac eye-drops administration|
48446258|NCT01694212|DRUG|placebo|
48620389|NCT03546959|DRUG|Botulinum Toxin|Botulinum toxin injection for upper limb spasticity after stroke
48620390|NCT05296278|DRUG|IBI-323 combined with bevacizumab plus Platinum|IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
48620391|NCT05775653|OTHER|ADAPT program|The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
48278324|NCT00110305|DRUG|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
48278325|NCT00110305|DRUG|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
48446259|NCT03341182|PROCEDURE|Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20\~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
48446260|NCT03341182|PROCEDURE|conventional manner|A portable mirror is located at the side of surgical table and used in this procedure.
48446261|NCT06558981|RADIATION|Radiotherapy|Ppatients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. RAI would be administered as standard care. The treatment window is within 6 months after surgery.
48446262|NCT06558981|OTHER|radioiodine treatment|RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.
48446263|NCT05507580|DRUG|Upadacitinib|Oral tablet
48446264|NCT03354286|BEHAVIORAL|Developmental & Technological Demands|Education and training related to use of CGM in this age group
48446265|NCT03354286|BEHAVIORAL|Distress Reduction|Education and training on reducing distress
48446266|NCT03354286|BEHAVIORAL|Nutrition, Set Point, & C:I Ratio|Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
48446267|NCT03354286|BEHAVIORAL|Hypoglycemia management|Education and training on reducing worries of hypoglycemia
48446268|NCT03354286|BEHAVIORAL|Minimal Intervention|Minimal intervention to simulate standard care - serves as the control group
48446269|NCT05955534|DEVICE|TPUG|Tracheostomy shall utilize any FDA approved device for the performance of percutaneous dilatational tracheostomy. PUG shall be performed using the only FDA-cleared device for ultrasound gastrostomy, the PUMA-G System.
48446270|NCT05955534|PROCEDURE|PEG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
48446271|NCT05955534|PROCEDURE|PRG|Each site will perform the procedures of gastrostomy placement using the devices according to their institutional policy and guidelines.
48446272|NCT04365153|DRUG|Canakinumab Injection 600mg|Subjects will be given one-time intravenous infusion of 600 mg of canakinumab (8 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
48446273|NCT04365153|DRUG|Canakinumab Injection 300mg|Subjects will be given one-time intravenous infusion of 300 mg of canakinumab (4 mg/kg for patients \</= 40 kg) in 250 mL of 5% dextrose infused IV over 2 hours
48446274|NCT04365153|DRUG|Placebos|250 mL of 5% dextrose infused IV over 2 hours
48446275|NCT00061061|BEHAVIORAL|Behavior Therapy|
48446276|NCT06162169|DRUG|JAB-21822|JAB-21822 was administered orally
48446277|NCT06162169|DRUG|Itraconazole|Itraconazole was administered orally
48446278|NCT06162169|DRUG|Omeprazole|Omeprazole was administered orally
48446279|NCT06162169|DRUG|Midazolam , Rosuvastatin calcium and digoxin|Midazolam , Rosuvastatin calcium and digoxin was administered orally
48446280|NCT06162169|DRUG|Rifampicin|Rifampicin was administered orally
48446281|NCT04799314|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy
48446282|NCT03081481|DRUG|PRX302|Single prostate cancer lesion injected with PRX302
48446283|NCT03597243|OTHER|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
48446284|NCT02842632|OTHER|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
48098162|NCT02054247|DEVICE|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
48098163|NCT02054247|DEVICE|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
48278326|NCT00110305|DRUG|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
48278327|NCT02976506|BEHAVIORAL|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
48278328|NCT02976506|BEHAVIORAL|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
48446285|NCT02842632|OTHER|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
48446286|NCT00409162|DEVICE|Eraser TM device, with washing fluid|
48446287|NCT04278261|PROCEDURE|Focal therapy(high-frequency irreversible electroporation)|High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
48446288|NCT04278261|PROCEDURE|laparoscopic radical prostatectomy|Laparoscopic radical prostatectomy
48446289|NCT04421716|DRUG|Ursolic Acid|Ursolic Acid 150mg
48446290|NCT04421716|DRUG|Curcumin|Curcumin 600mg
48446291|NCT02297763|DRUG|quetiapine|"patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
48446292|NCT02297763|DRUG|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
48446293|NCT04533594|BEHAVIORAL|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) over the course of 4 hospice visits (one episode per visit). All four visits will be in person using telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
48446294|NCT06326697|DRUG|Azacitidine|Azacitidine 300 mg Film coated tablets
48446295|NCT06326697|DRUG|Onureg|Azacitidine 300 mg Film coated tablets
48446296|NCT05039112|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
48446297|NCT05039112|DEVICE|Stenfilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism, used as indicated
48446298|NCT00460733|DRUG|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
48446299|NCT00460733|DRUG|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
48446300|NCT00573066|DRUG|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
48446301|NCT03600805|DRUG|Sarilumab SAR153191|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48446302|NCT03600805|DRUG|Sarilumab matching placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48446303|NCT03600805|DRUG|Prednisone|Pharmaceutical form: tablets or capsules Route of administration: oral administration
48446304|NCT03600805|DRUG|Prednisone matching placebo|Pharmaceutical form: capsules Route of administration: oral administration
47928059|NCT02592642|DEVICE|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
48446305|NCT04891562|OTHER|interlimb coordination of the lower limbs and synchronization|4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. The m-ABC2 test, The MBEMA-s, Kids BESTest, interlimb coordination and synchronization investigation (visit 3 and 4)
48446306|NCT06432595|OTHER|Instability resistance training and Traditional resistance training|The 20 intervention actions were divided into three levels (primary, intermediate, and advanced) for instability resistance training and traditional resistance training. Both groups performed training for 60 minutes three times a week. The Swiss ball, BOSU ball, and Wobble boards only provided an unstable surface environment for instability resistance training. The intensity/load was body weight for both training methods.
48446307|NCT00687063|DRUG|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
48446308|NCT03266380|DIAGNOSTIC_TEST|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
48446309|NCT04457284|DRUG|Temozolomide (TMZ)|"TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +"
48446310|NCT04457284|DRUG|Cisplatin|Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
47928060|NCT02592642|DEVICE|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine \[NeuroTrac TENS from Verity Medical Ltd (U.K.)\] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
48446311|NCT04457284|DRUG|Nivolumab|Nivolumab 480 mg Q4W IV infusion Cycle 1 +
48446312|NCT03916393|DRUG|PF-06651600 20 mg|PF-06651600 in four (4) different oral formulations will be administered in different periods.
48446313|NCT03916393|OTHER|Bitrex solution|Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
48446314|NCT04074655|DEVICE|Driving Simulator in a Virtual Reality Environment|Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.
48446315|NCT03331445|DRUG|Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation|Inhaled Nitric Oxide 160ppm balance air
48446316|NCT00231829|DRUG|Celecoxib|
48446317|NCT06475924|DIAGNOSTIC_TEST|Caesarean scar defect evlauation by ultraosund|"Women will be examined in the lithotomy position with an empty bladder. The uterus will be examined in a standardized way excluding causes of abnormal uterine bleeding or pelvic pain (myoma, polyp, pelvic inflammatory disease, adenomyosis).~Upon detection of the SCD, the following will be measured:~In the midsagittal plane: the depth (the vertical distance between the base and apex of the defect), width (the length of the widest gap along the cervicoisthmic canal), residual myometrial thickness (RMT) overlying the defect, and the adjacent myometrial thickness fundal to the defect.~In the transverse plane: the length of the defect.~The uterine position will be classified as anteverted or retroverted.~Clinical symptoms of the patients will be reviewed such as :Postmenstrual spotting, Abnormal uterine bleeding, Pain, Secondary infertility."
48278329|NCT05973409|DEVICE|scleral lens|scleral lens with and without hydra-peg coating
48278330|NCT06253923|DRUG|Amantadine Hydrochloride|MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).
48278331|NCT06253923|DRUG|Placebo|The placebo for this study is 0.9% Sodium Chloride IV Solution.
48278332|NCT03773952|DRUG|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
48278333|NCT03773952|DRUG|Placebo oral capsule|Oral capsules
48278334|NCT02456584|DRUG|DMPA 150|injectable contraceptive
48278335|NCT02456584|DRUG|DMPA 300|injectable contraceptive
48278336|NCT02456584|DRUG|DMPA 104|injectable contraceptive
48278337|NCT00004373|DRUG|alprazolam|
48278338|NCT01167296|DEVICE|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
48278339|NCT04558502|DRUG|Minocycline hydrochloride capsule|Antibiotic for H. pylori eradication
48446318|NCT03598595|DRUG|Docetaxel|Given IV
48278340|NCT04558502|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
48278341|NCT04558502|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
48278342|NCT04558502|DRUG|colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
48278343|NCT04558502|DRUG|esomeprazole|Proton pump inhibitor
48278344|NCT06184438|DRUG|Micronized purified flavonoid fraction(Daflon 1000mg)|Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day to day 7
48278345|NCT06184438|DRUG|Placebo|Received placebo after surgery.
48446319|NCT03598595|DRUG|Gemcitabine|Given IV
48446320|NCT03598595|DRUG|Hydroxychloroquine|Given PO
48446321|NCT01468272|DRUG|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
48446322|NCT01468272|DRUG|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
48446323|NCT04548635|DEVICE|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
48446324|NCT03957447|OTHER|thermotherapy (application of heat): This part of the trial is on hold due to the Covid19-pandemia|Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
48446325|NCT00459420|DRUG|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
48446326|NCT00459420|DRUG|placebo|placebo
48446327|NCT00652977|PROCEDURE|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
48278346|NCT04917874|BIOLOGICAL|Open Label Topical Beremagene Geperpavec (B-VEC)|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
48278347|NCT00813748|DRUG|Xolair|
48278348|NCT02893267|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
48278349|NCT02893267|OTHER|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
48446328|NCT00652977|PROCEDURE|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
48446329|NCT04354285|OTHER|Observational|Observational
48446330|NCT01157130|OTHER|Exercise Regimen|Exercise instruction
48446331|NCT04742543|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted display|"For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant"
48446332|NCT02086214|DEVICE|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
48446333|NCT02086214|DEVICE|Control|LYCRA® non-compressive sleeve initially used in burn therapy : \< 5 mmHg.
48446334|NCT02956460|DEVICE|fanfilcon A|contact lens
48446335|NCT02956460|DEVICE|senofilcon A|contact lens
48446336|NCT02046746|OTHER|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
48446337|NCT02284867|OTHER|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
48446338|NCT05562622|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
48446339|NCT05562622|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
48446340|NCT00543205|DRUG|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
48446341|NCT00968812|DRUG|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
48446342|NCT00968812|DRUG|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
48446343|NCT00968812|DRUG|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
48446344|NCT03313323|BIOLOGICAL|89Zirconium-labeled ipilimumab|Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
48446345|NCT00023361|DRUG|Rifabutin|
48446346|NCT00440518|DRUG|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
48446347|NCT00440518|OTHER|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
48446348|NCT00440518|DRUG|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
48446349|NCT00439491|BEHAVIORAL|Hypocaloric diet|
48446350|NCT01646554|DRUG|Modified FOLFOX6|
48446351|NCT01646554|BIOLOGICAL|Aflibercept|Targeted therapy
48446352|NCT01646554|PROCEDURE|Surgery|
48446353|NCT00589186|BIOLOGICAL|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
48446354|NCT00589186|DRUG|celecoxib|
48446355|NCT00589186|OTHER|flow cytometry|
48446356|NCT00589186|OTHER|immunoenzyme technique|
48446357|NCT00589186|OTHER|laboratory biomarker analysis|
48446358|NCT05095181|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
48446359|NCT02598063|DRUG|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
48446360|NCT02598063|DRUG|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
48446361|NCT02598063|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
48446362|NCT03911258|PROCEDURE|nasopharyngeal swab versus nasal wash|The type of procedure will be determine according to patient collaboration
48446363|NCT04269642|DRUG|PT320 2.0mg Placebo|PT320 2.0mg Placebo
48446364|NCT04269642|DRUG|PT320 2.0 mg|Exenatide slowly released formulation
48446365|NCT04269642|DRUG|PT320 2.5 mg|Exenatide slowly released formulation
48446366|NCT05710783|BIOLOGICAL|AVX-COVID/12|Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
48446367|NCT05710783|BIOLOGICAL|ChAdOx-1-S[recombinant]|Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
48446368|NCT01881165|DRUG|Cranberry|
48446369|NCT01881165|DRUG|Placebo|
48446370|NCT01188135|BEHAVIORAL|Interactive voice messaging or Interactive voice messaging + psycho ed materials|Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
48446371|NCT01065610|DRUG|Oxytocin|
48446372|NCT01065610|DRUG|Placebo|
48446373|NCT00840476|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
48446374|NCT00840476|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
48446375|NCT03919058|OTHER|Baseline activity (control regime)|This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
48446376|NCT03919058|OTHER|Increased sitting time (sit regime)|Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
48446377|NCT03919058|OTHER|Non-exercise physical activity (sit less regime)|Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of \> 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
48446378|NCT03919058|OTHER|Structured exercise (exercise regime)|One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
48446379|NCT04757220|OTHER|Cognitive tasks with EEG recording|questionnaires and cognitives tasks
48446380|NCT02952456|OTHER|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
48446381|NCT02924363|DIAGNOSTIC_TEST|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
48446382|NCT02924363|DIAGNOSTIC_TEST|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
48446383|NCT04057872|PROCEDURE|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
48446384|NCT06337721|BEHAVIORAL|SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction)|This behavioral group intervention will consist of multiple group sessions to reduce AUDs and alcohol-related harms in Pacific Islander young adults. It will infuse culturally resonant narratives, language, and elements into existing evidence-based strategies.
48446385|NCT05163743|DIETARY_SUPPLEMENT|Low Calorie Ketogenic Diet|The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
48446386|NCT03340376|DRUG|Atezolizumab|atezolizumab
48446387|NCT03340376|DRUG|Doxorubicin|Doxorubicin
48446388|NCT01683474|DEVICE|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
48446389|NCT00404105|PROCEDURE|PRK|
48446390|NCT00404105|PROCEDURE|LASIK|
48446391|NCT00836004|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
48446392|NCT00836004|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
48446393|NCT04737707|OTHER|Dialectical Behavior Therapy (DBT)|Dialectical Behavior Therapy (DBT)
48446394|NCT03887910|OTHER|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
48446395|NCT03887910|OTHER|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
48446396|NCT03161158|DEVICE|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
48446397|NCT03161158|OTHER|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
47928061|NCT02592642|DEVICE|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
47928062|NCT02592642|DEVICE|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
48446398|NCT06380023|DEVICE|Enclosure barrier|Surgical mask \& Enclosure tent compared with open suction
48446399|NCT00175487|PROCEDURE|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
48446400|NCT03247933|DEVICE|Telemedicine: Maintenance Respiratory Rehabilitation|"Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed."
48446401|NCT04788823|DRUG|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
48446402|NCT00833586|DRUG|Terbinafine HCl 250mg tablets|1 x 250 mg
48446403|NCT00833586|DRUG|Lamisil® 250 mg Tablets|1 x 250 mg
48446404|NCT01499628|BEHAVIORAL|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
48446405|NCT01499628|BEHAVIORAL|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
48446406|NCT01499628|BEHAVIORAL|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
48446407|NCT05880056|DRUG|Nerkardou (5 mg) & (10 mg)|Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
48446408|NCT03081403|DEVICE|Quantitative Sensory Testing|Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
48446409|NCT02553564|OTHER|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~1. The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~2. Determination of the participants's estimated dry weight (EDW).~3. The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~4. Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~5. Write new dialysis orders.~6. Dialysis Access- review access and determine any changes required in treatment"
48446410|NCT00043394|DRUG|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
48446411|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
48446412|NCT00043394|DRUG|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
48446413|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
48446414|NCT00043394|DRUG|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
48446415|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
48446416|NCT00043394|DRUG|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
48446417|NCT00043394|DRUG|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
48446418|NCT00468455|PROCEDURE|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
47928063|NCT01138176|PROCEDURE|Cooling|Reduction of rectal temperature to 33.5 C
48446419|NCT00836056|DRUG|Clindamycin 300 mg capsule|1 x 300 mg
47928064|NCT00345644|DRUG|risedronate|risedronate sodium 35 mg tablets (once a week dose)
48446420|NCT00836056|DRUG|Cleocin HCl 300 mg capsules|1 x 300 mg
48446421|NCT06560437|OTHER|Chinese Jingjin Manual Therapy|Chinese Jingjin therapy is a form of manual therapy that utilizes the principles of Chinese Jingjin Theory (also known as Chinese Sinew Channel Theory) to alleviate nodular lesions in sinew channels caused by Jingjin injuries and to realign skeletal joints. Chinese Jingjin manual therapy is divided into three major parts: fascia manipulation, bone setting manipulation, and finishing techniques. The operation takes about 30 minutes, and there is one treatment every other day, three treatments per week, and five consecutive weeks of treatment.
48446422|NCT02537093|BEHAVIORAL|Psychiatric Consultation|
48446423|NCT04327128|DEVICE|LifePod|The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
48446424|NCT00429286|BEHAVIORAL|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
48446425|NCT03575585|BEHAVIORAL|BEST assessment only|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
48446426|NCT03575585|BEHAVIORAL|BEST assessment plus feedback report|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
47928065|NCT00345644|DRUG|risedronate placebo|placebo for risedronate tablets (once a week dose)
47928066|NCT01486043|DRUG|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
48098164|NCT04815057|BEHAVIORAL|Wellness Education|The wellness education given to fifth grade students and the quality of life, its effect on physical activity status
48446427|NCT03575585|BEHAVIORAL|Standard Counselor Training|2 hours of training on how to use the BEST patient feedback report
48446428|NCT03575585|BEHAVIORAL|Enhanced Counselor Training|Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
48446429|NCT04579770|DIETARY_SUPPLEMENT|Ketone ester|75g ketone ester in the form of a drink \[96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)\] will be provided.
48446430|NCT04579770|OTHER|Sodium bicarbonate|Sodium bicarbonate - widely accessible food ingredient will be provided.
48446431|NCT04579770|OTHER|Placebo|Placebo
48446432|NCT01424124|DRUG|YHD001 dose level 1|Tablet, three times daily / 8 weeks
48446433|NCT01424124|DRUG|YHD001 dose level 2|Tablet, three times daily / 8 weeks
48446434|NCT01424124|DRUG|Singulair|Tablet, one times daily / 8 weeks
48446435|NCT01424124|DRUG|Placebo|Tablet, one times daily / 7 days
48446436|NCT00681798|DRUG|Vandetanib|100mg/300mg
48446437|NCT05322967|OTHER|Time of ordinary antihypertensive medication intake|Time of ordinary antihypertensive medication intake
48446438|NCT04466553|DEVICE|NICO BrainPath™ System|Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
48446439|NCT00243425|PROCEDURE|Standard Quality Improvement|
48446440|NCT00243425|PROCEDURE|Patient-centered Intervention|
48446441|NCT01367145|DRUG|OMACOR|4 capsules OMACOR 1g per day
48446442|NCT01367145|DRUG|Placebo|4 capsules placebo per day
48446443|NCT04977739|DIAGNOSTIC_TEST|No intervention|No intervention
48446444|NCT06161350|COMBINATION_PRODUCT|Structured multi-disciplinary approach|Since 2010, a structured multidisciplinary team was formed to evaluate the child medically, support its nutrition, teach, treat and educate the children and parents and guide them through the process to obtain a normal and independent feeding behavior. The multidisciplinary team must have special expertise regarding digestive and nutritional as well as sensory and oral motor problems in children requiring artificial nutrition. The team must at least consist of a pediatrician, a dietician with experience in artificial nutrition in children, a speech therapist and/or physical therapist and a psychologist or orthopedagogue. The team should also be able to rely on a nurse with experience in artificial nutrition, a social assistant and a secretary.
48446445|NCT02814877|OTHER|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
48446446|NCT04528784|DEVICE|Transcutaneous tibial nerve stimulation|Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
48446447|NCT00819754|DRUG|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
48446448|NCT02322983|BEHAVIORAL|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
48446449|NCT02703194|DRUG|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
48446450|NCT02703194|DRUG|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
48446451|NCT01450189|BEHAVIORAL|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
48446452|NCT01450189|BEHAVIORAL|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
48446453|NCT01450189|DRUG|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
48446454|NCT01450189|DRUG|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
48446455|NCT06033274|DEVICE|Transcatheter Tricuspid Valve Replacement|All patients undergoing Transcatheter Tricuspid Valve Replacement for native tricuspid valve disease
48446456|NCT05460715|DEVICE|Quadra P anteverted|"* Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery.~* Assessment of functional recovery by gait analysis study~* Collect the rate of complications throughout the course of the study"
48446457|NCT03166345|OTHER|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
48446458|NCT04254484|BEHAVIORAL|SIESTA Rehab Education|Staff nurses will be trained on how to improve sleep in stroke patients in the acute rehabilitation setting.
48446459|NCT04254484|DIAGNOSTIC_TEST|ApneaLink|Stroke patients on the SIESTA Rehab unit will be screened for sleep disordered breathing using ApneaLink monitors. Results will be interpreted by a sleep specialist who will then advise the clinical team at SRALab.
48446460|NCT06559033|BIOLOGICAL|Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS|Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.
48446461|NCT04685486|OTHER|Virtual Reality|Immersive and interactive game played through a portable head-mounted display as a distraction mechanism
48446462|NCT04813692|PROCEDURE|Surgical repair|Surgical repair of post-infarction LVFWR or VSR
48446463|NCT04813692|PROCEDURE|Percutaneous treatment|Percutaneous closure of post-infarction VSR (or treatment for LVFWR)
48446464|NCT04813692|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement for post-infarction PMR
48446465|NCT06562049|RADIATION|musculoskeletal ultrasound|musculoskeletal ultrasound on both hands
48446466|NCT03362710|DIAGNOSTIC_TEST|simplified tools|"1. Skin temperature on the back of the foot with infra-red thermometry~2. Toe saturometry~3. ABI with an automatic sphygmomanometry~4. Skin Recoloration time at the foot"
48446467|NCT05239754|OTHER|Primary Services|Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.
48446468|NCT00287131|PROCEDURE|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
48446469|NCT05760144|DRUG|DMPA|The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
48446470|NCT05760144|DRUG|Etonogestrel implant|The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
48446471|NCT04932863|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
48446472|NCT05119946|BEHAVIORAL|Suicide prevention video|The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.
48446473|NCT05119946|OTHER|Standard suicide treatment|The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
48446474|NCT00834743|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
48446475|NCT00834743|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
48446476|NCT04832412|DIETARY_SUPPLEMENT|BrainPhyt|BrainPhyt low dose supplementation during 6 months
48446477|NCT04832412|DIETARY_SUPPLEMENT|100 % Maltodextrin|100 % Maltodextrin
48446478|NCT02975622|PROCEDURE|Central venous catheterization|Ultrasound guided central venous catheterization
48446479|NCT04048096|DIETARY_SUPPLEMENT|Krill Oil|Aker Biomarine Superba Krill Oil
48446480|NCT04048096|DIETARY_SUPPLEMENT|Placebo|Mixed vegetable oil
48446481|NCT05174741|OTHER|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT \*3 sets/session\*TD Walk (10-15 minutes) \* BD
48446482|NCT05174741|OTHER|Aerobic training Group|"Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day"
48446483|NCT00012974|BEHAVIORAL|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
48446484|NCT00012974|PROCEDURE|Provider education, computer reminders, nurse case management|
48446485|NCT00940693|DRUG|duloxetine|60 mg capsule once per day for 6 weeks
48446486|NCT00940693|DRUG|placebo|one capsule of placebo taken one a day for 6 weeks
48446487|NCT03422653|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
48446488|NCT03422653|DRUG|Placebo|IV medication delivered three times/week
48446489|NCT01593852|RADIATION|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
48446490|NCT01593852|RADIATION|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
48446491|NCT03453476|DEVICE|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
48446492|NCT01549353|BEHAVIORAL|gum chewing|
48446493|NCT06560814|DRUG|Cabergoline plus timed intercourse|Cabergoline 0.5 mg tab orally twice weekly (fridays and tuesdays) after meal at night for 24 weeks plus intercourse timed with LH kit
48446494|NCT06560814|DRUG|Dydrogesterone plus timed intercourse|Dydrogesterone 10 mg tab orally twice daily from day 5 to day 25 of menstrual cycle for 24 weeks plus intercourse timed with LH kit
48446495|NCT03763318|BIOLOGICAL|EQ001|Itolizumab \[Bmab 600\])
48446496|NCT03763318|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
48446497|NCT05183191|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|Participants arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants drive on a designated circuit using a driving simulator. Initially, a euglycaemic state (5.0-8.0 mmol/L) is kept stable and blood glucose is then progressively declined targeting at a level between 3.0-3.5 mmol/L by administering insulin. Blood glucose is kept stable in the hypoglycaemic range for 30 minutes. Thereafter, blood glucose is raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, the investigators analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression are recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively. Participants are blinded to the blood glucose values during the procedure and have to rate their symptoms and their driving performance on a 0-6 scale every 15 minutes.
48446498|NCT03562962|BEHAVIORAL|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle \& Linnerooth, 2000; Kohlenberg \& Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg \& Tsai, 1991).
48446499|NCT01816997|DRUG|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
48446500|NCT01816997|DRUG|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
48446501|NCT01816997|DRUG|Control|placebo
48446502|NCT02186691|OTHER|MRI|
48446503|NCT05239832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
48446504|NCT00011960|DRUG|cisplatin|
48446505|NCT00011960|DRUG|paclitaxel|
48446506|NCT00011960|PROCEDURE|adjuvant therapy|
48446507|NCT00011960|RADIATION|radiation therapy|
48446508|NCT00426647|DRUG|Buprenorphine|
48446509|NCT00426647|DRUG|Tramadol|
48446510|NCT00361751|DRUG|fenofibrate|
48446511|NCT00272779|DRUG|ATV|300mg Oral capsules for 96 weeks
48446512|NCT00272779|DRUG|RTV|100mg Oral Capsules for 96 weeks
48446513|NCT00272779|DRUG|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
48446514|NCT00272779|DRUG|LPV|400 mg (3 133mg capsules) BID for 96 weeks
48446515|NCT05315726|OTHER|Dynamometer|Measurement of elbow/wrist spasticity
48446516|NCT05315726|OTHER|Muscle vibrations|1 session of 10 minutes
48446517|NCT05315726|OTHER|Muscle vibrations|3 times/week for 6 weeks
48278350|NCT02893267|OTHER|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
48446518|NCT05315726|OTHER|Placebo muscle vibration|3 times/week for 6 weeks
48098165|NCT06629246|DRUG|Conventional heart failure treatment|Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
48446519|NCT06035315|DIETARY_SUPPLEMENT|Multiple Micronutrients during pregnancy|Pregnant women examine since 8 weeks gestation are being followed until delivery; are given additional micronutrients (Complete multi micronutrients-Calcium-Vitamin D-DHA); and perform ultrasound examinations each trimester and additional laboratory examination (Vitamin D level-Lipid profile-Zinc)
48446520|NCT04533269|OTHER|Arnica montana, Ledum palustre|Homeopathic
48446521|NCT05867862|OTHER|Test|"A dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist.~If dental treatments are needed, they will be done at the same time, or they will be programmed for another time at the center of dental care (CSD).~Due to the fact that most patient live far away from Nantes and the hospital, teleconsultation for patient in the test groups will happen every 2 months"
48446522|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
48446523|NCT02291250|DIETARY_SUPPLEMENT|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
48446524|NCT02291250|DIETARY_SUPPLEMENT|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
48446525|NCT02291250|DIETARY_SUPPLEMENT|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
48446526|NCT03306394|DRUG|Trifluridine/Tipiracil hydrochloride (S95005)|
48446527|NCT05596435|OTHER|No intervention|No intervention
48278351|NCT02893267|DEVICE|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
48446528|NCT02158741|BEHAVIORAL|Home Visits and Lifestyle Education Support|
48446529|NCT04924660|DRUG|TXA127|TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
48446530|NCT04924660|DRUG|TRV027|TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
48446531|NCT04924660|DRUG|Placebo|"NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses."
48446532|NCT04924660|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
48446533|NCT05750394|PROCEDURE|Uterine layers closed|Uterus closed with 1, 2 or 3 layers
48098166|NCT06629246|DRUG|Pogejiuxin decoction combined with conventional heart failure treatment|In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
48446534|NCT05750394|DEVICE|Suture Type|Barbed or smooth
48446535|NCT05750394|PROCEDURE|Endometrium|Included or excluded
48446536|NCT04882163|DRUG|CC-220|CC-220
48446537|NCT04882163|DRUG|Polatuzumab vedotin|Polatuzumab vedotin
48446538|NCT04882163|DRUG|Rituximab|Rituximab
48446539|NCT04882163|DRUG|Tafasitamab|Tafasitamab
48446540|NCT04882163|DRUG|Gemcitabine|Gemcitabine
48446541|NCT04882163|DRUG|Cisplatin|Cisplatin
48446542|NCT04882163|DRUG|Dexamethasone|Dexamethasone
48446543|NCT04882163|DRUG|Bendamustine|Bendamustine
48446544|NCT04882163|DRUG|Lenalidomide|Lenalidomide
48446545|NCT03696745|OTHER|autologous umbilical cord blood stem cells|autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation
48446546|NCT03696745|DRUG|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
48446547|NCT05956561|OTHER|dental implants were placed for all cases while assessing vitamin D levels|vitamin D assessment with measuring implant stability and clinical finding of early failure
48446548|NCT02163837|DRUG|rifaximine|
47928067|NCT06288594|BEHAVIORAL|Application Plus Online Therapist Support Group|Participants in the therapist-supported group will receive weekly 20-30 minute online sessions for five weeks, with content based on a semi-structured manual. After 80% completion of the psychoeducation module, the coping module becomes available, and similarly, the exposure module follows. These sessions will be conducted in adherence to a structured manual, with the therapist introducing the module of the week, guiding through exercises, assigning homework, and reviewing the previous assignments. Sessions include module introductions, exercises, homework assignments, and application use review. Feedback and PCL-5 scores guide post-session recommendations. A random 40% of sessions will undergo fidelity checks by doctoral-level psychologists.
48446549|NCT04036539|PROCEDURE|Placement of the mini-implant and verticalization|an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
48446550|NCT04518956|PROCEDURE|inter maxillary fixation with shockwave therapy|Shockwave therapy device which give 1500-4000 pulses per session with or without anesthesia, and the treatment session takes approximately 5-10 minutes at the day after surgery.
48446551|NCT04518956|PROCEDURE|Inter maxillary fixation and exposure to low intensity pulsed|Low-intensity pulsed ultra sound was applied three times weekly for six weeks from the second day after surgery.
48446552|NCT04518956|PROCEDURE|Inter maxillary fixation|Closed reduction will be done. Intermaxillary fixation (IMF) will be secured after proper reduction of the fractured segments to assure proper occlusion using upper and lower arch bars or eyelet wires for six weeks.
48446553|NCT04360161|DEVICE|swept-source optical coherence tomography|Aswe pt-source OCT (CASIA SS-1000; Tomey Corporation, Nagoya, Japan), which is specifically designed for anterior segment imaging using a 1310 nm wavelength with a scan speed of 30,000 A-scans per second and an axial resolution of \<10 μm.
48446554|NCT00027664|BIOLOGICAL|recombinant interferon alfa|
48446555|NCT00027664|DRUG|thalidomide|
48446556|NCT03853954|DEVICE|Methoxyflurane|Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
48446557|NCT03827707|BEHAVIORAL|Noise|Noise applied via headphones during 60 min after meal ingestion
48446558|NCT03827707|BEHAVIORAL|Silence|Headphones without sound applied during 60 min after meal ingestion
48446559|NCT03113877|OTHER|Autonomic Dysfunction Testing|The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
48446560|NCT01887691|DRUG|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
48446561|NCT00727480|PROCEDURE|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
48446562|NCT04009486|DEVICE|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
48446563|NCT00564408|DRUG|Carbachol|3 microgram per kg bodyweight infused intravenously
48446564|NCT06201650|DIAGNOSTIC_TEST|Neurofilament light chain|Neurofilament light chain as biomarker for amyotrophic lateral sclerosis
48446565|NCT00681161|OTHER|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
48446566|NCT02305732|BIOLOGICAL|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
48446567|NCT05649683|BIOLOGICAL|Evaluation of cytokine production|The patient will have samples at initiation of treatment (J0), after treatments 1 and 2 (S6), after the first radiological assessment at S11 and/or the progression of the disease and/or occurrence of a grade 3-4 adverse event
48446568|NCT03266393|DRUG|Envarsus XR|Once daily sustained-release tacrolimus
48446569|NCT03266393|DRUG|Tacrolimus|Twice daily immediate-release tacrolimus
48446570|NCT01534663|DRUG|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
48446571|NCT01534663|DRUG|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
48446572|NCT05820893|DRUG|Resistant Potato Starch|MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
48446573|NCT03491579|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
48446574|NCT03491579|DRUG|Cladribine|Standard chemotherapy
48278352|NCT03206502|DEVICE|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
48278353|NCT03871491|DRUG|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
48446575|NCT03491579|DRUG|Cytarabine|Standard chemotherapy
48278354|NCT03871491|DRUG|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
48278355|NCT02134886|DRUG|Erlotinib Hydrochloride|Given PO
48278356|NCT02134886|OTHER|Laboratory Biomarker Analysis|Correlative studies
48278357|NCT02134886|OTHER|Pharmacological Study|Correlative studies
48278358|NCT02134886|OTHER|Quality-of-Life Assessment|Ancillary studies
48278359|NCT04234217|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
48278360|NCT04234217|OTHER|Niacin|Suppression of lipolysis by niacin infusion
48278361|NCT05189899|DEVICE|Virtual reality|One hemodialysis session with virtual reality and one other without it
48278362|NCT05718401|DEVICE|NMR|nuclear magnetic resonance in genomics
48278363|NCT03987945|DEVICE|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
48278364|NCT00839631|DRUG|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
48278365|NCT04756544|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175|probiotic
48278366|NCT04756544|OTHER|placebo|placebo
48278367|NCT01453504|DRUG|DHAP|Dexamethasone, Cytarabine, Cisplatin
48278368|NCT01453504|DRUG|Everolimus|
48278369|NCT03985176|DEVICE|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
48278370|NCT03985176|PROCEDURE|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
48278371|NCT03985176|PROCEDURE|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
48278372|NCT04178590|DRUG|SRP + Injectable Platelet-Rich Fibrin|Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
48278373|NCT04178590|DRUG|SRP + placebo|Saline application during scaling and root planing
48278374|NCT04227691|DEVICE|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
48278375|NCT04227691|DEVICE|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
48446576|NCT05405881|OTHER|Proprioception measurement tool|No intervention, as it is a psychometric properties study
48446577|NCT01741948|DRUG|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
48446578|NCT02386618|PROCEDURE|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN \< 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN \> 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN \> 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
48446579|NCT01341730|DRUG|Atorvastatin 20mg|20 mg QD for 3 months
48446580|NCT01341730|DRUG|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
48446581|NCT03916861|DEVICE|Bioelectrical Impedance Analysis|We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.
48446582|NCT03916861|PROCEDURE|Physician-guided|This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
48446583|NCT03531021|BEHAVIORAL|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
48278376|NCT03717740|DRUG|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
48278377|NCT03717740|DRUG|Placebo|Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
48278378|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
48278379|NCT04222517|PROCEDURE|Incisional hernia repair by the mesh implant in sublay retromusuclar position with using a local hemostatic Hemoblock|"Incisional hernia repair using mesh prolene implant in sublay retromuscular position. Dissect the posterior rectus sheets, suture them continuously, formed a retromuscular space in which the standard prolene mesh implant is installed. Perform hemostasis. Install the drainage tube into the retromuscular space. Used a local hemostatic Hemoblock 15 ml in this space.~After that, the anterior rectus sheets were sutured, hemostasis was performed, a drainage tube was installed in the subcutaneous tissue. Used a local hemostatic Hemoblock 15 ml in subcutaneus space. Drainage tubes were connected to the UnoVac vacuum aspiration system (Unomedical, Denmark)."
48278380|NCT02758964|OTHER|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
48278381|NCT06335121|BEHAVIORAL|POWER Up strategies -|Clinics will implement adapted POWER Up intervention strategies when a patient is flagged as PrEP eligible.
48278382|NCT06102044|DIETARY_SUPPLEMENT|Zinc Supplements|Dispersible zinc sulfate tablets
48278383|NCT06102044|DIETARY_SUPPLEMENT|Placebo Supplements|Dispersible placebo tablets
48278384|NCT06144008|BEHAVIORAL|Answering questionnaire|A questionnaires for each group has been developped and will be distributed for voluntary and anonymous completion.
48278385|NCT03136939|OTHER|No intervention|No intervention
48278386|NCT00792779|DRUG|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
48278387|NCT06337396|DIAGNOSTIC_TEST|WGS and transcriptome analysis|In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways
48278388|NCT00321516|DRUG|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
48278389|NCT02882607|BEHAVIORAL|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
48278390|NCT06564454|OTHER|No intervention|Assessment of knowledge, attitude and practice of green Dentistry
48278391|NCT05646056|DEVICE|Software|Observation only
48278392|NCT06150157|DRUG|JNJ-88549968|JNJ-88549968 will be administered.
48278393|NCT02811705|OTHER|Quality of life|Quality of life
48278394|NCT02617355|DEVICE|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
48620392|NCT05775653|OTHER|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
48620393|NCT03120793|DEVICE|Esophageal balloon catheter|Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
48278395|NCT02617355|DEVICE|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
48278396|NCT02617355|DEVICE|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
48620394|NCT00351247|PROCEDURE|Postconditioning|
48620395|NCT01050153|DRUG|Dalteparin sodium|Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
48446584|NCT05063903|OTHER|Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition|"Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters"
48446585|NCT05422521|OTHER|blood samples and 18FDG PET-CT exams|"* 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~* blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)"
48446586|NCT00084526|PROCEDURE|computed tomography|
48446587|NCT00084526|PROCEDURE|ultrasound imaging|
48446588|NCT00080951|DRUG|fluorouracil|
48446589|NCT00080951|DRUG|irinotecan hydrochloride|
48446590|NCT00080951|DRUG|leucovorin calcium|
48278397|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
48278398|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
48278399|NCT05814445|OTHER|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
48278400|NCT05814445|OTHER|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
48278401|NCT06084806|DRUG|[18F]F-ARAG PET|Two imaging sessions
48278402|NCT00009672|DRUG|Nortriptyline|
48278403|NCT00009672|DRUG|Morphine|
48278404|NCT06217250|PROCEDURE|Traditional EMR|Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.Nevertheless, this technique is associated with the emergence of serious adverse events (SAEs), including delayed bleeding (PPB), electrocautery-induced post-polipectomy syndrome (PPS), and perforation(4).
48278405|NCT06217250|PROCEDURE|"the cold snare (CO), underwater technique (W), and the use of submucosal lift (L) in both study arms"|"The cold-EMR technique, as opposed to the conventional approach, employs a specialized snare that enables tissue transection without the need for electrical current, particularly in appropriately selected lesions. This approach yields the same efficacy outcome as the conventional procedure but offers the advantage of reducing the risks associated with polypectomy, which are often secondary to the use of diathermic current. Subsequently, the lesion fragments are retrieved for histological examination. Furthermore, the use of underwater setting, as demonstrated for hot EMR, could improve the effectiveness of cold-EMR."
48278406|NCT05373238|PROCEDURE|Early discharge|Early discharge
48278407|NCT04766853|DRUG|Dexamethasone|Dexamethasone 5mg/ml
48446591|NCT00080951|DRUG|oxaliplatin|
48278408|NCT04766853|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
48446592|NCT06462547|DRUG|INZ-701|INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
48278409|NCT01350869|DEVICE|Xience|Patients with Xience
48446593|NCT01654458|BEHAVIORAL|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
48446594|NCT03429959|DEVICE|SOCKNLEG|Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking
48278410|NCT03469076|OTHER|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
48278411|NCT06321575|DEVICE|Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)|Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
48278412|NCT06090071|DEVICE|LaseMD Laser|The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
48278413|NCT06090071|DEVICE|Sciton Laser|The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
48278414|NCT06090071|DRUG|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
48446595|NCT03429959|DEVICE|SIGVARIS Cotton|SIGVARIS Cotton
48446596|NCT02184260|DRUG|Metamizole|
48446597|NCT02184260|DRUG|Placebo|
48446598|NCT00085293|DRUG|Decitabine|Starting dose 6 mg/m\^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
48446599|NCT00085293|RADIATION|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
48446600|NCT00085293|BIOLOGICAL|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
48446601|NCT00085293|RADIATION|Fludeoxyglucose F 18|Optional correlative studies
48446602|NCT00085293|PROCEDURE|Positron emission tomography|Optional correlative studies
48446603|NCT06558669|OTHER|Fresh Sugarcane juice|Fresh sugarcane juice in different doses will be given to liver patients for 90 days
48446604|NCT03290326|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
48446605|NCT04306133|PROCEDURE|PENG block|After performing spinal anesthesia, PENG block with 20 mL of 0.375 % Ropivacaine will be executed as described by Giron-Arongo et al with a low frequency curvilinear probe. A 22G 80 mm needle (Stimuplex Ultra 360, Braun ) will be used.
48446606|NCT04306133|PROCEDURE|Wound Infiltration|At the end of operation, the surgeon will perform wound infiltration with 20 mL of 0.375 % Ropivacaine.
48446607|NCT04599998|DIAGNOSTIC_TEST|spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire|Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
48446608|NCT04011917|BEHAVIORAL|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
48446609|NCT04226027|BEHAVIORAL|T2.coach|"T2.coach is a smartphone app for low-burden capture of diet and blood glucose (BG) levels and for reviewing past records, integrated with FitBit for captured of physical activity and sleep. All captured data are sent to the computational inference engine that uses machine learning methods and expert system to formulate personalized behavioral goals. Examples of behavioral goals include the following: For high carbohydrate breakfasts, reduce your carbs to be about 1 carb choice. Examples of 1 carb choice are 1 slice of whole wheat toast, 1 cup of oatmeal, or 1 apple. The T2.coach chatbot companion uses text messages to help individuals set goals that are consistent with evidence based guidelines for diabetes self-management, inferences on data captured with T2.coach, and their own preferences, as well as send individuals goal reminders and prompts for reflection on goal achievement."
48446610|NCT03465761|DEVICE|ExAblate|Bilateral side treatment of Essential Tremor
48446611|NCT06216561|DRUG|CRS-HIPEC + LSTA1|LSTA1 given with hyperthermic intraperitoneal chemotherapy (HIPEC) at time of cytoreductive surgery (CRS)
48446612|NCT06216561|PROCEDURE|CRS-HIPEC alone|Hyperthermic intraperitoneal chemotherapy (HIPEC) alone (without LSTA1) at time of cytoreductive surgery (CRS)
48446613|NCT05300022|OTHER|TeKnO T1D: Parents|app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
48446614|NCT06068530|DRUG|DHA/piperaquine and a SLD-PQ|Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.
48620396|NCT01050153|DRUG|Dalteparin sodium/aspirin|Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
47928068|NCT06288594|BEHAVIORAL|Application Only Group|"Participants allocated to this group will have access to the TraumaRelief mobile application over a five-week period, with the exception of the online module component. The application's deployment strategy ensures a structured progression through its features: participants will gain access to the subsequent modules only after completing 80% of the preceding module. Initially, they will engage with the psychoeducation module; upon completion of at least 80% of this module, the coping with symptoms module will become available. Similarly, successful engagement with 80% of the coping module will unlock the imaginary exposure module. This sequential module access is designed to reinforce the acquisition of knowledge and skills in a stepwise manner, paralleling the structure provided to the TraumaRelief Mobile Application with Therapist Support group, yet without the additional therapist interaction."
47928069|NCT01143740|DRUG|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
48278415|NCT01536444|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
48278416|NCT05900115|BEHAVIORAL|Media Ready Parent|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
48278417|NCT05900115|BEHAVIORAL|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
48278418|NCT02920125|DRUG|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
48278419|NCT02920125|COMBINATION_PRODUCT|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
48278420|NCT02920125|OTHER|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
48278421|NCT04318392|OTHER|Breath Analysis|Breath analysis using the ReCIVA device will take place during each study visit.
48278422|NCT04318392|OTHER|Pulmonary Function Tests|Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.
48278423|NCT04318392|OTHER|Blood sampling and storage for genetic analysis|Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.
48278424|NCT04318392|OTHER|Blood sampling and storage of plasma for metabolomic analysis|Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.
48446615|NCT06068530|BIOLOGICAL|Study vaccine R21/Matrix-M™|The mixing prior to administration strategy will involve withdrawal of 0.5 mL antigen from one vial of R21 Malaria vaccine and adding it to Matrix-M1 vial. 0.5 mL of R21 antigen shall be withdrawn from another vial of R21 Malaria vaccine and be added to the same Matrix-M1 vial. The total volume in Matrix-M1 vial will be 1.5 mL. After addition the content will be mixed gently, and 0.75 mL of the mixture will be withdrawn and administered to participants. Each dose of 0.75mL (after mixing of R21 with Matrix-M1) will contain 10 µg of R21 and 50 µg for participants 14 years and older. In children up to 14 years a 5 μg will be used.
48446616|NCT00859872|DRUG|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
48446617|NCT00859872|DRUG|haloperidol|haloperidol IM injection (5-20mg/d)
48098167|NCT06226974|OTHER|Static Stretching|"* Shoulder extension - shoulder extension with the hand resting on a door;~* Doorway stretch - horizontal abduction with the shoulder in 90º of abduction, the elbow in 90º of flexion and the forearm leaning against a door;~* Shoulder flexion - arms above the head against a wall;~* Cross-body stretch - maximal horizontal adduction of the arm, with the opposite hand holding the stretch;~* Overhead triceps - arm above the head and elbow flexed, with the other hand pulling the elbow;~* Internal Rotation 90° stretch - with the shoulder at 90º of flexion and the elbow at 90º of flexion, the opposite hand and forearm forces the internal rotation."
48098168|NCT05343884|RADIATION|Myocardial perfusion imaging|Myocardial perfusion imaging
48278425|NCT04318392|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.
48278426|NCT04318392|OTHER|Sputum Culture|Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.
48278427|NCT04318392|OTHER|Spirometry|Spirometry will be performed on all healthy controls prior to enrolment into the study
48278428|NCT04708067|DRUG|Bintrafusp Alfa|Given IV
48278429|NCT04708067|PROCEDURE|Biopsy|Undergo biopsy
48278430|NCT04708067|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48278431|NCT06603883|BIOLOGICAL|Fecal microbiota transplantation (FMT) by nasal jejunal tube|FMT was administered via a naso-jejunal tube to inject 50ml commercial intestinal bacterial suspension into the jejunum.
48278432|NCT06529796|DRUG|IXP|Tablet for oral administration.
48278433|NCT03314805|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
48278434|NCT03314805|DRUG|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
48278435|NCT03314805|PROCEDURE|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
48278436|NCT01175369|BEHAVIORAL|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
48278437|NCT04693871|DEVICE|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
48278438|NCT05461443|DIETARY_SUPPLEMENT|Probiotic|
48278439|NCT06656975|BEHAVIORAL|Brief Cognitive Therapy|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
48278440|NCT06656975|BEHAVIORAL|Social Prescribing|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
48278441|NCT06656975|OTHER|Enhanced Usual Care|Participants will receive an informational booklet on improving loneliness. Participants may initiate or continue Collaborative Care for other conditions on a not research basis.
48278442|NCT03639740|DRUG|Secukinumab 150 milligram [Cosentyx]|For intervention description: see arm/group description
48446618|NCT01010555|DEVICE|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
48446619|NCT01010555|DEVICE|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
48446620|NCT01010555|DEVICE|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
48446621|NCT01010555|DEVICE|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
48446622|NCT06042335|DEVICE|DAISe EZ|DAISe Thrombectomy System for mechanical thrombectomy
48446623|NCT01825447|DRUG|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
48446624|NCT01825447|DRUG|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
48446625|NCT01825447|DRUG|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
48446626|NCT00854659|DRUG|ABT-102|BID tablets, 7 days of treatment
48446627|NCT00854659|DRUG|Placebo|BID tablets, 7 days of treatment
48446628|NCT03872596|DRUG|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
48446629|NCT03872596|DRUG|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
48446630|NCT03872596|DRUG|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
48446631|NCT03872596|DRUG|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
48446632|NCT03872596|DRUG|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
48446633|NCT01888523|BEHAVIORAL|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
48446634|NCT01888523|BEHAVIORAL|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
48446635|NCT00003647|DRUG|allovectin-7|
48446636|NCT00003647|DRUG|allovectin-7/dacarbazine|
48446637|NCT00003647|DRUG|dacarbazine|
48446638|NCT03145493|DEVICE|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
48446639|NCT04230330|DRUG|IV Nivolumab|240mg every 2 weeks.
48446640|NCT04230330|DRUG|IV Nivolumab|Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.
48446641|NCT04230330|DRUG|IV Gemcitabine|800mg/m2 on Days 1 and 8 every 21 days
48446642|NCT04230330|DRUG|IV Cisplatin|20mg/m2 on Day 1 to 4 every 21 days
48446643|NCT04230330|DRUG|IV/PO Dexamethasone|10mg on Days 1 to 4 every 21 days
48446644|NCT04230330|DRUG|IV L-asparaginase|6000 Units/m2 on Days 2 to 8 every 21 days
48446645|NCT02295163|PROCEDURE|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
48446646|NCT02295163|PROCEDURE|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
48446647|NCT04904705|OTHER|The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach|"The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school)."
48446648|NCT04904705|OTHER|Home Program|Home Program are activities that a participant can apply at home to improve their skills.
48446649|NCT05305248|DRUG|Remimazolam|After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
48446650|NCT05305248|DRUG|Dexmedetomidine|After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
48446651|NCT00204373|DRUG|Lansoprazole (Prevacid)|Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
48446652|NCT00365365|DRUG|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
48446653|NCT00365365|DRUG|Docetaxel (T) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel 100 mg/m\^2 IV~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
48446654|NCT00365365|DRUG|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
48446655|NCT00365365|DRUG|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~* bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~* docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~* trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~* Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
48446656|NCT00365365|DRUG|Bevacizumab and trastuzumab maintenance therapy|"* bevacizumab 15 mg/kg was infused IV followed by~* trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
48446657|NCT00365365|DRUG|Bevacizumab maintenance therapy|"- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
48620397|NCT06324591|OTHER|Collection biological sample and analysis|collection of a stool sample collected at clinical practice check-ups during the first year after diagnosis of Crohn's disease. This is followed by the evaluation of clinical, laboratory and instrumental data at the time of diagnosis
47928070|NCT01603524|OTHER|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~1. Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~2. Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~3. Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~4. Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
48620398|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
48620399|NCT01047501|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks
48446658|NCT04702581|DRUG|PCV chemotherapy|"1. cycle of PCV chemotherapy is given as:~   * Day 1: CCNU 110 mg/m2 orally;~  * Days 8 and 29: Vincristine 1.4 mg/m2 IV;~  * Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given."
48446659|NCT04702581|DRUG|Radiotherapy and PCV chemotherapy|"Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~* Day 1: CCNU 110 mg/m2 orally;~* Days 8 and 29: Vincristine 1.4 mg/m2 IV;~* Days 8 to 21: Procarbazine 60 mg/m2 orally"
48446660|NCT02740647|DRUG|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
48446661|NCT02740647|DRUG|Placebo|50 ml of 0.9% sodium chloride three times a day
48446662|NCT06407206|OTHER|Sub occipital muscle inhibition technique and conventional therapy|Patient is in supine position Therapist sits near the head of the participant and places his hand below the head of the participant With the pads of hand therapist palpates the arch of atlas between the occipital protuberance and spinous process of axis and place the middle and ring finger over it by flexing the metacarpophalangeal joint in 90 degrees of flexion, base of skull will rest on hands Pressure is exerted in upward direction towards the therapist and is maintained for two minutes so that the muscle scan relax Participants are guided to keep their eyes close in order to avoid movement which affects the tone of sub occipital muscle
48446663|NCT06407206|OTHER|conventional therapy|Transcutaneous electrical nerve stimulation at lower back and hamstring muscles (pulse rate: 4Hertz, pulse duration: 150µs for 15mins) Hot pack ( 15mins),Ankle pumps (15 reps with 5 sec hold), Knee Range of motions (flexion and extension,10 reps),Quadriceps set (10 reps,5 sec hold),Vastus Medialis oblique (10 reps 5 sec hold),Gluteus sets (10 reps, 5 sec hold),Single knee to chest (10 reps with 10 sec hold) McKenzie exercises (10 reps with 10 sec hold and 10 sec rest),Stretching of calf and hamstring muscles (passive stretching,7 reps with 5 sec hold).
48446664|NCT01250912|DRUG|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
48446665|NCT01505933|DRUG|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
48446666|NCT01505933|DRUG|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
48446667|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% BID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.
48446668|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% QID|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.
48446669|NCT04704531|DRUG|Sodium Hyaluronate Ophthalmic 0.4% Six times per day|Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.
48446670|NCT05318365|DRUG|Polyethylene Glycol 3350|PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
48446671|NCT05318365|BEHAVIORAL|Urotherapy|Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
48446672|NCT00852163|DRUG|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
48446673|NCT04390256|OTHER|Clove water extract|natural product
48446674|NCT04390256|OTHER|Carbopol|Bioadhesive polymer
48446675|NCT04390256|OTHER|Carboxymethyle cellulose|Bioadhesive polymer
48620400|NCT01047501|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks
48620401|NCT01405911|DRUG|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
48278443|NCT06655987|OTHER|Unrestrained Femoral Internal Rotation (UFIR) manipulation|This is the primary intervention applied to the experimental group. It involves a high-velocity, low-amplitude thrust at the greater trochanter of the affected hip, intended to improve joint mobility and potentially address neuromuscular dysfunction contributing to hip pain and weakness.
48278444|NCT06655987|OTHER|Sham manipulation|This serves as the control intervention. It involves gentle hand placement over the affected hip\&#39;s external rotators for a brief duration. This is intended to mimic the physical contact of the UFIR manipulation without actually delivering the therapeutic thrust.
48278445|NCT05426811|DRUG|Regorafenib|Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks
48278446|NCT05426811|DRUG|Raltitrexed|Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
48278447|NCT02570451|OTHER|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
48278448|NCT02570451|OTHER|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
48278449|NCT02570451|OTHER|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
48278450|NCT02570451|OTHER|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
48278451|NCT02570451|OTHER|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
48278452|NCT02570451|OTHER|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
48278453|NCT02570451|OTHER|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
48446676|NCT03569059|DEVICE|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
48446677|NCT03569059|BEHAVIORAL|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
48446678|NCT03569059|DEVICE|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
48446679|NCT01415986|DRUG|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
48446680|NCT01415986|DEVICE|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
48446681|NCT04480086|DRUG|Mivebresib|Tablet: Oral
48446682|NCT04480086|DRUG|Navitoclax|Tablet; Oral
48446683|NCT04480086|DRUG|Ruxolitinib|Tablet; Oral
48446684|NCT05378217|DIAGNOSTIC_TEST|AMR LFIA Assay|AMR LFIA will be performed in parallel to routine testing on appropriate sample types retrieved from routine testing : Blood, urine, BronchoAlveolar Lavage (BAL), Tracheal Aspirate (TA), Rectal swab
48446685|NCT03697798|BIOLOGICAL|Boostrix®-IPV combination vaccine|A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
48446686|NCT01158274|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
48446687|NCT01158274|DRUG|capecitabine|Given orally
48446688|NCT01158274|OTHER|laboratory biomarker analysis|Correlative studies
48446689|NCT06553664|DRUG|Treat with Vibrabot capsules for at least 7 weeks|Subjects in the trial group took Vibrabot capsules at least 7 weeks, doses ranging from 2 to 5 capsules orally per week.
48446690|NCT03973658|DEVICE|Hearing aids|Fitting of hearing aids (for the first time)
48446691|NCT06452472|DEVICE|I-LIMB|Use of a multi-grip myoelectric hand prosthesis (I-LIMB after using a standard myoelectric prosthesis)
48446692|NCT04391621|PROCEDURE|Autologous Adipose Derived stem cell transplantation|Through liposuction, harvested lipoaspirate will be processed in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for inflitration. This will then be infiltrated into the affected keloid.
48446693|NCT04391621|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|Triamcinolone Acetanoide 40mg/ml suspension will be diluted into 1ml of 0.5% lignocaine solution and infiltrated into the selected keloid.
48446694|NCT05014958|OTHER|Exercise training on whole body vibration|Participants will be included in the 6-week exercise training on whole body vibration
48446695|NCT01665690|OTHER|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
48446696|NCT01665690|BEHAVIORAL|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
47928071|NCT01603524|BEHAVIORAL|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
48098169|NCT00664846|DRUG|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
48446697|NCT04738539|DRUG|Contrast Enhanced Voiding Urosonography with Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
48446698|NCT04738539|DIAGNOSTIC_TEST|Urodynamic Testing|We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
48446699|NCT05963035|DRUG|18F-PFPN|For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
48446700|NCT05377931|DIAGNOSTIC_TEST|Changes in heart pulse rate|Measuring heart pulse rate using a wrest smart watch.
48446701|NCT05377931|DIAGNOSTIC_TEST|Changes in eye strain|Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
48446702|NCT06502340|DIAGNOSTIC_TEST|high sensitive troponin I|high-sensitive Troponin I levels
48446703|NCT04979377|OTHER|Clinical hyperandrogenism assessment|Modified Ferriman-Gallwey scale
48446704|NCT04979377|DIAGNOSTIC_TEST|Total testosterone (ng/dL)|Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase
48446705|NCT04979377|DIAGNOSTIC_TEST|A1c (%)|High Performance Liquid Chromatography (HPLC)
48446706|NCT04979377|DIAGNOSTIC_TEST|Total cholesterol|Determined by enzymatic methods
48446707|NCT04979377|OTHER|Body mass index (BMI) (kg/m2)|Defined as body weight divided by the square of body height, and expressed in kg/m2
48446708|NCT04979377|DIAGNOSTIC_TEST|Frequency of chronic vascular complications [n (%)]|Retinopathy, nephropathy, neuropathy, and macrovascular disease.
48446709|NCT04979377|DIAGNOSTIC_TEST|Polycystic ovary morphology|Sonographic assessment
48446710|NCT04979377|DIAGNOSTIC_TEST|Cardiovascular autonomic reflex tests (CARTs)|Cardioautonomic function assessement by Vital scan HW7-HW6T:
48446711|NCT04979377|DIAGNOSTIC_TEST|Sex hormone-binding globulin (SHBG) (nmol/L)|Circulating SHBG (IQL) at follicular phase
48278454|NCT02570451|OTHER|Grip Strength|Measured using the JAMAR dynamometer
48278455|NCT00759629|OTHER|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
48446712|NCT04979377|DIAGNOSTIC_TEST|Dehydroepiandrosterone-sulphate (IQL) (ng/mL)|Circulating DHEAS (IQL) at follicular phase
48446713|NCT04979377|OTHER|Waist circumference (cm)|Waist circumference measurement made at the top of the iliac crest
48446714|NCT04979377|OTHER|Waist-to-hip ratio|Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)
48446715|NCT04979377|OTHER|Body composition|Vital Scan HW7-HW6T
48446716|NCT04979377|DIAGNOSTIC_TEST|Mean glucose (mg/dL)|Continuous glucose monitoring (GCM) records
48446717|NCT04979377|DIAGNOSTIC_TEST|Time in target range (hours)|Continuous glucose monitoring (GCM) records
48446718|NCT04979377|DIAGNOSTIC_TEST|Time in hyperglycemia (hours)|Continuous glucose monitoring (GCM) records
48278456|NCT00759629|OTHER|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
48446719|NCT04979377|OTHER|Insulin dose (UI/Kg)|Daily insulin dose divided by body weight
48446720|NCT04979377|OTHER|Insulin sensitivity|Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference
48446721|NCT04979377|DIAGNOSTIC_TEST|High-density lipoprotein (HDL) (mg/dL)|Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+
48446722|NCT04979377|DIAGNOSTIC_TEST|Low-density lipoprotein (LDL) (mg/dL)|Estimated by the Friedewald's equation.
48446723|NCT04979377|DIAGNOSTIC_TEST|Triglycerides (mg/dL)|Determined by enzymatic methods
48446724|NCT02662933|OTHER|Bedside assessment|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
48446725|NCT03816072|DRUG|Phenylephrine infusion|Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.
48446726|NCT03816072|OTHER|Mechanical ventilation|Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (\~0.1 Hz).
48446727|NCT03816072|DRUG|Propofol|Propofol
48446728|NCT03816072|DRUG|Sevoflurane|Sevoflurane
48446729|NCT03407781|DRUG|68Ga-BBN-IRDye800CW|PET/NIR fluorescent imaging-guided surgery
48446730|NCT06559982|DIETARY_SUPPLEMENT|Brown seaweed and tart cherry blend|Blend of brown seaweed and tart cherry blend taken twice daily
48446731|NCT06559982|OTHER|Placebo|Identical in taste and colour to the supplement, but with no brown seaweed or tart cherry.
48446732|NCT05778110|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
48446733|NCT00120198|DRUG|CDOP plus rituximab|
48446734|NCT01268787|BIOLOGICAL|EV71 vaccine|Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
48446735|NCT01444378|DEVICE|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
48446736|NCT01612091|DEVICE|Monitoring Messenger|Monitoring Messenger prototype device
48446737|NCT01612091|DEVICE|Traditional tools|Paper based records, screenshots of monitors and therapy devices
48446738|NCT03872128|DRUG|Pregnenolone300|300mg
48446739|NCT03872128|DRUG|Pregnenolone500|500mg
48446740|NCT03872128|DRUG|Placebo|placebo
48446741|NCT03383354|OTHER|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
48446742|NCT06368219|DRUG|ketamine- midazolam versus ketamine- propofol|"* Group A: 25 patients will receive ketamine (0.5 mg/kg) plus midazolam (0.05 mg/kg)~* Group B: 25 patients will receive ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)"
48446743|NCT05099198|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the reference
48446744|NCT05099198|DRUG|Glimepiride|Glimepiride dispensing claim is used as the reference
48446745|NCT01467791|OTHER|Observation|Observe patients
48446746|NCT06027710|PROCEDURE|Extensive alveolar ridge augmentation with allogeneic bone blocks; dental implant insertion in allogeneic bone graft|Alveolar ridge augmentation procedure for extensive bone defect rehabilitation in the upper and/or lower jaw allogeneic bone blocks; dental implant insertion in allogeneic bone graft for oral rehabilitation after 6 month of healing
48446747|NCT02777372|DRUG|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
48446748|NCT04857008|DEVICE|BNT001|BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
48446749|NCT02769494|DRUG|Mesalazine Sustained-Release Tablets|Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
48446750|NCT02769494|DRUG|Riboflavin Sodium Phosphate Injection|gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
48446751|NCT01686386|DRUG|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
48446752|NCT01686386|DRUG|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
48446753|NCT01686386|DRUG|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
48446754|NCT00349843|DEVICE|Soft contact lens|
48446755|NCT00349843|DRUG|Marketed soft lens multipurpose disinfection regimen|
48446756|NCT04803058|BIOLOGICAL|TCD601|Investigational Product
48446757|NCT01108029|DRUG|memantine|2 tablets of 10 mg of memantine 1 time a day in the morning
48446758|NCT01108029|DRUG|placebo|2 tablets of placebo 1 time a day in the morning
48446759|NCT05822479|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg intramuscular (IM) meperidine was administered in the ward."
48098170|NCT00664846|DRUG|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
48098171|NCT03095508|DRUG|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
48098172|NCT03095508|DRUG|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
48446760|NCT05822479|OTHER|Control|"Patients in this group will not be performed interfacial plane blocks.~Multimodal analgesia :~Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, iv paracetamol 1 gr and iv morphine 0.05 mg/kg/ideal body weight (IBW) will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). Rescue analgesia, when necessary (if the resting NRS score is ≥4 despite PCA demand), 25 mg IV meperidine was administered in the recovery unit, and 50 mg IM meperidine was administered in the ward."
48446761|NCT05389722|DRUG|CC-92480|Specified dose on specified days
48446762|NCT05389722|DRUG|Rifampin|Specified dose on specified days
48446763|NCT05389722|DRUG|Itraconazole|Specified dose on specified days
48446764|NCT05389722|DRUG|Digoxin|Specified dose on specified days
48446765|NCT05389722|DRUG|Rosuvastatin|Specified dose on specified days
48446766|NCT06156670|DEVICE|PFO closure|"The operation of endovascular closure of PFO is performed on X-ray angiographic devices with digital processing of X-ray images. Endovascular closure of a PFO will be performed by femoral venous access using the following instruments: diagnostic catheter, diagnostic guidewire, high-stiffness guidewire for delivery system, interatrial septum occluders of PFO, UNI, ASD types.~Preoperative preparation and control of device implantation will be performed using modern echocardiographic equipment."
48278457|NCT05733455|DRUG|Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)|Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
48278458|NCT05733455|DRUG|Placebo (microcrystalline cellulose), 2 capsules|Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
48278459|NCT05733455|DEVICE|FreeStyle Libre Pro|Continuous glucose monitoring for 24 hours (double blinded)
48278460|NCT05733455|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) with Trutol glucose beverage|Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
48278461|NCT05733455|DIETARY_SUPPLEMENT|BOOST Plus nutritional beverage|Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
48446767|NCT00520988|BEHAVIORAL|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
48446768|NCT03402906|BEHAVIORAL|Family-Clinician Collaboration Program|Family-mediated treatment activities and collaboration between clinician and family members
48446769|NCT03919630|OTHER|Thrust Mobilization|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
48446770|NCT03919630|OTHER|Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
48278462|NCT06657495|DRUG|TD0015|TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.
48278463|NCT06657495|DRUG|TD0015 Placebo|Placebo was packed in pack 5g
48620402|NCT01405911|DRUG|Placebo for Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
48620403|NCT01405911|DRUG|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
48620404|NCT01405911|DRUG|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
48620405|NCT06398288|OTHER|Dermal matrix (Oracell, LifeNet, USA)|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health) + dermal matrix on the buccal aspect (Oracell, Lifenet Health)
48278464|NCT03757598|OTHER|ePartogram use|Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
48278465|NCT02318602|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
48278466|NCT03817671|OTHER|5% O2|Culturing embryos in 5% O2 just after thawing and till embryo transfer
48278467|NCT03817671|OTHER|2% O2|Culturing embryos in 2% O2 just after thawing and till embryo transfer
48278468|NCT01849133|RADIATION|external fractionated radiotherapy|conventional external beam radiotherapy
48278469|NCT01849133|RADIATION|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
48278470|NCT03173469|OTHER|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
48278471|NCT04740411|BEHAVIORAL|The Common Elements Toolbox (COMET)|COMET is an online unguided self-help intervention that lasts approximately 60-80 minutes.
48278472|NCT03411343|PROCEDURE|Interscalene Block|Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.
48278473|NCT03411343|PROCEDURE|Costoclavicular Infraclavicular Block|Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
48278474|NCT05021926|DEVICE|DKL crosslinked sodium hyaluronate 26|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
48278475|NCT05021926|DEVICE|Juvéderm Voluma™ with lidocaine (Allergan, Inc)|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
48278476|NCT03399461|OTHER|Patient Interview guide|The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.
48278477|NCT03399461|OTHER|Caregiver interview guide|The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
48278478|NCT03399461|OTHER|Sociodemographic questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.
48098173|NCT00175240|BEHAVIORAL|Evidence summaries endorsed by local opinion leaders|
48278479|NCT03399461|OTHER|Pediatric quality of life (PedsQL) questionnaire|The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.
48278480|NCT03399461|OTHER|Clinical questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
48278481|NCT00900003|GENETIC|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
48278482|NCT00900003|OTHER|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
48278483|NCT05818683|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
48098174|NCT00569946|DRUG|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
48446771|NCT02553044|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
48446772|NCT05859425|DEVICE|Real-time rehabilitative ultrasound imaging (RUSI)|Τhe ultrasound equipment used was B-K Μedical Mini Focus 1402 equipped with high frequency linear probe (8670, 5-12MHz) using standard musculoskeletal settings and the software: V 1.01.01.137. Ultrasound gel (AQUASONIC® 100, Parker Inc., Orange, NJ) was used as coupling agent. TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until tester (investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation
48446773|NCT05859425|OTHER|Tactile feedback (control intervention)|Palpatory-guided (manual) feedback for TrA activation
48446774|NCT01010932|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
48446775|NCT01010932|OTHER|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
48446776|NCT06558721|OTHER|Conventional rehabilitation|Lower extremity conventional rehabilitation in stroke patients
48446777|NCT06558721|OTHER|Mirror therapy|Mirror therapy of the lower extremity in stroke patients
48446778|NCT06558721|DEVICE|Bicycle ergometer with functional electric stimulation|Bicycle ergometer with functional electric stimulation therapy of the lower extremity in stroke patients
48446779|NCT01721850|OTHER|control formula|commercial stage 1 infant formula
48446780|NCT01721850|OTHER|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
48446781|NCT01721850|OTHER|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
48446782|NCT05265520|PROCEDURE|His-CRT implantation|The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.
48620406|NCT06398288|OTHER|No dermal matrix|Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health)
48620407|NCT02328105|DRUG|Carboplatin|Dosing: AUC = 6; on Day 1
48620408|NCT02328105|DRUG|Abraxane|100 mg/m\^2; Days 1, 8, 15
48620409|NCT05406089|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
48620410|NCT03823625|DRUG|Nivolumab plus Ipilimumab|Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.
48278484|NCT05818683|DRUG|Cetrelimab|Cetrelimab will be administered by intravenous infusion.
48278485|NCT05818683|DRUG|Cabazitaxel|Cabazitaxel will be administered by intravenous infusion.
48278486|NCT05818683|DRUG|Docetaxel|Docetaxel will be administered by intravenous infusion.
48278487|NCT05818683|DRUG|Apalutamide|Apalutamide will be administered orally.
48278488|NCT05818683|DRUG|Enzalutamide|Enzalutamide will be administered orally.
48278489|NCT05818683|DRUG|Darolutamide|Darolutamide will be administered orally.
48278490|NCT05818683|DRUG|Abiraterone acetate plus prednisone (AAP)|Abiraterone acetate plus prednisone (AAP) will be administered orally.
48278491|NCT01254344|DRUG|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
48278492|NCT01254344|DRUG|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
48278493|NCT01254344|DRUG|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
48278494|NCT01254344|DRUG|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
48278495|NCT01397851|DEVICE|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
48278496|NCT03466411|DRUG|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
48278497|NCT03466411|DRUG|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
48278498|NCT03466411|DRUG|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
48278499|NCT03466411|DRUG|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
48278500|NCT03466411|DRUG|Guselkumab Dose 5|Guselkumab will be by SC injection.
48278501|NCT03466411|DRUG|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
48278502|NCT03466411|DRUG|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
48278503|NCT03466411|DRUG|Placebo|Placebo will be administered as IV infusion.
48278504|NCT02785809|OTHER|Pausing oral contraceptive|
48278505|NCT01491087|BIOLOGICAL|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
48278506|NCT06657417|DEVICE|Video laryngoscopy|Standard video laryngoscopy before video laryngoscopy with additional larynGuide overlay
48278507|NCT06657417|DEVICE|Video larnygoscopy|Video laryngoscopy with additional larynGuide overlay before standard video laryngoscopy
48278508|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
48278509|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
48278510|NCT05902728|DRUG|HLX208|450 mg
48278511|NCT05902728|DRUG|HLX208|900 mg
48278512|NCT05902728|DRUG|Itraconazole 200 mg|200 mg
48278513|NCT05902728|DRUG|Rifampicin|600mg
48278514|NCT00146692|BEHAVIORAL|Free medical treatment|
48278515|NCT02712775|DRUG|Minocycline (yes/no)|
48278516|NCT02712775|DRUG|Placebo|Saline
48446783|NCT05265520|PROCEDURE|BIV-CRT implantation|Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
48446784|NCT05350917|DRUG|Tislelizumab|"Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
48446785|NCT00182429|DRUG|Metronidazole and Rifampin|
48446786|NCT00223925|DRUG|Maribavir|
48446787|NCT00223925|DRUG|Placebo|
48446788|NCT01346735|OTHER|No intervention|
48446789|NCT05157477|BEHAVIORAL|CBT-based VR exporsure program|This project seeks to establish a 8-week CBT-based VR exposure program to tackle sensory problems in ASD according to the theory of exposure and desensitization (both social and non-social scenarios) as well as identifying dysfunctional thought and searching for alternative thinking. In brief, this program aims to build up the core competence of the ASD individuals in facing the sensory environment, including (1) Relaxation skills (2) Ranking the fearful sensory situations (3) Anxiety coping strategy (3) Graded exposure (4) Cognitive appraisal and restructuring: identifying the dysfunctional thought when facing the social situations and figuring out alternative thinking.
48446790|NCT05241691|DEVICE|Guided Growth Plate System Plus|The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
48446791|NCT04587557|BEHAVIORAL|Storytelling with social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
48446792|NCT04587557|BEHAVIORAL|Storytelling without social contextual information|Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
48446793|NCT04587557|OTHER|Children with ASD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
48446794|NCT04587557|OTHER|Children with TD|Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
48278517|NCT06234904|BIOLOGICAL|IBR733 Cell Injection|The minimum initial dose is 5.0×10\^9 cells and then escalate to 7.5×10\^9 cells and 10.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
48098175|NCT04830254|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS) device|The Patients in group (A) received low-frequency TENS (frequency 4 Hz, pulse duration 200 μs,burst mode) was be applied through 2 output channels surface electrodes with an E2 TENS device, for 45 min per session, supramaximal stimulation to sympathetic ganglions in T12, L1, and L2, which innervate the lower extremity . For 45 min per session, three times per week, and for 12 weeks.
48098176|NCT03166319|DIAGNOSTIC_TEST|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
48278518|NCT04144972|DEVICE|Medtronic Summit RC+S or Percept RC|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
48278519|NCT00002850|DRUG|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
48278520|NCT00002850|DRUG|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
48278521|NCT00002850|DRUG|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \[TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole\] every 12 hours for two months..
48278522|NCT04657848|PROCEDURE|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
48278523|NCT03618030|DRUG|PRC-063 oral capsules|Daily dose
48278524|NCT03618030|DRUG|Placebo oral capsules|Daily dose
48278525|NCT02906553|DRUG|Glyceryl Trinitrate|
48278526|NCT02906553|DRUG|Placebo|
48278527|NCT03268629|BEHAVIORAL|Mindfulness-Based Joyful Sleep|"The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
48278528|NCT03268629|BEHAVIORAL|CBT-I|The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
48278529|NCT04300348|DEVICE|Heel2Toe|Heel to Toe (Heel2Toe) is a device that clips on the shoe and provides an instant auditory feedback (a beep) for each correct step characterized by putting the heel first and it provides data on gait parameters
48278530|NCT04300348|OTHER|No-feedback control group|The control group will follow the same protocol as the Heel2Toe group but the device will not be in feedback mode just in data acquisition mode.
48278531|NCT05003362|BEHAVIORAL|ACT|mindfulness intervention for patients with pain/migraine
48278532|NCT02954315|OTHER|Almonds|
48278533|NCT01867489|OTHER|No intervention|
48098177|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols|Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia
48098178|NCT05612243|OTHER|Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes|Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
48278534|NCT00956384|PROCEDURE|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
48278535|NCT00956384|PROCEDURE|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
48278536|NCT03525873|OTHER|Laboratory Biomarker Analysis|Correlative studies
48278537|NCT03525873|DRUG|Methylphenidate|Given PO
48278538|NCT03525873|OTHER|Physical Activity|Participate in physical activity
48278539|NCT03525873|OTHER|Placebo|Given PO
48278540|NCT03525873|OTHER|Quality-of-Life Assessment|Ancillary studies
48278541|NCT03525873|OTHER|Questionnaire Administration|Ancillary studies
48278542|NCT01028352|DRUG|Duloxetine|"Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
48278543|NCT01876589|DEVICE|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
48278544|NCT01876589|DEVICE|Xience Prime|Drug eluting metallic stent
48278545|NCT06103110|DEVICE|Photobiomodulation|Laser therapy using low level laser
48278546|NCT04429022|DRUG|Gabapentin|600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op
48278547|NCT04429022|DRUG|Acetaminophen|Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
48278548|NCT04429022|DRUG|Celecoxib|Celecoxib 200mg PO q 12h x 7d post op
48278549|NCT04429022|DRUG|Ketorolac|30mg IV once at end of hysterectomy procedure
48278550|NCT04429022|PROCEDURE|Paracervical block with ropivacaine|0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL
48278551|NCT04429022|PROCEDURE|Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites|0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total
48278552|NCT04429022|DRUG|Hydromorphone|1mg IV PRN q3h, post op, while inpatient
48278553|NCT04429022|DRUG|Oxycodone|To be discharged home with: 12 tabs of 5mg PRN q4h
48278554|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (low)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
48278555|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (high)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
48278556|NCT03417440|OTHER|Physical Activity (PA) Tracker App|This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
48278557|NCT03417440|OTHER|On Your Feet|On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity-a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
48278558|NCT03417440|OTHER|Coach Me|Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
48278559|NCT03417440|OTHER|Proof Positive|"Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity."
48278560|NCT03511339|DEVICE|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
48278561|NCT01986335|BIOLOGICAL|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
48278562|NCT03978273|DEVICE|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~* They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~* They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
48278563|NCT03978273|OTHER|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
48446795|NCT02161445|DEVICE|the acoustic cardiographic parameters were calculated|STIs were measured using simultaneous recording of the electrocardiogram and acoustic cardiography signals using an analogic numeric system (Biopac Systems, Goleta, CA). A3-minute acoustic cardiographic tracing for all patients was obtained and stored electronically. We measured the electromechanical activation time (EMAT) which is the time between the initial deflection of the electrocardiographic Q wave and the first phonocardiographic complex corresponding to the first heart sound (S1). The left ventricle ejection time (LVET) defined as the interval between the peak components from the S1 and S2 complexes was measured on the same cardiac cycles. All studies were performed in patients in a semi-recumbent position with head at 30 degrees position. For each patient, the acoustic cardiographic parameters were calculated from a 10-second free of artifact recording of data averaging 8 to 12 beats measurements.
48620411|NCT03823625|DRUG|Platinum-based chemotherapy plus Nivolumab|"Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~* Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~* Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~* Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days."
48620412|NCT03113097|OTHER|Embryo transfer|Transfer of different qualities of embryos at blastocyst stage
48278564|NCT00900796|OTHER|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
48278565|NCT05700461|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
48278566|NCT01819792|OTHER|Multiplex respiratory viral PCR|
48278567|NCT05657262|OTHER|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
48278568|NCT05657262|BEHAVIORAL|experimental group|The experiment group will be applied with the Z technique.
48278569|NCT03075839|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
48278570|NCT02793284|RADIATION|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
48278571|NCT06654648|OTHER|Combined exercise nutrition intervention group|Combination Product: Combined exercise and nutrition intervention Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
48278572|NCT06654648|OTHER|Conventional medial care group|"Conventional medial care Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
48278573|NCT04866927|DIETARY_SUPPLEMENT|Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability|Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
48278574|NCT04337957|OTHER|geriatric nephrology|Collection of the geriatrician's opinion
48278575|NCT04549987|DEVICE|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
48278576|NCT04549987|DEVICE|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
48278577|NCT01133743|DRUG|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
48278579|NCT00064922|BEHAVIORAL|Behavior Therapy|
48278580|NCT00021294|DRUG|eflornithine|
48278581|NCT00021294|DRUG|triamcinolone|
48446796|NCT05704426|DEVICE|Impulse Dynamics Optimizer Device|The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.
48446797|NCT05920720|BEHAVIORAL|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
48446798|NCT04325724|OTHER|General evaluation|Demographic characteristic, psoriasis duration, disease duration, treatments
48446799|NCT04325724|OTHER|Dermatological evaluation|treatment and evaluation
48446800|NCT04325724|OTHER|Rheumatological evaluation|joints, enthesis, tendons, and other ultrasound abnormalities
48446801|NCT04325724|OTHER|para clinical data|biological data, medical imaging data
48446802|NCT04325724|OTHER|Patient reported outcomes (PROs)|Psoriatic arthritis impact of disease 12 (PsAID12), hospital anxiety and depression scale (HAD), SF 36
48446803|NCT02820350|DEVICE|SCD-F40|CRRT with SCD
48446804|NCT00561834|DRUG|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
48446805|NCT01751594|BEHAVIORAL|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
48446806|NCT01751594|BEHAVIORAL|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
48446807|NCT03820310|BIOLOGICAL|autologous Tcm cellular immunotherapy|autologous cellular immunotherapy plus traditional therapy. • cells will be infused in 3-5×109 cells/100 ml 1 month after radical resection, then cells will be infused as the same dose followed by a 1 month rest period, Each subject in experimental group will receive a total of 5 cell infusions.
48446808|NCT04376203|PROCEDURE|Thyroidectomy|Typical Thyroidectomy
48446809|NCT06064331|DRUG|Lignocaine|IV bolus of 1.5 mg/kg of lignocaine 2% diluted in 10 ml syringe over 3 mins followed by infusion at 1 mg/kg/h of lignocaine 2% in 20 ml syringe
48446810|NCT06064331|DRUG|Placebo|IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe
48446811|NCT06559020|BEHAVIORAL|Kangroo mother care|Kangaroo Mother Care (KMC) involves continuous skin-to-skin contact between the mother (or another family member) and the infant, aimed at promoting thermal regulation, breastfeeding, and bonding. In this study, KMC was initiated in the hospital and continued at home for a minimum of 8 hours daily.
48446812|NCT02674880|DRUG|HMW-HA|Aerolized administration b.i.d.
48446813|NCT02674880|OTHER|Placebo|Standard therapy
48446814|NCT00919230|DRUG|Ferrous sulphate tablets|200mg twice daily for four weeks
48446815|NCT01746615|DEVICE|Dynamic Vessel Analyzer|retinal vessel diameter \& oxygen saturation
48446816|NCT01746615|OTHER|Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)|retinal blood velocity
48446817|NCT05672264|OTHER|Whole-Body Electromyostimulation|Consistently supervised, video-guided WB-EMS application 1.5 times per week for 28 weeks. Bipolar electric current with a frequency of 85Hz, an impulse-width of 350 µs will be used in an interval approach with 6 sec of EMS stimulation with a direct impulse boost and 4 sec of rest. Low intensity movements or exercises in a standing position were performed during the 6 s stimulation period.
48446818|NCT05672264|OTHER|Physiotherapy|Six standardised physiotherapy sessions (20 min each)
48446819|NCT03850795|DRUG|HC-1119|oral once daily 80 mg
48446820|NCT03850795|DRUG|Enzalutamide|oral once daily 160 mg
48446821|NCT01419093|OTHER|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on \[feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
48446822|NCT05736835|BIOLOGICAL|CVXGA|CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
48446823|NCT01376167|DRUG|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
48446824|NCT01376167|DRUG|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
48446825|NCT01376167|DRUG|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
48446826|NCT01376167|DRUG|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
48446827|NCT01376167|DRUG|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
48446828|NCT01376167|DRUG|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
48446829|NCT01376167|DRUG|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
48446830|NCT01376167|DRUG|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
48446831|NCT01376167|DRUG|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
48446832|NCT01376167|DRUG|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
48446833|NCT01376167|DRUG|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
48446834|NCT05195762|DRUG|NFX-179 Gel 1.50%|"Stanford University (Stanford) is studying a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179) that has been chemically engineered for topical application to treat epidermal nevus syndromes (ENS).~Preclinical studies evaluating topical application of NFX-179 to human nevus sebaceous explants demonstrated that NFX-179 can penetrate the tissue and suppress the p-ERK biomarker.~It was also determined that NFX-179, when incubated with the tissues in medium, also suppressed ERK phosphorylation in human keratinocytic epidermal nevi. This clinical study is designed to evaluate the safety, tolerability, and clinical effect of NFX-179 Gel in Subjects with Epidermal Nevi."
48446835|NCT00747565|DEVICE|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
48446836|NCT00747565|DEVICE|CeeOn 911A monofocal IOL|Monofocal Control IOL
48446837|NCT04968821|BEHAVIORAL|Physical activity intervention|Participants randomized to the physical activity intervention will receive a Fitbit and be enrolled in Fitabase (Fitbit tracking system). Participants will also participate in 8 tele-health sessions with a physical therapist. Sessions will involve setting weekly physical activity goals and reviewing the participant's physical activity on the Fitbit tracking system.
48446838|NCT04968821|OTHER|Usual care|Usual postoperative care includes surgeon-directed lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
48446839|NCT00003980|DRUG|BIBX 1382|
48446840|NCT06456073|BIOLOGICAL|E-CEL UVEC cells (AB-207)|Allogeneic (consented-maternal donor) E4ORF1+ (pro-survival gene transduced) human umbilical vein endothelial cells (percutaneous injection formulation)
48446841|NCT03965091|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm description.
48446842|NCT03965091|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
48446843|NCT05858463|OTHER|Modality of exercise training|muscle adaptations following intermittent high intensity interval exercise training and continuous low intensity exercise training
48446844|NCT01849003|DRUG|GS-6615|GS-6615 tablet(s) administered orally
48446845|NCT04229121|OTHER|nonintervention|nonintervention
48446846|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
48446847|NCT01020396|DRUG|Metronidazole|Vaginal Gel, 0.75%
48446848|NCT00305786|DRUG|gemcitabine hydrochloride|
48446849|NCT00305786|DRUG|oxaliplatin|
48446850|NCT00604474|DEVICE|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
48446851|NCT06524921|PROCEDURE|dental pulpectomy using metapex|Metapex: A dental pulpectomy treats tooth with irreversible pulpitis in primary and teeth by removing infected pulp tissue using files and irrigation in the radicular part. The procedure involves anesthesia, decay removal, pulp chamber access, filing and irrigation till we reach cleaned dried canals and applying a medicament like Metapex . The tooth is then restored with a filling, often a stainless steel crown. The loss of pulp tissue weakens the tooth's structure and increases the risk of fracture and infection.
48446852|NCT06524921|PROCEDURE|dental pulpectomy using biodentine|Biodentine: A dental pulpotomy treats tooth decay or trauma in primary and young permanent teeth by removing infected pulp tissue in the crown while preserving healthy root pulp. The procedure involves anesthesia, decay removal, pulp chamber access, hemostasis, and applying a medicament like MTA or Biodentine. The tooth is then restored with a filling, often a stainless steel crown. Pulpotomies preserve tooth structure, relieve pain, and are less invasive than full root canals, but require regular follow-up.
48446853|NCT01442753|BEHAVIORAL|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
48446854|NCT01619891|DIETARY_SUPPLEMENT|Vitamin D|100mcg per day
48446855|NCT06356103|DIETARY_SUPPLEMENT|Whey-Based Partially Hydrolyzed Formula|Peptamen junior, 100 kcal/100 ml (Nestlé Health Science, Vevey, Switzerland).
48446856|NCT06356103|DIETARY_SUPPLEMENT|received 50% of their caloric requirements as isocaloric polymeric formula (standard ) and 50% standard nutritional feeding according to ESPGHAN guidelines|protein and micronutrient requirements according to the recommended dietary allowance (RDA)
48446857|NCT06083259|DEVICE|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
48446858|NCT06083259|PROCEDURE|Gelatin sponge stabilization with cyanoacrylate|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
48446859|NCT02300935|DRUG|trametinib|
48446860|NCT02300935|DRUG|nab-paclitaxel|
48446861|NCT01900691|DEVICE|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
48446862|NCT02130856|DEVICE|Neonatal kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~7. Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker."
48446863|NCT03110874|DRUG|one-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
48446864|NCT03110874|DRUG|two-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
48278582|NCT05267626|DRUG|AU-007|Monoclonal Antibody Targeting IL-2
48278583|NCT05267626|DRUG|Aldesleukin|IL-2
48278584|NCT05267626|DRUG|Avelumab|Monoclonal Antibody Targeting PD-L1
48446865|NCT03994172|DRUG|Teriparatide or human parathyroid hormone (PTH) 1-34|Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
48446866|NCT03994172|DRUG|Cinacalcet|This drug is an orally active calcimimetic (drug that activates Ca-sensing receptors on target cells) that will be given daily orally to the men randomized to the Experimental Treatment Arm (#1). Cinacalcet tablets will be given simultaneously with the injection of PTH(1-34) or teriparatide. Cinacalcet will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
48446867|NCT03994172|DRUG|placebo tablet|The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
48446868|NCT03994172|DIETARY_SUPPLEMENT|Calcium citrate tablet|Ca citrate supplements (forms 200 or 250 mg elemental Ca/oral tablet) will be used in the study. Each subject will have average dietary Ca intake quantified by a Food Frequency Questionaire. Each subject will take sufficient Ca citrate supplements to make the total Ca intake equal \~1000 mg per day (diet+supplements). Ca supplements will be spread out during the day so that any amount of supplements over 500 mg will be taken at 2 different time-points. Ca citrate supplements will be sourced by our research pharmacist will be of high-quality and consistency. Ca supplements will be started at Screening Visit 2 and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily Ca supplements at the same dose and times as during the run-in period. That daily dosing will continue from day of Randomization through the end of 48 weeks or 11 months of the trial.
48446869|NCT03994172|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be given 1000 IU vitamin D3 in tablet form to be taken orally once a day at any time during the day. Vitamin D3 supplements will be sourced by our research pharmacist and supplements selected for use in the trial will be of high quality and consistency. Vitamin D3 supplements will be started at Screening Visit 2 in the trial and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily vitamin D3 supplements at the same dose and timing as during the run-in period. That daily dosing will continue from the day of Randomization Visit through to the end of the 48 weeks or 11 months of the trial.
48446870|NCT03423680|DRUG|Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
48446871|NCT03423680|DRUG|Placebo of Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
48446872|NCT04684901|OTHER|AlloWrap® Amniotic Membrane|AlloWrap is a human amniotic membrane designed to provide a biologic barrier following surgical repair.
48446873|NCT03507491|DRUG|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
48446874|NCT03507491|DRUG|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
48446875|NCT01212848|DEVICE|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
48446876|NCT01212848|DEVICE|Transcranial Magnetic Stimulation - Sham Comparator|"The control group will receive an identical dosing schedule of sham repetitive TMS over three days."
48446877|NCT04131842|OTHER|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
47928072|NCT05694377|BEHAVIORAL|electroencephalography-based neurofeedback (EEG-NFB)|The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
47928073|NCT04995523|DRUG|AZD2936|Anti-TIGIT/Anti-PD-1 Bispecific Antibody
47928074|NCT02402725|DRUG|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
47928075|NCT05765773|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
48446878|NCT04131842|OTHER|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
48446879|NCT04131842|OTHER|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
48446880|NCT04131842|OTHER|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
48446881|NCT04032977|DEVICE|PN40082|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
48446882|NCT04032977|DEVICE|Restylane Silk|To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
48446883|NCT00264394|BEHAVIORAL|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
48446884|NCT00264394|BEHAVIORAL|Guidelines|provision of guidelines for CHD risk factor management only
48446885|NCT02561520|BIOLOGICAL|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
48446886|NCT02561520|BIOLOGICAL|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
48446887|NCT06562426|BEHAVIORAL|Descriptive group on vitamin D awareness|300 mothers of under-five children will be recruited in the descriptive study to assess their awareness about vitamin D and observe children for their health status outcome. Three tools will be used which are; sociodemographic characteristics of children and their mothers, Mothers' Awareness of Vitamin D Structured Interview Schedule, and Health Status Outcomes of Under- Five Years Children. Permission to conduct the study will be obtained from the administrative authorities of the settings after an explanation of the aim of the study. Each mother will be interviewed individually to obtain characteristics of mothers and their children, as well as knowledge and performance regarding Vitamin D. Each child will be observed for the manifestation of vitamin D deficiency and to measure their weight and height.
48446888|NCT01502254|OTHER|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
48446889|NCT04145427|BEHAVIORAL|Control|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
48446890|NCT04145427|BEHAVIORAL|LCD|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
48446891|NCT03579303|OTHER|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
48098179|NCT05612243|OTHER|Consumption of a meal with plain Yogurt with oat flakes|Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
48098180|NCT05657912|DEVICE|ECG monitoring|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
48278585|NCT05200988|DRUG|Ipilimumab + nivolumab|"Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy"
48278586|NCT01122329|DIETARY_SUPPLEMENT|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
48278587|NCT01122329|DIETARY_SUPPLEMENT|Placebo|
48278588|NCT04957888|OTHER|none intervention|none intervention.
48278589|NCT06205030|DRUG|anti-diabetic herbal drug|All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
48278590|NCT01172379|DRUG|E2007|"Experimental 1 Drug: E2007~0.5 mg 1 tablet per day"
48278591|NCT01172379|DRUG|E2007|"Experimental 2 Drug: E2007~1.0 mg 1 tablet per day"
48278592|NCT01172379|DRUG|E2007|"Drug: E2007~2.0 mg 1 tablet per day"
48278593|NCT01172379|OTHER|Placebo Comparator|Placebo 1 tablet per day
48278594|NCT06059586|BEHAVIORAL|Pelvic health therapy|Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
48278595|NCT06059586|DEVICE|Dilator feasability|Patient Adherence to Vaginal Dilation Questionnaire
48278596|NCT00001189|PROCEDURE|radiotherapy|
48278597|NCT01520246|GENETIC|gene expression analysis|
48278598|NCT01520246|OTHER|laboratory biomarker analysis|
48278599|NCT01620125|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
48446892|NCT01355133|BIOLOGICAL|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
48446893|NCT00410865|GENETIC|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
48446894|NCT03251534|PROCEDURE|Centromedullary nailing|
48446895|NCT01334333|DRUG|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
48446896|NCT01334333|DRUG|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
48446897|NCT00471419|DRUG|Rimexolone|
48446898|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
48446899|NCT05506007|DRUG|DA-5216-R|"During the cross-over \[Part A\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.~* Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8."
48446900|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
48446901|NCT05506007|DRUG|DA-5216|"During the cross-over \[Part B\], patients will be randomly assigned to receive one of the following treatment sequences:~* Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8.~* Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8."
48446902|NCT01933360|DRUG|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
48446903|NCT01933360|DRUG|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
48446904|NCT01933360|DRUG|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
48446905|NCT01933360|DRUG|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
48446906|NCT01933360|DRUG|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
48446907|NCT01933360|DRUG|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
48446908|NCT01933360|DRUG|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
48446909|NCT01933360|DRUG|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
48446910|NCT04786626|DIAGNOSTIC_TEST|Ultrasound evaluation|After vaginal, all patients were followed by traditional 2D US scanning and Doppler velocimetry on Days: 0, 2, 30, 60 and 90. Authors evaluated: scar diameter and Doppler velocimetry and resistance index (RI) of the uterine arteries, at their ascending branch
48446911|NCT04278560|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
48446912|NCT04278560|DEVICE|Sham stimulation|An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
48446913|NCT04278560|BEHAVIORAL|Behavioral intervention to increase physical activity|Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
47928076|NCT03341780|PROCEDURE|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
47928077|NCT03521895|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
47928078|NCT00833417|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
48446914|NCT05022381|PROCEDURE|Radiofrequency thermal coagulation of articular branches of femoral and obturator nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points. Patients who do not have any complications after the procedure and who are mobilized are discharged in the 2nd hour.
48446915|NCT04046783|DEVICE|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
48446916|NCT00752635|DRUG|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
48446917|NCT05502250|DRUG|gemcitabine, cisplatin and tislelizumab|"All patients will receive 2 cycles of gemcitabine and cisplatin (GP) + tislelizumab. Each cycle lasts 21 days. Treatment is given through an IV line on day 1 and 8.~After 2 cycles a FDG-PET-CT scan will be performed. Patients who respond well will proceed with 2 additional cycles of GP + tislelizumab . Patients with insufficient response will stop with the study treatment and they will continue treatment according to local practice.~After 4 cycles of GP + tislelizumab another FDG-PET-CT scan will be performed. If this scan shows that the disease is under control (metabolic complete remission) patients will proceed with 13 cycles of tislelizumab consolidation treatment (21 day cycles). Treatment is given on day 1 through an IV line."
48446918|NCT04829981|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
48446919|NCT04829981|BEHAVIORAL|Behaviour change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
47928079|NCT02826720|OTHER|No intervention was applied|No intervention was applied
48098181|NCT02416635|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
48278600|NCT02810990|DRUG|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 \> 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
48278601|NCT00430118|DRUG|asparaginase|
48278602|NCT00430118|DRUG|cyclophosphamide|
48278603|NCT00430118|DRUG|cytarabine|
48278604|NCT00430118|DRUG|daunorubicin hydrochloride|
48278605|NCT00430118|DRUG|dexamethasone|
48278606|NCT00430118|DRUG|doxorubicin hydrochloride|
48278607|NCT00430118|DRUG|etoposide|
48278608|NCT00430118|DRUG|ifosfamide|
48278609|NCT00430118|DRUG|mercaptopurine|
48278610|NCT00430118|DRUG|methotrexate|
48278611|NCT00430118|DRUG|prednisone|
48278612|NCT00430118|DRUG|thioguanine|
48278613|NCT00430118|DRUG|vincristine sulfate|
48278614|NCT00430118|DRUG|vindesine|
48278615|NCT00430118|RADIATION|radiation therapy|
48278616|NCT05645094|DRUG|Envafolimab|Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
48278617|NCT03232307|DRUG|Dexamethasone|Given PO
48278618|NCT03232307|DRUG|Ibrutinib|Given PO
48278619|NCT03232307|DRUG|Lenalidomide|Given PO
48278620|NCT03232307|BIOLOGICAL|Rituximab|Given IV
48278621|NCT03904927|OTHER|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
48278622|NCT03904927|DRUG|Systemic therapy|"1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."
48278623|NCT03156530|DEVICE|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
48278624|NCT03156530|OTHER|Control|Not receive stimulation.
48278625|NCT02504541|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
48278626|NCT05335538|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
48278627|NCT02036229|DRUG|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
48278628|NCT05077761|DEVICE|Active High-intensity laser therapy|"High-intensity laser therapy will be used in the contact method, with the laser beam irradiated over the hamstring muscle. Dosage and parameters for the laser will be calculated.~Parameters-~1. Wavelength- 980 nm~2. Intensity/Power density- 3W/cm2~3. Emission mode- Continuous Emission~4. Energy (Joules)- 490 J~5. Irradiation time- 70 Sec on each point~6. Peak power- 15 Watt~7. Irradiation points- 09"
48278629|NCT05077761|DEVICE|Sham High-intensity laser therapy|Sham High-intensity laser therapy will be used in the contact method, without the laser beam irradiation over the hamstring muscle.
48278630|NCT03280212|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
48278631|NCT06657456|DIETARY_SUPPLEMENT|Phytosterol-rich extract|Experimental product: extract rich in phytosterols
48446920|NCT02045563|OTHER|prise de sang|
48446921|NCT02045563|OTHER|magnetic resonance imaging and magnetic resonance spectroscopy|
48446922|NCT06526338|DRUG|1.0% IP-001 for injection|Participants will receive a single injection of 1.0% IP-001 following local ablation or surgical resection and local ablation
48446923|NCT06526338|PROCEDURE|Surgical Resection and Local Ablation|Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)
48446924|NCT06526338|PROCEDURE|Local Ablation Alone|Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone
48446925|NCT03604198|DRUG|relacorilant|CORT125134 is supplied as capsules for oral dosing.
48446926|NCT04206358|BIOLOGICAL|OrienX010 combination with JS001|"OrienX010 Produced by Oriengene Biotechnology Co., Ltd. Strength: 1.0 mL/vial. Label claim: Titer 8.0 × 10\^7Pfu/mL, NMT 1 × 10 particles11VP/mL.~JS001 Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package."
48446927|NCT00904215|DRUG|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
48446928|NCT04975035|DRUG|Zolodine|Collect 200 patients who meet the criteria into the group. After enrollment, according to the principle of cross dressing change, the attending physician can decide the dressing change method according to the patient's condition, individual condition and other factors; within 2-4 weeks, the original antipsychotics should be gradually stopped, and Zoladine capsules will be gradually added to the target The dose is 120-160mg/d, orally 1-2 times a day, with meals.
48446929|NCT00088829|DRUG|paclitaxel|subjects will receive paclitaxel neoadjuvantly
48446930|NCT00088829|GENETIC|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
48446931|NCT00088829|PROCEDURE|biopsy|All subjects will have a biopsy to collect tissue
48446932|NCT00088829|PROCEDURE|neoadjuvant therapy|paclitaxel is given neoadjuvantly
48446933|NCT00088829|DRUG|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
48446934|NCT03950362|DRUG|Avelumab|Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
48446935|NCT03950362|DEVICE|Radiotherapy|60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
48446936|NCT05506956|DRUG|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
48446937|NCT01594203|OTHER|F18-FGD PET/CT|
48446938|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
48446939|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
48446940|NCT04336605|OTHER|Age & Development|Age, sex, pubertal onset and development
48446941|NCT04336605|OTHER|Socioeconomy|Family structure and economy
48446942|NCT04336605|OTHER|Traumatic Events|Violence and other traumatic events
47928080|NCT02217072|BEHAVIORAL|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
47928081|NCT02217072|BEHAVIORAL|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
47928082|NCT03613272|PROCEDURE|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
48446943|NCT04336605|OTHER|Psychosocial conditions|Family/social support
48446944|NCT04336605|OTHER|Lifestyle|Physical activity, BMI, nutrition, smoking ...
48446945|NCT04336605|OTHER|Chronic conditions|I.e. Epilepsy or juvenile rheumatoid arthritis ...
48446946|NCT04336605|OTHER|Somatic symptoms|Headache, pain, sleep disturbances ...
48446947|NCT04336605|OTHER|Psychological symptoms|PTSS, anxiety, depressive symptoms \& loneliness ...
48446948|NCT04336605|OTHER|Non-prescription analgesics|Non-prescription analgesics
47928083|NCT03613272|PROCEDURE|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
47928084|NCT00621621|DEVICE|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
47928085|NCT00852371|DRUG|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
48446949|NCT04336605|OTHER|Prescription drugs|Analgetic, sedative \& anxiolytic medication
48446950|NCT02821728|DIETARY_SUPPLEMENT|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
48446951|NCT02821728|OTHER|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
48446952|NCT04991194|DRUG|BIA 5-1058|Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
48446953|NCT06492876|GENETIC|FT-003|Administered via intraocular injection.
48446954|NCT00939718|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
48446955|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
48446956|NCT02738086|BEHAVIORAL|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
48446957|NCT01001403|DRUG|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
48446958|NCT01001403|DRUG|Normal saline|10 ml of normal saline
48446959|NCT03698981|BEHAVIORAL|Mothers Moving towards Empowerment (MME)|"MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children."
48446960|NCT00621491|DRUG|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
48446961|NCT03302780|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
48446962|NCT03302780|DEVICE|tDCS active|tDCS will be applied for 20 minutes.
48446963|NCT03302780|DEVICE|tDCS sham|
48446964|NCT04244097|DRUG|Bupivacaine Hydrochloride|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
48446965|NCT04244097|DRUG|Neostigmine|after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.
48446966|NCT06525389|DRUG|Liposomal Amphotericin B (LAmB)|Antifungal dosed at 10 mg/kg/day IV x one single dose.
48446967|NCT06525389|DRUG|Flucytosine (5FC)|Antifungal dosed at 25mg/kg oral 3x daily.
48446968|NCT06525389|DRUG|Flucytosine (5FC) placebo pill|Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
48446969|NCT06525389|DRUG|Deoxycholate Amphotericin B (DAmB)|Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
48446970|NCT03820427|DIAGNOSTIC_TEST|impulse oscillometry|impulse oscillometry
48446971|NCT03820427|DIAGNOSTIC_TEST|multiple breath washout test|multiple breath washout test
48446972|NCT03820427|DIAGNOSTIC_TEST|body plethysmography|body plethysmography
48446973|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|an acute dose of spirulina up to 5 g
48446974|NCT00680277|DIETARY_SUPPLEMENT|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
48446975|NCT03987191|DRUG|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
48446976|NCT04065035|OTHER|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
47928086|NCT00852371|DRUG|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
47928087|NCT00852371|DRUG|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
47928088|NCT00852371|OTHER|Placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
48446977|NCT04065035|OTHER|Body Cleanser|Body cleanser to be used by study participants
48446978|NCT04065035|OTHER|Sunscreen|Sunscreen to be applied after application of moisturizer
48446979|NCT04065035|OTHER|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
48446980|NCT03202459|DRUG|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
48446981|NCT03202459|DRUG|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
48446982|NCT03202459|DRUG|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
48446983|NCT05244863|OTHER|Test|Measurements
47928089|NCT01097200|DEVICE|Elevate mesh|The correction of the prolapse can be made by this new technique.
47928090|NCT01097200|DEVICE|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
48098182|NCT02416635|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
48446984|NCT05252377|OTHER|Breathing Exercise|"1. The patient will be asked to close their eyes~2. He will be asked to relax his head and neck in a semi-sitting position in bed~3. The patient will be asked to breathe through the nose for 3 seconds by counting~4. Then he will be told to hold his breath for 3 seconds~5. As the last step, he will be asked to breathe out again in 3 seconds."
48446985|NCT06307639|DIAGNOSTIC_TEST|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).|Measurement of PGK2 and ACRV1 levels in the semen of infertile males undergoing testicular sperm extraction (TESE).
48446986|NCT00014768|DRUG|glucose|
48446987|NCT00014768|DRUG|insulin|
48446988|NCT00014768|DRUG|leucine|
48446989|NCT04408794|DRUG|Zavegepant (BHV-3500)|10 mg IN up to 8 times per month, up to 1 year
48446990|NCT05857774|OTHER|Sonographic measurements|Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction
48446991|NCT05857774|OTHER|Physiological measurements|Airway occlusion pressure, maximal inspiratory pressure, muscle research council score
48446992|NCT05857774|OTHER|Biological measurements|Skeletal troponin-I
48446993|NCT04353063|BEHAVIORAL|Multidisciplinary care with a personalized care|During the 4-week intervention, participants will be given stickers by the research assistant to increase their motivation to walk. A sticker will be given once a participant reaches a daily walking-time goal. The number of stickers participants receive depends on the number of days they reach their daily goals. The stickers can be redeemed for the participant's choice of gift in the gift shelf of the ward or on a gift card. A final assessment will be conducted at week 4. The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4
48446994|NCT05319847|DIETARY_SUPPLEMENT|Daily Skin Supplement - Fountain of Youth|Skincare supplement
48446995|NCT02788240|DRUG|Peg GCSF|
48446996|NCT02788240|BIOLOGICAL|20% Albumin|
48446997|NCT02788240|DIETARY_SUPPLEMENT|Nutrition|
48446998|NCT02788240|OTHER|Bowel wash|
48446999|NCT02788240|DRUG|Terlipressin 1- 4mg,if indicated|
48447000|NCT02788240|DRUG|Meropenem or Imepenem, if indicated|
48447001|NCT02788240|DRUG|Placebo|
47928091|NCT04583709|DEVICE|ECG Belt|"ECG Belt Research System Procedure LBBP Native conduction RV pacing if available Bipolar LBBP Unipolar LBBP - nonselective and selective (different outputs) Fusion pacing with native conduction at different Atrioventricular (AV) delays~HOT-CRT Native conduction HBP / LBBP HOT-CRT AV delay optimization. Medtronic Device (pacemaker/ICD) based Holter recording during the ECG belt recording"
48447002|NCT06031766|DIETARY_SUPPLEMENT|Dietary supplement|The participation of the patients in the study will consist of performing the screening for malnutrition that is usually used in the hospital (CIPA) to which the GLIM test will be added, considered as the gold standard for this work. Subsequently, the sample of patients with a positive CIPA (as it is currently considered the screening test used in the hospital) will be implemented the therapeutic measures according to the usual protocol, while the subjects with a negative CIPA test but a positive GLIM will be studied. and constant monitoring taking the appropriate measures according to optional criteria. The patients will be followed up for the study of prognostic factors based on the variables obtained.
48447003|NCT03699696|DRUG|Propofol|Induction of anesthesia prior to surgery with propofol
48447004|NCT00001835|DRUG|Oxaliplatin|
48447005|NCT03676686|DEVICE|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
47928092|NCT01260675|DRUG|Buprenorphine HCl/Naloxone HCl|
47928093|NCT03131830|OTHER|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
48447006|NCT00256165|DEVICE|Tissue valve|Aortic valve replacement
47928094|NCT01687556|OTHER|topical EGCG application on acne|two times application of topical EGCG on acne lesion
47928095|NCT05950243|BEHAVIORAL|Questionnaire|Questionnaire survey for data collection
48098183|NCT04513028|DIETARY_SUPPLEMENT|Beta-Glucan|500mg (1 capsule) by mouth twice a day for 21 days.
48447007|NCT01358344|DRUG|Pantoprazole|40 mg delayed-release tablet administered orally in the morning of Days 1-7
48447008|NCT01358344|DRUG|SCH 530348 (high percentage)|2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
48447009|NCT01358344|DRUG|SCH 530348 (standard percentage)|2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
48447010|NCT06541886|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.
48447011|NCT00420303|DRUG|Etanercept|50 mg injection once weekly
48447012|NCT00420303|OTHER|Placebo|placebo
48447013|NCT04908007|OTHER|Qualitative analysis for professionals|"3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals"
48447014|NCT04908007|OTHER|Quantitative analysis for Professionals|"A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1."
48447015|NCT04908007|OTHER|Quantitative analysis for Patients|"A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient"
48447016|NCT04908007|OTHER|Tools development|"Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff."
48447017|NCT04849650|DRUG|Amisulpride IV|A single 10mg IV dose of Amisulpride given over 1 minute
48447018|NCT04849650|DRUG|Amisulpride Oral Tablet|A single 10mg dose given as an oral tablet
48447019|NCT04852978|DRUG|casirivimab+imdevimab|Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
48447020|NCT04852978|BIOLOGICAL|Moderna mRNA-1273 vaccine|Single intramuscular (IM) injection
48447021|NCT05934565|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
48447022|NCT05125211|DRUG|GB001 recombinant peptide spray|administrated oral spray
48447023|NCT05125211|DRUG|Placebo|administrated oral spray
48447024|NCT02045472|DRUG|VIS410|
48447025|NCT02045472|DRUG|Placebo|
48447026|NCT04070547|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
48447027|NCT04070547|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
48447028|NCT01537887|DRUG|LY2484595|Administered orally once daily for 10 days.
48447029|NCT01537887|DRUG|Placebo|Administered orally once daily for 10 days.
48098184|NCT02280161|OTHER|cytology specimen collection procedure|Correlative studies
48447030|NCT01537887|DRUG|Moxifloxacin|Single dose administered orally.
48447031|NCT06366581|DIAGNOSTIC_TEST|Transcriptomic analysis|high-throughput sequencing technology
48447032|NCT03392454|PROCEDURE|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
48447033|NCT03392454|PROCEDURE|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
48447034|NCT05898607|OTHER|continuous Thoracic paravertebral block|continuous infusion U/S-Guided TPVB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure intraoperative.
48447035|NCT05898607|OTHER|continuous Erector spinae plane block|continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
48447036|NCT04757298|BEHAVIORAL|Navigation Services|Navigation services include assessment and support with service referrals. Each participant will meet with a peer navigator in person or on Zoom Conferencing for 30 minutes to go over results from their social and health needs assessment that is retrieved from the baseline assessment. The navigator shares information about COVID-19, answers questions about testing, and makes referrals to other needed services
48447037|NCT04757298|BEHAVIORAL|Critical Dialogue|Critical Dialogue includes three one-hour-long, open-group-sessions facilitated in person or online by a trained licensed facilitator. Group critical dialogue is prompted by thematic images developed by the NCCB to foster a deeper understanding of how systematic stigma, feelings of rage as victims of discrimination, and/or apathy may impact participants' beliefs and behaviors related to COVID-19 and empower participants to make critical choices to protect their health and the health of their communities.
48447038|NCT04757298|BEHAVIORAL|Brief Counseling|Brief Counseling is a 15-minute post-COVID-19 test session delivered by a trained licensed clinician in person or via Zoom Conferencing. In the session, the clinician shares the test results and offers recommendations and information about COVID-19 treatment and prevention.
48098185|NCT01582945|DRUG|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
48447039|NCT04757298|BEHAVIORAL|Referral and Digital Brochure|Referral will consist of a five-minute phone call where an outreach worker offers participants information about COVID-19 testing and encourages them to get tested within one week. A digital brochure containing NJ recommendations is e-mailed or texted to participants.
48447040|NCT00764777|DEVICE|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
48447041|NCT05261802|OTHER|Descriptive Intervention|A trained facilitator, supported by Career and Family Coaches, leads every HMRE parenting workshop for adults via multiple delivery models: in recurring weekly workshops (2 hours each workshop for 7 weeks) and intensive weekend retreats (totaling 16 hours). Additionally, AVANCE offers the weekly workshops either virtually via Zoom or in-person. All workshop models were offered to program participants who were able to choose whether the weekly (either in-person or virtually) or the weekend (in-person only) format worked best for them. Curriculum content is consistent across all delivery methods and target hours for all participants is 14 hours.
48447042|NCT04093245|BEHAVIORAL|GEM nurse|hospital-based geriatric emergency nurse (GEM nurse) specialist to support patients during the post-discharge transition period
48447043|NCT04093245|BEHAVIORAL|pre- and post-hospitalization medication list reconciliation|pre- and post-hospitalization medication list reconciliation for elderly
48447044|NCT04093245|BEHAVIORAL|systematic discharge summaries|systematic discharge summaries given to patients and/or caregiver, and sent to their family physician
48098186|NCT05621798|OTHER|Hearing Aid Manufacturer's Software|"When using hearing aid manufacturer's software (s.c. first-fit or initial fit) the fitting will follow the guided fitting procedure in the fitting software."
48278632|NCT06657456|DIETARY_SUPPLEMENT|Placebo|Product with identical characteristics to the experimental product.
48278633|NCT04161040|BEHAVIORAL|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
48278634|NCT04232033|OTHER|Fibroblast growth factor 21 infusion|Infusion of Fibroblast growth factor 21
48278635|NCT04232033|OTHER|Placebo infusion (saline)|Infusion of Saline
48447045|NCT04093245|BEHAVIORAL|medical follow-up appointment|a planned follow-up appointment with their family physician
48447046|NCT04093245|BEHAVIORAL|follow-up phone call|a systematic follow-up phone call for discharged patients
48447047|NCT04093245|OTHER|Wiki-based Knowledge tools|access to wiki-based patient-oriented KT tools
48447048|NCT04093245|OTHER|Telemonitoring service|access to a community-based telemonitoring service
48447049|NCT04438187|OTHER|antimicrobial initiation|antimicrobial initiation based on protocol assignment.
48447050|NCT05718284|DEVICE|AIRVO2|APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY
48447051|NCT05718284|OTHER|STANDARD CARE|APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY
48447052|NCT04489641|BEHAVIORAL|Psychological treatment|Psychological treatment
48447053|NCT04489641|DRUG|Medication|Pharmacological intervention
48278636|NCT04493164|DRUG|Ivosidenib|Given PO
48278637|NCT04493164|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48447054|NCT00467363|DRUG|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
48447055|NCT00467363|DIETARY_SUPPLEMENT|Folic acid|400micrograms of folic acid.
48447056|NCT01309672|DRUG|abiraterone acetate|1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
48447057|NCT01309672|DRUG|Prednisone|5 mg, oral, 5 mg twice daily
48447058|NCT00833937|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
48447059|NCT00833937|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
48447060|NCT05793086|DIAGNOSTIC_TEST|Ultrasound|Using shear wave elastography and gray scale analysis of ultrasound.
48447061|NCT05793086|DIAGNOSTIC_TEST|Electrical impedance myography|Measurement of localized bioimpedance of muscle
48447062|NCT05793086|DIAGNOSTIC_TEST|Excitability testing|Electrical studies of myofiber excitability
48447063|NCT00520429|BEHAVIORAL|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
48278638|NCT05537038|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
48447064|NCT05761652|OTHER|Observe and record|The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.
48447065|NCT01195038|BIOLOGICAL|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
48447066|NCT00579345|BIOLOGICAL|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
48447067|NCT00579345|BIOLOGICAL|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
48447068|NCT00579345|BIOLOGICAL|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV_a administered.
48447069|NCT00579345|BIOLOGICAL|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
48447070|NCT02417298|DRUG|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
48447071|NCT02417298|DRUG|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
48447072|NCT03657550|DRUG|Levamlodipine, Amlodipine|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
48447073|NCT03657550|DRUG|Amlodipine, Levamlodipine|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
48447074|NCT00693628|DEVICE|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
48447075|NCT05613686|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
48447076|NCT01736878|DRUG|Sorafenib|
47928096|NCT01822314|DRUG|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
48278639|NCT05537038|BIOLOGICAL|BNT164b1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
48278640|NCT05537038|OTHER|Placebo|Placebo
48278641|NCT01339455|PROCEDURE|AHSCT|"AHSCT Procedure:~1. Mobilization and Harvesting:~   * Cyclophosphamide~  * Rituximab~  * GSCF~  * Dexamethasone~  * Apheresis~2. Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~   * Cyclophosphamide~  * MESNA~  * Rabbit ATG~  * Rituximab~  * Methylprednisolone~  * Stem Cell infusion~  * GSCF"
48278642|NCT00566787|DEVICE|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
48278643|NCT01053312|DRUG|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
48278644|NCT03423355|DRUG|Dapagliflozin (Forxiga®)|10mg p.o. daily
48278645|NCT03423355|DRUG|Hydrochlorothiazide 25 mg|25mg p.o. daily
48278646|NCT03423355|DRUG|Placebo matching Dapagliflozin|Placebo matching Dapagliflozin p.o. daily
48278647|NCT01729689|OTHER|counseling intervention|Undergo cognitive behavioral therapy
48278648|NCT01729689|OTHER|questionnaire administration|Ancillary studies
48278649|NCT01729689|PROCEDURE|quality-of-life assessment|Ancillary studies
48278650|NCT03963973|DRUG|RDN-929 oral capsule|low, medium and high dose
48278651|NCT03963973|DRUG|Placebo oral capsule|matching placebo dose
48278652|NCT06412341|BEHAVIORAL|Accepting your Body after Cancer|See 'Arm Description'
48278653|NCT06412341|BEHAVIORAL|Macmillan body image booklet|See 'Arm Description'
48278654|NCT06656871|DIETARY_SUPPLEMENT|iron supplementation|The iron tablet group received iron supplementation (30 mg, 1 tablet/day of iron) for 4 weeks
48278655|NCT06656871|DIETARY_SUPPLEMENT|Biostimulated lettuce supplementation|the intervention group SwE lettuce group received lettuce biostimulated with Ecklonia Maxima algae (SwE lettuce, 100 grams/day) daily for 4 weeks
48278656|NCT05107180|DIAGNOSTIC_TEST|drug screen|urine sample
48278657|NCT05660122|DRUG|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
48278658|NCT03919240|BIOLOGICAL|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
48278659|NCT03425903|DEVICE|Whole body cryotherapy sessions|Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
48278660|NCT04976465|DRUG|Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
48278661|NCT04976465|DRUG|Without Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
48278662|NCT05270603|OTHER|ICARUS intraoperative adverse events calculator|"The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language."
48447077|NCT04468867|DIAGNOSTIC_TEST|Automated whole breast ultrasound|This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy
48447078|NCT04468867|DIAGNOSTIC_TEST|Breast MRI|This will be performed by band 6 or 7 radiographer with MRI training
48447079|NCT05229133|DEVICE|CLEAR|FEMTO LDV Z8 Surgical Laser is intended for use in Corneal Lenticule Extraction for Advanced Refractive correction (CLEAR), also called Curved Lamellar Resection (CLR), for the reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude.
48447080|NCT06510998|BEHAVIORAL|isometric wall exercise|Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
48447081|NCT06510998|BEHAVIORAL|passive stretching|A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
48447082|NCT04819594|OTHER|Elequil aromatabs ®|100% pure essential oils in a unique controlled delivery system for relaxation, comfort, and sleep. Scented tabs on a self-adhesive label will be placed on the nurses's uniform for 4 hours to provide aromatherapy for the clinical setting.
48447083|NCT01676194|OTHER|Intra-arterial administration of DC BeadsR|
48447084|NCT05985343|DRUG|Neostigmine / Glycopyrrolate|Patients will receive standard of care for reversal of neuromuscular blockade
48447085|NCT05985343|DRUG|Sugammadex|Patients will receive sugammadex for reversal of neuromuscular blockade
48447086|NCT01521481|OTHER|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
48447087|NCT01521481|OTHER|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
48447088|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
48447089|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
48447090|NCT02504333|DRUG|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
48447091|NCT02504333|DRUG|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
48447092|NCT02504333|DRUG|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
48447093|NCT04508790|DRUG|Dexamethasone|Given PO
48447094|NCT04508790|DRUG|Leflunomide|Given PO
48447095|NCT04508790|DRUG|Pomalidomide|Given PO
48447096|NCT02220647|DRUG|Linagliptin/Metformin FDC|
48447097|NCT02220647|DRUG|Linagliptin|
48447098|NCT02220647|DRUG|Metformin|
48447099|NCT03112863|DRUG|Bakuchiol|This group will receive bakuchiol
48447100|NCT03112863|DRUG|Retinol|This group will receive retinol
48447101|NCT05579535|OTHER|gait training exercises|walking exercises in different directions
48447102|NCT02392195|OTHER|Non-interventional|Observational
48447103|NCT06318156|DIAGNOSTIC_TEST|Infrared thermal imaging|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
48447104|NCT05349513|OTHER|ESSME questionnaire|The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
48447105|NCT02702882|DIETARY_SUPPLEMENT|Fenugreek Seeds Extract|Furosap one caps OD
48447106|NCT04537481|OTHER|Lipid extraction|The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
48447107|NCT00412503|DRUG|Topotecan, Temozolomide|
48447108|NCT06421935|DRUG|M9466|Participants will be administered M9466 orally.
48447109|NCT06421935|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
48447110|NCT03755050|OTHER|general and specific data|General and specific data collected
48447111|NCT02953223|OTHER|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
48447112|NCT06323239|RADIATION|SBRT|SBRT for metastatic lesions
48447113|NCT06323239|RADIATION|Low-dose Radiotherapy (LDRT)|LDRT for metastatic lesions
48447114|NCT06323239|DRUG|Toripalimab|6 cycles for combined therapy. Toripalimab maintenance for 1 year.
48447115|NCT06323239|DRUG|Gemcitabine|6 cycles for combined therapy.
48447116|NCT06323239|DRUG|Cisplatin|6 cycles for combined therapy.
48447117|NCT06323239|RADIATION|IMRT|IMRT for primary lesion
48447118|NCT02963259|DEVICE|SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system|Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
48447119|NCT05824481|DRUG|Cadonilimab|Injectable solution
48447120|NCT05824481|DRUG|Lenvatinib|Capsule
48447121|NCT02177422|DRUG|Telmisartan|telmisartan 80 mg once daily
48447122|NCT02177422|DRUG|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure \< 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
48447123|NCT05960747|OTHER|Simulation group|Specific training for medical students by using an augmented virtual reality simulator for thoracentesis
48447124|NCT00561015|DRUG|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
48447125|NCT00561015|DRUG|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 \& PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
48447126|NCT00561015|DRUG|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
48447127|NCT06562088|DRUG|HDM1002 and rifampicin|Administered orally
48447128|NCT06562088|DRUG|HDM1002 and itraconazole|Administered orally
48447129|NCT04430985|DRUG|Oxaliplatin|Day 1 in cycle 1-4: 100 mg/m2 intrahepatic administration Day 1 in cycle 5-8: oxaliplatin 85 mg/m2 i.v.
48447130|NCT04430985|DRUG|5-Fluorouracil|Day 1 each cycle: 400 mg/m2 i.v. bolus, 2400 mg/m2 i.v.over 46 hrs
48447131|NCT04430985|DRUG|Leucovorin|Day 1 each cycle: 400 mg/m2 i.v.
48447132|NCT04430985|DRUG|Nivolumab|Day 3 in cycle 3 to 8: 3 mg/kg i.v.
48447133|NCT04430985|DEVICE|Ipilimumab|Day 3 in cycle 3 and 6: 1 mg/kg i.v.
48447134|NCT03253003|DEVICE|Line extension of the Phonak Audéo B product family|The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
48447135|NCT03157193|DRUG|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
48447136|NCT03157193|DRUG|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
48447137|NCT05391165|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
48447138|NCT01621893|PROCEDURE|Subchondroplasty|
48447139|NCT04440592|DRUG|MT-7117|MT-7117
48447140|NCT04440592|DRUG|Placebo|Placebo
48447141|NCT01056484|BEHAVIORAL|Mindfulness Based Relapse Prevention for Alcohol Dependence|"All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study."
48447142|NCT01056484|OTHER|"Wait-list control"|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
48447143|NCT05523986|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
48447144|NCT05523986|OTHER|Placebo|Placebo
48447145|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|800 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
48447146|NCT04368520|DIETARY_SUPPLEMENT|Vitamin D3|3,200 IU Fultium-D3, cholecalciferol (Internis), given daily for 3 months
48447147|NCT04368520|OTHER|Placebo|Hypromellose capsules, given daily for 3 months
48447148|NCT06187441|DRUG|Daratumumab Injection|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
48447149|NCT06187441|DRUG|Dexamethasone|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
48447150|NCT06187441|DRUG|Lenalidomide capsule|Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
47928097|NCT01822314|DRUG|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
48447151|NCT00764712|DRUG|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
48447152|NCT01837810|DRUG|Ibuprofen|800mg every 8 hours as needed for pain
48447153|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
48447154|NCT01055041|DRUG|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
48447155|NCT01055041|DRUG|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
48447156|NCT02008097|DEVICE|GE LOGIQ E9 Ultrasound System|"Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound."
48447157|NCT02601625|DRUG|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
48447158|NCT02601625|DRUG|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
48447159|NCT02601625|DRUG|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
48447160|NCT02601625|DRUG|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
48447161|NCT02601625|DRUG|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
48447162|NCT02601625|DRUG|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
48447163|NCT03289884|OTHER|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
48447164|NCT03289884|OTHER|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
48447165|NCT03289884|OTHER|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
48447166|NCT03289884|OTHER|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
48447167|NCT03289884|OTHER|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
48447168|NCT01937143|BEHAVIORAL|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
48447169|NCT01937143|BEHAVIORAL|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
48447170|NCT01937143|BEHAVIORAL|Control|General information about infant immunizations at birth of a newborn infant
48447171|NCT00834535|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
48447172|NCT00834535|DRUG|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
48447173|NCT03463850|RADIATION|Dual Energy CT (DECT)|Dual Energy CT (DECT)
47928098|NCT01843647|DRUG|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
47928099|NCT01843647|DRUG|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
48447174|NCT03463850|RADIATION|DEXA|Dual-energy x-ray absorptiometry for measurement of bone mineral density
48447175|NCT05878626|OTHER|Transcranial Direct Current Stimulation|The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
48447176|NCT00211653|DRUG|N-Acetylcysteine|
48447177|NCT01138163|DRUG|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
48447178|NCT06223932|DRUG|Molnupiravir|COVID-19 diagnosed patients receiving molnupiravir will be evaluated to show if Molnupiravir is effective in reducing the combined outcome of hospitalization/death due to COVID-19 in the first 28 days when used in real life.
48447179|NCT05035394|PROCEDURE|Cataract surgery|Cataract Surgery in a standardized fashion
48447180|NCT05035394|PROCEDURE|KDB|Goniotomy with KDB glide will be performed at the end of Cataract Surgery
48447181|NCT05035394|PROCEDURE|Istent|Two iStent inject W will be injected into Schlemms Canal at the end of Cataract Surgery
48447182|NCT02061917|OTHER|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
48447183|NCT02061917|OTHER|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
48447184|NCT02061917|OTHER|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
48447185|NCT04845802|OTHER|Inspiratory muscle training(high-IMT group)|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training. Training intensity will set at 60% of the maximum inspiratory pressure.
48447186|NCT04845802|OTHER|Inspiratory muscle training(low-IMT group)|Dancers will be perform at a load setting of level 1 (corresponding to \~10% baseline MIP), using the same device as the training group.
48447187|NCT01730638|DRUG|• TF2 and 68 Ga-IMP-288|
48447188|NCT06561971|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
48447189|NCT01380782|DRUG|BIBF 1120|200 mg BID oral for 28 day cycle
48447190|NCT06253403|BEHAVIORAL|psychotherapy|psychotherapy related to sexual intervention
48447191|NCT02810886|DRUG|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
48447192|NCT03108911|OTHER|Best Practice|Receive standard diet
48447193|NCT03108911|PROCEDURE|Biospecimen Collection|Provide stool sample
48447194|NCT03108911|OTHER|Dietary Intervention|Receive GFD
48447195|NCT03108911|OTHER|Laboratory Biomarker Analysis|Correlative studies
48447196|NCT02950805|DRUG|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
48447197|NCT02950805|DRUG|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
48447198|NCT05948683|DRUG|MDMA|The stimulant MDMA
48447199|NCT05948683|DRUG|Placebo|Dextrose
48447200|NCT02557347|BEHAVIORAL|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
48447201|NCT00849823|BEHAVIORAL|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
48447202|NCT00849823|BEHAVIORAL|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
48447203|NCT05004116|DRUG|Repotrectinib|TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).
48447204|NCT05004116|DRUG|Irinotecan and temozolomide|Irinotecan and temozolomide will be given as per institutional standard.
48447205|NCT06601894|DIAGNOSTIC_TEST|Platelets count|the study include will take medical investigation data for all sickle cell patients.
48447206|NCT03961230|DRUG|Jueyin granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
48447207|NCT03961230|DRUG|Jueyin Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
48447208|NCT05598658|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
48447209|NCT05598658|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
48447210|NCT00440934|DEVICE|Amplitude-modulated electromagnetic fields|
48447211|NCT01124305|DEVICE|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
48447212|NCT01124305|DEVICE|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
48447213|NCT06191094|DRUG|Faricimab Injection|Pre-operative injection of bevacizumab appears to have mixed results in lowering post-operative vitreous hemorrhage. One potential reason is due to aspiration and removal of medication in the vitreous humor at the time of pars plana vitrectomy leading to less than anticipated results in controlling neovascularization and vitreous hemorrhage post-operatively. To avoid attenuation of our desired effect we plan to repeat faricimab injection post-operatively around week one.
48447214|NCT06191094|DRUG|sham treatment|Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection
48447215|NCT05432687|DIAGNOSTIC_TEST|evaluation of deep abdominal wall before surgery|: cough test (L guillarme) + ulstrasonography of transversus abdominis
48447216|NCT04535076|PROCEDURE|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Implantation
48447217|NCT04535076|PROCEDURE|Surgical Aortic Valve Replacement|Surgical Aortic Valve Replacement
48447218|NCT00264966|DRUG|ASM8|
48447219|NCT04605783|DIETARY_SUPPLEMENT|Travelan®|Travelan® (600mg) taken as 1 sachet twice daily with meals. Product will be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
48447220|NCT04605783|OTHER|Placebo|Maltodextrin - To be started 2 days prior to arrival and maintained for a maximum duration of 20 days (minimum of 10 days) during travel or deployment.
48447221|NCT00962611|DRUG|Copanlisib (Aliqopa, BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
48447222|NCT03447353|DRUG|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
48447223|NCT03447353|DRUG|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
48447224|NCT03447353|DRUG|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
48447225|NCT02355418|PROCEDURE|Mitral valve repair|Standard mitral valve repair surgery
48447226|NCT04024163|DRUG|Benznidazole|Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
48447227|NCT02471820|DRUG|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
48447228|NCT02471820|DRUG|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
48447229|NCT02471820|DRUG|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
48447230|NCT04782232|OTHER|No intervention|No intervention due to observational design
48447231|NCT05198947|DRUG|Permethrin Lotion 5%|Topical permethrin 5% lotion to apply on day 1 and repeat after 1 week.
48447232|NCT05198947|DRUG|Permethrin Lotion 5% and Oral Ivermectin 200 mcg/kg|Topical permethrin 5% lotion and oral ivermectin 200 mcg/kg to be taken on day 1 only.
48447233|NCT01429870|DRUG|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
48447234|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
48447235|NCT00947076|DRUG|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
48447236|NCT03663322|PROCEDURE|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
47928100|NCT00484185|DRUG|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
47928101|NCT03751254|DEVICE|Stellaris Elite|The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length \> 25.0 mm) during cataract surgery
47928102|NCT00040846|BIOLOGICAL|alemtuzumab|Given IV
47928103|NCT00040846|DRUG|fludarabine phosphate|Given IV
48447237|NCT03663322|PROCEDURE|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
48447238|NCT03506386|OTHER|No Intervention|As it was an observational study, no intervention was administered.
48447239|NCT04678440|DRUG|[18F]F-AraG Imaging|Total body PET imaging using \[18F\]F-AraG
48447240|NCT01959568|PROCEDURE|Vitrectomy and tamponade|"In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location."
48447241|NCT02187354|DRUG|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment \& no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) \& 28μg/day for the escalated dose after dose step should not be exceeded.
48447242|NCT02187354|OTHER|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
48447243|NCT03097107|DRUG|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
48447244|NCT03097107|DRUG|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
48447245|NCT03097107|DRUG|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
48447246|NCT03097107|DRUG|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
48447247|NCT02514330|OTHER|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
48447248|NCT02514330|OTHER|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
48447249|NCT01022463|DRUG|Ivabradine|Ivabradine 5 mg BId for 4 weeks
48447250|NCT01022463|DRUG|Atenolol|50 mg od for 4 weeks
48447251|NCT02188563|OTHER|Comprehensive smoking cessation intervention|
48447252|NCT02188563|BEHAVIORAL|Enhanced usual care|
48447253|NCT06449053|PROCEDURE|ORGANIZATIONAL|A. a formalization of the recommendations to be applied to prevent DILH B. implemented and facilitated by an e-health application C. and will be based on adapting the hospital environment (connected mats, movement sensors, prescription assistance) D. and the dissemination of knowledge (production of summary and empowerment documents).
48447254|NCT03527485|DIAGNOSTIC_TEST|11UCB-J PET Scan|11UCB-J PET Scan
48447255|NCT04289532|DRUG|99mTc-RWY|99mTc-RWY were injected into volunteers and patients before the SPECT/CT scans .
48447256|NCT06560112|DRUG|AK104|ivgtt
48447257|NCT06560112|DRUG|AK112|ivgtt
48447258|NCT06560112|DRUG|Chemotherapy|ivgtt
48447259|NCT04736186|DRUG|Loperamide|Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
48447260|NCT04736186|DRUG|Loperamide and golden bifid|Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
48447261|NCT04736186|DRUG|Loperamide and montmorillonite powder|Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
48447262|NCT03415828|DEVICE|Ethanol gel|Intradiscal injection of ethanol gel
48447263|NCT03415828|DRUG|Prednisolone acetate|Intradiscal infiltration of steroids
48447264|NCT06486298|DEVICE|Vacuum Drain and Passive Drain insertion at abdominoplasty surgery|Compare the subcutaneous collection with Vacuum Drain and Passive Drain insertion at abdominoplasty surgery
48447265|NCT06115291|OTHER|Smell Test|Oils are used for each of the different scents. Each scent is administered via an aromatherapy inhaling stick.
47928104|NCT00040846|RADIATION|total-body irradiation|Undergo TBI
47928105|NCT00040846|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
47928106|NCT00040846|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
47928107|NCT00040846|DRUG|mycophenolate mofetil|Given PO
47928108|NCT00040846|DRUG|cyclosporine|Given IV or PO
48447266|NCT04437199|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)"
48447267|NCT04437199|DRUG|Placebo|Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
48447268|NCT04535388|DEVICE|LK scleral lens|LK scleral lens fitting and application were done for 12 weeks.
48447269|NCT05329103|DRUG|PEEL-224|Lyophilized powder reconstituted with D5W
48447270|NCT03306030|DRUG|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
48447271|NCT03306030|DRUG|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
48447272|NCT00096291|OTHER|Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"
48447273|NCT00096291|OTHER|Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
48447274|NCT05217225|PROCEDURE|Simple restorative treatment|Simple Occlusal Cavity class I then followed by final restoration
48447275|NCT05747807|DEVICE|Percutaneous intradiscal radiofrequency treatment|using heat created by radiofrequency electrode to destroy the nociceptive pain fibres and enhance the structural integrity of the disc
48447276|NCT03760939|OTHER|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
48447277|NCT03723993|DEVICE|Inflated cuff|After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
48447278|NCT03723993|DEVICE|Non inflated cuff|non inflated cuff around the arm for the control group
48447279|NCT02544672|DEVICE|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
48447280|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
48447281|NCT00545805|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
48447282|NCT04710381|DRUG|IMUNOR|The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
48447283|NCT02437747|DRUG|SRP + Aloe|Scaling and root planing along with aloe vera application was done
48447284|NCT02437747|PROCEDURE|SRP|Scaling and root planing was done
48447285|NCT01668264|PROCEDURE|Echocardiograph|
48447286|NCT01668264|PROCEDURE|Magnetic Resonance Imaging (MRI)|
48447287|NCT05549934|DRUG|PF-06651600|tablets containing active drug (a combined JAK3/TEC inhibitor)
48447288|NCT04907838|DRUG|Insulin clamp|Continous infusion insulin + glucose
48447289|NCT04907838|DRUG|BQ123|Continuous infusion of Insulin + glucose + BQ123
48447290|NCT04907838|DRUG|BQ123 + BQ788|Continous infusion of insulin + glucose + BQ123 + BQ788
48447291|NCT01299454|DRUG|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
48447292|NCT04444050|DRUG|BMS-986331|Specified dose on specified days
48447293|NCT04444050|OTHER|Placebo, Matching BMS-986331|Specified dose on specified days
48447294|NCT06560099|DRUG|Oxytocin|will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
48447295|NCT00089193|BIOLOGICAL|incomplete Freund's adjuvant|
48447296|NCT00089193|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
48447297|NCT00089193|BIOLOGICAL|sargramostim|
48447298|NCT01289262|PROCEDURE|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
48447299|NCT01289262|PROCEDURE|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
48447300|NCT05749887|PROCEDURE|salvage surgery|"Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~1. No parametrial involvement, extrafascial hysterectomy;~2. There is parametrial involvement, extensive hysterectomy(Q-MC);~3. Only bladder invasion, anterior pelvic exenteration;~4. Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~5. Invasion of bladder and rectum, total exenteration.~6. The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5."
48447301|NCT03490058|DRUG|Truvada|A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
48447302|NCT04862039|DEVICE|Virtual Reality (VR) devices|Virtual Reality (VR) devices. Subjects receiving the experimental treatment will be given a VR headset, headphones and wristband and the Philips wireless fetal-maternal monitoring system, after the necessary preparation of the abdominal skin.
48447303|NCT01223105|PROCEDURE|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
48447304|NCT01223105|PROCEDURE|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
48447305|NCT02732821|PROCEDURE|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
48447306|NCT03394235|DEVICE|Long-pulsed, 1064nm Nd-YAG laser|This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
48447307|NCT05420896|OTHER|Manual Therapy|Upper cervical spine mobilization Posterior-anterior mobilization of the fifth cervical vertebra Suboccipital inhibition Suboccipital mobilization Trigger point application to my masseter, temporal and sternocleidomastoid muscles Intraoral and extraoral myofascial release Intraoral sphenopalatine ganglion technique TMJ mobilization Massage for chewing muscles The 45-minute treatment program, which includes applications including the techniques above, will be applied to the patients randomly assigned to the study group once a week for a total of 4 weeks.The changes in muscle activity of the masseter and anterior temporalis bilaterally will be recorded with EMG.
48447308|NCT00003885|DRUG|arsenic trioxide|
48447309|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
48447310|NCT00076817|BIOLOGICAL|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
48447311|NCT00296062|BIOLOGICAL|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
48447312|NCT00296062|DRUG|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
48447313|NCT00296062|DRUG|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
48447314|NCT00296062|DRUG|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I"
48447315|NCT05977049|BEHAVIORAL|Takotsubo Support Group|Participants will undergo virtual group therapy/education. Participants will meet once every other week (at minimum), for 1 - 1.5 hours (on average). The frequency and/or length of the support group sessions may be adjusted according to participants' needs.
48447316|NCT05171179|PROCEDURE|Breast Reconstruction (Mammaplasty)|Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
48447317|NCT05171179|DEVICE|Pecs blocks|Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.
48447318|NCT05171179|DRUG|Exparel|Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
48447319|NCT05171179|DRUG|Bupivacaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arms 2 and 3.
48447320|NCT05171179|DRUG|Lidocaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in arm 1.
48447321|NCT03491072|DEVICE|Transcutaneous electrical nerve stimulation|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
48447322|NCT03491072|DRUG|Fentanyl|Patients will receive IV fentanyl
48447323|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
48447324|NCT01344863|DRUG|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
48447325|NCT05355441|DRUG|Paracetamol|Routine clinical practice treatments recommended by the medical team involved
48447326|NCT05355441|DRUG|Ibuprofen 600 mg|Routine clinical practice treatments recommended by the medical team involved
48447327|NCT05355441|DRUG|Tramadol|Routine clinical practice treatments recommended by the medical team involved
48447328|NCT05355441|DRUG|Morphine|Routine clinical practice treatments recommended by the medical team involved
48278663|NCT01882361|DRUG|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
48278664|NCT01882361|DRUG|placebo comparator|this placebo has no specific pharmacological activity
48278665|NCT02844361|OTHER|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
48278666|NCT02844361|OTHER|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
48278667|NCT06275217|BEHAVIORAL|Mindfulness-based yoga program|The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.
48278668|NCT06275217|OTHER|Psychoeducation|Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.
48278669|NCT01585389|GENETIC|gene expression analysis|
48278670|NCT01585389|GENETIC|genetic linkage analysis|
48278671|NCT01585389|GENETIC|microarray analysis|
48278672|NCT01585389|OTHER|immunohistochemistry staining method|
48278673|NCT01585389|OTHER|laboratory biomarker analysis|
48278674|NCT00492219|DEVICE|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
48278675|NCT00492219|DEVICE|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
48278676|NCT04341571|DIETARY_SUPPLEMENT|Probiotics|Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
48278677|NCT04341571|DRUG|Metformin|"Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention."
48278678|NCT06216093|BIOLOGICAL|EuRSV|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
48278679|NCT06216093|OTHER|Placebo Comparator|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
48278680|NCT05677139|OTHER|None (Observational Study)|Not applicable since it's an observational study.
48447329|NCT05326386|BEHAVIORAL|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
48447330|NCT05349695|DEVICE|Spinal cord stimulation|Eligible patients will undergo a SCS trial period for three weeks (as legally defined by the reimbursement authorities). The leads can be placed both surgically of percutaneously with an external trial stimulator. Surgical implantation of an implanted pulse generator (IPG) is performed if the patient achieves at least 50% pain reduction and a reduced pain medication use (reimbursement requirements) during the trial period. Subsequently, the implanted devices are programmed to the optimal parameters in collaboration with a nurse specialized in SCS treatment. The patients are educated on the use of the patient programmer.
48447331|NCT04164589|DEVICE|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
48447332|NCT06013293|PROCEDURE|Zinc oxide eugeonal based sealer|Zinc oxide-eugenol (ZOE)- based preparations, which have been used in root canal obturation (RCO) for over a hundered years and are known for their antimicrobial activities.slight microleakage and zinc oxide-eugenol's superior antibacterial property,slight microleakage and concerning the lower cytotoxicity, the zinc oxide-eugenol (ZOE) sealer can be used for root canal obturation as an endodontic sealer.After root canal prepartion , the root canal will be dried with paper points and obturated using gutta-percha cones and zinc oxide eugenol sealer.
48447333|NCT06013293|PROCEDURE|Resin Based Sealer|resin-based sealer used frequently as a gold standard for endodontic sealers, due to its good physicochemical properties and provide satisfactory adhesion interface with dentin radicular surface.After root canal preparation, the root canal will be dried with paper points and obturated using gutta-percha cones and Resin based sealer
48447334|NCT04941586|OTHER|Education in pain, Manual Therapy and Exercises|twice a week, lasting 60 minutes, for one month
48447335|NCT04941586|OTHER|Manual Therapy and Exercises|twice a week, lasting 40 minutes, for one month
48447336|NCT01987765|DRUG|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
48447337|NCT04850755|DRUG|Selinexor in combination with nivolumab and ipilimumab|Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
48447338|NCT01233622|DRUG|Vildagliptin|
48447339|NCT01233622|DRUG|Placebo|
48447340|NCT05379647|DRUG|QN-019a|Experimental Interventional Therapy
48447341|NCT05379647|DRUG|Rituximab|Monoclonal Antibody
48447342|NCT05379647|DRUG|Cyclophosphamid|Lympho-conditioning Agent
48447343|NCT05379647|DRUG|Fludarabine|Lympho-conditioning Agent
48447344|NCT05379647|DRUG|VP-16|Lympho-conditioning Agent
48447345|NCT05248308|DEVICE|Embozene Microspheres|"Embozene Microspheres are manufactured by Varian Medical Systems (Palo Alto, CA). These microspheres are non-resorbable hydrogel microspheres coated with polyzene-F. Embozene microspheres are approved for use in treating arteriovenous malformations, hypervascular tumors such as uterine fibroids and hepatomas, and prostatic arteries in patients with benign prostatic hyperplasia.~One of the causes of chronic pain in the setting of a knee arthroplasty may be increased blood flow to the specific area(s) of pain. The purpose of this procedure is to reduce blood flow (embolize) to specific parts of the knee which are contributing to your pain.~This procedure is performed by infusing the Embozene particles into specific knee arteries (genicular arteries) in the region of knee pain."
48447346|NCT04229225|DRUG|UBX0101|Investigational drug intra-articular (IA) injection
48447347|NCT04229225|OTHER|Placebo|Placebo intra-articular (IA) injection
48278681|NCT02360098|OTHER|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
47928109|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
48278682|NCT03668756|PROCEDURE|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
48278683|NCT06656832|OTHER|Heart Failure network care|Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic
48278684|NCT03142607|DRUG|Metronidazole gel|1% Metronidazole gel
48278685|NCT03142607|DRUG|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
48447348|NCT05840796|DIETARY_SUPPLEMENT|soy protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
48447349|NCT05840796|DIETARY_SUPPLEMENT|casein protein drink|"The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4 months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study."
48447350|NCT03977129|DEVICE|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR \> 0.80, then no CABG revascularization of target blood vessels will be carried out.
48447351|NCT03977129|OTHER|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
48447352|NCT04564053|DRUG|LNA043|Single intra-articular injection on Day 1
48447353|NCT04564053|DRUG|Placebo|Single intra-articular injection on Day 1
48447354|NCT05801484|OTHER|Linezolid continuous infusion|Continuous infusion of 1200 mg linezolid in 24h, after an initial dose of 600 mg linezolid administered as one hour infusion
48447355|NCT03530852|DEVICE|Relizorb|Tube feeds run across device to digest fats.
48447356|NCT01796171|DRUG|10 MBq/kg Betalutin|
48447357|NCT01796171|DRUG|15 MBq/kg Betalutin|
48447358|NCT01796171|DRUG|20 MBq/kg Betalutin|
48447359|NCT01796171|DRUG|40 mg lilotomab|
48447360|NCT01796171|DRUG|100 mg/m2 lilotomab|
48447361|NCT01796171|DRUG|60 mg/m2 lilotomab|
48447362|NCT01796171|DRUG|Rituximab|
48447363|NCT01796171|DRUG|12.5 mBq/kg Betalutin|
48447364|NCT05155683|DEVICE|Photobiomodulation (PBM) with infrared LED|All participants will receive 30 minutes of PBM (or PBM sham), with an abdominal strap containing 4 LED clusters with 72 devices that emit 830 nm wavelength with 20 nm spectral width, in continuous operating mode, 5 mW average radiant power per LED, 71 mW/cm² power density at aperture, 20.4 cm² of total area irradiated, 71 mW/cm² of irradiance at target, exposure duration of 1800 seconds, 127.8 J/cm² of radiant exposure, 2.6 kJ of radiant energy, per contact application technique, twice a week for a month, totaling 8 sessions.
48278686|NCT05250856|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
48278687|NCT05250856|DRUG|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
48278688|NCT04788264|OTHER|Medical Device Usage and Evaluation|Receive Fitbit
48278689|NCT04788264|OTHER|Consultation|Receive consultation from a physical therapist
48278690|NCT04788264|OTHER|Exercise Intervention|Attend exercise training sessions
48278691|NCT04788264|BEHAVIORAL|Behavioral Intervention|Attend sessions with a behavioral therapist
48278692|NCT04788264|OTHER|Questionnaire Administration|Ancillary studies
48278693|NCT04788264|OTHER|Quality of Life Assessment|Ancillary studies
48278694|NCT03668223|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
48278695|NCT02774590|DRUG|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
48278696|NCT02675777|OTHER|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~1. Identification of a clinical champion and Local Implementation Team.~2. Participatory Design.~3. Training primary care providers and Medical Assistants.~4. EHR clinical decision support tools~5. Weekly facilitated Local Implementation Team meetings.~6. Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~7. Learning sessions for primary care providers during implementation.~8. Social worker use of an EHR registry with weekly supervision.~9. Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
48278697|NCT01667848|DEVICE|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
48278698|NCT01667848|DEVICE|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
48278699|NCT06503198|BEHAVIORAL|Virtual care|"Through Cloud DX, intervention group participants will receive:~Remote Automated Monitoring: measurement of: blood pressure, heart rate, respiratory rate, oxygen saturation, temperature and weight.~Frailty-tailored daily symptom survey: The recovery survey consists of questions related to infection, bleeding, pain, appetite, dehydration, appetite, syncope and falls.~The tablet will prompt the participant to complete a Katz Index of Independence in Activities of Daily Living (IADL) survey. The FAM-CAM survey will also be pushed by Cloud DX to be completed.~Virtual RN assessment: a virtual RN assessment will be scheduled at a minimum of every 2 days for the first 7 days. The virtual RN will also perform the 4AT Delirium Assessment.~Medications: the virtual RN will undertake medication review and reconciliation. In addition, they will provide counselling regarding analgesic support and monitor for drug interactions."
48278700|NCT05766579|DEVICE|Elastic-compressive stockings|Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
48447365|NCT05155683|DEVICE|Low-frequency ultrasound (LOFU)|Subsequently the demarcation of the target area for LOFU treatment (Thoor DGM Electronica, Santo André, São Paulo, Brazil), the application of the neutral conductive gel will occur for the use of low-frequency ultrasound for 30 minutes, which will occur with 22 cm² effective radiating area (ERA) size, \<8 BNR emission intensity, 40 kHz frequency, continuous mode, 60W, 100 cm² of total treated area, twice a week for a month, totaling 8 sessions.
48447366|NCT05155683|DEVICE|Muscle electrostimulation|The session will end with 20 minutes of Russian Current (Tensor DGM Electronica, Santo André, São Paulo, Brazil), whose carrier frequency occurs in 2500 Hz, which will be adjusted according to the parameters described by Evangelista et al. (2003), which are: pulse frequency of 30 Hz; up/down ramp of 2 seconds each; support/rest time of 13 seconds each. The current intensity used will be the maximum supported by each participant and that is comfortable and sufficient to provide visible contraction. The treatment will consist of eight sessions that will occur twice a week, totaling a month of treatment.
48447367|NCT04092023|OTHER|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
48447368|NCT01839344|DIETARY_SUPPLEMENT|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
48447369|NCT01839344|DRUG|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
48447370|NCT01839344|DRUG|placebo|An oral single dose of a solid, colored empty capsule.
48447371|NCT00073307|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
48447372|NCT00073307|DRUG|Placebo|Placebo
48447373|NCT06331338|BEHAVIORAL|Decision Cycle for Person-Centered Glycemic Management|It is defined as a purposefully designed holistic care intervention that improve self-management .
48447374|NCT06331338|OTHER|Traditional diabetes self-management education|Traditional diabetes self-management education content focuses more on teaching relevant knowledge and some skills.
48447375|NCT03026374|BEHAVIORAL|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
48447376|NCT03708991|DIAGNOSTIC_TEST|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
48447377|NCT03708991|DIAGNOSTIC_TEST|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
48447378|NCT04530994|DRUG|maralixibat|Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
48447379|NCT04801589|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
48447380|NCT04801589|DRUG|Midazolam|For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
48447381|NCT01701492|OTHER|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
48447382|NCT01701492|OTHER|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
48447383|NCT01660789|BEHAVIORAL|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
48447384|NCT06169605|PROCEDURE|removal of primary tumor, neck dissection|removal of the primary tumor with safety margins and removal of the neck lymph node levels I, II, III and IV. histological assessment of tumor thickness and whether it is associated with positive nodes in level IV or not.
48447385|NCT04527107|DRUG|THR-149 dose level 1|3 intravitreal injections of THR-149 dose level 1, 1 month apart
48447386|NCT04527107|DRUG|THR-149 dose level 2|3 intravitreal injections of THR-149 dose level 2, 1 month apart
48447387|NCT04527107|DRUG|THR-149 dose level 3|3 intravitreal injections of THR-149 dose level 3, 1 month apart
48447388|NCT04527107|DRUG|THR-149 0.13mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
48447389|NCT04527107|DRUG|THR-149 0.13mg + aflibercept 2mg|3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by an intravitreal injection of aflibercept 2mg
48447390|NCT04527107|DRUG|aflibercept 2mg + THR-149 0.13mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by an intravitreal injection of THR-149 0.13mg (selected dose level)
48447391|NCT04527107|DRUG|Aflibercept 2mg|3 intravitreal injections of aflibercept 2mg, 1 month apart, followed after 1 month by a sham (pretend) injection
48447392|NCT00187720|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
48447393|NCT02022254|DRUG|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
48447394|NCT02022254|DRUG|placebo|Semaglutide placebo will be administered s.c.
48447395|NCT02022254|DRUG|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
48447396|NCT02022254|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
48447397|NCT00205621|DEVICE|Positron Emission Tomography|
48447398|NCT04678141|OTHER|Dyract XP (Dentsply De Trey), Kerr Herculite Classic (Kerr Corporation),R&D Series NOVA(Kuraray Medical Inc) Clearfil TM SE Bond (Kuraray Medical),Hydrocal LC (Medicept Dental)|compomer (Dyract XP,R\&D Series NOVA) , composite (Kerr Herculite Classic),Bonding (Clearfil TM SE Bond), Dycall (Hydrocal LC)
48447399|NCT05662826|BEHAVIORAL|Avatar-based Social Physical Activity|Exercise, group discussions, role-playing skits, and group painting done in a virtual setting.
48447400|NCT01136174|DRUG|Placebo|Placebo BID for cohort 1,2,3
48447401|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
48447402|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
48447403|NCT01136174|DRUG|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
48447404|NCT05244798|DRUG|Sintilimab|Sintilimab: D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W)
48447405|NCT05244798|RADIATION|radiotherapy|Radiotherapy: According to IMRT treatment plan, the total dose was 41.4Gy, divided into 23 times, 5 days a week.
48447406|NCT05244798|DRUG|Chemotherapy|Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
48447407|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on saturated fat.
48447408|NCT00813215|DIETARY_SUPPLEMENT|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
48447409|NCT01433718|PROCEDURE|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
48447410|NCT03587493|OTHER|BLOOD SAMPLE ANALYSIS|Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
48447411|NCT00824291|DRUG|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
48447412|NCT00824291|GENETIC|Genotyping|CYP2D6 genotyping at randomization
48447413|NCT00695162|OTHER|quiet|no noise
48447414|NCT00695162|OTHER|non-speech noise|noise without speech
48447415|NCT00695162|OTHER|speech noise|noise with speech present
48447416|NCT01887522|DRUG|Vinblastine + Nilotinib|"* Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~* Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
48447417|NCT01887522|DRUG|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
48447418|NCT01980771|BEHAVIORAL|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
48447419|NCT01980771|BEHAVIORAL|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
48447420|NCT00044135|DRUG|clevudine (drug)|
48447421|NCT06563011|OTHER|Counselling|Tailored Dietary Counselling
48447422|NCT01442155|DRUG|Capecitabine|Administered according to the Summary of Product Characteristics.
48447423|NCT01442155|BIOLOGICAL|Oxaliplatin|Administered according to the Summary of Product Characteristics.
48447424|NCT03859102|DIETARY_SUPPLEMENT|Pre-operative Carbohydrate PreLoad drink|Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.
48447425|NCT03859102|DRUG|Oral Gabapentin pre-op|One dose of Gabapentin pre-operatively, 300mg orally.
48447426|NCT03859102|DRUG|Oral Lansoprazole pre-op|One dose of Lansoprazole pre-operatively, 30mg orally.
48447427|NCT03859102|DRUG|Intravenous Paracetamol intra-operatively|One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
48447428|NCT03859102|DRUG|Intravenous Dexamethasone intra-operatively|One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.
48447429|NCT03859102|DRUG|Intravenous Ondansetron intra-operatively|One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous
48447430|NCT03859102|DRUG|Infiltration of surgical wounds with local anaesthetic|Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
48447431|NCT03859102|DRUG|Intravenous Magnesium intra-operatively|One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.
48447432|NCT03859102|DRUG|Post-operative Gabapentin analgesia|Post-operative oral Gabapentin 300mg, three times daily as an analgesic.
48447433|NCT03859102|DRUG|Post-operative oral Paracetamol analgesia|Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.
48447434|NCT03859102|DRUG|Post-operative Ondansetron anti-emesis|Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.
48447435|NCT03859102|PROCEDURE|Early extubation|Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.
48447436|NCT03859102|PROCEDURE|Early mobilisation/physiotherapy|Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.
48447437|NCT03859102|OTHER|Encourage early oral food intake|Patients will be encouraged to start eating as soon as possible post-operatively
48447438|NCT00858793|PROCEDURE|PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)|Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
48447439|NCT01673685|DEVICE|Portable Oxygen|
48447440|NCT04890418|DRUG|Ketalar, 5 mg/mL Injectable Solution|The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
48447441|NCT04890418|OTHER|Placebo|The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.
48447442|NCT02890992|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form: solution Route of administration: subcutaneous injection
48447443|NCT02890992|DRUG|statins|Pharmaceutical form: tablet Route of administration: oral
48447444|NCT02890992|DRUG|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
48447445|NCT02890992|DRUG|cholestyramine|Pharmaceutical form:tablet Route of administration: oral
48447446|NCT02890992|DRUG|fenofibrate|Pharmaceutical form: tablet Route of administration: oral
48447447|NCT02890992|DRUG|omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
48447448|NCT02890992|DRUG|nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
48447449|NCT04012892|COMBINATION_PRODUCT|CD19 CART|CD19 CART
48447450|NCT06433388|DEVICE|MRI|Magnetic Resonance Imaging (MRI) is a non-invasive imaging technology that produces three dimensional detailed anatomical images. Patients will be subjected to MRI scans and imaging of the kidneys and liver
48447451|NCT01177020|OTHER|Biological specimen|Biological specimen taken from placenta
48447452|NCT02067611|DRUG|X0002|Parallel Assignment
48447453|NCT02067611|DRUG|Placebo|Parallel Assignment
48447454|NCT04116463|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
48447455|NCT04116463|BEHAVIORAL|Financial Self-Management Program (FSMP)|
48447456|NCT00835991|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
48447457|NCT00835991|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
48447458|NCT01778010|DRUG|Modafinil 0 mg|Modafinil (0 mg/day)
48447459|NCT01778010|DRUG|Modafinil 200 mg|Modafinil (200 mg/day)
48447460|NCT01778010|DRUG|Modafinil 400 mg|Modafinil (400 mg/day)
48447461|NCT01778010|DRUG|Cocaine 0 mg|Cocaine (0 mg/day)
48447462|NCT01778010|DRUG|Cocaine 12 mg|Cocaine (12 mg/day)
48447463|NCT01778010|DRUG|Cocaine 25 mg|Cocaine (25 mg/day)
48447464|NCT01778010|DRUG|Cocaine 50 mg|Cocaine (50 mg/day)
48447465|NCT05180422|DRUG|AMG 510|Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.
48447466|NCT05180422|DRUG|MVASI|Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).
48447467|NCT01065740|OTHER|Patient education|
48447468|NCT00541788|OTHER|Administration of Common Sage|Administration of Common Sage
48447469|NCT01421277|DRUG|Statin Therapy|Investigator's choice of any statin.
48447470|NCT04829240|BEHAVIORAL|Veterans Anxiety Skills Training Intervention|Modular anxiety intervention designed for Primary Care-Mental Health Integration settings, including up to six 30-minute sessions occurring approximately every 2 weeks, in which Veterans select modules of interest to them to complete, with an emphasis on psychoeducation and cognitive-behavioral coping strategies for self management of anxiety symptoms
48447471|NCT04829240|BEHAVIORAL|PCMHI Usual Care|Appointment with Primary Care-Mental Health Integration provider at local primary care clinic for anxiety treatment; provider delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PCMHI care
48447472|NCT01808794|DEVICE|Mucograft|Mucograft Collagen Matrix
48447473|NCT01808794|DEVICE|Dynamatrix|Dynamatrix
48447474|NCT01015300|DRUG|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
48447475|NCT05821647|OTHER|HPI guided treatment advice|Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
48447476|NCT02760927|DEVICE|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
48447477|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
48447478|NCT03031847|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
48447479|NCT05382858|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
48447480|NCT03397251|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
48447481|NCT05234567|BIOLOGICAL|Asfotase Alfa|All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged \< 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
48447482|NCT02927639|OTHER|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
48447483|NCT06126263|DRUG|Linezolid|Adjunctive antitoxin therapy
48447484|NCT06126263|DRUG|Clindamycin|Adjunctive antitoxin therapy
48447485|NCT02072577|BEHAVIORAL|Video|"The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially."
48447486|NCT04834128|DRUG|TCB008|administration of gamma delta T cells by IV bolus injection
48447487|NCT06339645|PROCEDURE|PRP|Patients who meet all eligibility requirements for entry into the study of intravesical PRP injection
48447488|NCT06052917|OTHER|DECIdE|DECIdE is a decision aid. Its a communication tool to help health providers as general practitioners or community pharmacists, to practice shared medical decision about optional prescription drug. DECIdE provide robust scientific data about benefit and risks associated to the drug under consideration. DECIdE was built based on the consensus of potentials users ( care providers and patients ), tested on users testing and finally validated by a expert consensus ( DELPHI method).
48447489|NCT01855750|DRUG|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
48447490|NCT01855750|DRUG|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
48447491|NCT01855750|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
48447492|NCT01855750|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
48447493|NCT01855750|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
48447494|NCT01855750|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
48447495|NCT01855750|DRUG|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
48447496|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
48447497|NCT06560008|DIETARY_SUPPLEMENT|Caffeine (200 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
48447498|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Caffeine (200 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
48447499|NCT06560008|DIETARY_SUPPLEMENT|Placebo (MCC 300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
48447500|NCT01208727|PROCEDURE|postconditioning|Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.
48278701|NCT03744650|BEHAVIORAL|"Care4Heart programme"|"A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation"
48278702|NCT03431220|DEVICE|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
48278703|NCT00896961|DRUG|EF5|
48278704|NCT00896961|OTHER|diagnostic laboratory biomarker analysis|
48278705|NCT00896961|OTHER|pharmacological study|
48278706|NCT02790489|DIETARY_SUPPLEMENT|Valedia|
48447501|NCT06560775|COMBINATION_PRODUCT|Standard Treatment for SLE|Standard Treatment for SLE
48447502|NCT00904423|DRUG|Vitamin D|up to 2400 mg; oral tablet
48278707|NCT03886168|OTHER|Signal processing intervention of a biomedical device|This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
48278708|NCT04873687|DEVICE|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
48278709|NCT06256848|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48278710|NCT06256848|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
48278711|NCT01491178|DRUG|Prazaxa|Dabigatran etexilate
48278712|NCT05439616|DRUG|Cariprazine|Oral Capsules or Oral Solution
48278713|NCT05439616|DRUG|Placebo|Oral capsules or Oral Solution
48278714|NCT00779129|DRUG|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
48278715|NCT00779129|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
48278716|NCT03088514|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
48278717|NCT03793543|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
48278718|NCT03643692|DEVICE|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
48278719|NCT04604925|BEHAVIORAL|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
48278720|NCT01607892|DRUG|KPT-330|
48278721|NCT06001606|DRUG|Shingrix|Shingrix vaccination
48447503|NCT00354835|DRUG|Cyclophosphamide|Given IV
48447504|NCT00354835|BIOLOGICAL|Dactinomycin|Given IV
48447505|NCT00354835|DRUG|Irinotecan Hydrochloride|Given IV
48278722|NCT06001606|DRUG|Placebo|Placebo vaccination
48447506|NCT00354835|OTHER|Laboratory Biomarker Analysis|Correlative studies
48447507|NCT00354835|OTHER|Questionnaire Administration|Ancillary studies
48447508|NCT00354835|RADIATION|Radiation Therapy|Undergo radiotherapy
48447509|NCT00354835|DRUG|Vincristine Sulfate|Given IV
48447510|NCT03004703|DRUG|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
48447511|NCT03004703|DRUG|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
48447512|NCT02950987|DEVICE|Whole Body MRI|
48447513|NCT03956784|DEVICE|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~* Normal situation~* Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~* Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
48447514|NCT03956784|OTHER|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~1. Immediate complications and warning signs:~   * Tachycardia\> 120 bpm~  * Dyspnea~  * Rectorragies and / or melena~  * Vomiting with or without presence of blood~  * Major abdominal pain (visual analogue scale\> 6/10)~  * Fever\> 38~2. Management to deal with complications: call the service and / or the surgeon~3. Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
48447515|NCT05135104|DRUG|Palbociclib|"Palbociclib, an orally active pyridopyrimidine, is a potent and highly selective reversible inhibitor of CDK 4 and CDK6. The compound prevents cellular DNA synthesis by prohibiting progression of the cell cycle from G1 into the S phase. Specifically, Palbociclib inhibits CDK4/6-catalyzed phosphorylation of the retinoblastoma protein (Rb), which is required for cell division.~Palbociclib has selectivity for CDK4/6, with little or no activity against a large panel of 274 other protein kinases including other CDKs and a wide variety of tyrosine and serine/threonine kinases.~Therapeutic indications:~Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or MBC:~* in combination with an aromatase inhibitor;~* in combination with fulvestrant in women who have received prior endocrine therapy."
48447516|NCT03100084|OTHER|Blood sampling|Maternal blood sampling
48447517|NCT06485323|DEVICE|MRI pelvimetry|MRI of the pelvis
48447518|NCT00682500|DRUG|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
48447519|NCT00682500|DRUG|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
48447520|NCT03916263|DRUG|Metformin|Traditional care including diet, exercise and metformin
48447521|NCT03916263|OTHER|One-On-One Dietary Instruction|Participant receives one-on-one dietary counseling from study personnel
48447522|NCT03916263|OTHER|Video Dietary Instruction|Participant receives video dietary instruction
48447523|NCT05374876|OTHER|Hand Therapy Until CIPN|Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
48447524|NCT03346902|DRUG|EB-001|Injection of EB-001 into area of scarring (forehead)
48447525|NCT03346902|DRUG|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
48447526|NCT04924920|DIAGNOSTIC_TEST|SIGH|To add the Sigh35 to PSV, the ventilator is set in pressure controlled synchronized intermittent mandatory ventilation plus PSV \[SIMV (PC) + PS mode\], with SIMV rate set a 1/min and inspiratory time of 4 seconds. SIMV (PC) = 35 cmH20 of total inspiratory support (PEEP + PS).
48447527|NCT04924920|DIAGNOSTIC_TEST|EEOT|• The EEOT is performed by interrupting the mechanical ventilation for 15 seconds, by using and end-expiratory hold on the ventilator. The ventilator trigger is set at 2 L/min.
48278723|NCT06657014|OTHER|mind-mindedness|The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
48278724|NCT01943656|DEVICE|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
48278725|NCT03245814|BEHAVIORAL|Service Dog|A service dog trained to perform tasks that are specific to PTSD
48278726|NCT05261217|DEVICE|The motion 3D II appliance|The motion 3D II appliance treating class II malocclusion
48278727|NCT02931448|DEVICE|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
48278728|NCT05388669|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
48278729|NCT05388669|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Amivantamab injection will be administered subcutaneously by manual injection.
48278730|NCT05388669|DRUG|Amivantamab Intravenous|Amivantamab will be administered by IV infusion.
47928110|NCT02577393|DRUG|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
48278731|NCT03419793|DEVICE|segmental vibration device|segmental vibration device
48278732|NCT03419793|OTHER|physical therapy exercises|
48278733|NCT00332787|DRUG|Fluoxetine|
48278734|NCT05928806|DRUG|Botensilimab|Botensilimab 75mg IV
48278735|NCT05928806|DRUG|Balstilimab|Balstilimab 450mg IV
48278736|NCT05928806|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV
48278737|NCT05928806|DRUG|Nivolumab|Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
48447528|NCT04924920|DIAGNOSTIC_TEST|Fluid challenge|Bolus of fluids of 4 ml/kg given within 10 minutes
48447529|NCT00000885|DRUG|Indinavir sulfate|
48278738|NCT02000843|PROCEDURE|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
48278739|NCT02505048|DRUG|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
48278740|NCT05073692|DRUG|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
48278741|NCT05073692|DRUG|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
48278742|NCT05073692|DRUG|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
48278743|NCT05073692|DRUG|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
48278744|NCT05073692|DRUG|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
48278745|NCT05073692|DRUG|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
48278746|NCT05073692|DRUG|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
48278747|NCT05073692|DRUG|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
48278748|NCT05073692|DRUG|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
48278749|NCT05073692|DRUG|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
48278750|NCT05073692|DRUG|Glipizide (SU)|Exposure to Glimepiride (SU)
48278751|NCT05073692|DRUG|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
48278752|NCT05073692|DRUG|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
48278753|NCT05073692|DRUG|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
48278754|NCT00001515|DEVICE|virtual bronchoscopy|
48278755|NCT00618722|DRUG|Deoxycholic Acid Injection|
48278756|NCT00618722|DRUG|Placebo|
48278757|NCT00354302|DIETARY_SUPPLEMENT|calcium carbonate|
48278758|NCT00354302|DIETARY_SUPPLEMENT|calcium citrate|
48447530|NCT00000885|DRUG|Abacavir sulfate|
48447531|NCT00000885|DRUG|Nelfinavir mesylate|
48447532|NCT00000885|DRUG|Efavirenz|
48447533|NCT00000885|DRUG|Levocarnitine|
48278759|NCT00354302|DIETARY_SUPPLEMENT|cholecalciferol|
48278760|NCT00354302|DRUG|alendronate sodium|
48278761|NCT00354302|DRUG|calcium gluconate|
48278762|NCT00354302|DRUG|risedronate sodium|
48278763|NCT00354302|OTHER|laboratory biomarker analysis|
48278764|NCT00354302|PROCEDURE|dual x-ray absorptometry|
48278765|NCT06260163|DRUG|Guselkumab Subcutaneous|Guselkumab will be administered subcutaneously.
48278766|NCT06260163|DRUG|Guselkumab Intravenous|Guselkumab will be administered intravenously.
48278767|NCT00817414|DRUG|LCI699-matching placebo|LCI699-matching placebo oral capsules
48278768|NCT00817414|DRUG|LCI699|LCI699 oral capsules
48278769|NCT02033226|DEVICE|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
48278770|NCT02033226|DEVICE|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
48278771|NCT00525291|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
48278772|NCT00525291|DEVICE|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
48278773|NCT03756090|DRUG|Palbociclib|Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
48278774|NCT03756090|DRUG|Placebo oral capsule|Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
48278775|NCT03756090|DRUG|Epirubicin|Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
48278776|NCT03756090|DRUG|Cyclophosphamide|Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
48447534|NCT00000885|DRUG|Adefovir dipivoxil|
48447535|NCT00000885|DRUG|Lamivudine|
48447536|NCT00000885|DRUG|Stavudine|
48447537|NCT00000885|DRUG|Zidovudine|
48447538|NCT00000885|DRUG|Didanosine|
48447539|NCT03325881|DRUG|SHP465|SHP465 capsule 6.25 mg orally once daily for 4 weeks
48447540|NCT03325881|DRUG|Placebo|Placebo matching to SHP465 capsule orally once daily for 4 weeks
48447541|NCT02938351|BEHAVIORAL|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
48447542|NCT00900094|GENETIC|fluorescence in situ hybridization|
48447543|NCT00900094|GENETIC|polymerase chain reaction|
48447544|NCT00900094|GENETIC|protein expression analysis|
48447545|NCT00900094|OTHER|immunohistochemistry staining method|
48447546|NCT00900094|OTHER|laboratory biomarker analysis|
48447547|NCT00900094|OTHER|mass spectrometry|
48447548|NCT05232786|OTHER|No treatment given|No treatment given
48447549|NCT05221021|DRUG|Vaginal estrogen|0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
48447550|NCT05221021|DRUG|Mirabegron 50 MG [Myrbetriq]|50mg oral Mirabegron once daily
48447551|NCT02106156|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
48447552|NCT02106156|DRUG|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
48447553|NCT01787565|OTHER|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
48447554|NCT01787565|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
48447555|NCT02062489|DRUG|Tamoxifen|20 mg(2#)/day, PO, daily
48447556|NCT02062489|DRUG|Placebo|2#/day, PO, daily
48447557|NCT01293474|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
48447558|NCT04147845|OTHER|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
48447559|NCT04147845|OTHER|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
48447560|NCT04147845|OTHER|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
48447561|NCT04147845|OTHER|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
48278777|NCT03756090|DRUG|Paclitaxel|Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
48278778|NCT03459040|DRUG|Alpha 1-Antitrypsin|AAT will be given either in the hospital or the outpatient clinic two times per week.
48278779|NCT02601417|OTHER|Ignoring result of bile culture|the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
48278780|NCT05786482|BEHAVIORAL|Online mind-body wellness program|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
48278781|NCT05786482|BEHAVIORAL|Online mind-body wellness program + Weekly Check-ins|Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
48278782|NCT02582671|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
48278783|NCT02582671|DRUG|Dasabuvir|Tablet
48447562|NCT04418310|PROCEDURE|Lay open and curettage|Lay open and curettage
48447563|NCT04418310|PROCEDURE|Endoscopic (E.P.Si.T) method|Endoscopic (E.P.Si.T) method
48447564|NCT00805779|DEVICE|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
48447565|NCT03083574|DEVICE|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
48447566|NCT05796869|BEHAVIORAL|Assigned Interventions|The laughter therapy session will be administered to the application group face to face for 25-30 minutes once a week for 2 months by a researcher with a laughter therapy certificate. In the laughter therapy session, introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, maintaining the rhythm with music, turning laughter that starts like a child's play into reality and meditation practices will be carried out.
48447567|NCT03774303|OTHER|Mobile application|A mobile application that will be used to prepare families for day surgery
48447568|NCT03774303|OTHER|current practice|the current practice used to prepare families for day surgery
48447569|NCT03341156|DRUG|Kcentra|Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
48447570|NCT03341156|DRUG|Frozen Plasma Product, Human|If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
48447571|NCT00186147|PROCEDURE|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
48278784|NCT02582671|DRUG|Ribavirin|Tablet
48278785|NCT00783627|PROCEDURE|Angiography|Angiography done at the J1 visit
48278786|NCT04702737|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
48278787|NCT01925703|DRUG|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
48278788|NCT05844384|DEVICE|Nanodropper|Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
48278789|NCT05844384|DEVICE|Regular dropper|Delivers full eye drop volume
48278790|NCT01923025|DRUG|RO5545965|Single dose
48447572|NCT06164860|OTHER|Meditteranean Diet|The MD provided 20% proteins, 40% fat and 40% carbohydrates. Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
48447573|NCT06164860|OTHER|Ketogenic Diet|The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates. The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med. Lunch and dinner were natural protein-rich dishes. Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
48447574|NCT01975623|DEVICE|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
48447575|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.
48447576|NCT01381848|DRUG|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients \>=8 weeks CA.
48447577|NCT06560749|OTHER|Physical Exercise|Measure the impact of physical exercise in the cognition of pacients diagnosed with Bipolar Disorder
48447578|NCT04875117|DEVICE|Hearing aid|One or two behind the ear hearing aids provided by the UK National Health Service.
48447579|NCT03444090|PROCEDURE|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size \<10 mm are removed as they are identified on insertion and withdrawal. Polyps with size \>10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
48447580|NCT01660945|DRUG|placebo|
48447581|NCT01660945|DRUG|vytorin|
48447582|NCT04196335|DEVICE|intra-procedural intracardiac echocardiography|use of intra-procedural intracardiac echocardiography during Watchman FLX devices
48447583|NCT02451267|OTHER|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
48447584|NCT02451267|OTHER|physical therapy treatment|neck exercise strengthening program with neck massage
48447585|NCT06282874|DRUG|Lorlatinib|Lorlatinib 100 mg once daily on days 1 to 28 of each 28-day cycle
48447586|NCT01220635|BEHAVIORAL|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
48447587|NCT01220635|BEHAVIORAL|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
48447588|NCT02700750|DEVICE|OCT exam|OCT exam
48447589|NCT03787641|DRUG|Protamine Sulfate|Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
48447590|NCT01033877|BIOLOGICAL|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
48447591|NCT01033877|BIOLOGICAL|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d)
48447592|NCT06281834|DRUG|Rifapentine|Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
48447593|NCT06281834|DRUG|Dolutegravir|All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
48447594|NCT04826874|BEHAVIORAL|Affect labeling|Short behavioral intervention teaching affect labeling
48447595|NCT05108779|DRUG|QLF32004|In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
48447596|NCT06558851|BEHAVIORAL|High intensity endurance training|12 weeks of high intensity endurance training three times a week. Two of the weekly sessions are supervised.
48447597|NCT02606708|RADIATION|Accelerated intensity modulated radiation therapy (AIMRT)|
48447598|NCT02529709|OTHER|High-Protein Condition|The participants will be fed a high-protein meal
48447599|NCT02529709|OTHER|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
48447600|NCT01141374|OTHER|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
48447601|NCT01141374|OTHER|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
48447602|NCT02197260|DRUG|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
48447603|NCT00359489|DEVICE|cardiac echosonography|
48447604|NCT00165685|DRUG|Sibutramine Hydrochloride Monohydrate|
48447605|NCT01494532|DRUG|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
48447606|NCT01494532|DRUG|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
48447607|NCT01891994|DRUG|Eltrombopag|Oral administration of eltrombopag 150mg/day (75 mg/day for East Asian ancestry) for 6 months
48447608|NCT00699296|DRUG|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
48447609|NCT03115177|DRUG|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
48447610|NCT03115177|DRUG|Cefazolin|
48278791|NCT06657755|DIAGNOSTIC_TEST|Immunohistochemistry|This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.
48278792|NCT05601206|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
48447611|NCT03568565|BEHAVIORAL|ePREP Program|see arm descriptions
48447612|NCT03568565|BEHAVIORAL|OurRelationship Program|see arm descriptions
48447613|NCT00202722|DRUG|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
48447614|NCT01319383|DRUG|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
48447615|NCT03467399|DEVICE|Nucleus 7 Cochlear Implant System|A new cochlear implant sound processor system.
48447616|NCT06153485|DEVICE|AutoO2|Automated Titration of Oxygen (Auto-O2) using a closed-loop system in which the oxygen flow to the participant is continuously adjusted on the basis of pulse oximetry signals to maintain a target range of oxygen saturation to meet the participant's immediate needs.
48447617|NCT06153485|OTHER|FixedO2|Fixed flow oxygen delivery administered using manual flow meters according to standard clinical procedures.
48447618|NCT02911792|DRUG|Dapagliflozin|SGLT2 inhibitor
48447619|NCT02911792|DRUG|Metformin|Oral diabetes medicine that helps control blood sugar levels.
48447620|NCT02911792|DRUG|Glipizide 5 MG|Oral diabetes medicine that helps control blood sugar levels.
48447621|NCT00376493|DRUG|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
48447622|NCT01610245|DRUG|Nitazoxanide|
48447623|NCT01610245|DRUG|Oseltamivir|
48447624|NCT01610245|DRUG|Placebo Oral Tablet|
48447625|NCT01610245|DRUG|Placebo Oral Capsule|
48447626|NCT01445691|DRUG|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
48447627|NCT03126747|DRUG|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
48447628|NCT02688023|DRUG|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
48447629|NCT04881968|BEHAVIORAL|Hopewell Hospitalist Video Game|Hopewell Hospitalist is a customized theory-based adventure video game that uses narrative engagement to educate physician players on advance care planning to increase physicians' likelihood of engaging in and billing for ACP conversations.
48447630|NCT02017119|DRUG|Comparison between Lactulose and Lactulose-Paraffin|
48447631|NCT02401607|OTHER|Karasek questionnaire and Saliva prelevement|Karasek questionniare and Saliva collection will be assessed on any health care worker working in any emergency department in France at day 1 and at 5 years
48447632|NCT03384602|OTHER|Dalcroze Eurhythmics Program|music-based multi-task exercise in group setting
48447633|NCT03384602|OTHER|home exercise strength program|simple strength exercise program to perform individually at home
48447634|NCT00749177|OTHER|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
48447635|NCT00003484|DRUG|carmustine|
48447636|NCT00003484|DRUG|irinotecan hydrochloride|
48447637|NCT00003484|PROCEDURE|surgical procedure|
48447638|NCT00003484|RADIATION|iodine I 131 monoclonal antibody 81C6|
48447639|NCT04576494|OTHER|Monthly assessments of functional motor abilities by a trained therapist|Monthly assessments of functional motor abilities in adult 5q-SMA type 2 and type 3 patients by a trained therapist
48447640|NCT04576494|DRUG|Nusinersen|nusinersen
48447641|NCT04074603|DEVICE|The needle-free jet injector|Continuous insulin therapy for 2 weeks
48447642|NCT04074603|DEVICE|Conventional insulin pen|Continuous insulin therapy for 2 weeks
48447643|NCT03381274|BIOLOGICAL|Oleclumab|Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.
48447644|NCT03381274|DRUG|Osimertinib|Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.
48447645|NCT03381274|DRUG|AZD4635|Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
48447646|NCT05492279|DIETARY_SUPPLEMENT|sheep ghee|natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
48447647|NCT05492279|DIETARY_SUPPLEMENT|sunflower oil|natural sunflower oil, given to patients in a commercial box and patient use 10 gr of it
48447648|NCT02311686|DIETARY_SUPPLEMENT|10 g ethanol|Alcohol single oral dose
48447649|NCT02311686|DIETARY_SUPPLEMENT|20 g ethanol|Alcohol single oral dose
48447650|NCT02311686|DIETARY_SUPPLEMENT|40 g ethanol|Alcohol single oral dose
48447651|NCT02311686|DIETARY_SUPPLEMENT|60 g ethanol|Alcohol single oral dose
48447652|NCT02311686|DIETARY_SUPPLEMENT|80 g ethanol|Alcohol single oral dose
48447653|NCT01293526|DEVICE|Control|Patients who respond will have leads will be placed using standard procedures.
48447654|NCT01293526|DEVICE|Experimental|Patients who respond will have their leads placed based on study measurements.
48447655|NCT01293526|DEVICE|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
48447656|NCT00787553|DRUG|cefazolin|2.0 g, IV, 2 hours before surgery
48447657|NCT00787553|DRUG|tinidazole|2.0 g orally, 12 hours before surgery
48447658|NCT00787553|DRUG|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
48447659|NCT02687126|DEVICE|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
48447660|NCT01400984|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
48447661|NCT00573417|DRUG|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
48447662|NCT00573417|DRUG|Placebo|
48447663|NCT03868891|DEVICE|EMST150|The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
48447664|NCT05707507|OTHER|Place of treatment|Patients with an infectious diseases have to be treated with a specify antimicrobial therapy. The differences between the arms is about the possibility to continue with the treatment in or out of the hospital.
48447665|NCT03105947|OTHER|Coconut oil|50g extravirgin coconut oil daily for four weeks
48447666|NCT03105947|OTHER|Butter|50g butter daily for four weeks
48447667|NCT03105947|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
48447668|NCT03851250|DRUG|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
48447669|NCT03851250|DRUG|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
48447670|NCT03826745|OTHER|Plasma/Urine|Plasma of normal male and female normotensive, hypertensive, and/or resistant hypertensive subjects.
48447671|NCT04405765|DEVICE|NPWT and lyopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
47928111|NCT02577393|DRUG|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
48278793|NCT05601206|BEHAVIORAL|Enhanced Usual Care|Usual care from health providers
48278794|NCT00674011|DRUG|Bevacizumab|Given as part of standard of care or another research protocol
48447672|NCT04405765|DEVICE|NPWT and cryopreserved Stravix|Subjects will be treated with NPWT and lyopreserved Stravix
48447673|NCT00897377|RADIATION|Radiation therapy|
48447674|NCT00897377|DRUG|Temozolomide|
48447675|NCT01607918|DRUG|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
48447676|NCT01607918|DRUG|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
48447677|NCT02181647|BEHAVIORAL|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
48447678|NCT01972490|DRUG|avastin|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.
48447679|NCT01972490|DRUG|mFOLFOX6|mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)
48447680|NCT01767103|DRUG|Ferriprox®|
48447681|NCT01265056|DRUG|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
48447682|NCT01265056|DRUG|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
48447683|NCT01173692|DRUG|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
48447684|NCT01173692|DRUG|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
48447685|NCT00002318|DRUG|Doxorubicin hydrochloride (liposomal)|
48447686|NCT00002318|DRUG|Bleomycin sulfate|
48447687|NCT00002318|DRUG|Vincristine sulfate|
48447688|NCT00002318|DRUG|Doxorubicin hydrochloride|
48447689|NCT04887480|DEVICE|Abthera™ Open Abdomen Negative Pressure Therapy Device System|Suction set at -125mmHg
48447690|NCT04887480|DRUG|Dianeal PD-2 with 2.5% Dextrose|800mL to 1000mL of Dianeal PD-2 into Abthera™ and dwell for 1 hour.
48447691|NCT02392286|DRUG|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
48447692|NCT05747950|OTHER|Vibration|Vibration is used as an alternative to physical exercise in various areas to increase muscle performance and flexibility, improve balance and proprioception, reduce spasticity and increase bone density.
48447693|NCT05747950|OTHER|Modified Constraint-İnduced Movement Therapy|Compulsory use therapy is a form of treatment in which the movements of the healthy side are prevented and the use of the weak side is encouraged in the stroke patient.
48447694|NCT05747950|OTHER|Conventional Therapy|Conventional exercises
48447695|NCT03147768|DEVICE|Distal Pancreatectomy Sealing Using LTW|The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
48447696|NCT00685607|DRUG|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
48447697|NCT00685607|DRUG|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
48447698|NCT00057538|BEHAVIORAL|Mantram Repetition|
48447699|NCT00067535|DRUG|Cocaine-Related Disorders|
48447700|NCT03301363|DEVICE|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
48447701|NCT00879918|DRUG|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
48447702|NCT02107456|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
48447703|NCT04411966|DIAGNOSTIC_TEST|18F-fluorothymidine|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
48447704|NCT05240989|PROCEDURE|pulmonary rehabilitation|one-year regular lung rehabilitation treatment and control the intensive monitoring of hemodynamic parameters
48447705|NCT03956862|DRUG|GB001|film-coated oral tablet
48447706|NCT03956862|DRUG|Placebo|film-coated oral tablet
48447707|NCT00280644|DRUG|Leflunomide|
48447708|NCT06039735|OTHER|Chemotherapy and/or autologous hematopoietic stem cell transplantation|Didn't interfere patients' treatment plan. Patients with chemotherapy (lenalidomide,bortezomib and dexamethasone) and/or autologous hematopoietic stem cell transplantation(ASCT) which is assessed by clinical doctors and only conventional treatments were used
48447709|NCT05320146|OTHER|MRI-PDFF|Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
48447710|NCT00938795|OTHER|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
48447711|NCT00938795|OTHER|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
48447712|NCT04819009|OTHER|the Enhanced Transtheoretical Model Intervention (ETMI)|"ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~1. Creating a therapeutic alliance (communication skills and reassurance)~2. Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~3. Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~4. Postcard with reminder messages on how to self manage the back."
48447713|NCT02532621|DEVICE|Venous InterGraft Connector|The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.
48447714|NCT02532621|PROCEDURE|sutured arterial anastomosis of an implanted vascular graft for hemodialysis|The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.
48447715|NCT02532621|PROCEDURE|hemodialysis|The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
48278795|NCT01846780|PROCEDURE|PTA & stenting|PTA \& stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
48447716|NCT05401734|DEVICE|Observation and follow up measurement|"The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)"
48447717|NCT04351425|DEVICE|Weaning to crib|We weaned the infants into two groups. Group A, 1.6 kg
48447718|NCT04351425|DEVICE|Weaning from incubator|We weaned the infants into two groups. group B, 1.4 kg
48278796|NCT05452382|PROCEDURE|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
48278797|NCT05452382|PROCEDURE|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
48447719|NCT01334307|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
48447720|NCT01334307|DEVICE|Control|Standard of Care
48447721|NCT05770648|DEVICE|Transcatheter Annuloplasty|Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.
48447722|NCT05770648|OTHER|The guidelines guide medication|The guidelines guide medication
48447723|NCT05238168|OTHER|ePIPARI digital follow up tool|A digital platform includes questions to parents about child wellbeing and development and parent wellbeing. A notification by email or app comes two weeks before the follow up time point. The parents respond via a link to a webpage or via an app.They also receive information (text and video) about age-appropriate child development. ePIPARI includes 8 assessment points from term age until 2 years of corrected age.
48447724|NCT04509063|BEHAVIORAL|Information about hypothetical mammography screening without benefits|We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.
48447725|NCT05170607|DIAGNOSTIC_TEST|Proteomic analysis by antibody microarrays|Proteomic analysis by antibody microarrays can be used to identify novel biomarkers and to investigate various signaling pathways including protein phosphorylation and protein-protein interactions. Microchips are manufactured as a matrix of a number of immobilized antibodies covalently bound to the glass, membrane, or gel surfaces. Microchips are used for serum proteomic studies in patients with cardiovascular diseases and cancer
48447726|NCT00308152|DRUG|Infusion of 1 litre of normal saline before colonoscopy|Prehydration with normal saline
48447727|NCT02663960|OTHER|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
48447728|NCT02663960|OTHER|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
48447729|NCT00723047|PROCEDURE|Fibrin glue injection in fistula|
48447730|NCT05755763|OTHER|Anal incontinence patients with St. Mark's Incontinence Score|The scale was applied to the patients who applied to our clinic with the diagnosis of anal incontinence.
48447731|NCT03400020|OTHER|Ascorbic acid|Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
48447732|NCT03400020|OTHER|Normal Saline|Normal saline IV two hours before the operation and thereafter for three days.
48447733|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel.
48447734|NCT05886660|DRUG|Placebo Nasal Gel|Subjects will self-administer Placebo Nasal Gel.
48447735|NCT05886660|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel. Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject.
48447736|NCT05886660|DRUG|Placebo Nasal Gel|"Subjects will self-administer Placebo Nasal Gel.~Vibrotactile feedback of tilt direction and magnitude will be provided on a sensory augmentation belt worn by the subject."
48447737|NCT04239872|DRUG|Fluoride mouthwash|Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.
48447738|NCT04239872|DRUG|Calcium and fluoride mouthwash|Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
48447739|NCT06470425|OTHER|Standard therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
48447740|NCT06470425|OTHER|AI-Guided group|Participants receive supplement prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
48447741|NCT01619904|PROCEDURE|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
48447742|NCT01619904|PROCEDURE|Standard Therapy|Following standard protocol during peri-operative period
48447743|NCT01831362|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|
48447744|NCT01831362|BEHAVIORAL|Focused Attention (FA)|
48447745|NCT01831362|BEHAVIORAL|Open- Monitoring|
48447746|NCT01447017|DRUG|DPK-060|DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
48447747|NCT01447017|DRUG|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
48447748|NCT05235386|DEVICE|Automated oxygen titration|Automated oxygen administration to maintain the SpO2 target at a predefined value during emergency length of stay
48447749|NCT02774785|DEVICE|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
48447750|NCT05671965|DIETARY_SUPPLEMENT|Xylitol|33.5g xylitol dissolved in 300mL tap water.
48447751|NCT05671965|DIETARY_SUPPLEMENT|Sucrose|33.5g sucrose dissolved in 300mL tap water.
48447752|NCT05671965|DIETARY_SUPPLEMENT|Acesulfame Potassium|0.1675g Ace-K dissolved in 300mL tap water.
48447753|NCT05671965|DIETARY_SUPPLEMENT|Water|300mL tap water.
48447754|NCT01203267|DRUG|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
48447755|NCT06288035|DRUG|Dexamethasone Oral|Patients in the intervention group will receive oral 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded.
48447756|NCT06288035|DRUG|Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensations in injection.
48447757|NCT05907421|BEHAVIORAL|Acceptance mindset|Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
48447758|NCT06510634|OTHER|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
48447759|NCT01056861|DRUG|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
48447760|NCT06176534|DRUG|Experimental: chemotheyapy|nab-paclitaxel 130mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2，day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2，day 1 and day 8 + Capecitabine 2000mg/m2，from day1 to DAY 14
48447761|NCT06176534|DRUG|Active Comparator: endocrine therapy|palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
48447762|NCT06028204|DRUG|Biologic Agent|Biologic group will have biological agent commenced if considered necessary as part of routine care.
48447763|NCT04435067|GENETIC|Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia|The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.
48447764|NCT04435067|OTHER|Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor|This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D_average, Gray Level Co-occurrence Matrix 3D_combined, Gray Level Run Length 3D_average, Gray Level Run Length 3D_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.
48447765|NCT05527561|BEHAVIORAL|Latin dance: Rumba|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
48447766|NCT05527561|BEHAVIORAL|Latin dance: Cha Cha Cha|Latin dance is a kind of sports dance, which originated in Latin America, includes the rumba, samba, Cha Cha Cha, bullfighting dances and cowboy dances. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes.
48447767|NCT03923660|OTHER|Incremental Concentric-eccentric exercise test|Patients will perform incremental exercise test on semi recumbent eccentric ergometer
48447768|NCT03923660|OTHER|Incremental Eccentric-concentric exercise test|Patients will perform incremental exercise test on semi recumbent concentric ergometer
48447769|NCT00309101|DRUG|tacrolimus|Oral
48447770|NCT00000294|DRUG|Carvedilol|
48447771|NCT02255292|DRUG|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study
48447772|NCT05921227|BEHAVIORAL|VAULT Phase 6|VAULT is an input-based word learning intervention based on principles of statistical learning.
48447773|NCT02070458|DRUG|ixazomib|Given PO
48447774|NCT02070458|DRUG|mitoxantrone hydrochloride|Given IV
48447775|NCT02070458|DRUG|etoposide|Given IV
48447776|NCT02070458|DRUG|cytarabine|Given IV
48620413|NCT03931122|DEVICE|Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)|"The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width."
48447777|NCT06205602|DRUG|3BNC117-LS|30 mg/kg to be administered via IV at Step 1 (Day 1)
48447778|NCT06205602|DRUG|10-1074-LS|10 mg/kg to be administered intravenously at Step 1 (Day 1)
48620414|NCT00992875|BEHAVIORAL|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
48278798|NCT01839474|DEVICE|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
48447779|NCT06205602|DRUG|Placebo for 3BNC117-LS|0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
48447780|NCT06205602|DRUG|Placebo for 10-1074-LS|0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
48447781|NCT00748072|DRUG|DDAVP|0.3 mcg/kg subcutaneous
48447782|NCT00748072|DRUG|saline solution|saline solution 1 ml subcutaneous
48447783|NCT00745420|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~* Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~* Fludarabine: 30 mg/m\^2/day IV on Days -8 through -4~* Melphalan: 140 mg/m\^2 IV on Day -3~* Rest on Days -2 and -1~* Transplant occurs on Day 0~* GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
48447784|NCT03804749|DRUG|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
48447785|NCT03804749|OTHER|placebo|Placebo is 0.9% sodium chloride injection.
48278799|NCT00885443|DRUG|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
48447786|NCT03717350|DRUG|Meropenem|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
48447787|NCT03717350|DRUG|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously once
48447788|NCT05734157|DEVICE|Peripheral PTA with a drug coated balloon|Peripheral artery angioplasty
48447789|NCT03876639|OTHER|Application of emulsion|Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
48447790|NCT03876639|PROCEDURE|Measurement of physiological skin parameters|Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®
48447791|NCT03876639|PROCEDURE|Tape stripping|Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
48278800|NCT00885443|DRUG|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
48278803|NCT06296264|DEVICE|Standard ultrasound|Placement of IV line using standard ultrasound.
48278804|NCT06296264|DEVICE|Ultra-portable ultrasound|Placement of IV line using ultra-portable ultrasound.
48278805|NCT06582602|BIOLOGICAL|MK-2060|Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
48447792|NCT01566617|OTHER|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
48278806|NCT06582602|BIOLOGICAL|Placebo|Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
48278807|NCT00740805|DRUG|Cyclophosphamide|Given IV
48447793|NCT01566617|OTHER|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
48447794|NCT06264960|BEHAVIORAL|Music therapy|After the patient was admitted to the angiography laboratory, approximately 10 minutes before the angiography procedure commenced, they were seated and allowed to relax. Music was played using a digital MP3 player.
48447795|NCT06264960|BEHAVIORAL|Breathing exercise|Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography. The exercises were performed in a single patient room, in a quiet and calm environment. During the first 5 minutes, the researcher explained how the exercise was done with pictures and showed it to the patient. The patient was then asked to do the exercise for 10 minutes under the supervision of the researcher.
48447796|NCT03498391|DRUG|Propofol|Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
48447797|NCT03498391|DRUG|Ketamine Injectable Product|Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
48447798|NCT03432182|DIAGNOSTIC_TEST|electroencephalography|Sleep states definition by electroencephalograpy
48447799|NCT01469351|DRUG|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
48447800|NCT01469351|DRUG|non-active study drug|placebo
48447801|NCT02811666|DEVICE|Assessment of sarcopenia by CT-Scan|
48447802|NCT02811666|DEVICE|hand gauge|
48447803|NCT06523842|OTHER|questionnaire|cronell questionnaire for assessment muscloskeletal discomfort in sedentary and standing workers males and females
48447804|NCT02807597|DRUG|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
48447805|NCT02807597|DEVICE|Cancer Vision Goggles and standard fluorescence imaging systems|-Member of the operating team will wear the CVG during surgery
48447806|NCT02807597|PROCEDURE|Surgery|-Standard of care
48447807|NCT04188080|DIETARY_SUPPLEMENT|Jarlsberg Cheese|Oral daily intake of Jarlsberg cheese
48447808|NCT02532439|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
48447809|NCT02532439|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
48447810|NCT02532439|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
48447811|NCT04478435|OTHER|glucose loaded clear fluid|Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
48447812|NCT01867164|DRUG|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
48447813|NCT01867164|DRUG|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
48447814|NCT01855035|OTHER|prolonged ECG monitoring|10-day Holter ECG measurement
48447815|NCT01855035|OTHER|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
48447816|NCT04259476|DRUG|Ketamine Hydrochloride|low dose perioperative ketamine infusion. and its effects on post-operative pain.
48447817|NCT03144050|DEVICE|SFDI Imaging|Imaging with SFDI device
48447818|NCT03327805|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
48447819|NCT03327805|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
48447820|NCT01375920|DRUG|Metyrapone|500 milligrams to be taken twice a day orally
48447821|NCT01375920|DRUG|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
48447822|NCT02604420|DRUG|eculizumab|
48447823|NCT02169063|RADIATION|carbon-11 acetate|Given IV
48447824|NCT02169063|RADIATION|fluorine F 18 sodium fluoride|Given IV
48447825|NCT02169063|PROCEDURE|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
48447826|NCT02169063|OTHER|laboratory biomarker analysis|Correlative studies
48447827|NCT00196651|DRUG|IL-2|
48447828|NCT00196651|BIOLOGICAL|LIPO-6T|
48447829|NCT00196651|BIOLOGICAL|ALVAC VIH 1433|
48447830|NCT04879719|BEHAVIORAL|Ego-depletion|The surgery video lasts for 9 minutes and participants are asked to suppress their emotions. After the intervention several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed.
48447831|NCT04879719|BEHAVIORAL|Control|The surgery video lasts for 9 minutes and participants in the control group are asked to watch the surgery video without the need to suppress their emotions. Several implicit aggression tests, as well as a task, measuring cognitive performance in general are assessed after the 9 minute video sequence.
48447832|NCT03249454|DEVICE|Anodal tsDCS|During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
48447833|NCT03249454|DEVICE|Cathodal tsDCS|During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
48447834|NCT03249454|DEVICE|Sham tsDCS|During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
48447835|NCT01915186|DIETARY_SUPPLEMENT|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
48447836|NCT04763733|OTHER|laparoscopic splenectomy|surgical
48447837|NCT02375386|PROCEDURE|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
48278808|NCT00740805|DRUG|Doxorubicin Hydrochloride|Given IV
48278809|NCT00740805|OTHER|Laboratory Biomarker Analysis|Correlative studies
48278810|NCT00740805|OTHER|Pharmacological Study|Correlative studies
48278811|NCT00740805|DRUG|Veliparib|Given PO
48278812|NCT06124703|DRUG|Prednisone tablet|Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
48278813|NCT06124703|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
48278814|NCT06107829|DRUG|Valbenazine Oral Capsule|Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
48278815|NCT06559709|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
48278816|NCT06559709|OTHER|Dietary Intervention|Receive 3 meals per day and snacks
48278817|NCT06559709|OTHER|Dietary Intervention|Meet with dietitian
48278818|NCT06559709|OTHER|Medical Chart Review|Ancillary studies
48278819|NCT06559709|OTHER|Questionnaire Administration|Ancillary studies
48447838|NCT02375386|PROCEDURE|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
48447839|NCT02375386|PROCEDURE|fMRI|Both groups will receive an fMRI.
48447840|NCT02375386|BEHAVIORAL|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
48447841|NCT02375386|OTHER|Questionnaires|Both groups will receive Questionnaires
48447842|NCT02375386|BEHAVIORAL|Physical Impairment|Both groups will receive testing on physical impairment.
48447843|NCT05684276|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, sodium chloride and glucose 5% solution solution or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of ech center."
48447844|NCT05684276|DRUG|Paclitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexa-hydroxy-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines on Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
48447845|NCT05684276|DRUG|Nivolumab|"Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains. Route of administration: Intravenous infusion. Product Description: Nivolumab (BMS-936558-01) Injection drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated in 10 mg/ml.~Storage Conditions: It must be stored at 2 to 8 degrees Cº and protected from light and freezing.~Guidelines: The administration of nivolumab infusion must be completed within 24 hours of preparation.The dose of Nivolumab for the adjuvant treatment is 360 mg administered as an intravenous infusion over 30 minutes every 3 weeks (+/-3 days) for 3 cycles.~For the maintenance adjuvant treatment the dose is nivolumab 480 mg Q4W (+/-3 days) over 30 minutes for 6 months (6 cycles).~Subjects should be carefully monitored during nivolumab administration to follow infusion reactions. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment."
48447846|NCT02308059|OTHER|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
48447847|NCT02308059|OTHER|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
48447848|NCT03338933|BEHAVIORAL|magnetic resonance imaging (MRI)|All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
48447849|NCT03227991|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
48447850|NCT03227991|BEHAVIORAL|Risk factors and Warning signs|Printed information sheet listing suicide risk factors and crisis hotlines
48447851|NCT00271115|BEHAVIORAL|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
48447852|NCT04022954|DEVICE|Catheter ablation|Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
48447853|NCT06167122|PROCEDURE|Craniofacial reconstruction|"Zone 1 lesions: radical excision and immediate reconstruction with bone grafts for fibrous dysplasia lesions.~Zone 2 lesions: trimming \& recontouring. Zone 3 lesions: observation or conservative recontouring; optic nerve decompression performed when continuous deterioration of vision, and external auditory canal surgery performed when cholesteatoma/near total ear canal stenosis.~Zone 4: observation or conservative recontouring; orthognathic surgery performed when malocclusion or midface retrusion noted."
48447854|NCT03609866|PROCEDURE|rapid thoracic compression technique|in the expiratory time of the ventilation set, it will be applied a rapid thoracic compression
48447855|NCT03609866|PROCEDURE|inferior limb passive mobilization|it will be performed a passive mobilization technique on the patient
48447856|NCT03414450|DRUG|ETC-1907206|ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
48447857|NCT03414450|DRUG|dasatinib|dasatinib tablets at 140 mg will be dosed every day
48447858|NCT05311046|DIAGNOSTIC_TEST|Pediatric sepsis screening tool (either algorithmic or manual)|All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
48447859|NCT05829733|DEVICE|SYNOLIS VA 80/160|SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
48278820|NCT02639676|OTHER|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
48278821|NCT06600711|DRUG|Nitazoxanide|5 mL suspension (100 mg), 2x/day for 3 days
48278822|NCT06600711|DRUG|Placebo|identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days
48278823|NCT06037954|OTHER|Questionnaires|Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)
48447860|NCT02756663|DRUG|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
48447861|NCT02756663|DRUG|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
48447862|NCT02756663|DRUG|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
48447863|NCT01273779|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
48447864|NCT01273779|DRUG|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
48447865|NCT00848146|PROCEDURE|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
48447866|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
48447867|NCT03643250|OTHER|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
48447868|NCT03643250|OTHER|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
48447869|NCT03643250|OTHER|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
48447870|NCT03643250|OTHER|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
48447871|NCT01727180|OTHER|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
48447872|NCT06415045|DRUG|BI 1015550|BI 1015550
48447873|NCT03776058|DRUG|Cinacalcet|Tablets for oral administration
48447874|NCT03776058|DRUG|Placebo|Tablets for oral administration
48447875|NCT05358405|OTHER|Müller maneuver|The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
48447876|NCT04194476|DIAGNOSTIC_TEST|StatStrip blood glucose meter and strips|We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
48447877|NCT01871662|DRUG|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
48447878|NCT01871662|DRUG|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
48447879|NCT01871662|DRUG|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
48447880|NCT02960568|DRUG|Primaquine|30 mg oral primaquine one time
48447881|NCT05034094|OTHER|VEMP recording|"* Clinical evaluation: All participants will undergo detailed medical and neurological histories and examinations.~* The severity of manifestations of PD will be assessed using the Movement Disorder Society (MDS)-sponsored new version of Unified PD Rating Scale (MDS-UPDRS)."
48447882|NCT04904718|DEVICE|DreaMed Advisor Pro|Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data consisting of glucose levels, insulin delivery history and meal consumption reported
48447883|NCT01804244|DRUG|TMC278|1 25-mg tablet \[27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
48447884|NCT04817904|DRUG|Rosuvastatin 10mg|The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
48447885|NCT02281084|DRUG|Oral Azacitidine|Oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.
48098187|NCT05621798|OTHER|REM (Real Ear Measurements)|Participants' hearing aids are fitted by using REM. In this method REM measurement tube is placed inside participant's ear canal near the tympanic membrane and the Real Ear Unaided Gain (REUG) is measured. REUG is used to measure the ear canal without any hearing device and shows the patients ear acoustics. Next the hearing aid is placed on the patients ear together with the REM measurement tube. In REM measurements the Real-Ear Occluded Gain (REOG) is measured with the hearing aid off. REOG allows consideration of the attenuation caused by the earpiece and its obstructing effect of external sounds. Next Real Ear Aided Response (REAR) is measured with the hearing device on. REAR allows measurement of the hearing device's amplification effect within the patients' ear and includes the effect of the patient's ear acoustics.
48447886|NCT02281084|DRUG|Durvalumab|Durvalumab 1500 mg by IV infusion on Day 1 of each 28 day treatment cycle.
48098188|NCT03275896|OTHER|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
48098189|NCT03093610|PROCEDURE|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
48098190|NCT03093610|PROCEDURE|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
48447887|NCT02011295|PROCEDURE|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
48447888|NCT02011295|OTHER|Bone Marrow Aspirate injection|
48447889|NCT05192720|DIETARY_SUPPLEMENT|Andosan|See also detailed study design, Mushroom juice based on Agaricus Blazei and two other types of mushroom.
48447890|NCT05192720|DIETARY_SUPPLEMENT|Placebo|drinking water with food colour
48447891|NCT04932837|BIOLOGICAL|Blood and Saliva collection|Serological, viral RNA and antigenic test
48447892|NCT03129373|DEVICE|Cryogenic treatment of warts|Treatment of common and plantar wart by cryotherapy treatment.
48447893|NCT06167694|DRUG|HRS-8080; Dalpiciclib Isethionate Tablets|HRS-8080 combined with Dalpiciclib Isethionate Tablets
48447894|NCT03659994|DIETARY_SUPPLEMENT|Multivitamin|Vitabeard
48447895|NCT03659994|DIETARY_SUPPLEMENT|Placebo|Placebo
48447896|NCT01827163|DRUG|Paclitaxel|
48447897|NCT01827163|DRUG|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
48447898|NCT01827163|DRUG|Lapatinib|
48447899|NCT01827163|DRUG|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
48447900|NCT03396120|DIAGNOSTIC_TEST|Pulmonary function test|forced vital capacity and diffusing capacity
48447901|NCT02587871|DRUG|Cytarabine|Given IV
48447902|NCT02587871|OTHER|Laboratory Biomarker Analysis|Correlative studies
48447903|NCT02587871|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
48447904|NCT02587871|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
48447905|NCT02587871|BIOLOGICAL|G-CSF mobilized peripheral blood cells|microtransplantation
48447906|NCT06411847|BEHAVIORAL|Virtual appointments|This group will receive the same information as the control group with additional virtual appointments at 1 week, 2 weeks and 6 weeks after fitting a Twin Block appliance. These will be scheduled and held via BlueEye Clinic (RedZinc Services Ltd.), a web-based GDPR compliant platform that allows patients to access a remote video consultation via a link sent to the participant/parent's device. The content of these appointments will follow a template that addresses the patient's experience, difficulties faced and how to overcome these, and would incorporate use of visual aids to highlight expected changes over the duration of wear. The appointments would be held in the late afternoons (after school).
48447907|NCT05170594|DRUG|Bevacizumab|Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
48447908|NCT05170594|DRUG|chemotherapy|The non-platinum chemotherapy regimen will be determined by the investigator.
48447909|NCT05170594|DRUG|Fluzoparib|Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
48447910|NCT03676946|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
48447911|NCT03676946|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
48447912|NCT03676946|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
48447913|NCT04308850|DRUG|Vitamin D drops|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
48447914|NCT00033917|DRUG|indomethacin|an anti-inflammatory drug
48447915|NCT00033917|DRUG|placebo|saline
48447916|NCT00385320|BIOLOGICAL|HRV vaccine|
48447917|NCT00909753|DRUG|Ursodiol|Ursodiol Tablets, 500 mg
48447918|NCT00909753|DRUG|Urso Forte™|Urso Forte™ Tablets, 500 mg
48447919|NCT03225547|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.
48447920|NCT03225547|DRUG|Mifepristone|Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
48447921|NCT04853563|OTHER|PEEP|High PEEP targeted to 10 cmH2O to be maintained during the period of mechanical ventilation compared with low PEEP maintaining 3-5 cmH2O
48447922|NCT05499481|DRUG|Antibiotic|"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."
48447923|NCT00128167|DRUG|Liquid CAIV-T|
48447924|NCT04596007|DRUG|HEC83518 tablets|Each dose of HEC83518 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
48447925|NCT04596007|DRUG|Placebo|placebo
48447926|NCT03964662|DEVICE|WeReha|Rehabilitation of stroke patients with the device WeReha
48447927|NCT03351998|DRUG|Lipitor 20Mg Tablet|20 mg/day pills.
48447928|NCT03351998|DRUG|Lipitor 80Mg Tablet|80 mg/day pills.
48447929|NCT03351998|DRUG|Placebo Oral Tablet|Matching placebo pill.
48447930|NCT03948022|DRUG|Dydrogesterone 10Mg Tablet (duphaston)|40 mg daily oral tablets
48447931|NCT03948022|DRUG|Progesterone 50Mg/mL Oil|100 mg daily intramuscular injections
48447932|NCT03948022|DRUG|Crinone 8% Vaginal Gel|180 mg daily vaginal gels
48447933|NCT03734718|DRUG|GIP|Infusion of Glucose-dependent insulinotropic peptide
48447934|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Two intravenous infusions delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 100x10\^6 cells at day 0 and day 84
48447935|NCT05362786|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)|Single intravenous infusion delivered systemically through a peripheral IV(over 30 minutes to 2 hours) of 200x10\^6 cells at day 0
48447936|NCT03950336|DIETARY_SUPPLEMENT|Prebiotics|Oligofructose-enriched inulin \[a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %\] 12 g/day for 6 weeks
48447937|NCT03950336|OTHER|Low n-6 PUFA Diet|The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.
48447938|NCT03950336|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (5 g/days for 6 weeks) will be used as a placebo for the prebiotic treatment
48447939|NCT03950336|OTHER|Control Diet|"Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention."
48447940|NCT00963482|BEHAVIORAL|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra \& Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
48447941|NCT00963482|BEHAVIORAL|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
48447942|NCT00620074|DRUG|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
48447943|NCT00620074|DRUG|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
48447944|NCT06561841|DRUG|HSK39297|HSK39297 tablets for 24 weeks
48278824|NCT06037954|OTHER|Interviews|Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.
48447945|NCT01975948|OTHER|Mental Health Practice Support Program|"1. training and (2) practice support.~   * Three half day workshop sessions over a 24 week period.~  * Practice support:~     3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
48447946|NCT01975948|OTHER|Treatment as Usual|Physicians manage patients with depression as usual
48447947|NCT04932447|BEHAVIORAL|Inspiratory Muscle Strength Training|30 breaths/ day, 5 days/week for 24 weeks.
48447948|NCT02233985|DRUG|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
48447949|NCT02233985|DRUG|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
48447950|NCT02431221|DRUG|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
48447951|NCT02431221|DRUG|Placebo|
48447952|NCT04513587|BEHAVIORAL|CBT-based weight loss model|Methods of cognitive behavioral psychotherapy
48447953|NCT04513587|BEHAVIORAL|Control|Treatment as usual
48447954|NCT01117220|DRUG|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
48447955|NCT01117220|DRUG|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- \< 45kg max dose 40 mg BID).
48447956|NCT05253950|OTHER|Questionnaire|answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
48447957|NCT00006682|DRUG|docetaxel|Docetaxel 70mg/m2 on day 1 of every 21-day cycle
48447958|NCT00006682|DRUG|vinorelbine ditartrate|Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
48447959|NCT06560320|BEHAVIORAL|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the vaccination procedure.
48447960|NCT04521218|OTHER|Thrust Joint Manipulation|"Experimental group included TJM, Cervical hot pack, strengthening exercises and home plan; 3 sessions of manipulation per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold."
48620415|NCT02508792|DEVICE|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
48098191|NCT06172660|DRUG|Nirsevimab|Immunoprophylaxis against RSV
48098192|NCT05258006|PROCEDURE|Autogenous demineralized dentin nanoparticles|Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect
48098193|NCT06614374|DIETARY_SUPPLEMENT|Low-dose fish oil capsules|Patients in the low-dose group will receive four fish-oil and refined olive oil mixed capsules containing 1.5 g of marine n-3 PUFAs per day.
48278825|NCT06037954|OTHER|30-minute telephone or videoconference sessions|"Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~1. Provide education about depression and treatment options~2. Identify treatment preferences and a personal goal achievable with mental health care~3. Assess barriers to treatment initiation~4. Recommend a referral using standardized referral options~5. Address barriers to accessing care"
48278826|NCT04708587|DRUG|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
48278827|NCT04708587|DRUG|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
48278828|NCT03107195|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
48278829|NCT01245244|DRUG|Morphine|Morphine oral mixture
48278830|NCT01245244|OTHER|orange juice|orange juice
48278831|NCT00332904|DRUG|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
48278832|NCT00332904|DRUG|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
48278833|NCT01390389|DRUG|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~* Visit 1 (baseline) start at 400mg once a day for two weeks~* Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
48278834|NCT03135886|OTHER|Information Control|The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
48278835|NCT03135886|OTHER|HIV and HCV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).
48278836|NCT03135886|OTHER|HIV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
48278837|NCT04214080|OTHER|Neurodevelopmental treatment (NDT)|NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
48278838|NCT04214080|OTHER|Feeding and oral-motor intervention strategies|Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
48278839|NCT04214080|OTHER|Neck and trunk stabilization exercises|Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
48278840|NCT04082247|BEHAVIORAL|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
48278841|NCT00316875|DRUG|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
48278842|NCT00316875|DRUG|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
48620416|NCT02508792|DEVICE|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
48620417|NCT04491487|OTHER|pre-operative counselling|pre-operative Speech-Language Pathology (SLP) counselling before Total Laryngectomy
48098194|NCT06614374|DIETARY_SUPPLEMENT|High-dose fish oil capsules|Patients in the high-dose group will receive four fish oil capsules containing 3 g of marine n-3 PUFAs (72% EPA and 28% DHA) per day.
48098195|NCT06614374|DIETARY_SUPPLEMENT|Refined olive oil|Participants in the control group will receive 4 g refined olive oil daily
48447961|NCT04521218|OTHER|Reverse Sustained Natural apophyseal glides|"Control group included Moist Hot Pack (Cervical contour- 8.25 x 10 x 2) for 10 Mins, Reverse SNAGS (10 Repetitions holding for 10 sec in each glide with a rest time of 30 seconds in between), Strengthening exercise and home plan. 3 sessions of mobilization per week and total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. Pain intensity, pain pressure threshold, ROM, and disability.~These exercises included. Cervical Flexion, Extension Rotation, lateral flexion and back strengthening exercises. These all exercises were performed 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week.~Home plan exercises includes Craniocervical Flexion, Craniocervical Extension, Rotation Exercise, Lateral Flexion Exercise, Chin Tuck in and Shoulder blade exercise were advised to perform 3 x 10 Repetition with 10 - 30 sec hold"
48447962|NCT04739475|PROCEDURE|Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
48447963|NCT01695538|OTHER|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
48447964|NCT06627764|BEHAVIORAL|SER Familia|SER Familia is a six-session intervention co-developed and delivered by community health workers (CHWs) that uses strategies to reduce acculturative stress, promote resilience, improve parent-child and family level health, while simultaneously helping families maintain strong social networks and better navigate community resources to address social determinants of health (SDOH).
48447965|NCT03680053|DRUG|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
48447966|NCT03680053|DRUG|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
48447967|NCT04809584|DRUG|F18-DCFPyL|Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL
48447968|NCT04809584|DRUG|Gadolinium|Contrast agent
48447969|NCT04809584|PROCEDURE|Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan|Imaging test that combines PET (positron emission tomography) and MRI (magnetic resonance imaging)
48447970|NCT05026294|OTHER|plyometric exercises|Exercises for strength and flexibility
48447971|NCT05026294|OTHER|Exercises for flat feet rehabilitation|Exercises for intrinsic muscles strength
48447972|NCT04742686|OTHER|Aerobic exercise training|5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme. Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
48447973|NCT04664556|OTHER|observational study|observational study
48447974|NCT03122535|DEVICE|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
48447975|NCT03122535|DEVICE|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
48447976|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Outdoor Education|The intervention will include outdoor education and physical activity opportunities at various outdoor parks. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Each session will have a special theme relevant to the outdoors. Families will also receive a home toolbox to facilitate activity and learning outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
48278843|NCT01360203|OTHER|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
48278844|NCT02427165|DRUG|RPL554|A dual PDE3 and PDE4 inhibitor
48278845|NCT02427165|DRUG|Salbutamol|a beta-2 receptor agonist
48278846|NCT02427165|DRUG|Placebo|RPL554 placebo containing no active ingredients
48278847|NCT03494283|BEHAVIORAL|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
48278848|NCT00425490|DRUG|sitagliptin|
48278849|NCT03707717|DRUG|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
48278850|NCT06656104|DEVICE|Reference strategy|Routine strategy based on the usual catheters and infusion systems used during the reference period
48447977|NCT04505085|BEHAVIORAL|Active Dads Healthy Families: Fitness|The intervention will include physical activity opportunities at a community center. The program will be held one day a week for eight consecutive weeks. Parks and Recreation will facilitate and run the program. Each session will last 60 minutes and include a brief educational discussion and opportunities for various games and activities. Families will also receive a home toolbox to facilitate activity outside of the program. Feedback on physical activity will be provided at the beginning and the end of the program.
48447978|NCT00620711|DEVICE|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
48447979|NCT06310668|BEHAVIORAL|group cognitive behavioral therapy sessions|12 group CBT sessions based on catching and challenging cognitive errors and behavioral techniques to deal with substance use problems
48447980|NCT04354974|BEHAVIORAL|Evaluation|Evaluation of a cognitive remediation program for mood disorders
48447981|NCT03421717|DEVICE|Chitosan brush|If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
48447982|NCT01044485|DRUG|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
48447983|NCT01044485|DRUG|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
48447984|NCT05975697|OTHER|Experimental group to be applied FES|"In the first 24 hours after the thrombectomy procedure, the relatives of the patients in the experimental and control groups who meet the inclusion criteria will be informed by the researcher and their consent will be obtained.~FES treatment to the deltoid, triceps, extensor carpi radialis muscles for a total of 10 sessions, 30 minutes twice a day (in the morning and in the evening), for 5 days after the first 24th hour after the thrombectomy procedure in the experimental group patients (Program duration is 15 minutes and resting time is 15 minutes). minutes) will be applied.Patient information form (Appendix 1), Fugl-meyer upper extremity motor assessment scale (Appendix-2) and Quick DASH (Arm, Shoulder and Hand Injury Questionnaire Short Form) (Appendix-3) were given to both groups within the first 24 hours after the thrombectomy procedure. ) will be applied. All patients will be re-evaluated before and on the 5th day after treatment."
48447985|NCT03480321|DRUG|Cilostazol 100 mg|One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
48447986|NCT03480321|DRUG|PMR 150 mg|Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
48447987|NCT03480321|DRUG|PMR 200 mg|Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
48447988|NCT04377087|DRUG|Olaparib|Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death.
48447989|NCT02427763|DEVICE|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
48098196|NCT05483842|OTHER|Reiki|"Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body."
48098197|NCT05483842|OTHER|Sham Reiki|Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
48278851|NCT06656104|DEVICE|Experimental strategy|EDELVAISS multi-infusion strategy as routine strategy during the experimental period
48278852|NCT01087554|DRUG|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
48278853|NCT01087554|DRUG|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
48278854|NCT01087554|DRUG|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
48447990|NCT02427763|OTHER|collect saliva|the patient spit during 30 seconds in a small bottle
48447991|NCT02427763|OTHER|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
48447992|NCT02427763|OTHER|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
48447993|NCT02846285|OTHER|No intervention|
48447994|NCT05608486|DEVICE|aerSleep II|The aerSleep® II System includes a soft silicone collar, which is placed on the anterior neck. Integrated with the collar is a vacuum pump module (VPM), which cordlessly powers the generation of negative pressure within the collar's cavity. This negative pressure pulls the underlying tissues forward, maintaining airway patency.
48447995|NCT05519150|DIAGNOSTIC_TEST|low dose radiation abdomen/pelvis CT scan (stone protocol)|Kidney donors who consent will undergo a low dose radiation abdominal CT scan to identify new kidney stones in the remaining kidney. The will come to an IU Health Hospital for a low dose radiation abdomen/pelvis CT scan (stone protocol).
48447996|NCT05519150|PROCEDURE|Blood draw|To compare the changes changes in eGFR in evaluated kidney donors Blood will be draw by a trained phlebotomist.
48447997|NCT05519150|OTHER|24 hour urine collection|To compare the changes in metabolic kidney stone risk parameters in 24-hour urine assessments to pre-donation urine studies in evaluated kidney donors.
48447998|NCT02647944|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
48447999|NCT02647944|DRUG|Placebo|
48448000|NCT04793607|OTHER|Pleural procedures|Any pleural procedure that removes fluid
48448001|NCT00924547|DIETARY_SUPPLEMENT|Docosahexanoic Acid Supplement|"The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.~These dosages will be divided BID-TID and will be given for 4 weeks."
48448002|NCT00924547|DIETARY_SUPPLEMENT|Placebo|Placebo identical to active treatment.
48448003|NCT03556618|BEHAVIORAL|Whole Person Care (WPC) Reentry Program - Pre & Post Release services|Social network intervention to provide care coordination and social support during youth reentry before release and post-release from jail.
48448004|NCT01350908|OTHER|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
48448005|NCT01777711|BEHAVIORAL|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
48448006|NCT01777711|BEHAVIORAL|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
48278855|NCT01087554|DRUG|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
48278856|NCT04940923|DIAGNOSTIC_TEST|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
48278857|NCT06656637|BEHAVIORAL|Memory Drilling|"The experimental group will receive the additional intervention during their seven sessions with their care providers. The intervention is computerized memory drills training. This training includes the completion of a list learning memory task (HVLT) and then a PM practice task conducted on the computer at each session."
48278858|NCT06656637|BEHAVIORAL|Compensatory Strategies|Participants learn compensatory strategies to assist with their memory performance. This involves both external strategies, such as calendering and setting alarms, and internal strategies, like imagery and mnemonics.
48278859|NCT06656637|BEHAVIORAL|Cognitive Processing Therapy|This is PTSD-targeted therapy.
48278860|NCT04488822|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
48278861|NCT03106779|DRUG|Asciminib|40 mg tablets was taken orally twice a day (BID)
48278862|NCT03106779|DRUG|Bosutinib|500 mg tablets was taken orally once daily (QD)
48278863|NCT06422182|DRUG|Bupivacain 25% (Erector Spinae Plane Block)|Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
48278864|NCT06422182|DRUG|Morphine (Intravenous patient-controlled analgesia)|Patients received intravenous patient-controlled analgesia (IV-PCA) by morphine
48278869|NCT02828267|BEHAVIORAL|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
48278870|NCT02828267|BEHAVIORAL|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
48278871|NCT02828267|BEHAVIORAL|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
48278872|NCT04740229|BEHAVIORAL|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
48278873|NCT00289705|PROCEDURE|Surgery|Laparoscopic Roux-en-Y gastric bypass
48278874|NCT06012669|DIETARY_SUPPLEMENT|High dose Human Lactoferrin|Dietary Supplement and Food Ingredient
48278875|NCT06012669|DIETARY_SUPPLEMENT|Low dose Human Lactoferrin|Dietary Supplement and Food Ingredient
48278876|NCT06012669|DIETARY_SUPPLEMENT|Active Control Bovine Lactoferrin|Dietary Supplement and Food Ingredient
48278877|NCT05628844|PROCEDURE|Continuous enteral feeding|Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day
48278878|NCT06657105|DRUG|EE/LNG|EE/LNG tablet will be administered orally.
48278879|NCT06657105|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
48278880|NCT05702034|DRUG|Milvexian|Milvexian will be administered orally.
48278881|NCT05702034|DRUG|Placebo|Placebo will be administered orally
48278882|NCT04714372|DRUG|Daratumumab/rHuPH20|Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
48278883|NCT04714372|DRUG|FT538|FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
48278884|NCT04714372|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
48278885|NCT04714372|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
48278886|NCT02834130|BEHAVIORAL|Evaluation of psychological and psychopathological|
48278887|NCT06606028|PROCEDURE|Blood Specimen Collection|Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point
48448007|NCT04906772|DRUG|Dexmedetomidine|participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
48448008|NCT04906772|DRUG|Propofol|participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
48098198|NCT00121940|BEHAVIORAL|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
48278888|NCT06606028|PROCEDURE|Tumor Tissue Collection|Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening
48278889|NCT06606028|OTHER|Medical Record Review|Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care
48278890|NCT03898934|DRUG|Vitamin D|receive 6000iu daily for 8 weeks
48278891|NCT03898934|DRUG|Placebo Oral Tablet|placebo for the same period
48278892|NCT01696812|PROCEDURE|electrode position|
48278893|NCT00156663|BEHAVIORAL|Caring for Women Veterans|
48278894|NCT01663441|DRUG|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
48278895|NCT01663441|DRUG|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
48278896|NCT01663441|DRUG|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
48278897|NCT01663441|DRUG|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
48278898|NCT05929495|DRUG|Metformin|"The investigator will identify potential participants and confirm the diagnosis of GBM. Subjects will be screened within 6 weeks before starting treatment.~Treatment will involve:~* Administration of the standard or partial Stupp protocol (Radiotherapy + Temozolomide) in combination with Metformin for 6 weeks,~* Treatment with only Metformin for 4 weeks;~* Resumption of adjuvant TMZ + Metformin treatment continuously until the end of the enrollment period."
48278899|NCT00183846|DRUG|irinotecan|
48278900|NCT00183846|PROCEDURE|radiation therapy|
48278901|NCT02614209|DEVICE|In Vitro diagnostic tests|Prospective blood collection
48278902|NCT03325309|OTHER|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
48278903|NCT03482661|OTHER|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
48278904|NCT03784196|OTHER|Conservative rehabilitation|WAD participants underwent 2-weeks rehabilitation.
48278905|NCT06237881|DRUG|KSQ-001EX|Given by IV
48278906|NCT06237881|DRUG|Interleukin-2|Given by IV
48278907|NCT06237881|DRUG|Cyclophosphamide|Given by IV
48278908|NCT06237881|DRUG|Fludarabine|Given by IV
48278909|NCT00303810|DRUG|carboplatin|
48278910|NCT00303810|DRUG|cisplatin|
48278911|NCT00303810|DRUG|cyclophosphamide|
48278912|NCT00303810|DRUG|etoposide phosphate|
48278913|NCT00303810|DRUG|high-dose chemotherapy|
48278914|NCT00303810|DRUG|lomustine|
48278915|NCT00303810|DRUG|methotrexate|
48278916|NCT00303810|DRUG|thiotepa|
48278917|NCT00303810|DRUG|vincristine sulfate|
48278918|NCT00303810|RADIATION|radiation therapy|
48278919|NCT02276261|PROCEDURE|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
48278920|NCT02276261|PROCEDURE|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
48278921|NCT05930860|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
48278922|NCT04253392|DEVICE|LINX Reflux Management System|"The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by."
48278923|NCT04697225|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.
48278924|NCT04697225|BEHAVIORAL|weight loss coaching sessions and email support|Participants will receive weekly coaching sessions and tailored support emails.
48278925|NCT01412437|DIETARY_SUPPLEMENT|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
48278926|NCT01412437|DRUG|sapropterin dihydrochloride|20 mg/kg for 4 months
48278927|NCT01412437|DRUG|sapropterin dihydrochloride|
48278928|NCT06346522|DRUG|Gabapentin (Gaptin ®) 400mg oral capsule once|After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
48278929|NCT06346522|DRUG|Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule|After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
48278930|NCT04827355|DEVICE|External Upper Esophageal Sphincter (UES) Compression Device|External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.
48278931|NCT04827355|DEVICE|Sham Device|External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
48448009|NCT01425086|DEVICE|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
48448010|NCT02324660|OTHER|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
48448011|NCT06215976|DRUG|Metformin Hydrochloride 500 MG|Metformin 500mg tablets twice daily
48448012|NCT02130518|DRUG|Auriclosene Irrigation Solution, 0.2%|
48448013|NCT02130518|DRUG|Auriclosene Vehicle Solution|
48448014|NCT03100344|DRUG|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
48448015|NCT03100344|DRUG|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
48448016|NCT05569512|DRUG|Uproleselan|Administered by intravenous infusion
48448017|NCT05569512|DRUG|Fludarabine|Administered by intravenous infusion
48448018|NCT05569512|DRUG|Clofarabine|Administered by intravenous infusion
48448019|NCT05569512|DRUG|Busulfan|Administered by intravenous infusion
48448020|NCT02540603|DEVICE|F&P Jupiter Full Face Mask|Investigative F\&P Jupiter full face mask to be used for OSA therapy
48448021|NCT05079425|DRUG|NXC736|Oral administration
48448022|NCT05079425|DRUG|Placebo|Oral administration
48448023|NCT00003015|DRUG|carboplatin|
48448024|NCT00003015|DRUG|vincristine sulfate|
48448025|NCT00003015|PROCEDURE|conventional surgery|
48448026|NCT00003015|RADIATION|radiation therapy|
48448027|NCT06225622|DRUG|Irinotecan Liposome|"In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible."
48448028|NCT06225622|DRUG|Oxaliplatin|85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.
48448029|NCT06225622|DRUG|5-FU|2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.
48278932|NCT05549388|OTHER|Front-of-pack labeling|The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
48448030|NCT06225622|DRUG|LV|400mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.
48448031|NCT06225622|DRUG|Bevacizumab|5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.
48448032|NCT06225622|DRUG|Cetuximab|500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
48098199|NCT05365607|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
48278933|NCT01629849|DRUG|Placebo to BI 1021958 qd|tablet
48278934|NCT01629849|DRUG|BI 1021958 bid|tablets
48278935|NCT01629849|DRUG|Placebo to BI 1021958 bid|tablets
48448033|NCT02535611|DRUG|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
48448034|NCT02535611|DRUG|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
48448035|NCT05352789|OTHER|Non validated Survey|Overall inclusion of metabolic and nutritional parameters in prehabilitation practices will be assessed as the proportion of each parameter conducted from the mandatory queries presents as yes/no/unsure responses for each centre. Intervention or process details for included parameters will be described based on the response variable. The survey presents 4 question formats; free text (thematic qualitative analysis), 5 and 6 point likert scales (proportional response), categorical data (proportional response) and yes/no/unsure response sets (Binary response (no and unsure - grouped). All categorical data versions are parameter dependent and response variables can be requested from the research team.
48448036|NCT00712777|DRUG|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
48448037|NCT06280183|OTHER|Functional Inspiratory Muscle Training|Inspiratory muscle training is a technique that combines aerobic training with inspiratory muscle training. will be applied simultaneously with aerobic exercise. Participants will work with bicycle ergometry and then continue with IMT in the same session for the first three weeks. The intensity of IMT exercise will be set at 40-60% of MIP.
48448038|NCT06280183|OTHER|Aerobic+Resistive Exercise Traning|Aerobic exercise is planned at 60-85% of the Maximum Heart Rate on a cycle ergometer for 30-40 minutes. Resistive exercise will cover all major muscle groups. The upper body (pectoralis, latissimus dorsi, rotator cuff muscles, deltoid, biceps, triceps), abdominal muscles, and lower extremities (quadriceps, hamstring, gastrosoleus) will be exercised to strengthen. For upper body, abdominal, and lower extremity muscles, 1-3 sets of 10-15 repetitions will be planned as 40-70% of 1 maximum repetition (1RM).
48448039|NCT04730466|OTHER|Neuropsychological rehabilitation|The intervention can be carried out in the research unit or in the Parkinson's association. Each session will consist of a series of cognitive stimulation tasks aimed at improving attention, perception and processing speed. These tasks will be applied through the NeuronUp cognitive neurorehabilitation platform to achieve maximum homogeneity and objectivity in their application. The program is programmed and is identical for all patients. Performing tasks through the platform allows us to objectively record the performance of each patient in all tasks.
48448040|NCT02478983|DEVICE|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
48620418|NCT04626076|OTHER|Comparative Observational Cohort Study|This is a comparative observational cohort study; therefore, no preventive interventions, visits or laboratory tests are mandated. Dosing and duration of potential prophylactic treatment is at the discretion of the institution and/or healthcare provider, in accordance with regular local practice. However, serology testing for SARS-CoV-2 antibodies will be offered to the first 50% of participating HCWs per country, at enrollment and at the last follow-up (i.e. at Week 12)
48620419|NCT02719795|DRUG|Ropivacaine|Local injection of local anesthetic into the fascial spaces
48620420|NCT02719795|DRUG|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
48620421|NCT04807413|DRUG|Nitric Oxide|The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
47928112|NCT05420753|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation|During a TIPS procedure, the interventional radiologist, with the help of x-ray and ultrasound guidance, makes a channel through the liver to connect the portal vein (the vein that carries blood from the digestive organs to the liver) to one of the hepatic vein (three veins that carry blood away from the liver back to the heart) using a special type of needle. The interventional radiologist then replaces the needle with a wire and catheter, and a small tubular device called a stent graft is placed in this channel to keep the pathway open between the two blood vessels.
47928113|NCT00475423|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
47928114|NCT01147133|DRUG|Plavix|1x75 mg
47928115|NCT01147133|DRUG|Kardogrel|1x75 mg
48098200|NCT05365607|DEVICE|Sham NightWare|NightWare device will not deliver an intervention (i.e., no vibration)
48278936|NCT01629849|DRUG|BI 1021958 qd|tablet
48278937|NCT05627245|DRUG|Belinostat|Given IV
48278938|NCT05627245|PROCEDURE|Biopsy|Undergo biopsy
48278939|NCT05627245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48278940|NCT05627245|PROCEDURE|Computed Tomography|Undergo CT scan
48278941|NCT05627245|OTHER|Pharmacokinetic Study|Pharmacokinetic study
48278942|NCT05627245|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT
48278943|NCT05627245|DRUG|Tazemetostat|Given PO
48278944|NCT03138564|BEHAVIORAL|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
48278945|NCT03138564|BEHAVIORAL|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
48278946|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using a vial and syringe.
48278947|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using AI.
48278948|NCT04706572|OTHER|Stimulation with external auditory bio-feedback|Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
48278949|NCT04333966|BEHAVIORAL|Interactive Social Networking Site Parent Based Intervention|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
48278950|NCT04333966|BEHAVIORAL|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
48278951|NCT04923893|DRUG|Bortezomib|Bortezomib will be administered SC.
48278952|NCT04923893|DRUG|Dexamethasone|Dexamethasone will be administered orally.
48278953|NCT04923893|DRUG|Lenalidomide|Lenalidomide will be administered orally.
48278954|NCT04923893|DRUG|Cilta-cel|Cilta-cel infusion will be administered.
48278955|NCT04923893|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
48278956|NCT04923893|DRUG|Fludarabine|Fludarabine will be administered intravenously.
48278957|NCT04545736|DRUG|Metformin hydrochloride|Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants \>=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants \>= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
48278958|NCT06651957|OTHER|Biospecimen Collection|Specimen swabs will be obtained.
48278959|NCT06651957|OTHER|Questionnaires|Given to participants
48278960|NCT05409105|DIETARY_SUPPLEMENT|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
48278961|NCT05409105|DIETARY_SUPPLEMENT|Water|2 cups/day bottled water, 2 weeks
48278962|NCT06585306|BEHAVIORAL|jaw lift, increasing oxygen flow, mask ventilation, intubation|When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.
48278963|NCT04526184|PROCEDURE|aerobic exercise with blood flow restriction|Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
48278964|NCT05884658|PROCEDURE|vNOTES : natural vaginal orifice transluminal endoscopic system for hysterectomies|hysterectomy via the vaginal approach by vNOTES (natural vaginal orifice transluminal endoscopic system for hysterectomies)
48448041|NCT02478983|DEVICE|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
48448042|NCT06081569|DIAGNOSTIC_TEST|gait video; speech video; facial expression video;|The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
48448043|NCT04362020|OTHER|Distal radial access|Distal radial access and No anticoagulation
48448044|NCT04362020|OTHER|Distal radial access|Distal radial access and ACT-guided anticoagulation
48448045|NCT04360694|PROCEDURE|Incremental hemodialysis|95 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.
48448046|NCT04360694|PROCEDURE|Conventional hemodialysis|95 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
48448047|NCT01681745|DEVICE|Cryo-Touch III|
48448048|NCT05176015|DEVICE|Frenzel Lens|pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.
48448049|NCT05176015|DIAGNOSTIC_TEST|Diagnostic Algorithm|"A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score"
48448050|NCT04266405|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50 mL) per day for 28 days
48448051|NCT04266405|DIETARY_SUPPLEMENT|Collagen Cubilose Drink|consume 1 bottle (50 mL) per day for 28 days
48448052|NCT05742971|DEVICE|Virtual reality intervention performed through the Oculuc Go VR glasses|The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
48448053|NCT00179231|DRUG|olanzapine vs. clozapine|
48448054|NCT02711449|DRUG|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
48448055|NCT02711449|DRUG|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
48448056|NCT01114893|DRUG|Travoprost 0.004%|1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
48448057|NCT01114893|DRUG|Travoprost Vehicle|1 drop in each eye 8 times daily for 5 days
48448058|NCT01114893|DRUG|Travoprost (Groups A, B and C)|1 drop in each eye 8 times daily for 5 days
48448059|NCT03444792|PROCEDURE|mechanical dilatation of the cervix|"the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~- If failed the surgeon will use artery forceps to dilate cervix"
48448060|NCT05951192|DRUG|Daprodustat|Commercially manufactured daprodustat (JESDUVROQ) is provided in tablet strengths of 1, 2, 4, 6 and 8 mg. Tablets will be taken whole and patients will be instructed not to cut, crush, or chew tablets.
48448061|NCT03615105|RADIATION|Hyperfractionated total body irradiation|Hyperfractionated TBI is administered by a linear accelerator at a dose rate of \<20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
48448062|NCT03615105|DRUG|Thiotepa|Thiotepa 5 mg/kg IV
48448063|NCT03615105|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV
48448064|NCT03615105|DRUG|Busulfan|Busulfan (adult/ped dose)
48620422|NCT04807413|OTHER|standard of care treatment|standard of care treatment
48448065|NCT03615105|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV
48448066|NCT03615105|DRUG|Melphalan|Melphalan 70 mg/m2 IV
48448067|NCT03615105|DRUG|Clofarabine|Clofarabine 20-30 mg/m2 IV
48448068|NCT03615105|PROCEDURE|HPC(A) stem cell allograft|All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
48448069|NCT03615105|DRUG|Rituximab|Rituximab 200 mg IV flat dose
48448070|NCT03615105|DEVICE|Rabbit antithymocyte globulin|Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
48448071|NCT02765724|DRUG|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
48448072|NCT03409133|DEVICE|Stimulating nerve electrodes and intramuscular recording electrodes|See Arm Description
48448073|NCT00637117|BIOLOGICAL|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
48448074|NCT00859534|DRUG|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
48448075|NCT06165367|DRUG|EmbryoGlue Medium|Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
48448076|NCT02213263|BIOLOGICAL|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
48448077|NCT02213263|BIOLOGICAL|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
48448078|NCT06560125|OTHER|Standard care|Treatment appropriate for wound condition
48448079|NCT02665715|OTHER|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
48448080|NCT02665715|OTHER|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
48448081|NCT02656186|DIETARY_SUPPLEMENT|Pre-intervention|First 2-weeks : keeping routine dietary habit
48448082|NCT02656186|DIETARY_SUPPLEMENT|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
48448083|NCT01504763|PROCEDURE|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
48448084|NCT01073657|OTHER|Supported Education|Rehabilitation counseling using peers to achieve educational goals
48448085|NCT01073657|OTHER|General Peer Support|Matched peer support for any personal goal other than education
48448086|NCT00360763|DRUG|candesartan cilexetil|
48448087|NCT06560697|RADIATION|SABR VS Intracavitary 3D Brachytherapy|Arm 1 will be the experimental arm and will consist of patients with CC clinical stages IB3-IIIC1 who will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with SBRT of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at PTV D90% of 83.9Gy. Arm 2 will be the control arm that will consist of patients with CC clinical stages IB3-IIIC1 and will be treated with CT/RT with a minimum dose of 45Gy and boost in the case of macroscopic nodes (1.8Gy per fraction from Monday to Friday) with cisplatin and cervical boost with high-dose-rate 3D brachytherapy with a dose of 28Gy in 4 fractions administered at least every 40 hours to achieve an EQD210(Gy) at point A of 83.9Gy.
48448088|NCT04199741|DRUG|89Zr-DFO-SC16.56|Injection of 2 mCi of 89Zr-DFO-SC16.56 for Phase I participants. Dose for Phase II will be determined by results from Phase I.
48448089|NCT04199741|DRUG|SC16.56, Phase I, Cohort 2|7.5mg
48448090|NCT04199741|DRUG|SC16.56, Phase I, Cohort 3|22.5mg
48448091|NCT04199741|DRUG|SC16.56, Phase II|Dose for Phase II will be determined by results from Phase I.
48448092|NCT06561867|DRUG|Ticagrelor 90 MG|Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects
48448093|NCT06561867|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
48448094|NCT00539110|DRUG|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
48448095|NCT00539110|DRUG|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
48448096|NCT04576234|DIETARY_SUPPLEMENT|entral feeding|Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
48448097|NCT02818218|PROCEDURE|Liver Transplant|liver transplant recipient surgery
48448098|NCT03199872|BIOLOGICAL|RV001V|Sc injection
48448099|NCT00211263|BEHAVIORAL|Enhanced Clinical Intervention|
48098201|NCT03964285|OTHER|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
48448100|NCT00211263|DRUG|mood stabilizer|
48448101|NCT05985772|OTHER|Non-Operative Pain Management|The non-operative treatment arm will receive analgesics, physical therapy and will remain non-weight bearing. This will consist in anti-inflammatory drugs daily for 8-12 weeks and supervised physical therapy at least twice a week over a period of 8 weeks. Subjects in the non-operative arm will be offered the opportunity to crossover to the operative arm (ARM 2) of the study if the subjects do not report symptomatic improvement within 3 months after entry in this study.
48448102|NCT05985772|PROCEDURE|Operative treatment arm will undergo transtibial medial meniscus root repair within 3 weeks of enrollment|The operative treatment group (ARM 2) will be treated acutely with a transtibial medial meniscus root repair and will be non-weight bearing for 6 weeks as well. For ARM 1 subjects if no subjective improvement is seen at 3 months, crossover will be allowed to a transtibial medial meniscal root repair (acute operative pathway (ARM 2)
48448103|NCT03413839|BEHAVIORAL|Physiotherapeutic Scoliosis Specific Exercises (PSSE)|Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.
48448104|NCT03413839|BEHAVIORAL|Conventional Physical Therapy (PT)|Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
48448105|NCT06561724|DIETARY_SUPPLEMENT|Biscuits maltodextrin|Biscuits includes maltodextrin
48448106|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics tartoufa inulin|Biscuits prebiotics
48448107|NCT06561724|DIETARY_SUPPLEMENT|Biscuits includes prebiotics chicory inulin|Biscuits prebiotics
48448108|NCT06407505|OTHER|Acupressure group|LI4 acupressure applied group.
48448109|NCT06407505|OTHER|Placebo group|Group where acupressure was applied to an area 1.5 cm away at the LI4 acupressure point
48448110|NCT00817440|OTHER|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
48448111|NCT00817440|OTHER|Fasting|3 days of fasting and then the same as arm 1
48448112|NCT04013841|OTHER|Oral-agents/Enema|"1. Oral-agents for mechanical bowel preparation prior to left-side colorectal resection~2. Enema for mechanical bowel preparation prior to left-side colorectal resection"
48448113|NCT00006051|DRUG|cisplatin|
48448114|NCT00006051|DRUG|fluorouracil|
48278965|NCT05884658|PROCEDURE|laparoscopic hysterectomy|laparoscopic hysterectomy uses a standardized procedure with or without surgical robot
48278966|NCT04312126|DEVICE|MRI system|MRI system - GE Discovery MR750 3T
48278967|NCT04312126|DEVICE|MEG system|MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
48448115|NCT00006051|RADIATION|radiation therapy|
48448116|NCT04416451|DRUG|Rituximab|Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
48448117|NCT04416451|DRUG|Venetoclax|"Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab."
48448118|NCT03883412|OTHER|Exercise|16 weeks of treatment
48098202|NCT03964285|OTHER|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
48098203|NCT06492954|PROCEDURE|Surgical Resection|Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.
48098204|NCT06492954|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
48278968|NCT03487822|BEHAVIORAL|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
48278969|NCT00831376|DRUG|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
48278970|NCT00831376|DRUG|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
48278971|NCT00831376|DRUG|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
48278972|NCT04000646|OTHER|standard care|standard care non-pharmacologic interventions during anesthesia induction
48278973|NCT04000646|OTHER|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
48278974|NCT05859451|DEVICE|Tobacco Heating System (THS)|Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
48278975|NCT05859451|OTHER|Smoking abstinence|Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
48278976|NCT01819935|DRUG|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
48278977|NCT01819935|DRUG|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
48278978|NCT00499551|DEVICE|Iontophoresis second generation Eyegate II device|
48278979|NCT04865848|PROCEDURE|Dental local anesthesia|Dental local anesthesia
48278987|NCT06351293|DEVICE|Defyne Treatment in Nasolabial Fold|Defyne will be injected into left or right nasolabial fold, per randomization.
48278988|NCT06351293|DEVICE|RHA3 Treatment in Nasolabial Fold|RHA3 will be injected into left or right nasolabial fold, per randomization.
48448119|NCT03883412|DRUG|Liraglutide|16 weeks of Liraglutide
48448120|NCT04852380|PROCEDURE|PRP injections|The 5 mL PRP concentrate was injected every week for three times, starting from recruitment. The patient was placed supine whit a knee flexion of 90°.All the procedures were carried out in an aseptic condition, injected in the knee soft spot through an anterior approach, using a 21-gauge needle.
48448121|NCT05105633|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
48448122|NCT05105633|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
48448123|NCT00835081|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
48448124|NCT00835081|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
48098205|NCT06492954|DRUG|Atezolizumab|For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
48278989|NCT02246361|PROCEDURE|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
48278990|NCT00710190|DEVICE|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
48278991|NCT00986531|DRUG|AZD8529|2 capsules by mouth for 3 days
48278992|NCT00986531|DRUG|Placebo to match AZD8529|2 capsules by mouth for 3 days
48278993|NCT02495779|DRUG|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
48098206|NCT03278197|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
48448125|NCT06065150|PROCEDURE|Standard support|See arm/group descriptions
48448126|NCT06065150|PROCEDURE|Early surgery proposed according to the radiological score|"* If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~* If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management."
48448127|NCT00222118|BEHAVIORAL|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
48448128|NCT00222118|OTHER|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
48448129|NCT00222118|OTHER|usual care|no intervention
48448130|NCT04290858|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.
48448131|NCT01049334|DRUG|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
48448132|NCT01049334|DRUG|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
48448133|NCT02514382|DRUG|Bortezomib|Given SC or IV
48448134|NCT02514382|DRUG|Dexamethasone|Given PO, IV, or IM
48448135|NCT02514382|OTHER|Laboratory Biomarker Analysis|Correlative studies
48448136|NCT02514382|OTHER|Pharmacological Study|Correlative studies
48448137|NCT02514382|BIOLOGICAL|Wild-type Reovirus|Given IV
48448138|NCT05260697|OTHER|sexual counselling with plissit model|sexual counselling
48448139|NCT00905606|DRUG|Topiramate Tablets|
48448140|NCT00905606|DRUG|Topamax® Tablets|
48448141|NCT04513418|DIETARY_SUPPLEMENT|Preoperative immunonutrition|Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
48448142|NCT04275895|BEHAVIORAL|Evaluation of different attention or/and postural activities|"1. The children, equipped with a head-mounted display (HMD), will indicate as quickly as possible the direction of a fish that can be surrounded by congruent or not flankers (Inhibition) and/or preceded by signal (Alert)~2. The children, equipped with a HMD and a joystick, will vertically turn a randomly inclined stick~3. The children will stand on a force plate watching a cartoon, gazing a fixation cross or eyes closed~4. The children, equipped with an augmented reality headset, will perform 2 levels of difficulty of 3 attention tasks standing on a force plate:~   * They will click as quickly as possible when they see a frog among successively appearing animals (vigilance task)~  * They will give the name of an animal appearing at one of the windows displayed (visual search task)~  * They will count the number of yellow lions oriented to the right among several animals of different color and direction (inhibition task)~5. Growth trajectory will be retrieved from health booklet"
48448143|NCT00327379|DRUG|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
48448144|NCT00327379|DRUG|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
48448145|NCT02608177|DRUG|Linagliptin|Receives 4 weeks of study drug linagliptin
48448146|NCT02608177|DRUG|Glipizide|Receives 4 weeks of study drug glipizide
48448147|NCT05802485|OTHER|collection of blood and tumor samples|"The study consists of the collection of a 25 ml blood sample:~* Before the start of treatment~* Approximately 2 months after the start of induction chemotherapy~* At the end of induction chemotherapy~* Prior to local treatment (radiotherapy, surgery)~* At the time of tumor progression~At the time of collection of tumor material:~* During the initial diagnostic biopsy~* On the operating room in case of surgery~* During a tumor biopsy in case of recurrence or progression (optional) and a questionnaire evaluating the patient's spontaneous physical activities."
48448148|NCT03523039|DEVICE|CytoSorb® Hemoadsorption|The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
48448149|NCT01756326|DRUG|PREOB® Implantation|
48448150|NCT01756326|PROCEDURE|Bone Autograft|
48098207|NCT03278197|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
48098208|NCT03278197|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
48448151|NCT05925010|DIETARY_SUPPLEMENT|Supplementation with soluble fibre from guar (Optifibre©)|10g of soluble fibre from guar in the form of Optifibre© (dietary food for special medical purposes) is added to the standardized meal (Resource cereal porridge©).
48448152|NCT06334991|BIOLOGICAL|CD19 t-haNK|"CD19t-haNK erived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).~Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM."
48448153|NCT00398983|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days
48448154|NCT01144494|DRUG|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
48448155|NCT01144494|DRUG|Artificial tears|Lubricating drops added three times a day for six weeks
48098209|NCT03278197|OTHER|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
48448156|NCT02075463|DRUG|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
48278994|NCT02495779|BEHAVIORAL|CBT-based counseling|Brief CBT-based counseling to promote adherence
48448157|NCT02075463|DRUG|Placebo|Matching placebo tablet for GSK1278863
48448158|NCT03777826|OTHER|PKU Synergy|PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
48448159|NCT06560658|DRUG|Psilocybin|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period.
48448160|NCT06560658|BEHAVIORAL|Meditation|Participants will receive four 2-hour sessions of supervised microdosing of psilocybin in a two week period. In addition to meditating during their sessions, participants will also meet online five days a week for meditation instruction and practice.
48448161|NCT01199718|DRUG|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
48448162|NCT02362997|DRUG|Pembrolizumab|Anti-PD-1 monoclonal antibody
48448163|NCT05754983|DRUG|Solid tumor patients receiving immunotherapy for the first time were included in the study|Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
48448164|NCT02305394|DRUG|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
48448165|NCT02305394|DRUG|propofol and normal saline|propofol 1.5 mg/kg and normal saline \[weight(kg)×0.3÷10\]ml will be administered to participants separately by intravenous infusion.
48448166|NCT05732363|DEVICE|Ultrasonography|The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7
48448167|NCT05732363|RADIATION|Dual-energy X-ray Absorptiometry|The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
48620423|NCT05354934|OTHER|quetionnaire|"The questionnaire includes the following modules~* Demography and socio-economic conditions~* Screening and modalities of discovery and announcement of HIV infection~* Time and modalities of introduction of antiretroviral drugs after diagnosis~* Knowledge of HIV infection~* The perception of follow-up in the health care service~* Experiences of stigma~* Barriers to accessing care~* Periods of loss of sight and reasons for this~* Perceived health status, mental health (PHQ4), chronic illness, functional limitations~* Addictions~* Social network and support~* Clinical data Date of HIV diagnosis Date of introduction of antiretrovirals CD4 count at diagnosis Viral load at diagnosis Period without follow-up for more than 12 months CD4 nadir Last CD4 count Last viral load Antiretroviral treatment at last consultation Comorbidities Initial hospitalisation Recent hospitalization"
48278995|NCT03609164|PROCEDURE|Suture-bridge augmentation of single-row repair|
48278996|NCT00577187|DEVICE|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
48278997|NCT06390137|DEVICE|Frequency Specific Microcurrent|The participant will receive an FSM treatment of 40 Hz on channel A and 97 Hz on channel B at 200 uamp with alternating current with a sharp square wave slope for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest. The TENS unit will be wrapped in an opaque bag so that the device is indistinguishable from that of the sham treatment.
48278998|NCT06390137|DEVICE|Sham microcurrent treatment|The participant will receive a sham FSM treatment with the machine off wrapped in an opaque bag for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest.
48448171|NCT03221543|DEVICE|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
48448172|NCT01293591|OTHER|Control|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
48448173|NCT01293591|OTHER|Garlic treatment|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.
48448174|NCT03948100|OTHER|Educational Intervention|Undergo dyadic education program
48448175|NCT03948100|OTHER|Quality-of-Life Assessment|Ancillary studies
48448176|NCT03948100|OTHER|Questionnaire Administration|Ancillary studies
48448177|NCT03948100|PROCEDURE|Yoga|Undergo dyadic yoga
48448178|NCT05705180|BIOLOGICAL|recombinant adjuvanted zoster vaccine|vaccination with recombinant adjuvantes zoster vaccine
48448179|NCT01414933|OTHER|Biopsy|Breast metastases biopsy
48278999|NCT00866437|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
48448180|NCT05499897|PROCEDURE|ultrasoud guided interscalene block|Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
48448181|NCT05499897|PROCEDURE|general anesthesia|Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
48448182|NCT05438550|DRUG|14-day high-dose Tegoprazan Dual Therapy (HDDT)|14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
48448183|NCT00246922|DRUG|Roflumilast|
48448184|NCT03201523|OTHER|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
48448185|NCT01202734|DRUG|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
48448186|NCT02160015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48448187|NCT02160015|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48448188|NCT02160015|PROCEDURE|Computed Tomography|Undergo CT
48448189|NCT02160015|PROCEDURE|Electrocardiogram|Undergo ECG
48279000|NCT00866437|DRUG|Skin test panel|"Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
48448190|NCT02160015|DRUG|Ibrutinib|Given PO
48279001|NCT06618157|DEVICE|Cerebellothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the cerebellothalamic pathway on the patient-specific connectomic deep brain stimulation model
48279002|NCT06618157|DEVICE|Pallidothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the Pallidothalamic pathway on the patient-specific connectomic deep brain stimulation model
48279003|NCT06618157|OTHER|No deep brain stimulation|Patients will also be tested without any deep brain stimulation
48448191|NCT02160015|DRUG|Lenalidomide|Given PO
48448192|NCT02160015|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48448193|NCT02160015|BIOLOGICAL|Rituximab|Given IV
48620424|NCT02008370|DRUG|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
48279004|NCT06618157|DEVICE|Usual care deep brain stimulation|Patient will also be tested with the deep brain stimulation clinical settings that were previously established during usual care with their neurologist
48279005|NCT01770340|BIOLOGICAL|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
48279006|NCT01770340|PROCEDURE|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
48279007|NCT00668005|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
48279008|NCT00668005|DRUG|Placebo|Matching placebo
48279009|NCT03427437|DRUG|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
48279010|NCT03427437|DRUG|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
48279011|NCT03427437|DEVICE|Ultrasound|caudal block was performed by ultrasound method
48279012|NCT05420766|BEHAVIORAL|Shortened Sleep|In this experimental condition, children go to bed 90 minutes later than their typical bedtime during Week 2 of the 4-week protocol.
48279013|NCT05420766|BEHAVIORAL|Stabilized sleep|In this control condition, children go to bed at their usual time throughout the 4-week protocol.
48279014|NCT00047411|OTHER|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
48279015|NCT00047411|DEVICE|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
48279016|NCT00030576|DRUG|cisplatin|
48279017|NCT00030576|DRUG|erlotinib hydrochloride|
48279018|NCT01752283|PROCEDURE|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
48279019|NCT01752283|PROCEDURE|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
48279020|NCT04968418|DEVICE|APDM OPAL system wearable IMU|The OPAL system contains wearable IMUs with a sampling rate of 128 Hz and a resolution of 17.5 bits. Each IMU has a size of about 44mm 40mm 14mm × × and weighs less than 25 gm.
48279021|NCT04610099|DEVICE|Banded Sleeve Gastrectomy|banded sleeve gastrectomy
48279022|NCT04610099|DEVICE|Standard SG|Standard SG
48279023|NCT05035420|DEVICE|Fitbit|Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
48279024|NCT05035420|DEVICE|Douglas Bag|The Douglas Bag will be used for inducing hypercapnia.
48279025|NCT05035420|DEVICE|Periflux 6000 EPOS|Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
48279026|NCT05035420|DEVICE|BIOPAC|The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
48279027|NCT05035420|DEVICE|Flowmet|Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
48279028|NCT05035420|DEVICE|NIRS|a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
48279029|NCT02285829|DRUG|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF \>0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
48279030|NCT04253132|DRUG|Tolfenamic Acid|Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
48279031|NCT04253132|DRUG|Placebos|oral placebo
48279032|NCT05258227|OTHER|Conservational Physical Therapy and Proprioceptive Strength Training|The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.
48279033|NCT05258227|OTHER|Conservational Physical Therapy and Core Instability Strength Training|Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
48279034|NCT03254056|PROCEDURE|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
48279035|NCT03254056|PROCEDURE|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
48279036|NCT01407120|BEHAVIORAL|New Beginnings Program|A preventive intervention for divorced families.
48279037|NCT04528485|OTHER|Sea swimming|8 sessions of swimming activities in the sea
48279038|NCT00140855|BIOLOGICAL|ipilimumab|
48448194|NCT04078022|BIOLOGICAL|SF2a-TT15 Shigella Vaccine|0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
48448195|NCT04078022|OTHER|Placebo|0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
48448196|NCT04078022|BIOLOGICAL|S. flexneri 2a strain 2457T Challenge Agent|Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
48448197|NCT01531894|DRUG|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
48448198|NCT01528163|DRUG|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
48448199|NCT01528163|DRUG|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
48448200|NCT04968405|DEVICE|Catalyst CSR Total Shoulder System|The Catalyst CSR Shoulder System is a bone preserving total shoulder prosthesis designed for use in patients where the humeral head, neck and glenoid vault are of sufficient bone stock and there is an intact or reconstructable rotator cuff. The design requires minimal bone resection, thus giving the patient an alternative to other total shoulder designs where more bone is removed.
48448201|NCT03725969|DIETARY_SUPPLEMENT|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
48448202|NCT03725969|DIETARY_SUPPLEMENT|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
48448203|NCT04270721|BEHAVIORAL|The EAGLE Safe Anastomosis Quality Improvement Intervention|"The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts:~1. Introduction of a routine patient risk stratification for anastomotic leak~2. Implementation of the ESCP Safe Anastomosis Checklist~3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence."
48448204|NCT02691130|BIOLOGICAL|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
48448205|NCT02691130|BIOLOGICAL|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
48448206|NCT02691130|BIOLOGICAL|Saline|0.9% NaCl in double distilled water
48448207|NCT01104025|DRUG|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
48448208|NCT01104025|DRUG|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
48448209|NCT01104025|DRUG|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
48448210|NCT01104025|DRUG|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
48448211|NCT01104025|DRUG|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
48448212|NCT05453422|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
48448213|NCT01826058|RADIATION|Stereotactic body radiation therapy|
48448214|NCT03528187|OTHER|MRI|"MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher"
48448215|NCT03528187|OTHER|Written Consent|Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
48448216|NCT00834249|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
48448217|NCT00834249|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
48448218|NCT06628336|DEVICE|HARMONY EVOLUTION|It is planned to include consecutive eligible subjects which will be treated with the HARMONY EVOLUTION devices.
48448219|NCT05570981|DIAGNOSTIC_TEST|Laryngeal sensitivity testing|Direct stimulation of the laryngeal adductor reflex, measurement of laryngeal EMG and our capability to assess functional laryngeal response to an inhalational challenge with laryngoscopic techniques.
48448220|NCT01116362|PROCEDURE|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
48448221|NCT01116362|PROCEDURE|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
48448222|NCT04187352|DRUG|CS1001+ Fluorouracil+Cisplatin|"CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
48448223|NCT04187352|DRUG|Placebo+ Fluorouracil+Cisplatin|"Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle."
48448224|NCT02000362|BIOLOGICAL|Stem cells|
48448225|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus acidophilus 207, Bifidobacterium lactis B420/205|Cultures containing 3.7 × 10 \^ 9 CFU/mg
48448226|NCT04988594|DIETARY_SUPPLEMENT|Lactobacillus bulgaricus and Streptococcus thermophillus|Cultures containing 3.7 × 10 \^ 6 CFU/mg
48448227|NCT04988594|DIETARY_SUPPLEMENT|No culture|No probiotic cultures
48448228|NCT06563479|DIAGNOSTIC_TEST|FMISO-PET Scan|Patients will undergo 18F-FMISO scan (only 1 injection) that occurs at week two of radiation treatment, typically day 10 but a window of 8-10 radiation treatment days\* after start of radiation is allowed.
48448229|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
48448230|NCT06563479|COMBINATION_PRODUCT|Chemoradiation|70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)
48448231|NCT06563479|OTHER|Assessments|EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions).
48448232|NCT03598894|OTHER|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
48448233|NCT01319162|OTHER|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (\<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
48448234|NCT00529464|PROCEDURE|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
48448235|NCT00529464|PROCEDURE|Colposcopy|A standard colposcopy will be performed.
48448236|NCT00529464|PROCEDURE|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
48448237|NCT04882150|DRUG|BMS-986196|Specified dose on specified days
48448238|NCT04882150|OTHER|Placebo|Specified dose on specified days
48448239|NCT00835536|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
48448240|NCT00835536|DRUG|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
48448241|NCT05462327|PROCEDURE|Low Fresh Gas Flow in Prone Position|In the low fresh gas flow group, the flow rate was reduced to 0.5 L/min
48448242|NCT05462327|PROCEDURE|Normal Fresh Gas Flow in Prone Position|In the normal flow rate group, the gas flow rate was reduced to 2 L/min during the maintenance phase.
48448243|NCT04630431|OTHER|Best Practice|Undergo standard of care follow-up
48448244|NCT04630431|OTHER|Educational Intervention|Undergo clinical trial education via a video and educational booklet
48448245|NCT04630431|OTHER|Electronic Health Record Review|Review of medical record
48448246|NCT04630431|BEHAVIORAL|Patient Navigation|Undergo clinical trial navigation
48448247|NCT04630431|OTHER|Questionnaire Administration|Complete questionnaire
48448248|NCT06157905|DRUG|Oral Tofacitinib citrate|oral tofacitinib citrate was initiated at 5 mg twice daily after ruling out contraindications
48448249|NCT00131391|DRUG|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
48448250|NCT00131391|DRUG|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
48448251|NCT04216329|DRUG|Selinexor|Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
48448252|NCT04216329|DRUG|Temozolomide|Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m\^2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-radiation therapy (RT), the adjuvant temozolomide will be given per standard of care.
48448253|NCT04216329|RADIATION|Generic Radiation therapy (RT)|Radiation therapy (RT) will be administered daily (Monday to Friday)
48448254|NCT04216329|OTHER|Selective serotonin receptor (5-HT3) antagonists|Anti-emetic for breakthrough nausea.
48448255|NCT04216329|OTHER|Olanzapine|2.5mg to 5mg once a day if weight loss is rapid.
48448256|NCT04216329|DIETARY_SUPPLEMENT|Salt tablets|To treat hyponatremia, add salt tablets to participants diet per institutional guidelines.
48448257|NCT04216329|OTHER|Anti-diarrheal|Treat diarrhea with an anti-diarrheal per institutional guidelines
48448258|NCT04632550|PROCEDURE|Circumferential pulmonary vein isolation(CPVI) group|"1. PVI(pulmonary vein isolation) will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Evaluation of procedure time, radiofrequency ablation time~4. Evaluation of the complication after the procedure.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
48448259|NCT04632550|PROCEDURE|Posterior box isolation(POBI) group|"1. PVI will be performed using a radiofrequency catheter~2. Additional POBI(Posterior box isolation) is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
48620425|NCT00858546|DEVICE|Repetitive transcranial stimulation|Repetitive transcranial stimulation
48620426|NCT00207688|DRUG|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
48620427|NCT00207688|DRUG|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
48448260|NCT04632550|PROCEDURE|POBI+Anterior linear ablation(AL) group|"1. PVI, POBI will be performed using a radiofrequency catheter~2. Additional AL(anterior linear) ablation is performed according to the traditional method and experience of the practitioner.~3. Esophageal temperature will be monitored to prevent esophageal injury.~4. The bidirectional block of each lesion set is the target of the procedures. But, we remain the incomplete block if three times of linear ablation failed to achieve the bidirectional block for the safety purpose.~5. Evaluation of procedure time, radiofrequency ablation time~6. Evaluation of the complication after the procedure.~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
48448261|NCT00006376|DRUG|chemotherapy|
48448262|NCT00006376|DRUG|tipifarnib|
48448263|NCT04364581|DRUG|Letrozole|Women will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention
48448264|NCT04364581|DRUG|Placebo|Women will be treated with placebo for 10 days before hysteroscopic intervention
48448265|NCT00620893|DRUG|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
48448266|NCT00620893|DRUG|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
48448267|NCT00811655|PROCEDURE|therapeutic conventional surgery|Surgery of a single brain metastasis.
48448268|NCT00811655|RADIATION|stereotactic radiosurgery|Pre-operative single fraction SRS
48448269|NCT01791751|DRUG|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
48448270|NCT03706794|BEHAVIORAL|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
48448271|NCT03706794|BEHAVIORAL|Headache Education|Non-tailored education provided via a smartphone application.
48448272|NCT02828033|DRUG|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
48448273|NCT01255085|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
48448274|NCT01255085|DIETARY_SUPPLEMENT|yellow pea fiber|Served in a tomato soup
48448275|NCT01255085|DIETARY_SUPPLEMENT|Control Tomato Soup|Served in a tomato soup
48448276|NCT04197492|RADIATION|Hypofractionated Stereotactic Radiotherapy|Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)
48448277|NCT04197492|DRUG|Anlotinib|Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
48448278|NCT00633594|DRUG|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
48448279|NCT00633594|DRUG|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
48448280|NCT00633594|DRUG|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
48279039|NCT05841472|DRUG|Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin|"* 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."
48279040|NCT04613206|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
48448281|NCT01111045|DRUG|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
48448282|NCT01111045|DRUG|Placebo|Placebo
48448283|NCT01163461|BEHAVIORAL|speech therapy|individuals will receive 60 hours of behavioral speech therapy
48448284|NCT03682601|DRUG|5% sinecatechins ointment|Topical 5% sinecatechins ointment will be applied once daily.
48448285|NCT03682601|DRUG|Placebo|Aquaphor/vehicle
48448286|NCT03682601|DRUG|10% sinecatechins ointment|Topical 10% sinecatechins ointment will be applied three times per week up to once daily.
48448287|NCT06562023|OTHER|Botulinum Toxin Type A|Patients will receive BTA injection within a period of 5 days after primary closure.
48448288|NCT06562023|OTHER|Mesotherapy|Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
48448289|NCT06562166|RADIATION|online adaptive radiotherapy|Patients in ART group received daily online adaptive radiotherapy with a prescription dose of 50.4Gy/28f.
48448290|NCT05734677|BEHAVIORAL|Emotion regulation group|90 minute sessions once a week for 8 weeks, in groups of eight participants. DBT, MBT and MBI inspired, psychoeducative intervention.
48279041|NCT04613206|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
48448291|NCT03936101|DIAGNOSTIC_TEST|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
48448292|NCT04215510|PROCEDURE|endonasal endoscopic surgery|143 patients will undergo endonasal endoscopic surgery
48448293|NCT04215510|RADIATION|radiation therapy(IMRT)|143 patients will undergo radiation therapy.
48448294|NCT02135263|DRUG|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
48448295|NCT02135263|DRUG|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
48448296|NCT05276635|BEHAVIORAL|The Sleep Hygiene Education (SHE)|Patients were randomized into two equal groups of 30 participants each. One group received a Sleep Hygiene Education (SHE) intervention
48448297|NCT05276635|BEHAVIORAL|Emotional Freedom Techniques (EFT)|30 participants had a form of Emotional Freedom Techniques (EFT) adapted for use with insomnia (EFT-I).
48448298|NCT05612867|DIETARY_SUPPLEMENT|Vitamin C|Due to clinical research supporting high dose vitamin C, the institution's surgical intensivists started utilizing a high IV vitamin C dose in higher total body surface area burns while continuing to use the standard PO vitamin C dose of 500 mg to 1,000 mg daily on patients with lower total body surface area burns. Looking at the initial 72 hours, patients with smaller burns were given 2,500 mg PO vitamin C and larger total body surface area burns were given 15,000 mg IV vitamin C.
48448299|NCT05952544|DRUG|essential amino acids and keto-analogues supplementation|very low protein diet plus essential amino acids and keto-analogues supplementation
48448300|NCT05952544|OTHER|low protein diet|patients were on low protein diet only
48448301|NCT06559111|DEVICE|2-week casting followed by 4-week bracing|Participants in the bracing group had a cast for 2 weeks after the surgery followed by ankle brace for 4 weeks.
48448302|NCT06559111|DEVICE|6-week casting|Participants in the casting group had a cast for 6 weeks after the surgery.
48448303|NCT02697747|OTHER|Education|Educational intervention in the use of ultrasound to identify landmarks
48448304|NCT04560335|BEHAVIORAL|Coach to FIt|"CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly."
48448305|NCT04560335|BEHAVIORAL|Treatment as Usual|Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
48448306|NCT00908128|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
48448307|NCT00908128|DRUG|CellCept®|CellCept® Tablets, 500 mg
48448308|NCT00987740|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
48448309|NCT05878964|OTHER|EQ-5D-5L questionnaire|Quality of life evaluation questionnaire
48448310|NCT05878964|OTHER|FACT-G (Functional Assessment of Cancer Therapy - General)|Quality of life evaluation questionnaire
48448311|NCT05878964|OTHER|FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)|Self reported evaluation of cutaneous toxicity questionnaire.
48448312|NCT05982691|RADIATION|Radiation Therapy|Radiation Therapy(General guideline) Patients will receive radiotherapy after induction chemotherapy or right after diagnosis without diagnosis. The dose and fields of radiation will be according to the histology, presence of dissemination, and response to the induction chemotherapy or radiotherapy. Radiation therapy can be administered using either of photons or protons. When induction chemotherapy is administered, radiotherapy is recommended to be started within 6 weeks from the last chemotherapy.
48448313|NCT01880853|OTHER|mammography|participants were screened by mammography alone every year
48448314|NCT01880853|OTHER|ultrasound|participants were screened by ultrasound alone every year
48448315|NCT01880853|OTHER|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
48448316|NCT05747469|DRUG|local anaesthetic injection|Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
48448317|NCT05747469|PROCEDURE|Human Adipose Allograft|Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
48448318|NCT03207503|PROCEDURE|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
48448319|NCT06324825|DRUG|Fuzhegn Nizeng Decoction|Subjects taking prepared Fuzhegn Nizeng granules twice daily for 6 month.
48448320|NCT06324825|DRUG|Moluodan granules|Subjects taking prepared Moluodan granules 9g twice daily for 6 month.
48448321|NCT02787876|DRUG|Pegteograstim|
48448322|NCT03890796|BEHAVIORAL|Activity Scheduling|AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
48448323|NCT03890796|BEHAVIORAL|Educational|A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
48620428|NCT00207688|DRUG|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
48448324|NCT04656353|BEHAVIORAL|Intervention Arm|Participants randomized to the Intervention Arm will be provided with the website link to the online self-help program and a questionnaire and a distress survey. They will be asked to use the website within two weeks and then to complete these documents after using it and mail them back in a self-addressed stamped envelope. Same documents will be administered at the 3-month follow-up period, and the participant will be given two weeks to complete and return it in a self-addressed stamped envelope. Additionally, participants will also be asked in the 3-month follow-up questionnaire if they are interested in attending a focus group to elaborate on their experience with the psychosocial self-help program. Those who have expressed an interest will be contacted. The focus groups will last about 1-1.5 hours and consist of 3-4 participants. Focus groups will be audio-taped and conducted in either English or Chinese.
48448325|NCT04656353|BEHAVIORAL|Control Group|Participants randomized to the Control group will receive standard care (no intervention). They will be used as a baseline to compare groups and assess the effect of the intervention (i.e., the online psychosocial program). At the two weeks following randomization (T1) and the 3-month follow-up periods (T2), they will be asked to complete the questionnaire and distress survey and return them in a self-addressed stamped envelope. Participants will be given two weeks to complete the questionnaire and distress survey. The same documents will be administered at the 3-month follow-up period (T2). Once the 3-month follow-up is completed, each participant will be provided with the website link to view the self-help program.
48448326|NCT04303884|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
48448327|NCT03512925|OTHER|Standardized debriefing session of coercive measures|Debriefing session following the developed guidelines including setting and themes.
48448328|NCT01890057|DRUG|Sugammadex|The dose of sugammadex
48448329|NCT02897414|OTHER|Surveillance of state medical examiner databases|
48448330|NCT04914351|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
48448331|NCT03069183|DRUG|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
48448332|NCT03069183|DRUG|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
48448333|NCT03378492|DEVICE|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
48448334|NCT03378492|PROCEDURE|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
48448335|NCT00804856|DRUG|Volasertib|Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
48448336|NCT00804856|DRUG|Cytarabine|Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
48448337|NCT05283850|DRUG|High Calcium, Low Sodium (HCLS) Crystalloid Therapy|Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
48448338|NCT05283850|DRUG|High Calcium, High Sodium (HCHS) Crystalloid Therapy|Normal saline IV drip and 1g IV bolus Calcium Chloride.
48448339|NCT04804605|DRUG|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream
48448340|NCT02564965|DEVICE|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
48448341|NCT02564965|DEVICE|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
48448342|NCT04999501|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
48448343|NCT02974556|PROCEDURE|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
48448344|NCT02974556|PROCEDURE|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
48448345|NCT02974556|DRUG|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
48448346|NCT05247463|OTHER|Increase in upper age of eligibility for breast cancer screening from 64 to 70|The upper age limit of eligibility for Breast Cancer Screening increased in England from 64 to 70 as a result of the NHS Cancer Plan, so women were offered an additional 2 rounds of screening.
48448347|NCT05247463|OTHER|Screening round length|The target round length (frequency) of breast cancer screening in England is every 3 years. However in practice there is variability in this due to local centre capacity. The exposures are round lengths of approximately 2 years and approximately 3 years
48448348|NCT05247463|DIAGNOSTIC_TEST|Screening test threshold|Radiologists and equivalent health professionals examine women's screening mammograms for potential signs of cancer, and recall some women for further diagnostic tests. Each has a different test threshold for recall, characterised by the proportion of previous cases that they have recalled.
48448349|NCT03492320|OTHER|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
48448350|NCT04534790|RADIATION|Low Dose Radiotherapy|anti-inflammatory effect with low-dose radiation to the lungs
48448351|NCT00910221|DRUG|Atorvastatin|Atorvastatin tablet
48448352|NCT00910221|DRUG|Placebo|Placebo tablet
48448353|NCT06586112|DRUG|ESK-001|ESK-001
48448354|NCT06586112|DRUG|Apremilast|Apremilast
48448355|NCT06586112|DRUG|Placebo|Placebo
48448356|NCT03219853|DIETARY_SUPPLEMENT|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched environment
48448357|NCT03219853|DIETARY_SUPPLEMENT|Conventional parsnips|Parsnips which have been grown in a conventional environment
48448358|NCT01901783|PROCEDURE|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
48448359|NCT01901783|PROCEDURE|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
48448360|NCT03167515|DEVICE|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
48448361|NCT05200663|DRUG|Tab Tamoxifen 10 mg|Tablet tamoxifen 10mg twice a day for 6 months.
48448362|NCT05200663|DRUG|Tab Tamoxifen 10mg,Cap vitamin E 400mg|Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
48448363|NCT02009163|DRUG|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
48448364|NCT02009163|OTHER|Placebo|Placebo capsule once per day (double-blind period)
48448365|NCT02984098|DRUG|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
48279042|NCT05153382|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
48448366|NCT04077723|DRUG|Englumafusp alfa|Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
48279043|NCT04868123|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).
48279044|NCT04868123|BEHAVIORAL|Mindfulness Meditation|Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.
48448367|NCT04077723|DRUG|Obinutuzumab|"A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III)."
48448368|NCT04077723|DRUG|Glofitamab|A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III
48448369|NCT04077723|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
48448370|NCT05327608|OTHER|Short-Term Fasting|Undergo intermittent fasting
48448371|NCT00838279|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
48448372|NCT00838279|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
48448373|NCT00851877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
48448374|NCT00851877|DRUG|Cisplatin|Cisplatin is an anti-cancer chemotherapy drug
48448375|NCT00851877|DRUG|Nab-Paclitaxel|paclitaxel albumin-stabilized nanoparticle formulation
48448376|NCT00851877|RADIATION|intensity-modulated radiation therapy|intensity-modulated radiation therapy
48448377|NCT02361905|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
48448378|NCT02361905|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
48448379|NCT05951660|BEHAVIORAL|Educational intervention|"Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences."
48448380|NCT06094517|OTHER|Interview|Persistent Lower Back Pain Patients on waiting list under going a usual care pathway following referral to Physiotherapy will be interviewed for views on sleep health
48448381|NCT05697211|DRUG|Ferric maltol 30 mg (Feraccru®)|In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.
48448382|NCT06161961|DEVICE|WRL TTP|evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
48448383|NCT05782634|DEVICE|immediate satellite implant with immediate loading|"Infiltration anesthesia will be administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 . Injection to control pain and bleeding for hemostasis.~Dental extraction will be done with minimal force to avoid trauma to the bone. Flab will be released, different drilling sizes will be used to attain the final drill size of the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, a satellite implant device is attached to the implant's abutment placed on the buccal and palatal plates of bone and retention between the abutment and microplate will help in neglecting the lateral destructive forces . sutures will be done . Impression will be taken for immediate loading with the final crown. Cone beam will be done."
48448384|NCT04551976|BEHAVIORAL|Mindfulness|Pay attention to the present moment, on purpose, in a nonjudgemental way.
48448385|NCT02074020|DRUG|Blisibimod|Administered via subcutaneous injection once per week
48448386|NCT02074020|DRUG|Placebo|Administered via subcutaneous injection once per week
48448387|NCT06560515|DRUG|Vaginal Dinoprostone|induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
48448388|NCT03024515|DRUG|opioids titration|Standard Practice Arm
48279045|NCT05057390|DIETARY_SUPPLEMENT|New Human Milk Fortifier (NHMF)|"The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use."
48279046|NCT03204344|DIETARY_SUPPLEMENT|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
48448389|NCT03024515|DRUG|predefined titration steps|comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
48448390|NCT03763435|BEHAVIORAL|Antenatal pregnancy classes|At least three comprehensive full-day educational program covering all the stages of pregnancy.
48448391|NCT00599664|DRUG|OMS201|OMS201 irrigation solution during surgery
48448392|NCT00599664|DRUG|Vehicle|Vehicle irrigation solution during surgery
48448393|NCT05628311|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
48448394|NCT05628311|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
48448395|NCT00438945|DRUG|Eprosartan|
48448396|NCT01278953|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
48448397|NCT00834418|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
48448398|NCT00834418|DRUG|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
48448399|NCT03682653|DRUG|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
48448400|NCT03682653|DRUG|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
48448401|NCT06281847|GENETIC|CCTx-001|Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)
48448402|NCT06266533|BEHAVIORAL|Conventional Ultra-processed Food Nutrition Education|The participants will receive a conventional nutrition education session with slides, flyers/handouts, and a lecture with discussion.
48448403|NCT06266533|BEHAVIORAL|Arts-based Ultra-processed Food Nutrition Education|The participants will receive an arts-based nutrition education session with video, animation, music, and discussion.
48448404|NCT00859430|DRUG|Levetiracetam|1000 mg Tablet
48448405|NCT00859430|DRUG|Keppra®|1000 mg Tablet
48448406|NCT01521715|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
48448407|NCT00418561|BIOLOGICAL|rhASA - Dose Level 1|Intravenous infusion 25 U/kg as a single dose - hereafter 50 U/kg every other week for 26 weeks
48448408|NCT00418561|BIOLOGICAL|rhASA - Dose Level 2|Intravenous infusion 100 U/kg every other week for 26 weeks
48448409|NCT00418561|BIOLOGICAL|rhASA - Dose Level 3|Intravenous infusion 200 U/kg every other week for 26 weeks
48448410|NCT06429540|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will be dried using air, then ground and partially demineralized with the Tooth Transformer device following the manufacturer's protocol. Dentin particles will be obtained with dimensions of 400-800 μm. The partially demineralized dentin will then be prepared by cutting the Leukocyte-Platelet Rich Fibrin (L-PRF) membranes into small pieces and mixing them with the dentin particles. Liquid fibrinogen will be added to the homogeneous mixture. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming the dentin block. After that, the sockets will be carefully packed with the dentin block and it will be covered with L-PRF membrane. To ensure stability and prevent displacement, the wounds will be secured using non-resorbable sutures."
48448411|NCT06429540|BIOLOGICAL|Xenograft|In the control group using the Xenograft, the same extraction and socket debridement procedure will be performed. Following that, the extraction socket will be thoroughly filled with deproteinized bovine bone mineral, and a collagen membrane will be employed to cover the socket. The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa. To ensure its stability, a cross-suture will be performed, securing the membrane in place.
48448412|NCT06560242|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
48448413|NCT06412016|BEHAVIORAL|Peer Nutritional Counseling + Urban Gardening|Peer nutritional counseling and urban gardens
48448414|NCT02534272|OTHER|Stool sampling and sequencing of gut microbiota.|
48448415|NCT06265298|PROCEDURE|Conjunctival reconstruction|Conjunctival reconstruction using buccal mucosa taken from the patient's mouth. Following the reconstruction operation, an additional biopsy of buccal mucosa will be taken to develop a laboratory protocol for the transdifferentiation of these buccal cells into corneal epithelial stem cells.
48448416|NCT04819243|DRUG|Pabociclib, Endocrine, Talazoparib, Atezolizumab|"* Palbociclib 125mg~* AI~* GnRH agonist~* Talazoparib~* Atezolizumab"
48448417|NCT04819243|DRUG|Pabociclib, Endocrine, Talazoparib,|"* Palbociclib 125mg~* AI~* GnRH agonist~* Talazoparib"
48448418|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
48448419|NCT02877433|DEVICE|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
48448420|NCT03037697|OTHER|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
48448421|NCT03037697|OTHER|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
48448422|NCT04594252|DRUG|ALXN1840|Administered orally as tablets.
48448423|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
48448424|NCT06160908|DEVICE|sham NirsCure|Non near-infrared light irradiation；only the equipment appearance is consistent with the test device；Once a day, once for 30 minutes, 6 times a week
48448425|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
48448426|NCT01863030|DEVICE|Phasix mesh implant|
48279047|NCT03204344|OTHER|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
48279048|NCT06041555|OTHER|3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed|Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
48279049|NCT06656208|OTHER|Pubic symphysis manipulation|Manipulation was applied in the crook lying position with 5 repetitions hold for 10 sec and ask the patient to apply max. Contraction in Abduction and then relax. Whereas, the therapist applies a rapid stretch to a new barrier and is held for 10 seconds.
48279050|NCT06656208|OTHER|Traditional sacroiliac treatment|Mobilization was applied in prone lying position on sacroiliac joint, 30 Oscillations per set for 15 seconds, 3 sets on effected side.
48279051|NCT01340183|DRUG|AZD5099|IV Dose
48279052|NCT01340183|DRUG|Placebo|IV Dose
48448427|NCT04481919|DRUG|Protocolized diuretic therapy|The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
48448428|NCT01074203|DRUG|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery \>12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
48448429|NCT00461786|DRUG|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
48448430|NCT00088192|DRUG|pegaptanib sodium|
48448431|NCT01074541|RADIATION|UVB|0.375 SED x 4 in a week
48448432|NCT01074541|RADIATION|UVB|0.75 SED x 4 in a week
48448433|NCT01074541|RADIATION|UVB|1.5 SED x 4 in a week
48448434|NCT01074541|RADIATION|UVB|3.0 SED x 4 in a week
48448435|NCT04539470|DRUG|Efmarodocokin Alfa|Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.
48448436|NCT04328935|BEHAVIORAL|WET|The manual is based on established CBT interventions in trauma such as exposure. In short, the treatment is that the participant should be able to approach their intrusive memories and by doing this repeatedly, the memory will give rise to less discomfort.
48448437|NCT03563872|OTHER|Intervention|Enhancements to team-based care include clinical decision support and improved protocols for telehealth prescribing.
48448438|NCT03563872|OTHER|Active Comparator|Usual, team-based care
48448439|NCT05901090|OTHER|M-TAPA block|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. M-TAPA block with the same standard technique and drug dose was applied to the contralateral side for each group of M-TAPA patients.
48448440|NCT05901090|OTHER|TAP block|After the necessary sterilization conditions were established, the linear ultrasound probe was sterilely coated and placed in the middle of the iliac crest with the end limit of the ribs. Starting with skin, the layers in descending order, subcutaneous adipose tissue, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum were identified. As the tip of the 80 mm sonovisible needle passed through the muscular layers and fascia, a fascial click was felt and the needle was advanced with ultrasound in a controlled manner. After receiving the second click sensation (passage of the fascia of the internal oblique muscle), the location of the needle was fixed and frequently aspirated and applied to the plane so that 20 ml of 0.25% bupivacaine was applied to each side. (40 ml in total)
48448441|NCT02286739|DEVICE|"TKA with Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA pre-market submission (510K) clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
48448442|NCT02286739|PROCEDURE|"TKA without Verasense"|TKA will be performed manually without the use of Verasense
48448443|NCT04278391|DRUG|DWJ1421|1 tablet administered in fasting condition
48448444|NCT04278391|DRUG|DWC201903|1 tablet administered in fasting condition
48448445|NCT05167474|OTHER|breast milk smell|yenidoğanlara fototerapi tedavisi esnasında anne sütü kokusu uygulanmıştır.
48448446|NCT05439148|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.
48448447|NCT01502696|BIOLOGICAL|PEG IFN alfa-2b|3µg/kg weekly injections
48448448|NCT02023229|DIETARY_SUPPLEMENT|Branched-chain aminoacids|
48448449|NCT02023229|OTHER|High-fiber high protein diet|
48448450|NCT00988715|BIOLOGICAL|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
48448451|NCT00988715|DRUG|Cyclosporine|Given IV
48448452|NCT00988715|DRUG|Mycophenolate Mofetil|Given PO
48448453|NCT00988715|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
48448454|NCT00988715|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
48448455|NCT00988715|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
48448456|NCT00988715|DRUG|Fludarabine Phosphate|Given IV
48448457|NCT00988715|OTHER|Pharmacological Study|Correlative studies
47928116|NCT05466487|DEVICE|Transcranial Alternating Current Stimulation (tACS)|Stimulation frequency and peak-to-peak intensity will be set to 10Hz and 1.5 milliampere (mA), phase offset will be set to 0 and 100 cycles will be used for ramping up. At the start of the neglect training session, the tACS will be started. When the neglect training session is finished, after maximally 40 minutes, the tACS will be switched off.
48279053|NCT01836861|DRUG|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
48279054|NCT03755622|DEVICE|Conventional Transpalatal Arch (TPA)|In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
48279055|NCT03755622|DEVICE|Transpalatal Arch (TPA) fabricated from 3D reconstructed model|In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
48279056|NCT00104130|DRUG|KOS-862|
48279057|NCT00629083|DEVICE|Bulkamid|Bulking injection with Bulkamid injection device
48279058|NCT00629083|DEVICE|Contigen|Transurethral bulking injection
48448458|NCT00988715|OTHER|Laboratory Biomarker Analysis|Correlative studies
48448459|NCT04979910|DRUG|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
48448460|NCT00123734|DRUG|ThromboView|
48448461|NCT00864591|PROCEDURE|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
48448462|NCT00864591|PROCEDURE|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
48448463|NCT04992611|BEHAVIORAL|Sleep Extension (Early)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping rise time the same as the sleep restriction period, but extending sleep by going to bed earlier. This produces a sleep extension that is aligned for Morning Larks and misaligned for Night Owls.
48448464|NCT04992611|BEHAVIORAL|Sleep Extension (Late)|Following a periods of time meant to stabilize their sleep patterns and to induce mild sleep restriction, participants will be randomly assigned to one of two sleep extension conditions, both of which are designed to allow recommended sleep duration. The Early Sleep Extension condition does so by keeping bedtime the same as the sleep restriction period, but extending sleep by rising later. This produces a sleep extension that is misaligned for Morning Larks and aligned for Night Owls.
48448465|NCT04889586|DEVICE|EMG-biofeedback armband (REMO)|After clinical evaluation, the subjects execute an instrumental test. By wearing EMG-biofeedback device (REMO), the subjects have to perform 10 different hand gestures: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The muscle activations (EMG signals) during the execution of each movements, are recorded for 3 seconds.
48448466|NCT01956591|DRUG|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
48448467|NCT04256720|BEHAVIORAL|No intervention|No intervention - questionnaire study
48448468|NCT06131437|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
48448469|NCT06131437|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
48448470|NCT06131437|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
48448471|NCT05183204|DRUG|Paxalisib|Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
48448472|NCT05183204|DRUG|Metformin|Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
48448473|NCT05183204|OTHER|Ketogenic Diet|The ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis starting on Cycle 1, Day 1 and continuing throughout the trial.
48448474|NCT02082392|DRUG|Escitalopram|
48448475|NCT02082392|DRUG|Placebo|A substance or treatment of no intended therapeutic value in a pill form.
48448476|NCT01832350|DRUG|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
47928117|NCT05466487|BEHAVIORAL|Visual Scanning Training (VST)|The most common treatment for neglect is VST, which is an intensive compensation training (see Dutch guidelines for rehabilitation of neglect: Ten Brink, Van Kessel, \& Nijboer, 2017). The aim of this training is to improve visual scanning behavior, that is, to encourage neglect patients to actively and consciously pay attention to stimuli on the contralesional side.
48448477|NCT01462708|DRUG|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not \>10% of 10 mCi limit)of \[18F\]MK-9470, followed by PET imaging.
48448478|NCT06448221|BEHAVIORAL|a web-based Relationship Teaching(RT)/communication education programs|receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system.
48448479|NCT06448221|BEHAVIORAL|Helper of Emotional Assessment Relationship Teaching (HEART) program|receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system
48448480|NCT06560710|OTHER|vitrectimy|Clinical characteristics and surgical outcomes
48448481|NCT05489289|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 16 cycles
48448482|NCT05489289|BIOLOGICAL|placebo|Subjects will receive placebo until disease progression or for a maximum of 16 cycles
48448483|NCT01885117|BIOLOGICAL|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
48448484|NCT06430177|BEHAVIORAL|Su Jok|Su Jok will be done
47928118|NCT03048383|DRUG|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
48448485|NCT02795572|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000 IU oral once daily
48448486|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 100 mg oral once daily
48448487|NCT02795572|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 100 mcg oral once daily
48448488|NCT02795572|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
48448489|NCT06248827|OTHER|Data Collection|Patient data : gender, age, height, weight, daily life (type of job) Diagnostic data : Description of first symptoms/medical history (pain), previous medical history, MRI exams
48448490|NCT06562309|OTHER|take feces and blood samples from patients|this study does not involve any intervention
48448491|NCT02267187|PROCEDURE|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
48448492|NCT02267187|DRUG|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
48448493|NCT02267187|DEVICE|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
48448494|NCT02267187|OTHER|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
48448495|NCT03214952|DRUG|Vonoprazan|Vonoprazan tablets
48448496|NCT06244043|OTHER|Initial Coaching Call|Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).
48448497|NCT06244043|OTHER|Email Support|Email-based support throughout study period
48448498|NCT06244043|OTHER|Text Messages|All participants with receive text messages encouraging them to engage in the practices taught in the app.
48448499|NCT04946864|DRUG|APG-2575|APG2575 monotherapy
48448500|NCT04946864|DRUG|Palbociclib|combination APG2575+pablociclib
48448501|NCT00675142|PROCEDURE|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
48448502|NCT03806166|OTHER|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
48448503|NCT03806166|OTHER|Standard treatment|Standard duration of systemic antibiotic treatment
48448504|NCT00570609|OTHER|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
48448505|NCT00966485|DRUG|80 mg ASA dosing|
48448506|NCT00966485|DRUG|500 mg ASA dosing|
48448507|NCT02645500|BEHAVIORAL|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
48448508|NCT02645500|BEHAVIORAL|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
48448509|NCT06558370|OTHER|Empty bladder group|"Patients in the empty bladder group will be instructed to empty the bladder immediately before the procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is empty.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
48448510|NCT06558370|OTHER|Bladder distension group|"Patients in the bladder distension group will be instructed to drink one liter of water and to avoid urination during a period of 2 h before the scheduled procedure. A colleague will perform transabdominal ultrasound to confirm that the bladder is distended .~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures."
48448511|NCT04732117|DRUG|Secukinumab|Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
48448512|NCT04732117|DRUG|Placebo|Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
48448513|NCT02173834|OTHER|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
48448514|NCT06034483|OTHER|Pelvic floor exercise training|"* Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~* In the pelvic floor muscle training program:~* Fast and slow pelvic floor muscle contractions will be taught,~* Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~* 1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~* Individuals will be tracked with exercise diaries.~* At the end of the 8th week, post-intervention evaluations will be made again.~* The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day)."
48448515|NCT06034483|OTHER|Patient/individual education|"In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month."
48448516|NCT02493283|DRUG|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
48448517|NCT02493283|DRUG|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
48448518|NCT02493283|BIOLOGICAL|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
48448519|NCT02493283|BIOLOGICAL|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
48448520|NCT01200810|OTHER|placebo|Given orally
48448521|NCT01200810|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
48448522|NCT01200810|DRUG|bicalutamide|Given orally
48448523|NCT06524479|PROCEDURE|SEEG recording and CCEP|This study aims to utilize the clinical, imaging, and electrophysiological data of patients with drug-resistant epilepsy. By Performing CCEP detection at specific targets during both wakefulness and sleep and analyzing its electrophysiological characteristics, the study will compare the functional properties of white matter fibers during wakefulness and sleep.
48448524|NCT05053854|DRUG|Talazoparib|During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
48448525|NCT05226702|BIOLOGICAL|COVAC-2|Intramuscular vaccine against SARS-CoV-2
48448526|NCT05226702|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
48448527|NCT03475303|BEHAVIORAL|early hospital discharge|early hospital discharge at 8-12 hours for women undergone elective cesarean section
48448528|NCT02486081|DEVICE|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
48448529|NCT04408586|DRUG|Phentermine-Topiramate Extended Release|Dosing of 3.75/23 mg daily for 15 days, increased to 7.5/46 mg daily
48448530|NCT04408586|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient
48448531|NCT04408586|OTHER|Online support system|VitalCare (VitalTech Affiliates LLC) is a digital health platform that allows remote collection of date from the wearable tracker and digital wellness devices used as part of this study. It also will allow subjects to document study medication compliance and will allow the remote visits to be conducted through a video conference between subjects and appropriate study team members.
48448532|NCT00840866|DRUG|cefprozil|500 mg Tablet
48448533|NCT00840866|DRUG|Cefzil®|500 mg Tablet
48448534|NCT05204979|OTHER|Vaginal Versus Sublingual misoprostol|Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
48448535|NCT04965454|COMBINATION_PRODUCT|Fluorine-18 fluorocholine|18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
48448536|NCT04596670|DRUG|68Ga-ICAM-1pep|68Ga-ICAM-1pep PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-ICAM-1pep, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
48448537|NCT03730272|DRUG|analgesic drugs and methods|the patient will receive analgesic treatment at the discretion of the physician in charge
48448538|NCT04594577|DEVICE|Fluispotter|Fluispotter automated blood sampling system applied for venous blood sampling of 20 10 μL samples in a 20 hours sampling session.
48448539|NCT03281135|OTHER|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
48448540|NCT03931460|DRUG|Medical Abortion|Medical Abortion
48448541|NCT05457920|BEHAVIORAL|continuous treatment|The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFN α-2b 180μg once a week, or every 8 weeks of injection, 4 weeks off, periodically, the total treatment course does not exceed 96 weeks.
48448542|NCT05457920|BEHAVIORAL|pulse therapy|pulse therapy
48448543|NCT03286439|OTHER|there will be offered a follow up visit|The investigators will offer the patients a follow up visit 3 and 12 months after discharge from the hospital.
48448544|NCT05278130|OTHER|Additional vaginal swabs|Every 2 weeks from 16 weeks gestational age to 34 weeks gestational age
48448545|NCT01031394|OTHER|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
48448546|NCT04258735|DIAGNOSTIC_TEST|Genomic analysis|WES, RNASeq, ctDNA, Exosome
48448547|NCT06269952|OTHER|No intervention|No intervention. The participants are asked questions from and questionnaire and later also interviewed guide by an interview-guide
48448548|NCT01015625|PROCEDURE|Surgery|lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
48448549|NCT01015625|PROCEDURE|Surgery on Demand|if necessary local therapy on demand
48448550|NCT03679091|DRUG|low-dose ticagrelor|low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
48448551|NCT03679091|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
48448552|NCT06560060|OTHER|No intervention|There are no interventions. The only medical procedure is a blood draw
48448553|NCT00070148|DRUG|Megestrol Acetate|Megace by mouth for 12 weeks
48448554|NCT00070148|DRUG|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
48448555|NCT05168735|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
48448556|NCT05168735|BEHAVIORAL|Brief Mindfulness Exercises|30min guided training in mindfulness meditation immediately prior to infusion
48448557|NCT05168735|BEHAVIORAL|Academic Exercises|30min of mental math and other academic cognitive puzzles completed silently/mentally
48448558|NCT05146492|PROCEDURE|MRI|MRI with gadolinium contrast media injection
48448559|NCT06166277|PROCEDURE|Ablation procedure|Cardioneuroablation procedure or permanent pacemaker placement
48448560|NCT05877339|DIAGNOSTIC_TEST|Survey|Survey
48448561|NCT03880461|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention
48448562|NCT06562114|DRUG|TML-6 Granules|Administered orally
48448563|NCT06562114|DRUG|Placebo|Administered orally
48448564|NCT01948258|DEVICE|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
48448565|NCT01250080|DIETARY_SUPPLEMENT|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
48448566|NCT01250080|OTHER|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
48448567|NCT03016858|PROCEDURE|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
48448568|NCT03893487|DRUG|Fimepinostat|Fimepinostat capsules
48448569|NCT03893487|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48448570|NCT00418145|DRUG|megadose oral methylprednisolone|1400 mg qd/5 days
48448571|NCT00418145|DRUG|IV methylprednisolone|1000 mg/qd/5 days
48448572|NCT01528462|OTHER|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
48448573|NCT04754035|DRUG|Venetoclax|venetoclax 20 mg, 50 mg, 100 mg
48448574|NCT04754035|DRUG|Imbruvica Oral Product|Imbruvica 140 mg
48448575|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5mL oral dose
48448576|NCT00829790|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
48448577|NCT05547711|DIAGNOSTIC_TEST|drawing blood|drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
48448578|NCT03070119|DRUG|Tofersen|Participants will receive a loading dose regimen followed by maintenance dosing.
48448579|NCT01744587|OTHER|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
48448580|NCT01744587|DIETARY_SUPPLEMENT|Placebo|Placebo qd (2# bid) for 3 years
48448581|NCT06253533|BIOLOGICAL|ICVAX|ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
48448582|NCT06253533|OTHER|Placebo|Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
48448583|NCT05976815|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
48448584|NCT00663481|DRUG|CoFactor|
48448585|NCT00663481|DRUG|Leucovorin|
48448586|NCT04931810|BEHAVIORAL|All Nations Breath of Life|Same.
48448587|NCT05213286|DIAGNOSTIC_TEST|Application of ZAQ and RAADS-R-DK|Test of the questionnaires in each of the three groups.
48448588|NCT04717960|PROCEDURE|nasal submucosal injection of platelet rich plasma|"* The selected region will be inﬁltrated with a cold saline solution with addition of 1 mL of adrenaline and 25 mL of 2% lignocaine per 500 mL saline.~* Platelet-rich plasma is prepared by drawing 10 mL of blood sample from the patient.~* The blood will be centrifuged at 1530 g for 10 min to obtain platelet-poor plasma.~* This will again centrifuged at 2720 g for 10 min to get platelet-rich plasma.~* Approximately 1 mL of platelet-rich plasma will be obtained from 10 mL blood. Usually amount of about 3ml is needed to be injected in each nostril at the affected sites of inferior and middle turbinates, septum and floor of the nose. Platelet rich plasma injected into the affected area after degranulating the platelet by adding 0.5 mL of calcium chloride.~  * Injection interval of 2 weeks (up to total 3 consecutive injections).~ * Follow-up duration: 4 months"
48448589|NCT04814095|BEHAVIORAL|QOL|QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
48448590|NCT04814095|DIAGNOSTIC_TEST|CT imaging|CT radiographic imaging every 12 weeks +/- 2 weeks
48448591|NCT04499677|DRUG|Favipiravir|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
48448592|NCT04499677|DRUG|Lopinavir/ Ritonavir|Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
48448593|NCT04499677|OTHER|Favipiravir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
48448594|NCT04499677|OTHER|Lopinavir/ Ritonavir Placebo|Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
48448595|NCT03932058|DRUG|Chemotherapy|all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
48448596|NCT06248879|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48448597|NCT06248879|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48279059|NCT04563364|OTHER|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
48279060|NCT04563364|OTHER|Convencional treatment|Control group will receive a conventional treatment given by the institutions
48279061|NCT00863616|DEVICE|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
48279062|NCT04495660|DEVICE|Near InfraRed Spectroscopy (fNIRS)|Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
48279063|NCT04495660|BEHAVIORAL|Passive perceptual stimulation|Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
48279064|NCT04495660|BEHAVIORAL|Task A not B|Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
48279065|NCT04495660|BEHAVIORAL|VSWMT task|VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
48279066|NCT04495660|BEHAVIORAL|Perceptual Go-No-Go|Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
48279067|NCT04495660|BEHAVIORAL|Verbal memory task|Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
48279068|NCT04495660|BEHAVIORAL|The sensory room|The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
48279069|NCT00312130|DRUG|Vildagliptin|
48279070|NCT02214849|BEHAVIORAL|LATCH Intervention|
48279071|NCT00921869|DRUG|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
48279072|NCT04271462|OTHER|Comparing two CO2 absorbers in the ventilator circuit|"General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow."
48279073|NCT03874234|DRUG|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
48279074|NCT03874234|DRUG|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
48448598|NCT06248879|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48448599|NCT01452815|DRUG|Placebo|Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
48448600|NCT01452815|DRUG|10mg TZP-102|One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
48448601|NCT01452815|DRUG|20mg TZP-102|Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
48448602|NCT05388305|BIOLOGICAL|CAR--γδT cells|Biological: CAR-γδT; Drug:
48448603|NCT00006218|DRUG|triapine|
48448604|NCT06562764|OTHER|Counselling by the Trained Pharmacist|The intervention group 1 is verbally counselled about the proper use of their inhaler devices.
48448605|NCT06562764|OTHER|Pictograms Cards and Counselling by the Trained Pharmacist|The investigator developed pictogram cards for the use of inhalers (MDI and DPI) and pictogram cards are attached to the inhalers of patients in the intervention group with counselling by the trained pharmacist.
48448606|NCT06421337|DEVICE|BraiN20(R)|"SEP monitoring will be carried out using the BraiN20® medical device and appropriate electrodes. SEP of both median nerves will be recorded, transferred, and stored to the internal card for their evaluation. BraiN20® Medical Device provides an automatic reading of the presence and feature of a N20 response both ipsilateral and contralateral (as control) to the cerebral hemisphere affected by the stroke and do not require specific training. Furthermore, the device provides an outcome prediction (percentage of likelihood of having mRS ≤ 2 day 7 and 90 after stroke onset) based on an internal algorithm.~BraiN20® measures one N20 wave per 33 seconds. Scalp electrodes are easily embedded on a headband and the wrist electrodes on a glove."
48448607|NCT02794584|DRUG|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
48448608|NCT02794584|PROCEDURE|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
48448609|NCT02794584|PROCEDURE|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
48448610|NCT06243796|PROCEDURE|Flap fixation technique|After complete the modified radical mastectomy procedure, the researcher will use absorbable sutures (vicryl), multiple alternating stitched 2.5 cm apart between the subcutaneous of the flap and underlying muscle
48448611|NCT05970484|BEHAVIORAL|DrinksRation|DrinksRation (www.drinksration.app; formerly called InDEx) app was developed following the Medical Research Council Complex Intervention Guidelines and using a co-design methodology. It was developed by the King's Centre for Military Health Research (King's College London) and Lancaster University, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app was designed to support veterans drinking at a hazardous or harmful level by providing bespoke advice and support.
48448612|NCT05970484|BEHAVIORAL|BeAlcoholSmart|BeAlcoholSmart is a progressive web app (PWA). The app can take advantage of smartphone features such as push notifications and haptics without requiring the participant to download via an app store. The app will contain a 7-day alcohol unit calculator and generic public health guidance on safe drinking. Participants will also receive reminders via email prompting them to consult the guidance as part of the BeAlcoholSmart. Control participant participants will be invited to complete all questionnaires via Qualtrics, with an email reminder being sent when they are due.
48448613|NCT04712045|OTHER|New PPE|The use of a new protocol of level 2 PPE which involves wearing a short-sleeve gown and a single pair of gloves
48448614|NCT04712045|OTHER|Old PPE|The use of a standard protocol of level 2 PPE which involves wearing a long-sleeve gown and double pairs of gloves
48448615|NCT03556813|OTHER|survey|non-inferiority study, randomized, blind, excluding health product, with no risk or constraint, in which all the acts are performed in the usual way and do not modify the patient's management.
48448616|NCT00298961|DEVICE|Videoconference equipment FALCON/IP|
48448617|NCT01498939|DRUG|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
48448618|NCT00039286|PROCEDURE|positron emission tomography|
48448619|NCT00039286|PROCEDURE|radionuclide imaging|
48448620|NCT00039286|RADIATION|fludeoxyglucose F 18|
48448621|NCT06558890|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation
48448622|NCT04989491|DRUG|Rituximab|One single dose of rituximab intravenously (IV)
48448623|NCT04989491|OTHER|control group|No treatment
48448624|NCT05925621|DRUG|Lecanemab|Observational study
48448625|NCT00859521|DRUG|Levetiracetam|1000 mg Tablet
48448626|NCT00859521|DRUG|Keppra®|1000 mg Tablet
48448627|NCT05315557|DRUG|Terlipressin|1mg/24 hour and titrate according to MAP
48448628|NCT05315557|DRUG|vasopressin|0.03 U/hour and titrate according to MAP
48448629|NCT01725529|DRUG|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
48448630|NCT01725529|DRUG|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
48448631|NCT01725529|DRUG|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
48448632|NCT01725529|DRUG|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
48448633|NCT00001991|DRUG|Atovaquone|
48448634|NCT00575159|DRUG|GSK189075|investigational drug
48448635|NCT00575159|DRUG|placebo|placebo comparator
48448636|NCT00572637|DRUG|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
48448637|NCT05491187|DRUG|0.5% bupivacaine heavy|Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
48448638|NCT05491187|DRUG|0.5% bupivacaine heavy with fentanyl|Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
48448639|NCT00066391|DRUG|cisplatin|
48448640|NCT00066391|DRUG|irinotecan hydrochloride|
48448641|NCT00066391|PROCEDURE|neoadjuvant therapy|
48448642|NCT05007470|DRUG|VSL #3 112.5 Capsule|VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
48448643|NCT05007470|OTHER|Placebo|100 mg sugar
48448644|NCT05246293|DRUG|Tofacitinib|"Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months"
48448645|NCT05829824|BEHAVIORAL|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
48448646|NCT05829824|OTHER|AutoReach|Phone call / SMS Text
48448647|NCT05829824|PROCEDURE|Biospecimen samples|Optional saliva sample
48448648|NCT05388266|OTHER|Mask ventilation|Mask ventilation is performed under paratracheal pressure or no pressure in a randomized, crossover manner.
48448649|NCT02061553|BEHAVIORAL|Motivation|Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.
48448650|NCT02061553|BEHAVIORAL|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
48448651|NCT02061553|BEHAVIORAL|BA-Tech|Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
48448652|NCT04246476|BEHAVIORAL|Mentally singing|All participants (people with PD and age-matched controls) sing their song in their head and match their footfalls or finger tapping to the beat.
48448653|NCT04246476|BEHAVIORAL|Listening to music|All participants (people with PD and age-matched controls) listen to their song and match their footfalls or finger tapping to the beat.
48448654|NCT00932477|DRUG|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
48448655|NCT00932477|DRUG|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
48448656|NCT00932477|DRUG|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
48448657|NCT01763177|OTHER|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
48448658|NCT04704323|DRUG|CAP-100|CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)
48448659|NCT06560086|DRUG|Ketoconazole|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
48448660|NCT06560086|DRUG|Luteinizing Hormone|A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
48448661|NCT03316963|DRUG|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
48448662|NCT04632927|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
48448663|NCT04632927|BIOLOGICAL|Ustekinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
48448664|NCT06267703|OTHER|Metabolomic profiling|Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
48448665|NCT05443750|BEHAVIORAL|Motivational Behavioral Economic Alcohol Intervention|The intervention combines an alcohol brief motivational intervention (US-THRIVE \[Tertiary Health Research Intervention via Email\]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.
48448666|NCT05443750|BEHAVIORAL|Health Education|Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
48448667|NCT06560528|DRUG|combination with Disitamab Vedotin and with Tislelizumab and Capecitabine|"Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W."
48448668|NCT06598332|DRUG|5-Azacytidine|"Patients will be treated with 5 azacytidine at a dose of 32 mg/m2 SQ or IV. The investigators aim to start AZA on Day 1 of steroids but it can be started up to 72 hours after steroids are started . Patients will be premedicated with antiemetics.~Patients must receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Steroid Taper for responding patients (Prednisone/Methylprednisolone) Days 1-5 2 mg/kg/day (taper cannot start until 3 days after enrollment) Days 6-10 1.5 mg/kg/day Day 11-15 1.0 mg/kg/day Days 16-20 0.5 mg/kg/day Days 21-28\* 0.25 mg/kg/day Days 29-56 Gradual further taper with a goal of reaching \< 0.2 mg/kg/day of prednisone (or \< 0.16 mg/kg/day of methylprednisolone) by Day 56."
48448669|NCT03037554|DEVICE|Sleepwear with Lateralized Thermal Characteristics|Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
48448670|NCT03037554|DEVICE|Sham-Lateralized Sleepwear|Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
48448671|NCT06561672|DRUG|tramadol plus paracetamol|Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anesthesia (induction agent will be propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
48448672|NCT06561672|DRUG|Fentanyl|Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).
48448673|NCT06561672|DRUG|propofol and muscle relaxant (cisatracurium)|propofol 2mg/kg and muscle relaxant (cisatracurium) 0.15 mg/kg)
48448674|NCT06561672|DRUG|Propofol|propofol 2mg/kg
48448675|NCT00583453|DRUG|Celecoxib|"Celecoxib 200 mg capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
48448676|NCT00583453|DRUG|Placebo|"Placebo capsule~1. capsule the night before surgery~2. capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
48448677|NCT03299829|DRUG|Trientine|Trientine is a chelating agent for removing the copper from the body
48448678|NCT04402151|DRUG|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
48448679|NCT04402151|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
48448680|NCT03834376|DRUG|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram \[mg\]) over a time period of 5 days.
48448681|NCT03379883|PROCEDURE|Pulsed radiofrequency (P-RF)|"Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.6 V"
48448682|NCT03379883|PROCEDURE|Platelet rich plasma (PRP)|Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
48448683|NCT02914990|DRUG|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
48448684|NCT03676764|DRUG|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
48448685|NCT03676764|DRUG|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
48448686|NCT01149733|DRUG|Tamsulosin|Test 0.4 mg Capsule
48448687|NCT01149733|DRUG|Tamsulosin|Reference Listed 0.4 Capsule
48448688|NCT03113708|DRUG|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
48448689|NCT00545792|DRUG|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
48448690|NCT00573599|DRUG|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
48098210|NCT04449744|OTHER|MySafeRx Inspire Plus|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
48448691|NCT00573599|DRUG|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
48448692|NCT04887415|BEHAVIORAL|Respiratory Strength Training (RST) Program|Participants will complete RST exercises 5 days per week by performing 5 sets of 5 repetitions of both expiratory and inspiratory muscle strength training (a total of 50 repetitions per day). Trainer devices will be calibrated to 50% of participants' maximum expiratory pressure (MEP) and maximum inspiratory pressure (MIP) as determined via respiratory assessment prior to and during the RST program.
48448693|NCT06491420|OTHER|fixation with arthroscopy|the pipkin fracture is fixed with the help of arthroscopy and percutaneous methods.
48448694|NCT06562569|DEVICE|non-invasive cervical vagal nerve stimulation ncVNS|The ncVNS device is a rechargable, handheld device that generate a proprietary frequency-modulated electrical stimulus at low voltage (max 24V) with a max current output of 60mA. The signal consists of 1ms bursts of 5kHz sine waves repeated at 25Hz. Two stainless steel contact surfaces coated with conductive gel deliver the stimulus to the neck in the vicinity of the vagus nerve.
48448695|NCT04862767|DRUG|TASO-001((TGF-β2 targeting anti-sense oligonucleotide)|96 hour continuous infusion
48448696|NCT04862767|COMBINATION_PRODUCT|Aldesleukin|SC, Bid
48448697|NCT05600907|BIOLOGICAL|JSP191|A monoclonal antibody that targets human CD117
48448698|NCT05093205|DRUG|PF-06882961|Tablets
48448699|NCT05093205|DRUG|Atorvastatin|Tablets
48448700|NCT05093205|DRUG|Midazolam|Syrup
48448701|NCT05093205|DRUG|Levonorgestrel & Ethinyl Estradiol|Tablet
48448702|NCT01300676|DRUG|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
48448703|NCT06407700|PROCEDURE|Brugger's exercise.|Participant was in a high sitting position. An elastic resistance band was be wrapped on each hand of the participant leaving the palm open and instructed to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant were instructed to perform scapular retraction with chin tucked in ,shoulder external rotation, elbow extension, shoulder abduction, and extension. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds, 4 sets 12 times repetitions.
48448704|NCT06407700|PROCEDURE|Kendall Exercise.|Kendall exercises with the frequency 5 sets of consisting of 12 repetitions of postures, each taking 30 seconds,3 times a week for total of 6 weeks.
48448705|NCT06366815|OTHER|Different Phenotypes of non ambulant patients with Duchenne Muscular Dystrophy|clinical and functional data collection of non ambulant patients with Duchenne muscular dystrophy
48448706|NCT03827356|DEVICE|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
48448707|NCT06559891|DEVICE|TIVUS™ Renal Denervation System|Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
48448708|NCT06559891|OTHER|Sham|For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
48448709|NCT00477594|DRUG|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
48448710|NCT01218867|BIOLOGICAL|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
48448711|NCT01218867|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
48448712|NCT01218867|BIOLOGICAL|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
48448713|NCT01218867|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
48448714|NCT06333171|DRUG|4-Aminopyridine|Active study drug
48448715|NCT06333171|OTHER|Placebo|Placebo comparator
48448716|NCT04961190|BEHAVIORAL|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
48448717|NCT04961190|DRUG|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
48448718|NCT04410263|DIAGNOSTIC_TEST|Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)|"Most data and part of the biological material required for addressing the research questions in this project are generated in the treatment of the patients. The following data and samples are collected specifically for this project according to the study schedule (i.e. extra sampling or additional questioning):~* blood samples (day 0= 40 ml EDTA, day 2= 20 ml EDTA, day 3= 30 ml EDTA, day 5=10 ml EDTA, every 5 days = 20 ml EDTA)~* Swabs (oral +/- nasal +/- nasopharyngeal)~* Sublingual microscopy"
48448719|NCT03575650|OTHER|Cardiac imaging modalities|Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
48448720|NCT05885971|DIAGNOSTIC_TEST|Administration of the SCOFF-F and EDE-Q questionnaires|The participants will answer to the SCOFF-F and EDE-Q questionnaires as well as socio-demographic questions
48448721|NCT04378621|DRUG|TNF-α inhibitor OR JAK inhibitor|Pharmacological anti-rheumatic treatment
48448722|NCT04378621|OTHER|Hand training|Physical hand training 10 min twice daily while on stable treatment
48448723|NCT05745038|BEHAVIORAL|SONATA|The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
48448724|NCT05212363|DEVICE|Lower extremity compression garments|Compression garments are used to exert external pressure on the lower extremities to reduce vascular wall tension and prevent gravity form pooling blood in the lower extremities which will improve venous return and lymphatic output. Following the resting measurements, subjects will be instructed to wear the garments and moved to the seated gaming position for 2 hours.
48448725|NCT05212363|BEHAVIORAL|Active break|"An active break is currently considered gold standard for increasing blood flow after prolonged sitting. The 6-minute walk will be conducted indoors next to the esport lab in the Wisser library at NYIT, Old Westbury. Participants will be asked to walk for 6 minutes on a flat surface back and forth following one hour of game play."
48620429|NCT04521803|DRUG|high dose Rifampicin (RIF)|Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
48620430|NCT04011072|RADIATION|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
48098211|NCT04449744|OTHER|MySafeRx Inspire Flex|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine/naloxone medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. Based on clinical need, the participant may be assigned an electronic pill dispenser for the duration of the study by their clinical team.
48098212|NCT04320264|PROCEDURE|Weight loss surgery|Severely obese women (BMI \>40) undergo sleeve gastrectomy
48098213|NCT05394402|DRUG|SHR0410 Injection|SHR0410 Injection
48098214|NCT05394402|DRUG|Placebo for SHR0410 Injection|SHR0410 Injection blank preparation
48279078|NCT02421393|OTHER|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
48279079|NCT02235818|DEVICE|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
48279080|NCT02235818|DEVICE|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
48279081|NCT01578902|RADIATION|Stereotactic ablative body radiotherapy|35Gy/5 fractions/29 days
48279082|NCT01636557|DRUG|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
48279083|NCT01636557|DRUG|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
48279084|NCT01636557|DRUG|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
48279085|NCT01636557|DRUG|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
48279086|NCT01636557|DRUG|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
48279087|NCT01636557|DRUG|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
48279088|NCT02522819|DEVICE|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
48279089|NCT00022932|DRUG|Iodine-131 Anti-B1 Antibody|
48279090|NCT00534534|BEHAVIORAL|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
48279091|NCT00676507|BIOLOGICAL|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
48279092|NCT00676507|OTHER|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
48279093|NCT04470895|DIAGNOSTIC_TEST|Failure Track patients analysis|"The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview."
48448726|NCT01434953|BEHAVIORAL|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
48448727|NCT01434953|BEHAVIORAL|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
48448728|NCT06521021|BEHAVIORAL|AVOID|"Behavioral: Home food environment and grocery delivery (AVOID) Participants will receive coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices~Behavioral: WW Participants assigned to all arms will receive of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
48448729|NCT06521021|BEHAVIORAL|RESIST|"Behavioral: Inhibitory control training (RESIST) Participants assigned to RESIST will receive coaching (Zoom and/or email/text) and gamified inhibitory control training.~Behavioral: WW Participants assigned to all arms will receive coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
48448730|NCT00161850|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
48448731|NCT05347719|BEHAVIORAL|MBCT Intervention|Eight weekly two-hour mindful MBCT intervention sessions involving training in mindfulness meditation and cognitive-behavioral methods. Sessions will be designed to increase participant awareness of internal reactions that trigger relapse in MDD and to provide participants with techniques to detach from dysfunctional cognitive processes and redirect their attention to experiences. Outside of the sessions, participants will be assigned daily homework exercises and provided with handouts and audio recordings of mindfulness exercises to use in their practice.
48448732|NCT02300103|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
48448733|NCT02300103|DRUG|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48448734|NCT06319976|OTHER|open chain exercises for rotator cuff muscles|open chain exercises for rotator cuff muscles, three times per week for six weeks.
48448735|NCT06319976|OTHER|Advices for postural correction|Advices for postural correction like neutral position of head and neck, aliening the shoulder and hip and using a foot stool to rest the feet.
48448736|NCT04984902|DEVICE|Extracorporal therapy|Extracorporal therapy
48448737|NCT01510938|DIETARY_SUPPLEMENT|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
48448738|NCT01510938|DIETARY_SUPPLEMENT|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
48448739|NCT00164463|DRUG|Moxifloxacin|400 mg po qd 5/7 days per week
48448740|NCT00164463|DRUG|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
48448741|NCT06393387|DRUG|DTG/3TC versus BIC/F/TAF|A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).
48448742|NCT00616863|DRUG|Oxcarbazepine|
48448743|NCT04084197|DRUG|HIP1402|Tamsulosin (HanmiTams Capsule) 0.4mg
48448744|NCT04084197|DRUG|HIP1801|Tamsulosin 0.4mg
48448745|NCT04167267|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
48448746|NCT04167267|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
48448747|NCT00838630|DRUG|Cilostazol 100 mg tablets|1 x 100 mg
48448748|NCT00838630|DRUG|Pletal® 100 mg tablets|1 x 100 mg
48448749|NCT03853616|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
48448750|NCT02574377|DRUG|A: myDC vaccination|
48448751|NCT02574377|DRUG|B: pDC vaccination|
48448752|NCT02574377|DRUG|C: combined myDC/pDC vaccination|
48448753|NCT05909085|DEVICE|Traditional ultrasound|Labor epidural will be performed after marking patient skin using traditional ultrasound guidance
48448754|NCT05909085|DEVICE|Automated ultrasound|Labor epidural will be performed after marking patient skin using an automated ultrasound device
48448755|NCT06475053|DEVICE|NaturalVue Enhanced Multifocal 1 Day contact lens|Daily disposable multifocal contact lens
48448756|NCT06475053|DEVICE|MiSight 1 Day contact lens|Daily disposable dual-focus contact lens
48448757|NCT00893685|DEVICE|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
48448758|NCT02576938|DRUG|Baricitinib|Administered orally
48448759|NCT02576938|DRUG|Placebo|Administered orally
48448760|NCT02576938|DRUG|Triamcinolone (Optional)|Administered topically
48448761|NCT06453980|DEVICE|sham tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 1 session.
48448762|NCT06453980|DEVICE|active tDCS|Participants will receive HD-tDCS at 3 milliAmp for 20 minutes, for 1 session.
48448763|NCT06330142|OTHER|Participation in 10 horse-assisted therapy sessions|supporting children and teenagers undergoing radiotherapy with a horse-assisted therapy approach
48448764|NCT05584397|PROCEDURE|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
48620431|NCT06190366|PROCEDURE|Bloodletting acupuncture at the fossa poplitea|This group is treated with bloodletting acupuncture at the fossa poplitea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
48448765|NCT05584397|PROCEDURE|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
48448766|NCT05584397|PROCEDURE|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
48448767|NCT05584397|PROCEDURE|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
48448768|NCT05584397|PROCEDURE|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
48448769|NCT03047343|OTHER|Retrospective data extraction in medical files|Retrospective data extraction in medical files
48448770|NCT05215535|RADIATION|Abbreviated MRI of the liver/abdomen|"The MRI examinations of the liver/abdomen will be performed at the same time as the pelvic MRI. A 1,5 T scanner will be used together with a dedicated torso/abdominal coil. An abbreviated MRI liver protocol includes 3 different sequences as follows:~1. Axial T2-weighted respiratory triggered sequence with 5 mm slice thickness.~2. Axial diffusion weighted spin echo respiratory triggered sequence with fatsat with b-factors 50/800 s/mm2 and ADC calculation maps, 5 mm slice thickness~3. An axial breath-hold 3D T1-weighted gradient echo with fatsat with 4 mm slice thickness, gap 2 mm, contrast enhanced venous phase and in a 3 min equilibrium phase, using regular i.v bolus injection of gadolinium contrast medium with standard clinical dose."
48448771|NCT05215535|RADIATION|Combined single venous and 3 min equilibrium phase CT of the abdomen/liver|The CT examination of the liver will be performed as a combined examination in a single venous phase starting with the thoracic region directly followed by the abdomen down to the pelvis. An additional 3 min equilibrium phase of the liver only will end the examination. Regular iodinated low-osmolar non-ionic contrast media will be used of 350 mg I/ml using a power injector, 2-4 ml/s, 100-150 ml dependent on patient weight and kidney function. Reconstructed images in axial, coronal and sagittal plane will be performed.
48448772|NCT00111397|PROCEDURE|Cytokine therapy|
48620432|NCT06190366|PROCEDURE|Bloodletting acupuncture at the regio glutaea|This group is treated with bloodletting acupuncture at the regio glutaea. The treatment takes place twice a week from week 1 to week 3. This means that 6 treatments of approx. 20 minutes each should be carried out within the 3 weeks.
48279094|NCT02131844|OTHER|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
48279095|NCT02131844|OTHER|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
48279096|NCT06657326|DEVICE|BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent|Stent implantation
48279097|NCT06657326|DEVICE|BioFreedom™ stainless steel Biolimus A9™-coated stent|Stent implantation
48279098|NCT01478958|DIETARY_SUPPLEMENT|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
48279099|NCT01478958|DIETARY_SUPPLEMENT|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
48279100|NCT01478958|DIETARY_SUPPLEMENT|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
48279101|NCT01702116|PROCEDURE|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
48279102|NCT01702116|PROCEDURE|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
48279103|NCT01042262|OTHER|Oxygen|100% Oxygen at a flow of 2 L/min
48279104|NCT01042262|OTHER|Placebo|No oxygen flow
48279105|NCT06478953|DIAGNOSTIC_TEST|FA Pneumonia Panel|A single BioFire® FilmArray® Pneumonia Panel assay will be performed on a respiratory clinical specimen.
48279106|NCT00187590|BEHAVIORAL|Case manager phone call after an ER visit|
48279107|NCT06041750|PROCEDURE|Elective surgical procedure under general anesthesia|The incidence of postoperative pulmonary complications in OSAS patients undergoing elective surgery under general anesthesia will be determined.
48279108|NCT06653777|DRUG|Pemigatinib|Pemigatinib will be administered orally once daily for 2 weeks followed by a 1-week off (intermittent schedule 2/1).
48279109|NCT04746326|PROCEDURE|Failure conservative treatment|Surgery was performed in patients who failed conservative treatment.
48279110|NCT04746326|PROCEDURE|Surgery|Surgery was performed in patients who had generalized peritonitis and perforation.
48279111|NCT04746326|OTHER|Conservative treatment|Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
48279112|NCT00590161|DRUG|pentoxifylline (PTX)|400 mg PO tid
48279113|NCT00590161|DRUG|placebo|placebo tid
48448773|NCT00111397|DRUG|Interferon Gamma, GM-CSF|
48448774|NCT04403672|DEVICE|performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection|"IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit."
48448775|NCT02435160|BIOLOGICAL|Fecal Microbiota Transplantation|
48448776|NCT02069535|BIOLOGICAL|AVANZ Cupressus|AVANZ Cupressus
48448777|NCT05305690|OTHER|No intervention|This study did is a retrospective case series and does not involve an intervention. Investigators will compare patients managed operatively vs nonoperatively, focused on nonoperative therapy.
48448778|NCT03651739|DEVICE|Knee Connect|An electronic goniometer with smart phone application
48448779|NCT03835286|DRUG|Vitamin C|6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
48448780|NCT03835286|DRUG|Placebos|Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
48448781|NCT02969616|BIOLOGICAL|Trinity Elite|cell based allograft
48448782|NCT06099795|DEVICE|eBAM Cov Testing|Evaluation of presence/absence of infection with SARS-CoV-2 assessed by eBAM-CoV on air exhaled by the patient compared with the presence/absence of infection based on RT-PCR testing of nasopharyngeal swabs
48448783|NCT04952857|DRUG|cholecalciferol 6 lakh IU|vitamin D levels and serum calcium will be assessed at day 3,7, 14.
48448784|NCT01066598|DRUG|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
48448785|NCT04848987|PROCEDURE|Etching|Etching enamel surface using phosphoric acid
48448786|NCT01885572|DEVICE|TiLOOP Bra|Titaniferously coated polypropylene mesh
48448787|NCT06480032|DEVICE|Blood Flow Restriction band|Blood Flow Restriction (BFR) band operate by partially occluding arterial blood flow to distal structures, but more significantly impeding venous outflow from under the cuff, thereby also hindering venous return. The compression of vasculature proximal to the skeletal muscle leads to inadequate oxygen supply (hypoxia) within the muscle tissue, resulting in a localized hypoxic environment. Additionally, the reduction in venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks.
48448788|NCT06480032|DEVICE|Non-Blood Flow Restriction band|The Occlusion Band/Blood Flow Restriction (BFR) band functions by partially restricting arterial blood flow to distal structures, with a more pronounced effect on venous outflow from under the cuff, thereby impeding venous return. Proximal compression of the vasculature leads to inadequate oxygen supply (hypoxia) in the skeletal muscle tissue. Additionally, reduced venous blood flow causes blood to accumulate in the capillaries of the occluded limb, often manifesting as visible erythema. This temporary restriction will be maintained for a duration of 8 weeks, facilitating targeted exercise training and rehabilitation.
48448789|NCT04238754|DRUG|Epidiolex|Epidiolex 100 mg/mL Oral Solution
48448790|NCT04238754|DRUG|Placebo|Cherry syrup oral solution
48448791|NCT03934281|DEVICE|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
48448792|NCT03934281|DEVICE|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
48448793|NCT05239585|DEVICE|Epilog device|Pilot the use of wireless EEG technology in neonates with mild neonatal encephalopathy and neonates with spells to see if this device can be used to determine the risk for neonatal seizure and need for escalation of care and full scalp EEG
48448794|NCT05687552|DEVICE|pet -ct|assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding
48448795|NCT02844660|BIOLOGICAL|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
48448796|NCT02844660|OTHER|Standard of Care|moist wound therapy and offloading
48448797|NCT06562478|BEHAVIORAL|Zazen Meditation|The sessions will last a maximum of 40 minutes in total, comprising 10 minutes of introduction with general practice instructions, followed by 15 minutes of Zazen meditation practice. The final 15 minutes will be allocated for participants to provide feedback on the session.
48448798|NCT03125447|OTHER|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
48448799|NCT05479552|DIAGNOSTIC_TEST|Syn-One Test|CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
48448800|NCT06251180|DRUG|Rocbrutinib|orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
48448801|NCT06251180|BIOLOGICAL|Rituximab|375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
48448802|NCT06251180|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
48448803|NCT06251180|DRUG|doxorubicin|50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
48448804|NCT06251180|DRUG|Vincristin|1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
48448805|NCT06251180|DRUG|Prednisone|100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
48448806|NCT01978730|DRUG|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
48448807|NCT01978730|DRUG|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
48448808|NCT01978730|DRUG|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
48448809|NCT05074745|DIAGNOSTIC_TEST|ELISA POCT vs RT-PCR|3 swabs taken, buccal for RT-PCR and ELISA POCT, nasopharyngeal for RT-PCR
48448810|NCT00759317|DRUG|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
48448811|NCT04510597|PROCEDURE|Cytoreductive Nephrectomy|Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
48448812|NCT04510597|DRUG|Active Comparator|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
48448813|NCT00835666|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
48448814|NCT00835666|DRUG|PROSCAR®|1 x 5 mg, single dose fasting
48448815|NCT05194059|BEHAVIORAL|Home-based physical activity|Participants will follow a personalized activity pacing program
48448816|NCT05866263|OTHER|green walking and intelligence gam|The randomized controlled study to examine the effects of green walking and intelligence games on the cognitive skills of individuals aged 50-70 years who had COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group.
48448817|NCT02281994|DEVICE|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
48620433|NCT03201107|OTHER|Pilates|"Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
48620434|NCT02466503|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
48620435|NCT02466503|DRUG|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
48620436|NCT06038630|DRUG|Hyperpolarized Xe129|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
48620437|NCT06038630|OTHER|Oxygen Administration|Oxygen administration
48279114|NCT06294600|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
48279115|NCT06294600|DRUG|Tablets|Oral tablets of similar appearance to active study drug
48279116|NCT06656494|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
48279117|NCT06656494|DRUG|Azacitidine|Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol，once daily on days 1-7 of each 28-day cycle.
48279118|NCT00036114|DRUG|aripiprazole|
48279119|NCT02038062|PROCEDURE|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
48279120|NCT03822910|DIAGNOSTIC_TEST|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
48279121|NCT03822910|DIAGNOSTIC_TEST|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
48279122|NCT03822910|DIAGNOSTIC_TEST|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
48279123|NCT00363961|BEHAVIORAL|Resistance exercise|resistance exercise vs sham comparison
48279124|NCT02966314|DRUG|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
48279125|NCT02966314|DRUG|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
48279126|NCT06645340|OTHER|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.
48279127|NCT02924701|OTHER|Blood samples, fibroscan and questionaires|
48279128|NCT01901887|DRUG|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
48448818|NCT06562322|DEVICE|Placebo|Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
48448819|NCT06562322|DEVICE|300 J|Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
48448820|NCT06562322|DEVICE|600 J|Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
48279129|NCT01901887|DRUG|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
48448821|NCT06562322|DEVICE|1260 J|Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
48448822|NCT02100917|DRUG|DMB-3111|
48448823|NCT02100917|DRUG|trastuzumab|
48448824|NCT03646175|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
48279130|NCT01992029|OTHER|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
48448825|NCT03646175|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
48448826|NCT03502148|DRUG|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
48448827|NCT04831307|OTHER|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
48448828|NCT06310291|BIOLOGICAL|VTP-1000|Intramuscular (IM) injection comprised of self-assembling nanoparticles of gluten peptides and a rapamycin component
48448829|NCT06310291|OTHER|Matched Placebo|Intramuscular (IM) injection comprised of saline solution
48448830|NCT02517294|DEVICE|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
48448831|NCT02517294|DEVICE|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
48448832|NCT05019560|DRUG|Sevoflurane|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
48448833|NCT05019560|DRUG|TIVA|IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
48448834|NCT06559618|DRUG|Phage Therapy|A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
48448835|NCT06559618|OTHER|Placebo|Sterile 0.9% saline solution also 20 mL, followed with a 10 mL flush of the same solution.
48448836|NCT05630586|DRUG|Semaglutide|Subcutaneous Semaglutide, 0.5 mg weekly for 4 weeks. First dose given at inclusion.
48448837|NCT05630586|OTHER|Standard care|Treatment according to Danish national clinical guidelines on stroke treatment, including reperfusion therapy if eligible.
48448838|NCT06559345|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
48620438|NCT01344564|DRUG|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
48279131|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy at M0
48279132|NCT01992029|PROCEDURE|Lumbar puncture|Lumbar puncture at M0 and M12
48279133|NCT01992029|PROCEDURE|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
48279134|NCT01992029|OTHER|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
48279135|NCT01992029|PROCEDURE|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
48279136|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy for patient explored for myopathy
48279137|NCT01992029|PROCEDURE|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
48620439|NCT01850329|OTHER|computed-assisted information program|
48448839|NCT06559345|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
48448840|NCT06559345|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
48448841|NCT00380679|BIOLOGICAL|Influenza vaccination|
48448842|NCT00380679|BIOLOGICAL|Pneumococcal polysaccharide vaccination|
48448843|NCT03251807|DEVICE|Twin-block|Functional treatment will be achieved using the Twinblock appliance
48620440|NCT03236792|DRUG|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
48448844|NCT03251807|OTHER|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
48448845|NCT00746421|DRUG|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
48448846|NCT00746421|DRUG|Placebo|200mg, 300mg or 400mg
48448847|NCT00905658|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
48448848|NCT00905658|PROCEDURE|standard follow-up care|Patients undergo standard monitoring
48448849|NCT03146156|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
48448850|NCT02412085|DRUG|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~* body weight \< 80kg: 50 mg every 4 weeks~* body weight ≥ 80 kg: 100 mg every 4 weeks"
48448851|NCT05786118|OTHER|No intervention|There is no intervention in this study
48448852|NCT04042233|DRUG|Experimental Intraosseous vancomycin 500mg in 250 mL NS|500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
48448853|NCT04042233|DRUG|Standard IV administration of vancomycin|IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
48448854|NCT06103058|OTHER|Cross sectional|Cross sectional
48448855|NCT04725747|DRUG|Midazolam/Ketamine HCl 3mg-50mg sublingual|Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery
48448856|NCT04725747|DRUG|Midazolam 3mg Sublingual|Single sublingual administration of Midazolam 3mg sublingually prior to surgery
48448857|NCT04725747|DRUG|Ketamine 50mg Sublingual|Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
48448858|NCT02558491|DEVICE|Decision Support System|"The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~1. An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~2. An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.~3. A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation."
48448859|NCT02558491|OTHER|Usual Care|During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.
48448860|NCT06443151|PROCEDURE|Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid)|The brachial artery in the non-dominant arm will be catheterized to infuse endothelium-dependent vasodilator acetylcholine, endothelium-independent vasodilator nitroprusside, and antioxidant ascorbic acid at concentrations to have isolated effect in the forearm.
48448861|NCT06443151|PROCEDURE|venous occlusion plethysmography|Whole forearm blood flow will be measured by mercury-strain gauge while venous occlusion is applied to the forearm and hand by rapid-cuff inflation to sub-arterial pressures. Changes in whole forearm blood flow with be measured at baseline, endothelial agonists, and removal of oxidative stress via acorbic acid.
48620441|NCT03236792|DRUG|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
47928119|NCT03048383|DRUG|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
48279138|NCT01992029|DEVICE|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
48279139|NCT01328587|DRUG|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
48279140|NCT01454804|DRUG|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
48279141|NCT01454804|DRUG|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
48279142|NCT01454804|DRUG|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
48279143|NCT01454804|DRUG|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
48279144|NCT02792140|DRUG|Naltrexone|one week
48279145|NCT02792140|OTHER|Placebo|one week
48279146|NCT04475341|BIOLOGICAL|BMS + Bone Marrow Aspirate Concentrate|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
48279147|NCT04475341|PROCEDURE|BMS alone|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
48279148|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
48279149|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
48279150|NCT02144649|OTHER|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
48448862|NCT06443151|DRUG|Acetylcholine|Endothelium-dependent vasodilation will then be assessed by changes in FBF in response to intra-arterial infusions of the endothelial agonist acetylcholine infused at rates of 4.0, 8.0, 16.0 μg/100 mL of forearm tissue/min to generate a dose-response curve.
48448863|NCT06443151|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation will be assessed by changes in forearm blood flow in response to intra-arterial infusions of sodium nitroprusside at 1.0, 2.0, 4.0 μg/100 mL forearm tissue/min.
48448864|NCT06443151|DRUG|Ascorbic acid|Ascorbic acid will be infused at a constant rate (12 mg/100 mL tissue/min) and maintained at the same rate while the acetylcholine and sodium nitroprusside dose-response curves are repeated.
48448865|NCT06443151|PROCEDURE|venous phlebotomy|Venous blood samples will be collected to measure baseline cardiometabolic characteristics and isolate endothelial cell microvesicles for characterizations and in vitro experiments.
48448866|NCT00911274|DRUG|Mycophenolate Mofetil|250 mg Capsule
48448867|NCT00911274|DRUG|CellCept®|250 mg Capsule
48448868|NCT05713058|BEHAVIORAL|eTRC diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) focusing on the distribution of macronutrients within the day so as to avoid carbohydrate consumption after lunch
48448869|NCT05713058|BEHAVIORAL|Control diet|12-week dietary prescription with moderate energy restriction (approximately 200 kcal/day) without any recommendations on the distribution of macronutrients within the day
48448870|NCT01944072|OTHER|Aerobic exercise training intensity|
48279151|NCT02144649|OTHER|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
48279152|NCT00184457|BEHAVIORAL|Strength training intervention|
48279153|NCT01397019|DRUG|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
48279154|NCT05116657|DIAGNOSTIC_TEST|Nasal Lavage and Oral Wash|"* Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~* Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
48279155|NCT01766648|DEVICE|Far Cortical locking screw fixation|Standard screw fixation
48279156|NCT01766648|DEVICE|Standard screw fixation|
48279157|NCT01843010|DRUG|Parecoxib|Parecoxib 40mg will be intravenously infused.
48279158|NCT01843010|DRUG|Placebo|Normal saline 5ml will be intravenously infused.
48279159|NCT02643550|BIOLOGICAL|Monalizumab|
48279160|NCT02643550|BIOLOGICAL|Cetuximab|
48279161|NCT02643550|BIOLOGICAL|Anti-PD(L)1|
48279162|NCT03481270|BEHAVIORAL|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
48279163|NCT04561180|DRUG|EG-009A|Administered as an Intramuscular injection
48279164|NCT04561180|DRUG|EG-009A Placebo|Administered as an Intramuscular injection
48279165|NCT04561180|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
48279166|NCT04561180|DRUG|Dexamethasone|The comparator, Administered as an Intravenous infusion
48279167|NCT01956006|DRUG|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
48279168|NCT04814979|DEVICE|Low-intensity pulsed ultrasound (LIPUS)|Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities \<100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.
48448871|NCT01343303|DRUG|Placebo|Placebo tablet/capsule every 12 hours for 21 days
48448872|NCT01343303|DRUG|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
48448873|NCT01343303|DRUG|Naproxen|500 mg capsule every 12 hours for 21 days
48448874|NCT01343303|DRUG|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
48279169|NCT04814979|OTHER|Routine physical therapy|"Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days."
48279170|NCT00849589|BEHAVIORAL|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
48448875|NCT03538327|DRUG|Silybin|After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
48448876|NCT02853643|DRUG|ASN002|Single dose study with food effect
48448877|NCT01359696|DRUG|GDC-0425|Oral escalating dose
48448878|NCT01359696|DRUG|gemcitabine|Intravenous repeating dose
48448879|NCT03873272|DEVICE|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
48098215|NCT04635436|OTHER|Split-belt treadmill walking.|"The intervention will consist of split-belt treadmill walking. During the test session, participants will walk on a split-belt treadmill mounted on force sensors with the belts running at the same or at different velocities. They will walk freely without any support. The test sequence will be the following:~1. Baseline phase. 3 minutes walking at increasing speed, speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Habituation phase. 30 seconds walking at 0.2 m s-1.~3. Adaptation phase. The velocity of the belt under the non-affected lower limb will be increased to 0.6 m s-1, while the other belt will maintain its velocity of 0.2 m s-1 for 6 minutes.~4. Post-adaptation phase. Belts' velocities will be restored at 0.2 m s-1 for 6 minutes.~Participants will be informed before the changes in belts' velocities with a verbal warning.~Participants will repeat the same protocol with the affected lower limb on the fast belt after one week."
48279171|NCT00849589|BEHAVIORAL|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
48279172|NCT05773391|DRUG|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
48279173|NCT05504109|PROCEDURE|mitral valve replacement through full sternotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
48279174|NCT05504109|PROCEDURE|mitral valve replacement through right mini thoracotomy approach.|compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
48279175|NCT02034123|DRUG|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
48279176|NCT01126346|BEHAVIORAL|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
48279177|NCT01126346|BEHAVIORAL|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
48279178|NCT01126346|OTHER|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
48279179|NCT05384301|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
48279180|NCT03311126|DRUG|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.
48279181|NCT03311126|DRUG|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
48279182|NCT06165588|OTHER|Tour de France|Participating in the Tour de France as cyclist
48279183|NCT02909153|DRUG|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
48279184|NCT06190483|DRUG|Diazepam 5 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
48279185|NCT06190483|DRUG|Ascorbic Acid 50 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
48279186|NCT03862456|OTHER|Azithromycin|azithromycin (500 mg/24h/3 days)
48279187|NCT03862456|OTHER|Metronidazole|metronidazole (500 mg/8h/7 days)
48279188|NCT01617538|DRUG|atorvastatin|40mg per day,duration for 24 weeks
48279189|NCT00632580|DRUG|intraarticular injection with ropivacaine|
48279190|NCT00632580|DRUG|extraarticular injection with ropivacaine|
48279191|NCT05078489|OTHER|Action-observation therapy|Action observation therapy involves the observation and perception of human movement performed by others. The observation of actions performed by others activates in the perceiver the same neural structures responsible for the actual execution of those same actions.
48279192|NCT05078489|OTHER|Placebo|Participants will watch a natural landscape without any human.
48279193|NCT02303054|PROCEDURE|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
48279194|NCT02133417|DEVICE|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
48620442|NCT03236792|DRUG|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
48620443|NCT01867255|DRUG|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
48448880|NCT03873272|DEVICE|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
48448881|NCT03873272|DEVICE|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
48448882|NCT06563024|DEVICE|18F-FET PET/CT|The enrolled patients receive the 18F-FET PET/CT.
48448883|NCT01354626|OTHER|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
48448884|NCT01354626|OTHER|low-protein|The control group will get a diet which is according to healthy eating guidelines.
48448885|NCT00004796|DRUG|lactulose|
48448886|NCT00974558|DEVICE|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
48448887|NCT02464254|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
48448888|NCT02464254|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
48448889|NCT03750903|BEHAVIORAL|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
48448890|NCT03750903|BEHAVIORAL|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
48448891|NCT01631331|DRUG|vismodegib|Given PO
48448892|NCT01631331|PROCEDURE|Mohs surgery|Undergo Mohs surgery
48448893|NCT06559358|DEVICE|electrical stimulation|A two-channel portable electrical stimulation unit (BTL-4620, Czech Republic).
48448894|NCT03508011|DRUG|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
48448895|NCT05357235|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
48098216|NCT00787956|BEHAVIORAL|Internet Chronic Disease Self-Management Program (ICDSMP)|
48098217|NCT02606292|PROCEDURE|Photoacoustic endoscopy|
48448896|NCT06196307|COMBINATION_PRODUCT|Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization|"Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.~History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)"
48448897|NCT04870606|DRUG|Proxalutamide (GT0918)|Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
48448898|NCT04870606|DRUG|Placebo|Placebo+Standard of care determined by PI and local regulatory
48448899|NCT05435196|OTHER|Therapeutic exercise|"The control group and the experimental group will receive the training with high-intensity interval exercise. For a period of 12 weeks both groups will participate in their exercise program, which will be supervised by the physiotherapist in charge of the study; different from the one who will carry out the randomization and the one who will perform the evaluations. Women will attend 3 times a week for an hour to the Hospital de especialidades to receive their exercise program in which they participated. Both groups will receive therapeutic education to encourage adherence and self-management, which include aspects such as flexibility, musculoskeletal pain, physical performance, quality of life focused on physical and mental health, etc."
48448900|NCT00028951|DRUG|fibrin sealant|
48448901|NCT00028951|PROCEDURE|surgical wound closure|
48448902|NCT00709254|DRUG|i.v. fentanyl|single dose, 200 ug
48448903|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
48448904|NCT00709254|DRUG|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
48448905|NCT00229021|DRUG|doripenum|
48448906|NCT05194020|OTHER|Primary Services|Participants receive 16 hours of Father Factor curricula, 4 hours of The New Playbook curricula, 4 hours of Money Smart curricula over the course of five weeks. Participants also receive on-going job readiness support and post-employment support.
48448907|NCT04435197|DRUG|Pembrolizumab Injection|Pre-operative Pembrolizumab+chemoradiotherapy
48448908|NCT00005785|DRUG|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
48448909|NCT04560738|DRUG|[14C]-CC-92480|Oral
48448910|NCT01910688|DEVICE|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
48448911|NCT03934476|BEHAVIORAL|Ketogenic diet|The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.
48448912|NCT03934476|BEHAVIORAL|Exercise HIIT|The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
48098218|NCT02606292|PROCEDURE|Endoscopic ultrasound (standard of care)|
48098219|NCT02606292|PROCEDURE|Endoscopic surgery (standard of care)|
48448913|NCT01924377|PROCEDURE|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance \>5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
48448914|NCT01924377|PROCEDURE|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
48448915|NCT05044364|DRUG|This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.|Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
48448916|NCT03954808|OTHER|Motor Imagery Training|Motor imagery training will be designed for the individual basis with standard protocols
48448917|NCT03954808|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
48620444|NCT04321395|DRUG|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
48448918|NCT02259972|DRUG|BI 113823 solution|
48448919|NCT02259972|DRUG|BI 113823 tablet|
48448920|NCT02259972|DRUG|Placebo|
48448921|NCT02259972|OTHER|High fat, high calorie breakfast|only for dose group 5
48448922|NCT06356766|OTHER|Telerehabilitation|Modified Duran Protocol via Telerehabilitation
48448923|NCT06356766|OTHER|Face-to-face rehabilitation|Modified Duran Protocol
48448924|NCT04972864|OTHER|Exercise training group|A regular advanced exercise program was given and followed.
48448925|NCT04972864|OTHER|Control training group|Basic exercises was given at the beginning and did the same exercises
48448926|NCT02010463|OTHER|Exercise|
48448927|NCT03037671|DEVICE|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
48448928|NCT04031001|DEVICE|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
48448929|NCT00829452|DRUG|Ramipril 10 mg capsule|1 x 10 mg
48448930|NCT00829452|DRUG|Altace® 10 mg capsule|1 x 10 mg
48448931|NCT06272266|DEVICE|Kardiopulmonary exercise test (Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system)|"For the cardiopulmonary exercise test, a Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system, supported by analyzers that measure oxygen uptake and carbon dioxide output, and a bicycle ergometer connected to the ergoline rehab system 2 Version 1.08 SPI system were used. At the end of the test, the individual's RER , VAT, VO2peak, VO2AT, VE/CO2, HRR, HRR1 values were recorded. These values were estimated by the device based on the wasserman extended protocol on the Quark KPET C12x/T12x device connected to the Omnia version 1.6.8 COSMED system.The test was repeated after 15 sessions of aerobic exercise training in the Covid-19 group.This intervention was applied to 14 people in the COVID-19 group and 15 people in the control group. It was repeated at the end of 15 sessions of aerobic exercise training in the COVID-19 group."
48448932|NCT06272266|DEVICE|Peripheral muscle strength measurement (microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) and JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook).|Quadriceps and triceps muscle strength was measured in kilograms using the microFET3 (Hoggan Health Industries, Fabrication Enterprises, lnc) manual muscle strength measurement device in the lower and upper extremity. Hand grip strength was evaluated in the dominant upper extremity using a JAMAR hydraulic hand dynamometer (Sammons Preston, Rolyon, Bolingbrook)This intervention was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
48448933|NCT06272266|DEVICE|Standard exercise tolerance test (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|At the beginning of this test, resting pulse and blood pressure were measured and recorded. The test was performed following a bicycle ergometer protocol recommended by the American Cardiovascular and Pulmonary Rehabilitation Society. After a 2-minute warm-up period at 0 load (W), a submaximal exercise test was performed by increasing the load by 25 W in 2-minute periods. At the end of the test, exercise intensity was evaluated with the perceived difficulty level (borg scale), test duration, maximum heart rate, maximum work (W). , metabolic equivalent (MET) values were recorded. VO2peak and VO2peakpredictive levels were calculated. This test was repeated for individuals in both groups at the beginning and at the end of the 15-session aerobic exercise training planned for the COVID-19 group.
48448934|NCT06272266|DEVICE|Aerobic exercise training (a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI.)|Aerobic exercise training was planned for the COVID-19 group with the help of a bicycle ergometer and recorded through the ergoline rehabilitation system 2 Version 1.08 SPI. Aerobic exercise training was applied for a total of 15 sessions, at least 3 days a week, under the supervision of a physician.
48448935|NCT06216756|PROCEDURE|osteochondral transplant on the femoral condyle|Patients who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 2.0-8.0 cm2 in size, and cystic changes requiring osseous repair present in less than or equal to 12 mm of subchondral bone will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
48448936|NCT04559386|OTHER|Survey|Questionnaire
48448937|NCT06559566|PROCEDURE|USG|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
48448938|NCT06559566|PROCEDURE|BCT|The aim of this study is to measure the intracranial pressure of patients planned for brain tumor surgery by measuring the optic nerve sheath diameter (ONSD) under USG guidance and compare its correlation with the computed brain tomography.
48448939|NCT04518059|PROCEDURE|punch skin biopsy|An anesthetic medication is injected to numb the areas of skin and two samples of skin are obtained from punch biopsy.
48448940|NCT03158727|BIOLOGICAL|Cx611|Two intravenous infusions, one on day 1 and another one on day 3.
48448941|NCT03158727|OTHER|Placebo|Two intravenous infusions, one on day 1 and another one on day 3.
48448942|NCT06360887|PROCEDURE|Conservative|Conservative treatment
48448943|NCT06360887|PROCEDURE|ORIF|Open surgery
48448944|NCT06360887|PROCEDURE|CRPP|Minimal invasive surgery
48448945|NCT03100422|DEVICE|ARMin|arm therapy robot
48448946|NCT03100422|OTHER|Occupational Therapy|bilateral arm training
48448947|NCT01643135|DRUG|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
48448948|NCT01643135|DRUG|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
48448949|NCT02489461|DRUG|VM-1500|VM-1500 up to 96 weeks
48448950|NCT02489461|DRUG|Efavirenz|Efavirenz up to 48 weeks
48098220|NCT02922972|DEVICE|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
48279195|NCT03898648|OTHER|Waiting room task|"The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed."
48279196|NCT05676710|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
48279197|NCT03596346|OTHER|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
48279198|NCT03596346|OTHER|Control product without added RI|2 snack bars daily containing 0 g of RI.
48279199|NCT02628587|DRUG|Generic clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
48279200|NCT02628587|DRUG|Patent clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
48279201|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
48279202|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
48448951|NCT02489461|DRUG|Antiretroviral therapy (ART)|Antiretroviral therapy up to 96 weeks
48448952|NCT06106490|OTHER|the effect of adding pulsed radiofrequency (PRF) modality to suprascapular nerve injection with ultrasound glenohumeral steroid in chronic shoulder pain patients|"Suprascapular nerve block group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine~Pulsed radiofrequency group: Patients will receive ultrasound guided intra articular Gleno-humeral steroid injection of Diprofos® (betamethasone 14 mg/ 2ml) and ultrasound guided suprascapular nerve block US SSN with 10mL of 0.25% preservative-free bupivacaine with application of pulse PRF at 42 Celsius of suprascapular nerve for 480 seconds."
48448953|NCT04531605|BEHAVIORAL|YBank program|Adolescents participated in a 12-week peer-led life skills trainings at clinics and received financial incentives via mobile money upon clinic attendance and demonstration of suppressed viral load.
48448954|NCT06099652|DRUG|611 300 mg Q2W|611 subcutaneous (SC) injection
48448955|NCT06099652|DRUG|611 450 mg Q2W|611 subcutaneous (SC) injection
48448956|NCT06099652|DRUG|Matching placebo|placebo subcutaneous (SC) injection
48448957|NCT05148273|BEHAVIORAL|telenursing|7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
48448958|NCT06332170|DRUG|HS-20093|administered as an IV infusion
48448959|NCT06332170|DRUG|Adebrelimab|administered as an IV infusion
48448960|NCT06332170|DRUG|Cisplatin/ Carboplatin|administered as an IV infusion
48448961|NCT06332170|DRUG|Cetuximab|administered as an IV infusion
48098221|NCT03996239|BEHAVIORAL|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., \~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
48448962|NCT06332170|DRUG|Enzalutamide|160mg once daily (QD) orally
48448963|NCT03515694|DRUG|Sugammadex Injection [Bridion]|Injection of 10mL of translucide solution
48279203|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
48448964|NCT05172947|DRUG|Resveratrol|This group received resveratrol with the conventional therapy
48448965|NCT05172947|DRUG|Placebo|This group received placebo with the conventional therapy
48448966|NCT05172947|OTHER|Resveratrol plus Pharmaceutical care|This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy
48448967|NCT05172947|OTHER|Placebo+Pharmaceutical care|This group received placebo with Pharmaceutical care in addition to the conventional therapy
48448968|NCT06321263|OTHER|Peripheral Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
48448969|NCT06321263|OTHER|Inspiratory Muscle Training and step aerobics training|First 5-minute warm-up in the protocol (calisthenic exercises); 30-40 minutes of resistance exercises and step aerobic exercises and the last 5 minutes cooling (stretching exercises) period will be applied.
48448970|NCT05138003|DIAGNOSTIC_TEST|cardiac MRI|"T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified."
48448971|NCT05138003|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
48448972|NCT05138003|DIAGNOSTIC_TEST|RootiRx for the ECG monitoring during the cycling ride|The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate \> 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
48279204|NCT02086019|DRUG|Conservative Arm|crossover to angiogram only if predefined criteria met
48279205|NCT02086019|PROCEDURE|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
48279206|NCT02137044|BEHAVIORAL|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
48279207|NCT00703313|DRUG|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
48279208|NCT00703313|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
48279209|NCT00703313|DRUG|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
48279210|NCT02252367|DRUG|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
48279211|NCT02252367|OTHER|Placebo|Placebo tablet once daily for 12 weeks.
48279212|NCT02814721|DEVICE|Sonic Window ultrasound device|
48279213|NCT02446392|OTHER|No intervention.|
48279214|NCT01833871|OTHER|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
48279215|NCT01833871|OTHER|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
48279216|NCT05675709|BEHAVIORAL|Training and Education|Undergo group trainings
48279217|NCT04617288|OTHER|Ultrasound Therapy, SNAGs|
48279218|NCT00238264|RADIATION|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
48279219|NCT00446030|DRUG|Docetaxel|"75 mg/m\^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
48279220|NCT00446030|DRUG|Doxorubicin|50 mg/m\^2 administered IV on Day 1 for Cycles 1-6
48279221|NCT00446030|DRUG|Carboplatin|6 mg/mL/min (target area under the curve \[AUC\] dose) administered IV on Day 1 for Cycles 1-6
48448973|NCT05138003|DIAGNOSTIC_TEST|Blood sample|Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
48448974|NCT02832921|BEHAVIORAL|cognitive training by virtual reality|
48448975|NCT02832921|BEHAVIORAL|watching a scientific TV documentary|
48448976|NCT02832921|DEVICE|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking-i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill-places greater demand on cognitive resources than a single task."
48448977|NCT06561568|DIAGNOSTIC_TEST|Conventional physical therapy|Conventional physical therapy protocol for chondromalacia patellae consist of stretches to warm up and cool down Resistance training ,in which patient will perform each exercise for 3 sets of 10 repetitions. Each repetition will be given with a 10 second hold.
48448978|NCT06561568|OTHER|Kinesiotaping|"Kinesio tape will be applied on Vastus medialis Oblique and around the patella.~• Frequency: 3 times a week for 4 weeks."
48448979|NCT02411903|DRUG|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
48448980|NCT02411903|DRUG|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
48448981|NCT06464315|PROCEDURE|Functional Substrate-Only Mapping without VT Induction|In this arm, invasive maps will be constructed by annotating the latest deflection and peak frequency during voltage mapping of stable intrinsic rhythm to localize areas of slow conduction. Annotated algorithms are cleared by the FDA. No VT will be purposefully induced in this experimental arm.
48448982|NCT06464315|PROCEDURE|Standard-of-Care Mapping/Imaging|Conventional invasive scar (voltage) and electrical VT (entrainment, activation, pace) mapping will be used to guide VT ablation. Functional substrate mapping will not be used in this arm. VT will be induced using standard protocols.
48448983|NCT06516692|DIAGNOSTIC_TEST|Inferior Vena Cava Collapsibility/distensibility Index (IVC CI/DI) assessment|Assessment of hydration status in critically ill patient recruited to this arm will be intervened through an ultrasound guided calculation of collapsibility and distensibility index of Inferior Vena Cava. This method of intervention will be continued and repeated as needed throughout the stay of the participant in intensive care unit.
48448984|NCT01383694|DRUG|Piperine|
48448985|NCT05564091|DEVICE|Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device|360 degree microcatheterization and viscodilation of Schlemm's canal
48448986|NCT05564091|PROCEDURE|Cataract surgery|Cataract surgery alone
48448987|NCT02753179|OTHER|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
48448988|NCT02753179|OTHER|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
48448989|NCT02753179|OTHER|VEMPs & VEMPo|VEMPs \& VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
48448990|NCT02753179|OTHER|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
48448991|NCT02753179|OTHER|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
48448992|NCT05935631|DIETARY_SUPPLEMENT|Salt with folic acid and iodine|Assess serum and RBC folate levels in women at baseline and 1 month after ingesting salt with folic acid
48448993|NCT01384591|DRUG|N-acetylcysteine|50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
48448994|NCT01384591|DRUG|Losartan|25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
48448995|NCT01384591|DRUG|Placebo losartan|Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
48448996|NCT01384591|DRUG|Placebo N-acetylcysteine|Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
48448997|NCT00104910|RADIATION|Internal Radiation Therapy|
48448998|NCT00104910|RADIATION|3-Dimensional Conformal Radiation Therapy|
48448999|NCT00104910|BIOLOGICAL|Cetuximab|Given IV
48449000|NCT00104910|DRUG|Cisplatin|Given IV
48449001|NCT00532077|DRUG|rhPTH(1-34)|
48449002|NCT00532077|DRUG|SB-751689 100 mg|
48449003|NCT00532077|DRUG|SB-751689 400 mg|
48449004|NCT03609203|OTHER|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
48449005|NCT03609203|OTHER|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment\*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
48449006|NCT02096185|RADIATION|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
48449007|NCT02096185|RADIATION|2 dimensional digital imaging|
48449008|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with scissors|In hysteroscopic septoplasty with scissors arm, incision of the septum was done by continuous flow hysteroscopy and scissors using saline as distension media.
48449009|NCT05802784|PROCEDURE|Hysteroscopic septoplasty with resectoscope|In hysteroscopic septoplasty with resectoscope arm, incision of the septum was done by 26 Fr monopolar resectoscope with collin's knife using glycine1.5% as distension media.
48449010|NCT00840632|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
48449011|NCT00840632|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
48449012|NCT04994847|DRUG|Amyloid and Tau PET|NAV4694 and MK6240 PET scans completed every two years
48449013|NCT04982094|BEHAVIORAL|Mental Health First Aid and Relationship Building Training|"Relationship Building Training (RBT) is a 2 hour training session conducted live over zoom, that aims to equip business advisors the communications skills they need to enhance trustworthiness and quality of the relationship with their clients.~Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~Two Booster sessions are delivered 1- and 3-months after the last MHFA session that aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
48449014|NCT04982094|BEHAVIORAL|Mental Health First Aid|"Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions in addition to online reading, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~MHFA online training is conducted two-weeks before the two MHFA sessions (with a 1 day break in between each MHFA). Two Booster sessions are delivered 1- and 3-months after the last MHFA session. The Booster sessions aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program."
48449015|NCT01501786|DRUG|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
48449016|NCT01501786|DRUG|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
48098222|NCT03996239|OTHER|plasma samples|Plasma samples will be obtained at baseline.
48449017|NCT01501786|DRUG|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
48279222|NCT00446030|DRUG|Cyclophosphamide|500 mg/m\^2 administered IV on Day 1 for Cycles 1-6
48279223|NCT00446030|DRUG|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
48279224|NCT00446030|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
48279225|NCT04591093|DEVICE|FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated|Cochlear implant with FineHearing Strategy with 10 more apical electrodes activated or with 10 more basal electrodes activated
48449018|NCT02138539|OTHER|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
48449019|NCT02138539|DRUG|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
48449020|NCT06380816|DRUG|UCB4594|Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
48449021|NCT03874143|OTHER|mHealth Intervention for Quality of Care|Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
48098223|NCT03996239|OTHER|blood draw|fasting blood
48279226|NCT00382837|DRUG|Epratuzumab|
48279227|NCT02351362|BEHAVIORAL|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
48279228|NCT00263926|BIOLOGICAL|wasp venom|
48279229|NCT00342355|DRUG|Zidovudine|600 mg once daily
48279230|NCT00342355|DRUG|Stavudine|40 mg once daily
48279231|NCT00342355|DRUG|Didanosine|\<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
48279232|NCT00342355|DRUG|Lamivudine|300 mg once daily
48279233|NCT00342355|DRUG|Efavirenz|600 mg once daily
48279234|NCT00342355|DRUG|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
48098224|NCT04446689|BEHAVIORAL|Biofeedback|This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
48098225|NCT01450943|DEVICE|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
48279235|NCT01447238|DEVICE|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
48279236|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
48279237|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
48279238|NCT05426356|DEVICE|Surgical Intervention|Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ
48279239|NCT05426356|OTHER|Non-Surgical Management|Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
48449022|NCT01039363|DRUG|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~* Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~* Gemtuzumab will be omitted in a consolidation schedule.~* Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
48449023|NCT03630471|BEHAVIORAL|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
48449024|NCT03630471|BEHAVIORAL|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
48449025|NCT03687762|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
48449026|NCT03687762|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
48449027|NCT03687762|BEHAVIORAL|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
48449028|NCT04852393|PROCEDURE|Block|cervical medial branch block
48449029|NCT05812118|BEHAVIORAL|Physical active learning|The intervention will last for 8-10 weeks. The ALPHYL intervention will be conducted in physical education (PE) and non-PE lessons by teachers. In addition to the PE lessons, at least three physically active activities in subjects other than PE will be conducted every day (5 days per week), with a total duration of approximately 30 minutes of light and moderate-to-vigorous physical activity per day. The weekly dose of physically active learning will thus be 100-150 minutes, so that a volume of 800-1200 minutes is foreseen during the 8-10 weeks. The PE classes will also be conducted in a mix of cooperative learning, non-linear pedagogy and health-based PE.
48449030|NCT03298880|DEVICE|Supine VM VAD|Valsalva strain delivered using VAD
48449031|NCT03298880|DEVICE|Supine VAD manometer|supine Valsalva strain delivered using manometer
48449032|NCT03298880|OTHER|Modified VM VAD|modified VM using VAD
48449033|NCT03298880|OTHER|Modified VM Manonmeter|Postural modified position VM using manometer
48449034|NCT05323916|BEHAVIORAL|"Neuroproprioceptive facilitation, inhibition"|"Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of neuroproprioceptive facilitation, inhibition physical therapy."
48098226|NCT01450943|PROCEDURE|debridement, irrigation|debridement, irrigation
48098227|NCT01450943|DEVICE|Dermagraft|Dermagraft per company protocol
48098228|NCT01450943|DEVICE|Oasis|Oasis per company protocol
48098229|NCT06631261|OTHER|No intervention; Observational study|No intervention
48279240|NCT00000264|DRUG|30% Nitrous oxide|
48279241|NCT00000264|OTHER|0.35 g/Kg ethanol|
48279242|NCT00000264|OTHER|0.7 g/Kg ethanol|
48279243|NCT00000264|OTHER|0 g/Kg ethanol|
48279244|NCT05581043|DIETARY_SUPPLEMENT|3-hydroxybutyrate (3-OHB)|The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
48279245|NCT01920906|PROCEDURE|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
48279246|NCT04821284|DRUG|Gemcitabine Hydrochloride|Given IV
48279247|NCT04821284|DRUG|Nab-paclitaxel|Given IV
48279248|NCT04821284|DRUG|Fluorouracil|Given IV
48449035|NCT05323916|BEHAVIORAL|Technology based physical therapy|Participants will undergo a standard comprehensive intensive rehabilitation program three hours a day for three weeks and moreover one hour a day of technology based physical therapy.
47928120|NCT03048383|DRUG|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
47928121|NCT04418401|DRUG|Donafenib and anti-PD-1 antibody|Donafenib was taken orally twice daily, and anti-PD-1 antibody was applied biweekly.
48449036|NCT05323916|BEHAVIORAL|Effectively managed rehabilitation implementing the recommendations of the World Health Organization|Participants will undergo a four hour a day for three weeks of effectively managed comprehensive intensive rehabilitation implementing the recommendations of the World Health Organization.
48449037|NCT05323916|BEHAVIORAL|Standard care|Participants will undergo standardly provided care including face to face physiotherapy (bed mobility, transfers, gait, therapeutic exercises, positioning, education).
48449038|NCT04451746|DRUG|Combined Oral Contraceptive|The investigators consistently include patients who have been prescribed hormonal tablets for contraception, namely 1) COCs with bioidentical estrogen; 2) COCs with ethinyl estradiol 30mkg according to the scheme 21 + 7; 3) COCs with ethinyl estradiol 20mkg according to the scheme 21 + 7.
47928122|NCT02299973|PROCEDURE|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
47928123|NCT02299973|PROCEDURE|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
47928124|NCT01322776|DRUG|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
47928125|NCT05196711|DRUG|MAX-40070|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days."
47928126|NCT05196711|DRUG|Placebo|"In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 2 subjects randomly assigned to placebo~In the MAD phase, the treatment will be administered once a day for 14 consecutive days. Each cohort will consist of 10 subjects, with 2 subjects randomly assigned to placebo"
48449039|NCT01621945|BIOLOGICAL|MenBvac|Blood test
48449040|NCT02365363|OTHER|Control|Non pulse ingredient bagel
48449041|NCT02365363|OTHER|Pea flour|Pulse ingredient bagel
48449042|NCT02365363|OTHER|Pea fibre|Pulse ingredient bagel
48449043|NCT02365363|OTHER|Pea flour and pea fibre|Pulse ingredient bagel
48449044|NCT02365363|OTHER|Pea flour and pea protein|Pulse ingredient bagel
48449045|NCT02365363|OTHER|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
48449046|NCT00176020|DRUG|nicotinic acid|
47928127|NCT04325555|DRUG|PrEP|The investigators measure self-reported PrEP status as exposure, i.e., PrEP status is not confirmed via matched medical records or any other type of information directly collected form subjects.
47928128|NCT02770209|BIOLOGICAL|biomimetic cartilage matrix + autologous chondrocytes|
47928129|NCT02770209|PROCEDURE|arthroscopic debridement|
48279249|NCT04821284|DRUG|Irinotecan Hydrochloride|Given IV
48279250|NCT04821284|DRUG|Leucovorin Calcium|Given IV
48279251|NCT04821284|DRUG|Oxaliplatin|Given IV
48279252|NCT04821284|OTHER|Perflubutane Microbubble|Oxaliplatin
48279253|NCT04821284|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
48449047|NCT02220985|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
48449048|NCT02220985|DRUG|Cyclophosphamide|Given IV
47928130|NCT02770209|PROCEDURE|microfracture surgery|
47928131|NCT06299371|DRUG|Adebrelimab|Adebrelimab IV
48279254|NCT04821284|OTHER|Quality-of-Life Assessment|Ancillary studies
48279255|NCT04821284|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48279256|NCT04821284|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48449049|NCT02220985|DRUG|Fludarabine Phosphate|Given IV
48449050|NCT02220985|OTHER|Laboratory Biomarker Analysis|Correlative studies
48449051|NCT02220985|DRUG|Methotrexate|Given IV
48449052|NCT02220985|DRUG|Mycophenolate Mofetil|Given IV and PO
48449053|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
48449054|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
48449055|NCT02220985|DRUG|Tacrolimus|Given IV or PO
48449056|NCT02220985|DRUG|Thiotepa|Given IV
48449057|NCT02220985|RADIATION|Total-Body Irradiation|Undergo TBI
48449058|NCT01527006|DRUG|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
48449059|NCT02588339|DRUG|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
48449060|NCT02588339|DRUG|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
48449061|NCT02588339|DRUG|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
48449062|NCT02191059|DRUG|Icotinib|
48449063|NCT02191059|DRUG|Docetaxel|
48449064|NCT03769896|DRUG|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
47928132|NCT06299371|DRUG|paclitaxel for injection (albumin bound)|paclitaxel for injection (albumin bound) IV
48449065|NCT03769896|DRUG|Placebo|capsule, corn starch, daily basis
48449066|NCT00471133|BIOLOGICAL|Xenogeneic Tyrosinase DNA Vaccine|
47928133|NCT06299371|DRUG|Cisplatin or Carboplatin|Cisplatin or Carboplatin IV
48449067|NCT00471133|DEVICE|TriGrid Delivery System for Intramuscular Electroporation|
48449068|NCT00281749|PROCEDURE|TELEPHONE CALL|
48449069|NCT05950035|BEHAVIORAL|Written Exposure Therapy (WET)|WET is a trauma-focused intervention in which individuals write about their worst traumatic experience following scripted instruction from the therapist.
48449070|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi focuses on stimulus control, eliminating maladaptive coping habits, reducing arousal, and challenging maladaptive thoughts about sleep in an effort to reduce time to fall asleep and time awake during the night.
48449071|NCT05950035|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares (CBTn)|CBTn involves writing about a distressing or frequent nightmare, rewriting the narrative of the nightmare to target trauma-related themes, and reading the rescripted nightmare narrative.
48449072|NCT05950035|BEHAVIORAL|Waitlist|Waitlist for delayed intervention.
48449073|NCT02907983|DRUG|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
48449074|NCT02907983|DRUG|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
48449075|NCT00200187|PROCEDURE|low venous pressure general anesthesia|
48449076|NCT00200187|PROCEDURE|combined spinal-epidural anesthesia|
48449077|NCT04102085|OTHER|no intervention|no intervention
47928134|NCT05823740|OTHER|Bioelectrical impedance Analysis (BIA)|Bioelectrical impedance analysis (BIA) is a method for estimating body composition, in particular, body fat and muscle mass, where a weak electric current flows through the body and the voltage is measured in order to calculate the impedance (resistance) of the body. BIA will be done at baseline, during the study related to routine medical imaging, and end of the study.
48449078|NCT00838136|DRUG|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
48449079|NCT00838136|DRUG|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
48449080|NCT04874454|DIAGNOSTIC_TEST|ultrasound|evaluate the vocal cord movement among the stroke patients
48449081|NCT01746472|BEHAVIORAL|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
48449082|NCT01746472|BEHAVIORAL|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
48449083|NCT01746472|BEHAVIORAL|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
48449084|NCT01746472|BEHAVIORAL|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
48449085|NCT00007423|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
48449086|NCT00007423|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
47928135|NCT05823740|OTHER|D3-Creatine Dilution (D3Cr)|The D3-Creatine dilution method is a safe and noninvasive measure of skeletal muscle mass that has previously been validated in adults, neonates, healthy children, and children. D3-Creatine Dilution will be done at baseline, during the study related to routine medical imaging, and end of the study.
47928136|NCT05823740|OTHER|6-Minute Walk Test (6MWT)|Cardiovascular fitness will be measured with the 6-minute walk test (6MWT). 6MWT will be done at baseline, during the study related to routine medical imaging, and end of the study.
47928137|NCT05823740|OTHER|Timed Up and Go (TUG)|Balance and mobility will be assessed by the timed-up-and-go test (TUG). TUG will be done at baseline, during the study related to routine medical imaging, and end of the study.
47928138|NCT05823740|OTHER|30-second Sit-to-Stand (STS)|Strength and muscular function will be evaluated by modified 30-second sit-to-stand (STS). STS will be done at baseline, during the study related to routine medical imaging, and end of the study.
48449087|NCT02895373|DRUG|Alprostadil|5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
48449088|NCT02895373|DRUG|0.9% sodium chloride solution|continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
48449089|NCT06485700|OTHER|Peer Delivery of Medications|Door-to-door peer delivery of medications within patients' communities will be implemented.
48449090|NCT06485700|OTHER|Health Information Technology (HIT) Platform|The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.
48449091|NCT05431699|DIAGNOSTIC_TEST|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
48449092|NCT05431699|DIAGNOSTIC_TEST|careHPV test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
48449093|NCT05431699|PROCEDURE|Colposcopy and biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
48449094|NCT05431699|PROCEDURE|Gas-based cryotherapy|"Cryotherapy is performed to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, a metal probe is inserted into the vagina and the tip is pressed against the cervix. Compressed carbon dioxide or nitrous oxide gas at a temperature of approximately -50ºC/-58ºF freezes the tip and creates an ice ball on the cervix. The ice ball ablates or destroys the abnormal cells."
48449095|NCT05431699|PROCEDURE|Thermal ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
48449096|NCT03547271|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
48449097|NCT03547271|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
48449098|NCT03547271|BIOLOGICAL|DTaP-IPV-HB-Hib vaccine|Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
48449099|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (13-valent)|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
48449100|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (10-valent)|Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
48449101|NCT03547271|BIOLOGICAL|MMR vaccine|Measles, mumps, and rubella vaccine
48449102|NCT01770223|DRUG|boceprevir|
48449103|NCT01770223|BIOLOGICAL|PegIFN-2b|
48449104|NCT01770223|DRUG|RBV|
48449105|NCT05401786|DRUG|Ipilimumab|Anti-CTLA-4
48449106|NCT05401786|DRUG|Cemiplimab|PD-1 inhibition
48449107|NCT05401786|RADIATION|SBRT|Stereotactic Body Radiotherapy
48449108|NCT04901169|DRUG|Angiotensin II|Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
48449109|NCT04901169|DRUG|Saline|Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
48449110|NCT03867721|DEVICE|Ventilator|Comparison of two ventilators for mouthpiece ventilation
48449111|NCT01471886|DRUG|Ketorolac Tromethamine|Every 8 hours for 4 days.
48449112|NCT01471886|DRUG|Naproxen|Every 8 hours for 4 days.
48449113|NCT04403347|DIETARY_SUPPLEMENT|Innovative Dietary Formulation (Patent ID: CN110250417A)|In addition to regular diets and usual care of hypertension, additional innovative natural dietary formulation derived from tartary buckwheat will be orally taken 3 times per day.
48449114|NCT04403347|DRUG|Losartan 50mg per day|In addition to regular diets and usual care of hypertension, antihypertensive medication will be orally taken (Losartan 50mg per day).
48449115|NCT06268665|DRUG|Tart Cherry Juice|Given PO
48449116|NCT04428307|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
48449117|NCT04428307|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
48449118|NCT01444053|DEVICE|No Intervention|No Intervention
48449119|NCT02572713|PROCEDURE|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
48449120|NCT02572713|PROCEDURE|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
48449121|NCT02572713|DRUG|DaTSCAN™|
48449122|NCT05456763|DIETARY_SUPPLEMENT|sodium butyrate|add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
48449123|NCT05456763|OTHER|placebo|placebo
48449124|NCT03781622|DEVICE|WOLF Thrombectomy Device|Mechanical thrombectomy for the neurovasculature
48449125|NCT05150691|BIOLOGICAL|DB-1303/BNT323|Administered IV
48449126|NCT05150691|DRUG|Pertuzumab Injection|Administered IV
48449127|NCT05150691|DRUG|Ritonavir|Administered oral
48449128|NCT05150691|DRUG|Itraconazole|Administered oral
48449129|NCT06043037|PROCEDURE|Elamrousy Novel Approach for Immediate Implant Placement Using Socket Shield Technique|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was grafted with ADDG
48449130|NCT06043037|PROCEDURE|Immediate Implant Placement Using Socket Shield Technique alone|The flapless strategy was used. To prepare the SS, tooth decoronation followed by root splitting mesio-distally. The palatally splitted portion of the root is atraumatically extracted while the intact buccal root portion is kept in place with thickness of 1.5mm.(12) The implant fixture is then placed palatally with 2mm gap distance in between. finally, that gap was left without grafts.
48449131|NCT03016650|DRUG|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
48449132|NCT03016650|DRUG|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
48449133|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.
48449134|NCT04194801|DRUG|Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
48449135|NCT04194801|DRUG|Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg|Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
48449136|NCT03494127|DEVICE|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
48449137|NCT03494127|DEVICE|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
48449139|NCT04710758|PROCEDURE|Laparoscopic total gastrectomy|LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
48449140|NCT04710758|PROCEDURE|Open total gastrectomy|OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
48449141|NCT00270634|DRUG|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
48449142|NCT00270634|DRUG|tacrolimus|tacrolimus 0.05 mg/kg po BID
48449143|NCT04028843|BEHAVIORAL|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
47928139|NCT05823740|OTHER|Hand Grip Strength (GS)|Strength and muscular function will be evaluated by grip strength (GS). GS will be done at baseline, during the study related to routine medical imaging, and end of the study.
47928140|NCT05823740|OTHER|PBTL p16 expression|Peripheral Blood biospecimen for PBTL p16 expression will be used for the assessment of biological aging. Blood biospecimens will be collected at baseline and end of the study for PBTL p16 analysis.
48449144|NCT05679024|DRUG|Apixaban 2.5 milligram Oral Tablet|Oral Tablet
48449145|NCT04892615|DEVICE|drainage tube was removed on 5th days after surgery.|drainage tube was removed on 5th days after surgery.
48449146|NCT04892615|DEVICE|drainage tube was removed on 7th days after surgery.|drainage tube was removed on 7th days after surgery.
48449147|NCT05990907|PROCEDURE|Remote ischemic preconditioning|The empty tourniquet (VBM Tourniquet Touch®, Sulz a.N. Germany) is attached to the right upper arm. The measurement starts from this point in time. After lying flat for 10 minutes, the upper arm tourniquet is inflated to 250 mmHg. In all subjects, the ischemia was verified by palpation and Doppler signal of the radial artery. The ischemia phase is carried out for 10 minutes, so the tourniquet is opened and a 10-minute reperfusion phase is started, followed by a total of 3 cycles. After the 3rd ischemia phase, the tilting table test is followed by a 15-minute lying interval.
48449148|NCT02311361|BIOLOGICAL|Durvalumab|10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
48620445|NCT00448045|BEHAVIORAL|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
48279257|NCT00803114|DRUG|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
48449149|NCT02311361|BIOLOGICAL|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
48449150|NCT02311361|RADIATION|Sterostatic body radiation therapy (SBRT)|8 Gray (Gy) x 1; 5Gy x 5
48449151|NCT02468518|DRUG|Vitamin E capsule|Capsules will be distributed to each participant free of cost
48449152|NCT05705219|DIAGNOSTIC_TEST|3D-MPUS|Participants will receive approximately \< 20 minutes ultrasound scan to locate the lesion followed by acquisition of 3D-MPUS acquisition.
48449153|NCT02891863|DEVICE|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
48449154|NCT03545022|PROCEDURE|Acupuncture|"The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes."
48449155|NCT01349218|OTHER|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
48449156|NCT01349218|OTHER|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
48449157|NCT04551066|DRUG|parsaclisib|parsaclisib will be administered QD orally
48449158|NCT04551066|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
48449159|NCT04551066|DRUG|placebo|placebo will be administered QD orally
48449160|NCT06195579|BEHAVIORAL|Transforming the Intense Child Workbook (Glasser, 2016)|The NHA was delivered in a guided self-help format, using the Transforming the Intense Child workbook (Glasser, 2016) and weekly phone calls.
48449161|NCT02554877|DRUG|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
48449162|NCT02554877|DRUG|Placebo|oral tablet
47928141|NCT05823740|OTHER|CT, MR and PET Imaging|Participants will undergo routine imaging with either computed tomography (CT), Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan. Skeletal muscle mass and fat mass will be calculated at several different vertebral levels from imaging studies.
47928142|NCT05624047|BEHAVIORAL|Breastfeeding education using hybrid simulation method|In addition to the verbal breastfeeding training given to the pregnant women assigned to the experimental group, breastfeeding training will be given using the hybrid simulation method consisting of a wearable breast model and standard patient practice.
48449163|NCT01818024|DRUG|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
48449164|NCT01818024|DRUG|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
48449165|NCT01818024|DRUG|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
48098230|NCT00657774|DRUG|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
48279258|NCT00803114|DRUG|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
48279259|NCT03226990|OTHER|impression technique|impression technique with and without wax spacer
48279260|NCT03947229|DRUG|Clopidogrel mono-therapy|Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.
48279261|NCT03947229|DRUG|Dual-antiplatelet therapy|Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
48279262|NCT04791943|DRUG|Melatonin 10 MG|3 melatonin 10mg capsules will be given to the treatment arm
48279263|NCT04791943|DRUG|Lactose pill|3 lactose pills will be provided to the control arm
48279264|NCT00794586|DRUG|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
48279265|NCT00794586|DRUG|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
48279266|NCT04697914|DIAGNOSTIC_TEST|Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.|to protect the metatarsus and prevent the appearance of foot pain.
48279267|NCT01696461|DRUG|Plerixafor|
48279268|NCT01046188|OTHER|Knowledge Questionnaire|Administered before and after teaching intervention
48449166|NCT01818024|DRUG|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
48279269|NCT01046188|OTHER|Perceived Stress Scale|Administered before and after teaching intervention
48279270|NCT01046188|OTHER|Satisfaction questionnaire|Administered after the intervention and at study completion
48279271|NCT01046188|OTHER|Web-based IVF teaching|Web-based IVF teaching
48279272|NCT01046188|OTHER|Didactic lecture|Didactic lecture
48279273|NCT03488199|DEVICE|Stent Acculink ™|Carotid Artery Revascularization using Stents
48279274|NCT03488199|DEVICE|CGuardTM™|Carotid Artery Revascularization using Stents
48279275|NCT04767425|RADIATION|Brachytherapy|• 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
48279276|NCT01089192|DRUG|Metformin|
48279277|NCT03959436|DRUG|Carbetocin|Carbetocin as the primary uterotonic for all cesarean sections
48279278|NCT04844138|BEHAVIORAL|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
48279279|NCT03483532|DIETARY_SUPPLEMENT|Lit Control pH Up|dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
48279280|NCT03483532|DIETARY_SUPPLEMENT|dry cocoa extract|(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
48279281|NCT01322828|PROCEDURE|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
48279282|NCT00846742|DRUG|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
48279283|NCT00846742|RADIATION|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
48449167|NCT01818024|DRUG|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
48449168|NCT01818024|DRUG|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
48449169|NCT01818024|DRUG|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
48449170|NCT01818024|DRUG|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
48449171|NCT02962752|DIETARY_SUPPLEMENT|Blackadder Juice|
48449172|NCT02962752|OTHER|Placebo|
48449173|NCT02403947|DRUG|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
48449174|NCT02403947|DRUG|Suspension media|injection suspension media
48449175|NCT00835263|DRUG|Lamotrigine|200 mg Tablet
48449176|NCT00835263|DRUG|Lamictal®|200 mg Tablet
48449177|NCT00455312|DRUG|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
48449178|NCT00455312|DRUG|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
48449179|NCT00455312|DRUG|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
48098231|NCT00657774|DRUG|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
48279284|NCT05422729|BEHAVIORAL|mHealth-supported coaching|The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.
48279285|NCT05422729|BEHAVIORAL|Conventional Health coaching|Three individual consultation sessions delivered by a nurse.
48279286|NCT06381583|DIAGNOSTIC_TEST|EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)|A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.
48279287|NCT05792384|PROCEDURE|transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe
48279288|NCT05792384|PROCEDURE|transbronchial lung biopsy with biopsy forceps|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung biopsy with biopsy forceps
48279289|NCT01283256|DRUG|zonisamide|zonisamide 100mg tablets
48279290|NCT02604004|DRUG|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
48279291|NCT02604004|DRUG|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
48279292|NCT06519656|DRUG|Mazdutide|In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.
48279293|NCT02048904|DRUG|Sitagliptin|Sitagliptin 100 mg/day for 3 months
48279294|NCT02048904|DRUG|Placebo|Placebo 1 pill/day for 3 months
48279295|NCT05995704|DRUG|Apraglutide|Peptide analogue of GLP-2
48279296|NCT05995704|DRUG|Placebo|Matching placebo to apraglutide
48279297|NCT05995704|DRUG|Acetaminophen|Acetaminophen mixed with a liquid meal
48279298|NCT05278234|BEHAVIORAL|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
48449180|NCT00455312|PROCEDURE|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
48449181|NCT00455312|PROCEDURE|Stem Cell Transplantation|Infusion of stem cells on Day 0.
48449182|NCT00455312|DRUG|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
48449183|NCT00455312|DRUG|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
48449184|NCT05954650|BEHAVIORAL|Rehabilitation|Physical therapy and multisensory stimulation adjusted to the needs of each patient.
48449185|NCT00840216|DRUG|Clarithromycin ER 500 mg tablets|1 x 500 mg
48449186|NCT00840216|DRUG|BIAXIN® XL 500 mg tablets|1 x 500 mg
48449187|NCT06559410|OTHER|Electroencephalogram (EEG), CT Brain, Echocardiogram|analyze the etiology, electroencephalographic (EEG) findings, neuroimaging, and neurological sequalae of newborns with congenital heart disease who were presented with seizures
48449188|NCT01273350|DEVICE|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
48449189|NCT05660655|DRUG|Baricitinib 4 MG Oral Tablet|baricitinib 4 mg once daily
48449190|NCT05660655|DRUG|Baricitinib 2 MG|baricitinib 4mg once daily in group A
48449191|NCT01564238|OTHER|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
48449192|NCT01564238|OTHER|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
48620446|NCT00448045|BEHAVIORAL|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
48449193|NCT06202755|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
48449194|NCT06202755|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
48449195|NCT01421901|DRUG|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
48449196|NCT01421901|PROCEDURE|appendectomy|
48449197|NCT03851354|OTHER|Ultrasound meal acommodation test|to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
48449198|NCT06563206|PROCEDURE|Exergame|Hand Training assisted with Virtual-Reality
48449199|NCT06563206|PROCEDURE|Robotic|Hand Training assisted with Robotic Syrebo
48098232|NCT00657774|DRUG|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
48279299|NCT02628925|DEVICE|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
48279300|NCT06162455|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
48279301|NCT06162455|DRUG|200- ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
48279302|NCT00371267|BEHAVIORAL|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
48279303|NCT00371267|OTHER|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
48279304|NCT02091440|DEVICE|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
48279305|NCT00975091|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
48279306|NCT00975091|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
48279307|NCT05038761|DEVICE|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
48279308|NCT05038761|PROCEDURE|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
48279309|NCT03027167|DRUG|Aspirin|
48279310|NCT03027167|DEVICE|(Post- discharge) Mechanical Compression Device|
48279311|NCT03571464|DEVICE|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
48279312|NCT04052737|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
48279313|NCT04052737|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
48279314|NCT06655922|DIAGNOSTIC_TEST|FAPI Imaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPI imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
48279315|NCT04360304|DEVICE|Echocardiographic exam|"An echocardiographic exam is realised after inclusion, measuring especially :~* LVOT VTI~* Respiratory variation of inferior veina cava diameter For theses two measurements, the manual method is first recorded, and then the automated one is done.~For patients that need fluid resuscitation of at least 250mL in less than 10minutes (indication at the discretion of the physician in charge of the patient), a second echocardiography is done according to the same protocol described before."
48279316|NCT06036966|DRUG|Hetrombopag|All the enrolled 34 patients will be given hetrombopag 5mg per day for 8 weeks when they start to take Niraparib as maintenance therapy
48279317|NCT01962220|BEHAVIORAL|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~* Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~* Providing tailored individualized health education during home visits.~Additional intervention components include:~* Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~* Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
48449200|NCT06563206|PROCEDURE|Conventional|Hand Training with Physical Therapist
48449201|NCT04825847|DEVICE|BIS monitor|Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
48620447|NCT04058691|DEVICE|Surgical repair|Open surgery
48449202|NCT04825847|OTHER|Control group|In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
48449203|NCT05510908|OTHER|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
48449204|NCT05510908|OTHER|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
48449205|NCT04855279|OTHER|neutral sodium fluoride|Topically applied
48449206|NCT04855279|OTHER|ACP-CCP gel|Topically applied
48449207|NCT04855279|OTHER|nano-hydroxyapatite solution|Topically applied
48449208|NCT04855279|OTHER|glycerine|Topically applied
48449209|NCT06150963|DEVICE|Virtual Reality|Study participants assigned to the VR intervention group were fitted with an HP Reverb G2 Head Mounted Display (HMD) and a wireless mouse prior to preparation for procedure. One virtual environment was utilized, integrating passive and active participant input via gyroscopic motion detection and computer mouse input.
48449210|NCT06150963|PROCEDURE|Standard Procedure Thyroid Biopsy|In this procedure the patient lies down on a bed with their neck tilted back to reveal the thyroid gland. The doctor cleans the skin over the nodule and numbs it with a local anesthetic. The doctor will then use an ultrasound device to visualize the nodule and guide a needle to obtain cells through the syringe. This process may be repeated several times to retrieve adequate tissue for analysis.
48449211|NCT06150963|PROCEDURE|Standard Procedure PICC Placement|In this procedure the patient lies down on a bed and has their arm cleaned and then numbed with a local anesthetic. The doctor then uses an ultrasound to locate a suitable vein in the arm, typically above the elbow. The physician then makes a small incision in the skin and inserts a needle into the vein, followed by guidance of the Peripherally Inserted Central Catheter (PICC) through the needle until it reaches a large vein near the heart. The final position is confirmed by X-ray and the PICC line is secured at the site of insertion.
48449212|NCT03137251|DEVICE|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
48449213|NCT03137251|DEVICE|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
48449214|NCT03137251|DEVICE|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
48449215|NCT01655654|BEHAVIORAL|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
48449216|NCT01655654|BEHAVIORAL|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
48449217|NCT01655654|OTHER|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
48449218|NCT05726669|OTHER|Self-help materials for depression|Self-help materials for depression based on cognitive behavioural therapy have been created and tailored to those with PH by researchers involved in this project, using the evidence base and theory plus clinical experience. The Medical Research Council Frameworks for complex interventions (Craig et al., 2008; Skivington et al., 2021) have been followed as well as the quality appraisal tool for self-help interventions in depression (Cape, 2015). The self-help materials will be shared for feedback with a readership panel of people with PH and caregivers who are members of Pulmonary Hypertension Association UK (a charity for people with PH) prior to being given to participants. The self-help materials will be provided online or posted in paper form to the intervention group and will take four weeks for the person to complete at home (one booklet per week).
48449219|NCT02525445|PROCEDURE|acupuncture|acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
48620448|NCT00989885|OTHER|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
48279318|NCT01797718|DRUG|Testosterone|1mg/kg every 4 weeks for 6 months
48279319|NCT01797718|DRUG|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
48279320|NCT04341779|COMBINATION_PRODUCT|Point-of-care viral load testing and tenofovir adherence testing|Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
48279321|NCT02555800|DRUG|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
48279322|NCT02555800|DRUG|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
48279323|NCT02555800|OTHER|Placebo|Saline solution
48449220|NCT02525445|PROCEDURE|sham acupuncture|"sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle \[20\]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no needle sensation occurred, and then lifted the needles up from the skin."
48449221|NCT02525445|PROCEDURE|positive communication|"During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension."
47928143|NCT05624047|BEHAVIORAL|Routine verbal breastfeeding education|Women in this group will receive oral breastfeeding training, which is routinely given in the pregnant education class and consists of one session.
47928144|NCT04218565|BIOLOGICAL|Golimumab (GOL)|Patients with refractory BD associated uveitis will receive Golimumab therapy, the efficacy and corticosteroids-sparing effects will be evaluated.
47928145|NCT00773227|PROCEDURE|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
47928146|NCT01695278|BEHAVIORAL|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
48279324|NCT05086679|DEVICE|Compression Stockings with 25-30 mm Hg pressure|The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
48449222|NCT02525445|PROCEDURE|neutral communication|"During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,"
48449223|NCT04487158|BEHAVIORAL|Small Changes|The Small Changes program is an evidence-based 6-month weight-management program. The program runs weekly for 3 months followed by by-weekly contact for 3-months (1x in-person group and 1x phone call). This program uses behaviour change strategies to help with weight loss. The Small Changes approach is different from traditional dieting programs because it encourages modest changes to diet and physical activity which are not overly taxing to maintain. Participants are asked to reduce their nutritional intake by 200-400 calories per day. You will also be asked to increase their daily step count by 2000-3000 steps. Weekly intervention topics include: Monitoring, Nutrition, Physical Activity, Breaking the Chain, External Cues, Mindful Eating, Body Image, Stress, Sleep, Social Support, Social Eating, and the Stoplight Guide.
48449224|NCT04487158|BEHAVIORAL|INSPIRE|The INSPIRE program is a modification to the Small Changes program. It combines elements of positive psychology and behaviour change to help with weight loss. The first four weeks of the program are oriented towards improving well-being and include topics such as values, self-compassion/mindfulness, character strengths, and gratitude. The remaining 8 weeks mirrors the Small Changes program in making modest changes to diet and physical activity to achieve weight loss. Participants are asked to reduce their nutritional intake by 200-400 calories per day. Participants will also be asked to increase their daily step count by 2000-3000 steps.
48449225|NCT00376285|DRUG|CP-742,033|
48449226|NCT00376285|DRUG|Fenofibrate|
48449227|NCT04841096|DRUG|A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
48449228|NCT04841096|DRUG|B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
48449229|NCT04841096|DRUG|(A2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
48449230|NCT04841096|DRUG|(B2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
48449231|NCT06331910|DRUG|insulin eye drops|Insulin eye drops deliver insulin directly to the cornea, They exploit insulin's ability to stimulate cell growth, potentially reducing healing time with minimal side effects.
48449232|NCT00235352|DRUG|CX516 (Ampakine)|
48449233|NCT04159103|BIOLOGICAL|mRNA-3927|mRNA-3927 dispersion for IV infusion
48449234|NCT00802763|DEVICE|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
48449235|NCT06561659|BEHAVIORAL|Exercise Condition|Already described in the arm description
47928147|NCT04363398|OTHER|Comprehensive Follow-up|Trained research staff members will provide weekly support to coaches on the NMT warm-up.
47928148|NCT04363398|OTHER|Standard Follow-up|Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
48449236|NCT06561659|BEHAVIORAL|Relaxation Control Condition|Already described in the arm description
48449237|NCT06299319|DRUG|Psilocybin|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.
48449238|NCT04660747|DRUG|Oral anticoagulant|Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
48449239|NCT04567082|DIAGNOSTIC_TEST|Examination of saliva|Collection of saliva samples
48449240|NCT00840073|DRUG|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
48449241|NCT00840073|DRUG|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
48449242|NCT05893290|OTHER|Therapeutic Exercise Group|Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
48449243|NCT05893290|OTHER|Therapeutic Exercise+Basic Body Awareness Therapy Group|This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
48449244|NCT02956525|DRUG|Dexibuprofen|Dexibuprofen 200 mg
48449245|NCT05011695|OTHER|physiotherapy|The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
47928149|NCT04695613|DRUG|Aminoacid|amino acid infusion 150 ml/kg/hr starting preoperative
47928150|NCT04695613|DRUG|Magnesium sulfate|magnesium sulphate bolus and infusion 60 mg/kg starting preoperative
47928151|NCT04096183|OTHER|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
48449246|NCT01020474|DRUG|placebo|matching placebo capsules twice daily.
48449247|NCT01020474|DRUG|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
48449248|NCT03839719|PROCEDURE|Group PI|Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
48449249|NCT03839719|PROCEDURE|Group OC|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
48449250|NCT03839719|PROCEDURE|Group CHX|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
48449251|NCT01725958|DIETARY_SUPPLEMENT|Nutritional supplement and protein shakes|
48449252|NCT02816450|BEHAVIORAL|Water Intake|
48449253|NCT00365430|BEHAVIORAL|safety program|Education, patient involvement, tailored implementation and a computerized registration system
48449254|NCT00473863|PROCEDURE|Coronary Computed Tomographic Angiography|CCTA will be performed
48449255|NCT00746395|DRUG|Lubiprostone|24 mcg oral administration
48449256|NCT00746395|DRUG|Placebo|Oral administration
48449257|NCT02257658|DRUG|Doxycycyline|
47928152|NCT00416897|DRUG|chemotherapy|
48449258|NCT02257658|BEHAVIORAL|Incentive|
47928153|NCT00416897|DRUG|dexamethasone|
48449259|NCT03135301|DRUG|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
48449260|NCT03135301|DRUG|letrozole|letrozole 5 milligram tablets
48449261|NCT00834561|DRUG|Lamotrigine|200 mg Tablet
48449262|NCT00834561|DRUG|Lamictal®|200 mg Tablet
48449263|NCT06067438|DRUG|Amiodarone Hydrochloride|Given IV and via feeding tube
48449264|NCT06067438|OTHER|Saline|Given IV
48449265|NCT06559813|BEHAVIORAL|Step-by-step: A cognitive behavioral parent program with role-plays in virtual reality|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), incorporating virtual reality for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality is used as an additional way to practice skills.
47928154|NCT00416897|PROCEDURE|plasmapheresis|
47928155|NCT00252941|DEVICE|Memokath 028SW Urethral Stent|
47928156|NCT06177574|DRUG|BIC/FTC/TAF|TEST and TREAT strategy: Study group will start the intervention at the first visit with their healthcare provider.
48449266|NCT04954573|RADIATION|infrared-A (wIRA)|Local-water filtered infrared-A (wIRA) irradiation
48449267|NCT00875524|BIOLOGICAL|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
48449268|NCT00875524|BIOLOGICAL|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
48449269|NCT05457452|DEVICE|Knee Brace|Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
48449270|NCT01310998|BEHAVIORAL|High intensity exercise|4x4 intervals
48449271|NCT02651272|DRUG|macitentan|10mg macitentan tablets
48449272|NCT01160666|DRUG|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
48449273|NCT05560698|OTHER|Motivation-enhancing intervention|The web app is designed as an efficient and easy-to-use app configurable to personal preferences. Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. The questionnaire addresses the same questions as the questionnaire in the standard intervention, but the format is different, and some shortcuts makes it easier to answer. When the questionnaire is answered, the web app gives access to different features. The following features distinct the motivation-enhancing intervention from the standard intervention (1) only complete the entire questionnaire on days with symptoms, (2) integration of grass pollen counts and forecasts, (3) showing personal response rate, (4) access to own data via a graph, (5) advice against grass pollen allergy, (6) status of the study, (7) individually choosing the time of response, (8) option to download an icon for the home screen and (9) contact information. The development is an ongoing iterative process
48449274|NCT05560698|OTHER|Standard intervention|Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. When the questionnaire is answered, the tab needs to be closed.
48449275|NCT01628835|BEHAVIORAL|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
48449276|NCT01628835|BEHAVIORAL|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
48620449|NCT01926210|OTHER|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
48620450|NCT01926210|OTHER|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
48620451|NCT03445169|DRUG|Belzutifan|Belzutifan Tablets
48449277|NCT01246258|OTHER|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
48449278|NCT01246258|OTHER|Utricular centrifugation test|Standard test of balance function
48449279|NCT02767791|OTHER|Acupuncture|Acupuncture
48449280|NCT02767791|OTHER|Auriculotherapy|Auriculotherapy
48449281|NCT00556322|DRUG|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
48449282|NCT00556322|DRUG|erlotinib [Tarceva]|150mg po daily
48449283|NCT03060486|DEVICE|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
48449284|NCT01823263|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
48449285|NCT01823263|PROCEDURE|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
48620452|NCT02112201|BEHAVIORAL|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
48620453|NCT04040699|BIOLOGICAL|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
48449286|NCT01823263|PROCEDURE|Interference task|30-minute interference task
48620454|NCT01991795|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
48449287|NCT01823263|BEHAVIORAL|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
48449288|NCT01823263|BEHAVIORAL|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
48449289|NCT01823263|BEHAVIORAL|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
48449290|NCT00574847|DRUG|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
48620455|NCT01991795|DRUG|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
48620456|NCT02234271|OTHER|Mobile Health Application|Mobile Health application for contraception information
48620457|NCT02234271|OTHER|Health Educator Counseling|Counseling via health educator
48620458|NCT00489242|PROCEDURE|Procedure / Percutaneous angioplasty|
48620459|NCT02679105|DRUG|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
48620460|NCT02679105|DRUG|ALK diluent|0,3% human albumin
48620461|NCT02260271|OTHER|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
48620462|NCT03653078|DEVICE|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
48620463|NCT01809652|OTHER|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
48449291|NCT00574847|DRUG|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
48449292|NCT05487989|OTHER|Clinical examen|MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
48449293|NCT06319495|BEHAVIORAL|Rehabilitation therapy|"During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
48449294|NCT06319495|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48449295|NCT06319495|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48449296|NCT06319495|BEHAVIORAL|placebo injection|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48449297|NCT00906399|DRUG|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
48449298|NCT00906399|DRUG|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
48449299|NCT05215483|BEHAVIORAL|Customised testing advice|Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.
48449300|NCT05215483|BEHAVIORAL|Regular testing advice|"Government guideline testing advice: With Corona related symptoms, get tested at a test facility."
48449301|NCT05215483|BEHAVIORAL|LFT available|LFT availability: Enough lateral flow tests available at home
48449302|NCT05215483|BEHAVIORAL|No LFT available|LFT availability: No lateral flow tests available at home
48449303|NCT02100761|DRUG|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance \<50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
48449304|NCT04185493|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis with the use of CT imaging post-processing techniques.
48449305|NCT03168763|BEHAVIORAL|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
48449306|NCT03168763|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
48449307|NCT00752466|DRUG|Topiramate; flunarizine|
48449308|NCT04925791|DIAGNOSTIC_TEST|standardized pre-conditioning treatment|3 rounds of 5 minutes of full occlusion alternating with 5 minutes of reperfusion while seated.
48449309|NCT04925791|DIAGNOSTIC_TEST|Partial occlusion|3 rounds of 5 minutes of partial occlusion alternating with 5 minutes of reperfusion while seated.
48449310|NCT04456842|OTHER|Patient Registry Data|To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.
48449311|NCT03125473|BIOLOGICAL|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
48449312|NCT04252001|DEVICE|YESS! game|"The YESS! game is a real-life game for smartphone or tablet in which the player has to solve a mystery. The adolescent plays an active role in the course of the story. This results in an interactive experience. During the game, the adolescent is challenged with regard to self-management and responsible behaviour in general life, with parallels to medical selfmanagement and responsible behaviour.~The adolescent has to decide at several different moments whether to take action or not, whether to accept help or not and whether to share (fictive) confidential information or not. Other aspects that are covered are 'taking responsibility' and 'being on time'. The choices the adolescent makes throughout the game are registered in a coded manner, for later analysis. The game is available in Dutch, English and Spanish."
48620464|NCT04144829|PROCEDURE|HIFU|Intravaginal HIFU procedure, lengths 1.5, 3 and 4.5 mm - 200, 200 and 100 impulses respectively
48620465|NCT04144829|PROCEDURE|Fibrin|Injection of 2ml platelet-rich fibrin from centrifuged for 5 min patient's blood under the urethra
48620466|NCT00182819|DRUG|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
48620467|NCT00182819|RADIATION|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
48620468|NCT04275037|OTHER|Isometric Handgrip Training|The 8-week exercise program will include three sessions of isometric handgrip training per week
48449313|NCT04252001|DEVICE|Snake '97|Snake '97 is a game for smartphone or tablet which is free and can be downloaded in the App Store. The game is a remake of the original snake on the mobile phone in 1997 in which the player moves the snake around and makes the snake 'consume food' (little dots) which causes the snake to grow longer. The goal is to make the snake as large as possible. The game has 12 difficulty levels.
48449314|NCT04252001|OTHER|Transition-toolkit|The transition toolkit consists of paper cards with assignments, ideas and tips regarding medical self-management.
48449315|NCT03221530|BEHAVIORAL|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
48449316|NCT03221530|BEHAVIORAL|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
48449317|NCT06181422|DRUG|Metformin|metformin 500 mg
48449318|NCT06181422|DRUG|Lactoferrin|lactoferrin 100 mg
48449319|NCT03650985|PROCEDURE|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
48449320|NCT06258421|OTHER|No Intervention|Observatory Study
48620469|NCT04275037|OTHER|Aerobic Exercise Training|The 8-week exercise program will include three sessions of aerobic exercise per week
48098233|NCT00657774|DRUG|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
48279325|NCT05086679|DEVICE|Compression stockings with up to <=10 mm Hg pressure|The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
48279326|NCT05086679|BEHAVIORAL|Lifestyle modification|All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
48279327|NCT05666089|DRUG|N-acetyl cysteine|intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
48279328|NCT05666089|DRUG|Calcium hydroxide|intracanal medication of calcium hydroxide paste (metapaste)
48279329|NCT00251602|DRUG|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
48279330|NCT00251602|DRUG|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
48279331|NCT00251602|DRUG|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
48279332|NCT03176849|DIETARY_SUPPLEMENT|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
48279333|NCT03176849|DIETARY_SUPPLEMENT|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
48279334|NCT03026582|DEVICE|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
48279335|NCT00061386|BEHAVIORAL|Nutrition and physical activity program|
48279336|NCT00932997|BEHAVIORAL|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
48279337|NCT00932997|OTHER|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
48279338|NCT00932997|OTHER|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
48279339|NCT00932997|OTHER|questionnaire administration|Baseline and 9 months after enrollment and intervention
48279340|NCT00932997|PROCEDURE|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
48279341|NCT00932997|PROCEDURE|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
48449321|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy|the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer
48449322|NCT06561646|PROCEDURE|single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection|the single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection in the management of breast cancer
48098234|NCT00387361|PROCEDURE|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
48098235|NCT03076450|DEVICE|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
48098236|NCT03076450|DIAGNOSTIC_TEST|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
48098237|NCT00182520|DRUG|Topiramate|25 mg - 400 mg/day x 12 weeks
48098238|NCT00182520|DRUG|placebo|25 - 400 mg/day x 12 weeks
48449323|NCT05410002|DIETARY_SUPPLEMENT|Dietary Supplement: N-111|Dietary supplement N-111
48449324|NCT05410002|OTHER|Placebo|Dietary placebo
48449325|NCT02817867|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
48449326|NCT02817867|DEVICE|TMS|Transcranial magnetic stimulation
48449327|NCT02817867|DEVICE|tDCS + TMS|Association between tDCS and TMS.
48449328|NCT06434753|DRUG|Zinc Acexamate|"The experimental group will receive ACZ at a daily dose of 600 mg, equivalent to 100mg of elemental zinc (one hard gelatin capsule of 300 mg of ACZ twice a day). Treatment will be stopped when the patient presents any of the events that define the main endpoint of the study.~The control group will receive twice a day orally hard gelatin capsules, identical to those of ACZ, in color, weight and nature, but containing an inert preparation (isomaltose)."
48449329|NCT05382715|DRUG|Ozanimod|Specified Dose on Specified Days
48449330|NCT06625463|BEHAVIORAL|Home based cardiac rehabilitation|12 week home based cardiac rehabilitation include Physical exercise, dietary management, smoking cessation and stress management
48449331|NCT02838160|BEHAVIORAL|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
48449332|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
48449333|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
48449334|NCT02838160|BEHAVIORAL|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
48449335|NCT00706277|DRUG|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
48449336|NCT00706277|DRUG|propofol|propofol 2mg
48449337|NCT00706277|DRUG|remifentanil|remifentanil 0,25mcg/kg/hour
48449338|NCT00706277|DRUG|fentanyl|fentanyl 100mcg
48449339|NCT00706277|DRUG|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
48449340|NCT06382636|BEHAVIORAL|Standard Care|This group will utilize standard care with respect to healthcare provider practices.
48449341|NCT06382636|BEHAVIORAL|Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot|This group will be exposed to the AI enabled healthcare chatbot.
48449342|NCT06562621|BIOLOGICAL|ON-01|ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.
48449343|NCT06562621|DRUG|ONF|ONF is an extended-release formulation of flucytosine.
48449344|NCT03933592|PROCEDURE|Serratus anterior block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
48449345|NCT03933592|PROCEDURE|thoracic epidural|In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
48449346|NCT06180980|DRUG|Pirtobrutinib|Administered orally.
48449347|NCT00025818|DRUG|Ophthalmic Emulsion|
48449348|NCT01561391|DRUG|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
48449349|NCT01561391|DRUG|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
48449350|NCT01561391|OTHER|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
48449351|NCT01561391|DRUG|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
48449352|NCT04201353|BEHAVIORAL|Conditional Cash Transfer|The intervention is a monthly cash transfer of 22,500 Tanzanian Shillings (\~$10) for up to 6 months conditional on visit attendance.
48449353|NCT02566850|DEVICE|Ekso|powered lower extremity exoskeleton
48449354|NCT03789565|OTHER|Biomarker test|Diagnostic biomarker study
48449355|NCT05294783|PROCEDURE|ACL reconstruction|ACL reconstruction is a standard surgery for ACL injured patients
48449356|NCT04914286|DRUG|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
48449357|NCT04914286|DRUG|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
48449358|NCT00750243|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
48449359|NCT00750243|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
48449360|NCT04373096|DEVICE|current IPAC-UHN PPE|"* Fit-tested N95 mask~* Open face shield~* Double extended-cuff"
48449361|NCT04373096|DEVICE|modified IPAC-UHN PPE|"* Fit-tested N95 mask~* Hood~* Double extended-cuff gloves"
48449362|NCT04443790|DRUG|Leptin Human|
48449363|NCT02095054|DRUG|Regorafenib|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."
48449364|NCT02095054|DRUG|Cetuximab|"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."
48449365|NCT02095054|BEHAVIORAL|Questionnaire|Symptom questionnaire completed at each study visit.
48449366|NCT01842477|PROCEDURE|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
48449367|NCT05053763|DRUG|Remimazolam|The study was carried out using a biased coin design up-and-down sequential method, where the dose of remimazolam administered to each patient depended on the response of the previous one with success/failure duodenoscopy insertion during ERCP are required for reliable estimates. The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement). if a patient had a failure duodenoscopy insertion, the dose of remimazolam was increased by 0.025mg/kg in the next subject. If a patient had a successful duodenoscopy insertion the next subject was randomised to receive either a lower dose (with a decrement of 0.025mg/kg), with a probability of b = 0.11, or the same dose, with a probability of 1-b = 0.89.
48449368|NCT04685291|PROCEDURE|Ultrasound-guided block of the supraclavicular nerves|The supraclavicular nerves (SCN) arise from the 3rd and 4th roots of the spinal nerves. After emerging from the spine, they run at the rear margin of the sternocleidomastoid muscle and divide into their three terminal branches. With a high-resolution Ultrasound (US)-probe they can be visualized as a grape-like structure under the skin. At this location, patient's skin is disinfected and covered with a sterile perforated blanket. The US-probe is covered with a sterile sheath. The patient is positioned as comfortably as possible so that the broken clavicle is not mobilized. SCN are shown by US and a 0.5 mm needle is advanced through the patient's skin in order to direct it to the nerves under US-guidance. Both the nerves and the needle are permanently visualized. As soon as the needle tip is placed next to the SCN, 2-3 millilitres of a long-acting LA are injected. The distribution of the LA around the nerves is controlled.
48449369|NCT04685291|DRUG|Conventional pain management|"* oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* oral pain medication in patients older than or equal 70 years: Acemetacin 60mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)~* Rescue analgesic medication for all patients: oxycodone hydrochlorid (drops) p.o. (10 mg/ml) 0.1mg/kg p.o. hour~* In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)"
48449370|NCT05295550|OTHER|Realibility|measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
48449371|NCT03129763|BEHAVIORAL|60mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.
48449372|NCT03129763|BEHAVIORAL|70mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.
48449373|NCT03129763|BEHAVIORAL|80mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.
48449374|NCT03129763|BEHAVIORAL|90mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
48449375|NCT03129763|BEHAVIORAL|100mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
48449376|NCT04416386|OTHER|Vitamin C|Pre and post-operative blood plasma levels of vitamin C will be investigated
48449377|NCT02718326|DRUG|Intravitreal aflibercept injection [IAI]|
48449378|NCT02718326|DRUG|Sham|
48449379|NCT03656367|DIETARY_SUPPLEMENT|Cheddar cheese|The reference product is a commercial matured cheddar cheese
48449380|NCT03656367|DIETARY_SUPPLEMENT|Blended and homogenized cheddar cheese|A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
48449381|NCT03656367|DIETARY_SUPPLEMENT|An analog milk|An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
48449382|NCT03656367|DIETARY_SUPPLEMENT|An analog cheese|This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
48449383|NCT06124638|DIAGNOSTIC_TEST|Panbio™ COVID-19/Flu A&B Panel|The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.
48449384|NCT04260217|DRUG|APG2575 400 mg|APG2575 400 mg
48449385|NCT04260217|DRUG|APG2575 600 mg|APG2575 600 mg
48449386|NCT04260217|DRUG|APG2575 800 mg|APG2575 800 mg
48449387|NCT02247791|PROCEDURE|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
48449388|NCT02247791|PROCEDURE|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
48449389|NCT00705003|DRUG|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
48449390|NCT00705003|DRUG|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
48449391|NCT00705003|DRUG|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
48449392|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
48449393|NCT02057835|DRUG|BI 691751 high dose|BI 691751 high dose
48449394|NCT02057835|DRUG|BI 691751 middle dose|BI 691751 middle dose
48449395|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
48449396|NCT02057835|DRUG|BI 691751 low dose 1|BI 691751 low dose 1
48449397|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
48449398|NCT02057835|DRUG|Placebo to BI 691751|Placebo to BI 691751
48449399|NCT02057835|DRUG|BI 691751 low dose 2|BI 691751 low dose 2
48449400|NCT03967938|DRUG|Olaparib Oral Capsule|Olaparib tablets 300mg twice daily
48449401|NCT05807074|DRUG|Tranexamic Acid|Applied intraoperatively
48449402|NCT05807074|OTHER|Saline|Applied intraoperatively
48449403|NCT05187481|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
48449404|NCT05187481|DRUG|Placebo granule|once a day in the morning and evening, 30 days as a course of treatment, a total of 3 courses.
48449405|NCT02341846|OTHER|Qualitative interviews|
48449409|NCT01503957|DEVICE|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
48449410|NCT01503957|DEVICE|Saline solution|Nasal spray, 2 sprays in each nostril
48449411|NCT06614725|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.
48449412|NCT06614725|COMBINATION_PRODUCT|Placebo|1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.
48449413|NCT00489177|DEVICE|A|QuickOpt intra-cardiac electrogram optimization
48449414|NCT00489177|DEVICE|B|Single optimization in initial month post-implant
48449415|NCT03548363|DIETARY_SUPPLEMENT|Gingest powdered extract obtained from Ginger rhizomes|"Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate"
48449416|NCT03548363|DIETARY_SUPPLEMENT|Placebo|200 mg/d maltodextrin
48449417|NCT06254781|DRUG|Luspatercept|Erythroid Maturation Agent
48279342|NCT01120626|DRUG|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
48279343|NCT01120626|DRUG|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
48279344|NCT03989830|DRUG|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
48449418|NCT01791686|DRUG|CDX-1135|
48449419|NCT03343535|DEVICE|OCS Lung Preservation|OCS Lung Preservation
48449420|NCT00760825|BIOLOGICAL|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
48449421|NCT02739503|DEVICE|Ultrasound|Patients will receive ultrasound in the ultrasound unit at Hillel Yaffe Medical Center within 10 days before onset of induced or spontaneous labors. The ultrasound team has been trained in FHC , Estimated Fetal Weight (EFW) and Biparietal Diameter (BPD) measurement .Optimal ultrasound measurements of FHC and BPD will be obtained. The average of 3 fetal head circumference measurements will be recorded. Investigators consider the FHC and BPD to be optimal when a clear outline of the entire fetal skull is measured, and the landmarks (the thalamus, cavum septum pellucidum and choroid plexus in the atrium of the lateral ventricles) are visualized. Subsequent information of labor outcome as well as normal head circumference ,post-delivery will be obtained from maternal and neonatal medical records.
48449422|NCT03719040|DEVICE|Physiologic pacing device implant|An alternative and potentially more effective pacing strategy for patients with electrical conduction abnormalities is physiologic pacing. Physiologic pacing is achieved by delivering a pacing stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch (LBB) of the His-Purkinje system, with a permanent lead. Physiologic pacing activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct electrical dyssynchrony. Physiologic pacing has emerged as a feasible and safe alternative to pacemaker therapy and CRT with clinical and electrophysiological advantages.
48449423|NCT04737863|PROCEDURE|Endodontic retreatment|Root canal retreatment in cases with secondary root canal infection
48449424|NCT03799835|DRUG|BCG|Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
48449425|NCT03799835|DRUG|Atezolizumab|IV perfusion
48449426|NCT03730168|OTHER|circuit weight training program|30 male diabetic patients performed circuit weight training for 12 weeks
48449427|NCT03612440|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
48449428|NCT03612440|OTHER|normal saline|receive matching placebo (equal volum of normal saline)
48449429|NCT05686694|OTHER|Video Education|"Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as Instagram, which is the most used social media platform by pregnant women. In the Instagram user name @ogttegitim account, 6 education videos that will be created and shared."
48449430|NCT03025984|BEHAVIORAL|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
48449431|NCT05636319|BIOLOGICAL|ABO1020|Vaccine
48449432|NCT05636319|BIOLOGICAL|Placebo|Placebo
48449433|NCT03975075|BEHAVIORAL|Psychophysiological monitoring|30 minutes of one channel (ECG) physiological monitoring with Mindfield eSense Pulse.
48449434|NCT03975075|BEHAVIORAL|Biofeedback training|Traditional resonance frequency training with the Mindfield eSense Pulse smartphone application. Using visual feedback of real time parameters of HRV and the use of controlled breathing, participants are trained to reach a relaxed state.
48449435|NCT03254225|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
48449436|NCT06272669|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
48449437|NCT06272669|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
48449438|NCT06491706|OTHER|the was no intervention|there was no intervention in this observational study
48449439|NCT01552317|OTHER|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
48449440|NCT01112254|PROCEDURE|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
48449441|NCT05916131|BEHAVIORAL|Basic Education|2-week text message intervention for providing knowledge about hypoglycemia management and prevention.
48449442|NCT05916131|BEHAVIORAL|Hypoglycemia Symptom Detection Training|10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.
48449443|NCT05916131|BEHAVIORAL|Education Plus|10-week text message intervention for helping people consider how they think of hypoglycemia.
48449444|NCT05124366|PROCEDURE|dental prophylaxis + oral hygiene instructions|Follow up: 2 weeks and 4 weeks
48449445|NCT02724605|BIOLOGICAL|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
48449446|NCT02724605|BIOLOGICAL|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
48449447|NCT05383807|BEHAVIORAL|Warna-Warni Waktu|Six videos and eighteen reinforcer activities
48449448|NCT01466166|BIOLOGICAL|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
48449449|NCT01804608|OTHER|Strength|
48449450|NCT01804608|OTHER|Sensorimotor|
48449451|NCT02441621|OTHER|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
48449452|NCT02441621|OTHER|premedication|patients receive premedication with midazolam 7.5 mg p.o.
48449453|NCT02441621|OTHER|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
48449454|NCT02441621|OTHER|central venous catheter|a central venous catheter in the right or left internal jugular vein.
48449455|NCT02441621|OTHER|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
48449456|NCT02441621|OTHER|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
48449457|NCT02441621|OTHER|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
48449458|NCT05266313|BEHAVIORAL|Oncosexology program|Thematic workshops throughout the year
48449459|NCT06064968|OTHER|Intermittent bladder catheterization|Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
48449460|NCT06628219|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
48449461|NCT00679081|DEVICE|CelTx|Single application; split-mouth design
48449462|NCT00679081|OTHER|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
48449463|NCT03853005|OTHER|HVHDF|Patients will receive HVHDF treatment for 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 70 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.
48449464|NCT03853005|OTHER|controlled|Patients will receive the usual care
48449465|NCT04537663|DRUG|Bacille Calmette-Guérin (BCG)|Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
48449466|NCT04537663|DRUG|Placebo|Intradermal injection of sterile 0.9% NaCl.
48449467|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3 and low dose total body irradiation (TBI) 200 cGY on day -2 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
48620470|NCT04925440|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714® strain|Probiotic capsules containing 5 x 10\^9 CFUs, corn-starch and magnesium stearate.
48620471|NCT04925440|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn-starch and magnesium stearate only.
48620472|NCT03345797|DRUG|Testosterone Nasal Gel [Natesto]|nasal gel containing 4.5% w/w testosterone
48620473|NCT00090688|BIOLOGICAL|meCS6 + LT(R192G)|
48620474|NCT03630900|OTHER|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
48620475|NCT05047926|BEHAVIORAL|Behavioral Counseling|Undergo behavioral counseling
48620476|NCT05047926|DIETARY_SUPPLEMENT|Nutritional Supplement Drink|Given Boost or Ensure
48449468|NCT04362293|DRUG|hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus|"The conditioning regimen will consist of hydroxyurea (30mg/Kg) and azathioprine (3mg/Kg) by mouth daily from day -60 to day -8, alemtuzumab subcutaneously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on days -5 to -3), thiotepa intravenously (10mg/Kg) on day -3, plerixafor (0.24mg/Kg) subcutaneously every 12 hours on days -3 and -2 and low dose total body irradiation (TBI) 200 cGY on days -2 and -1 with gonadal shielding (if possible). The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x10\^6/kg recipient weight.~GVHD prophylaxis will be cyclophosphamide (50mg/Kg) intravenously on days +3 and +4 and sirolimus with a loading dose 3 mg/m2 starting on day +5. Sirolimus dose will be adjusted to maintain a target trough level 5-15 ng/mL. Low dose donor lymphocyte infusions will begin on day +28 and continue till donor lymphocyte chimerism reaches at least 90% donor."
48449469|NCT06486623|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
48449470|NCT06486623|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
48449471|NCT01978743|DRUG|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
48449472|NCT06448104|OTHER|Dry needling and immersive virtual reality|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~The procedure will be carried out simultaneously with the use of immersive virtual reality distraction software, applied through MetaQuest 2 virtual reality glasses. This procedure consists of immersive visualization (video and sound images that represent scenes related to relaxation).~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
48449473|NCT06448104|OTHER|Dry needling|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
48449474|NCT00766701|PROCEDURE|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
48449475|NCT05535062|DEVICE|repetitive Transcranial Magnetic Stimulation|the administration of a series of magnetic stimuli to the brain for the purpose of altering brain function
48449476|NCT05657860|DRUG|Guanfacine Extended Release|Initial dose for all participants will be 1mg per day. If the medication is well tolerated, the dose can be raised to 2 mg until day 28 and increased to 3 mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed., the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8 timepoint, the study will be unblinded.and subjects will continue treatment for 8 weeks.
48449477|NCT05657860|OTHER|Placebo|Placebo will be administered concurrently with GXR during trials.
48449478|NCT02226432|PROCEDURE|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~* Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~* Comparision of both groups will be statistified"
48449479|NCT02226432|DEVICE|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
48449480|NCT02226432|OTHER|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
48449481|NCT05084677|COMBINATION_PRODUCT|Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy|Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
48449482|NCT04363359|BIOLOGICAL|0.5ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
48449483|NCT04363359|BIOLOGICAL|0.25ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
48449484|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/V)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains
48449485|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/Y)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains
48449486|NCT01143311|GENETIC|Arm A|"4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor"
48449487|NCT03611608|DRUG|LY3316531|Administered IV
48449488|NCT03611608|DRUG|Placebo|Administered IV
48620477|NCT05047926|OTHER|Physical Activity|Complete physical activity assignments
48620478|NCT05047926|OTHER|Survey Administration|Complete surveys
48620479|NCT05047926|PROCEDURE|Computed Tomography|Undergo CT scans
48449489|NCT02470247|OTHER|Remote Ischemic Preconditioning (RIPC)|"RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
48449490|NCT02470247|OTHER|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
48449491|NCT03953287|DRUG|Paracetamol|A randomized, cross over design
48449492|NCT06626529|BEHAVIORAL|Guided mindfulness meditation|Watching a video of a guided mindfulness meditation include paying attention to the breath, promoting natural breathing without force; body scan, directing awareness from the head down to the toes, allowing tension to release in each area. The intervention emphasizes observing sensations without judgment, fostering a state of relaxed awareness.
48449493|NCT06626529|BEHAVIORAL|Scenery video|Watching a ten-minute video of calming music and images
48449494|NCT04492540|OTHER|aerobic exercise and MIND diet program|the aerobic exercise in form of treadmill training intensity of exercise moderate intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX), time of session 60 min initial 10 min warm up exercise on treadmill in low intensity and target phase 40 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercise 3 times per week for 12 weeks
48449495|NCT04492540|OTHER|MIND diet program|control group will receive diet program for 12 weeks
48449496|NCT01699191|DIETARY_SUPPLEMENT|Probiotic|
48449497|NCT01699191|DIETARY_SUPPLEMENT|Placebo|
48449498|NCT03407287|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
48449499|NCT03407287|PROCEDURE|Standard of care invasive vascular monitoring|Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
48449500|NCT03407287|PROCEDURE|Standard noninvasive vascular monitoring|Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
48449501|NCT02891980|BIOLOGICAL|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
48449502|NCT02891980|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
48449503|NCT06227858|DIETARY_SUPPLEMENT|Safr'Inside supplement (Activ'Inside, SAS)|Dietary supplementation will be taken in addition to habitual diet of the patients
48449504|NCT06227858|OTHER|Plcebo|Placebo capsule (matched to the experimental intervention in terms of colours and taste, without the active compounds saffron)
48620480|NCT05047926|PROCEDURE|Biospecimen Collection|Undergo blood collection
48620481|NCT05047926|BEHAVIORAL|Health Education|Complete Resilient Living program
48098239|NCT05921409|DIETARY_SUPPLEMENT|Extra Virgin Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Extra Virgin Olive Oil (treatment group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
48279345|NCT03989830|DRUG|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
48279346|NCT01355406|DEVICE|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
48279347|NCT03809624|DRUG|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
48279348|NCT03809624|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
48279349|NCT00443521|DRUG|Triamcinolone Acetonide 4 mg intravitreal injection|
48279350|NCT00443521|PROCEDURE|Panretinal photocoagulation|
48279351|NCT05319860|DRUG|Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)|Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
48279352|NCT05319860|DRUG|Aromatherapy Care|An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
48279353|NCT06656585|OTHER|Individual food selectivity protocol|"Children in the experimental group wear Oculus headsets and interact with virtual foods for 20 minutes. In the Pairing in the Kitchen phase, Oculus is removed. Two identical plates with 6 foods are placed in front of the child. The operator, seated next to the child, interacts with the food without eating it, maintaining a positive expression, and discussing non-food topics. No prompts to eat are given, and the child can leave at any time. Progress to the next phase if the child sits calmly for 30 seconds across 3 sessions.~Shaping Phase: Two identical plates are prepared. The operator comments on the food and keeps a small container of the child's favorite food visible but out of reach. Any food-related behavior is reinforced with praise and the favorite food. Target behaviors are adjusted if no response occurs for 15 seconds or if negative emotions are observed. Differential reinforcement is used."
48449505|NCT03463226|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
48449506|NCT03463226|DIAGNOSTIC_TEST|Muscle Sympathetic Nerve Activity|Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
48449507|NCT03463226|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry|Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
48449508|NCT03463226|DIAGNOSTIC_TEST|Venous occlusion plethysmography|Venous occlusion plethysmography was used to assess non-invasively blood flow.
48449509|NCT03463226|DIAGNOSTIC_TEST|Blood sample collection|Blood samples were drawn in the morning after 12h overnight fasting.
48449510|NCT03463226|DIAGNOSTIC_TEST|Dynamometers for Handgrip Strength|Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
48449511|NCT02485977|DEVICE|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
48279354|NCT06656585|OTHER|Traditional food selectivity protocol|"Step 1:Pairing in the Kitchen Propose enjoyable activities in the kitchen. Move to Step 2 when the child plays in the kitchen for 5 minutes over 3 consecutive sessions.~Step 2:Transition to Kitchen Two plates with 6 identical foods are placed in the kitchen. The operator engages the child in a welcome game, waiting 30 seconds for spontaneous interaction. If no response, the operator prompts the child to go to the kitchen. If the child doesn't follow within 30 seconds, the session is postponed. The operator sits next to the child and interacts with the food, without encouraging the child to eat. Progress when the child stays seated for 30 seconds without problem behavior for 3 sessions.~Step 3:Shaping Two plates are prepared, and the operator comments on the food. A visible container with the child's favorite food is used for reinforcement. Target behaviors are reinforced with praise and the favorite food. Adjust behaviors if there's no response for 15 seconds or negative emotions occur"
48449512|NCT06269744|BEHAVIORAL|Proactive Screening Outreach|Individuals in the interventional arm will receive an information letter, followed by mailed FIT kit. Individuals that do not respond will receive reminder phone calls. Individuals that do respond will receive navigation to assist with completion of FIT and the colonoscopy if FIT is abnormal. Clinic processes will be closely followed and the primary care provider will be informed of the program.
48449513|NCT05651191|DRUG|Human CD19 Targeted DASH CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
48449514|NCT00599079|DRUG|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
48449515|NCT01249651|DRUG|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
48449516|NCT04236856|DEVICE|Robotic Endovascular Procedure|After providing written informed consent, subjects with cerebral aneurysms may have their aneurysm treated using the CorPath GRX System.
48449517|NCT03590782|OTHER|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
48449518|NCT03155672|BEHAVIORAL|Art therapy|Art Therapy
48449519|NCT03437265|DRUG|PLENVU powder for oral solution|PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
48449520|NCT03267381|OTHER|Blood draw (before surgery)|Blood will be drawn before surgery
48449521|NCT03267381|OTHER|Blood draw (every 3 months)|Blood will be drawn every 3 months
48449522|NCT03267381|OTHER|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
48449523|NCT04308785|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on the first day of each 21-day cycle.
48449524|NCT04308785|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each 21-day cycle.
48449525|NCT04308785|OTHER|Placebo|Placebo matching to tiragolumab will be administered at a dose of 600 mg intravenously on the first day of each cycle.
48449526|NCT00935012|DRUG|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
48449527|NCT00665470|DRUG|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
48449528|NCT03774680|DRUG|Cetuximab nanoparticles|The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
48449529|NCT03774680|DRUG|Oral approved anticancer drug|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
48449530|NCT00870662|DEVICE|AFS System|AFS System with patient specific flow rate
48449531|NCT01721681|BIOLOGICAL|FACTOR X|
48449532|NCT03380845|DEVICE|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
48449533|NCT03380845|DEVICE|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
48449534|NCT00041392|DRUG|Magnesium|100 mg/kg
48449535|NCT00041392|DRUG|0.9% saline|Placebo
48449536|NCT00000925|DRUG|Optimune oral nutritional supplement|
48449537|NCT05545826|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with early stage Parkinson's disease
48620482|NCT05047926|OTHER|Medical Device Usage and Evaluation|Wear a FitBit
48620483|NCT00687518|DRUG|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
48620484|NCT00687518|DRUG|Placebo|Intravenous injection of equivalent volume of saline serum
48449538|NCT01706094|OTHER|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
48449539|NCT01183910|DIETARY_SUPPLEMENT|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
48449540|NCT01183910|DIETARY_SUPPLEMENT|Calcium Carbonate|Oral Tablet Taken Twice a Day
48449541|NCT04019015|DRUG|Prothrombin Complex Concentrate, Human|Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors
48449542|NCT04019015|DRUG|Placebo|Normal saline solution
48449543|NCT05605535|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
48449544|NCT05605535|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
48449545|NCT05605535|DRUG|Carboplatin|AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)
48449546|NCT05605535|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
48449547|NCT06152458|DRUG|Vitamin C|Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
48449548|NCT00571935|DRUG|insulin aspart|
48449549|NCT00571935|DRUG|soluble human insulin|
48449550|NCT03011476|DRUG|Donepezil|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
48449551|NCT03011476|DRUG|Placebos|"1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks"
48449552|NCT01471353|DRUG|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
48449553|NCT06321016|OTHER|Physical exercise program|At least two sessions a week for a 6-month supervised and individualized physical exercise program that will have two phases: one that will be carried out in person in the hospital environment taking advantage of medical visits, and a second phase that will allow the patient to carry out the exercise sessions from home with live virtual supervision.
48449554|NCT06321016|OTHER|Type of the physical exercise program|Two types of intervention are proposed depending on the age of the patients: Exercise intervention for adolescents (12 to 18 years): training will be based on strength training (2 - 3 sets of 8 - 12 repetitions) with elastic bands, weights, weights, medicine balls or body weight and aerobic work on a stationary bike, treadmill or other aerobic exercises. Sessions will last about 30-60 minutes (depending on the patient's situation). Exercise intervention for children (4 to 11 years old): The aim will be to work on basic motor skills through play, thus trying to avoid the delay in motor development, and to indirectly work on their physical condition to better cope with the effects of the treatments. Music, games that require movement and materials such as balls, hoops, etc., will be used to motivate the child to move while enjoying themselves. This will be done in sessions of 20 - 40 minutes.
48449555|NCT00958334|DRUG|Proellex®|25 mg daily (two 12.5 mg capsules)
48449556|NCT05758415|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
48449557|NCT05758415|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
48449558|NCT03364192|BEHAVIORAL|Whole Health Coaching|Veterans Health Administration variation of integrative health coaching.
48620485|NCT03954210|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.
48620486|NCT03954210|BEHAVIORAL|Sleep and Lifestyle Education|Participants in the sleep and lifestyle education group will attend six weekly, in-person, one-on-one, stretching, and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
48620487|NCT03111433|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
48449559|NCT04178850|BIOLOGICAL|GB242|GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
48449560|NCT04178850|BIOLOGICAL|Infliximab|Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
48449561|NCT06553235|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a multi-component intervention consisting of sleep restriction, stimulus control therapy, relaxation therapy, cognitive therapy, and sleep hygiene education
48449562|NCT06553235|BEHAVIORAL|Sleep hygiene education|- Sleep hygiene education includes information on lifestyle factors (diet, exercise, substance use) and environmental variables (noise, light, temperature) affecting sleep quality.
48449563|NCT03076593|OTHER|Exposure: Fall|Participants will be asked about prior falls
48449564|NCT05306158|OTHER|CC+ECIG Condition|Participants will push CC- and ECIG-related pictures.
48449565|NCT05306158|OTHER|CC Condition|Participants will push CC-related images and push and pull ECIG-related pictures equally often.
48449566|NCT05306158|OTHER|Sham Condition|Participants will pull and push CC- and ECIG-related pictures equally often.
48620488|NCT03111433|DRUG|Insulin|multiple dose insulin injection therapy
48620489|NCT00516607|DRUG|enzastaurin hydrochloride|
48620490|NCT00516607|DRUG|temozolomide|
48620491|NCT00516607|OTHER|pharmacological study|
48449567|NCT02942563|DRUG|FOLFOXIRI|"Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME."
48449568|NCT03757845|OTHER|Mediterranean Diet|subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
48449569|NCT00649987|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
48449570|NCT00649987|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
48449571|NCT02744794|DEVICE|Dermal Cooling System|Treatment with cryotherapy.
48449572|NCT03958396|DRUG|Remifentanil Infusion|15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
48449573|NCT06561997|DEVICE|Robot-assisted|received percutaneous pedicle screw fixation (PPSF) with robotic assistance
48449574|NCT06561997|DEVICE|Free-hand|received percutaneous pedicle screw fixation (PPSF) without robotic assistance
48449575|NCT03370263|DRUG|Benlysta|Benlysta will be administered intravenously or subcutaneously.
48449576|NCT04741217|OTHER|Not an interventional study|No interventions are implemented. This is an observational study of respiratory droplet aerosolisation during respiratory procedures.
48449577|NCT00304538|DRUG|very low dose (VLD) glucagon|
48449578|NCT02525458|DEVICE|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
48449579|NCT02525458|DEVICE|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
48449580|NCT05806853|DRUG|68Ga-PSMA|Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)
48449581|NCT05806853|DRUG|68Ga-RM2|Bombesin receptor antagonist (68Ga-RM2)
48449582|NCT04476160|DIETARY_SUPPLEMENT|Cinnamon|children recipe 3 grams by day of cinnamon
48449583|NCT04974684|DEVICE|HeartMate 3|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
48449584|NCT04974684|DRUG|Apixaban|Patients implanted with HeartMate 3 will be randomized in 2:1 ratio in interventional and control group. Patients in interventional group will be switched to therapy with apixaban instead of warfarin.
48449585|NCT03913065|DIAGNOSTIC_TEST|CT|"Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI)."
48449586|NCT06035250|DRUG|Neoadjuvant Chemotherapy|Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.
48449587|NCT06121973|BEHAVIORAL|educational group|Experimental group received online video-supported breastfeeding education in an online classroom for 6-8 people and individual counselling via phone and Whatsapp application when needed for 3 weeks.
48449588|NCT05625412|DRUG|BMS-986360|Specified dose on specified days
48449589|NCT05625412|DRUG|Docetaxel|Specified dose on specified days
48449590|NCT05625412|DRUG|Nivolumab|Specified dose on specified days
48449591|NCT05625412|DRUG|Capecitabine|Specified dose on specified days
48449592|NCT00777972|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
48449593|NCT03861247|DRUG|Phosphate-binder intervention|Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
48449594|NCT03861247|DIETARY_SUPPLEMENT|Phosphorus-restricted dietary intervention|Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
48449595|NCT04236596|DEVICE|Participants received a Neurostimulator, which was used to map the pudendal nerve|Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.
48449596|NCT05884190|OTHER|Remote Medical Model (RMM)|Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
48449597|NCT05884190|OTHER|Community Health Model (CHM)|Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
48620492|NCT06439680|OTHER|"HASCV-R Health Programme"|"HASCV-R program Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
48620493|NCT02995148|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)
48620494|NCT02995148|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
48449598|NCT05884190|OTHER|SoC|SoC for Postpartum Hypertension
48449599|NCT04913974|PROCEDURE|Uni-condylar knee arthroplasty|Surgical replacement of medial compartment of arthritic knee with an implant
48449600|NCT04243538|BEHAVIORAL|I-HoME|I-HoME will consist of two components: (1) synchronous live video interactions between patients/CGs and a hospice nurse; and (2) educational videos.
48449601|NCT03919435|DRUG|Trimethoprim Sulfamethoxazole|Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
48449602|NCT05286047|DIETARY_SUPPLEMENT|Bifidobacterium longum CCFM1029|Subjects take one capsule containing Bifidobacterium longum CCFM1029 daily at bedtime.
48449603|NCT05286047|DIETARY_SUPPLEMENT|Placebo|Subjects take one capsule containing maltodextrin daily at bedtime.
48449604|NCT04940312|BEHAVIORAL|App-based physical activity coaching|Individualized app-based coaching via a smartphone
48449605|NCT04940312|BEHAVIORAL|No Intervention: Observational Cohort|no Intervention
48449606|NCT04940312|BEHAVIORAL|Intervention Group 1|pedometer-based tracking of physical activity
48449607|NCT01932177|DRUG|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
48449608|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
48449609|NCT01932177|DRUG|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
48449610|NCT01932177|DRUG|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
48449611|NCT05929352|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
48449612|NCT03935880|DEVICE|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
48449613|NCT03935880|PROCEDURE|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
48449614|NCT06155721|DEVICE|Virtual Reality Cognitive Stimulation Program|Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.
48449615|NCT00268879|DRUG|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
48449616|NCT00303940|DRUG|carboplatin|
48449617|NCT00303940|DRUG|talabostat mesylate|
48449618|NCT00303940|DRUG|temozolomide|
48449619|NCT00303940|OTHER|pharmacological study|
48279355|NCT01518530|DEVICE|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
48449620|NCT02388971|DRUG|MLN1202|MLN1202 solution
48449621|NCT02388971|DRUG|Placebo|MLN1202 placebo-matching solution
48449622|NCT02901379|DRUG|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
48449623|NCT02901379|DRUG|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
48449624|NCT03969693|RADIATION|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
48449625|NCT06542458|BEHAVIORAL|Assessments|Participants will undergo a standard battery of neuropsychological measures, behavioral questionnaire, and functional assessment to monitor cognition and function over time. Clinical data obtained as part of standard of care will be collected from the medical record
48449626|NCT06542458|OTHER|Neuroimaging volumetric measures|Neuroimaging volumetric measures will be obtained from already conducted standard of care neuroimaging.
48449627|NCT06542458|OTHER|Biofluid samples|Biofluid sampling data will be obtained through another protocol. All participants will be required to sign that consent to participate in this trial.
48449628|NCT01997372|DRUG|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) \>1×109/L.
48449629|NCT06111248|OTHER|Training|Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
48449630|NCT03118557|OTHER|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
48449631|NCT04715295|DRUG|Doxycycline Tablets|Doxycycline 200 mg daily for 7 days
48449632|NCT04715295|DRUG|Rivaroxaban 15Mg Tab|Rivaroxaban 15 mg tablets daily from day 1 to day 10
48449633|NCT04715295|COMBINATION_PRODUCT|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5
48449634|NCT03158467|OTHER|Surveys|Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
48449635|NCT01115647|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
48620495|NCT05672056|PROCEDURE|Computer guided placement of a stock plate pre-bent on a 3D printed model|We aim to design a novel guide that can secure the construct of the fibular segments and pre bent plate onto the native mandible and effectively and efficiently translate the VSP into the surgical field.
48449636|NCT01115647|DIETARY_SUPPLEMENT|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
48449637|NCT01115647|BEHAVIORAL|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
48449638|NCT03280862|DEVICE|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
48449639|NCT01966666|DRUG|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
48449640|NCT01966666|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
48449641|NCT01966666|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
48449642|NCT01966666|DRUG|Placebo|500mL 0.9% sodium chloride.
48449643|NCT04350723|PROCEDURE|Awake Proning|The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.
48449644|NCT03450057|DRUG|Daratumumab with dexamethasone|"Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients \>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle."
48449645|NCT06046430|OTHER|Assessment|The same assessments will be made to participants in both groups.
48449646|NCT01450592|OTHER|No drug|Diabetic Population
48449647|NCT01450592|OTHER|No drug|Non-Diabetic Population
48449648|NCT04548375|DEVICE|SCS|Conventional SCS implants approved through all payors(government and private) for FDA approved indications
48449649|NCT01788423|DEVICE|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
48449650|NCT06563297|DRUG|Alfentanil|We first start with alfentanil 100 ng/ml, and use the up and down method as adjust 25 ng/ml of concentration of alfentanil each time. An SPI higher than 80 and hyperdynamics (the increased HR and MBP up 20% of baseline or HR\>100bpm and ABP\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 25 ng/ml at the next patient; an SPI lower than 80 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 25 ng/ml during skull pin fixation. If the analgesia is inadequate, increase alfentanil concentration will be prescribed. On the other hand, if analgesia is adequate, however hyperdynamics was noted, beta blocker or calcium channel blocker will be prescribed. If hypotension (ABP\<90/50 mmHg) or bradycardia (HR\<50 bpm) occur, we first stop alfentanil infusion and treated with ephedrine or atropine, respectively.
48449651|NCT00944294|DRUG|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
48449652|NCT00944294|DRUG|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
48449653|NCT04222790|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin paclitaxel (GM1 is a single infusion).
48449654|NCT04222790|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin paclitaxel (placebo as a single infusion)
48449655|NCT06627725|BEHAVIORAL|Patient-Family Communication|Patient-Family Communication
48449656|NCT04354363|OTHER|Platelet rich plasma|Giving women PRP before ICSI
48449657|NCT00469521|DRUG|Refresh Tears, 9582X|
48279356|NCT01569581|BIOLOGICAL|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
48279357|NCT01569581|BIOLOGICAL|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
48279358|NCT01569581|BIOLOGICAL|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
48449658|NCT03319108|OTHER|Exercise|Pulmonary Rehabilitation Program for 8 weeks
48449659|NCT05363059|DRUG|Hypoglycemic drugs|drug
48449660|NCT05363059|PROCEDURE|Bariatric surgery|surgery
48449661|NCT06216964|DIAGNOSTIC_TEST|Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) NAAT(s)|Test every week after the start of treatment, until NAAT negativation and up to a maximum of 4 weeks
48620496|NCT03991767|OTHER|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
48620497|NCT03991767|DIAGNOSTIC_TEST|Serology HIV|Realization of HIV serology for included patients.
48620498|NCT01750437|DRUG|YH1885L(Revaprazan)|
48620499|NCT01750437|DRUG|Esomeprazole 20mg|
48620500|NCT01750437|DRUG|placebo|
48620501|NCT03877809|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
48620502|NCT06480630|DRUG|Basiliximab|Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
48449662|NCT06561516|PROCEDURE|Arm I (Red ginseng)|"Step 1. Confrim the inclusion and exclusion criteria to select participants and abtain informed consent before surgery.~Step 2. Before surgery, research nurses randomly assign patients to either the Red ginseng or Control group (single-blind study).~Step 3. Blood tests and stool samples following rectal enema are collected from all patients before surgery.~Step 4. Depending on the type of gastrointestinal cancer (stomach cancer, pancreatobiliary cancer, colorectal cancer), radical resection surgery is performed.~Step 5. From 1 to 4 months after surgery, a three months period is designated for the Red ginseng group to take red ginseng tablets as instructed, with compliance assessements included.~Step 6. Four months after surgery, blood tests and stool samples are collected from all patients.~Step 7. After obtaining samples from the final registered patients, we will commission a contracted institution to conduct microbiome analysis test."
48449663|NCT03606174|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
48449664|NCT03606174|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
48449665|NCT03606174|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
48449666|NCT03606174|DRUG|Enfortumab vedotin|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
48449667|NCT03082872|DEVICE|Cemented K-wire|Fracture of proximal phalanx was treated with Cemented K-wire.
48449668|NCT03082872|DEVICE|Transfixion Pinning|Fracture of proximal phalanx was treated with transfixion pinning.
48449669|NCT02414711|OTHER|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (\<1.75)
48449670|NCT02414711|OTHER|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
48449671|NCT05947591|BEHAVIORAL|foot posture index|the tendency to foot pronation in healthy subjects will be compared during one hour of walking versus one hour of running in subjects who usually run.
48449672|NCT00127985|DRUG|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
48449673|NCT02892747|BEHAVIORAL|Educational Program|
48449674|NCT05826327|DRUG|Esketamine|The drug esketamine will be added to the experimental group as opposed to the control group.
48449675|NCT05826327|DRUG|Sufentanil|Sufentanil for labour analgesia in the control group
48449676|NCT02299453|BEHAVIORAL|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
48449677|NCT03910231|DRUG|Tolvaptan Oral Tablet|Tolvaptan, to block V2R
48449678|NCT02305225|BEHAVIORAL|Sleep Deprivation|
48449679|NCT04642820|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
48449680|NCT04642820|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
48449681|NCT06313034|BEHAVIORAL|Breastfeeding education based on motivational interviewing technique|"Breastfeeding education based on motivational interviewing technique; Breast milk properties, benefits to mother and baby, breastfeeding positions, the relationship between breastfeeding and attachment, signs of hunger in the newborn, Breastfeeding frequency, duration and termination, Breast milk expressing methods, Expressions showing that the newborn has enough milk, Breast milk storage will cover the topics. These topics will be given based on motivational interviewing technique.~According to the motivational interviewing technique, the mother's intention, importance and confidence-sufficiency regarding breastfeeding will be determined and firstly, an agenda will be created on issues related to breastfeeding with the mother. Each session will be conducted by following the open-ended questioning, verification, reflective listening and summarizing approaches of the motivational interviewing technique."
48449682|NCT02917525|DIETARY_SUPPLEMENT|Vitamin K2|
48449683|NCT02917525|OTHER|Placebo|
48449684|NCT00834964|DRUG|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
48449685|NCT00834964|DRUG|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
48449686|NCT02906540|PROCEDURE|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
48449687|NCT02906540|PROCEDURE|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
48449688|NCT06561373|BEHAVIORAL|Calm & Alert yoga and mindfulness|The Calm \& Alert protocol is multisensorial, with successive opportunities to practice the explicit concepts taught throughout the lessons using yoga and mindfulness-techniques. Each class has a similar structure of songs, breathing, warm-ups, yoga poses, mindful games, and rest involving meditation with child-friendly language. The study includes the recommended materials of a Hoberman sphere (breathing ball), chime, mind/body/breath icons, two small mason jars (one with mud and one with clear water), yoga mats for students, pictures of feelings (happy, sad, angry, scared, surprised, disgusted), and an on/off switch.
48449689|NCT02209194|DEVICE|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
48449690|NCT05628545|BIOLOGICAL|GDKM-100 injection|Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
48449691|NCT02757105|DRUG|BEKINDA|
48449692|NCT02757105|DRUG|Placebo|
48449693|NCT03521973|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
48449694|NCT03521973|OTHER|Normal Saline|0.9% Sodium chloride
48449695|NCT02603055|BIOLOGICAL|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
48449696|NCT02603055|BIOLOGICAL|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
48449697|NCT02251886|OTHER|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
48449698|NCT02251886|OTHER|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
48449699|NCT04514757|DEVICE|active tVNS|20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.
48449700|NCT04514757|DEVICE|sham tVNS|Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
48449701|NCT06559670|OTHER|Blood sampling|- Collection and analysis of blood samples
47928157|NCT05050591|DEVICE|Patient-Specific Silicone Airway Stent|The Patient-Specific Airway Stent is a silicone stent indicated for use in adults that have stenosis of the airway. Current silicone stents have stock dimensions that do not conform to the patient's airway anatomy. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally design the stent to his/her desired dimensions. Finally, according to the physician's design, a patient-specific stent can be manufactured using additive manufacturing technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
47928158|NCT00344942|DRUG|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
48449702|NCT00650377|DRUG|Finasteride Tablets 5 mg|5mg, single dose fed
48449703|NCT00650377|DRUG|Proscar® Tablets 5 mg|5mg, single dose fed
48449704|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, fructooligosaccharides, inulin|"The first round supplementation will be administered for 3-month period (i.e. 12 weeks). One dose/day (2g sachet) is intended to be administered orally once a day after dissolving in water.~At the scheduled visits/phone contacts \[i.e., baseline, 12 weeks, and 16 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
48449705|NCT06448663|DIETARY_SUPPLEMENT|alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin|"The second round supplementation will be administered for 3-month period (i.e. 12 weeks). For participants weighing \<30 kg, a 4 g dose (i.e., one 4 g sachet) is intended to be administered orally once a day after dissolving in water. For participants weighing ≥30 kg, a 4 g dose (i.e., 4 g sachets) is intended to be administered orally twice a day (12h interval) after dissolving in water.~At the scheduled visits/phone contacts \[i.e., 28 weeks and 32 weeks (post washout)\], seizure frequency and entity of the critical episodes will be recorded. Gut microbiome characterization, clinical scales and dietary intake will be assessed."
48449706|NCT01626287|OTHER|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
48449707|NCT01626287|OTHER|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
48449708|NCT04776226|DRUG|Citalopram|Antidepressant use in patients with depression
48449709|NCT05187208|DRUG|Niraparib|"Niraparib 200mg or 300mg (once daily \[QD\])\*~\*The recommended starting dosage of niraparib is 200mg QD. For patients who weigh ≥77 kg and have baseline platelet count ≥150,000/μL, the recommended starting dosage is 300 mg QD."
48449710|NCT06223191|OTHER|Brief Negotiated Interview|"The BNI is a specialized brief intervention for the medical setting, has foundations in motivational interviewing techniques. The BNI helps health care providers explore health behavior change with patients in a respectful, non-judgmental way within a finite time period. The BNI is in the form of an algorithm, or script, that guides providers through the health intervention with carefully phrased key questions and responses, all at the providers' fingertips"
48449711|NCT06223191|OTHER|Narrative Interview|The Narrative Interview is a therapeutic approach that aims to motivate the individual's conscious and transformative knowledge, skills, and capabilities. This interview is based on the technical components of narrative therapy, where the patient narrates their story, using externalizing language and considering social and political aspects related to the issue. It will focus on exploring past and present feelings, thoughts, and actions.
48449712|NCT04675372|DRUG|Dexmedetomidine|Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
48449713|NCT04675372|DRUG|Midazolam|Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
48449714|NCT04374630|DRUG|Paclitaxel|Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.
48449715|NCT04374630|DRUG|Afuresertib|"Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)"
48449716|NCT02464657|DRUG|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
48449717|NCT02464657|DRUG|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
48449718|NCT02464657|DRUG|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
48449719|NCT02464657|DRUG|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
48449720|NCT02464657|DRUG|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
48449721|NCT00834275|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
48449722|NCT00834275|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
48449723|NCT00194454|BEHAVIORAL|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
47928159|NCT00344942|DRUG|placebo|a double spray into each nostril once daily
47928160|NCT00401388|DRUG|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
48449724|NCT00194454|OTHER|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
48449725|NCT01613872|OTHER|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
48449726|NCT05915091|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a treatment that healthcare providers use for pain and movement issues associated with myofascial trigger points. With this technique, a provider inserts thin needles into or near your trigger points. The needles stimulate your muscles, which causes them to contract or twitch
48449727|NCT05915091|OTHER|Cross Friction Massage|Cross friction massage breaks down scar tissue and remodels the tissue into more flexible, pliable, and functional, healthy soft tissue. Also known as transverse friction massage, this technique is a deep tissue massage technique performed at the site of injury
48449728|NCT01899755|DRUG|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
48449729|NCT01899755|DRUG|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
48449730|NCT01899755|DRUG|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
48279359|NCT01569581|BIOLOGICAL|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
48279360|NCT04391764|DRUG|Naltrexone|Naltrexone at a dose of 50 mg per day
48279361|NCT04391764|DRUG|Placebo oral tablet|Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
48279362|NCT01497392|DRUG|dovitinib lactate|Given PO
48279363|NCT01497392|DRUG|gemcitabine hydrochloride|Given IV
48279364|NCT01497392|DRUG|capecitabine|Given PO
48279365|NCT01497392|OTHER|laboratory biomarker analysis|Correlative studies
48279366|NCT01497392|OTHER|enzyme-linked immunosorbent assay|Correlative studies
48279367|NCT01497392|OTHER|pharmacological study|Correlative studies
48279368|NCT05433129|PROCEDURE|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
48279369|NCT05433129|PROCEDURE|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
48279370|NCT05433129|PROCEDURE|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
48279371|NCT05433129|PROCEDURE|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
48279372|NCT03814746|DRUG|Crizanlizumab (SEG101)|"Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV."
48279373|NCT03814746|DRUG|Placebo|Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
48279374|NCT00448461|DRUG|heparin|comparison between heparin and bivalirudin
48279375|NCT00448461|DRUG|bivalirudin|comparison between heparin and bivalirudin
48279376|NCT01288768|PROCEDURE|Knee arthroscopy|Knee arthroscopy within 4 weeks.
48279377|NCT03091023|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|
48279378|NCT02279316|DRUG|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
48279379|NCT02279316|OTHER|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
48279380|NCT02279316|OTHER|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
48279381|NCT05635708|DRUG|Tislelizumab|Administered by intravenous infusion
48279382|NCT05635708|DRUG|BGB-A445|Administered by intravenous infusion
48279383|NCT05635708|DRUG|LBL-007|Administered by intravenous infusion
48279384|NCT05635708|DRUG|Carboplatin|Investigator's choice; administered by intravenous infusion
48279385|NCT05635708|DRUG|Cisplatin|Investigator's choice; administered by intravenous infusion
48279386|NCT05635708|DRUG|pemetrexed|Investigator's choice; administered by intravenous infusion
48279387|NCT05635708|DRUG|Paclitaxel|Investigator's choice; administered by intravenous infusion
48279388|NCT05635708|DRUG|Nab paclitaxel|Investigator's choice; administered by intravenous infusion
48449731|NCT02982577|DRUG|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
48449732|NCT02982577|OTHER|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
48449733|NCT03989648|OTHER|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
48449734|NCT03989648|OTHER|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
48449735|NCT06540716|DEVICE|Inspire System|Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
48449736|NCT01093963|DRUG|Lisdexamfetamine|oral; 20-70mg/day
48449737|NCT01093963|DRUG|Placebo|oral; 20-70mg/day
48449738|NCT04075578|DRUG|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
48449739|NCT03125135|DEVICE|MightySat RX Pulse Oximeter Sensor|Noninvasive pulse oximeter finger sensor.
48279389|NCT05635708|DRUG|BGB-15025|Administered Orally
48279390|NCT05408858|BEHAVIORAL|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
48279391|NCT04120493|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
48279392|NCT04120493|OTHER|Imitation (sham) surgery|Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull
48279393|NCT00476086|DRUG|Gemcitabine|
48279394|NCT00476086|DRUG|Oxaliplatin|
48279395|NCT00476086|RADIATION|Radiation|
48279396|NCT05177796|DRUG|Carboplatin|Given IV
48279397|NCT05177796|DRUG|Cyclophosphamide|Given IV
48279398|NCT05177796|DRUG|Doxorubicin|Given IV
48279399|NCT05177796|DRUG|Paclitaxel|Given IV
48279400|NCT05177796|BIOLOGICAL|Panitumumab|Given IV
48279401|NCT05177796|BIOLOGICAL|Pembrolizumab|Given IV
48279402|NCT05904587|DEVICE|SureSmile® VPro™|the pain is recorded when the patient is biting on the mouthpiece of the device during the debonding procedure
48279403|NCT05904587|OTHER|ortho technology, sports advantage, thermal forming soft EVA 3mm|the pain is recorded when the patient is biting on the EVA sheet during the debonding procedure
48279404|NCT05904587|OTHER|cotton roll|the pain is recorded when the patient is biting on the cotton roll during the debonding procedure
48279405|NCT01332708|BEHAVIORAL|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
48279406|NCT05033002|BEHAVIORAL|Labda Siku Moja stigma reduction intervention|The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
48279407|NCT03880812|OTHER|Societal cost|Annual societal cost information to the US for carpal tunnel release surgery was displayed.
48279408|NCT03101072|OTHER|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
48279409|NCT03101072|OTHER|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
48279410|NCT03101072|OTHER|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
48279411|NCT00367757|PROCEDURE|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
48279412|NCT00367757|PROCEDURE|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
48279413|NCT00367757|PROCEDURE|Combined approach for AF ablation|Combined trigger and substrate based approach
48279414|NCT00326261|PROCEDURE|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
48279415|NCT00326261|PROCEDURE|Ultrasound|
48279416|NCT00646893|PROCEDURE|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
48279417|NCT02072629|OTHER|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
48279418|NCT06006975|RADIATION|Computed Tomography (CT) and Computed Tomography Angiography (CTA)|CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.
48279419|NCT06006975|DIAGNOSTIC_TEST|Multimodal physiological monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
48279420|NCT03404362|PROCEDURE|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
48279421|NCT02506530|PROCEDURE|intensive decongestive treatment|intensive decongestive treatment
48279422|NCT02506530|DEVICE|Cellu M6|Use of Cellu M6
48449740|NCT03825328|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
48449741|NCT03825328|DRUG|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
48449742|NCT03825328|DRUG|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
48449743|NCT03825328|DRUG|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
48449744|NCT03815903|DRUG|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
48449745|NCT03815903|COMBINATION_PRODUCT|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
48449746|NCT06253260|DRUG|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair|Analgesic Efficacy of Sequential Rapid Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine Injection in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
48449747|NCT06253260|DRUG|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery|Analgesic Efficacy of Sequential Slow Intrathecal Injection Of Dexmedetomidine Followed by Slow Injection of Hyperbaric Bupivacaine in Patients Undergoing Unilateral Inguinal Hernia Repair Surgery
48449748|NCT06318130|DEVICE|Fixed helix, lumenless pacing lead.|Patients will be randomised to the fixed helix, lumenless pacing lead design during LBBP implantation.
48449749|NCT06318130|DEVICE|Extendable helix, stylet-driven pacing lead.|Patients will be randomised to the extendable helix, stylet-driven pacing lead design during LBBP implantation.
48449750|NCT05505747|DRUG|Fisetin|Fisetin is a plant flavanol senolytic found in strawberries, persimmons, and cucumbers. This naturally derived senolytic has few side effects and previous animal models of both osteoarthritis and rheumatoid arthritis have demonstrated that the senolytic supplement fisetin reduces inflammation and slows cartilage breakdown.
48449751|NCT05505747|DRUG|Placebo oral capsule|The oral placebo will consist of corn starch and gelatin capsules
48449752|NCT04277403|RADIATION|Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost|Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a prescribed dose of 30Gy in 12 fractions, 2.5Gy per fraction and a simultaneously integrated boost (SIB) to each brain metastasis of 51Gy to 95% of PTV in 12 Fractions, 4.25Gy per fraction.
48449753|NCT04277403|RADIATION|Single session or hypofractionated stereotactic radiosurgery|Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases. Single session SRS will be delivered in 18 to 22Gy to the tumour encompassing 80% Isodose. Hypofractionated stereotactic radiosurgery (HfSRS) will be delivered in 5 sessions of 6Gy each to the tumour encompassing 80% isodose.
48449754|NCT05674734|BEHAVIORAL|4FM Acceptance Training|4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at IPIN Mental Health Centre for Mokotów and IPiN (1 meeting weekly).
48449755|NCT04979663|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
48449756|NCT01547286|BIOLOGICAL|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is \< 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
48449757|NCT01547286|RADIATION|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
48449758|NCT01547286|DRUG|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
48449759|NCT05947734|DEVICE|"VTS surgical robotic system"|"TheVTS surgical robotic system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track and locate the surgical instruments during the operation. With the help of the robotic arm, the surgeon can make the operation procedure more accurate and safer."
48449760|NCT05841654|DRUG|Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI|The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
48449761|NCT03136627|DRUG|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
48449762|NCT03136627|DRUG|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
48449763|NCT05735145|DRUG|paclitaxel combined with platinum|Adjuvant chemotherapy with paclitaxel combined with platinum
48449764|NCT00835692|DRUG|Clarithromycin|500 mg Tablet
48449765|NCT00835692|DRUG|Biaxin®|500 mg Tablet
48449766|NCT04708028|OTHER|Dog Therapy|The intervention is a therapy dog interaction (e.g. petting) for up to 2 minutes before their appointment and first interaction with the doctor. The subject can pet the dog for as long as they like up until the 2 minute mark.
48449767|NCT00781794|DRUG|NSA-789 at 2 different doses|
48449768|NCT03372187|BEHAVIORAL|DIET-MS|Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
48449769|NCT02082808|DRUG|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
48449770|NCT02082808|DRUG|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
48449771|NCT05954728|BEHAVIORAL|Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)|CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
48449772|NCT05954728|BEHAVIORAL|Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder|Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
48449773|NCT06558500|PROCEDURE|Uterocervical angle|"With the patient in the lithotomy position and empty bladder, care was taken to avoid applying pressure to the cervix with the transvaginal probe. The cervix was aligned in the midline, and the endocervical canal was visualized throughout its length.During cervical measurement, care was taken to ensure that the internal os, external os, and entire endocervical canal were visible in the same image. With the endocervical canal, external os, and internal os linearly displayed on the screen, the angle between the endocervical canal, anterior and posterior uterine segment was measured using the ultrasound's angle measurement feature.For the measurement of the uterocervical angle, the first line of the angle was defined along the endocervical canal used for measuring cervical length, and the second line was drawn from the internal os along the anterior uterine segment for a minimum of two centimeters. The angle between these two lines was recorded as the uterocervical angle in the form."
48449774|NCT02545283|DRUG|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m\^2) intravenous (IV) infusion for 5 days of every treatment cycle.
48449775|NCT02545283|DRUG|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
48449776|NCT02545283|OTHER|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
48449777|NCT06623591|DEVICE|active Transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
48449778|NCT06623591|DEVICE|sham Transcutaneous auricular vagus nerve stimulation|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
48449779|NCT03927300|DEVICE|Telemonitoring Software|Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
48449780|NCT04045925|OTHER|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
48449781|NCT05829421|OTHER|Impairment-specific occupational therapy (OT) intervention|"In parallel with standard practice, patients receive an OT intervention adapted to the specific underlying cognitive impairments that are likely to disturb their performance of ADLs.~The intervention is individualised through a 3-step process: a) a list of dysfunctional ADL process skills is forwarded by the OT to the neuropsychologist (NP), b) the NP identifies the cognitive impairments which are most likely to cause the dysfunctional ADL process skills through a cognitive assessment, c) based on the identified cognitive impairments, the NP and the OT select in collaboration the cognitive strategies that are most likely to benefit the individual patient from a pre-prepared intervention manual. Because of the large heterogeneity in how cognitive impairments impact on ADL performance, the exact way of implementing the selected cognitive strategies into the practice of the individual patient is left to the OT´s clinical judgement."
48449782|NCT01701063|DRUG|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
48449783|NCT01701063|DRUG|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
48449784|NCT01701063|DRUG|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
48449785|NCT06563401|OTHER|prognosis of adult-onset t1d|We are comparing mortality and vascular outcomes in adult-onset T1D to T2D and diabetes-free people
48449786|NCT01958450|PROCEDURE|Er:YAG laser|acne scar treatment using Er:YAG laser
48449787|NCT01958450|PROCEDURE|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
48449788|NCT01895335|DRUG|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
48279423|NCT04775823|PROCEDURE|Hybrid composite nano-ceramic|Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
48449789|NCT05967390|DEVICE|Transcranial Magnetic Stimulation|One time for each day, lasting for three weeks.
48449790|NCT01124175|DRUG|Losartan|100 mg Tablets
48449791|NCT01124175|DRUG|Cozaar®|100 mg Tablets
48449792|NCT04638179|OTHER|Not intervention.Use retrospective case contrl study.|Use retrospective case contrl study.
48449793|NCT03567447|DRUG|Droxidopa|starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
48449794|NCT03567447|OTHER|Placebo|appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
48449795|NCT05350163|BIOLOGICAL|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions|T-cell Receptor α/β Depleted Donor Lymphocyte Infusions following CD34+-selected Allogeneic Stem Cell Transplantation from Related and Unrelated Donors for Patients
48449796|NCT00794547|DRUG|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
48449797|NCT00794547|DRUG|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
48449798|NCT03110848|DRUG|Atorvastatin|Atorvastatin 20 mg daily
47928161|NCT00401388|OTHER|Loperamide|All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
47928162|NCT00401388|OTHER|Allopurinol|Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
48279424|NCT06357286|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
48279425|NCT06441630|DRUG|AD-227A|Per Oral, 1 Tablet, Once a day for 8 weeks
48279426|NCT06441630|DRUG|AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
48279427|NCT06441630|DRUG|AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
48279428|NCT06441630|DRUG|Placebo of AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
48279429|NCT06441630|DRUG|Placebo of AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
48279430|NCT05986643|BEHAVIORAL|Exergame+Neurofeedback|Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
48279431|NCT05986643|BEHAVIORAL|Exergame [alone]|"The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback."
48279432|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
48279433|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
48279434|NCT04912167|DRUG|Sacubitril-Valsartan|After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
48279435|NCT04912167|DRUG|Enalapril|After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
48279436|NCT04912167|DRUG|Valsartan|For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
48279437|NCT04212000|DRUG|Levoketoconazole|Levoketoconazole tablet
48279438|NCT04212000|DRUG|Ketoconazole|Ketoconazole tablet
48279439|NCT02669693|DIETARY_SUPPLEMENT|bread without olives|
48279440|NCT02669693|DIETARY_SUPPLEMENT|bread with olives|
48279441|NCT01073150|DRUG|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
48279442|NCT05669521|DRUG|TK-112690|TK112690 treatment Post 5-FU chemotherapy
48279443|NCT05669521|DRUG|Placebo|Placebo treatment Post 5-FU chemotherapy
48279444|NCT05555810|PROCEDURE|clipping or ligation of the cystic duct and the cystic artery in Laparoscopic cholecystectomy|The investigators will make a comparison between clipping and ligation of cystic duct and cystic artery during Laparoscopic cholecystectomy and trying to know advantages and disadvantages of each technique .
48279445|NCT00374556|DRUG|Placebo|3mg placebo capsule, once daily at bedtime
48279446|NCT00374556|DRUG|Eszopiclone|3mg capsule, once daily at bedtime
48279447|NCT06427109|DIETARY_SUPPLEMENT|Dietary intake of omega-3 fatty acid|Participants were stratified into omega-3 consumption quartiles to assess colorectal adenoma incidence trends
48279448|NCT00284388|PROCEDURE|Simultaneous controlled power measurement|
48279449|NCT00284388|PROCEDURE|Surface EMG measurement|
48449799|NCT03110848|DRUG|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
48449800|NCT06524219|PROCEDURE|unilateral intrafascial resection|Conducting unilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
48449801|NCT06524219|PROCEDURE|bilateral intrafascial resection|Conducting bilateral intrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
48449802|NCT06524219|PROCEDURE|bilateral extrafascial resection|Conducting bilateral extrafascial resection in Retzius-sparing robot-assisted radical prostatectomy
48449803|NCT01492556|DRUG|Etoposide|Lastet (Etoposide Capsules, 25mg\*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
48449804|NCT03785730|PROCEDURE|Non-restorative cavity control - NRCC group|The proximal cavities will be enlarged with metallic sandpaper, exposing the cavity, to allow access for toothbrushing associated with 1000 ppm fluoride toothpaste.
47928163|NCT00401388|OTHER|Antiemetics|Antiemetic prophylaxis will be administered at the treating investigator's discretion.
47928164|NCT01993095|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
48449805|NCT03785730|PROCEDURE|Restoration with resin composite - RCR group|In control group, the treatment will be performed after prophylaxis and relative isolation. The selective carious tissue removal will be performed with appropriate dentin curettes. The acid conditioning will be performed only in enamel for 15 s with 37% phosphoric acid gel, and then the application of the adhesive system and restoration of resin composite will be conducted.
48449806|NCT04169633|DIAGNOSTIC_TEST|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
48449807|NCT02243579|OTHER|Laboratory Biomarker Analysis|Correlative studies
48449808|NCT02243579|BIOLOGICAL|Pembrolizumab|Given IV
48449809|NCT01810419|DEVICE|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
48449810|NCT01810419|DEVICE|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
48449811|NCT01863745|DRUG|nilotinib|Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
48449812|NCT01090791|DEVICE|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
48449813|NCT01090791|DEVICE|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
48449814|NCT04486794|DEVICE|Restylane®|Hyaluronic acid
48449815|NCT03675269|OTHER|HBOT|Standard practice
47928165|NCT01993095|BEHAVIORAL|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
47928166|NCT01358279|PROCEDURE|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
48279450|NCT04836286|BEHAVIORAL|Emotive Intelligent Spaces (EIS)|The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
48279451|NCT05142592|DRUG|IPG7236|The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
48279452|NCT04052139|DRUG|Low-dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.
48279453|NCT04052139|DRUG|Gabapentin|Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
48279454|NCT04052139|DRUG|Placebo|In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
48279455|NCT05021809|DRUG|Calcium hydroxide intracanal medication application|The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
48279456|NCT00618150|BEHAVIORAL|Patient education|An educational program: Three lessons spaced over 2 weeks.
48279457|NCT05283993|OTHER|No intervention|No intervention
48279458|NCT05486078|DEVICE|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
48279459|NCT05110066|PROCEDURE|Pulmonary endarterectomy|Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
48279460|NCT05110066|PROCEDURE|Balloon pulmonary angioplasty|Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
48449816|NCT03675269|BEHAVIORAL|Standard wound care|Standard wound care
48449817|NCT06455514|DRUG|Magnesium Sulfate|4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
48449818|NCT06455514|DRUG|Saline|Control subjects will receive an equivalent volume of normal saline intravenously.
48449819|NCT05685498|BEHAVIORAL|Peer-led HIV self-testing among male fisherfolk in Uganda|This behavioral intervention is centered on the distribution of HIV self-test kits to men through their respective peer-leaders. The investigators have identified up to 18 social network groups; each group is represented by 1-2 peer-leaders who were selected during community engagement meetings. Peer-leaders have received a 3-day training in the HIV self-testing processes, communication skills, existing referral mechanisms, and basic counseling skills. After the training, each peer-leader nominated up to 20 male members (15+ years) from within their social networks who were screened for study eligibility. Eligible male social network members were administered a baseline interview and requested to go to their peer-leaders to obtain their HIV self-test kits.
48449820|NCT00650871|DRUG|GW679769|
48449821|NCT00650871|DRUG|Placebo|
48449822|NCT04715646|DRUG|Brivaracetam|"Brivaracetam (BRV) tablets or oral solution will be administered twice daily (bid) in 2 equally divided doses.~Tablet strengths: 10 mg, 25 mg, 50 mg Route of administration: oral~Oral solution Concentration: 10 mg/ml Route of administration: oral"
48449823|NCT01326494|DRUG|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
48449824|NCT01013077|DRUG|Optive|Use a minimum of 2 drops per day for 1 month.
48449825|NCT01013077|DRUG|Soothe|Use a minimum of 2 drops per day for 1 month.
48449826|NCT01013077|DRUG|New Emulsion|Use a minimum of 2 drops per day for 1 month.
48449827|NCT06265727|DRUG|CRB-701|Nectin-4 targeted Antibody Drug Conjugate (ADC)
48449828|NCT04523168|DEVICE|The Neovasc Reducer™ System|A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.
48449829|NCT04873063|DRUG|Beclomethasone dipropionate|BDP 3 mg bid (R product) BDP 6 mg qd (T product)
48449830|NCT00462345|DRUG|rituximab|1000 mg i.v. on Days 1 and 15
48449831|NCT00462345|DRUG|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
48449832|NCT00462345|DRUG|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
48449833|NCT00462345|DIETARY_SUPPLEMENT|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
48449834|NCT02256683|DRUG|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
48449835|NCT02256683|DRUG|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
48449836|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
48449837|NCT00829764|DRUG|Doxycycline Monohydrate|25 mg 5 mL dose
48449838|NCT06561789|OTHER|Functionalized Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
48449839|NCT06561789|OTHER|Nano ᵦ tricalcium phosphate particles|The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)
48449840|NCT06561789|OTHER|sodium fluoride mouth wash|The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
48449841|NCT02224586|DEVICE|light treatment|clinical routine treatment according to the doctor's advice
48449842|NCT04300946|DEVICE|TMS targeted on the cerebellum|Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.
48449843|NCT06057727|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.
48449844|NCT06057727|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
48449845|NCT06057727|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.
48449846|NCT06057727|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
48449847|NCT01642277|DRUG|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
48449848|NCT05900713|OTHER|dynamic neuromuscular stabilization training|DNS methods demonstrated efficacy in improving global trunk stabilizing patterns with noted gains in extremity movement and strength
48449849|NCT05900713|OTHER|balance exercises plus diaphragmatic breathing|The balance exercises is balance exercises while standing and walking The patient assume a semi-Fowler's position and perform diaphragmatic breathing.
48449850|NCT01043952|DRUG|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
48449851|NCT01043952|DRUG|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
48449852|NCT01043952|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
48449853|NCT06562517|OTHER|Digital training module|The intervention is a 24/7 accessible educational website for pediatric oncology nurses, based on the EONS Cancer Nursing Education Framework. It features five validated training modules, enhanced with visual and auditory materials such as videos and infographics. Nurses will receive login credentials, allowing them to access the platform and participate in the training. Each module ends with a 20-question test, requiring a score of 60 to advance. A support line enables nurses to ask questions directly to researchers. Successful completion of each module earns a certificate. The website will be piloted with 15 nurses, and feedback will be used to refine its design and content.
48449854|NCT04205123|GENETIC|sickle cell syndrome|"Academic Study prospective multicenter observational factors responsible for nephropathy in patients with sickle cell disease followed by Belgium and the Nord-Pas -De- Calais Region and creating a biobank of blood and urine.~In the population of patients with SCD followed in all participating centres.~Know the prevalence of nephropathy and the relationship between it with their some of their genotypic mutations and clinical phenotype promoting mutated hemoglobin polymerization.~Determine the behaviour of dense cells in the basal state and in a hypeosmolaire environment~Determine the place of the erythrocyte microparticles as a biomarker of sickle cell nephropathy~Studying genes known as risk factor for proteinuria~Create a BioBank of samples of sickle cell patients in clinically stable condition for other research purposes."
48449855|NCT05367986|DEVICE|electro-acupuncture|"Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~1. Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~2. Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave."
48449856|NCT02230605|OTHER|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
48449857|NCT02230605|OTHER|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
48449858|NCT02230605|OTHER|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
48449859|NCT02230605|OTHER|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
48449860|NCT02230605|OTHER|Short Form 36 Health Survey|To be completed at the Screening Visit
48449861|NCT02230605|OTHER|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
48449862|NCT02230605|OTHER|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
48449863|NCT02230605|OTHER|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
48449864|NCT06293586|PROCEDURE|peribulbar block|"Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.~Gentle digital oculopression was performed for 5 minutes"
48449865|NCT06293586|PROCEDURE|sub-tenon block|Children in the sub-Tenon group received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
48449866|NCT06293586|DRUG|Paracetamol|Children in the control group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
48449867|NCT05574647|DIAGNOSTIC_TEST|bpMRI|biparametric MRI takes 30-40 minutes and requires a contrast injection called gadolinium (like a dye). This is also called long MRI and is most commonly used in the NHS.
47928167|NCT03811275|BEHAVIORAL|Virtual Reality (A) then Task (B)|Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
47928168|NCT03811275|BEHAVIORAL|Task (B) then Virtual Reality (A)|Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
48449868|NCT05574647|DIAGNOSTIC_TEST|Image-Fusion targeted and systematic Biopsy|During image fusion targeted biopsy, the biopsy operator uses the MRI scans that were taken beforehand but laid on top of the live ultrasound images during the biopsy. This uses software and takes a few minutes longer to perform. Once the MRI images and ultrasound images are 'fused', the actual biopsies are taken as normal.
48449869|NCT06558708|DRUG|GZR101 Injection|Once daily
48449870|NCT06558708|DRUG|GZR33 Injection|Once daily
48449871|NCT06558708|DRUG|Insulin aspart|Once daily
48449872|NCT01528696|DEVICE|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
48449873|NCT01528696|DEVICE|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
48449874|NCT06481475|BIOLOGICAL|YY003|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
48449875|NCT06481475|BIOLOGICAL|Vehicle Control|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
48449876|NCT01923753|DEVICE|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
48449877|NCT01923753|DEVICE|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
48449878|NCT01923753|DEVICE|Sham Aerosure|Deactivated but identical Aerosure HFAO device
48449879|NCT02087553|BIOLOGICAL|Transfusion of red blood cells|(non-experimental) PRBC transfusion
48449880|NCT02087553|BIOLOGICAL|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
48449881|NCT06027528|PROCEDURE|dentin graft mixed with autologous fibrin glue|extracted tooth will be grinded into small particles to form dentin graft that will be mixed with autologous fibrin glue to be grafted in the extracted socket using centrifuge
48449882|NCT06027528|PROCEDURE|dentin graft|extracted tooth will be grafted in the socket
48449883|NCT05918835|DEVICE|High-frequency repetitive transcranial magnetic stimulation (active rTMS)|HF-rTMS is applied with a figure-of-8 coil using the Magstim TMS System. Participants receive one administration of HF-rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). HF-rTMS is delivered at a frequency of 10 Hz for approximately 37 minutes (3000 total pulses).
47928169|NCT05604183|PROCEDURE|non-invasive hyperspectral retinoscopy|The Principal Investigator or a trained medical nurse (under the supervision of the principal investigator) will take an image of the retina of the patient with the Mantis Photonics hyperspectral retinoscopy camera.
47928170|NCT05604183|PROCEDURE|blood sample|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will draw a small blood sample according to the standard medical procedures for drawing blood samples.
47928171|NCT05604183|DIAGNOSTIC_TEST|Test of cognitive ability on tablet computer with CoGNIT software|The Principle Investigator or a trained medical nurse (under the supervision of the Principal Investigator) will give the patient to perform the digital cognitive test on a commercial tablet computer. The Principal Investigator or the medical nurse will be available for the patient to ask questions while the test is ongoing.
48279461|NCT03406026|OTHER|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
48449884|NCT05918835|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|Sham rTMS is applied with a figure-of-8 sham coil using the Magstim TMS System, which is identical to the active coil, replicates the sounds of HF-rTMS, and is designed to mimic sensations of HF-rTMS. Participants receive one administration of sham rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). Sham rTMS is delivered for approximately 37 minutes (3000 total pulses).
48449885|NCT00466401|DRUG|Simvastatin|
48449886|NCT00466401|DRUG|Ezetimibe|
48449887|NCT06023433|DEVICE|Elastomeric powerchain|Canine distalization by engaging the elastomeric power chains onto the canine brackets.
48449888|NCT06394973|DRUG|T4090 0.2%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
48449889|NCT06394973|DRUG|T4090 0.3%|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
48449890|NCT06394973|DRUG|Rhopressa®|1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
48449891|NCT04630795|DEVICE|ViscoTurf insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest.
48449892|NCT04630795|DEVICE|Control insole|Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
48279462|NCT03406026|OTHER|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
48449893|NCT04503603|DRUG|Lanadelumab|Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
48449894|NCT04503603|OTHER|Placebo|Participants will receive placebo matching to lanadelumab IV infusion on Day 1 followed by Day 4.
48449895|NCT04757883|OTHER|Study of the synthesis of antibodies directed against SARS|Between 5 mL and 45 mL of additional blood will be collected to study the synthesis of antibodies against CoV-2 SARS and to investigate whether specialised immune cells also show an effective response against the virus.
48449896|NCT00001035|DRUG|Interferon alfa-2b|
48449897|NCT00001035|DRUG|Zidovudine|
48449898|NCT00001035|DRUG|Zalcitabine|
48449899|NCT00001035|DRUG|Didanosine|
48449900|NCT00274651|DRUG|belinostat|
48279463|NCT05273151|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
48449901|NCT02659358|DEVICE|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
48449902|NCT05472350|DRUG|Breztri Aerosphere|Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
48449903|NCT05472350|OTHER|Placebo|placebo is 0.9% normal saline
48449904|NCT05036707|DEVICE|Xenodiagnosis Ticks|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
48449905|NCT05036707|PROCEDURE|skin biopsy|2-3 mm skin punch biopsies will be performed.
48449906|NCT05036707|PROCEDURE|blood draw|Peripheral blood draws will be performed.
48449907|NCT02902211|DEVICE|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
48449908|NCT02902211|OTHER|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
48449909|NCT03256695|DRUG|Albuterol sulfate (ABS)|ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
48449910|NCT05041075|DEVICE|Weighted Blanket|Weighted blankets provide Deep Pressure Stimulation (DPS) or Deep Touch Pressure (DTP) which has advantages in both physical and psychological domains.
48449911|NCT06559475|PROCEDURE|Super-Bore 8F Thrombosis Aspiration Catheter treatment group|For the subjects randomized to the Super-Bore 8F Thrombosis Aspiration Catheter treatment group, Mechanical thrombectomy will be performed using a Super-Bore 8F Thrombosis Aspiration Catheter.
48449912|NCT06559475|PROCEDURE|Conventional thrombectomy device treatment group|For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8F Thrombosis Aspiration Catheter.
48449913|NCT00772603|DRUG|Placebo|Non-active tablet identical to study drug tablets
48449914|NCT00772603|DRUG|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
48449915|NCT00772603|DRUG|1200mg SPN-804|two active tablets and two non-active tablets, all identical
48449916|NCT06558656|DRUG|NTQ5082 capsule|"Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle."
48449917|NCT00834405|DRUG|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
48449918|NCT00834405|DRUG|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
48449919|NCT03714594|DRUG|Dapagliflozin 10mg|Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[
48449920|NCT03714594|DRUG|Saxagliptin 5mg|Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
48449921|NCT03714594|DRUG|Saxagliptin 5mg + Dapagliflozin 10 mg|Please see Intervention 1 and 2
48449922|NCT06095401|OTHER|Inelastic adjustable compression garment (INCOM)|Immediately following surgery, participants randomized to INCOM will wear an inelastic adjustable compression garment set to a minimum of 30mm Hg of compression utilizing a standardized garment tensioning tool. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
48449923|NCT06095401|OTHER|Elastic compression garment (CONTROL)|Immediately following surgery, participants randomized to CONTROL will wear a thigh-length elastic compression garment (thromboembolism-deterrent \[TED\] hose) for the first 3 weeks after TKA. Participants will be instructed to wear the compression garment during waking hours with a target wear time of 80% of waking hours. Participants will participate in a standardized rehabilitation program
48449924|NCT06102850|BEHAVIORAL|Critical Time Intervention for Young Adults with Mental Health conditions|SIx month supportive intervention involving CTI phased based casemanagement, support from a peer support specialist, and support from a mental health liaison
48449925|NCT05846022|OTHER|Dry Needling|This dry needling study involves bilaterally insertion of a fine sterile needle into upper trapezius muscle fibers using a clean needling technique.
48279464|NCT04345185|OTHER|Infant egg consumption (i.e., age of introduction and frequency of intake)|
48279465|NCT05886361|OTHER|No intervention involved|No intervention involved
48449926|NCT05846022|OTHER|Sham Needle|"Shallow penetration of a solid monofilament needle into the skin alone with the in and out plunging movement of the needle simulated with the needle's guide tube."
48449927|NCT05984303|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
48449928|NCT06361407|BEHAVIORAL|Illusion task|The task is the illusion already described in the arm description. All participants will additionally benefit from a short neuropsychological evaluation exploring attention (CPT-AX) and semantic knowledge (fNART) and a clinical evaluation exploring the sense of self (EASE).
48449929|NCT03208374|BEHAVIORAL|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
48279466|NCT02478684|OTHER|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
48449930|NCT03208374|BEHAVIORAL|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
48449931|NCT05305092|DEVICE|PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample|Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.
48449932|NCT02464553|OTHER|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
48449933|NCT03899077|DRUG|Apalutamide|Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
48449934|NCT03899077|DRUG|Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial|Leuprorelin acetate 45mg for 6 months; subcutaneous use
48449935|NCT03899077|DRUG|Goserelin Acetate 10.8 MG Subcutaneous Implant|Goserelin acetate 10.8mg for 6 months; subcutaneous use
48449936|NCT03899077|DRUG|Triptorelin Pamoate|Triptorelin pamoate 22.5mg for 6 months; intramuscular use
48449937|NCT03899077|DRUG|Degarelix acetate|Degarelix acetate 80mg for 6 months; subcutaneous use
48449938|NCT03835715|DRUG|Vortioxetine|Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
48449939|NCT00784472|DRUG|oxycodone|intravenous according to patients weight, pn.
48449940|NCT00784472|DRUG|morphine|intravenous administration according to patients weight, pn.
48449941|NCT06552780|DEVICE|TENs , ultrasound therapy|effect of high intensity laser versus ischemic compression on myofascial trigger points in the upper trapezius
48449942|NCT02006212|PROCEDURE|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
48449943|NCT02753231|BEHAVIORAL|Low physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
47928172|NCT03872076|OTHER|Experimental|"The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee."
48449944|NCT02753231|BEHAVIORAL|High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
48449945|NCT02753231|BEHAVIORAL|Low and High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
48449946|NCT02753231|BEHAVIORAL|Conventional physical activity program|One Physical Education sessions / week
48449947|NCT04045197|BEHAVIORAL|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
48449948|NCT01180322|DRUG|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (\>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
48449949|NCT01180322|DRUG|Idarubicin|"First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (\>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
48449950|NCT01180322|DRUG|Etoposide|"Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (\>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
48449951|NCT01180322|DRUG|Azacitidine|"Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
48449952|NCT01180322|DRUG|Lenograstim|"Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count \> 0.5 x 109/l."
48279467|NCT02478684|OTHER|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
48449953|NCT05402202|OTHER|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
48449954|NCT05402202|OTHER|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
48449955|NCT01098591|OTHER|cell therapy|
48449956|NCT00835588|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
48449957|NCT00835588|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
48449958|NCT06559748|DEVICE|transcranial magnetic thetaburst stimulation （TBS）|TBS group: iTBS was administered to stimulate RMFC, 80-100% RMT, 10 times a course, twice a day, for a total of 5 days; Conventional drugs group: pantoprazole 40 mg orally once a day; itopride 50 mg orally three times a day; treatment for 4 weeks. （Standard medication regimen）
48449959|NCT06533943|OTHER|Exercise program|Each intervention session is divided into three different parts according to the specific aim such as warm-up (about 15 minutes) at the beginning, main exercises (about 30 minutes), and stretching and relaxation (about 15 minutes) at the end.
48449960|NCT03776552|OTHER|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
48449961|NCT03776552|OTHER|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
48449962|NCT03471065|DEVICE|SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV|Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.
48449963|NCT05162222|DRUG|Danicamtiv|Specified dose on specified days
48449964|NCT05162222|DRUG|Itraconazole|Specified dose on specified days
48449965|NCT05162222|DRUG|Diltiazem|Specified dose on specified days
48449966|NCT05722184|DIAGNOSTIC_TEST|BactInsight blood culture system|A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
48449967|NCT00216242|BIOLOGICAL|Influenza virus vaccine (Fluviral)|
48449968|NCT00216242|BIOLOGICAL|Saline placebo|
48449969|NCT03151876|DRUG|Chidamide|30 mg oral twice weekly for 2 weeks
48449970|NCT03151876|DRUG|Cladribine|6 mg/m2 intravenously daily for 5 days
48449971|NCT03151876|DRUG|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
48449972|NCT03151876|DRUG|Busulfan|3.2 mg/kg intravenously daily for 4 days
48449973|NCT03151876|PROCEDURE|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
48449974|NCT04343196|RADIATION|Diagnostic Angiography (DSA or DVA based on randomization result)|After radial/brachial/femoral artery puncture using Seldinger technique, the investigators first position a pigtail catheter above the level of the renal arteries. With Siemens Artis Zee Pure DSA machine the examiner will use a postero-anterior X-ray view for the first image, which is an aortography of some part of the iliac system. Then, the catheter will be repositioned to the aortic bifurcation and 15-18 mL contrast media (CM) with 9-10 mL/s flow for the ilio-femoral region will be injected. All of the following image series will be made from this catheter position, with a 9 mL/s flow rate. In cases for when the recorded image series will be inconclusive, image series with left/right oblique position will be recorded. All femoro-popliteal images will be recorded with 10-16 ml CM and crural regions with 12-22mml. DSA images will be calculated from all series on a dedicated Syngo workstation and used for diagnosis. DVA images will be calculated by the Kinepict Medical Imaging Tool
48449975|NCT01625715|DRUG|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
48279468|NCT02179840|PROCEDURE|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
48449976|NCT01902394|OTHER|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
48449977|NCT01902394|OTHER|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
48449978|NCT05526183|BIOLOGICAL|Adeno-viral vector vaccine|The vaccine will be injected intramuscularly, as two doses 28 days apart. Two different dosages will be given to volunteers (low dose: 5x1010 and high dose: 1x1011)
48449979|NCT04380181|DRUG|dobu|Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
48449980|NCT04811235|DEVICE|Near Infra-Red Spectroscopy (NIRS) Sensor|The NIRS sensor is laid on top of the dura, at the site of the SCI, and emits near-infrared light signals into the cord to measure tissue oxygenation and tissue hemodynamics in real-time.
48449981|NCT06544200|DEVICE|Polymeric Hydrogel Matrix|application of Polymeric Hydrogel Matrix along the suture line at the completion of lung resection
48449982|NCT02641444|PROCEDURE|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
48449983|NCT02641444|PROCEDURE|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
48449984|NCT02641444|PROCEDURE|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
48449985|NCT01090687|RADIATION|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
48449986|NCT01090687|DEVICE|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
48449987|NCT01120340|DRUG|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
48449988|NCT01120340|OTHER|placebo|2 pills/day for ten days/month until 24 months
48620503|NCT02061800|DEVICE|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
48449989|NCT00313937|DRUG|Insulin glargine|
48449990|NCT04937062|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|"Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf)."
48449991|NCT06562387|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is one of the most studied techniques in noninvasive neuromodulation. With a very good safety profile and low cost, it has been widely used to modulate cognition and behavior in both experimental and clinical settings. A growing body of literature, including randomized controlled trials, reports the clinical benefits of tDCS for many psychiatric symptoms, such as depression, anxiety, psychosis, addiction, and cognitive functions. tDCS has considerable potential as a treatment due to its relative cost, portability, safety, and ease of use compared to other neuromodulation methods. Early studies evaluated the effects of tDCS on the motor cortex; however, more recent research has also focused on its effects on the dorsolateral prefrontal cortex (DLPFC), in particular for treating psychiatric disorders and modulating cognitive performance.
48449992|NCT06562387|OTHER|cognitive stimulation|This brain stimulation program is based on cognitive reserve and neuronal plasticity to improve mental performance through online games. The activities presented in this tool combine different therapeutic exercises, rehabilitation and learning techniques aimed at retraining and improving the skills most needed by each person. The intervention battery has multi-disciplinary tasks organized in a systematic and strategic way. To make these materials accessible, they are presented in the form of simple games that can be easily practiced through any computer or device. These cognitive stimulation tools are aimed at both healthy subjects and people concerned about their brain health, or patients with some kind of injury or decline in the central nervous system.
48449993|NCT06562387|DEVICE|sham transcranial direct current stimulation|Regarding the simulated condition or sham, the equipment has the option inside to program it. It gives the options: Active / sham protocol, by default: ON - enables active stimulation and OFF - enables sham stimulation. The devices will be programmed, such that a few seconds of stimulation are administered at the beginning and end of the programmed time period to mimic the cutaneous perceptions (itching, tingling) that tend to be reported within the first few moments of stimulator on, without being able to modify cortical excitability.
48449994|NCT01961947|BIOLOGICAL|ASP7374|subcutaneous
48449995|NCT01961947|BIOLOGICAL|approved egg-derived TIV|subcutaneous
48449996|NCT03772821|OTHER|Data collection|Between D0 and D90: local and general complications, demographic, clinical, paraclinical and biological data
48449997|NCT03772821|OTHER|Incision/scar measurement|Between D0 and D90
48449998|NCT06249360|OTHER|Veins with reflux|This group included patients who used only recipient veins with reflux
48449999|NCT06249360|OTHER|Reflux-free recipient veins|This group included patients who utilized only reflux-free recipient veins
48450000|NCT01163435|DRUG|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
48450001|NCT01163435|DRUG|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
48450002|NCT01163435|DRUG|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
48450003|NCT01163435|DRUG|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
48450004|NCT04854798|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
48279469|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
48279470|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
48450005|NCT04292873|OTHER|Vitamin D supplement|Enteral supplement of 569,600 IU vitamin D
48450006|NCT00309881|BIOLOGICAL|rituximab|
48450007|NCT00309881|DRUG|cyclophosphamide|
48450008|NCT00309881|DRUG|doxorubicin hydrochloride|
48450009|NCT00309881|DRUG|prednisone|
48279471|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
48450010|NCT00309881|DRUG|vincristine sulfate|
48450011|NCT06025110|BIOLOGICAL|TCD601|Investigational Product
48450012|NCT06025110|OTHER|Placebo|Comparator
48450013|NCT05454683|DIETARY_SUPPLEMENT|melatonin plus zinc|One capsule with melatonin 1mg plus zinc 10 mg o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
48450014|NCT05454683|OTHER|isomaltose and magnesium stearate|One capsule with excipients o.d. 30 minutes before bedtime, at least 1 hour after dinner during 4 months
48279472|NCT01755988|OTHER|Educational website (in addition to usual care).|
48279473|NCT01755988|OTHER|Website and interactive platform with telemonitoring.|
48279474|NCT04205552|DRUG|Nivolumab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
48279475|NCT04205552|DRUG|Relatlimab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
48279476|NCT01152606|DRUG|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
48279477|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
48279478|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
48450015|NCT05816564|BEHAVIORAL|Attention Bias Modification (ABM) for depression|"Both groups will be asked to engage in mindfulness activities but only one group will receive the train-positive ABM task. The control group will receive a sham task that is not programmed to train attention towards positive stimuli."
48450016|NCT05816564|BEHAVIORAL|Sham Attention Bias Modification (ABM)|The sham intervention will be given to the control group (but they will still receive mindfulness exercises).
48450017|NCT02283463|DEVICE|Intrauterine device (IUD) insertion|
48450018|NCT02283463|PROCEDURE|Endometrial biopsy|
48450019|NCT04215718|PROCEDURE|fistulotomy and marsupialization|the anal fistula was laid open and the the wound edges was marsupialized using vicryle 3\\0 sutures
48450020|NCT04215718|PROCEDURE|fistulectomy and wound closure|anal fistula was excised with both openings and the wound was closed
48450021|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
48450022|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
48450023|NCT00170547|BIOLOGICAL|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
48450024|NCT03110627|DEVICE|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
48450025|NCT03110627|DEVICE|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
48450026|NCT02701556|DEVICE|Complete MPS|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
48450027|NCT02701556|DEVICE|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
48450028|NCT01370369|DRUG|Testosterone gel (FE 99903)|
48450029|NCT04571021|OTHER|I-DEPT|Implementation of the novel triage algorithm
48279479|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
48279480|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
48279481|NCT00520598|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
48279482|NCT00520598|BIOLOGICAL|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
48450030|NCT04571021|OTHER|DEPT|Existing triage algorithm
48279483|NCT06003062|DRUG|Narcissus Tazetta Bulb Extract and Novel Hemp Extract|Topical nightly application of phytonutraceutical
48450031|NCT02849496|DRUG|Atezolizumab|Given IV
48450032|NCT02849496|PROCEDURE|Biopsy|Undergo a biopsy
48450033|NCT02849496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48450034|NCT02849496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48450035|NCT02849496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48450036|NCT02849496|PROCEDURE|Bone Scan|Undergo a bone scan
48450037|NCT02849496|PROCEDURE|Computed Tomography|Undergo a CT scan
48450038|NCT02849496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48450039|NCT02849496|DRUG|Olaparib|Given PO
48450040|NCT02849496|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
48450041|NCT02849496|OTHER|Questionnaire Administration|Ancillary studies
48450042|NCT02849496|PROCEDURE|X-Ray Imaging|Undergo an x-ray
48279484|NCT02220881|DEVICE|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
48279485|NCT02220881|OTHER|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
48279486|NCT03971981|DIETARY_SUPPLEMENT|100% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
48279487|NCT03971981|DIETARY_SUPPLEMENT|22% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
48450043|NCT06158386|DRUG|Chidamide combined with Linperlisib|Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
48450044|NCT03891784|DRUG|Abemaciclib|Given PO
48450045|NCT00445796|DRUG|Artesunate|
48450046|NCT00445796|DRUG|Amodiaquine|
48450047|NCT06081153|DRUG|Evolocumab|See arm description.
48450048|NCT06081153|DRUG|Placebo|See arm description.
48450049|NCT00789386|DRUG|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
48450050|NCT00789386|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
48450051|NCT00109265|DRUG|Erlotinib HCl (OSI-774)|
48450052|NCT03347487|PROCEDURE|Deep brain stimuation system implantation|All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
48450053|NCT05843864|DEVICE|Photobiomodulation Therapy with Standard Physical Therapy|Photobiomodulation Therapy (PBMT) will be provided by a trained individual in addition to standard physical therapy. Treatment will be delivered for approximately 10-16 minutes. Participants will then be instructed to rest for 5 minutes after the treatment.
48450054|NCT05843864|OTHER|Sham Photobiomodulation Therapy with Standard Physical Therapy|Sham Photobiomodulation Therapy (PBMT) will be provided by a trained to the some location and with the same contact time and frequency as the active intervention (PBMT) in addition to standard physical therapy. Participants will then be instructed to rest for 5 minutes after the treatment.
48279488|NCT01974791|BEHAVIORAL|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
48450055|NCT03536091|DIAGNOSTIC_TEST|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
48450056|NCT02921893|DRUG|Dexamethasone|Given PO
48450057|NCT02921893|DRUG|Ixazomib Citrate|Given PO
48450058|NCT02921893|DRUG|Lenalidomide|Given PO
48450059|NCT02921893|OTHER|Questionnaire Administration|Ancillary studies
48450060|NCT02399423|BEHAVIORAL|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
48450061|NCT02399423|BEHAVIORAL|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
48450062|NCT00883233|DRUG|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
48450063|NCT00883233|DRUG|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
48450064|NCT00883233|DRUG|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
48450065|NCT00883233|DRUG|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
48450066|NCT06547541|BEHAVIORAL|Exercise|A body weight based resistance training.
48450067|NCT02287961|PROCEDURE|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
48450068|NCT02287961|PROCEDURE|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
48450069|NCT02287961|PROCEDURE|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
48450070|NCT02287961|PROCEDURE|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
48450071|NCT01526174|DRUG|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
48450072|NCT04153877|OTHER|Kinesiotape|Kinesio-tape® is an elastic, hypoallergenic, cotton-fiber tape with acrylic heat-activated backing and is widely used within sports.
48450073|NCT01714895|OTHER|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
48279489|NCT01086787|OTHER|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
48279490|NCT04947202|DEVICE|Hernioplasty|Hernioplasty is the repair of the defect using mesh patches.
48279491|NCT00222911|DEVICE|dorsiflexion night splint|
48279492|NCT00222911|DEVICE|medial arch support|
48279493|NCT05747924|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
48279494|NCT05747924|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion
48279495|NCT00552266|DRUG|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
48279496|NCT04093830|DEVICE|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
48279497|NCT02665689|DRUG|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
48279498|NCT06601712|OTHER|Adherence support strategy A|Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs
48279499|NCT06601712|OTHER|Adherence support strategy B|SMS/phone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs
48279500|NCT06601712|OTHER|Control|No reminders
48279501|NCT05281523|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre-filled syringe.
48279502|NCT05281523|DRUG|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
48279503|NCT05714904|DRUG|ZVS101e|ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
48279504|NCT06573853|PROCEDURE|Focal Pulsed Field Ablation (PFA)|Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.
48279505|NCT06573853|PROCEDURE|Focal Radiofrequecy Ablation (RFA)|Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.
48279506|NCT01525758|DRUG|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
48279507|NCT01525758|DRUG|microcrystalline cellulose|identical number of tablets to active drug groups
48450074|NCT01714895|OTHER|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
48450075|NCT02322593|DRUG|TAS-118 plus Oxaliplatin|
48450076|NCT02322593|DRUG|S-1 plus Cisplatin|
48450077|NCT05867017|OTHER|Measure of physiologic parameters|Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
48450078|NCT03031184|DRUG|Mirtazapine|
48450079|NCT03031184|OTHER|Placebo|
48450080|NCT03348553|DIETARY_SUPPLEMENT|control group|no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products
48450081|NCT03348553|DIETARY_SUPPLEMENT|Omega2|2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
48450082|NCT03348553|DIETARY_SUPPLEMENT|Omega4|4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
48450083|NCT03348553|DIETARY_SUPPLEMENT|Omega2+OGV|2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
48450084|NCT02554890|DRUG|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
48450085|NCT02554890|DRUG|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
48450086|NCT02554890|DRUG|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
48450087|NCT02554890|DRUG|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
48450088|NCT04842123|DIAGNOSTIC_TEST|Electrocardiogram|Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
48450089|NCT06485908|DRUG|administration of axitinib in combination with etoposide|"1. st stage:~   * Axitinib (Inlyta®) PO, in the morning and in the evening every day~  * Level -1 : Dose 1.2 mg/m²~  * Level 1: Dose 1.6 mg/m²~  * Level 2: Dose 2.0 mg/m²~  * Level 3: Dose 2.4 mg /m² (equivalent to 4 mg in adults)~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m²/day in the evening orally every day fasting (capped to a maximum of 50 mg/day) First patient will be enrolled at dose level 1~2. nd stage:~   * Axitinib (Inlyta®) dosing as selected at the 1st stage~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m2/ day in the evening orally every day fasting(capped to a maximum of 50 mg/day)"
48450090|NCT04016415|BEHAVIORAL|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
48450091|NCT04016415|BEHAVIORAL|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
48450092|NCT06558695|DRUG|Sevoflurane|Sevoflurane was managed for maintenance of the general anestesia during spinal surgeries
48450093|NCT06558695|DRUG|TIVA|TIVA was managed for maintenance of the general anesthesia during spinal surgeries
48450094|NCT00829530|DRUG|Ramipril 10 mg capsule|1 x 10 mg
48450095|NCT00829530|DRUG|Altace® 10 mg capsule|1 x 10 mg
48450096|NCT05763537|BEHAVIORAL|Standard Doula Care Plus PMAD Intervention|Doulas trained in the DONA training, and the PMAD-focused training will provide care to perinatal people.
48450097|NCT05763537|BEHAVIORAL|Standard Doula Care|Doulas trained in the DONA training will provide care to perinatal people.
48450098|NCT03572868|OTHER|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter \< 5th centile during the second or the third trimester of pregnancy.
48450099|NCT02269657|DEVICE|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
48450100|NCT01815320|PROCEDURE|Contrast-enhanced ultrasound (CE-US)|
48450101|NCT01815320|DEVICE|SonoVue|
48450102|NCT06133920|OTHER|Early Range of Motion|The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
48620504|NCT02061800|DRUG|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
48620505|NCT02061800|DRUG|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
48620506|NCT02061800|DRUG|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
48450103|NCT06133920|OTHER|Immobilization|"The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery."
48450104|NCT06279039|DRUG|Exosome liquid dressing|This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.
48450105|NCT06242613|PROCEDURE|Robot-Assisted Gastrectomy|Gastrectomy performed with a robotic system.
48450106|NCT06242613|PROCEDURE|Laparoscopic Gastrectomy|Gastrectomy performed with conventional laparoscopic approach.
48450107|NCT00906477|PROCEDURE|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
48450108|NCT01627158|DRUG|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
48450109|NCT01627158|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler
48450110|NCT01627158|DRUG|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
48450111|NCT01627158|DRUG|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
48450112|NCT05967286|DRUG|Alpelisib|Given PO
48450113|NCT05967286|PROCEDURE|Biopsy|Undergo biopsy
48450114|NCT05967286|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48450115|NCT05967286|PROCEDURE|Bone Scan|Undergo bone scans
48450116|NCT05967286|PROCEDURE|Computed Tomography|Undergo CT
48450117|NCT05967286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48450118|NCT05967286|DRUG|Olaparib|Given PO
48450119|NCT05967286|PROCEDURE|Positron Emission Tomography|Undergo PET
48450120|NCT00954590|DRUG|Dimebon (latrepirdine)|20 mg orally three times daily
48450121|NCT00954590|DRUG|Placebo|Placebo orally three times daily
48450122|NCT02785887|OTHER|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
48450123|NCT00915694|DRUG|nelfinavir mesylate|
48450124|NCT00915694|DRUG|temozolomide|
48450125|NCT00915694|PROCEDURE|adjuvant therapy|
48450126|NCT00915694|RADIATION|radiation therapy|
48450127|NCT05369884|DRUG|WPQW granule|WPQW granule, 2 sachets / time, 3 times / day.
48450128|NCT05369884|DRUG|WPQW granule simulant|WPQW granule simulant, 2 sachets / time, 3 times / day.
48450129|NCT04362085|DRUG|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
48450130|NCT02354560|DRUG|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
48450131|NCT06559722|DRUG|Insulin Degludec/liraglutide Injection|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
48450132|NCT06559722|DRUG|XULTOPHY®|Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
48450133|NCT04170894|OTHER|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
48450134|NCT04170894|OTHER|Control Arm - No Periods of Apnea|Standard of care atrial fibrillation ablation.
48450135|NCT03003091|OTHER|Needs-based patient education|
48450136|NCT03003091|OTHER|Traditional patient education|
48450137|NCT06544941|DEVICE|Smart Bassinet|The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.
48450138|NCT06544941|DEVICE|HALO|The HALO is a commercially available bassinet
48450139|NCT05036070|DEVICE|Model C0001|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
48450140|NCT05036070|DEVICE|Model ZCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
48450141|NCT03625115|BEHAVIORAL|Family Navigator (FN)|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
48450142|NCT05637333|DIAGNOSTIC_TEST|Contrast Stress Echocardiography|Dipyridamole will be infused at 0.56mg/kg of body weight over 4mins. After 2 minutes, if the patient has tolerated the infusion well, a further 0.28mg/kg will be infused over 2 minutes. Tolerance will be determined by the absence of 1) myocardial ischaemia (significant chest pain with ECG ST depression or T wave inversion or wall motion abnormality on ECHO) 2) a significant drop in blood pressure 3) significant arrhythmia and 4) intolerable symptoms. One minute after completion of Dipyridamole infusion Sonazoid will be infused at the same rate as was used during acquisition of the rest images. After 45 seconds when steady state is reached, the ultrasound images will be acquired as stated below in contrast imaging. If the Dipyridamole is not well tolerated by one minute after the 0.56mg/kg infusion, we will move straight to the infusion of Sonazoid with no extra 0.28mg/kg infusion.
48450143|NCT00190840|DRUG|pemetrexed|
48450144|NCT05458583|PROCEDURE|Baseline periodontal measurements (T0)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the bonding session.
48450145|NCT05458583|PROCEDURE|Periodontal measurements (T1)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 6 months after bonding.
48450146|NCT05458583|PROCEDURE|Periodontal measurements (T2)|Periodontal measurements including plaque index, gingival index and calculus index were recorded at the 12 months after bonding.
48450147|NCT05458583|PROCEDURE|Retainer failure rates|A retainer with at least one composite pad detachment was considered to be a failure during 1-year follow-up.
48450148|NCT06562933|DEVICE|Sham vacuum|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. The vacuum electrodes will apply continuous vacuum mode for only 10 minutes without delivering interferential current. Following the sham vacuum therapy, a hot pack will be applied to the painful neck area for 20 minutes.
48450149|NCT06562933|DEVICE|Interferential Current Therapy Vacuum Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the vacuum electrodes. After the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
48450150|NCT06562933|DEVICE|Interferential Current Therapy Carbon-silicon Pad Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four carbon-silicon pad electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the carbon-silicon pad electrodes. Following the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
48450151|NCT06366113|OTHER|Pulmonary rehabilitation|"Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education"
48450152|NCT03396276|DRUG|Suboxone|8mg of buprenorphine/2mg of naloxone
48450153|NCT03396276|BEHAVIORAL|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
48450154|NCT03396276|BEHAVIORAL|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
48450155|NCT03396276|BEHAVIORAL|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
48450156|NCT04571684|OTHER|HITSystem 2.1|HITSystem 2.1 is an intervention that tracks HIV+ pregnant women and their infants to improve the completeness and efficiency of PMTCT services. Key intervention features include: (1) SMS messages sent to enrolled women and mothers to support essential PMTCT services, (2) automated, algorithm-driven alerts for providers when per-guidelines PMTCT services are missed, and (3) automatic enrollment of infants into early infant diagnosis (EID) and linkage with maternal PMTCT file at documentation of infant birth to improve the continuum of care for HIV+ mothers and HIV-exposed infants. The HITSystem 2.1 intervention aims to facilitate complete PMTCT retention and viral load (VL) monitoring with prompt clinical action (adherence support, antiretroviral therapy (ART) regimen change) in the antenatal, delivery, and 6-month postpartum periods to increase viral suppression during windows critical for HIV prevention.
48450157|NCT00835575|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
48450158|NCT00835575|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
48450159|NCT00202462|DRUG|Testosterone gel|Testosterone gel 7.5 gm qd
48450160|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
48450161|NCT03110991|BEHAVIORAL|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
48450162|NCT06350747|BEHAVIORAL|Laughter Yoga|A laughter yoga session lasts approximately 30 minutes and consists of four parts. These parts are hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. The sections of laughter yoga are explained below (Kataria, 2011). Each laughter yoga session includes the same first three parts, with variations in the laughter exercises in the fourth part. In each new group, the first session will introduce participants to laughter yoga, its purpose, and objectives. Ten minutes are allocated for this section in the first session of each group. Therefore, the first sessions are 40 minutes long in each group, while all subsequent sessions are 30 minutes long. The total duration of the session, broken down by section, is as follows: Section 1: Hand Clapping and Warm-up Exercises - 5 minutes Section 2: Deep Breathing Exercises - 10 minutes Section 3: Playful Games - 5 minutes Section 4: Laughter Exercises - 10 minutes
48450163|NCT06515405|DRUG|Hydrocortisone|"Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023)."
48450164|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and warm and humidified CO2 Insufflation|low pressure pneumoperitoneum (5-7mmHg) and use warm (35°C), humidified (95% relative humidity) CO2 insufflation.
48450165|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and conventional Insufflation|low pressure pneumoperitoneum (5-7mmHg), and use standard room temperature with dry insufflation.
48450166|NCT01512628|DRUG|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
48450167|NCT02589301|BIOLOGICAL|Pegfilgrastim|
48450168|NCT03658954|BEHAVIORAL|Advice|Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.
48450169|NCT03658954|BEHAVIORAL|Self-monitoring|Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.
48450170|NCT03658954|BEHAVIORAL|Feedback|Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Philips actiwatches and SCRAM ankle biosensors \& tailored coaching with a health coach
48450171|NCT05835349|DEVICE|transcatheter pulmonary valve implantation (TPVI)|A stent-mounted valve is introduced over a guidewire and positioned in the RVOT, followed by balloon inflation to deploy the valve.
48450172|NCT05355545|BEHAVIORAL|Virtually supervised exercise|Participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
48450173|NCT05355545|BEHAVIORAL|Health education|Participants will first participate in a once weekly live health education class that they will access through a computer connected to the Internet. During the second half of the study, participants will participate twice weekly in an live exercise program that they will access through a computer connected to the Internet.
48450174|NCT03044210|OTHER|Metabolic evaluation|"* diet assessment~* biological evaluation~* clinical evaluation~* metabolic evaluation (calorimetry)"
48450175|NCT03581097|OTHER|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
48450176|NCT06133933|DEVICE|Pain Threshold using algometer/dolorimeter|These patients who consent to participation in the study will receive a preoperative pain threshold measured using a pain algometer/dolorimeter. We will rely on the completion of the questionnaires, opioid consumption journal, and surveys to establish a correlation between pre-operative pain threshold and post-operative outcomes.
47928173|NCT03872076|OTHER|Control|"Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions."
48450177|NCT02193763|PROCEDURE|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
48450178|NCT00852696|DRUG|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
48450179|NCT00852696|OTHER|Placebo|Take orally once daily for 9 weeks.
48450180|NCT05133440|DRUG|Radium dichloride|Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
48450181|NCT05133440|DIAGNOSTIC_TEST|PET Scan|For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
48450182|NCT03168126|DEVICE|Pro-AQT|Use of the device for advanced hemodynamic monitoring
47928174|NCT04066764|DRUG|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
47928175|NCT04066764|DRUG|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
48450183|NCT06475846|DRUG|HRS5580|HRS5580; low dose
48450184|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
48450185|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
48450186|NCT06475846|DRUG|Ondansetron|Ondansetron
48450187|NCT06475846|DRUG|blank preparation|blank preparation.
48450188|NCT03972306|DRUG|Ocrelizumab|Administered by subcutaneous Injection
48450189|NCT03972306|DRUG|Ocrelizumab|Administered by Intravenous (IV) Injection
48450190|NCT03972306|DRUG|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
48450191|NCT01422291|DRUG|paracetamol|1 gr
48450192|NCT01422291|DRUG|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
48450193|NCT01422291|DRUG|Dexketoprofen|50 mg
48450194|NCT01422291|DRUG|Paracetamole|1 gr
48450195|NCT01666262|BIOLOGICAL|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
47928176|NCT04066764|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
47928177|NCT02810444|BIOLOGICAL|IgG Next Generation (BT595)|
47928178|NCT00207324|DEVICE|Silver Leaf Dressing|
48450196|NCT01666262|OTHER|Placebo:Stabilizer|5% sucrose
48620507|NCT02061800|DRUG|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
48450197|NCT05187065|OTHER|The mobile-based education and exercise program|Starting from the preoperative period, mobile-based patient education, progressive relaxation exercise and knee exercise program will be applied to the patient as a whole. Mobile-based education will include pre-operative and discharge education. The patient will be given a progressive relaxation exercise with the support of the mobile application and the exercises included in the knee exercise program that should be done after the surgery will be shown. Progressive relaxation exercises will be applied twice a day in the afternoon and evening. Postoperative knee exercises will be performed 3 to 5 times a day, depending on the type of exercise. These exercises will be continued regularly for up to 4 weeks after discharge.
48450198|NCT05911633|DEVICE|BioPearl™|TACE
48450199|NCT04966741|DRUG|Setmelanotide|SC injection once daily.
48450200|NCT03264521|OTHER|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
48450201|NCT01318551|DRUG|BAY85-3934|single dose, 20 mg
48450202|NCT01318551|DRUG|BAY85-3934|single dose, 40 mg (optional)
48450203|NCT01318551|DRUG|BAY85-3934|single dose, 80 mg (optional)
48450204|NCT01671696|OTHER|Cardiac MRI|Cardiac MRI
48450205|NCT06426225|OTHER|General Anesthesia|General Anesthesia Applied Group 2 Patients.
48450206|NCT06426225|OTHER|Spinal Aneshtesia|Spinal Anesthesia and Ketofol Sedation Applied Group 1 Patients.
48450207|NCT05234788|PROCEDURE|Transfemoral Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via femoral artery access
48450208|NCT05234788|PROCEDURE|Transradial Renal Denervation|Radiofrequency renal denervation using the Iberis Renal Denervation System treated via radial artery access
48450209|NCT06627140|DIAGNOSTIC_TEST|Diagnostic procedures|Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning
48450210|NCT03843190|BEHAVIORAL|Take of Pounds Sensibly (TOPS)|Dietician-facilitated classes
48450211|NCT03843190|OTHER|Waitlist Control|At end of study, offered peer-led classes to attend.
48450212|NCT01988376|DEVICE|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
48450213|NCT01988376|DEVICE|Conventional Pap smear|Conventional Pap smear
48450214|NCT05668689|OTHER|Preliminary testing|The pilot test will be administered by local investigators via a computer-based application to 35-50 trainees and consultants. The cohorts will include an equal number of trainees and consultants of varying experience, based on the new RCOA curriculum and the extent of their regional experience (stage 1 (CT1-3); stage 2 (ST4-5); stage 3 (ST6-7); stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The pilot test will contain short video clips and images of ultrasound guided regional anaesthesia with questions in a constructed response question (CRQ) format to identify relevant structures, anatomy and clinical knowledge.
48450215|NCT05668689|OTHER|Psychometric main study testing (Phase 5)|The main study assessment tool will be administered to trainees of all levels and consultants, aiming to recruit an equal number across different stages of the RCoA curriculum and of varying regional anaesthesia experience (stage 1; stage 2; stage 3; stage 3 + regional fellowship trained; consultant; consultant with special interest in regional; consultant + regional fellowship trained). The exam will consist of constructed response questions (CRQs), which will require the participant to write free-text responses to questions, in line with RCoA examinations.
48450216|NCT04405102|DRUG|Ozanimod|The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
48450217|NCT04405102|OTHER|Standard of care|During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
48450218|NCT02885285|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
48450219|NCT02885285|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
48450220|NCT02885285|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
48450221|NCT02885285|OTHER|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
48450222|NCT00363077|BIOLOGICAL|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
48450223|NCT00363077|BIOLOGICAL|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
48450224|NCT01385930|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
48450225|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
48450226|NCT00712959|BIOLOGICAL|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
47928179|NCT04918342|OTHER|Multidimensional Exercise Program|The multidirectional exercise program will include cardiovascular training, strengthening, balance training, and flexibility training. This will be delivered 2 times per week for 8 weeks using telehealth and will be delivered by a physical therapist. The exercises will be modified to meet the participants needs. Intensity of exercise interventions will be monitored through patient self report and use of continuous heart rate monitoring.
47928180|NCT00472758|BIOLOGICAL|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
47928181|NCT00472758|OTHER|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
48450227|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine|Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
48450228|NCT06561763|DRUG|Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine|Cisplatin 80 mg/m2， Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ，D1,D8； Triprolizumab injection 240mg, intravenous ； Nivolumab 400mg, intravenous； Q3W 1 cycle, 3 cycles
48620508|NCT02061800|DRUG|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
48450229|NCT03235271|DEVICE|BrainPulse Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the skull motion caused by pulsatile cerebral blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile cerebral blood flow. The system is powered by a rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
48450230|NCT02517554|BEHAVIORAL|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
48450231|NCT02517554|BEHAVIORAL|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
48450232|NCT02517554|BEHAVIORAL|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
48450233|NCT06561191|OTHER|Hemodialysis mode, dialyzer type|Change of hemodialysis mode and dialyzer type
48450234|NCT01834183|DRUG|Tivozanib|
48450235|NCT01834183|DRUG|Gemcitabine|
48450236|NCT06512909|OTHER|Virtual Reality Glasses Application|A video containing relaxing nature images will be shown to a group via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video.
48450237|NCT06512909|OTHER|Stress Ball Application|One group will be given a stress ball in the hand on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, intramuscular injection will begin and the procedure will be performed while squeezing the ball.
47928182|NCT05184010|DEVICE|ulnar nerve mini open release|the ulnar nerve mini open release was performed before arthroscopic release for elbow
47928183|NCT05184010|DEVICE|without ulnar nerve mini open release|arthroscopic release for elbow stiffness alone without ulnar nerve mini open release
47928184|NCT03232125|DRUG|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
48450238|NCT04934098|DEVICE|Adjustable Compression Wrap|The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.
48450239|NCT04934098|DEVICE|Compression Bandage|Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
48450240|NCT03734861|DEVICE|BreatheSmart System|"* BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor adherence"
48450241|NCT03734861|OTHER|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
48450242|NCT03589430|OTHER|Laboratory investigations ( protein C, protein S , antithrombin III)|laboratory investigations ( protein C , protein S , antithrombin)
48450243|NCT06559878|DIAGNOSTIC_TEST|13C-α-Ketoisocaproic Acid Breath Test|13C-α-Ketoisocaproic acid with L-Leucine soluted in citric acid drink. The solution is administered orally during metabolic visits (3.-5.).
48450244|NCT06559878|DIETARY_SUPPLEMENT|Ethanol|6% ethanol soluted in normal saline is given intravenously during one metabolic visit.
48450245|NCT06559878|DIETARY_SUPPLEMENT|Lipid Emulsion|Lipid emulsion, heparin and normal saline are given intravenously during one metabolic visit.
48450246|NCT06559878|OTHER|Normal Saline|Normal saline is given intravenously during one metabolic visit.
48450247|NCT05402137|BEHAVIORAL|Weight stigma intervention|Those undergoing the weight stigma manipulation will be exposed to an interaction partner (a trained confederate) who will endorse anti-fat attitudes. The purpose of this interaction is to examine the causal effects of weight stigma on eating behaviors, physical activity, and sleep.
48450248|NCT05452785|DRUG|DFD-29 (Minocycline) Fasting|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
48450249|NCT05452785|DRUG|DFD-29 (Minocycline) Fed|In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
48450250|NCT05452785|DRUG|Solodyn (Minocycline) Fasting|In each study period, a single 105 mg dose of SOLODYN® Tablets will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast.
48450251|NCT01318369|DRUG|Namisol|Single dose delta-9-tetrahydrocannabinol
47928185|NCT03232125|DRUG|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
47928186|NCT05206656|DRUG|Eribulin Mesylate|Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
47928187|NCT05206656|DRUG|Anlotinib|12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
47928188|NCT05387499|DRUG|NP-011 (Single Ascending Dose Phase)|The participants will receive assigned single dose of NP-011 after a minimum 8 hour fast on Day 1
48450252|NCT01318369|DRUG|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
48450253|NCT04822259|DEVICE|JOURNEY II BCS Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II BCS Total Knee System
48450254|NCT04822259|DEVICE|JOURNEY II CR Total Knee System|Undergoing Total Knee Replacement(resurfaced patella) with JOURNEY II CR Total Knee System
48450255|NCT05312983|OTHER|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~* Session A : objective audiological tests~* Session B ; subjective audiological tests~* Session C : balance tests."
48450256|NCT05312983|OTHER|Blood sampling|A 10 mL blood sample will be collected during the study.
48450257|NCT05312983|OTHER|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
48450258|NCT02987153|RADIATION|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
48450259|NCT06056414|OTHER|Energy Resonance by Cutaneous Stimulation|Energy Resonance by Cutaneous Stimulation session
48450260|NCT01310257|OTHER|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
48450261|NCT02158494|DEVICE|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
47928189|NCT05387499|DRUG|NP-011 (Multiple Ascending Dose Phase)|The participants will receive assigned dose of NP-011 after a minimum 8 hour fast once daily for 7 days
48450262|NCT02158494|DEVICE|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
48450263|NCT06563115|DRUG|(PEG)-BHD1028 Single Ascending Dose|4, 8, 16, 32, and 64 μg/Kg
48450264|NCT06563115|DRUG|(PEG)-BHD1028 Multiple Ascending Dose|8, 16, and 32 μg/Kg
48450265|NCT06563115|OTHER|Placebo|Diluent
48450266|NCT05032807|DRUG|Standard formulation|Cannabidiol 1000mg standard formulation, single dose, oral
48450267|NCT05032807|DRUG|Novel formulation|Cannabidiol 1000mg with lipid matrix, single dose, oral
48450268|NCT02749266|OTHER|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
47928190|NCT05387499|OTHER|NP-011 (Placebo)|The participants will receive single dose of NP-011 after a minimum 8 hour fast on Day 1 in Single Ascending Dose part and will receive once daily for 7 days after a minimum 8 hour fast in Multiple Ascending dose part of the study
47928191|NCT03167567|BEHAVIORAL|Presence of a medical clown during labor|Presence of a medical clown during labor
47928192|NCT03906916|DIAGNOSTIC_TEST|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
47928193|NCT03906916|DRUG|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
47928194|NCT02195011|DEVICE|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
48450269|NCT02749266|OTHER|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
48450270|NCT05336643|DEVICE|Radiofluorescence|Assessment of pelvic sidewall with Firefly and Sensei
48450271|NCT06338748|DEVICE|Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode|Dexcom G7 used in blinded mode
48450272|NCT04322292|DRUG|C-CAR088|"Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg.~Divided into three dose ranges of low(1.0-3.0×10\^6 CAR+T cells/kg),medium(3.0-6.0×10\^6 CAR+T cells/kg) and high(6.0-9.0×10\^6 CAR+T cells/kg).~Other Name: CBM.BCMA Chimeric Antigen Receptor T cell."
48450273|NCT04512586|PROCEDURE|Conduction System pacing and AV node ablation|See study arm description.
48450274|NCT04512586|PROCEDURE|Atrial fibrillation ablation by pulmonary vein isolation|See study arm description
47928195|NCT02195011|DRUG|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
47928196|NCT05054660|OTHER|caring chatbot|The investigators will use the developed caring chatbot to provide care to the cases and to collect case treatment data and interaction data between the case and the caring chatbot.
47928197|NCT04648969|DRUG|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
48450275|NCT02183311|DRUG|BI 1356 BS - single rising dose|
48450276|NCT02183311|DRUG|BI 1356 BS - multiple rising dose|
48450277|NCT02183311|DRUG|Placebo|
48450278|NCT01649921|DRUG|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
48450279|NCT01649921|OTHER|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
48450280|NCT04155450|OTHER|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~1. Flexing one upper extremity~2. Extending one lower extremity with a leg slide~3. Extending one lower extremity by lifting it off the mat~4. Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~   Progress to prone position:~5. Extending one lower extremity~6. Extending both lower extremity"
48450281|NCT04155450|OTHER|McKenzie Extension Exercise Protocol|"Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
48450282|NCT04155450|OTHER|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
48450283|NCT04371081|DEVICE|Amplatzer Piccolo Occluder|Interventional placement of vascular occluder
48450284|NCT05975905|BIOLOGICAL|Dose A KER-012|Dose A KER-012 (Q4W);
48450285|NCT05975905|BIOLOGICAL|Dose B KER-012|Dose B KER-012 (Q4W);
48450286|NCT05975905|BIOLOGICAL|Dose C KER-012|Dose C KER-012 (Q4W);
48450287|NCT05975905|BIOLOGICAL|Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks|Treatment Period (24 weeks): Placebo SC (Q4W) Extension Period (72 weeks after Placebo treatment): KER-012 (Dose B) SC (Q4W)
48450288|NCT01882686|OTHER|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
48450289|NCT01889407|DRUG|Idarubicin|8 mg/m2, iv drip on days 1-3
48450290|NCT03745963|BEHAVIORAL|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
48450291|NCT03745963|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
48450292|NCT01340495|RADIATION|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
48450293|NCT04747535|DEVICE|Auto-CPAP|AIrSense 10, Auto-CPAP, Minimum pressure 5 cm water, maximum pressure 10 cm water
48450294|NCT04747535|DEVICE|CPAP since before|A CPAP the patient uses since before because of previously diagnosed obstructive sleep apnea
48450295|NCT00740103|DRUG|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
48450296|NCT00838539|DRUG|Neratinib|
48450297|NCT00838539|DRUG|Temsirolimus|
48450298|NCT01038960|BEHAVIORAL|Exercise training|3 months supervised interval training
48450299|NCT04456881|OTHER|Patients with patellar dislocation undergo patellar femoral medial reconstruction|Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament
48450300|NCT02440711|DEVICE|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
48450301|NCT02440711|DEVICE|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
48450302|NCT03238183|DRUG|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
48450303|NCT03238183|DEVICE|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
48450304|NCT03716466|OTHER|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
48450305|NCT03716466|OTHER|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
48450306|NCT05279742|DRUG|MANP|Single subcutaneous injection 5 µg/Kg
48450307|NCT05279742|DRUG|Sacubitril/Valsartan|Oral single dose 97/103 mg
48450308|NCT05279742|DRUG|Oral Placebo|Oral single dose that contains no active ingredient
48450309|NCT05279742|DRUG|Injection Placebo|Single subcutaneous injection that contains no active ingredient
47928198|NCT04648969|DRUG|GnRH|1 intravenous dose of GnRH
48450310|NCT04776447|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02"
48450311|NCT04776447|DRUG|Placlitaxel|"Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
48450312|NCT04776447|DRUG|Atezolizumab|"Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions."
48450313|NCT03786016|BEHAVIORAL|8-Days in an Isolation, Confinement Unit|"Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study."
48450314|NCT05364853|BEHAVIORAL|In-Person Testing|Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
48450315|NCT05364853|BEHAVIORAL|Remote Testing|Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
48450316|NCT04740632|BEHAVIORAL|Personalized Nutritional Counseling by a multidisciplinary team|Active diet therapy, instructions on reading labels, cross-contamination, allergen-free, foods recipes
48450317|NCT00127153|BIOLOGICAL|V110, pneumococcal vaccine polyvalent|
47928199|NCT03719534|PROCEDURE|haplo-HCT|HCT will be performed with a haploidentical donor
48450318|NCT05831449|DRUG|Local anesthetic injection of CPL-01|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
48450319|NCT05831449|DRUG|Naropin, 0.5% Injectable Solution|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
48450320|NCT05831449|DRUG|Placebo|Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
48450321|NCT05191550|BEHAVIORAL|Virtual reality brain tumor simulation|"Task: Complete removal of a simulated tumour - distinguishable by colour and haptic properties - with minimal bleeding and damage to surrounding healthy brain using two surgical instruments (Cavitron Ultrasonic Aspirator and Bipolar pincers) of the NeuroVR (CAE Healthcare) surgical simulator.~Intervention: A single 28-minute simulation session, including six virtual subpial tumour resection attempts. Five simple practice scenarios (3 minutes per task) and one complex realistic scenario (13 minutes). Pre- and post-questionnaires to obtain participant demographics and assess face and content validity of the simulated tasks."
48450322|NCT02866357|OTHER|No intervention|Just collection of nasopharyngeal aspirate for assessment
48450323|NCT02537457|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
48450324|NCT02537457|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
48450325|NCT03269838|DIAGNOSTIC_TEST|ECG|Primary Percutaneous coronary intervention
48450326|NCT04830462|DRUG|Rifampicin 300 Mg Oral Capsule|Rifampicin 600 mg orally once daily for 4 months
48450327|NCT04830462|DRUG|Isoniazid 300 Mg ORAL TABLET|Isoniazid 300 mg daily for 6 months
48450328|NCT06146972|DRUG|Iguratimod|Iguratimod 25mg bid + tofacitinib 5mg bid
48450329|NCT06018285|BEHAVIORAL|Stepped Approach to Reducing Risk of Suicide in Primary Care|Intervention consists of implementation of clinical pathway for youth suicide risk
48450330|NCT03840291|DRUG|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
48450331|NCT04020952|OTHER|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
48450332|NCT04020952|OTHER|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
48450333|NCT04020952|OTHER|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
48450334|NCT00494338|DRUG|Docetaxel|
48450335|NCT06146374|OTHER|Placebo for SLV213|Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
48450336|NCT06146374|DRUG|SLV213|SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
48450337|NCT06558994|PROCEDURE|Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis.
48450338|NCT06558994|PROCEDURE|Ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
48450339|NCT02804815|DRUG|Aspirin 100mg|Aspirin 100mg
48450340|NCT02804815|DRUG|Aspirin 300mg|Aspirin 300mg
48450341|NCT02804815|DRUG|Placebo 100mg|Placebo 100mg
47928200|NCT03719534|PROCEDURE|haplo-cord HCT|Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
47928201|NCT00369629|DRUG|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.
48450342|NCT02804815|DRUG|Placebo 300mg|Placebo 300mg
48450343|NCT03684538|OTHER|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
48450344|NCT03684538|OTHER|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
48450345|NCT03684538|OTHER|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
48450346|NCT03684538|OTHER|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
48450347|NCT05956925|BEHAVIORAL|Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.|The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
48450348|NCT00443651|DRUG|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
48450349|NCT00443651|DRUG|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
48450350|NCT01421264|DRUG|Gabapentin|300mg capsules by mouth
48450351|NCT04543357|OTHER|Blood Draw|Blood Samples for NAb and ADA to AAV9
48450352|NCT02149420|DRUG|VAY736|
48450353|NCT02149420|DRUG|Placebo|
48450354|NCT06559085|PROCEDURE|Laproscopic posterior mesh rectopexy (Wells or LPMR)|After complete rectal mobilization, a mesh is inserted between the sacrum and the posterior rectum, sutured into the rectum, and fixed to the promontory. The mortality rates ranged from 0% to 1.2%, and recurrence rates ranged from 0% to 11% There was an overall improvement in continence (74%-100%), with conflicting results regarding constipation. New-onset constipation in 5% to 44% of patients was reported
48450355|NCT06559085|PROCEDURE|Laparoscopic lateral mesh rectopexy (Orr-Loygue)|This procedure involves complete mobilization of the rectum with two mesh strips sutured laterally to the rectal wall on both sides, and they were suspended to the promontory. There are several studies on this procedure using a laparoscopic approach. Lechaux et al. performed laparoscopic Orr-Loygue rectopexy in 35 patients. Incontinence improved in 27% of patients, and constipation improved in 19% but worsened in 27%. The recurrence rate was 3% (1/35) after a mean follow-up of 36 months. A study on 46 patients with laparoscopic Orr-Loygue procedure with posterior mobilization found a significant reduction in incontinence score after 1 year, but there were no changes in the use of laxatives. The recurrence rate was 4% after a median follow-up of 1.5 years
48450356|NCT05658783|OTHER|Hot water foot bath|Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
48450357|NCT04450069|COMBINATION_PRODUCT|CLBR001 and SWI019|Investigational immunotherapy for B cell malignancies
48450358|NCT06563336|OTHER|EMG-driven hand robot training|"Robot rehabilitation program was applied with Hand of Hope®(Rehab-Robotics Company, Hong Kong), and EMG-driven exoskeleton. The biggest advantage of this system is that it measures the residual muscle activity values with surface EMG(sEMG) sensors. The residual muscles activity is used by giving feedback to the patient.~This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick."
48450359|NCT06563336|OTHER|conventional occupational training|This treatment program, which was applied to both groups in the study, consisted of joint range of motion (ROM) exercises, stretching exercises for burn scars, strengthening exercises using putty or bands, and fine motor training such as writing and using a chopstick.
48450360|NCT04267276|DRUG|Part 1: BI 1265162 - intravenous|Intravenous solution
48450361|NCT04267276|DRUG|Part 2: BI 1265162 - oral|Oral solution
48450362|NCT04740658|OTHER|No intervention|There is no intervention
48450363|NCT01519258|OTHER|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
48279508|NCT06404190|COMBINATION_PRODUCT|Diode laser and 3% hydrogen peroxide|"Hydrogen peroxide due to its super radicals has a local antimicrobial effect. Since hydrogen peroxide can be easily available in a clinical setting and is cost-effective. It could be used for photo disinfection along with lasers.~The diode lasers that belong to the 655-980 nm spectrum could represent a safer alternative. Because of the transmission or scattering effect on hydroxyapatite, diode lasers have no effect on hard tissues and deposits. The photoactivation procedure uses photolysis of hydrogen peroxide with 810nm laser.~Hydrogen peroxide acts as an endogenous dye, which can increase the laser effect at this level and also generate ROS. Thus the combination of 3% H2O2 and laser light generate hydroxyl radicals as a result of photoactivation.~Therefore, the diode laser stimulation of 3%hydrogen peroxide has been utilized adjunctive to SRP to optimize clinical outcomes."
48279509|NCT05427474|DRUG|Propranolol , gabapentin|The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
48279510|NCT04690699|BIOLOGICAL|Lerapolturev|Lerapolturev administered via intravesical instillation once
48450364|NCT01519258|DEVICE|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
48098240|NCT05921409|DIETARY_SUPPLEMENT|Olive oil-supplemented Mediterranean Diet Intervention|"This intervention (treatment) consist of taking Olive Oil (placebo group made up of 103 patients and 22 healthy people) for 6 months, accompanied by Mediterranean diet-based menus. During this time, blood and stool samples were taken at different points: before the start of the intervention (T0), 3 months after the start (T1), at the end of the intervention in the sixth month (T2) and 6 months after leaving the study (TF). Hence, a total of 4 time points were taken for analysis: T0, T1, T2, TF. Additionally, and following these same time points, the physical and psychological health status of the participants will be evaluated using the SF-36 health questionnaire. Similarly, the course of the pathology in terms of the Fibromyalgia Impact Questionnaire (FIQ) score were recorded."
48279511|NCT04690699|OTHER|5% DDM|5% DDM and saline washes
48279512|NCT02354833|DRUG|Phenylephrine|
48450365|NCT04496349|DRUG|APG-115|QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
48450366|NCT04496349|DRUG|APG-2575|APG-2575 given orally each day in cycle, in repeated 21-day cycles
48450367|NCT06562348|OTHER|Standard of care|Patients will be offered palliative systemic treatment according to standard of care. Response evaluation will be performed with the imaging-based RECIST according to standard guidelines. Treatment pauses according to institutional guidelines. Blood samples will be analyzed retrospectively to evaluate ctDNA.
48620509|NCT02061800|DRUG|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
48620510|NCT02061800|DRUG|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
48620511|NCT02061800|DRUG|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
48620512|NCT06524531|PROCEDURE|Pulsed RF Neuromodulation|RF neuromodulation will be applied to the L2 and L3 segments bilaterally. Each segment will receive treatment for 6 minutes, either sequentially or simultaneously on both sides.
48279513|NCT02354833|DRUG|Norepinephrine|
48279514|NCT03251547|DRUG|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
48450368|NCT06562348|OTHER|ctDNA-RECIST guided palliative systemic treatment|"Patients are offered palliative systemic treatment according to standard of care. Response evaluation will be performed using ctDNA-RECIST.~ctDNA is measured before start of treatment. If the baseline sample is ctDNA negative the patient is transferred to an observational cohort, and sampling procedures continues as in the standard arm. If the baseline sample is ctDNA positive the patient continues in the ctDNA-RECIST guided arm. Treatment response is evaluated according to ctDNA-RECIST, and further sampling follows a predefined decision schedule."
48450369|NCT06239350|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (\~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.
48450370|NCT06239350|BEHAVIORAL|Contingency management|Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).
48450371|NCT06239350|BEHAVIORAL|Text-based support|All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
48450372|NCT05905640|OTHER|Method of PrEP delivery and consultation|All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
48450373|NCT05748990|DRUG|Intranasal insulin|160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
48450374|NCT05748990|DRUG|Placebo|0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
48450375|NCT00812786|DRUG|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
48450376|NCT06563362|RADIATION|De-escalation of irradiated volume|De-escalation of elective clinical target volumes as recommended by a model-based approach
48450377|NCT00856167|DRUG|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
48450378|NCT00856167|BEHAVIORAL|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
48450379|NCT00304187|DRUG|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
48450380|NCT00304187|DRUG|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
48450381|NCT05136001|DEVICE|polysomnography|Duration of sleep was collected with polysomnography on second postoperative night. (from 20:00pm to 06:00am).
48450382|NCT00849576|DRUG|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
48450383|NCT00849576|DRUG|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
48450384|NCT00849576|DRUG|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
48450385|NCT00849576|DRUG|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
48450386|NCT03506763|DRUG|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
48450387|NCT03506763|DRUG|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
48450388|NCT03506763|DRUG|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
48450389|NCT00617396|DRUG|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
48450390|NCT06172283|OTHER|Intermittent Fasting|Dietary intervention
48450391|NCT03631628|DEVICE|Bilateral Transcutaneous electrical nerve stimulation (Bi-TENS)|The stimulator is a 120z Dual-Channel TENS Unit (ITO Physiotherapy \& Rehabilittaion, Co, Ltd, Tokyo, Japan). The TENS stimulation will be at 100 Hz, with 0.2 ms square pulses at an intensity of twice the sensory threshold (defined as the minimum intensity at which subject reported feeling a tingling sensation and below the motor threshold as indicated by the absence of muscle twitching, to provide sensory stimulation to both paretic and intact arms. Two pairs of disposable surface electrodes will be applied over the median nerve from the carpal tunnel to the flexor digitorum superficialis and the superficial radial nerve from the extensor pollicis longus to the extensor digitorum communis, with the cathode on the proximal site, and the anode on the distal site.
48450392|NCT03631628|BEHAVIORAL|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of mirror, and paretic arm will be placed behind the mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively.~Participants will be encouraged to focus on the image of intact arm when performing upper limb exercises bilaterally."
48450393|NCT03631628|BEHAVIORAL|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~1. Elbow flexion and extension exercise~2. Forearm pronation and supination exercise~3. Wrist flexion and extension exercise~4. Wrist radial and ulnar deviation exercise~5. Fingers opposition exercise~6. Gripping exercise~The subject will complete bilaterally upper limb exercises during the 30 minutes period.~Intact arm will be placed in front of covered mirror, and paretic arm will be placed behind the covered mirror.~Joints involved will be flexed and extended in full available range in sitting positon, in order to improve the active control of elbow joint, wrist joint and all fingers joint respectively."
48450394|NCT03631628|BEHAVIORAL|Conventional Rehabilitation Program|Standardized upper limb training
48620513|NCT06524531|BIOLOGICAL|Leukocyte-Rich PRP Injection|Leukocyte-rich PRP will be prepared from the patient's blood and injected into the multifidus muscle at the L2 and L3 levels.
48450395|NCT06470906|DIETARY_SUPPLEMENT|Probiotic Group|The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.
48450396|NCT06470906|DIETARY_SUPPLEMENT|Placebo Group|The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.
48450397|NCT01262001|DRUG|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
48450398|NCT01262001|DRUG|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
48450399|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
48450400|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
48450401|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
48450402|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
48450403|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
48450404|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
48450405|NCT00841191|DRUG|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H\&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
48450406|NCT05356481|DEVICE|segmental muscle vibration|Segmental muscle vibration will delivered over the target muscles by means of vibrator with general physical therapy session
48450407|NCT00959153|DEVICE|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
48450408|NCT05572281|DRUG|Tasimelteon Oral Capsule|No additional information
48450409|NCT05572281|DRUG|Tasimelteon Oral Suspension|No additional information
48450410|NCT06321653|RADIATION|Hypofractionated radiotherapy scheme|Hypofractionated radiotherapy scheme with 2.67Gy/fraction for 15 fractions. WBRT with simultaneous integrated boost to the tumor bed
48450411|NCT06493019|DRUG|Pembrolizumab|Chemoradiation Pembrolizumab 200mg IV
48450412|NCT06493019|DRUG|Paclitaxel|Paclitaxel 50 mg/m\^2 IV
48450413|NCT06493019|DRUG|Carboplatin|Carboplatin AUC 2 IV
48450414|NCT06493019|RADIATION|Radiation|Delivered as per institutional standards
48450415|NCT06493019|DRUG|Pembrolizumab|Maintenance Pembrolizumab 400mg IV
48450416|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Survivors|The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
48450417|NCT04927013|BEHAVIORAL|Standard Outreach for Survivors|The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
48450418|NCT04927013|BEHAVIORAL|Message-based Outreach Intervention for Close Relatives|Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.
48098241|NCT05913739|OTHER|Oxygen Therapy|Nocturnal oxygen therapy minimum 6 hours
48098242|NCT05159141|BEHAVIORAL|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
48098243|NCT04026191|DEVICE|OrthoVisc®-T (OVT)|Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
48098244|NCT06468657|OTHER|mortality rates|mortality rates
48450419|NCT04927013|BEHAVIORAL|Standard Outreach for Close Relatives|The invitation letter shared by the survivor will provide a unique login code for each relative to visit the standard website with sections specifically for relatives that include information about genetic risk, the value of completing an online short validated risk screener, and the offer of free genetic counseling with the option to schedule an appointment.
48450420|NCT03702608|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - (PBMA) and CarboSil®~* Ridaforolimus drug"
48450421|NCT00942968|DRUG|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
48450422|NCT00463684|BIOLOGICAL|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
48450423|NCT00463684|BIOLOGICAL|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
48450424|NCT00078039|DRUG|Paliperidone ER|
48450425|NCT05674240|DEVICE|Intrathecal Targeted Drug Delivery|Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.
48450426|NCT05674240|COMBINATION_PRODUCT|Conservative medical management|Including physical therapy, oral or transdermal medications and injections
48450427|NCT04816461|DRUG|Amodiaquine Sulfadoxine-Pyrimethamin administration|SMC treatment
48450428|NCT04816461|DRUG|Dihydroartemisinin-Piperaquine|Roommates treatment if they are positive to malaria
48450429|NCT04816461|DIAGNOSTIC_TEST|Standard HRP2-RDT|Roommates screening with standard HRP2-RDT
48450430|NCT04816461|DIAGNOSTIC_TEST|Highly sensitive RDT|Roommates screening with highly sensitive RDT
48450431|NCT00205686|DRUG|DHEA|
48450432|NCT00205686|BEHAVIORAL|exercise|
48450433|NCT00761813|DEVICE|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
48450434|NCT00761813|DEVICE|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
48450435|NCT01426633|DRUG|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
48450436|NCT03747276|OTHER|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
48450437|NCT02157974|DRUG|Byetta 5Mcg Pen Injection|10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
48450438|NCT05015114|OTHER|Sarcopenia Assessment|Sarcopenia Assessment
48450439|NCT02926677|BEHAVIORAL|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
48450440|NCT02926677|BEHAVIORAL|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
48450441|NCT02926677|BEHAVIORAL|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
48450442|NCT02926677|DEVICE|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
48450443|NCT04118335|OTHER|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
48450444|NCT02704585|DEVICE|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
48450445|NCT02704585|DEVICE|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
48450446|NCT05259657|BEHAVIORAL|Lymfit Intervention|"Participants will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The research team will reach out to the participant via videoconferencing and help them to: download the Fitbit smartphone application; log-in using the anonymous study identification information; and pair their Fitbit with their smartphone application.~A kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed, plus an acceptability assessment survey."
48450447|NCT05259657|BEHAVIORAL|Wait-list control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
48450448|NCT04485767|BEHAVIORAL|Progressive Resistance Training Exercise|Progressive Resistance Training Exercise 2x weekly for 6 months.
48450449|NCT04485767|BEHAVIORAL|Flexibility and Balance Exercise|Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
48450450|NCT04207437|DEVICE|Vibration therapy|vibration therapy using hand held vibration device
48450451|NCT06165354|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.
48450452|NCT06165354|COMBINATION_PRODUCT|LiveSpo X-secret|"In Vietnam, LiveSpo X-SECRET is manufactured as two product lines: (1) Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam and ISO 13485:2016 (Certificate No YT117-19) and (2) comestic (Product declaration No.14981/22/CBMP-HA) under manufacturing standards approved by Hanoi Department of Health, Ministry of Health, Vietnam (Certificate No 118/CNĐĐKSXMP. Both product lines have the same probiotic composition.~The cosmetic type was used for the clinical trial conducted at Hanoi OGH. The Class-A medical device type was used for the clinical trial conducted at Bac Ninh CDC."
48450453|NCT04937439|OTHER|Traditional Physical Therapy program|"1. Facilitation of head control will be conducted.~2. Facilitation of trunk control will be applied~3. Facilitation of rolling~4. Facilitation of righting, protective and equilibrium reactions from supine, prone and sitting on a ball~5. Stretching exercises for the muscles liable to be tight~6. Facilitation of sitting"
48450454|NCT04937439|OTHER|Segmental trunk training A|Group (A) will wear an external segmental trunk support extended from the level of pelvis to a level just below the rib cage.
48450455|NCT04937439|OTHER|Segmental trunk training B|Group (B) will receive the same program given to (group A) while wearing an external segmental trunk support extended from the level of pelvis to a level just below the inferior angle of scapula.
48450456|NCT04937439|OTHER|Segmental trunk training C|Group (C) will receive the same program given to (group A and B) while wearing an external segmental trunk support extended from the level of last rib to the level of the inferior angle of scapula.
48279515|NCT01903876|BEHAVIORAL|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
48279516|NCT01903876|BEHAVIORAL|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
48450457|NCT05830084|DRUG|regorafenib tablet|"Regorafenib will be escalated/de-escalated, starting at DL0:~* DL1: 82 mg/m\^2 once daily for 21 days/28 days (max 160mg) (100% of the RP2D)~* DL0 (starting dose): 66 mg/m\^2 once daily for 21 days/28 days (max 120mg) (80% of the RP2D)~* DL-1: 50 mg/m\^2 once daily for 21 days/28 days (max 80mg) (60% of the RP2D)"
48450458|NCT04962594|OTHER|Experimental formulas (EF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
48450459|NCT04962594|OTHER|Control formulas (CF)|First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months
48450460|NCT04962594|OTHER|Breast feeding (BF)|Exclusive breast feeding up to 4 months
48450461|NCT05450107|PROCEDURE|Open Reduction Internal Fixation|Surgical intervention by lag screw or plate fixation
48450462|NCT05450107|PROCEDURE|Cast immobilisation|Cast immobilsation for a total of 6 weeks with gradual increase in weight bearing after 2 weeks
48450463|NCT02317263|DRUG|testosterone|
48450464|NCT02317263|DRUG|placebo gel|
48450465|NCT00346385|DRUG|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
48450466|NCT04071652|DEVICE|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
48279517|NCT01393587|PROCEDURE|Taking blood samples|
48279518|NCT05229965|DRUG|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
48450467|NCT01194648|OTHER|questionnaire administration|
48450468|NCT01194648|PROCEDURE|assessment of therapy complications|
48450469|NCT01194648|PROCEDURE|high-intensity focused ultrasound ablation|
48450470|NCT01194648|PROCEDURE|multiparametric magnetic resonance imaging|
48450471|NCT01194648|PROCEDURE|quality-of-life assessment|
48450472|NCT01194648|PROCEDURE|transperineal prostate biopsy|
48279519|NCT05229965|DRUG|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
48279520|NCT05229965|DRUG|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
48279521|NCT04433117|BIOLOGICAL|Shefabone|Silica-calcium phosphate composite.
48279522|NCT04433117|BIOLOGICAL|Bio-Oss|Xenograft Bone substitute. Bone from animals.
48279523|NCT01931865|DRUG|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
48450473|NCT01194648|PROCEDURE|transrectal prostate biopsy|
48450474|NCT03730363|DRUG|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
48450475|NCT05044338|DIAGNOSTIC_TEST|imaging|(1) Build the first full information big data cloud platform for diagnosis, treatment and clinical research of senile valvular disease in China (2) To establish a cohort of elderly patients with valvular disease in China and a complete database covering clinical information, functional, imaging evaluation, treatment and follow-up; (3) To analyze the clinical characteristics, functional status and imaging characteristics of senile valvular disease in China, and to understand the current situation of diagnosis and treatment; To establish a whole process standardized comprehensive evaluation system of clinical indicators of senile valvular disease combined with a variety of imaging for Chinese people.
48450476|NCT03720691|DEVICE|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
48279524|NCT06003959|OTHER|Routine nursing care|Preterm infants in the control group did not receive any intervention other than the routine feeding protocol applied in the clinic.
48279525|NCT06003959|OTHER|breastfeeding support system|The body weight of preterm infants in the experimental group was measured and recorded each morning before their first feeding. Mothers of these infants were asked to complete the Mother-Infant Attachment Scale (MIAS) prior to the procedure. The physician determined the appropriate amount of breast milk the infant should receive during feeding. Before each feeding, the neonatal nurse ensured the sterile preparation of the milk and transferred it to the Breastfeeding Support System. The mothers were then prepared for the procedure, with the neonatal nurse explaining how the breastfeeding support system worked. Once both the mother and baby were ready, the baby was placed at the mother's breast. After feeding, the mothers were asked to complete the MIAS again.
48279526|NCT06458764|OTHER|Questionnaire|none, it's a incidence-prevalence study
48279527|NCT03392766|DEVICE|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
48279528|NCT03392766|DEVICE|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
48279529|NCT02317510|PROCEDURE|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
48279530|NCT02317510|PROCEDURE|general anesthesia|General anesthesia for laparoscopic cholecystectomy
48279531|NCT03180736|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
48279532|NCT03180736|DRUG|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
48279533|NCT03180736|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
48279534|NCT06657235|OTHER|Transitional Care Program|Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. The participant will be monitored continuously while on the platform and up-to-date reports will be shared with the participant's relevant care providers every 30 days or as needed. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.
48279535|NCT03547141|DRUG|MBA-P01|injection of MBA-P01 into the muscle of each contralateral foot in equal doses
48279536|NCT03547141|DRUG|BOTOX|injection of BOTOX into the muscle of each contralateral foot in equal doses
48279537|NCT05527184|DRUG|IMGN151|IMGN151 is an antibody-drug conjugate (ADC).
48279538|NCT06342310|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
48279539|NCT01627145|DRUG|Solifenacin|Solifenacin 5 mg qd,
48279540|NCT05569135|DEVICE|Laser ablation|A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
48279541|NCT03871907|BEHAVIORAL|Digital technology|Lifestyle-Focused Text Messaging
48279542|NCT04083495|BIOLOGICAL|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells
48279543|NCT04083495|DRUG|Bendamustine|70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
48279544|NCT04083495|DRUG|Fludarabine|30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
48279545|NCT04083495|DRUG|Cyclophosphamide|300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
48279546|NCT04882878|OTHER|Placebo|Placebo will be administered intravenously.
48279547|NCT04882878|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
48279548|NCT04882878|DRUG|Standard-of-care treatment|Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
48279549|NCT04118803|DEVICE|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
48279550|NCT05987644|DRUG|Alectinib|600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)
48279551|NCT05987644|RADIATION|Stereotactic Radiosurgery|SRS dose varies by brain met size and location
48279552|NCT05875168|DRUG|DS-3939a|One IV infusion Q3W on Day 1 of each 21-day cycle
48279553|NCT03132077|PROCEDURE|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
48279554|NCT03220412|BEHAVIORAL|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
48279555|NCT06656767|OTHER|No intervention|This study utilises pre-collected samples only.
48279556|NCT06041243|OTHER|Game-Based Exercises|Exercises aimed to improve postural balance with four different games
48279557|NCT05328947|OTHER|Modified Functional Reach and Functional Reach|Establishment of Modified Functional Reach Test (mFRT) and Function Reach Test (FRT) values for individuals with no functional impairments.
48450477|NCT03720691|DEVICE|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
48450478|NCT06597370|OTHER|Gene expression mRNA of IgG anti-spike|"b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.~c) Sample processing:~* tRNA extraction from all samples.~* cDNA synthesis~* Real time PCR performance."
48450479|NCT05365308|BEHAVIORAL|Clinical supports|Quality improvement tools for iron deficiency anemia that include computer-assisted identification, an EHR registry, facilitated GI referral, an EHR tool for documentation, and physician education
48450480|NCT01631552|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered via intravenous (IV) infusion
48450481|NCT06280781|DIAGNOSTIC_TEST|MRI Scans|"The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4."
48450482|NCT01931553|OTHER|Standardized attending morning rounds|
48450483|NCT01101620|DRUG|Levosimendan|
48450484|NCT03681470|DRUG|Aczone Gel|Aczone Gel 7.5%
48450485|NCT03876054|DEVICE|Spinal cord stimulation (SCS)|Subjects will be implanted with market-released Abbott SCS systems
48450486|NCT03876054|DEVICE|Dorsal root ganglion stimulation (DRG)|Subjects will be implanted with market-released Abbott DRG system
48450487|NCT01837914|PROCEDURE|Maxillary expansion|
48450488|NCT01837914|PROCEDURE|Adenotonsillectomy|
48450489|NCT04538677|DEVICE|Video consultation|A two-way audio and visual connection between patients and surgeons
48450490|NCT05113953|DRUG|Centanafadine|Sustained-release oral tablets
48450491|NCT05113953|DRUG|Placebo|Oral tablets
48450492|NCT05074472|DRUG|ZB131|ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
48450493|NCT03016806|RADIATION|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
48450494|NCT03016806|RADIATION|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
48279558|NCT04990167|DRUG|Tiotropium Bromide|Using Tiotropium as a single agent asthma controller medication
48279559|NCT01116193|DRUG|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
48279560|NCT03258814|BEHAVIORAL|Active Supervised Training (AST)|The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
48450495|NCT03016806|DRUG|Cyclophosphamide|50 mg/kg or 60 mg/kg
48450496|NCT03016806|DRUG|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
48279561|NCT03258814|BEHAVIORAL|Standard of Care (SOC) Physiotherapy|Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
48279562|NCT06586489|BEHAVIORAL|Virtual Reality Natural Landscape Exposure|Participants will view immersive virtual natural landscapes using virtual reality (VR) headsets for 10 minutes, three times a week, over eight weeks. They will choose the natural landscapes they wish to visit and admire, allowing for personalized engagement with the virtual environment.
48279563|NCT06586489|BEHAVIORAL|Tablet Screen Natural Landscape Exposure|Participants will watch immersive virtual natural landscapes on a tablet screen for 10 minutes, three times a week, over eight weeks. Participants can select the natural landscapes they prefer to view during the sessions, providing a personalized experience.
48279564|NCT04406571|OTHER|Data record|Data record
48279565|NCT03171922|BEHAVIORAL|Internet Diet|ID group have online dietary coach every 2 weeks
48450497|NCT03016806|PROCEDURE|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
48450498|NCT03016806|DRUG|Busulfan|0.8 mg/kg x 16 doses
48450499|NCT03016806|DRUG|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
48450500|NCT03016806|DRUG|Melphalan|140 mg/m2
48450501|NCT04247243|DEVICE|Rapid testing|Abbott ID NOW Strep A testing
48450502|NCT04247243|DIAGNOSTIC_TEST|Reference testing|Culture-based testing
48450503|NCT03320863|DEVICE|Enso device|An active Enso device that delivers neuromodulation therapy.
48450504|NCT06201390|BEHAVIORAL|Sleep consistency|Participants will be asked to maintain a consistent bed- and wake-time.
48450505|NCT03107091|DRUG|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
48450506|NCT01844050|DRUG|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
48450507|NCT01844050|DRUG|Placebo|
48450508|NCT00672984|DRUG|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
48450509|NCT00672984|DRUG|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
48450510|NCT00672984|DRUG|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
48450511|NCT03651219|DRUG|Apatinib|Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
48450512|NCT03651219|DRUG|Irinotecan|Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
48450513|NCT03035643|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
48450514|NCT05332002|DRUG|Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)|"This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC).~The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:~1. mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:~2. FOLFIRI: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2~3. Nivolumab(Optional) The chemotherapy combination of FOLFOX and FOLFIRI is a FDA approved treatment for advanced bowel and gastric"
48450515|NCT01650350|DRUG|Naltrexone|"4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study."
48450516|NCT00688571|DEVICE|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
48450517|NCT05450653|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the delivery Microcatheter (BALTACCI-BDPE100)|A Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus with severe congenital diaphragmatic hernia (o/e LHR \<25% with liver up) during the FETO procedure between gestational age 27 weeks 0 days and 29 weeks and 6 days. The fetal tracheal balloon will be removed at between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
48450518|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
48450519|NCT01028586|DRUG|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
48279566|NCT03171922|BEHAVIORAL|Clinic Diet|CD group have every 2 weeks visit at clinic
48450520|NCT01028586|DRUG|Placebo|matching placebo tablets
48450521|NCT03012529|DRUG|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
48450522|NCT03012529|DRUG|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
48450523|NCT06465927|OTHER|Clinical data collection|Clinical data of elderly acute appendicitis patients with an appendicolith who underwent emergency appendectomy were collected and analyzed.
48450524|NCT05511363|DRUG|KarXT|KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
48450525|NCT05511363|DRUG|Placebo|Placebo Capsules
48450526|NCT04939571|OTHER|Registry of preterm born infants with treatment-requiring ROP|All prematurely born infants who develop treatment requiring ROP and are treated (independent of the kind of treatment modality) at a center that participates in the registry are eligible for database entry.
48098245|NCT06630026|OTHER|The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.|• The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society and to make its validity and reliability in Turkish. It has 5 questions. This study will be conducted with Parkinson patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
48450527|NCT01175135|DRUG|PF-02545920|5 mg tablet every 12 hours for 28 days
48450528|NCT01175135|DRUG|PF-02545920|15 mg tablet every 12 hours for 28 days
48450529|NCT01175135|DRUG|Placebo|One tablet/capsule every 12 hours for 28 days
48450530|NCT01175135|DRUG|Risperidone|3 mg capsule every 12 hours for 28 days
48450531|NCT00130377|BIOLOGICAL|cell therapy|autologous or allogeneic cells
48450532|NCT04870320|BEHAVIORAL|Endeavor: Computer-Based Cognitive Stimulation Intervention|Endeavor application will be utilized by participant on iPad
48450533|NCT04870320|BEHAVIORAL|Words!: Computer-Based Cognitive Stimulation Intervention|Words! application will be utilized by participant on iPad
48450534|NCT04870320|OTHER|Quality of Life (QOL) Questionnaires|Standardized QOL questionnaire will be administered at each study visit
48450535|NCT06485804|OTHER|Smartphone application guided exercises|"Participants in the intervention group will use a smartphone application to execute a self-rehabilitation program. The app will integrate:~* Basic information about neck pain and ergonomic advice.~* A series of evaluation questions on pain and function.~* Appropriate sets of exercises with videos and instructions.~* Daily reminders.~* Evaluation reports providing feedback and adherence."
48450536|NCT00551863|BEHAVIORAL|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
48450537|NCT02259244|BEHAVIORAL|Weight reduction program|
48450538|NCT06420687|DEVICE|Clinically prescribed prosthesis|Clinically prescribed prosthesis:
48450539|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + 1-DOF|1-DOF wrist rotation and1-DOF hand
48098246|NCT05608499|DRUG|Duobrii|topical contains active drug lotion, once daily for 4 weeks then twice daily for 8 weeks
48098247|NCT05608499|DRUG|Placebo|Topical does not contain active properties of study drug
48279567|NCT01477905|DEVICE|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
48450540|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Wrist flexion +1-DOF|2-DOF wrist (rotation and flexion) and 1-DOF hand
48450541|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Multi DOF hand|1-DOF wrist rotation and multi-DOF hand
48450542|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + wrist flexion + Multi DOF hand|2-DOF wrist (rotation and flexion) and multi-DOF hand
48450543|NCT04534621|OTHER|Electronic survey|Brazilian chiropractors will be invited by email and social media to answer an electronic survey.
48620514|NCT06524531|PROCEDURE|Physiotherapy Alone|Standard physiotherapy regimen tailored to each participant's needs. This may include exercises to improve flexibility, strength, and endurance of the back muscles, as well as education on posture and body mechanics.
48450544|NCT03061591|DIETARY_SUPPLEMENT|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
48450545|NCT03061591|OTHER|Placebo|Placebo capsules
48450546|NCT06046820|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
48450547|NCT06046820|DRUG|Control Arm (Conventional Therapy)|Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
48450548|NCT04505163|PROCEDURE|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone
48450549|NCT04505163|DEVICE|Cryoballoon PVI + Posterior Wall Isolation|Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
48450550|NCT06562257|OTHER|Honey|Honey has a long-standing reputation for promoting wound healing and offers a more economical treatment modality. Nusantara Honey, a GMP-certified product available on the market, met our criteria for quality and safety.
48450551|NCT06562257|OTHER|PHMB Solution|PHMB is an antimicrobial polymer that is effective against intracellular and biofilm forms of S. aureus. PHMB is quite effective in the treatment of wounds in deep neck abscesses.
48450552|NCT01490567|DRUG|Donepezil|5 mg/day
48450553|NCT01490567|DRUG|placebo|placebo 5mg/d
48450554|NCT01532635|RADIATION|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
48450555|NCT01532635|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
48450556|NCT01532635|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
48450557|NCT01532635|DRUG|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
48450558|NCT01532635|DRUG|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
48450559|NCT01532635|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
48450560|NCT05911308|DRUG|Durvalumab|1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.
48450561|NCT05911308|DRUG|Carboplatin|Carboplatin IV infusion will be given on day 1 of each cycle for 3 cycles. The dose will be AUC 5.
48450562|NCT05911308|DRUG|Abequolixron|100 or 120 mg Abequolixron will be administered by mouth twice a day for 5 days followed by 2 days off throughout your treatment (5 days a week for up to 9 weeks).
48450563|NCT05911308|DRUG|Abraxane|100 mg/m2 Abraxane will be given by IV infusion on days 1, 8, and 15 of each cycle for 3 cycles.
48450564|NCT05911308|DRUG|Pemetrexed|500 mg/m2 pemetrexed will be given by IV infusion on day 1 of each cycle for 3 cycles.
48450565|NCT00907907|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
48450566|NCT00907907|DRUG|CellCept® Tablets|CellCept® Tablets, 500 mg
48098248|NCT05608499|DRUG|Bryhali|Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii. Bryhali lotion once daily up to 12 weeks only if Duobrii is not tolerated.
48098249|NCT00447434|DRUG|Natto extract (Nattokinase)|
48450567|NCT01370083|BEHAVIORAL|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
48450568|NCT01370083|BEHAVIORAL|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
48450569|NCT00121901|DRUG|glyceryl nitrate|
48450570|NCT05840133|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
48450571|NCT02175602|DRUG|Escitalopram|10 milligrams administered each morning
48450572|NCT02175602|DRUG|Sertraline|50 milligrams administered each morning
48450573|NCT02175602|DRUG|DCV 3DAA FDC|Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
48450574|NCT02175602|DRUG|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
48450575|NCT06242028|DRUG|Group P|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
48450576|NCT06242028|DRUG|Group S|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
48450577|NCT03781102|BEHAVIORAL|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
48450578|NCT05393050|DRUG|Colquhounia Root Tablet|Colquhounia Root Tablet is a tripterygium preparation
48450579|NCT05393050|DRUG|Methotrexate tablets|Methotrexate is a drug used to treat rheumatoid arthritis
48620515|NCT01980758|PROCEDURE|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
48450580|NCT06558617|DIAGNOSTIC_TEST|SARC-F Questionnaire|The SARC-F scale consists of five components: strength, walking assistance, rising from a chair, stair climbing, and falls. These elements were selected to reflect changes in health status related to the effects of sarcopenia. Scores on the SARC-F scale range from 0 to 10, composed of five domains, assesses strength, walking assistance, raising from a chair, stair climbing and falls. Each domain score ranges from 0-2. A SARC-F score of ≥4 was considered abnormal. The Thai-version SARC-F questionnaire has been validated in Thai older adults.
48450581|NCT06558617|DIAGNOSTIC_TEST|Calf Circumference Measurement|Calf circumference was measured using a nonelastic tape measure while the participant was standing with relaxed legs. The tape was placed snugly and flat around the widest part of the calf, parallel to the floor. According to the AWGS 2019 criteria, calf circumferences were considered abnormal if they were less than 34 cm for males and less than 33 cm for females.
48450582|NCT06558617|DIAGNOSTIC_TEST|SARC-CalF Questionnaire|This questionnaire integrates the SARC-F and calf circumference as a trigger for case finding. If the calf circumference is below the cut-off value, 10 points are added to the SARC-F score for evaluation. The SARC-CalF score ranges from 0 to 20, with a score of ≥11 considered abnormal for sarcopenia screening.
48450583|NCT02807987|DRUG|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
48450584|NCT00830258|DRUG|Pravastatin sodium 80 mg tablets|1 x 80 mg
48450585|NCT00830258|DRUG|Pravachol® 80 mg tablets|1 x 80 mg
48450586|NCT03834077|OTHER|Tissue flossing|Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
48450587|NCT03834077|OTHER|Placebo comparator|Conventional physiotherapy in addition to flossing without tension
48450588|NCT05412485|OTHER|Robotic assisted gait training|Robotic assisted gait training is advanced technology used in the rehabilitation of neurological injuries and conditions like spinal cord injury, brain injury, stroke, multiple sclerosis, Parkinson's, cerebral palsy. It provides a repetitive task-specific motor training and modulates afferent input to spinal cord to generate rhythmic gait patterns that may be transformed to overground walking. The intensive repetitions of the rhythmic stepping movement during the training stimulates dependent plasticity and it may lead to brain reorganization. It facilitates cortical neural activities associated with motor control of walking.
48450589|NCT06410638|DIAGNOSTIC_TEST|Six Minute Walking Test|It is applied in a 30 m long corridor in an indoor environment, and the distance walked by the patient in a six-minute period, oxygen saturation, heart rate, and change in dyspnea are recorded. For this, before starting the test, oxygen saturation, heart rate, arterial blood pressure and dyspnea level according to the Borg scale are recorded. The same parameters are measured again at the end of the test. The feature of this test is that the person walks at his own pace, stopping when necessary and allowing the use of oxygen. It is an exercise test that is easy to perform and well tolerated.
48450590|NCT06410638|DIAGNOSTIC_TEST|Shuttle walking test|Shuttle walking test at increasing speed is an exercise test in which walk between two cones 10 m apart at an increasing speed throughout the test and each 10-meter journey between the two cones is counted as a shuttle.
48450591|NCT06346483|PROCEDURE|Dusting without Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
48450592|NCT06346483|PROCEDURE|Dusting with Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
48450593|NCT06346483|OTHER|Moses 2.0 Modulation|Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology used for lithotripsy and BPH treatments
48450594|NCT04629963|OTHER|Pain Evaluation and BPISF|Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
48450595|NCT04629963|OTHER|Surveys, a fingerstick blood sample, EMAs, and a digital wearable device|The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
48450596|NCT05572437|DEVICE|Music Therapy|Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
48450597|NCT05582915|DIAGNOSTIC_TEST|Blood sampling|4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
48098250|NCT03350737|OTHER|Physical rehabilitation|Standard treadmill exercise session
48450598|NCT00350389|BEHAVIORAL|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
48450599|NCT06426290|BEHAVIORAL|post-surgery psychological evaluation|"Following questionnaires will be done :~Patient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) Three Factor Eating Questionnaire (TFEQ-R21) Quality of life for obesity and dietetic questionnaire (EQVOD) Body Esteem Scale (BES) Figure Rating Scale (auto-questionnaire)"
48450600|NCT00629122|DRUG|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
48620516|NCT03725553|DRUG|Intramyometrial Vasopressin|a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
48098251|NCT03350737|DRUG|Heparin|Heparin i.v.
48098252|NCT03350737|OTHER|Placebo|Sodium Chloride 0.9% i.v.
48098253|NCT02050958|DRUG|OXP001|
48098254|NCT02050958|DRUG|Ibuprofen|
48098255|NCT05317962|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Abbreviated transthoracic echocardiogram
48098256|NCT06406543|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|an oral solution of vitamin D in a refined olive oil solution
48450601|NCT00629122|DRUG|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
47928202|NCT00369629|DRUG|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
48450602|NCT00629122|DRUG|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
48450603|NCT00629122|DRUG|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
48450604|NCT06208358|DEVICE|tACS|We aim to use tACS devices to improve the disrupted interpersonal interaction among gaming disorder individuals.
48450605|NCT06562452|DIAGNOSTIC_TEST|Injectable platelet rich fbirin|fter the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.
48450606|NCT00070915|BEHAVIORAL|Tai chi|
48450607|NCT00070915|BEHAVIORAL|Mindfulness-based Stress Reduction program|
48450608|NCT00070915|PROCEDURE|Therapeutic massage|
48450609|NCT05600322|DRUG|Hexaminolevulinate Hydrochloride|Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
48450610|NCT05600322|DEVICE|Richard Wolf Photodynamic Diagnostic Equipment (PDD) system|Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
48450611|NCT04392999|DRUG|Intraarticular platelet rich plasma cervical facet injection|Injection of PRP into the cervical facet joints.
48450612|NCT04392999|DRUG|Corticosteroid injection|Injection of corticosteroid into the cervical facet joints.
48450613|NCT04349553|BIOLOGICAL|ZH9PA and ZH9|150mL vaccine for oral administration
47928203|NCT05535218|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|"Neoadjuvant treatment: 10 mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
47928204|NCT00427180|DEVICE|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
47928205|NCT03126552|BIOLOGICAL|Necator americanus L3 larvae|50 Necator americanus L3 larvae
47928206|NCT03928093|DRUG|Pregabalin|Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant \< 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
48098257|NCT05448066|DIAGNOSTIC_TEST|Component resolved diagnosis|Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
48450614|NCT04349553|BIOLOGICAL|Placebo|150mL vaccine for oral administration
48450615|NCT04349553|BIOLOGICAL|ZH9PA|150mL vaccine for oral administration
48450616|NCT01094054|PROCEDURE|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
48450617|NCT01094054|BEHAVIORAL|Dietary and lifestyle modification|"Dietary and lifestyle modification~Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
47928207|NCT06442631|BEHAVIORAL|MyStroke|MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.
47928208|NCT00003001|DRUG|fluorouracil|
48450618|NCT00051233|PROCEDURE|World Wide Web-Based Psychoeducation|
48450619|NCT03648580|DIETARY_SUPPLEMENT|Ensure Complete powder|Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
48620517|NCT03725553|DRUG|Placebo|the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
47928209|NCT00003001|DRUG|gemcitabine hydrochloride|
47928210|NCT00003001|DRUG|leucovorin calcium|
48279568|NCT01477905|DEVICE|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
48279569|NCT01564784|DRUG|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
48279570|NCT01564784|DRUG|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
48279571|NCT01564784|DRUG|HIDAC (high dose cytarabine)|cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times
48279572|NCT01564784|DRUG|cytarabine and mitoxantrone|mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
48279573|NCT03372525|DEVICE|HFOV|Infants were randomized to HFOV
48279574|NCT03372525|DEVICE|CMV|Infants were randomized to CMV
48279575|NCT05237557|BEHAVIORAL|Preoperative nurse dialogue|Performance of a preoperative nurse dialogue prior major visceral surgery
48279576|NCT06656429|DRUG|Transforaminal Epidural Steroid Injections|Transforaminal Epidural Steroid Injections
48279577|NCT00250393|DRUG|Istradefylline (KW-6002)|
48279578|NCT06657768|DRUG|LY4006895|Administered IV
48279579|NCT06657768|DRUG|Placebo|Administered IV
48279580|NCT03071718|OTHER|Mediterranean diet|"Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~* 7 portions of milk or yogurt plus whole grain cereals,~* 7 portions of nuts (30g)~* At least 3 portion of absolute legumes~* 14 portions of vegetables~* 21 portions of fruit~* 4 portions of whole grain pasta~* 3 portions of whole grain pasta with vegetables or legumes~* 7 portions of whole grain bread~* 3 portions of fish~* Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period."
48279581|NCT03071718|OTHER|Control Diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
48279582|NCT06651476|DRUG|oxytocin|Oxytocin 10 IU will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
48279583|NCT06651476|DRUG|placebo|A placebo will be administered over 30 minutes by intravenous infusion and repeated 30 minutes after the end of the first infusion.
48279584|NCT03981029|OTHER|4.0mg Folic Acid received through participation in FACT (NCT01355159)|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"
48279585|NCT03981029|OTHER|Placebo received through participation in FACT|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."
48279586|NCT00843180|OTHER|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
48279587|NCT04700267|DRUG|GLPG3970 film-coated tablet|GLPG3970 for oral administration
48279588|NCT04700267|DRUG|Placebo film-coated tablet|Placebo for oral administration
48279589|NCT04680884|DRUG|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
48279590|NCT04680884|DRUG|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
48279591|NCT04680884|DRUG|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
48279592|NCT04680884|OTHER|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
48279593|NCT05412706|DRUG|Niraparib|"Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles."
48279594|NCT00278876|DRUG|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
48279595|NCT01624142|BIOLOGICAL|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
48279596|NCT04288024|BEHAVIORAL|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
48279597|NCT01793987|DEVICE|Coblation polypectomy|
48279598|NCT01475890|DIETARY_SUPPLEMENT|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
48450620|NCT03648580|OTHER|verbal nutrition education|give the verbal nutrition education
48450621|NCT01923545|DRUG|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
48450622|NCT01923545|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
48450623|NCT03186651|DEVICE|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
48450624|NCT01923909|DRUG|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
48450625|NCT01923909|DRUG|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
48450626|NCT06225921|DRUG|Adebrelimab|Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
48450627|NCT06225921|DRUG|Dalpiciclib 100mg|Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
48450628|NCT06225921|DRUG|Dalpiciclib 150mg|Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
48450629|NCT05458687|OTHER|Chinese herbal medicine decoction、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application、Nursing/Diet and health education and guidance|"* Chinese herbal medicine decoction: prescribed three times a day, seven days a week, and lasts for up to one weeks.~* Acupuncture or Laser acupuncture pen treatment: twice a week, once for 20 minutes,up to a total of one week.~* Acupoint Tuina massage: once a day for up to 20 minutes each time, for up to a week.~* Acupoint application of traditional Chinese herbal medicinal cake: Apply warm navel ointment in our hospital to CV 4 (Guanyuan) point every day, and remove after getting up the next day, seven days a week for up to one week.~* Nursing and health education and guidance: teach the patients and their family members the matters needing attention in daily life.~* Diet and health education:give personalized Traditional Chinese Medicine diet guidance and recommendations in accordance with Traditional Chinese Medicine physique syndrome."
48450630|NCT00573443|DRUG|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
48450631|NCT00573443|DRUG|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
48450632|NCT00573443|DRUG|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
48450633|NCT00178802|OTHER|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
48450634|NCT02599558|DEVICE|Cytosponge|A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
48450635|NCT00373256|DRUG|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
48450636|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
48450637|NCT00373256|DRUG|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
48450638|NCT00373256|DRUG|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
48450639|NCT00002880|DRUG|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
48450640|NCT04509453|DEVICE|McGRATH laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
48450641|NCT04509453|DEVICE|Macintosh laryngoscopy|Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
48450642|NCT04353362|DRUG|Ofloxacin|400 mg, 1 time per day for 5 days
48450643|NCT04353362|DRUG|Amoxicillin|500 mg, 3 times per day for 7 days
48450644|NCT04353362|DRUG|Metronidazole|500 mg, 3 times per day, for 7 days
48279599|NCT01475890|DIETARY_SUPPLEMENT|Placebo|Once a day for 12 months.
48279600|NCT06487949|DRUG|valsartan-amlodipine 80/5 mg FDC|fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
48450645|NCT03362294|DRUG|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
48450646|NCT03362294|DRUG|GA Depot 25mg once monthly|Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
48450647|NCT05498662|DEVICE|T3 Pro dental implant system|treatment of tooth loss with T3 Pro dental implants
48620518|NCT04344444|DRUG|Hydroxychloroquine|tablets provided as described in Arm B
48620519|NCT04344444|DRUG|Azithromycin|tablets provided as described in Arm C
48279601|NCT06487949|DRUG|valsartan 80 mg and amlodipine 5 mg as free combination|Free combination of valsartan 80 mg and amlodipine 5 mg given separately
48279602|NCT00699790|DRUG|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
48279603|NCT00699790|DRUG|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
48279604|NCT05352191|DRUG|Beclomethasone|inhaled 800ug
48279605|NCT06071611|OTHER|Experimental: Oxygen-Ozone (O2-O3)|Oxygen-Ozone (O2-O3) treatment by rectal insufflations for 5 weeks (3 sessions for week).
48450648|NCT06402799|BEHAVIORAL|Home-based E-biking|The e-biking intervention consists of 3 sessions per week at the beginning of the study and gradually increases over the training period to 6 sessions per week, with three of these sessions being online and group-supervised. Heart rate will be monitored as well as power in Watt at each session.
48450649|NCT02222818|DEVICE|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
48450650|NCT02222818|DEVICE|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
48098258|NCT05448066|DIAGNOSTIC_TEST|Standard diagnosis|Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
48450651|NCT00526188|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
48450652|NCT00394485|DRUG|Procaterol|
48450653|NCT00394485|DRUG|Tiotropium|
48450654|NCT01653951|OTHER|nurse-led care management or peer-led self management|
48450655|NCT02684747|OTHER|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
48450656|NCT02684747|OTHER|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
48450657|NCT05921864|OTHER|Passive heat exposure|Participants will be exposed to heat in a chamber.
48450658|NCT05921864|OTHER|Active heat exposure|Participants will participate to a 6-hour run.
48450659|NCT02818530|DEVICE|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
48450660|NCT02818530|DEVICE|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
48450661|NCT03874052|DRUG|Ruxolitinib|Given PO
48450662|NCT03874052|DRUG|Venetoclax|Given PO
48450663|NCT02623647|RADIATION|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
48450664|NCT04365387|DRUG|Nemolizumab|Nemolizumab will be administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
48450665|NCT04365387|DRUG|Placebo|Placebo will be administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
48450666|NCT04654182|DRUG|Chlorhexidine Gluconate|Product used in accordance with manufacturers Hand Hygiene instructions
48098259|NCT00154713|BIOLOGICAL|CEA pulsed dendritic cells|
48450667|NCT00830349|DRUG|Risperidone|1 mg Tablet
48450668|NCT00830349|DRUG|Risperidone|1 mg Tablets
48450669|NCT00994058|DEVICE|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (\< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
48450670|NCT05746104|DRUG|Administration of Indocyanine Green (ICG) and Visualization of Tumor|A single dose of the study drug, ICG, of less than 2 mg/kg will be administered on the day of surgery. The visualization of second window ICG for tumor will be performed approximately one to four hours after administration, depending on how long it takes for the neurosurgeon to get through the skin/skull or lamina/dura to the tumor.
48098260|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
48450671|NCT06452251|DIAGNOSTIC_TEST|OPG, OC, RANKL, IL-10, IL-1β, Ca, TNF-α and Caspase-1 ELISA|The levels of OPG, OC, RANKL, IL10, IL1β, Ca, TNF-α and Caspase1 in bone and PICF of patients with or without Vitamin D sufficiency were measured by ELISA.
48450672|NCT06452251|DIAGNOSTIC_TEST|Resonance Frequency Analysis|Implant stability was measured by a device (Penguin RFA, Integration Diagnostics, Sweden) based on Resonance Frequency Analysis (RFA) and categorized by Implant Stability Quotient (ISQ) scale.
48450673|NCT06452251|DIAGNOSTIC_TEST|Periodontal clinical examination|Clinical periodontal indices including plaque index (PI) (Silness and Löe 1964), gingival index (GI) (Löe 1967), probing depth (PD), and bleeding on probing (BOP) (Ainamo and Bay 1975) were recorded using a Williams periodontal probe. The BOP percentage (%) was calculated by dividing the number of bleeding sites by the total number of sites examined.
48450674|NCT06452251|PROCEDURE|Dental implant placement and bone sample collection|All patients were received by a single examiner a bone level implant (standard type and Sandblasted, Large-grit, Acid-etched surface) (Implant Swiss, Yverdon, Switzerland).
48620520|NCT02825810|BEHAVIORAL|Cervical motor control|Intervention will consist in a tailored exercise training following a previous published motor control protocol
48620521|NCT04571034|PROCEDURE|Sham Therapeutic Ultrasound|A standard ultrasound machine (Vectratm by Chattanooga Group, Inc.) with inactive probe will be used to deliver sham massage.
48620522|NCT04571034|PROCEDURE|Medium-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (25 newtons of force directed perpendicular to the surface of the thigh).
48450675|NCT06452251|PROCEDURE|Gingival Crevicular Fluid Sampling|One month after the healing caps were inserted, peri-implant crevicular fluid (PISF) samples were collected from 6 different sides of each implant. Before sampling, the area was isolated and dried, and paper strips were gently kept in periimplant sulcus for 30 seconds. Strips with blood or saliva contamination were discarded. PISF volumes of each strip were measured by a device (Periotron 8,010, Oraflow Inc, USA). Strips were then pooled, and inserted into tubes. PISF was recovered from paper strips through agitation in phosphate buffer saline (50 mM Tris-HCl, 5 mM CaCl2, 0.2 M NaCl,pH 7.5). All samples were stored at -80C until the day of analysis.
48450676|NCT03114748|OTHER|EEG|
48450677|NCT03114748|OTHER|DBS switched OFF and ON|
48450678|NCT05437068|OTHER|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
48450679|NCT03502889|PROCEDURE|SPANK Block (Sensory Posterior Articular Nerves of the Knee)|Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
48450680|NCT03502889|PROCEDURE|Adductor Canal Block|Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
48450681|NCT03502889|DRUG|Ropivacaine Hcl 0.5% Inj Vil 30Ml|Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
48450682|NCT03502889|DEVICE|Pajunk sonoplex stim needle|Echogenic needle used for ultrasound guided nerve blockade.
48450683|NCT06628102|DIAGNOSTIC_TEST|Chest CT Scan|Chest CT Scan
48450684|NCT04896580|BEHAVIORAL|Nature based exercise|Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
48450685|NCT05756634|BEHAVIORAL|Care Coordination after Preterm Birth (CCAPB)|For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
48450686|NCT03303781|OTHER|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
48450687|NCT00107991|DRUG|etanercept|etanercept 50 mg/week subcutaneous injection
48450688|NCT04581304|DEVICE|Geistlich Bio-Oss® Collagen|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.
48450689|NCT04581304|DEVICE|Geistlich Bio-Oss® Granules|Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
48450690|NCT03911583|BEHAVIORAL|Control Group (CG)|The control group does not receive these notifications (PUSH)
48450691|NCT03911583|BEHAVIORAL|Moderate physical activity group (MPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
48450692|NCT03911583|BEHAVIORAL|Intense physical activity group (IPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
48450693|NCT06006273|DRUG|Eribulin|Given by vein (IV)
48450694|NCT06006273|DRUG|Irinotecan|Given by vein (IV)
48450695|NCT06006273|DRUG|Temozolomide|Given by PO
48450696|NCT06626932|RADIATION|18 FDG (Fludeoxyglucose 18F)|18-f FDG
48450697|NCT02258074|DRUG|Nicotinamide|
48450698|NCT02258074|DRUG|Lanthanum Carbonate|
48450699|NCT02258074|DRUG|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
48450700|NCT02258074|DRUG|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
48450701|NCT02977403|BEHAVIORAL|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
48450702|NCT02977403|BEHAVIORAL|Sham Comparator: AB Control|"Sham Comparator training where the probe randomly replaces the neutral or food pictures. There is no correlation between picture type and probe location"
48450703|NCT04275479|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.
48279606|NCT06071611|OTHER|Active Comparator: Oxygen (O2)|Oxygen (O2) treatment by rectal insufflations for 5 weeks (3 sessions for week).
48279607|NCT06071611|OTHER|Placebo Comparator: Placebo (Air)|Air treatment by rectal insufflations for 5 weeks (3 sessions for week).
48279608|NCT00260130|OTHER|food in fluid form|dietary intake of fluid forms of vegetables
48279609|NCT00260130|OTHER|food in solid form|dietary intake of solid forms of vegetables
48450704|NCT04275479|OTHER|Modified Oral Glucose Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.
48450705|NCT04275479|OTHER|Modified Mixed Meal Tolerance Test|The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.
48450706|NCT04275479|DEVICE|Continuous Glucose Monitor|The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).
48450707|NCT04275479|OTHER|Food Diary|The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.
48450708|NCT04275479|OTHER|Medical History Questionnaires|The participant will be asked to provide detailed medical history
48450709|NCT00881634|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
48450710|NCT00881634|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
48620523|NCT04571034|PROCEDURE|High-Intensity Roller Massage|This group will receive a single bout of roller massage at medium intensity (45 newtons of force directed perpendicular to the surface of the thigh).
48450711|NCT03058614|DRUG|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
48450712|NCT03058614|DIAGNOSTIC_TEST|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
48450713|NCT03058614|DIAGNOSTIC_TEST|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
48450714|NCT03972163|BEHAVIORAL|NIA Medication Management - Active Comparator|"As the attention control, we will refer staff in control offices to the National Institution on Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
48450715|NCT03972163|BEHAVIORAL|STOPPFrail (Screening Tool of Older Persons Prescriptions)|A screening tool used by clinicians with frail older adults with life-limiting illness to review medications
48450716|NCT03972163|BEHAVIORAL|"Discontinuing Medication Appropriately and Understanding the Art of Communication about Deprescribing"|Education resoruce used by clinicians to simplify and align medications with goals of care
48450717|NCT03972163|BEHAVIORAL|"Key Approaches to Support Informal Family Caregivers in Managing Medications"|Education resource used by clinicians to support Family Care Givers (FCGs)
48450718|NCT06085703|DRUG|Henagliflozin|Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
48450719|NCT06085703|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
48450720|NCT02022150|BEHAVIORAL|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
48450721|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
48450722|NCT00830024|DRUG|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
48450723|NCT00097734|DRUG|ertapenem|
48450724|NCT04935554|OTHER|Person centred care|physical activity, nutrition, motivation, health competence, psychosocial.
48450725|NCT03302039|DRUG|Single shot phenylephrine|A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
48450726|NCT03302039|DRUG|Fixed infusion phenylephrine.|Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
48450727|NCT03302039|DRUG|Variable infusion phenylephrine.|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
48450728|NCT03302039|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
48450729|NCT05143047|BEHAVIORAL|Medication counseling|"Participants will receive a customized written medication instruction sheet which includes a picture of an oral dosing syringe indicating the patient's dose as well as a chart showing medication name, dose, route, frequency, duration, next dose due, side effects, and storage information. In addition, participants will be shown how to draw up their child's dose using an oral syringe and then will be asked to practice this task (show-back). Teach-back will be used to ensure participant's understanding of medication details."
48450730|NCT04150133|OTHER|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
48450731|NCT00003003|BIOLOGICAL|sargramostim|
48450732|NCT00003003|DRUG|mitomycin C|
48450733|NCT00003003|DRUG|mitoxantrone hydrochloride|
48450734|NCT05442034|BIOLOGICAL|growth factors to help in regeneration|regenerative therapy
48450735|NCT02890069|BIOLOGICAL|PDR001|anti-PD1 antibody
48450736|NCT02890069|DRUG|LCL161|
48450737|NCT02890069|DRUG|Everolimus|
48450738|NCT02890069|DRUG|Panobinostat|
48450739|NCT02890069|DRUG|QBM076|
48450740|NCT02890069|DRUG|HDM201|
48450741|NCT02716311|DRUG|Afatinib|
48450742|NCT02716311|DRUG|Cetuximab|
48450743|NCT03261167|DRUG|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
47928211|NCT01467635|DEVICE|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
48450744|NCT03261167|DRUG|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
48450745|NCT00242554|DRUG|Zoledronic acid|
48450746|NCT04921956|DRUG|Concizumab|Injected under the skin (subcutaneous, sc) once daily, individual dose adjustment.
48450747|NCT05164354|OTHER|Aromatherapy|Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
48450748|NCT05164354|OTHER|music concert|Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
48450749|NCT00507117|DRUG|Lunesta|Lunesta 3mg prior to PSG
48450750|NCT00507117|DRUG|Placebo control|matching placebo
48450751|NCT05344053|OTHER|Community-based precise management|The community-based precise management is a modified management strategy beyond the traditional standard community-based care under the hierarchical medical system of China. In the intervention arm, the community doctors receive training to improve their skills on coronary artery disease management. Patients will be under management for 1 year according to the strategies of community-based precise management and rehabilitation model.
48450752|NCT05344053|OTHER|Standard community-based management|The standard community-based management is the usual community-based care under the hierarchical medical system of China. In this arm, the community doctors will not receive any training on precise management strategies to improve their skills on coronary artery disease management, and patients will be under usual care for 1 year.
48450753|NCT05074576|OTHER|Mulligan group|"Ultrasound (8minutes, 1.5 w/cm2, pulsed), conventional transcutaneous electrical nerve stimulation (TENS) (20 minutes, 60-120 Hz frequency) and hot pack application (20 minutes) and interferential current (100 rpm) as electrotherapy agents. In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied. Mobilization is performed by giving 15-20 seconds rest between 3 sets of 4-5 repetations.~Patients were treated in a sitting position. SNAG technique was applied by the physiotherapist at each on spinal level. Active movement with using passive manual force in the direction of translation or rotation was applied to the cervical vertebrae. At the end range of the joint, overpressure was applied by the patient himself"
48450754|NCT05074576|OTHER|Control group|Electroterapy agents are applied in the same conditions with Mulligan Group. Active neck, shoulder and thoracic region exercises for correction postural misalignment are performed in both groups. All exercises were done in 3 sets of 10 repetitions. Stretching exercises of upper part of Trapezius, sternocleidomastoideus and pectoral muscles are done with 10 repetitions and for 15-30 seconds.
48450755|NCT00395980|DEVICE|surgical table pressure mat|
48450756|NCT01239862|OTHER|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
48450757|NCT02286050|OTHER|CF Nursing Program|
48450758|NCT05594693|OTHER|Questionnaire|Electronic self-report questionnaires before and after integrative interventions, and monthly.
48620524|NCT05399771|DEVICE|Laser Doppler|Study team will use a PeriScan PIM 3 System Laser Doppler to scan for blood perfusion before and after the Thermofield treatment. The PeriScan PIM 3 System is for non-invasive two-dimensional imaging of peripheral tissue.
48620525|NCT05399771|DEVICE|Radiofrequency Heating System|The radiofrequency will be set to achieve 42°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 42°C, and the treatment time with consistent temperature application will be 30 minutes.
48620526|NCT05399771|DEVICE|Thermal Imaging|Study team will take thermal imaging photographs of the treatment area following each treatment.
48620527|NCT05399771|OTHER|Healthcare Questionnaire & Measurement|"A survey tool created to collect info from participants including:~1. Name~2. Age~3. Weight/ height~4. Pregnant or nursing?~5. History of blood clots?~6. Any wound healing problems?~7. Any active open wounds on the legs?~8. Any autoimmune disorders?~9. Phone number~10. Email address~A measurement of the participants calf will be taken as well using a measuring tape."
48620528|NCT06346158|DIAGNOSTIC_TEST|Cognitive testing|Preoperative cognitive battery test
48620529|NCT06346158|DEVICE|electroencephalogram|Preoperative 24 channel EEG
48620530|NCT06346158|DEVICE|High density electroencephalogram|preoperative 128-channel electroencephalogram
48620531|NCT06346158|PROCEDURE|General anesthesia|induction of general anesthesia using propofol 1%
48620532|NCT01586325|DRUG|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
48620533|NCT01586325|DRUG|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
48620534|NCT01586325|DRUG|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
48620535|NCT01586325|DRUG|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
48620536|NCT06125665|DRUG|Aminophylline-Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.
48620537|NCT06125665|DRUG|Dexmedetomidine|10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
48450759|NCT05594693|OTHER|Physical Exam|Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
48620538|NCT03362320|PROCEDURE|double layer fixation|
48620539|NCT03362320|PROCEDURE|single layer fixation|
48620540|NCT04038827|DIAGNOSTIC_TEST|D-CEC counting|By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted
48620541|NCT02429466|DRUG|Guadecitabine (SGI-110)|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
48620542|NCT04335864|PROCEDURE|Laparoscopic salpingectomy|39 patients with hydrosalpinx will have laparoscopic salpingectomy
48620543|NCT04335864|PROCEDURE|Hystroscopic proximal tubal occlusion|39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
48620544|NCT04410822|OTHER|Clinical tests|Semi-qualitative interviews and questionnaire FITAS
48620545|NCT06008717|DEVICE|active subthalamic nucleus deep brain stimulation plus optimal drug therapy|active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
48620546|NCT06008717|DEVICE|inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy|optimal drug therapy alone with DBS device turned off
48450760|NCT01417663|DRUG|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
48450761|NCT01417663|BEHAVIORAL|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
48450762|NCT03896126|OTHER|Observational|There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
48450763|NCT04547192|OTHER|Improving initial care of the injured|Improvement in Care Processes
48450764|NCT03692663|DRUG|TABP EIC|A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
48450765|NCT03692663|BIOLOGICAL|Cyclophosphamide|Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
48450766|NCT03692663|BIOLOGICAL|fludarabine|Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
48450767|NCT06560827|BIOLOGICAL|CT011 CAR-GPC3 T Cells Injection|The dose selection for this trial was mainly based on the preliminary safety and efficacy results of CT011-HCC-01 trial in subjects with advanced HCC, in which 3 and 5 subjects in the 2.5 × 108 cell and 5.0 × 108 cell dose groups, respectively, completed a single infusion of CT011. The results showed that the two dose groups of CT011 were generally well tolerated in HCC subjects who failed to standard treatment, with controllable safety, and showed preliminary anti-tumor efficacy.
48450768|NCT05383794|OTHER|Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.|Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
48450769|NCT04995783|DIAGNOSTIC_TEST|Coral FRS test|A novel clinical test to predict autoimmune medication response
48450770|NCT03724695|OTHER|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
48450771|NCT06055764|DEVICE|PET/CT|"Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.~Procedure:~All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.~PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images."
48450772|NCT03664063|DRUG|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
48450773|NCT03664063|DRUG|Albendazole|"Single dose of Albendazole weight based dosing~- 400mg"
48450774|NCT03664063|DRUG|Ivermectin|Ivermectin weight based dosing - max 21mg
48450775|NCT03664063|DRUG|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
48620547|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants will receive Human interferon alfa 1b inhalation solution orally for a single dose.
48620548|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants will receive Human interferon alfa 1b inhalation solution placebo orally for a single dose.
48450776|NCT00395694|DRUG|lamictal|anti-epileptic drug
48450777|NCT01439451|PROCEDURE|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
48450778|NCT02635750|DRUG|BI 409306|
48450779|NCT02635750|DRUG|Donepezil|
48450780|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition while wearing surgical face mask
48450781|NCT05143801|DEVICE|High-intensity interval exercise with surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition while wearing surgical face mask
48450782|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a hot environment|Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask
48450783|NCT05143801|OTHER|High-intensity interval exercise without using a surgical face mask in a temperate environment|Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
48450784|NCT01470560|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
48450785|NCT01470560|BEHAVIORAL|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
48620549|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
48620550|NCT06277167|DRUG|Human interferon alfa 1b inhalation solution placebo|Participants in the 1,200,000 IU and 1,800,000 IU dose groups will be given multiple consecutive doses after a single dose safety assessment, i.e. Human interferon alfa 1b inhalation solution placebo administered by aerosol inhalation twice a day at the dose of the corresponding group, for 5 consecutive days respectively (only one morning dose on the last day, for a total of 10 doses during the study).
48620551|NCT01856933|DRUG|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
48620552|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 1|Danicopan (200 milligrams) will be administered orally on Day 1.
48620553|NCT04609696|DRUG|Danicopan: Powder-In-Capsule 2|Danicopan (200 milligrams) will be administered orally on Day 1.
48620554|NCT04609696|DRUG|Danicopan: Tablet|Danicopan (200 milligrams) will be administered orally on Day 1.
48450786|NCT06562738|DRUG|Hetrombopag|Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
48450787|NCT01554007|OTHER|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
48450788|NCT03353896|DEVICE|Wear novoTTF-200A|Wear novoTTF-200A device
48450789|NCT03353896|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
48450790|NCT03964935|DRUG|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
48450791|NCT03964935|DRUG|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
48450792|NCT03964935|OTHER|Distilled water|Used to irrigate periodontal pockets after SRP
48279610|NCT06042140|DEVICE|NEOX Cord 1K applied fetoscopically|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (human umbilical cord) will be used for skin closure at the discretion of the Pediatric Neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
48450793|NCT05464186|BEHAVIORAL|Whole milk|Weekly home delivery of whole milk, daily text messages, monthly virtual visits
48450794|NCT05464186|BEHAVIORAL|Nonfat milk|Weekly home delivery of nonfat milk, daily text messages, monthly virtual visits
48450795|NCT04504617|BEHAVIORAL|Nutrition education intervention to enhance complementary feeding practices|The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
48450796|NCT06395246|BEHAVIORAL|Active Comparator: Continuous calorie restriction|Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
48450797|NCT06395246|BEHAVIORAL|eTRE|early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
48450798|NCT06439576|DRUG|Faricimab|The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
48450799|NCT01131637|DRUG|rhNRG-1|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
48450800|NCT01131637|DRUG|placebo|day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
48450801|NCT03644888|OTHER|Cycle ergometer training|Already in arm/group descriptions
48450802|NCT03644888|OTHER|Airway clearance program|Already in arm/group descriptions
48450803|NCT03644888|DEVICE|Vibration therapy|Already in arm/group descriptions
48450804|NCT03644888|DEVICE|Sham vibration therapy|Already in arm/group descriptions
48450805|NCT01125163|DIETARY_SUPPLEMENT|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
48450806|NCT01125163|DIETARY_SUPPLEMENT|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
48450807|NCT00352989|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
48450808|NCT00316277|BEHAVIORAL|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
48450809|NCT00316277|BEHAVIORAL|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
48450810|NCT01022983|DRUG|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
48450811|NCT01022983|DRUG|Placebo|ml/kg/hours - same infusion rate as active comparator
48620555|NCT03502109|OTHER|Medication review with follow-up|Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
48620556|NCT06378970|OTHER|Audio Book Application|The Audio Book Application Preference Form asked about book preferences other than horror and thriller genres. The selected audiobook was played with headphones via tablet/smartphone. Separate headphones were used for each patient. Patient Follow-up Form and Facial Anxiety Scale evaluations; the initial measurement (M0) was evaluated before the intervention, the first measurement (M1) at the 15th minute of the intervention, the second measurement (M2) at the 30th minute of the intervention, and the third measurement (M3) 30 minutes after the end of the intervention. Care was taken to ensure that there was no deterioration in the comfort of individuals due to the intervention. In the selection of audio books, language fluency, spelling rules and accessibility were taken into consideration and audiobook platforms to which the researchers were members were used.
48450812|NCT06559124|OTHER|Traditional Physiotherapy + Sham Kinesiotape|"As exercise training, joint range of motion, flexion and abduction external cycle will be practiced with the gymnasts.~Circumference measurements will be taken for shoulder bone swelling and for atrophy.~Shoulder joint mobilizations will be applied (posterior cutting for flexion limitation, downward shifting and scapular mobilizations for abduction limitation).~Flexion and abduction will be stretched externally. Friction massage will be applied. Strengthening exercises for flexion, abduction and external rotation in the lower and upper segments of the shoulder with dumbbells and theraband, shoulder wheel and finger ladder will be practiced.~Codman exercises and staff exercises will be practiced."
48450813|NCT06559124|OTHER|Kinesiotape with Facilitation Method + Traditional Physiotherapy|Kinesio tape will be applied with 0 tension at the starting point when the arm is in a relaxed position and will be slightly heated. Since the deltoid muscle is a three-headed muscle, it will be applied with 0 tension in the flexed position at the elbow, for the front part, the arm with the elbow in full extension, and for the middle part of the deltoid, the I tape will be applied along the muscle without applying tension.
48450814|NCT06559124|OTHER|Kinesiotape with Inhibition Method + Traditional Physiotherapy|The Y-shaped kinesio tape will be placed on the deltoid muscle with inhibition and mechanical correction technique, and the Y-shaped kinesio tape will be placed on the supraspinatus muscle with inhibition technique, 3 cm below the humerus tuberculum deltoidea without tension. The Y tape will be applied along the outer edge of the anterior deltoid of the forearm with 15-25% light tension, and the posterior arm will be applied along the outer edge of the posterior deltoid with 15-25% light tension up to the lateral acromion. The last 3-5 cm of the tails will be applied to their permanent locations without tension. The shoulder will be held in maximum transverse extension and external rotation for the forearm of the Y support, and in 45 degrees transverse flexion and horizontal adduction for the posterior arm of the Y support. In addition, ultrasound, electrotherapy and cold application will be applied to the participants depending on their tolerance.
48450815|NCT04461964|DEVICE|Machine-vision Image Guided Surgery (MvIGS) spine navigation system.|"The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~* A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~* Proprietary imaging software (P/N 60-0007); and,~* Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006)."
48450816|NCT02137330|DEVICE|Swallowable Obalon® Gastric Balloon|
48450817|NCT06135051|DEVICE|Diadem prototype|The device delivers low-intensity ultrasonic waves into specific brain targets.
48450818|NCT06560372|PROCEDURE|Additional realization of a brain perfusion scan sequence which would allow the radiological diagnosis of CV|"Neurological monitoring by daily TCD will be carried out.~* If monitoring finds, between 3rd and 12th day of treatment, a neurological deterioration or an uncontrolled increase in intracranial pressure, a new cerebral CT scan will be performed, as recommended in such a case.~* As part of this research, a specific interventional act will be implemented: additional brain perfusion scan sequence which would allow the radiological diagnosis of CV.~* Interventions related to improving cerebral perfusion and reducing intracranial pressure recommended in head trauma patients will be implemented without modification of management linked to protocol.~The additional perfusion sequences will be analyzed independently and blindly by 2 experienced interventional neuroradiologists (double reading blinded to the patient's characteristics)."
48620557|NCT00005769|DRUG|Hormone Replacement Therapy|
48620558|NCT00073931|BIOLOGICAL|filgrastim|5 µg/kg/day subcutaneously
48620559|NCT00073931|BIOLOGICAL|sargramostim|250µg/m2/d subcutaneously
48620560|NCT00073931|PROCEDURE|autologous bone marrow transplantation|autologous stem cells given via central catheter
48620561|NCT00073931|PROCEDURE|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
48620562|NCT00073931|RADIATION|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with \~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
48620563|NCT05255822|DRUG|INNA-051|Liquid for intra-nasal administration
48620564|NCT05255822|OTHER|Placebo|Liquid for intra-nasal administration
48620565|NCT02689778|DRUG|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
48620566|NCT02689778|DRUG|Placebo|Identical tablets without active substance
48620567|NCT01750346|DRUG|Topical acetyl hexapeptide-8|
48620568|NCT01750346|DRUG|Placebo|
47928212|NCT03690336|DRUG|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
47928213|NCT05774392|OTHER|Observational|Observational
47928214|NCT02831907|PROCEDURE|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
48450819|NCT03635320|DEVICE|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
48450820|NCT03635320|DEVICE|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
48450821|NCT06556017|DIAGNOSTIC_TEST|Diagnosis of SSI|Comparison of the manual system and ChatGPT for SSI diagnosis in colorectal surgery procedures enrolled in the SSI surveillance programme.
48450822|NCT00545428|PROCEDURE|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
48450823|NCT01499602|DRUG|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
48450824|NCT01499602|DRUG|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
48450825|NCT03785301|DEVICE|Freestyle Libre Flash Glucose Monitoring|Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
48450826|NCT00418938|DRUG|Panitumumab|6mg/kg IV
48450827|NCT00418938|DRUG|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
48450828|NCT00418938|DRUG|Leucovorin|400mg/m\^2 IV (in the vein)
48450829|NCT00418938|DRUG|Irinotecan|180mg/m\^2 IV (in the vein)
48450830|NCT00418938|DRUG|5-Fluorouracil|400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
48450831|NCT03089983|DRUG|Methadone|Participants will receive daily or weekly doses of oral methadone.
48450832|NCT03089983|DRUG|Isoniazid|Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
48450833|NCT03089983|DRUG|Rifapentine|Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
48450834|NCT02777580|DRUG|Tenecteplase|Half dose Tenecteplase
48450835|NCT02777580|DRUG|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
48279611|NCT05129150|OTHER|Ultrasound examination|Ultrasound examination with Tissue Pulsatility Imaging (TPI) TPI is a relatively simple, rapid and non-invasive ultrasound examination which consists of applying a standard ultrasound probe to the acoustic window of the temporal bone to first measure the velocity of the middle cerebral artery in Doppler mode and secondly the cerebral pulsatility (CP) of a region of approximately 10cm2 centred on the middle cerebral artery in B-Echo mode. After collecting the information, the TPI examination will be performed by MRRC staff specially trained in TPI by engineers. The duration of the examination is between 20 and 30 minutes, including hardware installation. Four 30-second PC acquisitions will be collected per examination, with the patient lying supine on the bed in the day hospital room, then one measurement every minute for 3 minutes after standing.
48279612|NCT03960528|PROCEDURE|Erector spinae plane block|Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
48279613|NCT03960528|PROCEDURE|Control group|20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
48450836|NCT02777580|PROCEDURE|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
48450837|NCT02777580|PROCEDURE|Primary PCI|Primary PCI accoring to local standards
48450838|NCT01044537|DRUG|Placebo|Placebo to match PF-04937319 will be provided.
48450839|NCT01044537|DRUG|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
48279614|NCT04203303|OTHER|Observational|Observational
48450840|NCT03354858|PROCEDURE|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
48450841|NCT04499664|DEVICE|Monitoring of the autonomic nervous system|Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
48450842|NCT06352645|DEVICE|Bixdo Ultra Compact Water Flosser|Use of water flosser, in addition to standard tooth brushing, twice a day for 8 weeks.
48450843|NCT06352645|DEVICE|Manual toothbrush|For those in the control group, they will be asked to use only the study-provided manual toothbrush, twice a day for 8 weeks.
48450844|NCT00838188|OTHER|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
47928215|NCT00521300|DRUG|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
47928216|NCT00521300|PROCEDURE|Direct surgery for acromegaly|Direct transsphenoidal surgery
48279615|NCT06062719|DRUG|PPI group|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
48450845|NCT04820829|OTHER|High RM, low NSS|Participants in this group will consume nine 3-oz-eq servings of RM per week and 2-oz-eq servings of NSS per week.
48450846|NCT04820829|OTHER|Moderate RM, Moderate NSS|Participants in this group will consume five 3-oz-eq servings of RM per week and 5-oz-eq servings of NSS per week.
48450847|NCT04820829|OTHER|Low RM, High NSS|Participants in this group will consume one 3-oz-eq serving of RM per week and 8-oz-eq servings of NSS per week.
48450848|NCT03748381|PROCEDURE|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
48450849|NCT06440343|DIETARY_SUPPLEMENT|Carbohydrates|60g of maltodextrin + fructose, 2:1 ratio
48450850|NCT06440343|DIETARY_SUPPLEMENT|Placebo|Placebo
48450851|NCT02781883|DRUG|BP1001 in combination with Ventoclax plus decitabine|BP1001 in combination with Ventoclax plus decitabine
48450852|NCT02781883|DRUG|BP1001 plus decitabine|BP1001 plus decitabine in ventoclax intolerant or resistant subjects
48450853|NCT01118598|DRUG|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
48450854|NCT01118598|DRUG|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
48450855|NCT06628128|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
48450856|NCT06563141|OTHER|traction and mobilization|The patient undergoes a 15-minute infrared therapy session, followed by flexibility and stretching exercises targeting the trunk and four extremities muscles. Land manipulation techniques are used for cervical, dorsal, and lumbar spine to assess and treat spinal dysfunctions. Deep breathing exercises with rib mobilization are also performed to promote respiratory function and thoracic flexibility. The session aims to improve overall health.
48450857|NCT06563141|OTHER|active exercise therapy|Patients with adolescent idiopathic scoliosis will receive exercise programs from seven major schools under SOSORT, focusing on realigning the spine, rib cage, shoulders, and pelvis to normal anatomical postures.
48450858|NCT04865003|OTHER|treatment of infection|
48450859|NCT04823169|OTHER|podobarometry|podobarometric measures on day 7 and day 30
48279616|NCT06062719|DRUG|PPI plus octreotide|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
48450860|NCT05264363|DEVICE|VIPUN Gastric Monitoring System prototype|The Investigational Medical Device (IMD) is used simultaneously with the reference device (solid state high-resolution manometry) to record gastric intraluminal pressure for approximately 2.5 hours.
48450861|NCT02974621|BIOLOGICAL|Bevacizumab|Given IV
48450862|NCT02974621|DRUG|Cediranib|Given PO
48450863|NCT02974621|DRUG|Cediranib Maleate|Given PO
48450864|NCT02974621|DRUG|Olaparib|Given PO
48450865|NCT01794845|DRUG|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
48450866|NCT01794845|DRUG|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
48450867|NCT01794845|RADIATION|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
48450868|NCT04890353|DRUG|Dimethyl fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
48450869|NCT02698579|GENETIC|No interventional drug product utilized in this follow-up study|"Participants received a single IV infusion of Lenti-D Drug Product (also known as elivaldogene autotemcel or eli-cel) in either parent Study ALD-102 or ALD-104.~The objectives of this long-term follow-up study are to assess long-term safety and efficacy following completion of participation in parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant are conducted in this study."
48450870|NCT05091151|DRUG|Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg|Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
48620569|NCT01972828|DRUG|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
48279617|NCT01117376|DRUG|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
48279618|NCT01117376|DRUG|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
48279619|NCT04957173|OTHER|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~1. A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~2. A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~3. A maintenance phase of weight loss for 16 weeks.~4. An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
48450871|NCT05146336|DEVICE|CytoSorb|Sorbent hemoperfusion system
48620570|NCT01972828|DRUG|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
47928217|NCT03691740|DEVICE|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
48279620|NCT00162773|DRUG|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
48279621|NCT00162773|OTHER|Placebo|150-375 milligrams depending on body weight and serum IgE.
48279622|NCT00343902|DRUG|Crataegus Special Extract WS 1442|
48279623|NCT05989503|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titration at the discretion of the treating physician
48450872|NCT00966589|PROCEDURE|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
48450873|NCT01456221|DIETARY_SUPPLEMENT|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
48450874|NCT01456221|DIETARY_SUPPLEMENT|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
48450875|NCT06154408|DIETARY_SUPPLEMENT|omega-3 fatty acids|The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.
48450876|NCT06154408|DIETARY_SUPPLEMENT|Placebo|placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
48450877|NCT05086835|OTHER|Working Memory Task|A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.
48450878|NCT05086835|OTHER|Visual Search Task|A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.
48450879|NCT02180321|DRUG|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
48450880|NCT02180321|DRUG|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
48450881|NCT03811418|DRUG|Trastuzumab|"administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
48620571|NCT06199739|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
48620572|NCT05322486|PROCEDURE|surgery of the primary tumour|Surgical resection of the colon tumour, R0. No surgical intervention on metastasis.
48620573|NCT05322486|DRUG|chemotherapy|Chemotherapy with or without biological drugs.
48620574|NCT05502887|DIAGNOSTIC_TEST|Sublingual in vivo microscopy with the Glycocheck microscope|For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
48620575|NCT04764890|OTHER|Electroacupuncture|Electroacupuncture in several point
48620576|NCT04764890|OTHER|Manual therapy|Manual therapy in the lower spine.
48620577|NCT04679207|PROCEDURE|Vacuum-assisted excision|Vacuum-assisted biopsy (VAB) is a minimally invasive technique performed under local anaesthetic as an outpatient procedure by radiologists using x-ray or ultrasound guidance. It was developed in the USA in the mid 1990s and has become well established as a diagnostic test for suspected breast disease. It uses the combination of a large gauge biopsy needle and suction to allow larger pieces of tissue to be removed than can be obtained with a standard needle biopsy device. The technique is used widely for diagnostic purposes and, in some centres, for the therapeutic removal of benign breast lumps such as fibroadenomas and papillomas.
48620578|NCT01776229|BEHAVIORAL|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
48620579|NCT05225831|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|A single infusion of CD19 and CD22 CAR-T cells.
48620580|NCT05225831|DRUG|Cyclophosphamide,Fludarabine|Given
48620581|NCT03892733|BEHAVIORAL|calorie health education knowledge and skills|45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
48620582|NCT06280651|OTHER|dietary preferences and their implications for oral health in children with Autism Spectrum Disorder|This study design typically does not involve interventions. Instead, it observes and analyzes existing conditions or behaviors-in this case, dietary preferences and their implications for oral health in children with Autism Spectrum Disorder (ASD)-without the researchers applying any specific treatment or experimental condition to the participants. The aim is to identify correlations or patterns at a specific point in time, rather than to assess the effects of an intervention.
48620583|NCT06189963|BIOLOGICAL|SNK01|SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
48620584|NCT06189963|OTHER|Placebo|Sodium Lactate Hartmann's Solution
48620585|NCT01809067|OTHER|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
48620586|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
47928218|NCT02139059|PROCEDURE|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
48279624|NCT05989503|DRUG|SGLT2 inhibitor|Either empagliflozin or dapagliflozin 10 mg/day
48620587|NCT01039441|PROCEDURE|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
48620588|NCT01039441|PROCEDURE|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
48450882|NCT03811418|DRUG|Pertuzumab|"administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
48450883|NCT03811418|DRUG|Vinorelbine|"administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
48450884|NCT03811418|DRUG|Docetaxel|"administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m\^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m\^2 (up to 100 mg/m\^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
48450885|NCT05025085|DRUG|AGEN1777|An immunoglobulin gamma (IgG1) antibody
48450886|NCT05025085|DRUG|a PD-1 inhibitor|Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody
48450887|NCT00841698|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
48450888|NCT00841698|DRUG|Paxil®|40 mg Film-Coated Tablet
48450889|NCT03311061|OTHER|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
48450890|NCT04398056|DRUG|Chemotherapy plus radiotherapy and Toripalimab|"1. Chemotherapy:~   The PF regimen included 5 g/m2 5-fluorouracil via a continuous intravenous infusion over 120 h and an intravenous administration of 100 mg/m2 cisplatin on day 1 for a maximum of six cycles.~2. Radiotherapy, intensity-modulated radiation therapy (IMRT), PTVnx:66-70Gy/30-33F; PTVnd:66～70Gy/30～33F; PTV1:60～64Gy/30～33F; PTV2:50～54Gy/30～33F, 5 fractions per week, for 6 weeks~3. Toripalimab 240mg every three weeks (Q3W) began on the first day of radiotherapy until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
48450891|NCT00004933|DRUG|hydroxyurea|0.5 to 5 grams PO per day
48450892|NCT00004933|DRUG|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
48450893|NCT05012254|DRUG|Ipilimumab|"Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion."
48450894|NCT05012254|DRUG|Nivolumab|"Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion."
48450895|NCT05012254|DRUG|Carboplatin|"Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
48450896|NCT05012254|DRUG|Cisplatin|"Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center."
48450897|NCT05012254|DRUG|Paclitaxel|"Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
48620589|NCT01039441|OTHER|normal saline|
47928219|NCT02139059|PROCEDURE|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
48620590|NCT02575625|DEVICE|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
48620591|NCT02575625|BIOLOGICAL|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
48620592|NCT02575625|DEVICE|MRI|Liver MRI
48620593|NCT01785901|OTHER|without interventions|without interventions
48620594|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
48620595|NCT00886236|DRUG|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
48450898|NCT05012254|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol \[2,3 d\]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
48450899|NCT06447948|BEHAVIORAL|Keep Exercising and Stay Steady|"Digital Health, home exercise intervention containing a digital NHS approved falls prevention exercise App (Keep On Keep Up), fitness watches, telephone and/or social media communication, and behavior change techniques.~Currently (date, 13 May 2024) the intervention has not been developed with the community of practice group. Further details of the phase 1 and phase 2 interventions will be provided after the community of practice events."
48450900|NCT00333645|DRUG|Caspofungin|
48450901|NCT01464450|DRUG|Rivaroxaban|Single 20 mg-dose
48450902|NCT06374134|BEHAVIORAL|Community Engagement Practice|Community engagement includes pre- and post-approval clinical trials that partnered and engaged with diverse public and patient communities; trusted community leaders; local advocacy groups; faith-based and civic organizations; community influencers; community health and government health communities.
48450903|NCT06374134|BEHAVIORAL|Patient-Centric Protocol Element|Patient-centric clinical trial designs include those that solicited patient, investigative site and community input into protocol design and clinical trial feasibility; offered solutions that improved patient participation convenience and access; and that more fully and effectively communicated clinical trial knowledge to diverse public and patient communities, health care providers and community influencers.
48450904|NCT01343004|DRUG|Placebo|Placebo 0 mcg subcutaneous daily
48450905|NCT01343004|DRUG|BA058 80 mcg|BA058 80 mcg subcutaneous daily
48450906|NCT01343004|DRUG|teriparatide|teriparatide 20 mcg subcutaneous daily
48450907|NCT00030186|DRUG|CEP-701 60mg|60mg orally 2 times a day for 28 days
48450908|NCT00030186|DRUG|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
48450909|NCT00030186|DRUG|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
48450910|NCT05438940|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
48450911|NCT05438940|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
48450912|NCT05438940|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
48450913|NCT06350955|DRUG|Iron isomaltoside|single dose of 500 mg iron isomaltoside
48450914|NCT06350955|DRUG|Iron Carboxymaltose|single dose of 500 mg ferric carboxymaltose
48450915|NCT06218394|PROCEDURE|microneedling|The microneedling technique (Electric microneedle, F6, China Bohui Meicui Bioengineering Technology Guangzhou Co., LTD.) performed in the targeted areas using a sterile micro needles stamp. In this study, the needle length was adjusted to 0.7\~1 mm according to the grade of hair loss and the degree of tolerance of the patient. Before microneedling treatment, the scalp was disinfected with 75% alcohol, and then 1 ml of nutritional dressing for the scalp was applied externally, and the microneedle pen was gently touched to the scalp vertically for pricking. Patients are instructed to refrain from shampooing, warm baths, and strenuous exercise for 8 hours after treatment. Each patient was treated by microneedling once every 2 weeks for a total of 12 treatments.
48450916|NCT06218394|PROCEDURE|Autologous Concentrated Growth Factor|"1. 27\~36ml of autologous venous blood is collected in a sterile Vacuette tube without anticoagulant solution, and centrifuged by Medifuge variable speed centrifuge (Silfradent company, Italy) for about 13min (accelerated for 30s; 2700 r/min, 2 min; 2400 r/min, 4min; 2700r/min, 4min; 3300r/min, 3 min; decelerated for 36s to stop). The lowest layer retains 2.5ml of CGF per 9ml of venous blood.~2. The scalp is cleaned, disinfected and anesthetized, CGF is extracted with a 2.5ml syringe, and the disposable sterile needle roller handle is slowly rolled in the hair loss area, and the CGF is applied to the corresponding scalp part for introduction treatment while rolling, and the force is uniform and stable, repeating back and forth several times, to the extent that the patient can tolerate and the skin in the treatment area is slightly red. The operation time is about 15\~20 minutes."
48450917|NCT06218394|DRUG|5% minoxidil|topical 5% minoxidil, 1 ml, once daily
48450918|NCT05411913|DRUG|GoodFOR Pain|GoodFOR Pain is a FDA registered topical analgesic.
48279625|NCT03058484|BEHAVIORAL|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
48450919|NCT05411913|DRUG|Icy Hot|a FDA OTC registered topical analgesic.
48450920|NCT05411913|DRUG|Tiger Balm|a FDA OTC registered topical analgesic
48450921|NCT05411913|DRUG|Bengay|a FDA OTC registered topical analgesic.
47928220|NCT01766700|BEHAVIORAL|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
47928221|NCT01766700|BEHAVIORAL|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
48279626|NCT04996719|DRUG|Rapamune|We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
48450922|NCT05411913|DRUG|CBD Clinic Muscle and Joint Pain Relief Ointment|a non FDA registered topical analgesic.
48450923|NCT05411913|DRUG|CBD FX CBD Muscle and Joint Cream: Cooling Formula|a non FDA registered topical analgesic.
48450924|NCT05411913|DRUG|Essential Wholesale Muscle Gel|a non FDA registered topical analgesic.
48450925|NCT05411913|DRUG|Extract Labs Muscle Cream|a non FDA registered topical analgesic.
48450927|NCT05725928|BEHAVIORAL|Mobility technician|Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.
48450928|NCT06626958|BEHAVIORAL|Stress Ball|Stress Ball app
48450929|NCT04733183|DRUG|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
48450930|NCT04733183|DRUG|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
48450931|NCT02132663|OTHER|Control: Marketed routine infant formula|
48450932|NCT02132663|OTHER|An investigational infant formula containing an alternate source of DHA|
48450933|NCT01911676|DRUG|PF-03463275|
48450934|NCT01911676|DRUG|Placebo|
48450935|NCT05217108|DEVICE|FitBit|All participants in each study group will receive a Fitbit. Participants will be asked to wear a Fitbit every day for 8 weeks to record the number of steps you take
48450936|NCT01997983|DEVICE|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
48450937|NCT01058668|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
48450938|NCT01058668|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
48450939|NCT02995720|DRUG|Fimasartan/Amlodipine combination drug, Rosuvastatin|
48450940|NCT01019421|DRUG|Lu AE58054|Add-on treatment to donepezil
48450941|NCT01019421|DRUG|Placebo|Add-on treatment to donepezil
48450942|NCT03801980|DRUG|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
48450943|NCT03801980|DRUG|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
48450944|NCT06509568|RADIATION|Neoadjuvant chemoradiotherapy followed by immunotherapy|Patients in the nCRIT group will receive neoadjuvant concurrent chemoradiotherapy: radiation therapy will be administered using IMRT or VMAT with involved-field irradiation at a dose of PTV 41.4 Gy/23 fractions/31 days. Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC 2) for five weeks, given on the days of radiotherapy. Patients who do not progress on CT and meet immunotherapy criteria will receive fixed-dose toripalimab (200 mg IV) on days 8 and 29 after chemoradiotherapy, followed by minimally invasive esophagectomy four weeks after completing immunotherapy.
48450945|NCT06509568|DRUG|Neoadjuvant chemoimmunotherapy|Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and toripalimab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
48450946|NCT06561893|DIETARY_SUPPLEMENT|Broccoli sprouts extract supplementation|Intake of broccoli sprouts extract supplement (Brand: Source Naturals, Scotts Valley, CA 95066 - USA) in an acute dose (84 umol of glucoraphanin) before and after 2 weeks of probiotic or placebo supplementation, to assess sulforaphane bioavailability measured in urine metabolites
48450947|NCT05883215|OTHER|Pain catastrophizing scale|"The pain catastrophizing scale is a self-report questionnaire used to assess an individual's tendency to engage in catastrophic thinking when experiencing pain. It measures the extent to which a person magnifies, feels helpless, and feels unable to cope with pain. The scale typically consists of several items that ask individuals to rate the degree to which they experience specific thoughts or emotions related to pain catastrophizing, such as I worry all the time about whether the pain will end or I feel like I can't stand it anymore. Participants provide responses on a Likert scale indicating the intensity or frequency of their agreement with each statement. The scale helps researchers and healthcare professionals gain insights into an individual's cognitive and emotional responses to pain, which can have implications for pain management strategies and overall well-being."
48450948|NCT05883215|OTHER|Beck Anxiety Inventory|"Beck Anxiety Inventory (BAI), which is designed to measure the severity of anxiety symptoms in individuals. The BAI is a self-report questionnaire consisting of 21 items that assess various symptoms of anxiety, such as nervousness, fear, and physiological manifestations of anxiety. Participants rate the intensity of their symptoms over the past week on a scale ranging from 0 (not at all) to 3 (severely). The scores obtained on the BAI can help clinicians and researchers evaluate the presence and severity of anxiety symptoms, monitor changes over time, and guide treatment decisions. It is important to note that the BAI is not a diagnostic tool but rather a measure of self-reported anxiety symptoms."
48450949|NCT05883215|OTHER|Social Media Use Integration Scale|The Social Media Use Integration Scale (SMUIS) is a self-report measure that assesses the degree to which individuals integrate social media into their daily lives. It aims to capture the extent to which individuals incorporate social media use into various aspects of their routines, behaviors, and identity. The scale typically consists of items that assess factors such as the frequency and duration of social media use, the importance and impact of social media on personal relationships, the integration of social media into daily activities, and the emotional connection to social media.
48620596|NCT00886236|DRUG|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
48620597|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
48450950|NCT05883215|OTHER|Fibromyalgia Impact Questionnaire|"The Fibromyalgia Impact Questionnaire (FIQ) is a widely used self-report measure specifically designed to assess the impact of fibromyalgia on various aspects of a person's life. It is a multidimensional questionnaire that evaluates the physical functioning, social functioning, and overall well-being of individuals with fibromyalgia.~The FIQ typically consists of items that ask individuals to rate the impact of fibromyalgia on their ability to perform daily activities, such as work, household chores, and recreational activities. It also assesses the severity of fibromyalgia symptoms, including pain, fatigue, sleep disturbances, and cognitive difficulties. Additionally, the questionnaire may include items related to emotional well-being, social support, and overall quality of life."
48450951|NCT04294303|OTHER|web based telemonitoring system|Subjects in the telemonitoring group were given an iPad with installed iHealth application, a scale, and an electronic blood pressure monitor (a mobile web-based telemonitoring system). These devices were interconnected via Bluetooth. The iPad had permanent internet connection. Patients were taught to use the equipment to check and record their weight, blood pressure, and heart rate every morning, for 45 days after the hospital discharge. Data was automatically uploaded via iHealth application in a secure database.
48450952|NCT04294303|OTHER|Conventional|Subjects in the control group received the standard patient teaching, including an instruction to self-monitor their weight.
48450953|NCT04626050|BEHAVIORAL|Medical Music|Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
48450954|NCT04626050|BEHAVIORAL|Narrative Writing|Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
48450955|NCT04626050|BEHAVIORAL|Prolonged Exposure Therapy|Psychotherapy including imaginal exposure for PTSD
48450956|NCT04626050|BEHAVIORAL|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
48450957|NCT02765880|OTHER|fMRI|Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.
48450958|NCT02765880|OTHER|EEG|link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
48450959|NCT00089011|DRUG|fludarabine phosphate|Given IV
48450960|NCT00089011|RADIATION|total-body irradiation|Undergo radiotherapy
48450961|NCT00089011|DRUG|mycophenolate mofetil|Given IV or PO
48450962|NCT00089011|DRUG|tacrolimus|Given IV or PO
48450963|NCT00089011|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
48450964|NCT00089011|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
48450965|NCT00089011|OTHER|laboratory biomarker analysis|Correlative studies
48450966|NCT00507572|OTHER|Medical Chart Review|Medical records are reviewed
48450967|NCT02348281|DRUG|Bicalutamide|150mg, po, qd, d1-28
48450968|NCT04916548|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
48450969|NCT00224718|PROCEDURE|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
48450970|NCT00224718|PROCEDURE|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
48450971|NCT03823924|PROCEDURE|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
48620598|NCT03014362|DEVICE|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
48620599|NCT04262349|BEHAVIORAL|sleep education|As a training program to increase sleep, pregnant women will be given 2 training sessions per week for two weeks and four sessions in total for 60 minutes.
48620600|NCT04044508|DIETARY_SUPPLEMENT|Ketocal 4:1 liquid Nutricia (intervention)|Modified ketogenic diet
48620601|NCT04044508|DIETARY_SUPPLEMENT|Fortini multifibre Nutrica (placebo)|Placebo diet
48620602|NCT04168489|DEVICE|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
48620603|NCT04168489|DEVICE|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
47928222|NCT04693143|OTHER|A randomized controlled open-label clinical trial.|This was a single-center; open-label randomized controlled trial performed at a Pediatric Intensive Care Unit (PICU) in tertiary care hospital
47928223|NCT05334056|DRUG|Cocaine Nasal|2 ml of 4% cocaine given as a nasal spray immediately prior to nasal intubation
48279627|NCT00558090|DRUG|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
48279628|NCT03593694|BEHAVIORAL|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
48620604|NCT01610193|PROCEDURE|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
47928224|NCT01908946|BEHAVIORAL|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
48450972|NCT05853445|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
48450973|NCT03590795|OTHER|Sleep survey|The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry \[including Philips\]).
48450974|NCT06560762|DRUG|STM01|Neonatal mesenchymal stem cells (nMSCs),
48450975|NCT05597982|OTHER|Kidney Transplant Fast Track (KTFT)|Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
48450976|NCT05597982|OTHER|Peer Navigation (PN)|Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
48450977|NCT02842853|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
48450978|NCT02842853|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
48450979|NCT04034290|BIOLOGICAL|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
48450980|NCT04034290|OTHER|Placebo|Placebo
48450981|NCT04021563|DRUG|SR419|Ascending single and multiple doses of SR419 orally
48450982|NCT04021563|DRUG|Placebo|Ascending single and multiple doses of placebo orally
48279629|NCT03593694|BEHAVIORAL|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
48450983|NCT06558929|BEHAVIORAL|Occupational Therapy|Participants will redesign their daily routine (particularly the sleep-wake rhythm) with support from occupational therapists and an online health management platform.
48450984|NCT06558929|OTHER|Conventional Treatment|Participants will receive conventional treatment and education on sleep hygiene.
48450985|NCT01665495|PROCEDURE|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return\<30 ml.
48450986|NCT05982860|BEHAVIORAL|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been established by Morris et al. (2015) to improve brain health, and reduce the risk or slow progression of neurodegenerative diseases. In this diet model, which is similar to the Mediterranean diet, the diet score changes according to the frequency of consumption of some foods. The more consumption of foods such as green leafy vegetables, other vegetables, berries, nuts, whole grains, fish (not fried), beans, poultry (not fried), and the limited consumption of butter/margarine, cheese, red meat and products, fast fried foods, and pastries \& sweets ensure more score. Also, regular consumption of wine (1 glass/d) and using olive oil as primary oil in meals increases the score. Berries, fish, and hardaliye (instead of wine) will be supplied to players as well as recommendations for consumption frequencies of food components in MIND diet to increase total score.
48450987|NCT04926818|DRUG|Fingolimod|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
48450988|NCT04926818|DRUG|Ofatumumab|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
48450989|NCT04926818|DRUG|Siponimod|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
48450990|NCT04926818|OTHER|Fingolimod placebo|Fingolimod matching placebo capsule
48450991|NCT04926818|OTHER|Siponimod placebo|Siponimod matching placebo tablet
48450992|NCT04926818|OTHER|Ofatumumab placebo|Ofatumumab matching placebo autoinjector
48450993|NCT03786172|BEHAVIORAL|Smoking cessation Intervention|"* A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~* A motivational gadget distributed to the patients~* Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
48450994|NCT03786172|BEHAVIORAL|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
48450995|NCT03406156|DRUG|Obinutuzumab|Administered via intravenous infusion
48450996|NCT03406156|DRUG|Bendamustine|Administered via intravenous infusion
48637402|NCT05702619|OTHER|Baseline bloods - for germline testing|"Arm 1 -~* 1-2 x 3.5mL blood samples collected into EDTA tubes for germ line DNA extraction and processing to PBMC for banking and future profiling of immune cell populations~* 1 x 10mL serum tubes for future, biobank related research projects, ie lipidomics, metabolics and microRNA analysis~ARM 2 -~A blood sample (maximum 20ml) will be taken for standard of care blood tests prior to prostatectomy including Full Blood Count, Renal Function and PSA. At the same time these standard of care bloods are taken, additional bloods - a maximum of 30ml - will be taken for research purposes as required for the following downstream analysis:~* Germ line DNA extraction and optional processing to PBMC for banking and future profiling of immune cell populations~* Biobank related research projects, ie lipidomics, metabolics and microRNA analysis"
48279630|NCT03593694|BEHAVIORAL|TECH DMBAT Other|Technology delivered diabetes education
48279631|NCT03732924|DIAGNOSTIC_TEST|Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement|To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
48279632|NCT03006211|OTHER|Nitrogen protoxide|
48279633|NCT03006211|OTHER|Oxygen|
48279634|NCT00875758|PROCEDURE|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
48450997|NCT03406156|DRUG|Venetoclax|The venetoclax dose was administered according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. Venetoclax was continued for a total duration of up to 53 weeks, including the 5-week ramp-up schedule. Participants were instructed to take venetoclax tablets with a meal and water at approximately the same time each day. Venetoclax tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
48450998|NCT03399214|DRUG|IOP Injection|T1 and T2
48450999|NCT00781339|DRUG|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
48451000|NCT06628141|OTHER|Nutritional support tool|Nutritional support tool
48451001|NCT05748561|DRUG|Recombinant human erythropoietin 4,000 UI and 2,000 UI|Intravenous recombinant human erythropoietin (10,000 IU every 24 hours for 5 days)
48451002|NCT05748561|DRUG|Methylprednisolone succinate 500 mg|Intravenous Methylprednisolone succinate (1 g daily for 5 days)
48451003|NCT04447313|OTHER|Survey Administration|Ancillary studies
48451004|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive ACT telephone coaching
48451005|NCT04447313|BEHAVIORAL|Telephone-Based Intervention|Receive SBT telephone coaching
48451006|NCT02197741|DRUG|opiate with bolus|
48451007|NCT01585792|DRUG|TAK-875|
48451008|NCT01585792|DRUG|TAK-875|
48451009|NCT01585792|DRUG|Glimepiride|
48451010|NCT01585792|DRUG|Placebo|
48451011|NCT01876992|DRUG|Metformin|
48451012|NCT04855058|OTHER|online survey(or phone survey)|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over google survey(or the phone survey) for patients.
48451013|NCT00404183|DRUG|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
48451014|NCT00404183|DRUG|Placebo|2 tablets BID
48451015|NCT00164307|BEHAVIORAL|Parent assisted social skills training|
48451016|NCT00106223|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
48451017|NCT06560619|BEHAVIORAL|MENTOR|Participants will attend a group-based, 8-week online program (a total of 40 hours) via Zoom videoconferencing. The program is split into three wellness sections (Mindfulness, Exercise, and Nutrition) and eight other sections (self-care skills, core values, outdoor time in nature, rest/relaxation, contribution to others, arts and leisure, relationships, and spiritual practice). Participants will access all assessment and intervention tools on any mobile device (phone, tablet, laptop, desktop) using a password-protected identification (ID) to log in via their devices. Health coaches can create intake flows to collect health data and track analytics. Participants can see their goals, upcoming intervention sessions, and activities through the study application (app). Features of the study app include goal setting, where participants record their goals, zoom videoconferencing links for online classes and coaching sessions, and the ability to share materials with participants.
48451018|NCT06439238|OTHER|ventilated non-menthol cigarettes|"a 4-week intervention where participants will be using ventilated non-menthol cigarettes.~Weekly telehealth visits will be conducted during baseline and the 4 weeks on study cigarettes to collect study measures followed by a follow-up one month after end of intervention."
48451019|NCT06439238|OTHER|minimally ventilated non-menthol cigarettes|"a 4-week intervention where participants will be using minimally ventilated non-menthol cigarettes.~Weekly telehealth visits will be conducted during baseline and the 4 weeks on study cigarettes to collect study measures followed by a follow-up one month after end of intervention."
48451020|NCT05928156|OTHER|Myeloma Coach or CLL Coach Mobile App|"Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources."
48451021|NCT05928156|OTHER|Springboard Beyond Cancer informational website|Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
48451022|NCT03242213|BEHAVIORAL|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
48451023|NCT00298415|DRUG|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
48451024|NCT00298415|DRUG|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
48451025|NCT06626698|OTHER|Static stretching|A passive static stretch of the posterior leg muscles will be performed with the subject in a supine position and knees extended, starting with the ankle at 90º and continuing until reaching the maximum tolerated dorsiflexion.
47928225|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
48637403|NCT05702619|OTHER|Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1|2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
48637404|NCT05702619|OTHER|Post-pimonidazole bloods for CTCs and ctDNA|ARM 1 - 2 x 10mL Streck cell-free DNA blood collection tubes® for circulating tumour cell (CTC) collection and circulating tumour DNA (ctDNA) extraction.
48637405|NCT03823885|OTHER|e-cigarette|use e-cig for 30 minutes
48451026|NCT06626698|DEVICE|Electrical muscle elongation|The intervention will be performed with the subject in a supine position with knees extended. Electrodes will be placed on the gastrocnemius muscles of the leg being assessed. The parameters will be selected. Static stretching will begin until resistance is felt, at which point the intensity of the electrical current will be increased to induce a visible and tolerable contraction. Simultaneously, the subject will be asked to perform an isometric contraction of the antagonist muscles, resisted by the investigator. When the subject feels the stretch again, the intensity of the current will be increased once more until a new movement barrier is reached.
48451027|NCT06437691|PROCEDURE|Self-Expandable Metallic Stent Placement|
48451028|NCT06396286|PROCEDURE|single rod|surgical correction of severe adolescent idiopathic scoliosis with screws and a single rod.
48451029|NCT03832361|DRUG|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
48451030|NCT02225405|DRUG|Cisplatin|Given IV
48451031|NCT02225405|DRUG|Docetaxel|Given IV
48451032|NCT02225405|OTHER|Laboratory Biomarker Analysis|Correlative studies
48451033|NCT02225405|DRUG|Nintedanib|Given PO
48451034|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser|1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
48451035|NCT05827991|DRUG|5% minoxidil external use|The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
48451036|NCT05827991|DEVICE|1565nm Non-ablative Fractional Laser combined with 5% minoxidil|The two treatment mentioned above
48451037|NCT03913377|DEVICE|Spectacles|Subjects' own habitual spectacles
48451038|NCT03913377|DEVICE|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
48451039|NCT06474936|BEHAVIORAL|Food education|During the consultations are planned at least 6 nutritional education sessions in which the general nutritional advice provided by the Mediterranean Diet will be exposed, and some paper materials can be delivered according to the needs of each individual. 3 in-person meetings and 3 online meetings are planned. Both online and in-person food education sessions will be conducted by experienced nutrition experts monthly. These sessions will cover a range of topics, including the principles of the Mediterranean diet, practical cooking skills, meal-planning strategies, and tips for incorporating Mediterranean-style dishes into daily life
48451040|NCT05476588|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
48451041|NCT05513677|DEVICE|M4D|Coated catheter
48451042|NCT05513677|DEVICE|Standard of Care|Standard of Care
48451043|NCT00151593|OTHER|Celsior®|Graft preservation solution
48451044|NCT00624286|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
48451045|NCT00624286|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
48451046|NCT06562127|BEHAVIORAL|TRAIN-Vets|The TRAIN-Vets intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in monthly lifestyle coaching based at SFVAHCS focused on other risk factors and symptoms.
48451047|NCT06562127|BEHAVIORAL|Health Education Control|The Health Education Control (HEC) receives mailed educational materials about brain health and healthy lifestyles over 8 months, as well as regular contact with study staff.
48451048|NCT06318117|OTHER|Rice infant formula|Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.
47928226|NCT03313232|OTHER|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
47928227|NCT01607203|DRUG|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
47928228|NCT01607203|DRUG|pregnyl|5000 IU SC
48279635|NCT00875758|PROCEDURE|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
48279636|NCT02739087|PROCEDURE|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
48451049|NCT06627465|DEVICE|MS Sherpa|The MS Sherpa application is a CE-certified smartphone application (installed on the mobile phone of the patient) that collects digital biomarkers using tests (\~six minutes/test: self-monitoring questionnaires, smartphone 2-MWT, and a smartphone SDMT) once per week in the home environment of the patient.
48279637|NCT02739087|DEVICE|Magnetic resonance imaging|
48451050|NCT06627465|DEVICE|Neurokeys|The NeuroKeys application is a CE-certified application (installed on the mobile phone of the patient) that passively and continuously monitors keystroke dynamics of everyday typing as a digital biomarker.
48279638|NCT01851096|DRUG|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
48451051|NCT05854784|DRUG|Afamelanotide 16 MG|Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.
48637406|NCT03823885|OTHER|empty (-cigarette sham control)|use empty e-cig (sham control)
48637407|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/CT|Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.
48637408|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/MR|Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
48637409|NCT02959892|DRUG|Amphetamine|Amphetamine tablets.
48637410|NCT02959892|DRUG|TAK -041|TAK-041 oral suspension.
48451052|NCT05464394|DRUG|Tranexamic Acid Injection [Cyklokapron]|A set dose of 1500 mg will be used, based on the study population with morbid obesity. It will be administered intravenous dissolved in 100 ml sodium chloride 0.9% in a time frame of 15-30 minutes, with a maximum of 100 mg/min.
48451053|NCT05464394|DRUG|Sodium chloride 0.9%|100 ml sodium chloride 0.9% will be administered in a time frame of 15-30 minutes
48451054|NCT05615909|RADIATION|Online MR-guided radiotherapy|Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).
48451055|NCT05615909|RADIATION|CT-guided radiotherapy|CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
48451056|NCT05908097|DEVICE|Virtual Reality Avatar Intervention|In the Virtual Reality Avatar Intervention experience, participants will see an avatar resembling themselves in a park setting. The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
48620605|NCT04728256|BEHAVIORAL|Laughter therapy+Music listening+Keeping diary|"Laughter therapy was carried out by the researcher as a total of three sessions every 15 days, and each session lasted 30 minutes.~Participants listened to the types of music that they like (pop, Turkish folk music). In the meeting room in FHC, Two professional artists performed music recitals with a guitar and saz (qopuz) to pregnant women, and pregnant women actively participated in this process. The performance was carried out as three sessions, once every 15 days, and each session took 40 minutes.~In addition to music listening and laughter therapy, the pregnant women were asked to keep a diary to write down their emotions about their health status, pregnancy and baby. Then, each participant had an opportunity to explain her emotions or replies to the questions during the group therapy sessions every 15 days so that pregnant women were able to express their feelings."
48620606|NCT05700864|DRUG|Cenegermin-Bkbj|Cenegermin-bkbj ophthalmic solution administered as one drop in both eyes every 3 hours 4 times daily for 4 weeks
48620607|NCT06424353|PROCEDURE|Endoflas pulpectomy|obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files
48620608|NCT02981589|DEVICE|Invasive mechanical ventilation|Invasive ventilation was performed to all eligible patients. When patients met predefined criteria, spontaneous breathing trial was performed. Given spontaneous breathing trial passed, patients were extubated; on the contrary, patients would continue to receive invasive ventilation. If patients had respiratory failure after extubation, reintubation and invasive ventilation were necessary.
48620609|NCT02131883|BEHAVIORAL|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
48620610|NCT02131883|OTHER|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
48620611|NCT05218876|OTHER|Low- to moderate intensity strength and endurance training|Combination of strength and endurance training with low- to moderate intensity during chemotherapy
48620612|NCT05218876|OTHER|High intensity strength and endurance training|Combination of strength and endurance training with high intensity during chemotherapy
48620613|NCT02820415|OTHER|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
48620614|NCT04650620|DEVICE|Plenhyage® thin|0.75%
48620615|NCT04650620|DEVICE|Plenhyage® medium|2%
48620616|NCT04650620|DEVICE|Plenhyage® strong|2.5%
48620617|NCT01124240|DRUG|Cilengitide|"Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.~Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).~After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA \< 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles."
48620618|NCT03922373|DRUG|Group A: Benzonatate 100mg|Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
48620619|NCT03922373|DRUG|Group B: Benzonatate 200mg|Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
48620620|NCT03922373|DRUG|Group C: Benzonatate 400mg|Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
48620621|NCT05323851|BEHAVIORAL|COVID-surg-SPIGC questionnaire|The questionnaire aimed to evaluate how the COVID-19 pandemic determined a shift in daily practice through a multidimensional assessment of surgical clinical care in three different time frames.
48620622|NCT01807455|DEVICE|Restylane Vital Lidocaine|
48620623|NCT00523575|DIETARY_SUPPLEMENT|Cubitan|400 ml/d
48620624|NCT00839826|DRUG|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
48620625|NCT00839826|DRUG|Enoxaparin|40 mg bid
48620626|NCT01537796|BEHAVIORAL|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
48451057|NCT05908097|DEVICE|Virtual Reality Empty Park|The Virtual Reality Empty Park experience is a habituation experience that does not contain avatars.
48451058|NCT06562868|OTHER|Bulk-fill Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
48451059|NCT06562868|OTHER|Traditional Posterior Composite Resin|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
48451060|NCT06562868|OTHER|High-filler Flowable Composite|The evaluation of the restorative material according to FDI criteria at baseline, 1 year and 2 years after application
48637411|NCT02959892|DRUG|[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)|\[11C\]PHNO injection.
48279639|NCT04785612|BIOLOGICAL|RSVPreF|A single dose of 120 mcg RSVpreF for intramuscular injection
48279640|NCT04785612|OTHER|Placebo|A single Placebo dose for intramuscular injection to match experimental vaccine
48279641|NCT04100525|BEHAVIORAL|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
48279642|NCT00613626|DRUG|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
48279643|NCT00613626|DRUG|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
48279644|NCT00613626|DRUG|Placebo|Matched placebo oral daily
48279645|NCT00613626|DRUG|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
48279646|NCT06596304|OTHER|Low intensity-resistance training with lower limb blood flow restriction|In the LIRT-BFR, participants will perform 4 sets of 20 bilateral leg presses and knee extensions repetitions with BFR at 30% of 1-RM, with 30-second rest intervals between sets, in an estimated total of 30-minute session per participant. Cuffs will be placed in the upper thighs and inflated with a pressure that is 1.3 times the individual's ankle systolic blood pressure in the data collection day for the entirety of the training session with a commercial cuff (width×length; 11×85 cm, SC10™, Hokanson, Inc., WA, USA).
48279647|NCT06596304|OTHER|High Intensity Resistance Training|In the HIRT participants will perform bilateral leg presses and knee extension without BFR at 75% of one-repetition maximum (1-RM), for 3 sets of 10 reps, with 2-minute rest intervals, in an estimated total of 30-minute session per participant.
48279648|NCT05200793|DRUG|Empagliflozin 25 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
48279649|NCT05200793|DRUG|Linagliptin 10 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
48279650|NCT05200793|DRUG|Metformin 1500 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
48279651|NCT01871506|BEHAVIORAL|Standard Care (SC)|"1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
48279652|NCT01871506|BEHAVIORAL|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
48279653|NCT05973370|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
48279654|NCT05973370|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
48279655|NCT02554305|DEVICE|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
48279656|NCT02554305|DEVICE|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
48279657|NCT04888611|BIOLOGICAL|Camrelizumab plus GSC-DCV|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
48279658|NCT04888611|BIOLOGICAL|Camrelizumab plus Placebo|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
48279659|NCT00680225|DRUG|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
48279660|NCT02623179|OTHER|culture versus Molecular diagnostics|Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
48279661|NCT05411302|OTHER|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
48279662|NCT01287754|DRUG|erlotinib [Tarceva]|150 mg daily orally
48637412|NCT01765881|DRUG|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
48637413|NCT01765881|DRUG|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
48451061|NCT05224531|DRUG|CS1 Administration|CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
48451062|NCT03679598|DRUG|Alvelestat (MPH966)|Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
48451063|NCT03679598|OTHER|Placebo|Placebo is a pill or tablet that does not contain any study drug.
48451064|NCT01391273|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
48451065|NCT01391273|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
48451066|NCT06138821|DEVICE|ESG + lifestyle modification|Endoscopic sleeve gastroplasty - an endoscopic weight loss procedure where an endoscopic suturing device is utilized to reduce the size of the stomach by 70%.
48451067|NCT06138821|BEHAVIORAL|Lifestyle modification|Lifestyle modification program consisting of diet and exercise therapy
48451068|NCT00003291|GENETIC|cytogenetic analysis|
48451069|NCT00003291|GENETIC|mutation analysis|
48451070|NCT00003291|OTHER|laboratory biomarker analysis|
48451071|NCT04173247|DEVICE|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
48451072|NCT04173247|OTHER|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
48451073|NCT04342663|DRUG|Fluvoxamine|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
48620627|NCT01537796|BEHAVIORAL|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
48620628|NCT01537796|BEHAVIORAL|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
48620629|NCT05632991|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 20 ml local anesthetic each side
48620630|NCT05632991|OTHER|Subcostal Transversus Abdominis Plan Block Group|ultrasound guided Subcostal Transversus Abdominis Plan Block Group 20 ml local anesthetic each side
48620631|NCT02916927|DRUG|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
48620632|NCT02916927|DRUG|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
48620633|NCT00815074|OTHER|No intervention|no intervention
48637414|NCT06035497|DRUG|BMS-986369|Specified dose on specified days
48279663|NCT02059824|DEVICE|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
48279664|NCT03551522|DRUG|Seladelpar|10 mg, 20 mg, or 50 mg
48279665|NCT03551522|DRUG|Placebos|Matching placebo Capsule
48451074|NCT04342663|DRUG|Placebo|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
48451075|NCT04467151|DRUG|anti-SARS-CoV-2 plasma|Administration of anti-SARS-CoV-2 convalescent plasma
48451076|NCT04467151|OTHER|Placebo|Administration of placebo (albumin 5%)
48451077|NCT05921760|DRUG|Ivosidenib|ivosidenib taken once daily
48451078|NCT05921760|DRUG|Recommended Combination Dose (RCD) of ivosidenib|The RCD of ivosidenib taken once daily
48451079|NCT05921760|DRUG|Nivolumab|Nivolumab taken by intravenous infusion
48451080|NCT05921760|DRUG|Ipilimumab|Ipilimumab taken by intravenous infusion
48451081|NCT03442322|OTHER|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
48451082|NCT03442322|OTHER|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
48451083|NCT06025279|OTHER|Ultrasound Scan|Clinical professionals will conduct non-invasive ultrasound scans from the specified body views and subsequently save the acquired data.
48451084|NCT05698589|BEHAVIORAL|Compassion Focused Therapy|CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, ...) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, ...). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
48451085|NCT05698589|BEHAVIORAL|Ending Self Stigma|Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
48451086|NCT00702377|OTHER|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
48451087|NCT00702377|OTHER|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
48451088|NCT03909607|DRUG|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
48451089|NCT03909607|DRUG|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
48451090|NCT03909607|DRUG|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
48451091|NCT01126762|BEHAVIORAL|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
48451092|NCT01126762|BEHAVIORAL|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
48620634|NCT03909503|DEVICE|Porcine-derived collagen wound dressing|Patients who meet the inclusion criteria will be treated with porcine-derived collagen dressings. The dressing will be used in accordance with its label. After cleansing the wound, the dressing will be placed on the wound. Appropriate primary and secondary dressings will be placed over the intervention product. Patients will visit the clinic once per week to have their dressings re-applied. Wound evaluations will take place once per week with the intervention lasting up to twelve weeks. Concomitant standard of care such as compression for venous ulcers will be provided according to individual patient needs.
48620635|NCT02278354|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
48620636|NCT02278354|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post injection
48620637|NCT02896842|DRUG|Posology dose modification|
48620638|NCT02896842|OTHER|active comparator|
48620639|NCT00000442|DRUG|naltrexone (Revia)|
48279666|NCT03118622|DEVICE|Pentax|Intubation using Pentax video laryngoscope in Pentax group
48279667|NCT06656416|DRUG|ALTO-100|ALTO-100 40 mg tablet BID
48279668|NCT06656416|DRUG|Placebo|Placebo tablet BID
48279669|NCT06642480|DRUG|Post Operative Analgesia|administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
48279670|NCT06642480|DRUG|Post Operative Analgesia|VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
48279671|NCT06325449|BEHAVIORAL|STREAM program|The STREAM program is a 24-week weight-loss program which includes meal replacement, dietician coaching/teaching and weekly visits with a physician.
48279672|NCT04430907|BIOLOGICAL|HPV 9-valent Vaccine, Recombinant|"After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey."
48279673|NCT05965037|DEVICE|FLUYDO NC percutaneous transluminal coronary angioplasty balloon catheter|The FLUYDO NC is a rapid exchange percutaneous transluminal non-compliant coronary angioplasty balloon catheter. It is a single use only medical device, non-implantable, non-pyrogenic and sterilized with ethylene oxide and CO2 mixture. The distal portion has a hydrophilic coating and consists of two lumens: one for balloon inflation and deflation, the other for guidewire advancement and retraction. The product is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.
48279674|NCT05302752|OTHER|Magnetic phrenic nerve stimulation|"The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated."
48279675|NCT03367156|DRUG|Dexamethasone|Given PO
48279676|NCT03367156|OTHER|Placebo|Given PO
48279677|NCT03367156|OTHER|Questionnaire Administration|Ancillary studies
48279678|NCT05040529|PROCEDURE|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
48279679|NCT05040529|PROCEDURE|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
48279680|NCT02012010|PROCEDURE|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
48279681|NCT02012010|PROCEDURE|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
48279682|NCT05455320|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
48620640|NCT03432520|GENETIC|SPK-8011|Observational long-term safety follow-up study of subjects previously treated with SPK-8011 in any Spark-sponsored SPK-8011 study
48620641|NCT02987868|DRUG|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
48451093|NCT04690985|BEHAVIORAL|Dietary behaviour change|The intervention consists of dietary guidance and behaviour change techniques, which will last for 15 weeks. The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive the dietary behaviour change guidance in 6 times face-to-face meetings and weekly telephone calls. They will also be asked to take daily food diary.
48451094|NCT04690985|OTHER|Social contact|The control group will not be required any dietary changes. The investigator will contact with the control group with the same frequency and numbers of experimental group. But the chat topic will not be related to sarcopenic obesity or dietary guidance.
48451095|NCT01515891|DRUG|BIA 9-1067|90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
48451096|NCT05574114|RADIATION|Bridging radiotherapy (BRT)|RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
48451097|NCT05574114|DRUG|Conditioning chemotherapy|Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
48451098|NCT05574114|BIOLOGICAL|CAR T-cell product|Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
48451099|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
48451100|NCT00768963|DRUG|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
48451101|NCT04898647|OTHER|fundoscopic picture|A central review of numerised fundoscopic picture will be performed.
48451102|NCT04898647|BIOLOGICAL|blood sample|"Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.~One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling"
48451103|NCT04898647|PROCEDURE|bone marrow sample|Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM
48451104|NCT05651958|OTHER|Nebulizer|Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
48451105|NCT05651958|OTHER|Breathing Technique|15 repeatations of Breathing in morning and evening
48451106|NCT01079845|BEHAVIORAL|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
48451107|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
48620642|NCT02987868|DRUG|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
48620643|NCT02987868|DRUG|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
48620644|NCT02987868|DRUG|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
48279683|NCT05455320|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
48279684|NCT05455320|DRUG|Pomalidomide|Pomalidomide will be administered orally.
48279685|NCT05455320|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
48279686|NCT00267241|OTHER|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
48279687|NCT05180812|DEVICE|ExoNet Tuned to Gravity Support|This study's primary goal is to test the safety, feasibility, and efficacy of the ExoNET device developed in the Robotics Lab at the Shirley Ryan AbilityLab. We want to observe if individuals using the ExoNET tuned to gravity support will notice a reduction in bicep muscle activity, leading to an improvement in functional outcome measures in stroke patients.
48279688|NCT00917384|BIOLOGICAL|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
48279689|NCT00917384|DRUG|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
48279690|NCT00917384|OTHER|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
48279691|NCT04381234|DEVICE|dialyzer|Asymmetric triacetate dialyzer
48279692|NCT04381234|COMBINATION_PRODUCT|hemodialysis with citrate-containing dialysate|acetate-free dialysate
48279693|NCT04381234|OTHER|predilution hemodiafiltration|predilution hemodiafiltration
48279694|NCT01440725|BIOLOGICAL|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
48279695|NCT01440725|PROCEDURE|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
48279696|NCT05327114|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
48279697|NCT05327114|DRUG|Placebo|Placebo will be administered intravenously.
48279698|NCT03731663|BEHAVIORAL|Exposure to pictures of appetizing food (known as Foodporn)|- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
48279699|NCT03731663|BEHAVIORAL|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
48279700|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg twice daily
48279701|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg once daily
48279702|NCT00317044|DRUG|Placebo|Placebo twice daily
48279703|NCT01235676|BEHAVIORAL|diet|calorie restriction to reduce weight gain
48620645|NCT00580281|OTHER|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
48620646|NCT05407896|OTHER|myKIDNEY decision aid|Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
48620647|NCT03749200|OTHER|Obemat2.0 therapy|
48620648|NCT03749200|OTHER|Regular practise in primary care|
48620649|NCT04445415|DIAGNOSTIC_TEST|COVID-19 antibodies testing|antibodies aganist COVID-19 detected in the serum of patients
48620650|NCT06060366|PROCEDURE|Pulmonary endarterectomy|removal of chronic thrombus from pulmonary arterial system
48620651|NCT04089722|DRUG|Deoxycholic Acid|The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
48279704|NCT01235676|BEHAVIORAL|Exercise|Exercise to reduce weight gain
48451108|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
48451109|NCT02965859|DRUG|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
48451110|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
48451111|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
48451112|NCT02965859|DRUG|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
48451113|NCT02965859|DRUG|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
48451114|NCT02965859|DRUG|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
48451115|NCT02825160|DRUG|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
48451116|NCT03168503|DIETARY_SUPPLEMENT|LGG+Promitor™|synbiotic
48451117|NCT03168503|DIETARY_SUPPLEMENT|Promitor™|Soluble Corn Fiber
48451118|NCT03168503|DIETARY_SUPPLEMENT|LGG-PB12+Promitor™|synbiotic
48451119|NCT03168503|DIETARY_SUPPLEMENT|Maltodextrin|Control
48451120|NCT03034694|OTHER|teledermatology consult|teledermatology consult
48620652|NCT02863042|PROCEDURE|Repair Deltoid Tendon|
48620653|NCT02863042|OTHER|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
48620654|NCT00147238|DRUG|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
48620655|NCT00147238|PROCEDURE|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
48620656|NCT05550519|OTHER|Entecavir (ETV)|ETV will continue throughout screening and will be stopped at baseline.
48279705|NCT06657521|DIETARY_SUPPLEMENT|osteoimplant|Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
48279706|NCT06657521|DIETARY_SUPPLEMENT|Placebo Oral Tablet|2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
48451121|NCT03034694|OTHER|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
48451122|NCT02577653|OTHER|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
48451123|NCT01441297|DRUG|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
48451124|NCT01640197|DIETARY_SUPPLEMENT|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
48451125|NCT01640197|OTHER|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
48451126|NCT04988464|BEHAVIORAL|Sleep Scholar|A single-session, internet-based insomnia intervention for college students
48451127|NCT04988464|BEHAVIORAL|Building Healthy Habits|A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
48451128|NCT04363554|OTHER|Fluid intake|The participants will intake fluid
48451129|NCT04363554|OTHER|Thirsting|The participants will thirst
48451130|NCT06090994|DRUG|Huaier granule|Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.
48451131|NCT06090994|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
48451132|NCT05909358|BIOLOGICAL|CAd3|CAd3 candidate vaccine which is one of the investigational products
48451133|NCT05909358|BIOLOGICAL|ChAdox1|ChAdox1 candidate vaccine which is one of the investigational products
48451134|NCT05909358|BIOLOGICAL|rVSV-SUDV|rVSV-SUDV candidate vaccine which is one of the investigational products
48451135|NCT05909358|OTHER|Control|Placebo
48451136|NCT04732065|DRUG|ONC206|Given orally (PO)
48451137|NCT04732065|RADIATION|Standard of Care Radiation Therapy|Undergo RT
48451138|NCT04732065|PROCEDURE|Optional Proton (1H) MR spectroscopy (MRS)|Optional imaging procedure
48451139|NCT06177418|PROCEDURE|Transumbilical laparoscopic appendectomy + Glove finger technique|Ssince the appendix becomes infected when it is removed from the umbilicus, the infected appendix contacts the edge of the incision during release, thus contaminating the incision and causing postoperative wound infection. Additionally, in the experimental, to prevent this wound infection, after the appendix is taken out through the umbilical incision, the appendix is placed inside the glove finger, thus preventing the appendix from touching the wound during its release. This reduces wound infection in the postoperative period.
48620657|NCT05550519|OTHER|Tenofovir Disoproxil Fumarate (TDF)|TDF will continue throughout screening and will be stopped at baseline.
48620658|NCT05550519|OTHER|Tenofovir Alafenamide (TAF)|TAF will continue throughout screening and will be stopped at baseline.
48620659|NCT01228045|DRUG|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
48620660|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
48620661|NCT02607072|DRUG|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
48620662|NCT02607072|DRUG|Placebo|
48620663|NCT00620906|PROCEDURE|Manipulation|HVLA manipulation to Sacroiliac Joint
48620664|NCT01144832|DRUG|ebastine|20 milligram capsule once daily
48451140|NCT06177418|PROCEDURE|Standard transumbilical laparoscopic appendectomy|Standart transumbilical laparoscopic appendectomy
48451141|NCT06626815|BEHAVIORAL|Lateral Kangaroo Position|Newborns in the lateral kangaroo position group will be positioned diagonally on their mothers chests, with their heads placed between the mothers breast and collarbone.
48451142|NCT06626815|BEHAVIORAL|Reverse Kangaroo Position|Newborns in the reverse kangaroo position group will be positioned vertically with their backs in contact with the mothers chest.
48451143|NCT05140759|DEVICE|automated continual water removal system|The device removes excess fluids in heart failure patients with diuretic resistance
48451144|NCT03685305|BEHAVIORAL|Hypocaloric diet with hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
48451145|NCT03685305|BEHAVIORAL|Hypocaloric diet without hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
48451146|NCT06476977|PROCEDURE|Dorsal webspace combined corticosteroid and anesthetic injection|The dorsal webspace injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
48451147|NCT06476977|PROCEDURE|Palmar combined corticosteroid and anesthetic injection|The palmar injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
48279707|NCT06170645|OTHER|APA program|An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.
48451148|NCT03407677|DEVICE|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
48451149|NCT03420053|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
48451150|NCT03420053|OTHER|Normal Saline Placebo|0.9% sodium chloride solution
48451151|NCT03420053|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
48279708|NCT06170645|OTHER|Active transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
48451152|NCT01937234|DRUG|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
48620665|NCT01144832|DRUG|placebo capsule|one capsule once daily
48620666|NCT00146068|DRUG|Avonex/Zocor|
48279709|NCT06170645|OTHER|Sham transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
48451153|NCT01937234|DRUG|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
48451154|NCT05754203|RADIATION|Super-hyperfractionation Pulse Radiotherapy|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
48451155|NCT05997108|DIAGNOSTIC_TEST|CBC|Platelet and red blood cell volume indices
48451156|NCT02490072|DRUG|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
48451157|NCT02490072|DRUG|normal saline(Saline 0.9%)|
48451158|NCT00444353|DEVICE|DL6049 (injectable poly-L-lactic acid)|
48451159|NCT06560801|DRUG|Dapagliflozin 10mg Tab|Randomization will take place at visit 1 to either the group receiving standard care and dapagliflozin or standard care only.
48451160|NCT00080392|DRUG|DNA Plasmid Vector|
48451161|NCT00080392|DRUG|EW-A-401 DNA Plasmid Vector|
48620667|NCT02961660|DRUG|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
48620668|NCT00742677|PROCEDURE|nutritional support|Given orally
48279710|NCT03607344|PROCEDURE|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
48279711|NCT00627666|BIOLOGICAL|anti-thymocyte globulin|
48279712|NCT00627666|DRUG|busulfan|
48451162|NCT05906251|GENETIC|SRP-6004|Single IV infusion of SRP-6004
48279713|NCT00627666|DRUG|fludarabine phosphate|
48451163|NCT01050556|OTHER|Placebo|daily, 24 weeks
48620669|NCT05677230|PROCEDURE|Balloon occluded/plug assisted retrograde transvenous obliteration.|Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
48620670|NCT05677230|PROCEDURE|Endoscopic Variceal Obturation|Endoscopic Variceal Glue Therapy will be done till obturation every 3 weekly.
48279714|NCT00627666|DRUG|leucovorin calcium|
48279715|NCT00627666|DRUG|methotrexate|
48279716|NCT00627666|PROCEDURE|allogeneic bone marrow transplantation|
48279717|NCT00627666|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48620671|NCT06415331|PROCEDURE|Pulsed radiofrequency|Individualized dose of pulsed radiofrequency is given for 6 minutes.
48637415|NCT00493558|DEVICE|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
48637416|NCT02082093|DEVICE|Telemedicine System|
48620672|NCT06415331|OTHER|Conventional therapy|"Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise"
48620673|NCT01067235|DRUG|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
48620674|NCT01067235|DRUG|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
48620675|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
48620676|NCT03261401|DRUG|Placebo|Participants received placebo matched to M5717
48620677|NCT03261401|DRUG|M5717|Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
48620678|NCT02603133|BEHAVIORAL|Three Good Things|"In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others."
48620679|NCT02603133|BEHAVIORAL|Gratitude|In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
48620680|NCT02603133|BEHAVIORAL|Random Acts of Kindess|In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
48620681|NCT02603133|BEHAVIORAL|Awe|This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
48620682|NCT02603133|BEHAVIORAL|1 Good Chat|This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
48451164|NCT01050556|DIETARY_SUPPLEMENT|folic acid|400 ug/d for 12 or 24 weeks
48620683|NCT02661971|DRUG|Docetaxel|Docetaxel 50 mg/m², d1
48620684|NCT02661971|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m², d1
48451165|NCT01050556|DIETARY_SUPPLEMENT|folic acid|800 µg/d for 12 or 24 weeks
48620685|NCT02661971|DRUG|Calciumfolinat|Leucovorin 200 mg/m², d1
48620686|NCT02661971|DRUG|5-Fluorouracil|5-FU 2600 mg/m², d1
48620687|NCT02661971|BIOLOGICAL|Ramucirumab|Ramucirumab 8mg/kg, d1
48620688|NCT01799694|DRUG|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
48451166|NCT01050556|DIETARY_SUPPLEMENT|creatine|3 mg/d for 12 weeks
48620689|NCT04906798|DRUG|CKD-385|Test Drug
48451167|NCT01050556|DIETARY_SUPPLEMENT|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
48451168|NCT00903877|DRUG|T3|Patients receive T3 in a dose of 25mcg and 50mcg
48620690|NCT04906798|DRUG|D744|Reference Drug
48620691|NCT02797730|BEHAVIORAL|art-therapy sessions|
48620692|NCT00804271|DRUG|memantine|memantine tablets, OD, 12 weeks
48620693|NCT02779296|OTHER|2-Octyl Cyanoacrylate Glue|topical
48620694|NCT05813496|DRUG|Alpha-Lipoic Acid (ALA)|Oral tablet
48620695|NCT05813496|DRUG|Placebo|Microcrystalline cellulose (Ph 101) 427.5 mg, Magnesium stearate 71.25 mg, Sodium laurayl sulphate 6 mg, Croscarmellose sodium 11.25 mg, Silica, colloid anhydrous 11.25 mg, and Purified talc 30 mg.
48620696|NCT01798290|BEHAVIORAL|narrative medicine: reading workshop|
48620697|NCT01798290|BEHAVIORAL|critical reading|
48620698|NCT05041465|OTHER|Clay mask|Clay mask powders- French green, Rhassul and bentonite
48620699|NCT04100057|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
48637417|NCT03511209|BEHAVIORAL|CBTI plus taper method A|This intervention includes CBTI plus the novel hypnotic tapering method.
48637418|NCT03511209|BEHAVIORAL|CBTI plus taper method B|This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
48451169|NCT00135850|GENETIC|VEGF-A165 plasmid|
48451170|NCT05510830|PROCEDURE|diagnostic cervical conization|For the patients who met the inclusion criteria, the gynecologists perform cervical conization and pathological examinations. Then the patients will be followed-up for at least two years with the tests of cervical TCT \& HPV, and colposcopy if necessary. The data will be analyzed and see if the patients with high risk factors benefit from the surgery or not.
48279718|NCT00627666|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
48451171|NCT00857454|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
48451172|NCT06601140|DEVICE|EMOCARE software|Use of the EMOCARE software on the digital device of participant (smartphone, computer, etc.). The participant can activate and deactivate the software whenever he wishes.
48451173|NCT05133804|DRUG|Methylphenidate|Ritalin 10mg
48620700|NCT04100057|BEHAVIORAL|Desensitization Therapy for insomnia (DT-I)|"DT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. DT-I has been validated as an active-placebo control condition. Therapists help each DT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, DT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
48620701|NCT05939947|DRUG|ALE.F02|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
48620702|NCT05939947|DRUG|Placebo|Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
48620703|NCT01659905|DRUG|Montelukast|Chewable Tablet
48451174|NCT05133804|DRUG|Reboxetine|Reboxetine 4mg
48451175|NCT05133804|DRUG|Placebo|Placebo matched to Reboxetine
48620704|NCT01659905|DRUG|Singulair|5 mg Chewable Tablet
48620705|NCT02080078|DRUG|Theophylline|
48620706|NCT02080078|DRUG|Erlotinib|
48620707|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (Z-Drug-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (Z-drug monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for Z-Drug. Increasing LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment from the first treatment phase. Changing LEM dose is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
48620708|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-mono cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV monotherapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed."
48620709|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (SUV-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (SUV and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for SUV and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
48620710|NCT04742699|DRUG|Lemborexant (LEM) 5 mg (RMT-combination cohort)|"1. Pretreatment phase: Continue pre-registration treatment (RMT and BZRA combination therapy) without LEM.~2. First treatment phase: Administer LEM 5 mg/day as a substitute for RMT and continue BZRA. Increasing to LEM dose to 10 mg/day is allowed.~3. Maintenance phase: Succeed the treatment of the first treatment phase. Changing LEM dose is allowed. Decreasing dose or discontinuation of BZRA is allowed. Rescue administration of Z-drug or RMT is allowed under a defined condition."
48620711|NCT01626313|BEHAVIORAL|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
48620712|NCT00632359|DRUG|Lenalidomide|10 mg daily given for 12 months
48279719|NCT06543992|DRUG|Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir|Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
48451176|NCT05133804|DRUG|Placebo|Placebo matched to Ritalin
48451177|NCT03431961|DRUG|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
48451178|NCT03431961|DRUG|Placebo|twice daily for 14 days
48451179|NCT05400694|OTHER|Food|Dairy products with reduced sugar content
48451180|NCT03589313|DRUG|GLPG3067 single dose|GLPG3067 film coated tablets provided at Day 1.
48451181|NCT06133101|DRUG|Standard Soy Milk|Consumption of commercially available soy milk
48451182|NCT06133101|DRUG|2% Fat Cow's Milk|Consumption of commercially available 2% cow's milk
48451183|NCT01901263|BEHAVIORAL|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
48451184|NCT05795504|OTHER|resistive exercise|They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.
48451185|NCT05795504|OTHER|high intensity interval training|They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,
48451186|NCT05795504|DIETARY_SUPPLEMENT|calcium and vitamin D|they will receive calcium and vitamin D supplements only.
48451187|NCT02462681|DRUG|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
48620713|NCT05568004|BEHAVIORAL|Combined exercise|aerobic plus resistance exercise
48620714|NCT05568004|BEHAVIORAL|Aerobic exercise|Only aerobic exercise
48620715|NCT02641821|DRUG|Nifedipine GITS|
48620716|NCT03575156|BIOLOGICAL|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
48620717|NCT03575156|BIOLOGICAL|urine sample|6 ml
48620718|NCT03421587|BEHAVIORAL|Processing of social olfactory and tactile stimuli|Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
48279720|NCT05521165|OTHER|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
48279721|NCT00013078|PROCEDURE|Physical restoration intervention|
48279722|NCT02010203|BIOLOGICAL|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
48620719|NCT02467816|BEHAVIORAL|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
48620720|NCT02467816|BEHAVIORAL|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
48620721|NCT02467816|BEHAVIORAL|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
48451188|NCT03701594|OTHER|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
48451189|NCT03701594|OTHER|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
48620722|NCT02195323|BIOLOGICAL|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
48620723|NCT04651712|DIAGNOSTIC_TEST|POC-PCR|The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
48620724|NCT03594838|OTHER|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
48620725|NCT00211367|DRUG|Anecortave Acetate|
48620726|NCT02232230|DRUG|Provenge|
48620727|NCT01975441|DRUG|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
48620728|NCT01975441|DRUG|Albendazole|Albendazole 400mg
48620729|NCT01975441|DRUG|Ivermectin|Ivermectin 200 mcg/kg
48620730|NCT01966783|DRUG|Budesonide 2 mg suppository|per day
48620731|NCT01966783|DRUG|Budesonide 4 mg suppository|per day
48620732|NCT01966783|DRUG|Mesalazine 1 g suppository|per day
48620733|NCT01966783|DRUG|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
48620734|NCT03424304|DEVICE|Excel V™ Laser With Green Genesis|Subject(s) will receive treatments with a Cutera Excel V™ Laser
48279723|NCT02010203|BIOLOGICAL|Placebo|Injection containing sterile solution but no cells
48279724|NCT02010203|BIOLOGICAL|BCG|Vaccine derived from a live bacterium
48279725|NCT06179992|DEVICE|GGED mobile app|The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
48279726|NCT02243384|PROCEDURE|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
48620735|NCT00000335|DRUG|Morphine|
48279727|NCT02243384|PROCEDURE|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
48620736|NCT02471183|DRUG|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
48620737|NCT05401851|DEVICE|Left Bundel Area Pacing|RV Lead will be placed deep in the interventricular septum
48620738|NCT01039675|DRUG|500mcg/25mcg once daily|GSK573719/GW642444
48620739|NCT01039675|DRUG|Placebo once daily|Inactive, excipients only
48620740|NCT01697046|DRUG|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
48620741|NCT05169905|COMBINATION_PRODUCT|RSV MAT vaccine|"Single dose of the RSV MAT vaccine reconstituted with NaCl solution was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~RSV MAT vaccine was no longer administered to participants at Day 31. No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it."
48451190|NCT03701594|OTHER|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
48451191|NCT03490864|DIETARY_SUPPLEMENT|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
48451192|NCT03490864|DIETARY_SUPPLEMENT|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
48451193|NCT03490864|OTHER|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
48451194|NCT03490864|OTHER|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
48451195|NCT00620880|BEHAVIORAL|Blood sample|
48451196|NCT06119763|DIAGNOSTIC_TEST|anti dfs70 antibodies|blood sample is taken from SLE cases and is tested for antiDFS70 antibodies titre
48451197|NCT05493735|DRUG|Lidocaine Hcl 2% Jelly|Participants in the experimental arm will undergo pessary removal and reinsertion after the application of lidocaine topical gel.
48451198|NCT05493735|DRUG|Placebo Jelly|Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
48620742|NCT05169905|COMBINATION_PRODUCT|dTpa vaccine|"Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study.~The participants in RSV_dTpa-P and RSV_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.~No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it."
48451199|NCT06308484|DEVICE|Transcutaneous vagus nerve stimulation|Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.
48451200|NCT06308484|DEVICE|Closed-loop AM-tACS|Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.
48451201|NCT05571462|OTHER|Activity monitor group|No intervention will be applied. All included patients will be monitored with body-worn physical activity monitors during two periods.
48451202|NCT02580279|DRUG|EGCG|
48451203|NCT02580279|DRUG|placebo|
48451204|NCT04150029|DRUG|MBG453|Solution for intravenous infusion
48451205|NCT04150029|DRUG|Venetoclax|Tablet for oral administration
48451206|NCT04150029|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
48451207|NCT05911711|OTHER|Prognostic factor|normal person (no sepsis group)
48451208|NCT06047171|BIOLOGICAL|ALE.F02|ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
48451209|NCT06047171|DRUG|Rituximab|Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
48451210|NCT06047171|DRUG|GlucoCorticoid|Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
48451211|NCT06047171|DRUG|Cyclophosphamid|Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
48451212|NCT06047171|DRUG|Placebo|Drug product that will contain no active ingredient
48451213|NCT06047171|DRUG|Immunosuppressive Agents|Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
48451214|NCT06430294|OTHER|Spinal mobilisation|Application of a force on pediatric manikins.
48620743|NCT04828967|OTHER|Hypnosis|Hypnosis is added to the conventional group
48279728|NCT02207907|DRUG|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
48279729|NCT02207907|DRUG|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
48279730|NCT01478555|DRUG|ISV 101|Bromfenac in DuraSite
48279731|NCT03506503|PROCEDURE|Nanofat grafting|hair loss area will be treated by processed autologous Nanofat grafting
48279732|NCT05531357|DIAGNOSTIC_TEST|Transvaginal ultrasound scans|"Transvaginal ultrasound scans to map ovarian follicle growth and ovulation, finger-prick blood sampling for dried blood spot (DBS) hormonal assays and urine sampling for hormone metabolites, every consecutive day for an interovulatory interval.~Weekly venipuncture samples will be taken for standard ELISA hormonal assays. The hormones of interest are FSH, LH, estradiol, progesterone, AMH, inhibins A and B, GDF-9 and BMP-15."
48279733|NCT04242537|DEVICE|High flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
48279734|NCT04242537|DEVICE|Low flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
48451215|NCT05770388|DEVICE|App Take Care of Your Mood|The app provides psychoeducational information, contains several thematic modules (mindfulness, emotional regulation, healthy lifestyle habits, safety plan for crisis management, among others), allows mood monitoring, contains motivational messages and videos aimed at promoting help-seeking in mental health, and information on available support services.
48451216|NCT05770388|BEHAVIORAL|Reminder messages and counseling|Participants receive reminder messages (by email and chat) encouraging them to use the app and to request a counseling session (via phone call, videoconference or chat) with a clinical psychologist if they think it is necessary.
48451217|NCT03997019|PROCEDURE|opioid analgesia|opioid analgesia will be used with general anaesthesia
48451218|NCT03997019|PROCEDURE|ESP block|ultrasound guided ESP Block before anaesthesia induction
48451219|NCT04482465|DIAGNOSTIC_TEST|blood sample|blood sample to determine omega6/omega 3 ratio, EPA, DHA, zinc, cupric oxide, vitamine D
48451220|NCT04652856|DEVICE|Electrical Brain Stimulation|Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.
48451221|NCT04652856|DEVICE|Sham Electrical Brain Stimulation|Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
48451222|NCT02045667|DRUG|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
48451223|NCT02045667|DRUG|Placebo|Placebo tablets do not contain any active medicinal component.
48451224|NCT02642835|PROCEDURE|vaginal wall mesh|retrospective review of case series
48451225|NCT06455137|DEVICE|Epidural Stimulator|Participants will have a 16-electrode epidural array implanted in the C4-C7 and T11-L2 areas of the spinal cord. Following a 2 weeks recovery period, patients will engage in a structured training of physical rehabilitation and electrical stimulation.
48451226|NCT06042738|COMBINATION_PRODUCT|proxeed plus|Group 1 was recommended to receive a food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg selenium, 3750 µg vitamin B12 and 500 µg folic acid as one sachet in the morning and evening
48451227|NCT05616728|DRUG|EDP-235|capsule
48451228|NCT05616728|DRUG|Placebo|capsule
48451229|NCT04676503|DIETARY_SUPPLEMENT|BIOVAGINIL|Biovaginil is a notified food supplement formulated as 480 mg capsules. Each capsule contains Lactobacillus crispatus NTCVAG04 3 billion and Vitamin A 120 μg.
48451230|NCT01619241|OTHER|PET/CT|F-18 FLT PET/CT
48451231|NCT03140631|DRUG|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
48451232|NCT03998150|PROCEDURE|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
48451233|NCT03998150|PROCEDURE|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
48451234|NCT03874715|DRUG|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
48451235|NCT03874715|DRUG|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
48451236|NCT03874715|DRUG|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
48451237|NCT05167981|OTHER|RETAINWORKS|The experimental group is eligible to receive the full set of RETAINWORKS intervention activities. The program includes a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Participants receive intensive case management and care coordination by health and employment services RTW navigators. Financial incentives are offered to participants and medical providers for milestone attainment and training achievement.
48451238|NCT01851135|OTHER|Neuropsychological examination and quality of life measures|
48279735|NCT03231514|DIETARY_SUPPLEMENT|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
48279736|NCT03231514|OTHER|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
48451239|NCT00990535|DRUG|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
48451240|NCT05609617|DEVICE|injection|Intradermal injection on the face and neck/or décolleté by the NCTF135 HA
48451241|NCT05609617|OTHER|Cream application|Application of hydra filler cream on the face and neck/or décolleté
48451242|NCT00239382|DRUG|Meloxicam ampoule|
48451243|NCT00239382|DRUG|Meloxicam tablet|
48451244|NCT06602544|DEVICE|Robotic Apparel|A robotic apparel system is a portable, lightweight textile-based wearable robot that is worn around the waist and thighs. The apparel provides assistive flexion moment about the hip joint during the swing phase of gait by spooling in a cable that connects the thigh wraps to the front of the waist belt. Inertial measurement units embedded in the thigh wraps are used to control the timing of the robotic apparel assistance. Robotic apparel assistance magnitude is delivered as a small percentage of the bodyweight of the wearer.
48451245|NCT03089515|OTHER|Cardio-Pulmonary Exercise Testing (CPET)|This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
48451246|NCT03405688|PROCEDURE|Blood sampling|Extra blood samples taken for laboratory analysis
48279737|NCT03231514|OTHER|Exercise|All groups will participate in a standardized exercise intervention.
48451247|NCT04165252|DIAGNOSTIC_TEST|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
48451248|NCT05517681|OTHER|non-ICG|Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
48451249|NCT05517681|DRUG|ICG|Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
48451250|NCT03689595|OTHER|Sample of Blood|Collection of blood sample from participants
48451251|NCT04521426|OTHER|No other than standard care|No other than standard care.
48451252|NCT05193461|PROCEDURE|Pulsed mood radiofrequency on dorsal root ganglion|3) Pulsed radio frequency (PRF): PRF of the dorsal root ganglion (DRG) will be performed to all participants in this study. The procedures will be performed in the operating room under fluoroscopic guidance following radiation safety standards. The dorsal root ganglion of lumbosacral roots will be targeted. The patients will be positioned prone .Lidocaine 1% will be infiltrated at the skin entry site. A 10 cm, 22-gauge radiofrequency needle with a 5 mm curved active tip will be used. A radiculogram will be done to confirm appropriate placement and DRG will be stimulated for confirmation of the appropriate nerve root involved. Proximity of the needle to the DRG will be determined by appropriate sensory stimulation with 50 Hz (0.4-0.6 V), and motor stimulation at 2 Hz will be used to determine a threshold 1.5-2.0 times greater than the sensory threshold to avoid placement near the anterior nerve root. A pulsed lesion will be generated by applying 45 V to the DRG for 6 minutes at 42°C.
48451253|NCT03523377|OTHER|prolonged overnight fasting|Three phone calls using motivational interviewing, support via SMS text.
48451254|NCT03523377|OTHER|usual care|Eat a heart-healthy diet and exercise for at least 30 minutes five days a week
48451255|NCT02968992|DRUG|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
48451256|NCT02968992|OTHER|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
48451257|NCT00174551|DRUG|prazosin|
48451258|NCT01274988|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
48451259|NCT01274988|OTHER|methadone maintenance treatment|methadone maintenance treatment
48620744|NCT03841292|DRUG|Varenicline|Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
48620745|NCT03841292|DEVICE|Active tDCS|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
48620746|NCT03841292|DEVICE|Sham tDCS|Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
48620747|NCT05869409|BEHAVIORAL|Physical activity and sedentary behavior education|Enrolled patients will participate in an individual face-to-face education session, addressing: definitions and examples of sedentary and physical activity behaviors; physical health-related and mental health-related consequences of these behaviors; ways to break sedentary behaviors; age-adjusted physical activity recommendations (based on the guidelines of the World Health Organization).
48620748|NCT01197066|DRUG|Certolizumab Pegol|Certolizumab Pegol 200mg
48451260|NCT00996684|DRUG|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
48451261|NCT00996684|DRUG|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
48451262|NCT06196515|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
48451263|NCT06196515|DRUG|nano calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
48451264|NCT06628167|BEHAVIORAL|Transportation|Participants with ordered low dose CT and participants with scheduled low dose CT are offered free transportation to and from appointment. Participants with ordered low dose CT are also offered assistance in connecting with scheduling staff.
48451265|NCT06628167|BEHAVIORAL|Scheduling|Participants with ordered low dose CT are offered assistance in connecting with scheduling staff.
48451266|NCT03584919|DRUG|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
48451267|NCT03584919|DRUG|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
48620749|NCT01691651|PROCEDURE|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
48620750|NCT01691651|DRUG|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
48279738|NCT06311578|DRUG|JNJ-87704916|JNJ-87704916 will be administered as an intratumoral injection.
48279739|NCT06311578|DRUG|Cetrelimab|Cetrelimab will be administered.
48451268|NCT03584919|OTHER|control subjects|no intervention
48620751|NCT01878266|RADIATION|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
48451269|NCT02742194|DIETARY_SUPPLEMENT|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
48451270|NCT02742194|DIETARY_SUPPLEMENT|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
48451271|NCT05978986|DIAGNOSTIC_TEST|Determining of the clinical class of chronic venous disorders by artificial intelligence|The doctor takes pictures of the lower extremities and uploads them to the IVENUS application, which automatically determines the clinical class according to CEAP. Further, the doctor independently determines the clinical class according to CEAP and enters the data into the register.
48451272|NCT04936581|PROCEDURE|Open Total Mesorectal Excision|Open approach for Total Mesorectal Excision
48451273|NCT04936581|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic approach for Total Mesorectal Excision
48279740|NCT02522637|OTHER|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
48620752|NCT01878266|RADIATION|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
48620753|NCT01878266|RADIATION|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
48620754|NCT00738088|DRUG|gliclazide|Gliclazide 80mg bd for 6 weeks
47928229|NCT01654913|DEVICE|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~* at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~* with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~* with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
47928230|NCT02280122|OTHER|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
48279741|NCT05428709|BEHAVIORAL|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
48279742|NCT04550494|PROCEDURE|Biopsy|Undergo biopsy
48279743|NCT04550494|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48279744|NCT04550494|PROCEDURE|Computed Tomography|Undergo CT scan
48279745|NCT04550494|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48279746|NCT04550494|DRUG|Talazoparib|Given PO
48279747|NCT06618651|DRUG|SHR-3821 injection|SHR-3821 injection
48279748|NCT05574140|DIAGNOSTIC_TEST|Cardiac MRI|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
48279749|NCT06278623|DEVICE|Focal Muscle Vibratory Energy (EVM) Treatment|"The patients involved in the study will undergo muscle vibratory stimulation in association with conventional rehabilitation treatment three times a week, for three weeks for a total duration of 9 sessions in association with conventional treatment.~The vibration will be applied at a frequency of 100 Hz and an amplitude of 0.2 cm for 30 minutes (three sessions of 10 min each with 1 min break in between) three times a week for three weeks at the level of the quadriceps femoris and triceps surae bilaterally for balance improvement and stimulation of proprioception and in the trapezius and trunk extensor muscles bilaterally for pain relief."
48279750|NCT00977652|PROCEDURE|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
48279751|NCT00977652|PROCEDURE|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
48279752|NCT01075087|DRUG|Placebo|Bilateral TAP block using sterile normal saline.
48279753|NCT01075087|DRUG|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
48279754|NCT00016458|DRUG|anti-thymocyte globulin|
48279755|NCT00016458|DRUG|cyclophosphamide|
48451274|NCT04936581|PROCEDURE|Robotic Total Mesorectal Excision|Robotic approach for Total Mesorectal Excision
48451275|NCT04936581|PROCEDURE|Transanal Total Mesorectal Excision|Transanal approach for Total Mesorectal Excision
48451276|NCT01798264|DRUG|ITCA 650 (exenatide in DUROS)|
48451277|NCT03600363|DRUG|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
48451278|NCT03600363|DRUG|Placebos|oral placebos as a maintenance therapy
48451279|NCT03893123|OTHER|Observational study, prostate cancer is outcome of interest|Observational study
48451280|NCT03810963|COMBINATION_PRODUCT|HIIT-FES Cycling combined with Nutritional Counseling|High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
48451281|NCT03810963|OTHER|Nutritional Counseling Only|Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
48620755|NCT04304703|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep, resting heart rate, and heart rate variability.
48620756|NCT00867880|DRUG|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
48620757|NCT03052036|PROCEDURE|Coronary Angiography|Coronary angiography to determine location of blocked or narrowed arteries.
48620758|NCT03052036|PROCEDURE|Coronary revascularisation|PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
48451282|NCT04501003|DEVICE|Bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen)|With the bipolar cutting electrode (26040 BL1 Karl Storz, Tuttlingen. Germany), a single incision was made from the bottom of the ostium onto the lateral walls up to the isthmus, with both lateral horns perpendicular to myometrium. The depth of the incision was between 5 and 7 mm. The cavity was widened to be triangular and symmetrical. Both tubal ostium surgeries were clearly observed at the end of the surgery. All patients were discharged on the day of surgery and no hormonal therapy and intrauterine balloon was applied after surgery. Approximately 3 months after the hysteroscopic T-shaped operation, an office hysteroscopy operation was planned to control patients in the secretory phase, to perform uterine cavity and post-operative fly control and to receive post-operative control endometrial biopsy specimens.
48620759|NCT03052036|OTHER|Optimal Medical Therapy|Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
48620760|NCT01858948|DRUG|Omega|Omega-3 supplements
48620761|NCT01858948|DRUG|Placebo|Similar in shape and color to Omega supplements
48620762|NCT01858948|DRUG|Quetiapine fumarate|Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
48620763|NCT02505061|BEHAVIORAL|Hospital-based Program|"The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team."
48620764|NCT02505061|BEHAVIORAL|Regular Therapy Program|"The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the childs natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase"
48620765|NCT02967575|DEVICE|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~* Implantation through a standard anterior cervical approach~* Midline identification~* Routine discectomy with endplate preparation and decompression~* Implant sizing and trial implantation~* Keel preparation~* Implant preparation and loading of the appropriate Triadyme-C implant~* Triadyme-C insertion, positioned as close to the midline as possible"
48620766|NCT02517723|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
48279756|NCT03767244|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
48279757|NCT03767244|DRUG|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).
48279758|NCT03767244|DRUG|Placebo|Participants will receive matching placebo oral tablets daily.
48279759|NCT06447012|DIAGNOSTIC_TEST|Colonoscopy|No intervention required from this study, however images will be obtained from patient presenting for colonoscopy
48279760|NCT06320444|PROCEDURE|232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)|"Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task.~Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation.~These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)"
48279761|NCT01065935|DRUG|ALN-RSV01|Administered by nebulization once daily for 5 days
48279762|NCT01065935|DRUG|Normal Saline|Administered by nebulization once daily for 5 days
48279763|NCT03588689|PROCEDURE|Continuous fascia iliaca block|Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.
48279764|NCT03588689|DRUG|Ropivacaine|Ropivacaine local anesthetic will be used for the fascia iliaca block
48279765|NCT03384992|OTHER|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
48279766|NCT03384992|OTHER|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
48279767|NCT03384992|OTHER|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
48620767|NCT02517723|BEHAVIORAL|Dialectical Behavior Therapy|"Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings."
48620768|NCT02517723|BEHAVIORAL|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
48620769|NCT02517723|OTHER|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
48620770|NCT04877002|DIAGNOSTIC_TEST|Sona Saliva C-19 Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
48620771|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
48620772|NCT00564239|BEHAVIORAL|Cognitive Behavioral Group Therapy|12 children group sessions
48620773|NCT04089319|OTHER|Music recording|Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
48620774|NCT04089319|OTHER|Mindfulness recording|Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
48620775|NCT03067415|DRUG|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
48620776|NCT03067415|DRUG|D565(Latanoprost 50㎍/㎖)|D565 once daily
48620777|NCT05714761|DEVICE|Dexcom glucose sensor|Use of a Dexcom G6 Pro
48620778|NCT01571791|DRUG|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
48620779|NCT01571791|DRUG|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
48620780|NCT00309179|DRUG|E7820 plus cetuximab|Escalating doses from 40 mg/m\^2 irinotecan plus E7820 in combination with cetuximab.
48620781|NCT00102635|DRUG|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
48279768|NCT03384992|OTHER|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
48620782|NCT00102635|DRUG|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
48620783|NCT04664114|BEHAVIORAL|Virtual Reality|Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
48620784|NCT02841046|DEVICE|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
48620785|NCT02841046|DEVICE|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
48620786|NCT00635713|DRUG|Fulvestrant|125mg
48620787|NCT00635713|DRUG|Anastrozole|ARIMIDEX
48620788|NCT00635713|DRUG|Fulvestrant|250mg
48620789|NCT02627716|PROCEDURE|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~* Contact details / contact person~* Treatment and current follow-ups~* Medical care in the event of a crisis~* Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
48620790|NCT04069858|DRUG|Switching to Generic Entecavir (Baracle®)|switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
48279769|NCT03384992|OTHER|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
48279770|NCT01769911|DRUG|carmustine|Given IV
48620791|NCT02050204|BEHAVIORAL|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
48279771|NCT01769911|DRUG|cytarabine|Given IV
48279772|NCT01769911|DRUG|melphalan|Given IV
48620792|NCT02194465|DRUG|LY2623091|Administered orally
48620793|NCT02194465|DRUG|Tadalafil|Administered orally
48620794|NCT02194465|DRUG|Spironolactone|Administered orally
48620795|NCT02194465|DRUG|Placebo|Administered orally
48620796|NCT04922281|DEVICE|Insertable Cardiac Monitor or external non-invasive LT-ECG patch|"Implantable device that provides accurate daily transmission. Patients without an existing CIED who prefer to use noninvasive LT-ECG monitoring will be offered to use the Carnation Ambulatory Monitor (CAM™; Bardy Diagnostics) the CAM™ patch approved for LT-ECG monitoring applied to the skin over the chest for a time-period of 7-days every 2 months for cardiac electrical data for arrhythmia detection."
48620797|NCT02150005|PROCEDURE|Periodontal treatment|
48620798|NCT04525196|OTHER|Physical activity.|"The procedure under study (physical activity program) will include, each week for 12 months, two sessions dedicated to the development of aerobic capacity and a muscle building session.~The experimental group will therefore be offered 3 sessions of Physical Activity (PA) per week. The PA will be positioned in the first two hours after the start of the dialysis session. Each session will include 5 minutes of general warm-up, then 15 minutes of PA itself and finally 5 minutes of cool down period. The PA time itself will be increased as the sessions progress, according to the progress and improvement of physical capabilities of patients."
48451283|NCT04584294|BEHAVIORAL|MyPath Web-Based Informational and Decision Support Tool|"The MyPath Decision Support Tool includes the following sections and features:~* Questions to capture reproductive goals and orientations towards a potential pregnancy~* Education modules about the menstrual cycle, fertility, and prepregnancy health with the opportunity to flag topics that are relevant and of interest to the patient~* A contraceptive decision module that provides education, elicits patient preferences about different aspects of contraception, and suggests methods most appropriate based on the patient's preferences~* A feature for adding free-text questions that patients may have for their provider~* An email with a summary page that the patient can bring to a visit to guide discussions with primary care providers about reproductive needs"
48451284|NCT00414180|DRUG|Bupropion SR|
48620799|NCT02924961|DEVICE|Triathlon PS total knee system with mobile-bearing|
48620800|NCT02924961|DEVICE|Triathlon PS total knee system with fixed-bearing|
48620801|NCT05445960|PROCEDURE|Tourniquet|This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
48620802|NCT02186041|DEVICE|Sacral Nerve Modulation|
48620803|NCT05283837|BIOLOGICAL|Pertuzumab (ZRC-3277)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
48451285|NCT03617198|BIOLOGICAL|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
48451286|NCT02257554|BEHAVIORAL|education|Discussion of surgical expectations with patients
48451287|NCT04009434|DEVICE|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
48451288|NCT04009434|DEVICE|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
48451289|NCT01983969|DRUG|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
48451290|NCT01983969|DRUG|Vorinostat|1000 mg by vein on Day -11 through Day -2.
48451291|NCT01983969|DRUG|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
48451292|NCT01983969|DRUG|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
48620804|NCT05283837|BIOLOGICAL|Pertuzumab (Perjeta®)|Pertuzumab in combination with Trastuzumab and Docetaxel will be administered via intravenous (IV) infusion every 3 weeks for 06 cycles.
48620805|NCT00963235|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
48620806|NCT00963235|PROCEDURE|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
48620807|NCT05284253|OTHER|Gold microparticles|Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
48620808|NCT05284253|OTHER|Gold thiosulphate|Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
48620809|NCT05363280|DRUG|AL8326 low dose group|Taken AL3826 at low dose orally
48620810|NCT05363280|DRUG|AL8326 middle dose group|Taken AL3826 at middle dose orally
48620811|NCT05363280|DRUG|AL8326 high dose group|Taken AL3826 at high dose orally
48279773|NCT01769911|DRUG|etoposide|Given IV
48451293|NCT01983969|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
48620812|NCT05926921|OTHER|music|Brahms' Lullaby will be played from a speaker at 50 decibels
48620813|NCT02929004|DEVICE|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
48620814|NCT00576537|BIOLOGICAL|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
48620815|NCT00559000|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children
48620816|NCT03579537|OTHER|Intradyalisis without exercise programe|patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).
48620817|NCT03579537|OTHER|Intradyalisis with exercise programe|After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
48620818|NCT03533933|DEVICE|Collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
48620819|NCT03533933|OTHER|autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
48279774|NCT01769911|DRUG|O6-benzylguanine|Given IV
48279775|NCT01769911|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
48279776|NCT01769911|PROCEDURE|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
48620820|NCT06514131|PROCEDURE|Pre-moistened wipes|Patients receiving the experimental treatment will have perineal hygiene performed with the pre-moistened wipes without water
48620821|NCT04799990|DRUG|Risankizumab|Subcutaneous Injection
48620822|NCT04799990|BIOLOGICAL|Comparator 1|Subcutaneous or Intravenous Injection
48620823|NCT04799990|DRUG|Comparator 2|Oral, Opthalmic, Subcutaneous or Intravenous Injection
48451294|NCT01983969|DRUG|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
48451295|NCT01983969|OTHER|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
48451296|NCT01983969|DRUG|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
48620824|NCT02266017|BEHAVIORAL|Pain Coping Skills Training|
48620825|NCT00590473|DEVICE|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
48620826|NCT00205062|PROCEDURE|PET-CT|
48620827|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
48620828|NCT00480116|BIOLOGICAL|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
48620829|NCT00480116|BIOLOGICAL|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
48620830|NCT00066456|RADIATION|3-Dimensional Conformal Radiation Therapy|
48620831|NCT00066456|DRUG|Chemosensitization/Potentiation Therapy|
48620832|NCT00066456|DRUG|Docetaxel|Given IV
48451297|NCT01983969|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
48451298|NCT01983969|DRUG|Rituximab|375 mg/m2 by vein on Days -9.
48620833|NCT02320409|DRUG|Sulfatinib|250mg Sulfatinib ,single dose,oral
48620834|NCT01539200|DIETARY_SUPPLEMENT|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
47928231|NCT01336361|OTHER|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
48620835|NCT01539200|DIETARY_SUPPLEMENT|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
48620836|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
47928232|NCT04278105|DEVICE|HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.
48279777|NCT01769911|OTHER|laboratory biomarker analysis|Correlative studies
48451299|NCT03342157|DRUG|senna/docusate|Stimulant laxative
48451300|NCT00345696|DRUG|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
48451301|NCT00345696|DRUG|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
48451302|NCT00345696|DRUG|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
48451303|NCT05465863|BIOLOGICAL|SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)|When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment
48451304|NCT04722458|OTHER|Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)|LURN SI-29
48451305|NCT04722458|OTHER|IPSS|International Prostate Symptom Score
48451306|NCT04722458|OTHER|UDI-6|Urogenital Distress Inventory
48451307|NCT04519515|DEVICE|Allergan Vollure|Injection of Allergan Vollure into Atrophic Scars
48279778|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
48451308|NCT04266340|DRUG|dexmedetomidine|2.5µg/kg intranasal dexmedetomidine group
48451309|NCT04266340|DRUG|midazolam|0.5mg/kg oral midazolam
48451310|NCT04266340|DRUG|midazolam|0.05mg/kg intravenous injection midazolam
48451311|NCT04266340|DRUG|Saline|no premedication
48451312|NCT03264339|BEHAVIORAL|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
48620837|NCT01401166|DRUG|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
48620838|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
48620839|NCT01401166|DEVICE|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
48620840|NCT00304577|PROCEDURE|Bilateral recession|
48620841|NCT00304577|PROCEDURE|Unilateral recession and resection|
48620842|NCT00154388|DRUG|Imatinib mesylate|
48620843|NCT02812043|DEVICE|1,064nm Long-pulsed Nd:YAG|Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
48620844|NCT02812043|DRUG|Amorolfine|Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
48620845|NCT06057857|OTHER|conventional oral examination|conventional oral examination
48620846|NCT03943485|DEVICE|The uterine manipulator which is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We adopted this device in abdominal hysterectomy.|The uterine manipulator is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We hypothesized that adoption of a uterine manipulator would help the surgeon to better identify the colpotomy site by moving the uterus cranially and thus providing better visualization of the colpotomy site.
48620847|NCT00909974|DIETARY_SUPPLEMENT|UNIMMAP - multiple micronutrients|"Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
48620848|NCT00909974|DIETARY_SUPPLEMENT|Food supplement enriched with multiple micronutrients|"One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
48620849|NCT03406676|DRUG|Methylene Blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
48620850|NCT02659904|OTHER|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
48620851|NCT02659904|OTHER|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
48620852|NCT03117127|BEHAVIORAL|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
48620853|NCT03117127|OTHER|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
48620854|NCT03117127|OTHER|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
48620855|NCT02596087|OTHER|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
48620856|NCT03233750|BEHAVIORAL|Stress Inoculation Training|see description in arm/group descriptions
48620857|NCT03233750|BEHAVIORAL|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
48620858|NCT01939457|DRUG|Misoprostol|
48620859|NCT01194310|PROCEDURE|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
48620860|NCT01194310|PROCEDURE|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
48620861|NCT01194310|PROCEDURE|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
48620862|NCT01909271|BEHAVIORAL|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
48620863|NCT01909271|OTHER|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
48620864|NCT03847207|DRUG|HTL0030310|Solution for Subcutaneous injection
48620865|NCT03847207|DRUG|Pasireotide|Pasireotide 600 μg for subcutaneous injection
48620866|NCT03847207|DRUG|Placebo|Matching placebo Solution
48620867|NCT01349387|DRUG|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
48620868|NCT02221414|DRUG|Linagliptin/Metformin FDC|
48620869|NCT02221414|DRUG|Linagliptin|
48620870|NCT02221414|DRUG|Metformin|
48620871|NCT00407875|PROCEDURE|Intensity Modulated External Beam Radiation Therapy|
48620872|NCT05166096|DRUG|Rho-11|Subjects will be administered 325 mg aspirin by rapid IV push
48620873|NCT05166096|DRUG|aspirin 325mg|Subjects will be administered 325 mg aspirin orally
48620874|NCT05856435|BEHAVIORAL|Chicago Parent Program for Foster Care|The Chicago Parent Program for Foster Care FC consists of a 12-session parent training program that focuses on building caregiver-child relationships, behavioral management strategies, managing caregiver stress, and skill maintenance.
48620875|NCT06339840|DIETARY_SUPPLEMENT|Low-carbohydrate diet group|During the initial 8-week weight loss phase, participants will adopt a low-carbohydrate dietary pattern (with carbohydrate energy ratio of 20-30%, protein energy ratio of 30-40%, and fat energy ratio of 40-45%), with a caloric intake approximately 75% of their usual daily intake, but not less than 1200 kcal. Throughout the intervention period, participants will receive a daily nutritionally balanced meal replacement for 8 weeks to substitute for staple foods and control carbohydrate intake. Nutritionists will reinforce interventions by setting health goals, providing health education, implementing dietary and exercise interventions, and monitoring through a combined approach using a mobile platform. During the subsequent 4-week transition phase, participants' diets will gradually transition to a balanced dietary pattern (with carbohydrate energy ratio of 45-60%, protein energy ratio of 20-30%, and fat energy ratio of 20-25%) under the guidance of nutritionists.
48620876|NCT06339840|BEHAVIORAL|Health Education Group|Upon enrollment, nutritionists will provide lifestyle guidance to patients, including personalized adjustments such as limiting total energy intake to \<1600 kcal/day, adjusting macronutrient distribution to 45-55% for carbohydrates, 20-30% for fats, and 20-30% for protein. Participants are advised to accumulate at least 150 minutes of moderate-intensity aerobic exercise per week (achieving 50%-70% of maximum heart rate). At enrollment, nutritionists will educate participants on healthy lifestyle principles, train them on nutritional intervention tools, and assist in food selection for weight management planning. Throughout the intervention, nutritionists will conduct follow-ups with patients via phone or mobile platforms to monitor weekly dietary and exercise habits, weight changes, and address any participant concerns promptly.
48637419|NCT06457321|PROCEDURE|Sequence in receiving the fabricated dentures made using the conventional and partial digital method|Participants is not informed on the sequence they have been randomized hence they are not able to determine which denture is fabricated from which method. This would reduce bias when collecting the participants' responses in the satisfaction questionnaire during the review visits.
48637420|NCT06532344|DRUG|ONO-7913|Specified dose on specified days
48620877|NCT01614223|PROCEDURE|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
48620878|NCT01614223|DRUG|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
48620879|NCT02115152|DRUG|fluorouracil|
48620880|NCT02115152|DRUG|capecitabine|
48620881|NCT02115152|DRUG|cyclophosphamide|
48620882|NCT02115152|DRUG|Epirubicin|
48620883|NCT06262867|DIETARY_SUPPLEMENT|Ready. Set. Food! Stage 1 Mix ins|These supplements contain cow's milk, eggs, and peanuts.
48620884|NCT01866670|BEHAVIORAL|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
48620885|NCT01866670|BEHAVIORAL|relaxation therapy|Relaxation Therapy: deep breathing
48620886|NCT03080285|DEVICE|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
48620887|NCT03080285|DEVICE|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
48620888|NCT04674956|DRUG|Camrelizumab|PD-1 antibody（Camrelizumab）, 200mg, D1; every 21 days as a cycle.
48620889|NCT04674956|DRUG|Paclitaxel(Albumin Bound) and Gemcitabine|Paclitaxel(Albumin Bound), 125 mg/m2D18; Gemcitabine, 1000mg/m2D1, 8;every 21 days as a cycle.
48620890|NCT04674956|DRUG|Placebo|Placebo, 200mg, D1; every 21 days as a cycle.
48620891|NCT01562691|PROCEDURE|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
48451313|NCT05019261|OTHER|Multi-component Family Support Intervention|The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
48451314|NCT01348438|DEVICE|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
48451315|NCT03614039|DIETARY_SUPPLEMENT|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
48451316|NCT03614039|DIETARY_SUPPLEMENT|Placebo|
48451317|NCT05676749|BIOLOGICAL|C-TIL051|C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab
48451318|NCT02771353|RADIATION|WT_vDIBH|
48451319|NCT02771353|RADIATION|VMAT_FB|
48451320|NCT04226248|DRUG|Rivastigmine Transdermal System|Rivastigmine Trandermal Patches applied once a day for up to 12 months
48451321|NCT04226248|OTHER|Placebo Transdermal System|Placebo Trandermal Patches applied once a day for up to 12 months
48451322|NCT04330534|DRUG|BCX9930|BCX9930 capsules for oral administration
48451323|NCT04330534|DRUG|Placebo|placebo to match BCX9930 capsules for oral administration
48451324|NCT03904381|DRUG|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
48451325|NCT03904381|PROCEDURE|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
48451326|NCT03904381|PROCEDURE|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
48451327|NCT02709018|DRUG|losartan|Angiotensin receptor blocker (ARB)
48451328|NCT02709018|DRUG|Placebo|Placebo
48620892|NCT01562691|PROCEDURE|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
48620893|NCT01562691|PROCEDURE|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
48451329|NCT02477787|BIOLOGICAL|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
48620894|NCT05138562|DRUG|Placebo Comparator: Placebo|4 x placebo capsules, QD
48620895|NCT05138562|DRUG|Active Comparator: TU2670 320mg|320mg (80mg x 4), QD
48620896|NCT05138562|DRUG|Active Comparator: TU2670 240mg|240mg (80mg x 3 + placebo x 1), QD
48620897|NCT05138562|DRUG|Active Comparator: TU2670 120mg|120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
48620898|NCT00008177|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
48620899|NCT00008177|RADIATION|total-body irradiation|Undergo total-body irradiation
48620900|NCT00008177|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
48620901|NCT00008177|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
48620902|NCT00008177|DRUG|fludarabine phosphate|Given IV
48620903|NCT00008177|DRUG|cyclosporine|Given orally or IV
48620904|NCT00008177|DRUG|mycophenolate mofetil|Given orally or IV
48451330|NCT02896010|OTHER|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
48451331|NCT02896010|OTHER|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
48451332|NCT04603482|BEHAVIORAL|Resourcefulness Training|A cognitive-behavioral intervention presented within an audiovisual format that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
48451333|NCT04603482|BEHAVIORAL|Biofeedback Training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior."
48451334|NCT04603482|BEHAVIORAL|Diversional Activites|An audiovisual format presenting 12 activities for adults including but not limited; crossword puzzles, reading, gardening, exercise, cooking/baking, board games, learning a new language, social activities, online games, etc.
48451335|NCT05329961|DRUG|Gardasil9|The Gardasil 9 vaccine is a recombinant L 1 VLP vaccine containing HPV types 6, 11,16,18, 31, 33, 45, 52 and 58 VLP. The vaccine is not currently licensed for children under 9 years of age but it is licensed in the USA for males and females ages 9 to 45 years old.
48451336|NCT06377605|PROCEDURE|ESPB|the target vertebral level ( T7 transverse process ) \[8\] in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process . The Erector Spinae muscle and transverse process will be then identified, and a blunted tip , 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30 mL into each side) \[16\] into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally (at the most lateral part of the transverse process) and since it is a fascial plane block , the greater the volume of the local anaesthetic injected ,
48451337|NCT06377605|PROCEDURE|local anaesthetic infiltration|the participant will receive 5 ml bupivacaine infiltration to each trocar site (total of 25 ml 0.5 %) at the beginning of the operation.
48451338|NCT06377605|DRUG|midazolam and lidocaine|midazolam administration intravenous , and 5 cm lidocaine 1% infiltration
48451339|NCT06377605|DRUG|Bupivacain|bupivacaine infiltration
48451340|NCT03711760|BEHAVIORAL|telepsychology|CBT delivered by telepsychology
48451341|NCT03106415|DRUG|Binimetinib|Given PO
48451342|NCT03106415|OTHER|Laboratory Biomarker Analysis|Correlative studies
48451343|NCT03106415|BIOLOGICAL|Pembrolizumab|Given IV
48451344|NCT05117489|DRUG|Miricorilant 150 mg|Miricorilant 150 mg for oral dosing
48451345|NCT05117489|DRUG|Miricorilant 100 mg|Miricorilant 100 mg for oral dosing
48451346|NCT05117489|DRUG|Miricorilant 50 mg|Miricorilant 50 mg for oral dosing
48451347|NCT05117489|DRUG|Miricorilant 10 mg|Miricorilant 10 mg for oral dosing.
48451348|NCT00275366|DEVICE|Robotic Therapy|
48451349|NCT05005026|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
48451350|NCT05005026|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
48451351|NCT06534996|DRUG|SCD-2101|Tradictional Chinese Medicine formula (SCD-2101)
48451352|NCT01860638|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
48451353|NCT01860638|DRUG|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m\^2 PO Q6W, with a cap of 200 mg per dose.
48451354|NCT01860638|DRUG|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
48451355|NCT01860638|RADIATION|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
48451356|NCT01860638|DRUG|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m\^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m\^2 per day for the first 5 days of Cycle 1, then 200 mg/m\^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
48451357|NCT01860638|DRUG|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
48451358|NCT04966299|DIETARY_SUPPLEMENT|Eryhtritol|"Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit~EryClot:~Erythritol 50g dissolved in 300mL water administered once per visit"
48451359|NCT04966299|DIETARY_SUPPLEMENT|Sucrose|Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
48451360|NCT04966299|DIETARY_SUPPLEMENT|Glucose|Glucose 75g dissolved in 300mL water administered once per visit
48620905|NCT00008177|OTHER|laboratory biomarker analysis|Correlative studies
48637421|NCT06532344|DRUG|ONO-4538|Specified dose on specified days
48451361|NCT04966299|DIETARY_SUPPLEMENT|Fructose|Fructose 25g dissolved in 300mL water administered once per visit
48451362|NCT04966299|DIETARY_SUPPLEMENT|Xylitol|Xylitol 33.5g dissolved in 300mL water administered once per visit
48451363|NCT04966299|DIETARY_SUPPLEMENT|Water|300mL water administered once per visit
48451364|NCT02095379|OTHER|oligosecretary|not abvailable
48451365|NCT06559202|DIAGNOSTIC_TEST|chest and abdominoplevic CT|chest and abdominopelvic computed tomography on the same day for health screening purposes
48451366|NCT06558968|OTHER|aesthetic functional space maintainers|evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.
48451367|NCT02412553|OTHER|Specific carbohydrate diet|
48451368|NCT02412553|OTHER|Elemental diet|
48451369|NCT05636735|OTHER|data collection|evaluation of self -confidence
48451370|NCT00641134|OTHER|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
48451371|NCT05064891|PROCEDURE|Ultrasound guided injection|Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
48451372|NCT00006256|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
48451373|NCT00006256|PROCEDURE|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
48451374|NCT00006256|RADIATION|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
48451375|NCT05569629|PROCEDURE|Bronchial washing before endobronchial biopsy and brushing|Bronchial washing: adding bronchial washing once to the standard endoscopic sampling sequence (endobronchial biopsy and brushing first, followed by bronchial washing once) in the experimental arm
48451376|NCT03448263|PROCEDURE|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
48451377|NCT03448263|PROCEDURE|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
48451378|NCT03448263|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
48451379|NCT04286074|OTHER|50% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 50% of the maximum inspiratory pressure of each athlete
48451380|NCT04286074|OTHER|10% resistance|Prior to training, the muscle training technique will be performed. The objective of applying the intervention using the Powerbreathe® device is to produce an increase in inspiratory force. The technique will be performed with the athlete standing, holding the device with his hand and his lips sealed on the mouthpiece. After a full expiration, you will make a quick and deep inspiration. The principal investigator of the study will ensure that the technique is performed correctly. There will be 2 series of 30 maximum inspirations. These interventions will be faced with a resistance of 10% of the maximum inspiratory pressure of each athlete
48451381|NCT02211924|DRUG|BI 44847|
48451382|NCT02211924|DRUG|Placebo|
48451383|NCT01877317|DEVICE|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
48451384|NCT02327559|BEHAVIORAL|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
48451385|NCT02327559|BEHAVIORAL|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
48451386|NCT01449383|DIETARY_SUPPLEMENT|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
48451387|NCT01449383|DIETARY_SUPPLEMENT|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
48451388|NCT06235723|DEVICE|Virtual Reality|Virtual Reality was used before and during punctures. For every observation patients underwent either port puncture or peripheral venous puncture. One examination was carried out according to the Standard-of-Care. The other one was carried out with the additional use of VR. Participants watched a passive distraction video.
48451389|NCT06130215|OTHER|Simple meal management|"* Regular meal: Total Carbs per Day x 0.6 / 3~* Large meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5"
48451390|NCT06130215|OTHER|Precise meal management|precise carbohydrate counting for each meal
48451391|NCT01811758|BEHAVIORAL|Culturally Specific CBT|
48451392|NCT01811758|BEHAVIORAL|Standard CBT|
48620906|NCT05709613|DEVICE|Use of a chest compressions' feedback device|The participants will have access to a chest compressions' feedback device
48620907|NCT04034472|OTHER|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
48620908|NCT00152048|DRUG|Eflornithine hydrochloride|
48620909|NCT01006629|BIOLOGICAL|palivizumab|palivizumab 15 mg/kg intramuscularly
48620910|NCT00502879|DRUG|Enbrel (etanercept)|
48620911|NCT00472238|BEHAVIORAL|endurance training|control group.
48620912|NCT00472238|BEHAVIORAL|exercise training|Treadmill exercise training to optimize physical endurance
48620913|NCT00340093|BEHAVIORAL|Managing Diabetes|
48620914|NCT02173951|DRUG|Deferiprone|"in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d"
48620915|NCT05509504|OTHER|Low-intensity online intervention|The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills. Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for \~45 minutes. Participants will attend these sessions once a week.
48620916|NCT02804893|PROCEDURE|VATS|Thorax thoracoscopic surgery (lobectomy)
48620917|NCT02804893|PROCEDURE|RATS|Thorax robotic surgery (lobectomy)
48620918|NCT02363491|DRUG|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
48620919|NCT06063889|DIAGNOSTIC_TEST|Maximal Rate of Force Development Test for Ankle Muscles|This test is designed to measure the maximal rate of force development in the ankle muscles, specifically the plantar flexors. It aims to assess the relationship between the strength of these muscles and the functional ability in patients with knee osteoarthritis. The results from this test will help to understand how lower limb muscle strength influences the symptoms and progression of knee osteoarthritis.
48620920|NCT06259526|DRUG|Placebo group|(1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
48620921|NCT06259526|DRUG|JS1-1-01 low-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 placebo pills +1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
48620922|NCT06259526|DRUG|JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules|(1 pill of 25 mg JS1-1-01 placebo pills+1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
48620923|NCT06259526|DRUG|JS1-1-01 high-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
48620924|NCT06259526|DRUG|Active drug group|(1 Duloxetine hydrochloride enteric coated capsule+1 pill of 25mg JS1-1-01 placebo pills+1 pill of 50mg JS1-1-01 placebo pills)/dose, 2 times per day, administered postprandial, for 8 consecutive weeks.
48620925|NCT03343028|OTHER|Psychotherapy|
48620926|NCT01983930|BEHAVIORAL|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
48620927|NCT01983930|BEHAVIORAL|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
48620928|NCT06021379|DRUG|Trastuzumab|AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
48620929|NCT03755817|DEVICE|SCENAR application|Active SCENAR application on the painful area
48620930|NCT03755817|DEVICE|SCENAR application with the device off|Placebo SCENAR application on the painful area
48620931|NCT02383615|PROCEDURE|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
48620932|NCT04841265|DIETARY_SUPPLEMENT|Vitamin D3|The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.
48620933|NCT02054156|DRUG|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
48620934|NCT02054156|DRUG|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
48620935|NCT02054156|DRUG|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
48620936|NCT02975596|OTHER|Awareness|Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
48620937|NCT02975596|OTHER|Education|Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
48620938|NCT02975596|OTHER|Empowerment|"Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines."
48620939|NCT02975596|OTHER|Accessibility|Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
48637422|NCT06532344|DRUG|Oxaliplatin|Specified dose on specified days
48637423|NCT06532344|DRUG|Levofolinate|Specified dose on specified days
48637424|NCT06532344|DRUG|Irinotecan|Specified dose on specified days
48637425|NCT06532344|DRUG|Fluorouracil|Specified dose on specified days
48620940|NCT02826473|OTHER|BRAINCHECK|Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
48620941|NCT00729586|OTHER|Laboratory Biomarker Analysis|Correlative studies
48620942|NCT00729586|DRUG|Megestrol Acetate|Given PO
48620943|NCT00729586|DRUG|Tamoxifen Citrate|Given PO
48620944|NCT00729586|DRUG|Temsirolimus|Given IV
48620945|NCT02525523|DRUG|Alicaforsen|
48620946|NCT02525523|DRUG|Placebo|
48620947|NCT04189523|OTHER|SOC Pain Management|Study subjects will be compared to historical controls selected for same age +/- 5yrs, gender, fracture type who meet the inclusion criteria and do not have historical documentation of one of the exclusion criteria. Controls will be identified by the ICD-10 injury codes selected for use in this study. Clinical course and pain management data will be collected through the EMR only.
48451393|NCT02730650|OTHER|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
48451394|NCT05092191|DRUG|Cannabis oil vs placebo|"Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being."
48451395|NCT00841659|DRUG|Paroxetine HCl|40 mg Film-Coated Tablet
48451396|NCT00841659|DRUG|Paxil®|40 mg Film-Coated Tablet
48451397|NCT02615249|BIOLOGICAL|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
48451398|NCT06560957|BEHAVIORAL|Time restricted eating|Time restricted eating involves restricting the window in which calories are consumed to 8-10 hours, without altering diet quality or caloric intake. In this study, time restricted eating will be a consistent 10-h eating window between 06:00 and 19:00, considered an early TRE pattern, for all days of the week, as chosen by the participant. They will need to consume all food and beverages (except water) during this window for the duration of the 8-week intervention.
48620948|NCT04189523|PROCEDURE|Early US Guided Nerve Block Administration|US-Guided regional anesthesia (fascia illiaca compartment block or brachial plexus block)
48620949|NCT04676776|DRUG|Levonorgestrel|All participants receive 1.5 mg levonorgestrel on day 1
48620950|NCT04676776|DRUG|Mifepristone|All participants receive 200 mg mifepristone on day 3
48620951|NCT00779337|BIOLOGICAL|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
48620952|NCT01777724|BEHAVIORAL|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
48620953|NCT02780388|DRUG|VIB4920|Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
48620954|NCT02780388|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
48620955|NCT00080106|BIOLOGICAL|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
48620956|NCT00080106|OTHER|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
48620957|NCT03160170|DEVICE|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator \& Retractor (SISTER) device during surgery
48620958|NCT05500755|DEVICE|Implant Treatment|Surgical placement of a DS Prime Taper implant and its posterior prosthesis.
48451399|NCT06560957|BEHAVIORAL|Eating ad libitum with nutritional counselling|Nutritional counselling will include customized advice delivered by a registered dietician about dietary choices while allowing individuals to eat at any time of day.
48451400|NCT02565160|PROCEDURE|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
48451401|NCT02565160|PROCEDURE|Joint irrigation washout|Procedural washout for treatment purposes
48451402|NCT02565160|PROCEDURE|Total Joint Arthroplasty|
48451403|NCT02565160|PROCEDURE|Revision Joint Arthroplasty|
48620959|NCT00084253|DRUG|Atazanavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
48620960|NCT00084253|DRUG|Atazanavir-Ritonavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD\*, Once daily, 96 weeks.
48620961|NCT03991143|DRUG|ATH3G10|intravenous
48620962|NCT03991143|DRUG|Placebo|intravenous
48620963|NCT02661724|BEHAVIORAL|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
48637426|NCT04940052|DRUG|Dabrafenib|Dabrafenib will be administered orally twice daily
48620964|NCT02747160|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
48451404|NCT05110963|BEHAVIORAL|Uniform Standard of Care Counseling|Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence
48451405|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.
48451406|NCT05110963|BEHAVIORAL|Behavioral Self-Regulation Skills Counseling + Stigma Management|Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
48451407|NCT00644137|DRUG|pregabalin|Help stop smoking
48451408|NCT00644137|OTHER|cigarettes|help stop smoking with study medication
48451409|NCT00256230|DRUG|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
48451410|NCT04274374|DIETARY_SUPPLEMENT|Gluten-Free Diet|Dietary supplement without gluten
48620965|NCT06053190|BEHAVIORAL|Sentence stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
48620966|NCT06053190|BEHAVIORAL|Speaking style|The sentences will be presented either in A. conversational speaking style, or B. hyper-articulated clear speech style. Clear and conversational speech samples will be elicited from a single male talker. In the conversational speech condition, which will be recorded first, the talker will be instructed to read the sentences as they would in everyday conversation. In the clear speech condition, the talker will be instructed to produce the sentences as if they would if they were talking to a person with hearing loss.
48620967|NCT02866981|OTHER|Observation|
48620968|NCT00187434|DEVICE|Infant Flow System|
48620969|NCT00187434|DEVICE|Bubble CPAP|
48620970|NCT03060928|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
48620971|NCT03060928|PROCEDURE|Micro-perforations|Biological stimulation with micro-perforations
48620972|NCT03060928|PROCEDURE|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
48451411|NCT04274374|DIETARY_SUPPLEMENT|Gluten Diet|Dietary supplement with gluten
48451412|NCT01718873|DRUG|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
48620973|NCT05422508|BIOLOGICAL|MG1111 (BARICELA)|0.5ml, single dose, subcutaneous injection
48620974|NCT05422508|BIOLOGICAL|VARIVAX|0.5ml, single dose, subcutaneous injection
48620975|NCT05422508|BIOLOGICAL|Suduvax|0.5ml, single dose, subcutaneous injection
48451413|NCT01718873|DRUG|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
48451414|NCT01718873|DRUG|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
48451415|NCT01718873|DRUG|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
48620976|NCT02880176|OTHER|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
48620977|NCT00120744|DRUG|Ondansetron Oral Disintegrating Tablet|
48620978|NCT02255864|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
48620979|NCT01176929|OTHER|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:~* A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~* A systematic telephone contact with the referring physician~* A telephone helpline for people who made a suicide attempt and referring physicians."
48620980|NCT01176929|OTHER|Usual Treatment|Usual Treatment
48620981|NCT01522053|PROCEDURE|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
48620982|NCT01522053|PROCEDURE|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
48451416|NCT01718873|DRUG|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
48620983|NCT01339169|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
48620984|NCT03056053|DRUG|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
48620985|NCT03491592|BEHAVIORAL|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
48620986|NCT03491592|BEHAVIORAL|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
48451417|NCT00571064|DRUG|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
48620987|NCT02049762|DRUG|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
48620988|NCT01489423|GENETIC|RNA analysis|
48620989|NCT01489423|GENETIC|in situ hybridization|
48620990|NCT01489423|GENETIC|polymerase chain reaction|
48620991|NCT01489423|OTHER|enzyme-linked immunosorbent assay|
48620992|NCT01489423|OTHER|flow cytometry|
48620993|NCT01489423|OTHER|immunohistochemistry staining method|
48620994|NCT01489423|OTHER|laboratory biomarker analysis|
48620995|NCT04159064|DIAGNOSTIC_TEST|Thromboelastometry, Impedance Aggregometry|Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
48620996|NCT01481467|BEHAVIORAL|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
48620997|NCT05759910|DIETARY_SUPPLEMENT|Brainphyt high dose|Participants will take BrainPhyt capsules during 3 months
48451418|NCT05504902|DEVICE|Vibrotactile coordinated reset|The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
48451419|NCT04728828|BIOLOGICAL|Serological COVID-19 vaccine immunogenicity|Serological test
48451420|NCT06366750|BIOLOGICAL|barzolvolimab|subcutaneous administration
48451421|NCT06366750|OTHER|Matching Placebo|subcutaneous administration
48451422|NCT04835363|OTHER|Early Occupational Therapy intervention|four-week OT intervention program with the support of the main caregiver in patients who have suffered a stroke with the aim of improving the functional result and facilitating the return home by providing knowledge to the caregiver about specific care and neurorehabilitation.
48620998|NCT05759910|DIETARY_SUPPLEMENT|Placebo|Participants will take placebo capsules during 3 months
48620999|NCT00932256|DRUG|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
48621000|NCT03474575|OTHER|Prevention|The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
48621001|NCT04736875|DIAGNOSTIC_TEST|Doppler ultrasound study|Transcutaneous Doppler ultrasound (DUS) study was performed at the mid brachial artery to assess diameter, VF and RI, and at the mid segment of the efferent vein to assess the diameter and wall thickness.
48621002|NCT01334359|BEHAVIORAL|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
48621003|NCT04148404|PROCEDURE|Normothermic group|"1. Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~2. Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
48621004|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy with and without laryngeal restriction|To reduce the laryngeal movement and St.Eso excursion we will use a device constructed in our laboratory which can induce an adjustable resistance to excursion of the larynx. This handmade device that is worn around the neck consists of a band and a concave plastic disk which serves as a support structure for an inflatable polyethylene bag which is connected to a hand pump and pressure gauge. When worn around the neck the inflatable bag rests in position on the thyroid cartilage with a portion of it hung over above the cartilage creating resistance to its superior excursion when fixed by closure straps. A known external force may be applied to the thyroid by partially inflating the bag to a specific pressure reading on the gauge. The soft and compliant bag conforms to the larynx while applying a resistive force to anterior and superior distraction of the hyolaryngeal complex during swallowing.
48621005|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy before and after six weeks of using swallow muscle exercising device|Use the previously mentioned wearable device (sRED) and exercise regimen described previously for studying the effect of increase in anterosuperior excursion of the larynx/St.Eso on St.Eso peristaltic function.
48621006|NCT04452006|DRUG|ACT-541478 10 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
48279779|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
48621007|NCT04452006|DRUG|ACT-541478 30 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
48621008|NCT04452006|DRUG|ACT-541478 100 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 50 mg.
48279780|NCT00752986|DRUG|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
48279781|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
48279782|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
48279783|NCT04640714|BEHAVIORAL|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|Video visit by nurse practitioner within 3 business days of hospital discharge.
48279784|NCT04705467|DEVICE|Gynecological brachytherapy|Management of gynecological malignancies is done through brachytherapy treatment, which involves the delivery of radiation via radioactive sources that are placed into or in close proximity to the tumour.
48279785|NCT06258525|RADIATION|Standard of care oxaliplatin-based chemotherapy|mFOLFOX6 or CAPOX
48279786|NCT06258525|DIETARY_SUPPLEMENT|S-adenosylmethionine (SAMe) supplement|(400 mg tablet): 2 tablets taken orally AM and 1 tablet PM daily (total 1,200 mg daily) prior to surgical resection
48279787|NCT06258525|PROCEDURE|Surgery|At 1-Month
48279788|NCT04586426|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
48279789|NCT04586426|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
48279790|NCT04586426|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
48621009|NCT04452006|DRUG|ACT-541478 300 mg|ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 50 mg and 250 mg.
48621010|NCT04452006|DRUG|ACT-541478 1000 mg|ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 250 mg.
48621011|NCT04452006|DRUG|ACT-541478 high or low dose (or placebo)|Cross-over design: ACT-541478 will be provided in HPMC capsules for oral administration at high or low dose strengths (to be defined after completion of Part A).
48621012|NCT04452006|DRUG|ACT-541478 dose E1|E1 is a dose level that has been investigated and well tolerated in the adult dose level groups C1 to C3. ACT-541478 will be provided in HPMC capsules for oral administration at dose strengths of 10, 50, and 250 mg.
48621013|NCT04452006|DRUG|Matching placebo|Matching placebo will be provided in HPMC capsules for oral administration.
48621014|NCT02991521|PROCEDURE|Fast exam|Positional change before Fast exam
48621015|NCT02711787|DEVICE|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
48621016|NCT02711787|DEVICE|Control group|Physiotherapy and occupational therapy.
48621017|NCT02711787|DEVICE|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
48621018|NCT02833909|OTHER|surgery|
48621019|NCT05213091|OTHER|Otago Exercise Programme|The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
48621020|NCT05398588|OTHER|Cyriax Deep Friction Massage|Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week Cyriax DFM on targeted muscles (Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis) 3 minutes each muscle (15 mins in total ) x 1 set , 3 days / week
48621021|NCT05398588|OTHER|Spencer Muscle energy technique|"Hotpack : 10 min TENS : 20 min, High frequency(100 Hz pulse ), 3 days/week Kaltenborn mobilization: End range - Anterior, posterior and caudal glides :10 repetitions with 10 sec hold x 3 sets, 3 days/week The Spencer technique will be applied in Abduction, External rotation and Internal rotation for targeting muscles Supraspinatus, Infraspinatus, subscapularis, Deltoid and Pectoralis.~10 repetitions x 3set , 3 days/week."
48621022|NCT04373733|DRUG|Favipiravir|Anti-viral
48621023|NCT04373733|OTHER|Standard of care management|Standard of care management for COVID-19
48621024|NCT05324202|DEVICE|Cynosure Cynergy Nd:YAG Laser 1064nm|The Nd:YAG Laser 1064nm is intended to be used as a treatment option in individuals suffering from low-risk basal cell carcinoma(s).
48621025|NCT04075149|DRUG|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if \> 60 kg, 100 mg twice daily.
48621026|NCT00445718|PROCEDURE|computed tomography|
48621027|NCT00445718|PROCEDURE|3-Tesla magnetic resonance imaging|
48451423|NCT01663233|DRUG|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
48451424|NCT01663233|DRUG|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
48451425|NCT01663233|DRUG|Placebo|Matching placebo to LCZ696
48621028|NCT00445718|PROCEDURE|Abdominal Sonogram|Sonogram of the abdomen area
48621029|NCT04684316|OTHER|Electronic survey with selective consultations|Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
48621030|NCT00144885|BEHAVIORAL|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
48621031|NCT05619341|DIETARY_SUPPLEMENT|psyllium|psyllium 20g
48451426|NCT03639181|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
48621032|NCT05619341|DIETARY_SUPPLEMENT|inulin|long chain fructan
48451427|NCT00714935|BEHAVIORAL|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
48451428|NCT00714935|BEHAVIORAL|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
48451429|NCT05146076|OTHER|home-based physical training|home-based physical training minimum 150 min./week with telemonitoring
48451430|NCT05146076|OTHER|institutional physical training|institutional physical training supervised by physiotherapist 2-3 times 60 min./week
48451431|NCT06120465|OTHER|Yoga|Yoga classes
48451432|NCT00598052|DRUG|Escitalopram|10mg/day
48621033|NCT05820438|DEVICE|Electromyography|"Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient."
48621034|NCT03175939|RADIATION|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
48451433|NCT02960295|DEVICE|1-Self-monitoring of blood glucose|"Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range."
48451434|NCT02960295|DEVICE|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.
48451435|NCT02960295|DEVICE|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.
48451436|NCT02960295|DEVICE|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.
48451437|NCT02960295|PROCEDURE|5-Visits with caregivers|Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
48451438|NCT04369937|RADIATION|IMRT (Intensity Modulated Radiotherapy)|Radiation therapy
48451439|NCT04369937|DRUG|Pembrolizumab|A potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death protein 1 (PD-1) and its ligands, PD-L1 and PD-L2.
48451440|NCT04369937|DRUG|Cisplatin|Chemotherapy
48279791|NCT04193683|OTHER|Myofascial Release Technique|Myofascial release technique will bi applied bottom of the feet, back of the legs and hamstrings in both extremities. The practitioner will decide how long she should stay in a region according to the feeling of releasing in the tissue. The technique will be applied to a region at least 3 times.
48279792|NCT04193683|OTHER|Sham-Ultrasound|Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.
48451441|NCT04369937|BIOLOGICAL|ISA101b|ISA101b is a therapeutic cancer vaccine that induces specific immune responses to the oncogenic E6 and E7 antigens from HPV16.
48451442|NCT05245006|DRUG|89Zr-DFO-YS5|3 mCi will be administered intravenously
48451443|NCT05245006|BIOLOGICAL|YS5 antibody|20 or 50 mg administered intravenously
48451444|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging which combines a CT scan and a PET scan
48451445|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)|Imaging which combines an MRI scan and a PET scan
48451446|NCT01966484|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
48451447|NCT01966484|DRUG|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
47928233|NCT04278105|DEVICE|Sham HD-tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
48451448|NCT06074328|DEVICE|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
48451449|NCT03808376|DEVICE|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
48451450|NCT05744232|BEHAVIORAL|Low calorie total diet replacement|"Summary~1. Weeks 1-12: TDR phase~2. Weeks 13-14: Food reintroduction phase I~3. Weeks 15-16: Food reintroduction phase II~4. Weeks 17 till 20: Food reintroduction phase III~5. Weeks 21 till 24: Maintenance phase"
48451451|NCT05744232|OTHER|Usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
48451452|NCT01776138|OTHER|Collect Blood and Survey Instruments|
48451453|NCT00798603|BIOLOGICAL|bevacizumab|
48451454|NCT00798603|DRUG|carboplatin|
48451455|NCT00798603|DRUG|pemetrexed disodium|
48451456|NCT06517719|OTHER|lutetium (177Lu) vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.
48451457|NCT05524051|DRUG|TIN816|TIN816
48451458|NCT05524051|OTHER|Placebo|Placebo
48621035|NCT03175939|DRUG|Cisplatin|cisplatin IV injection over 3 hours
48621036|NCT03175939|DRUG|5-FU|5-FU IV 24 hours continuous infusion
48279793|NCT01337401|DRUG|Cediranib|30mg once daily, oral until disease progression
48279794|NCT01337401|DRUG|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
48279795|NCT00249379|DRUG|Acamprosate|Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
48621037|NCT00587457|DRUG|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
48621038|NCT00587457|DRUG|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
48621039|NCT00587457|DRUG|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
48621040|NCT00334399|DRUG|Miglitol|
48621041|NCT06552169|DRUG|Arm 1: SOC (mTOR + CNI)|Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.
48621042|NCT06552169|BIOLOGICAL|Arm 2A: TRACT/MONO mTOR|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
48621043|NCT06552169|BIOLOGICAL|Arm 2B: TRACT/MONO CNI|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
48621044|NCT04697901|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|"Active simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
48621045|NCT04697901|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|"Sham simulation will be applied to the right PPC. To target this region for stimulation, the anode electrode will be placed on the subject using the 10-20 EEG system as reference location (Thair et al., 2017). Stimulation intensity for all conditions will be set to 2 mA, which was chosen based on previous studies that have compared 1 mA to 2 mA and found the higher intensity produced reliable changes to performance (e.g., Moos et al., 2012). Total time of active stimulation will be the same for each group (20 minutes). Sham stimulation will consist of active stimulation for 120s, including the ramping up to 2 mA and down to no stimulation. Delivery times of the stimulation will vary based on Group assignment:~Group A: During pre-flight brief/checklist, for 20 minutes. Group B: First delivered at 30 minutes into flight for 10 minutes, second delivered at 60 minutes into flight for 10 minutes."
48621046|NCT03979404|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
48621047|NCT01795612|OTHER|physical activity|
48621048|NCT00768053|DRUG|Etanercept|Etanercept 50 mg once a week
48621049|NCT00308776|PROCEDURE|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
48621050|NCT00308776|PROCEDURE|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
48637427|NCT04940052|DRUG|Trametinib|Trametinib will be administered orally once daily
47928234|NCT04278105|OTHER|Upper extremity rehabilitation|Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
47928235|NCT04787523|RADIATION|Radiotherapy|Patients have received neoadjuvant radiotherapy
47928236|NCT05634356|BEHAVIORAL|vocal-social reinforcement|experimental manipulation of social reinforcement in response to vocalizations
48451461|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
48451462|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
48451463|NCT01083264|DRUG|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
48451464|NCT05842135|PROCEDURE|Laparoscopic approach to small bowel obstrcuction|Bowel viability assessment by indocyanine green fluorescent angiography during laparoscopic approach to small bowel obstruction
48451465|NCT02307994|DRUG|75IU uFSH|
48451466|NCT00164684|BEHAVIORAL|Father Friendly Initiative|
48451467|NCT04605211|BEHAVIORAL|Online Mindfulness Meditation|Complete online audio-based mindfulness meditation exercises
48451468|NCT04605211|OTHER|Internet-Based Webinars|Attend webinars
48451469|NCT05028608|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as a single dose in Period 1 and in Period 2.
48621051|NCT00350285|BEHAVIORAL|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
48621052|NCT00350285|BEHAVIORAL|Marijuana education|Information about health and behavioral effects of marijuana use.
48621053|NCT06306703|OTHER|group1, group2, group 3|to teaching with verbal instruction to teaching with digital vaginal palpation to teaching with perineometer
48621054|NCT05055596|BEHAVIORAL|Tai Chi|Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).
48621055|NCT05055596|BEHAVIORAL|Health Coaching|The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
48451470|NCT05028608|DRUG|Midazolam|Midazolam given orally as single dose in Period 1 and in Period 2.
48451471|NCT05028608|DRUG|Carbamazepine|Carbamazepine given orally twice daily in Period 2 .
48451472|NCT05912127|DEVICE|implant supported fixed full arch prosthesis|the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
48451473|NCT02826694|GENETIC|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
48451474|NCT02826694|GENETIC|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
48451475|NCT04313751|BEHAVIORAL|Education, Physical Activity, and Stress Management Program|Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
48451476|NCT04313751|OTHER|Wait-list|The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
48451477|NCT01312844|DRUG|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
48451478|NCT02281253|DIETARY_SUPPLEMENT|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals."
48451479|NCT02281253|DIETARY_SUPPLEMENT|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
48451480|NCT01484912|DRUG|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
48451481|NCT01484912|DRUG|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
48451482|NCT03905980|PROCEDURE|vaginal delivery|pregnancy ended by vaginal delivery
48451483|NCT03905980|PROCEDURE|Cesarean section|pregnancy ended by cesarean delivery
48451484|NCT02699463|DEVICE|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
48451485|NCT02699463|OTHER|Control Group|Standard sleep hygiene counseling as per published guidelines
48451486|NCT03927768|DIAGNOSTIC_TEST|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
48451487|NCT03927768|DIAGNOSTIC_TEST|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
48451488|NCT03036748|DIETARY_SUPPLEMENT|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
48451489|NCT03036748|DRUG|Tbl amiloride|Drug: Amiloride Amiloride tablet 10 mg two times daily (morning and afternoon) for one day
48451490|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using allograft|Participants will receive Surgically facilitated orthodontics therapy (SFOT) along with bone grafting using particulate allograft and collagen membrane, prior to orthodontics treatment.
48451491|NCT06627829|DEVICE|Surgically facilitated orthodontics therapy (SFOT) using xenograft|Participants will receive SFOT using particulate xenograft and collagen membrane, prior to orthodontics treatment.
48451492|NCT06627829|DEVICE|Usual care|Participants will have conventional orthodontics treatment with Invisalign aligners, without any surgical intervention
48451493|NCT00869193|DIETARY_SUPPLEMENT|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
48621056|NCT00564356|PROCEDURE|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
48621057|NCT02887001|OTHER|Pharmacist consultation|
48621058|NCT06400810|DEVICE|Analog Devices Inc.|Wearable wrist device that collects Photoplethysmography, accelerometer data among other parameters.
48637428|NCT04940052|DRUG|Trametinib placebo|Trametinib will be administered orally once daily
48637429|NCT04940052|DRUG|Dabrafenib placebo|Dabrafenib placebo will be administered orally twice daily
48451494|NCT00869193|DIETARY_SUPPLEMENT|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
48621059|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food|The intensive iDiet® group behavioral weight loss program will be delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the iDiet® intervention will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
48621060|NCT02593240|BEHAVIORAL|The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher|The intensive iDiet® group behavioral weight loss program delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the Diet® intervention will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
48621061|NCT02593240|BEHAVIORAL|Human Performance Institute©|The Human Performance Institute© (HPI) training workshop is a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
48621062|NCT05255419|DEVICE|OnCall mobile health peer support app|"Mobile health platform that provides anonymous access to peer support services that has been co-design by and for Canadian public safety personnel. OnCall is for frontline public safety providers; features include links to mental health self-assessment tools, a wellness toolbox, tips to cope articles and peer wisdom videos, and options to reach out to a peer support provider of their choice via telephone or text. The OnCallSupport app is for the peer support providers which includes a list of resources and an opportunity to create post-action reports following the peer support encounter. Connections are made to peer support via a telephone service that disguises the contact information of both parties. The app platform includes options to complete feedback surveys related to the app and to the peer support encounter."
48621063|NCT04308694|DRUG|Pharmacy-based methadone administration and dispensing|Eligible participants receiving between 6- and 13-days of methadone take-home doses will have methadone administration and dispensing transferred from the opioid treatment program to the partnered community pharmacy. Each participant will be assessed monthly for 3 months (at 1, 2, and 3 months following intake/baseline) to explore the feasibility of transferring their methadone administration and dispensing to the select community pharmacy.
48621064|NCT04808037|DRUG|Belantamab mafodotin|Belantamab mafodotin in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed Multiple Myeloma transplant-ineligible
48451495|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)/RIV|Combination of BNT162b2 (Omi XBB.1.5) and RIV
48637430|NCT04566510|OTHER|long lasting insecticidal nets with alpha-cypermethrin + pyriproxyfen (PPF LLIN, Royal Guard))|Next-generation bed net combining insecticides with different modes of action
48451496|NCT06237049|BIOLOGICAL|BNT162b2 (Omi XBB.1.5)|Licensed COVID-19 vaccine
48451497|NCT06237049|BIOLOGICAL|RIV|Licensed recombinant influenza vaccine
48451498|NCT06237049|OTHER|Normal saline placebo|Normal saline (solution for injection)
48451499|NCT03393754|BIOLOGICAL|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
48451500|NCT03155503|DRUG|SUVN-911|Oral Tablet
48451501|NCT03155503|DRUG|Placebo|Oral Tablet
48451502|NCT01261039|RADIATION|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
48451503|NCT04793971|PROCEDURE|percutaneous paratenon release|percutaneous paratenon release for chronic midportion Achilles tendinopathy
48451504|NCT03591458|DRUG|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
48451505|NCT03591458|DRUG|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
48451506|NCT05253443|BEHAVIORAL|Mentalizing Imagery Therapy and caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training and Mentalizing Imagery Therapy techniques with optional weekly group meetings.
48451507|NCT05253443|BEHAVIORAL|Caregiver skills mobile application|8-week long mobile application intervention course including caregiver skills training with optional weekly group meetings.
48451508|NCT02364713|BIOLOGICAL|Bevacizumab|Given IV
48451509|NCT02364713|DRUG|Gemcitabine Hydrochloride|Given IV
48451510|NCT02364713|OTHER|Laboratory Biomarker Analysis|Correlative studies
48451511|NCT02364713|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
48451512|NCT02364713|DRUG|Paclitaxel|Given IV
48451513|NCT02364713|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48451514|NCT02364713|OTHER|Quality-of-Life Assessment|Ancillary studies
48451515|NCT02364713|DRUG|Topotecan Hydrochloride|Given IV
48451516|NCT06152796|DRUG|Paracetamol|Anti_inflammatory drug
48451517|NCT06152796|DRUG|Ibuprofen|Non steroidal anti_inflammatory drug
48621065|NCT04308135|DIAGNOSTIC_TEST|Neuro-radiological tools:|"MRI brain: to measure white matter~c) Ultrasonographic examination of extracranial vessels: The intimal medial thickness of the common carotid artery (CCA-IMT) will be measured in B-mode. The carotid arteries will be evaluated for the presence of atherosclerotic lesions (plaques) either soft or hard .The residual lumen and degree of stenosis will be measured. The peak systolic velocity will be detected."
48621066|NCT04308135|DIAGNOSTIC_TEST|cognitive tests|"All patients will be evaluated for global cognitive assessment by: Montreal Cognitive Assessment (MoCA) (Arabic version) Visuospatial skills will be assessed by Clock Drawing Tests from MoCA test and copy the intersecting pentagons from Addenbrooke's test (Arabic version) Language will be examined by semantic fluency from Addenbrooke's test (Arabic version) and similarities from Wechsler Adult Intelligence Scale (WAIS) Attention will be evaluated by digit span from Wechsler test),and by the number of seconds needed to sequence numbers using a pencil (Trail making test A) from MoCA test . For the evaluation of memory, participants will complete Wechsler memory subset~, and the investigators also will use their three-item recall from the Mini-Mental State Examination( MMSE). Executive functions will be measured by Wisconsin card sorting test and also verbal fluency test from Addenbrooke's test. Frontal Assessment Battery (FAB) scale"
48621067|NCT04308135|DIAGNOSTIC_TEST|lab investigations|Each patient will undergo full lab investigations:\[lipid profile ,complete blood count, uric acid ,Hemoglobin A1c (HbA1c), liver functions, renal functions, and electrolytes\]
48621068|NCT04308135|DIAGNOSTIC_TEST|Beck depression inventory (BDI)(Arabic version)|Clinical Tool for depression
48621069|NCT04308135|DIAGNOSTIC_TEST|Clinical Tools for Urinary symptoms:|the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Scale (Arabic version)
48621070|NCT04308135|DIAGNOSTIC_TEST|Freezing of gait questionnaire|"Clinical Tools for Gait (in on and off state ), Gait will be assessed by:~* .Freezing of gait questionnaire~* Berg balance scale.~* 10 meter walk test .~* Timed up and go test."
48621071|NCT04308135|DIAGNOSTIC_TEST|non-motor symptoms scales (NMSS).|Clinical Tool for assessment of non-motor symptoms of PD
48621072|NCT04308135|DIAGNOSTIC_TEST|Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS):|"Clinical Tools for assessment of the neurological severity and stage of disease Clinical Tool for assessment of the neurological severity and stage of disease during OFF and ON states, Hoehn and Yahr scale. The presence of lower limb parkinsonism will be determined by a two-point difference between upper limb and lower limb scores of bradykinesia, rigidity or postural instability from part III of the MDS-UPDRS. Patients will be examined in the early morning, in 'OFF' state, with MDS-UPDRS, Hoehn and Yahr and freezing of gait questionnaire(FOG-Q) scales. Immediately afterwards, they will take their regular first dose of levodopa. After 1 hour, patients will be examined again with the same tests and scales.~Response to levodopa will be determined as patients who reached a percentage reduction exceeding 25% in part III of the MDS-UPDRS"
48621073|NCT04308135|DIAGNOSTIC_TEST|ELIZA for alpha-synuclein|measuring serum of alpha-synuclein, tau and their autoantibodoies
48621074|NCT04308135|OTHER|transcranial color-coded duplex(TCCD)|TCCD using phase array 2.4 Hz probe for evaluation of cerebral vasomotor reactivity (CVR) by measuring the Breath holding index(BHI),flow velocities and pulsatility index of middle cerebral artery and posterior cerebral artery on both sides.
48621075|NCT04308135|OTHER|extracranial carotid duplex|to assess atherosclerosis, stenosis of carotids
48621076|NCT04308135|OTHER|The Arabic version of Parkinson's Disease Questionnaire( PDQ-39)|Clinical tool for quality of life of PD patients
48621077|NCT02124174|DRUG|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m\^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~\*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
48621078|NCT04400994|DRUG|Rituximab|"Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
48621079|NCT04400994|OTHER|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min \& beyond: 180ml/hour"
48451518|NCT03961828|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
48451519|NCT02510118|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
48451520|NCT02510118|DRUG|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
48451521|NCT02510118|DRUG|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
48451522|NCT02510118|DRUG|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
48451523|NCT05301881|PROCEDURE|Surgery|resection of the oligometastatic lesion(s)
48451524|NCT05301881|RADIATION|Radiotherapy|radiation of the oligometastatic lesion(s)
48451525|NCT05301881|OTHER|Radiofrequent ablation|radiofrequent ablation of the oligometastatic lesion(s)
48621080|NCT02181738|DRUG|Nivolumab|Specified dose on specified days
48621081|NCT02181738|DRUG|Doxorubicin|Specified dose on specified days
48621082|NCT02181738|DRUG|Vinblastine|Specified dose on specified days
48621083|NCT02181738|DRUG|Dacarbazine|Specified dose on specified days
48621084|NCT03237754|DEVICE|tDCS device from neuroConn|weak electrical direct current stimulation
48621085|NCT04447365|DIAGNOSTIC_TEST|device interrogation|All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.
48451526|NCT01215279|DRUG|AZD2423|100 mg oral treatment once daily for 28 days
48451527|NCT01215279|DRUG|Placebo to AZD2423|Oral treatment once daily for 28 days
48451528|NCT00858754|DRUG|methylnaltrexone|
48621086|NCT06417047|OTHER|Hand Holding|During the intramuscular injection, the aim is to draw the patients' attention elsewhere by holding their hand.
48451529|NCT00858754|DRUG|placebo|
48451530|NCT01634139|DRUG|Tiotropium low dose QD|2 actuations once daily in the evening
48451531|NCT01634139|DRUG|Tiotropium high dose QD|2 actuations once daily in the evening
48621087|NCT00167570|DEVICE|Prosthetic socket fabricated using selective laser sintering|
48621088|NCT03834116|DEVICE|Inspiratory muscle training|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
48621089|NCT03118882|BEHAVIORAL|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
48621090|NCT03118882|BEHAVIORAL|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
48451532|NCT01634139|DRUG|Placebo|2 actuations once daily in the evening
48451533|NCT03787758|DRUG|SAGE-718|SAGE-718
48621091|NCT03118882|BEHAVIORAL|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
48621092|NCT04287179|DRUG|Semaglutide|Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
48621093|NCT02724644|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
48621094|NCT02724644|BIOLOGICAL|Placebo Comparator|
48621095|NCT00958074|DRUG|vorinostat|Given PO
48621096|NCT00958074|OTHER|flow cytometry|correlative study
48621097|NCT00958074|OTHER|laboratory biomarker analysis|correlative study
48621098|NCT00088855|DRUG|Bortezomib|Given IV
48621099|NCT00088855|OTHER|Laboratory Biomarker Analysis|Correlative studies
48451534|NCT05519787|DEVICE|Central Veinous access devices' insertion|"Medical doctor should complete a questionnaire with medical history or any important clinical data that could help for the selection of the location of the port and catheter placement. The insertion will be planned only by a surgeon, interventional radiologist, or anaesthesiologist in the surgery block.~For the patient with a medical history of PICC line, PAC implantation, Central venous access device of any kind, or clinical risk of veinous compression (cervical or subclavian adenopathy, pelerine syndrome, mediastinal involvement...). An echo Doppler exam of the veinous cervical system is required before surgery. This exam should identify potential thrombosis that required a special treatment. It is important that the surgeon who will perform the device's insertion is aware of any history or risks of veinous thrombosis, stenosis, or phlebitis for the patient to avoid procedure's failure."
48621100|NCT00088855|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48621101|NCT01435941|DRUG|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
48621102|NCT01435941|DRUG|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
48621103|NCT01562444|OTHER|Blood draw|Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
48621104|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
48621105|NCT02208622|DIETARY_SUPPLEMENT|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
48621106|NCT02208622|DIETARY_SUPPLEMENT|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
48451535|NCT05334875|DIAGNOSTIC_TEST|Electroretinogram (ERG)|Applying electrodes to assess retinal function
48451536|NCT05334875|DIAGNOSTIC_TEST|Visual evoked potential (VEP)|Applying electrodes to assess visual pathway function
48451537|NCT00926887|DEVICE|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
48451538|NCT00926887|DEVICE|Placebo Laser|Inactive light
48451539|NCT06416241|DRUG|EYLEA 2 MG in 0.05 ML Injection|Intravitreal injection
48451540|NCT03285594|DRUG|Sotagliflozin|"Pharmaceutical form: Tablet~Route of administration: Oral"
48451541|NCT03285594|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
48451542|NCT03285594|DRUG|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
48451543|NCT03285594|DRUG|Oral Antidiabetes Drugs (OADs)|OADs (including metformin) as prescribed by the investigator as per local labeling.
48451544|NCT02016274|OTHER|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
48451545|NCT04367766|PROCEDURE|Prosthetically driven implant placement|Insertion of an osseointegrated implant into the bone of anterior maxilla/mandible, following the right prosthetic plan
48621107|NCT02707497|DRUG|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
48621108|NCT02707497|DRUG|Placebo|The control group will not use any platelet-increased drugs.
48621109|NCT06086249|PROCEDURE|Regeneration using Injectable platelet-rich fibrin|root canals of affected molars will be cleaned and shaped chemo-mechanically, after two weeks I-PRF will be applied.
48621110|NCT06086249|PROCEDURE|Root canal treatment|Conventional root canal treatment using gutta-percha obturation
48621111|NCT05578547|OTHER|combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"• The combined exercise will be done as follow:~1) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
48621112|NCT05578547|OTHER|ultrasound, hot packs, cervical extensors stretching and strengthening exercise.|"Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises"
48621113|NCT04026425|OTHER|Two-day cardiopulmonary exercise test|A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
48621114|NCT02988609|DEVICE|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
48621115|NCT05181384|OTHER|isolated pelvic floor muscles training|isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
48621116|NCT05181384|OTHER|comprehensive stabilization exercise program|incorporated the contraction of PFMs with other spinal or extremity muscles
48621117|NCT05181384|OTHER|education of pelvic girdle|educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
48621118|NCT00482144|PROCEDURE|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
48621119|NCT00482144|PROCEDURE|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
48621120|NCT05000827|DEVICE|PSMA-PET/CT|In the intervention arm patients will only undergo ePLND in addition to robot-assisted radical prostatectomy (RARP) in case of suspected LNI on PSMA PET/CT (miN1), whereas ePLND will be omitted in those without PSMA positive lymph nodes (miN0).
48621121|NCT05000827|OTHER|Nomogram|Current standard of care includes performing extended pelvic lymph node dissection (ePLND) in all patients with primary prostate cancer and a nomogram-based risk of LNI \>5%
48621122|NCT00968162|DRUG|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
48621123|NCT03104413|DRUG|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
48621124|NCT03104413|DRUG|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
48621125|NCT03104413|DRUG|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
48451546|NCT06558734|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared according to the manufacturer's recommendations for Figaro Crowns. Fiberglass crowns (Figaro Crowns Inc., USA) of the most suitable size in terms of the mesio-distal dimension of the tooth were selected. Following the establishment of anesthesia, the teeth were prepared using diamond cutting burs with a high-speed, water-cooled turbine handpiece. In order to achieve adequate interocclusal space, an occlusal reduction of 1-2 mm was executed along with a proximal reduction reaching 1 mm below the gingival margin. A more conservative reduction was applied to the buccal and lingual surfaces. After preparation, any remaining decayed dentin tissue was removed using a steel round bur with a low-speed micromotor. To ensure occlusal harmony, diamond burs were used to perform abrasion on the crown edges, and the trimmed crown edges were polished using rubber aids before cementation.
48621126|NCT03514797|DRUG|Bleaching Agents|In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
48621127|NCT03514797|DRUG|Bleaching Agents|At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
48621128|NCT03653481|DIETARY_SUPPLEMENT|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
48621129|NCT03653481|DIETARY_SUPPLEMENT|Maltodextrin|Consumed as a powder, 8g/d for children \<50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
48621130|NCT00437762|DRUG|Botulinum Toxin A Injection|Botulinum Toxin A Injection
48621131|NCT00437762|DRUG|Placebo injection|Placebo Injection
48621132|NCT00119704|DRUG|Botulinum toxin A injection or normal saline|
48621133|NCT05370326|OTHER|Enhanced Opioid Stewardship Program|The goal of the enhanced opioid stewardship intervention is to manage chronic pain while reducing risk of inappropriate/risky opioid use and preventing harms of opioid use.
48621134|NCT06478095|BEHAVIORAL|Visual aids|Diagrams, models, and videos
48621135|NCT05875480|PROCEDURE|synchronized telerehabilitation|In the synchronized telerehabilitation group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. after 2 weeks, they were treated 2 days a week until the 6th week by meeting with the physiotherapist in real time via the Albert Health Assistant application. In the remaining days, they were asked to follow the exercise videos uploaded to the Albert system, it will be checked whether they have done the daily exercises, and a daily reminder message will be sent through the system.
48621136|NCT05875480|PROCEDURE|asynchronized telerehabilitation|The exercise program for the asynchronized telerehabilitation group will be uploaded to the Albert Health Assistant in the form of 2-week programs in video form from the first Day. Whether the patients apply these videos on a daily basis will be checked through the system, a message reminding the daily routine exercise program will be sent through the system.
48621137|NCT05875480|PROCEDURE|supervised (face to face) rehabilitation|In the supervised physiotherapy group, the exercise program of the first 2 weeks was submitted via Albert Health Assistant application and patients were asked to do these exercises regularly during this process. After 2 weeks, they attended the rehabilitation program in the physical therapy department of the hospital accompanied by a physiotherapist, starting from the 14th postoperative day, 2 days a week until the 6th week. The ROM, pain, functional and general health evaluations of the patients in this group were carried out on the online platform. In addition, on the days when they did not come to treatment, their daily routine exercises were followed through the Albert system.
48451547|NCT06558734|PROCEDURE|Cementation|Figaro crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
48451548|NCT03469401|OTHER|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
48621138|NCT03084484|DIETARY_SUPPLEMENT|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
48621139|NCT03084484|PROCEDURE|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
48621140|NCT01137786|DRUG|Non ionic contrast media comparator|One time administration for PCI
48621141|NCT01137786|DRUG|Non ionic contrast media comparator|one time administration for PCI
48621142|NCT03354377|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
48621143|NCT03354377|BEHAVIORAL|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
48621144|NCT03354377|BEHAVIORAL|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
48621145|NCT05576896|DRUG|Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab|"Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
48621146|NCT06360484|DIAGNOSTIC_TEST|investigations for Hepatitis D virus|Investigations included liver function tests, abdominal ultrasounds to identify features of chronic liver disease, and evidence of decompensation. ELISA for Ant-HDV-IgG was conducted.
48451549|NCT04673721|DIETARY_SUPPLEMENT|Fortified eggs|Average 12 eggs consumed per week
48621147|NCT02323438|OTHER|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
48451550|NCT04673721|BEHAVIORAL|Intermittent fasting|16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).
48451551|NCT04673721|DIETARY_SUPPLEMENT|Non-egg supplemented|2 or less eggs consumed per week
48451552|NCT04673721|BEHAVIORAL|Usual care diet|Consistency with current diet without consideration of intermittent fasting
48451553|NCT00984022|DEVICE|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
48451554|NCT00984022|DEVICE|Type of dressing - Aquacel|Aquacel dressing
48451555|NCT05362344|PROCEDURE|Stool tests|Non-invasive, stool-based tests for colorectal cancer screening.
48451556|NCT04407403|BEHAVIORAL|Tai Chi tailored for lowering blood pressure (PRESSURE)|PRESSURE Tai Chi routine consisted of eight forms following Yang style. PRESSURE was tailored for the targeted health outcome of BP in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored PRESSURE to emphasize slow, deep breathing and relaxation by utilizing Tai Chi movements that: 1) were slow and smooth; 2) without break or pause; and 3) had minimal muscular force and exertion. Investigators included the following eight forms in PRESSURE: 1) Begin Tai Ji Quan; 2) Part the Horse's Mane; 3) Brush Knee and Push; 4) Cloud Hands; 5) Open and Close; 6) Part the Grass; 7) Single Whip; and 8) Finish Tai Ji Quan.
48621148|NCT02323438|OTHER|Electronic Cigarette #1|Electronic cigarette
48621149|NCT02323438|OTHER|Electronic Cigarette #2|Electronic cigarette
48621150|NCT02323438|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
48621151|NCT04298385|OTHER|Traction orthosis|Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
48621152|NCT05758454|BEHAVIORAL|Caries and Obesity Prevention|A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
48621153|NCT01718691|DRUG|SyB L-0501|A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
48621154|NCT01718691|DRUG|rituximab|A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
48621155|NCT03120273|DRUG|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
48621156|NCT03120273|DRUG|Lansoprazole Injection|30 mg q12h for 5 days.
48621157|NCT04125459|PROCEDURE|Joint Biopsy|a synovial biopsy of a joint that has been affected by a gout attack
48621158|NCT03213236|DIAGNOSTIC_TEST|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
48621159|NCT00139516|BEHAVIORAL|self-help|
48621160|NCT00139516|DRUG|nicotine replacement therapy|
48621161|NCT00139516|BEHAVIORAL|smoking cessation|
48621162|NCT05804903|DEVICE|(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
48621163|NCT03803137|OTHER|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry
48621164|NCT00001931|DRUG|N-0923|
48621165|NCT06115980|DEVICE|lead extraction (Xtrac O.S. system)|"This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).~Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction.~A multidisciplinary team evaluation involving cardiac surgery, electrophysiologist, and cardiac anesthesiology should allow for a rapid and successful response to major complications"
48621166|NCT02065557|BIOLOGICAL|Adalimumab|Subcutaneous (SC) injection
48621167|NCT02065557|BIOLOGICAL|Placebo|Subcutaneous (SC) injection
48621168|NCT03117270|DRUG|filgotinib|one filgotinib oral tablet q.d.
48621169|NCT03117270|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
48621170|NCT02886663|OTHER|stimulation of the blind visual field|
48621171|NCT06212791|BEHAVIORAL|Self- Report Evaluation-Duke Activity Status Index|Complete the Self- Report Evaluation-Duke Activity Status Index
48621172|NCT06212791|BEHAVIORAL|Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire|Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire
48621173|NCT06212791|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise test (CPET)
48621174|NCT06212791|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Transthoracic echocardiogram at rest and immediately following peak exercise during CPET
48621175|NCT06212791|DIAGNOSTIC_TEST|Ambulatory cardiac rhythm assessment|Ambulatory cardiac rhythm assessment
48621176|NCT06212791|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)
48621177|NCT04825522|DRUG|Vancomycin|During spinal surgery, participants will receive intrawound vancomycin powder in their wound before closure.
48621178|NCT06305039|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant or acoustic hearing function|Because the cochlear implant participants in the study will use cochlear implant devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of cochlear implant or acoustic hearing function. This will include perceptual tests of sound localization, speech understanding in noise, binaural fusion, and loudness comparisons.
48621179|NCT06305039|BEHAVIORAL|Targeted aural rehabilitation of the poorer performing ear|Subjects will undergo listening practice on a tablet computer over headphones at home. For the test group, the aural rehabilitation will be targeted at the poorer ear. For the comparison control group, a sham aural rehabilitation will present speech to both ears.
47928237|NCT05291468|RADIATION|FDG-PET/CT|Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
48621180|NCT00448149|DRUG|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
48621181|NCT00448149|DRUG|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
48621182|NCT00825006|DEVICE|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
48621183|NCT03978767|DRUG|Ibuprofen 600 mg|NSAID pain medication to be used in the experimental bundle for postpartum analgesia
48621184|NCT03978767|DRUG|Ketorolac|NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
48621185|NCT03978767|DRUG|Acetaminophen|Analgesic medication to be used in both treatment arms
48621186|NCT03978767|DRUG|Oxycodone|Analgesic medication to be used in both treatment arms
48621187|NCT02309359|BIOLOGICAL|ALX-0061|
48621188|NCT02309359|OTHER|Placebo|
48621189|NCT02309359|DRUG|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
48621190|NCT05953727|OTHER|Low level laser therapy with proprioceptive stimulation|10 minutes of low level laser therapy and 10-15 minutes of proprioceptive stimulation and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
48621191|NCT05953727|OTHER|Low level laser therapy without proprioceptive stimulation|10 minutes of low level laser therapy and 10 minutes of heating pack. Assessment and data collection will be done at baseline (initial), after 4 weeks of treatment protocol and patients will be followed up for the further 2 weeks to notice and report any change in condition and health status.
47928238|NCT00021073|DRUG|alvocidib|Given IV
47928239|NCT00021073|DRUG|leucovorin calcium|Given IV
47928240|NCT00021073|DRUG|fluorouracil|Given IV
48621192|NCT05424055|BEHAVIORAL|Multicomponent exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
48621193|NCT06319118|DRUG|Placebo|placebo + usual care, placebo 5 mg daily; 2.5mg 2 times daily, after breakfast and dinner.
48621194|NCT06319118|DRUG|dihydroergotine mesylate sustained-release tablets|Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.
48621195|NCT00785889|PROCEDURE|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
48621196|NCT03570593|PROCEDURE|REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY|Removal of urinary catheter on the first day after radical surgery
48621197|NCT02153281|OTHER|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
48621198|NCT05304325|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
48621199|NCT05304325|OTHER|Blood sampling|Blood samples will be collected to measure glucose, insulin, albumin, uric acid, HbA1c, lipids, hepatic enzymes, TSH, hs-CRP, complete blood cell counts and persistant organic pollutants
48621200|NCT05304325|OTHER|Blood pressure|Systolic and diastolic blood pressure will be measured.
48621201|NCT05304325|OTHER|Anthropometric measurements|Body weight, height and waist circumference will be measured.
48621202|NCT05304325|OTHER|Body composition|Body composition will be evaluated by dual-energy X-ray absorptiometry.
48621203|NCT05304325|OTHER|Resting metabolic rate|Resting metabolic rate will be measured by indirect calorimetry.
48621204|NCT05304325|OTHER|Food intake|Food intake, energy intake and food quality will be evaluated using the food frequence questionnaire.
48621205|NCT05304325|PROCEDURE|Adipose tissue biopsy|A sample of 3-5g of adipose tissue will be collected under local anesthesia by needle aspiration in the periumbilical region.
47928241|NCT00021073|DRUG|irinotecan hydrochloride|Given IV
47928242|NCT06449274|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.
47928243|NCT06449274|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
47928244|NCT05018351|BEHAVIORAL|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
47928245|NCT05018351|BEHAVIORAL|Peer Navigation|Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
47928246|NCT06514196|DEVICE|Hintermann Series H3 Total Ankle Replacement System|The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.
47928247|NCT00410709|DRUG|NatrOVA Creme Rinse (1%)|
47928248|NCT02048241|BEHAVIORAL|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
47928249|NCT02048241|OTHER|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
48621206|NCT01237730|DRUG|cefuroxime|Use the cefuroxime as prophylaxis.
47928250|NCT02048241|DRUG|Intuniv|Weekly administration of medication in doses as per protocol
47928251|NCT01009840|DRUG|IV busulfan|PK-directed dosing of IV busulfan for 4 days
47928252|NCT01009840|DRUG|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m\^2.
48621207|NCT01237730|DRUG|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
48621208|NCT00005988|DRUG|cyclophosphamide|
48621209|NCT00005988|DRUG|cyclosporine|
48621210|NCT00005988|DRUG|leucovorin calcium|
48621211|NCT00005988|DRUG|methotrexate|
48621212|NCT00005988|DRUG|methylprednisolone|
48621213|NCT00005988|PROCEDURE|in vitro-treated bone marrow transplantation|
48621214|NCT00005988|RADIATION|radiation therapy|
48621215|NCT05907265|BEHAVIORAL|Behavioral: ONCOBrain_ImmersiveVR|A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
48621216|NCT05907265|BEHAVIORAL|Behavioral: Control_Condition|Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
48621217|NCT02768155|OTHER|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
48621218|NCT02768155|OTHER|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
48451557|NCT04407403|BEHAVIORAL|Tai Chi tailored for improving balance (BALANCE)|BALANCE Tai Chi routine consisted of eight forms following Yang style. BALANCE was tailored for the targeted health outcome of balance in consultation with the professional, certified Tai Chi instructor and an experienced physical therapist. Specifically, investigators tailored BALANCE to provide moderate to high levels of challenge to balance control by emphasizing movement principles (e.g., consciously control weight shifting during multi-directional stepping), and integrating Tai Chi movements that: 1) reduced the base of support; 2) moved the center of gravity; and 3) improved lower-extremity strength. Investigators included the following eight forms in BALANCE: 1) Begin Tai Ji Quan; 2) Roll the Ball; 3) Kick with Heel; 4) Repulse the Monkey; 5) Gather the Earth's Qi; 6) White Crane Spread Wing; 7) Fairy Weaves the Shuttle; and 8) Finish Tai Ji Quan.
48451558|NCT00830414|DRUG|medroxyprogesterone acetate|IM Injection
48451559|NCT00830414|DRUG|medroxyprogesterone acetate|IM injection
48451560|NCT00938509|DRUG|ibuprofen suppositories|5-10 mg/kg/day-suppositories
48451561|NCT00431041|DRUG|solifenacin|Oral
48451562|NCT00431041|DRUG|oxybutynin immediate release|Oral
48451563|NCT01919112|DEVICE|tDCS|Anodal tDCS will be administered with swallowing exercises
48451564|NCT06210984|DRUG|Low caffeine dose|2 mg/kg dose of caffeine in pill form
48451565|NCT06210984|DRUG|Moderate caffeine dose|5 mg/kg dose of caffeine in pill form
48451566|NCT06210984|DRUG|Placebo|5 mg/kg dose of maltodextrin in pill form
48451567|NCT05130762|DEVICE|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
48451568|NCT05384769|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
48451569|NCT05384769|PROCEDURE|Low Dose Computed Tomography of the Chest|Undergo low dose CT
48451570|NCT05384769|OTHER|Survey Administration|Ancillary studies
48451571|NCT05706909|DEVICE|Genex with ABMC|Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
48621219|NCT02768155|OTHER|Placebo Control|Normal Saline
48451572|NCT05104723|DRUG|XELJANZ (tofacitinib)|The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.
48451573|NCT02248051|DRUG|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
48451574|NCT01221129|OTHER|Acclimation|11 mg Zn/day as a controlled intake level
48451575|NCT01221129|OTHER|Dietary zinc depletion|\< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
48451576|NCT01221129|OTHER|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
48451577|NCT05398094|DRUG|Sotorasib|AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
48451578|NCT03273153|DRUG|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
48451579|NCT03273153|DRUG|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
48451580|NCT03273153|DRUG|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
48451581|NCT05257564|DEVICE|Determine the accuracy of quantitative measurements of GLU, HbA1c,CHOL and CRE with POC devices compared to a laboratory reference method (Roche)|Fingerstick capillary blood will be collected according to each manufacturer's Instructions for use. The fingerstick capillary blood samples will be used immediately on the point-of-care assays. The venous blood will be collected in specific tubes for plasma (GLU), for whole blood (HbA1c) and for serum (CREP, CHOL). Plasma will be separated by centrifugation at the PHC facility and health post and aliquots will be prepared. Serum will be left to clot prior to centrifugation and serum aliquots will be prepared at the PHC facility and health post. The samples will be stored until transfer to the BPKIHS reference lab.
48451582|NCT05665205|OTHER|Aerobic plus strength group|A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
48451583|NCT05665205|OTHER|Aerobic group|This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
48451584|NCT01842750|DEVICE|Endorectal Balloon insertion|
48451585|NCT05115357|PROCEDURE|Pecto-Intercostal Fascial Block|A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
48451586|NCT05115357|PROCEDURE|Transversus Thoracis Muscle Plane Block|The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
48621220|NCT03749161|DEVICE|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
48621221|NCT03749161|DEVICE|Monofocal IOL|Lentis L-313, monofocal IOL
48621222|NCT04683575|DRUG|Selenium Yeast|oral medication
48621223|NCT04683575|DRUG|Placebo|oral medication
48621224|NCT02949934|DRUG|Tolcapone|
48621225|NCT02949934|DRUG|Placebo|
48621226|NCT01529996|PROCEDURE|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
48621227|NCT01779661|OTHER|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
48621228|NCT01779661|OTHER|Infant Massage|Infant Massage
48621229|NCT03447145|DRUG|TQ-B3203|dose escalation, 2/4/6/10/14/18mg/m2
48621230|NCT04749446|OTHER|Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)|"This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments~Reorder Outcome Measures"
48621231|NCT05426460|BEHAVIORAL|Approach/Avoidance Task|The Approach/avoidance task (AAT) training is done using a joystick. The AAT tasks involves having participants push away pictures of smoking stimuli that appear on the screen by pushing the joystick forward, and pulling in pictures of nonsmoking stimuli that appear on the screen by pulling the joystick towards themselves. Pushing smoking-related pictures away causes the picture to shrink in size, whereas pulling a picture closer causes the picture to increase in size. This task consists of 4 blocks of 24 pictures, taking 30 minutes.
48621232|NCT05426460|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation active (2.0 mA) (tDCS) will be used to temporarily increase cortical excitability of the dorsolateral prefrontal cortex (dlPFC) in healthy daily smokers. Participants assigned to active tDCS conditions will receive active (2.0 mA) tDCS, with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. tDCS will be administered the first 20 minutes of each of the five 30 minute AAT training sessions.
48621233|NCT05426460|BEHAVIORAL|AC|During Active Control (AC) participants press a button on the left of right of the joystick to indicate the position the picture on a screen. Position of pictures will be balanced across the 4 blocks of 24 pictures, taking 30 minutes.
48621234|NCT05426460|DEVICE|Sham tDCS|Sham transcranial Direct Current Stimulation (0.1 mA) (sham tDCS) will be used as a control for active tDCS with anode electrode placement over the right dlPFC and cathode electrode placement over the left bicep. Sham tDCS will be administered during the first 20 minutes of each of the four blocks of 24 pictures, taking 30 minutes, across the 5 training sessions.
48621235|NCT03477981|OTHER|Alginate bread|White bread with 4% alginate (wet weight of dough) included into the bread.
48621236|NCT01675726|OTHER|questionary on quality of life|
48621237|NCT02318264|DEVICE|Kinesio Tape|Elastic tape placed over the skin
48451587|NCT06533345|BEHAVIORAL|Behavior Change Coaching|Done by Dr. Hollingsworth or students via consultations with participants. Participant's health behavior aspirations or target outcomes will be clarified, informed by the participant's interactions with other MERCI providers. Behaviors that move the participant towards their aspirations/outcomes will be explored to find target behaviors that the participant is motivated and able to do. Target behaviors and supporting habits will be designed into the participant's existing routine. The Fogg Behavior Model will be used 1) to find the participant's primary motivation for engaging in target behaviors and 2) to make target behaviors easier to do. Implementation intentions - When/then or If/then plans - will be used to form habits and promote behavior engagement. Adopting a growth mindset will also be discussed. Subsequent consultations will focus on troubleshooting, iterative improvements, and incorporation of new aspirations/outcomes, target behaviors, and supporting habits.
48621238|NCT03181997|DEVICE|Native aortic valve|Native valve, with any transcatheter heart valve type
48621239|NCT03181997|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
48621240|NCT05900154|BIOLOGICAL|RSVpreF 120 µg|RSVpreF standard dose level
48621241|NCT05900154|BIOLOGICAL|RSVpreF 60 µg|RSVpreF low dose level
48621242|NCT02453022|DRUG|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
48621243|NCT02453022|DRUG|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
48621244|NCT02453022|DRUG|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
48621245|NCT05250869|DIAGNOSTIC_TEST|HPLC/MS|Quantification of MTX and its metabolites by HPLC/MS under various preanalytical conditions
48621246|NCT02819817|DRUG|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
48621247|NCT02819817|OTHER|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
48621248|NCT05884450|OTHER|Acupressure|Acupressure is an integrated method of applying physical pressure to acupuncture points on the body surface with hands, elbows or various tools. With good counseling, patients can apply this method, which is non-invasive, easy to apply and safe, on their own.
48621249|NCT02896023|DRUG|human menopausal gonadotropin|Induction of ovulation followed by ICSI
48621250|NCT01148732|PROCEDURE|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
48621251|NCT04558242|DEVICE|Genix|Low Level Light (LEDs)
48621252|NCT04558242|DEVICE|Sham|Incandescent Bulbs Colored Red
48621253|NCT01703156|PROCEDURE|Stress Test|
48621254|NCT01703156|PROCEDURE|No Stress Test|
48621255|NCT01895842|DRUG|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
48621256|NCT06392087|DRUG|Methoxyflurane|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
48637431|NCT04566510|OTHER|long lasting insecticidal nets with deltamethrin + piperonyl butoxide (PBO LLIN, PermaNet 3.0))|Next-generation bed net combining an insecticide with a synergist
48621257|NCT06392087|OTHER|Standard Care|Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
48621258|NCT01303419|DEVICE|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
48621259|NCT01303419|DEVICE|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
48621260|NCT05817604|RADIATION|SBRT|"Tumors ≤ 4cm: Single SBRT 26Gy dose or Multifraction SBRT dose 14Gyx3 fraction-squeme.~Tumors ≥ 4cm: Multifraction SBRT dose 14Gyx3 or 9Gyx5 fraction-squeme."
48621261|NCT01543191|DRUG|PUR118|low dose and high dose for 3 doses, BID
48451588|NCT06533345|BEHAVIORAL|Nutrition|Nutrition: The nutrition intervention will be conducted as a 12-week protocol with assessment points at baseline, 1 month, and 3 months. Following consent, eligible participants will work through a self-taught educational module detailing the anti-inflammatory dietary program. Once the module is completed, participants will be scheduled for one-on-one counseling sessions with a Registered Dietitian or a supervised Dietetic Intern or Medical Student on the research team to receive personalized guidance on implementation of the dietary intervention. A dietary recall will be conducted via the automated self-administered dietary assessment tool (ASA24®), which takes about 20 minutes to complete. This survey will be conducted on two non-consecutive days at each timepoint (baseline, 1 month, and 3 months).
48621262|NCT06022575|PROCEDURE|Telehealth integrated care|Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
48621263|NCT06022575|PROCEDURE|Conventional health care|Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
48621264|NCT04820504|DEVICE|Augmented Infant Resuscitator (AIR)|Device provides visual feedback related to air leak, obstruction, hyperventilation, hypoventilation, and harsh breaths
48451589|NCT06533345|OTHER|Autonomic Recalibration|Participant will be outfitted with the Empatica wrist sensor. An initial history to rule out pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance. The pattern of sympathetic dominance is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. Day 2 is the same until the initial history and r/o. Here, the history is from the previous day, asking about perception of pain, sleep, digestion, or other pertinent issues brought up on the first visit. Treatment proceeds same as Day 1. Any emotional tags to trigger points are identified and acknowledged. Subjects may be scheduled for follow-up visits if their pain persists.
48451590|NCT06533345|PROCEDURE|Dry Needling|An initial history to document a chief complaint relevant to pain is conducted and to identify and potential contraindications (infection of overlying skin, patient on anticoagulation drugs, 1st trimester of pregnancy, etc.) A physical exam is performed to identify the trigger points causing pain. The subject is educated about the risks/benefits/indications and alternative treatments. The subject is also educated about dry needling aftercare. The skin over the trigger points is cleaned with 70% isopropyl alcohol. The pertinent trigger points are treated with dry needling (95% of time), direct inhibition (2 - 3% of time) or injection of 1% lidocaine in a fan-like fashion (1 - 2 % of the time). Subject is assessed for any bleeding. An office note, including a procedure note, is documented in the subject's record. Subject is scheduled for additional follow-up meeting.
48451591|NCT06533345|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment: After inform and consent process, the subject will enter patient room and meet with Dr. Hayes, who will conduct a brief history of patient pain, injuries, and procedures. Subjects will be asked to wear, or change into, athletic shorts or a tank top or loose-fitting T-shirt to facilitate treatment. Subject will undergo a brief somatic dysfunction screen, which involves light tough and manipulation. Once Hayes has diagnosed potential dysfunctions, he will proceed with osteopathic manipulative treatment. Treatment will last anywhere from 15 minutes to 1 hour. At the end of the treatment, subjects will be scheduled for a follow-up visit.
48621265|NCT04820504|DEVICE|AIR device without feedback|Device provides no visual feedback to clinician but records data on ventilation effectiveness
48621266|NCT04021797|DEVICE|transcutaneous vagal nerve stimulation|The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
48621267|NCT05612321|DEVICE|Vacuum application|vacuum-assisted delivery
48621268|NCT02996786|DIETARY_SUPPLEMENT|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
48621269|NCT02996786|OTHER|Placebo|Consisting of corn starch and carboxymethyl cellulose
48621270|NCT00677287|BIOLOGICAL|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
48621271|NCT01537588|OTHER|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
48621272|NCT01537588|OTHER|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
48621273|NCT00532467|DRUG|SRX251|
48621274|NCT05124548|DIAGNOSTIC_TEST|Sleep diagnostics|On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.
48621275|NCT02204462|DRUG|FBnTP|A PET imaging radiotracer
48621276|NCT02692079|PROCEDURE|T-PRF|Flap Surgery
48621277|NCT02692079|PROCEDURE|Allograft|Flap Surgery
47928253|NCT01009840|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
47928254|NCT00528541|BIOLOGICAL|botulinum toxin type A|200 Units at Visit 1 (Day 1)
47928255|NCT00528541|BIOLOGICAL|botulinum toxin type A|750 Units at Visit 1 (Day 1)
47928256|NCT02211911|DRUG|Bisacodyl|
48621278|NCT00528151|DRUG|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
48621279|NCT03220789|PROCEDURE|Drilling at low speed|
48621280|NCT03220789|PROCEDURE|Drilling at conventional or high speed|
48621281|NCT00580840|DRUG|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
48621282|NCT00580840|DRUG|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
48621283|NCT00580840|OTHER|Placebo|placebo (saline) administered as two injections every 2 weeks
48621284|NCT01040819|DRUG|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin \>162 mg/d, steroids and prostaglandin analogs will be prohibited.
48621285|NCT00283959|DRUG|migalastat HCl|
48621286|NCT02341079|DRUG|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
48621287|NCT02341079|DRUG|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
47928257|NCT02211911|DRUG|Sodium picosulfate|
47928258|NCT06189235|OTHER|Biofeedback training|The target of additional biofeedback training is to provide hints which are related to the essential aspects during hand therapy such as the stress on the tissue and the distance of tendon gliding.
48621288|NCT03834012|DRUG|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 µg HFA per day
48621289|NCT03834012|DRUG|Placebo|Intervention: Drug: placebo
47928259|NCT01673152|DIETARY_SUPPLEMENT|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
48621290|NCT03834012|DRUG|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg HFA per day
47928260|NCT01673152|DIETARY_SUPPLEMENT|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
48451592|NCT06533345|BEHAVIORAL|Counseling Psychology|Psychoeducation Workshop and Counseling: The psychoeducational group intervention will be done according to the standardized Empowered Relief (Darnall et al., 2024) protocol. Empowered Relief is a single-session, 2-hour group workshop (online or in person) that teaches participants pain neuroscience education, mindfulness principles, and cognitive-behavioral skills. During the program, participants will complete a personalized plan to work toward pain relief. This program requires a certified instructor; Marilyn Cornish (Co-I), a licensed psychologist, is certified. After completion, participants can attend up to 4 individual counseling sessions with a counseling psychology doctoral student (supervised by Marilyn Cornish). Sessions will be approximately 50-60 minutes and will occur every other week. Specific in-session interventions will be tailored to the participant's unique needs but will focus on participants' pain relief plan and overall psychological wellbeing of participants.
48451593|NCT06533345|OTHER|Multiple Treatments|"Subjects receiving multiple treatment interventions over the same period of time.~Example: A subject joins the Osteopathic Manipulative Treatment group and meets with Dr. Hayes for treatment visits. At the same time, they are meeting with Dr. Kirby in a separate visit (or at the same time, if scheduling allows) to discuss Nutrition. Any subjects who were in multiple/overlapping treatment groups will fit this description."
48451594|NCT04574219|OTHER|Use of Facetime with child and parents during induction|Families will be able to use Facetime with their child when the child is taken to the operating room
48451595|NCT00627016|DRUG|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
48451596|NCT00627016|DRUG|Placebo|1 capsule, orally, once daily for 4 weeks
48621291|NCT03834012|DRUG|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day
48098261|NCT05464212|PROCEDURE|USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency|With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
48451597|NCT05844605|PROCEDURE|Non-invasive neuromodulation (TMS and/or tDCS)|Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
48621292|NCT05112120|DRUG|Olumiant|Olumiant (4mg) will be administered in line with standard of care guidance.
48621293|NCT04760626|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
48621294|NCT04760626|DRUG|Insulin Glargine 100U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
48621295|NCT04760626|DRUG|Insulin Degludec|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
48621296|NCT04760626|DRUG|Insulin Glargine 300U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
48621297|NCT04032938|PROCEDURE|extracorporeal circulation during cardiac surgery|We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
48621298|NCT02110693|OTHER|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
48621299|NCT01081990|DRUG|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
48621300|NCT03819127|DRUG|Vildagliptin 50 MG Oral Tablet|
48621301|NCT03819127|DRUG|Metformin Pill|
48621302|NCT04742218|DRUG|K-877|K-877 Tablet
48451598|NCT02722239|DRUG|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
48451599|NCT02722239|DRUG|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
48451600|NCT02722239|DRUG|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
48451601|NCT06258681|OTHER|Incentive spirometer|The incentive spirometry group will continue training with Volumetric Triflo. It is asked to exhale at first and then hold their breath for at least 3 seconds after taking as deep a breath as possible.
48451602|NCT06258681|OTHER|Individualized respiratory training group|Participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle.
48451603|NCT02343926|DRUG|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
48451604|NCT02343926|DRUG|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
47928261|NCT03814421|DRUG|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
48451605|NCT02343926|DRUG|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
48451606|NCT05674513|DRUG|Ulipristal acetate|Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
48451607|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection|IF Weight \> 60kg，150ug, H. Administer the drug once every 14 days for 64 weeks；IF Weight \>≤60kg，100ug, H. Administer the drug once every 14 days for 64 weeks
48451608|NCT06561594|DRUG|recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo|0.5ml, H. Administer the drug once every 14 days for 64 weeks
48451609|NCT05234463|OTHER|IgAN patients|Adult patients Histologically proven diagnosis of IgA nephropathy Primary and secondary forms of the disease With or without kidney transplantation history Regardless of kidney/graft function Patients followed in the Nephrology Department of Strasbourg University Hospital.
48451610|NCT04962945|PROCEDURE|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
48451611|NCT04962945|PROCEDURE|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
48451612|NCT05598320|DRUG|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
48451613|NCT05598320|DRUG|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
48451614|NCT05629728|BEHAVIORAL|Tai Chi exercise|Sun-style Tai Chi (21 forms)
48451615|NCT03703154|DRUG|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
48451616|NCT03703154|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
48451617|NCT03831256|DIAGNOSTIC_TEST|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
48451618|NCT03831256|DIAGNOSTIC_TEST|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
48451619|NCT03831256|DIAGNOSTIC_TEST|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
48451620|NCT03831256|DIAGNOSTIC_TEST|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
48451621|NCT05351957|PROCEDURE|Dry needling|Only dry needling of the lower limbs will performed in all patients with acupunture needling
47928262|NCT04308031|DRUG|Ivabradine 5 mg [Corlanor]|Starting dose: Ivabradine 2.5mg twice daily (BID) Max Dose: Ivabradine 7.5 mg twice daily (BID)
48451622|NCT02561845|DRUG|rosuvastatin|5mg, 10mg, 20mg
48098262|NCT05975554|DRUG|Interleukin-2 [IL-2]|5 sequential days of treatment (1.5MIU/day subcutaneously)
48098263|NCT05975554|PROCEDURE|Standard care - Carotid Endarterectomy|Standard care for patients with carotid stenosis undergoing carotid endarterectomy
48451623|NCT03199963|DRUG|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
48451624|NCT03199963|DRUG|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
48451625|NCT01798719|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
48451626|NCT01798719|BEHAVIORAL|General Advice|Only general advice about diet
48451627|NCT03948503|PROCEDURE|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
48451628|NCT03948503|PROCEDURE|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
48451629|NCT00003470|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48451630|NCT01788800|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
48621303|NCT02078037|DEVICE|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
48621304|NCT02078037|OTHER|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
48451631|NCT00525213|DRUG|Rob 803|two capsules per day during 12 weeks
48451632|NCT00525213|DRUG|Placebo|two capsules per day during 12 weeks
48451633|NCT00721435|PROCEDURE|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis \& ultrasound imaging for scanning masses or healthy breast tissue
48451634|NCT06558942|DEVICE|incisional negative pressure wound technology|Negative pressure device used directly on closed or sutured incisions
48451635|NCT06623643|DIAGNOSTIC_TEST|The investigation of melatonin and cortisol levels in the saliva|In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.
48451636|NCT00465621|DRUG|Xalatan|
48451637|NCT06308861|DRUG|Single administration Amg dose Group|Orally, Amg tablet single administration
48451638|NCT06308861|DRUG|Single administration Bmg dose Group|Orally, Bmg tablet single administration
48451639|NCT06308861|DRUG|Single administration Cmg dose Group|Orally, Cmg tablet single administration
48451640|NCT06308861|DRUG|Single administration Dmg dose Group|Orally, Dmg tablet single administration
48451641|NCT06308861|DRUG|Single administration Emg dose Group|Orally, Emg tablet single administration
48451642|NCT06308861|DRUG|Single administration Amg dose Group-Placebo|Orally, Placebo Amg tablet, single administration
48451643|NCT06308861|DRUG|Single administration Bmg dose Group-Placebo|Orally, Placebo Bmg tablet, single administration
48451644|NCT06308861|DRUG|Single administration Cmg dose Group-Placebo|Orally, Placebo Cmg tablet, single administration
48451645|NCT06308861|DRUG|Single administration Dmg dose Group-Placebo|Orally, Placebo Dmg tablet, single administration
48451646|NCT06308861|DRUG|Single administration Emg dose Group-Placebo|Orally, Placebo Emg tablet, single administration
48451647|NCT06308861|DRUG|Multiple administration Amg dose group|Orally, Amg 1 tablet, once a day for 3 days, multiple administration
48451648|NCT06308861|DRUG|Multiple administration Bmg dose group|Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
48451649|NCT06308861|DRUG|Multiple administration Cmg dose group|Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
48451650|NCT06308861|DRUG|Multiple administration Dmg dose group|Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
47928263|NCT04308031|DRUG|Digoxin 0.25 mg|Starting dose: 0.125mg once daily (QD) in estimated Glomerular filtration rate(eGFR)\>60， 0.125mg once every other day (QOD) in estimated Glomerular filtration rate(eGFR)\<60 Max dose: 0.25 once daily (QD)
47928264|NCT02251548|DRUG|Ibrutinib|Oral BTK inhibitor
47928265|NCT02251548|DRUG|Fludarabine|IV purine analogue chemotherapy agent
47928266|NCT02251548|DRUG|Cyclophosphamide|IV alkylator chemotherapy agent
47928267|NCT02251548|DRUG|Rituximab|IV anti-CD20 monoclonal antibody
48451651|NCT06308861|DRUG|Multiple administration Emg dose group|Orally, Emg 1 tablet, once a day for 3 days, multiple administration
48451652|NCT06308861|DRUG|Multiple administration Amg dose group - Placebo|Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
48451653|NCT06308861|DRUG|Multiple administration Bmg dose group - Placebo|Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
48451654|NCT06308861|DRUG|Multiple administration Cmg dose group - Placebo|Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
48451655|NCT06308861|DRUG|Multiple administration Dmg dose group - Placebo|Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
48451656|NCT06308861|DRUG|Multiple administration Emg dose group - Placebo|Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
48451657|NCT03480230|DRUG|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
48451658|NCT02012335|DRUG|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
48451659|NCT00819169|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
48451660|NCT00819169|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
48451661|NCT06429592|OTHER|education|nursing care practice
48451662|NCT01527890|DRUG|Fentanyl|intravenous patient-controlled analgesia
48451663|NCT01601158|BIOLOGICAL|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
48451664|NCT01601158|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
48451665|NCT06561009|DRUG|Anti-BAFFR CART|Anti-BAFFR CART
48451666|NCT06487273|DEVICE|SIMEOX|Use of the CE-marked SIMEOX medical device. No specific limitation of the number of use but recommendation to use it daily (and more if needed).
48451667|NCT06487273|OTHER|Remote Physiotherapy|Remote Physiotherapy with physiotherapists, once a month for the first 3 months and once every 3 months after
48621305|NCT06208332|BEHAVIORAL|Photo-Narrative|Photo-Narratives include 1-3 photos of the pediatric patient and their family to tell a story about palliative care topics that are shared with the child's clinicians.
48621306|NCT03434262|DRUG|Gemcitabine|Given intravenously (IV).
48621307|NCT03434262|DRUG|ribociclib|Given orally (PO).
48451668|NCT05870332|DEVICE|GI Genius (GIG)|"GIG is an artificial intelligence unit that assists human colonoscopist in real-time to detect polyps during colonoscopy.~Four months collection period prior to activating GIG, then four months with GIG, and Four months afterwards without GIG"
48621308|NCT03434262|DRUG|sonidegib|Given PO.
48621309|NCT03434262|DRUG|trametinib|Given PO.
48621310|NCT03434262|BIOLOGICAL|filgrastim|Given subcutaneously (SQ).
48621311|NCT02479282|PROCEDURE|natural cesarean section|
48621312|NCT02479282|PROCEDURE|traditional cesarean section|
48621313|NCT05213130|OTHER|Information|A reminder to inform donors that their blood has saved patient's life in a questionnaire.
48621314|NCT03197129|OTHER|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
48621315|NCT05869747|BEHAVIORAL|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
48621316|NCT05869747|BEHAVIORAL|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
48621317|NCT05869747|BEHAVIORAL|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
48621318|NCT05869747|BEHAVIORAL|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
48098264|NCT05464134|RADIATION|x-ray|plain radiographs of lower limb anteroposterior and lateral views , lumbar spine plain radiographs (anteroposterior, lateral, lateral in flexion and lateral in extension views )
48451669|NCT03031821|DRUG|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
48621319|NCT05869747|BEHAVIORAL|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
48621320|NCT05029947|PROCEDURE|Microsurgical Clipping of Unruptured Intracranial Aneurysm|Microsurgical Clipping of Unruptured Intracranial Aneurysm
48621321|NCT06233656|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing.
48621322|NCT02757014|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - R84-087)
48621323|NCT00209482|DRUG|glucophage XR|
48621324|NCT05229900|DRUG|SGN-ALPV|Given into the vein (IV; intravenously)
48621325|NCT05945407|COMBINATION_PRODUCT|Indication-extended Fertility-sparing Therapy|"Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions."
48621326|NCT05062473|BEHAVIORAL|Lifestyle Modification Webinars Focused on Hypertension Control|Participation in a 12-week health education telemedicine curriculum
48621327|NCT03588520|DIAGNOSTIC_TEST|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
48621328|NCT02891967|OTHER|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
48621329|NCT02891967|OTHER|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
48451670|NCT03031821|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
48621330|NCT03661775|DRUG|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
48621331|NCT02127853|DRUG|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
48451671|NCT06479096|OTHER|Brush / Espresso Mild Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
48451672|NCT06479096|OTHER|Brush / Espresso Intense Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
48451673|NCT06479096|OTHER|Brush / Fresh Breath Oral Rinse|Subjects will brush and rinse with their assigned mouthwash twice daily.
48451674|NCT06479096|OTHER|Brush / Hydroalcohol|Subjects will brush and rinse with their assigned mouthwash twice daily.
48451675|NCT05418647|OTHER|high dialysate Na|high dialysate sodium (Na = 141 mmol/L) for 8 weeks
48451676|NCT05418647|OTHER|low dialysate Na|low dialysate sodium (Na = 136 mmol/L) for 8 weeks
48451677|NCT05439252|BEHAVIORAL|Exercise Snacking|Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are sit-to-stand from a chair, seated overhead arm raises, march on the spot, seated arm raises and shoulder touches, and seated calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
48621332|NCT02127853|DRUG|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
48621333|NCT04697706|DIETARY_SUPPLEMENT|Moonstone|"Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
48621334|NCT04697706|OTHER|Water|"Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period."
48451678|NCT04476511|DRUG|Cholecalciferol|tablet containing 30.000IU cholecalciferol
48451679|NCT01368991|DEVICE|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
48621335|NCT02212067|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
48621336|NCT02212067|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
48621337|NCT04455932|DIAGNOSTIC_TEST|Abbreviated non-contrast MRI of the liver|every 6 months
48621338|NCT04455932|DIAGNOSTIC_TEST|Ultrasound surveillance|every 6 months
48621339|NCT04455932|DIAGNOSTIC_TEST|Multiphase contrast-enhanced liver MRI|screening
48621340|NCT03823157|BEHAVIORAL|Tai Chi|mind-body exercise
48621341|NCT05420740|DEVICE|Aerobika OPEP|Subjects given Aerobika OEP to assess changes in small airway disease parameter , CAT Score , 6 minute walking test and exacerbation
48621342|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
48621343|NCT02936765|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
48621344|NCT01046942|DRUG|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
48621345|NCT01046942|DRUG|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
48621346|NCT04573270|BIOLOGICAL|PrimePro|Intravenous Injection
48621347|NCT04573270|OTHER|Placebo|Intravenous Injection
48621348|NCT05046704|DEVICE|peripartum transperineal Ultrasound|The anovaginal distance (AVD) will be measured by transperineal ultrasound ,The distance between the anal edge of the internal sphincter and the probe will then be measured in millimeters The ultrasound assessment of the anal sphincters at rest and during contraction will be performed postnatally using a dynamic 2-dimensional transperineal ultrasound with the patient in a supine position, an empty bladder.
48621349|NCT04553315|PROCEDURE|chest expansion exercises|Chest mobility exercises with Incentive spirometer and segmental breathing exercise ) and breath stacking technique e.
48621350|NCT01837303|PROCEDURE|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
48451680|NCT01368991|PROCEDURE|Conventional closure|conventional closure, no kryptonite applied
48451681|NCT02816996|PROCEDURE|Hand-holding|Subject will have their hand held.
48451682|NCT02816996|PROCEDURE|Stress Ball|Subject will be given a stress ball to hold.
48451683|NCT04306952|BEHAVIORAL|Brief MBI|The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
48621351|NCT00102921|DRUG|CCX282-B|
48621352|NCT04045171|DRUG|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
47928268|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 10 mg|Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (10 mg QD) for 17 weeks
47928269|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 30 mg|Delamanid (300 mg once daily \[QD\]) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (30 mg QD) for 17 weeks
48451684|NCT04306952|BEHAVIORAL|Standard MBI|The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
48621353|NCT03047252|DEVICE|Home-based rehabilitation with a digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises"
48451685|NCT04306952|BEHAVIORAL|Extended MBI|"The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours)."
48621354|NCT03047252|OTHER|Conventional Home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application"
48621355|NCT02452411|BEHAVIORAL|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
48621356|NCT04139525|BIOLOGICAL|unfractionated heparin|A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.
48621357|NCT04139525|BIOLOGICAL|8% trisodium citrate|8% trisodium citrate in the dose of 150 ml/h.
48621358|NCT03625024|BEHAVIORAL|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
48621359|NCT02814019|DRUG|Idebenone 150 mg film-coated tablets|
48451686|NCT04509167|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 8 weeks.
48451687|NCT01169558|DRUG|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
48621360|NCT02814019|DRUG|placebo|
48451688|NCT01169558|DRUG|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
48451689|NCT02143245|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial biopsy is a procedure using a guided needle, where 6 to 8 small tissue samples with be extracted from the shoulder using an x-ray guided needle.
48451690|NCT02143245|DIAGNOSTIC_TEST|Open Tissue Biopsy|During the standard of care revision surgery, 6 to 8 small tissue samples will be taken in order to test for infection. This is standard of care treatment. As part of this study, an additional 1 to 2 samples of tissue would be taken in order to develop a test to determine more precisely what type of infection there may be.
48451691|NCT04345653|DRUG|Hydroxychloroquine Sulfate (HCQ)|Open-label, consecutive at-risk subjects allocation with chemoprophylaxis with HCQ.
48451692|NCT02833181|DEVICE|BIS monitor|Monitoring circadian variation of EEG
48451693|NCT06627569|BEHAVIORAL|Exercise|12 weeks of aerobic exercise, with 4 sessions per week.
48451694|NCT00320034|DRUG|R-albuterol, S-albuterol|
48451695|NCT01908556|DRUG|Letrozole|
48621361|NCT05461495|BEHAVIORAL|Treatment Group|"This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in Chinese and Korean American dementia caregivers has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is participation in an on-line chat group to provide peer support. The fourth component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
48621362|NCT04695678|DIAGNOSTIC_TEST|COVID-19 nasal/pharyngeal swab|each study participant receives a nasal/pharyngeal swab
48637432|NCT04566510|BEHAVIORAL|Social behaviour change communication|SBCC activities will use digital and other platforms, similar to those used for the COVID-19 response, including the following: (1) LLIN launch on television and radio; (2) regional advocacy meetings on Zoom; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about COVID-19, malaria, and use, care, repair and repurposing of LLINs.
48637433|NCT01881633|DRUG|ISU302|
48637434|NCT01881633|DRUG|Placebo|
47928270|NCT05221502|DRUG|Delamanid + Bedaquiline + OPC-167832 90 mg|Delamanid (300 mg QD) + Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks
47928271|NCT05221502|DRUG|RHEZ|RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)
47928272|NCT00280111|BIOLOGICAL|116E AGMK|Single dose of 116E 10\^5 FFu
47928273|NCT00280111|DRUG|I321|Single dose of I321 10\^5 FFu
47928274|NCT00280111|DRUG|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
47928275|NCT02085642|OTHER|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
47928276|NCT02085642|OTHER|Sham needle|Retractable needle with no skin puncture
47928277|NCT01001299|DRUG|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
48451696|NCT04325321|OTHER|Stress reactivity test|"The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP.~Resting Baseline (BL - 10 min). The participant is instructed to rest quietly.~Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked.~Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP."
48451697|NCT03597256|DEVICE|Restylane Defyne|Intradermal injection
48451698|NCT00222625|DRUG|rFVIIa + (vit K in AO patients)|
48451699|NCT00222625|DRUG|FFP or aPCC+ vit K in AO treated patients|
48451700|NCT00446966|DRUG|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
48451701|NCT00002939|DRUG|irinotecan hydrochloride|
48451702|NCT00002939|DRUG|paclitaxel|
48451703|NCT06031883|DRUG|Ketamine|Total intravenous anesthesia in craniotomy
48451704|NCT06627868|DIETARY_SUPPLEMENT|NAD+ precursor|NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)
48451705|NCT06627868|OTHER|Placebo|Oral placebo daily intake for 6 months
48451706|NCT04790526|OTHER|Eccentric Exercises Dose|Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
48451707|NCT06472167|BEHAVIORAL|Breathing exercises|Breathing exercises as diaphragmatic breathing exercises and pursued lip breathing and incentive spirometry
48451708|NCT04723134|COMBINATION_PRODUCT|Folinic acid calcium salt|Folinic acid (2.5%) by combination with Placebo
48451709|NCT05977686|DEVICE|Masimo Root Radical 7 Pulse CO-Oximeter|The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
48451710|NCT05977686|DEVICE|HemoCue Hb 801|The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
48451711|NCT06275321|OTHER|Synchronous-supervised online home-based group|An online exercise program combining endurance and strength training
48451712|NCT06275321|OTHER|Exercise recommendation group|General recommendation about physical exercise. No supervised
48451713|NCT03746795|DEVICE|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
48451714|NCT03746795|DEVICE|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
48451715|NCT06628115|DEVICE|cerament V or G|Cerament V or G implantation into forefoot or mid foot bone, and 7-10 days of oral antibiotics.
47928278|NCT01001299|DRUG|RO5185426|960 mg orally twice daily
48451716|NCT06547177|OTHER|fruit juice|During labor, one group will follow the routine while the water group will only take water and fruit juice group will take water and fruit juice.
48451717|NCT00027053|DRUG|Trazodone|50 to 150 mg qhs
48451718|NCT00027053|DRUG|Placebo|
48621363|NCT05428618|OTHER|e-BariS app group|"During the discharge process, informed consent will be obtained from the patients and the measurement tools will be filled and the mobile application will be downloaded to their phones. The intervention group will have access to all the content of the mobile application, which includes the Self-Monitoring Module and the Patient Education Module. Passwords will be defined so that patients in the intervention group can access the Patient Education Module. Information on the introduction and use of the application will be presented to the patient by the researcher.~The patients will be followed for six months within the scope of the project. In addition, reminder notifications will be sent to patients via the mobile application in line with the areas that patients can access. At one, three, and six months after surgery, he will complete other assessment scales during outpatient follow-up. For patients providing remote control, the scale will be sent online."
48621364|NCT05428618|OTHER|Self-Monitoring Group|"Patients in the control group will only have access to the Self-Monitoring Module in the application. Other fields will be encrypted. Patients in the control group will also be informed about the area they can access. Patients in the control group will only have access to the self-monitoring section. One, three, and six months after surgery, she will complete other assessment scales during her outpatient follow-up. Scales will be sent online for patients providing remote control. After the project is completed, all content will be opened to the control group patients."
47928279|NCT00146055|PROCEDURE|Reduced intensity conditioning with allogeneic transplant|
47928280|NCT03523923|BEHAVIORAL|Collaborative Care|"Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~* Care Management Weekly monitoring of response to treatment using standardized measures.~* Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~* Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals."
47928281|NCT05631678|DRUG|Rifampicin; ASK120067|Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
47928282|NCT05631678|DRUG|ASK120067;itraconazole|Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
47928283|NCT02229656|RADIATION|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
48621365|NCT03716427|DRUG|CT1812|
48621366|NCT03716427|DRUG|tolbutamide|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
48451719|NCT04784338|BEHAVIORAL|Virtual shared medical visit|a shared medical visit done by zoom in a group, 1.5 hours
48451720|NCT04784338|BEHAVIORAL|Nutritional classes|A cooking class done by the teaching kitchen demonstrating cooking skills
48451721|NCT01602939|DRUG|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
48621367|NCT03716427|DRUG|dextromethorphan|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
48621368|NCT03716427|DRUG|Omeprazole|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
48621369|NCT03716427|DRUG|midazolam|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
48621370|NCT05415007|BEHAVIORAL|GOLD Program|Participant will receive a 2-hour interventional session
48621371|NCT05415007|BEHAVIORAL|Treatment as usual (TAU)|Participant will receive treatment-As-Usual which consist of information about diagnosis routinely-disseminated by personnel and providers.
48621372|NCT03423472|BEHAVIORAL|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake|Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children \< 2y; especially diet diversity and vitamin A intake.
48621373|NCT03423472|BEHAVIORAL|Healthy Baby Toolkit|The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.
48621374|NCT03423472|BEHAVIORAL|Standart of care|Government standard of care for nutrition education through the Health Development Army
48621375|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
48621376|NCT00952913|DRUG|Bosutinib|4 x 100-mg oral tablets, single dose
48621377|NCT00952913|DRUG|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
48621378|NCT03260400|DEVICE|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
48451722|NCT04948905|OTHER|Evaluation using the Self-Defining Memory Questionnaire|"This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number)."
48451723|NCT01462279|DRUG|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
48621379|NCT05173636|OTHER|cervical lateral glide|A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.
48621380|NCT05173636|OTHER|thoracic mobilization technique|Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.
48621381|NCT06134388|DRUG|Sulfasalazine|Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
48621382|NCT00870727|DRUG|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
48621383|NCT00870727|DRUG|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
48621384|NCT01022580|DRUG|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
48621385|NCT01022580|DRUG|Sham (No Treatment)|Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
48621386|NCT05505552|DIETARY_SUPPLEMENT|Vitamin K|1 mg/day phylloquinone (vitamin K1)
48621387|NCT05505552|DIETARY_SUPPLEMENT|Placebo|Placebo capsule once daily
48621388|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
48621389|NCT03191968|BEHAVIORAL|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
48621390|NCT05496764|DRUG|Dexamethasone|we planned to inject steroid( 4 mg of dexamethasone acetate combined with 1% lidocaine into the carpal tunnels) directly into the carpal tunnel in group A
48621391|NCT05496764|DRUG|Glucose Injection|inject10 ml glucose 5% into the carpal tunnel in group B
48621392|NCT06173648|DEVICE|Laser and ICG solution.|Intervention consists of addition of a combined laser absorption solution and infrared diode laser. The solution is introduced into the prepared pulp chamber and root canals, allowed to dwell for 1 minute, followed by exposure to the laser energy delivered via a fiber optic introduced into the root canal, and while activating the laser at 2.5 watts of optical output with a pulse duration of 100 msec and a pulse gap of 300 msec, the solution and residual structures in the root and pulp chamber are exposure over the course of 30 seconds, moving and relocating the fiber tip throughout the canals and chamber during that time. The laser is halted and a wait time of 30 seconds is applied. The laser fiber is then reintroduced and another 30 second exposure, repeating the same settings and technique.
48621393|NCT03846791|OTHER|Observational Study Post MAKO Robotic Surgery|To assess clinical outcomes and surgery related resource use in the year post surgery for patients undergoing hip replacement surgery using the MAKO robot
48621394|NCT01510756|DRUG|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
48621395|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine|NAC capsules
47928284|NCT02229656|DRUG|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
47928285|NCT01278927|BEHAVIORAL|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
48451724|NCT00429416|DRUG|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
48621396|NCT05986318|DRUG|Dexamethasone Oral|Dexamethasone tablets
48621397|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine Placebo|Matching placebo for NAC capsules
48621398|NCT05986318|DRUG|Dexamethasone Placebo|Matching placebo for dexamethasone tablets
48621399|NCT05986318|RADIATION|Radiation Therapy|All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.
48621400|NCT01405573|OTHER|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
48621401|NCT01405573|DRUG|sorafenib|400 mg twice a day
48621402|NCT01663376|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 \~3x10e8 cells
48621403|NCT01285089|DRUG|activated recombinant human factor VII|Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
48621404|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 5 mL|A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
48621405|NCT03310047|DRUG|Infusion, Lidocaine, 0.5%, 10 mL|A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
48621406|NCT01949896|OTHER|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
48621407|NCT01949896|OTHER|Control group: continue feedings|Feedings will be continued in this group.
47928286|NCT01278927|BEHAVIORAL|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
48451725|NCT00429416|DRUG|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
48451726|NCT00429416|DRUG|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
48451727|NCT00429416|DRUG|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
48451728|NCT00429416|DRUG|Tacrolimus|Tacrolimus given before and after HSCT infusion
48451729|NCT00429416|DRUG|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
48451730|NCT00429416|BIOLOGICAL|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
48451731|NCT00429416|PROCEDURE|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
48451732|NCT00388531|DRUG|Depocyte®|Depocyte® is a cytostatic drug
48451733|NCT06354894|DEVICE|Proximal humeral fracture fixation|percutaneous pinning VS plate and screws
48098265|NCT05581160|DIAGNOSTIC_TEST|Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)|"Proposal of the study to all eligible adult patients coming for pre-exposure prophylaxis (PrEP) consultations from the Infectious Diseases Department of Saint-Antoine and Tenon Hospitals (with delivery of a patient's information and signing an informed consent form).~During each visit (D0, M3, M6, M9, M12 and intermediate visits), patients will be asked to:~* Respond to a questionnaire on their history of taking antibiotics, STIs, their foreign travels, their consumption of tobacco, drugs, alcohol and their sexual practices.~* Perform the following additional samples at each visit, including the intermediate: rectal and throat swabs, urine sample and swab from the lesions in the case of ulceration presence due to STIs.~The diagnosis of STIs (NG and MG) will be carried out using 2 techniques: the reference technique and the Next-Generation-Sequencing (NGS) technique.~A serum sample will be collected during routine care. All samples will be stored after the analysis under -80° C."
48098266|NCT03451643|PROCEDURE|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
48098267|NCT01719536|DRUG|Icotinib|Icotinib: 125 mg is administered orally three times per day.
48098268|NCT01719536|DRUG|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
48098269|NCT00218556|BEHAVIORAL|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
48098270|NCT03298464|BIOLOGICAL|NGM313|Subcutaneous injection
48098271|NCT03298464|DRUG|Pioglitazone|White to off-white round tablet
48451734|NCT04709081|DRUG|ACH-0145228|ACH-0145228 was dosed as 2 x 60 milligram (mg) (Part 1) or 1 x 40 mg (Part 2) powder in capsules.
48451735|NCT04709081|DRUG|Midazolam|Midazolam was dosed at 2 mg (1 milliliter \[mL\] of a 2 mg/mL syrup).
48451736|NCT04709081|DRUG|Digoxin|Digoxin was dosed as Lanoxin (or generic equivalent) at 1 x 0.25 mg tablet.
48451737|NCT04709081|DRUG|Itraconazole|Itraconazole was dosed as Sporanox (or generic equivalent) at 200 mg (20 mL of a 10 mg/mL oral solution).
48451738|NCT04786496|BEHAVIORAL|ITP+SA Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults. It includes two components: a self-affirmation (SA) activity and an ITP intervention. The SA component includes a list of values so that they could choose the three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component resembled the intervention developed by David S. Yeager and colleagues and it was adapted to first year university students. It consisted of three parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled pathways in the brain that have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by second year university students to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative (self-persuasive writing exercise).
48451739|NCT04786496|BEHAVIORAL|ITP Wise intervention|Intervention designed to promote well-being and resilience in late adolescents and young adults based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes the ITP component described above for the ITP+SA Wise intervention.
48621408|NCT04419259|DRUG|AMG 334|30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
48621409|NCT05732389|DRUG|Nivolumab|Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
48621410|NCT05732389|DRUG|Ipilimumab|Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
48621411|NCT05331898|BEHAVIORAL|Education|the education given increased the rational drug use of the parents.
48621412|NCT03948490|DEVICE|ReMind iPad app|Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.
47928287|NCT01278927|BEHAVIORAL|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
48621413|NCT03948490|DEVICE|Healthy SMS texting|Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
48621414|NCT03948490|BEHAVIORAL|In-person cognitive rehabilitation|The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
48621415|NCT03948490|BEHAVIORAL|Telehealth cognitive rehabilitation|The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning
48621416|NCT02327481|PROCEDURE|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
47928288|NCT01278927|OTHER|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
47928289|NCT01809470|BEHAVIORAL|FIFA2013|Playing FIFA2013 for 1 hour
47928290|NCT01809470|BEHAVIORAL|Call of Duty|Playing Call of Duty for 1 hour
47928291|NCT01809470|BEHAVIORAL|Watching TV|Watching TV for 1 hour
47928292|NCT00568633|PROCEDURE|Allogeneic HSCT|Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and \< 7 x 10e8 CD3+ cells/kg.
47928293|NCT00568633|DRUG|Anti-thymocyte globulin (ATG)|1.5 mg/kg for 5 days by IV
48621417|NCT02327481|PROCEDURE|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
48621418|NCT02908230|BEHAVIORAL|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
47928294|NCT00568633|DRUG|Cyclosporine (CSP)|6.25 mg/kg twice daily oral
47928295|NCT00568633|DRUG|Mycophenolate mofetil (MMF)|15 mg/kg twice daily oral
47928296|NCT00568633|RADIATION|Total lymphoid irradiation (TLI)|80 cGy/fraction radiotherapy in 10 fractions.
47928297|NCT00568633|DRUG|Methylprednisolone sodium succinate|1.0 mg/kg for 5 days by IV
47928298|NCT00568633|DRUG|Best standard care|"Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation"
48098272|NCT04025905|BEHAVIORAL|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
48621419|NCT02908230|BEHAVIORAL|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
48098273|NCT04025905|BEHAVIORAL|Informations|informations about work environment, social environment, stress management, sleep management, treatments
48621420|NCT02908230|BEHAVIORAL|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
48621421|NCT00217230|BIOLOGICAL|CAIV-T|
48621422|NCT04226677|OTHER|aerobic exercise|Treadmill training is include warming, cooling and training phase according to rating of perceived exertion for participants.
48621423|NCT04226677|OTHER|Video based exercise|Exergame training include virtual reality games by xbox kinect.
48621424|NCT04226677|OTHER|Control group|first and last evaluations will be made
48621425|NCT01341470|DRUG|LY2495655|administered intravenously or subcutaneously
48621426|NCT01341470|DRUG|Placebo|administered intravenously or subcutaneously
48621427|NCT03477175|DRUG|E7080|Oral Administration.
47928299|NCT00594425|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
47928300|NCT01488344|DRUG|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
47928303|NCT01538784|DRUG|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A \& B were dosed alternately, at weekly intervals"
47928304|NCT02617485|DRUG|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
48621428|NCT03477175|DRUG|Comparator Drug|Per parent study.
48621429|NCT03477175|DRUG|Comparator Drug: Sorafenib|Per parent study.
48621430|NCT01587404|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)|Variable contact force as measured at the catheter tip within the left atrium
48621431|NCT03754543|OTHER|Labeled iron salt Fe54|Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
47928305|NCT02617485|DRUG|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
48279796|NCT06560359|DIETARY_SUPPLEMENT|F&V|The intervention includes the healthy breakfast plan (daily delivery of balanced breakfast containing at least one piece of fruits, vegetables and other regular diet) and fruit box plan (weekly delivery to home). The selection of fruits and vegetables will consider seasonal availability to ensure freshness and variety. The standardized breakfast will be prepared and delivered by a professional catering service, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
47928306|NCT02617485|DRUG|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
47928307|NCT02617485|DRUG|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
48279797|NCT06560359|DIETARY_SUPPLEMENT|No F&V|The intervention only includes breakfast plan (daily delivery of balanced breakfast containing regular diet without fruits and vegetables) for 12 weeks. The standardized breakfast will be prepared and delivered by a professional catering service, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
48279798|NCT06655961|OTHER|Garden Activities Program|When we look at the studies evaluating the effect of gardening activities on hospitalized children; it is seen that mostly children's opinions about therapeutic gardens are included and studies involving active gardening activities are limited. Shao et al. (2020) gave hospitalized children a task about garden plants and made them full this task through active participation and mobile games. However, it is seen that the gardening activity applied in this study was limited to a 5-minute task. The most important difference of our study from these studies is that a standardized gardening activity program will be applied to hospitalized children during their hospitalization and the active participation of the child will be ensured.
48451740|NCT04786496|BEHAVIORAL|Control condition|The control intervention was designed to have a similar structure than the experimental interventions, including also reading and writing tasks, but that they were not in any way related to the contents of the experimental interventions. In particular, participants were asked to read an article about the fire that took place in the Notre Dame cathedral in Paris that had been recently published in a newspaper. Starting from the accident of the Notre Dame cathedral, the article focuses on reflecting on the problem of heritage conservation and analyzing the situation of other important cathedrals. After reading the article, the participants were asked to write a few lines evaluating in their opinion the importance of the conservation of historical buildings such as those mentioned and how much of the public economic budget should be used for heritage conservation.
48451741|NCT00850148|PROCEDURE|Anwar|Anwar surgical method
48451742|NCT00850148|PROCEDURE|Melles|Melles surgical method
48451743|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #1|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
48451744|NCT05755282|DRUG|Post-market foam alcohol-based hand sanitizer #2|Automated dispenser will dispense 1 mL of hand sanitizer product onto hands.
48451745|NCT06603532|OTHER|low-load blood flow restriction (BFR) training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in the BFR group exercised with blood flow restriction caused by an inflatable cuff placed on the proximal part of the thigh and inflated to 120-140 mmHg. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
48451746|NCT06603532|OTHER|low-load resistance training|The training program lasted four weeks with three training sessions per week, for a total of 12 training sessions. Participants in SHAM-BFR group performed an identical exercise protocol as experimental (BFR) group, while having thigh cuff inflated to only 20 mmHg, which did not affect normal muscle blood flow. Subjects trained against the maximum mechanical resistance they could overcome thirty times (30 repetitions maximum; 30 RM). All training sessions were performed under the supervision of a physiotherapist and included leg press and knee extension exercises.
48451747|NCT03216967|DRUG|everolimus|Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
48451748|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
48451749|NCT01811953|DRUG|Metformin|oral administration
48451750|NCT01811953|DRUG|Empagliflozin|low dose of Empagliflozin oral administration
48451751|NCT01811953|DRUG|Empagliflozin/Metformin|low dose of Empagliflozin
48451752|NCT01811953|DRUG|Metformin|oral administration
48621432|NCT03754543|OTHER|Labeled iron salt Fe57|Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
48621433|NCT03754543|OTHER|Labeled iron salt Fe58|Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
48621434|NCT00429247|DRUG|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
48621435|NCT02122276|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
47928308|NCT02617485|DRUG|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
48451753|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
48451754|NCT01811953|DRUG|Empagliflozin|medium dose oral administration
47928309|NCT01453387|DRUG|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
48451755|NCT01811953|DRUG|Metformin|oral administration
48451756|NCT01811953|DRUG|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
48451757|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 0.5 mg|0.5 mg IT once/week (week 1)
48451758|NCT03262103|BIOLOGICAL|Intratumoral (IT) Poly ICLC 1.0 mg|1.0 mg IT once/week (week 1)
48451759|NCT03262103|BIOLOGICAL|Intramuscular (IM) Poly ICLC|1 mg IM twice weekly (weeks 3-6)
48451760|NCT03262103|PROCEDURE|Radical Prostatectomy|as per standard care
48451761|NCT06196554|DRUG|Oxaliplatin|"According to the first-line drugs provided by the NCCN guidelines, the concentration of each drug was added to the organoid culture medium after setting 5-6 concentration gradients according to literature reports. Chemo-sensitive and drug-resistant.~Construction of gastric cancer organoid T cell co-culture system to screen sensitive immunotherapy drugs."
48451762|NCT03410784|DRUG|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
48451763|NCT03410784|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
48451764|NCT03410784|DRUG|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
48451765|NCT02919540|OTHER|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
48451766|NCT05337540|DEVICE|EVI-01|Single intra-articular injection of high molecular weight hyaluronic acid
48451767|NCT05337540|DEVICE|Active comparator Synvisc-One|Single intra-articular injection of active comparator Synvisc-One
47928310|NCT01453387|DRUG|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
47928311|NCT00998218|DRUG|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
47928312|NCT00998218|DRUG|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
48098274|NCT06630494|DRUG|Recombinant human thrombopoietin for injection (rhTPO)|Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
48451768|NCT04313855|DIAGNOSTIC_TEST|SMS in the early detection of postoperative neuropathic pain|"7 days after the intervention, the patient receives a standardized questionnaire by SMS, to determine whether the patient has pain at the operating site and whether this pain has the characteristics of neuropathic pain. After replying to the SMS, the patient will be contacted by phone to assess: the intensity of pain at the operating site using a numerical scale and the existence of neuropathic pain. Depending on the responses received by SMS and/or phone, a consultation appointment with an anesthesiologist specializing in pain may be offered within a maximum of 2 weeks.~Ninety days after your surgery, the patient receives the same standardized questionnaire by SMS. The patient will be contacted by telephone, in order to assess the intensity of pain at the operating site and the existence of neuropathic pain using. If the patient has post-operative pain, a consultation appointment with an anesthesiologist specializing in pain will be offered to him within a maximum of 2 weeks."
48451769|NCT02889380|DRUG|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
48451770|NCT01153503|PROCEDURE|TAP block|"Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
48451771|NCT04651335|DEVICE|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
48451772|NCT04651335|DEVICE|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
48451773|NCT01442558|DRUG|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
48451774|NCT01192932|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
48451775|NCT04550702|DRUG|Mirabegron 25mg|Mirabegron 25 mg per day
48451776|NCT03192163|OTHER|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
48098275|NCT00466791|DRUG|Methylphenidate Transdermal System|Placebo
48098276|NCT01473719|BEHAVIORAL|motivational intervention|7-session individual motivationally-based intervention
48098277|NCT01473719|BEHAVIORAL|health education|7 individual sessions focusing on health education
48098278|NCT06043271|BEHAVIORAL|The EMPOWER Program|The EMPOWER Program is a web-based, self-administered SSI for parents that takes about 30 minutes to complete.
48098279|NCT00609648|BEHAVIORAL|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
48098280|NCT00609648|BEHAVIORAL|Pamphlet|A pamphlet reassuring patients about dental injections.
48098281|NCT04004702|DRUG|Levetiracetam|Levetiracetam 500mg twice a day
47928313|NCT00732901|DRUG|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
47928314|NCT00732901|DRUG|Placebo|Once daily days 1-28
47928315|NCT00854412|OTHER|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
47928316|NCT05850494|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
48621436|NCT01458977|DRUG|Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
48098282|NCT05358717|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
48621437|NCT01458977|DRUG|Placebo|Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
48621438|NCT01805336|OTHER|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
48621439|NCT01805336|OTHER|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
48621440|NCT01805336|OTHER|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
48621441|NCT01805336|OTHER|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
48621442|NCT01805336|OTHER|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
48621443|NCT02512562|DRUG|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
47928317|NCT05850494|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage Level: 4 inhalations, single dose~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 or 2 possible sequences AB or BA"
48451777|NCT02632864|RADIATION|Proton arm|Proton beam therapy
48451778|NCT02937948|OTHER|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
48451779|NCT02937948|RADIATION|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
48621444|NCT02512562|DRUG|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
48621445|NCT02512562|DRUG|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
48621446|NCT00910585|BEHAVIORAL|Coaching, providing social support|Active telephone and in person coaching
48621447|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
47928318|NCT06173115|DEVICE|Perclose Proglide system|"Preclosure technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site."
47928319|NCT02365142|BIOLOGICAL|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
47928320|NCT02365142|BIOLOGICAL|Platelet Rich plasma (PRGF)|3 injections of PRGF
47928321|NCT04613843|OTHER|Water Stirring|Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.
47928322|NCT04613843|OTHER|No Water Stirring|Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
47928323|NCT03205592|DIAGNOSTIC_TEST|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
47928324|NCT01705067|DEVICE|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
47928325|NCT03712007|DEVICE|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
48098283|NCT05358717|DRUG|Placebo|Placebo matching to PTC518 will be administered per schedule specified in the arm.
48451780|NCT00000915|BEHAVIORAL|Vaccine preparedness|
48451781|NCT01440803|DRUG|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
48451782|NCT01440803|DRUG|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
48451783|NCT04640142|BIOLOGICAL|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion.
48621448|NCT00705419|DRUG|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
48621449|NCT00705419|DRUG|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
48621450|NCT00705419|DRUG|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
48621451|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
47928326|NCT03712007|DEVICE|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
48451784|NCT03169062|DEVICE|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
48451785|NCT01369368|DRUG|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
48621452|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
47928327|NCT04389437|PROCEDURE|Ophthalmological exam|OCT-A and AO
47928328|NCT04389437|PROCEDURE|Blood pressure measurement|Blood pressure measurement before the ophthalmological exam
47928329|NCT01964040|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
48621453|NCT01456117|DRUG|Pioglitazone|Pioglitazone once daily for up to 14 days.
47928330|NCT04645277|DEVICE|Scanning with magnetic resonance imaging|Facial nerves and adjacent blood vessels are scanned using MRI in the patients with hemifacial spasm (HFS). Then multiplanar reconstruction (two dimensional), along with curved planar reconstruction and magnetic resonance virtual endoscopy (three dimensional), will be performed in the different groups of HFS.
47928331|NCT03176017|PROCEDURE|Ejaculatory sparing TUIP|The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
48451786|NCT01385163|BEHAVIORAL|Treatment as usual|Standard psychosocial counseling
48621454|NCT01456117|DRUG|Placebo|Pioglitazone matching placebo once daily for up to 14 days.
48621455|NCT06052124|DEVICE|Augmented Reality Device|AR device will be used to determine where to place SEPS drain
47928332|NCT03176017|PROCEDURE|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
47928333|NCT01589770|OTHER|cardiac Magnetic Resonance imaging|
47928334|NCT05309876|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
47928335|NCT00265356|PROCEDURE|PET diagnostic imaging|PET diagnostic imaging
47928336|NCT00265148|DRUG|Rosiglitazone|Extended Release Tablets
47928337|NCT00265148|OTHER|Placebo|Placebo dummy to match
48621456|NCT05256264|DRUG|Ketamine|Ketamine infusion at different dose to observe EEG DSA changes
47928338|NCT03493932|DRUG|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
47928339|NCT03493932|DRUG|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
48451787|NCT01385163|BEHAVIORAL|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
48451788|NCT01385163|BEHAVIORAL|Cognitive Processing Therapy|group 12 session intervention
48451789|NCT03867838|DEVICE|compliant support|Participants will be given compliant arm support and their reachable workspace measured
48451790|NCT06561607|DRUG|TQB2102 for Injection|TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
48621457|NCT03127059|OTHER|Breathing Exercises|"Key points in the intervention are~* Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~* Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~* Inclusion of the breathing modification into walking and other physical activities.~* Daily home exercise of BrEX."
48621458|NCT03127059|OTHER|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
48621459|NCT03743194|DRUG|Exparel 266 MG Per 20 ML Injection|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
48621460|NCT03743194|DRUG|Placebo|Patients randomized to standard analgesia technique will be given pain medications.
48621461|NCT05619224|OTHER|Neurodevelopmental stimulation + Oral stimulation|"Neurodevelopmental intervention seeks to reduce abnormal postures and movement patterns in premature infants, allowing them to experience physiological postures in flexion and receive sensory stimulation. To this is added oral stimulation.~These stimulations are performed on alternate days."
48621462|NCT05619224|OTHER|Oral stimulation|This intervention consists of performing a sensorimotor stimulation of oral structures: stimulating for 7 minutes perioral structures( cheeks, lips and jaw)intraoral structures for 5 minutes and in the last 3 minutes non-nutritive suction stimulation with pacifier or finger.
48621463|NCT05953467|OTHER|No intervention, observational.|None, observational study
48621464|NCT04489368|RADIATION|Neo-Adjuvant Radiotherapy|Neo-Adjuvant Radiotherapy via any technique, delivered concurrently with Neo-Adjuvant Chemotherapy.
47928340|NCT02222025|OTHER|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
48621465|NCT04489368|DRUG|Neo-Adjuvant Chemotherapy|Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
47928341|NCT03678870|OTHER|Opioid Education Handout|a single page handout with information about how to use medications for pain after discharge.
48621466|NCT04489368|PROCEDURE|Esophagectomy|Esophagectomy, performed 4-6 weeks after completion of Neo-Adjuvant Concurrent ChemoRadiation
48451791|NCT06561607|DRUG|Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)|"Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment.~* Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle.~* Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly.~* Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle."
48451792|NCT00741780|DRUG|Placebo|
48451793|NCT00741780|DRUG|plerixafor|
47928342|NCT01106092|BIOLOGICAL|GSK2036874A vaccine|Intramuscular, single dose
47928343|NCT01106092|BIOLOGICAL|Zilbrix™/Hib vaccine|Intramuscular, single dose
48279799|NCT06655961|OTHER|Clinical routine treatment and nursing care protocol|Within the scope of the clinic routine treatment and nursing protocol; the decision to hospitalize the child, orientation to the clinic, execution of hospitalization paperwork, room placement, invasive intervention and treatment procedures are carried out. Treatment and care hours are revised according to individual order characteristics; 08.00-20.00, 08.00-16.00-00.00, 06.00-12.00-18.00-00.00 are planned considering the time order. 13.00-15.00 are the visiting hours. The child is not allowed to leave the clinic except for any medical purpose. No intervention will be applied to the control group of this study until the discharge process takes place.
48279800|NCT03023748|DRUG|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
48279801|NCT05916872|OTHER|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
48279802|NCT05916872|OTHER|control group|Patients will receive conventional therapy.
48279803|NCT05239104|OTHER|No intervention|This is an observational study with no intervention
48279804|NCT01748227|BEHAVIORAL|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
47928344|NCT01106092|BIOLOGICAL|Poliorix™|Intramuscular, single dose
48098284|NCT05227313|DIETARY_SUPPLEMENT|Eefooton oral solution|Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
48451794|NCT00741780|DRUG|granulocyte colony-stimulating factor (G-CSF)|
48451795|NCT06626802|PROCEDURE|Balloon Dilation + Topical Mitomycin|Patients with recurrent esophageal strictures in Group A will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Mitomycin applied topically at stricture site (post dilation)
48451796|NCT06626802|PROCEDURE|Balloon Dilation + Injection Triamcinolone|Patients with recurrent esophageal strictures in Group B will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Triamcinolone, injected with a sclerotherapy injector, at stricture site (post dilation)
48451797|NCT03532035|DRUG|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
48621467|NCT00530166|DRUG|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
48621468|NCT00530166|DRUG|sham comparator|3(100 mg) tablets once daily for 12 weeks
48621469|NCT04015063|OTHER|Anti-Aging Skin Care product|Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
48621470|NCT01803542|RADIATION|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
48621471|NCT04612400|OTHER|Oral amino acid tracer|Whole body protein metabolism response to a dose of the supplement will be measured using a continuous oral sip-feeding (every 10 minutes) method of stable isotope tracer.
48621472|NCT03527602|PROCEDURE|Foraminal enlargement|After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
48621473|NCT03149315|DRUG|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
48637435|NCT05409612|BIOLOGICAL|Supemtek®|"Quadrivalent recombinant high-dose influenza vaccine containing 45 µg of hemagglutinin (HA) for each of the 4 strains included (2 strains A and 2 strains B).~Solution for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0."
48279805|NCT02725502|DRUG|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
48279806|NCT02725502|DRUG|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
48279807|NCT02852226|OTHER|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
48621474|NCT04641637|PROCEDURE|TACE|Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
48621475|NCT00620919|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
48279808|NCT02852226|BEHAVIORAL|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
48279809|NCT02852226|BEHAVIORAL|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
48279810|NCT00885365|DRUG|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
48279811|NCT00885365|DRUG|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
48279812|NCT04279197|DRUG|Fuzheng Huayu Tablet|FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
48279813|NCT04279197|DRUG|Vitamin C tablets|Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；
48279814|NCT04279197|DRUG|Placebo|Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
48279815|NCT04279197|OTHER|respiratory function rehabilitation training|Health exercise, once a day
48621476|NCT02707744|OTHER|no intervention|
48621477|NCT04638244|BEHAVIORAL|Music|Brief Online Music
48621478|NCT04638244|BEHAVIORAL|Reading messages|Reading psychoeducational messages
48621479|NCT06466200|DIAGNOSTIC_TEST|Schiff Test|Use of an air syringe positioned perpendicular to the tooth surface at a distance of 1 cm. A scale to determine the intensity of DH was created, with the SASS (Shiff Analog Sensitivity Scale) ranging from 0 to 3 (0 being the absence of pain felt by the patient and 3 being pain considered intolerable). If the pain is greater than 1 then the patient is considered hypersensitive.
47928345|NCT01114230|DRUG|AGS-16M8F|IV
48098285|NCT05227313|DIETARY_SUPPLEMENT|Placebo oral solution|oral solution matched placebo
48279816|NCT01568723|GENETIC|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
48621480|NCT06466200|OTHER|GOHAI questionnaire|Oral health-related quality of life assessment by questionnaire
48621481|NCT06466200|OTHER|OHIP questionnaire|Oral health-related quality of life assessment by questionnaire
48621482|NCT06466200|OTHER|DHEQ fr questionnaire|dentin hypersensitivity and oral health-related quality of life assessment by questionnaire
48621483|NCT00214435|DRUG|once daily minimum 3-drug regimen of anti-retroviral medications|
48621484|NCT00634556|DRUG|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
48621485|NCT00634556|DRUG|placebo|normal saline
47928346|NCT05048550|DEVICE|Near vision spectacles|Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
48279817|NCT02337842|BIOLOGICAL|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.
48451798|NCT03532035|DRUG|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
48279818|NCT02337842|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
48451799|NCT01165450|DRUG|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
48451800|NCT01165450|DRUG|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
48451801|NCT05562778|OTHER|Chatbot|A chatbot is a software program designed to simulate human conversation, typically via text. Chatbots utilize natural language processing to gather patient data, anticipate questions, and predict responses. In this study, the Chatbot will simulate a text-like conversation with patients via a smartphone and use this platform to deal with the time-consuming nature of family history collection. The chatbots can then triage the collected family history against medical guidelines to determine which patients warrant genetic testing. For those patients meeting criteria for genetic testing, the chatbot can offer pre-test education and assist physicians with ordering genetic testing for interested patients meeting high-risk criteria.
48451802|NCT02208128|DRUG|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
48451803|NCT05637125|OTHER|aerobic exercise for upper limb|aerobic exercise for upper limb in the form of arm ergometer 3 session/week for 12 weeks. Patient started with warming up for 5 minutes in form of stretching. Patients used arm ergometer without resistance for upper limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion, after 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
48451804|NCT05637125|OTHER|aerobic exercise for lower limb|received aerobic exercise for lower limb in the form of cycling 3session/week for 12 weeks. Patient started with warming up for 5 minutes. Patients used bicycle for lower limb aerobic exercise for 20 minutes and instructed to take rest if they feel tired or fatigue. The intensity was according to rate of perceive exertion. After 20 minutes, patients were asked to cool down for 5 minutes in the form of stretching at the end of an exercise session.
48451805|NCT05131113|OTHER|Physical exercise|Physical exercise
48451806|NCT05239195|OTHER|Video Laryngoscope|Laryngoscope with a camera and a video screen
48621486|NCT05481437|DRUG|Brentuximab Vedotin|Brentuximab Vedotin injection, 50 mg, once every 2 weeks
48637436|NCT05409612|BIOLOGICAL|Vaxigriptetra®|Quadrivalent inactivated influenza vaccine containing 15 µg of hemagglutinin (HA) for each of the 4 strains included. Suspension for injection is sterile liquid supplied in 0.5mL single dose pre-filled syringe. Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.
48637437|NCT03697408|DRUG|Itacitinib|A JAK 1 selective small molecule inhibitor
48637438|NCT03697408|DRUG|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
48098286|NCT03915262|BIOLOGICAL|Search for exocrine pancreatic insufficiency at week 0 and 12|"We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record."
48098287|NCT02624778|BIOLOGICAL|LY3002813|Administered IV
48098288|NCT02624778|DRUG|Placebo|Administered IV
48098289|NCT00573703|PROCEDURE|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
48098290|NCT00573703|PROCEDURE|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
48098291|NCT05825235|DRUG|Pramipexole|6 months of treatment with add-on Pramipexole
48098292|NCT05286424|PROCEDURE|fat grafting|Fat will be removed from abdomen or legs, processed and re-injected into grafting sites.
48098293|NCT06209060|BEHAVIORAL|Hammock Position|Researchers will make a hammock by using a soft rectangular cotton cloth with ropes that pass through the circular openings of the incubator and are tied on the upper part of it. Babies will be placed in this hammock in a supine position with their extremities in the midline. The spine of the preterm neonate will support while arms and knees are flexed. Additionally, a small rectangular roller will be placed between the cervical and scapular region of the newborn in the hammock position to ensure that no hyperflexion or hyperextension position of the head occurs, which may impair respiratory function.
48098294|NCT06209060|BEHAVIORAL|Nesting|In the nesting group, a nest will be made using rolls prepared with materials such as towels and blankets, and the baby will be placed in this nest. The baby's head and body will be positioned on the same axis, its extremities will be positioned in the midline, and its hands will be positioned close to its face.
48098295|NCT04423393|BIOLOGICAL|VIR-3434|VIR-3434 given by subcutaneous injection or intravenous infusion.
48098296|NCT04423393|OTHER|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.
48098297|NCT01393470|PROCEDURE|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
48451807|NCT05239195|OTHER|Direct Laryngoscope|Laryngoscope without a camera or a video screen
48451808|NCT06345053|BEHAVIORAL|Narrative Exposure Therapy|The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.
48451809|NCT06258746|DRUG|[14C]HSK31679|A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
48451810|NCT00429962|DRUG|intravitreal ranibizumab|intraocular injection
48451811|NCT00429962|DRUG|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
48451812|NCT02436005|DEVICE|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
48451813|NCT02436005|DEVICE|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
48451814|NCT03115957|OTHER|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
48451815|NCT05402358|OTHER|Acceptance and Commitment Therapy Group Intervention|The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.
48451816|NCT05387408|BEHAVIORAL|Best Practice Health and Employment Opioid-related Policies|The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
48451817|NCT04241757|DIAGNOSTIC_TEST|ElectroCardioGram (ECG)|Collection of results ElectroCardioGram (ECG).
48451818|NCT06302335|DRUG|Povidone-iodine|Application of Povidone-iodine to the surgical wound of patients submitted to colorectal resections.
48451819|NCT06302335|DRUG|Saline solution|Application of saline solution to the surgical wound of patients submitted to colorectal resections.
48451820|NCT06094023|OTHER|Food Frequency Questionnaire|Food frequency questionnaires (FFQs) are a common method for measuring dietary intake in large epidemiological studies, in particular in low literacy settings were diaries and food history would not be viable.
48451821|NCT06094023|OTHER|24 Hour food recall|Standardized and validated approach of collecting all foods, beverages, and supplements consumed during the past 24 hours.
48451822|NCT00191815|DRUG|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
48451823|NCT00191815|DRUG|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
48451824|NCT04596891|BEHAVIORAL|Psychotherapy|Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
48451825|NCT03767374|PROCEDURE|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
48451826|NCT03767374|PROCEDURE|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
48451827|NCT03767374|PROCEDURE|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
48451828|NCT03767374|OTHER|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
48451829|NCT02125435|DRUG|ASP2408|intravenous
48451830|NCT02125435|DRUG|Placebo|intravenous
48451831|NCT04677075|PROCEDURE|mastectomy|mastectomy either simple or modified radical
48451832|NCT01717339|OTHER|Sleep Study|
48451833|NCT06626971|DRUG|ARA290|4 mg subcutaneous injections of ARA290 over an 84 day period
48451834|NCT06242145|DRUG|Clopidogrel tablet|Efficacy and safety of a 300mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
48451835|NCT06242145|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
48451836|NCT01242098|DRUG|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
48451837|NCT01242098|DRUG|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
48451838|NCT06559735|DEVICE|CereVu Device|Observational, non-invasive measurements
48451839|NCT02102815|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
48451840|NCT02102815|DRUG|Normal saline|NSS 50 mL IV slowly push over 5 minutes
48451841|NCT03033810|DEVICE|Fractional flow reserve and instantaneous wave-free ratio|"1. To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~2. The development of software for the automatic detection of the lowest point of microvascular resistance."
47928347|NCT06437431|DRUG|glenzocimab|Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total dose of 1g of glenzocimab as an IV infusion over 6 hours, with 1/4 of the dose administered by a 15-minutes bolus and 3/4 of the dose administered by 5h45minutes continuous infusion.
47928348|NCT06437431|DRUG|placebo|Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
48621487|NCT03769493|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
48621488|NCT00847314|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 35yrs in medical practices fulfilling all criteria for documentation.
48451842|NCT03197818|DRUG|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
48621489|NCT04320537|OTHER|abstinence from use of marijuana and other abused drugs|abstinence from use of marijuana use and other abused drugs
48279819|NCT05634499|DRUG|Giredestrant|Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles. After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
48279820|NCT05085002|DRUG|Lerociclib + Letrozole or Fulvestrant|All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
48279821|NCT04723030|DRUG|carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)|"Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week."
48279822|NCT01586091|DRUG|Levocetirizine Oral Tablet|
48279823|NCT01586091|DRUG|Fexofenadine 60 Mg Oral Tablet|
48621490|NCT00432432|DRUG|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
48621491|NCT01250938|BEHAVIORAL|ESI - Community Outreach|This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
48621492|NCT03600350|BIOLOGICAL|pTVG-HP|Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
48621493|NCT03600350|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
48621494|NCT03600350|DRUG|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
48621495|NCT02595749|DRUG|Oxytocin|
48621496|NCT02595749|DRUG|Placebo|
48621497|NCT05167539|PROCEDURE|Aortic valve surgery|mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
48621498|NCT04172233|BIOLOGICAL|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
48621499|NCT04172233|BIOLOGICAL|placebo|matching placebo
48621500|NCT01007877|OTHER|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
48621501|NCT04556175|BEHAVIORAL|Oral Health|Motivational interviewing for mothers pre-and postpartum; fluoride varnish for infants/children.
48621502|NCT04556175|BEHAVIORAL|Healthy Lifestyle|Didactic maternal and child health educational sessions for mothers pre-and postpartum; fluoride varnish for infants/children.
48621503|NCT02090881|OTHER|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
47928349|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm bevel|Class IV cavity with 2 mm bevel will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
47928350|NCT06220890|PROCEDURE|Tooth preparation in Class IV lesions with 2mm stair-step chamfer|Class IV cavity with 2 mm stair step chamfer will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
47928351|NCT01634425|DEVICE|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
47928352|NCT05780268|BIOLOGICAL|LY3819253|LY3819253 is a neutralizing immunoglobulin G (IgG)-1 monoclonal antibody (mAb) to the receptor binding domain (RBD) of the S protein of SARS-CoV-2
48279824|NCT01586091|DRUG|Placebo Oral Tablet|
47928353|NCT05780268|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
48621504|NCT04324840|DRUG|CC-90010|Specified dose on specified days
48621505|NCT04324840|DRUG|Temozolomide|Specified dose on specified days
48621506|NCT04324840|RADIATION|Radiotherapy|Specified dose on specified days
48621507|NCT04225156|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
48621508|NCT01181882|DIETARY_SUPPLEMENT|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
48621509|NCT01171534|DEVICE|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
48621510|NCT01171534|DEVICE|Vessel loop|Vessel loops and staples for fasciotomy closure
47928354|NCT05780268|BIOLOGICAL|Remdesivir|Antiviral agent
47928355|NCT05202938|DIAGNOSTIC_TEST|ultrasound cardiography|Ultrasound to check heart functions and systolic ejection fraction.
47928356|NCT05202938|DIAGNOSTIC_TEST|FDG PET scan|FDG venous injection and positron emission tomography scan.
48451843|NCT03197818|DRUG|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
48621511|NCT02337582|OTHER|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
47928357|NCT05202938|DIAGNOSTIC_TEST|Palmitate PET scan|C11-Palmitate venous injection and positron emission tomography scan.
47928358|NCT05202938|DIAGNOSTIC_TEST|Acetate PET scan|C11-Acetate venous injection and positron emission tomography scan.
48451844|NCT02905435|DEVICE|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
47928359|NCT05202938|DIAGNOSTIC_TEST|Blood sampling|Collecting 20ml of venous blood.
47928360|NCT02891785|BEHAVIORAL|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
48279825|NCT05526534|DEVICE|heated humidified high flow nasal cannula oxygen therapy, HFNC|HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
48451845|NCT05801315|DEVICE|Glycine powder air polishing|Peri-implant mucositis sites treated with a glycine powder air polishing device (Air-Flow Master Piezon®).
48451846|NCT05801315|DEVICE|Full mouth ultrasonic debridement|Peri-implant mucositis sites are treated with thin ultrasonic tips.
48621512|NCT02337582|OTHER|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
48621513|NCT05694585|DRUG|Esmolol|Esmolol 50μg/kg /min is intravenously administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, esmolol 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
48621514|NCT05694585|DRUG|saline|Saline 50μg/kg /min were iv administered before Operation beginning. If HR（heart rate）is greater than 90 beats/min, saline 50μg/kg/min is added each time, with interval more than 5 min and the peak value is 200 μg/kg/min. If the heart rate is lower than 60 times/minute, Stop medication.
48279826|NCT05526534|DEVICE|Nasal cannula oxygen|Nasal cannula oxygen has become a routine part of postoperative treatment
48279827|NCT02038322|DEVICE|The Stork - Conception Aid|
48279828|NCT02406157|DEVICE|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
48279829|NCT02406157|DEVICE|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
48621515|NCT00089648|DRUG|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
47928361|NCT02262182|OTHER|KP group|
47928362|NCT02262182|OTHER|KM group|
48279830|NCT02712502|DRUG|Levofloxacin|"* Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
48279831|NCT02712502|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
48279832|NCT01365221|DRUG|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
48279833|NCT01365221|DRUG|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
48279834|NCT00420914|PROCEDURE|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
48279835|NCT02226354|DIETARY_SUPPLEMENT|Ahiflower oil|9.73 ml per day for 28 days
48279836|NCT02226354|DIETARY_SUPPLEMENT|Flaxseed oil|9.73ml per day for 28 days
48637439|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine tumor DNA test|Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer
48637440|NCT06218433|DIAGNOSTIC_TEST|Urothelial cancer screening using urine cytology (comparator)|Urine cytology sample
48637441|NCT06249672|OTHER|Local excision|Organ preservation after RCT (radiochemotherapy) of rectal cancer
47928363|NCT05587946|OTHER|Experimental group|In recent years, virtual reality has been widely used as a distraction practice in clinical medical care to relieve pain. Virtual reality is a method of viewing computer images to isolate the individual from real life for a while. Virtual reality glasses, consisting of a head-mounted display and glasses connected to a mobile phone, is a computer technology that creates a 3D environment. The virtual reality application, which was originally designed for entertainment purposes, started to be used in the medical field to reduce pain during invasive procedures in parallel with the developments in computer technologies. It is preferred in clinical practice as an easily accessible, non-invasive and inexpensive method.
47928364|NCT05191056|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day for 8 weeks
48621516|NCT04516876|OTHER|Camp-based bimanual intensive training(BIT)|The day-camp BIT model will be delivered in a group-based design. In day-camp model, each child is assigned to a trained therapist to maintain at least a 1:1 to 1:2 ratios of therapy and child. The therapist will monitor and modify the activities to fit each individual's ability and need to make sure the intervention quality is equivalence to the individualized treatment method. The chosen tasks of each intervention session have to be considering the child's preference, age-appropriated, and at the right level of difficulty. Target movements are embedded in the functional activities, whereby the environment is manipulated to vary task requirement and the difficulty is graded to match the child's capacity.
48621517|NCT02856217|PROCEDURE|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
48621518|NCT02856217|PROCEDURE|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
48621519|NCT03901300|BEHAVIORAL|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
48621520|NCT03901300|BEHAVIORAL|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
48621521|NCT00218959|BEHAVIORAL|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos \& Monelli).
48621522|NCT00218959|BEHAVIORAL|treatment as usual|
48621523|NCT05998447|DRUG|GEN-001|The capsules taken by mouth. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
48621524|NCT05998447|DRUG|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
48621525|NCT05998447|DRUG|mFOLFOX|mFOLFOX given by intravenous (IV) once every 2 weeks for only cohort 3
48621526|NCT01373619|DRUG|Ivabradine|ivabradine titrated to 7.5 mg BID
48621527|NCT00049569|DRUG|cytarabine|Given IT
48621528|NCT00049569|DRUG|methotrexate|Given IT
48621529|NCT00049569|DRUG|vincristine sulfate|Given IV
48621530|NCT00049569|DRUG|prednisone|Given PO
48621531|NCT00049569|DRUG|pegaspargase|Given IM
48621532|NCT00049569|DRUG|doxorubicin hydrochloride|Given IV
48621533|NCT00049569|DRUG|imatinib mesylate|Given PO
47928365|NCT05191056|DIETARY_SUPPLEMENT|MelaGene drink|consume 1 bottle per day for 8 weeks
47928366|NCT03610100|DRUG|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
48279837|NCT06132256|DRUG|Axatilimab|Administered as intravenous (IV) infusion
48621534|NCT00049569|DRUG|cyclophosphamide|Given IV
48621535|NCT00049569|DRUG|etoposide|Given IV
48621536|NCT00049569|BIOLOGICAL|filgrastim|Given SC
48621537|NCT00049569|DRUG|leucovorin calcium|Given IV
48621538|NCT00049569|DRUG|asparaginase|Given IM
48621539|NCT00049569|DRUG|therapeutic hydrocortisone|Given IT
48621540|NCT01868672|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
48621541|NCT03517982|DRUG|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
48621542|NCT01636843|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
48621543|NCT01636843|DRUG|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
48279838|NCT06132256|OTHER|Placebo|Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
48621544|NCT00795574|DRUG|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
48621545|NCT00795574|DRUG|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
48621546|NCT03881787|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
48621547|NCT03881787|DRUG|Cetuximab injection|Cetuximab injection
48621548|NCT00435942|DEVICE|Relay Thoracic Stent-Graft|implant
48621549|NCT00435942|PROCEDURE|Open Repair|Open surgery
48621550|NCT02871596|OTHER|Placebo|A combination of maltodextrins and red and blue food colors.
48621551|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids|A combination of blueberry extract, black current extract, and black rice extract.
48621552|NCT02871596|DIETARY_SUPPLEMENT|Flavonoids+Prebiotics|A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
48621553|NCT05078619|PROCEDURE|No PCI|Omission of PCI of significant coronary artery disease prior to TAVI
48621554|NCT01792232|OTHER|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
48621555|NCT01792232|OTHER|Saline|Saline will be placed in the lung on day 1 of each triad
48621556|NCT03778632|BEHAVIORAL|individualized desensitization exercises|implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
48451847|NCT04306068|OTHER|Plyometric protocol|"Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets."
47928367|NCT03610100|DRUG|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
47928368|NCT06272097|BEHAVIORAL|Intervention program based on TIME-CDST tool led by wound specialist nurses|Based on the TIME CDST tool led by wound specialist nurses, which includes the following four areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment.
48451848|NCT05256147|DRUG|Ibuprofen|Patient will receive ibuprofen 400 mg before the phototherapy session.
48451849|NCT04272216|DEVICE|Treatment with HydroPearl via radial access|This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
48451850|NCT05240417|PROCEDURE|"Pontic-shield technique"|A 1mm thick fragment of the vestibular aspect of the root will remain after extraction (partial extraction)
48451851|NCT05240417|PROCEDURE|Alveolar ridge preservation|Particulate deproteinized bovine bone and porcine collagen membrane will be placed after tooth extraction
48451852|NCT00829309|DRUG|Pravastatin|80 mg Tablet
48451853|NCT00829309|DRUG|Pravastatin|80 mg Tablets
48451854|NCT03417960|DEVICE|iTBS|"The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold.~In study 1, the accelerated paradigm will consist of 10 such sessions separated by 15 minutes, for three treatment days per week. There will be 2 weeks of 10 sessions on each of three days for a total of six treatment days, divided by one treatment-free week between treatment weeks. In study 2, the accelerated paradigm will consist of 12 sessions per day for 5 total treatment days. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method."
48451855|NCT06626581|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L
48451856|NCT06626581|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
48451857|NCT04296994|BIOLOGICAL|QL1706|QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
48451858|NCT06627127|DEVICE|Target stimulation (HGN, AC, GG, Strap muscles)|Stimulation of the HGN or GG along with AC or strap muscles.
48621557|NCT04403139|DRUG|Shingrix|All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
48621558|NCT01200914|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
48621559|NCT01200914|PROCEDURE|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
48621560|NCT00226655|DRUG|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
48621561|NCT03945136|BEHAVIORAL|Dynamic Interpersonal Therapy|Dynamic Interpersonal Therapy is a time-limited, manualized, interpersonal and affect-focused psychodynamic treatment that is frequently used to target depression and anxiety.
48621562|NCT05173311|BEHAVIORAL|Intervention arm|The intervention arm groups were instructed to use the Mole's Veggie Adventures mobile application for 3-4 weeks.
48621563|NCT04452175|OTHER|JUUL E-CIGARETTE|JUUL E-CIGARETTE USAGE FOR 24 WEEKS
48621564|NCT04240561|DEVICE|High level of signal manipulation|Hearing aid will be programmed to a high level of signal manipulation.
48621565|NCT04240561|DEVICE|Low level of signal manipulation|Hearing aid will be programmed to a low level of signal manipulation.
48621566|NCT00389870|BIOLOGICAL|panitumumab|
48621567|NCT00389870|DRUG|cyclosporine|
48621568|NCT00389870|DRUG|irinotecan hydrochloride|
48621569|NCT00610948|BIOLOGICAL|panitumumab|Given IV
48621570|NCT00610948|DRUG|everolimus|Given orally
48621571|NCT00610948|DRUG|fluorouracil|Given IV
47928369|NCT06272097|BEHAVIORAL|A routine wound care program|A routine wound care program of wound cleaning and dressing changes
47928370|NCT05810818|DIAGNOSTIC_TEST|Dry Needling|Dry needling treatment will be consisting of two treatments per week
47928371|NCT05810818|DIAGNOSTIC_TEST|Self Stretching|Self stretching groups both will receive a TrP manual interventions and stretching protocol
47928372|NCT00338975|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
48621572|NCT00610948|DRUG|leucovorin calcium|Given IV
48621573|NCT00610948|DRUG|oxaliplatin|Given IV
48621574|NCT02769520|DRUG|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
48621575|NCT04341051|OTHER|Case|Mesure with NIRS regional saturation in patients undergoing popliteal block during vascular surgery for chronic obliterating arteriopathy (IIa to III Fontaine Classification)
48621576|NCT04285411|DEVICE|Accuracy of the VitalDetect™ pulse oximetry system|The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
48621577|NCT03611543|DEVICE|New investigational curved paddle|X-ray imaging of breast tissue
48621578|NCT01055327|DRUG|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
48621579|NCT01055327|DRUG|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
48621580|NCT01055327|DRUG|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
48621581|NCT03734341|DEVICE|EZ START Titration|"The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours."
48621582|NCT03734341|DEVICE|APAP Titration|"The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours."
48621583|NCT03217825|DRUG|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
48621584|NCT03217825|DRUG|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-\[p-(o-1H-tetrazol-5-ylphenyl)benzyl\]imidazole- 5-methanol monopotassium salt.
48621585|NCT02705170|PROCEDURE|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
48621586|NCT01877798|PROCEDURE|volume resuscitation, vasoactive drug|
48621587|NCT05941936|BIOLOGICAL|LM103|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
48621588|NCT01592955|DEVICE|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
48621589|NCT04422886|DEVICE|active transcranial direct current stimulation (tDCS)|20 minutes at 2.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines)
48621590|NCT04422886|BEHAVIORAL|Physiotherapy|motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
48621591|NCT04422886|DEVICE|sham transcranial direct current stimulation (sham)|1 minutes at 1.0 mA with electrodes positioned at Cz and Fpz (as per 10-20 electrode placement guidelines) and 19 minutes with unit shut off and electrodes remaining on the scalp
48621592|NCT00634972|DRUG|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
48621593|NCT00634972|DRUG|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
48621594|NCT00634972|DRUG|placebo|
48621595|NCT04050605|DEVICE|somofilcon A toric contact lens|Contact Lens
48621596|NCT04050605|DEVICE|fanfilcon A toric contact lens|Contact Lens
48621597|NCT06291363|DRUG|Esmolol Hydrochloride|Patients in the experimental group will receive esmolol during general anesthesia
48621598|NCT06291363|DRUG|Saline|Patients in the standard of care group will receive saline as placebo during general anesthesia
48621599|NCT02273947|DRUG|BMS-955176|Single dose by mouth for each treatment specified
48621600|NCT02666599|RADIATION|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
48621601|NCT00005849|DRUG|bryostatin 1|
48621602|NCT00005849|DRUG|paclitaxel|
48621603|NCT00022373|DRUG|iseganan HCl oral solution|
48621604|NCT00022373|PROCEDURE|management of therapy complications|
48621605|NCT00824668|DRUG|biphasic insulin aspart 30|
48621606|NCT00824668|DRUG|insulin glargine|
48621607|NCT00824668|DRUG|insulin glulisine|
48451859|NCT04521764|BIOLOGICAL|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Given IT
48621608|NCT05534542|OTHER|exercıse|ıntradıalıtıc core stabılızatıon
48621609|NCT00788333|DRUG|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
48621610|NCT00788333|DRUG|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
48621611|NCT01579864|DRUG|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
48621612|NCT01579864|DRUG|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
48621613|NCT05963659|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|nitrate-rich beetroot juice, \~750 mg NO3- /d
48621614|NCT05963659|DIETARY_SUPPLEMENT|nitrate-depleted beetroot juice|nitrate-depleted beetroot juice, \~1 mg NO3- /d
48621615|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
48621616|NCT01462942|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
48621617|NCT01462942|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
48621618|NCT01462942|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
48621619|NCT01462942|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
48621620|NCT03823027|DEVICE|SiPore15™|SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
48621621|NCT04681378|PROCEDURE|double layer step up-step down technique|the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
47928373|NCT00338975|BEHAVIORAL|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
47928374|NCT00338975|BEHAVIORAL|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
48621622|NCT02325778|PROCEDURE|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
47928375|NCT00338975|BEHAVIORAL|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
47928376|NCT02519855|BIOLOGICAL|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
47928377|NCT02519855|BIOLOGICAL|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
47928378|NCT02519855|BIOLOGICAL|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
47928379|NCT00002642|DRUG|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
47928380|NCT00002642|DRUG|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
47928381|NCT00002642|PROCEDURE|conventional surgery|surgery some time between weeks 9 and 12
48451860|NCT04521764|PROCEDURE|Computed Tomography|Undergo CT scan
48451861|NCT04521764|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48451862|NCT04521764|PROCEDURE|Biopsy|Undergo tumor biopsy
48451863|NCT04521764|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47928382|NCT00002642|RADIATION|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
47928383|NCT04739176|OTHER|One-on-one rehabilitation program including computerized mirror therapy in addition to standard rehabilitation.|atients will be admitted to the day hospital 2 days a week for 9 weeks. They will participate in a one-on-one rehabilitation program conducted by a multidisciplinary team including a physiotherapist, psychomotor therapist, occupational therapist and a physical activity monitor. Patients will also participate in 12 computerized mirror therapy sessions (twice a day, 2 days a week, from week 4 to 6 of the program).
47928384|NCT02925533|DRUG|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
47928385|NCT02925533|DRUG|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
48451864|NCT03425344|DIAGNOSTIC_TEST|Diagnostic|No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
48451865|NCT03884894|DIAGNOSTIC_TEST|molecular assay|performed with blood culture simultaneously
48451866|NCT03884894|DIAGNOSTIC_TEST|Blood culture|performed with molecular assay simultaneously
48451867|NCT01793558|PROCEDURE|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
48451868|NCT05469997|BEHAVIORAL|Mediterranean-Ketogenic Diet|In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (\~70-75% of your daily caloric intake) and lean proteins (\~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
48451869|NCT05469997|DIETARY_SUPPLEMENT|Mediterranean diet supplemented with medium-chain triglyceride oil|"The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level \[ATP\]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive."
48451870|NCT03283358|BEHAVIORAL|Person-centered follow up|
48451871|NCT02597374|DEVICE|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
48451872|NCT03275363|DIAGNOSTIC_TEST|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span."
48451873|NCT03275363|DIAGNOSTIC_TEST|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
48451874|NCT03275363|BIOLOGICAL|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
48451875|NCT03275363|DIAGNOSTIC_TEST|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
48451876|NCT03275363|DIAGNOSTIC_TEST|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
48451877|NCT04254133|BEHAVIORAL|Questionnaire|Complete questionnaire
48451878|NCT04254133|PROCEDURE|Biospecimen Collection|Provide saliva samples
48451879|NCT04254133|DIAGNOSTIC_TEST|Genetic Testing|Undergo genetic testing
48451880|NCT04254133|OTHER|Genetic Counseling|Undergo counseling
48451881|NCT04254133|OTHER|Laboratory Biomarker Analysis|Correlative Studies
48451882|NCT05646251|DEVICE|Heart Ultrasound|A wand is placed on the chest to use soundwaves to make a picture of the heart and shows how the muscle and valves work. This helps with device placement.
48621623|NCT00306488|DRUG|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
48451883|NCT06066047|OTHER|TOUCH ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue."
48451884|NCT06066047|OTHER|AUDITORY ATTENTIVE TREATMENT|"15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period."
48451885|NCT06626984|DRUG|Imatinib|Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
48451886|NCT06626984|DRUG|Compound sodium lactate solution|Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
48451887|NCT03053362|DRUG|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
48451888|NCT03053362|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
48451889|NCT03501511|BEHAVIORAL|IDF modules|Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
48451890|NCT03501511|BEHAVIORAL|Conversational Maps|Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
48621624|NCT05770310|DRUG|JS015|Patient receives specific dose of JS015. The administration method of JS015 is intravenous infusion.
48621625|NCT02503046|OTHER|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
48451891|NCT04013217|COMBINATION_PRODUCT|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
48621626|NCT02503046|GENETIC|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
48621627|NCT01936155|DEVICE|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
48637442|NCT06569277|OTHER|A mobile application|Those who agreed to download a mobile app for colonoscopic bowel preparation on their smartphones.
47928386|NCT03487601|OTHER|transcranial direct current stimulation|Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
47928387|NCT03487601|OTHER|sham transcranial direct current stimulation|Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
47928388|NCT06434402|BEHAVIORAL|Behavioral Intervention|Write about cancer experiences
47928389|NCT03099343|BEHAVIORAL|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
47928390|NCT04898205|OTHER|Treadmill Exercise|The cardiopulmonary rehabilitation protocol utilizes progressive treadmill exercise with alternating increases in intensity and incline with no more than 0.5 Met increase per session.
47928391|NCT04898205|OTHER|Concentrated Oxygen|Supplemental oxygen from a concentrator (6 liters per minute) will be provided via nasal cannula regardless of oxygen saturation.
47928392|NCT04898205|OTHER|Concentrated Air|Room air will be delivered through an concentrator provided via nasal cannula.
47928393|NCT02901665|OTHER|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
48451892|NCT06366386|BEHAVIORAL|Screening and treatment of hypertension among PLHIV in DSD models for HIV|In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.
48451893|NCT04023981|DEVICE|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
47928394|NCT03920904|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
47928395|NCT01904773|DRUG|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
47928396|NCT00430183|DRUG|docetaxel|75 mg/m\^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
47928397|NCT00430183|DRUG|LHRH agonist|Given intramuscularly
47928398|NCT00430183|PROCEDURE|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
48451894|NCT03173872|PROCEDURE|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
48451895|NCT00304733|DEVICE|cast vs. shoe|
48451896|NCT06627374|DIAGNOSTIC_TEST|Patent Ductus Arteriosus in neonates|Neonates admitted to Neonatal care Unit after birth, undergoing hsPDA (hemodynamically significant Patent Ductus Arteriosus) closure according to standard clinical practice, will be included.
48451897|NCT04204395|DEVICE|Peanut Ball|The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
48451898|NCT03957226|DEVICE|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
48451899|NCT06218524|DRUG|Haloperidol Tablets|Haloperidol tablet 6mg, Oral, Triple/Day
48451900|NCT06218524|DRUG|Temozolomide|Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
48621628|NCT01801254|OTHER|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
48621629|NCT01801254|OTHER|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
48621630|NCT01712516|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
48621631|NCT01712516|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
48621632|NCT01712516|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
48621633|NCT01712516|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
47928399|NCT03769584|OTHER|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
47928400|NCT03769584|OTHER|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
47928401|NCT04322370|PROCEDURE|Standard of Care Surgical Procedure|Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
47928402|NCT04322370|DEVICE|VersaWrap Treatment|is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
47928403|NCT04348227|BEHAVIORAL|Enhanced hygiene measures|Wether or not hygiene measures dictated by the pandemic of severe acute respiratory syndrome coronavirus 19 , reduce multi drug resistant pathogens isolated in endotracheal aspirates.
48279839|NCT02790229|OTHER|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
47928404|NCT05552144|DEVICE|Hum by Colgate Smart Kids Toothbrush (battery powered) - 490000006871|The first 15 caregivers and their children who meet the inclusion/exclusion characteristics and sign an Informed Consent Form/provide assent will be entered into the study. The caregivers will be asked to supervise the tooth brushing experience of the children with hum Kids toothbrush twice a day for 4 weeks using the associated app. The caregivers will also be asked to fill out questionnaires and participate in interviews regarding the children's brushing habits and experiences.
48279840|NCT02790229|OTHER|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
48451901|NCT03969628|DIAGNOSTIC_TEST|ICCMS|Risk caries assessment will consider ICCMS criteria
48451902|NCT06408519|OTHER|Placebo (open-label)|P-Tabletten weiss 10mm (Lichtenstein, Zentiva) pills 3x/day
48451903|NCT06408519|DRUG|Ibuprofen 400 mg|Ibuprofen pills 3x/day
48451904|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
48451905|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
48451906|NCT05370807|DRUG|Regorafenib 40 MG Oral Tablet|Patients take 2 regorafenib oral tablets of 40 mg daily
48451907|NCT05370807|DRUG|Triplet therapy|Regorafenib in combination with BRAF- / MEK- inhibitors
48451908|NCT02375477|OTHER|Educational Intervention|Given educational presentation
48451909|NCT05474079|OTHER|Moderate intensity exercise training|The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
48451910|NCT04099758|BEHAVIORAL|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
48451911|NCT04099758|BEHAVIORAL|Audio-recording control|10 minute non-fiction audio-recording delivered online
48451912|NCT05247723|DEVICE|Standard IV Cannula for aspiration of testicular sperm|After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
48451913|NCT05247723|PROCEDURE|Micro-TESE|Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
48451914|NCT01710748|DEVICE|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
48451915|NCT01710748|DEVICE|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
48451916|NCT01137591|DRUG|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
48279841|NCT05524883|DRUG|DYNE-251|Administered by IV infusion
48279842|NCT05524883|DRUG|Placebo|Administered by IV infusion
48279843|NCT01783665|OTHER|aerobic exercise|
48279844|NCT01783665|OTHER|home exercise program|
48279845|NCT03617926|DEVICE|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
48279846|NCT03617926|OTHER|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
48279847|NCT05098184|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
48279848|NCT02743858|OTHER|Bilateral arm measurements|Pts treated with ALND, bilateral arm measurements will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder \& the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements. Measurements will be performed before surgery, post-operatively \& at timepoints of 6,12,18, \& 24 months after surgery for 2 years will be obtained using the Perometer (Model 350 NT Perometer, Per-System) for bioimpedance measurements. Pts who have not yet developed lymphedema by 2 years, an additional measurement at approx 3 years post-surgery will be performed. If pt is diag with lymphedema at the 3-year visit, she will be asked to continue on study for an additional year. Pts treated with SLNB alone, following re-consent, a long-term follow-up volumetric arm measurement will be obtained using the perometer \& circumferential arm measurements at a minimum of 2 years post-surgery.
48279849|NCT02743858|OTHER|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
48279850|NCT02743858|BEHAVIORAL|Quality of Life Questionnaire|
48279851|NCT02743858|OTHER|Blood draw|Patients enrolled in the translational study (Cohort 3) will undergo blood draws for serum collection preoperatively and 12-24 months postoperatively to test for FGF2, IL4, IL10, TGFB, Leptin, IL6, and CRP. At both timepoints, up to 20 mL of blood will be collected.
48279852|NCT01858103|DRUG|BMN 110|
48279853|NCT02883699|BEHAVIORAL|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
48279854|NCT02883699|BEHAVIORAL|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
48279855|NCT02883699|BEHAVIORAL|Standard resistance training|Machine based hypertrophy training 2 x per week
48279856|NCT02883699|BEHAVIORAL|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
48621634|NCT00485303|DRUG|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
48451917|NCT01137591|DRUG|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
48451918|NCT03680313|PROCEDURE|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
48451919|NCT03476603|DRUG|Irbesartan|Patients are tested for their normal prescription irbesartan medication
48451920|NCT00557050|OTHER|Training|10-week eccentric hamstring muscle training
48451921|NCT05412576|DRUG|Lidocaine Hydrochloride 2% Injection Solution|Injectable
48451922|NCT05412576|DRUG|0.9% NaCl|Injectable
48451923|NCT06561061|DRUG|zinc sulfate|Dispersible (20 mg) tablet
48451924|NCT06561061|DRUG|Placebo|Dispersible tablet
48451925|NCT00004148|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
48451926|NCT04112823|DRUG|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
48451927|NCT04112823|DRUG|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
48451928|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
48451929|NCT01845272|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
48451930|NCT04732325|DEVICE|Spinal cord stimulation|Researchers will program the spinal cord stimulation (SCS) system to deliver, according to the randomization status of the participant, burst, kHz, tonic, and sham stimulation.
48451931|NCT02584907|OTHER|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
48451932|NCT06112626|BEHAVIORAL|CHG Skin Treatment Video|Short CHG skin treatment video that reviews the rationale/importance of CHG bathing, and the appropriate process for bathing
48451933|NCT00152451|DRUG|Seletracetam (ucb 44212)|"* Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration"
48451934|NCT05745363|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor
48451935|NCT04906538|PROCEDURE|all- inside anterior cruciate ligament reconstruction|all- inside anterior cruciate ligament reconstruction with internal suture augmentation technique
48451936|NCT03526757|OTHER|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
48621635|NCT00485303|DRUG|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
48621636|NCT00589264|DIETARY_SUPPLEMENT|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
48621637|NCT00589264|DIETARY_SUPPLEMENT|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
48621638|NCT03736720|DRUG|Fluorouracil|Given IV
48621639|NCT03736720|DRUG|Leucovorin|Given IV
48621640|NCT03736720|DRUG|Liposomal Irinotecan|Given IV
48621641|NCT03736720|PROCEDURE|Quality-of-Life Assessment|Correlative studies
48621642|NCT00000640|DRUG|Primaquine|
48451937|NCT03526757|OTHER|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
48451938|NCT03030664|DIETARY_SUPPLEMENT|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10\^8 CFU) of the study product in connection with feeding
48451939|NCT03030664|DRUG|Placebo|Same formulation as study product, without probiotics.
48451940|NCT05635812|OTHER|Neuropsychological assessment|neuropsychological assessment and clinical scales duration: 3 hours
48451941|NCT05635812|OTHER|EEG experimentation|duration: 1 hour
48451942|NCT05635812|OTHER|Oculometry experimentation|duration: 30 minutes
48451943|NCT03428880|DRUG|Morphine|spinal morphine is done before cesarean section
48451944|NCT03428880|DRUG|Quadratus lumborum block|a US Block QLB is done after surgery
48451945|NCT01718704|DEVICE|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
48451946|NCT06483646|OTHER|Gaseous sampling:|the subject is asked to aspirate the gaseous contents of his oral cavity using a 1ml plastic syringe.
48451947|NCT05150041|DEVICE|Guardian connect|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
48621643|NCT00000640|DRUG|Sulfamethoxazole-Trimethoprim|
48621644|NCT00000640|DRUG|Dapsone|
48621645|NCT00000640|DRUG|Clindamycin|
48621646|NCT03838874|DRUG|Low-Dose Bupivacaine|10 mg (2 mL of 0.5%) administered as an isobaric spinal anesthetic
48621647|NCT03838874|DRUG|Mepivacaine|70 mg (3.5 mL of 2%) administered as an isobaric spinal anesthetic
48621648|NCT03061942|OTHER|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
48621649|NCT03061942|OTHER|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
48621650|NCT03788330|DEVICE|Fresh air system with filtration|Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
48451948|NCT05150041|DEVICE|iPro2|"* Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period."
48451949|NCT02714465|OTHER|hyperbaric oxygen therapy|hyperbaric oxygen therapy
48451950|NCT04183335|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
48451951|NCT04183335|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
48451952|NCT04183335|DRUG|Moisturizers|"Pharmaceutical form:~Route of administration: Topical"
48451953|NCT04183335|DRUG|Low to medium potent topical corticosteroids|"Pharmaceutical form:~Route of administration: Topical"
48451954|NCT04183335|DRUG|Topical calcineurin inhibitors|"Pharmaceutical form:~Route of administration: Topical"
48451955|NCT06200116|OTHER|Non-Interventional Study|Non-interventional study
48621651|NCT00338078|DEVICE|nocturnal oxygen treatment from oxygen concentrators|
48621652|NCT02543411|DRUG|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
48621653|NCT02543411|DRUG|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
48621654|NCT04029597|BEHAVIORAL|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the RPMS. The RPMS was developed in collaboration with the University of Mississippi Medical Center (UMMC) Center of Telehealth. Patients enrolled in this open trial of the RPMS will interact with the RPMS system on a daily basis and with UMMC's Center for Telehealth nurse care coordinators and research and clinical staff on an as needed basis. The RPMS will provide patients with include an electronic tablet (i.e., iPad) and the ability to receive data from the patient's weight scale and pedometer. Patients will be asked to wear the pedometer daily to track engagement in physical activity and weigh themselves weekly to track weight during the 3 month period. Educational information specific to pediatric obesity and healthy eating and engagement in physical activity will be presented daily through brief presentations and video clips.
48621655|NCT00609505|OTHER|Telemedicine|Telemedicine genetic counseling
48621656|NCT00609505|OTHER|Face-to-Face|Face-to-face genetic counseling
48621657|NCT05727644|DRUG|NNC0194-0499|Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.
48621658|NCT03990974|DRUG|postoperative antimicrobial prophylaxis|The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
48621659|NCT03990974|OTHER|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy unless necessary.
48621660|NCT03561207|DIAGNOSTIC_TEST|EV3D Assay|The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
48621661|NCT05595954|OTHER|Preoperative data collection|Preoperatively, patients will be assessed with Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Clinical Frailty Scale, 3-minute Diagnostic interview for Confusion Assessment Method-defined delirium (3D-CAM, incl. severity score), modified National Institutes of Health Stroke Scale (mNIHSS), and hand grip strength measurement (using a hand dynamometer) to establish a baseline measurement of the physical, cognitive and mental status.
48621662|NCT05595954|DIAGNOSTIC_TEST|Intraoperative NIRS|Intraoperatively, NIRS data will be collected and recorded in real-time.
48621663|NCT05595954|DIAGNOSTIC_TEST|Intraoperative TCD|Intraoperatively, TCD data will be collected and recorded in real-time.
48621664|NCT05595954|DIAGNOSTIC_TEST|Intraoperative invasive MAP|Intraoperatively, invasive arterial blood pressure data will be collected and recorded in real-time.
48621665|NCT05595954|DIAGNOSTIC_TEST|Postoperative NIRS|Postoperatively, NIRS monitoring will be continued in the ICU after the surgery until (i) endotracheal extubation, or (ii) for the first 24 hours or (iii) until emergency re-operation, whichever occurs first.
48621666|NCT05595954|OTHER|Postoperative data collection|Postoperatively patients will be evaluated for POD with 3D-CAM or CAM-ICU and for clinical stroke with mNIHSS. Postoperative neurocognitive disorders will be assessed using MoCA.
48621667|NCT05595954|DIAGNOSTIC_TEST|Collection of serum biomarker panel|The serum biomarker panel will consist of four markers of neurological injury glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), t-tau and ubiquitin-C-terminal-hydrolase-L1 (UCH-L1). Blood samples will be obtained preoperatively, after ICU admission, on postoperative day 1, 2, 6 (or hospital discharge, whichever occurs first) and between 6 and 12 weeks after surgery.
48621668|NCT05595954|DIAGNOSTIC_TEST|Collection of blood sample for genetic study|A blood sample for the genetic study will be obtained preoperatively.
48621669|NCT01617109|DIETARY_SUPPLEMENT|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
48621670|NCT01617109|OTHER|Placebo|administered as 5 pills daily or as 2 snack bars
48621671|NCT03628326|OTHER|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
48621672|NCT02332707|DRUG|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
48621673|NCT02332707|DRUG|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
48621674|NCT02332707|DRUG|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
48451956|NCT05747625|BIOLOGICAL|Panitumumab|Given IV
48451957|NCT05747625|DRUG|Zirconium Zr 89 Panitumumab|Given IV
48451958|NCT05747625|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48451959|NCT05747625|PROCEDURE|Computed Tomography|Undergo PET/CT
48451960|NCT05747625|OTHER|Electronic Health Record Review|Ancillary studies
48451961|NCT06555458|DRUG|Dexmedetomidine|Patient group to be given dexmedetomidine
48451962|NCT06555458|DRUG|Saline|Patient group to be given salin
48451963|NCT05537129|PROCEDURE|Total Gastrectomy|The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
47928405|NCT04564768|BEHAVIORAL|Online Mindfulness-Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
48451964|NCT02120872|DRUG|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
48451965|NCT02120872|BIOLOGICAL|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
48451966|NCT02120872|PROCEDURE|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
48451967|NCT02651948|PROCEDURE|Transperineal, MRI-guided, prostate biopsy|
48451968|NCT02651948|PROCEDURE|Transrectal prostate biopsy (TRB):|
48451969|NCT01429363|PROCEDURE|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
48451970|NCT05069688|DRUG|rifampicin|Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety
48451971|NCT02134821|PROCEDURE|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
48451972|NCT02480660|BEHAVIORAL|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
48451973|NCT01995227|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine
48451974|NCT01995227|BIOLOGICAL|CRCL|Personalized anti-cancer vaccine
48451975|NCT01995227|BIOLOGICAL|AlloStim|ID injections IV infusion
48451976|NCT06261294|DIAGNOSTIC_TEST|OncoSweep Lung Spotligh|This study is to develop and validate the performance of OncoSweep Lung Spotlight for detecting circulating miRNA expression, ctDNA methylation status, platelet RNA, and tumor marker expressions by utilizing real-time polymerase chain reaction (qPCR). The method is to collect venous blood from subjects during their routine visit to the healthcare facilities.
48451977|NCT01438593|PROCEDURE|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
48451978|NCT02121067|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
48451979|NCT00091377|DRUG|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
48451980|NCT00091377|DRUG|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
48451981|NCT00091377|DRUG|phenoxodiol|IV 3 mg/kg
48451982|NCT05625178|DEVICE|Transcutaneous vagus nerve stimulation|tVNS will be performed by the application of an auricular electrode placed at the cymba concha of the left ear. The auricular electrode containing the anode will be applied with a conductive gel without prior disinfection. Once the electrode fits the cymba concha comfortably, the participant will lie down or take a position that is comfortable for them. Once in position, investigators initiate tVNS for 60 minutes with a below-discomfort-threshold intensity with 25 Hz and pulse width 250 uS. The electrical parameters will be modified accordingly to keep the below-discomfort threshold during the intervention.
48451983|NCT05651243|DIETARY_SUPPLEMENT|Ketone Ester Supplement|Oral ingestion of a ketone supplement combined with a flavoring agent and diluted in water
48451984|NCT05651243|OTHER|Placebo|Oral ingestion of cellulose combined with a flavoring agent and diluted in water
48451985|NCT00907387|DRUG|RT001|Dose A RT001
48451986|NCT00907387|DRUG|RT001|Dose B RT001
48451987|NCT00907387|OTHER|Placebo|Dose C Placebo
48451988|NCT02442687|DRUG|JKB-121: 5 mg twice daily|
48621675|NCT02332707|DRUG|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
48451989|NCT02442687|DRUG|JKB-121: 10 mg twice daily|
48621676|NCT02332707|DRUG|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
48621677|NCT02332707|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
48621678|NCT03535415|DRUG|Recombinant Human Growth Hormone Injection (rhGH)|rhGH 0.05mg/kg/d by subcutaneous injection
48451990|NCT02442687|DRUG|Placebo|
48451991|NCT06561074|DRUG|Decitabine|Given by vein
48451992|NCT06561074|DRUG|Venetoclax|Given by mouth
48451993|NCT06561074|DRUG|Calaspargase pegol-mknl|Given by vein
48451994|NCT02990286|DRUG|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
48621679|NCT03564262|OTHER|Low Sodium Meal (138 mg sodium)|One Low Sodium Meal
48621680|NCT03564262|OTHER|High Sodium Meal (1,495 mg sodium)|One High Sodium Meal
48621681|NCT00883727|DRUG|Stem cell|IV infusion of stem cells
48621682|NCT00883727|DRUG|Plasmalyte A|IV infusion
48279857|NCT02183454|DEVICE|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
48279858|NCT05929599|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
48279859|NCT05929599|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
48279860|NCT00761215|DRUG|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
48279861|NCT00761215|DRUG|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
48279862|NCT00761215|DRUG|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
48279863|NCT06568094|DRUG|HRS-5041 tablets|HRS-5041 tablets
48279864|NCT06568094|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
48279865|NCT06568094|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
48279866|NCT06568094|DRUG|Docetaxel Injection|Docetaxel Injection
48279867|NCT06568094|DRUG|HRS-1167 tablets|HRS-1167 tablets
48279868|NCT06568094|DRUG|SHR2554 tablets|SHR2554 tablets
48279869|NCT00279747|DRUG|meloxicam 0.25 mg/kg|
48279870|NCT00279747|DRUG|meloxicam 0.125 mg/kg|
48279871|NCT00279747|DRUG|naproxen 10 mg/kg|
48451995|NCT02990286|DRUG|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
48451996|NCT02990286|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
48451997|NCT00833209|PROCEDURE|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
48451998|NCT00833209|PROCEDURE|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
48451999|NCT00833209|PROCEDURE|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
48452000|NCT06371807|DRUG|Pembrolizumab injection|(KXCb - PA\[E\]C) vs (KPA\[E\]C - KXCb) Pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab in the adjuvant setting vs Pembrolizumab + doxorubicin or epirubicin (A or E) + cyclophosphamide (C) followed by pembrolizumab (K) + paclitaxel (X) + carboplatin (Cb) followed by pembrolizumab in the adjuvant setting
48452001|NCT01344590|OTHER|Normal Saline|Standard saline procedure will be utilized.
48621683|NCT01163799|DRUG|Alefacept (ASP0485)|Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
47928406|NCT05946434|OTHER|Kinesio Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28."
48279872|NCT03740334|DRUG|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
48279873|NCT03740334|DRUG|Dexamethasone|Corticosteroids are commonly used to treat ALL.
48279874|NCT03740334|DRUG|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
48279875|NCT00223340|BEHAVIORAL|Patient Activation and Diabetes Registry|
48452002|NCT01344590|OTHER|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
48452003|NCT01449981|BEHAVIORAL|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
48452004|NCT01449981|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
48279876|NCT06158139|BIOLOGICAL|iC9-CAR.B7-H3 T cell infusion|iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.
48279877|NCT05802030|OTHER|Plyometric training|Plyometric training can be described as a type of exercise that involves a rapid and forceful movement that consists of an eccentric contraction, followed by an immediate and explosive concentric contraction. Upper and lower limb plyometrics are exercises that enable an upper and lower body muscle group to react quickly to produce maximal strength
48279878|NCT05802030|OTHER|Routine training|Regular tennis training, including normal fitness training, and injury prevention drills
48279879|NCT06196502|OTHER|Gentle Human Touch (GHT)|Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior. GHT Hepatitis-B vaccine will start 5 minutes before the application and continue during and after the procedure. It is planned to take 10 minutes in total. The researcher will place one hand on the baby's head and the other hand on the baby's lower abdomen, covering the waist and hips, for 10 minutes.
48452005|NCT01165047|DRUG|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
48452006|NCT05329922|BEHAVIORAL|ALICE: Audiological rehabilitation|Persons who are randomised into this arm of the study will be asked to train their listening and communication skills using the ALICE app.
48452007|NCT01463579|OTHER|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
48452008|NCT01463579|OTHER|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
48452009|NCT06627712|DRUG|SBRT+PD-1 Inhibitor + Chemotherapy|"Radiotherapy: 24Gy/3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
48452010|NCT06627712|DRUG|PD-1 Inhibitor + Chemotherapy|"Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle; Carboplatin AUC=5, IV, administered on day 1 of each cycle.~Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks"
48452011|NCT02376114|DRUG|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
48452012|NCT02376114|DRUG|Placebo to Ginkgo biloba|
48452013|NCT00261391|DRUG|Marimastat|
48452014|NCT04723693|OTHER|Qualitative Interview|A single one hour semi structured qualitative interview
48452015|NCT03979768|OTHER|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
48452016|NCT05277896|DRUG|Ketamine|Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation
48452017|NCT05277896|DRUG|Etomidate|Intravenous etomidate as the sedative for induction of anesthesia during emergency tracheal intubation
48452018|NCT05724784|BEHAVIORAL|Flourish|Flourish is a text messaging program that aims to improve coping following cyberbullying and reduce suicide risk among youth.
48452019|NCT01602575|BEHAVIORAL|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
48452020|NCT00387933|DRUG|hydroxyurea|
48452021|NCT00387933|DRUG|imatinib mesylate|
48452022|NCT00387933|DRUG|vatalanib|
48452023|NCT00500201|DRUG|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
48452024|NCT00500201|DRUG|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
48452025|NCT00500201|DRUG|Placebo|Placebo tablets will be administered orally by subjects.
48452026|NCT00198835|BEHAVIORAL|Maternal nutrition and infant feeding advice|
48621684|NCT06349278|PROCEDURE|Pancreatic resection and non-anatomic liver resections.|Pancreatic resection and non-anatomic liver resections.
48621685|NCT05951686|DRUG|Desflurane|In inhalation group, desflurane will be used for general anesthesia maintenance under the screening with Patient State Index (PSI) between a score of 25-50. Remifentanil infusion is used with desflurane with a dose of 0.05-2 mcg/ kg/ min according to PSI . Fresh gas flow is used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
48621686|NCT05951686|DRUG|Remifentanil infusion|Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
48621687|NCT05951686|OTHER|Fresh gas|Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
48621688|NCT05951686|DRUG|Propofol infusion|Propofol infusion will be used for general anesthesia maintenance with a dose of under the screening of Patient State Index (PSI) between a score of 25-50 in group tiva.
48621689|NCT01451658|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
48621690|NCT01682031|DIETARY_SUPPLEMENT|selenomethionine|Given PO
48621691|NCT01682031|OTHER|placebo|Given PO
48621692|NCT01682031|DRUG|cisplatin|Given IV
48621693|NCT01682031|RADIATION|radiation therapy|Undergo radiotherapy
48621694|NCT01682031|PROCEDURE|quality-of-life assessment|Ancillary studies
48621695|NCT05403918|OTHER|conventional physiotherapy|Hot pack, TENS, and therapeutic ultrasound will be applied for 10 minutes. Then glides will be given 30 x 3 times in grades III and IV. The rest of the exercises will be prescribed as 3 sets for 10 repetitions with 2 minutes of rest between sets for 6 weeks with respect to 3 sessions per week.
48452027|NCT02332863|DEVICE|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
48452028|NCT02332863|DEVICE|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~* total length of procedure~* how many markers are successfully deployed~* technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
48452029|NCT01711632|DRUG|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
48452030|NCT00840203|DRUG|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
48452031|NCT00840203|DRUG|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
48452032|NCT00377260|DRUG|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
48452033|NCT00377260|DRUG|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
48452034|NCT03586622|DIETARY_SUPPLEMENT|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
48452035|NCT03586622|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum\* BL03, B. infantis\* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus\*\* BD08; \*Recently reclassified as B. animalis subsp. lactis \*\* Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
48452036|NCT00755313|BIOLOGICAL|trastuzumab|
48452037|NCT00755313|DRUG|aromatase inhibition therapy|
48452038|NCT00755313|DRUG|carboplatin|
48452039|NCT00755313|DRUG|cyclophosphamide|
48452040|NCT00755313|DRUG|docetaxel|
48452041|NCT00755313|DRUG|doxorubicin hydrochloride|
48452042|NCT00755313|OTHER|metabolic assessment|
48452043|NCT00755313|OTHER|questionnaire administration|
48452044|NCT00755313|OTHER|study of socioeconomic and demographic variables|
48452045|NCT00755313|PROCEDURE|cognitive assessment|
48452046|NCT00755313|PROCEDURE|positron emission tomography|
48452047|NCT00755313|RADIATION|fludeoxyglucose F 18|
48452048|NCT00729976|DRUG|Ibuprofen suppository|5-10mg/Kg of ibuprofen
48452049|NCT00729976|DRUG|Ibuprofen Suspension|5-10mg/Kg
48452050|NCT01701323|BIOLOGICAL|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
48452051|NCT01701323|DRUG|Cytarabine|Given IV
48452052|NCT01701323|DRUG|Filgrastim|Given SC or IV
48452053|NCT01701323|DRUG|Fludarabine Phosphate|Given IV
48452054|NCT05125900|OTHER|Proximal box elevation using one of the tested materials|Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
48452055|NCT06626724|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma.
48452056|NCT00169364|DEVICE|positron emission tomography|
48452057|NCT01015703|BIOLOGICAL|CoVaccine HT|intramuscular injection, dose escalation
48452058|NCT06623227|DIETARY_SUPPLEMENT|Placebo|Capsule contains substances that are safe, non-active, and commonly used in pharmaceuticals (microcrystalline cellulose) with an appropriate coloring dye and in the active arms, Vitamin E and C. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
48452059|NCT06623227|DIETARY_SUPPLEMENT|Vitamin E and C|Capsule Vitamin E (Natural Vitamin E, d-alpha tocopherol) 150 IU or 200 IU containing also Vitamin C 100 mg or 200 mg b.id depending on age. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
48452060|NCT01066858|DRUG|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
48452061|NCT04569773|BEHAVIORAL|Impact of Event Scale-Revised|The IES-R is a validated 22-item self-report scale measuring psychological stress reactions after a major life or traumatic event.1-3Items are rated with reference to the past 7 days on a 5-point scale, ranging from 0 to 4. Three subscale scores are calculated by taking the mean of the item responses: Intrustion (8 items), Avoidance (8 items), and Hyperarousal (6 items). The total score is similarly computed by taking the mean of all 22 items. All scores range from 0 to 4, with higher scores indicating higher event-related distress. Internal consistency estimates(Cronbach's alpha) for all scores range between 0.79 to 0.92.
48452062|NCT04569773|BEHAVIORAL|Reproductive Concerns Scale|The RCS is a 14-item, 5-point Likert-type self-report measure that assesses concern among cancer survivors whose reproductive ability may have been impaired or lost due to disease and/or treatment. Answers are rated on a 5-point scale (0 to 4), and a single total score is produced by summing responses to all 14 items (range, 0-56 points). A higher score represents more reproductive concerns, and a lower score represents fewer reproductive concerns. In the RCS validation study, internal consistency reliability was 0.91 among long-term female cancer survivors and 0.81 among control women.
48452063|NCT04569773|BEHAVIORAL|Decision Regret Scale|"The DRS is a 5-item, 5-point Likert-type self-report measure that assesses distress or remorse after a health-care decision.5 Items are rated on a scale from 1 (strongly agree) to 5 (strongly disagree). Two of the statements (items 2 and 4) are phrased in the negative direction.~A single, total score is produced by first reversing the scores of the 2 negatively phrased items, then taking the mean of the 5 items. This mean is then rescaled to range from 0 to 100 by subtracting 1, then multiplying by 25. A score of 0 indicates no regret, whereas a score of 100 indicates high regret. Internal consistency reliability coefficients for the DRS range from 0.81 to 0.92."
48452064|NCT06093984|PROCEDURE|duostim vs. two antagonist ovarian stimulations|Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
48452065|NCT02908776|DIETARY_SUPPLEMENT|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
48452066|NCT02908776|OTHER|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
48452067|NCT05006794|DRUG|GS-9716|Tablet(s) administered orally
48452068|NCT05006794|DRUG|Docetaxel|Administered intravenously
48452069|NCT05006794|DRUG|sacituzumab govitecan-hziy|Administered intravenously
48452070|NCT04418219|DRUG|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
48452071|NCT04418219|BIOLOGICAL|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
48452072|NCT04418219|BIOLOGICAL|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
48452073|NCT04418219|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
48452074|NCT04418219|OTHER|Questionnaire Administration|Ancillary studies
48452075|NCT04418219|OTHER|Quality of Life Assessment|Ancillary studies
48452076|NCT00247195|BEHAVIORAL|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
48452077|NCT04200586|DRUG|Dapagliflozin|Dapagliflozin, one of the SGLT-2 inhibitors, will be prescribed to DM patients on clinical ground.
47928407|NCT05946434|OTHER|Rigid Tape Group|"Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28"
47928408|NCT02153879|DRUG|Fenofibrate|fenofibrate 145/day for 12 weeks
47928409|NCT02153879|DRUG|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
47928410|NCT04457895|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
47928411|NCT04457895|OTHER|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
47928412|NCT03235180|DRUG|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
48452078|NCT02393144|DEVICE|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
48452079|NCT02393144|DEVICE|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
48452080|NCT02393144|OTHER|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
48452081|NCT02393144|DRUG|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
48452082|NCT02393144|DRUG|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
48452083|NCT02393144|DRUG|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
48452084|NCT02393144|DRUG|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
48452085|NCT02125461|DRUG|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
48452086|NCT02125461|OTHER|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
48452087|NCT03599362|DRUG|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
47928413|NCT03235180|DEVICE|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
47928414|NCT03235180|DEVICE|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
47928415|NCT03235180|DEVICE|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
47928416|NCT01565304|BEHAVIORAL|POWER Through Choices|10-session group-based sexual education curriculum
47928417|NCT05406193|OTHER|Patient-centred complex intervention in complicated multimorbidity (CIM2)|CIM2 is the second version of the Patient-centred complex intervention in complicated multimorbidity
47928418|NCT00636350|DIETARY_SUPPLEMENT|Pepper|pepper carotenoids as meals
48452088|NCT03599362|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
48452089|NCT03723044|OTHER|EEG and occulometry|Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
48452090|NCT00635648|DRUG|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
48452091|NCT02748707|DRUG|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
48452092|NCT02748707|DRUG|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
48621696|NCT05403918|OTHER|scapular stabilization exercises along with conventional physiotherapy|Each stretch will be repeated 3 times. Each active exercise will be progressed from 3 sets of 10 reps to 3 sets of 15 reps. If the subject easily completed 3 sets of 15 reps of active exercise, they will go on to resisted exercises. These will be performed once a day, for 6 weeks, 3 sessions per week.
48621697|NCT03217097|DRUG|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
48621698|NCT03217097|DRUG|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
47928419|NCT04121624|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the smartphone application and the non-invasive reference method (upper arm cuff).
47928420|NCT03286127|OTHER|specialized palliative care|specialized palliative care provided in different settings
47928421|NCT03216928|DIAGNOSTIC_TEST|Blood test|
47928422|NCT05355493|BEHAVIORAL|Time to Exhaustion cycling test|After completing the MF/control task. Participants will be asked to take place on the cycle ergometer. Participants will perform a 3-min warm-up at 40% of peak power output followed by a rectangular workload at a power output corresponding to their predetermined respiratory compensation point (±80% PPO). RPM was freely chosen between 60 and 100 RPM and was recorded every minute. TTE was measured from the start until the pedal frequency was less than 60 RPM for more than 5s. This TTE task was chosen, based on a previous study of Marcora et al. (2009), who found that mental fatigue impairs physical performance. A researcher will sit behind the subject to ensure compliance with treatment. Subjects will be equipped with a heart rate monitor to continuously follow up heart rate. Subjective psychological assessment will take place with a M-VAS-scale, the NASA-TLX, the success motivation and intrinsic motivation scales, Karolinska Sleepiness Scale and visual analog scale for boredom.
48452093|NCT02748707|DRUG|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
48452094|NCT02748707|OTHER|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
48452095|NCT01717352|BEHAVIORAL|Weight Loss Education|
48452096|NCT01717352|BEHAVIORAL|Sleep and Eating Routine|
48452097|NCT03462342|DRUG|Olaparib Pill|"For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
48452098|NCT03462342|DRUG|AZD6738|"For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
47928423|NCT05355493|BEHAVIORAL|Go/NoGo task|Participants are to react to different stimuli displayed on a computer screen, preceded by a screen with general instructions. Two different stimuli were present at the same time: a Go or NoGo stimulus, and a left or right stimulus (meaning that four combinations are possible: GoRight, GoLeft, NoGoRight and NoGoLeft). If a Go-stimulus is presented, participants are instructed to react to the left or right stimuli with the corresponding arrows. However, if a NoGo stimulus is presented, participants are instructed to refrain from reacting to the either the left or right stimuli. This proposed paradigm measures attention, response inhibition and working memory. Stimuli will be presented for 500 ms, with a varying interstimulus time between 1100 and 1700 ms. Outcomes for Go trials include reaction time and accuracy while the outcome for NoGo trials is only accuracy.
47928424|NCT00000128|DEVICE|Bifocal Spectacle Lenses|
47928425|NCT04646564|DRUG|standard of care|patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
47928426|NCT04646564|RADIATION|radiotherapy + standard of care|"Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT.~Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist."
47928427|NCT05024643|PROCEDURE|Endonasal endoscopy|"Complete sphenoethmoidectomy; Draf type IIa, IIb, and III according to defect location.~Defect less than 3 mm closed by a plug of fat and facia lata or middle turbinate mucosa.~Defect more than 3 mm closed by underlying facia lata, underlying cartilage, and overlay facia lata."
47928428|NCT00334178|DRUG|Laxymig ER (drug)|
47928429|NCT02756988|DRUG|Coppertone (BAY987704)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: X71-109)
47928430|NCT00503945|DEVICE|Nasal continuous positive airway pressure (nCPAP)|
47928431|NCT02946931|DRUG|Prizbind®|Prizbind®
47928432|NCT05449470|DEVICE|CDSS|A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
47928433|NCT05449470|DEVICE|Patient Portal|A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
47928434|NCT00123890|DRUG|GW873140|
47928435|NCT00203814|DRUG|Sulfadoxine-pyrimethamine|
47928436|NCT00203814|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
47928437|NCT00714571|BEHAVIORAL|Mnemonic strategy training (MST)|
47928438|NCT00714571|BEHAVIORAL|Repeated exposure (XP)|
47928439|NCT00714571|BEHAVIORAL|Subtracting Cues training|
48452099|NCT06626893|BIOLOGICAL|Functional tests|Functional analyses will be performed on primary sample from each enrolled patient. Isolated blast cells are cultered and incubated with a specific library of drugs (175 drugs) at four different concentrations for 72 hours.
48452100|NCT06626893|GENETIC|Next Generation Sequencing analysis|For each patient, sequencing analyses will be performed on blast cells (for somatic mutations) and on epithelial cells from buccal swab (for germline mutations)
48621699|NCT01422109|DRUG|YH14659|YH14659 capsule by oral
47928440|NCT01850576|BEHAVIORAL|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
47928441|NCT05863598|BEHAVIORAL|Enhancing protective factors|Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.
47928442|NCT05863598|BEHAVIORAL|Expressive writing|Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
47928443|NCT00282464|DRUG|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
47928444|NCT00282464|DRUG|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
48452101|NCT06626893|BIOLOGICAL|Microvesicles analysis|Analyses on microvesicles isolated from both Bone Marrow samples and Peripheral Blood Samples will be performed to investigate the microenvironment of the disease.
48452102|NCT01600963|DRUG|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
48452103|NCT01600963|DRUG|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
48452104|NCT01600963|DRUG|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
48452105|NCT01600963|DRUG|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
48452106|NCT04035187|DRUG|fast itraconazole tablet|100mg dose
48452107|NCT04035187|DRUG|medium itraconazole tablet|100mg dose
48452108|NCT04035187|DRUG|slow itraconazole tablet|100mg dose
48452109|NCT04035187|DRUG|oral itraconazole solution|100mg dose
48452110|NCT04532684|DRUG|Duloxetine|
48621700|NCT01422109|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
48452111|NCT04532684|DRUG|Pregabalin|
47928445|NCT05767879|DRUG|Encorafenib + Binimetinib|"In the open label phase II study, the combination of BRAF/MEK inhibition with encorafenib/binimetinib in the neo-adjuvant setting will be investigated.~Furthermore, efficacy of adjuvant BRAF/MEK inhibition with encorafenib/binimetinib, for 44 weeks will be evaluated."
47928446|NCT04108351|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
47928447|NCT04108351|OTHER|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
47928448|NCT04108351|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
47928449|NCT04465136|DEVICE|CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)|CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
47928450|NCT04321785|OTHER|Placebo|placebo capsule (mannitol)
47928451|NCT04321785|OTHER|Caffeine|caffeine capsule (80 mg of caffeine plus mannitol)
47928452|NCT04112589|DRUG|Quizartinib|Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
47928453|NCT04112589|DRUG|Fludarabine|30 mg/m2 intravenous days 1 to 4 of the cycle
47928454|NCT04112589|DRUG|Cytarabine|2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
47928455|NCT04112589|DRUG|Idarubicin|10 mg/ 2 intravenous days 1 to 3 of the cycle
47928456|NCT04112589|DRUG|glycosylated G-CSF|daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
47928457|NCT00940472|DRUG|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
47928458|NCT00940472|DRUG|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
47928459|NCT00331552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
47928460|NCT00331552|DRUG|cyclophosphamide|Given orally
47928461|NCT00331552|BIOLOGICAL|trastuzumab|Given IV
47928462|NCT06309394|DRUG|INCB099280|INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
48452112|NCT02610647|DRUG|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
48452113|NCT02610647|OTHER|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
48452114|NCT02610647|OTHER|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
47928463|NCT01319331|DRUG|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
47928464|NCT01464905|BIOLOGICAL|NU100|0.25 mg SQ, every other day for 12 months
47928465|NCT01464905|BIOLOGICAL|Placebo|1 mL SQ, every other day for 4 months
47928466|NCT01464905|BIOLOGICAL|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
47928467|NCT05814354|DRUG|SHR-A1811|SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.
47928468|NCT05814354|DRUG|Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization).
47928469|NCT06092125|DEVICE|PET/MR|PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases
47928470|NCT01153776|PROCEDURE|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
47928471|NCT00729391|BEHAVIORAL|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
47928472|NCT00729391|BEHAVIORAL|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
47928473|NCT00729391|BEHAVIORAL|VCT Only|Participants in this group will receive VCT only.
48621701|NCT04607031|DIAGNOSTIC_TEST|measurement of serum ST2 concentrations in serum of patients with acute, ischemic stroke|7 measurements of serum ST2 concentrations from day 0 to day 6, modified Rankin scale before, 6th and 90th day, NIHSS from day 0 to day 6 and 90, TOAST and OCSP classifications
47928474|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
47928475|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
47928476|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
47928477|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
47928478|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
47928479|NCT00669409|DRUG|PF-04383119 (tanezumab)|single dose of Placebo IV
47928480|NCT00672659|DRUG|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
47928481|NCT00672659|DRUG|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
47928482|NCT02836509|DRUG|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
47928483|NCT02836509|DRUG|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
47928484|NCT03387384|OTHER|Non-interventional study|Non-interventional study
47928485|NCT05763589|OTHER|No intervention is involved|No intervention is involved
47928486|NCT01800175|DEVICE|Punctum Plug|
48452115|NCT02610647|OTHER|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
48452116|NCT03024086|DRUG|DWJ1252|DWJ1252 and Placebo of Gasmotin
48452117|NCT03024086|DRUG|Gasmotin|Gasmotin and Placebo of DWJ1252
48452118|NCT03069963|DRUG|Z0063|"Pharmaceutical form: chewable tablets~Route of administration: oral"
48452119|NCT03069963|DRUG|Gaviscon|"Pharmaceutical form: chewable tablets~Route of administration: oral"
48452120|NCT02421822|OTHER|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
48452121|NCT04807426|OTHER|Multi Sensory stimulation exercises|Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity is added by increasing speed of task performance. Conservative Management:Passive stretching exercises for paretic upper extremity muscles .Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set.
48452122|NCT04807426|OTHER|Task Oriented Exercises|"Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
48452123|NCT04807426|OTHER|Task-oriented exercises and Multisensory stimulation Exercises|"Multi Sensory stimulation exercises:Identification tasks will be given to a blindfolded patient. Which includes recognizing shapes, sizes , textures ,Identifying heights , hardness , weight discrimination .Difficulty will be added by increasing the objects to be identified. Joint angle perception training will be started with one joint perception and will advance to multiple joints position perception. Task Oriented Exercises: Patient will perform upper limb functional activities such as Reaching for objects, putting up and down an object, hand to mouth activity, combing hair, folding piece of cloth grasp and release activity, opening a jar, putting beads in jar and writing letters or draw something will be done. Complexity will be added by increasing speed of task performance.~Conservative Management:Passive stretching exercises for paretic upper extremity muscles . Stretchings will be applied for 30 sec with 30 sec rest, 10 repetitions for1 set."
48452124|NCT02705573|DRUG|Mannitol|In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
48452125|NCT04343794|DEVICE|BIOVITALS|Biovitals platform including (1) armband with multiple physiological sensor, (2) remote monitoring, and (3) Analytic platform. The arm will be worn 23 hours a day and off for 1 hour during showering for recharging battery during 24 hr quarantine period
48452126|NCT05309135|DRUG|HCEC-1|HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor
48452127|NCT01501253|DRUG|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
48452128|NCT01501253|DRUG|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
48452129|NCT01501253|DRUG|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
48452130|NCT06560671|OTHER|novel type of health education|animation video based health education
48452131|NCT00606281|DRUG|Aripiprazole|oral, 24mg/day
48452132|NCT00606281|DRUG|placebo|oral, 0mg(4tablets)/day
48452133|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
48452134|NCT00656786|DRUG|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
48452135|NCT00151229|OTHER|target blood pressure|
48452136|NCT02505347|OTHER|No splint|Can move arm as tolerated with no restrictions on mobility
48452137|NCT02505347|DEVICE|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
48452138|NCT04620057|DIETARY_SUPPLEMENT|butyrate|sodium butyrate (20 mg/kg body weight/day)
48452139|NCT04620057|OTHER|placebo|cornstarch
48452140|NCT05594238|BEHAVIORAL|Telephone Engagement|Brief phone session with a study counselor.
48452141|NCT05594238|BEHAVIORAL|Portal Engagement|Access to a virtual portal where participant messages with study counselors.
48452142|NCT05594238|BEHAVIORAL|MI-CBT|8 one-on-one sessions done over the phone or video chat with a study counselor
48452143|NCT03542669|DRUG|6B11-OCIK Injection|Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
48452144|NCT03542669|DRUG|Doxorubicin|Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
47928487|NCT06297252|DIAGNOSTIC_TEST|standardized clinical psychiatric evaluations|"The intervention consists of a psychiatric consultation including :~* assessment of psychiatric disorders using a MINI test~* information gathering (medical, obstetrical and family history, expected term of pregnancy).~* assessment of suicidal behaviour using the Columbia-Suicide Severity Rating Scale (CSSR-S)~* collection of negative life events over the past 12 months, assessed using the Paykel questionnaire"
47928488|NCT06297252|DIAGNOSTIC_TEST|self-administered psychiatric questionnaire assessments|"* EPICES Score: (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé):~* MIBS: (Mother to Infant Bonding Scale)~* PAI: (Prenatal Attachment Inventory)~* EDEQ: (Eating Disorder Examination Questionnaire)~* PCL-5: (Post-traumatic Stress Disorder Checklist for DSM-V)~* MARS: (Medication Adherence Rating Scale)~* EPDS: (Edinburgh Postnatal Depression Scale)"
47928489|NCT06297252|OTHER|blood sampling|"A blood sample is taken to form an optional biological collection, comprising 3 samples:~* A tube to collect RNA from whole blood.~* A tube to collect serum~* A tube to collect native DNA"
47928490|NCT00348933|DRUG|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
47928491|NCT00348933|DRUG|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
47928492|NCT00348933|DRUG|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
47928493|NCT00348933|DRUG|Vitamin B12|1 mg by mouth per day for all weights and ages
47928494|NCT06436664|OTHER|Tooth brushing|Firstly, the toothbrush must be positioned at a 45° angle to the gingival margin. Secondly, the brush should be moved back and forth in small horizontal jerks. Thirdly, with a vertical movement, the brush should be moved in the occlusal direction, i.e. upwards in the lower jaw and downwards in the upper jaw to remove debris.
47928495|NCT00266877|DRUG|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
47928496|NCT05594615|DRUG|EDP-235|Subjects will receive EDP-235 once daily on Days 5-15
47928497|NCT05594615|DRUG|Midazolam|Subjects will receive midazolam once daily on Days 1 and 12
48452145|NCT06352775|DIETARY_SUPPLEMENT|Calcium Carbonate|We will be using it in routes and doses consistent with its approved uses. Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours. Therefore, using a dosing of 500mg every 4 hours will be well below that guidance. When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
48452146|NCT04061746|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
48452147|NCT04061746|OTHER|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
48452148|NCT02581553|DRUG|lesinurad/allopurinol 200/300 FDC tablets|
47928498|NCT05594615|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Days 2 and 13
47928499|NCT05594615|DRUG|Caffeine|Subjects will receive caffeine once daily on Days 1 and 12
47928500|NCT01086839|DRUG|sodium chloride 6%|"* one ampoule sodium chloride 6% per day~* inhalation use~* for 28 days"
47928501|NCT01086839|DRUG|sodium chloride 0,9%|"* one ampoule sodium chloride 0,9% per day~* inhalation use~* for 28 days"
47928502|NCT01213667|DRUG|Ranibizumab|upload (three monthly injections), re-treatment as needed
47928503|NCT00225927|PROCEDURE|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
47928504|NCT05637814|DIAGNOSTIC_TEST|SpO2/PIx Measurement and ML Algorithm|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured and an online ML inference model will be used to classify a newborn as healthy versus CCHD as new pulse oximetry data is collected.
48452149|NCT02581553|DRUG|lesinurad 200 mg|
48452150|NCT02581553|DRUG|allopurinol 300 mg|
48452151|NCT02581553|DRUG|lesinurad/allopurinol 200/200 FDC tablets|
48452152|NCT02581553|DRUG|allopurinol 200 mg|
47928505|NCT03830905|DRUG|XC221|Participants will receive 200 mg XC221 once a day during 3 days
48452153|NCT00161785|BIOLOGICAL|FSME-IMMUN 0.5ml|
47928506|NCT03830905|DRUG|Placebo|Participants will receive Placebo once a day during 3 days
47928507|NCT01698710|DRUG|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
47928508|NCT05993013|OTHER|LudoFit|Game-based, technology-enabled home exercise software, done at least 3 times per week. Video games for a variety of exercises that promote balance, strength, endurance, and coordination.
47928509|NCT01038869|DRUG|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
47928510|NCT00595374|DRUG|insulin detemir|
47928511|NCT00595374|DRUG|insulin NPH|
47928512|NCT00595374|DRUG|insulin aspart|
47928513|NCT04434170|DRUG|Sacubitril-Valsartan|outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation
47928514|NCT00923988|OTHER|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
47928515|NCT01847807|DRUG|low dose Astragalus|
47928516|NCT01847807|DRUG|high dose astagalus|
47928517|NCT03635580|OTHER|Negative control|Untreated-control group
47928518|NCT01257360|DRUG|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
47928519|NCT01257360|RADIATION|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
47928520|NCT02805270|OTHER|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
47928521|NCT01174433|DEVICE|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
47928522|NCT01685333|DRUG|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
47928523|NCT00159822|DRUG|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
47928524|NCT05026814|OTHER|Interview after one year or more from the treatment received|Questionnaires to evaluate the satisfaction with treatment, the motivations and expectations for the treatment, the general well-being, the sexual function and the genital selfimage
47928525|NCT00600145|DRUG|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
47928526|NCT00600145|OTHER|Placebo|Placebo
47928527|NCT02884700|BIOLOGICAL|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
47928528|NCT05247528|DRUG|MANP|Novel designer peptide to represent a pGC-A/cGMP therapeutic
47928529|NCT05247528|DRUG|Placebo|Placebo Comparator
47928530|NCT03206996|BEHAVIORAL|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
47928531|NCT03206996|BEHAVIORAL|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
47928532|NCT03206996|BEHAVIORAL|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
47928533|NCT01235598|OTHER|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
47928534|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
47928535|NCT01235598|BIOLOGICAL|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
47928536|NCT04276727|DRUG|MINT study IMP|Application of gel for 6 weeks.
47928537|NCT03390101|DRUG|BCD-085 Q2W|"In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
47928538|NCT03390101|DRUG|BCD-085 Q4W|In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
48621702|NCT01859000|OTHER|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
48621703|NCT01859000|OTHER|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
48621704|NCT00083915|DRUG|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
48621705|NCT00083915|DRUG|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
48621706|NCT00083915|DRUG|Adriamycin|20mg/m2 continuous infusion -3 and -2.
48621707|NCT00083915|DRUG|Etoposide|80mg/m2 continuous infusion -3 and -2.
48621708|NCT00083915|DRUG|Melphalan|200 mg/m2 IV over \<20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
48621709|NCT00083915|DRUG|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets \>50 thousand (K).
48621710|NCT00083915|DRUG|Dexamethasone|40 mg po days 1 - 4 (4 days)
48621711|NCT03076242|OTHER|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
48621712|NCT02695459|DRUG|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
48621713|NCT03565289|DIAGNOSTIC_TEST|Blood sample collection|During a routine blood draw an additional tube of blood will be taken for the study.
48621714|NCT02710747|GENETIC|CYP2C9;VKORC1|
48621715|NCT06535568|DEVICE|Drug-coated balloon|Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.
48621716|NCT06535568|DRUG|Single antiplatelet therapy (SAPT)|The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
48621717|NCT06535568|DRUG|Dual antiplatelet therapy (DAPT)|The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.
48621718|NCT00840125|DRUG|erlotinib|150mg tablet daily
48621719|NCT00840125|DRUG|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
48621720|NCT00068523|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
48621721|NCT00068523|DRUG|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
48621722|NCT00068523|DRUG|cyclosporine|oral cyclosporine on days -1 to 100
48621723|NCT00068523|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
48621724|NCT00068523|DRUG|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
48621725|NCT00068523|PROCEDURE|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
48621726|NCT00068523|PROCEDURE|allogeneic bone marrow transplantation|
48621727|NCT00068523|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
48621728|NCT04546698|OTHER|blood sampling|Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group
48621729|NCT00169832|DRUG|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
48621730|NCT02402751|PROCEDURE|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
48621731|NCT02402751|DEVICE|MRI|
48621732|NCT05706701|OTHER|Nicotine vaping visit 1 (free-base nicotine)|Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
48621733|NCT05706701|OTHER|Nicotine vaping visit 1 (protonated nicotine)|Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
48621734|NCT05706701|OTHER|Nicotine vaping visit 2 (free-base nicotine)|Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
48621735|NCT05706701|OTHER|Nicotine vaping visit 2 (protonated nicotine)|Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
48621736|NCT04329455|PROCEDURE|Endoscopic thyroidectomy|Endoscopic thyroidectomy in Thyroid Nodules
48621737|NCT06485505|DRUG|ISOtretinoin 10 MG|Low dose isotretinoin as an adjuvant for itraconazole in treating onychomycosis
48621738|NCT06485505|DEVICE|excimer light|excimer light as an adjuvant for itraconazole in treating onychomycosis
48621739|NCT06485505|DRUG|Itraconazole 200 mg|Itraconazole alone
48621740|NCT05490082|DRUG|Mirabegron, Propevirine, Solifenacin|Efficacy comparison
48621741|NCT03138681|DRUG|Placebo|placebo is given intravenously twice a day for 14 days
48621742|NCT03138681|DRUG|ATP|ATP (100mg) is given intravenously twice a day for 14 days
48621743|NCT03138681|DRUG|Phosphocreatine|Phosphocreatine (1g) is given intravenously twice a day for 14 days
47928539|NCT03390101|DRUG|Placebo|"In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
47928540|NCT02866851|OTHER|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
47928541|NCT06324227|OTHER|multimodal music therapy|music therapy
47928542|NCT06324227|OTHER|no intervention|no intervention
47928543|NCT04939506|BEHAVIORAL|COVID-19 Vaccine Education at the Point of COVID-19 Testing|A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
47928544|NCT03911843|DRUG|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
47928545|NCT03911843|DRUG|Vitamin D supplementation|Cholecalciferol 1000 IU/die
47928546|NCT06203951|DIAGNOSTIC_TEST|Xpert® CT/NG and TV testing|Participants randomized to universal STI testing will be offered Xpert® CT/NG and TV testing regardless of symptoms, and they will receive a standard syndromic STI assessment. Participants randomized to the asymptomatic only testing will be offered Xpert® CT/NG and TV testing if no signs or symptoms of CT, NG, or TV are identified during STI assessment. Participants assigned to receive Xpert® testing will be counseled on CT/NG/TV testing, including the benefits of testing even in the absence of symptoms to detect asymptomatic infections (as informed by pilot evaluation). If a client accepts Xpert® testing, she will be instructed by the study nurse on how to self-collect a vaginal swab.
47928547|NCT00573287|DRUG|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
47928548|NCT00573287|DRUG|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
47928549|NCT00562666|OTHER|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
47928550|NCT00869778|BIOLOGICAL|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
47928551|NCT00869778|OTHER|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
47928552|NCT01059929|DRUG|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
47928553|NCT01059929|DRUG|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
47928554|NCT01059929|DRUG|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
47928555|NCT01059929|DRUG|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)
47928556|NCT01059929|BEHAVIORAL|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
47928557|NCT03705936|DEVICE|rTMS|rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
47928558|NCT04545970|COMBINATION_PRODUCT|Facial cleanser|Facial cleanser to be used by study participants
47928559|NCT04545970|COMBINATION_PRODUCT|Facial moisturizer|Bland moisturizer to be used by study participants after serum in the evening.
47928560|NCT04545970|COMBINATION_PRODUCT|Sunscreen|Sunscreen to be applied after application of serum in the morning.
47928561|NCT03726567|PROCEDURE|Bariatric surgery|Roux-en-Y surgery
47928562|NCT05249335|DRUG|OST|The subject will receive Orafang for colonoscopy
48452154|NCT06559917|OTHER|life review|"After consenting, they will complete the first questionnaire before receiving the Happiness Ledger intervention via social media. Family members will have one week to organize photos, after which patients will share the meaning of the photos. This process will be recorded by the researcher and will last approximately 40 to 60 minutes. The researcher will then create a three-minute video using the photos, and the participating family members will assist in uploading the photos to the family LINE group as feedback to the subjects. The second questionnaire will then be completed."
48452155|NCT03115697|DRUG|Lactulose|Lactulose 20 mL
47928563|NCT05249335|DRUG|2L-PEG/Asc|The subject will receive 2L-PEG/Asc for colonoscopy
47928564|NCT06194019|DEVICE|lung ultrasonography|N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for detection volume overload.
47928565|NCT02853799|OTHER|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
47928566|NCT02853799|DIETARY_SUPPLEMENT|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
47928567|NCT04814238|PROCEDURE|Aortic Root Surgery|First time, isolated, minimally invasive (mini-sternotomy, RALT) aortic root or aorta surgery
47928568|NCT01836874|DRUG|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
47928569|NCT03272269|DRUG|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
47928570|NCT03272269|OTHER|Placebo|Solvent: alum hydroxide
48452156|NCT03115697|DRUG|Rifaximin|Rifaximin 550 BD
48452157|NCT03115697|BIOLOGICAL|Plasmapheresis|Plasmapheresis 8 hrly duration
48452158|NCT05163691|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
48452159|NCT05163691|DRUG|Placebo|GH001 Placebo administered via inhalation
48452160|NCT01229800|DRUG|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
47928571|NCT02052414|DRUG|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
47928572|NCT01947907|DRUG|ACP-001|Once weekly subcutaneous injection
47928573|NCT01947907|DRUG|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
47928574|NCT02166177|DRUG|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
47928575|NCT00694538|DEVICE|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
47928576|NCT03844295|DEVICE|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
47928577|NCT03844295|DEVICE|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
47928578|NCT01640327|BIOLOGICAL|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
47928579|NCT02402738|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|
47928580|NCT02402738|BEHAVIORAL|Enhanced Treatment as Usual|
47928581|NCT02014870|OTHER|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
47928582|NCT02014870|OTHER|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
47928583|NCT02014870|OTHER|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
48452161|NCT01229800|DRUG|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
48452162|NCT00216736|DRUG|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
48452163|NCT00216736|DRUG|placebo|Single dose oral placebo at ED discharge
48452164|NCT06263842|PROCEDURE|modified Elamrousy approach for socket shield technique|the jumping gap will be filled with AWTG
47928584|NCT05277948|OTHER|active thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
47928585|NCT05277948|OTHER|sham thumbtack needle|"The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles"
47928586|NCT00289055|DEVICE|stent|Cordis SMART™ Nitinol Stent
47928587|NCT00289055|DEVICE|angioplasty|balloon angioplasty
47928588|NCT01191216|DRUG|1-methyl-d-tryptophan|
47928589|NCT01191216|DRUG|docetaxel|
47928590|NCT01191216|OTHER|diagnostic laboratory biomarker analysis|
48452165|NCT06263842|PROCEDURE|conventional socket shield|the jumping gap will be left ungrafted
48621744|NCT06544590|DEVICE|taVNS|TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).
48621745|NCT06544590|DRUG|Betahistine Mesylate tablet|Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
47928591|NCT01191216|OTHER|pharmacological study|
47928592|NCT01445548|DRUG|Sirolimus|
48621746|NCT01223677|BEHAVIORAL|Rumination Focused CBT|see arms
48621747|NCT00033644|BIOLOGICAL|sargramostim|
48621748|NCT00033644|DRUG|cisplatin|
48621749|NCT00033644|DRUG|dacarbazine|
48621750|NCT00033644|DRUG|doxorubicin hydrochloride|
48452166|NCT06263842|PROCEDURE|combined socket shild with xenograft|the jumping gap will be filled with xenograft
48452167|NCT05441670|BEHAVIORAL|Art and Physical Therapy|45 minutes of Art Therapy followed by 30 minutes of Physical Therapy, Monday through Friday for 2 weeks
48452168|NCT05441670|BEHAVIORAL|Physical Therapy|30 minutes of Physical Therapy, Monday through Friday for 2 weeks
48452169|NCT06457308|BIOLOGICAL|Physical training of agility|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Use rope ladders and cones to perform multiple tasks of direction changes, acceleration and deceleration of footsteps, hand and foot coordination and spatial orientation training,
48621751|NCT00033644|DRUG|mitomycin C|
47928593|NCT04531774|BEHAVIORAL|RECHARGE|"RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches."
47928594|NCT04531774|BEHAVIORAL|Self Study|HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
47928595|NCT00859261|PROCEDURE|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
48621752|NCT02333032|OTHER|Inclined treadmill training|
48621753|NCT06109298|OTHER|Cold spray|Cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedu
47928596|NCT00859261|PROCEDURE|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
47928597|NCT00897338|OTHER|flow cytometry|laboratory analysis
47928598|NCT00897338|OTHER|fluorescence activated cell sorting|laboratory analysis
47928599|NCT00897338|OTHER|immunohistochemistry staining method|laboratory analysis
47928600|NCT00897338|OTHER|immunologic technique|laboratory analysis
47928601|NCT00897338|OTHER|biomarker analysis|laboratory analysis
48452170|NCT06457308|BIOLOGICAL|Physical training of resistance|A grouped training for older adults in the community. The training classed lasted for 12 weeks, one session a week for 120 mins, and are under instructed by a trained experienced sport instructor. Resistance training for upper and lower limb muscles and core muscles, including squats, use of elastic bands, and simple bars
48621754|NCT06109298|OTHER|Refrigerated gel ice|Refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated.
48621755|NCT01014091|BIOLOGICAL|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
48452171|NCT03844334|DEVICE|WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.
48452172|NCT06627777|BEHAVIORAL|Laboratory tasks in early adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
48621756|NCT02821845|BEHAVIORAL|Untrained and Trained SCI Hip or Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control or knee control, members of this group will be trained at slow to moderate gait speeds,
48452173|NCT06561425|GENETIC|GLPG5101|Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
48452174|NCT03828708|OTHER|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
48452175|NCT04198363|DRUG|Vonoprazan|Vonoprazan Tablets
48452176|NCT04198363|DRUG|Amoxicillin|Amoxicillin Capsules
48452177|NCT04198363|DRUG|Clarithromycin|Clarithromycin Tablets
48452178|NCT04198363|DRUG|Bismuth Potassium citrate|Bismuth Potassium citrate
48452179|NCT04198363|DRUG|Esomeprazole|Esomeprazole Tablets
48621757|NCT04445649|DIAGNOSTIC_TEST|Coma-Recovery-Scale-Revised (CRS-R)|CRS-R assessments (15 minutes) are repeated weekly after study entry
48621758|NCT03625674|BEHAVIORAL|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
48621759|NCT05190133|DRUG|UIC201602 and co-administration of UIC201601 and UIC201602|"* UIC201602 4 Cap/day for 14 days~* Wash out 21 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
48621760|NCT05190133|DRUG|UIC201601 and co-administration of UIC201601 and UIC201602|"* UIC201601 4 Tab/day for 7 days~* Wash out 14 days~* UIC201601 4 Tab + UIC201602 4 Cap / day for 14 days"
48621761|NCT01481025|DRUG|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months"
48621762|NCT01481025|DRUG|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months"
48621763|NCT01481025|DRUG|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
48621764|NCT02214082|OTHER|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
47928602|NCT01498094|PROCEDURE|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
47928603|NCT01498094|OTHER|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
47928604|NCT01190735|DRUG|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
47928605|NCT00885001|PROCEDURE|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
47928606|NCT02125604|DRUG|dimethyl fumarate|capsules administered according to the prevailing product label
47928607|NCT00075270|DRUG|Paclitaxel|Active Comparator
47928608|NCT00075270|DRUG|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
47928609|NCT03653871|BEHAVIORAL|Performing Arts Instruction|Professionally delivered performing arts curriculum
47928610|NCT02661711|DRUG|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
47928611|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
47928612|NCT00555425|BEHAVIORAL|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
47928613|NCT00177710|DRUG|Amphotericin B|
47928614|NCT04061993|PROCEDURE|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
47928615|NCT04061993|PROCEDURE|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
47928616|NCT02341937|OTHER|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
47928617|NCT00868179|DRUG|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
47928618|NCT02767544|PROCEDURE|Vaginal wound local analgesia after laparoscopic hysterectomy|
47928619|NCT01585012|DEVICE|Cervical cap (Focus Touch™ Conception System)|Cervical cap
47928620|NCT01874678|DRUG|TS-1/Cisplatin|
47928621|NCT02879396|BEHAVIORAL|PA4LE Program|"1. Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~2. Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~3. Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~4. Patient understanding of red flag indicators of worsening condition and appropriate next steps~5. Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness \& Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
47928622|NCT01429909|DEVICE|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2\* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2\*.
47928623|NCT00570232|DRUG|Erlotinib|150 mg per day by mouth for 12 months
47928624|NCT00373061|DRUG|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
47928625|NCT04687176|DRUG|Oral Arsenic Trioxide Formulation|"Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days. Daunorubicin or idarubicin will only be used during induction in patients \<65 with presenting white blood cell count (WBC) ≥ 10 x 10\^9/L. In patients not receiving daunorubicin, hydroxyurea if WBC ≥ 5 x 10\^9/L within the first 14 days of induction. A reassessment bone marrow aspirate will be performed on day 28 of induction for assessment of morphologic remission.~Four weeks after the completion of induction phase, all patients, regardless of initial WBC, will receive two cycles of chemotherapy-free AAA consolidation (14 days every 28 days).~Four weeks after completion of consolidation, all patients will receive 12 cycles of chemotherapy-free AAA maintenance (14 days every 8 week)."
48621765|NCT00610519|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
48621766|NCT00610519|DIETARY_SUPPLEMENT|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
48621767|NCT01143324|DEVICE|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
47928626|NCT05658523|BIOLOGICAL|Bivalent Moderna|A single standard dose of the bivalent Moderna (mRNA-1273.214) COVID-19 vaccine containing equal amounts of mRNAs (25μg of each mRNA sequence) that encode the prefusion stabilized spike glycoproteins of the ancestral SARS-CoV-2 (Wuhan-Hu-1) and the Omicron variant (B.1.1.529 \[BA.1\]) with mRNAs encapsulated in lipid nanoparticles, will be administered on day 0 of the study.
47928627|NCT05658523|BIOLOGICAL|Novavax|A single dose of Novavax contains 5μg of SARS-CoV-2 spike protein and is adjuvanted with Matrix-M. Adjuvant Matrix-M contains, per 0.5 mL dose: Quillaja saponaria saponins fraction A (42.5 micrograms) and Quillaja saponaria saponins fraction C (7.5 micrograms), will be administered on day 0 of the study.
47928628|NCT04644731|DEVICE|Aquadex™ System|Ultrafiltration for fluid removal
47928629|NCT05098977|PROCEDURE|Heart rate variability measurement|HRV will be measured at the moment of patients' admission to the cardiac catheterization laboratory on the top of therapy guided by European guidelines. Both, time- and frequency-domain parameters (respectively, SDNN, SDANN, RMSSD and LF, HF, LF/HF ratio) of the HRV will be obtained using a validated medical device during 5-minute segments before and after revascularization of the culprit artery. In addition, HRV will be evaluated in ambulatory setting, at 1 month and at 6 months after the index event. Obtained interbeat interval data will be further analysed using a dedicated software in order to derive specified HRV parameters.
47928630|NCT05098977|PROCEDURE|Percutaneous coronary intervention|Coronary angiography and PCI will be performed using femoral or radial approach after local anesthetic infiltration with Lidocaine and arterial sheath placement. Following the culprit lesion detection and guidewire placement, thromboaspiration and glycoprotein IIb/IIIa inhibitors will be left to the operator decision. Also, the choice of coronary stenting technique and stent sizing will be performed according to the operator experience. Antiplatelet and anticoagulant drugs will be administered in concordance with latest European guidelines.
47928631|NCT03702244|DIAGNOSTIC_TEST|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
47928632|NCT03190044|DIETARY_SUPPLEMENT|PACR|Daily assumption of PACR for a 3-month period
47928633|NCT03190044|DIETARY_SUPPLEMENT|Placebo|Daily assumption of placebo
47928634|NCT01350544|BEHAVIORAL|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
48621768|NCT01808742|DEVICE|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
48621769|NCT00691964|BIOLOGICAL|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
47928635|NCT03400956|DRUG|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
47928636|NCT03400956|DRUG|Placebo|Orally, coated tablet, once daily
48621770|NCT00691964|BIOLOGICAL|etanercept|SQ injection 50 mg BIW
48621771|NCT00691964|DRUG|placebo|SQ placebo injections for ABT-874 and etanercept
47928637|NCT04731857|GENETIC|Retrospective data analysis|The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.
47928638|NCT05061680|DEVICE|endoscopic short duration papillary large balloon dilation|During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
47928639|NCT01624805|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
47928640|NCT01624805|DRUG|Cyclosporine|Given PO
47928641|NCT01624805|BIOLOGICAL|Filgrastim|Given SC
47928642|NCT01624805|DRUG|Methylprednisolone|Given IV or PO
47928643|NCT01624805|BIOLOGICAL|Pegfilgrastim|Given SC
47928644|NCT02117206|DRUG|L-arginine (L-arginine Veyron)|
47928645|NCT02117206|DRUG|Nacl|
48452180|NCT00274781|DRUG|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
48621772|NCT02786966|OTHER|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
48621773|NCT05562921|BEHAVIORAL|Controls-ususal care|Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases
48621774|NCT05562921|BEHAVIORAL|Cases-remote patient monitoring prescribed|Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
48621775|NCT02448108|BEHAVIORAL|i-IPSRT|"internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT."
48621776|NCT02448108|OTHER|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
48621777|NCT01286324|DIETARY_SUPPLEMENT|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
48621778|NCT01286324|DRUG|Placebo Tablet|
48452181|NCT00274781|DRUG|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
48452182|NCT05457413|PROCEDURE|Sleeve gastrectomy|Bariatric surgery
48452183|NCT05243251|DRUG|Olanzapine 5 MG|, Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC
48452184|NCT05243251|DRUG|Placebo|Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
48452185|NCT04370509|DRUG|Axitinib (VEGF-TKI)|Given PO
48452186|NCT04370509|PROCEDURE|Cytoreductive Nephrectomy (CN)|Undergo CN
48452187|NCT04370509|PROCEDURE|Metastasectomy (MET)|Undergo MET
48452188|NCT04370509|BIOLOGICAL|Pembrolizumab|Given IV
48452189|NCT01724515|OTHER|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
48452190|NCT01746056|DEVICE|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
48452191|NCT05406050|DRUG|reference eldecalcitol soft capsule|0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
48452192|NCT05406050|DRUG|test eldecalcitol soft capsule|0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
48452193|NCT03429582|DEVICE|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
48452194|NCT03429582|DEVICE|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
47928646|NCT05721807|OTHER|functional magnetic stimulation|"When applying functional magnetic stimulation, the stress urinary incontinence program P2 stress was chosen. The first 20 min. current frequency was 35 Hz, modulation - rising amplitude (from 0 to maximum per second), total wave duration 12 s. active time 6 s., pause time 6 s. After 20 min. current frequency changed to 5 Hz, modulation and wave remained the same. After 2 min. current frequency changed to 35 Hz, modulation - amplitude, one-sided sinusoidal, wave remained the same. The total duration of the procedure was 30 min. A magnetic spring is installed at the bottom of the chair. During the treatment, each subject was instructed to sit on a chair so that the perineum was centered on the spring and that the subjects felt the contraction of the muscles. The intensity of the magnetic field was adjusted so as to feel comfortable during the study procedure (Vadalà et al., 2017)."
47928647|NCT05721807|OTHER|pelvic floor muscle training program|The program consisted of two parts. From procedures 1 to 6, 6 exercises were performed, after 6 times the exercises were adjusted, and from procedures 7 to 12, another 5 exercises were performed. The program consists of breathing, pelvic floor muscle strength, endurance, speed training exercises and exercises to strengthen the thighs, buttocks, deep back and deep abdominal muscles. Exercises were performed in 2 sets of 10 repetitions at an intensity from various positions: lying on the back, side, sitting, quadruped (Oliveira et al., 2017; Walton et al., 2019).
48452195|NCT03429582|DEVICE|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
48452196|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
48452197|NCT06627088|DRUG|[14C]-LY4100511 (DC-853) Administered oral dose|Administered oral dose
48452198|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
48452199|NCT06627088|DRUG|[14C]-LY4100511 (DC-853)|Administered IV infusion
48452200|NCT06377410|DRUG|Syrup Prospan|Participant with stable COPD who received Syrup prospan for 1 month
48452201|NCT06377410|DRUG|N-Acetylcysteine|Participant with stable COPD who received N-Acetylcysteine for 1 month
48452202|NCT05404490|DRUG|Bupivacain|20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
48452203|NCT05404490|DRUG|Placebo|20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
48452204|NCT03806257|OTHER|Enhanced Physical Therapy Protocol|A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
48452205|NCT04096664|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
48452206|NCT05047536|DRUG|KZR-261|KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
48452207|NCT00271492|DRUG|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
48452208|NCT00271492|DRUG|Atrasentan|1 10mg capsule per day for the 6 month study period.
48452209|NCT00271492|DRUG|atrasentan|One 10 mg capsule per day for 6 month study period
48452211|NCT05957003|PROCEDURE|Combined end-expiratory occlusion and end-inspiratory occlusion test|"The EEO test will be performed by interrupting the mechanical ventilation at end-expiration over 15 seconds using the end-expiratory hold button available on the ventilator.~The EIO test will be performed by interrupting the mechanical ventilation at end-inspiration over 15 seconds using the end-inspiratory hold button available on the ventilator."
48452212|NCT05957003|PROCEDURE|Tidal volume challenge test|elevating tidal volume from 6 ml/kg to 8 ml/kg for only 60 seconds
48452213|NCT05350072|BIOLOGICAL|VAY736|ianalumab s.c.
48452214|NCT05350072|OTHER|Placebo|placebo s.c.
48452215|NCT02272803|DRUG|Lenalidomide|
48452216|NCT02272803|DRUG|Dexamethasone|
48452217|NCT02272803|BIOLOGICAL|Elotuzumab (BMS-901608)|
48452218|NCT05034874|DRUG|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
48452219|NCT05034874|OTHER|Placebo|Saline
48452220|NCT05372744|OTHER|Active Placebo labelled as antidepressant|Participants receive an active nasal spray that is in fact a placebo with a specific framing in regards to its affect-regulatory characteristics, respectively.
47928648|NCT02678598|DRUG|Micafungin|Intravenous
48452221|NCT01852721|BEHAVIORAL|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
48452222|NCT01852721|BEHAVIORAL|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
48452223|NCT00975754|DRUG|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
48452224|NCT00975754|DRUG|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
48452225|NCT00975754|DRUG|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
48452226|NCT00975754|DRUG|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
47928649|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.
47928650|NCT05027295|DRUG|riboflavin ophthalmic solution|Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
47928651|NCT03387644|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
47928652|NCT03387644|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
47928653|NCT04718844|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
47928654|NCT04718844|DRUG|Placebo|Sodium chloride for s.c. injection
47928655|NCT03157570|BEHAVIORAL|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
47928656|NCT02133170|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
48452227|NCT04626245|BEHAVIORAL|Mindfulness training|Phone-delivered brief mindfulness training based on principles of MBSR
48452228|NCT02977221|PROCEDURE|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
48452229|NCT00792753|DEVICE|Medtronic Endeavor Coronary Stent System|coronary stent implantation
48452230|NCT00792753|DEVICE|DESyne BD Novolimus Stent System|coronary stent implantation
48452231|NCT00792753|DEVICE|DESyne Novolimus Stent System|coronary stent implantation
48452232|NCT02125981|DRUG|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
48452233|NCT02125981|DRUG|Placebo|taking placebo drug
47928657|NCT02133170|BEHAVIORAL|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
47928658|NCT02133170|BEHAVIORAL|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
47928659|NCT06245278|OTHER|ELISA (Enzyme-Linked ImmunoSorbent Assay)|A total of 60 individuals, 15 with IBD and periodontitis, 15 with IBD and periodontal health, 15 with systemic health and periodontitis, and 15 with systemic and periodontal health, will be included in the study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and serum, saliva and gingival samples will be obtained from all individuals. Individuals with periodontitis will receive non-surgical periodontal treatment in half jaws within 2 weeks. Clinical measurements, serum and saliva sample collection will be repeated 3 months after the treatment. Biomarker levels in serum and saliva samples will be analysed by ELISA.
47928660|NCT03467152|DRUG|Irsenontrine|Oral hypromellose capsules.
47928661|NCT03467152|DRUG|Placebo|Oral hypromellose capsules.
47928662|NCT00118521|PROCEDURE|Foot Orthotics|
47928663|NCT00118521|PROCEDURE|Physiotherapy|
47928664|NCT00722371|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
48452234|NCT03487081|BEHAVIORAL|Social regulation|Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
48452235|NCT03487081|BEHAVIORAL|Self regulation|Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
48452236|NCT04992390|BEHAVIORAL|Brief digital imagery-competing task intervention|"First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring)."
48452237|NCT02287844|OTHER|XOS|5 g of XOS everyday for 4 weeks.
48452238|NCT02287844|OTHER|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
48621779|NCT01359423|DRUG|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
48621780|NCT01359423|DRUG|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
48621781|NCT00876395|DRUG|Everolimus|Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
48621782|NCT00876395|DRUG|Placebo|Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
48621783|NCT00876395|DRUG|Trastuzumab|Trastuzumab, 2 mg/kg weekly was used intravenously.
48621784|NCT00876395|DRUG|Paclitaxel|Paclitaxel, 80 mg/m2 weekly was used intravenously.
48621785|NCT04470427|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
48621786|NCT04470427|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48452239|NCT02287844|OTHER|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
48452240|NCT03932045|DEVICE|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
48621787|NCT04327271|BEHAVIORAL|Text-based VMMC follow-up|2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts or return for any visit by day 14, they will be traced by SMS, phone or home visit. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 21, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
48621788|NCT05510817|OTHER|Multiparametric assessment|neuropsychological assessment, PRO measures, non-conventional MRI metrics
48621789|NCT05861271|DRUG|Capecitabine，Pyrotinib|Pyrotinib and Capecitabine for half a year
48621790|NCT04624243|DRUG|MK-8189|MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
48621791|NCT04624243|DRUG|Risperidone|Risperidone administered QD at a dose of 6 mg via oral capsule.
48621792|NCT04624243|DRUG|Placebo to MK-8189|MK-8189-matching placebo administered QD via oral tablet.
48621793|NCT04624243|DRUG|Placebo to risperidone|Risperidone-matching placebo administered QD via oral capsule.
48621794|NCT02632942|PROCEDURE|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~1. 60% or greater diameter of the main AVF~2. 50% diameter of AVF with at least one more av\>40% in diameter.~3. 50% in diameter and divides into branches of same size.~4. av likely to interfere with cannulation on physical examination.~5. \>30% in diameter and associated with stenosis at site of origin."
48621795|NCT02632942|PROCEDURE|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
48621796|NCT01449032|BIOLOGICAL|MSC|No of cells after culture expansion
48621797|NCT01449032|BIOLOGICAL|Saline|3 cc saline
48621798|NCT00296595|BEHAVIORAL|Nutrition|
48621799|NCT04227600|DRUG|JR-171 (lepunafusp alfa)|IV infusion
48621800|NCT05203016|OTHER|Hipotermia/Normotermia|The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.
48621801|NCT04051580|DRUG|Lactated Ringer|Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
48621802|NCT02955693|DRUG|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
48621803|NCT01428245|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
48621804|NCT01428245|DRUG|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
48452241|NCT03932045|DEVICE|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
48452242|NCT01726933|DRUG|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
48621805|NCT02760303|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
48621806|NCT02760303|BEHAVIORAL|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
48452243|NCT01726933|DRUG|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
48452244|NCT01726933|DRUG|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
48452245|NCT03641079|DRUG|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
48452246|NCT06012812|DRUG|SHR-1819 injection|SHR-1819 injection 300 mg Q2W
47928665|NCT00722371|DRUG|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
47928666|NCT00722371|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
47928667|NCT00722371|DRUG|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
47928668|NCT00722371|DRUG|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
47928669|NCT05587465|DEVICE|Lobster Device|The intervention is performed percutaneously using the dedicated instrument set.
47928670|NCT05080244|DIETARY_SUPPLEMENT|Probiotics|2 strains 10x10\^9 UFC/capsule
47928671|NCT05080244|DIETARY_SUPPLEMENT|Placebo|Potato starch and magnesium stearate
47928672|NCT03516903|DRUG|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
48621807|NCT02760303|BEHAVIORAL|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
48621808|NCT02529332|DIETARY_SUPPLEMENT|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
48621809|NCT01626716|OTHER|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
48621810|NCT04568200|DRUG|Durvalumab|Durvalumab 1500mg i.v. day 1-22-43-64
48621811|NCT04568200|DRUG|Carboplatin|Chemotherapy
48621812|NCT04568200|DRUG|Paclitaxel|Chemotherapy
48621813|NCT04568200|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy 23 x 1.8 Gy
48621814|NCT05316467|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|"* dietary guidance~* exercise guidance~* lifestyle intervention"
48621815|NCT05316467|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
48621816|NCT06055582|DIETARY_SUPPLEMENT|Bread|81g (3 slices) harvest gold white bread as standard food.
48621817|NCT06055582|DIETARY_SUPPLEMENT|Mango|250g of mango pulp of each mango variety was given to the subjects.
48621818|NCT02177357|DRUG|Pramipexole|
48621819|NCT02177357|DRUG|Placebo|
47928673|NCT03516903|DRUG|Placebo|Placebo-LDE (Lipid nanoemulsion)
47928674|NCT03516903|DRUG|Folic Acid|Folic acid pill
47928675|NCT01625260|BIOLOGICAL|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
47928676|NCT01625260|DRUG|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
47928677|NCT04678479|DRUG|Ganaxolone|ganaxolone
47928678|NCT00314483|DRUG|Mesenchymal Stem Cell Infusion|
47928679|NCT03821844|BEHAVIORAL|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
47928680|NCT05623865|OTHER|kinesiotaping|"Kinesio tape will be attached with lymphedema technique.~The bands will be removed prior to each assessment so that they do not affect the evaluator's blinding. After evaluation, the new tape will be fitted by the invesitgatör"
47928681|NCT05623865|OTHER|exercise|"Wrist, finger, elbow range of motion and stretching exercises will be taught to the patients and given as home exercises.~In addition, patients will be given a leaflet containing illustrated and explanatory exercise visuals."
47928682|NCT02601807|DEVICE|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
47928683|NCT02601807|DEVICE|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
48621820|NCT01679470|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
48621821|NCT02891824|DRUG|atezolizumab + avastin + platinum-based chemotherapy|"* atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
48621822|NCT02891824|DRUG|placebo + avastin + platinum-based chemotherapy|"* placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
48452247|NCT06350240|BEHAVIORAL|Exercise|An exercise program that can be easily applied at home and in the park, which will support the psychomotor, tactile and proprioceptive-rich sensory development specific to children with joint hypermobility. The family will be instructed to do these exercises for 30 minutes a day for 5 days in total, 2 days a week in the playground and 3 days at home for 6 weeks, and the family will be asked to keep a diary to see whether they do the exercises or not.
48452248|NCT06350240|BEHAVIORAL|Exercise+texture insoles|In addition to exercise, children in this group will have an individual textured insoles made to suit the child's foot. The child will be asked to place textured insoles inside his shoes and use the textured insoles for 6-8 hours.
48621823|NCT00533988|DEVICE|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
48621824|NCT03853928|DIETARY_SUPPLEMENT|Probiotics|"Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII)."
48621825|NCT01104844|DRUG|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
48621826|NCT01104844|DRUG|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
48621827|NCT01104844|DRUG|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
48621828|NCT01104844|DRUG|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
48621829|NCT01104844|DRUG|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
48621830|NCT01104844|DRUG|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
48621831|NCT01104844|DRUG|Placebo|2 placebo tablets
47928684|NCT03739229|BIOLOGICAL|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
48452249|NCT06469307|OTHER|DIVERSE Review Process|A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
48452250|NCT00633672|DRUG|Esomeprazole|20mg Oral tablet once daily
47928685|NCT03739229|BIOLOGICAL|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
47928686|NCT02710162|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
48452251|NCT00633672|DRUG|Ranitidine|150mg oral twice daily
48452252|NCT00633672|DRUG|Esomeprazole|40mg oral tablet once daily
48452253|NCT03446768|OTHER|Peer support|Access to educational and informational support by a trained peer coach
48452254|NCT03446768|OTHER|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
48452255|NCT03446768|OTHER|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
48452256|NCT06559657|DEVICE|eKare Insight, imitoMeasure Mobile App, Visitrak|The wound size of the patients was measured with three different methods. Wound depth was measured using manual method and three-dimensional imaging devices.
48452257|NCT01074424|GENETIC|proteomic profiling|
48621832|NCT01843231|DEVICE|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
48621833|NCT01843231|OTHER|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
47928687|NCT02710162|DEVICE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
48452258|NCT01074424|OTHER|laboratory biomarker analysis|
48452259|NCT02552758|BIOLOGICAL|omega-3 fatty acid|omega-3 fatty acid
48452260|NCT02552758|BIOLOGICAL|placebo|placebo
48452261|NCT02552758|DEVICE|positron emission tomography (PET)|
48452262|NCT01154712|DEVICE|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
48621834|NCT04203056|DRUG|Aripiprazole Lauroxil|12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through
48621835|NCT04203056|DRUG|ARI-ORAL|oral aripiprazole
47928688|NCT02710162|DEVICE|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
47928689|NCT02710162|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
47928690|NCT02710162|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
47928691|NCT02710162|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
47928692|NCT02710162|OTHER|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
47928693|NCT02710162|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
47928694|NCT02710162|OTHER|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
47928695|NCT02710162|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
47928696|NCT02710162|OTHER|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
47928697|NCT02710162|OTHER|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
47928698|NCT04662827|DIETARY_SUPPLEMENT|Palmithylethanolamid|PEA 3x/d
47928699|NCT04662827|OTHER|placebo|placebo 3x/d
47928700|NCT00400608|DRUG|ADVAIR HFA|
47928701|NCT00400608|DRUG|ADVAIR DISKUS|
47928702|NCT02763592|DRUG|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
47928703|NCT02763592|OTHER|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
47928704|NCT03330002|DEVICE|CE-marked MANTA vascular closure device (VCD)|Compile real word data on MANTA VCD.
47928705|NCT00006439|BEHAVIORAL|Counseling in the home|
48452263|NCT01154712|DEVICE|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
48452264|NCT03307577|DRUG|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
47928706|NCT04121351|OTHER|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
47928707|NCT03443557|OTHER|oral nutrition supplement|receiving prescription of oral nutrition supplement during hospitalization
47928708|NCT05370703|BEHAVIORAL|My A:care|Mobile application with Motivational messages
47928709|NCT05370703|BEHAVIORAL|Smart Coach|Mobile application with Motivational messages
47928710|NCT00997113|DRUG|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
47928711|NCT00997113|DRUG|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
47928712|NCT04800952|OTHER|blood samples and filtered fluid will be collected.|"Arterial blood samples will be collected just before the commencement of continuous venovenous haemofiltration (CVVHF) and 1 h after the termination of CVVHF.~Prefilter and post-filter venous blood samples and filtered fluid will be collected 1 and 3 h after the commencement of CVVHF and at the end of CVVHF."
47928713|NCT06071728|DIETARY_SUPPLEMENT|Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)|Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
48452265|NCT03307577|OTHER|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
47928714|NCT01413347|PROCEDURE|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
47928715|NCT01413347|PROCEDURE|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
47928716|NCT00871507|DRUG|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
47928717|NCT00871507|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
47928718|NCT00871507|DRUG|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
47928719|NCT00871507|DRUG|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
48452266|NCT02189226|DEVICE|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
48452267|NCT02291796|DRUG|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration \>500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
48452268|NCT00834873|DRUG|Carvedilol 25 mg tablets|1 x 25 mg
48452269|NCT00834873|DRUG|COREG® 25 mg tablets|1 x 25 mg
48621836|NCT04203056|DRUG|AL-NCD|Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release
48621837|NCT00435058|DRUG|timolol maleate 0,5%|
48621838|NCT00435058|DRUG|brimonidine tartrate 0,2%|
48621839|NCT00435058|DRUG|travoprost 0,004%|
48621840|NCT01937338|DRUG|AZD7624|nebuliser solution; 20 mg/mL for inhalation
48621841|NCT01937338|DRUG|Placebo|nebuliser solution for inhalation
48621842|NCT01550185|DRUG|eltrombopag olamine|Given PO
48621843|NCT01550185|PROCEDURE|standard follow-up care|Receive standard care
48621844|NCT03586193|PROCEDURE|Pars plana vitrectomy|pars plana vitrectomy without ICG staining and ILM peeling
48621845|NCT04831658|DRUG|the dose-escalation phase|"The study adopts the 3+3 design,The dose planned to be explored is the daily oral dose of the BTK inhibitor abutinib, which is 100 mg, 150 mg and 200 mg, respectively.Orelabrutinib continues to be taken orally until the tumor is relieved for 3 months; PD-1 monoclonal antibody is used by intravenous drip, 21 days as a treatment cycle, and a total of 1 year of observation; formustine is used by intravenous drip for 21 days It is a treatment cycle, a total of 6 cycles of observation; after 2 cycles, the efficacy is evaluated, and adverse reactions are recorded. At the same time, MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times."
48621846|NCT06496490|DRUG|TQB2102 for injection|HER2 dual-antibody-drug Conjugate (ADC).
48621847|NCT05410067|OTHER|Cervicothoracic Junction Mobilization Technique|It is a part of manual therapy technique. Patient would be in prone position with his forehead in the palm of the therapist. Maitland mobilization to the C7- T1 level, according to their primary movement restriction (for flexion-extension restriction- central PA glide, for rotation restrictions unilateral PA glide) is given. For central PA glide, a central pressure angled towards the participant's head was given with overlapping thumbs of the therapist placed on the spinous process of C7. The therapist's thumbs were placed on the posterior surface of the articular process to be mobilized (C7 on the side of restriction), and anteriorly directed oscillatory pressure was applied for unilateral PA mobilization.
47928720|NCT06227598|OTHER|Procedure: Additional biopsies collection|Procedure: Additional biopsies collection We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
48621848|NCT05410067|OTHER|Eccentric Muscle Energy Technique|Eccentric muscle energy technique would be applied to the patient's cervical spine. The cervical spine would be brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then patient would be asked to push their heads into the direction opposite that of the barrier.
48621849|NCT00368550|DRUG|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
48621850|NCT00368550|DRUG|Placebo|Placebo for 14-week treatment period
48621851|NCT00994539|DRUG|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
48621852|NCT01279200|OTHER|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
48621853|NCT01279200|OTHER|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
48621854|NCT01695746|DRUG|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
48621855|NCT00867932|DRUG|Eculizumab|5 mg/mL solution in 5% Dextrose
48452270|NCT02875392|OTHER|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
48452271|NCT02875392|OTHER|placebo pills|taking placebo pills as if patients are under treatment.
48452272|NCT05191680|DRUG|Apalutamide Oral Tablet [Erleada]|Apalutamide is a selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
48452273|NCT05191680|DRUG|Placebo|Placebo to match apalutamide
48621856|NCT00580086|OTHER|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
48621857|NCT06280677|OTHER|AURORA-Donor|Explorative study of cumulus cells gene expression in relation to the oocyte competence for good quality blastocyst formation and predictive for clinical pregnancy.
48621858|NCT00328536|DRUG|Omacor|
48621859|NCT01940146|DRUG|SPARC Placebo|Placebo
48621860|NCT01940146|DRUG|SPARC1310 I|SPARC1310 I
47928721|NCT01879579|OTHER|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
47928722|NCT04577157|BEHAVIORAL|"mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence"|"This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~1. Daily notes for medication reminders,~2. Daily a voice message with the same content will be delivered.~3. Daily Graphics-based Reminder (GBR).~4. Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~5. Once-weekly lifestyle advice through video~6. Hypertension at a glance, complete information will be provided(Optional)~7. 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional)."
47928723|NCT01311635|DRUG|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
47928724|NCT01311635|DRUG|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
47928725|NCT01311635|DRUG|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
47928726|NCT02194257|DRUG|[14C]-cyclohexane ambroxol oral solution|
47928727|NCT02194257|DRUG|[14C]-benzyl ambroxol oral solution|
47928728|NCT02194257|DRUG|Ambroxol lozenge|
47928729|NCT01873703|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi)
47928730|NCT01873703|DRUG|Placebo|Placebo
47928731|NCT01873703|DRUG|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
47928732|NCT03709576|DRUG|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
47928733|NCT03709576|PROCEDURE|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
47928734|NCT03709576|DRUG|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
48621861|NCT01940146|DRUG|SPARC1310 II|SPARC1310 II
47928735|NCT04607278|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic supplementation was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
47928736|NCT04607278|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic was made up of inulin from the chicory plant and provided by the Fibrelle (Belgium) company. Five grams packs were given to the participants in boxes. Each participant was requested to take a total daily 10 g dose.
47928737|NCT04607278|DIETARY_SUPPLEMENT|Placebo|It was composed of maltodextrin, and provided by the manufacturer Fibrelle; (Belgium). The prescription was similar to probiotics or prebiotics groups.
47928738|NCT01789931|DEVICE|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
47928739|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.3 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
47928740|NCT05951465|DRUG|Esketamine|esketamine dose will be 0.6 mg/kg. Propofol dose for the first patient will be 2.0 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
47928741|NCT05951465|DRUG|Propofol|propofol
47928742|NCT06164821|DRUG|luspatercept|Adult patients with TD thalassemia were given luspatercept subcutaneous injection.
47928743|NCT06401213|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.
48279880|NCT06196502|OTHER|Kangaroo Care|"Kangaroo care will be provided to randomly selected volunteer moms in their own gynecological ward rooms, where they will have skin-to-skin contact with their babies while maintaining their privacy. Kangaroo care is a strategy that promotes bonding and engagement between a mother and her infant by allowing skin-to-skin contact with the newborn's face facing the mother and only the diaper remaining.~The infant is positioned such that his or her shoulders are totally on the mother's chest, ensuring the baby's airway is open. To avoid heat loss while the baby is in skin-to-skin contact with his mother, a tiny blanket will be placed on his back and a beanie will be placed on his head. Kangaroo care will begin 5 minutes before the Hepatitis-B vaccine is administered and will continue throughout the operation. It is estimated that it will take 10 minutes in total."
48279881|NCT06196502|OTHER|Lactation|Breastfeeding will become standard medical practice. Breastfeeding will start as soon as the baby is given the vaccination and continue throughout the process.
48452274|NCT04570748|PROCEDURE|Capsule repair|Direct anterior hip arthroplasty with or without capsule repair
48621862|NCT01940146|DRUG|SPARC1310 III|SPARC1310 III
48621863|NCT00623129|OTHER|questionnaire administration|
47928744|NCT06401213|OTHER|Placebo|Matching Placebo-- Normal Saline
47928745|NCT03696927|DEVICE|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
48452275|NCT04570748|PROCEDURE|capsulectomy|capsulectomy without repair
48452276|NCT02151981|DRUG|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
48621864|NCT00623129|PROCEDURE|electroacupuncture therapy|
48621865|NCT00623129|PROCEDURE|management of therapy complications|
48452277|NCT02151981|DRUG|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
48452278|NCT04168398|DRUG|Combination drug|Anticoagulation
48452279|NCT05620511|BEHAVIORAL|Mindfulness based stress reduction|Mindfulness based stress reduction v.s.Relaxation
48452280|NCT06071468|DEVICE|UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
48621866|NCT00623129|PROCEDURE|quality-of-life assessment|
47928746|NCT02984943|DEVICE|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
48621867|NCT02525978|BEHAVIORAL|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
48621868|NCT02525978|OTHER|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
48621869|NCT02594111|DRUG|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
48621870|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using HAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of HAP-containing toothpaste twice daily for 1 month.
47928747|NCT05380362|OTHER|Venous Angioplasty|venous angiogram to look for lesions or flaps and then plastying vessels open.
47928748|NCT05380362|OTHER|Sham Angioplasty|Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
47928749|NCT02593071|BIOLOGICAL|RSV-F Vaccine|
47928750|NCT02593071|BIOLOGICAL|Phosphate Buffer Placebo|
47928751|NCT02412488|OTHER|Out of cathlab insertion|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
47928752|NCT02427178|BIOLOGICAL|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
47928753|NCT04477278|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation recording consisted of instruction in focused attention on breath and body sensations and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and pain.
47928754|NCT04477278|BEHAVIORAL|History of Osteopathy|The history of osteopathy recording introduced patients to the founder of osteopathy, Andrew Taylor Still, and his philosophy of healing.
47928755|NCT02536183|DEVICE|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
47928756|NCT02536183|DRUG|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
47928757|NCT02793856|DRUG|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
47928758|NCT02793856|OTHER|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
47928759|NCT04548492|OTHER|Survey|to assess and validate how healthcare professionals can trigger or inhibit the use of modern technology applications in home isolation
47928760|NCT05733403|DRUG|isotonic solution|Isotonic solutions are IV fluids that have a similar concentration of dissolved particles as blood.
48621871|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using Zn Mg HAP-containing)|Toothbrushing using standardised technique and pear-sized amount of Zn Mg HAP-containing toothpaste twice daily for 1 month.
47928761|NCT05733403|DRUG|Noradrenaline|Noradrenaline itself is classified as a sympathomimetic drug: its effects when given by intravenous injection of increasing heart rate and force and constricting blood vessels make it very useful for treating medical emergencies that involve critically low blood pressure.
47928762|NCT00424255|DRUG|Lapatinib|Dual ErbB1/2 inhibitor
47928763|NCT00424255|RADIATION|Chemoradiation|Radiation plus platinum based chemotherapy
47928764|NCT00424255|OTHER|Placebo|Placebo
47928765|NCT00043550|BEHAVIORAL|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
47928766|NCT00043550|DRUG|Sertraline|Participants will receive sertraline.
47928767|NCT00043550|DRUG|Pill Placebo|Participants will receive a pill placebo.
47928768|NCT00043550|DRUG|Venlafaxine|Participants will receive venlafaxine.
47928769|NCT02043340|DRUG|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
47928770|NCT02043340|DEVICE|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
47928771|NCT02043340|PROCEDURE|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
47928772|NCT03457779|DIETARY_SUPPLEMENT|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV"
47928773|NCT05849961|DEVICE|Exactech Hip Systems|The Exactech Hip System comprises a fixed-bearing hip joint prostheses used in treating human hip joint diseases as part of THA. These prostheses include a combination of the components and are available in a range of sizes to accommodate varying anatomical requirements.
47928774|NCT01488123|BEHAVIORAL|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
47928775|NCT01104376|DRUG|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
47928776|NCT01104376|DRUG|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
47928777|NCT02165839|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBT-I)|
47928778|NCT02165839|BEHAVIORAL|Healthy Eating Education Learning (HEAL)|
47928779|NCT00735189|OTHER|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
47928780|NCT00735189|OTHER|usual care|patient receives usual anticoagulation care from their regular primary care physician
47928781|NCT02409108|DEVICE|Exatherm-TBH system|One treatment of Total Body Hyperthermia
47928782|NCT00423787|BIOLOGICAL|Ragweed MATA MPL|"4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml"
47928783|NCT04138979|DRUG|cyclophosphamide|First use of chemotherapy after breast cancer
48452281|NCT06071468|PROCEDURE|Endocscopic CTR|"Endoscopic CTR makes one or two short incisions to introduce instruments for visualizing. The key procedural steps involved in Endoscopic CTR are listed below.~1. Following the delivery of anesthesia, the surgeon makes a small wrist incision (usually less than 1.5 cm), with or without a small palmar incision (usually less than 1.5 cm, depending on whether they are using a single portal or double portal technique, respectively.~2. A series of dilators and raspers are used to create space in the carpal tunnel and clear synovial tissue from the undersurface fo the TCL.~3. A camera attached to a narrow tube (endoscope) is inserted into the carpal tunnel.~4. The transverse carpal ligament (which forms the roof of the carpal tunnel) is identified.~5. Using specialized cutting instruments and endoscopic guidance, the surgeon transects the TCL.~6. Endoscopic visualization and/or probing are used to confirm a complete release.~7. The wound(s) is/are typically closed with sutures."
47928784|NCT05622409|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
47928785|NCT02763969|DRUG|BMS-986202|
47928786|NCT02763969|DRUG|Placebo|
47928787|NCT02763969|DRUG|Interferon alpha-2a recombinant|
47928788|NCT02763969|DRUG|Famotidine|
47928789|NCT02763969|DRUG|Ustekinumab|
47928790|NCT03024580|DRUG|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
47928791|NCT03024580|DRUG|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
47928792|NCT03024580|DRUG|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
48452282|NCT06071468|PROCEDURE|Open CTR|"OCTR is the most commonly used CTR technique in the United States.The key procedural steps involved in OCTR are listed below.~1. Following the delivery of anesthesia, an incision is made in the palm directly over the carpal tunnel.~2. The surgeon cuts through the palmar fascia to identify the TCL.~3. The surgeon transects the TCL with a scalpel and/or similar cutting instruments.~4. The surgeon inspects the carpal tunnel to ensure proper decompression.~5. The wound is closed with sutures."
47928793|NCT03024580|DRUG|Exemestane 25 MG|Exemestane 25 mg PO daily
47928794|NCT03024580|DRUG|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
47928795|NCT03024580|DRUG|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
47928796|NCT03273569|PROCEDURE|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
47928797|NCT00832039|DRUG|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
47928798|NCT00832039|DRUG|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
47928799|NCT00832039|PROCEDURE|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline \>=50%: no change in causal therapy; PCT drop from baseline \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT \<=1.0 ng/ml: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \>=50%: finish antimicrobial therapy; PCT \>1.0 ng/ml and PCT drop from last PCT measurement \<50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
48452283|NCT01683045|DEVICE|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
48452284|NCT05187923|DIAGNOSTIC_TEST|Artificial Intelligence Algorithm|Different machine learning and deep learning computer aided strategies for model construction and validation.
48452285|NCT03352362|DRUG|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
48621872|NCT04896294|COMBINATION_PRODUCT|Hygienic procedure (toothbrushing using FAP-containing toothpaste)|Toothbrushing using standardised technique and pear-sized amount of FAP-containing toothpaste twice daily for 1 month.
48621873|NCT04311957|DRUG|Continuation of boosted PI|"Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs"
47928800|NCT03893344|DIAGNOSTIC_TEST|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
47928801|NCT00204555|DRUG|Imiquimod|
47928802|NCT02648633|RADIATION|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
47928803|NCT02648633|DRUG|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
47928804|NCT02648633|DRUG|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
47928805|NCT04456231|DRUG|Plenvu|Patients will receive Plenvu for preparation of endoscopy
47928806|NCT00558688|PROCEDURE|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
47928807|NCT00466492|PROCEDURE|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
47928808|NCT03952390|OTHER|control|
47928809|NCT03952390|OTHER|sepsis|
47928810|NCT03717428|DEVICE|Daily Weighing Group|The Experimental group will weigh themselves everyday
47928811|NCT03717428|DEVICE|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
47928812|NCT00231556|DRUG|topiramate|
47928813|NCT03458715|DRUG|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
47928814|NCT03458715|DRUG|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
47928815|NCT00409331|DRUG|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
47928816|NCT00409331|PROCEDURE|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
47928817|NCT03096041|DEVICE|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
47928818|NCT03096041|DEVICE|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
47928819|NCT00076375|DRUG|Nanocrystalline silver cream (NPI)|
48452286|NCT03352362|DRUG|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
48452287|NCT03352362|DRUG|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
48452288|NCT02812420|BIOLOGICAL|Durvalumab|Given IV
48452289|NCT02812420|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
48452290|NCT02812420|BIOLOGICAL|Tremelimumab|Given IV
48621874|NCT04311957|DRUG|B/F/TAF|Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
48621875|NCT01684605|DRUG|NESP 60μg|Administrated NESP 60μg once intravenously
48621876|NCT01684605|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
48621877|NCT03729440|BEHAVIORAL|development of complications or not|assessment of development of complications
48621878|NCT04426032|DIAGNOSTIC_TEST|Renal Doppler Ultrasound|Measurement of Renal resistive index
48621879|NCT02749929|OTHER|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
48621880|NCT02749929|OTHER|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
47928820|NCT05060809|DRUG|oral vitamin k1 (phylloquinone)|The enrolled patients received 5 mg of oral vitamin K1 (phylloquinone) three times /week for 6 months at the end of HD session to ensure compliance. We measured the serum dephosphorylated- uncarboxylated matrix Gla protein (dp-ucMGP) before and 6 months after vitamin K1 supplementation. In addition, plain lateral abdominal x-ray was conducted prior to and after 6 months of vitamin K supplementation to assess lumbar aorta calcification. The extent of aortic calcification score (AAC) was assessed by a semi-quantitative grading system developed by Kauppila.
48452291|NCT06627114|BEHAVIORAL|nutrition education program|"Nutritional Guidance: Emphasizing a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while reducing processed foods, sugars, and saturated fats.~Weight Management: Encouraging gradual weight loss if overweight, as this can significantly improve liver health.~Individualized Plans: Tailoring nutrition education to the individual needs, preferences, and any other underlying health conditions.~Monitoring and Support: Providing ongoing support and education to help participants make sustainable changes and track their progress."
47928821|NCT05171452|BIOLOGICAL|Urine and stoll samples|Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)
48452292|NCT06627114|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules twice daily, to be taken orally with meal.
48452293|NCT06627114|OTHER|control group|receive routine care at the outpatient clinic. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
48452294|NCT02937259|OTHER|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
48452295|NCT02577458|DRUG|CM082|CM082 tablets taken orally once a day on 28-day cycles
47928822|NCT00115323|BEHAVIORAL|Problem Solving|Problem solving intervention
47928823|NCT00115323|BEHAVIORAL|Attention Control|Attention control intervention
47928824|NCT00450008|DRUG|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
47928825|NCT00450008|DRUG|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
47928826|NCT00450008|DRUG|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
48452296|NCT02577458|DRUG|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
48452297|NCT05931458|PROCEDURE|Appendectomy|Laparoscopic appendectomy is a relatively simple surgical procedure that can be performedby most surgeons, either on an outpatient basis or with a single-night hospital stay. The laparoscopic approach is now the recommended option due to faster recovery times and fewer wound complications.
48452298|NCT05931458|DRUG|Infliximab|Administration of Infliximab (Anti-TNF-a biologic drug)
48452299|NCT03831139|BEHAVIORAL|TIM&SARA|
48452300|NCT06561477|OTHER|Intensive care cirrhosis outcome (ICCO) score|ICCO score will be calculated for the participants to use it as a predictor for mortality and ICU outcome The ICCO score is 0.3707 + (0.0773 x bilirubin (mg/dl)) - (0.00849 x cholesterol (mg/dl)) -(0.0155 x creatinine clearance (ml/min)) + (0.1351 x lactate (mmol/l))
48452301|NCT04442503|DRUG|SAGE-217|SAGE-217 oral capsules.
48452302|NCT04442503|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
47928827|NCT00204243|DRUG|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
47928828|NCT00204243|DRUG|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
47928829|NCT01037621|DRUG|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
47928830|NCT05045950|DRUG|Memantine -Twice Daily or Extended Release|"Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4)."
47928831|NCT05045950|RADIATION|WBRT utilizing the PRDR technique|The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
47928832|NCT05208918|PROCEDURE|Epidural steroid|Injection of Depo-Medrol of affected dermatomes
47928833|NCT05208918|PROCEDURE|PRF plus steroids injection|Pulsed radiofrequency with temperature 42 degrees for 6 minutes to be applied to the dorsal root ganglion plus injection of Depo-Medrol of affected dermatomes
48452303|NCT03489629|DRUG|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if \< 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
48452304|NCT03489629|DRUG|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if \< 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
47928834|NCT01937104|DRUG|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60"
47928835|NCT01937104|DRUG|Remifentanil|"Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%"
47928836|NCT01937104|DEVICE|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
47928837|NCT01937104|PROCEDURE|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
47928838|NCT01937104|PROCEDURE|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
47928839|NCT01937104|PROCEDURE|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
47928840|NCT00815178|BEHAVIORAL|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
47928841|NCT00815178|BEHAVIORAL|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
47928842|NCT03989869|OTHER|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
47928843|NCT00000931|BEHAVIORAL|Behavioral intervention|
47928844|NCT00000931|BEHAVIORAL|Risk-reduction counseling|
47928845|NCT00923364|DRUG|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
47928846|NCT00923364|DRUG|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
47928847|NCT00923364|PROCEDURE|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
47928848|NCT00923364|PROCEDURE|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
47928849|NCT00923364|DRUG|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
47928850|NCT03265964|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
47928851|NCT03265964|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
48452305|NCT03489629|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
48452306|NCT03489629|DRUG|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
48452307|NCT03489629|BEHAVIORAL|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
47928852|NCT02386670|OTHER|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
47928853|NCT02386670|OTHER|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
48452308|NCT06488846|OTHER|INVITE-Home|Curriculum to train Treatment Buddies, selected by the people with HIV, to administer LAI-ART at home with supervision of a Study Nurse.
48452309|NCT06488846|OTHER|Clinic-Administered LAI-ART|People with HIV who continue to receive LAI-ART in clinic
48452310|NCT06488846|OTHER|Oral ART|Oral ART
48452311|NCT06627257|DRUG|LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose|2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
48621881|NCT03752827|DEVICE|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
48621882|NCT03752827|DRUG|Corticosteroid|Corticosteroid injection into subacrominal space
47928854|NCT04597060|DEVICE|Thermomechanical system with corticosteroids|The device in this study using Novoxel - Tixel®
48452312|NCT06627257|DRUG|LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose|10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
47928855|NCT04597060|OTHER|corticosteroid injection|corticosteroid injection using TA 10mg/ml
47928856|NCT01459289|OTHER|leaflet|
47928857|NCT01459289|OTHER|counseling and leaflet|
47928858|NCT01544088|BEHAVIORAL|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
47928859|NCT01544088|BEHAVIORAL|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
47928860|NCT00663442|DRUG|OROS methylphenidate|18, 36, 54 mg
47928861|NCT04260932|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
47928862|NCT05896280|PROCEDURE|EST|Stones are taken by cutting the papillary sphincter
47928863|NCT05896280|PROCEDURE|ECPP|During ERCP, a generous biliary sphincterotomy (\>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
47928864|NCT06444009|DRUG|Ivonescimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
47928865|NCT06444009|DRUG|Cadonilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
47928866|NCT06444009|DRUG|Penpulimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
47928867|NCT05818605|BEHAVIORAL|Moderate Intensity Exercise Program|Subjects randomized to the EXER arm will undergo 24 weeks of Moderate Intensity Exercise Training (MIET). Patients will be signed up for 60-minute exercise sessions, 3 times a week
47928868|NCT05117671|OTHER|data collection to classify infection status|Review of medical records of all selected cases (TKA/THA patients) to classify infection status according to different classifications (EBJIS, MSIS/ICM 2013, ICM 2018).
48452313|NCT06627257|OTHER|Placebo Comparator: Placebo|Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.
48452314|NCT05824897|OTHER|Serum levels of vitamin D|Subjects in this study are grouped according to baseline serum levels of 25(OH)D. The serum level of total 25(OH)D ≥30ng/ml (75nM) is sufficient, 20-30ng/ml (50-75 nm) is insufficient, and less than 20ng/ml (50nM) is deficient.
47928869|NCT05337033|DRUG|MPL-001|"CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol."
48452315|NCT00217113|BEHAVIORAL|Geriatric home visit and Action Plan|
48621883|NCT00598403|DRUG|cefditoren pivoxil|400 mg, oral, single dose during 3 days
48621884|NCT00598403|DRUG|Ciprofloxacin|250 mg, oral, twice a day for 3 days
47928870|NCT04155411|DRUG|Dasatinib|70 mg of Dasatinib orally daily for 12 months
47928871|NCT06451731|BEHAVIORAL|PHOLEXSEM|Phonological, Lexical, and Semantic training
47928872|NCT06451731|BEHAVIORAL|PACE|See arm description
47928873|NCT02369601|OTHER|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
47928874|NCT02555280|DEVICE|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
47928875|NCT02555280|PROCEDURE|Decompression|Decompression alone
47928876|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
47928877|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks
47928878|NCT05503901|DRUG|STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks
47928879|NCT02758379|DEVICE|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
47928880|NCT01510288|DRUG|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
47928881|NCT05820659|BEHAVIORAL|peer rejection task and impossible puzzle task|"Peer rejection task: Adolescents will be informed that two peers will take turns to choose who they will chat with for different topics. Participants will not be chosen by virtual White peers 75% of the time. In reality, White peers are computerized avatars and whether or not adolescents are chosen by those peers is programmed with PsychoPy software.~Impossible puzzle task: Adolescents will be asked to fit all puzzle pieces into a wooden frame with a wrong piece provided."
47928882|NCT01268280|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
48621885|NCT02558569|DRUG|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
47928883|NCT01268280|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
47928884|NCT01268280|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
47928885|NCT00246571|DRUG|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
47928886|NCT00246571|DRUG|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
47928887|NCT02250833|DRUG|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
48452316|NCT04711057|OTHER|Community-based PA program|After completing the PR program, the experimental group (EG) will enroll in a 6-month personalized community-based PA program, which should be attended twice-weekly, minimum. During the first month the physiotherapist will guide patients through all available physical activities; afterwards, patients will be asked to choose one or two activities, according to their preference, which they'll attend for five more months. Physiotherapists' support will gradually decrease over time.
48452317|NCT04711057|OTHER|Pulmonary Rehabilitation|Exercise training, twice a week, and education and psychosocial support once every other week during 12 weeks.
48452318|NCT04430725|PROCEDURE|Computed Tomography with Contrast|Undergo contrast-enhanced CT
48452319|NCT04430725|PROCEDURE|Microwave Ablation|Undergo microwave ablation
48452320|NCT04430725|OTHER|Questionnaire Administration|Ancillary studies
48452321|NCT04430725|PROCEDURE|Wedge Excision|Undergo wedge resection
48452322|NCT04964440|DEVICE|Pure-EP|Advanced Signal Acquisition and Processing
48452323|NCT06628050|DEVICE|ORIGIN® PS Modular devices|Consecutive eligible subjects have been included which have been treated with the ORIGIN® PS Modular devices.
48452324|NCT05512104|PROCEDURE|bone marrow aspirate and biopsy|fiow cytometry of bone marrow aspirate
47928888|NCT02250833|DRUG|Telmisartan|- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
47928889|NCT02250833|DRUG|S-amlodipine|- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
47928890|NCT04269850|BIOLOGICAL|allogeneic fecal microbiota|Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
47928891|NCT04269850|DRUG|Ruxolitinib|Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
47928892|NCT04269850|DRUG|Methylprednisone|Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
47928893|NCT03348592|DIETARY_SUPPLEMENT|Oligofructose-enriched inulin (p-inulin)|
47928894|NCT03348592|OTHER|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
47928895|NCT05282914|DRUG|administration of UI058|UI058 1Tab/day for 7days
47928896|NCT05282914|DRUG|administration of UIC202004|UIC202004 1Tab/day for 7days
47928897|NCT03014882|DRUG|L-Carnitine and N-acetyl cysteine|
47928898|NCT04572360|OTHER|Cardiorespiratory Exercise|Each exercise session (40-60 minutes) will include warm-up, aerobic training, resistance training, cool-down, as well as inspiratory muscle training
47928899|NCT04572360|OTHER|Modified Bai He Gu Jin Tang|The Chinese herbal formula of Modified Bai He Gu Jin Tang will be prescribed in granules. A dose of 10g a day (5g, b.i.d) will be ingested. Patients will dissolve a sachet of granules (5.0g) in 200ml of hot water, twice a day after breakfast and dinner, seven days a week for three months.
47928900|NCT04772742|DRUG|Placebo|Placebo - solution for infusion
47928901|NCT04772742|DRUG|Eptinezumab|Eptinezumab - 100 mg, solution for infusion
47928902|NCT03894371|DEVICE|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
48452325|NCT02949739|BEHAVIORAL|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
48452326|NCT03847688|DEVICE|Transcranial Magnetic Stimulation|Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
48452327|NCT03942770|BEHAVIORAL|Contingency Management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
48452328|NCT03942770|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
48452329|NCT02028715|DRUG|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
48452330|NCT02028715|DRUG|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
48452331|NCT03577938|DRUG|Chinese herbal medicine|One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.
48452332|NCT03577938|OTHER|Control (blank)|SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.
48452333|NCT03991273|OTHER|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
48452334|NCT03991273|OTHER|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
48452335|NCT02767804|DRUG|X-396 (ensartinib)|oral ALK inhibitor
48452336|NCT02767804|DRUG|crizotinib|oral ALK inhibitor
48452337|NCT02625974|DRUG|Nifurtimox (Lampit, BAYA2502)|"For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days or 30 days of nifurtimox treatment"
48452338|NCT02625974|DRUG|Placebo|Matching placebo
48621886|NCT02558569|OTHER|NSS|Clear intravenous fluid looks alike local anesthetic.
48621887|NCT01590875|DRUG|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
48452339|NCT05811247|DRUG|AD109|Oral administration at bedtime.
48452340|NCT05811247|DRUG|Placebo|Oral administration at bedtime.
48452341|NCT06562231|OTHER|quality of life scale|This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients.
48452342|NCT04211779|DEVICE|Real tDCS|Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.
48452343|NCT04211779|DEVICE|Sham tDCS|Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
48452344|NCT04211779|OTHER|Exercise|The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
48452345|NCT00378963|DEVICE|ProAdjuster|
48621888|NCT06476730|OTHER|Telerehabilitation exercise program|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased
48621889|NCT06476730|OTHER|Routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
48621890|NCT02237664|PROCEDURE|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
48621891|NCT02237664|PROCEDURE|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
48621892|NCT00226213|PROCEDURE|Peripherally Inserted Central Catheter Placement|
48621893|NCT05392660|OTHER|assumed upright position during first stage of labor|The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling \& squatting positions )
48621894|NCT00195793|DRUG|fenofibrate|
48621895|NCT00195793|DRUG|ezetimibe|
47928903|NCT00838864|DRUG|ceftrioxone|500 mg iv q12h for 3 days
47928904|NCT00838864|DRUG|ceftrioxone|500 mg q12h for 7 days
48621896|NCT00195793|DRUG|atorvastatin|
48621897|NCT01830686|OTHER|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
48621898|NCT01830686|OTHER|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
48621899|NCT01830686|OTHER|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
48621900|NCT03785028|BEHAVIORAL|working memory and attention|working memory and attention tasks
48621901|NCT06167902|OTHER|Ginseng oligopeptide (Ginseng extract）|The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.
47928905|NCT05410951|DIAGNOSTIC_TEST|Illumina panel|"Determination of germline mutations using a recent panel including 113 genes from the Illumina protocol"
47928906|NCT03302182|DRUG|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
47928907|NCT03302182|DRUG|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
47928908|NCT03562767|BEHAVIORAL|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
47928909|NCT03562767|BEHAVIORAL|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
47928910|NCT03562767|BEHAVIORAL|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
47928911|NCT05886985|DRUG|MatriPlax|MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
47928912|NCT01649843|PROCEDURE|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
47928913|NCT04989452|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
47928914|NCT02216812|DRUG|500 mg vitamin c, 1 pill per day for 6 weeks|
48621902|NCT06167902|OTHER|Maltodextrin|The control group was treated with placebo maltodextrin 1.2g/d
48621903|NCT04822415|DRUG|Mepivacaine|IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
47928915|NCT02216812|DRUG|1 placebo pill for 6 weeks|
47928916|NCT04011371|PROCEDURE|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
47928917|NCT04246931|OTHER|No intervention (survey)|No intervention -\> survey at 1 timepoint
47928918|NCT05726877|OTHER|ventilation strategy|Titrating positive end-expiratory pressure
47928919|NCT06229171|OTHER|adherence support system based on a vocal assistant|"Participants in the intervention group will receive a vocal assistant device and the instructions/support for the activation of the system at their homes. The device will remind the participant, at the times defined during set-up, which therapy should be taken and with what dosage. The participant will have 30 minutes from the first reminder to confirm vocally that the therapy has been taken, which will otherwise be considered as not having been taken.~Participants in the control group will receive verbal advice from the physician about the need to follow the treatment recommendations and simple indications on possible solutions to maintain adherence, as by the usual practice of the Centre."
47928920|NCT04482023|BEHAVIORAL|Training video on anxiety, fear and loneliness in the COVID-19 environment.|Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
47928921|NCT05273073|DIETARY_SUPPLEMENT|Probiotics|Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).
47928922|NCT05273073|DIETARY_SUPPLEMENT|Placebo|Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
47928923|NCT02811627|DRUG|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
47928924|NCT02811627|DEVICE|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
47928925|NCT04430075|DEVICE|Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System|Transcatheter Valve Repair with Edwards PASCAL and PASCAL Precision System
47928926|NCT02603796|OTHER|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
48452346|NCT02450539|DRUG|Abemaciclib|Administered orally
48452347|NCT02450539|DRUG|Docetaxel|Administered IV
48452348|NCT04806035|BIOLOGICAL|TG-1801|It is a bispecific, first-in-class, CD47 and CD19 antibody
48621904|NCT04822415|DRUG|Articaine|IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
48621905|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
48621906|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
48621907|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
47928927|NCT03483922|DIAGNOSTIC_TEST|ctDNA methylation in and it's Correlation wth Development and prediction of HCC|Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
47928928|NCT05905614|DRUG|SPH4336 Tablets|Open-label SPH4336 Tablets ：Administered by oral
47928929|NCT01931085|DRUG|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
47928930|NCT05444140|BEHAVIORAL|Health coaching|The health coaching programme includes four monthly health coaching sessions for three months.
47928931|NCT05150639|OTHER|IVF|Women planning to undergo frozen embryo transfer IVF procedure will be included. Samples will be obtained, but no study intervention will be applied. Pregnancy outcome data will be obtained, following frozen embryo transfer, to correlate against other data from samples (vaginal microbiome etc).
48452349|NCT04806035|BIOLOGICAL|Ublituximab|recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
48452350|NCT01116739|DEVICE|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
48452351|NCT01116739|BEHAVIORAL|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
48452352|NCT01116739|OTHER|Dental services delivered by the Indian Health Service.|
48452353|NCT02854800|DRUG|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
47928932|NCT03470532|DRUG|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
47928933|NCT03470532|DRUG|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
48452354|NCT05248711|BEHAVIORAL|Calm Daily Move|The Daily Move is a series of short, 5-min videos outlining mindful movement exercises. The Daily Move is part of the Calm app's library of content.
47928934|NCT01961583|DRUG|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
47928935|NCT05198375|DIAGNOSTIC_TEST|Lung ultrasound score (LUS)|LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
47928936|NCT05099224|BEHAVIORAL|Mindfulness meditation|similar to the information included in arm/group descriptions
47928937|NCT03088085|PROCEDURE|Self-mobilization|Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
47928938|NCT03088085|PROCEDURE|Sleep Education|Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
48452355|NCT04513912|DRUG|Seltorexant|Participants will receive seltorexant over-encapsulated tablet orally.
48452356|NCT04513912|DRUG|Matching placebo to Seltorexant|Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
48452357|NCT04513912|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
48452358|NCT04513912|DRUG|Matching placebo to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
48452359|NCT03418753|DIAGNOSTIC_TEST|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
48452360|NCT00835432|DEVICE|Ossix|Test group
48452361|NCT00835432|DEVICE|Biogide|controls
48452362|NCT01112761|DEVICE|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
48452363|NCT00955448|DEVICE|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
48452364|NCT00955448|PROCEDURE|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
48621908|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
48452365|NCT03641222|DEVICE|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
48452366|NCT00187928|DRUG|Topiramate|
48452367|NCT03749187|DRUG|PARP Inhibitor BGB-290|Given PO
48452368|NCT03749187|DRUG|Temozolomide|Given PO
48452369|NCT02226250|DIETARY_SUPPLEMENT|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
48452370|NCT02045849|DRUG|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
48452371|NCT02045849|DRUG|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
48621909|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
48621910|NCT04640402|BIOLOGICAL|Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
48452372|NCT02045849|DRUG|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
48452373|NCT00932841|OTHER|Placebo|One packet PO daily x 8 weeks.
48452374|NCT00932841|DRUG|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
48452375|NCT00932841|DRUG|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
48452376|NCT05825716|OTHER|Ifaa Basic|"* PSNP Systems: (1) Provision of food aid commodities (wheat, oil, and pulse) per the PSNP transfer schedule for 3-6 months; 2) Food System Taskforce (FSTF) capacity building, and 3) private sector engagement~* Health and Nutrition: 1) Government of Ethiopia (GoE) basic health extension program; 2) GoE supportive supervision coaching; 3) GoE-led community social behavior change (SBC) sessions; and 4) Community Management of Acute Malnutrition (CMAM) Programming.~* Water and Sanitation: 1) Water infrastructure development; 2) improved governance via water, sanitation and hygiene (WASH) committees; and 3) water source monitoring.~* Natural Resource Management: 1) Public works projects; 2) community training in planning and sustaining community assets; 3) Implementation of the environment and social management framework; 4) enhance participation of watershed committees"
48452377|NCT05825716|BEHAVIORAL|Ifaa Enhanced|"* PSNP Systems: 1) establishment and training of Community Technical Coordinating Forum; 2) Case management capacity building; and 3) private sector construction of infrastructure~* Health and Nutrition:1) the Care Group Model approach; 2) home garden promotion; 3) the nutrition budget calculator; and 4) labor and time-saving technologies.~* Community-level interventions are 1) adolescent nutrition school clubs; 2) religious leader mobilization and training vulnerable groups; 3) audio toolkit against harmful traditional practice; 4) enhanced SBC tools for health/nutrition promotion; 5) additional health extension programs~* Water and Sanitation: 1) Community Led Total Sanitation and Hygiene; 2) WASH systems assessments and strengthening; 3) Ensuring water quality and safety via routine monitoring; 4) Private sector engagement of WASH-related businesses;"
48452378|NCT05825716|OTHER|Ifaa Enhanced + Livelihoods|"* Additional resources provided to the groups, including 1) Engagement of Private Service Providers to enable access to sustainable credit and larger loans; 2) Financial Education using an expanded 'Smart Skills' curriculum focusing on savings, smart borrowing and effective financial management; and 3) Life Skills Training for Youth.~* Additional supports include: 1) Seven Steps of Marketing Training; 2) Climate Smart Agriculture to reduce water needs and increase soil health and vegetation coverage; 3) Producers Groups and linkages to markets/suppliers/buyers; Selected financial institutions will be provided with a credit guarantee fund and capacity-building support to help facilitate loans. Private sector value chain assessment and financing. Additional private sector engagement and linkage facilitation."
48452379|NCT01639911|DRUG|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
48452380|NCT01639911|DRUG|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
48452381|NCT06562179|DEVICE|da Vinci SP® Single-Port Robotic Surgical System|The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.
48452382|NCT04398147|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
48452383|NCT04398147|BIOLOGICAL|Placebo|Intramuscular administration
48452384|NCT03675633|DIAGNOSTIC_TEST|FEUrea|FEUrea in decompansated liver cirrhosis
48452385|NCT01728181|DRUG|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
48452386|NCT01728181|DRUG|Erlotinib|150 mg/day for 28 day cycle. No rest period.
48452387|NCT01728181|OTHER|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
48452388|NCT00218257|DRUG|Progesterone|200mg progesterone twice daily
48452389|NCT00218257|OTHER|Placebo|placebo
48452390|NCT00834717|DRUG|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
48452391|NCT00834717|DRUG|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
48452392|NCT05244720|DIAGNOSTIC_TEST|Fibroscan|A percutaneous scan, that measures shear wave velocity. It estimates liver stiffness.
48452393|NCT05244720|DIAGNOSTIC_TEST|Blood samples|Blood samples to asses the function of liver, kidney and bone marrow, as well as nutrition/vitamin status.
48452394|NCT00834431|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
48452395|NCT00834431|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
47928939|NCT01814280|OTHER|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
47928940|NCT05709132|BEHAVIORAL|iPeer2Peer Program|Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
48452396|NCT03612960|DRUG|Very low nicotine content cigarettes|Very low nicotine content cigarettes
48621911|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.
48621912|NCT04640402|BIOLOGICAL|High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
48621913|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
48621914|NCT04640402|BIOLOGICAL|Low-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
47928941|NCT05116527|DRUG|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
47928942|NCT05116527|DRUG|Placebo|Placebo THC - marijuana flower with no THC content
47928943|NCT00815854|DIETARY_SUPPLEMENT|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
47928944|NCT00815854|OTHER|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
48452397|NCT03612960|DRUG|Normal nicotine content cigarettes|Normal nicotine content cigarettes
48621915|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Two dose regimen|18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
48621916|NCT04640402|BIOLOGICAL|High-dose placebo (18-59 years) & Three dose regimen|18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
48452398|NCT06459258|OTHER|Motion-triggered NMES training protocol|Experimental group subjects undergo a motion-triggered NMES shoulder strengthening training program (3x/week, 30 minutes for 6 weeks) using the Shoulder Pacemaker (NCS Lab Srl, Modena, Italy), a motion activated stimulation device to strengthen muscular disbalances. This is accomplished through varying neuromuscular electrical stimulation intensity based on the angle of motion of the arm producing subtetanic contraction and provoking supraspinal neural adaptations. Electrode placement: electrode 1, inferior to the scapular spine (infraspinatus, teres minor, + posterior deltoid); electrode 2, medial to the medial scapula border (lower trapezius + rhomboids) . Sets x repetitions: 3x20 Levels: Level 1-3; Exercise 1: L1: Supported row, L2: Front raises in 45°, L3 Front raises (thumbs up) Exercise 2: L1: Resisted front raises, L2: Crossbody resisted raises, L3: Crossbody; forehand swing; Exercise 3: L1: Rear dealt fly, L2: Single arm resisted row, L3: Underhand volleyball
48452399|NCT06459258|OTHER|Non-Motion-triggered NMES training protocol|Arm Description: Subjects of the control group undergo a conventional standardized strength training program (3x/week, 30 minutes for 6 weeks) with concentric, eccentric, and functional training exercises.
48452400|NCT06545474|DEVICE|bilateral theta burst stimulation|Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.
48452401|NCT06545474|DRUG|SSRI treatment|Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.
48452402|NCT06543355|DEVICE|Modified Battlefield Acupuncture + National Acupuncture Detoxification Association protocol|The delivery of modified BFA + NADA will be administered in a setting designed to ensure that patients are comfortable, with their backs well-supported. With regards to needling technique, participants' ears will be cleaned, and sterile acupuncture needles will be placed on the BFA or NADA points, using proper technique. Auricular acupuncture needles are thin, between 0.12 - 0.18mm, and are less than 1 inch long. The needles will remain in the ear until the session is complete. On the alternative ear, seeds are another modality of auricular acupuncture treatment that will be used. Seeds are comprised of small circular balls comprised of a natural plant, no more than 1.5 mm diameter size. The seeds are attached to a small piece of adhesive tape and are placed on one's ear. The seeds remain on the ear and the given point can be massaged and stimulated as indicated.
48452403|NCT00194363|BEHAVIORAL|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
48452404|NCT06556849|DEVICE|Defocus Incorporated Multiple Segments (DIMS)|To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.
48452405|NCT04515095|OTHER|Water-only Fasting|Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
48452406|NCT06626555|DRUG|Letermovir|Letermovir 480mg PO once daily
48452407|NCT05041855|BEHAVIORAL|The Healthy Living Program/La Vida Saludable|A whole-family group childhood obesity intervention delivered at community recreation centers
48452408|NCT05041855|BEHAVIORAL|Recommended Treatment of Obesity in Primary Care|A healthy lifestyle counseling protocol that enhances usual primary care
48452409|NCT05201339|PROCEDURE|Standard method|Insert I-gel™ according to the manufacturer's instruction. Take the sniffing position and gently move the i-gel™ along the hard palate to the soft palate and the posterior oropharynx.
48452410|NCT05201339|PROCEDURE|Hean and Neck Rotation|After rotating the patient's head and neck to the left maximally, insert the i-gel™ from the right side of the tongue to the midline. When the tip reaches the soft palate and oropharynx positions, turn the head and neck back to the neutral position.
48452411|NCT02163382|DEVICE|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
48452412|NCT02163382|DEVICE|Neurovent Monitor XIII|RIP jacket installation
48452413|NCT02163382|DEVICE|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
48452414|NCT02163382|DEVICE|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
48452415|NCT02163382|DEVICE|Neurovent Monitor XIII|Second period with conventional NIV settings
48452416|NCT00295477|GENETIC|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
48452417|NCT05594095|DRUG|PIK3CA inhibitor|PIK3CA inhibitor
48452418|NCT05594095|DRUG|AKT inhibitor|AKT inhibitor
48452419|NCT05594095|DRUG|Carrelizumab|Pd-1 mab
48452420|NCT05594095|DRUG|Famitinib|VEGFR inhibitor
48452421|NCT05594095|DRUG|Fluzoparib|PARP inhibitor
48452422|NCT05594095|DRUG|Dalpiciclib|CDK4/6 inhibitor
48452423|NCT05594095|DRUG|SHR-A1811|HER2 ADC
48452424|NCT05594095|DRUG|Everolimus|mTOR inhibior
48452425|NCT05594095|DRUG|Aromatase Inhibitors or Fulvestrant|Letrozole/Anastrozole/Exemestane or Fulvestrant
48452426|NCT05594095|DRUG|Goserelin|For premenopause
48621917|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.
48621918|NCT04640402|BIOLOGICAL|Low-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.
48452427|NCT05594095|DRUG|TPC|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
48452428|NCT05594095|DRUG|Sorafenib|RTK Inhibitor
48452429|NCT05594095|DRUG|Apatinib|Apatinib 250mg po qd
48452430|NCT05594095|DRUG|SHR-A1921|TROP2 ADC
48452431|NCT05594095|DRUG|SHR-A2102|NECTIN4 ADC
48452432|NCT05594095|DRUG|SHR-A2009|HER3 ADC
48452433|NCT05594095|DRUG|SHR-1167|PARP1i
48452434|NCT05594095|DRUG|SHR-6209|CDK4i
48452435|NCT05594095|DRUG|bevacizumab|bevacizumab
48452436|NCT06194877|DRUG|BGB-3245|Oral capsule
48452437|NCT06194877|DRUG|Panitumumab|Intravenous (IV) infusion via an infusion pump
48621919|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Two dose regimen|60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
48621920|NCT04640402|BIOLOGICAL|High-dose placebo (60-85 years) & Three dose regimen|60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
48452438|NCT05766553|OTHER|Virtual reality pod|The first two sessions provide guided training in relaxation and mindfulness through immersion in a virtual forest environment for the first session, and in a virtual beach environment for the second. Sessions 3 and 4 present environments with addiction-related stimuli (Cues). The session 3 consists of a walk through the virtual street environment, buying a bottle of water from the store, and then ordering a coffee from a virtual bar. The session 4 takes place in a virtual party environment in an apartment: people smoke and drink alcohol in the living room, the session consists of sitting with them, then going to the kitchen to get a water bottle. Sessions 5 and 6 present stressful environments. Session 5 consists of a virtual parachute jump. The 6th session takes place in a virtual airplane environment, which will encounter turbulence.
48452439|NCT05766553|OTHER|nicotine patches and chewing gum|Participants in this group will be prescribed a Gold Standard smoking cessation treatment with nicotine patches adapted to their consumption and 4mg nicotine chewing gum for a period of 3 months.
48452440|NCT00491192|DRUG|Diclofenac|
47928945|NCT01576159|OTHER|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
47928946|NCT01576159|OTHER|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
47928947|NCT01576159|OTHER|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
48279882|NCT03652922|DRUG|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
48279883|NCT06551623|DRUG|Midazolam|Midazolam Oral Solution 2 mg
48279884|NCT06551623|DRUG|Clarithromycin|Clarithromycin tablets 0.5 g
47928948|NCT00252044|DRUG|Pergolide|
47928949|NCT04564638|DRUG|Corticosteroid|
47928950|NCT00004904|BIOLOGICAL|anti-thymocyte globulin|
48098298|NCT05384132|OTHER|SRP + Livfresh Dental Gel|SRP at baseline with use of LDG (test dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use LDG as their primary dentrifice (toothpaste) for the next 6 months. They're instructed to use LDG twice daily with toothbrushing for 2 minutes. LDG in previous studies have been reported to be superior to conventional over-the-counter toothpaste in terms of reducing bacterial plaque and gingival inflammation due to its EDTA (ethylenediaminetetraacetic acid) ingredient. EDTA prevents adhesion of bacterial plaque to teeth.
48098299|NCT05384132|OTHER|SRP + standard flouride dentifrice|SRP at baseline with use of standard fluoride dentifrice (control dentifrice) for twice daily brushing between study visits. Scaling and root planing is the physical removal of dental plaque, calculus, and bacterial exotoxins embedded onto the root surface of effected teeth with hand instruments and ultrasonic devices. In addition to scaling and root planing, the participants will use standard fluoride toothpaste (commercial over-the-counter toothpaste) as their primary dentrifice (toothpaste). They're instructed to use standard fluoride toothpaste twice daily with toothbrushing for 2 minutes.
48098300|NCT01087177|OTHER|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
48098301|NCT06630741|OTHER|alternative midwifery units (AMU)|"Alternative midwifery birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative midwifery birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative midwifery birth units named Filière physiologique co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room"
48098302|NCT02405390|PROCEDURE|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
48098303|NCT02405390|PROCEDURE|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
48098304|NCT02405390|DEVICE|Storz C-Mac® laryngoscope|
48279885|NCT06551623|DRUG|TNP-2198|TNP-2198 Capsules 400 mg
48279886|NCT04200612|BEHAVIORAL|Equine-Assisted Psychotherapy|Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
48279887|NCT04200612|BEHAVIORAL|Equine-Assisted Activities|Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
48452441|NCT03596567|DRUG|Glasdegib single 100 mg dose in normal healthy subjects|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
47928951|NCT00004904|BIOLOGICAL|filgrastim|
47928952|NCT00004904|DRUG|cladribine|
47928953|NCT00004904|DRUG|cyclophosphamide|
47928954|NCT00004904|DRUG|etoposide|
47928955|NCT00004904|DRUG|methylprednisolone|
47928956|NCT00004904|DRUG|tacrolimus|
48452442|NCT03596567|DRUG|Glasdegib single 100 mg dose in moderate renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
48452443|NCT03596567|DRUG|Glasdegib single 100 mg dose in severe renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
48452444|NCT06412861|DRUG|Ketamine|0.5 mg/kg ketamine + 1 mg/kg propofol, Ramsey Sedation Score \> 4 will be targeted. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
48452445|NCT06412861|DRUG|Fentanyl|1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
48452446|NCT03616405|DRUG|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
47928957|NCT00004904|PROCEDURE|allogeneic bone marrow transplantation|
47928958|NCT00004904|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
47928959|NCT00843778|BIOLOGICAL|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 \[NCT00674362\], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
47928960|NCT05909800|DRUG|Phenofibrate|Administred orally, once daily, for 12 months.
47928961|NCT05909800|DRUG|Placebo|Administred orally, once daily, for 12 months.
47928962|NCT03856268|PROCEDURE|'Surgical Menopause' Group|Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
47928963|NCT03856268|DRUG|'Drug-Induced Menopause' Group|Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
47928964|NCT00954252|DRUG|CHF 5074|1x, oral capsule, single dose
47928965|NCT00954252|DRUG|placebo|placebo, oral capsule, single dose
47928966|NCT00954252|DRUG|CHF 5074|2x, oral capsule, single dose
47928967|NCT00954252|DRUG|CHF 5074|4x, oral capsule, single dose
47928968|NCT00954252|DRUG|CHF 5074|8x, oral capsule, single dose
48452447|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
47928969|NCT00954252|DRUG|CHF 5074|16x, oral capsule, single dose
47928970|NCT00954252|DRUG|CHF 5074|24x, oral capsule, single dose
47928971|NCT03007888|DRUG|Sinemet|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
47928972|NCT03007888|DRUG|IPX203|Extended Release capsules containing carbidopa-levodopa flexible dosing
47928973|NCT04253886|DEVICE|Ovassapian Fibreoptic Intubating Airway|The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
47928974|NCT03587285|BIOLOGICAL|Tcm+ Goserelin acetate+ Bicalutamide|Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily
47928975|NCT03587285|BIOLOGICAL|Tcm+Goserelin acetate+Abiraterone acetate|Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
47928976|NCT05438901|BIOLOGICAL|leech therapy|effects of medicinal leeches
47928977|NCT01704612|DRUG|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
47928978|NCT01768884|DRUG|Nitric Oxide|
47928979|NCT01768884|DRUG|Placebo|
47928980|NCT01411553|OTHER|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
47928981|NCT01529801|DEVICE|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
47928982|NCT01529801|DEVICE|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
47928983|NCT01529801|DEVICE|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
48452448|NCT04803487|OTHER|robot-assisted cholecystectomy|cholecystectomy was performed for patients using the da Vinci surgical robot.
47928984|NCT00029510|DRUG|Magnesium|
47928985|NCT04164693|DRUG|Low molecular weight heparin|patients began to use low molecular weight heparin or warfarin sodium tablets.
47928986|NCT04164693|OTHER|non anticoagulant therapy group|no anticoagulant was used after operation.
47928987|NCT03441672|BEHAVIORAL|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
48452449|NCT01461785|BIOLOGICAL|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
47928988|NCT03475953|DRUG|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
48452450|NCT01461785|PROCEDURE|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
48452451|NCT01564394|BEHAVIORAL|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
48452452|NCT01564394|BEHAVIORAL|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
48452453|NCT01957059|DRUG|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg"
48452454|NCT01957059|DRUG|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg"
48452455|NCT01957059|DRUG|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
47928989|NCT03475953|DRUG|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
47928990|NCT03475953|DRUG|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
48452456|NCT01957059|DRUG|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
48452457|NCT01957059|DRUG|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
48452458|NCT02199873|DRUG|BIIX 1 XX - single rising dose|
48452459|NCT02199873|DRUG|Placebo|
48452460|NCT03525639|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
48452461|NCT05884320|DRUG|Sacituzumab Govitecan|Given by IV (vein)
48452462|NCT06500858|OTHER|Exercise Intervention|Receive a welcome package with exercise equipment
48452463|NCT06500858|OTHER|Exercise Intervention|Participate in virtual-exercise sessions
47928991|NCT03475953|DRUG|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
47928992|NCT03475953|DRUG|Phase 2: low-dose Regorafenib|Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
47928993|NCT05570331|DIAGNOSTIC_TEST|HPV integration test|HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.
47928994|NCT02727543|OTHER|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
48098305|NCT04416139|BIOLOGICAL|Infusion IV of Mesenchymal Stem cells|Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
48098306|NCT05231122|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
48452464|NCT06500858|OTHER|Exercise Intervention|Receive access to optional drop-in classes
48452465|NCT06500858|OTHER|Health Promotion and Education|Receive monthly newsletters
48452466|NCT06500858|OTHER|Internet-Based Intervention|Receive access to online fitness buddy matching program
48452467|NCT06500858|OTHER|Physical Activity|Participate in a walking program
48452468|NCT06500858|OTHER|Questionnaire Administration|Ancillary studies
48452469|NCT03537807|DRUG|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
48452470|NCT04222023|DRUG|Intravenous immunoglobulins (IVIG)|"Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day."
48452471|NCT06626620|DRUG|Magnesium Sulphate infusion|Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes
48452472|NCT06626620|DRUG|Terbutaline Infusion|Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours
48452473|NCT05226533|DRUG|DWRX2003|Intramuscular injection of DWRX2003
48452474|NCT05226533|DRUG|Placebo|Intramuscular injection of placebo
48452475|NCT06300411|DRUG|SRG-514|SRG-514 monotherapy
48452476|NCT05108948|BEHAVIORAL|Quality of life questionnaires|Oswestry Disability Index Scoliosis Research Society-22R Short Form 36 Health Survey Questionnaire Tobacco, Alcohol, Prescription medication, and other Substance use Core Outcome Measures Index : back and neck
48098307|NCT05231122|BIOLOGICAL|Bevacizumab|Given IV
48098308|NCT05231122|BIOLOGICAL|Pembrolizumab|Given IV
48279888|NCT04200612|OTHER|Placebo-control group|This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
48452477|NCT05108948|PROCEDURE|Radiography|Spinal radiography : full, face, profile
48452478|NCT00840879|DRUG|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
48452479|NCT00840879|DRUG|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
48452480|NCT01148186|BEHAVIORAL|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
48452481|NCT06234423|DRUG|CUSP06|Antibody drug conjugate (ADC)
48452482|NCT01946477|DRUG|Pomalidomide|
48452483|NCT01946477|DRUG|Dexamethasone|
48098309|NCT05231122|OTHER|Quality-of-Life Assessment|Ancillary studies
48098310|NCT05231122|OTHER|Questionnaire Administration|Ancillary studies
48098311|NCT06037616|OTHER|powerpoint and tutor|Powerpoint on indication of skin suture and tutor for the skill to perform skin suture
48452484|NCT01946477|DRUG|Daratumumab|
48452485|NCT05214794|DRUG|nemolizumab|nemolizumab will be administered subcutaneous injection
48452486|NCT06182722|DIAGNOSTIC_TEST|Mental assessments|Patients will receive psychiatric rating scales evaluation every visit.
48452487|NCT03930732|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48098312|NCT06037616|OTHER|video skill|Video showing skill to perform a skin suture
48098313|NCT06037616|OTHER|video errors|Video showing errors of skin suture
48098314|NCT05478902|PROCEDURE|Exercise Therapy|Exercise protocol for rotator cuff related shoulder pain
48098315|NCT05478902|PROCEDURE|Extracorporeal Shockwave Therapy|High Energy Extracorporeal Shockwave Therapy
48452488|NCT03930732|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
48452489|NCT03930732|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
48452490|NCT03930732|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
48452491|NCT03930732|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48452492|NCT05003232|DEVICE|Near-infrared spectroscopy (NIRS) and ICM+|The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.
48452493|NCT04118192|PROCEDURE|Tumour bed core biopsy|Collection of up to 8 core biopsies across 4 zones of the whole tumour bed to detect residual cancer post neo-adjuvant treatment
48452494|NCT00876967|DEVICE|metallic single use blade|metallic single use blade
48452495|NCT00876967|DEVICE|plastic single use blade|plastic single use blade
48452496|NCT00876967|DEVICE|metallic reusable blade|metallic reusable blade
48452497|NCT01689077|OTHER|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
47928995|NCT04465201|DEVICE|Impella CP with Smart Assist (Circulatory Support System)|Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.
47928996|NCT04006600|PROCEDURE|Sphincter saving proctectomy|"After rectal resection, when colorectal anastomosis is subperitoneal, it is currently recommended to perform a protective stoma to reduce the potential consequences of a fistula. This stoma, which is intended to be temporary, appears to be permanent in 6 to 32% of cases in the literature.~The objective of the study is therefore to look for a statistical link between the persistence of a permanent stoma and the intraoperative difficulty represented by pelvic anatomical stress."
47928997|NCT00862420|DRUG|clopidogrel (SR25990)|oral administration (tablets)
47928998|NCT00862420|DRUG|ticlopidine|oral administration (tablets)
47928999|NCT00105053|BIOLOGICAL|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
47929000|NCT04619160|DRUG|Propofol|TCI 4 µg/mL start until BIS-value of 50
47929001|NCT04619160|DRUG|Sevoflurane|start 1 MAC, until BIS-value of 50
47929002|NCT05950152|DRUG|Meloxicam Injection 30mg|meloxicam injection 30mg every 24 hours for up to 2 dose
47929003|NCT05950152|DRUG|Meloxicam Injection 60mg|meloxicam injection 60mg every 24 hours for up to 2 dose
47929004|NCT05950152|DRUG|Nacl 0.9%|IV Placebo every 24 hours for up to 2 doses
47929005|NCT03189498|DRUG|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.
47929006|NCT05524116|BEHAVIORAL|Mindful Exercise program|In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.
47929007|NCT05524116|BEHAVIORAL|Exercise|In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
47929008|NCT01440543|PROCEDURE|Water immersion insertion AND CO2 insufflation|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection"
47929009|NCT01440543|PROCEDURE|Water immersion insertion|"* room temperature water infused by water pump into the colon just to facilitate scope insertion~* standard room air insufflation during colonoscope withdrawal and mucosal inspection"
47929010|NCT01440543|PROCEDURE|CO2 insufflation|- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
48279889|NCT03114033|OTHER|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg
48452498|NCT00031395|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
48452499|NCT00031395|DRUG|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
48452500|NCT00031395|OTHER|placebo|an inactive substance
48452501|NCT03059979|DRUG|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
47929011|NCT04707547|BIOLOGICAL|immunotherapy with Nivolumab|After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
47929012|NCT04707547|PROCEDURE|Radiofrequency Ablation|The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
47929013|NCT04280809|DEVICE|GaAlAs laser|GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
48452502|NCT03059979|OTHER|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
48452503|NCT04654143|DRUG|BVL-GSK098 capsule, placebo|Oral QD
48621921|NCT02741817|DRUG|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
48621922|NCT03036943|RADIATION|Fluciclovine|Fluciclovine (18F) PET/CT scan completed \>= 48 hours prior to surgical resection for breast cancer
48098316|NCT05478902|PROCEDURE|Ultrasound-Guided Percutaneous Irrigation|Two sessions of Ultrasound-Guided Percutaneous Irrigation
48452504|NCT05445180|BEHAVIORAL|Contingency management|Contingency management will be used to encourage abstinence
48621923|NCT03691532|BEHAVIORAL|Seated control (CON)|Seated rest
48621924|NCT03691532|BEHAVIORAL|Arm cycle exercise (ACE)|Arm cycling at a continuous power output
48621925|NCT03691532|BEHAVIORAL|Liquid meal|Liquid meal of 0.5 L volume containing 20 kcal/kg fat free mass (FFM) and 5 mg/kg FFM of uniformly 13-carbon labeled palmitate (\[U-13C\]palmitate) at a macronutrient distribution of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
48621926|NCT00034385|DRUG|Valganciclovir|
47929014|NCT05258370|OTHER|Dosage|Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin
47929015|NCT05258370|OTHER|Cardiac echography|12 months after patient enrollment
47929016|NCT00506636|BEHAVIORAL|Tissue engineering for hair follicle regeneration|
47929017|NCT02246712|DRUG|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
47929018|NCT02246712|OTHER|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
47929019|NCT02246712|OTHER|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
47929020|NCT02246712|GENETIC|CYP2B6 genotype|The single nucleotide polymorphism 516G\>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
47929021|NCT05062395|PROCEDURE|Computed Tomography|Undergo FDG PET CT
47929022|NCT05062395|OTHER|Fludeoxyglucose F-18|Undergo FDG PET CT
47929023|NCT05062395|OTHER|Low Carbohydrate High Fat Diet|low carbohydrate and high fat diet for 48-72 hours
47929024|NCT05062395|PROCEDURE|Positron Emission Tomography|Undergo FDG PET CT
47929025|NCT00998777|PROCEDURE|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
47929026|NCT00263861|PROCEDURE|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
47929027|NCT03878693|DRUG|Fomepizole|IV 4-MP.
47929028|NCT03878693|DRUG|APAP|Oral APAP
47929029|NCT06074042|OTHER|previous pulmonary tuberculosis|Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
47929030|NCT01765309|PROCEDURE|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
48098317|NCT03426579|DEVICE|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
48098318|NCT05893303|OTHER|1st Group|1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
48621927|NCT01814085|DRUG|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
48621928|NCT06398587|DRUG|Onvansertib|Given PO
48621929|NCT06398587|DRUG|Gemcitabine|Given IV
48621930|NCT06398587|DRUG|Nab-paclitaxel|Given IV
47929031|NCT01517971|OTHER|laboratory biomarker analysis|Correlative studies
47929032|NCT04538209|RADIATION|Abdominal computed tomography with angiography.|technique of combing a Computed Tomography scan with the injection of dye to create pictures of the portal circulation and portosystemic collaterals veins.
47929033|NCT05264948|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
47929034|NCT01962168|DEVICE|Evolution® Biliary Stent - Uncovered|Commercially available device
47929035|NCT03233880|DRUG|Azithromycin 1gm|Azithromicin 1 gm oral single dose
47929036|NCT03233880|OTHER|PLACEBO|placebo
47929037|NCT03331510|OTHER|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
47929038|NCT02217527|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
47929039|NCT02217527|DRUG|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
47929040|NCT04686058|DRUG|Propofol 10 MG/ML Injection|
47929041|NCT04686058|DRUG|Midazolam injection|
47929042|NCT04686058|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|
47929043|NCT04686058|DEVICE|target controlled infusion pump|
47929044|NCT04686058|DEVICE|patient-controlled sedation pump|
47929045|NCT04572555|OTHER|Heat Treatment|Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak.
48621931|NCT06398587|PROCEDURE|Electrocardiography|Undergo electrocardiography
48621932|NCT06398587|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48621933|NCT06398587|PROCEDURE|Positron Emission Tomography|Undergo PET
47929046|NCT01967381|DRUG|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
48452505|NCT06491797|BEHAVIORAL|Immediate reactivation|Our intervention will be booster measure of the existing PTP elements that will be designed for each unit that has been randomized to the immediate intervention group. The booster will consist in a reactivation through audit and feedback of 2-3 elements of the PTP program. The selection of the elements to boost will be done locally in each unit through a coordinated discussion between representants of the PTP organization and representants of the unit's medical and nursing professionals. This will create an adaptable intervention that will feature selected standards among the list of 36 existing standards. The boost will be performed over 3 months
48621934|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48621935|NCT06398587|PROCEDURE|Biospecimen Collection|Undergo tumor biopsy
48621936|NCT06398587|PROCEDURE|Computed Tomography|Undergo CT
48621937|NCT02883556|DRUG|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
48621938|NCT05798312|OTHER|Customizable support material|Customizable support material will enable patients to identify their personal breast cancer information.
48621939|NCT05798312|OTHER|Non-customizable support material|Non-customizable support material will include general breast cancer information.
48621940|NCT03940677|PROCEDURE|Brain MRI|3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
48621941|NCT03940677|PROCEDURE|TMS-EEG|Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
48621942|NCT03940677|BEHAVIORAL|Behavioral and cognitive battery|Emotional, attentional and behavioral assessment using predefine scales and measures
48621943|NCT03940677|OTHER|Clinical evaluation and clinical scales|Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
48621944|NCT00167271|BEHAVIORAL|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
48621945|NCT05103033|BEHAVIORAL|Systems Analysis and Improvement Approach for Mental Health (SAIA-MH)|The 5 steps of SAIA-MH include: (1) cascade analysis to visualize treatment cascade drop-offs and prioritize areas for system improvements; (2) process mapping to identify modifiable facility-level bottlenecks; (3) identification and implementation of modifications to improve system performance; (4) assessment of modification effects on the cascade; and (5) repeated analysis and improvement cycles.
48621946|NCT05103033|BEHAVIORAL|Attentional Placebo Control|Facilities randomized to attentional placebo control will attend a 1-week in-person training which will include the same minimum staff above for SAIA-MH. This training will focus on reviewing data collection tools, ethics, mental health stigma and burnout for mental health professionals. Following the 1-week in person training, attentional placebo control facilities will receive regular supervision following the same schedule as SAIA-MH focused on reviewing data collection tools.
48621947|NCT01961492|OTHER|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
48621948|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment A
48621949|NCT03530228|DRUG|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment B
48621950|NCT03530228|DRUG|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
48621951|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 1
48621952|NCT03530228|DRUG|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 2
48621953|NCT03530228|DRUG|Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days. Group 3
47929047|NCT03016143|BIOLOGICAL|Allantoic Split Inactivated Seasonal flu Vaccine|Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
48621954|NCT03530228|DRUG|Tegoprazan (C3)|Tegoprazan QD, oral administration
48621955|NCT02572154|OTHER|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
48621956|NCT02517788|DRUG|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
48621957|NCT02517788|DRUG|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
48621958|NCT02517788|DRUG|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
48621959|NCT02331407|DEVICE|Robotic arm therapy|Training with the ReoGo device
48621960|NCT00146471|DRUG|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
48621961|NCT00146471|DRUG|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
47929048|NCT03016143|BIOLOGICAL|VAXIGRIP|Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
47929049|NCT05170776|OTHER|Pilates and postural correction exercise|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1 postural correction exercise~1-Strengthening deep cervical flexors 2-Stretching cervical extensors 3- Strengthen shoulder retractors 4-Unilateral and bilateral pectoralis stretch"
47929050|NCT05170776|OTHER|Pilates exercises|"ten exercises will be performed:~1. Hip Twist Level 1~2. Double leg stretch Level 1~3. Double leg stretch Level 2~4. One leg stretch Level 1~5. Clam Level 1~6. Scissors Level 1~7. Arm openings Level 1~8. Breast stroke prep Level 1t~9. Hip Twist Level 1.~10. Breast stroke prep Level 2 as for level 1"
47929051|NCT05170776|OTHER|postural correction exercises|"postural correction exercise in the form of :~1. Strengthening deep cervical flexors through chin tucks,~2. Stretching cervical extensors through a chin drop~3. Strengthen shoulder retractors~4. Unilateral and bilateral pectoralis stretch alternating each two-week period."
47929052|NCT05256706|DIAGNOSTIC_TEST|SomaSignal Informed Medical Management SSCVD|For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.
47929053|NCT05256706|OTHER|Standard of Care|Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
47929054|NCT03003299|DEVICE|Edwards SAPIEN 3/SAPIEN 3 Ultra THV|Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
47929055|NCT01650012|DRUG|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
47929056|NCT01650012|DRUG|Placebo|Placebo
47929057|NCT06377488|DEVICE|JJVC Investigational Multifocal Toric Contact Lens manufactured in Senofilcon A (C3) material with UV blocker / HEV filter|Test Lens
47929058|NCT03626298|DRUG|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
47929059|NCT03626298|DRUG|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
48621962|NCT02509702|BEHAVIORAL|Connected to Care|10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
47929060|NCT03626298|DRUG|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
48621963|NCT02127541|OTHER|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
48621964|NCT02504203|BIOLOGICAL|BCG-Denmark 1331 (Statens Serum Institute)|See above
48621965|NCT01565551|OTHER|N/A (Observational Study)|No Interventions: Observational Study
48621966|NCT01060488|OTHER|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
48621967|NCT01060488|OTHER|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
48621968|NCT02818543|DRUG|LYC-30937|
48621969|NCT03603704|DRUG|LY3209590|Administered SC
48621970|NCT03603704|DRUG|Placebo|Administered SC
48621971|NCT02783625|DRUG|Romidepsin|
48621972|NCT02783625|DRUG|Bortezomib|
48621973|NCT02783625|DRUG|duvelisib|
48621974|NCT02657863|PROCEDURE|Urine collection and blood draw|
48621975|NCT00574639|DRUG|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
48621976|NCT00574639|DRUG|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
48621977|NCT03748667|DIAGNOSTIC_TEST|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
48621978|NCT03748667|DIAGNOSTIC_TEST|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
48621979|NCT00754923|DRUG|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
48621980|NCT03797612|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
48621981|NCT03797612|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
48621982|NCT03797053|PROCEDURE|Biological sample|"Biological sample performed :~* before treatment~* 1 months after the beginning of treatment~* every tumoral assessment"
48621983|NCT04718701|DRUG|Anlotinib+Toripalimab+Nab-paclitaxel|Using combination treatment of anlotinib (12 mg, po. qd.) plus toripalimab (240 mg, ivgtt. q3w.) and nab-paclitaxel (260 mg/m2, ivgtt, q3w) with every 3 weeks as a cycle.
48621984|NCT00463424|DEVICE|NeuFlex metacarpophalangeal implant|
48621985|NCT00463424|DEVICE|Swanson metacarpophalangeal implant|
48621986|NCT00171288|DRUG|fluvastatin, ezetimibe|
47929061|NCT02812888|DRUG|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
48452506|NCT02709057|BEHAVIORAL|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
47929062|NCT01659554|DRUG|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
48452507|NCT05780463|DRUG|MP0420|MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
47929063|NCT01659554|DRUG|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
47929064|NCT04069364|BEHAVIORAL|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
48452508|NCT05780463|DRUG|Placebo|Commercially available 0.9% sodium chloride solution
48452509|NCT05780463|BIOLOGICAL|Remdesivir|Antiviral agent
48452510|NCT05356091|DRUG|Sevoflurane|Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
48621987|NCT05309005|BEHAVIORAL|VR TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT. The stimulus material in the Virtual Reality version is perceived through a head mounted display. This allows the test person to watch the scenes in three dimensions and a 360 degree angle, increasing the sense of social presence.
48621988|NCT05309005|BEHAVIORAL|DT TASIT|Consists of a Norwegian adaptation of the 59 videos of social scenes that constitute the A Form in the original TASIT, with identical content as the VR TASIT. The stimulus material in the desktop version is perceived on a two dimensional desktop computer screen.
48621989|NCT00891397|DRUG|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
48621990|NCT00891397|OTHER|Placebo|Sugar pill
48621991|NCT05766748|DRUG|Azeliragon|Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
48621992|NCT04462172|DEVICE|FNS|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
48621993|NCT04462172|DEVICE|MCS|three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
48621994|NCT02411955|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
48621995|NCT02411955|DRUG|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
48621996|NCT02411955|DRUG|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
48621997|NCT01056679|DRUG|Doxorubicine|50mg/m2 day 1 + 15
48621998|NCT01056679|DRUG|DTIC|375mg/m2 day 1 + 15
48621999|NCT01056679|DRUG|Lenalidomide|day 1 - 21
48622000|NCT01056679|DRUG|Vinblastine|6mg/m2 day 1 + 15
48622001|NCT00297011|DRUG|valacyclovir+clobetasol gel|
48622002|NCT00696566|DRUG|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days"
48622003|NCT02841735|DEVICE|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
47929065|NCT00139867|DRUG|PARCOPA|
47929066|NCT00167297|DRUG|Atomoxetine|
48452511|NCT05356091|DRUG|Remimazolam|Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
48452512|NCT06354023|DRUG|Recombinant human growth hormone|All participants will receive six weeks of treatment. Once per week, they will receive one intra-articular injection of 2cc (15IU) recombinant human growth hormone in their affected knee. The injection will also contain 1cc (1%) Lidocaine and 1cc (0.5%) Marcaine and Epinephrine for anesthetic purposes. The participants will receive a total of 6 growth hormone injections.
48622004|NCT02841735|DEVICE|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
48622005|NCT02841735|DEVICE|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
48622006|NCT03737019|BEHAVIORAL|Education with Acceptance and Commitment Therapy|Group education with Acceptance and Commitment Therapy of the personnel at each center.
48622007|NCT03737019|OTHER|Control, no intervention|Control, no interventions.
47929067|NCT05292300|DIETARY_SUPPLEMENT|Cornelian Cherry (Cornus mas L.)|"Patients in Cornelian Cherry Group and Cornelian Cherry and Diet Group will receive 20 g/day freeze-dried powder Cornelian Cherry supplement."
47929068|NCT05292300|BEHAVIORAL|Diet|"Patient in Diet Group and Cornelian Cherry and Diet Group will be given a personalized diet and be followed up by a dietician."
47929069|NCT02789267|OTHER|Regular dietary support|Systematic and regular dietary support after radiotherapy
48452513|NCT02949167|BEHAVIORAL|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
48452514|NCT05457985|BEHAVIORAL|Prolonged Exposure for Primary Care (PE-PC)|Treatment follows the standardized PE-PC manual and workbook.PE-PC consists of four weekly 30-minute sessions. In vivo and imaginal exposure are introduced at the first session and reviewed at Sessions 2-4. To conduct in vivo exposure, participants repeatedly and systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma. At the 4th session or 9-week assessment point (whichever comes first), early responders will step down to every-other-week sessions for the duration of the second stage.
48452515|NCT05457985|BEHAVIORAL|Full Prolonged Exposure|Treatment will follow the standardized PE manual. Participants will have 60 minute sessions once a week for eight weeks During these sessions, participants will practice in vivo, imaginal, and emotional exposure as well as continue these exposure exercises every day at home.
47929070|NCT05758701|COMBINATION_PRODUCT|Iodinated Contrast Agent (Omnipaque)|Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
47929071|NCT05758701|DEVICE|Dual Energy CT|Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
47929072|NCT05015985|OTHER|Music-Care|music relaxation by a specific hardware and software program application (MUSIC-CARE)
48279890|NCT03114033|OTHER|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg.
48279891|NCT04807894|DRUG|Vaginal Cream with Applicator|Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
48452516|NCT05457985|BEHAVIORAL|Clinician Supported PTSD Coach App|This is a brief psychotherapy that uses the PTSD Coach mobile app developed by the study team. The PTSD Coach app incorporates evidence-based assessment, psychoeducation, and cognitive behavioral therapy and self-management strategies that are customizable to the user.
48452517|NCT01010503|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
48452518|NCT05790772|BEHAVIORAL|Vigorous Exercise|50 minutes of running on a treadmill
48452519|NCT04994535|DRUG|OnabotulinumtoxinA|Injection
48452520|NCT04994535|DRUG|Placebo|Saline injection
48452521|NCT00404963|DRUG|placebo|
47929073|NCT05015985|OTHER|control group|music relaxation using a music playlist supply (control group)
48098319|NCT05893303|OTHER|2nd Group|2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
48098320|NCT05919849|BEHAVIORAL|Brief online writing intervention|Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.
48098321|NCT05919849|OTHER|Control condition|Participants will be instructed to write in order to control for time and writing engagement.
48279892|NCT02101437|PROCEDURE|miRNA within 24hr|miRNA within 24hr
48279893|NCT02101437|PROCEDURE|miRNA after 1 week|miRNA after 1 week
48279894|NCT02101437|PROCEDURE|miRNA after 1 month|miRNA after 1 month
48452522|NCT00404963|DRUG|GSK376501|
48452523|NCT00835484|DRUG|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
48452524|NCT00835484|DRUG|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
48622008|NCT05040659|DEVICE|AROMHA Longitudinal Smell Test|The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.
47929074|NCT05697978|DEVICE|Monofocal intraocular lens Clareon (Alcon LLC)|monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
47929075|NCT02373371|DRUG|Metvix®|
47929076|NCT02373371|PROCEDURE|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
47929077|NCT02373371|PROCEDURE|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
47929078|NCT02744742|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
47929079|NCT02744742|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
47929080|NCT02744742|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
47929081|NCT02744742|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
48622009|NCT01331902|OTHER|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
47929082|NCT04858971|OTHER|Perception of information source|Participants will see the same health advice, with no source or one of three other sources indicated
47929083|NCT05218954|DIAGNOSTIC_TEST|Biomechanical analysis of risk fall|Biomechanical analysis of risk fall in terms of balance
48279895|NCT04008017|DIAGNOSTIC_TEST|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
48452525|NCT02535923|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
48622010|NCT01331902|OTHER|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min-1•kg-1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
48622011|NCT03097263|OTHER|Physical Rehabilitation program|
48622012|NCT04935632|BEHAVIORAL|prevention training|Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room
48622013|NCT03479554|OTHER|Early antihypertensive treatment|"The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~* Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~* Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward."
48622014|NCT03479554|OTHER|Delayed antihypertensive treatment|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP \<140 mmHg (but not lower than 120 mmHg) and diastolic BP \<90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
48622015|NCT04978779|DRUG|VIP152|Weekly IV infusion for 28 day cycles.
48622016|NCT04978779|DRUG|BTKi|Taken per local prescribing information
48622017|NCT01898078|DRUG|Alisertib|Alisertib ECT
48622018|NCT06299072|OTHER|Survey|Quantitative questionnaire
48622019|NCT00150553|DRUG|Extended-release carbamazepine|
48622020|NCT01905072|OTHER|Education Home Visits|"Intervention will include educational home visits on:~1. Growth monitoring and feedback~2. Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~3. Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~4. Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~5. Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
48622021|NCT00874133|PROCEDURE|Acupuncture|Acupuncture treatment for 12 weeks.
48622022|NCT00874133|DRUG|Motilium|20 mg motilium thrice daily
48622023|NCT00230737|DRUG|Melatonin 0.4 mg|
48622024|NCT00230737|DRUG|Melatonin 4.0 mg|
48622025|NCT00230737|DRUG|Placebo|
47929084|NCT02990247|DEVICE|anharmonic morphological analysis of the respiratory signals (AMARS)|
47929085|NCT00889616|DRUG|BSAM2/Alhydrogel + CPG 7909|
47929086|NCT04183751|OTHER|scale study|Forms and questionnaires will be used. The data will be collected by the researchers by face to face interview technique.
47929087|NCT00151203|DRUG|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
47929088|NCT01910077|DRUG|Tacrobell capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
48279896|NCT05916352|DIETARY_SUPPLEMENT|Caffeine Supplement|Caffeine tablet
48279897|NCT01360996|DRUG|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
48279898|NCT03191786|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
48279899|NCT03191786|DRUG|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
48622026|NCT05125432|DEVICE|Acupuncture group|Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
48622027|NCT03677401|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
48622028|NCT03677401|DRUG|Placebo Tablets|Placebo Tablets
48622029|NCT04250480|DIETARY_SUPPLEMENT|beta-alanine|beta-alanine tablet
48622030|NCT04250480|DIETARY_SUPPLEMENT|placebo|rice powder tablet
48622031|NCT02217033|OTHER|'R' (Electro-kinetically altered beverage)|
48622032|NCT02217033|OTHER|Placebo (water)|
48622033|NCT02959268|DEVICE|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
48622034|NCT00102973|DRUG|TLK286 in Combination with Carboplatin|Experimental Arm
48622035|NCT00102973|DRUG|Doxorubicin HCl Liposome Injection|Active Comparator
48622036|NCT04687722|OTHER|High Intensity Aerobic Training.|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of high intensity aerobic training at 80-90% of heart rate maximum increased gradually on treadmill and elliptical trainer and then 2-5 minutes of low to moderate intensity cool down exercises.
48622037|NCT04687722|OTHER|Low intensity Aerobic Training|Participants will perform 2-5 minutes of low to moderate intensity warm up exercises and then 20 minutes of low intensity aerobic training at 40-60% of heart rate maximum increased gradually on elliptical trainer and jogging and then 2-5 minutes of low to moderate intensity cool down exercises.
48622038|NCT06282055|OTHER|No intervention|Observational prospective longitudinal data collection
48622039|NCT05548907|BEHAVIORAL|sleep restriction treatment|"Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support"
48622040|NCT05548907|BEHAVIORAL|sleep diary monitoring|As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
48622041|NCT03454958|OTHER|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer \& skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
48622042|NCT02641041|BIOLOGICAL|BIIB033|single or multiple dose
48622043|NCT02641041|OTHER|Placebo|single or multiple dose
48622044|NCT05303285|DRUG|Secukinumab 300mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks
48622045|NCT05303285|DRUG|Secukinumab 150mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
48622046|NCT02421510|DRUG|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
48622047|NCT02421510|DRUG|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
48622048|NCT02421510|DRUG|Placebo|Placebo, once daily, before the first meal of the day
48622049|NCT00254072|PROCEDURE|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
48622050|NCT00766220|DRUG|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
48622051|NCT00766220|DRUG|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
48622052|NCT00766220|DRUG|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
48622053|NCT00410488|DRUG|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
48622054|NCT00410488|DRUG|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
48622055|NCT00410488|DRUG|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
48622056|NCT00410488|DRUG|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
48622057|NCT00410488|DRUG|Zinecard|750 mg/m2 as an IV bolus.
47929089|NCT01910077|DRUG|Prograf capsule 1mg|1 capsule, oral, over the period I\&II(crossover)
47929090|NCT02523469|BIOLOGICAL|ALT-803|
48622058|NCT00410488|DRUG|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
48622059|NCT00410488|DRUG|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
48622060|NCT00410488|DRUG|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
48622061|NCT00257530|DRUG|Imiquimod|
48622062|NCT04292951|PROCEDURE|Fluid and inotropic/vasoactive management protocol|GDT protocol: keep SVV 10-13% and give fluid when SVV \> 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
48622063|NCT06357767|BEHAVIORAL|Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence|A culturally-tailored, trauma-informed group intervention to support smoking cessation by leveraging Lakota values, mindfulness, and a storytelling approach.
47929091|NCT02523469|BIOLOGICAL|Nivolumab|
47929092|NCT03158792|DRUG|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
47929093|NCT03158792|DRUG|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
47929094|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
47929095|NCT00684047|BIOLOGICAL|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
47929096|NCT00684047|PROCEDURE|Manual Compression|Manual Compression. Primary Part (II)
47929097|NCT03573011|DIAGNOSTIC_TEST|[18F]PSMA-11|18F-PET imaging
47929098|NCT05394493|DRUG|avelumab|as provided in real world setting
47929099|NCT05394493|DRUG|axitinib|as provided in real world settings
47929100|NCT05170633|DEVICE|Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)|70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
47929101|NCT04122456|RADIATION|Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
47929102|NCT04122456|OTHER|No Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
47929103|NCT05940454|PROCEDURE|Pericapsular nerve group block|"The patient's arm is externally rotated and abducted at 45 degrees. A longitudinal linear ultrasound probe is placed between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle on it, a 50 mm needle is inserted with the in-plane technique. When the needle passes through the deltoid muscle and touches the subscapularis tendon, a hard bone-like tissue is felt and the needle is not advanced any further. It is noteworthy that the subscapularis tendon is very rigid and resistant to needle penetration when performing the pericapsular nerve group block. The needle tip is placed between the deltoid muscle and the subscapularis tendon and a local anesthetic drug (20 ml, %0.5 bupivacain hydrochlorur) is injected"
47929104|NCT04140123|DRUG|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
47929105|NCT04140123|DRUG|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
47929106|NCT05022511|BEHAVIORAL|Screening status|Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
47929107|NCT04810728|DRUG|Extract Psidii guava|2 Capsule Extract Psidii guava, three times daily
47929108|NCT04810728|COMBINATION_PRODUCT|Standard therapy for Covid-19 patient|(Vitamin C, Zinc, medication for clinical symptoms such as: antipyretic agent, decongestan and mucolytic.)
48098322|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
48279900|NCT03191786|DRUG|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
48452526|NCT02535923|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
48452527|NCT00989950|DRUG|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
48622064|NCT06523790|BEHAVIORAL|Yoga|Participants in the yoga group will attend 90-minute yoga sessions, 3 times per week, for 8 months. The sessions will include a combination of asanas (postures), pranayama (breathing exercises), and meditation.
48622065|NCT06523790|BEHAVIORAL|Brisk walking|Participants in the brisk walking group will engage in one-hour fast-paced walking sessions, 6 times per week, for 8 months. The walking regimen is designed to improve cardiovascular fitness, endurance, and support weight loss.
48622066|NCT00512668|DRUG|leuprolide acetate|Given intramuscularly
48622067|NCT00512668|DRUG|goserelin acetate|Given subcutaneously
48622068|NCT00512668|DRUG|bicalutamide|Given PO
48098323|NCT01496638|PROCEDURE|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
48279901|NCT04643184|OTHER|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
48279902|NCT06657586|OTHER|neuromuscular exercises|The exercise was applied in 18 sessions of 6 weeks.The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
47929109|NCT02772198|BIOLOGICAL|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
47929110|NCT06240767|BIOLOGICAL|Granulocyte infusion|The number of single granulocytes per infusion was 2.0-5.0×10\^10, with an interval of 2±1 day and 5 continuous infusions.
47929111|NCT00807573|DRUG|Paclitaxel|Day 1: Paclitaxel (90 mg/m\^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m\^2 over 60 minutes)
48279903|NCT06657586|OTHER|conservative treatment|The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
48279904|NCT05705726|DEVICE|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
48279905|NCT05705726|DRUG|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
48279906|NCT06649994|DEVICE|Active iTBS of the DLPFC|Participants will receive a 3 minutes intermittent Theta Burst Stimulation of the DLPCF of the left hemisphere while not performing any other task
48279907|NCT06649994|DEVICE|Active iTBS of the vmPFC|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vmPFC while not performing any other task
48279908|NCT06649994|DEVICE|iTBS of the vertex (sham)|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vertex while not performing any other task
48452528|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
48452529|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
48452530|NCT00989950|DRUG|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
48452531|NCT00704639|DRUG|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
47929112|NCT00807573|DRUG|Pemetrexed|Day 1: Pemetrexed (500 mg/m\^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
47929113|NCT00807573|DRUG|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
47929114|NCT04065165|DRUG|Telotristat Ethyl|250 mg TID orally
48452532|NCT00704639|DRUG|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
48452533|NCT00704639|RADIATION|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
48452534|NCT03548194|DRUG|BNC210|BNC210 300 mg b.i.d
48452535|NCT03548194|DRUG|Placebo|Placebo b.i.d.
47929115|NCT04065165|DRUG|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
47929116|NCT05517278|OTHER|SurgX Antimicrobial Wound Gel|In addition to standard of care, at time of surgery, SurgX applied on the incision after closure and then re-applied at the time of first bandage change on day of discharge.
47929117|NCT05517278|OTHER|Standard of Care|The control group will receive standard of care.
47929118|NCT03643471|DEVICE|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
47929119|NCT00104598|DRUG|Bupropion|
48452536|NCT00834444|DRUG|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
48452537|NCT00834444|DRUG|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
48452538|NCT04170452|PROCEDURE|liver biopsy|Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
48452539|NCT06492590|BEHAVIORAL|Multicomponent intervention|Multicomponent intervention based on psycho-education and physical rehabilitation.
48452540|NCT04334863|DRUG|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
48452541|NCT04631562|DRUG|ALXN1820 SC|ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
48452542|NCT04631562|DRUG|ALXN1820 IV|ALXN1820 IV (450 mg) will be administered as an IV infusion.
48452543|NCT04631562|DRUG|Placebo SC|Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
48452544|NCT04631562|DRUG|Placebo IV|Placebo IV will be administered as an IV infusion.
48452545|NCT04522258|DIETARY_SUPPLEMENT|Dietary fiber|Fermentable cereal bran
48452546|NCT04522258|DIETARY_SUPPLEMENT|Placebo|Refined cereal flour
48452547|NCT02792816|DRUG|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
48452548|NCT02348463|DRUG|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
47929120|NCT00104598|BEHAVIORAL|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
47929121|NCT02775240|DRUG|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
47929122|NCT02775240|DRUG|Maribavir|200mg twice a day for 8 days
47929123|NCT02775240|DRUG|Dextromethorphan|30 mg oral dose
47929124|NCT02241096|DRUG|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
47929125|NCT00268580|BEHAVIORAL|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
47929126|NCT02312687|BIOLOGICAL|KRN23|solution for SC injection
47929127|NCT03207165|DRUG|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
48452549|NCT05620823|DRUG|Povorcitinib|Oral; Tablet
48452550|NCT05620823|DRUG|Placebo|Oral; Tablet
48452551|NCT04352062|DRUG|Melatonin|
48452552|NCT04352062|OTHER|placebo|
48452553|NCT04352062|DRUG|Pantoprazole 40mg|pantoprazole 2 x 40mg
48452554|NCT04352062|DRUG|Amoxicillin|Amoxicillin 2 x 1000mg
48452555|NCT04352062|DRUG|Levofloxacin 500mg|Levofloxacin 2 x 500mg
48622069|NCT00512668|DRUG|nilutamide|Given PO
48622070|NCT00512668|DRUG|flutamide|Given PO
48622071|NCT00512668|DRUG|temsirolimus|Given IV
48622072|NCT00512668|OTHER|laboratory biomarker analysis|Optional correlative studies
47929128|NCT03207165|DRUG|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
47929129|NCT06286176|BEHAVIORAL|Videos with breastfeeding education material and encouraging messages|Distributed videos aim to increase breastfeeding related knowledge and to receive support
47929130|NCT06286176|BEHAVIORAL|Whatsapp group|The Whatsapp group is used in the intervention as a platform for interpersonal exchange of information and experience, in addition to peer support.
47929131|NCT04337710|PROCEDURE|Exclusive Enteral Nutrition|Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.
47929132|NCT04337710|PROCEDURE|Progressive Enteral Nutrition|Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
47929133|NCT01700868|OTHER|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
47929134|NCT01700868|OTHER|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
47929135|NCT04802629|DEVICE|Near-infrared spectroscopy|For NIRS measurements the t-NIRS 1 and NIRO 200 NX (Hamamatsu, Japan) will be used. A cerebral sensor will be placed and fixed with a CPAP (Continuous Positive Airway Pressure) cap on the left forehead and a peripheral sensor on the right forearm. Duration of measurement will be two hours.
47929136|NCT02840084|DEVICE|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
47929137|NCT03345966|DIAGNOSTIC_TEST|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
47929138|NCT04048733|DEVICE|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
47929139|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
47929140|NCT00258843|BIOLOGICAL|Inactivated Poliomyelitis vaccine|0.5 mL, IM
47929141|NCT01592656|RADIATION|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
47929142|NCT01592656|OTHER|Lung compliance measurement|At baseline
47929143|NCT01592656|DEVICE|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 \> 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
47929144|NCT04880330|DEVICE|Cryo-Auriculotherapy|1 session of cryo-auriculotherapy with device with nitrous oxyde on 15 auricular points.
47929145|NCT04880330|DEVICE|Sham comparator|1 session of cryo-auriculotherapy with device without nitrous oxyde on 15 auricular points.
47929146|NCT05275361|BEHAVIORAL|Social Contact Reminder|-The social contact will remind patient about screening mammogram appointment
47929147|NCT04803123|DRUG|Copanlisib|Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
47929148|NCT02009384|DRUG|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
47929149|NCT02434601|PROCEDURE|Treatment of Dentin Surface|"* Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~* Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
47929150|NCT02434601|PROCEDURE|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
47929151|NCT02434601|PROCEDURE|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
47929152|NCT03415386|DRUG|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
47929153|NCT05753579|BEHAVIORAL|Spinal Mobilization|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion.
47929154|NCT05753579|BEHAVIORAL|Stabilization Exercise|Diyafragmatik solunum ile kombine edilen, pasif-aktif kas iskelet sistemi ve nöral sistemi aktive eden bir yaklaşımdır. Bu yaklaşımda derin çekirdek kaslar olarak transversus abdominis, multifudus kasları aktive edilmektedir
47929155|NCT06200142|DIAGNOSTIC_TEST|Untargeted metabolomics|Untargeted metabolomics in bloodspots and in plasma
47929156|NCT06200142|GENETIC|WES and WGS|WES reanalysis and WGS analysis
47929157|NCT00001860|DRUG|Sandostatin LAR Depot versus transsphenoidal surgery|
48622073|NCT04852822|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48622074|NCT04852822|OTHER|Electronic Health Record Review|Medical records are reviewed
48622075|NCT00669344|DRUG|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
47929158|NCT06435559|OTHER|Neurotablet® and Neuropsychological evaluations|The experimental group will carry out cognitive rehabilitation using the Neurotablet device. The cognitive rehabilitation will be performed for 10 consecutive weeks, once a week for 1 hour. Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
47929159|NCT06435559|OTHER|Neuropsychological evaluations|Neuropsychological evaluations will be conducted before the start of chemotherapy (T0), 6 months (T1) and 12 months (T2) after the start of chemotherapy. Neuropsychological evaluations will include tests to analyze the main cognitive domains of memory, attention, executive functions and learning.
47929160|NCT00573729|OTHER|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
47929161|NCT00573729|OTHER|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
47929162|NCT06055335|OTHER|Medium flow anesthesia|Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
47929163|NCT06055335|OTHER|Minimal flow anesthesia|Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
47929164|NCT00202527|DEVICE|Nasal continuos positive airway pressure|
47929165|NCT02085031|PROCEDURE|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
47929166|NCT02085031|PROCEDURE|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
47929167|NCT01658813|DRUG|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
48622076|NCT00669344|DRUG|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
47929168|NCT03633877|DEVICE|DuraporeTM and Hy-Tape®|Medical tapes
47929169|NCT03507530|OTHER|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
47929170|NCT04868630|DEVICE|Pulsewave Health Monitor (PAD-2A) Device|This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
47929171|NCT03899636|DRUG|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
47929172|NCT03899636|DEVICE|NanoKnife System|IRE using NanoKnife System
47929173|NCT03492840|DRUG|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
47929174|NCT04352153|DRUG|Febuxostat|Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
47929175|NCT04352153|DRUG|Uralyt-U|Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.
47929176|NCT05834855|DRUG|Rituximab|Treatment with rituximab
47929177|NCT05898997|BEHAVIORAL|Acupressure|Massage the following acupoints in order: Jing Ming, Zan Zhu, Mei Chong, Yu Yao, and Si Zhu Kong. Use the joint of your thumb to massage each acupoint for 30 times, and repeat the cycle at least once. Then, continue to promote the circulation of qi by gently making a fist and using the four fingers to scrape along the upper eye socket from inside to outside. Scrape each side 30 times, and do it separately for the left and right sides. It is recommended to do this process at least once in the morning and once in the evening.
47929178|NCT04994470|BEHAVIORAL|Two-week web-based self-help intervention based on principles of positive psychology|"The web-based self-help intervention consists of 14 exercises based on the following positive psychology domains: personal strengths, pleasure, gratitude, engagement (flow, mindfulness) and positive relationships.~The (partly interactive) exercises are created to be implemented by the participants themselves without support of a therapist.~Before starting the intervention, the participants are told that they will receive a daily email with an instruction for a short exercise over the period of two weeks. The participants are instructed to complete the exercises every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
47929179|NCT04994470|BEHAVIORAL|Two-week web-based text messages containing fun facts|"The web-based sham comparator consists of 14 text messages containing random interesting facts (fun facts).~Before starting the sham comparator, the participants are told that they will receive a daily email with a text message to read every over the period of two weeks. The participants are instructed to read these text messages every day and are told that they will be asked to evaluate these exercises at the next appointment (post-test, week 2)."
48622077|NCT01567410|OTHER|e-learning|Braden scale and pressure ulcer classification
48622078|NCT01567410|OTHER|traditional classroom training|Braden scale and pressure ulcer classification
48622079|NCT03817983|DIAGNOSTIC_TEST|MRE review for axSpA|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease followed by clinical and MRI assessment
48622080|NCT00832806|BEHAVIORAL|Extended IVR (integrated voice response technology)|See detailed description
48622081|NCT00832806|DRUG|Varenicline (Champix)|See detailed description
48622082|NCT00832806|BEHAVIORAL|IVR treatment|See detailed description
48622083|NCT02038842|BIOLOGICAL|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
48622084|NCT02038842|BIOLOGICAL|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
47929180|NCT01138878|OTHER|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
47929181|NCT01138878|OTHER|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
48279909|NCT06649994|BEHAVIORAL|Computerized inhibitory control training|"Participants will perform the task of the FoodT app for 10 minutes immediately after iTBS (taking advantage of time of maximum brain potentiation, Rossi et al., 2009).~This task pairs high-calorie meals with the no-go cue. Images appear on the left, right or center of the smartphone screen and they must touch it or not (depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses: If the image has a green border around it, you must tap the image and win 1 point. But if the image has a red border around it, you must inhibit the tapping response or you will lose 1 point. Participants must respond as quickly and accurately as possible and improve reaction time.~Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal"
48279910|NCT01215084|DRUG|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
48279911|NCT05066685|OTHER|All participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
48279912|NCT02544776|DRUG|Clomifene citrate ( clomid 50 mg )|
48279913|NCT02544776|DRUG|Amlodipine|
48279914|NCT05777928|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.
48279915|NCT05777928|PROCEDURE|OverStitch™ Endoscopic Suturing System|Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications
48279916|NCT02252861|OTHER|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
48279917|NCT03040154|OTHER|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
48279918|NCT03040154|OTHER|Usual Care Video that is publicly available|
48279919|NCT00239031|DRUG|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
48279920|NCT01130506|DRUG|Cytarabine|Given IV
48452556|NCT03739502|DRUG|Hyperbaric oxygen|"The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant."
48452557|NCT03638063|DIAGNOSTIC_TEST|Adenosine Triphosphate|Adenosine Triphosphate aerosol
48452558|NCT03638063|DIAGNOSTIC_TEST|capsaicin|capsaicin aerosol
48452559|NCT02369822|DIETARY_SUPPLEMENT|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
48452560|NCT01608360|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
48452561|NCT01608360|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
48452562|NCT05133180|DRUG|Oxervate|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
48452563|NCT05133180|OTHER|Vehicle|Vehicle will be instilled with the same scheme of the test product
48452564|NCT06223516|DRUG|Subcutaneous (SC) ABBV-383|SC Injection
48452565|NCT06223516|DRUG|Intravenous (IV) ABBV-383|IV Infusion
47929182|NCT01138878|OTHER|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
47929183|NCT01138878|OTHER|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
47929184|NCT03720392|DRUG|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
47929185|NCT03720392|DRUG|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
48279921|NCT01130506|DRUG|Decitabine|Given IV
48279922|NCT01130506|OTHER|Laboratory Biomarker Analysis|Correlative studies
48279923|NCT01130506|OTHER|Pharmacological Study|Correlative studies
48279924|NCT01130506|DRUG|Vorinostat|Given PO
48452566|NCT02030223|PROCEDURE|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
48452567|NCT01437761|DEVICE|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
48452568|NCT06501222|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
48622085|NCT02038842|BIOLOGICAL|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
48622086|NCT01627717|DRUG|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
47929186|NCT05926375|DIETARY_SUPPLEMENT|HINEX Jelly ( jelly high protein supplement)|In self-controlled phase,which intake 400\~500 kcal breakfast, or in supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg BCAA per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks.
47929187|NCT01844167|PROCEDURE|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
47929188|NCT01844167|PROCEDURE|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
47929189|NCT02491229|OTHER|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
47929190|NCT02491229|OTHER|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
47929191|NCT06422234|OTHER|Exergame|Video-based game exercises will be performed 3 days a week for 6 weeks. Participants will be taught how to play the games before starting the game called Ring Fit Adventure, one of the Nintendo Switch games. Among the games within Ring Fit, games that aim to increase lower extremity muscle strength, core stabilization and balance have been selected, and game types and number of repetitions are changed every week.
47929192|NCT06422234|OTHER|Game-free Exercise|All activities in the exergame group were done without games and screens. The progression of the exercises proceeds in the same way as the other group.
47929193|NCT02776319|DEVICE|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
47929194|NCT02776319|DEVICE|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
47929195|NCT01262352|DRUG|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
47929196|NCT01262352|DRUG|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
48279925|NCT03378570|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
48452569|NCT01910753|PROCEDURE|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
48452570|NCT05900648|DRUG|Regorafenib|Given by PO
48452571|NCT05900648|DRUG|XmAb20717|Given by (IV) vein
48452572|NCT00818558|BIOLOGICAL|ISET Methode|Sampling of blood - ISET Methode
48622087|NCT01627717|DRUG|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
47929197|NCT05012670|DRUG|[14C]-Paxalisib Capsule|Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.
47929198|NCT02375789|DEVICE|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
48279926|NCT04945382|DEVICE|Scotchbond Universal 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Scotchbond universal 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
48279927|NCT04945382|DEVICE|Single Bond 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Single Bond 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
48279928|NCT03545282|BEHAVIORAL|Amigas Latinas Motivando el Alma (ALMA)|"In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions."
48279929|NCT04837014|OTHER|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
48622088|NCT05362084|PROCEDURE|lumbar medial branch block|lumbar medial branch block
47929199|NCT02375789|DEVICE|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
47929200|NCT01801371|DRUG|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
47929201|NCT01136200|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
47929202|NCT05579600|BEHAVIORAL|Caring Contacts letters|Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.
47929203|NCT05579600|BEHAVIORAL|Reports, re-engagement, and training|Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
47929204|NCT06185140|OTHER|cardiac rehabilitation program|Cardiac rehabilitation program
47929205|NCT06185140|OTHER|TELEA platform|TELEA platform
47929206|NCT01737229|DEVICE|Application of Biodentine™ (RD94), dentin substitute|
47929207|NCT01728233|DRUG|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
47929208|NCT01143805|DRUG|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
47929209|NCT01143805|DRUG|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
47929210|NCT05441878|DRUG|20% albumin|Albumin arm for resuscitation fluid
47929211|NCT05441878|DRUG|Balanced salt solution|Only Balanced salt solution will be used.
47929212|NCT02097017|DRUG|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
47929213|NCT02097017|OTHER|placebo comparator|
47929214|NCT05205577|DEVICE|Tens Eco Plus|30min/day of stimulation at 25Hz frequency, 100 microsc pulse with intensity escalation up to 25 mA max
47929215|NCT01890629|DRUG|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
47929216|NCT03011892|DRUG|Ruxolitinib 0.15% Cream QD|Ruxolitinib 0.15% cream QD
47929217|NCT03011892|DRUG|Ruxolitinib 0.5% Cream QD|Ruxolitinib 0.5% cream QD
47929218|NCT03011892|DRUG|Ruxolitinib 1.5% Cream QD|Ruxolitinib 1.5% cream QD
48452573|NCT03865563|DRUG|Retrograde venous infusion of gemcitabine/lipiodol|Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
47929219|NCT03011892|DRUG|Ruxolitinib 1.5% Cream BID|Ruxolitinib 1.5% cream BID
47929220|NCT03011892|DRUG|Triamcinolone 0.1% Cream BID|Triamcinolone 0.1% cream BID
47929221|NCT03011892|DRUG|Vehicle Cream BID|Vehicle cream BID
47929222|NCT02969603|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
47929223|NCT02969603|OTHER|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
48452574|NCT01712906|BIOLOGICAL|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
47929224|NCT02994888|DRUG|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
47929225|NCT01821573|DRUG|botulinum toxin type A|"Experimental arm group:~* 150 Units in rectus femoris ( 3 ml and 3 points)~* 70 units in medial gastrocnemius (1.4 ml and 1 point)~* 70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~* 60 units in soleus ( 1.2 ml and 3 points)"
47929226|NCT01821573|DRUG|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points"
47929227|NCT05946304|BEHAVIORAL|moderate-intensity continuous exercise training (MICT) group|Exercise session: Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 70-85% peak HR - 35min; Cool-down: 60-70% peak HR - 15min.
47929228|NCT05946304|BEHAVIORAL|high-intensity interval training (HIIT) group|Warm-up: 60-70% peak heart rate (HR) - 10min; Training: 85-95% peak HR - 25 minutes (4x4-minutes of high-intensity intervals interspersed with 3 minutes of low-intensity intervals); Cool-down: 60-70% peak HR - 10min.
47929229|NCT06506487|BEHAVIORAL|Doll Therapy|Doll therapy involves the use of lifelike dolls to provide comfort and reduce behavioral and psychological symptoms in people with dementia. The therapy includes activities such as holding, dressing, and interacting with the dolls under the guidance of trained caregivers.
47929230|NCT02012868|PROCEDURE|bariatric surgery|
47929231|NCT00721253|DEVICE|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
47929232|NCT00721253|DEVICE|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
47929233|NCT00721253|DEVICE|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
47929234|NCT02516540|BEHAVIORAL|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
47929235|NCT01699971|PROCEDURE|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
47929236|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
47929237|NCT01699971|PROCEDURE|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
47929238|NCT04671953|DRUG|BMS-986165|Specified dose on specified days
48098324|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized.~No PK samples will be collected in this cohort."
48622089|NCT04675476|BEHAVIORAL|Provider Prompt & Patient Outreach and Education|To target lack of provider-prompted discussion about lung screening, an electronic medical record (EMR) message will be sent to primary care providers prior to scheduled visits with screening-eligible patients to notify them of the patient's eligibility and to encourage discussion of the benefits and limitations of the test. To target patient-level knowledge about lung screening, an outreach specialist will educate screening-eligible patients about the benefits and limitations of the test prior to their visit.
48622090|NCT01890577|DRUG|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
48622091|NCT04113993|DRUG|Bazedoxifene Acetate|Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
48622092|NCT04113993|DRUG|Placebo|Identically packaged placebo capsule daily
48622093|NCT00049829|DRUG|Zoledronic Acid|
48622094|NCT05984459|DIETARY_SUPPLEMENT|VLCKD|The analysis will focus on the observation of the evolution of anthropometric and clinical parameters,such as the improvement or normalization of HbA1c, as well as on the evolution of the hypoglycemic medication between patients who accept VLCKD method
48622095|NCT04792268|OTHER|Access to eCDSS on wards|"Electronic clinical decision support (eCDSS) will be available to clinicians on wards recruited to this arm.~An eCDSS is a health information technology system designed to assist clinicians and other health care professionals in clinical decision-making.~The key digital tool to be used for eCDSS in this study is CogStack. This eCDSS has been developed to alert clinicians automatically regarding patients admitted under their care, triggered by the presence of new, old or absent HbA1c pathology reports on the electronic health record (EHR)."
48622096|NCT00543465|DRUG|MK0782|
48622097|NCT05057208|BIOLOGICAL|COVID|COVID vaccination
48622098|NCT06201325|OTHER|virtual reality based exercises|play VR games
48622099|NCT06201325|OTHER|conventional physical therapy|streching and strengthening exercises
48622100|NCT06201325|OTHER|home exercises program|home exercises
48622101|NCT05285969|BEHAVIORAL|Motivational interview|The new CR program with MI will be structured in 4 sessions and an optional fifth during the six months after discharge. The methodology of the MI sessions will follow the four phases logical sequence of MI proposed by Rollnick and Millner. 1) engage in a collaborative relationship, 2) focus on a particular change, 3) evoke intrinsic motivations for change, and 4) plan an immediate step for change
48622102|NCT05285969|BEHAVIORAL|Active Comparator: Standard care group|All patients in the control group will receive a kit with informative material with the actions and procedures to follow (diet, physical activity, smoking cessation, and other recommendations about secondary prevention).
48622103|NCT03199105|OTHER|Preoperative education with image illustrations and/or local tetracaine mucilage|The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
48622104|NCT00005850|DRUG|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
48622105|NCT00005850|DRUG|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
48622106|NCT00005850|DRUG|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
48622107|NCT04288791|OTHER|Equia Forte Fil|Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
48622108|NCT04288791|OTHER|Zirconomer Improved|Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
48622109|NCT05076500|PROCEDURE|Biopsy and blood sample collection|"A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected."
48622110|NCT03557944|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
48622111|NCT01648959|OTHER|EEG Recording|
48622112|NCT03049566|OTHER|preoperative questionnaires|no intervention, cross-sectional survey in a single group
47929239|NCT04671953|DRUG|Metformin|Specified dose on specified days
47929240|NCT06131671|OTHER|Whole-body electrical stimulation|"The parameters adopted for the treated group will be: symmetrical biphasic current, pulse width of 400 µs, frequency of 80 Hz, contraction time of five seconds and decreasing rest time, varying from 10 to 5 s. The intensity will be individually adjusted to the patient's maximum tolerance limit to produce visible muscle contraction.~The session time will be 15 to 20 minutes and the number of contractions will increase with each week of training.~Concomitant to the electrical stimuli, exercises will be performed for the elbow flexors and extensors, spine flexors and extensors, knee flexors and extensors, hip flexors and extensors and the calf muscles."
47929241|NCT02108262|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
48098325|NCT04699669|DRUG|CBL-514, placebo|"One side of the abdominal region will receive CBL-514, while the other will receive placebo with equal volume.~Which side of the abdominal region to receive CBL-514 or placebo would be randomized."
48098326|NCT04699669|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
48279930|NCT04837014|OTHER|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
48452575|NCT01712906|BIOLOGICAL|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
48452576|NCT01712906|BIOLOGICAL|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
48452577|NCT01712906|BIOLOGICAL|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
48452578|NCT01712906|BIOLOGICAL|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
48452579|NCT03049748|DEVICE|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
48452580|NCT03049748|OTHER|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
48622113|NCT03337412|OTHER|Adapted physical activity|"Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire"
48622114|NCT05288257|BEHAVIORAL|Learning Module|Safe Cholecystectomy Learning Module
48622115|NCT00933127|GENETIC|DNA analysis|
48622116|NCT00933127|GENETIC|polymerase chain reaction|
48622117|NCT00933127|GENETIC|polymorphism analysis|
48622118|NCT00933127|OTHER|laboratory biomarker analysis|
48622119|NCT05027282|DEVICE|CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.|CLEAR + BRILLIANT TOUCH(R) diode laser 1440-nm and 1927-nm Combination Wavelength Treatment.
48622120|NCT00355641|DRUG|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
48622121|NCT03079492|DEVICE|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
48622122|NCT00075374|DRUG|docetaxel|"Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.~Patients are followed at 1 month and then every 2-3 months thereafter."
48622123|NCT03697746|DRUG|paracetamol|paracetamol 1000 mg vial
48622124|NCT03697746|DRUG|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
47929242|NCT02108262|BIOLOGICAL|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
47929243|NCT01940978|DRUG|Methylphenidate ER|Watson generic, starting dose 18mg QD
48452581|NCT05643638|BIOLOGICAL|CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)|Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
48452582|NCT05643638|BIOLOGICAL|Placebo|The placebo product is identical to CYP-001, except that it contains no active agent
48452583|NCT05643638|DRUG|Corticosteroids|All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
48452584|NCT03162315|PROCEDURE|Freeze all|
48452585|NCT02331563|DRUG|Dexmedetomidine|ultrasound guided transvers abdominis plane block
48622125|NCT03697746|DRUG|Ibuprofen|ıbuprofen 400 mg vial
47929244|NCT01940978|DRUG|Cyproheptadine|cyproheptadine hydrochloride
47929245|NCT04224545|DRUG|Colchicine Pill|Colchicine at a dose of 1 mg a day before surgery, 2, 3, 4, 5 days after surgery.
47929246|NCT04224545|DRUG|Placebo|Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
47929247|NCT05409378|DEVICE|The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)|Aortic valve replacement with the HLT Meridian TAVR Valve to treat aortic regurgitation
48622126|NCT01095770|PROCEDURE|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
48279931|NCT00886938|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
48279932|NCT02369783|OTHER|Questionnaire and interview|The aim is to detect social fragility.
48279933|NCT01740336|DRUG|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
48279934|NCT01740336|DRUG|Placebo|Placebo matching to GDC-0941
48279935|NCT01740336|DRUG|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
48622127|NCT01095770|PROCEDURE|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
48622128|NCT01095770|DEVICE|Reveal XT|Reveal XT implantable loop recorder monitored group
48622129|NCT01095770|DEVICE|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
48622130|NCT03863912|OTHER|Disney movie|Disney movie on portable DVD Player.
48622131|NCT03863912|OTHER|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
47929248|NCT02975362|OTHER|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
48098327|NCT02728271|BIOLOGICAL|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
48279936|NCT06030011|BEHAVIORAL|NYU Electronic Patient Visit Assessment (ePVA)|The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).
48622132|NCT01635140|RADIATION|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
48452586|NCT02331563|DRUG|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
48452587|NCT00002890|BIOLOGICAL|lintuzumab|
48622133|NCT01635140|RADIATION|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
48622134|NCT02295319|OTHER|Individual discharge|"See previous description in Arms"
48622135|NCT01078545|DRUG|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
48622136|NCT03274297|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
48622137|NCT03274297|DRUG|HMW PIB patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
48622138|NCT01713517|OTHER|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
48622139|NCT01713517|DEVICE|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
48622140|NCT03451032|OTHER|Non Interventional Study|Non Interventional Study
48622141|NCT05321784|OTHER|Dermoscopy|Take digital dermoscopy images (DDI)
48622142|NCT05321784|OTHER|Digital Photography|Take smartphone clinical images (SCI)
48622143|NCT05321784|PROCEDURE|Self-Skin Examination|Perform self-skin exam (SSE)
48622144|NCT05321784|DEVICE|Skin Examination with Sklip|Apply Sklip System
48622145|NCT05321784|PROCEDURE|Skin Examination|Undergo in-person full body skin examination (FBSE)
48622146|NCT05321784|OTHER|Survey Administration|Ancillary studies
48622147|NCT04680039|DEVICE|Continuous monitoring|Identifying intradialytic hypotension using a PPG-based wearable monitor
48098328|NCT03758339|DRUG|tucatinib|Single dose of 300 mg of \[¹⁴C\]-tucatinib containing approximately 150 μCi of \[¹⁴C\] radioactivity
48098329|NCT02195557|DRUG|Synvisc®|
48098330|NCT00303303|BIOLOGICAL|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
48622148|NCT04664387|DIAGNOSTIC_TEST|coronary angiography|A coronary angiography is a test to find out if there is stenosis in coronary artery.
48622149|NCT00092729|DRUG|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
48622150|NCT00092729|DRUG|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
48622151|NCT00092729|DRUG|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
48622152|NCT00811408|DRUG|carboplatin|
48622153|NCT00811408|DRUG|cidofovir|
48622154|NCT00811408|GENETIC|protein expression analysis|
48622155|NCT00811408|OTHER|laboratory biomarker analysis|
48622156|NCT00811408|RADIATION|brachytherapy|
48622157|NCT00811408|RADIATION|radiation therapy|
48622158|NCT04767516|OTHER|no intervention|no intervention
48622159|NCT00410527|DRUG|Merrem|
48622160|NCT04428749|DIAGNOSTIC_TEST|Yale Swallow Protocol|The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
48452588|NCT06249139|BEHAVIORAL|Compass for Care (Well-being intervention)|Participants receive 12 weekly modules containing interactive activities and static content and tailored messages delivered via text message or email. The intervention focuses on five self-care behaviors critical to ADRD caregiver well-being: 1) taking time to recharge; 2) finding information about your loved one's diagnosis and needs; 3) discovering your strengths and limits; 4) exploring outside help; and 5) seeking emotional support.
47929249|NCT02975362|OTHER|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
48452589|NCT06249139|BEHAVIORAL|Compass for Care (Safety intervention)|Participants receive 12 weekly modules and tailored messages delivered via text message or email. The intervention focuses on safety behaviors (e.g., weather safety, first aid, home safety, etc.)
48452590|NCT02028221|DRUG|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
48452591|NCT02028221|DRUG|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
47929250|NCT02398279|DIETARY_SUPPLEMENT|L-Arginine|Experimental supplement
47929251|NCT02398279|OTHER|Placebo|Placebo capsules in the same color and shape with the experimental supplement
48452592|NCT04032418|BIOLOGICAL|Pembrolizumab|Given IV
48452593|NCT00325663|PROCEDURE|Acupuncture|
48452594|NCT02330939|OTHER|Low fat- Low glycemic index meal|
48452595|NCT02330939|OTHER|MUFA- Low glycemic index meal|
48452596|NCT02330939|OTHER|SAFA- Low glycemic index meal|
48452597|NCT02330939|OTHER|Low fat- High glycemic index meal|
48622161|NCT04428749|DIAGNOSTIC_TEST|FEES (fiberoptic endoscopic evaluation of swallowing)|"The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords."
48622162|NCT06520384|DEVICE|Radiofrequency|Patients will receive radiofrequency.
48452598|NCT02330939|OTHER|MUFA- High glycemic index meal|
48452599|NCT02330939|OTHER|SAFA- High glycemic index meal|
48622163|NCT06520384|DRUG|Alcohol 30%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
48452600|NCT01326663|DRUG|Medication Trial|
48452601|NCT06622239|DRUG|Naltrexone|naltrexone 50mg for 6 weeks
48452602|NCT06622239|DRUG|Placebo|placebo for 6 weeks
48622164|NCT06520384|DRUG|Alcohol 50%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
48622165|NCT06520384|DRUG|Alcohol 70%|Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
48622166|NCT04179682|PROCEDURE|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
48622167|NCT01244659|DRUG|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
48622168|NCT01244659|DRUG|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
48622169|NCT01486433|DRUG|Simvastatin|40 mg (1 tablet) simvastatin once a day
48622170|NCT01486433|DRUG|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
48622171|NCT01486433|DRUG|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
48622172|NCT06419166|DRUG|GC012F injection|"Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.~Other Name: CD19-BCMA CAR-T cells"
48622173|NCT05510453|OTHER|Low-intensity online intervention (LiON)|"The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills.~Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for 45 minutes. Participants will attend these sessions once a week.~The control group will receive the intervention after a waiting period of 4 weeks."
48622174|NCT02388009|BIOLOGICAL|Flexyn2a|Intramuscular doses of 0.5 mL
48622175|NCT02388009|BIOLOGICAL|Placebo|Intramuscular doses of 0.5 mL
47929252|NCT00592774|DRUG|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
47929253|NCT00592774|DRUG|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
47929254|NCT02582177|DRUG|Candicort®|Apply on the affected area and around it twice a day
48452603|NCT05502835|DEVICE|pulse pressure variation|Infusion of 2 ml/kg/hr. Ringer's solution guided by pulse pressure variation.
48452604|NCT05502835|OTHER|conventional fluid management|Infusion of 6 ml/kg/hr. Ringer's solution.
48452605|NCT06618092|DEVICE|Relisten|Patients will be attended using Relisten
48452606|NCT06391450|DRUG|Empagliflozin 10 MG|Oral
48452607|NCT06391450|DRUG|Placebo|Oral
48452608|NCT01409499|PROCEDURE|hepatic resection|palliative hepatectomy followed by sorafenib
48452609|NCT01409499|PROCEDURE|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
48452610|NCT01409499|DRUG|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
48622176|NCT02388009|BIOLOGICAL|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
48452611|NCT05826119|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
48452612|NCT05826119|DRUG|Placebo|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
48452613|NCT05740098|BEHAVIORAL|Best Practices|Five As plus referral to a quit line
48452614|NCT05740098|BEHAVIORAL|Financial Incentives|Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
48452615|NCT05740098|DRUG|Nicotine Replacement Therapy|Nicotine patches and gum/lozenge provided together for dual therapy
48452616|NCT05001958|BEHAVIORAL|Action observation|Participants will view a video of a task performed by a non-disabled actor and then the participants perform the task from the video with their weaker arm \& hand.
48452617|NCT03442491|PROCEDURE|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
48452618|NCT04515719|BIOLOGICAL|Belimumab|Belimumab 2mg/kg intravenously
48452619|NCT04515719|BIOLOGICAL|Placebo|Placebo intravenously
48452620|NCT00241020|DRUG|Octreotide|
48452621|NCT03665194|DRUG|Cortexolone 17α-propionate solution|Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
48452622|NCT03665194|DRUG|Placebo|matching placebo
48452623|NCT02587663|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
48452624|NCT02587663|PROCEDURE|Mammography|Undergo bilateral mammography
48452625|NCT02587663|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast conserving surgery
48452626|NCT02587663|PROCEDURE|Ultrasonography|Undergo bilateral whole-breast ultrasound
48452627|NCT02587663|PROCEDURE|Ultrasonography|Undergo targeted breast ultrasound
47929255|NCT02582177|DRUG|Nizoral®|Apply on the affected area and around it twice a day
47929256|NCT02582177|DRUG|Baycuten N®|Apply on the affected area and around it twice a day
47929257|NCT02582177|DRUG|Canesten®|Apply on the affected area and around it twice a day
47929258|NCT05828927|BEHAVIORAL|Eco-mapping tool|The web application allows caregivers to visually identify and organize their existing social network (family, friends, community of worship, and others) to assist with their support needs, tailored to their context. For each of the six support social support domains (in-home, informational, communication, financial, emotional and spiritual, transportation (e.g., emotional, informational, practical), the enCompass web application prompts the individual to identify members of their network. After completing each domain, caregivers are presented with a visual social support
47929259|NCT05828927|BEHAVIORAL|Caregiver-coach study visits|Caregivers engage in up to 8 manualized, telephone/videoconference visits with a trained caregiver coach. The caregiver coach uses the study manual and interview guide to provide support for caregiver support-seeking and problem-solving.
48452628|NCT02587663|OTHER|Gadolinium|Contrast agent used in MRI
48452629|NCT05426395|DRUG|Vitamin B12 2.6 µg|There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
48452630|NCT05426395|DRUG|Vitamin B12 10 µg|There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).
48622177|NCT05486728|DRUG|SHJ002/Vehicle|Topical ophthalmic
48622178|NCT02522741|BEHAVIORAL|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
48622179|NCT01388426|DEVICE|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
48622180|NCT01756755|DEVICE|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
48452631|NCT05426395|DRUG|Vitamin B12 50 µg|The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
48452632|NCT03461445|DRUG|Envarsus|Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
48452633|NCT03461445|DRUG|IR Tacrolimus|Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
48452634|NCT02220049|DRUG|Bortezomib|
48452635|NCT00625222|PROCEDURE|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
48452636|NCT06562062|PROCEDURE|Extra-articular Lateral Column Lengthening Procedure|Lateral column lengthening (LCL), originally described by Evans, is an established procedure to correct stage II adult acquired flatfoot deformity (AAFD). However, the relative position between the facets is violated, and other problems may include nonunion, malunion, and calcaneocuboid (CC) joint subluxation. Herein, we report a modified extra-articular technique of LCL with hockey-stick osteotomy, which preserves the subtalar joint as a whole, increases bony apposition to enhance healing ability, and preserves the insertion of the calcaneofibular ligament to stabilize the posterior fragment to promote adduction of the forefoot
47929260|NCT01935310|DRUG|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
48452637|NCT00299871|DRUG|LIXISENATIDE (AVE0010)|
47929261|NCT05910671|BEHAVIORAL|Physical Activity Phone Calls and Notebook|This intervention encouraged parents to model physical activity behaviors and co-participate in physical activity with their young child. Each week behavioral strategies for promoting physical activity change will be discussed to help parents work towards meeting their activity goals. As part of the physical activity intervention parents will receive a physical activity notebook that has newsletters, suggested activities that can be done with their child, and other material that will help the parent and child be active active together. The behavioral strategies and the information in the notebook will will be discussed weekly for 30 minutes via telephone.
47929262|NCT06553859|OTHER|No intervention conducts.|The type and method of breast reconstruction with sillicon implants and ADM implanting is now the standard treatment of breast cancer in korea. no any specific intervention has occurred during the surgery.
47929263|NCT01271582|DRUG|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
47929264|NCT04180384|DRUG|Oraxol|"Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate"
47929265|NCT05428124|OTHER|In vitro fertilisation|In vitro fertilisation
47929266|NCT00912444|DRUG|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
47929267|NCT00912444|DRUG|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
47929268|NCT05243173|OTHER|Sequencing|Laboratory analysis of samples
47929269|NCT04987944|DRUG|Zavegepant|150 mg BID
47929270|NCT04987944|DRUG|Placebo|Placebo matching active drug
47929271|NCT01891045|BEHAVIORAL|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
48452638|NCT06054633|DIETARY_SUPPLEMENT|L-arginine tablet|L-arginine, 2 g, three times daily, for 12 weeks
48452639|NCT06054633|DIETARY_SUPPLEMENT|Placebo tablet|Identical inert placebo, three times daily, for 12 weeks
48452640|NCT06559605|PROCEDURE|zirconia barrier|barrier membrane used for guided bone regeneration and augmentation of ridge defect
48452641|NCT06559605|PROCEDURE|titanium mesh|barrier membrane used for guided bone regeneration
48452642|NCT06559553|DRUG|Selinexor+pegaspargase+dexamethasone|Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
48452643|NCT04722198|DIETARY_SUPPLEMENT|PS128|daily ingestion 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
48452644|NCT01349257|DRUG|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
48452645|NCT04836494|DRUG|BBP-671|BBP-671, oral suspension
48452646|NCT04836494|DRUG|Placebo|Placebo matching BBP-671
48622181|NCT01620099|DRUG|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
48622182|NCT02056678|DRUG|acetaminophen, IV preparation|
47929272|NCT01891045|BEHAVIORAL|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
47929273|NCT02532166|OTHER|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
47929274|NCT05795478|DRUG|Oxycodone and Pregabalin|Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14
47929275|NCT05795478|DRUG|Oxycodone and placebo capsules|Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
47929276|NCT05795478|DRUG|Pregabalin and NS|Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively
48452647|NCT04836494|DRUG|BBP-671|BBP-671, tablet
47929277|NCT05795478|DRUG|placebo capsules and NS|placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
47929278|NCT02446171|DRUG|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
47929279|NCT02446171|DRUG|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
48452648|NCT02110277|DEVICE|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
48452649|NCT04176835|DRUG|Oxytocin nasal spray|Single-dose oxytocin will be administered intranasally
48452650|NCT04176835|DRUG|Placebo|
48452651|NCT05360394|DEVICE|Paclitaxel Coated Balloon|CAS treated with PCB only
48452652|NCT05360394|DEVICE|Paclitaxel Coated Balloon and Stent Graft|CAS treated with PCB first before deployment of stent graft
48452653|NCT02611440|BEHAVIORAL|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
48452654|NCT03768635|OTHER|necrotizing external otitis|description of necrotizing external otitis
48452655|NCT04311164|OTHER|Questionnaire-based survey|The online questionnaire-based survey is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions, rating scales and validated questionnaire scales to measure general and diabetes/insulin pump-specific behavior, psychological concepts and preferences.
48452656|NCT04311164|OTHER|No intervention given.|No intervention was given.
48452657|NCT05079828|DIAGNOSTIC_TEST|18F-PSMA-1007|PET/CT scan using 18F-PSMA-1007
48452658|NCT05079828|DIAGNOSTIC_TEST|68Ga-PSMA-11|PET/CT scan using 68Ga-PSMA-11
48452659|NCT04196907|DEVICE|Rad-67 Pulse CO-Oximeter and DCI Mini sensor|Noninvasive Pulse CO-Oximeter device and sensor are used to measure hemoglobin.
48452660|NCT05609981|OTHER|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
48452661|NCT06627218|DRUG|Prothrombin Complex Concentrate|Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
48452662|NCT06627296|OTHER|Exercise Training|"Individuals in the NMES group will have a total of 24 sessions of NMES application with 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face. They will also be given home exercises to continue at home.~In the NMES group, NMES training will be performed for extensor carpi radialis longus (ECRL), extensor carpi radialis brevis (ECRB), abductor pollicis longus (APL), flexor carpi radialis (FCR) muscles. The pencil electrode will be used to stimulate the ECRL, ECRB, FCR and APL muscles in such a way that 30+30+30=90 contractions will be obtained from each muscle. According to the morphologic characteristics of each muscle, different current and will be applied.~P11th program to ECRL and APL : 65 Hz. 200 μs, P13th program to ECRB and FCR 50 Hz, 200 μs will be applied. Exercises includes intrinsic and extrinsic muscle strengthening, stabilization exercises and dart exercises, wrist neuromuscular exercises and perturbation exercises."
47929280|NCT02446171|DRUG|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
48622183|NCT05563857|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
48622184|NCT05563857|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
48622185|NCT02748993|DRUG|PAC-14028 Cream 0.1%|Topical application
47929281|NCT02446171|DRUG|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
47929282|NCT01629199|DRUG|rhEGF(recombinant human Epidermal Growth Factor)|
47929283|NCT01629199|DRUG|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
48622186|NCT02748993|DRUG|PAC-14028 Cream 0.3%|Topical application
48622187|NCT02748993|DRUG|PAC-14028 Cream 1.0%|Topical application
48622188|NCT02748993|DRUG|PAC-14028 Cream Vehicle|Topical application
48622189|NCT02702856|OTHER|ExoIntelliScore Prostate|
48622190|NCT00696592|DRUG|Bevacizumab (Avastin), Verteporfin (Visudyne)|
48622191|NCT03003468|DRUG|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
47929284|NCT00004644|DRUG|acyclovir|
47929285|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|32 mg
47929286|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|48 mg
47929287|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|64 mg
47929288|NCT04672707|DRUG|Bromhexine Hydrochloride Tablet|80mg
47929289|NCT04834960|OTHER|Minimizing Missed Opportunities for Vaccination (MOV)|This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
47929290|NCT05443139|BEHAVIORAL|Well-being online|Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
47929291|NCT02760043|DRUG|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
47929292|NCT02760043|OTHER|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
48452663|NCT06627296|OTHER|Exercise Training (Control Group)|"Patients in the control group will have face-to-face exercise programs with a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks. Exercises will be performed 3 days a week with a physiotherapist. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.~Exercises will be at the limit of pain. Until the 6th month, overloading, strong gripping, weight transfer, rotations and lifting heavy objects should be avoided. Rehabilitation with functional range of motion is important. Exercises will be performed with a physiotherapist 3 days a week. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises."
48452664|NCT06627296|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation
48452665|NCT04374864|DRUG|Trelagliptin|Anti diabetic
48452666|NCT01783366|DEVICE|TUBE EXCHANGER|
48452667|NCT01545193|OTHER|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
48452668|NCT04089553|DRUG|AZD4635|"In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first."
48452669|NCT04089553|DRUG|Oleclumab|In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
48452670|NCT04089553|DRUG|Durvalumab|In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
48452671|NCT05513196|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
48452672|NCT03835767|OTHER|Peanut powder and Oat flour|Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.
48452673|NCT03835767|OTHER|Peanut flour and Oat flour (placebo for peanut flour)|Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.
48452674|NCT03835767|OTHER|Dry Milk Powder and Corn Starch (placebo for Milk powder)|Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.
48452675|NCT03835767|OTHER|Baked milk and Rice milk (placebo for Baked milk)|Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
48452676|NCT06253572|OTHER|Education|"Educational Skills Program Based on Constructivist Learning Approach~Instructors need to receive training to improve their teaching skills during their graduate education and after their appointment as instructors. In this study, it is aimed to design and implement an Educational Skills Program based on the Constructivist Learning Approach. The design of the training program was based on the Dick, Carey and Carey (DCC) Instructional Design Model, which is widely known among instructional design models and influenced by constructivism theory. It is aimed that the training skills training program will be carried out by taking adult education into consideration and will be learner-centered. In this study, the training plan is based on the Constructivist Learning Approach 5E model, which is proven to be effective in the literature and widely used. The training program will be conducted through distance education to reach instructors living in different cities and to create common time."
48622192|NCT03003468|DRUG|MK-3475|200mg IV
48622193|NCT03003468|DRUG|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
48622194|NCT04350502|PROCEDURE|chest tube drainage|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day).
48622195|NCT04350502|BIOLOGICAL|antibiotic concentration in pleural fluid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
48622196|NCT04350502|DRUG|Amoxicillin + clavulanic acid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
48098331|NCT00303303|BIOLOGICAL|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
48098332|NCT00303303|BIOLOGICAL|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
48098333|NCT06629077|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and a simulated postural change task.
48098334|NCT06629077|DRUG|Prazosin|A dose of prazosin will be administered based on body weight.
48098335|NCT06629077|DRUG|Placebo|Oral placebo
48098336|NCT02744508|DRUG|palonosetron|
47929293|NCT02760043|DRUG|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
47929294|NCT04089800|OTHER|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
47929295|NCT06514534|DRUG|ABL001/Asciminib|"The study treatment for this clinical trial is an investigational drug called asciminib, which is marketed under the brand name Scemblix®. Asciminib is a compound that is being evaluated for its efficacy and safety in the treatment of the target condition.~The minimum dose of asciminib to be administered in this study is 200 mg, while the maximum dose is 400 mg. The dose is planned as 200 mg twice a day (BID).~The drug will be administered orally, allowing for convenient and non-invasive administration."
47929296|NCT00000460|BEHAVIORAL|Low intensity exercise|
47929297|NCT00000460|BEHAVIORAL|High intensity exercise|
47929298|NCT06131528|OTHER|Relaxation Breathing Exercises Group|This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing
47929299|NCT06131528|OTHER|Usual Care Group|The control group received lifestyle modifications that are an important part of hypertension management
47929300|NCT05618561|DIAGNOSTIC_TEST|EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test|Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
48452677|NCT05436028|DEVICE|Transcatheter Tricuspid Valve Intervention|"Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb).~Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement."
48452678|NCT05905276|OTHER|ERAS Protocol|The ERAS protocol for ambulatory TURBT has been designed based on patient and provider input, a needs assessment of 150 patients in the hours after TURBT, a review of the literature, and experience with other ambulatory ERAS protocols already implemented at Johns Hopkins Hospital. The ERAS protocol for ambulatory TURBT aims to optimize care delivered in the pre, intra and postoperative settings.
48452679|NCT05905276|OTHER|Standard of Care|Patients in the usual care arm of the EMBRACE trial will experience the present-day care pathway of ambulatory TURBT at Johns Hopkins Hospital.
48452680|NCT03135236|BEHAVIORAL|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
48452681|NCT01891773|BEHAVIORAL|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
48452682|NCT06557239|DRUG|Lysergic Acid Diethylamide (LSD)|one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department
48452683|NCT03349567|BEHAVIORAL|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
48452684|NCT01936662|DEVICE|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
48452685|NCT01936662|DEVICE|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
48452686|NCT06469645|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day on top of their regular medications.
48452687|NCT01167829|DRUG|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
48452688|NCT01167829|DRUG|Acyline|300 ug/kg injection on Day 0
48452689|NCT00015665|DRUG|Voriconazole|
47929301|NCT02251522|DEVICE|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
47929302|NCT02251522|DEVICE|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
47929303|NCT02785237|DEVICE|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
47929304|NCT02785237|DEVICE|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
48452690|NCT03280953|DIAGNOSTIC_TEST|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
47929305|NCT04109339|DRUG|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
47929306|NCT04919447|PROCEDURE|pacemaker implantation|cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients.
47929307|NCT04450810|OTHER|Observation of serum and salivary NLRP3 levels|Evaluation of serum and salivary NLRP3 levels
47929308|NCT00211744|DRUG|topiramate|
47929309|NCT04628533|BEHAVIORAL|Four Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 16 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
47929310|NCT04628533|BEHAVIORAL|Six Month Duration Online Behavioral Weight Loss Program|"Participants meet weekly on line with other group participants for 24 weeks. The group-based online behavioral weight control program incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted, and reinforced throughout the program. Weekly group meetings in a video chat forum led by an experienced group weight control counselor are the venue for the group process, and extensive web-based resources to support behavior changes are offered. The online groups are closed such that those individuals who start the group remain in that group for the duration of their participation. Weight loss counselor will provide feedback and encouragement to participants after reviewing food diaries via weekly emails."
47929311|NCT05472701|BEHAVIORAL|Diet order: WFPB, PBMA, Animal|Participants followed the WFPB, PBMA, and Animal diets (in this order) for 4 weeks each.
47929312|NCT05472701|BEHAVIORAL|WFPB, Animal, PBMA|Participants followed the WFPB, Animal, and PBMA diets (in this order) for 4 weeks each.
47929313|NCT05472701|BEHAVIORAL|PBMA, WFPB, Animal|Participants followed the PBMA, WFPB, and Animal diets (in this order) for 4 weeks each.
48098337|NCT02744508|DRUG|palonosetron with dexamethasone|
48098338|NCT05349864|DRUG|PF-07284890 Treatment A|PF-07284890 tablet by mouth while fasting
48452691|NCT06274762|OTHER|Training and BSE application on a model|A breast cancer awareness training designed according to the headings of sensitivity, seriousness, benefit, obstacle perception, health motivation and self-efficacy, which are the steps of the health belief model, followed by applied BSE on a model.
48452692|NCT05159921|OTHER|Access to an automated conversational agent (SurgInfoBot)|See above under arm/group descriptions.
48452693|NCT03887884|DRUG|CVT-301|Levodopa Inhalation Powder
48452694|NCT03887884|DRUG|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
48452695|NCT03984565|DRUG|Cannabidiol|High-CBD, low-THC sublingual product formulated in palm oil
48452696|NCT03984565|DRUG|Placebo|Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
48622197|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
48622198|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
48622199|NCT01440920|DRUG|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
48098339|NCT05349864|DRUG|PF-07284890 Treatment B|PF-07284890 tablet after low fat meal
48098340|NCT05349864|DRUG|PF-07284890 Treatment C|PF-07284890 tablet after high fat meal
48098341|NCT00817050|DRUG|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
48098342|NCT00817050|DRUG|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
48098343|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
48452697|NCT05444803|OTHER|femoral nerve block|Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
48452698|NCT05444803|OTHER|peri-capsular nerve group block|Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
48452699|NCT03873363|DEVICE|PS TKA|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
48452700|NCT03873363|DEVICE|CR TKA|Implantation of a cruciate retaining Total Knee Arthroplasty.
48452701|NCT01857947|OTHER|AECOPD Mr proADM|
48452702|NCT05459571|BIOLOGICAL|Axicabtagene Ciloleucel|Administered intravenously
48452703|NCT05459571|DRUG|Cyclophosphamide|Administered intravenously
48452704|NCT05459571|DRUG|Fludarabine|Administered intravenously
48452705|NCT05459571|DRUG|Dexamethasone|Administered orally or intravenously
48452706|NCT05189106|DRUG|Baricitinib|Each participant will be treated with open-label baricitinib for 24 weeks. Participants will receive 2 mg baricitinib by mouth daily for the first 8 weeks and 4 mg baricitinib by mouth daily for the remaining 16 weeks.
48452707|NCT06563271|DRUG|Dexketoprofen Trometamol 50 Mg/mL Solution for Injection|Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
48622200|NCT05391152|DEVICE|robotic assisted total knee replacement|the study group used robotic-arm assisted total knee replacement.
48622201|NCT05391152|DEVICE|traditional total knee replacement|the control group used traditional total knee replacement
48622202|NCT05185856|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
48622203|NCT05185856|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
48622204|NCT03480074|PROCEDURE|Staple Ligation|Using a stapler that staples the DVC and then cuts it.
48622205|NCT03480074|PROCEDURE|Selective Suture Ligation|Suture the DVC, suspend it to the pubic bone, and then cut.
48622206|NCT03480074|PROCEDURE|Single Suture Ligation|Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
48452708|NCT06563271|DRUG|Ibuprofen 100 MG/ML Solution for Injection|"Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion)."
48452709|NCT06563271|DRUG|Paracetamol 10 Mg/mL Solution for Injection|Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).
48452710|NCT06563271|DRUG|isotonic saline|Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
48452711|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
48452712|NCT03649763|DRUG|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
48452713|NCT03649763|DRUG|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
48452714|NCT05039996|BEHAVIORAL|education and relaxation program|randomized controlled trial
48452715|NCT05487625|BEHAVIORAL|High-ventilated cigarette alone|High-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
48452716|NCT05487625|BEHAVIORAL|Low-ventilated cigarette alone|Low-ventilated cigarettes are the only available cigarettes in the Experimental Tobacco Marketplace which increases in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
48452717|NCT05487625|BEHAVIORAL|High- and low-ventilated cigarette with high-ventilated cigarettes increasing in price|High- and low ventilated cigarettes are available in the Experimental Tobacco Marketplace with high-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
48452718|NCT05487625|BEHAVIORAL|Low- and high-ventilated cigarette with high-ventilated cigarettes increasing in price|Low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with low-ventilated cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
48452719|NCT05487625|BEHAVIORAL|Usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|Usual cigarette, low- and high-ventilated cigarettes are available in the Experimental Tobacco Marketplace with usual cigarettes increasing in price across trials. Other nicotine/tobacco products are available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
48452720|NCT04221113|PROCEDURE|physiotherapy|Two protocols have been described for physiotherapy of post extensor tendon injuries. one is immobilization till 3 weeks and than gradual increase in active motion of hand. The second protocol is early active motion. this would be done under senior physiotherapist.
48452721|NCT03923374|DRUG|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
48452722|NCT03923374|DIAGNOSTIC_TEST|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
48452723|NCT03923374|DIAGNOSTIC_TEST|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
48452724|NCT06560294|DRUG|Micronized purified flavonoid fraction (Daflon ®)|Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
48452725|NCT06560294|OTHER|Glue embolization|Patients will receive transcatheter glue embolization.
48452726|NCT04797663|DEVICE|Nd-YAG laser|laser hair removal device
48452727|NCT04797663|DRUG|TCA 20%|chemical peel
48098344|NCT01219855|DRUG|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
48098345|NCT01219855|DRUG|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
48098346|NCT01219855|DRUG|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
48452728|NCT05694676|OTHER|Assessment of the quality of Genaral Movements (GMs)|The variation, complexity and fluency of movements over a video recording is done and the quality of GMs is classified as normal-optimal, normal-suboptimal, mildly abnormal, and definitely abnormal movements.
48452729|NCT05694676|OTHER|State-Trait Anxiety Inventory-Trait, (STAI-T)|The scale consists of 20 items in total and provides a four-point Likert type measurement (1- anxiety symptom is not present, 4- the symptom lasts all the time). Scores range from 20 (low anxiety) to 80 (high anxiety).
48452730|NCT05694676|OTHER|Beck Depression Inventory, (BDI)|BDI contains 21 items and rates the depressive symptoms for the last week. Each item has four options and is scored between 0 and 3. The total score ranges from 0 to 63. Higher scores indicate more severe depression
48452731|NCT03579615|DEVICE|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
48452732|NCT03579615|DEVICE|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
48452733|NCT04512781|DEVICE|Control Cannula - Prosoft Cannula - Unicorn Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
48452734|NCT04512781|DEVICE|Control Cannula - Unicorn Cannula - Prosoft Cannula|The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
48452735|NCT01208935|DRUG|Nicotine Patch|
48452736|NCT01208935|DRUG|Nicotine Gum|
48452737|NCT01836380|BEHAVIORAL|Exercise Training|
48452738|NCT00841542|DRUG|Amlodipine Besylate|10 mg Tablet
48452739|NCT00841542|DRUG|Norvasc®|10 mg Tablet
48452740|NCT06626841|DIAGNOSTIC_TEST|Pelvic floor muscles contractile capacity and activation|"An initial assessment of the pelvic floor is carried out when athletes arrive at the facility. Participants then complete a FFT workout, which consists of performing as many rounds as possible (AMRAP type) of 20 wallballs, 15 box jumps, and 10 burpees within 15 minutes. These plyometrics and load lifting exercises are chosen to fatigue the PFM and are simple to execute. The pelvic floor assessment is performed again at 3 minutes following the FFT workout.~Measurements of the pelvic floor parameters are conducted by a specialist physiotherapist. The muscle activation and strength of the PFM are obtained using a vaginal dynamometer (i.e. pelvimeter probe fixed at a vertex with two arms that can be separated by up to 25°), connected to the Phenix USB2, Vivaltis (Pelvimètre Phenix, Vivaltis)."
47929314|NCT05472701|BEHAVIORAL|PBMA, Animal, WFPB|Participants followed the PBMA, Animal, and WFPB diets (in this order) for 4 weeks each.
48452741|NCT02115165|DRUG|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
48452742|NCT02157051|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
47929315|NCT05472701|BEHAVIORAL|Animal, WFPB, PBMA|Participants followed the Animal, WFPB, and PBMA diets (in this order) for 4 weeks each.
47929316|NCT05472701|BEHAVIORAL|Animal, PBMA, WFPB|Participants followed the Animal, PBMA, and WFPB diets (in this order) for 4 weeks each.
47929317|NCT01753050|DEVICE|Stroke volume monitoring|Pulse contour stroke volume monitoring
47929318|NCT04673123|OTHER|Core stabilization exercises|"In our study, core stabilization exercises to be applied in the intervention group are arranged according to the patients with stroke and will be at three different difficulty levels. Exercises will be done on the back (hooked) and sitting positions where the risk of falling is low. First of all, activation of the transversus abdominis muscle, which is the basis of core stabilization, will be taught to patients. With this activation at the first level, the healthy side, at the second level the affected side, and at the third level, reciprocal upper and lower extremity movements will be requested. In addition to these, there will be exercises to bridge and curl up in supine position, and weight transfer in sitting position. In order to increase the difficulty level of the exercises, first of all, the number of exercises will be increased and then it will be asked to move on to the next level."
47929319|NCT04673123|OTHER|Multifactorial Education Program|The content of this program includes rehabilitation practices that are routinely applied in stroke rehabilitation and that patients will receive at the specified hospital. In the content of these applications; patient-specific upper and lower extremity stretching, and strengthening exercises; application of functional electrical stimulation (FES) to upper and lower extremity muscles; balance, coordination and gait training are included. he content of multifactorial fall prevention training includes the first brochure titled '' General Recommendations for the Prevention of Fall in Chronic Stroke Patients '', which will include general recommendations for preventing falling according to the fall risk factors specific to the stroke, and the recommendations to minimize the risk of falling in the home. A second brochure titled 'Suggestions for Making Your Home Safer' will be given. The information in these brochures will also be communicated to patients face to face verbally
47929320|NCT00157287|PROCEDURE|Evidence based weaning protocol|
47929321|NCT00635076|OTHER|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
47929322|NCT00635076|DRUG|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
47929323|NCT04426760|PROCEDURE|Transcervical resection of fibroids|Transcervical resection of fibroids
48452743|NCT02157051|OTHER|Laboratory Biomarker Analysis|Correlative studies
48452744|NCT05048667|DEVICE|Shock Wave therapy (SWT)|Each SWT will administer 720 shocks in the treatment arm. Total of 3600 shocks are given over 5 weeks treatment period.
48452745|NCT05048667|DRUG|Platelet Rich Plasma (PRP)|5 mL PRP will be administered via intracavernous injection
48452746|NCT05048667|OTHER|Sham SWT|Sham Shockwave Therapy will be administered in the sham arm.
48452747|NCT05048667|OTHER|Placebo Saline|5 mL Placebo saline will be administered via intracavernous injection in the sham arm.
48452748|NCT06441591|DRUG|Vinpocetine|Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
48452749|NCT06441591|DRUG|Standard Therapy|Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
48452750|NCT06441591|OTHER|Placebo|Starch-filled capsules, matching those of the intervention
48452751|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
48452752|NCT00570635|DRUG|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
48452753|NCT05943665|DRUG|MDMA|medication and therapy combined
48452754|NCT01575457|BEHAVIORAL|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
48452755|NCT04184167|OTHER|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
48452756|NCT04247945|BIOLOGICAL|Cotransplant with MSCs|Co-transplantation of MSCs during allogeneic HSCT
48452757|NCT05921981|BEHAVIORAL|Multisensorial Stimulation|Multisensory stimulation in newborns involves the deliberate and simultaneous activation of multiple sensory modalities to provide sensory experiences that promote development and enhance learning. Newborns are naturally inclined to explore and make sense of their environment through their senses, including touch, sight, sound, taste, and smell.
48452758|NCT05921981|BEHAVIORAL|White Noise|White Noise
47929324|NCT04426760|PROCEDURE|Myomectomy per laparoscopy or laparotomy|Myomectomy per laparoscopy or laparotomy
47929325|NCT01315821|DRUG|Saccharomyces boulardii|5 million units/day for 3 months
47929326|NCT01315821|DRUG|Placebo|Placebo for 3 months
47929327|NCT04421547|DRUG|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
47929328|NCT04421547|DRUG|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
48452759|NCT05954741|OTHER|Motor rehabilitation alone|Participants will undergo motor training consisting of a walking session (20 minutes), balance exercises, postural control exercises, proprioceptive exercises, joint mobilization exercises, and muscle strengthening exercises for a total of 25 minutes. A muscle relaxation session will follow (45 minutes).
47929329|NCT04837677|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
47929330|NCT00423527|DRUG|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
47929331|NCT05154968|DRUG|Sodium chloride|Administered SC infusion.
47929332|NCT05154968|DRUG|Citrate buffer|Administered SC infusion.
48452760|NCT05954741|OTHER|Motor rehabilitation and Cognitive rehabilitation (paper-based)|Group 2 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a standard cognitive intervention, with the execution of cognitive exercises in the domains of attention, memory, executive function, visuo-spatial abilities, space-time orientation, by paper-pencil support (45 minutes per day).
48452761|NCT05954741|OTHER|Motor rehabilitation and cognitive rehabilitation (digital-based)|Group 3 will perform motor training, with an analogous modality of Group 1 (45 minutes) and a digital cognitive intervention, with the execution of cognitive exercises on attention, memory, executive functions, visual-spatial ability, space-time orientation, employing device support (tablet) with interactive exercises presented by specific software (VRRS Home tablet Khymeia Srl) (45 minutes).
48452762|NCT00949143|OTHER|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
48452763|NCT00949143|OTHER|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
48452764|NCT05618587|DRUG|Lithium|Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
48452765|NCT05618587|DRUG|Placebo|Inactive pill
48452766|NCT06627699|DEVICE|Total Knee Arthroplasty|Post-Market Surveillance of the Freedom Total Knee System for Primary TKA
48452767|NCT04188392|DRUG|Pimavanserin|pimavanserin tablet
48452768|NCT03374176|DRUG|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
48452769|NCT03374176|DRUG|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
48452770|NCT02380794|DRUG|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
48452771|NCT02380794|DRUG|Placebo|
48452772|NCT06496568|DRUG|Inavolisib|Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
48452773|NCT06496568|DRUG|Atezolizumab|Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
48452774|NCT06093932|DRUG|Songling Xuemaikang Capsules|3 capsules at a time, three times a day, duration: 12 weeks
48452775|NCT06093932|BEHAVIORAL|Lifestyle intervention|everyday, duration: 12 weeks
48452776|NCT06093932|DRUG|Placebo|3 capsules at a time, three times a day, duration: 12 weeks
48452777|NCT00919737|DRUG|NPC-08|Polifeprosan 20 with Carmustine 3.85%
48452778|NCT04987554|DIETARY_SUPPLEMENT|glycophosphopeptical AM3|3 g/day of AM3
48452779|NCT04987554|OTHER|Placebo|3 g/day of placebo
48452780|NCT04235595|OTHER|Connective Tissue Manipulation|The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.
47929333|NCT05154968|DRUG|Mannitol|Administered SC infusion.
47929334|NCT05154968|DEVICE|Prefilled Autoinjector|Used to administer the drug through SC infusion.
47929335|NCT04187287|OTHER|Radial Extracorporeal Shock Wave Therapy|Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session
48098347|NCT01219855|DRUG|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
48452781|NCT04235595|OTHER|Transcutaneous Electrical Nerve Stimulation|TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
48452782|NCT05785832|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM|The t:slim X2 insulin pump with Control-IQ technology 1.5 is derived from the commercially available t:slim X2 with Control-IQ, with additional features. It will be used with the Dexcom G6 CGM.
48452783|NCT05785832|DEVICE|Standard Therapy plus continuous glucose monitoring (CGM)|Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
48452784|NCT01748773|DRUG|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m\^2 IV on Day 1 of Cycles 1-3.
48452785|NCT01748773|RADIATION|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
48098348|NCT04996667|DRUG|inhaled nitric oxide (iNO)|"Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
48098349|NCT03873324|DRUG|CPL500036 compound|IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
48098350|NCT03873324|DRUG|Placebo|matching placebo capsules
48098351|NCT06631066|RADIATION|neoadjuvant chemoradiation|Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.
48452786|NCT01748773|DRUG|Capecitabine|Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
48452787|NCT01748773|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
48452788|NCT01315990|DRUG|FOLFIRI + Cetuximab|"1. Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~2. FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~* Irinotecan 180 mg/m² iv , 90 min on day 1~* Folic acid (racemic) 400 mg/m², 120 min on day 1~* 5-FU 400 mg/m² bolus on day 1~* 5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
48452789|NCT06152081|DEVICE|LumiCare rinse|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. Lumicare rinse will be applied onto the test areas for 30 seconds and the excess removed using a saliva ejector. The sites will then be rinsed with plain water for 10 seconds and excess will be removed using high volume suction. A blue curing light will then be held 1-2 inches from the test surfaces while the examiner assesses the surfaces for the presence or absence of fluorescent illumination.
48452790|NCT06152081|DEVICE|QLF Inspektor Pro Imaging|The teeth being assessed will be cleaned of any debris ,plaque and calculus. The areas being assessed will be air dried. A dry field will be maintained using cotton rolls and a saliva ejector. The QLF device will be positioned over the tooth surface to be tested and an image will be taken. The images will be stored automatically and assessed by the examiners for the presence of green fluorescence using the QA2 program (Version 1.25, Inspektor Research systems BV, Amsterdam, The Netherlands) . The trend in green fluorescence will also be calculated using this software algorithm.
48452791|NCT02083328|DIETARY_SUPPLEMENT|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
48452792|NCT02083328|DIETARY_SUPPLEMENT|Placebo (Mannitol)|Mannitol filled in gelatine capsules
48452793|NCT01410227|BIOLOGICAL|Recombinant von Willebrand factor (rVWF)|Intravenous administration
48452794|NCT01410227|DRUG|Placebo|Syringe supplied with physiologic saline solution for infusion
48452795|NCT01410227|BIOLOGICAL|Recombinant factor VIIII (rFVIII)|Intravenous administration
48452796|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Local Anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL
48452797|NCT04636034|PROCEDURE|Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Block performed with bilaterally inserted q-tips with isotone NaCl
48452798|NCT04636034|PROCEDURE|"Sham-block with Placebo (Isotone NaCl)"|Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.
48452799|NCT04086108|DIETARY_SUPPLEMENT|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
48452800|NCT04086108|DIETARY_SUPPLEMENT|GABA supplement|1 gram of GABA dissolved in water.
48452801|NCT04086108|DIETARY_SUPPLEMENT|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
48452802|NCT06502327|OTHER|Instructions A|"Instructions A are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
48452803|NCT06502327|OTHER|Instructions B|"Instructions B are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
48452804|NCT06136039|PROCEDURE|Arm I (Sarcopenia)|Same as standard treatment
48098352|NCT04489784|DEVICE|Infrared Laser|An aluminum gallium arsenide (AlGaAs) diode laser device (Twin laser, MMOptics, São Carlos, SP, Brazil) was used. The irradiation parameters were as follows: infrared laser (808 nm wavelength) with a spot area of 0.04 cm2, and an average optical power of 100 mW operated in a continuous mode during 1 minute per point, leading to an irradiance of 2,500 mW/cm2, energy of 6 J and fluence of 125 J/cm2 per point. The laser was applied on ballerina's feet twice a week during three months.
48098353|NCT04002830|DRUG|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
48098354|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
48098355|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp).
48098356|NCT02325050|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]).
48098357|NCT02325050|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 1\*10\^11 viral particles (vp).
48098358|NCT02325050|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline.
48098359|NCT01268891|DRUG|Placebo|Once daily; tablet; orally; 18 weeks
48452805|NCT06136039|PROCEDURE|Arm II(Normal)|Same as standard treatment
48452806|NCT03578939|PROCEDURE|Biopsy EUS guided|NGS Sequencing on Biopsy samples
48452807|NCT01515163|BEHAVIORAL|Exercise training|Aerobic exercise training, two times a week
48452808|NCT04356508|DRUG|Nivolumab|Single dose at 0.3mg/kg
48452809|NCT04284787|DRUG|Azacitidine|Given IV or SC
47929336|NCT04187287|OTHER|Deep Friction Massage|Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
47929337|NCT06363188|DEVICE|Radial Extracorporeal shockwave|a device used by physiotherapist to treat various musculoskeletal problems and it was here firstly used to accelerate the bone healing process after bone fracture
47929338|NCT02239120|DRUG|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
47929339|NCT02239120|DRUG|placebo to ASA|placebo to comparator drug
47929340|NCT02239120|DRUG|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
48622207|NCT05486286|DEVICE|NCKU-NG system|A live-video system (NCKU-NG system) was developed to assist in the placement of enteral feeding tubes. This system consists of a camera and light source that can be inserted into the commercial NG tube to view live video during feeding tube placement. Manual air insufflation may aid feeding tube placement and improve visualization of anatomic landmarks. After the procedure, an abdominal X-ray is done to confirm the position of the feeding tube.
48622208|NCT02838355|DEVICE|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
48279937|NCT06030011|BEHAVIORAL|Usual Care|Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
48279938|NCT00503191|BEHAVIORAL|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
48622209|NCT02838355|OTHER|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
48622210|NCT04323475|BIOLOGICAL|Bacteriophage cocktail spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages at a concentration of 1.4 x 10\^8 PFU/mL for an effective dosage of 2.5 x10\^5 PFU/cm\^2 of burned area. The study intervention will be applied in conjunction with standard of care.
48622211|NCT04323475|DRUG|Xeroform|Standard of care will consist of Xeroform primary dressing and Kenacomb topical antibiotic cream (for wounds with signs of localized infection)
48622212|NCT01242787|DRUG|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
48622213|NCT01242787|DRUG|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
48279939|NCT04030195|GENETIC|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
48279940|NCT04030195|DRUG|Fludarabine|Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
48279941|NCT04030195|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
48279942|NCT02636309|BEHAVIORAL|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
48279943|NCT00525252|DRUG|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
48279944|NCT00525252|DRUG|placebo|Placebo will be orally administered for 12 consecutive weeks
48279945|NCT04108507|PROCEDURE|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
48279946|NCT04466124|RADIATION|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
48279947|NCT05575310|PROCEDURE|Total Knee Arthroplasty|Articular knee surface replacement
48279948|NCT05089708|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
48279949|NCT05089708|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
48452810|NCT04284787|PROCEDURE|Biopsy|Undergo biopsy
48452811|NCT04284787|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
48452812|NCT04284787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48452813|NCT04284787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
47929341|NCT02239120|DRUG|placebo to dabigatran etexilate|placebo
47929342|NCT02239120|DRUG|ASA 100 mg|active comparator drug
47929343|NCT02239120|DRUG|dabigatran etexilate|active drug
47929344|NCT02160002|PROCEDURE|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
47929345|NCT02160002|PROCEDURE|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
47929346|NCT04677478|OTHER|Impact of respiratory isolation on quality of life|Semi-structured interviews
47929347|NCT01958827|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
47929348|NCT01920646|OTHER|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
47929349|NCT01146860|DRUG|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
47929350|NCT01146860|DRUG|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
48098360|NCT01268891|DRUG|Azilect®|1 mg daily; tablet; orally; 18 weeks
48622214|NCT02901860|OTHER|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
48622215|NCT02648906|DRUG|Choline alfoscerate|
48622216|NCT02648906|DRUG|Placebo|
48622217|NCT02136589|DRUG|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
48622218|NCT02057991|OTHER|educational intervention|Watch an educational video
48622219|NCT02057991|PROCEDURE|CAM exercise therapy|Watch a mindfulness exercise video
48622220|NCT02057991|OTHER|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
48622221|NCT02057991|OTHER|questionnaire administration|Ancillary studies
48622222|NCT02057991|OTHER|laboratory biomarker analysis|Correlative studies
48622223|NCT01815619|OTHER|on-site specimen evaluation|The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
48622224|NCT01815619|OTHER|off-site specimen evaluation|The specimen will be evaluated off-site by a cytopathologist
48622225|NCT04187521|OTHER|Meal A|A breakfast meal with a specific macronutrient proportions.
48622226|NCT04187521|OTHER|Meal B|A breakfast meal with a specific macronutrient proportions.
48622227|NCT01568541|DRUG|Regular toothpastes|One tooth brushing
48622228|NCT01568541|DRUG|Children's toothpastes|One tooth brushing
48622229|NCT00452569|DRUG|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
48622230|NCT00452569|DRUG|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
48622231|NCT00202488|DRUG|H. pylori treatment|
48622232|NCT05489432|BEHAVIORAL|Exercise|A twelve-week prehabilitation program consisting of physical exercises, nutritional measures and psychosocial interventions based on the KTCs personal needs as indicated by an assessment consisting of questionnaires and physical tests. The prehabilitation program will be followed by a twelve-week consolidation program, in which the intensity and frequency of the interventions will be lower, in order to enhance the incorporation of the interventions into the daily life of the KTC. During the intervention period, participants will receive counseling by a lifestyle coach.
48622233|NCT04176523|DRUG|Carglumic Acid|Maintenance therapy with carglumic acid
48622234|NCT05939518|OTHER|Lactated Ringer's Fluid Bolus Response to Low Urinary Output|During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.
48622235|NCT05939518|OTHER|Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol|During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
48622236|NCT04678674|PROCEDURE|tooth root augmentation|Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
48622237|NCT05783973|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from bile，tissue and tissue sample, minimum DNA amount should be over 50ng.
48622238|NCT04029844|DEVICE|Colibri TAVI System|Implantation of Colibri heart valve
48622239|NCT05807503|DRUG|Cerebrolysin|Cerebrolysin administration in short period of time after TBI
48622240|NCT03972033|BEHAVIORAL|EMDR|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
48098361|NCT06628388|BEHAVIORAL|Nurse-Led Risk-Based 5As Primary Healthcare Model|The intervention is developed based on the 5As model (ask, advice, assess, assist, arrange). In this model, nurse will play the central role in delivering the service as a case manager. In Ask, all participants will be assessed on the demographics, health related status, and health risk stratification (i.e. 3-tier risk stratification). In Advice, all participants will be given the education booklet. Those assessed to be at low risks will receive general advice, while those at medium risk will receive condition-specific advice instead. High risk participants will be provided with referral suggestions. The assessment of medium or high risk participants willingness and any barriers in seeking changes will be conducted in Assess. In Assist, active referrals will be provided to high risk participants, with weekly advice messages provided to medium and high risk participants. In Arrange, all participants will receive their follow-ups.
48452814|NCT04284787|BIOLOGICAL|Pembrolizumab|Given IV
47929351|NCT03997578|PROCEDURE|NIPSA (Non-incised papilla surgical approach)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
47929352|NCT03997578|PROCEDURE|NIPSA plus connective tissue graft|In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
47929353|NCT04643301|DRUG|Liraglutide Pen Injector|Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
47929354|NCT00929214|DRUG|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
47929355|NCT00929214|PROCEDURE|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
48452815|NCT04284787|DRUG|Venetoclax|Given PO
48452816|NCT05190068|DRUG|HMPL-760|HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.
48452817|NCT03759717|OTHER|Observation|Understanding the biology of skull base tumors will teach the investigators about the genesis and/or mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.
47929356|NCT02983097|DRUG|Rituximab|Rituximab 375 mg/m²
48452818|NCT05643677|DRUG|Fruquintinib|4 mg PO, QD (3 weeks on, 1 week off)
48452819|NCT05643677|DRUG|Irinotecan|participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks
48452820|NCT06469671|DEVICE|The system based on real - time artificial intelligence - assisted for colonoscopy|"Russian medical decision support system based on artificial intelligence ArtInCol"
48452821|NCT05877261|DEVICE|Cementless Total Knee Replacement|Artificial knee implant inserted by cementless fixation.
48452822|NCT02645253|DRUG|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
47929357|NCT02983097|DRUG|Cisplatin|Cisplatinum 100 mg / m²
47929358|NCT02983097|DRUG|Carboplatin|Carboplatinum AUC5
48452823|NCT02645253|DRUG|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
48452824|NCT02645253|DRUG|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
47929359|NCT02983097|DRUG|Dexamethasone|Dexamethasone 40 mg
47929360|NCT02983097|DRUG|Cytarabine|Cytarabine 2000 mg/m², administered twice
47929361|NCT02983097|DRUG|Lenalidomide|5-20 mg administered either d1-d7, or d-6-d7
47929362|NCT02983097|DRUG|PegFilgrastim|PegFilgrastim 6 mg
47929363|NCT02983097|PROCEDURE|peripheral stem cell collection|collection of peripheral stem cells for autologous stem cell transplantation
47929364|NCT01974765|DRUG|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
47929365|NCT00731042|DRUG|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
48452825|NCT02645253|DRUG|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
48452826|NCT02645253|DRUG|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
48452827|NCT06627010|OTHER|description|study of file
48452828|NCT06039306|DIETARY_SUPPLEMENT|Immunonutrition oral nutrition supplementation|Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
48622241|NCT03972033|BEHAVIORAL|CBT|"Treatments will be independent and blinded to the clinical psychologists conducting the clinical assessments. EMDR and CBT treatments will be provided for 16 weeks, each comprising 16 weekly individual sessions. Interventions will be conducted according to published treatment manuals. All treatment sessions will be video recorded for fidelity rating and supervision.~As a safety criterion, if severe worsening of symptoms is observed, patients are withdrawn from their assigned treatment arm."
48622242|NCT04479046|OTHER|PMMA crowns|New type of pediatric crowns
47929366|NCT00731042|DRUG|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
47929367|NCT00704665|DRUG|Relaxin|10 ug/kg/day or 25 ug/kg/day
47929368|NCT00704665|DRUG|Relaxin|Placebo
48452829|NCT03138967|DRUG|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
48452830|NCT03138967|DRUG|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
48452831|NCT03138967|DRUG|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
48452832|NCT03138967|DRUG|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
48452833|NCT06267625|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, cough strength, functional mobility and hand grip strength.They will be asked to answer the Standardized Mini Mental Test, Modified Medical Research Council Scale, Physical Activity Scale for the Elderly, Berg Balance Scale. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
48452834|NCT03629054|DRUG|Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination)|single dose
48452835|NCT03629054|DRUG|Empagliflozin|single dose
48452836|NCT03629054|DRUG|Linagliptin|single dose
48452837|NCT03629054|DRUG|Metformin HCl|single dose
48452838|NCT00023166|DRUG|PEG-paclitaxel|
48452839|NCT04312113|DRUG|Adipose derived, autologous mesenchymal stem cells|Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
48452840|NCT05419739|OTHER|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
48452841|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
48452842|NCT00663663|BEHAVIORAL|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
48452843|NCT00665925|DRUG|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
48452844|NCT00665925|DRUG|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
48279950|NCT03976089|BEHAVIORAL|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
48452845|NCT00665925|DRUG|Placebo|Placebo, orally, either once a day, or twice a day
48452846|NCT03881943|DRUG|Ticagrelor 60 mg|Potent antiplatelet agent, 60mg twice daily for 3 months
48452847|NCT03881943|DRUG|Aspirin 100 MG Oral Tablet, Enteric Coated|antiplatelet agent, 100mg once daily for 3 months
48452848|NCT06213649|DRUG|Polyhexamethylene biguanide (PHMB)|PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
48452849|NCT06213649|DRUG|Topical corticosteroid|Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
48452850|NCT06213649|OTHER|Topical placebo|An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
48452851|NCT03639077|DEVICE|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
48452852|NCT03639077|DEVICE|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
48452853|NCT02530333|OTHER|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
48452854|NCT04116957|DEVICE|RTLS current tag|Validate location system performance against manual observation of nursing activity
48452855|NCT04116957|DEVICE|RTLS tag revised|Test a next-generation RTLS tag for healthcare process validation
48452856|NCT02339558|OTHER|Laboratory Biomarker Analysis|Correlative studies
48452857|NCT02339558|BIOLOGICAL|Nivolumab|Given IV
48452858|NCT06516354|DEVICE|Portable sleep apnea screening|Screening of stroke and TIA patients on the stroke inpatient unit using theSTOP BANG questionnaire and portable sleep testing (PST) during inpatient hospitalization, early interpretation of PST results by neurology with prescribed treatment upon discharge from hospital
48452859|NCT06060145|OTHER|Plants placed in an office environment|The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
48452860|NCT06060145|OTHER|Devoid of any plant presence in an office environment|Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
48452861|NCT03294460|DRUG|Alcohol (Oral)|Oral Self-administration
48452862|NCT03294460|DRUG|Alcohol (IV)|IV Self-administration
47929369|NCT05592873|DRUG|Neoadjuvant chemoradiotherapy (CRT)|Patients with histological diagnosis of locally advanced rectal adenocarcinoma \[clinical T3-T4N0M0 or T(any)N+M0\] were treated with neoadjuvant CRT followed by curative intent elective surgery between January 2014 and December 2019.
47929370|NCT03054129|OTHER|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in Proprioceptive Neuromuscular Facilitation for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
47929371|NCT03054129|OTHER|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
47929372|NCT04168710|DRUG|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
47929373|NCT04168710|OTHER|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
47929374|NCT05245396|DRUG|Ref (TF2)|Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
47929375|NCT05245396|DRUG|Evobrutinib MR-T1|Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
47929376|NCT05245396|DRUG|Evobrutinib MR-T2|Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
47929377|NCT05245396|DRUG|Evobrutinib MR-T3|Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
47929378|NCT05245396|DRUG|Evobrutinib MR-T4|Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
47929379|NCT05245396|DRUG|Evobrutinib MUPS-C1|Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
47929380|NCT05245396|DRUG|Evobrutinib MUPS-C2|Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
47929381|NCT05245396|DRUG|Evobrutinib MUPS-C3|Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
47929382|NCT05245396|DRUG|Evobrutinib MUPS-C4|Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
47929383|NCT05245396|DRUG|Evobrutinib MR-T adapated|Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
47929384|NCT06127537|BEHAVIORAL|Therapeutic Intervention Group|"The therapeutic group factors that are worked on in the group session with a psychologist are:~* Altruism.~* Cohesion: feeling of belonging and acceptance in a group.~* Universality: identification with the feelings, ideas or problems of the other group members.~* Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group.~* Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others.~* Counselling.~* Identification: assumption of behavioural patterns of other members as one's own.~* Reactualisation of the family experience.~* Understanding of one's own internal motivations.~* Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way.~* Existential factors: empowerment of the individual."
47929385|NCT02673047|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
47929386|NCT05478629|OTHER|Survey|Questioning through google forms
48452863|NCT03294460|DRUG|Alcohol (Ethanol)|IV and Oral Self-administration
47929387|NCT05676593|DEVICE|Freestyle Libre 2|The FSL will be placed on patient for 28 days to measure interstitial glucose
47929388|NCT05676593|OTHER|Therapeutic education|Therapeutic education
47929389|NCT03398278|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
47929390|NCT03398278|DRUG|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
48098362|NCT06628388|BEHAVIORAL|Minimal Intervention|Consisting general advice on women health with the education booklet. No risk-based services nor active referral will be offered during the waitlist control exposure. Participants will be switched to receive intervention from 6-month.
48279951|NCT03976089|BEHAVIORAL|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
48279952|NCT01011257|DRUG|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
48452864|NCT03592420|BEHAVIORAL|Interdisciplinary multicomponent interventions|
47929391|NCT05602896|OTHER|Sepsis education|The education program has been reviewed and approved by BJH Center for Practice Excellence
47929392|NCT03920540|COMBINATION_PRODUCT|GC1111|GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
47929393|NCT03920540|COMBINATION_PRODUCT|Comparator|Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
48452865|NCT03592420|BEHAVIORAL|Usual care|standard care
48452866|NCT05163847|BIOLOGICAL|Cam2020 M2SR H3N2 influenza vaccine|Administered intranasally on Day 1
47929394|NCT04902300|OTHER|Data collection|evaluation of internet addiction
47929395|NCT00006212|DRUG|cisplatin|
47929396|NCT00006212|DRUG|vinblastine sulfate|
47929397|NCT00006212|RADIATION|phosphorus P32|
47929398|NCT00006212|RADIATION|radiation therapy|
48279953|NCT01011257|DRUG|Clopidogrel|clopidogrel 75 mg bid
48279954|NCT00603005|DEVICE|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
48279955|NCT01886664|DRUG|sevoflurane|
48279956|NCT01886664|DRUG|Desflurane|
48452867|NCT05163847|BIOLOGICAL|Fluzone HD IIV|Administered intramuscularly on Day 1
48452868|NCT05163847|OTHER|IN Placebo|Administered intranasally on Day 1
48452869|NCT05163847|OTHER|IM Placebo|Administered intramuscularly on Day 1
47929399|NCT02057042|BEHAVIORAL|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
47929400|NCT02057042|BEHAVIORAL|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
47929401|NCT04872270|PROCEDURE|Total Shoulder Arthroplasty|Participant will have total shoulder replacement
47929402|NCT04872270|DRUG|Caffeine Pill|2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen
47929403|NCT04872270|DRUG|Percocet 10Mg-325Mg Tablet|given postoperatively as standard post-op pain management
47929404|NCT04872270|DRUG|Zofran 4Mg Tablet|given postoperatively as standard post-op management
47929405|NCT01467778|DEVICE|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
47929406|NCT01467778|DEVICE|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
48622243|NCT01021384|BEHAVIORAL|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
47929407|NCT04783675|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
47929408|NCT05043376|DRUG|Standard of care|Standard COVID-19 care as per the hospital guidelines
47929409|NCT05043376|DIETARY_SUPPLEMENT|BLIS K12|Daily 2 oral BLIS K12 tablets for up to 14 days.
47929410|NCT02871882|RADIATION|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA \[diethylenetriaminepentaacetic acid\] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
48622244|NCT04426656|BEHAVIORAL|Phone application|"The mini-app (used in Part 2) has four main functions:~1. a knowledge center that contains a series of HIV-, sexual health-, and PrEP-related educational articles in Chinese;~2. an HIV self-test toolkit ordering system that allows users to order a finger-prick HIV rapid test toolkit and shipped to home for free (one piece at a time);~3. an asynchronous message function that allows users to chat with a study staff (C.Li); and~4. a user profile page where users can manage all HIV test orders."
47929411|NCT02871882|OTHER|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
47929412|NCT02871882|DRUG|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
48279957|NCT00134914|DRUG|Buprenorphine|single doses given by sublingual and parenteral routes
48622245|NCT04718753|BEHAVIORAL|Mindful breathing intervention|Mindful breathing intervention audio, which is used in mindfulness-based interventions, will be sent to the participants once per day.
48622246|NCT05448937|PROCEDURE|Lesion sterilization and tissue repair|Pulp therapy for necrotic primary molars
48622247|NCT05448937|PROCEDURE|zinc oxide and eugenol pulpectomy|Pulp therapy for necrotic primary molars
48622248|NCT05619523|BEHAVIORAL|Developing Inclusive Youth (DIY)|Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
48622249|NCT02235740|DRUG|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
47929413|NCT02871882|OTHER|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
47929414|NCT01246154|OTHER|EXERCISE TRAINING|EXERCISE TRAINING
47929415|NCT05624710|DRUG|INCB054707|INCB054707 75 mg will be administered orally on Day 1.
47929416|NCT00004071|DRUG|leflunomide|
47929417|NCT00004071|DRUG|mitoxantrone hydrochloride|
47929418|NCT00004071|DRUG|prednisone|
47929419|NCT03876301|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
47929420|NCT03869801|PROCEDURE|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
47929421|NCT03869801|PROCEDURE|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
47929422|NCT00706498|DRUG|BI 2536|
48279958|NCT03038022|DRUG|MGL-3196|Oral
48279959|NCT03038022|DRUG|Placebo|Oral
47929423|NCT03603171|DIAGNOSTIC_TEST|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
48452870|NCT03465839|BEHAVIORAL|Education for improving handovers quality|Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
47929424|NCT03603171|DIAGNOSTIC_TEST|R-PAct|A Rasch-built Pompe-specific activity scale.
47929425|NCT03603171|DIAGNOSTIC_TEST|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
47929426|NCT03603171|DIAGNOSTIC_TEST|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
47929427|NCT03603171|DIAGNOSTIC_TEST|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
47929428|NCT03603171|DIAGNOSTIC_TEST|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
47929429|NCT03603171|DIAGNOSTIC_TEST|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
47929430|NCT03603171|DIAGNOSTIC_TEST|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
47929431|NCT03603171|DIAGNOSTIC_TEST|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
47929432|NCT03603171|DIAGNOSTIC_TEST|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
47929433|NCT03603171|DIAGNOSTIC_TEST|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference \> 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
48452871|NCT03465839|BEHAVIORAL|Education for improving bedside handovers|In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
48452872|NCT05464563|DEVICE|Electroencephalogram|An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
48452873|NCT03469843|OTHER|Non intervention|patients without intervention
48452874|NCT04089917|DEVICE|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
48452875|NCT05178927|DEVICE|HoloLens v2|The HoloLens v2 will be used to access the participant's hologram \& set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
47929434|NCT03603171|DIAGNOSTIC_TEST|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
47929435|NCT03603171|DIAGNOSTIC_TEST|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
47929436|NCT03603171|DIAGNOSTIC_TEST|Quick motor function test|Assessment of proximal motor function.
47929437|NCT03603171|DIAGNOSTIC_TEST|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
47929438|NCT03603171|DIAGNOSTIC_TEST|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
47929439|NCT03603171|DIAGNOSTIC_TEST|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
47929440|NCT03603171|DIAGNOSTIC_TEST|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
47929441|NCT03603171|DIAGNOSTIC_TEST|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
47929442|NCT03239665|BEHAVIORAL|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
48452876|NCT05571592|DRUG|Cannabidiol|Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a CBD purity ≥98%. Imported from Ananda Scientific
48452877|NCT05571592|DRUG|Placebo|"Drug: Placebo~Placebo softgel capsule formulation."
48452878|NCT01222234|DRUG|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
48452879|NCT01222234|DEVICE|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
48452880|NCT01222234|DRUG|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
48452881|NCT03835689|BEHAVIORAL|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focused on skill learning for parents
48452882|NCT01316055|DRUG|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
48452883|NCT00426621|DRUG|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
48452884|NCT00426621|DRUG|Placebo|4 grams per knee, 4 times per day, for 12 weeks
48452885|NCT01111448|DRUG|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
48452886|NCT02951858|BEHAVIORAL|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
48452887|NCT02951858|BEHAVIORAL|Control Group|The participants only receive the materials about the harm of substance use.
48452888|NCT06120803|DRUG|Esomeprazole 40 mg|Enrolled patients will receive 40 mg of esomeprazole (two pills of 20 mg strength of esomeprazole) once daily before breakfast for the entire duration of TRT (including the weekends and any interim gap period) and for two weeks after completion of thoracic radiation therapy.
48452889|NCT04728542|DEVICE|ORIGIN PS System|70 surgeries with the ORIGIN PS System
48452890|NCT04728542|DEVICE|VANGUARD PS System|70 surgeries with the VANGUARD System
48452891|NCT02055547|DRUG|MK-8521 35μg|Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)
47929443|NCT03239665|BEHAVIORAL|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
47929444|NCT00481507|OTHER|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
47929445|NCT00481507|OTHER|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
48098363|NCT04904757|DEVICE|Contrast-enhanced spectral mammography (CESM)|CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
48098364|NCT03999944|DEVICE|positive airway pressure system|Positive Airway Pressure System
48622250|NCT02235740|DRUG|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
47929446|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
48098365|NCT03732820|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
48098366|NCT03732820|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
48098367|NCT06294951|DIAGNOSTIC_TEST|fMRI|The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
48098368|NCT03919617|DRUG|REMD-477|4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
48098369|NCT01434303|DRUG|Entinostat|Given PO
48098370|NCT01434303|OTHER|Laboratory Biomarker Analysis|Correlative studies
48098371|NCT01434303|DRUG|Lapatinib Ditosylate|Given PO
48098372|NCT01434303|BIOLOGICAL|Trastuzumab|Given IV
48098373|NCT02712619|DRUG|Metformin|
48098374|NCT02396940|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
48098375|NCT02396940|DEVICE|2D HD laparoscopy|Placebo
48098376|NCT00881335|DEVICE|flutter mucus clearance device|five minutes every sessions, three sessions per day
48279960|NCT05887635|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
48279961|NCT03139292|DEVICE|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
48279962|NCT03139292|DEVICE|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
48279963|NCT04958785|DRUG|Magrolimab|Administered intravenously
48279964|NCT04958785|DRUG|Nab-Paclitaxel|Administered intravenously
48279965|NCT04958785|DRUG|Paclitaxel|Administered intravenously
48279966|NCT04958785|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
48279967|NCT06220604|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
48279968|NCT06220604|DRUG|JNJ-77242113 Matching Placebo|JNJ-77242113 matching placebo will be administered orally.
48279969|NCT06220604|DRUG|Deucravacitinib|Deucravacitinib will be administered orally.
48279970|NCT06220604|DRUG|Deucravacitinib Matching Placebo|Deucravacitinib matching placebo will be administered orally.
48279971|NCT05269355|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
48279972|NCT05269355|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
47929447|NCT05579171|DEVICE|Picosecond 755nm Alexandrite Laser|Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
47929448|NCT05117957|DRUG|Sorafenib|Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
47929449|NCT05666115|DIETARY_SUPPLEMENT|Probiotic group|During the first 4 weeks, patients will be instructed to take two capsules of Enterelle plus (Bromatech lab, Manno, Switzerland) during morning time, before or after breakfast. Enterelle plus contains specific strains, i.e., S boulardi, E faecium, and acidophilus, that contribute to reduce the mycotic flora and modulate the gastrointestinal transit. For the next 8 weeks, participants will be told to ingest two capsules of Adomelle (Bromatech lab, Manno, Switzerland) at night, during or right after dinner. Adomelle contains several strains, including Bifidobacterium breve, that help to reduce abdominal fat, pain, and gas, and control the frequency of deposition
47929450|NCT05666115|OTHER|Exercise group|This type of intervention has shown to benefit patients with several chronic conditions 23, including axSpA 13. Exercises combined high knees, lunges, basic burpees, plank, skipping, mountain climbers, and squats with jumps. The training routine will be conducted three times per week, and each session will last around 8 minutes (2 sets of 4 minutes, with a 10 second rest between them). All sessions will be individually tailored and supervised by a senior professional with a degree in Physiotherapy and Sciences of Physical Activity and Sport. Overall, participants will be told to continue exercising if low to moderate bearable pain appeared during training.
47929451|NCT02236182|DRUG|Ipratropium Bromide low dose|
47929452|NCT02236182|DRUG|Placebo|
47929453|NCT02236182|DRUG|Ipratropium Bromide high dose|
47929454|NCT04964193|DRUG|Elzsa film-coated tablet|Administered with 240 mL of water
47929455|NCT04964193|DRUG|Diane-35 Sugar-coated tablet|Administered with 240 mL of water
47929456|NCT02346890|DRUG|AZD1722|
47929457|NCT02346890|DRUG|Renvela|
47929458|NCT05306821|OTHER|Comprehensive electronic tool in the electronic medical chart|Use of a comprehensive electronic tool in the electronic medical chart to help the stratification of risk of VTE and the subsequent prescription of an adequate thromboprophylaxis
47929459|NCT05306821|OTHER|Educative sessions|Educative sessions on thromboprophylaxis
47929460|NCT05306821|OTHER|Pocket card|Pocket card (guide for thromboprophylaxis)
47929461|NCT05178745|DRUG|Fluorouracil|Pharmaceutical Form: solution for injection Route of Administration: intravenous (IV), intravenous or intra-arterial infusion
47929462|NCT05178745|DRUG|Aflibercept|Pharmaceutical Form: concentrate solution for infusion Route of Administration: IV infusion
47929463|NCT05178745|DRUG|Irinotecan|Pharmaceutical Form: solution for injection Route of Administration: IV infusion
47929464|NCT03567317|DEVICE|CPAP withdrawal|Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
47929465|NCT00041587|DRUG|IL13-PE38QQR|
47929466|NCT00041587|PROCEDURE|targeted fusion protein therapy|
47929467|NCT00041587|PROCEDURE|surgery|
47929468|NCT05290376|PROCEDURE|surgical placement of long dental implants|Two interforaminal implants were placed in the canine region
47929469|NCT05290376|DEVICE|overdenture supported by RTX attachment system|Control group: Implants were loaded after three months by RTX supported overdenture study group: Implants were loaded after four weeks by RTX supported overdenture
47929470|NCT05384951|DIETARY_SUPPLEMENT|HMB + Vitamin D3|The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
47929471|NCT06294743|PROCEDURE|Posterior tibial nerve neuroprolotherapy|Real-time ultrasound guided needle injecting 10ml of 5% dextrose solution around the posterior tibial nerve to elicit a neurostimulatory response.
47929472|NCT06294743|DRUG|Acetaminophen 500Mg Tab|Oral acetaminophen 500mg tab stat, followed by Q6h if needed.
47929473|NCT03120988|BIOLOGICAL|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
47929474|NCT06388044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is a third-wave cognitive behavioral therapy. ACT aims to increase psychological flexibility through six core processes: acceptance, cognitive defusion, present-moment awareness, self as context, values, and committed action.
47929475|NCT03450980|OTHER|EyeTurn App|App software which analyzes the position of ocular surface reflections in a photograph to quantify eye misalignment (strabismus)
48098377|NCT01759979|PROCEDURE|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
48098378|NCT01759979|PROCEDURE|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
47929476|NCT04401527|DRUG|Sodium Nitrite|Continuous intravenous infusion of Sodium Nitrite Injection
47929477|NCT04401527|DRUG|Normal Saline|Continuous intravenous infusion of Normal Saline
47929478|NCT01868919|BEHAVIORAL|Positive Parenting Program|Level 3 or 4 of Triple P
47929479|NCT05307367|BEHAVIORAL|Exercise training|Patients will be enrolled in a 8 week, supervised, single-leg kicking training intervention (1h, or as long as possible, 60-70% peak workload (PWL), 2-5 days a week). Healthy age-, body weight-, gender- and activity level-matched control subjects will undertake the intervention matched to the %PWL obtained by the patients who complete the study.
47929480|NCT05577273|DRUG|Cefuroxime axetil (trimethoprim/sulfamethoxazole if penicillin allergy)|single dose of P.O. Cefuroxime Axetil 500 mg. For penicillin allergy patients, single dose of P.O. Trimethoprim/Sulfamethoxazole 160mg/800mg
47929481|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
48098379|NCT03146351|OTHER|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
47929482|NCT00701623|DRUG|heparin|patients will receive the application of one of two types of heparin directly on the injured area
47929483|NCT00701623|DRUG|folder water|patients will receive the application of folder water directly on the injured area
47929484|NCT02220998|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
47929485|NCT02220998|DRUG|SOF|SOF 400 mg tablet administered orally once daily
48452892|NCT02055547|DRUG|MK-8521 100μg|Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)
48452893|NCT02055547|DRUG|MK-8521 125μg|Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)
48452894|NCT02055547|DRUG|MK-8521 150μg|Single dose 150μg SC injection in a treatment period (Part 1, Panel B)
48452895|NCT02055547|DRUG|MK-8521 175μg|Single dose 175μg SC injection in a treatment period (Part 1, Panel B)
48452896|NCT02055547|DRUG|MK-8521 200μg|Single dose MK-8521 200μg SC injection in a treatment period (Part 1, Panel B)
48452897|NCT02055547|DRUG|MK-8521 300μg|Single dose 300μg SC injection in a treatment period (Part 1, Panel A)
48452898|NCT02055547|DRUG|MK-8521 50/72μg|MK-8521 50μg SC injection Days 1-5 and 72μg Days 6-10 (Part 2, Panel C)
48452899|NCT02055547|DRUG|MK-8521 72/125μg|MK-8521 72μg SC injection Days 1-7 and 125μg Days 8-14 (Part 2, Panel F)
47929486|NCT02220998|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
47929487|NCT02721771|PROCEDURE|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
47929488|NCT04566445|DRUG|GT005: Medium Dose|The study will test two doses of GT005: Medium Dose and High Dose.
47929489|NCT04566445|DRUG|GT005: High Dose|The study will test two doses of GT005: Medium Dose and High Dose.
47929490|NCT03219463|DIETARY_SUPPLEMENT|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
47929491|NCT05664698|BEHAVIORAL|SKILLS-ER|The intervention (SKILLS-ER) has been developed by the research group, and aims to increase a participant's emotion regulation capacity by targeting different stages of the emotion regulation process proposed by the extended process model of emotion, i.e. identification, selection, implementation and monitoring (Sheppes, Suri \& Gross, 2015). SKILLS-ER will comprise of eight sessions and include identification and differentiation of emotions, tolerance/acceptance of emotions, education of different regulatory skills, as well as on how to select, implement and monitor strategies. Sessions will take place at the Uppsala child- and adolescent psychiatry outpatient unit and consist of activating and experiential exercises administered by a clinical psychologist. Participants will gain access to internet-delivered material, such as homework assignments in-between sessions. SKILLS-ER will be delivered individually to the participants, where their parents will be involved in some sessions.
47929492|NCT03557996|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush
47929493|NCT03557996|DRUG|Sodium Fluoride Varnish|NaF will be applied with a brush
48098380|NCT06561165|DEVICE|Standard HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
47929494|NCT01302977|PROCEDURE|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
47929495|NCT05642650|DEVICE|novel wearable device|Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge.
48098381|NCT06561165|DEVICE|Multifocal network targeted HD-tDCS intervention|Participants will have three sessions along with behavioral assessments.
48098382|NCT06561165|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will have an MRI before or after having HD-tDCS intervention.
48098383|NCT06107920|DRUG|Neoadjuvant chemotherapy|Diverting stoma- neoadjuvant chemotherapy - colectomy - +/- adjuvant chemotherapy
48098384|NCT03061344|BIOLOGICAL|DVIU treated with liquid buccal mucosal graft|DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
48452900|NCT02055547|DRUG|MK-8521 100/150μg|MK-8521 100μg SC injection Days 1-5 and 150μg Days 6-10 SC in a treatment period (Part 2, Panel D)
48452901|NCT02055547|DRUG|MK-8521 125/150μg|MK-8521 SC 125μg SC injection Days 1-5 and 150μg Days 6-10 (Part 2, Panel E)
48452902|NCT02055547|DRUG|Placebo|Placebo to MK-8521 SC injection in a treatment period (Parts 1, 2, and 3)
48452903|NCT06001463|DRUG|CSMed Dressing|Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
48452904|NCT06386094|DIAGNOSTIC_TEST|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
48452905|NCT01058213|BEHAVIORAL|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (\~1-2 seconds for concentric and eccentric contraction) will be used.
47929496|NCT03642704|DRUG|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
47929497|NCT02235727|DRUG|GBR 900|
47929498|NCT02235727|DRUG|Placebo|
47929499|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Full dose|350 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts
47929500|NCT03034668|DIETARY_SUPPLEMENT|CS16-003 Half dose|175 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + maltodextrin 175 mg
47929501|NCT03034668|DIETARY_SUPPLEMENT|Placebo|Maltodextrin: 350 mg
48452906|NCT01058213|BEHAVIORAL|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
47929502|NCT05883826|BEHAVIORAL|sexual health training|The 16-hour sexual health training will be given for 4 weeks. Case discussions using the PLISSIT Model will be held in the training content.
47929503|NCT01251640|DRUG|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
47929504|NCT04052802|OTHER|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
47929505|NCT02819778|PROCEDURE|usual care|
48452907|NCT03600883|DRUG|sotorasib|Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
48452908|NCT03600883|DRUG|Anti PD-1/L1|Administered as an intravenous (IV) infusion
48452909|NCT03600883|DRUG|Midazolam|Administered as an oral hydrochloride (HCI) syrup
48452910|NCT04942535|BEHAVIORAL|Social Incentive Gamification|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Each participant signs a pre-commitment contract. Participants are entered into a game with their family members. Each family receives 70 points weekly. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family keeps its points; if not, they lose 10 points. The participant is notified the following day if they were the family rep.~At the end of the week, if the family has 40 points or more, they advance 1 level. If they have less than 40 points, the family drops down 1 level. Each family team starts in the middle of 5 levels.~At the end of the intervention, families in the top 2 levels receive a small gift.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
48622251|NCT02178956|DRUG|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
48622252|NCT02178956|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
47929506|NCT02819778|PROCEDURE|S100B|
47929507|NCT00886652|OTHER|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
47929508|NCT03130647|DEVICE|Focused ultrasound|Focused ultrasound
47929509|NCT05463198|DEVICE|CM-1600|Subjects undergoing blood donation will be connected to the CM-1600 device.
47929510|NCT02864901|DRUG|KSL-W|Plaque reducing gum
48622253|NCT02178956|OTHER|Placebo|Orally two times daily
47929511|NCT02864901|DRUG|Chewing Gum Placebo|
47929512|NCT03997045|BEHAVIORAL|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
47929513|NCT05677672|BIOLOGICAL|Human TH-SC01 Cell Injection|Single injection of 0.6×10\^7,1.2×10\^8, 1.8×10\^8 cells/kg
47929514|NCT05677672|OTHER|Saline solution|saline solution will be given at the same quantity and following the same schedule
47929515|NCT01537107|DRUG|vismodegib|Given PO
47929516|NCT01537107|DRUG|sirolimus|Given PO
47929517|NCT01537107|PROCEDURE|positron emission tomography|Correlative studies
47929518|NCT01537107|PROCEDURE|computed tomography|Correlative studies
47929519|NCT01537107|OTHER|pharmacological study|Correlative studies
47929520|NCT01537107|OTHER|laboratory biomarker analysis|Correlative studies
47929521|NCT01537107|RADIATION|fludeoxyglucose F 18|Correlative studies
47929522|NCT01998984|DRUG|ingenol mebutate|
47929523|NCT01998984|OTHER|Placebo|
47929524|NCT03782831|PROCEDURE|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
47929525|NCT03782831|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
47929526|NCT03782831|DRUG|Placebos|intravenous injection every 2 weeks
48098385|NCT05042791|COMBINATION_PRODUCT|radiation combined with pyrotinib and capecitabine|This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
47929527|NCT00941577|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
47929528|NCT00941577|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
47929529|NCT04425044|OTHER|Other|No Intervention
47929530|NCT03340103|DIETARY_SUPPLEMENT|LUTEIN ofta 0,5 gocce|LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,5% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
47929531|NCT03340103|DRUG|Placebo|Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
48622254|NCT03185351|DRUG|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
48622255|NCT03185351|DRUG|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
48622256|NCT03185351|DRUG|Midazolam|0.03 mg/kg of midazolam by I.V. route
48622257|NCT02115698|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
48622258|NCT02115698|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
48622259|NCT02115698|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
48622260|NCT02115698|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
48622261|NCT02115698|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
48622262|NCT03318458|OTHER|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
48622263|NCT06305325|BEHAVIORAL|eHealth Antenatal Coparenting Intervention|This intervention focuses on developing conflict management, problem solving, communication, and mutual support to foster positive joint parenting of an infant. A modification in the delivery of this intervention was made in the current study in order to make it deliver online. The eACoP intervention included eight antenatal videos from Feinberg's Family Foundation intervention. A website for the eACoP intervention was developed, and all the videos were uploaded to the website. These videos were 30-40 minutes each. The videos were in English and subtitles in Urdu were added to the videos. These videos were accompanied by an activity-based coparenting workbook. The coparenting workbook includes a worksheet and homework for each video and was also translated into Urdu
48622264|NCT01859091|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
48622265|NCT05117476|DRUG|CLN-619|Anti-MICA/MICB monoclonal antibody
48622266|NCT05117476|DRUG|Pembrolizumab|Keytruda
48622267|NCT04393012|OTHER|Provide alternative nurse call and communication device|Evaluate impact of providing access to the nurse call system and a speech generating device.
48622268|NCT03469804|DRUG|Pembrolizumab|Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
48622269|NCT05788380|OTHER|EXERCİSE|EXERCISE FOR HEALTH AND PAIN IMPROVEMENT
48622270|NCT03846375|BEHAVIORAL|Psychotherapy|DBT is a well-established treatment for recurrent self-harm and suicidal thoughts. The program is principle-based, but the skills training follow a manualized curriculum.
47929532|NCT02822547|DRUG|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
48622271|NCT03846375|OTHER|Pre-intervention testing|Pre-intervention testing for baseline measures.
47929533|NCT02102503|BEHAVIORAL|Standard Treatment|
47929534|NCT02102503|BEHAVIORAL|MI and Medication review|
47929535|NCT05357729|DEVICE|MultiSense® remote monitoring|At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
47929536|NCT02102256|DEVICE|Auditory Brainstem Implant|
47929537|NCT00674154|DRUG|Cholecalciferol|2800 IE daily in 52 weeks
47929538|NCT03584945|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
47929539|NCT03584945|OTHER|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
47929540|NCT01848782|BEHAVIORAL|interpretation of the abstract of the systematic review|
47929541|NCT01376440|OTHER|household water treatment|household water treatment with 1.25% sodium hypochlorite
48622272|NCT03796663|BEHAVIORAL|Mindful Parenting Program|"The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines."
47929542|NCT04457388|OTHER|Tele-Yoga Therapy|Yoga practices combining with joint loosening exercises (Sukshma Vyayama), postures (Asana), breathing exercises (Pranayama), relaxation techniques and chanting ( A, U, M, and AUM { ૐ}) syllable chants meditation. Each session ended with home practice exercises given to the participants to practice everyday.
47929543|NCT04972643|DIETARY_SUPPLEMENT|EPA|EPA 2000mg Soft capsules
47929544|NCT04972643|DIETARY_SUPPLEMENT|DHA|DHA 2000mg Soft capsules
47929545|NCT04972643|DIETARY_SUPPLEMENT|Placebo|Placebo Soft capsules
47929546|NCT02715297|RADIATION|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
47929547|NCT02788877|DRUG|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
47929548|NCT00061282|DRUG|Clotrimazole|One retention enema, administered nightly
48098386|NCT06256445|DRUG|Polyene Phosphatidylcholine|Formulated as an injectable solution containing Polyene Phosphatidylcholine at concentration of 25 mg/mL
48098387|NCT06256445|DRUG|Matching placebo of AYP-101|Phosphate buffered saline placebo for injection
48452911|NCT04942535|BEHAVIORAL|Social Goals through Incentives to Charity|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Families select a charity at the beginning of the intervention. They are informed that $20 is available each week to be donated to a charity of their choice. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family gets credit for meeting their goal; if not, the entire family does not get credit. The participant is notified the following day if they were the family rep.~If the family achieves their goal on at least 4 of 7 days in a week, $20 is donated to charity.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
48452912|NCT04942535|BEHAVIORAL|Daily Performance Feedback|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
48279973|NCT05269355|OTHER|Placebo|Placebo will be administered as per the schedule specified in the arm description.
48279974|NCT03935971|DRUG|Dupilumab|See arm/group description
48279975|NCT06655077|OTHER|RA PRO Dashboard|The RA PRO Dashboard was developed by UCSF rheumatology investigators in collaboration with the UCSF SOMTech Unit. Briefly, investigators used a human-centered design approach to build a new, EHR-integrated, patient-facing visualization tool that displays RA outcome data to RA patients during clinical visits. The RA PRO dashboard was tailored for deployment at the UCSF Health's rheumatology clinic using a EHR side-car application (Salesforce). The dashboard was launched into the production environment in August 2021. With the launch, investigators integrated quality improvement, user monitoring, and lean management techniques to promote use of RA outcomes and the dashboard (for clinicians granted access) during clinical visits.
48452913|NCT05336422|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
48452914|NCT06289738|OTHER|ICF|Matching the answers given to the question set consisting of 6 open-ended questions with ICF
48622273|NCT03796663|BEHAVIORAL|MATCH BPT Program|The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
47929549|NCT01128023|OTHER|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
47929550|NCT02483871|DRUG|Rosuvastatin|
47929551|NCT05535205|OTHER|Digital preoperative assessment|a digital preoperative assessment for patient requiring surgery
47929552|NCT05535205|OTHER|Face-to-face preoperative assessment|a face-to-face preoperative assessment for patient requiring surgery
48098388|NCT04678934|PROCEDURE|TAVR|Transcatheter aortic valve replacement
48098389|NCT00270114|DRUG|epoetin alfa|
48098390|NCT05173571|COMBINATION_PRODUCT|Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)|Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
48098391|NCT01711918|DRUG|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
48098392|NCT06042114|BEHAVIORAL|Surah Inshirah|Patients in the experimental group will be listened to the Surah al-Inshirah after surgery and its effect on pain and anxiety levels will be evaluated.
48279976|NCT02087566|DRUG|600 mg linezolid|
48279977|NCT06250387|PROCEDURE|Endobronchial ultrasound transbronchial cryobiopsy|"Endobronchial Ultrasound (EBUS) :~EBUS is usually performed under general anesthesia using a laryngeal masque. It has a linear ultrasonography with a 7.5 MHz frequency. The distal part of the endoscope contains a water filled balloon used as a liquid interface, camera, light source and a working channel. The needle is protected by a sheath to prevent working channel damage. The endoscope is connected to a processor that reflects both endobronchial and ultrasound images on a screen.~EBUS - TBNA : EBUS - Transbronchial needle aspiration EBUS - TBCB: EBUS - Transbronchial Cryo Biopsy"
47929553|NCT02009605|DRUG|Icotinib|125mg, oral administration, three times per day.
47929554|NCT00606047|RADIATION|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
47929555|NCT02181517|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
47929556|NCT02181517|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
47929557|NCT02181517|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
47929558|NCT05065554|DRUG|Acalabrutinib|Dose per protocol, oral twice daily per cycle
47929559|NCT05065554|DRUG|Rituximab|Premedications (including acetaminophen, an antihistamine, and a steroid) will be given per institutional guideline Dosage determined per protocol and cycle timepoint, Route IV or SQ per protocol and cycle timepoint, schedule per protocol and cycle timepoint
47929560|NCT02846220|BEHAVIORAL|Overcoming Immunity to Change health coaching|
47929561|NCT00622271|BEHAVIORAL|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
47929562|NCT00637143|DRUG|Tacrolimus|Oral
47929563|NCT00637143|DRUG|Cyclosporine|Oral
47929564|NCT03495609|DRUG|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
47929565|NCT02562118|DRUG|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
47929566|NCT03737227|RADIATION|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
47929567|NCT01044329|DRUG|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
47929568|NCT01044329|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
47929569|NCT04138966|DEVICE|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
47929570|NCT04138966|DEVICE|Skin Conductance|Measures skin conductance as a surrogate to nociception
47929571|NCT02758405|DRUG|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
47929572|NCT02758405|DRUG|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
47929573|NCT02758405|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
47929574|NCT02528721|DEVICE|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
47929575|NCT05628688|DIAGNOSTIC_TEST|Insight Pro Device for Diagnosis|Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders
47929576|NCT02232880|DRUG|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
47929577|NCT02232880|DRUG|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
47929578|NCT03643978|OTHER|Decision aid|The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
48098393|NCT01049620|DRUG|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
48098394|NCT04461756|DRUG|PPP001|inhalation (vape)
48098395|NCT05235750|BEHAVIORAL|Self-affirmation writing|Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
48279978|NCT06448988|OTHER|Park Bench position|To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
48622274|NCT02166879|BEHAVIORAL|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
47929579|NCT05375773|OTHER|PVP-I Nasal Irrigation and gargling|The solution is prepared by the researcher, which contains 0.5% PVP-I and 2.27% hypertonic saline
47929580|NCT06309550|DIAGNOSTIC_TEST|exercise test|exercise test
47929581|NCT00600054|BIOLOGICAL|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
47929582|NCT03905252|OTHER|sample analysis|blood, Random urine sample and 24-hour urine samples
47929583|NCT05974423|DRUG|Tylenol, Ibuprofen, and Oxycodone|A script for these three medications will be provided
48452915|NCT06531122|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
47929584|NCT05974423|DRUG|Tylenol and Ibuprofen only|A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
47929585|NCT00654147|DRUG|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
47929586|NCT00654147|DRUG|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
47929587|NCT00003296|BIOLOGICAL|filgrastim|
47929588|NCT00003296|DRUG|pegylated liposomal doxorubicin hydrochloride|
47929589|NCT05026190|DIAGNOSTIC_TEST|transrectal ultrasound|we perform trus to identify the cause of azospermia and its type either obstructive or not
47929590|NCT02475824|DRUG|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
47929591|NCT02475824|DRUG|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
47929592|NCT02475824|DRUG|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
47929593|NCT02475824|DRUG|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
47929594|NCT04300959|DRUG|Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks."
47929595|NCT04300959|DRUG|Gemcitabine Plus(+)Cisplatin|"Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks."
47929596|NCT03030742|OTHER|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~* Satisfaction with pain control 2-4 weeks postpartum~* Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~* Patient characteristics associated with high opioid use~* Methods of storage and disposal of unused opioids"
47929597|NCT01211431|DRUG|Reference|Intrathécale morphine is used for post-cesarean pain control
47929598|NCT01211431|DRUG|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
47929599|NCT02587247|DRUG|TF2 antibody/68Ga-IMP-288|TF2 antibody coupled with 68Ga-IMP-288
47929600|NCT02827656|DRUG|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
47929601|NCT02827656|DRUG|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
47929602|NCT04685161|PROCEDURE|Surgical extrusion|Invasive treatment option for fractured tooth
47929603|NCT04685161|DEVICE|Fibre post|Easy approach for treatment
47929604|NCT06505408|DIETARY_SUPPLEMENT|Multivitamin|4 capsules of Perelel Health Conception Support Multivitamin Pack (consisting of vitamins, minerals, and omega ingredients) consumed daily for 12 weeks
47929605|NCT06505408|DIETARY_SUPPLEMENT|Placebo|4 placebo capsules consumed daily for 12 weeks
48622275|NCT02511756|DEVICE|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
48622276|NCT05707169|PROCEDURE|Saphenous Ablation|Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.
48622277|NCT05707169|DEVICE|Endogenous Laser Ablation (EVLA)|Endogenous Laser Ablation (EVLA)
47929606|NCT02491359|DRUG|Carfilzomib|Given IV
47929607|NCT02491359|OTHER|Laboratory Biomarker Analysis|Correlative studies
48622278|NCT05707169|DRUG|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline|mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
47929608|NCT02491359|OTHER|Quality-of-Life Assessment|Ancillary studies
47929609|NCT02491359|OTHER|Questionnaire Administration|Ancillary studies
47929610|NCT02591329|BEHAVIORAL|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
47929611|NCT02591329|BEHAVIORAL|Standard Care|
47929612|NCT02761837|BEHAVIORAL|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
47929613|NCT02761837|BEHAVIORAL|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
47929614|NCT02069340|DRUG|zoledronic acid|Given IV
47929615|NCT02069340|OTHER|pharmacological study|Correlative studies
47929616|NCT01439698|DEVICE|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
47929617|NCT03419975|DRUG|TJO-002|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
47929618|NCT03419975|DRUG|Latanoprost|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
47929619|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
47929620|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
47929621|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
47929622|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
47929623|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
47929624|NCT01227629|DRUG|dabigatran with ASA|dose comparison in combination
47929625|NCT01227629|DRUG|warfarin|comparator
47929626|NCT01227629|DRUG|dabigatran without ASA|dose comparison
47929627|NCT01227629|DRUG|dabigatran without ASA|dose comparison
47929628|NCT01227629|DRUG|dabigatran without ASA|dose comparison
47929629|NCT00001131|DRUG|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10\^6 mIU per day for the entire duration of therapy
47929630|NCT00001131|DRUG|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
47929631|NCT02723071|DRUG|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
48452916|NCT06531122|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
47929632|NCT02298335|DRUG|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
47929633|NCT02933671|PROCEDURE|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
47929634|NCT02933671|PROCEDURE|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
47929635|NCT02933671|DRUG|Ropivacaine|Local anesthetic (numbing drug)
47929636|NCT02933671|DRUG|Saline|Salt water placebo
47929637|NCT04521712|DIAGNOSTIC_TEST|2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor|All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
47929638|NCT04985344|DRUG|Propranolol Oral Product|Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.
47929639|NCT04985344|DRUG|Placebo|Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
47929640|NCT04985344|OTHER|memory reactivation|90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
47929641|NCT00728143|DIETARY_SUPPLEMENT|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
47929642|NCT04664894|DRUG|Sofosbuvir|the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population
48452917|NCT00374231|DRUG|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
48452918|NCT00374231|DRUG|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
48452919|NCT00374231|DRUG|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
48452920|NCT04489719|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47929643|NCT00802113|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days
47929644|NCT00802113|DRUG|Busulfan|Busulfan 3.2 mg/kg/day x 2 days
47929645|NCT00802113|DRUG|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
47929646|NCT02040727|BEHAVIORAL|Resistance Training|Supervised strength training 3 days per week for 24 weeks
47929647|NCT02040727|BEHAVIORAL|No Resistance Training|No supervised strength training throughout the study
47929648|NCT00594724|PROCEDURE|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
47929649|NCT04608461|DRUG|Pumpkin seed extract containing cream|Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
47929650|NCT04153734|DRUG|Pembrolizumab|Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
47929651|NCT04153734|DRUG|Cis Platinum|In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
47929652|NCT04153734|DRUG|Carboplatin|In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
47929653|NCT04153734|DRUG|Pemetrexed|In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
47929654|NCT04153734|DRUG|nab paclitaxel|In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
47929655|NCT01027390|BEHAVIORAL|physical training exercise|physical exercise training at the work site during work time
48098396|NCT05216237|DRUG|Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)|for 2-6 cycles followed by Sindilizumab plus Tegafur gimeracil oteracil potassium capsules.
48279979|NCT03955367|RADIATION|Prophylactic extended-field Irradiation|CTV covers pelvis and para-aortic lymph nodes region.
48279980|NCT03955367|RADIATION|Pelvic irradiation|CTV covers pelvis.
48279981|NCT03955367|RADIATION|Intracavitary brachytherapy|The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.
47929656|NCT05622162|DRUG|Radiopharmaceutical 18F-JK-PSMA-7|"The Investigational product 18F-JK-PSMA-7 is a diagnostic radiopharmaceutical for use with positron emission tomography.~18F-JK-PSMA-7 is administered as direct intravenous injection. One single administration of 2-4 MBq/kg of 18F-JK-PSMA-7 is scheduled in each patient included in this study."
47929657|NCT05622162|DRUG|Radiopharmaceutical 18F-Fluorocholine|"The active substance of Comparator is 18F-Fluorocholine. The Comparator will be a 18F-Fluorocholine with a Marketing Authorisation in Italy that will be used in compliance with its Summary of Product Characteristics (SmPC).~18F-Fluorocholine is administrated as direct intravenous injection. One single administration of 18F-Fluorocholine is scheduled in each patient included in this study."
47929658|NCT06433596|OTHER|Platelet-rich plasma|3 injections of 10 cc of autologous Platelet Rich Plasma (PRP), weeks 1, 5 and 9
48452921|NCT04489719|OTHER|Questionnaire Administration|Ancillary studies
48452922|NCT04489719|DRUG|Radium Ra 223 Dichloride|Given IV
47929659|NCT06433596|OTHER|Shock waves therapy|6 sessions of focal shock waves, 1 per week
47929660|NCT06433596|OTHER|Placebo PRP|3 injections of 10 cc of saline solution, weeks 1, 5 and 9
47929661|NCT06433596|OTHER|Sham shock waves therapy|6 sessions of sham shock waves, 1 per week
47929662|NCT04645121|DEVICE|Carbon Monoxide-based Rebreathing|6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
47929663|NCT04645121|DEVICE|Bioimpedance|Measures total volume, intra and extracellular volume.
47929664|NCT04645121|RADIATION|Radioactive labelling of erythrocytes and albumin|Measure blood volume, plasma volume and erythrocyte volume.
48279982|NCT03955367|DRUG|Concurrent chemotherapy|Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
47929665|NCT00535574|DRUG|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
47929666|NCT00535574|DRUG|bexarotene|75 mg/day 6 weeks
47929667|NCT01090895|DRUG|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
47929668|NCT01090895|DRUG|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
47929669|NCT00693862|DRUG|levodopa, carbidopa, entacapone|
47929670|NCT00693862|DRUG|levodopa, carbidopa|
47929671|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Reference product
47929672|NCT01863654|DRUG|Montelukast 5 mg chewable tablets|Test product
47929673|NCT03473080|BEHAVIORAL|Internet CBT|The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
47929674|NCT02213133|DRUG|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
48452923|NCT06445049|OTHER|brief test|"The intervention is a simple brief test as follows: With the ventilator set with the patient clinical settings, it will be performed an up to 30sec-long or two inspiratory effort and-expiratory occlusion maneuver on the ventilator and/or switch the patient to pressure support for up to 30sec-long to assess the presence of intrinsic respiratory rate.~If an intrinsic respiratory rate ≥8 breaths per minute is present and P/F ratio is ≥150 it will be performed a 5-minute test in pressure support ventilation with the pressure support level to match the clinical setting of the patient. If the patient tolerates well 5 minutes in pressure support (see criteria below) the clinical team will be informed:~- It will be indicated that the patient tolerated 5 min of PSV and suggest to the clinicians and physician in charge to transition the patient to pressure support ventilation plus suggest reducing sedation."
47929675|NCT01811667|DRUG|Sirolimus|
48452924|NCT01897207|BIOLOGICAL|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
47929676|NCT03493659|BEHAVIORAL|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
47929677|NCT03493659|BEHAVIORAL|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
47929678|NCT03493659|BEHAVIORAL|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
47929679|NCT04120103|BEHAVIORAL|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
47929680|NCT04120103|OTHER|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
48279983|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
48279984|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
48279985|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
48452925|NCT00840281|DRUG|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
48452926|NCT00840281|DRUG|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
47929681|NCT01528865|DRUG|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
47929682|NCT01528865|DRUG|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
48279986|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
48279987|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
48279988|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
47929683|NCT01607827|PROCEDURE|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
47929684|NCT01607827|PROCEDURE|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
47929685|NCT03160547|OTHER|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
47929686|NCT03160547|OTHER|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI \>30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
47929687|NCT05864456|DEVICE|Prizvalve Pro™ transcatheter aortic valve system|Transcatheter Aortic Valve Replacement
47929688|NCT01659879|BEHAVIORAL|Multimedia information|
47929689|NCT01659879|BEHAVIORAL|verbal information|
47929690|NCT02342093|DRUG|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
47929691|NCT02342093|DRUG|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
48452927|NCT05251727|DRUG|thrombomodulin alfa|Weight based dose of reconstituted treatment
48452928|NCT05251727|DRUG|Placebo|Weight based dose of reconstituted treatment
47929694|NCT04357301|DEVICE|Closed-loop vasopressor|The system will adjust the norepineprhine infusion rate based on a target SAP of 130 mmHg in 20 patients
47929695|NCT03888638|PROCEDURE|Hepatectomy|Removal of a part of the liver because of tumor
47929696|NCT03706651|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
47929697|NCT04662580|DRUG|ARX517|ARX517 is an ADC consisting of a humanized anti-PSMA monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two (2) proprietary microtubule-disrupting toxins referred to as AS269.
47929698|NCT05214053|DEVICE|Cone Beam CT|Each patient will undergo a Cone Beam CT and a MDCT
47929699|NCT03593473|DRUG|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
47929700|NCT03593473|DRUG|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
47929701|NCT06257602|PROCEDURE|Tragal graft tympanoplasty|Comparison study between Endoscopic and microscopic tympanoplasty using tragal graft
47929702|NCT04304547|DRUG|CKD-828, D097, D337, CKD-348 T1, CKD-348 T2|"Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet"
48452929|NCT02193724|OTHER|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
47929703|NCT04304547|DRUG|CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,|"Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once"
47929704|NCT04304547|DRUG|CKD-348 T2, CKD-348 T1, CKD-828, D097, D337|"Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet"
48452930|NCT02193724|OTHER|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
48452931|NCT04512235|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
47929705|NCT04982601|OTHER|Yoga Exercises|Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
47929706|NCT06506370|OTHER|nonsurgical periodontal treatment|The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.
47929707|NCT05785910|DIAGNOSTIC_TEST|IUDS|a battery of neuropsychological test
47929708|NCT05401396|OTHER|Swimming immediately after eating|After having the last bite of lunch, the participants will swim in the pool with a specific distance.
47929709|NCT04996004|DRUG|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
47929710|NCT04996004|DRUG|Doxorubicin|75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
48279989|NCT00947349|DRUG|BI 201335 NA low placebo|Placebo
48452932|NCT04512235|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
48452933|NCT04512235|DRUG|cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen|According to institutional standard of care.
48279990|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
47929711|NCT01405066|BEHAVIORAL|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
48452934|NCT06559904|OTHER|Mediterranean diet|"The 'Mediterranean Diet Education Document', prepared by the researcher, which includes general information about the characteristics of the Mediterranean diet and the portion sizes that should be followed daily and weekly, and information on how often, how much and when to consume food groups, was provided as a diet education, and information was provided on how to record three-day food consumption.~A nutrition education compatible with the Mediterranean diet, organized by the researcher according to the individual's daily needs, was provided and a sample menu was explained to the individual face to face."
47929712|NCT01405066|BEHAVIORAL|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
47929713|NCT03532607|OTHER|Music|Patients will listen to soothing music for 30 minutes before their standard of care botox injection
47929714|NCT05915039|OTHER|Computer Assisted Learning (CAL) Module|The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.
47929715|NCT06036602|BIOLOGICAL|cAD3-Sudan Ebolavirus Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
47929716|NCT06036602|OTHER|Placebo|0.9% NaCl solution for injection.
47929717|NCT03381157|OTHER|Observational General Movements Assessments|GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
47929718|NCT02848729|DRUG|Oral Acetaminophen|Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
48452935|NCT05831657|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
47929719|NCT02848729|DRUG|IV Acetaminophen|Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
48452936|NCT05831657|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
48452937|NCT06627452|OTHER|Dynamic Neuromuscular Stabilization Training|Patients will be taught how to perform exercises in different developmental positions both manually and verbally by the DNS therapist. In the DNS concept, proper breathing patterns are important alongside stabilization, and elastic bands will be used to regulate intra-abdominal pressure (IAP) and teach correct breathing. The elastic band will be secured around the chest just below the ribcage, and the patient will be asked to expand the elastic band in all directions while inhaling, thereby regulating the IAP. After teaching IAP guidance, exercises will be conducted in developmental positions with IAP regulation. The exercises will be conducted twice a week under the supervision of a physiotherapist, and three days at home, with sessions lasting approximately 30 minutes, for a total of five days a week over a period of 12 weeks.
47929720|NCT02848729|DRUG|IV Morphine|Morphine for IV administration (0.125 mg/kg)
47929721|NCT02848729|DRUG|Placebo Tablets|Placebo tablets matching oral acetaminophen
47929722|NCT02848729|DRUG|Saline|Saline placebo matching IV acetaminophen
47929723|NCT04137107|DRUG|Oxaliplatin|Given standard of care oxaliplatin
47929724|NCT04137107|DRUG|Duloxetine Hydrochloride|Given PO
47929725|NCT04137107|DRUG|Duloxetine|Given PO
47929726|NCT04137107|OTHER|Quality-of-Life Assessment|Ancillary studies
47929727|NCT04137107|OTHER|Questionnaire Administration|Ancillary studies
47929728|NCT04137107|OTHER|Placebo|Given PO
47929729|NCT06052098|DEVICE|The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system|Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.
47929730|NCT06052098|DEVICE|The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system|Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.
47929731|NCT00004581|DRUG|Lopinavir/Ritonavir|
47929732|NCT00004581|DRUG|Nevirapine|
48279991|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
47929733|NCT00686634|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth once daily
47929734|NCT00393042|DRUG|Dexmethylphenidate|10, 20, 25-30 mg.
47929735|NCT00393042|DRUG|Mixed Amphetamine Salts, ER|10, 20, 25-30
47929736|NCT00393042|DRUG|placebo|randomized placebo week during each 4 week period
47929737|NCT04468399|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
47929738|NCT04468399|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
48279992|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
48279993|NCT00947349|DRUG|BI 201335 NA low|BI 201335 NA
48279994|NCT00947349|DRUG|BI 201335 NA high placebo|placebo
47929739|NCT05779774|BEHAVIORAL|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only \[comparison control\] v. WayToServe training plus WayToServe Plus in-service component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with \~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
47929740|NCT05779774|BEHAVIORAL|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only \[comparison control\] v. WayToServe Plus In-service Component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
47929741|NCT04191083|BEHAVIORAL|Motor imagery|This group will perform motor imagery training on motor learning of different motor tasks
47929742|NCT04191083|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.
47929743|NCT04191083|BEHAVIORAL|Action observation|This group will perform action observation training on motor learning of various motor tasks.
47929744|NCT04191083|BEHAVIORAL|Placebo intervention|This group will watch a video of a landscape without the presence of people.
47929745|NCT02935829|OTHER|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
47929746|NCT02935829|OTHER|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
47929747|NCT02935829|OTHER|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
47929748|NCT02935829|OTHER|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
47929749|NCT02935829|OTHER|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
47929750|NCT02935829|OTHER|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
47929751|NCT02349308|DEVICE|CentrosFLO Long Term Hemodialysis Catheter|
47929752|NCT01779271|DRUG|Pelubiprofen|
47929753|NCT01779271|DRUG|Loxoprofen|
47929754|NCT06086015|DEVICE|transcranial alternating current stimulation (tACS)|2mA tACS over right hemisphere, at positions F4, P4, T8 (10-10 convention)
47929755|NCT05854927|DIAGNOSTIC_TEST|3D T1 MRI sequences injected with fat saturation and black blood|3D T1 MRI sequences injected with fat saturation and black blood
47929756|NCT03813368|PROCEDURE|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
47929757|NCT03357939|DRUG|HLX03|A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
47929758|NCT03357939|DRUG|adalimumab|A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
47929759|NCT06221527|PROCEDURE|conventional group|fixation of parasymphyseal fracture using two four-hole titanium miniplates that will be placed on inferior border and another one on superior border
47929760|NCT06036147|BEHAVIORAL|Concussion-focused cognitive behavioral therapy|Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
48098397|NCT02224833|BEHAVIORAL|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~* Determination of recommended pharmacotherapeutic alternatives.~* Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
48279995|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
48622279|NCT03629301|BEHAVIORAL|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
48622280|NCT03629301|OTHER|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
48622281|NCT02588365|BEHAVIORAL|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
48622282|NCT02588365|BEHAVIORAL|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
48622283|NCT02588365|BEHAVIORAL|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
48622284|NCT02600793|DRUG|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
48622285|NCT02489201|DRUG|donafenib tosilate tablets|200mg,bid
48637443|NCT04188626|BEHAVIORAL|Driving simulator sessions|The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
48098398|NCT04827459|BEHAVIORAL|Sleep Coach App|Participants will be encouraged to interact with the mobile app daily for as much time as they wish, or for as little as 5 - 10 minutes, over a 7-week period.
48098399|NCT06632132|OTHER|Antimicrobial resistance Training in Hemodialysis Units|"The educational program developed by the researcher is meticulously designed, drawing on extensive insights from the WHO curricula guide (nurses' education and training on antimicrobial resistance; 2019) and the literature review addressed the use of antibiotics and prevention of AMR in hemodialysis facilities. The curriculum, using simple English, provides a broad set of learning objectives tailored to the expected roles of nurses.~The education program includes four main modular outline:~1. Foundations that build awareness of antimicrobial resistance~2. Appropriate use of antimicrobial agents~3. Infection prevention and control~4. Diagnostic stewardship and surveillance~The educational material was sent by a study researcher (X) to the WhatsApp number for all members of the experimental group via Chatbot software, which was designed by software engineer. The educational materials were sent in the form of written materials, photos, and videos."
48098400|NCT03790397|DRUG|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
48098401|NCT01721564|DRUG|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
48098402|NCT00543725|DRUG|TMC278|25 mg tablet once daily for 96 weeks
48279996|NCT00947349|DRUG|Placebo|
48279997|NCT03596164|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
48279998|NCT03596164|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
48279999|NCT03596164|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
48280000|NCT03596164|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
48280001|NCT00188084|PROCEDURE|DNA Index|
48280002|NCT00188084|PROCEDURE|S-Phase%|
48280003|NCT00188084|PROCEDURE|CD45 expression|
48280004|NCT00188084|PROCEDURE|P16 metabolic way|
48280005|NCT02298101|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
48280006|NCT02298101|DEVICE|Aeroneb Solo Adapter|Nebulizer
48280007|NCT02298101|DEVICE|Opti-Mist Plus Nebulizer|Standard jet nebulizer
48280008|NCT02298101|OTHER|Planar scintigraphy|Imaging technique to investigate whole lung deposition
48280009|NCT02298101|OTHER|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
48280010|NCT02298101|OTHER|Spirometry|FEV1, FVC assessment
48280011|NCT05999799|DRUG|GSK1070806|GSK1070806 will be administered.
48280012|NCT05999799|DRUG|Placebo|Placebo will be administered.
48280013|NCT04299529|DIAGNOSTIC_TEST|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
48280014|NCT05049785|OTHER|Counseling|Attend nutrition counseling sessions
48098403|NCT00543725|DRUG|efavirenz|600 mg tablet once daily for 96 weeks
48280015|NCT05049785|BEHAVIORAL|Exercise Intervention|Complete PA sessions
48280016|NCT05049785|OTHER|Informational Intervention|Receive nutrition handouts
48280017|NCT05049785|DIETARY_SUPPLEMENT|Nutritional Intervention|Attend tasting sessions
48280018|NCT05049785|OTHER|Questionnaire Administration|Ancillary studies
48280019|NCT05446948|DEVICE|beveled 27G+ vitrectomy system|The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.
48280020|NCT05446948|DEVICE|standard 25G+ vitrectomy system|The device is a traditional instrument, and its probe tip is flat.
48280021|NCT05083169|DRUG|Daratumumab|Daratumumab will be administered SC injection.
48280022|NCT05083169|DRUG|Pomalidomide|Pomalidomide will be administered orally.
48280023|NCT05083169|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously.
48280024|NCT05083169|DRUG|Bortezomib|Bortezomib will be administered SC injection.
48280025|NCT05083169|DRUG|Teclistamab|Teclistamab will be administered SC injection.
48280026|NCT03380858|DEVICE|colectomy|colectomy resection
48280027|NCT00902629|PROCEDURE|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
47929761|NCT06036147|BEHAVIORAL|Parent skills training|The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
47929762|NCT06036147|BEHAVIORAL|Care management|In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
47929763|NCT02558829|DRUG|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
47929764|NCT02558829|DRUG|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose
47929765|NCT04900064|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI). The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
47929766|NCT04900064|BEHAVIORAL|Self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering self-help CBT will need four days of reading and two days of training as well as regular supervision to be able to make initial assessments and problem profiling and use the self-help books.
47929767|NCT00146783|DRUG|Sulphadoxine-pyrimethamine|
48280028|NCT00058864|DEVICE|Energy absorbing and distributing trochanteric pad|
48637444|NCT03751748|DEVICE|AFR implantation|Implantation of atrial flow regulator (AFR) device
47929768|NCT00146783|DRUG|Sulphadoxine-pyrimethamine, amodiaquine|
47929769|NCT03478436|DRUG|Doxycycline|Doxycycline 40 mg capsules
48280029|NCT03124225|DRUG|DMARD|
48280030|NCT03308851|PROCEDURE|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
48280031|NCT03308851|PROCEDURE|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
48280032|NCT05911022|DRUG|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
48637445|NCT03751748|DEVICE|Sham procedure|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
47929770|NCT00667173|DRUG|IDP-115|Topical application for 12 weeks
47929771|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
47929772|NCT00667173|DRUG|Vehicle|Topical application for 12 weeks
47929773|NCT00002805|BIOLOGICAL|filgrastim|
47929774|NCT00002805|DRUG|cladribine|
47929775|NCT00002805|DRUG|cytarabine|
47929776|NCT00002805|DRUG|etoposide|
47929777|NCT00002805|DRUG|methotrexate|
48280033|NCT05911022|DIETARY_SUPPLEMENT|Probiotic Formula|oral sachets once daily for two weeks
48280034|NCT05911022|OTHER|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
48280035|NCT04355286|DRUG|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
48280036|NCT02951052|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
47929778|NCT00002805|DRUG|mitoxantrone hydrochloride|
47929779|NCT00002805|DRUG|therapeutic hydrocortisone|
47929780|NCT00002805|PROCEDURE|allogeneic bone marrow transplantation|
47929781|NCT00002805|PROCEDURE|autologous bone marrow transplantation|
47929782|NCT00002805|PROCEDURE|peripheral blood stem cell transplantation|
47929783|NCT00002805|RADIATION|low-LET cobalt-60 gamma ray therapy|
47929784|NCT00002805|RADIATION|low-LET electron therapy|
47929785|NCT00002805|RADIATION|low-LET photon therapy|
47929786|NCT02461472|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
47929787|NCT02310009|DRUG|Anakinra (AN)|
47929788|NCT02310009|BEHAVIORAL|Exercise (EX)|
47929789|NCT02310009|BEHAVIORAL|Control (CON)|
47929790|NCT05117918|OTHER|SUFU Clinical Care Pathway for Overactive Bladder|Treatment of OAB via the SUFU clinical care pathway
48452938|NCT06627452|OTHER|Pelvic Floor Muscle Training|Pelvic floor exercises involving both slow and fast muscle contractions will be taught to patients through vaginal palpation. During fast contractions, patients will be instructed to quickly contract and relax their pelvic floor muscles. During slow contractions, patients will be asked to gradually squeeze their pelvic floor muscles, hold for 10 seconds, and then slowly relax. Each set of pelvic floor exercises will consist of 10 fast contractions and 10 slow contractions. Patients will perform pelvic floor exercises twice a week with a physiotherapist and three days at home. The exercises will be done in sets throughout the day, lasting approximately 30 minutes, and will be conducted over a period of 12 weeks.
48280037|NCT02951052|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
47929791|NCT05117918|OTHER|Telemedicine|Delivery of care via telemedicine
47929792|NCT05696028|DEVICE|Gamma counter|DTpA
47929793|NCT01577290|BEHAVIORAL|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
48452939|NCT04456972|DIAGNOSTIC_TEST|One arm only|Samples of plasma to analyze ctDNA
48637446|NCT05447078|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
47929794|NCT01577290|BEHAVIORAL|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
47929795|NCT05785481|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"During the neonatal period:~neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days.~After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:~Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month."
47929796|NCT00000750|DRUG|Zidovudine|
47929797|NCT06032845|DRUG|Tislelizumab|a PD-1 immune check inhibitor
47929798|NCT06032845|DRUG|Lenvatinib|Lenvatinib capsules
47929799|NCT06032845|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
47929800|NCT01447212|DRUG|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
47929801|NCT01447212|DRUG|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
47929802|NCT01447212|DRUG|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
47929803|NCT01447212|DRUG|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
47929804|NCT05579743|OTHER|Remote wound monitoring technology|Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
47929805|NCT02385227|OTHER|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
47929806|NCT02385227|OTHER|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
47929807|NCT02385227|OTHER|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
48098404|NCT03969277|OTHER|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
48280038|NCT02951052|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
48452940|NCT04684186|PROCEDURE|Endovascular fiducial marker insertion|Fiducial markers will be inserted using an endovascular route
48452941|NCT04684186|PROCEDURE|Bronchoscopic fiducial marker insertion|Fiducial markers will be inserted using an endoscopic route
47929808|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
47929809|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
47929810|NCT02385227|OTHER|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
47929811|NCT02385227|OTHER|Nicotine product cessation C|Nicotine cessation
47929812|NCT04840030|BEHAVIORAL|Multimodal intervention (MM-int)|"1. Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~2. Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~3. Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~4. Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~5. Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication"
47929813|NCT02618356|DRUG|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d"
47929814|NCT02151773|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
47929815|NCT05053373|DEVICE|Electroacupuncture group|
47929816|NCT05053373|DEVICE|Sham electroacupuncture group|
47929817|NCT05053373|BEHAVIORAL|Pelvic floor muscle training|
48452942|NCT00447941|DRUG|SCA-136|
48452943|NCT00233415|DEVICE|Stereotactic Radiosurgery (Cyberknife)|
48452944|NCT06055686|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test|Electrical stimulation test measures sensory/motor responses
48452945|NCT00360607|DRUG|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
48452946|NCT00360607|DRUG|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
48452947|NCT00360607|DRUG|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
47929818|NCT02880085|DRUG|Local anesthetic|local injection
47929819|NCT05939778|BIOLOGICAL|TH-SC01(Umbilical cord mesenchymal stem cells)|"5+7 principle:~1. In medium and high dose groups, 5 subjects were included in each dose group in the first step, and the first 3 subjects had good safety The investigator evaluated safety and efficacy data and could enroll a fourth and fifth subject.~1. If the number of successful participants in these 5 subjects is less than 2, the study in this dose group will be ended due to drug ineffectiveness, and the researcher will evaluate the safety and enter the next dose group.~2. If the number of successful participants in these 5 cases is greater than or equal to 2, then proceed to the second step.~2. 7 subjects were included in the second step."
47929820|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
47929821|NCT03131401|DIAGNOSTIC_TEST|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
47929822|NCT03131401|DIAGNOSTIC_TEST|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
47929823|NCT01905423|DRUG|Albendazole (annual)|Albendazole 400 mg pnce annually
47929824|NCT01905423|DRUG|Diethylcarbamazine (annual)|Diethylcarbamazine 6 mg/kg once annually
48452948|NCT00360607|DRUG|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
47929825|NCT01905423|DRUG|Albendazole (semiannual)|Albendazole 400 mg twice annually
47929826|NCT01905423|DRUG|Diethylcarbamazine (semiannual)|Diethylcarbamazine 6 mg/kg twice annually
47929827|NCT04839562|DRUG|Solriamfetol 75 MG|Daily oral consumption
47929828|NCT04839562|DRUG|Solriamfetol 150 MG|Daily oral consumption
47929829|NCT04839562|OTHER|Placebo|Placebo
48452949|NCT03990662|OTHER|Physiotherapy - Manual Therapy|Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
48452950|NCT02072096|DRUG|Glimepiride|Administered orally
48452951|NCT02072096|DRUG|Metformin|Administered orally
48452952|NCT02072096|DRUG|Pioglitazone|Administered orally
48452953|NCT02072096|DRUG|Acarbose|Administered orally
47929830|NCT04134403|DRUG|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
47929831|NCT01150669|OTHER|laboratory biomarker analysis|Samples are analyzed in laboratory studies
47929832|NCT03220698|DEVICE|Tracheal ultrasonography|Tracheal ultrasonography
47929833|NCT04170478|DEVICE|Echolaser X4 system|Transperineal laser ablation
48452954|NCT02072096|DRUG|Linagliptin|Administered orally
48452955|NCT02072096|DRUG|Sitagliptin|Administered orally
48452956|NCT02072096|DRUG|Liraglutide|Administered subcutaneously (SC)
48452957|NCT02072096|DRUG|Insulin Glargine|Administered SC
48452958|NCT02072096|DRUG|Exenatide once weekly (QW)|Administered SC
48452959|NCT02072096|DRUG|Exenatide twice daily (BID)|Administered SC
48637447|NCT05447078|DIETARY_SUPPLEMENT|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.
48452960|NCT05025527|DIAGNOSTIC_TEST|biparametric MRI (bpMRI)|Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test
48452961|NCT05025527|DIAGNOSTIC_TEST|Prostate cancer antigen (PSA)|Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test
48452962|NCT02334722|DRUG|Levetiracetam|
48622286|NCT00818272|BIOLOGICAL|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
47929834|NCT02974751|PROCEDURE|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
47929835|NCT06113380|DEVICE|NTUH-ii, am upper limb rehabilitation robot arm|Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.
47929836|NCT06113380|OTHER|Traditional upper limb physical therapy|Traditional upper limb physical therapy is performed by the therapist.
47929837|NCT00797966|DRUG|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
47929838|NCT00797966|DRUG|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
47929839|NCT00797966|DRUG|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
47929840|NCT01293227|PROCEDURE|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
47929841|NCT05783427|OTHER|liberal hydration|evaluate the effect of 'Sip Til Send' on overall gastric volume pregnant women undergoing elective caesarean delivery
47929842|NCT05337397|PROCEDURE|Laser ablation|Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
47929843|NCT00266669|DRUG|Topical organogel with nitroglycerin|
47929844|NCT00991952|DRUG|alvocidib|Given IV
47929845|NCT00991952|DRUG|irinotecan hydrochloride|Given IV
47929846|NCT00991952|OTHER|laboratory biomarker analysis|Correlative studies
47929847|NCT05647278|DRUG|Tegoprazan|Tegoprazan 50 mg, tablets, orally, qd given in combination with amoxicillin 750mg capsules, orally, qid for up to 2 weeks.
47929848|NCT05647278|DRUG|Esomeprazole|"esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg，clarithromycin 500mg bid，colloidal bismuth pectin 200mg bid for up to 2 weeks.~OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks."
47929849|NCT04176042|BEHAVIORAL|Track 1|Intervention + Follow-up
47929850|NCT04176042|BEHAVIORAL|Track 2|Wait list + Intervention
47929851|NCT01126047|OTHER|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
47929852|NCT02676128|BEHAVIORAL|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
47929853|NCT02676128|BEHAVIORAL|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
47929854|NCT03550859|DRUG|Telmisartan/Rosuvastatin 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
47929855|NCT03550859|DRUG|Telmisartan 40mg|Telmisartan 40mg qd for 48 weeks
47929856|NCT05193227|DRUG|ST-01|Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
47929857|NCT05193227|DRUG|Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)|Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
48452963|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (1 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
48452964|NCT06015958|OTHER|Streptococcus salivarius M18 toothpaste (10 million cfu)|"Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g~In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity."
47929858|NCT06478628|BEHAVIORAL|Inpatient rehabilitation|Inpatient multimodal rehabilitation in specialist health care
47929859|NCT06478628|BEHAVIORAL|Outpatient day rehabilitation|Multimodal rehabilitation in specialist health care with program lasting whole work days
47929860|NCT06409832|DRUG|Rimegepant 75 mg|Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention
47929861|NCT04801940|DRUG|Apixaban|Apixaban 2.5mg orally twice daily for 14 days.
47929862|NCT04801940|DRUG|Atorvastatin|Atorvastatin 40mg orally once daily for 12 months.
47929863|NCT03859973|DRUG|BI 425809|Tablet
47929864|NCT03859973|DRUG|Placebo|Tablet
47929865|NCT00782431|BIOLOGICAL|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
47929866|NCT00782431|BIOLOGICAL|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
47929867|NCT02727530|OTHER|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
48452965|NCT00776763|DRUG|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
47929868|NCT02727530|OTHER|ADVICES|Advices for parents to improve the management of infant colic
47929869|NCT02047318|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
47929870|NCT02995369|DEVICE|DryShield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
47929871|NCT02995369|OTHER|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
47929872|NCT04098055|DEVICE|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
47929873|NCT04098055|DEVICE|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
47929874|NCT06515535|DRUG|Topical tranexamic acid|Topical tranexamic acid will be applied after placental delivery on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%
47929875|NCT06515535|DRUG|Intravenous tranexamic acid|Intravenous tranexamic acid will be given in the form of an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
47929876|NCT04199702|OTHER|Same day discharge|Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.
47929877|NCT03405779|PROCEDURE|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
47929878|NCT00852514|DEVICE|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
48622287|NCT02090257|BEHAVIORAL|TRANSIT|Educational Modules, staff follow up.
47929879|NCT03848156|OTHER|biopsy|Biopsy of nasal polyp for RNA sequencing
47929880|NCT05861622|OTHER|Moisturizer|The test product is a novel moisturizer, that contains active ingredients, including rambutan extract, niacinamide, and glycoin.
47929881|NCT02996032|OTHER|Vascular and Pulmonary Ultrasound|
47929882|NCT05694143|OTHER|Education Intervention|"This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~* To know facts, statistics and harmful effects of obesity and overweight.~* To know facts about physical activity and its importance.~* To know facts about a healthy diet and its importance.~* Definition of BMI and calculating the BMI.~* To read the Nutrition Facts label.~* To develop decision-making and self-care education."
47929883|NCT05694143|OTHER|No Intervention|They will have their regular curriculums and normal physical activity routine
47929884|NCT02192840|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
47929885|NCT00718237|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
47929886|NCT00718237|BIOLOGICAL|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
48622288|NCT04277585|OTHER|Telehealth|Early Psychosis Coordinated Specialty Care Services via telehealth.
48622289|NCT00440687|DRUG|Fluticasone 500mcg BD via accuhaler or identical placebo|
48622290|NCT04529980|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (LGG) Probiotic|Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.
48622291|NCT04529980|DIETARY_SUPPLEMENT|Placebo|Placebo
48098405|NCT03969277|OTHER|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
48098406|NCT03969277|OTHER|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
48098407|NCT03969277|OTHER|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
48098408|NCT01497444|DRUG|hypoxia-activated prodrug TH-302|
48098409|NCT01497444|DRUG|sorafenib tosylate|
48622292|NCT04142827|DEVICE|High Flow Humidification|myAirvo2 gives at home for long therapy treatment
48622293|NCT02562885|DEVICE|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
48622294|NCT00848432|DRUG|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
48622295|NCT03597867|OTHER|Placebo|Artificial tears for 3 days preoperatively
48622296|NCT03597867|DRUG|Dicloftil|Dosing of drug 3 days prior to surgery
48622297|NCT03597867|DRUG|Nevanac|Dosing of drug 3 days prior to surgery
48622298|NCT03597867|DRUG|Indom|Dosing of drug 3 days prior to surgery
48622299|NCT03597867|DRUG|Yellox|Dosing of drug 3 days prior to surgery
48622300|NCT01997931|DEVICE|Bispectral Index Sedation monitor|
48622301|NCT05100667|OTHER|Hypoxia|altitude (3800m)
48622302|NCT05100667|OTHER|Normoxia|sea level
47929887|NCT06482242|BEHAVIORAL|My Best Alaska Life|MBAL's combination of digital innovation, inclusive content, and youth-driven design positions it as a leading-edge intervention in the field of sexual health, with the potential to significantly impact the lives of Y/YA in AK and beyond. The open-access digital website enhances the reach and engagement of MBAL, particularly among adolescents who may prefer to seek information and support online in a private, self-paced setting. By allowing youth to fill out this tool at their own pace and return to their home page as they want to reflect/change answers, they can update it as their lives change. Additionally, MBAL incorporates interactive elements (question types of open response, ranking, scales, drag/drop; journaling prompts \& space) and personalized features (ex. avatars of common AK animals designed by Y/YA), allowing users to tailor their life planning experience according to their individual needs and preferences and return to their answers.
47929888|NCT02095132|DRUG|Adavosertib|Given PO
47929889|NCT02095132|DRUG|Irinotecan Hydrochloride|Given PO
47929890|NCT05814276|BEHAVIORAL|Training on non-pharmacological therapies' methodology|"The San Rocco study encompasses a training on the non-pharmacological therapies' methodology. It allows the professional caregiver to methodological definition of the non-pharmacological interventions and a comparison of shared readings of the challenging behaviors by the group of colleagues. Participants will follow:~* Five meetings, lasting 11 hours overall, on the multidimensional assessment, the shared readings of behavioral disorders of each person and identification of the objectives through the discussion of cases, and administration of non-pharmacological therapies within the framework of the personalization of the interventions~* Five meetings, lasting five and a half hours, for the supervision of the staff which implement the non-pharmacological therapies.~As usual control group Participants will continue the usual care activities and non-pharmacological interventions already in use in the Nursing Homes without participating in the training."
47929891|NCT03254615|BEHAVIORAL|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
47929892|NCT03967691|DRUG|Tocilizumab infusion|Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
47929893|NCT03967691|DRUG|Saline 0.9%|100 ml NaCl 0.9% will be infused over 1 hour
47929894|NCT02324543|DRUG|Gemcitabine|IV on days 4 and 11 of a 21 day cycle
47929895|NCT02324543|DRUG|Taxotere|IV on days 4 and 11 of a 21 day cycle
47929896|NCT02324543|DRUG|Xeloda|Twice a day orally on days 1 through 14 of a 21 day cycle
47929897|NCT02324543|DRUG|Cisplatin|IV on days 4 and 11 of a 21 day cycle
47929898|NCT02324543|DRUG|Irinotecan|IV on days 4 and 11 of a 21 day cycle
47929899|NCT01335022|BEHAVIORAL|lecture|6 lectures on cardiovascular disease covering obesity, diet \& exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
47929900|NCT01227824|DRUG|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
47929901|NCT01227824|DRUG|raltegravir|raltegravir 400mg taken twice daily
47929902|NCT01227824|OTHER|GSK1349572 Placebo|GSK1349572 placebo taken once daily
47929903|NCT01227824|OTHER|ABC/3TC|Abacavir/Lamivudine background therapy once daily
48452966|NCT02316223|BEHAVIORAL|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
48452967|NCT04047641|DRUG|Cladribine|Given Intravenous
48452968|NCT04047641|DRUG|Cytarabine|Given Intravenous
48452969|NCT04047641|DRUG|Idarubicin|Given Intravenous
47929904|NCT01227824|OTHER|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
47929905|NCT01227824|OTHER|raltegravir Placebo|raltegravir placebo taken twice daily
47929906|NCT06534892|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
47929907|NCT04729400|DEVICE|Vacuum Myofascial Therapy device|Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.
47929908|NCT04729400|OTHER|physical therapy program|The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.
47929909|NCT04729400|PROCEDURE|Therapeutic Percutaneous Electrolysis|Therapeutic Percutaneous Electrolysis
47929910|NCT04729400|PROCEDURE|ultrasound pulsatil therapy (US) and massage|ultrasound pulsatil therapy (US) and massage
47929911|NCT00527488|DRUG|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
47929912|NCT00527488|DRUG|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
47929913|NCT00527488|DRUG|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
47929914|NCT00527488|DRUG|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
47929915|NCT05576974|DRUG|Pegsitacianine|Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
48452970|NCT04047641|DRUG|Quizartinib|Given by mouth
48452971|NCT04618900|PROCEDURE|Sinus floor elevation with a grafting material|The use of grafting material for sinus floor elevation
48452972|NCT04838353|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
48622303|NCT01848808|DIETARY_SUPPLEMENT|Wobenzym PS|
48098410|NCT05584020|PROCEDURE|ACL Repair|Patients are undergoing arthroscopic anterior cruciate ligament repair. The native ACL is repaired using very strong sutures. This device is used to repair the native ACL and restore knee stability.
47929916|NCT04514354|BEHAVIORAL|GEST|On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
47929917|NCT06080724|DRUG|Comparison of intralesional injection of bleomycin alone and combined with injection dexamethasone|already described
47929918|NCT05444998|DRUG|Intuzumab, pyrrolidone, nab-paclitaxel|"Pyrrolidone 400 mg, qd; nab-paclitaxel 125 mg/m2, qw, D1/8/15; inituzumab 6 mg/kg (first dose 8 mg/kg) q3w, D1; 4 cycles in total (q3w as 1 cycle).~The patient's postoperative adjuvant therapy was 4 cycles of epirubicin + cyclophosphamide + physician's choice of anti-HER2 targeted therapy.~Multiple drug interruptions for adverse events were allowed throughout."
47929919|NCT06521879|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v probiotic support|Addition of Lactobacillus plantarum 299v (L. plantarum 299v) probiotic supplementation to iron replacement therapy.
47929920|NCT06300593|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of C-reactive protein (CRP), interleukin-1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-alpha) in PCOS phenotypes A, B, C and D|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in the four study arms
47929921|NCT06300593|DIAGNOSTIC_TEST|Evaluation of the correlation of serum concentrations of selected inflammatory markers (leucocytosis, CRP, IL-1, IL-6, IL-10, TNF-alpha) with metabolic and hormonal parameters|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to test the above correlations in the four study arms
47929922|NCT00391183|PROCEDURE|Biliary stenting|ERCP and stenting
47929923|NCT04707859|DIAGNOSTIC_TEST|Head to head comparison: Rubidium vs 15O-water PET|Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation
47929924|NCT02384057|OTHER|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
47929925|NCT02384057|OTHER|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
47929926|NCT01141062|DEVICE|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
48452973|NCT02421653|DIETARY_SUPPLEMENT|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
47929927|NCT01595945|PROCEDURE|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
47929928|NCT01595945|BEHAVIORAL|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
48452974|NCT02421653|DIETARY_SUPPLEMENT|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
48452975|NCT02421653|DIETARY_SUPPLEMENT|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
48452976|NCT02421653|DIETARY_SUPPLEMENT|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
48452977|NCT02421653|DIETARY_SUPPLEMENT|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
48452978|NCT02421653|DIETARY_SUPPLEMENT|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
48452979|NCT05199064|OTHER|Ultrasound guided greater occipital nerve (GON) radiofrequency|After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
48452980|NCT05043103|COMBINATION_PRODUCT|Lecigon® based on European Medicines Agency (EMA) SmPC|There might be different brand names in other countries
48452981|NCT05723393|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound
48452982|NCT05633862|DRUG|BI 1015550|BI 1015550
48452983|NCT06571266|DRUG|Risankizumab|• Subcutaneous Injection via prefilled syringe
48452984|NCT00110604|BEHAVIORAL|folic acid (0.8 mg)|
48452985|NCT04347018|DEVICE|BRIUS|This is a device that is designed based on movements planned virtually on a computer program. Then all the planned movements are embedded into the wire causing the wire to have the necessary bends to move every tooth into its pre-planned final position. This causes the pre-activated wire to consistently express a low force over a long period of time onto all the teeth. This allows the teeth to move into the final position and treatment progresses towards completion
48452986|NCT05957549|OTHER|Speech discrimination|Two different speech sounds are played at the same sound intensity.
48452987|NCT00029263|DRUG|herbals|
47929929|NCT02299739|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
47929930|NCT02299739|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
48622304|NCT01848808|DIETARY_SUPPLEMENT|Placebo|
47929931|NCT02299739|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
47929932|NCT02299739|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
47929933|NCT02299739|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
47929934|NCT00950677|DRUG|Byetta (exenatide)|exenatide 5 mcg subcutaneously
47929935|NCT00950677|DRUG|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
47929936|NCT00645710|DRUG|gemcitabine hydrochloride|Given IV
47929937|NCT00645710|DRUG|floxuridine|Given via hepatic arterial infusion
47929938|NCT00645710|GENETIC|proteomic profiling|Correlative studies
47929939|NCT00645710|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
48098411|NCT05584020|PROCEDURE|ACL Reconstruction|Patients are undergoing arthroscopic anterior cruciate ligament reconstruction. The torn ligament is removed and replaced with a band of tissue that usually connects muscle to bone. The graft tendon is taken from another part of your knee or from a deceased donor.
48098412|NCT05553041|DRUG|18F-Fluciclovine PET-MRI|18F-Fluciclovine will be injected via IV prior to Positron emission tomography (PET)-Magnetic resonance imaging (MRI)
48452988|NCT00042783|BIOLOGICAL|D1/3-MAGE-3-His fusion protein|
48098413|NCT03588065|DIAGNOSTIC_TEST|FMS|"The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception"
48098414|NCT03588065|OTHER|TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
48098415|NCT03588065|OTHER|CONFERENCE|The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
48098416|NCT01045317|DRUG|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
48098417|NCT03327155|DRUG|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
48622305|NCT01995201|DRUG|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
48622306|NCT01995201|DRUG|methotrexate|stable dose
48622307|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
48452989|NCT00042783|BIOLOGICAL|SB-AS02B adjuvant|
48622308|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
48622309|NCT01995201|DRUG|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
48622310|NCT04790799|OTHER|Treatment at the skin department at Gentofte Hospital|Treatment in a hospital setting at Gentofte Hospital skin department
48622311|NCT01127360|DRUG|Bevacizumab|Intravitreal injections
48622312|NCT01127360|DRUG|Ranibizumab|Intravitreal injections
48622313|NCT02937922|OTHER|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: \[(HR max - HR rest) x desired intensity\] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
48637448|NCT05672537|DRUG|Durvalumab|1500mg intravenous injection for 21d cycle
48637449|NCT05672537|PROCEDURE|Surgery|Surgery
48637450|NCT05672537|DRUG|Gemcitabine|gemcitabine 1000mg/m2, D1\&D8, 21d cycle.
47929940|NCT00645710|OTHER|liquid chromatography|Correlative studies
47929941|NCT00645710|RADIATION|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
47929942|NCT00645710|OTHER|laboratory biomarker analysis|Correlative studies
47929943|NCT00645710|OTHER|mass spectrometry|Correlative studies
47929944|NCT00645710|OTHER|pharmacological study|Correlative studies
48637451|NCT05672537|DRUG|Cisplatin|cisplatin 25mg/m2, D1\&D8, 21d cycle.
47929945|NCT02811276|OTHER|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
47929946|NCT03133962|OTHER|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
47929947|NCT04514302|DRUG|Placebo|Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.
47929948|NCT04514302|DRUG|Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)|INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.
47929949|NCT01752036|RADIATION|Post-operative, Stereotactic Body Radiation Therapy (SBRT)|All participants received SBRT at 600 cGy x 5 fractions
47929950|NCT06505720|PROCEDURE|Arthroscopic management of acute pediatric septic hip infecion|Three-portals tractionless hip arthroscopy will be used to treat acute pediatric septic hip infection
47929951|NCT06505720|PROCEDURE|Open debridement of acute pediatric septic hip|surgical drainage and debridement of acute septic hip in children via classic lateral approach
47929952|NCT01964456|OTHER|Joint perception task|
47929953|NCT01964456|BEHAVIORAL|Body Shape Questionnaire|
47929954|NCT01964456|OTHER|Measure of the heart rate|
47929955|NCT02879045|OTHER|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
47929956|NCT02737033|DRUG|Rhodiola|Rhodiola rosea 800mg
47929957|NCT02737033|DRUG|Placebo|innocuous pill manufactured to mimic Rhodiola
47929958|NCT05857280|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms."
47929959|NCT03940976|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 28 day cycle.
48098418|NCT04499131|DRUG|Progesterone|Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
47929960|NCT06070220|BEHAVIORAL|traditional occupational therapy intervention and client-centered intervention|"Traditional occupational therapy intervention and client centered intervention were given to the participants.~CC intervention is a dynamic approach that involves a systematic therapy process, that is, in which the participant and the therapist are active in the treatment process. In the current study, a treatment program was designed over a maximum of 5 occupations in which participants evaluated after THA indicated problems in activities of daily living according to COPM. This systematic and dynamic program consists of 4 phases: (1) client-centered goal setting, (2) negotiating an intervention plan, (3) the actual intervention, (4) an evaluation of the outcome and finally reporting to relevant others."
47929961|NCT06070220|BEHAVIORAL|Traditional occupational therapy intervention|"The following training procedure, which included exercise, transfer activities and home arrangements, was followed in common in both groups:~1. st day: After the operation, exercises to strengthen the muscles of the participants (thigh, hip and trunk muscles) were explained verbally and visually. Each exercise consists of 3 sets of 12 repetitions. Exercises were updated in bed, sitting or standing, depending on the participant's functional status, pain and fatigue. Additionally, transfer activities training was provided.~2. nd day: The exercises taught to the participants on the first day were repeated. Following these exercises, participants were given verbal instructions on gait training, and then gait training began. According to the pain and fatigue status of the participants, gait exercises were continued.~3. rd day: The work done on the first and second day was repeated. Pre-discharge home arrangements training was provided."
47929962|NCT05945862|BEHAVIORAL|NUTRIGANDO|Program consisting in nutrition education and physical activity training to promote healthy lifestyles
47929963|NCT00908739|GENETIC|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
48098419|NCT04499131|OTHER|Artificial Cycle (no intervention)|Control group of 19 subjects in the context of a natural cycle with only endogenous progesterone present
48098420|NCT04181632|DEVICE|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
48637452|NCT04274465|DIAGNOSTIC_TEST|digital PCR (dPCR) assay|It is a highly sensitive and specific droplet digital PCR assay for absolute quantification of circulating tumor HPV DNA for the most prevalent HPV types that will determine if a woman has cHPVDNA
47929964|NCT00908739|OTHER|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
48452990|NCT06042166|BEHAVIORAL|Connecting and Reflecting Experience (CARE) Program|The intervention consists of a 12-session mentalizing-focused parenting group, which will involve weekly one-hour telehealth therapy sessions with up to 7 postpartum parents per group and 1 to 2 facilitators. CARE is a therapy focused on parents' reflective capacity, or the ability to consider how our own and our children's thoughts, feelings, intentions, and other mental states shape behavior and parent-child relationships.
48452991|NCT04802057|DRUG|SAR445088|"Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)"
48452992|NCT00774540|DRUG|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
48452993|NCT00774540|DRUG|Placebo|Saline
48452994|NCT06488911|DRUG|FDC tablet (OCA 5 mg + BZF 400 mg SR)|Participants will be administered with FDC tablets once daily.
48452995|NCT02726360|BEHAVIORAL|survey|The ILR Scale, a non-English language proficiency self-assessment.
48452996|NCT02726360|BEHAVIORAL|Audio record|Audio record the initial visits between patients and their treating physician
48452997|NCT02175095|DRUG|Regorafenib|Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
48452998|NCT02175095|DIAGNOSTIC_TEST|[18F]FLT-PET|\[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.
48452999|NCT02175095|DIAGNOSTIC_TEST|[18F]FDG-PET|\[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.
48453000|NCT00294047|BIOLOGICAL|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48453001|NCT00294047|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48453002|NCT05315063|OTHER|Eccentric Training|Once achieved, this flexed hip position will be held for 5 seconds. This procedure will be repeated 6 times with no rest between repetitions
48453003|NCT05315063|OTHER|Muscle Energy Technique (PIR)|"The participant will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb.~On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch was applied and maintained for 30 seconds.3 repetitions of this process will be done"
48453004|NCT05280288|DEVICE|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
48453005|NCT04159285|BEHAVIORAL|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
48453006|NCT04159285|OTHER|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
48453007|NCT03537482|DRUG|APG-2575|APG-2575 will be administered as an oral tablet
48453008|NCT00707330|DRUG|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
48453009|NCT01260389|BEHAVIORAL|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
48453010|NCT04466111|DEVICE|Intellis neurostimulator system|The study will use the commercially available IntellisTM neurostimulator and compatible SCS system components from Medtronic using stimulation parameters within the specifications approved for use in the approved indications. The study will stimulate the cervical dorsal columns of the spinal cord.
48453011|NCT02408367|BEHAVIORAL|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
48453012|NCT02408367|BEHAVIORAL|Relaxation|30
48453013|NCT04738448|BEHAVIORAL|Art Therapy Group|The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
48622314|NCT02937922|OTHER|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
47929965|NCT00908739|OTHER|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
48098421|NCT04181632|DEVICE|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
48098422|NCT04181632|DEVICE|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
48453014|NCT01977521|DEVICE|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
48453015|NCT01977521|DEVICE|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
48453016|NCT00346190|DRUG|Alendronate|
48453017|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
48453018|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
48453019|NCT01524874|DIETARY_SUPPLEMENT|Vitamin D3|10,000 IU per Day for 12 Weeks
48453020|NCT06627361|DEVICE|PRO-FLEX PIVOT Foot evaluation|The subject will wear the PRO-FLEX PIVOT foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
48453021|NCT06627361|DEVICE|Class III ESAR Foot evaluation|The subject will wear his usual Class III ESAR Foot foot for 4 weeks, following which they will complete questionnaires and undergo a Time Up and Go test
48453022|NCT06081634|BEHAVIORAL|Enhancing cognitive reserve|Intervention in group format (6-8 patients) consisting of 12 weekly sessions, each lasting approximately 60 minutes. The aim of this intervention is to offer a series of strategies to increase academic and/or work achievements, leisure and free time activities, as well as an improvement in the level of neurocognitive functioning. Most of the tasks to be carried out are based on the use of pencil and paper with audiovisual support. Technological resources such as the use of the Internet and some telephone applications will also be used in some sessions. For those sessions in which the practice of mindfulness techniques will be promoted, a virtual reality device will be used per patient.
48453023|NCT06081634|OTHER|Treatment as Usual|The group will only receive the pharmacoloical treatment according to the based guidelines.
48453024|NCT03292458|DRUG|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
48453025|NCT04884841|OTHER|Patients diagnosed with postoperative complications|Patients diagnosed with postoperative complications (Acute kidney injury, Chronic Kidney disease, Infection, Delirium, MACCE, Myocardial infarction, Postoperative pulmonary complications, major bleeding, ECMO, IABP....)
48453026|NCT04884841|OTHER|Patients without postoperative complications|Patients without postoperative complications
48453027|NCT01983501|DRUG|Tucatinib (ONT-380)|Given twice per day, orally
48453028|NCT01983501|DRUG|T-DM1|Given intravenously once every 21 days
48453029|NCT06103812|DEVICE|Hyalo4 Skin Gel|The evaluation of performance and safety of Hyalo4 Skin Gel in the amelioration of bed wound appearance after 14 days of treatment.
48453030|NCT03628209|DRUG|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
48280039|NCT02951052|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
48453031|NCT03628209|DRUG|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
48453032|NCT03628209|PROCEDURE|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
48453033|NCT02770222|DRUG|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
48453034|NCT02770222|DRUG|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
48453035|NCT02770222|DRUG|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
48453036|NCT03935815|DRUG|Ropivacaine injection|30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
48453037|NCT03935815|PROCEDURE|Sham treatment|A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
48453038|NCT00052377|BIOLOGICAL|aldesleukin|Given SC
48453039|NCT00052377|BIOLOGICAL|recombinant interleukin-12|Given SC
48453040|NCT00052377|OTHER|laboratory biomarker analysis|Correlative studies
48453041|NCT06324864|BEHAVIORAL|START NOW Adapted|"The START NOW skills-training combines aspects of cognitive behavioral therapy (CBT), motivational interviewing (MI), dialectical behavior therapy (DBT), Acceptance and Commitment Therapy (ACT) and trauma-sensitive care. Studies in different contexts have shown START NOW's effectiveness in terms of reducing behavioral problems, reducing hospitalization rates, improving mental health functioning and increasing satisfaction rates. The culturally adapted version will be contextually adapted to different cultural backgrounds and the experience of migration. In ten sessions, participants learn about emotions and are introduced to the START NOW skills. These skills, called SLOW DOWN, TAKE A STEP BACK, ACCEPT, RESPECT and TAKE ACTION, are strategies or techniques that can be used to better manage stress and difficult emotions."
48098423|NCT05505929|DEVICE|Biofreedom Ultra|The BioFreedomTM Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
48453042|NCT06370104|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention|see arm description
48453043|NCT06370104|BEHAVIORAL|Living under control|see arm description
48453044|NCT02606032|DRUG|Metronidazole|active comparator
48453045|NCT02606032|DRUG|Doxycycline|active comparator
48453046|NCT02606032|DRUG|Terbinafine|active comparator
48453047|NCT02606032|DRUG|Placebo|identical placebos to all antibiotics
48453048|NCT06507176|PROCEDURE|flexible ureteroscopic lithotripsy|This group of patients underwent flexible ureteroscopic lithotripsy.
48453049|NCT06507176|PROCEDURE|percutaneous nephrolithotomy|This group of patients underwent percutaneous nephrolithotomy.
48453050|NCT00684697|DIETARY_SUPPLEMENT|iron|High, intermediate and low iron dosage orally for 2 months
48453051|NCT06547294|DEVICE|Osprey IV|Utilization of novel needle over catheter commercial insertion device
48453052|NCT06547294|OTHER|Historical Controls|Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
48453053|NCT02943343|OTHER|No intervention|
48453054|NCT00348543|PROCEDURE|laser treatment|
48453055|NCT02491099|DRUG|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
48453056|NCT02651506|PROCEDURE|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
48453057|NCT02651506|PROCEDURE|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
48453058|NCT03134664|PROCEDURE|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
48453059|NCT03134664|PROCEDURE|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
48453060|NCT05502679|OTHER|Weight bearing as tolerated|Bearing weight on lower limb extremity
48453061|NCT05502679|OTHER|Pragmatic Exercise protocol|Designed exercise prescriptions according to the patients' needs
48453062|NCT03850938|DEVICE|Conventional Kyphoplasty|The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
48453063|NCT03850938|DEVICE|Kyphoplasty with Rotary Cutter|The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
48098424|NCT05507281|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|ultrasound-guided ipsilateral Erector Spinae Plane Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
48453064|NCT00159458|DRUG|Gemcitabine and oxaliplatin|
48453065|NCT01101022|DRUG|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
48453066|NCT01101022|OTHER|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
48453067|NCT00835705|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
48453068|NCT00835705|DRUG|Augmentin®|400 mg-57 mg chewable tablet
48453069|NCT05133479|BEHAVIORAL|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
48453070|NCT03783897|DRUG|EDP-305|Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3
48453071|NCT03783897|DRUG|Oral Contraceptive|Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
48622315|NCT02937922|OTHER|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
48622316|NCT00123877|DRUG|GPX-100 (13-deoxydoxorubicin)|
48098425|NCT05507281|PROCEDURE|Retrolaminar Block|ultrasound-guided ipsilateral Retrolaminar Block (20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg)).
48098426|NCT05507281|PROCEDURE|Control|General anesthesia
48098427|NCT00878384|DRUG|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
47929966|NCT06267378|OTHER|Frailty measure|"All participants will be asked to complete baseline assessments and a blood test.~30 participants out of the 100 will be selected to wear a digital motion device before their surgery for seven days. (15 participants will be non-frail and 15 patients will be frail).~Where possible, all baseline assessments will be scheduled to coincide with a routine clinic/hospital visit. The first assessment will complete functional, frailty, nutritional, and quality of life questionnaires. A blood test will be taken for baseline tests and metabolomic assessment. Participants who opt into having a digital motion device will also be shown how to use the device and will wear this for seven days. Written instructions to fit the device will also be given."
47929967|NCT03779243|DIETARY_SUPPLEMENT|Melatonin 5mg and Sleep Education|Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
47929968|NCT03779243|OTHER|Placebo|Daily placebo pills for 6 weeks following injury or surgery.
47929969|NCT03243708|BEHAVIORAL|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
47929970|NCT04748588|DRUG|Anti-SARS-CoV-2 mAb|"Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used."
47929971|NCT04569071|DEVICE|Sinovation Laser Ablation System|In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
47929972|NCT03708562|DEVICE|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
47929973|NCT02294760|DEVICE|Subsensory|The stimulation is set to 90% of the sensory threshold.
47929974|NCT02294760|DEVICE|OFF|The stimulation is turned OFF.
47929975|NCT00322621|DRUG|Duloxetine|
47929976|NCT04381988|DRUG|Hydroxychloroquine|400mg daily
47929977|NCT04381988|OTHER|Placebo|400mg daily
47929978|NCT04381988|RADIATION|Radiation therapy|Standard radiation therapy will be prescribed and administered as per the patient's radiation oncologist.
47929979|NCT02958683|OTHER|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
47929980|NCT06427343|DRUG|High-dose ferric derisomaltose|"After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.~In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up."
47929981|NCT06427343|DRUG|Low-dose ferric derisomaltose|In the low-dose group, participants will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \>20% during follow-up.
47929982|NCT01599364|DRUG|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
47929983|NCT02698995|DRUG|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
47929984|NCT02698995|DRUG|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
48453072|NCT02570958|DRUG|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
48453073|NCT04285814|DIAGNOSTIC_TEST|Whole Fetal Cell (WFC) Testing|Performing WFC testing on blood specimens.
48453074|NCT04629326|OTHER|68Ga-WL12 PET/CT|WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
48453075|NCT03124511|PROCEDURE|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
48622317|NCT03493971|PROCEDURE|Carotid revascularization performed using CAS|Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke
47929985|NCT02698995|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
47929986|NCT02698995|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
48453076|NCT01732224|DRUG|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
47929987|NCT02698995|DRUG|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
47929988|NCT03707028|DRUG|Rivoceranib|Film-coated tablet
47929989|NCT03707028|DRUG|Paclitaxel|Solution administered intravenously
47929990|NCT03777631|PROCEDURE|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
47929991|NCT01390064|BIOLOGICAL|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
47929992|NCT05748652|DEVICE|digital CBT|An app-based intervention based on principles from cognitive behavioral therapy for anxiety.
47929993|NCT05748652|OTHER|Psychoeducation|Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.
47929994|NCT06162390|DRUG|Remifentanil|"Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients."
47929995|NCT03739788|DRUG|BMS-986165|Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
47929996|NCT02149771|PROCEDURE|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
47929997|NCT02149771|DEVICE|endovascular stents implantation|Bare stents implant within portal vein.
47929998|NCT02149771|PROCEDURE|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
47929999|NCT00256477|BEHAVIORAL|Sudarshan KRIYA Breathing Technique|
47930000|NCT05272436|DEVICE|Virtual Reality Upper Limb Motor Impairment Rehabilitation|Patients wore a VR headset while undergoing their physical rehabilitation at home
47930001|NCT03503890|DRUG|rovalpituzumab tesirine|intravenous
47930002|NCT03986073|DRUG|TQ-F3083 capsule 10 mg|Subjects in the low dose group administrated TQ-F3083 capsule 10mg, once daily for 12 weeks.
47930003|NCT03986073|DRUG|TQ-F3083 capsule 20 mg|Subjects in the high dose group administrated TQ-F3083 capsule 20 mg, once daily for 12 weeks.
47930004|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
47930005|NCT03986073|DRUG|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
47930006|NCT03986073|DRUG|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
47930007|NCT03986073|DRUG|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
47930008|NCT04062500|OTHER|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
47930009|NCT04843436|DEVICE|Symani Surgical System|Robotically Assisted Microsurgery
47930010|NCT06287203|BEHAVIORAL|Addiction Risk Feedback Program|This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.
47930011|NCT02225613|OTHER|Usual protocol|
47930012|NCT02225613|OTHER|Spa protocol|
47930013|NCT02620371|PROCEDURE|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
48622318|NCT03493971|PROCEDURE|Carotid revascularization performed using CEA|Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
47930014|NCT05313776|OTHER|Magnetic Resonance Imaging|IMR is a non-invasive imaging technology that produces three dimensional detailed anatomical images. It is often used for disease detection, diagnosis, and treatment monitoring. It is based on sophisticated technology that excites and detects the change in the direction of the rotational axis of protons found in the water that makes up living tissues.
47930015|NCT06105671|DRUG|Symbicort|Participants are administered 54 μg Formoterol and 1920 μg Budesonide
47930016|NCT06105671|DRUG|Formoterol|Participants are administered 54 μg Formoterol from an inhaler device
47930017|NCT06105671|DRUG|Formoterol|Participants are administered 120 μg Formoterol in a capsule, which is taken orally
47930018|NCT06105671|DRUG|Placebo|Participants are administered placebo
47930019|NCT06105671|DRUG|Mannitol|Participants are administered 600 mg Bronchitol
47930020|NCT05287360|DRUG|Rivoceranib|Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
48622319|NCT01642160|BEHAVIORAL|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
48622320|NCT01642160|BEHAVIORAL|Standard of care|participants will receive education from staff nurses as needed.
47930021|NCT04877509|BIOLOGICAL|Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization|Micronutrient assays on heparinized plasma.
48453077|NCT01732224|DRUG|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
48453078|NCT01876667|OTHER|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
48453079|NCT01876667|OTHER|Placebo|Usual Care
48453080|NCT06223139|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
48453081|NCT05661591|DRUG|SHR2554 Tablets|SHR2554 Tablets+ Fluconazole Capsules
48453082|NCT05661591|DRUG|Fluconazole Capsules|SHR2554 Tablets+ Fluconazole Capsules
48453083|NCT02649647|PROCEDURE|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
48453084|NCT02649647|PROCEDURE|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
48453085|NCT05850676|DIAGNOSTIC_TEST|Sleep study|Participants will spend two nights in the Penn Sleep Center
48453086|NCT02511535|BIOLOGICAL|TBE booster vaccination|
48453087|NCT05877274|OTHER|Sodium channel mutation|Mutation of the genes SCN9A and SCN10A, which encode for Sodium channel 1.7 and 1.8.
48453088|NCT01524185|BEHAVIORAL|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
48453089|NCT01524185|BEHAVIORAL|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
48453090|NCT05460520|BEHAVIORAL|VOR Readaptation|"The stimulus will be a combination of horizontal visual motion and a head maneuver. The subject will sit in a stationary chair, and a treatment provider will stand behind the subject. While the subject views the slow horizontal motion up to 10°/s of vertical stripes, the provider will gently hold the head of the subject above the ears and tilt the head in the roll (side-to-side) or pitch (up-down) plane by approximately ±20° at the frequency of 0.2 to 0.05 Hz for up to 10 min. The treatment will be repeated with breaks of approximately 5 min. A treatment session will last no longer 120 min including the breaks.~In Groups 1, 3, and 4, subjects will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius, and full-field visual motion will be generated with light projected on the wall of this chamber. In Group 2, visual motion will be presented on the screen of a VR headset. Unlike groups 3 and 4, groups 1 and 2 do not receive any complementary treatment."
48453091|NCT05460520|BEHAVIORAL|VOR Habituation|The subject will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius. Physical motion will be generated by rotating the chair sinusoidally to the left and right, and full-field visual motion will be generated with light projected on the wall of this chamber. Velocity storage will be weakened by inducing a conflict between physical and visual motions. Subjects will be first treated with a stimulus with a peak speed of 5°/s. The stimulus speed will be gradually increased from 5°/s on Day 1 to 40°/s on Day 5. In total, the subjects are expected to undergo 200-280 min of treatment over the five days, broken up into several 10-20 min sessions per day with a 10-min break in between. If signs or symptoms of motion sickness are reported by the subject (nausea, sweating), the session will be immediately paused. Treatment may be continued after a short rest if the discomfort is alleviated or on the following day.
48453092|NCT05460520|BEHAVIORAL|Visual Motion Desensitization|The subject will be situated in darkness and view the movement of a visual pattern presented on a disk, sized 1 m in diameter and placed 1 m away from the subject with its center at the eye level. The disk will be rotated clockwise and counter-clockwise for up to 10 min at a fixed maximal speed within a treatment session but varying across sessions between 5 to 60°/s. Within a single session, the visual stimulus will be first presented with the subject sitting upright in a chair, and then the treatment will be repeated with the subject standing. The disk will be mounted on a vertical sled, so the center of rotation can be kept at the eye level when sitting and standing. A treatment session will be repeated or conducted with an increased visual motion speed up to 60°/s according to the subject's readiness. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions per day with a 10-min break in between
48622321|NCT02421211|DRUG|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
48453093|NCT05460520|BEHAVIORAL|Opposing visual motion stimulus|"The investigators characterize gravitational pull as a misaligned sense of upright in the velocity storage mechanism, and hypothesize that that this misalignment can be corrected with an opposing visual motion stimulus, e.g., backward pulling will be corrected with upward visual motion.~Patients in Group 5 will undergo view visual motion in a physical setting, and those in Group 6 under a VR setting. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions of 1-10 min per day with an approximately 5-min break in between."
48622322|NCT02421211|DRUG|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
48622323|NCT02421211|DRUG|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
48622324|NCT04999787|DRUG|HSK21542|HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
48622325|NCT04999787|DRUG|Placebo|Placebo
47930022|NCT01975831|DRUG|Durvalumab|Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
47930023|NCT01975831|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
47930024|NCT00830778|PROCEDURE|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
47930025|NCT00830778|PROCEDURE|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
48453094|NCT01826838|DRUG|Dasatinib|"1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib."
48453095|NCT06558825|BEHAVIORAL|Integrated Intervention to Promote PrEP Uptake|Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.
48453096|NCT06558825|OTHER|Standard Treatment Condition|Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
48453097|NCT02266095|DEVICE|Oval-8 Splint|Splinting with Oval-8
47930026|NCT02814500|DRUG|DP-R212|Investigational product is prescribed to all of randomized subjects
48098428|NCT00878384|PROCEDURE|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
48453098|NCT02266095|DEVICE|Tee Pee Splint|Splinting with Tee Pee
48453099|NCT02266095|DEVICE|Forearm Based Splint|Splinting with Forearm based
48453100|NCT05612204|PROCEDURE|Biopsy under MRI|Biopsy under MRI
48453101|NCT02179788|BEHAVIORAL|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
48453102|NCT02179788|DRUG|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~* Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~* Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~* Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
48453103|NCT02179788|DRUG|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
48453104|NCT04965935|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
48453105|NCT04965935|DRUG|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
48453106|NCT00634205|DRUG|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
48453107|NCT03886129|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound (TCD)|Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
48453108|NCT03013413|PROCEDURE|Shear Wave Elastography|Undergo ultrasound-based elastography imaging using the Aixplorer system
47930027|NCT02814500|DRUG|Amlodipine|Investigational product is prescribed to all of randomized subjects
47930028|NCT02814500|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
47930029|NCT04173598|BEHAVIORAL|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
48098429|NCT00000988|DRUG|Stavudine|
48453109|NCT03013413|PROCEDURE|Ultrasound Elasticity Imaging|Undergo ultrasound-based elastography imaging using the Aixplorer system
48453110|NCT03013413|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo standard of care ultrasound-guided prostate biopsy
48453111|NCT02993562|DRUG|Levothyroxine|Normal treatment with levothyroxine.
48453112|NCT06603103|PROCEDURE|SPHERIKA prosthesis|total knee arthroplasty with kinematic alignement with SPHERIKA prosthesis
48453113|NCT06603103|PROCEDURE|ORIGIN prosthesis|total knee arthroplasty with kinematic alignement with ORIGIN prosthesis
48453114|NCT02795663|DEVICE|NIRS EEG HR recording|NIRS EEG HR recording
48453115|NCT04057287|OTHER|No intervention|No intervention
48453116|NCT02007733|OTHER|Serial Weights|We will collect serial weights on all children enrolled in this study.
48453117|NCT02007733|OTHER|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
48453118|NCT02007733|OTHER|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
48453119|NCT02081105|OTHER|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
48453120|NCT05271890|PROCEDURE|Immediate non-surgical periodontal treatment and oral hygiene instructions|
48453121|NCT03710629|OTHER|Patients with driver genes|Patients with driver genes
47930030|NCT04173598|BEHAVIORAL|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
48280040|NCT02951052|DRUG|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)"
48453122|NCT02882776|DIETARY_SUPPLEMENT|Ginger drink|Ginger powder dissolved in water
48453123|NCT04422457|OTHER|68Ga-DX600 PET/CT|DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
48453124|NCT01852487|DIETARY_SUPPLEMENT|400mg /day during 6 months|
48453125|NCT02882282|OTHER|Laboratory Biomarker Analysis|Correlative studies
48280041|NCT04042480|DRUG|SGN-CD228A|SGN-CD228A administered into the vein (IV; intravenously)
48453126|NCT02882282|OTHER|Patient Observation|Undergo observation
48453127|NCT02882282|BIOLOGICAL|Pembrolizumab|Given IV
48453128|NCT05434364|OTHER|Facilitated Tucking|giving facilitated tucking before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
47930031|NCT04661761|DIAGNOSTIC_TEST|Paraffin Pellets from Aurosan GmbH|1 to 2 minutes pre-chewing time chewing Paraffin Pellets from Aurosan GmbH, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
47930032|NCT04661761|DIAGNOSTIC_TEST|Chewing wax from the Saliva-Check Buffer from GC Europe|1 to 2 minutes pre-chewing time chewing wax from the Saliva-Check Buffer from GC Europe, after which the amount of saliva is collected over a period of five minutes. The patient may chew the chewing gum once per second; after each minute the produced amount of saliva is spit in a cup, the whole amount measured after 5 minutes.
48453129|NCT05434364|OTHER|Swaddling|swaddling before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
48453130|NCT05434364|OTHER|Prone Position|giving prone position before (1st and 3th minutes), during and after (1st and 3th minutes) the procedure
48453131|NCT05911321|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
48453132|NCT05911321|DRUG|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
48453133|NCT05911321|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
48453134|NCT04972565|BEHAVIORAL|Usual Care plus Inspiratory Muscle Training (IMT)|Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
48453135|NCT06571747|BEHAVIORAL|Cardiovascular-Focused Nudge Communication|Intervention arms will receive a behavioral economic rooted nudge communication highlighting the potential cardiovascular benefits of vaccination.
48453136|NCT05362292|DRUG|Tolterodine Tartrate ER|Anticholinergic
48453137|NCT05362292|DRUG|Mirabegron|Beta-3-adrenergic agonist
48453138|NCT05362292|DRUG|Placebo|matching placebo pill
48453139|NCT00586989|PROCEDURE|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
48453140|NCT00715442|DRUG|Sunitinib|50 mg by mouth daily for 28 consecutive days
48453141|NCT00715442|PROCEDURE|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
48453142|NCT05587790|BEHAVIORAL|Weight Management Intervention|Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
48453143|NCT03686540|PROCEDURE|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
48453144|NCT04440436|DRUG|IM19 CAR-T Cells|"IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days"
48453145|NCT03407963|PROCEDURE|Embolization|Embolization by microparticles (300-500 microns)
48453146|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
48453147|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
48453148|NCT01970566|OTHER|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
48453149|NCT01970566|OTHER|Behavioral|Intense Exercise/Moderate Calorie Restriction
48453150|NCT03647293|PROCEDURE|Ultrasound Guided Central Catheter Insertion|
48453151|NCT03647293|PROCEDURE|Peripherally Inserted Central Catheter|
48622326|NCT06122545|PROCEDURE|Greater Occipital Nerve Block|"Patients will receive Greater Occipital Nerve Block (GONB) either with local anesthetic (bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.~Ultrasound-guided GONB will be performed to more accurately locate the nerve through searching for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process and injection will be done medial to the artery"
48622327|NCT06122545|OTHER|Medical Treatment|Patients who will receive medical treatment
48622328|NCT06122545|DRUG|bupivacaine or onabotulinum toxin A injection.|bupivacaine 0.5% 1.5 mL) or with onabotulinum toxin A injection.
47930033|NCT00599131|DRUG|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a \< 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, \> 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
47930034|NCT00599131|DRUG|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
47930035|NCT00599131|DRUG|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
47930036|NCT00599131|DRUG|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
47930037|NCT03344523|DRUG|Iron protein succinylate oral solution|Iron protein succinylate oral solution
47930038|NCT03344523|OTHER|standard treatment|standard treatment
47930039|NCT05245448|DRUG|Tetrandrine|Administered orally
47930040|NCT05245448|DRUG|Placebo|Administered orally
47930041|NCT04234724|OTHER|Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.|Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
48622329|NCT06054425|DRUG|Risankizumab|Infusion; intravenous
48622330|NCT00334919|BEHAVIORAL|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
48098430|NCT05602116|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The Investigational Product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure Aps, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The excipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
48098431|NCT05074498|DRUG|TB006|intravenous infusion
48098432|NCT05074498|DRUG|Placebo|intravenous infusion
48098433|NCT03468920|DRUG|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
48453152|NCT01191996|BIOLOGICAL|MIS416|MIS416 intravenously every week
48453153|NCT06561906|OTHER|Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing|Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP
48453154|NCT05765708|OTHER|Motor Imagery|Motor imagery is the mental execution of a movement without any overt movement or without any peripheral (muscle) activation. It has been shown that motor imagery leads to the activation of the same brain areas as an actual movement. Therefore, it is used to acquire new motor skills. Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
48453155|NCT05765708|DIAGNOSTIC_TEST|Action Observation|Action Observation (AO) involves the dynamic process of observing purposeful actions with the intention of imitating and then practicing those actions.
48453156|NCT01304823|DIETARY_SUPPLEMENT|lactisole|flavoring agent/sweet taste antagonist
48453157|NCT01304823|OTHER|mixed liquid meal|Ensure Plus
48453158|NCT04993274|DIAGNOSTIC_TEST|PASS-MS|protocol using short motor tasks performed by the subject and recorded by a depth camera, motion analysis by visuo-perceptive computing
48453159|NCT05709496|RADIATION|De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac|30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
48453160|NCT05911152|PROCEDURE|Intracorporeal anastomosis|Surgeons perform totally laparoscopic intracorporeal digestive reconstruction after specimen resection
47930042|NCT05479669|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiograms will be performed at inclusion. Echocardiographic parameters that will be evaluated are measures of atrial size (including left atrial volume, right atrial dimensions, left ventricular function and dimensions (including left ventricular dimensions, septal wall thickness, posterior wall thickness, systolic function, Simpson biplane left ventricular ejection fraction), parameters of diastolic dysfunction (including E, A, E/A ratio, deceleration time, E' and E/E' ratio) and valve (dys)function.
47930043|NCT05479669|DIAGNOSTIC_TEST|24 hour Holter monitoring|24-hours Holter monitoring will be used to determine markers of increased risk of ventricular arrhythmias, such as non-sustained ventricular tachycardias, and ventricular premature beats and doublets. Also the presence and pattern of AF and runs of supraventricular tachycardias are determined.
47930044|NCT05479669|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Multiple short-axis cine images will be acquired throughout the entire LV with a steady-state free precession sequence. Left ventricular volumes, ejection fraction and myocardial mass will be measured on the short-axis stacks at end diastolic and end systolic frames. Ten to 15 minutes after an intravenous bolus injection of a gadolinium-based contrast agent late gadolinium enhancement will be performed with a segmented inversion recovery gradient-echo sequence, using the same image orientation as in the short-axis stacks. The presence, location and morphology of myocardial fibrosis will be described. The extent of myocardial scar will be quantified using computer-assisted planimetry and expressed as a percentage of left ventricular mass. Pre- and post-contrast T1 measurements will be obtained using a single-shot modified Look Locker inversion recovery sequence. Extracellular volume (a measure of diffuse myocardial fibrosis) will be quantified.
47930045|NCT05479669|DIAGNOSTIC_TEST|99mTc-HDP scan|Patients will receive a 99mTc-HDP scan. 3 hours after the technetium 99m-hydroxymethylene diphosphonate bolus injection, imaging will be performed using a gamma-camera equipped with a collimator which guides individual gamma-rays emitted by the radionuclide. For planar imaging, a collimator will be used to transfer only those gamma-rays which pas in a perpendicular course. Sequentially, a SPECT-CT will be performed in the same session to improve sensitivity. SPECT/CT will be performed on a SPECT/CT dual head gamma camera system. SPECT images will be acquired using a 128 x 128 matrix, 180 degrees of rotation, 64 views, 15s per view. Visual image analysis will be performed by two blinded and experienced nuclear medicine physicians. Data will be scored according to a routine scoring system on a scale from 0 (no cardiac uptake of 99m technetium and normal bone uptake) to 3 (high cardiac uptake, higher than bone uptake).
47930046|NCT05479669|DIAGNOSTIC_TEST|ECG|A 12-lead electrocardiogram will be performed at the 1-year and 2-year follow-up visit to determine the heart rhythm and heart rate.
47930047|NCT05575921|DIAGNOSTIC_TEST|Polysomnography|Children underwent at-home polysomnography in routine clinical practice. The exam is interpreted in 2 ways by the physician with sleep stages (PSG) and without sleep stages (PG). The data are retrospectively collected from the patient's recording
47930048|NCT03750370|DEVICE|Doppler ultrasound|Colored Doppler Sonography is well established to illustrate microvascularity and therefore perfusion of the testis. The arterial flow velocities (peak systolic velocity \[PSV\] and end diastolic velocity \[EDV\]) and the resistance indices against this flow (resistive index \[RI\] and pulsatility index \[PI\]) in the testis can be measured with this technique.
48098434|NCT03468920|DRUG|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
48098435|NCT03468920|DRUG|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
48098436|NCT03468920|DRUG|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
48280042|NCT06108661|PROCEDURE|Conventional Physical Therapy|"Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks."
48280043|NCT06108661|PROCEDURE|Slump Stretching|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
48280044|NCT06108661|PROCEDURE|ELDOA|"ELDOA will be performed as per the tolerance of the patient (Max hold time=60sec) for 2 weeks (alternatively). For L4/L5 spinal segment patient sits on the floor, arms at the side legs relaxed.~For L5/S1 segment the patient lies on his or her side with torso perpendicular to a wall with the sitz bone pressing into the wall. The patient swing the legs up so that he or she is lying on his or her back with the legs perpendicular up the wall and the sitz bone pressing into the wall. The arms are lying by the sides."
48453161|NCT03246763|BEHAVIORAL|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
48453162|NCT01930903|DEVICE|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
48453163|NCT06555913|OTHER|Maitland Mobilization|"MM applies a passive oscillatory technique, classified from Grade I-IV with respect to intensity, to the shoulder in order to treat pain and stiffness.~Grade I refers to an intensity of small amplitude that is applied at the beginning of the joint ROM, where there is no loading on connective tissue; it is often used in cases of severe pain"
48453164|NCT06555913|OTHER|Scapular Stabilization|"Scapular stabilization exercises are thought to have an important role in improving pain and dysfunction in the shoulder. The concept that an unstable~scapula is associated with pathology and dysfunction of the shoulder is well accepted. The predominant theory emphasizes that for optimal function of the glenohumeral joint, the scapula must provide a stable base upon which upper extremity tasks are completed. Impaired scapular stability increases the risk for pathologies such as impingement or rotator cuff tears"
48453165|NCT06555913|OTHER|Traditional Physical Therapy|ROM exercises, stretching exercises and strengthening exercises for shoulder muscles
48453166|NCT01948167|BEHAVIORAL|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
48453167|NCT01948167|BEHAVIORAL|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
48453168|NCT00272519|BEHAVIORAL|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
47930049|NCT05003271|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions.
47930050|NCT03726554|DEVICE|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
47930051|NCT03726554|DEVICE|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
47930052|NCT04307342|PROCEDURE|MIPO with Extra-articular Distal Humeral Anatomical Plate|MIPO with Extra-articular Distal Humeral Anatomical Plate
48453169|NCT01735994|BEHAVIORAL|Healthy Weight|Eating Disorder Prevention Program for Athletes
48453170|NCT01735994|OTHER|Brochure|Brochure on the Female athlete triad
48453171|NCT04739358|DRUG|Tepotinib|Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
48453172|NCT03227835|OTHER|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR \>29mL/min/1.73m2
48453173|NCT04614155|OTHER|Educational Intervention|Take part in health education session
48453174|NCT04614155|PROCEDURE|HPV Self-Collection|Receive HPV self-collection kit
48453175|NCT04614155|OTHER|Questionnaire Administration|Complete questionnaires
48453176|NCT04018768|OTHER|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
48453177|NCT04018768|OTHER|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
48453178|NCT00881751|BIOLOGICAL|bevacizumab|Given IV
48453179|NCT00881751|DRUG|erlotinib hydrochloride|Given orally
48453180|NCT00881751|DRUG|sorafenib tosylate|Given orally
48453181|NCT04500015|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.
48453182|NCT04500015|DRUG|Placebo Comparator|3 tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
48453183|NCT05866588|BEHAVIORAL|Physical, psychological and spiritual nursing care (Nursing Therapeutics)|"1. Follow-up: To make a presentation about the physiological and psychological changes during pregnancy. do dream work~2. Follow-up: Providing education and counseling for childbirth.~3. Follow-up: Training and role rehearsal on mother-infant interaction, breastfeeding and infant care.~4. Follow-up: To provide counseling on the issues needed with the approaching of the birth.~5. Follow-up: Teaching about conscious parenting and mother-infant, father-infant interaction.~6. Tracking. To provide education, counseling and social support on the other roles of the mother in life such as wife role, working woman role, social role.~7. Follow-up: To evaluate the transition to motherhood.~8. Follow-up: To evaluate the outcomes of transition to motherhood and adjustment to motherhood according to expected completion time."
48453184|NCT05543135|DIAGNOSTIC_TEST|basic audiological evaluation|pure tone audiometry\&immitancemetry
48453185|NCT06242912|BEHAVIORAL|QOL - quality of life|QOL assessments using EQ5D (Euroqol 5 dimension) +/- ESAS (Edmonton Symptom Assessment Scale) +/- CPC (Canadian Problem Checklist) every 4-8 weeks +/- 2 weeks
48453186|NCT06242912|DIAGNOSTIC_TEST|Radiographic or laboratory evaluation|Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
48453187|NCT06558916|DRUG|Dexketoprofen Trometamol|
47930053|NCT01872325|BEHAVIORAL|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
47930054|NCT02973880|DRUG|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
48453188|NCT06558916|DRUG|Meperidine Injectable Solution|
48622331|NCT05897151|DRUG|Continuous spinal anesthesia|"Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure \< 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics."
47930055|NCT02973880|DRUG|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
47930056|NCT05371873|PROCEDURE|Liver resection method|undergo anatomical or non-anatomical resection of liver cancer
47930057|NCT03044574|DEVICE|SCD|Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
47930058|NCT03044574|DEVICE|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
47930059|NCT03044574|DRUG|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
48622332|NCT05897151|DRUG|General anesthesia|After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
48453189|NCT06558916|DRUG|Paracetamol|
48453190|NCT06558916|DRUG|Fentanyl|Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
48453191|NCT00979147|PROCEDURE|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
48453192|NCT00979147|PROCEDURE|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
48453193|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
48622333|NCT03664258|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor|The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).
48622334|NCT06121505|RADIATION|low-dose radiation therapy and stereotactic body radiation therapy|Patients will receive radiation therapy.
48622335|NCT06121505|DRUG|chemotherapy|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
47930060|NCT03957460|OTHER|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
48622336|NCT06121505|DRUG|Sintilimab|Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
48622337|NCT03976700|DRUG|Bufei Jianpi granule|Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
47930061|NCT05999162|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery includes laparoscopic surgery or robotic surgery for the treatment of colorectal surgery.
47930062|NCT01718977|OTHER|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
47930063|NCT01718977|OTHER|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
48453194|NCT00979147|DEVICE|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
48453195|NCT03086460|DRUG|CHF 1531 pMDI|Dose Response: Test one of five different doses of CHF 1531
48453196|NCT03086460|DRUG|Formoterol Inhalation Solution|Active Control
48453197|NCT03086460|DRUG|Placebo pMDI|Matched Placebo
48453198|NCT00197353|DRUG|Epidural bupivacaine (dose/concentration/volume ranging)|
47930064|NCT01913587|DEVICE|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
47930065|NCT01913587|PROCEDURE|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
47930066|NCT00821444|DRUG|ziprasidone|40 mg capsule, single dose x 3
47930067|NCT00821444|DRUG|B16 Fasted|40 mg tablet, single dose X 3
47930068|NCT00821444|DRUG|B16 Fed|40 mg tablet, single dose X 3
47930069|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
47930070|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
47930071|NCT02106923|DRUG|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
47930072|NCT02106923|DRUG|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
47930073|NCT02106923|DRUG|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
47930074|NCT02106923|DRUG|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
47930075|NCT04951297|OTHER|None, just observation|None ,just observation test
47930076|NCT03516474|DEVICE|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
47930077|NCT03956069|BIOLOGICAL|blood sample|for patient and its parents
47930078|NCT03956069|GENETIC|genome sequencing|whole genome sequencing
47930079|NCT02984072|DRUG|Menthol|Topical menthol in aqueous cream
47930080|NCT02984072|DRUG|Aqueous Cream|placebo
47930081|NCT02937584|DRUG|GP MDI (PT001) 14.4 μg|Glycopyrronium
48453199|NCT03274492|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
48453200|NCT03274492|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
48453201|NCT03274492|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
48453202|NCT03274492|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
47930082|NCT02937584|DRUG|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
47930083|NCT00575835|DIETARY_SUPPLEMENT|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
48098437|NCT04639154|PROCEDURE|Erector spinea plane block|ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
47930084|NCT00575835|DIETARY_SUPPLEMENT|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
47930085|NCT03460743|BIOLOGICAL|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
47930086|NCT03460743|BIOLOGICAL|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
47930087|NCT01652300|BEHAVIORAL|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
47930088|NCT01652300|BEHAVIORAL|no education|women in the control group received no education
48098438|NCT01855464|PROCEDURE|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
48453203|NCT03274492|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
48453204|NCT03274492|DRUG|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
48453205|NCT03274492|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
48453206|NCT03274492|DRUG|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
48453207|NCT06545890|DRUG|Ketamine|continous infusion during surgery
48453208|NCT06545890|DRUG|Dexmedetomidine|continous infusion during surgery
48453209|NCT00836472|DRUG|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
48453210|NCT00836472|DRUG|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
48453211|NCT03133260|DIAGNOSTIC_TEST|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
48453212|NCT03133260|DRUG|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
48453213|NCT03133260|DRUG|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
48453214|NCT02390518|RADIATION|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a \*Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~\*\*Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
48453215|NCT01850173|DEVICE|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
48453216|NCT03877939|DIAGNOSTIC_TEST|Blood samples collection for analysis|"Blood samples:~Blood samples will be collected for the determination of the levels of various biomarkers (Kisspeptins and miRNAs), which are molecules that regulate the expression of proteins and can serve as markers for predicting pregnancy viability. Additionally, after biochemical or week 10 of clinical pregnancy confirmation, blood samples will be collected for KIR and HLA-C typing, Oral glucose tolerance test (OGTT) and analysis of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.~Uterine biopsy (only in patients with BP):~Uterine biopsy samples will be collected also after biochemical pregnancy confirmation for the determination of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b."
48453217|NCT01016782|DRUG|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
48453218|NCT05181969|DEVICE|Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV)|Lipoprotein apheresis Method I
48453219|NCT05181969|DEVICE|Lipid filtration (Octo Nova®, Diamed Medizintechnik)|Lipoprotein apheresis Method II
48453220|NCT05181969|DEVICE|Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)|Lipoprotein apheresis Method III
48453221|NCT05181969|DEVICE|Therasorb (TheraSorb® - LDL adsorbers, Miltenyi Biotec)|Lipoprotein apheresis Method IV
48453222|NCT04050254|DEVICE|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
48453223|NCT04050254|DEVICE|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
48453224|NCT04050254|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
48453225|NCT03807180|OTHER|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
48453226|NCT05281861|OTHER|Zirconia reinforced Lithium disilicate (Vita Ambria) ceramic onlay restoration|In experimental group, Participants will be restored with onlay ceramic restorations constructed from zirconia reinforced Lithium disilicate (Vita Ambria) glass ceramic
48453227|NCT05281861|OTHER|Lithium disilicate (IPS e-max press) ceramic onlay restoration|In control group, Participants will be restored with onlay ceramic restorations constructed from Lithium disilicate (IPS e-max press) glass ceramic
48453228|NCT05119504|BEHAVIORAL|Acceptance and Commitment|"During the 90-minute, one-on-one interventionist led session, participants will learn three inter-related acceptance-based techniques tailored for coping with physical discomfort and negative affect during physical activity. (1) cognitive defusion (i.e., disentangling physical sensations and thoughts from behavior), (2) acceptance (i.e., increasing willingness to experience unpleasant physical sensations/negative affect without trying to change or control them), and (3) valued action (i.e., evaluating the role of physical activity as a valued behavior). Participants will be taught these techniques via didactic instruction, metaphors, and experiential activities.~All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week."
48453229|NCT05119504|BEHAVIORAL|Multi-Health Behavior|The multi health behavior condition will include didactic material focused broadly on healthy lifestyle recommendations including physical activity. It will also emphasize that physical activity is one of several interconnected health behaviors including balanced diet, sleep, stress management. All participants will receive a two-week physical activity prescription based on national guidelines recommending 150 minutes of at least moderate intensity physical activity per week.
48453230|NCT03183609|OTHER|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
48453231|NCT03183609|OTHER|Rice Flour in Protein Shake|15 Grams Rice Flour BID
48453232|NCT01301794|DIETARY_SUPPLEMENT|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
47930089|NCT03874260|DRUG|Fenofibrate|statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
47930090|NCT01244490|DRUG|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
47930091|NCT01244490|DRUG|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
47930092|NCT01244490|DRUG|Placebo Comparator|Placebo
47930093|NCT02350751|DRUG|MEDI8852|
47930094|NCT02350751|DRUG|Placebo|
48453233|NCT03642808|OTHER|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
48453234|NCT01447511|DRUG|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
48453235|NCT01447511|DRUG|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
48453236|NCT01447511|DRUG|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
48453237|NCT03698357|BEHAVIORAL|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
47930095|NCT06144762|BIOLOGICAL|Biological/Vaccine: Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data"
47930096|NCT04405232|OTHER|Non-interventional|Observational study
47930097|NCT01185301|BIOLOGICAL|adalimumab|Pre-filled syringe every other week
48453238|NCT03698357|BEHAVIORAL|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
47930098|NCT01185301|DRUG|methotrexate|weekly oral capsule dosing
47930099|NCT00923949|DRUG|Pioglitazone|45 mg tablet daily by mouth for six weeks
47930100|NCT03105544|OTHER|simulation-based training|As described under group descriptions
47930101|NCT04651101|DIAGNOSTIC_TEST|coronary angiography|extent of coronary artery disease in invasive coronary angiography
47930102|NCT05036811|OTHER|data collection|data collection
47930103|NCT01908400|BIOLOGICAL|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
48453239|NCT02695472|DRUG|80 Milligrams NSI-189|Orally Administered
48453240|NCT02695472|DRUG|Placebo|Orally administered
47930104|NCT05398081|DRUG|Cefuroxime (Zinnat®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Cefuroxime (Zinnat®), a second generation cephalosporin will be used
48453241|NCT02695472|DRUG|40 Milligrams NSI-189|Orally Administered
48622338|NCT03976700|DRUG|Placebo Bufei Jianpi granule|Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
47930105|NCT05398081|DRUG|Ceftriaxone (Rocephin®)|Antibiotic for prophylaxis against surgical site infection following craniotomy and laminectomy Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used
47930106|NCT02355873|DEVICE|AN69ST hemofilter|
47930107|NCT02355873|DEVICE|AN69 hemofilter|
47930108|NCT01343823|DRUG|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
47930109|NCT01343823|DRUG|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
47930110|NCT01343823|DRUG|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
47930111|NCT01343823|DRUG|placebo|Administered as two SC 3 mL injections
47930112|NCT01343823|DRUG|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
47930113|NCT01343823|DRUG|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
47930114|NCT03505710|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
48098439|NCT01855464|PROCEDURE|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
48098440|NCT04878042|DEVICE|Hydrogen peroxide|Mouth wash and nasal spray 3 times a day for 3 days
48098441|NCT04878042|DEVICE|Placebo|Mouth wash and nasal spray 3 times a day for 3 days
48098442|NCT01242085|PROCEDURE|trumatch group|these patient will have CT based customized knee instruments used for surgery
48453242|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with flowable giomer|removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x
48453243|NCT06000085|PROCEDURE|restoration of proximal cavities of primary molars with highly viscous glass ionomer cement|removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
48453244|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators"
48453245|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model - Providers|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience."
48453246|NCT01322880|BEHAVIORAL|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
48622339|NCT04002700|DRUG|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
47930115|NCT06393959|PROCEDURE|Caudal epidural pulsed radiofrequency|The patient lied in prone position. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a 22- gauge 150-mm RF cannula with 20 mm active tip was advanced through the sacrococcygeal ligament into the caudal epidural space under floroscopic guidence. A few milliliters contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, an electrode was connected to the cannula, and stimulation was conducted with impedance measured between 250 and 350 Ohms A different sensation or feeling such as fullness, impression, tingling, pulling or plethora at the rectal and/or coccygeal region was observed by the patients when 50 Hz was applied with 0,4 to 0,7 V sensory stimulation. No leg muscle contraction was observed with 2 Hz motor stimulation at 2 V. PRF was performed for 600 s at 5 Hz using a 5-ms pulse width at 55 V, avoiding electrode tip temperatures above 42 C.
47930116|NCT06393959|PROCEDURE|Caudal epidural steroid enjection|The patient lied in prone position and aseptic techniques were adopted. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a spinal needle was advanced through the sacrococcygeal ligament into the caudal epidural space under fluoroscopic guidance. The needle tip was confirmed by negative aspiration for blood or cerebrospinal fluid, then a few milliliters of contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, a total of 10 ml mixture of saline and 8 mg dexametzone was administered into the epidural space.
47930117|NCT00721903|PROCEDURE|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
47930118|NCT00721903|PROCEDURE|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
47930119|NCT01439815|DRUG|Fluticasone Propionate Nasal Spray|two sprays in each nostril once daily
47930120|NCT01439815|DRUG|Saline Nasal Spray|two sprays in each nostril once daily
47930121|NCT00320359|DRUG|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
47930122|NCT00320359|DRUG|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
47930123|NCT06396182|OTHER|group (A ) study group :virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).|"group (A ) study group : virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller):~The VR cycling session utilized the VZFIT VR Exercise Bike (VZFIT, Cambridge, MA), games were selected as preliminary pilot trials indicated these games to be most intense. Players maneuvered during VR gameplay by pedaling and steering their virtual character by leaning their bodies left and right. (Daniel et al., 2020).~group (B) control group :Cycling by traditional stationary bike: Participants will require to continuously pedal using the pulse oximeter for HR monitor. Research personnel monitored participants during the session adjusting pedal-resistance to ensure that the participants stayed within their target HR zone. (Daniel et al., 2020)."
47930124|NCT03253471|DRUG|AL-611|AL-611 tablets
47930125|NCT03253471|DRUG|Placebo|Placebo to Match AL-611
47930126|NCT00001965|DRUG|Cyclosporine A|
47930127|NCT03274375|DRUG|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
47930128|NCT03274375|DRUG|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)"
47930129|NCT01981057|OTHER|Numeta|parenteral receipt prescribed with Numeta
47930130|NCT01981057|OTHER|Individual|parenteral receipt prescribed individually
47930131|NCT02726308|DRUG|Dexamethasone|5 mg I.V. Dexamethasone just before induction
47930132|NCT02726308|DRUG|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
47930133|NCT02726308|DRUG|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
47930134|NCT03189381|RADIATION|Cohort A|Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
47930135|NCT03189381|RADIATION|Cohort B|Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
47930136|NCT02741180|OTHER|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
47930137|NCT02741180|OTHER|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
48622340|NCT04002700|DRUG|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
48622341|NCT04002700|DRUG|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
47930138|NCT00824070|DRUG|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
47930139|NCT00824070|DRUG|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
47930140|NCT00824070|DRUG|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
48622342|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
48622343|NCT02219542|DRUG|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
47930141|NCT05599776|OTHER|Smart ring assisted physiotherapeutic intervention|the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
47930142|NCT04095676|PROCEDURE|VATS group|VATS procedure with drainage, including rinse with NaCl
47930143|NCT04095676|PROCEDURE|Drain and intrapleural therapy group|Drainage with pigtail and Intrapleural therapy
47930144|NCT01568528|DRUG|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
47930145|NCT01568528|DRUG|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
47930146|NCT01568528|OTHER|Control|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
47930147|NCT03712423|DRUG|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
47930148|NCT03314246|OTHER|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
47930149|NCT03314246|OTHER|Standard of care|Standard of care
47930150|NCT02502006|DRUG|Celecoxib|
47930151|NCT02502006|DRUG|Naproxen|
47930152|NCT02502006|DRUG|Placebo|
47930153|NCT00002975|DRUG|aminolevulinic acid|
47930154|NCT05176561|BEHAVIORAL|Auditory-Cognitive Training|"Treatment Participants will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Participants with spend 1 hour auditory training use Angel Sound and one hour of auditory cognitive training using auditory portions of Posit Science. A clinical paradigm including reviewing results, providing strategies and positive feedback and strategies in the 1 hour virtual meeting of clinician and participant. Practice for next week is assigned.~Control group intervention follows the same time and procedure but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search)."
47930155|NCT05176561|BEHAVIORAL|Non-auditory Cognitive Training|Participant will complete 8 weeks of training for 2 hours per week and participate in a 1 hour meeting with clinician. Control group intervention follows the same time and clinical paradigm, but the materials are non-auditory puzzles (Sudoku, Cross Word Puzzles, Spot the Difference, Ken-Ken and Word Search).
47930156|NCT01125787|DRUG|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
47930157|NCT02830984|PROCEDURE|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
47930158|NCT02830984|PROCEDURE|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
47930159|NCT03487692|OTHER|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
47930160|NCT03487692|OTHER|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
47930161|NCT01190787|DRUG|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
47930162|NCT01190787|DRUG|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
47930163|NCT01190787|DRUG|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
47930164|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by APTT
47930165|NCT03426982|DRUG|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by anti-Xa
47930166|NCT00713310|DRUG|Asacol 400 mg|"High dose:~17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
47930167|NCT00713310|DRUG|Asacol 400 mg|"Low dose:~17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
48098443|NCT01242085|PROCEDURE|control group|these patients will have standard instrumentation used for for knee replacement
48098444|NCT02272699|DRUG|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
48098445|NCT02272699|DRUG|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
48098446|NCT02272699|DRUG|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
47930168|NCT02555501|OTHER|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
47930169|NCT02555501|RADIATION|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
47930170|NCT03513523|DIETARY_SUPPLEMENT|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
47930171|NCT03513523|DIETARY_SUPPLEMENT|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
47930172|NCT03513523|OTHER|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
47930173|NCT02817477|DRUG|Ketamine Hydrochloride|Delivered intranasally using an atomizer
47930174|NCT02817477|DRUG|Morphine|Delivered either as an IM injection or a slow IV bolus
47930175|NCT01574833|DEVICE|pulsed electromagnetic field|PEMF treatment
48453247|NCT01322880|BEHAVIORAL|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
48453248|NCT05177107|BIOLOGICAL|Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
48453249|NCT05177107|OTHER|Placebo|Placebo (normal saline)
48453250|NCT02903407|DRUG|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
48453251|NCT02903407|DRUG|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
47930176|NCT01574833|DEVICE|sham|sham treatment
47930177|NCT02188043|BEHAVIORAL|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
47930178|NCT03740815|PROCEDURE|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
47930179|NCT03740815|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
47930180|NCT03740815|PROCEDURE|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
48453252|NCT02903407|DRUG|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
48453253|NCT04483921|OTHER|Acute exercise|Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.
48453254|NCT02358538|DRUG|Ganaxolone|oral suspension or capsules
48453255|NCT04388722|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).
48453256|NCT06624267|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Two 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. One 5-minute scan is conducted of the brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
48453257|NCT01147939|DRUG|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
48453258|NCT01147939|DRUG|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
48453259|NCT03690960|PROCEDURE|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
47930181|NCT01931631|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
47930182|NCT01931631|BEHAVIORAL|ADA diet|Diet in accordance with the American Diabetes Association
47930183|NCT01556347|DRUG|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
47930184|NCT00542438|BEHAVIORAL|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
47930185|NCT00542438|BEHAVIORAL|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
47930186|NCT02540889|BEHAVIORAL|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
47930187|NCT01126671|DRUG|Supplemental Vitamin D|Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.
47930188|NCT06430827|DRUG|irinotecan hydrochloride liposome injection|rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
47930189|NCT06430827|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle
47930190|NCT03175055|DEVICE|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
47930191|NCT02311101|DRUG|Mitomycin C|Given intravesically
47930192|NCT01528423|PROCEDURE|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
47930193|NCT03693729|DEVICE|HD-tDCS|Participants will complete a metamemory and memory task
47930194|NCT02338336|DRUG|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
47930195|NCT02338336|DRUG|Placebo|Matching placebo liquid for topic administration.
47930196|NCT02617901|RADIATION|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
47930197|NCT00830076|DRUG|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
47930198|NCT00830076|DRUG|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
47930199|NCT00830076|DRUG|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
47930200|NCT00830076|DRUG|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
47930201|NCT01753778|DEVICE|Cryo-Touch III Device|Treatment with Cryo-Touch III
47930202|NCT00130351|DEVICE|formoterol|
47930203|NCT04156516|BEHAVIORAL|HEART|sexual health intervention
47930204|NCT04156516|BEHAVIORAL|HealthyMinds|Growth mindsets of personality and mental health
47930205|NCT04590248|DRUG|Adavosertib|The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
47930206|NCT03660085|BEHAVIORAL|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
47930207|NCT04387643|DIETARY_SUPPLEMENT|Ayurvedic Kadha|Kadha (also called Kwath and Kashaya) is a type of ayurvedic formulation prepared by boiling herbs in water. Water and herbs are main ingredients of these preparations. The preparation of Kadha uses dry herbs, which are dried under the sun or in the shade, as directed for the individual herb. Then, the herbs are pounded to form a coarse powder
48098447|NCT02272699|RADIATION|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
48098448|NCT02272699|PROCEDURE|Surgery|Esophagectomy
48098449|NCT05080595|OTHER|Transportation assistance (Lyft rides)|Lyft rides will be provided to patients for any transplant-related medical visits
47930208|NCT04360655|PROCEDURE|bronchoscopic microwave intervention|bronchoscopic microwave intervention
47930209|NCT04360655|DRUG|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy|anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
47930210|NCT01687374|DRUG|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
47930211|NCT01687374|DRUG|Placebo|Saline injection daily for 8 weeks.
47930212|NCT01229462|DRUG|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
47930213|NCT01229462|DRUG|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
47930214|NCT01229462|DRUG|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
48098450|NCT03018145|DEVICE|Wagon|
48098451|NCT03018145|DEVICE|Standard stretcher car|
48098452|NCT04266561|OTHER|hernia repair|Two 3-mm needle holders were used for stitching the wide IIR. Then the suture was continued along the upper margin of IIR, but in a deeper plane to include the peritoneum and the deeper fascia transversalis.
48098453|NCT06343285|DEVICE|Encora Therapeutics Tremor Reduction Device|The proposed therapeutic device uses vibration motors positioned around the wrist that provide on-demand-therapy to suppress resting, postural, or action tremors of the hand.
48098454|NCT00029380|DRUG|Sangstat|
48098455|NCT00029380|DRUG|Cyclophosphamide|
48098456|NCT00029380|DRUG|Busulfan|
48098457|NCT00029380|DRUG|Mycophenolate Mofetil|
48098458|NCT00029380|DRUG|Cyclosporine|
47930215|NCT01229462|OTHER|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
47930216|NCT02500576|BIOLOGICAL|Aldesleukin|Given IV or SC
48453260|NCT03690960|PROCEDURE|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
48453261|NCT00851305|DEVICE|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
47930217|NCT02500576|DRUG|Cyclophosphamide|Given IV
47930218|NCT02500576|DRUG|Fludarabine Phosphate|Given IVPB
47930219|NCT02500576|OTHER|Laboratory Biomarker Analysis|Correlative studies
47930220|NCT02500576|BIOLOGICAL|Pembrolizumab|Given IV
47930221|NCT02500576|OTHER|Quality-of-Life Assessment|Ancillary studies
47930222|NCT02500576|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
47930223|NCT01602133|PROCEDURE|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
47930224|NCT02398994|DRUG|Intravenous Methylprednisolone|
47930225|NCT02398994|DRUG|Intravenous Immunoglobulin|
47930226|NCT02261025|DRUG|acetylsalicylic acid|75-100mg,per day
47930227|NCT01535300|PROCEDURE|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
47930228|NCT00911378|PROCEDURE|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
47930229|NCT00911378|PROCEDURE|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
47930230|NCT03889301|BEHAVIORAL|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
47930231|NCT03889301|BEHAVIORAL|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
47930232|NCT05204407|DIETARY_SUPPLEMENT|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
47930233|NCT05204407|DIETARY_SUPPLEMENT|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
47930234|NCT05321056|DEVICE|masks (surgical mask, respirator)|The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
47930235|NCT01456975|PROCEDURE|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
47930236|NCT03257917|OTHER|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
47930237|NCT03295565|DRUG|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
47930238|NCT03295565|DRUG|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
47930239|NCT03295565|DRUG|Enzalutamide|Enzalutamide 160mg oral taken daily
47930240|NCT04980326|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
47930241|NCT04980326|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
47930242|NCT04980326|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
47930243|NCT00672113|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
47930244|NCT00672113|DRUG|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
47930245|NCT01915329|DEVICE|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
48098459|NCT00029380|PROCEDURE|Cord Blood Transplantation|
47930246|NCT01915329|DEVICE|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
48453262|NCT00851305|DEVICE|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
47930247|NCT05392933|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
47930248|NCT01877733|OTHER|Maximal strength training|
47930249|NCT04733794|PROCEDURE|Stoma reversal|Patients will receive a comprehensive intervention to addresses bowel, sexual, and urinary dysfunction. Patients meeting appropriate inclusion criteria will be approached at a clinic visit with their surgeon. If they agree to participate, they will complete an initial baseline questionnaire. Questionnaires will be distributed on iPads during their clinic visit
47930250|NCT00569751|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
47930251|NCT04309123|DEVICE|TransAeris System|The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
47930252|NCT04937400|OTHER|Daily screening for delirium|Each child will be screened twice daily for delirium throughout the transplant hospitalization
47930253|NCT03529071|BEHAVIORAL|CKD-Question Prompt Sheet|The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
48453263|NCT00651131|DRUG|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
47930254|NCT03915860|DRUG|Trifarotene|Topical Cream
48453264|NCT04888039|OTHER|quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)|"Excepted the delivery of quality of life questionnaires (a maximum of 5 times during the course of treatment) specific to this study, only the data available during the course of patient care will be collected.~The quality of life questionnaires and the perceived stress questionnaire will be given to patients :~* At diagnosis (before starting 1st line of treatment),~* after the induction phase (before autologous transplantation for patients who will be transplanted),~* after the consolidation phase,~* after the maintenance phase : 1 year and 2 years after the start of the maintenance."
48453265|NCT06082102|DRUG|Orelabrutinib|Orelabrutinib Tablets
48453266|NCT06082102|DRUG|Lenalidomide|Lenalidomide Capsules
48453267|NCT06082102|DRUG|Rituximab|Rituximab Injection
48453268|NCT06082102|DRUG|Orelabrutinib Placebo|Orelabrutinib Placebo Tablets
48453269|NCT03817151|PROCEDURE|posterior chamber intraocular lens implantation|patients who underwent transscleral sutured posterior chamber intraocular lens implantation
48453270|NCT05988840|OTHER|Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.|Using the tool developed by Emobot, EMOACQ-1 is a study that passively and non-interventionaly collects data by capturing patients' facial expressions throughout the day, and then measures the correlation between emotional signals and the results of measurement questionnaires used in psychiatry.
48453271|NCT05693623|OTHER|cold application|cold application
47930255|NCT06019338|OTHER|Pain Diary use|Validation of a pain diary specifically designed to capture pain dimensions of Trigeminal Neuralgia
47930256|NCT05853731|DEVICE|Green light emitting diode|Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.
47930257|NCT05853731|DEVICE|White light emitting diode|Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
47930258|NCT05958693|DRUG|Artemether-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
48098460|NCT06224270|BIOLOGICAL|Adjuvanted Recombinant Zoster Vaccine (RZV)|The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
48098461|NCT05708833|DEVICE|Intraosseous venous access|Immediate placement of humeral intra-osseous venous access (after a first failed attempt of peripheral venous access)
48622344|NCT06333964|DRUG|AST-001|AST-001, PO bid for 24weeks (dosage according to weight range)
48622345|NCT06333964|DRUG|Placebo of AST-001|Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
47930259|NCT05958693|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
47930260|NCT00921245|DRUG|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
48453272|NCT06157268|OTHER|Natural history and non therapeutical therapy|"This study concerns a natural history study part and a muscle fatigability part.~For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation."
48453273|NCT04814160|PROCEDURE|mixture of bioactive glass and autogenous bone graft|bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
48453274|NCT04814160|PROCEDURE|autogenous bone graft|bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
48622346|NCT00310518|DRUG|ARQ 501|
48622347|NCT04136132|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
47930261|NCT03018665|DRUG|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
47930262|NCT03018665|DRUG|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
47930263|NCT03018665|DRUG|Metformin|oral，0.85g，twice a day in three months
47930264|NCT02608333|BEHAVIORAL|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
47930265|NCT02608333|BEHAVIORAL|control group|"heteregenous as usual community intervention"
47930266|NCT04112498|DRUG|relatlimab|Specified dose on Specified days
47930267|NCT04112498|DRUG|nivolumab|Specified dose on Specified days
47930268|NCT04112498|DRUG|rHuPH20|Specified dose on Specified days
47930269|NCT06074770|OTHER|no intervention|Natural exposure of iodine
47930270|NCT06332469|BEHAVIORAL|Internet based education and support program for patients awaiting kidney transplantation|"A guided internet based support an education program consisting of 9 modules running over 9 weeks. First, an introductory module is given that involves goal setting, followed by two educational modules with information regarding kidney disease, treatment and self-care in severe renal failure and while waiting for kidney transplantation, and kidney transplant-specific areas. Supportive content consist of three behavioral components spread over five modules/weeks and are based on cognitive behavioural therapy principles. The last module is a summation focusing on consolidating the knowledge learned during the program.~Each module consists of texts, illustrations, short films, reminders to practice physical activity and weekly homework for which the participants receive feedback from a contact person."
47930271|NCT05551442|PROCEDURE|To explore the comparative study of different positioning methods in robot assisted laparoscopic pyeloplasty.|The incidence of surgical positioning time and secondary berths, surgical time, intraoperative blood loss and intraoperative complications were compared among the three groups.
47930272|NCT05551442|DEVICE|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform|To discuss the comparative study of different position placement methods of renal pelvis ureteroplasty on the Da Vinci robotic Xi platform
47930273|NCT02562690|OTHER|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
47930274|NCT06147375|DRUG|Tacrolimus or Cyclosporine A|The protocol of IS withdrawal:Week 1-4 take Tacrolimus (Tac) or Cyclosporine A (CsA) once daily for weeks. Week 5-8 medication reduction to taking Tac / CsA 4 times a week . Week 9-12 reduction to taking Tac/ CsA 3 times a week. Week 13-18 reduction to taking Tac / CsA 2 times a week . Week 19-24 reduction to taking Tac/ CsA once per week. Week 25, the recipients will stop taking Tac/ CsA.
47930275|NCT00306111|DRUG|pegfilgrastim|Single dose (6mg) one day after chemotherapy
47930276|NCT01111929|DRUG|Counseling for LAM+ LNG-EC|"They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer."
47930277|NCT01711060|DRUG|oxytocin|
47930278|NCT01711060|PROCEDURE|balloon catheter|
47930279|NCT06458075|BEHAVIORAL|CO-LEAD|The investigators will provide clinicians with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill data and the DOSE-Nonadherence-SLE survey, and engage and formulate solutions to adherence barriers together. The study team will provide the clinician intervention training in-person or virtually and will include didactics, demonstration, and practice that include two one-hour sessions one month apart. After training, CO-LEAD clinicians will be encouraged to incorporate the intervention in regular clinic visits with all patients.
47930280|NCT03700541|DRUG|Morphine|Morphine intravenous
47930281|NCT03700541|DRUG|Piritramid|Piritramid intravenous
48453275|NCT00115063|BEHAVIORAL|group sessions|group sessions lead by a trained primary care clinic employee
47930284|NCT02438358|DRUG|LUM015|
47930285|NCT02438358|DEVICE|LUM 2.6 Imaging Device|
47930286|NCT02890615|BEHAVIORAL|Depression self-care|Toolkit and coaching
47930287|NCT00296608|DRUG|fluorouracil|
47930288|NCT00296608|DRUG|leucovorin calcium|
47930289|NCT00296608|PROCEDURE|conventional surgery|
47930290|NCT00296608|RADIATION|radiation therapy|
47930291|NCT01230203|PROCEDURE|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
47930292|NCT06246942|DEVICE|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, Bonn, Germany).
47930293|NCT06246942|DEVICE|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, Bonn, Germany).
47930294|NCT06246942|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Structural, diffusion, and functional MRI with a 3-Tesla Siemens scanner
47930295|NCT05506605|DRUG|Doravirine 100Mg Tab|Switch from Etravirine to Doravirine
47930296|NCT04049682|BEHAVIORAL|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
47930297|NCT01150344|DRUG|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
48453276|NCT00115063|DRUG|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
48453277|NCT00115063|BEHAVIORAL|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
48453278|NCT00115063|OTHER|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
48453279|NCT00115063|OTHER|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
48453280|NCT00492076|BIOLOGICAL|Pangramin Plus D. pteronyssinus 100%|"1. Active. Pangramin Plus D. pteronyssinus 100%~2. Placebo. Pangramin Plus placebo"
48453281|NCT00828321|DRUG|Ramipril 10 mg capsule|1 x 10 mg
48453282|NCT00828321|DRUG|Altace® 10 mg capsule|1 x 10 mg
48453283|NCT02518945|DRUG|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
48453284|NCT02518945|DRUG|Insulin|
48453285|NCT02518945|DRUG|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
48622348|NCT05580120|BEHAVIORAL|Online-supervised exercise group|Participants in the online-supervised exercise group were provided with an online-supervised exercise program by using the video conferencing method three times a week for 6 weeks on the Zoom application. The exercise program was carried out synchronously
48622349|NCT05580120|BEHAVIORAL|Unsupervised-exercise training group|The unsupervised-exercise training group was informed about how to do the same exercises by another researcher, a nurse academician, on the online platform by using the lecturing method. Each training intervention took approximately 30 minutes.
48622350|NCT00186797|PROCEDURE|Allogeneic stem cell transplant|
47930298|NCT01150344|DRUG|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
47930299|NCT01107379|DEVICE|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
48622351|NCT00186797|DRUG|Fludarabine, Cyclophosphamide|
47930300|NCT01143233|OTHER|control formula|infants are fed a commercial hydrolyzed formula
48622352|NCT02578797|DRUG|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
47930301|NCT01143233|OTHER|intervention formula 1|formula has hydrolysed protein and a different protein content
47930302|NCT01143233|OTHER|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
47930303|NCT01143233|OTHER|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
47930304|NCT00928122|DEVICE|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
47930305|NCT00928122|DEVICE|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
47930306|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
47930307|NCT00928122|DEVICE|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
48098462|NCT05708833|DEVICE|Peripheral venous access|Looking for peripheral venous access, changing the site of puncture, the caliber of the catheter and/or the operator and/or assistance tools (ultrasound, infra-red guidance...) and/or using another route (oral, rectal, subcutaneous, intramuscular route and central venous access)
48098463|NCT03556605|OTHER|OneTouch Reveal® Mobile APP system|Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
48453286|NCT02518945|DRUG|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
48453287|NCT05772702|DEVICE|Closed-loop tACS|Individual alpha tACS
48453288|NCT02855853|OTHER|serious game et virtual reality|
48453289|NCT02855853|OTHER|Nintendo Wii|
48453290|NCT04356729|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
48453291|NCT04356729|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
48453292|NCT04963270|DRUG|Satralizumab|Satralizumab will be administered as a subcutaneous injection
48453293|NCT04963270|OTHER|Placebo|Satralizumab placebo will be administered as a subcutaneous injection
48453294|NCT05154890|DRUG|Pegtarviliase IV|Administered IV
48453295|NCT05154890|DRUG|Pegtarviliase SC|Administered SC
48453296|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- anodal group|2mA/20mins/session;
48453297|NCT06562504|DEVICE|Transcranial direct current stimulation (tDCS)- sham group|0mA/20mins/session
48453298|NCT06562504|DEVICE|transcranial alternating current stimulation (tACS)-tACS group|1.5 mA/20 min/session; 6HZ, theta
48453299|NCT06056115|DRUG|Tislelizumab,Platinum|"1. Induction therapy stage:~   Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment.~2. Maintenance treatment phase:~After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy ."
48453300|NCT03162159|OTHER|Collection of growth and bone maturation data|
48453301|NCT04452786|PROCEDURE|Endoscopic sleeve gastroplasty|Four-hour solid mixed meal test
48622353|NCT05330949|DIAGNOSTIC_TEST|Optical coherence Tomography Angiography, Uterine artry doppler|vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
48453302|NCT04452786|PROCEDURE|Laparoscopic sleeve gastrectomy|Four-hour solid mixed meal test
48453303|NCT05613972|OTHER|Brief Suicide and Trauma Therapy|12-week trauma therapy
48453304|NCT00486187|DRUG|rosiglitazone|
48453305|NCT00486187|DRUG|metformin or sulfonylurea|
48453306|NCT06619093|OTHER|blood sampling|3 additional citrate tubes (2.7mL)
48453307|NCT00873587|PROCEDURE|Chest tube pull on inspiration|Pull chest tube on Inspiration
48453308|NCT00873587|PROCEDURE|Expiration|Pull chest tube on Expiration
48453309|NCT04547309|RADIATION|68Ga/18F-HER2 Affibody PET/CT scan|HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
47930308|NCT00928122|DEVICE|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
47930309|NCT03290482|DIAGNOSTIC_TEST|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
47930310|NCT03290482|DEVICE|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
47930311|NCT03290482|DIAGNOSTIC_TEST|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
47930312|NCT01311869|DIETARY_SUPPLEMENT|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
47930313|NCT01311869|DIETARY_SUPPLEMENT|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
47930314|NCT02158364|DRUG|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
47930315|NCT01247805|DRUG|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
47930316|NCT01247805|DRUG|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
47930317|NCT01247805|DRUG|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
47930318|NCT05838989|DEVICE|Prefabricated Orthoses|Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.
47930319|NCT05838989|OTHER|general and lumbrical muscle stretching|Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.
48453310|NCT06389448|DEVICE|pCLE-gastr|After identifying the location of the lesion through white light endoscopy, the pCLE operation is performed to acquire images from the specific gastric lesions, and finally the ESD routine is performed.
48453311|NCT02704091|DRUG|Smecta|
48453312|NCT02704091|DRUG|Smecta placebo|
48453313|NCT05127057|OTHER|PRIME Parkinson Care|A novel model of care
48453314|NCT05127057|OTHER|Usual Care|Usual NHS Care
48453315|NCT00833300|DRUG|Haloperidol|"* 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
48453316|NCT00833300|DRUG|Olanzapine|"* 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician."
48453317|NCT01730846|DRUG|Doxazosin 4mg/day|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
48098464|NCT03556605|OTHER|Current Blood Glucose Monitor|Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
48098465|NCT04487587|DRUG|Cediranib, Olaparib|Cediranib film coated tablet, Olaparib film coated tablet
48453318|NCT01730846|DRUG|Placebo|Placebo
48453319|NCT01730846|DRUG|Doxazosin 8mg/day|8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
48453320|NCT04056585|PROCEDURE|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
48622354|NCT01952951|DRUG|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
48453321|NCT04056585|PROCEDURE|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
48453322|NCT00348764|DRUG|lauromacrogol|
48453323|NCT02393014|PROCEDURE|Simple physical exercises|"1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
48453324|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + pembrolizumab|MIV-818 - oral capsules; pembrolizumab - IV
48453325|NCT03781934|DRUG|MIV-818 (fostroxacitabine bralpamide) + lenvatinib|MIV-818 - oral capsules; lenvatinib - oral capsules
48453326|NCT01236287|DRUG|Voclosporin|Subjects will receive voclosporin capsules, twice daily
48453327|NCT03195595|DEVICE|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
48453328|NCT03195595|DEVICE|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
48453329|NCT06507553|BIOLOGICAL|Trivalent-Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48453330|NCT06507553|BIOLOGICAL|Augment-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48453331|NCT06507553|BIOLOGICAL|TIV-2X Darwin influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48453332|NCT06507553|BIOLOGICAL|Trivalent-Tasmania influenza vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48453333|NCT05119725|DEVICE|continous 3 day EKG monitoring with S-Patch Cardio|continous 3 day EKG monitoring with S-Patch Cardio
48453334|NCT04660864|DEVICE|Nasal cavity cooling device.|The RhinoChill® system cools by intranasal evaporation of a liquid coolant sprayed onto the surface of the nasal cavity. The RhinoChill® system is intended for use for the relief of pain and symptoms associated with acute migraine attack.
48453335|NCT00932763|DRUG|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
48453336|NCT00932763|DRUG|Norvasc|10 mg dose (Pfizer, USA)
48453337|NCT03272685|DRUG|Very Low Nicotine Content Cigarettes|0.4 mg nicotine/g tobacco; 9 mg tar
48453338|NCT03272685|DRUG|Normal Nicotine Content Cigarettes|15.8 mg nicotine/g tobacco; 9 mg tar
48453339|NCT01009229|DIETARY_SUPPLEMENT|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
48453340|NCT03072030|BIOLOGICAL|GamEvac-Combi (vaccine)|vaccination
48453341|NCT03072030|BIOLOGICAL|Placebo|vaccination
48453342|NCT06541327|DRUG|Chimeric Antigen Receptor|CAR-T
48453343|NCT05166109|DRUG|Vamorolone|Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
48098466|NCT02646592|DRUG|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
48280045|NCT04114305|BEHAVIORAL|ECD Intervention|"Modeled on the Early Learning Resource Unit's Family \& Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits."
48280046|NCT01485874|DRUG|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
48098467|NCT02646592|DRUG|sevoflurane or propofol|
48098468|NCT05383872|DEVICE|Focused Ultrasound (Exablate Model 4000)|BBB opening via Exablate Type 2 system with microbubble resonators and drawing blood before and after opening
48280047|NCT01485874|DRUG|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"
48280048|NCT03652909|DEVICE|Ascending Hearing Technologies device|Personal Sound Amplification Device
48280049|NCT04516304|DIETARY_SUPPLEMENT|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
48280050|NCT04516304|DIETARY_SUPPLEMENT|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
48280051|NCT06362785|DEVICE|Virtual Reality|The intervention group will engage in immersive virtual reality sessions with interactive activities involving functional movements of the spine and limbs in a virtual environment using Meta Quest 3 goggles. The intervention will last for 6 weeks, comprising a total of 12 sessions, with a maximum duration of 30 minutes of virtual reality and 15 minutes of rest (45 minutes in total per session).
48280052|NCT03728244|DRUG|MEBO ointment|The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
48280053|NCT03728244|DRUG|Hyaluronic Acid gel|Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
48453344|NCT05166109|DRUG|Placebo|Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
48453345|NCT02061280|DRUG|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
48453346|NCT02061280|DRUG|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
47930320|NCT05838989|OTHER|Placebo|Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
47930321|NCT00002165|DRUG|Nelfinavir mesylate|
47930322|NCT02253927|DRUG|BILR 355 - D1|
47930323|NCT02253927|DRUG|BILR 355 - D2|
47930324|NCT02253927|DRUG|BILR 355 - D3|
47930325|NCT02253927|DRUG|BILR 355 - D4|
47930326|NCT02253927|DRUG|Ritonavir|
47930327|NCT02253927|OTHER|high fat breakfast|
47930328|NCT01216371|DRUG|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
47930329|NCT01216371|DRUG|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
47930330|NCT03914846|PROCEDURE|Ultrasound|Undergo ultrasound with elastography
47930331|NCT04626141|DRUG|Abaloparatide|Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
47930332|NCT04626141|DRUG|Placebo|Placebo will be dispensed as a 30-day supply of disposable pen injections.
47930333|NCT04353804|OTHER|Treatment Arm: Computerized Cognitive Rehabilitation|Treatment Arm: Computerized Cognitive Rehabilitation
47930334|NCT04353804|OTHER|Active Control computer games|Active Control computer games
47930335|NCT05408793|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
47930336|NCT03086564|BIOLOGICAL|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2\*10\^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
47930337|NCT03086564|PROCEDURE|TACE|TACE solely in the first day of a clinical course.
48453347|NCT02061280|DRUG|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
48453348|NCT02640235|DEVICE|CELSTAT|
48453349|NCT02640235|DEVICE|Surgicel Original|
47930338|NCT03757013|DRUG|Apremilast|Apremilast
47930339|NCT03306797|OTHER|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~* ulnarization radialization~* prono-supination~* horizontal flexion-extension~* vertical flexion-extension hand~* grasping~* pinching~* extensors~* interosseous shoulder-elbow~* vertical flexion-extension~* push forward"
48453350|NCT00582387|GENETIC|specimen samples|blood, urine and tissue
47930340|NCT03306797|DEVICE|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
47930341|NCT00744354|DRUG|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
47930342|NCT00744354|DRUG|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
47930343|NCT00744354|DRUG|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
47930344|NCT03584529|DRUG|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
48098469|NCT04733300|BEHAVIORAL|Mindfulness-Based College for Young Adults|"MB-College (MBC) is a 9-week, 9 session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to young adults (18-29). The curriculum, which is based on the manualized and standardized Mindfulness-Based Stress Reduction (MBSR) curriculum is designed to teach participants how to integrate and apply mindfulness in their everyday lives to the range of challenges arising from medical and psychological conditions and life stresses.~MBC will be administered live, online via a video conferencing platform to participants enrolled in the active arms of the study: (1) standard dose MBC and (2) low-dose MBC. Standard dose MBC meets once a week for 2.5 hours for 9 weeks, while low-dose MBC meets for 1.5 hours per week for 9 weeks. There is an all-day retreat that takes place around week six of the program that applies to both MBC programs."
48453351|NCT00582387|BEHAVIORAL|questionnaires|
47930345|NCT05679427|RADIATION|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
47930346|NCT05505994|DRUG|DWP16001|DWP16001 A mg tablet
47930347|NCT05505994|DRUG|Dapagliflozin|Dapagliflozin tablet
47930348|NCT05505994|DRUG|DWP16001 Placebo|DWP16001 Placebo tablet
47930349|NCT05505994|DRUG|Dapagliflozin Placebo|Dapagliflozin Placebo tablet
47930350|NCT05128422|OTHER|Normobaric oxygen therapy|it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
48453352|NCT03856320|BEHAVIORAL|Educational Video|An educational video describing obesity treatment options available in the VA.
48453353|NCT03196258|BEHAVIORAL|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
47930351|NCT03221764|DRUG|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients \[8\]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
47930352|NCT03221764|DEVICE|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
48453354|NCT05054777|PROCEDURE|oncoplastic breast-conserving surgery|The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
48453355|NCT05054777|PROCEDURE|conventional breast-conserving surgery|conventional breast-conserving surgery without any oncoplastic operations
48453356|NCT03123315|DEVICE|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
48453357|NCT01212276|DRUG|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
48453358|NCT05270499|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.
48453359|NCT06562400|DIETARY_SUPPLEMENT|Palmitoyl ethanolamide|PEA supplementation (600mg twice a day for three months)
48453360|NCT06562400|BEHAVIORAL|Ketogenic diet|Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
48453361|NCT00860938|DRUG|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
48453362|NCT01299662|DRUG|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
47930353|NCT06087419|DRUG|chidamide|30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
47930354|NCT06087419|DRUG|Venetoclax Oral Tablet|400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
48280054|NCT05191628|BIOLOGICAL|Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
48453363|NCT06446479|DRUG|Dronabinol Pill|Dronabinol 20 mg
47930355|NCT06087419|DRUG|Inotuzumab Ozogamicin|0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
47930356|NCT03386877|PROCEDURE|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
47930357|NCT04661254|OTHER|Lymphapheresis|- From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin
48453364|NCT06446479|DRUG|Placebo|placebo
48453365|NCT04349475|DIETARY_SUPPLEMENT|Intervention Omega 3 Supplementation|Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)
48453366|NCT04349475|DIETARY_SUPPLEMENT|Control Safflower Oil|Participants will consume 2.5g of a Safflower oil supplement daily
48453367|NCT00091195|DRUG|romidepsin|
48453368|NCT04026815|OTHER|medical history, blood and urine tests|The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
48453369|NCT03506672|OTHER|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
48453370|NCT03506672|OTHER|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
48280055|NCT02966457|DRUG|Colistimethate Sodium|Selective oral intestinal decolonization
48453371|NCT03453268|OTHER|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities"
48453372|NCT03453268|OTHER|Control|usual treatment
48453373|NCT06284941|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound guided iliac fascia block, administered with 30ml of 0.25% ropivacaine+0.05% methylene blue
48453374|NCT02895802|BEHAVIORAL|Verbal instructions with picture diagram|verbal instructions and picture diagram
48453375|NCT02895802|BEHAVIORAL|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
48453376|NCT02895802|BEHAVIORAL|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
48453377|NCT02895802|BEHAVIORAL|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
48453378|NCT05896995|OTHER|Pilates Exercise|Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.
48453379|NCT05896995|OTHER|Mckenzie Exercise|The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
48453380|NCT06438640|BEHAVIORAL|My Anesthesia Choice-HF Model|Brief clinician training on shared decision making, paired with provision of a 1-page tabular format conversation aid listing answers to frequently asked questions regarding common anesthesia options for hip fracture surgery (spinal anesthesia; general anesthesia)
48453381|NCT02647463|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|
48453382|NCT00985439|DRUG|Diclofenac Test (lower dose)|18-mg Single dose
47930358|NCT01695876|DRUG|AMG 357|Oral administration available in varying dose strength.
48453383|NCT00985439|DRUG|Diclofenac Test (upper dose)|35-mg Single dose
48453384|NCT00985439|DRUG|Celecoxib 400 mg|Capsules 2 x 200 mg Single-dose
47930359|NCT01695876|DRUG|Placebo|Matching placebo to AMG 357 containing no active drug
47930360|NCT02574572|BIOLOGICAL|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
47930361|NCT03721445|DEVICE|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
47930362|NCT05532696|DRUG|ABT-101|Patients will receive ABT-101 by oral administration on a 28-day cycle
47930363|NCT01516333|OTHER|High GL 107|Three meals a day
47930364|NCT01516333|OTHER|Medium GL 76|Three meals a day
47930365|NCT01516333|OTHER|Medium GL 68|Three meals a day
47930366|NCT01516333|OTHER|Low GL 48|Three meals a day
47930367|NCT01547780|DRUG|[11C]PBR28 and Positron Emission Tomography (PET)|Brain PET with \[11C\]PBR28. 11C\]PBR28 is a new PET ligand that images TSPO with high levels of specific binding.
47930368|NCT04929665|PROCEDURE|Two different block and combination of these two blocks|Thoracic paravertebral block, erector spina block, and a combination of paravertebral block and erector spinae block will be applied to the patients under real-time ultrasound guidance.
47930369|NCT03761771|DEVICE|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU \> 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
47930370|NCT00480948|BEHAVIORAL|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing \~49% of C16:0 at sn-2 position), 24 wk
47930371|NCT00480948|DIETARY_SUPPLEMENT|Control|Standard vegetable oil based infant formula
47930372|NCT04434378|DRUG|Tamsulosin|0.4 mg tamsulosin will be given to a randomized group of patients
47930373|NCT04434378|DRUG|Placebo|placebo will be given to a randomized group of patients
47930374|NCT01133990|DRUG|FOLFIRI|FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
47930375|NCT01133990|DRUG|E7820|E7820 will be administered orally in tablet form once daily, every day of each 28-day treatment cycle.
47930376|NCT01133990|DRUG|Bevacizumab|Bevacizumab will be administered at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle.
47930377|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
47930378|NCT02702245|DIETARY_SUPPLEMENT|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
47930379|NCT02702245|OTHER|Placebo Comparator: Control|75 g pure glucose.
47930380|NCT01924429|DRUG|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
48453385|NCT00985439|DRUG|Placebo|Capsules 2 Single-dose
47930381|NCT00911885|BEHAVIORAL|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
47930382|NCT06518161|OTHER|Voluntary|Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
47930383|NCT02882152|PROCEDURE|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
48280056|NCT04491279|PROCEDURE|Home 'General' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the general exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
47930384|NCT02882152|PROCEDURE|morphine|Intrathecal morphine injection
48280057|NCT04491279|PROCEDURE|Home 'Neuropilates' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the neuropilates exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
48453386|NCT06627959|DEVICE|Statseal|This is a vascular closure device which works independently of the clotting cascade to seal access sites
48453387|NCT06627959|DEVICE|Figure of eight suture|The figure of eight suture is commonly used for vascular access closure
48453388|NCT04481958|BEHAVIORAL|I-PROTECT|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application (the I-PROTECT GO), including modules tailored for coaches, players, club administrators, and caregivers, respectively. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Due to pandemic restrictions, the mobile application could not be finalized, and only the module for coaches was available.
48453389|NCT05167487|DRUG|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
48453390|NCT05167487|DRUG|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
48453391|NCT01470976|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~* The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~* When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%."
48453392|NCT01470976|OTHER|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
48453393|NCT02566122|OTHER|measurements|
48453394|NCT02362464|BIOLOGICAL|Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine|dose of 20 x 10\^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally at weeks 3, 6, 9, 12, 15 and 24.
48453395|NCT05105607|DRUG|D-4517.2|Subcutaneous (SC) injection
48453396|NCT05800262|BEHAVIORAL|Dynamic stability exercises|A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
48453397|NCT02818751|DRUG|Escitalopram|Patients being randomized to receive escitalopram.
48453398|NCT02818751|OTHER|Placebo|Patients being randomized to receive placebo.
48453399|NCT05059028|OTHER|Oxytocin massage AND music therapy|"Oxytocin massage: It is a massage that will accelerate the work of the parasympathetic nerves in order to transmit the oxytocin production stimulus to the posterior lobe of the brain. Massage the scapula from the cervical 7th to the 5th-6th spine, spinal (vertebral), 1-2 cm around the spine, both thumbs up and then 2-3 times down, in a small circular clockwise, downward and upward movements. It is a form of massage by pressing hard.~Music intervention: In order to decide on the type of music to be played to the mothers during breastfeeding, three samples (Pentatonic, Büzürk makam and classical music) selected by the researcher will be asked to the postpartum mother, and the music preferred by the mothers will be determined. It will be ensured that mothers listen to the music determined 5 minutes before the breastfeeding session for 7 days and continue breastfeeding while the same music is playing."
48453400|NCT01161420|DEVICE|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
48453401|NCT06124339|BEHAVIORAL|Physical Activity|There will be three sessions a week over the course of 16 weeks.
48453402|NCT06124339|BEHAVIORAL|Cognitive Activity (VR)|There will be three sessions a week over the course of 16 weeks.
48453403|NCT06124339|BEHAVIORAL|Physical and Cognitive Activity|There will be three sessions a week over the course of 16 weeks.
48453404|NCT06371703|RADIATION|automated system in reducing radiation exposure|evaluate the effectiveness of the automated system in reducing radiation exposure for radiographers involved in PET/CT procedures.
48453405|NCT00951457|DRUG|Bendamustine|
48453406|NCT00951457|DRUG|Alemtuzumab|
48453407|NCT03923192|DEVICE|Vistacam|device for early proximal caries detection
48453408|NCT03923192|RADIATION|Bitewing radiograph|radiograph for proximal caries detection
47930385|NCT00559832|OTHER|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
48453409|NCT04820309|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
48098470|NCT04733300|OTHER|Health Education for Young Adults|The health education control group will receive young adult-specific online health resources offered through www.youngwomenshealth.org and www.youngmenshealthsite.org. Both websites provide resources to improve mental and physical health, and include opportunities to ask health questions, and learn ways to improve mental and physical well-being.
48098471|NCT03767114|DIAGNOSTIC_TEST|RT-PCR for ERAP1 detection|Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
48453410|NCT00262392|DRUG|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
48453411|NCT06072339|OTHER|Lung Ultrasound for PEEP setting|NIV is started and adjusted by the physiotherapist. For the adjustment of PEEP, the ultrasound probe is placed on the thorax, facing the intercostal space having obtained the highest score during the initial LUS (synonym of the worst pulmonary aeration) and the images observed in real time. PEEP is increased until the physiotherapist cannot see any additional benefit on pulmonary aeration or appearance of a patient discomfort or an increasing of air leaks.
48453412|NCT06072339|PROCEDURE|Non invasive ventilation session|"The session will be done via a mouthpiece preferably, or a face mask if it is impossible for the patient to close their mouth properly or to hold the mouthpiece.~The duration of the NIV session will be defined by the prescribing doctor (usually between 30 and 60 minutes), without being able to be less than 30 minutes. The session will be stopped in the event of the appearance of one of the contraindications to NIV mentioned above."
48453413|NCT06072339|BIOLOGICAL|Arterial blood gas|Arterial blood gas will be done at inclusion, at Visit 1 (at the 30th minute from the start of the 1st Non-invasive ventilation session) and at Visit 2 (at the 60th minute from the start of the 1st Non-invasive ventilation session) in both groups of patients in order to calculate the Pa02/Fi02 ratio.
47930386|NCT03036475|DEVICE|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
47930387|NCT02045953|DEVICE|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
47930388|NCT02045953|DEVICE|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
47930389|NCT00191087|DRUG|Duloxetine|
47930390|NCT00893620|DEVICE|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
47930391|NCT04139200|BEHAVIORAL|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
47930392|NCT04139200|BEHAVIORAL|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
47930393|NCT00002167|DRUG|Tin ethyl etiopurpurin|
47930394|NCT03632486|OTHER|Bedside Ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~* Lung ultrasound to assess for pleural effusions and sonographic b lines."
47930395|NCT04971330|DIAGNOSTIC_TEST|Access HCV|"All samples were tested with both reference anti-HCV assay and Access anti-HCV assay according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity. Reference assay was Abbott Architect anti-HCV assay. For blood donors, Abbott PRISM HCV was used as reference.~For the specificity cohorts (blood donor and hospitalized patient samples), all HCV Ab positive results will have supplemental confirmation testing with HCV Immunoblot for final HCV Ab status"
47930396|NCT04641520|OTHER|Shoulder clinical testing with isokinetic strength assessment|All the participants had a shoulder clinical testing including shoulder rotators range of motion and isokinetic rotator muscle strength testing
47930397|NCT01789918|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
47930398|NCT05251129|DRUG|Atorvastatin 80 Mg Oral Tablet|Higher intensity statin
47930399|NCT03203343|PROCEDURE|Operation - PIRS|Operation by its known design for PIRS group
47930400|NCT03203343|PROCEDURE|Operation - MARCY|Operation by its known design for MARCY group
47930401|NCT02095496|DEVICE|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
48453414|NCT06072339|OTHER|Interview on pain and comfort|The investigator physiotherapist interviews the participant to measure pain and comfort scores using a visual analogue scale (score from 0 to 10).
47930402|NCT02095496|DEVICE|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
48453415|NCT04264221|BEHAVIORAL|New management mode|"* New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
48453416|NCT05752721|BEHAVIORAL|Transition to Online Ordering|The intervention food pantry will transition to online ordering at least once.
48453417|NCT06548789|DIETARY_SUPPLEMENT|Prebiotic Xnack Packouts|Prebiotic snack packouts (distributed every two weeks) and diet counseling to support increased consumption of prebiotic foods which provide dietary fiber, plant-based protein and other nutrients selectively fermented by the microbiome (e.g., pulses and legumes).
47930403|NCT01238588|DRUG|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
47930404|NCT06258473|COMBINATION_PRODUCT|Multicomponent decentralized care|"1. Training and support on Simple app for HTN/DM management \& training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner~2. CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs \& CHCP care coordination supported by Simple app at community clinics~3. CHWs assist in screening, counselling, referral, and follow-up for CHW at village level"
47930405|NCT06258473|COMBINATION_PRODUCT|mHealth|Training and support on Simple app for HTN/DM patient management \& training NCD corner clinicians on clinical guidelines of Upazila Health complex
48453418|NCT04468126|OTHER|Standard oxygen|Standard low flow oxygen therapy through facemask or non-rebreathing mask at least 10 L/min.
48453419|NCT04468126|OTHER|High-flow nasal oxygen therapy|Humidified and heated oxygen with a gas flow at least 50 l/min through nasal cannula and inspired fraction of oxygen adjusted in order to maintain a SpO2 between 92 and 96%
48453420|NCT05049746|OTHER|Discussion|Participate in discussion
48453421|NCT05049746|OTHER|Interview|Participate in interview
48453422|NCT05049746|OTHER|Questionnaire Administration|Complete questionnaire
48622355|NCT01952951|RADIATION|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
47930406|NCT03102190|DRUG|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
47930407|NCT01706900|OTHER|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
47930408|NCT01706900|OTHER|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
47930409|NCT01532193|OTHER|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
47930410|NCT01910311|DRUG|Baricitinib|Administered orally
47930411|NCT01910311|DRUG|Rifampicin|Administered orally
47930412|NCT03252600|DRUG|Cyclophosphamide|Given IV
47930413|NCT03252600|DRUG|Dexamethasone|Given IV
47930414|NCT03252600|BIOLOGICAL|Elotuzumab|Given IV
47930415|NCT03252600|OTHER|Laboratory Biomarker Analysis|Correlative studies
47930416|NCT03252600|DRUG|Lenalidomide|Given PO
47930417|NCT03252600|OTHER|Pharmacological Study|Correlative studies
47930418|NCT02093351|DRUG|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
47930419|NCT02093351|DRUG|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
47930420|NCT02093351|DRUG|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
47930421|NCT02093351|DRUG|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
47930422|NCT02093351|PROCEDURE|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
47930423|NCT05470257|OTHER|Cast|Application of fiberglass long arm cast.
47930424|NCT04501029|DRUG|Gimatecan|Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.
47930425|NCT00473980|DRUG|Indomethacin, celecoxib, esomeprazole|
47930426|NCT04403009|OTHER|no intervention|no intervention
47930427|NCT05977881|OTHER|CHECKIT!|"Participants will not be assigned to the intervention as it will be available to everyone.~Check it will be a van-based HIV- and overdose-prevention program offered in the four areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not.~Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months."
47930428|NCT05081102|DRUG|FDC of oxycodone 5 mg/ibuprofen 400 mg|receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo.
47930429|NCT05081102|DRUG|Tylex|receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
47930430|NCT01221740|DRUG|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
47930431|NCT01653379|DRUG|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
47930432|NCT00767182|OTHER|blood sample|biological markers evaluated : D-Dimer, sEPCR
47930433|NCT00584740|DRUG|AIN457|10 mg/kg
47930434|NCT00584740|DRUG|Placebo|Matching placebo to AIN457
47930435|NCT00647829|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
47930436|NCT00647829|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
47930437|NCT00647829|DRUG|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
47930438|NCT00239525|DEVICE|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
47930439|NCT00239525|DRUG|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
47930440|NCT02850133|OTHER|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
47930441|NCT05062993|PROCEDURE|caudal epidural pulse radio frequency|A needle is inserted into the caudal epidural space under ultrasound guidance and pulse radiofrequency is administered at 5 Hz using a 5. ms pulse width for 600 seconds at 55 V.
47930442|NCT04368247|DIAGNOSTIC_TEST|Skin Fluorescent Imaging|Application of reagents, then imaging and scoring
47930443|NCT06078800|DRUG|YL-17231|After a screening period of approximately 14 days, eligible patients will receive oral YL-17231 once or twice daily until documented disease progression, unacceptable AEs, intercurrent illness preventing further administrations of study treatment, investigator's decision to withdrawal, the patient's consent of withdrawal, pregnancy, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient's consent of withdrawal, lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
47930444|NCT02856191|OTHER|Holter|
48098472|NCT05020795|PROCEDURE|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
48280058|NCT04491279|PROCEDURE|Supervised Neuropilates Group Class|Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor).
47930445|NCT04178356|OTHER|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
47930446|NCT04178356|OTHER|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
47930447|NCT04930380|OTHER|phone interview|Cases and controls will receive a phone interview
47930448|NCT04903821|DRUG|BAY3427080|Orally administered, single dose on Day 1 and single does once daily on Day 3 to 8
47930449|NCT02145702|OTHER|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
47930450|NCT02145702|PROCEDURE|Standard Care Dialysis|12 weeks of standard of care.
48280059|NCT04491279|PROCEDURE|Supervised General Exercises Group Class|Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility
48453423|NCT03243786|BEHAVIORAL|Lifestyle- Supportive Care|The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
48453424|NCT03829670|DIAGNOSTIC_TEST|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
48453425|NCT06449066|OTHER|Non applicable|Non applicable (data collection)
48453426|NCT05109377|DIAGNOSTIC_TEST|Endocan|Endocan will measured before and after treatment
48453427|NCT05109377|DRUG|tadalafil|tadalafil
47930451|NCT04191460|DRUG|cRGD-ZW800-1.|Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery
47930452|NCT00942071|BIOLOGICAL|MVA-NP+M1|1. Intradermal injection at 5 x 10\^7 pfu at day 0
47930453|NCT00942071|BIOLOGICAL|MVA-NP+M1|2.Intramuscular injection at 5 x 10\^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10\^8 pfu/ml at day 0
47930454|NCT00942071|BIOLOGICAL|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
48098473|NCT05090384|DRUG|Prednisone|Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
48098474|NCT02490982|DRUG|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
48098475|NCT04822129|BEHAVIORAL|Treatment as Usual|Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
48280067|NCT01989663|DRUG|1% vaginally applied tenofovir gel|
48280068|NCT01989663|DRUG|Tenofovir film- 10mg|
48280069|NCT01989663|DRUG|Tenofovir Film-40 mg|
48453428|NCT00310271|BIOLOGICAL|pPJV7630 with pPJV2012 administered by PMED|
48453429|NCT00735540|OTHER|Observational|Data summary only
48453430|NCT02070783|DRUG|ARA290|
48280070|NCT01989663|OTHER|HEC Placebo Gel|
48280071|NCT01989663|OTHER|Placebo Vaginal Film|
48280072|NCT00098787|BIOLOGICAL|bevacizumab|Given IV
48280073|NCT00098787|DRUG|fluorouracil|Given IV
48280074|NCT00098787|DRUG|irinotecan hydrochloride|Given IV
48280075|NCT00098787|DRUG|leucovorin calcium|Given IV
48280076|NCT00098787|DRUG|Oxaliplatin|Given IV
48280077|NCT00445783|GENETIC|gene expression analysis|
48280078|NCT00445783|GENETIC|mutation analysis|
48280079|NCT00445783|OTHER|immunohistochemistry staining method|
48280080|NCT00445783|OTHER|laboratory biomarker analysis|
48280081|NCT00445783|PROCEDURE|examination|
48280082|NCT00445783|PROCEDURE|mutation carrier screening|
48280083|NCT00445783|PROCEDURE|study of high risk factors|
48280084|NCT06656273|BEHAVIORAL|FT LCP|FT LCP is a behavior change software application, used as an adjunct to the standard National Diabetes Prevention Program
48453431|NCT02070783|DRUG|Placebo|
48453432|NCT00028587|DRUG|bortezomib|Given IV
48453433|NCT00028587|DRUG|paclitaxel|Given IV
48453434|NCT00028587|DRUG|carboplatin|Given IV
48453435|NCT00028587|OTHER|laboratory biomarker analysis|Optional correlative studies
48453436|NCT01034358|BIOLOGICAL|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
48453437|NCT06331715|DRUG|Palbociclib 125mg|Pharmacokinetic parameters AUC and Cmax will be evaluated to establish bioequivalence betweeen the Test and Reference products
48453438|NCT02318420|OTHER|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
48453439|NCT05547737|DRUG|Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer
48453440|NCT01053585|DRUG|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
48453441|NCT01053585|DRUG|Placebo|Placebo single 'dose' 90 minutes prior to study
47930455|NCT05198544|DEVICE|Hēlaquis Matrix is a hyaluronic acid matrix (HaM)|Hēlaquis Matrix is a hyaluronic acid matrix (HaM) derived from the American Alligator and indicated for the treatment of chronic wounds. Hyaluronic Acid (HA) is a naturally occurring non sulphated glycosaminoglycan consisting of a linear sequence of D-glucuronic and N -acetyl-Dglucosamine. It is present in connective tissue and plays a role in several biological processes including tissue repair.
47930456|NCT01797770|DRUG|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
47930457|NCT01797770|OTHER|No Preparation|No laxatives or bowel preparation
47930458|NCT00522132|DRUG|Artesunate|intravenous application
47930459|NCT02202330|OTHER|Video Arm|"1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
47930460|NCT00227071|BEHAVIORAL|exercise|
47930461|NCT06345196|BEHAVIORAL|motivational interview|Motivational interviewing will be conducted in four sessions and the session duration will be maximum 40 minutes. The session will be conducted individually and online once a week. For the individual interview, the appropriate day and time will be determined with the individuals with diabetes and the researcher before the first session and the sessions will continue on the same day and time every week. The researcher will remind the participant about the time of the session by calling the participant by phone one day before each session. Motivational interview sessions will be held online on the Whatsapp platform.
47930462|NCT01710410|DEVICE|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
47930463|NCT01710410|DEVICE|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
47930464|NCT04097782|BEHAVIORAL|Antenat education|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
47930465|NCT00312754|DRUG|Atazanavir|
47930466|NCT01722227|DRUG|Liraglutide|
47930467|NCT01722227|DRUG|Placebo|
47930468|NCT00392379|DRUG|Nicotine Lozenges|Nicotine lozenges, 4 mg
47930469|NCT00392379|DRUG|Placebo lozenge|Placebo lozenge
47930470|NCT06046352|PROCEDURE|Electrophysiological study (and ablation when appropriate)|Electrophysiological study (and ablation when appropriate)
47930471|NCT01781091|DEVICE|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
48453442|NCT05921188|BEHAVIORAL|VAULT Phase 4|Children will receive an input-based word learning treatment that is designed based on principles of statistical learning.
48280085|NCT02984462|PROCEDURE|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
48453443|NCT06466733|PROCEDURE|Embolization of the middle meningeal artery|Embolization of the middle meningeal artery ipsilateral to the chronic subdural hematoma is performed infusing embolic polyvinyl alcohol (PVA) microparticles.
48453444|NCT06466733|PROCEDURE|Surgical Evacuation via burr hole or craniotomy|The standard of care for chronic subdural hematoma, burr hole or craniotomy are performed ipsilateral to the lesion.
48453445|NCT04863560|OTHER|Auditory Cueing|Metronome beat to step in time with
48453446|NCT04863560|OTHER|Visual Cueing|Lines on the floor to step over
47930472|NCT01781091|DEVICE|Conventionals Modes|
47930473|NCT05988502|OTHER|auricular acupressure|"The well-trained researcher nurse in this study was performed the AA intervention. First of all, the participant was instructed to find a comfortable position. Disinfect the ears using cotton with 75 % alcohol was then provided and followed by placed vaccaria seeds (Beijing, China) with an adhesive patch onto the unilateral each selected auricular acupoint (left ear first) Participants were pressed each acupoint by thumb and index finger for one minute, four times a day, five days a week, remove the taped seeds on the 6th day, and then replaced the opposite ear two days after. They were noted that they experienced various sensations while pressing, including numbness, swelling, mild pain, or warmth. Seeds were taped on the other side of the ear weekly for two weeks.~Two TCM physicians verified the conduct of the AA protocol, which consisted of a selection of acupoints, length of stimulation time, finding location of acupoint, and procedure of practice."
47930474|NCT04692727|OTHER|Exercise program|"* Hamstring, quadriceps, gastrocnemius, iliopsoas, iliotibial band (ITB), lateral and medial retinaculum stretching exercises~* Isometric exercises of vastus medialis, gluteus medius and external rotators~* Isotonic exercises of vastus medialis, gluteus medius and external rotators~* Closed kinetic chain exercises~* Balance and coordination exercises~* Core stabilization exercises"
47930475|NCT04692727|OTHER|McConnel patellar taping technique|Individuals are placed in a supine position with their knees extended and the quadriceps relaxed. A 5 cm wide hypoallergenic band is applied transversely over the patella without affecting the position of the patella. Then, it is started at the lateral edge of the patella with a rigid tape. The tape is terminated at the medial femoral condyle after a medial pull and / or medial tilt to the patella.
47930476|NCT04692727|OTHER|Femoral rotational taping technique|This technique is applied in a standing position and hip extreme external rotation. Taping is started on the vastus medialis and is pulled diagonally from the anterior of the leg to the lateral and ends on the trochanter major.
47930477|NCT01514162|DEVICE|Trifecta valve|surgical replacement of aortic valve
47930478|NCT00497809|DRUG|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
47930479|NCT03766282|DEVICE|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
47930480|NCT01373671|DEVICE|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
47930481|NCT04033588|DEVICE|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
47930482|NCT03479645|BEHAVIORAL|Serial text messages and mailed FIT kit|"1. Pre-alert SMS offering Opt-out of mailed FIT kit~2. Mailed home FIT kit~3. SMS A - Reciprocity message~4. SMS B - Offer for second FIT kit if lost/did not receive~   * Plus SMS A + C if second mailed FIT is requested.~5. SMS C - Salience message"
47930483|NCT02781740|DEVICE|Continous Positive Air Pressure Device|
47930484|NCT03787381|DEVICE|Ultrasound|Vaginal ultrasound examination
47930485|NCT00635024|BIOLOGICAL|anti-thymocyte globulin|2.5 mg/kg
47930486|NCT00635024|DRUG|melphalan|16 mg/m\^2
47930487|NCT05504876|DRUG|Midazolam Syrup|Administered Midazolam Syrup 5 mg orally once daily in fed state;
47930488|NCT05504876|DRUG|HEC74647PA|Administered HEC74647PA 100 mg orally once daily in fed state;
47930489|NCT05504876|DRUG|HEC110114|Administered HEC110114 600 mg orally once daily in fed state;
47930490|NCT04507373|DRUG|Simvastatin 40mg|40mg oral daily for 10 weeks
47930491|NCT06275529|PROCEDURE|Transforaminal Epidural Steroid Injection|"Epidural injections have been used since about 1900 for the treatment of low back and lower extremity pain, with steroids added to local anesthetics in about 1950. The epidural space can be entered by 3 approaches: caudal, interlaminar, and transforaminal. Transforaminal Epidural Steroid Injections:~After the patient is monitored in pron position and asepsis is ensured, the epidural space is entered with the appropriate needle through the transforaminal space by giving the necessary angles to the fluoroscopy. Then the location is confirmed with radiopaque agent and steroid injection is performed. The procedure takes 15-20 minutes."
47930492|NCT00314587|PROCEDURE|1 or 2 elastic stable intramedullary nails|
47930493|NCT06273683|OTHER|Hand-held bipolar energy instrument|A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.
47930494|NCT06273683|OTHER|Traditional suture ligation|Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
47930495|NCT00352352|PROCEDURE|Tongue Acupuncture (Procedure)|
48453447|NCT04863560|OTHER|tactile Cueing|Vibration to step in time with (metronome like)
48453448|NCT03260686|OTHER|experimental|video guide for upper limb exercise
47930496|NCT05982067|OTHER|mindfulness-based phsycial exercise intervention|The intervention is 12 weeks, two times a week. The MIPE intervention will be conducted in a hybrid way, a combination of face-to-face and at home, by a qualified mindfulness therapist and a qualified sport coach. Specifically, the participants will attend the face-to-face sessions once every two weeks and in other weeks, they will perform the intervention at home using videos and templates. The face-to-face sessions will be conducted at the health care centre. The intervention of each session will include 1) introduce the theme of this session, 2) mini lectures about the theme; 3) mindfulness practice related to the theme; 4) tips of keeping mindfulness during PE; 5) warm up: lead with mindfulness words; 6) resistance exercise; 7) cool down: lead with mindfulness words; 8) discussion.
47930497|NCT05982067|OTHER|health education|The number of sessions, duration, frequency, group size and delivery modality will be similar to the intervention group. The topics of the health education are the care of common diseases in the older adults, including hypertension, diabetes, osteoporosis, COPD, dementia, depression. Each session is about 70 min (same as intervention group), including 10-20 min lecture and 50-60 discussion and sharing.
47930498|NCT03829800|DIETARY_SUPPLEMENT|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
47930499|NCT03829800|DIETARY_SUPPLEMENT|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
47930500|NCT03829800|DIETARY_SUPPLEMENT|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
47930501|NCT03829800|DIETARY_SUPPLEMENT|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
47930502|NCT02982512|DRUG|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
48280086|NCT04358458|BIOLOGICAL|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
48280087|NCT04358458|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
48280088|NCT05912517|DRUG|Nipocalimab|Nipocalimab will be administered as an intravenous infusion.
48453449|NCT04940494|OTHER|collection of data|collection of data for all Obstetrical Anal Sphincter Injury women (score of quality of life, experimenting anal incontinence...)
48280089|NCT05912517|DRUG|Placebo|Placebo will be administered as an intravenous infusion.
48280090|NCT00004486|DRUG|fluoxetine|
48280091|NCT03162289|OTHER|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
48280092|NCT03162289|OTHER|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
48280093|NCT01916772|OTHER|no interventions|no interventions
48280094|NCT05106530|DIAGNOSTIC_TEST|Holter, ECG|Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.
48453450|NCT00155220|DEVICE|Low Stretch Bandage and Kinesio Tape|
48453451|NCT03740295|DIETARY_SUPPLEMENT|Coconut oil and epigallocatechin gallate|600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)
48453452|NCT03740295|OTHER|Placebo|Lactose
48453453|NCT02173886|DRUG|Bupropion SR and XL|
48453454|NCT04322344|DRUG|Escin|treatment with escin or escinate sodium
48453455|NCT04322344|DRUG|standard therapy|antiviral drugs
48453456|NCT01069536|DRUG|metoclopramide 10 mg|
47930503|NCT04770077|OTHER|Intubation on manikin|Training of medical student to focus on manikin vocal cord before intubation
47930504|NCT03331471|PROCEDURE|alveolar recruitment maneuver|applying alveolar recruitment maneuver using the anesthesia machine
47930505|NCT03331471|PROCEDURE|conventional ventilation|conventional ventilation using the anesthesia machine
48453457|NCT04376190|RADIATION|low level laser therapy|In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
48453458|NCT01075282|DRUG|Insulin Glargine|
48453459|NCT01075282|DRUG|LY2189265|
48453460|NCT01075282|DRUG|Metformin|
48453461|NCT01075282|DRUG|Glimepiride|
48453462|NCT04066088|OTHER|Placebo|Placebo will be administered same times as GXR
48453463|NCT04066088|DRUG|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
48453464|NCT05497063|DRUG|Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine|Two tablets of 250 mg sulfadoxine / 12.5 mg pyrimethamine or 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
48453465|NCT05497063|DRUG|G-COSPE® tablets|One tablet of G-COSPE® tablets, 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
48453466|NCT02120677|DRUG|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
48453467|NCT04410380|BEHAVIORAL|Electronic tablet provision with teaching|Spanish-speaking parents are provided with an electronic tablet and taught how to use it to access health information for their children.
48453468|NCT01032213|DRUG|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
48453469|NCT01032213|DRUG|normal saline|Group S received the same volume of isotonic saline as same method.
47930506|NCT04537780|OTHER|Placebo|Placebo tabled every day
47930507|NCT04537780|DRUG|Montelukast|Montelukast 10 mg daily at bed time.
47930508|NCT06520969|OTHER|Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)|Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients
47930509|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
47930510|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
47930511|NCT00395057|DRUG|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
47930512|NCT00395057|DRUG|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
47930513|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
47930514|NCT04858178|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
47930515|NCT04858178|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
47930516|NCT04858178|DEVICE|Transcutaneous spinal cord stimulation|Transcutaneous spinal cord stimulation will be applied at T7-L1 spinal segments to assess alterations in autonomic neuroregulation.
47930517|NCT00627614|OTHER|breast imaging study|"1. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
47930518|NCT00880464|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
48453470|NCT03049215|DEVICE|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
48453471|NCT03049215|DEVICE|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
48453472|NCT03488147|DRUG|Esomeprazole|20 mg esomeprazole tablet
48453473|NCT03488147|DRUG|Placebo Oral Tablet|resembling esomeprazole tablet
47930519|NCT01797172|PROCEDURE|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
47930520|NCT01797172|PROCEDURE|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
47930521|NCT04140032|BEHAVIORAL|Multi-level preschool obesity control intervention|The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
47930522|NCT04303923|PROCEDURE|Ultrasonography|The diameters of both the radial artery and the distal radial artery were measured by ultrasonography.
47930523|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
47930524|NCT00591578|DRUG|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
47930525|NCT00591578|DRUG|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
47930526|NCT00782587|DRUG|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
47930527|NCT04571229|DRUG|L-MTP-PE|L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
47930528|NCT03620656|DIAGNOSTIC_TEST|FibriCheck|Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
47930529|NCT04200040|BIOLOGICAL|OrienX010 injection|"OrienX010 to be used in this study have been developed and manufactured by OrienGene Biotechnology Ltd.~Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd."
47930530|NCT04200040|DRUG|Dacarbazine (DTIC)|Dacarbazine to be used in this study was manufactured by Sinopharm A-Think Pharmaceutical Co., Ltd.
47930531|NCT03462901|PROCEDURE|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .|A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
47930532|NCT02643056|DRUG|Panitumumab|IV administration every 2 weeks
47930533|NCT04816409|OTHER|conventional therapy|"Range of motion and Resistance training Linear actions are used to regularize extensor muscle tone (Neck extensors, back extensors hip extensors, knee extensors).(49) Postural control exercises Bouncing on gym ball in sitting, kneeling, or standing~- Linear swinging using a platform and swing, glider, hammock, and barrel; swinging in the kneeling, standing, sitting,"
47930534|NCT04816409|OTHER|Neurodevelopmental therapy|"Starting Posture~* Start and evaluate the supreme effective posture to move from(usually straight)~* Reassemble to mid plane (head/trunk)~* Neutral position of body (47) Identify the Missing Components Detect starting posture and compare to normal.(47)~Neurodevelopmental therapy application :~Tonic postural extensor muscle strengthening:~Push-pull scooter board games contrary to resistive tubing strips.(48) 2. Developmental movement patterns training: Obstacle crawl, hold swing's ropes in kneeling and half kneeling position, throw balls to aim kneeling and standing position. Manual Cues .Use hands on key points of control to assist normal posture, movement and prevent abnormal posture and movement. Balance and corrective reactions was established by means of ball and tilt board after the development of the skill of~li"
47930535|NCT05207189|BIOLOGICAL|UVT|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.
47930536|NCT05214079|DEVICE|Left paratracheal pressure|Applying Left Paratracheal pressure and testing its effectiveness using gastric tube . in addition , by using the dynamometer , the CP 50 is defined.
47930537|NCT06521450|PROCEDURE|anti incontinence surgery|anti incontinence surgery with prolapse surgery will be performed simultaneously
47930538|NCT05764070|DEVICE|non-invasive auricular vagus stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.
48453474|NCT04665596|DEVICE|Ultrasound treatment|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
48453475|NCT02226289|DRUG|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
47930539|NCT05764070|DEVICE|Placebo Non Invasive Vagus Stimulation|Placebo Non Invasive Vagus Stimulation
47930540|NCT03787979|OTHER|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
47930541|NCT03787979|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
47930542|NCT05763355|PROCEDURE|Biopsy|Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
47930543|NCT05713669|BEHAVIORAL|Encounter visit with Patients|Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
47930544|NCT05713669|BEHAVIORAL|Non-encounter surveys|Surveys will be completed pre and post patient follow-up.
47930545|NCT03303027|DEVICE|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
47930546|NCT03303027|DEVICE|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
47930547|NCT00924781|DRUG|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
48453476|NCT04480983|DEVICE|Multidetector Computerized Tomography (MDCT)|To evaluate the role of MDCT in diagnosis of non traumatic causes of acute abdomen in pediatric patients with clinical and surgical correlation.
48453477|NCT06408168|DRUG|Fulvestrant|Given by PO
48453478|NCT06408168|DRUG|Repotrectinib|Given by IV
48453479|NCT02042859|DEVICE|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
48453480|NCT00815087|DEVICE|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
48453481|NCT00815087|BEHAVIORAL|Exercise home program|Daily exercise training
48453482|NCT02839252|BEHAVIORAL|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
47930548|NCT00924781|DRUG|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
47930549|NCT00924781|DRUG|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
47930550|NCT00796887|DRUG|Extended-Release Niacin|500mg tablet once daily
47930551|NCT00796887|DRUG|Extended-Release Niacin|1000mg tablet once daily
47930552|NCT00796887|DRUG|Placebo|Placebo tablet once daily
48098476|NCT04822129|BEHAVIORAL|Cogtrastim Model|The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.
48098477|NCT00913328|DRUG|Montelukast (Singulair)|10 mg tablet once daily
48098478|NCT00913328|DRUG|Placebo|Oral placebo once daily
48453483|NCT00809250|BIOLOGICAL|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
48453484|NCT04486066|BEHAVIORAL|Mindfulness-Based Stress Reduction|In MBSR, participants meet by video for 2 hours per week for 8 weeks in a group format and receive instruction in mindfulness meditation according to a standardized curriculum, are given daily homework, participate in group discussions, and can ask questions.
48453485|NCT04486066|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 video sessions in a group format, while retaining all essential elements.
48453486|NCT04486066|OTHER|Usual Care|Veterans randomized to usual care will continue to be followed by their usual care providers for all medical and mental health care. This can include continued use of medications, specialty referrals and other usual elements of care. They will be asked to not enroll in the specific MBSR or CBT-CP interventions during the 8-month study period, but can attend other groups interventions, such as CBT-Insomnia, Acceptance and Commitment Therapy for Chronic Pain, and other groups for chronic pain and PTSD as directed by their treating providers. They can also enroll in MBSR or CBT-CP at the completion of the study.
47930553|NCT06485115|DEVICE|Digital Telerehabilitation (Euleria Home)|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the EG patients will perform the Digital Telerehabilitation program at home. The three weekly sessions will be asynchronous (with the caregiver's supervision if necessary). At each Unit, the physiotherapist will develop the training sessions on the Home- based Digital Telerehabilitation program and monitor the training execution provided by the digital device to adapt the rehabilitation treatment to the patients' improvements/difficulties. The Digital Telerehabilitation device (Euleria Home, Euleria Health) will consist of one wearable sensor and an app on a tablet that guides the patient through the customized exercise-therapy path configured by the professional. The sensor is worn on different body segments to monitor movements and provides real-time feedback on angles, balance, and repetitions.
47930554|NCT06485115|OTHER|Conventional therapy|After the in-hospital rehabilitation treatment (1 h/day, 3 days/week), the CG patients will be advised to perform the Self-management activities learned during the in-hospital rehabilitation training without home-based Digital Telerehabilitation devices.
47930555|NCT04479462|PROCEDURE|total joint arthroplasty|The surgery includes primary, revision or partial joint arthroplasty.
47930556|NCT03109912|BEHAVIORAL|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
47930557|NCT03109912|BEHAVIORAL|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
47930558|NCT03109912|BEHAVIORAL|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
47930559|NCT03109912|BEHAVIORAL|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
47930560|NCT01335802|GENETIC||Genetic counseling
47930561|NCT03862508|OTHER|Plyometric exercises|"Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model)."
47930562|NCT01330017|DRUG|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
47930563|NCT01330017|DRUG|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
47930564|NCT01330017|DRUG|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
47930565|NCT04689412|DRUG|Resveratrol|Nasal administration of resveratrol
47930566|NCT01649453|DEVICE|Pathwork® Tissue of Origin Test|
47930567|NCT05364801|OTHER|Survey|Online anonymous survey
47930568|NCT01642810|BEHAVIORAL|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
47930569|NCT01642810|OTHER|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
47930570|NCT06482216|BIOLOGICAL|Varicella vaccine|lyophilized powder,subcutaneous injection
47930571|NCT05023824|DRUG|alpha-blocker or 5-ARI withdrawal|Withdrawal of either alpha-blocker or 5-ARI
48453487|NCT05647005|OTHER|Classical music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to classical music for 30 minutes after the babies are fed.
47930572|NCT05023824|DRUG|Maintenance of alpha-blocker and 5-ARI|Maintenance of alpha-blocker and 5-ARI
47930573|NCT02067052|PROCEDURE|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
47930574|NCT02067052|PROCEDURE|Surgery|Vulvectomy \& lymphadenectomy
48098479|NCT05585580|DRUG|Serplulimab|300mg d1 q3w
48098480|NCT05585580|DRUG|Lenvatinib|8mg po qd
48453488|NCT05647005|OTHER|Harp music|A total of 15 sessions of music will be applied to this group, two or three days a week, on different days, 3 sessions a day. Sessions will be in the form of listening to harp music for 30 minutes after the babies are fed.
48453489|NCT00827463|BIOLOGICAL|dosage of the NFS and iron|a blood test will be made.
48098481|NCT05585580|DRUG|Paclitaxel/Paclitaxel-albumin/Paclitaxel liposome|135\~175mg/m2 /260mg/m2/135-175mg/m2 d1 q3w
48453490|NCT02928185|BEHAVIORAL|semi-structured interviews|
48453491|NCT06627751|BIOLOGICAL|Mezigdomide|Given PO
48453492|NCT06627751|DRUG|Carfilzomib|Given IV
48453493|NCT06627751|DRUG|Dexamethasone|Given PO
48453494|NCT06627751|PROCEDURE|Echocardiography|Undergo ECHO
48453495|NCT06627751|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48453496|NCT06627751|PROCEDURE|Computed Tomography|Undergo PET/CT
48453497|NCT06627751|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT guided tumor Biopsy
48453498|NCT06627751|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration biopsy
48453499|NCT06627751|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
47930575|NCT03614975|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
47930576|NCT03614975|BIOLOGICAL|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
48453500|NCT06627751|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
47930577|NCT05985564|OTHER|imaging diagnosis|no intervention
47930578|NCT03289520|DRUG|Clopidogrel|
47930579|NCT03289520|DRUG|Placebo|
47930580|NCT01605578|PROCEDURE|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
47930581|NCT03947554|DIETARY_SUPPLEMENT|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
48098482|NCT06317636|DRUG|Ketamine|0.5 mg/kg ketamine infused intravenously over 40 minutes
48098483|NCT06317636|DRUG|Normal saline|0.9% normal saline infused intravenously over 40 minutes
48453501|NCT04375943|DRUG|Antidiabetic|Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
48453502|NCT00000458|DRUG|sertraline (Zoloft)|
48453503|NCT00000458|BEHAVIORAL|cognitive behavior therapy|
48453504|NCT06627946|PROCEDURE|TAP group|Local anesthesia 0.25% bupivacine was administered in the TAP plane
48453505|NCT00004786|DRUG|iloprost|
47930582|NCT03947554|DIETARY_SUPPLEMENT|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
48453506|NCT01548586|DEVICE|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
48453507|NCT06395792|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
47930583|NCT03947554|DIETARY_SUPPLEMENT|Placebo|800 mg excipient
47930584|NCT04139746|PROCEDURE|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
47951280|NCT06534749|DEVICE|ultrasound|Ultrasound screening: by (SonoScape A6, Yizhe Building, Yuquan, Road Shenzhen, 518051, China). General-purpose diagnostic abdominal ultrasound equipment was used, with a 7.5-MHz linear-type probe. Screenings will be performed by radiologist with appropriate practice. The ultrasound examination will take 10 min for each patient. The recordings will consist of two bilateral renal images will be obtained and one transverse and longitudinal images. The urinary bladder will be observed with the patient in a supine position, and images will be recorded when abnormalities will be identified. The following will be investigated by ultrasound: number, size (including differences between sides), and location of the kidneys; pelvic dilatation; echogenicity, and other findings indicating cysts or tumours. Shape and wall thickening of the urinary bladder, as well as ureter dilatation, will be also examined
48098484|NCT06096428|DEVICE|Pulsed-field ablation|Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
48098485|NCT06096428|DEVICE|Radiofrequency ablation|Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
48098486|NCT06390592|DEVICE|PD cycler|"Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)"
48098487|NCT03758625|BIOLOGICAL|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
48453508|NCT03875547|DRUG|Refixia®|Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
48453509|NCT04210557|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
48453510|NCT05800457|PROCEDURE|Partial synovectomy|Patients in the intervention group will undergo partial synovectomy during total knee replacement surgery
48453511|NCT00217763|DRUG|3APS|
48453512|NCT00747305|DRUG|sunitinib malate|
48453513|NCT00747305|GENETIC|gene expression analysis|
48453514|NCT00747305|GENETIC|reverse transcriptase-polymerase chain reaction|
48453515|NCT00747305|GENETIC|western blotting|
48453516|NCT00747305|OTHER|immunohistochemistry staining method|
48453517|NCT00747305|OTHER|laboratory biomarker analysis|
48453518|NCT00747305|PROCEDURE|adjuvant therapy|
48453519|NCT00747305|PROCEDURE|neoadjuvant therapy|
48453520|NCT00747305|PROCEDURE|therapeutic conventional surgery|
48453521|NCT03553979|BEHAVIORAL|Stress management program (SM)|Participants follow the SM program.
48453522|NCT03553979|BEHAVIORAL|Stress management + Buddy program (SM-B)|In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
48453523|NCT00006453|DRUG|carboplatin|
48453524|NCT00006453|DRUG|gemcitabine hydrochloride|
47930585|NCT04139746|PROCEDURE|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
47930586|NCT03320694|DRUG|Metformin|metformin 500mg twice daily \& increased until 2500mg till normoglycemia was achieved and was continued till delivery
48453525|NCT04878263|OTHER|Conventional hospitalization|Conventional care pathway : patients will be hospitalized as long as necessary and then followed according to High Health Authorities recommendations and usual practices.
48453526|NCT04878263|OTHER|FIL-EAS ic care pathway|Organized care pathway with a maximum 4 working day long conventional hospitalization followed by hospitalization at home with a follow up combining hospital and private practice competences.
48453527|NCT02075333|DIETARY_SUPPLEMENT|Ingestion of solution|Participants will ingest the solution
47930587|NCT03320694|DRUG|Insulin|The insulin group was given 3 S/C injections of regular insulin \& one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
48453528|NCT02075333|DIETARY_SUPPLEMENT|Rinising of solution|Participants rinse the solution in the oral cavity
48453529|NCT06628258|OTHER|Moiz Cleansing Lotion|"Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.~Frequency: Twice a Day Route of Administration: Topical."
48453530|NCT01747668|DIETARY_SUPPLEMENT|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
48453531|NCT01747668|DIETARY_SUPPLEMENT|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
48453532|NCT05619692|DRUG|SAGE-718|Softgel lipid capsules.
48453533|NCT05619692|DRUG|SAGE-718-matching Placebo|Softgel lipid capsules.
48453534|NCT01395628|DRUG|in vitro sensitivity-directed chemotherapy|
48453535|NCT01395628|OTHER|cell proliferation assay|
48453536|NCT01395628|OTHER|fluorescence activated cell sorting|
47930588|NCT03056599|DRUG|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
48098488|NCT03758625|BIOLOGICAL|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
48098489|NCT03758625|BIOLOGICAL|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
48453537|NCT01395628|OTHER|laboratory biomarker analysis|
48098490|NCT03758625|BIOLOGICAL|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
48453538|NCT01395628|OTHER|microscopy|
48453539|NCT06561490|RADIATION|sonographic assesment of placental thickness and volume|sonographic assesment of placental thickness and volume
48453540|NCT00041015|DRUG|cisplatin|
48453541|NCT00041015|DRUG|etoposide|
48453542|NCT00041015|DRUG|topotecan hydrochloride|
48453543|NCT03693014|RADIATION|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
48453544|NCT03693014|BIOLOGICAL|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
48453545|NCT05387603|DRUG|177Lu-DOTATOC|"The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor).~The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing."
48453546|NCT05387603|DRUG|Capecitabine|Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
48098491|NCT03758625|BIOLOGICAL|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
48098492|NCT03758625|BIOLOGICAL|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
48453547|NCT00051779|DRUG|CAL|
48453548|NCT01126463|DRUG|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
48453549|NCT05059262|DRUG|vimseltinib|CSF1R inhibitor
48453550|NCT05059262|DRUG|Placebo|Placebo
48453551|NCT00120887|DRUG|Atorvastatin|
48453552|NCT01438203|PROCEDURE|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
48453553|NCT01438203|PROCEDURE|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
48453554|NCT06433739|OTHER|standardized algorithm|standardized algorithm for the correct selection of peripheral venous catheters
47930589|NCT03056599|DEVICE|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.
47930590|NCT01889381|DRUG|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
47930591|NCT03332511|DRUG|Nilotinib|Nilotinib 300mg twice-daily
47930592|NCT01354054|PROCEDURE|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
47930593|NCT01354054|PROCEDURE|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
47930594|NCT01354054|PROCEDURE|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
47930595|NCT02003274|OTHER|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
47930596|NCT02003274|OTHER|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
47930597|NCT00005646|DRUG|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
47930598|NCT02821143|OTHER|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
47930599|NCT02821143|OTHER|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~* Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~* Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~* Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~* In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
48280095|NCT05832762|PROCEDURE|Endovascular treatment (EVT) + Best medical treatment (BMT)|"Endovascular treatment (EVT) in the experimental arm can be performed with any recanalization strategy based on the operator's choice, and anatomical and radiological situation: MT using aspiration or stent retriever, with or without stenting (CE-labelled) or angioplasty. In case of acute stenting, the use of antiplatelet drugs will be based on the operator's preference, anatomical situation, and risk of hemorrhage.~Best medical treatment (BMT) : Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies."
48280096|NCT05832762|PROCEDURE|Best medical treatment (BMT)|Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies.
48280097|NCT06275126|OTHER|CONSYDER decision aid|Web-based breast cancer surgery decision aid
47930600|NCT03171428|PROCEDURE|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
47930601|NCT03199443|DIAGNOSTIC_TEST|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
47930602|NCT00727532|DRUG|Sorafenib|400mg by mouth twice daily for 28 consecutive days
48453555|NCT01007994|DRUG|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg \> 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg \> 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg \>40 kg starting dose 20 mg titrate to 40 mg"
48453556|NCT04702685|DRUG|Ropivacaine|Local anesthetic for injection
48453557|NCT04702685|OTHER|Placebo|Bandage will be placed in the presumed injection site while patients in under general anesthesia
48453558|NCT00840398|DRUG|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
48453559|NCT00840398|DRUG|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
48453560|NCT05293106|BIOLOGICAL|Platelet Transfusion|All platelet transfusions will be given as 10mL/kg as is considered standard of care.
48280098|NCT01501487|DRUG|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
48280099|NCT01501487|DRUG|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
48280100|NCT01501487|DRUG|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
48280101|NCT01501487|DRUG|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
48453561|NCT03398486|DIAGNOSTIC_TEST|Kinesiotaping|Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
48453562|NCT03398486|DIAGNOSTIC_TEST|inactivation of trigger points (TrP)|A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
48453563|NCT06619275|DRUG|Ripretinib|Switch-Control Tyrosine Kinase Inhibitor
48453564|NCT01793584|PROCEDURE|Laparoscopic hysterectomy|LAVH, TLH
48622356|NCT02857153|DRUG|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
47930603|NCT00560521|BEHAVIORAL|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
47930604|NCT02940106|DEVICE|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
47930605|NCT02940106|DEVICE|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
47930606|NCT02363023|PROCEDURE|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
47930607|NCT01461057|DRUG|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
47930608|NCT01461057|DRUG|Cisplatin|80 mg/m2 on Day 1 of each cycle
47930609|NCT01461057|DRUG|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
47930610|NCT01461057|DRUG|Pertuzumab|840 mg once every three weeks
48280102|NCT01501487|DRUG|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
48280103|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
48280104|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
48453565|NCT01793584|PROCEDURE|Abdominal hysterectomy|TAH
48453566|NCT05312216|DRUG|Durvalumab plus Lenvatinib|"Durvalumab: 1500mg, iv.drip, Q4w Lenvatinib: 8mg, QD (body weight \< 60kg) or 12mg, QD (body weight ≥ 60kg)~Number of cycle: until subjects withdrawing the informed consent OR progressive disease OR developing unacceptable toxicity events"
48453567|NCT06558786|OTHER|EORTC QLQ-C30 questionnaire|"The EORTC QLQ-C30 has 30 items arranged into 9 scales and 6 single items. The scales are divided into 5 function scales (physical, role, cognitive, emotional, and social function), 3 symptom scales (fatigue, pain, and nausea or vomiting), and 1 global health status/quality-of-life scale. The 6 single items address specific symptoms (dyspnea, appetite loss, insomnia, constipation, and diarrhea) and the financial impact of the disease. Each item has 4 response alternatives: (1) not at all, (2) a little, (3) quite a bit, and (4) very much, except for the global health status/quality-of-life scale, which has response options ranging from (1) very poor to (7) excellent. For analysis, all questionnaire responses will be transformed into scores on a linear scale of 0 to 100 in accordance with the EORTC scoring manual. Mean scores with standard deviations will be calculated, with a higher score indicating a better health-related quality of life."
48453568|NCT06558786|OTHER|QLQ-OGS25 questionnaire|The QLQ-OGS25 is specific for esophageal, GEJ, or gastric cancer and consists of a symptom scale only. The QLQ-OGS25 has 6 scales: dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety. Scales have good reliability (α range, 0.67-0.87), and they distinguish between tumor sites and disease stage. The response format is a 4-point Likert scale. Responses to the questionnaires will be transformed into a scale of 0 to 100 using the EORTC guidelines, with a higher score indicating a deterioration of symptoms.
48453569|NCT05687123|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
48453570|NCT05687123|PROCEDURE|Computed Tomography|Undergo a CT scan
48453571|NCT05687123|DRUG|Lutetium Lu 177 Dotatate|Given IV
48453572|NCT05687123|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48453573|NCT05687123|PROCEDURE|Positron Emission Tomography|Undergo a SSR PET/CT scan
48453574|NCT05687123|DRUG|Sunitinib Malate|Given PO
48453575|NCT06626750|BEHAVIORAL|Summer Treatment Program for Pre-Kindergarteners and Kindergarteners|Children will be concurrently enrolled in our Summer Treatment Program for Pre-Kindergarteners and Kindergarteners (STP-PreK/K). The STP-PreK/K simulates a school-like schedule and runs for 7-weeks and last 7 hours/day, Monday through Friday, with periods of seatwork, large/small group activities, circle time, and classroom meetings along with a recreational period. Academic curriculum are individualized depending upon child's current level. The behavioral modification program uses a visual response cost system in which children lose points for not following classroom rules (these rules are operationalized and determined during the development phase). Dots earned are then used for daily and weekly rewards. In addition to the academic and behavioral modification program, one group of children will participate in social-emotional/self-regulation training exercises on a daily basis designed to teach them social skills and how to control their emotions, behaviors, and attention.
48453576|NCT06626750|BEHAVIORAL|School Readiness Parenting Program (SRPP)|The School Readiness Parenting Program (SRPP) helps parents of young children develop skills that support their child\&#39;s readiness for kindergarten and first grade. It focuses on positive parenting practices that enhance social, emotional, and cognitive development. The sessions cover managing child behaviors, promoting early literacy, and fostering problem-solving skills. Parents learn effective communication, consistent routines, and how to create a supportive home environment.
48453577|NCT06626750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a structured, goal-oriented therapy that helps individuals identify and change negative thought patterns and behaviors. It focuses on the link between thoughts, emotions, and actions to improve mental health. Specific to the current project, CBT can reduce stress by teaching parents to reframe unhelpful thoughts, manage challenging emotions, and develop effective coping strategies for difficult situations, leading to more positive parenting experiences.
48453578|NCT03922555|DRUG|ASTX727|ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
48453579|NCT01954277|DEVICE|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
48453580|NCT01954277|DEVICE|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
47930611|NCT01461057|DRUG|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
47930612|NCT06165770|PROCEDURE|laparoscopy|Conservative or surgery treatment for cornual pregnancies
47930613|NCT05428189|DIAGNOSTIC_TEST|Plaque Disclosing Agent|A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
47930614|NCT05428189|DEVICE|Airpolishing and ultrasonic debridement|Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
47930615|NCT02110602|OTHER|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
47951281|NCT06159608|DRUG|Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)|Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
47951282|NCT06159608|OTHER|Chronic estrogen exposure|differences in urine estrogen levels across the menstrual cycle between women groups only
48453581|NCT01686438|BEHAVIORAL|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
48453582|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
48453583|NCT01955200|DRUG|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
48453584|NCT01955200|DRUG|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
48453585|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
47930616|NCT02110602|OTHER|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
47930617|NCT03492008|OTHER|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
47930618|NCT03492008|OTHER|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
47930619|NCT03492008|OTHER|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
47930620|NCT04148729|DRUG|ESP block|Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally. 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly will perform for postoperative analgesia.
47930621|NCT04148729|DRUG|Control Group|In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
47951283|NCT02876627|BEHAVIORAL|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
48098493|NCT01912326|DEVICE|Pacemaker Implantation|Implantation of a dual chamber pacemaker
48098494|NCT00533416|DRUG|ON 01910 Na|
48453586|NCT01955200|DRUG|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
48453587|NCT04819386|OTHER|Active vision therapy sessions with the NEIVATECH Virtual Reality-based system|The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday).
48453588|NCT04552990|DRUG|Jet injection of ALA|The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
48453589|NCT04552990|PROCEDURE|Surgical excision|In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).
48453590|NCT04552990|PROCEDURE|Illumination|For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).
48453591|NCT04552990|OTHER|Incubation|After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).
48453592|NCT04263506|OTHER|Vignette with emphasis on supervisor's opinion|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without the description of supervisor's advice that does not oppose to detrimental research practice (i.e. the supervisor is fine with whatever the PhD student decides in the dilemma).
48453593|NCT02264977|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
48453594|NCT01516762|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
48453595|NCT00408018|DRUG|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
48453596|NCT02374710|PROCEDURE|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
48453597|NCT02374710|PROCEDURE|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
48453598|NCT04193241|PROCEDURE|Closure of chest tube wound|At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
48453599|NCT00506831|DRUG|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
48453600|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
48453601|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
48453602|NCT02630797|DIETARY_SUPPLEMENT|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
48453603|NCT02630797|DIETARY_SUPPLEMENT|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
48453604|NCT00137254|DRUG|Insulin|IV insulin
48453605|NCT00137254|DRUG|Stable Isotopes|IV administration of stable isotopes
48453606|NCT00137254|DRUG|Indocyanine Green|IV administration of ICG
48453607|NCT06219031|OTHER|no intervention|no intervention
48098495|NCT01188486|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Standard of care diagnostic radiotherapy procedure
48098496|NCT01188486|RADIATION|Computed Tomography (CT)|For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
48098497|NCT01188486|DEVICE|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
48098498|NCT01188486|DEVICE|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
48098499|NCT01188486|DEVICE|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
48098500|NCT01188486|DRUG|Iohexol|Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
48453608|NCT01121601|PROCEDURE|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
48453609|NCT01121601|PROCEDURE|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
48453610|NCT06563037|OTHER|No intervention|This is an observational study
48453611|NCT01710722|DRUG|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
48453612|NCT01710722|DRUG|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
48453613|NCT01710722|DRUG|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
48453614|NCT00730691|DRUG|Placebo|Placebo-matching capsules
48453615|NCT00730691|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
48453616|NCT00730691|DRUG|Duloxetine|Overencapsulated duloxetine capsules
48453617|NCT03499353|DRUG|TALAZOPARIB|Talazoparib 1mg/day
48453618|NCT02479763|PROCEDURE|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
48453619|NCT06183788|BEHAVIORAL|Remote cognitive rehabilitation program|Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
48453620|NCT05942469|BEHAVIORAL|FOREST|"The skill sessions will include didactic content defining the skill, rationale for including the skill in FOREST, and research demonstrating that practice of the skill increases positive emotion. In addition, the group will practice the skill together and will discuss ways to practice the skill at work as well as outside of work. Throughout the month, PEAs will implement the FOREST skill of the month in other existing meetings, check-ins, and team outings.~Concurrently, a module in UCAN's learning management system (LMS) will become available. The LMS modules will contain skill-related content similar to what is taught in the skill sessions, including a thorough definition of the skill, examples of ways to utilize the skill, a review or summary of the skill, and several knowledge questions to check for comprehension. The LMS content may include text, audio, images, and video components."
48453621|NCT05915858|OTHER|muscle energy technique|"Group 1: Group 2:~Muscle energy technique (Reciprocal inhibition) Stretching exercises Static stretching 2 weeks (twelve treatment session) patient supine, the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra-lateral knee (the leg on the side to be treated is crossed over the other, straight leg).~* The angle of hip flexion should not exceed 60 degree.~* The practitioner places one hand on the contra-lateral ASIS to prevent pelvis motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis for 7-10 seconds."
48453622|NCT05915858|OTHER|stretching exercise|"Following the contraction the practitioner eases the treated side leg into adduction until a sense of resistance is noted; this is held for 10-30 seconds. 2 week (twelve treatment session) practitioner manual stretches the piriformis:~* The patient lies in supine position the affected leg is placed into flexion at hip and knee so that the foot rests on the table lateral to the contra-lateral knee.~* The practitioner places one hand over the contra-lateral ASIS to stabilize the pelvis during the exercise and passively abducts and internally rotates the hip medially till the pain is bearable.~* The process is repeated 3-5 times with a 30"
48453623|NCT05173350|OTHER|RETAIN KY|The experimental group receives a combination of medical provider services, stay-at-work (SAW)/return-to-work (RTW) coordination services, and other SAW/RTW services. Services offered by the project include individualized intensive vocational services from RETAIN RTW Coordinators, with an emphasis on assistive technology, universal design, and peer support. The project provides training on SAW/RTW best practices and RETAIN, as well as financial incentives to health care professionals. The treatment group is eligible to receive the full set of RETAIN intervention activities.
48453624|NCT05173350|OTHER|Active Comparator|Those in the active comparator arm continue to receive medical services. A RTW coordinator creates a RTW plan with the enrollee and refers them to existing resources. The RTW coordinator works with enrollees for 2.5 hours total.
48098501|NCT01188486|DRUG|Iodixanol|Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
48622357|NCT02857153|DRUG|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
48622358|NCT02857153|PROCEDURE|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
48622359|NCT02857153|PROCEDURE|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
48098502|NCT03239925|RADIATION|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
47951284|NCT04294667|DRUG|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
48098503|NCT03239925|RADIATION|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
48453625|NCT06376500|DEVICE|tDCS with cognitive training programme|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes and it is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
48453626|NCT01862601|DEVICE|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
48453627|NCT04295486|DRUG|Aspirin|Non-enteric coated 81 mg Aspirin tablet.
48453628|NCT05921214|BEHAVIORAL|VAULT Phase 5|This is an input-based vocabulary learning treatment based on principles of statistical learning.
48453629|NCT05839262|OTHER|Conventional physical rehabilitation plus Active video games (CPR+AVG)|"In each session a routine of conventional physical rehabilitation and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR+AVG: Consists of conventional exercises (aerobic, muscle strengthening, postural balance and flexibility) added to a set of interactive video games available for the Nintendo Switch console."
48453630|NCT05839262|OTHER|Conventional physical rehabilitation alone (CPR)|"In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility)."
48453631|NCT01302548|DEVICE|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
47930622|NCT02755532|DRUG|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
48453632|NCT01302548|PROCEDURE|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
48453633|NCT05286229|DRUG|ABBV-383|Intravenous (IV) Infusion
48453634|NCT03864380|DIAGNOSTIC_TEST|Color retinography|Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
48453635|NCT03864380|DIAGNOSTIC_TEST|OCT-A|Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
48453636|NCT03864380|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement within 1 month before and within 1 hour after the marathon
48453637|NCT02313558|DRUG|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
48453638|NCT02313558|DRUG|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
48453639|NCT01945450|DRUG|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
48453640|NCT01945450|DRUG|Ampicillin|
48453641|NCT01945450|DRUG|Gentamycin|
48453642|NCT01945450|DRUG|Clindamycin|
48453643|NCT04277507|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
48453644|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
47951285|NCT04294667|OTHER|Placebo|Subjects will receive placebo at prespecified time-points.
47951286|NCT03814083|DEVICE|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
48453645|NCT06596226|BEHAVIORAL|Pathways Parent Mediated Intervention without Mutual Gaze|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written version of the program manual. Sessions will review information about social communication, social sensory routines, and naturalistic developmental behavioral strategies described in the program manual. Interventionists will demonstrate intervention strategies and provide caregivers with practice feedback and self-reflection.
48453646|NCT00606658|PROCEDURE|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
48453647|NCT05037318|BEHAVIORAL|Stress arousal reappraisal|Participants will watch a video explaining that stress arousal is not harmful but rather functional and adaptive for performance in stressful situations.
48453648|NCT05037318|BEHAVIORAL|Worked examples|The worked example will be in form of brief video sequences showing a physician (played by an actor) delivering the bad diagnosis of lung cancer to an SP following the SPIKES protocol.
48453649|NCT05913128|PROCEDURE|Glandular Urethral Disassembly technique|For Primary Distal Hypospadius Repair
48453650|NCT04889898|DEVICE|Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone|\[Patients only\] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
48453651|NCT04889898|RADIATION|Modified Barium Swallow Study (MBSS)|\[Patients only\] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
48453652|NCT04889898|BEHAVIORAL|Speech Intelligibility Test (SIT)|\[Patients only\] The SIT is a standardized test for measuring speech intelligibility.
48453653|NCT04889898|BEHAVIORAL|SIT Scoring|\[Listeners only\] Listeners will judge the intelligibility of speech recordings made by patients in the study.
48453654|NCT00045786|DRUG|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
48453655|NCT03097445|DRUG|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
48453656|NCT01960296|DRUG|Clopidogrel|Continue home dose of clopidogrel into surgery
48453657|NCT01960296|DRUG|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
48453658|NCT00185757|DRUG|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
48453659|NCT05096286|DEVICE|Ethos Therapy|FDA-approved treatment planning system
48453660|NCT04544033|DIAGNOSTIC_TEST|interleuken 6 level measurment|Detection of IL6 level using ELISA technique.
48453661|NCT04544033|DIAGNOSTIC_TEST|Interleukin-6 Gene-174C detection|The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
48453662|NCT05859984|DRUG|recombinant human interferon ω spray|8 ml/bottle（contain 2 million IU recombinant human interferon ω）
48453663|NCT02401906|OTHER|MRI|
48453664|NCT00735176|PROCEDURE|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
48453665|NCT00735176|PROCEDURE|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
47930623|NCT02755532|DRUG|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==\>140.1 m/z. The methodology was validated according to the international FDA recommendations.
47930624|NCT05623488|DRUG|huCART-meso cells|Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3ζ signaling domains
48453666|NCT01756807|DEVICE|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
48453667|NCT02319980|PROCEDURE|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
48453668|NCT04560725|DRUG|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
48453669|NCT01506622|DRUG|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
48453670|NCT01506622|DRUG|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
48453671|NCT01506622|DRUG|Administration of saline|Saline will be administered to control group at the end of anesthesia.
48453672|NCT03713866|DIAGNOSTIC_TEST|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
48453673|NCT03036228|DRUG|Karonudib|Dose escalation of administration with Karonudib.
48453674|NCT06628076|DIAGNOSTIC_TEST|Culture specific antibiotic therapy|Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.
48453675|NCT06628076|DIAGNOSTIC_TEST|Antibiotic|Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\&#39;s disc diffusion method on Mueller Hinton Agar.
48453676|NCT06628076|DIAGNOSTIC_TEST|Biofilm assessment|The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique
48453677|NCT06628076|DIAGNOSTIC_TEST|nanoparticle zinc oxide|Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method
48453678|NCT06628076|DIAGNOSTIC_TEST|Molecular detection of antibiotic resistance|- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.
48453679|NCT03785262|DEVICE|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
48453680|NCT03785262|DEVICE|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
48453681|NCT05981794|DEVICE|Electrical heating pad|A powered heating pad
48453682|NCT05981794|DEVICE|Sham heating pad|A heating pad that is not powered on
48453683|NCT05751447|DIAGNOSTIC_TEST|Lymph node puncture, bronchoscopy|Included patients will undergo an extra lympn node punction through oesophagus and/ or an extra bronchoscopy.
48453684|NCT05628103|DRUG|SEP-363856|SEP-363856 flexibly dosed
48453685|NCT03210363|OTHER|Human Biological samples|Blood sample
48453686|NCT04101396|DIETARY_SUPPLEMENT|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
48453687|NCT06562998|DRUG|Pentoxifylline|Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
48453688|NCT00754858|DRUG|belotecan hydrochloride|
48453689|NCT00754858|DRUG|cisplatin|
48453690|NCT01473173|DRUG|CJ-12420|
48453691|NCT01473173|DRUG|Esomeprazole 40mg|
48453692|NCT01427062|OTHER|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
48453693|NCT01427062|OTHER|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
48453694|NCT05701384|DRUG|Lazertinib|160mg po qd
48453695|NCT06272643|DIAGNOSTIC_TEST|IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography)|OCT and IVUS in Patients with LMCA lesion (25-60%)
48453696|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
48453697|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
48453698|NCT01660243|DRUG|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
48453699|NCT01660243|DRUG|Placebo|Placebo (2capsules) once daily for 8 weeks
48453700|NCT05452707|OTHER|Observation and questionnaire of active therapy|There will be an observation of the usual care; no intervention will be added.
48453701|NCT00018213|DRUG|Naltrexone Hydrochloride|
48453702|NCT00018213|DRUG|Transdermal Nicotine|
48453703|NCT03878121|BIOLOGICAL|Ad4-Env145NFL|10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
48453704|NCT03878121|BIOLOGICAL|Ad4-Env150KN|10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
48453705|NCT03878121|BIOLOGICAL|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
48453706|NCT06626165|DRUG|Mirikizumab|Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2.
48453707|NCT06626165|DRUG|Vedolizumab|Vedolizmab will be administered based on the result of Geboes score Grade 3.1.
48453708|NCT04350697|PROCEDURE|Aortic Surgery|Surgery for aortic and/or aortic valve diseases
48453709|NCT04157335|BIOLOGICAL|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
48453710|NCT04157335|BIOLOGICAL|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
48453711|NCT02336074|DRUG|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
48453712|NCT02336074|DRUG|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
48453713|NCT02336074|DRUG|Vorinostat|"Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
48453714|NCT02336074|BIOLOGICAL|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
48453715|NCT02336074|BIOLOGICAL|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
47930625|NCT05623488|DEVICE|Mesothelin Expression Testing|Laboratory Developed Test
47930626|NCT01597115|PROCEDURE|Duplex ultrasonography|
47930627|NCT00828438|DRUG|Lorcaserin 10mg|
47930628|NCT01363414|DRUG|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
47930629|NCT01363414|DRUG|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
48453716|NCT03187821|PROCEDURE|Laser peripheral iridotomy|location of laser peripheral iridotomy
47930630|NCT01403233|DIETARY_SUPPLEMENT|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
48453717|NCT01934816|OTHER|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
48453718|NCT06560593|DRUG|NTQ5082|single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
48453719|NCT06560593|DRUG|Placebo|multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
48453720|NCT06574620|GENETIC|Genetic testing|Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
48453721|NCT06574620|PROCEDURE|Optional biopsy|Optional collection of tumour tissue and normal tissue prior to the first dose of treatment and/or after the last dose of treatment.
48453722|NCT04965688|DRUG|Drug determined by treating oncologist based on recommendation from systems biology analysis.|All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.
48453723|NCT02441686|DRUG|Bortezomib|
48453724|NCT02441686|DRUG|Lenalidomide|
48453725|NCT02441686|DRUG|Dexamethasone|
48453726|NCT02441686|PROCEDURE|Stem Cell Mobilization|
48453727|NCT02441686|PROCEDURE|Autologous Stem Cell Transplant|
48453728|NCT04666636|DRUG|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
48453729|NCT04666636|DRUG|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
48453730|NCT00604162|DEVICE|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
48453731|NCT00604162|PROCEDURE|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
48453732|NCT04584749|DRUG|Lidocaine Iv|"2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine ."
48453733|NCT00744679|DRUG|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
47930631|NCT01403233|DIETARY_SUPPLEMENT|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
47930632|NCT01403233|DIETARY_SUPPLEMENT|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
48453734|NCT01983735|DRUG|TELMINUVO Tab. (80/2.5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks."
48622360|NCT02941497|BEHAVIORAL|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
48622361|NCT01769586|DRUG|Diphenhydramine|
48622362|NCT01769586|DRUG|Midazolam|
48622363|NCT01603147|BIOLOGICAL|normal saline|saline 225 ml
47930633|NCT00130442|DRUG|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
47930634|NCT00130442|DRUG|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
47930635|NCT03203278|BEHAVIORAL|Web-based exercise programme|Aerobic, resistance and balance exercises
47930636|NCT04918901|COMBINATION_PRODUCT|NO Severe COVID-19|Non-severe and critically ill patients with COVID-19
47930637|NCT02723045|PROCEDURE|Open Lichtenstein Hernioplasty|
48453735|NCT01983735|DRUG|TELMINUVO Tab. (80/5mg)|"* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks."
48453736|NCT01983735|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks."
48453737|NCT01983735|DRUG|S-amlodipine 5mg|"* S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks."
48622364|NCT01603147|BIOLOGICAL|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
48453738|NCT05635448|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
48453739|NCT05635448|BEHAVIORAL|No intervention - waitlist control|No intervention - waitlist control
48453740|NCT03459235|OTHER|quality of life|Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
48453741|NCT06560723|DIAGNOSTIC_TEST|Quality of life test|The results of the various quality-of-life scores used to compile the study statistics (ADL, iADL, MMS, GDS, MNA, EPICES, SPPB, SF-36) will be provided to the doctor, but without any specific comments or recommendations, and then presented to the patient. Number of emergency room visits and hospitalization days, drug untake evalautions and thepareutic compliance (GIRERD score) will be also collected.
48453742|NCT01103713|DRUG|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
47930638|NCT02723045|PROCEDURE|Laparoscopic TEP Hernioplasty|
48453743|NCT05232825|DRUG|Ocrelizumab IV|IV Injection
48453744|NCT05232825|DRUG|Ocrelizumab SC|SC Injection
48453745|NCT05232825|DRUG|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
48622365|NCT06315166|DEVICE|triLift/Legend Pro+ Fractional RF System|The triLift/Legend Pro+ Fractional investigational device is intended for the treatment of acne vulgaris when using Fractional RF energy.
48622366|NCT02967887|DRUG|cisplatin and 5-fluorouracil|Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
48622367|NCT00112333|PROCEDURE|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
47930639|NCT00879879|DRUG|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
47930640|NCT02810353|DEVICE|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
47951287|NCT03814083|DEVICE|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
48098504|NCT05750095|BEHAVIORAL|Incredible Years Autism Spectrum and Language Delay Programme|Incredible Years Autism Spectrum and Language Delay Programme is a manualised group based intervention in 13 weekly 2-hour sessions. The programme targets parents of children aged 2-6 years, with autism spectrum disorder or language delay.
48453746|NCT05232825|DRUG|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
48453747|NCT05232825|DRUG|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
48453748|NCT05232825|DRUG|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
48453749|NCT00663234|DRUG|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
48453750|NCT00461435|PROCEDURE|hyperbaric oxygen therapy|
48453751|NCT04021511|OTHER|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
48453752|NCT01943695|BEHAVIORAL|Aerobic Training|
48453753|NCT01943695|BEHAVIORAL|Educational Information|Subjects will be given material regarding cancer and it's impact.
48453754|NCT01943695|BEHAVIORAL|Supervised Home Based Training|Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
48453755|NCT04180969|DRUG|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
48453756|NCT04180969|DEVICE|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
48453757|NCT04180969|DRUG|Placebo oral tablet|placebo stressor
48453758|NCT04180969|DEVICE|sham rTMS|sham mPFC rTMS
48453759|NCT06336993|DRUG|herbal compound|patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.
48453760|NCT06336993|DRUG|Celecoxib|Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
48453761|NCT01371435|DRUG|Paroxetine|
47930641|NCT02810353|DEVICE|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
47930642|NCT04111978|DRUG|Letrozole 2.5mg|Aromatase inhibitor
47930643|NCT04111978|OTHER|Placebo|Placebo tablet of Femara
47930644|NCT03234881|BEHAVIORAL|MOVE!|Participants randomized to the MOVE!(or TeleMOVE!) arm only. MOVE! is 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries. TeleMOVE! is a 90-day program utilizing technology to provide home-based messaging focusing on health education and as needed clinician contact. \*TeleMOVE! was added as an option since many in-person MOVE! programs were on pause due to the pandemic.
47930645|NCT03234881|BEHAVIORAL|MOVE!+CBT|Participants randomized to the MOVE!+CBT arm will attend the 16 weeks of 60-minute weekly MOVE! or 90-days of the TeleMOVE! Treatment groups, along with up to 10 clinician-led individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and gradually increase daily physical activity.
47930646|NCT06371183|DEVICE|Colonoscope|Endoscopy for lower GIT
47930647|NCT05441306|DEVICE|Personal Health Library (PerHL) + MyChart|Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).
47930648|NCT05441306|DEVICE|Epic®MyChart|Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
48453762|NCT02293928|PROCEDURE|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
48453763|NCT00241982|DRUG|long-circulating liposomal prednisolone|
48453764|NCT00018460|DRUG|Vitamin B|
47930649|NCT04744376|OTHER|QoR15|Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.
47930650|NCT04744376|OTHER|ACS risk calculator|American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.
47930651|NCT04744376|OTHER|Clavien - Dindo classification|It is a classification for postoperative complications.
47930652|NCT00026611|BIOLOGICAL|Dryvax vaccine|
47930653|NCT02183103|DRUG|meloxicam rapid release tablet, 12mg, UH AC62MU|
48453765|NCT02854826|OTHER|SAFE Care model of care|"SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
48453766|NCT06265753|OTHER|Gastrocinemius Function Massage|The purpose of gastrocnemius massage is to alleviate muscle stiffness in the gastrocnemius muscle and enhance mobility in the foot and ankle of the individuals involved. During the GFM application, the patient assumes a prone posture on a suitable treatment bed. The therapist positions themselves behind the patient's side and secures the patient's foot between their hip and ilium.The therapist firmly holds the gastrocnemius muscle using both hands and applies pressure to the ankle, causing it to move in the direction of dorsiflexion. Simultaneously, the therapist applies mobilisation in the cranial direction, following the same path as the gastrocnemius muscle fibres, using both hands. Afterwards, the therapist gently pulls the arm and trunk backwards until the foot and gastrocnemius muscle become relaxed. The application is sustained in a rhythmic manner . We will apply this massage aproximately 10 min to experimental group.
48622368|NCT01600859|DRUG|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
48622369|NCT01600859|DRUG|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
48622370|NCT01319968|DRUG|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
48622371|NCT05924932|DEVICE|Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6|type of hybrid close loop insulin delivery system
48622372|NCT05924932|DEVICE|MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4|type of hybrid close loop insulin delivery system
47930654|NCT06129513|BEHAVIORAL|Bilateral resistance exercise|A bout of bilateral resistance exercise consisting of barbell back squat, leg leg press and leg extension
47930655|NCT06129513|DIETARY_SUPPLEMENT|Whey protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from whey protein isolate
47930656|NCT06129513|DIETARY_SUPPLEMENT|Plant-blend protein|Following execution of bilateral resistance exercise, participants will ingest 32 g protein from plant-blend protein isolate
47930657|NCT02906384|RADIATION|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
47930658|NCT05606003|BEHAVIORAL|Multi-Level Multi-Component Intervention (MLI)|The strategic components of our multi-level, multi-component intervention (MLI) include: 1. Building testing access for vulnerable populations, 2) Community Health Worker (CHW)-delivered navigation to SARSCoV- 2 testing and access and reinforce risk mitigation recommendations, 3) 2-1-1 helpline-referrals and navigation to FDA approved SARSCoV- 2 testing (and self sampling once approved) and risk mitigation education, and 4) social marketing and small media campaign to provide geo-targeted messages promoting testing and COVID risk mitigation behaviors. We selected these components because of their evidence base, their current use by partners in response to COVID 19, and confidence that they can be adapted through a community engaged process as described.
47930659|NCT05606003|BEHAVIORAL|Community Just-In-Time Adaptive Intervention (Community JITAI)|This intervention includes the same MLI components described above, with an added JITAI approach. Community and stakeholder partners will use real-time data related to testing and other relevant information generated by the Epidemiologic Surveillance and Analysis team (ESA) in Aim 1, as well as other information based on their community and stakeholder experience and tacit knowledge about factors influencing testing determinants, to adapt intervention activities as needed to optimize access to testing.
47930660|NCT00868517|OTHER|True group auricular acupuncture|Received true group auricular acupuncture
47930661|NCT00868517|OTHER|Sham group auricular acupuncture|Received sham auricular acupuncture.
48453767|NCT06265753|OTHER|Sham application|The sham application was conducted when the patient was lying face down, with the hands placed on the gastrocnemius muscle without any movement. We will apply this application aproximately 10 min to experimental group.
47930662|NCT00868517|OTHER|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
47930663|NCT01514786|BEHAVIORAL|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
47930664|NCT03869268|DRUG|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
47930665|NCT03869268|DRUG|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
47930666|NCT06001411|BEHAVIORAL|Prone Position Training|All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.
47930667|NCT06001411|BEHAVIORAL|control group|Patients in the control group (C group) received standard perioperative care without any prone position training.
47930668|NCT03699475|BIOLOGICAL|rivogenlecleucel|Biological: T cells transduced with caspase 9 safety switch
47930669|NCT03699475|DRUG|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
47930670|NCT03699475|DRUG|Cyclophosphamide|GVHD prophylaxis
47930671|NCT03699475|PROCEDURE|haplo-HSCT|treatment for disease
48098505|NCT05750095|BEHAVIORAL|First Aid for Parents|"First Aid for Parents is a program consisting of three full day work-shops targeting communication, interaction and daily living skills for parents of children with autism spectrum disorders"
48098506|NCT00536380|DRUG|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
48098507|NCT00536380|DRUG|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
47930672|NCT06157216|DRUG|MRD-guided therapy|MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
48098508|NCT00536380|DRUG|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
48098509|NCT02540642|DIETARY_SUPPLEMENT|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
48098510|NCT03997123|DRUG|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
48098511|NCT03997123|DRUG|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
48453768|NCT04200274|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
48453769|NCT01366781|OTHER|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
48453770|NCT05058430|DEVICE|Electrical salivary stimulator system assigned to subjects with xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
48622373|NCT03860688|DRUG|TED + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
47930673|NCT01109056|DRUG|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
47930674|NCT01109056|DRUG|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
47930675|NCT06397521|PROCEDURE|Crown lengthening|Investigation of the three techniques for aesthetic crown lengthening
47930676|NCT05954104|DRUG|Calcipotriol|To evaluate the efficacy of Calcipotriol on Alopecia Areata.
47930677|NCT00828373|DRUG|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
47930678|NCT00828373|DRUG|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
47930679|NCT02602678|PROCEDURE|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
47930680|NCT02602678|PROCEDURE|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
47930681|NCT01930331|DRUG|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
47930682|NCT01930331|DRUG|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
48453771|NCT05058430|DEVICE|No Electrical salivary stimulator system assigned to subjects without xerostomia|SaliPen is an electrical salivary stimulator system, intended to electrically stimulate a relative increase in saliva production. It is an intraoral device indicated for use in patients with xerostomia (dry mouth).
47930683|NCT01711385|BEHAVIORAL|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
47930684|NCT00877097|DRUG|Klodronate and Kliogest|
48453772|NCT01894802|DEVICE|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
48453773|NCT00064831|DRUG|Black Cohosh Extract (BCE)|
48453774|NCT04921696|OTHER|RBC transfusion|RBC was transfused to the infants.
47930685|NCT00877097|PROCEDURE|Placebo+ Kliogest|
47930686|NCT00877097|DRUG|Bonefos|
47951288|NCT03814083|OTHER|Wait-list|No intervention
47951289|NCT05516277|BEHAVIORAL|Behavioral Sleep Education Intervention|Manual-based education program focusing on behavioral sleep provided in individual 60-minute sessions for 5 weekly sessions.
47951290|NCT05516277|BEHAVIORAL|General Sleep Education Intervention|Manual-based education program focusing on general sleep provided in individual 60-minute sessions for 5 weekly sessions.
47951291|NCT02623478|DRUG|Insulin Lispro|Administered subcutaneously (SC)
48453775|NCT04921696|OTHER|no-RBC transfusion|RBC was not transfused to the infants.
48453776|NCT06560983|OTHER|The investigators are planning to do a observational cohort study, hence won't be doing any intervention.|The investigators won't be doing any intervention since this is an observational study.
48453777|NCT06596148|OTHER|Access to Shingrix dashboard|The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions.
48453778|NCT06182449|DEVICE|Virtual Reality Distraction|In a private NICU room, mothers will wear a head-mounted VR device when they will initiate the expression of their maternal milk. The video within the VR system will provide a calm forest environment with waterfalls, animals, and birdsong (INSPIRE® Program). The baby may or may not be present in the room during the intervention. This will be documented.
48453779|NCT06182449|OTHER|Standard Protocol|Mothers will express their maternal milk in a private room in the NICU with their baby or a photo of the baby. Use of any co-interventions for anxiety management (e.g. music) durign this sequence will be documented.
48622374|NCT02249325|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (\>7.5 x10\^9 L. acidophilus, \>6.0 x10\^9 .B. lactis, and \>1.5 x10\^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
48453780|NCT04207528|BEHAVIORAL|Writing|After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
48453781|NCT06626633|DRUG|CRD3874|CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.
48453782|NCT03121716|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
48453783|NCT03121716|DRUG|Gemcitabine|gemcitabine
48453784|NCT03121716|DRUG|cis-platinum|cis-platinum
48453785|NCT03904329|DRUG|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
48453786|NCT03510923|OTHER|Inspection and palpation of the appendix|The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
48453787|NCT03510923|OTHER|Inspection and palpation of the gallbladder|The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
48453788|NCT06592222|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
48453789|NCT06592222|DRUG|Standard of care|Standard of care
48453790|NCT01497587|DRUG|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
48098512|NCT03997123|DRUG|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
48453791|NCT05269069|OTHER|Assessment of body composition, bone mineral density and bone marrow adiposity.|DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)
48453792|NCT03119077|DRUG|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
48453793|NCT03119077|DRUG|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
48453794|NCT03119077|DRUG|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
48453795|NCT06214507|OTHER|No intervention|No intervention
48453796|NCT04888338|OTHER|Data Capture|Treatment related data is collected
48453797|NCT04888338|OTHER|Electronic Medical Record|Medical records are reviewed
48453798|NCT04948476|OTHER|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~* Cool dialysate (35.0◦C)~* Dialysate sodium of 145mmol/L~* Dialysate calcium of 1.5mmol/L~* Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~  * Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~* Most recent pre-dialysis potassium \<6mmo/L and bicarbonate \>12mmol/L~* Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis \<1L/session~* If available, timed urine collection with result for mean creatinine and/or urea clearance \>12mL/min"
48453799|NCT04948476|OTHER|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
48453800|NCT02555137|OTHER|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
48453801|NCT02266407|PROCEDURE|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
48453802|NCT02734511|DRUG|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
47951292|NCT03434769|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
47951293|NCT03434769|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
48453803|NCT05370417|OTHER|Use of fluoride toothpaste|The participants received oral hygiene instructions - routine brushing twice per day with toothpaste containing 1000 ppm of fluoride. All participants received a toothbrush and toothpaste to ensure standardization. The aim of this intervention was to assess whether the participants' brushing technique would improve with desensitization.
48453804|NCT05370417|RADIATION|Photobiomodulation|"For laser application, the following dosimetric parameters will be used:~Low level laser diode (infra red) wavelength 808nm with a power of 100mW. Three sessions: initial session, after 48 hours and after one month. LLL was applied to three perpendicular points in contact with the surface on the mesial vestibular and distal cervical faces and in the center of the occlusal face. An energy of 1 J was applied for 10 seconds at each point."
48453805|NCT05370417|PROCEDURE|Simulated Laser Therapy|The same application described in the laser therapy group will be simulated, with the device turned off.
48453806|NCT05370417|PROCEDURE|Sealant application|A glass ionomer sealant will be applied to the occlusal surface of the first permanent molar.
48453807|NCT00068731|DIETARY_SUPPLEMENT|lycopene|
48453808|NCT00247923|PROCEDURE|Hysteroscopic resection of endometrial polyps. (TCRP)|
48453809|NCT04085861|BEHAVIORAL|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
48453810|NCT04085861|BEHAVIORAL|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
48453811|NCT03045458|DEVICE|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
48453812|NCT03045458|DEVICE|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
48453813|NCT00959790|DIETARY_SUPPLEMENT|Vegetables|200 or 50 grams of vegetables daily for four weeks
48453814|NCT00959790|DIETARY_SUPPLEMENT|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
48453815|NCT00611364|OTHER|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
48453816|NCT00611364|OTHER|education meetings|This group only participed of education meeting (every fifteen days)
48453817|NCT05893563|OTHER|Standard Post-Operative Clinic Visit|In clinic, the joint will be assessed (ROM, stability testing), standard X-rays will be taken of the joint, and patient reported outcomes (questionnaires) will be completed by patient (WOMAC, UCLA, VR12, EQ5D, Oxford Hip).
48453818|NCT05893563|OTHER|Study-Specific Outcomes|Patients will complete additional questionnaires (SF12 and HHS), will undergo RSA and CT imaging for implant stability analysis, and will provide a stool sample for gut microbiome analysis.
48453819|NCT04938635|DRUG|VIT-2763 60 mg QD|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
48453820|NCT04938635|DRUG|VIT-2763 60 mg BID|Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
48453821|NCT04938635|DRUG|VIT-2763 120 mg BID|Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
48453822|NCT04938635|DRUG|Placebo|Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
48453823|NCT05581329|PROCEDURE|Acupuncture|Acupuncture is a method of inserting very thin needles into special points on the body which are called acupoints. To conduct this intervention, we will use disposable acupuncture needles the size of 0.30 x 13 mm to acupuncture the control acupoint (Yuji - LU10) in the first session and the research acupoint (Houxi - SI3) in the second session.
48453824|NCT02342535|BEHAVIORAL|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
48453825|NCT01782053|BEHAVIORAL|Picture warning|Warning contains picture proposed for each text statement by FDA
48453826|NCT01782053|BEHAVIORAL|Control|
48453827|NCT05361252|PROCEDURE|SVV-guided fluid management|fluid will be guided by value of stroke volume variation
48453828|NCT00960414|BEHAVIORAL|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
48453829|NCT05858333|OTHER|Extended culture for Group 2: (day 3-5 group)|To investigate thawing day three embryos and culturing them to be transferred as blastocyst that will improve pregnancy rate when compared to transfer thawed frozen blastocyst.
48453830|NCT01601405|DRUG|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
48453831|NCT01601405|DRUG|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
48453832|NCT01647828|DRUG|OMP-59R5|OMP-59R5 administered intravenously
48453833|NCT01647828|DRUG|Gemcitabine|administered intravenously
48453834|NCT01647828|DRUG|Placebo|administered IV
47930687|NCT00311298|DIETARY_SUPPLEMENT|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
47930688|NCT00311298|DIETARY_SUPPLEMENT|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
47930689|NCT03190642|DRUG|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
47930690|NCT01142089|DRUG|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
47930691|NCT01142089|DRUG|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
47930692|NCT04125264|DEVICE|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
47930693|NCT06321341|DRUG|Vespireit|Buspirone
47930694|NCT06321341|DRUG|Arlevert|Dimenhydrinate + Cinnarizine
47930695|NCT02619773|PROCEDURE|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
47930696|NCT03249688|OTHER|Regular health advice|Routine healthy lifestyle counseling
47930697|NCT03249688|BEHAVIORAL|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
47930698|NCT03249688|DIETARY_SUPPLEMENT|Medical food|Medical food product (Fortasyn Connect)
48453835|NCT01647828|DRUG|Nab-Paclitaxel|administered intravenously
48453836|NCT05620862|DRUG|Mitoxantrone Hydrochloride Liposome|In phase Ia, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 . In phase Ib, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion of 24mg/m2. Up to 6 cycles (21 days per cycle)
48453837|NCT05620862|DRUG|Irinotecan|50mg/ m2，d1-5, 21 days per cycle
48622375|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
47930699|NCT02553668|DRUG|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
47930700|NCT02553668|DEVICE|Facemask|
47930701|NCT04178369|OTHER|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
48098513|NCT02358187|BIOLOGICAL|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
48098514|NCT06157879|DEVICE|WVI-MIS-01-2022|Microwave scans
48098515|NCT01002443|DRUG|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
48098516|NCT01002443|DRUG|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
48098517|NCT00013143|BEHAVIORAL|Patient risk profiling (potential ADEs) w/provider feedback|
48098518|NCT05461924|OTHER|questionnaire survey|questionnaire survey the long term outcomes of long-segment HSCR and compared with rectosigmoid HSCR
48098519|NCT03881631|BEHAVIORAL|Mindfulness Based Stress Reduction Program|Group-based intervention
48098520|NCT03881631|BEHAVIORAL|Living Well Program|Group-based intervention
48098521|NCT02377362|DRUG|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
48098522|NCT02377362|DRUG|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
48098523|NCT02377362|DRUG|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
48098524|NCT02377362|DRUG|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
48098525|NCT02377362|DRUG|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
48453838|NCT05620862|DRUG|Vincristine|Vincristine 1.5mg/ m2，d1 , 21 days per cycle
47930702|NCT04178369|OTHER|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
47930703|NCT02323360|RADIATION|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
47930704|NCT02323360|PROCEDURE|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
47930705|NCT05604053|BEHAVIORAL|Motivation Manipulation|On some trials, participants have lower motivation and on other trials participants have higher motivation.
47930706|NCT04510636|DRUG|Pembrolizumab|Pembrolizumab is a intravenously administered humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
47930707|NCT04510636|DRUG|Bendamustine Hydrochloride|Bendamustine is a unique alkylating agent with substantial activity in hematologic malignancies.
47930708|NCT01522885|DEVICE|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
47930709|NCT01522885|PROCEDURE|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
47930710|NCT04161768|DRUG|Norfloxacin|Norfloxacin 400 mg daily
47930711|NCT04161768|DRUG|Itopride|Itopride 50 mg three times daily
47930712|NCT04995289|OTHER|Prone position on ECMO patient|blood gas analysis before and after PP
47930713|NCT05858840|OTHER|Urinary Artificial Sphincter (UAS) in Children|Patients aged under 18 years old with UAS
47930714|NCT04291001|DEVICE|ENG implant|This is an FDA-approved contraceptive device
47930715|NCT04291001|DRUG|oral ulipristal acetate|This is an FDA-approved oral emergency contraceptive
47930716|NCT02146144|PROCEDURE|ILM Peeling|"common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~* Central and peripheral 25 Gauge vitrectomy~* dissection of the epimacular membrane~* injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~* Intraoperative picture to see the possible spontaneous ILM peeling~* If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~* Arm 1: no peeling, where the ILM peeling will not be made~* Arm 2: active peeling, where the ILM peeling will be made"
47930717|NCT00539760|DRUG|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
48098526|NCT02377362|DRUG|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
48453839|NCT01906372|DRUG|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
48453840|NCT04880616|DRUG|NBI-827104|Capsules for oral administration
48453841|NCT04880616|DRUG|Placebo|Capsules matching NBI-827104 for oral administration
47930718|NCT00539760|DRUG|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
47930719|NCT00133978|OTHER|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
48098527|NCT04820621|DRUG|Runcaciguat (BAY1101042)|Given as 1 x 15 mg modified release \[MR\] tablet
47930720|NCT00133978|OTHER|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
47930721|NCT00133978|OTHER|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
47930722|NCT00133978|OTHER|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
47930723|NCT03812627|OTHER|Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections|"All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~1. at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~2. at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter"
47930724|NCT03812627|OTHER|Autopsy|Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
47930725|NCT05344755|OTHER|Plantar Sensorial Training|In addition to the routine treatment, plantar sensorial training will be added.
48453842|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
47930726|NCT05344755|OTHER|Control Group|Routine physiotherapy management of the Hallux valgus
47930727|NCT04745273|DRUG|Ondansetron 4 MG (Kemoset 4mg)|Ondansetron 4mg (iv) will administer to participants
47930728|NCT04745273|OTHER|Salin solution|Salin solution 2ml (iv) will administer to participants
48098528|NCT04659031|DRUG|ABC008|ABC008
48453843|NCT02010918|DRUG|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
48453844|NCT02010918|DRUG|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
48453845|NCT04366544|OTHER|Part A1: Survey|Online
48453846|NCT04366544|OTHER|Part A2: Sample collection|Blood and Stool
48453847|NCT04366544|OTHER|Part B:|EEG and fMRI
48453848|NCT06562374|DEVICE|Low Frequency Ultrasound Therapy|The ultrasound will be delivered at a frequency of 33 kHz at power levels of 4-10 Pascals with a program of 1.6 seconds on and 1.6 seconds off. The generators will be encased in epoxy within the Osteoarthritis baths. The intervention will be repeated on every second or third day to allow time for healing
48453849|NCT05439707|DEVICE|transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the left ear trunk, which is dominated only by the auricular branch of the vagus nerve. Continuous stimulation was performed at a frequency of 25Hz with pulse width of 300 μs. The stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, and the treatment lasted for 9 consecutive days.
47930729|NCT01407003|DRUG|LIK066|Participants will receive a single or multiple doses of LIK066
47930730|NCT01407003|DRUG|Placebo|Participants will receive a single or multiple doses of a matching placebo
47930731|NCT05520242|OTHER|Use of small animation movies to increase response in a national health survey|Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.
48453850|NCT05439707|DEVICE|fake transaricular vagus nerve stimulation|The transaricular vagus nerve stimulator was placed in the same position as the experimental group, covered with an insulating film and placed at the site of the stimulation, so that the patient could not actually receive the electrical stimulation. Continuous stimulation was performed at a frequency of 25Hz and pulse width of 300 μs, and the stimulation was adjusted to be higher than the perception threshold and lower than the pain threshold. Each stimulation lasted for 30 minutes, three times per day (morning, noon, evening), from 1 day before surgery to 7 days after surgery, for 9 consecutive days.
47930732|NCT02364401|DEVICE|Ablation|Catheter ablation for atrial fibrillation
47930733|NCT04150406|DIETARY_SUPPLEMENT|Flexofytol|Curcuma extract
48453851|NCT05572398|BEHAVIORAL|STAC-T|Middle school participants will complete online modules to learn about anti-bullying techniques and bystander intervention.
48453852|NCT02225782|DRUG|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
48453853|NCT00673010|RADIATION|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
48453854|NCT03913676|BEHAVIORAL|Velibra|"Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention."
48622376|NCT01033071|DRUG|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
47930734|NCT04150406|OTHER|Placebo|placebo
47930735|NCT03032770|DEVICE|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (\<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
47930736|NCT03089762|BIOLOGICAL|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
47930737|NCT00023127|PROCEDURE|Integrated Pest Management|
47930738|NCT03932006|DRUG|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
47930739|NCT03932006|DRUG|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
47930740|NCT03932006|DRUG|Imrecoxib|Imrecoxib 0.1g twice a day,orally
47930741|NCT04232709|OTHER|Shared electronic patient record|MedChart allows access to a shared electronic patient record that contains selected information related to a patient's cancer treatment. If a patient contacts the after-hours telemedicine service, the oncology nurse will have access to this shared record
47930742|NCT04999852|DEVICE|Safe and Sound Protocol|SSP is a non-invasive acoustic vagus nerve stimulator consisting of 5 hours of filtered and processed music designed to promote efficient regulation of autonomic state, and available through an app. The SSP is delivered via a mobile app and may fall under the heading of medical devices under the category of software functions/mobile medical applications.
47930743|NCT04999852|BEHAVIORAL|Psychotherapy|All participants, regardless of study arm, will be recruited from the pool of Spencer Psychology clients who are actively recieving psychotherapy. Participants will continue to recieve psychotherapy during the course of the study.
47951294|NCT03434769|BIOLOGICAL|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
48453855|NCT05543720|DEVICE|Medly|Medly will enable patients with HF, COPD, Hypertension, Mental Health, or Diabetes to input measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
47930744|NCT04650061|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.
47930745|NCT04650061|DEVICE|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
47930746|NCT04703101|DRUG|Capecitabine|Given IV
47930747|NCT04703101|DRUG|Fluorouracil|Given IV
47930748|NCT04703101|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
47930749|NCT04703101|DRUG|Leucovorin|Given IV
47930750|NCT04703101|DRUG|Oxaliplatin|Given IV
47930751|NCT04703101|OTHER|Quality-of-Life Assessment|Ancillary studies
47930752|NCT04703101|BEHAVIORAL|Surveillance|Undergo NOM
47930753|NCT04703101|PROCEDURE|Total Mesorectal Excision|Undergo TME
47930754|NCT00870233|BEHAVIORAL|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
47930755|NCT00101829|DRUG|Rituximab|1000 mg intravenous infusion
47930756|NCT06054204|DEVICE|lateral bony window|bony window will be made on lateral maxillary sinus wall using piezo-electric device after elevation of full thickness mucoperiosteal membrane
47930757|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
47930758|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
47930759|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
47930760|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
47930761|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
47930762|NCT01905215|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
47930763|NCT01905215|DRUG|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
47930764|NCT01274260|DRUG|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
47930765|NCT01274260|DRUG|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
47930766|NCT04241679|DEVICE|Auditory Nerve Test System|"The Auditory Nerve Test System provides an electrically-evoked signal from within the cochlea to facilitate intraoperative auditory nerve monitoring. The auditory nerve can be measured both at the root entry zone of the brainstem (eCNAP) and with scalp electrodes (eABR). Data on the health of the auditory nerve will be collected immediately prior to tumor dissection, during tumor dissection, and immediately after tumor dissection. The main purpose of this study is to determine feasibility of this novel intraoperative monitoring protocol.~Secondarily, if the auditory nerve is visually confirmed to be intact following tumor resection then the patients will receive a cochlear implant during the same surgery."
47930767|NCT05461573|DRUG|Drospirenone|LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
47930768|NCT02697669|OTHER|18F-FDG PET|Imaging
47930769|NCT04330105|DEVICE|ECG, HolterECG ,Echocardiography|ECG, HolterECG ,Echocardiography to determine any type of arrythmia,ischaemic heart disease,valvular heart disease,systolic and diastolic dysfunction
47930770|NCT04620707|DEVICE|RGS based training and monitoring|The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
47930771|NCT04620707|BEHAVIORAL|Therapy as usual|The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
47930772|NCT02254239|DRUG|Brentuximab Vedotin|Given IV
47930773|NCT02254239|DRUG|Everolimus|Given PO
47930774|NCT02254239|OTHER|Laboratory Biomarker Analysis|Correlative studies
47930775|NCT02254239|OTHER|Pharmacological Study|Correlative studies
47930776|NCT00081861|DRUG|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
48453856|NCT02825680|OTHER|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
48453857|NCT02825680|OTHER|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
48453858|NCT03076437|COMBINATION_PRODUCT|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
48453859|NCT06322264|DIAGNOSTIC_TEST|Measurement of variation in heart rate|The children will be given a portable device that will monitor their heart rate, enabling the recording of the rate of their pulse.
48453860|NCT03560843|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
48453861|NCT05162105|OTHER|Short rest (8 hour) between two consecutive shifts.|Participants will have shortened rest opportunity (8 hours) between two consecutive shifts, due to the shift work schedule.
47930777|NCT00081861|DRUG|Rituximab|375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
47930778|NCT01476202|DRUG|nicotine|nicotine in the form of a mouth strip, lozenge and gum
47930779|NCT05987176|DRUG|Lutathera|"Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity."
47930780|NCT05503667|DRUG|Furmonertinib|Furmonertinib 80 mg/day for 16 weeks
47930781|NCT05503667|DRUG|Bevacizumab|bevacizumab 400 mg/4 weeks i.v. for 4 times
47930782|NCT00007007|PROCEDURE|management of therapy complications|
47930783|NCT00007007|PROCEDURE|quality-of-life assessment|
48453862|NCT05162105|OTHER|16 hour rest opportunity between to consecutive shifts.|Participants will have a 16 hour rest opportunity between shifts, due to shift work schedule.
47930784|NCT05573412|OTHER|Cellular analysis|Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
47930785|NCT02380690|BEHAVIORAL|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
47930786|NCT04869553|OTHER|Management pain with distraction methods ABC|"Every patient will receive :~* The usual pain management of their ward (Treatment A),~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)"
47930787|NCT04869553|OTHER|Management pain with distraction methods BCA|"Every patient will receive :~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)"
48453863|NCT00486239|BEHAVIORAL|TLE Arm 1|Behavioral/cognitive testing
48453864|NCT00486239|BEHAVIORAL|Emotion Memory Test|Behavioral/cognitive Measure
48453865|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
48453866|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
48453867|NCT02047305|DEVICE|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
47930788|NCT04869553|OTHER|Management pain with distraction methods CAB|"Every patient will receive :~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)~* The usual pain management of their ward with a hypnosis session (Treatment B)"
47930789|NCT04860908|OTHER|no intervention, observation only|no intervention, observation only
47930790|NCT01095094|DRUG|ritonavir|Given orally
47930791|NCT01095094|DRUG|lopinavir|Given orally
47930792|NCT01677390|DRUG|SGN-75|1-2 mg/kg IV every 21 days
47930793|NCT01677390|DRUG|everolimus|10 mg PO daily
47930794|NCT01456377|DRUG|predinose oral|1 mg for kg for 3 wekees
47930795|NCT01456377|DRUG|placebo group|use a oral placebo
47930796|NCT05612412|OTHER|Morning Exercise|Standardized treadmill exercise session starting at approximately 0700
48453868|NCT04736303|DEVICE|BIS|The implementation of BIS monitoring
48453869|NCT04251429|OTHER|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
48453870|NCT05124444|GENETIC|High throughput DNA and RNA sequencing|High throughput DNA and RNA sequencing
48453871|NCT05885412|GENETIC|RP-A601|RP-A601 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, human plakophilin 2 (PKP2), transcript variant 2a (PKP2a)
48453872|NCT02376881|DRUG|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
48453873|NCT02376881|OTHER|placebo|100 ml normal saline in 2 hr for 3 successive days
48453874|NCT04982523|BEHAVIORAL|Online Mental Health Program|The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
48453875|NCT00243347|DRUG|AZD2171|oral tablet
48453876|NCT04313764|DRUG|Bupivacaine Hcl 0.25% ESP block|Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine, per side
48453877|NCT04313764|DRUG|Bupivacaine Hcl 0.25% infiltration|Wound infiltration with 20 ml %0.25 bupivacaine
47930797|NCT05612412|OTHER|Evening Exercise|Standardized treadmill exercise session starting at approximately 1800
47930798|NCT02258984|DEVICE|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
47930799|NCT01503112|OTHER|No intervention, observational study|
47930800|NCT02325973|DEVICE|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
47930801|NCT05898269|DIAGNOSTIC_TEST|Trendelenburg maneuver|Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
47930802|NCT05898269|DIAGNOSTIC_TEST|End-expiratory occlusion test (EE OCC)|"End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause"
47930803|NCT05898269|DIAGNOSTIC_TEST|End-expiratory and end-inspiratory occlusion test (EI OCC)|"End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test)."
48453878|NCT04026243|PROCEDURE|QL block|U/S guided Transmuscular Quadratus Lumborum Block
48453879|NCT04026243|PROCEDURE|TF block|U/S guided Transversalis Fascia Plane Block
47930804|NCT05898269|DIAGNOSTIC_TEST|Tidal volume challenge|"Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1."
47930805|NCT05898269|DIAGNOSTIC_TEST|Fluid bolus (reference diagnostic method)|"After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index \> 15% will be identified as being fluid responders, and the others as non-responders."
48453880|NCT03546738|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
47930806|NCT04515862|OTHER|Breastfeeding education|The importance of breastfeeding Benefits of breastfeeding for mother and baby Structure of the breast and milk production Breastfeeding techniques and positions Breastfeeding problems and breast care
47930807|NCT04045509|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
47930808|NCT04045509|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
47930809|NCT04045509|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
47930810|NCT02530047|GENETIC|MSC-INFβ|"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments."
47930811|NCT02530047|BEHAVIORAL|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
47930812|NCT01028690|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
47930813|NCT01028690|DIETARY_SUPPLEMENT|Placebo|placebo
47930814|NCT02844686|OTHER|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
47930815|NCT04095637|DEVICE|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
48453881|NCT03546738|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
48453882|NCT03546738|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
47930816|NCT02034136|DIETARY_SUPPLEMENT|Ginsenoside|3.0 g/ d for 28 days
47930817|NCT02034136|DIETARY_SUPPLEMENT|Dietary fiber fill|3g/day, 28days
47930818|NCT01190423|BEHAVIORAL|Family Based Therapy for young adults|Individual and Group Therapy Sessions
48453883|NCT00955838|OTHER|Rehabilitation technique|12 therapy session
48453884|NCT04626154|DIAGNOSTIC_TEST|Objectively monitoring thoracoabdominal asynchrony|Objectively monitoring thoracoabdominal asynchrony
47930821|NCT03509415|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
48453885|NCT03999645|PROCEDURE|Early laparoscopic cholecystectomy|within 72h from symptom onset
48453886|NCT03999645|PROCEDURE|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
48453887|NCT02680444|BEHAVIORAL|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
48453888|NCT02680444|BEHAVIORAL|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
48453889|NCT02680444|BEHAVIORAL|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
48453890|NCT03559569|BIOLOGICAL|Biological samples will be done to evaluate the endothelial and leukocyte senescence.|Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
48453891|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
47930822|NCT06112873|OTHER|Quality of Life Questionnaire|Patient (or Parent)-Reported Outcomes via specific questionnaires
47930823|NCT03168529|DRUG|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
47930824|NCT03168529|DRUG|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
47930825|NCT00887744|DEVICE|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
48453892|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
48453893|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
48453894|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
48453895|NCT00264108|DRUG|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
48453896|NCT00264108|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length.
48453897|NCT05428826|DRUG|Prednisone|Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
48453898|NCT00669162|DRUG|Docetaxel|20mg/m2 IV weekly for 7 weeks
47930826|NCT00338897|DRUG|SR123781A|
47930827|NCT04013243|DRUG|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
47930828|NCT04013243|DRUG|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
47930829|NCT05346445|DRUG|Fluoxetine 20 MG|Participants received non-hormonal treatment with fluoxetine.
48453899|NCT00669162|RADIATION|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
47930830|NCT05346445|DRUG|Citalopram 20mg|Participants received non-hormonal treatment with citalopram.
47930831|NCT06271473|PROCEDURE|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.|vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
47930832|NCT04239430|DIAGNOSTIC_TEST|Serum Bactericidal Assays|Blood samples will be taken from participants at two time points in the study. Serum Bactericidal Assays from participant serum using relevant MenB and MenACWY strains will be undertaken at 18 and 30 months post two doses of 4CMenB (Bexsero, GSK) and MenACWY-conjugate (Menveo, GSK) vaccine. The Vaccines were given to participants during an earlier clinical trial (Propositive). This trisal is a follow up study.
47930833|NCT03935399|DRUG|Oxytocin|10 IU oxytocin (Pitocin) for intramuscular injection
47930834|NCT03935399|DRUG|Saline|1.5 ml preservative free saline for intramuscular injection
47930835|NCT05512468|DRUG|carbon dye|Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
47930836|NCT00401362|DRUG|SC Methylnaltrexone|Dose 1
47930837|NCT00401362|DRUG|SC Placebo|
47930838|NCT00401362|DRUG|SC Methylnaltrexone|Dose 2
47930839|NCT04896645|DEVICE|Digihaler Albuterol Device by TEVA|Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home
47930840|NCT04617873|PROCEDURE|Bilateral STN-DBS and T10-T12 SCS|simultaneous stimulation of bilaterally-STN-DBS combined with spinal cord stimulation
47930841|NCT06246955|BEHAVIORAL|Behavioral Intervention: Group Therapy Session|Attend virtual group therapy sessions
47930842|NCT06246955|OTHER|Survey Administration|Ancillary study
47930843|NCT00912561|BEHAVIORAL|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
47930844|NCT04739371|DRUG|Insulin, Regular, Human|The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
47930845|NCT04739371|DRUG|Placebo|The spray will last a few seconds and then the participant will be asked to sniff to aid the saline into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
48453900|NCT00669162|DRUG|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
48453901|NCT00918645|DRUG|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
48453902|NCT04633564|BIOLOGICAL|Bevacizumab as MYL-1402O|Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
48453903|NCT04633564|BIOLOGICAL|Bevacizumab as Avastin|Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV
48453904|NCT04767347|OTHER|23.0°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~23.0°C WBGT (29°C, 46% relative humidity) @ 60 min exercise per hour"
48453905|NCT04767347|OTHER|25.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~25.5°C WBGT (31°C, 52% relative humidity) @ 45 min exercise per hour"
47930846|NCT00634270|DRUG|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
47930847|NCT02373501|PROCEDURE|Intra-abdominal repair|Intra abdominal repair of uterine incision
48453906|NCT04767347|OTHER|27.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~27.5°C WBGT (33°C, 53% relative humidity) @ 30 min exercise per hour"
48453907|NCT04767347|OTHER|28.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~28.5°C WBGT (34°C, 54% relative humidity) @ 15 min exercise per hour"
48453908|NCT04767347|OTHER|35.5°C WBGT - Fixed Work Rate|"For four hours, participants will walk on a treadmill to elicit 430 W of metabolic heat production in the following conditions:~35.5°C WBGT (40°C, 65% relative humidity) @ 15 min exercise per hour"
48453909|NCT04767347|OTHER|26.0°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~26.0°C WBGT (31°C, 55% relative humidity) @ 530 W metabolic heat production"
48453910|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 230 W metabolic heat production"
48453911|NCT04767347|OTHER|30.5°C WBGT - Fixed work-to-rest ratio (high intensity)|"For four hours, participants will walk on a treadmill at differing levels of metabolic heat production and environmental conditions (noted below), but at a fixed work-rest ratio of 30 minutes per hour.~30.5°C WBGT (36°C, 55% relative humidity) @ 530 W metabolic heat production"
47930848|NCT02373501|PROCEDURE|Extra-abdominal repair|Extra abdominal repair of uterine incision
47930849|NCT01924702|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
47930850|NCT01924702|DEVICE|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
47930851|NCT05143710|DIAGNOSTIC_TEST|PRES in PE or E|patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
47930852|NCT00445016|PROCEDURE|peripheral regional anesthesia|evaluation and description of adverse effects
48453912|NCT06562855|GENETIC|Peripheral blood sampling|
48622377|NCT01033071|DRUG|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
48622378|NCT01540539|DRUG|REGN1154 or placebo|Participants will receive active drug or placebo
47930853|NCT00753090|DEVICE|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
47930854|NCT00753090|DEVICE|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
47930855|NCT06522984|DRUG|Tranexamic acid injection|"to evaluate and compare efficacy of:~* Fractional Er: YAG laser combined with topical hydroquinone.~* Intradermal injection of tranexamic acid combined with topical hydroquinone cream.~* Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma."
47930856|NCT04306991|DEVICE|Auscultation using an electronic stethoscope (EKO CORE 4)|"* Auscultation using an electronic stethoscope (EKO CORE 4). Record of at least 3 cardiac cycles.~* Measurement of cardiac output using echocardiography."
47930857|NCT00636987|DEVICE|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
48453913|NCT00064038|DRUG|dexamethasone|Given orally
47930858|NCT02166671|BIOLOGICAL|HBV booster vaccination 1dose|
47930859|NCT01864356|DRUG|NT100|
47930860|NCT01864356|DRUG|Placebo|
47930861|NCT04054947|BEHAVIORAL|Suicide Prevention Program|Structured care management to improve adherence to discharge planning.
47930862|NCT03026101|OTHER|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
47930863|NCT00103727|DRUG|Talnetant|talnetant
47930864|NCT00103727|OTHER|placebo|Placebo Comparator
47930865|NCT00103727|OTHER|risperidone|Active Comparator
47930866|NCT05585944|DIAGNOSTIC_TEST|Genotyping of rs1883832C/T related single-nucleotide polymorphism|Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
47930867|NCT00400153|DRUG|Atrovent Respimat (20 mcg)|
47930868|NCT00400153|DRUG|COMBIVENT MDI (36/206 mcg)|
47930869|NCT00400153|DRUG|Combivent Respimat (20 mcg/100 mcg)|
47930870|NCT00400153|DRUG|Placebo via corresponding inhaler for blinding purposes|
47930871|NCT02331160|BEHAVIORAL|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
47930872|NCT02686281|DRUG|GMC-252-L-Lysine|
47930873|NCT02686281|OTHER|Placebo|
48453914|NCT00064038|DRUG|lenalidomide|Given orally
48453915|NCT00064038|OTHER|placebo|Given orally
48622379|NCT04871113|BIOLOGICAL|GSK3810109A|GSK3810109A available as sterile aqueous solution.
48622380|NCT04871113|BIOLOGICAL|Dolutegravir+lamivudine SOC regimen|Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines
48622381|NCT00697164|DRUG|Placebo|Saline Admission, day 1, day 2 3 days
48622382|NCT00697164|DRUG|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
47930874|NCT06116240|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
48453916|NCT05848115|DEVICE|Bi-level Positive Airway Pressure|An appropriately sized vented BiPAP face mask with a good seal will be applied and monitored by trained respiratory therapists. Patients will be started on an inspiratory peak airway pressure (IPAP) of 10 cm of water and expiratory positive airway pressure (EPAP) of 5 cm of water per Children's Hospital Colorado (CHCO) clinical pathway. BiPAP pressures will be titrated to effect per the treating physician, using assessment of physical examination, vitals, and asthma score per institutional clinical pathway. Study participants will remain on BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the ongoing use of BiPAP or not.
47930875|NCT06116240|DRUG|AL2846 capsule|AL2846 is a multi-targeted tyrosine kinase receptor inhibitor
47930876|NCT06116240|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium is a multi-target antifolate antineoplastic drug.
47930877|NCT06116240|DRUG|Cisplatin injection|Cisplatin is a chemotherapy drug.
47930878|NCT05324488|OTHER|No intervention|In this registry no intervention is carried out
47930879|NCT00794027|BEHAVIORAL|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
47930880|NCT00794027|BEHAVIORAL|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
47930881|NCT01845987|DRUG|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
47930882|NCT01845987|DRUG|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
47930883|NCT04942457|BEHAVIORAL|Fasting|Prolonged fasting for 7-10 days (caloric intake \<500 kcal in liquid form)
47930884|NCT01289782|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
47930885|NCT01289782|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
47930886|NCT01289782|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
48622383|NCT03436927|OTHER|Nintendo Wii Fit Balance exercises|Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section
48622384|NCT03436927|OTHER|Balance Trainer Balance Exercises|Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
48622385|NCT03401333|BEHAVIORAL|Text Messaging and Brief Negotiation Interview|An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
48622386|NCT01001156|OTHER|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
48622387|NCT05259215|OTHER|physiotherapy|Standard usual care physiotherapy after stroke
47930887|NCT01289782|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
47930888|NCT02225054|DRUG|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
47930889|NCT02225054|DRUG|Ropivacaine|15 ml 0.5%
47930890|NCT02225054|DRUG|Normal Saline|1 mL 0.9%
47930891|NCT02882074|DRUG|Human albumin|human albumin 5% during surgery
47930892|NCT02882074|DRUG|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
47930893|NCT05959642|DEVICE|dentapen|"Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle"
47930894|NCT05959642|DEVICE|Traditional metal Syringes|"Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars"
47930895|NCT04168632|OTHER|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
47930896|NCT04845529|DEVICE|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
47930897|NCT01701518|DRUG|Ozurdex|biodegradable 0.7mg dexamethasone implant
47930898|NCT05451927|DIETARY_SUPPLEMENT|Phaseolus Vulgaris|Weight loss
47930899|NCT05451927|DIETARY_SUPPLEMENT|Placebo|Placebo
47930900|NCT05856591|BEHAVIORAL|Food Resources & Kitchen Skills (FoRKS)|Food Resources \& Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.
47930901|NCT05856591|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
47930902|NCT00853268|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
47930903|NCT00853268|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
48453917|NCT05848115|DEVICE|Sham Bi-level Positive Airway Pressure|The sham BiPAP will have pressure attenuated using an orifice restrictor as described in previous double blinded studies using sham non-invasive ventilation. With this set-up pressures no greater than 2 cm of water have been documented at the location of the face mask. This will ensure that the patient is not receiving positive pressure with any effectiveness or deleterious effects. Study participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the use of BiPAP or not.
48453918|NCT02091713|OTHER|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
48453919|NCT02528279|DRUG|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
47930904|NCT05980767|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation.
47930905|NCT04622228|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
47930906|NCT04622228|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
47930907|NCT04622228|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
47930908|NCT04622228|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
47930909|NCT04622228|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent thoracic radiation therapy (TRT) treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle.
47930910|NCT02281097|OTHER|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
47930911|NCT02281097|OTHER|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
47930912|NCT00476567|OTHER|standard|standard antenatal care
47930913|NCT00476567|BEHAVIORAL|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
48453920|NCT03579394|PROCEDURE|Retarded IDS (Interval Debulking Surgery)|"Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
48453921|NCT03579394|PROCEDURE|Standard IDS (Interval Debulking Surgery)|"Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~* paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~* paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~* Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
48453922|NCT02075645|OTHER|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
47930914|NCT02557074|DRUG|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
47930915|NCT02557074|DRUG|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
47930916|NCT04284150|DRUG|Dexmedetomidine; Midazolam;|Treatment of supraventricular tachycardia in patients with non-cardiac surgery by dexmedetomidine during the perioperative period
47930917|NCT06372743|OTHER|INTEGREAT-CKD Intervention|"The participant is reviewed once in 12 weeks by a CKD-trained APN, during a 30-minute timeslot, an extended duration compared to the timeslot of 10 to 15 minutes that routinely is designated for a recurrent review of a CKD patient in any restructured hospital in Singapore. The review consists of a 15-minute medical review centred on a discussion of the biochemical reports and clinical data relevant to CKD management, and educating on CKD knowledge and lifestyle modification.~Patients self-report the monitored parameters to a community-based nurse through a telehealth AI-based platform. The APN oversees monitoring the community-based parameters and titration of appropriate medications. The APNs have received a Master's in Nursing, with training that is primarily centred on generalist-led care, with additional clinical training in CKD management. They are supported with protocols to detect anomalies in blood pressure trends, glycemia ranges, and abnormalities in fluid status."
47930918|NCT00321087|DRUG|T2000|Dose escalation from 600 to 1000 mg
47930919|NCT00321087|DRUG|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
47930920|NCT00321087|DRUG|T2000|Placebo followed by dose escalation from 600 to 1000
48453923|NCT02466490|DRUG|Fimasartan|Fimasartan tablets
48453924|NCT02466490|DRUG|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
48453925|NCT01468623|OTHER|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
48453926|NCT01468623|OTHER|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
47930921|NCT02538783|BEHAVIORAL|Escalating Lottery|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
47930922|NCT05216666|PROCEDURE|Lateral approach|Total hip arthroplasty performed through a lateral surgical approach (Gammer)
47930923|NCT05216666|PROCEDURE|Posterior approach|Total hip arthroplasty performed through a posterior surgical approach (Moore)
47930924|NCT05724043|DEVICE|SmartJournal|SmartJournal is a tablet application with three modules: Module 1 offers a system for simple check-box registration of daily oral hygiene routines. This module also includes an open text field where the caregiver can give a brief description of strategies used if the patient shows resistant behaviors. Module 2 offers a system for monitoring the patient's oral health through monthly check-ups. This module is an image-based, interactive learning- and assessment tool. Upon completion of the monthly oral health assessment health personnel receive a summary report with suggestions for tailored preventive and/or curative measures to be initiated. Module 3 offers an easily accessible knowledge base which includes information on geriatric oral health, standard equipment and procedures for daily oral hygiene routines for patients with various care needs. It also includes scientifically documented strategies that may be used to approach patients with dementia refusing oral care assistance.
47930925|NCT04932798|DIAGNOSTIC_TEST|Resting ECG (if first visit is done on site only)|"The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface.~This test requires around 15 minutes of the participant's time."
47930926|NCT04932798|DIAGNOSTIC_TEST|24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)|The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.
47930927|NCT04932798|DIAGNOSTIC_TEST|3-month AF detection monitoring using the Apple Watch|Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.
47930928|NCT04616742|DRUG|[14C]SHR6390|Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
47930929|NCT04319822|OTHER|blood sample and muscular biopsy|blood sample and muscular biopsy
48098529|NCT04109118|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 5 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).
48453927|NCT06114836|DRUG|Omeprazole|Omeprazole will be the PPI prescribed for 4 weeks.
48453928|NCT06114836|OTHER|AR formula|Added rice formula will be ordered for 4 weeks.
48453929|NCT02878018|DRUG|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
48453930|NCT02878018|DRUG|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
48453931|NCT03810586|DEVICE|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
48453932|NCT00154258|DRUG|Clozapine|
48453933|NCT01576705|DRUG|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
48453934|NCT01062490|DRUG|Treosulfan|14 g/m2/d, day -6 to -4
47930930|NCT01022827|OTHER|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes \[about 6 minutes for each muscle and order was random\] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
47930931|NCT06505811|BEHAVIORAL|Guaranteed Income ($500/monthly)|Participants receive $500 monthly for up to 18 months.
47930932|NCT06505811|BEHAVIORAL|Active Comparison ($20/monthly)|Participants receive $20 monthly for up to 18 months.
47951295|NCT06205615|DRUG|BXP154B|BXP154B will be self-administered topically following wound induction
47951296|NCT06205615|DRUG|Placebo|Placebo will be self-administered topically following wound induction
47930933|NCT06212687|BEHAVIORAL|Digital pre-therapy patient education program (StartHjelp)|After randomization the intervention group receives access to a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is presented stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos as they please.
47930934|NCT06212687|BEHAVIORAL|Comparator intervention|After randomization, while on waiting list, the control group gets sent all the same information as the intervention group in written form, by mail.
47930935|NCT06371820|OTHER|ESPRESSO [The study has no intervention]|This study has no interventions.
47930936|NCT01528540|DRUG|Placebo|This group will include placebo.
47930937|NCT01528540|DRUG|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
47930938|NCT05255185|PROCEDURE|domino therapy|The investigators evaluated routine blood test results, C-reactive protein level, the erythrocyte sedimentation rate, and other indicators. X-rays and CT scans of the surgical site were obtained and the Musculoskeletal Tumor Society (MSTS) score was calculated. Treatment involved debridement and lavage of the prosthesis, and systemic and local antibiotics.
47930939|NCT00476671|PROCEDURE|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
47930940|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws.
47930941|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE+collagen membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws and covered with a Collagen membrane subsequently.
47930942|NCT04612296|GENETIC|Research genetic analysis|Genetic analysis of DNA extracted from saliva. Participants can opt in to receive individual results of research genetic analysis for a predefined panel of clinically actionable cardiomyopathy genes.
47930943|NCT03733431|DEVICE|Gammacore device|Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
47930944|NCT03733431|DEVICE|Gammacore sham device|Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
47930945|NCT00712062|DRUG|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
47930946|NCT01115803|DRUG|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
47930947|NCT01115803|DRUG|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
47930948|NCT01115803|DRUG|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
47930949|NCT00852332|DIETARY_SUPPLEMENT|Curcumin|
47930950|NCT00852332|DRUG|Taxotere|
47930951|NCT01492543|DRUG|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
47930952|NCT02472509|DRUG|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
47930953|NCT03787043|DRUG|FDC(MP-513 10mg/Metformin XR 750mg)|
47930954|NCT05036473|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
47930955|NCT05036473|DRUG|Placebo|placebo tablets-matching the active groups.
47930956|NCT00830791|DRUG|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
47930957|NCT00830791|DRUG|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
47930958|NCT00481975|DRUG|rimonabant (SR141716)|
47930959|NCT02879149|DEVICE|AUGMENT® Bone Graft|AUGMENT® Bone Graft
47930960|NCT02879149|PROCEDURE|Standard of Care|Autologous Bone Graft
47930961|NCT05535010|PROCEDURE|Transforaminal epidural steroid injection(TFESI)|TFESI procedure will be applied again in the 3rd week and 3rd month for the patients whose NRS score decreased by less than 50 percent after the first procedure.
47930962|NCT06047184|DRUG|BEBT-209 capsules|BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.
47930963|NCT06047184|DRUG|Letrozole tablets|Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.
47930964|NCT06047184|DRUG|Fulvestrant|Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle
47930965|NCT01450904|PROCEDURE|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
47930966|NCT01450904|PROCEDURE|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
47930967|NCT01450904|PROCEDURE|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
47930968|NCT02764190|BEHAVIORAL|I-ACT with Check Yourself|
47930969|NCT02970201|OTHER|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
47930970|NCT02518880|OTHER|Parabolic flight|
47930971|NCT02518880|OTHER|plasma volume measurements|
47930972|NCT00105365|DEVICE|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
47930973|NCT00105365|OTHER|walking shoes|walking shoes
48453935|NCT06432751|OTHER|Post Operative Acute Kidney Injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
48453936|NCT02147379|DRUG|Lurasidone|
47930974|NCT02372214|PROCEDURE|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
47930975|NCT01006603|DRUG|Saxagliptin|5 mg, oral tablet, once daily
47930976|NCT01006603|DRUG|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
47930977|NCT00210938|DRUG|Doripenem|
47930978|NCT04433143|DRUG|Minocycline hydrochloride capsules were taken orally|Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
48098530|NCT04109118|DRUG|BZD discontinuation protocol|All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
48098531|NCT04551417|PROCEDURE|Free graft urethroplasty|Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
48098532|NCT05967442|DRUG|Magnesium Sulfate|Magnesium Sulfate 2gm in 50ml D5W over 20 minutes
48453937|NCT05288686|PROCEDURE|sentinel lymph node biopsy procedure|Patient received respective tracer injection and sentinel lymph node biopsy was performed in the operation theatre with the corresponding device.
48453938|NCT03721718|BIOLOGICAL|GLS-5300|\[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
48453939|NCT03721718|DEVICE|Cellectra 2000 Electroporation|GLS-5300 administered ID followed by Cellectra 2000 Electroporation
48453940|NCT04215328|DIETARY_SUPPLEMENT|Mixed-Meal|Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
48453941|NCT04215328|DIETARY_SUPPLEMENT|Electrolyte Solution|Electrolyte Solution 500mLs by tube daily in 4 doses
47930979|NCT00235170|DEVICE|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
47930980|NCT02623231|DRUG|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
47930981|NCT02623231|DRUG|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
47930982|NCT00627146|DRUG|ChAgly CD3|6 days treatment 8mg/d intravenous
47930983|NCT00627146|DRUG|Placebo|6 days
47930984|NCT04635670|DIETARY_SUPPLEMENT|Pro-/prebiotic Mix|Soluble powder for oral use of pre-/probiotic mix 3.0 g twice daily.
48453942|NCT00035139|DRUG|methylphenidate|
48453943|NCT05696626|DRUG|Lasofoxifene in combination with abemaciclib|5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
47930985|NCT04635670|DIETARY_SUPPLEMENT|Placebo|Soluble powder for oral use twice daily.
47930986|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
47930987|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
47930988|NCT00724880|DRUG|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
47930989|NCT06092060|DIETARY_SUPPLEMENT|the group GS (probiotic)|The probiotic-supplemented group will receive 2 capsules of freeze-dried powder of a probiotic mixture containing the following bacterial strains twice a day, 3-month: Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus salivarius W24
48098533|NCT05967442|DRUG|Metoclopramide 10mg|Metoclopramide 10mg in 50ml D5W over 20 minutes
48098534|NCT05967442|DRUG|Prochlorperazine (Compazine) Injection|Prochlorperazine 10mg in 50ml D5W over 20 minutes
48098535|NCT06130878|OTHER|Rhythmic exercise|"A multicomponent rhythmic physical training will be carried out, with a predominance of QMT, following the principles of Animal Flow \[46\] and including the following components: wrist mobilizations; activations; specific stretching positions; special locomotor movements or traveling forms; interruptions and transitions with dynamic movements and choreographic sequences of Flow. Aspects related to the control of intensity, volume and progression strategy have yet to be defined."
48453944|NCT05696626|DRUG|Fulvestrant in combination with abemaciclib|Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
48453945|NCT06508905|OTHER|Sleep buddy|The toy chosen as a sleep companion was introduced to the children in the experimental group and they were told that it would accompany them for 3 days during their hospitalization. Before giving the sleep companion, parents and children were informed about the sleep companion and their questions about the study were answered. Children who did not have their own sleep companion were included in the sample. The child was encouraged to sleep and spend time with the given sleep buddy and the family was also informed.
48453946|NCT05644106|DEVICE|personal sound amplification product, hearing aid|the device for hearing gain in sensorineural hearing loss
48453947|NCT03123094|DRUG|Spesolimab|single dose
48453948|NCT03123094|DRUG|Placebo|single dose
48453949|NCT06287281|OTHER|heel hight shoes|stand upright for 2 hours wearing your own shoes with heels at least 7 cm high
47930990|NCT06092060|DIETARY_SUPPLEMENT|the group GP (placebo)|The placebo group will receive 2 capsules consisting of the probiotic product carrier, which is corn starch and maltodextrin, twice a day, 3-month.
47930991|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + My First- Colgate|Positioning of the FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
47930992|NCT04642001|OTHER|Photon Laser III-DMC (without radiation emission) + Sensodyne® Rapid Relief / GSK|Positioning of FBM (Photon Laser III / DMC) without emitting radiation, the equipment's sound was mimicked with the Beep application (Foncannon Inc, Google, © 2018), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
47930993|NCT04642001|RADIATION|Photon Laser III-DMC (with irradiation emission) + My First- Colgate|Emission of FBM therapy (Photon Laser III / DMC), followed by the use of fluoride-free toothpaste (My First- Colgate) and brushing three times a day.
47930994|NCT04642001|COMBINATION_PRODUCT|Photon Laser III-DMC (with irradiation emission) +Sensodyne® Rapid Relief / GSK|Emission of FBM therapy (Photon Laser III / DMC), followed by the application of toothpaste containing strontium acetate (Sensodyne® Rapid Relief / GSK) and brushing three times a day.
47930995|NCT06480162|PROCEDURE|Mechanical ventilation|After replacing the electrode, we'll monitor the EEG activity of the hippocampus and other cortex regions while weaning off mechanical ventilation.
47930996|NCT02556476|PROCEDURE|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
47930997|NCT02556476|PROCEDURE|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
47930998|NCT02556476|PROCEDURE|renal replacement therapy|the procedures used to treat acute kidney injury
47930999|NCT02556476|PROCEDURE|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
48453950|NCT00540423|DRUG|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
48453951|NCT00540423|DRUG|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
47931000|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Semestrial administration
47931001|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Annual administration
47931002|NCT00124839|DRUG|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
47931003|NCT04673110|DIAGNOSTIC_TEST|Neutrophil to Lymphocyte Ratio and C-reactive protein|Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
47931004|NCT00357929|PROCEDURE|Permissive hypercarbia|
47931005|NCT00040456|DRUG|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
47931006|NCT00040456|DRUG|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
47931007|NCT01599143|BEHAVIORAL|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
47931008|NCT01073371|DRUG|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
47931009|NCT05046444|DIAGNOSTIC_TEST|Next Generation Sequencing|NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
47931010|NCT00309660|DRUG|Rosiglitazone|
47931011|NCT00534469|BIOLOGICAL|aldesleukin|
47931012|NCT00534469|BIOLOGICAL|filgrastim|
47931013|NCT00534469|DRUG|busulfan|
47931014|NCT00534469|DRUG|cytarabine|
47931015|NCT00534469|DRUG|etoposide|
47931016|NCT00534469|DRUG|idarubicin|
47931017|NCT00534469|PROCEDURE|autologous hematopoietic stem cell transplantation|
47931018|NCT00534469|PROCEDURE|bone marrow transplantation|
47931019|NCT00534469|PROCEDURE|peripheral blood stem cell transplantation|
47931020|NCT00534469|RADIATION|total-body irradiation|
48453952|NCT00540423|DRUG|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
48453953|NCT00540423|DRUG|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
48453954|NCT03644550|DRUG|LMB-100|Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.
47931021|NCT02417493|BEHAVIORAL|Simulation of epinephrine self-injection|
47951297|NCT02540616|DEVICE|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
47951298|NCT06009029|RADIATION|Stereotactic body radiation(SBRT)|"SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects."
47951299|NCT06009029|DRUG|Zimberelimab (GLS-010)|Zimberelimab (GLS-010),240mg d1 iv Q21D
47951300|NCT03719443|BIOLOGICAL|VIS649|Single IV dose of study product on Day 1 of study
47951301|NCT03719443|BIOLOGICAL|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
47951302|NCT00004364|DRUG|desmopressin|
48453955|NCT03644550|BIOLOGICAL|Pembrolizumab|Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
48622388|NCT05804968|OTHER|Digital HIV Self Disclosure Intervention|This project will develop a digital HIV disclosure intervention, drawing from the HEADSUP manual (Evangeli et al., 2020), which consists of four modules, including a HIV disclosure planning component. A SCED will be used to explore HIV disclosure intention, amongst other variables throughout baseline, intervention and follow up phases. Participants will further be asked to complete a participant experiences questionnaire to explore how they found the digital intervention and assess acceptability. This project will recruit a diverse sample of Sub-Saharan Africa adults living with HIV and residing in the U.K.
47931022|NCT03780400|BEHAVIORAL|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
47931023|NCT01596556|DRUG|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
47931024|NCT01596556|OTHER|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
47931025|NCT01565343|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi)
47931026|NCT06437704|OTHER|Brain training game Lumosity|. Group A, the experimental group will be trained using five selected games i.e. Speed Match, Memory Matrix, Tidal treasure, Ebb and Flow and Lost in Migration from Lumosity for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
47931027|NCT06437704|OTHER|Simulation game simcity buildit|Group B, the active control will be trained for the same number of sessions using a simulation game, SimCity Build it, for a period of 30 sessions , 30 min/ day over the span of 6 weeks.
47931028|NCT05519293|DRUG|H002|Small molecule, Capsule
47931029|NCT01894412|BIOLOGICAL|Etanercept (Enbrel)|
47931030|NCT01894412|BIOLOGICAL|HD203|
47931031|NCT02663726|OTHER|Yoga|10 weekly 75-min sessions of specialised yoga
47931032|NCT02663726|BEHAVIORAL|Written advice|Written advice about physical activity
47931033|NCT03819907|COMBINATION_PRODUCT|Audiovisual Guided Relaxation|Five-minute guided relaxation delivered via a computer screen and speakers
47931034|NCT03819907|COMBINATION_PRODUCT|Virtual Reality Guided Relaxation|Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
47931035|NCT03027284|DRUG|Merestinib|Administered orally
47931036|NCT03027284|DRUG|Cisplatin|Administered IV
47931037|NCT03027284|DRUG|Gemcitabine|Administered IV
47931038|NCT04334538|DIETARY_SUPPLEMENT|S-RUTF|Children will receive approximately 175 kcal/kg/d of standard ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
47931039|NCT04334538|DIETARY_SUPPLEMENT|oat RUTF|Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
47931040|NCT00499057|RADIATION|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
47931041|NCT02508298|PROCEDURE|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
47931042|NCT02508298|DRUG|Indocyanine Green Retention test|As decribed in arm descriptions
47931043|NCT02508298|DEVICE|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
47931044|NCT02508298|DEVICE|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
47931045|NCT02742246|BEHAVIORAL|Individual clinician-provided CBT|Individual clinician-provided CBT
47931046|NCT02742246|BEHAVIORAL|CBT4CBT|CBT computer program assisted therapy
47931047|NCT00958997|DRUG|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
47931048|NCT00958997|BIOLOGICAL|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
47931049|NCT03725423|DRUG|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
47931050|NCT04652414|DRUG|Prednisone|Prednisone 50mg will be administered enterally for 7 days.
47931051|NCT04652414|DRUG|Placebo|This is a matching placebo to prednisone.
48453956|NCT00615667|DRUG|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
48622389|NCT06117137|DRUG|SGLT2 inhibitor|"Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin"
47931052|NCT03093688|BIOLOGICAL|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.
47951303|NCT02841189|DEVICE|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
47951304|NCT01303328|DRUG|C1|Local application of the experimental gel or placebo gel.
47951305|NCT01046162|DRUG|Alprazolam|Single tablet
47951306|NCT01046162|DRUG|Alprazolam|Single tablet
47931053|NCT05138471|DEVICE|transcranial direct current stimulation (tDCS)|tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.
47931054|NCT05138471|DEVICE|TENS|TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
47931055|NCT05138471|BEHAVIORAL|Exercise and General Education|The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
47931056|NCT00618553|OTHER|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
47931057|NCT00618553|BEHAVIORAL|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
47931058|NCT00689442|DRUG|JTT-705 600 mg and atorvastatin 20 mg|"* JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~* Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
47931059|NCT00689442|DRUG|Placebo and atorvastatin 20 mg|"* Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
47931060|NCT03549793|BEHAVIORAL|Dance Therapy|the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
47931061|NCT03549793|BEHAVIORAL|exercises without dance|the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
47931062|NCT04738305|OTHER|Dignity Therapy|"The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones."
47931063|NCT00112398|PROCEDURE|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
47931064|NCT02661178|DRUG|emodepside (BAY 44-4400)|
47931065|NCT02661178|DRUG|placebo|
47931066|NCT01371032|DEVICE|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
48453957|NCT05241639|DIAGNOSTIC_TEST|Pentacam|Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
48453958|NCT05404789|OTHER|Centrifugation|Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.
47931067|NCT01371032|DEVICE|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
47931068|NCT00045474|PROCEDURE|adjuvant therapy|
47931069|NCT00045474|RADIATION|iodine I 125|
47931070|NCT03055377|DRUG|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
47931071|NCT03055377|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
47931072|NCT02328053|PROCEDURE|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
48453959|NCT04231643|DRUG|Dronabinol|one-time oral administration of 5 mg dronabinol
48453960|NCT04231643|DRUG|Epidiolex|one-time oral administration of 600 mg Epidiolex
48453961|NCT04231643|DRUG|Placebos|one-time oral administration of placebo
47931073|NCT02328053|DRUG|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
47931074|NCT03963401|DRUG|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
47931075|NCT03963401|OTHER|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
47931076|NCT01758445|RADIATION|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol \& physician.
47931077|NCT04757428|PROCEDURE|Endocrown|Endocrown
47931078|NCT02847572|PROCEDURE|Cataract Surgery|All patients wil be having intraocular lens surgery
48453962|NCT05815394|DRUG|177Lu-labeled NY108|Patients will receive a tracer (40-60ug) dose of 177Lu(28.5-31.5mCi) labelled NY108.
48453963|NCT03954483|DRUG|Buspirone 10 Mg Oral Tablet|Orally administered prior to experiments.
48453964|NCT03954483|DRUG|Triazolam 0.25 MG Oral Tablet|Orally administered prior to experiments.
48453965|NCT03954483|DRUG|Placebo oral tablet|Orally administered prior to experiments.
48453966|NCT01261663|OTHER|oral nutritional energy and protein enriched supplement (NOS)|
47931079|NCT04042935|DRUG|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
48453967|NCT01386853|DRUG|Pitavastatin|2 mg QD
48453968|NCT01386853|DRUG|Atorvastatin|10 mg QD
47931080|NCT05378139|DEVICE|Vital signs measurements with new app|Patients vital signs are monitored through an app for the nurses to use
47931081|NCT01733212|DRUG|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
47931082|NCT01733212|DRUG|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
47931083|NCT04473482|BEHAVIORAL|Michigan Alcohol Improvement Network-Alcohol Reduction and Treatment tool|The intervention corrects misconceptions about alcohol use, liver disease, and alcohol treatment and matches patients to their top three choices of treatment while providing them with brief explanations of each treatment option.
47931084|NCT03824509|OTHER|Chart Review|"Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017."
47931085|NCT03971877|DIAGNOSTIC_TEST|Rapid Polymyxin NP test|From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
47931086|NCT05477433|BEHAVIORAL|diabetes mellitus type 1|"Pittsburgh Sleep Quality Index PSQI: It is used to detect sleep disturbance or deficits. The PSQI has a scoring key that can be used to calculate a patient's seven subscores, which range from 0 to 3. The subscores are added together to produce a global score that ranges from 0 to 21. A global score of 5 or higher denotes poor sleep quality, The Strengths and Difﬁculties Questionnaire (SDQ) The SDQ is a well-validated screening tool for children and adolescents aged 4-17 years that can identify behavioural and emotional issues,Emotional Avoidance Strategy Inventory for Adolescents (EASI) is used. The EASI-A is a 17-item assessing the use of emotionally avoidant strategies in adolescents and higher scores means significants use avoidant strategies, The Toronto Alexithymia Scale (TAS-20) is a self-administered 20-item questionnaire which assesses difficulties in identifying and describing emotions. TAS scores were significantly higher in alexithymia"
47931087|NCT00062816|DRUG|ISIS 14803, peginterferon alfa, ribavirin|
47931088|NCT02240147|BEHAVIORAL|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
47931089|NCT05911594|DRUG|Solifenacin group|Patients in this group will receive medical treatment (Solifenacin 5 mg once or twice daily) without any second line of treatment
47931090|NCT05911594|PROCEDURE|Percutaneous tibial nerve stimulation group|Patients in this group will receive Percutaneous tibial nerve stimulation after failure of medical therapy
47931091|NCT05911594|DRUG|Intradetrusor BOTOX group|Patients in this group will receive Intradetrusor BOTOX after failure of medical
47931092|NCT05911594|COMBINATION_PRODUCT|Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation group|Patients in this group will receive Intradetrusor BOTOX combined with Percutaneous tibial nerve stimulation after failure of medical
47931093|NCT03603366|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
47951307|NCT02642302|BEHAVIORAL|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
47951308|NCT02642302|BEHAVIORAL|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
47951309|NCT02642302|BEHAVIORAL|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
47951310|NCT01397201|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
48453969|NCT04764175|BEHAVIORAL|Telephone All Nations Breath of Life|Same as described above.
48453970|NCT04764175|BEHAVIORAL|Comparison Program|Same as described above.
48453971|NCT01910038|DRUG|corticoids+ tocilizumab 8mg/Kg/4 weeks|
48453972|NCT01406353|PROCEDURE|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
48453973|NCT03480763|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
48453974|NCT03480763|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose
47931094|NCT04244812|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
47931095|NCT04244812|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
47931096|NCT01433276|DRUG|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
47931097|NCT01433276|DRUG|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
48453975|NCT03480763|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
48622390|NCT05735470|DEVICE|antibacterial bone traction needles|Whether to use bone traction needles containing antibacterial coatings
47931098|NCT02943083|BEHAVIORAL|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
47931099|NCT03673761|OTHER|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
47931100|NCT04601454|DEVICE|Spinal Cord Stimulation System|Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
47931101|NCT04829578|OTHER|Hypnosis|Chronic idiopathic pruritus is treated by hypnosis
47931102|NCT03487978|DIAGNOSTIC_TEST|resting-state functional MRI|"1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not."
47931103|NCT01215916|DRUG|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\]."
47931104|NCT01215916|DRUG|Pemetrexed|"375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
48622391|NCT00042978|BIOLOGICAL|oblimersen sodium|Given IV
48622392|NCT00042978|DRUG|carboplatin|Given IV
48622393|NCT00042978|DRUG|etoposide|Given IV
48622394|NCT06552026|DEVICE|repeated transcranial magnetic stimulation|repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability
47931105|NCT04340219|OTHER|Survey administration|Covid-19 Peritraumatic Distress Index, Depression Anxiety Stress Scale-21, WHO Quality of Life-BREF
47931106|NCT05790161|DRUG|Caffeine|2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
47931107|NCT04710771|OTHER|Prone Lying Position|patient lies on his/ her stomach facing floor.
47931108|NCT04710771|OTHER|alternate nostril breathing|patient inspires with one nostril at a time, right or left one by one and expires by mouth.
47931109|NCT03718975|DEVICE|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
48453976|NCT05589753|OTHER|Hyperoxia|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
48453977|NCT05589753|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
48453978|NCT03575351|DRUG|Standard of Care|Standard of Care
48622395|NCT04871438|DEVICE|Flash glucose monitoring|Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
47931110|NCT03718975|DEVICE|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
48453979|NCT03575351|GENETIC|JCAR017|JCAR017
48622396|NCT01454284|DRUG|Glargine|
48622397|NCT01454284|DRUG|LY2605541|
47931111|NCT01585584|DRUG|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
47931112|NCT05443633|BEHAVIORAL|individualized speech-language training|Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).
48453980|NCT03914365|PROCEDURE|Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)|Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
48453981|NCT06146959|DEVICE|Corrective Kinesiology taping|corrective kinesiology tape is a form of biomechanical tape that is used with specific tension to get a corrective effect
48453982|NCT06146959|DEVICE|Non corrective kinesiology tape|Non-corrective kinesiology tape is a form of biomechanical tape that is used without any tension
48453983|NCT06146959|OTHER|Home exercise program|Intrinsic foot strengthening and stretching exercises
48453984|NCT03668015|OTHER|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
48453985|NCT03668015|OTHER|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
48453986|NCT00615823|DRUG|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
48453987|NCT00615823|DRUG|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
48622398|NCT01454284|DRUG|Insulin Lispro|
48622399|NCT02939391|DRUG|KW-6356|Oral administration
48622400|NCT02939391|DRUG|KW-6356|Oral administration
48622401|NCT02939391|DRUG|Placebo|Oral administration
48622402|NCT02981641|RADIATION|Intraoperative radiotherapy (IORT)|Total dose: 18\~22 Gy; Single dose: 18\~22 Gy; Frequency: 1
48622403|NCT02981641|DRUG|Sequential chemotherapy|Sequential chemotherapy
48622404|NCT02981641|RADIATION|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
48622405|NCT02981641|DRUG|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
47931113|NCT05443633|BEHAVIORAL|standard language intervention|Participants will undergo standard speech-language naming therapy
47931114|NCT05895799|OTHER|Tuition from a expert clinical trainer|Each group was initially provided with an online tutorial on the complete physical examination of the cardiovascular system as performed on a standardized patient by the trainer. At the beginning of each session, the trainer performed the examination on a hybrid patient wearing the auscultation vest and provided additional teaching, explanations, and rationale. Following the demonstration, each participant was invited to perform repeated physical examinations in front of their peers with real-time one-to-one feedback from the trainer. After each performance, the participant was encouraged to critique their own performance(s), peers were invited to provide some insights, and the trainer gave some overall feedback. At the end of the session and after each participant had had the opportunity to perform the complete examination at least once, the participants were taken through a range of abnormal signs using the auscultation vest with explanations provided by the trainer.
47931115|NCT04486001|BIOLOGICAL|PSC-04|adipose stem cells derived from screened donor lipoaspirate and culture expanded.
47931116|NCT04097743|BEHAVIORAL|Coping Statement|Daily practice of coping statement
48622406|NCT02852083|DRUG|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
48622407|NCT02852083|DRUG|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
48622408|NCT02852083|DRUG|Treosulfan|Treosulfan 250 mg twice daily, p.o.
48622409|NCT02852083|DRUG|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
48622410|NCT00386828|DRUG|Bevacizumab:|
48622411|NCT04785729|DRUG|Almonertinib combine with Pyrrolitinib|110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
48622412|NCT05361837|PROCEDURE|Single level serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third rib
48622413|NCT05361837|PROCEDURE|Single level serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib
48622414|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block|Serratus anterior plane block with local anesthetics at the third and fifth rib
48622415|NCT05361837|PROCEDURE|Bilevel serratus anterior plane block with dexmedetomidine|Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib
48622416|NCT04428944|PROCEDURE|Wide Circumferential Pulmonary Vein Antrum Isolation (PVAI)|Standard PVI
48622417|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Driver Ablation (PVAI+drivers)|Standard PVI + Ablation of drivers in LA and RA
48622418|NCT04428944|PROCEDURE|Pulmonary Vein Antrum Isolation Plus Box Isolation of Posterior Wall (PVAI+box)|Standard PVI + Electrical isolation of the posterior wall of the left atrium
48453988|NCT04444063|PROCEDURE|Non-Incised Papilla Surgical Approach|"Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture."
48453989|NCT05716490|DEVICE|Incisional negative pressure wound therapy|Application of negative pressure wound therapy for prophylaxis of surgical site occurrences
48453990|NCT05716490|OTHER|Control group - standard wound dressing|Covering of surgical wound with standard wound dressing
48453991|NCT06627335|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
47931117|NCT03325751|DIAGNOSTIC_TEST|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
47931118|NCT05793229|OTHER|observation|observation
47931119|NCT05242796|DEVICE|Low frequency magnetic therapy|
47931120|NCT05778383|DIETARY_SUPPLEMENT|Zinc Acetate|Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
48453992|NCT06627335|DRUG|TCS|Topical corticosteroid
48453993|NCT00765635|DRUG|drops intilation (Taponoto ® )|four drops, unique doses
48453994|NCT00765635|DRUG|drops intilation (Otocerum®)|four drops, unique doses
48453995|NCT00765635|DRUG|drops intilation (Placebo)|Placebo
48453996|NCT04577651|DEVICE|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with 16-contact Directional Lead
48453997|NCT04905082|OTHER|Best Practice|Receive usual care
48453998|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics tool after genomic test results are available
48453999|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics before sequencing results are available
48454000|NCT04905082|PROCEDURE|Genomic Profile|Receive genomics test results
48454001|NCT04905082|OTHER|Survey Administration|Ancillary studies
48454002|NCT05606458|BEHAVIORAL|İntervention Group|Before the procedure, the baby was started to be breastfed (1st stimulus). The mother supported her baby's back and bottom with one hand. He started to touch by positioning the thumb of the other hand to prevent the baby's nose from being blocked, and the other fingers of the same hand to touch the baby's face (2nd stimulus). The mother started to talk to her baby with a gentle tone of voice, sometimes using sentences (lullaby, song, etc.) that she wanted to increase the volume of her voice (3rd stimulus). The mother was in the baby's sight (4th stimulus). Clothes were removed as much as possible for the smell of the mother's skin (5th stimulus). The baby's foot in the mother's arms was warmed in the nurse's hand for a minute. The area was determined, and the baby's heel was wiped with 70% alcohol. It was expected to dry. Heel piercing was performed while the stimuli continued. Heel blood was taken. When the evaluation period is complete, the process is over.
48454003|NCT04985435|DRUG|Filgotinib|200 mg tablet once daily or 100 mg once daily
48454004|NCT04985435|DRUG|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
48454005|NCT04985435|BEHAVIORAL|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
48454006|NCT06562010|BEHAVIORAL|iCT-SAD-PK|The intervention arm will receive a Pakistani version of Internet-delivered Cognitive Therapy for Social Anxiety Disorder (iCT-SAD), assessing its effectiveness in reducing social anxiety symptoms among Pakistani individuals. This will involve culturally tailored online therapy modules, therapist support, and regular progress assessments.
48454007|NCT04050709|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK Suspension for Infusion
48454008|NCT04471922|DRUG|Anaprazole Sodium enteric-coated tablet|Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
47931121|NCT04779749|OTHER|Data extraction from medical files|Data extraction from medical files
48454009|NCT04471922|DRUG|Placebo|Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
47931122|NCT02150902|PROCEDURE|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF \>10g, FTI \> 500 g-sec and minimum ablation duration \>10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
48454010|NCT04471922|DRUG|Active controlled (rabeprazole)|Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
48454011|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
48454012|NCT00829712|DRUG|Dexmethylphenidate Hydrochloride|10 mg Tablet
47951311|NCT01397201|DRUG|BI 54903|BI 54903
47951312|NCT01397201|DRUG|Fluticasone propionate|Fluticasone propionate
47951313|NCT03458975|RADIATION|MRI|Magnetic Resonance Imaging
47951314|NCT03458975|RADIATION|Perfusion CT scan|Perfusion Computerized tomography scan
48454013|NCT03797703|DRUG|Lidocaine Hydrochloride 2% gel enema|Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
48454014|NCT04511039|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
48454015|NCT04511039|DRUG|Talazoparib Tosylate|Given PO
47931123|NCT02150902|PROCEDURE|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
47931124|NCT00465309|PROCEDURE|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat \< 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH \> 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
47931125|NCT01031420|DRUG|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
47931126|NCT05146453|PROCEDURE|Pectointercostal fascia blocks|PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
47951315|NCT03458975|OTHER|Contrast enhanced ultrasound|Contrast enhanced ultrasound
48454016|NCT05391451|PROCEDURE|efficacy of quadratus lumborum block in post-operative analgesia in kidney transplant surgery|no premedication for anxiolytic purposes before surgery. Cimetidin 200mg can be administrated for Mendelson syndrome prevention. After general anesthesia induction, echo-guided quadratus lumborum block is performed by applying 20ml of levobupivacaine
48454017|NCT05391451|PROCEDURE|general anesthesia|general anesthesia is the current technique for kidney transplant surgery. The protocol involves the combination of several drugs: Propofol, Remifentanil, Ketamin, Atracurium or Cisatracurium. Curarization monitoring is systematic.
48454018|NCT04504747|OTHER|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
48622419|NCT02262871|DEVICE|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
48454019|NCT06559995|DIETARY_SUPPLEMENT|"ketone supplement D-beta-hydroxybutryric acid and R-1,3 butanediol 12g of ketones,"|ketone supplement
48454020|NCT06559995|DIAGNOSTIC_TEST|magnetic resonance imaging session|1.5 hour magnetic resonance imaging session
48454021|NCT06559995|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage, visually matched, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit.
48622420|NCT02262871|DEVICE|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
48622421|NCT05803317|OTHER|usual care : Evaluation of walking on a baropodometric platform|Pure observationnal study
48622422|NCT00782067|DRUG|Midostaurin (PKC412)|Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
48622423|NCT03550209|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
48622424|NCT03550209|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
48622425|NCT02323815|DIETARY_SUPPLEMENT|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
48622426|NCT02323815|BEHAVIORAL|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
48622427|NCT03372421|OTHER|Social Story|A short story written in the third person about what it's like to attend an assessment for ASD.
48622428|NCT03372421|OTHER|Standard Information|Information the host site currently sends out to patients informing them about what to expect from the assessment
48622429|NCT01308710|DIETARY_SUPPLEMENT|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
48622430|NCT01076933|PROCEDURE|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
48622431|NCT01076933|PROCEDURE|sham rTMS|sham rTMS
48622432|NCT01577121|DRUG|indomethacin|50 mg / 6 hours during 5 days
48622433|NCT01577121|DRUG|placebo|50 mg / 6 hours during 5 days
48622434|NCT01687699|DRUG|Spironolactone|
48622435|NCT00782444|PROCEDURE|Computer navigated knee replacement|Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
48622436|NCT00782444|PROCEDURE|Conventional knee replacement|Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
47931127|NCT05146453|OTHER|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
47931128|NCT02183753|OTHER|wood smoke|
47931129|NCT02183753|OTHER|clean air|
47931130|NCT05871515|DEVICE|3D ultrasound|A 3D ultrasound is performed preoperatively to measure various aneurysm characteristics
47931131|NCT00065130|DRUG|human insulin|
47931132|NCT00065130|DRUG|insulin NPH|
47931133|NCT00065130|DRUG|insulin aspart|
47931134|NCT05402033|BEHAVIORAL|Survey / Interview Group|Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
47931135|NCT03829878|DRUG|CP101|Orally administered donor derived full spectrum microbiota
47931136|NCT03829878|DRUG|Placebo|Placebo for CP101
47931137|NCT03415776|PROCEDURE|Hemodialysis|Renal replacement therapy
47931138|NCT01067443|DRUG|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
48622437|NCT05877105|OTHER|Ventilator-associated pneumonia prevention Evidence-based practices (VAPPEBP) which consists of ten items bundle|VAP prevention EBP which consists of ten items bundle; hand hygiene, head-of-bed elevation, oral care with cetylpyridinium chloride, avoidance of oversedation, proper breathing circuit management, appropriate maintenance of endotracheal tube cuff pressure, closed system and subglottic suctioning, daily assessment for extubation, early ambulation and rehabilitation, and peptic ulcer and deep vein thrombosis (DVT) prophylaxis.
47931139|NCT01067443|DRUG|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
47931140|NCT01067443|DRUG|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
47931141|NCT02442401|DEVICE|The negative pressure wound therapy|
47931142|NCT06167343|PROCEDURE|ACL reconstruction|In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
47931143|NCT04421768|BEHAVIORAL|cervical exam training|Each nurse will then examine 1 sets of 10 high-fidelity silicone task trainers approximately three per week for a maximum of 20 sessions (200 repetitions total). For each set of 10 exams, the estimates will recorded on an answer sheet. A cumulative summation analysis will be performed on each participant. When an individual nurse achieves competence her training will be suspended
47931144|NCT02835053|OTHER|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
47931145|NCT00184769|DRUG|somatropin|
47931146|NCT00420641|DRUG|GSK372475|GSK372475 1.0-1.5 mg/day
47931147|NCT00420641|DRUG|Paroxetine|Paroxetine 20-30 mg/day
47931148|NCT00420641|OTHER|Placebo|Placebo to Match
47931149|NCT00197067|BIOLOGICAL|RTS,S/AS02D and RTS,S/AS02A|
47931150|NCT03680742|DEVICE|Contour Neurovascular System|The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
48280105|NCT01501487|DRUG|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
47931151|NCT05301374|BEHAVIORAL|Watching Cartoon|Children in the cartoon group before the procedure, they chose one of the cartoons predetermined by the researchers. The children in the cartoon group started watching a cartoon of their choice 2 minutes before the procedure and they kept watching until the procedure was ended.
47931152|NCT03761797|DRUG|TRADIANCE® Combination Tablets AP|Fixed dose combination
48280106|NCT00644267|BEHAVIORAL|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
47931153|NCT03761797|DRUG|TRADIANCE® Combination Tablets BP|Fixed dose combination
47931154|NCT01185834|DEVICE|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
47931155|NCT04184258|BIOLOGICAL|Pooled mesenchymal stem cell|Pooled allogenic mesenchymal stem cell derived from olfactory mucosa
47931156|NCT04184258|OTHER|Standard treatment according to the Clinical protocols|Standard SLE treatment according to the Clinical protocols approved by the Ministry of healthcare of Republic of Belarus
47931157|NCT05837169|OTHER|Mindfulness-based stress reduction|The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
47931158|NCT01373827|DEVICE|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
47951316|NCT03458975|DRUG|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
48622438|NCT04521452|DRUG|Evogliptin|Subjects will receive evogliptin 5 mg daily
48622439|NCT00308347|DRUG|MK0954, losartan / Duration of Treatment: mean 3.4 years|
48622440|NCT00308347|DRUG|Placebo / Duration of Treatment: mean 3.4 years|
47931159|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
47931160|NCT03743974|PROCEDURE|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
47931161|NCT00789074|DRUG|Varenicline|Varenicline 1mg twice daily
48280107|NCT05369806|BEHAVIORAL|Interactive two-way SMS dialogue|This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
47931162|NCT00789074|DRUG|Placebo|Placebo 1mg BD
47931163|NCT04911374|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants
47931164|NCT04911374|OTHER|Aveeno Face Milk SPF 40+|Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
47931165|NCT05336344|BEHAVIORAL|ENCODE|a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
47931166|NCT00377130|OTHER|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
47931167|NCT02205554|DRUG|Omnitram|Nine 20 mg doses administered every 6 hours
47931168|NCT02205554|DRUG|Tramadol|Nine 50 mg doses administered every 6 hours.
47931169|NCT02205554|DRUG|Placebo|Nine doses administered every 6 hours.
47931170|NCT01435551|OTHER|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
47931171|NCT01436162|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
47931172|NCT01436162|DRUG|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
47931173|NCT03965000|OTHER|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
47931174|NCT00743236|PROCEDURE|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
47931175|NCT00743236|PROCEDURE|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
47951317|NCT00920101|DRUG|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
48280108|NCT02687269|DRUG|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
48280109|NCT02687269|DRUG|Placebo|Patients receive Placebo twice daily in the three days before surgery
48280110|NCT02028949|DRUG|Zavedos®|
48280111|NCT02028949|OTHER|Blood samples|
48280112|NCT01907685|DRUG|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
48280113|NCT01907685|DRUG|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
48280114|NCT04449861|DRUG|Durvalumab plus chemotherapy|"Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks"
48280115|NCT04637867|OTHER|Collection of blood, salivary and nasopharyngeal samples.|"Each visit M6 and M12~* Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~* Salivary sample~* Nasopharyngeal sample"
48280116|NCT04701307|BIOLOGICAL|Dostarlimab|Given IV
48280117|NCT04701307|DRUG|Niraparib|Given PO
48280118|NCT01097902|DRUG|Ibuprofen|800 mg oral one time only
48454022|NCT05550064|OTHER|Structured contraceptive counseling|"1. Educational video - healthcare providers (Medical doctors and nurse-midwives)present available contraceptives that could be used after delivery, with emphasis on effectiveness, how they should be used, mechanism of action and health benefits.~2. The four key questions are to be asked to all pregnant women to make them reflect on factors that highly affects choice of contraceptives.~3. A tiered effectiveness chart will be used to visualize the effectiveness of different contraceptives, and guide the prospective user in her choice depending on the answers to the key questions~4. The box of contraceptive models are used for the prospective user to inspect, hold, feel the different contraceptives, as this has been shown to decrease fear regarding specific methods."
48454023|NCT00003766|DRUG|O6-benzylguanine|
48454024|NCT03789110|DRUG|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
47931176|NCT00969280|DEVICE|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20\*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
48454025|NCT03789110|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
48454026|NCT00881569|DRUG|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
48454027|NCT00052286|DRUG|modafinil|
48454028|NCT03937557|DIAGNOSTIC_TEST|photofinder levicam|Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
48454029|NCT04422730|BEHAVIORAL|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
48454030|NCT04425941|OTHER|artificial intelligence diagnosis|artificial intelligence prediction of colorectal polyp histology
47931177|NCT00969280|DEVICE|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20\*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
47931178|NCT03046914|GENETIC|HLA-B*5801 test|Check whether a participant has HLA-B\*5801 allele or not, before administration of allopurinol
47931179|NCT00169858|BIOLOGICAL|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
47931180|NCT04594057|BEHAVIORAL|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
47931181|NCT02841878|GENETIC|Analysis on colorectal biopsy|
47931182|NCT00732043|DIETARY_SUPPLEMENT|pomegranate extract|8 oz per day, 48 months
48454031|NCT02648438|DRUG|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
48454032|NCT02648438|DRUG|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
48454033|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
48622441|NCT06322498|DIAGNOSTIC_TEST|Uterine lavage|Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid
47931183|NCT00732043|DIETARY_SUPPLEMENT|pomegranate juice|8 oz per day, 48 months
47931184|NCT00732043|DIETARY_SUPPLEMENT|placebo|8 oz per day, 48 months
47931185|NCT03584373|DRUG|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
48280119|NCT01097902|DRUG|Placebo tablet|Placebo tablet oral one time only
48454034|NCT02648438|DRUG|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
48454035|NCT02648438|DRUG|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
48622442|NCT01989273|DEVICE|Ultrasound of inferior vena cava|
48622443|NCT05098561|OTHER|Music Treatment|The nurse will set up the appropriate music genre for the each music treatment patient, based on patient's preference obtained from the pre-operative questionnaire, by using the bedside computer and using Pandora, the internet music streaming service.
48622444|NCT05408988|DIAGNOSTIC_TEST|hs-TnT (high-sensitive cardiac troponin T) plasma concentration|hs-TnT plasma concentration measured once every 12 hours
48622445|NCT05408988|DIAGNOSTIC_TEST|CK-MB (creatine kinase myocardial band) plasma concentration|CK-MB plasma concentration measured every 12 hours
48622446|NCT05408988|DIAGNOSTIC_TEST|CPK (creatine phosphokinase) plasma concentration|CPK plasma concentration measured every 12 hours
48622447|NCT05408988|DIAGNOSTIC_TEST|NT-proBNP (N-terminal prohormone of brain natriuretic peptide) plasma concentration|NT-proBNP plasma concentration measured every 12 hours
48622448|NCT05408988|DIAGNOSTIC_TEST|Metanephrine concentration in urine|Metanephrine concentration measured in 12-hour urine collection using spectrophotometry.
48622449|NCT00916734|PROCEDURE|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
48622450|NCT00916734|PROCEDURE|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
47931186|NCT03584373|DRUG|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
47931187|NCT03584373|DRUG|Oxycodone Acetaminophen|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
47931188|NCT05830110|DEVICE|Active Vibrotactile Coordinated Reset|Gloves providing vibrotactile coordinated reset stimulation
47931189|NCT05830110|DEVICE|Sham vibrotactile coordinated reset|Gloves providing sham vibrotactile coordinated reset stimulation
47931190|NCT05513118|DIAGNOSTIC_TEST|Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling|"Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit."
47931191|NCT04372056|BEHAVIORAL|Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic|Health care professionals
47931192|NCT00093665|DRUG|cisplatin|
47931193|NCT00093665|DRUG|fluorouracil|
47931194|NCT00093665|RADIATION|radiation therapy|
47931195|NCT05232370|DRUG|Angiotensin converting enzyme inhibitor|Angiotensin-converting enzyme inhibitors after Kidney Transplant
47931196|NCT05232370|DRUG|Angiotensin Receptor Blockers|Angiotensin receptor blockers after Kidney Transplant
47931197|NCT02378805|DRUG|ACE-inhibitor|observational study!
47931198|NCT02378805|DRUG|AT1-inhibitor|observational study!
47931199|NCT02378805|DRUG|HMG-Coenzyme inhibitor (statin)|observational study!
48280120|NCT01299025|OTHER|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
48280121|NCT04469491|DRUG|inhaled type I interferon|The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
48280122|NCT04469491|DRUG|WFI water nebulization|The interventional arm includes a WFI water nebulization comparator.
48280123|NCT05274750|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) will be administered using a pre- filled syringe.
48280124|NCT05274750|DRUG|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
48280125|NCT04748029|OTHER|Systemic immune inflammation index|The systemic immune inflammation index (SII) was calculated using the formula, SII = platelet count x neutrophil count / lymphocyte count. Systemic immune inflammation index (SII) is a new index related to systemic inflammation calculated by the numbers of lymphocytes, neutrophils and platelets in peripheral blood.
48280126|NCT01146470|DIETARY_SUPPLEMENT|RGC|dosage of Red Grape Cells once a day, during 3 months
48280127|NCT01146470|DIETARY_SUPPLEMENT|Placebo|dosage of Placebo once a day, during 3 months
48280128|NCT01966731|DRUG|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
48280129|NCT03337659|OTHER|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
48280130|NCT00455637|BIOLOGICAL|Botulinum toxin type A|
48280131|NCT03591887|BIOLOGICAL|ABY-035|ABY-035 solution for injection
48280132|NCT03591887|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
48280133|NCT01021943|DRUG|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
48280134|NCT01021943|DRUG|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
47931200|NCT02378805|DRUG|Spironolactone|observational study!
47931201|NCT02378805|DRUG|Paricalcitol|observational study!
48280135|NCT00606515|DRUG|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
48280136|NCT00606515|DRUG|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
48280137|NCT00961532|DRUG|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
48622451|NCT02965833|DEVICE|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix|For cleaning, disinfection and overnight storage of contact lenses
48622452|NCT02965833|DEVICE|Habitual Multi-Purpose Contact Lens Solution|
47931202|NCT02378805|DRUG|SGLT2 inhibitor|observational study!
47951318|NCT00920101|BEHAVIORAL|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
48280138|NCT03429218|DRUG|TP-0184|Oral dose once weekly for 4 weeks
48454036|NCT00496860|BIOLOGICAL|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
47931203|NCT02480140|OTHER|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
47931204|NCT02480140|OTHER|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
47931205|NCT02480140|OTHER|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
47931206|NCT04690062|DRUG|Brolucizumab-Dbll|intravitreal injection of Brolucizumab (BEOVU)
47931207|NCT00002543|DRUG|gallium nitrate|
47931208|NCT04800666|PROCEDURE|Stellate Ganglion Block|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
47931209|NCT04800666|PROCEDURE|Facial Nerve Block|Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )
47931210|NCT04800666|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
47931211|NCT01763242|OTHER|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
47931212|NCT00594945|DRUG|Clonazepam|1 Dose
47931213|NCT05324865|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
47931214|NCT05049720|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
48454037|NCT03994952|DEVICE|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
47931215|NCT02655770|DRUG|Liraglutide|
47931216|NCT02655770|DRUG|Placebo|
47931217|NCT04315584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT Scans
47931218|NCT04315584|PROCEDURE|Computed Tomography|Undergo PET/CT Scans
47931219|NCT04315584|PROCEDURE|Multiparametric Magnetic Resonance Imaging Scan|Undergo a multiparametric MRI scan
47931220|NCT04315584|RADIATION|Fludeoxyglucose F-18|IV (intravenous) administration of radiotracer
47931221|NCT04315584|RADIATION|fluorine F 18 fluorodopa|IV (intravenous) administration of radiotracer
47931222|NCT05167552|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
47931223|NCT05167552|OTHER|Standard treatment of type Allergic Rhinitis according to the clinical protocols|Standard treatment of type Allergic Rhinitis according to the clinical protocols
47931224|NCT05167552|OTHER|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols|Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols
47931225|NCT01857557|OTHER|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
47931226|NCT01488474|PROCEDURE|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
47931227|NCT05820997|DRUG|Ropivacaine|Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
47931228|NCT02420782|DRUG|ASP6282|oral
47931229|NCT02420782|DRUG|Itraconazole|oral
48454038|NCT03994952|DEVICE|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
47931230|NCT02420782|DRUG|Pilocarpine|oral
47931231|NCT02420782|DRUG|Placebo|oral
47931232|NCT02420782|DRUG|Midazolam|oral
48454039|NCT01521780|PROCEDURE|MRI|Participants undergo volumetric \& diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
47931233|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
47931234|NCT01470443|DRUG|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
47931235|NCT02276027|DRUG|BYL719|BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
47951319|NCT02154074|DRUG|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
48454040|NCT01521780|PROCEDURE|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
47931236|NCT02276027|DRUG|INC280|INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
47931237|NCT02276027|DRUG|LDK378|LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
47931238|NCT02276027|DRUG|MEK162|MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
48454041|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
48454042|NCT01521780|PROCEDURE|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
48454043|NCT00945490|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
47931239|NCT04413227|DRUG|Pegylated Recombinant Human Endostatin（PEG-ENDO）|PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
47931240|NCT05757362|OTHER|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
47931241|NCT05782816|DRUG|Oxytocin|Low dose oxytocin
48454044|NCT00945490|DRUG|Placebo|Single intraprostatic injection of placebo
47931242|NCT05782816|DRUG|Oxytocin|High dose oxytocin
47931243|NCT00534261|DRUG|Interferon beta-1a|IM injection
48454045|NCT01665404|DRUG|Fluvoxamine|Multiple doses of fluvoxamine
48454046|NCT01665404|DRUG|RO4917523|Single dose of RO4917523
47931244|NCT00913692|DRUG|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
47931245|NCT00913692|DRUG|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
48454047|NCT05049291|BEHAVIORAL|telehealth advance care planning|An education information sheet containing prognosis and outcomes of acute care and intensive treatments
48454048|NCT04542746|PROCEDURE|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
47931246|NCT04613401|OTHER|questionnaire (observational study)|questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
47931247|NCT04883723|DEVICE|Shotblocker|Shotblocker is a small, flat, horseshoe-shaped plastic tool that can be used to reduce pain due to intramuscular injection, suitable for all age groups, without drug properties. It is used by keeping it on the skin surface during injection and has no side effects. Shotblocker has short, non-pointed blunt protrusions on one side that connect with the skin, there is a hole in the middle of the vehicle to expose the injection site. The protruding surface of the vehicle is placed in the area to be applied just before injection. The protrusions on the surface of the Shotblocker do not pierce the skin and provide a warning for the Door Control Theory, which is thought to exist regarding pain
47951320|NCT02154074|DRUG|Isoflurane|inhale Isoflurane 1.5MAC
48280139|NCT04770103|BEHAVIORAL|Balance recovery|"Balance recovery by stepping ascertains the capability of the participant to recover when subjected to a loss of balance in the forward direction.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
48622453|NCT02965833|DEVICE|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
48622454|NCT02193152|DRUG|Pazopanib|
48622455|NCT00119639|DRUG|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
47951321|NCT02154074|DRUG|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
47951322|NCT02154074|DRUG|normal saline|the same volume of saline + Isoflurane during operation
47951323|NCT05540444|DEVICE|RadConnect|"The study will be performed in a clinical setting at the department of radiology of LUMC, meaning that we aim to test the hypothesis that (RadConnect) can reduce the number of phone calls from a select set of extension used by technologists (the Sending Extensions) to another select set of extensions manned by radiologists (Receiving Extensions)."
48280140|NCT04770103|BEHAVIORAL|Postural Sway|"Postural sway is a pseudo-static measure of postural control that evaluates a participants balance recovery ability when the perturbation does not require a dynamic step recovery.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
48280141|NCT04133636|DRUG|JNJ-68284528|Participants in Cohorts A,B,C, D, E, F, G, and H will receive JNJ-68284528 intravenously.
48454049|NCT03287154|DEVICE|Active tDCS stimulations|20 min, 2mA
48454050|NCT03287154|DEVICE|Sham tDCS|20 min, Sham
48622456|NCT04370496|PROCEDURE|Minimally invasive surgery using endoscopic stapler|Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
48622457|NCT01910441|DRUG|Vildagliptin|Vildagliptin 50 mg twice daily
48622458|NCT01910441|DRUG|Glimepiride|Glimepiride 1-6 mg once daily
48622459|NCT01910441|DRUG|Metformin|Metformin (1000-1500 mg daily)
48622460|NCT00250003|BEHAVIORAL|Preventive home visits|
47931248|NCT04883723|OTHER|Manual Pressure|The patient was placed in a prone position and the appropriate left or right ventrogluteal region was determined. Pressure was applied to the determined injection area with the thumb of the active hand for 10 seconds. Immediately after the application of pressure was terminated, the injection site was cleaned with an alcohol cotton pad with circular movements of 5 cm diameter from inside to outside, and the alcohol was allowed to dry. With a single movement at a 90 ° angle, the compression area was entered quickly and the injection was performed. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated. There are many studies in the literature that prove the effectiveness of this method.
47931249|NCT02728973|OTHER|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
47931250|NCT04520269|DRUG|Pacritinib|3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
47931251|NCT03513848|DEVICE|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
47931252|NCT03513848|DEVICE|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
47931253|NCT04415970|OTHER|Flotation therapy sensory deprivation tank|Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
47931254|NCT04415970|OTHER|Sleep Pod|Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
47931255|NCT00943943|DRUG|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
48454051|NCT05835804|DRUG|GCP intratumoral catheter|After local anaesthesia, intratumoral catheter will be place (one or several depending tumour criteria).The catheter placement could be guided by radiological imaging. Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%. GCP will be administered successively for 8hours, at 20ml/h with a total duration of 24hours. The ITC will be done every 28 days for 6 times maximum in case of good response and tolerance. Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response, complete response or stabilization. Evaluation of tumour size will be done by CT-scan, or MRI 2every 2 months and PET-FDG every 3 months.
48454052|NCT00042874|DRUG|alvocidib|Given IV
48454053|NCT00042874|DRUG|irinotecan hydrochloride|Given IV
48454054|NCT00042874|DRUG|fluorouracil|Given IV
48454055|NCT00042874|DRUG|leucovorin calcium|Given IV
48454056|NCT00042874|OTHER|laboratory biomarker analysis|Correlative studies
48454057|NCT04884308|BIOLOGICAL|BCG TICE Vaccine|Intradermal vaccination with BCG TICE
48454058|NCT04958915|DIAGNOSTIC_TEST|Knee joint 30° flexion scan|The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
48454059|NCT03717805|OTHER|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
48454060|NCT06558955|BEHAVIORAL|Technology-enabled anticipatory guidance and peer support|The intervention includes 4 online sessions led by an oral health therapist (OHT) or dentist, as well as push notifications and information delivered to participants via a mobile/web app.
48454061|NCT06558955|BEHAVIORAL|Conventional health education|Participants on this arm will receive conventional child oral health education materials at 4 time points.
48454062|NCT04580784|RADIATION|Weekly hypofractionation for early breast cancer|Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
48454063|NCT05442086|BEHAVIORAL|Music and Theta Auditory Beat Stimulation|Participants will listen to calm music with theta auditory beat stimulation for 24 minutes
48454064|NCT05442086|BEHAVIORAL|Pink Noise (control)|Participants will listen to pink noise for 24 minutes
47931256|NCT00943943|DRUG|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
47931257|NCT00943943|DRUG|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
48454065|NCT02557035|DRUG|Palonosetron|
48454066|NCT02557035|DRUG|Dexamethasone|
47931258|NCT05532670|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
47931259|NCT01401959|DRUG|Eribulin|1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles
47931260|NCT01401959|DRUG|Trastuzumab|6 mg/kg IV Day 1 every 21 days
47931261|NCT01312623|OTHER|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
47931262|NCT01030601|DRUG|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
47931263|NCT05895916|BEHAVIORAL|High-volume road cycling|1,144 km of road cycling performed on seven consecutive days with an increase in energy intake to maintain a stable body weight
47931264|NCT00017485|DRUG|HPPH|
47931265|NCT02294942|DRUG|RANCAD|Extended-Release RANCAD
47931266|NCT00859638|BEHAVIORAL|Physiotherapy|group self-management classes
47931267|NCT00859638|BEHAVIORAL|Occupational Therapy|group self-management classes
47931268|NCT00859638|BEHAVIORAL|Capacity Building|workshops and case reviews with primary health care team members
47931269|NCT04486274|OTHER|MOSE|After each pass, the stylet will be introduced into the needle, the material will be released onto a smear slide, and a macroscopic on-site quality evaluation (MOSE) of the specimen will be performed by the endoscopist.
47931270|NCT01976988|DRUG|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
47931271|NCT06210932|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum videos|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), A series of videos are developed based on the SEED curriculum, with specific themes for children in K2 and K3, each video last for approximately 10-12 minutes. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
47931272|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
47931273|NCT00169442|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
48454067|NCT06562842|OTHER|Regular exercise|Participants will perform regular exercise training for 12 weeks, followed by 4 weeks of detraining.
48454068|NCT06562842|OTHER|Control comparator|Participants will remain sedentary throughout the 16-weeks intervention period.
48454069|NCT00887419|BEHAVIORAL|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
48454070|NCT00887419|BEHAVIORAL|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
48454071|NCT02643407|DRUG|Docetaxel|60mg/m2
47931274|NCT00169442|BIOLOGICAL|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
47931275|NCT00169442|BIOLOGICAL|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
47931276|NCT00169442|BIOLOGICAL|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag \[Kft\] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
48280142|NCT04133636|DRUG|Lenalidomide|Some participants in Cohort D and all participants in Cohorts E, G, and H will also receive lenalidomide capsules orally.
47931277|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
47931278|NCT01307020|DRUG|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
47931279|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
47931280|NCT01307020|DRUG|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
47931281|NCT01307020|DRUG|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
47931282|NCT01307020|DRUG|Placebo|Placebo, oral film-coated table, once
48280143|NCT04133636|DRUG|Daratumumab|Participants in Cohorts E, G, and H will also receive daratumumab subcutaneous (SC) injection.
48280144|NCT04133636|DRUG|Bortezomib|Participants in Cohorts E and H will also receive bortezomib subcutaneously.
48280145|NCT04133636|DRUG|Dexamethasone|Participants in Cohorts E, G, and H will also receive dexamethasone orally or intravenously.
48280146|NCT01044355|DEVICE|CPAP|6 weeks treatment with fixed CPAP
48280147|NCT01044355|DEVICE|APAP|6 weeks of treatment with auto-titrating positive airway pressure
48454072|NCT02643407|DRUG|Nedaplatin|80mg/m2
48454073|NCT02643407|DRUG|Cisplatin|75mg/m2
48454074|NCT02102191|DEVICE|e-cigarette|smoking cigarette without tobacco
48454075|NCT02102191|DEVICE|cigarette|smoking cigarette with tobacco
47931283|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
47931284|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
47931285|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
48454076|NCT04917419|OTHER|Luminotherapy and /or Psychoeducation Program|TO complete
47931286|NCT01307020|DRUG|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
47931287|NCT04013399|DEVICE|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
47931288|NCT04104269|DIAGNOSTIC_TEST|Heart rupture|Free wall rupture and Ventricular septal rupture
47931289|NCT04726098|DRUG|Dexamethasone high dose|High doses: dexamethasone 20 mg/day 5 days + 10 mg/day 5 days (total 10 days)
47931290|NCT04726098|DRUG|Dexamethasone low dose|Low doses: dexamethasone 6 mg/day 10 days.
48454077|NCT02729987|BEHAVIORAL|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
48454078|NCT06559293|DIAGNOSTIC_TEST|laryngeal ultrasound|laryngeal ultrasound with linear probe will be positioned on the patient's neck. A list of anatomical sites to be visualised will be determined beforehand. Once all the pre-determined structures have been visualised, in an axial and sagittal plane, we will note the position of the ultrasound probe and its orientation. This will enable us to determine the ideal position of the ultrasound probe for obtaining all the elements of interest on a section that will be called the reference section.
48454079|NCT02043522|DRUG|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
48454080|NCT06338826|DRUG|TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI|"The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir"
48454081|NCT06338826|DRUG|Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)|dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
48454082|NCT06626997|DIETARY_SUPPLEMENT|Kombucha tea|"During Visit 1 (week 0), a fasting blood test must be performed at the IMDEA Alimentación facilities to obtain different markers: blood lipids, blood glucose, etc. Approximately 20 mL will be extracted (for comparison, keep in mind that a donation requires 450 mL). The blood sample will be extracted by qualified nursing staff from the UNILABS Laboratory. The blood tests based on the security and privacy requirements for handling samples will be carried out by the same laboratory.~You will also be asked to provide the stool sample that you must have collected at home prior to attending that visit with the material provided at the screening visit (V0) and at the intermediate visit (V2)."
48454083|NCT06563258|DEVICE|Biodex Balance Training|"Sixty Subjects of both genders aged 40-60 years old with grade 2 knee osteoarthritis years will diagnosed by orthopedists they will assigned randomly into three groups:~* Group A Will receive WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.~* Group B will receive Biobex training and traditional exercises Total time of training was 10 minutes each set is 3 minutes with 20-second rest intervals~* Group C Patients will receive only traditional exercises, 3 sessions per week for four weeks. a good general guideline is 2-3 sets of 10-15 repetitions for each exercise."
48454084|NCT06563258|DEVICE|A vibration device|WBV Training with frequency of 35 Hz, peak-to-peak amplitude of 4- to 6-mm Vertical sinusoidal vibration, and the total exposure time of 30 minutes (vibration 60 seconds, interval rest 60 seconds) in addition to traditional exercises,3 sessions per week for four weeks. , A vibration device (My7™ model Personal Plate, Power Plate, Northbrook, IL, USA) will used in all WBVT sessions.
48622461|NCT02214732|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
47931291|NCT05527938|OTHER|web-based intervention|"1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing."
47931292|NCT00130312|DRUG|Sulodexide|100 mg gelcap in the morning and evening
47931293|NCT00130312|DRUG|Placebo|1 placebo gelcap in the morning and evening
48280148|NCT01151072|DRUG|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
48280149|NCT00011115|BEHAVIORAL|Weight loss motivations|
47931294|NCT01569243|OTHER|Text messages|"* Participants will receive diabetic medical care as usual.~* Participants will be given an ActiHealth pedometer to measure daily activity.~* In addition, they will be enrolled to receive the study text messages."
47931295|NCT01569243|OTHER|Usual care|"* Participants will receive diabetic medical care as usual.~* In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
47931296|NCT05583513|DIAGNOSTIC_TEST|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
47931297|NCT05583513|DIAGNOSTIC_TEST|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
48454085|NCT06563258|OTHER|traditional exercises|"1. Stretch exercises (flexibility exercise) Rectus femoris, Iliotibial band, Hamstring and self-stretch for calf muscle (3sets, each stretch 30 sec hold, between each set 5sec rests).~2. Strengthen exercises(resistance exercise)~   1. Isometric Exercises for quadriceps (10 rep,3sets)~  2. Hip abductors strengthening 45 degree (10 rep,3sets)~  3. Hip extensor strengthening 15 degree (10 rep,3sets)~  4. Straight leg raising 45-70 degree (10 rep,3sets)~  5. Short arc knee extension (10 rep,3sets)"
47931298|NCT01471431|OTHER|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia \<100 for \>15 seconds or oxygen saturation by pulse oximetry \<85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
47931299|NCT03848871|DRUG|Enstilar|Enstilar foam applied to affected area once daily
47931300|NCT02976220|OTHER|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
47931301|NCT03894176|OTHER|Plasma PTX3 concentration|Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
47931302|NCT04998201|DRUG|ARO-APOC3|ARO-APOC3 Injection
47931303|NCT04998201|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
47931304|NCT02100709|DEVICE|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
47931305|NCT05113303|DEVICE|Navigated Revision Total Knee Arthroplasty|Patients in the case group receive a Columbus® Revision knee prosthesis, implanted with computer assisted surgery
47931306|NCT05113303|DEVICE|Manual Revision Total Knee Arthroplasty|Patients in the control group will correspond to a historical cohort of patients in which manual jig-assisted knee revision was done.
47931307|NCT00829933|DRUG|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
48454086|NCT06185088|DEVICE|Coda® Balloon Catheters|A balloon device that will be introduced into participants' intestine over a guide wire to test the radial stretch of the small bowel.
48454087|NCT06185088|DEVICE|Double Balloon Endoscope (DBE)|A balloon device that will be introduced retrograde through the ileostomy and the inter-balloon distance will be increased causing stretch on the intestine to test longitudinal stretch. The DBE will only be used if a participant tolerated the Coda® Balloon Catheter intervention.
48454088|NCT02611687|DRUG|pitolisant|Tablet
48454089|NCT02611687|DRUG|Placebo|Tablet
48454090|NCT04008563|PROCEDURE|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
48454091|NCT04957979|OTHER|Nursing/Medical Model of Care Coordination|"No social worker on the clinic's care coordination team.~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Referrals for continuing care~* Referral to community resources~* Referral to mental health services if needed or requested~* Referral to interventional counseling for behavioral health issues"
48454092|NCT04957979|OTHER|Medical/Social Model of Care Coordination|"Social worker is part of the clinic's care coordination team.~* Need not be licensed as a social worker~* Must have time dedicated to care coordination for a specific clinic or clinics~* Must interact with individual patients to provide them with services~* Must interact with individual clinicians about their individual patients in care coordination~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Assistance with referrals for continuing care~* Assessment and plan to address social and resource needs including housing, transportation or financial needs; Assist patient in locating and obtaining needed community resources~* Assistance with identifying and addressing psychological/emotional issues and referrals as needed~* Interventional counseling for behavioral health issues or referrals to interventional counseling, depending on licensure"
48454093|NCT05920447|DEVICE|LMA|Monitor the ventilatory parameter and incidence of complications
48454094|NCT02275143|RADIATION|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
47931308|NCT00829933|DRUG|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
47931309|NCT03619811|DIAGNOSTIC_TEST|Reflux Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
47931310|NCT05832554|DEVICE|nasal airway|nasopharyngeal airway
47931311|NCT05832554|DEVICE|oral airway|oropharyngeal airway
47931312|NCT01671943|DEVICE|Ice-Sense3TM|Ice-Sense Cryoprobe
47931313|NCT01832168|PROCEDURE|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
47931314|NCT01832168|OTHER|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
47931315|NCT01832168|OTHER|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
47931316|NCT04492215|BEHAVIORAL|Interaction between patient and trained general practitioners in motivational interviewing|Impact of the medical interview on the patient
47931317|NCT02208401|PROCEDURE|conventional cold snare polypectomy|conventional cold snare polypectomy
47931318|NCT02208401|PROCEDURE|Cold snare polypectomy with suction|Cold snare polypectomy with suction
47931319|NCT06129357|BEHAVIORAL|180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).|Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
47931320|NCT00146159|DRUG|Mitoxantrone|dosage
47931321|NCT03989739|DEVICE|Da Vinci|
47931322|NCT03780023|OTHER|Questionnaire|All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.
47931323|NCT05009433|BEHAVIORAL|High intensity interval training program for pregnant women|"Pregnant women will participate in 8-week HIIT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression and stage of pregnancy. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month HIIT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
47931324|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for pregnant women|"Pregnant women will participate in 8-week MICT cycles until the day of delivery, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate intensity continuous exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises, relaxation and visualization of pregnancy or childbirth (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~After birth, women will participate in 3-month MICT cycles from the moment of achieving postpartum readiness to training until one year postpartum. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
47931325|NCT05009433|BEHAVIORAL|Standard obstetric care with extended education on healthy lifestyle|Pregnant women will get standard obstetric care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity in the perinatal period and selected aspects of pregnancy and motherhood. Educational classes will be conducted online in real time, at least once every two weeks, until one year postpartum.
47931326|NCT05009433|BEHAVIORAL|High intensity interval training program for nonpregnant women|"Nonpregnant women will participate in 8-week HIIT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (15-20 min) will be conducted in a form of high intensity intervals, approx. 85-90% of maximum exercise capacity. The intervals will consist of performing exercises for 30-60 seconds, alternating with a 30-60 second rest break, in the ratio of exercise time to rest 1:2, 1:1 or 2:1, according to the individual possibilities of the participant and taking into account the training progression. The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month HIIT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
48280150|NCT03333577|DEVICE|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
48454095|NCT05964140|DRUG|Different post-operative antibiotic regimens following surgical treatment of mandible fractures|"The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach.~All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery.~The participants will be randomised to the following (1:1:1):~Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control)."
48454096|NCT00592579|DRUG|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
48454097|NCT03018925|DRUG|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
48454098|NCT01398085|RADIATION|I131 1.1 GBq|Radio-iodine
48454099|NCT04332445|OTHER|Hyaluronic Acid Gel|Health care product - to be apllied on the subject's skin
48454100|NCT04185363|DRUG|Maralixibat|All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily
48454101|NCT02241577|PROCEDURE|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
48622462|NCT06520280|OTHER|polyamide and 3D printed complete denture|pts. receive 2 sets of complete dentures made from polyamide and 3d printed to use
48622463|NCT01482221|DRUG|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
48622464|NCT01482221|DRUG|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
48622465|NCT01482221|DRUG|Placebo|0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
48622466|NCT02894138|DRUG|alteplase|
48622467|NCT02894138|DRUG|Placebo|
48454102|NCT02241577|PROCEDURE|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
48454103|NCT00834132|DRUG|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
48280151|NCT02812004|DEVICE|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
48454104|NCT00834132|DRUG|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
48454105|NCT03605342|DRUG|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
48454106|NCT03605342|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
48454107|NCT03605342|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
48454108|NCT00636129|BEHAVIORAL|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
48454109|NCT03516539|DEVICE|Group ML|Mcgrath videolaryngoscope
48454110|NCT03516539|DEVICE|Group DL|Macintosh laryngoscope
48454111|NCT00620958|BEHAVIORAL|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
48454112|NCT00620958|BEHAVIORAL|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
48454113|NCT00620958|BEHAVIORAL|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
48454114|NCT05144451|DIAGNOSTIC_TEST|Transcranial Doppler|"Transcranial Doppler-derived parameters; pulsatility index (PI), resistance index (RI), mean flow velocity (Vmean) will be recorded before induction of anesthesia (T1).~After induction, TCD parameters, Hemodynamic variables including heart rate (HR), invasive mean arterial blood pressure (MAP), and central venous pressure (CVP) together with Arterial blood gases (ABG analysis with values of PH, PCO2, PO2, blood oxygen saturation SO2 and bicarbonate HCO3), end-tidal carbon dioxide (ETCO2) and body temperature will be recorded too. Just before skin incision (T2), at the end of anhepatic phase 5 minutes before reperfusion (T3), 5 minutes after reperfusion (T4) and at the end of surgery (T5).~Postoperatively at ICU, TCD parameters, Hemodynamic variables, and ABG will be obtained 24 hours postoperative (T6) and at discharge from ICU (T7)."
48454115|NCT06115317|OTHER|Prism|Prism
48280152|NCT04975958|DRUG|AN2025|oral administration
48454116|NCT06115317|OTHER|Sham|Sham
48454117|NCT03276559|BEHAVIORAL|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
48454118|NCT03276559|OTHER|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
48454119|NCT05351567|OTHER|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY|EDUCATIONAL PROGRAM CREATED ACCORDING TO TRANSFORMATIONAL LEARNING THEORY FOR INFERTILITY FEMALES
48454120|NCT04775004|OTHER|Bone marrow venting procedure (BMVP)|The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.
48454121|NCT04775004|OTHER|Platelet Rich Plasma (PRP)|The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
48454122|NCT02319655|PROCEDURE|Air tamponade|Air tamponade
48454123|NCT02319655|PROCEDURE|Balanced salt solution filling|BSS filling
48454124|NCT06560502|OTHER|Standard of Care-DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
48280153|NCT04975958|DRUG|AN0025|oral administration
48280154|NCT04975958|DRUG|Atezolizumab 1200 mg in 20 ML Injection|infusion
48454125|NCT06560502|OTHER|AmnioCore - DFU|Participants will receive weekly applications of AmnioCore and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
48280155|NCT00303550|DRUG|Intravenous iclaprim|
48454126|NCT06560502|OTHER|Amnio Quad-Core - DFU|Participants will receive weekly applications of Amnio Quad-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
48454127|NCT06560502|OTHER|Standard of Care-VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
48454128|NCT06560502|OTHER|Amnio Tri-Core - VLU|Participants will receive weekly applications of Amnio Tri-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
48454129|NCT06560502|OTHER|AmnioCore Pro|Participants will receive weekly applications of AmnioCore Pro and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
48454130|NCT06560502|OTHER|Amniocore Pro +|Participants will receive weekly applications of Amniocore Pro + and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
48454131|NCT04256486|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
48454132|NCT03240991|OTHER|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
48454133|NCT05869721|OTHER|Yoga|The yoga forms are designed from the modified traditional Hatha yoga style consisting of pranayama, asana, meditation with additional relaxation elements. The selected postures will engage core and upper limb muscle and which proposed to strengthen the whole body, increase flexibility of shoulder and limbs, particularly, improve upper limb mobility and functions; also, the progression of the yoga therapy is targeted to reach the variations of postures. The combined relaxation elements reinforced to achieve restoration of the body so as to improve sleep.
48454134|NCT03432663|DRUG|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
48454135|NCT03432663|DRUG|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
48454136|NCT01305109|BIOLOGICAL|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10\^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
48454137|NCT01305109|BIOLOGICAL|Placebo|3 doses of 0.5 mL at 4 week intervals
48454138|NCT01709903|DRUG|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
48454139|NCT01709903|DRUG|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
48454140|NCT01709903|DRUG|Placebo to QVA149|Placebo to QVA149 with SDDPI
48454141|NCT01709903|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
48454142|NCT05107635|DEVICE|AtriCure Commercially Available Devices|Epicardial and endocardial hybrid ablation procedure used to treat the IST or POTS using AtriCure commercially available devices.
48454143|NCT02086474|DRUG|Hyaluronan|Intra-articular injection
48454144|NCT02086474|DRUG|Bupivacaine|Extra-capsular injection
48454145|NCT01844843|DEVICE|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
48454146|NCT04721834|DEVICE|Low-intensity Extracorporeal Shockwave Therapy|Low intensity shockwave energy would be delivered to stimulate angiogenesis in corporal tissue. Therapy would be delivered through a linear probe in 6 sessions. It would be conducted as a day procedure.
48454147|NCT04721834|DEVICE|Sham Therapy|Same device as the active treatment arm would be used, with the addition of sham probe which block all shockwaves.
48454148|NCT01830335|DRUG|Indomethacin|
48454149|NCT01830335|DRUG|Placebo|
48454150|NCT03669250|DRUG|CVN058|CVN058 will be given at two doses, a low does and a high dose
48454151|NCT03669250|OTHER|Placebo comparator|inactive placebo
48454152|NCT05278221|DEVICE|Software EstimLT|Healthy volunteers will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo and then the software will be tested
48454153|NCT00429221|BEHAVIORAL|Tailored Medication Messages for Parents|
48454154|NCT02466451|OTHER|Questionnaires|"For not collaborative patients, under the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~* Spirometry~* 6-minutes walk test (WT 6')~* Prick tests~* Children Quality of life questionnaire (KINDL questionnaire)~* Psychological test (Raven Matrices)~* Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
48454155|NCT04137835|DEVICE|Showmotion|Each healthy volunteers will wear sensors at the interested joint and do the measurement.
48454156|NCT05724394|OTHER|Culturally Adapted Getting Better Bite By Bite (Ca-GBBB) intervention|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months.
48280156|NCT00303550|DRUG|Intravenous linezolid|
48454157|NCT00070291|DRUG|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
48454158|NCT04699396|PROCEDURE|Mobilisation With Movement 1|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the talus were performed, followed by 3 sets of 10 repetitions of a glide applied to the fibula."
48280157|NCT05754957|DRUG|Milvexian|Milvexian will be administered orally.
47931327|NCT05009433|BEHAVIORAL|Moderate intensity continuous training program for nonpregnant women|"Nonpregnant women will participate in 8-week MICT cycles for a period of 8 months, 3 times a week, in a volume of each session of 60 minutes. The main part (20-25 min) will be conducted in a form of moderate continuous intensity exercise, of 70-80% of the maximum exercise capacity, e.g. in the form of high- and low-impact aerobics choreography with music. The sessions will also include resistance, neuromotor, body posture and flexibility exercises (25 min), breathing exercises and relaxation (10 min). The exercise intensity will be monitored with the use of heart rate monitors, the Borg Rating of Perceived Exertion (RPE) and the Talk Test.~For the next 12 months of the project, women will participate in 3-month MICT cycles. Classes will be carried out stationary or online, depending on the pandemic situation and the availability of the woman."
48454159|NCT04699396|PROCEDURE|Mobilisation With Movement 2|"Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the fibula were performed, followed by 3 sets of 10 repetitions of a glide applied to the talus."
48454160|NCT04699396|OTHER|Placebo|The Placebo group participants performed the same number of sets and repetitions (6 sets of 20 repetitions) of lean/lunge forward into dorsiflexion, without any glide application.
48454161|NCT02013882|PROCEDURE|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
48454162|NCT04778501|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
48454163|NCT00452920|DRUG|docetaxel|
48454164|NCT00452920|RADIATION|cesium Cs 137|
48454165|NCT00452920|RADIATION|radiation therapy|
48280158|NCT05754957|OTHER|Placebo|Placebo will be administered orally.
48454166|NCT02667951|OTHER|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
48454167|NCT04754984|BEHAVIORAL|Pelvic floor workshop|Physiotherapist-led workshop on managing pelvic floor symptoms
48454168|NCT05561088|OTHER|Scalp Acupuncture|mplementation plan of head needle: The middle frontal line (MS1), the middle parietal line (MS5) and the back parietal and temporal oblique line (MS7) in the International Standardization Program for the Name of the first needle Point in 1989 were selected, and the needles were inserted along the shape of each section. One needle was inserted into the middle frontal line and the middle parietal line, and two needles were inserted into the back parietal and temporal oblique line. The KWD-808I pulse electrotherapy instrument produced by Changzhou Wujin Great Wall Medical Equipment Co., Ltd. is used on the needle handle after lifting, inserting and twisting. The continuous waveform was used, the voltage was 2-4 V, the frequency was 60-80 times /min, the intensity was tolerated by the patient, the needle was kept for 30min, and the treatment was performed once a day.
48454169|NCT05561088|OTHER|The treatment recommended in the guidelines for acute ischemic stroke was administered|The treatment recommended in the guidelines for acute ischemic stroke was administered
48454170|NCT03797248|COMBINATION_PRODUCT|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
48454171|NCT05874843|DIAGNOSTIC_TEST|Thromboelastography (TEG 6S)|The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
48454172|NCT03911037|DRUG|G-CSF|G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
48454173|NCT03911037|DRUG|Placebo|Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
48454174|NCT04953520|PROCEDURE|ultrasound-CT fusion imaging|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging
48454175|NCT04953520|PROCEDURE|pure ultrasound guidance|The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
48454176|NCT02042547|OTHER|Tissue samples from the right atrium|
48454177|NCT02042547|OTHER|Blood samples|
48454178|NCT00063687|DRUG|Oxypurinol|
48454179|NCT00371839|PROCEDURE|Audiological Evaluation|Tests of hearing, cognition, and speech perception
48280159|NCT02290210|DRUG|URC102 0.25mg|
48280160|NCT02290210|DRUG|URC102 0.5mg|
48454180|NCT02622867|OTHER|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
48454181|NCT02622867|DIETARY_SUPPLEMENT|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
48454182|NCT04976179|DRUG|Ferric carboxymaltose|Ferric carboxymaltose to be given as an intravenous infusion
48454183|NCT04976179|DRUG|Ferrous sulfate|Ferrous sulphate tablet to be taken orally
48454184|NCT04173858|DRUG|Naloxegol|25 mg oral naloxegol once daily.
48622468|NCT01461837|DRUG|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
48622469|NCT05726136|DRUG|acetated Ringers|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
48280161|NCT02290210|DRUG|URC102 1.0mg|
48280162|NCT02290210|DRUG|URC102 2.0mg|
47931328|NCT05009433|BEHAVIORAL|Standard health care with extended education on healthy lifestyle|Nonpregnant women will get standard health care according to the national law. They will attend educational sessions on a healthy lifestyle, physical activity and selected aspects of preparation to pregnancy and motherhood. Classes will be conducted online in real time, at least once every two weeks, for a period of 20 months.
47931329|NCT06146998|OTHER|3D health education model|explanation combined with 3D health education model
47931330|NCT06146998|OTHER|Verbal explanation|Regular explanation
48454185|NCT03372876|DIETARY_SUPPLEMENT|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
48454186|NCT03849547|OTHER|App Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program."
48454187|NCT03849547|OTHER|Home Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics."
48454188|NCT05592574|OTHER|Blood sample|Blood samples required to performe IL-17 Dosage
48454189|NCT02916862|DIETARY_SUPPLEMENT|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
48454190|NCT02916862|COMBINATION_PRODUCT|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
48454191|NCT02916862|DIETARY_SUPPLEMENT|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
47931331|NCT04970953|PROCEDURE|Right heart catheterization|Right heart catheterization will be performed via a brachial access under sonographic guidance and hemodynamic measurements will be performed in a semi-supine position.
47931332|NCT00977301|DRUG|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
47931333|NCT00977301|DRUG|olanzapine|15 mg olanzapine single dose
47931334|NCT00977301|DRUG|olanzapine|10 mg olanzapine single dose
47931335|NCT03729362|BIOLOGICAL|Cipaglucosidase Alfa|Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
47931336|NCT03729362|DRUG|Miglustat|Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
47931337|NCT03729362|BIOLOGICAL|Alglucosidase Alfa|Participants received an IV infusion dose over a 4-hour duration Q2W.
47931338|NCT03729362|DRUG|Placebo|Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
47931339|NCT01155882|PROCEDURE|Whipple at the Splenic Artery (WATSA)|
47931340|NCT02706223|OTHER|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
48454192|NCT02916862|COMBINATION_PRODUCT|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
47931341|NCT02706223|OTHER|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
47931342|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
47931343|NCT04517357|DRUG|Fluzoparib|Fluzoparib monotherapy
47931344|NCT04517357|DRUG|Fluzoparib+Apatinib|Fluzoparib-Apatinib combination
48454193|NCT03856580|BEHAVIORAL|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
48454194|NCT03856580|BEHAVIORAL|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
48454195|NCT04418349|PROCEDURE|"posterior component separation modified TAR technique Transversus Abdominids Release"|"Evaluation of posterior component separation modified TAR technique Transversus Abdominids Release in the treatment of parastomal hernia"
48454196|NCT06015984|BEHAVIORAL|Traning|In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
48622470|NCT05726136|DRUG|albumin 5%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
47931345|NCT01761071|DRUG|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
48098536|NCT06068166|COMBINATION_PRODUCT|TEA plus GDMT|Thoracic epidural anesthesia (TEA), the infusion of anesthetic agents (eg, lidocaine or ropivacaine) into the epidural space, is used to achieve sympathetic block at the T1 to T4 levels in thoracic and abdominal surgical procedures. Since 1995, Professor Liu Fengqi has pioneered the use of TEA to treat end-stage HFrEF and achieved surprising results. TEA could reduce the enlarged heart cavity, halt and reverse cardiac remodeling, and improve cardiac systolic and diastolic function. Currently, thousands of HFrEF patients have received TEA procedure. All the patients received maximally tolerated guideline-directed medical therapy (GDMT).
48622471|NCT05726136|DRUG|albumin 20%|After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
47931346|NCT01761071|DRUG|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
48280163|NCT02290210|DRUG|placebo|
48280164|NCT03804151|BEHAVIORAL|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
48454197|NCT06559930|OTHER|Traditional Neurological Rehabilitation + Dual Task Focused Training|Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration. Dual-task exercises, an important aspect of post-stroke rehabilitation, target both motor and cognitive functions. Dual tasks are activities that require performing two different tasks at the same time. These types of exercises are used to increase patients' attention, improve coordination, and help them perform daily living activities more effectively.
48454198|NCT06559930|OTHER|Traditional Neurological Rehabilitation|Rehabilitation programs that start early after stroke and continue at regular intervals throughout life support the individual in regaining his quality of life and performing his daily functions. These programs can help patients increase their functional independence, improve their quality of life, and ensure their social integration. Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration.
48454199|NCT01802112|DIETARY_SUPPLEMENT|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
48454200|NCT01802112|OTHER|placebo|15gr placebo
48454201|NCT00673842|DEVICE|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)
47931347|NCT01444807|DRUG|sorafenib|sorafenib 400 mg bid
47931348|NCT00294710|DRUG|Aliskiren|
48454202|NCT00673842|OTHER|Usual care|Usual post-MI care
48454203|NCT02856308|DEVICE|Hairstetics hair implant device|
48454204|NCT04178122|GENETIC|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
48454205|NCT06443385|BEHAVIORAL|PDMP Legal Mandate E-mail|E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.
48454206|NCT06443385|BEHAVIORAL|PDMP Clinical Benefit E-mail|E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.
48454207|NCT01597791|DEVICE|Foley catheter|Foley catheter placement after CSE.
48454208|NCT01597791|OTHER|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
48454209|NCT00550329|DRUG|Glipizide GITS|
48454210|NCT05608642|OTHER|Intravenous hydration|500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.
48454211|NCT05608642|OTHER|Intravenous prednisolone|The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.
47931349|NCT05488821|DRUG|QLH11906|QLH11906 only
47931350|NCT06257043|PROCEDURE|Transcatheter aortic valve replacement|A total of 3000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled at 30-50 centers. The devices used will be all post-market transcatheter aortic valves approved for use in China. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
47931351|NCT00004190|DRUG|gemcitabine hydrochloride|
48280165|NCT02367846|DRUG|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
48454212|NCT05608642|OTHER|Intravenous lidocaine|The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
48454213|NCT05245500|DRUG|MRTX1719|"MRTX1719 is a potent PRMT5-MTA inhibitor~Specified dose on specified days"
48454214|NCT02332967|OTHER|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
48454215|NCT02332967|OTHER|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
48454216|NCT02332967|OTHER|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
47931352|NCT00004190|DRUG|oxaliplatin|
48098537|NCT06068166|DRUG|GDMT|All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
48454217|NCT06557954|DIAGNOSTIC_TEST|human PAX1 and JAM3 gene methylation assays (PAX1m/JAM3m)|PAX1m/JAM3m, with or without HPV testing and cytological pathology for cervical cancer screening
48454218|NCT05865652|DIAGNOSTIC_TEST|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy|Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
48454219|NCT00319696|DRUG|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
48454220|NCT00319696|DRUG|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
48622472|NCT04652648|DRUG|Hydroxychloroquine|Randomization was 2:1 to HCQ 200 mg BID or 41 observation for 10 days
48454221|NCT02222064|BEHAVIORAL|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
48454222|NCT03034356|DRUG|Levetiracetam|Anticonvulsant drug
47931353|NCT06008912|OTHER|Calisthenic Exercises|Exercises for upper extremity, lower extremity and trunk which applying just patient's own body weight via using body mechanics. There is no need for any tools for exercises.
47931354|NCT06008912|OTHER|Aerobic Exercises|Exercises which loading cardiovascular, respiratory and muscular system at the same time. Treadmill training will apply in the study.
47931355|NCT01787344|DRUG|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
47931356|NCT01787344|DRUG|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
47931357|NCT02747433|DEVICE|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
47931358|NCT02747433|DEVICE|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home \& community.
47931359|NCT01552733|DEVICE|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
47931360|NCT01552733|OTHER|Standard of care|Rehabilitation Therapy
47931361|NCT05843227|OTHER|questionnaire on the organizational management|Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.
47931362|NCT02034344|PROCEDURE|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
47931363|NCT02034344|PROCEDURE|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
48454223|NCT03034356|DRUG|Placebo|Placebo
48454224|NCT05208892|PROCEDURE|SZMN block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally
48454225|NCT05208892|PROCEDURE|SZMN block with Dexmedetomidine|Suprazygomatic Maxillary Nerve (SZMN) Blocks with local anesthetic and Dexmedetomidine bilaterally
48454226|NCT05238857|OTHER|Assessment|There will be no intervention. Only assessments will be taken from the patients and data will be analyzed.
48454227|NCT02559843|DIETARY_SUPPLEMENT|pomegranate juice|
48454228|NCT02559843|BEHAVIORAL|lifestyle modification|
48454229|NCT04007796|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
47931364|NCT02034344|PROCEDURE|Urine collection|Urine will be collected from all participants.
47931365|NCT00174772|DRUG|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
47931366|NCT00174772|DRUG|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
47931367|NCT04597242|DRUG|Exebacase|Patients will receive a single IV infusion of exebacase in addition to antistaphylococcal antibiotics prescribed by the treating physician. Patients with normal renal function or mild renal impairment will be administered a dose of 18 mg of exebacase; patients with moderate or severe renal impairment will be administered a dose of 12 mg; patients with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg.
48454230|NCT04007796|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
48454231|NCT00023881|DRUG|bortezomib|
48454232|NCT02750878|OTHER|Informational Handout|
48454233|NCT00031434|DRUG|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
48454234|NCT00031434|DRUG|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
48454235|NCT06259630|DRUG|Nicotine|Participant receives oral dose of nicotine
48454236|NCT06259630|DRUG|Placebo oral capsule|Participant receives oral dose of placebo
48454237|NCT00755677|OTHER|Pulses|subjects consume 1 pulse food daily for eight weeks
48454238|NCT05664243|BIOLOGICAL|Autologous genetically modified gamma-delta T cells|Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance
47931368|NCT02290431|DRUG|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
47931369|NCT02290431|DRUG|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).
47931370|NCT02290431|DRUG|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)
47931371|NCT04935671|DIETARY_SUPPLEMENT|chamomile tea n saffron|20 mg of chamomile and 1 mg saffron in a teabag given twice daily for a month in combination with allopathic treatment for depression.
47931372|NCT05224011|DEVICE|Boppli Infant Blood Pressure Monitor|The intervention is a medical device for the non-invasive measurement of blood pressure in infants
47931373|NCT04322539|DRUG|Fruquintinib|Oral VEGFR inhibitor
47931374|NCT04322539|DRUG|Placebo|Placebo capsule
47931375|NCT06036446|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
48622473|NCT00303953|DRUG|belinostat|Given IV
47931376|NCT06036446|DRUG|Vaginal Suppository Progesterone|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
48454239|NCT05664243|BIOLOGICAL|Allogeneic genetically modified gamma-delta T cells|"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"
48454240|NCT01539239|DEVICE|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
48454241|NCT01539239|PROCEDURE|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
48454242|NCT00443391|DRUG|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
47931377|NCT00188708|PROCEDURE|hypoxia measurement|transrectal oxygen measurement
47931378|NCT01653132|DRUG|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
47931379|NCT01653132|DRUG|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
47931380|NCT02522871|DEVICE|OCS™ Liver System|
47931381|NCT02522871|OTHER|Control|
48454243|NCT01341951|DRUG|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
48454244|NCT03475251|BIOLOGICAL|CS1003|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
48454245|NCT03475251|BIOLOGICAL|CS1003|CS1003 to be intravenously administered at the dose level determined during the dose escalation part
48454246|NCT03475251|DRUG|Regorafenib|Regorafenib to be orally administered at the protocol-specified dose level, once daily for the first 21 days of each 28-day cycle
47931382|NCT00983697|PROCEDURE|therapeutic conventional surgery|
47931383|NCT00983697|RADIATION|fludeoxyglucose F 18|
47931384|NCT04474548|OTHER|Ultrasound use|Ultrasound will be used to determine location of IUD after insertion.
47931385|NCT03947411|DRUG|Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
47931386|NCT03947411|DRUG|Xiyanping injection+Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
47931387|NCT02700503|BEHAVIORAL|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
47931388|NCT03255330|DRUG|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
47931389|NCT03255330|DRUG|Metamizol|Standardized treatment
47931390|NCT03255330|DRUG|Tramadol|Standardized treatment
47931391|NCT02394197|DRUG|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
47931392|NCT02394197|DRUG|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
47931393|NCT00208546|DRUG|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
48454247|NCT05387109|DRUG|penpulimab combined with anlotinib|penpulimab: fixed dose of 200 mg, administered on the first day of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14, orally once a day, about half an hour before breakfast (the daily dose should be as much as possible), taken with warm water, and repeated every 3 weeks
48454248|NCT00113958|DRUG|Cinacalcet|
48622474|NCT04057235|DEVICE|FlareHawk Interbody Fusion System|Expandable lumbar intervertebral body fusion device
48622475|NCT05731596|DRUG|Rosuvastatin 20 Mg Oral Tablet|Rosuvastatin 20 mg will be administered orally once daily for 3 Months
48622476|NCT05731596|DRUG|Coenzyme Q10 100 MG Oral Capsule|Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
48622477|NCT04601376|BEHAVIORAL|Mobile Monitoring Tool|a text-messaged based outcomes collection system
48622478|NCT04229901|DRUG|HepaStem|HepaStem will be administered as an intravenous (IV) infusion
48622479|NCT04229901|DRUG|Placebo|Placebo will be administered as an intravenous (IV) infusion
48622480|NCT00001270|DRUG|interleukin-1|
48622481|NCT02733328|PROCEDURE|CPB Surgery|
47931394|NCT00208546|DRUG|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
47931395|NCT02739737|OTHER|Blinded manuscript|Blinded version of sham manuscript
48454249|NCT05444647|PROCEDURE|stool and blood collection|Patients will collect fecal and blood samples prior to treatment and at the time of response evaluation, and completion of therapy using a standard stool-collection-kit. At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
48454250|NCT00585286|DEVICE|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
48454251|NCT05282901|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution|Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.
48454252|NCT05315713|DRUG|Mosunetuzumab SC|Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
48454253|NCT05315713|DRUG|Tiragolumab|Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
48454254|NCT05315713|DRUG|Atezolizumab|Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
48454255|NCT05315713|OTHER|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
48454256|NCT02922569|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
48454257|NCT02922569|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
47931396|NCT02739737|OTHER|Unblinded manuscript|Unblinded version of sham manuscript
47931397|NCT01063933|DRUG|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
47931398|NCT04840836|BEHAVIORAL|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
47931399|NCT06425627|PROCEDURE|spinal anesthesia|An intrathecal anesthetic technique.
47931400|NCT06425627|PROCEDURE|general anesthesia|An intravenous (combined with inhalation) anesthetic technique.
47931401|NCT01326325|DRUG|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
47931402|NCT01326325|DRUG|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
47931403|NCT05614167|OTHER|correlation|A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
48280166|NCT02367846|DRUG|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
48454258|NCT02922569|OTHER|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
48454259|NCT02922569|OTHER|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
48454260|NCT06556602|OTHER|MPACT|Four components are part of this intervention: 1) accredited training about patient centered, trauma-informed care and the standard of care under the current federal regulation (42CFRpart8), 2) education about trauma and trauma symptoms including vicarious (work related) trauma and navigation to symptoms screening and resources including treatment, 3) reflective supervision for counseling, case management and peer staff, and 4) clinic self assessment for trauma-informed and patient centered care
48454261|NCT02153203|BEHAVIORAL|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
48454262|NCT02153203|OTHER|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
48454263|NCT05219864|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
48454264|NCT05219864|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
48280167|NCT02086227|DRUG|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
48454265|NCT05892081|BIOLOGICAL|Colloidal oatmeal|The colloid oatmeal had the following component: Colloidal Oat (5gm), stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
48454266|NCT05892081|BIOLOGICAL|Cold cream|It is composed of stearic acid 5, cretoctryl alcohol 2.5, cetyl alcohol 2.5, koh 02, potassium sorbate 1gm, paraffin oil 5ml, and soft paraffin 10gm
48454267|NCT03811977|DIETARY_SUPPLEMENT|Lutein syrup|12- week dietary supplementation with lutein syrup (20 mg lutein/day)
48454268|NCT03811977|DIETARY_SUPPLEMENT|Placebo syrup|12- week dietary supplementation with placebo syrup (0 mg lutein/day)
48454269|NCT05881798|DEVICE|Celect Platinum Vena Cava Filter|Inferior vena cava filter
48454270|NCT06396858|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
48454271|NCT06396858|DRUG|Colchicine 0.5 MG|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
47931404|NCT06021860|DRUG|Spironolactone Oral Suspension|"Spironolactone will be dosed on a mg/kg basis, with actual weight on Day 1 (pre-dose) determining the spironolactone suspension volume administered. Therefore, for a given patient, the dose administered on Day 1, based on the weight measured on Day 1, will be administered throughout their participation in the study.~Spironolactone will be administered as a single dose in the single-dose periods (Group 4, Parts 1 and 2), and as QD dosing in the multiple-dose periods (Groups 1 to 4, Parts 1 and 2).~The low and high doses to be administered during Part 2 of the study will be determined by the Safety Review Committee following their review of Part 1 data."
47931405|NCT00167856|DRUG|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
48454272|NCT06396858|DRUG|Placebo Rivaroxaban|Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
48280168|NCT02086227|DRUG|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
48280169|NCT04247048|OTHER|infusion of tracer [5,5,5-2H3] -L-leucine|A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
48454273|NCT06396858|DRUG|Placebo Colchicine|Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
48454274|NCT05464836|DRUG|CB-103|Given by PO
48454275|NCT05464836|DRUG|Venetoclax|Given by PO
48454276|NCT00154739|DRUG|Gemcitabine|
48454277|NCT00154739|DRUG|Cisplatin|
48454278|NCT00154739|DRUG|Epirubicin|
48454279|NCT01215760|OTHER|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
48454280|NCT01215760|OTHER|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
48454281|NCT06433258|BEHAVIORAL|Enhanced TSSC curriculum|In addition to the original TSSC curriculum participants will also be educated with the enhanced curriculum which includes components related to alcohol and social determinants of health needs) to promote cancer prevention through healthy lifestyles.
48454282|NCT06433258|BEHAVIORAL|Original TSSC curriculum|Participants will be educated with evidence-based modules focused on topics such as introduction to TSSC, physical activity, fruit and vegetable consumption, reduce sugar intake, diabetes, portion control, cancer, and high blood pressure.These modules are provided by community health workers who have been trained in the contents of the modules, as well as motivational interviewing techniques for delivering the modules.
48454283|NCT06626607|DRUG|CCB use|Postoperative antihypertensive medication includes CCB
48454284|NCT06626607|DRUG|non-CCB use|Postoperative antihypertensive medication does not include CCB
47931406|NCT00335270|DRUG|fos-amprenavir calcium, ritonavir|
47931407|NCT00335270|DRUG|abacavir/lamivudine as Epzicom|
47931408|NCT05421650|RADIATION|CCRT|"1. Radiation: Extended field-external beam radiation therapy (EF-EBRT) + brachytherapy + lymph node boost.~2. Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~3. Radiation and chemotherapy are administered concurrently."
47931409|NCT05421650|PROCEDURE|Surgical debulking of bulky or multiple lymph nodes|"1. Open/minimally invasive method.~2. Surgical debulking of bulky or multiple lymph nodes.~3. Postoperative imaging evaluation to determine whether the lymph node has been successfully removed."
48280170|NCT05035498|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
48280171|NCT05035498|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
48280172|NCT02909868|DEVICE|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
48280173|NCT02580058|BIOLOGICAL|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
48454285|NCT04190160|DRUG|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
48454286|NCT04876001|BEHAVIORAL|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
48454287|NCT05236348|DEVICE|Aktiia.product-us|The study will collect data from subjects by means of the device under test and collect data from subjects by means of double-auscultation, pulse oximetry and volume-clamp BP reading while subjects wear the devices at different body positions and induce BP changes, during eight visits that will be held over the span of seven days, and generate performance reports.
48454288|NCT02463786|OTHER|No intervention|No intervention
48454289|NCT03078608|BEHAVIORAL|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
48454290|NCT03078608|BEHAVIORAL|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
48454291|NCT05937451|OTHER|PRIME solution|The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.
48454292|NCT06563505|DRUG|Mosunetuzumab|Given by IV
48454293|NCT06563505|DRUG|Zanubrutinib|Given by IV
48454294|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
48454295|NCT00636545|DRUG|Oblimersen (Genasense)|Intravenous
48454296|NCT06627660|PROCEDURE|Valsalva maneuver|Closure of the nose and mouth during expiration for 20 sec
48454297|NCT03862573|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
48454298|NCT01022879|PROCEDURE|vitrectomy|
48098538|NCT05512260|DEVICE|Individual decision aid (iDA)|A web-based iDA (accessible online with various content), will be developed towards individuals approached to cancer screening, although public and accessible to all who are interested in cancer and screening. DAs in screening usually include information on the disease, screening, screening tests, benefits and harms and some value clarification exercise (e.g., interactive questions) aiming at shedding light on the individual´s values and preferences, knowledge and lifestyle.
48454299|NCT04292548|DIAGNOSTIC_TEST|taking saliva samples to determine TAS, TOS and LL-37|
48454300|NCT02933658|DRUG|Telmisartan|
48454301|NCT02933658|DRUG|Amlodipine|
48454302|NCT02933658|DRUG|Rosuvastatin|
48454303|NCT00952939|GENETIC|fluorescence in situ hybridization|At time of surgery
48454304|NCT00952939|OTHER|laboratory biomarker analysis|At time of surgery
48454305|NCT00952939|PROCEDURE|fine-needle aspiration|At time of surgery
48454306|NCT00952939|PROCEDURE|therapeutic conventional surgery|At time of surgery
48454307|NCT00952939|OTHER|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
48454308|NCT00820885|DRUG|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
48454309|NCT00820885|DRUG|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
48098539|NCT00360126|DRUG|lamotrigine|
48098540|NCT01525433|BEHAVIORAL|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
48454310|NCT00820885|DRUG|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
48454311|NCT03359863|DRUG|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
48454312|NCT03502811|DEVICE|MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
48454313|NCT01927744|DRUG|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
48454314|NCT01927744|DRUG|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
48454315|NCT01927744|OTHER|Placebo|150 mg by mouth daily continuously until the day before surgery.
48454316|NCT01927744|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
48454317|NCT01927744|BEHAVIORAL|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
48454318|NCT01927744|DRUG|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
48280174|NCT02580058|DRUG|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
48454319|NCT06150196|BEHAVIORAL|Mindfulness-based Stress Reduction class|9-week standard Mindfulness-based Stress Reduction class training on mindfulness techniques, medication, and yoga
48454320|NCT06150196|BEHAVIORAL|Brain Health Education class|9-week Brain Health education class that involves lectures/discussion about how the brain works and recovers after brain injury
48454321|NCT06359002|DRUG|BYON4413|BYON4413 will be administered by IV infusion.
48454322|NCT03373968|DRUG|Givinostat|suspension of givinostat (10 mg/mL)
47931410|NCT05421650|RADIATION|CCRT|"1. Radiation: EBRT/EF-EBRT + brachytherapy + lymph node boost.~2. Chemotherapy: Cisplatin 40mg/m2, every week, 4 to 6 cycles.~3. Radiation and chemotherapy are administered concurrently."
47931411|NCT05710380|OTHER|Risk Map Decision Support System (DSS).|The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
47931412|NCT05710380|RADIATION|Magnetic Resonance Imaging (MRI)|A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
47931413|NCT05710380|PROCEDURE|Magnetic Resonance Imaging (MRI) Guided Biopsy|A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
47931414|NCT01894568|DRUG|Insulin Peglispro|Administered SC using a prefilled pen.
47931415|NCT01894568|DRUG|Insulin Glargine|Administered SC using a prefilled pen
48098541|NCT01525433|BEHAVIORAL|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
48098542|NCT03035656|DRUG|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
48280175|NCT02037126|DRUG|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
48280176|NCT02037126|DRUG|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
48454323|NCT03707587|DRUG|M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
48454324|NCT05797207|DIAGNOSTIC_TEST|Artificial Intelligence-assisted Fecal Microbiome Testing|Next-generation sequencing of fecal samples and artificial intelligence analysis of test results
48454325|NCT05797207|PROCEDURE|Colonoscopy|Colonoscopy procedure
48454326|NCT06311929|DRUG|PD-1 monoclonal antibody and lenvatinib|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
48454327|NCT06311929|DRUG|PD-1 monoclonal antibody|Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
47931416|NCT01894568|DRUG|Oral Antihyperglycemic Medications (OAMs)|Administered orally
47931417|NCT03705273|DRUG|Dexamethasone IV for PO|Common pediatric emergency department practice
47931418|NCT03705273|DRUG|Dexamethasone crushed tablets|Alternative route of administration for patients unable to swallow tablet whole
47931419|NCT06185270|DIAGNOSTIC_TEST|SPPB|Short Physical Performance Battery using the automated device (Andantefit)
47931420|NCT05154370|DRUG|Intravenous steroid|This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.
47931421|NCT00233831|DEVICE|Generator of electromagnetic millimeter waves|
48454328|NCT06559631|BEHAVIORAL|Indigenously Adapted CRA|Treatment group will receive psychotherapy based on CRA which is an evidence based approach. This adapted version of CRA also consists emotional management, behavioral interventions, drug addiction treatment and islamically integrated psychotherapy for drug addiction and comorbid mental disorders.
47931422|NCT00159562|BEHAVIORAL|individual education|individual sessions of psycho-education
47931423|NCT00159562|BEHAVIORAL|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
47931424|NCT00000843|DRUG|Adefovir dipivoxil|
47931425|NCT05884801|DRUG|QLS1103|Oral dose
47931426|NCT06082401|DEVICE|hemodiafiltration (HDF)|Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
47931427|NCT06082401|DEVICE|Ex vivo lung perfusion (EVLP)|"Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications."
47931428|NCT01701752|BIOLOGICAL|FP-01.1 + Placebo|
48454329|NCT01134549|DRUG|Etelcalcetide|Administered as a single intravenous (IV) injection
48454330|NCT01134549|DRUG|Placebo|Administered as a single intravenous (IV) injection
48454331|NCT02741687|DRUG|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) \> 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
47931429|NCT01701752|BIOLOGICAL|FP-01.1 + TIV|
47931430|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + Placebo|
47931431|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant + TIV|
47931432|NCT01701752|BIOLOGICAL|Adjuvant + TIV|
48454332|NCT02741687|DRUG|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
47931433|NCT01701752|BIOLOGICAL|Placebo + TIV|
47931434|NCT01701752|BIOLOGICAL|FP-01.1|
47931435|NCT01701752|BIOLOGICAL|FP-01.1-Adjuvant|
47931436|NCT01701752|OTHER|Placebo|
47931437|NCT03486275|DEVICE|Hygie|Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
47931438|NCT03486275|DEVICE|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
47931439|NCT05675683|DRUG|Capmatinib|Patients receiving Capmatinib
47931440|NCT03978793|DEVICE|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
47931441|NCT04074239|OTHER|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
48098543|NCT03035656|OTHER|Saline|Administration of saline via epidural injection intra-operatively
48622482|NCT03669471|OTHER|Testing of performance|"The cross-sectional evaluation will involve assessment of:~1. Hip muscle function~2. Single leg jump performance~3. Self-reported hip and groin function~4. Evaluation of return to sport~5. Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
48098544|NCT02219490|DRUG|ABT-450/r/ABT-267|Tablet for oral use
47931442|NCT05384977|DRUG|[14C]-NV-5138|Single dose, given as oral solution, 1600 mg
47931443|NCT04879602|BEHAVIORAL|suction with bronchoscopy|suction with bronchoscopy
47931444|NCT03703401|DIAGNOSTIC_TEST|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
47931445|NCT00327470|DRUG|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
47931446|NCT04575597|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
47931447|NCT04575597|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
47931448|NCT04926402|OTHER|Kangaroo Care Education Program|It is a special method of caring for a premature infant in which the baby is positioned for at least 1 hour a day in an upright skin-to-skin and chest-to-chest contact with its mother.
47931449|NCT01921088|OTHER|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
47931450|NCT01921088|BEHAVIORAL|Ambulatory Training|Subjects are provided with an ambulatory training.
47931451|NCT04422275|DRUG|Budesonide|The drug intervention budesonide (0.5 mg /capsule) will be dissolved in 240 ml nasal saline lavage.
47931452|NCT04422275|BEHAVIORAL|High-Concentration Essential Oil|High-concentration essential oil will include 1 ml of essential oil per jar.
47931453|NCT04422275|DRUG|Placebo|The placebo (lactose monohydrate) drug will be dissolved in 240 ml of nasal saline lavage.
48454333|NCT02741687|DRUG|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
48622483|NCT05104125|DRUG|ASC40 25mg|25mg of ASC40 orally once daily for 12 weeks.
47931454|NCT04422275|BEHAVIORAL|Low-Concentration Essential Oil|Low-concentration essential oil will include 0.1 ml of essential oil per jar.
47931455|NCT04856670|PROCEDURE|Cataract surgery|Cataract surgery- Manual or femtosecond laser assisted
47931456|NCT02604121|DEVICE|Orcellex® Rovers brush|transepithelial brushing
47931457|NCT01721980|DRUG|GLPG0974|
47931458|NCT01721980|DRUG|Placebo|
47931459|NCT05879510|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
47931460|NCT06206954|BEHAVIORAL|MyHealthPath Tool|Tailored, brief online tool to help patients learn about weight treatment options
47931461|NCT06206954|BEHAVIORAL|MyHealthPath Guide|Informational material to help patients learn about weight treatment options
47931462|NCT06298344|DRUG|Thiamine|Daily Thiamine 100 mg in 28 days
47931463|NCT00821509|BEHAVIORAL|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
47931464|NCT00821509|BEHAVIORAL|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
47931465|NCT00726141|BEHAVIORAL|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
47931466|NCT03662243|BEHAVIORAL|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
47931467|NCT04652739|DRUG|Lycopene Softgel, 10 Mg|Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.
47931468|NCT04652739|DRUG|Prednisolone|Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
47931469|NCT04329689|OTHER|The Septal myectom|"The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary"
47931470|NCT01670578|BIOLOGICAL|PRP|
47931471|NCT01670578|DEVICE|Hyaluronic acid|
47931472|NCT06432296|DRUG|M701|Intra-peritoneal infusion of M701 in experimental group (M701 group_
47931473|NCT06432296|PROCEDURE|paracentesis|Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group
47931474|NCT02864485|PROCEDURE|live donor liver transplantation|live donor liver transplantation
47931475|NCT00004393|DRUG|risperidone|
47931476|NCT00212017|DRUG|voglibose|
47931477|NCT00212017|BEHAVIORAL|diet and exercise therapy|
48098545|NCT02219490|DRUG|ABT-333|Tablet for oral use
48622484|NCT05104125|DRUG|ASC40 50mg|50mg of ASC40 orally once daily for 12 weeks.
48622485|NCT05104125|DRUG|ASC40 75mg|75mg of ASC40 orally once daily for 12 weeks.
48622486|NCT05104125|DRUG|Placebo|Placebo orally once daily for 12 weeks.
47931478|NCT04959071|PROCEDURE|Vacuum assisted closure VAC vs conventional dressing|"In participants undergoing vacuum assisted closure a drainage tube was placed in the wound followed by dressing with sterile foam sheet and application of occlusive transparent film over the whole assembly. The drainage tube was connected to a suction machine. Intermittent negative pressure of -125mmHg was applied every 15 minutes; the suction was stopped for 10 minutes. The dressing was changed every 48 hours.~In participants with conventional dressings, after wound wash, pyodine soaked gauze pieces were used for initial 48 hours followed by dressings of normal saline soaked gauze pieces, twice daily."
47931479|NCT04184986|DIAGNOSTIC_TEST|dry blood test|screening test for Fabry disease
47931480|NCT02571738|BIOLOGICAL|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
47931481|NCT02571738|OTHER|Control|Standard of Care
47931482|NCT05436873|DEVICE|MR-HIFU|MRI guided High Intensity Focused Ultrasound sonication.
47931483|NCT02473692|OTHER|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~1. Introduction to the series~2. Getting to know migraine~3. Making the most of your medical care~4. Partnering with your doctor~5. Best use of migraine medication~6. Keeping tabs on your migraine~7. Take home message (summary)"
47931484|NCT01952782|DRUG|Kisspeptin 112-121|Subjects will receive up to 10 IV doses of kisspeptin 112-121
47931485|NCT01952782|DRUG|Naloxone|Subjects will receive one IV dose of naloxone followed by an IV infusion of naloxone.
48454334|NCT02741687|DRUG|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) \>240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
48454335|NCT02741687|DRUG|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
48622487|NCT05701735|BEHAVIORAL|CECIL Patient Decision Aid|"The CECIL patient decision aid explicitly identifies the disease, the index decision, and the treatment options, describes the positive and negative features and consequences of each option, and guides the patient in examining personal values and preferences, to arrive at a quality and realistic decision.~The decision aid will be developed and validated according to the guidelines and standards published by the International Patient Decision Aids Standards (IPDAS) Collaboration."
47931486|NCT01952782|DRUG|GnRH|Subjects will receive up to 10 doses of IV GnRH
47931487|NCT01574001|BEHAVIORAL|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
47931488|NCT01574001|BEHAVIORAL|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
47931489|NCT01574001|BEHAVIORAL|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
47931490|NCT03716570|DRUG|BIIB054|Administered as specified in the treatment arm.
47931491|NCT03716570|DRUG|Placebo|Administered as specified in the treatment arm.
47931492|NCT01548144|DRUG|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
48280177|NCT01129193|OTHER|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
48280178|NCT01129193|OTHER|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
48280179|NCT01129193|OTHER|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
48280180|NCT01129193|DRUG|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
47931493|NCT01548144|DRUG|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
48280181|NCT04820270|OTHER|Autologous T regulatory cells|Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
47931494|NCT01548144|DRUG|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
47931495|NCT03189290|PROCEDURE|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
47931496|NCT00068133|GENETIC|Plasmid based Gene Transfer product-VLTS-589|
47931497|NCT04892056|OTHER|Friction Mechanics|anterior segment retraction using elastomeric power chains
48280182|NCT06376149|BEHAVIORAL|M3 Intervention group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
47931498|NCT04892056|OTHER|Frictionless Mechanics|anterior segment retraction using closing loops
47931499|NCT00914303|DRUG|AZD3241|Oral Tablet, Repeated Administration
47931500|NCT00914303|DRUG|Placebo Tablet|Oral Tablet. Repeated Administration
47931501|NCT04822584|DRUG|Baricitinib Oral Product|Baricitinib 4 mg/day orally for 36 weeks
47931502|NCT04822584|DRUG|Placebo|Placebo once a day orally for 36 weeks
47931503|NCT02282878|DIETARY_SUPPLEMENT|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
47931504|NCT00328302|DRUG|Candesartan|
47931505|NCT00328302|DRUG|Placebo|
47931506|NCT04791527|BEHAVIORAL|Mind-body therapy|Online yoga, meditation, behavior change tips, and nutrition tips
47931507|NCT02031965|BIOLOGICAL|oncolytic HSV-1716|Given IT
47931508|NCT02031965|DRUG|dexamethasone|Given IV
47931509|NCT02031965|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
47931510|NCT02031965|OTHER|laboratory biomarker analysis|Correlative studies
47931511|NCT01792570|DRUG|RPV + DRV/r|Switch to dual HAART
48098546|NCT02219490|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
48098547|NCT04784741|OTHER|Conventional static hamstring muscle stretching|Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.
48098548|NCT04784741|DEVICE|Low amplitude whole body vibration therapy|"Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle."
48098549|NCT04784741|DEVICE|Biodex Balance System|Pre and post balance assessment by Biodex balance system
48280183|NCT06376149|BEHAVIORAL|M3 Waitlist Group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
48280184|NCT02160418|BEHAVIORAL|Financial Incentives|
47931512|NCT01792570|DRUG|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
47931513|NCT04382664|BIOLOGICAL|UV1|UV1 vaccine (300 μg) will be injected intradermally.
47931514|NCT04382664|BIOLOGICAL|Sargramostim|Sargramostim (75 μg) is used as a vaccine adjuvant.
47931515|NCT04382664|BIOLOGICAL|Ipilimumab|Ipilimumab is dosed according to label.
47931516|NCT04382664|BIOLOGICAL|Nivolumab|Nivolumab is dosed according to label.
47931517|NCT02576769|OTHER|No intervention|
47931518|NCT04309799|DEVICE|Tear Restore Mask|The Tear Restore Mask will be used for 10 minutes
47931519|NCT00376818|BEHAVIORAL|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
47931520|NCT00376818|OTHER|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
47931521|NCT00376818|OTHER|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
47931522|NCT00376818|OTHER|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
47931523|NCT00376818|BEHAVIORAL|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
47931524|NCT00376818|PROCEDURE|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
47931525|NCT05700643|DIETARY_SUPPLEMENT|Montmorency cherry supplement|Montmorency cherry supplement
47931526|NCT05700643|DIETARY_SUPPLEMENT|Control|Placebo
48280185|NCT02160418|BEHAVIORAL|Cognitive Incentives|
48280186|NCT02160418|BEHAVIORAL|Financial and Cognitive Incentives|
47931527|NCT00816023|DRUG|ecallantide|infusion administered IV over the duration of the surgical procedure
47931528|NCT00816023|DRUG|placebo|solution for IV infusion over the duration of the surgical\>\> procedure
47931529|NCT04722055|DIAGNOSTIC_TEST|Multigene Methylation Detection Kit|Eligible participants are required to take stool samples for multigene methylation detection and gene sequencing, undergo colonoscopy examination, and have a biopsy when necessary (gold standard).
48280187|NCT02635204|DRUG|DFD06 Cream|Twice daily topical application for 14 days.
47931530|NCT04698850|DRUG|Aflibercept 40 MG/ML [Eylea]|Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
47931531|NCT04698850|DRUG|Brolucizumab-Dbll 120 MG/ML [Beovu]|Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
47931532|NCT04698850|DRUG|Ranibizumab 6 MG/ML [Lucentis]|Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
47931533|NCT03149848|DRUG|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
47931534|NCT03149848|DRUG|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
47931535|NCT05165589|DEVICE|ActiveInsights accelerometer device|Accelerometer device
47931536|NCT06213675|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
47931537|NCT06213675|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
47931538|NCT01294527|DEVICE|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
47931539|NCT03309046|OTHER|REACH Individual Session|Individual telephone session with parent
47931540|NCT03309046|OTHER|Education Webinar|Videos with information on caregiving
48454336|NCT02741687|DRUG|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) \>180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~* Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~* Fasting and pre-meal BG between \>180-240 mg/dl: increase detemir or glargine dose by 10% every day~* Fasting and pre-meal BG \>241 mg/dl: increase detemir or glargine dose by 20% every day~* Fasting and pre-meal BG \<100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
47931541|NCT02073266|PROCEDURE|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
48098550|NCT04784741|PROCEDURE|Range of motion of hamstring muscle|Straight Leg Raising to check pre and post Range of Motion by using Goniometer
48098551|NCT04811287|DEVICE|Carpal Tunnel Release with Platelet-Rich Plasma|CTR is performed with adjuvant PRP placed intra-operatively.
48098552|NCT04811287|PROCEDURE|Carpal Tunnel Release without Platelet-Rich Plasma|CTR is performed without adjuvant PRP placed intra-operatively.
48098553|NCT02509390|PROCEDURE|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
48454337|NCT03426657|COMBINATION_PRODUCT|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
48454338|NCT01076491|DRUG|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
48454339|NCT04454229|OTHER|Direct oral penicillin challenge|The patient will receive a single dose of oral penicillin, following baseline vital signs.
48454340|NCT04454229|OTHER|Standard of care|Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
48454341|NCT03981731|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
48454342|NCT01929486|BIOLOGICAL|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
48622488|NCT02859012|DRUG|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
48098554|NCT01129778|DRUG|Zegerid (proton pump inhibitor)|
48098555|NCT01129778|PROCEDURE|Bravo pH monitoring|
48098556|NCT06629090|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.
48098557|NCT06629090|DRUG|Prazosin|A dose of prazosin will be administered based on body weight
48098558|NCT06629090|DRUG|Placebo|Oral placebo
48098559|NCT02842658|OTHER|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
48098560|NCT02842658|OTHER|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
48098561|NCT04965883|PROCEDURE|Excision and Grafting|reconstruction of deep burn by grafting
48622489|NCT02859012|OTHER|Observation|this group is observational ones.
47931542|NCT03375229|OTHER|Dry Needling|"It will be used acupuncture needles, individually packaged and sterilized, with 0.25 mm of thickness and 0.40 mm of length. The therapist will perform the grip in upper trapezius on the site of one of the two previously marked locations, according to the subject group allocation, and will insert the needle in the skin with help of a guide tube and will deepen the needle approximately 10 to 15 mm inside the trigger point. The needle will be moved up and down as in the fast-in and fast-out technique described by Hong and the movement will be repeated during 30 seconds in a cadence of approximately 1 Hz. The protocol will be the same for the groups that will receive the application directly on the trigger point and for the group that will receive the application away from the trigger point"
47931543|NCT03375229|DEVICE|Low-Level Laser Therapy|The laser protocol used the PainAway Laser™ cluster equipment composed of one pulsed infrared laser of 905 nm, four red LEDs of 640 nm, and four infrared LEDs of 875 nm, with full device aperture of 4 cm2, total delivered energy of 39,8 J, a magnetic field of 35 Mt and treatment time of 300 seconds. The equipment was turned on only for the DNP group and it remained in slight contact with the skin during 300 s for all groups.
47931544|NCT05944978|DRUG|GNC-035|GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
47931545|NCT03603509|DRUG|Fluad Vaccine|FLUAD is an inactivated influenza vaccine indicated for active immunization against influenza. disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is. approved for use in persons 65 years of age and older.
47931546|NCT03603509|DRUG|Fluzone High-Dose|FLUZONE® HIGH-DOSE vaccine is indicated for people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.
47931547|NCT04758000|DRUG|Metformin Hydrochloride|"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI \> 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."
47931548|NCT05121571|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
47931549|NCT05121571|DRUG|Sorafenib|sorafenib 400mg bid
47931550|NCT03603327|DRUG|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
47931551|NCT01642121|OTHER|laboratory biomarker analysis|Correlative studies
47931552|NCT00813176|DEVICE|Double Lumen Endotracheal Tube|
47931553|NCT00813176|DEVICE|Arndt Bronchial Blocker|
47931554|NCT03211806|BEHAVIORAL|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
47931555|NCT03211806|DEVICE|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
47931556|NCT01490398|DRUG|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
47931557|NCT02101814|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery)|
47931558|NCT02115126|BIOLOGICAL|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be \> 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be \> 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
47931559|NCT02115126|BIOLOGICAL|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
47931560|NCT01041378|DRUG|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
47931561|NCT00667446|DRUG|Leuprolide Acetate 3 Month Depot|
48454343|NCT03608228|OTHER|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
47931562|NCT05911282|DRUG|N Acetylcysteine|"The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study."
48098562|NCT04965883|PROCEDURE|dressing then delayed grafting|multiple dressing and delayed grafting
48098563|NCT00143650|BEHAVIORAL|House dust|
48098564|NCT06507657|DRUG|empagliflozin|"intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
48098565|NCT06507657|DRUG|Placebo tablet|"intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
48454344|NCT03610542|BEHAVIORAL|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
48454345|NCT03610542|BEHAVIORAL|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
47931563|NCT05911282|OTHER|Lemon juice|"The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study."
47931564|NCT00433264|PROCEDURE|peritoneal dialysis|individualised
47931565|NCT05098275|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
47931566|NCT05098275|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
47931567|NCT03387475|DRUG|Deferasirox|iron chelation
47931568|NCT01413633|PROCEDURE|cholecystectomy|single incision laparoscopic cholecystectomy
47931569|NCT05073094|DRUG|Esmolol|Esmolol injected intravenously and added to cardioplegia solution
47931570|NCT05073094|DRUG|Placebo|Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution
47931571|NCT05578027|PROCEDURE|Mild moxibustion with moxa stick|To conduct this intervention, we used moxa sticks which were 1.5 cm in diameter, 13 cm long, and weighed 12 gram to perform mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) or Mingmen acupoint in 2 trial phases. The main ingredient of the moxa was dried mugwort leaf, produced in Vietnam. All moxa materials were obtained from the Sai Gon TCS Co., Ho Chi Minh City, Vietnam.
47931572|NCT00172159|PROCEDURE|Hepatic resection|
47931573|NCT01567228|OTHER|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
47931574|NCT01610375|OTHER|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
47931575|NCT02695212|DRUG|Apremilast|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
47931576|NCT03554265|DRUG|Somatropin|Genotropin given by injection
47931577|NCT04409639|DRUG|Cobimetinib|Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.
48280188|NCT02635204|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
48454346|NCT03610542|BEHAVIORAL|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
48454347|NCT03610542|BEHAVIORAL|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
48454348|NCT03610542|BEHAVIORAL|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
48454349|NCT00059332|DRUG|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
48622490|NCT04298853|DRUG|Morphine PRN|Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.
47931578|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
47931579|NCT02219243|BEHAVIORAL|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
47931580|NCT00827931|DRUG|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
47931581|NCT00827931|PROCEDURE|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
47931582|NCT00001282|DRUG|Zidovudine (AZT) & Interleukin-2 (IL2)|
47951324|NCT03610451|BEHAVIORAL|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (\~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
48280189|NCT03226093|PROCEDURE|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
48280190|NCT01939795|OTHER|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
48098566|NCT05310929|DRUG|Labetalol and Glyceril trinitrate|for control of blood pressure
48280191|NCT06488950|BIOLOGICAL|GC203 TIL(gene-edited TIL) or autologous TILs|the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample
48280192|NCT04833439|OTHER|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
48280193|NCT05153343|DRUG|flonoltinib 25mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
48454350|NCT00059332|DRUG|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
48454351|NCT01322321|DRUG|ACZ885|
48454352|NCT01322321|DRUG|Placebo|
48454353|NCT04379739|DRUG|Camrelizumab|camrelizumab 200mg, q3w, i.v., 2-4 cycles;
48454354|NCT04356313|DEVICE|GORE® EXCLUDER® Iliac Branch Endoprosthesis|Compare between patients where Gore Excluder Iliac Branch Endoprosthesis and the Hipogastric component can be used with the group where the Hipogastric component can't be used for anatomical issues and a Gore Viabahn VBX is used instead of the Hipogastric component
48454355|NCT02367872|DRUG|TAK-272|TAK-272 tablet
48454356|NCT03373643|DIAGNOSTIC_TEST|OSA screening|Full night polysomnography
48454357|NCT03026153|BEHAVIORAL|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
48454358|NCT03026153|BEHAVIORAL|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
48454359|NCT00193960|PROCEDURE|1) Intraocular pressure 2) visual acuity|
48454360|NCT00396929|DRUG|local intracoronary dosis of Paclitaxel|
48454361|NCT01103843|DRUG|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
48454362|NCT01103843|DRUG|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
48280194|NCT05153343|DRUG|flonoltinib 50mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
48280195|NCT05153343|DRUG|flonoltinib 100mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
48280196|NCT05153343|DRUG|flonoltinib 150mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
48454363|NCT04161898|DRUG|Upadacitinib|Upadacitinib will be administered as oral tablet
48454364|NCT04161898|DRUG|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
48454365|NCT04161898|DRUG|Prednisolone|Prednisolone will be administered as oral tablet
48454366|NCT00954460|DRUG|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
48454367|NCT03260153|DRUG|Deproteinised Calf Blood Serum Injection|
48454368|NCT03260153|DRUG|Placebo (Sodium Chloride)|
48454369|NCT06559280|DRUG|esketamine|During the operation, 0.25mg/kg esketamine was induced, and 1mg/kg esketamine was added to the postoperative analgesia pump
48454370|NCT00767481|DRUG|Travoprost/Brinzolamide|Eye drop suspension, once daily
48454371|NCT00767481|DRUG|Cosopt|Eye drop solution, one drop BID
47951325|NCT03610451|BEHAVIORAL|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
48454372|NCT05398809|DRUG|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
48454373|NCT05452772|DRUG|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
48098567|NCT01874184|OTHER|counseling intervention|Take part in weekly group counseling sessions
48454374|NCT05452772|DRUG|Niacin|Participants will received two niacin sessions, 1 week apart
48454375|NCT05553444|BEHAVIORAL|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
48454376|NCT05971394|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
48280197|NCT05153343|DRUG|flonoltinib 225mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
48454377|NCT05770076|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotic)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
48454378|NCT05770076|DIETARY_SUPPLEMENT|Placebo|Placebo
48454379|NCT05625490|DRUG|Ga-68 Galmydar|Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.
48454380|NCT05625490|DRUG|13N-ammonia|Two intravenous injections of PET radiotracer \[13N\]Ammonia.
48454381|NCT03552003|OTHER|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
48454382|NCT04215705|PROCEDURE|Quadratus block versus peritubal local infiltration|Quadratus lumborum block III versus peritubal local infiltration in patients undergoing Percutaneous Nephrolithotomy operation
48454383|NCT05778630|OTHER|Focus group meetings|Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.
48098568|NCT01874184|BEHAVIORAL|behavioral dietary intervention|Set goals for changing dietary habits
48098569|NCT01874184|BEHAVIORAL|exercise intervention|Attend group exercise activities
48098570|NCT01874184|OTHER|questionnaire administration|Ancillary studies
48454384|NCT05778630|OTHER|Individual interviews|Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.
47931583|NCT05047627|BEHAVIORAL|Smartphone-Based Digital Intervention|The digital intervention will be a prototype, and the current trial will be used to continue to both develop and refine the intervention. The current intervention will be based on a combination of cognitive-behavioral principles. As with prior research, the mobile platform will be delivered via Qualtrics, a HIPAA compliant and mobile-friendly platform. The cognitive-behavioral therapy will be primarily based on components with strongest support in digital interventions. The app will continuously collect passive sensing data on patterns in 1) sleep duration and quality;(2) light (3) location; (4) movement (5) social contact including duration and frequency of incoming and outcoming calls and text messages; (6) screen time; and (7) heart rate variability; (8) sound levels captured through passively collected smartphone The platform will deliver interactive interventions where participants will view texts and images, and it will also allow user interaction.
47931584|NCT05356728|DRUG|Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop|One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
47931585|NCT00791076|DRUG|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
47931586|NCT00791076|DRUG|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
47931587|NCT00540098|DRUG|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
48454385|NCT02504450|DRUG|Adasuve|Inhaled medication to treat acute agitation in the emergency department
48454386|NCT02504450|DRUG|Alternative medications|Medication given to treat acute agitation in the emergency department
48454387|NCT02957942|DEVICE|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
48454388|NCT04635020|PROCEDURE|iStent|2 trabecular Stent injected at the end of the cataract surgery to the trabecular meshwork
47931588|NCT00540098|DRUG|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
47931589|NCT00540098|DRUG|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
47931590|NCT00540098|DRUG|Placebo + relaxation|placebo pill once daily + regular relaxation training
47931591|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
47931592|NCT00136604|BIOLOGICAL|Mencevax ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
47931593|NCT00136604|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
47931594|NCT00136604|BIOLOGICAL|Meningitec|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
47931595|NCT04718103|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
47931596|NCT04718103|BIOLOGICAL|Placebo|Placebo will be administered as normal saline using a pre-filled syringe.
48280198|NCT05153343|DRUG|flonoltinib 325mg|1 case,The starting dose,Take the medicine once on D1,D 5-21.
48280199|NCT06390670|DIETARY_SUPPLEMENT|Colostrum Bovinum supplementation|In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.
48454389|NCT04635020|PROCEDURE|SLT-laser|1 month after cataract surgery laser treatment to the trabecular meshwork (100 applications, 360 degrees)
48454390|NCT04635020|PROCEDURE|Cataract surgery|Conventional cataract surgery
48454391|NCT00372086|DRUG|Rosiglitazone|
48454392|NCT03129841|BEHAVIORAL|Early dinner+Diet|Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
48454393|NCT03129841|BEHAVIORAL|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
48454394|NCT02964663|DEVICE|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
48454395|NCT06627673|DEVICE|Total Knee Arthroplasty|Primary Total Knee Arthroplasty with a PEEK femoral component
48454396|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
48454397|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
48454398|NCT02407548|DIETARY_SUPPLEMENT|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
48454399|NCT04571294|PROCEDURE|removal of para-aortic lymphnodes (PALN)|During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
47931597|NCT05806684|OTHER|ROP|Correlation between neonatal indirect bilirubin jaundice and ROP.
47931598|NCT02296879|GENETIC|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
47931599|NCT00781352|DRUG|nitrous oxide|65% nitrous oxide administered during surgery
47931600|NCT00781352|DRUG|nitrogen|Nitrogen administration during surgery
47931601|NCT04227054|DEVICE|IMPEDE-FX Embolization Plug|Fill an abdominal aortic aneurysm (AAA) sac outside of an endovascular aneurysm repair (EVAR) stent graft
47931602|NCT05635188|PROCEDURE|Intestinal ostomy confection|Surgical procedure for fecal diverting
47931603|NCT02859818|OTHER|therapeutic education program|
47931604|NCT00256282|DRUG|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
47931605|NCT00256282|DRUG|Docetaxel|40mg/m2 IV over 1 hour every 14 days
47931606|NCT00256282|DRUG|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
48098571|NCT01874184|OTHER|laboratory biomarker analysis|Correlative studies
48454400|NCT05832658|DEVICE|With EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with game-based emg-biofeedback.
48454401|NCT05832658|BEHAVIORAL|Without EMG-Biofeedback|Once a day for a total of 15 sessions, the Mendelsohn maneuver will be performed for 15 minutes and the effortful swallow maneuver will be performed for 15 minutes with only verbal feedback.
48454402|NCT05832658|BEHAVIORAL|Usual Care|Patient and family education will be provided by the investigator. In addition, each patient will be evaluated and oral motor exercises and thermal tactile stimulation will be given to each patient when necessary.
48454403|NCT06241976|OTHER|Glucose drink|75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)
48454404|NCT06241976|OTHER|Pure orange juice|300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket
48622491|NCT04298853|DRUG|Morphine scheduled|Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.
48454405|NCT01698645|DRUG|PecFent® (fentanyl) nasal spray|
47931607|NCT04144491|DIETARY_SUPPLEMENT|Probiotic|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks."
47931608|NCT04144491|DIETARY_SUPPLEMENT|Placebo|100ml of custard will be consumed 5 days per week, for 9 weeks.
47931609|NCT02326545|BEHAVIORAL|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
47931610|NCT02326545|BEHAVIORAL|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
48098572|NCT06556212|OTHER|Real-time feedback using smart swim goggles|Smart swim goggles (Form Athletica Inc.) with activity metrics (such as heart rate, swimming pace, and workout instructions) displayed in real-time during a swimming activity.
48098573|NCT05771090|DEVICE|Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
48098574|NCT01854437|DRUG|Mg Oxide|250 mg orally for 4 weeks
48098575|NCT03317353|DEVICE|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
48098576|NCT03317353|DEVICE|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
48098577|NCT03317353|OTHER|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
48280200|NCT06390670|OTHER|Placebo treatment|In the control procedure each athlete was supplemented with a chronic dose of 25 g/day of placebo (PLA). PLA was particularly prepared for the study, and was an isoenergetic/isomacronutrient product (high quality protein) prepared for the trial (Agrapak, Poland). The PLA was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the PLA preparation in 250 mL of plain water.
48454406|NCT05009212|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy for bowel stricture (\<5 cm)
48454407|NCT05009212|PROCEDURE|Endoscopic balloon dilatation|Endoscopic balloon dilatation for bowel stricture (\<5 cm)
48454408|NCT03611335|BEHAVIORAL|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
48454409|NCT02579733|DRUG|Azathioprine|
48454410|NCT02579733|DRUG|Placebo|
48454411|NCT03968328|OTHER|Interview|Take part in interview
48454412|NCT03968328|OTHER|Survey Administration|Respond to survey
48454413|NCT06212492|DRUG|NMBAs|Early and systematic use of NMBAs
48454414|NCT06212492|OTHER|Prone positioning|Early and systematic use of prone positioning
48454415|NCT03986034|DRUG|During Venetoclax|Patients with CLL/SLL will enroll on the study. Subjects will be treated at the NIH Clinical Center for the duration of the ramp-up phase of venetoclax. After the ramp-up phase is complete, subjects will be transitioned to the care of their local hematologist/oncologist and receive venetoclax monotherapy or in combination with other agent(s) at the discretion of the treating oncologist. Subjects will have the option to follow-up at the NIH every 6 months (from initiation of venetoclax) and at (suspected) progression.
48454416|NCT05878080|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
48454417|NCT02153645|DRUG|240mg Amantadine HCl ER tablets|
48454418|NCT02153645|DRUG|Placebo tablets|
48454419|NCT02153645|DRUG|320mg Amantadine HCl ER tablets|
48622492|NCT05743582|PROCEDURE|Bronchoscopy for sample collection|Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
48622493|NCT05743582|PROCEDURE|Blood donation|Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
48454420|NCT01824940|BEHAVIORAL|Standard care|"Standard Care:~* Exclusive breastfeeding promotion for all infants, birth to 6 months~* Strengthened PMTCT (prevention of mother to child transmission of HIV) services~* Strengthened Village Health Worker system"
48622494|NCT06430060|DRUG|zinc containing toothpaste|Toothpaste
48622495|NCT06430060|DRUG|MFP Fluoride toothpaste|toothpaste
48622496|NCT04572815|DRUG|Placebo Administration|Given IV and SC
48622497|NCT04572815|OTHER|Quality-of-Life Assessment|Ancillary studies
48622498|NCT04572815|OTHER|Questionnaire Administration|Ancillary studies
47931611|NCT05841173|DIETARY_SUPPLEMENT|"PanTrek"|"The intervention is represented by the investigational product PanTrek, shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product PanTrek (per 1 dose):~* Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg);~* Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial);~* Apple juice concentrated 2.5% - 7,5 g;~* Potassium beta-hydroxybutyrate - 4,5 g;~* Magnesium beta-hydroxybutyrate - 500 mg;~* E211 sodium benzoate - no more than 5 mg;~* E202 Potassium sorbate - no more than 3,6 mg;~* Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021."
47931612|NCT05841173|BEHAVIORAL|Physical Trainings|Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
47931613|NCT05841173|OTHER|Placebo|The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
47931614|NCT05841173|BEHAVIORAL|Diet|The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
48454421|NCT01824940|OTHER|WASH|"WASH:~* Standard care interventions~* Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~* Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
47931615|NCT03188042|DEVICE|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
47931616|NCT03188042|DEVICE|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
47931617|NCT01153464|BEHAVIORAL|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
48454422|NCT01824940|DIETARY_SUPPLEMENT|Infant and young child feeding|"IYCF:~* Standard care interventions~* Provide 20 g/d Nutributter from 6-18 months~* Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
48454423|NCT01824940|OTHER|WASH and Nutrition|"WASH AND IYCF interventions~* Standard care interventions~* All WASH interventions~* All IYCF interventions"
48622499|NCT04572815|BIOLOGICAL|Ustekinumab|Given IV and SC
47931618|NCT03177629|DRUG|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
47931619|NCT04757454|DIAGNOSTIC_TEST|5-item SARC-F questionnaire|Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit
47931620|NCT01459939|DIETARY_SUPPLEMENT|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
47931621|NCT01459939|DIETARY_SUPPLEMENT|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
47931622|NCT01373736|DRUG|123I-meta-iodobenzylguanidine|
48280201|NCT06033001|DRUG|[Lu-177]-PNT2002|\[Lu-177\]-PNT2002, is a radiopharmaceutical investigational drug. \[Lu-177\]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. \[Lu-177\]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. \[Lu-177\]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.
48454424|NCT06013150|DRUG|Epinephrine|Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.
48454425|NCT06013150|DRUG|Placebo|Participant in Part 1 of the study will receive matching doses of placebo
48454426|NCT06563154|DIAGNOSTIC_TEST|Exercise Capacity Assessment|To examine the relationship between exercise capacity and physical fitness of dyslipidemia patients and quality of life, cognitive status and health literacy.
48622500|NCT00386698|BIOLOGICAL|Fluarix|
48622501|NCT00386698|BIOLOGICAL|adjuvanted influenza vaccine|
48622502|NCT05158803|RADIATION|ultrasound and C.T|lung ultrasound in comparison to C.T
48622503|NCT00525304|BEHAVIORAL|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
48622504|NCT01913353|BIOLOGICAL|MVA BN®|0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
48622505|NCT01913353|BIOLOGICAL|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
48622506|NCT03999047|DIAGNOSTIC_TEST|PRISMA score|Screening for frailty using PRISMA-7
48454427|NCT06563154|DIAGNOSTIC_TEST|Physical Fitness Assessment|"* 1-Minute Sit-to-Stand Test: Participants will be asked to sit down and stand up for 1 minute without pausing, and the repetition number will be recorded.~* Timed Up-and-Go Test: Participants will be asked to get up, walk a distance of 3 meters, return and sit down again. The time spent during this track will be recorded.~* Peripheral muscle strength assessment: Participants will be asked to resist the resistance by producing maximum isometric force during the movement, and the maximal force will be evaluated with a dynamometer. The quadriceps femoris muscle, shoulder abductor muscles and hand grip strength will be used for the assessment.~* Flexibility assessment: Participants will be asked to reach towards the tips of their toes while sitting. During this time, the distance between the participant's fingertips and toes will be measured."
48454428|NCT06563154|OTHER|Quality of Life Assessment|Participants' quality of life will be assessed with the Turkish version of the Short Form Quality of Life Questionnaire (SF-36). The questionnaire consists of 36 questions that examine quality of life from different perspectives. It examines quality of life in the subcategories of physical function, physical role difficulty, pain, general health, vitality (energy), social function, emotional role difficulty and mental health. The score for each category varies between 0-100, with a high score indicating a good quality of life.
48454429|NCT06563154|OTHER|Physical Activity Assessment|Participants' physical activity level will be assessed with the Turkish version of the International Physical Activity Scale - Short Form (IPAQ-SF). The IPAQ-SF evaluates the physical activities of the participants in the last 7 days based on sitting time, walking time, moderate and vigorous physical activities.
48454430|NCT06563154|OTHER|Cognitive Health Assessment|Participants' cognitive health will be assessed with the with the Turkish version of the Mini Mental State Examine (MMSE). The test is scored between 0-30. Scores of 25 and above are considered normal. A total score of less than 10 indicates severe impairment. Scores between 10-19 indicate moderate dementia. Scores between 19-24 indicate early dementia.
48454431|NCT06563154|OTHER|Health Literacy Assessment|Participants' health literacy will be assessed with the Turkish version of the HLS-EU-47 health literacy survey. The survey consists of 47 questions. Each item is assessed with one of the following options: Very difficult (1), difficult (2), easy (3), very easy (4) and I don't know. A high total score indicates good health literacy. A total score of 0-25 points indicates insufficient health literacy, \>25-33: problematic - limited health literacy, \>33-42: sufficient health literacy, \>42-50: excellent health literacy.
48454432|NCT01650194|DRUG|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
48454433|NCT01650194|DRUG|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
48454434|NCT01650194|DRUG|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
48454435|NCT05972759|OTHER|Forced and voluntary exercise|Twenty-five participants with PD utilizing the Medtronic Percept PC DBS system will be enrolled for this project and complete a single bout of both FE and VE. The 150-minute experimental session will be completed in the OFF antiparkinsonian and Off-DBS state.
48454436|NCT03099915|OTHER|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
48454437|NCT04796480|DIETARY_SUPPLEMENT|YOGURT|Group 1 was given yogurt
48454438|NCT04796480|DIETARY_SUPPLEMENT|LACTOSE FREE FORMULA MILK|Group 2 was given lactose free formula milk
48454439|NCT06627543|DIAGNOSTIC_TEST|echo|echocardiographic
48454440|NCT02702895|BEHAVIORAL|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
48454441|NCT01321567|DRUG|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
48454442|NCT03045198|DRUG|Azithromycin|
48454443|NCT00795821|DRUG|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
48622507|NCT00762905|DEVICE|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
48454444|NCT00795821|DRUG|Placebo|Dose: 3 tablets QD for 10 weeks
48454445|NCT05730920|DRUG|Methadone|IV Methadone
48454446|NCT05730920|DRUG|Liposomal bupivacaine (LB, Exparel)|LB and bupivacaine hydrochloride via erector spinae plane blocks
48454447|NCT04114890|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
48454448|NCT03889912|DRUG|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW), or at less frequent dosing into the lesion at the assigned dose level for 3-12 weeks prior to scheduled surgery
48454449|NCT04703504|OTHER|Multiple intervention program|Support for patient follow-up assisted by a computer program
48454450|NCT02129140|DEVICE|Hernia graft/mesh|observational group
48454451|NCT02097160|OTHER|Vitamin D fortified yogurt and cheese products|
48454452|NCT02097160|OTHER|Control Group 1|
48622508|NCT00762905|DEVICE|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
48622509|NCT04303637|BEHAVIORAL|Phone use|Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
48622510|NCT06551493|OTHER|Observation of postnatal wound assessment|Observation of postnatal wound assessment
48622511|NCT06551493|OTHER|Interview|Interview to elicit individual perspectives of wound assessment
48454453|NCT06003335|BEHAVIORAL|Regular message delivery|Regular messages will be sent regularly to each participant over the 12-week study period. As personalisation is a core process in enabling behavioural change, the intervention content, frequency, and timing of the messages will be based on the participants' self-care needs and preferences, which will be surveyed at baseline. If no specific preferences are provided, we will plan the message delivery to decrease in frequency over time as this trend has shown the highest effectiveness in existing studies. The format of messages will be mainly texts, but other formats such as pictures and voice messages will also be considered for addition to the content library to suit a wide range of preferences.
48454454|NCT06003335|BEHAVIORAL|Chat-type support message delivery|Chat-based support will be given to the participants in addition to the regular message delivery. Instant messaging will be used to communicate directly with the participants. We plan to recruit 10 student RAs who have been trained in the delivery of interactive instant messages (IMs) to provide chat-type support to encourage increased physical activity and interaction. Participants will be invited to set physical activity goals and action plans through the chat-type support. Participants will receive a personalised summary of their physical activity weekly and will be encouraged to reflect on this through a real-time chat (around 5 minutes). They will also be encouraged to establish a plan of how they can adjust their physical activity goal going forward. When addressing the participants' queries or any ethical concerns, the student RAs will be instructed to immediately report to the Principal Applicant and supervisors who are experienced and trained research nurses.
48454455|NCT05806177|DRUG|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
48622512|NCT05949840|OTHER|Expressive Interviewing|Automated computer system designed to engage participants in discussion about challenges faced during the COVID-19 pandemic.
48622513|NCT05488470|DEVICE|LINQ/LINQ II|Algorithm developed and validated to continuously measure QT intervals for every beat using LINQ/LINQ II ECG. This study is aimed at determining if QT interval changes can be detected during and after antiarrhythmic drug loading by the designed QT detection algorithm from LINQ/LINQ II ECG.
47931623|NCT04633408|BEHAVIORAL|STAR-C Virtual Training and Follow-up (STAR-VTF)|STAR-C Virtual Training and Follow-up (STAR-VTF) is adapted from an evidence-based, in-person program that trains family caregivers to manage BPSD (behavioral and psychological symptoms of dementia)
47931624|NCT03665857|BEHAVIORAL|a multicomponent intervention|"1. School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~2. Monitoring of students' weight and height Students will be monitored their weight and height monthly.~3. Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~4. Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~5. The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
47931625|NCT06283927|PROCEDURE|Re-resection|Resection of the recurrent tumor
47931626|NCT06283927|DRUG|Temozolomide|Re-challenge Temozolomide chemotherapy
47931627|NCT06283927|DRUG|Lomustine|Second line chemotherapy with Lomustine
47931628|NCT06283927|RADIATION|Re-irradiation|Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor
47931629|NCT06283927|PROCEDURE|Experimental therapy|Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)
47931630|NCT06283927|OTHER|Best supportive care|Best supportive care, focused on alleviating symptoms
47931631|NCT00360152|PROCEDURE|Fine needle aspiration biopsy (FNAB)|
47931632|NCT00360152|PROCEDURE|Sentinel Lymph Node Biopsy|
47931633|NCT03291418|DRUG|ATB-346 OR Placebo|Comparison of gastrointestinal effects
47931634|NCT03291418|DRUG|Naproxen sodium|Comparison of gastrointestinal effects
47931635|NCT04644367|OTHER|Tai Chi intervention|TC classes will be 60 minutes long, offered three times per week over a 12-week period. The participants who receive the TC intervention will be encouraged to attend at minimum two of the three sessions offered per week. The TC classes will follow the same order that will begin with a 5 to 10 minutes warm up, 40 minutes of core activities, and 5 minutes of cool-down. The training intensity and difficulty level of the TC program will gradually proceed from low, moderate, to advance. The classes will be offered in a group setting at a convenient location within a community centre or gymnasium. Alternatively, classes will be offered outdoors in the park or by the canal during the spring-summer months. Due to the COVID-19 situation, additional adaptive measures will be taken using online social platforms such as ZOOM or Hangout to deliver the classes.
47931636|NCT04644367|OTHER|Regular Physical Activity (control) group|Regular Physical Activity group who will not be receiving the TC intervention
47931637|NCT00432601|BEHAVIORAL|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
47931638|NCT05457894|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine|solution for intramuscular injection, 0.5 ml
47931639|NCT05457894|BIOLOGICAL|Ultrix®, Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
47931640|NCT06229314|DEVICE|Inspiratory muscle training|In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
47931641|NCT01050478|DRUG|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
48454456|NCT05806177|DRUG|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
48454457|NCT02402660|DRUG|ALK-001|Daily, oral administration for 24 months
47931642|NCT01050478|DRUG|Benzodiazepine|Participants may receive the benzodiazepine lorazepam \[0-7.5 milligram (mg) per day\] as needed for sedation or rescue medication at the investigator's discretion.
48454458|NCT02402660|DRUG|Placebo|Daily, oral administration for 24 months
47931643|NCT02325791|DRUG|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
47931644|NCT02325791|DRUG|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
47931645|NCT02325791|DRUG|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
47931646|NCT02325791|DRUG|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
47931647|NCT02719873|OTHER|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
47931648|NCT00471809|DRUG|Budesonide + Salmeterol + Azithromycin|
47931649|NCT00471809|DRUG|Budesonide + Salmeterol + Montelukast|
47931650|NCT00471809|DRUG|Budesonide + Salmeterol + Placebo|
47931651|NCT04485065|DRUG|IBI188+azacitidine|"Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W"
47931652|NCT06057740|BEHAVIORAL|Acceptance and commitment therapy (ACT)|ACT is a psychological intervention that aims to improve psychological flexibility, the ability to hold thoughts and emotions lightly in a given context and pursue valued ends (Hayes et al., 1999; Twohig \& Levin, 2017).
47931653|NCT06057740|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT is a psychological intervention which targets cognitions and behaviors in attempt to change emotions.
47931654|NCT00536861|DRUG|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
47931655|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
47931656|NCT01027273|BEHAVIORAL|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
47931657|NCT06236191|DEVICE|transcranial pulsed current stimulation|A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.
47931658|NCT06236191|DRUG|Melatonin|Melatonin
47931659|NCT05447741|DIAGNOSTIC_TEST|Quantitative Ultrasound|Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
47931660|NCT03916107|PROCEDURE|Levator muscle and tarsus resection|Shortening the levator muscle with resection of tarsus to correct severe ptosis
47931661|NCT03916107|PROCEDURE|Frontalis flap|Using frontal muscle flap to correct severe ptosis
47931662|NCT04489901|OTHER|Olive oil|To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
47931663|NCT03304444|DRUG|Bupivacaine|bupivacaine hydrochloride used in TAP block
47931664|NCT03304444|DRUG|liposomal bupivacaine|liposomal bupivacaine used in TAP block
47931665|NCT02616601|DRUG|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
47931666|NCT02616601|DRUG|Carac® (Fluorouracil) Cream|Topical cream, brand product.
47931667|NCT02616601|DRUG|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
47931668|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.5km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
47931669|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 0.8km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
48454459|NCT03167437|DRUG|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
48454460|NCT03167437|DRUG|Ustekinumab|Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
48454461|NCT00573313|DRUG|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
48454462|NCT00573313|DRUG|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
48454463|NCT02570828|DEVICE|Thermal Imaging|FLIR ONE attachment to an iPhone
47931670|NCT04909151|DEVICE|Robot-assisted gait training (walking speed: 1.1km/h)|Robot-assisted gait training RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
47931671|NCT01176942|DIETARY_SUPPLEMENT|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
47931672|NCT03381742|DRUG|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
48280202|NCT06656624|DRUG|Ribociclib combined with AI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
48454464|NCT05418374|PROCEDURE|Continous Spinal Anestheisa|Continuous spinal anesthesia (CSA) describes subarachnoid blockade maintained by local anesthetics administered through an indwelling spinal catheter. CSA provides fewer episodes of hypotension and no severe hypotension versus single dose bupivacaine also it offers the ability to titrate the dose of local anesthetics needed while maintaining hemodynamic stability.
48454465|NCT04518072|OTHER|Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)|assessed biomarker in clinical samples
48454466|NCT05114512|OTHER|RAPTOR protocol: hybrid in-person + telehealth physical therapy services|All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program.
48454467|NCT01197391|BIOLOGICAL|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
48454468|NCT02458664|GENETIC|Genetic analysis on tumor kept in tumor bank|
48454469|NCT06162572|DRUG|S095018|Via IV infusion on Day 1 of each 21-day cycle
48454470|NCT06162572|DRUG|S095024|Via IV infusion on Day 1 of each 21-day cycle
48454471|NCT06162572|DRUG|S095029|Via IV infusion on Day 1 of each 21-day cycle
48454472|NCT06162572|DRUG|S095018 Recommended Dose Expansion (RDE)|Via IV infusion on Day 1 of each 21-day cycle
48454473|NCT06162572|DRUG|S095024 RDE|Via IV infusion on Day 1 of each 21-day cycle
48454474|NCT06162572|DRUG|S095029 RDE|Via IV infusion on Day 1 of each 21-day cycle
48454475|NCT06162572|DRUG|Cemiplimab|350 mg via IV infusion on Day 1 of each 21-day cycle
48454476|NCT04005690|DRUG|Cobimetinib|Given PO
48454477|NCT04005690|DRUG|Olaparib|Given PO
48454478|NCT04005690|DRUG|Onvansertib|Given PO
48454479|NCT04005690|DRUG|Azenosertib|Given PO
48454480|NCT04005690|DRUG|Saruparib|Given PO
48454481|NCT04005690|BIOLOGICAL|Tremelimumab|Given IV
47931673|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
47931674|NCT03381742|DRUG|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
47931675|NCT03381742|DRUG|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
47931676|NCT02029690|DRUG|ADI-PEG 20|
47931677|NCT00830869|DRUG|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
48454482|NCT05539157|DRUG|JCXH-211|JCXH-211 administered once every 28 days
48454483|NCT06627530|DRUG|Darolutamide Oral Tablet|darolutamide 600 mg PO BID for 24 weeks
48454484|NCT06627530|DRUG|leuprorelin|leuprorelin depot 22.5 mg SC every 12 weeks
48454485|NCT03609762|BEHAVIORAL|EQ-5D-5L HRQOL results be available to the attending doctor|all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
48454486|NCT06619184|PROCEDURE|NCEHFORSCS transplantation|One vitiligo lesion of participans treated with NCEHFORSCS transplantation including follicle unit extraction (FUE) procedure from the occipital area, laboratory procedure for preparation of cell suspension, and transplantation of NCEHFORSCS.
47931678|NCT01466543|DRUG|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
48454487|NCT06619184|PROCEDURE|MPG procedure|"Another vitiligo lesion treated with MPG procedure~Follow up The dressing was removed by the researcher on day 8 The participants were asked to attend for follow-up at the clinic on week 2, 4, 8, 12, and 16 after the two procedure were done.~At 2, 4, 8, 12 and 16 weeks of follow-up visits, any possible complications were evaluated and digital photographs of the lesions were taken for evaluating the two procedure efficacy using its parameter: appearance of repigmentation (AOR), total number of repigmentation NSV lesions, extent area of repigmentation, and color match"
48454488|NCT01366963|BEHAVIORAL|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 \& 7 (visual search and attention processes) Trails A \& B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
48454489|NCT01366963|BEHAVIORAL|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
47931679|NCT01466543|DRUG|Placebo|Placebo
47931680|NCT05990621|BIOLOGICAL|Anti-CD70 CAR-T cells|0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
47931681|NCT02484859|DRUG|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
47931682|NCT02484859|DRUG|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
48454490|NCT01366963|BEHAVIORAL|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
48454491|NCT05646823|DIETARY_SUPPLEMENT|Probiotic blend|Bifidobacterium longum CCT 1934; Bifidobacterium lactis CCT 7858; Lactobacillus rhamnosus CCT 7863; Streptococcus thermophilus ATCC 19258) Final concentration: 1 x 10e10 CFU/ day
48454492|NCT05646823|DIETARY_SUPPLEMENT|Placebo|vehicle only - Maltodextrin gluten free
47931683|NCT02484859|DRUG|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
47931684|NCT06364293|OTHER|Observational design does not include interventional behavior.|Observational design does not include interventional behavior.
47931685|NCT01895361|DRUG|SelG1|
47931686|NCT01895361|DRUG|Placebo|
47931687|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
47931688|NCT00695201|DRUG|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
47931689|NCT00829985|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
47931690|NCT00829985|BIOLOGICAL|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
47931691|NCT00817479|DRUG|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
47931692|NCT00817479|DRUG|Placebo|Placebo saline
47931693|NCT06324916|RADIATION|Xray|X rays for ankle to see distal fibular remenant
47931694|NCT02218476|DRUG|CoQ10|
47931695|NCT02218476|DRUG|Placebo|
48454493|NCT02236858|DEVICE|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
47931696|NCT01834859|BEHAVIORAL|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
47931697|NCT01834859|BEHAVIORAL|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
48280203|NCT06656624|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS|Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
47931698|NCT00965328|PROCEDURE|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
47931699|NCT00965328|PROCEDURE|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
47931700|NCT06402994|OTHER|Electrophysiological experiment|Neural envelope tracking to conversational speech at different intensities
47931701|NCT06402994|BEHAVIORAL|Speech audiometry|Speech perception assessment at different intensities
47931702|NCT00877773|DRUG|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
47931703|NCT03671590|DRUG|TG-1701|Oral daily dose
48280204|NCT01747902|PROCEDURE|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
48622514|NCT03395964|PROCEDURE|Hybrid Dyna-CT guided localization|We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
47931704|NCT03671590|DRUG|Umbralisib|Oral Daily Dose
48280205|NCT01747902|PROCEDURE|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
48280207|NCT00300027|DRUG|BMS-582664|
48280208|NCT04314687|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
48280209|NCT04314687|BIOLOGICAL|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
47931705|NCT03671590|BIOLOGICAL|Ublituximab|IV infusion
47931706|NCT02370576|OTHER|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application"
47931707|NCT03433339|DEVICE|Active transcutaneous spinal direct current stimulation|Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
47931708|NCT03433339|DEVICE|Sham transcutaneous spinal direct current stimulation|Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
47931709|NCT00005566|BEHAVIORAL|Desperation Scale|
47931710|NCT05301712|DRUG|Naloxone hydrochloride 5.0mg/5ml|"* Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg"
47931711|NCT05301712|DRUG|Sodium Chloride 45mg/5ml|"* Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml"
47931712|NCT04370483|DRUG|Leflunomide|Gievn PO
47931713|NCT04370483|OTHER|Quality-of-Life Assessment|Ancillary studies
48280210|NCT04314687|OTHER|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
48280211|NCT06056427|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive autologous HB-adMSCs through intravenous infusion only, with a treatment duration of 18 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1 and infusion 2, and 4 weeks between the remaining infusions.
48280212|NCT02475200|DEVICE|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
48280213|NCT01841619|DRUG|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
48280214|NCT03628157|OTHER|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
48454494|NCT02236858|DEVICE|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
48454495|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Rockwood Clinical Frailty Scale
48454496|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Frail NonDisabled Questionnaire (FiND)
48454497|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Clinician's subjective 'end-of-bed' test
48454498|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Healthcare Improvement Scotland FRAIL Scale
48454499|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|11-item modified Frailty Index (mFI-11)
48454500|NCT03423654|OTHER|Spatial Training|Spatial Training using a 5x5 grid
48454501|NCT03423654|OTHER|Letter number matching|Letter number matching
48454502|NCT05275881|DEVICE|Virtual Reality|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.
48454503|NCT05275881|DRUG|Usual Practices|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
48454504|NCT05100212|BIOLOGICAL|cord blood-RBC concentrates|Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 31 weeks of postmenstrual age (31+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).
48454505|NCT05100212|BIOLOGICAL|adult donor RBC concentrates|Patients in the comparator arm are candidates to receive adult donor-RBC units
48454506|NCT05535868|OTHER|SPN3 innoculation|Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
48454507|NCT00835614|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
48454508|NCT00835614|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
47931714|NCT00075439|DRUG|gefitinib|Given orally
47931715|NCT00075439|OTHER|laboratory biomarker analysis|Correlative studies
47931716|NCT02873585|DEVICE|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
47931717|NCT02873585|DEVICE|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
47931718|NCT02816164|DRUG|Neupogen|Subcutaneous injections
47931719|NCT05648656|DRUG|TXA Nebulization|Nebulization with TXA 500mg/ 5mL 8 hourly for 2 days plus standard care of therapy
47931720|NCT05648656|OTHER|0.9% NS Nebulization|Nebulization with 0.9% normal saline (NS) 5mL 8 hourly for 2 days plus standard care of therapy
47931721|NCT05238571|PROCEDURE|Re-surgery|Re-surgery with meshectomy and selective neurectomy
47931722|NCT02179138|DRUG|TFV 1% gel|
47931723|NCT00625703|DRUG|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
47931724|NCT00251004|DRUG|Everolimus|oral, bis in diem/twice a day (bid)
47931725|NCT00251004|DRUG|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
47931726|NCT00251004|DRUG|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
47931727|NCT00251004|DRUG|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
47931728|NCT00251004|DRUG|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
47931729|NCT04991818|OTHER|OneBiome microbiome profiling service|participants will be asked to complete the user experience of the OneBiome service
47931730|NCT06506305|DRUG|FB1001|Intravitreal (IVT) injection
47931731|NCT04397666|DIAGNOSTIC_TEST|conjunctival RT PCR|conjunctival sample in covid-19 patients
47931732|NCT05210764|DRUG|propofol|General anesthesia is induced and maintained mainly with propofol.
48454509|NCT05512650|DEVICE|Virtual Reality Meditation|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
47931733|NCT05210764|DRUG|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
47931734|NCT05210764|DRUG|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
47931735|NCT00865488|BIOLOGICAL|ADHEXIL|Adhesions prevention
48454510|NCT05512650|DEVICE|Non-VR Meditation|Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
47931736|NCT01275339|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
47931737|NCT01275339|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
47931738|NCT06468384|PROCEDURE|thoracic erector spinae plane (ESP) block|The thoracic erector spinae plane (ESP) block is a regional anesthesia technique used for pain management in complex regional pain syndrome. This procedure involves injecting 20 ml of 0.25% bupivacaine into the deep layers of the erector spinae muscles. The patient is positioned appropriately, and the injection site is identified using anatomical landmarks and ultrasound guidance, at the T2 level. A needle is then inserted perpendicularly until it contacts the transverse process, at which point the local anesthetic is administered. The primary objective is to provide significant pain relief.
47931739|NCT05860101|OTHER|Compassion-Focused Therapy|Compassion Focused Therapy (CFT) is based on the premise that we have three emotion regulation systems, the threat, drive and soothing systems. It has been suggested that our psychological wellbeing is dependent on maintaining a balance between these three systems, and if we lose this balance, e.g. the threat or drive systems become more dominant, then we start to experience emotional difficulties (Gilbert, 2009). In this study, participants are given various exercises to develop their soothing system, and help them to balance overactive threat.
47931742|NCT03239561|DRUG|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
47931743|NCT02960776|BEHAVIORAL|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
47931744|NCT03443947|DEVICE|Tongue depressor group|using a tongue depressor to assess airway score without tongue protrusion
48622515|NCT03395964|PROCEDURE|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
47931745|NCT03443947|PROCEDURE|control group|airway assessment after tongue protrusion
47931746|NCT04047797|DRUG|Ixazomib|Given by mouth
47931747|NCT04047797|DRUG|Ixazomib Citrate|Given by mouth
47931748|NCT04047797|BIOLOGICAL|Rituximab|Given Intravenous
47931749|NCT05404360|DEVICE|BrainsWay Deep TMS HAC/H7-Coil|The BrainsWay HAC/H7-Coil Deep TMS System is composed of four main components: an electromagnetic H7/HAC-Coil, TMS stimulator, cooling system and positioning arm.
47931750|NCT05404360|DEVICE|BrainsWay Deep TMS Sham Coil|"The experimental system has two coils in the same helmet, a sham and active coil.~The sham coil has a similar acoustic artifact as the active coil and it administers a superficial stimulation to maintain blinding. The system assigns the active or sham coil based on the patient ID during the high frequency treatment."
47931751|NCT02541383|DRUG|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
48280215|NCT03882918|DRUG|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
47931752|NCT02541383|DRUG|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
48454511|NCT05614453|DRUG|Tislelizumab|Tislelizumab is an investigational, humanised-IgG4 monoclonal antibody with high affinity/binding specificity for PD-1. It is engineered to minimise binding to FcγR on macrophages to abrogate antibody-dependent cellular phagocytosis.
48454512|NCT05614453|DRUG|Sitravatinib|Sitravatinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential anti-neoplastic activity.
48454513|NCT04964973|DEVICE|Control|Post-surgical physiotherapeutic activity.
48454514|NCT04964973|DEVICE|Experimental|Post-surgical physiotherapeutic activity with the application of the technique
48454515|NCT04964973|DEVICE|Placebo|Post-surgical physiotherapeutic activity with the application of the non-activated technique
48454516|NCT05971056|OTHER|Care transition|Cancer care is transitioned to a satellite site.
48454517|NCT05971056|OTHER|No care transition|Cancer care is not transitioned to a satellite site.
48454518|NCT05492032|DEVICE|Active-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
48454519|NCT05492032|DEVICE|Sham-tDCS|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
48454520|NCT05492032|BEHAVIORAL|Cognitive training|Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
48454521|NCT06588738|DRUG|ESK-001|ESK-001
48622516|NCT06042075|OTHER|Questionnaire on congenital birthmarks|Questions will be put to health professionals on representation using a semi-quantitative questionnaire.
47931753|NCT02541383|DRUG|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
47931754|NCT01850927|PROCEDURE|Remote ischaemic preconditioning|
47931755|NCT01850927|PROCEDURE|Control|
48280216|NCT06023108|DEVICE|Orthokeratology|OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.
48280217|NCT06023108|DEVICE|Spectacles|Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
48454522|NCT06588738|DRUG|Placebo|Placebo
48454523|NCT06588738|DRUG|Apremilast|Apremilast
48454524|NCT02174926|PROCEDURE|Elective laparoscopic sigmoid resection|
48454525|NCT02174926|DIETARY_SUPPLEMENT|Conservative treatment|Written lifestyle guidance and fiber supplements
48454526|NCT06043388|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
48454527|NCT06043388|BIOLOGICAL|Placebo|Inoculate one dose, 0.5ml，Intramuscular injection into the deltoid muscle of the upper arm
48454528|NCT00221299|DRUG|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
48622517|NCT03315364|DRUG|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
48622518|NCT03315364|DRUG|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
47931756|NCT02542930|RADIATION|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
47931757|NCT02542930|DRUG|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
47931758|NCT05125185|OTHER|The Effectiveness of USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in Improving Insulin Adherence, Glycemic Control and Inflammation|To study the effect of counseling using USM-Insulin Adherence Module (U-IAM) for Type 2 Diabetes in improving Insulin Adherence, Glycemic Control and Inflammation
47931759|NCT01456910|BEHAVIORAL|Resistance Training Program|Frequency, volume, repetitions, load, interval
47931760|NCT01536275|OTHER|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
47931761|NCT02315443|DRUG|Nerinetide (NA-1)|
47931762|NCT02315443|DRUG|Placebo|
48280218|NCT06208488|DRUG|Gefurulimab PFS-SD|Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
48454529|NCT00221299|DRUG|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
48454530|NCT02476045|DRUG|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
48454531|NCT02476045|DRUG|panitumumab|Maintenance treatment (ARM B)
48454532|NCT02476045|DRUG|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
48454533|NCT05281120|DEVICE|Low-level mechanical vibrations WITH vertical sinusoidal acceleration|Small platform designed to induce vertical, sinusoidal acceleration.
48454534|NCT05281120|DEVICE|Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration|Small platform designed to NOT induce vertical, sinusoidal acceleration
48454535|NCT04018404|OTHER|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
48454536|NCT05323981|DRUG|HS627(210mg/7ml)|Intravenous drip of 420mg HS627
48454537|NCT05323981|DRUG|HS627(420mg/14ml)|Intravenous drip of 420mg HS627
48454538|NCT05323981|DRUG|Perjeta|Intravenous drip of 420mg PERJETA
48454539|NCT05496868|DRUG|Reparixin 600mg|Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days
48454540|NCT05496868|OTHER|Matching Placebo|"Placebo tablets. Administered crushed through nasogastric tube with the same schedule as reparixin as add-on to the standard of care. After extubation and if the patient can swallow placebo may be administered orally.~Total duration of the treatment: 14 days"
48454541|NCT04387786|DRUG|Dornase Alfa|nebulized in-line endotracheal dornase alfa co-administered with albuterol
48454542|NCT04681391|DEVICE|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
48454543|NCT00253305|DRUG|Organogel of naftifine, 2%|
48454544|NCT00253305|DRUG|Organogel of terbinafine, 2%|
48454545|NCT00253305|DRUG|Organogel of naftifine, 6%|
48454546|NCT00253305|DRUG|Organogel of terbinafine, 6%|
48454547|NCT03612154|DRUG|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
48454548|NCT04716582|BEHAVIORAL|Sitting interrupted by light physical activity|Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
48454549|NCT04716582|BEHAVIORAL|Sitting with cognitive task|Participants will perform online cognitive task during prolonged sitting.
48454550|NCT04716582|BEHAVIORAL|uninterrupted sitting|Participants will watch documentary during prolonged sitting.
48454551|NCT05509023|DRUG|ADX-914|Subcutaneous administration of ADX-914
48454552|NCT05509023|DRUG|Placebo|Subcutaneous administration of Placebo
48454553|NCT05590039|DEVICE|MyEllevate Procedure|"The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline."
48454554|NCT00868660|DRUG|ZP1848|sc. bolus
48454555|NCT01828203|DRUG|Minocycline|
48454556|NCT01828203|DRUG|Placebo|
48454557|NCT01828203|PROCEDURE|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
48454558|NCT01828203|PROCEDURE|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
48454559|NCT06060834|DIETARY_SUPPLEMENT|Topical Botanical Agent|Cayenne Pepper, Coconut Water, Kelp, Lemon Juice, Oxynex LM, Potassium Sorbate, Red Palm Oil, Rose Water, Saw Palmetto, vitamin C
48454560|NCT00003035|BIOLOGICAL|filgrastim|
48454561|NCT00003035|DRUG|doxorubicin hydrochloride|
48454562|NCT00003035|DRUG|paclitaxel|
47931763|NCT02397564|DEVICE|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
47931764|NCT01622283|DRUG|Levocetirizine|Levocetirizine
47931765|NCT01622283|DRUG|Cetirizine|Cetirizine
48280219|NCT06208488|DRUG|Gefurulimab AI|Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
48280220|NCT06559436|DRUG|Intravenous thrombolysis|Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,
48280221|NCT06559436|OTHER|Standard medical management|Standard medical management
48454563|NCT00003035|DRUG|tamoxifen citrate|
48454564|NCT00003035|PROCEDURE|surgical procedure|
48454565|NCT00003035|RADIATION|radiation therapy|
48454566|NCT01853722|DRUG|DCN01|Three serial applications per periocular region.
48454567|NCT01853722|DRUG|Unisol|Three serial applications per periocular region.
48454568|NCT02394860|OTHER|echo Doppler lower limbs|
48454569|NCT04223791|DRUG|DOR/ISL|100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily
48454570|NCT04223791|DRUG|BIC/FTC/TAF|50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
48454571|NCT04223791|DRUG|Placebo to BIC/FTC/TAF|Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
48454572|NCT04223791|DRUG|Placebo to FDC DOR/ISL|Placebo to FDC DOR/ISL in a tablet taken orally, once daily
48454573|NCT05721794|OTHER|A multicentric prospective observational longitudinal cohort study.|Observational study on the accuracy of TPUS and MRI in the investigation of perianal fistulae in CD patients.
48454574|NCT00227370|DRUG|valganciclovir|valgan 900mg QD x 9 months post lung transplant
48454575|NCT00227370|OTHER|Placebo|
48454576|NCT00170729|DRUG|Prednisolone acetate|
47931766|NCT01523470|DEVICE|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
47931767|NCT04578080|DEVICE|Transcranial direct current stimulation|Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
47931768|NCT02655146|DRUG|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
47931769|NCT02655146|DRUG|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
47931770|NCT02655146|DRUG|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
48454577|NCT02483195|DRUG|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
48454578|NCT02483195|DRUG|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
48454579|NCT02483195|DRUG|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
48454580|NCT02483195|OTHER|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
48454581|NCT02197195|DIETARY_SUPPLEMENT|Chocolate Milk|
48622519|NCT04585594|BEHAVIORAL|Mi Propio Camino (MPC)|The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.
47931771|NCT02655146|DRUG|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
47931772|NCT00966784|OTHER|Dietary Fibers|
48454582|NCT02197195|DIETARY_SUPPLEMENT|Fruit Drink|
47931773|NCT02282345|OTHER|Laboratory Biomarker Analysis|Correlative studies
48280222|NCT05095935|OTHER|N/A observational registry|N/A observational registry
48280223|NCT00488631|BIOLOGICAL|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
48454583|NCT02197195|BEHAVIORAL|Exercise|
47931774|NCT02282345|DRUG|Talazoparib|Given PO
47931775|NCT03558412|COMBINATION_PRODUCT|CODOX-M/IVAC|Given ivgtt
47931776|NCT03558412|DRUG|Decitabine|Given ivgtt
48280224|NCT00488631|BIOLOGICAL|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
48280225|NCT00488631|BIOLOGICAL|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
48280226|NCT00488631|BIOLOGICAL|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
48454584|NCT00265681|BEHAVIORAL|Phone counseling and written materials|
48454585|NCT02729090|OTHER|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
48454586|NCT02729090|OTHER|Device: treadmill Train_Comb_aerobic|Device: treadmill Train_Comb_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train_Comb_aerobic
48454587|NCT04806763|DEVICE|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
48454588|NCT04806763|DEVICE|Control|Distance, single-vision glasses were used as control
48454589|NCT01769898|DRUG|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
48454590|NCT01769898|DRUG|Theophylline|Theophylline 0.1 Q12H
48454591|NCT01769898|DRUG|Placebo|Placebo for theophylline 0.1 Q12H
48454592|NCT04794816|OTHER|Questionnaire Administration|Complete questionnaire
48454593|NCT04882241|BIOLOGICAL|Pembrolizumab|IV infusion
48454594|NCT04882241|DRUG|Placebo|IV infusion
48454595|NCT04882241|DRUG|Cisplatin|IV infusion
48454596|NCT04882241|DRUG|Capecitabine|Oral tablets
47931777|NCT02176720|DRUG|FDOPA PET|\[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
47931778|NCT00734760|BEHAVIORAL|education|face-to-face education and counseling intervention
47931779|NCT02596282|PROCEDURE|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
47931780|NCT04494022|DIAGNOSTIC_TEST|contrast enhanced ultrasound|Perflubutane enhanced ultrasound for evaluating hepatic tumor
47931781|NCT00240474|DRUG|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
47931782|NCT00240474|DRUG|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
47931783|NCT00677430|BEHAVIORAL|Questionnaire|A brief questionnaire packet will be completed.
47931784|NCT00677430|PROCEDURE|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
47931785|NCT00241501|DRUG|Esomeprazole (Nexium)|
47931786|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
47931787|NCT01501045|DEVICE|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
47931788|NCT05058495|OTHER|Mobile Lymphedema Self-Care Support Program|The Mobile Lymphedema Self-Care Support Program is composed of three section. First section includes the information about lymphedema and lymphedema self care. Second section includes the exercises videos which women can concurrently exercise with application and an alarm to remind to exercise. Last section is a social network form the women could chat and share anything with eachother. Patients will be told how to use the Mobile Lymphedema Self-Care Support Program and a contact number will be provided to ask questions about the program at any time.
48098578|NCT05224362|DEVICE|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability.|A repeated measures acute study using using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. Bertec force plate analysis will be performed to assess the acute effects on balance and stability. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/ dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
48454597|NCT04882241|DRUG|5-fluorouracil|IV infusion
48098579|NCT06245109|DRUG|Duloxetine|60 mg, oral
48098580|NCT06245109|DRUG|Celecoxib|200 mg, oral
48098581|NCT06245109|DRUG|Placebo|Matching placebo, oral
48454598|NCT04882241|DRUG|Docetaxel|IV infusion
48454599|NCT04882241|DRUG|Oxaliplatin|IV infusion
48454600|NCT04882241|DRUG|Leucovorin|IV infusion
47931789|NCT05058495|OTHER|standart lymphedema education|The control group will receive standard lymphedema education. The standard lymphedema education is an online education composed of information about lymphedema and lymphedema self-care.
47931790|NCT01106469|DRUG|JNJ-41443532|25mg tablet once daily
47931791|NCT01106469|DRUG|JNJ-41443532|250mg tablet once daily
47931792|NCT01106469|DRUG|JNJ-41443532|1500mg once daily (with 250mg tablets)
47931793|NCT01106469|DRUG|JNJ-41443532|100mg tablet once daily
47931794|NCT01106469|DRUG|JNJ-41443532|1000mg once daily (with 250mg tablets)
48098582|NCT00938340|DIETARY_SUPPLEMENT|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
48098583|NCT00938340|DIETARY_SUPPLEMENT|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
48098584|NCT00938340|DIETARY_SUPPLEMENT|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
48280227|NCT06368947|BEHAVIORAL|Therapeutic Play|Therapeutic play sessions will be organized twice a week for 4 weeks during chemotherapy treatment for children diagnosed with acute lymphoblastic leukemia in the intervention group.
48454601|NCT05027503|OTHER|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
48454602|NCT05027503|OTHER|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
48454603|NCT04242823|DIAGNOSTIC_TEST|Automated visual evaluation|Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
47931795|NCT01106469|DRUG|Placebo|Matching placebo
47931796|NCT01106469|DRUG|JNJ-41443532|500mg once daily (with 250mg tablets)
48454604|NCT01874535|DRUG|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
47931797|NCT05329571|BEHAVIORAL|Low-FODMAP diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
47931798|NCT05329571|BEHAVIORAL|Gluten-free Diet|Participants will be instructed to maintain their usual diet, while eliminating all dietary gluten.
47931799|NCT05329571|BEHAVIORAL|Control group|Patients of this group will have dietary consultation but will not change their regular diet for the period of the study.
47931800|NCT05179551|PROCEDURE|Proximal Medial Gastrocnemius Recession|. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied
47931801|NCT02208778|DRUG|Duloxetine|54 participants will be allocated for duloxetine treatment
47931802|NCT02208778|DRUG|Remifentanil|27 participants will be allocated to Remifentanil infusion
47931803|NCT02208778|DRUG|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
47931804|NCT02208778|DRUG|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
47931805|NCT03504943|OTHER|Early Intradialytic Exercise|Timing of intradialytic exercise first half of HD
47931806|NCT03504943|OTHER|Late Intradialytic Exercise|Timing of intradialytic exercise second half of HD
47931807|NCT00539201|DRUG|GSK706769|
47931808|NCT03631108|DIAGNOSTIC_TEST|OCTA (ZEISS)|All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
47931809|NCT02636140|OTHER|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
47931810|NCT04046588|DIAGNOSTIC_TEST|Infrared thermography|A thermal imager (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) will be used to record thermal images. The temperature of corresponding sites on the Heart and Lung meridians will be analyzed.
47931811|NCT04046588|PROCEDURE|Moxibustion|"Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian, respectivey. During moxibustion, the temperature change of relevant sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~1. Intervention in the Heart meridian: moxibustion will be performed above the acupoint HT3 of the Heart meridian~2. Intervention in the Lung meridian: moxibustion will be performed above the acupoint LU5 of the Lung meridian."
47931812|NCT00590837|DRUG|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
48280228|NCT02688413|DEVICE|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
48454605|NCT05169710|DRUG|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg Tablet (supplied in one 200mg tablet and one placebo tablet)
48454606|NCT05169710|DRUG|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg tablet (supplied in two 200mg tablets)
48454607|NCT05169710|DRUG|Placebo|Placebo tablet (supplied in two tablets)
47931813|NCT04615585|OTHER|Aloe vera after SRP|Subgingival administration of Aloe vera gel was preceded by flushing the area with saline to wash away any debris. Aloe vera (1cc) gel was applied subgingivally using atraumatic needle. Patients were instructed not to rinse or drink any liquid for at least 30 minutes. The application was performed at baseline and after 1 and 2 weeks.
48454608|NCT06622330|OTHER|Positioning|Children in the experimental group were given 30 minutes of wrapping and 30 minutes of fetal position after aspiration.
48454609|NCT04996316|OTHER|Electronic Health Record Review|Health record reviewed
47931814|NCT04615585|PROCEDURE|Scaling and root planing (SRP)|Removal of supragingival and sub-gingival calculus and debris was performed, followed by smoothing root surfaces and removing cementum or dentine that is impregnated with calculus and toxins.
47931815|NCT05996991|OTHER|Positive expectation speech regarding spinal manipulative therapy|Patients will watch a short video with positive expectations regarding spinal manipulative therapy.
47931816|NCT05996991|OTHER|Neutral expectation speech regarding spinal manipulative therapy|Patients will watch a short video with neutral expectations regarding spinal manipulative therapy.
47931817|NCT05996991|OTHER|Negative expectation speech regarding spinal manipulative therapy|Patients will watch a short video with negative expectations regarding spinal manipulative therapy.
48098585|NCT00938340|DIETARY_SUPPLEMENT|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
48098586|NCT02688972|OTHER|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
48454610|NCT04996316|OTHER|Interview|Participate in interview
48454611|NCT04996316|OTHER|Media Intervention|Use MammoScreen
48454612|NCT04996316|OTHER|Survey Administration|Complete survey
48454613|NCT04996316|OTHER|Training and Education|Undergo training
48454614|NCT00540995|DRUG|busulfan|Given IV
48454615|NCT00540995|DRUG|etoposide|Given IV
48454616|NCT00540995|RADIATION|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
48454617|NCT00540995|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
48454618|NCT00540995|PROCEDURE|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
48454619|NCT00540995|PROCEDURE|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
48454620|NCT00540995|RADIATION|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
48454621|NCT06628063|OTHER|ultrasound evaluation|Ultrasound scan of fetus in second and third trimestrers
48454622|NCT03168659|DEVICE|HeartLight|HeartLight Endoscopic Ablation System
48454623|NCT03168659|PROCEDURE|Ablation|Pulmonary vein isolation ablation
48454624|NCT01196390|DRUG|Carboplatin|Given IV
48454625|NCT01196390|OTHER|Laboratory Biomarker Analysis|Correlative studies
48454626|NCT01196390|DRUG|Paclitaxel|Given IV
48454627|NCT01196390|OTHER|Quality-of-Life Assessment|Ancillary studies
48454628|NCT01196390|RADIATION|Radiation Therapy|Undergo radiation therapy
48454629|NCT01196390|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48454630|NCT01196390|BIOLOGICAL|Trastuzumab|Given IV
48454631|NCT01934205|DRUG|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
48454632|NCT01934205|DRUG|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
48454633|NCT04762966|DRUG|Metformin|Level of Metformin blood concentration
48454634|NCT03637764|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48454635|NCT03637764|DRUG|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48280229|NCT02688413|OTHER|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
48454636|NCT00196963|BIOLOGICAL|Meningococcal (vaccine)|
48454637|NCT04674072|OTHER|Reverse Nordic curl exercise|The reverse Nordic curl is a body-weight exercise which mainly works the quadriceps and hip flexors. It has a large eccentric component, meaning the muscles are working whilst lengthening.
48454638|NCT04674072|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
48454639|NCT01342939|OTHER|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
48454640|NCT01342939|OTHER|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
48454641|NCT01342939|DIETARY_SUPPLEMENT|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
48454642|NCT01342939|OTHER|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
48454643|NCT01342939|OTHER|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
48454644|NCT02179294|DRUG|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
48454645|NCT02179294|DRUG|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
48454646|NCT06558240|DEVICE|HERADERM Hydrogel Wound Dressing (Sterile)|HERADERM Hydrogel Wound Dressing (Sterile) is a transparent, composite hydrogel dressing. The outer layer is a waterproof and breathable polyurethane film (PU film), which can prevent external bacterial invasion and reduce the risk of infection. The inner layer is A+ polymer hydrogel, which can keep the wound bed in a moist state and reduce the infiltration problem caused by wound exudate.
48098587|NCT02688972|OTHER|Control group|The volunteers stayed in rest about 10 minutes
48098588|NCT03230591|OTHER|Echocardiography|LV vortex flow in Echocardiography
48280230|NCT02432807|DRUG|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
48280231|NCT02432807|DRUG|Placebo|Placebo
48280232|NCT03584009|DRUG|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
48454647|NCT05968638|OTHER|Regular Diet|Regular Diet
48454648|NCT05968638|OTHER|Ketogenic Diet|Ketogenic Diet
48454649|NCT01055795|DRUG|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds"
48454650|NCT05723250|OTHER|Table-based Educational Intervention|Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.
48454651|NCT03621995|OTHER|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
47931818|NCT05996991|PROCEDURE|Spinal Manipulative Therapy|One session of Spinal Manipulative Therapy. The researcher will administer a posterior and inferior push on the opposite anterior superior iliac spine (ASIS) while passively rotating the subject on the side to be manipulated. The spinal manipulations will be repeated four times during a 5-minute period, with impulses oscillating between the right and left ASIS. In addition, we will administrate mobilizations (anterior-posterior central mobilization), applied for 1 minute in each lumbar vertebra (from L5 to L1), using grade I joint mobilization (patients positioned in the ventral decubitus position).
47931819|NCT02324127|DEVICE|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
47931820|NCT02487342|OTHER|milk|small serving (217 mL) of british semi-skimmed milk
47931821|NCT02487342|OTHER|orange fruit-juice|small serving (217 mL) of orange juice
47931822|NCT04841473|OTHER|TRAIN Concussion Education|Participants will receive the TRAIN concussion education module.
48454652|NCT06627062|PROCEDURE|moderate and severe subluxated lens extraction|A double-strand polypropylene suture (9-0 or 8-0) was looped and tied to one end of the preloaded CTR, which was then implanted into the capsular bag. The needle was inserted through the main incision, traversed the anterior chamber, under the posterior iris, and exited 2.0 mm behind the limbus at the central zonular weakness. The CTR was secured to the sclera using the knotless Z-suture technique to center the capsular bag, allowing safe insertion of the intraocular lens (IOL).
47931823|NCT04841473|OTHER|Standard Concussion Education|Participants will receive a standard concussion education module.
48454653|NCT05845723|DRUG|tocilizumab|Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
48454654|NCT05845723|DRUG|tofacitinib|Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
47931824|NCT02586883|OTHER|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
48454655|NCT05845723|DRUG|cyclophosphamide|Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
48454656|NCT02538627|DRUG|MM-151|MM-151
47931825|NCT01000038|OTHER|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
47931826|NCT01000038|OTHER|Walking|Half hour daily, five days a week for 8 weeks
48454657|NCT02538627|DRUG|MM-121|MM-121
48454658|NCT02538627|DRUG|MM-141|MM-141
48454659|NCT02538627|DRUG|trametinib|trametininb
48454660|NCT03922490|DEVICE|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
48454661|NCT03922490|PROCEDURE|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
48454662|NCT06627387|OTHER|Balance Training Using Augmented Reality|"The intervention will be carried out in two phases. The first phase will take place at Vall d\&amp;#39;Hebron Hospital, where patients will undergo balance training under the supervision of a physiotherapist. The scheduled dose will be 60 minutes daily, three days a week for four weeks. If the patients meet the inclusion criteria, the intervention will be extended for two more weeks at home. For this task, the involvement of a family member as a training partner will be essential. Relatives will receive training on using the system in the hospital and must be present whenever the patient undergoes the training at home. Three assessments will be carried out during the six weeks of the study. At the beginning of the intervention (Day 0 ), a second is once the hospital intervention has been carried out (Week 4 ), and the last is once the home intervention has been carried out (Week 6)."
48454663|NCT02261389|OTHER|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
48454664|NCT06627686|DIAGNOSTIC_TEST|Air way occlusion pressure|Predictive Value of Airway Occlusion Pressure, Maximal Inspiratory Pressure and Their Ratio for Successful Extubation in Patients with Traumatic Brain Injury
48454665|NCT05294276|OTHER|no intervention related|no intervention related
48454666|NCT00513253|DRUG|lapatinib|
48454667|NCT06627647|DRUG|Rilvegostomig|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
48454668|NCT06627647|DRUG|Pembrolizumab|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
47931827|NCT05565417|DRUG|IMT-009|Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
47931828|NCT05565417|COMBINATION_PRODUCT|Fruquintinib|Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).
48454669|NCT06627647|DRUG|Carboplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
48454670|NCT06627647|DRUG|Cisplatin|Administered as one intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
48454671|NCT06627647|DRUG|Pemetrexed|Administered as one intravenously (IV) on Day 1 of each 21-day cycle
47931829|NCT03833518|OTHER|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
47931830|NCT03833518|OTHER|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
47931831|NCT03833518|OTHER|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
47931832|NCT02802670|DRUG|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
47931833|NCT00829283|BEHAVIORAL|Behavioral Weight Loss|weekly individual sessions for 6 months
47931834|NCT00829283|BEHAVIORAL|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
47931835|NCT00829283|DRUG|Placebo|One pill daily
48098589|NCT04262414|DEVICE|Functional Electrical Stimulation|"The device used was a prototype closed-loop FES system to improve standing balance by activating the ankle plantar flexors and dorsiflexors (i.e. A-FES system). As a closed-loop system, the body's position and velocity are continually monitored, and the level of stimulation adjusted accordingly on a moment-to-moment basis. This differs from currently available FES units, which do not monitor body movement and therefore, provide a constant level of stimulation unless manually adjusted by the user/PT. The control strategy used in the A-FES system mimics the physiological control system in able-bodied people, meaning it has the potential to re-educate normal movement patterns."
48454672|NCT02728999|PROCEDURE|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
48454673|NCT02728999|PROCEDURE|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
48454674|NCT03090321|BEHAVIORAL|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
48454675|NCT03090321|BEHAVIORAL|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
48454676|NCT03090321|BEHAVIORAL|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
48454677|NCT03090321|BEHAVIORAL|Read AHA website|Daily reminder to read the newsfeed from the American Heart Association (AHA) website, this is a control arm
48454678|NCT06550661|BEHAVIORAL|Ba duan jin|a kind of exercise
48454679|NCT05069571|OTHER|Endoangel|Collecting the colonoscopy videos and analyzing the correlation between withdrawal overspeed proportion and adenoma detection rate.
48454680|NCT05569291|DEVICE|Automated Coaching Program (ACP)|A semiautomated tele coaching program (application installed on a smartphone device with real time feedback and motivational messages) and a step counter (Fitbit Charge 4) providing direct feedback on total daily number of steps, walking time, time in at least moderate PA and movement intensity during walking.
48454681|NCT05569291|OTHER|Manual Coaching Program (MCP)|A telecoaching program using a step counter (Fitbit Charge 4) without this custom smartphone application but with the Fitbit application. This intervention will be more focused on weekly personal feedback from a coach by telephone.
48454682|NCT03098485|DRUG|Levofloxacin|5 days of levofloxacin administration
48454683|NCT03098485|DRUG|Azithromycin|5 days of azithromycin administration
48454684|NCT03098485|DRUG|Cefpodoxime|5 days of cefpodoxime administration
48622520|NCT04585594|BEHAVIORAL|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
48622521|NCT04092764|DEVICE|Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.
48454685|NCT06628011|OTHER|Intervention group/training group|We will assess the short-term effects through a 12-week intervention, and its long-term effects after 1-year. Both the intervention group (IG) and control group (CG) will receive two sessions of aerobic interval training at the Exercise Training Clinic, situated at the Department of Psychosis and Rehabilitation, Psychiatry Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. One training session consists of 36 minutes of high intensity training (HIT).
48454686|NCT01602380|DRUG|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
48454687|NCT01602380|DRUG|arimidex 1mg|oral tablet 1 daily
48454688|NCT01602380|DRUG|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
48454689|NCT01602380|DRUG|arimidex dummy|oral tablet 1 daily
48454690|NCT05007067|DEVICE|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
48454691|NCT03345043|BIOLOGICAL|VAL-339851|Escalating dose levels
48454692|NCT03345043|OTHER|Placebo|Saline
48454693|NCT01958294|DEVICE|MICHI Neuroprotection System|
47931836|NCT00829283|DRUG|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
47931837|NCT04559529|DRUG|Levetiracetam (LEV) 500 mg|The levetiracetam pill will look just like the placebo pill.
47931838|NCT04559529|DRUG|Placebo|The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
47931839|NCT05148520|BEHAVIORAL|5A's model|"(1) Ask - ask youth smokers about their smoking habit, (2) Advise - advise youth smokers to quit smoking, (3) Assess - assess youth smokers about their willingness to quit smoking, (4) Assist - assist youth smokers who are willing to make a quit attempt, and (5) Arrange~- arrange for follow-up."
48454694|NCT00205777|DRUG|Bazedoxifene Acetate|BZA 20mg, daily, oral
48454695|NCT00205777|OTHER|Placebo|Placebo, daily, oral
47931840|NCT02702596|OTHER|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
48454696|NCT06406725|DIAGNOSTIC_TEST|Point-of-Care Ultrasound of the Airway|Patients who are recruited will have an ultrasound performed of their larynx while they are on noninvasive positive pressure ventilation and then a second ultrasound when they are removed from noninvasive positive pressure ventilation. Between the two ultrasounds, the otolaryngology team will perform their fiberoptic nasolaryngoscopy, as per standard unit protocol and patient care.
47931841|NCT02702596|BEHAVIORAL|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
47931842|NCT02702596|BEHAVIORAL|Standard Education|The the use of a pamphlet to educate people about depression.
47931843|NCT00911001|BEHAVIORAL|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
47931844|NCT00134784|DRUG|[123I]B-CIT SPECT imaging|To assess \[123I\]B-CIT SPECT imaging
47931845|NCT05413577|BEHAVIORAL|Mindfulness training|The intervention recordings taught the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording had the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
47931846|NCT01985854|DRUG|Propofol|
47931847|NCT01985854|DRUG|Desflurane|
47931848|NCT06123182|BEHAVIORAL|Episodic Future Thinking|During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.
47931849|NCT06123182|BEHAVIORAL|Episodic Recent Thinking|During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.
48106812|NCT06189391|DRUG|CN201|"In fixed dosing group, patients will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks, followed by 1 week off for 4 weeks as a treatment cycle.~Patients in step-up dosing group will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks (without treatment off week). Patients who complete 4 treatment cycles and remain in complete response (CR) or partial response (PR) may also be considered by the investigator for 2-weekly dosing (Q2W, window: -3 days, 4 weeks in a treatment cycle), which allows further comparative observation of the long-term efficacy and safety of Q2W. Treatment will be continued untill confirmed disease progression, intolerable toxicity, withdrawal of consent, patient being lost to follow-up, receipt of other antitumor therapy, death or study termination by sponsor, whichever occurs earlier, or up to 12 months in the absence of disease progression."
48280233|NCT03584009|DRUG|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
48280234|NCT01140087|PROCEDURE|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
48454697|NCT00840840|DRUG|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
48454698|NCT00840840|DRUG|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
48454699|NCT03586219|BEHAVIORAL|Opioid-specific educational patient pamphlets|See prior description
48280235|NCT02603523|BEHAVIORAL|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
48280236|NCT03290014|DIAGNOSTIC_TEST|polysomnography|Monitoring of brain activity and respiratory variables during sleep
48280237|NCT03290014|DIAGNOSTIC_TEST|Actigraphy|monitoring daily physical activity for 7 days
48280238|NCT03290014|DIAGNOSTIC_TEST|Osler test|Evaluation of subjects´ ability to remain awake
48454700|NCT05509309|BEHAVIORAL|APERS-based model|APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
48454701|NCT06068855|DRUG|BOTOX|Intramuscular Injections
47931850|NCT06123182|BEHAVIORAL|Positive Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.
47931851|NCT06123182|BEHAVIORAL|Neutral Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the physical sensations associated with an exercise bout.
47931852|NCT06123182|BEHAVIORAL|HIIT Exercise Intervention|"The high intensity interval training (HIIT) will be conducted 2 times per week for 6 weeks. The duration of each individual exercise session will last about 45 minutes. After the 5-minute warm-up at 30% peak workload, HIIT will consist of repeated 1-minute high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 80% of peak watts (range: 75%-85%) followed by the off interval at 10% of peak watts. The session will end with up to 10 minute cool-down at 20% peak workload."
47931853|NCT01723696|DIETARY_SUPPLEMENT|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
47931854|NCT01723696|DIETARY_SUPPLEMENT|Placebo tablet+prenatal vitamin|
47931855|NCT05632744|DEVICE|CG-100 Intraluminal Bypass Device|Subjects will be treated with the CG-100 Intraluminal Bypass Device
47931856|NCT02951676|PROCEDURE|Extraction|Extraction of impacted third molar teeth
48454702|NCT06068855|DRUG|Placebo|Intramuscular Injections
48454703|NCT04310345|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
48454704|NCT02273492|DRUG|Asasantin ER|
48454705|NCT02273492|OTHER|Standardized breakfast|
48622522|NCT04092764|DEVICE|NeuroMetrix|The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy
48622523|NCT04092764|DEVICE|Rydel-Seiffer tuning fork|The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
48622524|NCT03394573|OTHER|OCT guided treatment arm|Intravitreal injection of Aflibercept for DME OCT guided
48622525|NCT03394573|OTHER|VA guided treatment arm|Intravitreal injection of Aflibercept for DME VA guided
48622526|NCT00001956|PROCEDURE|Blood draw|
47931857|NCT01325792|DEVICE|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
47931858|NCT00212940|BEHAVIORAL|Supportive Therapy for Adherence to ART (behavior)|
47931859|NCT00860977|DRUG|valacyclovir|oral valacyclovir 500mg twice daily
47931860|NCT00860977|DRUG|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
47931861|NCT04597151|DIETARY_SUPPLEMENT|Dietary Intervention|Attend diet education sessions
48280239|NCT02249052|DRUG|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
48280240|NCT02249052|DRUG|placebo|Placebo
48280241|NCT00004386|GENETIC|recombinant adenovirus containing the ornithine transcarbamylase gene|
48280242|NCT06430892|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment
48280243|NCT02714530|DRUG|Erlotinib|Tarceva daily during radiotherapy course
48280244|NCT02714530|RADIATION|Radiation|Radiotherapy
48280245|NCT06656988|DRUG|CO2|CO2 will be used as contrast medium sparing strategy during peripheral angiography
48280246|NCT06656988|DRUG|Iodinated Contrast Media (ICM)|Iodinated contrast medium will be used as in routine care during peripheral angiography
48280247|NCT00779168|DRUG|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
48454706|NCT04037722|DIETARY_SUPPLEMENT|Whey|45 g whey + 20 g maltodextrin
48454707|NCT04037722|DIETARY_SUPPLEMENT|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
48622527|NCT00001956|PROCEDURE|Oral surgery|
48454708|NCT04081558|DEVICE|Electronic patient reported outcomes tool|Electronic patient reported outcomes
47931862|NCT00386971|DIETARY_SUPPLEMENT|L-carnitine|3 grams daily in liquid form by mouth
47931863|NCT00386971|OTHER|placebo|1 oz sweet tasting liquid daily by mouth
47931864|NCT01326559|DRUG|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
47931865|NCT00873470|PROCEDURE|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
47931866|NCT04983303|OTHER|TICK-B group|These interventions will distract the child during venipuncture
47931867|NCT05847712|OTHER|Simulated work in the heat|Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
47931868|NCT05861180|DEVICE|inclinometer, smart phone goniometer and laser beam|devices to objectively assess proprioception of the neck
47931869|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|150,000 IU orally given once
47931870|NCT01240265|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU given orally daily for 28 days
47931871|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene cocrystal|One capsule with Pterostilbene cocrystal
47931872|NCT05561075|DIETARY_SUPPLEMENT|Pterostilbene free form|One capsule with Pterostilbene free form
47931873|NCT03745820|DRUG|BIIB104|Administered as specified in the treatment arm
47931874|NCT03745820|OTHER|Placebo|Administered as specified in the treatment arm
48454709|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48454710|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48622528|NCT00001956|PROCEDURE|Tissue biopsy|
48622529|NCT02680275|DRUG|Dead Sea Peloid Gel|intravaginally
48454711|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48454712|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48454713|NCT01117623|DRUG|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48622530|NCT03818568|DIETARY_SUPPLEMENT|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
48622531|NCT03415880|BEHAVIORAL|Interactive workshops LiPAT intervention group|Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.
48622532|NCT03415880|DEVICE|Wrist-worn feedback physical activity monitor|Participants receive the feedback monitor (Fitbit inspire®; commercially available consumer product (https://www.fitbit.com/inspire)
48280248|NCT00779168|OTHER|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
48280249|NCT00779168|OTHER|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
48280250|NCT00779168|OTHER|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
48280251|NCT00779168|OTHER|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
48280252|NCT00779168|OTHER|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
48280253|NCT05746624|BEHAVIORAL|keypresses|benign behavioral intervention-- keypresses
48280254|NCT01877655|BIOLOGICAL|ASP0113|Intramuscular injection
48280255|NCT01877655|DRUG|Placebo|Intramuscular injection
48280256|NCT06460350|DEVICE|NEUROCUPLE™ Patch|nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year.
48280257|NCT06460350|DEVICE|Placebo Patch|The placebo patch is identical to the active patch but with no active agents.
48280258|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
48280259|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
48280260|NCT00845429|BIOLOGICAL|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
48280261|NCT04673981|DIAGNOSTIC_TEST|diagnostic tes for neuropathic pain|Thermotest and hot water, cold water (for the oral cavity), Von frey filament and the brush
47931875|NCT02900144|BEHAVIORAL|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
48106813|NCT01693614|DRUG|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
48106814|NCT04872829|DEVICE|cataract surgery|"All patients underwent cataract surgery under 1 year of age (mean age 8 months, range 6-12) performed with the same surgical technique: two 1.2 mm clear corneal incision, continuous curvilinear capsulorhexis with a diameter of approximately 6.0 mm and intraocular lens implantation, posterior capsulotomy and anterior vitrectomy.~IOL power was calculated using Sanders-Retzlaff-Kraff (SRK)/II formula. Multifocal IOL implantated was Alcon AcrySof ReSTOR SN60D3, while the monofocal one was Alcon AcrySof SN60AT.~According to the Infant Aphakia treatment Study, the IOL power was calculated as a function of the child age17, with an undercorrection ranging from 4 to 6 D."
48106815|NCT01559519|DRUG|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
48106816|NCT02321748|DRUG|Montelukast|
48106817|NCT02321748|DRUG|ASP2151|
48106818|NCT00235040|BEHAVIORAL|Smart Form|Computer Decision Support System
48106819|NCT05263960|DRUG|CM350_group 1|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 5ug of CM350 on the first day of first cycle (C1D1), 5ug on C1D8, 5ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48454714|NCT01117623|DRUG|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48454715|NCT01117623|DRUG|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48454716|NCT01117623|DRUG|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
48280262|NCT00644592|DRUG|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
48280263|NCT00644592|DRUG|Fenofibrate|160 mg/day orally for 4 weeks
48280264|NCT01947023|PROCEDURE|Biopsy|Undergo tumor biopsy
48280265|NCT01947023|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48280266|NCT01947023|PROCEDURE|Computed Tomography|Undergo CT
48280267|NCT01947023|DRUG|Dabrafenib|Given PO
48280268|NCT01947023|DRUG|Dabrafenib Mesylate|Given PO
48280269|NCT01947023|PROCEDURE|Echocardiography|Undergo ECHO
48280270|NCT01947023|DRUG|Lapatinib|Given PO
48280271|NCT01947023|DRUG|Lapatinib Ditosylate|Given PO
48280272|NCT01947023|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48280273|NCT01947023|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48280274|NCT01947023|PROCEDURE|Positron Emission Tomography|Undergo PET
48280275|NCT04670705|OTHER|patients' characteristics|There was no intervention.
48280276|NCT01687790|DEVICE|molecular breast imaging (Discovery)|
48280277|NCT04697563|DEVICE|Laser|real laser beam administered
48280278|NCT04697563|DEVICE|Placebolaser|no laser beam admitted
48280279|NCT04627740|DRUG|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
48454717|NCT02856594|DRUG|Dexmedetomidine|Dexmedetomidine
48454718|NCT02856594|DRUG|Placebo|Placebo
48454719|NCT02152046|PROCEDURE|ROP exam with spring loaded retractor|
48280280|NCT06651567|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
48280281|NCT06651567|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
48280282|NCT01167608|OTHER|No Intervention. This is a cross-sectional survey study.|No intervention.
48280283|NCT04177836|BEHAVIORAL|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
48280284|NCT05779163|DRUG|LBL-033 for Injection|Initial dose - MTD; Q2W; intravenous infusion
48280285|NCT05098483|PROCEDURE|Regeneration in primary molars by using MTA|Regenerative endodontic procedure in nonvital primary molars using MTA capping material
48280286|NCT05098483|PROCEDURE|Regeneration in primary molars by using biodentine|Regenerative endodontic treatment in primary molars with biodentine as capping material
48280287|NCT05098483|PROCEDURE|Conventional Root canal treatment in primary molars|Removal of pulp tissue from the canals of primary molars
48280288|NCT05238051|OTHER|Gastric residual volume measurement stopped.|GRV is checked during routine enteral nutrition, but we think that GRV prolongs the time to reach target calories and does not reduce complications.
48280289|NCT00041314|DRUG|carboplatin|
48280290|NCT00041314|DRUG|exisulind|
48280291|NCT00041314|DRUG|gemcitabine hydrochloride|
48280293|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
48280294|NCT03660878|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
48280295|NCT03660878|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
48280296|NCT02515240|BIOLOGICAL|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
48280297|NCT03469011|DRUG|Imatinib Oral Tablet|3+3 trial design. Cohorts of 3-6 patients with escalating imatinib doses. No intra-patient dose escalation allowed.
48280298|NCT06046560|DRUG|SGLT2 inhibitor, GLP-1 RA|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
48280299|NCT06046560|BEHAVIORAL|Education-First|For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
48280300|NCT01573442|DRUG|testosterone|10.4 mg
48280301|NCT01573442|OTHER|placebo|
48280302|NCT02910440|DRUG|DCL-101 vs Golytely|
48280303|NCT02451956|DRUG|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
48280304|NCT02451956|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
48280305|NCT06069791|DRUG|Bupivacaine Injection|subcutaneous injection around bilateral greater occipital nerves
47931876|NCT02900144|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
47931877|NCT00004229|BIOLOGICAL|recombinant human endostatin|
47931878|NCT00474656|DEVICE|High-frequency oscillation|
47931879|NCT00474656|DEVICE|Conventional lung-open mechanical ventilation|
47931880|NCT02553954|PROCEDURE|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
47931881|NCT05770674|DRUG|1 Month vs. 12 Months DAPT|"Dual antiplatelet therapy with aspirin plus clopidogrel will be given for the following period after PCI according to patient allocation~1. 1 Month following PCI, followed by clopidogrel monotherapy~2. 12 Months following PCI"
47931882|NCT01423604|DRUG|Capecitabine|Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
47931883|NCT01423604|DRUG|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
47931884|NCT01423604|DRUG|Placebo|Placebo matching ruxolitinib
47931885|NCT05920083|OTHER|CPAP withdrawal|2 weeks of CPAP withdrawal
47931886|NCT05280483|DRUG|ABSK021 with fed state|25 mg ABSK021 (1x25 mg ABSK021 capsule) with food
47931887|NCT05280483|DRUG|ABSK021 with fasted state|25 mg ABSK021 (1x25 mg ABSK021 capsule) without food
47931888|NCT03276520|DIAGNOSTIC_TEST|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
47931889|NCT03276520|DIAGNOSTIC_TEST|ethanol|alcohol urine screening with ethanol
47931890|NCT04914039|COMBINATION_PRODUCT|Combination Product|Cases of brain death confirmed by the classic brain death confirmation test
47931891|NCT04914039|OTHER|NO CTA examination|NO CTA examination
47931892|NCT02305043|OTHER|non-interventional|non-interventional
47931893|NCT03504137|OTHER|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
47931894|NCT02799420|DEVICE|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
47931895|NCT02799420|DEVICE|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
47931896|NCT04270903|DEVICE|EPR measurement|Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
47931897|NCT03046277|OTHER|No intervention|No intervention
47931898|NCT02036554|DRUG|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
47931899|NCT02036554|DRUG|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
47931900|NCT02036554|DRUG|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
48454720|NCT02152046|PROCEDURE|ROP exam with screw retractor|
47931901|NCT05160987|DRUG|Remimazolam|Remimazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
47931902|NCT05160987|DRUG|Midazolam|Midazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
47931903|NCT02230527|DRUG|Ticagrelor|90mg twice a day by mouth
47931904|NCT02230527|DRUG|Clopidogrel|75mg once a day by mouth
47931905|NCT01456273|PROCEDURE|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
47931906|NCT01456273|PROCEDURE|Therapeutic Encounter|"Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo."
47931907|NCT02550769|PROCEDURE|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
47931908|NCT02550769|PROCEDURE|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
47931909|NCT01432210|OTHER|Post-prandial Feeding Study|
47931910|NCT04739865|DRUG|Psilocybin|Open label
47931911|NCT05834595|DRUG|CKD-828, D064, D701|QD, PO
47931912|NCT06020729|OTHER|General Exercises without occlusion training|General Exercises as bench press, squats , maximum sprint, leg power without occlusion training
48280306|NCT05324072|OTHER|no intervention|observational study
48454721|NCT03824691|DRUG|Cabozantinib|cabozantinib 40 mg orally once daily
48454722|NCT03824691|DRUG|Durvalumab|1500 mg durvalumab (MEDI4736) IV infusion every 28 days
48454723|NCT06298877|OTHER|Frailty and Quality of Life evaluation|Frailty and Quality of Life evaluation after surgery
48454724|NCT04124315|OTHER|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
48454725|NCT04124315|OTHER|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
47931913|NCT06020729|OTHER|Occlusion Training|In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
48454726|NCT05994066|OTHER|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).|Demographic data of the individuals were recorded. All participants completed NDI, Chalder Fatigue Scale (CFS) and Pittsburgh Sleep Quality Index (PSQI).
47931914|NCT05934188|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
47931915|NCT05934188|BEHAVIORAL|Neuropsychological protocol|Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
47931916|NCT05934188|BEHAVIORAL|Eating habits|Information on eating habits will be derived from food questionnaires.
47931917|NCT05934188|DIAGNOSTIC_TEST|Microbiome analyses|The Microbiome analyses will be derived from a stool sample (16S rRNA sequencing targeted metagenomic analyses).
47931918|NCT05934188|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers will be evaluated in terms RNA expression level in plasma blood sample.
47931919|NCT05934188|DIAGNOSTIC_TEST|Alzheimer's Disease biomarkers|The Alzheimer's Disease biomarkers will be measured in the plasma of prodromal Alzheimer's Disease patients.
47931920|NCT02686190|OTHER|Luxtherapy|
47931921|NCT02712814|DRUG|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
47931922|NCT02712814|PROCEDURE|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
47931923|NCT02712814|PROCEDURE|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
47931924|NCT00294281|DEVICE|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
47931925|NCT03758885|DRUG|Nolasiban|Nolasiban single oral administration
47931926|NCT03758885|DRUG|Placebo|Placebo single oral administration
48454727|NCT06535932|DEVICE|Amara View Minimal Contact Full Face Mask|The Amara View Full-Face Mask is a minimal contact full face mask manufactured by Philips Respironics (Murrysville, PA) that covers the mouth and seals under the nose compared to traditional full-face masks which seal over the nose. The Amara View mask is intended to reduce discomfort on the bridge of the nose. There is no forehead arm, offering patients an enhanced design to keep the field of vision clear.
48454728|NCT06535932|DEVICE|F40 Minimal Contact Full Face Mask|The AirFit F40 is a minimal contact FFM manufactured by ResMed (San Diego, CA) that rests softly and securely under the patients nose and is designed to let patients sleep in any position and move freely throughout the night. The mask consists of three cushion sizes and three headgear sizes. Headgear adjustments can be made with magnetic clips that easily snap on and off.
48622533|NCT03415880|DEVICE|Smartphone application LiPAT|With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.
47931927|NCT02724670|RADIATION|IGRT|MR-based IGRT
47931928|NCT05381337|PROCEDURE|sideburns mini incision|The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.
47931929|NCT05381337|PROCEDURE|coronal scalp incision|Coronal scalp incisions were used as control group.
47931930|NCT03934814|DRUG|TJ011133|TJ011133 will be administered weekly.
47931931|NCT03934814|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks.
47931932|NCT03934814|DRUG|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses.
47931933|NCT05918198|DRUG|Ven+CAG|"100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC \> 30 × 10\^9/L pause)"
47931934|NCT00003409|DRUG|motexafin gadolinium|
47931935|NCT00003409|RADIATION|radiation therapy|
47931936|NCT05880823|DEVICE|Synergy cervical disc system|motion preservation disc
47931937|NCT00126880|DRUG|AVX754|apricitabine, 600mg BID or 800mg BID
47931938|NCT00126880|DRUG|3TC|3TC, 150mg BID
47931939|NCT04632914|OTHER|trunk stabilizing exercise|trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
47931940|NCT04632914|OTHER|cardiac rehabilitation programe|all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
47931941|NCT05399576|DRUG|Nicorandil|Prophylactically combined intracoronary of Nicorandil and verapamil
47931942|NCT05399576|DRUG|Saline|intracoronary of 4ml saline
47931943|NCT01271790|DRUG|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
47931944|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
47931945|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
47931946|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
47931947|NCT01271790|DRUG|GS-9451|GS-9451 tablet, 200 mg QD
47931948|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
47931949|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
47931950|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
47931951|NCT01271790|DRUG|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
47931952|NCT01271790|DRUG|GS-9451 placebo|placebo matching GS-9451 tablet QD
47931953|NCT01271790|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
47931954|NCT01271790|DRUG|Copegus®|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
47931955|NCT05093790|DRUG|Ticagrelor|Specified dose on specified days
47931956|NCT05093790|DRUG|BMS-986141|Specified dose on specified days
48622534|NCT03415880|BEHAVIORAL|Telephone Coaching|participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with Fitbit Inspire® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.
48622535|NCT03415880|BEHAVIORAL|Workshops control group LiPAT|During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
47931957|NCT05093790|DRUG|Aspirin|Specified dose on specified days
47931958|NCT04130737|DEVICE|TORUS Stent Graft System|The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
47931959|NCT03937635|BIOLOGICAL|Daratumumab|Given IV
47931960|NCT03937635|DRUG|Dexamethasone|Given PO
47931961|NCT03937635|DRUG|Lenalidomide|Given PO
47931962|NCT03937635|OTHER|Quality-of-Life Assessment|Ancillary studies
47931963|NCT03937635|OTHER|Questionnaire Administration|Ancillary studies
47931964|NCT04149275|DRUG|Cabozantinib|Treatment with oral Cabozantinib once daily
47931965|NCT04149275|DRUG|Ipilimumab|IV administration of Ipilimumab on 21 day cycles
47931966|NCT04149275|DRUG|Nivolumab|IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
47931967|NCT03281993|OTHER|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
48098590|NCT05245097|DEVICE|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
47931968|NCT05340270|DRUG|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
47931969|NCT05340270|DRUG|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
47931970|NCT04438564|OTHER|Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer|Diagnosis and acceptance of breast cancer, colon rectal cancer, ovarian cancer, and endometrial cancer by the clinical Western medicine team.
47931971|NCT05150444|OTHER|Cognitive and physical exercise training|"12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (\~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities."
47931972|NCT00204945|DRUG|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
47931973|NCT01302015|BIOLOGICAL|RNL-Vascostem®|
47931974|NCT02814331|DEVICE|multimodal high-resolution EEG-NIRS|
47931975|NCT02699788|DEVICE|Multifunction Cardiogram|
47931976|NCT03643614|PROCEDURE|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
48622536|NCT04554251|OTHER|Survey|invited questionnaire
48622537|NCT01474187|DRUG|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
48622538|NCT01474187|DRUG|Capecitabine|625mg/m2,bid,d1-5,qw
48622539|NCT01474187|RADIATION|Radiotherapy|50Gy for whole pelvis
48622540|NCT02756520|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
48622541|NCT01211249|DRUG|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
48622542|NCT01211249|DRUG|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
48622543|NCT01211249|DRUG|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
48622544|NCT01211249|DRUG|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
48622545|NCT06214390|PROCEDURE|Single strategy|In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use
48622546|NCT06214390|PROCEDURE|Combined strategy|In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine \> 5.2mmol/day \[5\] and 3) urinary urea \> 1.35mmol/kg/day (using the patient's body weight at ICU admission) \[6\], RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume.
48622547|NCT02257151|DRUG|BMS-986142|
48622548|NCT02257151|DRUG|Placebo|
48622549|NCT00601627|BIOLOGICAL|panitumumab|
48622550|NCT00601627|DRUG|capecitabine|
48622551|NCT00601627|DRUG|fluorouracil|
48622552|NCT00601627|DRUG|gemcitabine hydrochloride|
48622553|NCT00601627|RADIATION|radiation therapy|
48622554|NCT06370585|DRUG|PRO-229|- Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.
48622555|NCT06370585|DRUG|Lagricel® Ofteno PF|- Sodium hyaluronate 0.4%. Ophthalmic solution.
48622556|NCT01634594|DRUG|Group R|
47931977|NCT05969171|DRUG|Sofantinib、abraxane、gemcitabine|The combination of 3 weeks was a treatment cycle, and AG chemotherapy was defined as a maximum of 6 treatment cycles, and soantinib was continued until disease progression (PD, RECIST 1.1) or death (during patient treatment) or toxicity intolerance or other criteria for discontinuation of study therapy were met in the protocol.
47931978|NCT05969171|DRUG|Abraxane combined with gemcitabine|Abraxane combined with gemcitabine
48622557|NCT01634594|DRUG|Group N|
48622558|NCT01634594|DRUG|Group D|
48622559|NCT03243799|BEHAVIORAL|Group psychoeducation|Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
48622560|NCT01245062|DRUG|GSK1120212|MEK inhibitor
48622561|NCT01245062|DRUG|Chemotherapy|Investigator Choice of DTIC or paclitaxel
48622562|NCT05052008|DRUG|Erenumab|Erenumab is monoclonal antibody used for management of migraine
48622563|NCT03213717|OTHER|Heavy Casall HIT weight vest|A weight west with a weight of 10 % compared to the study subject
48622564|NCT03213717|BEHAVIORAL|Standing|Study subjects will be standing for at least 50 minutes every hour
48622565|NCT03213717|DIETARY_SUPPLEMENT|Water load|Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
48622566|NCT03213717|BEHAVIORAL|Sitting|Study subjects will be sitting for at least 50 minutes of every hour
48622567|NCT03213717|OTHER|Light Casall HIT weight vest|A weight west with a weight of 1 % compared to the study subject
48622568|NCT02451878|BEHAVIORAL|E-Couch|e-couch is an online CBT based intervention
48622569|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
48622570|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
48622571|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
48622572|NCT00912119|DRUG|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
48622573|NCT05570422|DRUG|KRC-01|KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.
48622574|NCT05570422|RADIATION|External Beam Radiation Therapy|"* Target definition for EBRT will be based on 3D imaging by computed tomography, positron emission tomography with computed tomography, or MRI.~* Intensity-modulated radiotherapy (IMRT) must be used.~* IMRT should be given once daily Monday-Friday, 5 fractions per week."
48622575|NCT05570422|DRUG|cisplatin|"* Weekly concomitant cisplatin (40 mg/m2) during EBRT~* Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~* Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed."
48622576|NCT05570422|RADIATION|brachytherapy|"* BT treatment planning will be based on 3D-image-guided BT by MRI.~* Low-dose-rate, pulsed-dose-rate, or high-dose-rate BT"
48622577|NCT04395001|DRUG|duloxetine|All participants will receive duloxetine 30 mg once daily for one week and 60 mg once daily for 24 weeks.
48622578|NCT04395001|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (CBT)|The web-based CBT program is an automated program (i.e., users learn skills with interactive, personalized training without any therapist contact) that includes 8, 35- to 45-minute training sessions, each of which provides an educational rationale and training in cognitive or behavioral pain coping skill drawn from face-to-face CBT.
48622579|NCT04395001|OTHER|Nurse-delivered Motivational Interviewing|Subjects randomized to the duloxetine and web-based Cognitive Behavioral Therapy (CBT) with nurse support will receive 6 phone calls from MI trained nurse at week 3, 6, 10, 14, 18 and 22. Telephone sessions may run for 20 minutes on the average.
48280307|NCT06656845|DEVICE|Genus, a self-management app for patients with knee osteoarthritis|The self-management app (Genus) will include weekly reminders with information videos on knee osteoarthritis and treatment options, exercise videos, quizzes, questionnaires, and a platform for remote monitoring by health professionals.
48454729|NCT05920486|DEVICE|High-Intensity Laser Therapy (HILT)|High-Intensity Laser Therapy (HILT) is a non-invasive treatment that utilizes high-powered lasers to deliver therapeutic doses of energy to damaged tissue. In this study, HILT will be used to treat sacroiliitis, a condition that affects the sacroiliac joint in the lower back and pelvis. HILT will be administered using a Class IV laser with a wavelength of 980 nm, power output of 10 W, spot size of 0.5 cm, and a dose of 60 J/cm2 per session. The laser will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of HILT is to promote cellular repair and regeneration, reduce pain, and improve function in patients with sacroiliitis. Participants in the HILT group will receive HILT treatment as the primary intervention in this study.
48622580|NCT05651256|DRUG|Botulinum toxin type A injection|The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
48622581|NCT02734667|DEVICE|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
48622582|NCT03336970|OTHER|EDTA|
48622583|NCT03336970|OTHER|NaOCl|
48622584|NCT03336970|OTHER|CHX|
48622585|NCT03336970|OTHER|Calcium hydroxide|
48622586|NCT01530919|PROCEDURE|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
48622587|NCT00177671|DRUG|Escitalopram|Escitalopram, 10mg to 20mg daily.
48622588|NCT00177671|DRUG|Donepezil|Donepezil, 5mg to 10mg daily.
48622589|NCT00177671|DRUG|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
48622590|NCT00177671|DRUG|Placebo|
48622591|NCT00177671|DRUG|Duloxetine|
48622592|NCT05311969|OTHER|cognitive evaluations and non cognitive evaluations|"Cognitive evaluations with executive functions evaluations :~* Mini Mental State Examination~* Stroop Victoria Test~* Hayling test~* Frontal Assessment Battery test mental flexibility:~* Trial Making Test (TMT) A and B~* Connection test~* Alphaflex test~* Verbal and visuospatial working memory~* Wechsler Adult Intelligence Scale (WAIS) span~* Visuo-spatial span~* Visuo-spatial span simplified version~* Month Of the Year Backwards (MOTYB) Planning~* Tinker Toy test~* Clock Test~Non-cognitive evaluations:~The Katz Autonomy Scale Neuropsychiatric Inventory version Care team Geriatric Depression Scale 15-item version Apathy inventory"
48622593|NCT02145819|DRUG|hCG|
48622594|NCT02145819|OTHER|LH peak|
48622595|NCT03801252|DRUG|Cefazolin|intravenous drugs used as prophylactic antibiotics
48622596|NCT03801252|DRUG|Placebo|Intravenous saline
48622597|NCT03801252|DRUG|Azithromycin|prophylactic antibiotic
48622598|NCT04972721|OTHER|No treatment given|The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
48622599|NCT00261040|PROCEDURE|Minimally Invasive Surgery|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
48622600|NCT00261040|PROCEDURE|Standard Surgery|The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
47931979|NCT00703703|DRUG|Darifenacin|Darifenacin tablets 15 mg once daily
47931980|NCT00703703|DRUG|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
48280308|NCT00184587|DRUG|candesartan cilexetil|
48280309|NCT00184587|DRUG|placebo|
48280310|NCT03395678|DEVICE|Microneedling|The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
48280311|NCT03395678|DEVICE|Fractional non-ablative 1,540nm laser|The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
48280312|NCT03153852|DRUG|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
48280313|NCT03153852|DRUG|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
48280314|NCT03153852|DRUG|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
48280315|NCT06334679|OTHER|Cold Gel Packet Application|Cold gel packs will be placed on the burn areas of the patients in the maturation phase and applied for 20 minutes.
48280316|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
48280317|NCT00982566|DRUG|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
48280318|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
48280319|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
47931981|NCT00703703|DRUG|Placebo|Placebo tablet once daily
47931982|NCT05977725|DIAGNOSTIC_TEST|Hand Doppler Ultrasound|Hand Doppler Ultrasound to assess the Hand Acceleration Time (HAT)
47931983|NCT03794882|COMBINATION_PRODUCT|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
47931984|NCT03794882|PROCEDURE|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
47931985|NCT01568801|BEHAVIORAL|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
47931986|NCT04002570|OTHER|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
47931987|NCT01293578|OTHER|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
47931988|NCT05326724|DEVICE|Acupuncture|The stainless steel needles are used to insert into the three points of Sishencong and the Baihui, and the Dazhui, once a week, once for 20 minutes, for 12 consecutive weeks.
47931989|NCT06420258|PROCEDURE|Deeper endotracheal intubation|After general anesthesia, endotracheal intubation was conducted using an ultrafine endoscope (GIF-XP260NS, Olympus Corp., Japan), which allows observation of the exact position and avoids blindness caused by laryngoscopy. To prevent balloon compression of the CE after inflating, the endotracheal intubation tube was inserted above the tracheal carina, roughly the upper thoracic esophagus.
47931990|NCT00706849|DRUG|mipomersen sodium|200 mg /mL
48622601|NCT04591015|BEHAVIORAL|Hospital: DD-CA|In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
48622602|NCT04591015|BEHAVIORAL|Hospital: Usual Care (UC)|In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
48622603|NCT01813643|DRUG|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
48622604|NCT01813643|DRUG|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
47931991|NCT00706849|DRUG|placebo|1 mL matching placebo
47931992|NCT02753244|OTHER|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
47931993|NCT02753244|OTHER|iPad Apps|Commercially available iPad game applications
47931994|NCT01809977|PROCEDURE|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
48098591|NCT05304520|DRUG|Natalizumab|Administered as specified in the treatment arm.
48098592|NCT03818659|OTHER|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
47931995|NCT01809977|PROCEDURE|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
47931996|NCT00137839|DRUG|Erlotinib|
47931997|NCT04386915|DRUG|GST-HG141 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
47931998|NCT04386915|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.
47931999|NCT02478398|BIOLOGICAL|Short ragweed pollen allergen extract|One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
47932000|NCT02478398|BIOLOGICAL|Placebo|One placebo sublingual tablet, QD for up to 35 weeks.
47932001|NCT02478398|DRUG|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
47932002|NCT02478398|DRUG|Albuterol/Salbutamol|Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
47932003|NCT02478398|DRUG|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
47932004|NCT02478398|DRUG|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
48454730|NCT05920486|DEVICE|Sham High-Intensity Laser Therapy (HILT)|Sham HILT is a non-invasive treatment that mimics the appearance and sensation of HILT but does not deliver any laser energy to the affected tissue. In this study, Sham HILT will be used as a control intervention for the treatment of sacroiliitis. The device used for Sham HILT will look and feel the same as the HILT device, but will not emit any laser energy. The device will be applied to the affected area of the sacroiliac joint, with the aim of achieving a sensation of warmth in the region. The treatment sessions will be delivered for 10 minutes per session, with a total of 12 sessions over 8 weeks. The aim of Sham HILT is to provide a credible control intervention that does not have any specific therapeutic effect on the sacroiliac joint. Participants in the Sham HILT group will receive Sham HILT treatment as the primary intervention in this study.
48454731|NCT03545880|OTHER|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
48454732|NCT03545880|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
48454733|NCT05891522|PROCEDURE|portable scanner|performing a portable cranial scanner on cerebro-injured intensive care patients
48454734|NCT05891522|PROCEDURE|fixed scanner|performing a conventional fixed cranial scanner on cerebro-injured intensive care patients
48454735|NCT03049631|DIETARY_SUPPLEMENT|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
47932005|NCT02478398|DRUG|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
47932006|NCT00159497|DEVICE|porous coated Trilogy®|THA
48454736|NCT03049631|DIETARY_SUPPLEMENT|Raspberry|Red raspberries (1 cup equivalent)
48454737|NCT06059625|PROCEDURE|rotatori cuff repair|rotatori cuff repair
48454738|NCT01745679|DRUG|Ceftriaxone treatment|ceftriaxone will be administered à high dose : \> or equal to 75mg/kg/day or 4 gr/day
48454739|NCT06559644|BIOLOGICAL|Hema-NeoTIL01|Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.
48106820|NCT05263960|DRUG|CM350_group 2|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 15ug of CM350 on the first day of first cycle (C1D1), 15ug on C1D8, 15ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48280320|NCT06656546|DIAGNOSTIC_TEST|Tracheal Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. A linear transducer will be placed perpendicular to the trachea at the level of the cricoid membrane. During ETI, visualization of the ETT moving within the trachea, specifically behind the cricothyroid membrane, indicates successful intubation. In contrast, if the ETT is mistakenly placed in the esophagus, a double-lumen appearance lateral to the trachea, created by the ETT within the esophagus, suggests esophageal intubation.
48454740|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 \*120mg new formulation tablet as test treatment
48454741|NCT03708133|DRUG|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment
48454742|NCT05602766|DRUG|NGENLA (Somatrogon)|Dosage, Frequency: Refer to the latest package insert.
47932007|NCT00159497|DEVICE|Trilogy Calcicoat®|THA
48454743|NCT05413096|COMBINATION_PRODUCT|Combination of diclofenac potassium and propolis|Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel
48454744|NCT05413096|OTHER|placebo|placebo
48454745|NCT05637762|OTHER|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
48454746|NCT00858780|DRUG|Etanercept|50 mg etanercept once weekly + methotrexate
48454747|NCT00858780|DRUG|Etanercept|25mg etanercept once weekly + methotrexate
48454748|NCT00858780|DRUG|Placebo|Placebo comparator once weekly + methotrexate
47932008|NCT01481129|DRUG|Akt Inhibitor MK2206|Given PO
47932009|NCT01481129|OTHER|Laboratory Biomarker Analysis|Correlative studies
47932010|NCT01481129|OTHER|Pharmacological Study|Correlative studies
47932011|NCT03726398|DRUG|Opsumit 10 Mg Tablet|Oral tablet taken once daily
47932012|NCT01054183|DEVICE|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
47932013|NCT01054183|DEVICE|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
47932014|NCT02547883|DRUG|Cessation of statin|The intervention evaluated is the cessation of statin
47932015|NCT01398878|BEHAVIORAL|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
48454749|NCT00402103|DRUG|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
48454750|NCT00402103|DRUG|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
48454751|NCT00402103|DRUG|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
47932016|NCT06148194|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 30 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 30 mL-bottle that is used for probiotic 1 and 2.
47932017|NCT06148194|COMBINATION_PRODUCT|Probiotic 1|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device (Product declaration: No. 210001337/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax product is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL.
47932018|NCT06148194|COMBINATION_PRODUCT|Probiotic 2|In Vietnam, LiveSpo Navax Kid is manufactured as a Class-A medical device (Product declaration: No. 220002534/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax Kid is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL.
47932019|NCT04259723|OTHER|VR during TAVI|Virtual Reality (VR) glasses
47932020|NCT03252340|DRUG|ADSTEM Inj.|"1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
47932021|NCT03590431|DIETARY_SUPPLEMENT|extrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.
48454752|NCT02235922|OTHER|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
47932022|NCT03590431|DIETARY_SUPPLEMENT|intrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).
47932023|NCT03590431|DIETARY_SUPPLEMENT|water iodine solution|300 ml water delivering ≈ 200 µg iodine (control)
47932024|NCT06432868|DIETARY_SUPPLEMENT|Solarplast (R)|Daily supplementation for 28 days prior to heavy resistance exercise.
47932025|NCT06432868|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 28 days prior to heavy resistance exercise.
48454753|NCT02235922|OTHER|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
47932026|NCT02598336|DEVICE|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
47932027|NCT02598336|DEVICE|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
47932028|NCT05204875|RADIATION|X-ray Velocimetry|X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
47932029|NCT05926076|OTHER|Treatment plan|Patients with different diagnoses will get different treatment options
47932030|NCT01141777|DIETARY_SUPPLEMENT|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
48454754|NCT03492138|DRUG|ONC201|625mg
48454755|NCT03492138|DRUG|Ixazomib|Dose to be determined in Phase 1 of study
48454756|NCT03492138|DRUG|Dexamethasone|40mg
48454757|NCT04006808|BIOLOGICAL|PED-HZ/su|GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
48454758|NCT02323256|OTHER|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
48454759|NCT02323256|OTHER|Speech-ABR|
48454760|NCT02323256|OTHER|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
48454761|NCT02323256|OTHER|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
48454762|NCT05213663|OTHER|assessment|To examine the awareness of parents of Cerebral Palsy children about the disease, physiotherapy and rehabilitation.
47932031|NCT01141777|DIETARY_SUPPLEMENT|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
48454763|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
48454764|NCT00419640|DEVICE|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
48454765|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
48454766|NCT00419640|DEVICE|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
48454767|NCT06623162|DRUG|gemcitabine + cisplatine|4 cycles
48454768|NCT01173835|BEHAVIORAL|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
48454769|NCT04802655|OTHER|Video-game based exercise - Exergame|Selected Kinect compatible video games from Microsoft Xbox one will be applied in this group. Four video games will be selected for a session (each game will last 10 mins). Video games are active video games which participants have to use their body parts in order to control games.
48454770|NCT04802655|OTHER|Activity Based Exercise Group (AG)|Task-oriented exercises to be performed in standing and sitting positions, including upper extremity and trunk, will be applied to the activity-based exercise group in addition to routine NDT training. Examples for activities; stepping and putting stickers on the wall, treading the play dough placed on a step board within one leg stance; reach-grasp activities progressively from sitting to standing, throwing and catching balls on a balance board.
48454771|NCT01188863|DRUG|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
48454772|NCT01188863|DRUG|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
48454773|NCT01188863|DRUG|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
48454774|NCT00582179|PROCEDURE|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
48454775|NCT00582179|DEVICE|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I\&D.
48454776|NCT03166267|DEVICE|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
48454777|NCT01198964|PROCEDURE|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
48454778|NCT03375957|DRUG|ATx201|two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
48454779|NCT03375957|DRUG|ATx201 Placebo Gel|two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
48454780|NCT03157115|DEVICE|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to cardiac contractility.~During a standard echocardiography appointment for a patient suffering from a cardiovascular condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
48454781|NCT06020430|RADIATION|CTV omitted or delineated|Patients who responded to the induction therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radical radiotherapy group or CTV-delineated radiotherapy group.
48454782|NCT06626906|DIAGNOSTIC_TEST|Echocardiography, Blood sampling for biomarker assays|
48454783|NCT00603499|DIETARY_SUPPLEMENT|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
48454784|NCT00603499|OTHER|Placebo|Subjects in the control group received inert placebo once per day during 4 months
48454785|NCT02374112|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
48454786|NCT02374112|OTHER|Placebo|Placebo supplementation
48098593|NCT03818659|OTHER|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
48454787|NCT03723733|BEHAVIORAL|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
48454788|NCT00473772|DEVICE|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
48454789|NCT03319394|BEHAVIORAL|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
48454790|NCT03319394|BEHAVIORAL|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
48454791|NCT06031844|DRUG|DFV890|oral film-coated tablets
48098594|NCT04735354|DRUG|sacubitril/valsartan|There was no treatment allocation. Patients administered sacubitril/valsartan by prescription that started before inclusion of the patient into the study were enrolled.
48454792|NCT06031844|DRUG|Placebo|oral film-coated tablets
47932032|NCT03218683|DRUG|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
47932033|NCT03218683|DRUG|AZD5991 + Venetoclax|Ascending oral doses of AZD5991 and/or venetoclax until no longer tolerated or disease progression
48454793|NCT03424915|BEHAVIORAL|Harvard Health Professionals survey|Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
47932034|NCT06514651|DRUG|MAQ-001|MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
48454794|NCT03424915|OTHER|Blood draw|Participant will provide a blood sample
48454795|NCT03424915|OTHER|CPET Procedures|CPET with 12-lead ECG
48454796|NCT03424915|OTHER|stool sample|Research stool sample (within ±1 week of surgery), if possible
48098595|NCT00281762|DRUG|NSAID|
48098596|NCT02430532|DRUG|dimethyl fumarate|capsule
48454797|NCT03424915|PROCEDURE|Research Tissue sampling|Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
48454798|NCT01105299|DRUG|CJ anastrozole 1 mg tablet|
48622605|NCT03578913|OTHER|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
48622606|NCT03578913|OTHER|PFM Crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
47932035|NCT06514651|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
47932036|NCT00477958|OTHER|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
47932037|NCT00477958|PROCEDURE|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
47932038|NCT00477958|PROCEDURE|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
47932039|NCT06335901|DRUG|Drug:Standard therapy|Percutaneous coronary Intervention
47932040|NCT05849285|OTHER|TLC Clinic|Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team
47932041|NCT00388427|DRUG|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
47932042|NCT00388427|DRUG|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m\^2 on Day 1 of Cycle 1; IV 250 mg/m\^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
47932043|NCT02385136|DRUG|Temozolomide|
48098597|NCT02430532|OTHER|Placebo|matched placebo capsule
48098598|NCT03545217|BEHAVIORAL|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
48106821|NCT05263960|DRUG|CM350_group 3|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 45ug on C1D8, 45ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48106822|NCT05263960|DRUG|CM350_group 4|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48454799|NCT04268615|OTHER|Covert Saccades and Virtual Reality|During this intervention, patients will undergo head impulse testing while wearing virtual reality Headsets. During the head impulse tests the visual information will be modified in order to create a conflict between head rotation and rotation of the visual scene. Recording of head and eye movement will be done during these head impulses in order to verify if visual information modifies compensatory eye movements during head impulses.
48454800|NCT04268615|OTHER|Actives versus passives Head Impulses|Patients will undergo classic passive head rotation as well as active head rotation in order to compare latencies of covert saccades in both conditions.
48454801|NCT04268615|OTHER|Visually guided saccades|Patients as well as healthy control subjects will undergo testing of visually guided saccades in different conditions (step, gap, overlap) in order to compare latencies of covert saccades between both groups.
48454802|NCT00957021|DEVICE|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
48622607|NCT00446875|OTHER|Administration of oral Sucrose|Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
48622608|NCT00446875|OTHER|Administration of oral Placebo|Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
47932044|NCT01584570|DRUG|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
47932045|NCT04054427|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
47932046|NCT02975583|DRUG|Vorapaxar|2.08 mg oral tablet daily
47932047|NCT02975583|DRUG|Placebos|Placebo oral tablet daily
47932048|NCT02199327|DRUG|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
47932049|NCT02199327|DRUG|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
47932050|NCT02339220|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
48106823|NCT05263960|DRUG|CM350_group 5a|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48454803|NCT04298086|OTHER|Exercise Treatment|Exercise treatment will consist of individualized walking delivered up to 7 times weekly to achieve the patient-specific goal energy expenditure. Training sessions will be performed on a treadmill at under remote surveillance using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service.
48454804|NCT04298086|OTHER|Plant-Based Diet|Pre-prepared meals, including 6 dinners and 6 lunches per week, will be shipped to the partipant's home during the intervention.
48454805|NCT04298086|OTHER|Physical activity|Treadmills and low-calorie recipes will be provided to patients in the counseling arm.
48454806|NCT04298086|OTHER|Nutrition counseling|Nutrition program including regular counseling by exercise physiologists and registered dieticians (RDs).
48454807|NCT04298086|OTHER|Replication Exercise Test|Exercise capacity will be reassessed by a replication exercise test at week 6 in the intervention group only.
48454808|NCT04479527|DRUG|Camrelizumab|Camrelizumab for injection is used to treat patients with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy. Approved by the Drug Administration (NMPA) on March 4, 2020, for the treatment of patients with advanced hepatocellular carcinoma who have previously received sorafenib therapy and/or oxaliplatin-containing chemotherapy.Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor. It mainly treats malignant tumors by inhibiting VEGFR to play an anti-angiogenic effect. It has been approved by the China Food and Drug Administration (CFDA) in November 2014. It is used as a monotherapy for advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma that has progressed or relapsed after receiving two kinds of systemic chemotherapy. Apatinib Mesylas can effectively inhibit VEGFR2 at very low concentrations, and higher concentrations can also inhibit PDGFR, c-Kit and c-Src and other kinases.
48454809|NCT06627322|DRUG|Dual-combination therapy|Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
48454810|NCT06627322|DRUG|Triple-combination therapy|Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
48454811|NCT06627322|DEVICE|Dexcom G7, Pasta|Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
48454812|NCT02278809|BEHAVIORAL|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring..."
48454813|NCT00567463|DEVICE|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
48454814|NCT06182293|OTHER|Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota|Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.
48454815|NCT04405479|BEHAVIORAL|Examination of tremor and upper hand functions|Participants will be only examined. They will not undergo any intervention.
48454816|NCT06543303|DRUG|BTV100 Low dose|1% Cevimeline Ophthalmic Solution
48454817|NCT06543303|DRUG|BTV100 Mid dose|2% Cevimeline Ophthalmic Solution
48454818|NCT06543303|DRUG|BTV100 High dose|4% Cevimeline Ophthalmic Solution
48454819|NCT06543303|DRUG|Placebo|Placebo
48454820|NCT05605652|PROCEDURE|microosteoperforations|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
48454821|NCT06409377|DRUG|Precedex 200 MCG in 2 ML Injection|Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
48454822|NCT06409377|OTHER|C group:|Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).
48454823|NCT03587545|OTHER|Probiotic nasal spray|Total daily nasal administration of 2\*10\^8 CFU of probiotic bacteria delivered via 2 servings.
48622609|NCT02126332|OTHER|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
48454824|NCT03587545|OTHER|Placebo nasal spray|Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
47932051|NCT02339220|BEHAVIORAL|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
47932052|NCT02339220|BEHAVIORAL|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
47932053|NCT02339220|BEHAVIORAL|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
47932054|NCT02592187|BEHAVIORAL|ReMemory-MCI training|
47932055|NCT02592187|BEHAVIORAL|Control intervention|
47932056|NCT01415089|BEHAVIORAL|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
47932057|NCT06391528|PROCEDURE|Transversalis Fascia Plane Block|application of local anesthetic between the transversus abdominis muscle and the transversalis fascia surrounding it from the inside, at the level of the posterior axillary line.
47932058|NCT02927405|DRUG|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
47932059|NCT02927405|PROCEDURE|TAP Block|a procedure done anesthetize the anterior abdominal wall
47932060|NCT01643980|DRUG|Vaginal micronized progesterone|200 mg vaginal route per day
47932061|NCT01643980|DEVICE|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
47932062|NCT05353803|OTHER|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure|Digital App and Platform for Supporting Medicines Control and Optimizationin Older Individuals With Heart Failure
48098599|NCT03751878|BEHAVIORAL|Evaluation of reporting inconsistencies|"1. The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~2. DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~3. This editor will include the report in the letter to authors alongside the standard peer review reports."
48098600|NCT03751878|BEHAVIORAL|Standard Peer Review.|Manuscripts will undergo the usual peer review process.
48454825|NCT02584608|DRUG|ACTIMMUNE|
48098601|NCT04667988|DIAGNOSTIC_TEST|JAK expression|JAK2 assessment in blood by PCR
48454826|NCT05795621|BIOLOGICAL|IBI311|10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
48454827|NCT05795621|BIOLOGICAL|placebo|4 does of placebo for phase II; 8 does of placebo for phase III.
48454828|NCT04981704|DRUG|Poziotinib|Poziotinib Tablets
48454829|NCT04981704|DRUG|Itraconazole|Itraconazole Oral solution
48622610|NCT02126332|OTHER|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
48622611|NCT00104234|DRUG|N-acetylgalactosamine 4-sulfatase|
48622612|NCT00104234|DRUG|Placebo/rhASB|
48098602|NCT04151121|BEHAVIORAL|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
48098603|NCT03842150|DIAGNOSTIC_TEST|biliary atresia screen score|The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
48454830|NCT04981704|DRUG|Phenytoin|Phenytoin Capsules
48454831|NCT04981704|DRUG|Paroxetine|Paroxetine Tablets
48454832|NCT04068818|DEVICE|ANTERION|Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center
48454833|NCT00387530|DRUG|oral sodium phenylbutyrate|
48454834|NCT00387530|DRUG|valganciclovir|
48454835|NCT00387530|GENETIC|polymerase chain reaction|
48454836|NCT00387530|GENETIC|protein expression analysis|
48622613|NCT06249971|PROCEDURE|Dermal subsitute Glyaderm + skin graft|A human donor-derived dermal substitute will be implanted together with a skin graft
48454837|NCT00387530|PROCEDURE|biopsy|
48454838|NCT02035163|PROCEDURE|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
48622614|NCT06249971|PROCEDURE|Skin graft alone|Skin graft alone with no dermal substitute
48622615|NCT06465056|DRUG|Botulinum toxin type A|Botulinum toxin application between 3-14 days after direct eyebrow lift surgery.
48622616|NCT03697590|DRUG|No curettage|Standard PDT without curettage
47932063|NCT05329038|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
47932064|NCT04898621|DIETARY_SUPPLEMENT|75g fructose solution|Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.
47932065|NCT04898621|DIETARY_SUPPLEMENT|150g fructose solution|Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.
47932066|NCT00214604|DRUG|Rosuvastatin|10mg
47932067|NCT00214604|DRUG|rosuvastatin|20mg
47932068|NCT00214604|DRUG|pravastatin|40mg
47932069|NCT04456153|DRUG|Experimental Group|Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
47932070|NCT04456153|DRUG|Placebo Group|Continued standard of care therapy together with matching placebo
47932071|NCT05300373|DIAGNOSTIC_TEST|ADENOSINE DEAMINASE TEST|ADENOSINE DEAMINASE DEFICIENCY TEST
47932072|NCT01817517|DEVICE|Medtronic Activa Deep Brain Stimulation System|
47932073|NCT00000527|DRUG|aspirin|
47932074|NCT00000527|DRUG|dipyridamole|
47932075|NCT04692740|DRUG|Chlorambucil, Oral, 2 Mg|Eligible patients will be treated with Chlorambucil 6 mg/m2 daily p.o. for 42 consecutive days (weeks 1-6). After restaging, responder patients (complete or partial response) and those with stable disease will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days every 28 days until disease progression or unbearable toxicity, patient refusal or medical decision. Patients' clinical data will be collected pseudo-anonymously and a sequential identification code number will be assigned to each patient enrolled in the study.
47932076|NCT02269189|DRUG|BIIL 284 BS, high dose|
47932077|NCT02269189|DRUG|BIIL 284 BS, low dose|
47932078|NCT02269189|DRUG|Placebo|
47932079|NCT04551339|DIETARY_SUPPLEMENT|PreserVision AREDS formulation soft gels or tablets|Two tabs taken daily for three months
47932080|NCT04551339|DIETARY_SUPPLEMENT|Multivitamin with 11mg of zinc|One tab taken daily for three months
47932081|NCT06198140|OTHER|myofascial release and quick icing|In experimental group the individuals will receive myofascial release and quick icing. Quick icing will be on ankle dorsiflexors by using ice pack in the target area. Quick icing will be applied for 10 minutes (time of application 10 seconds and a rest for 20 seconds). This treatment protocol will be 6 times/week for 4 weeks in the hospital setting. Mayofascial release will be given on the target ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
47932082|NCT06198140|OTHER|myofascial release|In control group the individuals will receive only myofascial release on ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
47932083|NCT04438070|DIAGNOSTIC_TEST|COVID-19 Swab|Nasal, Oral-Nasal combined or Nasopharyngeal swab
48454839|NCT03257735|DIAGNOSTIC_TEST|next-generation sequencing|"1. Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.~2. Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).~3. Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.~All the samples were tested by next-generation sequencing."
47932084|NCT05498701|DRUG|Tafamidis free acid tablet (Test)|12.2 mg tafamidis free acid tablet (Test)
47932085|NCT05498701|DRUG|Tafamidis meglumine capsule (Reference)|Commercial 20 mg tafamidis meglumine capsule (Reference)
48454840|NCT04658225|PROCEDURE|0.12% chlorhexidine|the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
48454841|NCT05755113|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
48622617|NCT03697590|DRUG|Curettage|Standard PDT
47932086|NCT00397943|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
47932087|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
47932088|NCT00397943|BIOLOGICAL|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
47932089|NCT00397943|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
47932090|NCT00769665|OTHER|Systane Ultra|Re-wetting ocular eye drop
47932091|NCT00769665|OTHER|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
47932092|NCT06391190|DRUG|Albumin-Bound Paclitaxel, cisplatin, Sintilimab|with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles
47932093|NCT05651204|DIAGNOSTIC_TEST|GABA Blood Level|Blood specimens will be collected by a registered phlebotomist according to hospital's specimen collection procedures.
47932094|NCT02642939|DRUG|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
48098604|NCT00475813|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
48098605|NCT00692562|PROCEDURE|simultaneous islet-kidney transplantation|
48098606|NCT03158948|DRUG|Nangibotide 0.3 mg/kg|Formulated LR12 peptide
48098607|NCT03158948|DRUG|Placebo|placebo
48454842|NCT05954663|OTHER|Basic demographic information|"Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~* Clinical examination carried out 1 month after the operation and more than 6 months after the operation~* Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation"
48454843|NCT05098223|BEHAVIORAL|Intervention to remove price promotions on unhealthy foods when online shopping|Removal of price promotions on unhealthy foods
48454844|NCT01559363|DRUG|Tesevatinib|Pharmaceutical form: Tablets Route of administration: Oral
48454845|NCT03946462|DRUG|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
48454846|NCT03946462|OTHER|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
48454847|NCT04682327|OTHER|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
48454848|NCT04682327|OTHER|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
48454849|NCT03151577|PROCEDURE|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
48454850|NCT04919005|OTHER|Virtual Environment|The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
48454851|NCT06556823|OTHER|CLNDT+ Conventional PT in Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
48454852|NCT06556823|OTHER|CLNDT+ Conventional PT in non Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
48454853|NCT06556823|OTHER|SMWLM+ Conventional PT in Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
48454854|NCT06556823|OTHER|SMWLM+ Conventional PT in non Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
48454855|NCT03979664|DEVICE|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
48098608|NCT03158948|DRUG|Nangibotide 1 mg/kg|Formulated LR12 peptide
48098609|NCT03158948|DRUG|Nangibotide 3 mg/kg|Formulated LR12 peptide
48098610|NCT05846165|DEVICE|Field-Cycling Imaging (FCI)|FCI scan
48098611|NCT06596668|DRUG|bomedemstat|Oral tablet
48098612|NCT06596668|DRUG|carbamazepine|Oral extended-release capsule
48106824|NCT05263960|DRUG|CM350_group 5b|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 135ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
47932095|NCT05937464|OTHER|Exoskeleton ExoAthlet group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with exoskeleton ExoAthlet (ExoAtlet 1 model/2019, Russia). Participants were assessed at baseline and post-intervention.
47932096|NCT05937464|OTHER|Lokomat Free-D group|This group included 16 patients who had stroke. The patients was evaluated with Functional Independence Measure (FIM), physical function with 30-second chair stand test (30-CST), functional capacity with 6-Minute Walk Test (6MWT), and their quality of life with Short Form 36 (SF36). Conventional physiotherapy program was applied to groups for eight weeks, three days a week, each session 60 minutes. Then, one group received walking exercise training with Lokomat Free-D (Hocoma, Lokomat Pro Free-D model/2015, Switzerland). Participants were assessed at baseline and post-intervention.
47932097|NCT00413088|DRUG|bemiparin|
48454856|NCT03979664|DEVICE|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
48454857|NCT03979664|DRUG|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
48454858|NCT00842062|DEVICE|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
48454859|NCT05997797|OTHER|FAAM|The FAAM is made out of two subscales including ADL and Sports subscales that have a complete score of 84 and 32, individually
47932098|NCT00749814|DIETARY_SUPPLEMENT|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
47932099|NCT00749814|OTHER|Placebo tablets|Placebo
48454860|NCT03324139|DRUG|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
47932100|NCT03276273|DEVICE|recording of Bispectral Index|recording of Bispectral Index
47932101|NCT03521804|DEVICE|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
47932102|NCT04941443|DRUG|Methadone Pill|All participants will be given a 5mg methadone tablet to be taken immediately following the misoprostol dose.
47932103|NCT04941443|DRUG|Ibuprofen|All participants will be provided additional analgesics (ibuprofen 800mg x4 tabs) available for use as needed every eight hours.
47932104|NCT02854475|PROCEDURE|Venous blood collection|weekly within two weeks
47932105|NCT02854475|PROCEDURE|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
47932106|NCT04957433|DIAGNOSTIC_TEST|Blood Specimen|Blood and Sputum Specimen Samples
47932107|NCT03682809|DRUG|Systane Complete|Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
47932108|NCT04397887|PROCEDURE|micro-surgical varicocelectomy|Sub-inguinal micro-surgical varicocelectomy
47932109|NCT04390932|OTHER|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
47932110|NCT04390932|OTHER|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
47932111|NCT04390932|OTHER|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
47932112|NCT05258669|BIOLOGICAL|BBV152|Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.
47932113|NCT06224920|DIAGNOSTIC_TEST|magnetic resonance imaging|MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
47932114|NCT06224920|OTHER|electroencephalography|A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
48454861|NCT03324139|DRUG|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
48454862|NCT00975494|DRUG|Sildenafil|
48454863|NCT00975494|DRUG|Placebo|
48454864|NCT02484807|OTHER|no intervention, only observation of different groups|
48454865|NCT01902719|BEHAVIORAL|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
48454866|NCT01902719|BEHAVIORAL|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
48454867|NCT01902719|BEHAVIORAL|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
48454868|NCT03218787|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
48454869|NCT03218787|DRUG|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
48454870|NCT02654145|DRUG|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
48454871|NCT02654145|DRUG|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
48454872|NCT02654145|DRUG|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
48454873|NCT00343681|BIOLOGICAL|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
48454874|NCT01203215|BEHAVIORAL|2 print based physical activity interventions|physical activity promotion
48454875|NCT01969123|DRUG|Drug: EVP-6124|
48454876|NCT01969123|DRUG|Placebo|
48454877|NCT04261374|DIAGNOSTIC_TEST|Measurement of sublingual microcirculation|Measurement of sublingual microcirculation
48454878|NCT00343213|PROCEDURE|colposcopy|
48454879|NCT06356636|BEHAVIORAL|Financial Inclusion Improves Sanitation and Health|This innovative model engages transformative partnerships which include four key stakeholders (communities, communities, governments, entrepreneurs, and financiers) to improve sanitation services and supply value chains. The work is two-sided: to create demand for improved sanitation facilities in communities while facilitating microcredit access for people and sanitation businesses on the supply side.
48454880|NCT04423835|PROCEDURE|Paley's Principle osteotomy|. The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
47932115|NCT06224920|DIAGNOSTIC_TEST|blood and CSF biomarker|Aβ1-42 and 1-40, total tau protein and phosphorylated tau protein 181 (p-Tau), apolipoprotein E (APOE), soluble TREM2 protein, neurofilament light chain and glial fibrillary protein (GFAP) will be determined.
48454881|NCT04296123|BEHAVIORAL|Step training|A 12-week step training consisting of two 30-minute training session per week. The participants will be instructed to stand upright and step on different targets on a plastic mat repeatedly.
48454882|NCT00837564|OTHER|CBASP psychotherapy|specific psychotherapy for chronic depression
48454883|NCT00837564|DRUG|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
48454887|NCT04001062|PROCEDURE|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
48454888|NCT04001062|OTHER|Non-Operative Management|"1. For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~2. For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
48454889|NCT06133816|BEHAVIORAL|Framed Introductory Message A|Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).
48454890|NCT06133816|BEHAVIORAL|Framed Introductory Message B|Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).
48098613|NCT06492577|OTHER|Pulmonary rehabilitation protocol|In the initial phase (days 1-7), aerobic exercise sessions will be 20-30 minutes, strength training will include 1-2 sets at 50% of 1RM, and breathing exercises will last 10 minutes daily. In the progressive phase (days 8-14), aerobic exercise sessions will increase to 30-40 minutes, strength training to 2-3 sets at 60% of 1RM, and breathing exercises to 10-15 minutes daily. In the advanced phase (days 15-21), aerobic exercise sessions will be 40-45 minutes, strength training will be 2-3 sets at 70% of 1RM, and breathing exercises will continue for 10-15 minutes daily.
47932116|NCT06224920|DIAGNOSTIC_TEST|positron emission tomography|According to an established and standardized protocol, PET scans are performed with the TSPO receptor ligand \[18F\]-GE-180, \[18F\]flutemetamol for assessment of fibrillar Aβ 162 accumulation and the Tau ligand \[18F\]-PI-2620. In brief, \[18F\]GE-180 TSPO PET images (mean dose: 177 ± 17 MBq) with an emission window of 60-80 min after injection will be acquired to measure the activation of glial cells. \[18F\]Flutemetamol Aβ PET images (average dose: 182 ± 11 MBq) are acquired with an emission window of 90-110 min after injection to assess fibrillar Aβ accumulation. Dynamic \[18F\]PI-2620 tau PET (average dose: 186 ± 14 MBq) with an emission window of 0-60 minutes after injection are performed for quantification of tau aggregation. Static images of the late phase (20-40 min) are reconstructed. These images are used for further processing and analysis.
47932117|NCT06224920|DIAGNOSTIC_TEST|neuropsychological test|Trained psychologists at the Memory Clinic of the LMU Hospital administered the CDR, CERAD-NB and Mini-Mental State Examination (MMSE). The CERAD-NB battery was used to generate a total score for the six subscales: semantic fluency (animals/60 s), modified Boston naming test, lexical items, construction practice, lexical items retrieval, and lexical items discrimination, with higher scores indicating better performance.
47932118|NCT05999760|DEVICE|evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge|Evaluation of retention of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
47932119|NCT05999760|DEVICE|chewing efficiency by electromyograph(E.M.G)|Evaluation of chewing efficiency of Versacryle and CAD/CAM partial dentures by force gauge on day one, on first month, and on the second month of prosthesis delivery.
47932120|NCT05999760|OTHER|masticatory performance(questionnaire)|Evaluation of masticatory performance of Versacryle and CAD/CAM partial dentures by questionnaire on day one, on first month, and on the second month of prosthesis delivery.
47932121|NCT04482985|DRUG|Meclizine Hydrochloride|Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
47932122|NCT04764266|DIAGNOSTIC_TEST|Heparansulfate and Syndecan 1|Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
47932123|NCT01802970|DRUG|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle), or capecitabine (1000mg/m\^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m\^2 intravenous on day 1 \& 8 of a 21 day cycle), or vinorelbine (25mg/m\^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
47932124|NCT03976180|DEVICE|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
47932125|NCT03976180|DEVICE|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
47932126|NCT03976180|DEVICE|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
48454891|NCT06133816|BEHAVIORAL|Framed Introductory Message C|Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).
48454892|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message A|Randomly assign patients to receive norming message related to tobacco use (version A).
48454893|NCT06133816|BEHAVIORAL|Framed Tobacco Use Message B|Randomly assign patients to receive norming message related to tobacco use (version B).
48454894|NCT06133816|BEHAVIORAL|Financial Incentive|Randomly assigned patients to be entered into a drawing to receive a $100 gift card.
48454895|NCT06626139|DRUG|Psilocybin|Healthy participants will receive up to 25 mg psilocybin.
48454896|NCT06626139|BEHAVIORAL|Context 1|Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.
48454897|NCT06626139|BEHAVIORAL|Context 2|Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.
47932127|NCT03976180|DEVICE|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
47932128|NCT01884727|DIETARY_SUPPLEMENT|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
48106825|NCT05263960|DRUG|CM350_group 6a|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 45ug of CM350 on the first day of first cycle (C1D1), 135ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48454898|NCT06626139|DRUG|Placebo|Healthy participants will receive an inactive placebo.
48454899|NCT03600753|OTHER|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
48454900|NCT03600753|OTHER|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
48454901|NCT06415760|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
48454902|NCT05718687|DRUG|GBT021601|Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
48454903|NCT06134453|OTHER|Reiki/Sham Reiki|Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
48454904|NCT00011063|DRUG|Ginkgo Biloba|
48454905|NCT03882762|DRUG|Cebranopadol 200 μg tablet|200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
48454906|NCT06625021|PROCEDURE|Chiropractic manipulation|"Chiropractic manipulation: Lower cervical chiropractic manipulation is a technique used to increase mobility and relieve pain in the lower vertebrae of the neck. However, such procedures should only be performed by trained chiropractors; if done incorrectly, they can lead to serious problems. The patient should be placed in a comfortable position. The supine or side-lying position is usually preferred. Contact is established with the transverse processes of the lower cervical vertebrae. High-velocity, Low-amplitude thrust is applied within anatomical limits.~As a graduate of Bahcesehir University Chiropractic Masters Degree, I applied chiropractic twice a week for 3 weeks."
48454907|NCT06625021|PROCEDURE|Exercises to be done for neck pain of mechanical origin|Conservative treatment, which is frequently used in the treatment of mechanical neck pain, was planned. A warm-up period was defined with stretching exercises in all areas of neck movement. Again, isometric exercise should be 10 seconds in all directions. In addition to neck and shoulder mobility exercises, neck region posture exercises were included. It was planned to do these exercises for 4 weeks, 5 days a week, in all 4 groups.
48454908|NCT06625021|PROCEDURE|Classic Hand-Wrist Exercises|The participants of this group will be subjected to wrist range of motion (ROM), stretching and strengthening exercises. Measurements will be made in all axes of motion of the wrist, which are extension, flexion, ulnar and radial deviation. ROM exercises and stretching exercises were applied passively to all axes of motion within anatomical limits. At the last angles of the movement, the individual was forced and stretched without causing discomfort and waited at the last angles for a short time. Stretching exercises were performed five times for each movement. Strengthening exercises for all axes of movement of the wrist will be performed using dumbbells weighing 1 and 2 kilograms and an exercise band suitable for the persons endurance and strength. In exercises performed with dumbbells, all movements of the wrist will be performed against gravity. All applications were applied to the classical hand-wrist exercise group for at least half an hour every day for 4 weeks.
48454909|NCT06625021|PROCEDURE|Proprioceptive exercise group|Similar to the classical wrist exercise group, the participants in this group were applied joint range of motion, stretching and strengthening exercises as well as proprioceptive exercises such as joint approximation, traction and mobilization. In addition to all axes of motion of the wrist, active and passive stretching exercises were applied to the forearm flexor and extensor muscles five times each. The resistance and repetition number were gradually increased according to the wrist strength and endurance of the individuals to at least 10 repetitions. Repetitive contraction and rhythmic stabilization techniques were used from proprioceptive neuromuscular facilitation methods. Joint approximation technique and taping of forearm flexor and extensor muscles were used to increase the level of contraction and stimulation of joint receptors. External stabilization and perturbation exercises were performed with an exercise ball against the wall at different angles of the upper extremity.
48454910|NCT01487720|DRUG|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
48454911|NCT01108445|DRUG|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
48454912|NCT01108445|DRUG|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
48454913|NCT02550535|GENETIC|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
48454914|NCT03601403|DEVICE|inhaler technique|The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
48454915|NCT02991196|DRUG|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
48454916|NCT04941638|PROCEDURE|Distal radial access|Vascular access for primary PCI in patients with STEMI
48454917|NCT05928247|BEHAVIORAL|Functional Communication Training (FCT)|During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), the investigators also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), the investigators will recommend using a chained schedule FCT (chained-FCT).
48454918|NCT05928247|BEHAVIORAL|Non-Contingent Reinforcement (NCR)|During NCR, the investigators will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).
48622618|NCT05521477|DIETARY_SUPPLEMENT|SLAB51|One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
48454919|NCT05928247|BEHAVIORAL|Competing Items and Response Blocking|The investigators will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. The investigators will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. The investigators will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
48454920|NCT05928247|BEHAVIORAL|Research Units in Behavioral Intervention (RUBI) protocol|Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
47932129|NCT01884727|DIETARY_SUPPLEMENT|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
48454921|NCT03653299|DEVICE|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
48454922|NCT05062564|DEVICE|LipiFlow Thermal pulsation system|Single treatment with LipiFlow thermal pulsation system on the eyelids within two months before surgery
47932130|NCT00224653|PROCEDURE|Mechanical Ventilation|
47932131|NCT00981773|DRUG|Maraviroc|Maraviroc 150 mg bid
48454923|NCT05062564|PROCEDURE|Eyelid warm compresses plus massages|Eyelid warm compresses plus massages twice a day for the preoperative month
47932132|NCT00981773|DRUG|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
47932133|NCT01813045|PROCEDURE|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
47932134|NCT01813045|RADIATION|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
47932135|NCT01813045|RADIATION|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
47932136|NCT02652767|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
47932137|NCT02652767|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
47932138|NCT01138943|DRUG|Synthodont|"15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse"
47932139|NCT01138943|DRUG|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse"
47932140|NCT02311218|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
47932141|NCT02311218|DIETARY_SUPPLEMENT|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
47932142|NCT00409305|DRUG|Betahistine|
47932143|NCT00409305|BEHAVIORAL|Dietary counseling|
47932144|NCT04572438|PROCEDURE|Tracheostomy|Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.
47932145|NCT03188172|DRUG|Cyclophosphamide|Chemotherapy
47932146|NCT03188172|DRUG|Bortezomib|Chemotherapy
48098614|NCT06492577|OTHER|Progressive muscle relaxation protocol|Participants in this arm will undergo a 21-day progressive muscle relaxation (PMR) program aimed at reducing anxiety and improving sleep quality in patients with long-term COVID-19 symptoms. Each daily session lasts 20 minutes and involves systematic muscle tensing and relaxation, starting from the feet and progressing to the head, combined with slow, deep breathing. During the initial phase (days 1-7), the focus is on introducing PMR techniques and targeting different muscle groups. In the progressive phase (days 8-14), full-body PMR sessions enhance relaxation and breathing techniques. The advanced phase (days 15-21) maximizes relaxation and incorporates visualization techniques.
48454924|NCT00473954|GENETIC|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
48454925|NCT02263703|BIOLOGICAL|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
47932147|NCT03188172|DRUG|Lenalidomide|Chemotherapy
47932148|NCT03188172|DRUG|Daratumumab|Chemotherapy
47932149|NCT03188172|DRUG|Dexamethasone|Chemotherapy
47932150|NCT03188172|DRUG|Melphalan|Chemotherapy
48454926|NCT02164435|PROCEDURE|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
48454927|NCT05451264|DIAGNOSTIC_TEST|blood pressure measurement|Completion of the physical activity and quality of life questionnaire (PedSQL adapted to the age of the child), measurement of weight and height; Measurement of VOP (Pulse wave velocity), AI (increase index) and ECG (electro cardiogram) collection at rest lying down; Stimulation test by slow breathing at 6 cycles/min for three minutes; Continuation of the measurements in a standing position for 5 minutes; Installation of blood pressure holter (MAPA) which will be kept for 24 hours and then returned by post.
48454928|NCT03227939|PROCEDURE|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
48454929|NCT03227939|PROCEDURE|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
47932151|NCT03188172|DRUG|Filgrastim|Haematopoietic agent for the stem cell harvest
47932152|NCT00384111|DRUG|Zevalin Therapeutic Regimen|Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
47932153|NCT00384111|DRUG|R-CVP|Standard R-CVP
47932154|NCT01376557|DRUG|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
47932155|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
47932156|NCT01376557|DRUG|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
47932157|NCT01376557|DRUG|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
47932158|NCT01376557|DRUG|Placebo|Subjects will receive placebo once daily.
47932159|NCT04259892|BIOLOGICAL|2019-nCoV PCR|Nasopharyngeal swabs
47932160|NCT04785690|DEVICE|CureSight|Subjects assigned to the binocular treatment group will be prescribed the CureSight treatment to watch for 90 minutes per day, 5 days a week for 16 weeks for the total of 120 hours. Parents of subjects will be instructed that the 90 minutes of daily treatment should be completed in a single 90-minute session, but if this is not possible for whatever reason, the treatment may be divided into two shorter sessions totaling 90 minutes per day
47932161|NCT04785690|DEVICE|Patching|"Subjects assigned to the patching group will wear an adhesive patch over the dominant eye for 2 hours per day, 7 days per week for 16 weeks. Parents of subjects will be instructed that the 2 hours of daily patching should be completed in a single 2-hour session, but if this is not possible for whatever reason, the treatment may be divided into shorter sessions totaling 2 hours.~Parents will be asked to complete a usage diary by manually recording the patch usage time on daily basis."
47932162|NCT01283854|BEHAVIORAL|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
47932163|NCT01546402|DRUG|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
47932164|NCT01546402|PROCEDURE|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
47932165|NCT05112276|OTHER|Diet|A review has been undertaken to both identify specific bacteria associated with cardiometabolic risk factors and food items that have been shown to affect such bacteria in a beneficial direction. The intervention diet will include a variety of food items e.g. vegetables, fermented vegetables, fermented dairy products and cereal products. The control diet is based on a Swedish Average Diet
47932166|NCT01252303|BEHAVIORAL|Nutrisystem|Nutrisystem meal replacements for 12 weeks
47932167|NCT06436300|BEHAVIORAL|Motivational text messaging|Intervention sends up to 4 motivational messages by text or email to Alaska Native men who are active patients and due for colorectal cancer screening. Incentive arms include promise of a $50 gift card or entry into a raffle for prize worth about $200 if they complete screening.
47932168|NCT00072527|DRUG|carboplatin|IV
47932169|NCT00072527|DRUG|cisplatin|IV
47932170|NCT00072527|DRUG|etoposide|IV
47932171|NCT00072527|DRUG|irinotecan hydrochloride|IV
47932172|NCT00072527|RADIATION|radiation therapy|
47932173|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 1|Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
47932174|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part a dose arm 2|High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)
47932175|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 1|Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3
48622619|NCT03602781|DRUG|Placebo|Placebo at a dose setting of 75 mcg/kg IBW/hr
48622620|NCT03602781|DRUG|iNO|iNO at a dose setting of 75 mcg/kg IBW/hr
48280321|NCT06656546|DIAGNOSTIC_TEST|Lung Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. Following ETI, the presence of lung sliding will be evaluated using ultrasound with the aid of a linear probe.The transducer will be placed bilaterally along the mid-axillary line, between the second and fifth intercostal spaces, in a coronal orientation. After the ETT is placed and ventilation is initiated, the movement of the visceral and parietal pleura will be assessed. The presence of sliding motion between these pleural layers during ventilation indicates successful intubation, whereas the absence of this movement suggests a failed intubation.
48454930|NCT05255393|OTHER|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
48454931|NCT02385708|DRUG|2% Chlorohexidine Gluconate Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
48454932|NCT02385708|DRUG|2% Chlorohexidine Gluconate Chin to Toe|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
48454933|NCT03412058|PROCEDURE|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
48454934|NCT03412058|PROCEDURE|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
48454935|NCT03412058|PROCEDURE|Biopsy|To be performed at disease progression if medically feasible
48454936|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
48454937|NCT01034215|BEHAVIORAL|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
48454938|NCT03257956|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
48454939|NCT03257956|DEVICE|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
48454940|NCT01803594|DIETARY_SUPPLEMENT|Krill Oil|Neptune Krill Oil Gold
48454941|NCT01803594|DIETARY_SUPPLEMENT|Lutein|Jarrow Formulas
48454942|NCT01803594|DIETARY_SUPPLEMENT|Nicotinic acid|Natures Way
47932176|NCT06254820|BIOLOGICAL|influenza B/Connecticut/1/21 virus part b dose 2|Addition of a 3rd dose, TBD depending on outcome of Part A
47932177|NCT00761150|DRUG|ABT-712|ABT-712 extended-release tablet
47932178|NCT00761150|DRUG|Placebo|Placebo tablet
47932179|NCT05480774|DRUG|KRG hard capsule|Each subject was given orally 2 KRG hard capsules/day for 12 weeks
48454943|NCT01803594|DIETARY_SUPPLEMENT|Dairy phospholipids|PC700 manufactured by Fonterra
48454944|NCT01803594|OTHER|Control|Control shake without dietary supplements
47932180|NCT05480774|DRUG|Placebo hard capsule|Each subject was given orally 2 placebo hard capsules/day for 12 weeks
47932181|NCT00321893|DRUG|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
47932182|NCT00321893|OTHER|Placebo|Inhaled placebo twice daily for one year.
47932183|NCT06080139|BEHAVIORAL|Refugee parenting education in a participatory community|"Parents will vote for one of the 5 previously studied refugee parenting curriculums: 1) Creating Opportunities Through Mentoring Parenting Involvement and Safe Space (COMPASS); 2) GenerationPMTO; 3) Happy Families; 4) Family Strengthening Intervention for Refugees (FSI-R).~Researchers will use a model of Learning by Observing and Pitching In (LOPI), to empower community members in the learning process. LOPI is a multicomponent way of organizing group learning that improves collaboration, alertness, and executive functions such as perspective-taking and self-regulation in addition to specific skills learning and has been used in many indigenous and indigenous-heritage communities of the Americas."
48098615|NCT05014555|BIOLOGICAL|COVID-19 Vaccine|Three-dose mRNA COVID-19 vaccine per standard of care
48454945|NCT05366582|DEVICE|Macintosh Laryngoscope|"After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal carbon dioxide (CO2). Failed intubation will be considered if not achieved within 2 minutes"
48454946|NCT05366582|DEVICE|Video Laryngoscope|"After the induction, laryngoscopy will be performed with a Video laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. Patients will be intubated with the Medtronic Xomed Nerve Integrity Monitor Standard Reinforced ElectromyographyEndotracheal Tube (size 6.0, 7.0 or 8.0). The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2. Failed intubation will be considered if not achieved within 2 minutes"
48454947|NCT02951247|DEVICE|Hearing Aid|Successor of Phonak Virto V90-10 NW O
48454948|NCT03413202|DRUG|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
47932184|NCT03541876|OTHER|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
48454949|NCT03413202|DRUG|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
47932185|NCT02486627|DRUG|plazomicin|
47932186|NCT02486627|DRUG|meropenem|
47932187|NCT02486627|DRUG|levofloxacin (oral)|
47932188|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
47932189|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
47932190|NCT02257801|DIETARY_SUPPLEMENT|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
47932191|NCT04079673|PROCEDURE|Patient controlled epidural analgesia|Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control
47932192|NCT04079673|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
47932193|NCT03396757|PROCEDURE|Standard strategy|"RRT is initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),"
47932194|NCT03396757|PROCEDURE|Delayed strategy|"RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice."
47932195|NCT06463275|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument).
47932196|NCT00234247|OTHER|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
47932197|NCT00611871|DRUG|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
47932198|NCT00611871|DRUG|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
47932199|NCT03129256|DRUG|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
47932200|NCT00746408|OTHER|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
47932201|NCT02127268|DRUG|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
47932202|NCT00400478|DRUG|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
47932203|NCT00259129|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
47932204|NCT04272879|OTHER|Observational Group|Those requiring NIV following an acute exacerbation of COPD
47932205|NCT02634476|BEHAVIORAL|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
47932206|NCT02634476|BEHAVIORAL|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
48454950|NCT03317444|DRUG|TRC101|Oral suspension
48454951|NCT03317444|DRUG|Placebo|Oral suspension
48454952|NCT04624360|DRUG|Dexamethasone|Intravenous of Dexamethasone 8 mg post clamping of the umbilical cord
48454953|NCT04624360|OTHER|Placebo|2cc 0.9% Saline
48454954|NCT00433719|DRUG|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
48622621|NCT01932606|DRUG|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
48622622|NCT01932606|DRUG|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
47932207|NCT03442400|DEVICE|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire|We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
47932208|NCT05384145|OTHER|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
47932209|NCT01331018|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow harvest
47932210|NCT01331018|BIOLOGICAL|Filgrastim|Given SC
47932211|NCT01331018|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
47932212|NCT01331018|OTHER|Laboratory Biomarker Analysis|Correlative studies
47932213|NCT01331018|PROCEDURE|Leukapheresis|Undergo leukapheresis
48622623|NCT05525468|DRUG|TDM-180935|TDM-180935 topical ointment
47932214|NCT01331018|DRUG|Methylprednisolone|Given IV
47932215|NCT01331018|DRUG|Plerixafor|Given SC
47932216|NCT01331018|DRUG|Prednisone|Given PO
47932217|NCT02318108|OTHER|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
47932218|NCT02318108|OTHER|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
47932219|NCT03444077|DIAGNOSTIC_TEST|Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.|The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS \< 10 will be classified as not in need for DCR.
47932220|NCT03444077|DIAGNOSTIC_TEST|Regular care|Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.
47932221|NCT03444077|OTHER|STTTOPPP the bleeding|"* Surgical team pre-activation~* Trauma team pre-activation~* Transfusion team pre-activation~* Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~* O negative RBC transfusion as soon as possible~* Plasma and Platelets transfusion as soon as possible~* Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~* Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)"
47932222|NCT03444077|OTHER|Regular Care|Regular local pre-hospital care.
47932223|NCT01281527|DRUG|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
47932224|NCT02284932|OTHER|No specific intervention for this study|No specific intervention for this study
47932225|NCT00003798|DRUG|motexafin gadolinium|
47932226|NCT00003798|RADIATION|radiation therapy|
47932227|NCT01173887|DRUG|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
47932228|NCT01173887|BIOLOGICAL|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
47932229|NCT02962375|DIETARY_SUPPLEMENT|Active|100% orange juice with orange pomace fiber
47932230|NCT02962375|DIETARY_SUPPLEMENT|Control|100% orange juice
47932231|NCT01367080|DRUG|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
47932232|NCT01367080|DRUG|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
47932233|NCT05582954|BEHAVIORAL|EsteemUp|EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
47932234|NCT05582954|BEHAVIORAL|EsteemUp-G|The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
47932235|NCT01574079|OTHER|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
47932236|NCT01574079|OTHER|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
47932237|NCT03199339|DRUG|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
47932238|NCT03199339|DRUG|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
47932239|NCT00937885|BEHAVIORAL|Implementation of reminiscence|
47932240|NCT05270161|PROCEDURE|Tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The incision was extended to the adjacent tooth on both sides of the multiple recessions. Dissection of the entire buccal aspect was performed as a partial-thickness flap using sharp tunnel elevators preserving the papillae. The flap was extended beyond the mucogingival junction and under each papilla allowing a tension-free flap mobilization in the coronal direction. The connective tissue graft was placed in the tunnel and was stabilized using absorbable suspensory sutures. The mobilized mucous flap was advanced coronally to the cemento enamel junction, and suspensory sutures were stitched.
48622624|NCT05525468|DRUG|Placebo|Placebo for TDM-180935 topical ointment
47932241|NCT05270161|PROCEDURE|Laterally closed tunnel technique|Intrasulcular incisions on the buccal surface were made using a n°15 C blade, preserving the integrity of the papillae. The tunnel elevators were mobilized apically beyond the mucogingival line and extended medially and distally from the recession defect by undermining the facial surface of the interdental papillae. The insertion of muscles and fibers must be removed until a tension-free flap is obtained in the mesial, apical and distal directions. The preparation of the flap will be done carefully to avoid rupture of the papillae and perforation of the flap. As a result of this procedure, the mesial and distal margins of the flap must be brought together without tension to cover the exposed part of the root surface. The connective tissue graft was placed in the tunnel and was fixed mesially and distally at the inner aspect of the flap. Margins of the flap were pulled together over the graft and sutured with interrupted sutures.
47932242|NCT05270161|PROCEDURE|Free gingival graft|In the recipient area, a marginal horizontal linear incision will be made in the mucogingival junction with a n°15 C blade, creating a partial thickness flap, keeping the periosteum intact. The horizontal dimension of the receiving area will be determined according to the mesiodistal extension of the area without keratinized gingiva. All mobile soft tissues, including epithelium, connective tissue and muscle fibers will be removed from the donor area using scissors to ensure stability in the recipient area. The connective tissue graft will be obtained by the free gingival graft technique and will be sutured in the recipient area.
48454955|NCT04866979|DEVICE|Experimental: Continuous TBS (cTBS)|Application of cTBS. cTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), with a stimulation intensity equal to 80% of the motor threshold value at rest.
47932243|NCT05270161|PROCEDURE|Gingival graft - donor area|The connective tissue graft will be obtained by the free gingival graft technique for all groups (T1, T2, T3 and T4). The mold of the prepared receiving area will be performed using sterile aluminum foil. The mold will be transferred to the donor area on the palate and the edges of the mold delimited with a scalpel blade. Deeper incisions will be made on the edges with the scalpel perpendicular to the palate, aiming to obtain a graft approximately 1.5 mm thick. With the scalpel blade parallel, the graft will be removed (epithelium and connective graft) maintaining its uniform thickness. For T1 and T2, the free gingival graft will be de-epithelialized. In donor area, a hyaluronic acid gel and green tea will be applied by the participant 3 times a day for 7 days (gel group) or no material will be placed in the donor area and the clot will be kept in position by means of sutures (clot group).
47932244|NCT01455129|DRUG|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
47932245|NCT01455129|DRUG|placebo|placebo, once daily, inhaled by HandiHaler
47932246|NCT01245361|DRUG|Infliximab|Infliximab 3 mg/kg wk 0,2,6
47932247|NCT01245361|DRUG|sodium chloride|Group II : Placebo wk 0,2,6
47932248|NCT05244980|DRUG|TDM-105795|TDM-105795 topical solution
47932249|NCT05244980|DRUG|Placebo|Placebo for TDM-105795 topical solution
47932250|NCT04532424|DEVICE|Transcranial magnetic stimulation|Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
47932251|NCT01955798|PROCEDURE|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
47932252|NCT01955798|PROCEDURE|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
48454956|NCT04866979|DEVICE|Intermittent TBS (iTBS)|Application of iTBS. iTBS will be applied to the left dorsolateral prefrontal cortex (left DLPFC). The coil will be placed at the EEG 10-20 International System position of the F3 electrode. Stimulation parameters will be TBS delivery of of 600 pulses divided into blocks of 3 pulses at 50 Hz, which are applied at 5 Hz (every 200 ms), alternating 2 seconds of stimulation with a pause of 8 seconds, with a stimulation intensity equal to 80% of the motor threshold value at rest.
48454957|NCT04866979|BEHAVIORAL|Cognitive training (CT).|Cognitive training (memory rehabilitation via RehaCom computer software) of 25 min. The training will be focused on memory rehabilitation, implementing a face-name association paradigm. The software uses an individualized adaptive methodology based on the participant's performance.
48454958|NCT04866979|DEVICE|Sham Stimulation (shamTBS)|"Sham rTMS (TBS) will be administered by applying a 30mm thick piece of wood or plastic to a real TMS coil during stimulation, and this additional element will be constructed in such a way that it appears to be an integral part of the apparatus such that the patient remains unaware that they are not receiving stimulation (Rossi et al., 2007 ).This 30mm distance is adequate to ensure that the magnetic pulse does not reach the cortex."
47932253|NCT01955798|DEVICE|Trocar|
47932254|NCT01955798|DEVICE|Veress needle|
47932255|NCT03609398|BIOLOGICAL|RVF Vaccine|1.0 mL dose given SQ in upper arm
47932256|NCT05045378|DRUG|Midazolam (active placebo)|Arm1: Two 0.045mg/kg midazolam infusions at Day1 and Day3。
47932257|NCT05045378|DRUG|Ketamine and Midazolam (active placebo)|Arm2: First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion。
47932258|NCT05045378|DRUG|Ketamine|Arm3: Two 0.5mg/kg ketamine infusions。
47932259|NCT02162576|DEVICE|Propeller Health intervention|The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
47932260|NCT05002920|PROCEDURE|alveolar bone grafting|the surgery of alveolar bone graft for alveolar defect in cleft patients
47932261|NCT02403687|DRUG|baclofen 2%|compound topical cream
47932262|NCT02403687|DRUG|Bupivacaine hydrochloride 1%|compound topical cream
47932263|NCT02403687|DRUG|Cyclobenzaprine hydrochloride 2%|compound topical cream
47932264|NCT02403687|DRUG|Diclofenac Sodium 3%|compound topical cream
47932265|NCT02403687|DRUG|Flurbiprofen 10%|compound topical cream
47932266|NCT02403687|DRUG|Gabapentin 6%|compound topical cream
48454959|NCT00268203|BIOLOGICAL|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
47932267|NCT02403687|DRUG|Ketamine 10%|compound topical cream
47932268|NCT02403687|DRUG|Lidocaine 2%|compound topical cream
48454960|NCT02206893|BEHAVIORAL|Self-monitoring via Smartphone|
48454961|NCT02206893|BEHAVIORAL|Peer support via Smartphone|
47932269|NCT02403687|DRUG|Prilocaine 2.5%|compound topical cream
47932270|NCT02403687|DRUG|Meloxicam 0.09%|compound topical cream
47932271|NCT02403687|DRUG|Sumatriptan 5%|compound topical cream
47932272|NCT02403687|DRUG|Tizanidine 0.1%|compound topical cream
47932273|NCT02403687|DRUG|Topiramate 2.5%|compound topical cream
47932274|NCT02403687|DRUG|Capsaicin, USP 0.0375%|compound topical cream
47932275|NCT02403687|DRUG|Menthol, NF 5.00 %|compound topical cream
47932276|NCT01463137|BEHAVIORAL|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
47932277|NCT03744143|PROCEDURE|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
47932278|NCT03744143|PROCEDURE|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
47932279|NCT03744143|PROCEDURE|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
47932280|NCT06057155|DIAGNOSTIC_TEST|ultrasound optic nerve sheath diameter assessment|ultrasound optic nerve sheath diameter assessment
48454962|NCT02206893|BEHAVIORAL|Professional support via Smartphone|
48454963|NCT02206893|BEHAVIORAL|Self-monitoring via Web (Static)|
48454964|NCT04800718|OTHER|Intervention Arm|Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
48454965|NCT00767260|DRUG|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
48622625|NCT02597114|DRUG|AGT-181|intravenous infusion over 3-4 hours
47932281|NCT02054871|PROCEDURE|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
47932282|NCT06234332|OTHER|No Interventions|No intervention This is an observational study without any intervention
47932283|NCT03085277|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
47932284|NCT03085277|DIETARY_SUPPLEMENT|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
47932285|NCT01145638|DRUG|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
47932286|NCT01145638|DRUG|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
47932287|NCT03889483|DEVICE|NeuroCatch™ Platform|The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
47932288|NCT03121976|DEVICE|Ultrasound|Femoral catheter inserted using ultrasound only
47932289|NCT03121976|DEVICE|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
47932290|NCT02510755|OTHER|MRI|
48106826|NCT05263960|DRUG|CM350_group 6b|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 270ug on C1D8, 270ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48454966|NCT00767260|DRUG|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
48454967|NCT00767260|DEVICE|HOT|Hyperbaric Oxygen Therapy
48454968|NCT00767260|DRUG|SMT|hypoglycemic drugs or exogenous insulin
48622626|NCT03588468|OTHER|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
48622627|NCT03588468|OTHER|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
47932291|NCT06091072|OTHER|Image-guided navigation|A patient-specific 3D model will be created using an available pre-operative SPECT/CT scan. Pre-operatively, three electromagnetic patient trackers will be attached to the patients' skin, close to the pelvis, allowing tracking the patient's position during surgery. After anesthesia and before the skin disinfection procedure, the patient is placed in the final surgical position, where an intra-operative CBCT scan is performed required for the image-guided surgery workflow. During surgery, the preoperative images and 3D model will be visible for the surgeon together with a blunt-tip electromagnetic pointer enabling surgical navigation during robotic surgery. Anatomical structures will be used to validate the accuracy of the navigation. When the target is identified by the surgeon, the pointer is used to store the location digitally. Scheduled standard clinical 99mTc will be used as validation for target(s) identification.
47932292|NCT02575066|RADIATION|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
47932293|NCT02575066|DRUG|pazopanib|pazopanib QD 800 mg
47932294|NCT03431272|DRUG|Lifitegrast|Eye drop
47932295|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
47932296|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
47932297|NCT04973189|DRUG|SHR-1707|A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
47932298|NCT04973189|DRUG|Placebo|A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
47932299|NCT01216605|DRUG|Syntocinon 24 IU|
47932300|NCT01216605|DRUG|Placebo|
47932301|NCT02043600|BEHAVIORAL|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
47932302|NCT02043600|BEHAVIORAL|Self-care|Self-care books are provided for self-directed use
47932303|NCT04516837|DRUG|Eltrombopag|Eltrombopag 25-75 mg oral daily according to platelet response.
47932304|NCT04516837|DRUG|rhTPO|Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
47932305|NCT00718562|DRUG|AMN107|
47932306|NCT05435040|DEVICE|proprioceptive knee brace|the patient will perform the tests with the knee brace
47932307|NCT05435040|DEVICE|No knee brace|the patient will perform the tests without the knee brace
47932308|NCT04473573|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
47932309|NCT00437970|DRUG|Pioglitazone|15mg of Pioglitazone taken orally twice a day
47932310|NCT00437970|DRUG|Metformin|500 mg of Metformin taken orally twice a day
47932311|NCT02203175|DRUG|saline|Before the anesthesia induction, 5 ml isotonic saline
47932312|NCT02203175|DRUG|fentanyl|before the anesthesia induction 50 mcgr fentanyl
47932313|NCT02203175|DRUG|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
47932314|NCT01606878|DRUG|Crizotinib|Given PO
47932315|NCT01606878|DRUG|Cyclophosphamide|Given IV
47932316|NCT01606878|DRUG|Dexrazoxane Hydrochloride|Given IV
47932317|NCT01606878|DRUG|Doxorubicin Hydrochloride|Given IV
47932318|NCT01606878|OTHER|Laboratory Biomarker Analysis|Correlative studies
47932319|NCT01606878|OTHER|Pharmacological Study|Correlative studies
47932320|NCT01606878|OTHER|Questionnaire Administration|Ancillary studies
47932321|NCT01606878|DRUG|Topotecan Hydrochloride|Given IV
47932322|NCT01606878|DRUG|Vincristine Sulfate|Given IV
48098616|NCT00815321|BIOLOGICAL|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
47932323|NCT00416728|DRUG|Aliskiren|
47932324|NCT00416728|DRUG|Valsartan|
47932325|NCT03461354|OTHER|MucoLox|MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
47932326|NCT03461354|OTHER|Sodium Bicarbonate|Sodium bicarbonate oral rinse
47932327|NCT02013583|OTHER|No intervention|This is an observational registry. No interventions are required or provided.
47932328|NCT06325332|OTHER|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
47932329|NCT02496507|OTHER|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
47932330|NCT04604691|DRUG|Blinatumomab for Injection|Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
47932331|NCT04250311|DRUG|MMH-407|MMH-407: For oral use.
47932332|NCT04250311|DRUG|Placebo|Placebo: For oral use.
47932333|NCT06154681|OTHER|World Digital Detox Family Program|The Self-Help World Digital Detox Family Program spans four weeks and offers a structured approach to tackle the rising issues associated with the overuse of screens, social media, and digital devices within families. This intervention provides practical tools and strategies to be implemented on a weekly basis.
47932334|NCT05110001|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.
47932335|NCT05110001|DRUG|Chlorhexidine Gluconate|Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
47932336|NCT05110001|DRUG|Natamycin|Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
47932337|NCT05110001|DRUG|Rose Bengal|Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
47932338|NCT05110001|OTHER|Placebo|Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
47932339|NCT05204303|DIAGNOSTIC_TEST|24-hour pH-impedance monitoring|Ambulatory transnasal reflux device to detect reflux events in the oeosphagus and pharynx.
47932340|NCT05204303|OTHER|Symptom questionnaires|Reflux Symptom Index (RSI) Gastroesophageal Reflux Disease Questionnaire (GERDQ) Short-form Esophageal Hypervigilance and Anxiety Scale (SF-EHAS)
48454969|NCT03732144|BEHAVIORAL|Connect Staff-based PA intervention|After school program sites receiving the Connect intervention will receive a 16 week program that includes three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum. Compared to control ASPs, ASPs receiving the 'Connect' program are expected to show greater improvements from baseline to post- and 6 mo follow-up in PA-related social mechanisms, youth PA, and staff PA.
48454970|NCT03732144|OTHER|Connect Health Curriculum Control|After school program sites receiving the general ASP health curriculum control will address the prevention of several negative health behaviors (e.g., substance use, stress, etc) and also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff. This arm will serve as the comparison group to the Connect Staff-based PA intervention
48454971|NCT05068284|DRUG|ABBV-154|Intravenous (IV) Infusion; Subcutaneous Injection
48454972|NCT05068284|DRUG|Placebo|Intravenous (IV) infusion; Subcutaneous Injection
48454973|NCT05068284|DRUG|ABBV-154|Subcutaneous Injection
48454974|NCT05068284|DRUG|Placebo|Subcutaneous Injection
48454975|NCT01861535|DRUG|Imiquimod|
48454976|NCT01861535|PROCEDURE|Surgery|
48454977|NCT01899352|PROCEDURE|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
48454978|NCT04084795|BEHAVIORAL|Eye Movement Desensitization and Reprocessing therapy|"EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation."
47932341|NCT05204303|OTHER|ROME IV Diagnostic Questionnaire|A symptom-based questionnaire used to diagnose disorders of gut-brain interaction (DGBI)
47932342|NCT01625533|PROCEDURE|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
47932343|NCT01625533|PROCEDURE|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
47932344|NCT05778643|BEHAVIORAL|TaKeTiNa music therapy|TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
47932345|NCT01325220|DRUG|arbaclofen|5 mg bid
47932346|NCT01325220|DRUG|arbaclofen|10 mg bid
47932347|NCT01325220|DRUG|arbaclofen|10 mg tid
47932348|NCT01325220|DRUG|Placebo|tid
47932349|NCT04667143|DRUG|Retagliptin, Henagliflozein, metformin XR|Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
48106827|NCT05263960|DRUG|CM350_group 7|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 135ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
47932350|NCT01551420|DEVICE|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
47932351|NCT01551420|DEVICE|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
47932352|NCT04730414|DRUG|Full-spectrum hemp (0.018% THC)|Topical Application
48106828|NCT05263960|DRUG|CM350_group 8|CM350 will be administered intravenously (IV) once a week (QW). Patients will take 405ug of CM350 on the first day of first cycle (C1D1), 405ug on C1D8, 405ug on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48106829|NCT05263960|DRUG|CM350_MTD level|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
48454979|NCT04084795|OTHER|Multifocal transcranial Current Stimulation|MtCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. F3 anodal; AF3, FC1, FC3, FC5, F5, return montage will be used with the anode over the left DLPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
48454980|NCT01323491|DRUG|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
48454981|NCT05999253|PROCEDURE|Modified thoracolumbar plane block (mTLIP)|"Modified thoracolumbar plane block (mTLIP): under ultrasound-guided, the lateral compartment of the longissimus muscle and iliocostal muscle muscles are imagined and the block needle is placed in the interfascial plane of these two muscles and local anesthesic solution is appliced.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia."
48454982|NCT05999253|PROCEDURE|Erector spinae plane block (ESP)|"Erector spinae plane block (ESP): After determining the vertebral spinal process and trapezius, rhomboid major and erector spinae muscles with ultrasound guidance, the block needle is advanced in the cranio-caudal direction with an in plane approach and local anaesthetic solution is applied to the plane between the erector spinae muscle and the transverse process when the needle rests on the transverse process.~* 20 ml of 0.25% bupivacaine will be used on each side (total of 40 ml of 0.25% bupivacaine will be used)~* to be administered only approximately 20-30 minutes before the onset of anaesthesia"
48454983|NCT03705117|BIOLOGICAL|V565|Capsules for oral administration
48622628|NCT04154345|OTHER|Exercise therapy (exercising into pain)|The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS for 9 weeks, then pain ratings are 0-2 for the remaining 3 weeks. Every physiotherapy session includes also 15 minutes of manual therapy.
48622629|NCT04524923|OTHER|visual motor integration|investigate the relation between touch screen usage and visual motor integration in preschoolers
47932353|NCT04738318|DRUG|Glucocorticoids|Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
47932354|NCT04738318|DRUG|Saline|Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
47932355|NCT03624530|DRUG|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
47932356|NCT00899080|GENETIC|gene expression analysis|
47932357|NCT00899080|GENETIC|reverse transcriptase-polymerase chain reaction|
47932358|NCT00899080|OTHER|immunoenzyme technique|
47932359|NCT00899080|OTHER|laboratory biomarker analysis|
47932360|NCT00899080|OTHER|platelet aggregation test|
47932361|NCT03149627|OTHER|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
47932362|NCT02447783|DIETARY_SUPPLEMENT|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
47932363|NCT02447783|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
47932364|NCT02264873|DRUG|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
47932365|NCT06109922|DIETARY_SUPPLEMENT|Active|40g bio-active whey protein concentrate powder containing phospholipids
47932366|NCT06109922|DIETARY_SUPPLEMENT|Placebo|Around 40g pea protein powder not containing phospholipids
47932367|NCT00141583|DRUG|Enalapril 20 mg bd|
47932368|NCT00141583|DRUG|Candesartan 8 mg bd|
47932369|NCT04612023|OTHER|Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)|Injectable acellular amniotic membrane derived allograft tissue (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) to a placebo (sterile saline) in the treatment of knee osteoarthritis. Injection is minimally invasive and is FDA regulated (HCT/P regulation).
47932370|NCT04043390|DIAGNOSTIC_TEST|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
47932371|NCT04043390|DIAGNOSTIC_TEST|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
47932372|NCT04043390|DIAGNOSTIC_TEST|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
47932373|NCT04043390|DIAGNOSTIC_TEST|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
47932374|NCT06134531|DRUG|MR001|"Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle"
47932375|NCT04761627|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injection of ustekinumab.
47932376|NCT04761627|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
47932377|NCT00155870|BEHAVIORAL|questionnaires|
47932378|NCT03544788|DEVICE|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
47932379|NCT00454831|DEVICE|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
47932380|NCT04706416|DIETARY_SUPPLEMENT|N-acetyl glucosamine (NAG)|Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.
47932381|NCT04706416|OTHER|Control|Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
47932382|NCT01077375|DRUG|Placebo|"* Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
48454984|NCT00531180|PROCEDURE|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
48454985|NCT00531180|PROCEDURE|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
48454986|NCT02448862|DEVICE|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
48454987|NCT00197938|PROCEDURE|Measurement of rectal lactic acid.|
48454988|NCT05275699|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
48454989|NCT06078748|BEHAVIORAL|EX|"EX involves 2.5hrs of moderate intensity aerobic and resistance exercise per week. EX will be instructed by a clinical exercise physiologist (CEP) or registered kinesiologist (RKIN). The EX session will include a 5min warm-up, 20-30min of moderate intensity aerobic exercise, 20-30min of moderate intensity resistance training, and a 5min cool down. The virtual video session will be pre-recorded, have similar composition, and will be led by the same instructor as the group sessions. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on exercise in order to overcome barriers and increase maintenance of lifestyle changes."
47932383|NCT01077375|DRUG|Milnacipran|"* Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~* Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
47932384|NCT01908738|DRUG|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
47932385|NCT01908738|DRUG|10%lidocaine spray|
47932386|NCT01434316|DRUG|Dinaciclib|Given IV
48622630|NCT04524923|OTHER|Quality of life assessment|investigate the relation between touch screen usage and Quality of life assessment in preschoolers
47932387|NCT01434316|DRUG|Veliparib|Given PO
48454990|NCT06078748|BEHAVIORAL|DIET|"DIET involves one session per week of diet education delivered by a Registered Dietitian. The DIET session will be 90 minutes during months 1-4, and 30 minutes in months 5 and 6. DIET was developed by our team, emphasizing foods identified as supporting executive function, memory, and other cognitive abilities. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on diet in order to overcome barriers and increase maintenance of lifestyle changes."
48454991|NCT06078748|BEHAVIORAL|STRETCH|STRETCH sessions will be time/frequency-matched to EX sessions (2.5hrs/week: 1.5hr in virtual group sessions; 1hr virtual video session) to control for social aspects and placebo effects of EX.Each STRETCH session will include a 5min warm-up, 5min of balance exercises, and 50min of stretching. Difficulty will not be progressed. STRETCH sessions will also be led by a CEP/RKIN instructor and video sessions will be pre-recorded by the same instructor.
48454992|NCT06078748|BEHAVIORAL|ED|ED sessions designed to be of equal intensity and social engagement to the DIET intervention. Participants will engage in group discussion and receive information on the brain and cognitive processes, the effect of age on cognition, and tips to promote healthy aging. This will include lectures, watching documentaries and participating in various games.
48622631|NCT04524923|OTHER|Cognitive Functioning|investigate the relation between touch screen usage and Cognitive Functioning assessment in preschoolers
48622632|NCT05174624|OTHER|No intervention|No intervention
48622633|NCT01392937|DEVICE|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
48622634|NCT01392937|DEVICE|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
47932390|NCT03535571|DIETARY_SUPPLEMENT|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
48106830|NCT05263960|DRUG|CM350_MTD-1 level|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
48106831|NCT03698708|BEHAVIORAL|CARES Intervention|A group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
47932391|NCT03008564|OTHER|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:~* Age~* Gender~* Weight~* Height~* BMI~* Distance of ASIS to base of patella~* Distance of Point A to base of patella~* Distance of Point B to base of patella~* Distance of apex of femoral triangle to base of patella"
47932392|NCT01285947|DEVICE|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
47932393|NCT01285947|OTHER|Needle Application|30-gauge needle insertion into skin
47932394|NCT01285947|DEVICE|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
47932395|NCT01285947|DEVICE|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
47932396|NCT01133028|BEHAVIORAL|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
48454993|NCT04382963|OTHER|High Risk - intensive coaching|"The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis."
47932397|NCT01133028|BEHAVIORAL|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
47932398|NCT04411862|DIETARY_SUPPLEMENT|Phosphatidyl Choline|2.1 g Phosphatidylcholine daily in addition to lifestyle modification
47932399|NCT04411862|BEHAVIORAL|Lifestyle modification|Lifestyle modification and health education by Clinical Pharmacist
47932400|NCT00494598|DRUG|Sufentanil|200 mcg intra-arterial one time bolus
47932401|NCT03652623|DRUG|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
47932402|NCT03785743|PROCEDURE|TLPD Surgery|TLPD
47932403|NCT03785743|PROCEDURE|OPD Surgery|OPD
47932404|NCT00280670|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
47932405|NCT00586664|DRUG|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
47932406|NCT00586664|DRUG|placebo comparator|sterile ophthalmic solution
47932407|NCT00586664|DRUG|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
48454994|NCT04382963|OTHER|High Risk - standard care|The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.
48454995|NCT04382963|OTHER|Low Risk - control|Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
47932408|NCT05184439|PROCEDURE|Adductor magnus tenodesis for recurrent patellar dislocation|In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
47932409|NCT00895011|DRUG|Placebo|One dose 30 minutes prior to initiation of sexual activity
47932410|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
47932411|NCT00895011|DRUG|Avanafil|One dose 30 minutes prior to initiation of sexual activity
47932412|NCT05463627|DRUG|Metformin|All participants among the three groups were treated with metformin
47932413|NCT03433729|OTHER|Patient agenda form|On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
47932414|NCT03271294|DEVICE|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
47932415|NCT06181045|DRUG|LY3410738|Administered orally.
47932416|NCT06181045|DRUG|Placebo|Administered orally.
47932417|NCT04591574|BIOLOGICAL|Red Blood Cells (Transfusion)|Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines
47932418|NCT04501562|OTHER|Examinations|Participants will undergo focused examinations that include measurement of height, weight, waist circumference, body composition analysis, baseline data collection and blood pressure examinations. Resting electrocardiography will be performed to ascertain sinus rhythm.
47932419|NCT04501562|OTHER|Cardiovascular Tests|Specific quantitative cardiac ageing-related outcome parameters will be examined by multimodal techniques including two-dimensional transthoracic echocardiogram, and/or non-contrast magnetic resonance imaging/magnetic resonance spectroscopy.
47932420|NCT04501562|OTHER|Bio-specimen collection|Bio-specimens collected will include fresh blood, urine and/or stool specimens.
47932421|NCT04501562|OTHER|Clinical/health outcome collection|Health status will be tracked by telephone follow-up and/or matching at national disease registries at periodic intervals within one to five years, up to three decades.
47932422|NCT00716833|DRUG|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
48454996|NCT06462027|DRUG|Packed Red Blood Cells (1 unit)|500 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
48454997|NCT06462027|DRUG|Packed Red Blood Cells (2 units)|1000 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
48454998|NCT06462027|OTHER|Saline|Control subjects will receive 500mL of normal saline intravenously.
48454999|NCT05895383|DRUG|Nitrous oxide|Nitrous oxide administered at concentrations of minimal sedation (0-50%). Participants will be able to adjust the level of gas throughout the vasectomy using a handheld remote control.
48622635|NCT01290250|OTHER|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
47932423|NCT00716833|DRUG|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
47932424|NCT04535167|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
47932425|NCT04535167|DRUG|Placebo|Placebo will be formulated for intravenous delivery
47932426|NCT00799773|DRUG|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
47932427|NCT00799773|PROCEDURE|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
47932428|NCT00799773|DRUG|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
47932429|NCT03413176|DRUG|Cardiac complication induced by VEGF/VEGFR inhibitor|Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
47932430|NCT05155462|OTHER|One or two phone call|Phone call to collect patient data
47932431|NCT00716950|DRUG|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
47932432|NCT00716950|DRUG|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
47932433|NCT04496934|BEHAVIORAL|Exercise|Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
47932434|NCT03785275|RADIATION|gallium-68-exendin PET/CT|PET/CT scan after injection with gallium-68-exendin
47932435|NCT00196183|PROCEDURE|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
47932436|NCT00196183|PROCEDURE|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
47932437|NCT03560739|COMBINATION_PRODUCT|ofatumumab with PRF|ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
47932438|NCT03560739|COMBINATION_PRODUCT|ofatumumab with AI|ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
47932439|NCT02646202|PROCEDURE|Sclerotherapy|Injection of varices
47932440|NCT02646202|PROCEDURE|Band ligation|endoscopic banding of varices
47932441|NCT02646202|PROCEDURE|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
47932442|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 6 g/day|dark chocolate 6 g/day
47932443|NCT00661986|DIETARY_SUPPLEMENT|dark chocolate 25 g/day|dark chocolate 25 g/day
47932444|NCT02133443|DEVICE|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
47932445|NCT02133443|DEVICE|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
47932446|NCT01687647|OTHER|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
47932447|NCT01018446|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
47932448|NCT03195296|OTHER|No intervention|No intervention related to the study is foreseen
48455000|NCT00240032|DRUG|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
48455001|NCT00240032|DRUG|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
48455002|NCT03296956|DIETARY_SUPPLEMENT|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
48455003|NCT03296956|OTHER|Placebo|Matching placebo for appearance, taste
47932449|NCT00005001|BIOLOGICAL|HIV-1 Immunogen|
47932450|NCT06290245|DEVICE|PEP Buddy|It is a hands-free, oral PEP device (PEP buddy) which held by the patient's lips like a whistle and is attached to a necklace/lanyard. Different grades of PEP-buddy generate expiratory pressures of 5-17cm H2O
47932451|NCT06290245|OTHER|aerobic exercise|Exercise training will start and finish with a 5-minute warm-up and cool-down on the cycle ergometers at (40% of PHR). The cycling active phase will last for 30 min. at 70% of HRmax (moderate-intensity continuous exercise).
47932452|NCT05124418|DIAGNOSTIC_TEST|palatal masticatory mucosa thickness measurement|Measure the thickness of palatal masticatory mucosa by a dynamic navigation system (Navident®, ClaroNav Inc., Toronto, Canada) and periodontal probe piercing.
47932453|NCT00675207|DRUG|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
47932454|NCT00675207|DRUG|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
48455004|NCT01798628|DRUG|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
48455005|NCT01798628|DRUG|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
48455006|NCT01798628|DRUG|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
48622636|NCT02628977|BEHAVIORAL|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
47932455|NCT00675207|DRUG|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
47932456|NCT05354674|DRUG|Bevacizumab|"AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0"
47932457|NCT05011279|OTHER|Move Together app/Garmin Activity Tracker|"* The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~* Garmin activity tracker in this study is for participants to track their steps and sedentary time."
47932458|NCT04564131|OTHER|Reflexology|"* Hands are washed.~* The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~* The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~* Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~* Exercises to warm and relax the feet for five minutes.~* General massage is applied to the whole foot for five minutes.~* Reflexology massage is applied to the application areas for neuropathic pain.~* The individual is helped to take a comfortable position.~* Hands are washed."
47932459|NCT04564131|OTHER|Control|No intervention was performed to reduce pain in the control group
48455007|NCT06628349|DIETARY_SUPPLEMENT|Whey Protein Isolate 90%|Commercially available animal based protein powders
47932460|NCT05694221|DRUG|Supaglutide injection|Administered subcutaneously in the Supaglutide arms
47932461|NCT05694221|DRUG|Digoxin|Oral Administration
48455008|NCT06628349|DIETARY_SUPPLEMENT|Soy Protein Isolate (90% Protein)|Commercially available plant based protein powders
47932462|NCT05694221|DRUG|Metformin|Oral Administration
47932463|NCT03575481|DIAGNOSTIC_TEST|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
48455009|NCT06628349|DIETARY_SUPPLEMENT|Organic Pea Protein Isolate|Commercially available plant based protein powders
48455010|NCT06628349|DIETARY_SUPPLEMENT|Placebo (Water)|Normal drinking water
48455011|NCT03396939|DEVICE|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
48455012|NCT01843179|DRUG|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
48455013|NCT01843179|DRUG|Sulindac|Taken orally twice per day at home for 12 months
48455014|NCT04494607|DIETARY_SUPPLEMENT|lowest Glycemic Index for a selected type fo cereal product|determination of lowest Glycemic Index for a selected type fo cereal product
47932464|NCT04529187|DRUG|Midazolam|To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
47932465|NCT04529187|DRUG|Dexmedetomidine|To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
47932466|NCT03790631|OTHER|The study is observational.|The study is observational.
47932467|NCT00236951|DRUG|iron sucrose injection USP|
47932468|NCT00236951|DRUG|stable erythropoietin therapy|
47932469|NCT04823416|PROCEDURE|Resection|Left hemicolectomy
48455015|NCT05490563|DRUG|SLS-005|SLS-005
48455016|NCT05490563|DRUG|Placebo|Placebo (sodium chloride injection, 0.9%, USP)
48455017|NCT04739735|PROCEDURE|Dental Local Anaesthesia|lower primary molar teeth indicated for extraction will be given a local anaesthetic injection according to the random allocation to one of the two arms mentioned previously
48455018|NCT05399446|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
48455019|NCT05399446|BEHAVIORAL|Educational Group|We selected a T1D management/Eating disorder psychoeducational comparison condition to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
48455020|NCT04699084|OTHER|Mozart music|A 20-minute piece composed by W.A Mozart ( Sonata K. 448 in D Major for 2 pianos) was applied in music group, directly after the arrival of patients in the Post Anesthesia Care Unit (PACU), while they were receiving usual postoperative care.
47932470|NCT04823416|PROCEDURE|Stoma|Colostomy
47932471|NCT01716871|DEVICE|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
47932472|NCT01716871|DEVICE|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
47932473|NCT00495079|DRUG|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
47932474|NCT06102018|DIAGNOSTIC_TEST|Collect blood and urine，pathological specimens if necessary|Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube
48106832|NCT02012543|DIETARY_SUPPLEMENT|Agar jelly|
47932475|NCT06023576|OTHER|antihypertensive medications|"One or more of the following medications may be used in both randomization groups to achieve SBP goals:~* Angiotensin converting enzyme inhibitors (ACEI)~* Angiotensin receptor blockers (ARBs)~* Beta-blockers (BB)~* Thiazide-type diuretics~* Calcium channel blockers~* Aldosterone antagonists~* Alpha1-receptor blockers.~* Direct vasodilators~* Loop diuretics"
47932476|NCT06023576|DIAGNOSTIC_TEST|Blood pressure measurement|Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
47932477|NCT06023576|DIAGNOSTIC_TEST|Echocardiogram|At baseline, month 6, and month 12
47932478|NCT06023576|OTHER|Symptom-limited cardiopulmonary exercise test|Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
47932479|NCT06023576|OTHER|Quality of Life Measures|FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
47932480|NCT06023576|DIAGNOSTIC_TEST|Biomarkers|Research blood samples will be collected at baseline, 3 months, and 6 months
47932481|NCT02430129|PROCEDURE|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
47932482|NCT02430129|PROCEDURE|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
47932483|NCT02430129|DEVICE|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
47932484|NCT02430129|DEVICE|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
47932485|NCT00657826|DEVICE|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
47932486|NCT04598399|BEHAVIORAL|Mindfulness Based Relapse Prevention|7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
47932487|NCT04598399|BEHAVIORAL|Relaxation/ meditation|7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants
47932488|NCT03726996|DRUG|Desipramine|Study drug (desipramine) provided in tablet form to be taken daily.
47932489|NCT05304832|OTHER|Aqua-Plyometric Exercise|The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
47932490|NCT05304832|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.
47932491|NCT03774823|DEVICE|RF and PEMF|RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
47932492|NCT03774823|DEVICE|Ultrasound|Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
47932493|NCT01830777|DRUG|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
47932494|NCT01830777|DRUG|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
47932495|NCT01830777|DRUG|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
47932496|NCT01830777|DRUG|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
47932497|NCT04294745|PROCEDURE|Buccal infiltration|Injection of local anaesthetic parallel to the Long axis of the tooth in the depth of buccal sulcus
47932498|NCT04294745|PROCEDURE|Inferior alveolar nerve block|Standard technique of mandibular nerve block
47932499|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
47932500|NCT01167985|DEVICE|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
47932501|NCT01167985|DEVICE|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
47932502|NCT02288377|DRUG|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
47932503|NCT02288377|DRUG|Placebo|
48106833|NCT01492387|OTHER|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
48106834|NCT04039971|PROCEDURE|ACL Reconstruction|Surgical techniques
48455021|NCT01094457|DRUG|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
48098617|NCT04469218|DEVICE|SafeBreak Vascular|SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
48455022|NCT01094457|DRUG|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
48455023|NCT00499759|BEHAVIORAL|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
48455024|NCT00499759|BEHAVIORAL|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
48455025|NCT00499759|BEHAVIORAL|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
48455026|NCT00499759|BEHAVIORAL|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
48455027|NCT00499759|BEHAVIORAL|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
48455028|NCT00499759|BEHAVIORAL|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
48455029|NCT00919113|DRUG|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
48455030|NCT00919113|DRUG|Placebo|The identical buffer used in Uracyst for the same administration
48455031|NCT06627803|DRUG|Alcohol (Oral)|Participants will drink a beverage that will have alcohol or no alcohol. The amount of alcohol consumed will be similar to consuming around 3-4 drinks, with breath alcohol concentration peaking at or around the legal limit for driving (0.08%).
48455032|NCT04022122|PROCEDURE|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
48455033|NCT04051307|DRUG|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
48455034|NCT04051307|DRUG|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
48455035|NCT01360333|OTHER|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
48455036|NCT00143364|DRUG|varenicline (CP-526,555)|
48455037|NCT03328026|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
48455038|NCT03328026|DRUG|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
48455039|NCT03328026|DRUG|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
48455040|NCT03328026|DRUG|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
48455041|NCT06520904|DRUG|PCSK9 inhibitor|PCSK9 inhibitors combined with moderate-intensity statin therapy
48098618|NCT05591079|DRUG|CS0159 (Linafexor)|Oral QD
48455042|NCT06520904|DRUG|Statin|Intensive statin therapy
48455043|NCT04211935|DEVICE|Use of PCA|A commercially available PCA pump will be connected to the patient's intravenous line at the end of the MIRPE operation.
48455044|NCT04211935|DEVICE|Use of ESB for postoperative pain control after MIRPE|Pediatric anesthesiologists will place ESB at the time of the MIRPE operation if study participants are randomized into this group.
48455045|NCT04211935|DEVICE|Use of INC for postoperative pain control after MIRPE|Pediatric surgeons will perform INC during the MIRPE operation if they are randomized to this group.
48455046|NCT01283503|DRUG|BKM120|
48455047|NCT04598763|OTHER|smell the odors of the olfactory rehabilitation kit according to the classic or intensive method|regardless of the randomization group, the patient will smell each odor for 10 seconds with a 10 second interval between odors.
48455048|NCT04697173|OTHER|Single consent|A single consent form for possible procedures the child may undergo while in the PICU
48455049|NCT06560034|DEVICE|VicorderCS|"1. Vascular Sensor (VCS-VAS-1000) measurement device used with accessories (cuffs and tubes) connected to the device;~2. Data Station (VCS-DAT-1000) for data collection and analysis"
48455050|NCT04715451|OTHER|Novel Swaddle|A novel swaddling method.
48455051|NCT01685762|DRUG|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
48455052|NCT01855685|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
48455053|NCT04025021|DIETARY_SUPPLEMENT|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
48455054|NCT04025021|DEVICE|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
48455055|NCT05986188|OTHER|Pathways to Potential|Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
47932504|NCT03965273|BEHAVIORAL|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
47932505|NCT03965273|BEHAVIORAL|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
47932506|NCT00531687|DRUG|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
47932507|NCT00531687|DRUG|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
48455056|NCT03811158|DEVICE|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
48455057|NCT03811158|DEVICE|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
48455058|NCT04309968|DRUG|Drug: SYHA1801|Drug: SYHA1801 administered orally
48455059|NCT06416800|DRUG|Digoxin|Oral; Tablet
48455060|NCT06416800|DRUG|Rosuvastatin|Oral; Tablet
48455061|NCT06416800|DRUG|Metformin|Oral; Tablet
48455062|NCT06416800|DRUG|Povorcitinib|Oral; Tablet
48455063|NCT06416800|DRUG|Probenecid|Oral; Tablet
47932508|NCT00531687|DRUG|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
47932509|NCT01081548|DRUG|atorvastatin|20 mg
47932510|NCT01081548|DRUG|atorvastatin|20 mg
48098619|NCT06629558|DRUG|Silver Nitrate|bronchoscopic lung volume reduction in management of localized emphysema
48455064|NCT05850728|DRUG|TLC-ART|TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
48455065|NCT05316454|BEHAVIORAL|self-efficacy support|self-efficacy support
48455066|NCT05962476|DEVICE|Transcutaneous vibro-acoustic device|Wearable device which sends low-frequency sound vibrations through the skin.
48455067|NCT04784663|BEHAVIORAL|Messaging|Four brief video messages, each approximately 1.5 minutes in length, focused on facilitating treatment seeking by addressing barriers and improving attitudes. Intervention delivered to participant by study mobile app downloaded to participants' own smartphone.
48455068|NCT04784663|OTHER|Wait list control|one push notification each week thanking individuals for participation, informing them that they will receive messages in the near future or reminding them of the length of the study.
47932511|NCT06163820|DRUG|Bevacizumab|Bevacizumab is a humanised monoclonal antibody with molecular weight 167kD that inhibits all isoforms of the vascular endothelial growth factor (VEGF) and is produced from a Chinese hamster ovary mammalian system. It has high specificity for isoform-A and has a half-life of \~21 days.
47932512|NCT06163820|DRUG|Ipilimumab|Ipilimumab is an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Ipilimumab is a recombinant human immunoglobulin monoclonal antibody that binds CTLA4 and blocks the interaction between CD80/86 and CTLA4.
47932513|NCT06163820|DRUG|Nivolumab|Nivolumab ia an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Nivolumab is a fully human monoclonal IgG4 antibody targeting PD-1 which demonstrates activity across a range of tumours.
48455069|NCT04801654|DIAGNOSTIC_TEST|blood sample|preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
47932514|NCT06163820|RADIATION|Hypofractionated stereotactic radiotherapy|Hypofractionated stereotactic radiotherapy (hSRT) will be delivered to previously untreated brain metastases in eligible participants. hSRT will be delivered to all symptomatic brain metastases, all brain metastases \>1 cm and all brain metastases located in eloquent areas of the brain. hSRT will be commenced after the first cycle of nivolumab plus ipilimumab and completed before the second cycle of nivolumab plus ipilimumab. hSRT should be commenced within 1 week from the planning MRI.
47932515|NCT02842905|OTHER|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
47932516|NCT02842905|OTHER|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
47932517|NCT04500275|DRUG|Vancomycin Hydrochloride|Vancomycin will be spread on sternal edge immediately after sternotomy and before sternal closure
47932518|NCT04500275|OTHER|Normal Saline|2 ml normal saline will be spread on sternal edge immediately after sternotomy and before sternal closure
47932519|NCT00002455|BIOLOGICAL|Corynebacterium granulosum P40|
48455070|NCT06328829|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48622637|NCT02628977|BEHAVIORAL|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
48622638|NCT04865705|DRUG|tislelizumab|Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
48622639|NCT05208320|BEHAVIORAL|Adherence|"Patients received interventions as follow:~* The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~* Home health education by Community Health Workers every month for 6 months"
48622640|NCT03918200|OTHER|Serum amyloid A level|For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
48622641|NCT03129646|DRUG|Miltefosine|Miltefosine 10mg and 50mg capsules
48622642|NCT03129646|DRUG|Paromomycin|Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
47932520|NCT00002455|PROCEDURE|adjuvant therapy|
47932521|NCT00641316|PROCEDURE|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
47932522|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
47932523|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
47932524|NCT00641316|PROCEDURE|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
47932525|NCT04906915|DRUG|Ketamine|The efficacy of ketamine was assessed by calculating oxygen supply and consumption
47932526|NCT04824716|PROCEDURE|Postconditioning|The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).
47932527|NCT04824716|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention as per European Society of Cardiology guidelines.
47932528|NCT01230775|DRUG|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
48622643|NCT03129646|DRUG|Sodium stibogluconate|Sodium stibogluconate 33% 30 ml inj.
48622644|NCT03611062|BEHAVIORAL|VR Executive Functions Training|"The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs."
47932529|NCT01230775|DRUG|Placebo|"Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
47932530|NCT03540043|DRUG|Administration of Placebo|Botanical Drug Phase 2 clinical study
47932531|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.05%|Botanical Drug Phase 2 clinical study
47932532|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.1%|Botanical Drug Phase 2 clinical study
47932533|NCT03540043|DRUG|Administration of PUR0110 (Thykamine) 0.25%|Botanical Drug Phase 2 clinical study
47932534|NCT06418464|DEVICE|AP-A Dosage Decision Support System|The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
47932535|NCT04038632|OTHER|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
47932536|NCT04357691|BEHAVIORAL|Conventional training|Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
47932537|NCT04357691|BEHAVIORAL|AI-led training|Participants will perform an AI-led training for 4 weeks
47932538|NCT05320497|DEVICE|Transparent cap|Add a self-made transparent cap (made by cutting a silicone drainage tube) to the end of the SpyGlass choledochoscope, and then perform routine choledochoscopy and biopsy operations
48455071|NCT06328829|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48622645|NCT03611062|BEHAVIORAL|VR Placebo Game|In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
47932539|NCT05869084|DIAGNOSTIC_TEST|pulmonary function tests|pulmonary function tests
47932540|NCT03539796|PROCEDURE|Dural puncture epidurals (DPE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
47932541|NCT03539796|PROCEDURE|Traditional epidurals (EPI)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
47932542|NCT03539796|PROCEDURE|Combined-spinal epidural technique (CSE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
47932543|NCT06391931|DRUG|Cipepofol|0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain
47932544|NCT06391931|DRUG|Propofol|3.0 mg/kg induce + 5.0 mg/kg/h maintain
47932545|NCT02319356|DIETARY_SUPPLEMENT|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
47932546|NCT02319356|DIETARY_SUPPLEMENT|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
48622646|NCT04130087|DRUG|Selegiline Hydrochloride 10 MG|Single 10mg tablet of Selegiline Hydrochloride
48622647|NCT04130087|DRUG|Placebo|Single Placebo Tablet, identical appearance to experimental tablet.
48622648|NCT02200081|DRUG|MGN1703|
48622649|NCT02200081|OTHER|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
47932547|NCT06086262|DEVICE|Hydraulic hand dynamometer (Jamar, Product model J00105, U.S.A)|"The hydraulic hand dynamometer is a reliable and valid an evaluation tool that's used to measure isometric grip force (hand grip strength) .~The hydraulic pinch gauge is a reliable and valid an evaluation tool that's used to measure isometric pinch force."
47932548|NCT00719797|BIOLOGICAL|bevacizumab|Given IV
47932549|NCT00719797|DRUG|fluorouracil|Given IV
47932550|NCT00719797|DRUG|irinotecan hydrochloride|Given IV
47932551|NCT00719797|DRUG|leucovorin calcium|Given IV
47932552|NCT00719797|DRUG|oxaliplatin|Given IV
47932553|NCT02456480|DRUG|CLS001|topical gel
47932554|NCT02456480|DRUG|Vehicle|topical gel
47932555|NCT03109847|DRUG|Metformin Hydrochloride|Given Orally
47932556|NCT03109847|OTHER|Radioactive Iodine|Undergo radioactive iodine treatment
47932557|NCT03109847|OTHER|Placebo|Given orally
47932558|NCT02628665|DRUG|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
47932559|NCT02628665|DEVICE|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
47932560|NCT01280201|DRUG|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
47932561|NCT06454266|DRUG|ORM regimen|"The subjects received ORM regimen treatment every 21 days for a total of 6 cycles. The specific medication is as follows  Obutinib tablets 150mg qd d1-21 (suspended 2 days before MTX use until MTX drops to safe concentration) Rituximab 375mg/m2, d1 Methotrexate 3g/m2, d2"
47932562|NCT02026570|BEHAVIORAL|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
47932563|NCT02026570|BEHAVIORAL|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
47932564|NCT05945212|DEVICE|Vibration|The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz
47932565|NCT05945212|DEVICE|Sham vibration|The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.
47932566|NCT05945212|OTHER|10 meters Walk Test|Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.
48455072|NCT06328829|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48455073|NCT02172781|DRUG|Ipratropium - unit dose vial|
47932567|NCT05945212|OTHER|2 Minute Walk Test (2MWT)|Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.
47932568|NCT05945212|OTHER|Fugl-Meyer (FMA-LE)|The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34
47932569|NCT05945212|OTHER|Modified Ashworth scale|The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4
47932570|NCT05945212|OTHER|ABILOCO questionnaire|The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)
47932571|NCT05945212|OTHER|Barthel index|The Barthel index measure autonomy in daily life.
47932572|NCT05945212|OTHER|isometric ergometer|Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.
47932573|NCT05945212|OTHER|Electromyograms (EMG)|Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.
47932574|NCT05945212|OTHER|Traditional quantified gait analysis|Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.
47932575|NCT05945212|OTHER|SPM - Statistical Parametric Mapping|Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.
47932576|NCT05945212|OTHER|FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)|A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.
47932577|NCT03229460|OTHER|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
47932578|NCT03229460|DEVICE|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
47932579|NCT03229460|DEVICE|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
48098620|NCT06629558|DRUG|Nano-silver nitrate|bronchoscopic lung volume reduction in management of localized emphysema
48455074|NCT02172781|DRUG|Tiotropium - inhalation capsule|
47932580|NCT00000253|DRUG|10% N2O|
47932581|NCT00000253|DRUG|20% N2O|
47932582|NCT00000253|DRUG|30% N2O|
47932583|NCT00000253|DRUG|40% N2O|
47932584|NCT02973633|DEVICE|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
47932585|NCT02973633|DRUG|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
47932586|NCT03239691|DRUG|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
47932587|NCT03239691|DRUG|Placebo|Matching placebo available as matching capsules for oral administration
47932588|NCT04334109|BEHAVIORAL|Family Diabetes Self-Management Education and Support|Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
47932589|NCT04334109|BEHAVIORAL|Standard Diabetes Self-Management Education and Support|Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
47932590|NCT04306679|OTHER|Animation clips|The first animation clip focuses on the importance of pain assessment introduce three pain scales (categorical, NPS and faces) followed by explanations on their properties and on the appropriate way to use them.The second movie was aimed to provide an opportunity to implement the new knowledge in case studies
47932591|NCT04306679|OTHER|Instructions|Routine preoperative preparations, which included a section on pain assessment instructions.
47932592|NCT04016584|BEHAVIORAL|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
47932593|NCT00925743|DRUG|cabazitaxel (XRP6258)|"* administered by IV infusion~* in addition to cisplatin treatment"
47932594|NCT01085500|BEHAVIORAL|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
47932595|NCT01085500|PROCEDURE|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
47932596|NCT03393533|PROCEDURE|Group I|Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
48098621|NCT06629558|DEVICE|Bronchoscopic lung volume reduction|bronchoscopic lung volume reduction in management of localized emphysema
48098622|NCT06628973|BEHAVIORAL|Social prescribing|The intervention consists of SP, wherein patients identified as having significant SDOH-related vulnerabilities on the SPARK questionnaire or during an interview will have a consultation with a LW who will provide them with social prescriptions. LWs are individuals who LINK individuals with social needs to existing community supports and services within the community
48098623|NCT03493178|DIETARY_SUPPLEMENT|Glycine|Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks
48455075|NCT02172781|DRUG|Placebo matching tiotropium|
48622650|NCT01033942|DRUG|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
47932597|NCT03393533|PROCEDURE|Group II|Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
47932598|NCT05930366|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
47932599|NCT05930366|PROCEDURE|Gingival Depigmentation using Diode Laser|GINGIVAL DEPIGMENTAION USING DIODE LASER
47932600|NCT00976508|DRUG|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
47932601|NCT00976508|DRUG|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
47932602|NCT00776685|BEHAVIORAL|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
47932603|NCT05672667|DRUG|intravenous oxytocin|Oxytocin given by intravenous route
47932604|NCT05672667|DRUG|intranasal oxytocin|Oxytocin given by intranasal administration
47932605|NCT03460015|DRUG|Sevoflurane|"During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped)."
47932606|NCT03460015|DRUG|Propofol|"In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped."
47932607|NCT02691598|DRUG|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
47932608|NCT01520831|DRUG|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
47932609|NCT01520831|DRUG|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
47932610|NCT01520831|DRUG|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
47932611|NCT01520831|DRUG|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
47932612|NCT01082822|BIOLOGICAL|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
47932613|NCT00540371|OTHER|Port wine stain Birthmark|Port wine stain Birthmark
47932614|NCT02660008|DRUG|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
48098624|NCT03493178|DIETARY_SUPPLEMENT|N-acetylcysteine (NAC)|Dietary Supplement: NAC will be supplemented in the active arm for 12-weeks
47932615|NCT02660008|DRUG|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
47932616|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
47932617|NCT03023670|PROCEDURE|cardiopulmonary bypass|Low rate (4\\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
47932618|NCT00489190|DRUG|Insulin Glulisine|
48098625|NCT03493178|DIETARY_SUPPLEMENT|Alanine|Dietary Supplement: Alanine will be supplemented in the placebo arm for 12-weeks
48455076|NCT02172781|DRUG|Placebo matching ipratropium|
48455077|NCT01867658|DEVICE|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
48455078|NCT04584138|BEHAVIORAL|Study of eye movements|The assessment of eye movement during autobiographical retrieval (i.e., retrieval of personal memories) in patients with Alzheimer's Disease.
48622651|NCT01033942|DRUG|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
48622652|NCT01033942|BEHAVIORAL|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
48622653|NCT06031129|DRUG|Butorphanol|The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
48622654|NCT06031129|DRUG|normal saline|normal saline contain 0.9% NaCl sodium.
48622655|NCT00315367|DRUG|Donepezil HCI (drug)|
48622656|NCT05845073|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules twice daily, for the duration of antibiotic therapy, and 14 days thereafter.
48622657|NCT05845073|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for for the duration of antibiotic therapy, and 14 day thereafter.
48622658|NCT06106997|RADIATION|brain radiotherapy|brain radiotherapy planned on synthetic CTs
48622659|NCT00232882|DRUG|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
48622660|NCT00232882|DRUG|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
48622661|NCT00232882|DRUG|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
48622662|NCT03650647|PROCEDURE|Carious dentin removal|Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
48622663|NCT04351815|BEHAVIORAL|Short term prehabilitation (2 weeks)|"* Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patient will be asked to follow a 2 weeks prehabilitation program~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
48622664|NCT04351815|OTHER|No specific intervention|"* Standard care: Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patients will be asked to maintain regular physical activity without support~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)"
48622665|NCT02190201|DEVICE|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
48622666|NCT02190201|DEVICE|Direct laryngoscope|A kind of traditional laryngoscopes
48622667|NCT06551467|BEHAVIORAL|Online Ayurveda Program for Detox and Lifestyle|The program includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices.
48622668|NCT02395367|PROCEDURE|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
48455079|NCT04053153|DEVICE|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
48455080|NCT04129177|OTHER|Implementation of a bundle of surgical infection preventive measures|A bundle of six preventative measures is recommended to the VINCat hospitals. Bundle measures were: systemic and oral antibiotic prophylaxis, mechanical bowel preparation (MBP), laparoscopic surgery, maintenance of normothermia, and the use of a double-ring wound retractor.
48622669|NCT02395367|RADIATION|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
48622670|NCT02395367|DRUG|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
47932619|NCT02680678|OTHER|Colloid Preload|preload infusion
48455081|NCT03978442|BEHAVIORAL|Smoking Cessation Cognitive Behavioral Therapy (CBT)|12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
48622671|NCT03116867|OTHER|sonosalpingography|transvaginal ultrasound with saline infusion
47932620|NCT02680678|OTHER|colloid co-load|co-load infusion
47932621|NCT02680678|OTHER|Crystalloid preload|preload infusion
47932622|NCT02680678|OTHER|Crystalloid Co-load|co-load infusion
47932623|NCT03631797|PROCEDURE|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
48098626|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
48098627|NCT04638777|DEVICE|rTMS with H-coil|Real repetitive transcranial magnetic stimulation with H-coil over M1 and sham repetitive transcranial magnetic stimulation with H-coil over PFC
48098628|NCT04638777|DEVICE|rTMS with H-coil|Sham repetitive transcranial magnetic stimulation with H-coil over M1 and PFC
47932624|NCT05271708|DRUG|Fespixon cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
47932625|NCT05271708|DRUG|Placebo Cream|Bounded by the midpoint of the scar, each patient received two topical scar formulations consisting of Fespixon cream on one side, and placebo cream on the other side. Treatment was given twice a day for 84 days.
47932626|NCT02940002|DRUG|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
47932627|NCT02940002|DRUG|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
47932628|NCT02940002|DRUG|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
47932629|NCT03195842|OTHER|Recordable card|
47932630|NCT02407652|BEHAVIORAL|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
47932631|NCT02407652|BEHAVIORAL|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
47932632|NCT00734955|DEVICE|49-channel optical spectrometer|
47932633|NCT00136383|DRUG|paroxetine versus duloxetine|
47932634|NCT01226121|BIOLOGICAL|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
47932635|NCT01267695|DRUG|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
47932636|NCT01267695|PROCEDURE|conventional surgery|All the patients should receive elective surgery with R0 resection.
47932637|NCT00708253|DEVICE|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
47932638|NCT00708253|DEVICE|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
47932639|NCT02238171|DRUG|Atrovent® inhalets|
47932640|NCT03444532|BEHAVIORAL|12-week aerobic exercise and cognitive-behavioral therapy|12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy
47932641|NCT04999774|DIAGNOSTIC_TEST|Different diagnostic tests|Each SAC will be tested with all tests
47932642|NCT02755792|BEHAVIORAL|Calligraphy Training|
47932643|NCT02755792|BEHAVIORAL|iPad Training|
48455082|NCT03978442|DRUG|Bupropion|All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
48455083|NCT03978442|BEHAVIORAL|Cognitive Processing Therapy|12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
48622672|NCT04903977|DIAGNOSTIC_TEST|Laboratory tests: blood and faeces tests|To be performed at V2
48622673|NCT04903977|DIAGNOSTIC_TEST|Gynaecological and proctological examinations|To be performed at V1 (Examination with a gynaecological speculum, Bimanual examination, Rectal examination, and Anoscopy)
47932644|NCT01403272|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
47932645|NCT02048293|DRUG|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
48622674|NCT04903977|DIAGNOSTIC_TEST|3-D Endoanal Ultrasound|To be performed at V1 (as a reference and for group assignment)
47932646|NCT02048293|DRUG|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
47932647|NCT02048293|DRUG|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
47932648|NCT01926327|BIOLOGICAL|PRP injection|Injection of PRP in patients with knee osteoarthritis.
47932649|NCT01926327|BIOLOGICAL|Placebo|
47932650|NCT05688826|DIETARY_SUPPLEMENT|Sugar|75 g sugar dissolved in 0.8 dl water and flavored with lemon. Ingested during 5 minutes
47932651|NCT01002820|DRUG|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
47932652|NCT06076278|PROCEDURE|resistance exercise|Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
47932653|NCT00777218|DRUG|propranolol|standard pediatric doses, based on body weight
47932654|NCT00777218|DRUG|zonisamide|standard pediatric dosages, based on body weight
47932655|NCT00777218|DRUG|topiramate|standard pediatric dosages, based on body weight
47932656|NCT01634178|DRUG|Apremilast|Tablet for oral administration
47932657|NCT03800472|DRUG|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
47932658|NCT03800472|DRUG|Placebo|Placebo tablets
47932659|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
48098629|NCT00679276|PROCEDURE|Prolift|surgical repair of vaginal prolapse
47932660|NCT03800472|DRUG|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
47932661|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
47932662|NCT03800472|DRUG|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
47932663|NCT03800472|DRUG|Placebo|Placebo optimized tablets
47932664|NCT00035347|DRUG|IV azithromycin|500 mg once daily
47932665|NCT00035347|DRUG|ceftriaxone|1 gram once daily for 2 to 5 days
47932666|NCT00035347|DRUG|oral azithromycin|2 x 250 mg once daily
47932667|NCT00035347|DRUG|IV levofloxacin|500 mg once daily
47932668|NCT00035347|DRUG|oral levofloxacin|500 mg once daily
47932669|NCT04584307|DRUG|Elotuzumab|Elotuzumab 10-20mg/kg
48455084|NCT03978442|BEHAVIORAL|Smoking Abstinence Reinforcement Therapy|Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
48455085|NCT03978442|BEHAVIORAL|Yoked Contingency Management|Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
47932670|NCT04584307|DRUG|Pomalidomide|Pomalidomide 2mg
47932671|NCT05304091|OTHER|Questionnaire on a smartphone application|Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
47932672|NCT02776020|DEVICE|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
47932673|NCT02725489|BIOLOGICAL|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
48622675|NCT04903977|DEVICE|ONIRY measurement|To be performed at V2 (the electrical impedance of anal sphincter muscles will be measured)
48622676|NCT04903977|DIAGNOSTIC_TEST|High-resolution anorectal manometry|To be performed at V3
48622677|NCT04903977|DIAGNOSTIC_TEST|ECG|To be performed at V1 and V2 (for safety reasons)
47932674|NCT02725489|DRUG|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
48098630|NCT00941031|DRUG|AIN457|
48098631|NCT00941031|DRUG|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
48098632|NCT00941031|DRUG|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
48455086|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
48455087|NCT00081653|DRUG|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
48622678|NCT03807843|BIOLOGICAL|V184|Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.
48622679|NCT03807843|OTHER|Placebo|Sterile physiological saline for IM injection
48622680|NCT01104766|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
47932675|NCT03288792|DEVICE|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
47932676|NCT01721785|DRUG|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
47932677|NCT06061614|GENETIC|NGGT002|NGGT002
47932678|NCT02096575|OTHER|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB."
47932679|NCT00129298|DRUG|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
47932680|NCT04334018|DEVICE|conventional CRT|"Conventional CRT or biventricular pacing resynchronizes left ventricular contraction by pacing the right and left ventricles (LV) simultaneously"
47932681|NCT04334018|DEVICE|MPP CRT|CRT with Multipoint pacing (MPP) where pacing can occur from more than one LV site simultaneously
47932682|NCT03900962|OTHER|Home-based resistance training|"Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets."
47932683|NCT03900962|OTHER|Walking intervention|After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
47932684|NCT05820737|DIETARY_SUPPLEMENT|EF2001|One capsule to be consumed once a day
47932685|NCT05820737|DIETARY_SUPPLEMENT|beLP1|One capsule to be consumed once a day
47932686|NCT05820737|DIETARY_SUPPLEMENT|Placebo|One capsule to be consumed once a day
47932687|NCT06506071|DIAGNOSTIC_TEST|Spectral CT|Myocardial tissue characterization with Spectral CT
47932688|NCT04422795|DEVICE|External thermomechanical device delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings frozen and the vibration mechanism switched on, delivering vibration and cold stimuli to the area for 30 seconds before the intramatricial injection and until needle withdrawal
47932689|NCT04422795|DEVICE|External thermomechanical device without delivering cold and vibration stimuli|the thermomechanical device will be placed on the digit 2 cm proximally to the injection site with the ice wings at unfrozen and the vibration mechanism switched off, for 30 seconds before the intramatricial injection and until needle withdrawal
47932690|NCT04422795|DRUG|Ethyl chloride skin refrigerant spray|Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
47932691|NCT02677324|DRUG|ABT199|Oral BCL-2 antagonist
47932692|NCT00298753|PROCEDURE|fluid restriction for 14 days (15ml fluid per kg weight)|
47932693|NCT05060939|DIAGNOSTIC_TEST|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
47932694|NCT06132581|DEVICE|Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
47932695|NCT06132581|DEVICE|Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
47932696|NCT06132581|DEVICE|Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
47932697|NCT05279404|OTHER|electroacupuncture|Electroacupuncture at Neiguan and Jianshi acupoint
47932698|NCT04050020|BIOLOGICAL|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
48455088|NCT06283147|BEHAVIORAL|Risk assessment and Management Programme - Knee Osteoarthritis|"(i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis What Do People With Knee or Hip Osteoarthritis Need to Know~(ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings.~(iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2.~(iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment.~(v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management."
48455089|NCT01443195|DRUG|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~1. Before starting iron supplementation (maximum one week before).~2. At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~3. Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
48455090|NCT03351296|DRUG|LV5FU2|LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
48455091|NCT03351296|DRUG|Streptozocin|streptozotocin 800 mg/m² day 1 every 14 days
48455092|NCT03351296|DRUG|Capecitabine|Capecitabine 750 mg/m² twice daily, days 1-14
48455093|NCT03351296|DRUG|Temozolomide|temozolomide 200 mg/m² once daily, days 10-14, every 28 days
47932699|NCT04050020|BIOLOGICAL|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
48455094|NCT03351296|DRUG|Bevacizumab|bevacizumab 5 mg/kg every 14 days
48455095|NCT02827682|DEVICE|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
48455096|NCT02827682|DEVICE|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
48455097|NCT03889639|DRUG|SAR442168|Pharmaceutical form: Film coated tablet; Route of administration: Oral
47932700|NCT04260243|OTHER|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
47932701|NCT04260243|OTHER|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
48098633|NCT00941031|DRUG|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
48098634|NCT00138632|DRUG|PTK787|Visudyne® + PTK787, 500 mg/day
48098635|NCT00138632|DRUG|PTK787|Visudyne® + PTK787 1000 mg/day
48098636|NCT00138632|DRUG|Placebo|Visudyne® + Placebo
48455098|NCT03889639|DRUG|Placebo|Pharmaceutical form: Film coated tablet; Route of administration: Oral
48622681|NCT01104766|DRUG|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
48455099|NCT03889639|DRUG|Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
48622682|NCT01104766|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
47932702|NCT06255366|DRUG|Caroxime sodium sulfonate|Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
47932703|NCT06255366|DRUG|Desmopressin|Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
47932704|NCT06255366|DRUG|0.9% Sodium Chloride Injection|Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
47932705|NCT04678206|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
47932706|NCT04678206|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
47932707|NCT06104839|DRUG|NXC736|oral administration
47932708|NCT06104839|DRUG|Placebo|oral administration
47932709|NCT01077752|DRUG|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
47932710|NCT01077752|DRUG|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
47932711|NCT01077752|DRUG|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
47932712|NCT01077752|DRUG|NaCl|NaCl
47932713|NCT05415384|DEVICE|Cryoablation of Intercostal Nerves|Using Atricure device, cryoice, intercostal nerves 3-8 will be ablated in the experimental arm. This is in addition to mechanical fixation of rib fractures and multimodal systemic therapy.
47932714|NCT05415384|PROCEDURE|Standard surgical treatment of patients with multiple rib fractures|Standard surgical treatment of patients with multiple rib fractures
47932715|NCT02249247|DRUG|Low dose of BIIL 284 BS tablets|
47932716|NCT02249247|DRUG|Medium dose of BIIL 284 BS tablets|
48098637|NCT00364442|DRUG|fluticasone propionate/salmeterol|investigational drug
48280322|NCT06656546|DIAGNOSTIC_TEST|Diaphragm Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Curvilinear Probe (2-8 MHz) or the eSaote MyLab Seven Curvilinear Probe (1-8 MHz), will be selected based on suitability for the procedure at the time. Using a curvilinear transducer, the probe will be placed along the mid-axillary line, approximately at the seventh to ninth intercostal spaces, in a coronal orientation. The movement of the diaphragm during ventilation will be assessed over the spleen and liver. Diaphragmatic motion during ventilation indicates successful ETI, while the absence of bilateral diaphragmatic movement suggests esophageal intubation. If diaphragmatic movement is only observed on one side, it is indicative of endobronchial intubation.
47932717|NCT02249247|DRUG|High dose of BIIL 284 BS tablets|
47932718|NCT02249247|DRUG|Placebo|
47932719|NCT04861402|DEVICE|The ICP monitoring will be performed in a non-invasive method developed by Brain4Care|"The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc.~The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar)."
48098638|NCT03429387|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET performed with low dose CT
48622683|NCT00505583|DRUG|MOA-728|
48280323|NCT02293109|DRUG|carfilzomib|Given IV
48280324|NCT02293109|DRUG|cyclophosphamide|Given IV
48280325|NCT02293109|DRUG|vincristine sulfate|Given IV
48622684|NCT03179267|DEVICE|SNAP40|SNAP40 ambulatory monitoring device
48622685|NCT02610673|DEVICE|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
48622686|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
48622687|NCT02842866|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined|0.5 mL, Subcutaneous (SC), single dose on Day 0.
48622688|NCT02774278|DRUG|Erlotinib|Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
48098639|NCT03429387|DIAGNOSTIC_TEST|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
48098640|NCT02359435|DRUG|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
48098641|NCT02359435|DRUG|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
48280326|NCT02293109|DRUG|doxorubicin hydrochloride|Given IV
48455100|NCT03214588|DRUG|TAK-831|TAK-831 tablets
48455101|NCT03214588|DRUG|TAK-831 Placebo|TAK-831 placebo matching tablets
48455102|NCT03966911|DEVICE|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
48455103|NCT02435264|OTHER|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
48455104|NCT05638490|OTHER||no intervention
47932720|NCT04512287|DRUG|Autologous Platelet Rich Plasma|2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.
47932721|NCT04512287|OTHER|Saline Solution|2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
47932722|NCT00000973|DRUG|Pyrimethamine|
47932723|NCT00000973|DRUG|Leucovorin calcium|
47932724|NCT00000973|DRUG|Zidovudine|
47932725|NCT00375869|DRUG|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
47932726|NCT00375869|DRUG|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
47932727|NCT00558129|DEVICE|X-STOP®|Surgical implantation of X-STOP IPD device
47932728|NCT00558129|PROCEDURE|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
47932729|NCT00004382|DRUG|tin mesoporphyrin|
47932730|NCT00004382|PROCEDURE|Phototherapy|
48455105|NCT06358469|PROCEDURE|Surgery|Re-excision of vulvar cancer margin
48455106|NCT06358469|OTHER|Active Surveillance|The investigator will follow the patient to watch for side effects and keep track of patient's health
48455107|NCT05624788|OTHER|No Intervention|Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
47932731|NCT00612729|PROCEDURE|Polylens Y30 intraocular lens|cataract surgery
47932732|NCT00612729|PROCEDURE|Orange Series Model PC 440 Y intraocular lens|cataract surgery
47932733|NCT06251479|BEHAVIORAL|behavioral 1|verbal and non verbal tasks
47932734|NCT06251479|BEHAVIORAL|behavioral 2|verbal and non verbal tasks with other partecipants
47932735|NCT06251479|DEVICE|neuromodulation 1|registration with neurophysiological tecniques during verbal and non verbal tasks
48280327|NCT02293109|DRUG|dexamethasone|Given PO
48455108|NCT03196284|DRUG|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
48455109|NCT03196284|DRUG|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
48455110|NCT06425562|OTHER|Full lung function|This includes spirometry, body plethysmography and single breath gas transfer test. These are all non-invasive physiological measurements / lung function tests. Measures flow volumes, lung volumes and gas transfer respectively.
47932736|NCT06251479|DEVICE|neuromodulation 2|registration with neurophysiological tecniques during verbal and non verbal tasks with other partecipants
47932737|NCT02140476|DEVICE|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
47932738|NCT02140476|PROCEDURE|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
47932739|NCT03597217|DRUG|PF-05221304|3, 10, 50 mg
47932740|NCT03597217|DRUG|PF-05221304|50 mg multiple dose
47932741|NCT03597217|DRUG|Placebo|Placebo
48280328|NCT02293109|DRUG|methotrexate|Given IV
48455111|NCT06425562|OTHER|Multiple breath nitrogen washout|Non-invasive physiological measurement / lung function test. 100% oxygen is inhaled and the nitrogen concentration in the lungs is measured. This test gives information on the ventilation distribution in the lungs.
48455112|NCT06425562|OTHER|Impulse oscillometry|Non-invasive physiological measurement / lung function test. This technique superimposes sound waves on tidal breathing. The patient can breathe normally trough the device, no forced respiratory maneuvers are required. It gives information on the reactance and resistance of the lung.
48455113|NCT03156816|DRUG|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
47932742|NCT00195845|DRUG|Galantamine|
47932743|NCT00195845|DRUG|Placebos|
47932744|NCT04716556|BIOLOGICAL|Convalescent plasma|Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
47932745|NCT02263131|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
47932746|NCT02263131|BIOLOGICAL|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
47932747|NCT03633760|DRUG|Bilastine 40mg single dose|Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
47932748|NCT03633760|DRUG|Bilastine 20mg single-dose followed by multiple-dose|Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
48280329|NCT02293109|DRUG|cytarabine|Given IV
48280330|NCT02293109|DRUG|leucovorin calcium|Given IV or PO
48280331|NCT02293109|DRUG|methylprednisolone|Given IV
48280332|NCT02293109|BIOLOGICAL|rituximab|
48455114|NCT03156816|DRUG|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
48455115|NCT01662960|BEHAVIORAL|Mirror therapy|A home-based therapy involving mirrored visual feedback
48455116|NCT01662960|BEHAVIORAL|Divider therapy|A home-based therapy involving removed visual feedback.
47932749|NCT02996643|DEVICE|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
47932750|NCT00082472|DRUG|Doxorubicin HCl Inhalation Solution|
47932751|NCT00082472|DRUG|Docetaxel|
47932752|NCT00082472|DRUG|Cisplatin|
47932753|NCT04951739|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy involves an initial incision on the internal lining of the oesophagus. This permits entry of the endoscope to within the wall of the oesophagus, where the muscle will be exposed. The inner layer of the muscle near the lower oesophagal sphincter will be cut (this is termed myotomy). At the conclusion of the procedure, the oesophagal incision will be closed with standard endoscopic clips.
47932754|NCT05474664|DRUG|Camostat mesylate|"1. 4\~12 years old: Camostate mesylate 100 mg, 2 times a day~2. greater than 13 years old: Camostate mesylate 100 mg, 3 times a day"
47932755|NCT00973349|BIOLOGICAL|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
47932756|NCT00297024|PROCEDURE|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
47932757|NCT04763876|DRUG|Ketorolac Injection 15 mg|A single dose of 15 mg ketorolac administered intramuscularly.
47932758|NCT04763876|DRUG|Ketorolac Injection 60 mg|A single dose of 60 mg ketorolac administered intramuscularly.
48455117|NCT03218813|BEHAVIORAL|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
48455118|NCT02718963|DEVICE|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
48455119|NCT02241551|DRUG|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
47932759|NCT03841305|PROCEDURE|Liver preparation before major hepatectomy|Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
47932760|NCT03874312|DIAGNOSTIC_TEST|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
47932761|NCT00907660|BEHAVIORAL|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
47932762|NCT00907660|DIETARY_SUPPLEMENT|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
47932763|NCT00119600|DRUG|AMG 114|
47932764|NCT01039012|OTHER|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
47932765|NCT01039012|OTHER|Standard Care|Participant follow the standard care recommended by their physician.
47932766|NCT01007682|OTHER|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
48622689|NCT03110835|RADIATION|Radioiodine|Administration of radioiodine
47932767|NCT04949919|OTHER|aerobic training by a cycle ergometer and Biodex system 4 pro|cyclic aerobic training in moderate-intensity and high-intensity interval training plus isokinetic resistance training prior to HD. 60 training sessions in 6 months.
48622690|NCT01886560|DRUG|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
48622691|NCT01886560|DRUG|Placebo|Tablets placebo one PO per day for 12 weeks
47932768|NCT03347578|DIAGNOSTIC_TEST|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
47932769|NCT03110939|OTHER|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
47932770|NCT03773445|DIAGNOSTIC_TEST|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
47932771|NCT03773445|DIAGNOSTIC_TEST|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
47932772|NCT03773445|DIAGNOSTIC_TEST|Histology|Histology of colonic biopsies using the Geboes Index
47932773|NCT03773445|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
47932774|NCT00170924|DRUG|Valsartan|
47932775|NCT01867073|OTHER|Biomarker|
47932776|NCT00016900|DRUG|liposomal paclitaxel|
48455120|NCT02241551|DRUG|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
48455121|NCT02404753|DRUG|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
48455122|NCT02404753|PROCEDURE|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
48455123|NCT02404753|PROCEDURE|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
47932777|NCT02355600|OTHER|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
48455124|NCT02404753|DRUG|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
47932778|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
47932779|NCT02609997|PROCEDURE|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
47932780|NCT02609997|DRUG|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
48455125|NCT04842435|DRUG|COVID-globulin|"In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study."
48455126|NCT04842435|DRUG|Placebo|"In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose."
48455127|NCT02885909|DEVICE|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
47932781|NCT02609997|DEVICE|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
47932782|NCT02609997|DRUG|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
47932783|NCT02958384|BIOLOGICAL|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
47932784|NCT03355443|PROCEDURE|Retroflexion|Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
47932785|NCT03355443|PROCEDURE|Re-examination|Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
47932786|NCT05965648|BEHAVIORAL|Families FORWARD (Focusing on Relationships, Well-being, and Responsibility aheaD)|Families FORWARD aims to engage families in planning for adulthood earlier and more actively. Program skills include communication and problem-solving; guided practice in setting realistic goals, breaking down goals into incremental action steps, and problem-solving barriers to goal attainment; repeated engagement in future-oriented communication; and training on how to navigate transition-related and adult services. Parents/caregivers will participate in six or seven telehealth sessions (60-75 minutes each). Youth on the autism spectrum will have the option of participating in up to three program sessions to increase collaborative planning within the family. Families will identify and work toward individualized transition planning goals that may fall within any area of planning or functioning (e.g., housing, education, guardianship).
47932787|NCT01412918|DEVICE|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
47932788|NCT04268849|DRUG|Ferumoxytol|Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
47932789|NCT04268849|DRUG|Saline|Placebo for Ferumoxytol
47932790|NCT04268849|DRUG|Ferrous sulfate tablets|ferrous sulfate tablets containing 60 mg elemental iron
47932791|NCT04268849|DRUG|Vitamin C|Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
48280333|NCT02293109|OTHER|laboratory biomarker analysis|Correlative studies
48455128|NCT02885909|PROCEDURE|Insulin protocal|Using insulin protocal based on glucose monitor
48280334|NCT06008548|PROCEDURE|TACE|
48280335|NCT03293654|DRUG|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
48455129|NCT02244190|DRUG|Tipranavir|New oral solution (back up) formulation
48455130|NCT02244190|DRUG|Tipranavir|
48455131|NCT02244190|DRUG|Ritonavir|
48280336|NCT03293654|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
48455132|NCT05215197|DRUG|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
48455133|NCT03363555|DRUG|SHR-1210|A humanized monoclonal immunoglobulin.
48455134|NCT02169323|OTHER|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
48455135|NCT02380976|DRUG|combination drug: DW330SR, DW1030|
48455136|NCT02380976|DRUG|DW340|
48455137|NCT01664767|OTHER|Sulfur Thermal water|
48455138|NCT01664767|OTHER|Placebo|
47932792|NCT01116479|OTHER|Blood transfusion|Blood transfusion with packed erythrocytes
47932793|NCT00636701|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
48455139|NCT05327777|DRUG|Oxycodone|Investigators provided set opioid prescriptions for 10 pills each patient.
48455140|NCT05327777|BEHAVIORAL|Zero Opioid Protocol|Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
48455141|NCT06193213|PROCEDURE|measurement of train of four ratio (TOFR) to assess residual neuromuscolar block|Upon arrival of the spontaneously breathing patient in the Post-Anesthesia Care Unit, a researcher will evaluate the TOFR to detect any residual neuromuscular block using the acceleromyographic method at the level of thumb adductor.2 TOFR measurements will be performed 30 seconds apart. If the difference between the two measurements will be ≤ 0.1, the average value will be considered for the purposes of the analysis. In case of a difference \> 0.1, a third measurement will be taken and the average of the two closest results will be considered. If a residual block is detected sugammadex will be administered (2 mg/kg in the case of at least 2 contraction responses to TOF stimulation or 4 mg/kg in the case of no contraction response) to restore normal neuromuscular function , assessed by subsequent TOFR measurement.
48455142|NCT05822375|BEHAVIORAL|Better Together Physician Coaching|Better Together Physician Coaching Program thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
48455143|NCT02286466|BEHAVIORAL|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
48455144|NCT02286466|BEHAVIORAL|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
48455145|NCT03270254|DEVICE|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
48455146|NCT04816396|BEHAVIORAL|reminiscence Therapy|Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
48455147|NCT05337241|DEVICE|Saline Enhanced Radiofrequency (SERF) Ablation|The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
48455148|NCT00880139|PROCEDURE|Blood sampling|Determination of cytokine plasma levels (ELISA)
48455149|NCT00880139|PROCEDURE|Noninvasive measurement of systemic hemodynamics|performed once
48455150|NCT00880139|PROCEDURE|Visual acuity assessment|ETDRS charts
48455151|NCT00880139|DEVICE|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
48455152|NCT00880139|PROCEDURE|Ophthalmic examination and fundus photography|7 + 1 standard fields
47932794|NCT01407042|PROCEDURE|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
47932795|NCT05144334|DRUG|BTX-1188|One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
47932796|NCT00182702|DRUG|ixabepilone|Given IV
47932797|NCT00182702|OTHER|laboratory biomarker analysis|Correlative studies
47932798|NCT05340647|PROCEDURE|Preserflo microshunt|Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
47932799|NCT05340647|PROCEDURE|Trabeculectomy|Trabeculectomy surgery to lower intraocular pressure
47932800|NCT05340647|PROCEDURE|Other MIGS|Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
47932801|NCT03175848|RADIATION|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
47932802|NCT05441332|OTHER|EOS Radiation|One EOS exam of lower extremities
47932803|NCT05441332|BEHAVIORAL|Semi-structured interview|Semi-structured interview to identify factors influencing patient adherence behavior for a sub-group of 15 patients. By phone, between 1 to 3 months after inclusion.
47932804|NCT00711074|DRUG|AZD5672|single dose 200mg aqueous solution
47932805|NCT00174239|DRUG|cabergoline|
47932806|NCT00174239|DRUG|controlled-release levodopa / carbidopa|
48455153|NCT00880139|DEVICE|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
48455154|NCT00880139|DEVICE|High resolution optical coherence tomography (OCT)|performed once
48455155|NCT04724616|OTHER|Educational Program (CARTOON)|CARTOON is an interdisciplinary psychoeducational intervention program. It consists of five teaching sessions: 1) hand hygiene, not grasping the face, 2) sneezing etiquette, 3) wearing a mask, 4) social distancing, and 5) theoretical knowledge about the coronavirus. Using special exercises and games, information about the coronavirus is conveyed in a child friendly manner.
48455156|NCT00940433|PROCEDURE|open properitoneal hernia repair|suprapubic retro-inguinal approach
48455157|NCT00940433|PROCEDURE|Lechtestien hernia repair|onlay mesh repair
48455158|NCT00940433|PROCEDURE|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
48455159|NCT00940433|PROCEDURE|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
48455160|NCT01293097|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
48622692|NCT01182363|BEHAVIORAL|Project Solve Education|Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
47932807|NCT03095768|OTHER|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
47932808|NCT06245551|DRUG|Budesonide/albuterol metered-dose inhaler 160/180 μg|Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)
48455161|NCT01293097|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
47932809|NCT06245551|DRUG|Placebo metered-dose inhaler|Placebo aerosol for inhalation, single dose (given as 2 actuations)
47932810|NCT04879979|BEHAVIORAL|MAAT|MAAT consists of 8 weekly visits of 45 minutes duration and can be delivered effectively through videoconference technology (Vidyo). Participants will be asked to download the Vidyo App on their mobile phone or tablet. Vidyo is a HIPPA compliant, encrypted software with adequate bandwidth for highest quality videoconferencing intended for telehealth. It is the primary software for UPMC Telemedicine. Survivors are provided a workbook to reinforce learning, mastery and application of skills in daily life covered in each MAAT visit. The workbook provides reading structured within each of the 8 visits with guides for application of strategies as homework
47932811|NCT04786509|DIAGNOSTIC_TEST|Field tests|In this study we used three different standardized running tests, one sub-maximal test - Cooper 2400 m (C), and two maximal (all-out) tests - 100 m sprint (S) and shuttle run (SR).
47932812|NCT04036643|RADIATION|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
47932813|NCT01343225|DRUG|atripla|once a day
47932814|NCT01343225|DRUG|darunavir ritonavir raltegravir|as directed
48280337|NCT03293654|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
48280338|NCT03934762|BIOLOGICAL|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
48455162|NCT05395052|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy
48455163|NCT05395052|DRUG|Cyclophosphamide|Lympho-conditioning agent
48455164|NCT05395052|DRUG|Fludarabine|Lympho-conditioning agent
48455165|NCT05395052|DRUG|IL-2|For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD
48455166|NCT05395052|COMBINATION_PRODUCT|Avelumab|Monoclonal antibody
48455167|NCT05395052|COMBINATION_PRODUCT|Pembrolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
48455168|NCT05395052|COMBINATION_PRODUCT|Nivolumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
48455169|NCT05395052|COMBINATION_PRODUCT|Atezolizumab|For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.
48455170|NCT05395052|COMBINATION_PRODUCT|Trastuzumab|Monoclonal antibody
48455171|NCT05395052|COMBINATION_PRODUCT|Cetuximab|Monoclonal antibody
48622693|NCT01113749|OTHER|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
48455172|NCT05395052|COMBINATION_PRODUCT|Amivantamab|Monoclonal antibody
48455173|NCT05395052|DRUG|IL-2|For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
48455174|NCT06187142|BEHAVIORAL|Initial phase: Personalized Chat Support (PCS)|Participants will receive three months of personalized chat support through WeChat. A total of 24 pre-set messages will be sent with the schedule of 3 times a week for 2 weeks, twice a week for the next 8 weeks and once a week for the last 2 weeks. These messages cover generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and hazards of smoking for chronic diseases experienced by different participants. Counsellors will respond to the participants' messages instantly. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PCS (subgroup PCS-1). Incomplete responders (smokers) will be randomly assigned to continue PCS (subgroup PCS-2) or receive PCS and MOS (subgroup PCS-3).
48455175|NCT06187142|BEHAVIORAL|Second phase: Multi-component Optional Support (MOS)|For incomplete responders (subgroup PCS-3) randomized to MOS, the available intervention options include phone counseling, family/peer support group and financial incentive for nicotine replacement therapy. Participants will be guided by cessation counsellors at 1-month follow-up to choose any combination of MOS based on their prefer choice or combination of MOS. If MOS participants cannot be followed up at 1-month, they will continue PCS by default.
48455176|NCT06187142|BEHAVIORAL|Initial phase: Group Chat Support (GCS)|Participant will receive three months of group chat support through WeChat. In this group, participants can send 'No Smoking' and the smart quit-smoking assistant will record it. A smoking cessation clinic doctor in the group will respond to participants' questions about smoking cessation. At the end of the initial phase (1-month), complete responders (quitters) will continue to receive GCS (subgroup GCS-1). Incomplete responders (smokers) will be randomly assigned to continue GCS (subgroup GCS-2) or receive GCS and PCS (subgroup GCS-3).
48455177|NCT06187142|BEHAVIORAL|Second phase: Personalized Chat Support (PCS)|For incomplete responders (subgroup GCS-3) randomized to PCS, participants will receive the same intervention as Group PCS delivered at the initial stage. Participants will receive two months of personalized messages through WeChat. Please refer to Intervention Group 'Initial phase: Personalized Chat Support (PCS) for details.
48455178|NCT06187142|BEHAVIORAL|5A's / 5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
48622694|NCT05614076|PROCEDURE|conserved chalky white enamel margins of class V cavities|during cavity preparation, we conserved chalky white enamel margins of class V cavities and then restored them with resin composite restorations,we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
48622695|NCT05614076|PROCEDURE|Total removal of demineralized enamel margins of class V cavities|during cavity preparation, we removed the total chalky white enamel margins of class V cavities and then restored them with resin composite restorations, we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
48455179|NCT06187142|BEHAVIORAL|health warning leaflet|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
48455180|NCT06187142|BEHAVIORAL|Self-help booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
48455181|NCT05888311|DEVICE|Liquid bandage|Liquid elastic collodion- and benzethonium chloride-based topical solution
48455182|NCT04698473|OTHER|NCPAP|NCPAP infants will be randomized into two different non invasive ventilation groups
48622696|NCT00800540|DRUG|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
48622697|NCT00800540|DRUG|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
48622698|NCT02410330|PROCEDURE|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
48622699|NCT02410330|PROCEDURE|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all \<2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
48622700|NCT00692796|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
48622701|NCT02464358|BEHAVIORAL|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
48622702|NCT02464358|BEHAVIORAL|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
48622703|NCT03407456|OTHER|Gastroesophageal reflux symptoms questionnaire|Reflux Symptom Questionnaire, 7-day recall (RESQ-7).
48622704|NCT00293891|DRUG|Tacrolimus Cream|
48622705|NCT06153550|OTHER|preparation in Respiratory Physiotherapy|"preparation in Respiratory Physiotherapy consist to:~* 3 sessions per week with the physiotherapist~* spirometry and pulse oximetry test 3 weeks before surgery, the day before surgery and the day after surgery."
48098642|NCT03742219|BEHAVIORAL|Lifestyle Modification|"1. Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~2. Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
48455183|NCT04698473|OTHER|NIPPV|NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
48455184|NCT05722496|OTHER|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
48455185|NCT02624297|OTHER|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
48455186|NCT01933282|DRUG|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
48622706|NCT03415256|OTHER|passive vibration|The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).
48622707|NCT03415256|OTHER|no passive vibration|The control group will not receive any treatment and continue their usual lifestyle.
48622708|NCT00000629|DRUG|Valproic acid|
48622709|NCT00000629|DRUG|Zidovudine|
48622710|NCT03670628|DEVICE|Shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
48622711|NCT03670628|OTHER|Sham shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
47932815|NCT05271279|BIOLOGICAL|OVV-01 Injection+IBR900 Cell Injection|"2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively."
47932816|NCT00069888|DRUG|Docetaxel|
47932817|NCT00412490|BEHAVIORAL|Questionnaire|Written survey at 1 Month \& 6 Months post surgery.
47932818|NCT00412490|BEHAVIORAL|Interview|One-on-One meeting lasting about one hour, at 1 Month \& 6 Months post surgery.
47932819|NCT03667300|DRUG|Evogliptin|This group will take daily evogliptin 5mg per oral, not linagliptin.
47932820|NCT03667300|DRUG|Linagliptin|This group will take daily linagliptin 5mg per oral, not evogliptin
47932821|NCT01652911|DEVICE|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
47932822|NCT06398405|OTHER|Epigallocatechin-3-gallate|Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
47932823|NCT02721186|DRUG|MDA with DHAp and SLD Primaquine|
48455187|NCT01933282|DRUG|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
48455188|NCT06414200|OTHER|multidisciplinary structured tailored made nutritional advice|The goal is a structured follow-up after discharge. Parents need to fill in questionnaires about eating behavior en feeding difficulties about their child. They also need to fill in a questionnaire about their stress. Together with their nutritional intake (3-days food diary) and growth a tailor-made nutritional plan is made. All the information I showed in a dashboard and discussed it with their dietitian. Who discusses this information in a multi-disciplinary team (pediatrician, psychologist and if needed a speech therapist).
48455189|NCT06556043|OTHER|cM1 transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cM1 group will receive AtDCS stimulation at 2 mA during acquisition phase.
47932824|NCT04561999|DEVICE|Elastography|Performance of Ultrasound, Elastography
47932825|NCT02901756|DIETARY_SUPPLEMENT|Antemig|Participants were instructed to take one tablet every morning for three months.
47932826|NCT00700076|DRUG|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
47932827|NCT00700076|DRUG|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
47932828|NCT02101112|DRUG|Apixaban|
47932829|NCT04322201|DEVICE|continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter|Ultrasound-guided placement of an intra-abdominal double lumen central venous catheter, using aseptic Seldinger technique, for continuous drainage of ascitic fluid up to 7 days in Intensive Care
47932830|NCT04322201|PROCEDURE|Ultrasound-guided intermittent large-volume paracentesis|Ultrasound-guided intermittent large-volume paracentesis through 14 Gauge catheter
47932831|NCT03533686|DEVICE|Adhear Bone Conduction System|Non-invasive bone conduction hearing device using adhesive
47932832|NCT03533686|DEVICE|Bone anchored hearing aid (BAHA)|Non-invasive bone conduction hearing device using a headband
47932833|NCT01113476|DRUG|Nab-paclitaxel|Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
47932834|NCT01113476|DRUG|Bevacizumab|Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
47932835|NCT01113476|DRUG|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
47932836|NCT04044443|DEVICE|IMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill|Peripheral vascular embolization
47932837|NCT06099145|DEVICE|Hephaï|Used of the HEPHAI medical device as a tool to improve the delivery of inhaled treatments for asthma and COPD
47932838|NCT06275490|BIOLOGICAL|Partially Demineralized Dentin Block|"The extracted tooth will undergo grinding using the tooth transformer device. The produced dentin graft will be of a particle size 400-800 μm. Afterwards.~-Prepare the partially demineralized dentin block, the L-PRF membranes will be cut into small pieces and mixed with the dentin particles at a ratio of 2 membranes to 0.5 g of dentin, providing a 1:1 volume ratio. The liquid fibrinogen will be added to the homogeneous mixture, and while shaping the mixture into the desired form it will be gently stirred for approximately 10 seconds. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming a sturdy block known as the dentin block, which serves as a convenient and compact graft .The extracted socket will be filled with partially demineralized autogenous dentin graft."
47932839|NCT06275490|BIOLOGICAL|L-PRF block|The same procedure will be performed for preparing the L-PRF block by mixing the L-PRF membranes with xenograft. In both groups, the placed graft will be covered with a L-PRF membrane .The L-PRF clots obtained after 12 min of centrifugation will be placed in the Xpression box (IntraSpin, Intra-Lock, Florida, USA) for 5 min to gently compress (by gravity) into membranes.
47932840|NCT04335201|DRUG|Defibrotide Injection|Patients will be treated according to the standard institutional procedures and will receive the best available treatment as per institutional guidelines in association with the experimental drug: Defibrotide 25 mg/kg body weight total dose in 2 hours duration infusion each, every 6 hours (Defibrotide 6.25 mg/kg body weight each dose) Treatment duration = 7 days
47932841|NCT01074047|DRUG|Azacitidine|75 mg/m\^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
48098643|NCT06631326|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
48098644|NCT06631326|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
47932842|NCT01074047|DRUG|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end"
48455190|NCT06556043|OTHER|cPPC transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cPPC group will receive AtDCS stimulation at 2 mA during acquisition phase.
48455191|NCT06556043|OTHER|iCBM transcranial direct current stimulation|During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The iCBM group will receive AtDCS stimulation at 2 mA during acquisition phase.
48455192|NCT06556043|OTHER|sham transcranial direct current stimulation|For the Sham group, the montages of the paired electrode placements will be randomly selected from the other three pairs using blocks of size 3, so that the three types of montages will have equal opportunities to be used in the Sham group. The intensity will be set at 0 mA for the Sham group. There will be a 30-second ramp-up for the Sham group. Once the current reaches 2 mA in the ramp-up period, it will drop to 0 mA for the entire 20 minutes during learning for the Sham group.
48455193|NCT03922763|PROCEDURE|Anatomical cut|Surgeon-derived cut based on patient's anatomy
48455194|NCT03922763|PROCEDURE|Cutting guide|Angle cut at 132.5 degrees based on cutting guide
48455195|NCT00467597|DRUG|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
48622712|NCT03022175|DRUG|SPR741|"SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days."
48098645|NCT06413303|BEHAVIORAL|Experiential Classroom|Experiential classroom emphasizes putting pregnant women at the center, based on their subjective willingness and previous knowledge and experience, creating an environment for free discussion, exchange, and reflection, and utilizing peer education to fully mobilize the subjective initiative of pregnant women. This approach allows them to explore, discuss, reflect, and learn autonomously, aiming to truly absorb, master, and apply theoretical knowledge.
48455196|NCT06563232|DEVICE|FNA group|Fine-needle-aspiration (22G EchoTip Ultra Echo-3-22)
48455197|NCT06563232|DEVICE|Adapt FNB group|Fine-needle-biopsy (22G Adapt Aspiration)
47932843|NCT02604017|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
47932844|NCT01527266|DIETARY_SUPPLEMENT|Carbohydrate drink|sucrose beverage
47932845|NCT01527266|DIETARY_SUPPLEMENT|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
47932846|NCT05428982|PROCEDURE|Postoperative Modified Trendelenburg position|Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
47932847|NCT03742648|OTHER|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
47932848|NCT06522191|OTHER|Physiotherapy Training (PT)|Both groups received the same therapist-led standardized PT for 5 days a week including 2 days of RR plus 3 days of conventional rehabilitation (CR) for 5 weeks. RR training will be given 40 min per session using an intelligent feedback robotic system. The system allows patients to move a cursor to targets on a monitor using a unilateral exoskeleton robotic arm and handle, which supports shoulder, elbow, forearm, and optionally multi-joint movements. The system provides visual and auditory feedback, offering exergame training with 1Dimension (D), 2D, and 3D options adjustable to three levels (low to high). Exergames and their parameters will be customized based on each patient's capacity. The CR protocol consists of joint range-of-motion, correct movement, stretching and balance exercises, gait training (walking on level surfaces, stairs), strengthening of antagonist muscle pattern will be provided. Each CR session will last 45 min of active treatment.
47951326|NCT03945695|PROCEDURE|"Pneumatic Vitreolysis in combination with Drinking-Bird-Technique"|"1. Appropriate anesthesia and antiseptic preparation of the surgical field~2. Prophylactic paracentesis of the anterior chamber~3. One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~4. Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)"
48455198|NCT05894148|DRUG|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
48098646|NCT01071694|DRUG|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
48098647|NCT05843656|OTHER|Non-invasive brain stimulation|based on sleep-physiology (slow-wave and spindles)
48098648|NCT04606264|DRUG|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
48098649|NCT04606264|DRUG|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
48098650|NCT04606264|DRUG|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
48455199|NCT05894148|DRUG|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
48455200|NCT03711448|DRUG|prednisone treatment|tapering prednisone regimen
47932849|NCT06522191|DEVICE|Cross-Education Intervention|Participants in the CE group will have the less affected upper extremity undergo game-based, unilateral, repetitive movement training using RR to enhance the effectiveness of the training to be provided to the affected side. Similar therapeutic games (exergames) planned for the more affected upper extremity will be selected through the unilateral exoskeleton RR device. As described in the PT section, upper extremity movements will be performed using the robotic arm and handle during the games. The difficulty level will be adjusted by the supervisor physiotherapist based on the grip threshold on the robotic handle, the game's difficulty level (low to high), workspace arrangement before each session, and suspension level according to the patient's needs. An approximately 20-minute program will be implemented, consisting of 8 games, each lasting about 2.5 minutes, tailored to the patient's capacity.
47932850|NCT06522191|OTHER|Control Intervention|The exercises to be administered in the control intervention will be selected based on the patient's level of impairment but will be planned without progression or intensity increase, and the involvement of the upper extremity will be kept to a minimum. The exercises will include lower limb joint range of motion exercises, weight bearing, weight shifting, and gait training.
47951327|NCT02225769|OTHER|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
47951328|NCT02225769|OTHER|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
48455201|NCT03711448|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
48455202|NCT03711448|OTHER|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
48455203|NCT03711448|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
48455204|NCT04225715|DRUG|Nucleos(t)ide (NUC)|Nucleos(t)ide (NUC) will be administered orally
48455205|NCT04225715|DRUG|CpAM (RO7049389)|CpAM (RO7049389) will be administered orally
48455206|NCT04225715|DRUG|TLR7 (RO7020531)|TLR7 (RO7020531) will be administered orally
48455207|NCT04225715|DRUG|siRNA (RO7445482)|siRNA (RO7445482) will be administered subcutaneously
48455208|NCT04225715|DRUG|PEG-IFN|PEG-IFN will be administered subcutaneously
48455209|NCT04225715|DRUG|PD-L1 LNA (RO7191863)|PD-L1 LNA (RO7191863) will be administered subcutaneously
48455210|NCT05815667|BEHAVIORAL|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
48455211|NCT06446869|DIETARY_SUPPLEMENT|Gyntima Menopause|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021
48455212|NCT06446869|OTHER|Placebo|Placebo comparator
48455213|NCT06066749|OTHER|NIOSH certified N95 personal face covering (mask)|During the this final exposure session, participants will be randomly assigned to wear an N95 respirator (3M cat. #: 9205+). Participants will be instructed on how to wear the mask to ensure a proper fit before entering the chamber.
48455214|NCT06066749|OTHER|Surgical Mask|During the this final exposure session, participants will be randomly assigned to wear an ear loop style surgical mask. Participants will be instructed on how to wear the mask to ensure a proper fit before entering the chamber.
48455215|NCT01394419|DRUG|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
48455216|NCT01394419|DRUG|Saline|Equal volume of normal saline
48455217|NCT03677960|DRUG|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
48455218|NCT05812638|OTHER|Mental imagery technique|Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors
48455219|NCT05812638|OTHER|Virtual Reality technique|Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
48455220|NCT02456285|PROCEDURE|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
48622713|NCT03022175|DRUG|Placebo|0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
48455221|NCT02456285|PROCEDURE|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
48455222|NCT02456285|PROCEDURE|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
48455223|NCT02456285|PROCEDURE|No surgery|Patients who have no surgery.
48622714|NCT01205308|DIETARY_SUPPLEMENT|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
48455224|NCT03167606|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
48455225|NCT02863822|BEHAVIORAL|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
48455226|NCT02863822|BEHAVIORAL|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
48455227|NCT05173792|DRUG|AK119|Subjects will receive AK119 intravenously.
48455228|NCT06319482|DEVICE|Proactive CPAP Therapy|CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.
47932851|NCT03233269|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
47932852|NCT05991921|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|"TENS application, postpartum 10-12. at hours and 14-16. It was applied twice for 30 minutes each. Researcher 1 programmed the TENS unit and was the only researcher who knew whether TENS was active or in placebo mode.~Two pairs of TENS electrodes were placed on the upper and lower border of the cesarean section incision line. A total of 4 electrodes were used in a sterile package for each participant. TENS stimulation was applied at a frequency of 100 Hz and was increased starting from 0 mA. The participant's stimulation was fixed at the mA level, where he felt optimal but did not feel discomfort.~The pretest data were applied to the participants who met the inclusion criteria and volunteered to participate in the study, by the researcher 2 in the patient rooms 10 hours after the cesarean section. Post-test data were obtained by the same investigator 16 hours after cesarean section."
47932853|NCT05991921|OTHER|Plasebo-Fake TENS|Participants in the placebo group 10-12 postpartum. at hours and 14-16. Two pairs of TENS electrodes were placed at the same time as the intervention group. TENS electrodes were attached to the participants in this group for 30 minutes, the device was operated but no electric current was applied.
47932854|NCT02633618|BIOLOGICAL|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
47932855|NCT02633618|BIOLOGICAL|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
47932856|NCT01695668|DRUG|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
47932857|NCT01695668|DRUG|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
47932858|NCT04325399|OTHER|Volitional help sheet|
47932859|NCT02785289|DEVICE|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
47932860|NCT05370456|DEVICE|Local application of a HA gel for the treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction and HA gel will be applied.
47932861|NCT05370456|PROCEDURE|Treatment of MAGRs with mCAF technique and XCM|After local anaesthesia, mCAF technique with two releasing vertical incisions will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
47932862|NCT06178705|BEHAVIORAL|Helpful Parenting Program Intervention|8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional \& behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
47932863|NCT01631019|BEHAVIORAL|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
47932864|NCT01631019|BEHAVIORAL|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
47932865|NCT04417426|OTHER|Survey|A survey was conducted, which was filled voluntarily and completely anonymously; the demographic data asked were: sex, age, religion, and semester. We included questions about their sexual behavior: if they considered having enough knowledge about STDs, sexual intercourse onset, number of sexual partners in the last year, the total number of sexual partners, sexual orientation, the use of condoms and contraceptives, exclusive or non-exclusive sexual intercourses, frequency of STDs screening, and then if they know the location of STD testing centers.
47932866|NCT05404984|OTHER|Dry cupping with core stabilization exercises|12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
47932867|NCT05404984|OTHER|Core stabilization exercises|A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
47932868|NCT00419809|DRUG|SB-681323 oral tablets|
47951329|NCT05085574|DRUG|Famotidine|80 mg tablet, QID for 14 days
48098651|NCT04606264|DRUG|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
48455229|NCT06319482|DEVICE|Conventional APAP Therapy|CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.
48455230|NCT06014424|DRUG|CBD|Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
47932869|NCT06336759|DEVICE|Restylane Defyne|Twenty (20) subjects with thin skin will be recruited and treated with Restylane Defyne.
47932870|NCT06336759|DEVICE|Restylane Lyft|Twenty (20) subjects with thick skin will be recruited and treated with Restylane Lyft.
48280339|NCT03934762|BIOLOGICAL|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
48280340|NCT03934762|BIOLOGICAL|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
48280341|NCT00803556|DRUG|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
47932871|NCT00127621|PROCEDURE|early tracheotomy|
47932872|NCT00127621|PROCEDURE|prolonged endotracheal intubation|
47932873|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
48455231|NCT06014424|OTHER|Placebo|Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
48455232|NCT05799677|OTHER|Reflexology|Additive reflexology treatment
48455233|NCT06320067|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.
48622715|NCT05627115|DRUG|Tislelizumab, AVD, Radiotherapy|"GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy."
48280342|NCT00803556|DRUG|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
48280343|NCT00803556|DRUG|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
48455234|NCT06320067|OTHER|177Lu-PSMA-617|177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).
48455235|NCT06320067|DRUG|Niraparib and Abiraterone Acetate Dual Action Tablet DAT|Combination product containing Niraparib (PARP inhibitor) and Abiraterone Acetate (ARSI). The regular-strength dual-action tablet (DAT) contains 100 mg niraparib/500mg AA per tablet. Patients take 2 tablets a day and receive a of total dose 200 mg niraparib/1000 mg AA. A low-strength DAT tablet containing 50 mg niraparib/500 mg AA may be available for participants requiring a dose reduction of niraparib.
48455236|NCT06320067|DRUG|Abiraterone Acetate|Abiraterone Acetate is an ARSI. Single agent Abiraterone Acetate may be used in patients randomised to receive Niraparib and Abiraterone Acetate.
47932874|NCT01827358|DRUG|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
47932875|NCT04281953|DIAGNOSTIC_TEST|High frequency audiometry|Simple hearing test
47932876|NCT04281953|OTHER|Short-Form 36-Item Questionnaire (SF-36)|Questionnaire on quality of life (Short Form 36 Item- SF-36)
47932877|NCT04281953|OTHER|Hearing handicap inventory for adults/elderly (HHIA/HHIE)|Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)
47932878|NCT04281953|OTHER|Tinnitus handicap inventory (THI)|Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
47932879|NCT01206387|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
47932880|NCT01206387|DRUG|placebo comparator|Placebo administered to affected area twice a day for 28 days
47932881|NCT00014755|DRUG|anti-thymocyte globulin|
47932882|NCT00014755|DRUG|cyclophosphamide|
47932883|NCT00014755|DRUG|filgrastim|
47932884|NCT00014755|DRUG|prednisone|
47932885|NCT00014755|PROCEDURE|peripheral blood stem cell transplantation|
47932886|NCT00014755|PROCEDURE|irradiation|
47932887|NCT06343714|DRUG|FB1003|Subcutaneous (SC) injection
47932888|NCT06343714|DRUG|Placebo|Subcutaneous (SC) injection
47932889|NCT03403387|DIETARY_SUPPLEMENT|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
47932890|NCT03403387|OTHER|Placebo|Avicel (cellulose) and bentonite powder
47932891|NCT03849027|DRUG|Methoxyflurane|Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.
47932892|NCT03849027|DRUG|Placebo|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
47932893|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
47932894|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
48280344|NCT04073745|OTHER|Quality-of-Life Assessment|Ancillary studies
48280345|NCT04073745|OTHER|Questionnaire Administration|Ancillary studies
48280346|NCT04073745|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48280347|NCT00876642|DRUG|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
48280348|NCT00576771|PROCEDURE|PSV|Pressure Support Ventilation
48280349|NCT00576771|PROCEDURE|NAVA|Neurally Adjusted Ventilatory Assist
48280350|NCT00576771|PROCEDURE|patient-controlled|assisted controlled MV through a button
48455237|NCT06320067|DRUG|Apalutamide|Apalutamide is an ARSI administered as a 240mg oral dose (four tablets taken together at the same time every day) with or without food. It is given daily in 28-day cycles.
48455238|NCT06320067|DRUG|Androgen Deprivation Therapy (ADT)|Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
48455239|NCT06320067|DRUG|Androgen Receptor Signalling Inhibitor (ARSI)|"Second generation ARSI (Abiraterone Acetate and Prednisolone \[AA+P\], Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines.~Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess.~Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles.~Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring.~Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles."
48280351|NCT02534649|PROCEDURE|Newly obtained biopsy and Blood samples collection|"For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
48280352|NCT03354845|OTHER|Deprescribing intervention|Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
48455240|NCT06320067|RADIATION|Local Radiotherapy|Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
48455241|NCT06320067|DRUG|Prednisolone|Prednisolone should also be administered 5mg daily using local pharmacy prescribing.
48455242|NCT06320067|DRUG|Docetaxel|Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
48455243|NCT05978791|PROCEDURE|collection of venous blood or arterial blood|"1. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~2. Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~3. Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~4. Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay)."
48455244|NCT00973388|DRUG|Telaprevir; Moxifloxacin; Placebo|
47932895|NCT00677053|DRUG|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
47932896|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
47932897|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
47932898|NCT00677053|DRUG|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
47932899|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
48455245|NCT03585556|DRUG|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
48455246|NCT03585556|BIOLOGICAL|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
48455247|NCT03585556|DRUG|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
48455248|NCT05364177|DRUG|68Ga-Pentixather|After intravenous injection of 68Ga-pentixather, PET/CT scan will be performed.
47932900|NCT00677053|DRUG|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
47932901|NCT00677053|DRUG|Placebo|Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
47932902|NCT04043780|DEVICE|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
47951330|NCT05085574|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
48280353|NCT06386328|DRUG|CKD-378, QD, PO|CKD-378, QD, PO
48280354|NCT04774250|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
48280355|NCT04774250|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
48280356|NCT03567187|DEVICE|iovera|The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
48455249|NCT05364177|DRUG|68Ga-Pentixafor|After intravenous injection of 68Ga-pentixafor, PET/CT scan will be performed.
48455250|NCT05285865|OTHER|Conventional Treatment|Thrice a day for complete length of stay. This is Conventional treatment The total duration of session will be of 15-20 mins.
47932903|NCT04043780|DEVICE|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
47932904|NCT06202651|DEVICE|Nd:YAG Laser|"Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure."
47932905|NCT04009083|DEVICE|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
47932906|NCT04009083|OTHER|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
47932907|NCT03021174|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
47932908|NCT03021174|BEHAVIORAL|Nutrition Education Control|12 weeks of implementing eating tips
47932909|NCT02911207|BEHAVIORAL|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
47932910|NCT00576680|DRUG|RAD001|Given orally once a day
47932911|NCT00576680|DRUG|Temozolomide|Taken orally once a day for one week followed by a one-week break period
47932912|NCT01099709|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
47932913|NCT01099709|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
48622716|NCT04155554|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
47932914|NCT04101201|DIETARY_SUPPLEMENT|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
47932915|NCT04101201|OTHER|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
47932916|NCT00215670|DRUG|pegaptanib sodium (Macugen)|
47932917|NCT00357032|DRUG|belinostat|Given IV
48280357|NCT01796132|DRUG|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
48280358|NCT06100432|DRUG|DLBS5055 200mg|1x1 caplet
47932918|NCT00357032|OTHER|laboratory biomarker analysis|Correlative studies
47932919|NCT04493840|DRUG|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
47932920|NCT04493840|DRUG|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
47932921|NCT06332638|DRUG|Tegoprazan 12.5mg|Oral administration of one tablet of Tegoprazan 12.5mg twice daily for 14 days.
47932922|NCT06332638|DRUG|Tegoprazan 25mg|Oral administration of one tablet of Tegoprazan 25mg once daily for 14 days.
47932923|NCT06332638|DRUG|Famotidine 20mg|Oral administration of one tablet of Famotidine 20mg twice daily for 14 days.
47932924|NCT05277480|DRUG|Apatinib+IE|apatinib po； ifosfamide ivgtt ; etoposide ivgtt .
47932925|NCT05277480|DRUG|IE|ifosfamide ivgtt ; etoposide ivgtt .
47932926|NCT03411837|BIOLOGICAL|Dupilumab|Biologic (monoclonal antibody)
47932927|NCT06177275|PROCEDURE|Placement of BLX implants 2 mm sub-crestal i|Placement of BLX implants 2 mm sub-crestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
47932928|NCT06177275|PROCEDURE|Placement of BLX implants equicrestal|Placement of BLX implants equicrestal in single missing anterior or premolar teeth in the esthetic zone with immediate provisionalization via a straight emergence profile temporary crown on a temporary abutment.
47932929|NCT00676221|DRUG|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
47932930|NCT02468011|OTHER|vibration|vibration will be applied at 35 Hz
47932931|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
47932932|NCT01346215|BIOLOGICAL|heparin sodium|5000 UI/mL
47932933|NCT02853227|OTHER|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
47932934|NCT02968589|BEHAVIORAL|Training|
48280359|NCT06100432|DRUG|Placebo DLBS5055|1x1 caplet
47932935|NCT02937974|DRUG|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
47932936|NCT02937974|DRUG|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
48098652|NCT04606264|DRUG|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
48098653|NCT04606264|DRUG|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
48098654|NCT04606264|DRUG|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
48098655|NCT04606264|DRUG|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
48280360|NCT06100432|DRUG|Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)|1x2 caplets
48280361|NCT06100432|DRUG|Placebo Multivitamin|1x2 caplets
48455251|NCT05285865|OTHER|Scapular Mobilization|Thrice a day for complete length of stay including two sets of repetitions with a rest interval of 30 seconds between sets. Grade 1-3 As reported in a study Scapular mobilization (SM) i.e., Scapular superior, inferior glides, upward and downward rotations and scapular distraction, along with Conventional treatment according to American Heart Association Guidelines i.e., Incentive spirometer, chest clearance, expectoration of the sputum (suctioning if needed), mobilizing the patient out of bed, AAROM and AROM exercises.
47932937|NCT01923168|DRUG|alpelisib|BYL719 + Letrozole
47932938|NCT01923168|DRUG|buparlisib|BKM120 + Letrozole
47932939|NCT01923168|DRUG|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
47932940|NCT01509690|OTHER|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access \[arteriovenous (AV) fistula or graft\] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
47932941|NCT02103543|OTHER|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
47932942|NCT02103543|PROCEDURE|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
47932943|NCT02103543|DRUG|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
47932944|NCT04358601|DEVICE|Triathlon PS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
47932945|NCT04358601|DEVICE|Triathlon PS Knee System with metal-backed modular components|Primary Total Knee Replacement
47932946|NCT01445054|DRUG|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
47932947|NCT01613976|DRUG|Panobinostat|
47932948|NCT03121651|DEVICE|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~1. young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~2. young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~3. young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
47932949|NCT02220127|RADIATION|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
47932950|NCT02220127|RADIATION|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
48455252|NCT01602328|BIOLOGICAL|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
48455253|NCT01602328|BIOLOGICAL|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
48455254|NCT01943045|BIOLOGICAL|NGM282|
48455255|NCT01943045|OTHER|Placebo|
47932951|NCT02273739|DRUG|Enasidenib|Enasidenib tablets administered orally once a day in 28-day treatment cycles until disease progression or unacceptable toxicities.
47932952|NCT06370078|DRUG|Albumin Human|To investigate the effect of early administration of albumin in the ICU after onset of septic shock compared to volume replacement therapy without albumin on patient outcome.
47932953|NCT02925793|DRUG|DS107|
48280362|NCT06631079|BIOLOGICAL|NECVAX-NEO1|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
48280363|NCT04269551|DRUG|BIVV020|Pharmaceutical form:solution for injection Route of administration: intravenous
47932954|NCT02925793|OTHER|Vehicle cream|
47932955|NCT05358340|DIAGNOSTIC_TEST|Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)|A dye, known as a contrast agent, will be injected through a needle that is inserted into a vein in the arm or hand. Subsequent magnetic resonance imaging will follow.
47932956|NCT06040242|OTHER|Exercise|Participants will perform 3 min of the different activities, followed by a 10-min recovery window.
47932957|NCT00085228|BIOLOGICAL|oblimersen sodium|
47932958|NCT00085228|DRUG|docetaxel|
47932959|NCT05683431|BEHAVIORAL|Cognitive Control of Emotion (CCE) Training|Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
47932960|NCT01303003|DRUG|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
47932961|NCT01303003|PROCEDURE|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
47932962|NCT02554279|DRUG|menotropin|
47932963|NCT02554279|DRUG|recombinant FSH|
47932964|NCT03108781|DRUG|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
48455256|NCT01749553|OTHER|Sleeper Stretch|Posterior shoulder stretch technique
48455257|NCT03145623|DRUG|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
48622717|NCT04155554|DRUG|Dolutegravir/lamivudine/abacavir|Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
48622718|NCT00104260|DRUG|sapropterin dihydrochloride|
47932965|NCT03108781|DRUG|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
47932966|NCT04508543|OTHER|Non-verbal communication score|1. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
47932967|NCT03603067|PROCEDURE|Ocular surgery|Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
47932968|NCT03374618|OTHER|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
47932969|NCT03559426|DRUG|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
47932970|NCT03559426|DRUG|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
47932971|NCT04570059|BEHAVIORAL|Counselling on textured food introduction between 8 and 15 months|"Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months."
47932972|NCT03725254|PROCEDURE|lymphadenectomy|The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
47932973|NCT03725254|RADIATION|chemoradiotherapy|Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
47932974|NCT05916911|DIETARY_SUPPLEMENT|Glizigen|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
47932975|NCT05916911|OTHER|Placebo|"Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food."
47932976|NCT05475782|PROCEDURE|Spyglass-guided lithotripsy|Spyglass-guided lithotripsy
48622719|NCT04156529|BEHAVIORAL|ESU position|Semi-elevated supine (ESU) position was given during tube feeding
47932977|NCT05475782|PROCEDURE|ESWL|ESWL+ERCP
47932978|NCT00652691|BIOLOGICAL|filgrastim|
47932979|NCT00652691|DRUG|carboplatin|
47932980|NCT00652691|DRUG|cyclophosphamide|
47932981|NCT00652691|DRUG|topotecan hydrochloride|
47932982|NCT00652691|PROCEDURE|autologous hematopoietic stem cell transplantation|
47932983|NCT00652691|PROCEDURE|peripheral blood stem cell transplantation|
47932984|NCT05546801|OTHER|questionnaire|questionnaire on postnatal development
47932985|NCT01874990|DIETARY_SUPPLEMENT|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
47932986|NCT01874990|DIETARY_SUPPLEMENT|low-salt diet|
47932987|NCT05553743|BIOLOGICAL|COVID-19 Exposure|Have been or may have been exposed to COVID-19.
47932988|NCT05553743|DRUG|Antibiotic|Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
47932989|NCT04705740|OTHER|ERCP|ERCPs performed annually by an endoscopist
47932990|NCT05134532|DRUG|regorafenib|Regorafenib 160 mg orally every day for 3 weeks of every 4-week cycle (i.e. 3 weeks on, 1 week off) plus best supportive care
47932991|NCT02914145|DRUG|Dihydroartemisinin-piperaquine|Mass drug administration
47932992|NCT03020446|DEVICE|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
47951331|NCT05085574|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
48622720|NCT04156529|BEHAVIORAL|ESRL position|Semi-elevated right lateral (ESRL) position was given during tube feeding
48622721|NCT00492869|DRUG|AEB071|
48622722|NCT04727008|BIOLOGICAL|CXCR4 modified anti-BCMA CAR T cells|intravenous infusion
48455258|NCT04154592|OTHER|Humeral Head Depressor Muscle Co-Activation Training- Experimental Group|In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 14 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
48455259|NCT04154592|OTHER|Control Group|"The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., \& Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 20 weeks (a total of 14 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above."
48455260|NCT01159145|DRUG|D961H|Oral, capsule
48455261|NCT01159145|DRUG|Omeprazole|Oral, tablet
48455262|NCT05235854|DRUG|Injection of corticosteroids (Diprostène®)|Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
48455263|NCT04067739|OTHER|non interventional study|non interventional study
48455264|NCT02127463|DRUG|MC-1101|Topically, two times a day, morning and bedtime
48455265|NCT02127463|DRUG|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
47932993|NCT02694718|DRUG|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
47932994|NCT02694718|DRUG|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
47932995|NCT01726660|DEVICE|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
48455266|NCT05559736|DEVICE|Artemis Proximal Femoral Nail (PFN) implant|Artemis Proximal Femoral Nail (PFN) implant
47933005|NCT01261468|DEVICE|Active SCS|SCS IPG activated
47933006|NCT01261468|DEVICE|Deactivated|SCS IPG deactivated
47933007|NCT00089674|DRUG|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
47933008|NCT00089674|DRUG|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
47933009|NCT05969327|DRUG|Vitamin D|oral supplementation of two different doses
47933010|NCT05330078|DRUG|Botulinum toxin type A|Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.
47933011|NCT05330078|DRUG|Vehicle|Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
47933012|NCT00983398|DRUG|Carboplatin|Given IA
47933013|NCT00983398|DRUG|Mannitol|Given IA
47933014|NCT00983398|DRUG|Melphalan|Given IA
47933015|NCT00983398|OTHER|Quality-of-Life Assessment|Ancillary studies
47933016|NCT00983398|OTHER|Questionnaire Administration|Ancillary studies
47933017|NCT00983398|DRUG|Sodium Thiosulfate|Given IV
47933018|NCT01902771|BIOLOGICAL|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
47933019|NCT01902771|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
47951332|NCT01431131|PROCEDURE|Intrasocket graft|Intrasocket mineralized cancellous allograft
48098656|NCT05407519|DRUG|Tislelizumab + Sitravatinib|Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
48280364|NCT01021007|DRUG|Iodine|Rinse 2 times per day for 6 weeks
48455267|NCT04134910|PROCEDURE|Physical Therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
48455268|NCT01181635|BEHAVIORAL|Psychotherapy|Standard psychotherapy for psychiatric disorders.
47933020|NCT01902771|OTHER|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
48280365|NCT01021007|OTHER|water|Use 2 times per day for 6 weeks
48622723|NCT04392804|PROCEDURE|scaling and root planing|one appointment for scaling and root planing of selected periodontal pockets, with periodontal curette (HuFriedy, Chicago, IL, USA), rinsing with saline solution
48622724|NCT00070525|DRUG|tipifarnib|Given orally
47933021|NCT01902771|PROCEDURE|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
47933022|NCT05908058|OTHER|Emotional Changes Investigation|Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel Emotional Adjustment
47933023|NCT04785521|RADIATION|Stereotactic radiosurgery|Gamma Knife stereotactic radiosurgery (SRS-GK)
47933024|NCT04785521|DIAGNOSTIC_TEST|Blood samples|Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
47933025|NCT02004639|RADIATION|Masticators sparing techniques|
47933026|NCT02004639|OTHER|electro-acupunture treatment|electro-acupunture treatment and sham-EA
47933027|NCT03191578|DRUG|RUTI®|Administration of RUTI®
47933028|NCT03191578|DRUG|Placebo|Administration of placebo
47933029|NCT05254054|OTHER|whole body vibration|The whole body vibration is used when vibrations (mechanical oscillations) of a certain frequency are transferred to the human body. Humans are exposed to vibration through a contact surface that is in a mechanical vibrating state. It has been considered as an alternative and safe method for neuromuscular training and may be incorporated into current neuromuscular rehabilitation programs so as to enhance muscle recovery
47933030|NCT05254054|OTHER|Conventional exercise training|A set of conventional exercises designed for ACL rehabilitation
47933031|NCT04656483|OTHER|Telemedicine Video Feedback Intervention|Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.
47933032|NCT04656483|OTHER|Psychoeducational Booklet Intervention|Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
47933033|NCT05836779|DRUG|CBL-514 injection|CBL-514 will be administered at the raised area of cellulite.
47933034|NCT05662566|PROCEDURE|Epidural replacement|"Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter"
47933035|NCT04403269|DRUG|IgIV|2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
47933036|NCT01487577|DRUG|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
47933037|NCT02600754|BEHAVIORAL|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
47933038|NCT02600754|BEHAVIORAL|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
47933039|NCT00216866|DRUG|Dalteparin|
47933040|NCT00216866|DRUG|Warfarin|
47933041|NCT02329366|OTHER|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
47933042|NCT01113047|DRUG|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
47933043|NCT02263170|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
47933044|NCT02263170|OTHER|US (ultra sound)|Assessment of the sphincter morphology
47933045|NCT02263170|OTHER|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
47933046|NCT02263170|OTHER|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
47933047|NCT02894008|DRUG|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
48280366|NCT03002506|DRUG|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
48280367|NCT00269009|BEHAVIORAL|CHERL|
48280368|NCT03104582|PROCEDURE|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
48622725|NCT02290418|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
48622726|NCT02290418|PROCEDURE|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
47933048|NCT02095314|BIOLOGICAL|Pentavalen|Batch 5010613
48280369|NCT03104582|PROCEDURE|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
48455269|NCT05548465|DRUG|Remifentanil Hydrochloride|Subjects will receive remifentanil anesthesia for operative analgesia.
48455270|NCT05548465|DRUG|Sufentanil Citrate|Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
48622727|NCT03555344|OTHER|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
48622728|NCT02402036|DRUG|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
47933049|NCT03636698|OTHER|chorioamnionitis|It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
48455271|NCT03613038|BEHAVIORAL|Phonetic complexity effects on speech motor performance|Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
48455272|NCT01670890|DRUG|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
48455273|NCT01670890|DRUG|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
48455274|NCT04579653|DEVICE|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
48455275|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 20 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
48455276|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 15 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
48455277|NCT05794685|PROCEDURE|adductor canal block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg of dexamethasone at a point anterior to the femoral artery, deep to the sartorius muscle (adductor canal block).
48455278|NCT05794685|PROCEDURE|4 in one block|patients will receive an injection of 30 ml of .25% of Bupivacaine including 4mg dexamethasone at the adductor hiatus where the descending genicular artery branches from superficial femoral artery (4 in one block).
48455279|NCT02659462|OTHER|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
48455280|NCT03068780|DRUG|Oleogel-S10|10% birch bark extract in 90% sunflower oil
48455281|NCT03068780|DRUG|Control gel|Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)
48455282|NCT05437848|DRUG|Experimental: Cotadutide|Cotadutide: subcutaneous (SC) injection
48455283|NCT05437848|OTHER|Placebo|Placebo subcutaneous injection
48455284|NCT06348329|OTHER|Birth Preparation Training|Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.
48455285|NCT06513052|OTHER|Commercial cocoa|daily intake of a beverage made with 8 grams of commercial cocoa low in flavanols, dissolved in 200 mL of low-fat, lactose-free milk
48098657|NCT06361940|DRUG|Aromatase inhibitors or tamoxifen|Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
48455286|NCT06513052|OTHER|High flavonols Cocoa|Daily intake of a beverage made with 8 grams of cocoa high in flavanols, dissolved in 200 mL of low-fat, lactose-free milk.
48455287|NCT04352205|DRUG|Bortezomib|Given SC
48455288|NCT04352205|BIOLOGICAL|Daratumumab|Given IV
48455289|NCT04352205|DRUG|Dexamethasone|Given PO and IV
48455290|NCT04352205|DRUG|Lenalidomide|Given PO
48455291|NCT04352205|DRUG|Thalidomide|Given PO
48455292|NCT01572051|BEHAVIORAL|Educational Course|2 Educational courses
48455293|NCT01572051|BEHAVIORAL|Phone Calls|Phone Calls
48455294|NCT01572051|BEHAVIORAL|Printed Material|Printed Material
48455295|NCT01354886|DRUG|FSH-GEX™|single dose
48455296|NCT01354886|DRUG|Gonal-f|150 IU single dose
47933050|NCT03956355|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
47933051|NCT03956355|DRUG|Vehicle Cream|Vehicle cream applied once daily
47933052|NCT05367375|PROCEDURE|removing osteophyte at patellofemoral joint|to compare anterior knee pain between removing patellofemoral joint osteophytes and non-removing patellofemoral joint osteophytes after medial unicompartmental knee arthroplasty
48455297|NCT01354886|DRUG|Bravelle|150 IU single dose
48455298|NCT01354886|DRUG|Placebo|single dose
48455299|NCT00896688|PROCEDURE|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
48455300|NCT05444296|OTHER|Superficial Dry Needling|"1/2 needles will placed into defined innervation fields of the trigeminal nerve and rotated. Total time will be 5-7 minutes."
48455301|NCT05444296|OTHER|Non-thrust Mobilizations only|Non-thrust mobilizations to be applied to the most symptomatic level of the upper cervical spine as determined by a treating physical therapist. The mobilization technique will be applied for 3 bouts of 30 seconds.
48455302|NCT05600699|DEVICE|Cardiac pacemaker and Select Secure lead|model 3830, 69cm, Medtronic, Inc., Minneapolis, MN, USA
48455303|NCT01695239|DRUG|Ixekizumab|Administered SC
48455304|NCT01695239|DRUG|Placebo|Administered SC
48455305|NCT01695239|DRUG|Adalimumab|Administered SC
48455306|NCT03419247|PROCEDURE|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
48455307|NCT03419247|PROCEDURE|Blood draw|Blood will be taken by a needle from a vein.
48455308|NCT03419247|PROCEDURE|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
48455309|NCT03342846|DEVICE|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
48455310|NCT02128308|DRUG|Levofloxacin and Streptomycin added|
48455311|NCT02128308|DRUG|Moxifloxacin and Kanamycin added|
48455312|NCT05764096|OTHER|No intervention|No intervention
48455313|NCT02828449|BEHAVIORAL|therapeutic education program|
48455314|NCT05168163|BIOLOGICAL|Atezolizumab|Given IV
48455315|NCT05168163|DRUG|Cabozantinib|Given PO
48455316|NCT05168163|DRUG|Lenvatinib|Given PO
48455317|NCT01024855|DEVICE|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
47933053|NCT03563144|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
47933054|NCT03563144|DRUG|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
48455318|NCT04210947|OTHER|30 rolls per minute(30RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
48455319|NCT04210947|OTHER|15 rolls per minute(15RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
47933055|NCT03563144|DRUG|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
47933056|NCT03563144|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
47933057|NCT03563144|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
47933058|NCT03563144|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
47933059|NCT03563144|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
47933060|NCT03563144|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
47933061|NCT03563144|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
47933062|NCT03563144|BIOLOGICAL|GI-6207|CEA yeast vaccine
47933063|NCT03563144|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
47933064|NCT03563144|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
47933065|NCT03563144|DRUG|Avelumab|Avelumab
47933066|NCT03563144|DRUG|Bevacizumab|Bevacizumab
47933067|NCT03563144|DRUG|Capecitabine|Capecitabine
47933068|NCT03563144|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
47933069|NCT03563144|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
47933070|NCT03563144|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
47933071|NCT03563144|DRUG|Oxaliplatin|Oxaliplatin
48455320|NCT04210947|OTHER|self-determined|Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
47933072|NCT05160610|BEHAVIORAL|Multilevel intervention|Multilevel intervention based on AACTT theory
47933073|NCT01500343|DRUG|Saccharomyces boulardii|1 gram per day, during 3 months
48455321|NCT05887427|OTHER|Neural Mobilisation|Transcutaneous Electrical Stimulation, hotpack, ultrasound and neural mobilization(radial,ulnar,median)
47933074|NCT01235871|DRUG|SB1578|JAK2 Inhibitor
47933075|NCT01235871|DRUG|Placebo|Control arm
47933076|NCT03328182|DEVICE|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
47933077|NCT03872011|DRUG|Vitamin C,thiamine,hydrocortisone|"Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU."
47933078|NCT03872011|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
47933079|NCT02850081|DRUG|Statin|"Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)"
47933080|NCT02850081|DRUG|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"
47933081|NCT02850081|OTHER|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
47933082|NCT01097083|DRUG|Coriolus Versicolor|
47933083|NCT03817450|BEHAVIORAL|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
47933084|NCT03315052|DRUG|Budesonide|Oral steroid with high first-pass metabolism in liver
47933085|NCT03315052|DRUG|Tacrolimus（FK506）|Calcineurin immunosuppressant
47933086|NCT03315052|DRUG|Mycophenolate Mofetil|Immunosupressant
47933087|NCT03315052|DRUG|Prednisone|Immunosuppresant
47933088|NCT01278654|BEHAVIORAL|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
47933089|NCT00998764|DRUG|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
47933090|NCT04589715|OTHER|electroacupuncture|the same as described in experimental arm.
47933091|NCT04589715|OTHER|sham electroacupuncture|the same as described in sham comparator.
47933092|NCT05729802|DEVICE|HoloSIM Software via Hololens 2|Participants will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
47933093|NCT05729802|OTHER|Training by Mannequin Based Simulation|Participants will train a via traditional mannequin based medical crisis scenario
47933094|NCT03375073|OTHER|Positive communication during medical transmission|Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
48106835|NCT05035199|BEHAVIORAL|Spiritual Distress and Resources Questionnaire (SDRQ)|The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
47933095|NCT06278610|DIAGNOSTIC_TEST|PELVIC EXENTERATION|PELVIC EXENTERATION
47951333|NCT01431131|PROCEDURE|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
47933096|NCT03361644|BEHAVIORAL|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
48455322|NCT05887427|OTHER|Conservative physiotherapy|Hotpack,Transcutaneous Electrical Stimulation ,Ultrasound
48455323|NCT02451163|DIETARY_SUPPLEMENT|wheat polysaccharides|Consumed once daily for 12 weeks.
48455324|NCT02451163|DIETARY_SUPPLEMENT|maltodextrin|Consumed once daily for 12 weeks.
48455325|NCT05733585|DEVICE|Purabond|hemostatic efficacy of PuraBond
48455326|NCT06627881|OTHER|Continuous aerobic kayak training program|Sitting in a special chair on the Kayak Pro® Speed Stroke PRO ergometer. 5-minute warm-up and continuous training, for 30 minutes on the ergometer at a moderate to vigorous intensity, 5 days a week.
48455327|NCT06627881|OTHER|Aerobic Endurance Circuit Program|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, light intensity training with upper body strengthening, 5 days a week.
48455328|NCT06627881|OTHER|High intensity interval program with rope|Sitting with feet flat on the floor and shoulder-width apart, in each session with a 5-minute warm-up, vigorous intensity undulating rope training using the interval method, 5 days a week.
48455329|NCT02465125|BIOLOGICAL|red blood cell transfusion|
47933097|NCT03361644|BEHAVIORAL|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
47933098|NCT01850433|BEHAVIORAL|Internet based CBT for body dysmorphic disorder|
47933099|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
47933100|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
47933101|NCT00219544|DRUG|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
48106836|NCT05165888|BEHAVIORAL|Communication and Bias Mitigation Training|Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior
47933102|NCT00219544|DRUG|Placebo|Placebo
47933103|NCT02708303|OTHER|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research."
47933104|NCT06247397|DEVICE|Added high-flow oxygen therapy|Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.
47933105|NCT06247397|OTHER|Standard care|Standard care with low-flow oxygen therapy in accordance with clinical routine.
47933106|NCT04344743|DEVICE|Cryoballoon ablation without contrast|Cryoballoon ablation without contrast
47933107|NCT06098677|DIETARY_SUPPLEMENT|Carotenoids supplementation|Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).
47933108|NCT06098677|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation of a soft gel capsule containing only placebo oil
47933109|NCT02176824|BEHAVIORAL|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
47933110|NCT02176824|BEHAVIORAL|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
47933111|NCT02176824|OTHER|Treatment as usual|
47933112|NCT04666077|BEHAVIORAL|Home-based MT through Supervised, Supported Singing (H3S)|"Daily singing of song of kin. The song of kin will be derived from an assessment session and evaluation inclusive of an interview under the supervision of Dr. Joanne Loewy and her team at the Louis Armstrong Center for Music and Medicine (LACMM). The interview will include the participant and their study partner who will assist in identifying musical preferences and relevant cultural experiences. A recording of prescribed song protocols will be provided. Participants and study partners will be directed to plan a minimum of 1 hour a day in which the participant will sing along with the study partner-administered song of kin. A diary will be provided to the study partner to record the time of day, amount of time spent and comments on the activity. Study staff will contact the members of this group to confirm compliance with the activity."
47933113|NCT04666077|BEHAVIORAL|Individualized Music Therapy (IMT)|The Individualized Music therapy (IMT) conducted by the LACMM staff. It will be administered by a certified music therapist twice weekly for 45 minutes. The sessions will employ extensive clinical improvisation based on the songs of kin utilized in the H3S condition. Compliance will be measured with a weekly log which will record dates and times of each condition.
47951334|NCT02906904|OTHER|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
48106837|NCT05165888|BEHAVIORAL|Communication skills training|Training to improve communication skills between physicians and caregivers.
48106838|NCT02570295|OTHER|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
48455330|NCT03336580|DRUG|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
48455331|NCT06467513|DRUG|Esketamine hydrochloride injection|The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
48455332|NCT03459339|DEVICE|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
48455333|NCT01367054|DRUG|Metformin|500 mg tablet
48455334|NCT01367054|DRUG|Glifage|500 mg tablet
48455335|NCT00789308|DRUG|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
48455336|NCT00789308|DRUG|Heparin|Anticoagulation
48455337|NCT00789308|DRUG|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
48455338|NCT00789308|DRUG|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
48455339|NCT00789308|DRUG|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
47933114|NCT04666077|OTHER|Attention Control (AtCon)|"The attention control (AtCon) will meet with the LACMM team for an interview in which they will be asked about music preferences and music experiences. They will answer any questions from participant and caregiver about music experiences. Study staff will contact the members of this group at the same schedule as the H3S group to assess music activity engagement. This will measure unplanned exposure and minimize drop-in music activity which could contaminate the control condition."
47933115|NCT03072771|DRUG|Blinatumomab|-Blinatumomab is a bispecific T cell engaging antibody
47933116|NCT03072771|PROCEDURE|Autologous stem cell transplant|-Standard of care
47933117|NCT03072771|DRUG|Carmustine|-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
47933118|NCT03072771|DRUG|Etoposide|-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
47933119|NCT03072771|DRUG|Cytarabine|-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
47933120|NCT03072771|DRUG|Melphalan|-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
47933121|NCT03072771|PROCEDURE|Peripheral blood draws|-Day +42, Day + 43, Day +56, and Day +100
48455340|NCT00789308|DRUG|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
48455341|NCT00789308|DRUG|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
48455342|NCT00789308|DRUG|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
48455343|NCT00789308|DRUG|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
47933122|NCT05292144|DEVICE|Xperience Pro|Patients in whom treatment with (Xperience Pro) has been attempted
47933123|NCT01348971|DIETARY_SUPPLEMENT|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
47933124|NCT01348971|OTHER|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
47933125|NCT04944862|BIOLOGICAL|CDX-0159|administered intravenously
47933126|NCT04944862|DRUG|Normal saline|administered intravenously
47933127|NCT01569464|DRUG|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
47933128|NCT01569464|OTHER|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
48455344|NCT00694187|DRUG|Zaleplon|
48455345|NCT01637376|DRUG|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
48455346|NCT03259165|DRUG|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~2. SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to \< 120 mmHg)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
47933129|NCT04879524|PROCEDURE|Percutaneous infracoccygeal Botulinum toxin injection to puborectalis|"The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete."
47933130|NCT03687164|OTHER|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
47933131|NCT01812980|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
47933132|NCT02777749|DRUG|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
48106839|NCT00271700|BEHAVIORAL|Order Set, Education, Feedback|
48106840|NCT00800163|OTHER|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
48106841|NCT02517411|OTHER|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
48455347|NCT03259165|DRUG|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. Patients receive 1 inch topical nitropaste~2. IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
48455348|NCT06561269|PROCEDURE|Multifidus plane block|"Using the in-plane technique,The fascial plane between the multifidus muscle and the median sacral crests of S2 and S3, will be injected by bupivacaine."
48455349|NCT06561269|PROCEDURE|caudal block|"The ultrasound transducer will first be placed transversely at the midline to obtain the transverse view of sacral hiatus. At this level, the ultrasound transducer is rotated 90 degrees to obtain the longitudinal view of sacral hiatus. The block needle is inserted using the in-plane technique."
48455350|NCT04908735|DRUG|Ruxolitinib|Participants will receive ruxolitinib orally twice daily for 24 weeks.
48455351|NCT05843994|OTHER|online survey|Participants will complete an online survey and submit photographs.
48455352|NCT05235568|DEVICE|VALVOSFT intervention|Treatment of the calcific aorta valve by non-invasive ultrasound therapy
48455353|NCT05645120|OTHER|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
48455354|NCT02485951|PROCEDURE|Central air injection|Air was injected inside the trephination site in the central injection group.
48455355|NCT02485951|PROCEDURE|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
48455356|NCT04737330|DRUG|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
48455357|NCT04737330|DRUG|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
48455358|NCT05561166|OTHER|EPIDREAM Questionnaire|EPIDREAM Questionnaire (questionnaire about dreams and epileptic seizures)
48455359|NCT05448235|OTHER|conventional treatment|the patient will be asked to make pursed lip breathing (Breathe in for 2 seconds through his nose and Breathe out for 4 seconds through pursed lips)for 5-10 min ,3-4 times , 8-10 rep each cycle then asked to make diaphragmatic breathing exercise (Lie on his/her back and Inhale deeply through his/her nose for a count of three)for 5-10 min , 3-4 times , 8-10 repetition then postural drainage , furthermore the patient takes different position (prone to make percussion on lower lobes, side lying on anterior basal segment then sitting position on the upper lobe). After that a vibration on the chest (place a flat hand firmly atop the lung segment to be drained., and should apply light pressure and create a rapid, shaking movement) 1 min inhale and 5 time of repetition at the exhale and finally asked the patient to make productive cough for 5 times to get out the sputum.
48455360|NCT05448235|OTHER|thoracic mobilization|we will use A SNAG to mobilization using type 3 oscillatory and sustain for 90 second, at first put the patient in 3 position (side lying to make mobilization of upper 6 ribs in downward direction then make on lower 6 ribs ,furthermore flexion of the thoracic and next rotation toward the midline then ask the patient to transfer to supine lying position and mobilize the sternum in downward direction the next mobilize the clavicle and ask the patient to take sitting position and put his hand on his head in adduction position and make extension on the thoracic vertebrae with inward mobilize with the investigator knees ,take each 4 vertebrae along the 12 thoracic vertebrae.
48455361|NCT02256943|DRUG|Amitriptyline|100 mg single dose
47933133|NCT01779076|PROCEDURE|30% oxygen|
48455362|NCT02256943|DRUG|Tolterodine|Placebo 1 mg single dose
48455363|NCT05299463|DIAGNOSTIC_TEST|Exercise Testing|"* Tele-Six-minute walk test (T6MWT)~* 1 Minute Sit-to-stand test (STS)~* 2-minute symptom-limited Step test (ST)~* 3-metre Timed up and go test (TUG)."
48455364|NCT03330990|DRUG|Entrectinib|600 mg oral capsule (fasted and fed)
48455365|NCT03330990|DRUG|Midazolam Hydrochloride|2 mg oral syrup (fasted)
48455366|NCT04341883|DRUG|anti-PD-1+Albumin-Bound Paclitaxel|"anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years.~Other Name: Programmed cell death 1 antibody"
48455367|NCT02247362|BIOLOGICAL|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
48455368|NCT02247362|OTHER|Placebo|Vaccine Diluent
48455369|NCT00537095|DRUG|Vandetanib|300 mg oral once daily oral dose
48455370|NCT00537095|OTHER|Placebo|
48455371|NCT04773600|DRUG|Roflumilast Cream|Roflumilast cream 0.15% for topical application
48455372|NCT04773600|DRUG|Vehicle cream|Vehicle cream for topical application
48455373|NCT02828631|DEVICE|Macintosh laryngoscope|
48455374|NCT02828631|DEVICE|McGrath videolaryngoscope|
48455375|NCT02828631|DEVICE|Pentax videolaryngoscope|
48455376|NCT04981262|DIETARY_SUPPLEMENT|Stimulance|Intervention with Prebiotic supplement
48455377|NCT06348888|DRUG|BAY2927088|Oral
48455378|NCT06348888|DRUG|Itraconazole|Capsule, 100 mg, oral.
48455379|NCT06348888|DRUG|Carbamazepine|Tablet, 100 mg, 200mg and 300mg, oral.
48455380|NCT02600247|DRUG|Duloxetine|"Experimental: Duloxetine group~1. Phase I (preemptive): 1day before operation (30mg for 1 day)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
48622729|NCT00198120|DRUG|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
47933134|NCT01779076|PROCEDURE|100% oxygen|
47933135|NCT05343533|DIETARY_SUPPLEMENT|Probiotic|After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
47933136|NCT01060345|DRUG|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
47933137|NCT03500185|OTHER|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
47933138|NCT03500185|OTHER|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
47933139|NCT01309893|DEVICE|Investigational Lens|Lenses worn on a daily wear basis for one week
48455381|NCT02600247|DRUG|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
48455382|NCT01756885|DRUG|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
47933140|NCT01309893|DEVICE|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
47933141|NCT04647487|DRUG|LY3484356|Administered orally.
47933142|NCT02402842|DRUG|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
47933143|NCT06242444|DRUG|Experimental Dentifrice|Dentifrice containing 1150 ppm fluoride and 5% KNO3.
47933144|NCT06242444|DRUG|Placebo Control Dentifrice|Dentifrice containing 0 ppm fluoride and 5% KNO3.
47933145|NCT06242444|DRUG|Reference Dentifrice|Dentifrice containing 1100 ppm fluoride as SnF2.
47933146|NCT02102373|DEVICE|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
48455383|NCT01756885|DRUG|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
47933147|NCT00122733|DRUG|loxapine|
47933148|NCT05608928|DIETARY_SUPPLEMENT|VSL#3|VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis. VSL#3 contributes to balancing the gut and vaginal microbiota and is used as a food supplement for management of diseases like irritable bowel syndrome, ulcerative colitis or ileal pouch.
47933149|NCT05608928|DEVICE|Capscan device|"The CapScan device is a short-term single-use class IIa ingestible medical device that collects fluids from the gastrointestinal (GI) tract and is collected in the stool. GI samples are then extracted from the device and analyzed outside the body."
47933150|NCT05608928|COMBINATION_PRODUCT|Placebo|microcrystalline cellulose
47933151|NCT04332809|PROCEDURE|saline-gentamicin irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline-gentamicin solution
47933152|NCT04332809|PROCEDURE|saline irrigation|Layer-by-layer irrigation of the appendectomy wound will be performed using saline solution
47933153|NCT00604214|DRUG|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
47933154|NCT00604214|DRUG|Placebo|0.9% sodium chloride, intravenous, 96 hours
47933155|NCT03647787|OTHER|observational study|This study is a longitudinal observational study
47933156|NCT01042782|DRUG|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
47933157|NCT02954042|DEVICE|Pelvital probe|Pelvital probe
47933158|NCT02954042|DEVICE|Placebo Probe|Placebo Probe
47933159|NCT01246466|DEVICE|Hybrid: AtriCure Bipolar System & EP ablation procedure|AtriCure Bipolar System plus a catheter ablation
47933160|NCT04340427|DRUG|TQB3455|TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
47933161|NCT01386905|DEVICE|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
47933162|NCT02836743|DRUG|Circadin|Slow-release melatonin
47933163|NCT02836743|DRUG|Placebo|
47933164|NCT02599051|DEVICE|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
47933165|NCT02599051|DEVICE|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
47933166|NCT02697110|BEHAVIORAL|Edutainment based intervention|Edutainment intervention package
47933167|NCT01067547|DRUG|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
47933168|NCT01067547|DRUG|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
48622730|NCT00198120|DRUG|Placebo|Placebo: same dosing schedule and capsule strength
47933169|NCT02150408|OTHER|PET-CT|
47933170|NCT01197001|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan low dose
47933171|NCT01197001|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
47933172|NCT05200494|PROCEDURE|Recruiting Maneuver|Airway pressure will be increased to 30 cmH2O for 30 seconds at the end of the bronchoscopy
47933173|NCT04554004|DIAGNOSTIC_TEST|CCTA, CT-MPI, DSA, FFR|The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
47933174|NCT04935450|DIAGNOSTIC_TEST|Bronchoalveolar lavage|Low volume Broncho alveolar lavage. During optic flexible bronchoscopy through the tracheal tube or the tracheostomy cannula a maximum of 4 aliquots of 20 ml normal saline will be instilled in a wedged position in the right medium lobe of the patients and then aspirated untill reaching a total of 25ml of fluid (BALF) for analysis
47933175|NCT03551262|DEVICE|OTSC|Positioning of OTSC in bleeding peptic ulcer
47933176|NCT03551262|DEVICE|TTS clip|Positioning of TTS clip in bleeding peptic ulcer
47933177|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - More Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.
47933178|NCT05742178|BEHAVIORAL|Educational Materials|Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
47933179|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - Less Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
47933180|NCT02924415|BEHAVIORAL|Tele-care support|Psychoeducation treatment based on telemedicine
47933181|NCT02924415|OTHER|Control group|Standard care
47933182|NCT03689933|DEVICE|Root analog implant|a custom made root analogue implant made from milled titanium
47933183|NCT03656471|DEVICE|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
47933184|NCT01351870|RADIATION|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
47933185|NCT01351870|RADIATION|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
47933186|NCT04649372|PROCEDURE|EndoVE|On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.
47933187|NCT05313152|DRUG|TAVO103A|TAVO103A single ascending dose IV infusion.
47933188|NCT05313152|OTHER|Placebo|Placebo single ascending dose IV infusion.
47933189|NCT04153214|BEHAVIORAL|cycling|Participants will have a portable pedal machine under their desk and will use it 60minutes per day
47933190|NCT04341753|OTHER|pulmonary rehabilitation|"the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry."
47933191|NCT06089369|DRUG|Sintilimab (9 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）
47933192|NCT06089369|DRUG|Sintilimab (18 cycles)|IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）
47933193|NCT06089369|OTHER|Active surveillance|Active surveillance
47933194|NCT04903379|OTHER|Education|An explanation of contemporary pain science and a description of effective treatment strategies used by people with a history of persistent pain.
47933195|NCT00000791|DRUG|Glycovir|
47933196|NCT00000791|DRUG|Zidovudine|
47933197|NCT01418560|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
47933198|NCT00480987|DRUG|Oxaliplatin|30 mg/m\^2 IV days 1-4
47933199|NCT00480987|DRUG|Fludarabine|30 mg/m\^2 IV days 2-6
47933200|NCT00480987|DRUG|Cytarabine|500 mg/m\^2 by IV continuous infusion days 2-6
47933201|NCT04047927|DEVICE|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
47933202|NCT00064298|DIETARY_SUPPLEMENT|fruit and vegetable extracts|Given orally
47933203|NCT00064298|DIETARY_SUPPLEMENT|placebo|Given orally
47933204|NCT00644644|OTHER|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
47933205|NCT06233760|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
47933206|NCT06233760|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
47933207|NCT06233760|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
47933208|NCT06233760|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
47933209|NCT06233760|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
47933210|NCT06233760|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
47933211|NCT06233760|OTHER|Big Five Inventory|The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
47933212|NCT06233760|OTHER|Family APGAR Questionnaire|Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
47933213|NCT02456103|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
47933214|NCT00248885|PROCEDURE|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
47933215|NCT06094985|GENETIC|DNA exome sequencing of tumor and blood|A piece from tumor and a blood sample will be collected during surgery. DNA will be extracted and presence of tumor specific mutations/aberrations will be analysed with a DNA exome seq panel. Presence of identified markers will be followed in blood samples with the same panel and these blood samples will be collected in routine follow-up during the first two years. Presence of markers over time in blood will be correlated to outcomes 1-5.
47933216|NCT06341803|DEVICE|Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100|MagproX 100 and Axilium Cobot with Localite camera
47933217|NCT05557318|DEVICE|Vaginal swab for RT-PCR|Screening for Bacterial vaginosis (BV) / Trichomonas / Chlamydia trachomatis / Candida albicans
47933218|NCT05557318|DEVICE|Vaginal swab for culture|Screening for Group B streptococcus / Neisseria gonorrhoeae / Escherichia coli
47933219|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by participant)|The participant operates the Ainos Flora to collect signatures of metabolic gases in the vagina by herself.
47933220|NCT05557318|DEVICE|Metabolic gas signatures detected by Ainos Flora (operated by medical staff)|The medical staff operates the Ainos Flora to collect signatures of metabolic gases in the participant's vagina.
47933221|NCT05245279|DIAGNOSTIC_TEST|3 dimensional ultrasound investigation|Images that contributed to the determination of placental volume and 3-DPD indices were obtained at the time of visit. All 3-D scans ultrasound measurements were performed by a Voluson 730 Expert ultrasound machine equipped with a multifrequency probe (2-5 MHz) to acquire images. Each sample was examined using 3-D rendering mode, in which the colour and gray value information was processed and combined to supply 3-D image. For laterally located placentas, the investigator positioned the transducer on a slight lateral inclination to obtain proper images. Power Doppler window was placed over the placenta to map the vascular tree from basal to chorionic plates. The 3-D static volume box was placed over the entire placenta volume. The sweep angle was set at maximum 70°. Each image was recovered from the disk in succession for processing. During gestation, the investigator recorded one sample from each patient.
47933222|NCT05245279|DIAGNOSTIC_TEST|2 dimensional ultrasound investigation|The two-dimensional (2-D) transabdominal conventional study provided data about fetal position, biometry, body movements and fetal heart rate as well as placental localization. The factorial default setting 'Obstetrics' was applied in 2-D mode.
47933223|NCT03495544|DIAGNOSTIC_TEST|PD-L1 expression|IHC testing of PD-L1 expression level in tumor tissue samples
47933224|NCT06303791|BEHAVIORAL|Digital Psychosocial intervention|The psychosocial program with digital support has been developed by combining different theoretical perspectives on intervention in children with ASD without intellectual disabilities and children with ADHD. The contents of the program are based on three main approaches, each of which has separately demonstrated evidence in the treatment of these neurodevelopmental disorders: psychoeducation and stress management, cognitive behavioral techniques, and techniques in social and communication skills (Dahl et al., 2020; DuPaul et al., 2020; Tan-MacNeill et al., 2021).
47933225|NCT04330326|DRUG|Metabolic Cofactor Supplementation|Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
47933226|NCT04330326|DRUG|Sorbitol|As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
48455384|NCT01756885|BEHAVIORAL|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
48455385|NCT04003363|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
48455386|NCT02282124|BEHAVIORAL|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
48106842|NCT02517411|OTHER|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
48455387|NCT02282124|BEHAVIORAL|Usual Care, containing one session|Session takes place within the first three months after transplantation
48455388|NCT03721471|OTHER|Scoring of frailty|"1. Patients will be scored by the Clinical frailty Scale~2. Patients' hand-grip-strength will be measured by a dynamometer."
48455389|NCT06403033|DEVICE|Mini-implant-supported Twin-Block|Mini-implants will support the Twin-Block appliance during the functional treatment.
48455390|NCT06403033|DEVICE|Twin-Block|This is the main appliance that will be used to correct the Class II deformity.
48455391|NCT02116595|OTHER|high or low acid diet|high or low acid diets
47933227|NCT06259851|BEHAVIORAL|Dialectical behavioral therapy program|Dialectical behavioral therapy (DBT) program with all the standard DBT modules (individual therapy 1 hour per week, skills group 3 hours per week, phone coaching, and therapist consultation team 1,5 hour per week). The program takes 24 weeks in total comprising two 12-week runs of skills training. The program will be precluded with 4 individual sessions of pretreatment before the start of the main program part.
48455392|NCT00597454|OTHER|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
48455393|NCT02901028|OTHER|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
48455394|NCT02901028|OTHER|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
48455395|NCT01852799|DRUG|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
48455396|NCT00177164|DRUG|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
48455397|NCT04431505|OTHER|apoptosis|study of apoptotic changes due to anaesthesia
48455398|NCT04084639|DIETARY_SUPPLEMENT|Mycoprotein Ingestion|Ingestion of various doses of mycoprotein compared to placebo control
48455399|NCT04122950|BEHAVIORAL|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
48622731|NCT06201091|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
48622732|NCT01823900|DRUG|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
48455400|NCT05231603|DRUG|Ivermectin|0.4 mg/kg/day-maximum dose is 24 mg.
48455401|NCT05231603|OTHER|Placebo|Similar to drug in term of tablets
48455402|NCT00809705|DRUG|Placebo|sc once weekly for 12 weeks
48622733|NCT01823900|DRUG|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
48622734|NCT05389267|DRUG|Kinezodianone R hydrochloride|Eyedrops
48622735|NCT05389267|DRUG|Placebo|Placebo
48622736|NCT02208440|PROCEDURE|Best Repair of torn Rotator Cuff|
48622737|NCT02208440|DEVICE|InSpace™ system|
48455403|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
47951335|NCT02906904|OTHER|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
47951336|NCT00549874|DRUG|Rosiglitazone|oral 8 mg/once daily for 6 months
47951337|NCT00549874|DRUG|Glyburide|20 mg/ once daily for 6 months
47951338|NCT04269707|DRUG|Ferric carboxymaltose|IV iron
48455404|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 12 weeks
48455405|NCT06150807|DEVICE|ultrasound and doppler|Ultrasound examinations of the liver and spleen including color Doppler imaging of the portal veins, hepatic veins, splenic vein, and superior mesenteric vein will done in the Department of Pediatric
48455406|NCT01870258|OTHER|ANN prediction of myocardial infarction|
48455407|NCT04872075|OTHER|Concert|People attending a concert in a closed area, with a mask
48455408|NCT04872075|DIAGNOSTIC_TEST|Rapid nasopharyngeal antigen test for Sars-Cov-2|A nasopharyngeal swab at inclusion (up to 3 days before concert) to confirm eligibility
48455409|NCT04872075|DIAGNOSTIC_TEST|Saliva Sample|Saliva samples sent by participant at Day0 and Day7
48455410|NCT02937935|BIOLOGICAL|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
48455411|NCT02937935|BIOLOGICAL|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
48455412|NCT00375284|DRUG|Pramipexole|
48455413|NCT00250263|DRUG|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
48455414|NCT00250263|DRUG|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
48455415|NCT04042415|OTHER|Caloric restriction|Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
48455416|NCT04042415|OTHER|Caloric restriction without cow's milk and gluten|Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
48455417|NCT05435638|DIAGNOSTIC_TEST|Serum chemistry|"Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126).~Serum chemistries will include assessment of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase, glucose, sodium, potassium, blood urea nitrogen (BUN), and creatinine."
48455418|NCT05435638|DIAGNOSTIC_TEST|Hematology|Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126). The CBC assessment will include a red blood cells (RBC), hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MCV), white blood cells (WBC), neutrophils (% and abs.), lymphocytes (% and abs.), monocytes (% and abs.), eosinophils (% and abs.), basophils (% and abs.), large unstained cells (% and abs.).
48455419|NCT05435638|DIAGNOSTIC_TEST|Urinalysis|"General urinalysis will be performed, by dipstick, during Screening, on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Cohort 2: Day 112) and follow-up EoS visits (arm 1: Day 91; Arm 2: Day 126).~Approximately 7-10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin urobilinogen and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated."
48455420|NCT05435638|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed at Screening, at all in-clinic study visits, and at the End of Study visit.~The physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~• Symptom-directed physical examinations will be performed at all other study visits."
48455421|NCT05435638|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (body temperature, pulse and resting systolic and diastolic blood pressure) will be measured at Screening, at all in-clinic study visits, and at the End of Study visit. Vital signs will be measured in supine position after at least five minutes of rest.
48455422|NCT05435638|DIAGNOSTIC_TEST|ECG Test|A 12-lead, resting, digital ECG will be taken for each participant during Screening, on Days 42 and 84 (for both arms), and on day 112 (Arm 2 only), after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT and QRS intervals and QTC. The report will be signed by the Investigator, who will record in the CRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the participants will be reviewed.
48455423|NCT05435638|DIAGNOSTIC_TEST|PK|"Blood PK analyses will be performed on ≥5ml blood collected in 5-mL K-EDTA CRO coded pre-labeled tubes, refrigerated immediately after collection. Plasma will be separated by centrifugation within 2h, and then frozen at -20C.~Blood samples will be collected pre-dose on Days 0, 7, and 84, as well as pre-dose at EoT (Arm 2: Day 112), and at any point during the in-clinic visit at EoS (Arm 1: Day 91; Arm 2: Day 126)."
48455424|NCT05435638|DIAGNOSTIC_TEST|IGA scoring|"Lesions severity will be assessed using the Investigator's Global Assessment (IGA) scale,which is a 5-point scale (from 0 =no disease to 4=severe disease) based on Simpson et al. 2020, IGA for atopic dermatitis (see Table 4; Simpson et al. 2020).~The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions at a given timepoint. It is not necessary that all characteristics under morphological description are present. Excoriations should not be considered when assessing disease severity."
48455425|NCT05435638|DRUG|KM-001 1% cream 12 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
48455426|NCT05435638|DIAGNOSTIC_TEST|Clinician global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
48455427|NCT05435638|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"The VAS score will be collected on every in-clinic visit during the treatment period (Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.).~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
48455428|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI-C scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) answering the question Since the start of the trial, my overall status has."
47933228|NCT06259851|DEVICE|Prefrontal rTMS treatment|rTMS will be performed by DuoMag XT with 70BF cool coil. Patients will undergo 15 daily stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds. Gradual titration of the individual resting motor threshold (RMT) will apply, meaning probands will undergo first session with 90% RMT intensity, second session with 100% RMT intensity, third session with 110% RMT intensity. All the following sessions will use the final 120% RMT intensity. In case a session is left out because of any reason, the total duration of treatment will be prolonged by one day, so that the total number of sessions underwent is the same in all patients. Patients will receive 2000 pulses during one session (total 30000 pulses during the whole procedure) with 10 Hz frequency.
48455429|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI-S scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) answering the question Please rate the severity of your disease right now."
48455430|NCT05435638|DIAGNOSTIC_TEST|Lesion photography|High-quality photographic documentation of the treated lesions will be performed on screening, and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, pre-dose, if applicable.
48622738|NCT05320471|OTHER|This is an observational study|This is an observational study
48622739|NCT03647007|OTHER|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
48622740|NCT02401230|DRUG|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
48622741|NCT02401230|DEVICE|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
48622742|NCT04736433|DRUG|ACE inhibitor|ACE inhibitor dispensing claim is used as the reference
48622743|NCT04736433|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan dispensing claim is used as the reference
48622744|NCT00932711|BEHAVIORAL|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
48622745|NCT00477022|DEVICE|Vasotrain-447|
48622746|NCT04766333|BEHAVIORAL|Healthcare Worker Focused Outreach|This a focused outreach intervention strategy specifically designed for healthcare workers.
47933229|NCT06259851|DEVICE|Sham rTMS sessions|Sham TMS will be performed by sham coil that looks identical to DuoMag XT in the active group. Patients will undergo 15 daily sham stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds.
47933230|NCT04924803|BEHAVIORAL|No video|Weekly text messages
48622747|NCT04766333|BEHAVIORAL|Community Organization Led Outreach|This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
48622748|NCT05162092|OTHER|Conventional physiotherapy|Participants will be given Conventional Physiotherapy. It included Passive Soft tissue elongation of tight muscles, Lower limb resistance exercises, Movement transitions, balance board and foam board standing, walking and stair climbing.
48622749|NCT05162092|OTHER|Vestibular stimulation with conventional physiotherapy|Participants in group B will be given conventional physiotherapy and vestibular stimulation exercises. It included conventional is same as given to the conventional and Vestibular Stimulation
47933231|NCT04924803|BEHAVIORAL|Video Text|Weekly text messages including links to intervention videos
47933232|NCT02362568|PROCEDURE|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
47933233|NCT05024344|PROCEDURE|Erector Spinae Plane Block|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
47933234|NCT05024344|DRUG|Ropivacaine 0.5% Injectable Solution|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
47933235|NCT05024344|DRUG|Dexamethasone|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
48455431|NCT05435638|DRUG|KM-001 1% cream 16 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
48455432|NCT02007863|PROCEDURE|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
48455433|NCT02007863|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
48622750|NCT01015196|DRUG|Zavedos|
48622751|NCT01015196|DRUG|Cerubidine|
47933236|NCT03016676|OTHER|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
48455434|NCT02007863|DRUG|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
48455435|NCT02007863|DRUG|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
48455436|NCT00002562|DRUG|paclitaxel|
48455437|NCT00845637|DRUG|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
48455438|NCT00845637|DRUG|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
47933237|NCT03016676|OTHER|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
47933238|NCT04817852|OTHER|CBCT data of c-shaped canal in mandibular second molar.|Detection of variation in root canal morphology in mandibular second molar by using CBCT.
47933239|NCT00631761|OTHER|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
48455439|NCT01096329|DRUG|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
48455440|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
48455441|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
48455442|NCT02271035|DRUG|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
48455443|NCT02271035|DRUG|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
48455444|NCT00452738|BEHAVIORAL|Therapy dog|
48455445|NCT00452738|BEHAVIORAL|Costumed character|
48455446|NCT00452738|BEHAVIORAL|Parents-only|
48455447|NCT03389113|DEVICE|Whole body vibration|Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
48455448|NCT03389113|OTHER|Exersice|Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
48455449|NCT06623357|OTHER|Pilot Training Protocol|The pilot training protocol uses principles based on evidence-based research on factors that support caregiver learning of and adherence to home-therapy techniques/recommendations.
48455450|NCT06623357|OTHER|Standard Training Protocol|The standard training protocol uses the caregiver training methods that are currently used in our clinics.
48455451|NCT05744492|OTHER|Vivifrail multicomponent exercise program|"Resistance: 3 sets of 2 repetitions of 3-4 exercises with a 1 to 3-minute break between sets. Intensity from 30-repetition maximum (RM) at weeks 1-6 to 20-RM at weeks 7-12.~Balance training: both static and dynamic. Subjects will increase the number of repetitions, the difficulty of the exercises or will add external perturbations to the tasks (unstable surfaces, obstacles, or visual deprivation) along the duration of the interventions to guaranteeing progression. In the case of high risk of falling the number, frequency and volume of balance exercises will be increased.~Flexibility: a set of stretching exercises at the end of each session. Subjects will be instructed to stretch until they feel tension in their muscles without reaching discomfort. Stretching will be maintained for 10 sec. and repeated 2-3 times.~Cardiovascular: walking-based activities oriented to increase cardiorespiratory fitness. They will range from 5-10 sec. to 45 min/session."
48455452|NCT06628232|OTHER|pacifier with breast milk|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk
48455453|NCT06628232|OTHER|heel heating|swaddling in the mother\&#39;s lap together with local dry heat application
48455454|NCT06628232|OTHER|interventions combined|swaddling in the mother\&#39;s lap together with giving a pacifier dipped in breast milk and heel heating
48455455|NCT06628232|OTHER|Control|swaddling the baby in the mother\&#39;s lap
48455456|NCT00004398|DRUG|heme arginate|
48455457|NCT00004398|DRUG|tin mesoporphyrin|
48622752|NCT04144764|OTHER|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
48455458|NCT02992964|DRUG|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
48455459|NCT01895764|DRUG|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
48455460|NCT01895764|DRUG|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
48455461|NCT04468880|OTHER|Group (A1 → A2)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
48455462|NCT04468880|OTHER|Group (A2 → A1)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
47933240|NCT00631761|OTHER|no intervention (usual resident activities)|usual activities
48455463|NCT04777305|OTHER|Physical activity training|Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
48455464|NCT03034096|DRUG|Propofol|Maintenance of general anesthesia with propofol infusion
48455465|NCT03034096|DRUG|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
48106843|NCT05172154|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test Kit|The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
48106844|NCT05670951|DRUG|ELGN-2112|Human insulin \[rDNA\]
48455468|NCT03574805|DRUG|PRS-060|Study drug
48455469|NCT03574805|DRUG|Placebo|Inhalant designed to mimic PRS-060
48455470|NCT01554410|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
48455471|NCT01554410|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
48455472|NCT01554410|DRUG|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
47933241|NCT01489111|DRUG|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
48455473|NCT04745234|DRUG|Mogamulizumab|"For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle."
48455474|NCT02105220|OTHER|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
48455475|NCT00096655|DRUG|Infliximab|
48622753|NCT04144764|OTHER|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
48622754|NCT02189447|PROCEDURE|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
47933242|NCT01744145|OTHER|Interventional 40-60|This group will receive the intervention aged 40-60
47933243|NCT01744145|OTHER|Interventional 60 and above|This group will receive the intervention aged 60 and above.
47933244|NCT01251627|DRUG|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
48455476|NCT00245882|BEHAVIORAL|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
47933245|NCT04431089|DRUG|SHC014748M|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
47933246|NCT05549427|OTHER|Ventilation|Ventilation in ICU
47933247|NCT04691947|BIOLOGICAL|ERUCOV-VAC|Vaccination on Day 0 and Day 21
47933248|NCT04691947|OTHER|Placebo Vaccine|Placebo Vaccination on Day 0 and Day 21
47933249|NCT01426789|DRUG|Placebo|Matching placebo to secukinumab I.V.
47933250|NCT01426789|DRUG|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
47933251|NCT03638843|PROCEDURE|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
47933252|NCT03794960|BIOLOGICAL|TOL-3021|A plasmid expression vector containing the coding sequences for full-length human proinsulin.
47933253|NCT03794960|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
47933254|NCT03277820|DIETARY_SUPPLEMENT|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
47933255|NCT05191264|OTHER|EQ5D (EuroQol 5 Dimensions)|The evaluation of the quality of life was conducted with the EQ5D (EuroQol 5 Dimensions) score (min 0: bad health and max:100 good health).
48455477|NCT00245882|BEHAVIORAL|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
48622755|NCT02359708|PROCEDURE|Surgical hand disinfection.|Bacterial recolonization
48455478|NCT05659576|DRUG|Sucralfate|"1. Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.May increase frequency up to 4 times per day, per physician discretion. Or~2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion."
48455479|NCT05659576|OTHER|Usual Care|Standard supportive care by using opioids.
48455480|NCT05659576|OTHER|One consent|Patient will sign one consent form.
48455481|NCT05659576|OTHER|Two consent|Patient will sign two consent forms.
48455482|NCT03007524|DRUG|High dose Rosuvastatin|20mg/d qN, at least 6 months
48455483|NCT03007524|DRUG|Low dose Rosuvastatin|10mg/d qN, at least 6 months
48455484|NCT06449703|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
48455485|NCT06449703|DRUG|Xultophy®|Xultophy®
48455486|NCT04492930|BEHAVIORAL|14:10 Regimen|14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
48455487|NCT04492930|BEHAVIORAL|12:12 Regimen|12 hours of fasting, followed by a 12-h diet regimen
48455488|NCT03915600|OTHER|Quinoa|Personalized diet added with quinoa
48455489|NCT03915600|OTHER|Flaxseed|personalized diet added with flaxseed
48455490|NCT03915600|OTHER|Quinoa and Flaxseed|personalized diet added with quinoa and flaxseed
48455491|NCT06563193|DIAGNOSTIC_TEST|NERVE GROWTH FACTOR|urinary neurotrophins
47933256|NCT05191264|OTHER|Numerical Rating Scale (NRS)|the type and intensity of pain will be evaluated by Numerical Rating Scale (NRS) from 0 to 10 in different positions and in different activities (e.g. background pain, general maximum/minimum pain, pain of the site treated by the procedure, pain at rest, in lying position, in sitting position, in standing position, at bearing weight, in walking, description of painful irradiations, nocturnal awakenings).
47933257|NCT05191264|OTHER|evaluated the consumption of analgesics|the consumption of analgesics by step and by dosage will be evaluated.
48455492|NCT06624735|DIAGNOSTIC_TEST|psychometry|ADHD test and measurement of IQ level
48455493|NCT02412358|DEVICE|toothbrush|
47933258|NCT03021564|OTHER|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
47933259|NCT00119873|BIOLOGICAL|VRC-HIVADV014-00-VP|
48455494|NCT01539096|PROCEDURE|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
48455495|NCT01539096|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
48455496|NCT01539096|PROCEDURE|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
47933260|NCT05185011|DRUG|TPN171H|10 mg TPN171H tablets，single dose
47933261|NCT04490330|OTHER|questionnaire|AUDIT questionnaire (alcohol use disorders identification test)
48106845|NCT05670951|DRUG|Placebo|Placebo
48455497|NCT01851772|DEVICE|Treatment with Electronic Brachytherapy|
48455498|NCT02942823|OTHER|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
48455499|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
48455500|NCT03499873|DRUG|Placebos|Placebo
48455501|NCT03499873|DRUG|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
47933262|NCT05260281|DEVICE|MONA algorithm|most artificial intelligence algorithms, like the MONA algorithm used in this study, are trained on 45-degree fundus photographs. In order to incorporate the use of the algorithm, the study intervention consists of taking 1 extra 45-degree fundus photograph per eye per patient using the Zeiss Cirrus Photo 800 system.
48106846|NCT04694248|DRUG|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
48455502|NCT02355730|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
48455503|NCT00996697|DRUG|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
48455504|NCT00996697|DRUG|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
48455505|NCT01714622|PROCEDURE|subtotal gastrectomy with gastroduodenostomy|
48455506|NCT01714622|PROCEDURE|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
48455507|NCT01714622|PROCEDURE|total gastrectomy with Rou-en-Y esophagojejunostomy|
48455508|NCT04169815|DIAGNOSTIC_TEST|Access Immunodiagnostic Products|Access Natriuretic Peptide Assay
48455509|NCT03540758|DRUG|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
47933263|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
47933264|NCT02538861|DIAGNOSTIC_TEST|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
47933265|NCT02538861|DIAGNOSTIC_TEST|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
48455510|NCT03540758|DRUG|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
48455511|NCT03540758|DRUG|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
48455512|NCT04418297|DRUG|CT-G20|oral tablet
48455513|NCT04418297|DRUG|Placebo|oral tablet
48455514|NCT05603351|DIAGNOSTIC_TEST|magnetic resonance|biparametric MRI with protocol including anatomical T2 sequence and diffusion-weighted images (DWI), according to the standards
48455515|NCT05603351|DIAGNOSTIC_TEST|serum PSA examination|testing of prostate-specific antigen (PSA) in serum
48455516|NCT05603351|PROCEDURE|Biopsy|"Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35."
48455517|NCT06173050|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
48622756|NCT05272917|OTHER|Sensorial tests|Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
48622757|NCT05272917|BEHAVIORAL|food preferences questionnaires|Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
48622758|NCT05095337|DRUG|[14C]SHR1459|Patients will receive single dose of orally \[14C\]SHR1459 on Day 1.
48622759|NCT03941483|DRUG|ASP1128|Intravenous Infusion
47933266|NCT05275660|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
47933267|NCT05275660|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
47933268|NCT05045066|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
47933269|NCT05045066|OTHER|Quality-of-Life Assessment|Ancillary studies
47933270|NCT05045066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48455518|NCT06173050|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
48455519|NCT04123587|DRUG|discontinuation of Sulfonylureas|"1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
48455520|NCT01538459|DRUG|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
48455521|NCT01538459|DRUG|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
48455522|NCT01576458|DRUG|ursodeoxycholic acid|450 mg/day for 14 days
48455523|NCT01576458|DRUG|Placebo|placebo
48455524|NCT05502380|DRUG|Standard antibiotic prophylaxis|One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
48455525|NCT02627963|DRUG|Tivozanib hydrochloride|Tivozanib hydrochloride
48455526|NCT02627963|DRUG|Sorafenib|Sorafenib
48455527|NCT03095248|DRUG|Selumetinib|Continuous twice daily dosing; oral agent
48455528|NCT02588781|DRUG|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
48455529|NCT04511845|DRUG|SPYK04|SPYK04 capsule
48455530|NCT00099151|BEHAVIORAL|Caloric Restriction (CR)|
48455531|NCT00099151|BEHAVIORAL|Exercise|
48622760|NCT03941483|DRUG|Placebo|Intravenous Infusion
48622761|NCT05887492|DRUG|TNG260|CoREST inhibitor, administered orally
48622762|NCT05887492|DRUG|Pembrolizumab|Pembrolizumab, an anti-PD-1 antibody, administered intravenously
48622763|NCT02734147|DRUG|Ascorbic Acid|
48622764|NCT02734147|OTHER|Normal Saline|
47933271|NCT06135194|DRUG|T-DXd|Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib
47933272|NCT04983212|OTHER|periodontal control|patient were called and visited in the dentistry department and gingival sulcus were gentle probed to assess gingiva and peri-implant tissues status
47951339|NCT03511664|DRUG|177Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
47951340|NCT03511664|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
47933273|NCT01432509|OTHER|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~* Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and \< 1,26 g/l) or fasting blood glucose ≥ 1 g/l and \< 1,10 g/l with HbA1c ≥ 6,5%.~* First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~* Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~* End of study phone call"
47933274|NCT04144218|DRUG|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
47933275|NCT04144218|DRUG|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
47933276|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
47933277|NCT01047098|DIETARY_SUPPLEMENT|Iron|Iron as iron sulfate
47933278|NCT01047098|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
48455532|NCT03001596|PROCEDURE|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
48455533|NCT03001596|PROCEDURE|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
48455534|NCT03001596|PROCEDURE|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
47933279|NCT01035450|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
47933280|NCT01035450|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
47933281|NCT03269552|DRUG|Carfilzomib|Given IV
47933282|NCT03269552|OTHER|Laboratory Biomarker Analysis|Correlative studies
47933283|NCT03269552|BIOLOGICAL|Rituximab|Given IV
47933284|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
47933285|NCT00622739|DRUG|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
47933286|NCT02648828|OTHER|Clinical deterioration|Patients at risk of clinical deterioration
47933287|NCT05025748|BEHAVIORAL|Behavioral Intervention|Complete questionnaires
47933288|NCT04231591|DIAGNOSTIC_TEST|NT-proBNP|Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
47933289|NCT06299423|DEVICE|Howdy Senior® device|Standard perioperative management plus three preoperative and twelve postoperative (until 90 days after surgery) HOWDY Senior® device assessments.
47933290|NCT03170232|DRUG|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
48455535|NCT03563833|OTHER|Minimal Flow Anesthesia|Minimal Flow Anesthesia with 0,4 L min-1
48455536|NCT03563833|OTHER|High Flow Anesthesia|High Flow Anesthesia with 2 L min-1
48455537|NCT05591729|OTHER|Pilates exercises|Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.
48622765|NCT00990288|DRUG|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
47933291|NCT03170232|DRUG|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
48106847|NCT04694248|DRUG|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
48622766|NCT03757923|DRUG|TAB METFORMIN|INSULIN SENSITIZING AGENTS
48622767|NCT03757923|DRUG|TAB PIOGLITAZONE|INSULIN SENSITIZING AGENT
47933292|NCT03170232|DEVICE|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
48622768|NCT05690243|BEHAVIORAL|Group psychotherapy delivered via video telehealth|Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
47933293|NCT03170232|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
47951341|NCT01238185|DRUG|acetylsalicylic acid|
47951342|NCT01238185|GENETIC|gene expression analysis|
47951343|NCT01238185|GENETIC|protein expression analysis|
48106848|NCT04289610|DEVICE|Transcutaneous pulse radiofrequency therapy|Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
47933294|NCT01449695|BEHAVIORAL|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
47933295|NCT01449695|BEHAVIORAL|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
47933296|NCT01449695|BEHAVIORAL|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
47933297|NCT03120455|BEHAVIORAL|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
47933298|NCT03120455|BEHAVIORAL|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
47933299|NCT03120455|BEHAVIORAL|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
47933300|NCT06278233|DEVICE|Transcranial direct current stimulation|TDCS involves applying a weak electrical current across the head through electrodes placed on the scalp and modulating the resting membrane potential of neurons in the underlying cortex.
48455538|NCT05591729|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
47933301|NCT01171833|DRUG|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
47933302|NCT01171833|DRUG|Desflurane|6.0 vol% prefilled in a corrugated circuit.
48455539|NCT04532879|DEVICE|HygiPrep (HyGIeaCare System)|Controlled gravity-based high-volume colon irrigation
48455540|NCT03595254|BEHAVIORAL|Thrive|Computerized Cognitive Behavior Therapy program
48455541|NCT00583999|OTHER|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
48455542|NCT00728754|DEVICE|Dental implant Osseotite Prevail|Root form titanium dental implant
48455543|NCT00728754|DEVICE|Dental implant Osseotite|root form titanium dental implant
47933303|NCT01171833|DRUG|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
47933304|NCT03447197|PROCEDURE|The use of extracorporeal circulation|The use or not of extracorporeal circulation during the coronary artery bypass procedure.
47933305|NCT02270437|DRUG|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
48455544|NCT02719665|DIETARY_SUPPLEMENT|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
48455545|NCT02719665|DIETARY_SUPPLEMENT|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
48455546|NCT02719665|DIETARY_SUPPLEMENT|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
48455547|NCT06033417|OTHER|Increased lifestyle walking (intervention)|Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
48622769|NCT02612675|OTHER|ONS|
48622770|NCT00765076|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
48622771|NCT00765076|BIOLOGICAL|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
47933306|NCT05982951|PROCEDURE|Shoulder PENG block|Ultrasound guided insertion of a needle between subscapularis tendon and deltoid with injection of 10 mi 0.25% bupivacaine after confirming right plane of injection
47933307|NCT01362595|DRUG|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
47933308|NCT05010642|DEVICE|Use of Eko DUO electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
47933309|NCT05682573|DIAGNOSTIC_TEST|hospitalized patient|Collect the patient's whole blood for testing
48622772|NCT01980888|DRUG|Idelalisib|150 mg tablet administered orally twice daily
48622773|NCT01980888|DRUG|Bendamustine|Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
47933310|NCT03490981|OTHER|Treatment as usual (TAU)|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
47951344|NCT01238185|OTHER|laboratory biomarker analysis|
47951345|NCT01238185|OTHER|questionnaire administration|
47951346|NCT01238185|PROCEDURE|biopsy|
47951347|NCT06310200|DRUG|Lidocaine Topical 4% Topical Solution|Intranasal administration
48455548|NCT06033417|OTHER|Health education only (control)|Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
47933311|NCT03490981|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
47933312|NCT04142879|DEVICE|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
47933313|NCT02153710|BEHAVIORAL|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
47933314|NCT02153710|BEHAVIORAL|Phonomotor Therapy|Experimental therapy.
47933315|NCT04211233|DEVICE|invasive subdural grid electrode|A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.
47933316|NCT04211233|OTHER|Control arm|Standard Treatment based on Brain Trauma Foundation
48280370|NCT06656780|BEHAVIORAL|SIT|"Participants will undergo 2 day (8 hours each) Stress Inoculation Training . This will be done in 3 steps:~Step 1: focus on education about the human body and brain and shift to hands on skills practice to improve performance in stressful conditions and is designed to improve self-and-situational awareness and the ability to manipulate reactions and responses in the body on purpose to enhance performance~Step 2: focuses on improving mental self-awareness and gaining skills in Mental Agility and Mental Flexibility~Step 3: participants will have specific simulations and real-world opportunities to practice the skills learnt."
48455549|NCT05777005|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
48455550|NCT05777005|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
48455551|NCT05777005|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
48455552|NCT05777005|BEHAVIORAL|Counselor-led individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
48455553|NCT05777005|BEHAVIORAL|Chatbot-led group support|Participants will receive three months of chatbot-led group support via WeChat.
48455554|NCT03850457|OTHER|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
48622774|NCT01980888|DRUG|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
47933317|NCT03272984|PROCEDURE|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
47951348|NCT06310200|DRUG|Bitrex|Bittering agent
48455555|NCT02113722|PROCEDURE|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
48455556|NCT02113722|PROCEDURE|Standard of Care|Medical therapy
48455557|NCT00000653|DRUG|Zalcitabine|
48455558|NCT02284035|DRUG|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
48622775|NCT01980888|DRUG|Placebo|Placebo to match idelalisib administered orally twice daily
47951349|NCT06310200|DRUG|normal saline|Placebo
48280371|NCT06656780|BEHAVIORAL|DCA-FF|Participants will undergo 8-week Standard Firefighting Training
48280372|NCT02272790|DRUG|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
48455559|NCT02284035|DRUG|EFV/TDF/FTC|standard combination therapy
48455560|NCT02284035|DRUG|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
48622776|NCT03513731|DEVICE|Adipose-derived stem cell injection|ADRC injection into the facet joint
48622777|NCT03513731|DRUG|Corticosteroid injection|Corticosteroid injection into the facet joint
48622778|NCT01002105|DRUG|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
48622779|NCT01002105|OTHER|Control group|psychosocial intervention and placebo for 12 weeks
48622780|NCT01013753|DRUG|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
48622781|NCT01013753|DRUG|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48622782|NCT01013753|DRUG|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48455561|NCT02284035|DRUG|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
48455562|NCT02284035|DRUG|EFV plus ABC/3TC or RPV/TDF/FTC|
48455563|NCT02284035|DRUG|ATV/r plus ABC/3TC|
48455564|NCT02284035|DRUG|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
48455565|NCT02284035|DRUG|RAL plus ABC/3TC|
48455566|NCT02284035|DRUG|Other ART regimens|
48455567|NCT04218435|DRUG|Sacubitril / Valsartan Oral Tablet|"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."
48455568|NCT04322513|DIAGNOSTIC_TEST|Biomarkers expression|Evaluation in biomarkers expression between 2 groups
48455569|NCT03671954|BEHAVIORAL|Home Strengthening Exercises|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
48455570|NCT03671954|OTHER|Standard Physical Therapy|Physician determined standard of care for individual TKA patients.
48622783|NCT01013753|DRUG|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48622784|NCT01013753|DRUG|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
47933318|NCT03272984|PROCEDURE|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
47933319|NCT01702181|DRUG|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
47933320|NCT01702181|DRUG|Tacrolimus|0.1% concentration of tacrolimus.
47933321|NCT01702181|DRUG|Placebo|
47933322|NCT05542277|DEVICE|ClearPlasma|ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
47933323|NCT00266565|DRUG|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
48106849|NCT06134466|DIETARY_SUPPLEMENT|Liquid Extensively hydrolyzed cow's milk protein infant formula|Liquid Investigational Formula (Extensively hydrolyzed cow's milk protein infant formula) 2.8 g protein/100 kcal
48455571|NCT03671954|OTHER|Preoperative Assessments|"Assessments will include:~* TUG (timed up and go test) \>12 sec indicates increased fall risk~* Tandem balance test \< 10 sec indicates increased fall risk~* Sit to Stand test (age based norms)~* Knee Range Of Motion (ROM)~* Quadriceps and hamstring strength (MMT or hand held dynamometer)~* Lower Extremity Functional Score (LEFS questionnaire)"
48455572|NCT01146223|OTHER|laboratory biomarker analysis|Correlative studies
48455573|NCT06627023|DEVICE|Implant Placement with Conical or Butt-Joint Connection|Thirty eight patients were enrolled in the study and received randomly allocated implants with conical and butt-joint implant-abutment connection type. A standard healing abutment was placed after 6 months for two weeks. The definitive screw retained crowns were manufactured in a digital workflow. The soft tissue profile was digitized using IOS on following stages: pre-op, post-op: immediately, two, 7 and 14 days, pre-exposure, immediately after exposure, two weeks after exposure (pre-delivery), immediately after crown delivery, 6 and 12 months post-op.
48455574|NCT05291234|DRUG|ABBV-916|Intravenous administration
48455575|NCT05291234|DRUG|Placebo|Intravenous administration
48455576|NCT00754455|BIOLOGICAL|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
48455577|NCT00754455|BIOLOGICAL|Placebo|Placebo as a single injection of 0.5 mL.
48455578|NCT01717950|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
48455579|NCT01717950|BIOLOGICAL|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
48455580|NCT03603990|PROCEDURE|Vitrectomy|"During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
47933324|NCT02630199|DRUG|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
47933325|NCT02630199|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
47933326|NCT02153476|DRUG|2.0mg of ALG-1001|
47933327|NCT02153476|DRUG|Balanced Salt Solution|
47951350|NCT00469651|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
47951351|NCT00469651|BIOLOGICAL|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
47951352|NCT00469651|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
47951353|NCT00469651|BIOLOGICAL|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
48106850|NCT06425068|DEVICE|Exposure of the patient to a novel air mattress.|"see information provided in the Arms section (experimental)"
48106851|NCT06425068|DEVICE|Exposure of the patient to a conventional foam mattress.|"see information provided in the Arms section (active comparator)"
48280373|NCT02272790|DRUG|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
48455581|NCT03603990|PROCEDURE|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
47933328|NCT06409455|BEHAVIORAL|Positive Dementia Caregiving in 30 Days|Based on an evidence-based face-to-face Benefit-Finding Intervention, a computer-delivered web-based program supporting 24/7 access without location restriction, is developed. It is a psychoeducation program with an emphasis on strengthening caregivers' coping capacity through skills training and developing a positive way of looking at caregiving challenges. The program consists of reading materials, illustrated texts, caregivers' testimonies, a chatbot, and several interactive apps to facilitate self-learning at the caregiver's own pace.
47933329|NCT02306733|DRUG|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
47933330|NCT02306733|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
47933331|NCT03280043|PROCEDURE|Hematoma|Hematoma requiring return to operating room.
47933332|NCT04080271|DEVICE|18F-FDG PET/CT|18F-fludeoxyglucose positron emission tomography/computed tomography
47933333|NCT01692873|PROCEDURE|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
47933334|NCT00812695|DEVICE|CPAP|Gold standard treatment for Obstructive sleep apnea
47933335|NCT00098982|DRUG|bortezomib|
47933336|NCT00098982|DRUG|fluorouracil|
47933337|NCT00098982|DRUG|leucovorin calcium|
48455582|NCT02970123|BEHAVIORAL|Sit Less, Interact, Move More (SLIMM)|
48455583|NCT02571686|DEVICE|Surveyor S4|
48455584|NCT02033902|DRUG|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
48455585|NCT02488239|DEVICE|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
48455586|NCT03220958|DRUG|Metoclopramide|Metoclopramide 20mg
48455587|NCT03220958|DRUG|Diphenhydramine|Diphenhydramine 25mg
47933338|NCT00098982|DRUG|oxaliplatin|
47933339|NCT00476047|COMBINATION_PRODUCT|Tositumomab and Iodine I 131 Tositumomab|Give IV
47933340|NCT02113839|PROCEDURE|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
47933341|NCT02113839|PROCEDURE|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
47933342|NCT02113839|PROCEDURE|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
47933343|NCT02113839|PROCEDURE|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
48455588|NCT03220958|DRUG|Normal saline|100ml normal saline
48455589|NCT06432985|BEHAVIORAL|Focus Group|In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.
48455590|NCT06432985|BEHAVIORAL|Contingency Management|Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM.
48455591|NCT06432985|BEHAVIORAL|Behavioral Counseling (Cognitive Behavioral Therapy, CBT)|Participants will receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.
48455592|NCT06432985|BEHAVIORAL|TUD Treatment as Usual (TAU)|Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.
48455593|NCT01205035|DRUG|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
48455594|NCT01758601|OTHER|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
48455595|NCT01758601|OTHER|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
47933344|NCT04524338|DEVICE|Transcranial Direct Current Stimulation|Brain Stimulation Devices attached to scalp
47933345|NCT01662414|DIETARY_SUPPLEMENT|Whey protein|1 sachect (10 g) 2times/ day
47933346|NCT01662414|DIETARY_SUPPLEMENT|Soy protein|1 sachect (10g) 2times/day
47933347|NCT04875247|DEVICE|IOLMaster 700 with central topography|The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.
47933348|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Cassini|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.
47933349|NCT04875247|DEVICE|IOLMaster 700 without central topography plus Pentacam|The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
47933350|NCT03277079|DRUG|statin + ezetimibe|Combination of two drugs
47933351|NCT03277079|DRUG|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
48455596|NCT04293653|OTHER|Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy|See above section
47933352|NCT04809077|OTHER|Reverse total shoulder replacement|Long-term radiographic and clinical data of patients who underwent a reverse shoulder replacement
47933353|NCT04249609|OTHER|HCHO meals and exercise|Exercise will be conducted after high carbohydrate dinner and prior to high carbohydrate breakfast
47933354|NCT04249609|OTHER|LCHO meals and exercise|Exercise will be conducted after high fat dinner and prior to high fat breakfast
48455597|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
48455598|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
47933355|NCT06517797|DRUG|S1B-509|S1B-509 has multiple neurotransmitter activities
47933356|NCT00815724|BEHAVIORAL|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
47933357|NCT03342300|DRUG|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
47933358|NCT03342300|DRUG|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
47933359|NCT02019901|OTHER|Nurse-led clinic|
47933360|NCT00216164|DRUG|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
47933361|NCT00216164|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
47933362|NCT01733927|DEVICE|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
47933363|NCT00459979|DRUG|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
47933364|NCT00459979|PROCEDURE|conventional surgery|nephrectomy
47933365|NCT01072565|OTHER|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
47933366|NCT01072565|OTHER|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
47933367|NCT00005031|DRUG|irofulven|
47933368|NCT00993044|DRUG|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
47933369|NCT00993044|DRUG|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
47933370|NCT00993044|DRUG|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
47933371|NCT00993044|DRUG|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5\* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~\* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
48455599|NCT02353936|DRUG|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
48455600|NCT02651987|DRUG|Lanreotide autogel 120 mg|
47933372|NCT06174740|BEHAVIORAL|Music-cued audiovisual motor training|In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).
47933373|NCT06174740|BEHAVIORAL|Visually-cued motor training|Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
48455601|NCT00382083|DRUG|1000 mg acetaminophen|
47933374|NCT01613196|OTHER|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion\*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~\*except if already done in the last 15 days."
47933375|NCT04048785|OTHER|Behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
47933376|NCT05543434|DRUG|Hyaluronic acid|anti-inflammatory, anti-edematous, osseoinductive.
47933377|NCT02732743|DIETARY_SUPPLEMENT|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
47933378|NCT00366340|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
47933379|NCT00366340|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
47933380|NCT00158821|DRUG|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
47933381|NCT00158821|DRUG|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
47933382|NCT00158821|DRUG|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
47933383|NCT00158821|DRUG|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
47933384|NCT02252276|PROCEDURE|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
47933385|NCT02252276|PROCEDURE|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
48455602|NCT00382083|DRUG|800 mg ibuprofen|
47933386|NCT01887743|DRUG|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
47933387|NCT01011478|DRUG|rosuvastatin|
47933388|NCT01011478|OTHER|placebo|
47933389|NCT02853630|DRUG|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
48455603|NCT00382083|DRUG|1 oz 4% lidocaine gel|
47933390|NCT02853630|DRUG|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
47933391|NCT00696475|DRUG|Diazoxide choline|
47933392|NCT00696475|DRUG|Diazoxide choline|
48455604|NCT04200872|OTHER|biological adjuvants|patients with aseptic pseudarthrosis clinically treated with biological adjuvants
48455605|NCT04200872|OTHER|no biological adjuvants|patients with aseptic pseudarthrosis clinically treated without biological adjuvants
47933393|NCT00696475|DRUG|Diazoxide choline|
47933394|NCT00696475|DRUG|Placebo|
47933395|NCT01440790|DIETARY_SUPPLEMENT|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
47933396|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
47933397|NCT01440790|DIETARY_SUPPLEMENT|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
47933398|NCT01440790|DIETARY_SUPPLEMENT|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
47933399|NCT02165176|DRUG|Oral cannabis|
47933400|NCT04584697|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
47933401|NCT04584697|DRUG|Placebo|Diluent solution
47933402|NCT00669760|OTHER|non-interventional study|does not apply
47933403|NCT00924625|OTHER|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
47951354|NCT00469651|BIOLOGICAL|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
48455606|NCT04026048|BEHAVIORAL|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
48455607|NCT04212845|DRUG|Bupivacaine;Dexamethasone Solution for Injection|8 mg Dexamethasone and %0.25 bupivacaine
48455608|NCT04212845|DEVICE|Fluoroscopy|Fluoroscopy-guided transforaminal injection
48455609|NCT04212845|DEVICE|Ultrasound|Ultrasound-guided erector spinae plane block
48622785|NCT01013753|DRUG|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
48622786|NCT03506126|OTHER|Leucine|There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
48622787|NCT04490707|DRUG|Azacitidine|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
47933404|NCT00924625|OTHER|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
47933405|NCT01251146|DRUG|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
47933406|NCT01251146|DRUG|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
47933407|NCT05018936|DRUG|Hetrombopag|Hetrombopag starting at 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
47933408|NCT00755911|BIOLOGICAL|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
47933409|NCT00755911|DEVICE|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
47933410|NCT04969003|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
48622788|NCT04490707|DRUG|Lenalidomide|Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
47933411|NCT01244360|DIETARY_SUPPLEMENT|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
47933412|NCT01244360|OTHER|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
47933413|NCT02097927|BEHAVIORAL|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
47933414|NCT02068768|DEVICE|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
48622789|NCT05123924|OTHER|Evaluation of respiratory capacity, respiratory muscle strength and fatigue|"The demographic information of the participants will be taken with the form prepared for the people in this group. Then, respiratory function with Minispir Light Spirometer, respiratory muscle strength with MD Diagnostics RP Check and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale will be evaluated. All assessments will be completed on the same day and will not be repeated after a certain period of time."
47933415|NCT05648071|DRUG|Sintilimab|The specific treatment regimen is as follows :Non-squamous NSCLC: Sintilimab (200 mg) plus Bevacizumab (7.5mg/kg) is started on the first day of each treatment cycle and administered every three weeks. Nedaplatin (80-100 mg/m2) (d2) +pemetrexed 500 mg/m2 (d2) Q3W is administered in this regimen for 4 cycles followed by sintilimab plus Bevacizumab until disease progression or intolerable toxicity.
47933416|NCT05297435|DIAGNOSTIC_TEST|Questionnaires|Questionnaire study
47933417|NCT01505504|DRUG|mirtazapine|30 mg at bedtime
48622790|NCT05347355|OTHER|Spencer technique along with conventional treatment|"Subjects in this group will receive conventional exercises and 7 stages of Spencer technique: (A) extension, (B) flexion, (C) circumduction with compression, (D) circumduction with traction, (E) abduction, (F) internal rotation, (G) lymphatic pump.~Spencer technique will be used to increase range of motion of the glenohumeral joint. The patient will be positioned lying on the side with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand will provide force into the restrictive barrier of shoulder in 7 different movements. These will be shoulder extension, circumduction with distraction, abduction, adduction with internal rotation and glenohumeral pump. During all the movements, patient will be asked to use muscle energy against the slight resistance offered by the therapist for 3-5 seconds. The exercise will be repeated 3-5 times with rest intervals over 3 sessions per week on alternate days for 4 weeks."
47951355|NCT00749060|OTHER|conventional treatment|with our without brace
48455610|NCT04044573|PROCEDURE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
48455611|NCT00307996|DRUG|Coenzyme Q10 (drug)|
48455612|NCT00503867|DEVICE|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
48455613|NCT00902538|DRUG|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
48455614|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
48455615|NCT00902538|DRUG|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
48455616|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
48455617|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
48455618|NCT00902538|DRUG|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
48455619|NCT02280707|OTHER|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
48455620|NCT04871308|DRUG|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
48455621|NCT04871308|DRUG|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
48455622|NCT05802563|DEVICE|fitness tracker|Study subjects will wear a Fitbit fitness tracker
48455623|NCT02351700|DRUG|IV Caldolor|IV Caldolor (IV ibuprofen) intraoperatively and postoperatively
48455624|NCT02351700|DRUG|IV Placebo|IV Placebo intraoperatively and postoperatively
48455625|NCT00042835|DRUG|cisplatin|Given IV
48455626|NCT00042835|DRUG|etoposide|Given IV
48455627|NCT00042835|DRUG|erlotinib hydrochloride|Given orally
48455628|NCT00042835|RADIATION|radiation therapy|Undergo radiotherapy
48622791|NCT05347355|OTHER|Gongs Mobilization along with conventional treatment|The Gong's mobilization can be done either in high sitting or in side-lying position with the affected shoulder upward. The subject's shoulder will be abducted at 90° so that the humerus will be maintained at vertical position. The elbow joint will be flexed and maintained at 90°; the therapist will maintain this position by placing his/her hand below the subject's elbow. The humeral head will be pressed from anterior to posterior direction with the other hand. The therapist will hold the vertical axis of the humerus by maintaining the shoulder in abduction and the elbow in 90°. The therapist will raise his own body by slightly pulling on the anterior capsule and this pull will be maintained for 10-15 seconds and then relax for five seconds and will be performed for about two to three minutes. At this moment the subject will be asked to perform shoulder abduction with no external rotation, while elbow flexion will be maintained throughout.
48455629|NCT00042835|DRUG|docetaxel|Given IV
48455630|NCT00042835|DRUG|paclitaxel|Given IV
48455631|NCT00042835|DRUG|carboplatin|Given IV
48622792|NCT06461884|OTHER|Percussions|Group A: Percussions and diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
48622793|NCT06461884|OTHER|, Diaphragmatic breathing exercise|Group B: Diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
48622794|NCT03077776|PROCEDURE|Biopsy|Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
48622795|NCT03077776|PROCEDURE|Biopsy (optional)|\[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
48280374|NCT02272790|DRUG|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
48455632|NCT00042835|OTHER|laboratory biomarker analysis|Correlative studies
48455633|NCT01011413|DRUG|Efavirenz 600mg|3 x EFV 200 milligram (mg) tablets once daily
48455634|NCT01011413|DRUG|Efavirenz 400mg|2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily
48455635|NCT03544216|DEVICE|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
48455636|NCT03544216|DEVICE|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
48455637|NCT06054984|DRUG|TCR-T Cells Injection（GB3010 Cells Injection）|The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced to express a T-cell Receptor that recognizes the RAS/TP53.Patients were sequentially enrolled into 3 dose escalation groups(dose level 1-3) :5×10\^8±20%,5×10\^9±20%,5×10\^10±20%.
47933418|NCT03945175|DRUG|MYDAYIS|MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
47933419|NCT03945175|DRUG|Placebo|During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
47933420|NCT05907343|DEVICE|Sham TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.
47933421|NCT05907343|DEVICE|Closed-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.
47933422|NCT05907343|DEVICE|Open-loop TBS|A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
47933423|NCT01070147|OTHER|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
47933424|NCT02902679|DRUG|BMS-986177|
47933425|NCT06298604|DEVICE|EUS-guided standard fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 19-gauge standard fine needle biopsy device (Boston Scientific, USA) is inserted on it to obtain the sample or specimen.
47933426|NCT06298604|DEVICE|EUS-guided motorized fine needle biopsy|Using the echoendoscope, a pancreatic lesion or liver parenchyma will be identified, and a 20-gauge motorized fine needle biopsy device (Limaca, Israel) is inserted on it to obtain the sample or specimen.
47933427|NCT02832583|DEVICE|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
47933428|NCT03034291|DIETARY_SUPPLEMENT|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
47933429|NCT03034291|DIETARY_SUPPLEMENT|White chocolate|
47933430|NCT02099071|DRUG|ACT-389949 1 mg|
47933431|NCT02099071|DRUG|ACT-389949 5 mg|
47933432|NCT02099071|DRUG|ACT-389949 20 mg|
47933433|NCT02099071|DRUG|ACT-389949 50 mg|
47933434|NCT02099071|DRUG|ACT-389949 100 mg|
47933435|NCT02099071|DRUG|ACT-389949 200 mg|
48280375|NCT02272790|DRUG|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
48280376|NCT02272790|DRUG|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
47933436|NCT02099071|DRUG|ACT-389949 500 mg|
47933437|NCT02099071|DRUG|ACT-389949 1000 mg|
48280377|NCT05381909|DRUG|BGB-24714|administered orally
48280378|NCT05381909|DRUG|Paclitaxel|administered intravenously
48280379|NCT05381909|DRUG|Carboplatin|administered intravenously
48280380|NCT05381909|DRUG|Docetaxel|administered intravenously
48280381|NCT03140826|DRUG|meropenem|Antibiotics to treat infections.
47933438|NCT02099071|DRUG|Placebo|
47933439|NCT02528266|DEVICE|Nerve Capping Device|
48280382|NCT06656728|OTHER|Blood-based liquid biopsy|Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center
48280383|NCT02631304|PROCEDURE|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
48280384|NCT06657664|PROCEDURE|cryotherapy with sterile saline at 2.5ºC|the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes before obturation
48280385|NCT06657664|PROCEDURE|intaoral cryotherapy|ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezed sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes
48455638|NCT04613167|DRUG|Alirocumab|The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
48455639|NCT04613167|DRUG|Evolocumab|The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
48455640|NCT04613167|DRUG|Control group|The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
48455641|NCT05210647|DEVICE|robotic surgery|by da Vinci Xi
47933440|NCT00968032|DEVICE|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
47933441|NCT01871103|PROCEDURE|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
47933442|NCT00084591|DRUG|capecitabine|
47933443|NCT00084591|PROCEDURE|conventional surgery|
47933444|NCT00084591|PROCEDURE|neoadjuvant therapy|
47933445|NCT00084591|RADIATION|radiation therapy|
47933446|NCT02060448|BEHAVIORAL|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
47933447|NCT02060448|BEHAVIORAL|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
47933448|NCT03098888|PROCEDURE|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
47933449|NCT01377285|DRUG|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
47933450|NCT01377285|DRUG|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
47933451|NCT01377285|DRUG|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
48280386|NCT06657664|PROCEDURE|Both intracanal and intraoral cryotherapy|Canal is irrigated with iced saline for 5 minutes before obturation . Root canal is obturated and coronal restoration is done. Then, application of intraoral cryotherapy is performed by ice sticks for 30 minutes.
48455642|NCT02524691|DEVICE|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
48455643|NCT06626919|BIOLOGICAL|anito-cel|Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
48280387|NCT06657664|DEVICE|Low Level Laser Therapy|laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively
48455644|NCT06626919|DRUG|Standard Lymphodepletion regimen|Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
47933452|NCT01611454|DEVICE|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
48455645|NCT02853019|OTHER|Electroencephalogram|electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
47933453|NCT01611454|DEVICE|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during the same type of comparator fluoroscopy guided interventions. Comparator arm uses same type of lead thyroid collar but the XPF under investigation.
47933454|NCT00719264|DRUG|RAD001(everolimus)|10 mg qd
47933455|NCT00719264|DRUG|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
48455646|NCT02853019|BEHAVIORAL|Cognitive tasks|- clinical scales and subjective assessments of emotional and motivational stimuli
48455647|NCT02853019|BEHAVIORAL|subjective evaluation scales|- clinical scales and subjective assessments of emotional and motivational stimuli
48455648|NCT03911206|BEHAVIORAL|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
48455649|NCT03911206|BEHAVIORAL|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
48455650|NCT03911206|BEHAVIORAL|IMT and Exercise|Combining IMT training and exercise
48455651|NCT00000159|DRUG|Sorbinil|
48455652|NCT05936996|DEVICE|MANTA Vascular Closure Device|The MANTA® Vascular Closure Device consists of a 14F or 18F MANTA® Closure Device, a 14F or 18F Sheath with Introducer, and an 8F Depth Locator. In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.
48455653|NCT05846282|BEHAVIORAL|STRIVE|The STRIVE intervention will include all activities and BREATHE skill training components of L2B with content framed within the needs of high achieving college-bound BIPOC students who can benefit from health promoting practices to offset the costs of resilience. The intervention will include twelve 60-minute group sessions, with two sessions on each of the six core themes. Each session will include an opening mindful movement, short didactic presentation of the topic or theme of that week, group activities that illustrate the theme, guided discussion about the activity, and in-session group mindfulness meditation practice.
48455654|NCT05846282|BEHAVIORAL|Study Skills|The sessions will focus on goal setting (4 sessions), organization and time management (3 sessions), and study skills for reading comprehension, writing papers, note-taking, and test-taking (4 sessions). Parallel to the final L2B session, the last meeting will include activities to share and reflect on how students plan to incorporate and sustain new skills.
48455655|NCT06120153|DIAGNOSTIC_TEST|POC PCR-test device|"The analysis will follow an intention-to-treat principle, that is, contacts in the intervention period will be analyzed as randomized, regardless of whether the POC PCR test was actually performed for a given contact. As sensitivity analysis, the data will be analyzed in a per-protocol spirit, defining the intervention at the contact level as a POC PCR test performed."
48455656|NCT02956681|BEHAVIORAL|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
47933456|NCT00719264|DRUG|bevacizumab|10 mg/kg every 2 weeks
47933457|NCT03464565|DEVICE|Penumbra System|Penumbra System
48622796|NCT03077776|PROCEDURE|Biopsy (metastatic)|Biopsy of metastatic site to be performed at the time of relapse
48622797|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract LD and white bread|109g of white bread with 0.5g of seaweed extract
48622798|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract HD and white bread|109g of white bread with 1g of seaweed extract
48622799|NCT05460884|DIETARY_SUPPLEMENT|White bread|109g of white bread
47933458|NCT03505827|DIAGNOSTIC_TEST|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
47933459|NCT02065271|DIETARY_SUPPLEMENT|herbal supplement|
47933460|NCT02065271|OTHER|placebo supplement|
47933461|NCT03522142|DRUG|INCB081776|INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
47933462|NCT03522142|DRUG|INCMGA00012|INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
47933463|NCT04230720|DRUG|Systane Complete|1 drop 4 times a day for 14 days
47933464|NCT03037723|OTHER|CT simulation|
47933465|NCT04028661|DEVICE|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
47933466|NCT00479921|BIOLOGICAL|Trivalent influenza subunit vaccine|
47933467|NCT02577783|DRUG|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
48622800|NCT04245761|DIETARY_SUPPLEMENT|Sonidor®|Sonidor® triple layer release tablets are developed with a specialized process to improve stability and bioavailability of the formulation based on hawthorn, lavender and hop extracts. The hawthorn, lavender and hop extracts used to product Sonidor® have an elevated content of vitexin (3%), monoterpens (4% as linalool) and flavonoids (4%), respectively.
48622801|NCT00544882|DRUG|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
48622802|NCT00544882|DRUG|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
48622803|NCT00544882|DRUG|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
48622804|NCT04302285|OTHER|PKU type meal and Exercise|"* Exercise was conducted prior to PKU type meal.~* PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat."
48622805|NCT04302285|OTHER|PKU type meal|PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
48622806|NCT06520059|COMBINATION_PRODUCT|Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration|"Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day.~Group 2 will only receive two intra-articular injections of PRP, separated by one week."
48622807|NCT03276143|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
48622808|NCT03276143|DRUG|Apixaban|2.5 mg apixaban administered as tablet orally twice daily
48622809|NCT03276143|DRUG|BAY1213790|Single dose of BAY1213790 administered as intravenous infusion
48622810|NCT03317496|DRUG|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
48622811|NCT03317496|DRUG|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
48622812|NCT03317496|DRUG|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
48622813|NCT03317496|DRUG|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
48622814|NCT05396391|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q2w
48622815|NCT00959452|BEHAVIORAL|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
48622816|NCT03942731|OTHER|Behavioral allergy testing protocol|skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
47933468|NCT02577783|DRUG|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
47933469|NCT05070546|BIOLOGICAL|Ad26.RSV.preF-based Vaccine|Participants will receive a single IM injection of an RSV vaccine.
47933470|NCT05070546|OTHER|Placebo|Participants will receive a single IM injection of matching placebo.
47933471|NCT00880165|DEVICE|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
48622817|NCT00532623|DRUG|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
48622818|NCT00532623|DRUG|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
48622819|NCT05707325|DRUG|engineered red blood cell|engineered red blood cell
48622820|NCT04415918|DRUG|Bezlotoxumab Injection|A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
48622821|NCT03188185|DRUG|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
48622822|NCT03188185|DRUG|ALKS 5461 Placebo|Placebo tablet, administered sublingually
48622823|NCT05527080|OTHER|physiotherapy|Some infants will receive physiotherapy as a part of their clinically indicated care.
48622824|NCT05527080|DEVICE|brace|Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
48622825|NCT04120324|OTHER|Eligible for Same Day Discharge|Preoperative Physiotherapy and Anesthesia Criteria met.
48622826|NCT04120324|PROCEDURE|Primary Single Joint Total Hip Arthroplasty|Total Hip Replacement Surgery
48622827|NCT04120324|OTHER|Discharge Same Day|Postoperative criteria for Same Day Discharge met.
48622828|NCT04530851|PROCEDURE|ERAS|"* Counseling~* H2- antagonist and metroclopramide for prevent aspiration~* Drink clear liquid until 2 hour before surgery~* First generation cephalosporin in 60 minute before surgery~* Clorhexidine for skin cleansing and Povidine for vaginal cleansing~* Regional anesthesia~* Keep warming~* Blunt expansion of uterine incision~* Do not peritoneal suture and subcuticular suture if less than 2 cm~* Local wound anesthesia.~* Paracetamol and NSAIDs for for pain control~* Early remove catheter and ambulation~* 5-HT3 antagonist for prevent nausea"
48622829|NCT02194075|DRUG|Fluvoxamine+Methylphenidate hydrochloride|
48622830|NCT02194075|DRUG|Fluvoxamine+sugar pill|
48622831|NCT01928849|DRUG|Valproic Acid|"Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital."
48622832|NCT01928849|OTHER|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
47933472|NCT02793128|DRUG|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
47933473|NCT03920072|DRUG|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
47933474|NCT01389362|DRUG|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
47933475|NCT01389362|DRUG|Placebo comparator|2 sachets to be taken daily
47933476|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
47933477|NCT00817687|DRUG|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
48098658|NCT00207649|BEHAVIORAL|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
48098659|NCT06630572|DRUG|Rifaximin|Patients randomized to receive Rifaximin for 14 days
48280388|NCT06657664|PROCEDURE|Control (Standard treatment)|, all occlusal contacts were reduced by 1 mm
48455657|NCT02956681|BEHAVIORAL|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
48455658|NCT03103360|DEVICE|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
48455659|NCT03103360|PROCEDURE|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
48455660|NCT04342936|DRUG|Camrelizumab|A humanized monoclonal immunoglobulin
48455661|NCT04342936|DRUG|Investigator's choice of Chemotherapy|"Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin."
48455662|NCT05325515|DRUG|Conventional alendronate|Conventional alendronate 70mg weekly
48455663|NCT05325515|DRUG|Effervescent and buffered alendronate|Effervescent and buffered alendronate 70mg weekly
47933478|NCT01795066|DEVICE|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
47933479|NCT00287170|DRUG|Delayed Release 6MP or Calcitriol vs. Purinethol|
47933480|NCT02414503|DRUG|8IU intranasal oxytocin|
47933481|NCT02414503|DRUG|24IU intranasal oxytocin|
47933482|NCT02414503|DRUG|Placebo|
47933483|NCT02414503|DEVICE|OptiNose Breath Powered Bi|
47933484|NCT05265377|DEVICE|Stelo|Use of Stelo exoskeleton in nine rehabilitation sessions
47933485|NCT06111547|DRUG|TAK-279|TAK-279 oral tablet.
47933486|NCT06111547|DRUG|Placebo|TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
47933487|NCT01966692|DRUG|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
48098660|NCT06630572|DRUG|Placebo|Patients randomized to receive Placebo for 14 days
48098661|NCT03822351|DRUG|Durvalumab + Oleclumab|Durvalumab + Oleclumab
48098662|NCT03822351|DRUG|Durvalumab|Durvalumab
48098663|NCT03822351|DRUG|Durvalumab + Monalizumab|Durvalumab + Monalizumab
48098664|NCT03180190|DRUG|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
48280389|NCT06346795|OTHER|High-filling flowable dental composite|Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
48280390|NCT01640847|DRUG|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
48455664|NCT05406518|OTHER|Psychosocial intervention|Psychosocial intervention based on the model of family therapy.
48455665|NCT06562920|DRUG|adebrelimab and chemotherapy|3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
48455666|NCT04949737|BIOLOGICAL|Helicobacter Pylori detection|"Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire."
48455667|NCT06627998|DIAGNOSTIC_TEST|Diagnostic (chest x-ray /DXA)and clinical data collected for clinical practice|Biochemical, clinical and radiological data performed for clinical practice will be retrospectively collected. Osteoporosis and vertebral fractures will be diagnosed through DXA scan and vertebral morphometry.
48622833|NCT03166176|DRUG|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
48622834|NCT03346343|DEVICE|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
47933488|NCT01966692|DRUG|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
47933489|NCT01966692|DRUG|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
47933490|NCT01966692|DRUG|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation."
47933491|NCT05952271|OTHER|Hospitalization|Population of patients hospitalized for Herpes Zoster (ICD9-CM 053.xx)
47933492|NCT04132375|DRUG|INM004|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
47933493|NCT04132375|DRUG|Placebo|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
48455668|NCT04317417|BEHAVIORAL|EMPOWER|"Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a diary format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention."
48455669|NCT05795959|BEHAVIORAL|Receive education on precision medicine|Patients who consent to participating in the study and are randomized to the intervention group, will meet 1 on 1 with a trained lay VA volunteer. The trained lay VA volunteer will conduct phone calls with patients until the end of the 1 month enrollment period to deliver education regarding precision medicine.
48280391|NCT01596491|PROCEDURE|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
48455670|NCT03073798|DRUG|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
48455671|NCT03073798|DRUG|Placebo|500 mcg of placebo is used
48455672|NCT05638087|DRUG|Dexamethasone|Dexamethasone Oral Suspension
48455673|NCT05638087|DRUG|Placebo Control|Placebo Oral Mix
48455674|NCT05046340|OTHER|Passive leg raising|We perform the PLR test by adjusting the bed and not by manually raising the patient's legs. Bronchial secretions must be carefully aspirated before PLR. If awake, the patient should be informed of what the test involves. And measure the cardiac output by using certain devices at the bedside. The end-expiratory occlusion consists in interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output.
48280392|NCT05984745|DRUG|Coenzyme Q10 Forte® capsules|Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
48280393|NCT05111314|RADIATION|Gallium Ga 68 Gozetotide|Given IA
48280394|NCT05111314|PROCEDURE|Hepatic Artery Embolization|Undergo hepatic artery embolization
48280395|NCT05111314|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
48455675|NCT04506918|OTHER|IVR survey|Participants will receive an IVR survey
47933494|NCT02440412|OTHER|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
47933495|NCT02440412|OTHER|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
48455676|NCT04506918|OTHER|SMS survey|Participants will receive a SMS survey
48455677|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|Concentration-controlled
48455678|NCT00337493|DRUG|mycophenolate mofetil [CellCept]|1g po bid
48455679|NCT00337493|DRUG|Cyclosporine or tacrolimus|Reduced
47933496|NCT03230201|PROCEDURE|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
47933497|NCT03582228|BEHAVIORAL|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback"
47933498|NCT00003395|DRUG|arsenic trioxide|
47951356|NCT00749060|PROCEDURE|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
48098665|NCT05674617|BEHAVIORAL|Written Exposure Therapy|WET will be conducted in accordance with the Written Exposure Therapy for PTSD: A Brief Treatment Approach for Mental Health Professionals Manual and the VA evidence-based practice (EBP) rollout training.
48280396|NCT04899336|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
48280397|NCT04899336|OTHER|Placebo|Matching placebo will be administered as an IM injection.
48280399|NCT04687124|DIETARY_SUPPLEMENT|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
48280400|NCT04687124|OTHER|standard care|No specified intervention
48455680|NCT00337493|DRUG|Cyclosporine or tacrolimus|Standard, as prescribed
48455681|NCT04277793|BEHAVIORAL|Monitored self-guided problem solving|Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
47933499|NCT01983150|BEHAVIORAL|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
47933500|NCT01983150|BEHAVIORAL|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
47933501|NCT00352716|DRUG|Smecta (Diosmectite), duration of treatment - 7 days|
47933502|NCT02051816|DEVICE|Video Laryngoscopy|
47933503|NCT02051816|DEVICE|Apneic Oxygenation|
47933504|NCT02051816|DEVICE|Direct Laryngoscopy|
47933505|NCT02051816|DEVICE|No Apneic Oxygenation|
48622835|NCT05141799|DEVICE|high intensity laser therapy|Laser treatment is noninvasive and painless and can be easily administered in therapy units for a wide range of conditions. High-intensity laser therapy (HILT) has gained importance for the treatment of different kinds of sports injuries such as tendon injuries, contusions, and muscle spasms.
48622836|NCT05592691|PROCEDURE|Fascial block|The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
48455682|NCT05031260|DEVICE|applying COMORAL®|The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
48455683|NCT05022979|OTHER|Observational only|"The investigator collected the patient's data from the medical record and interviewed the patient to complete the nutritional questionnaire.~The required biological, blood and urine samples were collected during routine blood sampling upon entry and hospitalization."
48622837|NCT02768181|BEHAVIORAL|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
47933506|NCT03695276|BEHAVIORAL|PushCon Model|Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.
47933507|NCT03695276|BEHAVIORAL|Usual care|The standard of care, which usually means management within primary care.
47933508|NCT03277833|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
47933509|NCT03277833|DIETARY_SUPPLEMENT|Placebo|Placebo, parallel design
47933510|NCT05320627|DRUG|Edoxaban|Eligible patients will receive Edoxaban tablet once a day for 12 weeks
47933511|NCT03348787|BEHAVIORAL|Behavioral and Cognitive Therapies|"Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV"
47933512|NCT05767801|PROCEDURE|Evaluation of subclinical inflammation|Minimally invasive synovial tissue biopsy for the semiquantitative and qualitative assessment of synovial immune and stromal cells; Peripheral blood collection for MBDA assessment and phenotyping of immune cells;
47933513|NCT03520244|BEHAVIORAL|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
48455684|NCT03921879|DRUG|OT-82 Dose Escalation|The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
48455685|NCT03921879|DRUG|OT-82 Dose Expansion|A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
47933514|NCT05143359|DIAGNOSTIC_TEST|Wharfe and Pederson difficulty index|Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.
48455686|NCT00147563|DRUG|Eplerenone|
48455687|NCT01002963|DRUG|PF-04418948|solution, 30 mg, single
47933515|NCT05143359|DIAGNOSTIC_TEST|Winters difficulty index|Efficiency of Winters Difficulty index in extraction of third molars.
47933516|NCT02981355|PROCEDURE|Microfracture treatment|Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
47933517|NCT02981355|DEVICE|BST-CarGel|BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
47933518|NCT02815488|DRUG|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
47933519|NCT02815488|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
47933520|NCT02815488|DRUG|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
47933521|NCT02815488|DRUG|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
47933522|NCT02815488|DRUG|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
47933523|NCT02815488|DRUG|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
47933524|NCT02815488|DRUG|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
48455688|NCT01002963|DRUG|PF-04418948|solution, 100 mg, single
48455689|NCT01002963|DRUG|PF-04418948|solution, 300 mg, single
48455690|NCT01002963|DRUG|PF-04418948|solution, 1000 mg, single
48455691|NCT01002963|DRUG|PF-04418948|solution, 3000 mg, single
48455692|NCT01002963|DRUG|PF-04418948|solution, 4500 mg, single
48455693|NCT01002963|DRUG|PF-04418948|solution, 6000 mg, single
48455694|NCT03890237|BEHAVIORAL|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
48455695|NCT03890237|BEHAVIORAL|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
48455696|NCT03890237|BEHAVIORAL|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
48455697|NCT03890237|BEHAVIORAL|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
48622838|NCT02768181|DIETARY_SUPPLEMENT|Nutrient supplement to pregnant women (PNS)|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA \~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
47933525|NCT02815488|DRUG|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
47933526|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
47933527|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
47933528|NCT00911443|BIOLOGICAL|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
47933529|NCT00911443|BIOLOGICAL|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
47933530|NCT00911443|DRUG|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
47933531|NCT05503927|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
47933532|NCT04958512|DRUG|Yangxue Qingnao pill|The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
48280401|NCT02812511|PROCEDURE|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
48455698|NCT03448094|DIETARY_SUPPLEMENT|Resveratrol|Participants will consume one of the treatment types daily for a period of three months.
48455699|NCT03448094|DIETARY_SUPPLEMENT|Placebo|Participants will consume one of the treatment types daily for a period of three months.
48455700|NCT03724890|DRUG|M3814|Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
48455701|NCT03724890|DRUG|M3814|Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
48455702|NCT03724890|DRUG|Avelumab|Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
47933533|NCT04958512|DRUG|Hydergotoxine mesylate tablets|The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
47933534|NCT04958512|OTHER|blank control group|There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
47933535|NCT00570479|DRUG|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
47933536|NCT03813797|DEVICE|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
47933537|NCT03813797|DEVICE|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
47933538|NCT04856475|DRUG|Neratinib|"As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)"
47933539|NCT03860935|DRUG|acoramidis|TTR stabilizer administered orally twice daily (BID)
47933540|NCT03860935|DRUG|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
47933541|NCT03924271|DIAGNOSTIC_TEST|Iron deficiency testing|Blood sample for complete iron status
48455703|NCT03724890|RADIATION|Radiotherapy|Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
47933542|NCT06041776|DRUG|Befotertinib + Icotinib placebo|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis)."
47933543|NCT06041776|DRUG|Icotinib + Befotertinib placebo|"Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis."
47933544|NCT03722043|BEHAVIORAL|Parenting Program|Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
48280402|NCT06656091|DRUG|simmitinib|simmitinib 6mg,QD ,3 weeks on 1 week off
47933545|NCT05840029|PROCEDURE|VIDEO-ASSISTED THORACOSCOPIC SURGERY|A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
47933546|NCT00468039|DRUG|vildagliptin + metformin|
47933547|NCT00266851|DRUG|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
47933548|NCT00266851|DRUG|Placebo|Matching placebo
47933549|NCT03472443|OTHER|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
47933550|NCT02708082|DEVICE|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
48280403|NCT06656091|DRUG|investigator's choice of chemotherapy,include docetaxel or irinotecan.|docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
48455704|NCT04893408|OTHER|observational study|
48455705|NCT00258687|BIOLOGICAL|GVAX|4 vaccines every two weeks
48455706|NCT00857779|BIOLOGICAL|subcutaneous immunotherapy|7 injections
48455707|NCT04009447|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
48455708|NCT00408616|BIOLOGICAL|Grazax-R|Grass tablet, 75.000 SQ per day for one year
48455709|NCT00408616|BIOLOGICAL|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
48455710|NCT03025087|DRUG|Hydroxychloroquine|Participants will be getting hydroxychloroquine
48455711|NCT04980170|DRUG|Clindamycin 300 mg|patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
48455712|NCT04980170|DRUG|Amoxicillin with Clavulanic Acid 635mg|patients will be given Amoxicillin with Clavulanic Acid 635mg, three times daily for 5 days after dental implant
48455713|NCT00926835|DRUG|paroxetine|6 weeks, 20-50mg/day
48455714|NCT00926835|DRUG|Escitalopram|10-20mg/day for 6 weeks
48455715|NCT00926835|DRUG|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
48455716|NCT00926835|DRUG|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
48455717|NCT00926835|DRUG|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
48455718|NCT00926835|DRUG|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
48455719|NCT00926835|DRUG|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
47933551|NCT05163873|PROCEDURE|Extra-peritoneal|Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH
47933552|NCT00375947|OTHER|Hand Exercise|
47933553|NCT00375947|OTHER|sham hand cream|placebo intervention
47933554|NCT03751774|BEHAVIORAL|MAMAACT|Post graduate training and health education materials
47933555|NCT00762424|DRUG|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
47933556|NCT00762424|DRUG|placebo|cornstarch
47933557|NCT03539224|DRUG|Dolutegravir (DTG)|DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
47933558|NCT03539224|DRUG|Lamivudine (3TC)|Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
47933559|NCT03607643|DRUG|Cannabidiol|"* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~* Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal"
47933560|NCT03607643|DRUG|Bortezomib|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 \& 11 schedule to be repeated every 21 days.
47933561|NCT03607643|DRUG|Leucovorin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
48455720|NCT00926835|DRUG|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
48455721|NCT00926835|DRUG|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
47933562|NCT03607643|DRUG|5-FU|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
47933563|NCT03607643|DRUG|Oxaliplatin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
47933564|NCT03607643|DRUG|Bevacizumab|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
47933565|NCT03607643|DRUG|Irinotecan|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
47933566|NCT03607643|DRUG|Gemcitabine|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
48098666|NCT05674617|BEHAVIORAL|PTSD Education|"The 5-session PTSD psychoeducation and skills protocol we will be utilizing for our PTSD education control condition was developed by PTSD clinical team (PCT) clinicians at the Washington DC VA Medical Center as a group protocol for Veterans admitted to the PCT and who were on the waitlist for individual therapy with an EBP for PTSD. The PTSD 101 protocol consists of psychoeducation on topics related to PTSD symptoms and an introduction to PTSD-related coping skills. Its duration and structure will be similar to WET (5 weekly individual 50-minute sessions). To parallel the time an attention given in individual WET sessions more closely, participants will quietly review any written materials or videos that are a part of the manualized curriculum for 30 minutes of the session, bookended by a 10-minute check-in with their provider on symptoms and introduction to new materials at the start of session and another 10-minute debrief of reviewed materials at the end of session."
48098667|NCT05943938|OTHER|Epic Sepsis Model Version - 1|The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
47933567|NCT03607643|DRUG|Temozolomide|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
47933568|NCT04934943|DIAGNOSTIC_TEST|mini_FC|100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
47933569|NCT04113811|DEVICE|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
47933570|NCT01871064|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
47933571|NCT02658097|DRUG|Pembrolizumab|200mg Pembrolizumab by IV infusion
47933572|NCT02658097|RADIATION|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
47933573|NCT02379845|DEVICE|NBTXR3|One intratumor implantation by injection
47933574|NCT02379845|DEVICE|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
47933575|NCT04783142|OTHER|High-fiber, low-protein diet|Diet will consist of at least 15g fiber above baseline and less than 10% of calories from protein.
47933576|NCT04783142|OTHER|Low-fiber, high-protein diet|Diet will consist of less than 15g fiber and greater than 18% of calories from protein
47933577|NCT02628769|DRUG|Solithromycin|
47933578|NCT02628769|DRUG|Placebo|
47933579|NCT03007069|OTHER|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
48455722|NCT01347749|BEHAVIORAL|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
48455723|NCT01347749|BEHAVIORAL|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
48455724|NCT01916915|DRUG|Tramadol infusion via wound catheter|
48455725|NCT01916915|DRUG|Levobupivacaine|
48455726|NCT02754089|DRUG|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
48455727|NCT02754089|DRUG|Placebo|500 mg twice daily after meals for 6 weeks
48455728|NCT06344143|DIAGNOSTIC_TEST|Various labs and imaging tests|Dexamethasone Suppression Test, Adrenocorticotropic Hormone (ACTH), Salivary Cortisol Levels, Vasopressin Stimulation test, Fasting Glucose, Fasting Insulin, Complete Metabolic Panel (CMP), Gamma-glutamyl transferase (GGT), Sex Hormone Binding Globulin, Cat scan of abdomen/Pelvis, Whole body dual energy x-ray absorptiometry (DXA) scan, Ultrasound Fibroscan Transient Elastography
48455729|NCT01513239|BIOLOGICAL|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
48455730|NCT01513239|BIOLOGICAL|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
48455731|NCT01513239|BIOLOGICAL|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
48455732|NCT01513239|DRUG|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
48455733|NCT05204368|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for injection
47933580|NCT03007069|OTHER|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
47933581|NCT02875574|DRUG|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
47933582|NCT02875574|OTHER|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
47933583|NCT02425527|BEHAVIORAL|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
47933584|NCT02425527|BEHAVIORAL|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
47933585|NCT00002779|DRUG|fludarabine phosphate|
47933586|NCT00002779|DRUG|octreotide acetate|
47933587|NCT00973570|BEHAVIORAL|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
47933588|NCT04727281|OTHER|Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form and Malnutrition-Inflammation Score|"Data about nutritional status using the Malnutrition-Inflammation Score, and Quality of life assessment using the Kidney Disease Quality of Life 36 (KDQOL-36) short form. Dialysis related data, The time needed for the patient to recover from a dialysis session (in minutes), Detailed history taking, Thorough physical examination, Laboratory Investigations:~• Hemoglobin , Serum sodium and potassium , Serum creatinine and blood urea , Serum phosphorus, serum calcium , Serum PTH level , Serum albumin ,CRP ,Total iron-binding capacity ."
47933589|NCT01036061|DRUG|GSK618334 Low Dose|GSK618334 low dose
47933590|NCT01036061|DRUG|GSK618334 PET subjects|PET subjects
48098668|NCT05943938|OTHER|Epic Sepsis Model Version - 2|The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
48455734|NCT05204368|DRUG|Meropenem|Meropenem 1g for injection
48098669|NCT05943938|OTHER|Emory Sepsis Model|Emory internal algorithm
48098670|NCT00001129|DEVICE|Electronic Medication Reminder System|
48455735|NCT03903796|DRUG|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
48455736|NCT03903796|DRUG|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
48455737|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
47933591|NCT01036061|DRUG|GSK618334 Medium Dose|Medium Dose
47933592|NCT01036061|DRUG|GSK618334 High Dose|GSK618334 High Dose
48098671|NCT00001129|BEHAVIORAL|Medication Manager|
48098672|NCT03392337|DEVICE|Narrowband UVB phototherapy|Ultraviolet B phototherapy
48455738|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
48455739|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
48455740|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
48455741|NCT04554290|DIAGNOSTIC_TEST|temporal artery biopsy|description of temporal artery biopsy features, and its correlation with diagnosis of giant cell arteritis or other differential diagnoses.
48455742|NCT04005222|DRUG|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
48455743|NCT04005222|DRUG|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
48455744|NCT05787678|BIOLOGICAL|Dupilumab|600 mg (two 300 mg injections), followed by 300 mg monthly
48455745|NCT00367133|PROCEDURE|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
48455746|NCT00367133|DRUG|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
48455747|NCT00367133|DRUG|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
48455748|NCT04144998|DIAGNOSTIC_TEST|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
48455749|NCT04345640|OTHER|no intervention|no intervention
47933593|NCT06312969|BEHAVIORAL|Video game based training|"Type of intervention: Cognitive training through 3 types of video games:~* Serious games or brain-training games.~* Exer-gaming~* Skill-training games~Method of administration: The patient will receive the treatment for a period of 12 weeks, in which they will commit to use the video games of the intervention with the following pattern:~* Brain-training game: sessions of 7-12 minutes with a frequency of 4 days a week.~* Exer-gaming: sessions of 15-20 minutes 2 days a week.~* Skill-training games: sessions of 15-20 minutes 2 days a week."
47933594|NCT03729687|COMBINATION_PRODUCT|radiotherapy, capecitabine, oxaliplatin|5x5 Gy radiotherapy in 1 week, 4 cycles of CAPOX (capecitabine 1000 mg/m2 x2 d 1-14, oxaliplatin 130 mg/m2 d 1 every third week), surgery
47933595|NCT00349271|PROCEDURE|Stem cell|Stem cell
47933596|NCT00349271|DRUG|Filgrastime (G-CSF)|Filgrastime (G-CSF)
47933597|NCT00349271|DRUG|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
47933598|NCT04781660|DEVICE|Implantable Alginate Hydrogel|"Implantable Alginate Hydrogel is a single use, multiple component device. It is expected to be used as a space-occupying material implanted into the myocardium to affect the shape of the left ventricle and reduce the clinical symptoms of patients with left ventricular ischemia and non-ischemic cardiomyopathy.~The hydrogel serves as an artificial myocardial filler to stop the continuous expansion of the ventricle and restore it to a more favorable shape and size. The expected clinical effect of the Implanted Alginate Hydrogel is to reduce the clinical symptoms of patients and improve the quality of life by improving the structure and function of the failing heart."
48280404|NCT04328480|DRUG|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
48280405|NCT04328480|OTHER|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
48455750|NCT03222531|DRUG|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
48455751|NCT02343796|OTHER|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
48455752|NCT02343796|DEVICE|everStick|GC, Belgium
48455753|NCT01003938|DRUG|Topotecan|
48455754|NCT01003938|DRUG|Erlotinib|
48455755|NCT05251805|PROCEDURE|Blood, bone marrow and lung tumor tissue collection|"Blood sampling: 12ml of blood will be collected during the routine pre-operative blood collection~Bone marrow aspiration during thoracic surgery: following the surgical intervention, bone marrow aspiration will be performed through the incisions made for the thoracic procedure. The ribs lying directly above and below the trocar incision will be exposed. A bone marrow needle will be advanced into the periost until the needle tip reaches the bone marrow. After removing the stylet a 2ml syringe will be attached to the aspiration needle and 0.5ml to 2ml of bone marrow will be aspirated before removing the needle. This procedure will be repeated twice for every trocar site, for a maximum of 3 trocar sites, or until 5ml of bone marrow aspirate is obtained.~Lung tumor collection: all surgical samples will be analyzed by our anatomopathological department. Viable and fresh material, not used for the diagnostic purposes, will be sent to the LMCT."
48455756|NCT05959187|DIAGNOSTIC_TEST|pharmacogenomic testing|Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
48455757|NCT00161551|DEVICE|Vitatron T70 DR|
48455758|NCT06193889|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
48455759|NCT06193889|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
48098673|NCT06352294|OTHER|Core stability training|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult
48455760|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: excitatory iTBS|600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
48455761|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: inhibitory cTBS|600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
48455762|NCT05303649|BEHAVIORAL|Individual speech-language therapy (SLT)|45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
48455763|NCT05303649|DEVICE|Sham TBS simulating left hemispheric iTBS|Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
48455764|NCT04185272|BIOLOGICAL|analysis of BTN and BTNL status|analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
47933599|NCT05011448|OTHER|Music Therapeutic Interaction and Verbal Interaction|"In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice."
47933600|NCT01586273|DEVICE|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
48455765|NCT04143516|DIAGNOSTIC_TEST|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
48455766|NCT04143516|PROCEDURE|Tumor ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.
48455767|NCT04143516|DIAGNOSTIC_TEST|PET/CT Scan|Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
48455768|NCT05005728|COMBINATION_PRODUCT|vudalimab + carboplatin + cabazitaxel|Vudalimab IV, carboplatin IV, cabazitaxel IV
48455769|NCT05005728|COMBINATION_PRODUCT|vudalimab + olaparib|Vudalimab IV, olaparib oral
48455770|NCT05005728|BIOLOGICAL|vudalimab monotherapy|Vudalimab IV
48622839|NCT02768181|DIETARY_SUPPLEMENT|Nutrienr supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in \~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets \~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
48455771|NCT05005728|COMBINATION_PRODUCT|vudalimab + docetaxel|Vudalimab IV, docetaxel IV
48455772|NCT05005728|COMBINATION_PRODUCT|vudalimab + cabazitaxel or docetaxel|Vudalimab IV, cabazitaxel or docetaxel IV
47933601|NCT05390190|DEVICE|Non ablative radiofrequency|Device
48280406|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status|In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
48455773|NCT04179058|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
48455774|NCT00078923|DIETARY_SUPPLEMENT|soy isoflavones|
48455775|NCT00078923|PROCEDURE|neoadjuvant therapy|Prostatectomy or Brachytherapy
48455776|NCT00078923|OTHER|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
48455777|NCT06623084|OTHER|Platelets characterization|To identify platelet features that correlate with liver disease progression and to study the mechanistic relationship between gut dysbiosis, metabolome composition, inflammation, and platelet activation in chronic liver disease.
48455778|NCT01847495|DRUG|Irinotecan|40mg/m2 x 3-5 days
48455779|NCT01847495|RADIATION|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
48455780|NCT04304209|DRUG|Oxaliplatin|130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion
48455781|NCT04304209|DRUG|Capecitabine|1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
48455782|NCT04304209|DRUG|Sintilimab|200mg, d1 q3w, intravenous infusion
48455783|NCT04304209|RADIATION|radiotherapy|neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.
48455784|NCT04304209|PROCEDURE|total mesorectal excision|total mesorectal excision after neoadjuvant treatment
48455785|NCT04304209|OTHER|Watch and wait|Watch and wait for cCR patients after neoadjuvant treatment
48455786|NCT01746550|DEVICE|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
48455787|NCT05394714|BIOLOGICAL|Magicell-NK contains NK cells suspended in 100 mL normal saline|Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
48455788|NCT00675779|DRUG|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
48455789|NCT00675779|DRUG|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
48455790|NCT01306838|DIETARY_SUPPLEMENT|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
48455791|NCT01306838|OTHER|Routine care|Routine care
48455792|NCT03334058|DRUG|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
48455793|NCT05324033|RADIATION|multiparametric MRI on the bladder|comparison between mpMRI and histopathology
48455794|NCT05324033|PROCEDURE|diagnostic cystoscopy +/- TURBT|conventional way of diagnosis
48455795|NCT05860777|OTHER|Complexity score and implementation|AI machine learning model to identify patients with complex care needs and implementation with active reaching out to clinicians to offer interpreter services
48455796|NCT03420092|DRUG|Form 1 of AZD5718 tablets|The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
48455797|NCT03420092|DRUG|Form 2 of AZD5718 tablets|The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
48455798|NCT03420092|DRUG|Form 3 of AZD5718 tablets|The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
48455799|NCT03420092|DRUG|Form 4 of AZD5718 tablets|The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
48455800|NCT03420092|DRUG|Form 5 of AZD5718 tablets|The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
48455801|NCT03420092|DRUG|Selected form (Form 2 - 5) of AZD5718 tablets|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
48455802|NCT03356691|OTHER|Complementary Spiritist Therapy|"Complementary Spiritist Therapy:~1. Prayer: for 1 to 2 minutes.~2. Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~3. Spiritist passe, for 2-min.~4. Fluid therapy."
48455803|NCT03356691|OTHER|Prayer|Individuals will receive prayer during 1 to 2 minutes.
47933602|NCT01112683|DRUG|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).
47933603|NCT01112683|DRUG|Placebo|These are identically-looking pills to those in the Memantine Arm.
47951357|NCT00749060|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
48455804|NCT03356691|OTHER|"Spiritist passe"|"Individuals will receive Spiritist passe during 5 to 10 minutes."
48455805|NCT03356691|OTHER|laying on of hands with intent to heal|Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.
48455806|NCT03356691|OTHER|Fluid therapy.|Individuals will receive fluid therapy.
48455807|NCT03356691|OTHER|No-fluid therapy.|Individuals will receive no-fluid therapy.
48455808|NCT00629304|DEVICE|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
48455809|NCT00629304|DEVICE|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
48455810|NCT00629304|DEVICE|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
48455811|NCT00705666|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
48455812|NCT00705666|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
48455813|NCT02997345|OTHER|There is no intervention associated with this study.|There is no intervention associated with this study.
48455814|NCT01991548|DEVICE|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
48455815|NCT03476226|OTHER|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
48455816|NCT00785603|DRUG|Paroxetine|tablets of 20 mg paroxetine
48455817|NCT00785603|DRUG|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
48455818|NCT00785603|DRUG|Tramadol|Capsules of 50 mg tramadol
48455819|NCT01693523|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day).
48455820|NCT01693523|OTHER|Placebo|Matching placebo capsules by mouth twice a day.
48455821|NCT01693523|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
48455822|NCT01488435|DIETARY_SUPPLEMENT|Cow's milk|Powdered whole cow's milk
48455823|NCT01488435|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
48455824|NCT00725322|DRUG|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
48455825|NCT00725322|DRUG|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
48455826|NCT00829894|DRUG|Risperidone|1 mg Tablet
48455827|NCT00829894|DRUG|Risperidone|1 mg Tablet
48455828|NCT02011945|DRUG|Dasatinib|
48455829|NCT02011945|DRUG|Nivolumab|
48455830|NCT05247567|BIOLOGICAL|serum punction|A blood sample inclusion and at the end of study visit
48455831|NCT05247567|BIOLOGICAL|skin swab in elbow folds|passage of a cotton swab in the crease of the elbow at the inclusion
48455832|NCT05221554|PROCEDURE|Computer-navigated THA surgery|Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.
48455833|NCT05221554|PROCEDURE|Standard of care THA surgery|Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
48622840|NCT04228939|BEHAVIORAL|Recovery Record aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16."
48622841|NCT04228939|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
48622842|NCT05112133|DIETARY_SUPPLEMENT|Mulberry leaf extract|Oral administration
48622843|NCT05112133|DIETARY_SUPPLEMENT|Water|Oral administration
48622844|NCT02338830|DRUG|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
48622845|NCT04186273|DRUG|Fibrosis-Inhibiting-Compound-FS2|There are three (3) experimental interventions: vehicle moisture balancing base, FS2-0.25 moisturizer, and 0.5 moisturizing base.
48622846|NCT04186273|OTHER|Vehicle moisture balancing base|Vehicle base without FS2.
48622847|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
48455834|NCT01160796|DRUG|placebo|1x14-day course of treatment during 4 cycles
48455835|NCT01160796|DRUG|Lcr35®|1x14-day course of treatment during 4 cycles
48455836|NCT03170219|COMBINATION_PRODUCT|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
48455837|NCT02761525|OTHER|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
48455838|NCT02761525|OTHER|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
48455839|NCT04972578|DEVICE|Suture Button vs Screw Fixation|Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
48455840|NCT04540094|DRUG|Human albumin|Any preparation of 5% Human Albumin Solution which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study
48455841|NCT04540094|DRUG|Balanced crystalloid solution|"Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study."
48455842|NCT06488157|OTHER|I-HoME|Video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs
48455843|NCT06628089|OTHER|Questionnaire|A questionnaire for primary healthcare physicians designed to evaluate knowledge about H. Pylori mode of transmission, symptoms, complications and treatment.
48622848|NCT03759184|DRUG|rhIL-15|Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
48455844|NCT06241222|DRUG|Probiotic Blend Oral Tablet|In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
48455845|NCT01741545|BIOLOGICAL|Pegylated-Interferon-lambda|
48455846|NCT01741545|DRUG|Ribavirin|
48455847|NCT01741545|DRUG|Daclatasvir|
48455848|NCT04632641|DEVICE|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
48455849|NCT04632641|OTHER|Figure 8 Suture - LARGE-BORE PROCEDURES|A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
48455850|NCT05025163|DRUG|1.23% fluoride foam application|topical application of fluoride foam every 6 months
48455851|NCT05025163|DRUG|2.26% fluoride varnish application|topical application of fluoride varnish every 6 months
47933604|NCT02309619|PROCEDURE|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
48455852|NCT05479058|DRUG|Filgotinib|Administered orally once daily
48455853|NCT05479058|DRUG|Placebo|Administered orally once daily
48455854|NCT00726830|DRUG|methadone hydrochloride|Given orally
48455855|NCT00726830|DRUG|morphine sulfate|Given orally
48455856|NCT00726830|DRUG|oxycodone hydrochloride|Given orally
48455857|NCT03098901|DIAGNOSTIC_TEST|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
48455858|NCT02873845|OTHER|Preliminary validation of the COBQoL questionnaire|
48455859|NCT02004769|DRUG|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
48098674|NCT06352294|OTHER|Core stability training and myofascial relase|Before starting core stabilization exercises, hotpack will be given for 15 minutes in the warm-up phase, TENS application, then craniocervical flexion training will be given. Core stabilization exercises consist of three stages: easy, medium and difficult. In addition, myofascial relaxation will be applied with roller bar along the superficial back line.
48455860|NCT02004769|DRUG|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
48455861|NCT02004769|DRUG|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
48455862|NCT03864094|DRUG|Ephedrine|0,1 mg/kg
48455863|NCT03864094|DRUG|Phenylephrine|1 microg/kg
48455864|NCT03864094|DRUG|Norepinephrine|0,1 microg/kg
48455865|NCT03864094|DRUG|Sodium chloride|0,1 ml/kg
48455866|NCT03864094|DRUG|Propofol|2 mg/kg
48098675|NCT05553119|BEHAVIORAL|Home Rehabilitation Monitoring System|Established home-based pulmonary rehab system consists of three commercial devices (Garmin Vívofit™ activity monitor, Nonin 3150 WristOx2® Pulse Oximeter, Android tablet) and two software applications for telemonitored home pulmonary rehabilitation.
48455867|NCT03864094|DRUG|Remifentanil|1,7 microg/kg
48455868|NCT03046550|DRUG|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
48455869|NCT03046550|DRUG|Placebo|placebo
48455870|NCT05957146|DEVICE|Routine hemodialysis|"* Dialyzers: Cordiax FX80 dialyzers; membrane material HelixonePlus (polysulfone); (Fresenius Medical Care Bad Homburg, Germany)~* Dialysis machines: Baxter Gambro AK 98 (Gambro Lundia AB, Lund, Sweden; part of Baxter Healthcare Corporation)~* Needles for vascular access: Nipro SafeTouch dialysis cath 1.6x25 mm (16G) or 1.9x25 mm (15G); or Nipro SafeTouch Tulip needles (15G; all Nipro Medical Europe Mechelen, Belgium)~* Ultrapure dialysis fluids (less than 0.1 colony forming units/ml, less than 0.03 endotoxin units/ml) will be mixed with AC-F 219/1 or 213/4 liquid acid concentrates and BiBag dry bicarbonate concentrate. Hence, the electrolyte composition of the dialysis fluid will be: Na 138-142 mmol/L; K 2.0-3.0 mmol/L; HCO3 26-35 mmol/L; Ca 1.25-1.50 mmol/L; Mg 0.5 mmol/L; Cl 108.5-109 mmol/L; glucose 5.6 mmol/L; acetate 3 mmol/L. Dialysate flow rate will be 500 mL/min.~* Anticoagulation: nadroparin."
47933605|NCT02900001|PROCEDURE|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
48098676|NCT05553119|BEHAVIORAL|Health coaching calls|Coaching calls based on motivational interviewing principles will occur weekly for twelve weeks following a standard protocol, lasting no more than 5-10 minutes.
48455871|NCT05000957|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1.5 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
48455872|NCT05000957|DIAGNOSTIC_TEST|Blood analysis|Taking blood from a vein for clinical blood analysis, glucose test, hepatitis B, C viruses, human immunodeficiency viruses and syphilis test, blood clotting tests, blood type and rhesus factor determination (to include the participant in the study).
48455873|NCT05000957|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
48455874|NCT05000957|DIAGNOSTIC_TEST|Electrocardiography|Electrocardiography investigation to determine cardiac abnormalities (to include the participant in the study).
48455875|NCT05000957|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation, oncocytology (to include the participant in the study).
48455876|NCT05000957|DIAGNOSTIC_TEST|Colposcopy|Colposcopy investigation to determine pre-malignant and malignant lesions of cervix, vagina or vulva (to include the participant in the study).
47933606|NCT02900001|PROCEDURE|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
48455877|NCT05000957|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
48455878|NCT05000957|DIAGNOSTIC_TEST|Doppler ultrasonography|Ultrasound investigation for assessing blood flow in the tissues of vulva region (to evaluate procedure efficiency).
48622849|NCT03759184|BIOLOGICAL|Obinutuzumab|Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
48280407|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status and monthly GWG monitoring|In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
48455879|NCT05000957|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
48455880|NCT05000957|DIAGNOSTIC_TEST|Biopsy of the vaginal wall|Sampling of the vaginal wall material in the posterior fornix area including the mucous membrane and muscle layer will be performed during colporrhaphy or any pelvic surgical procedure for histological, immunohistochemical studies, and optical coherence tomography (elastography) (to evaluate procedure efficiency)
48455881|NCT05000957|DIAGNOSTIC_TEST|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
48455882|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Distress Inventory Questionnaire|Pelvic Floor Distress Inventory Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
48455883|NCT05000957|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire - Short Form|International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
48455884|NCT05000957|DIAGNOSTIC_TEST|Pelvic Floor Impact Questionnaire|Pelvic Floor Impact Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
48455885|NCT05000957|PROCEDURE|Anterior and/or posterior colporrhaphy|Surgical procedure to repair pelvic organ prolapse followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
48455886|NCT05000957|PROCEDURE|Pelvic surgical procedure|Any pelvic surgical procedure which do not affect condition of vagina, vulva and paraurethral region followed by biopsy for histological, immunohistochemical studies, and optical coherence tomography (elastography).
48455887|NCT05000957|OTHER|Physical examination|Pelvic examination (to include the participant in the study and observe throughout the study)
48455888|NCT05000957|OTHER|Сonsultation|Сonsultation of a therapist about the absence of contraindications for surgical treatment (to include the participant in the study)
48455889|NCT05000957|GENETIC|Buccal smear|"Buccal smear to performing genetic testing.~The following markers will be analyzed:~ESR1 rs2234693, ESR1 rs2228480, COL3A1 rs1800255, COL14A1 rs4870723, MMP9 rs3918253, MMP10 rs17435959, LOXL1 rs2304719, WNT4 rs3820282, MMP2 rs243865, TIMP2 rs2277698, CD31 / PECAM1 rs1131012, Ki67 rs11016076."
48455890|NCT04631393|DRUG|Propofol Alfentanil|Propofol and Alfentanil are self-administered by the participant.
48455891|NCT04198701|DEVICE|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
48455892|NCT03595800|PROCEDURE|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
48455893|NCT01682421|DRUG|Weak steroid (Flurolon, Allergan)|
48455894|NCT01682421|DRUG|Potent steroid (Maxidex, Alcon)|
48455895|NCT04583423|DRUG|MK-3655|MK-3655 50, 100 or 300 dose for injection
48455896|NCT04583423|DRUG|Placebo|Matching placebo to MK-3655
48455897|NCT00174980|DRUG|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
48455898|NCT06406088|DEVICE|EarGenie MVP test|The EarGenie MVP test consists of placing the EarGenie headgear containing light emitting diodes (LEDs) and light detectors on the infant and running the fNIRS tests of sound detection or sound discrimination via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation in temporal and prefrontal regions of the cortex. Automatic analyses are run to determine whether the infant heard the sounds (at levels 35, 50, and 65 dBSPL) or discriminated between two sounds (Ba/Tea, Ba/Bee, or Ba/Ga). The infant will be in a natural sleep or quiet awake state when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
48455899|NCT01441349|DRUG|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days"
48455900|NCT01441349|DRUG|IP chemotherapy plus simvastatin|"* Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1"
48455901|NCT04672044|DEVICE|Active rTMS and exercise|active
48455902|NCT04672044|COMBINATION_PRODUCT|Sham rTMS+Exercise|sham
47933607|NCT05338398|DEVICE|Bocaliner|Bocaliner is a soft, orally inserted device that has been demonstrated to increase the oral retention of oral, topical therapies such as mouthwashes and gels.
48280408|NCT06125860|DIETARY_SUPPLEMENT|Universal BEP|In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
48280409|NCT05977842|DEVICE|CTO PCI using DCB-only strategy|Successful CTO recanalization treated with DCB at the occlusion site
48280410|NCT00109421|BEHAVIORAL|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
48280411|NCT05412433|BEHAVIORAL|Patient Level|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations
48455903|NCT03413423|BEHAVIORAL|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
48455904|NCT03413423|BEHAVIORAL|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
48455905|NCT05597228|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
48455906|NCT04936529|DIETARY_SUPPLEMENT|β-glucan|"Group 1 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14). This schedule includes annual booster vaccinations, with a 2-week cycle of β-glucan, administered at months 36 (3 years), 48 (4 years), and 60 (5 years).~Group 2 participants receive oral β-glucan (40 mg/kg/day) starting week 1 and continue with \~2 weeks on, \~2 weeks off, up to 1 cycle after vaccination #7, then 1 cycle with each subsequent vaccination (#8-#14).~Group 3 participants will be treated as in Group 1."
48455907|NCT04936529|DRUG|GM-CSF|"Group 1 participants will not receive GM-CSF.~Group 2 participants will receive GM-CSF (250 mcg/m2/day) x3 days with vaccinations #1-#3; x7 days with vaccinations #4-#11; and x5 days with vaccinations #12-#14.~Group 3 participants will be treated as in Group 1."
48455908|NCT04936529|BIOLOGICAL|OPT-821|Vaccine injections must occur a minimum of 6 days apart. After the first four vaccine injections, vaccines can be administered up to two weeks earlier or later than indicated without representing a protocol violation.
48455909|NCT00354159|DEVICE|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
48455910|NCT03193021|DEVICE|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
48455911|NCT03193021|OTHER|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
48455912|NCT02736123|DRUG|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
48455913|NCT02736123|DRUG|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
48455914|NCT06625255|BEHAVIORAL|Parent Education - Promoting Playfulness|Parents will participate in 2, 45 minute parent education sessions promoting playfulness through information about child development, parent stressors, and parent advocacy.
48455915|NCT02167659|DEVICE|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
48455916|NCT04604938|DRUG|Losartan|administration of losartan (50 mg) (oral)
48455917|NCT04604938|DRUG|Placebo oral tablet|administration of placebo (oral)
48622850|NCT02709369|DEVICE|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
48622851|NCT02560467|DRUG|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
47933608|NCT05338398|DRUG|Benzydamine|Benzydamine is an anti-inflammatory and antibiotic mouthwash that has shown promise for the treatment of radiation-induced oral mucositis.
48280412|NCT05412433|BEHAVIORAL|Multilevel|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts
48098677|NCT05931198|OTHER|Modified illusion of the rubber (syncrhone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis at the same time (synchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
48280413|NCT05412433|BEHAVIORAL|Control|Standard of care
48455918|NCT05702905|DRUG|Metformin Hydrochloride 500 MG|Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
48455919|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
48455920|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG|Both Semaglutide injection and Metformin oral tablet will be administered as described above.
48455921|NCT05702905|BEHAVIORAL|calorie-restricted diet|All subjects after randomization will be reviewed and evaluated by a nutritionist, and then will receive diet guidance. The clinical nutritionist will develop a written nutrition plan for each subject. The nutrition plan of this study adopted the method of calorie restriction diet (CRD) to develop a diet, which required 83.68 kJ/kg of energy per day, 1.2 g/kg of protein per day, 40%\~55% of carbohydrate energy supply ratio, and 20%\~30% of fat energy supply ratio, to ensure the intake of vegetables, fruits and other rich dietary fiber, and drinking more than 1.5 L per day. The nutritionist will explain the method of food exchange in detail to enrich the food types of patients. The diet diary will be distributed to each subject, and the subjects will be required to make a return visit once every four weeks, return the diet diary each time, and receive guidance according to their compliance.
48455922|NCT05702905|BEHAVIORAL|physical exercise|All subjects after randomization will be reviewed and evaluated by a trainer, and then will receive guidance of physical exercise.The trainer will formulate an exercise plan for each subject. The exercise plan consists of 30 minutes of moderate and low intensity continuous aerobic exercise every day, with a frequency of 5-7 days/week. The form of exercise can be determined according to personal hobbies, such as fast walking, jogging, climbing, swimming, etc. The exercise diary will be distributed to each subject, and the subjects are required to make a return visit once every four weeks, return the exercise diary each time, and the trainer will provide guidance to the subjects according to their compliance.
48455923|NCT06015035|DRUG|Sintilimab and anlotinib in combination with chemotherapy|Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
48455924|NCT01943877|PROCEDURE|scaling root planing|scaling root planing
48455925|NCT01943877|DRUG|Propolis|experimental
48455926|NCT02452463|BIOLOGICAL|Durvalumab|Given IV
48455927|NCT02452463|DRUG|Nintedanib|Given PO
48455928|NCT02452463|OTHER|Placebo|Given PO
48455929|NCT02452463|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
48455930|NCT04682951|PROCEDURE|Decompressive Craniectomy|
48455931|NCT04849390|DRUG|ESO-101|Daily administration in the evening at bedtime for 28 days
48455932|NCT04849390|DRUG|Placebo|Daily administration in the evening at bedtime for 28 days
48455933|NCT05049239|BEHAVIORAL|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
48455934|NCT05049239|BEHAVIORAL|Physical training combined with cognitive support.|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions."
48455935|NCT03192007|DEVICE|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
48455936|NCT04567303|DRUG|Zifibancimig|"Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant."
48455937|NCT04567303|DRUG|Ranibizumab|Participants will receive ranibizumab 100 mg/mL through the PD implant
48455938|NCT04567303|DEVICE|Port Delivery Platform|Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
48455939|NCT01806272|DRUG|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
48622852|NCT05219786|BEHAVIORAL|Appendicitis Decision Support Tool|Viewing of a decision support tool.
48622853|NCT05219786|BEHAVIORAL|Control Infographic|Viewing of a standardized infographic
48622854|NCT02399020|BEHAVIORAL|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
48622855|NCT05688657|DEVICE|Lens A|Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
48622856|NCT05688657|DEVICE|Lens B|Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
48455940|NCT01806272|DRUG|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
48455941|NCT04388358|DRUG|Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day|All patients were treated with mixed formula of Chinese medicine for one month
48622857|NCT00820300|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
48622858|NCT00514696|DRUG|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
48455942|NCT00924638|DEVICE|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
48455943|NCT04728750|PROCEDURE|Enucleation of a tumor of the pancreas|Enucleation of a tumor in the pancreas is feasible and safe, as it offers a minimally invasive approach, and morbidities are fewer than open or conventional approach
48455944|NCT05201235|DEVICE|MAEVAD|"MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character."
48455945|NCT05201235|DEVICE|DeCaLigne|"DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game."
48455946|NCT04107064|BEHAVIORAL|NaW|Participants will receive assistance with finding employment, onboarding, training, and so on.
48455947|NCT04107064|BEHAVIORAL|NaW-DS|Participants will receive assistance with onboarding and training 6 months after the initiation of their employment.
48455948|NCT04238715|DRUG|E7090|E7090 tablets orally.
48455949|NCT00757419|DRUG|AZD3355|capsules, oral, single or twice daily dose
48455950|NCT00757419|DRUG|Placebo|To match dosing of AZD3355
48455951|NCT02763345|OTHER|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
48455952|NCT02763345|OTHER|Standard care|
48455953|NCT05206851|OTHER|Manual Lymphatic Drainage and Hot Pack|"Application of hot pack for 20 minutes at low back in sitting, and then the participant will perform deep diaphragmatic breathing for 10 minutes, following these steps:~1. Sitting in comfortable position~2. One hand is placed over chest and other on abdomen.~3. Inhale deep through the nose.~4. Exhale through mouth, completely, counting back from 4 to 1. Application rotary or stationary circle over low back in side lying position, in pregnant females. A session of 20-30 minutes of Manual Lymphatic Drainage will be given biweekly.~And at the end of Manual Lymphatic Drainage application, deep breathing for 10 minutes will be performed again."
48455954|NCT05206851|OTHER|Hot Pack|Hot pack will be applied at low back, for 20 minutes as home based protocol.
48455955|NCT05544123|OTHER|pathological stage|breast cancer molecular subtyping and pathological TNM stage
48455956|NCT00348517|OTHER|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
48455957|NCT00348517|OTHER|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
48455958|NCT03482180|DRUG|KI1106 4g, QD|KI1106 4 Capsules
48455959|NCT03482180|DRUG|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
48455960|NCT02768974|DRUG|OPRX-106|Oral delivery, once daily.
48455961|NCT00983099|DRUG|Neramexane|single and multiple dose, tablets, oral
48455962|NCT05098743|BEHAVIORAL|Medisafe smartphone mobile application|The medication adherence smartphone mobile application (app) will provide reminders to take individual patient medications and offers medication information and a social support feature.
48455963|NCT05098743|BEHAVIORAL|Printed medication list|Patients will receive a printed out medication list from their electronic medical record.
48455964|NCT00506376|BEHAVIORAL|Interview|Interview that will take about 20 minutes to complete.
48455965|NCT00364559|DRUG|Rosuvastatin|20 mg 10 days daily
48455966|NCT05652257|DRUG|[14C]-brensocatib|Oral solution.
48455967|NCT05853653|BEHAVIORAL|Using dolls in breastfeeding education|Using dolls in breastfeeding education
48455968|NCT01237444|DRUG|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
48455969|NCT01237444|DRUG|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
48622859|NCT01150682|GENETIC|RNA analysis|
48622860|NCT01150682|GENETIC|reverse transcriptase-polymerase chain reaction|
48098678|NCT05931198|OTHER|Modified illusion of the rubber (asynchrone)|The residual limb of the patient will be hide for the patient. The prothesis and the other hand of the patient will be visible. The investigators are going to touch the residual limb and the prothesis not at the same time (asynchrone) during at least 2 min. The investigators will ask to the patient to point where they felt the touching spot on a tray with measurement grid and to asnwer to the pre-prepared questionnaire.
48455970|NCT06415903|DRUG|TQB3117 tablets|TQB3117 is a protein inhibitor.
48098679|NCT06306846|RADIATION|SBRT+immunochemotherpy|SBRT radiotherapy，followed with PD-1 monoclonal antibody and TP chemotherapy
48622861|NCT01150682|OTHER|enzyme-linked immunosorbent assay|
48622862|NCT01150682|OTHER|immunohistochemistry staining method|
48622863|NCT01150682|OTHER|laboratory biomarker analysis|
48455971|NCT01261949|DEVICE|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
48098680|NCT06306846|DRUG|Immunochemotherapy|PD-1 monoclonal antibody and TP chemotheapy
48098681|NCT06306846|DRUG|cetuximab+immunochemotharpy|PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab
48455972|NCT01261949|DEVICE|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
48455973|NCT00120783|DRUG|Indinavir|
48455974|NCT00120783|DRUG|Lamivudine|
48455975|NCT00120783|DRUG|Ritonavir|
48455976|NCT04038866|OTHER|rehabilitation gait with dual task|
48455977|NCT04038866|OTHER|rehabilitation gait without dual task|
48455978|NCT01957280|DRUG|patritumab|
48455979|NCT06425757|DRUG|ciprofol|Patients who intended to undergo elective surgery under general anesthesia were induced by a single intravenous injection of 0.3mg/kg and ciprofol, and the experimental drug was manually injected by CVC within 30s. 2ml of venous blood was collected before and after administration 0.5min, 1min, 2min, 3min, 5min, 8min, 15min 30min, 1h, 2h and 4h respectively. The concentration of cyclopofol in blood was measured
48455980|NCT02243982|OTHER|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
48455981|NCT03704103|OTHER|iSage|The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
48455982|NCT01706757|DEVICE|go-cart|conducts exercises with the help of a go-cart
48455983|NCT05315297|DEVICE|PEMF device|PEMF device wear overnight daily for four weeks
48280414|NCT01834495|DEVICE|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
48455984|NCT05315297|DEVICE|Sham PEMF device|Sham PEMF device wear overnight daily for four weeks. Sham PEMF devices do not emit a radiofrequency electromagnetic field but are otherwise identical in appearance to the PEMF device
48455985|NCT05129176|DRUG|Levofloxacin|levofloxacin-tetracycline-containing quadruple regimens
48455986|NCT05129176|DRUG|Metronidazole|Metronidazole-tetracycline-containing quadruple regimens
48455987|NCT04031690|OTHER|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
48455988|NCT04031690|OTHER|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
47933609|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was given mefenamic acid as a medication.
48098682|NCT04296032|BEHAVIORAL|virtual reality game traning|The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.
48098683|NCT04296032|BEHAVIORAL|standard treatment|The program included bilateral hand, grasp/release, and pinch activities.
48098684|NCT06027151|DRUG|1ml of 1% metronidazole gel|1ml of 1% metronidazole gel subgingivally at baseline visit
48098685|NCT06027151|DRUG|1ml of 2% minocycline gel|1ml of 2% minocycline gel sub gingivally at baseline visit
48455989|NCT00013390|PROCEDURE|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
48455990|NCT00013390|PROCEDURE|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
48455991|NCT04823832|PROCEDURE|pancreaticoduodenectomy|resection of the head of pancreas and the duodenum followed by triple anastomosis
48455992|NCT03676634|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
48455993|NCT02105272|DRUG|OPC-1085EL ophthalmic solution|
48455994|NCT02105272|DRUG|Latanoprost ophthalmic solution|
48455995|NCT03946436|DEVICE|Active video games|Participants played the active video game Virtua tennis 4 on a playstation kinect device
48455996|NCT03946436|OTHER|tennis training process|Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
48280415|NCT01834495|DEVICE|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
48455997|NCT06628297|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
48455998|NCT05668650|DRUG|Pembrolizumab|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
48622864|NCT04065620|DIAGNOSTIC_TEST|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration \<24 hours, those without one good reading per hour and those with \<70% of satisfactory readings will be excluded
48622865|NCT02582632|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet
48622866|NCT02582632|DRUG|dasabuvir|Tablet
48622867|NCT02310308|DIETARY_SUPPLEMENT|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
48280416|NCT03855072|PROCEDURE|customized fixation plate|"* All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together after setback"
48280417|NCT03855072|PROCEDURE|maxillomandibular fixation|"* All cases will undergo one surgery under general anesthesia.~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position."
48280418|NCT00762346|DRUG|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
48280419|NCT04342065|DRUG|Celecoxib capsules|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
48280420|NCT04342065|DRUG|Pregabalin 150mg|received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
48280421|NCT02134600|DIETARY_SUPPLEMENT|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2."
48280422|NCT02405533|DIETARY_SUPPLEMENT|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
48280423|NCT02405533|OTHER|Placebo|Placebo supplementation x 12 months
48280424|NCT03735940|OTHER|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
48280425|NCT03277196|DRUG|IVA|Granules for oral administration.
48280426|NCT01312194|PROCEDURE|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
48280427|NCT01312194|PROCEDURE|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
48280428|NCT06387615|OTHER|Active cTBS|Active stimulation
48280429|NCT06387615|OTHER|Sham|Control stimulation
48280430|NCT00264407|DRUG|Hormone Replacement Therapy - HRT|
48280431|NCT02204865|DEVICE|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
48280432|NCT06590116|OTHER|Physical therapy|Patients with low back pain will receive a combination of education, spinal manipulative therapy, and exercise as prescribed by their physical therapist
47933610|NCT06280014|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures. After extraction of impacted wisdom tooth, the patient was dexketoprofen as a medication.
47933611|NCT04562753|PROCEDURE|Maïa® TMC Prosthesis (Lépine Groupe)|Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
47933612|NCT04562753|PROCEDURE|APL Suspensionplasty|Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
48622868|NCT04726904|PROCEDURE|Sacral neuromodulation in conventional implantation technique|Sacral neuromodulation is implanted with the patients in a prone position, then the insert point of the needle is decided according to anatomical landmarks; afterwards, the lead will be inserted.
47933613|NCT02607644|DEVICE|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
47933614|NCT02607644|DEVICE|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
48455999|NCT05668650|DRUG|Pembrolizumab biosimilar|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
48280433|NCT06590116|OTHER|Physical therapist provider|Physical therapists will provide a combination of education, spinal manipulative therapy, and exercise to their patients with low back pain participating in the study
48456000|NCT06561451|PROCEDURE|intracytoplasmic sperm injection and artificial oocyte activation|A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
48456001|NCT06561451|PROCEDURE|intracytoplasmic sperm injection|A single sperm will be injected within 4 hours after the follicular aspiration.
48622869|NCT02315625|DRUG|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
48622870|NCT02315625|DRUG|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
48622871|NCT00827242|DRUG|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
48622872|NCT00827242|DRUG|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
48456002|NCT00942838|DRUG|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
48280434|NCT04744558|OTHER|Low carb high fat ketogenic dieting|Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
48280435|NCT04744558|OTHER|Low carb high fat non-ketogenic dieting|Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
48456003|NCT00942838|RADIATION|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
48456004|NCT05597631|DEVICE|G-IVF PLUS|Experimental
48456005|NCT06502301|OTHER|Cross-sectional study|This is not intervention study.
48456006|NCT01149057|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
48456007|NCT00270582|DRUG|Taxotere, Cisplatin, Gemcitabine|
48622873|NCT05883488|OTHER|Robot-assisted upper extremity rehabilitation|The robotic rehabilitation program (with the Armeo Spring Pediatric Robotic Rehabilitation system) will be implemented 3 days a week for 30 minutes in addition to the conventional rehabilitation program. Participants will receive a total of 4 weeks of treatment.
48622874|NCT05883488|OTHER|Conventional rehabilitation|Conventional rehabilitation program will be applied 5 days a week, lasting 60 minutes.
47933615|NCT03442764|DRUG|mavacamten|MYK-461
47933616|NCT03442764|DRUG|Placebo|Placebo
47933617|NCT05648253|DEVICE|Hyivy Intravaginal Device|Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.
47933618|NCT03705624|OTHER|Enhanced Community Case Management (CCM)|Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
48098686|NCT06027151|DRUG|1ml of combination of 1% metronidazole gel and 2% minocycline|1ml of the combination of 1% metronidazole gel and 2% minocycline subgingivally at baseline visit
47933619|NCT03705624|OTHER|Monthly Screening and Treatment (MSAT)|Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
48456008|NCT04693533|DRUG|Fremanezumab Prefilled Syringe [Ajovy]|The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
48456009|NCT05150223|OTHER|traditional strength training|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.
48456010|NCT05150223|OTHER|Power training|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
48456011|NCT06003933|DRUG|Bupivacaine Hydrochloride|10 ml of 0.25% bupivacaine on each side of cervical region at C5
48456012|NCT06003933|DRUG|Lidocaine Hydrochloride|10ml xylocaine on each side of cervical region at C5
48456013|NCT06003933|DEVICE|Ultrasound|The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block.The five-layered posterior cervical muscles were identified at the level of C5 with a 6-15-MHz linear probe oriented in the transverse plane (SonoSite Edge, Bothell, Washington). The fifth cervical spine was counted from the C7 spinous process with the probe sliding cranially.
48622875|NCT06475976|DIAGNOSTIC_TEST|Chest computed tomography (CT) with angiography|A CT scan uses a doughnut-shaped machine to take x-rays in a circle around the body. CT scans help doctors learn about the structure of the lungs, heart, and blood vessels in the chest. A CT scan provides more information than regular x-rays. CT w/angiography - injection of intravenous contrast during the CT to image the blood vessels within the chest.
47933620|NCT00812643|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
47933621|NCT01840644|OTHER|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
47933622|NCT04562272|PROCEDURE|LV mechanical unloading by Impella-CP|The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
47933623|NCT01285687|DEVICE|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
47933624|NCT01689909|DRUG|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
48456014|NCT06003933|DEVICE|Needle|the needle (22- G, 50-mm block needle (Visioplex, Vygon) was introduced in-plane through the skin and advanced into the fascial plane between the semispinalis cervicis and semispinalis capitis muscles. After negative aspiration for blood, 20 ml of bupivacaine 0.25% was injected5.
48456015|NCT03572335|DIAGNOSTIC_TEST|PFT's (pulmonary function testing)|The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
48456016|NCT04333264|PROCEDURE|suction drainage|After primary total hip arthroplasty closed suction drainage will be used.
48456017|NCT04333264|PROCEDURE|no suction drainage|After primary total hip arthroplasty closed suction drainage won't be used.
48456018|NCT03444883|DRUG|Ilaprazole|10mgx2 tablet once daily for weeks
48456019|NCT02036086|DRUG|Vemurafenib|Drug
48622876|NCT06475976|DIAGNOSTIC_TEST|Bronchoscopy with bronchoalveolar lavage|During a bronchoscopy, a lung doctor inserts a small flexible camera into the breathing tube and main branches of the airways within the lungs. During the test, a small amount of sterile fluid is placed into the lung and then retrieved (lavage). This fluid is tested for evidence of infection.
48622877|NCT06475976|DIAGNOSTIC_TEST|Echocardiography|An echo uses sound waves to create computer pictures of the heart.
48622878|NCT06475976|DIAGNOSTIC_TEST|"24 hour esophageal pH (potential of hydrogen) - multichannel intraluminal impedance (MII) monitoring (reflux testing)"|24 hour pH/MII testing is used to measure gastroesophageal reflux. A small feeding tube like catheter is passed through the nose or mouth into the esophagus. The catheter is used to measure the frequency and acidity of reflux episodes during a 24 hour monitoring period.
48622879|NCT05524129|OTHER|rehabilitation exercise|Conventional rehabilitation exercise.
48622880|NCT05524129|OTHER|electrotherapy|A middle frequency electro-therapy
48622881|NCT02876081|DRUG|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
48622882|NCT02631681|BEHAVIORAL|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
47933625|NCT01689909|DRUG|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
47933626|NCT04255797|BEHAVIORAL|baby massage|The steps are as follows:1. Monitor the physiological indicators before massage, 2. Assist premature babies to lie on prone, take off their clothes and diapers, and then apply the baby's massage oil to the hands of both parents to warm them. 3. In the incubator, slight pressure touch the baby's body with warm palms and fingers.
48098687|NCT01646502|BIOLOGICAL|Esp protein|
48098688|NCT01646502|OTHER|Standard wound care|
48456020|NCT02036086|DRUG|Cobimetinib|Drug
48456021|NCT01193972|OTHER|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
48456022|NCT05633186|BEHAVIORAL|Moodbuster Life|All participants get access to the Moodbuster Life intervention. Moodbuster Life is an online self-help intervention that contains 5 web-based modules focusing on lifestyle and coping: psycho-education, behavioral activation, physical activity, problem-solving, and worrying. All participants start with module 1, psycho-education. Next, participants can choose what module they wish to continue with. All modules take about 45 minutes to complete and contain text, exercises, video clips and preparing the home-work assignments. Executing the home-work assignments may take 20 minutes each week.
48456023|NCT05633186|BEHAVIORAL|Mobile application|The participants randomized to receive this component will receive access to a mobile application. The aim of this app is two-folded, (1) used for diary ratings, (2) sending out personalized automated messages. First, the participants will rate their mood, sleep and related factors on a daily basis. The participants are prompted to rate the diary ratings three times a day (morning, afternoon, evening). Moreover, the application graphically pictures progression over time. Second, the application will send personalized automated messages. The content of the messages is informative, affirmative or encouraging. The investigators will use reinforcement learning (RL) to find so-called policies that show best long-term engagement and most sustained improvement of participants' mood. To drive choices, the investigators will use the data mentioned in the advising for the modules as well as behavioral data (mood ratings), data across all users is exploited.
48456024|NCT05633186|BEHAVIORAL|Guidance by a coach|A coach will provide support once per week at a scheduled time to participants who are allocated to receive support. The coaches are psychologists who are not part of the research team. The support will be provided via the Moodbuster Life messaging system and is focused on helping the participant work through the modules, showing empathy and motivating the participants to continue with the modules. The coaching is not aimed at developing a patient-therapist relationship.
48456025|NCT05633186|BEHAVIORAL|Motivational Content|Participants who are randomized to this component, receive access to extra content that is based on the principles of motivational interviewing. This includes an extended first module that contains psychoeducation on the importance of motivations and on how persons can motivate themselves to engage with the interventions. Participants are asked about their life goals (long term) and intervention goals (short time) and are guided in how they should formulate these goals to increase the chance of success. Moreover, in each of the 4 modules a short exercise aimed at increasing motivation is included.
48456026|NCT00433745|DRUG|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
48456027|NCT04637360|DRUG|Cinacalcet Tablets|All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.
48456028|NCT04637360|DRUG|calcitriol|All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
48456029|NCT02282722|OTHER|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
48456030|NCT02282722|OTHER|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
48456031|NCT00948792|PROCEDURE|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
48456032|NCT00948792|PROCEDURE|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
47933627|NCT02718300|DRUG|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
47933628|NCT02718300|DRUG|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
47933629|NCT02718300|DRUG|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
48280436|NCT00976430|PROCEDURE|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
48622883|NCT02082951|BEHAVIORAL|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
48456033|NCT01152645|DRUG|ARQ 197|Orally twice daily administration of ARQ 197
48456034|NCT04544800|DEVICE|Use of Splint for UADT Visualization|The use of a splint to assist the patient and the surgeon with UADT procedures.
48456035|NCT05803135|DRUG|Iguratimod combined with Tofacitinib;|Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily); Placebo of Iguratimod (taken orally, 25mg, bid, daily) combined with Tofacitinib (taken orally, 5mg, bid, daily)
47933630|NCT02718300|DRUG|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
47933631|NCT02718300|DRUG|Parsaclisib|"2 dose strategies will be compared:~1. 5 mg parsaclisib beginning on Day 1 until end of treatment.~2. 20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
47933632|NCT02820701|PROCEDURE|OMT|Osteopathic Manipulative Treatment to low back region
47933633|NCT04010539|DRUG|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
48280437|NCT04199923|BEHAVIORAL|Single leg immobilisation|Immobilisation with single leg suspension immobilisation
48280438|NCT00476138|DRUG|Epigallocatechin-gallate|
48280439|NCT02948894|DEVICE|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
48280440|NCT06494579|DRUG|Lamivudine|Lamivudine is used in the management of human immunodeficiency virus (HIV) and Hepatitis B Virus. It is being repurposed here to assess if this can improve response to cancer immunotherapy
48456036|NCT06485284|BEHAVIORAL|El Camino|"El Camino is a goal-setting sexual health promotion program. El Camino's lessons and activities:~* Are anchored in sexual health promotion and goal-setting~* Incorporate a goal achievement model throughout the curriculum~* Are designed with a focus on the needs of Latino youth~* Focus on the most effective forms of contraception, including long-acting reversible contraceptives~The El Camino curriculum contains eleven 45-minute lessons and is divided into three sections, or arcs. The three arcs focus on goal setting, sexual and reproductive health, and healthy relationships."
48456037|NCT06485284|BEHAVIORAL|Life skills program|Youth enrolled in the control condition will receive one of several curricula focused on life skills or leadership, depending on the site and implementation period. These curricula include PODER, an 11-session curriculum that focuses on youth leadership development; Youth Encuentros, a psychoeducational curriculum focused on mental health; El Joven Noble, a youth leadership curriculum; and Courageous Queens, a socio-emotional and character strengthening curriculum.
48456038|NCT01325909|BEHAVIORAL|Exercise programme|
48456039|NCT05567003|PROCEDURE|Percutaneous transhepatic cholangioscopic (PTCS) laser incision|Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.
48456040|NCT03793803|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
47933634|NCT04010539|DRUG|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
48456041|NCT06596889|PROCEDURE|Successful airway management|"* Types of equipment: Traditional oral airways, new airways, etc.~* Professional experience of the airway management practitioner (in years).~* If advanced, type of airway complication (bleeding, dental damage, mucosal damage, etc.), number of attempts~will be recorded separately for each patient."
48456042|NCT03866265|DIETARY_SUPPLEMENT|Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)|Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.
48456043|NCT03866265|OTHER|Placebo|Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
48456044|NCT06200363|DRUG|T3011|T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.
48456045|NCT06200363|DRUG|Regorafenib|Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.
48456046|NCT00170677|DRUG|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
48456047|NCT00170677|DRUG|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
48456048|NCT00464763|DRUG|Dexmedetomidine|
48456049|NCT00464763|DRUG|Placebo|
48456050|NCT03986294|DRUG|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
48456051|NCT03986294|DRUG|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
48456052|NCT03778307|BEHAVIORAL|Psychophysiological fear conditioning and extinction task|Behavioral task to assess psychophysiological measures of fear
48456053|NCT03778307|BEHAVIORAL|Eyetracking task|Behavioral task to assess dysphoria-relevant attention allocation
48456054|NCT03073850|DRUG|Antiplatelet|ASA or clopidogrel
48456055|NCT03073850|DRUG|Low dose oral anticoagulant|Edoxaban of 30mg
48456056|NCT03073850|DRUG|Standard dose oral anticoagulant|Edoxaban of 60mg
48456057|NCT03786341|DEVICE|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
48456058|NCT06556329|OTHER|Robot (Intervention)|The research team will bring a socially assistive, artificially-enhanced robot during intravenous insertion procedures.
48456059|NCT02512900|DRUG|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
47933635|NCT04010539|DRUG|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
48456060|NCT05884957|DIAGNOSTIC_TEST|Nitric oxide synthase gene|Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
47933636|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which \<2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
48456061|NCT05297227|PROCEDURE|Non surgical periodontal Therapy|Non-surgical periodontal therapy comprising oral hygiene instruction and motivation, professional mechanical plaque removal, and subgingival instrumentation will be performed. It consists in the use of an ultrasuond (piezoeletric device) and manual curettes.
48456062|NCT00700739|DEVICE|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
48456063|NCT00700739|DEVICE|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
48456064|NCT01773408|DRUG|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
48280441|NCT06494579|DRUG|PD-L1 Blocker|PD-1 or PD-L1 blocking antibodies; there are around a dozen of these FDA approved for varying indications, and whatever is administered to a patient as standard of care (FDA APPROVED) will be continued in the patients and administered in combination with lamivudine.
48456065|NCT01773408|DRUG|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
48456066|NCT01773408|DRUG|Idarubicin|Idarubicin will be administered as per standard clinical practice.
48456067|NCT01773408|DRUG|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
48456068|NCT01773408|DRUG|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m\^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m\^2 IV infusion daily.
48456069|NCT05750849|PROCEDURE|BLOOD COLLECTION FOR P4 DETERMINATION|Serum progesterone levels on the pregnancy test day
48456070|NCT03632031|DEVICE|Oasis Extracellular Matrix|Patients will receive OASIS Extracellular Matrix according to the Instruction for Use
48456071|NCT05073380|BEHAVIORAL|Intervention Group - PRO-ECO Intervention|The PRO-ECO intervention will be tailored to individual sites. Through collection of focus group and baseline data, the intervention will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective interventions outlined in the literature have informed the development of the intervention foundation and potential tailoring.
48456072|NCT05073380|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO intervention.
48456073|NCT01572857|BIOLOGICAL|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
48456074|NCT03393780|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
48456075|NCT03017729|BIOLOGICAL|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
48456076|NCT03300011|DEVICE|stent|PTCA or PCI
48456077|NCT04175158|BIOLOGICAL|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
48456078|NCT04175158|BIOLOGICAL|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
48456079|NCT03997799|PROCEDURE|uniportal lobectomy with complete lymphadenectomy|uniportal lobectomy with complete lymphadenectomy
48456080|NCT00669721|DRUG|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
48456081|NCT00669721|DRUG|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
48456082|NCT03867890|OTHER|no intervention|
48456083|NCT06476093|DRUG|Anlotinib hydrochloride|Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends
48280442|NCT04205435|BIOLOGICAL|β-globin restored autologous HSC|gene edited autologous hematopoietic stem cells with β-globin restoration
48280443|NCT00282243|DRUG|tacrolimus modified release (MR)|Oral
48280444|NCT00282243|DRUG|tacrolimus|Oral
48280445|NCT03487445|DRUG|Selatogrel 8 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.
48280446|NCT03487445|DRUG|Selatogrel 16 mg|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
48280447|NCT00751894|DRUG|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
48456084|NCT05163886|DRUG|LAM-002A|LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
48456085|NCT05163886|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, size 0 capsules.
48456086|NCT02036788|OTHER|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
48456087|NCT02036788|OTHER|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
48456088|NCT04652622|DEVICE|Mindful Garden|Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
48456089|NCT01216865|BIOLOGICAL|umbilical cord mesenchymal stem cells|5\*10/7 per ischemic limb
48456090|NCT01216865|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
48456091|NCT00835146|DRUG|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
48456092|NCT00835146|DRUG|COPEGUS™|1 x 200 mg, single-dose fasting
48456093|NCT03520972|DRUG|PB-119 75ug|60 eligible patients will be included in this group
48456094|NCT03520972|DRUG|PB-119 150ug|60 eligible patients will be included in this group
48280448|NCT01449838|DRUG|Colistimethate sodium|active
48456095|NCT03520972|DRUG|PB-119 200ug|60 eligible patients will be included in this group
48456096|NCT03520972|DRUG|placebo|60 eligible patients will be included in this group
48456097|NCT06628180|DEVICE|LIFU|Application of low-intensity focused ultrasound for neuromodulation
48456098|NCT06628180|DEVICE|Sham LIFU|Sham application of LIFU - will appear the same to participants.
48456099|NCT04670107|DRUG|Anlotinib in combination with Immune checkpoint inhibitors|Enrolled patients received anlotinib plus Pembrolizumab treatment (anlotinib, 8-12mg, qd, 2 weeks in a row and 1 week off; anti-PD1 injection or anti-PDL1 injection, Following instructions, iv.)
48456100|NCT04917991|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil-enriched chocolate spread|the intervention consists in the administration of 100g Extra Virgin Olive Oil-enriched chocolate spread each day for 14 days.
48456101|NCT04917991|DIETARY_SUPPLEMENT|Palm Oil-enriched chocolate spread|the intervention consists in the administration of 100g Palm Oil-enriched chocolate spread each day for 14 days.
48456102|NCT06196047|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
48456103|NCT06196047|DRUG|Cilostazol 100 MG|Efficacy and safety of 200 mg loading dose of cilostazol administered within 24 hours of first-ever ischemic stroke followed by 100 mg bid for 3 months will be assessed through NIHSS, mRS, new ischemic stroke, and possible adverse effects.
48456104|NCT05917522|BIOLOGICAL|Abatacept|Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
48456105|NCT05917522|PROCEDURE|Standard of Care at US Transplant Centers|Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
48098689|NCT05980468|OTHER|music therapy|Music intervention sessions will be applied to each participant for 5 weeks, 3 days a week, 20 minutes per session.
48098690|NCT00225719|DRUG|rHDL|
48098691|NCT04903028|DEVICE|Sham rTMS|Two electrodes on the scalp will be connected to transcutaneous electrical nerve stimulation.
48280449|NCT01449838|DRUG|Saline|placebo
48280450|NCT04673357|DRUG|Ustekinumab|Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.
48280451|NCT04673357|DRUG|Placebo|Matching placebo will be administered as SC injection.
48280452|NCT02945592|BEHAVIORAL|Cueing|
48280453|NCT04126837|OTHER|Diagnosis and treatment|Monocentric, Prospective and Biomedical Research excluding Health Product
48280454|NCT01262898|DRUG|GSK962040 (5 mg tablet)|5 mg tablet
48456106|NCT02658487|DRUG|Cytarabine|Given IV
48456107|NCT02658487|DRUG|Vosaroxin|Given IV
48456108|NCT05329311|PROCEDURE|ERATS protocol applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying the ERATS protocol will be investigated.
48456109|NCT05329311|PROCEDURE|ERATS protocol not applied|Inflammatory parameters (such as; C-reactive protein (CRP), white blood cell count, neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), lymphocyte/monocytes ratio (LMR) of the operated patients by applying without the ERATS protocol will be investigated.
48456110|NCT03172286|DEVICE|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
48456111|NCT06149767|DRUG|Adebrelimab|"The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances:~Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times.~First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。"
48456112|NCT04906148|OTHER|Advertisement content (explicit vs. implicit)|Participants will be randomly assigned to view an advertisement with either implicit or explicit harm messaging content
48456113|NCT04906148|OTHER|Advertisement content (true vs. misleading)|Participants will be randomly assigned to view an advertisement with either true or misleading messaging content
48456114|NCT04904094|OTHER|Casting of the lower limb and homebased stretching exercise program.|Lower leg casting in combination with removable upper leg casts for approximately 2 weeks and stretching exercises during casting and 4 weeks after casting.
48456115|NCT04125394|DEVICE|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
48456116|NCT01637480|OTHER|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
47933637|NCT00702572|DRUG|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
48456117|NCT04766905|PROCEDURE|Mini Lateral Shoulder Approach (MLSA)|"The skin incision is about 4 to 5 cm made by the distal acromial edge in sagittal plane, The dissection takes place slightly over the acromial edge proximally and over the origin of the acromial deltoid part (the middle part of deltoid origin) distally.~After clearly revealing the region of the medial deltoid origin on the acromion, the acromionic deltoid origin is skinned only; of the edge of the acromion, and that maybe accrued by electric knife pen or periosteal elevator, without exposure the clavicular deltoid origin in the front and the deltoid origin on the spine of scapula in the back, the origin of the acromial deltoid is distanced laterally and distally, where the lateral edge, the lower surface of the acromion, under acromial bursa and the rotator cuff are exposed clearly."
47933638|NCT01178827|DRUG|trospium chloride|trospium chloride (60mg) once daily for 10 days
47933639|NCT01178827|DRUG|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
47933640|NCT01178827|DRUG|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
47933641|NCT03518749|OTHER|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
47933642|NCT03518749|OTHER|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
48622884|NCT02082951|BEHAVIORAL|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
47933643|NCT03518749|BEHAVIORAL|Cognitive control training|cognitive control training with the PASAT
47933644|NCT03865576|DIAGNOSTIC_TEST|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
47933645|NCT00006487|DRUG|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
47933646|NCT00006487|DRUG|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
47933647|NCT00006487|DRUG|tirapazamine|"During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
47933648|NCT00006487|RADIATION|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
47933649|NCT02591771|DRUG|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
47933650|NCT00688207|DRUG|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
47933651|NCT01155479|DRUG|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
48098692|NCT04903028|DEVICE|Active rTMS 10 Hz DLPFC|10 Hz repetitive transcranial magnetic stimulation (rTMS) will be delivered over left dorsolateral prefrontal cortex (DLPFC).
48622885|NCT00149643|DRUG|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
47933652|NCT01155479|DRUG|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
47933653|NCT01155479|DRUG|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
47933654|NCT01155479|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
47933655|NCT01155479|DRUG|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
48098693|NCT00422201|DRUG|Mifepristone|Singe dose
48280455|NCT01262898|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
47933656|NCT01155479|DRUG|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
47933657|NCT00442884|BEHAVIORAL|Trier Social Stress Test (TSST)|
47933658|NCT02514954|DRUG|Biochaperone® Combo|Subcutaneous injection of an individualized dose
47933659|NCT02514954|DRUG|Humalog® Mix25|Subcutaneous injection of an individualized dose
47933660|NCT05956210|DEVICE|Evaluation of implementation regarding Philips Healthdot as monitoring device of hospitalized patients at one surgical ward|Hospitalized patients at one surgical ward will receive a Healthdot as monitoring device which will be used as primary monitoring after 3 months of preparation with education of hospital staff, improving infrastructure and training with application, activation and interpretation
47933661|NCT05644847|OTHER|Whole Body Vibration Training|WBV training will be performed on a commercial vibrating platform (Healthmate HM01-08VF Gym Fitness Equipment Step Vibration Machine, China), which produces vertical sinusoidal vibrations. Participants in the dynamic WBV group will be provided with dynamic exercises along with WBV training. The vibration speed level will be progressed from level 5 to level 10 during the course of the treatment sessions
48098694|NCT00506519|DRUG|Antithrombin alfa (INN name)|
48098695|NCT00506519|DRUG|Control (Standard treatment)|
48098696|NCT01333514|DRUG|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
48098697|NCT01333514|DRUG|aspart- Insulin|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
48456118|NCT00848536|DRUG|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
48456119|NCT00848536|DRUG|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
48456120|NCT03633721|DRUG|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
48456121|NCT03633721|OTHER|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
48456122|NCT01750073|DRUG|Cyclophosphamide|Given IV
48456123|NCT01750073|DRUG|Doxorubicin Hydrochloride|Given IV
48456124|NCT01750073|OTHER|Laboratory Biomarker Analysis|Correlative studies
48456125|NCT01750073|DRUG|Paclitaxel|Given IV
48456126|NCT01750073|RADIATION|Radiation Therapy|Undergo RT
48456127|NCT01750073|PROCEDURE|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
48456128|NCT01750073|BIOLOGICAL|Trastuzumab|Given IV
48456129|NCT03210038|DRUG|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
48456130|NCT03210038|DRUG|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
48456131|NCT06620939|DRUG|Levonorgestrel Intrauterine System (LNG-IUS)|Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy
48456132|NCT02294981|DEVICE|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
48456133|NCT03090880|DRUG|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
48456134|NCT03185208|DRUG|Lithium Carbonate|See lithium carbonate arm
48456135|NCT03185208|DRUG|Placebo oral capsule|See placebo arm
48456136|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy
48456137|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab
48456138|NCT06485557|DRUG|sintilimab plus platinum-based chemotherapy|The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.
48456139|NCT06314633|OTHER|Hair cut|Hair locks and follicles will be cut twice in winter and spring
48456140|NCT06314633|OTHER|Socio-economic questionnaires|Information about parents education levels and professional occupation, geographic area, children gender, indoor and outdoor children's environmental exposures
48456141|NCT00870558|DRUG|ethiodized oil|Given as an intra-arterial infusion
48456142|NCT00870558|RADIATION|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
48098698|NCT04962334|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula.|Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
48456143|NCT06212076|DRUG|IPG1094|IPG1094 Activity: An inhibitor of macrophage migration inhibitory factor (MIF) Dosage form: Tablet Strength: 50 mg and 100 mg
48456144|NCT04125862|DIAGNOSTIC_TEST|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
48456145|NCT04125862|DIAGNOSTIC_TEST|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
48456146|NCT04125862|DIAGNOSTIC_TEST|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
48456147|NCT04125862|DIAGNOSTIC_TEST|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be \~3-4 mSv.
48456148|NCT00637533|PROCEDURE|Lumbar sympathetic block with Botulinum Toxin type A|
48456149|NCT03808519|DIETARY_SUPPLEMENT|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
48456150|NCT03808519|DIETARY_SUPPLEMENT|Placebo|Organic Sunflower Oil 5000mg per day
48622886|NCT00149643|OTHER|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
48456151|NCT06449534|BEHAVIORAL|Patient Education|It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.
48456152|NCT06449534|BEHAVIORAL|Exercise Therapy|Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.
48456153|NCT06449534|BEHAVIORAL|Cold Application|Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.
48456154|NCT05570539|DRUG|BLU-5937 IR|Each subject will receive two single and multiple administrations of Immediate Release reference formulation
48456155|NCT05570539|DRUG|BLU-5937 ER|Each subject will receive single and multiple oral administrations of Extended Release formulation
48456156|NCT05657587|DEVICE|SPRINT PNS|Each subject will have 2 leads placed for 60 days. The Sprint system delivers mild electrical stimulation to the shoulder. The Sprint system includes up to two leads (small wires) that are placed through your skin in your shoulder. The leads attach to devices worn on your body that delivers stimulation (stimulators).
48456157|NCT05870215|OTHER|Visit 1: Clinical exam and questionnaires|Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.
48456158|NCT05870215|OTHER|Visit 1: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
48456159|NCT05870215|OTHER|Visit 1: Inflammometry|Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray
48456160|NCT05870215|OTHER|Visit 2: Clinical exam and questionnaires|Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.
48456161|NCT05870215|OTHER|Visit 2: Respiratory physiology|FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).
48456162|NCT05870215|OTHER|Visit 2: Inflammometry|SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)
48456163|NCT05870215|OTHER|Visit 3: e-mail|ACQ-5, peak flow measurement, and questions about the patient's asthma management.
48456164|NCT04640129|DRUG|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
48456165|NCT04640129|DRUG|Tenofovir Disoproxil Fumarate|TDF monotherapy
47933662|NCT05644847|PROCEDURE|Core Stability Training|Core stability exercises will include pelvic bridge, straight leg bridge, modified kneeling with elbow support and leg lifts and squats, with 60 seconds rest interval between each activity. All these core exercises will be performed on a stable surface and will be progressed in difficulty by increasing the no. of repetitions and no. of sets on a weekly basis. Every session will be preceded by 5 minutes of warm-up and end with 5 minutes of cool-down exercises.
48456166|NCT05328908|DRUG|Nivolumab-relatlimab FDC|Specified dose on specified days
48456167|NCT05328908|DRUG|Regorafenib|Specified dose on specified days
47933663|NCT03224780|DIAGNOSTIC_TEST|maternal serum creatine kinase|Biochemical marker
47933664|NCT03224780|DIAGNOSTIC_TEST|3D Doppler ultrasound|Doppler for placental vessels
47933665|NCT03272789|OTHER|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
47933666|NCT00456807|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
47933667|NCT00456807|BIOLOGICAL|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
47933668|NCT01040078|BIOLOGICAL|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
47933669|NCT01040078|BIOLOGICAL|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
47933670|NCT01040078|BIOLOGICAL|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
48456168|NCT05328908|DRUG|TAS-102|Specified dose on specified days
48622887|NCT04661631|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.
47933671|NCT04059367|DRUG|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
48280456|NCT01262898|DRUG|GSK962040 (125 mg tablet)|125 mg tablet
47933672|NCT04059367|DRUG|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
47933673|NCT05651568|OTHER|Periodized resistance training|"It consists of patients who will receive periodized resistance training 3 sessions per week for 8 weeks. Resistance training has been performed according to FITT principal and as per ACSM recommendation.~Frequency:~Three days in a week~Intensity:~60% intensity with one repetition maximum and 10% intensity were added each the two weeks.4 sets and 8-12 rep as per ACSM criteria. There will be rest of 60 second after every set and 120 seconds after every exercise.~Type:~8 types of resistance exercises were performed. There were 4 set of each exercise with 8 to 12 repetitions. These exercises are smith press, seated press, squat, lying dumbbell leg curls, leg extension, leg press, standing barbell, lying barbell and sit ups.~Time:~40 minutes per session."
47933674|NCT05651568|OTHER|High intensity interval training|"It consists of patients who will receive high intensity interval training 3 sessions per week for 8 weeks for 30 to 35 minutes.~Active phase: Two weekly sessions of four times four minutes at 90-95% of individual heart rate maximum, separated by three minutes of active rest period and one weekly session of ten times one minute with maximal intensity, separated by one minute of active rest. The exercise mode will be treadmill or outdoor walking/running or cycling (self-selected)."
47933675|NCT00647218|DRUG|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
47933676|NCT00647218|DRUG|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
48456169|NCT06558812|DEVICE|prefabricated space maintainer|"i. Prefabricated band will be selected for the abutment tooth by measuring the mesiodistal diameter of the abutment tooth with a caliper and will be adjusted with the internal diameter of the prefabricated band.~ii. The loop will be selected based on the available mesiodistal space and buccolingual width of the abutment tooth, excessive length with be cut by cutting plier and will then place inside the band's tube by using a HOWE pliers.~iii. Cotton roll isolation will use, then will be cemented with glass ionomer,"
48456170|NCT06558812|DEVICE|conventional space maintainer|"i. A full arch Impressions will be taken with alginate material. ii. Impressions will be poured up using dental stone within 30 min of the impression taking.~iii. The children will be given an appointment for space maintainer insertion. iv. In the second visit , Cotton roll isolation will use, cementation will be performed with glass ionomer ."
47933677|NCT00647218|PROCEDURE|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
48456171|NCT02267707|DRUG|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
48456172|NCT02267707|DRUG|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
48456173|NCT02975856|DIETARY_SUPPLEMENT|Table Red Wine|
48456174|NCT02975856|DIETARY_SUPPLEMENT|Young Port Red Wine|
48456175|NCT01370122|OTHER|Survey|
48456176|NCT06209749|OTHER|Sensory-based intervention module|Consists of sensory-based activities (Set A-F) with six weeks of individual sessions and six weeks of group sessions
47933678|NCT00647218|RADIATION|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
47933679|NCT00647218|DRUG|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
47951358|NCT04021108|DRUG|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
48098699|NCT04962334|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (powder added to water) without added vitamins and minerals
48106852|NCT03772379|DEVICE|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
48456177|NCT02507128|DRUG|liraglutide|Liraglutide were taken 30 min before PCI.
48456178|NCT02507128|DRUG|placebo|Placebo were taken 30 min before PCI.
48456179|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
48456180|NCT03131895|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
48456181|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
48456182|NCT03131895|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
48456183|NCT05814783|BEHAVIORAL|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
48456184|NCT05814783|DEVICE|digital CBTI|CBTI app
48622888|NCT04942600|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
48622889|NCT04925934|DRUG|VIB7734|VIB7734
48622890|NCT04925934|OTHER|Placebo|Placebo
48622891|NCT01986998|DRUG|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
48622892|NCT01986998|DRUG|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
48622893|NCT02515253|OTHER|Bra prescription|
48622894|NCT02515253|OTHER|Standard Care|
48622895|NCT05693220|DEVICE|Zymot Multi sperm separation device|Sperm preparation with Zymot Multi sperm preparation device
48622896|NCT05693220|OTHER|Density gradient centrifugation|Sperm preparation with density gradient centrifugation
48456185|NCT05291819|OTHER|Imaging informed treat-to-target|"A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~* If evidence of enthesitis (power Doppler\>0 in enthesis) or axial inflammation (SPARCC score ≥ 2\* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~* If evidence of ongoing inflammation (power Doppler\>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target"
48456186|NCT05291819|OTHER|Conventional treat-to-target|Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
47933680|NCT03899688|PROCEDURE|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
47933681|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
47933682|NCT02155946|DEVICE|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
47933683|NCT00736177|PROCEDURE|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
47933684|NCT00736177|PROCEDURE|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
47933685|NCT01989260|DEVICE|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
47933686|NCT01603238|DRUG|[14C]-LC15-0444|A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
47933687|NCT00081965|PROCEDURE|acupuncture therapy|
47933688|NCT00081965|PROCEDURE|hot flashes attenuation|
47933689|NCT00081965|PROCEDURE|management of therapy complications|
47933690|NCT06288789|OTHER|Social Frailty Index|Social Frailty Index will be applied twice, one week apart.
47933691|NCT02914405|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
47933692|NCT02914405|DRUG|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
48456187|NCT03125408|DIAGNOSTIC_TEST|HCV Assay|Molecular diagnostic test to detect Hepatitus C
48456188|NCT02216981|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|
48456189|NCT00000956|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
47933693|NCT05649202|OTHER|Xpert® HCV Viral test|an additional sample of 5 ml of blood will be taken for real-time HCV PCR by Xpert®, in addition to the blood samples taken as part of routine care.
47933694|NCT05649202|OTHER|FibroScan® test|A non invasive test made on a small area of skin coated with a gel
47933695|NCT03052543|DEVICE|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
48456190|NCT01430533|DRUG|azelaic acid pre foam formulation|
48456191|NCT01430533|DRUG|Vehicle pre foam formulation|
48456192|NCT01430533|DRUG|Water|
47933696|NCT00358072|BEHAVIORAL|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
48456193|NCT05586880|OTHER|Experimental: EnXtra 300 mg/ capsule|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
48456194|NCT05586880|OTHER|Microcrystalline cellulose (MCC) 300mg|One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
48456195|NCT03602339|DRUG|Gadoterate (Dotarem/Clariscan)|Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
48456196|NCT03602339|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
48622897|NCT04735302|OTHER|Radiographic Feature|Radiographic rewiev
48622898|NCT03361345|DRUG|Tranexamic Acid|Topical tranexamic acid in cream form applied to dark spots on right side of face.
47933697|NCT02025556|DRUG|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
48280457|NCT01262898|DRUG|Placebo|matching placebo tablet
48456197|NCT04320563|PROCEDURE|Rexon-eye|This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
48456198|NCT05311072|PROCEDURE|pulmonary endarterectomy or balloon pulmonary angioplasty|A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
48456199|NCT06128967|DRUG|Fluvoxamine Maleate 100 MG|Fluvoxamine Maleate 100 mg each pills
48622899|NCT03361345|DRUG|Vehicle|The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
48622900|NCT04832217|OTHER|Pyrenees´ Beef diet|24 participants were randomly assigned to a Pyrenees' beef diet, 3 serving per week during of 8 weeks.
47933698|NCT02025556|DRUG|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
47933699|NCT02025556|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
48456200|NCT06128967|DRUG|Placebo|Placebo talc pills of same shape, color, weight if compared with active comparator
48456201|NCT06128967|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended release oral tablets of 750 mg each pill
48456202|NCT05936645|PROCEDURE|A temporary sub-placental Uterine Tourniquet in management of Placenta Accreta Spectrum disorder by a retrograde cesarean hysterectomy (Bladder Last)|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
48456203|NCT05936645|PROCEDURE|Retrograde cesarean hysterectomy (Bladder Last) for management of Placenta Accreta Spectrum disorder|Comparing the use of a temporary sub-placental uterine tourniquet versus no tourniquet in reducing blood loss in patients with Placenta Accreta Spectrum disorder undergoing cesarean hysterectomy.
48456204|NCT05837832|DIETARY_SUPPLEMENT|Milk-based phospholipids|Powder based, fat-rich fraction of whey dissolved in water. Contains lactose.
48456205|NCT06555939|BEHAVIORAL|Collaborative Care Model|The interprofessional team will meet weekly to review survey scores, endorsed psychological and physical health needs, as well as other concerns. They will conduct assessments as a group that may include referrals for additional support.
48456206|NCT06555939|BEHAVIORAL|Promoting Resilience in Stress Management|PRISM targets 4 resilience resources: stress management, goal-setting, cognitive reframing and meaning-making. It is delivered one-on-one by trained coaches in English or Spanish via HIPAA compliant video-conference or in-person. Sessions are delivered every 1-2 weeks based on patient preference. To facilitate practice between sessions, all participants 13 or older have access to the digital PRISM app.
48456207|NCT06119685|DRUG|IDP-023|NK cell therapy
48456208|NCT06119685|DRUG|Rituximab|Anti-CD20 antibody therapy
48456209|NCT06119685|DRUG|Daratumumab|Anti-CD38 antibody therapy
48456210|NCT06119685|DRUG|Interleukin-2|Immune cytokine
48456211|NCT06119685|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
48456212|NCT06119685|DRUG|Fludarabine|Lymphodepleting chemotherapy
48456213|NCT06119685|DRUG|Mesna|Chemoprotectant
48456214|NCT03223779|DRUG|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
48456215|NCT03223779|RADIATION|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
48456216|NCT06626854|DEVICE|RF-PNS|Noninvasive peripheral nerve stimulator using interferential multi source radio frequency
48456217|NCT04609280|RADIATION|Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)|Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
47933700|NCT05478954|DRUG|Sulfadoxine pyrimethamine|"Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~The medicine is no longer recommended for the treatment of malaria. However, it is being used for Intermittent Preventive Treatment during pregnancy (IPTp) and as a co-packaged combination with amodiaquine for seasonal malaria chemoprevention.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug."
48280458|NCT06657287|OTHER|Mixed meal test|The biochemical parameters, blood pressure, and heart rates of participants undergoing the mixed meal test will be recorded over a 5-hour period.
48456218|NCT00849797|DRUG|Oxcarbazepine|600 mg Tablet
48280459|NCT05502289|DEVICE|TEST LENS|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
48456219|NCT00849797|DRUG|Trileptal®|600 mg Tablet
48280460|NCT05502289|DEVICE|CONTROL LENS|PRECISION1™ for Astigmatism Contact Lenses (P1fA)
48456220|NCT02424435|DRUG|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
48456221|NCT04922554|DRUG|Omadacycline Oral Tablet|omadacycline 300 mg orally, once daily (150 mg tablets x 2)
48456222|NCT04922554|DRUG|Placebo|placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
48456223|NCT02495207|DEVICE|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
48456224|NCT05546060|DRUG|Venetoclax|Venetoclax 100mg qd d1，200mg qd d2，400mg qd d3-56
48456225|NCT05546060|DRUG|Dexamethasone|Dexamethasone 10mg/m2 qd d1-14, 5mg/m2 qd d15-28, 2.5 mg/m2 qd d29-42, and 1.25mg/m2 qd43-56
48456226|NCT05546060|DRUG|Etoposide|Etoposide 75mg/m2 qw d1-56
48456227|NCT03599193|DRUG|Tazarotene Lotion, 0.1%|DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
48456228|NCT03599193|DRUG|Tazarotene Cream, 0.1%|Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
48456229|NCT01609257|BIOLOGICAL|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
48456230|NCT01609257|BIOLOGICAL|Saline Comparator|2 doses IM 28 days apart
47951359|NCT03267251|OTHER|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
47951360|NCT03267251|OTHER|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
47951361|NCT00000432|BEHAVIORAL|Education about disease prevention|
48456231|NCT06118697|PROCEDURE|Esophageal stimulation with high resolution esophageal manometry and nutritive oral feeding therapy|Subjects will be given weekly pharyngo-esophageal stimulation guided by high resolution impedance manometry for 4 weeks. During this time of study intervention, every feed will start with nutritive oral stimulation with at least 5 mL of the infant's prescribed diet.
48456232|NCT01277276|DEVICE|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
48456233|NCT05025137|OTHER|Flexi-Bar Exercise|"In the experimental group, the Flexi-Bar was adopted as the tool for active vibration exercises. Featuring light weight and ease of operation, it weighs only 460 grams and has a vibration frequency of 4-5 Hz. With diversified functions, the Flexi-Bar can improve posture, burn fat, strengthen connective tissue, enhance body shape, and increase muscle strength.~The 12-week Flexi-Bar exercise course in this study was created by two assistant professors specializing in rehabilitation (one with an occupational therapy certificate and the other with a physical therapy certificate). The course, composed of one 60-minute class per week for a total of 12 weeks, progressed gradually from basic activities (e.g., standing with both feet) to advanced activities (e.g., standing with one foot)."
48456234|NCT05025137|OTHER|Multi-Component exercise|Alternatively, in the control group, the Multi-Component exercise was adopted, which included aerobic, resistance, flexibility, and balance exercises. The course was composed of one 60-minute class per week for a total of 12 weeks. The design was based on the ACSM's recommendations for the multiple-component exercise of the elderly (Chodzko-Zajko et al., 2009) and videos of the National Health Exercises for the Elderly formulated by the Ministry of Health and Welfare (Ministry of Health and Welfare, 2017). The course was created and led by a physical therapist to gradually progress from sitting postures to standing and walking postures. Additionally, the intensity of the exercises was adjusted according to the participants' physical conditions; fitness equipment was introduced when appropriate.
48456235|NCT01993186|DRUG|UX007|oral liquid
48456236|NCT01993186|DRUG|Placebo|oral liquid
48456237|NCT00807495|DRUG|Alisertib|Alisertib capsules
48456238|NCT05212350|PROCEDURE|Total pancreatectomy|Patients randomized to receive total pancreatectomy at the time of transection of the pancreas will undergo completion total pancreatectomy according to each Institution's operative standards.
48456239|NCT05212350|PROCEDURE|Pancreatic anastomosis|Patients randomized to receive pancreatic anastomosis at the time of transection of the pancreas will undergo pancreatico-jejunosomy or pancreatico-gastrostomy according to each Institution's operative standards.
48456240|NCT06561542|DRUG|LX22001 for Injeciton|single dose: 25mg,50mg,100mg,200mg ,intravenous infusion. repeat doses: 50mg,100mg , intravenous infusion,once daily for 3 days.
48456241|NCT06561542|DRUG|Tegoprazan tablet|50mg,oral,single dose
48456242|NCT06561542|DRUG|Esomeprazole sodium for injection|80 mg intravenous infusion for 30 min followed by a continuous infusion of 8 mg/h for 71.5h
48456243|NCT04857138|DRUG|RO7300490|Participants will receive RO7300490, as described in the Arm Descriptions.
48456244|NCT04857138|DRUG|Atezolizumab|Participants will receive Atezolizumab, as described in the Arm Descriptions.
48456245|NCT05542056|OTHER|Data and biosample collection|Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
48456246|NCT04404439|DRUG|Nortriptyline + topiramate|Treatment group 1
48456247|NCT04404439|DRUG|Verapamil + paroxetine|Treatment group 2
48456248|NCT04404439|OTHER|Placebo|Placebo comparator
48456249|NCT06190977|OTHER|Otago Exercise Program|Exercises will include Intensity: 10 repetitions of each set for the first two weeks and 15 repetitions of each set for the last two weeks, Frequency 3 sessions per week for 4 weeks. Time= 40-45 minutes
48456250|NCT06190977|OTHER|General TKR pprotocol|Exercises will include Intensity: 10 repetitions of each set, Frequency 5 sessions per week for 4 weeks. Time= 30 minutes
48456251|NCT01264523|OTHER|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
48456252|NCT03354338|DRUG|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
48456253|NCT03354338|OTHER|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
48456254|NCT00976443|DRUG|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
48456255|NCT00976443|DRUG|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
48456256|NCT00773149|DRUG|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
48456257|NCT01687335|OTHER|answering questionnare in differents time of the treatment|
48456258|NCT02926040|PROCEDURE|Irreversible electroporation|
48456259|NCT01394094|BEHAVIORAL|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
48456260|NCT05250323|OTHER|observational tests in face-to-face visit|All necessary evaluations will be carried out for data collection. Also, that same day, the investigators will give the device to participants for the 7-day home assessment
48456261|NCT03531827|DRUG|enzalutamide|enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
48456262|NCT03531827|DRUG|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
48456263|NCT06219941|DRUG|AZD0901|Antibody-drug conjugate/Biologic
47951362|NCT04879225|BEHAVIORAL|Tobacco e-liquids|Marketplace includes tobacco flavored e-liquids
48456264|NCT06219941|DRUG|5-Fluorouracil|Chemotherapy agents
47933701|NCT05478954|DRUG|Amodiaquine|"Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine. Desethylamodiaquine is responsible for all the antimalarial effect. Adverse effect of amodiaquine includes abdominal discomfort and vomiting weakness and when used for prophylaxis it causes agranulocytosis. Amodiaquine is recommended as a partner drug in artemisinin based combination therapy."
47933702|NCT03843710|DRUG|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
47933703|NCT02088515|DRUG|Nedaplatin|
47933704|NCT02088515|DRUG|Cisplatin|
47933705|NCT02088515|DRUG|Docetaxel|
47933706|NCT04052724|BEHAVIORAL|Intervention group LINGI|Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
47933707|NCT01692821|DRUG|100% oxygen breathing|100% oxygen breathing - 30 minutes
47933708|NCT01692821|DRUG|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
47933709|NCT01692821|DRUG|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
47933710|NCT02696187|BEHAVIORAL|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
47933711|NCT04396184|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
47933712|NCT03891667|DRUG|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
47933713|NCT06408155|OTHER|Isometric Task|The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
47933714|NCT06381271|PROCEDURE|Transcatheter aortic valve replacement|A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
47933715|NCT04109898|DEVICE|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
47933716|NCT00531986|DRUG|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
47933717|NCT00531986|DRUG|HAART|Patients will continued their current HAART
47933718|NCT01991639|OTHER|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
48098700|NCT06475599|DRUG|Anlotinib hydrochloride capsule + TQB2450 injection|"Anlotinib hydrochloride capsule is a multi-target tyrosine kinase inhibitor, which targets VEGFR (VEGFR-1, VEGFR-2 and VEGFR-3), PDGFR, FGFR and c-Kit, etc. It can inhibit tumor progression by inhibiting angiogenesis and tumor growth at the same time.~TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1) that prevents the binding of PD-L1 to the PD-1 and B7.1 receptors on the T-cell surface, allowing T-cell reactivation and thus enhancing the immune response."
48280461|NCT06203431|DRUG|ET-26|freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
47933719|NCT01736657|DEVICE|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
47933720|NCT00453960|DIETARY_SUPPLEMENT|Genivis|54 mg/day daily for 6 months
47933721|NCT00453960|DRUG|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
47933722|NCT00453960|OTHER|placebo|tablets daily for 6 months
47933723|NCT03227341|OTHER|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
47933724|NCT05366010|DEVICE|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
47933725|NCT03279471|DRUG|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.
47933726|NCT03279471|BEHAVIORAL|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
47933727|NCT03279471|DRUG|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
47933728|NCT01580371|DRUG|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
47951363|NCT04879225|BEHAVIORAL|Menthol and Tobacco e-liquids|Marketplace includes menthol and tobacco flavored e-liquids
47951364|NCT04879225|BEHAVIORAL|Mint, Menthol and Tobacco e-liquids|Marketplace includes mint, menthol and tobacco flavored e-liquids
48280462|NCT06203431|DRUG|Etomidate Injectable Emulsion|lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
48280463|NCT02531516|DRUG|Apalutamide|
48280464|NCT02531516|DRUG|Bicalutamide|
48280465|NCT02531516|DRUG|Bicalutamide Placebo|
48456265|NCT06219941|DRUG|Leucovorin|Chemotherapy agents
48456266|NCT06219941|DRUG|l-leucovorin|Chemotherapy agents
48456267|NCT06219941|DRUG|Irinotecan|Chemotherapy agents
47933729|NCT00546221|BEHAVIORAL|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
47933730|NCT00546221|BEHAVIORAL|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
47933731|NCT03313908|PROCEDURE|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
47933732|NCT05765227|DEVICE|Lehfilcon A multifocal contact lenses|Investigational silicone hydrogel multifocal contact lenses
47933733|NCT05765227|DEVICE|Lotrafilcon B multifocal contact lenses|Commercially available silicone hydrogel multifocal contact lenses
47933734|NCT05765227|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
47933735|NCT04439565|GENETIC|movement|aortic dissection or aneurysm patients this is an observation cohort study about a Non-syndromic Familial Aortic Dissection without intervention.
47933736|NCT03608761|DRUG|Rebamipide|rebamipide 2%
47933737|NCT03608761|BIOLOGICAL|autologous serum|AS for 3 months
47933738|NCT03608761|OTHER|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
47933739|NCT01048489|BEHAVIORAL|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
47933740|NCT00223236|DRUG|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
47933741|NCT00223236|DRUG|Placebo|Placebo matching active medication in all other aspects.
47933742|NCT04385927|BEHAVIORAL|e-Net for Parents of Neurodiverse Children|One-on-one distance coached intervention; approx. 12 sessions at 60-90 minutes.
47933743|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks \& 9 months
47933744|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks \& 9 months
48098701|NCT06475599|DRUG|Chemotherapy drug|Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs (including Paclitaxel, Albumin, Doxorubicin and Doxorubicin hydrochloride) for treatment.
48456268|NCT06219941|DRUG|Nanoliposomal Irinotecan|Chemotherapy agents
48456269|NCT06219941|DRUG|Gemcitabine|Chemotherapy agents
48456270|NCT05946486|DRUG|immunomodulatory treatment by rituximab|1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
47933745|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6\&14 weeks \& 9 months
47933746|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks \& 9 months
47933747|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks \& 9 months
47933748|NCT02943902|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6\&14 weeks \& 9 months
47933749|NCT03139942|DEVICE|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
47933750|NCT05523687|DRUG|[14C]-PC14586|Single, oral dose of \[14C\]-PC14586
47933751|NCT06152471|DRUG|SPC-flakes|Aktive drug
47933752|NCT06152471|DRUG|Salovum|Active drug
47933753|NCT06152471|DRUG|Placebo|Placebo drugs
48456271|NCT03774537|DRUG|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
48456272|NCT03774537|DRUG|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
48622901|NCT05378152|DEVICE|Pipelle biopsy catheter|A speculum will be inserted into the vagina. A Pipelle biopsy catheter will be inserted through the cervix up to the fundus of the uterus. The internal piston will be withdrawn to create negative pressure. The catheter will be moved back and forth and rotated to collect the biopsy. The catheter will then be removed, followed by the speculum. The sample will be sent to the laboratory for assessment.
47951365|NCT04879225|BEHAVIORAL|All e-liquid flavors|Marketplace includes fruit, dessert, mint, menthol and tobacco flavored e-liquids
48280466|NCT02531516|DRUG|Apalutamide Placebo|
48280467|NCT02531516|DRUG|GnRH (agonist)|
48280468|NCT02531516|RADIATION|74-80 Grays (units of radiation)|
48280469|NCT05745662|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
48280470|NCT01306981|DRUG|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
47933754|NCT03127800|DRUG|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
47933755|NCT01221844|DIETARY_SUPPLEMENT|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
48456273|NCT05137093|DEVICE|Actigraphy Device|Patients will wear actigraphy device which detects scratching events.
48456274|NCT04752605|BEHAVIORAL|Finnish ENGAGE together|Early childhood education workers play games with children during day care. The games (e.g. ball games, puzzles, Simon says) target children's executive functions and self-regulatory skills, e.g. inhibition, attention, and emotion regulation. The first phase of the intervention (6 weeks) includes play sessions (15 minutes each day) for all children as well as a parents' evening to encourage playing at home. In the second phase (8 weeks), more individualized small group play sessions (3 times a week, 30 minutes at once) are arranged for the children that show difficulties in self-regulation after the first phase. Also, a parents' group including 6 group sessions and 2 phone calls is arranged for their parents in this phase. The participating parents are asked to play the games for 20 minutes each day with their children. During the group meetings, the parents share their experiences of playing at home and receive support and guidance from 2 health care professionals.
48456275|NCT03659565|BEHAVIORAL|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
48456276|NCT03659565|BEHAVIORAL|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
48456277|NCT06359015|DRUG|Metformin|"Oral Metformin schedule:~Day 1: 500 milligrams in morning Day 2: 500 milligrams two times a day Day 3: 1000 milligrams in morning, 500 milligrams in evening Day 4 onwards: 1000 milligrams two times a day based on individual tolerance~Oral Esomeprazole schedule:~40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance."
48456278|NCT06359015|DRUG|Esomeprazole|40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
48456279|NCT02455947|OTHER|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
48456280|NCT04955158|DRUG|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
48456281|NCT04955158|DRUG|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
48456282|NCT04955158|OTHER|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
48456283|NCT06562465|PROCEDURE|dietary and exercise management|Dietary and exercise management: dietary management by providing tailored recipes, health education lectures, science competitions, etc；exercise management:develop weekly and monthly exercise plans for children of different ages, and have physical education teachers lead them in exercising.
48456284|NCT06562465|PROCEDURE|no dietary and exercise management|NO dietary and exercise management:do not implement dietary and exercise management related to the experimental group
48456285|NCT01446770|DEVICE|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
48456286|NCT06007729|DRUG|HS-20093|Participants in all subjucts will receive HS-20093 at 10mg/kg
48456287|NCT05748626|DEVICE|Anti-snoring device|For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.
48456288|NCT05748626|PROCEDURE|No anti -snoring device during their procedure.|For group 2 there will be no anti snoring device used during the case.
47933756|NCT01221844|DRUG|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
47933757|NCT01445626|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
48456289|NCT05529576|DRUG|Omega 3 fatty acid|Omega-3 fatty acids complementation according to the patient's CRP level
47933758|NCT04044027|BEHAVIORAL|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
47933759|NCT00600860|OTHER|No interventions|Only registration of clinical practice
47933760|NCT03867409|BEHAVIORAL|message delivered via virtual technology|The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
48456290|NCT04184947|DRUG|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
48456291|NCT04184947|DRUG|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
48456292|NCT05422469|DEVICE|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
47951366|NCT02080910|BEHAVIORAL|Psychoeducation|
48280471|NCT01306981|DRUG|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
48280472|NCT03323749|COMBINATION_PRODUCT|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
47933761|NCT01209832|DRUG|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
47933762|NCT01209832|DRUG|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
48456293|NCT04589286|BEHAVIORAL|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
48456294|NCT04589286|OTHER|Electronic Handouts|Generic wellness-related electronic handouts
48456295|NCT05341453|PROCEDURE|Individual physiotherapy (SMA-SOC)|Therapeutic procedures according to the recommended standard (SMA-SOC) will be used in the therapy. Elements of breathing gymnastics, vibration techniques, stretching, eccentric and concentric exercise procedures will be combined. Individual physiotherapy will be conducted on the basis of set goals from the kinesiological examination, it will be adapted to the individuality of the child - his cooperation, fatigue and sleep time.
48456296|NCT05341453|PROCEDURE|Hippotherapy|"HT by CP is an accredited form of hippotherapy, whose methodology is based on the clinical picture of cerebral palsy, but its procedures are applicable to a wider group of children with disabilities. Therefore, investigators anticipate it´s effect for children with SMA.~Based on a special type of examination, this method precisely determines the type / breed of the horse according to the biomechanics of the movement of its back in the step, the position of the child and the neurophysiological function of the back - differentiation or sensorimotor skills. Furthermore, according to the course of therapy, the physiotherapist determines the pace of the horse's step, its length, selects special manual contacts according to the current situation and adjusts the duration of therapy to the client's fatigue.~Therapy will be performed by therapists with professional competence to perform hippotherapy by children with CP."
48456297|NCT05341453|PROCEDURE|Therapeutic grooming|In order to influence the psychomotor development in a comprehensive way, the psychosocial activity of therapeutic grooming will also be included in the study. Its goal is to support children's communication, their interaction with the environment, the ability to establish contact with the horse and the overall emotional support of children with SMA. The purpose of this activity is to clean the horse, its possible guide, stroking and contact with the horse, work from the ground.
48456298|NCT01750294|DRUG|Chlorthalidone|
48456299|NCT01787695|PROCEDURE|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
47933763|NCT06043284|DEVICE|Hyperbaric Oxygen Therapy|Subjects received 100% medical grade oxygen for 60 minutes at 2.0 ATA for 40 sessions in a hard-sided monoplace hyperbaric chamber
47933764|NCT02518503|DRUG|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
48456300|NCT02253329|PROCEDURE|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
48456301|NCT02253329|PROCEDURE|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
48456302|NCT06022107|BEHAVIORAL|LDART|LDART is a newly developed web-based social support intervention that can be accessed by smartphone or computer. Each night, the participant sets a recovery goal for the next day (e.g., drink less than usual, go to a support group meeting). The next night, they log on to LDART to indicate whether they reached their goal for the day. Depending on their response, they will be shown either a celebratory or encouraging message from someone in the addiction recovery community, along with specific information on that person's recovery organization.
47933765|NCT02518503|DRUG|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
47933766|NCT02518503|DRUG|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
48456303|NCT05496920|DIAGNOSTIC_TEST|FD-PET/CT|Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
47933767|NCT02518503|DRUG|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
48622902|NCT05378152|DEVICE|Sham procedure|A speculum is inserted into the vagina and then removed
48622903|NCT04905290|DEVICE|Left ventricular coronary sinus configuration|For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle.
47933768|NCT02518503|DRUG|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
47933769|NCT02518503|DRUG|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
47933770|NCT02518503|DRUG|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for \<10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
47933771|NCT02518503|DRUG|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
47933772|NCT02518503|DRUG|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
47933773|NCT03891160|OTHER|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
48456304|NCT05496920|DIAGNOSTIC_TEST|LD-PET/CT|Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
48456305|NCT06453915|DRUG|18F-DPA-714|positron emission tomography scan using 18F-DPA-714 as an imaging tracer.
48456306|NCT06453915|DRUG|18F-FDG|positron emission tomography scan using 18F-FDG as an imaging tracer.
48456307|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
48456308|NCT00493805|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
48456309|NCT05288972|DEVICE|Mattress 1|A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
48456310|NCT05288972|DEVICE|Mattress 2|A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
48456311|NCT03510260|OTHER|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
48456312|NCT03510260|OTHER|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
48456313|NCT03510260|OTHER|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
47933774|NCT00612898|DRUG|apricitabine|800mg BID apricitabine orally for 48 weeks
47933775|NCT00612898|DRUG|lamivudine|150mg BID lamivudine orally for 48 weeks
47933776|NCT01992159|DRUG|Romosozumab|Administered by subcutaneous injection
47933777|NCT01992159|DRUG|Placebo|Administered by subcutaneous injection
47933778|NCT02017600|DRUG|ND-420|ND-420 50 mg/m2 on day1
47933779|NCT02017600|PROCEDURE|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
47933780|NCT02017600|DRUG|Cisplatin|cisplatin 70 mg/m2 on day1
47933781|NCT02017600|DRUG|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
47933782|NCT00946400|OTHER|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
48280473|NCT03323749|COMBINATION_PRODUCT|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
48622904|NCT04905290|DEVICE|Conduction system pacing-only configuration|Conduction system pacing (CSP) of the left bundle branch.
48622905|NCT04905290|DEVICE|Conduction System Pacing Optimized Therapy (CSPOT) configuration|A combination of left ventricle (LV) pacing and conduction system pacing (CSP) of the left bundle branch.
47933783|NCT00946400|OTHER|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
47933784|NCT06301243|OTHER|Inactivity|Low physical activity level prior to the exercise intervention.
47933785|NCT00719433|DEVICE|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
47933786|NCT00719433|OTHER|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
47933787|NCT01778179|DRUG|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2) treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
47933788|NCT01778179|PROCEDURE|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
48280474|NCT03323749|COMBINATION_PRODUCT|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
48280475|NCT04512261|DRUG|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
48456314|NCT01112722|BIOLOGICAL|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
48456315|NCT01112722|BIOLOGICAL|histamine|imitates pain and erythema of honeybee venom
48456316|NCT01899989|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
48456317|NCT01899989|DRUG|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
48456318|NCT01328652|DRUG|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
48456319|NCT05256992|OTHER|Standard Servies + Ray of Hope Curriculum|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.
48456320|NCT05256992|OTHER|Standard Services|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula.
48456321|NCT01736007|DEVICE|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
48456322|NCT01736007|DEVICE|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
48098702|NCT04669405|DEVICE|High intensity laser therapy|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
48456323|NCT05429463|BIOLOGICAL|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
48456324|NCT05429463|DRUG|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
48456325|NCT05429463|DRUG|Albumin-Bound Paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
48280476|NCT04512261|DRUG|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
48456326|NCT03505151|DRUG|BI 409306 (C-13/N-15)|i.v solution
48456327|NCT03505151|DRUG|BI 409306|Film-coated tablet
48456328|NCT02722421|DRUG|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
48456329|NCT02722421|DRUG|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
48456330|NCT04906070|DEVICE|HB-001|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
48456331|NCT04171115|DRUG|G03-52-01|G03-52-01 administered intramuscularly
48456332|NCT04171115|DRUG|Placebo|Placebo administered intramuscularly
48456333|NCT03259139|BEHAVIORAL|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
48456334|NCT05578443|DRUG|10g Astragalus|Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
48456335|NCT05578443|BEHAVIORAL|Routine treatment|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
48456336|NCT05578443|DRUG|20g Astragalus|Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
48456337|NCT02727725|OTHER|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
48456338|NCT02588144|PROCEDURE|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
48280477|NCT04512261|DRUG|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
48456339|NCT02588144|PROCEDURE|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
48456340|NCT05581407|BIOLOGICAL|TETRALITE|LiteVax Adjuvanted Seasonal Influenza Vaccine
48456341|NCT01373515|BIOLOGICAL|DCP-001|4 bi-weekly vaccinations
48622906|NCT00274456|DRUG|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
48622907|NCT00274456|DRUG|Docetaxel|Docetaxel dosed q3w at 100 mg/m\^2
48280478|NCT05983848|RADIATION|99mMaracticaltide imaging|7.3.1 99mTc-maraciclatide imaging This will be undertaken at baseline and optionally at 8-12 weeks. Not more than 75 µg of 99mTc-maraciclatide will be administered intravenously with an activity as close as possible to 740 MBq. Static whole-body imaging will be undertaken after a maximum of 2 hours with further dedicated views of the hands and feet. Total image acquisition time will be approximately 30 minutes. Images will be scored by quantitative and semi-quantitative methods by a blinded observer.
48456342|NCT03750448|OTHER|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
48622908|NCT02060162|OTHER|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
48622909|NCT05948488|OTHER|Questionnaires|The questionnaires focus on anxiety, fear and quality of life.
48456343|NCT03750448|OTHER|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
48622910|NCT02190058|DRUG|DS-1971a|suspension
47933789|NCT02643069|OTHER|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
47933790|NCT00149448|BEHAVIORAL|TB Contact Priority Model|
47933791|NCT01437800|DRUG|Glimepiride / Extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
47933792|NCT01422967|BEHAVIORAL|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
47933793|NCT01577810|DEVICE|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
47933794|NCT04175509|DRUG|Rectal acetaminophen|Rectal 1300mg
47933795|NCT04175509|DRUG|Intravenous acetaminophen|Intravenous 1000mg
48456344|NCT03750448|OTHER|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
48456345|NCT06063460|DIAGNOSTIC_TEST|Periodontal examination|Periodontal Examination Routine In routine periodontal examination, measurements of plaque score, gingival score, pocket depths, and attachment loss will be utilized.
48456346|NCT06063460|OTHER|baseline questionnaire about sociodemographic characteristics, smoking habits, oral hygiene habits, halitosis, smell and taste perception|"Each patient participating in the study will complete a questionnaire detailing their age, gender, height, weight, smoking status, frequency of dental brushing, diabetes status, total annual household income, and Covid-19 history. In addition, a visual analogue scale and self-reported periodontal status questionnaire will be completed.~Personal Periodontal Condition Questionnaire This questionnaire comprises of eight questions regarding the participants' periodontal condition.~Graphical Analog Scale Patients were asked to rate their perception of taste, smell, and bad breath between 0 and 100 on this scale. Sense of smell (0-I cannot smell at all, 100-I can smell perfectly), sense of taste (0-I cannot taste at all, 100-I can smell perfectly), mouth. The odor will be graded from 0 (no bad breath) to 100 (extremely awful breath)."
48456347|NCT06063460|OTHER|phase I periodontal treatment|Phase I periodontal treatment will be applied by same expert.
48456348|NCT06063460|OTHER|1. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.
48456349|NCT06063460|OTHER|3. month periodontal evaluation and repeat questionnaire|Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.
48622911|NCT02190058|DRUG|placebo|placebo matching DS-1971a
47933796|NCT01879540|BIOLOGICAL|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
47933797|NCT00919841|OTHER|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
47933798|NCT00447200|PROCEDURE|Esophagus Doppler monitoring|
47933799|NCT00447200|PROCEDURE|Fluid optimization|
47933800|NCT01663753|DEVICE|18F-FDG-PET|
47933801|NCT04719832|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
47933802|NCT04719832|DRUG|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
47933803|NCT01889095|DRUG|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
47933804|NCT01889095|DRUG|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
47933805|NCT00924170|DRUG|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
47933806|NCT00924170|DRUG|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and \>18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day"
47933807|NCT00924170|DRUG|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day"
47933808|NCT02477423|DRUG|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
47933809|NCT02477423|DRUG|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
48280479|NCT01217606|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
47933810|NCT02477423|DRUG|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
48280480|NCT01217606|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
48456350|NCT01026402|DRUG|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
48456351|NCT06628037|BIOLOGICAL|SN514-066b|Enzyme debrider
48456352|NCT05715463|OTHER|Resource sheets|Arm 1 is the control arm which will receive the standard of care resource sheets. Patients in this arm will receive cultivated resource sheets for any SDoH-related needs that they screen positive for or request additional information on.
48622912|NCT04857710|DEVICE|Wide-pulse neuromuscular electrostimulation (WP NMES)|The WP NMES program consists of electrical stimulation trains of 1000 symmetrical biphasic pulses (1 ms, 100 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s. A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé).
47933811|NCT02673541|DEVICE|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
47933812|NCT02673541|DEVICE|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
47933813|NCT05371171|PROCEDURE|skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
47933814|NCT05371171|PROCEDURE|no skin graft|In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing \[Alleyvn, Smith, \& Nephew\] was placed on the regrafted skin for fixation
47933815|NCT00801307|DEVICE|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
47933816|NCT03324581|DRUG|OPC-64005|OPC-64005 film coated tablets
47933817|NCT03324581|DRUG|Atomoxetine|Atomoxetine gelatin capsules
48280481|NCT04709549|BEHAVIORAL|Diabetes Prevention Program + Job and Legal Services|"Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.~Job readiness services will be provided by YMCA SF service connectors, trained staff with expertise in employment services who are bi-lingual in English/Spanish and/or Cantonese/English to serve the needs of the community. Service Connectors will assist with providing employment services (e.g job search, potential placement and retention services, relationship development with partners and employers) and job readiness instruction/training."
48280482|NCT04709549|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
47933818|NCT03324581|DRUG|Placebo|OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
47933819|NCT03473938|DEVICE|Spatz3 AIGB|Implantation of Spatz3 AIGB balloon.
47933820|NCT05797545|DIAGNOSTIC_TEST|Breast MRI for Breast Cancer Detection|Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
47933821|NCT00822809|DRUG|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
47933822|NCT00822809|DRUG|Prednisolone|25 mg premedication
47933823|NCT04037878|PROCEDURE|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
47933824|NCT04037878|PROCEDURE|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
47933825|NCT04037878|DRUG|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
47933826|NCT03279627|OTHER|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
47933827|NCT00550056|BEHAVIORAL|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
48456353|NCT05715463|OTHER|Community Resource Specialist|The CRS will help guide patients to the necessary community-based resources to help address their specific SDoH needs that impact their health and their ability to access sustained, high quality medical care. This may include forms to arrange for subsidized transportation to and from medical appointments or applications for Section 8 housing. The community resource specialist will reach out to patients in Arm 2 a minimum of 2 times per month, with more interactions guided by patients needs. All outreach attempts and contacts will be documented in EPIC and in REDCap. Actions taken by the CRS will be shared with members of the patient's healthcare team as appropriate (with EPIC notes routed to the rheumatologist and primary care provider, and if indicated and relevant, a social worker, nutritionist, prior CRS, nurse or mental health provider if previously involved in the patient's care).
48456354|NCT05715463|OTHER|Nurse Navigator|The nurse navigator will both work with the CRS to connect the patient with community-based resources, independently connect the patient with relevant resources, and also help coordinate the patient's medical care and mental health needs. The nurse patient navigator will conduct her own needs assessment (the nurse navigator high risk assessment questionnaire at the time of the first conversation with the patient, originally developed as part of the MGB integrated care management program) and her actions will be guided by their responses. She will reach out to patients a minimum of 2 times per month with an increase in communication around patient appointments as reminders, and more frequent communication on a case-by-case basis depending on active illnesses, frequency of outpatient appointments, and needs of the patient. All outreach attempts and contact will be documented in EPIC and in REDCap and similar to the CRS, be shared via EPIC with the care team as indicated.
48456355|NCT04281472|BIOLOGICAL|efgartigimod PH20 SC in stage B|Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
47933828|NCT00550056|BEHAVIORAL|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
47933829|NCT01286831|DRUG|[14C]GW642444|Single 200μg dose of \[14C\]GW642444 given on Day 1.
48098703|NCT04669405|OTHER|Therapeutic Exercise|A prospective, randomized, controlled study was undertaken. A total of 44 patients who met inclusion criteria were randomly divided into two groups. HILT group (n=22) received 3 sessions of HILT per week for 3 weeks in addition to the multidisciplinary stroke rehabilitation and exercise program which performed 5 sessions per week for 3 weeks. Control group (n=22) received a multidisciplinary stroke rehabilitation and exercise program for HSP of 5 sessions per week for 3 weeks.
48098704|NCT04083651|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
47933830|NCT00603772|DRUG|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
47933831|NCT01284049|DRUG|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
47933832|NCT01284049|DRUG|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
48098705|NCT04083651|DRUG|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
48098706|NCT01835340|DEVICE|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
48098707|NCT02243592|OTHER|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
48098708|NCT04591184|BIOLOGICAL|Covigenix VAX-001 placebo|Placebo vaccine
48098709|NCT04591184|BIOLOGICAL|Covigenix VAX-001|Active Covigenix VAX-001
48098710|NCT05402228|DIAGNOSTIC_TEST|temporomandbular joint disorders|no intervention
48098711|NCT03331328|DEVICE|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
48098712|NCT05709873|BEHAVIORAL|Imagery rehearsal therapy|Therapy to reduce nightmares, delivered via videoconference sessions
48456356|NCT04281472|OTHER|placebo in stage B|Stage A: N/A, stage B: placebo
48456357|NCT02145273|BEHAVIORAL|Interpersonal Psychotherapy for Depression -Group|
48456358|NCT04093570|DRUG|ASTX727|ASTX727 film-coated, immediate-release FDC tablets
48456359|NCT00501735|DRUG|Forodesine 200 mg|2 x 100mg tablets once daily
48456360|NCT06503900|BIOLOGICAL|mRNA COVID-19 vaccine|ACIP-CDC recommended vaccine
47933833|NCT03025789|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
48098713|NCT05709873|BEHAVIORAL|Targeted dream control|Therapy to reduce nightmares, delivered in videoconference sessions and lab session. Lab session will involve a sleep study during a daytime nap.
48098714|NCT02096289|DRUG|Thioridazine|
48098715|NCT06016686|OTHER|VNS stimulation and intraneural recordings|A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.
48280483|NCT05516914|DRUG|LBL-007 Injection|Initial dose - MTD; Q3W; intravenous infusion
48280484|NCT05516914|DRUG|Tislelizumab Injection|Initial dose; Q3W; intravenous infusion
48280485|NCT05516914|DRUG|Cisplatin Injection|Initial dose；Q3W; intravenous infusion
48280486|NCT05516914|DRUG|Gemcitabine Hydrochloride for Injection|Initial dose；Q3W; intravenous infusion
48280487|NCT05516914|DRUG|Docetaxel injection|Initial dose；Q3W; intravenous infusion
48456361|NCT06503900|BIOLOGICAL|IIV4 (quadrivalent inactivated influenza vaccine)|ACIP recommended vaccine
48456362|NCT00000950|DRUG|Ethambutol hydrochloride|
48456363|NCT00000950|DRUG|Isoniazid|
48456364|NCT00000950|DRUG|Pyrazinamide|
48456365|NCT00000950|DRUG|Pyridoxine hydrochloride|
48456366|NCT00000950|DRUG|Rifampin|
48456367|NCT02632968|PROCEDURE|Pinhole surgery with and without buttons|
48456368|NCT02939703|OTHER|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
48456369|NCT01591564|BEHAVIORAL|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
48456370|NCT02535936|PROCEDURE|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
48456371|NCT06300216|DRUG|Octreotide microspheres|20mg/30mg Q4W
48456372|NCT05738421|DIAGNOSTIC_TEST|fiberoptic endoscopic evaluation of swallowing|Questionnaire, FEES, OPES
48456373|NCT05658393|BEHAVIORAL|ReLiver-N App|Web-based mobile health application for patients with liver cirrhosis
48456374|NCT02681939|DRUG|Tulsi(Ocimum sanctum Linn.) capsules|
48456375|NCT02809196|BEHAVIORAL|1: Tailored SMS program implicating friend and mother|
48456376|NCT02809196|BEHAVIORAL|2: Standardized SMS program implicating friend and mother|
47933834|NCT04715334|DEVICE|Mollii suit|The Mollii suit is a new technology of electrical stimulation in the form of whole-body garment with multiple electrodes individually programmed to stimulate the selected muscles. Based on preliminary studies, it is suggested that the Mollii suit improves spasticity. Recent studies also proposed that it improves mobility, gait, function and quality of life. However, these studies are based on qualitative and subjective measures.
48456377|NCT02809196|BEHAVIORAL|3: Tailored SMS program implicating friend, not mother|
48456378|NCT02809196|BEHAVIORAL|4: Standardized SMS program implicating friend, not mother|
48456379|NCT02809196|BEHAVIORAL|5: Tailored SMS program implicating mother, not friend|
48456380|NCT02809196|BEHAVIORAL|6: Standardized SMS program implicating mother, not friend|
47933835|NCT06114108|OTHER|Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)|The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
47933836|NCT06114108|OTHER|Surgery|Surgery
47933837|NCT06114108|RADIATION|Radiotherapy|Radiotherapy
47933838|NCT02762851|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
47933839|NCT02762851|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
48280488|NCT06018883|DRUG|Ascorbate|Vitamin C 900 mg/day, three times a day, orally.
48456381|NCT02809196|BEHAVIORAL|7: Tailored SMS program not implicating mother or friend|
48456382|NCT02809196|BEHAVIORAL|8: Standardized SMS program not implicating mother or friend|
48456383|NCT02809196|BEHAVIORAL|9: No SMS program|
48456384|NCT00503789|PROCEDURE|fecal bacteria analysis|ad lib feeding
48456385|NCT03850522|BIOLOGICAL|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
48456386|NCT01573663|DRUG|Ambroxol and Levodropropizine|Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose
48456387|NCT01573663|DRUG|Ambroxol|Ambroxol HCl 30mg, PO, single dose
48456388|NCT01573663|DRUG|Levodropropizine|Levodropropizine 60mg, PO, single dose
48456389|NCT00828815|DRUG|TMC125|
48456390|NCT05490095|DRUG|SVG101 (T)|5mg of SVG101
48456391|NCT05490095|DRUG|Afinitor (R)|5mg of Afinitor
48456392|NCT02254005|DRUG|bivatuzumab mertansine|
48456395|NCT05315791|PROCEDURE|different methods for maxillary sinus floor elevation|a: 0\~3mm+ground into pieces; b: 0\~3mm+replace the bone; c: 0\~3mm+turn inward to hold up the membrane; d: 3\~5mm+ground into pieces; e: 3\~5mm+replace the bone; f: 3\~5mm+turn inward to hold up the membrane
48456396|NCT03368443|BEHAVIORAL|treadmill training and overground gait training|The participants will be randomized into two different groups, and they will receive treadmill and overground gait training in one or two rooms.
48456397|NCT05739019|OTHER|frozen embryo transfer|transfer one or two embryos in frozen embryo transfer cycles
48456398|NCT01207479|DEVICE|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
48456399|NCT05583409|RADIATION|SBRT+Osimertinib|Received SBRT after three months of Osimertinib treatment
48456400|NCT05583409|DRUG|Osimertinib 80 MG|Osimertinib 80mg, po, Qd
48456401|NCT02108535|DRUG|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
48456402|NCT02108535|DRUG|Silver Sulfadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
48456403|NCT03807440|DRUG|Empagliflozin|Empagliflozin
48456404|NCT03807440|DRUG|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
48456405|NCT03807440|DRUG|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
48456406|NCT03807440|DRUG|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
48456407|NCT02024048|OTHER|OCT|Optical coherence tomography in enhanced depth imaging mode
48456408|NCT02775994|DRUG|Canakinumab|interleukin beta (IL-1) antagonist
48456409|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
48456410|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
48456411|NCT00584753|RADIATION|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
48456412|NCT04563481|OTHER|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
48456413|NCT04563481|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
48456414|NCT03625973|BEHAVIORAL|3D-RT|Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
48456415|NCT03625973|BEHAVIORAL|RT-Verbal|Verbal cues will be used as stimuli in Reminiscence Therapy
48456416|NCT06154096|OTHER|Acute glucagon infusion|All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
48456417|NCT05374057|OTHER|Chiropractic spinal manipulative therapy (CSMT)|See study arm.
48456418|NCT05374057|OTHER|CSMT sham manipulation|See study arm.
48456419|NCT05374057|DRUG|Ibuprofen|See study arm.
48456420|NCT05374057|DRUG|Placebo medication|See study arm.
48456421|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with explainable AI|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with explainable AI.
48456422|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with deep learning|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with deep Iearning.
48456423|NCT02419339|PROCEDURE|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
48456424|NCT06542237|DRUG|YCT-529|In the Phase 1b part of the study, 4 dosing cohorts and one optional 5th cohort with 4 participants will be evaluated (up to 20 participants): 15, 45, 90 and 180 mg. In the Phase 2a part, up to 3 cohorts of up to 10 participants (up to 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion.
48456425|NCT04741776|BEHAVIORAL|Resilience Enhancement Skills Training|Family therapy
48456426|NCT04741776|BEHAVIORAL|Problem-Solving Individual Therapy|Individual therapy
48456427|NCT06563284|OTHER|AURORA Mobile App|"Enrolled subjects will be asked to download the app for free from their smartphone store.~Weekly/bi-weekly updates were collected, and therapy adherence was facilitated with timed alerts. Patients completed the EQ-5D-5L, PSQI, PHQ-9 and GAD-7 questionnaires every four months to track quality of life, sleep quality, depression and anxiety."
48456428|NCT06621784|OTHER|Core stabilization exercises|In most studies, exercises focused on the extremities have been researched. We believe that the positive effects of the core region on walking and postural stability will play a significant role in the treatment of knee osteoarthritis.
48456429|NCT06621784|OTHER|Classical exercise therapy|In the first group of our study, we prescribed exercises that have been proven effective in many studies, are frequently prescribed, and focus on joint range of motion and quadriceps strengthening
48456430|NCT03905967|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.
47933840|NCT04256889|DEVICE|nfant(R) feeding system|Use of nfant(R) technology feeding system as an adjunct to visual assessment and cue-based feedings for infants born less than 30 weeks GA
47933841|NCT06455618|PROCEDURE|not Indwelling the ureteral stent|"Before the end of surgery, the urologist does not Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
47933842|NCT06455618|PROCEDURE|Indwelling the ureteral stent|"Before the end of surgery, the urologist Indwell the ureteral stent in the patient's body. The ureteral stent is usually called Double-J Stent."
47933843|NCT04331197|DRUG|Clomiphene Citrate 50mg|Clomid 50 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
47933844|NCT04331197|DRUG|Letrozole 2.5mg|Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
47933845|NCT01385228|DRUG|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
47933846|NCT01385228|DRUG|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
48280489|NCT06018883|DRUG|Nab paclitaxel|Nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks
48280490|NCT06018883|DRUG|Gemcitabine|Gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks
48456431|NCT03905967|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
48456432|NCT00387153|DRUG|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
48456433|NCT05015595|DRUG|Memantine Oral Tablet|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
48456434|NCT05015595|DRUG|Placebo|Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
48456435|NCT04516915|DRUG|IMU-838|IMU-838 twice daily at 22.5mg doses for 14 days
48456436|NCT04516915|DRUG|Oseltamivir|Oseltamivir twice daily at 75mg doses for 14 days
48456437|NCT03012451|BEHAVIORAL|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
48456438|NCT04164706|DEVICE|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
48456439|NCT04164706|OTHER|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
48456440|NCT02177617|DRUG|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
48456441|NCT02177617|BEHAVIORAL|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
48456442|NCT02177617|PROCEDURE|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
48456443|NCT01942239|DEVICE|real time continuous glucose monitoring|
48456444|NCT06555640|DRUG|DR10624 Injection|Drug: DR10624 injection
48098716|NCT06016686|OTHER|Record multi-unit activity from intraneural sites|Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
48456445|NCT06555640|DRUG|Placebo|Drug: placebo
48456446|NCT05533411|DRUG|Donanemab|Administered IV.
48456447|NCT05533411|DRUG|Placebo|Administered IV.
48456448|NCT04124354|BEHAVIORAL|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
48456449|NCT06004973|DEVICE|STAR Particles|A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
48456450|NCT00538239|DRUG|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
48456451|NCT00538239|DRUG|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
48456452|NCT04756921|DRUG|Pyrotinib|Pyrotinib 400mg po qd
48622913|NCT04857710|DEVICE|Conventional neuromuscular electrostimulation (CONV NMES)|"The CONV NMES program consists of electrical stimulation trains of 500 symmetrical biphasic pulses (0.2 ms, 50 Hz). The duration of a train is of 10 s and the rest between trains is of 30 s (duty cycle: 1/3). A WP NMES session includes 30 evoked contractions. The stimulation intensity is monitored online and adjusted to the highest tolerable by the subjects.~During the stimulation, subjects are seated with the knee joint fixed a 60° angle. Three self-adhesive electrodes are placed over the right thigh. The positive electrodes, measuring 25 cm² (5 x 5 cm), are placed as close as possible to the motor point of the vastus lateralis and vastus medialis muscles. The negative electrode, measuring 50 cm² (10 x 5 cm), is placed 5-7 cm below the inguinal ligament. Electrical stimulations are delivered by a stimulator BioStim (Mazet Santé)."
47933847|NCT01385228|DRUG|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
47933848|NCT01385228|DRUG|Prednisone|5mg Prednisone given twice daily days 1-21.
47933849|NCT01385228|DRUG|Pegfilgrastim|
47933850|NCT04581460|OTHER|Questionnaire|Questionnaire intended for patients on the course of pregnancy and postpartum, the neonatal period and contraceptive modalities.
47933851|NCT00740051|DRUG|Linagliptin|5mg once daily
48456453|NCT05431491|DEVICE|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
48456454|NCT03681977|DEVICE|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
48456455|NCT03681977|DEVICE|Zimmer Persona Knee-PS|Persona the personalized knee system
48456456|NCT05072535|DRUG|HA121-28 tablet B|HA121-28 tablet B 200 mg
48456457|NCT05072535|DRUG|HA121-28 tablet A|HA121-28 tablet A 200 mg
48456458|NCT00457067|DRUG|Ranibizumab|
48456459|NCT06442956|OTHER|Rapid Heat Condition|The heat condition is the intervention. Personal protective equipment will be used to create the rapid heat stress condition, resulting in a rapid rise in core temperature. This will be in combination with the physiological heat produced by the treadmill protocol.
48456460|NCT06442956|OTHER|Gradual Heat Condition|The gradual heat condition is the control. Physiological heat will be produced by exercise on a treadmill, and light exercise clothing will help moderate the rise in core temperature.
47933852|NCT00740051|DRUG|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
48456461|NCT01309763|BIOLOGICAL|AFFITOPE AD03|s.c. injection
48456462|NCT01309763|BIOLOGICAL|AFFITOPE AD03 + Alum|s.c. injection
47933853|NCT00740051|DRUG|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
47933854|NCT03932097|BEHAVIORAL|REAL Parenting|REAL Parenting digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
47933855|NCT03932097|OTHER|Active Control Materials|NIAAA materials on underage drinking for parents
47933856|NCT05703633|OTHER|uDCD treatment|Thrombolytic treatment/prevention ex-vivo to kidneys procured from patients after circulatory arrest
47933857|NCT00904410|OTHER|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
47933858|NCT02112955|BEHAVIORAL|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
47933859|NCT02112955|BEHAVIORAL|Usual care|Usual care such as hospital-based or community-based health education or services.
47933860|NCT05106790|BEHAVIORAL|Educational support with peer counseling|This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
47933861|NCT05106790|BEHAVIORAL|mHealth intervention|"This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp."
47933862|NCT05106790|BEHAVIORAL|mHealth intervention and Educational support with peer counseling|This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
47933863|NCT02387255|DEVICE|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
47933864|NCT06239818|DEVICE|Photobiomodulation therapy (PBMt)|Participants will be asked to use the photobiomodulation (PBM) device for 20 minutes, daily (e.g., Monday - Sunday) for a total of 30 days. The device will be preprogrammed and automatically switched off after 20 minutes.
47933865|NCT06239818|OTHER|Standard of Care|The patient is provided with verbal and written education including what a mild traumatic brain injury (mTBI) is, favorable expectations for recovery, and advice about how to manage specific symptoms. Relative rest for the first 24-48 hours after an mTBI is recommended as the main goal is to alleviate symptoms and reduce demands on the brain. After an initial period of relative rest and symptom stabilization, patients are encouraged to gradually resume normal daily activities as tolerated. Physical and cognitive activities can be progressively resumed at a pace that does not worse existing or create new symptoms. Education, return to activity advice, and symptom management are all reviewed in subsequent visits as needed.
47933866|NCT00084773|BIOLOGICAL|cetuximab|
48456463|NCT06068491|OTHER|Vet-CALD|Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
48456464|NCT02046863|DEVICE|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
47933867|NCT00084773|DRUG|fluorouracil|
48098717|NCT05753137|OTHER|Acupuncture|The treatment will take place once a week, over six weeks. The needles will placed in the body for 20 minutes. A total of 12 Needles(6 acupoints, bilaterally) will be used in each session.Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation.
48098718|NCT05753137|OTHER|Acupuncture placebo|A total of 12 Needles(6 acupoints, bilaterally) will be used in each session. Acupuncture points are different from the experimental group.The control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation.
48098719|NCT01391013|DRUG|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
48456465|NCT00178178|DEVICE|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
48456466|NCT00178178|DRUG|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
48456467|NCT00178178|DRUG|Placebo|Drug: Placebo
48456468|NCT05238428|BEHAVIORAL|Trust boost|The investigators adapt the wording of the vaccination invitation to foster trust and increase vaccination acceptance.
48456469|NCT06561984|BEHAVIORAL|antenatal education|Giving educational sessions to the intervention group regarding modes of delivery
48622914|NCT04857710|DEVICE|Control (CONT) modality|Control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations.
47933868|NCT00084773|PROCEDURE|neoadjuvant therapy|
47933869|NCT00084773|RADIATION|radiation therapy|
47933870|NCT01981369|DRUG|Dexmedetomidine|Intravenous sedation with dexmedetomidine
47933871|NCT01981369|DRUG|Propofol|Intravenous sedation with propofol
47933872|NCT01981369|PROCEDURE|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
48098720|NCT01391013|DRUG|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
48456470|NCT06627634|PROCEDURE|Metastatectomia and standard treatment for resectable disease.|Rather than palliative chemotherapy, the intervention offered to participants is preoperative chemotherapy, resection of primary tumour and metastatectomia of oligometastatic spread to the liver. If fit for post-operative chemotherapy, this is offered as well.
48456471|NCT03332732|DRUG|VNRX-5133|β-lactamase inhibitor
48456472|NCT03332732|DRUG|VNRX-5022|Approved β-lactam antibiotic
48456473|NCT03332732|DRUG|Metronidazole|Approved antibiotic and antiprotozoal medication
48456474|NCT03332732|DRUG|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
48456475|NCT00031707|DIETARY_SUPPLEMENT|eicosapentaenoic acid|
48456476|NCT00031707|DRUG|megestrol acetate|
48456477|NCT00031707|OTHER|placebo|
48456478|NCT02469363|DEVICE|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
48456479|NCT02469363|DEVICE|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
48456480|NCT02469363|DEVICE|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
48456481|NCT02469363|DEVICE|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
48456482|NCT06288217|DEVICE|NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)|Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements
48456483|NCT06288217|OTHER|Upper Limb Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
48456484|NCT06288217|OTHER|Sham Stimulation|Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.
48456485|NCT05168722|OTHER|No interventions|No interventions
48456486|NCT05789173|DRUG|Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
48622915|NCT02530242|DEVICE|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
48098721|NCT01391013|DRUG|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
48098722|NCT00554801|PROCEDURE|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
48280491|NCT06657469|OTHER|Attention Functions Training (AFT)|The AFT protocol included 18 group-based sessions, 75 minutes each, administered twice a week over a nine-week period. The training focused on improving sustained attention, selective-spatial attention, and executive attention through computerized tasks like the Conjunctive Continuous Performance Task and Go/No-Go tasks.
48280492|NCT06657469|OTHER|Executive Functions Training (EFT)|The EFT protocol included similar session structures with a focus on executive functions such as working memory, cognitive flexibility, and problem-solving. Tasks included computerized games such as visual puzzles.
48280493|NCT00384956|DRUG|Azacitidine|
48456487|NCT05789173|DRUG|Efavirenz, Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
48456488|NCT02638428|PROCEDURE|CancerSCAN™|Targeted deep sequencing
48456489|NCT02638428|DRUG|Ifosfamide|
47933873|NCT00588952|DRUG|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
48280494|NCT02071940|DRUG|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
48280495|NCT01870466|DRUG|Cilostazol|cilostazol bid for 7 days
48280496|NCT01870466|DRUG|Simvastatin|simvastatin qd for 7 days
48280497|NCT01870466|DRUG|Rosuvastatin|rosuvastatin qd for 7 days
48280498|NCT00586365|DRUG|Naproxen|500 mg Naproxen twice a day for two weeks
48280499|NCT02426307|PROCEDURE|TAVR|TAVR: Transcatheter Aortic Valve Replacement
48280500|NCT02426307|PROCEDURE|SAVR|SAVR: surgical Aortic Valve Replacement
48280501|NCT03567655|DRUG|Farlutal tab. 500mg/ Pfizer|Medroxyprogesterone Acetate
48280502|NCT01784887|DRUG|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
48280503|NCT06656962|DRUG|Telitacicept 160mg|Telitacicept for Injection combined with standard therapy (Prednisone and Cyclophosphamide) for the treatment of ANCA-associated nephritis (AAGN).
48280504|NCT06656962|DRUG|Prednisone (and methylprednisolone)|Methylprednisone shock therapy (500mg, 3 times), followed by Prednisone (1 mg·kg·d and a pre-determined tapering guideline \[PEXIVAS regimen\]).
48280505|NCT06656962|DRUG|Cyclophosphamide|Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
48280506|NCT04939155|BIOLOGICAL|SARS-CoV-2 mRNA vaccine|mRNA vaccine for COVID
48456490|NCT02638428|DRUG|Carboplatin|
48456491|NCT02638428|DRUG|Etoposide|
48456492|NCT02638428|DRUG|Fludarabine|
48456493|NCT02638428|DRUG|Cytarabine|
48456494|NCT02638428|DRUG|Pazopanib|
48456495|NCT02638428|DRUG|Sorafenib|
48456496|NCT02638428|DRUG|Axitinib|
48456497|NCT02638428|DRUG|Crizotinib|
48456498|NCT02638428|DRUG|Dasatinib|
48456499|NCT02638428|DRUG|Erlotinib|
48456500|NCT02638428|DRUG|Everolimus|
48456501|NCT02638428|DRUG|Imatinib|
48456502|NCT02638428|DRUG|Ruxolitinib|
48456503|NCT02638428|DRUG|Vandetanib|
48456504|NCT02638428|DRUG|Vemurafenib|
48456505|NCT02638428|DRUG|Trastuzumab|
48622916|NCT02530242|DEVICE|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
48456506|NCT04125186|DIAGNOSTIC_TEST|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
48456507|NCT04125186|DIAGNOSTIC_TEST|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
48456508|NCT04125186|DIAGNOSTIC_TEST|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
48456509|NCT04125186|OTHER|No other intervention|No other intervention
48456510|NCT04285268|DRUG|Bortezomib|Given IV or SC
48456511|NCT04285268|BIOLOGICAL|Rituximab|Given IV
48456512|NCT04285268|DRUG|Venetoclax|Given PO
48456513|NCT00774189|DRUG|clarithromycin 250 mg tablets|
48456514|NCT06287216|BEHAVIORAL|Mental Hygiene|Mental hygiene are daily evidence based practices that support mental wellbeing.
48456515|NCT06287216|BEHAVIORAL|Self-Care|Instructed to do 10 minutes of self-care daily.
48456516|NCT06077786|DRUG|Lu AG06474|Oral solution
48456517|NCT06077786|DRUG|Placebo to Lu AG06474|Oral solution
48280507|NCT04610255|OTHER|Assigned Interventions|"* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
48280508|NCT04610255|OTHER|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
48280509|NCT02312024|DEVICE|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
48456518|NCT06077786|DRUG|Ibuprofen|Capsule
48456519|NCT06077786|DRUG|Pregabalin|Capsule
48456520|NCT06077786|DRUG|Placebo|Capsule
48456521|NCT04065607|PROCEDURE|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
48456522|NCT00044434|DRUG|bupropion (Wellbutrin)|
48456523|NCT02565836|DRUG|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
48456524|NCT02565836|DRUG|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
48456525|NCT03822754|BIOLOGICAL|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
48456526|NCT03822754|BIOLOGICAL|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I \& type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
48622917|NCT03509090|PROCEDURE|erector spinae block|erector spinae block will be performed in this group as postoperative analgesia treatment.
48622918|NCT03509090|PROCEDURE|Control group|patients will receive only multimodal analgesic treatment including patient-controlled analgesia
47933874|NCT06209385|DRUG|YZJ-5053 tablets|YZJ-5053 tablets will be administrated orally QD for 21 days
47933875|NCT04388371|DRUG|Glutamine|Glutamine will be administered by IV injection prior to PET imaging.
48456527|NCT04170335|PROCEDURE|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
48456528|NCT03067987|DEVICE|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
48456529|NCT05941390|DEVICE|VR without positive psychology|Using VR goggles showing relaxing short videos without sound
48456530|NCT05941390|DEVICE|VR with positive psychology|Using VR goggles showing relaxing short videos with positive psychological messages
48456531|NCT01987128|PROCEDURE|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
48456532|NCT01987128|PROCEDURE|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
48456533|NCT01987128|DRUG|Ropivacaine|
48456534|NCT01987128|DEVICE|PAJUNK SonoPlex 22G needle.|
48456535|NCT02959879|DRUG|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
48456536|NCT02959879|DRUG|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
48456537|NCT02959879|PROCEDURE|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
48456538|NCT02959879|DRUG|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
48456539|NCT02959879|DRUG|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
48622919|NCT00435643|PROCEDURE|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
48622920|NCT05436288|DRUG|KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)|KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
48622921|NCT04908033|DEVICE|pacemaker implantation|pacemaker implantation
48622922|NCT06109740|DIETARY_SUPPLEMENT|lactobacillus GG|probiotic
47933876|NCT01915628|DEVICE|BioMatrix Flex|Percutaneous coronary intervention
47933877|NCT04281238|OTHER|Yoga group|Yoga training 3 days a week for 8 weeks. In addition to this, home exercises 5 days a week for 8 weeks
47933878|NCT04281238|OTHER|Control group|Home exercises 5 days a week for 8 weeks
47933879|NCT03446261|DRUG|Rosuvamibe® Tab|Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
47933880|NCT03446261|DRUG|Monorova® Tab|Rosuvastatin 10mg qd for 8 weeks
48098723|NCT03098290|PROCEDURE|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
48098724|NCT03098290|PROCEDURE|Bypass-Surgery|Venous or alloplastic or comparable Bypass
48280510|NCT04807361|BEHAVIORAL|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
48280511|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
48280512|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
48280513|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
48280514|NCT04907851|BIOLOGICAL|Denosumab|Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
48280515|NCT04907851|BIOLOGICAL|pembrolizumab|Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
48280516|NCT01798303|DRUG|LY2940094|Administered orally
48280517|NCT01798303|DRUG|Placebo|Administered orally
48280518|NCT05363917|DRUG|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
48280519|NCT05363917|DRUG|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
48280520|NCT06656533|OTHER|Repeated Transcranial magnetic stimulation (rTMS)|Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.
48280521|NCT06181955|OTHER|Extracorporeal Shock Wave Therapy|The ESWT was performed by an ESWT instrument (Chattanooga) once a week for four consecutive weeks (a total of four sessions).
48280522|NCT06181955|OTHER|conventional physical therapy|Conventional physical therapy consisted of ultrasound therapy and three types of knee-strengthening exercises.
48280523|NCT02936752|DRUG|Entinostat|Given PO
48280524|NCT02936752|BIOLOGICAL|Pembrolizumab|Given IV
48280525|NCT04543500|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
48456540|NCT00000245|DRUG|Desipramine|
48456541|NCT00847535|BIOLOGICAL|autologous muscle cell injection|Injection of autologous muscle cells
48456542|NCT00627744|DRUG|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
48456543|NCT00973219|DRUG|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
48456544|NCT05017935|DEVICE|Renal Denervation|Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
48456545|NCT00167453|PROCEDURE|Exercise, Education|
48622923|NCT03875417|PROCEDURE|liver resection|resection of one or more HCC nodules within the liver
48622924|NCT03875417|PROCEDURE|Thermic ablation|ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
47933881|NCT01767831|BEHAVIORAL|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
48098725|NCT03098290|PROCEDURE|Endarterectomy|Endarterectomy, Patchplasty
48280526|NCT01526148|DRUG|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels \> 0.6mEq/L.
48098726|NCT04553302|OTHER|This study does not contain any intervention.|This study does not contain any intervention.
48280527|NCT01526148|DRUG|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
48280528|NCT05087888|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48280529|NCT05087888|PROCEDURE|Magnetic Resonance Imaging|Undergo functional MRI
48280530|NCT05087888|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
48280531|NCT05087888|OTHER|Questionnaire Administration|Complete questionnaires
48280532|NCT01561664|OTHER|muscle and fat biopsy|muscle and fat biopsy
48280533|NCT01599559|OTHER|observation|observation
48280534|NCT01599559|RADIATION|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
48280535|NCT03115190|DIAGNOSTIC_TEST|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
48280536|NCT01162850|DIETARY_SUPPLEMENT|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
48280537|NCT01162850|DIETARY_SUPPLEMENT|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
48280538|NCT02284165|OTHER|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
48280539|NCT05239689|BIOLOGICAL|CD38 CAR T-cells|Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
48280540|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
48280541|NCT01991561|BIOLOGICAL|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
48280542|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
48280543|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
48280544|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
48280545|NCT01991561|BIOLOGICAL|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
48280546|NCT05649176|OTHER|Diet without soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the experimental diet but does not contain soy.
48280547|NCT05649176|OTHER|Diet with soy|The diet is designed to moderate the blood glucose response with a similar macronutrient composition as the comparator diet but contains soy.
48280548|NCT04820179|DRUG|Cabozantinib + Atezolizumab|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
48280549|NCT02270567|DEVICE|NETest|Non-invasive blood test
48280550|NCT02265328|DIETARY_SUPPLEMENT|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
48280551|NCT02265328|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
48280552|NCT02265328|OTHER|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. (If Lilli score \> 0.45 after 7 days, then prednisolone would be stopped)
48280553|NCT06656182|OTHER|Cervical and Thoracic SNAGs|cervical SNAGs (C3-C7) and thoracic SNAGs (T1-T12) with 6 repetitions of 1 set three times per week for 4 weeks along with scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
48280554|NCT06656182|OTHER|traditional physical therapy and scapular mobilizations|scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
48280555|NCT06292897|OTHER|observational study|observational study
48280556|NCT05017545|BIOLOGICAL|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
48280557|NCT05017545|BIOLOGICAL|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
48622925|NCT03875417|PROCEDURE|Transcatheter arterial chemoembolization|embolization of HCC nodule via drug-eluted microbeads.
47933882|NCT05465720|BEHAVIORAL|falls-prevention programs|Each group will receive 10-minute warm up, followed by 20-minute exercises in the ICF body function level, 20-minute exercises in the ICF activity level, and finally 10-minute cool down. The 10-minute war up include dynamic mobility exercises of the upper extremity and trunk (ribbons dancing on a chair) and of the lower extremity (marching in place). The 10-minute cool down include flexibility exercises of multiple muscles especially focusing on neck, hamstring, and calf muscles.
47933883|NCT02614469|DRUG|Inosine|Inosine, 1000 mg
48280558|NCT05017545|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
48280559|NCT00972608|OTHER|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
48280560|NCT01961427|DIETARY_SUPPLEMENT|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
48280561|NCT01961427|DIETARY_SUPPLEMENT|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
48280562|NCT01315574|DRUG|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
48280563|NCT01315574|DRUG|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
48280564|NCT06656611|OTHER|HPV self sampling|Selected women will perform a vaginal self-sampling using a swab
48280565|NCT05896345|DEVICE|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
48280566|NCT05896345|COMBINATION_PRODUCT|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
48280567|NCT04390685|DRUG|Tacrolimus ointment|Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
48280568|NCT03373019|DRUG|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
48280569|NCT03310125|DRUG|Colchicine|Over-encapsulated 0.5mg tablet twice daily
48280570|NCT03310125|DRUG|Placebo|Matching placebo capsule twice daily
48280571|NCT00042809|DRUG|paclitaxel|Given IV
48280572|NCT00042809|BIOLOGICAL|trastuzumab|Given IV
48280573|NCT00042809|DRUG|erlotinib hydrochloride|Given orally
48280574|NCT00042809|OTHER|laboratory biomarker analysis|Correlative studies
48280575|NCT00042809|OTHER|pharmacological study|Correlative studies
48280576|NCT06479603|DRUG|Nintedanib|The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
48280577|NCT06479603|DRUG|Standard of care|The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
48280578|NCT00428168|DRUG|Betahistine|Betahistine 24mg BID
48280579|NCT06025747|DRUG|Abemaciclib|Given PO
48280580|NCT06025747|PROCEDURE|Computed Tomography|Undergo CT
48280581|NCT06025747|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48280582|NCT06025747|RADIATION|Radiation Therapy|Undergo radiation therapy
48280583|NCT06025747|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
48280584|NCT02718820|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
48280585|NCT02718820|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
48280586|NCT02240862|DEVICE|Carotid Artery Stent|Placement of a stent within the carotid artery
48280587|NCT05640648|BEHAVIORAL|User-Centered Implementation Strategy|"1. 4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~2. 3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs."
48280588|NCT05640648|BEHAVIORAL|Standard Implementation Strategy|Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
48280589|NCT06601192|DRUG|zelicapavir (therapeutic dose)|Subjects will receive zelicapavir (TD) once per treatment period.
48280590|NCT06601192|DRUG|zelicapavir (supratherapeutic dose)|Subjects will receive zelicapavir (SD) once per treatment period.
48280591|NCT06601192|DRUG|Placebo|Subjects will receive zelicapavir matching placebo once per treatment period.
48280592|NCT06601192|DRUG|moxifloxacin|Subjects will receive moxifloxin once per treatment period.
48456546|NCT04020458|PROCEDURE|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
48456547|NCT05106803|DRUG|ciprofloxacin|Antibiotics used in vitro n the study
48456548|NCT03734263|DRUG|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
48456549|NCT02063139|DRUG|Flutiform 50/5 ug (2 puffs bid) pMDI|
48456550|NCT02063139|DRUG|Fluticasone 50 ug (2puffs bid) pMDI|
48456551|NCT02063139|DRUG|Beclometasone Autohaler 50 ug (2 puffs bid)|
48456552|NCT02637141|BIOLOGICAL|AMG 714|AMG 714 administered by subcutaneous injection
48456553|NCT02637141|BIOLOGICAL|Placebo|Matching placebo to AMG 714 administered by subcutaneous injection
48456554|NCT02637141|OTHER|Placebo Gluten Challenge|Gluten-free cookies (Finnish rusks)
48456555|NCT02637141|OTHER|Gluten Challenge|Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
48456556|NCT03534076|OTHER|Cohort Observational study|Cohort Observational study - there is no intervention
48456557|NCT04999280|OTHER|Fiber Croissant (FIBCRO) Group|Subjects will consume for 2 weeks at breakfast a fiber-enriched sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
48622926|NCT03483103|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
48456558|NCT04999280|OTHER|Control Croissant (CONCRO) Group|Subjects will consume for 2 weeks at breakfast a sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
48456559|NCT05811793|DRUG|Tislelizumab and Bevacizumab|Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
48456560|NCT06205264|OTHER|Strength training at high and low speeds.|"The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises."
48456561|NCT06123195|OTHER|Constipation treatment|Lactulose 15 mL (10 g) will be taken orally once daily (in the evening), which can be titrated at 1-week intervals in 15 mL (10 g) increments or decrements up to 60 mL (40 g) as a total daily dose.
48456562|NCT02312154|DEVICE|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
48456563|NCT05582967|OTHER|Completion of focused Electronic Case Report Form|All patients will have a focussed Electronic Case Report Form completed collecting information around Presenting complaint, Past Medical History, Family History, Physical Examination findings, and Investigations.
48456564|NCT04922827|DRUG|Infliximab|single intravenous administration of 5 milligrams/kilogram
48456565|NCT04922827|OTHER|Standard of Care|Standard of Care
48456566|NCT05913245|DIETARY_SUPPLEMENT|Maltodextrin 12.5%|Preoperative Maltodextrin 12.5%
48456567|NCT05913245|OTHER|Water|Preoperative water
48456568|NCT06249113|DRUG|NaCl 0.9%|NaCl 0.9% continous intravenous on tumor craniotomy surgery
48456569|NCT06249113|DRUG|Adjuvant lidocaine continous|Adjuvant lidocaine continous intravenous on tumor craniotomy surgery
48456570|NCT01266902|DRUG|Rilpivirine|25 mg once daily
48456571|NCT05691153|DRUG|ThisCART19A with Dose Level 1|ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
48456572|NCT05691153|DRUG|ThisCART19A with Dose Level 2|ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
48456573|NCT04367519|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography was performed with the patients placed in supine position with closed eyes. A layer of ultrasound gel was applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine was placed on the temporal area of the eyelid with the hand holding it resting on the forehead of the patient. The probe is then adjusted to a suitable angle in order to display the entry of the optic nerve into the globe. ONSD is then measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. it was performed for all enrolled parturients within 24 hour before delivery and at 24 hour post-delivery.
48456574|NCT05463601|DRUG|Mecapegfilgrastim|Mecapegfilgrastim
48622927|NCT04032223|PROCEDURE|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
48456575|NCT05463601|DRUG|dalpiciclib|dalpiciclib
48456576|NCT05463601|DRUG|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
48622928|NCT00055107|DRUG|Nitazoxanide|
48622929|NCT03583346|DRUG|M6495|Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
48622930|NCT03583346|DRUG|Placebo|Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
48456577|NCT02742558|BIOLOGICAL|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
48456578|NCT02742558|BIOLOGICAL|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
48456579|NCT03340623|DEVICE|Venous coupler|A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
48456580|NCT01731457|DRUG|etanercept|adding appropriate dose of etanercept to the perfusion fluid
47933884|NCT05038176|BEHAVIORAL|MANUP|Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
47933885|NCT02663687|DRUG|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
47933886|NCT02663687|DRUG|Placebo|Subjects will receive matching placebo
47933887|NCT02663687|DRUG|SHP623|SHP623
48098727|NCT01553513|OTHER|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
48456581|NCT01299935|BEHAVIORAL|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
48456582|NCT01299935|BEHAVIORAL|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
48456583|NCT00796562|DRUG|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
48456584|NCT00796562|DRUG|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
48456585|NCT00796562|RADIATION|Total body irradiation|Patients will receive TBI once a day for 4 days.
48456586|NCT01888276|OTHER|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop"
48456587|NCT02873832|BIOLOGICAL|Blood sample|
48456588|NCT02873832|OTHER|Flow cytometry|
48456589|NCT02873832|OTHER|western blot|
48456590|NCT05972590|OTHER|Biological samples collection (blood + feces)|Blood + stools samples will be collected from each volunteer
48456591|NCT02496104|BEHAVIORAL|Package n°1 of the APIB|
48456592|NCT00351039|DRUG|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
48456593|NCT00351039|DRUG|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
48456594|NCT00351039|DRUG|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
48456595|NCT06451653|BEHAVIORAL|Men in Maternity Health (MiM) Intervention|The six-month MiM education program focused on maternal health education for male partners of pregnant women in the intervention area. Assigned midwives offered two-hour-long, face-to-face health education and discussion sessions at five selected health centres every second and fourth Sunday, respectively, to accommodate participants' work schedules. Attendance consistently remained high at 80% of participants every month, with home visits for absentees to provide health education.
48456596|NCT01285713|DRUG|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
48456597|NCT01285713|DRUG|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
48456598|NCT01522820|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
48456599|NCT01522820|OTHER|Laboratory Biomarker Analysis|Correlative studies
47933888|NCT02663687|DRUG|Placebo|Placebo
47933889|NCT03148119|DRUG|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
47933890|NCT03148119|DEVICE|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
48456600|NCT01522820|OTHER|Pharmacological Study|Correlative studies
48456601|NCT01522820|DRUG|Sirolimus|Given PO or PEG
48456602|NCT05215587|DEVICE|TEVAR|A TEVAR stent graft will be placed in the descending aorta in order to cover the primary entry of the dissection.
48456603|NCT02336087|DRUG|Gemcitabine Hydrochloride|Given IV
48456604|NCT02336087|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
48456605|NCT02336087|DRUG|Metformin Hydrochloride|Given PO
48456606|NCT02336087|DIETARY_SUPPLEMENT|Therapeutic Dietary Intervention|Given PO
48456607|NCT02336087|OTHER|Laboratory Biomarker Analysis|Correlative studies
48456608|NCT02336087|OTHER|Quality-of-Life Assessment|Ancillary studies
48456609|NCT04443998|DEVICE|Bone reducion forceps|Repositioning forceps provide a more accurate anatomical reduction and higher pre-compression can be achieved compared to IMF or manual reduction
48456610|NCT03515707|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
48456611|NCT03515707|DRUG|Busulfan|Given IV or oral
48456612|NCT03515707|DRUG|Etoposide|Given IV
48456613|NCT03515707|OTHER|Laboratory Biomarker Analysis|Correlative studies
48456614|NCT05943613|DRUG|Clonidine|compare the effect of intrathecal Clonidine and Neostigmine as adjuvants to Bupivacaine in elective cesarean section
48456615|NCT04562935|OTHER|admission to pediatric intensive care with mechanical ventilation|admission to pediatric intensive care with mechanical ventilation
48622931|NCT02016118|DEVICE|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
48098728|NCT01553513|PROCEDURE|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
48456616|NCT05024682|DEVICE|conventional pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)
48456617|NCT05024682|DEVICE|pulse dosed pulsed radiofrequency|After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).
48456618|NCT03931616|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
48456619|NCT03931616|PROCEDURE|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
48456620|NCT06188663|DIETARY_SUPPLEMENT|Salt supplementation (encapsulated sodium chloride)|A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
48456621|NCT04635007|DRUG|Tranexamic acid|100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.
48456622|NCT04635007|DRUG|Misoprostol 200mcg Tab|100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
48456623|NCT01916239|DIETARY_SUPPLEMENT|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
48456624|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-1|New pomegranate extract formulation-1
48456625|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-2|New pomegranate extract formulation-2
48456626|NCT01814904|DRUG|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
48456627|NCT01814904|DRUG|colestilan-M|BSAeq 6 g/day
48456628|NCT01814904|DRUG|colestilan-H|BSAeq 9 g/day
48456629|NCT01814904|DRUG|CBPB|
48622932|NCT04307563|BEHAVIORAL|Mindfulness session|1.5 hour weekly session with health educator
48456630|NCT02189811|BIOLOGICAL|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
48456631|NCT02189811|BIOLOGICAL|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
48456632|NCT02189811|BIOLOGICAL|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
48456633|NCT02189811|BIOLOGICAL|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
48456634|NCT02189811|BIOLOGICAL|tOPV|tOPV till 22 weeks of age
48456635|NCT04706637|DRUG|Evogliptin|evogliptin 5mg + metformin, oral administration once a day for 48 weeks
48456636|NCT04706637|DRUG|Dapagliflozin|dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks
48622933|NCT03972917|DIAGNOSTIC_TEST|Transvaginal ultrasonographic examination|Evaluation of endometrial thickness; myoma size and volume
48098729|NCT01553513|PROCEDURE|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
48456637|NCT04574960|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, IV infusion on days 1 and 8 of each 3-week cycle
48456638|NCT04574960|DRUG|Cisplatin|Cisplatin 70 mg/m\^2, IV infusion on day 1 of each 3-week cycle
48456639|NCT04574960|DRUG|Carboplatin|Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
48456640|NCT05084963|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
48456641|NCT05084963|DRUG|Placebo|Matching placebo for IRL201104
47933891|NCT04378452|BEHAVIORAL|COM-COVID anonimous survey|Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
47933892|NCT02910128|BEHAVIORAL|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
48456642|NCT00440063|DRUG|epoetin beta [NeoRecormon]|
48456643|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
48456644|NCT00743535|PROCEDURE|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
47933893|NCT05843773|PROCEDURE|Low Load Strength Training under Blood Flow Restriction|"The first training includes one initiation/warm up set and two sets of normal training. Every set lasts 60 seconds and the patient is asked to bend and stretch the knee with a standard speed of 20°/s.~From the second to the ninth training, the patient will have one warm up set plus three trainings sets. The speed of execution will be increased every training.~The 20-40% range of the 1RM will be applied according to the values of the theoretical maximal strength.~If no strength progression is observed in the three last training sessions, the speed of execution will automatically be increased by 15°/s.~In order to keep the training intensity low and to not overload the knee, participants will be instructed to control the intensity with the Borg CR10. The volunteers will have to keep their efforts between 2/10 and 4/10. They will also be asked to stay in the range defined thanks to the theoretical maximal strength shown by the screen."
48280593|NCT03550248|BEHAVIORAL|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
48280594|NCT03808155|DRUG|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
48456645|NCT03221049|DIAGNOSTIC_TEST|radiomics|
48622934|NCT03940534|DEVICE|TAD|TAD is a device used to aid medication adherence.
48280595|NCT03808155|DRUG|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
48280596|NCT01552876|DEVICE|etafilcon A|A daily wear contact lens
48280597|NCT01552876|DEVICE|nelfilcon A|A daily wear contact lens
48280598|NCT01552876|DEVICE|Filcon II 3|a daily disposable
48280599|NCT02509208|DEVICE|SurgiClot haemostatic dressing|haemostatic dressing
48456646|NCT00611676|DRUG|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
48456647|NCT02112123|DRUG|Icariin|
48456648|NCT02112123|DIETARY_SUPPLEMENT|Matching placebo|
48456649|NCT01624272|DEVICE|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
48456650|NCT01624272|OTHER|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
48622935|NCT03003689|PROCEDURE|Scaling and Root Planing|Standard of care scaling and root planing using hand instruments and ultrasonic scaler
48622936|NCT03003689|DEVICE|Er:YAG Laser|Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
48622937|NCT05139147|DEVICE|DAISe Thrombectomy System|DAISe Thrombectomy System for mechanical thrombectomy
48622938|NCT05057520|OTHER|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
48622939|NCT00637182|DRUG|Anastrozole|
48456651|NCT05069480|DEVICE|Virtual reality-based training equipment.|It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
48456652|NCT05069480|OTHER|Traditional physical therapy program|The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
48456653|NCT06423014|BEHAVIORAL|Wearable devices only|self-monitoring
48456654|NCT06423014|BEHAVIORAL|Wearable devices with the 1st behavior change technique|reminder
48456655|NCT06423014|BEHAVIORAL|Wearable devices with the 2nd behavior change technique|social support
48456656|NCT06423014|BEHAVIORAL|Wearable devices with the 3rd behavior change technique|Competition
48456657|NCT06423014|BEHAVIORAL|Wearable devices with the 4th behavior change technique|Goal-setting
48456658|NCT06423014|BEHAVIORAL|Wearable devices with the 5th behavior change technique|health coach
48456659|NCT06423014|BEHAVIORAL|Wearable devices with all behavior change techniques|Self-monitoring, health coach, goal-setting, competition, social support, and reminder
48456660|NCT06356558|OTHER|Educational intervention (VISACT)|The intervention is an implementation strategy called VISACT: VISuAl aids, Coach providers in communication, and Train organizations in health literacy. This strategy will be delivered to patients, providers, and organizations through a novel interactive response platform.
48456661|NCT00265226|BIOLOGICAL|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
48456662|NCT03333551|DRUG|F18 Florbetapir (amyvid) cardiac PET/CT imaging|Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
47933894|NCT02184351|DRUG|Roxanes's clotrimazole troches|
48456663|NCT03867760|BEHAVIORAL|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
48456664|NCT03867760|BEHAVIORAL|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
48456665|NCT05169931|BIOLOGICAL|RegenerEyes|Biologic eye drop
48456666|NCT06342830|DRUG|nanocurcumin gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of nanocurcumin gel until shown fill the canal under magnification and by using lentulospirals
48456667|NCT06342830|DRUG|Curcumin Gel|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5% between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of curcumin gel until shown fill the canal under magnification and by using lentulospirals
48622940|NCT02104102|OTHER|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
47933895|NCT02184351|DRUG|Mycelex® troches|
47933896|NCT04573647|DRUG|Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]|Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.
47933897|NCT06520540|DRUG|HDM1002 100 mg QD 12weeks|Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)
47933898|NCT06520540|DRUG|HDM1002 200 mg QD 12weeks|Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)
47933899|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 2W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration
48622941|NCT02104102|OTHER|Kinesiotherapy|Hands movements.
48622942|NCT00382512|DRUG|Raptiva (efalizumab)|
48622943|NCT04510415|DRUG|Olmutinib|"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
48456668|NCT06342830|DRUG|Ciprofloxacin 500 mg +ibuprofen 400mg|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of ciprofloxacin + ibuprofen gel until fill the canal under magnification and by using lentulospirals
48456669|NCT06342830|DRUG|Metapaste [calcium hydroxide paste (control group)]|firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of calcium hydroxide paste until fill the canal under magnification by using lentulospirals
48456670|NCT06559800|BEHAVIORAL|YourSkills: Cognitive behavioral therapy for children/youth with role-plays in virtual reality|A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
48456671|NCT01298050|PROCEDURE|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
48456672|NCT01501448|DRUG|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
48456673|NCT01501448|DRUG|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
48456674|NCT06012006|OTHER|constant work-rate cycling exercise test|Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion
48456675|NCT01875562|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
48456676|NCT03163160|PROCEDURE|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
48456677|NCT03163160|PROCEDURE|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
48456678|NCT04303221|OTHER|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
48456679|NCT00003223|DRUG|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
48456680|NCT03649581|OTHER|compare the two groups of schizophrenic patients|"Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~1. abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~2. abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia)."
48456681|NCT03649581|OTHER|compare the two groups of schizophrenic patients versus volunteers|compare the results of the schizophrenic patient group with healthy volunteers
48456682|NCT01002287|DEVICE|SprayShield Adhesion Barrier System|Adhesion Barrier Device
48456683|NCT01002287|PROCEDURE|Good Surgical Technique Alone|Good Surgical Technique Alone
47933900|NCT06520540|DRUG|HDM1002 400 mg QD 12weeks，Q 3W for titration|Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration
47933901|NCT06520540|DEVICE|Placebo|Placebo
48456684|NCT00831103|DRUG|EPB-348|Treated over seven days
48456685|NCT00831103|DRUG|Valacyclovir|Treated over seven days
48456686|NCT03835780|OTHER|No intervention|A observation of outcomes in usual practice
48456687|NCT04168307|DEVICE|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
48456688|NCT04168307|OTHER|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
48622944|NCT00578526|DRUG|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
48622945|NCT00578526|DRUG|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
48622946|NCT02358629|DEVICE|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
47933902|NCT01511666|DEVICE|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
47933903|NCT01511666|OTHER|Standard care|Standard care as per recent guidelines will be provided.
47933904|NCT05384704|BEHAVIORAL|Empower@Home|The intervention is a 9-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive weekly support from a trained research staff.
47933905|NCT02463552|DRUG|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
48456689|NCT05326880|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
48456690|NCT05326880|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
48456691|NCT04791813|OTHER|Alginate impressions , Photographic data and panoramic radiographs .|Upper and lower alginate impressions will be poured and dental casts produced and converted to 3D digital cast using a 3D scanner-(3Shape )-the 3D data will be imported to a revers modeling software . Also Photographic data using Canon750 camera and panoramic radiographs to be taken.
48456692|NCT02342873|PROCEDURE|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
48456693|NCT02342873|PROCEDURE|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
48456694|NCT01665508|DRUG|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
48456695|NCT03497130|OTHER|skin care regimen|These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
48456696|NCT04069936|BIOLOGICAL|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with locally advanced and unresectable or metastatic NSCLC
48456697|NCT04069936|BIOLOGICAL|nivolumab|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab in subjects with locally advanced and unresectable or metastatic NSCLC
48456698|NCT04069936|DRUG|tadalafil|To evaluate the efficacy of MILs™ - NSCLC in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC
48456699|NCT01789463|OTHER|Self rehabilitation|
48456700|NCT01789463|OTHER|Self rehabilitation plus physiotherapy|
48456701|NCT03153605|OTHER|Common toothpaste|different toothpaste
48456702|NCT04366635|PROCEDURE|Impacted third molar surgery|Under local anesthesia, flap will be raised and mesioangular or horizontal impacted third molar tooth will be removed with routine technique. And then extraction socket will be irrigated with salin and will be primarily closed.
48456703|NCT04366635|PROCEDURE|Application of mineralised plasmatic matrix|After extraction of impacted third molar tooth, Mineralized Plasmatic Matrix will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
48456704|NCT04366635|PROCEDURE|Application of β-tricalcium phosphate|After extraction of impacted third molar tooth, β-tricalcium phosphate will be placed to the socket as a graft material and will be covered with Platelet Rich Fibrin membrane. Then wound will be primarily closed.
48456705|NCT02462837|DRUG|Mirabegron|
48622947|NCT01927588|DRUG|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
48456706|NCT02462837|DRUG|Placebo|
48456707|NCT03498235|DRUG|Sevoflurane|In Team Sevoflurane,patients undergo sevoflurane.
48622948|NCT01927588|DRUG|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
48622949|NCT00683995|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
48456708|NCT03498235|DRUG|Propofol|In Team Propofol ,anesthesia is maintained with propofol
48456709|NCT00496990|BEHAVIORAL|Enhanced care|this group received counseling, contingency management and methadone or detoxification
48456710|NCT00496990|BEHAVIORAL|control|this group receives the opportunity to participate in a support group
48622950|NCT00022477|DRUG|BMS-247550|
48622951|NCT01164475|DRUG|Granulocyte-colony stimulating factor (G-CSF)|
48622952|NCT01164475|DRUG|Fixed Dose Plerixafor|
48622953|NCT01164475|DRUG|Weight-Based Plerixafor|
48622954|NCT00542308|DRUG|Zalutumumab|Individual dose titration weekly i.v. doses
48622955|NCT04892407|DEVICE|Algeness® DF 3.5%|dermal filler CE Mark approved for treatment of cheek and midface volume loss
48622956|NCT04892407|DEVICE|Juvéderm Voluma|dermal filler CE Mark approved for treatment of cheek and midface volume loss
48622957|NCT04601285|DRUG|JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)|"Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose."
48622958|NCT03062839|DRUG|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
48622959|NCT04542564|DEVICE|telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
48622960|NCT04542564|OTHER|usual care|These patients have unrestricted access to healthcare resources such as general outpatient clinics and emergency departments
48622961|NCT05457543|DIAGNOSTIC_TEST|Adult|Investigational use of a novel liver function diagnostic test that involves a paper-based test device and a smartphone application.
48456711|NCT06026163|DRUG|Caffeine citrate|Caffeine citrate in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base)
48456712|NCT06026163|OTHER|Placebo|Equivalent volume of saline
48456713|NCT05697679|BEHAVIORAL|Treatment group|WeChat groups will be set up, and once a week on Monday, articles on physical exercise and once a week on Wednesday, 3-minute films about health education will be shared. For the duration of the 3-month intervention period, the following technologies will be used to deliver the GAT-pap: (1) Short Messaging Service (SMS) text (batch messaging); (2) WeChat (e.g., physical activity guidelines, group chats); and (3) monthly face-to-face interviews (behaviour change promotion, risk factor management). Although not essential, participants will be urged to register their daily exercise in the group chat. In order to determine if they are accomplishing their goals and what objectives they should be pursuing, the researchers will develop customised training regimens for each participant.
48456714|NCT05697679|BEHAVIORAL|Contral group|One or two times each week, participants in the control group will get general lifestyle advice through SMS. They will not participate in the intervention's fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group's complaints or questions will always be answered with basic health information and suggestions. Researchers won't ask for individual advice or comments from other professionals.
48456715|NCT04985149|OTHER|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be \< 3.8 ms, amplitude \> 10 Mv, and conduction velocity \> 36 m/sec in sensory response of the sural nerve."
48456716|NCT04985149|OTHER|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
48456717|NCT04472039|DEVICE|optical coherence tomography (OCT)|OCT visualizes the retinal layers by backreflection of light
48456718|NCT00874276|DRUG|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
48456719|NCT00874276|GENETIC|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
48456720|NCT02471027|PROCEDURE|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
48456721|NCT00048334|DRUG|Depsipeptide, FR901228, FK228|
48456722|NCT00625560|DRUG|Entecavir|entecavir 1.0 mg QD
48456723|NCT00625560|DRUG|Lamivudine|lamivudine 100 mg QD
48622962|NCT04475510|OTHER|Antiplatelet treatment discontinuation|All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
48622963|NCT00056264|DRUG|Infliximab|
48622964|NCT04758338|OTHER|VUMC telehealth services|Participants will access the CTS link (sent to them via email), which will connect them directly to a videoconference and enable them to see and hear the facilitators and other patients in the group.
48622965|NCT04758338|OTHER|Interview|25-30 participants will be interviewed
47933906|NCT04369820|OTHER|draw blood|40 mL blood sample will be taken within the first three days of hospitalization, a second sample will be taken between the 5th and 10th day of hospitalization and a third sample will be taken on the 10th day of hospitalization or the day of discharge if earlier.
47933907|NCT05172479|DIAGNOSTIC_TEST|Measurement of qSOFA score|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.
47933908|NCT05172479|DIAGNOSTIC_TEST|Measurement of SIRS criteria|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.
48456724|NCT05198622|PROCEDURE|Intercostobrachial Nerve Preserving Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be completely preserved during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
47933909|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.
48622966|NCT04758338|OTHER|Educational materials|Participants will be provided educational materials
48456725|NCT05198622|PROCEDURE|Intercostobrachial Nerve Sacrificing Axillary Lymph Node Dissection|"A single standardized technique will be used in all of the patients. For patients undergoing mastectomy, ALND will be carried out using the incision given for mastectomy. A separate incision may be required for patients undergoing breast conservation surgery. Flaps of skin and subcutaneous tissue will be raised and dissection will be carried out till the edge of pectoralis major muscle. Clavipectoral fascia will be opened to gain access to axillary fat and the nodes. These will be removed en block and the intercostobrachial nerve will be sacrificed during this dissection.~All of the surgeons carrying out the intervention would have completed formal training (Fellowship Level) in breast surgery."
48456726|NCT04817722|DRUG|Intravenous Solution|Intraoperative hydration
48456727|NCT04946708|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions. All participants (and immediate caregiver if necessary) will receive training in: 1) basic device management (join a zoom meeting, watch a YouTube video), 2) use of the portable spirometer and its associated app, 3) use of finger pulse oximeter and 4) recording of the values in a dairy.
48456728|NCT04573569|BEHAVIORAL|Behavioral testing|Patients recruited for this study have already undergone surgical implantation of invasive electrodes for purpose of localizing and characterizing electrographic seizures as part of the second phase of surgical epilepsy evaluation. Patients who consent and complete enrollment will then be asked to complete cognitive and behavioral tasks on a portable computer or tablet PC while the invasive electrodes remain implanted. Tasks typically require the patient to think or act and then respond by interacting minimally with the portable computer. These tasks are performed at the will of each patient during their stay in the intensive care unit while surgical electrodes remain.
48456729|NCT00182260|DRUG|Proton Pump Inhibitors|
48456730|NCT00182260|PROCEDURE|Laparoscopic Nissen Fundoplication|
48456731|NCT04768114|BEHAVIORAL|Genetically-Informed RiskProfile|"* Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing."
48456732|NCT04768114|OTHER|Brief Cessation Advice|"* Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing."
48456733|NCT06272617|DEVICE|verum acupuncture|a type of acupuncture which is useful
48456734|NCT06272617|DEVICE|sham acupuncture|a type of acupuncture which is useless
48456735|NCT06000163|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the skin, which is non-invasive, and skin thickness and blood flow parameters will be measured.
48456736|NCT03692611|BEHAVIORAL|Skills TO Manage Pain (STOMP)|12 week pain self management (PSM) intervention incorporating social cognitive theory constructs.
48456737|NCT03692611|BEHAVIORAL|comparison group|Participants in this arm will receive usual care as given by providers but no behavioral PSM intervention.
48456738|NCT03245658|DRUG|THC and CBD Mixture|Individually titrated doses on daily basis
48456739|NCT01566435|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
48456740|NCT01566435|DRUG|Cisplatin|
48456741|NCT01566435|DRUG|Fluorouracil|
48456742|NCT01566435|RADIATION|Intensity modulated radiation therapy|
48456743|NCT01566435|DRUG|Cetuximab|
48456744|NCT01566435|PROCEDURE|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
47933910|NCT05172479|DIAGNOSTIC_TEST|Measurement of NEWS2|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.
47933911|NCT05172479|DIAGNOSTIC_TEST|Measurement of MEWS|At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
48456745|NCT02131220|DRUG|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
48456746|NCT02131220|DRUG|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
48456747|NCT02131220|DRUG|normal saline|intracoronary bolus infusion using selective catheter during PCI
48456748|NCT02471807|DEVICE|Edwards FORMA Tricuspid Transcatheter Repair System|
48456749|NCT02213705|BIOLOGICAL|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
48456750|NCT02811003|DEVICE|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
48456751|NCT04002648|PROCEDURE|Right minithoracotomy|Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space
48456752|NCT04002648|PROCEDURE|Sternotomy|Longitudinal resection of the sternum
48456753|NCT06559527|DRUG|NNC0487-0111|Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.
48456754|NCT04411680|DRUG|Sargramostim|Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). Dosage for inhaled sargramostim: 125 mcg twice a day. Dosage for intravenous sargramostim: 125mcg/m2/day given over a 4 hour period.
48622967|NCT00620542|DRUG|Rosuvastatin|capsule, oral, once daily
48622968|NCT00620542|DRUG|Atorvastatin|capsule, oral, one daily
47933912|NCT02382250|BEHAVIORAL|Survey|Survey will be given to all participants
48456755|NCT04411680|DRUG|Standard of care|Standard of care for COVID-19
48622969|NCT02490579|BEHAVIORAL|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
48456756|NCT01582464|BEHAVIORAL|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), \& a demographic \& functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
48456757|NCT03369496|OTHER|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
48456758|NCT06338891|OTHER|Main questionnaire|Main questionnaire will evaluate the demographic and genetic characteristics, clinical manifestations, and self-perception of sensitivity to wheat or other food and the possible relationship between the intake of wheat or other foods and the flare-ups of the disease in FMF patients
48456759|NCT06338891|OTHER|Secondary questionnaire|Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis
48456760|NCT03388905|DEVICE|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
48280600|NCT05863247|OTHER|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
48280601|NCT05865327|PROCEDURE|Cryoneurolysis|Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
48280602|NCT05865327|PROCEDURE|Sham Cryoneurolysis|Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
48280603|NCT02844855|BEHAVIORAL|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
48280604|NCT01492010|DIETARY_SUPPLEMENT|whey protein|25 g whey protein
48280605|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
48280606|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
48280607|NCT01455350|PROCEDURE|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
48280608|NCT01455350|DRUG|lidocaine|10 weeks of daily topical 5% lidocaine application
48280609|NCT03088501|BEHAVIORAL|Interactive voice response system|IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
48280610|NCT03088501|BEHAVIORAL|Mother and baby affairs workshop|Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
48280611|NCT02588378|PROCEDURE|multi-modal cSLO imaging|
48280612|NCT04964258|DRUG|TAK-105-a|TAK-105-a subcutaneous solution.
48280613|NCT04964258|DRUG|TAK-105-a Placebo|TAK-105-a placebo-matching solution.
48280614|NCT01560351|DEVICE|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
48456761|NCT00685464|DRUG|Abciximab|Intravenous.
48456762|NCT00685464|DRUG|Abciximab|Intracoronary
48456763|NCT03517319|DRUG|Normal Saline 0.9% 1.2 ml|
48456764|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U|
47933913|NCT02361580|OTHER|Diary|Subject keeps diary of recovery
47933914|NCT00910247|DRUG|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
47933915|NCT06136442|DRUG|Atogepant|atogepant in real life in Italy
48456765|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U|
48456766|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U|
48456767|NCT03517319|DRUG|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U|
48456768|NCT04989244|BEHAVIORAL|Weight loss program|Women with obesity were included to the weight loss program which included physical exercise and dietary guidelines
48622970|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
47933916|NCT03088462|OTHER|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
47933917|NCT03088462|BEHAVIORAL|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
47933918|NCT03088462|BEHAVIORAL|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
47933919|NCT05655806|DRUG|Aminophylline bolus then infusion|half an hour before discontinuation of isoflurane
47933920|NCT05655806|DRUG|aminophylline bolus|after discontinuation of isoflurane
47933921|NCT05655806|DRUG|normal saline|given as placebo
47933922|NCT03355664|DRUG|ACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
47933923|NCT03355664|DRUG|TACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
47933924|NCT06327542|OTHER|Group Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
48280615|NCT02367950|BEHAVIORAL|Exercise|10 exercise sessions with a personal trainer
48280616|NCT05833217|PROCEDURE|Adipose Tissue Biopsy|After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
48280617|NCT05833217|DIAGNOSTIC_TEST|Steady State Plasma Glucose (SSPG) Test|An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
48280618|NCT03036930|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48280619|NCT03036930|PROCEDURE|HPV Self-Collection|Undergo self-collection of vaginal/cervical samples
48280620|NCT03036930|OTHER|Questionnaire Administration|Ancillary studies
48280621|NCT03036930|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
48280622|NCT00787293|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
48280623|NCT02060734|PROCEDURE|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
48280624|NCT02060734|OTHER|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
48280625|NCT04960358|PROCEDURE|Surface Electromyography|will be applied Surface Electromyography to assess Flexion Relaxation Response
48280626|NCT03622645|DEVICE|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
48280627|NCT01650805|DRUG|ponatinib|45 mg tablet, taken orally once daily
48280628|NCT01650805|DRUG|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
48280629|NCT03849729|DRUG|Phentermine|This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
48280630|NCT03849729|OTHER|Placebo|his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
48280631|NCT05443022|RADIATION|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
48280632|NCT05443022|RADIATION|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
48280633|NCT04881838|DRUG|P regimen|Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
48456769|NCT01654419|DEVICE|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
48456770|NCT01654419|DEVICE|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
48456771|NCT04837469|PROCEDURE|fissure sealant application|fissure sealants were placed after differnt adhesive strategies used
48456772|NCT00736658|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
48456773|NCT00736658|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
48456774|NCT04146805|DRUG|BLD-0409|For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
48456775|NCT04146805|DRUG|Control: Placebo|Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
48456776|NCT00748722|DEVICE|CT Angiography|Injection of contrast material (iodine)
48456777|NCT03867071|OTHER|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
48456778|NCT03867071|OTHER|placebo injection|Intravenous injection 0,9% saline solution.
48456779|NCT05492162|OTHER|well-being promotion intervention|"The intervention will be organized on both conferences and workshops.~Four themes will be covered :~* Well-being (Workshops)~* Smoking prevention (Conference)~* Balanced diet (Workshop)~* Optimal organization for daily healthy living (Conference)"
48456780|NCT04383587|OTHER|Serologic testing|COVID19 IgG antibody testing to be performed
48456781|NCT01896479|DRUG|Cabozantinib (XL184) 140 mg|
48456782|NCT01896479|DRUG|Cabozantinib (XL184) 60 mg|
48456783|NCT01896479|DRUG|Placebo tablet|
48456784|NCT01896479|DRUG|Placebo capsule|
48456785|NCT06464549|DIAGNOSTIC_TEST|EEG-EOG recording at rest and during an auditory oddball paradigm|Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.
48456786|NCT03108235|BEHAVIORAL|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.
48456787|NCT03108235|BEHAVIORAL|HOM-HEMP with smartphone app|"a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference."
48456788|NCT03108235|BEHAVIORAL|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
48456789|NCT05216562|DRUG|Exosome-MSC Intravenous injection|Intravenous injection of Exosome-MSC
48456790|NCT05216562|DRUG|Placebo Intravenous Injection|Intravenous injection of Placebo
48456791|NCT05216562|DRUG|COVID-19 Standard Treatment|Specific drugs considered standard treatment for COVID-10 by each location may vary
47933925|NCT06327542|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
47933926|NCT00335231|DRUG|gatifloxacin ophthalmic (ZYMAR)|
47933927|NCT02292784|DRUG|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
47933928|NCT02292784|DRUG|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
47933929|NCT02292784|DRUG|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
47933930|NCT03095547|DRUG|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
48280634|NCT04881838|DRUG|Course A1 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
48280635|NCT04881838|DRUG|Course B1 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
48280636|NCT04881838|DRUG|Course A2 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
48280637|NCT04881838|DRUG|Course B2 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
48456792|NCT05701163|OTHER|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
48456793|NCT01185158|DRUG|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
48456794|NCT04548258|DEVICE|electric intraoral weilding|weilding metal framework to the implants in completely edentulous maxilla using electric weilding device intraorally
48456795|NCT04548258|DEVICE|casting|casting metal framework
48456796|NCT01440179|DRUG|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
48622971|NCT02490579|BEHAVIORAL|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
47933931|NCT03095547|DRUG|Posaconazole|Pharmacokinetic assessment AUC 0-tau
47933932|NCT03095547|DRUG|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
48456797|NCT00391365|PROCEDURE|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
47933933|NCT03095547|DRUG|F901318|Pharmacokinetic assessment AUC 0-tau
47933934|NCT03095547|DRUG|Tacrolimus|Pharmacokinetic assessment AUC 0-t
47933935|NCT01295268|OTHER|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
47933936|NCT01295268|OTHER|Inert oil|A specified amount of inert oil will be applied daily to area.
47933937|NCT01525173|DRUG|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
48456798|NCT01174849|DRUG|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
48456799|NCT01174849|DRUG|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
48456800|NCT01174849|DRUG|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
48456801|NCT01065857|DRUG|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
48456802|NCT01065857|DRUG|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
48456803|NCT03029364|BEHAVIORAL|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~* 3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~* 2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~* Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
48456804|NCT01370863|DRUG|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
48456805|NCT01370863|DRUG|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
48456806|NCT05895435|DEVICE|radiofrequancy|"* Power of device: 150 W~* Duration of the session: 40 minutes~* Frequency: 2 sessions per week for 8 week.~* Heating temperature: According to patient tolerance."
48622972|NCT04674527|DRUG|Elemene|Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.
47933938|NCT01525173|DRUG|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
47933939|NCT01525173|DRUG|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
47933940|NCT01525173|DRUG|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
47933941|NCT02824861|BEHAVIORAL|Bemobile|
47933942|NCT03611842|OTHER|preservation of mucosal otitis media|Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
47933943|NCT00214500|DRUG|migalastat HCl|
47933944|NCT06450951|DIAGNOSTIC_TEST|Urinary EDC metabolite testing|Mail-in urine samples tested for metabolites of bisphenols, phthalates, parabens, and oxybenzone.
47933945|NCT06450951|BEHAVIORAL|Educational curriculum|A self-directed online interactive curriculum of EDC material, with access to live coaches and an online forum.
47933946|NCT04988633|BEHAVIORAL|Intervention CFG App|Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.
47933947|NCT04988633|BEHAVIORAL|Control Group|Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
47933948|NCT01360775|BEHAVIORAL|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
47933949|NCT04695587|DIAGNOSTIC_TEST|123 MIBG scintigraphy testing|123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.
48280638|NCT04881838|DRUG|Course A3 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
48280639|NCT04881838|DRUG|Course B3 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
47933950|NCT04695587|DIAGNOSTIC_TEST|MSNA|MSNA in subacute phase and 12 months after the acute episode
47933951|NCT04695587|DIAGNOSTIC_TEST|ABPM|ABPM in subacute phase and 12 months after the acute episode
47933952|NCT04695587|DIAGNOSTIC_TEST|ECHO|ECHO in subacute phase and 12 months after the acute episode
48280640|NCT04881838|DRUG|Maintenance therapy|Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
47933953|NCT04695587|DIAGNOSTIC_TEST|24hour ECG|24hour ECG in subacute phase and 12 months after the acute episode
47933954|NCT04695587|DIAGNOSTIC_TEST|CMR|CMR in 12 months after the acute episode
47933955|NCT00738621|DRUG|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
47933956|NCT00738621|DRUG|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
47933957|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
48456807|NCT05895435|OTHER|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
47933958|NCT03774095|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
47933959|NCT05287542|OTHER|Hypnotic suggestion|The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.
47933960|NCT05287542|OTHER|Mindfulness|The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
47933961|NCT00058539|DRUG|rhuMAb 2C4 (pertuzumab)|
47933962|NCT05811650|BEHAVIORAL|Oral Health Counseling and promotion|The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
47933963|NCT00422318|DRUG|Benzbromarone (drug)|
47933964|NCT02923258|DRUG|Docetaxel|20mg/m2/w
47933965|NCT02923258|DRUG|Cisplatin|100mg/m2/q3w
47933966|NCT02923258|RADIATION|IMRT|a total dose of 60Gy in 30fractions over 6 weeks
47933967|NCT00800462|DRUG|Oxybutynin Cl|15 mg qd for 3 months
48098730|NCT01553513|OTHER|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
48098731|NCT02834689|BEHAVIORAL|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
48456808|NCT05325268|PROCEDURE|Osteosynthesis|Treatment of fracture with open reduction and osteosynthesis
48456809|NCT06627985|DIAGNOSTIC_TEST|GPT-4o|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
48456810|NCT06627985|DIAGNOSTIC_TEST|GPT-4o mini|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o mini. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
48456811|NCT06627985|DIAGNOSTIC_TEST|MedicalGPT|Input all patient medical records, including text, examination reports, and imaging data, into MedicalGPT. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
48456812|NCT06627985|DIAGNOSTIC_TEST|Claude-3.5 Sonnet|Input all patient medical records, including text, examination reports, and imaging data, into Claude-3.5 Sonnet. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
48456813|NCT06627985|DIAGNOSTIC_TEST|Claude 3 Haiku|Input all patient medical records, including text, examination reports, and imaging data, into Claude 3 Haiku. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
48622973|NCT04674527|DRUG|Temozolomide|Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
47933968|NCT00800462|DRUG|Trospium Cl|20mg bid for 3 months
47933969|NCT00800462|DRUG|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
47933970|NCT04809636|OTHER|This is not an interventional study|While this is not an intervention, there will be separate participants for the survey study and for the other components of the study (focus groups, interviews, conjoint analysis, piloting the vignettes
47933971|NCT01876433|DRUG|Mirabegron|
47933972|NCT01876433|DRUG|Placebo|
47933973|NCT00290407|DRUG|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
47933974|NCT00290407|DIETARY_SUPPLEMENT|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
47933975|NCT03573102|DRUG|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
47933976|NCT03573102|DRUG|ACE inhibitor|ACE inhibitor once daily
47933977|NCT02492737|DRUG|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
47933978|NCT03400982|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone densitometry and measurement of body composition
47933979|NCT03461679|PROCEDURE|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
47933980|NCT03461679|PROCEDURE|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
47933981|NCT01115582|DRUG|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
47933982|NCT01931176|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
47933983|NCT01931176|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
48456814|NCT06627985|DIAGNOSTIC_TEST|Real Doctors|Retrospectively collect the diagnostic and treatment recommendations from the corresponding departments involved in the multidisciplinary treatment of past patients, as well as the overall recommendations.
47933984|NCT00354185|DRUG|tanespimycin|Given IV
47933985|NCT00354185|DRUG|belinostat|Given IV
47933986|NCT00354185|OTHER|laboratory biomarker analysis|Correlative studies
48456815|NCT05244876|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
48456816|NCT00893919|DRUG|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
48456817|NCT06454214|DEVICE|Multi-photon microscopy|To conduct 3D structural imaging on human breast tissues
48456818|NCT04340063|DEVICE|Gait training performed on a treadmill|Participants randomized to the Control group will complete high intensity gait training on a treadmill.
48456819|NCT04340063|DEVICE|Gait training performed in a Movement Amplification Environment|The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
48456820|NCT02744287|BIOLOGICAL|BPX-601|Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
48456821|NCT02744287|DRUG|Rimiducid|Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
48456822|NCT03415308|OTHER|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
48456823|NCT03415308|OTHER|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
47933987|NCT00354185|OTHER|pharmacological study|Correlative studies
47933988|NCT03843242|DEVICE|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
47933989|NCT03843242|DEVICE|Pacemaker with VpS® algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
47933990|NCT03843242|DEVICE|Pacemaker with IRSplus algorithm on|"1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
47933991|NCT01733797|DEVICE|Wooden spatula|Lollipop sticks placed between incisors
47933992|NCT01733797|DEVICE|Therabite|Hand held device placed in mouth that exercises the jaw
47933993|NCT03238846|OTHER|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
47933994|NCT03238846|OTHER|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
48280641|NCT05449353|BEHAVIORAL|Trauma-informed Cognitive Behaviour Therapy (TiCBT)|Group: Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
48280642|NCT05222139|BIOLOGICAL|COVID-19 vaccination|Monitoring COVID-19 vaccination
48456824|NCT03415308|OTHER|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
48456825|NCT02438735|PROCEDURE|laparoscopic endometrioma excision|
47933995|NCT02119676|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
47933996|NCT02119676|DRUG|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
48280643|NCT00807664|DEVICE|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
48456826|NCT02438735|OTHER|Conservative follow up|
48456827|NCT00308906|DRUG|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
48456828|NCT00003808|DRUG|theophylline|
48456829|NCT00899951|DRUG|fentanyl citrate|
48456830|NCT00899951|OTHER|pharmacological study|
48622974|NCT04808921|DIAGNOSTIC_TEST|Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test|Rapid Antigen diagnostic device performance comparative to RT-PCR
48456831|NCT03701945|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
48456832|NCT04606550|DEVICE|Microablative Fractional CO2 Laser Therapy|Microablative Fractional CO2 Vaginal Laser Therapy
48456833|NCT04750239|DRUG|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
48456834|NCT04426851|DRUG|BI 1358894|BI 1358894
48456835|NCT03181620|OTHER|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
48456836|NCT04531969|OTHER|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
48456837|NCT02849951|DRUG|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
48456838|NCT02849951|DRUG|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
48456839|NCT03921762|PROCEDURE|Cataract surgery with Artis Active IOLs|Patients will be implanted with the Artis Active IOLs during cataract surgery
48456840|NCT03921762|PROCEDURE|Cataract surgery with AT Lara IOLs|Patients will be implanted with the AT Lara IOLs during cataract surgery
48456841|NCT00822744|DRUG|SSR411298|"Form: capsule~Route: oral administration with food"
48456842|NCT00822744|DRUG|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
48456843|NCT00822744|DRUG|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
48456844|NCT01632215|DRUG|Gabapentine|Gabapentine 600 mg 01 dose
48456845|NCT01632215|OTHER|Sugar pill|Sugar pill 01 dose
48456846|NCT01408654|BEHAVIORAL|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
48456847|NCT00608322|DRUG|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
48456848|NCT00608322|OTHER|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
48456849|NCT04511208|DEVICE|Cooling Vest|Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
48456850|NCT04511208|DEVICE|Without cooling vest|Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
48456851|NCT04411576|DIAGNOSTIC_TEST|Throat swab sample for measuring current infection with SARS-CoV-2|Throat sample taken by the study participant to be analyzed with RT PCR for the presence of SARS-CoV-2 viral nucleic acids.
48456852|NCT04411576|DIAGNOSTIC_TEST|Blood sample for serology to measure past infection with SARS-CoV-2|Blood samples for serology to be analyzed for the presence of SARS-CoV-2 antibodies.
48456853|NCT01186458|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
47933997|NCT02119676|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
48456854|NCT01186458|DRUG|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
48456855|NCT01186458|DRUG|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
48456856|NCT00587730|DEVICE|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
48456857|NCT01688011|DRUG|Luspatercept|Prescribed by treating physician as per product label.
48456858|NCT06560450|DEVICE|Stride One|Stride One is a smart insole that provides real-time audio feedback (cues) to the patient when performing a certain exercise. The goal of Stride One is to allow patients to practice walking more intensively and with higher quality during rehabilitation.
48456859|NCT02258035|OTHER|Blood draw|Sampling of 100-150 ml of blood
48456860|NCT03578497|DRUG|IL-1 receptor antagonist Anakinra|IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
48098732|NCT02834689|BEHAVIORAL|Seated Control|Sitting for 50 minutes
48456861|NCT05277402|DRUG|ADG116|IV infusion
48456862|NCT04173611|DRUG|EXPAREL|Injection into the Intrathecal space.
48456863|NCT04173611|DRUG|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
48622975|NCT04448301|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
47933998|NCT03924466|DRUG|68GaNOTA-Anti-HER2 VHH1|"All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.~A second injection of the IMP can be administered before or during standard-of-care treatment, depending on cohort."
47933999|NCT03808103|BIOLOGICAL|Placebo|Orally, twice a day, for a period of fifteen days
48098733|NCT04071223|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48098734|NCT04071223|PROCEDURE|Bone Scan|Undergo bone scan
48098735|NCT04071223|DRUG|Cabozantinib S-malate|Given PO
48098736|NCT04071223|PROCEDURE|Computed Tomography|Undergo CT
48098737|NCT04071223|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48456864|NCT04173611|OTHER|Placebo|Injection into the Intrathecal space.
48456865|NCT01262235|DRUG|TKM-080301|Repeat dose IV infusion.
48456866|NCT01448096|DRUG|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
48456867|NCT01448096|PROCEDURE|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
48456868|NCT03262051|DIAGNOSTIC_TEST|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
48456869|NCT05990127|DRUG|AK104|AK104 IV, q3w
48456870|NCT05990127|DRUG|Tislelizumab|Tislelizumab IV, q3w
48456871|NCT05990127|DRUG|carboplatin|carboplatin IV, q3w
48456872|NCT05990127|DRUG|Pemetrexed|Pemetrexed IV, q3w (for Nonsquamous NSCLC)
48456873|NCT05990127|DRUG|Paclitaxel|Paclitaxel IV, q3w (for squamous NSCLC)
48456874|NCT00680940|DRUG|Paclitaxel & Cisplatin|Chemotherapeutic agent
48280644|NCT00807664|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
48456875|NCT00680940|BIOLOGICAL|Mycobacterium w.|Immunomodulator
48456876|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 6(Draf III).|Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).
48456877|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)|Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
48456878|NCT06052839|DRUG|Pembrolizumab|Immunotherapy that works by helping the immune system to kill cancer cells by targeting and blocking a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
48456879|NCT06052839|DRUG|Carboplatin|A chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
48456880|NCT06052839|DRUG|Paclitaxel|A chemotherapeutic agent used as a treatment for various cancers; paclitaxel is a mitotic inhibitor.
48456881|NCT01885897|BIOLOGICAL|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
48098738|NCT04071223|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET or NaF-PET
48280645|NCT03069651|OTHER|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
48456882|NCT00229944|DRUG|Azithromycin|
48456883|NCT01442051|PROCEDURE|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB \< 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB \<7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
48456884|NCT03512483|BEHAVIORAL|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
48456885|NCT03783663|BEHAVIORAL|Misfit Shine 2|The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
48456886|NCT02586350|DRUG|Anlotinib|
48456887|NCT02586350|DRUG|Placebo|Placebo p.o. qd
48456888|NCT01640743|DRUG|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
48456889|NCT01640743|DRUG|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
48456890|NCT00377117|PROCEDURE|Management|
48456891|NCT00377117|PROCEDURE|Screening|
48456892|NCT03965429|OTHER|Blood samples (additional tubes from care) longitudinal|Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
48456893|NCT03965429|OTHER|Blood samples (additional tubes from care) at inclusion|"In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification."
48456894|NCT00239005|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
48456895|NCT00239005|DRUG|Mycophenolate Mofetil (MMF)|
48098739|NCT04071223|OTHER|Quality-of-Life Assessment|Ancillary studies
48098740|NCT04071223|OTHER|Questionnaire Administration|Ancillary studies
48622976|NCT03848078|DEVICE|Optical Coherence Tomography|"OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not."
48622977|NCT01741818|OTHER|Measuring IVC collapsibility index by bedside ultrasonography|
47934000|NCT03808103|BIOLOGICAL|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
47934001|NCT04461600|DRUG|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
48622978|NCT03060681|DRUG|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
47934002|NCT03956797|DEVICE|Recens Cooling Anesthesia Device|Application of cooling anesthesia device prior to intravitreal injection
47934003|NCT06095622|DIETARY_SUPPLEMENT|Fenugreek Seeds and Indian Rennet|Food herbs like fenugreek Seeds and Indian rennet to formulate rice dish.
47934004|NCT02454231|BIOLOGICAL|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
47934005|NCT02454231|BIOLOGICAL|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
47934006|NCT00162955|DRUG|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
47934007|NCT03080077|DRUG|Ricrolin+|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
47934008|NCT03080077|DRUG|Epi-Off|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of \~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
47934009|NCT05064839|PROCEDURE|Bony scintigraphy|Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
47934010|NCT03049293|DRUG|Midazolam|The impact of Midazolam levels in follicular fluid.
47934011|NCT05977478|DEVICE|SPECTRA IMDx™|In this study, SPECTRA IMDxTM system will be used to capture the Raman spectra to correlate to histopathology results and mass spectrometry profiling results.
47934012|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
47934013|NCT00645788|DRUG|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
47934014|NCT00645788|DRUG|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
47934015|NCT00645788|DRUG|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
48622979|NCT01968317|DRUG|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
48622980|NCT01968317|DRUG|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
47934016|NCT05059899|BEHAVIORAL|Exercise group|The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
47934017|NCT02792621|DIETARY_SUPPLEMENT|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
47934018|NCT02792621|DIETARY_SUPPLEMENT|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
48622981|NCT01888588|DRUG|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
48622982|NCT03943082|BEHAVIORAL|Cancer Educational Materials|Receive FRP brochure
48622983|NCT03943082|OTHER|Follow-Up Care|Receive follow-up phone call
48622984|NCT03943082|BEHAVIORAL|Questionnaire|Ancillary studies
47934019|NCT00786851|DRUG|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
47934020|NCT04610164|DRUG|Tranexamic acid|Prior to surgery, the patient will receive 1 gram of IV TXA
47934021|NCT06416995|DIAGNOSTIC_TEST|first trimester serum diagnostic test|First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
48456896|NCT05869136|PROCEDURE|microneedling and hyaluronic acid for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered.~Hyaluronic acid:~HA will be injected in the attached gingiva and MN will be carried out 1mm below the gingival margin on the keratinized gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles in the test group."
48456897|NCT05869136|PROCEDURE|microneedling for increasing gingival thickness in thin gingival phenotype|"All the participants will undergo phase-I therapy. Oral hygiene instructions will be imparted and will be reinforced at each appointment.~Local anaesthesia in the form of xylocaine spray will be administered and microneedling alone will be performed in control group"
48456898|NCT05312554|DEVICE|Iris FIT™ PFO closure system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Iris Patent foramen ovale occluder according to the INSTRUCTIONS for Use (IFU)
48456899|NCT03198923|BIOLOGICAL|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10\^9 NK and NKT cells in one course of treatment.
48456900|NCT04895553|OTHER|Observation of ICH and VTE|The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
48456901|NCT00472212|DEVICE|Spectacles|Hyperopic spectacle lenses
48456902|NCT00472212|DEVICE|Control|Plano (no power, control) spectacle lenses
48456903|NCT05196334|OTHER|No intervention|No intervention
48456904|NCT05862805|PROCEDURE|Sample Collection and Endometrial Biopsy|Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
48456905|NCT03908736|DRUG|Zinc Picolinate 15 Mg|zinc picolinate, 15 mg/day for 6 months
48622985|NCT01373229|DRUG|Lenalidomide + Plerixafor (+ Rituximab)|"1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression."
48456906|NCT01751087|OTHER|Mifepristone|oral mifepristone 200 mg on Day 1.
48456907|NCT01751087|DRUG|misoprostol|buccal misoprostol 400 mcg on Day 2
48456908|NCT01751087|DEVICE|Osmotic dilators|osmotic dilators on Day 1
48456909|NCT01751087|OTHER|placebo|placebo for mifepristone, on day 1
48456910|NCT01751087|OTHER|placebo|placebo for misoprostol, on day 2
48456911|NCT05526313|DRUG|Prilinostat Mesylate 1.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
48456912|NCT05526313|DRUG|Prilinostat Mesylate 2.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
48456913|NCT05526313|DRUG|Prilinostat Mesylate 4.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
48456914|NCT05526313|DRUG|Prilinostat Mesylate 6.0mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
48456915|NCT05526313|DRUG|Prilinostat Mesylate 8.4mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
48456916|NCT05526313|DRUG|Prilinostat Mesylate 11.2mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
48456917|NCT05526313|DRUG|Prilinostat Mesylate 15mg/m2|1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
48456918|NCT01252953|DRUG|Anacetrapib|tablet, 100mg daily
47934022|NCT05171829|OTHER|Track U|Track U diary
48456919|NCT01252953|DRUG|Placebo anacetrapib|tablet, 1 tablet daily
48456920|NCT01049581|PROCEDURE|aquatic therapy|two hours per week, one hour per time, total 12 weeks
48456921|NCT05608239|DEVICE|Sculptra aesthetic|The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
48456922|NCT03893617|DRUG|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
48456923|NCT03893617|DRUG|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
48456924|NCT03893617|BEHAVIORAL|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
48456925|NCT03893617|BEHAVIORAL|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
48456926|NCT04604262|DEVICE|Waterpik|Waterpik dental water jet
48456927|NCT06626789|BIOLOGICAL|Amygdala neurofeedback|Real-time fMRI neurofeedback from amygdala's blood oxygenation level dependent (BOLD) signal + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
47934023|NCT03993093|OTHER|CD4 cell count|CD4 cell count from treatment naive HIV patients
48098741|NCT04071223|RADIATION|Radium Ra 223 Dichloride|Given IV
48456928|NCT06626789|BEHAVIORAL|Sham neurofeedback|Recorded neurofeedback from a different participant + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
48456929|NCT04556045|BEHAVIORAL|Exercise therapy|The exercise therapy intervention will last 4 weeks. Each participant assigned to this intervention will receive a personalized ET regimen, including in-person, supervised exercise sessions; other activities to be followed at home. Participants will exercise between one and seven times per week depending on their tolerance to the treatment and exercise program.
48456930|NCT06230094|OTHER|moderate intensity|Arm Circles, Leg Swings, Lunges, brisk walk
48456931|NCT06230094|OTHER|high intensity|Arm circles, Leg swings, Lunges, skipping rope
47934024|NCT02353143|DRUG|MEN1112|"Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).~Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration)."
47934025|NCT03742440|BIOLOGICAL|GrafixPL PRIME|GrafixPL PRIME
47934026|NCT06400017|DEVICE|microelectrode stimulation of DBS|"Contact selection: According to the electrode position in the image (target reconstruction through CT scan), the electrode located in the substantia nigra is selected as the negative electrode, the contact near the upper part of the substantia nigra is selected as the positive electrode, and the bipolar stimulation mode is selected.~Stimulation parameters: The frequency was selected as 0/10/130Hz, the pulse width remained unchanged at 90μs, the side effects of patients were observed, and the voltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious stimulation. The washout period was 1 hour"
47934027|NCT04560244|DRUG|SHR1701|PD-L1 / TGF-β RII double antibody
48456932|NCT03439085|BIOLOGICAL|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|Given IM and via electroporation
47934028|NCT03684252|BEHAVIORAL|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
48456933|NCT03439085|BIOLOGICAL|Durvalumab|Given IV
47934029|NCT03684252|OTHER|Treatment as Usual|Participants' will receive treatment as usual.
47934030|NCT00171054|DRUG|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
47934031|NCT00171054|DRUG|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
47934032|NCT00171054|DRUG|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
47934033|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention|"Focus of the SEMC-protocol is on increasing PA gradually towards the national recommendations. Emphasis of counseling is on incidental exercise, endurance, and strength training. Techniques of motivational interviewing are utilized.~Baseline; MD+PT counseling, medical clearance, mapping lifestyle \& life situation, goal setting, measurements, questionnaires, feedback. weeks 1-6: guided group resistance training 1hr, 1x/week. 5-10-minute warm-up, 9 exercises with weight stack equipment on large muscle groups. 2-3 sets, 12-15 repetitions. Modified individually, e.g. according to musculoskeletal problems. Emphasis on learning the basics and safety aspects. After 6 weeks unsupervised training. 3-month: MD counseling and questionnaires. 6-month: MD+PT counseling, assessing safety of PA, measurements, questionnaires, feedback. 12-month: MD+PT counseling (feedback, ensuring continuity of lifestyle changes; redirecting to municipality/NGO activities), measurements, questionnaires, feedback"
48456934|NCT05359965|DEVICE|Positive Airway Pressure|Gentle and steady pressure (with or without supplemental oxygen) delivered to the airways of the lungs while subjects are sleeping.
48456935|NCT01368380|BEHAVIORAL|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
48456936|NCT00425841|DRUG|gemcitabine hydrochloride|
48456937|NCT00425841|DRUG|oxaliplatin|
48456938|NCT00425841|PROCEDURE|adjuvant therapy|
48456939|NCT00425841|PROCEDURE|neoadjuvant therapy|
48098742|NCT06629337|GENETIC|H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)|Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
48098743|NCT02760381|DEVICE|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
48456940|NCT00425841|RADIATION|hypofractionated radiation therapy|
48456941|NCT00425841|RADIATION|stereotactic radiosurgery|
48456942|NCT03447535|OTHER|Semi-directive interview (Kiddy Sads)|semi-directive interview (Kiddy Sads) conducted as part of the care
48456943|NCT03447535|OTHER|SDQ questionnaires (strenghs and difficulties questionnaire)|SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
48456944|NCT00867360|DRUG|Mifepristone (RU-486)|
48456945|NCT00867360|DRUG|Placebo|Placebo medication
48456946|NCT04738968|DEVICE|Cochlear implant|A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
48456947|NCT02531620|OTHER|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
48456948|NCT02531620|OTHER|Routine Care|Usual care for your disease process
48456949|NCT03066544|DRUG|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
48456950|NCT03066544|DRUG|Naratriptan Pill|one pill will be administered twice each day for 5 days
48456951|NCT03066544|DRUG|Dexamethasone|one tablet will be administered twice each day for 3 days
48456952|NCT03066544|DRUG|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
48456953|NCT01275664|PROCEDURE|Adjuvant Therapy|Ancillary studies
48456954|NCT01275664|DRUG|Aprepitant|Given IV and PO
48456955|NCT01275664|DRUG|Carboplatin|Given IP
48456956|NCT01275664|DRUG|Cisplatin|Given IP
48456957|NCT01275664|DRUG|Dexamethasone|Given PO
48456958|NCT01275664|DRUG|Granisetron Transdermal Patch|Apply one patch to upper arm
48456959|NCT01275664|PROCEDURE|Management of Therapy Complications|Ancillary studies
47934034|NCT06382883|BEHAVIORAL|Individually tailored lifestyle and physical activity intervention combined with enhanced behavioral support -intervention (EBS)|"In addition to the SEMC-protocol, the participants will be contacted 3 times during the first 3 months (live / online as preferred). Themes:~Session 1: Motivation and illness perceptions. Exploring CPAP use, PA, and SB. Session 2: Self-regulation (feedback, goal setting, self-monitoring, action planning, problem solving), activating social support, prompts/cues, and preparatory behaviors. (Included BCTs from Michie et al 2013 taxonomy: 3.2, 12.2, 8.3,) Session 3: Assessing progress and agenda setting, self-regulation, maintenance of PA.~Measurements and questionnaires as with SEMC-protocol."
48456960|NCT01275664|OTHER|Questionnaire Administration|Ancillary studies
48456961|NCT03102385|BEHAVIORAL|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
48456962|NCT03102385|BEHAVIORAL|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
47934035|NCT06391801|BEHAVIORAL|Neuroathletic training|Specific Neuroathletic training exercises were performed to improve balance ability of post stroke patients
47934036|NCT06391801|BEHAVIORAL|Traditional movement therapy in outpatient rehabilitation|Traditional movement therapy in outpatient rehabilitation
47934037|NCT02496676|DIETARY_SUPPLEMENT|Magnesium L-threonate|"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
48456963|NCT05462080|DIAGNOSTIC_TEST|Ceraxis product|All patients will have their symptoms evaluated using the Ceraxis product
48456964|NCT02396888|DRUG|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
48456965|NCT02396888|DRUG|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
48456966|NCT05874596|BEHAVIORAL|AI-aided clinical feedback system coupled with multi-aspect intervention basd on Behaviour Change Wheel model|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
48456967|NCT04626440|PROCEDURE|Diagnostic stage or the Clinical outcome|After enrollment, individual subject will be assigned into one of the four groups according to the medical management received, the diagnostic stage of breast cancer (BC), or the clinical outcome of BC at enrollment.
48456968|NCT01131260|DEVICE|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
48456969|NCT03022643|BEHAVIORAL|Interpersonal Social Rhythms Psychotherapy|The treatment involves 8-weeks of individual psychotherapy. Weekly sessions will be 60-minute long and will take place at the Pain Research Center. The treatment focuses on 1) the link between life events, pain severity, sleep disturbances, fatigue, and mood, 2) social and behavioral rhythms and sleep-wake disturbances, 3) identification and management of rhythm dysregulation and the triggers for it, 4) allowing and facilitating the mourning of the loss healthy self, 5) identification and appropriate management of symptoms.
48456970|NCT03022643|OTHER|Bright Light Device|All patients will be provided with a bright light device (Re-Timer) and will be instructed to use it in the first 2-hours of the day (for a minimum of 30 minutes) throughout the 8-week treatment period.
48456971|NCT06276660|OTHER|BCTT|"Participants will complete the Buffalo Concussion Treadmill Test, which involves individuals walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter."
48456972|NCT06276660|OTHER|Dynamic ExIT|The modified EXiT test will complete a 12 minute treadmill interval program followed by a dynamic circuit (10 squat jumps, 10 side to side push ups and 10 medicine ball rotations), jump ball toss, zig zag agility and arrow agility. Parameters will be recorded the same as the established dynamic EXiT test; heart rate and RPE will be recorded at 0, 2, 6:30 and 12 minutes of the treadmill program as well as after the second trial of each activity. The time to complete two trials of the zig zag agility and arrow agility will also be recorded.
48456973|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
47934038|NCT02496676|OTHER|Placebo|In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
47934039|NCT02496676|DRUG|Intravenous (IV) magnesium sulfate (MgSO4)|In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
48280646|NCT00380562|BEHAVIORAL|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
48622986|NCT01323218|DRUG|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
47934040|NCT04545203|OTHER|Slow-stroke back massage|Slow-stroke back massage was performed to the breast cancer patients in intervention group. The SSBM sessions were administered 10 minutes before and after chemotherapy treatment.The SSBM was applied for 20 minutes in total, on each cycle. The intervention group received 20-minute SSBM sessions 3 chemotherapy cycle in addition to the routine care.
47934041|NCT00278408|BIOLOGICAL|filgrastim|
48456974|NCT03485118|DRUG|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
48456975|NCT03485118|DRUG|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m\^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
48456976|NCT03694535|DRUG|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
48456977|NCT00538031|DRUG|cyclophosphamide|Given orally
48456978|NCT00538031|DRUG|celecoxib|Given orally
48456979|NCT02210117|BIOLOGICAL|Bevacizumab|Given IV
48456980|NCT02210117|PROCEDURE|Biopsy|Undergo biopsy
48456981|NCT02210117|BIOLOGICAL|Ipilimumab|Given IV
48456982|NCT02210117|OTHER|Laboratory Biomarker Analysis|Correlative studies
47934042|NCT00278408|BIOLOGICAL|rituximab|
47934043|NCT00278408|DRUG|cyclophosphamide|
47934044|NCT00278408|DRUG|doxorubicin hydrochloride|
47934045|NCT00278408|DRUG|prednisone|
47934046|NCT00278408|DRUG|vincristine sulfate|
47934047|NCT00278408|RADIATION|radiation therapy|
47934048|NCT05767476|DIAGNOSTIC_TEST|Clinical and instrumental neurological assessment|"Participants will be involved in serial assessment:~* Neonatal Cranial Ultrasonography~* Brain magnetic resonance imaging~* Neurological assessment~* Neurodevelopmental and cognitive assessment~* Electroencephalogram (EEG)~* Motor performance assessment"
47934049|NCT01815203|DRUG|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
47934050|NCT01815203|DRUG|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
48456983|NCT02210117|PROCEDURE|Metastasectomy|Undergo metastasectomy
48456984|NCT02210117|BIOLOGICAL|Nivolumab|Given IV
48456985|NCT02210117|PROCEDURE|Therapeutic Conventional Surgery|Undergo nephrectomy
48456986|NCT03331458|BEHAVIORAL|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
48456987|NCT03097198|OTHER|Plum-blossom Needle|"* acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~* plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
48456988|NCT03097198|DRUG|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
48456989|NCT03562182|OTHER|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
48456990|NCT03807037|DIETARY_SUPPLEMENT|Tocotrienols|Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
48622987|NCT05679310|DIETARY_SUPPLEMENT|Hydroxytyrosol/Essential oils|A dietary supplement containing 10 mg of hydroxytyrosol, synthesised using genetically modified Escherichia coli strains and equal amounts (8.33 μL) of essential oils from oregano vulgaris, sage officinalis and crithmum maritimum.
47934051|NCT05165745|BEHAVIORAL|Individualized Feedback|Participants taking PrEP will receive questionnaires regarding self-reported weekly PrEP adherence; they will then receive individualized text-message or email feedback based on their self-reported adherence.
47934052|NCT03513081|BEHAVIORAL|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
47934053|NCT00972647|PROCEDURE|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
48456991|NCT03807037|DRUG|Placebo oral capsule|Matching placebo to be administered orally at 1 capsule, twice daily
48456992|NCT03736577|OTHER|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
48456993|NCT01904513|DIETARY_SUPPLEMENT|Pasteurized Whole Milk|
48456994|NCT01904513|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1|
48456995|NCT05174390|DIAGNOSTIC_TEST|Coala Heart Monitor Pro|thumb- and chest-ECG
48456996|NCT04384289|PROCEDURE|Nursing care based on the Transitonal Care Model|Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
48456997|NCT03314857|DEVICE|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
48456998|NCT03939364|DRUG|SBS-101|Isotretinoin Oral-Adhesive Film
48456999|NCT03939364|DRUG|Placebo|Placebo
48457000|NCT02290262|OTHER|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
48457001|NCT02889107|OTHER|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
48457002|NCT06398522|DIETARY_SUPPLEMENT|Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3|Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3
48457003|NCT06398522|OTHER|Placebo|Placebo
48457004|NCT03341013|DRUG|MEDI0382 Formulation 2|Sequence 1 Period 1 and Sequence 2 Period 2.
48457005|NCT03341013|DRUG|MEDI0382 Formulation 3|Sequence 1 Period 2 and Sequence 2 Period 1
48457006|NCT03306277|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
48457007|NCT06628024|OTHER|Milk|Milk
48457008|NCT06628024|OTHER|Yoghurt|Yoghurt
48457009|NCT05804786|DEVICE|Guided bronchoscopy|It is performed when a pulmonary lesion with a possibility of malignancy is found on chest CT and histological diagnosis and differentiation are required.
48457010|NCT05636254|DIAGNOSTIC_TEST|MRI Brain and spine|"* MRI Brain~* Ax T2 TSE~* 3D Sag T1~* Ax DWI~* 3D Sag Flair~* Ax SWI~* Post-gad 3D Sag T1~* 3D TOF Circle-of-Willis~* MRI Spine~* Sag T2 whole spine (2 stations)~* Post-gad Sag T1 whole spine (2 stations)"
47934054|NCT04976153|BIOLOGICAL|aSMDC|Autologous Muscle Derived Cells for injection into the external anal sphincter
47934055|NCT04976153|OTHER|Placebo|Placebo control is the vehicle solution used for the study product
48457011|NCT05636254|DIAGNOSTIC_TEST|Reference standard diagnostic criteria|"Diagnostic criteria-TBM~* Microbiologic evidence of TB in CSF~* Microbiologic evidence of TB from pulmonary or extrapulmonary sites~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~* Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~* Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis"
48457012|NCT01300273|DIETARY_SUPPLEMENT|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
48457013|NCT04488380|OTHER|dental restoration|Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
48457014|NCT03706508|PROCEDURE|Robot-assisted laparoscopic radical prostatectomy|Patients with localized prostate cancer underwent transperitoneal robot-assisted laparoscopic radical prostatectomy
48457015|NCT00163345|DRUG|Ciclesonide|
48457016|NCT05919199|OTHER|No intervention|No intervention
48457017|NCT05936554|DEVICE|whole body vibration|to improve muscle power and balance.
47934056|NCT04828473|DEVICE|Allay Lamp|"The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~* It is not an implant~* It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today."
47934057|NCT05585281|DRUG|Fluzoparib|Fluzoparib Orally twice daily
48280647|NCT02656472|DRUG|Tranexamic acid|TXA Loading dose: 31 mg/kg diluted to 2 ml/kg Normal saline (NS) -in syringe
48280648|NCT02656472|DRUG|Epsilon Aminocaproic Acid|Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
48457018|NCT05936554|OTHER|Functional strength training|used in treatment of hemiparetic cerebral palsy and provides postural stability while promoting balance independence with confidence and muscle power
48457019|NCT04584541|BIOLOGICAL|blood tests|Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)
48457020|NCT04584541|BIOLOGICAL|Nasopharyngeal swabs|SarS-Cov-2 viral load assessment
48457021|NCT04584541|BIOLOGICAL|Stools|SarS-Cov-2 viral load assessment
48457022|NCT05377164|BEHAVIORAL|food choices|Analysis of lymphocytes isolated from the peripheral blood of participants who had been on vegetarian, ketogenic or normal mixed diet for at least one year will be performed.
48457023|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
48457024|NCT01172249|DRUG|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
48457025|NCT02665780|PROCEDURE|Periodontal debridement|teeth cleaning
48457026|NCT02665780|OTHER|Cetylpyridium chloride|mouthrinse
48457027|NCT02131077|BIOLOGICAL|ALLO-ASC-TI|
47934058|NCT05585281|BIOLOGICAL|QL1101|Maintenance QL1101 7.5 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. QL1101 will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of QL1101 received with chemotherapy.
48280649|NCT04401059|DRUG|Elemene plus first or third generation EGFR-TKIs|"Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label."
48280650|NCT04401059|DRUG|First or third generation EGFR-TKIs|refer to the drug label.
48280651|NCT00956826|DEVICE|Agit Vacuum|With an electrode and a regular vacuum device
48280652|NCT02700529|DRUG|ubenimex|
48280653|NCT02700529|OTHER|placebo|
48280654|NCT00319514|DRUG|Docetaxel|
48280655|NCT05292755|DRUG|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
48280656|NCT05292755|DRUG|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
48280657|NCT04854655|OTHER|Conventional resin composite|nanofilled resin composite
48280658|NCT04854655|OTHER|Activa Presto|calcium and phosphate hybrid material
48280659|NCT04854655|OTHER|Giomer|fluoride releasing hybrid material
48280660|NCT04049279|PROCEDURE|BiMobile standard cement|BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
48280661|NCT04049279|PROCEDURE|BiMobile larger cement|BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
48280662|NCT04049279|PROCEDURE|Avantage standard cement|Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
48280663|NCT02249715|DEVICE|Brainsway Multiway deep TMS device (two channels)|
48457028|NCT02131077|DRUG|Placebo|
48457029|NCT02923336|DRUG|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
48457030|NCT01200186|DRUG|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
48457031|NCT01200186|DRUG|Progestin Only Pills|At the discretion of the attending physician
48457032|NCT00476034|DRUG|lumiracoxib|
48457033|NCT04628663|DRUG|Dexmedetomidine|Administration
48457034|NCT04628663|OTHER|Normal Saline|Administration
48457035|NCT02325180|DRUG|Dihydroartemisinin-Piperaquine|
48280664|NCT01490593|BEHAVIORAL|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
48280665|NCT03424226|DRUG|Acetazolamide|a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
48280666|NCT04887298|DRUG|Liposomal Annamycin (L-Annamycin)|2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
48280667|NCT06644989|PROCEDURE|Spencer Technique|Spencer technique on the hip
48280668|NCT06644989|OTHER|Sham (No Treatment)|Spencer technique position but no pressure
48457036|NCT02325180|DRUG|Artemether-lumefantrine|
48457037|NCT03921801|OTHER|Gait retraining|"Gait retraining using real-time electromyography biofeedback performed once per week for eight weeks.~During the gait retraining session the participant is walking on a treadmill while receiving information on calf muscle activation. A single session includes five bouts of walking each lasting for 5 minutes. During the first bout, the participant is receiving feedback (visual and auditive) on soleus muscle activation with the aim to increase it by 20% from their normal walking. During the second bout, the participant is receiving feedback (visual and auditive) on medial gastrocnemius muscle activation with the aim to decrease it by 20% from their normal walking. During the last three bouts, the participant is receiving feedback (visual and auditive) on the soleus to medial gastrocnemius muscle activation ratio with the aim to increase it by 20% from their normal walking. If hitting the target, the aim is increased by 5% for the subsequent bout."
48457038|NCT03921801|OTHER|Gait retraining + strength training|"Gait retraining using real-time electromyography biofeedback performed once per week and home-based calf muscle strength training performed three times per week for eight weeks.~The gait retraining is identical to the one intervention described for the intervention group Gait retraining.~The strength training is performed three times per week except for the first week in which it is performed two times. The session contained a warm-up (3x10 repetitions of two-legged heel raises) and maximal isometric calf muscle contractions. The maximal contractions are performed using a custom device with the ankle in dorsiflexion and the knee flexed by 100-120 degrees. Three sets of 10 repetitions (3-second contraction and 3-second rest) are performed with both legs and with maximal effort and 1-minute rest between the sets."
48457039|NCT02169752|DRUG|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
48457040|NCT02915445|BIOLOGICAL|EpCAM CAR-T cells|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
48457041|NCT01937182|DRUG|Citalopram|Citalopram 10-40 mg per day administered orally
48457042|NCT01937182|DRUG|Placebo|1/2-2 tablets per day with no intrinsic drug activity
48457043|NCT01165632|PROCEDURE|biopsy|Correlative studies
48457044|NCT01165632|PROCEDURE|computed tomography|Undergo computed tomography
48457045|NCT01165632|PROCEDURE|therapeutic conventional surgery|Undergo stereotactic craniotomy
48457046|NCT01165632|RADIATION|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
48457047|NCT01165632|RADIATION|radiation therapy|Undergo radiation therapy
48280669|NCT05405426|OTHER|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
48457048|NCT01165632|PROCEDURE|magnetic resonance imaging|Undergo magnetic resonance imaging
48457049|NCT01165632|PROCEDURE|positron emission tomography|Undergo positron emission tomography
48457050|NCT01165632|DRUG|fluorine F 18 fluorodopa|Given IV
48457051|NCT03849846|OTHER|Focus groups|Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
48457052|NCT02364531|OTHER|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
48457053|NCT00101439|DRUG|ezetimibe|
48457054|NCT00101439|DRUG|Comparator: placebo|
48457055|NCT04691960|OTHER|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
48457056|NCT04691960|DRUG|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
48457057|NCT06345235|DIAGNOSTIC_TEST|blood test|Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3
48457058|NCT04950426|DRUG|Propranolol|One administration of propranolol, once a week during six weeks. Reading by the participant of his/her traumatic story, 75 minutes (+/- 15 min) after propranolol intake.
48457059|NCT03028545|BEHAVIORAL|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
48457060|NCT02625298|DEVICE|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
48457061|NCT02625298|DEVICE|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
48280670|NCT02154594|DRUG|Acacia catechu|
48457062|NCT01023113|PROCEDURE|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
48457063|NCT01023113|PROCEDURE|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
48457064|NCT04029545|DEVICE|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
48457065|NCT03259841|OTHER|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
48280671|NCT02154594|DRUG|Chlorhexidine gluconate|
48457066|NCT03081897|DRUG|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
48457067|NCT03081897|DRUG|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
48280672|NCT02154594|OTHER|Distilled water|
47934059|NCT01740505|BEHAVIORAL|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
48457068|NCT03513185|DRUG|Deanxit, SSRI or SRNI|After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
48457069|NCT00006153|BIOLOGICAL|HIV-1 Immunogen|
47934060|NCT01740505|BEHAVIORAL|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
48457070|NCT00834353|DRUG|ATT|
48457071|NCT02068651|BEHAVIORAL|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
48457072|NCT01418573|OTHER|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
48457073|NCT01418573|OTHER|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
48457074|NCT01418573|OTHER|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
48457075|NCT00372983|DRUG|NOV-205|
48457076|NCT03725345|BEHAVIORAL|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
48457077|NCT01825694|BEHAVIORAL|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
48457078|NCT03222921|PROCEDURE|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
48457079|NCT02518360|OTHER|Osteopathic|Body adjustment in three sessions (20 minutes/session).
48457080|NCT02518360|OTHER|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
48457081|NCT02255149|DEVICE|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
47934061|NCT01740505|BEHAVIORAL|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
47934062|NCT04038203|DEVICE|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
47934063|NCT05249218|OTHER|Phase B - Extra 1 Phe exchange from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 60g fruits/vegetables containing Phe from 76-100mg/100g
47934064|NCT05249218|OTHER|Phase C - Extra 2 Phe exchanges from fruits/vegetables containing Phe from 76-100mg/100g|Usual low Phe diet + 120g fruits/vegetables containing Phe from 76-100mg/100g
47934065|NCT05249218|OTHER|Phase D - Extra 1 Phe exchange from milk or yoghurt|Usual low Phe diet but 1 x 50 mg extra Phe exchange from milk or yoghurt
47934066|NCT05249218|OTHER|Phase E - Extra 2 Phe exchanges from milk or yoghurt|Usual low Phe diet but 2 x 50 mg extra Phe exchange from milk or yoghurt eaten daily
47934067|NCT04661098|PROCEDURE|(Darwish hymenotomy technique)|Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
47934068|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10\^7 cells/m\^2~Day 14: 2 x 10\^7 cells/m\^2~The doses are calculated according to the total T cell number."
48457082|NCT01530048|DRUG|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
48457083|NCT05846139|COMBINATION_PRODUCT|PerioTabs® brushing solution|PerioTabs® contains a non-antibiotic biofilm removal complex called NitrAdine®.Its anti-biofilm action is based on the combination of surfactant-induced protein denaturation and slow release of a non-toxic concentration of hypochlorite (0.02%).
47934069|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10\^7 cells/m\^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10\^8 cells/m\^2 on Day 0, Day 1, or Day 2"
47934070|NCT05147779|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
47934071|NCT01920035|DEVICE|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
48457084|NCT05846139|COMBINATION_PRODUCT|Chlorhexidine 0.12 %|chlorhexidine 0.12 % toothpaste and chlorhexidine 0.2% mouth rinse
48457085|NCT00292929|DRUG|Intravenous artesunate|
48457086|NCT04934007|DEVICE|rTMS Treatment|1 Hz rTMS
47934072|NCT06523192|OTHER|Questionnaires|No intervention
47934073|NCT04575792|BEHAVIORAL|Practicing oral habits|children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
47934074|NCT01501084|DRUG|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
47934075|NCT01501084|DRUG|Normal saline .2cc subcutaneous injection|sterile saline injection
47934076|NCT02203084|OTHER|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
47934077|NCT02898584|OTHER|BP Track|
47934078|NCT01323920|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 IV
47934079|NCT01323920|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
47934080|NCT01323920|DRUG|Methotrexate|Methotrexate 15 mg/m\^2 IV
47934081|NCT03036800|DRUG|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
47934082|NCT03036800|OTHER|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
47934083|NCT05331079|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant knee with ice bags
47934084|NCT03440177|DRUG|Ramipril|Patients are tested for their normal prescription ramipril medication
47934085|NCT04307875|DIAGNOSTIC_TEST|Blood pressure measurement (sphygmomanometer)|measuring blood pressure with standard sphygmomanometer
47934086|NCT04307875|DIAGNOSTIC_TEST|Blood glucose measurement|measuring blood glucose using standard measurement devices
47934087|NCT04307875|OTHER|psychometric tests|WHODAS 2.0, PHQ-9, CAPS-5
47934088|NCT03917433|BEHAVIORAL|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
47934089|NCT03917433|BEHAVIORAL|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
47934090|NCT03917433|BEHAVIORAL|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
47934091|NCT02126748|OTHER|inhalation 4ml hypertonic saline 3% 3x/day|
48457087|NCT06245928|DEVICE|Individualized Respiratory Exercise Device|The Individualized Respiratory Exercise device will include both inspiratory muscle training, expiratory muscle training, and intensive spirometer features.
48457088|NCT06245928|DEVICE|Threshold® IMT + Threshold™ PEP|The Threshold® IMT device allows inspiratory muscle training and the Threshold™ PEP device allows expiratory muscle training.
47934092|NCT02126748|DEVICE|Intrapulmonary Percussive Ventilation|
47934093|NCT02126748|PROCEDURE|Assisted Autogenic Drainage|
47934094|NCT01146210|OTHER|laboratory biomarker analysis|Correlative studies
47934095|NCT02274038|DRUG|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
47934096|NCT02274038|DRUG|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
47934097|NCT02274038|DRUG|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
47934098|NCT03905447|DRUG|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
47934099|NCT03905447|DRUG|Standard of Care|Standard of Care antifungal medication
47934100|NCT04686045|OTHER|observational study|observational study
47934101|NCT00610584|PROCEDURE|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
47934102|NCT00610584|PROCEDURE|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
47934103|NCT00610584|DRUG|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
47934104|NCT01685645|DEVICE|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
48098744|NCT01304394|DRUG|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
48457089|NCT00218322|DRUG|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
48457090|NCT00218322|DRUG|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
48457091|NCT00614861|OTHER|Non-cancer pain management survey|Non-cancer pain management survey
48457092|NCT02878148|DEVICE|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
48098745|NCT06630481|DRUG|neoadjuvant therapy|Neoadjuvant chemotherapy, neoadjuvant radiotherapy, or both.
48280673|NCT06656819|DEVICE|Magstim Rapid2|"AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females"
48280674|NCT03880877|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
48280675|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
48280676|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
48280677|NCT03880877|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
48280678|NCT03880877|DRUG|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
48280679|NCT00847340|PROCEDURE|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
48280680|NCT04285528|DRUG|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
48280681|NCT04285528|COMBINATION_PRODUCT|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
48280682|NCT01571492|PROCEDURE|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
48280683|NCT01571492|PROCEDURE|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
48280684|NCT06378827|DRUG|Dexmedetomidine|Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
48280685|NCT05731960|DRUG|Dexamethasone|10 mg IV dexamethasone provided immediately after spinal anesthesia
48280686|NCT05731960|DRUG|Metoclopramide|10 mg IV metoclopramide provided immediately after spinal anesthesia
48457093|NCT00659828|DRUG|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
48457094|NCT06626867|DIETARY_SUPPLEMENT|Dietary Fiber Supplementation|Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan\&#39;s Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.
48457095|NCT06626867|OTHER|Placebo|The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
48280687|NCT03429075|DRUG|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
48280688|NCT03429075|DRUG|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
48280689|NCT05634603|DIETARY_SUPPLEMENT|Lactose-free milk formula (Frisolac LF ®)|Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
48280690|NCT02593370|DRUG|Lidocaine-epinephrine added gadoterate meglumine|
48280691|NCT03759275|OTHER|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
48280692|NCT04283877|DRUG|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
48280693|NCT04283877|DRUG|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
48280694|NCT05200767|OTHER|completing surveys|"The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results."
48457096|NCT02589093|DEVICE|Stimulation|
48457097|NCT03390790|DRUG|Lidocaine gel 2%|If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
48098746|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
48280695|NCT04057170|OTHER|accelerated protocol and mulligan method|manual therapy technic
48098747|NCT01268345|DEVICE|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
48280696|NCT05902585|BEHAVIORAL|Virtual reality|In the virtual reality group, patients will view a video with the virtual reality glasses from the beginning to the end of the venipuncture.
48280697|NCT01958567|OTHER|Optical Coherence Tomography|
48280698|NCT03534648|DRUG|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
48280699|NCT03534648|DRUG|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
47934105|NCT01348009|DRUG|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
47934106|NCT02218177|DRUG|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
47934107|NCT02218177|DRUG|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
47934108|NCT02218177|PROCEDURE|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
47934109|NCT04897139|DRUG|Flu-Bu-Mel-E|Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
47934110|NCT00466687|BIOLOGICAL|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
48280700|NCT03534648|DRUG|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
48280701|NCT03534648|DRUG|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
48457098|NCT03390790|OTHER|Standard lubricant gel|If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
48457099|NCT02286479|PROCEDURE|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
48280702|NCT04938856|DRUG|Lamotrigine tablet|Lamotrigine 100 mg immediate release Tablet
48280703|NCT02568904|OTHER|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
48280704|NCT02568904|OTHER|Glucose|oral Glucose tolerance test
47934111|NCT00466687|DRUG|erlotinib hydrochloride|150mg PO qd
48280705|NCT02568904|OTHER|Fructose|oral fructose tolerance test
48280706|NCT02568904|OTHER|vehicle|control (water)
48280707|NCT05109312|DRUG|Bupivacaine Hydrochloride|100 mg
48280708|NCT05109312|DRUG|Bupivacaine Hydrochloride|125 mg
48280709|NCT05109312|DRUG|HTX-011|400 mg
48457100|NCT02286479|PROCEDURE|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
48457101|NCT01325740|DRUG|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
48457102|NCT01206803|DRUG|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg \& daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
48457103|NCT06065839|OTHER|non-nutritive sucking 5 minutes|Give pacifier non-nutritive sucking for 5 minutes before feeding
48457104|NCT06065839|OTHER|non-nutritive sucking 15 minutes|Give pacifier non-nutritive sucking for 15 minutes before feeding
47934112|NCT00466687|GENETIC|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
47934113|NCT00466687|GENETIC|gene expression analysis|gene expression analysis
47934114|NCT00466687|OTHER|immunologic technique|immunologic technique
47934115|NCT00466687|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
47934116|NCT00466687|PROCEDURE|biopsy|biopsy
47934117|NCT00000187|DRUG|Ritanserin|
47934118|NCT02127060|DRUG|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
47934119|NCT02127060|DRUG|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
47934120|NCT00237510|DRUG|terazosin|
47934121|NCT02918981|BEHAVIORAL|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
47934122|NCT02918981|DIETARY_SUPPLEMENT|14 g Whey protein|
47934123|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine|
47934124|NCT02918981|DIETARY_SUPPLEMENT|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
47934125|NCT02918981|DIETARY_SUPPLEMENT|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
47934126|NCT02918981|OTHER|Water control|
47934127|NCT06433271|BEHAVIORAL|Transdiagnostic Behavior Therapy (TBT)|TBT manualized treatment incorporates daily exposure exercises from up to four categories of avoidance that are most characteristic of the emotional disorders (i.e., situational, interoceptive, imaginal, and positive emotional).
48098748|NCT02714803|BEHAVIORAL|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
48280710|NCT05109312|DEVICE|Luer lock applicator|Applicator for instillation
48280711|NCT05109312|DRUG|Ibuprofen|400 mg
48280712|NCT05109312|DRUG|Acetaminophen|1 g
48280713|NCT03026387|BEHAVIORAL|Neuropsychological battery tests|"The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test and N-back test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention,verbal fluidity and working memory."
48280714|NCT00815789|BEHAVIORAL|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
48280715|NCT02549950|PROCEDURE|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
48280716|NCT02549950|PROCEDURE|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
47934128|NCT06433271|BEHAVIORAL|Treatment as Usual-Problem Solving Therapy (TAU-PST)|PST is an evidence- based psychotherapy implemented in VA Primary Care - Mental Health Integration (PC-MHI), with hundreds of VA providers trained in the intervention nationally. The primary aim of PST is to improve a patient's ability to cope with stressful events by adopting an adaptive perspective to stressors and using goal-focused, problem-solving behaviors to manage the problems associated with the stressors.
47934129|NCT03456609|DRUG|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
47934130|NCT03456609|DRUG|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
47934131|NCT03808987|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
47934132|NCT03808987|BEHAVIORAL|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
48457105|NCT03821675|DEVICE|Electrical Stimulation - Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
47934133|NCT00203281|DRUG|tacrolimus|
47934134|NCT00203281|DRUG|mycophenolate mofetil|
48280717|NCT03840876|DEVICE|WEI NASAL JET (WNJ)|Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
48280718|NCT04990076|PROCEDURE|Hysterectomy|Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
48457106|NCT03821675|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
48280719|NCT01812161|OTHER|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
48457107|NCT06040723|DEVICE|EndoMind|The EndoMind system is equipped with an AI model for predicting the Hill grade during gastroscopy.
48457108|NCT04566497|OTHER|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
48457109|NCT04566497|PROCEDURE|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
48457110|NCT00180401|BEHAVIORAL|CRT-P and CRT-D devices|
48457111|NCT02045108|BEHAVIORAL|Active Retraining|
48098749|NCT02714803|BEHAVIORAL|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
48098750|NCT02714803|BEHAVIORAL|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
48098751|NCT02228811|DRUG|DCC-2701 tablet|
48457112|NCT02045108|DEVICE|Sham TDCS|
48457113|NCT02045108|DEVICE|Active TDCS|
48457114|NCT02045108|BEHAVIORAL|Sham Retraining|
48457115|NCT05411276|DRUG|Pyrotinib maleate|Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
48457116|NCT02182713|DRUG|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
47934135|NCT00203281|DRUG|daclizumab|
47934136|NCT00203281|DRUG|intravenous immune globulin|
47934137|NCT00203281|PROCEDURE|plasmapheresis|
47934138|NCT00872625|DRUG|cyclophosphamide|
47934139|NCT00872625|DRUG|docetaxel|
47934140|NCT00872625|DRUG|epirubicin hydrochloride|
47934141|NCT00872625|DRUG|fluorouracil|
48457117|NCT02182713|DRUG|Salbutamol|Salbutamol 100 mcg per puff
47934142|NCT00872625|PROCEDURE|neoadjuvant therapy|
47934143|NCT00872625|PROCEDURE|therapeutic conventional surgery|
47934144|NCT00872625|RADIATION|hypofractionated radiation therapy|
47934145|NCT00872625|RADIATION|image-guided radiation therapy|
47934146|NCT00872625|RADIATION|radiation therapy|
48457118|NCT06082505|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
48457119|NCT06082505|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
47934147|NCT00872625|RADIATION|stereotactic radiosurgery|
47934148|NCT00025805|DRUG|G-CSF|
48457120|NCT05680272|BEHAVIORAL|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
48457121|NCT03382041|DEVICE|Carbon Fiber Implant|A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
47934149|NCT01043042|OTHER|No interventions will be used in this study|No interventions will be used in this study
48457122|NCT03382041|DEVICE|Titanium Implant|An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
48457123|NCT00448825|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
48457124|NCT00448825|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
48457125|NCT01905605|DRUG|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
48457126|NCT01905605|DRUG|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
48457127|NCT05694546|BEHAVIORAL|Community Health Worker Post-Discharge Intervention|Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
47934150|NCT02320903|DEVICE|VillageWhere App|
47934151|NCT02439333|DEVICE|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
48457128|NCT01269658|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
48457129|NCT01269658|DRUG|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
48457130|NCT05272813|DRUG|MS-553|MS-553
48457131|NCT03504085|OTHER|Yoga: Active Hatha|Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
48457132|NCT03504085|OTHER|Yoga: Restorative|Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
47934152|NCT02439333|DEVICE|nasal catheter or Venturi mask|Conventional oxygen therapy
47934153|NCT04577339|PROCEDURE|Laparotomy or laparoscopy|"Laparotomy is the opening of the abdominal cavity usually through a midline incision.~Laparoscopy is using minimal access keyhole surgery to perform the surgery instead of laparotomy Interventional radiology is the use of imaging to perform a procedure on the abdomen without surgery, for example, using ultrasound to guide a needle to drain an abscess Best supportive care is usually end-of-life care concentration on relieving symptoms rather than treating the cause."
47934154|NCT05860010|DRUG|Epinephrine injection|patients will be placed on left lateral position and drug will be given the caudal space
47934155|NCT05860010|DRUG|Dexmedetomidine|patients will be placed on left lateral position and drug will be given the caudal space
47934156|NCT05860010|DRUG|Bupivacaine|patients will be placed on left lateral position and drug will be given the caudal space
47934157|NCT00629278|BIOLOGICAL|trastuzumab|
47934158|NCT00629278|DRUG|aromatase inhibition therapy|
47934159|NCT00629278|DRUG|cyclophosphamide|
48280720|NCT01812161|OTHER|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of \<5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
48457133|NCT03392051|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
47934160|NCT00629278|DRUG|docetaxel|
48457134|NCT03392051|DRUG|Clopidogrel|75mg tablet administered orally
48457135|NCT01457092|DEVICE|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
48622988|NCT06232343|OTHER|Parachute Resistance Training|The training programmed duration is of four weeks.The groups will follow the training programmed three times a week. The daily schedule (training group) included four repetitions of maximum intensity 30 m \& 50 m dashes (4 × 30 m, 4 × 50 m). The duration of recovery time between the 30 m \& 50 m runs will be 4 and 6 minutes respectively. Between the last 30 m dash and the first 50 m dash, a 10-minute recovery will be applied. Moreover, sprint speed training should not exceed 400-500 meters in total . To this end, the training programmed of the present study consisted of 4x30m and 4x50m runs, at a frequency of 3 times a week.
48622989|NCT06232343|OTHER|Sprinters|control group perform sprinters without any external resistance training for four weeks.
48622990|NCT04572035|BEHAVIORAL|Behavioural Coaching|behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)
47934161|NCT00629278|DRUG|doxorubicin hydrochloride|
47934162|NCT00629278|DRUG|epirubicin hydrochloride|
47934163|NCT00629278|DRUG|fluorouracil|
47934164|NCT00629278|DRUG|paclitaxel|
47934165|NCT00629278|DRUG|releasing hormone agonist therapy|
47934166|NCT00629278|DRUG|tamoxifen citrate|
47934167|NCT00629278|PROCEDURE|adjuvant therapy|
47934168|NCT00629278|RADIATION|radiation therapy|
48280721|NCT01363843|DRUG|FOLFOX6|FOLFOX6
48280722|NCT01363843|RADIATION|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
48280723|NCT01363843|PROCEDURE|Surgery|
48280724|NCT04855695|DRUG|Acalabrutinib|"Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol"
47934169|NCT04272138|BEHAVIORAL|Calm Meditation|"The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview."
47934170|NCT04272138|BEHAVIORAL|Educational Podcast Control|The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
47934171|NCT02732197|DRUG|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
48457136|NCT00870129|PROCEDURE|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
48457137|NCT06466317|BEHAVIORAL|Honey intake with walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines in addition to consuming natural honey (2ml/kg honey will be taken.. This dose will be divided into two halves, the first half will be taken at 7 am and the other half will be taken at 7 pm for 12 weeks)
48457138|NCT06466317|BEHAVIORAL|Walking exercise|20 Children with metabolic syndrome will receive free walking continuous exercise (thirty minutes daily in nearby sport club in the presence of their parents and walking will supervised by authors via Videoconferencing Imo Program) and this group also will healthy diet guidelines for 12 weeks)
48457139|NCT04432636|OTHER|Data collection of environmental factors|- Data collection of environmental factors (including maternal nutrition and social level, mode of delivery, birth weight, mode of infant feeding, antibiotic treatments) at the recruitment
48457140|NCT04432636|OTHER|Collection of maternal feces|- Collection of maternal feces: the first sample after delivery and once a week during the period of hospitalization of their infant (i.e. 5 to 8 samples per mother)
48457141|NCT04432636|OTHER|Collection of infant feces|- Collection of infant feces: the first sample after birth and once a week during the period of hospitalization of the baby (i.e. 5 to 8 samples per mother) and a sample collected at the corrected age of 1 year and 2 years (i.e. 8 to 10 samples per infant)
47934172|NCT02732197|DRUG|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
47934173|NCT03029637|DEVICE|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
47934174|NCT03029637|DEVICE|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
47934175|NCT05937776|OTHER|Fludeoxyglucose F-18|Given IV
48280725|NCT04855695|DRUG|Venetoclax|Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol
48457142|NCT04432636|OTHER|food questionnaire|- A food questionnaire completed by the mother the week after delivery,
48457143|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 2 and 10 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 1 year
48457144|NCT04432636|OTHER|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age|a food questionnaire on the infant alimentation and food behavior during the period of 12 and 24 months of age, completed by the parents and given to the pediatrician at the medical check-up at the corrected age of 2 years
48622991|NCT04572035|BEHAVIORAL|Self-compassion psychoeducation|self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)
48622992|NCT04572035|OTHER|Exercise|aerobic exercise program either delivered in a laboratory setting or via Zoom
48622993|NCT01583361|DRUG|Oxaliplatin+S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
48622994|NCT01583361|DRUG|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
48280726|NCT04855695|DRUG|Obinutuzumab|Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
48280727|NCT06589726|DRUG|Placebo|Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.
48457145|NCT04432636|OTHER|Sample of milk|A sample of 15 mL of milk drunk by the preterm at the 7th postnatal day (if not possible between the 7th and the 10th postnatal days).
47934176|NCT05937776|OTHER|Gadoterate Meglumine|Given IV
48457146|NCT04432636|OTHER|The 'Ages and Stages Questionnaire' ASQ|- The 'Ages and Stages Questionnaire' ASQ survey completed by the parents and given to the pediatrician at the corrected age of 2 years medical check-up
48457147|NCT03077451|OTHER|Laboratory Biomarker Analysis|Correlative studies
48457148|NCT03077451|DRUG|Nelfinavir Mesylate|Given PO
48457149|NCT05274763|OTHER|Quality-of-Life Assessment|Ancillary studies
48457150|NCT05274763|OTHER|Questionnaire Administration|Ancillary studies
48457151|NCT05274763|PROCEDURE|Spiritual Therapy|Deliver or undergo Compassion Centered Spiritual Health (CCSH) session
47934177|NCT05937776|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo PET/contrast-enhanced MRI
48457152|NCT04921631|BEHAVIORAL|Early Integration of Specialty Palliative Care with Critical Care|The PC team will visit the patient within 24 hours of randomization and the consultation will address the following domains of PC: illness understanding and goals of care conversations with patients/surrogates; symptom assessment and management; spiritual needs; patient and family coping and support; and care coordination and transitions. The initial family meeting will be scheduled to occur within two days of randomization. Follow-up visits will be conducted by the PC MD/APP every weekday. During this time, the ICU and PC team will be in daily communication. The PC team will continue to follow the patient in the hospital once discharged from ICU. Prior to discharge, the PC team will document patient goals and preferences for future treatment, coordinate appropriate PC services in the home and/or outpatient clinic settings and contact the patient's primary physician to provide an update on the patient's hospital stay.
48457153|NCT04702191|BEHAVIORAL|Triple P|Triple P - level 4 group is a group-based parenting intervention for families with children who exhibit behavioural or emotional difficulties. Group sessions typically focus on topics such as positive parenting, helping children develop, managing misbehaviour, and planning ahead. Practitioners then provide individual feedback on progress using positive parenting strategies and goal setting. Trained practitioners will deliver the program according to the manualized protocol (Turner, Markie-Dadds, \& Sanders, 2010). This will include eight weekly sessions with maximum of 12 parents. The first four sessions will be as group sessions. These four group sessions will be followed by three one-to-one practical and personalised telephone consultations. Finally, there will be one group session, which will complete the programme and parents' contact with the Triple P practitioners. The main aim of this session is to review progress and plan for the future.
48457154|NCT04702191|BEHAVIORAL|Circle of Security Parenting|Circle of Security - Parenting (COS-P) will be delivered according to the protocol outlined by Cooper, Hoffman and Powell (Cooper et al., 2009). COS-P is a manualized eight-session parent-education group program which has the same broad aims and core components of the COS-Intensive model from which it was developed (i.e., to increase caregiver sensitivity and responsiveness to child cues, empathy for the child by supporting parental reflective functioning, recognition and understanding of child attachment cues, and awareness of the impact of the caregiver's own attachment history on caregiving patterns). The program is led by one or two facilitators and includes 10-12 caregivers. The program uses clinical DVD clips of problematic parent-child interaction and healthy alternatives to illustrate attachment patterns and parenting styles, and to promote group discussion.
48457155|NCT04833205|DRUG|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
48457156|NCT01379313|PROCEDURE|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
48457157|NCT01379313|PROCEDURE|1:1 ratio|I:E ratio of 1:1 is applied.
48457158|NCT01379313|PROCEDURE|2:1 group|Inverse I:E ratio of 2:1 is applied.
48457159|NCT01379313|PROCEDURE|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
48457160|NCT01240850|DRUG|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
48457161|NCT01240850|DRUG|Prednisone|
48457162|NCT02871076|DEVICE|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
48457163|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
47934178|NCT05937776|PROCEDURE|Positron Emission Tomography|Undergo PET/contrast-enhanced MRI
47934179|NCT01967368|DRUG|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
48457164|NCT00521586|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
48457165|NCT01215721|DRUG|Vesicare|5 mg daily
48457166|NCT02132910|OTHER|RESTORE Intervention|
48457167|NCT02779400|DEVICE|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
48457168|NCT00731939|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
48457169|NCT00408304|DRUG|omega-3 fatty acid|
48457170|NCT00594035|DEVICE|Spinal Sealant System|
48457171|NCT00594035|DEVICE|Standard of care|Standard of care: devices intended to provide a watertight closure
48457172|NCT02463981|DEVICE|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
48280728|NCT06589726|DRUG|Moxifloxacin|Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
48622995|NCT00346437|GENETIC|Ad5FGF-4 vs. Placebo|Intracoronary infusion
47934180|NCT01967368|DRUG|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
47934181|NCT05377073|OTHER|Hatha Yoga|Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.
48280729|NCT06589726|DRUG|Enpatoran low dose|Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.
48457173|NCT02772822|DRUG|SCT400 plus CHOP|
48457174|NCT02772822|DRUG|Rituximab plus CHOP|
48457175|NCT05813847|DRUG|local anaesthetic injection|Local infiltration of study drug
48457176|NCT04224584|DRUG|Duloxetine|Duloxetine will be administrated with a two weeks up titration followed by a 10 weeks full treatment (60 mg/daily) and finalized by a two weeks discontinuation.
48622996|NCT02556450|DRUG|Spironolacton|Administration of Spironolacton 25 mg per day
47934182|NCT05377073|OTHER|Stretching|Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
47934183|NCT02368925|DEVICE|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200\~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
47934184|NCT02386683|OTHER|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
47934185|NCT05413278|BEHAVIORAL|Behavioral|Patient education, information and empowerment
48457177|NCT04224584|DRUG|Placebo oral tablet|Placebo will act as a control for duloxetine.
48457178|NCT01067950|PROCEDURE|Isolated Pancreas Transplant|
48457179|NCT01067950|DRUG|Intensive Insulin Therapy|
48457180|NCT05029726|DRUG|Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine|Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
48457181|NCT05029726|DRUG|normal saline|normal saline in 30cc syringes administered using ESPB technique
48457182|NCT04269122|OTHER|No Intervention|No intervention
48457183|NCT04207333|BEHAVIORAL|Mental Arithmetic Test|The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
47934186|NCT02392832|BIOLOGICAL|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
48280730|NCT06589726|DRUG|Enpatoran high dose|Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.
48280731|NCT05388357|OTHER|Intervention Procedure: PCI|Percutaneous Coronary Intervention
48457184|NCT03683667|DRUG|Azithromycin Oral Product|Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
48457185|NCT03683667|DRUG|Placebos|Contain inert excipients only
48622997|NCT03295851|DRUG|Ferric carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
48622998|NCT03295851|DRUG|Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
48457186|NCT03683667|DIETARY_SUPPLEMENT|Protein Supplement|Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
48457187|NCT03683667|DIETARY_SUPPLEMENT|Isocaloric Supplement|Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
48457188|NCT03683667|DIETARY_SUPPLEMENT|Egg|Egg provided daily to infants from 6-12 months of age
48457189|NCT03683667|BEHAVIORAL|Nutrition Education|Monthly messaging on infant and young child feeding
48457190|NCT02684786|DRUG|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
48457191|NCT02684786|PROCEDURE|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
48457192|NCT02684786|DRUG|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
48457193|NCT02997176|DRUG|Talazoparib|Daily oral doses of talazoparib 0.5 mg
48457194|NCT05441592|DRUG|Tranexamic acid injection|The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
48457195|NCT05441592|OTHER|No additional irrigation|There will be no additional irrigation after the standard surgical procedure.
48457196|NCT04879381|OTHER|Sputum samples|During consultation, one expectoration will be performed.
48457197|NCT04821349|DEVICE|Capsule endoscopy|"A consecutive series of patients recruited by 12 European centers based on the indication of OGIB will undergo capsule endoscopy examination.~Capsule endoscopy will be performed in each site according to local rules and requirements, and the study protocol will concern only the post-procedure analysis on reading modalities for each patient."
48457198|NCT03190239|DRUG|Apatinib|Apatinib 250mg qd
48457199|NCT03190239|DRUG|Pemetrexed|Pemetrexed 500mg/m2 qm
48457200|NCT06013163|DRUG|Xenical® vs EMP 22|Each participant will first use Xenical® TID for 9 days and then EMP22TID for 9 days (in total 27 doses of each drug).
48457201|NCT06013163|DRUG|EMP 22 vs Xenical®|Each participant will first use EMP22 TID for 9 days and then Xenical® TID for 9 days (in total 27 doses of each drug).
48457202|NCT06013163|DRUG|EMP 16 vs Xenical®|Each participant will receive a single dose of EMP16 and then a single dose of Xenical®.
48457203|NCT05153304|BIOLOGICAL|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
48457204|NCT05153304|DRUG|Nivolumab|3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.
48457205|NCT05467163|DEVICE|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
48457206|NCT05467163|DEVICE|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
48457207|NCT05467163|PROCEDURE|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
48457208|NCT01004562|OTHER|informational intervention|
48457209|NCT02754219|DRUG|Evogliptin|DPP4-inhibitor, Evogliptin
48457210|NCT02184715|OTHER|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
48457211|NCT02230930|DRUG|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
48457212|NCT02230930|DEVICE|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
48457213|NCT02230930|DRUG|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
48622999|NCT00884949|DRUG|BMN 110|"Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~* Weeks 1-12: 0.1 mg/kg/week~* Weeks 13-24: 1.0 mg/kg/week~* Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week."
47934187|NCT00458874|BEHAVIORAL|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
47934188|NCT01396330|BEHAVIORAL|stress|3 professional safe drive training courses each lasting 30 minutes
48457214|NCT02230930|DRUG|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
48457215|NCT02225457|OTHER|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
48457216|NCT02225457|DIETARY_SUPPLEMENT|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
48457217|NCT02225457|DIETARY_SUPPLEMENT|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
48457218|NCT01923740|DEVICE|XIENCE V EECSS|Subjects receiving XIENCE V
48457219|NCT01923740|DEVICE|Absorb BVS System|Subjects receiving Absorb BVS System
48457220|NCT02557464|BEHAVIORAL|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
48457221|NCT02557464|BEHAVIORAL|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
48457222|NCT03928405|OTHER|Exercises with Nintendo Wii virtual reality device|In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
48457223|NCT04955990|OTHER|PAH Therapies|No Drug will be administered as part of this study. Real world data will be collected in participants who newly initiate PAH therapies in routine clinical setting or have already been receiving macitentan 10 mg for at least 3 months prior to the index date.
48457224|NCT05604014|BEHAVIORAL|My Health Coach|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
48457225|NCT00192257|BIOLOGICAL|CAIV-T and TIV|
48457226|NCT03461380|DIETARY_SUPPLEMENT|Menopause Relief EP-40|Fixed combination of black cohosh and Rhodiola rosea
48457227|NCT03461380|DIETARY_SUPPLEMENT|Low Dose Black Cohosh|6.5 mg black cohosh
48457228|NCT03461380|DIETARY_SUPPLEMENT|High Dose Black Cohosh|500 mg black cohosh
48457229|NCT03461380|DIETARY_SUPPLEMENT|Placebo|600 mg excipient
48457230|NCT04756739|DEVICE|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
48457231|NCT01046084|DRUG|Lansoprazole|30 mg Delayed-Release Capsule
48457232|NCT01046084|DRUG|Prevacid®|30 mg Delayed-Release Capsule
48457233|NCT02569138|DEVICE|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
48457234|NCT02569138|DEVICE|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
48457235|NCT04599751|DEVICE|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
48457236|NCT04221958|DEVICE|Electrocardiogram|"An electrocardiogram measures the electrical activity of the heartbeat. This intervention will be used on healthy adult volunteers whom are part of the staff at the institution."
48457237|NCT05779527|BEHAVIORAL|Mindful Parenting Programme|Online Mindful Parenting Programme with group support sessions
48457238|NCT00803816|DRUG|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
48457239|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
48457240|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
48457241|NCT00898508|GENETIC|gene expression analysis|
48457242|NCT00898508|GENETIC|mutation analysis|
48457243|NCT00898508|GENETIC|proteomic profiling|
48457244|NCT00898508|GENETIC|reverse transcriptase-polymerase chain reaction|
48457245|NCT00898508|OTHER|fluorescent antibody technique|
48457246|NCT00898508|OTHER|immunohistochemistry staining method|
48457247|NCT00898508|OTHER|laboratory biomarker analysis|
48457248|NCT00898508|OTHER|liquid chromatography|
48457249|NCT00898508|OTHER|mass spectrometry|
48280732|NCT04516252|BEHAVIORAL|BodyWorks Intervention|BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)
48457250|NCT00898508|OTHER|medical chart review|
48457251|NCT00898508|PROCEDURE|quality-of-life assessment|
48457252|NCT00603967|PROCEDURE|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
48457253|NCT00603967|PROCEDURE|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
48457254|NCT00603967|BEHAVIORAL|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
48457255|NCT03896594|DRUG|HL237|Experimental
48457256|NCT03896594|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
48457257|NCT04299087|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy using a magnet to target and stimulate certain areas of the brain.
48457258|NCT04299087|OTHER|Control group|No application of rTMS
48457259|NCT05699538|BEHAVIORAL|Minimal-Dose Home-Based Resistance Exercise|8-week home-based resistance exercise performed one day per week.
48457260|NCT04425577|DIAGNOSTIC_TEST|Transabdominal Ultrasound|Transabdominal Ultrasound
48457261|NCT03812913|BEHAVIORAL|psychological evaluation|"* Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning."
48457262|NCT01312064|DRUG|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
48457263|NCT01312064|DRUG|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
48457264|NCT03703258|BEHAVIORAL|App-based intervention|A app-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
48457265|NCT02331108|DRUG|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
48457266|NCT04130464|DRUG|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
48457267|NCT04130464|DRUG|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
48457268|NCT04130464|DRUG|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
47934189|NCT04999254|OTHER|Medical treatment|"Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~* place an ice pack on the sprain~* apply sports rest for three weeks~* compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~* raise the foot with crutches during the day~* elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain."
47934190|NCT04999254|OTHER|osteopathic treatment|Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
48280733|NCT04516252|BEHAVIORAL|Canine Curriculum|Using our team's expertise in veterinary medicine, human-animal interaction, and animal behavior modification, develop an empirically-based, 7-week module on canine health and behavior.
48457269|NCT00201396|RADIATION|CCRT|Radiation with weekly Cisplatin
48457270|NCT00201396|DRUG|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
48457271|NCT02518139|DRUG|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
48457272|NCT02518139|DRUG|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
48457273|NCT02083809|DRUG|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
48457274|NCT02083809|DRUG|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
48457275|NCT02553863|PROCEDURE|Acupuncture|Acupuncture for 30min \[twice weekly for 8 weeks\]
48457276|NCT02553863|PROCEDURE|Standard care|Standard care
47934191|NCT04430205|PROCEDURE|Adhesive restoration protocol|"The canal walls were etched with 37% orthophosphoric acid for 30 seconds with use of a microbrush.~The primer was applied on the wet canal walls, with a microbrush several times, after checking by drying the canal, that the appearance of the dentine was shiny and not opaque or chalky.~The next step was the application of bonding with a microbrush, blowing in the fracture line to make sure it is not loaded with bonding.~Flow composite was used to make it penetrate the fracture line with the help of a 0.06 mm k-file.~The canals were filled with dual composite parts more deeply, light cured at the canal entrance and pulp chamber; the following phase was the coronal restoration with a sandwich technique, covering the cusp with composite."
47934192|NCT01640093|DRUG|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
48280734|NCT04516252|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).
48280735|NCT04516252|BEHAVIORAL|Physical Activity Trackers|Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.
47934193|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
47934194|NCT01640093|DRUG|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
48457277|NCT05031858|OTHER|Respiratory physiotherapy|Respiratory physiotherapy
48457278|NCT04491422|COMBINATION_PRODUCT|Integrated Next Steps Counseling with Real-Time Drug Level Feedback|Integrated next steps counseling with real-time drug level feedback using point-of-care urine tenofovir testing at quarterly visits
48457279|NCT05949853|OTHER|the respiratory parameters (AHI) and time spent|interpret the recording will be evaluated for PSG, PV and PV+ASEEGA Apnea Hypopnea Index as assessed by PSG (respiratory signals + electro-encephalography + electro-oculography + chin electromyography), PV (respiratory signals) and PV+ASEEGA (respiratory signals + result of sleep stages and arousals scoring by ASEEGA algorithm based on automatic analysis of one EEG Cz-Pz channel)
48457280|NCT00873990|OTHER|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
48457281|NCT00873990|OTHER|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
48457282|NCT02044731|BEHAVIORAL|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
48457283|NCT01917227|BEHAVIORAL|Video|
48457284|NCT02730533|DRUG|Esomeprazole|Proton pump inhibitor
48457285|NCT02730533|DRUG|No PPI treatment|No PPI treatment before ESD procedure
48457286|NCT05471947|DRUG|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
48457287|NCT06452030|BEHAVIORAL|Specific sensorimotor control training|Participants allocated to the specific motor control group will receive sensorimotor training of the multifidus muscle.
48457288|NCT06452030|BEHAVIORAL|Aspecific extension training|Participants allocated to the aspecific group will receive spinal extension exercises.
48457289|NCT06452030|BEHAVIORAL|Fascia training|Participants allocated to the fascia group will receive general movement exercises.
48457290|NCT06627075|PROCEDURE|Surface Guided RadioTherapy (SGRT) without mask|"Firstly, patients are positioned in a vacuum mattress that moulds their head, neck and shoulders for a reference scan.~During the treatment sessions, patients are positioned according to the reference scan, using the surface camera system.~Once the observed offsets have been applied, the patient's surface is captured. Treatment can then begin, with continuous monitoring of displacements by the surface camera system. Automatic beam interruption is provided during treatment in the event of motion detection exceeding the standard tolerance threshold (\>3 mm).~If the use of a thermoformed mask during your treatment prove necessary, for whatever reason, will not result in a halt to the research.~Patients receive between 10 and a max of 35 radiotherapy sessions. The follow-up period begins after the last radiotherapy session, and patients are assessed at 4 or 6 weeks and at 3 months by a radiotherapist."
48457291|NCT05173298|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
48457292|NCT03986463|OTHER|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
48457293|NCT03251755|BEHAVIORAL|Yoga|Exercise promotion using Chinese Yoga
48457294|NCT02278757|OTHER|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
48457295|NCT02278757|OTHER|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
48457296|NCT01808716|DEVICE|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
48457297|NCT03018990|OTHER|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
48457298|NCT04233060|DRUG|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
48457299|NCT01534845|DRUG|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
48457300|NCT01679327|DRUG|Oxaliplatin|
48457301|NCT01679327|DRUG|Xeloda|
48457302|NCT01679327|DRUG|Calcium folinate (CF)|
48457303|NCT01679327|DRUG|5-FU|
48457304|NCT01679327|DRUG|Bevacizumab|
48457305|NCT02929472|BEHAVIORAL|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
48457306|NCT02929472|BEHAVIORAL|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
48457307|NCT05649358|DEVICE|Lactate sensor (Lactisense)|Non-invasive monitoring of interstitial lactate levels during and after exercise.
48623000|NCT01404481|DEVICE|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
47934195|NCT01640093|DRUG|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
48623001|NCT04525820|DRUG|Single high dose vitamin D|Patient receives either one dose orally of 140'000 IU (7 ml) of this drug once as an intervention treatment additionally to TAU or the patient receives 7 ml of the placebo Solution (7 ml) in addition to TAU
48623002|NCT04525820|DRUG|Placebo|Patient receives a single dose of a placebo solution
48623003|NCT04525820|DRUG|Treatment as usual vitamin D|Both groups receive the treatment as usual after the single high dose or the placebo which will be 800 IU per day
47934196|NCT01169597|DRUG|prednisone|prednisone 12.5 mg daily po
47934197|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
47934198|NCT01505647|BIOLOGICAL|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
47934199|NCT01089361|DRUG|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
47934200|NCT01089361|DRUG|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
48623004|NCT01650376|DRUG|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
47934201|NCT06064162|DRUG|ketamine|60mg (.5mg/kg over 40 minutes intravenously)
47934202|NCT00541190|OTHER|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
47934203|NCT02551952|DEVICE|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
47934204|NCT00936429|BIOLOGICAL|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
47934205|NCT00936429|BIOLOGICAL|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
47934206|NCT01830023|DEVICE|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
47934207|NCT02963961|BEHAVIORAL|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
47934208|NCT05711303|DIETARY_SUPPLEMENT|Superba Boost|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of intervention using a TEWAMetre.
48280736|NCT04228419|PROCEDURE|Total Shoulder Arthroplasty|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
48280737|NCT04228419|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
48280738|NCT02951598|DRUG|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
48280739|NCT05723146|BEHAVIORAL|Spatial cognition assessment|The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
48280740|NCT03643770|COMBINATION_PRODUCT|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
48280741|NCT00147927|BEHAVIORAL|Sequential emails and web support|
48280742|NCT05620342|BIOLOGICAL|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
48280743|NCT00257127|BIOLOGICAL|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
48280744|NCT00257127|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
48457308|NCT01412827|RADIATION|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
48623005|NCT01650376|DRUG|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
48623006|NCT01650376|DRUG|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
48623007|NCT00627978|DRUG|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
48280745|NCT00257127|BIOLOGICAL|Hepatitis B vaccine|0.5 mL administered intramuscularly
48280746|NCT00257127|BIOLOGICAL|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
48623008|NCT02331732|BEHAVIORAL|Virtually Observed Treatment|
47934209|NCT02201342|DRUG|Udenafil|Drug
47934210|NCT03528395|OTHER|Semi-immersive virtual reality|Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
47934211|NCT03528395|OTHER|Conventional Rehabilitation|Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
47934212|NCT03673735|DRUG|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
48280747|NCT02111811|OTHER|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
48280748|NCT02568436|RADIATION|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
48280749|NCT05855356|PROCEDURE|Rehabilitation|respiratory physiotherapy, personalized aerobic and strength training
48280750|NCT05855356|PROCEDURE|Standard of Care|Behavioural and Medical management
48623009|NCT02331732|OTHER|Directly Observed Treatment|
48623010|NCT03101345|OTHER|Peptamen® 1.5 vanilla|Administration orally
48623011|NCT04678102|DRUG|PHI-101 administration|Escalated doses of PHI-101 will be administered to each cohort.
47934213|NCT03673735|RADIATION|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
47934214|NCT03673735|DRUG|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
47934215|NCT03673735|DRUG|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
47934216|NCT02045303|DEVICE|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
47934217|NCT02045303|DEVICE|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
47934218|NCT03222492|BIOLOGICAL|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
47934219|NCT03222492|BIOLOGICAL|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
47934220|NCT02566408|OTHER|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
48457309|NCT04074707|DIETARY_SUPPLEMENT|Labeled iron solution (60mg and 120mg Ferrous Fumarate)|3 doses of 60mg iron as ferrous fumarate are given on one consecutive day and one alternate day (e.g., days 1, 2, 4); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as ferrous fumarate are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 200ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with 60mg iron daily vs alternate day dosing, 120mg daily vs alternate day dosing or 120mg daily vs every-third day dosing.
48457310|NCT01554397|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
48457311|NCT01554397|DRUG|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
48457312|NCT06435793|PROCEDURE|MEP measurement - Surface EMG - IOPI|"Participants will undergo serial expiratory maneuvers using variously-sized circular mouthpieces and a reference ovoid-shaped mouthpiece.~At each maneuver, the maximal expiratory mouth pressure at total lung capacity will be measured, alongside with the degree of neuromuscular activation of the internal oblique and transverse abdominal muscles using surface electromyography.~The Orbicularis Oris strength will also be measured using the Iowa Oral Performance Instrument."
48457313|NCT03993145|BEHAVIORAL|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
48457314|NCT00370539|DRUG|verteporfin, bevacizumab, triamcinolone acetonide|
48457315|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
48457316|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
48457317|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
48457318|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
48457319|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
48457320|NCT01011855|DEVICE|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
48457321|NCT04149691|DRUG|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
47934221|NCT02566408|OTHER|Survey Questions|Complete survey
47934222|NCT01181401|DRUG|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
47934223|NCT01181401|DRUG|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
47934224|NCT01181401|RADIATION|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
47934225|NCT05553054|OTHER|Quantification of IV drugs wastage|"Drugs are prescribed depending on physician discretion.~Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators."
47934226|NCT05334095|DEVICE|Perclose ProGlide|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.
47934227|NCT05334095|DEVICE|Angio-seal VIP|After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP
47934228|NCT01214174|DRUG|IBI-10090|
47934229|NCT03951168|BEHAVIORAL|Routine Management|Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
48457322|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
48457323|NCT02280863|DEVICE|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
48280751|NCT05260411|BIOLOGICAL|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
48280752|NCT05260411|BIOLOGICAL|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
48280753|NCT05260411|DRUG|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
48280754|NCT00862602|BEHAVIORAL|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet \& nutrition and prevention.
48457324|NCT04603547|DEVICE|Transcutaneous Carbon Dioxide Monitoring|Once an infant is identified as being eligible for TH treatment and hypothermia was initiated according to the department clinical practice guidelines, and written informed consent was obtained from one of the parents, tcPCO2 monitoring can be started. Transcutaneous CO2 will be measured by SenTec Digital Monitor (software version SW-V07.00; MPB SW-V05.00.12) with V-Sign™ Sensor (SenTec AG, Thervil, Switzerland). Also, we will use small blood samples (0.2 ml) from clinical blood draws up to 4 times following starting transcutaneous CO2 monitoring for measuring blood gas for research purposes.
48280755|NCT05152355|DRUG|Budesonide 200 microgram/Puff, HFA MDI|Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
48280756|NCT05152355|DRUG|Budesonide 100 microgram/Actuation Powder for Inhalation|Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
48280757|NCT00775021|DEVICE|etafilcon A|Contact Lens
48280758|NCT00775021|DEVICE|nelfilcon A|Contact Lens
48280759|NCT06657443|OTHER|First Session|Introductions, explanation of the purpose and content of the project, realisation of the pre-test application. Giving the assignment with the theme of 'Nursing and Society' between peer mentors and mentees.
48280760|NCT06657443|OTHER|Second Session|Training of peer mentors on communication techniques, interview methods and empathic approach.
48280761|NCT06657443|OTHER|Third session|Sharing postcasts on communication techniques, interview methods and empathic approach with peer mentors.
48280762|NCT06657443|OTHER|Fourth session|Training of peer mentors on social motivation and leader-member interaction
48280763|NCT06657443|OTHER|Fifth Session|Sharing postcasts with peer mentors on social motivation and leader-member interaction.
48280764|NCT06657443|OTHER|Sixth Session|Presentation of 'Nursing and Society' themed assignments of peer mentors and mentees as a group (Composition, poem, poster, presentation, role play, etc. are left free among the students) and post-test application.
48457325|NCT01426360|OTHER|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
48457326|NCT01426360|OTHER|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
48623012|NCT05251870|DRUG|autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70|Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
48623013|NCT05791110|DIAGNOSTIC_TEST|Fecal pancreatic elastase 1 test|Fecal pancreatic elastase 1 test are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
48623014|NCT01010178|DRUG|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
48280765|NCT06545604|OTHER|Yoga Therapy for Nutritional, Physical, and Psychosocial Prehabilitation|Usual care supportive services including nutrition counseling per usual care
48280766|NCT06657677|DIETARY_SUPPLEMENT|40mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
48280767|NCT06657677|DIETARY_SUPPLEMENT|100mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
48280768|NCT06657677|DIETARY_SUPPLEMENT|180mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
48280769|NCT04533711|BEHAVIORAL|OA-PCP Intervention|The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.
48280770|NCT04533711|BEHAVIORAL|Attention Control|"This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue."
47934230|NCT03951168|BEHAVIORAL|Standardized Management|Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
48280771|NCT06392815|DIAGNOSTIC_TEST|Cu DOTATATE PET|The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs
48280772|NCT02286102|DEVICE|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
48280773|NCT02286102|DEVICE|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
48280774|NCT05303493|BIOLOGICAL|Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI|Evaluate the safety and tolerability of CC prebiotic in addition to ICI in patients with NSCLC and melanoma
48280775|NCT01103739|DRUG|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
48280776|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
48280777|NCT01103739|DRUG|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
48280778|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
48280779|NCT04376619|OTHER|remote ischemic preconditioning|inflation and deflation of cuff 5min each cycle repeated 3 times
48280780|NCT04376619|OTHER|KDIGO guidelines|KDIGO stands for Kidney disease Improving global outcomes guidelines, and have guidelines for prevention and treatment of AKI which is considered standard of care.
48280781|NCT06143631|DRUG|Letrozole 2.5mg|Oral letrozole 2.5mg/day
48280782|NCT06143631|OTHER|Placebo|Placebo capsule
48280783|NCT01512589|RADIATION|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
48280784|NCT01512589|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
48280785|NCT01512589|BEHAVIORAL|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
48280786|NCT00481481|DRUG|tacrolimus|immunosuppression
48280787|NCT03176290|DIAGNOSTIC_TEST|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
48280788|NCT02861170|BEHAVIORAL|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
48280789|NCT03031561|DEVICE|Ultrasound|Undergo standard ultrasound
48280790|NCT03031561|DEVICE|MicoPure ultrasound|Undergo MicoPure ultrasound
48280791|NCT03031561|PROCEDURE|Biopsy of Breast|Undergo breast biopsy or surgical resection
48280792|NCT05966818|DRUG|Dapagliflozin and Standard therapy (ACEI or ARB).|Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).
48280793|NCT05966818|DRUG|Standard Therapy (ACEI or ARB).|Standard Therapy which include either ACEI or ARB for 24 weeks.
48280794|NCT02941367|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48280795|NCT02941367|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
48280796|NCT02941367|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
48280797|NCT02941367|DRUG|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48623015|NCT06076590|DRUG|maintenance fluid|Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
47934231|NCT05054842|DRUG|Retagliptin phosphate tablets、metformin sustained-release tablets|Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication
48280798|NCT03486730|DRUG|BT1718|Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
48280799|NCT05559814|DRUG|Intraluminal peppermint oil|Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
48623016|NCT03942588|BEHAVIORAL|High-intensity interval training|
48457327|NCT01170741|BEHAVIORAL|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
48457328|NCT01601353|DEVICE|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
48457329|NCT02429583|DRUG|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
48457330|NCT05517304|DEVICE|tcVNS|active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
48457331|NCT05517304|DEVICE|sham|sham stimulation
48457332|NCT06623695|OTHER|Exercise|SGG performed the exercise program on a fixed ground surface. SGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
48457333|NCT06623695|OTHER|Exercise|USGG participants completed the exercise program on a bosuball. USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
48457334|NCT01820091|DRUG|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
48457335|NCT01820091|DRUG|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
48457336|NCT06532513|OTHER|Family-Centered Goal-Oriented Physiotherapy and Rehabilitation Application|Family centered goal-oriented physiotherapy and rehabilitation applications aim to enhance the functional level of severely affected children with dyskinetic cerebral palsy children through individualized activities conducted by family members at home. The program focuses on specific goals determined collaboratively by the family, physiotherapists, and physician, with regular monitoring and assessments to track progress.
48457337|NCT05237635|OTHER|descriptive case-scenarios|Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
48457338|NCT03810937|OTHER|head position|head positioning in sniffing or flat position
48457339|NCT06212479|DIAGNOSTIC_TEST|MRI Scan|Whole Body MRI Scan
48457340|NCT05497986|DEVICE|High flow nasal cannula|HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
48457341|NCT05497986|DEVICE|Conventional low flow oxygenation|Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
48457342|NCT02507063|PROCEDURE|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
48457343|NCT05897619|BEHAVIORAL|Experimental: Maya Perinatal Cognitive Behavioral Skills App|The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
48457344|NCT06026657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48457345|NCT06026657|PROCEDURE|Computed Tomography|Undergo CT scan
48457346|NCT06026657|DRUG|Gemcitabine|Given IV
48457347|NCT06026657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48457348|NCT06026657|BIOLOGICAL|Naxitamab|Given IV
48457349|NCT06026657|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
48457350|NCT04789434|DRUG|PD-1 Inhibitor Tislelizumab maintenance therapy|PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times
48280800|NCT05559814|DRUG|Placebo|Intraluminal flushing of placebo solution through the scope during scope withdrawal
48280801|NCT06217991|PROCEDURE|PTST(parachute-tunnel-style technique)for esophagogastrostomy|Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
48457351|NCT03720444|OTHER|MDT (mechanical diagnosis and therapy) method|The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
48457352|NCT02985060|DEVICE|Arctic Sun|"1. Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~   Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~2. Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~3. Recovery phase:Rewarming velocity: 0.05\~0.1℃ (within 30 hours)"
48623017|NCT02300610|DRUG|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
48623018|NCT02300610|DRUG|Cisplatin|Cisplatin at 70 mg/m\^2 IV on day 1, repeated every 21 days for total of 6 cycles.
48457353|NCT02985060|OTHER|Standard treatment|"1. All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~2. In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~3. Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~4. Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
48457354|NCT02985060|DRUG|Saline|
47934232|NCT05054842|DRUG|Retagliptin phosphate placebo tablets、metformin sustained-release tablets|Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
48457355|NCT04436198|DEVICE|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length \> 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length \< 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
48457356|NCT04436198|DEVICE|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
48457357|NCT06183125|BEHAVIORAL|Traditional Chinese Medicine-based program|"Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support."
48457358|NCT05501704|DRUG|Tamoxifen|Taken orally
48457359|NCT05501704|DRUG|Anastrozole|Taken orally
48457360|NCT05501704|DRUG|Degarelix|Subcutaneous (under the skin) injection
48457361|NCT05501704|DRUG|Abemaciclib|Taken orally
48457362|NCT05726825|DEVICE|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
48457363|NCT05801822|DIAGNOSTIC_TEST|serum T.S.H level test|, the blood samples will be collected and to be assessed for the routine antenatal screening CBC, random blood sugar, HBV and HIV, the same blood sample will be used to asses TSH level.
48457364|NCT01261767|DRUG|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
48457365|NCT01261767|DRUG|placebo|Placebo for subcutaneous (under the skin) injection
48457366|NCT03791307|OTHER|Traditional Pilates group|The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
48457367|NCT03791307|OTHER|Modified Pilates group|The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
48457368|NCT01989884|DRUG|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
48457369|NCT02114788|OTHER|Internet-based|
48457370|NCT04809363|OTHER|CDPATH™|Crohn's disease risk prediction tool.
47934233|NCT00805233|DRUG|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
47934234|NCT00805233|DRUG|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
47934235|NCT05976984|OTHER|Aim 1 (case-cohort study)|"* Cases: All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020~* Subcohort: A random sample of all Medicaid enrollees age 15 years or older irrespective of their stimulant overdose history during 2016-2020"
47934236|NCT05976984|OTHER|Aim 2 (case-crossover study)|"* Case period: 60 days before the date of stimulant overdose through the day before the date of stimulant overdose~* Control period: 179 days before the date of stimulant overdose through 120 days before the date of stimulant overdose~* Washout period: 119 days before the date of stimulant overdose through 61 days before the date of stimulant overdose"
47934237|NCT05976984|OTHER|Aim 3 (cohort study)|All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020
47934238|NCT01382511|DRUG|Simvastatine|80 mg
48457371|NCT04809363|OTHER|Blood Draw|Three blood samples will be drawn.
48457372|NCT04970836|BIOLOGICAL|recombinant hepatitis B vaccine|Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
48457373|NCT01344031|DRUG|Akt Inhibitor MK2206|Given PO
48457374|NCT01344031|DRUG|Anastrozole|Given PO
48457375|NCT01344031|DRUG|Fulvestrant|Given IM
48457376|NCT01344031|OTHER|Laboratory Biomarker Analysis|Correlative studies
48457377|NCT02578277|DRUG|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
48457378|NCT02578277|DRUG|BMS-955176|BMS-955176
48457379|NCT02578277|DRUG|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
48457380|NCT03265860|DEVICE|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
48457381|NCT01604941|DRUG|SPD602|50 mg/kg/day orally twice daily for 24 weeks
47934239|NCT04531631|DRUG|Dorzagliatin|tablet
48457382|NCT03224663|OTHER|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
48457383|NCT03224663|OTHER|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
48623019|NCT02300610|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
47934240|NCT04531631|DRUG|placebo|placebo
47934241|NCT02000154|DRUG|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
48280802|NCT02473796|OTHER|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight \<2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term \& weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
48280803|NCT02717507|DRUG|Carvedilol|Given PO
48280804|NCT02717507|OTHER|Laboratory Biomarker Analysis|Correlative studies
48280805|NCT02717507|OTHER|Pharmacogenomic Study|Correlative studies
48280806|NCT02717507|OTHER|Pharmacological Study|Correlative studies
48280807|NCT02717507|OTHER|Placebo Administration|Given PO
48280808|NCT02717507|OTHER|Quality-of-Life Assessment|Ancillary studies
48280809|NCT02717507|OTHER|Questionnaire Administration|Ancillary studies
48280810|NCT04317807|DRUG|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
48280811|NCT04317807|OTHER|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
48280812|NCT05878028|COMBINATION_PRODUCT|L-TIL, Tislelizumab, Docetaxel|PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
48280813|NCT00691548|DRUG|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
48280814|NCT04936308|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
48280815|NCT04936308|DRUG|Placebo|Participants will receive matching placebo as SC injection.
48280816|NCT04141696|DRUG|Ketamine|Given intravenously over 40 minutes
48280817|NCT04141696|DRUG|Midazolam (placebo)|Given intravenously over 40 minutes
48457384|NCT06422286|DEVICE|low-level laser|children will be allocated to the device then the gag reflex will be re-evaluated
48457385|NCT06422286|BIOLOGICAL|microcurrent stimulation|children will be allocated to the device then the gag reflex will be re-evaluated
48457386|NCT06422286|DEVICE|placebo|children will be allocated to a deactivated meridian pen
48457387|NCT02601963|DRUG|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
48457388|NCT02601963|DRUG|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
48457389|NCT02601963|DRUG|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
48457390|NCT00714051|BEHAVIORAL|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
48457391|NCT00714051|BEHAVIORAL|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
48457392|NCT00056433|DRUG|Hydroxyurea|
48457393|NCT00056433|DRUG|L-Arginine|
48457394|NCT00056433|DRUG|Sildenafil|
48457395|NCT01939990|DRUG|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
48457396|NCT01939990|DRUG|Nebivolol|5 to 10mg per day
48457397|NCT03966651|DRUG|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
48457398|NCT02974907|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
48457399|NCT02974907|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
48457400|NCT06069037|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
48457401|NCT06627816|DRUG|Nefopam|efficacy of 3 drugs in preventing post-spinal anesthesia shivering
48457402|NCT03827395|BIOLOGICAL|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
48457403|NCT03827395|OTHER|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 \[4.5 - 7.0\]).
48457404|NCT06179953|OTHER|NAO intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts."
48457405|NCT06179953|OTHER|Traditional intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts."
48457406|NCT05370768|BEHAVIORAL|Parenting Mindfully Intervention|Includes meditation and using meditation and mindfulness in everyday life and in parenting interactions.
48457407|NCT03442530|BEHAVIORAL|ToPIC|Expanded tobacco cessation counseling for pregnant women.
48457408|NCT03442530|BEHAVIORAL|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
48623020|NCT01102283|DEVICE|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
47934242|NCT06403475|DEVICE|Transcutaneous Vagus Nerve Stimulation|"Transcutaneous auricular vagus nerve stimulation using the Nurosym (Parasym Ltd) device.~Stimulation parameters:~Pulse width: 250µs; Frequency: 25Hz; Intensity: Below pain threshold.~The active stimulation will be delivered to the left tragus. Participants will complete the intervention at home once they have received sufficient training on how to use the stimulation device."
48457409|NCT04990648|DEVICE|Buzzy|Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
48457410|NCT03056547|OTHER|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
48457411|NCT04640298|DEVICE|Cingal|Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
47934243|NCT06403475|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|Stimulation will be delivered at the same parameters however, sham stimulation will be delivered to the left earlobe. Earlobe stimulation has been used as a sham in other studies as it is not thought to activate the vagus nerve.
47934244|NCT06403475|BEHAVIORAL|Computer Based Speech and Language Therapy (Step by Step)|Computer-based Speech and Language Therapy will be completed whilst wearing the stimulation device in all groups. The Step by Step programme uses an errorless learning approach to practice naming. All participants will practice a set of 30 meaningful words during the intervention. Participants will complete the SLT programme at home on an ipad, whilst using the stimulation device.
48457412|NCT04435574|DRUG|Lactoferrin|Bovine Lactoferrin 100mg sachets.
48457413|NCT04435574|DRUG|Ferrous Sulfate|6mg/kg of ferrous sulfate.
48457414|NCT01690780|DRUG|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
48457415|NCT01690780|DRUG|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
48623021|NCT05967091|DEVICE|Targeted Lung Denervation|Targeted Lung Denervation (TLD) is a bronchoscopically guided, minimally invasive procedure using the Ryme Medical Lung Denervation System
47934245|NCT03473418|DRUG|Ketoconazole|Ketoconazole as a topical vaginal gel
47934246|NCT03473418|DRUG|Terconazole|Terconazole 80 mg as a topical vaginal cream
48623022|NCT02568423|DRUG|Mirikizumab - IV|Administered IV
48623023|NCT02568423|DRUG|Mirikizumab - SC|Administered SC
48457416|NCT00197249|BIOLOGICAL|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
48457417|NCT04823091|DRUG|Fludarabine + Cyclophosphamide + CAR7-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
48457418|NCT00137644|BEHAVIORAL|Preventing AIDS Through Live Movement and Sound (PALMS)|
48457419|NCT01920334|DRUG|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
48457420|NCT01920334|DRUG|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
48457421|NCT02939573|DRUG|Colchicine|Randomized to colchicine 0.6 mg x 2/day
48457422|NCT02939573|DRUG|Dapsone|Randomized to dapsone 150 mg/day
48457423|NCT02939573|DRUG|Azathioprine|Randomized to azathioprine 2 mg/kg/day
48457424|NCT03541538|DEVICE|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
47934247|NCT06214494|OTHER|Blood Flow Restricted High Intensity Treadmill Training|Blood Flow Restricted High Intensity Treadmill Training at 70% limb occlusion (on hemiparetic limb only) 2x weekly for 16 Sessions totaling minimum of 75 minutes weekly.
47934248|NCT06214494|OTHER|HITT|High Intensity Treadmill Training 2x weekly for 16 Sessions totaling minimum of 75minutes weekly.
47934249|NCT01288976|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
47934250|NCT01288976|DRUG|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
47934251|NCT01288976|PROCEDURE|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
48457425|NCT03541538|DEVICE|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
48457426|NCT03453840|DRUG|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
48457427|NCT01885819|BIOLOGICAL|Autologous stromal vascular fraction cells|
48457428|NCT00087529|DRUG|placebo|Intravenous repeating dose
47934252|NCT00958490|OTHER|Walking program|4 week physical activity walking program
47934253|NCT01680133|OTHER|Hyperinsulinemic euglycemic clamp|
47934254|NCT00284076|DRUG|L-arginine|
48280818|NCT05519696|BEHAVIORAL|Intervention|Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.
48280819|NCT05519696|BEHAVIORAL|Comparison|Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.
48457429|NCT00087529|DRUG|rituximab|Intravenous repeating dose
48457430|NCT00538863|DRUG|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
48457431|NCT03961204|OTHER|Data Collection|No study treatment was administered as part of this study
47934255|NCT05884632|RADIATION|Daily Adaptive RadioTherapy|Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
47934256|NCT05244642|DRUG|Penpulimab|A humanized monoclonal immunoglobulin.
48457432|NCT02042560|OTHER|Blood samples|
48457433|NCT02042560|OTHER|Spleen samples|
48457434|NCT05653934|BEHAVIORAL|Pre-operative use of virtual reality headset|Patient use the virtual reality headset the day before and / or the day of the surgery
48457435|NCT05653934|PROCEDURE|Standard surgery|Patient are operated as needed for treatment of colorectal cancer (usual care)
48457436|NCT05653934|BEHAVIORAL|Post-operative use of virtual reality headset|Patient use the virtual reality headset as many time as they want after the surgery during a maximum of 30 days
48457437|NCT02341690|OTHER|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
48457438|NCT02341690|OTHER|control|Standard care at the promotion centre in the municipality
48623024|NCT02568423|DRUG|Placebo - IV|Administered IV
48623025|NCT02568423|DRUG|Placebo - SC|Administered SC
48623026|NCT04503005|OTHER|Time Restricted Eating|Effect of 16, 14 or 12 hours of daily fasting
48457439|NCT04162171|RADIATION|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~* Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~* SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
48457440|NCT04303208|PROCEDURE|Blood sample|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
48457441|NCT04870333|DRUG|Niclosamide|140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
48457442|NCT04870333|DRUG|Placebo|140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
47934257|NCT05244642|DRUG|Investigator's choice of Chemotherapy|Participants will receive one of the following chemotherapies, including but not limited to DHAP (cisplatin 100mg/m2 D1, high dose cytarabine 2 mg/m2 q12h D2, dexamethasone 40mg D1-4, Q3W); ESHAP (etoposide 40 mg/m2 D1-4, cisplatin 25 mg/m2 D1-4, high dose cytarabine 2 mg/m2 D5, methylprednisolone 500mg D1-4, Q3W); DICE (dexamethasone 10mg/m2 D1-4, ifosfamide 1.0g/m2 D1-4, cisplatin 25mg/m2 D1-4, etoposide 60 mg/m2 D1-4, Q3W); ICE (ifosfamide 5 mg/m2 D2, carboplatin AUC 5 D2, etoposide 100 mg/m2 D1-3, Q3W); IGEV (ifosfamide 2 mg/m2 D1-4, gemcitabine 800 mg/m2 D1, D4, vinorelbine 20mg/m2 D1, prednisone 100 mg D1-4, Q3W); GVD (gemcitabine 1g/m2 D1, D8, vinorelbine 20 mg/m2 D1, D8, liposome doxorubicin 15 mg/m2 D1, D8, Q3W); MINE (etoposide 65mg/m2 D1-3, ifosfamide 1.33g/m2 D1-3, mitoxantrone 8mg/m2 d1, Q3W); GemOx (gemcitabine 800mg/m2 D1, D8, oxaliplatin 85mg/m2 D1, Q3W); GemOx (gemcitabine 1000mg/m2 D1, oxaliplatin 100mg/m2d1, Q2W).
47934258|NCT00002967|DRUG|cyclophosphamide|
47934259|NCT00002967|DRUG|doxorubicin hydrochloride|
47934260|NCT00002967|DRUG|octreotide pamoate|
47934261|NCT00002967|DRUG|tamoxifen citrate|
47934262|NCT04077476|BEHAVIORAL|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
47934263|NCT04077476|BEHAVIORAL|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
47934264|NCT02280083|DRUG|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
47934265|NCT02280083|DRUG|placebo|placebo
47934266|NCT02912143|OTHER|documentation only|
47934267|NCT01369485|DEVICE|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
47934268|NCT01369485|DEVICE|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
47934269|NCT01594151|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
47934270|NCT00311480|BIOLOGICAL|Influenza vaccine surface antigen adjuvanted with MF59|
47934271|NCT05939362|OTHER|MRI follow-up|MRI follow-up for patient with early onset Alzheimer's disease
47934272|NCT05236595|OTHER|Individualized drug matching per genetic disease|Patient phenotype and samples will be evaluated for individualized therapeutic drug development
47934273|NCT03316183|OTHER|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
47934274|NCT00328978|DRUG|Quetiapine|
47934275|NCT04279288|DEVICE|Hilotherm mask|a cooling mask used to treat localized swelling and bleeding
47934276|NCT00609362|DRUG|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
47934277|NCT00609362|DRUG|Placebo pill|One encapsulated placebo pill a day for 14 weeks
48280820|NCT00942162|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
47934278|NCT04665193|DIAGNOSTIC_TEST|Rapid Antigen Test|Antigen Technology Lab-based test and Point of care test
48280821|NCT04702230|DIAGNOSTIC_TEST|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
48280822|NCT04943588|DIAGNOSTIC_TEST|HCV RNA (PCR)|We will test HCV positive patients after treatment to observe if they achieve SVR
48457443|NCT04870333|DRUG|Ciclesonide|"Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
48457444|NCT04870333|DRUG|Placebo|"Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately."
48457445|NCT04870333|DRUG|Sotrovimab|"There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose."
48457446|NCT04870333|DRUG|Placebo|There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
48457447|NCT03694197|DRUG|Praluent|Subcutaneous (SC) administration
48457448|NCT06428539|DIAGNOSTIC_TEST|T-reg cells|laboratory test
48457449|NCT00891787|DIETARY_SUPPLEMENT|Probiotic Supplement|
48457450|NCT03065751|DEVICE|Plasmaexchange|TPE against fresh frozen plasma
48457451|NCT05016986|OTHER|Standard clinical management|outcomes in GSW cardiac injuries
47934279|NCT04932187|DRUG|Capecitabine, Camrelizumab|This is a single-arm study with all patients receiving these two drugs.
48457452|NCT03888235|PROCEDURE|Immediate corrective exercises|The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.
48457453|NCT03888235|DEVICE|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later."
48457454|NCT03888235|OTHER|Delayed treatment|Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
48457455|NCT05574036|DRUG|Febuxostat 80 MG Oral Tablet|Febuxostat used as 80 mg oral tablet once daily for 6 months
48457456|NCT05574036|DRUG|vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
48457457|NCT04002024|OTHER|Moisturizer with active ingredients|Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day
48457458|NCT04002024|OTHER|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
48457459|NCT03914664|DIAGNOSTIC_TEST|Electroencephalogram (EEG) testing procedure|EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG
48457460|NCT03914664|DIAGNOSTIC_TEST|Autonomic function testing procedure|Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)
48457461|NCT03552484|BEHAVIORAL|Home Visit Program|Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
48457462|NCT03552484|BEHAVIORAL|Usual Care/Online Survey|Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
48457463|NCT05809180|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt d1;
48457464|NCT05809180|DRUG|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
48457465|NCT05809180|DRUG|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
48457466|NCT05809180|DRUG|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
48623027|NCT04270955|PROCEDURE|Embolization of the Middle Meningeal Artery|Using established endovascular techniques and materials patient will have a diagnostic catheter based angiogram performed on the side(s) of the brain where the subdural hematoma is present. After verifying the vascular anatomy to ensure safety of the procedure the Middle Meningeal Artery will be embolized.
47934280|NCT06161077|DIAGNOSTIC_TEST|Voice Biomarker Screening Too|The investigators will develop a screening tool using voice that can predict disease severity in idiopathic subglottic stenosis
48280823|NCT04943588|DIAGNOSTIC_TEST|HCV Antibody test (Point of care)|HCV antibody test used to establish if patients have had or are actively infected with HCV
48280824|NCT04943588|DIAGNOSTIC_TEST|AST/ALT and platelets measurement|AST/ALT and platelets to determine APRI score
48457467|NCT05809180|DRUG|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
48457468|NCT04692155|DRUG|Ublituximab|Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
48457469|NCT04692155|DRUG|Umbralisib|Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
48457470|NCT04879537|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
48457471|NCT02075385|PROCEDURE|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
48457472|NCT00654186|DRUG|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
48457473|NCT00393250|OTHER|Hypnosis|Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.
48457474|NCT00393250|OTHER|Control|Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
48457475|NCT02066038|DRUG|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
48457476|NCT04341337|OTHER|interview|questionnaire about ethics in surgery
48457477|NCT01783535|DRUG|vincristine|Given via minibag/gravity flow.
47934281|NCT02599805|DEVICE|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
47934282|NCT03361176|DRUG|Injectable sodium deoxycholate|Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
48280825|NCT04932889|OTHER|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease...), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc..., treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
48457478|NCT01783535|DRUG|topotecan|Given IV over 30 minutes.
48457479|NCT01783535|DRUG|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is \>2,000/µL on one occasion after the expected nadir.
48457480|NCT01783535|DRUG|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is \>2,000/µL on one occasion after the expected nadir.
48457481|NCT01783535|DRUG|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
48457482|NCT01783535|OTHER|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
48457483|NCT01783535|DRUG|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
48457484|NCT01783535|DRUG|cyclophosphamide|Given IV.
48457485|NCT01783535|DRUG|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
48457486|NCT01783535|DRUG|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
48457487|NCT01783535|PROCEDURE|enucleation|Eye removal due to advanced disease in Strata C and D participants.
48457488|NCT01783535|RADIATION|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
48457489|NCT06179173|OTHER|HIIT-RCE|High-intensity interval training on semi-recumbent cycle ergometer
48457490|NCT06179173|OTHER|Conventional physiotherapy|Conventional physiotherapy
48457491|NCT06276153|OTHER|no interventions|retrospective registry cohort with no other specific interventions
48457492|NCT03142022|OTHER|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
48623028|NCT04270955|PROCEDURE|Standard of care including possible surgical evacuation of subdural hematoma|Standard of care could include observation or intervention including surgical drainage of subdural hematoma by bedside drain, Subdural Evacuating Port System (SEPS), burr hole or craniotomy
48457493|NCT05757830|DEVICE|UANGO suite exoskeleton|"Each subject will perform 3 experimental conditions (Condition 1: Walking without exoskeleton; Condition 2: Walking with exoskeleton; Condition 3: Walking with exoskeleton and walker).~Each condition includes 5 triasl (Trial 1 - Sitting: 5 minutes, sitting at rest in comfortable position; Trial 2 - Standing: 5 minutes, with assistance; Trial 3 - Comfortable speed Walking (100% assisted): 4 min during back-and-forth locomotion on a 20-m length linear flat path; Trial 4 - Comfortable speed Walking (75% assistance): 4 min during back-and-forth locomotion on a 20-m length linear flat path, Trial 4 is not available in condition 1; Trial 5 - 1 minute Sit to stand test). Nasa TLX and RPE will be requested at the end of each trial. Usability questionnaires will be fullfilled at the end of condition 2 and condition 3."
48457494|NCT02994147|DRUG|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
48457495|NCT02994147|DRUG|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
48457496|NCT03121898|DEVICE|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
48457497|NCT00529763|DRUG|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
48457498|NCT03759704|DRUG|Hyperpolarized 13CPyruvate|Bolus injection of study drug during MRSI.
48457499|NCT04869995|OTHER|Interview|An individual semi-structured interview per surgeon, according to an interview guide.
48457500|NCT00840658|BEHAVIORAL|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
47934283|NCT03361176|COMBINATION_PRODUCT|Injectable sodium deoxycholate with Triamcinolone acetate|Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
47934284|NCT01773447|PROCEDURE|Set-back suture|
48457501|NCT00840658|BEHAVIORAL|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
48457502|NCT00840658|BEHAVIORAL|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
48457503|NCT00840658|BEHAVIORAL|Lecture-format presentation|60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
48457504|NCT06322485|BEHAVIORAL|Internet-based self-management intervention|An internet-based cognitive-behavioral therapy with six modules.
48457505|NCT01403363|DRUG|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
48457506|NCT05488158|OTHER|Osteopathic manipulation|Pain and somatic disfunction were treated with osteopathic manipulations as deemed appropriate by a trained DO.
48457507|NCT02275962|DRUG|K-877|
48457508|NCT02275962|DRUG|Rifampin|
48457509|NCT00406393|DRUG|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."
48457510|NCT00406393|DRUG|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
47934285|NCT01773447|PROCEDURE|Vertical mattress suture|
47934286|NCT00025727|DRUG|Lopinavir/Ritonavir|
47934287|NCT00025727|DRUG|Ritonavir|
47934288|NCT00025727|DRUG|GW433908|
47934289|NCT00353028|DRUG|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
47934290|NCT00353028|DRUG|Placebo|Placebo
47934291|NCT02302430|DRUG|Oxytocin|20 International Units Intranasal Oxytocin
47934292|NCT02302430|OTHER|Placebo comparator|Saline nasal spray
47934293|NCT00002681|BIOLOGICAL|aldesleukin|
47934294|NCT00002681|BIOLOGICAL|daclizumab|
47934295|NCT06022484|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
48106853|NCT03772379|PROCEDURE|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
48457511|NCT00406393|DRUG|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."
47934296|NCT04367831|DRUG|Enoxaparin Prophylactic Dose|"Prophylactic dose anticoagulation (per Columbia University Irving Medical Center (CUIMC) Guidelines):~If eGFR ≥30 mL/min (stable kidney function):~1. BMI \< 40 kg/m2: Enoxaparin 40 mg SC daily~2. BMI 40 - 50 kg/m2: Enoxaparin 40 mg SC q12h~3. BMI \> 50 kg/m2: Enoxaparin 60 mg SC q12h"
48457512|NCT00558402|BEHAVIORAL|Meditation|meditation class 1/week for 8 weeks
48457513|NCT00558402|BEHAVIORAL|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
48457514|NCT00558402|BEHAVIORAL|Respite only|Respite care 90 mins per week for 8 weeks
48457515|NCT04915339|BEHAVIORAL|Physical activity|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables...) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation...).
48457516|NCT04915339|BEHAVIORAL|cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables...) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation...).
48457517|NCT04915339|BEHAVIORAL|combined physical and cognitive training|The intervention is administrated through a computerized application as prescribed exercises (cognitive or physical). The specific measures that will be used to determine the effect of the intervention are psychological variables (mood, anxiety, well-being, cognitive variables...) and physical ones (Heart rate variability, stress biomarkers, fat and muscle mass, blood circulation...).
47934297|NCT04367831|DRUG|Heparin Infusion|Unfractionated heparin infusion at 10 units/kg/hour with goal anti-Xa 0.1 -0.3U/mL.
47934298|NCT04367831|DRUG|Heparin SC|Unfractionated heparin at 5000-7500 units subcutaneous (SC) every 8 hours.
48457518|NCT06016582|DEVICE|Use of virtual reality hypnosis headset during frozen embryo transfer|"The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~* The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~* The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~* The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study."
48457519|NCT00171015|DRUG|valsartan plus hydrochlorothiazide|
48457520|NCT00421304|BIOLOGICAL|Motavizumab|A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
48457521|NCT00421304|OTHER|Placebo|A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
48623029|NCT02232698|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
47934299|NCT04367831|DRUG|Enoxaparin/Lovenox Intermediate Dose|If estimated glomerular filtration rate (eGFR) ≥ 30 mL/min: enoxaparin 1mg/kg subcutaneous (SC) daily.
47934300|NCT04449029|DRUG|GSK3228836|GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
47934301|NCT04449029|DRUG|Placebo|Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
47934302|NCT04449029|DRUG|Nucleos(t)ide therapy|Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
47934303|NCT00796354|DRUG|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
47934304|NCT00796354|DRUG|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
47934305|NCT03754231|OTHER|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
47934306|NCT03754231|OTHER|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
47934307|NCT01580748|DRUG|Roflumilast|500 microgram once daily for 16 weeks
47934308|NCT06134271|DRUG|Rezvilutamide|Rezvilutamide 240mg qd
47934309|NCT06134271|DRUG|Rezvilutamide plus abiraterone|Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
47934310|NCT06134271|DRUG|Continue previous treatment|Continue using the previous treatment regimen for treatment.
48098752|NCT06230874|BEHAVIORAL|HOME Protocol|The HOME Protocol is a newly developed nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Five components of the HOME Protocol include Reflect (1 minute of self-reflection and self-talk), Reset (2 minutes for breathing with stillness/silence and body check), Reach (3 minutes for stretching and progressive muscular relaxation), Renew (2 minutes for breathing with meditation/gratitude), and Re-engage (1 minute for self-reflection and self-talk).
48106854|NCT04505943|DRUG|Isonicotinic Acid Hydrazide|2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
48457522|NCT06562959|BEHAVIORAL|Fluid Restriction Program|In order to design the fluid restriction program content (booklet). The fluid restriction program included (a) General small-group discussion sessions, (b) individualized consultations, and (c) follow-up sessions. In the group discussion sessions, children in both the study and control groups were divided into subgroups (6 participants per each). In the group discussion sessions, children in both the study and control groups were divided into subgroups. The sessions were conducted in the meeting room of the Hemodialysis unit lasts for 45 minutes. In the Individualized Consultations, children then were provided tailored, age-appropriate education. The researchers also arranged for regular follow-up for one months.
48457523|NCT06562959|OTHER|Intervention Bundle (Fluid Restriction Program and Auricular Acupressure|the study group received the Fluid Restriction Program and Auricular Acupressure in four acupoints namely, Shenmen, Kidney Concha, Point Zero and Upper Tragus. The researcher's finger gently pressed on each determined acupoints in a circular movement with a clockwise direction for three minutes.
48457524|NCT00001058|DRUG|Indinavir sulfate|
48457525|NCT00001058|DRUG|Ritonavir|
48457526|NCT00001058|DRUG|Ethambutol hydrochloride|
48457527|NCT00001058|DRUG|Clarithromycin|
48457528|NCT00001058|DRUG|Rifabutin|
48457529|NCT03999216|DRUG|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
47934311|NCT00533091|BIOLOGICAL|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
48457530|NCT04694963|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
47934312|NCT00533091|OTHER|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
48457531|NCT04694963|PROCEDURE|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;"
48457532|NCT04694963|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
48457533|NCT00967135|DRUG|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
48457534|NCT00967135|DRUG|Placebo|Matching oral placebo twice daily for 5 consecutive days.
48457535|NCT01669980|DRUG|Ceftaroline fosamil|"* Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~* Subjects \< 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
48457536|NCT01669980|DRUG|IV Ceftriaxone and Vancomycin|"* IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~* IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~* PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~* PO clindamycin 13 mg/kg/dose~* PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
48457537|NCT04892953|DRUG|Carboplatin|Given IV
48457538|NCT04892953|BIOLOGICAL|Durvalumab|Given IV
48457539|NCT04892953|DRUG|Gemcitabine|Given IV
47934313|NCT01609478|DRUG|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
47934314|NCT01609478|DRUG|placebo|placebo delivered via Concept 1 inhaler
47934315|NCT01609478|DRUG|mometasone furoate|via Twisthaler inhaler
48457540|NCT04892953|PROCEDURE|Local Consolidation Therapy|Undergo LCT
48457541|NCT04892953|DRUG|Nab-paclitaxel|Given IV
48457542|NCT04892953|DRUG|Paclitaxel|Given IV
48457543|NCT04892953|DRUG|Pemetrexed|Given IV
48457544|NCT04892953|OTHER|Quality-of-Life Assessment|Complete questionnaire
48457545|NCT04892953|OTHER|Questionnaire Administration|Complete questionnaire
48457546|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_A|The participants will be exposed to 10% Tamarind pulp juice
47934316|NCT05030961|BEHAVIORAL|Virtual team-based clinic|Virtual team-based clinic will include consultation, counseling, and education from pediatric audiology, psychology, auditory verbal therapy, and education. Each session lasts approximately 30 minutes with a total of 3 sessions within the year.
47934317|NCT05030961|BEHAVIORAL|Remote cochlear implant programming|Remote cochlear implant programming will be provided via Zoom on a study-provided encrypted laptop.
48457547|NCT06058845|DIETARY_SUPPLEMENT|Tamarindus indica fruit juice_B|The participants will be exposed to 30% Tamarind pulp juice
48457548|NCT00761163|OTHER|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
47934318|NCT04128787|DRUG|AG881 Formulation 1|AG881 uncoated tablets
48457549|NCT00761163|OTHER|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
48457550|NCT00761163|OTHER|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
48457551|NCT06618339|BEHAVIORAL|Mindfulness-based intervention|8 Session Mindfulness-based intervention
48457552|NCT05580744|OTHER|Traditional occupational therapy|Motor training targeted to goals that are relevant to the functional needs of the patient
48457553|NCT05580744|OTHER|Mirror therapy using a mirror box|Mirror therapy using a mirror box
48457554|NCT05580744|OTHER|Augmented reality-based mirror therapy|Augmented reality-based mirror therapy
48457555|NCT04565587|OTHER|Xanthan-gum based thickener|Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
48457556|NCT00538109|DRUG|Glivec®/Gleevec®|Chemotherapy
48457557|NCT00940563|DRUG|Imatinib|
48457558|NCT04951778|DRUG|CC-91633|Administered orally according to the assigned treatment schedule
48457559|NCT06301386|DRUG|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
48457560|NCT06301386|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
48457561|NCT03798457|OTHER|No intervention|In this study there is no intervention
48457562|NCT05579548|DRUG|Pegvaliase|Pregnant women exposed to pegvaliase within 2 weeks prior to LMP.
48457563|NCT04431518|DRUG|JULUCA 50Mg-25Mg Tablet|One dose of JULUCA will be taken daily for up to 14 days
48457564|NCT00131417|DRUG|ready-to-use therapeutic food|
48457565|NCT02426450|PROCEDURE|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
48457566|NCT02426450|DRUG|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
48457567|NCT02426450|DRUG|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
48457568|NCT00794794|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
48457569|NCT00794794|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
48457570|NCT00070122|DRUG|oxaliplatin|Given IV
48457571|NCT00070122|DRUG|leucovorin calcium|Given IV
48457572|NCT00070122|DRUG|capecitabine|Given orally
48457573|NCT00070122|BIOLOGICAL|bevacizumab|Given IV
48457574|NCT00070122|DRUG|fluorouracil|Given IV
48457575|NCT00070122|OTHER|laboratory biomarker analysis|Correlative studies
48457576|NCT06491342|DIETARY_SUPPLEMENT|Probiotic|Probiotic-Lactobacillus Zeae and Lactobacillus reuteri
48457577|NCT06491342|DIETARY_SUPPLEMENT|Placebo|placebo
48457578|NCT02663921|OTHER|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~1. Immediately after the light exposure;~2. 30 minutes after light exposure; and~3. 1 hour after light exposure."
48457579|NCT02663921|OTHER|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~1. Visual Clinical Assessment~2. Spectroscopy~3. Colorimetry"
48457580|NCT05346172|DEVICE|PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the PanOptix or PanOptix Toric IOL in both eyes.
48457581|NCT06123689|DEVICE|AMT-Regenera activa|"Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~1. Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~2. Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~3. The samples are processed for 6 minutes~4. The Rigeneracon is extracted from the machine."
48457582|NCT06123689|DEVICE|Hyalubrix|"Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed"
48457583|NCT04060251|DEVICE|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
48457584|NCT04060251|OTHER|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
48457585|NCT06557421|DRUG|Venetoclax|complete discontinuation of Venetoclax
48457586|NCT06557421|DRUG|Azacitidine|complete discontinuation of Azacitidine
48457587|NCT06043349|COMBINATION_PRODUCT|Platelet-Rich Plasma and Topical 5% Minoxidil|The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
48457588|NCT06043349|DRUG|Topical 5% Minoxidil|The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
48457589|NCT03850158|DRUG|Indocyanine Green|Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
48457590|NCT06560866|BEHAVIORAL|Just Care for Families|Just Care for Families is a behavioral intervention to address the needs of families involved in or at-risk for involvement with the child welfare system. Just Care involves treatment components, supported by ongoing purposeful engagement: (1) Substance use treatment including contingency management and positive reinforcement, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; (4) Community building including indigenous and external social supports; (5) Systems navigation; and (6) provision of assistance with basic needs including assistance with housing and employment.
48457591|NCT05644184|BIOLOGICAL|Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)|Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
48457592|NCT05644184|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
48457593|NCT05039541|DEVICE|Alio Device|Subjects will wear the Alio device over their vasculature.
48457594|NCT01932021|PROCEDURE|adipose tissue grafting|
48457595|NCT05474651|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, the Fagerstrom Test of Nicotine Dependence,Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, smoking hazard questionnaire, motivation to quit smoking sheet, ability to quit smoking sheet, alcohol consumption, International Physical Activity Questionnaire.
48457596|NCT05343676|DEVICE|ultrasonography|"* For assessment of LNS ( cervical , axillary and inguinal LNS ), The choice of transducer is an important consideration when evaluating lymph nodes as higher frequencies provide better resolution for superficial structures~* For color Doppler assessment of the lymph nodes, scanning will be done using the slow frame rate, low pulse repetition frequency~* Assessment features including lymph node location, size, shape, border, echogenicity, calcifications, necrosis or cystic change, and adjacent soft tissue edema"
48457597|NCT03580915|BEHAVIORAL|Functional Literacy Program|The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
48457598|NCT03580915|BEHAVIORAL|Usual Care Management Services|The control group will receive the usual housing services without additional intervention.
48457599|NCT02275403|PROCEDURE|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
48457600|NCT02275403|OTHER|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
48457601|NCT03302832|OTHER|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
47934319|NCT04128787|DRUG|AG881 Formulation 2|AG881 film-coated tablets
47934320|NCT04128787|DRUG|Omeprazole|Omeprazole capsules
48457602|NCT03302832|OTHER|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
48457603|NCT03840577|DEVICE|Monitorization of sedation by Bispectral Index|The sedative dose administered through a continuous infusion pump will be adjusted based on the BIS value to maintain a target range of 40 to 60. If the BIS value is below the target range, the dose will be increased, and if it exceeds the range, the dose will be decreased, aiming to keep the BIS within the desired range.
48457604|NCT02913924|DRUG|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
48457605|NCT02913924|DRUG|Placebo|
48457606|NCT04404907|OTHER|no intervention|This is a secondary analysis of registry data.
48457607|NCT03371186|OTHER|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
48457608|NCT03371186|OTHER|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
48457609|NCT03371186|OTHER|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
47934321|NCT00401895|DEVICE|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
48457610|NCT03371186|OTHER|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
48457611|NCT03371186|OTHER|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
48457612|NCT05965908|DRUG|liraglutide|glucagon-like peptide 1 receptor agonist
48457613|NCT05965908|DRUG|Metformin|biguanide antihyperglycemic
48457614|NCT00728351|DRUG|vildagliptin + metformin|
47934322|NCT01551940|DRUG|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
47934323|NCT01551940|DRUG|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
47934324|NCT02793843|DRUG|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
48457615|NCT00728351|DRUG|metformin|1000 bid metformin
47934325|NCT02793843|DRUG|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
47934326|NCT02793843|OTHER|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
47934327|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in enhanced standard care
47934328|NCT01764802|OTHER|behavioral, psychological or informational intervention|Participate in psychological intervention
47934329|NCT04089215|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10\^8 CAR+T cells and 1.5 x 10\^8 CAR+T cells
47934330|NCT00042029|DRUG|MK0869, aprepitant|
47934331|NCT00042029|DRUG|Comparator: placebo|
47934332|NCT02523612|PROCEDURE|Biopsy|
47934333|NCT02523612|PROCEDURE|Blood sample|
48106855|NCT04505943|DRUG|dinoprostine|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
47934334|NCT06246279|BEHAVIORAL|Adaptation to Adolescence and Type 1 Diabetes Management Training Program|The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.
48457616|NCT04544618|DEVICE|Virtual reality operating room simulation|The virtual reality simulation will begin with the participant sitting on a hospital bed wearing the virtual reality headset and holding the controllers. Participants will be oriented to the environment and provided with an explanation of how to navigate through the simulation (for approximately 2 minutes). Next, participants will explore the virtual operating room for a minimum of 5 minutes, or longer if desired. Following the exploration period, the scripted portion of the simulation will be begin. Here, participants will be taken through the mock anesthetic induction process (the virtual anesthetist will speak to the patient and walk them through the steps and the virtual nurse will assist). The simulation ends after the virtual oxygen mask is placed over the participant's mouth and the screen darkens.
48457617|NCT00456898|DRUG|desvenlafaxine sustained release (DVS SR)|
48457618|NCT00456898|DRUG|Paroxetine|
48457619|NCT00456898|DRUG|Codeine|
48457620|NCT06626672|BEHAVIORAL|Digital Health Intervention|Access to a digital platform including weekly workout videos, live workouts, recipes, study summaries, and a consultation hour.
48457621|NCT06498986|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
48457622|NCT06498986|DRUG|Osimertinib Mesylate Tablets|Oral administration, 80mg daily for a cycle of 3 weeks.
48457623|NCT00459407|DIETARY_SUPPLEMENT|defined green tea catechin extract|Given orally
48457624|NCT00459407|DRUG|placebo|Given orally
48457625|NCT00459407|OTHER|immunohistochemistry staining method|Correlative studies
48457626|NCT00459407|OTHER|immunoenzyme technique|Correlative studies
47934335|NCT00874614|RADIATION|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
48457627|NCT00459407|OTHER|laboratory biomarker analysis|Correlative studies
48457628|NCT00459407|PROCEDURE|biopsy|Undergo biopsy
48457629|NCT00459407|OTHER|mass spectrometry|Correlative studies
48457630|NCT00459407|OTHER|high performance liquid chromatography|Correlative studies
48457631|NCT06397339|OTHER|INTACT Program|"The INTACT Program has three components:~1. provide a training for Primary Care Providers (PCPs) training in screening, diagnosis, and care for ADRD,~2. at the PCP level, provide quarterly webinars. Topics will address driving and dementia; communication tips for someone with dementia; eating and drinking in advanced dementia; and advanced care planning for dementia.~3. At the clinic level, provide a workflow model for cognitive evaluation and setting a plan for the newly diagnosed patient. The INTACT intervention lasts 12 months and Continuing Medical Education credits will be available to PCPs who complete the INTACT training program"
48457632|NCT01662050|DRUG|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
48457633|NCT06627790|DRUG|Mouthwash preparation|Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
48457634|NCT01808651|DRUG|Fluoxetine|Administered orally
48457635|NCT02115776|DRUG|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
48457636|NCT02115776|DRUG|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
48457637|NCT02115776|DRUG|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
48457638|NCT00377039|DRUG|AD 337|
48623030|NCT02232698|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
48457639|NCT04474405|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), single dose
48457640|NCT04474405|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
48457641|NCT04474405|PROCEDURE|Whole body PET scan|positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
48457642|NCT04474405|DRUG|Florbetapir F 18|IV injection, 370 MBq (10 mCi), single dose
48457643|NCT04474405|PROCEDURE|Brain MRI|Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
48623031|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
48457644|NCT01747174|DRUG|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
48457645|NCT01747174|DRUG|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
48457646|NCT01747174|PROCEDURE|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
48623032|NCT00859118|DRUG|AG-013736|Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
48623033|NCT05841576|OTHER|COMET monitoring device|Cellular Oxygen METabolism (COMET) mitochondrial oxygen tension monitoring device
48457647|NCT05698407|DRUG|Dexmedetomidine|loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
48457648|NCT05698407|DRUG|Sufentanil|loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
48457649|NCT06475651|GENETIC|Methylation analysis|Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
48457650|NCT01496495|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
48457651|NCT00677872|DRUG|PRX-08066|
47934336|NCT01216007|DRUG|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
47934337|NCT01216007|DRUG|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
48457652|NCT02227238|DRUG|DTG|DTG is supplied as 50 mg tablets
47934338|NCT02750215|DRUG|Capmatinib (INC280)|treatment with Capmatinib (INC280)
47934339|NCT01967784|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
47934340|NCT01618812|PROCEDURE|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
47934341|NCT01525901|DRUG|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
47934342|NCT01525901|DRUG|Normal saline|Saline solution will be administered for three months subcutaneously.
47934343|NCT02915328|DEVICE|Filterwire EZ™|
47934344|NCT02915328|DEVICE|MO.MA Ultra|
47934345|NCT02915328|DEVICE|Stent Roadsaver®|
48280826|NCT04932889|OTHER|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
48457653|NCT02227238|DRUG|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
48457654|NCT02227238|DRUG|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
48280827|NCT04932889|OTHER|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
48457655|NCT02373462|DRUG|Olmesartan|
47934346|NCT02915328|DEVICE|Carotid Wallstent|
47934347|NCT00976118|DRUG|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
48457656|NCT02373462|DRUG|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
48457657|NCT04013763|OTHER|wheat containing skin care products|stop or continue using wheat containing skin care products
48457658|NCT05515458|DRUG|Chiglitazar|Oral single dose 48 mg
48457659|NCT01139762|DRUG|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
48457660|NCT01139762|DRUG|Placebo|Administered orally, once daily for 26 weeks
48457661|NCT01139762|DRUG|Finasteride|5mg administered orally, once daily for 26 weeks
48457662|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
47934348|NCT00976118|DRUG|placebo|matching placebo to masitinib
47934349|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
47934350|NCT03518671|BEHAVIORAL|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
47934351|NCT04048161|DRUG|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is \< 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
48106856|NCT04505943|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
48106857|NCT02485041|DRUG|Dapoxetine 30mg|Tablet, Orally administered
48457663|NCT01018862|DRUG|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
48457664|NCT01018862|DRUG|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
48457665|NCT05373043|DIETARY_SUPPLEMENT|Mitoquinone|Mito-Q is a supplement that targets mitochondrial function. Linking a triphenyl-phosphonium cation to coenzyme-Q, to produce Mito-Q, results in a lipophilic compound, which, due to the large mitochondrial membrane potential, selectively accumulates within mitochondria. This targeted antioxidant approach results in 50- to 100-fold more Mito-Q accumulation compared to non-targeted antioxidant delivery.
48457666|NCT05373043|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
48457667|NCT05705869|DIAGNOSTIC_TEST|NT-proBNP|NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
48457668|NCT02927210|DRUG|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
48457669|NCT02927210|DRUG|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
48457670|NCT00272441|DRUG|inhaled corticosteroids|
48457671|NCT04872231|DRUG|Voriconazole Inhalation Powder|"PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID."
48457672|NCT04872231|DRUG|Placebo|"PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses."
48457673|NCT01140438|DRUG|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
48457674|NCT01140438|DRUG|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
48457675|NCT05086653|PROCEDURE|Surgery|Sutured by Prolene 3-0 with two layers of pledge
48457676|NCT00269386|DRUG|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
48457677|NCT00269386|DRUG|Placebo|
48457678|NCT02193022|DRUG|Miltefosine|
48457679|NCT04056338|OTHER|No intervention|No intervention.
48457680|NCT00694044|DRUG|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
48457681|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
48457682|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
48457683|NCT00694044|DRUG|Placebo|Placebo for 21 days
48457684|NCT00487695|DEVICE|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
48457685|NCT00487695|DEVICE|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
48457686|NCT01426854|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
47934352|NCT04048161|DRUG|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20\~30mg/kg/day，BID. The concentration for MPA-AUC is 30\~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
48457687|NCT01426854|OTHER|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
48457688|NCT04302961|OTHER|Auditory Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.
48457689|NCT04302961|OTHER|No Feedback|Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
48457690|NCT02770690|DRUG|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
48457691|NCT02770690|DRUG|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
48623034|NCT02719327|DRUG|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
48623035|NCT02719327|OTHER|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
47934353|NCT05883670|DRUG|Serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
48457692|NCT02770690|DRUG|placebo|apply normal saline before propofol iv injection
48457693|NCT03024801|DRUG|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
48457694|NCT03024801|DRUG|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
48457695|NCT02143726|DRUG|sorafenib|Given PO
48457696|NCT02143726|DRUG|everolimus|Given PO
47934354|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
47934355|NCT03042702|DRUG|Kevetrin|Kevetrin dose to associated cohort
48457697|NCT05266287|DIETARY_SUPPLEMENT|a supplement containing 2'-fucosyllactose (2'-FL)|Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
48280828|NCT01974323|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
48457698|NCT05266287|DIETARY_SUPPLEMENT|Placebo Supplement|Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
48457699|NCT03419260|OTHER|Clinically indicated EEG monitoring.|Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
48457700|NCT00004213|DRUG|triapine|
48457701|NCT04863144|OTHER|Blood samples|Plasma concentrations of paclitaxel and its metabolites will be obtained during the first treatment cycle. The samples for paclitaxel analysis will be collected in ethylenediamine tetraacetic acid tubes at 7-time points: just before infusion, in the middle of the infusion, at the end of infusion, at 1, 2, 4 and 6 hours post-infusion.
48457702|NCT00420095|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
48457703|NCT00420095|DRUG|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
48457704|NCT04805840|DEVICE|CoV-SCAN rapid COVID-19 antigen test|SARS-CoV-2 rapid antigen screening test
48457705|NCT03045536|DEVICE|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
48457706|NCT05913843|DEVICE|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
48457707|NCT02965261|DRUG|Torrent's Fluoxetine Tablets|
48457708|NCT02965261|DRUG|Warner Chilcott LLC Sarafem Tablets|
48457709|NCT01092455|DRUG|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
48457710|NCT02533466|OTHER|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
48457711|NCT02533466|OTHER|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
48457712|NCT01988636|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
48457713|NCT01988636|DRUG|Placebo|Placebo
48457714|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
47934356|NCT03905109|DRUG|ABX464|ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
48280829|NCT01974323|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
48457715|NCT01442376|DRUG|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
48457716|NCT01442376|DRUG|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
48457717|NCT01442376|DRUG|Placebo to Ondansetron|
48457718|NCT01442376|DRUG|Placebo to Ondansetron|
47934357|NCT03905109|DRUG|Placebo|In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
47934358|NCT05130671|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
47934359|NCT05130671|DIETARY_SUPPLEMENT|Investigational treatment|Combination of quercetin and curcumin as add-on to the standard of care
47934360|NCT02008578|BIOLOGICAL|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
48280830|NCT00337389|DRUG|5- Fluorouracil (5-FU)|
48280831|NCT00337389|DRUG|bevacizumab (Avastin)|
48280832|NCT00337389|DRUG|Leucovorin|
48280833|NCT00337389|DRUG|CoFactor (ANX-510)|
48280834|NCT06521489|DEVICE|Asymmetrical High Flow Nasal Cannula Oxygenation|Asymmetrical High Flow Nasal Cannula Oxygenation will be implemented in this study group. (1st study group, 60l/min airflow, 60% fiO2)
48280835|NCT06521489|DEVICE|Conventional High Flow Nasal Cannula Oxygenation|Conventional High Flow Nasal Cannula Oxygenation will be implemented in this study group. (2nd study group, 60l/min airflow, 60% fiO2)
48280836|NCT05159193|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w
48280837|NCT05159193|DRUG|cyclophosphamide (C)|cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w
48280838|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
48280839|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
48457719|NCT01442376|DRUG|Placebo to Palonosetron|
47934361|NCT02008578|BIOLOGICAL|Placebo|
47934362|NCT01925989|BIOLOGICAL|LY2605541|Administered SQ
47934363|NCT01925989|BIOLOGICAL|Insulin Glargine|Administered SQ
47934364|NCT00673270|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
47934365|NCT00673270|DRUG|Hydrocortisone|50 mg of intravenous hydrocortisone
47934366|NCT00673270|DRUG|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
48457720|NCT00009945|DRUG|clodronate|1600 mg PO daily
48457721|NCT00009945|DRUG|placebo|2 pills PO daily
48457722|NCT01880476|OTHER|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
48623036|NCT03662568|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
48623037|NCT03662568|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
47934367|NCT00673270|DRUG|Placebo of Hydrocortisone|2 ml of isotonic saline solution
48280840|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w
48280841|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
48280842|NCT05159193|DRUG|carboplatin (Cb)|carboplatin (Cb) AUC 6, i.v., d1, q3w
48280843|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
48280844|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
48280845|NCT03026803|DRUG|Oxaliplatin|Given IV
48280846|NCT03026803|DRUG|Capecitabine|Given PO
48280847|NCT06129084|GENETIC|FGFR Testing|Determine whether ctDNA testing for FGFR provides the same results as the standard tissue testing.
48280848|NCT05123157|OTHER|NO intervention|"N/:~NO intervention"
48280849|NCT00836940|DRUG|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
48280850|NCT00482963|DRUG|levonorgestrel, efavirenz|
48280851|NCT02693977|PROCEDURE|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
48280852|NCT02739464|OTHER|Exercise + SOC PT/OT|
48280853|NCT02739464|OTHER|SOC PT/OT|
48280854|NCT05207150|DEVICE|LINQII/Apple Watch Series 6|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear an Apple Watch Series 6 for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (Apple Watch) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
48280855|NCT05207150|DEVICE|LINQII/SkyLabs CART-I ring|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear a SkyLabs CART-I ring for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (CART-I ring) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
48280856|NCT05268848|OTHER|Thermographic photo|Barefoot patient, thermographic photo of the sole of the feet is taken
48280857|NCT05219812|DRUG|BAY2395840|Tablet, intake orally.
48280858|NCT05219812|DRUG|Placebo for BAY2395840|Tablet, intake orally.
48280859|NCT01583348|PROCEDURE|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
48280860|NCT06399757|DRUG|APL-5125|APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
48280861|NCT02024776|BEHAVIORAL|Prehabilitation|Tailored exercise training program
48280862|NCT06656442|DRUG|Trimetazidine|an anti-ischemic medication.
48280863|NCT00643149|DRUG|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
48280864|NCT00643149|DRUG|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
48280865|NCT01201499|DRUG|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
48280866|NCT01201499|DRUG|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
48280867|NCT06656130|OTHER|Pranayama|Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. Patient purposely inhale, exhale, and hold his/her breath in a specific sequence.
48280868|NCT06656130|OTHER|Jacobson's progressive muscle relaxation technique|Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, patient can become more aware of his/her body and physical sensations,
48280869|NCT05422079|OTHER|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week.
48623038|NCT03662568|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
48623039|NCT03662568|DRUG|TDF|Administered TDF 300 mg orally once daily in fasted state
47934368|NCT01087866|DRUG|Metformin|
47934369|NCT01087866|DRUG|Insulin|
47934370|NCT06311552|OTHER|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner|Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
47934371|NCT00133731|DRUG|Otamixaban (XRP0673)|
47934372|NCT00133731|DRUG|Unfractionated Heparin|
47934373|NCT00133731|PROCEDURE|Percutaneous Coronary Intervention|
47934374|NCT02431247|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
48106858|NCT02485041|DRUG|Mirodenafil 100mg|Table, Orally administered
48457723|NCT00353457|DRUG|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
48457724|NCT00353457|RADIATION|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
48280870|NCT05422079|OTHER|motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program.
48280871|NCT05422079|OTHER|motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
48280872|NCT01474577|OTHER|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
48280873|NCT05307471|OTHER|Thoracotomy/scopy|
48280874|NCT04988373|DEVICE|Modified aligner appliance|Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
48280875|NCT04988373|DEVICE|Traditional fixed appliance|Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
48280876|NCT02652000|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
48280877|NCT01193764|DIETARY_SUPPLEMENT|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
48280878|NCT01193764|DIETARY_SUPPLEMENT|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
48280879|NCT06489418|OTHER|Dew Restore Barrier Repair Cream|"Wash the face with the gentle cleanser to remove dirt, and oil and pat dry with the towel\| tissue paper. Afterwards take the pea side amount of the test product you finger tips, apply it over the face by small dotes and massage it in circular motion until it absorbed.~Frequency: Twice a Day Route of Administration: Topical"
48280880|NCT05811195|DEVICE|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
48280881|NCT05811195|DEVICE|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
48280882|NCT06037876|DRUG|IVM (200 µg/kg) + ALB (400 mg)|World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
48280883|NCT06037876|DRUG|ALB (400mg)|Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
48457725|NCT03849651|DRUG|Cyclophosphamide|"Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9"
48457726|NCT03849651|BIOLOGICAL|Fludarabine|"Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4"
47934375|NCT02431247|DRUG|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
47934376|NCT02431247|DRUG|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
48280884|NCT00281450|BEHAVIORAL|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
48280885|NCT03021902|DRUG|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
48280886|NCT03021902|DEVICE|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
48280887|NCT04079023|PROCEDURE|Sleeve Gastrectomy|Subtotal vertical gastrectomy
48457727|NCT03849651|DRUG|Thiotepa|Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
48457728|NCT03849651|DRUG|Melphalan|"Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1"
48457729|NCT03849651|BIOLOGICAL|G-csf|G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
48457730|NCT03849651|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
48457731|NCT03849651|DEVICE|CliniMACS|Cells for infusion are prepared using the CliniMACS
48457732|NCT03849651|BIOLOGICAL|ATG (rabbit)|"Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,"
48457733|NCT03849651|DRUG|Blinatumomab|"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI"
48457734|NCT03849651|BIOLOGICAL|TCRα/β+|IV on day 0 and may receive an additional dose on day 1
48457735|NCT03849651|BIOLOGICAL|CD19+|IV on day 0 and may receive an additional dose on day 1
48457736|NCT03849651|BIOLOGICAL|CD45RA-depleted DLI|infusion IV
48457737|NCT06626737|DRUG|Dapagliflozin (DAPA)|Participants will take Dapagliflozin 10mg every day in -1 to 14 days
48457738|NCT00012818|BEHAVIORAL|relaxation technique|
48457739|NCT00012818|BEHAVIORAL|educational program|
48457740|NCT06040606|PROCEDURE|In-Hospital COVID-19 Omicron Infection after surgery|Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
48457741|NCT03385135|DRUG|Allopurinol|300 mg for 4 weeks then 600 mg for 4 weeks in the active group
48457742|NCT05456594|OTHER|Conventional bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a conventional bra (bra condition #1).
48457743|NCT05456594|OTHER|Bounceless bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Bounceless bra (bra condition #2a).
48457744|NCT05456594|OTHER|Shefit bra|This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Shefit bra (bra condition #2b).
48457745|NCT01202435|DRUG|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
48457746|NCT01202435|DRUG|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
48457747|NCT03313895|BEHAVIORAL|Aerobic & Cognitive Training (ACT)|ACT stands for combined aerobic exercise and cognitive training.
48457748|NCT03313895|BEHAVIORAL|Cycling Only|Cycling on a recumbent stationary cycle
48457749|NCT03313895|BEHAVIORAL|Cognitive Training Only|Engage in cognitive training on a computer
47934377|NCT02431247|DRUG|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
47934378|NCT02431247|DRUG|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
47934379|NCT02431247|DRUG|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
47934380|NCT04653896|DEVICE|Keeogo|The Keeogo is the only commercially available (in Canada) robotic exoskeleton for a non-paralyzed population who can stand and initiate a stepping action, but have impaired mobility for functional tasks. Keeogo provides active assistance during stance and swing phases and assists users to perform functional mobility tasks including walking, stair climbing, sit-to-stand, bending, squatting, and kneeling.
48457750|NCT03313895|BEHAVIORAL|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
48457751|NCT04891276|OTHER|Data collection|Data collection on the national PMSI database
47934381|NCT01649479|BIOLOGICAL|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
48280888|NCT06617481|DRUG|18F-rhPSMA-7.3 (Posluma)|PET Scan using Posluma for detection of early recurrence of prostate cancer.
48280889|NCT05634577|DRUG|Mitotane|Given by PO
48457752|NCT06382896|OTHER|No intervention|This was an observational study
48457753|NCT04470739|DIAGNOSTIC_TEST|chest x-ray|First Chest X-ray in the first 6 hours of infants
48457754|NCT03071562|OTHER|Yoga-mindfulness|"Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals \& back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class."
48457755|NCT03960801|DRUG|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
48457756|NCT03960801|DRUG|neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
48623040|NCT01834794|BEHAVIORAL|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
48280890|NCT05634577|DRUG|Pembrolizumab|Given by vein (IV)
48280891|NCT03022461|OTHER|Long term follow-up|
47934382|NCT01649479|BIOLOGICAL|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~* antithrombin, protein C, protein S~* Factor V Leiden polymorphisms (F5 1691A)~* prothrombin 20210A gene polymorphism (F2 20210A)~* JAK2 617F Mutation~* Homocysteine~* Factor VIII"
48457757|NCT01166529|PROCEDURE|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
48457758|NCT02344550|DRUG|Everolimus(afinitor)|Everolimus 10mg p.o. daily
48457759|NCT02344550|DRUG|Letrozole|Letrozole 2.5 mg p.o. daily
48457760|NCT02344550|DRUG|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
48457761|NCT00834613|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
48457762|NCT00834613|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
48457763|NCT05766670|DRUG|Vancomycin Hydrochloride|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
48280892|NCT03245879|BEHAVIORAL|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for \>48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
48457764|NCT05766670|DRUG|Gentamicin|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
48457765|NCT05766670|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
48457766|NCT03801707|DRUG|Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]|fixed dose combination medication once a day for 12 weeks for the treatment of hepatitis C
47934383|NCT01649479|OTHER|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
48457767|NCT03801707|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]|Three tablets once a day for 12 weeks for treatment of hepatitis C
48457768|NCT01816230|DRUG|NiCord®|
48457769|NCT01731977|BEHAVIORAL|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
48457770|NCT00864396|DRUG|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
48457771|NCT00980941|DIETARY_SUPPLEMENT|soup with or without starch|
48457772|NCT04686435|OTHER|Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture|Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
48457773|NCT04686435|PROCEDURE|Surgery|Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
48457774|NCT06462976|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
48457775|NCT02516189|OTHER|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching."
48457776|NCT06094764|DEVICE|Group A|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group A will be fitted with a cooling and bio-harness. At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
48457777|NCT06094764|DEVICE|Group B|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group B will wear a bio-harness and no cooling vest.At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
48457778|NCT01943435|DRUG|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
48457779|NCT01943435|PROCEDURE|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
48457780|NCT01943435|OTHER|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
48457781|NCT01943435|OTHER|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
48457782|NCT01943435|OTHER|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
48457783|NCT06103097|OTHER|No interventions done (obervational)|Observational study
48457784|NCT00466167|DRUG|Pramipexol Extended Release|
48457785|NCT00466167|DRUG|Pramipexol Immediate Release|
48457786|NCT00466167|DRUG|Placebo|
48457787|NCT05717790|DRUG|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
48457788|NCT05717790|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
48457789|NCT05717790|DRUG|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
48457790|NCT05717790|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
48457791|NCT00295490|DRUG|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
48457792|NCT00295490|DRUG|Placebo|Placebo has same dosing freq as for active intervention and for same time period
48457793|NCT02509143|PROCEDURE|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
48457794|NCT02509143|DEVICE|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
48457795|NCT02509143|DRUG|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
48457796|NCT00599820|DRUG|Intravitreal Bevacizumab|
48457797|NCT05759715|OTHER|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
48457798|NCT04508205|DRUG|CGB-400|BID application
48457799|NCT03583398|PROCEDURE|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
48457800|NCT03006757|OTHER|titanium dioxide denture base|
48457801|NCT05612958|DEVICE|DKM-410|Injection up to 2.0ml
48457802|NCT05612958|DEVICE|Juvederm ULTRA PLUS XC 1.0ml|Injection up to 2.0ml
48457803|NCT04710290|DIETARY_SUPPLEMENT|Beta-Glucan|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
48457804|NCT04710290|DIETARY_SUPPLEMENT|Glutamine|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
48457805|NCT04710290|DIETARY_SUPPLEMENT|Immunoglobuin|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
48623041|NCT01939392|DEVICE|Renal Denervation (OneShot™ Renal Denervation System)|
47934384|NCT05325710|BEHAVIORAL|Study nurse intervention|Contact everay 4 months with a dedicated study nurse
47934385|NCT05911425|DRUG|envolizumab , sovalteinib|Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
47934386|NCT02378025|BEHAVIORAL|Yoga Group|A 10-week yoga course designed to treat pain.
47934387|NCT02378025|BEHAVIORAL|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
47934388|NCT02050126|DEVICE|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
48457806|NCT04710290|DIETARY_SUPPLEMENT|Corn starch|Solid beverage powders, capsules and placebo were randomly assigned. The main components of the solid beverage powder are beta-glucan combined with glutamine and immunoglobuin.and the main component of the capsule is beta-glucan . The main ingredient of placebo is corn starch.
48457807|NCT06353139|DEVICE|Modified olfactory training device|Conduct olfactory training in patients with olfactory disorders
48457808|NCT01079858|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
48457809|NCT01750827|DRUG|SB659032|single dose
48457810|NCT02183727|DEVICE|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
48623042|NCT02665117|DRUG|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
48623043|NCT02665117|DRUG|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
48457811|NCT02183727|PROCEDURE|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
48457812|NCT02161263|OTHER|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
48457813|NCT02959619|DRUG|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
48457814|NCT03721939|DEVICE|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
48457815|NCT01195233|DRUG|bioxtra|spray /mouth rinse
48457816|NCT00680498|DRUG|Ranibizumab|Ranibizumab 0.5 mg
48457817|NCT00680498|DRUG|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
48457818|NCT06478745|OTHER|Retrospective and prospective cohort|"* Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded.~* Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia."
48457819|NCT06478745|OTHER|Focus group, semi-structured interviews and Photovoice|The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.
48457820|NCT06478745|OTHER|Systematic review|No patient recruitment required
48457821|NCT04854460|DRUG|Revemact|1 tablet contains 6 mg Ivermecin
48457822|NCT04854460|DRUG|Stromectol (first dose)|2 tablet contain 6 mg Ivermecin
48457823|NCT04854460|DRUG|Stromectol (second dose)|2 tablet contain 6 mg Ivermecin
48457824|NCT01472432|DRUG|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
48457825|NCT01472432|DRUG|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
48457826|NCT02095613|OTHER|traditional food|
48457827|NCT02095613|OTHER|food that is nutrient dense|
48457828|NCT05040737|DEVICE|PS membrane versus PMMA membrane,|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
48457829|NCT00425308|DRUG|Everolimus + Cyclosporine|
48457830|NCT00425308|DRUG|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
48457831|NCT00425308|DRUG|Steroids|
48457832|NCT05538338|OTHER|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
48457833|NCT05538338|OTHER|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
48457834|NCT06368076|BEHAVIORAL|Exercise|High intensity interval training on a bike or pedaltrainer from the wheelchair.
48457835|NCT04815239|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
48457836|NCT04815239|BEHAVIORAL|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
48457837|NCT00414726|DRUG|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
48457838|NCT00414726|DRUG|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
48457839|NCT01243983|DRUG|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
48457840|NCT00580541|BEHAVIORAL|variety|variety and nonvariety
48457841|NCT00863330|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
48457842|NCT03949296|BEHAVIORAL|Mindfulness Intervention|"10-session program~1. Introduction to mindfulness and its potential benefits~2. Introduction to mindful practices and yoga poses~3. Conditioned reactions to stress; integrating mindfulness into everyday life~4. Challenges and insights gained in practicing mindfulness~5. Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~6. Reacting vs. responding to stressors~7. Self-regulation and coping with stressors and communication challenges~8. Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~9. Choosing and creating one's own blend of mindfulness practices~10. Maintaining momentum to practice mindfulness once the program ends"
48623044|NCT02665117|DRUG|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
48623045|NCT00585182|DRUG|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
48457843|NCT03949296|BEHAVIORAL|Sleep Hygiene|"Session includes a handout with15 sleep hygiene tips:~1. Maintain a regular sleep pattern~2. Only try to sleep when feeling tired or sleepy~3. If unable to sleep, do something calm until feeling tired and returning to bed~4. Avoid caffeine \& nicotine for 4-6 hours before going to bed~5. Avoid alcohol for 4-6 hours before going to bed~6. Use the bed only for sleeping and sex~7. Avoid naps during the day~8. Develop rituals to get relaxed and ready to sleep~9. Try a hot bath prior to bedtime~10. Avoid checking the clock during the night~11. Use a sleep diary for a few weeks to track progress~12. Avoid strenuous exercise before bedtime~13. Avoid a heavy meal before bedtime~14. Create a sleep environment that is quiet, comfortable, and dark~15. Maintain a regular daytime routine"
48457844|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
48457845|NCT06254014|DRUG|Exendin-4 Fc fusion protein injection|The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
48457846|NCT06254014|DRUG|Placebo|0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).
48457847|NCT02940457|DEVICE|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
48457848|NCT02940457|DEVICE|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
48457849|NCT06468254|DRUG|Statin|Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.
48457850|NCT06468254|DRUG|Sugar pill|Control Group: Conventional chemotherapy and maintenance therapy alone.
48457851|NCT01704105|BEHAVIORAL|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
48457852|NCT01704105|BEHAVIORAL|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
48457853|NCT01704105|BEHAVIORAL|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
48457854|NCT01704105|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
48457855|NCT01924247|BEHAVIORAL|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
48457856|NCT01924247|BEHAVIORAL|Standard treatment by family physician|Standard treatment by family physician.
48457857|NCT01129986|DEVICE|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
48457858|NCT05832957|BEHAVIORAL|Drive fun|"The Drive Fun intervention program aims to promote the development of adaptive self-awareness and facilitate the acquisition of management strategies that foster safe and confident driving among participants. The program utilizes a driving simulator to provide a guided learning experience, which incorporates various sources of information, as well as games and thinking tasks. Additionally, participants will engage in reflective exercises that draw upon their occupational experiences and their driving performance within the simulator. Parental involvement is also incorporated to ensure ongoing support for the continued practice of learned skills."
48457859|NCT05832957|BEHAVIORAL|educational intervention|7 individual sessions of one hour at the driving lab at Tel Aviv university and 4 group sessions- 90 minutes by Zoom of group sessions of an educational intervention of safe driving according to Ministry of Education. The intervention focuses only on the cognitive aspects since it is based on imparting educational knowledge regarding safe driving with opportunities for gamified, non-driving-related activities such as board games (e.g., rush hour) and social games
48457860|NCT05832957|OTHER|No intervention|one-time short guidance on safe driving at the end of the study.
48457861|NCT00595153|DRUG|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
48623046|NCT03188198|DRUG|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
48623047|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Preventicus®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
48457862|NCT05121194|BEHAVIORAL|Cognitive Behaviour Therapy|Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.
48457863|NCT05314257|DRUG|Granisetron Hydrochloride|IV granisetron 1mg
48457864|NCT05314257|OTHER|0.9% normal saline|IV 5ml of 0.9% normal saline
48280893|NCT03245879|BEHAVIORAL|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
48280894|NCT03245879|BEHAVIORAL|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
48280895|NCT04947137|DRUG|Tc99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
48280896|NCT05045040|BEHAVIORAL|Mobile-based empathetic communication support program to promote ACP discussion|Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
48280897|NCT02353949|DRUG|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
48280898|NCT06656455|DRUG|sevoflurane via LMA|In Group S, co-induction is used whereby the patient continues to receive 8% sevoflurane through the facemask followed after IV insertion by propofol 2mg/kg and fentanyl 1mic/kg administration. Thirty seconds afterwards, an age-appropriate LMA will be inserted. Sevoflurane is maintained initially at a concentration of 2%. The ventilation at first is assisted manually until the child starts breathing. If movement requires interruption of the exam, a bolus of propofol 1mg/kg is given and sevoflurane is increased by 1% until a maximal sevoflurane concentration of 4%. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, sevoflurane will be turned off until the proper airway intervention is taken to achieve saturation above 95% and sevoflurane will be resumed at a concentration decreased by 1%.
48280899|NCT06656455|DRUG|Propofol with oxygen via simple mask|"In group P, the sevoflurane will be discontinued, and propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV. Propofol pump is maintained initially at a rate of 200mic/kg/min. with oxygen at 3 liters/min via facemask.~If movement requires interruption of the exam, a bolus of propofol 1mglkg is given and the infusion rate is increased by 20mic/kg/min up to a maximal rate of 350mic/kg/min. The total number of boluses needed will be recorded as the need for additional sedation. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, the infusion pump will be stopped until the proper airway intervention is taken to achieve saturation above 95% with spontaneous breathing. Afterwards, the propofol pump will be resumed at a rate decreased by 20mic/kg/min."
48280900|NCT00407355|DRUG|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
48280901|NCT00407355|DRUG|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
48280902|NCT00283387|DRUG|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
48280903|NCT00283387|DRUG|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
48280904|NCT03217162|DRUG|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
48280905|NCT03217162|DRUG|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
48280906|NCT06656286|DEVICE|Intra-Uterine suturing by X-TACK device and hysteroscope|"After general anesthesia and entering the abdomen with the laparoscope, Truclear hysteroscope with X-tack attached will be inserted to the uterine cavity. Insertion of normal saline to the cavity and applying 4 points suturing to the uterus. The procedure will be monitored by external laparoscopic camera located in the abdominal cavity. After the hysterectomy the uterus will be opened and the suture will be examine.~A preoperative intrauterine incision using a hysteroscope, followed by suturing, will be considered based on the success of the first procedure."
48457865|NCT04309773|DRUG|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy|Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose
48457866|NCT04309773|DRUG|Placebo of Bezafibrate in addition to standard UDCA therapy|Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose
48457867|NCT00000666|DRUG|Pyrimethamine|
48457868|NCT03559907|BEHAVIORAL|Cooking Matters for Parents|Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
48457869|NCT03559907|BEHAVIORAL|Mealtime PREP|Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
47934389|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK transvaginal ultrasound|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day an ultrasound - ecoenema is performed. First, the Foley catheter is inserted via the transanal route with instillation of 180cc of serum under ultrasound guidance with a probe in the vagina, using a sagittal and midline cut. In case there is the appearance of free pelvic fluid (previously absent) or an increase in free fluid compared to the baseline examination (fluid present at the beginning of the examination) around the anastomosis/pelvic area, the test will be considered positive.
47934390|NCT05942209|DIAGNOSTIC_TEST|ECO-LEAK with CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed, along with an ecoenema.
47934391|NCT05942209|DIAGNOSTIC_TEST|CT-Scan or rectoscopy|After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed
48457870|NCT03225664|BIOLOGICAL|Pembrolizumab|Given IV
48280907|NCT06637176|DEVICE|Laser speckle contrast imaging|"LSCI measurements will be taken before and after the formation of the anastomosis, with the surgeon blinded to the measurements to prevent any influence on surgical decision-making. The surgery will be performed as standard-of-care, unaffected by the LSCI measurements.~Following the surgery, the LSCI images will be presented to the surgeon, who will complete a questionnaire assessing whether the LSCI images, if presented perioperatively, would have influenced their decision regarding the location of the anastomotic site. Additionally, the surgeon will be asked if they consider LSCI to be a useful intraoperative tool in general. The surgical case and the series of LSCI images will also be presented to an independent surgeon, who will answer the same set of questions.~The LSCI measurements will be correlated with 30-day complication rates, with a specific focus on anastomotic leakage (AL).~Microcirculation is assessed using LSCI at a wavelength of 785 nm (MoorFLPI-2, Moor Instruments"
48457871|NCT03225664|OTHER|Pharmacokinetic Study|Correlative studies
48457872|NCT03225664|DRUG|Trametinib|Given PO
48457873|NCT05887934|DEVICE|X-Ray Fluorescence Analyzer|The XRF analyzer (the ThermoFisher Niton XL3t GOLDD+) is a portable x-ray fluorescent analyzer specifically configured to measure low levels of metals, lead in particular, in bone. The device is designed to rapidly assess cumulative lead exposure, not to support or sustain human life.
48457874|NCT00922896|DRUG|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"* Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
48457875|NCT05782439|OTHER|Manual evaluation of ITB tension|There will be a double evaluation for each sampling session: 1) if there is a uniformity of the tension between the two sides, or if there is a prevalence on one side; 2) quantification of the difference, if present, with a graduation in 3 levels.
48457876|NCT06185244|BEHAVIORAL|Therapist-supported internet-delivered trauma-focused CBT|12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.
48457877|NCT06185244|BEHAVIORAL|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
48457878|NCT05239169|DRUG|Durvalumab|Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.
48457879|NCT05239169|DRUG|Tremelimumab|Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.
48457880|NCT05239169|DRUG|Capecitabine|Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
48280908|NCT04259502|PROCEDURE|Rhomboid intercostal block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
48457881|NCT02802852|DEVICE|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
48457882|NCT02802852|DRUG|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
48457883|NCT01167335|DRUG|BGG492|
48457884|NCT01167335|DRUG|Placebo|
48457885|NCT04423380|DRUG|SH3051 capsule treatment|Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
48457886|NCT00018616|BEHAVIORAL|MEMS caps|
48457887|NCT03780608|DRUG|AZD6738|AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
48457888|NCT03780608|DRUG|Durvalumab|. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
48457889|NCT02089282|DEVICE|Ultrasound|
48280909|NCT04259502|PROCEDURE|Erector spinae plane block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
48280910|NCT03943329|PROCEDURE|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
48280911|NCT03943329|PROCEDURE|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
48280912|NCT06498921|OTHER|Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel|No treatment will be provided to participants in the study. The decision on initiation of darolutamide (Nubeqa, BAY1841788) in combination with ADT and doctaxel and duration of treatment is solely at the discretion of the treating physician, guided by the recommendations outlined in the local product information.
48280913|NCT05307744|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>3 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
48280914|NCT05307744|OTHER|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
48457890|NCT00107263|DRUG|letrozole|
48457891|NCT00107263|DRUG|zoledronic acid|
48457892|NCT01401062|DRUG|Fresolimumab|
48457893|NCT01401062|RADIATION|Radiation Therapy|
48457894|NCT01994980|DRUG|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
48280915|NCT00495027|BEHAVIORAL|Internet-delivered Stress Innoculation Training|
48280916|NCT00121823|BIOLOGICAL|FP9 ME-TRAP|
48280917|NCT00121823|BIOLOGICAL|MVA ME-TRAP|
48280918|NCT04425655|DRUG|Fludarabine|30mg/m2 days 1 through 5
48280919|NCT04425655|DRUG|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
48280920|NCT03684655|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
48280921|NCT00195351|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
48280922|NCT00195351|DRUG|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
48457895|NCT00327145|DRUG|valsartan|
48457896|NCT00327145|DRUG|hydrochlorothiazide|
48457897|NCT00327145|DRUG|amlodipine|
48457898|NCT03741777|OTHER|Clear oral fluid|clear oral fluid including water, pulp-free juice and tea or coffee without milk.
48457899|NCT00623077|BIOLOGICAL|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) \> 1,000/mm\^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
48098753|NCT06230874|BEHAVIORAL|Control Journaling Protocol|The control journaling protocol is a nine-minute mindfulness and engagement protocol designed to decrease stress and to promote re-engagement in meaningful occupations of daily life by applying mindfulness self-talk and journaling strategies in a specific, timed format. The protocol requires special training for students: a) to recognize times of disengagement in occupations, and b) to learn how to apply specific mindfulness strategies to increase re-engagement in meaningful occupations. Three components of the control journaling protocol include Reflect (1 minute of self-reflection and self-talk), Write (journaling), and Re-engage (1 minute for self-reflection and self-talk).
48098754|NCT04222270|BEHAVIORAL|Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression|Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
48098755|NCT06627439|BEHAVIORAL|Comadres Saludables|Comadres Saludables is a web-based healthy living training for community health workers aimed at addressing obesity in Latinas. Comadres Saludables will combine both theory and evidence-based practices to provide participants with the self-efficacy, knowledge, and skills required to effectively implement an obesity intervention for Hispanic women. Participants (CHWs) will build their skillset through interactive quizzes, exercises, and video role-playing scenarios. Additionally, Comadres Saludables allows participants to utilize interactive mHealth tools to enhance implementation with Hispanic women. Participants will access the training for three months.
48623048|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
48457900|NCT00623077|DRUG|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
48457901|NCT00623077|DRUG|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
48457902|NCT00623077|DRUG|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
48457903|NCT00623077|DRUG|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
48457904|NCT00623077|DRUG|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.
48457905|NCT00623077|PROCEDURE|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
48457906|NCT00623077|RADIATION|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
48457907|NCT00623077|RADIATION|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
48457908|NCT00623077|DRUG|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
48457909|NCT00623077|RADIATION|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
48457910|NCT00397735|PROCEDURE|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
48457911|NCT00397735|DRUG|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
48457912|NCT03332082|PROCEDURE|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
48457913|NCT06467344|DRUG|ACDN-01|ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
48457914|NCT05108935|DRUG|Suboxone|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
48457915|NCT05108935|DRUG|Truvada|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
48457916|NCT05108935|DRUG|Mavyret|Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
48457917|NCT00069758|DRUG|SDX-105|
48457918|NCT05915351|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days
48457919|NCT05654363|PROCEDURE|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
48457920|NCT05654363|PROCEDURE|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
48457921|NCT04683913|BEHAVIORAL|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
48457922|NCT04683913|OTHER|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
48457923|NCT02277093|DRUG|Pacritinib|
48457924|NCT01087502|DRUG|Glimepiride|1-4 mg daily after 12 weeks
48457925|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
48457926|NCT01087502|DRUG|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
48457927|NCT01087502|DRUG|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
48457928|NCT01087502|DRUG|Linagliptin|5 mg once daily
48457929|NCT05725499|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous stimulation of the spinal cord. Mapping will be performed to determine sites for optimal modulation of blood pressure. During each mapping day, with participants in a supine or seated position, electrodes will be placed on the midline of one of the following spinous processes: C5/6, T7/8, T11/12, L1/2 and S1/2. Stimulation intensity will start at 5 mA and gradually increased in 5 mA increments up to 100 mA. The frequency will be 2 or 30 Hz. Profiles will be established to guide selection of optimal site locations for blood pressure modulation. The profile chosen will be used during training and testing.~During testing, stimulation will be applied using the selected profile in order to normalize SBP to the range of 110-120 mmHg and stabilize it within this range during a 30-min tilt test.~On each session during the 2-week training-period, stimulation will be applied for 30 minutes using the selected profile, while the participant remains in a seated position."
48457930|NCT05725499|DIAGNOSTIC_TEST|Tilt-table orthostatic stress testing|"While lying supine, participants will be strapped to a Hi-Low tilt-table bed. The bed will gradually be tilted to a 70 degrees tilt, during which time continuous hemodynamic measures will be recorded. This position will be maintained for 30 minutes.~During some of the sessions, the tilt test will be accompanied by spinal stimulation."
48623049|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with Apple Watch®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
47934392|NCT01732653|OTHER|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
48457931|NCT00137735|DRUG|Gabapentin|300mg tds
48457932|NCT00137735|OTHER|placebo|tds
48457933|NCT05028140|DRUG|PIEMONTE|Piemonte association 1 coated tablet once a day
47934393|NCT01732653|OTHER|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
47934394|NCT01214148|DEVICE|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
47934395|NCT05405127|OTHER|traditional physical therapy|breathing exercises 10 repetitions, 1set, 3 days/week and targeted abdominal muscles. Total 6 sessions were given each consisting of 30 minutes.
47934396|NCT05405127|OTHER|core stability exercises|core stability along with breathing exercise 10 repetitions, 1set, 3 days/week and targeted core muscles. Total 6 sessions were given consisting of 30 minutes.
47934397|NCT00479583|DRUG|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
47934398|NCT00479583|DRUG|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
47934399|NCT03206905|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
47934400|NCT03206905|BEHAVIORAL|Diet and Exercise|nutritional/exercise counseling
47934401|NCT01445886|DRUG|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
47934402|NCT01445886|DRUG|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
47934403|NCT01165580|DRUG|valganciclovir [Valcyte]|oral dose, Days 1 and 2
48457934|NCT05028140|OTHER|PIEMONTE PLACEBO|Placebo of Piemonte association 1 coated tablet once a day
48457935|NCT05028140|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg 1 coated tablet once a day
48457936|NCT05028140|OTHER|PLACEBO EMPAGLIFLOZIN|Placebo of empagliflozin 25 mg 1 coated tablet once a day
47934404|NCT05272085|PROCEDURE|Ultrasound Guided Lavage|After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.
47934405|NCT05272085|PROCEDURE|Ultrasound Guided Subacromial Bursa Injection|2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
47934406|NCT00188331|BEHAVIORAL|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
47934407|NCT00862108|DRUG|Methylphenidate|mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
48457937|NCT05028140|DRUG|PIOGLITAZONE|Pioglitazone 30 mg 1 tablet once a day
48457938|NCT05028140|OTHER|PLACEBO PIOGLITAZONE|Placebo of pioglitazone 30 mg 1 tablet once a day
48457939|NCT01918813|DRUG|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
48457940|NCT01558635|DEVICE|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
48623050|NCT06023290|DIAGNOSTIC_TEST|Heart rhythm measurements with 6L Kardia Mobile®|The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
48457941|NCT01558635|PROCEDURE|Mitral Valve surgery|Classic mitral valve surgery was performed
48457942|NCT01558635|DEVICE|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
48457943|NCT01558635|PROCEDURE|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
48457944|NCT02799992|PROCEDURE|689 nm Laser Treatment of the Macula|
48457945|NCT02799992|PROCEDURE|Half Dose Photodynamic Therapy|
48457946|NCT00301964|BIOLOGICAL|bevacizumab|Given IV
48457947|NCT00301964|OTHER|laboratory biomarker analysis|Correlative studies
48457948|NCT04237415|PROCEDURE|EMG biofeedback training|
48457949|NCT02287480|BIOLOGICAL|VSV-ZEBOV|See arm/group descriptions.
48457950|NCT01080703|OTHER|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
48457951|NCT03323450|BEHAVIORAL|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~1. Baseline before the participant is introduced to the CogMed® training program~2. Within 2 weeks of completion of the CogMed® program~3. At 3 months of completion of the CogMed® program to establish maintenance of gains~4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
47934408|NCT01973530|PROCEDURE|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
47934409|NCT01973530|PROCEDURE|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
47934410|NCT03083431|DRUG|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
47934411|NCT03083431|DRUG|Placebo|Oral solution containing the same excipients as propranolol solution
47934412|NCT04863209|OTHER|Upper cervical manipulation|The patient will receive an upper cervical manipulation as described in the Experimental Group 1.
47934413|NCT04863209|OTHER|Sphenopalatine ganglion manipulation|The patient will receive a sphenopalatine ganglion as described in the Experimental Group 2.
47934414|NCT06254222|OTHER|No intervention|No intervention
47934415|NCT03596632|DRUG|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib
47934416|NCT00273507|DRUG|Carboplatin and Paclitaxel|
47934417|NCT01574742|DRUG|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
47934418|NCT02526329|BIOLOGICAL|donor regulatory T lymphocytes|Given IV
47934419|NCT02526329|OTHER|laboratory biomarker analysis|Correlative studies
47934420|NCT00999921|DRUG|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
47934421|NCT00999921|DRUG|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
47934422|NCT06454175|BIOLOGICAL|Placebo|immunization schedule：Month 0，Month 2，Month 6
48457952|NCT00111696|BIOLOGICAL|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
48457953|NCT04254315|BEHAVIORAL|Group based cognitive therapy|"Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising."
48457954|NCT05026320|DRUG|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
48457955|NCT05026320|DRUG|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
48457956|NCT05026320|DRUG|Placebo gel|bid for 5 days (final application on morning of Day 6)
48457957|NCT01063244|DEVICE|foley balloon only|place foley balloon only in cervix
47934423|NCT06454175|BIOLOGICAL|15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)|immunization schedule：Month 0，Month 2，Month 6
47934424|NCT00507468|PROCEDURE|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
47934425|NCT01511055|DRUG|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
47934426|NCT02050542|PROCEDURE|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
47934427|NCT02050542|PROCEDURE|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
47934428|NCT01676597|DRUG|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
47934429|NCT01676597|DRUG|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
47934430|NCT05694000|DEVICE|On-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is on."
47934431|NCT05694000|DEVICE|Off-Stimulation|"The surgical electrode implanted in hippocampus by a pulse generating device is off."
47934432|NCT05610410|OTHER|Laser speckle contrast analysis|Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
47934433|NCT03097354|OTHER|no intervention/observational survey study design|no intervention/observational survey study design
47934434|NCT04441762|DRUG|Intravenous Ketorolac Tromethamine|30 mg ketorolac single dose
47934435|NCT04441762|DRUG|Intranasal Ketorolac Tromethamine|30 mg ketorolac single dose
47934436|NCT06136988|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
47934437|NCT06136988|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
47934438|NCT06136988|DRUG|Cisplatin for injection|Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
47934439|NCT06136988|DRUG|Paclitaxel|Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W
47934440|NCT06136988|RADIATION|Simultaneous Radiotherapy|Radiotherapy (28×1.8Gy)
47934441|NCT04604847|DIAGNOSTIC_TEST|blood test|blood test to explore BDNF level
47934442|NCT04873271|DEVICE|Medtronic Implantable Tibial Neuromodulation (TNM) System|Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
48457958|NCT01063244|DEVICE|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
48457959|NCT05219734|DIAGNOSTIC_TEST|Personalized Cancer Monitoring (PCM)|personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
48457960|NCT05368753|OTHER|Blood sample|Lidocaine blood sample 30 min before the end of the surgery Lidocaine blood sample at the end of the infusion lidocaine and ropivacaine blood sample 2 h after the ropivacaine infusion of the TEA Ropivacaine blood sample 24h after the infusion of the TEA
48457961|NCT05368753|DRUG|Lidocain|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end) The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
48457962|NCT05368753|DRUG|ropivacaine|Lidocaine will be injected during the anaesthetic induction and infused until the surgical closure (30 minutes before the end), then ropivacaine will be injected in the TEA at the same time and infused during 24h. The occurrence of adverse events will be monitor by a physical examination and blood samples of lidocainemia and ropivacainemia in the perioperative period.
48457963|NCT05392959|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
48457964|NCT05392959|DRUG|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
48457965|NCT02666807|DIETARY_SUPPLEMENT|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
48457966|NCT02666807|DIETARY_SUPPLEMENT|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
48457967|NCT02426918|DRUG|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
48457968|NCT02426918|DRUG|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
48457969|NCT02426918|DRUG|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
48457970|NCT02426918|DRUG|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
48457971|NCT02426918|DRUG|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
48457972|NCT02426918|DRUG|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
48457973|NCT00259896|DRUG|exenatide|
48457974|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
48457975|NCT00746850|PROCEDURE|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
48457976|NCT00512811|DRUG|furosemide|
48457977|NCT02440607|OTHER|Electronic Cognitive Aid|
47934443|NCT05116072|PROCEDURE|total pancreatectomy|"The total pancreatectomy will be performed in two steps: The pancreatectomy will begin by a standard pancreaticoduodenectomy procedure.~The section margin will be sent for intraoperative histological analysis to confirm the absence of invasion of the left remnant pancreas.~When absence of tumor invasion is confirmed and the high-risk of postoperative pancreatic fistula is validated intraoperatively, the extended left distal pancreatectomy will be performed, with splenic preservation when possible.~Then, the left side of the pancreas will be resected and cooled (4-6°) in the preservation solution and shipped to Lille Biotherapy platform to perform islet isolation and purification. The reconstruction after total pancreatectomy will be done as usually performed by center expert surgeon."
48457978|NCT02440607|OTHER|Static Cognitive Aid|
48457979|NCT00134485|DRUG|torcetrapib/atorvastatin|
48457980|NCT00134485|DRUG|atorvastatin|
48457981|NCT02697682|BIOLOGICAL|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
48457982|NCT05798884|DEVICE|Acupuncture|Disposable acupuncture needles (0.25 mm in diameter and 25 mm in length) are straightly into body acupuncture points (he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10)). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occur due to Capecitabine (Xeloda). Electrical stimulation will be delivered with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument. The needles will be retained in position for 25 minutes.
48457983|NCT05798884|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
48457984|NCT06557551|OTHER|Thin catheter surfactant|Surfactant given through thin catheter inserted under video laryngoscopy at or after 5 minutes of life
48457985|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
48457986|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
48457987|NCT04391270|BEHAVIORAL|blended intervention|A blended intervention group combining the web-based components with face-to-face workshops and posters
48457988|NCT04391270|BEHAVIORAL|web-based intervention|A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
48457989|NCT04046705|PROCEDURE|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
48457990|NCT04046705|OTHER|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
48457991|NCT05302128|OTHER|Cold vapor|Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of nausea and vomiting before and 15 minutes after the cold vapor application in the recovery room and at the 2nd, 6th,12th, and 24th hours after the cold vapor application in the postoperative service.
47934444|NCT05116072|BIOLOGICAL|intraportal islet autotransplantation|The final islet preparation will be cultured and shipped 48 hours after total pancreatectomy from the Lille laboratory to the surgical center, and finally transplanted into the patient through a venous catheter placed in the portal trunk (91% of the total islet mass) and at the same time, a small fraction of the isolated islet (5% of the total islet mass) will be transplanted into the forearm muscle.
48457992|NCT05579262|DIETARY_SUPPLEMENT|Beetroot juice|Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
48457993|NCT06139133|DRUG|Placebo supplementation|Placebo
48457994|NCT06139133|DRUG|Vitamin D supplementation|Vitamin D3 supplementation (2 00,000 IU/Week)
48457995|NCT03636386|DEVICE|Percutaneous microelectrolysis|284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
48457996|NCT03636386|DEVICE|Ultrasound therapy|Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
48457997|NCT05327894|DRUG|Blinatumomab|1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.
48457998|NCT05327894|DRUG|Blinatumomab|2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion
48457999|NCT05308186|BEHAVIORAL|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
48458000|NCT05308186|BEHAVIORAL|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
47934445|NCT00224627|PROCEDURE|Capsule GIVEN IMAGING LTD|
47934446|NCT03608423|DEVICE|Minimally-invasive endoscopy-guided surgery|Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
47934447|NCT01415739|OTHER|laboratory biomarker analysis|Correlative studies
47934448|NCT00140361|DRUG|Sulfadoxine-pyrimethamine|
47934449|NCT00140361|DRUG|sulfadoxine-pyrimethamine plus artesunate|
47934450|NCT00140361|DRUG|lumefantrine plus artemether|
47934451|NCT00140361|BEHAVIORAL|Sleeping under insecticide-treated bednet|
47934452|NCT05959980|PROCEDURE|Posterior cervical fixation surgery|These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.
47934453|NCT02392715|DEVICE|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
47934454|NCT02392715|DEVICE|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
48458001|NCT01904162|DRUG|400 mg finafloxacin (2 x 200 mg tablets)|
48458002|NCT03103594|DRUG|DMSO|DMSO will be instilled intravesically.
48458003|NCT03103594|DRUG|Botox|Botox will be instilled intravesically with DMSO.
48458004|NCT05196347|DRUG|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.
48458005|NCT05848908|OTHER|Telehealth Visit|telemedicine visit and follow-up surveys
48458006|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment A|
48458007|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment B|
48458008|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment C|
48458009|NCT01370811|DRUG|oxybutynin and clonidine oral solution treatment D|Placebo
48458010|NCT04182126|OTHER|Regular long-lasting insecticidal nets|Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
48458011|NCT04182126|OTHER|LLIN plus Piperonyl butoxide-treated LLIN|Olyset Plus: containing 2% permethrin and 1% PBO
48458012|NCT04182126|OTHER|Long-lasting microbial larvicide|Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
48458013|NCT04182126|OTHER|Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides|Each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year or twice a year. Other insecticides may be used to replace the Actellic 300 CS depends on Kenya government policy, current policy requires rotating different insecticides annually.
48458014|NCT02637180|DRUG|anti-osteoporotic medication|check previous information
48458015|NCT04558450|DIAGNOSTIC_TEST|carotid-femoral pulse-wave velocity|early vascular aging tests
48458016|NCT02144805|PROCEDURE|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
48458017|NCT02144805|PROCEDURE|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
48458018|NCT00592969|DRUG|metformin|
48458019|NCT00592969|DRUG|biphasic insulin aspart|
48458020|NCT06122805|DEVICE|Toothbrush|We will test three toothbrushes in patients undergoing surgery and a control no surgery group. These toothbrushes are manual toothbrushes, sonic toothbrushes, and sonic and dual light toothbrushes.
48458021|NCT01847235|DRUG|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
48458022|NCT06186414|DRUG|SIM0237|Several dose levels of SIM0237 will be administered as a single agent for evaluation
48458023|NCT06186414|DRUG|SIM0237 and BCG|Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
48458024|NCT06186414|DRUG|SIM0237|RD level of SIM0237 will be administered as a single agent for evaluation
48458025|NCT06186414|DRUG|SIM0237 and BCG|RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
48458026|NCT01677338|DRUG|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
48458027|NCT01677338|DRUG|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
48458028|NCT05470153|DEVICE|Continuous Positive Airway Pressure|For each patient with Obstructive Sleep Apnea, titration of Continuous Positive Airway Pressure (CPAP) pressure will be performed by conventional polysomnography or using auto-CPAP equipment using a validated protocol. The CPAP device should have an hour meter recording system, so that machine-on time hours could be checked at each clinical visit.
47934455|NCT00879944|OTHER|Blood pressure|Blood pressure will be measured once while patient is seated
47934456|NCT00879944|OTHER|Height|Height will be measured in centimeters at the time of enrollment
47934457|NCT00879944|OTHER|Weight|Weight will be measured in kilograms at enrollment
47934458|NCT00879944|OTHER|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
47934459|NCT00879944|OTHER|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
47934460|NCT02914587|DEVICE|ARTAS System|
48458029|NCT00816413|DRUG|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
48458030|NCT00816413|DRUG|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
48458031|NCT00816413|DRUG|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
48458032|NCT00816413|GENETIC|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
48458033|NCT00816413|GENETIC|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
47934461|NCT02914587|OTHER|Manual Implantation|
47934462|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
47934463|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
47934464|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
47934465|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
47934466|NCT00263276|DRUG|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
47934467|NCT00263276|DRUG|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
47934468|NCT00263276|DRUG|metformin|Tablets, Oral, \>/= 1500 mg, Once daily, 12 weeks.
48458034|NCT00816413|GENETIC|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
48458035|NCT00816413|OTHER|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
48458036|NCT00816413|OTHER|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
48458037|NCT00816413|OTHER|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
48458038|NCT00816413|OTHER|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
48458039|NCT00816413|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
48098756|NCT06627439|BEHAVIORAL|Control|Participants will access the web-based HHS Promoting Healthy Choices and Community Changes that includes a variety of content via text, audio, and video. The information is designed to educate CHWs on how to implement health interventions for positive community change. They are asked to review it for three months.
48280923|NCT03885284|DRUG|mFOLFIRINOX|"Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3."
48098757|NCT01784068|DRUG|Nilotinib followed by treatment-free|Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
48458040|NCT00816413|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
48458041|NCT00816413|RADIATION|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
48458042|NCT03764657|PROCEDURE|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
48458043|NCT03764657|PROCEDURE|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
48458044|NCT00471510|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
48623051|NCT05791084|OTHER|mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.|The DIBH-App consists of 1) a mobile application that patients download to their own smart mobile phone, and 2) associated stretch-sensors that are attached around the chest and connected to the mobile phone via Bluetooth. Visually, the graphics is similar to the software used for DIBH in the RT department. Coaching takes place through instructional videos, text, and audio recordings (Image 2). The following information will be recorded and stored: date and time of practice, outcome of each session (including sensor data and calibration parameters), and user behavior within the application (such as screen visits, FAQ sections viewed, and key button presses).
47934469|NCT02599948|OTHER|no intervention|
47934470|NCT03230669|OTHER|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
47934471|NCT04637009|DRUG|TAS1553|Form: tablet; Route of Administration: oral
48280924|NCT03885284|RADIATION|Proton beam radiation|Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
48458045|NCT06595342|OTHER|No intervention|no intervention
48458046|NCT04388787|DEVICE|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
48458047|NCT06203080|DRUG|ancetate gel|An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
48623052|NCT04214015|OTHER|No intervention|There is no intervention for this study
48623053|NCT03181555|OTHER|Exploratory|
47934472|NCT01931709|RADIATION|fludeoxyglucose F 18|Undergo FDG PET
47934473|NCT01931709|DEVICE|positron emission tomography|Undergo FDG PET
47934474|NCT01931709|DEVICE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
47934475|NCT01931709|OTHER|laboratory biomarker analysis|Correlative studies
47934476|NCT02820714|DRUG|BLI801 Laxative|BLI801 Laxative
47934477|NCT02044497|DRUG|oral oxycodone|
47934478|NCT05353140|DEVICE|The WATCHMAN/WATCHMAN FLX device|Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.
47934479|NCT05353140|DRUG|Rivaroxaban + Clopidogre|Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.
47934480|NCT05353140|DRUG|Aspirin + Clopidogrel|Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
47934481|NCT03674931|BEHAVIORAL|musical practice|Intensive weekly musical keyboard training over 12 months
48458048|NCT06203080|DRUG|nonoxinol gel|The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
48458049|NCT05480423|BEHAVIORAL|Mindfulness-based intervention|1. Psychoeducation video on mindfulness and mindful parenting. 2. Audio files of mindfulness exercises including mindfulness of breath, body scan, mindful stretching, mindfulness of soles of the feet, befriending exercises. 3. Informal mindfulness exercises by applying mindfulness in daily lives
48458050|NCT03914196|DIAGNOSTIC_TEST|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
47934482|NCT03674931|BEHAVIORAL|music education|Recreative weekly musical courses without practice over 12 months
48458051|NCT02542254|DRUG|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
48458052|NCT02542254|DRUG|Ipratropium|40 micrograms ipratropium administered using a pMDI
48458053|NCT02542254|DRUG|RPL554|6 mg RPL554 administered using a nebuliser
48458054|NCT02542254|DRUG|Salbutamol matched placebo|Placebo pMDI
48458055|NCT02542254|DRUG|Ipratropium matched placebo|Placebo pMDI
48458056|NCT02542254|DRUG|RPL554 matched placebo|Nebulised placebo
47934483|NCT05950139|BIOLOGICAL|Peptide vaccine|Peptide vaccine
47934484|NCT03303703|OTHER|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
47934485|NCT02300727|DRUG|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
48098758|NCT01007149|DRUG|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
48098759|NCT01007149|DRUG|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
48280925|NCT06418542|DEVICE|use of florescein|Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.
48458057|NCT03106545|DRUG|Liposome bupivacaine|
48458058|NCT00480038|OTHER|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
48458059|NCT02260063|DRUG|Epinastine syrup|
48458060|NCT02260063|DRUG|Epinastine tablets|
48458061|NCT00416780|OTHER|counseling intervention|
48458062|NCT00416780|OTHER|educational intervention|
48458063|NCT00416780|PROCEDURE|psychosocial assessment and care|
48623054|NCT05870436|DIAGNOSTIC_TEST|Methacholine Choline Provocation Test|Perform methacholine choline provocation test according to the protocol
48623055|NCT00767871|DRUG|Lexapro|12 week treatment with lexapro
48458064|NCT04837456|DIETARY_SUPPLEMENT|Calorie restricted diet and exercise intervention|the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.
48458065|NCT04837456|PROCEDURE|libitum diet and waiting list control group|libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
48458066|NCT04837456|PROCEDURE|Early arthroscopic partial menisectomy group|Early APM group participants received APM with syndrome within 3 to 6 months
48458067|NCT04837456|PROCEDURE|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
48623056|NCT00527059|DRUG|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
48623057|NCT00527059|DRUG|spironolactone, beta-blockers,ecc|
48458068|NCT06404463|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
48458069|NCT06404463|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
47934486|NCT02300727|DRUG|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
48280926|NCT00469937|DRUG|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
48458070|NCT06404463|DRUG|Doxorubicin|Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
48458071|NCT06404463|DRUG|Cyclophosphamide|Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
48458072|NCT06404463|DRUG|Epirubicin|Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
48458073|NCT01378962|DRUG|erlotinib|150 mg orally once a day for 12 months
48458074|NCT00521573|OTHER|Dark chocolate|
48458075|NCT06307288|DRUG|minocycline|The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
48458076|NCT06307288|DRUG|tranilast|The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
48458077|NCT06391372|DRUG|estriol cream|1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
48458078|NCT05415891|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.
48458079|NCT05415891|DEVICE|You℞ Decision prescribing platform|The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
48458080|NCT00405860|DRUG|CellCept (mycophenolate mofetil)|
47934487|NCT02300727|DRUG|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
47934488|NCT00586326|DEVICE|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
47934489|NCT02739672|DRUG|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
47934490|NCT02739672|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
47934491|NCT02739672|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
48280927|NCT00469937|PROCEDURE|cognitive assessment|cognitive assessment
48280928|NCT00469937|PROCEDURE|quality-of-life assessment|quality-of-life assessment
48280929|NCT00469937|RADIATION|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
48280930|NCT05591833|PROCEDURE|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
48280931|NCT05591833|PROCEDURE|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
48280932|NCT02980614|DEVICE|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
48458081|NCT00983996|DRUG|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
48458082|NCT00983996|DRUG|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
48458083|NCT05077449|DRUG|XZP-3287+Fulvestrant|XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
48458084|NCT05077449|DRUG|Placebo + Fulvestrant|Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
48458085|NCT01325935|DRUG|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
48458086|NCT02589067|DRUG|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
48458087|NCT02589067|DRUG|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
48458088|NCT04132115|DRUG|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
48458089|NCT04132115|DRUG|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
48458090|NCT04132115|DRUG|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
48458091|NCT04132115|DRUG|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
48458092|NCT04132115|DRUG|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
48458093|NCT04132115|DRUG|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
48458094|NCT04132115|DRUG|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
48458095|NCT04132115|DRUG|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
48458096|NCT04132115|DRUG|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
48458097|NCT04132115|DRUG|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
48458098|NCT04132115|DRUG|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
48458099|NCT05088551|OTHER|Patient Education|The education was divided into three parts. The information in the first part of the booklet (general information, preoperative preparation, and operation day) is given in the preoperative period. In the postoperative period, the patients were visited and the information in the second part (postoperative hospital stay, first, second, and third-day goals after surgery) was given. Before the patients were discharged, the information in the third section (things to be considered in the recovery process at home) was presented. According to the physical conditions of the clinic, patient education was carried out in an area suitable for teaching as much as possible.
48458100|NCT00645853|DRUG|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
48458101|NCT00645853|DRUG|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
48458102|NCT05301218|PROCEDURE|angioplasty|Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
48458103|NCT04627844|DIETARY_SUPPLEMENT|Immediate Feeding|Standard tube feeds begun at an earlier time point
48458104|NCT04627844|DIETARY_SUPPLEMENT|Delayed Feeding|Standard tube feeds begun at delayed time point
48458105|NCT02485938|DRUG|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
48458106|NCT03406598|OTHER|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
48458107|NCT01194908|DRUG|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
48458108|NCT01627431|DRUG|Acetylsalicylic acid|100 mg once per day
48458109|NCT01627431|DRUG|Clopidogrel|75 mg once per day
48458110|NCT00209690|DRUG|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48458111|NCT00209690|DRUG|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48458112|NCT00209690|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48458113|NCT02408653|DEVICE|EEG|
48458114|NCT01146080|DEVICE|Promus Element|Promus Element implanted to treat coronary artery lesions.
48458115|NCT01146080|DEVICE|Promus|Promus stent implanted to treat coronary artery lesions
48458116|NCT00660660|DRUG|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
48458117|NCT00660660|DRUG|Placebo|once daily
48458118|NCT04429113|DEVICE|Maxillary expansion with conventional Quad Helix bonded on molars.|Maxillary expansion with conventional Quad Helix bonded on molars
48458119|NCT03253354|DEVICE|repetitive magnetic stimulation|Neurostimulation
48458120|NCT00210223|PROCEDURE|Radiofrequency|
48458121|NCT05759663|PROCEDURE|MIRRAD|Repair of the diastasis with MIRRAD technique
48458122|NCT05759663|PROCEDURE|Plication of the entire diastasis arm|Plication of the entire diastasis
48458123|NCT03273751|PROCEDURE|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
48280933|NCT06620107|DEVICE|noninvasive high frequency oscillation ventilation|"cases of group A extubated on NHFOV, and it will be provided by CNO, Medin device, Germany) via binasal prongs with the following parameters:~* MAP of 6 cmH2O and will be titrated targeting a FiO2 ≤ 25-30%, maximum FiO2 will be 40% and target oxygen saturation will be 90-95%.~* Frequency of 8 Hz and can be changed within the range of 8-12 Hz.~* Amplitude of 7 cmH2O and can be titrated within the range of 7-10 cmH2O according to PaCO2."
48458124|NCT03273751|PROCEDURE|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
48458125|NCT04039022|DRUG|AXS-05 (dextromethorphan and bupropion) oral tablets|Oral tablets, taken twice daily for up to 12 months.
48458126|NCT04741477|DRUG|CBD|CBD will be topically applied
48098760|NCT03007758|PROCEDURE|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
48098761|NCT03007758|PROCEDURE|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
48098762|NCT05246553|PROCEDURE|Electrical stimulation of the vestibular system|Patients are implanted with a modified cochlear implant (CI) which comprises one to three extracochlear electrodes that are placed in the proximity of vestibular afferents (i.e., vestibular nerves or the ampullae of each semicircular canal), and an intracochlear array. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the implanted electrodes (cochlear or vestibular) and modulated via computer-controlled signals, audio signals (captured with a microphone) or by signals captured by head-mounted motion sensors.
48458127|NCT04741477|DRUG|THC|THC will be topically applied
48458128|NCT04741477|DRUG|Placebo|a placebo product (without cannabinoids) will be topically applied
48458129|NCT00464594|BEHAVIORAL|Standard lifestyle guidance|
48458130|NCT00464594|DRUG|Lifestyle guidance and monotherapy with acarbose|
48458131|NCT00464594|DRUG|Lifestyle guidance and monotherapy with metformin|
48458132|NCT00464594|DRUG|Lifestyle guidance and monotherapy with gliclazide|
48458133|NCT00736190|DRUG|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
48458134|NCT00981838|DRUG|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients \> 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
48458135|NCT01257633|PROCEDURE|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
48458136|NCT03164460|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
48458137|NCT03164460|RADIATION|Proton Radiation|Undergo IMRT/IMPT
48458138|NCT03164460|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48458139|NCT04244760|BEHAVIORAL|Pain assessment for verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
48458140|NCT04244760|BEHAVIORAL|Pain assessment for non-verbal patients|The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
48458141|NCT04823936|OTHER|core stability training|core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
48458142|NCT03090022|PROCEDURE|Strattice|Intra-abdominally Fixation
48458143|NCT03090022|PROCEDURE|Single running suture of abdominal fascia|Intra-abdominal suture
48458144|NCT00866476|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
48458145|NCT00866476|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
48458146|NCT01949324|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
48458147|NCT01949324|PROCEDURE|Sham procedure|Sham surgery for Sham arm
48458148|NCT01949324|DEVICE|NT-501 Implant|NT-501 encapsulated cell implant
48458149|NCT01949324|PROCEDURE|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
48458150|NCT00015925|DRUG|entinostat|
48458151|NCT01698554|DRUG|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
48458152|NCT01698554|DRUG|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
47934492|NCT06050603|DEVICE|TMS|"The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3."
47934493|NCT05547971|RADIATION|intensity-modulated radiation therapy|The patients got intensity-modulated radiation therapy during observation
48458153|NCT01698554|DRUG|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
48458154|NCT01698554|DRUG|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
48458155|NCT03249844|DRUG|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),"
48458156|NCT01120028|DRUG|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
48458157|NCT01120028|DRUG|Basiliximab|20 mg intravenously, two doses 96 hours apart
48458158|NCT01120028|DRUG|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
48458159|NCT01120028|DRUG|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
48458160|NCT03980522|DRUG|KPL-914|"KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks."
48458161|NCT03948854|OTHER|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
48623058|NCT03975634|DEVICE|Transcutaneous Spinal Stimulation|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
48623059|NCT00406380|DRUG|Bevacizumab|
48623060|NCT00406380|PROCEDURE|Intravitreal injection of Bevacizumab|
48623061|NCT03950804|DRUG|Eculizumab Injection|Patients receive eculizumab as deemed necessary by the primary physician
48623062|NCT01432951|DRUG|Enzastaurin|Administered orally
48623063|NCT05143502|DRUG|Montelukast|"Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.~We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes"
48623064|NCT05143502|DRUG|Prednisolone|Oral Prednisolone 40 mg/day for two weeks.
48623065|NCT05143502|DRUG|Fluticasone Furoate|fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily
48623066|NCT03404375|DEVICE|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
47934494|NCT04095533|OTHER|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm\^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
48623067|NCT04302324|DRUG|Daratumumab SC|Given as 1800mg via injection
48623068|NCT04302324|DRUG|Clarithromycin|Given as 500mg oral capsule
48623069|NCT04302324|DRUG|Pomalidomide|Given as 4mg oral capsule
48623070|NCT04302324|DRUG|Dexamethasone|Given as 20mg IV and 20mg or 40mg oral tablets
48623071|NCT00968487|BIOLOGICAL|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
48623072|NCT00968487|OTHER|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C (-0.4 °F) (or colder) within 6 hours of collection.
48458162|NCT03948854|OTHER|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
48458163|NCT03948854|OTHER|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
48458164|NCT03948854|OTHER|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
48458165|NCT06561308|DRUG|Pucotenlimab|Pucotenlimab is administered at 200mg, q3w，intravenous infusion
48458166|NCT06561308|DRUG|Carboplatin|AUC=4-6，q3w，intravenous infusion
48458167|NCT06561308|DRUG|Paclitaxel|175 mg/m2，q3w，intravenous infusion, administered over 30min.
48458168|NCT06561308|PROCEDURE|Surgery|Transabdominal hysterectomy + bilateral adnexectomy + pelvic lymph node dissection + pelvic-abdominal tumor resection +/- para-abdominal aortic lymph node dissection
48458169|NCT03129685|PROCEDURE|HALED|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
48458170|NCT03368209|DEVICE|WM3.4|Investigational Medical Device collecting spectral raman data from tissue.
48458171|NCT05064007|BEHAVIORAL|A: 40 Hz music|The participant will listen to the 40 Hz music playlist one hour each day, 5 days a week for 4 weeks
48458172|NCT05064007|BEHAVIORAL|B: 40 Hz sound|The participant will listen to the 40 Hz sound playlist one hour each day, 5 days a week for 4 weeks
48458173|NCT05064007|BEHAVIORAL|C: Preferred music|The participant will listen to the preferred music playlist one hour each day, 5 days a week for 4 weeks
48458174|NCT01635582|OTHER|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
48458175|NCT01635582|OTHER|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
48458176|NCT01889758|DRUG|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
48458177|NCT01889758|DRUG|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
48458178|NCT01889758|DRUG|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
48458179|NCT04125407|OTHER|Sensorimotor foot orthoses|The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, ...) focusing on the flatfoot deformity.
48458180|NCT03857828|OTHER|semen sample|• seminal sample for measuring clusterin level.
48458181|NCT02618460|DEVICE|Non contrast-enhanced magnetic resonance imaging|
48458182|NCT04143880|DRUG|Progesterone|intramuscular injection intranasal administration
48458183|NCT04143880|OTHER|saline|intramuscular injection intranasal administration
48458184|NCT03955276|OTHER|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
48458185|NCT00966160|DRUG|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
48623073|NCT04079959|PROCEDURE|endometrial biopsy|. Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
48623074|NCT02019537|PROCEDURE|Steroid injection into the subacromial space|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
48623075|NCT02019537|PROCEDURE|Allogeneic PRP injection into the subacromial space|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : subacromial space~* Material : 25-gauze spinal needle~* Subacromial injections were performed using ultrasonographic guidance."
48623076|NCT00689832|DRUG|Tacrolimus 0.03%|ointment
48458186|NCT00966160|DRUG|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
48458187|NCT00731458|DEVICE|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
48458188|NCT00310674|BIOLOGICAL|Meningococcal C Conjugate Vaccine|
48458189|NCT06144398|DEVICE|Single Use Bronchoscope|The interventional procedure is performed with a single use bronchoscope.
48458190|NCT06144398|DEVICE|Standard Bronchoscope|The interventional procedure is performed with a standard bronchoscope.
48458191|NCT04693611|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 24 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants without any neurocognitive disorder.
48623077|NCT00689832|DRUG|Fluticasone 0.005%|ointment
48458192|NCT04693611|PROCEDURE|Functional near-infrared spectroscopy (fNIRS)|The acquisition by fNIRS will be performed in each CS session in four regions of interest (ROIs) in the prefrontal cortex: left dorsolateral prefrontal cortex (LDLPFC); left medial prefrontal cortex (LMPFC); right medial prefrontal cortex (RMPFC); right dorsolateral prefrontal cortex (RDLPFC).
47934495|NCT04095533|OTHER|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
48458193|NCT02003391|DRUG|Beta-blocker monotherapy|Per participant's current prescribed therapy
48458194|NCT02003391|DRUG|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
48458195|NCT04884022|PROCEDURE|Miniplates in mandibular symphysis & infrazygomatic|Fixed functional appliance (pushing orthopedic force) in conjunction with direct skeletal anchorage
48458196|NCT04884022|PROCEDURE|Miniplates in external oblique ridge & anterior maxillary region|Coil spring (pulling orthopedic force) in conjunction with direct skeletal anchorage
48458197|NCT04862806|DIAGNOSTIC_TEST|COVID-19 serology|Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value \> 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value \>15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value \>1.1; range 1.1-10).
48458198|NCT00981344|OTHER|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
48458199|NCT04848090|DIAGNOSTIC_TEST|Neonate WGS Testing|"Neonates will undergo whole genome sequencing, and analysis with a targeted panel of genes likely to cause genetic disorders in the first year of life. If no diagnosis is identified, sequenced data will be analyzed using a whole exome filter. Performed in a CLIA-certified lab. Pathogenic, likely pathogenic, and VUS in genes related to the phenotype will be returned to the care team and family.~Parents will be enrolled for the purpose of trio analysis with the child to assist in determining the pathogenicity of variants in genomic sequencing. Pathogenic and likely-pathogenic findings will be reported to the parents in the setting of genetic counseling.~Sibling will be enrolled and have samples collected for use in the genetic analysis only if deemed essential. Results will be reported to the parents in the setting of genetic counseling."
48458200|NCT04202484|DRUG|Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules|Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
48458201|NCT03914105|PROCEDURE|Without music|"The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration."
47934496|NCT00607932|BEHAVIORAL|behavioral dietary intervention|
48458202|NCT03914105|PROCEDURE|With music|"The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration."
48458203|NCT05029427|OTHER|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
48458204|NCT05029427|OTHER|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
48458205|NCT01714141|BEHAVIORAL|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
48458206|NCT01714141|BEHAVIORAL|Asthma education active control|
48458207|NCT03574545|BIOLOGICAL|ianalumab|Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
48458208|NCT01598896|DRUG|Dronabinol|Dronabinol titrated to 5 mg three times daily
47934497|NCT00607932|DIETARY_SUPPLEMENT|Brassica vegetable|
47934498|NCT00607932|DRUG|indole-3-carbinol|follow up at 2,4,6 months post baseline.
47934499|NCT00607932|OTHER|counseling intervention|2, 4, 6 months post baseline
48458209|NCT01598896|DRUG|Clonidine|Clonidine 0.1 mg twice daily
48458210|NCT01598896|DRUG|Placebo|One placebo capsule by mouth twice daily
47934500|NCT00607932|OTHER|medical chart review|2,4,6 months post baseline
48458211|NCT05979311|DRUG|Dolutegravir|Dolutegravir will be administered once daily.
48458212|NCT05979311|DRUG|Lamivudine|Lamivudine will be administered once daily.
48458213|NCT05979311|DRUG|Bictegravir|Bictegravir will be administered once daily.
48458214|NCT05979311|DRUG|Emtricitabine|Emtricitabine will be administered once daily.
48458215|NCT05979311|DRUG|Tenofovir alafenamide|Tenofovir alafenamide will be administered once daily.
48458216|NCT02867358|DRUG|KT07 Capsule|
48458217|NCT02867358|OTHER|Placebo|
48458218|NCT05836311|DEVICE|One Perclose Proglide Suture|One Perclose Proglide Suture
48458219|NCT05836311|DEVICE|Two Perclose Proglide Suture|One Perclose Proglide Suture
48458220|NCT00396162|DRUG|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
48458221|NCT00396162|OTHER|Placebo|Placebo pill
48458222|NCT05623592|DRUG|Methotrexate|17,5/15/10 mg Methotrexate subcutaneously
48458223|NCT05623592|DRUG|Sodium chloride|Sodium chloride subcutaneously
48458224|NCT06405243|DRUG|Myoinositol|Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
48623078|NCT00113139|BEHAVIORAL|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
47934501|NCT00607932|OTHER|questionnaire administration|
47934502|NCT00607932|PROCEDURE|adjuvant therapy|
47934503|NCT04455243|DRUG|N-Acetyl cysteine|150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
47934504|NCT04455243|DRUG|Placebo|Matching placebo administered in the same schedule and volume as NAC
48458225|NCT06405243|DRUG|Chromium|chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
48458226|NCT06405243|DRUG|l-arginine|new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
48458227|NCT06405243|DRUG|Letrozole 2.5mg|selective aromatase inhibitor
48458228|NCT04615741|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
48458229|NCT04615741|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
48458230|NCT00702507|DRUG|0.25 % Miconazole Nitrate Ointment|Topical Application
48458231|NCT00486993|BEHAVIORAL|Dietary and nutritional modification|
48458232|NCT00486993|BEHAVIORAL|Stop smoking|
48458233|NCT00486993|BEHAVIORAL|Regular physical activities|
48458234|NCT00486993|BEHAVIORAL|Weight reduction to normal ranges|
48458235|NCT00486993|BEHAVIORAL|Regular intake of polyphenols, esp. from Ilex paraguayensis|
48458236|NCT03255733|DEVICE|Intense Therapeutic Ultrasound Treatment|
48458237|NCT01720953|OTHER|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
48458238|NCT01696305|DEVICE|Hyalobarrier|
47934505|NCT02787070|DRUG|PQ supervised|
47934506|NCT02787070|DRUG|PQ unsupervised|
47934507|NCT03737071|BEHAVIORAL|Low Carbohydrate Diet|Ketogenic dietary intervention
48458239|NCT01696305|DEVICE|Guardix-SG|
48458240|NCT04332198|OTHER|biological test|dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
48458241|NCT03672240|DRUG|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
48458242|NCT00249197|DRUG|levofloxacin|
48458243|NCT03187925|PROCEDURE|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
48458244|NCT05757960|PROCEDURE|Physiotherapy|Various physiotherapeutic techniques are used in three defined sessions. Before the first session, a dental examination is performed and a clinical functional status is obtained to assess the extent of temporomandibular dysfunction. The results are recorded on validated questionnaires.
48458245|NCT04762251|OTHER|Time-restricted eating|Time restricted eating for a self-selected 9 hour window per day
48623079|NCT00113139|OTHER|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
48458246|NCT04762251|OTHER|Current Best Practice|Best practice guidelines to improve diet quality
48623080|NCT03877822|BEHAVIORAL|Habitual activity|Two days of habitual physical activity, under normal free-living conditions
47934508|NCT03737071|BEHAVIORAL|Simple Calorie Restriction Diet|Simple calorie restriction dietary intervention
47934509|NCT04709939|OTHER|OPAT|Observation of patients who are discharged from the hospital on OPAT.
47934510|NCT04709939|OTHER|Focus Group|Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
47934511|NCT04467996|DEVICE|Intrauterine balloon tamponade|Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.
47934512|NCT06497036|DRUG|GP404141|subcutaneous injection
47934513|NCT06497036|DRUG|Nplate|subcutaneous injection
47934514|NCT01198171|OTHER|Laboratory Biomarker Analysis|Correlative studies
47934515|NCT01198171|OTHER|Study of Socioeconomic and Demographic Variables|
47934516|NCT03123185|DRUG|Placebo|Tablet and solution formulation
47934517|NCT03123185|DRUG|BI 705564 (Test)|Fed state
47934518|NCT03123185|DRUG|BI 705564 (Reference)|Fasting state
47934519|NCT05366205|DIETARY_SUPPLEMENT|Oral nutritional supplement|Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
47934520|NCT05366205|BEHAVIORAL|Nutrition consultation|Nutritional treatment advice will be given
47934521|NCT00931346|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
47934522|NCT00931346|DRUG|Placebo|Placebo
47934523|NCT04592263|OTHER|EPD Questionnaire|A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
48458247|NCT00129038|DRUG|modified-release dipyridamole/aspirin|
48458248|NCT00129038|DRUG|aspirin|
48458249|NCT04403620|RADIATION|Intensity-modulated Radiation Therapy (IMRT)|Patients will receive adjuvant radiation therapy using intensity-modulated radiation therapy (IMRT) within 8 weeks of surgical resection
48623081|NCT03877822|BEHAVIORAL|Bed rest|Two days of bed rest, to induce whole-body physical inactivity
48623082|NCT02233088|BEHAVIORAL|ELM Group|"ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity."
48458250|NCT04406545|OTHER|evaluation of skin microvascular flow and reactivity|evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
48458251|NCT01812993|DEVICE|Non-invasive ventilatory treatment with auto-BPAP|
48458252|NCT00474058|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
48458253|NCT00474058|OTHER|Placebo|Placebo transdermal patches
48458254|NCT04987216|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
48458255|NCT01187823|DEVICE|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
48458256|NCT01187823|DEVICE|Nocturnal oxygen|Nocturnal use of oxygen
48458257|NCT01614288|PROCEDURE|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
48458258|NCT01614288|OTHER|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
48458259|NCT02050321|DRUG|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
48458260|NCT02050321|DRUG|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
48098763|NCT05246553|PROCEDURE|Electrical stimulation of the auditory system|A cochlear implant (CI) is a device providing a sense of sound to a person who suffers from severe to profound sensorineural hearing loss. A CI comprises the following parts, a microphone (capturing the sound from the environment), a speech processor (receiving and encoding the sounds captured by the mircophone), a transmitter-receiver antenna pair (transmitting the information from the external to the implanted components), an implanted stimulator (converting the signal into a tonotopically arranged set of electrical pulses) and an electrode array inserted in the cochlea that will deliver the electrical pulses to different portions of the auditory nerve. Trains of electrical stimulation in the form of charge-balanced, biphasic pulses can be delivered through each of the electrodes in the cochlear array and modulated via computer-controlled signals or audio signals (captured with a microphone).
48458261|NCT03678363|OTHER|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
48458262|NCT02582307|DRUG|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
48458263|NCT02582307|DRUG|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
48458264|NCT04602754|DRUG|BERLIM 25/20 ASSOCIATION|Berlim 25/20 association coated tablet.
48098764|NCT05246553|DIAGNOSTIC_TEST|Bilateral vestibulopathy Patients (BV)|Diagnosis established on the basis of the consensus document of the Classification Committee of the Bárány Society (Strupp et al., Journal of Vestibular Research, vol. 27, no. 4, pp. 177-189, 2017).
48458265|NCT04602754|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
48458266|NCT04602754|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin calcium placebo coated tablet.
48458267|NCT04602754|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
48458268|NCT04602754|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 20 mg coated tablet.
48458269|NCT04602754|OTHER|BERLIM 25/20 ASSOCIATION PLACEBO|Berlim 25/20 association placebo coated tablet.
48458270|NCT00417677|DRUG|Combination of Temsirolimus and Sunitinib|
48458271|NCT01855880|BIOLOGICAL|AbGn-168H|
48458272|NCT01855880|BIOLOGICAL|placebo|
48458273|NCT00510848|PROCEDURE|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
48458274|NCT00510848|PROCEDURE|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
48458275|NCT06516172|OTHER|Comprehensive disease-specific rehabilitation|"Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes."
48458276|NCT03174158|DRUG|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
48458277|NCT03174158|BEHAVIORAL|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
48458278|NCT03174158|BEHAVIORAL|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
48458279|NCT04744467|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
48458280|NCT06028477|DEVICE|Stanford Glove|The non-invasive neuromodulation hardware system comprises two wireless controllers/battery packs which are fastened to the top of each hand via an adjustable elastic strap. Each controller is equipped with four vibrotactile fingertip stimulators, also known as tappers. There is a total of eight tappers (for index, middle, ring and pinkie of each hand) per system.
48458281|NCT02042599|DRUG|Sedation with sevoflurane during 48-hr in ICU|
48458282|NCT06561555|DRUG|RC48|RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
48623083|NCT02233088|OTHER|ELM Classes|ELM classes will be administered through Rush Generations program and focus on health education.
48458283|NCT06406257|DEVICE|3M™ Bair Hugger™ Warming Unit|Utilizing the 3M Temperature Management Unit to ensure intraoperative body temperature of elderly hip surgery patients remains consistent with their preoperative baseline, while patients in Group C receive no intervention.
48458284|NCT05487664|DEVICE|Transcutaneous Auricular Neruostimulation (tAN)|The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
48458285|NCT03431493|BEHAVIORAL|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
48458286|NCT05530811|DRUG|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
48458287|NCT05530811|DRUG|Bupivacaine|0.5% bupivacaine
48458288|NCT03141853|OTHER|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
48458289|NCT03141853|OTHER|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
48098765|NCT05246553|DIAGNOSTIC_TEST|Unilateral vestibulopathy Patients (UV)|Patients with documented diagnosis of unrecovered unilateral vestibulopathy, consistent with the current classification of vestibular disorders of the Bárány Society (www.jvr-web.org/ICVD.html).
48098766|NCT03563053|COMBINATION_PRODUCT|EryDex System|"EryDex System was a combination product that was used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which was infused into the patients.~EryDex treatment consisted of a dose range correspondent to the ATTeST High Dose (obtained by loading 125 mg of DSP to the EryDex process and that, in the ATTeST, resulted in a mean of 17.4 ± 5.4 mg (mean ± standard deviation) of DSP infused to patients) administered via ex vivo encapsulation into EDS that were infused into the patient with A-T.~The dose of EryDex treatment was selected to allow collection of long-term safety data on the dose of erythrocyte encapsulated DSP that was considered more effective among the two different doses that were employed in the ATTeST study, based on the analysis of the ATTeST blinded, Phase 3 study data."
48458290|NCT02764853|BEHAVIORAL|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
48458291|NCT02764853|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
48458292|NCT05274022|OTHER|Standard of Care Physical Therapy Program|Standard of care will follow best practice. The subjects and their physical therapists will be provided with a standardized set of exercises and guidance on what to cover during skilled physical therapy visits. As part of the study, all patients will receive the same exercise program. Exercises will include lower extremity strengthening, balance, and mobility exercises with the use of modalities as needed
48458293|NCT05274022|OTHER|Speed Walking Intervention|The 4-6 week program will consist of a warm up of active stretching. Following the warm up, subjects will perform a 2 minute warm up followed by 1 minute of walking at their fastest comfortable speed followed by 2 minutes of active recovery where they will walk at a speed of their choosing for 4cycles and then a 2 minute cool down. The program will be performed 12 visits over 4-6 weeks.
48458294|NCT03224624|OTHER|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
48458295|NCT00052923|BIOLOGICAL|filgrastim|
48458296|NCT00052923|BIOLOGICAL|rituximab|
48458297|NCT00052923|DRUG|carmustine|
48458298|NCT00052923|DRUG|cyclophosphamide|
48458299|NCT00052923|DRUG|etoposide|
48458300|NCT00052923|PROCEDURE|peripheral blood stem cell transplantation|
48458301|NCT00052923|RADIATION|radiation therapy|
48458302|NCT02918058|OTHER|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
48458303|NCT00991796|DRUG|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
48458304|NCT00991796|DRUG|Placebo|Placebo
48458305|NCT00991796|DRUG|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
48458306|NCT00991796|DRUG|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
48458307|NCT01878864|DRUG|Bupivacaine lozenge|
48098767|NCT03474562|DRUG|Duowell®|Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
48458308|NCT01878864|DRUG|Lidocaine-adrenalin injection|
48458309|NCT03467360|DRUG|acetazolamide in combination with platinum and etoposide-based radiochemotherapy|Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
48458310|NCT01662011|DEVICE|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
48458311|NCT01662011|DEVICE|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
48458312|NCT00621660|PROCEDURE|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
48458313|NCT00621660|PROCEDURE|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
48458314|NCT00073580|DRUG|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) \>300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
48458315|NCT04748991|DRUG|Vernakalant|Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
48458316|NCT04748991|DRUG|Amiodarone|Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
48458317|NCT06128824|OTHER|MR Imaging|Serial magnetic resonance imaging (MRI)
48458318|NCT02745600|DEVICE|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
48458319|NCT01670097|DRUG|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
48458320|NCT01670097|DRUG|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
48458321|NCT01670097|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
48458322|NCT01670097|DEVICE|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
48458323|NCT01670097|OTHER|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
48458324|NCT03051776|OTHER|Kinesio Taping|
48458325|NCT03051776|OTHER|Compression Garment|
48458326|NCT00867763|PROCEDURE|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
48098768|NCT03474562|DRUG|Monorova® + Amlopin®|Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)
48098769|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
48458327|NCT00867763|PROCEDURE|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
48458328|NCT05213052|OTHER|Topical cream|Topical cream applied to painful joint or muscle
48458329|NCT01679158|DEVICE|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
48458330|NCT05053360|BEHAVIORAL|Healing Touch|"Healing Touch (HT), with a foundation in holistic nursing, is a gentle therapy that uses touch to promote health and well-being by balancing the human energy system. Healing Touch (HT) is a biofield therapy in which practitioners use their hands in a heart-centered and intentional way to provide energetic balance to support physical, emotional, mental and spiritual health. It is safe for all ages and works in harmony with, is complementary to, and may be integrated with standard medical care. Healing Touch is a collection of standardized, noninvasive techniques that clear, energize, and balance the human and~environmental energy fields."
48458331|NCT05053360|OTHER|Control|Quiet Time (QT) session is when a subject is provided with quiet for 15 minutes
48458332|NCT05812625|OTHER|Myokinetic stretching technique|Myokinetic stretching technique (MST) is a form of myofascial release, which involves active or passive stretching and movement as well as muscle energy techniques until a desirable release from the taut band is achieved.
48098770|NCT02828683|DEVICE|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
48098771|NCT00624546|DRUG|Prevacid Solutabs|BID Prevacid Solutabs
48098772|NCT00624546|PROCEDURE|Antireflux surgery|Lap Nissen
48458333|NCT05812625|OTHER|Post Isometric Relaxation|Post Isometric Relaxation (PIR) is the effect of the decrease in muscle tone in a single or group of muscles, after a brief period of submaximal isometric contraction of the same muscle.
48458334|NCT03721653|DRUG|Bevacizumab|5 mg/kg iv over 30 minutes day 1
48458335|NCT03721653|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes day 1
48458336|NCT03721653|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
47934524|NCT02436655|PROCEDURE|surgical aortic valve replacement|open heart aortic valve replacement
48458337|NCT03721653|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
48458338|NCT03721653|DRUG|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
48458339|NCT03721653|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
48458340|NCT03519139|OTHER|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
48458341|NCT06235203|PROCEDURE|endoscopic surgery|The tumor was resected by endoscopic nasopharyngectomy.
48458342|NCT06235203|DRUG|Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy|Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.
48458343|NCT06235203|DRUG|Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy|Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.
48458344|NCT06235203|DRUG|Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy|Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
48458345|NCT04007835|DRUG|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
47934525|NCT02550977|DRUG|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
47934526|NCT01076894|PROCEDURE|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
48458346|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 1)|"* 3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~* Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs"
48458347|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 2 and 3)|"* 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)"
48458348|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
48458349|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
48458350|NCT04166162|BEHAVIORAL|Brief Intervention Motivational Interviewing (BIMI) Intervention|BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
48458351|NCT04166162|BEHAVIORAL|Tomando Buenas Decisiones (TBD) Intervention|The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
48458352|NCT04166162|BEHAVIORAL|Social Development Strategy (SDS) Intervention|SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
48458353|NCT04166162|BEHAVIORAL|BTC Training Session|BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
48098773|NCT06628843|OTHER|cesarean section rate|Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries
48458354|NCT00735319|DEVICE|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
48098774|NCT00114933|DRUG|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
48098775|NCT05647356|DRUG|Bicalutamide 50 mg|Bicalutamide at a dose of 50mg once daily for 28 days.
48098776|NCT06628466|DRUG|Nuberol Forte|Quality of Life study
48098777|NCT03007459|OTHER|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
48458355|NCT05138094|PROCEDURE|Minimally invasive simultaneous resection|One minimally invasive surgical procedure wherein both the primary colorectal carcinoma and the liver metastases are removed.
48458356|NCT05138094|PROCEDURE|Minimally invasive two-stage resection|Two minimally invasive surgical procedures wherein the primary colorectal carcinoma and the liver metastases are removed
48458357|NCT00715676|DRUG|Placebo|oral, once daily
48458358|NCT00715676|DRUG|DP001|oral, once daily
48458359|NCT03762954|OTHER|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
48458360|NCT00465218|PROCEDURE|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
48458361|NCT03443492|DRUG|S-1|Intervention is administered to patients in this Arm.
48458362|NCT03443492|DRUG|Leucovorin(oral )|Intervention is administered to patients in this Arm.
48458363|NCT03443492|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
48458364|NCT03443492|DRUG|Oxaliplatin|Intervention is administered to patients in this Arm.
48458365|NCT03443492|DRUG|Irinotecan|Intervention is administered to patients in this Arm.
48458366|NCT03443492|DRUG|5-FU|Intervention is administered to patients in this Arm.
48458367|NCT03443492|DRUG|Leucovorin(IV)|Intervention is administered to patients in this Arm.
48458368|NCT02886676|DRUG|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
48458369|NCT03173651|DEVICE|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
48458370|NCT03173651|DEVICE|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
48458371|NCT03173651|DEVICE|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
48458372|NCT05290896|DEVICE|Phacoemulsification|Phacoemulsification for senile cataract.
48458373|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
48458374|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
48458375|NCT00974350|DRUG|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
48458376|NCT03456544|DRUG|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
48458377|NCT02054819|OTHER|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
48458378|NCT02054819|OTHER|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
48458379|NCT06462495|DRUG|[18F]F-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
48458380|NCT06462495|DRUG|[18F]F-PSMA-1007|Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
48458381|NCT00479531|DEVICE|AirCast Sequential Compression Device|
48458382|NCT04509154|OTHER|Multimodal pain therapy|For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.
48458383|NCT04509154|OTHER|Standardized treatment.|Face-to-face health education sessions led by nurses and physicians, with the possibility to have access to a non-interactive website with pain management materials from a self-help approach.
48458384|NCT02573779|OTHER|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
48458385|NCT02822716|PROCEDURE|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
48458386|NCT02822716|DEVICE|Ultrasound|
48458387|NCT04327401|DRUG|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
48458388|NCT04830540|DEVICE|OOFOS Recovery Footwear|The OOFOS shoes/ sandals are a commercially available footwear with a compliant, energy absorbing midsole material.
48458389|NCT00217503|BIOLOGICAL|bevacizumab|
48458390|NCT00217503|BIOLOGICAL|filgrastim|
48098778|NCT03007459|OTHER|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
48458391|NCT00217503|BIOLOGICAL|pegfilgrastim|
48458392|NCT00217503|DRUG|bortezomib|
48458393|NCT00217503|DRUG|cyclophosphamide|
48458394|NCT00217503|DRUG|doxorubicin hydrochloride|
48458395|NCT00217503|DRUG|etoposide|
48458396|NCT00217503|DRUG|ganciclovir|
48458397|NCT00217503|DRUG|valganciclovir|
48458398|NCT00217503|DRUG|zidovudine|
48458399|NCT04205539|DRUG|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
48458400|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation boosting|Auditory-closed loop stimulation: slow oscillation boosting
48458401|NCT04276064|DEVICE|Auditory closed-loop stimulation: slow oscillation disruption|Auditory closed-loop stimulation: slow oscillation disruption
48458402|NCT04276064|DEVICE|Sham stimulation|Sham stimulation
48098779|NCT01624558|DEVICE|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
48280934|NCT06620107|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be provided by any type of neonatal ventilator available in the unit via binasal prongs starting with the following parameters:~* Positive end expiratory pressure (PEEP) of 5 cmH2O and can be titrated to 8 cmH2O according to the oxygenation .~* Peak inspiratory pressure (PIP) of 15 cmH2O and can be titrated to 25 cmH2O ,according to oxygenation , PaCO2 level and the chest expansion .~* FiO2 ≤ 25-30% and can be increased to 40 % maximally targeting oxygen saturation of 90-95% .~* Inspiratory time of 0.40-0.50 s .~* Rate of 30 bpm and can be increased to maximum 50 bpm .~* Synchronization will not be applied."
48280935|NCT01158183|DRUG|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
48280936|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
48280937|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
48280938|NCT00146042|DRUG|Docetaxel|
48280939|NCT00146042|DRUG|Trastuzumab|
48280940|NCT00146042|PROCEDURE|Erythromycin Breath Test (ERMBT)|
48280941|NCT01588223|OTHER|Lipid identification|The lipids are identified using Mass Spectrometry
48280942|NCT03051633|BEHAVIORAL|Be Under Your Own Influence|School based anti-drug use communications campaign
48458403|NCT03342196|DRUG|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
48458404|NCT03342196|DRUG|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
48458405|NCT03342196|DRUG|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
48458406|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid with Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid with the addition of information on incidental findings for lung cancer screening.
48458407|NCT04432753|BEHAVIORAL|Lung Cancer Screening Decision Aid without Incidental Findings Information|The intervention consists of a previously tested and developed brief lung cancer screening video decision aid that does not include information on incidental findings.
48458408|NCT00002033|DRUG|Zidovudine|
48458409|NCT00002033|DRUG|AS-101|
48458410|NCT00213850|PROCEDURE|EFR|
48458411|NCT03640741|PROCEDURE|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
48458412|NCT04206267|DEVICE|Acceledent|Device for accelerating tooth movement
48458413|NCT04112199|DRUG|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
48098780|NCT00000676|DRUG|Clotrimazole|
48098781|NCT00000676|DRUG|Fluconazole|
48280943|NCT03815175|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
48280944|NCT03815175|DRUG|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
48280945|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia|FDA022-BB05, intravenously infusion, q3w
48280946|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib|FDA022-BB05, intravenously infusion, q3w
48280947|NCT03284450|OTHER|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
48280948|NCT03284450|OTHER|SSRS|The SSRS (Howatson \& Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
48280949|NCT04882098|DRUG|Guselkumab|Participants will receive guselkumab as SC injection.
48280950|NCT04882098|DRUG|Placebo|Participants will receive matching placebo as SC injection.
48280951|NCT04435340|DIAGNOSTIC_TEST|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
48280952|NCT04728945|PROCEDURE|lung recruitment|Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.
48458414|NCT01883713|DEVICE|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
48458415|NCT02653664|BEHAVIORAL|PsychoEducation|Condition #1
48458416|NCT02653664|BEHAVIORAL|Self-Hypnosis Training|Condition #2
48458417|NCT02653664|BEHAVIORAL|Mindfulness Meditation|Condition #3
48458418|NCT00827164|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
48458419|NCT00827164|BEHAVIORAL|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
48458420|NCT06628310|DRUG|ABBV-400|Intravenous (IV) Infusion
48458421|NCT06628310|DRUG|Budigalimab|IV Infusion
48458422|NCT06628310|DRUG|Fluorouracil|IV Infusion; IV Injection
48458423|NCT06628310|DRUG|Leucovorin|IV Infusion; IV Injection
48458424|NCT06628310|DRUG|Oxaliplatin|IV Infusion
48458425|NCT04603703|OTHER|HVLAT Manipulation|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
48458426|NCT04603703|OTHER|Conventional Physical Therapy|"Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins."
48458427|NCT01251068|DEVICE|near infrared spectroscopy: invos 5100|duration:six hours
48458428|NCT01251068|DEVICE|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
48458429|NCT01251068|DEVICE|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
48458430|NCT06158607|BEHAVIORAL|Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders|Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.
48458431|NCT06158607|OTHER|Standard of care treatment|Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
48458432|NCT02184936|OTHER|standard of care|
48458433|NCT04692558|BIOLOGICAL|HYALURONIC ACID|Hyaluronic acid will be applied on denuded root surface after reflection of isolated gingival recession.
48458434|NCT04692558|PROCEDURE|coronally advanved flap with connective tissue harvesting|Coronally advanced flap surgery with connective tissue harvesting from palate
48458435|NCT02679729|DRUG|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
48458436|NCT02679729|DRUG|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
47934527|NCT01076894|PROCEDURE|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
48458437|NCT02679729|OTHER|Placebo|inactive substance
48458438|NCT01099007|BEHAVIORAL|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
48458439|NCT01099007|BEHAVIORAL|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
47934528|NCT03372889|BEHAVIORAL|Patient educaiton materials - Print based|Print (paper) based materials
47934529|NCT03372889|BEHAVIORAL|Patient educaiton materials - Media based|Media (electronic) based materials
48458440|NCT00712816|DEVICE|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
48458441|NCT00712816|OTHER|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
48458442|NCT05226390|BIOLOGICAL|MVA-SARS-2-ST|In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
48458443|NCT01274143|BEHAVIORAL|TeleCARE|Personalized telephone-delivered cancer risk assessment.
48458444|NCT01274143|BEHAVIORAL|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
48458445|NCT06627036|DEVICE|Dermatoscope|For participants in the dermoscopy group, the marking will also be done preoperatively with a marker pen, but the lesion borders will be determined using a dermatoscope. A peripheral margin based on BAD guidelines will be marked similarly.
48458446|NCT04133311|DRUG|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
48458447|NCT04133311|DRUG|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
48458448|NCT04133311|DRUG|DE-130A/DE-130A|After Week 12, received DE-130A continuously.
48458449|NCT04133311|DRUG|Xalatan®/DE-130A|From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
47934530|NCT03751306|PROCEDURE|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
47934531|NCT03751306|PROCEDURE|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
47934532|NCT03751306|PROCEDURE|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
48458450|NCT03769428|PROCEDURE|erector spinae plane block|The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
48458451|NCT03769428|PROCEDURE|sham erector spinae plane block|The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
48458452|NCT01822119|DEVICE|Baha Attract System|
48458453|NCT00582205|DRUG|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
48458454|NCT03285438|DRUG|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
48458455|NCT03285438|DRUG|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 36 months (12 to 65 months)
48458456|NCT02604641|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
48458457|NCT02604641|DIETARY_SUPPLEMENT|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
48458458|NCT02604641|DIETARY_SUPPLEMENT|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
48458459|NCT06447753|PROCEDURE|Direct pulp capping|after caries excavation, the pulp will be inspected visually. If bleeding present, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Cases in which bleeding will not stop within 6 minutes will be excluded from the study and further managed by RCT. The exposed pulp will be capped with MTA which will be freshly mixed according to manufacturer's instructions and placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier following which the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. Then tooth will be restored using composite resin following etch and rinse technique.
48458460|NCT06447753|PROCEDURE|Complete Pulpotomy|exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant 28to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 6 minutes. After hemostasis, ProRoot MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier. After placement, the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. The tooth then will be restored using composite resin following etch and rinse technique.
48458461|NCT05210608|BEHAVIORAL|Working Memory Training (Active Intervention) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
47934533|NCT02849353|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
47934534|NCT02849353|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
47934535|NCT05268211|DIAGNOSTIC_TEST|urinary oxygen partial pressure|measuring urinary oxygen partial pressure and measuring US Doppler renal resistive index
47934536|NCT03562871|BIOLOGICAL|IO102|test immunotherapy
47934537|NCT03562871|BIOLOGICAL|pembrolizumab (Keytruda)|anti-PD-1 immunotherapy
47934538|NCT03562871|DRUG|Carboplatin (Carboplatin Kabi)|chemotherapy
47934539|NCT03562871|DRUG|Pemetrexed (Pemetrexed Alvogen)|chemotherapy
48458462|NCT05210608|BEHAVIORAL|Control Training (CT) + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Control Condition Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
48458463|NCT02995135|DRUG|BAY987517|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-094)"
47934540|NCT05943743|OTHER|Google form|"* Self-administrated Questionnaire will be used for online survey. A pilot study was conducted on 30 sample size to check the reliability of questionnaire via statistical test.~* A Five-point Likert scale (strongly disagree, disagree somewhat, Neutral, agree somewhat, strongly agree)"
47934541|NCT00548405|BIOLOGICAL|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
48458464|NCT02995135|DRUG|SFP Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
48458465|NCT04659096|DRUG|ION537|ION537 will be administered by IV injection.
48458466|NCT03040895|OTHER|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
48458467|NCT03040895|OTHER|Treatment as usual|Treatment as usual through the data collection period (6 months)
48458468|NCT02539628|DRUG|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
48458469|NCT06557603|DRUG|Ivermectin cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
48458470|NCT06557603|DRUG|Soolantra ® (Ivermectin) cream|\[1 gm ± 0.030 gm\] of product was applied in a thin layer over the entire face (avoiding the eyes, lips, and mucous membranes).
48458471|NCT02439515|DEVICE|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
48458472|NCT02439515|DEVICE|Balance|Balance control exercises with visual biofeedback
48458473|NCT02439515|OTHER|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
48458474|NCT04345107|DRUG|SY-009|The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
48458475|NCT04345107|DRUG|SY-009 matching placebo|SY-009 matching placebo
48458476|NCT04501848|PROCEDURE|adenotonsillectomy|adenotonsillectomy surgery
48458477|NCT05010135|DEVICE|Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment|To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
48458478|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
48458479|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every week
48458480|NCT03684928|DEVICE|Comfilcon A (test)|Daily wear contact lenses
48458481|NCT03684928|DEVICE|Senofilcon C (control)|Daily wear contact lenses
48458482|NCT02873182|DEVICE|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
48458483|NCT06331572|DIAGNOSTIC_TEST|17-HAMD|Patients were interviewed in a semi-structured manner and assessed using the 17-item Hamilton Depression Scale and the Hamilton Anxiety Scale
48458484|NCT03497858|OTHER|Coconut Water|participants will consume coconut water and complete a simulated basketball game
48458485|NCT03497858|OTHER|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
48458486|NCT03497858|OTHER|Sports drink|participants will consume a sports drink and complete a simulated basketball game
48458487|NCT05966922|PROCEDURE|Transcutaneous Electrical Stimulation|Electrical Stimulation and a sham will be administered through the skin in random consecutive sessions in a study group. A single monophasic square electrical pulse and transcutaneous electrical nerve stimulation will be applied to the forearm volar aspect.
48458488|NCT01953185|OTHER|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone \& Russo, 2006).
48458489|NCT01953185|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
47934542|NCT00548405|BIOLOGICAL|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
47934543|NCT00548405|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
48458490|NCT00326872|DRUG|Cediranib Maleate|
48458491|NCT04090021|DRUG|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
48458492|NCT04090021|DRUG|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
48458493|NCT04090021|DRUG|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
48458494|NCT04090021|DRUG|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
48458495|NCT04090021|DRUG|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
48458496|NCT04090021|DRUG|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
48458497|NCT01600313|DIETARY_SUPPLEMENT|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
48458498|NCT05438433|DEVICE|St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets|St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts
48458499|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
48458500|NCT00200785|DIETARY_SUPPLEMENT|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
48458501|NCT05758753|DEVICE|Quantitative Sensory Test|Quantitative Sensory Test (Medoc Ltd, Israel), QST is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli (modalities including heat, cold and vibration) for the purpose of characterizing somatosensory function or dysfunction. For this test, subjects will be seated comfortably on a chair in a quiet room, or laying supine in a horizontal examination chair, with ambient temperature of 24-25◦ C. Medial upper eyelid; just below the supraorbital notch, nasolacrimal sac area; 4-5 mm medial to nasal cantus, and non-dominant forearm will be used as test sites. Patients will be instructed in detail of the nature of the test and the need to react attentively and promptly to change in temperatures.
48458502|NCT05722080|OTHER|Eyesi simulator|Eyesi simulator learning curve for new ophthalmology residents
48458503|NCT05722080|OTHER|Sleep deprivation|See how experienced residents perform after sleep deprivation using the Eyesi simulator
48458504|NCT01174186|DRUG|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
48458505|NCT02940613|BEHAVIORAL|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
48458506|NCT02207764|BEHAVIORAL|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
48458507|NCT00165919|OTHER|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
48458508|NCT03505996|BIOLOGICAL|CS1001|Monoclonal antibody
48458509|NCT04852133|OTHER|Burn subjects|see eligibility criteria
48458510|NCT03590119|DRUG|Lutetium Lu 177-DOTATATE|Intra-arterial infusion of Lu-177-DOTATATE
48458511|NCT03923322|DRUG|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
48458512|NCT03923322|OTHER|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
48458513|NCT02942082|OTHER|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
47934544|NCT02225392|PROCEDURE|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
47934545|NCT02225392|DEVICE|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
48458514|NCT02942082|OTHER|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
48458515|NCT06628271|DIAGNOSTIC_TEST|Guidelines|Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency
48458516|NCT03643731|DEVICE|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
47934546|NCT01535976|DRUG|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
48458517|NCT00264134|DRUG|Docetaxel|
48458518|NCT00264134|DRUG|Irinotecan|
48458519|NCT00264134|DRUG|Carboplatin|
48458520|NCT03789487|DEVICE|Device programming of CRT pacemaker or defibrillator|Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
48458521|NCT02589366|DRUG|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
48458522|NCT00044876|DRUG|CDB-2914|
48458523|NCT06365086|DEVICE|Personalized brain state-dependent single-pulse TMS|Single-pulse TMS will be applied to the right hemisphere during brain activity patterns associated with strong and weak corticospinal tract activation
48458524|NCT06627413|DRUG|Lumateperone Capsule|Lumateperone 42 mg capsule, oral administration
48458525|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E2 IM injection
48458526|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E3 IM injection
48458527|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X2 IM injection
48458528|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X5 IM injection
48458529|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
48458530|NCT03694106|BEHAVIORAL|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
48458531|NCT01277835|DRUG|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
48458532|NCT01277835|DRUG|Placebo|Saline Infusion at same rate as experimental arm
48458533|NCT05493163|DRUG|Thrombolytic|Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
48458534|NCT05493163|DRUG|Standard anticoagulation|Standard anticoagulation therapy of acute pulmonary embolism.
48458535|NCT02884986|DRUG|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
48098782|NCT06631664|OTHER|Traditional physical therapy|Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
48458536|NCT02884986|DRUG|Placebo|120mg of placebo
48458537|NCT05050851|DIETARY_SUPPLEMENT|Measurement of nutritional parameters in children with pneumonia|measurement of Body Mass Index, head circumference, weight, length
48458538|NCT05038800|BIOLOGICAL|MK-0482|IV infusion
48458539|NCT04273971|OTHER|Plyometric exercises|Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
48458540|NCT04385485|PROCEDURE|Active mobilisation|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
48458541|NCT04385485|PROCEDURE|Passive mobilisation with place and hold|We investigate if active mobilisation is as good as passive mobilisation with place and hold after flexor tendon suture.
48458542|NCT06430632|DEVICE|Robotic Gait Training|Participants will complete standing and walking activities while wearing a robotic exoskeleton. Participants will also be asked to complete questionnaires about their walking and function.
48458543|NCT06430632|OTHER|Usual Care Gait Training|Participants will complete standing and walking activities such as body weight-supported treadmill training and conventional overground walking. Participants will also be asked to complete questionnaires about their walking and function.
48458544|NCT04483596|DRUG|melatonin effect on the Abbreviated Mental Test|"Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1"
48458545|NCT02086838|DRUG|Theragran Hematinic|
48458546|NCT02086838|DRUG|low molecular weight iron dextran|
48458547|NCT02482922|OTHER|Exercise & Dietary Supplement|
48458548|NCT06563063|DRUG|Flumazenil|The dose determination for flumazenil followed a biased-coin up-and-down design. Starting with an initial dose of 5 mcg, if there was an improvement in respiratory distress, the biased-coin method was used to give the same dose in the next patient with a probability of 8/9, and a decreased dose of 5 mcg in the next patient with a probability of 1/9.
48458549|NCT03552328|OTHER|Lunch with Medical Student|Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
48458550|NCT03552328|OTHER|Control|Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
48458551|NCT01165060|DRUG|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
48458552|NCT00109057|DRUG|Avastin (bevacizumab)|
48458553|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
48458554|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
48458555|NCT03306758|DRUG|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
48458556|NCT00886522|PROCEDURE|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
48458557|NCT00003795|PROCEDURE|quality-of-life assessment|
47934547|NCT01535976|DRUG|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
47934548|NCT00593580|DRUG|placebo|placebo
48458558|NCT01753362|DRUG|liraglutide|
48458559|NCT01753362|DRUG|placebo|
48458560|NCT02185144|BEHAVIORAL|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
48458561|NCT02185144|BEHAVIORAL|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
48458562|NCT05446519|BEHAVIORAL|Survey|Survey is proposed to all pilots who are members of the National Union of Airline Pilots
48458563|NCT04507698|OTHER|Intensive Exercise Intervention|INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC), randomised to either the supervised exercise arm or the self-directed exercise arm.
48458564|NCT05264207|BEHAVIORAL|Nursing students' home-visit programme|"12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~1. Self-care of chronic conditions and medication management~2. Healthy habits: physical activity and healthy eating~3. Access to social support resources~4. Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours."
48458565|NCT05264207|BEHAVIORAL|Standard care from Public Andalusian Health Service|Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
48458566|NCT03500094|DRUG|Migalastat HCl 150 mg|migalastat HCl 150 mg capsule
48458567|NCT05539937|OTHER|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
48458568|NCT02881541|PROCEDURE|Enhanced support|
48458569|NCT02881541|PROCEDURE|Usual care|
48458570|NCT06393530|DRUG|0.9%sodium chloride|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
48458571|NCT06393530|DRUG|0.2% ropivacaine|Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
48458572|NCT01218360|DRUG|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
47934549|NCT00593580|DRUG|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
47934550|NCT05449483|DRUG|tislelizumab+ Paclitaxel + Cisplatin|tislelizumab combined with chemotherapy
47934551|NCT01030367|DRUG|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
47934552|NCT05161039|DEVICE|Serranator|Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
47934553|NCT05161039|DEVICE|POBA|Plain balloon angioplasty device
47934554|NCT00000203|DRUG|Buprenorphine|
48458573|NCT00415935|DRUG|methotrexate|
47934555|NCT02782078|BIOLOGICAL|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
47934556|NCT06112964|PROCEDURE|MRI/ Functional MRI|Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.
47934557|NCT06112964|BEHAVIORAL|Self-reported questionnaires|Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.
47934558|NCT06112964|BEHAVIORAL|Computer based tasks|"Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake"
47934559|NCT00210860|DRUG|topiramate|
48458574|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 1|
48458575|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 2|
48458576|NCT01252758|DRUG|albuterol sufate DPI (TBS-7) dose 3|
48458577|NCT01252758|OTHER|Placebo|
48458578|NCT01252758|DRUG|Albuterol|
48458579|NCT01252758|DRUG|Albuterol|
48458580|NCT01872676|OTHER|Spine manipulation|
48458581|NCT01872676|OTHER|Manipulation sham|
48458582|NCT04593160|DRUG|Diclofenac potassium- acetaminophen combination|Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
48458583|NCT04593160|DRUG|Diclofenac potassium|Preoperative single dose of diclofenac potassium(50mg)
48458584|NCT04593160|DRUG|Placebo|Preoperative single dose of placebo
48458585|NCT00168558|BIOLOGICAL|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
48478751|NCT06433635|DRUG|Aripiprazole/Escitalopram combination|"1. 40-70% of bipolar patients use antidepressants, often with antipsychotics or mood stabilizers. Aripiprazole lacks efficacy in bipolar depression but is used for mania. Escitalopram, studied alongside mood stabilizers, showed some efficacy.~2. Aripiprazole in bipolar depression trials led to higher rates of akathisia, insomnia, nausea, fatigue, and impulse control disorders. Escitalopram's is generally safe but adverse effects include nausea, diarrhea, insomnia, dry mouth, ejaculatory dysfunction and dizziness.~3. Aripiprazole monotherapy in bipolar I patients reduced relapse rates and delayed relapse time, but not for depressive episodes.~4. Aripiprazole acts as a partial agonist at D2, D3, 5-HT1A, and 5-HT2C receptors, with antagonistic effects on α1 and possibly H1 receptors. Escitalopram is highly selective for the serotonin transporter, with no significant activity at other receptors."
48478752|NCT06433635|DRUG|Quetiapine|"1. Both immediate and extended-release quetiapine monotherapies showed superiority over placebo in acute BD depression across three 8-week randomized trials, confirmed by meta-analysis. Quetiapine exhibited significantly higher remission rates (52.8%) compared to placebo (34.7%) and improved various aspects of life, including quality of life, clinical global impression, sleep, functioning, and anxiety.~2. Common adverse events of quetiapine include sedation, hypotension, increased appetite, weight gain, dyslipidemia, and elevated glucose levels, particularly in a population already at risk.~3. Four studies examined quetiapine's maintenance effects in patients with manic, mixed, or depressive episodes. Overall, quetiapine prolonged the time to recurrence for both depressive and manic episodes."
48478753|NCT06433635|DRUG|Lurasidone|"1. Lurasidone, either alone or with lithium/valproate, proved more effective than placebo for acute BD depression in two 6-week randomized trials. Remission rates were significantly higher with lurasidone monotherapy (40.9%) and in combination (50.3%) compared to placebo (24.7% and 35.4% respectively). Lurasidone also improved anxiety, quality of life, and disability.~2. Common mild adverse events included nausea, headache, akathisia, somnolence, sedation, dry mouth, and vomiting. Weight gain, dyslipidemia, and increased glucose levels were not observed.~3. In a 6-month double-blind discontinuation study post-acute treatment response, lurasidone combined with lithium/valproate prolonged time to depressive episode recurrence compared to placebo (hazard ratio: 0.68). Although not statistically significant due to low placebo recurrence and shorter follow-up, it hints at maintenance efficacy."
48478754|NCT05060731|DRUG|Oral iron supplementation|Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
48478755|NCT05060731|DRUG|Intravenous iron supplementation|One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
48478756|NCT01355718|DRUG|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
48478757|NCT02330952|DRUG|Prednisone|40mg/day per os for 5 days
48478758|NCT02330952|DRUG|Placebo|40mg/day per os for 5 days
48478759|NCT02676791|DRUG|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
48478760|NCT05241418|DIAGNOSTIC_TEST|Atrial 3D late gadolinium enhancement|We will use cardiac MRI to take a picture of the atria. This picture will be used to identify scar tissue within the atria.
48478761|NCT06117943|OTHER|data collection|Pregnant women who smoke personally or are passively exposed to cigarette smoke
48478762|NCT05653635|RADIATION|Simultaneous-integrated boost with IMRT|Simultaneous-integrated boost guided by FDOPA-PET
48478763|NCT05390125|OTHER|A team, proficiency based progression, simulation training programme|The training programme will consist of two components (i) a short online training course including video examples of high performing teams and also poor practice (ii) a ward-based team huddle simulation training and assessment programme. The design and shape of the training and assessment will be based on the development of robust metrics. The design of the metrics and programme will centre around use in the acute hospital setting but will be readily adaptable to the obstetric, paediatric setting. The process of validating the metrics and building the online and simulation course involves the review of videotapes of safety huddle performance.
48478764|NCT05721651|DRUG|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
48478765|NCT02451150|DRUG|Azilsartan|Azilsartan tablets
48478766|NCT02336620|DRUG|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
48478767|NCT02336620|DRUG|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
48478768|NCT02740920|DRUG|Pembrolizumab|
48478769|NCT02740920|PROCEDURE|CT Scan|
48478770|NCT06068777|DRUG|Rosmary|inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar
48478771|NCT06068777|DRUG|Lemongrass Oil|inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
48478772|NCT03585426|DRUG|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
48458586|NCT06406010|DRUG|Ropivacaine 5mg/ml 20ml|administered in a pericapsular nerve group (PENG) block
48458587|NCT06406010|DRUG|Saline 0.9%|administered in a pericapsular nerve group (PENG) block
48458588|NCT00660387|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
48458589|NCT00660387|DRUG|Placebo Gel|
48458590|NCT00660387|DRUG|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
48458591|NCT00660387|DRUG|Placebo (PBO) oral capsules|
48458592|NCT00660387|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
48458593|NCT00660387|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
48458594|NCT00660387|DEVICE|J-tube|jejunal tube
48458595|NCT02920476|DRUG|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"
48458596|NCT03680001|BEHAVIORAL|Training in Rating Emotional Connection|Didactic education (video-supported educational module) on emotional connectivity will be offered to the subjects. Subjects will conference with PI to review ratings on modules.
48458597|NCT00163124|PROCEDURE|spinal manipulation & patient education/nutrition|
48458598|NCT04323527|DRUG|Chloroquine diphosphate|150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
48458599|NCT02893735|OTHER|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
48458600|NCT02893735|OTHER|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch\&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
48458601|NCT01675596|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
48458602|NCT01169272|DEVICE|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
48458603|NCT01497743|DRUG|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
48458604|NCT03521362|DEVICE|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
48458605|NCT03521362|DEVICE|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
48458606|NCT00834158|PROCEDURE|TACE|1 time
48458607|NCT00834158|PROCEDURE|PVE|1 time
48458608|NCT03811145|BIOLOGICAL|Tendoncel|Platelet lysate gel
48458609|NCT03811145|OTHER|Placebo control gel|Placebo control gel
48458610|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
47934560|NCT05589090|BEHAVIORAL|Super Skills for Life program|Children in the experimental group received eight sessions of the Super Skills for Life protocol. The intervention was implemented using a structured manual for the therapist and a workbook for the children \[Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández\]. The intervention was administered via an online virtual platform for eight weeks, with each session lasting approximately one hour.
47934561|NCT00572143|OTHER|ca coli follow-up by GP|patients randomized to follow up by GP
47934562|NCT01479218|DEVICE|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
47934563|NCT04288544|DIETARY_SUPPLEMENT|Microalgae|Open, monocentric intervention study in crossover design
47934564|NCT04288544|DIETARY_SUPPLEMENT|Omega-3-fatty acid capsule|Open, monocentric intervention study in crossover design
47934565|NCT04288544|DIETARY_SUPPLEMENT|sea fish|Open, monocentric intervention study in crossover design
48458611|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
48458612|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
48458613|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
48458614|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
48458615|NCT01140672|DRUG|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
48458616|NCT01125072|OTHER|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
48458617|NCT02265679|DRUG|BIIL 284 BS, low dose, pediatric patients|
48458618|NCT02265679|DRUG|BIIL 284 BS, medium dose, pediatric patients|
48458619|NCT02265679|DRUG|BIIL 284 BS, high dose, pediatric patients|
48458620|NCT02265679|DRUG|BIIL 284 BS, low dose, adult patients|
48458621|NCT02265679|DRUG|BIIL 284 BS, medium dose, adult patients|
48458622|NCT02265679|DRUG|BIIL 284 BS, high dose, adult patients|
48458623|NCT02265679|DRUG|Placebo|
48458624|NCT04811729|BEHAVIORAL|Motivational interview|The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program
48458625|NCT04811729|BEHAVIORAL|Medical advice|Usual care
48458626|NCT05990894|DRUG|Methylprednisolone|In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.
48458627|NCT01827696|DIETARY_SUPPLEMENT|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
48458628|NCT06236880|DRUG|GM-2505|IV
48458629|NCT05109104|DRUG|CAP UnScented|Sunscreen lip balm.
48458630|NCT05109104|DRUG|CAP Herbal Mint|Sunscreen lip balm.
48458631|NCT05109104|DRUG|CAP Mountain Berry|Sunscreen lip balm.
48458632|NCT05109104|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
48458633|NCT00348296|DRUG|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
48458634|NCT02125149|OTHER|Exercise Intervention|
48458635|NCT06174753|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg daily X 7 days
48458636|NCT06174753|DIAGNOSTIC_TEST|CMR|CMR 3-5 days post randomization
48458637|NCT01025141|DEVICE|Skeletal anchorage (MINISCREW)|Skeletal anchorage
48458638|NCT01025141|DEVICE|dental anchorage|dental anchorage (reference)
48458639|NCT01547728|DRUG|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
48458640|NCT02664792|OTHER|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
48458641|NCT06449690|PROCEDURE|Dog-assisted therapy|Dog-assisted therapy consists of the search for positive interactions resulting from the intentional human-animal relationship in the educational, therapeutic or social fields, practices as they are conducted in educational and medico-social institutions for example.
48458642|NCT06449690|PROCEDURE|Occupational activities|Occupational activities consist of origami, relaxation, sports or board games sessions.
48458643|NCT04750681|DIETARY_SUPPLEMENT|Placebo|Subjects orally ingested, with water, one capsule per day (in the evening)
48458644|NCT04750681|DIETARY_SUPPLEMENT|Saffron|Subjects orally ingested, with water, one capsule per day (in the evening)
48458645|NCT06143202|DEVICE|Freestyle Libre 3 Continuous Glucose Monitor|Pediatric participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
47934566|NCT06401187|OTHER|Bar overdenture|use of bar attachments as retentive mean of denture
47934567|NCT01663077|DRUG|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
47934568|NCT05089071|DEVICE|Assist by artificial intelligence system for colon polyp detection|Assist by artificial intelligence system for colon polyp detection
47934569|NCT06119022|PROCEDURE|Invasive coronary angiography|Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
47934570|NCT06119022|OTHER|routine medical treatment|Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
47934571|NCT05530629|DEVICE|resistance training|resistance training lasts for 12 weeks, three times a week, one hour each time, and the program of resistance training in the experimental group was divided into 10 exercises: Chest press, Lat pull down, Shoulder press, Squat, Leg extension, Leg curl, Bicep curl, Triceps extension, abdominal crunches, lower back exercises.
48280953|NCT04728945|PROCEDURE|Standard ventilatory management|"After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)"
48458646|NCT06152848|OTHER|Data and samples collection|Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
48458647|NCT04153539|BEHAVIORAL|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
48458648|NCT04153539|BEHAVIORAL|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
48458649|NCT00857558|DRUG|saxagliptin|orally administration at 1 mg once a day for 12 weeks
48458650|NCT00857558|DRUG|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
48458651|NCT00857558|DRUG|saxagliptin|orally administration at 5 mg once a day for 12 weeks
48458652|NCT00857558|DRUG|placebo|orally administration once a day for 12 weeks
48458653|NCT01360086|BIOLOGICAL|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
48458654|NCT01360086|DRUG|cisplatin|Cisplatine (50mg/m²)
48458655|NCT01360086|DRUG|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
48458656|NCT01360086|DRUG|leucovorin calcium|
48458657|NCT01360086|PROCEDURE|adjuvant therapy|
48458658|NCT01360086|PROCEDURE|neoadjuvant therapy|
48458659|NCT01360086|PROCEDURE|quality-of-life assessment|
47934572|NCT05530629|DEVICE|Normal P.E. course|Carry out general teaching content according to the college syllabus lasts for 12 weeks , three times a week, one hour each time, and the program of Normal P.E. course in the control group will be Physical recovery exercises, learn and practice queue formation, calisthenics, five step fists, long fist and Basic movements of Gymnastics gradually changed by week.
47934573|NCT06355674|BEHAVIORAL|Breastfeeding education provided with Lactation Simulation Model|The Lactation Simulation Model (LSM) is a high-fidelity simulator designed for interactive education, which educators can utilize for practical and wearable breastfeeding training. It is wearable like a shirt and is secured onto the chest by passing it over the shoulders and fastening it with a safety belt from the back. This allows the safety belt to be adjusted according to different body types and weights.
47934574|NCT03444987|GENETIC|Measurement of protein expression in tissues.|"The followings markers will be estimated in tissue~1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.~3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).~4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~5. Reduced glutathione, an antioxidant marker by a colorimetric method"
47934575|NCT05727384|DRUG|Clazakizumab|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
47934576|NCT05727384|DRUG|Placebo|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
47934577|NCT01865071|PROCEDURE|loop ileostomi|
47934578|NCT00739271|OTHER|Early feeding|
47934579|NCT00739271|OTHER|late feeding after bowel sounds return|Traditional method
48458660|NCT01360086|PROCEDURE|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
48458661|NCT06024980|PROCEDURE|Open partial horizontal laryngectomy(OPHL), Type I-III|An open partial horizontal laryngectomy(OPHL) was performed for patients with T2 supraglottic and glottic carcinoma, according to the American Joint Committee on Cancer(AJCC) criteria. Type I OPHL: Entails the resection of the supraglottis, including the pre-epiglottic space and the upper half of the thyroid cartilage. Type II OPHL: Entails the resection of the entire thyroid cartilage, with the inferior limit represented by the upper edge of the cricoid ring. Type III OPHL: Entails the resection of the entire supraglottic, glottic, and part of the subglottic sites, sparing both or at least one functioning crico-arytenoid unit.
48458662|NCT06024980|PROCEDURE|Transoral endoscopic laser cordectomy|"For patients with T1 glottic laryngeal carcinoma, according to the criteria of the American Joint Committee on Cancer(AJCC), transoral endoscopic CO2 laser(2-40Watts) cordectomy was performed. The classification comprises eight types of cordectomies:~* A subepithelial cordectomy (type I) is a resection of the epithelium of the vocal fold.~* A subligamental cordectomy (type II) is a resection of the epithelium, Reinke's space, and vocal ligament.~* Transmuscular cordectomy (type III), which proceeds through the vocalis muscle.~* Total cordectomy (type IV).~* Extended cordectomy encompasses the contralateral vocal fold and the anterior commissure (type Va).~* Extended cordectomy, which includes the arytenoid (type Vb).~* Extended cordectomy, which encompasses the subglottis (type Vc).~* Extended cordectomy, which consists of the ventricle (type Vd)."
48458663|NCT02387034|BEHAVIORAL|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
48458664|NCT02387034|OTHER|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
48458665|NCT03508596|OTHER|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
48458666|NCT01186835|PROCEDURE|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
48458667|NCT01186835|PROCEDURE|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
48458668|NCT03155867|OTHER|Meal replacement|The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
48623084|NCT02233088|OTHER|ELM Individual|ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
47934580|NCT03256890|BEHAVIORAL|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
48280954|NCT04899908|RADIATION|Stereotactic Radiation|Focused radiation beams to treat tumors
48280955|NCT04899908|DRUG|AGuIX gadolinium-based nanoparticles|Intravenous injection
48280956|NCT04899908|OTHER|Placebo|Intravenous infusion
48280957|NCT05217914|DRUG|Copanlisib (BAY80-6946)|Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
48280958|NCT02532231|OTHER|Laboratory Biomarker Analysis|Correlative studies
48280959|NCT02532231|BIOLOGICAL|Nivolumab|Given IV
48458669|NCT05062460|OTHER|1 hour Blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 1-hour postprandial blood glucose monitoring.
48458670|NCT05062460|OTHER|2 hour blood glucose monitoring|Consented patients who are diagnosed with gestational diabetes will be randomized to 2 hour post prandial blood glucose monitoring
48458671|NCT02024230|DRUG|Rivaroxaban or Warfarin|a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin
48458672|NCT01690260|DRUG|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
48458673|NCT01690260|PROCEDURE|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
48106859|NCT03978533|BEHAVIORAL|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
48458674|NCT03010605|DEVICE|Measuring Every Day Device|
48458675|NCT03010605|OTHER|Physical Therapy|
48458676|NCT06383845|DRUG|Lido-IV|Intravenous Lidocaine dose loading than a continuous infusion
48458677|NCT06383845|DRUG|ESP Block|ultrasound guided block with injection of Ropivacaine
48458678|NCT02888756|BIOLOGICAL|iHIVARNA-01|Therapeutic vaccination, followed by treatment interruption
48458679|NCT02888756|BIOLOGICAL|TriMix|Therapeutic vaccination, followed by treatment interruption
48458680|NCT02888756|BIOLOGICAL|Placebo|Therapeutic vaccination, followed by treatment interruption
48458681|NCT03314376|DEVICE|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
48458682|NCT01323062|DRUG|Bavituximab|Administered 3 mg/kg weekly
48458683|NCT04637139|DRUG|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi \[14C\]VBR.
48458684|NCT01198392|DRUG|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
48458685|NCT01198392|DRUG|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops."
48458686|NCT05717673|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph
48458687|NCT05625607|PROCEDURE|Transcatheter mitral valve-in-valve implantation|Transcatheter transfemoral mitral valve-in-valve implantation is an alternative for surgery redo in high-surgical-risk patients with bioprosthetic valve failure. The procedure is performed via femoral vein access. By the transseptal puncture (in the postero-inferior part of the interatrial septum) and balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle. The valve is expanded in the mitral position during rapid ventricle pacing.
48458688|NCT01715922|DRUG|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
48458689|NCT01715922|DRUG|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
48458690|NCT01715922|PROCEDURE|lumbar punctures|lumbar punctures to control intracranial pressure
48458691|NCT01545349|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
48458692|NCT01545349|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
48458693|NCT01545349|BIOLOGICAL|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
48458694|NCT04092387|OTHER|Varying the nicotine content of cigarettes|1) Altering the nicotine content of the tobacco research cigarettes
48458695|NCT04092387|OTHER|E-Cigarettes|Comparing effects of combining RC2 with EC 1 versus EC2
48458696|NCT03008005|DRUG|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
48458697|NCT03008005|DRUG|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
48458698|NCT03008005|DRUG|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
48458699|NCT04298151|DRUG|Zirconomer Improved|glass ionomer restoration reinforced with nano-zirconia particles to improve strength and esthetics
48458700|NCT04298151|DRUG|Ketac Molar quick Aplicap|highly viscous glass ionomer with improved mechanical properties than the conventional GI
48458701|NCT05592808|DEVICE|Extracorporeal Shockwave Therapy (ESWT)|Extracoporeal shock wave, 2000 shots/time, once a week for 3 weeks, shock wave freqency: 10Hz, total energy: 166 mJ/mm2, Pressure 2.5 Bar
48458702|NCT05592808|OTHER|Low-Dye Taping|After ESWT application, Low-Dye Taping will be applied 3 times, once a week.
47934581|NCT03256890|OTHER|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
47934582|NCT05609812|DRUG|Atacicept|Once weekly subcutaneous (SC) injections by prefilled syringe
47934583|NCT05609812|DRUG|Placebo|placebo
48458703|NCT05592808|OTHER|Kinesio Taping|After ESWT application, Kinesio Taping will be applied 3 times, once a week.
48458704|NCT06140082|GENETIC|GSTP1 A313G （AA）|Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
48458705|NCT05306496|DEVICE|Pre-shaped 4DMESH®|The 4DMESH® mesh is semi-resorbable parietal reinforcement implant made of 25% Polypropylene (non-resorbable) and 75% Poly-L-Lactic Acid (resorbable). 4DMESH® meshes are designed for the repair and reinforcement of inguinal and femoral hernias. 4DMesh is a CE-marked, class III medical device manufactured by Cousin Biotech.
48458706|NCT03749707|DIAGNOSTIC_TEST|HPV analysis|HPV analysis of SLNs
48458707|NCT02448160|DEVICE|alfapump|Implantation of alfapump
47934584|NCT03553030|DEVICE|coronary artery angiography|In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
48458708|NCT02448160|DRUG|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
48458709|NCT04642781|DIAGNOSTIC_TEST|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
48458710|NCT04203667|DEVICE|EndoRotor Resection|"The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter."
48458711|NCT06561581|BEHAVIORAL|Acuity|Enhancement to Motivity product for clinical decision support
47934585|NCT05888012|DEVICE|basket catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The basket catheter is made of nickel-titanium wires which can be manipulated to trap and withdraw stones.
47934586|NCT05888012|DEVICE|balloon catheter|Stone extraction is completed with either a basket or balloon catheter at the time of ERCP. The balloon catheter is made of latex, which is inflated after passing the stone, thus pushing the stone outwards.
47934587|NCT06052215|BEHAVIORAL|Online Information Cards Education|Providing family planning education to women through online information cards
48106860|NCT02250716|PROCEDURE|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
48106861|NCT02954848|DRUG|Placebo|TAK-438 placebo-matching tablets
48106862|NCT02954848|DRUG|TAK-438 10 mg|TAK-438 tablets
48280960|NCT05423379|DEVICE|XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)|XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system.
48280961|NCT04704934|DRUG|Trastuzumab deruxtecan|6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
48280962|NCT04704934|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
48280963|NCT04704934|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
48458712|NCT06448390|BEHAVIORAL|Physical training|The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session
48458713|NCT04106063|OTHER|KID SSQ12 questionnaire|During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
48458714|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal Plus (SC+)|
48458715|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal (SC), fortified oil, sugar|
48458716|NCT02077907|DIETARY_SUPPLEMENT|Plumpy Sup|
48458717|NCT02077907|DIETARY_SUPPLEMENT|Corn Soy Blend 14 (CSB14) and fortified oil|
48458718|NCT02491853|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
48478773|NCT05265065|BIOLOGICAL|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
48478774|NCT05265065|BIOLOGICAL|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
48106863|NCT04968119|OTHER|Exercise Intervention|Participate in telehealth exercise sessions
48280964|NCT02939521|PROCEDURE|Surgery|
48280965|NCT01686568|DRUG|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
48280966|NCT01686568|DRUG|placebo|
48280967|NCT04179903|OTHER|Physical activity|Physical Activity program is performed in a group in a gym and at home
48458719|NCT04330547|DRUG|Analgesic administration|"* Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
48458720|NCT04330547|DRUG|Placebo administration|Folavit (folic acid, 0.4 mg)
48458721|NCT01311596|OTHER|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
48280968|NCT04437264|DIETARY_SUPPLEMENT|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
48280969|NCT04437264|DIETARY_SUPPLEMENT|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
48280970|NCT03265587|OTHER|No intervention|No intervention
48458722|NCT05198973|BEHAVIORAL|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
48280971|NCT05212051|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
48280972|NCT05212051|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
48280973|NCT00432692|PROCEDURE|Falls Prevention Program|
48280974|NCT00838487|OTHER|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
48280975|NCT00838487|OTHER|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
48280976|NCT06430541|DRUG|Psilocybin|A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
48280977|NCT02040142|PROCEDURE|HIPEC|
48280978|NCT02040142|DRUG|Mitomycin C|
48280979|NCT01408238|BIOLOGICAL|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
48280980|NCT06509061|OTHER|Physical Activity Self-Definition|6 week behavioural change program designed to increase PASD and PA
48280981|NCT06509061|OTHER|Control|6 week program designed to as an attention control, delivering content on general health behaviour.
48280982|NCT02926339|BEHAVIORAL|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
48280983|NCT02782715|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
48280984|NCT02782715|PROCEDURE|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
48280985|NCT02762058|DEVICE|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
48280986|NCT02762058|PROCEDURE|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
48280987|NCT05244772|OTHER|Remote monitoring|Remote monitoring with a smartphone application of pain and nausea after day care surgery
48280988|NCT00953394|DRUG|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
48280989|NCT02509962|DIETARY_SUPPLEMENT|Slow sodium tablets|6 g sodium chloride per day over 14 days
48280990|NCT02860793|OTHER|Bone marrow aspiration|
48280991|NCT02860793|OTHER|Blood sampling|
48280992|NCT02868892|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
48280993|NCT01931514|DRUG|Torrent's Montelukast Sodium chewable Tablets 5mg|
48458723|NCT05779358|OTHER|Expectancy and gluten|Effect of expectancy to receive gluten and/or actual gluten intake
48458724|NCT03118687|OTHER|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
48458725|NCT01715779|DRUG|Eltrombopag|Eltrombopag exposure
48458726|NCT00535912|PROCEDURE|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
48458727|NCT05861973|BEHAVIORAL|Adaptive SMARTer intervention (SMARTer)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless bluetooth scale for 6 months.
48458728|NCT05861973|BEHAVIORAL|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
48458729|NCT04345133|DEVICE|Dental Implants Insertion Drilling Sequence|Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
48458730|NCT01260805|DRUG|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
48458731|NCT01260805|DRUG|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
48458732|NCT06361238|DRUG|Liraglutide injection|Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
48458733|NCT06361238|DRUG|Placebo injection|Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
48106864|NCT04968119|OTHER|Quality-of-Life Assessment|Ancillary studies
48458734|NCT02658214|DRUG|paclitaxel + carboplatin|IV infusion
48458735|NCT02658214|DRUG|carboplatin + etoposide|IV infusion
48458736|NCT02658214|DRUG|gemcitabine + carboplatin|IV infusion
48458737|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
48458738|NCT02658214|DRUG|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
48458739|NCT02658214|BIOLOGICAL|durvalumab|IV infusion
48458740|NCT02658214|BIOLOGICAL|tremelimumab|IV infusion
48458741|NCT02658214|DRUG|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
48458742|NCT02658214|DRUG|cisplatin + 5-fluorouracil (5FU)|IV infusion
48458743|NCT03101358|DRUG|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
48458744|NCT04541264|DIAGNOSTIC_TEST|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
48458745|NCT03820063|DRUG|PTC-Pz|"* Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles."
48458746|NCT01584882|BEHAVIORAL|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
48458747|NCT04552405|DIETARY_SUPPLEMENT|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
48458748|NCT03191305|DRUG|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
48458749|NCT03191305|DRUG|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
48458750|NCT02646488|BEHAVIORAL|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
48458751|NCT02646488|BEHAVIORAL|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
48458752|NCT02646488|BEHAVIORAL|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
48280994|NCT01931514|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
47934588|NCT03146598|OTHER|No intervention as it is a observational study|No intervention as it is a observational study
48458753|NCT02646488|BEHAVIORAL|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
48458754|NCT02646488|BEHAVIORAL|Standard Care Regimen 9 Months|
48458755|NCT02646488|BEHAVIORAL|Standard Care Regimen 12 Months|
48458756|NCT02646488|BEHAVIORAL|Standard Care Regimen 15 Months|
48458757|NCT02646488|BEHAVIORAL|Standard Care Regimen 18 Months|
48458758|NCT02646488|BEHAVIORAL|Standard Care Regimen 21 Months|
48458759|NCT02646488|BEHAVIORAL|Standard Care Regimen 24 Months|
47934589|NCT02798614|DEVICE|10-day cast|Removal of plaster cast fixation 10 days after reduction
48106865|NCT04968119|OTHER|Questionnaire Administration|Ancillary studies
48458760|NCT02646488|BEHAVIORAL|Standard Care Regimen 27 Months|
48458761|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 21 Months|
48458762|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 24 Months|
47934590|NCT02539615|DEVICE|ForeCYTE Breast Aspirator|
48280995|NCT06112925|OTHER|Medication Therapy Management|The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, \& smoking cessation), drug adherence, and self-monitoring of the diseases.
48458763|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 27 Months|
48458764|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 30 Months|
48458765|NCT02646488|BEHAVIORAL|Follow Up Post Intervention 33 Months|
48458766|NCT03555695|BEHAVIORAL|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
48458767|NCT03555695|BEHAVIORAL|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
48458768|NCT03555695|BEHAVIORAL|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
48458769|NCT03900039|DEVICE|Highly Cross Linked Polyethylene and oxidized zirconium femoral head|"Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads"
48458770|NCT01981044|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
48458771|NCT00759707|DRUG|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
48458772|NCT02349763|DRUG|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
48458773|NCT02349763|DRUG|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
48458774|NCT04898998|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).
47934591|NCT01527357|BIOLOGICAL|Fibrocaps|Human fibrinogen and thrombin powder, for topical administration.
47934592|NCT01527357|BIOLOGICAL|Gelatin sponge|Absorbable gelatin sponge for topical administration.
48106866|NCT01343173|DRUG|Imatinib stop|To stop imatinib after inclusion.
48280996|NCT05718102|OTHER|Population-health management|Population-health management
48106867|NCT00560014|DIETARY_SUPPLEMENT|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
48280997|NCT05975229|OTHER|Knitting and education (pamphlet)|Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.
48106868|NCT00560014|DIETARY_SUPPLEMENT|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
48106869|NCT03699488|BEHAVIORAL|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
48280998|NCT05975229|OTHER|Education (pamphlet)|Receive only the pamphlet, not the knitting program.
48280999|NCT06351358|DEVICE|Sculptra treatment|Subjects will receive treatment of Sculptra at baseline. Subjects will receive a second treatment of Sculptra at Week 4 visit. At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
48458775|NCT04898998|OTHER|routine care|routine care
48458776|NCT03548480|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo
48458777|NCT03548480|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic
48458778|NCT01653405|OTHER|Multifaceted behavioral intervention|The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
48478775|NCT04138706|DRUG|Vancomycin|Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)
48478776|NCT04138706|DRUG|Placebos|Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
48478777|NCT01702077|PROCEDURE|Neurofeedback|
48106870|NCT03671525|DRUG|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
48106871|NCT03671525|DRUG|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
48106872|NCT06348849|DEVICE|Low-level laser therapy|Wavelength 980nm (SmartM, Lasotronix, Poland)
48106873|NCT06348849|DRUG|Nanosilver fluoride|Optimized synthesis of Nanosilver Fluoride
48458779|NCT05475392|OTHER|Traditional Physical Therapy|A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
48478778|NCT01702077|PROCEDURE|Sham feedback|
48478779|NCT06142188|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
48098783|NCT06631664|DEVICE|A computerized electrical stimulator (Vectra®2C; Chattanooga, TS, USA)|"The patient was positioned in supine lying position with the affected arm beside the body and elbow extended, the skin over the anterior and posterior comportment of the upper arm was cleaned using medical cotton sacked in alcohol before the application.~The first two stimulating electrodes for the biceps muscle were placed at the superior and inferior 1/3 of anterior surface of the upper arm with a distance in between the two electrodes at least the size of one of them, while the other two electrodes for the triceps muscle were placed at the superior and inferior 1/3 of the posterior surface of the upper arm.~One millisecond pulse duration and a frequency of 50Hz with a rectangular shaped pulse were utilized and stimulation was applied for 15 minutes. At first a low-intensity current is applied and gradually increased till a gentle contraction of the muscles appears and allow time for the child to become accustomed to the current and maintained sufficient and observable contraction."
48098784|NCT00501020|DRUG|Rosiglitazone|
48098785|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
48281000|NCT06351358|DEVICE|Restylane Treatment|Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline. Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
48281001|NCT02220387|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
48281002|NCT02220387|OTHER|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
48281003|NCT06587256|DEVICE|Mouth Tape|A single piece of silicone tape placed vertically over the lips. When positioned properly the participant can still inhale/exhale and cough around the tape if needed, but will tend to keep mouth closed otherwise.
48281004|NCT06657729|OTHER|Succiometry|Assessement of sucking performance by measuring pressures (suction, crushing) with a succiometer every 10 days. This instrument consists of a standard silicone teat for premature newborns, which is connected via two silicone tubes to pressure micro-sensors. These pressure sensors measure the child's sucking activity on the teat. This activity is characterised by suction and crushing movements. It is a non-nutritive sucking activity (no fluid is delivered). Sucking performance is recorded during a period of calm awakening of the infant and over a period of 5 minutes, and is part of routine care since non-nutritive sucking is a common practice in neonatal unit. The first measurement will be taken in the first week of life and then every 7-10 days until discharge from the neonatal unit.
48281005|NCT04971590|OTHER|Participant completed survey|Participants will be required to complete the participant survey.
48281006|NCT04971590|OTHER|Medical chart review|Data will be collected from medical charts of participants.
48281007|NCT06126224|DRUG|KarXT|KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)
48281008|NCT06126224|DRUG|Placebo|Placebo Capsules
48281009|NCT00994188|PROCEDURE|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
48281010|NCT04147949|DRUG|AV-101|Oral capsules taken twice daily for 14 days
48478780|NCT00183586|BEHAVIORAL|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
48478781|NCT00183586|BEHAVIORAL|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
48281011|NCT04147949|DRUG|Placebo|Oral capsules taken twice a day for 14 days
48281012|NCT03233048|DEVICE|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
48281013|NCT04536194|DRUG|norepinephrine|to treat hypotension under general anesthesia with norepinephrine
48281014|NCT04536194|DRUG|dopamine|to treat hypotension under general anesthesia with dopamine
48281015|NCT03115450|DEVICE|Ultrasound|Type of imaging technology to look at organs and structures inside the body
48281016|NCT03115450|DEVICE|Pupilometer|A device that measures pupil size and how it changes.
48281017|NCT01041092|DRUG|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
48281018|NCT01047410|OTHER|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
48281019|NCT01047410|OTHER|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
48281020|NCT06656806|DRUG|Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD|Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD
48281021|NCT06656806|DRUG|Determine the presence and concentration of CBD in subject's plasma with inhaled CBD|Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD
48098786|NCT01704846|DRUG|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
48098787|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
48098788|NCT01704846|DRUG|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
47934593|NCT02982278|BEHAVIORAL|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
47934594|NCT00704275|DRUG|0.05% cyclosporin eye drop|bid dosage for 4 months
47934595|NCT00278915|DRUG|Fulvestrant|Participants will receive intramuscular injection of fulvestrant as stated in arm description.
47934596|NCT05918081|OTHER|Multi-Stage 20 m Shuttle Run Test|"The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer."
47934597|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Dose Ascention|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
47934598|NCT04318145|DRUG|PL-3994 Aqueous Intravenous Solution Single Dose|Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion
48098789|NCT06631924|DEVICE|Implant|Intramedullary headless hardware systems were utilized to place hardware in85 a retrograde manner from the metacarpophalangeal joint.
48098790|NCT06478043|DRUG|ivonescimab|20mg/kg, IV, D1, Q3W
48098791|NCT06478043|DRUG|irinotecan liposome|56.5mg/m\^2, IV, D1, Q2W
48098792|NCT01202851|OTHER|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
48098793|NCT01202851|BEHAVIORAL|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
48098794|NCT01202851|OTHER|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
48106874|NCT05427058|PROCEDURE|Superior Hypogastric Plexus Block|this procedure uses a transdiscal approach at the level of the L5-S1 vertebrae by injecting 5 ml of 1% lidocaine + 10 ml of 96% alcohol and confirmed by C-arm.
48281022|NCT02167269|DEVICE|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
48281023|NCT02186392|DEVICE|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
48281024|NCT01670500|DRUG|Cisplatin|administered intravenously every 3 weeks for 4 doses
48281025|NCT01670500|DRUG|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
48281026|NCT01670500|DRUG|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
48281027|NCT05346302|DRUG|Pneumovax 23|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
48281028|NCT05346302|DRUG|Typhim VI|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
48281029|NCT05346302|OTHER|Saline|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
48281030|NCT01606462|DRUG|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
48281031|NCT04707872|DIAGNOSTIC_TEST|MMDx diagnostic test|Microarray test of gene expression in heart biopsies
48281032|NCT04707872|DIAGNOSTIC_TEST|Prospera|Donor derived cell-free DNA in patient blood
48281033|NCT04707872|DIAGNOSTIC_TEST|HLA antibody|Centralized measurement of HLA antibodies in patient blood
48281034|NCT03808311|OTHER|Treatment strategy regarding different systolic BP goals|The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
48281035|NCT06178614|DRUG|JNJ-87890387|JNJ-87890387 will be administered.
48281036|NCT00004980|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
48281037|NCT00004980|DEVICE|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
48281038|NCT01249170|BEHAVIORAL|First year program|Information on group that underwent new educational program
48281039|NCT01249170|OTHER|Control comparison|Information from group that did not undergo new first year program
48281040|NCT06366373|OTHER|A mental health art exhibition|"The specific intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 27, 2024. Organized by Qixi Charity, an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health."
48281041|NCT06366373|OTHER|printed or online education materials|The specific intervention measure is to provide printed or online education materials within the first month after the baseline survey
48281042|NCT01495871|DIETARY_SUPPLEMENT|Amino Acids|15 grams amino acids two times per day for 6 weeks
48098795|NCT06099561|BEHAVIORAL|National specialized medical care unit for severe self-harm behaviour-Consultation model|Extensive assessments. Consultation and training for existing treatment providers and caregivers. Network-meetings for providers and caregivers.
48098796|NCT03572413|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
48098797|NCT03572413|DRUG|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
48458780|NCT05475392|OTHER|Post Isometric Relaxation|The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
48458781|NCT01590563|DEVICE|IUD|Insertion of a spherical IUD, one year follow-up
48458782|NCT00198133|DRUG|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
48458783|NCT03891095|DRUG|Oxytocin|intranasally administrated
48458784|NCT03891095|DRUG|L-DOPA|orally administered
48458785|NCT03891095|DRUG|Placebos|intranasally administrated and orally administered
48098798|NCT03391908|DIAGNOSTIC_TEST|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
48098799|NCT01597128|DEVICE|Flex HD|Flex HD mesh for hernia repair
48098800|NCT01597128|DEVICE|Strattice|Strattice mesh for hernia repair
48098801|NCT00312078|DIETARY_SUPPLEMENT|Yogurt Supplementation|
48281043|NCT01495871|DIETARY_SUPPLEMENT|Placebo of inert compounds|Placebo two times per day for 6 weeks
48281044|NCT01495871|DIETARY_SUPPLEMENT|Valine|2.5 grams valine supplementation two times a day for 6 weeks
48281045|NCT03693872|DRUG|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
48281046|NCT03693872|DRUG|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
48281047|NCT04036617|DRUG|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
48281048|NCT04036617|DRUG|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
48281049|NCT05670977|DIETARY_SUPPLEMENT|Study product plus collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
48281050|NCT05670977|DIETARY_SUPPLEMENT|Study product without collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
48281051|NCT05418049|DRUG|Baclofen|30mg - Supplied as 10mg and 20mg tablets
48458786|NCT00756171|DRUG|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
48458787|NCT00756171|DRUG|placebo|2 times 3 625mg tablets daily
48458788|NCT02025660|DRUG|Mw, 0.3ml x three days sc|
48458789|NCT02025660|DRUG|Placebo|
48098802|NCT02934958|BEHAVIORAL|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
48098803|NCT02934958|BEHAVIORAL|Standard of Care|Patients will be tracked to compare how effective are usual care methods
48106875|NCT05427058|PROCEDURE|Ganglion Impar Block|this procedure uses a trans-sacrococcygeal approach by injecting 4 ml of 1% lidocaine + 6 ml of 96% alcohol and confirmed by C-arm.
48106876|NCT06223529|BEHAVIORAL|Therapeutic Instrumental Music Performance|Exercises using musical instruments to improve hemiparetic hand and arm function
48106877|NCT04570956|DRUG|Tamoxifen|Oral Tamoxifen 10 mg/day
48106878|NCT04570956|DRUG|Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
48106879|NCT04570956|DRUG|Placebo|placebo pill or placebo gel
48281052|NCT05418049|DRUG|Memantine|two 10 mg tablets
48281053|NCT05418049|DRUG|Roflumilast|250 mcg capsule
48281054|NCT05418049|DRUG|Placebo|Placebo pill
48281055|NCT05135364|DRUG|Camrelizumab|Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
48281056|NCT05135364|DRUG|HAIC|A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks
48281057|NCT05135364|DRUG|TKI|Lenvatinib or Regorafenib
48458790|NCT03271125|BEHAVIORAL|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
48458791|NCT03271125|BEHAVIORAL|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
48458792|NCT04672603|PROCEDURE|Complete Preservation of Denonvilliers' Fascia|Patients accept L-PANP surgery with complete preservation of Denonvilliers Fascia
48458793|NCT03859050|OTHER|bronchoscopy with intrabronchial administration of lipopolysaccharide|The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
48458794|NCT05060458|OTHER|No intervention|No intervention
48458795|NCT04863131|BIOLOGICAL|EXG-5003|COVID-19 self-replicating mRNA vaccine
48458796|NCT04863131|BIOLOGICAL|Placebo|placebo solution
48458797|NCT02013050|DRUG|SGX942|
48281058|NCT02338986|DRUG|Plasma|Plasma
48458798|NCT02013050|DRUG|Placebo|
48458799|NCT03010657|OTHER|Intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
48458800|NCT04605835|DIAGNOSTIC_TEST|ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.|The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
48458801|NCT01389713|DRUG|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
48458802|NCT01389713|DRUG|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
48458803|NCT04647825|OTHER|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
48458804|NCT03406845|BEHAVIORAL|Chair-side mindfulness intervention|"Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP)."
48458805|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
48458806|NCT01466374|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
48458807|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
48458808|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
48458809|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
48458810|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
48458811|NCT01466374|DRUG|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
48458812|NCT05369039|DRUG|Roflumilust|A selective phosphodiesterase 4 Inhibitor
48458813|NCT05369039|DRUG|Prednisolone|Systemic corticosteroid
48458814|NCT06482606|OTHER|Flickering Checkerboard Stimulation|This visual stimulation is a succession of alternating black and white squares on a small monitor in the scanner, the black and white checkerboard creates the effect of flickering lights.
48458815|NCT04158128|OTHER|non-intervention|non-interventional, prospective cohort study
48458816|NCT04448730|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
48458817|NCT05405023|OTHER|Concentric exercises with wrist mobilization|Participants will receive concentric exercise including wrist flexion, extension, and abduction, adduction, supination and pronation plus wrist mobilizations with movements.
48281059|NCT05158348|DRUG|Dexmedetomidine Hydrochloride|Group A will receive post-operative nebulised dexametomidine and lidocaine.
48281060|NCT05158348|DRUG|Nebulized lidocaine|Group B will receive post-operative will receive nebulised lidocaine
48458818|NCT05405023|OTHER|Concentric exercises without wrist mobilization|Participants will receive concentric exercises only.
48458819|NCT06212869|DEVICE|Transcranial direct current stimulation|tDCS group will give active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
48106880|NCT04570956|OTHER|Questionnaire Administration|Ancillary studies
48106881|NCT01382342|DRUG|Rasagiline|1 mg daily
48281061|NCT05158348|DRUG|Local infiltration of lidocaine|group C will receive intra-operative local infiltration of lidocaine
48458820|NCT06212869|DEVICE|Sham transcranial direct current stimulation|Sham tDCS group will give sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
48458821|NCT06212869|DEVICE|Green light|Green light group will give green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
48458822|NCT02392858|OTHER|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
48458823|NCT01360437|DRUG|Prasugrel|Prasugrel 10mg/day
48458824|NCT01360437|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
48458825|NCT00895050|OTHER|Review of clinical records|
48458826|NCT00876265|DEVICE|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
48458827|NCT00876265|DEVICE|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
48458828|NCT06492109|BEHAVIORAL|Experimental sleep deprivation|Cognitive assessment of subjects: This study will collect the Mini-Mental State Examination (MMSE) results as a supplement to the Montreal Cognitive Assessment (MoCA). The sleep status of subjects will be screened using the Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). Subjects must maintain regular sleep and diet before sample collection. Peripheral blood samples will be taken the day before, the day of, and the day after acute sleep deprivation, whether voluntary or involuntary, along with anxiety and depression assessments. For chronic sleep deprivation (≥7 days), blood samples will be collected before and after the deprivation period, with anxiety, depression, and cognitive assessments. Voluntary sleep deprivation occurs under experimental conditions, while involuntary deprivation is due to factors like age or shift work.
48458829|NCT03790163|DRUG|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
48458830|NCT02152618|OTHER|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
48458831|NCT03414151|OTHER|Observation|No intervention administered.
48458832|NCT02512328|DEVICE|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
48458833|NCT00994604|DRUG|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
48458834|NCT03086876|BEHAVIORAL|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
48458835|NCT06174558|DEVICE|Sleep Tracking Devices|Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
48458836|NCT03852745|BEHAVIORAL|Cognitive Behavioral Therapy|cognitive behavioral therapy; focus on learning skills including acceptance and commitment
48458837|NCT04179539|DIAGNOSTIC_TEST|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
48458838|NCT04179539|DIAGNOSTIC_TEST|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
48458839|NCT03243591|OTHER|Livionex gel|Brushing area of mucositis with gel
48458840|NCT03243591|OTHER|Aquafresh gel|Aquafresh gel
48458841|NCT00609557|DRUG|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
48458842|NCT04934254|OTHER|Attitude Scale|26-item related to scale will construct and apply to nurses for creating scale
48458843|NCT04902963|DEVICE|PE tube|Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
48458844|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (25 mg/100 kcal )|
48458845|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (34 mg/100 kcal)|
48458846|NCT02092857|DIETARY_SUPPLEMENT|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
48458847|NCT05886803|OTHER|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
48458848|NCT03357380|DRUG|Semaglutide|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
48458849|NCT03357380|DRUG|Placebo|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
48458850|NCT02955901|OTHER|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
48458851|NCT02955901|OTHER|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
48458852|NCT02521103|DEVICE|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
48458853|NCT00263458|OTHER|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
48458854|NCT01080820|DRUG|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
48458855|NCT01080820|DRUG|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
48098804|NCT01757509|OTHER|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
48458856|NCT01080820|DRUG|Viread|One single oral dose of 300mg Viread.
48458857|NCT02893163|BEHAVIORAL|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
48458858|NCT02893163|OTHER|Usual Care|Usual Care by Family Doctor
48458859|NCT02986555|DEVICE|Existing Biofeedback|Using relaxing assisted biofeedback approach
48458860|NCT02986555|DEVICE|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
48106882|NCT01382342|DRUG|Placebo|1 mg daily
48458861|NCT01821157|PROCEDURE|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
48458862|NCT01821157|PROCEDURE|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
48458863|NCT05123885|OTHER|Study on Data|Study on Data
48458864|NCT02694536|DRUG|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
48458865|NCT02694536|DRUG|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
48458866|NCT00028925|BIOLOGICAL|filgrastim|
48458867|NCT00028925|DRUG|carboplatin|
48458868|NCT00028925|DRUG|topotecan hydrochloride|
48458869|NCT00028925|RADIATION|WBRT|
47934599|NCT02485678|OTHER|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
47934600|NCT02485678|OTHER|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
48281062|NCT03510793|DRUG|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
48458870|NCT01768260|DEVICE|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
48458871|NCT01768260|DRUG|Aspirin|Standard drug therapy
48281063|NCT03510793|DRUG|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
48458872|NCT02858037|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
48458873|NCT02064153|PROCEDURE|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
48458874|NCT02064153|PROCEDURE|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
48458875|NCT00691470|DRUG|ATI-5923|Dose Adjusted based on INR.
47934601|NCT02485678|OTHER|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
47934602|NCT00600509|DRUG|Levetiracetam|
48458876|NCT00691470|DRUG|Coumadin (warfarin)|Dose adjusted based on INR.
47934603|NCT00825773|DEVICE|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
47934604|NCT00564538|DRUG|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
47934605|NCT00564538|DRUG|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
48458877|NCT05762458|DRUG|Ammoxetine|Ammoxetine hydrochloride enteric-coated tablets
48458878|NCT05762458|DRUG|Placebo|placebo to Ammoxetine.
48458879|NCT06038760|PROCEDURE|Resection|Patients undergo a resection from a lesion, and give 40mL of blood
48458880|NCT02671058|DRUG|Cortenema|Hydrocortisone Administered as a Liquid Enema
48458881|NCT02671058|DRUG|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
48458882|NCT02805166|DRUG|PEG-rhG-CSF|
48458883|NCT00014469|DRUG|busulfan|
47934606|NCT00818675|DRUG|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
47934607|NCT00818675|DRUG|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
47934608|NCT00818675|DRUG|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
48458884|NCT00014469|DRUG|melphalan|
48458885|NCT00014469|DRUG|methotrexate|
48458886|NCT00014469|DRUG|tacrolimus|
48458887|NCT00014469|PROCEDURE|allogeneic bone marrow transplantation|
48458888|NCT03227276|DIETARY_SUPPLEMENT|Litramine|2 tablets to be taken 3 times a day after meals
47934609|NCT01837771|DEVICE|Diaphragmatic stimulation|
47934610|NCT02577276|DEVICE|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
48458889|NCT03227276|DIETARY_SUPPLEMENT|Placebo tablet|2 tablets to be taken 3 times a day after meals
48458890|NCT06050239|DRUG|177Lu-PSMA-0057|The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.
48458891|NCT02649335|DRUG|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
48458892|NCT02649335|PROCEDURE|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
48458893|NCT02832466|OTHER|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
48458894|NCT00486434|DRUG|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
48458895|NCT00486434|DRUG|SMC021 Placebo|Placebo orally, twice daily
48458896|NCT01929187|DRUG|Phytonail|
47934611|NCT04173208|OTHER|Fecal microbial transplant|Fecal microbial transplant
47934612|NCT04173208|OTHER|Placebo|Placebo
47934613|NCT02825407|DIETARY_SUPPLEMENT|Oral physiology|
47934614|NCT04936464|DEVICE|transcutaneous tibial nerve stimulation (TTNS)|TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.
47934615|NCT04936464|DEVICE|transcutaneous electrical stimulation (TENS)|The sham intervention is designed to appear almost identical to the TTNS intervention.
48458897|NCT01929187|DRUG|Loceryl|
48458898|NCT05345249|DRUG|Ropivacaine Hydrochloride Injection|Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.
48458899|NCT05345249|DRUG|Sodium chloride|Placebo comparator
48458900|NCT05352048|DEVICE|Triggered Electromyography|Triggered electromyography will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded.
48458901|NCT05352048|DEVICE|Mechanomyography|SENTIO MMG ball tip probe will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded, and the accuracy compared to the data from the triggered electromyography.
47934616|NCT03695874|OTHER|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
48458902|NCT00213122|DRUG|miglitol|
48458903|NCT01826760|OTHER|Using training and testing groups to construct ANN based on laboratory tests|
48458904|NCT02050165|DIETARY_SUPPLEMENT|KIND Bars|Consumption of KIND Bars for 12 weeks
48458905|NCT02050165|DIETARY_SUPPLEMENT|Typical American Snack|Consumption of typical American snacks for 12 weeks
48458906|NCT04956289|DRUG|Viltolarsen|Received during weekly intravenous infusions
48458907|NCT05388071|OTHER|Usage of telemedicine and tele-consultation for treatment|Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
48458908|NCT01102127|DEVICE|Elastography|Performance of US, elastography and FNA.
48458909|NCT04677517|DEVICE|Modification of active microphone positioning|"Patient will pass the experimental tests described above with 3 different active microphone positions :~* on the cochlear implant processor;~* on the antenna~* in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life."
48458910|NCT04677517|BEHAVIORAL|SPHERE protocol|"Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure."
48098805|NCT06428786|OTHER|Female Sexual Function Index|As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.
48098806|NCT00100659|DRUG|Pegylated Interferon/ribavirin|
48458911|NCT04677517|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
48458912|NCT04677517|BEHAVIORAL|Quality of life questionnaire|The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
48458913|NCT04677517|BEHAVIORAL|Likert scale|This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
48458914|NCT04076007|DIETARY_SUPPLEMENT|Beetroot juice|
48458915|NCT04076007|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|
48458916|NCT00085501|DRUG|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
48458917|NCT00085501|DRUG|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
48458918|NCT00085501|DRUG|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
48458919|NCT04163588|DRUG|Metolazone|Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
48458920|NCT04163588|DRUG|Loop Diuretics|Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
48458921|NCT06443125|OTHER|Natural psychotherapy|Draw ideas from traditional Chinese culture, learn from the practice of Morita therapy in Japan, and create local practice experience. At the same time, a variety of research methods such as cognitive assessment and brain imaging were used to establish the scientific, professional and objective evaluation indexes of the therapy.
48458922|NCT05432115|DRUG|Tetracyclin|Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid
48458923|NCT06268457|PROCEDURE|Chemoembolization with Doxorubicin|"* Identification of the main vessels afferent to the metastasis to be treated.~* Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~* Injection of embolizing material (hydrogel microspheres with doxorubicin)~* Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature)."
48458924|NCT02316054|DEVICE|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
48458925|NCT03951727|DEVICE|Endovascular treatment for PAD|Long femoropopliteal stenting with SuperA devices
48458926|NCT05146024|BEHAVIORAL|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
48458927|NCT02227550|DRUG|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
48458928|NCT02227550|DRUG|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine \>= 1.5 mg/dl (133mM), \<= 60 kg body weight or age \>= 80 years.
48458929|NCT03113227|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
48458930|NCT03113227|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
48458931|NCT03692455|PROCEDURE|Roux-en-Y Gastric Bypass|The Roux-en-Y gastric bypass procedure involves creating a stomach pouch out of a small portion of the stomach and attaching it directly to the small intestine, bypassing a large part of the stomach and duodenum. Not only is the stomach pouch too small to hold large amounts of food, but by skipping the duodenum, fat absorption is substantially reduced.
48458932|NCT03692455|PROCEDURE|Vertical Sleeve Gastrectomy|VSG surgery restricts food intake and decreases the amount of food used. Most of the stomach is removed during this surgery, which may decrease ghrelin, a hormone that prompts appetite. Lower amounts of ghrelin may reduce hunger more than other purely restrictive surgeries, such as AGB.
48458933|NCT02372006|DRUG|afatinib|
48623085|NCT00564980|PROCEDURE|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
48098807|NCT06630104|PROCEDURE|Biospecimen Collection|Undergo hair and saliva sample collection
48623086|NCT00564980|PROCEDURE|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
48623087|NCT02713620|BIOLOGICAL|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
48623088|NCT03848468|PROCEDURE|Hemorrhoidectomy|excision of 3rd and 4th degree hemorrhoids
48623089|NCT06478030|DIAGNOSTIC_TEST|questionnaire, Helicobacter pylori (H. pylori) test, fecal immunochemical test (FIT)|The questionnaire covers nine aspects: basic information of the participants, symptoms and previous examinations, medical history and surgical history, medication history, smoking history, alcohol consumption history, dietary habits, physical exercise, and family history.
48098808|NCT06630104|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48098809|NCT06630104|OTHER|Electronic Health Record Review|Ancillary studies
48098810|NCT06630104|PROCEDURE|Follow-Up|Undergo CFU
48098811|NCT06630104|OTHER|Genetic Counseling|Receive genetic counselor consultation
48458934|NCT01283763|DRUG|Topical Imiquimod|16 weeks
48458935|NCT01283763|PROCEDURE|Conization|Large loop excision of the transformation zone
48458936|NCT04070898|PROCEDURE|Remove urinary catheter after surgery|Remove bladder catheter after surgery
48458937|NCT00889486|DRUG|TZP-102|
48458938|NCT00889486|DRUG|Placebo|
48098812|NCT06630104|OTHER|Genetic Testing|Undergo sequencing analysis
48623090|NCT04136678|OTHER|walking training|15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
48098813|NCT00164489|BEHAVIORAL|Weight control and physical activity promotion|
48098814|NCT05014204|DEVICE|The Endogenex Device|The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.
48098815|NCT00635895|OTHER|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
48098816|NCT04159948|DIETARY_SUPPLEMENT|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
48098817|NCT00413491|PROCEDURE|MR mammography|MR mammography
48098818|NCT00413491|PROCEDURE|MR|MR
48098819|NCT01749787|DRUG|PRTX-100 at 1.5 mcg/kg|
48098820|NCT01749787|DRUG|PRTX-100 at 3.0 mcg/kg|
48098821|NCT01749787|DRUG|PRTX-100 at 6.0 mcg/kg|
48098822|NCT01749787|DRUG|PRTX-100 at 12.0 mcg/kg|
48281064|NCT05934214|DRUG|Immune checkpoint inhibitor|"Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab"
48281065|NCT05878717|BIOLOGICAL|Belimumab|Belimumab will be administered.
48281066|NCT05878717|OTHER|Placebo|.Placebo will be administered.
48281067|NCT05514665|DEVICE|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
48281068|NCT02101008|DRUG|disulfiram and chelated zinc|
48281069|NCT05265650|DRUG|BO-112 in combination with ablative radiotherapy (SABR) and nivolumab|Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
48281070|NCT05265650|PROCEDURE|Tissue Biopsies|Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
48281071|NCT03216616|BEHAVIORAL|Cognitive Behavioural Therapy|
48281072|NCT01568216|DRUG|AMG 747|Three dose levels once-daily oral administration
48281073|NCT01568216|DRUG|Placebo|Once-daily oral administration
48281074|NCT04929639|OTHER|measurment of intraabdominal surgery|Immediately after intubation, while the patient is lying in the supine position, an intra-abdominal measurement will be made from the bladder catheter and recorded. Then, after the surgical site antisepsis, when the trocar required for the operation is placed by the general surgeon, another measurement will be made from the trocar port. Measurements will be recorded.
48281075|NCT05839561|DRUG|Letrozole as monotherapy|Letrozole 5 mg daily orally for 10 days from day 0
48281076|NCT05839561|DRUG|MTX as monotherapy|MTX in a single dose of 100 mg intravenously on day 0
48281077|NCT05591911|DIAGNOSTIC_TEST|Urine PCR testing|The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
48281078|NCT03215030|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
48281079|NCT03215030|DRUG|Dexamethasone|Dexamethasone.
48281080|NCT02978222|BIOLOGICAL|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
48281081|NCT02978222|DRUG|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
48281082|NCT04538664|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
48281083|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
48281084|NCT04538664|DRUG|Carboplatin|Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
48281085|NCT04538664|DRUG|Pemetrexed|Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
48281086|NCT06182631|DEVICE|Buzzy Bee|The Buzzy is a vibrating palm-sized device with removable ice wings developed by MMJ Labs Atlanta, GA. It uses Melzack and Wall's Gait Control theorywhich asserts that activation of non-nociceptive fibers can interfere with signals from pain fibers thereby inhibiting pain.
48281087|NCT06182631|DRUG|Vapocoolent|Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
48281088|NCT06182631|OTHER|Placebo|A band will be placed on the arm before IV insertion for placebo effect.
48281089|NCT01172080|OTHER|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
48281090|NCT05127486|DRUG|Galcanezumab|Administered SC.
48281091|NCT05127486|DRUG|Rimegepant|Administered orally.
48098823|NCT01749787|DRUG|PRTX-100 at 240 mcg|
48098824|NCT01749787|DRUG|Placebo|Placebo administered via infusion once per week for 5 weeks
48098825|NCT01749787|DRUG|PRTX-100 at 420 mcg|
48098826|NCT03679546|DRUG|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
48098827|NCT03679546|DRUG|Vedolizumab Injection|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
48098828|NCT03365856|OTHER|observational study|as clinical practice
48098829|NCT06457607|DEVICE|LinearZ|High Intensity Focues Ultrasound
48281092|NCT05127486|DRUG|Placebo|Administered orally.
48281093|NCT05127486|DRUG|Placebo|Administered SC.
48281094|NCT02282761|DRUG|ITI-007|
48281095|NCT02282761|DRUG|Placebo|
48458939|NCT05197062|DRUG|14C-aticaprant|14C-aticaprant will be administered orally as capsule on Day 1.
48458940|NCT02672267|BIOLOGICAL|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
48458941|NCT02672267|OTHER|Placebo|Lactated Ringer's Solution
48458942|NCT05372419|DRUG|Lebrikizumab|Administered SC
48458943|NCT05348616|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease.
48458944|NCT05348616|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
48458945|NCT01449188|DRUG|ondansetron|FDA approved drug used to treat nausea and vomiting
48458946|NCT01449188|DRUG|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
48281096|NCT03210844|PROCEDURE|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
48458947|NCT01449188|OTHER|saline|USP saline IV solution used as placebo for ondansetron IV.
48458948|NCT00509301|DRUG|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
48458949|NCT06411873|DIETARY_SUPPLEMENT|Control Group|Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute load/RSL (27.5 mOsm/100 kcal)
48458950|NCT06411873|DIETARY_SUPPLEMENT|Intervention Group|Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate (13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L), renal solute load/RSL (27.7 mOsm/100 kcal)
48458951|NCT05123443|BIOLOGICAL|Blood sample provided|Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
48458952|NCT05123443|DIAGNOSTIC_TEST|7-T MRI scan|Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
48458953|NCT04220736|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
48458954|NCT02861560|OTHER|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
47934617|NCT03695874|OTHER|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
48281097|NCT03864276|DRUG|inhalation (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
48458955|NCT01051349|BIOLOGICAL|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
48106883|NCT00127179|DRUG|MK0906, finasteride / Duration of Treatment: 48 weeks|
48281098|NCT03864276|DRUG|total intravenous (propofol) anesthesia|Anesthesia is induced and maintained with propofol and sufentanil
48281099|NCT06386458|DEVICE|AThrough radiofrequency transseptal puncture system|Utilizing AThrough radiofrequency transseptal puncture system for left atrial access
48458956|NCT01051349|BIOLOGICAL|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
48458957|NCT01693809|DRUG|Caffeine|
48458958|NCT01327976|DEVICE|vBloc (Active Device)|Active device will deliver vBloc Therapy
48458959|NCT01327976|DEVICE|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
48458960|NCT04964687|PROCEDURE|Liver transplantation|Liver transplantation
48458961|NCT00890864|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
48458962|NCT03212820|PROCEDURE|Drilling at low speed|
48458963|NCT03212820|PROCEDURE|Drilling at conventional or high speed|
48458964|NCT06346535|DIAGNOSTIC_TEST|Cognitive Testing|Digital Cognitive Testing performed at home.
48458965|NCT00279045|DRUG|Rosiglitazone|
48458966|NCT00279045|DRUG|glyburide|
48458967|NCT00279045|DRUG|metformin|
48458968|NCT05055713|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
48458969|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
48458970|NCT05055713|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
48458971|NCT05055713|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
48458972|NCT05055713|PROCEDURE|Endoscopic therapy+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
48458973|NCT05055713|PROCEDURE|Endoscopic therapy+PSE+Somatostatin|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
48458974|NCT04487184|OTHER|Kinesiology taping|Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
48458975|NCT02957331|DRUG|Propranolol|
48458976|NCT04762069|DRUG|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
48458977|NCT04762069|DRUG|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
48458978|NCT02722798|DRUG|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
48458979|NCT05344118|OTHER|Survey|REDCap survey
48458980|NCT03694236|DRUG|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
48458981|NCT06175364|OTHER|Health Professionals in the Field of Orthotics Prosthetics|Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
48458982|NCT00109512|DRUG|NBI-56418 (GnRH antagonist)|
48458983|NCT00109512|DRUG|placebo|
48458984|NCT01978925|OTHER|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
48458985|NCT05139628|DIAGNOSTIC_TEST|microbiological identification of samples (skin and blood samples)|"Samples will be plated on blood culture plates and will be confirmed biochemically.~Complete Bacteriological diagnosis will be done. The TTP of each BC bottle will be recorded"
48458986|NCT04943107|OTHER|no intervention|no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
48458987|NCT04892420|DRUG|Dexamethasone|The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.
48458988|NCT04892420|DRUG|Dexmedetomidine|The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .
47934618|NCT03377088|OTHER|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
48458989|NCT04892420|DRUG|Magnesium sulfate|The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.
47934619|NCT03377088|OTHER|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
47934620|NCT03363425|DRUG|Lidocaine Iv|Lidocaine Iv
47934621|NCT03363425|DRUG|Dexmedetomidine|dexmedetomidine iv
48458990|NCT04892420|DRUG|Bupivacain|The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
47934622|NCT03363425|DRUG|Normal saline|placebo
47934623|NCT01535664|OTHER|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)"
47934624|NCT06492343|OTHER|fMRI based neurofeedback|participants will receive neurofeedback from their brain in order to modify their own brain function
47934625|NCT01888003|DRUG|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
47934626|NCT01888003|DRUG|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at -14 days and -7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb \< 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
48098830|NCT03299387|DRUG|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
48458991|NCT04198090|BEHAVIORAL|SGM Competency Training Program|A validated, two-hour long SGM curriculum created by the Fenway Institute and tailored for oncology
48458992|NCT03972696|RADIATION|Irradiation|BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
47934627|NCT01888003|OTHER|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb \< 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
47934628|NCT01357200|OTHER|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
47934629|NCT00347841|DRUG|Bimatoprost 0.03%, Latanoprost|
47934630|NCT06278909|DEVICE|Trigeminal Nerve Stimulation|Active trigeminal nerve stimulation
48281100|NCT06386458|DEVICE|Traditional mechanical transseptal puncture needle|Utilizing Traditional mechanical transseptal puncture needle for left atrial access
48281101|NCT00006383|DRUG|liposomal vincristine sulfate|
48281102|NCT05162157|DEVICE|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
48281103|NCT03234114|DRUG|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)
48281104|NCT03234114|DRUG|Dual antithrombotc therapy-1|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
48281105|NCT03234114|DRUG|Dual antithrombotc therapy-2|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
48281106|NCT04278131|DRUG|BS01|Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)
48281107|NCT06356740|BIOLOGICAL|Blood sample|"blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum."
48281108|NCT06356740|DRUG|Treatment :Abacavir 600 mg/lamivudine 300 mg|Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
48281109|NCT06356740|OTHER|Lupus Impact Tracker questionnaire|Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
48281110|NCT02792257|DRUG|Dronabinol (Marinol®)|5mg - 10mg daily dose
48281111|NCT02792257|DRUG|Placebo|Daily dose
48281112|NCT06145750|DIAGNOSTIC_TEST|Ability to order FirstLook™|FirstLook™ is a commercially available, validated next generation sequencing assay of plasma cell-free DNA (cfDNA) that analyzes the distribution of cfDNA fragment sizes to indicate the presence of possible lung cancer. FirstLook™ is intended to be used by a qualified healthcare provider and is not a replacement for computed tomography (CT) or low-dose computed tomography (LDCT). FirstLook™ is validated for use in individuals aged 50 or older who either currently or previously smoked cigarettes and accumulated 20 pack-years or more of exposure.
47934631|NCT05661201|DRUG|NEROFE|weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
47934632|NCT05661201|DRUG|Doxorubicin|weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
47934633|NCT05982210|OTHER|Breathing Exercises and Manual Therapy of the Muscle Diaphragm and Ribs Protocol|The intervention consists on applying a protocol based on five different exercises, compound by breathing exercises and manual therapy of the muscle diaphragm and the ribs, applied by a physiotherapist.
47934634|NCT06276985|DEVICE|low intensity pulsed ultrasound and iPRF|iPRF and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
47934635|NCT05988697|DRUG|Combind asprin with Trametinib and Dabrafenib|Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD
47934636|NCT02483052|DEVICE|RejuvenAir|RejuvenAir
47934637|NCT00621803|DRUG|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
47934638|NCT03920384|BEHAVIORAL|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
48281113|NCT06145750|OTHER|Continuing Medical Education for Lung Cancer|Physician practice will receive standard education on lung cancer screening for CME credit.
48281114|NCT05535361|DEVICE|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
48281115|NCT06169124|PROCEDURE|Biospecimen Collection|Undergo archived tissue and blood sample collection
48281116|NCT06169124|PROCEDURE|Chest Radiography|Undergo chest x-ray
48281117|NCT06169124|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
48281118|NCT06169124|DRUG|Darolutamide|Given PO
48281119|NCT06169124|DRUG|Exemestane|Given PO
48281120|NCT06169124|DRUG|Leuprolide Acetate|Given IM
48281121|NCT06169124|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48281122|NCT06169124|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48281123|NCT06078384|DRUG|Pembrolizumab 25 mg/ml|"Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion."
48281124|NCT06078384|DRUG|Paclitaxel injection|Injectable solution for IV administration. Dose of 80 mg/m² weekly.
48458993|NCT03483818|PROCEDURE|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
48623091|NCT02247544|DRUG|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
48623092|NCT04666298|DRUG|Inclisiran sodium|Subcutaneously injected on Day 1, 90 and 270.
48623093|NCT04666298|DRUG|Placebo|Subcutaneously injected on Day 1, 90, and 270.
48623094|NCT01379612|OTHER|Ultrasonic Elastography|Non-invasive
48281125|NCT00550498|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
48281126|NCT01420575|BEHAVIORAL|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
48281127|NCT01420575|BEHAVIORAL|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
48281128|NCT05385562|DRUG|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
48623095|NCT03514602|BEHAVIORAL|Multicomponent behavioral intervention|Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
48281129|NCT05385562|DRUG|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
47934639|NCT03920384|BEHAVIORAL|Active control arm|Standard psychological therapy for psychosis without new therapy components
48281130|NCT03270748|DRUG|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
48281131|NCT02379858|DRUG|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
48281132|NCT02379858|DRUG|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
48281133|NCT04412304|DRUG|Dose of Tinzaparin or Dalteparin|The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.
48281134|NCT03840629|OTHER|No study intervention.|
48281135|NCT02956655|OTHER|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
48458994|NCT04911218|DEVICE|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
48458995|NCT04911218|DEVICE|Conventional 5Fr arterial sheath|Placement of conventional 5Fr arterial sheath for coronary angiography through the distal radial artery (anatomical snuffbox).
48458996|NCT05818345|BEHAVIORAL|Pricing intervention|Participants will be provided with a menu with manipulated prices for products with lower kilocalories
48458997|NCT03166904|DRUG|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
48458998|NCT02387762|DRUG|acalabrutinib|
48458999|NCT02387762|DRUG|Placebo|
48459000|NCT03289260|DRUG|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
48459001|NCT03289260|DRUG|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
48459002|NCT03289260|PROCEDURE|Fulguration|Surgical Excision and Fulguration of condyloma
48459003|NCT02610881|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
48459004|NCT02610881|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
48459005|NCT02610881|BEHAVIORAL|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
48459006|NCT00393276|BIOLOGICAL|Twinrix|Combined hepatitis A and hepatitis B immunization
48459007|NCT00393276|BIOLOGICAL|Decavac|Diphtheria and tetanus toxoid vaccine
48459008|NCT05206838|PROCEDURE|Surgical reconstruction of gluteus medius with Achilles tendon allograft|Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
48459009|NCT03097692|PROCEDURE|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
48459010|NCT03097692|DRUG|Pharmacologic preconditionig|Pharmacologic preconditionig will be attained by sevoflurane anesthesia
48459011|NCT04143607|DRUG|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
47934640|NCT05216601|BIOLOGICAL|MVC-COV1901|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B
47934641|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-15|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
47934642|NCT05216601|BIOLOGICAL|MVC-COV1901(Beta)-25|Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
47934643|NCT01092065|DRUG|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
47934644|NCT01092065|DRUG|Placebo|hard gelatin capsule to be taken bid for six weeks
47934645|NCT02002585|PROCEDURE|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
47934646|NCT04264052|DIAGNOSTIC_TEST|CBE & MRI|"The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used."
47934647|NCT02093026|DRUG|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
48459012|NCT04143607|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
48459013|NCT04143607|DRUG|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
47934648|NCT02093026|DRUG|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
47934649|NCT02093026|DRUG|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
47934650|NCT02093026|DRUG|Folic Acid|Participants will receive folic acid \>= 5 mg/week or equivalent.
47934651|NCT02797054|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
47934652|NCT02797054|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
48459014|NCT04143607|DRUG|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
48459015|NCT06272877|OTHER|Fluidotherapy|Fluidotherapy is a dry environment created by mobilizing solid particles using heated air flow. Fluidotherapy will be applied 20 minutes a day, 5 days a week for 4 weeks.
48459016|NCT06272877|OTHER|conventional rehabilitation program|The conventional rehabilitation program determined before the study will be implemented by a physiotherapist in the hospital for 6 weeks.
48459017|NCT04471116|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|OMNi-BiOTiC® FLORA plus + is a dietary supplement for the treatment of a disturbed vaginal flora (dysbiosis). The product combines probiotic bacterial strains with a special fiber mixture. The product contains the following strains: Lactobacillus crispatus LBV88, Lactobacillus rhamnosus LBV96, Lactobacillus gasseri LBV150N and Lactobacillus jensenii LBV116
48459018|NCT04381871|DIETARY_SUPPLEMENT|Acacia Senegal|Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
48459019|NCT04381871|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
48459020|NCT04654429|DRUG|IV Ondansetron 4mg|IV ondansetron 4mg
48459021|NCT04654429|OTHER|Higher OT temperature range|OT temperature set to 19-22 degree celsius
48459022|NCT04654429|DRUG|Placebo|IV Normal Saline 2cc will be given
48459023|NCT04654429|OTHER|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
48623096|NCT03514602|BEHAVIORAL|Education only control|"The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists."
48623097|NCT02787291|DEVICE|Ellipse VR ICD and Durata/Optisure lead|Non-diagnostic MRI Scan sequence of head and chest
48623098|NCT03006679|DRUG|Meropenem-Vaborbactam|meropenem 2 g and vaborbactam 2 g
48623099|NCT03006679|DRUG|Piperacillin/Tazobactam|piperacillin 4 g and tazobactam 0.5 g
48623100|NCT04853875|DRUG|Tetracycline, Metronidazole, Bismuth subcitrate|52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
48623101|NCT04853875|DRUG|Amoxicillin, Metronidazole, Clarithromycin|52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
48281136|NCT02956655|DRUG|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
47934653|NCT02797054|BEHAVIORAL|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
47934654|NCT01555957|DRUG|intravenous lipid|intravenous given daily for 6 weeks
47934655|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
47934656|NCT01473927|OTHER|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
47934657|NCT00922701|DRUG|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
47934658|NCT02138526|DRUG|pazopanib|pazopanib 800mg OD without food
47934659|NCT02138526|OTHER|continental breakfast|pazopanib 600mg OD with food
47934660|NCT02408432|OTHER|Laboratory Biomarker Analysis|Correlative studies
47934661|NCT02408432|OTHER|Standard of Care|Undergo mesenchymal stem cell infusion
48281137|NCT02956655|OTHER|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
48281138|NCT02956655|BEHAVIORAL|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
48281139|NCT02956655|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
48281140|NCT06656247|OTHER|Online consenting|The design and establishment of an innovative digital tool (a software application) to implement the dynamic consent and allowing interaction among healthcare professionals and patients
48281141|NCT01213056|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
48281142|NCT01501643|DEVICE|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
48281143|NCT01501643|DEVICE|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
48281144|NCT05048290|OTHER|Communication Skills Training|Participate in communication workshops
48281145|NCT05048290|OTHER|Communication Skills Training|Participate in generic communication skills workshops
48281146|NCT05048290|OTHER|Educational Intervention|Develop a video
48281147|NCT05048290|OTHER|Survey Administration|Complete surveys
48281148|NCT01504503|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
48281149|NCT01504503|DRUG|Aricept|Aricept 10 mg Tablets
48281150|NCT00586690|DEVICE|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
48281151|NCT00586690|PROCEDURE|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for \>24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
48281152|NCT04853940|OTHER|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
48281153|NCT05917886|OTHER|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
48281154|NCT00722293|DRUG|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
48281155|NCT00722293|DRUG|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
48459024|NCT00525746|BEHAVIORAL|Interview|Interview lasting about 50 minutes.
48623102|NCT00820092|DRUG|Xerecept 1.0|24 hour infusion
47934662|NCT02408432|DRUG|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion
47934663|NCT03395132|DRUG|Fucicort® Lipid cream|The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
47934664|NCT03395132|DRUG|Fucidin® cream|The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
47934665|NCT03395132|DRUG|Fucicort® Lipid cream vehicle|The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
47934666|NCT03395132|DRUG|betamethasone (Lianbang Beisong®) cream|The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
47934667|NCT02116218|PROCEDURE|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
47934668|NCT02116218|PROCEDURE|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
47934669|NCT00216892|DRUG|Calcipotriol, (calcipotriol + betamethasone)|
47934670|NCT04610697|BEHAVIORAL|Cognitive Remediation|Cognitive Remediation consists of exercises, preferably supported by coaching, aimed at engaging cognitive skills and, as a result, at improving cognition as well as functional and clinical outcomes.
48281156|NCT00722293|DRUG|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
47934671|NCT04610697|BEHAVIORAL|Active Control|Active control condition for cognitive remediation, matched in terms of session modality, number, duration, frequency, and format.
48623103|NCT00820092|DRUG|Xerecept 2.0|24 hour infusion
47934672|NCT05365854|PROCEDURE|Alveolar Recruitment Maneuver (ARM)|"When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order."
47934673|NCT03465423|PROCEDURE|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
47934674|NCT01644370|DRUG|HAART|as per Thai HIV Treatment guidelines
47934675|NCT04381338|OTHER|Pulmonary and Motor Rehabilitation|Pulmonary and Motor Rehabilitation in ICU
47934676|NCT00355277|DRUG|Amitriptyline|
47934677|NCT04541251|DRUG|Camrelizumab + Nab-paclitaxel + Carboplatin|The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
47934678|NCT02257671|DRUG|Oral contraceptive|Neovletta
47934679|NCT03248700|OTHER|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
47934680|NCT05486741|OTHER|Optical cehernce tomography|OCT macula and disc
47934681|NCT05720754|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
47934682|NCT05720754|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
47934683|NCT06282887|OTHER|Music therapy|The intervention has two parts. The first part is an approximately 15-minute music therapy session to induce relaxation and positive memories attached to the relaxing live music provided by a credentialed music therapist. The second part is music listening during the scanning process.
48281157|NCT04597164|OTHER|Artificial liver support system|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
48281158|NCT04372264|DRUG|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb_UK) intravenous (IV) was given 70 patients,
48281159|NCT04372264|DRUG|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
48281160|NCT04372264|DRUG|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
48623104|NCT00820092|DRUG|Xerecept 3.0|24 hour infusion
48281161|NCT02114190|BEHAVIORAL|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
48623105|NCT03876353|OTHER|Floss|All participants will have half of their mouth flossed. Each participant will act as their own control.
48623106|NCT02319382|RADIATION|PET with the tracer 18F-DPA-714|
48623107|NCT02319382|RADIATION|PET with the tracer 11C-PE2I|
48623108|NCT02319382|OTHER|MRI|Magnetic field
48623109|NCT03787407|BEHAVIORAL|stress management and meditation|mindfulness training using mobile application
48623110|NCT05969691|DIAGNOSTIC_TEST|Validation of IDH1 mutations from the radiomics model|During surgery, clinicians will select several typical target sites for puncture based on the preoperative model outputs. After surgery, the acquired tumour tissues will be subjected to histological diagnosis and pathological diagnosis by professional pathologists, and the results will be compared with the model output to verify its accuracy.
48623111|NCT02530840|BEHAVIORAL|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
48098831|NCT03299387|DRUG|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
48281162|NCT02114190|BEHAVIORAL|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
47934684|NCT00739596|DRUG|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
47934685|NCT00739596|DRUG|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
47934686|NCT00374205|DRUG|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
47934687|NCT00374205|DRUG|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
47934688|NCT03346798|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
48281163|NCT06653218|OTHER|No interventions|It is a observational study
48281164|NCT06653218|OTHER|Not have interventions|It is a observational study
48281165|NCT01745003|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
48281166|NCT06228755|BEHAVIORAL|Integrative Medicine Group Visit|Integrative Medicine Group Visit (IMGV) is a 9-week group visit series co-facilitated by a billing primary care provider and a trained co-facilitator (such as a behavioral health provider, mindfulness instructor, or yoga teacher). The IMGV will be delivered virtually over a secure telehealth platform for 2 hours weekly. The IMGV curriculum focuses on principles of mindfulness-based stress reduction, and includes patient education on pain, insomnia, nutrition, yoga, depression, self-massage, and self-acupressure.
48459025|NCT03224143|BEHAVIORAL|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
47934689|NCT03346798|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
47934690|NCT03346798|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
47934691|NCT04157556|OTHER|Yo-Yo Intermittent Recovery Test Level 1|"The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., \& Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... \& Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine \& Science in Sports \& Exercise, 35(4), 697-705."
47934692|NCT04552262|DRUG|BAY2327949|Single dose of 90 mg BAY2327949
47934693|NCT04552262|DRUG|Placebo|Single dose of placebo to BAY 2327949
47934694|NCT02869984|DRUG|Ramosetron|
47934695|NCT03067233|OTHER|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
47934696|NCT01064245|DRUG|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
48623112|NCT02530840|BEHAVIORAL|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
48623113|NCT02530840|BEHAVIORAL|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
48098832|NCT03852433|DRUG|Bulevirtide|Administered via subcutaneous injections
48098833|NCT03852433|DRUG|Peginterferon Alfa-2a (PEG-IFN alfa)|Administered via subcutaneous injections
48623114|NCT02693418|DRUG|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
48623115|NCT02693418|DRUG|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
48623116|NCT02693418|DRUG|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
47934697|NCT01064245|OTHER|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
47934698|NCT04443751|DRUG|SHR-1702|SHR-1702 monotherapy, administered IV
48098834|NCT00477100|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and stool
48098835|NCT00477100|OTHER|Interview|Participate in interview
48098836|NCT00477100|OTHER|Medical Chart Review|Undergo collection of medical data
48098837|NCT00477100|OTHER|Questionnaire Administration|Ancillary Studies
48098838|NCT02410291|OTHER|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
48098839|NCT05566847|OTHER|Physician Education|The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
48459026|NCT03224143|BEHAVIORAL|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
48459027|NCT03087162|DRUG|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
47934699|NCT01639508|DRUG|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
47934700|NCT03473457|BIOLOGICAL|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
48281167|NCT06228755|OTHER|Implementation Strategies|"Package includes:~* Patient strategies will include an orientation session to introduce patients to the IMGV model.~* Provider strategies include training in delivery of IMGV with continuing education credits. Training may be delivered on-line or in-person. Ongoing coaching in the first year of IMGV implementation will also be offered to providers leading IMGV, to increase self-efficacy to deliver the curriculum, and enhance fidelity."
48281168|NCT01816087|OTHER|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
48281169|NCT04190550|DRUG|Cytarabine|Given IV
48281170|NCT04190550|DRUG|Idarubicin Hydrochloride|Given IV
47934701|NCT03096015|BEHAVIORAL|Intensive Comprehensive Aphasia Program|
47934702|NCT00752596|DRUG|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
48459028|NCT00096460|DRUG|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
48459029|NCT00096460|DRUG|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
48459030|NCT00096460|RADIATION|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of \< 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC \> 500/mm3 x 3 days."
48459031|NCT00096460|DRUG|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
48459032|NCT00096460|PROCEDURE|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
48623117|NCT02693418|DRUG|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
48623118|NCT03275922|DRUG|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
47934703|NCT04637828|DRUG|GNS561|study drug
47934704|NCT00733447|DEVICE|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
47934705|NCT06084598|DRUG|BMS-986446|Specified dose on specified days
47934706|NCT06084598|OTHER|Placebo|Specified dose on specified days
47934707|NCT02723318|BEHAVIORAL|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
48623119|NCT03275922|DRUG|ZNS|Zolmitriptan Nasal Spray
48623120|NCT04525092|DEVICE|Online Pre-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
47934708|NCT02723318|BEHAVIORAL|Access to Referrals to Social Services|
47934709|NCT01150474|DRUG|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
48281171|NCT04190550|DRUG|Navtemadlin|Given PO
48098840|NCT05566847|OTHER|Accountable Population Manager outreach|Patients will be referred to an Accountable Population Manager (APM) for proactive outreach, including supporting medication adherence and educational and overall support for T2D management. An APM is a non-physician clinician (for example, a clinical pharmacist) supporting diabetes management.
48281172|NCT03853421|DRUG|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
48281173|NCT03312218|BEHAVIORAL|Spaced educational intervention|A spaced educational intervention will be provided to participants
48459033|NCT00096460|PROCEDURE|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
48459034|NCT00096460|DRUG|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
48459035|NCT00096460|DRUG|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
48459036|NCT02611362|BEHAVIORAL|IMB Gaming Intervention|
48459037|NCT06225245|DEVICE|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
48459038|NCT04935580|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
48459039|NCT03757195|PROCEDURE|Augmentation|combination product
48459040|NCT05444205|BEHAVIORAL|Text4Baby or Bright by Text Referral|Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.
48098841|NCT06442995|DRUG|Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
48459041|NCT05444205|BEHAVIORAL|Nurture Program Warm Referral|Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
48459042|NCT05444205|BEHAVIORAL|Video Interaction Project|The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.
48459043|NCT05444205|BEHAVIORAL|Family Check-UP|"The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being."
48459044|NCT05444205|BEHAVIORAL|Smart Beginnings|Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.
48459045|NCT05444205|BEHAVIORAL|Healthy Families America Warm Referral|As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
48459046|NCT05444205|BEHAVIORAL|Family Center Warm Referral|There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
48098842|NCT06442995|DRUG|Injection of Isotonic saline + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
48098843|NCT00059917|DRUG|polyglutamate camptothecin|
48098844|NCT04820101|DRUG|Dexmedetomidine|administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
48459047|NCT02427919|DRUG|G-CSF|Comparison of the effect of G-CSF use
48623121|NCT04525092|DEVICE|Conventional Hemodialysis|Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
48098845|NCT03460574|BEHAVIORAL|INFORMATION|After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction.
48106884|NCT00127179|DRUG|Comparator: placebo / Duration of Treatment: 48 weeks|
48459048|NCT05591105|DRUG|Control Group|At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.
48459049|NCT05591105|DRUG|Placebo|At the end of surgery, they will continue receiving analgesia according the schedule.
48459050|NCT06339437|OTHER|ERAS Protocol|Ehanced recovery after surgery protocols were applied
48459051|NCT05878015|DRUG|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
48459052|NCT02725580|GENETIC|AT-GTX-501|CLN6 Gene delivered by Self-Complementary AAV9
48459053|NCT04432558|DIAGNOSTIC_TEST|Spielberger's State-Trait Anxiety Inventory|Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.
48459054|NCT04432558|OTHER|Visual analog scale, Ramsay's sedation scale|The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.
48459055|NCT04432558|DRUG|Tramadol, paracetamol, diclofenac sodium|The analgesic consumption of the patients will be recorded
48459056|NCT02840149|DRUG|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
48459057|NCT03304223|DIAGNOSTIC_TEST|[18F]FB-IL2 PET scan|\[18F\]FB-IL2 PET scan procedure
48459058|NCT04121507|DRUG|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
48459059|NCT04121507|PROCEDURE|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
48459060|NCT04121507|DIAGNOSTIC_TEST|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
48459061|NCT04121507|DIAGNOSTIC_TEST|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
48459062|NCT05770011|DEVICE|intraoral scanner of nonsplinted scan bodies|scanning of non splinted scan bodies
48459063|NCT05770011|DEVICE|impression material|conventional recording
48459064|NCT05770011|DEVICE|intraoral scanner of splinted scan bodies|scanning of splinted scan bodies
48459065|NCT00999687|DRUG|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
48459066|NCT00999687|OTHER|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
48459067|NCT00275249|DRUG|levorphanol|
48459068|NCT05576831|PROCEDURE|Re-excision|Re-excise (one take back only) Excise scar aiming for 1-2cm margin
48459069|NCT04434716|DEVICE|Feasibility of wearing a Readiband to monitor Sleep and Fatigue|On day one of the study participants will complete a demographic survey. On day one, every seventh day and at the end of the study each participant will complete all the scales; The Minnesota Living with Heart Failure Questionnaire (MLHFQ) and Self-Care of Heart Failure Index will be completed on day one and day 60. At the end of the intervention an Interview will be conducted to assess participants experiences using the Readiband: On a scale of 0-10, how would you rate your digital literacy? 2) Why that number? 3) Tell me about a day using the readiband? 4) Were there any challenges to wearing the band, forgetting to wear it, level of comfort wearing the band? Anything else etc..? 5) How did the digital tools enhance your health? 6) Did the use of digital tools cause you to take a proactive approach rather than a reactive approach to your health? 7) As I use the readiband in a next study, what suggestions do you have for me?
48459070|NCT02054715|BEHAVIORAL|print educational intervention|print educational intervention
48459071|NCT02054715|BEHAVIORAL|multimedia psychoeducational intervention|multimedia psychoeducational intervention
48459072|NCT05250960|DEVICE|SCD|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
48459073|NCT03669861|DRUG|Abatacept|Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
48459074|NCT04525027|DIAGNOSTIC_TEST|intra-abdominal pressure in severe acute pancreatitis|daily intra abdominal pressures in patients admitted to ICU will be measured and noted for intial 5 days and followed up until end outcome
48459075|NCT05689541|OTHER|Mobile app intervention|"A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes."
48459076|NCT00498264|BEHAVIORAL|walking program, resistance muscular exercise|
48459077|NCT00935805|DRUG|Metformin|850 mg TID
48459078|NCT00935805|DRUG|Glybenclamide|10 mg BID
48459079|NCT00935805|DRUG|NPH insulin|Variable SC dose
48459080|NCT00935805|DRUG|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
48098846|NCT03460574|BEHAVIORAL|SALIENCE|After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants.
48459081|NCT00935805|DRUG|Propranolol|40 mg BID
48459082|NCT00935805|DRUG|Captopril|50 mg TID
48459083|NCT00935805|DRUG|Amlodipine|10 mg QD
48459084|NCT05462548|DRUG|Luspatercept Injectable Product|1-1.25mg/kg every 3 weeks subcutaneous injection
48459085|NCT05203835|DRUG|Acebilustat|By mouth, once a day, 100 mg capsule
48459086|NCT05203835|DRUG|Placebo|Placebo to match acebilustat by mouth, once a day
48459087|NCT02179190|DEVICE|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
48459088|NCT00509990|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
48106885|NCT01569919|BIOLOGICAL|TroVax®|Dose of 1 x 10\^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
48106886|NCT01569919|DRUG|Pemetrexed|500 mg/m\^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
48459089|NCT04235660|RADIATION|Yttrium-90 Radiation Segmentectomy|This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
48459090|NCT04235660|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
48459091|NCT03480880|DEVICE|Bispectral Index|Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
47934710|NCT01150474|DRUG|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
47934711|NCT03449238|DRUG|Pembrolizumab|Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
47934712|NCT01097876|DRUG|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
47934713|NCT01097876|DRUG|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
47934714|NCT00300079|DRUG|brinzolamide 1.0%|
47934715|NCT00356837|PROCEDURE|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
48459092|NCT00556673|DRUG|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
48459093|NCT00556673|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
48459094|NCT00556673|DRUG|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
48459095|NCT03153462|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
48459096|NCT02278302|DRUG|Aggrenox®|
48459097|NCT02278302|DRUG|Placebo|
48459098|NCT02278302|OTHER|Ethanol|
48459099|NCT00223093|DRUG|TAIZ|
48459100|NCT02224144|DRUG|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
48459101|NCT02224144|DRUG|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
48459102|NCT02224144|DRUG|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
48459103|NCT04999423|DEVICE|LVIS EVO and HydroCoil Embolic System|Stent assisted Coiling
48459104|NCT05128058|DRUG|Ritlecitinib 50 mg|50 mg single dose
48459105|NCT05128058|DRUG|Ritlecitinib 200 mg|200 mg single dose
48459106|NCT00989716|DRUG|Transdermal glyceryl trinitrate patch|5mg per day
48459107|NCT00989716|DRUG|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
47934716|NCT03004248|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular Injection
47934717|NCT00527670|PROCEDURE|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
47934718|NCT00527670|PROCEDURE|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
47934719|NCT01513369|DRUG|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
47934720|NCT01513369|DRUG|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
47934721|NCT00140543|DRUG|sirolimus versus mycophenolate mofetil|
47934722|NCT00141570|DRUG|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
47934723|NCT04240678|OTHER|Electronic HBV Alert|Electronic HBV Alert deployed in electronic medical charts of at risk patients
47934724|NCT02005328|DEVICE|Tested product : DC161-DP0291|Application of product in the mouth twice daily
47934725|NCT02005328|DEVICE|Tested product : DC161-DP0292|Application of product in the mouth twice daily
47934726|NCT02005328|DEVICE|Tested product : DC161-DP0293|Application of product in the mouth twice daily
47934727|NCT02005328|DEVICE|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
47934728|NCT02780323|DRUG|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
47934729|NCT02780323|DRUG|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
47934730|NCT02780323|DRUG|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
47934731|NCT02780323|DRUG|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
47934732|NCT01329835|BEHAVIORAL|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
47934733|NCT01329835|OTHER|brochure|brochure given after randomization
47934734|NCT01499862|DEVICE|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
48098847|NCT03460574|BEHAVIORAL|ATTENTION|Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback.
47934735|NCT00005779|DRUG|Interleukin-12|
47934736|NCT00005779|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
48459108|NCT01975116|DRUG|azurin-derived cell-penetrating peptide p28|Given IV
48459109|NCT06170762|OTHER|Pulp capping|Pulp capping material for immature permanent teeth in case of carious or traumatic pulp expures
48459110|NCT06170762|DRUG|Sodiumhexametaphosphate|Sodiumhexametaphosphate
48459111|NCT06170762|OTHER|MTA|MTA
48459112|NCT00284791|DRUG|Lamotrigine (drug)|
48459113|NCT00284791|DRUG|Fluoxetine (drug)|
48459114|NCT00284791|DRUG|sertraline (drug)|
48459115|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
48459116|NCT02093728|DRUG|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
47934737|NCT00464243|DRUG|volinanserin|oral administration
47934738|NCT00464243|DRUG|placebo|oral administration
47934739|NCT05506137|DRUG|Pilocarpine|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
47934740|NCT05506137|OTHER|Placebo|study whether topical pilocarpine drops induce a clinically significant improvement in xerostomia
48098848|NCT03460574|BEHAVIORAL|CONTROL|This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm.
48098849|NCT05781269|OTHER|VLCKD|VLCKD diet treatment with medical food
48098850|NCT05781269|OTHER|r-MedDiet|Mediterranean diet treatment
48459117|NCT02093728|DRUG|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
48459118|NCT02093728|DRUG|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
48459119|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
48459120|NCT02093728|DRUG|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
48459121|NCT02093728|DRUG|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
48623122|NCT04525092|DEVICE|Online Post-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
47934741|NCT01465191|DRUG|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
47934742|NCT05939011|BEHAVIORAL|Well-formulated Ketogenic Diet|1:1 ketogenic diet that is focused on intake of high-quality fats (nuts/seeds, fatty fish, avocado) and reduction in processed food.
47934743|NCT02314143|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
47934744|NCT02314143|DRUG|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
48459122|NCT02093728|DRUG|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
48459123|NCT04820322|OTHER|Fibersym|RS4-type resistant modified wheat starch
48459124|NCT04820322|OTHER|Control cookie|control cookie
48623123|NCT01680263|DEVICE|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
48623124|NCT01680263|PROCEDURE|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
47934745|NCT03325660|OTHER|whole body vibration|pelvic floor exercises
47934746|NCT04615455|DRUG|ASCs|ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
47934747|NCT04615455|DRUG|Cryostor CS10|CryoStor® CS10 freeze medium
47934748|NCT01891526|DRUG|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
48098851|NCT04549051|DEVICE|Tenex|Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
48098852|NCT04549051|DRUG|Local anesthetic|Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
48098853|NCT00587132|DRUG|Synthetic Human Secretin|0.2mcg/kg one time dose.
48098854|NCT04097886|OTHER|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
48098855|NCT04097886|OTHER|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
48106887|NCT01569919|DRUG|Cisplatin|75mg/m\^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
48106888|NCT01569919|DIETARY_SUPPLEMENT|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
48459125|NCT02315963|OTHER|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
48478782|NCT06612229|PROCEDURE|Conservative surgical treatment of liver echinococcosis, verification of occult biliary fistulas and their elimination by weaving and using medical cyanoacrylate glue|In conservative surgical operations for liver echinococcosis, the biliary fistula is identified, onto which a U-shaped suture is applied, after which medical cyanoacrylate glue is applied between the suture stitches to the fibrous capsule in the fistula area and the suture threads are tied.
47934749|NCT03621345|PROCEDURE|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
47934750|NCT03621345|OTHER|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
47934751|NCT05776602|DIAGNOSTIC_TEST|Fast MRI (Neuromix)|Diagnostic performance, correlation, agreement
47934752|NCT04466345|BIOLOGICAL|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
47934753|NCT04466345|BIOLOGICAL|Placebo|Semaglutide placebo capsules
48478783|NCT02598895|DRUG|Carboplatin|Given IV
47934754|NCT02195687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
48478784|NCT02598895|DRUG|Docetaxel|Given IV
47934755|NCT02195687|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
47934756|NCT01101191|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
47934757|NCT01101191|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
47934758|NCT04676971|DRUG|hzVSF-v13|Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
47934759|NCT04676971|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
47934760|NCT01211587|DRUG|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
47934761|NCT01211587|DRUG|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
47934762|NCT00641927|DRUG|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
47934763|NCT00641927|DRUG|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
48106889|NCT01569919|DIETARY_SUPPLEMENT|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
47934764|NCT02981459|DRUG|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
47934765|NCT03831685|OTHER|Blood sample|Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.
47934766|NCT05088239|DRUG|prophylactic antibiotics duration|Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
47934767|NCT03631355|DRUG|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
47934768|NCT04609111|DRUG|No aspirin|1-month prasugrel monotherapy followed by clopidogrel monotherapy
47934769|NCT04609111|DRUG|1-month DAPT|1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
47934770|NCT02967380|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
47934771|NCT02967380|DRUG|Gadobenate Dimeglumine|Given IV
47934772|NCT02967380|DRUG|Gadobutrol|Given IV
47934773|NCT02967380|RADIATION|Gadopentetate Dimeglumine|Given IV
47934774|NCT03280927|DRUG|Jublia®|Jublia® topical solution
47934775|NCT00316550|DRUG|AV608|
47934776|NCT05084495|DIAGNOSTIC_TEST|Global peak atrial longitudinal strain and ECG|During the follow-up period the patient will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected
47934777|NCT05185843|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
48106890|NCT01569919|DRUG|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
48106891|NCT06533527|DRUG|Semaglutide|GLP1 medication
48106892|NCT06533527|DRUG|Tirzepatide|GLP1/GIP medication
48106893|NCT06533527|DRUG|Liraglutide|GLP1 medication
48106894|NCT06533527|DRUG|Dulaglutide|GLP1 Medication
48106895|NCT03101618|OTHER|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
48106896|NCT03101618|OTHER|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
48106897|NCT05323838|BEHAVIORAL|Subjective quality of live|The groups fill out scientifically validated questionnaires to know the differences in perceived stress, anxiety, quality of life, depression, quality of sleep, pain, fatigue, and impact of the disease on daily life.
48106898|NCT05323838|PROCEDURE|Blood extraction|Blood collection by qualified personnel.
48106899|NCT05323838|BEHAVIORAL|Accelerometry|To know the objective differences between physical activity/sedentary lifestyle, caloric expenditure and quality of sleep, we used the accelerometry technique
48106900|NCT05323838|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
47934778|NCT03722290|DRUG|Metformin|Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
47934779|NCT03551080|BIOLOGICAL|Lipopolysaccharide|Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
48459126|NCT05132426|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"Myofascial release of the thoracic inlet is a treatment involving gentle pressure applied to shoulders and neck to move the tissue in different directions.~Pectoral traction will have the doctor gently grasp and slowly pull the armpit area with a slow pulling force applied towards the shoulders.~Diaphragm release with MFR consists of the doctor touching below the ribs on each side and gently applying pressure to move the tissue from side to side.~Fascial release of the breast will have the doctor encircling the breast with their hands and inducing anterior traction. The doctor then induces motion in all directions. The doctor will then locate the affected spot and use a direct stripping motion from the base of the breast toward the areola until the restriction is released.~Thoracic pump has the doctor placing their hands over the chest wall on each side and applying pressure and releasing pressure several times to generate a pumping action of about 100 times per minute."
48459127|NCT06165419|RADIATION|SBRT to the spine|Stereotactic body radiation therapy (SBRT) administered to spine metastases
48623125|NCT05455398|PROCEDURE|Surgical treatment of round window niche enlargement via round window for inner ear drug delivery|The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
48623126|NCT05455398|PROCEDURE|Drum chamber drug injection|Injection of drugs into the tympanic chamber through the tympanic membrane
47934780|NCT03551080|BIOLOGICAL|Placebo|Saline administered intravenously
47934781|NCT02732522|DRUG|Sublingual misoprostol|
47934782|NCT02732522|DRUG|Vaginal misoprostol|
47934783|NCT01562067|DEVICE|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
47934784|NCT03402048|DRUG|Carboplatin|
47934785|NCT03402048|DRUG|Gemcitabine|
47934786|NCT03402048|DRUG|Pemetrexed|
47934787|NCT03402048|DRUG|Docetaxel|
47934788|NCT03402048|DRUG|Vinorelbine|
47934789|NCT01990144|DRUG|Bendamustine+Rituximab|"Patients will receive :~* Rituximab 375 mg/m2 intravenously on day 1\*~* Bendamustine 90 mg/m2 intravenously on days 2 and 3\*\* Treatment will be administered on a 28-day cycle basis.~  * Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~    * After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
47934790|NCT02906462|OTHER|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
48281174|NCT05918887|DEVICE|NJOY ACE commercial e-cigarette|"The NJOY ACE is the commercial version of the Standardized Research E-Cigarette (SREC), which was developed by NIDA with NJOY for research purposes.~Nicotine pods:~* Sealed, pre-filled, non-refillable~* 1.9 mL e-liquid with 5% w/w nicotine~* Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~* Volume of liquid per pod 1.9 mL~* Active (nicotine USP 5% wt/wt)~* Propylene Glycol USP \& Vegetable Glycerin USP - PG/VG Ratio 0.77~* Lactic Acid USP~Battery characteristics:~* USB Rechargeable~* Storage Capacity \~ 400 mAh~* Approx 200 (3s) puffs / charge~* 300 charge cycles to \> 80% initial capacity~* Time to full charge 75 - 85 min~* Voltage / Temperature settings not user adjustable"
48281175|NCT01926587|DRUG|oral rigosertib|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
48459128|NCT01968551|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
48623127|NCT02772588|DRUG|ARN-509|
48623128|NCT02772588|DRUG|Abiraterone|
48623129|NCT02772588|DRUG|Leuprolide|
48623130|NCT02772588|RADIATION|stereotactic, ultra-fractionated radiotherapy|
48623131|NCT05559541|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
48623132|NCT05559541|DRUG|AK104|AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
47934791|NCT02906462|OTHER|Usual practices|the centres applies their usual practices
47934792|NCT02392845|DRUG|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
47934793|NCT02948101|BIOLOGICAL|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
47934794|NCT02948101|DRUG|Cyclophosphamide|Given PO
47934795|NCT02948101|OTHER|Laboratory Biomarker Analysis|Correlative studies
47934796|NCT01439347|DRUG|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
47934797|NCT01439347|DRUG|Vincristine Sulfate Injection (VSI)|1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
47934798|NCT03783702|DRUG|OxyCODONE 5 Mg (milligram) Oral Tablet|Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
47934799|NCT03783702|DRUG|Ibuprofen 600 Mg (milligram) Oral Tablet|Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
47934800|NCT03783702|DRUG|Acetaminophen 650 MG (milligram) Oral Tablet|All patients will receive acetaminophen as the first-line analgesic.
47934801|NCT02670213|DRUG|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
47934802|NCT00649311|DRUG|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
47934803|NCT00649311|DRUG|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
47934804|NCT01915927|DRUG|MSC-AFP|
48459129|NCT01968551|DRUG|DRV|800 mg tablet administered orally once daily
48459130|NCT01968551|DRUG|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
48459131|NCT05319054|DEVICE|Sacral NeuroModulation|Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.
48459132|NCT05319054|DEVICE|Trans-Anal Irrigation|Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.
48459133|NCT05319054|OTHER|Optimised Conservative Management|Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
48459134|NCT00171145|DRUG|Darifenacin|Darifenacin 15 mg tablets once daily
48459135|NCT00171145|DRUG|Placebo|Placebo tablets once daily
48459136|NCT06627348|DEVICE|Hilotherm ChemoCare|Hilotherapy
48459137|NCT04463108|OTHER|No Intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
48459138|NCT04386122|DRUG|FABALOFEN 60|Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
48459139|NCT04386122|DRUG|JAPROLOX TABLET|Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
48459140|NCT04289805|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
48459141|NCT04289805|OTHER|standard-stimulated cohort|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
48459142|NCT03369132|DEVICE|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
48459143|NCT03369132|DEVICE|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
48459144|NCT01214590|DEVICE|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
48459145|NCT02741895|BEHAVIORAL|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
48459146|NCT02888964|DRUG|Add-on therapy|Pioglitazone therapy
48459147|NCT03717701|DRUG|metformin|Patients will take metformin single dose of 1000 mg orally once a day
48106901|NCT06553521|OTHER|MyHEARTSMAP Youth Self-assessment Tool (At Admission)|MyHEARTSMAP is a validated self-assessment tool for pediatric populations, demonstrating high sensitivity and specificity for identifying psychosocial concerns. Adapted from HEARTSMAP, it allows self- and proxy-reporting across 10 well-being domains, providing personalized recommendations. Currently, the clinician-reported HEARTSMAP is the standard of care at BC Children's Hospital ED for the initial assessment of youth with primary psychiatric concerns
48459148|NCT03717701|DRUG|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
48623133|NCT04007900|BEHAVIORAL|Positive Affect Treatment|PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
47934805|NCT01987947|DRUG|Placebo|Two administrations by subcutaneous injection
47934806|NCT01987947|DRUG|Quilizumab|Two administrations by subcutaneous injection
48459149|NCT03717701|DRUG|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
48459150|NCT03587129|DRUG|Apatinib|An anti-tumor Targeted drug
48459151|NCT02699762|OTHER|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
48459152|NCT04005638|BIOLOGICAL|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
48459153|NCT04005638|BIOLOGICAL|urine sample|12 ml
48459154|NCT04968925|DEVICE|ACUVUE Oasys 1-Day|TEST
47934807|NCT00332371|DEVICE|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.~It consists of:~1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~2. a hemofilter (polyethersulfone 1,4 m2)~3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
47934808|NCT02318576|OTHER|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
48106902|NCT05561803|RADIATION|Photobiomodulation Therapy|Focal low-level laser therapy, Red Laser (wavelength 633 nm to 685 nm), or Infrared Laser Laser (wavelength 780 nm to 830 nm), with a low-intensity laser equipment of 100 mW and a cross-sectional area of the device beam of 0.0434 cm². The parameters are 1 to 3 J per point, with equidistant points of 1.5 to 2 cm, covering the entire length of the open lesion. Therapy is carried out every 48 hours until the total wound healing, regardless of the number of sessions required.
48459155|NCT04968925|DEVICE|Precision 1|CONTROL
48459156|NCT04435782|DRUG|JNJ-67896049|Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
48459157|NCT02202057|OTHER|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
48459158|NCT02202057|OTHER|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
48459159|NCT05946239|OTHER|Manage My Pain App|This digital application helps patients measure, track, and manage chronic pain, functionality, and medication use. MMP can also be used to share patient pain experiences with their circle of care via reports and offers educational resources for patients.
48623134|NCT03329001|DRUG|Niraparib Tablet|Niraparib tablet formulation
48623135|NCT03329001|DRUG|Niraparib Capsule|Niraparib capsule formulation
48623136|NCT00805532|BEHAVIORAL|Behavioral Activation treatment|Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
48623137|NCT00805532|OTHER|Treatment as Usual|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
48623138|NCT01171573|PROCEDURE|Venepuncture|Venepuncture - Taking blood
48623139|NCT02069184|DRUG|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
48623140|NCT02069184|OTHER|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
48623141|NCT00866320|DRUG|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
48623142|NCT02504164|DRUG|midazolam 0.02mg/kg|
48623143|NCT02504164|DRUG|No premedication|No premedication before sedation for endoscopic submucosal dissection
48623144|NCT02281877|PROCEDURE|Neuromuscular electrical stimulation (NMES)|5x/week, 2x/day, for 45 minutes/session
48106903|NCT00003435|BIOLOGICAL|anti-thymocyte globulin|
48459160|NCT04516460|DEVICE|Interventional arm: endoscopic resection plus PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to prevent bleeding after endoscopic resection of colorectal neoplastic lesions
48459161|NCT02761915|OTHER|Leukapheresis|
48459162|NCT02761915|DRUG|Cyclophosphamide|
48623145|NCT02281877|BEHAVIORAL|Standard Rehabilitation Protocol|Standard physical therapy after TKA
48623146|NCT00782093|DRUG|volociximab|volociximab intravitreal injection
48623147|NCT02657941|BEHAVIORAL|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
48459163|NCT02761915|DRUG|Fludarabine|
48459164|NCT02761915|GENETIC|1RG-CART|
48459165|NCT04196062|DEVICE|EndoMASTER EASE Robotic system for ESD|EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
48478785|NCT02598895|OTHER|Laboratory Biomarker Analysis|Correlative studies
48478786|NCT05686759|BIOLOGICAL|Undiluted I.V.-Hepabig inj(GC5103)|undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
48459166|NCT03183622|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
48459167|NCT03486496|DRUG|gefitinib|Patients will be treated with gefitinib, 250 mg p.o., daily
48459168|NCT03486496|DRUG|Berberine|Patients will be treated with Berberine, 50 mg p.o., tid
48459169|NCT00860262|DRUG|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
48459170|NCT00860262|DRUG|telmisartan|telmisartan 80mg for the 8w, no titration required
48459171|NCT00860262|DRUG|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
48459172|NCT05168787|DRUG|sacubitril/valsartan|Sacubitril belongs to a class of drugs called neprilysin inhibitors and valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). They work by relaxing blood vessels so that blood can flow more easily, which makes it easier for your heart to pump blood to your body.
48459173|NCT02440997|OTHER|aromatherapy|
48098856|NCT05460663|BEHAVIORAL|Stress Management and Resilience Training (SMART)|The Stress Management and Resilience Training (SMART) program was developed by Dr. Amit Sood. SMART focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. The SMART program incorporates practices that focus on six individual factors that have been found to promote individual-level resilience: positive coping, positive affect, positive thinking, realism, behavioral control, and altruism. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) and in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks.
48098857|NCT01594502|DRUG|Dutasteride|0.5 mg daily
48459174|NCT02440997|OTHER|foot bath|
48459175|NCT02355847|OTHER|Lectures|Lectures
48459176|NCT03641001|BEHAVIORAL|Child feeding counselling, food voucher, micronutrient powder, WASH|Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
48623148|NCT02657941|BEHAVIORAL|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
48623149|NCT05246748|OTHER|Human Caring Theory based Education|The intervention group was given a breastfeeding education program based on the HCT for six face to face sessionconducted in parallel with asynchronous distance education sessions in prenatal period and continued with web based sessions and telephone support in postnatal period.
48623150|NCT05246748|OTHER|Standard Education|The control group received solely standard education program for one sessions in prenatal period.
48623151|NCT00979511|OTHER|milk and exercise|"* milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise"
47934809|NCT04572516|DRUG|BTX A Topical|In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
48098858|NCT01594502|DRUG|Placebo|Placebo Comparator
48459177|NCT05016427|BIOLOGICAL|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
48098859|NCT04881799|DRUG|Phentermine/Topiramate (Qsymia)|Maximum dose of 15 mg/92 mg orally once daily in the morning. The dose will be titrated to this level (described earlier).
48098860|NCT04881799|DRUG|Placebo|Daily injection
48098861|NCT06392932|DEVICE|QDOT Micro ablation catheter|QDOT Micro ablation catheter
48459178|NCT04146090|OTHER|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
48459179|NCT04146090|OTHER|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
48459180|NCT00178711|DEVICE|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
48459181|NCT04738864|DIAGNOSTIC_TEST|ultrasound|extracranial and intracranial ultrasound assessment
48459182|NCT06159647|BEHAVIORAL|Mouth cancer warning|Participants will view messages about the risk of mouth cancer from alcohol consumption.
48459183|NCT06159647|BEHAVIORAL|Throat cancer warning|Participants will view messages about the risk of throat cancer from alcohol consumption.
48459184|NCT06159647|BEHAVIORAL|Voice box (larynx) warning|Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
48459185|NCT06159647|BEHAVIORAL|Esophagus cancer warning|Participants will view messages about the risk of esophagus cancer from alcohol consumption.
48459186|NCT06159647|BEHAVIORAL|Liver cancer warning|Participants will view messages about the risk of liver cancer from alcohol consumption.
48459187|NCT06159647|BEHAVIORAL|Colon and rectum cancer warning|Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.
48459188|NCT06159647|BEHAVIORAL|Breast cancer|Participants will view messages about the risk of breast cancer from alcohol consumption.
48106904|NCT00003435|DRUG|melphalan|
48459189|NCT06159647|BEHAVIORAL|Cancer (generic, not site-specific)|Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
48459190|NCT06159647|BEHAVIORAL|Addiction and neurological changes|Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
48459191|NCT06159647|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
48459192|NCT06159647|BEHAVIORAL|Liver damage|Participants will view messages about the risk of liver damage from alcohol consumption.
48459193|NCT06159647|BEHAVIORAL|Harm to fetus|Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
48459194|NCT06159647|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
48459195|NCT06159647|BEHAVIORAL|Impaired sleep|Participants will view messages about the risk of impaired sleep from alcohol consumption.
48459196|NCT06159647|BEHAVIORAL|Drinking guidelines|Participants will view messages about guidelines for alcohol consumption.
48459197|NCT06159647|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
48459198|NCT06159647|BEHAVIORAL|Road injuries|Participants will view messages about the risk of road injuries from alcohol consumption.
48459199|NCT05485064|DRUG|fentanyl|The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
48459200|NCT05485064|PROCEDURE|eletroacupuncture(transcutaneous electrical acupuncture point stimulation )|The investigator 1 use electroacupunture(transcutaneous electrical acupuncture point stimulation )to coordinate with remimazolam
48459201|NCT05485064|DRUG|placebo needle|The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
48459202|NCT05485064|DRUG|remimazolam|The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
48459203|NCT05714293|RADIATION|CT scan with contrast medium|Multi-detector CT scan (if possible with prospective-ECG gated sequential scan) with contrast medium injection of nonionic contrast agent. All CT datasets will be analysed for the qualitative and quantitative assessment of the aortic root. The coronary height will be assessed at baseline in relation to the aortic annulus and in relation to the stent of the bioprostheses after aortic valve replacement.
48459204|NCT00174421|DRUG|Treatment with Genotropin in different dosages|
48459205|NCT05020444|DRUG|TriPRIL CAR T Cells|Intravenous infusion
48459206|NCT05020444|DRUG|Cyclophosphamide|Intravenous infusion
48459207|NCT05020444|DRUG|Fludarabine|Intravenous infusion
48459208|NCT03051945|DRUG|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
48459209|NCT03051945|OTHER|Normal saline|Placebo
48459210|NCT02940444|DRUG|Heparin|
48459211|NCT06626503|DRUG|Methadone based ERAS|Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision and 0.05 mg at the end of surgery) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
48459212|NCT06626503|DRUG|SOC non-methadone based group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
48459213|NCT03946787|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
48459214|NCT03946787|OTHER|Treatment as Usual|TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
48459215|NCT03207152|BIOLOGICAL|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
48459216|NCT00937664|DRUG|AZD7762|solution, intravenous, weekly
48459217|NCT00937664|DRUG|gemcitabine|intravenous, weekly
47934810|NCT04572516|DRUG|BTX A Injection|In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
48459218|NCT03621046|DRUG|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
48459219|NCT03621046|OTHER|Placebo|Placebo
48459220|NCT05826301|OTHER|Percutaneous neuromodulation in tibial nerve|The procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.
48623152|NCT01338389|DIETARY_SUPPLEMENT|CITICOLINE|"Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years"
48623153|NCT01338389|DIETARY_SUPPLEMENT|PLACEBO|"Oral administration of placebo:~Form: Powder for solution duration: 5 years"
47934811|NCT00844168|DRUG|sorafenib tosylate|Given orally
47934812|NCT00844168|OTHER|laboratory biomarker analysis|Correlative studies
47934813|NCT05776797|PROCEDURE|Atrioventricular junction ablation in patients with cardiac resynchronization therapy (CRT)|Ablation of the atrioventricular (AV) node is a procedure used to disrupt or break the electrical connection between the upper heart chambers (the atria) and the lower heart chambers (the ventricles).
48459221|NCT05826301|OTHER|Percutaneous electrolysis|"The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per weeK"
48459222|NCT04758208|DIAGNOSTIC_TEST|Hematology Parameters|Measurement of hematology parameters on BC-6800Plus
48459223|NCT00470379|DRUG|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
48459224|NCT05291195|DEVICE|Laser-device group|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s."
48623154|NCT06522802|DIAGNOSTIC_TEST|balance tests, reaction time evaluation|Only 3 tests were applied to participants
47934814|NCT05776797|DRUG|Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)|Optimal medication therapy according to the prescription of the physician.
47934815|NCT00559182|DRUG|Comparator: MK-8033|"MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed."
47934816|NCT00559182|DRUG|Comparator: MK-8033 +/- omeprazole|"Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended."
47934817|NCT04720261|DRUG|Caplacizumab|Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
47934818|NCT00950261|RADIATION|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
47934819|NCT06012643|OTHER|The purpose of this systematic review of case reports and case series was to evaluate the spectrum of subperiosteal implants for severely atrophied jaws using digital technology.|An electronic and manual search was conducted in the PubMed, Scopus, and Google Scholar databases. Publications of case reports and series written in English without data restrictions
47934820|NCT01124630|DRUG|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
47934821|NCT01124630|DRUG|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
47934822|NCT05451342|DIAGNOSTIC_TEST|Integrated Transcriptomics, Metabolomics, and Lipidomics Profiling|Blood samples and BALD samples will be collected for further integrated transcriptomics, metabolomics, lipidomics analysis, and exosome extraction.
47934823|NCT05151627|PROCEDURE|KINESIO TAPING|Kinesio taping The patient is in a supine position with full knee flexion. Prior to application, the skin surface was cleaned. This technique involved the use of two Y-cut strips and two I-cut strips.
47934824|NCT05151627|DEVICE|CONVENTIONAL PHYSICAL THERAPY|"Transcutaneous Electrical Nerve Stimulation TENS device settings, such as the frequency of 32-50 Hz, pulse width of 80 ms, and symmetrical biphasic waveform. The surface electrodes were placed on the medial and lateral superior borders of the patella, as well as the medial and lateral inferior borders of the patella.~Exercise therapy program The total duration of each exercise session was about 50 minutes, including warm-up-10 minutes, resistance exercise-20 minutes, balance and stability exercise-10 minutes, lower-limb stretching exercise-5 minutes, and cool-down exercise-5 minutes. The same assigned physical therapist supervised all of the sessions."
47934825|NCT03201627|DRUG|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
48098862|NCT06392932|DEVICE|ST SF ablation catheter|ST SF ablation catheter
47934826|NCT00003959|BIOLOGICAL|ras peptide cancer vaccine|
48281176|NCT01926587|DRUG|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
48281177|NCT03603743|BEHAVIORAL|exercise training in heart failure with HIIT|to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
47934827|NCT00003959|BIOLOGICAL|sargramostim|
47934828|NCT03445182|PROCEDURE|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
48098863|NCT00220935|DEVICE|Orthotrac Pneumatic Vest|
48098864|NCT01888406|BEHAVIORAL|Guided Self-Help|
48098865|NCT01888406|BEHAVIORAL|Pure Self-Help|
48098866|NCT02703155|DEVICE|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
48098867|NCT04859764|DEVICE|Reparel knee sleeve|Unlabelled thermo-active knee sleeve that improves bloodflow to knee and decreased pain
48098868|NCT04859764|DRUG|Corticosteroid injection|intraarticular knee injection of betamethasone and bupivacaine 0.5% (dose is determined by joint size)
48098869|NCT04859764|DEVICE|Placebo knee sleeve|unlabeled compression knee sleeve
48098870|NCT06631040|BIOLOGICAL|anti CD19 CAR NK cells|Ten eligible patients with relapsed Acute Lymphoblastic Leukemia will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of anti-CD19 CAR NK cells with close monitoring using one of the following dose levels: • Dose Level 1: 1×10\^7/Kg • Dose Level 2: 5×10\^7/Kg • Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow International Lymphoma Party (LWP) Group guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
48478787|NCT05686759|BIOLOGICAL|Diluted I.V.-Hepabig inj(GC5103)|Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
48098873|NCT00279058|PROCEDURE|Immunotherapy treatment for melanoma|
48281178|NCT03984409|DIETARY_SUPPLEMENT|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
48281179|NCT01725165|OTHER|Clinical Observation|Undergo clinical observation
48281180|NCT01725165|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48281181|NCT01725165|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48459225|NCT05291195|DRUG|Essential Oil|"After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)"
48459226|NCT05291195|DRUG|Sodium hypochlorite group|Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
47934829|NCT03445182|DEVICE|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
48459227|NCT04892147|BEHAVIORAL|Mobility-Oriented Behavioral Activation|12-weeks of mobility-oriented behavioral activation group
48459228|NCT02687958|DRUG|Everolimus|Maintenance therapy
48098874|NCT05095623|OTHER|Natural History Observation|This is a natural history study.
48459229|NCT03252990|DIAGNOSTIC_TEST|PET-MRI|Additional 18F-choline PET-MRI examination
48459230|NCT03252990|PROCEDURE|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
48459231|NCT06383130|DIAGNOSTIC_TEST|Oscillometry with reversibility testing|Oscillometry is a test that uses sound waves to measure the mechanical properties in the lungs during tidal breathing
48459232|NCT06383130|DIAGNOSTIC_TEST|Breath volatile testing|We will be optimising and evaluating the sensitivity and specificity of a novel breath volatile organic compound test of a combination of reactive aldehydes using a gas chromatography-ion mobility spectrometry device
48459233|NCT06383130|DIAGNOSTIC_TEST|Nasal eosinophil peroxidase|We will be evaluating the sensitivity and specificity of a novel nasal swab test for eosinophil peroxidase
48459234|NCT06383130|DIAGNOSTIC_TEST|Handheld capnometry|We will be evaluating handheld capnometry (carbon dioxide breath testing) to diagnose adult asthma
48459235|NCT00950300|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
48459236|NCT00950300|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
48459237|NCT00950300|DRUG|Docetaxel|Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
48459238|NCT00950300|DRUG|Epirubicin|Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
48623155|NCT05733299|DEVICE|aflo™ digital respiratory management platform|medical device, user app, clinician portal, data analytics hub
48623156|NCT05733299|OTHER|Standard care|Health service standard care will be continued
47934830|NCT02069288|DRUG|Fludrocortisone|50 µg of fludrocortisone per os
47934831|NCT02069288|DRUG|Placebo|1 tablet of placebo per os
47934832|NCT05166239|PROCEDURE|HAIC|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
47934833|NCT05166239|DRUG|Lenvatinib 1|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.
48098875|NCT02473562|DRUG|Varenicline|Tablet 1 mg BID
48098876|NCT02473562|DRUG|Placebo (for varenicline)|Tablet 1 mg BID
48098877|NCT00350831|DRUG|XL820|
48098878|NCT00387062|DEVICE|Computer-based Cognitive Training|
48098879|NCT06618898|OTHER|online questionnaire|The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.
48098880|NCT00515840|OTHER|Physiotherapist|Physiotherapist administered breathing retraining programme
48106905|NCT00003435|PROCEDURE|antiviral therapy|
48106906|NCT00003435|PROCEDURE|bone marrow ablation with stem cell support|
48281182|NCT01725165|OTHER|Quality-of-Life Assessment|Ancillary studies
48281183|NCT01725165|PROCEDURE|Standard Follow-Up Care|Undergo standard maintenance therapy
48281184|NCT01725165|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48281185|NCT05142241|PROCEDURE|Biopsy|Undergo biopsy
48281186|NCT05142241|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48281187|NCT05142241|PROCEDURE|Computed Tomography|Undergo CT
48281188|NCT05142241|DRUG|Talazoparib|Given PO
48281189|NCT05142241|DRUG|Temozolomide|Given PO
48281190|NCT04848805|PROCEDURE|liver transplantation|total hepatectomy material was examined by pathology laboratory
48459239|NCT00950300|DRUG|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
48459240|NCT00950300|DRUG|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
48459241|NCT02483507|OTHER|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
48459242|NCT00057226|DRUG|Radafaxine|
48478788|NCT05571072|OTHER|Opioid calculator|Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
48623157|NCT01025895|PROCEDURE|acl reconstruction - double bundle technique|
48623158|NCT01025895|PROCEDURE|acle reconstruction - single bundle technique|
48623159|NCT01294540|DRUG|Drug: E2609|E2609 orally at varying ascending doses
48623160|NCT01294540|DRUG|Placebo|Matching Placebo
48623161|NCT00211094|DRUG|Dapoxetine|
47934834|NCT05166239|DRUG|PD-1 Inhibitors|PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
48459243|NCT06298123|DRUG|Anti-PD-1 monoclonal antibody|The independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after hepatic resection surgery were analysed by retrospectively collecting patient data from the Centre for Liver Surgery, Tongji Hospital, during the period of February 2019 to February 2023, and comprehensively evaluating the patients' demographic characteristics, oncological parameters, surgical details, and response to immunotherapy, and establishing a prognostic model based on these factors.
48459244|NCT06315387|DRUG|4-MUST, 1 tablet|4-methylumbelliferyl trimebutine sulfate, 128 mg
48459245|NCT06315387|DRUG|4-MUST, 2 tablets|4-methylumbelliferyl trimebutine sulfate, 256 mg
48459246|NCT06315387|DRUG|4-MUST, 3 tablets|4-methylumbelliferyl trimebutine sulfate, 384 mg
48459247|NCT00290927|DRUG|insulin glulisine|
48459248|NCT02538211|BIOLOGICAL|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
48459249|NCT03655860|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
48459250|NCT03199196|DEVICE|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
48459251|NCT03199196|DEVICE|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
48459252|NCT03199196|BEHAVIORAL|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
48459253|NCT03199196|BEHAVIORAL|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
48459254|NCT03199196|BEHAVIORAL|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
48459255|NCT03199196|BEHAVIORAL|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
48459256|NCT01310855|DRUG|cediranib maleate|
48459257|NCT01310855|DRUG|gefitinib|
48459258|NCT01310855|DRUG|Placebo|
48459259|NCT00002158|DRUG|Nitazoxanide|
48459260|NCT02902601|DRUG|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
47934835|NCT05166239|DRUG|Lenvatinib 2|12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.
48098881|NCT04043767|PROCEDURE|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
48098882|NCT03667547|DRUG|Raltegravir|Raltegravir 600 mg tablet
48459261|NCT02902601|DRUG|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
48459262|NCT02902601|OTHER|Placebo|Matching placebo to JNJ-54175446
48459263|NCT05128396|BEHAVIORAL|Cognitive Stimulation|During the initial session, a member of the research team will visit the subject's home and introduce the subject to the Cogmed training program (www.cogmed.com). Individuals will start at the same low difficulty level. As training proceeds, task difficulty will be individually adjusted based on performance by increasing/decreasing the number of items individuals have to remember, such that a participant reaches approximately 60% correct per day for each task. Each training session will start at the task difficulty level where the participant ended in the previous session. Performance and reaction time data will be continuously recorded while subjects are doing the task, and these data will be sent via the internet to the research team after each session. A member of the research team will communicate with each subject on a weekly basis (via phone call or email) to provide feedback and address any questions or concerns.
48478789|NCT05571072|OTHER|Standard opioid prescription|Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
48478790|NCT00975741|DEVICE|OXIMAX|
48098883|NCT06111508|DEVICE|Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs|A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
48098884|NCT04642261|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg daily
48281191|NCT01262430|PROCEDURE|OtisMed|OtisMed Custom-fit Shapematching Guides
48281192|NCT01262430|PROCEDURE|Computer Assisted Surgery (CAS)|Stryker Navigation System
48281193|NCT03467230|DEVICE|NoL Index|Use of the PMD-200 in an observational study
48478791|NCT00975741|DEVICE|ASMANEX TWISTHALER|
48478792|NCT01955512|DRUG|Clopidogrel|Clopidogrel 75mg daily for 7 days
48478793|NCT01955512|DRUG|Placebo|Matched placebo
48478794|NCT00666887|DRUG|Minocycline|100 mg twice daily to be taken for up to 2 years
48478795|NCT00666887|DRUG|Placebo|placebo twice daily for 2 years
48623162|NCT03638791|BEHAVIORAL|Exposure and response inhibition|Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
47934836|NCT05166239|DRUG|PD-1 inhibitors 2|PD-1 inhibitors injection intravenously or percutaneously every 4 week.
47934837|NCT04033523|BEHAVIORAL|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
48281195|NCT04746040|DRUG|Test|2 inhalations of Test and Reference product in each study period
48281196|NCT04746040|DRUG|Reference|2 inhalations of Test and Reference product in each study period
48459264|NCT05128396|BEHAVIORAL|Mindfulness training|"The mindfulness meditations will be narrated by one guide and the tasks will be narrated by a different guide. We will have 7 mindfulness tasks in total, whose order of presentation will be counterbalanced across sessions: 1. mindful observing of place, 2. mindful eating, 3. mindful observing of object, 4. mindful observing of person, 5. mindful walking, 6. mindful listening, and 7. mindful writing with the non-dominant and dominant hand.~At the end of each session, participants will write brief reflections stored via the website (e.g., an estimate of the amount of time subjects experienced their thoughts as wandering) both as an integral part of the mindfulness process and as a means of increasing the likelihood that subjects fully participate in each session. Each session will be structured as follows: Login, Mindfulness Meditation Session, Mindfulness Task 1, Mindfulness Task 2, Mindfulness Task 3, Write Log Reflection, Logout."
48459265|NCT05128396|BEHAVIORAL|Physical Activity|Aerobic exercises will include relatively low impact activities like walking, jogging, or running in place, which will aim to put limited demands on balance. Each exercise will be explained and demonstrated in the video. All exercises can be done standing, sitting, or next to a chair that provides balance support as demonstrated in the videos. After the first session, for each subsequent session the difficulty level will start at one level below the previous session's average difficulty level (e.g. if they exercise at the most difficult level for most of the time during one session, the next session will start at the medium difficulty level). Each exercise will be explained and demonstrated in the video.
48459266|NCT05128396|BEHAVIORAL|Control Group|Individuals in the control group will participate in the same computerized Cogmed training program as described above. The main difference is that for the control group task difficulty will remain at the same low starting level, rather than increasing over time. The instructions given to subjects will be identical to the ones used in the cognitive training intervention.
48459267|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 50 mg QD
48459268|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD
48459269|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD
48459270|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
48459271|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
48459272|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
48459273|NCT01316237|DRUG|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
48459274|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900mg , BID
48459275|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900 mg
48459276|NCT04865120|OTHER|cream cyclic merocyanine|cream long-UVA absorber
48459277|NCT04865120|OTHER|placebo|placebo
48459278|NCT05659680|DEVICE|WiSE-CRT|Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
48098885|NCT04642261|DRUG|Placebo pills|Identical in appearance to empagliflozin 10mg daily
48459279|NCT05120388|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil Addition|Daily dietary addition of olive oil (three tablespoons)
48459280|NCT01712568|DRUG|Test Product (Ropinirole)|"one Tablet at 0 hour"
48459281|NCT01712568|DRUG|Reference Product (REQUIP )|"one Tablet at 0 hour"
48459282|NCT03531645|DRUG|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
48459283|NCT03531645|DRUG|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
48459284|NCT05139563|OTHER|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
48459285|NCT05139563|OTHER|Placebo implant|placebo subdermal implant rod
47934838|NCT00146107|BEHAVIORAL|Diet|10 percent weight loss through diet and behavioral modification
48098886|NCT05390476|DRUG|Capecitabine|500mg orally three times a day (continuously)
48098887|NCT05390476|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
48098888|NCT01105572|DEVICE|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
48106907|NCT00003435|PROCEDURE|peripheral blood stem cell transplantation|
48106908|NCT00003435|PROCEDURE|umbilical cord blood transplantation|
48459286|NCT00247013|BEHAVIORAL|Breast Cancer Screening Compliance|
48459287|NCT01711801|DRUG|Placebo|Single ascending dose
48459288|NCT01711801|DRUG|RO5545965|Single ascending dose
48459289|NCT01711801|DRUG|RO5545965|Single dose, in fed and fasted state
48459290|NCT05453487|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
48106909|NCT00003435|RADIATION|radiation therapy|
48106910|NCT03525119|BIOLOGICAL|TDV|TDV SC injection
48106911|NCT03525119|BIOLOGICAL|HAV Vaccine|HAV Vaccine IM injection.
48106912|NCT03525119|BIOLOGICAL|TDV Placebo|Placebo-matching (normal saline (0.9% NaCl) SC injection.
48459291|NCT05453487|BIOLOGICAL|COVID-19 vaccine|received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
48459292|NCT05453487|BIOLOGICAL|rabies vaccine|received three dose of rabies vaccine
48459293|NCT01647321|BEHAVIORAL|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
48459294|NCT01647321|BEHAVIORAL|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
48459295|NCT00484679|DRUG|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
48459296|NCT00084097|DRUG|Omalizumab|
48459297|NCT05316636|DEVICE|Vibrational forces|
48459298|NCT05316636|PROCEDURE|Orthodontic treatment with clear aligners|
48459299|NCT03648710|OTHER|Peer Community Health Worker|Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
48623163|NCT02408822|DEVICE|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
48623164|NCT02408822|DEVICE|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
48623165|NCT01680913|PROCEDURE|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
48106913|NCT03525119|BIOLOGICAL|HAV Vaccine Placebo|Placebo-matching (normal saline (0.9% NaCl) IM injection.
48281197|NCT01689558|DRUG|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
48281198|NCT05742945|PROCEDURE|Immediate lymphatic reconstruction|Breast cancer patients receive axillary lymph node dissection and immediate lymphatic reconstruction
48281199|NCT03883061|OTHER|regular medical treatment|regular medical treatment
48281200|NCT06468371|DRUG|Dopamine Agonist (Ropinirole)|Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
48281201|NCT06468371|OTHER|Excercise training|Exercise sessions will involve using a pedal bicycle twice a week for 12 weeks, integrated into the patients' hemodialysis schedule. Each session will last 20 minutes, scheduled between the second and third hours of dialysis. The first 5 minutes will be for warm-up with slow pedaling, followed by 10 minutes of intense pedaling, and concluding with a 5-minute cool-down period of slow pedaling to gradually reduce the heart rate.
48281202|NCT05923073|DRUG|Guselkumab|Guselkumab will be administered either intravenously or subcutaneously.
48281203|NCT05923073|DRUG|Placebo|Week 12 induction responders will be administered placebo (matching guselkumab up to Week 48) SC at protocol specified time points to maintain the blind.
48281204|NCT00601978|DRUG|carbidopa/levodopa|
48281205|NCT00601978|DRUG|Carbidopa/Levodopa/Entacapone|
48281206|NCT02509325|DEVICE|Parkinson's Kinetigraph|
48281207|NCT05992467|BEHAVIORAL|Wellness Enhancement for Caregivers (WECARE)|WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
48281208|NCT04576442|BEHAVIORAL|Asthma-PASS|The investigator will collaborate with the student's primary care provider (PCP) by sending a letter via facsimile, and/or email to ensure appropriate medications are prescribed or adjusted and rescue medications are available at school. Community Health Workers (CHWs) will follow up with PCPs as needed to provide reminders about prescriptions for controlled medications and to ensure a MAF is provided to schools to allow rescue medication administration by nurses. CHWs will work with local pharmacies when possible to have prescribed medications delivered to schools and homes. For students without a PCP, we will refer families to one of Montefiore Medical Center's 20 practices throughout the Bronx. For students without medical insurance or who are unable to go to a Montefiore clinic, the NYC DOE physicians who routinely attend NYC schools will provide medical care and prescribe appropriate medications.
48281209|NCT04576442|BEHAVIORAL|Basic Asthma Management (AM)|PCPs and caregivers will be notified that children in the AM group have persistent/uncontrolled asthma that warrants use of guideline-based preventative medications.
48281210|NCT04576442|BEHAVIORAL|Child/Caregiver Education session|The investigator will provide in-school child asthma education sessions delivered by trained, bilingual (English-Spanish) Community Health Workers (CHWs) using an established manualized protocol from past and current studies designed to improve knowledge and self-efficacy. Each child will receive two 1-on 1, 20-minute developmentally appropriate educational sessions at school 3-4 weeks apart. Sessions will cover: 1) asthma basics, symptoms and triggers; and 2) medications and correct administration technique. Caregivers will be called after each child session to highlight key points reviewed with the child and answer questions.
48281211|NCT00454597|PROCEDURE|omentectomy|surgery omentectomy
48281212|NCT01716819|OTHER|Urine sample|dosages on one spot and 24h collection
48281213|NCT01716819|OTHER|Blood sample|dosages
48281214|NCT01716819|OTHER|Assessment of sleep apnea syndrome|
48281215|NCT01716819|OTHER|Electrocardiogram|
48459300|NCT03648710|OTHER|Mobile Health|A mobile health application created as a resource for young adults transitioning.
48459301|NCT05686993|DRUG|Cinnarizine|Cinnarizine oral 30mg TDS
48459302|NCT05686993|DRUG|NIFEdipine ER|Nifedipine oral 60mg daily extended release
48459303|NCT05461157|DEVICE|Preoperative silicone ointment|The silicone ointment in this study is the Biodermis Scar Aid Silicone Stick, an FDA-approved silicone ointment that is available for purchase over the counter.
48459304|NCT05461157|OTHER|Preoperative placebo ointment|The placebo ointment in this study is a generic, non-flavored lip balm that is identical in packaging and texture to the Biodermis Scar Aid Silicone Stick used in the treatment arm.
48459305|NCT01096745|DRUG|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
48623166|NCT01680913|PROCEDURE|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
48459306|NCT01096745|DRUG|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
48459307|NCT00862212|BEHAVIORAL|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
48459308|NCT03825562|BEHAVIORAL|acceptance and commitment therapy, ACT|
48459309|NCT04945096|DRUG|decitabine|Decitabine (20mg/m2 intravenously from day -10 to day -8 of conditional regimen)
48459310|NCT04945096|DRUG|Acetylcysteine|Acetylcysteine: 1.2g twice a day, oral administration, from day -10 to day 365 after HSCT.
48459311|NCT04945096|DRUG|Semustine|Semustine: 250 mg/m2/day on day -9.
48459312|NCT04945096|DRUG|Cytarabine|Cytarabine: 2 g/m2 every 12 hours on day -8.
48459313|NCT04945096|DRUG|Busulfan|Busulfan: 3.2mg/kg/day on day -7 to -5.
48459314|NCT04945096|DRUG|Cyclophosphamide|Cyclophosphamide: 1.8g/m2/day on day -4 to -3.
48459315|NCT04945096|DRUG|Cyclosporin A|Cyclosporin A: 3mg/kg/d from day -8.
48459316|NCT04945096|DRUG|Anti-thymocyte globulin|Anti-thymocyte globulin (2mg/kg/d on day -5 to day -2) will be added for transplants with unrelated donor or HLA mismatched donor.
48459317|NCT04945096|DRUG|Mycophenolate|Mycophenolate (500mg, oral, twice a day from day -8) will be added for transplants with unrelated donor or HLA mismatched donor.
48459318|NCT01742403|RADIATION|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
48459319|NCT00818298|DRUG|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
48459320|NCT04797936|DRUG|BNO 1030|Imupret 25 drops х 6 times per day for 14 days
48459321|NCT04797936|OTHER|Standard care|isolation mode symptomatic therapy as needed: antipyretic (paracetamol) saline solutions in the nose x 4 times a day -14 days
48459322|NCT03155893|DRUG|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 \[mg\] ODV \[1\*25 mg tablet\]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
48459323|NCT03155893|DRUG|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV \[4\*50 mg tablets\]) on Days 1 and 2 in Treatment E.
48459324|NCT03155893|DRUG|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV \[2\*50 mg tablets + 1\*25 mg tablets\]) orally once daily on Days 3 to 7 in Treatment E.
48459325|NCT03155893|DRUG|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV \[2\*50 mg tablets\] orally once daily on Days 8 to 14 in Treatment E.
48459326|NCT03155893|DRUG|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV \[2\*75 mg capsules\]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
48459327|NCT03155893|DRUG|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 \[3\*400 mg tablets\]) administered orally on Day 15 in Treatment A and B.
48459328|NCT03155893|DRUG|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin \[1\*400 mg capsule\]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
48459329|NCT03155893|DRUG|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
48459330|NCT03155893|DRUG|ODV 200 mg|Participants will receive ODV 200 mg (4\*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
48459331|NCT03155893|DRUG|ODV 125 mg|Participants will receive ODV 125 mg (2\*50 mg tablets + 1\*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
48459332|NCT03155893|DRUG|ODV 100 mg|Participants will receive ODV 100 mg (2\*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
48459333|NCT03155893|DRUG|SMV 150 mg|Participants will receive SMV 150 mg (2\*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
48459334|NCT03155893|DRUG|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3\*400 mg tablets) administered on Day 15 in Treatment C.
48459335|NCT01986647|BEHAVIORAL|On the Move exercise - exercise leader|exercise physiologists
48459336|NCT01986647|BEHAVIORAL|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
48459337|NCT01986647|BEHAVIORAL|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
48459338|NCT01986647|BEHAVIORAL|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
48459339|NCT02417428|DIETARY_SUPPLEMENT|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
48459340|NCT02417428|OTHER|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
48623167|NCT01680913|PROCEDURE|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
48623168|NCT00940173|DEVICE|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
48459341|NCT02417428|BEHAVIORAL|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
48459342|NCT02417428|OTHER|without exercise|No exercise program will be assigned to participants.
48459343|NCT03528486|BEHAVIORAL|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
48459344|NCT03419403|DRUG|Steroid eye drops|Solution, eye drop
48459345|NCT03419403|DRUG|Vasoconstrictor eye drops|Solution, eye drop
48459346|NCT03419403|OTHER|Cold compress|Cold compress
48459347|NCT03419403|DRUG|Ophthalmic steroid ointment|Ointment
48459348|NCT03419403|DRUG|Depatuxizumab mafodotin|During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
48459349|NCT03419403|DRUG|Temozolomide|Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
48459350|NCT03419403|RADIATION|Radiation|Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
48459351|NCT00672373|DRUG|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
48459352|NCT00672373|DRUG|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
48459353|NCT03773653|BEHAVIORAL|BMT to be combined with BAT|Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
48459354|NCT03773653|BEHAVIORAL|BMT to be combined with MT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
48459355|NCT03773653|BEHAVIORAL|BMT to be combined with IOT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
48459356|NCT00948480|BIOLOGICAL|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
48459357|NCT00948480|DRUG|GM-CSF|500 mcg
48459358|NCT03148054|DEVICE|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
48459359|NCT01239303|DIETARY_SUPPLEMENT|Citrulline|single dose
48459360|NCT01239303|DIETARY_SUPPLEMENT|alanine|single dose
48459361|NCT02382224|BEHAVIORAL|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
48459362|NCT02382224|BEHAVIORAL|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
48459363|NCT00106886|DRUG|Folic acid, vitamin B6 and B12 or placebo|
48459364|NCT00218335|BEHAVIORAL|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
48459365|NCT00218335|BEHAVIORAL|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
48459366|NCT06363617|OTHER|FLI|Health professionals will use the FLI test in their clinical practice
48459367|NCT00697827|DEVICE|Interspinous Spacer device|Device: In-Space
48459368|NCT00697827|DEVICE|Interspinous Process Distraction Device|Device: X STOP
48459369|NCT02313545|DRUG|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%"
48281216|NCT01716819|OTHER|Glucose tolerance test|
48281217|NCT01716819|OTHER|Echocardiography|
48281218|NCT01716819|OTHER|cardiac and abdominal magnetic resonance imaging|
48459370|NCT01287351|DRUG|extra-fine hydrofluoroalkane beclometasone dipropionate|
48459371|NCT01287351|DRUG|Fluticasone propionate|
48459372|NCT00633022|DRUG|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
48459373|NCT00633022|DRUG|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
48459374|NCT01159873|DRUG|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
48459375|NCT01159873|DRUG|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
48459376|NCT00306306|DEVICE|Reprieve Endovascular Temperature Therapy System|
47934839|NCT00146107|OTHER|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
48459377|NCT03082586|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
48459378|NCT03082586|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
48459379|NCT03082586|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
48459380|NCT03082586|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
48459381|NCT03082586|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
48459382|NCT03082586|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
48459383|NCT04403035|DIAGNOSTIC_TEST|ID NOW vs. Accula|Comparison of the ID Now assay vs. the Accula assay in detecting Covid-19.
48459384|NCT02167594|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
48459385|NCT02167594|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
48459386|NCT02964039|BEHAVIORAL|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
48459387|NCT02964039|BEHAVIORAL|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
48459388|NCT02964039|BEHAVIORAL|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
47934840|NCT00146107|OTHER|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
48281219|NCT01716819|OTHER|Ambulatory blood pressure monitoring|
48281220|NCT01716819|OTHER|Echotracking|
48459389|NCT00003357|BIOLOGICAL|GM2-KLH vaccine|
48281221|NCT01716819|OTHER|Pulse wave velocity|
48459390|NCT00003357|BIOLOGICAL|QS21|
48623169|NCT00940173|DEVICE|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
47934841|NCT04507854|OTHER|Strength, range of motion and functional tests + Questionnaire|Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
47934842|NCT02970370|OTHER|no intervention|
48623170|NCT00940173|DEVICE|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
48623171|NCT00940173|DEVICE|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
48098889|NCT01105572|OTHER|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
48098890|NCT01599325|DRUG|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m\^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
48098891|NCT00322699|PROCEDURE|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
48623172|NCT02626611|DRUG|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
47934843|NCT02786524|BEHAVIORAL|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
48281222|NCT01716819|OTHER|Composition of body mass by Dual x-ray absorptiometry|
48281223|NCT05784246|DRUG|Mirikizumab IV|Administered IV
48459391|NCT04132063|DRUG|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
48459392|NCT00400452|BEHAVIORAL|wheelchair skills training|
47934844|NCT02125773|BEHAVIORAL|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
47934845|NCT03407339|OTHER|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
47934846|NCT03425422|DEVICE|VITARIA System|Chronic stimulation of the right cervical vagus nerve
47934847|NCT01776385|OTHER|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
47934848|NCT01776385|OTHER|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
47934849|NCT05669248|DIAGNOSTIC_TEST|mid covid-19 patients|Collect the patient's whole blood for testing
47934850|NCT03628261|DEVICE|Serious Game|Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
47934851|NCT03628261|OTHER|physical therapy|Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
47934852|NCT04444427|DRUG|GLR2007|Administered orally, once daily for 21 days followed by a 7-day treatment holiday.
48281224|NCT05784246|DRUG|Mirikizumab SC|Administered SC
48459393|NCT06627855|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
48459394|NCT06627855|PROCEDURE|Sham treatment|The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.
48459395|NCT01415596|DRUG|salbutamol|
48459396|NCT01415596|DRUG|Placebo|
48459397|NCT01573819|DRUG|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
48459398|NCT01573819|DRUG|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
48098892|NCT00322699|DRUG|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
48098893|NCT05302791|DEVICE|Muscle Cooling|Cooling wrap will be set to 10°C
48098894|NCT05302791|OTHER|Resistance Exercise|Resistance Machines (Leg Press and Knee extension). 12 rep Max
48098895|NCT00180102|DRUG|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
48098896|NCT00180102|PROCEDURE|early allogeneic PBSCT within induction therapy|
48098897|NCT00180102|PROCEDURE|autologous PBSCT|
48098898|NCT04543513|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
48281225|NCT05885555|BIOLOGICAL|Ianalumab|Intravenous infusion, prepared from concentrate solution
48281226|NCT02704104|DEVICE|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
48281227|NCT03139370|DRUG|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
48281228|NCT03139370|DRUG|Cyclophosphamide|Administered intravenously
48459399|NCT05934695|OTHER|Lymphedema severity stratification|"Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds"
48459400|NCT04614857|OTHER|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
48459401|NCT04727164|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
48459402|NCT05450549|DRUG|DNL919|Single doses
48459403|NCT05450549|DRUG|Placebo|Single doses
48459404|NCT05032963|BEHAVIORAL|Overnight polysomnography examinations|sleep lab for overnight polysomnography examinations
48459405|NCT05646277|OTHER|e-Consultation|first orthodontic consultation in remote
48459406|NCT05646277|OTHER|Consultation|first orthodontic consultation in face-to-face
48459407|NCT02670551|DRUG|Cariprazine|
48459408|NCT02670551|DRUG|Placebo|
48459409|NCT03478007|DEVICE|Intervention Technology|Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
48459410|NCT03478007|DEVICE|Intervention Technology Plus Coaching|Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
48459411|NCT02252016|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
48459412|NCT02252016|DRUG|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
48459413|NCT00064324|DRUG|perifosine|Given orally
48459414|NCT00064324|OTHER|laboratory biomarker analysis|Correlative studies
48459415|NCT00064324|OTHER|pharmacological study|Correlative studies
48459416|NCT04252716|DEVICE|OVD|Intraocular administration
48459417|NCT01135784|DIETARY_SUPPLEMENT|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
48459418|NCT01135784|DIETARY_SUPPLEMENT|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
48459419|NCT04712838|DRUG|SHR0302|Group A subjects were given oral F1 、F2 and F3 version SHR0302
48459420|NCT04712838|DRUG|SHR0302|Group B subjects were given oral F1 、F3 and F2 version SHR0302
48459421|NCT04712838|DRUG|SHR0302|Group C subjects were given oral F2 、F1 and F3 version SHR0302
48459422|NCT04712838|DRUG|SHR0302|Group D subjects were given oral F2 、F3 and F1 version SHR0302
48459423|NCT04712838|DRUG|SHR0302|Group E subjects were given oral F3 、F1 and F2 version SHR0302
48459424|NCT04712838|DRUG|SHR0302|Group F subjects were given oral F3 、F2 and F1 version SHR0302
48459425|NCT00624351|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
48459426|NCT00624351|OTHER|Placebo|Phosphate-buffered Saline (PBS) infusion.
48459427|NCT05064917|DIAGNOSTIC_TEST|Blood draw|The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
48459428|NCT04552665|DEVICE|KODEX-EPD system|To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R\&D)
48459429|NCT02833428|DEVICE|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
48459430|NCT02108639|DRUG|DCV 3DAA FDC|
48459431|NCT02108639|DRUG|BMS-791325|
48459432|NCT06057558|BIOLOGICAL|Probiotic throat spray|Throat spray containing Lacticaseibacillus casei AMBR2
48459433|NCT04576936|OTHER|AIRVO|Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
48459434|NCT02368262|OTHER|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
48459435|NCT02368262|PROCEDURE|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
48098899|NCT05139264|OTHER|Observational|Observation of diet, physical activity, sleep and interstitial glucose
48459436|NCT01782937|DRUG|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
48459437|NCT05646316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48459438|NCT05646316|PROCEDURE|Diagnostic Imaging|Undergo imaging
48459439|NCT05646316|PROCEDURE|Excisional Biopsy|Undergo sentinel lymph node excision
48459440|NCT05646316|DRUG|Indocyanine Green Solution|Given via injection
48459441|NCT05646316|PROCEDURE|Minimally Invasive Surgery|Undergo minimally invasive hysterectomy
48459442|NCT05646316|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymphadenectomy
48459443|NCT05646316|OTHER|Questionnaire Administration|Ancillary studies
48459444|NCT05646316|PROCEDURE|Sentinel Lymph Node Mapping|Undergo sentinel lymph node mapping
48459445|NCT02399462|DRUG|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly\* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly\* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly\* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly\* Weeks 27 through 28~\*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
48459446|NCT05572996|DRUG|Inhaled Treprostinil|
48459447|NCT01377441|DRUG|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
48459448|NCT01377441|DRUG|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
48459449|NCT00516295|DRUG|topotecan hydrochloride|Given IV
48459450|NCT00516295|DRUG|vincristine sulfate|Given IV
48459451|NCT00516295|DRUG|cyclophosphamide|Given IV
48459452|NCT00516295|BIOLOGICAL|bevacizumab|Given IV
48459453|NCT02979132|DRUG|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
48459454|NCT02979132|DRUG|Ferinject(R)|Single-dose Ferinject(R) administration
48459455|NCT02979132|DIETARY_SUPPLEMENT|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
48459456|NCT05756218|OTHER|nursing diagnoses - taboo game|Playing 7 weeks nursing diagnoses taboo cards
48459457|NCT06428305|OTHER|Providing hygiene education based on the method of teaching what has been learned in the context of a genital hygiene guide|As shown in the Flow Chart of the study, research data were collected from pregnant women who were in the control group at the December intervals with the experimental group. After the completion of the study, this group will also be given an education and training booklet.
48459458|NCT04499209|DRUG|XG005|XG005 Capsule
48459459|NCT04499209|DRUG|Combination of Naproxen and Pregabalin|Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
47934853|NCT06151184|PROCEDURE|Chiropractic adjustment|6 weeks of chiropractic care, with frequency and type of procedures determined by field clinician after initial examination.
48459460|NCT04499209|DRUG|Placebos|Placebo Capsule
48459461|NCT04816773|DEVICE|EVOLUTION® NitrX™|EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
48459462|NCT06628154|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
48459463|NCT06628154|OTHER|Placebo|Single tablet encapsulated identically to losartan
48459464|NCT05548335|PROCEDURE|Ocular Ultrasound|1. Patients presenting to the emergency department and have a normal head and/or ocular computed tomography scan will be considered for inclusion in this study. Study staff will discuss the study with the patient and obtain consent. At that point, operator will perform ocular ultrasound. Procedure will start with either the linear or microconvex probe. A single-use sterile gel packet will be used to apply gel to one closed eyelid. The probe will be placed with minimal pressure on the eye. A transverse measurement of the ONSD will be taken. In this same view the maximal transverse diameter of the eyeball will also be measured. Images of the eye with ONSD and ETD measurements will be captured. Repeat until three measurements have been obtained resulting in an average ONSD and ETD for that eye. Repeat for other eye. Switch probe and repeat on both eyes.
48459465|NCT06254560|DRUG|Rituximab|Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.
48459466|NCT06000579|OTHER|EFT|Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
48459467|NCT05821608|OTHER|Message variation 1|Message before call letting member know they will be called (variation 1)
48459468|NCT05821608|OTHER|Message variation 2|Message before call letting member know they will be called (variation 2)
48459469|NCT02005276|BEHAVIORAL|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
48459470|NCT02005276|BEHAVIORAL|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
48459471|NCT02005276|BEHAVIORAL|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
48459472|NCT02391233|BEHAVIORAL|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
48459473|NCT02391233|BEHAVIORAL|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
48459474|NCT01674387|DEVICE|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
47934854|NCT02393586|DRUG|Faropenem|Single oral dose
47934855|NCT02393586|DRUG|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
47934856|NCT02393586|DRUG|Rifampicin|Single oral dose
47934857|NCT05111275|OTHER|Cognitive exercises|Exercises that stimulate and train memory, attention, executive functions, language and gnosis.
47934858|NCT01680549|DRUG|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
47934859|NCT00020332|DRUG|alvocidib|
48098900|NCT02787967|DRUG|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
47934860|NCT00020332|DRUG|docetaxel|
47934861|NCT00381381|DRUG|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
47934862|NCT00231374|PROCEDURE|Myelogram|
47934863|NCT04932070|DIETARY_SUPPLEMENT|Berberine|2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
47934864|NCT00939952|DRUG|ertapenem|500 mg IV once
47934865|NCT00396448|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
48098901|NCT02787967|DRUG|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
48281229|NCT03139370|DRUG|Fludarabine|Administered intravenously
48459475|NCT01674387|OTHER|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
48459476|NCT05767905|DRUG|PF-06821497 Treatment A|A single dose of PF-06821497 administered under fasting conditions.
48459477|NCT05767905|DRUG|PF-06821497 Treatment B|A single dose of PF-06821497 administered under fasting conditions.
48459478|NCT05767905|DRUG|PF-06821497 Treatment C|A single dose of PF-06821497 administered under fasting conditions.
48459479|NCT05767905|DRUG|PF-06821497 Treatment D|A single dose of PF-06821497 administered under fasting conditions.
48459480|NCT05767905|DRUG|PF-06821497 Treatment E|A single dose of PF-06821497 administered after low fat meal
48459481|NCT05767905|DRUG|PF-06821497 Treatment F|A single dose of PF-06821497 administered after high fat meal.
48459482|NCT03578822|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
48098902|NCT05425264|OTHER|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
48098903|NCT05763004|DRUG|IOS-1002|monotherapy
48459483|NCT03578822|DRUG|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
48459484|NCT03578822|DRUG|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
48459485|NCT03578822|DRUG|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
48459486|NCT04168580|OTHER|Exercise Training Intervention|Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
48459487|NCT01344018|PROCEDURE|therapeutic conventional surgery|
48459488|NCT01344018|RADIATION|3-dimensional conformal radiation therapy|
48459489|NCT03147053|DRUG|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
48459490|NCT03147053|DRUG|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
48459491|NCT06059755|OTHER|Cross education|For strength training resistance exercises with a load of 60% of one repetition maximum will be performed targeting the muscle involved in upper limb function. Strength will be measured using the grip strength test/hand held dynamometer. Patients will undergo 45 minute session per day, 3 days per week for 6 weeks.
48459492|NCT06059755|OTHER|Mirror Therapy|Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks
48459493|NCT02583698|DRUG|Carvedilol|
48459494|NCT02583698|DRUG|Placebo|
47934866|NCT00396448|DRUG|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
48459495|NCT06219980|COMBINATION_PRODUCT|SBRT+chemoimmunotherapy|All eligible patients will receive SBRT (6Gy\*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.
48459496|NCT04506619|OTHER|No Intervention|This is a non-interventional study.
47934867|NCT00396448|DRUG|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
47934868|NCT01784627|BEHAVIORAL|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
47934869|NCT05796778|PROCEDURE|subomohyoid plane block|The block needle was inserted in line with the probe in a lateral-to-medial orientation toward the suprascapular nerve. Local anesthetic solution was then injected after negative aspiration for blood to achieve circumferential spread around the neurovascular bundle
47934870|NCT05796778|PROCEDURE|Interscalene brachial plexus block|The block needle is usually advanced in plane in a lateral-to-medial direction through the middle scalene muscle to contact the nerve roots and inject local anesthetic around them.
47934871|NCT00730262|DRUG|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
47934872|NCT01376531|PROCEDURE|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
48098904|NCT05763004|DRUG|IOS-1002 + KEYTRUDA® (pembrolizumab)|combination therapy
48098905|NCT02611648|OTHER|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
48098906|NCT02611648|OTHER|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
48098907|NCT02870543|DRUG|Phytolacca decandra|Treatment of bruxism
48098908|NCT02870543|DRUG|Melissa officinalis|Treatment of bruxism
48459497|NCT03983135|OTHER|Laparoscopic mini gastric by-pass|Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
48459498|NCT03983135|OTHER|LaparoscopicRe-sleeve gastrectomy|Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
48459499|NCT03983135|OTHER|Laparoscopic Roux-en-Ygastric bypass|all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
48459500|NCT05305586|DEVICE|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
48459501|NCT05305586|DEVICE|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
48459502|NCT01202253|DRUG|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
48459503|NCT06089330|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
48459504|NCT06089330|DRUG|SG001|240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
48459505|NCT06089330|DRUG|Irinotecan|180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
48459506|NCT06089330|DRUG|Regorafenib (Stivarga)|160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
48459507|NCT03088007|OTHER|Cognitive, adaptive, behavioral and academic assessment|Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
48459508|NCT05211505|DEVICE|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
48459509|NCT04807062|PROCEDURE|surgery|tunnel bone tamps method (TBTM) was used to reduce the depressed articular fragments and then structural bicortical autologous ICBG was used to fill the valley tunnel.
48459510|NCT04920695|DRUG|Nitric Oxide|Pulmonary vasodilator (gas).
48459511|NCT04920695|DRUG|Placebo|medical grade normoxic gas (FiO2 = 0.21)
48459512|NCT00870935|PROCEDURE|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
48623173|NCT02626611|DRUG|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
48459513|NCT00870935|PROCEDURE|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
48459514|NCT03862547|DIAGNOSTIC_TEST|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
48459515|NCT03699930|DEVICE|tDCS|Anodal or sham tDCS will be applied to the scalp.
48459516|NCT03699930|BEHAVIORAL|Speech and language therapy|A trained speech pathologist will administer the speech and language therapy.
48459517|NCT01037231|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks
48459518|NCT01037231|DRUG|Placebo|placebo
48459519|NCT06042296|OTHER|Expression of CD44, E-cadherin and PCNA|The investigators use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval. Histopathological and immunohistochemical staining findings will be reported using a Nikon light microscope and an image analysis system (Nikon Instruments Europe BV)
48459520|NCT02160613|PROCEDURE|Open flap debridement|an access flap
47934873|NCT01497145|DRUG|KRN321|
47934874|NCT00006157|DRUG|Desipramine|
47934875|NCT00006157|BEHAVIORAL|Cognitive Behavioral Treatment|
48459521|NCT03531060|DRUG|IRL790|IRL790 capsule 10 mg
48459522|NCT03531060|DRUG|Placebo|Placebo capsule
47934876|NCT01840839|DEVICE|brain stimulation|
47934877|NCT01840839|DEVICE|Sham Stimulation|
48098909|NCT02870543|DRUG|Phyt.decandra + Melissa offic.|Treatment of bruxism
48281230|NCT03139370|DEVICE|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
48459523|NCT00028613|RADIATION|iodine I 131 monoclonal antibody Lym-1|
48459524|NCT05776901|DEVICE|C-STRESS|Participants were asked to use the C-STRESS app daily for 6 weeks to participate in Cognitively Based Compassion Training (CBCT) lessons, watch guided meditation videos, complete short reflective exercises, and engage with other content provided in C-STRESS (i.e., attending drop-in sessions, journaling, completing mood and wellbeing check-ins, and reading educational articles on depression, anxiety, and stress)
48623174|NCT03646539|BEHAVIORAL|Use of smartphone application (app)|Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
48623175|NCT03646539|OTHER|Treatment as usual|Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
48459525|NCT01724463|OTHER|Severe Sepsis Management Bundle|"Management Bundle includes:~1. Securing Intravenous Access~2. Obtaining Blood Culture~3. Antibiotic Administration~4. Goal Directed Fluid Bolus Therapy~5. Oxygen Administration~6. Measuring Serum Lactate Levels"
48459526|NCT03599583|BEHAVIORAL|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
48459527|NCT03858933|DEVICE|eBrainFit Platform|Alpha/Theta regulation with eyes open
48459528|NCT03858933|DEVICE|eBrainFit Platform|Amygdala regulation with eyes open
48459529|NCT02545179|OTHER|web-based daily care training|12 week interactive web based caring training education
48459530|NCT04003441|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
48459531|NCT04003441|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
48459532|NCT01338090|DRUG|89Zr-bevacizumab|Intravenous injection 120 MBq
48459533|NCT01338090|DRUG|Everolimus|Oral use, 10 mg per day
48459534|NCT03493633|DEVICE|EzyGain|"Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (\<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks"
48459535|NCT00314288|DRUG|Sarizotan HCl|
48459536|NCT02162615|DEVICE|Restorelle Direct Fix A|
48459537|NCT02162615|DEVICE|Restorelle Direct Fix P|
48459538|NCT02162615|PROCEDURE|Native Tissue Repair Anterior|
48459539|NCT02162615|PROCEDURE|Native Tissue Repair Posterior|
48459540|NCT03828539|BIOLOGICAL|Erenumab|70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
48098910|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.
48459541|NCT03828539|DRUG|Topiramate|"Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase."
48459542|NCT03828539|BIOLOGICAL|Erenumab matching placebo|Erenumab matching placebo pre-filled syringue administered every 4 weeks
48459543|NCT03828539|DRUG|Topiramate matching placebo|Topiramate matching placebo administered daily
48459544|NCT00125385|BIOLOGICAL|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
48459545|NCT00125385|BIOLOGICAL|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
48459546|NCT00125385|BIOLOGICAL|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
48459547|NCT00125385|BIOLOGICAL|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
47934878|NCT04351061|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
47934879|NCT03588247|PROCEDURE|transcatheter aortic valve implantation|Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
47934880|NCT03383705|DEVICE|VBeam Prima|Up to four treatments will be performed every 4-6 (±1) weeks.
48098911|NCT01311648|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973)|Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion
48098912|NCT05266365|OTHER|The video-based exercise (VBE) group|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The physiotherapist will create a video record for the patients, including a detailed description of each exercise.~This video recording will be watched at home, and the patients will do video-based exercises by following the instructions in the video."
48459548|NCT00125385|BIOLOGICAL|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
48459549|NCT04186286|DRUG|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
48459550|NCT04186286|DRUG|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
48459551|NCT04186286|DRUG|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
47934881|NCT01673750|OTHER|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
47934882|NCT00146588|DRUG|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
47934883|NCT00146588|DRUG|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
48459552|NCT01528735|DRUG|BI 207127 NA|one fix dose
48459553|NCT01528735|DRUG|peginterferon|per package insert
48459554|NCT01528735|DRUG|Ribavirin|per weight BID
48459555|NCT01528735|DRUG|Ribavirin|per weight BID
48459556|NCT01528735|DRUG|BI 207127 NA|one fix dose
48459557|NCT01528735|DRUG|BI 201335 NA|high dose
48459558|NCT01528735|DRUG|BI 201335 NA|low dose
48459559|NCT01528735|DRUG|peginterferon|per package insert
48459560|NCT05193734|DRUG|Pertagen®|"Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
48459561|NCT05193734|DRUG|Revaxis®|"Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
48459562|NCT05073523|OTHER|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
48459563|NCT03776344|DEVICE|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
48459564|NCT01250730|DRUG|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
48459565|NCT01250730|DRUG|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
48459566|NCT01250730|DRUG|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
48459567|NCT04462276|DRUG|Atezolizumab|fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
48459568|NCT04462276|RADIATION|thoracic radiotherapy (TRT)|30 Gy in 10 fractions
47934884|NCT00146588|DRUG|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
47934885|NCT02217540|OTHER|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
47934886|NCT02217540|OTHER|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
47934887|NCT05369260|OTHER|Telerehabilitation-based cervical and scapular stabilization exercises|Telerehabilitation based cervical and scapular stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
47934888|NCT05369260|OTHER|Telerehabilitation-based cervical and core stabilization exercises|Telerehabilitation based cervical and core stabilization exercises will be applied via videoconference method for 8 weeks, one day a week , 45-60 minutes for each session.
48459569|NCT02519153|DRUG|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
47934889|NCT01066676|DRUG|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
47934890|NCT01066676|DRUG|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
47934891|NCT01646294|DRUG|YM178 modified release (OCAS)|oral
47934892|NCT01646294|DRUG|YM178 immediate release (IR)|oral
47934893|NCT01028378|DEVICE|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
47934894|NCT00383773|PROCEDURE|Retinal endo vascular surgery|
47934895|NCT06002022|DEVICE|REBECCA system (smartwatch + mobile app use)|Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
47934896|NCT00873860|OTHER|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
47934897|NCT00873860|BIOLOGICAL|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
47934898|NCT00873860|BIOLOGICAL|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
47934899|NCT00873860|BIOLOGICAL|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
47934900|NCT03044639|DRUG|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
48459570|NCT03564587|BEHAVIORAL|AWAKE|Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
48459571|NCT00419224|BIOLOGICAL|inactivated split-virus influenza vaccine|
48459572|NCT06363799|OTHER|4th ventricle compression technique|"For the CV4 the mediator's hands assume a specific position: one on top of the other, with the tips of the thumbs joined together in a V shape, positioned approximately on the process spinous between the patient's second and third cervical vertebrae, pointing downwards."
47934901|NCT00008827|BEHAVIORAL|Behavioral weight loss|
47934902|NCT04132245|BEHAVIORAL|behavioral intervention|Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention
48459573|NCT06363799|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 5 minutes.
48459574|NCT06363799|OTHER|Diaphragmatic breathing technique|For the diaphragmatic breathing the participant will place one hand on their chest and the other over their abdomen. Both of their hands will be overlapped by the mediator's, so it is easier to feel the correct breathing movements to be performed.
48459575|NCT06009796|DEVICE|Tooth Tissue Borne Rapid Palatal Expansion|In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.
48459576|NCT06009796|DEVICE|Tooth Bone Borne Rapid Palatal Expansion|After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
48459577|NCT01057368|BEHAVIORAL|Day of intensive meditation practice|Long-term meditators practice for \~6 hours of meditation at each time point
48459578|NCT01057368|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
48459579|NCT01057368|BEHAVIORAL|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
48459580|NCT01196949|OTHER|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
48459581|NCT01196949|OTHER|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
48478796|NCT00934596|PROCEDURE|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV \& Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
48098913|NCT05266365|OTHER|The standard exercise group (SE)|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~An exercise program will be performed at the clinic."
48098914|NCT00713739|DRUG|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
47934903|NCT04132245|BEHAVIORAL|Obesity prevention intervention trial|Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
48098915|NCT00713739|DRUG|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
48098916|NCT00713739|DRUG|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
47934904|NCT00208182|DRUG|Risperidone|
47934905|NCT05228457|DEVICE|Intensive intermittent theta-burst stimulation (iTBS)|Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
47934906|NCT05945680|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
47934907|NCT05945680|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
47934908|NCT02873403|DEVICE|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
47934909|NCT02873403|DEVICE|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
47934910|NCT04585139|DEVICE|Phase 1- Introduction to Dexcom G6 CGM|Examine whether non-adjunctive use of CGM improves glycemic control in adults with diabetes managed by intensive insulin therapy
47934911|NCT06518005|DRUG|Imlifidase|Imlifidase: single administration (dose is confidential), Lyophilized powder for concentrate for solution for infusion
47934912|NCT06518005|DRUG|GNT0003|GNT0003: single administration 5E+12 VG/kg, Sterile concentrate for solution for infusion
47934913|NCT02388048|DRUG|Ibrutinib + ofatumumab|
48281231|NCT02566512|OTHER|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
48459582|NCT05945472|OTHER|Positive reinforcement method|"A 30-minute talk based on mindfulness, positive thinking and teaching for the application of the cosmetic through positive messages (Ayuna method). Adapts the teachings of mindfulness to the field of beauty and stimulates the skin-brain connection through self-care. By applying cosmetics through intentional massages, with this technique is stimulated the brain in a positive positively in the general wellbeing.~The cosmetic is applied with a massage aimed at loving oneself, a ceremony for the skin and an invitation to enjoy the moment; positive messages are included during the application. In addition to favoring the penetration of the products, these maneuvers help to disconnect and achieve, in the long term, a healthier appearance. The technique consists of slow, intentional movements to create an ideal space to become aware of the present moment and draw a love story with oneself."
48459583|NCT05945472|OTHER|Standard method|"A 30-minute talk based on how to administer it according to the guidelines of general cosmetology, related to the use and application of the cream, following conventional techniques of the cosmetic industry, which focus on the application of the product in the areas of wrinkles or with more treatment needs: anti-aging anti-stain anti-sagging anti-sagging product, anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging anti-sagging product. rejuvenating results to try to reduce the skin years, reduce wrinkles, loss of firmness, flaccidity and spots."
48459584|NCT03169816|DRUG|Lorcaserin|Lorcaserin 10mg, twice daily
48459585|NCT03169816|DRUG|Placebo|Matched placebo for lorcaserin condition dosed twice daily
47934914|NCT05466448|DRUG|RZL-012|concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
47934915|NCT03612856|DRUG|AB023- Dose 1|Participants will receive a single dose of 0.25 mg/kg AB023.
48098917|NCT00713739|DRUG|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
48098918|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation according to body weight every other day
48459586|NCT06138561|BEHAVIORAL|Geriatric-8 Survey|A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring \> 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
48459587|NCT06138561|BEHAVIORAL|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)|Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
48459588|NCT06138561|BEHAVIORAL|Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)|Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
48459589|NCT00452023|DRUG|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
48459590|NCT00189553|DRUG|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
48459591|NCT00189553|DRUG|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
48459592|NCT00189553|DRUG|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
48459593|NCT01466894|BIOLOGICAL|IMM 124-E|Tablets orally twice a day for 24 weeks
48459594|NCT01466894|BIOLOGICAL|Placebo|Tablets orally twice daily for 24 weeks
47934916|NCT03612856|DRUG|AB023-Dose 2|Participants will receive a single dose of 0.5 mg/kg AB023.
47934917|NCT03612856|DRUG|placebo|Participants will receive a single dose of placebo.
47934918|NCT05448976|OTHER|Saliva and serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis.
48098919|NCT06631612|DRUG|ferric hydroxide polymaltose complex|participants will receive oral iron supplementation dose according to body weight daily
48098920|NCT06631612|DRUG|Albendazole.|both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
48098921|NCT00286741|OTHER|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
48098922|NCT06630715|DRUG|Upadacitinib 15 MG [Rinvoq]|15 mg/ day
48098923|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
48098924|NCT02947815|DRUG|Clostridium Botulinum Toxin Type A|
48098925|NCT05160675|OTHER||No intervention
48098926|NCT03970811|PROCEDURE|Immediate Implants|dental implants are immediately placed after tooth extraction
48098927|NCT03970811|PROCEDURE|temporary restoration|temporary restoration will be placed immediately after implant placement
48098928|NCT03970811|PROCEDURE|final restoration|final restoration (loading) will be placed 3 months postsurgical
48098929|NCT05677282|DRUG|Rifaximin 550 MG|Rifaximin 550 mg as a single dose administered orally.
48098930|NCT05677282|DRUG|Azithromycin 500 MG|Azithromycin 500 mg as a single dose administered orally.
48098931|NCT05677282|DRUG|Loperamide|4 mg loperamide administered orally with study antibiotic (rifaximin or azithromycin). Additional loperamide to use as needed, but not to exceed 16 mg/day for 2 days as per licensed use (one 2 mg capsule after each looses stool).
48098932|NCT03768206|BEHAVIORAL|Standard Physical Therapy|Participants will receive standard outpatient physical therapy that is typical following knee replacement
48098933|NCT03768206|BEHAVIORAL|Physical therapist discuss aerobic physical activity|Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
48459595|NCT03522532|PROCEDURE|Amalgam placement|Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
48459596|NCT03522532|PROCEDURE|Tetric EvoCeram placement|Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
48459597|NCT03522532|PROCEDURE|Beautifil placement|Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
48459598|NCT03522532|PROCEDURE|Zinc phosphate cement placement|Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
48459599|NCT03522532|PROCEDURE|Zinc polycarboxylate cement placement|Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
48459600|NCT03522532|PROCEDURE|Glass ionomer cement placement|Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
48459601|NCT02436200|DEVICE|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
48459602|NCT01437735|DRUG|QAW039|QAW039 po
48459603|NCT01437735|DRUG|Montelukast|Montelukast 10 mg po
48459604|NCT01437735|DRUG|Placebo|Placebo
48459605|NCT06529146|DRUG|BHV-4157|BHV-4157 (troriluzole) 200 mg QD
48459606|NCT03708536|DRUG|S-1|S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).
48459607|NCT03708536|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.
48459608|NCT03708536|DRUG|Capecitabine|Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
48459609|NCT06298162|OTHER|2 years after RYGB, no intervention. MRI measurement. Observational.|no intervention. MRI measurement. Observation.
48459610|NCT03229057|DRUG|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
48459611|NCT03229057|DRUG|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
48459612|NCT03229057|DRUG|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
48459613|NCT00114504|DRUG|simvastatin|simvastatin 5-10 mg/day
48459614|NCT03734354|DRUG|Brexpiprazole|Brexpiprazole , single/oral/with fasting
48459615|NCT06209255|PROCEDURE|Pelvic Osteotomy - Ganz Procedure|Ischial osteotomy was performed on the pubic arch; this was followed by iliac osteotomy, performed using Schanz screws in the iliac wing. The osteotomized acetabulum was overturned, and inclination was reduced.
48459616|NCT01426568|BEHAVIORAL|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
48459617|NCT06366555|PROCEDURE|Manual Acupuncture Twirling,|Manual Acupuncture twirling : using 0.14x 25 mm needle, punctured and penetrated the skin and then a twirling manipulation is carried out, 180 degrees, 3 rad/second, for 30 second each at LU5 and PC2. The needles retained for 20 minutes and manipulated at 0 minutes and 10 minutes.
48459618|NCT06366555|PROCEDURE|Manual Acupuncture Sham|Manual Acupuncture Sham : Using 0.14x25mm needles on plesterin without being penetrated into skin and no manipulation given, retained for 20 minutes
48459619|NCT02943538|DEVICE|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
48459620|NCT02943538|DEVICE|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
48459621|NCT02943538|OTHER|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
48459622|NCT02011828|DRUG|Ergocalciferol|50,000 IU/week
47934919|NCT00003567|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
47934920|NCT00003567|BIOLOGICAL|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
48459623|NCT02011828|DRUG|Placebo|Placebo tablet
48459624|NCT04778358|DRUG|Follitropin Delta, Recombinant|15 µg of follitropin delta will be administered subcutaneously daily
48459625|NCT03334734|DRUG|PBTZ169|Once a day for 14 days
48459626|NCT03334734|DRUG|Isoniazid|Once a day for 14 days
48459627|NCT04844411|DRUG|JNJ-67835989|JNJ-67835989 will be administered orally.
47934921|NCT00003567|BIOLOGICAL|therapeutic autologous lymphocytes|
47934922|NCT00003567|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
48459628|NCT04844411|DRUG|Placebo|Matching placebo will be administered orally.
48459629|NCT02030535|DRUG|olodaterol|free combination with tiotropium
48098934|NCT03768206|BEHAVIORAL|Physical activity session|Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
48459630|NCT02030535|DRUG|tiotropium|free combination with olodaterol
48459631|NCT02030535|DRUG|Placebo|
48459632|NCT02030535|DRUG|tiotropium|fixed dose combination with olodaterol
47934923|NCT00003567|DRUG|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
47934924|NCT00003567|DRUG|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
47934925|NCT00003567|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
48098935|NCT01899222|DEVICE|Handheld fundus photography|diagnostic imaging with two types of retina camera
48098936|NCT00631475|DRUG|Bosentan|"For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)"
48459633|NCT02030535|DRUG|olodaterol|fixed dose combination with tiotropium
48459634|NCT01791062|DEVICE|HYTOP®|HYTOP® will be implanted once during surgery.
48459635|NCT00292227|DRUG|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
48459636|NCT00292227|OTHER|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
48459637|NCT00292227|DRUG|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
48459638|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
48459639|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
48459640|NCT00913627|DRUG|ibuprofen|
48459641|NCT00913627|DRUG|ibuprofen|
48459642|NCT00913627|DRUG|naproxen|
48459643|NCT00913627|DRUG|Placebo|
48459644|NCT03248128|DRUG|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
48459645|NCT03248128|DRUG|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
47934926|NCT00769483|DRUG|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
48098937|NCT05686356|DRUG|Sutezolid|Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.
48098938|NCT05686356|DRUG|N-acetyl cysteine|NAC will be given at a dose of 1800 mg BID in arm 3
48098939|NCT05686356|DRUG|Pretomanid|Pretomanid will be given at its approved dose
48098940|NCT05686356|DRUG|Bedaquiline|Bedaquiline will be given at its approved dose
48098941|NCT05686356|COMBINATION_PRODUCT|Rifafour|Fixed dose combination tablets for TB treatment will be given at approved doses
48098942|NCT03738657|OTHER|Olfactory screening|Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
48098943|NCT03738657|OTHER|Quantative Gustatory Testing using Taste Strips|"Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip."
48459646|NCT04057105|DEVICE|Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)|Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
48459647|NCT04057105|DEVICE|MusicGlove|Both groups will undergo MusicGlove video-game based hand exercises.
48459648|NCT00068042|DRUG|Pegvisomant|
48459649|NCT00068042|DRUG|Sandostatin LAR|
48459650|NCT06454747|DRUG|SM-030 gel 0.64%|Topical application to face twice daily for 12 weeks
48459651|NCT06454747|DRUG|Placebo gel|Topical application to face twice daily for 12 weeks
48459652|NCT06454747|DRUG|SM-030 gel 0.08%|Topical application to face twice daily for 12 weeks
48459653|NCT03814122|BEHAVIORAL|Action-based cognitive remediation|Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
48459654|NCT03814122|OTHER|Waitlist Control Group|Receive treatment-as-usual through regular early psychosis programming.
48459655|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 1)|In Stage 1 the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest (where the vital signs are evaluated); II. Warming-up (composed of 15 minutes of stretching and global exercises); III. Aerobic exercise (composed of 30 minutes of treadmill or cycle ergometer exercise, the intensity established varies from 40 to 70% of the heart rate reserve for those diagnosed with cardiovascular diseases and from 60 to 80% of the heart rate reserve for those with only cardiac risk factors); IV. Cooldown (composed of 5 minutes of slow walking).
48459656|NCT04790643|OTHER|Exercise-based cardiac rehabilitation program (Stage 2)|In Stage 2, the volunteers will perform 24 sessions of exercise-based cardiac rehabilitation. The rehabilitation session is composed of the following activities: I. Initial rest; II. Warming-up; III. Aerobic exercise (these three activities are the same as stage 1); IV. Resistance training (composed of 15 minutes of individualized resistance exercises); V. Cooldown.
48459657|NCT00961376|BIOLOGICAL|PBMC re-infusion|Autologous PBMC re-infusion
48459658|NCT00961376|BIOLOGICAL|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
48459659|NCT03487939|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
48459660|NCT00318188|PROCEDURE|standardized reeducation and readaptation program|
48459661|NCT04737239|OTHER|Corticosteroid injections for CTS treatment|Treatment of carpel tunnel syndrome with corticosteroid injections for EMG mild and EMG negative patients
48459662|NCT04998526|OTHER|Experimental group|The cold gel pack will be applied to the nape.
48459663|NCT04998526|OTHER|Placebo group|The gel pack kept at room temperature will be applied to the nape.
48459664|NCT04260373|DRUG|[14C]SHR4640|Patients will receive single dose of orally \[14C\]SHR4640 on Day 1.
48459665|NCT06102148|OTHER|PNF Group|Exercise training and PNF training
48459666|NCT06102148|OTHER|Control Group|Exercise training
48459667|NCT00529191|DRUG|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
48459668|NCT00529191|OTHER|Placebo|One out of three subjects will receive a placebo.
48459669|NCT03999008|DRUG|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
48459670|NCT03999008|DRUG|Placebos|Apple Sauce 5 mL+ 1 mL saline
47934927|NCT00769483|DRUG|Gemcitabine|1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
47934928|NCT00769483|DRUG|Erlotinib|100 mg by mouth daily.
47934929|NCT06491667|DIAGNOSTIC_TEST|CBC|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
48459671|NCT01719770|DRUG|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
48459672|NCT01719770|OTHER|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
48459673|NCT05762705|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
48459674|NCT05762705|BEHAVIORAL|Treatment as Usual +|non-PrEP related mobile gaming application
48459675|NCT05461716|DEVICE|periodic use of Continuous Glucose Monitoring (CGM)|Identification of hypoglycaemia events, based on use of Continuous Glucose Monitoring (CGM) for at least 14days, in subgroups of T2DM patients with high risk of hypoglycaemia
48459676|NCT01663662|DRUG|Tolvaptan|
48459677|NCT01663662|DRUG|placebo|
48459678|NCT01739647|DRUG|AZD3293|Oral solution
48459679|NCT01739647|DRUG|Placebo|Oral solution
48459680|NCT05080387|OTHER|Blood sample|Blood samples will obtained for measurement of neopterin level through ELIZA
48459681|NCT00052221|BIOLOGICAL|Epoetin alfa|
48459682|NCT00052221|OTHER|Placebo|
48459683|NCT01995162|DEVICE|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
48459684|NCT03510208|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
48098945|NCT05717686|DRUG|AHB-137 injection|AHB-137 will be administered
48098946|NCT05717686|DRUG|Placebo|Placebo will be administered
48459685|NCT03510208|BIOLOGICAL|Panitumumab|Given IV
48459686|NCT03510208|DRUG|Panitumumab-IRDye800|Given IV
48459687|NCT03510208|DEVICE|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
48459688|NCT03007563|DEVICE|bilirubin concentration estimation from smartphone pictures|pictures taken of the skin covering the breast bone
48459689|NCT03007563|PROCEDURE|bilirubin concentration measured in standard blood samples|
47934930|NCT06491667|DIAGNOSTIC_TEST|C-reactive protein|Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
47934931|NCT05000333|OTHER|Self-questionnaire|The study will be proposed to caregivers who work at Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges, who agree to answer the questionnaire anonymously
47934932|NCT04188171|PROCEDURE|Polidocanol foam sclerotherapy|"* Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~* Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~* In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~* During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~* After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months."
47934933|NCT01490723|DRUG|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
48459690|NCT03007563|DEVICE|bilirubin concentration measured by transcutaneous device|
48459691|NCT01350986|BEHAVIORAL|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006)."
48459692|NCT01350986|BEHAVIORAL|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
48459693|NCT00314834|DRUG|Intradialytic parenteral nutrition|
48459694|NCT05411653|OTHER|Virtual reality training with motor imagery|comprised of 30 minutes, VRT (15 minutes) and MI (15 minutes) daily for 3 days respectively. Five Xbox Kinect gaming will be selected and explained to the patients for the virtual training session and additional 15 minutes will be given to them for practice. The games consists of 20,000 water leaks, river rush, reflex ridge, soccer and football for the patients.
48459695|NCT05411653|OTHER|Conventional physical therapy|range of motion exercises, muscle strengthening, functional training, balance training, and gait training. The specific tasks will be selected by the therapist based on the requirement of each patient. It will be performed for 30 minutes for 3 days a week for 6 weeks
48459696|NCT03879187|DIETARY_SUPPLEMENT|High-fat, high-energy diet|Participants consumed a diet that was high in fat and high in energy
47934934|NCT01490723|DRUG|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
47934935|NCT01490723|PROCEDURE|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
47934936|NCT01490723|DRUG|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
47934937|NCT01490723|DRUG|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
47934938|NCT01490723|DRUG|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
47934939|NCT01490723|DRUG|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
48098947|NCT06628791|DIETARY_SUPPLEMENT|BK329|Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks
48098948|NCT06628791|DIETARY_SUPPLEMENT|Placebo|Placebo 400 mg/day for 12 weeks
48098949|NCT03213470|OTHER|magnetic resonance imaging|
48459697|NCT02911909|DEVICE|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
48459698|NCT02911909|OTHER|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
48623176|NCT04557644|OTHER|7-items-questionnaires addressing CI, disgust and empathy|7-items-questionnaire including numerical rating scales (NRS) ranging from 0 (no itch/disgust/empathy) to 10 (worst itch/disgust/most empathy imaginable) to rate itch, disgust and empathy they experience when treating the infested families.
48623177|NCT04557644|OTHER|Saarbrucken Personality questionnaire (SPQ) addressing empathy.|Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.
48098950|NCT01207908|DRUG|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
48281232|NCT02566512|OTHER|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
48459699|NCT03584308|DIETARY_SUPPLEMENT|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
48459700|NCT03584308|DIETARY_SUPPLEMENT|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
48459701|NCT03584308|DIETARY_SUPPLEMENT|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
48459702|NCT03584308|DIETARY_SUPPLEMENT|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
48459703|NCT02173964|DRUG|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
48459704|NCT02173964|DRUG|water|same amount of water for pinverin administration
48459705|NCT02671630|OTHER|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
48459706|NCT06227741|OTHER|Concept Mapping: as a Tool for Problem Based Learning|Concept mapping is a visual representation and organizational tool that illustrates the relationships between concepts, ideas, and information. It involves creating a graphical depiction of knowledge, typically using nodes or boxes to represent concepts and connecting lines or arrows to signify the relationships between them. The central concept or main idea is often positioned in the center of the map, with subsidiary concepts branching out from it. These maps serve as a comprehensive overview of a subject, highlighting the hierarchical structure and interconnectedness of various elements.
48459707|NCT03503435|BEHAVIORAL|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
48459708|NCT00664053|DIETARY_SUPPLEMENT|DHEA|50mg daily for 6 months
48459709|NCT00664053|BEHAVIORAL|Yoga|2 sessions per week for 6 months
48459710|NCT00664053|DIETARY_SUPPLEMENT|Placebo|Placebo supplement every day for 6 months
48459711|NCT00664053|BEHAVIORAL|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
48459712|NCT05435534|OTHER|ActiveFLS intervention|"* A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~* A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~* Osteoporosis treatments according to national guideline~* A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~* An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~* Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
48459713|NCT05435534|OTHER|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
48459714|NCT01816360|OTHER|Olfactory aromatherapy|Inhalation of essential oils.
48459715|NCT01816360|OTHER|Yogatherapy|Yogatherapy respiratory exercises.
48459716|NCT02339038|DRUG|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
48459717|NCT03391505|BEHAVIORAL|Small-sided soccer game|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
48459718|NCT03391505|BEHAVIORAL|Walking soccer game|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
48459719|NCT03391505|BEHAVIORAL|Rest group watching soccer|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
48459720|NCT00266487|DRUG|Folic acid|
48459721|NCT00266487|DRUG|Vitamin B12|
48459722|NCT00266487|DRUG|Vitamin B6|
48459723|NCT03960762|OTHER|ESP block (Group ESP)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block
48623178|NCT04557644|OTHER|10-items-questionnaire addressing previous dermatological conditions, intensity of itch|10-items-questionnaire (completed by the hospitalised family) regarding demographic information (gender, age, profession), previous dermatological conditions, intensity of itch a.) on the first day of the hospitalisation, b.) when seeing the skin lesions of the other family members c.) when talking about the scabies/itch with the other family members, d.) when seeing other family members scratching themselves, and questions regarding their intensity of disgust of the scabies and empathy for the other family members (0-10 NRS).
48623179|NCT04557644|OTHER|ItchyQol-questionnaire composed of 22 items addressing itch-related symptoms, functions and emotions|ItchyQol-questionnaire to assess the itch-related quality of life impairment. The ItchyQoL is composed of 22 items addressing itch-related symptoms, functions and emotions.
48281233|NCT04407377|DRUG|Tolperisone Hydrochloride|Study Drug
48281234|NCT04407377|DRUG|Cyclobenzaprine Hydrochloride 10 MG|Active Comparator
48459724|NCT03960762|OTHER|SAP block (Group SAP)|In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
48459725|NCT00005967|DRUG|tipifarnib|
48459726|NCT05828290|BEHAVIORAL|Child Yoga|The children's yoga consists of compositions such as playing, stories, postures, breathing exercises, imitations things in nature, memory games, music, dance and daydreaming.
48459727|NCT02028039|DRUG|IPI-145|75 mg orally twice daily for 4 weeks.
48459728|NCT02028039|BEHAVIORAL|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
48459729|NCT02708251|DRUG|glyceryl trinitrate cream|
48459730|NCT02708251|DRUG|lidocaine cream|
48459731|NCT02708251|DRUG|placebo cream|
48459732|NCT05746143|DRUG|Zolpidem Tartrate 10 mg|two days preoperatively and five days postoperatively
48459733|NCT05746143|DRUG|Placebo|two days preoperatively and five days postoperatively
48459734|NCT06149949|OTHER|Observational study|the aim of the study is to define the prevalence of rhinosinusitis cronic in intestinal bowel disease patients, to assess how it affects the patient's quality of life, and any correlations between these two entities
48459735|NCT00978536|OTHER|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
48459736|NCT05172687|BEHAVIORAL|Overprescribing letter to attributed physician|Letter telling patient's attributed physician they were under review for high prescribing
48459737|NCT05172687|BEHAVIORAL|Placebo letter to attributed physician|Letter to patient's attributed physician about unrelated Medicare regulation
48459738|NCT02501863|DRUG|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
48459739|NCT02501863|DRUG|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
48459740|NCT01939080|PROCEDURE|Exercise training with supervised sessions|
48623180|NCT06034392|DEVICE|CHAMP App|CHAMP® App is a downloadable software mobile Application with a Software Platform. CHAMP® App is an electronic version of data entry for children with conditions that require close monitoring from their homes. The primary Intended Use is to relay monitoring information from homes to the health care team. This monitoring includes data options that can facilitate the collection of monitoring data of children in the home setting to improve communications between parents at home and remote caregivers. The CHAMP® App itself does not do home monitoring of the child's medical condition. It is not designed to alert parents if data entered has reached a red flag (problem) level. Users of the CHAMP App are advised in writing and in the informed consent process that urgent medical conditions should not be managed through the CHAMP App, and that appropriate emergency care should be obtained directly rather than through the CHAMP App.
48623181|NCT01819662|OTHER|Enhanced standard management|Echocardiogram followed by letter to GP about results.
47934940|NCT01490723|DRUG|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
48459741|NCT02498938|GENETIC|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
48281235|NCT04407377|OTHER|Placebo|Placebo Comparator
48281236|NCT03817918|PROCEDURE|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
48459742|NCT06626542|OTHER|resistance and aerobic training exercises|resistance and aerobic training exercises
48459743|NCT05284539|DRUG|Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab|Pemetrexed, 500mg/m2, ivgtt, every 21 days. Bevacizumab 15mg/kg, ivgtt, every 21 days. Pembrolizumab, 200mg ivgtt, every 21 days. Atezolizumab, 1200mg, ivgtt, every 21 days.
48459744|NCT06285448|DRUG|Lecanemab|Bi-weekly infusions of lecanemab \[exposure\].
48459745|NCT05565690|DEVICE|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
48459746|NCT03595462|OTHER|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be \~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be \~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
48459747|NCT03595462|OTHER|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
48459748|NCT00844922|DRUG|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
48459749|NCT00844922|DRUG|Placebo|Placebo
48459750|NCT00095160|DRUG|852A|
48459751|NCT03784534|OTHER|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
48459752|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
48459753|NCT03784534|BEHAVIORAL|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
48459754|NCT05723796|PROCEDURE|nasal endoscopy|nasal endoscopy and mucosal biopsy
48459755|NCT01101386|DRUG|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
48459756|NCT04872608|DRUG|Letrozole|Letrozole will be given daily on days 1-28.
48459757|NCT04872608|DRUG|Palbociclib|Palbociclib will be given daily on days 1-21 and held on days 22-28, as per standard FDA-approved dosing guidelines.
48459758|NCT04872608|DRUG|Onapristone ER|Onapristone will be given daily on days 1-28.
48459759|NCT04912726|DRUG|Sildenafil Injectable Product|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
48459760|NCT05545436|DRUG|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )|Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
48459761|NCT03911115|OTHER|Food preference questionnaire|This is an online questionnaire administrated once to the participants, to assess food preferences after bariatric surgery. The investigating team will also collect data on the type of surgery, anthropometry, nutrition, taste, smell, disgust and intolerance as well as sociodemographic data.
48459762|NCT03453554|OTHER|Digital Notebook app|Training in use of Digital Memory Notebook app
48459763|NCT03453554|OTHER|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
48459764|NCT03002935|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
48459765|NCT05092464|DEVICE|Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
48459766|NCT02832960|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
48459767|NCT02832960|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
48623182|NCT01819662|OTHER|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
47934941|NCT01490723|DRUG|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
47934942|NCT01490723|DRUG|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
47934943|NCT01490723|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
48459768|NCT03821974|PROCEDURE|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
48459769|NCT03821974|PROCEDURE|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
48459770|NCT00072514|DRUG|gemcitabine hydrochloride|Given IV
48459771|NCT00072514|DRUG|carboplatin|Given IV
48459772|NCT00072514|DRUG|dexamethasone|Given PO
48459773|NCT00072514|BIOLOGICAL|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
48459774|NCT04193150|DIAGNOSTIC_TEST|Full pulmonary specialist assessment|Please see description for the intervention arm.
48459775|NCT01586039|DEVICE|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
48459776|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
48459777|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
48459778|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
48623183|NCT01819662|OTHER|Standard management|Usual care
48623184|NCT04393948|RADIATION|Phase 1|Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
48623185|NCT04393948|RADIATION|Phase 1|Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
48623186|NCT04393948|RADIATION|Phase 2|Arm A - No irradiation
47934944|NCT01490723|PROCEDURE|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
48459779|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
48459780|NCT00985751|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
47934945|NCT03792984|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
48459781|NCT05644392|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
48459782|NCT05644392|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
48459783|NCT00109954|DRUG|cisplatin|
48459784|NCT00109954|RADIATION|brachytherapy|
48459785|NCT00109954|RADIATION|yttrium Y 90 glass microspheres|
47934946|NCT03792984|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate (1000 mg/daily). PO for 8 weeks.
47934947|NCT03792984|DRUG|Metformin|Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
47934948|NCT03792984|DRUG|Placebo|PO for 8 weeks.
47934949|NCT05141825|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
47934950|NCT04271280|OTHER|Non-interventional|This is a non-interventional study.
47934951|NCT01639586|BEHAVIORAL|respite platform|Impact of the respite platform patient care on health profit
48281237|NCT04970706|PROCEDURE|ACL reconstruction|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
48459786|NCT00483743|DRUG|TPI 1020|250 mcg/caps 2 caps BID x 42 days
48459787|NCT00483743|DRUG|Budesonide|400mcg mcg capsules- 2 capsules BID
48459788|NCT00483743|DRUG|Placebo|2 caps BID x42 days
48459789|NCT00533507|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
48459790|NCT00533507|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
47934952|NCT01639586|BEHAVIORAL|Day care|Impact of the day care on health profit of patient
47934953|NCT01639586|BEHAVIORAL|No access to a respite structure|Control group without access to a respite structure
47934954|NCT05814601|DRUG|norepinephrine|norepinephrine at a concentration of 5 mcg/ml is preemptively administered
47934955|NCT00749554|DEVICE|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
47934956|NCT00749554|DEVICE|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
47934957|NCT02267642|BIOLOGICAL|AbGn-168H|monoclonal antibody
47934958|NCT06240507|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
47934959|NCT06240507|PROCEDURE|fluoroscopy-guided intralesional radiofrequency thermocoagulation|The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
47934960|NCT02829541|DRUG|BIIB068|Administered as specified in the treatment arm.
48459791|NCT00533507|BIOLOGICAL|Rotarix|Oral, 2 doses.
48459792|NCT02910687|OTHER|This is an observational study|
48459793|NCT01667822|BEHAVIORAL|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
48459794|NCT01667822|BEHAVIORAL|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
48459795|NCT00357461|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
48459796|NCT00357461|BIOLOGICAL|gp100:280-288(288V) peptide vaccine|
48459797|NCT00357461|BIOLOGICAL|incomplete Freund's adjuvant|
47934961|NCT02829541|DRUG|Placebo|Administered as specified in the treatment arm
47934962|NCT04123028|OTHER|observatory|observation for 1 year period
47934963|NCT02410733|BIOLOGICAL|Lipo-MERIT|vaccination
48281238|NCT01468519|DRUG|Insulin|Insulin via continuous subcutaneous insulin infusion
48281239|NCT01468519|DRUG|Insulin|insulin via multiple daily injections
48281240|NCT00073190|BEHAVIORAL|Osteoporosis Education|
48459798|NCT00357461|BIOLOGICAL|ipilimumab|
48459799|NCT03892343|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
48459800|NCT04876716|DRUG|Azole|Dosing according to the SPC
48459801|NCT04876716|DRUG|Anidulafungin|200mg loading dose on day 1 and 100mg QD thereafter
48459802|NCT01046097|BIOLOGICAL|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
48459803|NCT01717313|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
48459804|NCT01717313|DRUG|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
48459805|NCT01717313|DRUG|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
48623187|NCT04393948|RADIATION|Phase 2|Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
48459806|NCT01717313|DRUG|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
48459807|NCT01717313|DRUG|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
48459808|NCT03095781|DRUG|XL888|Given PO
48459809|NCT03095781|BIOLOGICAL|Pembrolizumab|Given IV
48459810|NCT04807595|OTHER|None (Observational study)|The data source for this project will be HER2 IHC historical scores, local lab rescoring of historical HER2 fixed tissue slides, independent central retesting or local lab retesting (under special occasions) of HER2 IHC status for enrolled patients who have available tissue, other biomarker testing results based on historical testing and/or testing of archived tissue samples when available, and curated patient-level data. Real-world data sources include electronic health records/electronic medical records (EHR/EMR) and biobank registries. Data from EHR/EMR sources will be curated. Biobank tissue for enrolled patients who have multiple samples available will be selected consecutively when possible and will start with the latest available samples then move backward in time.
48459811|NCT00949819|OTHER|Active surveillance|Serial, long term data collection and active surveillance
48459812|NCT01085981|DRUG|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
47934964|NCT01415193|PROCEDURE|Selective Tibial Nerve block|Use of selective pain block.
47934965|NCT01415193|PROCEDURE|Sciatic Nerve Block|Use of Sciatic Nerve Block
47934966|NCT06219551|OTHER|Mobile messages via What's App|The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.
47934967|NCT02914015|PROCEDURE|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
48459813|NCT01085981|DRUG|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
48459814|NCT01085981|DRUG|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
48623188|NCT04393948|RADIATION|Phase 2|Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
48623189|NCT02258061|PROCEDURE|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
48623190|NCT02258061|PROCEDURE|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
47934968|NCT02914015|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
47934969|NCT02914015|DRUG|Ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~* followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
47934970|NCT02914015|DRUG|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
47934971|NCT02259075|DRUG|Botulinum Toxin Type A|
47934972|NCT02573038|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
47934973|NCT02011893|DEVICE|Tonic Stimulation|Prodigy Neurostimulation System with associated components
47934974|NCT02011893|DEVICE|Burst Stimulation|Prodigy Neurostimulation System with associated components
47934975|NCT03701737|OTHER|questionnaires|"* VAS on the feeling of hunger~* Evaluation of food wanting by the Finlayson test~* PREFQUEST Questionnaire~* 24-hour food recall~* Stunkard Questionnaire~* Measurement of daytime sleepiness by Epworth score"
47934976|NCT03701737|DEVICE|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
47934977|NCT03701737|BIOLOGICAL|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
47934978|NCT04700033|DEVICE|Somatic IVR (sIVR)|This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
47934979|NCT04700033|DEVICE|Distractive IVR (dIVR)|This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
47934980|NCT04700033|DEVICE|Control IVR (cIVR)|This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
47934981|NCT04923165|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
48459815|NCT01930409|BEHAVIORAL|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~* Health Status~* Medication Management~* Activity/Exercise Prescription and Goal-Setting~* Falls Prevention~* Clarification of Appointments~* Coordination of Post-Discharge Home Services~* What To Do If a Problem Arises"
48459816|NCT01930409|BEHAVIORAL|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
48281241|NCT03977233|DRUG|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
47934982|NCT04923165|DIAGNOSTIC_TEST|biochemical analyses|ematochemical and biochemical serum analyses at T0 and at T1; oxidative stress analyses;
48281242|NCT03977233|DRUG|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
48281243|NCT03977233|DRUG|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
48281244|NCT03977233|DRUG|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
48281245|NCT01848314|PROCEDURE|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
48281246|NCT04101890|DRUG|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
48281247|NCT05794139|DRUG|NMD670|Tablets
48281248|NCT05794139|DRUG|Placebo|Tablets
47934983|NCT04923165|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1) , muscular force with hand grip
48281249|NCT03003819|DEVICE|Control Collagen Wound Dressing|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
47934984|NCT04923165|DIAGNOSTIC_TEST|nutritional assessment, MNA|nutritional status assessment with MNA, body mass index measurements, weight loss detection, food income detection
47934985|NCT04645485|BIOLOGICAL|Nebulization of autologous non-hematopoietic peripheral blood stem cells (NHPBSC).|Participants received the investigational therapy through compressor (jet) nebulization, in two doses divided on Days 0 and 1. Each dose contains 10 mL of peripheral blood-derived stem cells CD45-/CD90+/CD133+.
47934986|NCT01368718|PROCEDURE|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
47934987|NCT00205400|PROCEDURE|medical care delivery model|
47934988|NCT03133988|BIOLOGICAL|Margetuximab|anti-HER2 monoclonal antibody
47934989|NCT02497976|BIOLOGICAL|Certolizumab pegol|400 mg
47934990|NCT02497976|DRUG|Placebo|Normal saline
47934991|NCT04759183|OTHER|Survey Administration|Ancillary studies
47934992|NCT04759183|PROCEDURE|Virtual Reality Game|"Participate in VR Game Angry Birds"
47934993|NCT04759183|PROCEDURE|Virtual Reality Meditation|"Participate in VR Meditation TRIPP"
47934994|NCT01486810|DRUG|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
47934995|NCT01486810|BEHAVIORAL|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
47934996|NCT04972747|OTHER|skin care with sunflower oil|The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
47934997|NCT05067998|DIETARY_SUPPLEMENT|IV Vitamin Infused Therapy Treatment|Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
47934998|NCT05067998|DRUG|Herbal medicine|Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
47934999|NCT05095376|DRUG|Lomustine|Given PO
47935000|NCT05095376|RADIATION|Photon Beam Radiation Therapy|Undergo radiation therapy
47935001|NCT05095376|OTHER|Quality-of-Life Assessment|Ancillary studies
47935002|NCT05095376|OTHER|Questionnaire Administration|Ancillary studies
47935003|NCT05095376|DRUG|Temozolomide|Given PO
47935004|NCT01656174|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
47935005|NCT04920227|PROCEDURE|phacoemulsification;|Group A: class combined with phacoemulsification
47935006|NCT00991068|DRUG|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
47935007|NCT01554631|DRUG|Acarbose (Glucobay ODT, BAYG5421)|
47935008|NCT01554631|DRUG|Acarbose (Glucobay, BAYG5421)|
48281250|NCT03003819|DEVICE|Test Collagen Matrix|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
48281251|NCT03435978|BEHAVIORAL|MetS+|
48281252|NCT03435978|OTHER|MetS-|Data processing from Patient Medical Files
48459817|NCT04179396|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
48459818|NCT04179396|DRUG|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
48459819|NCT04179396|DRUG|Abiraterone|Abiraterone will be administered once daily with prednisone
48459820|NCT01519947|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
48459821|NCT04935905|DEVICE|Mechanical Insufflator-Exsufflator|This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism
48459822|NCT02977416|OTHER|anti-TNFα|
48459823|NCT06563219|OTHER|Glasgow coma scale|The levels of response in the components of the Glasgow Coma Scale are 'scored' from 1, for no response, up to normal values of 4 (Eye-opening response) 5 ( Verbal response) and 6 (Motor response) The total Coma Score thus has values between three and 15, three being the worst and 15 being the highest.
48459824|NCT06563219|OTHER|Hunt-Hess scale|"The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5:~* Grade 1: Asymptomatic or minimal headache, slight neck stiffness.~* Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy.~* Grade 3: Drowsiness, confusion, or a mild focal deficit.~* Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance.~* Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance."
48459825|NCT06563219|OTHER|World Federation of Neurological Surgeons (WFNS) scale|"The World Federation of Neurological Surgeons (WFNS) scale, introduced in 1988, is used to evaluate the clinical severity of patients with SAH. This scale is derived from the GCS score and considers the presence of motor deficits:~* Grade 1: GCS score of 15, no motor deficit~* Grade 2: GCS score of 13 to 14, no motor deficit~* Grade 3: GCS score of 13 to 14, with motor deficit~* Grade 4: GCS score of 7 to 12, with or without motor deficit~* Grade 5: GCS score of 3 to 6, with or without motor deficit"
48459826|NCT06563219|OTHER|modified Fisher scale|"The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed:~* Grade 0: No hemorrhage apparent in CT.~* Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH).~* Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH.~* Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH.~* Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH."
48459827|NCT06563219|OTHER|VASOGRADE scale|"The VASOGRADE scale was established to estimate the risk of delayed cerebral ischemia following SAH. This scale is based on the WFNS and the modified Fisher scales at admission. There are three categories:~* Green: WFNS score of 1 or 2 and modified Fisher scale of 1 or 2.~* Yellow: WFNS score of 1 or 3 and modified Fisher scale of 3 or 4.~* Red: WFNS score of 4 or 5 and any modified Fisher scale score."
48459828|NCT06563219|OTHER|Ogilvy and Carter scale|"The Ogilvy and Carter scale is a grading system used to predict the outcomes of surgical treatment in patients with SAH due to a ruptured aneurysm. The scale considers multiple factors, including age, Hunt and Hess grade, Fisher grade, and aneurysm size, with a score assigned to each of these variables:~* Age greater than 50~* Hunt and Hess grade of 4 to 5~* Fisher grade scores of 3 to 4~* Aneurysm size \>10 mm~* An additional point is added for a giant posterior circulation aneurysm (≥25 mm)"
48459829|NCT00617825|OTHER|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
48459830|NCT00870116|RADIATION|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
48459831|NCT00870116|RADIATION|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
48459832|NCT00870116|RADIATION|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
48459833|NCT01499043|DRUG|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
48098951|NCT04204330|DEVICE|CardioQvark cardiac monitor and software, single-lead ECG|"Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~1. Download the CardioQVARK mobile application; create a profile.~2. Fill out the questionnaire:~   * age;~  * date of birth;~  * sex;~  * weight;~  * height;~  * blood type;~  * eye color;~  * hair color;~  * occupation;~  * town;~  * alcohol consumption;~  * tobacco use;~  * overeating;~  * insufficient sleep;~  * hypertension;~  * type 2 diabetes;~  * pacemaker;~  * the 10th revision of the International Classification of Diseases (ICD-10) code;~  * medicines.~3. Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~* time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~* abnormal rhythms;~  * heart rate variability;~ * additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server."
48459834|NCT01963663|DRUG|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
48459835|NCT01963663|DRUG|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
48459836|NCT03987295|DRUG|AL001|60 mg/kg of AL001 every 4 weeks
48459837|NCT03005366|DRUG|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
48459838|NCT03005366|DRUG|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
48459839|NCT01703754|GENETIC|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
48459840|NCT01703754|DRUG|Palifosfamide|Small molecule chemotherapy, IV administration
48459841|NCT00001698|DRUG|Ketorolac Rinse|
48459842|NCT06089395|DRUG|Jiajian Guishen granules|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
48459843|NCT06089395|DRUG|coenzyme Q10|This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
48459844|NCT02331511|DRUG|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
48459845|NCT02331511|DRUG|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
48459846|NCT02331511|DRUG|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
48459847|NCT04257838|DRUG|Piperacillin/tazobactam or Meropenem|"The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~1. Just before the antibiotic infusion (T0)~2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels."
48459848|NCT04948619|BIOLOGICAL|Vaccine|Patients will have lab evaluations for immune function at baseline, 3, 6, 12, and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
48459849|NCT04858126|DEVICE|ECOM cardiac output|Measure cardiac output during perioperative period and compare to pulmonary artery catheter thermal dilution cardiac output measurement.
48459850|NCT00673660|BEHAVIORAL|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
48459851|NCT01616550|OTHER|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
48459852|NCT01616550|OTHER|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
48459853|NCT01616550|OTHER|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
48098952|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
48098953|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
48098954|NCT00880490|DRUG|Inhaled PT005|single dose, inhaled
48459854|NCT01616550|OTHER|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
48459855|NCT04391829|DIAGNOSTIC_TEST|Ejaculated semen sample|SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
48459856|NCT01032590|BEHAVIORAL|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
48459857|NCT00235027|OTHER|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
48459858|NCT00841022|OTHER|Information with comics|Information of children with comic leaflet
48459859|NCT03619330|DRUG|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
48098955|NCT00880490|DRUG|Inhaled placebo|single dose, inhaled
48098956|NCT00880490|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
48098957|NCT06102174|DRUG|Placebo|Placebo
48098958|NCT06102174|DRUG|Active|Sisunatovir
48098959|NCT02180087|DRUG|Ketoprofen|
48098960|NCT00906698|DRUG|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
48098961|NCT00906698|DRUG|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
48098962|NCT00906698|DRUG|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
48098963|NCT00906698|DRUG|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
48098964|NCT00906698|DRUG|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
48098965|NCT00906698|DRUG|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
48098966|NCT02485743|OTHER|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
48459860|NCT03619330|DRUG|Testosterone|In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
48459861|NCT04443049|DRUG|Lenvatinib|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg
48459862|NCT04443049|DRUG|Mebendazole|mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
48459863|NCT04443049|OTHER|Placebo|Placebo (Tab Mecovit) orally twice a day (BD) daily
48459864|NCT05336097|OTHER|Pathways to Empowerment|Pathways to Empowerment (PTE) is a program for person-centered intervention. PTE is rooted in the Strengths Model by Rapp and Goscha (2011), and in the Social Quality Approach as described by Van der Maesen and Walker (2005). The general aim of PTE is to improve the quality of the daily lives of persons who experience loss of control in their lives by focusing on their strengths and stimulating their personal agency, participation in society, and self-direction in life. The main task of professionals is to help create the conditions in which growth and recovery are likely to occur.
48459865|NCT00989053|DRUG|escitalopram|10 mg/d for a duration of 8 weeks
48459866|NCT00989053|DRUG|placebo|1 pill per day for 8 weeks
48459867|NCT05341154|DRUG|Ketamine Hcl 50Mg/Ml Inj|Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
48459868|NCT01206751|OTHER|Chest imaging technique and case presentation|
48098967|NCT02485743|OTHER|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
48098968|NCT05427357|OTHER|Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)|"Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats."
48098969|NCT00438555|BEHAVIORAL|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
48459869|NCT04283851|DIAGNOSTIC_TEST|testing functional haemodynamic parameters for preload assessment|dynamic testing of preload responsivity plus echocardiography
48459870|NCT03218150|PROCEDURE|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
48459871|NCT00838838|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 18yrs in medical practices fulfilling all criteria for documentation.
48459872|NCT03715751|OTHER|ASV|Adaptive Support Ventilation
48459873|NCT03715751|OTHER|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
48459874|NCT02575651|DRUG|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
48459875|NCT05710354|DIETARY_SUPPLEMENT|Nutridrink Compact Protein|Oral Nutritional Supplement, a liquid, ready-to-drink, high protein, high calorie blend. Intended for adult patients (from 18 years of age) with malnutrition or risk of its development. Produced by Nutricia
48459876|NCT02663349|BEHAVIORAL|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
48459877|NCT06399445|PROCEDURE|conventional cold tonsillectomy and curettage adenoidectomy|After entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
48459878|NCT06399445|DRUG|Rocuronium Bromide|After entering the operating room, chlidren will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths. After loss of consciousness, we will turn off Sevoflurane, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, 1 mcg/kg Fentanyl, 2.5 mg/kg Propofol and 0.6 mg/kg Rocuronium bromide (esmeron). After 2 min, orotracheal intubation will be performed.
48459879|NCT03415867|DRUG|Glasdegib|A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
48459880|NCT03192397|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
48459881|NCT03192397|DRUG|Cyclophosphamide|Given IV
48098970|NCT00438555|BEHAVIORAL|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
48098971|NCT04866056|DRUG|Jaktinib|Jaktinib PO BID
48098972|NCT04866056|DRUG|azacitidine|Azacytidine SC
48098973|NCT06219785|DEVICE|Low-Intensity Shockwave therapy (LiSWT)|Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
48098974|NCT04413565|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeon bilateral TKA group
48098975|NCT04413565|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
48098976|NCT00116740|DRUG|APD356|
48098977|NCT04759131|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form: solution for injection Route of administration: IV
48459882|NCT03192397|DRUG|Fludarabine Phosphate|Given IV
48459883|NCT03192397|OTHER|Laboratory Biomarker Analysis|Correlative studies
48459884|NCT03192397|DRUG|Melphalan Hydrochloride|Given IV
48459885|NCT03192397|DRUG|Mycophenolate Mofetil|Given IV
48459886|NCT03192397|DRUG|Sirolimus|Given IV and PO
48459887|NCT03192397|RADIATION|Total-Body Irradiation|Undergo TBI
48459888|NCT03121937|BEHAVIORAL|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
48459889|NCT03926650|DEVICE|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
48459890|NCT04988737|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
48281253|NCT04661813|OTHER|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
47935009|NCT04228575|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
47935010|NCT05719987|OTHER|Biodentine|After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
48459891|NCT04174053|DEVICE|Enteric capsule|Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
48459892|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by ICG|Use of ICG during the targeted axillary dissection (TAD)
47935011|NCT05719987|OTHER|MTA|After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
47935012|NCT05366673|OTHER|massage|Perform a 10-minute back massage every day for a week
48281254|NCT06042686|DEVICE|RF Health MAC Device|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
47935013|NCT05578001|DRUG|Pilocarpine Ophthalmic|1 drop of Pilocarpine 1%
47935014|NCT03784287|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
47935015|NCT04389814|DIAGNOSTIC_TEST|Biochemical markers|Multiple biomarkers of myocaridial ishemia will be obtained serially to calculate thier time of their release according to their release kinetics
48459893|NCT06339658|PROCEDURE|Targeted axillary dissection (TAD) by Blue patent|Use of Blue patent during the targeted axillary dissection (TAD)
47935017|NCT02516735|DEVICE|I-scan with magnification|
48459894|NCT01707316|DRUG|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
47935018|NCT02516735|DEVICE|Standard endoscopy|
47935019|NCT05261776|OTHER|pilates exercise|"Pilates exercise for 40 minutes (5 minutes for warm-up and 30 minutes of pilates and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-A will get 40 minutes of session, Alternative three days/ week for 12 weeks."
47935020|NCT05261776|OTHER|brisk walk|"Brisk walk on treadmill for 40 minutes (5 minutes for warm-up and 30 minutes of brisk walk on treadmill and 5 minutes for cool down). These participants will continue their standard care.~Patients in Group-B of 40 minutes of session, Alternative three days/ week for 12 weeks."
47935021|NCT02992132|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
47935022|NCT02992132|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
47935023|NCT02992132|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth
47935024|NCT02749955|BEHAVIORAL|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
47935025|NCT02749955|BEHAVIORAL|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
47935026|NCT05260346|DIETARY_SUPPLEMENT|Cranberry juice|composition: Water, cranberry juice concentrate
47935027|NCT05260346|DIETARY_SUPPLEMENT|Placebo|composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
47935028|NCT04481009|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
47935029|NCT04481009|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
48106914|NCT02852863|OTHER|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
48459895|NCT01707316|DRUG|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
48459896|NCT01707316|OTHER|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
47935030|NCT04481009|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
48459897|NCT03340545|OTHER|Custom Magnetic Resonance Elastography Device|Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
47935031|NCT04481009|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
47935032|NCT06032897|OTHER|Individualized music listening (IML)|The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
47935033|NCT04604067|DRUG|Acalabrutinib|"Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days"
48459898|NCT00245739|DRUG|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
48459899|NCT00143273|DRUG|lasofoxifene|0.05 mg tablets
48459900|NCT00143273|DRUG|Placebo|0 mg
48459901|NCT00143273|DRUG|Lasofoxifene|0.25 mg tablets
48459902|NCT00143273|DRUG|Lasofoxifene|0.5 mg tablets
48459903|NCT02235558|DRUG|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
48459904|NCT05854563|OTHER|Observational only, all subjects; measure DNA mutation and proteomic survey.|Observational only, all subjects; measure DNA mutation and proteomic survey.
48459905|NCT01121744|DEVICE|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
48459906|NCT02804724|OTHER|No intervention|
48459907|NCT01756716|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
48459908|NCT01756716|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
48459909|NCT01756716|DRUG|Placebo|Placebo for 8 weeks
48459910|NCT04627857|DEVICE|Manual toothbrush|Patients in group 1 (''reference procedure'') receive a manual toothbrush with a small compact head to facilitate access to the posterior teeth and soft bristles.
48459911|NCT04627857|DEVICE|Manual toothbrush and water flosser (Philips Sonicare AirFloss)|- Group 2 patients receive a manual toothbrush with a small, compact head for easy access to the posterior teeth and soft bristles. They also receive a Philips brand interdental microjet (Philips Sonicare AirFloss Ultra) which must be filled with water.
48459912|NCT04627857|DEVICE|Sonic toothbrush|- Group 3 patients receive a rechargeable sonic electric toothbrush from Philipps with an integrated excess pressure sensor and a compact toothbrush head for easy access to the posterior teeth.
48459913|NCT04627857|DEVICE|Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)|- Group 4 patients receive a Philips Sonicare ProtectiveClean rechargeable sonic electric toothbrush with an integrated excess pressure sensor and 2 compact toothbrush heads for easy access to the posterior teeth. They also receive an interdental microjet from Philips (Philips Sonicare AirFloss Ultra) which must be filled with water.
47935034|NCT04461041|DRUG|Empagliflozin|Single oral tablet
48098978|NCT05309486|OTHER|Online and Face-to-face Pilates trainings|Key elements of Pilates, including breathing, focusing, rib cage position, shoulder position, and head and neck positions, will be taught in both groups on the first day. Individuals will be asked to maintain the smoothness of these critical elements throughout the exercises. Different imagery techniques will be used in the exercises, and the exercises will be combined with breathing exercises. The intensity of the exercises will be increased by using different positions and elastic bands (Theraband Elastic Band Hygienic Corporation, Akron, Ohio). Band Resistances will be increased in biweekly periods. Stretching and posture exercises will be used during the cool-down period. The subjects in pilates group will be informed about the side effects such as shortness of breath, dizziness, headache, and muscle pain. Participants will be asked to stop the exercise in case of any side effects.
48459914|NCT03431636|OTHER|immersion|cold water immersion
48459915|NCT03431636|OTHER|ice pack|ice packs through the body
48459916|NCT03431636|OTHER|rest|seated rest
48459917|NCT01167439|PROCEDURE|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
48459918|NCT05267444|PROCEDURE|Individualized motion-based interactive game program|The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
48459919|NCT05527639|BEHAVIORAL|strength training program|12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
48459920|NCT04608448|DRUG|Rapamycin Topical Ointment|8% topical rapamycin ointment
48459921|NCT04608448|OTHER|Placebo|Petrolatum ointment containing no active ingredient
48459922|NCT02677558|OTHER|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
47935035|NCT04461041|DRUG|Placebo|Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
47935036|NCT03178695|OTHER|Autologous PRP injection into human ovarian tissue|Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
48459923|NCT01143337|DRUG|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
47935037|NCT00804037|PROCEDURE|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
48459924|NCT01143337|DRUG|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
48459925|NCT02864836|PROCEDURE|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
48459926|NCT03909633|BEHAVIORAL|a series of tests|all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS
48459927|NCT03058107|DIETARY_SUPPLEMENT|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
48459928|NCT03058107|DIETARY_SUPPLEMENT|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
48459929|NCT05188404|BEHAVIORAL|Choice of cannabis product|Participants choose and purchase their own cannabis product
48459930|NCT04701216|DRUG|SHR8735|SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
48459931|NCT00112437|DRUG|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
48459932|NCT00112437|DRUG|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
48459933|NCT00112437|DRUG|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
48459934|NCT00112437|DRUG|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
48459935|NCT00112437|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
48459936|NCT00112437|DIETARY_SUPPLEMENT|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
48459937|NCT00112437|DRUG|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
48459938|NCT01732562|OTHER|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
48459939|NCT04646603|DRUG|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
48459940|NCT04646603|DRUG|Placebo|Subjects will receive subcutaneous placebo injections.
48459941|NCT02928744|OTHER|COPD|Plethysmography
48459942|NCT02928744|OTHER|COPD|Forced oscillations
48459943|NCT05992454|DEVICE|EOLIFE|Measurement of ventilatory parameters during manual ventilation by professional rescuers during out-of-hospital cardiac arrest
48459944|NCT00352196|DRUG|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
48459945|NCT00352196|OTHER|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
48459946|NCT02272335|BEHAVIORAL|Group Sessions|"10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
48459947|NCT02281539|DEVICE|Neuromotus|
48459948|NCT05182606|BEHAVIORAL|Pilot study of algorithms implementation package|"The Implementation Bundle will include a link to algorithms in the Electronic Health Record, Smartphrases, audited feedback, and instructions."
48459949|NCT03577535|DIETARY_SUPPLEMENT|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
48459950|NCT05882526|DEVICE|BURSTONE T-LOOP|Split mouth study one side using elastomeric power chain and other side using T loops
48459951|NCT03124758|DEVICE|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
48459952|NCT00854126|DRUG|GDC-0980|Escalating repeating dose
48459953|NCT01438060|DRUG|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
48459954|NCT01438060|DRUG|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
48459955|NCT04408924|DRUG|Abemaciclib|Administered orally
48459956|NCT03458741|OTHER|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (\~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
48459957|NCT04779827|BEHAVIORAL|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
48459958|NCT04779827|BEHAVIORAL|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
48623191|NCT01051284|RADIATION|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
48459959|NCT01596127|DRUG|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
48459960|NCT00642993|DRUG|SCH 497079|100 mg capsule administered orally
48459961|NCT00642993|DRUG|Placebo|Placebo capsules matching SCH 497079 administered orally
48459962|NCT00418158|BEHAVIORAL|use of Airlife (therapy)|
48459963|NCT04808362|BIOLOGICAL|OMO-103|OMO-103 will be administered intravenously as 30 min infusion once weekly
47935038|NCT05637658|OTHER|Exercise|aerobic exercise
47935039|NCT06318962|BEHAVIORAL|Aviva|Digital phone app for BCBT
48459964|NCT01723683|DRUG|Surfactant|
47935040|NCT04306185|PROCEDURE|OVARIAN FRAGMENTATION|BILATERAL OVARIAN CORTEX FRAGMENTATION USING LAPAROSCOPIC SCISSORS
47935041|NCT04498494|DEVICE|ECG|12-lead ECG
48459965|NCT06177743|DEVICE|Coroflex ISAR NEO stent|Percutaneous coronary intervention with Coroflex ISAR NEO stent
47935042|NCT02948218|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
47935043|NCT02536833|DRUG|SM04690|
47935044|NCT02536833|DRUG|Placebo|
47935045|NCT02480725|PROCEDURE|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
48459966|NCT03965065|DEVICE|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
48459967|NCT03965065|DEVICE|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
48459968|NCT02798458|DEVICE|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
48459969|NCT02798458|PROCEDURE|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
48459970|NCT03539926|DEVICE|Lit-control®pH Meter|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
48459971|NCT03539926|DIAGNOSTIC_TEST|Reactive strips|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
48459972|NCT04260035|DRUG|Vasoactive Intestinal Polypeptide (VIP)|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
48459973|NCT04260035|DRUG|Sterile saline|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
48459974|NCT02722187|PROCEDURE|subinguinal microscopic varicocelectomy|
47935046|NCT02117427|BIOLOGICAL|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
48459975|NCT02722187|PROCEDURE|laparoscopic varicocelectomy|
47935047|NCT01589627|DEVICE|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
47935048|NCT04389970|BEHAVIORAL|Time Restricted Feeding|Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
47935049|NCT00718081|DRUG|Oral sufentanil|Oral dosage of sufentanil
47935050|NCT00718081|DRUG|Placebo|Oral dosage of placebo
47935051|NCT02347696|BEHAVIORAL|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
47935052|NCT02347696|BEHAVIORAL|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
47935053|NCT02347696|BEHAVIORAL|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1."
47935054|NCT02347696|BEHAVIORAL|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~* weeks 1-4: 14.2 kcal\*kg-1\*week-1;~* weeks 5-8: 18.9 kcal\*kg-1\*week-1;~* weeks 9-12: 23.6 kcal\*kg-1\*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~* Progression: increase of 1-2.5 kg\*week-1~* Training of all muscle groups in the same session"
47935055|NCT02347696|BEHAVIORAL|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
47935056|NCT02347696|BEHAVIORAL|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
48098979|NCT06356584|DRUG|Sintilimab|Immunotherapy
48098980|NCT04392635|DEVICE|TauTona Pneumoperitoneum Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle during laparoscopic surgery.
48098981|NCT04392635|PROCEDURE|Standard of Care (SOC)|Standard of Care was used for Veress needle insertion.
48459976|NCT01090505|DRUG|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
48459977|NCT03032536|DRUG|AL-3778|AL-3778 tablets or capsules
48459978|NCT03032536|DRUG|Entecavir|Entecavir once daily for 14 days
48459979|NCT03032536|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
48459980|NCT02270697|DEVICE|Array|Applications of oligonucleotide array in diagnosis.
48459981|NCT02664415|BIOLOGICAL|VRC01|40 mg/kg; administered IV
48459982|NCT02664415|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
48459983|NCT01949922|PROCEDURE|Injection of autologous muscle fibers into the anal sphincter.|
48459984|NCT01949922|PROCEDURE|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
48098982|NCT03764345|DRUG|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
48459985|NCT01949922|BEHAVIORAL|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
48459986|NCT01949922|DRUG|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
48459987|NCT03302598|DIAGNOSTIC_TEST|serum C-reactive protein|
48459988|NCT06332690|DEVICE|dexamethasone implant|Intravitreal dexamethasone implant (Dex) slowly releases steroids into the vitreous over a period of up to 6 months. Dex 0.7 mg (Ozurdex™; Allergan, Irvine, CA, USA) has been used to reduce ME in patients with DR and RVO and its efficacy in terms of best corrected visual acuity (BCVA) improvement and central macular thickness (CMT) reduction has been demonstrated in many different studies.
48459989|NCT00273013|DRUG|GW274150|GW274150 will be available as 30 mg white oval tablets.
48459990|NCT00273013|DRUG|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
48459991|NCT00273013|DRUG|Placebo|Matching placebo for Singulair and GW274150 will be available.
48459992|NCT01875107|DRUG|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
48459993|NCT05065528|DIETARY_SUPPLEMENT|Magnesium|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
48459994|NCT05065528|DRUG|Placebo|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
48459995|NCT00779519|DRUG|TTP435|
48459996|NCT00779519|DRUG|Placebo|
48459997|NCT04672538|PROCEDURE|Low Vt protocol|Low Vt protocol - tidal volumes (Vt) 6 ml/kg, respiratory rate required for end tidal carbon dioxide (EtCO2) of 36-38 mmHg, PEEP 5 centimeter of water (cm-H20) , I:E ratio 1:2
48459998|NCT04672538|PROCEDURE|High Vt protocol|High Vt protocol - tidal volumes (Vt) 10 ml/kg, respiratory rate required for EtCO2 of 36-38 mm Hg, PEEP 5 cmH2O, I:E ratio 1:3.
48459999|NCT00576654|DRUG|Irinotecan Hydrochloride|Given IV
48460000|NCT00576654|OTHER|Laboratory Biomarker Analysis|Correlative studies
48460001|NCT00576654|OTHER|Pharmacological Study|Correlative studies
48460002|NCT00576654|DRUG|Veliparib|Given PO
48460003|NCT03667963|OTHER|Glucose|50g glucose dissolved in 250ml water
48460004|NCT03667963|OTHER|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
48098983|NCT00385658|DRUG|Fluvastatin extended release, fenofibrate|
48460005|NCT03667963|OTHER|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
48460006|NCT03667963|OTHER|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
48460007|NCT01807026|DRUG|LY2886721|
48460008|NCT01807026|DRUG|Placebo|
48460009|NCT03006835|DRUG|Clopidogrel|
48460010|NCT05521360|BEHAVIORAL|Autonomic Modulation Training|AMT is a six week online behavioral intervention comprised of two components. The first component is an adapted (to online format) version of an established and publicly available HRVBF protocol (Lehrer et al, 2013, Biofeedback).The second is the integration of meta-cognitive coping skills and autonomic modulation breathing techniques into the HRVBF protocol (Arpaia \& Andersen, 2019 Frontiers in Psychiatry; Andersen, Arpaia \& Gustafsberg, 2021 Int J Emerg Ment Health and Human Resilience).
48460011|NCT01548053|OTHER|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
48460012|NCT05206162|DEVICE|theta burst stimulation|TBS over the left motor hotspot, delivered at 80% of resting motor threshold (RMT), according to the Huang et al. protocol, consisting of bursts of stimuli that are presented every 200ms (5Hz), with bursts consisting of 3 stimuli at 50 Hz. A total of 600 pulses are delivered.
48460013|NCT04821232|OTHER|yoga|"Content of education;~1. Breath Awareness Training (10 minutes)~   Students will be checked on a routine basis~2. Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
48460014|NCT04821232|OTHER|Routin control|Students will be checked on a routine basis
48460015|NCT01196598|OTHER|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist."
48460016|NCT02966860|DRUG|Oral solution OC/APAP|
48478797|NCT00934596|DRUG|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
48098984|NCT00385658|DRUG|Fixed combination simvastatin/ezetimibe|
48098985|NCT04853576|GENETIC|EDIT-301|Administered by IV infusion after myeloablative conditioning with busulfan.
48098986|NCT02963220|BEHAVIORAL|CBT-AR|20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
48098987|NCT04887688|DEVICE|exciflex|untethered electronic bandage with all the components of a surface stimulation system mounted on a flexible substrate.
48460017|NCT01368354|BEHAVIORAL|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
48460018|NCT05008380|PROCEDURE|prone positioning|3-6 hours of prone-positioning twice a day
48460019|NCT04225364|DRUG|camrelizumab|Participants will receive camrelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
48460020|NCT04225364|DRUG|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound): 260mg/m2(in total), ivgtt d1, d8, q3w，for 2 cycle
47935057|NCT03872414|BEHAVIORAL|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
47935058|NCT03872414|BEHAVIORAL|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
48460021|NCT04225364|DRUG|Cisplatin|75mg/m2(in total), ivgtt d1-d3, q3w, for 2 cycles
48460022|NCT02963350|DRUG|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
48460023|NCT00246662|DRUG|Vosaroxin|All patients receive vosaroxin Injection
48460024|NCT00361049|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
48460025|NCT00361049|GENETIC|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
48098988|NCT01236989|PROCEDURE|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
48460026|NCT00361049|OTHER|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
48460027|NCT00361049|OTHER|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
48460028|NCT00361049|OTHER|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
48460029|NCT00361049|PROCEDURE|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
48098989|NCT01236989|PROCEDURE|Non-anatomical liver resection|non-anatomical liver resection
48460030|NCT00361049|PROCEDURE|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
48106915|NCT02504619|BIOLOGICAL|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
48460031|NCT03570060|BIOLOGICAL|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
47935059|NCT04459429|DEVICE|Change of cannula size|During nasal High Flow Therapy with fixed flow of 8 l/min, the cannula size will be changed from smaller-to-larger or larger-to-smaller
47935060|NCT05753397|DRUG|Ropivacaine injection|We are testing if single injection Ropivacaine is non-inferior to multiple-injection Ropivacaine when applied within the intertransverse tissue complex (that is: a paraspinal application mimicking the paravertebral block)
47935061|NCT05629000|PROCEDURE|Carotid revascularization|All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
47935062|NCT05629000|DIAGNOSTIC_TEST|MRI-PWI|Multi-modal MRI before and after surgery.
47935063|NCT05629000|DIAGNOSTIC_TEST|CTA|CTA before and after surgery.
48106916|NCT05193318|DRUG|Ketamine-assisted psychotherapy|Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
48460032|NCT03570060|PROCEDURE|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
48460033|NCT03570060|PROCEDURE|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
48460034|NCT03146143|PROCEDURE|ultrafiltration|ultrafiltration after cardiopulmonary bypass
48460035|NCT00136448|DRUG|cytosine arabinoside (ara-C)|
48460036|NCT00136448|DRUG|daunomycin|
48460037|NCT00136448|DRUG|interleukin-2|
48460038|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
48460039|NCT01780051|DRUG|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
48460040|NCT00685854|DRUG|Ranibizumab|
48460041|NCT06491927|GENETIC|No Intervention|Observational study
48460042|NCT03853187|RADIATION|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine or in-vivo \[89zr\]-Df-crefmirlimab labelled CD8+ T-cells after two courses of treatment, prior to surgery.
48460043|NCT03853187|DRUG|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
48460044|NCT02333123|DRUG|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
48460045|NCT02333123|DRUG|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
48460046|NCT04584073|PROCEDURE|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
48460047|NCT05318859|OTHER|Pharmacopuncture|Registry (observational study)
48281255|NCT04927312|DRUG|PF-06947386|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
48281256|NCT04927312|DRUG|Metronidazole|Metronidazole 0.5 g solution for injection.
48460048|NCT00936351|BEHAVIORAL|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
48460049|NCT00936351|BEHAVIORAL|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
48460050|NCT03543735|BEHAVIORAL|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
48460051|NCT03543735|OTHER|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
48460052|NCT06224088|OTHER|VV ECMO|treatment with VV ECMO in the ICU
48460053|NCT02375815|OTHER|Statin Choice Implementation|
48460054|NCT05289440|DRUG|Low-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 2 µg/kg/min until before suture the skin.
48460055|NCT05289440|DRUG|High-dose esketamine infusion|Patients received a bolus infusion of esketamine (0.5 mg/kg) before cutting the skin, and then esketamine was infused at a rate of 4 µg/kg/min until before suture the skin.
48460056|NCT05289440|DRUG|Saline infusion|Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
48460057|NCT05920395|OTHER|Electro-acupuncture|Patients lie supine on the treatment bed, and after routine disinfection, a 0.30×60mm or 0.30×40mm disposable sterile acupuncture needle is inserted directly into the acupoint. Once obtaining qi, the needle is manipulated with even reinforcing and reducing techniques to maintain needle sensation. Acupoints selected include Zhongwan, Zusanli, Neiguan, and Tianshu, connected to the 6805-All electro-acupuncture therapy device. Zhongtuo and Tianshu acupoints are connected to a set of electrodes, with the positive pole connected to Zhongtuo and the negative pole connected to one side of Tianshu. The stimulation uses sparse and dense wave pulses with a frequency of 2Hz/100Hz, with the stimulation intensity determined based on individual patient tolerance. Each session lasts for 30 minutes, with a treatment frequency of once every other day, for a total of 4 weeks.
48460058|NCT05920395|OTHER|Sham electro-acupuncture group|Shallow acupuncture needles are used and then disconnected from the electrode. They are tied with black tape and connected to the sham electrode. The device is not powered on, and the rest of the treatment is the same as the electro-acupuncture group.
48460059|NCT04807777|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
48460060|NCT01460628|DRUG|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
48460061|NCT02761122|PROCEDURE|Human biological samples|"* Blood sample~* Skin or mucosal brushing~* Skin or mucosal biopsy"
48460062|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
48460063|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
48460064|NCT04919785|DEVICE|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
48460065|NCT06562101|PROCEDURE|Intra-articular Stromal Vascular Fraction Injection|Adipose tissue was harvested using the Q-graft system (Human Med®) from the abdominal subcutaneous fat of patients under local anesthesia. After concentration and resuspension in normal saline, 5 mL of the SVF suspension was injected into the knee joint cavity under sterile conditions.
47935064|NCT05629000|DIAGNOSTIC_TEST|PET/MRI|PET/MRI before surgery.
47935065|NCT05629000|DIAGNOSTIC_TEST|Ultrasound|Ultrasound before and after surgery.
47935066|NCT03906188|OTHER|LitEmotion|LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
47935067|NCT02843737|OTHER|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
47935068|NCT03748043|DRUG|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
48460066|NCT05191862|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
48460067|NCT05191862|DRUG|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
48460068|NCT00354419|RADIATION|total-body irradiation|Undergo radiotherapy
48460069|NCT00354419|DRUG|cyclophosphamide|Given IV
48460070|NCT00354419|BIOLOGICAL|anti-thymocyte globulin|Given IV
47935069|NCT03748043|DRUG|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
47935070|NCT06465212|DEVICE|TopCon Maestro 2 OCT|Ophthalmic Coherence Tomography
48098990|NCT04010643|BEHAVIORAL|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
47935071|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
47935072|NCT01392521|DRUG|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
47935073|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (active)|Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
47935074|NCT05842473|BEHAVIORAL|Language therapy|Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.
47935075|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (sham)|Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
47935076|NCT04025476|DRUG|Steroids|IV and oral steroids
47935077|NCT05346367|RADIATION|SRT|SRT
47935078|NCT05346367|RADIATION|fSRT|fSRT
47935079|NCT06107179|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.
47935080|NCT04491097|DEVICE|Panavia V5 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia V5 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
48281257|NCT04266574|DEVICE|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
48460071|NCT00354419|DRUG|cyclosporine|Given IV
48460072|NCT00354419|PROCEDURE|umbilical cord blood transplantation|Undergo transplantation
48460073|NCT00354419|DRUG|mycophenolate mofetil|Given IV or orally
48460074|NCT00354419|PROCEDURE|bone marrow aspiration|Correlative study
48460075|NCT00354419|GENETIC|DNA analysis|Correlative study
48460076|NCT00354419|BIOLOGICAL|filgrastim|Given IV or SC
48460077|NCT04306601|DEVICE|Low-Intensity Focused Ultrasound|Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
48460078|NCT05215496|DIAGNOSTIC_TEST|[18F]fluoro-PEG-folate PET/CT scan|A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
48460079|NCT03822949|DEVICE|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
48460080|NCT03822949|DEVICE|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
48460081|NCT03822949|DEVICE|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
48460082|NCT03822949|DEVICE|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
48460083|NCT01164657|DEVICE|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
48460084|NCT03673267|BEHAVIORAL|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
48460085|NCT05485727|OTHER|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
48478798|NCT03291041|DRUG|Tasimelteon|capsule
48460086|NCT05485727|OTHER|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
48460087|NCT00694408|DRUG|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
48460088|NCT00694408|OTHER|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
48460089|NCT05871463|BIOLOGICAL|MSC-derived exosomes|Patients will receive standard medication plus MSC-derived exosomes at a final dose of 40mg in three weeks. Standard medication includes: a) treatment of the underlying cause of cirrhosis such as drug treatment of hepatitis B and C. b) symptomatic treatment of port complications such as ascites, prevention of variceal bleeding, treatment and prevention of hepatic encephalopathy.
48460090|NCT05963464|DEVICE|SCOUT® Radar occult breast lesion Localization|The SCOUT® Radar occult breast lesion Localization (SRL) uses non-radioactive micro-impulses to guide surgical excision in real time.
48460091|NCT03914898|OTHER|Nurse led intervention group|This program is based on cognitive restructuring tecniques.
48460092|NCT06390813|BEHAVIORAL|Otago Exercise Training|A total of 18 sessions of Otago Training were conducted 3 days a week for 6 weeks, each session lasting 60 minutes in total, including 5 minutes of warm-up and cool-down periods.
48460093|NCT06390813|BEHAVIORAL|Square Stepping Exercise Training|A total of 18 sessions of SSE were performed 3 days a week for 6 weeks, each session lasting 40 minutes.
48460094|NCT04206462|OTHER|Questionnaire of eating habits|frequency and type of aliments
48460095|NCT05481931|DRUG|prabotulinumtoxinA|Botulinum toxin Type A powder for solution for injection
48460096|NCT02582190|DRUG|Colchicine group|antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.
48460097|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
48460098|NCT01907048|BEHAVIORAL|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
48460099|NCT02634736|DEVICE|Exergame plus usual treatment|An individualised \[i.e. frequency and duration will be set according to each participant's baseline levels\] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
48460100|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
48460101|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
48460102|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
48460103|NCT00918684|DRUG|Escitalopram|10mg tab daily
48460104|NCT00252564|DRUG|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
48460105|NCT00252564|DRUG|Oxaliplatin|85 mg/m2 on Days 1 and 15
48281258|NCT04266574|DEVICE|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
48460106|NCT00252564|DRUG|Leucovorin|400 mg/m2 on Days 1 and 15
48460107|NCT00252564|DRUG|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
48460108|NCT00252564|DRUG|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
48460109|NCT05104996|BEHAVIORAL|Telephone Counseling|The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
48460110|NCT04364191|BEHAVIORAL|Multicomponent Behavioral Sleep Intervention for Insomnia|The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.
48460111|NCT04364191|BEHAVIORAL|Active Control|The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
48460112|NCT01336088|DRUG|ADX48621|oral administration
48460113|NCT01336088|DRUG|Placebo|oral administration
48460114|NCT01698736|DEVICE|Membrane filtration|Membrane filtration (Polysulfone)
48281259|NCT04513158|BIOLOGICAL|Convalescent Plasma|Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
48281260|NCT04831450|DRUG|Cemiplimab-Rwlc|350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
48460115|NCT01698736|DEVICE|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
48460116|NCT00028873|DRUG|docetaxel|
48460117|NCT00028873|DRUG|laniquidar|
48281261|NCT03941444|DRUG|ANAVEX2-73|Liquid oral solution
48281262|NCT03941444|DRUG|Placebo|Liquid oral solution
48281263|NCT05781048|DRUG|HRS-6209|HRS-6209
48460118|NCT00028873|DRUG|paclitaxel|
48460119|NCT03053856|DRUG|Pembrolizumab|Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
48460120|NCT03053856|PROCEDURE|Curative resection|Neoadjuvant concurrent chemoradiotherapy followed by curative resection
48460121|NCT03053856|PROCEDURE|Neoadjuvant concurrent chemoradiotherapy|RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
48460122|NCT03053856|DRUG|Cisplatin|25mg/m2 once weekly
48460123|NCT03053856|DRUG|Paclitaxel|50mg/m2 once weekly
48478799|NCT03291041|DRUG|Placebo|capsule
48478800|NCT00811434|DRUG|Lactulose|1.5cc/kg/day po for three months
48478801|NCT00811434|DRUG|placebo|1.5 ml sugar water/kg day for three months
48478802|NCT06164028|OTHER|cognitive interview|Participants will take part in a semi-structured qualitative interview (\~1 hour).
47935081|NCT04491097|DEVICE|Panavia F2.0 resin cement|Missing lateral incisor teeth will be restored by zirconia ceramic RBFDs and adhesively bonded with Panavia F2.0 resin cement.The preperation and restoration of the tooth will be done according to to the guidelines for ordinary prosthetic techniques.
47935082|NCT03141645|OTHER|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
48460124|NCT04010227|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
48460125|NCT04010227|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
47935083|NCT03141645|DRUG|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
47935084|NCT02669654|OTHER|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
47935085|NCT05573815|DEVICE|BT-M01|Clinical decision support system for detecting brain metastasis
47935086|NCT02882373|DIETARY_SUPPLEMENT|Arginine|Given PO
47935087|NCT02882373|DRUG|Placebo|Given PO
48281264|NCT04990739|DRUG|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
48281265|NCT06076044|DEVICE|toDCS 2mA 1Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.
48281266|NCT06076044|DEVICE|toDCS 2mA 10Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.
48281267|NCT06076044|DEVICE|tDCS 1mA|The subgroup treated by transcranial direct current stimulation of 1mA.
48460126|NCT01232660|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
48460127|NCT00254280|PROCEDURE|Intense Pulsed Light + paring versus paring alone|
48460128|NCT02676973|PROCEDURE|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
48460129|NCT02676973|PROCEDURE|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
48460130|NCT02676973|PROCEDURE|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
48460131|NCT04221347|OTHER|blood sampling|blood samples will be taken in specified time points
47935088|NCT03074942|DRUG|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
47935089|NCT04508764|OTHER|Families Accelerating Cascade Testing Toolkit|-Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
47935090|NCT00230477|DRUG|Hepsera|
47935091|NCT00230477|DRUG|Hepsera and lamivudine|
47935092|NCT01444677|DRUG|MB12066|MB12066 300mg
47935093|NCT01444677|DRUG|MB12066|MB12066 400mg
47935094|NCT01444677|DRUG|MB12066|MB12066 100mg
47935095|NCT01444677|DRUG|MB12066|MB12066 200mg
47935096|NCT01444677|DRUG|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
47935097|NCT00982696|BIOLOGICAL|Opioid Growth Factor|250ug per kilogram weekly IV infusions
47935098|NCT06325475|PROCEDURE|labor with neuraxial labor analgesia|"Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route."
47935099|NCT06325475|PROCEDURE|labour without noroaxial labor analgesia|"Pregnant women in Group B will not receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen."
47935100|NCT02496572|DRUG|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
47935101|NCT06488105|DRUG|Statin (rosuvastatin 10 or 40 mg daily, depending on risk)|moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
47935102|NCT06488105|BEHAVIORAL|Healthy Lifestyle Counseling|Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework
47935103|NCT06488105|OTHER|Outpatient Followup|Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral
47935104|NCT05779735|DIAGNOSTIC_TEST|Transperineal ultrasound measurements of AOP|The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head
47935105|NCT02038374|PROCEDURE|biopsies|
47935106|NCT03790423|DRUG|Injection of 18F-ASIS|Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
47935107|NCT03790423|OTHER|PET/CT scan|Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
48281268|NCT06076044|DEVICE|sham|The subgroup treated by sham stimulation.
48460132|NCT03624751|RADIATION|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
48460133|NCT03558295|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, edoxaban
48460134|NCT04262245|PROCEDURE|Traditional Irrigation|irrigation with syringe
48460135|NCT04262245|DEVICE|Xp-endo Finisher (XPF)|irrigation activation file
48460136|NCT04262245|DEVICE|Passive Ultrasonic Irrigation|irrigation activation method
48281269|NCT01902108|DRUG|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
48281270|NCT01902108|DRUG|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
48460137|NCT04262245|DEVICE|EndoActivator|irrigation activation method
48460138|NCT05471596|DEVICE|NeuWave Microwave Ablation System|The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
48460139|NCT02420353|DRUG|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
48460140|NCT02420353|DRUG|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
48460141|NCT06627621|PROCEDURE|Alveolar Ridge Reconstruction|scaffold guided alveolar bone regeneration
48460142|NCT02623218|DEVICE|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
48460143|NCT02623218|DEVICE|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
48460144|NCT01488448|DRUG|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
48460145|NCT01488448|DRUG|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
48460146|NCT05347953|DEVICE|Single night downgraded home polygraphy|All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
48460147|NCT03563443|DIAGNOSTIC_TEST|Genomic Imprinting Testing|The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
48281271|NCT03709615|BEHAVIORAL|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
48281272|NCT01660815|DRUG|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
48281273|NCT00393562|DRUG|modafinil|
48281274|NCT00393562|DRUG|methylphenidate|
48281275|NCT04985565|OTHER|Dietary Intervention|Participate in Mediterranean diet
48281276|NCT04985565|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
48460148|NCT03417076|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
48460149|NCT00735696|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
48460150|NCT00735696|DRUG|Paclitaxel|200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
48460151|NCT00735696|DRUG|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
48281277|NCT04662593|BEHAVIORAL|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
48281278|NCT03142100|DEVICE|cochlear implants and hearing aids|speech perception tests and bimodal fitting
48281281|NCT02163070|DIETARY_SUPPLEMENT|whey drink,|consumption of 220 milliliters of whey drink three times a week,
48281282|NCT02163070|DIETARY_SUPPLEMENT|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
48460152|NCT05807958|DEVICE|Skin Prick Automated Test|A skin prick automated test will be performed in each participant.
48281283|NCT02163070|DIETARY_SUPPLEMENT|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
48460153|NCT05303441|PROCEDURE|percutaneous coronary intervention|conventional coronary angiography
48460154|NCT03766360|BEHAVIORAL|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
48460155|NCT02919462|DRUG|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
48098991|NCT04010643|BEHAVIORAL|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
48098992|NCT06445231|DIAGNOSTIC_TEST|Implementation of echocardiography in nursing homes|An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
48098993|NCT06628674|BEHAVIORAL|core muscle exercise|Patients in experiment group will do core muscle exercise with online interactive videos
48098994|NCT06628674|BEHAVIORAL|pelvic muscle exercise|Patients in experiment group will do pelvic muscle exercise without online interactive videos
48098995|NCT01134419|OTHER|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
48098996|NCT01134419|OTHER|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
47935108|NCT02481427|PROCEDURE|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
47935109|NCT02481427|PROCEDURE|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
47935110|NCT03371771|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
47935111|NCT03371771|BEHAVIORAL|MSW-delivered Behavioral Activation|Behavioral Activation as delivered by trained MSWs
47935112|NCT02571036|DRUG|DCC-2618|50 mg formulated tablets
47935113|NCT02571036|DRUG|DCC-2618|10 mg and 50 mg formulated tablets
47935114|NCT02859506|OTHER|Respiratory quotient|
47935115|NCT02859506|OTHER|Olfactory liking|
47935116|NCT01142518|DRUG|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
47935117|NCT06516341|PROCEDURE|CD patients|The study will involve the collection of mucosal brushes and collection of additional volume of blood and feces of patients at the time of surgery
47935118|NCT06516341|PROCEDURE|UC patients|The study will involve the collection of mucosal brushes and collection of additional volume of blood and feces of patients at the time of surgery
47935119|NCT05352776|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
47935120|NCT01084447|DEVICE|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
47935121|NCT01084447|DEVICE|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
47935122|NCT04220853|DIAGNOSTIC_TEST|Rhinomanometry in patients after septoplasty and/or turbinoplasty|Rhinomanometry is an examination used to assess changes in resistance and airflow in patients after septoplasty and/or turbinoplasty.
48281284|NCT05056831|BEHAVIORAL|Behavioral Intervention|Attend face-to-face mind-body sessions
48281285|NCT05056831|OTHER|Best Practice|Receive usual care
48281286|NCT05056831|OTHER|Informational Intervention|Receive targeted text messages
48281287|NCT05056831|OTHER|Quality-of-Life Assessment|Ancillary studies
47935123|NCT04220853|DIAGNOSTIC_TEST|Acoustic rhinometry in patients after septoplasty and/or turbinoplasty|Acoustic rhinometry is an examination used to assess changes in the cross-sectional area of the nasal passage in patients after septoplasty and/or turbinoplasty.
47935124|NCT02157207|DIETARY_SUPPLEMENT|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
48281288|NCT05056831|OTHER|Questionnaire Administration|Ancillary studies
48281289|NCT02951273|OTHER|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
48281290|NCT06218901|DRUG|immunotherapy|
48281291|NCT06218901|DRUG|Targeted Therapy Agent|
48460156|NCT02919462|DRUG|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
47935125|NCT02157207|OTHER|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
48460157|NCT02919462|DRUG|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
48460158|NCT02919462|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
48281292|NCT02846519|DRUG|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
48281293|NCT02846519|DRUG|Rifampin|2 capsules (300 mg each) of rifampin.
47935126|NCT01133327|DEVICE|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
48460159|NCT02919462|DRUG|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
47935127|NCT02687659|DEVICE|TEMIS system|Wearing TEMIS system over the day during one week
48460160|NCT02919462|DRUG|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
48098997|NCT04213560|DEVICE|weighted waist-hooping|weighted waist-hooping
48098998|NCT06250816|OTHER|The hospital gown with cartoon characters|The patient will be asked to choose one of the hospital gowns with cartoon characters they want to wear and put it on with parental assistance.
48460161|NCT06255145|DEVICE|Bioelectrical Impedance Analysis|"Bioelectrical Impedance Analysis Beurer BF 1000 Super Precision device was used to measure the body composition of the participants. Operating on the principle of BIA, the device allows the body composition to be evaluated by giving an imperceptible electric current to the body.~Fatigue Severity Scale (FSS) Fatigue Severity Scale (FSS) was used to measure participants' fatigue levels. Rivermead Mobility Index Rivermead Mobility Index (RMI) was used to assess the mobility levels of the participants.~Functional Independence Measure Functional Independence Measure (FIM) was used to evaluate the functional status of the participants."
48460162|NCT05131516|DIAGNOSTIC_TEST|Alveolar recrutment maneuver|alveolar recruitment maneuver (30 mmHg for 30 seconds)
48460163|NCT03008616|BIOLOGICAL|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
48460164|NCT03008616|OTHER|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
48460165|NCT01129258|DRUG|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
48460166|NCT01129258|DRUG|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
48460167|NCT00177580|DRUG|Pravastatin|
48460168|NCT00894855|BEHAVIORAL|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
48098999|NCT05275842|BEHAVIORAL|Cognitive Processing Therapy- Lifesteps (CPT-L)|"CPT-L is designed to help people with HIV and PTSD take their medications as prescribed. Cognitive Processing Therapy (CPT) uses education and cognitive training to help individuals identify thoughts and feelings about their trauma and gives them tools to help them change unhelpful beliefs. Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will receive a 12-session Cognitive Processing Therapy-Lifesteps (CPT-L) treatment program at the Ryan White clinic. The CPT-L program will be delivered twice a week for 6 weeks. Each session last about 90-minutes."
48281294|NCT01162525|PROCEDURE|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
48281295|NCT04606381|DRUG|Ami-LC-MD|Participants will receive amivantamab admixed with rHuPH20 SC infusion.
48460169|NCT00894855|BEHAVIORAL|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
48460170|NCT00894855|OTHER|dermatologist skin exam|Full body skin exam.
48281296|NCT04606381|DRUG|Ami-LC|Participants will receive amivantamab SC infusion.
48281297|NCT04606381|DRUG|Ami-HC|Participants will receive amivantamab SC infusion.
48281298|NCT04606381|DRUG|Ami-HC-CF|Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
48281299|NCT04606381|DRUG|Lazertinib|Participants will receive lazertinib orally as a film-coated tablet.
48281300|NCT04116437|DRUG|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
48281301|NCT01295333|DRUG|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
48281302|NCT01295333|DRUG|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
48281303|NCT01966510|OTHER|Cord Blood Transplantation|
48460171|NCT03946995|OTHER|Dry Needling Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week."
48460172|NCT03946995|OTHER|Graston Technique Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week."
48460173|NCT04272437|DRUG|Concentrated herbal extract granules TRA|Concentrated herbal extract granules Subjects in the TRA group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
48281304|NCT05370911|DRUG|Psilocybin|"The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms"
48281305|NCT05145465|OTHER|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
48281306|NCT00322114|DIETARY_SUPPLEMENT|lycopene|Given orally
48460174|NCT04272437|DRUG|Placebo|Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
48281307|NCT00322114|OTHER|placebo|Given orally
48281308|NCT04657822|DRUG|Crizanlizumab|Concentrate for solution for infusion for Intravenous use
48460175|NCT03581630|DRUG|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
48460176|NCT03581630|BEHAVIORAL|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
48460177|NCT04877145|OTHER|drill|single 3.25 mm stainless steel drill
48460178|NCT05496192|DRUG|Nivolumab/rHuPH20|Specified dose on specified days
48460179|NCT05496192|DRUG|Nivolumab|Specified dose on specified days
48460180|NCT02186353|BEHAVIORAL|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
48460181|NCT01204138|DRUG|Apremilast|Apremilast 30mg BID
48460182|NCT01204138|DRUG|Placebo|Placebo BID
48478803|NCT01872702|DRUG|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
47935128|NCT06517680|OTHER|tight control management|Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.
48281309|NCT05819892|DRUG|Paclitaxel|Given by IV (vein)
48281310|NCT05819892|DRUG|Carboplatin|Given by IV (vein)
47935129|NCT06517680|OTHER|standard follow-up|Patients are monitored according to standard practice
47935130|NCT02974101|OTHER|registration of AdaptiveStim|
47935131|NCT01015001|PROCEDURE|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
47935132|NCT01015001|PROCEDURE|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
47935133|NCT01015001|PROCEDURE|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
48281311|NCT05819892|DRUG|Dostarlimab|Given by IV (vein)
48281312|NCT05819892|DRUG|Cisplatin|Given by IV (vein)
47935134|NCT03190356|DEVICE|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
48281313|NCT04630054|DEVICE|Face mask|Intervention individuals will be given cloth or surgical face masks.
48460183|NCT04070222|OTHER|Hysteroscopy|"1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
48460184|NCT02786433|OTHER|conventional physiotherapy|
48460185|NCT02786433|OTHER|Virtual Reality with X- Box Kinect®|
48460186|NCT00627796|DRUG|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were \> 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were \< 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels \<1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
48460187|NCT02768701|DRUG|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
48460188|NCT02768701|DRUG|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
48460189|NCT00207662|DRUG|infliximab or placebo|
47935135|NCT03688425|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
48460190|NCT04878211|DRUG|Ofatumumab|3 loading doses followed by monthly administrations
48460191|NCT04878211|BIOLOGICAL|mRNA COVID-19 vaccine|Pfizer or Moderna mRNA Vaccine
48460192|NCT04878211|DRUG|interferon or glatiramer acetate|iDMT
48460193|NCT01476904|DRUG|Placebo|0 mcg/inhalation, 2 inhalations QID
48460194|NCT01476904|DRUG|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
48460195|NCT01476904|DRUG|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
47935136|NCT03688425|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
47935137|NCT01804829|BIOLOGICAL|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
47935138|NCT04174950|OTHER|Routine nursing care|routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
47935139|NCT04174950|OTHER|Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model|Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
48281314|NCT04630054|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
48460196|NCT03681938|PROCEDURE|Autograft|Autograft
48460197|NCT05156086|DRUG|COVID-19 vaccine, booster|Additional dose of COVID-19 vaccine (booster shot)
48460198|NCT06060353|BEHAVIORAL|Regulation Focused Psychotherapy (RFP-C)|Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, \& Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.
48460199|NCT06060353|BEHAVIORAL|Parental Awareness and Child Social Skills Group|Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs \& rights, child temperament, praise \& acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play \& relationship skills, empathy \& praise, anger management.
48460200|NCT03166527|DRUG|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
48460201|NCT00866580|BIOLOGICAL|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
48460202|NCT00866580|BIOLOGICAL|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
48460203|NCT00866580|BIOLOGICAL|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
48460204|NCT01633281|PROCEDURE|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
48460205|NCT04436718|DIAGNOSTIC_TEST|Daily pocus exam|Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
48460206|NCT00199654|PROCEDURE|PET|
48460207|NCT03791541|BEHAVIORAL|Pharmacist services|Additional pharmacist/pharmacy student follow-ups, counseling, and other services
48460208|NCT04885751|DRUG|Eupatilin|take eupatilin to prevent NSAID induced gastroenteropathy
48460209|NCT04885751|DRUG|Rebamipide|take rebamipide to prevent NSAID induced gastroenteropathy
48460210|NCT06217432|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
48460211|NCT00156182|DRUG|Asoprisnil|10mg Tablet, oral Daily for 6 months
48460212|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
48460213|NCT05827263|DEVICE|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
48460214|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
48460215|NCT06149962|PROCEDURE|FLEXOR TENDON REPAIR|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.
48460216|NCT03997890|PROCEDURE|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
48460217|NCT01150422|OTHER|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
48460218|NCT00284518|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
48460219|NCT00284518|DRUG|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
48460220|NCT05283954|DRUG|Combination regimen: Fluoxetine, Prednisolone, Ivermectin|"Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days."
48460221|NCT05283954|DRUG|Combination regimen: Albendazole, Vitamin C|"Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days."
48460222|NCT01538160|DRUG|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
48460223|NCT01884701|DEVICE|ENABLER-P Catheter System|
48460224|NCT01406080|DRUG|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
48281315|NCT02757495|DRUG|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
48281316|NCT06635135|DRUG|Aticaprant|Aticaprant will be administered orally.
48281317|NCT06635135|OTHER|Placebo|Placebo will be administered orally.
48281318|NCT02085655|DRUG|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48281319|NCT02085655|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48281320|NCT02085655|DRUG|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
48281321|NCT02085655|DRUG|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48281322|NCT02085655|DRUG|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48281323|NCT02085655|DRUG|Thalidomide|100-200mg, PO, after chemotherapy
48281324|NCT03830281|DRUG|Ultra-Rapid Lispro|Administered SC
48281325|NCT03830281|DRUG|Insulin Lispro|Administered SC
48460225|NCT01406080|DRUG|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
48460226|NCT01116505|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-containing cereals removed from diet
48460227|NCT01320722|DRUG|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
48281326|NCT05638321|DEVICE|MIMS|sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
48281327|NCT04354454|OTHER|Fitbit|Participants will select a daily step goal and track their steps every day for 4.5 months.
48460228|NCT01320722|DRUG|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
48460229|NCT01320722|DRUG|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
48460230|NCT01320722|DRUG|Placebo|Placebo soft gel once per week for 8 weeks
48460231|NCT01320722|DRUG|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
48460232|NCT03369535|OTHER|CARB rich diet|Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
48460233|NCT03369535|OTHER|MUFA rich diet|Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
48460234|NCT03369535|OTHER|PROT rich diet|Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
48460235|NCT03498560|DEVICE|PSG|PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
48460236|NCT06251895|OTHER|DKA protocol|IV fluids and IV insulin as per guidelines. reference 1-2
48460237|NCT01604239|DRUG|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
48460238|NCT03044873|DRUG|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
48460239|NCT03044873|DRUG|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
48460240|NCT00921674|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
48460241|NCT01812239|DRUG|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
48460242|NCT01812239|PROCEDURE|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
48460243|NCT01812239|DRUG|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
48460244|NCT05204420|PROCEDURE|Gastric wide local excision for bleeding mass|Laparoscopic partial gastrectomy for gastric submucosal mass
48460245|NCT01198938|OTHER|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
48460246|NCT06382662|DRUG|metaxalone m640|A single dose of micronize metaxalone 640 mg
48460247|NCT06382662|DRUG|tizanidine|A single dose of tizanidine 8 mg
48460248|NCT03433404|PROCEDURE|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
48460249|NCT03433404|PROCEDURE|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
48460250|NCT02182596|DRUG|Mylotarg|Dose level study
48460251|NCT00191490|DRUG|Gemcitabine|
48460252|NCT00191490|DRUG|docetaxel|
48460253|NCT00191490|DRUG|cisplatin|
48460254|NCT01669460|OTHER|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
48460255|NCT01572662|DRUG|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
48460256|NCT01572662|DRUG|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
48460257|NCT01572662|PROCEDURE|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
48460258|NCT01572662|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
48460259|NCT01572662|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
48460260|NCT01572662|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
48460261|NCT02195401|OTHER|Cleanroom|Cleanroom with air the quality of the pre-industrial age
48460262|NCT06094140|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
48460263|NCT06094140|DRUG|Oxaliplatin|85mg/m2 intravenously on day 1
48460264|NCT06094140|DRUG|Irinotecan|150mg/m2 intravenously on day 1
48460265|NCT06094140|DRUG|Calcium folinate (leucovorin)|50mg as an intravenous bolus
48460266|NCT06094140|DRUG|Fluorouracil|2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
48460267|NCT06094140|DRUG|Pegylated G-CSF|6mg by subcutaneous injection to be given on day 3 of each cycle.
48460268|NCT03277963|DEVICE|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
48460269|NCT03113396|DRUG|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
48460270|NCT03113396|DRUG|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
48460271|NCT06026267|BIOLOGICAL|20% High Dose Albumin|"A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
48460272|NCT06026267|OTHER|Standard Medical Treatment|Standard Medical Treatment
48460273|NCT06026267|BIOLOGICAL|20% Reduced Dose Albumin|"B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.~Duration of albumin over 24 hours."
48460274|NCT06270745|DRUG|indocyanine green|Whether to use ICG to assess anastomotic perfusion during digestive system surgery
48460275|NCT06095180|OTHER|corticosteroid injection|In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
48460276|NCT06095180|OTHER|dry needling|In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
48460277|NCT06095180|OTHER|exercise|The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
48460278|NCT04207229|DEVICE|CODMAN CERTAS Programmable Valves|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
48460279|NCT05729048|DEVICE|Starling|"Starling is a portable, non-invasive, cardiac output detector system. The Starling monitor measures the cardiac output by employing electrical bioreactance. Bioreactance is a measure of the electrical characteristics of a volume of tissue and fluid. In the case of cardiac output measurements, the relevant tissue includes the heart and the immediate surrounding volume of the thorax. The relevant fluid is blood.~The Starling electrode is a double electrode sensor. Within each sensor, one electrode is used to transmit a high frequency sine wave into the body, while the resulting voltage is measured at the adjacent electrode.~This information is used to determine cardiac output. The Starling monitor also measures and displays associated hemodynamic parameters based on calculations of measurements already incorporated into the Starling monitor."
48460280|NCT03209505|DEVICE|Acuvue Oasys|FDA approved contact lens, fit for daily wear
48460281|NCT03209505|DEVICE|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
48460282|NCT05372250|OTHER|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound|Measurement of the diaphragmatic excursion according to the position of the body by ultrasound
48460283|NCT04828538|DIETARY_SUPPLEMENT|Vitamin D|Daily 4000 IU Vitamin D for 60 days
48460284|NCT04828538|DIETARY_SUPPLEMENT|Omega DHA / EPA|Daily 1000mg Omega DHA/EPA for 60 days
48460285|NCT04828538|DIETARY_SUPPLEMENT|Vitamin C, Vitamin B complex and Zinc Acetate|"Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)"
48460286|NCT04828538|OTHER|Placebo|Placebo
48460287|NCT01376882|DIETARY_SUPPLEMENT|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
48460288|NCT01376882|DIETARY_SUPPLEMENT|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
48460289|NCT01376882|DIETARY_SUPPLEMENT|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
48099000|NCT05275842|BEHAVIORAL|Lifesteps|"Lifesteps (L) includes education on the need for people with HIV to take their medications as prescribed and what could happen if you do not, as well as gives you tools to help motivate and remind you to take your medications on time.~Participants will complete one Lifesteps education session. This session lasts about 60 minutes. Participants may attend this session either in-person or over the internet if they have an internet ready device with audio."
48099001|NCT04310059|DIETARY_SUPPLEMENT|Folic acid|women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)
48460290|NCT01376882|DIETARY_SUPPLEMENT|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
48099002|NCT04310059|DIETARY_SUPPLEMENT|Materna|Materna
48281328|NCT04354454|OTHER|Fitbit + Game + Support from a Teammate|"Daily Fitbit tracking for 4.5 months, divided into 2 parts.~* 3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~* 1.5 month follow-up period with Fitbit and social support teammate only"
48460291|NCT03181386|DRUG|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
48460292|NCT03181386|DRUG|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
48460293|NCT03181386|DRUG|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
48460294|NCT00250354|DRUG|Risperidone oral solution|
48460295|NCT05518331|DRUG|avatrombopag|Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight \> 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
48460296|NCT02845154|OTHER|bolus purge|complete and uninterrupted purge
48460297|NCT02845154|OTHER|Intermittent purge|intermittent portal purge
48460298|NCT00835796|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
48460299|NCT00835796|DRUG|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
47935140|NCT05211687|OTHER|Smart-home for freezing of gait|"A projector, Kinect camera and computer are located 2 meters from the walking area. Participants walk nine times back and forth on the walking track, in each of three walking conditions:~1. Baseline: participants walk in a comfortable pace. The walking track consist a rectangle created by a white light projected on the floor. Based on in this walking condition, step width and cadence are calculated to determine the individual parameters of the cueing.~2. Light-stripes: The walking area consist of 4-5 white light-stripes. Space between the stripes is 110% of the participant step length. Participants are instructed to walk over the stripes.~3. Metronome: The walking track consist of a rectangle created by a white light projected on the floor, and in addition metronome beats are delivered by the computer. Beats frequency are 90% of the cadence. Participants are instructed to match their steps to the metronome beats.~Each walking condition up to 90 seconds."
47935141|NCT05719727|DIAGNOSTIC_TEST|colonoscopy|lower colonoscopy
47935142|NCT01975987|DEVICE|Bonfils fiberscope|
48460300|NCT01253564|DRUG|RO5185426|960 mg b.i.d. orally
47935143|NCT00967928|DRUG|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
47935144|NCT00967928|DRUG|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
47935145|NCT00967928|RADIATION|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
47935146|NCT06346808|DRUG|Oncolytic virus Plus Anti-PD1 and Chemotherapy|Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）
48460301|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
48460302|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days
48460303|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
48460304|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
47935147|NCT03112590|BIOLOGICAL|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m\^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
48281329|NCT06105138|DIETARY_SUPPLEMENT|200mg Cannabidiol oral solution|"200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
47935148|NCT03112590|DRUG|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m\^2/week, for 12 weeks.
47935149|NCT03112590|DRUG|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
48460305|NCT04695041|DRUG|PBI-4050/ Placebo|Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
48460306|NCT04561115|BIOLOGICAL|Gamunex-C|Intravenous infusion.
48460307|NCT04561115|BIOLOGICAL|IVIG-PEG|Intravenous infusion.
48460308|NCT05778760|OTHER|Retinol|Topical retinol (0.5%) applied to the face
48460309|NCT05778760|OTHER|Adapinoid|Topical Adapinoid (0.5%) applied to the face
48460310|NCT05673707|DIAGNOSTIC_TEST|Thyromental Height|its measure between thyroid and mentum
48460311|NCT01533038|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
47935150|NCT03112590|OTHER|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
47935151|NCT03112590|PROCEDURE|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
47935152|NCT01949337|DRUG|enzalutamide|Enzalutamide 160 mg daily, orally
47935153|NCT01949337|DRUG|abiraterone|abiraterone 1000 mg daily, orally
47935154|NCT01949337|DRUG|prednisone|prednisone 5 mg twice daily, orally
48460312|NCT01533038|PROCEDURE|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
48460313|NCT01728480|DRUG|entolimod|Given SC
48460314|NCT01728480|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48460315|NCT01728480|DRUG|cisplatin|Given IV
48460316|NCT01728480|OTHER|pharmacological study|Correlative studies
48460317|NCT01728480|OTHER|laboratory biomarker analysis|Correlative studies
48623192|NCT00591799|DEVICE|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
47935155|NCT05200741|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray
47935156|NCT05200741|BIOLOGICAL|Matching placebo|Solution for Intranasal Spray
47935157|NCT03657966|BIOLOGICAL|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
48460318|NCT06352762|OTHER|Conventional physiotherapy|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions.
48460319|NCT06352762|OTHER|Robotic Rehabilitation|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions. An additional 30 minutes of robotic rehabilitation was applied to the conventional physiotherapy program. Robotic rehabilitation was applied after each session of conventional physiotherapy applications.
48460320|NCT01965093|PROCEDURE|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
47935158|NCT03657966|DRUG|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
48460321|NCT01965093|PROCEDURE|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
48460322|NCT04385511|DEVICE|supraglottic jet ventilation|patients who were randomized into supraglottic jet ventilation group would be placed Wei Nasal Jet Tube after conducted. Then they will get the supraglottic jet ventilation to make sure their pulse oximetry is over 95%. After 3 minutes, endotracheal intubation was performed via mouth approach.
48460323|NCT06335927|DRUG|HAIC-GEMOX+Cadonilimab+Regorafenib|HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
48460324|NCT03259113|DEVICE|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
48460325|NCT04880876|DRUG|25mg Eluxadoline|Oral Tablets
48460326|NCT04880876|DRUG|100mg Eluxadoline|Oral Tablets
48460327|NCT02911701|DRUG|Acetaminophen|
48460328|NCT02911701|DRUG|Ibuprofen|
48460329|NCT02827045|DEVICE|Vestibular test|
48460330|NCT00163319|DRUG|Ciclesonide|
48460331|NCT03256396|PROCEDURE|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
48460332|NCT05995054|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
48460333|NCT05152745|OTHER|Placebo OGGT|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
48460334|NCT05152745|OTHER|Ginger aqueous extract|"After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis."
48460335|NCT03958812|DIAGNOSTIC_TEST|Circulating tumor cells, Volatile organic compounds|Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
47935159|NCT06208930|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.
48460336|NCT04092595|DRUG|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
48460337|NCT04092595|DRUG|Rosuvastatin|10 mg oral tablet
48460338|NCT05526703|DRUG|D064, D701, placebo of D012|Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
48460339|NCT05526703|DRUG|D012, placebo of D064, placebo of D701|Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
47935160|NCT02345746|DRUG|Oxaliplatin|infusion over 12 hours via HAI
47935161|NCT02345746|DRUG|Folinic Acid|as a 2-hour infusion via HAI on day 2
47935162|NCT02345746|DRUG|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
47935163|NCT00056498|DRUG|Placebo|Placebo capsule daily for 16 weeks
47935164|NCT00056498|DRUG|Risperdal|Risperdal 4 mg per day for 16 weeks
47935165|NCT01372982|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
47935166|NCT03718325|DEVICE|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
47935167|NCT03718325|DEVICE|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
47935168|NCT01906879|DRUG|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
47935169|NCT00384527|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
47935170|NCT00384527|DRUG|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
47935171|NCT00833079|DRUG|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
47935172|NCT00833079|DRUG|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
47935173|NCT00833079|DRUG|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
48460340|NCT05951205|BIOLOGICAL|Exa-cel|Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
47935174|NCT05421403|PROCEDURE|adenotonsillectomy|all patients with adenoid or tonsillar or adenotonsillar hypertrophy of grade \>2 will undergo adenoidectomy, tonsillectomy or adenotonsillectomy (AT) according to the indication. Overweight or obese patients with mild or moderate OSAS will undergo 6-m trial of lifestyle intervention (LSI) and CPAP if indicated, responders will undergo more follow-up otherwise surgical interference was indicated
47935175|NCT05421403|BEHAVIORAL|Lifestyle intervention|After baseline testing, all subjects began a structured 6-month LSI consisting of dietary modification and exercise. Intensive dietary counseling was provided weekly for the first 4 weeks of the intervention, monthly subsequently until 6 months. A target caloric deficit of \~250.500 cal/d was recommended throughout dietary counseling. Dietary regimen consisted of diets composed of nutrients contributing to total energy as 55% carbohydrate, 15% protein, and 30% fat. Other lifestyle changes included calorie restriction depending on reduction of the frequency of snack consumption, ingestion of low-calorie and low-fat snacks, limiting sugar-based carbonated drinks and the duration of television watching or mobile games. Exercise sessions consisted of both aerobic and strength training three times weekly.
47935176|NCT03857152|DIAGNOSTIC_TEST|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
47935177|NCT02480907|BEHAVIORAL|Workshop Group|Workshop support group
47935178|NCT02480907|BEHAVIORAL|Internet-based support group|Internet based support group with E-mail coaching
47935179|NCT01823510|DRUG|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
47935180|NCT01823510|DRUG|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
47935181|NCT04537221|BIOLOGICAL|Blood transfusion|Transfusion of red blood cells peri-operatively
48460341|NCT00235963|DRUG|Simvastatin|
47935182|NCT05088655|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
47935183|NCT06197425|DRUG|"FOLFIRI cures"|(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
47935184|NCT06197425|DRUG|Trifluridine cures|Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
47935185|NCT06197425|BIOLOGICAL|BIOLOGICAL ASSESSMENT|blood sample ACE markers
47935186|NCT06197425|OTHER|Questionnaires|Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
47935187|NCT06197425|OTHER|Thoracic-abdomino-pelvic scan or MRI|Thoracic-abdomino-pelvic scan or MRI
47935188|NCT06040268|DRUG|Advair HFA|6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily
47935189|NCT06040268|DRUG|Placebo|HFA134a inhaler
47935190|NCT00003046|BIOLOGICAL|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
47935191|NCT03063671|DRUG|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
47935192|NCT05072470|DEVICE|Roger microphone|Commercially available transmitter microphone which sends distant speech signals to a receiver that is attached/embedded into hearing aids.
47935193|NCT05072470|DEVICE|Phonak Audeo hearing aid|Commercially available receiver-in-canal hearing aid
47935194|NCT02979327|DRUG|Adderall capsule|Amphetamine
47935195|NCT02979327|DRUG|Placebo capsule|Placebo capsule
47935196|NCT04070976|RADIATION|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
48460342|NCT04173923|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
48623193|NCT03897621|DRUG|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
47935197|NCT04070976|RADIATION|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
48460343|NCT04173923|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
48460344|NCT04173923|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
48460345|NCT04173923|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48460346|NCT04173923|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48460347|NCT04173923|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
48460348|NCT04173923|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
48460349|NCT03947658|PROCEDURE|Surgical crown lengthening|Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
48460350|NCT04600635|PROCEDURE|Bariatric surgery|Some patients in the cohort are followed by a multidisciplinary team in preparation for bariatric surgery. Others have already undergone bariatric surgery and are being followed up postoperatively.
48460351|NCT04533620|RADIATION|Standardized CIRT|CIRT with a dose of 63 GyE/21 fx
48460352|NCT04533620|RADIATION|Individualized CIRT|A predictive model will be used to predict the chance of developing mucosal necrosis after salvage carbon-ion radiotherapy, and individualized dose prescription will be given. A dose of 60 GyE/20 fx, 63 GyE/21 fx and 66 GyE/22 fx will be given to patients with high, moderate and low risk of developing mucosal necrosis, respectively.
48460353|NCT00868998|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
48460354|NCT02571257|DRUG|Gemcabene|1-300 mg tablet, QD, 56 days
48460355|NCT02571257|DRUG|Gemcabene|3-300 mg tablets, QD, 56 days
48460356|NCT02571257|DRUG|Placebo|
48460357|NCT05936047|BIOLOGICAL|Vertebral bone marrow clot|vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
48460358|NCT00758797|OTHER|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
48460359|NCT06468839|BEHAVIORAL|digital addiction management model|The experimental group will implement a digital addiction model. No intervention will be made to the control group.
48460360|NCT01959828|DRUG|IK-3001|
47935198|NCT03304496|DRUG|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
47935199|NCT03304496|DRUG|Saline Solution|Previously described.
47935200|NCT05060484|BIOLOGICAL|SCT1000|HPV vaccine
47935201|NCT05060484|BIOLOGICAL|Gardasil®9|HPV vaccine
47935202|NCT05060484|BIOLOGICAL|Gardasil®|HPV vaccine
47935203|NCT05060484|OTHER|placebo|adjuvent
47935204|NCT00179244|DRUG|Rispridone (drug) and Bupropion ER (drug)|
47935205|NCT01172275|DRUG|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
47935206|NCT01172275|OTHER|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
47935207|NCT02862600|DRUG|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
48099003|NCT04934228|DRUG|Hydrochlorothiazide 12.5Mg Tab|"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"
48099004|NCT04934228|DRUG|Clonidine Pill|"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth"
48099005|NCT04934228|DRUG|Placebo|Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
48460361|NCT03675763|OTHER|Manual treatment|Craniosacral therapy protocol.
48460362|NCT02484716|DRUG|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
48099006|NCT05173493|DRUG|Amoxicillin,Furazolidone|Amoxicillin-Furazolidone-containing quadruple group
48099007|NCT05173493|DRUG|Amoxicillin,Levofloxacin|Amoxicillin-Levofloxacin-containing quadruple group
48460363|NCT02484716|DRUG|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
48460364|NCT00041860|PROCEDURE|Controlled Exposure to Environmental Contaminant|
48099008|NCT05173493|DRUG|Tetracycline,Furazolidone|Tetracycline-Furazolidone-containing quadruple group
48099009|NCT06156813|DIAGNOSTIC_TEST|Diagnostic test|Measurements for validity and reliability
48099010|NCT00966966|DRUG|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
48099011|NCT02694848|DRUG|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
48099012|NCT02694848|DRUG|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
48099013|NCT06540287|OTHER|Observational|No intervention
48099014|NCT06180148|DEVICE|Mechanical insufflator-exsufflator|"In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face."
48460365|NCT00657254|DRUG|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
48460366|NCT02508870|DRUG|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
48460367|NCT02508870|DRUG|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
48460368|NCT02889393|DRUG|Teduglutide|Daily 0.05 mg/kg Teduglutide administered subcutaneously.
48460369|NCT02889393|OTHER|Standard of Care|The standard of care treatment of ECF which includes meticulous wound care, optimizations of nutrition, use of acid-suppression medications and anti-motility agents as per treating physician discretion.
48460370|NCT03949062|DRUG|Ibrutinib|Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
48460371|NCT03949062|DRUG|Lenalidomide|Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
47935208|NCT02862600|DEVICE|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
47935209|NCT06520579|BEHAVIORAL|Proactive pharyngeal-laryngeal Exercise Program|This program consists of daily proactive pharyngeal-laryngeal exercises and weekly sessions with a speech-language pathologist post surgery. One week prior to surgery participants will begin daily proactive pharyngeal-laryngeal exercises and continue these daily exercises for 6 weeks post surgery. Beginning approximately one week after surgery, participants will meet with the speech-language pathologist. Sessions will occur weekly, for approximately 6 weeks, and will last approximately 45 minutes.
48099015|NCT06630780|RADIATION|Head and Neck Cancers|All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.
48099016|NCT02451943|DRUG|Olaratumab|Administered IV
48099017|NCT02451943|DRUG|Doxorubicin|Administered IV
48099018|NCT02451943|DRUG|Placebo|Administered IV
48099019|NCT01386086|DRUG|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
48099020|NCT06566534|BEHAVIORAL|Reminder|Flu shot messages via SMS
48099021|NCT01430702|DEVICE|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
48099022|NCT01174316|DEVICE|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
48460372|NCT03949062|DRUG|Rituximab|Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
48460373|NCT05710458|DEVICE|25 gauge 20,000 cpm Hypervit Dual Blade|Vitrectomy blade with increased cutting rate to 20,000 cut/min
48460374|NCT05710458|DEVICE|25 gauge 10,000 cpm Ultravit Vitrectomy Cutter|Existing Vitrectomy blade with cutting rate 10,000 cut/min
48460375|NCT04464005|DRUG|Magnesium sulfate 33% solution|Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes
48460376|NCT04464005|OTHER|Cold water|Topical pads with cold water will be given 5 times/day for 15 minutes
48460377|NCT04307680|DEVICE|Peritron perineometer|Perineometry will be used to assess quality of each observed treatment modality.
47935210|NCT06520579|DIETARY_SUPPLEMENT|Premier Protein Clear ® High Protein|Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink) 1 drink daily for 7 weeks.
48460378|NCT05424757|DRUG|PEG 3350|"Data and biospecimens will be collected from two groups of children:~* Children who have taken PEG 3350 daily for at least 30 days.~* Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
48460379|NCT00005873|DRUG|rubitecan|
47935211|NCT06520579|BEHAVIORAL|Hydration Counseling|Daily hydration goals are based on recommended guidelines for adults, by gender, from The United States National Academy of Medicine (US NAM) and the European Food Safety Authority (ESFA) (\~2.0 L/day for women; \~2.5 L/day for men of fluid intake, accounting for 20% daily fluid intake from food sources). Patients will be required to track via paper log whether they met their hydration goals daily.
47935212|NCT04213573|DRUG|silver diamine fluoride|38% silver diamine fluoride liquid will be applied with a brush
48460380|NCT03756233|DRUG|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
48460381|NCT02753985|OTHER|Survey|
48460382|NCT05092035|DIAGNOSTIC_TEST|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
47935213|NCT04213573|DRUG|MI Varnish|topical fluoride varnish with calcium and phosphate
47935214|NCT01958112|DRUG|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
47935215|NCT01958112|DRUG|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
47935216|NCT02399618|DRUG|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
48281330|NCT06105138|DIETARY_SUPPLEMENT|30mg Cannabidiol oral solution|"30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
47935217|NCT00003930|DRUG|cisplatin|
47935218|NCT00003930|DRUG|gemcitabine hydrochloride|
47935219|NCT00003930|DRUG|paclitaxel|
47935220|NCT00003930|PROCEDURE|conventional surgery|
47935221|NCT00003930|RADIATION|radiation therapy|
47935222|NCT02717377|BEHAVIORAL|physical activity|
47935223|NCT02978131|OTHER|Histopathological study|
48460383|NCT06297408|DRUG|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
48460384|NCT01049464|DRUG|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
48460385|NCT01049464|DRUG|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
48460386|NCT00842127|DRUG|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
47935224|NCT02978131|OTHER|Molecular study (Polymerase chain reaction)|
47935225|NCT01752712|DRUG|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
47935226|NCT01752712|DRUG|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
47935227|NCT02404532|DEVICE|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
47935228|NCT01872234|DEVICE|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
47935229|NCT01261832|DRUG|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
48460387|NCT06223724|DEVICE|STOP|Software to measure impedance telemetry data
48460388|NCT06223724|DEVICE|MAESTRO|Software to measure impedance telemetry data
48460389|NCT00083772|DRUG|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
48460390|NCT02102919|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
48460391|NCT02102919|DEVICE|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
48460392|NCT02102919|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
48460393|NCT02102919|DEVICE|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
48460394|NCT00057941|DRUG|anastrozole|Given orally
48460395|NCT00057941|DRUG|gefitinib|Given orally
48460396|NCT00057941|DRUG|fulvestrant|Given intramuscularly
48460397|NCT00057941|OTHER|laboratory biomarker analysis|Correlative studies
48460398|NCT00884390|DRUG|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
48460399|NCT00884390|PROCEDURE|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
48460400|NCT05063630|PROCEDURE|Medical treatment plus intracranial stenting|This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
48460401|NCT05063630|DRUG|Medical treatment alone|This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
48460402|NCT00019487|BIOLOGICAL|aldesleukin|
48460403|NCT00019487|BIOLOGICAL|gp209-2M antigen|
48460404|NCT00019487|BIOLOGICAL|incomplete Freund's adjuvant|
48460405|NCT00757172|BIOLOGICAL|panitumumab|
48460406|NCT00757172|DRUG|cisplatin|
48460407|NCT00757172|DRUG|docetaxel|
48099023|NCT01174316|DEVICE|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
48099024|NCT06414980|BEHAVIORAL|Experimental|The effect of suggestion given to patients with the olfactory memory method before the surgical operation on vital signs and systemic evaluation scoring during awakening.
48460408|NCT00757172|PROCEDURE|neoadjuvant therapy|
48460409|NCT00757172|PROCEDURE|therapeutic conventional surgery|
48460410|NCT00757172|RADIATION|radiation therapy|
48460411|NCT01927016|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
48460412|NCT03959150|DRUG|Capecitabine|Oral fluorouracil
48460413|NCT04268797|DEVICE|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
48460414|NCT04268797|DEVICE|sham|SHAM HF rTMS coil once daily x 20 days
48460415|NCT00625339|DRUG|Entecavir|entecavir 0.5 mg QD
48460416|NCT00625339|DRUG|Lamivudine|lamivudine 100 mg QD
48460417|NCT04197908|DEVICE|EUS-guided gallbladder drainage (EGBD)|As listed in the arms description
48460418|NCT05484908|OTHER|DPMAS+LPE|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times in two weeks. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
48460419|NCT05484908|OTHER|PE|Patients will receive treatment of plasma exchange (PE) for three times in two weeks. The volume of fresh frozen plasma used in PE is 2000 millilitre.
48460420|NCT05484908|OTHER|Comprehensive internal medical treatment|Patients will receive comprehensive internal medical treatment.
48460421|NCT02096692|DEVICE|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
48460422|NCT02096692|OTHER|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
48460423|NCT02994836|BIOLOGICAL|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
48460424|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
48460425|NCT02994836|BIOLOGICAL|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
48460426|NCT02994836|DRUG|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
48460427|NCT05429944|OTHER|Motor Relearning Program|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
48460428|NCT05429944|OTHER|Proprioceptive Neuromuscular Facilitation|"The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks."
48460429|NCT05429944|OTHER|Conventional Physical Therapy|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
48460430|NCT03404921|PROCEDURE|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
48460431|NCT03404921|PROCEDURE|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
48460432|NCT01273467|DRUG|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
48460433|NCT01273467|DRUG|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
48460434|NCT04194008|DEVICE|Nerivio|A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
48460435|NCT02694653|DRUG|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
48460436|NCT02694653|DRUG|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
48460437|NCT03401281|OTHER|Coconut oil|50g extra virgin coconut oil daily for four weeks
48460438|NCT03401281|OTHER|Butter|50g butter daily for four weeks
48460439|NCT03401281|OTHER|Olive oil|50g extra virgin olive oil daily for four weeks
48460440|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
48460441|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
48460442|NCT01559727|DRUG|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
48460443|NCT05191238|OTHER|IUD self-removal education|Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
48460444|NCT02082327|DRUG|IV migalastat HCl|
48460445|NCT02082327|DRUG|IV placebo|
48460446|NCT02082327|DRUG|oral migalastat HCl|
48460447|NCT01875055|DEVICE|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
48460448|NCT01875055|DEVICE|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
48460449|NCT03385863|DRUG|Surfactant, Pulmonary，Curosurf|All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
48460450|NCT03385863|OTHER|Perinatal risk factors of NRDS|Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
48460451|NCT03795012|DRUG|Eribulin|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
47935230|NCT03593941|OTHER|Standard Diet|Participants will consume the standard diet provided in care home
47935231|NCT05276648|DIAGNOSTIC_TEST|CAM ICU test|CAM ICU for delirium
47935232|NCT05276648|DIAGNOSTIC_TEST|MOCA test|MOCA for cognitif disfonction
48460452|NCT02981095|PROCEDURE|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
48460453|NCT02981095|DRUG|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
47935233|NCT05276648|DIAGNOSTIC_TEST|brief pain test|BRİEF PAİN for chronic pain
48460454|NCT02981095|DRUG|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
48460455|NCT00408577|DRUG|L-arginine|
47935234|NCT05276648|DIAGNOSTIC_TEST|VAS scale|VAS scale for acute pain
47935235|NCT05949944|DRUG|Linperlisib in combination with CHOP|Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
47935236|NCT05832476|OTHER|No intervention|No intervention
47935237|NCT04025671|DEVICE|Nasal Spray Naloxone|Nasal spray naloxone device.
48460456|NCT03899935|PROCEDURE|Laparoscopy|Laparoscopy for endometriosis
48460457|NCT03610607|BEHAVIORAL|Intense education|we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.
48460458|NCT04200833|DRUG|Golimumab|subcutaneous injection
48460459|NCT01211951|DRUG|KCT-0809|
48460460|NCT01211951|DRUG|KCT-0809|
48460461|NCT01211951|DRUG|KCT-0809|
48460462|NCT01211951|DRUG|Placebo|
47935238|NCT04025671|DEVICE|Intramuscular Naloxone|A vial of simulated naloxone and syringe with attached needle.
47935239|NCT04025671|DEVICE|Improvised Nasal Atomizer|A naloxone bristoject dose and nasal atomizer device.
47935240|NCT04356170|DRUG|Docetaxel|Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
47935241|NCT04356170|DRUG|Cisplatin|cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour
47935242|NCT04356170|DRUG|Fluoro Uracil|750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
48460463|NCT05663255|DRUG|Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)|Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
48460464|NCT05904639|GENETIC|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
48460465|NCT00515216|DRUG|5-fluorouracil|
48460466|NCT00515216|DRUG|Oxaliplatin|
48460467|NCT00515216|DRUG|Leucovorin|
48460468|NCT06102057|RADIATION|standard Radiotherapy|standard FDG-PET-based radiotherapy
48460469|NCT06102057|DRUG|Chemotherapy|concurrent standard of care chemotherapy
48460470|NCT06102057|DRUG|Immunotherapy|standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.
48460471|NCT06102057|RADIATION|Experimental Radiotherapy|FDG-PET-based small volume accelerated radiotherapy
48460472|NCT03774329|OTHER|Usual care|Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.
48460473|NCT03774329|OTHER|adapted physical activity|Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
48460474|NCT04096547|DRUG|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
48460475|NCT01540344|PROCEDURE|CRS|complete macroscopic cytoreduction (CC-0/1)
48460476|NCT01540344|DRUG|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
48460477|NCT04444141|BIOLOGICAL|AK104|The subjects will receive AK104 till disease progression or for a maximum of 24 months.
47935243|NCT00945854|OTHER|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
47935244|NCT00945854|OTHER|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
48099025|NCT00578214|DRUG|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
48460478|NCT02604680|DRUG|BLI1100-1|BLI1100-1 Topical gel
48460479|NCT02604680|DRUG|BLI1100-2|BLI1100-2 Topical gel
48460480|NCT02604680|DRUG|BLI1100-3|BLI1100-3 Topical gel
48460481|NCT02604680|DRUG|BLI1100-4|BLI1100-4 Topical gel
48460482|NCT02604680|DRUG|Placebo|Placebo - Topical gel
48460483|NCT04218994|OTHER|Flossing technique|Subjects instructed on flossing technique
48460484|NCT01286805|PROCEDURE|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
48460485|NCT01286805|PROCEDURE|Control|The control group will receive only a combined spinal-epidural.
48460486|NCT01620840|DRUG|Lacosamide 10mg/ml|intravenous administration up to 10 days
48460487|NCT04454307|DRUG|Tramadol|tramadol 100 mg twice daily for 10 days
48460488|NCT04454307|OTHER|Standard care delivered in the isolation hospitals.|Oxygen ventilation.
48460489|NCT00397657|DRUG|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
48460490|NCT00397657|DRUG|ezetimibe|Ezetimibe 10mg once daily
48460491|NCT00058435|BIOLOGICAL|abagovomab|
48460492|NCT02528019|DRUG|DPP-4 inhibiotors|
48460493|NCT02528019|DRUG|SGLT2 inhibitors|
48460494|NCT02528019|DRUG|Glimepiride|
48460495|NCT05294016|DEVICE|BRA CONNECT device|skin thermal analysis for the detection of breast abnormalities
48460496|NCT00942721|BEHAVIORAL|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
48460497|NCT01694563|DEVICE|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~* Coronary Artery Bypass Grafting (CABG)~* Mitral valve repair or replacement~* Aortic valve repair or replacement~* Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
48460498|NCT04534985|BEHAVIORAL|Dietary|Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted
48460499|NCT01374646|BEHAVIORAL|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
48460500|NCT03257254|DRUG|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
48460501|NCT02155153|OTHER|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
48460502|NCT04072003|DEVICE|intravascular ultrasound (IVUS)|use IVUS in the procedure
48460503|NCT04072003|OTHER|coronary angiography|Coronary angiography is required for all PCI procedure.
48460504|NCT02717260|DEVICE|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
48460505|NCT00629057|BIOLOGICAL|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
48460506|NCT00629057|BIOLOGICAL|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
48460507|NCT00629057|BIOLOGICAL|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
48460508|NCT04223349|DRUG|JNJ-70033093|JNJ-70033093 capsules will be administered orally .
48460509|NCT04223349|DRUG|Placebo|Matching placebo in capsule will be administered orally.
48460510|NCT05397977|DEVICE|mechanical traction group|"In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program."
48460511|NCT05397977|OTHER|manuel traction group|"Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program."
48460512|NCT01235260|OTHER|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
48460513|NCT01235260|DRUG|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
48460514|NCT03261843|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
48460515|NCT03261843|PROCEDURE|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
48460516|NCT03747107|BEHAVIORAL|P-DQIP|The 'intervention' is a health board quality improvement programme to be implemented across all practices in one Scottish NHS health board and comprises the following components: (i) Case finding via the P-DQIP informatics tool to identify patients with drug therapy risks for review; (ii) Decision support via the P-DQIP informatics tool to facilitate medication reviews; (iii) Practice pharmacists will be trained on the use of the P-DQIP informatics tool and instructed to target patients at risk of bleeding and hypoglycaemia first (iv) Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on review activity and targeted prescribing; (v) promotion of the P-DQIP tool and intervention among GP practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
48460517|NCT03757520|DIAGNOSTIC_TEST|Pain Pressure Threshold|The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
48460518|NCT03757520|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected."
48460519|NCT05711901|DEVICE|Efferon LPS|Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 12h immediately following admission to the intensive care unit
48460520|NCT04848688|DRUG|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
48460521|NCT04848688|DRUG|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
48460522|NCT04848688|DRUG|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
48460523|NCT03138044|PROCEDURE|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (\> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
48460524|NCT03822130|DRUG|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
48460525|NCT03822130|DRUG|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
48460526|NCT03822130|DRUG|Systemic Chemotherapy|Systemic Chemotherapy
48460527|NCT03822130|DRUG|Oral Chemotherapy|Oral Chemotherapy
48460528|NCT01307358|OTHER|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
47935245|NCT00013195|BEHAVIORAL|Telephone Care|
48460529|NCT00548431|DRUG|6-mercaptopurine|Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC\>0.5 T-count \>50)
48460530|NCT02955628|DRUG|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
48460531|NCT03492567|BIOLOGICAL|Blood test|Blood draw (max 15 ml)
48460532|NCT02708758|BEHAVIORAL|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
48460533|NCT00721162|BIOLOGICAL|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
48460534|NCT05562037|OTHER|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
48460535|NCT02046122|DRUG|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
48460536|NCT02046122|DRUG|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
48460537|NCT02046122|BIOLOGICAL|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10\^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
48460538|NCT02779933|OTHER|Epidemiology od HAP|no intervention
48460539|NCT02188628|DEVICE|H-Man|H-man is a portable end-effector planar upper limb robot.
47935246|NCT06329115|OTHER|Exercise training|Within the physical activity program, an aerobic training program will be applied to students for a total of 150 minutes per week for 8 weeks. Aerobic training includes moderate-intensity walking exercise. The concept of moderate walking will be explained to individuals at the beginning of the study. Maximal and submaximal heart rate calculations will be made with the formulas (220-age) / (220-age X 0.6) and this heart rate will be maintained throughout the training. Students will have a pedometer application installed on their phones and their step counts and exercise minute data will be recorded. At the same time, in order for students to use their respiratory functions properly during regular walking, diaphragmatic breathing and alternating nose breathing breathing exercises will be taught and they will be instructed to do them once a day with 5 repetitions.
47935247|NCT03425227|OTHER|FRED EXERGAME|biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
47935248|NCT02482207|DRUG|Rosuvastatin|
47935249|NCT02482207|BEHAVIORAL|Life style modification|
47935250|NCT06206343|OTHER|TENS application, Tele-rehabilitation treatment program|Exercise training
47935251|NCT02803515|BIOLOGICAL|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
47935252|NCT06404346|DIAGNOSTIC_TEST|High Velocity Thrust|Group A Participants assigned to the HVT will receive manual therapy sessions consisting of specific manipulative techniques targeting the sacroiliac joint and surrounding structures. participant lying on your side or on your stomach, depending on which SI joint needs to be manipulated.The physiotherapist will stabilize body to isolate the specific SI joint that needs adjustment. This may involve holding certain parts of your body in place or using props like a belt or cushion.With precise control and speed, the physiotherapist will apply a sudden thrust to the targeted SI joint. This thrust aims to mobilize the joint and restore its normal function. This procedure will perform in 3 sessions per week for 2 weeks
47935253|NCT06404346|OTHER|Bowen therapy|participants will undergo sessions involving gentle, rolling movements over muscles, tendons, and ligaments in sacroiliac joint . participant lie comfortably on a treatment bed fully clothed, typically face down or on your side. The physiotherapist will perform a series of gentle, rolling movements with their fingers and thumbs over specific points on your body, including the lower back, hips, and buttocks. These moves are designed to stimulate the nervous system and promote relaxation and healing in the affected area.
47935254|NCT05646472|DIAGNOSTIC_TEST|Frailty multidimensional assessment|"Each Centre will administer SUNFRAIL frailty assessment tool to the enrolled older adults and, according to the specific alerts triggered by the answers provided, older adults will be subjected (at the same time or subsequently) to one or more validated in-depth tests (already included in the SUNFRAIL+ platform) in order to perform further diagnostic or dimensional evaluations.~During the observation phase, subjects will be given different health promotion activities, depending on the assessment.~During the follow-up phase, 6 months after enrolment, SUNFRAIL tool and in-depth tests will be administered again. In addition, during the follow up, the extent to which exposure to interventions has influenced the quality of life of older adults will be measured and the number of users enrolled by territorial services, based on user care needs. In addition, the level of satisfaction and usability of the SUNFRAIL+ solution by health and social care professionals will be measured."
48460540|NCT02188628|OTHER|Additional Conventional Therapy|Repetitive goals based arm therapy
48460541|NCT01769222|BIOLOGICAL|Ipilimumab|Given intratumorally
48460542|NCT01769222|RADIATION|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
48460543|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
48460544|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
48460545|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
48460546|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
48460547|NCT02831920|OTHER|CEUS and targeted biopsies|
48460548|NCT02831920|OTHER|MRI and targeted biopsies|
48460549|NCT05570955|BEHAVIORAL|Text reminder|weekly text to remind use of drug
48460550|NCT01986725|BEHAVIORAL|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
48460551|NCT01986725|BEHAVIORAL|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
48460552|NCT00795158|DRUG|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
48460553|NCT05089903|BEHAVIORAL|Bulk Order|A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
48460554|NCT05089903|BEHAVIORAL|Texting|In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
48460555|NCT05089903|BEHAVIORAL|Clinician Endorsement|Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
48460556|NCT05089903|BEHAVIORAL|No Bulk Order|The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
48460557|NCT05089903|BEHAVIORAL|Standard Endorsement|Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
47935255|NCT01933815|DRUG|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
47935256|NCT01933815|DRUG|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
47935257|NCT03627390|DRUG|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
48460558|NCT00787605|DRUG|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
48460559|NCT00787605|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
48460560|NCT00787605|DRUG|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
48460561|NCT02623257|OTHER|mutation detection|
48460562|NCT02623257|OTHER|ARMS|
48460563|NCT02623257|GENETIC|ctDNA analysis|
48460564|NCT05270044|DRUG|Encorafenib and Binimetinib|Encorafenib 450 mg (6 × 75 mg capsules) once daily (QD) and binimetinib 45 mg (3 x 15 mg tablets) twice daily (BID) orally for a maximum of 12 months.
48460565|NCT05270044|DRUG|Placebo to match Encorafenib ; Placebo to match Binimetinib|Encorafenib (6 × 75 mg placebo capsules) QD and binimetinib (3 × 15 mg placebo tablets) BID placebos orally for a maximum of 12 months.
48460566|NCT01866124|OTHER|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
48460567|NCT04039360|COMBINATION_PRODUCT|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
48460568|NCT01296841|DEVICE|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
47935258|NCT03627390|DRUG|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
47935259|NCT04841200|DRUG|Chinese medicine compound combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd.~Each type of granule will be given orally, twice a day, for 52 weeks."
48099026|NCT00578214|OTHER|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
48099027|NCT00578214|DRUG|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
48460569|NCT05535998|PROCEDURE|TACE-HAIC|The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 2400 mg/m2 of continuous 5-FU infusion for 46 hours or 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks.
47935260|NCT04841200|DRUG|Chinese medicine compound placebo combined with symptomatic treatments|"All patients were given symptomatic treatment according to consensus of Chinese experts on pneumoconiosis treatment (2018).~There are 3 placebo Recipe for the 3 traditional Chinese syndrome.~Yang Qing Chen Fei Granules placebo for syndrome of yin deficiency and heat-dryness, Bao Jin Chen Fei Granules placebo for syndrome of pulmonary qi deficiency, Jin Shui Chen Fei Granules placebo for syndrome of deficiency of pulmonary and renal qi~All drugs were made into granules by Sichuan Neo-Green Pharmaceutical Technology Development Co., Ltd. The appearance, shape, color and packaging of Chinese medicine compound placebo are the same as those of drugs.~Each type of granule will be given orally, twice a day, for 52 weeks."
48460570|NCT05535998|PROCEDURE|TACE|TACE was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of MMC, mixed with 2-5 mL lipiodol. Up to 20 mL of additional pure lipiodol were injected into the tumor-feeding artery until stasis of blood flow was observed in the target artery. Repeated TACE was performed at intervals of 3-4 weeks.
48460571|NCT05535998|DRUG|Targeted therapy|The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.
48460572|NCT05535998|DRUG|PD-1 inhibitors|PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
48460573|NCT00004985|DRUG|Capravirine|
48460574|NCT00004985|DRUG|Nelfinavir mesylate|
48460575|NCT05004649|BEHAVIORAL|Psychophysical task|A psychophysical task will be used to measure participants' ability to discriminate the horizontal position of the central object that is presented within the context of background objects in a natural visual scene. The task will be a two-interval forced choice task that presents one stimulus per interval. Between the two stimulus intervals, two masks will be shown in succession at the center of the monitor. The task of the participant will be to determine whether, compared to the central object presented in the first interval, the central object presented in the second interval is to the left or to the right. One of two feedback tones will be presented after the response is entered, indicating whether the participant was correct or incorrect. For trials in which there is no difference in the position of the central object between the two intervals, the response that will receive the correct feedback tone will be randomly selected per trial.
48460576|NCT00970788|BEHAVIORAL|Video intervention|Video of goals of care
48460577|NCT00061464|DRUG|pemetrexed|
48460578|NCT00061464|DRUG|gemcitabine|
48460579|NCT05534113|DRUG|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
48460580|NCT05921812|DIAGNOSTIC_TEST|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
48460581|NCT00096850|DRUG|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
48460582|NCT00096850|DRUG|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
48460583|NCT00096850|DRUG|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
48460584|NCT01685008|DRUG|MOR00208 (formerly Xmab 5574)|
48460585|NCT04469751|DIAGNOSTIC_TEST|invasive blood pressure monitoring|radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
48460586|NCT04785963|BEHAVIORAL|Music with Suggestion|A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.
48460587|NCT04785963|BEHAVIORAL|Pain Information|The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.
48460588|NCT04785963|BEHAVIORAL|Music|The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
48623194|NCT03897621|DRUG|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
48623195|NCT01709344|BEHAVIORAL|PS-OT|
47935261|NCT03500081|DEVICE|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
47935262|NCT00184873|BEHAVIORAL|Health Counseling|
47935263|NCT01165736|DRUG|PF-05186462|single intravenous infusion of 100 microgram
47935264|NCT01165736|DRUG|PF-05186462|single oral administration of 100 microgram
48281331|NCT06105138|DIETARY_SUPPLEMENT|Placebo|"Placebo administered in the laboratory prior to a standard dose of alcohol.~The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at \<0.1%."
47935265|NCT01165736|DRUG|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
47935266|NCT01165736|DRUG|PF-05089771|single oral administration of 100 microgram PF-05089771
47935267|NCT01165736|DRUG|PF-05150122|single intravenous administration of 100 microgram PF-05150122
48460589|NCT02945618|DEVICE|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
48281332|NCT02730806|BEHAVIORAL|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
48460590|NCT02945618|OTHER|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
48460591|NCT01539564|DRUG|Minocycline HCl Microspheres|
48460592|NCT01093560|DIETARY_SUPPLEMENT|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
48460593|NCT05959915|DEVICE|device e-patch Implantation|"The ePatch device (Phillips) was used. This device is attached to the sternum, using a specific dressing adapted for the device itself. Manufacturer's recommendations for skin preparation and placement will be followed.~The device will remain in place for 4-5 days, at which time the patient will be readmitted for data extraction and reading.~The team of research nurses will analyze the data through the ePatch platform and later, the electrophysiologists will review the results and make a diagnosis."
48460594|NCT05947266|BEHAVIORAL|an adaptation of the iENGAGE|Haitian immigrant iENGAGE (H-iENGAGE) is an adaptation of the iENGAGE intervention culturally adapted for Haitian immigrants with HIV that will be tested in a quasi-experimental pilot for preliminary efficacy among recently diagnosed or nonvirally suppressed adults across two Federally Qualified Health Centers (FQHCs) in Miami.
48460595|NCT04516187|DIAGNOSTIC_TEST|signs and symptoms, blood tests|signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
48460596|NCT05305495|DRUG|Empagliflozin 25 MG|Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output \< 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
48460597|NCT00015691|DRUG|Metformin hydrochloride|
48460598|NCT00015691|DRUG|Rosiglitazone maleate|
48460599|NCT05368480|OTHER|Senior Companion Program|Receives a companion to socialize with them, help with daily tasks, etc.
48460600|NCT03283982|DEVICE|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
48460601|NCT03283982|DEVICE|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
48460602|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
48460603|NCT02620137|DRUG|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
48460604|NCT02749604|PROCEDURE|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
48460605|NCT02749604|PROCEDURE|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
48460606|NCT04396392|BEHAVIORAL|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
48460607|NCT04413799|COMBINATION_PRODUCT|lidocaine, ketamine intravenous infusion|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to lidocaine/ketamine group, the anesthesiologist led Acute Pain Service (APS) will prescribe lidocaine/ ketamine infusion, which will be monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
48623196|NCT01709344|OTHER|Usual care|Supportive and rehabilitation services available at DHMC
47935268|NCT01165736|DRUG|PF-05150122|single oral administration of 100 microgram PF-05150122
47935269|NCT01165736|DRUG|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
47935270|NCT01165736|DRUG|PF-05241328|single oral administration 100 microgram PF-05241328
48281333|NCT01744561|BEHAVIORAL|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
48460608|NCT04413799|DRUG|paravertebral block with ropivicaine|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to PVB, the anesthesiologist led Acute Pain Service (APS) will place a paravertebral block catheter. Ropivacaine infusion will be started, monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
48460609|NCT06466499|BEHAVIORAL|The intervention group|Is described in arm
48460610|NCT04651036|DRUG|QL0605|a pegfilgrastim biosimilar to US Neulasta.
48460611|NCT04651036|DRUG|US Neulasta|US Neulasta
48460612|NCT02096705|DRUG|Dapagliflozin|Tablet
48460613|NCT02096705|DRUG|Dapagliflozin Placebo|Tablet
48460614|NCT04803162|DIAGNOSTIC_TEST|High-resolution manometry|The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.
48460615|NCT04803162|DIAGNOSTIC_TEST|Serum biomarkers|The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.
48460616|NCT04803162|DIAGNOSTIC_TEST|Gastrointestinal Quality of Life index|The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.
47935271|NCT05857423|OTHER|Gentle Human Touch|"Gentle Human Touch procedure has 3 step as follows:~1. Mother/nurse must wash their hands with antimicrobial soap for 3 minutes before starting Gentle Human Touch procedure.~2. Next, mother/nurse must warm their hands.~3. Mother/nurse must place their one hand on the infant's head and the other hand on the lower abdomen that covers the waist and hips of the preterm infant, for 15 minute."
47935272|NCT03959228|DRUG|keto-analogs|The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
48281334|NCT05546489|BEHAVIORAL|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
48460617|NCT04803162|DRUG|Omeprazole 20 MG Oral Tablet|The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
48460618|NCT00857038|DRUG|Doxycycline|Doxycycline tablets, 100mg daily
48460619|NCT00857038|DRUG|Placebo|Placebo tablets 100mg
48281335|NCT02585427|DIETARY_SUPPLEMENT|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
48460620|NCT04121533|DIETARY_SUPPLEMENT|Placebo|Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.
48460621|NCT04121533|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.
48460622|NCT04121533|DIETARY_SUPPLEMENT|Glucosamine sulfate and omega-3 fatty acids|Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
48460623|NCT04383249|DIAGNOSTIC_TEST|Pathology result|Pathology result of the hernia sac
48460624|NCT06062615|PROCEDURE|Total knee replacement using Omnibot Knee System|total knee replacement with robotic assistance
48460625|NCT06062615|PROCEDURE|Conventional Total knee replacement|Conventional total knee replacement without robotic assistance
48460626|NCT06062615|DEVICE|Omnibot Robotic Knee System|utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
48460627|NCT05046951|BEHAVIORAL|Should I Screen website|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
47935273|NCT00150644|DRUG|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
47935274|NCT00150644|DRUG|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
47935275|NCT00150644|DRUG|Placebo|Placebo Tablet, oral Daily for 12 weeks
47935276|NCT00625573|DRUG|Abraxane|100mg/m2 every week X's 3
47935277|NCT01475071|DRUG|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
48281336|NCT03448744|DRUG|Thymosin Alpha1|Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
48281337|NCT03448744|DRUG|Entecavir|ETV (0.5 mg orally, daily) for 72 weeks
48460628|NCT05046951|BEHAVIORAL|Should I Screen print booklet|The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
48460629|NCT02421627|DEVICE|moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
48460630|NCT02421627|DEVICE|Sham moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
48460631|NCT03168035|DRUG|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
48460632|NCT03967262|BEHAVIORAL|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
48460633|NCT02541227|DRUG|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
48460634|NCT05783089|BIOLOGICAL|Anti-mesothelin CAR-T cells|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
48460635|NCT00108043|PROCEDURE|FES-evoked functional upright gait|
48460636|NCT02095522|DRUG|Colchicine|Colchicine 1mg per day for one month
48460637|NCT02095522|DRUG|Placebo|Placebo
48460638|NCT01608646|DRUG|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
48460639|NCT03069976|DRUG|Metronidazole|Flagyl x 14 days.
48460640|NCT03028792|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
48460641|NCT03028792|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
48460642|NCT01932905|DEVICE|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
48460643|NCT04364763|DRUG|RBT-9 (90 mg)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
48460644|NCT04364763|DRUG|0.9% sodium chloride (normal saline)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
48460645|NCT01016054|BIOLOGICAL|AGS-8M4|IV infusion
48460646|NCT01016054|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
48460647|NCT01016054|DRUG|gemcitabine|IV infusion
48460648|NCT01016054|DRUG|carboplatin|IV infusion
48460649|NCT06251206|BEHAVIORAL|ADL/Postoperative Instruction|This is an education video which includes demonstration of simple ADL tasks that the participant can do at home after surgery. Handout includes the same information and a QR code to watch the video.
48460650|NCT06251206|BEHAVIORAL|Postoperative Instruction|This is an education video that only includes the postoperative instructions. Handout includes the same information and a QR code to watch the video.
48460651|NCT03567551|OTHER|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
48460652|NCT03567551|OTHER|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
48460653|NCT03567551|OTHER|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
48460654|NCT02845336|DRUG|Celecoxib|celecoxib 100mg PO twice per day for 3 months
48281338|NCT05763407|DEVICE|FIRE1 System|FIRE1 System
48281339|NCT03406962|DRUG|MGTA-456|Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
48281340|NCT01331161|BIOLOGICAL|ZOSTAVAX|shingles vaccine, one dose
48460655|NCT02845336|DRUG|artificial tears|Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
48460656|NCT04031235|BEHAVIORAL|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
48460657|NCT04031235|BEHAVIORAL|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
48460658|NCT00686868|OTHER|placebo|placebo
48460659|NCT00686868|DRUG|ofatumumab|fully human anti-CD20 monoclonal antibody
48460660|NCT05262322|DRUG|Edoxaban|This was a non-interventional, observational study. No drug was administered in this study.
48460661|NCT05262322|DRUG|Apixaban|This was a non-interventional, observational study. No drug was administered in this study.
47935278|NCT01475071|DRUG|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
48460662|NCT05262322|DRUG|Rivaroxaban|This was a non-interventional, observational study. No drug was administered in this study.
48460663|NCT05281354|OTHER|Multimodal intervention|Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
48460664|NCT05203692|DRUG|DS-7011a|Intravenous or subcutaneous administration, single dose
48460665|NCT05203692|DRUG|Placebo|Intravenous or subcutaneous administration, single dose
48281341|NCT05178901|BIOLOGICAL|PHV02|live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
48281342|NCT05178901|OTHER|Placebo|Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
48281343|NCT04091217|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
48460666|NCT00285961|DEVICE|Cork splint materials (instead of plaster splint)|
48460667|NCT02452619|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
48099028|NCT00578214|DRUG|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (\>45 to 77 kg, 10 mg; \>77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
48099029|NCT05879978|DRUG|BI 764532|BI 764532
48460668|NCT01277510|DRUG|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
48460669|NCT01277510|DRUG|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
48460670|NCT01277510|DRUG|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
47935279|NCT00371761|BIOLOGICAL|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
47935280|NCT00371761|DRUG|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
48460671|NCT06065280|DRUG|Empagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
48460672|NCT06065280|DRUG|Dapagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
48460673|NCT05877326|DRUG|General anesthesia with propofol or sevoflurane|General anesthesia
48099030|NCT05879978|DRUG|Ezabenlimab|Ezabenlimab
47935281|NCT04394182|RADIATION|Ultra-Low-dose radiotherapy|The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
47935282|NCT04394182|DEVICE|ventilatory support with oxygen therapy|Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
47935283|NCT04394182|DRUG|Lopinavir/ritonavir|100/400 mg/12h; 7-10 days
48460674|NCT05877326|BEHAVIORAL|CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative|The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
48460675|NCT05682963|OTHER|Square Step Exercises Program|Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.
47935284|NCT04394182|DRUG|Hydroxychloroquine|200 mg/12h
47935285|NCT04394182|DRUG|Azithromycin|500 mg/24h, 3 days
48099031|NCT06501079|PROCEDURE|ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%|"ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound transducer should be placed in the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level.~Erector spinae muscle should be identified superficial to the transverse process. The needle inserted superior to the ultrasound probe in the cephalad to caudal direction. Once the needle tip is below the erector spinae muscle.~This separation from the transverse process confirms the proper needlemposition.~The local anesthetic should then be injected in 5 ml increments. The block will be performed preoperatively."
48281344|NCT04091217|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
48460676|NCT05682963|OTHER|Home Exercise Program|Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
47935286|NCT04394182|DRUG|Piperacillin/tazobactam|4 g / 0.5 g administered every 6-8 hours through a vein (directly into the bloodstream), for 5-14 days. Adjustment to kidney function
48281345|NCT02085811|OTHER|radiography standard|
48281346|NCT05067595|PROCEDURE|Colonoscopy|Undergo lower FMT via colonoscopy
47935287|NCT04394182|DRUG|Low molecular weight heparin|prophylactic doses
47935288|NCT04394182|DRUG|Corticosteroid injection|250mg x 3 boluses
47935289|NCT04394182|DRUG|Tocilizumab|600mg single dose
48281347|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Given upper FMT PO
48281348|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Undergo lower FMT via colonoscopy
48460677|NCT04735172|OTHER|specific MRI Acquisition (NMR spectroscopy) at 7T|"The MRI protocol will be performed at 7T on a Siemens NMR imaging system (Magnetom Terra, Siemens Healthcare, Erlangen, Germany), the radio frequency emission and signal reception will be done through a head quadrature resonator (64-channel phase-array coil). To avoid motion-related artifacts, the patient will be seated in a supine position, with the arms along the body and the head immobilized using a suitable head restraint. The MR protocol will take place in two phases:~* Acquisition of 3D multi-slice T1 and T2-weighted morphological images to identify areas of interest;~* Acquisition of 1D RMN spectra in the right and left putamen and STN. Spectra will be acquired in volumes of interest of 15mmx15mmx15mm using a localized spectroscopy sequence with and without suppression of the water signal. Main parameters are: TR (repetition time)=3000ms; TE (echo time)=20 ms; number of repetitions=128; scan time 6min)."
48460678|NCT01247103|DRUG|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
48460679|NCT01247103|DRUG|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
48460680|NCT01247103|OTHER|Placebo|Placebo to match AZD4316
48460681|NCT01767753|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
48460682|NCT02454595|BEHAVIORAL|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
48460683|NCT00409942|DRUG|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
48460684|NCT00409942|DRUG|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
48460685|NCT05263635|OTHER|Music therapy|Music therapy will include music intervention based on recommendations from literature such as slow, flowing rhythm, approximately 60-80 beats/minute and played by string instruments, played with a volume of approximately 45 decibel and will be reviewed by qualified music therapists.
48460686|NCT05263635|OTHER|Standard of Care Enhanced Recovery After Surgery (ERAS)|Patients will receive the standard of care treatment for surgery and post-operative pain management, following the Enhanced Recovery After Surgery (ERAS) protocol
48460687|NCT04440358|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
48460688|NCT04440358|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
48460689|NCT01226953|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
48460690|NCT00879164|DRUG|bupivacaine hydrochloride|
48460691|NCT00879164|OTHER|questionnaire administration|
48460692|NCT04366960|DRUG|Enoxaparin|Subcutaneous enoxaparin
48460693|NCT04738019|DIAGNOSTIC_TEST|Medical examination or treatment.|Medical examination or treatment when delayed on-set nodule or other side effects occur due to Y-Solution filler injection.
48460694|NCT03867916|BEHAVIORAL|Patient Navigation Program|Use patient navigation program
48460695|NCT03867916|OTHER|Quality-of-Life Assessment|Ancillary studies
48460696|NCT03867916|OTHER|Survey Administration|Ancillary studies
48460697|NCT02803827|OTHER|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
47935290|NCT03673410|PROCEDURE|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
47935291|NCT03673410|PROCEDURE|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
47935292|NCT01721577|DRUG|AXL1717|IGF-1 receptor inhibitor
47935293|NCT03754192|RADIATION|perfusion Computed Tomography|Will be carried before liver surgery
47935294|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP1|Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.
48281349|NCT05067595|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given dietary fiber supplementation PO
48281350|NCT05067595|OTHER|Survey Administration|Ancillary studies
48460698|NCT02803827|BIOLOGICAL|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
48460699|NCT02803827|OTHER|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
48460700|NCT03718039|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
48460701|NCT03718039|DEVICE|Luer Lock applicator|Applicator for instillation.
48460702|NCT03718039|DEVICE|Vial access device|Device for withdrawal of drug product.
48460703|NCT03718039|DRUG|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
48460704|NCT01216254|DEVICE|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
48460705|NCT05376423|BIOLOGICAL|OBI-833/OBI-821|OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.
48460706|NCT05633251|BEHAVIORAL|Variable (random) interval|Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
48460707|NCT05633251|BEHAVIORAL|Variable (non-random) interval|Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
48460708|NCT05633251|BEHAVIORAL|Variable (random) interval with table tents|Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
48460709|NCT05633251|BEHAVIORAL|Control|No intervention
48460710|NCT05683561|BIOLOGICAL|CoronaVac|D0; intramuscular injection
48460711|NCT05683561|BIOLOGICAL|SCTV01E|D0; intramuscular injection
48460712|NCT05472740|DEVICE|TENS 7000|TENS device to be used in both the active and placebo groups
48460713|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
48460714|NCT01257984|DRUG|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
48460715|NCT00611650|DRUG|defined green tea catechin extract|Given orally
48460716|NCT00611650|OTHER|placebo|Given orally
48460717|NCT01800838|DRUG|silicon phthalocyanine 4|Given topically
48460718|NCT01800838|DRUG|photodynamic therapy|Undergo PDT
48460719|NCT01800838|OTHER|pharmacological study|Correlative studies
48460720|NCT01800838|OTHER|laboratory biomarker analysis|Correlative studies
48460721|NCT06256224|DRUG|Toripalimab|Toripalimab combined with CCRT
48460722|NCT06256224|RADIATION|CCRT|CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)
48460723|NCT00045162|DRUG|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
48460724|NCT00045162|DRUG|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles
48460725|NCT00045162|DRUG|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
48460726|NCT06116396|GENETIC|Genetic analysis on isolated cells|Isolation of cells from blood and urine
47935295|NCT04787081|OTHER|Sleep Care Positioning Training Program GRP2|Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
48281351|NCT05067595|PROCEDURE|Biospecimen Collection|Undergo tissue, stool, stool swabs, and blood sample collection
48460727|NCT00111787|DRUG|Lapatinib|Daily-monotherapy \[1500 milligrams (mg)\] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
48460728|NCT00111787|DRUG|Paclitaxel|Weekly (80mg/m\^2) combination therapy (with daily Lapatinib) for 12 weeks
48460729|NCT06078176|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility and facilitate bowel emptying. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
48460730|NCT01519830|DRUG|Iron carboxymaltose (Ferinject)|Intravenous iron
48460731|NCT01519830|DRUG|Placebo|0.9% NaCl solution
48460732|NCT06562543|DRUG|Fruquintinib|Oral capsules
48460733|NCT03255980|DEVICE|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
47935296|NCT01007253|DRUG|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
47935297|NCT01007253|DRUG|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
47935298|NCT01007253|DRUG|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
47935299|NCT01007253|DRUG|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
48281352|NCT01994343|OTHER|Global posture reeducation|An assessment of the women is performed using global posture reeducation.
48460734|NCT03255980|OTHER|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
47935300|NCT00079131|BIOLOGICAL|oblimersen sodium|Given IV
47935301|NCT00079131|OTHER|pharmacological study|Correlative studies
47935302|NCT00079131|OTHER|laboratory biomarker analysis|Correlative studies
47935303|NCT04483687|DRUG|Filgotinib|Tablets administered orally once daily
48460735|NCT06486389|DEVICE|reading fairy tales|Reading fairy tales during inhaler medication administration.
48460736|NCT06486389|DEVICE|painting|painting during inhaler medication administration
48460737|NCT04385251|OTHER|Data Collection|"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status"
48460738|NCT00664196|BIOLOGICAL|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
48460739|NCT05773222|DRUG|Apixaban|Single Group Assignment
48460740|NCT03690063|OTHER|Follow up|Follow up of treatment, behavior, co-morbidity
48460741|NCT04414046|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
48460742|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
48460743|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-30g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
48460744|NCT03595436|DIETARY_SUPPLEMENT|Pea Protein-40g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
48460745|NCT03595436|DIETARY_SUPPLEMENT|Whey Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
48460746|NCT03595436|DIETARY_SUPPLEMENT|Carbohydrate Control|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to \~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
48460747|NCT04755335|DIAGNOSTIC_TEST|Ultrasound|In this project, The investigators will use Alpinion ECUBE-12R (Alpinion, Bothell, WA) US platform. This state-of-the-art research US machine provides beam formed as well as Plane-Wave imaging options that allow high frame rate imaging. The investigators have characterized the acoustic output of this system for safe human studies and obtained the IRB approval for human studies. It should be noted that our technique is not limited to the Alpinion system; the investigators can also use other US systems, such as Verasonics, Vantage, (Redmond, WA). This technique can be adapted to other modern US machines in the future.
48460748|NCT03624868|BEHAVIORAL|Tai Chi|See above description
48460749|NCT03624868|BEHAVIORAL|Wellness Education|See above description
48460750|NCT05006573|BIOLOGICAL|Benralizumab|Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
48460751|NCT05006573|BIOLOGICAL|Placebo to Benralizumab|Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
48460752|NCT03252457|DRUG|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
48460753|NCT03252457|DRUG|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
48460754|NCT04969562|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT, Emotional Freedom Technique) is a psychophysiological interpretation that combines elements of cognitive behavioral therapy (CBT), exposure therapy, and somatic stimulation using acupuncture points.
48460755|NCT01456949|DEVICE|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
48460756|NCT05651698|DEVICE|HeartMan Intervention group|The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
48460757|NCT03368027|BEHAVIORAL|A cognitive-behavioral intervention program|In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
48460758|NCT03368027|OTHER|Standard intervention|Participants receive different activities conducted by a psychologist in the association where the attend.
48460759|NCT02614196|DRUG|Galcanezumab|Administered SC
48460760|NCT02614196|DRUG|Placebo|Administered SC
48460761|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)|Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
48460762|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)|Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
48460763|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)|Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
48460764|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)|Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
48460765|NCT01906190|BIOLOGICAL|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
48460766|NCT05789121|DEVICE|walking 25 m in 4 different conditions|"The protocol consisted of walking 25 m in 4 different conditions in the following order:~Gait1, RAS-Slow, RAS-fast, Gait2.~* Gait 1 : preferred cadence without auditory stimulation~* RAS-Slow : Gait with low tempo rhythmic auditory stimulation by music (68.5 per minute).~* RAS-Fast : Gait with fast tempo (10% above each Gait1 cadence).~* Gait2 : preferred cadence without auditory stimulation"
48460767|NCT00327847|DRUG|Oral Vitamin D Supplementation|
47935304|NCT04483687|DRUG|Placebo to Match Filgotinib|Tablets administered orally once daily
48460768|NCT01944722|DEVICE|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
48623197|NCT04574557|DIAGNOSTIC_TEST|micro RNA|"miRNA was isolated from serum using a miRNeasy Mini Kit (Qiagen, Cat; 217004)cDNA was isolated from obtained miRNA samples using a miScript Reverse Transcription Kit (Qiagen, Cat; 218060) Quantitative Real-Time PCR (qPCR) will be done using (miScript SYBR Green PCR Kit Qiagen Cat. No: 218073)The qPCR assays were performed in duplicate The relative expressions of Three miRNAs were selected for RT-PCR validation Two were selected from over-expressed miRNAs (miR-34a, miR-146b), one from under-expressed miRNAs (miR-122) were analyzed using the standard 2-ΔΔCT method. These miRNAs were selected due to their pathophysiological relation with NASH.~Predicted gene targets of all differentially expressed miRNAs will be identified. Genes with functions that are potentially relevant to the pathogenesis of NASH and gene targets that are commonly studied e.g. lipogenesis (e.g. FAS), inflammation (c-JUN kinase) will be included in the study"
48623198|NCT01136954|DRUG|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
48460769|NCT01944722|PROCEDURE|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
48460770|NCT04043702|DRUG|The intervention being studied|Intervention Other Names have not been specified
48460771|NCT06180395|OTHER|Group 1|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
48460772|NCT06180395|OTHER|Group 2|"consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
48460773|NCT01627639|DRUG|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
48460774|NCT01627639|DRUG|Placebo|Placebo
48460775|NCT01131091|DRUG|SK-0403|SK-0403 400 mg
48460776|NCT05963750|OTHER|virtual reality|virtual reality
48460777|NCT03283748|DEVICE|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
48460778|NCT01873391|PROCEDURE|Diagnostic hysteroscopy|
48460779|NCT04900623|DEVICE|NavDx HPV ctDNA Testing|Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
48460780|NCT04900623|RADIATION|Radiotherapy|Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
48460781|NCT04900623|DRUG|Chemotherapy drug|"Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy."
48460782|NCT02379533|OTHER|Aerobic exercise|
48460783|NCT02711644|BEHAVIORAL|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
48623199|NCT06278649|BEHAVIORAL|Relaxation and Guided Imagery|Listening to a 15 minute relaxing pre-recorded script while laying down on an exercise mat
47935305|NCT01084096|BEHAVIORAL|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~* Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~* Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
47935306|NCT03901703|OTHER|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
47935307|NCT03360786|OTHER|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
47935308|NCT03360786|OTHER|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
47935309|NCT06305871|PROCEDURE|Ablation therapy|Ablative treatment of hyperthyroidism
48460784|NCT02711644|BEHAVIORAL|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
48460785|NCT04599842|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
48460786|NCT03454737|PROCEDURE|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
48460787|NCT03454737|PROCEDURE|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
48460788|NCT03337893|DIAGNOSTIC_TEST|blood pressure|it will be done both right and left arms
48460789|NCT03122522|DRUG|ipilimumab|ipilimumab 3mg/kg
48460790|NCT03122522|DRUG|nivolumab|nivolumab 1mg/kg
48460791|NCT02418754|DRUG|REGN2176-3|
48460792|NCT02418754|DRUG|Intravitreal Aflibercept Injection (IAI)|
48460793|NCT03534531|PROCEDURE|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
48460794|NCT03985657|DEVICE|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
48460795|NCT02155257|DRUG|Modafinil|
48460796|NCT02155257|DRUG|Gabapentin|
48460797|NCT02155257|DRUG|Placebo|
48460798|NCT05539794|BEHAVIORAL|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
48460799|NCT02473393|DRUG|OPS-2071 tablet|
48460800|NCT02733211|DEVICE|MD- Logic Closed Loop System|Closed Loop System
48460801|NCT02733211|DEVICE|sensor augmented pump therapy|Sensor augmented pump therapy
48460802|NCT06253117|DRUG|Pirfenidone|"Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months"
48460803|NCT06253117|DRUG|Placebo|Placebo
48460804|NCT01961817|OTHER|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
48460805|NCT01961817|OTHER|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
48460806|NCT04922957|DRUG|ALLOCETRA-OTS|The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
48460807|NCT04922957|OTHER|Placebo|Ringer's lactate solution
48460808|NCT00690495|DRUG|Propofol|Propofol (drug), intravenous, induction of anesthesia
48460809|NCT00690495|DRUG|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
48460810|NCT04020796|DIETARY_SUPPLEMENT|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
48460811|NCT03526484|BEHAVIORAL|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
48460812|NCT03526484|BEHAVIORAL|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
48460813|NCT05448209|BEHAVIORAL|walking exercise|Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
48460814|NCT00450567|PROCEDURE|computed tomography|
48460815|NCT00450567|PROCEDURE|positron emission tomography|
48460816|NCT00450567|RADIATION|fludeoxyglucose F 18|
48460817|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
48460818|NCT01020825|DRUG|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
48460819|NCT01020825|DRUG|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
48460820|NCT04516096|DRUG|AMX0035|Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
48460821|NCT05308316|OTHER|Sucrose cigarettes|Winston brand cigarettes will be modified by adding a mixture of sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular brands analyzed
48460822|NCT06010823|DEVICE|PlaXtreme|"A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist."
48460823|NCT00327587|DRUG|Valsartan + amlodipine|
48460824|NCT00327587|DRUG|Valsartan + HCTZ|
48460825|NCT00327587|DRUG|Amlodipine + HCTZ|
48460826|NCT00327587|DRUG|Valsartan + amlodipine + HCTZ|
47935310|NCT05664854|DEVICE|Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography|Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
48460827|NCT01841060|PROCEDURE|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
48460828|NCT01790685|DRUG|dexamethasone implant|
48460829|NCT02143258|PROCEDURE|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
48460830|NCT01751919|DRUG|Imatinib mesylate tablet 400 mg, 1 Tablet|
48460831|NCT01751919|DRUG|Glivec film-coated tablet 100 mg, 4 Tablets|
48460832|NCT03257228|GENETIC|comparative semiquantitative immunohistochemistry|
48460833|NCT04257695|BEHAVIORAL|TapPro|Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
48460834|NCT03828435|DEVICE|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
48460835|NCT03549897|DRUG|Placebo|Placebo Product
48460836|NCT03549897|DRUG|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
48460837|NCT03549897|DRUG|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
48460838|NCT03549897|DRUG|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
48460839|NCT01820962|PROCEDURE|heparin|when not in use CVCs are locked with heparin
48460840|NCT01820962|PROCEDURE|concentrated citrate|when not in use the CVC is locked with concentrated citrate
48460841|NCT06492252|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
48460842|NCT06492252|BEHAVIORAL|Adaptation|Auditory adaptation in speech
48460843|NCT06492252|BEHAVIORAL|Adaptation|Auditory baseline in speech
48460844|NCT00508651|BIOLOGICAL|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
48460845|NCT00508651|BIOLOGICAL|Placebo|Placebo was a frozen preparation filled into Becton Dickinson\^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
47935311|NCT01680237|BEHAVIORAL|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
47935312|NCT01680237|BEHAVIORAL|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
48460846|NCT00901524|DRUG|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
48460847|NCT05810636|DEVICE|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
48460848|NCT03975439|DIAGNOSTIC_TEST|Hemoglobin A1C|Finger stick hemoglobin A1C
48460849|NCT03975439|DIAGNOSTIC_TEST|Urinalysis|Urinalysis by dip stick looking for urine protein level
48460850|NCT03975439|DIAGNOSTIC_TEST|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
48460851|NCT05499728|OTHER|Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)|Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
48460852|NCT01246687|BEHAVIORAL|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
48460853|NCT05205096|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
48460854|NCT05823662|PROCEDURE|DJ stent|A 5 Fr DJ stent will be inserted and then removed after three weeks.
48460855|NCT05823662|DRUG|Silodosin|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
48460856|NCT01508065|DEVICE|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
48460857|NCT01574027|DRUG|Vitamin D3 (cholecalciferol)|One capsule per day for six months
48460858|NCT01574027|DRUG|Placebo|One capsule per day for six months
48460859|NCT01608984|PROCEDURE|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
48623200|NCT04194970|DEVICE|With WBM smart insole system to monitor compliance of specified weight bearing limits data in live feedback on and off situations|"Weight Bearing Protocol (Duration: Post-Op. 6 week)~* Post-op 3 week non-weight bearing (%0 body weight of patient)~* Post- op 3 week touch down weight bearing (%10-%20 body weight of patient) Group I - monitoring with device while the live feedback mechanism turned on Group II- monitoring with device while the live feedback mechanism turned off"
48460860|NCT01608984|PROCEDURE|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
48460861|NCT01608984|PROCEDURE|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
48460862|NCT06410157|BEHAVIORAL|Daily practice|Participants will be asked to undergo daily practice to regulate (either increase or decrease) heart rate oscillation
48460863|NCT05416424|OTHER|LIFE program|During the nutritionist visits, subjects will be asked to discuss and evaluate their current diet and will be given recommended dietary changes. The recommended dietary changes include focusing on eating nutrient dense foods, staying consistent with the timing of meals, limiting added sugars, aiming to have balanced meals and snacks, being a mindful eater, and aiming to drink approximately 2 liters of water a day. Additionally, they will review the nutrition survey with the registered dietician. During the office visits with a doctor, subjects will be given exercise counseling. They will be asked to do 150 minutes per week of moderate intensity aerobic activity
48460864|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
48460865|NCT00288704|DRUG|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
47935313|NCT06459141|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
48099032|NCT06555172|BEHAVIORAL|Action In Mindfulness (AIM)+|"AIM+ is a smartphone-based app that teaches mindfulness meditation to professionals working with legal-involved youth over a 30-day path. Each day of the path consists of a brief (approximately 5- to 10-minute) audio-guided meditation practice, with brief videos interspersed to illustrate key concepts and promote engagement. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they can use as relevant to their workday (e.g., for professionals to listen to before attending a meeting). AIM+ also includes a menu of audio-guided meditation practices that officers can share with the youth on their caseloads (e.g., for youth to listen to before attending court)."
48099033|NCT06555172|BEHAVIORAL|Resource+|Resource+ is a smartphone-based app that is matched to AIM+ for time and structure, but it includes information on community resources that professionals can provide to the youth with whom they work in place of the meditation content featured in AIM+.
48099034|NCT05419557|BEHAVIORAL|Virtual Family-Based Healthy Plate Club|IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
48460866|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
48460867|NCT06036121|DRUG|ADRX-0706|Antibody drug conjugate targeting Nectin-4
48460868|NCT05149209|PROCEDURE|cervical restoration|A class v cavity will be prepared after local anesthesia has been given as required. Rubber dam isolation will be done. Selective enamel etching and a universal adhesive agent (Beautibond, Shofu, Japan) will be applied over all the cavity surfaces. Followed by, placement of restorative material according to the randomization sequence. Finally, restoration finishing and polishing will be done.
48460869|NCT04386577|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
48478804|NCT01974882|OTHER|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
48478805|NCT03803111|BEHAVIORAL|Initial exercise training|Initial exercise training program
48478806|NCT03803111|DRUG|Initial FCM|Initial intravenous iron supplementation (FCM)
47935314|NCT00000506|DRUG|fenfluramine|
47935315|NCT00000506|DRUG|phentermine|
47935316|NCT06215664|BEHAVIORAL|Singularities Game|Singularities is a theory-based, community-informed, web-accessible, roleplaying game-based intervention incorporating 4 primary components: fostering healthy identity development in a safe environment; encouraging help-seeking behaviors; encouraging use of productive coping; alcohol-harm reduction; and encouraging healthy internet and social media use.
48099035|NCT02918916|OTHER|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
48099036|NCT02918916|OTHER|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
48460870|NCT04386577|DRUG|fish oil|Eligible participants were assigned by chance to one of four groups: (1) daily vitamin D3 and omega-3; (2) daily vitamin D3 and omega-3 placebo; (3) daily vitamin D placebo and omega-3; or (4) daily vitamin D placebo and omega-3 placebo. At baseline, year 2 and year 4 of the trial, a subcohort of 1,054 VITAL participants living within driving distance of Boston, Massachusetts received detailed in-clinic health assessments at the Clinical and Translational Science Center (CTSC) of Brigham and Women's Hospital. During CTSC visits, participants have a clinical exam, including measurement of height, weight, other anthropometrics, blood pressure, and physical performance. They also provide fasting blood and urine samples, and undergo 2-hour oral glucose tolerance testing, lung function testing (spirometry), electrocardiograms, bone mineral density testing, 2D-echocardiography, and assessments of thinking and mood.
48460871|NCT01942135|DRUG|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
48460872|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
48460873|NCT01942135|DRUG|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
48460874|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
48460875|NCT01909024|PROCEDURE|Coil embolisation|transjugular coil embolisation of pelvic veins
48460876|NCT01909024|PROCEDURE|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
48460877|NCT01127113|OTHER|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
48460878|NCT01127113|OTHER|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
48460879|NCT01963260|DRUG|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
48460880|NCT01963260|DRUG|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
48460881|NCT05485662|OTHER|Hydroxyapatite toothpaste|10% Hydroxyapatite toothpaste
48460882|NCT05485662|OTHER|Sodium Fluoride Toothpaste|1450 parts per million sodium fluoride toothpaste
48460883|NCT03284138|DEVICE|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
48460884|NCT03284138|DEVICE|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
48460885|NCT00487435|DRUG|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
47935317|NCT06215664|BEHAVIORAL|Psychosocial Education|Psychoeducational core components of the Singularities intervention delivered in an instructional text format to participants through a Qualtrics-based training program.
48099037|NCT00479180|BIOLOGICAL|Vascugel|One time implant on the day of surgery
48099038|NCT00479180|BIOLOGICAL|Placebo Comparator|One time implant on the day of surgery
48460886|NCT06627556|DRUG|H021|H021 oral tablet.
47935318|NCT05002153|OTHER|Fecal microbiota transplantation (FMT)|FMT is the process of transferring stool from a healthy donor to another.
47935319|NCT05002153|OTHER|Placebo|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
47935320|NCT04106024|DRUG|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
47935321|NCT05354154|PROCEDURE|endotracheal intubation|Consenting healthy patients of either sex will be endotracheally intubated under controlled environment
47935322|NCT06041971|DEVICE|AIDANET system|The study will involve testing a new AID system designed to enable full closed loop control and consisting of the following elements: the diabetes assistant (DiAs) prototyping platform (MAF 2019), connected to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing the University of Virginia (UVA) AIDANET algorithm.
47935323|NCT04288232|DRUG|Aflibercept Injection [Eylea]|Intravitreal aflibercept Injection 2.0mg/0.05 ml
48099039|NCT00569738|PROCEDURE|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
47935324|NCT03403842|DEVICE|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
47935325|NCT03403842|DEVICE|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
48099040|NCT06631313|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with either the PureWick Male External Catheter or the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
48099041|NCT04362501|BIOLOGICAL|dupilumab|300mg dupixent SC every two weeks for six months
48460887|NCT06627556|DRUG|H021 Placebo|H021 placebo oral tablet.
48460888|NCT00452348|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
48460889|NCT00452348|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
48460890|NCT05943522|OTHER|Asciminib|There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
48460891|NCT05583162|BEHAVIORAL|Healthy Sport Project|2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
48460892|NCT02123823|DRUG|Everolimus|10mg dose
48460893|NCT02123823|DRUG|Everolimus|at recommended dose as per Phase I data
48460894|NCT02123823|DRUG|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
48460895|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
48460896|NCT02123823|DRUG|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
48460897|NCT02123823|DRUG|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
48460898|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
48460899|NCT02123823|DRUG|Exemestane|Fixed dose at 25mg
48460900|NCT06066671|OTHER|GCO (Experimental copaiba oil resin gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the GCO will receive the application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
48460901|NCT06070480|OTHER|Spinal Anesthesia Group|Effect of spinal anesthesia on intraocular pressure
48460902|NCT06070480|OTHER|Desflurane Group|Effect of general anesthesia with desflurane on intraocular pressure
48460903|NCT06070480|OTHER|Propofol Group|Effect of general anesthesia with propofol on intraocular pressure
48460904|NCT05753904|PROCEDURE|Conjoint Tendon Resection|For conjoint tendon resection in the experimental group, the conjoint tendon will be released completely via a transverse incision made at a level 2 cm distal to the coracoid process for the patients assigned the conjoint resection group. Electrocautery will be used for the resection, and the underlying muscular portion of the conjoint tendon will be preserved.
48460905|NCT00301886|DRUG|ibandronate|
48460906|NCT00301886|DRUG|zoledronate|
47935326|NCT03403842|DRUG|PCA Morphine|Administration of endovenous morphine with a PCA
47935327|NCT02021656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
48460907|NCT00301886|PROCEDURE|quality-of-life assessment|
48460908|NCT01208194|DRUG|MGN1703|solution, 60 mg, twice a week, until progression
48460909|NCT01208194|DRUG|Placebo|solution, 60 mg, twice a week, until progression
48460910|NCT01166464|BEHAVIORAL|text messaging for smoking cessation|A 7-week program of daily text messages
48460911|NCT01166464|BEHAVIORAL|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
48460912|NCT04967170|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP)|Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart
48460913|NCT04967170|OTHER|Sham Procedure|Intralesional needle insertion without any injectate.
48460914|NCT02966782|DRUG|venetoclax|Tablet
48460915|NCT02966782|DRUG|azacitidine|Powder for injection, subcutaneously or intravenous
48460916|NCT03284697|PROCEDURE|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
48460917|NCT03284697|PROCEDURE|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
48460918|NCT00749658|DRUG|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
48460919|NCT00749658|DRUG|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
48460920|NCT01783392|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|
48460921|NCT01246453|DRUG|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
48460922|NCT03711253|DRUG|Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg|antiretroviral therapy
47935328|NCT03160196|OTHER|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
47935329|NCT03160196|OTHER|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
47935330|NCT01251471|DRUG|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
47935331|NCT02874768|DRUG|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
47935332|NCT02874768|DRUG|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
48460923|NCT04181736|DRUG|Guanfacine Pill|Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
48460924|NCT04181736|DRUG|Placebo|Placebo masked to mirror the treatment drug dose regimen.
48460925|NCT04987645|PROCEDURE|Water-only infusion technique|During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
47935333|NCT01673282|DRUG|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
48460926|NCT04987645|PROCEDURE|Water infusion and air insufflation|During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
48460927|NCT01393951|BIOLOGICAL|ASP7374|subcutaneous and intramuscular
48099042|NCT04362501|DRUG|placebo|placebo SC injection every two weeks for six months
48460928|NCT02203539|OTHER|exposure to normal light|exposure for 60 minutes in duration
48460929|NCT02203539|OTHER|exposure to bright light|exposure to bright light for 60 minutes of duration
48460930|NCT02203539|OTHER|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
48460931|NCT02988258|GENETIC|CMV-TCR transduced donor-derived T cells|Dose escalation
48460932|NCT06126939|BEHAVIORAL|Educational training based on the Denver model|In addition to routine health guidance, one-to-one parent classes were conducted to guide parents to interact with children once a week for 1h each time; A group leader was assigned to supervise the formulation of the intervention plan and ensure the quality of the intervention. The intervention lasted for 3 months
48460933|NCT02350257|BEHAVIORAL|Internet-based CBT|12 weeks of internet-based CBT
48460934|NCT01395017|DRUG|dasatinib|GEM 1000 mg/m2 by intravenous \[IV\] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
48460935|NCT01395017|DRUG|Placebo|Matching Placebo
48460936|NCT04971512|DRUG|EDP-721|Oral administration (Part 1)
48460937|NCT04971512|DRUG|Placebo (Part 1)|Placebo to match EDP-721, oral administration (Part 1)
48460938|NCT04971512|DRUG|EDP-721 (Part 2)|Oral administration (Part 2)
48460939|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-721 (Part 2)
48460940|NCT04971512|DRUG|EDP-514|Oral administration
48460941|NCT04971512|DRUG|Placebo (Part 2)|Placebo to match EDP-514
48460942|NCT04145635|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
48460943|NCT02840669|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|
48460944|NCT02840669|PROCEDURE|Exercise-stress test|
48460945|NCT02840669|PROCEDURE|Echocardiography (ECHO)|
48460946|NCT02840669|PROCEDURE|Cardiac-related blood studies|
48460947|NCT04156737|DEVICE|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
48460948|NCT04156737|DEVICE|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
48460949|NCT06018116|DRUG|Bicalutamide 150 mg|nonsteroidal antiandrogen
48460950|NCT06018116|DRUG|Placebo|placebo
48460951|NCT00564031|DRUG|Femanest|2mg/day
48460952|NCT00564031|DRUG|gestapuran|5mg/day
48099043|NCT02132702|DEVICE|Ekso|
48099044|NCT04950855|DIAGNOSTIC_TEST|Optical Coherence Tomography,Optical Coherence Tomography Angiography(Topcon)|Optical coherence tomography optical coherence tomography angiography
48099045|NCT04527614|DIAGNOSTIC_TEST|qRT-PCR and serology|qRT-PCR and serology
48099046|NCT00851942|DRUG|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
48460953|NCT00564031|DRUG|placebo|daily
48460954|NCT00564031|DRUG|Femanest plus Gestapuran|combined daily
48460955|NCT04883164|OTHER|Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples|Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
48460956|NCT01402050|DRUG|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
48460957|NCT01402050|DEVICE|FOLEY BALLOON|INDUCTION OF LABOR
48460958|NCT03835468|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
48460959|NCT03835468|DIETARY_SUPPLEMENT|Maltodextrin|sugar based placebo
48460960|NCT00128219|BIOLOGICAL|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
48460961|NCT00128219|BIOLOGICAL|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
48460962|NCT02218216|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
48460963|NCT06108557|DIAGNOSTIC_TEST|Serum Pararoxonase -1 level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
48460964|NCT06108557|DIAGNOSTIC_TEST|Diagnostic Test: Serum pseudocholinesterase enzyme level|"The individual's venous blood will be taken five milliliters under strict aseptic conditions of both control and case groups (before antidotal therapy). Then the blood will be left to be coagulated for 10-20 minutes at room temperature, then centrifugation will be done by laboratory centrifuge. Serum samples were obtained, then half of the separated serum will be used for pseudocholinesterase enzyme assay and the other one will be used for Paraoxanase-1 (PON-1) analysis .~Serum PON-1: The enzyme-linked immunosorbent assay (ELISA) will be used to measure it using human Pararoxonase (PON) ELISA kits.~Serum pseudocholinesterase: is based on spectrophotometric measurement."
48478807|NCT03803111|DRUG|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
48099047|NCT00368719|DRUG|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
48099048|NCT04950751|BIOLOGICAL|candidate vaccine, SCB-2020S|a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19
48460965|NCT05031455|DRUG|Aspirin Challenge|"Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. All subjects will be prescribed this at standard 300mg subcutaneous dosing every 2 weeks. The intervention will be the response to aspirin challenge.~All 16 subjects will receive dupilumab. All subjects will undergo an aspirin challenge/desensitization procedure. It is estimated that 50% of subjects will have a respiratory reaction to aspirin and 50% will not. There will not be any randomization."
48460966|NCT03407209|OTHER|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
48460967|NCT01751854|DRUG|SSRI|SSRI alone or with training
48460968|NCT01751854|DRUG|Placebo|Placebo alone or with training
48460969|NCT04702789|DRUG|Dorzolamide-timolol-brimonidine and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
48460970|NCT04702789|DRUG|Dorzolamide-timolol and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
48460971|NCT00591760|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
48460972|NCT04736537|DEVICE|4DCT|CT imaging conceptually similar to time-lapse photography.
48460973|NCT02956096|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
48460974|NCT02956096|DEVICE|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
48460975|NCT00394303|DRUG|Intraoperative continuous insulin infusion|Nomogram specified in appendix
48460976|NCT00394303|OTHER|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels \<200 mg.dl, reflecting current practice.
48460977|NCT06385301|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
48460978|NCT06385301|OTHER|6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
48460979|NCT01939106|DEVICE|One Piece Drainable Pouch|
48460980|NCT00358631|DRUG|SSR149415|
48460981|NCT00383916|DRUG|pantoprazole|
48460982|NCT03504020|DEVICE|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
48460983|NCT01949805|DRUG|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
48460984|NCT01949805|DRUG|Hydroxyurea|Hydroyurea capsules taken daily po
48460985|NCT02795858|DRUG|Ramucirumab|
47935334|NCT00730028|DRUG|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child \> 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
48460986|NCT02795858|DRUG|Somatostatin Analog|
48460987|NCT03066479|DEVICE|Fitbit|Wearable activity \& sleep tracker.
48460988|NCT03066479|OTHER|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
48099049|NCT06269874|DIAGNOSTIC_TEST|microvascular function assessment|mircovascular function parameters will be measured by administering adenosine in two different pathways
48460989|NCT03066479|DIAGNOSTIC_TEST|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
47935335|NCT00730028|OTHER|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
48460990|NCT03684330|DIETARY_SUPPLEMENT|Vitamin D|a dose once a week
48460991|NCT03684330|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
48460992|NCT04777552|OTHER|diazepam (or equivalence if other benzodiazepine)|
47935336|NCT00730028|DRUG|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
47935337|NCT04961970|DRUG|oxaliplatin , fluorouracil, and leucovorin|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
47935338|NCT04961970|DRUG|gemcitabine and cisplatin|administration of gemcitabine and cisplatin via vein
48460993|NCT03801876|DRUG|Carboplatin|Given IV
48460994|NCT03801876|PROCEDURE|Esophagectomy|Undergo esophagectomy
48623201|NCT02711137|DRUG|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
48460995|NCT03801876|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48460996|NCT03801876|DRUG|Paclitaxel|Given IV
48460997|NCT03801876|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
48460998|NCT03801876|OTHER|Quality-of-Life Assessment|Ancillary studies
48460999|NCT03801876|OTHER|Questionnaire Administration|Ancillary studies
48461000|NCT03801876|DRUG|FOLFOX regimen|Folinic acid, flurouracil and oxaliplatin
48461001|NCT03801876|DRUG|CAPOX regimen|Capecitabine combined with oxaliplatin
48461002|NCT03801876|DRUG|Docetaxel|Chemotherapy
48461003|NCT03801876|DRUG|5FU|Chemotherapy
48461004|NCT02665962|OTHER|Perioperative Caloric Restriction Program|
48461005|NCT02818790|BEHAVIORAL|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
48461006|NCT02818790|BEHAVIORAL|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
47935339|NCT04349293|PROCEDURE|Tissue sampling|Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room
48461007|NCT00276536|BIOLOGICAL|recombinant interferon alpha-1b|interferon
47935340|NCT04349293|PROCEDURE|Blood sampling|Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
47935341|NCT02942329|DRUG|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
48461008|NCT00276536|DRUG|IFN|IFN daily
48461009|NCT00000698|DRUG|Ganciclovir|
48461010|NCT06206148|DEVICE|Given novel electronic pain recording device|Patients in this arm will be given a custom-built pain recording device to see if the method of self-reported data collection has any effect on how many data points are collected.
47935342|NCT02942329|DRUG|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
47935343|NCT05489588|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
48461011|NCT06206148|OTHER|Given Hand-written pain journal|Patients in this arm will be given a hand-written pain journal to see if the method of self-reported data collection has any effect on how many data points are collected.
48461012|NCT06206148|OTHER|Smartphone app|Patients in this arm will be given a research smartphone with survey app to see if the method of self-reported data collection has any effect on how many data points are collected.
48461013|NCT01374451|DRUG|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
47935344|NCT01304784|DRUG|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
47935345|NCT01304784|DRUG|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
47935346|NCT01304784|DRUG|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
47935347|NCT01304784|DRUG|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
47935348|NCT01304784|DRUG|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
48099050|NCT02578212|OTHER|Placebo|
48461014|NCT01374451|DRUG|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
48461015|NCT01726803|OTHER|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
48461016|NCT01726803|OTHER|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
48461017|NCT04966403|OTHER|Standard physical therapy|building strength, enhancing developmental skills, boosting balance, coordination, and postural control
48461018|NCT04966403|OTHER|trampoline-based stretch-shortening cycle exercises|muscle strength
48623202|NCT02711137|DRUG|Gemcitabine|Standard of Care (SOC) agents
48623203|NCT02711137|DRUG|Paclitaxel|Standard of Care (SOC) agents
47935349|NCT03409042|BEHAVIORAL|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
47935350|NCT03838783|DRUG|Insulin Degludec|50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
47935351|NCT00947050|OTHER|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
47935352|NCT06374251|PROCEDURE|Discussion|Participate in narrative medicine sessions
47935353|NCT06374251|OTHER|Interview|Ancillary studies
47935354|NCT06374251|OTHER|Survey Administration|Ancillary studies
47935355|NCT01512290|OTHER|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
47935356|NCT02128100|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
47935357|NCT02128100|RADIATION|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
47935358|NCT05983783|DRUG|Docetaxel|This is Triple drug regimen for mHSPC
47935359|NCT05983783|DRUG|Rezvilutamide|This is doubling drug regimen for mHSPC
47935360|NCT02873520|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
48461019|NCT02934620|DEVICE|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
48461020|NCT02934620|DEVICE|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
48478808|NCT03803111|BEHAVIORAL|Subsequent exercise training|Subsequent exercise training program after 2 months
48623204|NCT02711137|DRUG|Rucaparib|Standard of Care (SOC) agents
48623205|NCT02711137|DRUG|Abiraterone|Standard of Care (SOC) agents
48623206|NCT02711137|DRUG|Ruxolitinib|Standard of Care (SOC) agents
48623207|NCT02711137|DRUG|Azacitidine|Standard of Care (SOC) agents
48461021|NCT02934620|BEHAVIORAL|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
48461022|NCT05323149|OTHER|Saline|Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).
48461023|NCT05323149|DRUG|Tranexamic acid|Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).
48461024|NCT01743898|DRUG|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
48461025|NCT01743898|OTHER|no anticoagulation|
48461026|NCT04275349|DRUG|Xingnaojing injection within 24 hours of symptom onset|intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
48461027|NCT06229912|DRUG|Revumenib|Given by PO
48461028|NCT02638922|DRUG|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
48461029|NCT04633122|DRUG|Ripretinib|Oral kinase inhibitor
48461030|NCT04633122|DRUG|Sunitinib|second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
48461031|NCT05347459|DRUG|Dapagliflozin|usual and customary doses for type 2 diabetes management
48461032|NCT05347459|DRUG|Empagliflozin|usual and customary doses for type 2 diabetes management
48461033|NCT05347459|DRUG|Canagliflozin|usual and customary doses for type 2 diabetes management
48461034|NCT05347459|DRUG|Sitagliptin|usual and customary doses for type 2 diabetes management
48461035|NCT05347459|DRUG|Saxagliptin|usual and customary doses for type 2 diabetes management
48461036|NCT05347459|DRUG|Linagliptin|usual and customary doses for type 2 diabetes management
48461037|NCT05347459|DRUG|Vildagliptin|usual and customary doses for type 2 diabetes management
48461038|NCT01354470|DRUG|Modafinil|600 mg Modafinil capsule
48461039|NCT04046380|DIAGNOSTIC_TEST|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
48461040|NCT01355835|DEVICE|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
48281353|NCT00093236|PROCEDURE|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
48461041|NCT01531816|DEVICE|Early Rehabilitation intervention|"1. Passive mobility: cycle ergometer~2. Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
48461042|NCT00681486|DRUG|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
48461043|NCT00681486|DRUG|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
48461044|NCT02349854|PROCEDURE|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
48461045|NCT05595980|DIETARY_SUPPLEMENT|Probiotic|Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
48461046|NCT05595980|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1 capsule containing maltodextrin once daily for 56 days
48461047|NCT05264896|DRUG|5-FU, Leucovorin, Oxaliplatin, Docetaxel|FLOT 4 cycles pre and post radical gastrectomy
48461048|NCT05264896|DRUG|XELOX|XELOX 8 cycles post radical gastrectomy
48461049|NCT02777307|OTHER|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
48461050|NCT02970188|BEHAVIORAL|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
48461051|NCT01994915|OTHER|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
48461052|NCT05214716|DIAGNOSTIC_TEST|FilmArray Pneumonia panel|A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
48461053|NCT03541252|DRUG|AFL-assisted cisplatin+5-FU|Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
48461054|NCT01740934|OTHER|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
48461055|NCT01740934|OTHER|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
48461056|NCT04234568|PROCEDURE|Biospecimen Collection|Correlative studies
48461057|NCT04234568|PROCEDURE|Computed Tomography|Undergo CT
48461058|NCT04234568|DRUG|Lutetium Lu 177 Dotatate|Given IV
48461059|NCT04234568|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48461060|NCT04234568|DRUG|Triapine|Given PO
48461061|NCT00901719|DRUG|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
48461062|NCT00901719|DRUG|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
48461063|NCT00901719|DRUG|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
48461064|NCT00901719|DRUG|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
48461065|NCT04064827|DRUG|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
48461066|NCT00197873|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
48461067|NCT00197873|OTHER|Placebo administration.|Placebo is administered during chemotherapy.
48461068|NCT03591276|DRUG|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
48461069|NCT00220844|DRUG|Desipramine|
48461070|NCT00220844|DRUG|Amitriptyline|
48461071|NCT06246591|OTHER|Extracorporeal Shockwave Therapy (Group A)|Each patient was evaluated before treatment for trigger points; patients underwent focal ESWT (PulseWave 2 - Mectronic Medicale s.r.l.) with a specific program for muscle contractures and myofascial pain (80-100 mJ with 2250 pulses of 5-10 Hz).
48461072|NCT06246591|OTHER|Mesotherapy (Group B)|Each patient was evaluated before treatment for trigger points; after disinfection with Chlorhexidine 2% and sterile gauze, Thiocolchicoside fl 4mg/2ml, and a local anesthetic, Mepivacaine fl 10mg/1ml, diluted in 0.9% NaCl saline, for a final volume of 10 ml, were inoculated mesodermally; 6 to 12 microinjections with needle 26G 0.40x4mm, were performed.
48461073|NCT02667769|OTHER|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
48461074|NCT06301269|OTHER||
48461075|NCT02294305|DRUG|Vortioxetine|
48461076|NCT02294305|DRUG|Placebo|
48461077|NCT06312462|BEHAVIORAL|health education|In the intervention group, we provide schistosomiasis health education to students once a month through community health volunteers for a duration of six months. After that, the community health volunteers no longer visit the school for health education until the completion of a one-year follow-up period.
48461078|NCT01328782|DRUG|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
48461079|NCT01328782|DRUG|Bupivacaine 0.25%|"* Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~* Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
48461080|NCT01328782|DRUG|Ropivacaine 0.20%|"* Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~* Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
48461081|NCT06339424|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
48461082|NCT06339424|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
48461083|NCT06339424|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
48623208|NCT03173963|DRUG|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
48623209|NCT03173963|OTHER|Placebo|1placebo tablet per day
47935361|NCT02873520|BIOLOGICAL|Precision Cell Immunotherapy|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
48461084|NCT02238587|OTHER|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
48461085|NCT02238587|DIETARY_SUPPLEMENT|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
48461086|NCT02835222|DRUG|Cytarabine|Given IV
48461087|NCT02835222|DRUG|Daunorubicin Hydrochloride|Given IV
48461088|NCT02835222|DRUG|Selinexor|Given PO
48461089|NCT01586208|DRUG|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
47935362|NCT02054481|DRUG|BI 655066|Medium dose
47935363|NCT02054481|DRUG|BI 655066|High dose
48281354|NCT00093236|PROCEDURE|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
48461090|NCT04888767|OTHER|Interval Training Hight Intensity Program|"* Rehabilitation stay in hospitalization with 18 days of training sessions~* Training on an ergometer~* Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist~  * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold~ * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible"
48461091|NCT03366792|DEVICE|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
48461092|NCT04852627|BEHAVIORAL|Brisk walking|Walking
48461093|NCT05937126|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
48461094|NCT05937126|DIAGNOSTIC_TEST|Culture and antimicrobial susceptibility testing|Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
48461095|NCT00095537|DRUG|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
48461096|NCT06266741|DIAGNOSTIC_TEST|Lubricin|Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
48478809|NCT03875690|DRUG|Injection of methylprednisolone|Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
47935364|NCT02054481|DRUG|Ustekinumab|
48281355|NCT02095561|OTHER|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
48281356|NCT01472276|BEHAVIORAL|Web-based program|Provided with the web-based program
48281357|NCT06656195|OTHER|glueus maximus strengthening|In week 1 SIJ Mobilization along with ,Single leg bridge ,alternating leg lifts ,clam Exercise,Prone hip extension with knee flexion. In week 2 SIJ Mobilization along with Side-squats,Star excursion exercise,Forward step-down.In week 3 SIJ Mobilization along with bilateral squat ,single leg squat ,split squat/lunge ,frontal step up ,lateral step up.In week 4 SIJ mobilization along with bilateral squat with a band and hip extension against resistance was done.Three times a week for 4 weeks In each session, a total of two sets of 12 repetitions each were carried out, with a 1 min rest time between sets.
48281358|NCT06656195|OTHER|hamstring stretching group|SIJ mobilization and Soft tissue mobilization along with Static Hamstrings stretching (3 sets, 15 repetitions with a holding time of 15 seconds ,3 times a week for 4 week) and Dynamic hamstrings stretching(3 set, 15 repetitions with a holding time of 1 second, 3 times a week for 4 weeks.
48281359|NCT05237388|DRUG|Baricitinib|One pill daily
48281360|NCT05237388|DRUG|Placebo|Baricitinib placebo pill
48281361|NCT05019456|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine (mRNA or J\&J)
48281362|NCT05410392|BEHAVIORAL|Physical exercise intervention|Home-based physical exercise with the use of a stationary recumbent style bike.
48281363|NCT05410392|BEHAVIORAL|Cognitive exercise intervention|Home-based cognitive exercise with the use of smartphone to complete cognitive activities.
48281364|NCT05410392|BEHAVIORAL|Health education|Provision of general information about a variety of topics
48478810|NCT03875690|DRUG|Injection of sodium chloride|patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
48478811|NCT03875690|BIOLOGICAL|Blood samples|electrolyte panel and glycemia performed within the first 24 hours after surgery.
47935365|NCT02054481|DRUG|BI 655066|Low dose
47935366|NCT00148551|DRUG|Triamcinolone Acetonide|
47935367|NCT05856890|BIOLOGICAL|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
47935368|NCT05856890|OTHER|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
47935369|NCT04969796|OTHER|REACH Hope|REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box. For REACH Hope, as the caregiver and interventionist work on strategies one-on-one, these will be integrated into the Hope Box for the caregiver to use between and after sessions.
48623210|NCT03907436|OTHER|USDA Diet|Participants will receive counseling and education on USDA Guidelines for Americans, 2010
48461097|NCT06471504|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
48461098|NCT01490190|DRUG|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
48461099|NCT06550869|PROCEDURE|Anterior Quadratus Lumborum Block at the lateral supra-arcuate ligament under laparoscopic direct vision|The urologists find the inner arcuate ligament. The scalp needle is inserted from the midpoint of the lower edge of the inner or outer arcuate ligament towards the head to the dorsal side of the diaphragm. After withdrawing without blood, air, or cerebrospinal fluid, 2 ml of normal saline is first administered to observe the fluid spreading towards the head Then, 20 ml of 0.375% ropivacaine hydrochloride injection is administered.
48461100|NCT06550869|PROCEDURE|Local infiltration anesthesia|The urologists give local infiltration anesthesia with 20 ml of 0.375% ropivacaine hydrochloride injection.
48461101|NCT05001698|BIOLOGICAL|Anifrolumab|intravenous infusion (IV)
48461102|NCT03234127|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
48461103|NCT01158118|DRUG|Sargramostim|
48461104|NCT01158118|DRUG|Plerixafor|
48461105|NCT02588911|PROCEDURE|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
47935370|NCT01934543|OTHER|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
48461106|NCT02588911|PROCEDURE|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
48461107|NCT00503477|DRUG|AZD2171|oral tablet
48461108|NCT04010045|DEVICE|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
48461109|NCT00685334|DRUG|Olanzapine|Participants will take olanzapine daily for 12 weeks.
48461110|NCT00685334|DRUG|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
48461111|NCT04633863|DEVICE|Artificial tear MDI - 101|Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
48099051|NCT05121155|DEVICE|ICP wave morphology comparison between a non-invasive (Brain4care) and a invasive method|We prospectively collected data of adults admitted to an intensive care unit (ICU) with subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH) or ischemic stroke (IS) in whom invasive ICP monitoring placed. Measures had been simultaneously collected from the following non-invasive indices: optic nerve sheath diameter (ONSD), pulsatility index (PI) using transcranial Doppler (TCD), a 5-point visual scale designed for Computed Tomography (CT) and two parameters (time-to-peak \[TTP\] and P2/P1 ratio) of a non-invasive ICP wave morphology monitor (Brain4care\[B4c\]). Intracranial hypertension was defined as an invasively measured ICP \> 20 mmHg for at least five minutes
48461112|NCT01059058|PROCEDURE|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
48461113|NCT01059058|PROCEDURE|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
48461114|NCT01059058|PROCEDURE|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
48461115|NCT05333107|DRUG|NNC0385-0434 G|Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
48099052|NCT02074956|BIOLOGICAL|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
48461116|NCT05333107|DRUG|NNC0385-0434 F|Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
48461117|NCT05333107|DRUG|NNC0385-0434 B|Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
48461118|NCT03633214|OTHER|Online training module|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
48478812|NCT04746079|BEHAVIORAL|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
48478813|NCT06611176|DRUG|Local levobupivacaine|submucosal injection of levobupivacaine during esophageal esad
48478814|NCT02631876|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
47935371|NCT01934543|OTHER|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
48461119|NCT03648931|BEHAVIORAL|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
47935372|NCT03680469|BEHAVIORAL|standard early rehabilitation|The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.
48461120|NCT03648931|BEHAVIORAL|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
48461121|NCT00204451|DRUG|0.75 levonorgestrel|
48461122|NCT00204451|DRUG|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
48461123|NCT02551640|OTHER|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
48461124|NCT03366428|DRUG|DS-8201a|DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
48461125|NCT03911635|PROCEDURE|URAGPI technique|the Urethral Advancement, Glanuloplasty and Preputioplasty
48461126|NCT05834751|DRUG|PEG-rhG-CSF|48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
48461127|NCT05834751|DRUG|RhG-CSF|After clinical evaluation, rhG-CSF was given 10μ g/kg/d for mobilization until the stem cell collection was completed.
48461128|NCT00075608|BIOLOGICAL|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
48461129|NCT00075608|DRUG|melphalan|140-200 mcg/kg IV over two days
48461130|NCT00075608|PROCEDURE|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
48461131|NCT00075608|PROCEDURE|stem cell infusion|infusion of previously collected stem cells on Day 0
48461132|NCT00147134|PROCEDURE|open colectomy|Procedure/Surgery: open colectomy
48461133|NCT00147134|PROCEDURE|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
48461134|NCT03431558|COMBINATION_PRODUCT|bLF (Bovine lactoferrin)|BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
48461135|NCT03431558|DRUG|Glucon-D 99.4% (Placebo)|This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
48461136|NCT02805764|DEVICE|Homeoblock|A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
48461137|NCT02117830|DRUG|Androxal 25 mg capsules|
48099053|NCT02074956|BIOLOGICAL|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
48099054|NCT04606251|OTHER|Exercise|The intervention to be carried out in the study consists of physical exercises for the neck, upper and lower extremities, and trunk; It is a program that includes the addition of cognitive tasks such as memory, word finding, processing during each repetition.
48461138|NCT02117830|DRUG|Androxal 250 Capsules|
48461139|NCT02117830|DRUG|Placebo Capsules|
47935373|NCT03680469|BEHAVIORAL|adding early out-of-bed mobilization|Early mobilization treatment involving out-of-bed, task-specific activities including rolling and sitting up, sitting unsupported out of bed, and standing within 24-72 hours of onset and accounting for more than two thirds of the treatment time in early rehabilitation .
48099055|NCT02396979|DRUG|Methadone|
48099056|NCT02396979|BEHAVIORAL|Holistic Health Recovery Program|
48099057|NCT04778410|DRUG|Magrolimab|Administered intravenously
48461140|NCT02117830|DRUG|Moxifloxacin 400 mg|
48461141|NCT03595787|PROCEDURE|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
48461142|NCT00503919|PROCEDURE|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
48461143|NCT02754076|DRUG|AX 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
48461144|NCT03993535|DRUG|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
48461145|NCT00412464|DRUG|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
48478815|NCT02631876|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
48099058|NCT04778410|DRUG|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
48099059|NCT04778410|DRUG|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
48461146|NCT02331823|DRUG|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
47935374|NCT02160483|OTHER|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
48461147|NCT02331823|DRUG|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
48461148|NCT05389813|DRUG|Oxycodone 20 Mg Oral Tablet|Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.
48461149|NCT05389813|DRUG|Pregabalin 150mg|Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Specifically it is a ligand of the auxiliary α2δ subunit site of certain voltage-dependent calcium channels (VDCCs), and thereby acts as an inhibitor of α2δ subunit-containing VDCCs. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and pregabalin shows similar affinity for (and hence lack of selectivity between) these two sites. Pregabalin is selective in its binding to the α2δ VDCC subunit. Despite the fact that pregabalin is a GABA analogue. r synthesizing GABA, and hence may have some indirect GABAergic effects by increasing GABA levels in the brain. In accordance, inhibition of α2δ-1-containing VDCCs by pregabalin appears to be responsible for its anticonvulsant, analgesic, and anxiolytic effects.
48461150|NCT05389813|DRUG|Multivitamin with Minerals|Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
48461151|NCT03616379|BEHAVIORAL|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
48461152|NCT03616379|BEHAVIORAL|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
48461153|NCT03616379|BEHAVIORAL|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
48461154|NCT05516953|DRUG|Baclofen Tablets|10 mg oral baclofen 1 h before anesthesia
48461155|NCT00934323|DRUG|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
48099060|NCT04778410|DRUG|Mitoxantrone|Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
48461156|NCT00934323|DRUG|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
48461157|NCT04401137|DRUG|Topiramate|Topiramate
48461158|NCT00533156|DEVICE|Vascular access site closure (7F Ensure)|
48461159|NCT01093833|DEVICE|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
48461160|NCT01093833|DEVICE|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
48461161|NCT01093833|DEVICE|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
48099061|NCT04778410|DRUG|Etoposide|Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
48099062|NCT04778410|DRUG|Cytarabine|Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
48478816|NCT02631876|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
48478817|NCT02631876|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
47935375|NCT01283243|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
48099063|NCT04778410|DRUG|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
48099064|NCT04806919|DRUG|Progesteron TID|increasing the dose
48099065|NCT03401398|DRUG|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
48099066|NCT03401398|DRUG|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
48099067|NCT02205151|DRUG|Fimasartan|
48099068|NCT02205151|DRUG|Amlodipine|
48099069|NCT02205151|DRUG|Fimasartan/Amlodipine combination|
48099070|NCT05283369|DEVICE|Videogame therapy|The usual dose of conventional physical therapy, plus 300 minutes a week of in-home videogame therapy for 8 weeks.
48099071|NCT05283369|OTHER|Conventional therapy|The usual dose of physical and occupational therapy, for 8 weeks.
48461162|NCT01127087|DRUG|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
48461163|NCT00965757|DRUG|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
48461164|NCT00965757|DRUG|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
48461165|NCT00301327|DRUG|Summers 5% L.A.|
48461166|NCT03428750|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
48461167|NCT03428750|BIOLOGICAL|Placebo|Placebo
48461168|NCT06251349|RADIATION|Radiation|Single dose radiation with 7-8 Gy
48461169|NCT06251349|DRUG|Diclofenac|postoperative treatment with diclofenac to prevent HO
48461170|NCT01404351|DEVICE|PEAK PlasmaBlade|
48461171|NCT01404351|PROCEDURE|Scalpel and Traditional Electrosurgery|
48461172|NCT02921958|BEHAVIORAL|occupational therapy|Family-centered occupational therapy services
48461173|NCT01685255|DRUG|Epacadostat|
47935376|NCT04767308|BIOLOGICAL|CT125A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.
47935377|NCT04767308|DRUG|Cyclophosphamide, fludarabine|Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day and fludarabine 30 mg/m2/day on days -4, -3 and -2
48099072|NCT05933720|DRUG|Polypeptides|The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
48461174|NCT01685255|DRUG|tamoxifen|
48461175|NCT02632253|PROCEDURE|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
48461176|NCT02632253|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
48461177|NCT05276986|OTHER|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
48461178|NCT00691782|OTHER|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
48461179|NCT01592240|DRUG|PBO|Placebo Q28d
48461180|NCT01592240|DRUG|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
48461181|NCT01592240|DRUG|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
48461182|NCT01592240|DRUG|PBO|Placebo, Q14d
48461183|NCT01592240|DRUG|PF-04950615|PF-04950615 50mg, Q14d
48461184|NCT01592240|DRUG|PF-04950615|PF-04950615 100 mg, Q14d
48461185|NCT01592240|DRUG|PF-04950615|PF-04950615 150mg, Q14d
47935378|NCT00997542|DRUG|Allopurinol|
47935379|NCT00997542|DRUG|Placebo|
47935380|NCT04950114|DRUG|GFB-887|GFB-887 is a potent, small molecule inhibitor of TRPC5.
48461186|NCT05766631|BEHAVIORAL|DynamiCare Health|"Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
48461187|NCT05766631|DRUG|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
48461188|NCT06065735|DRUG|Paroxetine|Paroxetine will be administered
48461189|NCT04419935|PROCEDURE|lymphadenectomy|Lymphadenctomy according with ESTS guidelines
48461190|NCT00893945|DRUG|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
48461191|NCT00893945|DRUG|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
48461192|NCT00893945|DRUG|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
47935381|NCT04934631|OTHER|Recording of CBT-ED session.|Therapists will deliver treatment as usual (CBT-ED) to eating disorder patients. Therapy session will be audio recorded.
48461193|NCT05393401|DEVICE|VOP1k|Photoplethysmographic records
47935382|NCT04934631|OTHER|Assessment of CBT-ED clinician competence.|Independent raters will assess CBT-ED competence using the Cognitive-Behavioural Therapy Scale for Eating Disorders (CBTS-ED).
47935383|NCT01840995|PROCEDURE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
48099073|NCT05933720|DEVICE|Femoral-popliteal bypass grafting with a synthetic graft above the knee|The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
48099074|NCT05933720|OTHER|Routine conservative treatment|The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
48099075|NCT04027972|DRUG|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
48099076|NCT04027972|DEVICE|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
48461194|NCT01567553|OTHER|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
48461195|NCT06372119|PROCEDURE|Letrozole-stimulated cycle strategy|"Letrozole (Femara® 2.5 milligrams, Novartis, Switzerland or Lezra® 2.5 milligrams, Actavis, Rumani) 5 milligrams/day for 5 days, starting on the second to fourth day of the menstrual cycle.~Post-letrozole, ultrasound checks follicle growth. If ≥18mm, Ovitrelle® 250 mcg (Merck, Kenilworth, New Jersey, USA) induces ovulation.~Luteal phase support with vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day starting two days post-hCG.~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: no follicle development on day 21 from the day of starting letrozole, spontaneous ovulation, letrozole intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
48461196|NCT06372119|PROCEDURE|Artificial cycle strategy|"Oral estradiol valerate (Progynova® 2 milligrams, Bayer Pharma AG, Germany or Valiera® 2 milligrams, Laboratories Recalcine, Chile) 6 milligrams/day for 10 days, starting on the second to fourth day of the menstrual cycle.~Post-estradiol, ultrasound checks endometrial thickness. If ≥7mm, start vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day. If \<7mm, increase the dose of oral estradiol valerate to 8 milligrams/day (5-6 days) and 12 milligrams/day (5-6 days).~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: endometrial thickness \<7mm on day 21 of using estradiol, spontaneous ovulation, oral estradiol valerate intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
48099077|NCT04282902|DRUG|pirfenidone|Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer
48099078|NCT04886596|BIOLOGICAL|Placebo|Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV_1 dose group.
48461197|NCT06476015|OTHER|Therapeutic exercise|Duration: 30 minutes. Frequency: Once a week. Type of excercise: Cardiovascular, strengthening and balance. Supervised by a health professional.
48099079|NCT04886596|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV_annual group.
48461198|NCT01896713|OTHER|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
48461199|NCT04872777|BEHAVIORAL|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days."
48461200|NCT00804011|OTHER|ATC|Automatic tube compensation
48461201|NCT00804011|OTHER|PSV|Pressure support ventilation
48478818|NCT06616532|DRUG|PM8002|Following a predefined dose and date.
48623211|NCT03907436|OTHER|Mediterranean Diet|Participants will receive counseling and education on a Mediterranean diet.
48623212|NCT06215937|OTHER|No Intervention|No intervention
48099080|NCT05448261|BEHAVIORAL|Emotion-centered problem-solving intervention (EPi)|"The EPi is built upon the model of relational/problem-solving model of stress and is aimed at supporting caregivers in (1) revisiting stressful caregiving and associated problem from a psychological distanced perspective; (2) adopting problem orientation toward one's experience in the present moments with curiosity, openness and acceptance; and (3) applying the problem-solving skills learned for the enhancement of their psychosocial wellbeing in the stressful caregiving context. To reduce the incongruence between caregivers and stroke survivors in problem-solving, we will adopt a shared problem, shared action plan approach for the family caregivers and stroke survivors."
48099081|NCT05448261|OTHER|stroke education|Information is related to stroke and recurrent stroke and strategies for assisting stroke survivors in day-to-day activities.
48099082|NCT00777556|DRUG|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
48099083|NCT01738555|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
48281365|NCT02795988|BIOLOGICAL|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
48099084|NCT01738555|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
47935384|NCT04282798|OTHER|Personalized Music Intervention|Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
48461202|NCT06071338|DIAGNOSTIC_TEST|Clinical Periodontal Examination|No details will be published from the clinical assessment.
48461203|NCT02947945|DRUG|Reslizumab|All subjects will receive Reslizumab
48461204|NCT03007706|PROCEDURE|Women undergo cesarean section delivery|
48461205|NCT01832922|DRUG|Bendamustine|
48461206|NCT01832922|DRUG|Rituximab|
48099085|NCT04994743|DRUG|CORT113176|CORT113176 lipid capsule formulation for oral administration
48461207|NCT04688333|OTHER|Internet-Based Intervention - Complete iConquerFear program|Online adaptation of a highly effective face-to-face treatment for fear of recurrence.
48461208|NCT04688333|OTHER|Quality-of-Life Assessment|Ancillary studies
48461209|NCT04688333|OTHER|Questionnaire Administration|Complete questionnaires
48461210|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
48461211|NCT03883126|BEHAVIORAL|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
48461212|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
47935385|NCT00194675|DRUG|Dutasteride|Dutasteride 0.5 mg orally daily
47935386|NCT00194675|DRUG|Testosterone gel|Testosterone gel 7.5 g daily topical
47935387|NCT00194675|DRUG|Placebo dutasteride|placebo dutasteride orally daily
48099086|NCT04994743|DRUG|Placebo matching CORT113176|Placebo matching CORT113176 lipid capsule formulation for oral administration
47935388|NCT04285580|DRUG|Bimatoprost SR|Consists of 1 Bimatoprost SR administration in the study eye.
47935389|NCT04285580|DRUG|LUMIGAN|Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
47935390|NCT04136756|DRUG|NKTR-255|NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
47935391|NCT04136756|DRUG|NKTR-255 Q21|NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
47935392|NCT04136756|DRUG|Rituximab|Rituximab administered intravenously at specified dose on specified days
47935393|NCT04136756|DRUG|Daratumumab|Daratumumab administered subcutaneously at specified dose on specified days
48099087|NCT03586167|DEVICE|LID014341 contact lenses|Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating
48099088|NCT03586167|DEVICE|Comfilcon A contact lenses|Silicone hydrogel contact lenses
47935394|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback assisted pelvic floor muscle training|participants will be doing surface electromyographic biofeedback assisted pelvic floor muscle training for 2 months
47935395|NCT05272644|BEHAVIORAL|surface electromyographic biofeedback and electrical stimulation|participants will be doing surface electromyographic biofeedback and electrical stimulation assisted pelvic floor muscle training for 2 months
48099089|NCT01638624|DRUG|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
48099090|NCT01638624|DRUG|Placebo|
48099091|NCT00886808|DRUG|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
48099092|NCT04571333|DEVICE|Mi2000 Totally Implantable Cochlear Implant|During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
48099093|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
48461213|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
48099094|NCT03483337|OTHER|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
48099095|NCT00533039|DRUG|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
48461214|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
48461215|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
48461216|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
48461217|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
48461218|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
48461219|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
48461220|NCT00362687|DRUG|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
48461221|NCT00362687|DRUG|FTC alone|emtricitabine 200 mg
48461222|NCT00362687|PROCEDURE|No HAART|No HAART
48461223|NCT00197834|DRUG|Depakote|
48461224|NCT04097041|PROCEDURE|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
48478819|NCT06616532|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 Q3W
48478820|NCT06616532|DRUG|Topotecan|1.25mg/m2/day via IV infusion on Days 1-5 Q3W
48478821|NCT06212050|DEVICE|Transcatheter Aortic Valve Implantation|TAVI in patients with severe BAV stenosis using ACURATE neo2
48461225|NCT04097041|PROCEDURE|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
48461226|NCT04595591|DRUG|2mg/kg/min|titration dosing speeds of propofol at 2mg/kg/min
48461227|NCT04595591|DRUG|1mg/kg/min|titration dosing speeds of propofol at 1mg/kg/min
48461228|NCT04595591|DRUG|0.5mg/kg/min|titration dosing speeds of propofol at 0.5mg/kg/min
48461229|NCT03921918|DEVICE|Breast Pump|Hydraulic Breast pump
48461230|NCT04440696|DRUG|Lanthanum Polystyrene Sulphonate Powder|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
48461231|NCT04440696|DRUG|Lanthanum Carbonate 500 MG|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
48461232|NCT04440696|DRUG|Placebo|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
48461233|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
48461234|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
48461235|NCT05006560|OTHER|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
48461236|NCT03246503|DEVICE|BiliCam estimated bilirubin (BCB)|Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
48461237|NCT03390257|DEVICE|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
48461238|NCT04643691|DRUG|Losartan 50 mg and Spironolactone 25 mg pillules oral use|Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
48461239|NCT06230692|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
48478822|NCT02568007|DRUG|Cyproheptadine|
47935396|NCT05965271|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
47935397|NCT04503291|PROCEDURE|Metal stent placement|Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
47935398|NCT03767803|OTHER|Non-interventional study|This is an observational, non-interventional study.
47935399|NCT00908011|DRUG|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
47935400|NCT00908011|DRUG|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
47935401|NCT00245583|DRUG|Topiramate|minimum does of 50mg/day
47935402|NCT00245583|DRUG|Placebo|matching tablet
48099096|NCT00533039|DRUG|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
48281366|NCT02795988|DRUG|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
47935403|NCT03734484|DIAGNOSTIC_TEST|InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
47935404|NCT02677727|OTHER|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
47935405|NCT02370446|OTHER|personalized medication log|
47935406|NCT02370446|OTHER|standard of care|
48461240|NCT01030796|BEHAVIORAL|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
48461241|NCT05128136|DEVICE|Impact of ring size on adherence|The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.
48461242|NCT02627274|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified under arm description.
48461243|NCT02627274|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified under arm description.
48461244|NCT02627274|DRUG|Cetuximab|Cetuximab will be administered as per the schedule specified under arm description.
48461245|NCT04785053|DEVICE|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
48461246|NCT04827251|DIETARY_SUPPLEMENT|Coffee|"Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over)."
48281367|NCT05553860|OTHER|Speech positioning technique|Speech positioning technique
48461247|NCT04535986|DRUG|Ensifentrine|Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks
48461248|NCT04535986|DRUG|Placebo|Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
48461249|NCT00079287|DRUG|carboplatin|
48461250|NCT00079287|DRUG|docetaxel|
47935407|NCT02370446|BEHAVIORAL|questionnaires|
47935408|NCT02370446|BEHAVIORAL|Cognitive Interview|
47935409|NCT02716896|RADIATION|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
47935410|NCT02716896|PROCEDURE|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
47935411|NCT05757973|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
47935412|NCT05459948|DEVICE|GMK SpheriKA|"The first objective is to study the FJS of patients who were implanted a GMK® SpheriKA knee prosthesis using the kinematic alignment technique"
47935413|NCT02330809|OTHER|Daily extra water intake|Amount of extra daily water intake to consume
47935414|NCT02330809|OTHER|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
47935415|NCT01205178|DRUG|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
47935416|NCT01205178|DRUG|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
47935417|NCT01205178|DRUG|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
47935418|NCT02972762|DRUG|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
47935419|NCT02606695|DEVICE|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
48281368|NCT01287663|DRUG|Permethrin impregnated|
48281369|NCT01287663|DRUG|no Permethrin impregnated|
48461251|NCT00079287|DRUG|gemcitabine hydrochloride|
48281370|NCT00728546|DRUG|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
48281371|NCT00538681|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
48281372|NCT00538681|DRUG|pemetrexed|500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
48281373|NCT00538681|DRUG|cisplatin|75 mg/m², IV, every 21 days, for each 21-day cycle
48281374|NCT00538681|DRUG|placebo|po, QD
48461252|NCT00079287|DRUG|paclitaxel|
48461253|NCT00079287|DRUG|vinorelbine tartrate|
48478823|NCT06610474|BEHAVIORAL|"Use of the online Talk to Nathan about Prostate Cancer decision aid"|This decision aid is publicly available at this website in both English or Spanish: https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html
48478824|NCT06610474|BEHAVIORAL|Use of a standard prostate cancer screening decision aid|The standard decision aid is available here and will be used in either English or Spanish: https://massclearinghouse.ehs.state.ma.us/PROG-CANC/CA1382kit.html
47935420|NCT02606695|DEVICE|NuvaMap|Clinical imaging software used to assess spinal alignment
47935421|NCT00121407|DRUG|Visudyne for injection|
47935422|NCT03906227|DEVICE|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
47935423|NCT00951782|DEVICE|High frequency TMS|deep TMS HADD coil
47935424|NCT00951782|DEVICE|Sham TMS|sham deep TMS HADD coil
48478825|NCT06610474|BEHAVIORAL|Use of standard prostate cancer education materials|The standard education materials are available from the National Cancer Institute (NCI) website in English or Spanish: https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq
48461254|NCT04316962|OTHER|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~1. Individual goal-setting~2. Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~3. Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~4. Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~5. Peer support."
48461255|NCT05374850|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|This intervention is applied mostly for cervical disc herniation.The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then combined local anesthetics and glucocorticoids is delivered to the epidural space.
48461256|NCT06559956|OTHER|Daytime titration polysomnography|A titration polysomnography assesses the device settings and, if necessary, the stimulation strength will be adjusted based on observed respiratory events and/or snoring. Patients in the daytime titration PSG cohort were instructed to refrain from sleeping during the night, and in the morning, they were permitted to sleep in a soundproof room without daylight at the sleep lab.
48461257|NCT05285358|DRUG|Cisplatin|Given IV
48461258|NCT05285358|DRUG|Gemcitabine|Given IV
48461259|NCT05285358|DRUG|Nab-paclitaxel|Given via PIPAC
48461260|NCT05285358|OTHER|Quality-of-Life Assessment|Ancillary studies
48461261|NCT05285358|OTHER|Questionnaire Administration|Ancillary studies
48461262|NCT05409651|BEHAVIORAL|Time restricted eating|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study.
48461263|NCT00268216|DRUG|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
48461264|NCT05529238|BEHAVIORAL|biofeedback training|participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
48461265|NCT02786953|BEHAVIORAL|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
48461266|NCT01216020|DRUG|cetuximab|"* Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
48461267|NCT01216020|DRUG|cisplatin (associated to radiotherapy)|"* CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
48461268|NCT02607826|PROCEDURE|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
48461269|NCT04301258|OTHER|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
48461270|NCT04157205|DIAGNOSTIC_TEST|Non-invasive ECG imaging - CardioInsight test|"1. Consent session~2. Fitting of ECGi vest and CT scan of the chest~3. Supervised exercise test and Valsalva maneuvre~4. Programmed stimulation via ICD (selected participants)~5. Blood tests - genetics"
48461271|NCT05475964|DEVICE|Endoscopic ultrasound|Endoscopic ultrasound and biopsy intake of suspected lesions
48623213|NCT04028960|DRUG|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
47935425|NCT00951782|DEVICE|Low frequency TMS|Deep TMS - HADD coil
47935426|NCT02592811|PROCEDURE|ERCP|Common bile duct cannulation with a cannulation catheter
47935427|NCT02592811|PROCEDURE|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
47935428|NCT02592811|DEVICE|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
47935429|NCT02592811|PROCEDURE|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
47935430|NCT05185336|DIAGNOSTIC_TEST|ultrasound assessment|gastric volume assessment by ultrasound
48461272|NCT03825198|PROCEDURE|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
48461273|NCT03825198|DRUG|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
48461274|NCT03825198|PROCEDURE|spine fusion|fusion of lumbar vertebral body on 1 or two levels
48461275|NCT03825198|DRUG|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
47935431|NCT04304157|DRUG|Dexmedetomidine|Dexmedetomidine (DEX) a potent α 2 agonist that have unique analgesic, anxiolytic and sedative profile has been called upon as attractive adjunct in general as well as regional anesthesia with enticing results. Several studies have pursued DEX median effective dose (ED50) in different settings e.g., co induction agent with Propofol, in laryngeal muscle insertion and with local anesthetic to enhance the quality of spinal anesthesia
47935432|NCT00899509|OTHER|laboratory biomarker analysis|correlative studies
47935433|NCT00003854|OTHER|immunohistochemistry staining method|
48461276|NCT03825198|DRUG|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
48461277|NCT03825198|DRUG|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
48461278|NCT03825198|DRUG|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
48461279|NCT03825198|DRUG|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
48461280|NCT03825198|DRUG|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
48461281|NCT03825198|DRUG|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
48461282|NCT03825198|DRUG|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
48461283|NCT03825198|DRUG|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
48461284|NCT03825198|DRUG|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
48461285|NCT04880954|PROCEDURE|Soft Tissue Mobilization|Soft Tissue Mobilization will be provided to participants by Licensed Chiropractor focusing on structures of the lower and upper leg. This will be provided for 20 minutes, once per week for 12 weeks.
48461286|NCT04880954|OTHER|Rehabilitation|Participants will engage in 20 minutes of prescribed at-home exercise 5 times per week, for 12 weeks.
48461287|NCT03711591|DEVICE|Conventus Cage PH device|The Conventus CAGE™ PH (PH Cage) is a permanent implant comprised of an expandable scaffold, made from nitinol and titanium, which is deployed into the medullary canal and provides a structure to which fractured bone fragments are attached using fragment screws.
48461288|NCT05674188|BEHAVIORAL|Augmented Reality Headset|Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
48461289|NCT03123874|DEVICE|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
48461290|NCT03123874|DEVICE|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
48099097|NCT01751997|DRUG|Transplants from 8/8-matched Unrelated donors|"* Myeloablative conditioning~  1. Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~ 2. Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~ 3. Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* Reduced-intensity conditioning; older patients (age \> 55 years) and/or patients with comorbidities~  1. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m\^2)~ 2. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~ 3. Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
48099098|NCT01751997|DRUG|Transplants from family-mismatched/haploidentical donors|"* Reduced-intensity conditioning~  1. Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~ 2. Fludarabine; 30 mg/m\^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m\^2)~ 3. Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ 4. ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~* GVHD prophylaxis~  1. Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~ 2. Methotrexate; 5 mg/m\^2/day, IV push, days +1, +3, +6, +11"
48099099|NCT04470102|PROCEDURE|mitral valve repair by edge-to-edge technique|transaortic access for mitral valve repair edge-to-edge
48461291|NCT04763161|PROCEDURE|Decompressive hemicraniectomy|Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident
48461292|NCT04763161|PROCEDURE|neurosurgical operation|neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
48461293|NCT05066334|DRUG|Autologous BM-MSC|intradiscal injection of autologous bone marrow mesenchymal stromal cells
48099100|NCT04470102|PROCEDURE|Septal myectomy|isolated extended septal myectomy
48461294|NCT05066334|PROCEDURE|Sham|local anaesthesia, no disc injection, no placebo injection
48461295|NCT02790658|DIETARY_SUPPLEMENT|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
48461296|NCT01089530|BEHAVIORAL|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
48461297|NCT01891357|PROCEDURE|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
48461298|NCT01891357|DRUG|paclitaxel|
48461299|NCT01891357|DRUG|lapatinib|
47935434|NCT00003854|PROCEDURE|lymphangiography|
47935435|NCT00003854|PROCEDURE|sentinel lymph node biopsy|
47935436|NCT00003854|PROCEDURE|therapeutic conventional surgery|
47935437|NCT00003854|RADIATION|whole breast irradiation|
47935438|NCT02666703|DEVICE|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
48461300|NCT01891357|DRUG|trastuzumab|
48461301|NCT04703166|DEVICE|Samsung Galaxy Watch Active2|The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
48461302|NCT04784169|DEVICE|free middle turbinate flap|Repairing low flow leak using free middle turbinate flap
48461303|NCT04784169|DEVICE|vascularized nasoseptal flap|Repairing low flow leak using fascia lata
48461304|NCT00260715|BEHAVIORAL|Community-Popular Opinion Leader Model|
48461305|NCT00260715|BEHAVIORAL|Diffusion of Innovations|
48461306|NCT00754507|DRUG|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
48461307|NCT00754507|DRUG|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
48461308|NCT00826241|DRUG|Temozolomide|Starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle.
48461309|NCT00826241|DRUG|Lapatinib|Starting dose 1250 mg daily by mouth.
48461310|NCT04567329|DRUG|NOV03|100% perfluorohexyloctane
48461311|NCT04567329|DRUG|Saline Solution|0.6% sodium chloride solution
48461312|NCT04129060|DRUG|Cholinergic antagonist|The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
48461313|NCT04759989|PROCEDURE|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
48461314|NCT04759989|PROCEDURE|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
48461315|NCT04759989|PROCEDURE|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
48461316|NCT04912739|BEHAVIORAL|Targeted health dialogues|"Before the targeted health dialogue, the participants fill in a questionnaire about health behaviors, background characteristics and self-rated health. Samples for blood glucose and total cholesterol are taken. BMI, waist-to-hip ratio and blood pressure are measured. The results are summoned in a health curve, which is discussed with specially trained healthcare personnel in a Targeted heath dialogue. In a sub-group, blood samples are collected for molecular analyses."
48461317|NCT00630253|BIOLOGICAL|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
48461318|NCT00630253|DRUG|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
48461319|NCT00630253|DRUG|Fludarabine|35 mg/m\^2 intravenously (IV) on days -6 through -2.
48461320|NCT00630253|PROCEDURE|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
48461321|NCT00630253|DRUG|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
48461322|NCT00630253|DRUG|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L
48461323|NCT00630253|DRUG|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
48461324|NCT00630253|DRUG|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
48461325|NCT04919616|DRUG|TILs（Tumor Infiltrating Lymphocytes）|10e9, 10e10, 10e11 dose range of TILs, 3+3 dose escalation
48461326|NCT04185857|DRUG|canrenone 50-100 mg orally once a day|After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
48461327|NCT04185857|DRUG|olmesartan 10-20 mg orally once a day|"After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone."
48461328|NCT04714060|BIOLOGICAL|UB-621|mAb by SC administration
48461329|NCT05863221|DRUG|ZYNRELEF 200Mg-6Mg Extended-Release Solution|ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
48461330|NCT02119637|DEVICE|Transcranial magnetic stimulation (TMS)|1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.
48461331|NCT02119637|DEVICE|MRI|Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
48461332|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
47935439|NCT02666703|DRUG|Methylprednisolone|
47935440|NCT04396054|DEVICE|Lag Screws|Method of internal fixation
48461333|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
47935441|NCT04396054|DEVICE|double Y-shaped plates|Method of internal fixation
48461334|NCT01859637|BIOLOGICAL|Filgrastim|Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
48461335|NCT05650307|DIAGNOSTIC_TEST|MRI|The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
48461336|NCT00796913|OTHER|Stop medication|Stop medication Stop medication + se supplement
48461337|NCT02363764|PROCEDURE|Nasal swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
48461338|NCT02363764|PROCEDURE|Cough swab|"Will be obtained by the physiotherapist in:~* Expectorating CF patients~* Non-expectorating CF patients~* Bronchoscopy CF patients"
48461339|NCT02363764|PROCEDURE|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~- Expectorating CF patients"
48461340|NCT02363764|PROCEDURE|Induced sputum|"Will be obtained by the physiotherapist in:~* Non-expectorating CF patients~* Bronchoscopy CF patients"
48461341|NCT02363764|PROCEDURE|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients"
48461342|NCT02363764|OTHER|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients \>6 years of age
48461343|NCT00005040|DRUG|arsenic trioxide|
48461344|NCT00002253|DRUG|Octreotide|
48461345|NCT03247686|DRUG|RSLV-132|RNase Fc fusion protein
48461346|NCT03247686|DRUG|Placebo|Placebo
48461347|NCT03126292|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
48461348|NCT03126292|OTHER|Child Safety Handout|Handout regarding early child safety
48461349|NCT03202927|DRUG|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
48461350|NCT03555136|DRUG|Vortioxetine|Treatment with vortioxetine as per local SmPC
48461351|NCT06089057|BEHAVIORAL|Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This is a 16-week power-training and physical activity-focused intervention that contains group in-center and individual at-home components and motivational coaching. Participants will meet 2-3 times per week for the in-center power training. Participants will also be asked to wear accelerometers at home in order for their physical activity frequency to be measured.
48461352|NCT06089057|BEHAVIORAL|Attention Control for Pro-social Power training Activity for Aging and Well-being with Chronic Kidney Disease|This will be the attention control arm that will involve receipt of a physical activity education booklet, use of an accelerometer, and weekly check-in calls. No power training or motivational coaching will be delivered.
48461353|NCT04733313|PROCEDURE|ultrasound guıded quadratus lumborum block|Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
48461354|NCT04127292|BEHAVIORAL|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
48461355|NCT00000136|DRUG|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
48461356|NCT00000136|DRUG|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
48461357|NCT02099318|OTHER|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
48461358|NCT02099318|OTHER|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
48461359|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Continuous combination therapy: pegylated interferon alpha-2b 180µg, subcutaneously once a week for 96 weeks, combined with NAs throughout the treatment period.
48461360|NCT05922306|DRUG|PEGylated recombinant human interferon alpha-2b injection|Pulsed combination therapy: pegylated interferon alpha-2b 180µg once weekly by subcutaneous injection for 8 weeks with 4 weeks off for a total treatment duration of 96 weeks, combined with NAs throughout the treatment period.
48461361|NCT04476277|DRUG|Biotin label|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
48461362|NCT05549687|OTHER|Questionnaire Administration|Ancillary studies
48461363|NCT05549687|PROCEDURE|Supportive Care|Participate in Pack Health, an electronic support program
48461364|NCT05549687|PROCEDURE|Supportive Care|Access to telephone triage line for support care services
48461365|NCT06627270|DRUG|Metronidazole|Participants will receive metronidazole (500 mg t.i.d. x 10 days)
48461366|NCT06627270|OTHER|Chlorhexidine|Mouth rinse chlorhexidine (10 ml t.i.d. x 10 days)
48461367|NCT04983862|DRUG|Illuminare-1|Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
48461368|NCT04983862|DEVICE|Karl Storz D-Light C photodynamic diagnostic (PDD)|The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
48461369|NCT00532012|DRUG|RhuDex®|
48461370|NCT05407064|DRUG|MM-120 (LSD D-Tartrate)|A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
48461371|NCT05407064|OTHER|Placebo|A substance that is designed to have no therapeutic value.
48461372|NCT04792723|DRUG|Sublingual aspirin|Vita Green Health Products sublingual aspirin 80 mg tablet
48461373|NCT04792723|DRUG|Oral aspirin|Synco (HK) oral aspirin 80mg tablet
48461374|NCT01968369|DIETARY_SUPPLEMENT|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
48461375|NCT06408727|DRUG|CNM-Au8|CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.
48461376|NCT02766257|PROCEDURE|Anesthesia for ambulatory paediatric surgery|
48461377|NCT01971645|DRUG|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
48461378|NCT01971645|DRUG|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
48461379|NCT02924025|BEHAVIORAL|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
47935442|NCT01698281|DRUG|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
48461380|NCT02962180|DEVICE|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
48461381|NCT06348277|BEHAVIORAL|Mindfulness plus mood monitoring|mobile app that provides guided mindfulness exercises in addition to prompting for mood monitoring three times per day
48461382|NCT06348277|BEHAVIORAL|Mood monitoring|mobile app that prompts for mood monitoring three times per day
48461383|NCT02125760|OTHER|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
48461384|NCT02125760|OTHER|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
48461385|NCT05280080|OTHER|Resistance exercise|Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
48461386|NCT03141580|DIAGNOSTIC_TEST|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
48461387|NCT02829684|OTHER|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
48461388|NCT00522223|BEHAVIORAL|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
48461389|NCT05269238|OTHER|performing lumbar punctures by students with standard training|performance of the puncture by the student have been previously trained with standard training
48461390|NCT05269238|OTHER|training students augmented reality simulator|performance of the puncture by the student have been previously trained using the augmented reality simulator
48461391|NCT03611387|DEVICE|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
48461392|NCT05501158|DRUG|Tamoxifen|Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
48461393|NCT05235022|OTHER|Questionnaires|"The participants included in the study will have to answer:~1. a questionnaire created specifically for the study concerning the possible difficulties encountered during their return to work,~2. the Multidimensional Fatigue Inventory (MFI), a questionnaire assessing fatigue through 5 dimensions (general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation).~These 2 questionnaires will be filled during a 30-minute face-to-face or phone interview."
48461394|NCT04027023|DRUG|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
48461395|NCT01715077|DRUG|Ipilimumab at 3 mg/kg dose|
48461396|NCT06433232|PROCEDURE|ROOT CANAL TREATMENT|ROOT CANAL TREATMENT
48461397|NCT00836862|OTHER|Biologic specimens|Banking of serum, DNA and tissue
48461398|NCT00748696|DIETARY_SUPPLEMENT|Fortimel Extra®|260kcal and 20g protein per day
48461399|NCT00748696|OTHER|resistance training|3 sessions of resistance training per week
48461400|NCT00748696|OTHER|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
48461401|NCT01175330|DRUG|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
48461402|NCT01175330|DRUG|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
48461403|NCT03141151|BEHAVIORAL|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
48461404|NCT03141151|BEHAVIORAL|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
48461405|NCT01939535|OTHER|No intervention|Evaluation of an imaging technique ic MRI
48461406|NCT03317067|DRUG|Dexmedetomidine|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
48461407|NCT03317067|OTHER|Placebo|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
48461408|NCT04358237|DRUG|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
48461409|NCT04358237|DRUG|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
48461410|NCT00383058|DRUG|the extract of green tea|
48461411|NCT06209996|BEHAVIORAL|L4 weight management intervention|he key goals of the intervention are to: (i) teach knowledge of weight loss benefits and health risks of obesity, (ii) offer skill-based dietary and physical activity advice, (iii) develop an achievable weight loss goal and plan, (iv) enhance weight management self-efficacy, (v) provide access to exercise equipment and resources, and (vi) teach strategies for managing cravings. The L4 intervention is a therapist- delivered intervention involving a registered dietitian and a cancer exercise specialist. Participants allocated to the intervention arm will be provided with a schedule to attend the L4 intervention within four weeks post-baseline via phone. They will receive five intervention sessions (120 min each) on a weekly basis, and will be given home-based practices and reading to practice the skills learnt in each session. The intervention sessions will be delivered in a group format with a maximum of 5 individuals per group, which is likely to enhance accountability.
48461412|NCT06209996|BEHAVIORAL|Active control|A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging, and be encouraged to follow the advice covered in the videos. The materials will be developed based on the existing dietary and physical activity guidelines for cancer survivors. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
48461413|NCT05882630|DRUG|Surufatinib,Serplulimab,Etoposide,Carboplatin|"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."
48461414|NCT02431949|OTHER|Admission to BCPP|There is no intervention associated with this study.
48461415|NCT02958176|BEHAVIORAL|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
48461416|NCT02958176|BEHAVIORAL|Autogenic Training|Autogenic training recording provided on a CD
48461417|NCT03366948|OTHER|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
48461418|NCT00799162|OTHER|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
48461419|NCT01956318|BEHAVIORAL|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
48461420|NCT05532631|PROCEDURE|Percutaneous coronary intervention|The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
48461421|NCT05532631|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
48461422|NCT01411462|DEVICE|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
48461423|NCT03917758|DRUG|SGLT2 inhibitor|Start of the treatment with SGLT2i.
48461424|NCT01872507|OTHER|Biofeedback training|usual treatment +12 biofeedback training
48461425|NCT03805633|DIAGNOSTIC_TEST|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
48461426|NCT03805633|DIAGNOSTIC_TEST|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
48461427|NCT05365698|BEHAVIORAL|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
48461428|NCT01151280|DEVICE|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
48461429|NCT05282693|DIETARY_SUPPLEMENT|ReMag|300 mg of ReMag dissolved in lemon flavor liquid
47935443|NCT01698281|DRUG|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
47935444|NCT01698281|DRUG|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
48461430|NCT05282693|DIETARY_SUPPLEMENT|Placebo|Lemon flavored liquid
48461431|NCT05232539|DEVICE|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
48461432|NCT04224753|DEVICE|INVSENSOR00027|Investigational, noninvasive sensor that will be placed on the subject's chest. INVSENSOR00027 detects falls for each subject.
48461433|NCT04826250|PROCEDURE|Timing of medication|Either morning or nighttime medication
48461434|NCT04942496|DRUG|Chlorhexidine Gluconate|Antimicrobial Skin Wash
48461435|NCT04942496|DEVICE|Hibi Universal Bathing System|Cloths used for patient bathing
48461436|NCT04942496|OTHER|0.1% SLS|Positive control
48461437|NCT04942496|OTHER|Distilled Water|Negative Control
48461438|NCT00065962|DRUG|secretin, synthetic porcine|
48461439|NCT00065962|DRUG|secretin, biologically derived porcine|
48461440|NCT05621252|DRUG|PLN-74809|160 mg PLN-74809
48461441|NCT05621252|DRUG|Placebo|Matching placebo
48461442|NCT05746468|BEHAVIORAL|Ecological assessment and intervention|The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
47935445|NCT06110975|OTHER|deprescribing-intervention|"The clinical guideline on Deprescribing drugs for OAB in The North Denmark Region serves as the basis for the intervention. The guideline provides recommended procedures for the deprescribing process. The guideline offers procedures for the deprescribing process and includes a deprescribing algorithm and a symptom questionnaire designed to evaluate the impact of medications utilized in the treatment of OAB."
48461443|NCT05746468|BEHAVIORAL|Audio-based Mindfulness intervention|The control group will receive audio recordings of how to practice mindfulness at home.
48461444|NCT04199494|OTHER|Antibiotic Stewardship Program|The patient do the routinely preoperative lab tests, including the rectal swab (RS). The Antibiotic Stewardship Program (ASP) has been shown to effectively reduce unnecessary antibiotic use and optimize the treatment of infectious diseases. To be successful, multiple aspects should be considered in the ASP. Initially, the infection control specialists will follow the routine activity of each department in order to define what could immediately be improved. Internal antibiotic prophylaxis and therapy guidelines will be defined and shared between groups. The RS, collected at the preoperative testing, is evaluated by the infection control specialist. In case of identification of MDR bacteria, each patient will receive a tailored AP based on the antibiograms of the RS. In any case, the infection control specialist will choose the best solution for the patient avoiding the key antibiotics
48461445|NCT01951209|DRUG|Rifaximin|550mg orally twice daily for 12 weeks
47935446|NCT01791556|OTHER|HIV-1 viral load testing|
48461446|NCT01951209|DRUG|Placebo|Matched placebo
48461447|NCT05341180|DRUG|Polyethylene Glycol|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Polyethylene glycol syrup at a dose of 15-30 ml will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
48478826|NCT05850884|DIAGNOSTIC_TEST|stool examination|Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
48461448|NCT05341180|DRUG|Isabgol + Lactulose|Patients will be advised Anobliss (lidocaine with nifedipine) ointment for local application in the anal canal for one month for relief of pain and anal sphincter spasm. Isabgol husk at a dose of 2 teaspoons in 200 ml of warm water before bedtime and 30 ml of syrup lactulose at bedtime will be used for 2 weeks for relief of acute constipation. Patients will be assessed at 1 week and 1 month and evaluated for primary and secondary outcomes.
48461449|NCT01169753|DRUG|Placebo|Oral tablet every morning for 2 weeks
48461450|NCT01169753|DRUG|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
48461451|NCT03904095|PROCEDURE|Psoas Compartment Block Group (GROUP I)|Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
48461452|NCT03904095|PROCEDURE|Erector Spinae Plane block ( Group II)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
47935447|NCT01988480|PROCEDURE|Image-guided surgery|Placement on residual bone around the implant
48461453|NCT03904095|PROCEDURE|Control Group (GROUP III)|Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
48461454|NCT02751437|DIETARY_SUPPLEMENT|Arginine|
48461455|NCT02245503|DRUG|Tamsulosin|
48461456|NCT01492439|BEHAVIORAL|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
48461457|NCT01492439|BEHAVIORAL|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
48461458|NCT03797196|DRUG|low dose tacrolimus in combination with everolimus|a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
48461459|NCT03797196|DRUG|standard dose tacrolimus with mycophenolate mofetil|A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
48461460|NCT04474587|OTHER|Indirect calorimetry|Measurements of REE by indirect calorimetry
48461461|NCT02031250|DRUG|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
48461462|NCT02031250|DRUG|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
47935448|NCT01988480|PROCEDURE|Sinus lift surgery|Allograft bone
47935449|NCT01866553|DRUG|Nilotinib|300 mg capsule BID oral use
47935450|NCT01866553|DRUG|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
47935451|NCT02255578|DEVICE|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
48461463|NCT02031250|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
47935452|NCT02255578|DRUG|clomiphene citrate treatment|
47935453|NCT01178996|BIOLOGICAL|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
47935454|NCT01178996|DRUG|Ribavirin|Ribavirin 1000 mg (\<75 kg) or 1200 mg (\>75 kg) daily with food divided in two doses orally for 48 weeks
47935455|NCT01178996|BIOLOGICAL|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
47935456|NCT01178996|DRUG|Placebo|Placebo
47935457|NCT05513131|DRUG|Venetoclax；Azacitidine；Homoharringtonine|A cycle every 28 days Treatment with Venetoclax 100mg d1，200mg d2，400mg d3\~d14； Azacitidine 75mg/m2/d，d1\~d7 Homoharringtonine 2mg/d d1\~d7
47935458|NCT05523518|DEVICE|The Buzzy®|From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)
47935459|NCT05523518|DEVICE|The AccuVein®|In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
47935460|NCT04266938|BEHAVIORAL|Rapid start of antiretrovirals|Utilize health navigators to link patients with newly diagnosed HIV into care and treatment within 7 days
47935461|NCT04266938|BEHAVIORAL|Retrospective analysis|Review historical standard of care relative to time to start antiretrovirals and impact on retention in care.
47935462|NCT04266938|BEHAVIORAL|Non- RAPID start|Review of patients who failed to establish care and start ART within 7 days of HIV diagnosis and analyze impact on retention in care.
48461464|NCT02031250|RADIATION|Boost Radiation to Hypoperfused Volumes|
48461465|NCT00635687|DEVICE|Fibroscan|transient elastography measure - Liver stiffness
48461466|NCT02647853|DRUG|TAT4 Gel concentration A|
48461467|NCT02647853|DRUG|TAT4 Gel concentration B|
48461468|NCT02647853|DRUG|Placebo|
48461469|NCT05014438|DRUG|BMS-986166|Specified dose on specified days
48461470|NCT05014438|DRUG|Branebrutinib|Specified dose on specified days
48461471|NCT05014438|OTHER|Placebo|Specified dose on specified days
48461472|NCT02817828|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
48461473|NCT01229150|DRUG|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
48461474|NCT01229150|DRUG|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
48461475|NCT01229150|DRUG|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
48461476|NCT06200480|OTHER|Telephone by nurse|Patient-initiated follow-up at week 2 and 6
48461477|NCT03548155|DRUG|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
48461478|NCT03548155|DRUG|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
48461479|NCT03548155|DRUG|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
48461480|NCT04194333|PROCEDURE|Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm|Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
48281375|NCT00816036|BEHAVIORAL|Smoking Cessation Guideline Implementation|"1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
48461481|NCT00214682|DRUG|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
48461482|NCT00214682|BEHAVIORAL|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
48461483|NCT00214682|BEHAVIORAL|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
48461484|NCT00214682|DRUG|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
48461485|NCT00214682|BEHAVIORAL|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
48461486|NCT00214682|BEHAVIORAL|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
48461487|NCT00388219|DRUG|Transtec (R) PRO (buprenorphine)|
48461488|NCT04082741|DRUG|BMS-986318|Specified dose on specified days
48461489|NCT04082741|OTHER|Placebo|Placebo Matching BMS-986318
48461490|NCT00452218|DRUG|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
48461491|NCT01172912|BIOLOGICAL|filgrastim|
48461492|NCT01172912|BIOLOGICAL|pegfilgrastim|
48461493|NCT01172912|DRUG|carboplatin|
48461494|NCT01172912|DRUG|cisplatin|
48461495|NCT01172912|DRUG|dexamethasone|
48461496|NCT01172912|DRUG|etoposide|
47935463|NCT03313661|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
48461497|NCT01172912|DRUG|ifosfamide|
48461498|NCT01172912|OTHER|high-dose chemotherapy with autologous stem cell rescue|
48461499|NCT01172912|OTHER|laboratory biomarker analysis|
48461500|NCT01172912|PROCEDURE|autologous hematopoietic stem cell transplantation|
48461501|NCT01172912|PROCEDURE|peripheral blood stem cell transplantation|
48461502|NCT03957096|DRUG|SGN-CD47M|SGN-CD47M administered intravenously
48461503|NCT05706415|DIAGNOSTIC_TEST|Clinicians will review the suggestions of a hypothetical AI|There is no intervention. Clinicians will review the suggestions of a hypothetical AI
48461504|NCT03300687|DRUG|FX-322|intratympanic injection
48461505|NCT03300687|DRUG|Placebo|intratympanic injection
48461506|NCT03201003|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
48461507|NCT03201003|OTHER|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
48461508|NCT00789464|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10\^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
48461509|NCT00789464|DRUG|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
48461510|NCT05841693|DRUG|Carbohydrate|The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
48461511|NCT05841693|DRUG|Placebo|The control group will be offered same amount of placebo fluid.
48461512|NCT03428542|BEHAVIORAL|Yin yoga|Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
47935464|NCT03313661|DRUG|Gliclazide|gliclazide (60-120 mg)
47935465|NCT01687036|DEVICE|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
48461513|NCT03428542|BEHAVIORAL|YOMI|"30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments."
48461514|NCT02349672|PROCEDURE|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
48461515|NCT02674711|BEHAVIORAL|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
48461516|NCT02827097|DRUG|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
48461517|NCT02827097|DRUG|denogan|administration of denogan
48461518|NCT02300168|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
48461519|NCT04298216|DIAGNOSTIC_TEST|Ultrasound Analysis of Inferior Vena Cavae (IVC)|Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
48461520|NCT05863026|BEHAVIORAL|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
48461521|NCT00929019|BIOLOGICAL|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
48461522|NCT06428162|OTHER|questionner|three sections questioner including: demographics, reported cases, unreported cases
48461523|NCT04840355|DRUG|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
48461524|NCT03232762|DIETARY_SUPPLEMENT|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
48461525|NCT03232762|DIETARY_SUPPLEMENT|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
48461526|NCT03956758|OTHER|Semi-directed interview|Semi-directed interview on ChemSex practice
48461527|NCT05391594|DEVICE|customized posture support|We will provide customized modifications for seated or standing or walking devices based on the child's segmental level of control
48461528|NCT03379636|DEVICE|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
48461529|NCT03379636|DEVICE|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
48461530|NCT04196296|BEHAVIORAL|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
48461531|NCT04196296|BEHAVIORAL|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
48461532|NCT01824498|OTHER|Low Fat diet|Low fat diet = 20% fat
48461533|NCT01824498|OTHER|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
48461534|NCT01824498|OTHER|High Fat Diet|High Fat Diet = 40% fat
48461535|NCT04883996|DRUG|1% EXP039|1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
48461536|NCT04883996|OTHER|Saline control|Saline
48461537|NCT01316536|OTHER|provide headphones with music playing|Participants will be provided with music through headphones
48461538|NCT01316536|OTHER|Sounds|recorded ICU sounds will be provided to participants through headphones
48461539|NCT04000776|DIAGNOSTIC_TEST|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
48461540|NCT04000776|DIAGNOSTIC_TEST|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
48461541|NCT04000776|DIAGNOSTIC_TEST|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
48461542|NCT04000776|OTHER|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
48461543|NCT04228822|OTHER|Low carbohydrate diet|25-35% of carbohydrates from total energy intake
48461544|NCT05044962|DRUG|Cabotegravir/ Rilpivirine|"For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709"
48461545|NCT05044962|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
48461546|NCT05044962|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
48461547|NCT05044962|DRUG|Levonorgestrel|Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
47935466|NCT00550251|DEVICE|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
47935467|NCT00550251|DEVICE|Placebo wristbands|Elasticated wrist bands without active bead.
47935468|NCT02985931|OTHER|Diagnostic imaging scans of SPECT and MRI|
48461548|NCT05044962|DRUG|NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens|ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
48461549|NCT03165669|DEVICE|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
48461550|NCT03165669|OTHER|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
48461551|NCT02749305|OTHER|Collection of patient-reported outcome measures|Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
48461552|NCT00958724|DRUG|Neratinib|
48461553|NCT00958724|DRUG|Vinorelbine|
48461554|NCT06380387|DIETARY_SUPPLEMENT|Meal|Liquid meal
48478827|NCT06177847|DEVICE|BIS|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
48478828|NCT02963584|OTHER|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
48478829|NCT02733627|DRUG|BI 1467335|
48461555|NCT05907694|PROCEDURE|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
48461556|NCT05907694|DRUG|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
48461557|NCT06465654|OTHER|Automated variable dose oxygen treatment|The participant will receive closed loop oxygen titration during a walking test based on oxygen saturation measurements every second measured by a pulse oximeter connected to the O2matic. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
48461558|NCT06465654|OTHER|Fixed dose oxygen treatment|The participant will receive a fixed oxygen dose during a walking test. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
48461559|NCT02840162|DRUG|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
48461560|NCT02840162|DRUG|Placebo|
48461561|NCT04202757|BIOLOGICAL|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors|12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
48461562|NCT04202757|OTHER|Saline|12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
48461563|NCT04148287|DRUG|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
48461564|NCT02721563|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
48461565|NCT02721563|DRUG|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
48461566|NCT02143596|OTHER|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
48461567|NCT06221124|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.
48461568|NCT05232487|OTHER|Swiss low back acupuncture (SLBA)|"Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes.~Swiss low back pain acupuncture The SLBA method is a further developed method from the Jiu Gong acupuncture technique, also known as the Nine Palace-Points on the spine. The following acupuncture points will be used: LV3/ LV5, Tai Xi (Kl 3), Fe Yang (BL 58), Tai Chong (LR 3), Guang Ming (GB 37), Tai Xi (Kl 3) and Fe Yang (BL 58)."
48461569|NCT05232487|OTHER|Standard acupuncture (SA)|Participants are placed in the prone position (if required with a pillow under the abdomen). Then acupuncture is applied to the back of the body. The treatment takes place for the duration of 9 weeks (2x per week from week 1 to 6 and 1x a week from week 7 to 9). One treatment session lasts about 50-60 minutes. The SA method is described in the acupuncture textbook for TCM in China and all acupuncture points are selected based on TCM principles, international literature, and the opinion of national and international TCM experts. The following points have been selected: Ming Men (GV 4), Zhi Shi (BL 52), Tai Xi (KI 3) Yao Guan (GV 3), Guan Yuan Shu (BL 26), Ge Shu (BL 17), Ci Liao (BL 32), Wei Zhong (BL 40), Ji Zhong (GV 6), Yao Yang Guan (GV 3), Shen Shu (BL 23), Da Chang Shu (BL 25) and A-Shi points.
48461570|NCT06343727|DIETARY_SUPPLEMENT|Egg white protein pudding|Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
48461571|NCT06343727|DIETARY_SUPPLEMENT|: Ensure Plus|Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
48461572|NCT02686567|PROCEDURE|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
48461573|NCT02686567|PROCEDURE|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
48461574|NCT04563260|DRUG|Normal saline injection|Normal saline 2 mL, intravenous injection
48461575|NCT04563260|DRUG|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
48281376|NCT04626713|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
48461576|NCT04371224|DRUG|Irinotecan Liposomal Injection [Onivyde]|both arm
48461577|NCT04371224|DRUG|Capecitabine|NaliCap
48461578|NCT04371224|DRUG|5-fluorouracil|NAPOLI
48461579|NCT04371224|DRUG|Leucovorin|NAPOLI
48461580|NCT01444196|DRUG|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
48281377|NCT03820492|DIAGNOSTIC_TEST|OCT, FFR, CTA and FFRCT|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
48281378|NCT00503399|DRUG|Teriparatide|20 µg/day sc for 18 months
48281379|NCT00503399|DRUG|Risedronate|35 mg/week po for 18 months
48281380|NCT00070447|BIOLOGICAL|rituximab|
48281381|NCT00070447|DRUG|cyclophosphamide|
48461581|NCT00246792|BEHAVIORAL|Group treatment|
48461582|NCT05000138|DIAGNOSTIC_TEST|FDG PET/CT|Patients with suspected giant cell arteritis, of which FDG PET/CT is indicated for diagnosis of large vessel involvement, will have the small cranial arteries analyzed for involvement.
48461583|NCT03031951|BEHAVIORAL|Lifestyle Intervention Group|The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from \~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
48461584|NCT01083329|BEHAVIORAL|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
48461585|NCT01083329|DRUG|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
48461586|NCT01083329|DRUG|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
48461587|NCT00967395|OTHER|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
48461588|NCT00967395|OTHER|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
47935469|NCT00312637|PROCEDURE|Magnetic Resonance Spectroscopy|
48461589|NCT00862563|DRUG|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
48461590|NCT00862563|DRUG|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
48461591|NCT00862563|DRUG|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
48461592|NCT00862563|DRUG|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
48461593|NCT05737160|BIOLOGICAL|Telitacicept|Administered as an SC infusion
48281382|NCT00070447|DRUG|doxorubicin hydrochloride|
48461594|NCT05737160|DRUG|Placebo|Administered as an SC infusion
48461595|NCT05125276|DRUG|No aspirin|No aspirin
48461596|NCT05125276|DRUG|Aspirin|75-100 mg once daily
48461597|NCT00619853|BEHAVIORAL|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
48461598|NCT00619853|BEHAVIORAL|treatment approach - HABIT|HABIT-2 months, 2Hr per day
47935470|NCT06143605|PROCEDURE|salvage treatment|salvage radical surgery or endoscopic resection
47935471|NCT02405936|PROCEDURE|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
47935472|NCT04638504|OTHER|ultrasonography|vascular and adipose tissue measurement by ultrasonography
47935473|NCT00132106|DRUG|phentolamine|
47935474|NCT05952076|DIETARY_SUPPLEMENT|B. infantis Bi-26|A once-daily oral dose of Bi-26 will be provided to infants for 28 days.
47935475|NCT05952076|DIETARY_SUPPLEMENT|Placebo|A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
47935476|NCT04178083|DIAGNOSTIC_TEST|medical examination|medical examination
47935477|NCT00168987|DRUG|oral nutritional supplement rich in eicosapentanoic acid|
47935478|NCT03794921|OTHER|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
48281383|NCT00070447|DRUG|prednisone|
48281384|NCT00070447|DRUG|vincristine sulfate|
48281385|NCT00070447|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48281386|NCT02592005|OTHER|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
48281387|NCT05639764|DEVICE|Oculus Quest 2|A specific immersive virtual reality software designed to address chronic shoulder pain on the Oculus Quest 2 device.
48281388|NCT05639764|DEVICE|Oculus Quest 2|"a VRi placebo intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces."
48461599|NCT02118324|BEHAVIORAL|Exergaming Program|Participants will exercise through exergaming play.
48461600|NCT03472196|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
48461601|NCT00006262|DRUG|becatecarin|
48461602|NCT04166058|DRUG|Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
48461603|NCT04166058|DRUG|Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)|Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
48461604|NCT00903292|DRUG|erlotinib (Tarceva)|chemotherapy with erlotinib
48461605|NCT00903292|DRUG|pemetrexed (Alimta)|Chemotherapy with pemetrexed
48478830|NCT02733627|DRUG|Placebo|
48461606|NCT03712891|DIETARY_SUPPLEMENT|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
48461607|NCT04345822|PROCEDURE|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
48461608|NCT05278403|OTHER|Virtual reality and video games|Use of a software in stroke patients' rehabilitation.
48461609|NCT05278403|OTHER|Neurological physiotherapy|Application of conventional physical therapy techniques.
48461610|NCT02726841|PROCEDURE|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
48461611|NCT02726841|PROCEDURE|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
48461612|NCT05719467|DRUG|Buscopan 20 MG/ML Injectable Solution|1 mL intravenously
48099101|NCT03832660|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
48099102|NCT03832660|DRUG|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
48461613|NCT05719467|DRUG|Sodium bicarbonate|4 g orally
48461614|NCT05719467|DRUG|Placebo|4g orally
48461615|NCT05719467|DRUG|Nacl 0.9%|1 mL intravenously
48461616|NCT04784416|DEVICE|Active tPBM-2.0|The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for \~11 minutes (666 seconds).
48461617|NCT04784416|DEVICE|Sham tPBM-2.0|"The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for \~11 minutes (666 seconds)."
48461618|NCT04784416|DRUG|18F-MK-6240|PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
47935479|NCT03174899|RADIATION|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient.
47935480|NCT04474353|DEVICE|Optune|Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure
48461619|NCT05390255|DRUG|Mometasone furoate nasal spray hormone|This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
48461620|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + oral hormone|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
48461621|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + omalizumab|The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
48461622|NCT03279250|DRUG|Abiraterone Acetate|Given PO
48461623|NCT03279250|DRUG|Apalutamide|Given PO
48461624|NCT03279250|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given IM
48461625|NCT03279250|DRUG|Prednisone|Given PO
48461626|NCT03279250|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
48461627|NCT04459754|DRUG|Fuzheng Yiliu Formulation|"The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption."
48461628|NCT01173536|DRUG|GDC-0449|Oral repeating dose
48461629|NCT01173536|DRUG|moxifloxacin|Oral single dose
47935481|NCT04474353|DRUG|Gadolinium|Gadolinium contrast medium
47935482|NCT04474353|DRUG|Temozolomide|Chemotherapy agent
47935483|NCT04474353|RADIATION|Stereotactic radiosurgery (SRS)|Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
47935484|NCT05240586|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
48461630|NCT01173536|DRUG|placebo|Oral repeating dose
48461631|NCT02027337|DRUG|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
48461632|NCT02027337|DRUG|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
48461633|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
48461634|NCT02027337|DRUG|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
48461635|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
48461636|NCT02027337|DRUG|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
48461637|NCT00740896|BEHAVIORAL|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
48461638|NCT00740896|BEHAVIORAL|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
48461639|NCT03651336|DEVICE|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
48461640|NCT04337658|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
48461641|NCT04337658|DRUG|Trastuzumab|Participants will receive trastuzumab (8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
48461642|NCT04337658|DRUG|Fulvestrant|500mg intramuscular injections at day 1, 15, 28 and 4 weeks thereafter
48461643|NCT04337658|DRUG|Capecitabine|1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
48461644|NCT05261191|BIOLOGICAL|MGD020|MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
48461645|NCT05261191|BIOLOGICAL|MGD014|MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
48461646|NCT03680144|PROCEDURE|Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Undergo DSC-MRI
48461647|NCT03680144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo diagnostic MRI
48461648|NCT00555893|DRUG|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
48461649|NCT00555893|DRUG|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
48461650|NCT03701451|DRUG|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
48461651|NCT02934633|BEHAVIORAL|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
48461652|NCT02934633|BEHAVIORAL|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
48461653|NCT01881763|DRUG|Ketamine|Ketamine 1-2 mgr/ kg IV
48461654|NCT01881763|DRUG|Methohexital|Methohexital 0.5-1mg/kg IV
48099103|NCT05165914|DRUG|Intravenous midazolam before emergence from general anesthesia|Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
48461655|NCT00141505|DRUG|Bifeprunox|
48461656|NCT01777815|DEVICE|NeoChord DS1000 Artificial Chordae Delivery System|
48461657|NCT05233254|BEHAVIORAL|Abdominal Hollowing exercise|Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
48461658|NCT01659073|PROCEDURE|Caloric Vestibular Stimulation|
48461659|NCT00662272|BIOLOGICAL|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
48461660|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
47935485|NCT05240586|PROCEDURE|acupuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
47935486|NCT05240586|PROCEDURE|physical therapy, medication(prn)|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
47935487|NCT01364675|DRUG|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
48099104|NCT05165914|DRUG|Intravenous normal saline before emergence from general anesthesia|Intravenous administration of normal saline just before emergence from anesthesia.
48461661|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
48461662|NCT01232244|OTHER|GLP-1 infusion|1 pmol/kg/min
47935488|NCT01364675|DRUG|Placebo tablet|Identical Placebo Tablet
48099105|NCT01600911|OTHER|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
48461663|NCT01232244|OTHER|Glucagon infusion|3ng/kg/min
48461664|NCT01232244|OTHER|Oxyntomodulin infusion|3 pmol/kg/min
48461665|NCT01232244|OTHER|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
48461666|NCT01232244|OTHER|Placebo|NaCl 9 g/L infusion
48461667|NCT05790863|DEVICE|Ergometer cycling|Paticipants will receive 21 sessions (3 sessions/week) of training for 7 weeks with the arm-leg cycle ergometer (SCIFIT, REX7000, US)
48461668|NCT00252161|PROCEDURE|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
48461669|NCT00252161|DRUG|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
48461670|NCT00160524|BIOLOGICAL|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
48461671|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
48461672|NCT01446445|DRUG|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
48461673|NCT03416673|PROCEDURE|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
48461674|NCT03416673|PROCEDURE|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
48461675|NCT00258024|DRUG|IPT-sulphadoxinepyrimethamine|
48461676|NCT02119936|BEHAVIORAL|Heart Rate Variability Biofeedback Tool|The Heart Rate Variability Biofeedback tool (emWave 2) will capture heart rate variability (HRV) before and after deep breathing exercises are used among participants. Participants will be able to visualize changes in their HRV and then fill-out self-reported anxiety measures to determine if the breathing exercises and visualization of HRV affected anxiety.
48461677|NCT03860441|OTHER|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
48461678|NCT02821676|PROCEDURE|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
48461679|NCT02821676|PROCEDURE|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
48461680|NCT03264092|PROCEDURE|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
48461681|NCT04956848|DEVICE|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
48461682|NCT04709757|DEVICE|Intermittent Dosing HF10 30/90|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF
48461683|NCT04709757|DEVICE|Intermittent Dosing HF10 30/360|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
48461684|NCT05999916|DEVICE|Personalized Miamind Neurostimulator|60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).
48461685|NCT05541198|OTHER|Pressure Injury Prevention Care Bundle|"1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management"
48461686|NCT03516058|OTHER|Simulation-Based Education|"Participating residents receive lectures on TAP block and the use of ultrasound devices from an expert before training, and then receive simulation-based training for an hour from the anesthesiologist's staff. The residents performed three ultrasound guided TAP blocks using an anesthetized porcine model during the training session.~The residents filled out a questionnaire before and after the training session. Ten multiple-choice questions tested general knowledge in abdomen ultrasound and TAP block. Subjective comfort levels with ultrasound machine and block device functionality, patient positioning, proper block technique, image documentation, needle safety and overall procedural confidence and anxiety levels were reported on a 5-point Likert scale before and after training."
48461687|NCT02395809|PROCEDURE|lateral internal sphincterotomy|
48461688|NCT02395809|PROCEDURE|TENS|
48461689|NCT03416049|DEVICE|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
48461690|NCT03416049|DEVICE|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
48461691|NCT03416049|DEVICE|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
48461692|NCT03416049|DEVICE|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
48461693|NCT03612973|DIAGNOSTIC_TEST|lipid profile|Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
48461694|NCT03612973|DIAGNOSTIC_TEST|fasting insulin|serum samples used for doing the test by ELISA after fasting for 8 h
48461695|NCT03612973|DIAGNOSTIC_TEST|fibro scan|liver stiffness by fibro scan before and after treatment
48461696|NCT02011451|DRUG|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
48461697|NCT02011451|DRUG|Placebo Comparator:|
48461698|NCT05601596|DIAGNOSTIC_TEST|Analysis of menstrual blood to predict endometriosis|Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
48461699|NCT01537718|DEVICE|REPLY 200|REPLY 200 pacemaker
48461700|NCT00102349|BEHAVIORAL|Behavior Therapy|
48461701|NCT05320237|OTHER|Immersive Virtual Reality Intervention|Eight week intervention with two sessions a week. Each session will be 30 minutes in duration and will involve participants partaking in VR and such games include targeting individual finger movement (playing piano); grasp and release and one game (catching falling stars) includes holding a controller for elbow flexion and extension (Whack-a-mole).
48461702|NCT01728636|DRUG|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
48461703|NCT02661022|DRUG|SL-401 7 µg/kg/day|SL-401 7 µg/kg/day in combination with pom/dex
48461704|NCT02661022|DRUG|SL-401 9 µg/kg/day|SL-401 9 µg/kg/day in combination with pom/dex
48461705|NCT01846091|OTHER|Laboratory Biomarker Analysis|Correlative studies
48461706|NCT01846091|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
48461707|NCT03873805|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
48461708|NCT03873805|DRUG|Cyclophosphamide|Given IV
48461709|NCT03873805|DRUG|Fludarabine|Given IV
48461710|NCT03873805|DRUG|Fludarabine Phosphate|Given IV
48461711|NCT02786784|OTHER|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
48461712|NCT05447416|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
48461713|NCT05447416|DEVICE|Intermittent Hypoxic Training - IHT|Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
48461714|NCT05623228|COMBINATION_PRODUCT|The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia|The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.
48461715|NCT01828294|DRUG|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
48461716|NCT04750590|PROCEDURE|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
48461717|NCT04750590|PROCEDURE|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
48461718|NCT05373576|BEHAVIORAL|TACHIDINO|"TACHIDINO is based on two principles a) selective stimulation of a cerebral hemisphere and specific reading strategies, and b) the training of selective visuospatial attention, as well as the perception of rapid movement and the visual characteristics of words even in the presence of so-called visual crowding or crowding, an automatic effect of our perceptual system that leads to obfuscation of the visual areas surrounding the object to be analyzed, to make its vision clearer (as suggested by the Magnocellular theory of dyslexia; Stein et al., 2019)."
48461719|NCT04142996|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
48461720|NCT01640041|DEVICE|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
48461721|NCT03103711|BEHAVIORAL|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
48461722|NCT04659668|DEVICE|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
48461723|NCT06267339|DEVICE|transcranial random noise stimulation|This intervention will give children tRNS during reaching or grasping repetitive movements.
48461724|NCT06267339|DEVICE|Sham stimulation|This intervention will give children sham stimulation during reaching or grasping repetitive movements.
48461725|NCT02739724|PROCEDURE|Adnexal surgery|
48461726|NCT01799850|DRUG|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
48461727|NCT01799850|DRUG|placebo|placebo assigned randomly, double blind
48461728|NCT03276767|OTHER|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
48461729|NCT02344849|DRUG|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
48461730|NCT04162899|DRUG|Drug: SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
48461731|NCT03024268|DEVICE|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
48461732|NCT03050424|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose injectable Product
48461733|NCT03050424|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9%
48461734|NCT03256149|DRUG|Dexamethasone|
48461735|NCT03256149|DRUG|Placebo|Normal saline (IV placebo)
48461736|NCT00349765|BEHAVIORAL|higher fat, high polyunsaturated fat diet|
48461737|NCT00349765|BEHAVIORAL|higher fat, high saturated and trans fat diet|
48461738|NCT00349765|BEHAVIORAL|lower fat diet|
48461739|NCT02472639|DEVICE|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
48461740|NCT02472639|OTHER|No Ostom-i Alert Sensor|Patient will not use device
48461741|NCT03342339|OTHER|cognitive examination|mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
48461742|NCT03342339|OTHER|viewing of video|viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
48461743|NCT03342339|OTHER|Iowa Gambling Task|Test of Iowa Gambling Task
48461744|NCT01459601|DRUG|Cabergoline|0,5mg per week
48461745|NCT04967469|DRUG|Calcitriol|end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
48461746|NCT04967469|DRUG|Alfacalcidol 0.5 MCG Oral Capsule|end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
48461747|NCT02784236|DEVICE|telemedicine|The study population corresponds to patients\> 18 and \<65 years with DM1 of\> 1 year of evolution, and treated with MDI HbA1c\> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
48461748|NCT04842019|DRUG|KRN23|KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL
48461749|NCT01664650|DIETARY_SUPPLEMENT|Genistein|
48461750|NCT01664650|DIETARY_SUPPLEMENT|Placebo|
48461751|NCT02386007|DRUG|DW-3101_150mg|
48461752|NCT02386007|DRUG|DW-3101_300mg|
48461753|NCT02386007|DRUG|DW-3101_600mg|
48461754|NCT02386007|DRUG|Placebo|
48461755|NCT03130335|PROCEDURE|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
48461756|NCT03130335|BIOLOGICAL|BMA|Bone marrow will be aspirated from the iliac crest.
48461757|NCT02707016|OTHER|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
48461758|NCT02707016|OTHER|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
48461759|NCT00553124|DRUG|selenium|
48461760|NCT00553124|DRUG|vitamin E|
48461761|NCT00553124|PROCEDURE|biopsy|
48461762|NCT00553124|PROCEDURE|chemoprevention|
48461763|NCT00553124|PROCEDURE|cryopreservation|
48461764|NCT00553124|PROCEDURE|cytology specimen collection procedure|
48461765|NCT00553124|PROCEDURE|diagnostic procedure|
48461766|NCT00553124|PROCEDURE|gene expression analysis|
48461767|NCT00553124|PROCEDURE|immunohistochemistry staining method|
48461768|NCT00553124|PROCEDURE|laboratory biomarker analysis|
48461769|NCT00553124|PROCEDURE|medical chart review|
48461770|NCT00553124|PROCEDURE|mutation analysis|
48461771|NCT00553124|PROCEDURE|polymerase chain reaction|
48461772|NCT00553124|PROCEDURE|quality-of-life assessment|
48461773|NCT00553124|PROCEDURE|questionnaire administration|
48461774|NCT00553124|PROCEDURE|study of socioeconomic and demographic variables|
48461775|NCT00405262|DRUG|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
48461776|NCT00405262|DRUG|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
48461777|NCT00405262|DRUG|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
48461778|NCT06042231|BEHAVIORAL|Exercise Intervention|Exercise and education intervention. Participants will be prescribed a tailored exercise program to complete before ('pre-habilitation') and after their AF ablation procedure (rehabilitation).
48461779|NCT06042231|BEHAVIORAL|Education Intervention|Education intervention. Participants will be given a 1-1 education session (up to 3 sessions) before and after their AF ablation procedure. Participants will be given behavioural strategies to improve adherence and compliancec to risk-factor modification.
48461780|NCT04899934|BEHAVIORAL|mobile and technology assisted aftercare|The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
48461781|NCT04899934|OTHER|Treatment as usual|Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
48461782|NCT03702816|DRUG|GE180 PET Scan|GE180 PET Scan
48461783|NCT03605641|OTHER|JUUL|JUUL Virginia Tobacco
48461784|NCT03605641|OTHER|VUSE Solo|VUSE SOLO Original
48461785|NCT03605641|OTHER|Conventional Cigarette|Subject preferred conventional cigarette
48461786|NCT03198663|BEHAVIORAL|POSSE|Popular-opinion leader
48461787|NCT02784262|DRUG|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
48461788|NCT03151954|PROCEDURE|functional endonasal sinus surgery|collect nasal polyps from patients
48461789|NCT03151954|PROCEDURE|nasal septal construction|collect inferior turbinates from patients as control arm
48461790|NCT01927991|BEHAVIORAL|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
48461791|NCT03354780|OTHER|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
48461792|NCT03354780|OTHER|Survey on first pregnancy|rate of miscarriage was noted
48461793|NCT00646984|DRUG|Standard continuous antiretroviral therapy|
48461794|NCT00646984|DRUG|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
48461795|NCT00646984|DRUG|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
48461796|NCT06123754|DRUG|Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection|The subjects receive Envafolimab/placebo treatment with a dosage of 600 mg/3 ml subcutaneously injected every 3 weeks.It will last about 3-4 cycles before surgery and 16 cycles after surgery.
48461797|NCT06123754|DRUG|placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection|The subjects received platinum-based doublet chemotherapy on day 1 of every cycle. It's 3 weeks per cycle and lasts 3-4 cycles before surgery.
48461798|NCT02731781|OTHER|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
48461799|NCT00627731|DRUG|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
48461800|NCT00627731|DRUG|prednisolone (PSL)|PSL 40 mg per day for 10 days
48461801|NCT03056287|BEHAVIORAL|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
48461802|NCT03056287|OTHER|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
48461803|NCT05909436|DRUG|GLS-012|"In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W.~In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W.~In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
48281389|NCT05613270|DIAGNOSTIC_TEST|18F-FES PET/CT scan|Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
48461804|NCT05909436|DRUG|GLS-010|"In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
48461805|NCT02350036|OTHER|ultrasound monitoring|Uterine artery Doppler assessment
48461806|NCT03690349|OTHER|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
48461807|NCT04311346|DIAGNOSTIC_TEST|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
48461808|NCT05397444|OTHER|No intervention|This is an observational study with no intervention.
48461809|NCT05582343|BEHAVIORAL|MINDBODYSTRONG™|"Digitalized MINDBODYSTRONG™ is designed for self-paced weekly use via an online platform.~MINDBODYSTRONG© Session Content~1. Thinking, feeling, \& behaving, The ABCs of CBT, Mindfulness Skills Building: Positive self-talk/The ABCs~2. Self-esteem \& positive self-talk, Intentional gratitude, Managing change Skills building: Self-esteem \& positive self-talk~3. Stress, Healthy coping, Abdominal breathing Skills Building: Managing stress~4. Problem solving, Setting goals, Steps to problem solving Skills building: Strategies to overcoming barriers~5. Dealing w/ emotions in healthy ways, Using guided imagery, Coping strategies, Effective communication Skills building: Dealing with emotions~6. Coping w/ stressful situations/valuable sleep Skills building: Coping w/ stressful situations~7. Distress tolerance \& added emotional regulation skills Skills bulding: RAIN practice, Self-love skill, Distracting using ACCEPTS~8. Putting it all together for a healthy YOU!"
48099106|NCT01168453|BEHAVIORAL|head position change|AL-US distance measure using the ultrasound in two different head position
48281390|NCT05015387|PROCEDURE|Minimally invasive non-surgical therapy|Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.
48461810|NCT00494013|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
48461811|NCT00494013|DRUG|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
48478831|NCT05076513|DRUG|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
48478832|NCT05076513|RADIATION|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
48461812|NCT04495543|BEHAVIORAL|Brief Skills for Safer Living|Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.
48461813|NCT04783337|DIAGNOSTIC_TEST|HR-pQCT (high resolution computertomograph)|In addition to determining the bone density, a quantitative bone structure analysis with measurement of the number of thickness and distribution of the trabeculae can also be carried out. In addition, the finite element analysis (FEA) allows strength models of the examined bone to be created from the data of the hr-pqCTs. In this way, the osseous consolidation of the fracture can not only be observed, but also tested for resilience with the help of mathematical models.
48461814|NCT04783337|DIAGNOSTIC_TEST|Blood withdrawal|Bone remodeling blood marker: S-CTX (Crosslaps), S-TRA5b ( tartrate-resistant acid phosphatase), S-PINP (Procollagen type 1 amino-terminal propeptide), BALP, Calcium, parathyroid hormone, 25-OH-Vitamin D3 (HPLC)
48461815|NCT05210049|DIAGNOSTIC_TEST|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
48461816|NCT02701101|DEVICE|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
48461817|NCT02701101|OTHER|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
48461818|NCT01927380|OTHER|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
48461819|NCT05562011|DEVICE|Caretaker Device placement|a continuous non-invasive blood pressure and vital signs monitor that is worn on the wrist
48461820|NCT05624424|DRUG|Rematazolam Besylate|Anesthesia was induced with Rematazolam Besylate 0.3\~0.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 1-3 mg/kg/h until the end of surgery.
48461821|NCT05624424|DRUG|Propofol|Anesthesia was induced with Propofol 2\~2.5 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by remimazolam 5\~12 mg/kg/h until the end of surgery.
48461822|NCT05624424|DRUG|Sevoflurane|Anesthesia was induced with etomidate 0.03 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC) and BIS\<60, followed by 2 %-3 % Sevoflorane until the end of surgery.
48461823|NCT05624424|DRUG|Sufentanil|Anesthesia was induced with Sufentanil 0.3\~0.5 ug/kg by intravenous injection after the LoC and BIS\<60.
48461824|NCT05624424|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.2-0.3 mg/kg by intravenous injection after the LoC and BIS\<60, followed by 0.1 mg/kg/h Cisatracurium Besylate during the operation.
48281391|NCT05015387|COMBINATION_PRODUCT|Subgingival application of collagen hydrogels with proanthocyanidins|Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.
48461825|NCT05624424|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
48461826|NCT04410653|DRUG|Afatinib 40 MG|single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
48461827|NCT01624233|DRUG|80 mg ixekizumab|Administered SC
48461828|NCT05269563|OTHER|Surgical intervention|Pars Plana Vitrectomy for Macular Hole Closure
48461829|NCT05212116|DRUG|SDI-118|SDI-118 is presented as low dose, and high dose capsules.
48461830|NCT05212116|DRUG|Placebo|The Matching Placebo for SDI-118 is mannitol in capsules.
48461831|NCT02171988|DRUG|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
48461832|NCT02171988|DRUG|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
47935489|NCT04167371|BEHAVIORAL|Biofeedback|Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
48281392|NCT05015387|DIAGNOSTIC_TEST|Collection of saliva samples|For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
48461833|NCT02171988|DRUG|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
48461834|NCT02171988|DRUG|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
48461835|NCT02450058|DRUG|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
48461836|NCT02450058|DRUG|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
48461837|NCT02450058|DRUG|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
48461838|NCT02450058|DRUG|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
48461839|NCT02450058|DRUG|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
48461840|NCT06357741|DRUG|Denosumab|Desumumab, 60mg single injection
48461841|NCT05421039|BEHAVIORAL|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
48461842|NCT02201316|DRUG|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
48461843|NCT02201316|DRUG|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
48461844|NCT02201316|DRUG|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
47935490|NCT04167371|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
47935491|NCT01655108|DRUG|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
47935492|NCT01655108|DRUG|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
48281393|NCT04837417|DIAGNOSTIC_TEST|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
48461845|NCT05912335|DRUG|Topical anesthetic|The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
48461846|NCT03371524|OTHER|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
48461847|NCT00339157|DRUG|Anakinra|
48461848|NCT00339157|BIOLOGICAL|Pneumo23|
48461849|NCT04318808|PROCEDURE|Laser acupuncture|Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
48461850|NCT05433090|BEHAVIORAL|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
48461851|NCT00253838|PROCEDURE|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
48461852|NCT00253838|PROCEDURE|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
48461853|NCT00195754|DRUG|divalproex sodium|
48461854|NCT03671343|BEHAVIORAL|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
48461855|NCT03234608|BEHAVIORAL|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
48461856|NCT04428645|DEVICE|DailyDose Decision Support|DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
48461857|NCT00000562|PROCEDURE|extracorporeal membrane oxygenation|
48461858|NCT00860145|PROCEDURE|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
48461859|NCT00860145|PROCEDURE|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
48461860|NCT05768334|DRUG|Lubiprostone 24Mcg Oral twice daily|"The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks."
48461861|NCT02997891|DIAGNOSTIC_TEST|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
48461862|NCT02997891|DIAGNOSTIC_TEST|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
48461863|NCT00796328|DRUG|Phenylephrine infusion|Up-down, biased coin design
48461864|NCT04461587|DRUG|Pirfenidone|see previous entries
48461865|NCT02560051|DRUG|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
48461866|NCT02560051|DRUG|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
48461867|NCT02560051|DRUG|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
48461868|NCT02560051|DRUG|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
48461869|NCT02560051|DRUG|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
48461870|NCT00413049|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
48461871|NCT00413049|DRUG|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
48461872|NCT04431973|DEVICE|Medacta Shoulder System|Surgical placement of the Medacta Shoulder System prothesis on patients with pathologies requiring the insertion of a total reverse shoulder prothesis for primary omarthrosis, cuff tear arthropathy, massive cuff rupture or post instability arthropathy
48461873|NCT04882254|PROCEDURE|Normothermic machine perfusion|Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
48461874|NCT02760433|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
48461875|NCT02760433|DRUG|Placebo|sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
48461876|NCT00658034|PROCEDURE|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
48461877|NCT00658034|PROCEDURE|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
48461878|NCT06271005|DIETARY_SUPPLEMENT|NeuroTears|Over-the-counter supplement
48461879|NCT06271005|DIETARY_SUPPLEMENT|Placebo|Oral placebo pill
48461880|NCT03039816|DEVICE|Nasaleze|Nasaleze cellulose powder
48461881|NCT03039816|DEVICE|Placebo|Lactose powder in the same plastic container as Nasaleze and with the same taste
48461882|NCT01509391|DRUG|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
48461883|NCT04808388|OTHER|MRI|Using MRI for fat fraction and Biodex for isometric strength
48461884|NCT06559761|PROCEDURE|Hepatectomy|According to guideline recommended procedure of hepatectomy
48461885|NCT02044939|OTHER|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
48281394|NCT04898114|DRUG|Magnesium sulfate|Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
48461886|NCT01971554|DRUG|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
48461887|NCT01971554|DRUG|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
48461888|NCT03090282|PROCEDURE|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
48461889|NCT03675815|DRUG|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
48461890|NCT03675815|DRUG|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
48461891|NCT03675815|DRUG|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
48461892|NCT03675815|DRUG|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
48461893|NCT03675815|DRUG|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
48461894|NCT03675815|DRUG|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
48461895|NCT03675815|DRUG|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
48461896|NCT05198505|DRUG|TQB2868 Injection|TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β
48461897|NCT04974580|DRUG|Nicotine patch|NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
48461898|NCT04974580|BEHAVIORAL|Phone Counseling|Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
48461899|NCT04974580|BEHAVIORAL|Digital Coaching|Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
48461900|NCT00333450|BIOLOGICAL|Pneumococcal vaccine|
48461901|NCT01924286|DRUG|Prednisone|
48461902|NCT01924286|DRUG|Placebo|
48461903|NCT03977441|DRUG|Agomelatine or PIacebo|control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
48461904|NCT02311894|DRUG|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
48461905|NCT05244213|BIOLOGICAL|Sintilimab|200mg Q3W
48281395|NCT04898114|DRUG|Sildenafil Citrate|Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
48461906|NCT05244213|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
48461907|NCT05244213|DRUG|Nab paclitaxel|260 mg/m2, d1 every 3 weeks
48461908|NCT02127216|BEHAVIORAL|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
48461909|NCT01257451|DRUG|Vildagliptin|vildagliptin 50mg bid
48461910|NCT01257451|DRUG|Placebo|Placebo 50mg bid
48461911|NCT02658435|DRUG|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
48461912|NCT02658435|DRUG|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
48461913|NCT02671474|OTHER|4-dimensional volume-rendered computed tomography|
48461914|NCT04836182|DRUG|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
48461915|NCT04836182|DRUG|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
48461916|NCT05563207|OTHER|traditional Chinese medicine health education standard path|Both groups of patients were given routine treatment, and were intervened by the same batch of nursing staff.During chemotherapy, the patient's condition was closely observed, patiently listened to the patient's chief complaint, answered their questions, and instructed the patient to follow the doctor's instructions to prevent complications such as infection and bleeding.
48461917|NCT05563207|OTHER|The contents of the health intervention mainly included:Graphic and text education|When the patient was admitted to the hospital, the responsible nurse had a comprehensive understanding of the patient's disease cognition and psychological state, and based on this, an individualized intervention plan was formulated. With the help of publicity boards, brochures and other forms of pictures and texts, to popularize the knowledge and precautions of disease treatment for patients
48461918|NCT05563207|OTHER|The contents of the health intervention mainly included:Language education|adopt one-to-one method to inform patients of the principles, effects and precautions of chemotherapy, eliminate patients' misunderstandings, and repeat language education for many times during the treatment process to strengthen patients' memory
48461919|NCT05563207|OTHER|The contents of the health intervention mainly included:Psychological education|guide patients to express their own emotions, according to the patient's personality, cultural background, etc., after communicating with family members and negotiating, selectively inform the patient's actual condition
48461920|NCT05563207|OTHER|The contents of the health intervention mainly included:Dietary education|instruct patients to follow the principles of light, easy to digest and balanced nutrition
48461921|NCT05563207|OTHER|The contents of the health intervention mainly included:Complication education|Actively inform patients about complications in advance, and guide their prevention methods, such as increasing water intake, avoiding activities of affected limbs after chemotherapy, etc. Patients with vomiting, hair loss and other adverse reactions are prone to negative emotions such as anxiety and depression , timely take corresponding measures and appease the patient, inform them that it is a normal phenomenon, and guide them to maintain a good attitude.
48461922|NCT04262739|DRUG|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
48461923|NCT04262739|DRUG|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
48461924|NCT04262739|DRUG|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
48461925|NCT00065949|DRUG|magnesium sulfate|
48461926|NCT00990574|DEVICE|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
48281396|NCT04898114|OTHER|Isotonic saline|Nebulized isotonic saline (4 ml) every 15 minutes
48461927|NCT00990574|DEVICE|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
48461928|NCT00730652|BIOLOGICAL|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
48461929|NCT04703933|OTHER|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
48461930|NCT01055886|DRUG|nicotine patch|Nicotine patch, 7-21 mg.
48461931|NCT01055886|DRUG|placebo patch|placebo patch used from weeks 4-6
48461932|NCT00684801|OTHER|questionnaire administration|Patients complete questionnaires.
48461933|NCT00684801|PROCEDURE|quality-of-life assessment|Patients undergo quality-of-life assessments.
48461934|NCT02517424|DRUG|High THC/Low CBD Cannabis|Dried cannabis
48461935|NCT02517424|DRUG|High THC/High CBD Cannabis|Dried cannabis
48461936|NCT02517424|DRUG|Low THC/Low CBD Cannabis|Dried cannabis
48461937|NCT01993940|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
48461938|NCT01993940|DRUG|Placebo|Placebo tablet taken orally once a day
48461939|NCT02988882|DRUG|Dexamethasone|
48461940|NCT02988882|OTHER|Placebo Vehicle|
48461941|NCT03614728|DRUG|GSK3326595|GSK3326595 will be administered.
48461942|NCT03614728|DRUG|5-Azacitidine|5-Azacitidine will be administered.
48461943|NCT00890916|DEVICE|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
48461944|NCT03086941|DEVICE|I-gel|To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
48461945|NCT01591720|BEHAVIORAL|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
48461946|NCT02629640|OTHER|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
48461947|NCT02629640|OTHER|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
48461948|NCT02629640|OTHER|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
48461949|NCT02629640|OTHER|Blood or buccal sample|Codon-129 genotyping; storage for future research.
48461950|NCT02629640|OTHER|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
48461951|NCT01077505|BIOLOGICAL|albiglutide|albiglutide 50mg weekly subcutaneous injection
48461952|NCT01077505|DRUG|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
48461953|NCT06228196|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
48281397|NCT03574207|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
48461954|NCT05232773|PROCEDURE|Assessment|Evaluation of clinical and kinematic parameters
48461955|NCT05642949|DRUG|MHB036C|MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
48461956|NCT01095887|DRUG|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
48461957|NCT05025033|DRUG|PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate|PD-1 antibody 200mg intravenous drip every 3 weeks; Apatinib 250mg/day; Chemotherapy: Irinotecan 150mg/m2, intravenous drip every 2 weeks, or Paclitaxel 150mg/m2, intravenous drip, once every 3 weeks.
48461958|NCT04133116|DRUG|LY3471851|Administered SC
48461959|NCT04133116|DRUG|Placebo|Administered SC
48461960|NCT03209115|DRUG|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
48461961|NCT03209115|DRUG|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
48461962|NCT02582944|DEVICE|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
48461963|NCT02582944|DEVICE|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
48461964|NCT02582944|DEVICE|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
48461965|NCT02582944|PROCEDURE|Biopsy|
48461966|NCT03064620|BIOLOGICAL|PCV|PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
48461967|NCT05296928|PROCEDURE|laparoscopic incision|laparoscopic umbilical trocar entry pathways
48461968|NCT05469958|OTHER|Hypothermia prevention bundle|pre-warming of the patient for 10 minutes with forced air blankets before the surgery starts, which will be maintained during surgery and during the immediate postoperative period, the intravenous perfusions will be warmed up to 38 Celsius degree (ºC) and the environmental temperature will be controlled at 21 Celsius degree (ºC) during surgery
48461969|NCT05469958|OTHER|Conventional care|the patient will be attended with textile blankets on patient demand
48461970|NCT04763096|DRUG|Advagraf|"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."
48461971|NCT04172480|OTHER|Blood sampling|Peripheral blood sampling on EDTA
48461972|NCT04707963|DIETARY_SUPPLEMENT|Peanut protein powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
48461973|NCT04707963|BEHAVIORAL|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
48461974|NCT04097444|BIOLOGICAL|Bevacizumab|Given IV
48461975|NCT04097444|DRUG|5-fluorouracil|Given IV
48461976|NCT04097444|DRUG|Leucovorin calcium|Given IV
48461977|NCT04097444|DRUG|Irinotecan hydrochloride|Given IV
48461978|NCT04097444|DRUG|Oxaliplatin|Given IV
48461979|NCT04097444|DRUG|Capecitabine|Given PO
48461980|NCT06129123|BEHAVIORAL|Live Free From E-cigarettes|This is a 30-minute online educational program that focuses on providing information about e-cigarette and smoking social norms, harms of e-cigarettes and cigarettes, and ways to quit or reduce using e-cigarettes.
48461981|NCT01626339|DRUG|Intravitreal Ranibizumab|
48461982|NCT01626339|DRUG|Intravitreal bevacizumab|
48461983|NCT04411654|GENETIC|LY3884961|Participants will receive a single dose of LY3884961 administered intracisternally.
48461984|NCT04411654|DRUG|Methylprednisolone|Single IV pulse administered as concomitant medication.
48461985|NCT04411654|DRUG|Sirolimus|Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
48461986|NCT04411654|DRUG|Prednisone|Administered orally as concomitant medication, followed by dose tapering.
48461987|NCT01467362|DRUG|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
48461988|NCT01467362|DRUG|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
48461989|NCT01467362|DRUG|desonide 0.1% cream|cream, once a day (in the evening) during flares
48461990|NCT01467362|OTHER|Foaming gel|for the washing and cleaning
48461991|NCT06179641|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anesthetics around the nerve.
48461992|NCT06179641|PROCEDURE|IPACK block|The IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where nineteen mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anesthetics will be observed above the posterior capsule.
48461993|NCT00674128|DEVICE|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
48461994|NCT00674128|DEVICE|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
48461995|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
48461996|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
48461997|NCT04385043|OTHER|plasma hyperimmune|patients will receive this as add on therapy
48461998|NCT04385043|DRUG|standard therapy|patients will receive only standard therapy for Covid-19 infection
48461999|NCT01206439|DRUG|nebivolol|nebivolol 5 or 10 mg oral, daily
48462000|NCT01292668|DRUG|methyl-5-aminolevulinate hydrochloride cream|Applied topically
48462001|NCT01292668|DRUG|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
48462002|NCT01292668|PROCEDURE|laser therapy|Undergo laser light photodynamic therapy
48462003|NCT01152112|DEVICE|Myomectomy|Removal of fibroids and / or polyps
48462004|NCT03250117|DRUG|Ropinirole oral product|oral immediate-release ropinirole
48462005|NCT03250117|DRUG|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
48462006|NCT02151149|DRUG|nab-paclitaxel|
48462007|NCT02151149|DRUG|Carboplatin|
48462008|NCT05065619|BIOLOGICAL|MT-2766 High dose (3.75 µg)|Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
48462009|NCT05065619|DRUG|Placebo|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
48462010|NCT05065619|BIOLOGICAL|MT-2766 Low dose|Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
48462011|NCT06017427|OTHER|Questionnaires|Submission of several questionnaires (Quality of Life and clinical scores) at three time points: before initiation of Dupilumab, after 6 months of Dupilumab treatment, and 6 months after stopping Dupilumab treatment
48462012|NCT00697918|DRUG|RWJ-333369|100 mg to 400 mg twice daily
48462013|NCT02924649|PROCEDURE|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
48462014|NCT01420614|PROCEDURE|Femoral approach|diagnostic and interventional procedures by femoral artery access
48462015|NCT01420614|PROCEDURE|Radial approach|diagnostic and interventional procedures by radial artery access
48462016|NCT02409797|OTHER|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
48462017|NCT03515473|DEVICE|cochlear implant|cochlear implant surgery
48462018|NCT03099590|DIETARY_SUPPLEMENT|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
48462019|NCT03099590|DIETARY_SUPPLEMENT|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
48462020|NCT01842555|OTHER|Registry|Registry
48462021|NCT01485068|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
48462022|NCT00755235|OTHER|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
48462023|NCT00916045|DRUG|Thiotepa|
48462024|NCT00916045|DRUG|Fludarabine|
48462025|NCT00916045|DRUG|Intravenous busulphan|
48462026|NCT00916045|DRUG|Thymoglobulin|
48462027|NCT00916045|DRUG|Ciclosporin|
48281398|NCT02884635|DRUG|ASP1707|Oral
48462028|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
48462029|NCT00916045|DRUG|Fludarabine|
48462030|NCT00916045|DRUG|Cyclophosphamide|
48462031|NCT00916045|RADIATION|Radiotherapy|
48462032|NCT00916045|DRUG|Thymoglobulin|
48462033|NCT00916045|DRUG|Ciclosporin|
48462034|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
48462035|NCT00916045|DRUG|Fludarabine|
48462036|NCT00916045|DRUG|Melphalan|
48462037|NCT00916045|DRUG|Thymoglobulin|
48462038|NCT00916045|DRUG|Ciclosporin|
48281399|NCT02884635|DRUG|Placebo|Oral
48462039|NCT00916045|DRUG|Mycophenolate mofetil (MMF)|
48462040|NCT00893776|OTHER|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
48462041|NCT04049097|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
48462042|NCT02769741|OTHER|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
48462043|NCT02769741|OTHER|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
48462044|NCT02261181|DEVICE|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
48281400|NCT02884635|DRUG|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
48462045|NCT03237156|DRUG|TAK-906|TAK-906 capsules.
48462046|NCT03237156|DRUG|TAK-906 Placebo|Placebo capsules.
48462047|NCT02643927|BEHAVIORAL|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
48478833|NCT02397213|DRUG|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
48462048|NCT02643927|BEHAVIORAL|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
48462049|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
48462050|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
48462051|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
48462052|NCT01070745|DRUG|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
48462053|NCT01070745|DRUG|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
48462054|NCT03100357|OTHER|Thyroidectomy|Thyroid surgery for benign nodular goiter
48462055|NCT00464386|DEVICE|Continuous Glucose Monitoring|measure glucose levels on burn patients
48462056|NCT05006833|BEHAVIORAL|Brief Provider Training - Bundled Approach|At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
48462057|NCT05006833|BEHAVIORAL|Brief Provider Training - Benefits Approach|At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
48462058|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Bundled Approach|Text messages sent to parents will focus on receiving all three adolescent vaccines.
48281401|NCT05589493|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
48281402|NCT06533592|PROCEDURE|Continous suture technique|Duct-to-duct anastomosis will be performed using continuous suture technique for study group
48462059|NCT05006833|BEHAVIORAL|Parent Interactive Text Message - Benefits Approach|Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
48462060|NCT02323555|OTHER|Paramedic telephone consultation|
48462061|NCT03922750|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
48462062|NCT03922750|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine OD for 16 weeks
48462063|NCT02835157|DRUG|Balanced crystalloid solution|Multiple electrolyte solution as boluses would be administered.
48462064|NCT02835157|DRUG|0.9%sodium chloride|saline as boluses would be administered
48462065|NCT03143049|DRUG|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
48462066|NCT03143049|DRUG|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
48462067|NCT01228539|BEHAVIORAL|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
48462068|NCT01228539|BEHAVIORAL|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
48462069|NCT04651816|BEHAVIORAL|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
48462070|NCT04651816|BEHAVIORAL|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
48462071|NCT04651816|BEHAVIORAL|DPP Program|All Participants will be enrolled in the DPP program.
48462072|NCT00157521|DRUG|L-arginine|
48462073|NCT04438434|DRUG|Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
48462074|NCT04438434|DRUG|Chlorhexidine mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
48478834|NCT02397213|DRUG|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
48478835|NCT01220609|DRUG|Ixabepilone|Given IV
48462075|NCT04438434|OTHER|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
48462076|NCT00286533|PROCEDURE|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
48462077|NCT00286533|PROCEDURE|Questionnaires|Questionnaires are used.
48462078|NCT05436626|PROCEDURE|Early BDI reconstruction without abdominal sepsis control|BDI reconstruction within 6 weeks after the injury without abdominal sepsis control
48462079|NCT05436626|PROCEDURE|Early BDI reconstruction with abdominal sepsis control|BDI reconstruction within 6 weeks after the injury with abdominal sepsis control
48462080|NCT05436626|PROCEDURE|Delayed reconstruction|BDI reconstruction after 6 weeks after the injury
48462081|NCT00914654|DRUG|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
48462082|NCT03647722|OTHER|Assessment of leukocyte function.|The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
48462083|NCT01360138|PROCEDURE|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
48462084|NCT06213792|OTHER|Adaptation of the VOR|Subjects will undergo adaptation of their VOR in virtual reality in two different conditions. The side on which the adaptation will take place and the type of condition with which the patients will start will be randomized. Subject will undergo passive rapid head movements done by an experienced examinator whilst fixing a target in front of them. The movement of the target relative to the movement of the head will increase every 90 seconds by 10% until the movement of the visual scene is twice that of the head movement. In one condition the visual scene will be only a target in a grey void. In the other condition the visual scene will be more complex and represent a target in the room in which the subject is seated. Subjects will undergo both conditions at least 7 days apart.
48462085|NCT04939558|DEVICE|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
48462086|NCT00560326|DRUG|Tacrolimus Ointment 0.03%|Once or twice daily topical application
48462087|NCT00323258|BEHAVIORAL|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
48462088|NCT00323258|DEVICE|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
48462089|NCT00323258|DEVICE|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
48462090|NCT00323258|BEHAVIORAL|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
48462091|NCT00323258|BEHAVIORAL|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
48462092|NCT00323258|BEHAVIORAL|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
48462093|NCT00323258|BEHAVIORAL|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
48462094|NCT00323258|OTHER|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
48462095|NCT01170715|DRUG|Etanercept|self-administered for 52 weeks
48462096|NCT02028455|BIOLOGICAL|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
48462097|NCT00210639|DRUG|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
48462098|NCT00432705|PROCEDURE|Checking stability of ankle|Flexing and walking
48462099|NCT04280224|BIOLOGICAL|NK Cells|twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
48462100|NCT00874549|BIOLOGICAL|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
48462101|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
48462102|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
48281403|NCT06533592|PROCEDURE|Interrupted suture technique|Duct-to-duct anastomosis will be performed using an interrupted suture for control group,
48281404|NCT03315429|DIAGNOSTIC_TEST|stress echocardiography|stress testing of patients with functional mitral regurgitation
48281405|NCT02233842|BEHAVIORAL|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
48462103|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
48462104|NCT02218398|DRUG|Albuterol|
48462105|NCT05915923|PROCEDURE|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
48462106|NCT05915923|PROCEDURE|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
48462107|NCT05915923|PROCEDURE|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
48462108|NCT04083326|DEVICE|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
48462109|NCT04273295|OTHER|Abdominal massage|The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
48462110|NCT01394133|DRUG|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
48462111|NCT01964872|DRUG|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
48462112|NCT01964872|DRUG|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
48462113|NCT01964872|DRUG|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
48462114|NCT01964872|DRUG|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
48462115|NCT01964872|DRUG|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
48462116|NCT01964872|DRUG|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
48462117|NCT01964872|DRUG|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
48462118|NCT03956420|BEHAVIORAL|Premedication visit|detailed information about surgery, anaesthesia and postoperative period
48462119|NCT03956420|DIETARY_SUPPLEMENT|Preoperative period|avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
48462120|NCT03956420|DRUG|Preoperative period|administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
48462121|NCT03956420|OTHER|Postoperative period|Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
48462122|NCT03956420|OTHER|Intraoperative period|deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
48462123|NCT03956420|DRUG|Intraoperative period|Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
48462124|NCT03956420|DRUG|Intraoperative period|Ketamine 30 mg i.v. after induction of anaesthesia
48462125|NCT03956420|DRUG|Intraoperative period|Sevoflurane 1.5 MAC higher in patients \< 60 years old
48462126|NCT03956420|DRUG|Intraoperative period|Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
48462127|NCT03956420|DRUG|Intraoperative period|Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
48462128|NCT03332264|DEVICE|SeQuent Please OTW|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
48462129|NCT03332264|DEVICE|Eluvia Vascular Stent System|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
48462130|NCT03332264|DEVICE|Nitinol stent|Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
48462131|NCT04075916|DRUG|Epclusa|All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
48462132|NCT04554186|PROCEDURE|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
48462133|NCT04554186|PROCEDURE|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
48462134|NCT04554186|PROCEDURE|Control|Place a fentanyl patch 50 microgram
48462135|NCT02407496|OTHER|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
48462136|NCT00170469|BIOLOGICAL|AVA|
48462137|NCT00170469|BIOLOGICAL|rPA vaccine containing alhydrogel|
48462138|NCT05636111|DRUG|Paclitaxel|Given by (IV) vein
48462139|NCT05636111|DRUG|Bevacizumab|Given by (IV) vein
48462140|NCT05636111|DRUG|Lurbinectedin|Given by (IV) vein
48462141|NCT03945916|DIETARY_SUPPLEMENT|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
48462142|NCT03945916|DIETARY_SUPPLEMENT|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
48462143|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
48462144|NCT01559116|DRUG|tiotropium|low dose
48462145|NCT01559116|DRUG|olodaterol|one dose only
48462146|NCT01559116|DRUG|tiotropium|high dose
48462147|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
48462148|NCT01559116|DRUG|Placebo|placebo matching tiotropium+olodaterol FDC
48462149|NCT01559116|DEVICE|Respimat|Respimat inhaler
48462150|NCT01876745|DRUG|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
48462151|NCT03989141|PROCEDURE|Repeated cannulation Buttonhole.|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
48462152|NCT03989141|PROCEDURE|Single cannulation Buttonhole.|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
48462153|NCT00216060|DRUG|Risedronate|Daily oral risedronate combined with androgen deprivation
48462154|NCT00216060|DRUG|Placebo|Daily oral placebo combined with androgen deprivation
48462155|NCT02041013|OTHER|Taking Card|Recordable greeting card-style discharge instruction card
48462156|NCT05511662|OTHER|PRO follow up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
48462157|NCT01654484|DRUG|DE-117|Ophthalmic Solution, QD, 28 Days
48462158|NCT01654484|DRUG|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
48462159|NCT01654484|DRUG|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
48462160|NCT01654484|DRUG|Placebo|Ophthalmic Solution, QD, 28 days
48462161|NCT05734716|DRUG|Erythropoietin|use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
48462162|NCT05734716|DRUG|Iron sucrose (Venofer)|use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
48462163|NCT05734716|DRUG|Sterile Sodium Chloride|sham treatment with sterile saline
48462164|NCT00004216|BIOLOGICAL|salmonella VNP20009|
48462165|NCT00004216|DRUG|cefixime|
48462166|NCT00004216|DRUG|ceftriaxone sodium|
48462167|NCT00004216|DRUG|ciprofloxacin|
48462168|NCT00004216|DRUG|trimethoprim-sulfamethoxazole|
48462169|NCT05385835|OTHER|Training|A training module was prepared by explaining the theoretical and practical parts of the application of blood pressure measurement from the brachial artery with a slide presentation and an animation video. The knowledge and skills of nurses in blood pressure measurement before education were measured. The training module was delivered to the nurses from the online system. At the end of the two-week training period, the knowledge and skill levels of the nurses will be measured again.
48462170|NCT04912063|DRUG|Lemzoparlimab|Intravenous (IV) Infusion
48462171|NCT04912063|DRUG|Azacitidine|Subcutaneous Injection or Intravenous (IV) Injection/Infusion
48462172|NCT04912063|DRUG|Venetoclax|Oral Tablet
48462173|NCT04891692|DEVICE|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
48462174|NCT04568707|OTHER|blood sample|blood sample for serum (serology, biomarkers) and DNA
48462175|NCT00190541|PROCEDURE|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
48462176|NCT00190541|PROCEDURE|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
48462177|NCT01546363|OTHER|Blood draw|phlebotomy
48462178|NCT01380613|BEHAVIORAL|Workshop|10 session intervention
48462179|NCT01380613|BEHAVIORAL|Workshop control|1 session intervention on standard HIV/STD information
48462180|NCT01102907|OTHER|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
48462181|NCT01102907|OTHER|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
48462182|NCT06002386|DEVICE|Vsling|Implantable ventricular repair device
48462183|NCT01834027|BEHAVIORAL|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
48462184|NCT01834027|BEHAVIORAL|No music|In this group no music will be played in PACU
48462185|NCT02931630|OTHER|Whey protein powder|60 g of whey protein powder
48462186|NCT02931630|OTHER|Maltodextrin powder|60 g of Maltodextrin powder
48462187|NCT02931630|OTHER|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
48462188|NCT02931630|OTHER|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
48462189|NCT05650151|DIETARY_SUPPLEMENT|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
48462190|NCT05650151|DIETARY_SUPPLEMENT|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
48462191|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID|vaccination
48462192|NCT02316457|BIOLOGICAL|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
48462193|NCT01090245|BEHAVIORAL|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
48478836|NCT01220609|OTHER|Laboratory Biomarker Analysis|Correlative studies
48462194|NCT01090245|BEHAVIORAL|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
48462195|NCT04189120|PROCEDURE|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
48462196|NCT00858416|DEVICE|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
48462197|NCT00858416|DEVICE|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
48462198|NCT04879927|OTHER|Resource Matching|Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.
48462199|NCT04879927|OTHER|Usual Care|Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
48462200|NCT01940159|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
48462201|NCT01940159|DRUG|Placebo|single oral dose placebo
48462202|NCT00991692|OTHER|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
48462203|NCT02480634|DRUG|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
48462204|NCT02480634|RADIATION|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
48462205|NCT02490800|DRUG|Lisavanbulin Phase 1 dose escalation portion|Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
48462206|NCT02490800|DRUG|Lisavanbulin Phase 2a expansion portion|Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
48462207|NCT04021407|DEVICE|LMA group|patients were ventilated with LMA
48462208|NCT04021407|DEVICE|AirQ group|patients were ventilated with AirQ airway
48462209|NCT01916694|DEVICE|Blue tooth enabled glucose meter with smart phone application|
48462210|NCT01916694|BEHAVIORAL|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
48462211|NCT02086617|OTHER|ultrasound of aorta|
48462212|NCT04721145|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
48462213|NCT03816449|OTHER|exercises|"Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks."
48462214|NCT03736460|BEHAVIORAL|Mindfulness|The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
48462215|NCT03736460|BEHAVIORAL|Physical training|This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
48462216|NCT03294122|RADIATION|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
48462217|NCT03294122|RADIATION|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
48462218|NCT02333162|DRUG|Fludarabine Phosphate|Given IV
48281406|NCT06574035|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
48462219|NCT02333162|DRUG|Melphalan|Given IV
48462220|NCT02333162|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMTMI
48462221|NCT02333162|RADIATION|Total Marrow Irradiation|Undergo IMTMI
48462222|NCT02333162|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
48462223|NCT02333162|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
48462224|NCT02333162|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
48462225|NCT02333162|DRUG|Tacrolimus|Given IV or PO
48462226|NCT02333162|DRUG|Mycophenolate Mofetil|Given IV or PO
48462227|NCT02333162|OTHER|Laboratory Biomarker Analysis|Correlative studies
48462228|NCT03098693|BEHAVIORAL|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
48462229|NCT03098693|BEHAVIORAL|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
48462230|NCT03098693|BEHAVIORAL|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
48462231|NCT00032227|PROCEDURE|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
48462232|NCT00032227|OTHER|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
48462233|NCT00009776|BIOLOGICAL|monoclonal antibody Lym-1|
48462234|NCT00009776|DRUG|cyclosporine|
48462235|NCT00009776|DRUG|paclitaxel|
48462236|NCT00009776|RADIATION|indium In 111 monoclonal antibody Lym-1|
48462237|NCT00009776|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
48462238|NCT00398073|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
48462239|NCT00398073|DEVICE|The Dermal PowderMed® devices|
48462240|NCT00398073|OTHER|intramuscularly (IM injection)|
48462241|NCT02445846|DEVICE|dual HIV/syphilis rapid diagnostics tests|
48462242|NCT03196557|DRUG|Prenisolone|Specified dose on specified days
48462243|NCT03196557|DRUG|Placebo|Specified dose on dose on specified days
48462244|NCT04657315|DRUG|MSC11FCD|"Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration"
48462245|NCT00960596|BEHAVIORAL|Health promotion and health education for smoking habits|We provide the education to intervention group.
48462246|NCT03577561|OTHER|Proficiency Based Progression Training in Phlebotomy|Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
48462247|NCT01625390|DRUG|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
48462248|NCT01625390|DRUG|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
48462249|NCT01625390|DRUG|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
48462250|NCT01588743|DRUG|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
48462251|NCT05646238|OTHER|psychoeducation|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
48462252|NCT05646238|OTHER|training|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles
48462253|NCT02352233|PROCEDURE|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
48462254|NCT00938782|DEVICE|Sedline|
48462255|NCT01614184|DRUG|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
48462256|NCT03333863|OTHER|descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.
48462257|NCT06405854|OTHER|Exercise|Children in the coordinative exercise intervention group will be encouraged to participate in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children. Duration of the intervention is eight weeks,
48478837|NCT05403957|OTHER|TID video|"Main intervention: A video introducing the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 6 screenshots from the video and 6 true or false questions."
48462258|NCT00530660|BIOLOGICAL|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
48462259|NCT04671147|PROCEDURE|Preoperative traction|Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
48462260|NCT02161705|DRUG|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
48462261|NCT02161705|DRUG|Saline|Up to 0.8 mL/kg of normal saline administered
48462262|NCT05775120|DIAGNOSTIC_TEST|OLGA and H.pylori culture|Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
48462263|NCT05685550|DRUG|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
48462264|NCT05341492|BIOLOGICAL|EGFR/B7H3 CAR-T|2 × 10\^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
48462265|NCT05207605|OTHER|Rhythmic Stabilization (RS)|Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes
48462266|NCT05207605|OTHER|McKenzie technique|McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
48462267|NCT06403150|DRUG|Levetiracetam Injection|Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes. After 30 minutes following Levetiracetam needle time reassessment of the patient will be done to determine the outcomes.
48462268|NCT06403150|DRUG|Fosphenytoin Injection|Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
48462269|NCT04065646|OTHER|Mobile|
48462270|NCT01912807|DRUG|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
48462271|NCT01912807|DRUG|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
48462272|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
48462273|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
48462274|NCT04835116|DRUG|Bupivacaine Hydrochloride 0.25% Injection. Paracetamol 650mg. Orphenadrine 50mg.|Group A patients were administered per-operative peri tract local anesthesia infiltration with 0.25% bupivacaine augmented by post-operative oral analgesia with a combination of Paracetamol 650 mg and Orphenadrine 50mg 6 hourly.
48462275|NCT04835116|DRUG|paracetamol 1000mg. Tramadol 50mg. Dimenhydrinate 50mg.|Group B patients were only given post-operative intra-venous analgesia by Paracetamol 1gm intravenous 8 hourly augmented with a combination of Tramadol 50mg and Dimenhydrinate 50mg as and when required
48462276|NCT02156219|OTHER|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~1. Control: Surveillance that men do not use cars corresponding to women.~2. Dosage: Regulation of entry women.~3. Assignment: Of the women, to the part of the platform where the first wagons stop."
48462277|NCT00838162|DRUG|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
48462278|NCT00838162|DRUG|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
48462279|NCT00838162|DRUG|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
48462280|NCT00838162|DRUG|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
48462281|NCT00838162|DRUG|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
48462282|NCT00838162|DRUG|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
48462283|NCT06048848|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
48462284|NCT06048848|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
48462285|NCT06048848|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
48462286|NCT02349022|RADIATION|[89Zr]Df-IAB2M|
48462287|NCT04883450|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
48462288|NCT01087567|DRUG|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
48462289|NCT01087567|DRUG|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
48462290|NCT05768087|RADIATION|Escalated proton therapy|According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
48462291|NCT02398734|DEVICE|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
48462292|NCT02484508|DRUG|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
48462293|NCT02484508|DRUG|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
47935493|NCT02632838|DEVICE|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
48281407|NCT06574035|BEHAVIORAL|Exercise|Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
47935494|NCT05089201|BEHAVIORAL|Animal-assisted interaction|A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
47935495|NCT05089201|BEHAVIORAL|Conversational control|A handler alone will visit participants without a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
48281408|NCT06574035|BEHAVIORAL|Group Discussions - Ongoing Support|Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.
48281409|NCT03180996|DEVICE|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
48462294|NCT03185741|BEHAVIORAL|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
47935496|NCT06142526|DEVICE|DividPro film|DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
47935497|NCT06132828|DRUG|DR30206|Subjects receive DR30206 intravenously
48281410|NCT06656013|BEHAVIORAL|Motivational Interview|After the preparation session, 4 sessions of motivational interviewing will be applied. Motivational interviewing techniques will be used in the interviews to target behavioral change.
48462295|NCT03185741|BEHAVIORAL|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
48462296|NCT03488108|OTHER|Platelet Rich Plasma|Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
48462297|NCT03488108|DRUG|Minoxidil Foam|Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
48462298|NCT04237220|DIAGNOSTIC_TEST|stomach biopsies|To determine the diagnostic performance in the detection of Helicobacter pylori in biopsies taken only from the gastric antrum for the determination of the positive predictive value, the negative predictive value, and sensitivity and specificity.
48462299|NCT01643239|OTHER|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
48462300|NCT01643239|OTHER|Hospital-based mCIT|the mCIT group with individualized intervention
48462301|NCT01643239|OTHER|Hospital-based TR|OT or PT or therapist-based training
48462302|NCT03226613|PROCEDURE|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
48462303|NCT03226613|PROCEDURE|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
48462304|NCT03226613|PROCEDURE|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
48462305|NCT04733456|BEHAVIORAL|Quality of life questionnaires|Mayo Clinic Score (UC) or HBI score (CD), short IBDQ73, \*EQ5D-5L, \*GAD-774, \*PHQ-975, \*PROMIS (Gastrointestinal Belly Pain), Multidimensional Assessment of Interoceptive Awareness (MAIA)77, \*Pain Catastrophizing Scale, Pittsburg Sleep Quality Index (PSQI) and Fatigue Severity Scale (FSS) at baseline and 16 weeks after the start of anti-TNF therapy
48462306|NCT04733456|DEVICE|NIRS|A TechEn NIRSOptix continuous-wave fNIRS system will be used to record changes in cerebral oxygenation, at a sampling rate of 25 Hz
48462307|NCT04733456|OTHER|Stool Collection|For assessment of the known biomarker fecal calprotectin, in addition to fecal bacterial and fungal microbiome
48462308|NCT04733456|OTHER|Blood and urine collection|for inflammatory markers and metabolomic \[IMC\] analysis
48462309|NCT02018263|DRUG|Cocaine hydrochloride|
48462310|NCT02018263|BEHAVIORAL|Exercise|
48462311|NCT02018263|DRUG|Nicotine|
48462312|NCT06468904|PROCEDURE|cervical stabilization exercises and integrated neuromuscular technique.|"Patients received cervical stabilization exercises and integrated neuromuscular inhibition technique. Cervical stabilization protocol included strengthening exercises of deep cervical flexors muscles which included chin tucks, isometric holds, ball squeeze, as well as deep cervical extensors muscles which included cranio-cervical flexion from neutral, upper cervical rotation and extension of cervical spine.~integrated technique includes ischemic compression, muscle energy technique and strain counter strain."
48462313|NCT02369458|DRUG|Mitomycin-C|
48462314|NCT02369458|DRUG|Pegfilgrastim|
48281411|NCT05731947|DRUG|Revumenib|Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
48281412|NCT05731947|DRUG|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
48281413|NCT03433625|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|CBT
48462315|NCT05998291|OTHER|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
48462316|NCT05947409|DRUG|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
48462317|NCT03990233|DRUG|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
48462318|NCT03990233|DRUG|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
48462319|NCT03609749|BEHAVIORAL|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
48462320|NCT04968951|DRUG|Metronidazole|Antibiotic treatment - 250 mg every 6 hrs for 5 days
47935498|NCT02963844|OTHER|Inspiratory Muscle Training|
48281414|NCT05576220|DEVICE|IDION iTempShield|Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
48281415|NCT02896478|OTHER|No intervention. Only observational study|
48281416|NCT06143384|DEVICE|Telemonitoring AirView (ResMed company)|Introduction of AirView telemonitoring of HMV, during a 6-months period.
48462321|NCT04968951|DRUG|Placebo|Placebo treatment
48462322|NCT04968951|DRUG|Vancomycin|Antibiotic treatment - 125 mg every 6 hrs for 5 days
48462323|NCT04968951|BIOLOGICAL|Fecal Microbiota Transplantation|Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.
48462324|NCT02489864|DRUG|Terlipressin|
48462325|NCT01572623|DRUG|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
48462326|NCT01572623|DRUG|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
48462327|NCT05421195|DRUG|corticosteroids therapy|Oral corticosteroids
48462328|NCT05421195|OTHER|Olfactory training|repeat and deliberate sniffing of a set of odorants
48281417|NCT03158402|OTHER|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
48281418|NCT03696784|BIOLOGICAL|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
48281419|NCT03696784|DRUG|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
48462329|NCT01878513|DRUG|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
48462330|NCT03201276|DRUG|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
48462331|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
48462332|NCT01742208|DRUG|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
48462333|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
48462334|NCT01415245|DEVICE|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
48462335|NCT04142658|DRUG|Apixaban 5 MG|"For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
48462336|NCT04142658|DRUG|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
48462337|NCT04142658|DRUG|Warfarin|Active Control Intervention
48462338|NCT04142658|DEVICE|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
48462339|NCT03086434|OTHER|Culturally Tailored Intervention|School-based substance use prevention
48281420|NCT03696784|DRUG|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
48462340|NCT03086434|OTHER|Standard Substance Abuse Education|Class room program
48462341|NCT05430464|DEVICE|1726nm Laser System|Subjects will receive 1726nm laser treatments on one side of the face
48462342|NCT05430464|DEVICE|Sham Laser System|Subjects will receive sham laser treatments on the other side of the face.
48281421|NCT03696784|DRUG|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
48281422|NCT03696784|DRUG|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
48281423|NCT03295305|BEHAVIORAL|Action-Based Cognitive Remediation|
48281424|NCT03295305|BEHAVIORAL|Unstructured support group|
48281425|NCT06011486|COMBINATION_PRODUCT|Lymphocyte infusion (ImmuneCellVir-I)|Infusion of donor CMV specific cells into patients eligible to the trial
48462343|NCT01581164|BIOLOGICAL|Influenza vaccine|Influenza vaccine: Injection, post transplant
48462344|NCT01581164|BIOLOGICAL|Varicella vaccine|Varicella vaccine: Injection, post transplant
48462345|NCT00274625|DEVICE|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
47935499|NCT02963844|OTHER|Inspiratory Muscle Training Sham|
47935500|NCT05791903|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Comfort-orientated care
48281426|NCT04001686|OTHER|incidence aplastic anemia|Ambispective chart review
48462346|NCT00274625|PROCEDURE|Control|Incision is closed without the placement of a graft material (standard of care control)
48462347|NCT03601845|OTHER|Stimuli|Visual stimulation while using additional sequencing
48462348|NCT03601845|OTHER|No stimuli|Additional sequencing only
48462349|NCT04484090|DEVICE|Vertica RF device|The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
48462350|NCT05993390|DRUG|Sugammadex|Intravenous administration of sugammadex 2mg/kg.
48462351|NCT05993390|DRUG|Neostigmine|Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
48462352|NCT00757705|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
48462353|NCT00544492|DEVICE|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
48281427|NCT04007614|OTHER|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
48462354|NCT04914546|DRUG|LY3819469|Administered SC.
48462355|NCT04914546|DRUG|Placebo|Administered SC.
48462356|NCT06445478|OTHER|Blood Flow Restrictive Exercise and Isokinetic Exercise|"Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants."
48462357|NCT00924053|DRUG|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
48462358|NCT00924053|DRUG|Placebo|Placebo capsules to match EGT0001474
48462359|NCT04817969|DEVICE|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
48462360|NCT00088608|DRUG|SOM230 s.c.|
48462361|NCT00997477|DRUG|Foradil Combi (Formoterol-budesonide)|
48462362|NCT04033484|PROCEDURE|Negative Pressure Wound Therapy|The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
48462363|NCT03410030|DRUG|Ascorbic Acid|combination therapy
48462364|NCT03410030|DRUG|Paclitaxel protein-bound|combination therapy
48462365|NCT03410030|DRUG|Cisplatin|combination therapy
48462366|NCT03410030|DRUG|Gemcitabine|combination therapy
48462367|NCT01643434|DRUG|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
48462368|NCT01643434|DRUG|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
48462369|NCT03347058|OTHER|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
48462370|NCT04746976|DRUG|Diroximel Fumarate|As described in the arm.
48462371|NCT00105157|DRUG|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
48462372|NCT00105157|DRUG|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
48462373|NCT00105157|DRUG|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
48462374|NCT00105157|DRUG|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
48462375|NCT00325780|DRUG|Pitavastatin|Pitavastatin 4 mg once daily
48462376|NCT02865824|DRUG|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
48462377|NCT02865824|DRUG|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
48462378|NCT03145987|DIETARY_SUPPLEMENT|Vitis vinifera extract|
48462379|NCT03145987|OTHER|Placebo|
47935501|NCT04623008|BEHAVIORAL|Goal-Oriented Episodic Future Thinking|Individuals in the intervention group will receive a 20-week web-based intervention and individual health coaching focused on stress management, healthy eating and physical activity.
47935502|NCT00686998|DRUG|AZD2624|Oral Suspension
47935503|NCT00686998|DRUG|Olanzapine|PO BID
48462380|NCT04712903|DRUG|Durvalumab|Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
48462381|NCT04712903|DRUG|Cisplatin|Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
48462382|NCT04712903|DRUG|Etoposide|Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
48462383|NCT04712903|DRUG|Carboplatin|Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
48462384|NCT01372930|DRUG|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
48462385|NCT01372930|DRUG|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
48462386|NCT00640341|DEVICE|PureVision Contact Lens|contact lens for daily wear
48462387|NCT00640341|DEVICE|Acuvue Oasys Contact Lens|contact lens for daily wear
48462388|NCT00640341|DEVICE|O2Optix Contact lens|contact lens for daily wear
48462389|NCT01177657|PROCEDURE|Stool sampling|Stool samples collected and checked for the presence of rotavirus
48462390|NCT05554887|OTHER|Thrust manipulation|Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.
48462391|NCT05554887|OTHER|Sham thrust manipulation|The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
48462392|NCT01639664|DEVICE|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
48462393|NCT03141216|DEVICE|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
48462394|NCT03141216|DEVICE|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
48462395|NCT01448434|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
48462396|NCT01448434|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
48462397|NCT05919901|OTHER|HPV Vaccine Communication Strategy|The intervention will include health promotions materials and provision of HPV vaccine
48462398|NCT03784274|BEHAVIORAL|Stakeholder analysis|"• INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~* Respondents who consent to participate in the study.~* Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA)."
48462399|NCT05797480|OTHER|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
48462400|NCT05797480|OTHER|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
47935504|NCT00686998|DRUG|Placebo|
47935505|NCT05868720|DRUG|Risperidone, Aripiprazole|The patients who are randomized to Risperidone group will receive Risperidone at a dose of 1mg/day during the study period that is for 6 weeks. The patients who are randomized to Aripiprazole group will receive Aripiprazole at a dose of 2mg/day during the study period that is for 6 weeks.
47935506|NCT04308811|BIOLOGICAL|platelet rich plasma|Platelet rich plasma and intrauterine balloon applied intrauterine after hysteroscopic adhesiolysis of intrauterine adhesions
48462405|NCT04589364|DRUG|Injection botulinum toxin A ( Dysport 100 unit or Neuronox 33.33 unit)|injection of toxin on facial muscle
48462406|NCT02235870|DEVICE|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
48462407|NCT02235870|DEVICE|Sham Device|Sham Intragastric Balloon
48462408|NCT02235870|BEHAVIORAL|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
48462409|NCT05244928|OTHER|"The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®"|"Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A stepped wedge cluster randomized controlled trial provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total."
48281428|NCT04674943|OTHER|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
48281429|NCT02734563|OTHER|Collagen turnover|Type IV and V collagen synthesis and breakdown
48281430|NCT00957853|DRUG|Cetuximab|First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.
48462410|NCT01503658|DRUG|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
48462411|NCT03117244|OTHER|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
48462412|NCT03117244|OTHER|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
48462413|NCT03008941|BIOLOGICAL|FMT|Capsules with fecal microbiota from healthy donors
48462414|NCT03008941|OTHER|Placebo|Placebo capsules
48462415|NCT03419962|DRUG|MaxSpiolto® Respimat® 160 Characters...|as per the approved SmPC
48462416|NCT03750695|BEHAVIORAL|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
48462417|NCT03750695|BEHAVIORAL|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
48462418|NCT03750695|BEHAVIORAL|Rest|40 minutes of quiet rest in semi-recumbent position
48462419|NCT01119625|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
48462420|NCT01119625|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, one dose
48462421|NCT03058640|OTHER|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes"
48462422|NCT03950674|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
48462423|NCT03950674|DRUG|Cisplatin|IV infusion
48462424|NCT03950674|DRUG|Carboplatin|IV infusion
48462425|NCT03950674|DRUG|Pemetrexed|IV infusion
48462426|NCT03950674|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
48462427|NCT03950674|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
48462428|NCT03950674|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
48281431|NCT00957853|DRUG|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
48281432|NCT00957853|PROCEDURE|Surgical tumor resection|Surgical tumor resection on Day 10.
48281433|NCT06657807|BEHAVIORAL|Online CBT|Online CBT targeting anxiety in pediatric asthma
48281434|NCT06023212|DRUG|Tranexamic Acid|"IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery."
48462429|NCT03950674|DRUG|Saline solution|IV infusion
48462430|NCT02559076|BEHAVIORAL|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
48462431|NCT00944190|BEHAVIORAL|Self-management intervention|Brief counseling technique, self-management,
48462432|NCT00944190|BEHAVIORAL|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
48462433|NCT02039635|DIETARY_SUPPLEMENT|Korean Red Ginseng|Given Orally
48462434|NCT02039635|DIETARY_SUPPLEMENT|Placebo|Given Orally
48478838|NCT05403957|OTHER|TID worksheet|"Main intervention: A worksheet using pictures and texts to introduce the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 8 pictures from the TID worksheet in the main intervention and 6 true or false questions."
48462435|NCT00966628|DRUG|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
48462436|NCT00966628|DRUG|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
48462437|NCT00000595|DRUG|deferoxamine|
48462438|NCT00396630|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
48462439|NCT00396630|BIOLOGICAL|Placebo|Two-dose oral administration.
48462440|NCT01459380|BIOLOGICAL|Bevacizumab|Given IV
48462441|NCT01459380|DRUG|Carboplatin|Given IV
48462442|NCT01459380|OTHER|Laboratory Biomarker Analysis|Correlative studies
48462443|NCT01459380|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48462444|NCT01459380|DRUG|Veliparib|Given PO
48462445|NCT06278090|DRUG|Ursodeoxycholic Acid Only Product|Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months
47935507|NCT04308811|COMBINATION_PRODUCT|amniotic membrane graft group|amniotic membrane applied on the intrauterine balloon after hysteroscopic lysis of intrauterine adhesions
47935508|NCT04308811|DEVICE|Intrauterine balloon|intrauterine balloon applied intrauterine after hysteroscopic lysis of intrauterine adhesions
47935509|NCT00762593|DEVICE|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
47935510|NCT00762593|DEVICE|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
47935511|NCT02985970|OTHER|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
48281435|NCT06023212|DRUG|stroke-physiological saline solution (SPSS)|IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
47935512|NCT03671278|OTHER|STarT Back Screening Tool Approach|Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
47935513|NCT01949285|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
47935514|NCT02477137|DEVICE|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
47935515|NCT04432220|DRUG|Anticoagulation group(Apixaban group)|Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
47935516|NCT01727778|BIOLOGICAL|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
47935517|NCT00088036|DRUG|Olanzapine|
48281436|NCT05366829|DRUG|Tislelizumab|Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
48281437|NCT06123156|DRUG|Sildenafil|Sildénafil during 10 months (50mg daily), start 30 days after surgery
48281438|NCT06123156|OTHER|Placebo|1 platelet during 10 months (daily), start 30 days after surgery
48462446|NCT05869162|DRUG|SY-3505|A Third-generation ALK TKI
48462447|NCT05951088|PROCEDURE|Cardio2U follow-up|During the follow-up period, participants will have access to the application and will be able to explore the different modules. At fixed time points, the application will allow them to fill in questionnaires about the application's usability and patient satisfaction. App user data will track how long and how often patients visit the application and which aspects are mostly used. In addition, at different time points during the study, patients will be asked to complete clinical questionnaires regarding e.g. patients' knowledge and self-care abilities. The results of these questionnaires can be used in a more clinical way as they will be accessible to doctors and nurses in the healthcare provider dashboard and can support targeted patient follow-up and guidance
48462448|NCT00616993|DRUG|Difluprednate|Difluprednate
48462449|NCT00616993|OTHER|Placebo|Vehicle
48462450|NCT02305134|DRUG|Tipepidine Hibenzate|
48462451|NCT02305134|DRUG|Placebo|
48462452|NCT04478526|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
48462453|NCT04478526|BEHAVIORAL|Electronic Cognitive Behavioural Therapy|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session was designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
48281439|NCT04297007|OTHER|PECS block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
48281440|NCT04297007|OTHER|Rhomboid intercostal block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
48462454|NCT03601585|DEVICE|Comparison of dental biofilm removal.|Comparison of the use of 4 methods for dental biofilm removal
48462455|NCT03475433|DEVICE|Actigraphy device|Both groups will receive an actigraphy device that will passively measure their movement data.
48462456|NCT00327691|DRUG|Atorvastatin|
48462457|NCT00427154|DRUG|rosiglitazone|Tablets, 4 mg once or twice daily.
48281441|NCT05493514|DEVICE|Robotic Assisted Gait Training with G-EO system|Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
48462458|NCT00427154|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
48462459|NCT00427154|DRUG|metformin|Tablets, 2000 mg/day.
48462460|NCT00427154|DRUG|glimepiride|Tablets, 8 mg/day.
48462461|NCT02159820|DRUG|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
48462462|NCT02159820|DRUG|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
48281442|NCT01261676|OTHER|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
48462463|NCT05423873|OTHER|Gentle Cleansing Lotion, Revision Skincare|Gentle cleansing lotion to be used by study participants twice daily
48462464|NCT04800926|DEVICE|Xavier wheelchair controller|Controlling a wheelchair using the Xavier surface EMG system
47935518|NCT05475613|PROCEDURE|Downstaging procedures containing immunotherapy|Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
47935519|NCT05475613|PROCEDURE|Liver transplantation|Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
48462465|NCT04167696|BIOLOGICAL|CYAD-02|CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
47935520|NCT02164149|OTHER|Patients with primary colon cancer|CT scan two days after surgery
47935521|NCT01594437|BIOLOGICAL|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
47935522|NCT01594437|BIOLOGICAL|Placebo|One or two doses administered by intravenous infusion.
47935523|NCT01946906|DRUG|Rifaximin|
47935524|NCT05683184|DRUG|[11C]OMAR|For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.
47935525|NCT06286371|PROCEDURE|Laparoscopic Endometriosis Surgery|Laparoscopic Excision of Deep Endometriotic Nodule related to pelvic pain
47935526|NCT03954327|DRUG|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)|Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
48462466|NCT04167696|DRUG|ENDOXAN|administered as preconditioning chemotherapy
48462467|NCT04167696|DRUG|Fludara|administered as preconditioning chemotherapy
48462468|NCT04804839|OTHER|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
48462469|NCT04804839|OTHER|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
48462470|NCT04804839|OTHER|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
48462471|NCT04548544|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
48462472|NCT01878435|OTHER|SMS reminder|
48462473|NCT01878435|OTHER|Travel subsidy|
48462474|NCT01878435|OTHER|Travel subsidy 2|
48462475|NCT04595669|BEHAVIORAL|Personalised advise|personalised dietary advice in combination with feedback on dietary behaviour and health status (i.e. waist circumference, blood pressure, cholesterol, glucose and triglycerides)
48462476|NCT01884844|DRUG|Vitamin D3, Cholecalciferol|
48462477|NCT01884844|DRUG|Placebo|
47935527|NCT03954327|DRUG|Raltegravir|Raltegravir (RTF) 600 mg two tablets by mouth once per day
47935528|NCT03954327|DRUG|Placebo Oral Capsule [CEBOCAP]|Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
47935529|NCT05526209|PROCEDURE|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia|using longitudinal relaxing incision as a technique for recurrence prevention in ventral hernia
47935530|NCT02551250|DEVICE|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
47935531|NCT02551250|DEVICE|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
48281443|NCT03672318|DRUG|CAR138 T Cells|"The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days."
48281444|NCT03944837|OTHER|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
48281445|NCT04281797|DIAGNOSTIC_TEST|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
48281446|NCT00371319|DRUG|tacrolimus|0.06-0.1 mg/kg/day
48462478|NCT03212651|DRUG|Pembrolizumab|Pembrolizumab 200mg IV infusion
48462479|NCT02702635|PROCEDURE|DCE MRI of the brain|An MRI of the brain including a DCE sequence
48462480|NCT01721551|OTHER|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
48462481|NCT01721551|OTHER|Usual Treatment|The CON group received no intervention but the usual treatment
48462482|NCT06316180|DRUG|drospirenone/estetrol 3mg/14.2mg|Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
48462483|NCT00858403|DRUG|Dasatinib|Take tablets of Dasatinib by mouth once a day.
48462484|NCT02609191|DEVICE|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
48462485|NCT02609191|DEVICE|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
48462486|NCT02609191|DEVICE|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
48462487|NCT04780451|DIETARY_SUPPLEMENT|Omega-3 supplementation in recreational runners|Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.
48462488|NCT00000205|DRUG|Buprenorphine|
48462489|NCT02359539|PROCEDURE|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
48462490|NCT02928627|OTHER|Analysis of microRNA expression|sample analysis
48462491|NCT02687789|OTHER|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
47935532|NCT03420027|OTHER|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
47935533|NCT01604759|DEVICE|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
47935534|NCT04293627|BEHAVIORAL|ATTAIN|ATTAIN is an 8-step model to identify co-occurring mental health conditions and facilitate linkage to mental health services for youth with an existing autism spectrum disorder diagnosis.
47935535|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
47935536|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
48462492|NCT02687789|OTHER|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
48462493|NCT04715906|BEHAVIORAL|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
48099107|NCT06631794|BEHAVIORAL|A short talk about the importance of HPV vaccination|"Investigator plan to set up a short talk to 3rd grade classes in addition to the usual sexual health training. The issue of HPV vaccination will be systematically addressed for 10 minutes to encourage catch-up vaccination.~The usual training include different themes such us : definition of sexual health, anatomy, sexually transmitted infections contraception/condoms, menstrual cycles, voluntary interruption of pregnancy, consent, sexual abuse/violence/harassment, pornography, anti-discrimination....~A 45-minute talk will include 2 or 3 topics from the above list. A ten minutes of talk will be added to the usual training to explain the HPV vaccination (a topic not usually addressed in sexual health training), covering the following elements: definition of HPV infection"
48462494|NCT05348928|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
48462495|NCT05348928|OTHER|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
48462496|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
48462497|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
48462498|NCT02573662|BIOLOGICAL|Blood and Urine sampling|Blood and Urine Sampling
48462499|NCT02573662|RADIATION|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
48281447|NCT00371319|DRUG|mycophenolate mofetil|2-3 gm/day
48462500|NCT02573662|BIOLOGICAL|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
48462501|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
47935537|NCT00498056|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
48462502|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
48462503|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
48462504|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
47935538|NCT00498056|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
47935539|NCT00531674|DIETARY_SUPPLEMENT|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
47935540|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
47935541|NCT00531674|DIETARY_SUPPLEMENT|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
47935542|NCT00531674|DIETARY_SUPPLEMENT|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
47935543|NCT00531674|DIETARY_SUPPLEMENT|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
48281448|NCT04986501|DEVICE|MucoPEG|Experimental
48281449|NCT04986501|DEVICE|Biotene|Active Comparator
48281450|NCT06260787|PROCEDURE|In Vitro Fertilisation|Assisted reproductive technology in the form of in vitro fertilisation
48281451|NCT02120417|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
48281452|NCT02120417|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
48281453|NCT02120417|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
48462505|NCT04425031|DRUG|Low oxygenation target|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
48462506|NCT04425031|DRUG|High oxygenation target|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
47935544|NCT00531674|DIETARY_SUPPLEMENT|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
47935545|NCT05072327|PROCEDURE|Mohs surgery|Mohs surgery of eyelid
47935546|NCT05072327|PROCEDURE|cryotherapy|cryotherapy of eyelid
47935547|NCT02593045|BIOLOGICAL|IPH4102|
47935548|NCT03050749|DEVICE|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
47935549|NCT03585127|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
48462507|NCT02404558|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
48462508|NCT02404558|DRUG|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
48462509|NCT02942810|DRUG|WCK 5222|IV infusion over a period of 60 minutes
48462510|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
48462511|NCT00945438|BIOLOGICAL|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
48462512|NCT01406249|DRUG|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
48462513|NCT01406249|DRUG|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
48462514|NCT05508490|DIAGNOSTIC_TEST|renal chemistry, serum electrolyte,|detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis
48462515|NCT05913115|DRUG|FPA144|FPA144 will be administered intravenously Q2W.
48462516|NCT04929821|DEVICE|Biliary Duct Stenting|UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
48462517|NCT01967901|BEHAVIORAL|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
48462518|NCT05613426|DRUG|Rosuvastatin 20 mg|Very early use of Rosuvastatin before primary PCI in anterior STEMI
48462519|NCT05613426|DRUG|Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]|Very early use of Evolocumab before primary PCI in anterior STEMI
48462520|NCT03885934|BIOLOGICAL|V114|V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
48462521|NCT03885934|BIOLOGICAL|Prevnar 13®|Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
48462522|NCT05531136|OTHER|Foot strengthening training|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
48462523|NCT00144222|DRUG|Telmisartan 40 mg/HCTZ 12.5 mg|
48462524|NCT00144222|DRUG|Telmisartan 40 mg|
48462525|NCT01116791|PROCEDURE|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"* CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~* HIPC is administered immediately after CRS"
48462526|NCT06363240|DEVICE|Broadband Light|Broadband Light treatment
48462527|NCT01156987|DEVICE|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~* an IV line is placed by nurse,~* patient is placed in the 4 T MRI scanner at CMRR,~* initial scout images and manual linear shims are adjusted,~* Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~* continuous SWIFT acquisition begins immediately before contrast injection,~* contrast injection,~* continuous SWIFT acquisition continues for 12 min after contrast,~* late enhancement images may also be obtained.~  10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
48462528|NCT04303624|OTHER|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
48462529|NCT03924154|DRUG|RVT-1201|RVT-1201 600 mg immediate-release tablet
47935550|NCT03585127|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
47935551|NCT00434395|DRUG|MOA-728|
47935552|NCT01799382|OTHER|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
47935553|NCT01799382|DEVICE|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
48462530|NCT03924154|DRUG|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
48462531|NCT00310492|BIOLOGICAL|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
48462532|NCT06154993|OTHER|static opening with slider+ Conventional PT|"Patient supine Maintaining neck flexion + contralateral flexion and rotation and applying median nerve slider mobilization while maintaining the neck static in mentioned position.~Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
48462533|NCT06154993|OTHER|dynamic opener with slider + Conventional PT|"Patient supine Neck flexion + contralateral flexion and rotation. And sliding the median nerve along with neck movement from contralateral flexion+rotation to neutal position in repetitive manner, by releasing tension from median nerve when bringing neck in neutral to ease tension from affected side.~Conventional PT includes hot pack for 10 mins and cervical isometrics. Frequency: 3 sets of 10 reps with 5 sec hold for 3 times/week for 4 weeks.~Duration: 30-40 mins"
48462534|NCT02028416|DRUG|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
48462535|NCT04416750|DRUG|Imatinib Mesylate|Treatment with Imatinib
48462536|NCT03387462|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
48462537|NCT03387462|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
48462538|NCT02577133|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
48462539|NCT02577133|DIETARY_SUPPLEMENT|Placebo|The placebo consisted of an identical bottle with distilled water
48462540|NCT04594434|OTHER|Scale SUD|Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
48099108|NCT04343807|PROCEDURE|PECS Block|PECS nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
48099109|NCT04343807|OTHER|Control Group|No nerve block will be performed and only intravenous nalbuphine will be given.
48462541|NCT04594434|OTHER|VOC scale|The VOC (Validity Of Cognition) scale is a scale of value given to cognition.
47935554|NCT01046760|BEHAVIORAL|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
48099110|NCT00069862|DRUG|Deferitrin (GT56-252)|
47935555|NCT06192589|DRUG|Cannabidiol|Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.
48099111|NCT00069862|DRUG|desferoxamine (DFO)|
48099112|NCT06179095|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI just before the intrauterine device insertion procedure, and again with STAI after the procedure.
48099113|NCT00904527|BEHAVIORAL|relaxation (Schultz)|Patients have relaxation consultations during 2 months
48281454|NCT03420638|DRUG|Adjunct Exparel (bupivacaine liposome suspension 1.3%)|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
47935556|NCT06192589|DRUG|Placebo|Placebo will be administered orally twice daily for 28 days in Part 1
47935557|NCT06192589|DRUG|Citalopram|Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.
47935558|NCT06192589|DRUG|Morphine|Morphine will be administered once at 15 mg on days 1, 4, and 11.
47935559|NCT03969966|OTHER|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
47935560|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
48099114|NCT06630975|DEVICE|Hemiepiphysiodesis|8 plate
48099115|NCT06630975|PROCEDURE|Eight-Plates first described by Stevens are simple to use|fewer complications in terms of implant loosening and fracture can be expected.Good results as well as low rebound and complication rates have been recorded
48462542|NCT04594434|OTHER|DES II scale|The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
48462543|NCT05012462|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
47935561|NCT04179890|DRUG|Erlotinib (Tarceva®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
47935562|NCT04179890|DRUG|Gefitinib (IRESSA®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
47935563|NCT04179890|DRUG|Osimertinib (Tagrisso®)|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
47935564|NCT04179890|DRUG|Afatinib (Gi(l)otrif®)|As first line therapy.
48099116|NCT06630975|DEVICE|Hemiepiphysiodesis by eight Plate|Extraperiosteal eight plate insertion
48462544|NCT01451541|DRUG|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
48462545|NCT01451541|DRUG|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
48462546|NCT01451541|DRUG|Placebo|Placebo - one dose per nostril
47935565|NCT04179890|DRUG|Osimertinib (Tagrisso®)|In the case the T790M resistance mutation was developed (second line therapy).
47935566|NCT00045721|DRUG|O6-benzylguanine|
47935567|NCT00045721|DRUG|polifeprosan 20 with carmustine implant|
47935568|NCT00045721|PROCEDURE|adjuvant therapy|
47935569|NCT00045721|PROCEDURE|conventional surgery|
47935570|NCT00045721|PROCEDURE|neoadjuvant therapy|
47935571|NCT04475809|PROCEDURE|group C|laparoscopy will be performed with 14-16 mmHg intra-abdominal pressure. At the end of the procedure routine method for CO2 removal, passive exsufflation, will be used by applying gentle abdominal pressure to evacuate the residual gas through the port site.
47935572|NCT04475809|PROCEDURE|Group L|laparoscopy will be performed with 8-10 mmHg intra-abdominal pressure and routine passive exsufflation will be applied for CO2 removal at the end of the procedure.
48462547|NCT01929681|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
47935573|NCT04475809|PROCEDURE|Group LR|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure pulmonary recruitment maneuver (PRM) will be done; which consists of five manual pulmonary inflations at a maximum pressure of 40 cm H2O and the fifth will be held for 5 seconds. During this procedure, the surgeon is instructed to keep the port sleeve valve fully opened to allow the CO2 to escape the abdominal cavity.
48462548|NCT01506349|DIETARY_SUPPLEMENT|gluten|4 grams of gluten.
48462549|NCT01506349|DIETARY_SUPPLEMENT|Placebo|
48462550|NCT05200442|DRUG|VS-6766/avutometinib|An oral anti-cancer medication.
48462551|NCT05200442|DRUG|Cetuximab|A chemotherapy drug used to treat head, neck and colorectal cancer.
48462552|NCT05200442|OTHER|Pill Diary|A diary where participants in phase 2 of study will log their medications and times they are taken on study.
48462553|NCT00006258|BIOLOGICAL|filgrastim|
48462554|NCT00006258|DRUG|cisplatin|
48462555|NCT00006258|DRUG|cyclophosphamide|
48462556|NCT00006258|DRUG|etoposide|
48462557|NCT00006258|DRUG|methotrexate|
48281455|NCT03420638|OTHER|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
48462558|NCT00006258|DRUG|vincristine sulfate|
48462559|NCT00006258|PROCEDURE|adjuvant therapy|
48462560|NCT00006258|RADIATION|radiation therapy|
48462561|NCT00722436|DRUG|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
48462562|NCT00722436|DRUG|saline|Placebo
48462563|NCT01158053|DEVICE|FFR and VH-IVUS|"* Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) \>48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~* No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~* FFR followed by VH-IVUS of study lesion(s)~* Any additional PCI based on routine clinical practice and FFR/IVUS data?~* If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~* If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
48462564|NCT01158053|DEVICE|IVUS and FFR|
48462565|NCT01614262|OTHER|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
48462566|NCT04631133|DEVICE|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
48462567|NCT04791007|DRUG|OB-002|vaginal or rectal administration
48281456|NCT01880450|BEHAVIORAL|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
48462568|NCT04791007|DRUG|Placebo|vaginal or rectal administration
48462569|NCT05339191|BEHAVIORAL|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
48462570|NCT04292691|DRUG|40ml of Ropivacaine 0.5% Injectable Solution|already outlined in the arm/group description
47935574|NCT04475809|PROCEDURE|Group LS|the intra-abdominal pressure will be kept at 8-10 mmHg during laparoscopy. At the end of the procedure, intraperitoneal normal saline (IPS) will be infused for removal of the intra-abdominal CO2; in which we fill the upper part of the abdominal cavity evenly and bilaterally with isotonic normal saline (15-20 mL/kg body weight)
48462571|NCT04292691|DRUG|40ml of Ringer's Lactate|already outlined in the arm/group description
48462572|NCT06504355|BEHAVIORAL|Training program incorporating video aerobic exercise, action video game and resistive action video game|Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session.
48462573|NCT04204590|OTHER|Deprescribing algorithm|For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
48462574|NCT02847624|DRUG|tolvaptan|
48462575|NCT05158660|DEVICE|transcranial duplex sonography|it is an imaging device that will measure the intracerebral hematoma expansion
48462576|NCT01896934|DRUG|Sertraline|50-200mg daily
48462577|NCT03266276|OTHER|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
48462578|NCT05729854|OTHER|acupressure ( traditional and complementary medicine)|Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
48462579|NCT01567527|DRUG|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
48462580|NCT01567527|DRUG|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
48462581|NCT05204537|PROCEDURE|Lung parenchyma resection|Lung parenchyma removal
48462582|NCT05204537|PROCEDURE|Empyemectomy|Intrapleural cavity effusion removal, parietal pleura removal.
48462583|NCT04050943|OTHER|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
48462584|NCT01436448|DRUG|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
48462585|NCT01291862|DEVICE|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
48462586|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
48462587|NCT01193387|DRUG|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
48462588|NCT01675973|DRUG|RANEXA|500mg BID up to 1000mg BID
48462589|NCT00008060|DRUG|FOLFIRI regimen|
48462590|NCT00008060|DRUG|FOLFOX regimen|
48462591|NCT00008060|DRUG|fluorouracil|
48462592|NCT00008060|DRUG|irinotecan hydrochloride|
48462593|NCT00008060|DRUG|leucovorin calcium|
48462594|NCT00008060|DRUG|oxaliplatin|
48462595|NCT00135187|DRUG|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."
48462596|NCT00135187|DRUG|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
48462597|NCT00135187|DRUG|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
47935575|NCT03373799|OTHER|Video-Based Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
48462598|NCT03234907|DRUG|Vedolizumab IV|Vedolizumab IV infusion
48462599|NCT03234907|DRUG|Placebo|Vedolizumab placebo-matching
48462600|NCT01304979|PROCEDURE|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
48462601|NCT01304979|PROCEDURE|Control|Indirect therapies that mimic direct therapy intervention
48099120|NCT06630182|OTHER|Bortner self-questionnaire|14 items
48099121|NCT06630182|OTHER|Self-questionnaire BFI-10|10 items
48099122|NCT00170573|DRUG|Caelyx|Caelyx 40 mg/ m2biweekly
48281457|NCT01880450|BEHAVIORAL|TEEN|Control condition the promote communication, decision-making skills etc.
48281458|NCT00839111|DRUG|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
48462602|NCT04728620|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
48462603|NCT04163094|DRUG|W_ova1 Vaccine|Patients will be treated with a W_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
48462604|NCT00372996|DRUG|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
48462605|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day.
48462606|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
48462607|NCT00372996|DRUG|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
48462608|NCT03201341|OTHER|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
48462609|NCT03201341|OTHER|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
48462610|NCT03201341|OTHER|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
48462611|NCT03201341|OTHER|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
48462612|NCT03201341|OTHER|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
48462613|NCT03201341|OTHER|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
48462614|NCT03201341|OTHER|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (\~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
48462615|NCT03201341|OTHER|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
48462616|NCT00616096|PROCEDURE|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
48462617|NCT04518553|DRUG|active comarator using antiviral drug of nucleoside analogues|using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.
48462618|NCT04518553|DEVICE|HA+purification|Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
48462619|NCT03458845|DIAGNOSTIC_TEST|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
48462620|NCT05721157|OTHER|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
48462621|NCT01529164|DRUG|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
48462622|NCT01529164|DRUG|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
48462623|NCT01529164|DRUG|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
48462624|NCT01529164|DRUG|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
48462625|NCT04182555|DEVICE|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
48462626|NCT04182555|DIAGNOSTIC_TEST|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
48462627|NCT04182555|DEVICE|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
48462628|NCT04182555|OTHER|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
48462629|NCT02581527|DRUG|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
48462630|NCT02581527|DRUG|Isoniazid|Isoniazid 75mg - all arms
48462631|NCT02581527|DRUG|Ethambutol|Ethambutol 275mg - all arms
48462632|NCT02581527|DRUG|Pyrazinamide|Pyrazinamide 400mg - all arms
48462633|NCT01457196|DIAGNOSTIC_TEST|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
48462634|NCT03100019|DIETARY_SUPPLEMENT|Resveratrol|
47935576|NCT03373799|OTHER|Physiotherapist-Supervised Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
47935577|NCT00066144|DRUG|Cimicifuga racemosa|
48462635|NCT03100019|DRUG|Placebo|
48462636|NCT05948072|DRUG|mFOLFOX6 + Cetuximab|Cetuximab + mFOLFOX6: Cetuximab (500mg/m2 IV ) will be given. Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
48462637|NCT05948072|DRUG|mFOLFOX 6|mFOLFOX6: Oxaliplatin (85 mg/m2 IV over 2 h on day 1), Leucovorin calcium (350 mg/m2 IV over 2 h on day 1) plus a bolus of 5FU (400 mg/m2) followed by a 46h-48h IV infusion of 5FU 2400 mg/m2 will be repeated for every 2 weeks. The regimens repeat every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
47935578|NCT00066144|DRUG|Trifolium pratense|
47935579|NCT00066144|DRUG|Black cohosh|
47935580|NCT00066144|DRUG|Red clover|
48462638|NCT05081193|DRUG|Testosterone Undecanoate|198mg taken twice daily
48462639|NCT05081193|DRUG|Enzalutamide|160mg taken once daily
48462640|NCT02812381|PROCEDURE|KT|to aplicate neuromuscular bandage technique(KT)
48462641|NCT02812381|PROCEDURE|SCS|To aplicate strain-counterstrain above trigger point
48462642|NCT04202705|DRUG|SYD1875|SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
48462643|NCT00000380|DRUG|GHRH|
48462644|NCT04572854|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
48281459|NCT00839111|DRUG|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
48281460|NCT02262637|DRUG|Micardis®|
48462645|NCT00978458|DRUG|temozolomide|Given orally
48462646|NCT00978458|RADIATION|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
48462647|NCT00978458|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
48462648|NCT04008680|OTHER|EQ-5D-5L survey internal consistency|To see how increasing the number of questionnaires affects the internal consistency of the EQ-5D-5L.
48462649|NCT01183884|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in \> or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
48462650|NCT00471094|DRUG|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
48462651|NCT00471094|DRUG|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
48462652|NCT00471094|DRUG|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
48462653|NCT00471094|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
48462654|NCT04230876|BEHAVIORAL|Auditory Brian Training Games/Activities|Game-based activities that encourage listening to words and sentences in noisy situations. Participants will receive subscriptions to the clEAR online auditory training activities and recommended protocol for those who recently received new hearing aids.
48281461|NCT02262637|DRUG|MicardisPlus®|
48281462|NCT02247869|DRUG|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
48462655|NCT01189747|BIOLOGICAL|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
48462656|NCT01189747|DRUG|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
48462657|NCT02233751|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Randomization then administration of combination product study medication according to group assignment
48462658|NCT02218541|DEVICE|abutment margin 0.5 mm subgingival|
48281463|NCT02153840|DRUG|PSORI-CM01（YXBCM01） granule|
48281464|NCT02153840|DRUG|placebo|
48281465|NCT03803215|DRUG|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
48281466|NCT02362607|BEHAVIORAL|Integrated Diabetes Management Protocol|
48281467|NCT02362607|BEHAVIORAL|Standard Diabetes Management Protocol|
48462659|NCT02218541|DEVICE|abutment margin 1.5 mm subgingival|
48462660|NCT05361057|DRUG|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
48462661|NCT05361057|DRUG|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
48462662|NCT02232945|DRUG|placebo of oseltamivir phosphate|
48462663|NCT02232945|DRUG|oseltamivir phosphate|
48462664|NCT02232945|DRUG|Banlangen (Radix Isatidis) granules|
48462665|NCT02232945|DRUG|placebo of Banlangen(Radix Isatidis) granules|
48462666|NCT05779943|DRUG|Furosemide|Given IV
48462667|NCT05779943|OTHER|F18-rhPSMA-7.3|Given IV
48462668|NCT05779943|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48462669|NCT05779943|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48462670|NCT02451696|DRUG|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
48462671|NCT00213551|DRUG|Glutamine|
48462672|NCT00213551|DRUG|Glucose|
48462673|NCT00213551|DRUG|glutamine-antioxidants containing solution|
48462674|NCT04309162|OTHER|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
48462675|NCT00021541|DRUG|tipifarnib|Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
48462676|NCT00021541|OTHER|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
48462677|NCT05028855|DIAGNOSTIC_TEST|Cerebral autoregulation assessment|Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
48462678|NCT01485718|DIETARY_SUPPLEMENT|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
48462679|NCT01485718|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
48462680|NCT01554111|DRUG|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
48462681|NCT01554111|DRUG|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
48623214|NCT04028960|DEVICE|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
48462682|NCT01554111|DRUG|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
47935581|NCT02519673|DEVICE|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
48462683|NCT02144844|BEHAVIORAL|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
48462684|NCT01828112|DRUG|Ceritinib|Ceritinib is the investigational treatment and is referred to as the investigational study drug and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
48462685|NCT01828112|DRUG|pemetrexed|Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m2 every 21 days.
48462686|NCT01828112|DRUG|docetaxel|Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m2 every 21 days.
47935582|NCT06073990|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTi)|The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
47935583|NCT03818984|BEHAVIORAL|Safer Conception for Men with At Risk Partners|CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
47935584|NCT06035055|DRUG|Ceftolozane/tazobactam|9g ceftolozane/tazobactam in 240 millilitres 0.9% sodium chloride IV infusion given over 24 hours for 10-14 days
47935585|NCT03877081|BIOLOGICAL|Probiotics|Administration of oral probiotics with 2 doses a day
47935586|NCT03877081|OTHER|Placebo|Administration of oral placebo with 2 doses a day
47935587|NCT00407290|DRUG|neostigmine|
48462687|NCT03714373|DRUG|DCCR|Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
48462688|NCT03714373|DRUG|DCCR|Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
48462689|NCT03714373|DRUG|Placebo for DCCR|Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
48462690|NCT01756313|PROCEDURE|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
48462691|NCT06105580|PROCEDURE|Conduction system pacing|Conduction system pacing implant as a Resynchronization therapy.
48462692|NCT06105580|PROCEDURE|Biventricular pacing|Biventricular pacing implant
48478839|NCT05403957|OTHER|SSB worksheet|"Main intervention: A worksheet using pictures and texts to introduce the beverage industry's marketing tactics to attract children and adolescents to drink SSBs and the health risks of SSBs.~Booster intervention: 8 pictures from the SSB worksheet in the main intervention and 6 true or false questions."
48623215|NCT02371811|DEVICE|uterine manipulator (v care)|
48623216|NCT00496457|DRUG|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
48623217|NCT00496457|DRUG|Placebo comparator|4 Capsules of PBO per day before noon meal
48623218|NCT01091259|DRUG|Irinotecan|
48623219|NCT01091259|DRUG|Bevacizumab|
48623220|NCT02151201|BEHAVIORAL|Influenza vaccination video education|Influenza vaccination video education
48623221|NCT02151201|BEHAVIORAL|Hand washing video education|Hand washing video education
48462693|NCT05363241|PROCEDURE|Cooled radiofrequency in classical targets (CRF-CT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.
48462694|NCT05363241|PROCEDURE|Cooled radiofrequency in revised targets (CRF-RT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
47935588|NCT03462290|DRUG|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
48099123|NCT06314594|PROCEDURE|Conventional treatment|Patients will randomly assigned to routine treatment group (control group) and individualized treatment model group (intervention group). All patients will observed and intervened for 4 months. Patients in the control treatment group will follow the treatment plan in the 2016SOSORT guidelines
48462695|NCT02946255|BEHAVIORAL|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
48462696|NCT02946255|BEHAVIORAL|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
48462697|NCT02946255|BEHAVIORAL|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
48462698|NCT04965233|BEHAVIORAL|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
48462699|NCT04965233|BEHAVIORAL|Information reports|Reports containing general information on eczema
48462700|NCT02751424|DRUG|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
48462701|NCT02751424|DRUG|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
48462702|NCT05255549|PROCEDURE|ESWT + Stretching|"3 weeks intervention:~* 3 sessions of ESWT, once a week~* 6 sessions of passive stretching, twice a week"
48623222|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
48623223|NCT03360968|PROCEDURE|SPN-CPAP/PS|SPN-CPAP/PS mode switched on for 1 hour
47935589|NCT03462290|DRUG|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
47935590|NCT00773383|DRUG|RG1507|iv 9mg/kg weekly
47935591|NCT00773383|DRUG|erlotinib [Tarceva]|150mg oral daily
47935592|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/1litter of water, 3drinks a day, daily for 1week (7 days) (current recommendation).
47935593|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
47935594|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
47935595|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
48623224|NCT03360968|PROCEDURE|Variable-PS|Variable-PS mode switched on for 1 hour
48623225|NCT02115477|PROCEDURE|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
48623226|NCT00042146|BEHAVIORAL|Cognitive-behavior therapy|
48623227|NCT00042146|DRUG|zolpidem|
48623228|NCT02253498|DEVICE|deep brain stimulation (DBS)|
48623229|NCT00327093|DRUG|cetuximab|indication : second intention treatment
47935596|NCT05440773|OTHER|Artemisia afra tea infusions|A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
48623230|NCT00327093|DRUG|bevacizumab|Indication: first intention treatment
48623231|NCT04954872|BEHAVIORAL|Standard Problem Management Plus training (training as usual)|10-day training on Problem Management Plus.
48623232|NCT04954872|BEHAVIORAL|Equip-based Problem Management Plus training|Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
48623233|NCT05714332|OTHER|Advanced practice physiotherapy and orthopedic surgeon management|Management of their musculoskeletal condition by an advanced practice physiotherapist and an orthopedic surgeon.
48623234|NCT05714332|OTHER|Orthopedic surgeon management|Management of their musculoskeletal condition by an orthopedic surgeon.
48623235|NCT05411978|DRUG|Idebenone+ placebo|Participants will receive Idebenone 30 mg+ placebo 60 mg for 12 weeks.
48623236|NCT05411978|DRUG|Idebenone|Participants will receive Idebenone 90 mg for 12 weeks.
48623237|NCT05411978|DRUG|Placebo|Participants will receive Placebo 90 mg for 12 weeks
48623238|NCT04192331|DRUG|nab-paclitaxel regimen1|nab-paclitaxel regimen1 means use abraxine with 125mg/m2 at day 1 and day 8 per 21d.
48623239|NCT04192331|DRUG|nab-paclitaxel regimen2|nab-paclitaxel regimen2 means use abraxine with 125mg/m2 at day 1 and day 8 and day 15 per 28d.
48623240|NCT03149770|DRUG|Naloxone then placebo|naloxone intranasal 4mg, then placebo
48623241|NCT03149770|DRUG|Placebo then Naloxone|placebo then naloxone intranasal 4mg
48623242|NCT05538845|DEVICE|Screw fixation|Screw fixation to patients
48623243|NCT05538845|DEVICE|Suture button|Suture button for patients
48623244|NCT00759096|DEVICE|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
48623245|NCT05125497|PROCEDURE|In Vitro Fertilisation (IVF)|Natural Cycle In Vitro Fertilisation (IVF): without hormonal stimulation Conventional In Vitro Fertilisation (IVF): conventional hormonal stimulation Minimal Stimulation In Vitro Fertilisation (IVF): low dose of hormonal stimulation will be applied
48623246|NCT00886457|DRUG|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
48623247|NCT01614119|OTHER|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
48623248|NCT02832999|DRUG|sub cutaneous liraglutide|Liraglutide 1.2mg/day
48623249|NCT02832999|DRUG|Oral Vildagliptin|Vildagliptin 50mg/day
48623250|NCT03915457|OTHER|Dry immersion Control Group|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
48623251|NCT03915457|OTHER|Thigh cuffs intervention|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
48623252|NCT03626896|DEVICE|NaviFUS System|BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system
48623253|NCT00232921|DRUG|caudal volume 1|
48462703|NCT05255549|PROCEDURE|ESWT and SHAM + Stretching|"3 weeks intervention:~* 1 sessions of ESWT + 2 sessions of Sham, once a week~* 6 sessions of passive stretching, twice a week"
48462704|NCT00193492|DRUG|Bevacizumab|
48462705|NCT00193492|DRUG|Rituximab|
48462706|NCT03513549|DRUG|Loxapine 10 MG|
48623254|NCT00232921|BIOLOGICAL|caudal volume 2|
48623255|NCT00232921|DRUG|caudal volume 3|
48623256|NCT00312416|DRUG|Clonidin|
48623257|NCT00312416|DRUG|Brimonidine|
48623258|NCT01027845|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
48623259|NCT01027845|BIOLOGICAL|DTPa|Subcutaneous injection, 4 doses
48623260|NCT04713683|DEVICE|Percutaneous Patent Foramen Ovale Closure|Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
48623261|NCT03547570|OTHER|Progressive heavy shoulder resistance training|The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
48623262|NCT01332162|DEVICE|Biventricular pacing|All patients will be pacing during two years
48623263|NCT01332162|DEVICE|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
48623264|NCT06196359|PROCEDURE|Combined Femoral and Popliteal nerve block|Patients who receive a combined femoral and popliteal nerve block during surgery, fill out a questionnaire and undergo a muscle strength test before surgery, undergo functional tests, a muscle strength test and are asked about pain intensity after surgery.
48623265|NCT06390215|BEHAVIORAL|School Readiness Coaching Intervention|Two 1-hr School Readiness Coaching Session
48623266|NCT00421993|DRUG|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
48623267|NCT00421993|DRUG|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
48623268|NCT00421993|DRUG|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
48623269|NCT00421993|DRUG|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
48623270|NCT03824431|DIAGNOSTIC_TEST|Endoscopic esophageal biopsies|
48623271|NCT01017497|RADIATION|Stereotactic Radiosurgery|PTV Diameter \< 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
48623272|NCT04235855|DEVICE|Endoscopic USG guided Liver biopsy|Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
47935597|NCT05440773|OTHER|Artemisia afra tea infusions|Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
47935598|NCT05440773|OTHER|Flavored placebo infusions|Flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
47935599|NCT05440773|OTHER|Regular tea placebo|Regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
47935600|NCT01275547|DRUG|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
48281469|NCT03543371|DIAGNOSTIC_TEST|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
48281470|NCT05714930|OTHER|Treat-to-target as a new treatment concept|After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
48462707|NCT02183376|DRUG|BI 1356|
48462708|NCT04793633|COMBINATION_PRODUCT|LINFU™ Technique|Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
48281471|NCT03577990|BEHAVIORAL|Interactive Technology Enhanced Coaching (ITEC)|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
48462709|NCT05894031|BEHAVIORAL|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
48462710|NCT00643305|BEHAVIORAL|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
48462711|NCT00643305|BEHAVIORAL|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
48462712|NCT02725515|BIOLOGICAL|XmAb5871|
48462713|NCT02725515|BIOLOGICAL|Placebo to match XmAb5871|
48462714|NCT00002160|DRUG|Ziconotide|
48462715|NCT03634735|DRUG|Thiamine|Vitamine B1
48462716|NCT03634735|OTHER|Placebo|Placebo tablets
48623273|NCT04235855|DEVICE|Percutaneous Liver Biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
47935601|NCT01275547|DRUG|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
47935602|NCT02533791|BIOLOGICAL|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10\^10vp/1ml per dose
47935603|NCT02533791|BIOLOGICAL|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10\^11vp/1ml per dose, with one dose to each arm at the same time
48462717|NCT00225329|PROCEDURE|Labour assessment and support|
48462718|NCT01684280|GENETIC|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
48462719|NCT06090708|DIETARY_SUPPLEMENT|yogurt with probiotic bacteria|Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
48462720|NCT03685409|DRUG|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
48623274|NCT01785316|PROCEDURE|IHP|
47935604|NCT02533791|BIOLOGICAL|placebo|
48623275|NCT04854746|BIOLOGICAL|VXA-GI.1.NN|GI.1 oral vaccine tablet
47935605|NCT00310453|BIOLOGICAL|ALK Grass tablet|
47935606|NCT01736332|DRUG|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
48623276|NCT04854746|BIOLOGICAL|Placebo Tablet|Tablets matching in number and appearance to active vaccine tablets
48623277|NCT02546570|DRUG|Oxytocin|See arm/group descriptions for dosage amount and procedure.
47935607|NCT01736332|OTHER|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
47935608|NCT02656212|DRUG|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
48623278|NCT02546570|DRUG|Placebo|See arm/group descriptions for dosage amount and procedure.
48623279|NCT02214472|BEHAVIORAL|Biofeedback|
48623280|NCT02214472|DRUG|Placebo|
48462721|NCT03685409|DRUG|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
48462722|NCT06502951|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
48462723|NCT06502951|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
48462724|NCT03214237|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
48462725|NCT00844974|OTHER|Prevalence|Mood and cognitive assessments
48462726|NCT02000258|PROCEDURE|Double-bundle ACL reconstruction|
48462727|NCT02000258|DEVICE|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
48462728|NCT01476501|DRUG|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
48462729|NCT04129554|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
48462730|NCT04129554|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
48462731|NCT04129554|DRUG|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
48462732|NCT04129554|DRUG|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
48462733|NCT04129554|DRUG|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
48462734|NCT04129554|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
48462735|NCT04129554|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
48462736|NCT03084263|PROCEDURE|Arthroscopic Assisted Open Reduction Internal Fixation|Surgical fixation of ankle fractures with use of arthroscopy.
48462737|NCT03084263|PROCEDURE|Open Reduction Internal Fixation|Surgical fixation of ankle fractures.
48462738|NCT04540068|DRUG|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
48462739|NCT04273386|OTHER|Evaluation|The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
48462740|NCT01547507|DEVICE|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
48462741|NCT01494090|DRUG|Rosuvastatin|5 or 20 mg per day during 6 months
48462742|NCT01494090|DRUG|Placebo|5 or 20 mg per day during 6 months
48462743|NCT00259194|BEHAVIORAL|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
48462744|NCT00259194|BEHAVIORAL|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
47935609|NCT02656212|DRUG|Placebo|Placebo pill, taken orally, one pill/day in the morning
47935610|NCT01771185|PROCEDURE|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
47935611|NCT01771185|DRUG|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
47935612|NCT05649839|OTHER|garment|patient randomized in the experimental arm will wear the specially designed garment
48462745|NCT04889365|DIAGNOSTIC_TEST|SG Diagnostics COVID-19 Antigen Rapid Test Kit|SG Diagnostics COVID-19 Antigen Rapid Test Kit (self-use)
48462746|NCT04889365|DIAGNOSTIC_TEST|Polymerase chain reaction (PCR) test|Professional collection of a second swab sample, for confirmation by PCR
48462747|NCT06503926|OTHER|SARS-COV-2 vaccination|Vaccination
48462748|NCT02527213|DRUG|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
48462749|NCT02527213|DRUG|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
48462750|NCT03408730|BIOLOGICAL|Hepatitis B Vaccination|Hepatitis B Vaccination
48462751|NCT01663896|DEVICE|OCT stent guidance|Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
48462752|NCT06124690|DEVICE|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
48462753|NCT02428348|OTHER|Interview about prototype EEG-cap|
48462754|NCT00132457|PROCEDURE|Self-collected vaginal swab for chlamydia testing|
48462755|NCT06466213|OTHER|single exercise bout about one-leg exercise|cycle exercise includes single leg
48462756|NCT03256864|DRUG|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
48623281|NCT01875237|DRUG|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
48623282|NCT01875237|DRUG|Melphalan|140 mg/m2 by vein on Day -2.
48623283|NCT01875237|DRUG|Alemtuzumab|50 mg by vein on Day -1.
48623284|NCT01875237|PROCEDURE|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10\^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
48281472|NCT03577990|BEHAVIORAL|Interactive Technology-No Coaching (IT)|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
48462757|NCT03359941|PROCEDURE|acupuncture|Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
48462758|NCT01496118|DRUG|panobinostat|Specified dose on specified days
48462759|NCT01496118|DRUG|carfilzomib|Specified dose on specified days
48462760|NCT00625157|DRUG|ASF 1096 0.5 % cream|
48462761|NCT00625157|DRUG|ASF 1096 placebo cream|
48462762|NCT06282562|OTHER|High-Intensity Interval Training (HIIT)|Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.
48462763|NCT01874041|OTHER|Massage|
48462764|NCT01874041|OTHER|Occlusal splint|
48462765|NCT03898908|DRUG|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
48462766|NCT03898908|DRUG|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
48462767|NCT03898908|RADIATION|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
48462768|NCT03898908|RADIATION|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV \> 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
48462769|NCT02207582|DEVICE|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
48462770|NCT02207582|DEVICE|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
48462771|NCT00450658|DRUG|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
48462772|NCT00450658|DRUG|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
48462773|NCT03505008|DRUG|Methotrexate|Route of Administration: Oral
48462774|NCT03505008|DRUG|Adalimumab|Route of Administration: Subcutaneous
48462775|NCT03770130|DRUG|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
48462776|NCT03770130|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment
48462777|NCT02032927|DRUG|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
48462778|NCT02032927|DRUG|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
48462779|NCT00734825|OTHER|Omnipaque|oral contrast for CT scan
48462780|NCT01100905|OTHER|Iron-containing food product|
48462781|NCT02416180|DEVICE|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
48462782|NCT02416180|DEVICE|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
48462783|NCT02416180|DEVICE|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
48462784|NCT04031560|BEHAVIORAL|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
47935613|NCT01712321|DRUG|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
47935614|NCT01712321|DRUG|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
48623285|NCT01875237|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
48623286|NCT01875237|DRUG|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
47935615|NCT04652596|OTHER|Produce prescription program|A monthly $150 stipend will be provided to participants for 6 consecutive months to purchase fresh food items at mobile markets and independent farmers markets across Boston.
48281473|NCT02415725|DRUG|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
48462785|NCT03700398|DEVICE|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
48462786|NCT03700398|DEVICE|first WLI|the routine in the clinical practice
48462787|NCT05665387|DRUG|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
48462788|NCT05665387|DRUG|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
48462789|NCT05665387|DRUG|Placebo|Placebo ophthalmic solution 1 drop BID for 2 months
48462790|NCT03291145|DRUG|Beta Blockers|With and without Beta Blockers
48462791|NCT03291145|DRUG|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
48462792|NCT03997253|OTHER|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
48462793|NCT03062176|DRUG|Anakinra|Anakinra (Kineret)
48462794|NCT04981457|DRUG|Misoprostol and iso sorbide mononitrates|drug
48462795|NCT02233374|OTHER|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
48462796|NCT02233374|OTHER|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
48462797|NCT02380534|PROCEDURE|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
48462798|NCT03161197|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
48462799|NCT04710823|PROCEDURE|Thoracic paravertebral block|A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
48462800|NCT04710823|PROCEDURE|Serratus anterior plane block|A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
48462801|NCT04553406|DRUG|SPR720|Capsules for oral administration
48462802|NCT04553406|DRUG|Placebo|Capsules for oral administration
48462803|NCT04553406|DRUG|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
48462804|NCT03151824|OTHER|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
48462805|NCT05545228|BEHAVIORAL|Link work intervention|Intervention from a link worker to support participants to access dental services.
48623287|NCT01875237|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
48623288|NCT01875237|PROCEDURE|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10\^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
47935616|NCT04652596|OTHER|Grocery store gift cards|A monthly value of $150 in grocery store gift cards redeemable at conventional grocery stores will be provided to participants for 6 consecutive months.
48281474|NCT05159180|DEVICE|cardioz mapping|Patients will be submitted to mapping of both voltage and tissue impedance.
48281475|NCT04012255|DRUG|Semaglutide (administered by DV3396 pen)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
48623289|NCT01875237|DRUG|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade \> 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
47935617|NCT00827671|DRUG|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
48281476|NCT04012255|DRUG|Semaglutide (administered by PDS290 pen)|Increasing doses of semaglutide given sc in the stomach for 21 weeks
48281477|NCT04489238|OTHER|Risk Factor Questionnaire|Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
48281478|NCT01646710|BEHAVIORAL|Pretesting food based recommendations|
48462806|NCT05440968|OTHER|Point of Care - Glycated Hemoglobin (A1c)|Test for diagnosis of Diabetes through a Point of care device
48462807|NCT05440968|OTHER|Oral Glucose Tolerance Test|Routinary diagnosis diabetes test by venous blood sample
48462808|NCT05036005|DRUG|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
48462809|NCT05036005|DRUG|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
48462810|NCT05036005|DRUG|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
48462811|NCT03076645|BEHAVIORAL|Facilitator support and education|Group engaged with facilitator support and education
48462812|NCT03345615|DIAGNOSTIC_TEST|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
48462813|NCT02707276|DEVICE|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
48462814|NCT02707276|DEVICE|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
48462815|NCT04333134|DRUG|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
48462816|NCT03050866|DRUG|Cabazitaxel|25mg/m2 q3w
48462817|NCT03050866|OTHER|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
48462818|NCT03050866|OTHER|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
48462819|NCT03050866|OTHER|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
48462820|NCT03050866|OTHER|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
48462821|NCT02967926|PROCEDURE|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
48462822|NCT00130949|DRUG|ALGRX 4975|
48462823|NCT04947761|DRUG|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
47935618|NCT00827671|RADIATION|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
47935619|NCT00247533|PROCEDURE|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
47935620|NCT01976078|DRUG|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
48099124|NCT06314594|BEHAVIORAL|intervention treatment|"Patients will be input into the health management platform. The optimal treatment scheme will be then determined through data calculation and sent to individuals (or their families) or schools for implementation under the guidance of the platform. It is important to note that the specific treatment plan varied from person to person. Patients were observed and intervened for a period of 4 months.~1. Massage therapy~2. Posture guidance~3. Schroeder\&#39;s gymnastics therapy~4. Bioelectric stimulation therapy"
48099125|NCT06630624|DRUG|IP-001|Intra-tumoral injection of IP-001 following ablation (RFA, MWA or IRE).
48281479|NCT03754933|BIOLOGICAL|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
48462824|NCT04947761|OTHER|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
48462825|NCT01813864|BEHAVIORAL|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
48462826|NCT05510141|OTHER|Virtual reality gaming|Instead of nitrous oxide, which is the standard procedure, virtual reality gaming is applied to reach pain reduction in minor surgery procedures
48462827|NCT05510141|DRUG|Nitrous oxide|Standard procedure
48462828|NCT06403137|BEHAVIORAL|Resistance exercise|4 single-leg exercise sessions
48462829|NCT06403137|BEHAVIORAL|Standardized diet|Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.
48623290|NCT01875237|DRUG|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
48623291|NCT01875237|BEHAVIORAL|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
48623292|NCT01976208|DRUG|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg，then dosing interval is every 2 weeks.
48623293|NCT01976208|DRUG|placebo|
48623294|NCT00095966|DRUG|sorafenib tosylate|Given orally
48623295|NCT00095966|DRUG|gemcitabine hydrochloride|Given IV
48623296|NCT03144999|BIOLOGICAL|AAVCAGsCD59|AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
48623297|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
48623298|NCT00976027|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
48623299|NCT04999969|DRUG|AZD0171|AZD0171
48623300|NCT04999969|DRUG|Durvalumab|Durvalumab
48623301|NCT04999969|DRUG|Gemcitabine|Chemotherapy (Standard-of-Care)
48623302|NCT04999969|DRUG|Nab-paclitaxel|Chemotherapy (Standard-of-Care)
48623303|NCT04337073|DRUG|Propofol|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
48623304|NCT04337073|DRUG|normal saline|Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
48623305|NCT01073475|OTHER|There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.|"There is no intervention associated with the parent MNHR study~For the MNHR COVID sub-study, each woman will be asked to provide a blood specimen of approximately 3-5 cc at or near delivery (at delivery or 14 days after) to be tested for COVID-19 antibodies. The person collecting the specimen will be a trained member of the registry staff. The ZEUS ELISA SARS-CoV-2 IgG Test System will be used and run at each site. RTI International will provide central quality support of the analyses."
47935621|NCT05972603|PROCEDURE|1.0 g Vancomycin powder into the wound|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation and additional application 1.0 g Vancomycin powder into the wound
47935622|NCT05972603|PROCEDURE|0,35% povidone-iodine solution lavage|0,35% povidone-iodine solution lavage left for 3 minutes following final implantation
47935623|NCT05829187|DRUG|Dihydroartemisinin|dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
47935624|NCT05829187|DRUG|Piperaquine|piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
48099126|NCT04796285|DEVICE|Lab Clasp|Finger-based interstitial fluid assessment device
48281480|NCT03754933|DRUG|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used to treatment patients with chronic lymphocytic leukemia.
48281481|NCT04723095|OTHER|Follow-Up|Receive follow up
48281482|NCT04723095|OTHER|Medical Chart Review|Review of medical records
48281483|NCT04194177|OTHER|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
48623306|NCT02557997|OTHER|Blood tube bottom analyses|
47935625|NCT05829187|DRUG|Primaquine|Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
47935626|NCT05829187|DRUG|Momordica Charantia Extract|Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
48099127|NCT03396913|DEVICE|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
48099128|NCT03396913|DEVICE|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
48623307|NCT02336503|DRUG|BBI-4000 Gel, 5%|BBI-4000 Gel, 5%
48623308|NCT02336503|DRUG|BBI-4000 Gel, 10%|BBI-4000 Gel, 10%
48623309|NCT02336503|DRUG|BBI-4000 Gel, 15%|BBI-4000 Gel, 15%
48623310|NCT02336503|DRUG|Vehicle|Placebo, BBI-4000 Gel, 0%
48623311|NCT05075369|DIAGNOSTIC_TEST|water drinking test|Water drinking test-glaucoma diagnostic test - marker for outflow facility reserve to detect IOP instability when the body ingests 800 ml of water within a 5 minute period of time
48623312|NCT00151515|DRUG|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
48623313|NCT00657566|OTHER|duration of antibiotics|4 +/- 1 days of antibiotics
48623314|NCT00657566|OTHER|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
48623315|NCT06286943|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFAs).|Colon-delivery capsules of SCFAs.
48623316|NCT06286943|DIETARY_SUPPLEMENT|Placebo|Microcrystaline cellulose placebo capsules.
48623317|NCT06286943|OTHER|Maastricht Acute Stress Task|The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
48462830|NCT06403137|DIETARY_SUPPLEMENT|Plant protein supplement|Dissolved in water with breakfast and prior to sleep.
48462831|NCT06403137|DIETARY_SUPPLEMENT|Maltodextrin supplement|Dissolved in water with breakfast and prior to sleep.
48623318|NCT06286943|OTHER|No-stress control task|The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
48623319|NCT04585360|OTHER|Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life|"Realization of specific questionnaires evaluating:~* psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~* fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~* quality of life (SF36 self-assessment questionnaire)"
48462832|NCT06403137|DIETARY_SUPPLEMENT|Milk protein supplement|Dissolved in water with breakfast and prior to sleep.
48462833|NCT04875585|DRUG|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
48462834|NCT04875585|PROCEDURE|Surgery|surgical resection of primary tumor and lymph-node-dissection.
48462835|NCT04875585|DRUG|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
48462836|NCT04840927|DRUG|E7386|Regimen A: 40 milligram (mg) IR Oral Tablet.
48462837|NCT03618615|BIOLOGICAL|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
48462838|NCT01608906|DRUG|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
48462839|NCT01608906|DRUG|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
48462840|NCT03567122|OTHER|Internal Focus of Attention|Information already included in arm/group descriptions.
48623320|NCT04208932|DRUG|SSRIs|Selective Serotonin Reuptake Inhibitors
48623321|NCT05508256|DEVICE|CE-marked Catheter Ablation|Once patients have been randomized to the catheter ablation (CA) group, the ablation procedure must be performed within 4 weeks. CA will initially aim at pulmonary vein isolation.
48623322|NCT03834298|OTHER|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
48623323|NCT06381284|BEHAVIORAL|Social media recruitment|Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
48623324|NCT06381284|BEHAVIORAL|Self-Assessment|Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
47935627|NCT01844479|DEVICE|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
47935628|NCT01844479|OTHER|Standard innersole|
47935629|NCT03076229|BEHAVIORAL|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
47935630|NCT00475475|BEHAVIORAL|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
48099129|NCT03396913|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
48281484|NCT05716919|DRUG|Ivaltinostat|Ivaltinostat capsule
48462841|NCT03567122|OTHER|External Focus of Attention|Information already included in arm/group descriptions.
48462842|NCT03567122|OTHER|Control|Information already included in arm/group descriptions.
48623325|NCT06381284|BEHAVIORAL|Follow-up|Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
48462843|NCT05710588|OTHER|motor-motor dual-task training|The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.
48462844|NCT05710588|OTHER|motor-cognitive dual-task training|The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
48462845|NCT00156650|DRUG|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
48462846|NCT00156650|DRUG|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
48462847|NCT00156650|DRUG|Depo-Medroxyprogesterone|300 mg IM every 3 months
48623326|NCT03156140|OTHER|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
48623327|NCT00238290|DRUG|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
48623328|NCT05319470|DIAGNOSTIC_TEST|Intraocular pressure (IOP)|Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.
48623329|NCT05319470|DIAGNOSTIC_TEST|Tear Break-up Time (TBUT)|TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.
48623330|NCT05319470|DIAGNOSTIC_TEST|Conjuctival Hyperemia|Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.
48281485|NCT05716919|OTHER|Placebo|Placebo capsule
48623331|NCT05319470|DIAGNOSTIC_TEST|Schirmer Test|Schirmer test will be performed on both eyes to asses tear production.
48623332|NCT05319470|DIAGNOSTIC_TEST|Visual Fields and OCT RNFL|Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.
48462848|NCT00293878|DRUG|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
48462849|NCT03947905|PROCEDURE|Virtual visit|Type of visit
48462850|NCT03755596|DRUG|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
48462851|NCT02217709|DRUG|phenelzine sulfate|Given by mouth
48462852|NCT02217709|OTHER|laboratory biomarker analysis|Correlative studies
48462853|NCT02217709|OTHER|questionnaire administration|Ancillary studies
48623333|NCT03734705|BEHAVIORAL|Imaginal Exposure Writing|Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.
48623334|NCT03734705|OTHER|Neutral Writing|Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
48623335|NCT05546762|DRUG|Povidone-iodine solution|Pleural irrigation with 2% povidone iodine
48462854|NCT01348958|DEVICE|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
48623336|NCT05546762|DRUG|Normal saline|Pleural irrigation with normal saline
48462855|NCT02579226|DRUG|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
48462856|NCT00613730|DRUG|Gemcitabine|Intravenous administration
48099130|NCT04966208|PROCEDURE|xenogeneic collagen matrix|xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue
48099131|NCT05092373|BIOLOGICAL|Atezolizumab|Given IV
48099132|NCT05092373|DRUG|Cabozantinib S-malate|Given PO
48099133|NCT05092373|DRUG|Nab-paclitaxel|Given IV
48099134|NCT05092373|PROCEDURE|Tumor Treating Fields Therapy|Receive TTF
48099135|NCT03210402|DEVICE|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
48281486|NCT04265391|DIETARY_SUPPLEMENT|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
48281487|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
48281488|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
48281489|NCT03629509|BEHAVIORAL|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
48462857|NCT00613730|DRUG|panitumumab|Intravenous administration
48462858|NCT05215873|DRUG|Misoprostol|a synthetic prostaglandin E1 analogue
48623337|NCT01276652|BEHAVIORAL|Environmental modification|Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
48623338|NCT03392857|OTHER|Assessment by caregivers of the quality of the end of life in intensive care units|Quality of the end of life in intensive care units perception will be explore from the side of the caregivers, trough the CAESAR scale.
48623339|NCT00394667|DRUG|Tesofensine|
48462859|NCT05215873|DRUG|Syntocinon|synthetic oxytocin
48462860|NCT05330780|OTHER|Breathing Room|8 total group classes performed twice a week over the course of 4 weeks, with IMTs utilized during the classes as well as 3 days outside of the class days at 5 sets of 5 breaths completed 5 times a day
48462861|NCT00469885|DRUG|Nicotine replacement|For reduction
48462862|NCT00469885|BEHAVIORAL|Motivational counseling|No drugs
48462863|NCT00175669|DRUG|Botox injections|Data not known.
48462864|NCT00804973|DRUG|LY2590443|200 milligrams (mg) as four 50-mg capsules, oral, once
48462865|NCT00804973|DRUG|Placebo injection|saline solution, injection, once
48462866|NCT00804973|DRUG|Sumatriptan|6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once
48462867|NCT00804973|DRUG|Placebo capsule|4 capsules, once
48462868|NCT01064960|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
48462869|NCT05963841|DEVICE|treatment program|the study aims to set up an artificial intelligence diagnostic assistance program
48281490|NCT04557904|OTHER|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
48623340|NCT00566033|BEHAVIORAL|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
48281491|NCT04557904|OTHER|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
48462870|NCT05118607|DEVICE|IG1|application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
48462871|NCT00686062|OTHER|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
48462872|NCT00686062|OTHER|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
48462873|NCT05100680|OTHER|Multicomp|Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
48462874|NCT05100680|OTHER|Placebo|Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
48462875|NCT05901116|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
48462876|NCT01886222|OTHER|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
48462877|NCT01886222|OTHER|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
48462878|NCT04543084|BEHAVIORAL|Logbook|Participants will record practice in a logbook.
48462879|NCT01120691|DRUG|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
48462880|NCT01120691|DRUG|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
48462881|NCT01120691|DRUG|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
48462882|NCT01120691|DRUG|Salbutamol/albuterol|As needed throughout the study
48462883|NCT05418790|DEVICE|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
48462884|NCT02538549|BEHAVIORAL|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
48462885|NCT04485208|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
48462886|NCT05236062|BEHAVIORAL|Exercise|aerobic and resistance exercise
48462887|NCT05236062|BEHAVIORAL|Attention control|stretching
48462888|NCT05492448|DIETARY_SUPPLEMENT|Placebo|Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
48281492|NCT00454233|DRUG|YM543|Oral
48281493|NCT00454233|DRUG|Metformin|Oral
48462889|NCT05492448|DIETARY_SUPPLEMENT|L. salivarius AP-32 and L. reuteri GL-104|Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
48623341|NCT01053468|BEHAVIORAL|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
48462890|NCT05492448|DIETARY_SUPPLEMENT|L. reuteri GL-104|Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.
48462891|NCT02789839|PROCEDURE|Blood test|Blood test of 30mL
48462892|NCT02789839|PROCEDURE|Medullar test|Medullar test for 2-5mL and a smear
48462893|NCT05489497|PROCEDURE|Primary closure with or without omental grafting|Primary closure with or without omental grafting
48462894|NCT04224662|OTHER|No intervention|There is no intervention for this study
48462895|NCT03724682|DEVICE|Carry Life UF device|Treatment with the Carry Life UF device compared to standard PD therapy
48462896|NCT06348576|DRUG|AD-209|PO, Once daily(QD), 8weeks
48462897|NCT06348576|DRUG|AD-2091|PO, Once daily(QD), 8weeks
48462898|NCT06348576|DRUG|AD-209 Placebo|PO, Once daily(QD), 8weeks
48462899|NCT06348576|DRUG|AD-2091 Placebo|PO, Once daily(QD), 8weeks
48462900|NCT02002130|DRUG|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
48462901|NCT02002130|DRUG|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
48462902|NCT02002130|DRUG|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
48099136|NCT03210402|DEVICE|Elevated night pacing off|Device will be programmed to normal lower rates
48281494|NCT00454233|DRUG|Placebo|oral
48281495|NCT01386671|DRUG|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
48462903|NCT01071876|DRUG|BF2.649|1 capsule in the morning before breakfast
48462904|NCT01071876|DRUG|Placebo|1 capsule in the morning before breakfast
48462905|NCT06144060|DRUG|HRS -8427|The dose and frequency of administration were adjusted according to the eGFR.
48462906|NCT06144060|DRUG|Imipenem and Cilastatin Sodium|The dose and frequency of administration were adjusted according to the eGFR .
48462907|NCT06160180|DRUG|Dexamethasone|Submucosal application
48462908|NCT04197154|BEHAVIORAL|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
48462909|NCT04197154|BEHAVIORAL|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
48462910|NCT04197154|BEHAVIORAL|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
48462911|NCT04197154|BEHAVIORAL|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
47935631|NCT00475475|BEHAVIORAL|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
48099137|NCT01201187|DRUG|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
48099138|NCT01201187|DRUG|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
48099139|NCT02824432|DRUG|TAK-085|TAK-085 capsules
48099140|NCT04442672|PROCEDURE|acute compartment syndrome model of health volunteer|the acute compartment syndrome model of health volunteer is induced by pressurizing the calves by the cuff, and the cuff is inflated and pressurized to a pressure value of 20, 30, 40, 50, 60, 70, 80 mmHg. the pressure inside the cuff was up to 10 s during pressurization and maintained stable for 1 min, measured and the above indicators were recorded within 3 min.
48099141|NCT04442672|PROCEDURE|sham|surrounding the cuff but not inflate it.
48099142|NCT02302209|DRUG|Oxytocin|
48281496|NCT01386671|DRUG|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
48462912|NCT04197154|BEHAVIORAL|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
48462913|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
48462914|NCT00385736|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
48462915|NCT00385736|BIOLOGICAL|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
48462916|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
48462917|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
48462918|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
48099143|NCT02302209|OTHER|Placebo Comparator|
48462919|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
48462920|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
48462921|NCT05917119|OTHER|BLT|Bright light therapy delivered via glasses
48462922|NCT05917119|OTHER|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
48462923|NCT03953664|OTHER|Experimental-Exercise training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
48462924|NCT02571530|DRUG|Intra-arterial Cerebral Infusion of Trastuzumab|
48462925|NCT03241836|DIAGNOSTIC_TEST|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
48462926|NCT03277248|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
48462927|NCT03277248|DRUG|Teriflunomide|Film coated tablets administered orally.
48462928|NCT03277248|DRUG|Oral Placebo|Administered orally.
48462929|NCT03277248|DRUG|IV Placebo|Administered as an IV Infusion.
48462930|NCT03329924|OTHER|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
48462931|NCT04323683|GENETIC|Microarray|High throughput technique for determining global gene expression of the condition of interest
48462932|NCT00898664|GENETIC|cytogenetic analysis|
48462933|NCT00898664|GENETIC|gene expression analysis|
48462934|NCT00898664|GENETIC|mutation analysis|
48462935|NCT00898664|GENETIC|polymerase chain reaction|
48462936|NCT00898664|OTHER|immunohistochemistry staining method|
48462937|NCT00898664|OTHER|laboratory biomarker analysis|
48462938|NCT00467805|PROCEDURE|Light therapy|
47935632|NCT00475475|BEHAVIORAL|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
47935633|NCT03699384|DRUG|Azacitidine|AZA 75 mg/m\^2 SC or IV D 1-7 28 day cycle x 1
48281497|NCT00904124|DIETARY_SUPPLEMENT|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
48462939|NCT02386358|DRUG|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
48462940|NCT02386358|DRUG|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
48099144|NCT03425526|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
48099145|NCT02483299|DRUG|Metformin|
48099146|NCT02483299|DRUG|Glucophage tablets and Victoza|
48462941|NCT05547048|BEHAVIORAL|Decision Aid|Decision aid for PrEP tailored for justice-involved women with opioid use disorder
48462942|NCT05547048|COMBINATION_PRODUCT|Athena strategy|eHealth for integrated PrEP/medications for opioid use disorder + decision aid
48462943|NCT02626260|OTHER|adhesive strip|Adhesive strip with a standard adhesive base
48462944|NCT00834314|PROCEDURE|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
48462945|NCT00834314|PROCEDURE|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
48462946|NCT03367260|OTHER|Preference Elicitation|Survey of patient preferences for treatment
48462947|NCT01751633|PROCEDURE|Surgical|
48462948|NCT01751633|PROCEDURE|Conservative treatment|
48462949|NCT05402046|OTHER|"Mobile phone application ProRodinki"|"Patient were underwent photography using mobile phone and tested application ProRodinkijust before preplanned excisional or incisional biopsy.~Application AI result than will be compared with pathology report by independent investigator"
48462950|NCT02093377|DEVICE|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
48462951|NCT01962298|DRUG|sugammadex 2mg/kg|
48462952|NCT01962298|DRUG|neostigmine|
48462953|NCT01962298|DRUG|sugammadex 4mg/kg|
48462954|NCT01962298|DRUG|placebo|
48462955|NCT01962298|DRUG|Single rocuronium dose|
48462956|NCT01962298|DRUG|Repeated rocuronium dose|
48462957|NCT01962298|DRUG|Continuous rocuronium infusion|
48462958|NCT03149900|DRUG|Secukinumab|See Arm Description
48462959|NCT02243137|DRUG|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
48462960|NCT02243137|DRUG|prasugrel|Administration: one loading dose (60mg)
48462961|NCT02243137|DRUG|lysine acetylsalicylate|Administration: one dose (450mg iv)
48462962|NCT00801515|DRUG|Maraviroc|150 mg twice per day
48462963|NCT04210544|DIETARY_SUPPLEMENT|Experimental dietary protein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of the experimental protein accompanied by a glass with 50 mL water.
48462964|NCT04210544|DIETARY_SUPPLEMENT|Casein|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of casein accompanied by a glass with 50 mL water.
48462965|NCT04210544|DIETARY_SUPPLEMENT|Water|Breakfast intake consisted on a 250 g custard intake mixed with 20 g of water accompanied by a glass with 50 mL water.
48462966|NCT04358627|DRUG|Dexmedetomidine Injectable Product|continuous intravenous infusion of dexmedetomidine
48462967|NCT00006516|BEHAVIORAL|Infant stimulation|
48281498|NCT03716726|BEHAVIORAL|WE CARE SDoH Screening Survey|The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR
48462968|NCT02225015|BEHAVIORAL|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
48281499|NCT03716726|BEHAVIORAL|Family Resource Book|The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
48462969|NCT02542462|DRUG|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
48462970|NCT02542462|DRUG|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
48623342|NCT01053468|BEHAVIORAL|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
48623343|NCT02139319|DRUG|Botulinum toxin|
48462971|NCT02542462|DRUG|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
48462972|NCT02542462|DRUG|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
48462973|NCT03995849|DIAGNOSTIC_TEST|Cone Beam CT Scan|In this study, children will receive one CBCT scan before starting RT as part of standard approach. Then after RT, another CBCT scan will be used to measure movement between the beginning and end of RT.
48462974|NCT01074827|OTHER|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
48462975|NCT02032316|DEVICE|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
48623344|NCT02139319|DRUG|Placebo|
48281500|NCT03716726|OTHER|Standard of care|Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
48623345|NCT04443829|BIOLOGICAL|CD19CAR T-cells|Infusion with: CD19CAR T-cells
48623346|NCT05115253|BEHAVIORAL|HAPA behavioural counselling + SMS text message boosters|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) paired with daily personalized HAPA guided SMS text message boosters to reduce consecutive workplace sedentary behaviour.
48623347|NCT05115253|DEVICE|JITAI|EMA monitoring mobile phone application that uses a phone's on-board accelerometer to monitor a participant's sedentary behaviour and deliver a push notification once a set condition has been met. This intervention will be utilized to reduce consecutive workplace sedentary behaviour.
48099147|NCT01440244|PROCEDURE|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
48099148|NCT02723851|DEVICE|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
48099149|NCT05809076|DEVICE|real tACS|tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
48462976|NCT01091363|BEHAVIORAL|Standard|10 minute brief cessation counseling
48462977|NCT01091363|BEHAVIORAL|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
48462978|NCT05726058|DEVICE|XyCAM with oxygen|After the standard imaging protocols, participants will be asked to inhale 100% oxygen through a mask and will be re-imaged using the XyCAM RI or XyCAM FC.
48462979|NCT01622764|RADIATION|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
48623348|NCT01476072|OTHER|MRI scan|MRI scan only, methodology study with no other intervention
48623349|NCT02450136|DRUG|pazopanib|
48623350|NCT02511353|DRUG|ivermectin|
48623351|NCT02511353|DRUG|placebo|Placebo for ivermectin.
48623352|NCT02511353|DRUG|dihydroartemisinin-piperaquine|
47935634|NCT03699384|DRUG|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
48099150|NCT05809076|DEVICE|sham tACS|In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
48623353|NCT02013362|DRUG|Pralatrexate injection|
48623354|NCT02013362|DIETARY_SUPPLEMENT|Vitamin B12|
48623355|NCT02013362|DIETARY_SUPPLEMENT|Folic Acid|
48623356|NCT03510936|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
48623357|NCT03149419|DRUG|Paroxetine|
48623358|NCT03149419|DRUG|Placebo oral capsule|
48623359|NCT05526768|DEVICE|VITLS Device|VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
48462980|NCT04348422|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period
48462981|NCT04348422|DIAGNOSTIC_TEST|COVID-19 Serology|Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.
48462982|NCT04348422|OTHER|Symptoms questionnare|Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period
48462983|NCT00960154|DEVICE|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
48462984|NCT00960154|PROCEDURE|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
48623360|NCT05439564|DRUG|Dexmedetomidine|Group morphine-Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine plus 5 mcg of dexmedetomidine.
48623361|NCT05439564|DRUG|Morphine|Group morphine (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 0.1 mg of morphine.
48462985|NCT05536960|OTHER|68Ga-Dotatate PET/CT|One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
48623362|NCT05439564|DRUG|Dexmedetomidine|Group Dex (35 patients): patients will be received given 0.5% heavy bupivacaine (3.5 ml) plus 5 mcg of dexmedetomidine.
48623363|NCT01235819|DRUG|Insulin|Exenatide Sitagliptin
48623364|NCT01235819|DRUG|Sitagliptin|Sitagliptin 100 mg per day oral
48623365|NCT01235819|DRUG|Exenatide|Exenatide 10 micrograms daily twice
48623366|NCT01639521|DRUG|cisplatin|Given IV
48623367|NCT01639521|DRUG|gemcitabine hydrochloride|Given IV
48462986|NCT04392596|DEVICE|Bone Mineral Density and Trabecular Bone score|"structural damage in the cervical and lumbar spine was scored according to the modified Stoke AS Spinal Score (mSASSS) which yielded a final summation score ranging from zero to 72.~BMD was measured using DXA (Lunar Prodigy densitometer, GE Healthcare, Madison, WI, USA).~BMD was measured at the lumbar spine (L1-L4) and the left hip (femoral neck and total proximal femur).~TBS was analyzed using DXA images over exactly the same region as the lumbar BMD assessment (L1-L4). Lumbar spine DXA images were reanalyzed using TBS iNight software version 2.1 (Med-I maps, Merignac, France). Patients were divided in 3 TBS groups according to guidelines for fracture risk \[22\]: any TBS \>1.31 was considered as normal; TBS values between 1.23 and 1.31 were consistent as partially degraded structure; and any TBS \<1.23 was considered as degraded structure."
48623368|NCT01639521|DRUG|methotrexate|Given IV
48623369|NCT01639521|DRUG|vinblastine|Given IV
48462987|NCT04238962|DRUG|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
48462988|NCT04238962|DRUG|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
48462989|NCT01476969|DEVICE|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
48462990|NCT00577655|DRUG|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
48462991|NCT00577655|DRUG|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
48478840|NCT03767517|OTHER|Active Intervention|Half of the patients will receive tele-consult program. Tele-consult intervention includes: initial consult and 2 follow up contacts. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
48623370|NCT01639521|DRUG|doxorubicin hydrochloride|Given IV
48623371|NCT01639521|BIOLOGICAL|pegfilgrastim|Given SC
48623372|NCT01639521|OTHER|laboratory biomarker analysis|Correlative studies
48623373|NCT05891444|DEVICE|High frequency transcranial random noise|High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
48623374|NCT05891444|DEVICE|Sham high frequency transcranial random noise|In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
48623375|NCT04073277|DEVICE|SCF-N-treated needles|The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..
48623376|NCT04073277|DEVICE|Untreated needles|he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
48623377|NCT01067300|PROCEDURE|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
48623378|NCT00474032|DRUG|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
48623379|NCT02686411|OTHER|Survey Administration|Complete survey
48623380|NCT02006654|DRUG|Placebo|Once daily, matching placebo capsules, orally
48623381|NCT02006654|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
48623382|NCT05793944|BEHAVIORAL|SmartMom text messaging|SmartMom is a mobile health program delivered via text messaging that guides participants through each week of pregnancy. Participants receive three messages per week with links to content focused on improving knowledge, providing information about prenatal assessments and screening, and encouraging the adoption of behaviours to support healthy pregnancy and physiologic birth. Messages are consistent with current professional guidelines and peer reviewed prenatal education curricula. SmartMom provides optional supplemental streams for individuals who wish to have additional messages addressing topics such as reducing use of tobacco, alcohol or illicit drugs, depression, obesity, and maternal age over 35.
48623383|NCT05793944|BEHAVIORAL|Control text messaging|Control arm participants will receive weekly text messages with accurate, general-interest information about pregnancy and about progress of the trial. Content is not geared to decision-making during pregnancy that may affect health outcomes.
48623384|NCT01855906|PROCEDURE|Gap balanced surgical technique|Gap balanced surgical technique
48623385|NCT01855906|PROCEDURE|Measured resection|Measured resection surgical technique
48462992|NCT00577655|DRUG|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
48462993|NCT01529554|DRUG|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
47935635|NCT01768247|DRUG|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
47935636|NCT01264627|BEHAVIORAL|Mindful Breathing (MB) Intervention|"The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor."
48462994|NCT01529554|DRUG|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
47935637|NCT01264627|BEHAVIORAL|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
48462995|NCT02119988|PROCEDURE|TIPS|TIPS will be performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
48462996|NCT02119988|PROCEDURE|Variceal Embolization|Embolization of gastroesophageal collaterals will be conducted via the same jugular vein before TIPS implantation. The major procedures includ (a) angiography of gastroesophageal collaterals after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of gastroesophageal collaterals with coils of varying diameters, which result in the gastroesophageal collaterals disappearing at postembolization angiography.
48462997|NCT01013818|DRUG|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
48478841|NCT03767517|OTHER|Usual Care|Half of the patients will receive usual care. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
48623386|NCT06531421|OTHER|Equity Report Cards|At month 2 the investigators will distribute EMS Agency-level 'Equity Report Cards' to both agency leadership and all frontline EMS providers. This 'Equity Report Card' will contain monthly pooled, agency-level information summarizing clinical data for injured children stratified by race/ethnicity. At month 7 the investigators will also distribute Battalion-level 'Equity Report Cards' to agency leadership and all frontline EMS providers.
48623387|NCT00209820|BEHAVIORAL|Supervised Nordic Walking|
48623388|NCT00209820|BEHAVIORAL|Unsupervised Nordic Walking|
48623389|NCT00209820|BEHAVIORAL|Advice to stay active|
47935638|NCT00458497|DEVICE|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
47935639|NCT00458497|DEVICE|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
48623390|NCT05579340|OTHER|Exercise|6 months of combined aerobic and resistance exercise
48623391|NCT04598113|DEVICE|Cervical Traction Device|"While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end."
47935640|NCT01954420|BEHAVIORAL|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
47935641|NCT01954420|OTHER|Attention Control|Standard care + Cancer education
48623392|NCT00186511|BEHAVIORAL|workbook/journal on coping with breast cancer|
48623393|NCT00186511|BEHAVIORAL|supportive expressive group therapy using videoconferencing|
48623394|NCT03947034|DRUG|Drugs inducing hyperammonemia|Drugs susceptible to induce metabolic toxicities such as hyperammonemia
48462998|NCT05452213|DRUG|Ribociclib|"All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion."
48623395|NCT05205395|DIAGNOSTIC_TEST|Transperineal ultrasound|Ultrasonography was used with curved linear-array transducer placed between the major labia and underneath the external urethral orifice. The measurement was done on the midsagittal plane to obtain the image of pubic symphysis, urethra, and bladder in a view. Ultrasonic measurement of the overall rest-stress distance was define as the linear distance of bladder neck position change from resting status to maximal strain.
48623396|NCT00369018|DRUG|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
48623397|NCT00000964|DRUG|Ranitidine hydrochloride|
48462999|NCT01231737|DRUG|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
48463000|NCT03669731|OTHER|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
48623398|NCT00000964|DRUG|Foscarnet sodium|
48623399|NCT06493747|DEVICE|Combined Low- and High-Frequency rTMS Intervention|This intervention involves the application of rTMS using an 8-shaped coil with a frequency of 1Hz for low-frequency stimulation and 5Hz for high-frequency stimulation, in accordance with the study protocol.
48623400|NCT06493747|DEVICE|Combined High- and Low-Frequency rTMS Intervention|Similar to Arm A, but the sequence of low and high-frequency rTMS is reversed.
48623401|NCT06493747|DEVICE|rTMS|Participants receive an individualized rTMS therapy plan based on integrated analysis of assessment data, targeting specific brain areas to enhance language function recovery post-stroke.
48623402|NCT06493747|DEVICE|rTMS + Acupuncture|"Participants undergo a combined treatment of rTMS as described for the rTMS Experimental Group and traditional Chinese acupuncture based on the Kaiqiao Jieyan method, targeting specific acupoints to facilitate recovery."
48099151|NCT00097253|BEHAVIORAL|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
48463001|NCT05471349|BEHAVIORAL|Flyer and video|Participants will view a flyer and video
48463002|NCT01439620|DEVICE|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
48463003|NCT05041426|DRUG|Letermovir|Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months. The duration of prophylaxis is per current standard of care. LET will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily. All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis. Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.
48623403|NCT06493747|DEVICE|rTMS|Participants receive a conventional rTMS treatment as per established guidelines, serving as an active comparator to the experimental interventions.
48623404|NCT06493747|DEVICE|Acupuncture|"Participants receive Kaiqiao Jieyan acupuncture therapy alone, without rTMS, following traditional Chinese medicine protocols for post-stroke aphasia rehabilitation."
48623405|NCT04705753|DIETARY_SUPPLEMENT|Cretan IAMA|Cretan IAMA (CAPeo) soft gels, 1 ml/day of a 1.5% essential oil combination from three aromatic plants (Thymbra 59 capitata (L.) Cav., Origanum dictamnus L., Salvia fruticosa Mill.) in extra virgin olive oil
48623406|NCT03974906|OTHER|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）|Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
48623407|NCT02939664|DEVICE|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
48623408|NCT02939664|PROCEDURE|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
48623409|NCT02413268|DRUG|Nitroglycerin|
48478842|NCT04908202|DRUG|Deucravacitinib|Specified dose on specified days
48623410|NCT03930433|DRUG|Nebivolol|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
48623411|NCT03930433|DRUG|Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
48623412|NCT03930433|DRUG|Nebivolol+Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
48623413|NCT00592111|DRUG|COPP/ABV|4 courses of COPP/ABV hybrid
47935642|NCT00176722|OTHER|table tilt|One group randomized to table tilt. One group will be flat.
47935643|NCT00882492|BIOLOGICAL|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
48099152|NCT00135967|DRUG|mycophenolate mofetil orally 1000 mg twice a day (BID)|
48099153|NCT00135967|DRUG|prednisone 0,5 mg/kg orally on alternate days|
48623414|NCT00592111|DRUG|COPP/ABV|6 courses of COPP/ABV hybrid
48623415|NCT00592111|DRUG|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
48623416|NCT06508814|PROCEDURE|Lower Insufflation Pressure|Participants underwent laparoscopic hysterectomy with an insufflation pressure that is lower than the standard insufflation pressure used in this type of surgery.
48623417|NCT06508814|PROCEDURE|Standard Insufflation Pressure|Participants underwent laparoscopic hysterectomy with a standard insufflation pressure.
48623418|NCT00957710|BEHAVIORAL|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
48281501|NCT01979107|BEHAVIORAL|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
48281502|NCT06656858|OTHER|Static stretching|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds
48281503|NCT06656858|OTHER|PNF stretching|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
48463004|NCT05041426|DRUG|Valganciclovir|Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
48463005|NCT03118063|DIAGNOSTIC_TEST|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
48463006|NCT01165749|BEHAVIORAL|stop exercising|
48463007|NCT00746460|BEHAVIORAL|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
48463008|NCT02022306|DRUG|TD-6450|
48463009|NCT02022306|DRUG|Placebo|
48463010|NCT05356169|DRUG|with or without venetoclax|Bcl-2 inhibitor
48463011|NCT06256562|DRUG|GZR18|Titrated to dose 1, dose 2, dose 3 or dose 4
48463012|NCT06256562|OTHER|Placebo|Administered the same volume as GZR18
48463013|NCT01859260|DEVICE|CPAP/autopap|
48463014|NCT06389227|OTHER|dynamic ecological approach (DEA)|The DEA completed 18 ninety-minute sessions (3 per week) for six weeks oriented to soccer training using the dynamic ecological approach
48463015|NCT06389227|OTHER|traditional training group|The TTG followed a traditional soccer training program for the same period and number of sessions without any intervention attributable to the dynamic ecological approach
48281504|NCT06656858|OTHER|Static stretching with BFR|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
48281505|NCT06656858|OTHER|PNF stretching with BFR|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
48281506|NCT06656858|OTHER|Control|No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
48463016|NCT03008655|PROCEDURE|intradermal tranexamic acid|intradermal tranexamic acid injection
48463017|NCT03008655|DEVICE|Nd-YAG|six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
48463018|NCT05594225|BEHAVIORAL|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
48463019|NCT03900234|OTHER|No intervention will be administered|No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
48463020|NCT05820828|DIAGNOSTIC_TEST|Volume control|Volume control in venous reservoir during extracorporeal circulation.
48463021|NCT03651973|OTHER|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
48463022|NCT03651973|OTHER|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
48463023|NCT02469480|DRUG|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
48463024|NCT02469480|DRUG|Ferro sanol|200 mg ferro sanol per day over 12 weeks
48463025|NCT02763488|DEVICE|DelfiPTS tourniquet system|
48463026|NCT02763488|OTHER|Standard physical therapy|
47935644|NCT00882492|BIOLOGICAL|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
47935645|NCT05588804|DRUG|Broncho-munal®|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
48281507|NCT05437796|DEVICE|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
48281508|NCT05437796|DEVICE|No Hypnotic virtual reality|Group without Hypnotic virtual reality
48463027|NCT01949532|DRUG|Carfilzomib|Carfilzomib was administered by IV injection.
48463028|NCT03013530|PROCEDURE|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
48463029|NCT02836587|BEHAVIORAL|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
48463030|NCT02803879|DEVICE|Cardiogoniometry|
48463031|NCT05179122|PROCEDURE|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
48099154|NCT00135967|DRUG|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
48463032|NCT04720547|DRUG|Zolpidem|A nonbenzodiazepine hypnotic
48463033|NCT04720547|OTHER|No Treatment|The Control condition in which participants do not receive medication.
48463034|NCT06306391|DRUG|Intravenous naloxone|Nyoxid 1.8 mg nasal spray, solution in single-dose container. Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
48623419|NCT04000256|BEHAVIORAL|Activity based rehabilitation|Activity based rehabilitation for the upper extremity involves various gross and fine movements, reach and object transportation, and object manipulation. The rehabilitation equipment used during training will include gaming and instrumented training equipment, conventional table-top tasks, and exercise aids.
48623420|NCT04549441|PROCEDURE|Distal radius fracture plating surgery|We performed open reduction and plating surgery for the distal radius fracture.
48623421|NCT00561327|DRUG|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
48623422|NCT06322303|OTHER|Placebo (CBD 0%)|Participants are required to vaporize placebo at 0% CBD concentration
48623423|NCT06322303|OTHER|CBD 15%|Participants are required to vaporize CBD at a concentration of 15%.
48623424|NCT06322303|OTHER|CBD 30%|Participants are required to vaporize CBD at a concentration of 30%.
48623425|NCT05891327|DIETARY_SUPPLEMENT|Maca|2.25 g Lepidium meyenii (Maca) extract twice per day for 12 weeks
48623426|NCT05891327|DIETARY_SUPPLEMENT|Placebo|Placebo
48623427|NCT01922011|DRUG|Daptomycin|IV daptomycin Infusion A in 12 to \<18 years old (7 mg/kg); in 7 to \< 12 year olds (9 mg/kg); in 24 months to \<7 year olds (12 mg/kg); in 12 to \<24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
48623428|NCT01922011|DRUG|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
48623429|NCT01922011|DRUG|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
48463035|NCT06306391|DRUG|Intranasal naloxone|Naloxone Kern Pharma 1 mg in total (from 0.4 mg/mL injectable solution). Study drugs (naloxone nasal spray and naloxone intravenously) will be administered in 8 subjects in two sequences in fasting conditions (10 hours pre-dose and 4 hours post dose): Intranasal -\> washout period -\>intravenous (n=4) and Intravenous -\>washout period -\> intranasal (n=4).
48463036|NCT04037488|DIAGNOSTIC_TEST|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
48463037|NCT05183282|DEVICE|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
48623430|NCT01536509|BEHAVIORAL|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
48623431|NCT01536509|BEHAVIORAL|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
48099155|NCT04312191|OTHER|Mantra Meditation|Mantra-based meditation will be taught using a standard one-word mantra (Om). Om is a non-English word that will help with focus as opposed to an English word which may cause distraction based on the word itself.
48463038|NCT02911636|RADIATION|Pelvic SABR with intra-prostatic SABR|described elsewhere
48623432|NCT04058301|OTHER|Text message information|Geographically proximate resources delivered by text message
48623433|NCT02298491|DRUG|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
48623434|NCT03619525|PROCEDURE|lung recruitment|During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute
48623435|NCT06532994|OTHER|Early rehabilitation intervention|"Based on the indications for early rehabilitation intervention outlined in the Chinese Expert Consensus on Neurological Critical Care Rehabilitation, early rehabilitation interventions are categorized into three stages according to the patient's consciousness level (GCS score), degree of cooperation (S5Q score), and sedation status (RASS score)"
48623436|NCT00884988|DRUG|Lymphomyosot|20 drops X3/day, until discharge
47935646|NCT05588804|DRUG|Placebo|1 capsule daily in the morning on an empty stomach, 30 minutes before meals, for 10 consecutive days
48463039|NCT02299869|DEVICE|Verde (Competitor-control)|contact lens
48463040|NCT02299869|DEVICE|Green (CVI-test)|contact lens
48463041|NCT02299869|DEVICE|Cinza (Competitor-control)|contact lens
48463042|NCT02299869|DEVICE|Grey (CVI-test)|contact lens
48099156|NCT06554132|OTHER|Scleroderma Group|Scleroderma patients will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
48463043|NCT02299869|DEVICE|Esmeralda (Competitor-control)|contact lens
48463044|NCT02299869|DEVICE|Jade (CVI-test)|contact lens
47935647|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
48463045|NCT02299869|DEVICE|Azul (Competitor-control)|contact lens
48463046|NCT02299869|DEVICE|Blue (CVI-test)|contact lens
48463047|NCT00353535|PROCEDURE|Total Lymphoid irradiation|
48623437|NCT00884988|DRUG|Placebo remedy|20 drops X3/day, until discharge
48623438|NCT01118923|DIETARY_SUPPLEMENT|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
48623439|NCT01118923|DIETARY_SUPPLEMENT|Placebo|3 placebo-tablets daily for 12 weeks
48623440|NCT01242007|OTHER|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
48623441|NCT03518606|DRUG|Durvalumab + Tremelimumab + metronomic Vinorelbine|Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
48623442|NCT04328194|DIAGNOSTIC_TEST|Serum Autotaxin|Marker
48623443|NCT04328194|RADIATION|chest x-ray|chest x- ray will be done for the study group
48623444|NCT04328194|DIAGNOSTIC_TEST|Breast ultrasound or mammography|Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer
48623445|NCT04328194|DIAGNOSTIC_TEST|Histopathological examination of breast mass specimens|by True cut or fine needle aspiration cytology
48281509|NCT03263091|DRUG|Roxadustat|Oral tablets
48623446|NCT04328194|RADIATION|Magnetic Resonance Imaging ( MRI) and Bone scan|will be done for the study group
48623447|NCT04328194|DIAGNOSTIC_TEST|Peripheral haemogram|blood sample will be taken from the patients
48623448|NCT04328194|DIAGNOSTIC_TEST|Renal and liver functions|to exclude any other morbidity
48623449|NCT04328194|DIAGNOSTIC_TEST|Prothrombin time and concentration|blood sample will be taken from the patients
48623450|NCT04328194|DIAGNOSTIC_TEST|Cancer Antigen 15-3 (CA15-3).|will be done for the 2 groups
48623451|NCT04328194|OTHER|Full medical history|full medical history will be taken from all patients
48623452|NCT04328194|OTHER|Full clinical examination|full clinical examination will be done for the patients
48623453|NCT02664493|DRUG|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
47935648|NCT01400438|OTHER|questionnaires|delivery of questionnaires and self-psychological interview
48099157|NCT06554132|OTHER|Healthy group|Healthy people will be evaluated in terms of respiratory muscle strength, aerobic capacity, pulmonary function test and fatigue.
48099158|NCT00994149|DRUG|Diazoxide|10mg/kg/d divide every 8 hours
48099159|NCT00994149|DRUG|Ora-plus|placebo, give every 8 hours.
48281510|NCT03263091|DRUG|Placebo|Oral tablets
48281511|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in capillary blood|After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.
48281512|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in other matrices|Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
48281513|NCT04358757|PROCEDURE|Elective cesarean delivery|scheduled cesarean delivery for maternal / obstetric indications
48281514|NCT04180592|PROCEDURE|CT Fusion + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
48463048|NCT05821426|DEVICE|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
48463049|NCT00320307|DRUG|abacavir|
48463050|NCT00475410|DRUG|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
48463051|NCT00475410|DRUG|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
48478843|NCT04908202|OTHER|Placebo|Specified dose on specified days
48478844|NCT03396874|DRUG|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
48478845|NCT01909934|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
48478846|NCT01130779|DRUG|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
48623454|NCT04623151|BEHAVIORAL|Online leaflet about foot care|Short text-based leaflet about foot care, presented online
48623455|NCT04691934|PROCEDURE|Anesthesia management|Patients who underwent cesarean section and had positive PCR nasopharyngeal swabs for COVID-19 were included in the study. Patients who tested negative and were clinically suspicious were excluded from the study. PCR test was not performed on all elective and emergency pregnant women to be taken for cesarean section in our hospital. It was only applied to patients with symptoms or patients who were suspected. All patient demographics and information about anesthesia were analyzed retrospectively from the patient files.
48623456|NCT00498550|DRUG|Clozapine|Clozapine up to 550mg per day
48623457|NCT00498550|DRUG|Treatment as usual|Remain on pre-study antipsychotic treatment
48623458|NCT00744198|PROCEDURE|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
48623459|NCT00744198|PROCEDURE|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
48623460|NCT00744198|PROCEDURE|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
48623461|NCT01186406|DRUG|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
48623462|NCT01186406|RADIATION|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
48623463|NCT01186406|DRUG|Avastin|"Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days."
48463052|NCT06175741|PROCEDURE|erector spinae plane block|The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
48623464|NCT01186406|DRUG|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
48623465|NCT04801082|DRUG|Alcohol injection|Chemical ablation is performed by injection of 10 mL of 0.25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol using a 22G FNA needle (Cook and Olympus)
48463053|NCT04893941|DRUG|CM310|IL-4Rα monoclonal antibody
48463054|NCT04893941|DRUG|Placebo|Placebo
48623466|NCT04801082|DEVICE|Radiofrequency Ablation|coeliac plexus is identified and punctured with 19G EUSRA RFA needle with 10W-30W of energy for 10-50s bilaterally or unilaterally depends on individual anatomical characteristics.
48623467|NCT01708603|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
48623468|NCT01708603|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
48623469|NCT01708603|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
48623470|NCT01708603|DRUG|placebo|Placebo administered SC
48623471|NCT01931605|DEVICE|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
48463055|NCT02705716|OTHER|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
48463056|NCT02705716|OTHER|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
48463057|NCT02195544|DRUG|Synvisc®|
48623472|NCT02272101|DIETARY_SUPPLEMENT|Vitamin D versus placebo|Cross-over design
48623473|NCT03778372|DRUG|Methadone|see desc above
48623474|NCT03494179|DRUG|ICP-022|The drug product is a white, round, uncoated tablet.
48463058|NCT03572582|DRUG|Nivolumab|Nivolumab therapy combined with standard TACE treatment
48623475|NCT03838705|PROCEDURE|hypoxia|It was accepted that hypoxia developed in patients with SpO2\< 92 or falling over 20% compared to preoperative values.
48623476|NCT03838705|PROCEDURE|normooxy|It was accepted that patients with SpO2 between 100-92 mmHg
48623477|NCT04607759|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume two capsules for eight weeks
48623478|NCT01684800|DRUG|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
48623479|NCT01684800|DRUG|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
48623480|NCT01684800|DRUG|C: Placebo|1 orally disintegrating tablet every night during study period
48623481|NCT02456064|BEHAVIORAL|Lifestyle counseling|"* Group medical visits~* Telephone medical consultations~* Expert patient~* Training workshops"
48623482|NCT04248179|DRUG|Ropivacaine injection|Ropivacaine 5mg/ml
48623483|NCT04248179|DRUG|Saline 0.9%|Saline 0.9%
48623484|NCT04248179|DRUG|Sufentanil and PONV prophylaxis|30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV prophylaxis) will be administered.
48281515|NCT05802329|DRUG|OCU200 Low Dose|Intravitreal Injection
48281516|NCT05802329|DRUG|OCU200 Medium Dose|Intravitreal Injection
48463059|NCT03572582|DRUG|TACE|TACE is performed by using drug eluting beads
48463060|NCT01680601|PROCEDURE|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
48463061|NCT01680601|PROCEDURE|Placebo|
48463062|NCT01260623|DRUG|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
48463063|NCT05191030|BEHAVIORAL|High-Stress Intervention|Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.
48463064|NCT00366639|OTHER|Acute Decompensated Heart Failure|Treatment \& outcomes during hospital admission for Acute DHF
48463065|NCT06316336|DRUG|Alfuzosin Hydrochloride 10 mg|Alfuzosin Hydrochloride 10 mg (test durg)
48463066|NCT06316336|DRUG|Xatral® XL 10 mg|Xatral® XL 10 mg (reference drug)
48463067|NCT04980105|BIOLOGICAL|Platelet-rich plasma|Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
48463068|NCT04980105|DRUG|Hyaluronic acid|Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
48463069|NCT04980105|DRUG|Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)|Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
48623485|NCT06229938|OTHER|Passive leg raise manoeuvre|"Stroke volume measurements are performed with the Nexfin hemodynamic monitor and the volemic state measurement is based on the principle of the classic passive leg raise test. The Nexfin monitor (Nexfin CC, Edwards Life Sciences, the Netherlands) uses a small inflatable cuff around the index finger of the right hand, to measure the blood pressure, and uses a specific algorithm to calculate the stroke volume.~First a baseline measurement is performed during supine position while the patient is lying in bed. Next, the head end will be lowered until lying flat, and the legs will be passively raised until the lower end of the bed is 30 degrees elevated. The change in stroke volume following the passive leg raise test is used to assess fluid responsiveness. An increase of 10% indicates a fluid responsive status or hypovolemia."
48623486|NCT05974553|BEHAVIORAL|Dialectical Behavior Therapy for Justice-Involved Veterans|16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans, including weekly 60-minute group therapy and biweekly 30-minute individual case management
48623487|NCT05974553|BEHAVIORAL|Supportive Group Psychotherapy for Justice-Involved Veterans|16 weeks of clinician-facilitated supportive group psychotherapy for justice-involved Veterans, including weekly 75-minute group psychotherapy (20 hours total intervention). All interventions delivered via telehealth.
48623488|NCT03846232|OTHER|No intervention|No intervention
48623489|NCT03022448|OTHER|No Intervention|This is a NIS. No intervention.
48623490|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
48623491|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
48463070|NCT01155531|DRUG|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
48623492|NCT02210754|OTHER|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
48623493|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
48623494|NCT02210754|OTHER|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
48623495|NCT02210754|OTHER|Marlboro Cigarette|cigarettes
48623496|NCT05220735|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)|"3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate."
48623497|NCT02197156|DRUG|10 mg HC-ER|Single dose
48623498|NCT02197156|DRUG|20 mg HC-ER|Single dose
48623499|NCT02197156|DRUG|30 mg HC-ER|Single dose
48623500|NCT02197156|DRUG|40 mg HC-ER|Single dose
48623501|NCT02197156|DRUG|10 mg HC / 325 mg APAP|Single dose
48623502|NCT02197156|DRUG|Matching Placebo|Single dose
48281517|NCT05802329|DRUG|OCU200 High Dose|Intravitreal Injection
48281518|NCT03456011|OTHER|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
48463071|NCT02188407|DRUG|Sevoflurane|MAC 3-5 V% during surgery
48463072|NCT02188407|DRUG|Propofol|Propofol group (P group)- The group anaesthesied with propofol
48463073|NCT04058977|OTHER|Power training|Progressive exercise protocol with focus on velocity of movement
48463074|NCT00491738|DRUG|bevacizumab|Intravenous repeating dose
48463075|NCT00491738|DRUG|sunitinib|Oral repeating dose
48463076|NCT00491738|DRUG|placebo|Intravenous repeating dose
48463077|NCT01676064|DRUG|ringer lactate solution|
48463078|NCT01676064|OTHER|restrictive fluid regime|
48463079|NCT04865471|PROCEDURE|Liver transplantation|Auxiliary liver transplantation and staged hepatectomy
48623503|NCT00001903|DRUG|RSV Polyclonal Immunoglobulin|
48623504|NCT02265744|DRUG|BMS-931699|
48623505|NCT02265744|DRUG|Placebo matching BMS-931699|
48623506|NCT05667129|DRUG|XEN-101|Capsule formulation
48623507|NCT05667129|DRUG|Placebo|capsule formulation
48623508|NCT04071886|BEHAVIORAL|Mindfulness-Based Training|Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
48623509|NCT04071886|BEHAVIORAL|Relaxation Training|Participants will listen to a 15-minute Relaxation Training tape twice a day.
48623510|NCT00255333|DRUG|INNO-105|
48623511|NCT04454502|OTHER|Oral colostrum administration|In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
48623512|NCT01186081|RADIATION|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
48623513|NCT01186081|RADIATION|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
48463080|NCT02847416|DEVICE|BreatheMAX breathing device|
48099160|NCT06629753|BEHAVIORAL|Differentiated service delivery model|The differentiated service delivery (DSD) intervention is a clinic-level intervention in which PMTCT clients are differentiated into those who are clinically stable or unstable, with each group offered a different package of services to meet their needs. The DSD model that is being tested in this study is an individual-focused, facility-based model designed for implementation within maternal-child health clinics offering integrated HIV services.
48281519|NCT01471327|BIOLOGICAL|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
48281520|NCT01471327|OTHER|Placebo|Saline IV, single dose at Day 1
48463081|NCT02231957|OTHER|educational text message reminders|
48099161|NCT04735939|RADIATION|radiotherapy|Determine whether there is a difference in outcomes seen when patients are assigned to take their radiotherapy at either a morning time or evening time.
48099162|NCT06411418|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.
48099163|NCT03342651|OTHER|Vitamin D|Vitamin D, general anesthesia, respiratory complications
48099164|NCT05602155|PROCEDURE|Group 1|Even numbered patients will partial weight bearing after treatment,
48463082|NCT02231957|OTHER|conventional text message reminders|
48463083|NCT02500615|OTHER|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
48099165|NCT05602155|PROCEDURE|Group 2|patients with odd numbers will walk with full weight bearing after treatment
48463084|NCT03053245|BEHAVIORAL|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
48281521|NCT01530490|DRUG|Cabergoline and Hydroxyethyl Starch|0.5mg
48281522|NCT01530490|DRUG|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
48281523|NCT02064764|DEVICE|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
48281524|NCT02064764|DEVICE|Arctic Front Advance™ Cardiac Cryoablation System|
48463085|NCT03053245|BEHAVIORAL|Attention Control|Patients in this group will receive regular wellness calls from the research team.
48463086|NCT02699866|DEVICE|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
48463087|NCT00785135|DEVICE|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
48463088|NCT00785135|DEVICE|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
48463089|NCT01664169|OTHER|laboratory biomarker analysis|
48463090|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
48463091|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
48463092|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
48463093|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
48463094|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
48463095|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
48463096|NCT00691704|DRUG|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
48478847|NCT00457210|PROCEDURE|Brain Radiotherapy/Stereotactic Radiosurgery|
48099166|NCT01444287|DEVICE|narafilcon B|test product
48281525|NCT04273984|DRUG|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
48281526|NCT00587223|DEVICE|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
48281527|NCT00587223|OTHER|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
48281528|NCT06261788|DEVICE|Temporary pacing|Transvenous temporary cardiac pacing - right internal jugular insertion
48281529|NCT01061008|OTHER|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
48463097|NCT00691704|DRUG|Sequential Maintenance Therapy|"Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
48463098|NCT01835548|DRUG|NT0102|NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
48623514|NCT01454999|BEHAVIORAL|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
48623515|NCT05356663|OTHER|Mulligan Mobilization|Medial glide MWM for knee flexion (supine) Lateral glide MWM for knee flexion (supine) Medial glide MWM for knee flexion.( prone ) Lateral glide MWM for knee flexion (prone)
48623516|NCT05356663|OTHER|Hold Relax|Hold-relax technique of PNF included, the affected knee will be flexed passively to the end of range with the therapist's hand on the patient's lower leg. Patients then performed 5 s of quadriceps contraction against the resistance of the therapist. Patients will be asked not to let move. At the end of 5 s, the patients will be asked to totally relax for 10 s and the therapist pushed the knee into more flexion and hold at that newly acquired range
48623517|NCT00134576|BEHAVIORAL|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
48623518|NCT00915525|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
48623519|NCT04225650|OTHER|Pulmonology consultation|In case of functional respiratory signs, a consultation with a pulmonologist will be booked. At the end of this consultation, if the doctor deems it necessary, other investigations will be proposed and/or regular follow-up will be organised.
48623520|NCT03763981|PROCEDURE|prolene seton treatment|patients with perianal fistulas will treated with seton placement by prolene thread
48623521|NCT03763981|PROCEDURE|silk seton treatment|patients with perianal fistulas will treated with seton placement by silk thread
48623522|NCT04604860|BEHAVIORAL|Fitness intervention|Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
48623523|NCT04540198|BEHAVIORAL|GamePlan4Care|GamePlan4Care; Experimental
48623524|NCT04540198|BEHAVIORAL|Resources4Care|R4C; Active Comparator
48623525|NCT04581746|OTHER|questionnaire|bi-monthly questionnaire and then one visit with questionnaire and covid-19 test
48623526|NCT04568772|DRUG|Atovaquone / Proguanil 250/100 mg|Atovaquone / Proguanil 250/100 mg tablet
48623527|NCT04568772|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
48623528|NCT04568772|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet
48463099|NCT01835548|DRUG|Placebo|Matching ODT placebo was given once daily.
48463100|NCT03645616|DIAGNOSTIC_TEST|6-minute walk test|"First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires."
48463101|NCT03645616|DIAGNOSTIC_TEST|10 meters walk test|"First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test."
48463102|NCT03645616|DIAGNOSTIC_TEST|30 Second Sit to Stand Test|At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.
48623529|NCT04568772|DRUG|Vonoprazan 20 mg|Vonoprazan 20 mg tablet
48623530|NCT02475668|DEVICE|Pulse oximeter|Hypoxia
48623531|NCT01410253|OTHER|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
48623532|NCT01410253|OTHER|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
48623533|NCT01410253|OTHER|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
48623534|NCT01410253|OTHER|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
48623535|NCT04804488|PROCEDURE|nasal polyp surgery|A retrospective study for patients with recurrent nasal polypi operated at Otorhinolaryngology Department, Sohag University Hospital will be carried out.
48623536|NCT04134871|BEHAVIORAL|Group walk and one to one coaching|Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
48099167|NCT01444287|DEVICE|Polymacon|marketed product
48099168|NCT01444287|DEVICE|Lotrafilcon A|marketed product
48099169|NCT01444287|OTHER|Spectacles|None - subject used own spectacles
48099170|NCT04441242|OTHER|Ambient lighting|Use of ambient lighting (75-150 lux) in endoscopy room.
48099171|NCT04441242|OTHER|Low lighting|Use of low lighting (\<75 lux) in endoscopy room.
48463103|NCT02933060|OTHER|Normal saline (1000 mL)|
48463104|NCT02933060|OTHER|Control|
48623537|NCT00853385|DRUG|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
48623538|NCT00853385|DRUG|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
48623539|NCT00853385|OTHER|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
48623540|NCT00853385|OTHER|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
48623541|NCT00853385|BIOLOGICAL|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
48623542|NCT05970458|OTHER|Quality of life assessment|EQ5D-5L and Stoma QoL
48623543|NCT01765998|DRUG|Probiotic|Clinical evaluation according to the Crohn's activity scale
48623544|NCT01765998|DRUG|Placebo|
48623545|NCT02837653|BEHAVIORAL|Physical Activity Counselling|
48463105|NCT02763631|OTHER|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
48463106|NCT02763631|OTHER|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
48463107|NCT02763631|OTHER|Sham Comparator: Stand Care Arm|No change will be made to participants care
48463108|NCT03105193|DRUG|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
48463109|NCT03105193|DRUG|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
48463110|NCT03105193|DRUG|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
48463111|NCT03105193|DRUG|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
48463112|NCT03819088|DIETARY_SUPPLEMENT|Zinc|Given PO
48463113|NCT02763696|OTHER|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
48463114|NCT05659316|OTHER|MRI imaging|Knee MRI imaging
48463115|NCT02000388|DRUG|Ketorolac Tromethamine|
48463116|NCT02000388|OTHER|Standard of Care|
48463117|NCT04966962|DIAGNOSTIC_TEST|serum and urine metabolomics|serum and urine samples will be collected for metabolomics analysis
48463118|NCT05330533|RADIATION|scrotal duplex|Scrotal colour doppler ultrasonography
48099172|NCT03044769|PROCEDURE|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
48281530|NCT01061008|OTHER|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
48463119|NCT04039230|DRUG|Talazoparib|Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
48463120|NCT04039230|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
48463121|NCT02757703|DRUG|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
48478848|NCT03609242|BEHAVIORAL|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
48623546|NCT02837653|OTHER|Therapeutic Exercise for LBP|
48623547|NCT02837653|OTHER|Superficial Thermotherapy|
48623548|NCT01794416|PROCEDURE|Thoracoscopic epicardial ablation|
48623549|NCT01794416|PROCEDURE|Endocardial catheter ablation|
48623550|NCT01794416|DEVICE|Implantable loop recorder|
48623551|NCT02874898|BEHAVIORAL|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
48623552|NCT04877054|BEHAVIORAL|Adherence Treatment Program|4 telehealth sessions including a combination of psycho/medical education plus a motivational interviewing component.
48623553|NCT04877054|BEHAVIORAL|Education only|The control group will receive an education-only session. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
48463122|NCT02757703|DRUG|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
48463123|NCT02757703|DRUG|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
48463124|NCT02757703|DEVICE|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
48463125|NCT02941159|BIOLOGICAL|SF2000SD|This is an intergrase inhibitor
48463126|NCT02941159|BIOLOGICAL|Placebo|
48463127|NCT02774018|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) program|
48463128|NCT03318133|PROCEDURE|anesthesia|in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
48463129|NCT04943887|BEHAVIORAL|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
48463130|NCT00697619|DRUG|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
48099173|NCT03789799|OTHER|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
48463131|NCT03585309|PROCEDURE|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
48463132|NCT01534754|DRUG|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
48463133|NCT01534754|DRUG|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
48463134|NCT01534754|DRUG|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
48463135|NCT01534754|DRUG|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
48463136|NCT01711567|DRUG|tenofovir|tenofovir 300 mg qd
48463137|NCT01711567|DRUG|entecavir|entecavir 0.5 mg qd
48463138|NCT01816789|DRUG|rFSH|
48463139|NCT01816789|DRUG|buserelin|
48463140|NCT00002592|BIOLOGICAL|c-myb antisense oligonucleotide G4460|
48463141|NCT00002592|BIOLOGICAL|filgrastim|
48463142|NCT00002592|DRUG|busulfan|
48463143|NCT00002592|DRUG|cyclophosphamide|
48463144|NCT00002592|PROCEDURE|autologous bone marrow transplantation|
48099174|NCT03789799|OTHER|Placebo|Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
48099175|NCT04791124|OTHER|Electroencephalography|"EEG evaluation Composed by three consecutive tests~1. Resting state EEG, with either eyes open or closed~2. Auditory steady-state response (ASSR)~3. Auditory evoked potential"
48099176|NCT05866081|DEVICE|Standard of care stent placement|Participants will have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
48099177|NCT05866081|OTHER|No stent placement|Participants not have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
48281531|NCT01403077|DEVICE|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
48281532|NCT03890055|DRUG|Anlotinib Hydrochloride|Best supportive care
48463145|NCT00002592|PROCEDURE|in vitro-treated bone marrow transplantation|
48463146|NCT05727579|OTHER|Salt-Diet and/or Ertugliflozin|The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
48463147|NCT02342938|PROCEDURE|MEG or fMRI And INtracranial EEG|
48463148|NCT02342938|PROCEDURE|fMRI|
48463149|NCT05736250|DIAGNOSTIC_TEST|biopsie|gingival biopsie
48463150|NCT02806063|PROCEDURE|intraoperative samples|
48099178|NCT05866081|OTHER|Surveys|"All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes."
48463151|NCT06134986|OTHER|Time restricted eating|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
48463152|NCT06134986|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
48463153|NCT01833039|DRUG|Ibrutinib|Ibrutinib
48099179|NCT00316784|DRUG|IDEA-033 (and rescue medication)|
48463154|NCT01985724|DRUG|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
48463155|NCT01985724|DRUG|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
48463156|NCT01985724|DRUG|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
48463157|NCT01985724|DRUG|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
48463158|NCT01985724|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
48463159|NCT03045016|DRUG|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
48463160|NCT06022588|DRUG|Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA|a solution containing butyrate of which 12C of the last 4 carbon positions of butyrate were replaced by 13C butyrate. Participants received 0.80 gram 13C-butyrate (7.3 mMol butyrate / 29 mMol 13C) dissolved in 50 mL water at baseline
48463161|NCT06022588|DRUG|U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA|a glucose solution in which all six 12C carbons were replaced by 13C D-Glucose. Participants received 0.75 gram 13C-glucose (4.2 mMol D-glucose/ 25 mMol 13C) dissolved in 50 mL water at baseline
48463162|NCT06022588|DIAGNOSTIC_TEST|Breath test|Breath tests were performed at the following time points baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours after ingestion of 13C-butyrate and 13C-glucose. Breath samples were obtained by blowing a single breath of air through a straw into a test tube. Two breath samples were collected at all mentioned time points. Measurement of 13CO2 is performed using mass spectrometry (IDMicro Breath, Compact Science Systems, Newcastle-Under-Lyme, United Kingdom) using procedures described earlier for galactose and methacetin breath tests, and expressed as an absolute increase in the 13CO2-to-12CO2 ratio in delta permil (δ‰).
48463163|NCT06022588|DIAGNOSTIC_TEST|Exercise + breath test|The intervention groups performed a standardized bicycle ergometer exercise test of 30 minutes and semi-continuous peripheral blood lactate monitoring. The bicycle ergometer protocol consists of three phases. The first 10 minutes of exercise was used to gradually increase the workload until submaximal exercise intensity was reached which is defined as a circulating blood lactate level between 3 and 5.5 mmol/L. From minute 10 to 20 submaximal exercise intensity was maintained by adjusting the workload based on lactate measurements. Minute 20 to 30 was used to reach maximal exercise intensity, the workload was increased by 10% of the submaximal workload until exhaustion
48463164|NCT01296607|DRUG|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
48463165|NCT01296607|DRUG|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
48463166|NCT01990807|DRUG|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
48463167|NCT03799224|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
48463168|NCT03799224|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
48463169|NCT03799224|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
48463170|NCT06024148|OTHER|phone survey|patients complete a 10-minute telephone questionnaire on their osteoporosis management
48463171|NCT04089462|BEHAVIORAL|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
48099180|NCT04222244|OTHER|No intervention will be administered. We are only performing tests and measures.|No intervention will be administered. We are only performing tests and measures.
48099181|NCT05687500|DRUG|Glibenclamide|Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
48099182|NCT05687500|BIOLOGICAL|Pharmacokinetics study|"0.2 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.~PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant ,apparent clearance and volume of distribution"
48099183|NCT05687500|BIOLOGICAL|C-peptide proinsulin ratio|blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio
48281533|NCT01209715|DRUG|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
48099184|NCT05687500|BIOLOGICAL|Blood glucose on fluorinated tube|0.3 ml blood sampling at 3 hours, 6 hours, 10 hours and 24 hours after the first administration and after 24 hours of blood glucose stabilization.
48281534|NCT01209715|DRUG|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
48463172|NCT04089462|BEHAVIORAL|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
48463173|NCT01728116|DEVICE|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
48463174|NCT01728116|PROCEDURE|Sham Procedure|Endoscopic evaluation but no device placement
48463175|NCT02934334|OTHER|Observational|
48463176|NCT03409315|PROCEDURE|Centralized Therapeutic Drug Monitoring|Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
48463177|NCT02146690|OTHER|osteopathic manipulative treatment|
48463178|NCT02146690|OTHER|sham therapy|
48463179|NCT02146690|OTHER|usual care|
48463180|NCT03134053|DEVICE|extracorporeal shock-wave|to treat painful and retracting scars
48463181|NCT03134053|OTHER|massage|to treat painful and retracting scars
48463182|NCT03373630|DEVICE|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
48463183|NCT02621190|DRUG|cabazitaxel|25mg/m2 q3w
48463184|NCT01919827|BIOLOGICAL|Endobronchial infusion of adult mesenchymal stem cells|
48463185|NCT01919827|BIOLOGICAL|Autologous mesenchymal stem cells derived from bone marrow|
48463186|NCT00743145|DRUG|Inactive Marijuana (0% THC)|Marijuana cigarette containing 0% THC
48463187|NCT00743145|DRUG|Active Marijuana (5.5% THC)|Marijuana cigarette containing 5.5% THC
48463188|NCT00743145|DRUG|Active Marijuana (6.2% THC)|Marijuana cigarette containing 6.2% THC
48463189|NCT00743145|DRUG|Naltrexone|Naltrexone (12mg/70kg)
47935649|NCT06046157|OTHER|Breast milk-scented PIOMI|"During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
48463190|NCT00743145|DRUG|Placebo naltrexone|Naltrexone (0mg)
48463191|NCT04815668|OTHER|Acupuncture group|Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
48463192|NCT04815668|OTHER|Placebo acupuncture group|The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
48463193|NCT04815668|OTHER|Rescue medication group|Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
48463194|NCT03087435|DEVICE|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
48463195|NCT01845064|DRUG|DM199|
48463196|NCT01845064|DRUG|Placebo|
48463197|NCT00344513|DRUG|Beta-blockers including Carvedilol|
47935650|NCT06046157|OTHER|Breast milk-tasting PIOMI|"The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength."
47935651|NCT06097143|OTHER|Flowable Giomer|Pre-reacted Glass Ionomer (PRG) filler is added to resin to create giomer, a dental adhesive material. Fluoride release and recharge, acid resistance, an anti-plaque effect, dentin remineralization, and acid buffering capacity are some of the benefits of giomer.
48463198|NCT00344513|DRUG|ACE inhibitors|
48463199|NCT00268515|DRUG|cyclosporine|
48463200|NCT00268515|DRUG|tacrolimus|
48463201|NCT00268515|DRUG|prednisone|
48463202|NCT00268515|DRUG|azathioprine|
48478849|NCT03919487|PROCEDURE|Back to back colonoscopy|After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
48478850|NCT03476317|DRUG|Vancomycin|Oral suspension 4 times daily (Day 1-14)
48478851|NCT03476317|DRUG|Neomycin|Oral three times daily (Days 1-3)
48623554|NCT05175365|BEHAVIORAL|Dance|Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
48623555|NCT02548182|DEVICE|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults \[REF\]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
48463203|NCT05011656|DEVICE|Seraph-100 + State of the Art Care|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.
48463204|NCT05011656|DEVICE|State of the Art Care|"State of the Art careis defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"
48463205|NCT02385760|DRUG|CTX-4430|
47935652|NCT06097143|OTHER|Flowable Nano-filled composite with S-PRG barrier coat|"Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.~The PRG Barrier Coat is a resinous coating substance that shields the enamel surface from demineralization brought on by acidic attack. Near the coated surface, S PRG filler ions in PRG Barrier Coat have been found to have an acid-neutralizing effect. F and Sr released by PRG Barrier Coat can be effectively absorbed by the tooth substrate to prevent demineralization thus hindering the progression of caries."
48463206|NCT02385760|DRUG|Placebo|
48463207|NCT03574051|DRUG|Probiotic|Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
47935653|NCT06097143|OTHER|Flowable Nano-filled composite|Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.
47935654|NCT03923478|DRUG|ABI-M201|Active Treatment
48463208|NCT02034513|DRUG|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
48463209|NCT02034513|DRUG|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
48463210|NCT02034513|DRUG|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
48463211|NCT06063590|BIOLOGICAL|StromaForte|100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
48463212|NCT00398593|BEHAVIORAL|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
48099185|NCT05687500|BIOLOGICAL|Routine biological monitoring|If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.
48099186|NCT05687500|BIOLOGICAL|glycose holter monitor|glucose levels will be collected with a smarter continuous glucose monitoring system, placed on inclusion and until the end of treatment
48099187|NCT04251351|DRUG|Paracetamol|Paracetamol 15 mg/kg/dose IV 6 hourly for 72 hours
48099188|NCT04251351|PROCEDURE|Mechanical antipyresis|"Mechanical antipyresis (i.e. loose clothing, tepid sponging, fanning and cooling blanket) if fever in the first 72 hours.~If a temperature \>38.5°C persists despite mechanical antipyresis, or if deemed necessary by the treating clinician, then paracetamol can be administered according to local practice (paracetamol IV 15 mg/kg as needed)."
48463213|NCT05727020|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of six hours prior to sample collection. For patients undergoing surgery or a procedure (e.g. endoscopy), breath samples must be obtained pre-operatively / prior to the administration of sedation, anaesthetic or other pharmacological agents.
48099189|NCT03699735|DEVICE|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
48463214|NCT05727020|DIAGNOSTIC_TEST|Collection of matched samples of breath, biofluids and pancreatic tissue|In accordance with routine clinical practices, patients will be fasted for a minimum of six hours prior to surgery. Exhaled breath, saliva, blood and urine will be collected immediately prior to surgery (before induction of general anaesthesia). Pancreatic tissue samples and duodenal aspirate which will be collected upon resection of the pancreatic specimen.
48463215|NCT03687619|OTHER|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
48463216|NCT03687619|OTHER|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
48463217|NCT00833534|BIOLOGICAL|rituximab|Given IV
48463218|NCT00833534|DRUG|lenalidomide|Given orally
48463219|NCT01724762|OTHER|Nursing Orientation|"* Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~* Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
48463220|NCT05386134|DEVICE|Adaptive Optics Retinal Camera|The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
48463221|NCT05731687|OTHER|Hybrid DEB approach with drug-eluting balloon|If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and \< TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.
48463222|NCT05731687|OTHER|Two-stent strategy|When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
48463223|NCT01104181|DEVICE|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
48463224|NCT00770952|DRUG|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
48463225|NCT00770952|DRUG|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
48099190|NCT03766438|BEHAVIORAL|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
48463226|NCT03695354|DEVICE|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
48463227|NCT03695354|PROCEDURE|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
48478852|NCT03476317|DRUG|Ciprofloxacin|Oral twice daily (Days 4-14)
47935655|NCT03923478|DRUG|Placebo|Control Treatment
47935656|NCT05999539|DEVICE|Transtibial prosthesis|A transtibial prosthesis to be used for at least one year.
47935657|NCT04696497|DIAGNOSTIC_TEST|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~* Shoulder Side muscular compartment~* Anterior Arm muscular compartment~* Anterior thigh muscular compartment~* Antero-lateral leg muscular compartment"
48099191|NCT05300451|BIOLOGICAL|Daratumumab and hyaluronidase-fihj|Daratumumab and hyaluronidase-fihj for subcutaneous (under the skin) injection has different dosing and administration instructions compared to daratumumab for intravenous (in the vein) infusion. Daratumumab and hyaluronidase-fihj contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes. Subjects will receive a 1800mg/30000u injection subcutaneously weekly for a total of 8 doses
48623556|NCT02548182|OTHER|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
48623557|NCT00614393|BIOLOGICAL|dalotuzumab|IV infusion
48623558|NCT00614393|DRUG|irinotecan hydrochloride|IV infusion
48623559|NCT00614393|BIOLOGICAL|cetuximab|IV infusion
48623560|NCT00614393|DRUG|placebo|IV infusion
48623561|NCT06305065|PROCEDURE|KUNWU Navigation TKA procedure|"In terms of technical specifications, KUNWU is the only robotic arm with seven degrees of freedom, while other systems have a maximum of six. The ergonomic and user-friendly design of the system contributes to physical relief and simplified instrument handling, which enhances surgical precision and reduces cognitive stress.~KUNWU's navigation system boasts a refresh rate of 335Hz, which is significantly higher than the current 60Hz rate of other navigation systems. This high refresh rate provides a clear and visually captivating display of the navigation procedure, eliminating blurriness and indecipherable output. It enables surgeons to react promptly during live procedures, enhancing safety for both clinicians and patients and reducing potential complications and hospitalization."
48623562|NCT06305065|PROCEDURE|CORI Surgical System TKA procedure|The CORI Surgical System (Smith and Nephew®) represents one of such recent advances in robotics that it can assist surgical planning, and increase the accuracy of implant position due to real-time feedback during the procedure (bone resection, implant position, ligamentous balance).
48099192|NCT04587479|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
48463228|NCT06315660|BEHAVIORAL|Cognitive Miljeu Therapy|TAU is an integrated voluntary inpatient treatment based on the principles of CBT, lasting between 12-20 weeks. This treatment includes exercise, close medical monitoring, group-based CBT for SUD, planning with social services, and is called Cognitive Milieu Therapy.
48463229|NCT06315660|BEHAVIORAL|Virtual Reality based CBT for Anxiety|The experimental intervention is a manualized add-on to TAU and comprises eight sessions of 60 minutes over a period of four weeks. Of these eight sessions, six will include 30 minutes of VR-based behavioral experiments targeting agoraphobic and social fear.
48099193|NCT06630325|DRUG|Abemaciclib|Given PO
48099194|NCT06630325|PROCEDURE|Biopsy|Undergo tumor biopsy
48463230|NCT05086913|OTHER|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
48463231|NCT05086913|OTHER|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
48463232|NCT05086913|OTHER|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
48463233|NCT03544242|OTHER|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
48463234|NCT03544242|DRUG|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
48463235|NCT03544242|DRUG|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
48463236|NCT04951856|DRUG|Evolocumab 140 MG/ML|Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
48463237|NCT04951856|DRUG|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
48463238|NCT00139594|DRUG|licarbazepine|
48463239|NCT02213887|DRUG|Pantoprazole|40 mg PO QAM
48463240|NCT02213887|DRUG|Pantoprazole|0 mg PO QAM
48463241|NCT06257979|OTHER|This study is with minimal risk and minimal constraints due to the addition of questionnaires|"In this study, the specific procedures compared to routine care are :~* Considering the addition of questionnaires, this study will be prospective. Due to the use of bacteriological samples, it is considered as a minimal-risk research.~* The research procedure involves a bacteriological analysis of operative elements (sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product)) used during the re-intervention. These usually discarded operative samples are collected for bacteriological analysis.~* Antibiotic treatment cannot be prescribed immediately after the surgery and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study."
48463242|NCT00048139|DRUG|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
48463243|NCT00048139|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
48463244|NCT00213590|DRUG|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
48623563|NCT06305065|PROCEDURE|Conventional TKA procedure|Total knee arthroplasty (TKA) is a highly successful and frequently performed surgical treatment to reduce disability caused by end-stage osteoarthritis and other conditions affecting articular cartilage. Technical outcomes for TKA are excellent, with favorable postoperative health-related quality of life. Also, survivorship of primary knee replacements is excellent with reported survivorship of 82.3% at 25 years. TKA has traditionally been indicated in the elderly population with relatively sedentary lifestyles, but more active, younger patients (\<55) are receiving TKA due to the desire for a pain-free, active lifestyle with the demand projected to continue to increase for this group. A recent systematic review has shown that functional outcomes are similar in this population compared to elderly patients with no increase in the burden of revision.
48623564|NCT04776772|DIETARY_SUPPLEMENT|Synbiotic complement|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic)."
48623565|NCT04776772|DIETARY_SUPPLEMENT|Placebo|"On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo)."
48463245|NCT06144034|DEVICE|Air polishing with erythritol powder|Air polishing with erythritol powder utilized for biofilm disclosing and, followed by an ultrasonic scaler to remove calculus if present.
48463246|NCT06144034|DEVICE|Conventional treatment|Rubber cup polishing with prophy paste after biofilm disclosing, followed by ultrasonic scaling of calculus if present.
48623566|NCT02342730|BEHAVIORAL|Weight Loss Specialist|Referred to a weight loss specialist
48623567|NCT02342730|OTHER|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
48623568|NCT02342730|OTHER|Medical Chart Review|Chart reviews are performed
48463247|NCT01911429|DRUG|Lurasidone 40 mg|Lurasidone 40 mg once daily
48463248|NCT01911429|DRUG|Lurasidone 80 mg|Lurasidone 80 mg once daily
48463249|NCT01911429|DRUG|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
48463250|NCT02736019|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
48463251|NCT02736019|DRUG|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
48463252|NCT02736019|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
48463253|NCT02736019|DRUG|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
48623569|NCT05052645|PROCEDURE|Auricular acupuncture|Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.
48623570|NCT02963324|DRUG|Ivermectin|
48623571|NCT02612155|BIOLOGICAL|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
48099195|NCT06630325|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48099196|NCT06630325|DRUG|Carboplatin|Given IV
48099197|NCT06630325|PROCEDURE|Echocardiography|Undergo echocardiography
48099198|NCT06630325|DRUG|Exemestane|Given PO
48099199|NCT06630325|DRUG|Fulvestrant|Given IM
48463254|NCT02342509|DRUG|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
48463255|NCT02342509|DRUG|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
48463256|NCT02342509|DRUG|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
48463257|NCT04436419|DIETARY_SUPPLEMENT|Alpha lipoic acid (plus full hospitalization)|"Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI\> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1\*04-03/06 polymorphisms; recent hospitalization (\<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals."
48463258|NCT04436419|DIETARY_SUPPLEMENT|Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)|Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
48463259|NCT06466135|DRUG|WAL0921|Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
48463260|NCT06466135|DRUG|Placebo|Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
48463261|NCT06248294|DIAGNOSTIC_TEST|CT follow-up|Computed tomography angiography assessment of BAV-related aorthopathy
48463262|NCT05712564|OTHER|Questionnaire|Questionnaire for fatigue assessment
48463263|NCT01732328|DIETARY_SUPPLEMENT|Calcium plus vitamin D|
48463264|NCT01050764|DRUG|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg"
48463265|NCT01050764|DRUG|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
48623572|NCT02612155|BIOLOGICAL|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
48623573|NCT06255483|OTHER|Osteoperiosteal pedicled clavicular flap for mandibular and facial bone reconstruction|"A clavicular flap with a vascular supply based on the transverse cervical artery which receives a reverse blood supply from the ascending cervical artery. This vascular pattern is reliable because of the existence of the sub-occipital microvascular network named the  Bosniak node ."
48623574|NCT02908321|BEHAVIORAL|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
48623575|NCT00366769|DEVICE|Wavefront-guided LASIK using CustomVue platform|
47935658|NCT04696497|DIAGNOSTIC_TEST|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
48099200|NCT06630325|DRUG|Gefitinib|Given PO
48463266|NCT01050764|DRUG|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
48463267|NCT01050764|DRUG|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
48463268|NCT01050764|DEVICE|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
48463269|NCT01050764|DRUG|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
48463270|NCT01050764|DRUG|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
48463271|NCT02364869|DIETARY_SUPPLEMENT|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
48463272|NCT02364869|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
48463273|NCT04731324|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
48463274|NCT02212457|BIOLOGICAL|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
48463275|NCT02212457|OTHER|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
48463276|NCT02212457|BIOLOGICAL|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
48463277|NCT02212457|BIOLOGICAL|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
48463278|NCT00531128|BEHAVIORAL|High/Low Sitosterol|
48463279|NCT02364986|DRUG|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
48463280|NCT02364986|DRUG|Avonex|Avonex 30µg (day 1 and 8) i.m.
48623576|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
48623577|NCT00652041|DRUG|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is \<Grade 2, dose should be increased to 200 mg/24 h. in day 15
48623578|NCT00652041|DRUG|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
48623579|NCT04115059|DRUG|Dasatinib|Oral, daily, dosing per protocol, once a day for cycle
48623580|NCT06445491|OTHER|Control order|Participants will perform an initial baseline of tests, order of 1- 2- 3
48623581|NCT06445491|OTHER|Randomized sequence|the testing order will be randomized for follow up testing.
48099201|NCT06630325|DRUG|Gemcitabine|Given IV
48099202|NCT06630325|DRUG|Letrozole|Given PO
48099203|NCT06630325|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48463281|NCT04339634|OTHER|Simulation of Repurposed Drugs for COVID-19|This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
48463282|NCT02599662|RADIATION|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
48623582|NCT00082316|DRUG|Capsaicin Dermal Patch|
48623583|NCT05540327|DRUG|M5049 low dose|Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 48 weeks.
48099204|NCT06630325|DRUG|Olaparib|Given PO
48099205|NCT06630325|DRUG|Osimertinib|Given PO
48099206|NCT06630325|DRUG|Paclitaxel|Given IV
48099207|NCT06630325|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48099208|NCT06630325|DRUG|Pemetrexed|Given IV
48099209|NCT06630325|OTHER|Survey Administration|Ancillary studies
48099210|NCT06630325|DRUG|Tamoxifen|Given PO
48099211|NCT06630325|DRUG|Temozolomide|Given PO
48099212|NCT04408183|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
48623584|NCT05540327|DRUG|M5049 medium dose|Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 48 weeks.
48623585|NCT05540327|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 48 weeks.
48623586|NCT05540327|DRUG|Placebo|Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.
48623587|NCT05540327|DRUG|M5049 very high dose|Participants will receive film-coated tablets of M5049 at a very high dose orally, BID for up to 48 weeks.
48623588|NCT05420454|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
48623589|NCT05420454|DRUG|Carboplatin|AUC 6, d1, q3w ,6 cycles
48623590|NCT05420454|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w ,6 cycles
48463283|NCT02599662|RADIATION|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
48463284|NCT02599662|RADIATION|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
48623591|NCT05420454|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w,6 cycles
48623592|NCT05420454|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
48623593|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q3w × 4 cycles,followed by docetaxel
48623594|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w ,4 cycles,followed by docetaxel
48623595|NCT05420454|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
48623596|NCT05420454|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles,followed by nab-paclitaxel
48623597|NCT05420454|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
48623598|NCT05420454|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
48623599|NCT01666977|DRUG|AMG 386|15mg/kg
48623600|NCT01666977|DRUG|AMG 386|30 mg/kg
48623601|NCT01666977|DRUG|AMG 386 Placebo|AMG 386 Placebo
48281535|NCT05117970|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
48623602|NCT01666977|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
48623603|NCT01666977|DRUG|Carboplatin|Carboplatin AUC 6
47935659|NCT04696497|DIAGNOSTIC_TEST|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
48281536|NCT05384730|OTHER|Group nutrition and exercise support|Weekly group nutrition and exercise support delivered online through trained volunteers
48478853|NCT03476317|DRUG|Polyethylene Glycol 3350|Dissolved in Gatorade on day 2
48478854|NCT03476317|DRUG|Fluconazole|Orally once daily (Day 1-14)
48623604|NCT00536835|DRUG|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
48623605|NCT00708669|DEVICE|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
48623606|NCT00708669|DEVICE|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
48623607|NCT02807259|BEHAVIORAL|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
48623608|NCT03893708|BEHAVIORAL|Prenatal yoga|The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
48623609|NCT03893708|BEHAVIORAL|Pregnancy education|Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
48623610|NCT06118320|DRUG|Potassium sodium hydrogen citrate|"Medication: Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/package).~Method: Preprandial urine pH was monitored to maintain an effective range of 6.2 to 6.8. One package should be taken after breakfast, one after lunch, and two after dinner. If the pH falls below 6.2, a half-package dose should be added; if it exceeds 6.8, a half-package dose should be reduced accordingly. Oral medication will be administered for a duration of three months.~Medication requirements: Abstain from alcohol and smoking during treatment period and avoid using any probiotics or drugs that lower uric acid levels."
48463285|NCT03506594|DEVICE|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
48463286|NCT06397716|GENETIC|ALDH2 Genotyping|Cheek swab for PCR testing of ALDH2 genotype.
48463287|NCT00789776|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
48463288|NCT00789776|DRUG|Cyclophosphamide|Given IV
48463289|NCT00789776|DRUG|Fludarabine Phosphate|Given IV
48463290|NCT00789776|OTHER|Laboratory Biomarker Analysis|Correlative studies
48463291|NCT00789776|DRUG|Mycophenolate Mofetil|Given PO
48463292|NCT00789776|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
48463293|NCT00789776|DRUG|Tacrolimus|Given IV or PO
48463294|NCT00789776|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
48463295|NCT05856058|DRUG|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
48463296|NCT01137864|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
48463297|NCT02339363|BEHAVIORAL|Sitting Meditation|4 weeks Sitting Meditation
48463298|NCT02339363|BEHAVIORAL|Hatha yoga|4 weeks of Hatha yoga
48463299|NCT02579005|BIOLOGICAL|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
48463300|NCT02579005|BIOLOGICAL|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
48281537|NCT00849550|DRUG|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
48463301|NCT05214677|DRUG|DW1809|pelubiprofen 30mg
48463302|NCT05214677|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
48463303|NCT01897324|DRUG|Growth hormone (Norditropin, Novo nordisk)|
48463304|NCT04665817|DIAGNOSTIC_TEST|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
48463305|NCT04665817|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
48463306|NCT04665817|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
48478855|NCT05188183|DEVICE|M1 anodal home-based tDCS|During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
48623611|NCT04185727|OTHER|Supervised strength training|12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
47935660|NCT01680510|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|
47935661|NCT01680510|OTHER|Placebo (starch)|
47935662|NCT02718950|DRUG|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
48281538|NCT03149835|OTHER|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
48463307|NCT01230229|PROCEDURE|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
48463308|NCT01230229|OTHER|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
48463309|NCT05319574|RADIATION|SBRT|Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
48463310|NCT05319574|DRUG|Tislelizumab|200mg q3w for two cycles administrated concurrently with chemotherapy
48463311|NCT04404725|DEVICE|comfilcon A|Subjects will be randomized to wear comfilcon A for one month.
48463312|NCT04404725|DEVICE|Samfilcon A|Subjects will be randomized to wear samfilcon A for one month.
47935663|NCT03630276|DIAGNOSTIC_TEST|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
47935664|NCT02828891|DEVICE|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
47935665|NCT05909527|BIOLOGICAL|CD7 CAR-T|A single infusion of autologous CD7 CAR-T cells administered intravenously
48463313|NCT00892749|DRUG|ASP1585|oral
47935666|NCT01280045|PROCEDURE|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
48623612|NCT05835700|OTHER|Gasdermin-d|Maternal serum Gasdermin-D levels in preterm labor and healthy pregnant women.
48623613|NCT02083211|DRUG|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
47935667|NCT05060523|DRUG|Tolvaptan Tablets|• Tolvaptan15 mg once a day for 7 days, stat with 7.5 mg and titrate to 15 mg in 24 hours max30 mg
47935668|NCT05060523|DRUG|Midodrine Oral Tablet|"• Midodrine 5 mg at 0 hours and then 5 mg every 8 hours to maintain Target MAP-80"
47935669|NCT05060523|OTHER|Placebo|Placebo of Midodrine
47935670|NCT05680259|OTHER|Maela connected follow-up|Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
47935671|NCT05680259|OTHER|traditional follow-up|medical recommendations and prescriptions at hospital discharge. Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
47935672|NCT01854944|DRUG|Brexpiprazole 1mg to 4mg|
47935673|NCT00756925|DRUG|Acthrel|1 ug/kg, i.v., 1 minute
47935674|NCT02340273|DEVICE|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
47935675|NCT02340273|DEVICE|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
47935676|NCT01380938|DRUG|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
47935677|NCT00911742|DRUG|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
47935678|NCT00911742|DRUG|Zytram|1 Zytram 200 mg tablet as a single dose
48099213|NCT04408183|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
48281539|NCT03352440|DEVICE|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
48281540|NCT03352440|DEVICE|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
48623614|NCT02083211|DEVICE|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
48623615|NCT01217450|DRUG|selumetinib|Given orally
48463314|NCT03582423|OTHER|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
48463315|NCT00211562|DRUG|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
48463316|NCT03530306|DEVICE|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
48463317|NCT03530306|DEVICE|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
48463318|NCT03530306|DEVICE|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
48463319|NCT03530306|DEVICE|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
48463320|NCT04353986|DRUG|Sofosbuvir and Ledipasvir|fixed dose tablet containing 400 mg sofosbuvir and 90 mg ledipasvir
48463321|NCT02247037|OTHER|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
48463322|NCT04460716|PROCEDURE|Major noncardiac surgery|Vascular, thoracic, visceral, orthopedic, gynecologic, urologic, ENT, maxillo-facial, plastic and reconstructive surgery
48463323|NCT01963455|BIOLOGICAL|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
48463324|NCT02308241|DRUG|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
48463325|NCT01151696|DRUG|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
48623616|NCT01217450|BIOLOGICAL|cetuximab|Given IV
48623617|NCT01217450|OTHER|laboratory biomarker analysis|Correlative studies
48623618|NCT01217450|OTHER|pharmacological study|Correlative studies
48623619|NCT02836106|OTHER|Butter|Butter with jam and three slices of bread
48623620|NCT02836106|OTHER|Cheese|Cheese with jam and three slices of bread
48623621|NCT02836106|OTHER|Whipped cream|Whipped cream with jam and three slices of bread
48623622|NCT02836106|OTHER|Sour cream|Sour cream with jam and three slices of bread
48623623|NCT00145561|DRUG|Saquinavir and Ritonavir|
48623624|NCT02993809|BIOLOGICAL|BM-ECs and PRPE|
47935679|NCT06400771|DRUG|DNP007|DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
47935680|NCT02005198|OTHER|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
48463326|NCT01151696|DRUG|Placebo|Placebo
48463327|NCT00510393|DEVICE|XIENCE V everolimus eluting coronary stent system|
48463328|NCT00510393|DEVICE|MULTILINK VISION coronary stent system|
48463329|NCT00687206|DRUG|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
48463330|NCT04440150|PROCEDURE|Appendectomy|Open or Laparascopic Surgery
48463331|NCT02509286|DRUG|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
48463332|NCT02509286|DRUG|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
48463333|NCT02509286|DRUG|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
48463334|NCT02509286|DRUG|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
48623625|NCT02993809|BIOLOGICAL|BM-ECs|
48463335|NCT02509286|DRUG|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
48463336|NCT02509286|DRUG|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
48463337|NCT02509286|RADIATION|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
48623626|NCT00430326|DRUG|Avotermin|
48623627|NCT01732783|OTHER|Panitumumab + Chemotherapy|Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
48463338|NCT06453837|OTHER|Mentha Suaveolens extract incorporated into a food supplement|Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days.
48623628|NCT00168532|DRUG|Sulfamethoxazole-Trimethoprim|
48623629|NCT06133166|DRUG|EG017 ointment|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
48623630|NCT06133166|DRUG|EG017 ointment placebo|Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
48623631|NCT01091207|DRUG|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
48623632|NCT05702268|DRUG|ICP-332|Tablet, 40 mg
48463339|NCT06453837|OTHER|Placebo product|Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days.
48463340|NCT02583048|DRUG|Bedaquiline|Four 100 mg tablets (400 mg) orally once a day for 2 weeks, followed by two 100 mg tablets (200 mg) orally three times a week for 22 weeks.
48623633|NCT05702268|DRUG|ICP-332 Placebo|Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
48623634|NCT03195530|DRUG|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
48623635|NCT05011032|DIAGNOSTIC_TEST|Homocysteine|It is an amino acid which is synthesized by the demethylation of dietary methionine. It is a highly reactive, Sulfur-containing amino acid as a by-product of metabolism of essential amino acid specifically methionine. It was proved to be a strong risk factor causing many cardiovascular diseases, neurological disturbances and other health related issues
48463341|NCT02583048|DRUG|Delamanid|Two 50 mg tablets (100 mg) orally with food twice a day for 24 weeks.
48463342|NCT02583048|DRUG|Dolutegravir|For HIV-positive participants only: one 50 mg tablet orally once daily, to be used in combination with two NRTIs until study completion. (NRTIs were not provided by the study.)
48463343|NCT02583048|DRUG|Multidrug Background Treatment (MBT) for TB|A standardized MBT regimen for MDR- or RR-TB except in cases where a participant had known resistance to one of the components of local standard treatment. MBT was provided by the local program.
48463344|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
48623636|NCT03034928|DEVICE|Contact lens with investigational coating 1|Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
48623637|NCT03034928|DEVICE|Balafilcon A contact lens|Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
48623638|NCT03034928|DEVICE|OPTI-FREE® RepleniSH® MPDS|Multipurpose contact lens solution
48623639|NCT03034928|DEVICE|Contact lens with investigational coating 2|Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
47935681|NCT05563480|DRUG|TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
47935682|NCT05563480|DRUG|Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection|Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
48281541|NCT03352440|DEVICE|Control Group - Kinect|Group with typical development that will perform the task on Kinect
47935683|NCT05563480|DRUG|TQB2618 injection; Penpulimab injection|TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
47935684|NCT02231047|DIETARY_SUPPLEMENT|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
47935685|NCT02231047|OTHER|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
47935686|NCT00320723|DRUG|bupropion, transdermal nicotine patch|
47935687|NCT04859114|BEHAVIORAL|Format of outcome data presentation|Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
48281542|NCT03352440|DEVICE|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
48463345|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
48463346|NCT00845130|BIOLOGICAL|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
48623640|NCT06097572|DIAGNOSTIC_TEST|Intranasal food challenge|Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein
48623641|NCT06097572|DIAGNOSTIC_TEST|Mast cell activation test|Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)
48623642|NCT01208909|PROCEDURE|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
48623643|NCT00972738|DRUG|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
48623644|NCT00972738|DRUG|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
48623645|NCT00972738|DRUG|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
48623646|NCT04924790|BEHAVIORAL|COVID-19 Pandemic|Comparison of the intervention preferences of patients diagnosed with obstructive urinary stones in the urology clinic and recommended for intervention during and before COVID-19
48623647|NCT05529953|DIETARY_SUPPLEMENT|Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)|Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
48623648|NCT05529953|DIETARY_SUPPLEMENT|Control commercial olive oil|Postprandial study of Oleanolic acid bioavailability in healthy subjects
48623649|NCT02314884|DRUG|Cafusertib Hydrochloride|
48623650|NCT02187055|DRUG|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
48623651|NCT02187055|DRUG|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
48281543|NCT02704962|DRUG|full-dose olanzapine|trifluoperazine 5mg/d
48281544|NCT00215254|DRUG|quetiapine|
48281545|NCT06411821|DRUG|Ulixertinib|300 mg twice daily, for every 28-day cycle.
47935688|NCT04859114|BEHAVIORAL|Displayed chance of survival|In the outcome data provided to participants, they view either a 30% or 60% chance of survival.
47935689|NCT03338309|OTHER|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
48463347|NCT03885336|OTHER|No Interventions|There are no interventions in this study. Participants are observed.
48463348|NCT04560231|DRUG|Remdesivir|200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
48623652|NCT02187055|BIOLOGICAL|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
48623653|NCT00152022|DRUG|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
48623654|NCT05389696|DRUG|Single subcutaneous administration and Blood collection|Single subcutaneous administration and Blood collection
48623655|NCT05389696|DRUG|Single subcutaneous administration and then IV injection.|Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
48623656|NCT05389696|DRUG|MIT-001 20mg and 40mg_Multiple administration|Multiple subcutaneous administration for 7 days and then blood collection
48623657|NCT02689479|PROCEDURE|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
48623658|NCT02689479|BIOLOGICAL|11C-5-HTP|150-400 MBq \[11C\]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
47935690|NCT01117792|DEVICE|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
48623659|NCT02689479|PROCEDURE|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
48623660|NCT02689479|PROCEDURE|Mixed-Meal Tolerance Test (MMTT)|
48623661|NCT02689479|PROCEDURE|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
48623662|NCT02689479|PROCEDURE|Glomerular Filtration Rate Testing|
48623663|NCT02689479|PROCEDURE|Blood draw|
47935691|NCT01355029|BEHAVIORAL|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
47935692|NCT01633580|DRUG|corifollitropin alfa|long acting FSH
48281546|NCT02226484|DRUG|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
48281547|NCT02848547|BEHAVIORAL|Text Messaging via Short Message Service|
48281548|NCT01183494|DRUG|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1\*1/\*1 and UGT1A1\*1/\*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
48463349|NCT03493919|BIOLOGICAL|rMenB+OMV NZ vaccine|Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.
48463350|NCT03493919|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|One dose of MenACWY vaccine were administered intramuscularly at Day 1.
48463351|NCT00421863|DRUG|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463352|NCT00421863|DRUG|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463353|NCT00421863|DRUG|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463354|NCT00421863|DRUG|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463355|NCT00421863|DRUG|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463356|NCT00421863|DRUG|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463357|NCT00421863|DRUG|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463358|NCT00421863|DRUG|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463359|NCT00421863|DRUG|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
48463360|NCT02597257|DRUG|Lidocaine HCl|lidocaine continuous infusion
48463361|NCT02597257|DRUG|Normal saline|Normal saline continuous infusion
48463362|NCT03001934|OTHER|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
47935693|NCT03291171|BEHAVIORAL|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
47935694|NCT03031327|DEVICE|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
47935695|NCT03031327|DEVICE|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
47935696|NCT03031327|DEVICE|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
47935697|NCT02117414|DEVICE|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
47935698|NCT02117414|OTHER|Waiting Period Visit|Waiting period time will equate to 1 hour
47935699|NCT00760084|DRUG|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
47935700|NCT00555139|DRUG|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
48463363|NCT01345539|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
47935701|NCT00555139|DRUG|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
47935702|NCT00555139|DRUG|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
48463364|NCT01345539|DRUG|Chemotherapy|Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
48463365|NCT02228486|DEVICE|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
48463366|NCT02228486|BEHAVIORAL|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
48463367|NCT05063591|OTHER|Transfusion support|Patients will be offered symptom-driven transfusion support in addition to standard hospice care
48463368|NCT05704491|DIAGNOSTIC_TEST|artificial intelligence (AI) algorithm of the MONA DR model|A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.
48463369|NCT06385158|DRUG|GS1-144 tablet|GS1-144 tablet is an NK3R antagonist.
48463370|NCT05871437|DRUG|Huaier granule|Huaier Granules: oral administration, 10g once, 3 times a day, used for 1 year, or intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that they no longer benefit. If the patient experiences grade 3-5 (NCI CTC AE V5.0) adverse reactions related to Huai'er granules, and the adverse reactions do not recover after 2 weeks (returning to grade 1 or 2), it can be considered to reduce dosage or stop Huai'er granules treatment. If the medication is suspended for more than 2 weeks, the medication can be interrupted according to the judgment of the researcher. If the same adverse reaction occurs again, the Huaier granules will be permanently discontinued.
47935703|NCT00555139|DRUG|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
47935704|NCT04169347|DRUG|Oxaliplatin|2 week cycles
48463371|NCT03522649|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
48463372|NCT03522649|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
48463373|NCT03522649|DRUG|Leucovorin|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
48463374|NCT03522649|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
47935705|NCT05281484|DRUG|CNM-Au8|"CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm)."
47935706|NCT03047681|DIAGNOSTIC_TEST|venous blood withdrawl|patients will be asked for a venous blood sample
47935707|NCT04545944|DRUG|Vonoprazan|20 mg tablets administered orally
47935708|NCT04545944|DRUG|Midazolam|2 mg syrup administered orally
47935709|NCT01995045|DRUG|Triamcinolone|Retrobulbar anesthesia
48463375|NCT02946424|DRUG|Placebo Oral Capsule|12 month course of daily placebo
48463376|NCT02946424|DRUG|Simvastatin|12 month course of daily simvastatin
48281549|NCT06656676|BEHAVIORAL|WePrEP: A shared decision-making tool|WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence.
48463377|NCT05702762|DRUG|Gentamicin|5 mg/kg intramuscular injection
48463378|NCT05702762|DRUG|Standard of Care|Usual oral antibiotic multi-day dosing based on local antibiogram
48463379|NCT05984823|OTHER|Home based body weight type exercises with blood flow restriction|"The participant will be asked to complete blood flow restricted exercises described below three times per week for 6 weeks.~Exercise protocol: Two tourniquets will be placed around the upper part of each thigh, these tourniquets will be inflated to an individualised and maintained for the duration of each exercise (including the inter-set rest period) but deflated during the 5 min rest in between. Five Body weight Exercises will be performed: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand."
48463380|NCT05984823|OTHER|Home based body weight type exercises|The participant will be asked to complete body weight exercises for three times per week for 6 weeks. These exercises include: Sitting knee extensions, standing knee raise, Heel-toe raises, Bilateral, mini-squat behind a chair, and Chair rise/sit to stand.
48463381|NCT00082160|BEHAVIORAL|Meditation|
48463382|NCT00082160|PROCEDURE|Functional Magnetic Resonance Imaging|
48463383|NCT01507662|BEHAVIORAL|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
48463384|NCT04828616|DRUG|DP303c injection|DP303c injection, every 3 weeks (Q3W)
47935710|NCT01995045|DRUG|Bupivicaine Hydrochloride|Retrobulbar anesthesia
48463385|NCT06205316|DRUG|Antiandrogen Therapy|Receive ADT
48463386|NCT06205316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48463387|NCT06205316|PROCEDURE|Bone Scan|Undergo bone scan
48463388|NCT06205316|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48463389|NCT06205316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47935711|NCT04005521|BEHAVIORAL|Preventive intervention|Preventive, structured exercise protocol
48463390|NCT06205316|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48463391|NCT06205316|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48463392|NCT06205316|OTHER|Survey Administration|Ancillary study
48463393|NCT06103383|DRUG|Controlled ovarian stimuation|3 days stimullation protocol using hMG-HP
48099214|NCT00964314|OTHER|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
48463394|NCT06103383|PROCEDURE|Oocyte pick up|Surgical oocyte pick up without triggering
48463395|NCT06103383|PROCEDURE|Oocyte in vitro maturation|In vitro maturation procedure
48463396|NCT06103383|PROCEDURE|Oocyte in vitro activation|In vitro oocyte activation procedure
48463397|NCT00458822|DRUG|bortezomib|Given IV
48463398|NCT00458822|DRUG|dexamethasone|Given orally
48463399|NCT04054258|DEVICE|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
48463400|NCT05762016|PROCEDURE|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
48463401|NCT00550147|DRUG|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM."
48463402|NCT00550147|DRUG|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
48463403|NCT01625403|DRUG|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
48463404|NCT01625403|DRUG|standard of care|standard of care for heart failure
48623664|NCT01351558|OTHER|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
48463405|NCT00031954|DRUG|carboplatin|
48463406|NCT00031954|DRUG|gemcitabine hydrochloride|
48463407|NCT00031954|DRUG|paclitaxel|
48463408|NCT01617096|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
48463409|NCT01617096|COMBINATION_PRODUCT|Placebo Ring|Vaginal ring containing no drug substance
48463410|NCT03470116|DEVICE|Laryngoscopy with Mac Grath|Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
48623665|NCT01351558|OTHER|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
48623666|NCT01351558|OTHER|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
48623667|NCT06343701|OTHER|Implicit motor imagery|Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).
48623668|NCT06343701|OTHER|Explicit motor imagery|In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
48281550|NCT06656676|BEHAVIORAL|Active comparator: CDC recommendations for discussing PrEP|Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC.
47935712|NCT05555771|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
47935713|NCT05555771|BEHAVIORAL|Usual Care|Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
47935714|NCT01607840|PROCEDURE|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
47935715|NCT03291301|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
48281551|NCT06380140|PROCEDURE|Open Tension-free Inguinal Hernia Repair|A blood sample is taken the day after surgery
48281552|NCT05609526|OTHER|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
48281553|NCT05609526|OTHER|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
48281554|NCT05609526|OTHER|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
48281555|NCT03097887|PROCEDURE|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
48463411|NCT03470116|DEVICE|direct laryngoscopy|Patients of this group will benefit direct laryngoscopy for intubation after curarization
48623669|NCT02112591|PROCEDURE|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
48623670|NCT02112591|PROCEDURE|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
48623671|NCT02390388|PROCEDURE|pudendal nerve block|nerve stimulator-guided Pudendal block
48623672|NCT02390388|PROCEDURE|caudal block|caudal block
48623673|NCT00397124|DEVICE|PET/CT imaging|
48281556|NCT03097887|DEVICE|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
48463412|NCT04541173|OTHER|Y-90 TARE|"This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres."
48463413|NCT04541173|DRUG|Atezolizumab|Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.
48623674|NCT05129709|BEHAVIORAL|"My Health Priorities Identification Program"|"The web-based My Health Priorities Identification Program may improve values solicitation and operationalization skills in primary care, but has not been optimized for AAs with MCCs and their FCGs. The Program is a facilitator-led evidence- and values-based care communication model for patients, clinicians, and caregivers that has reduced patient-reported treatment burden by aligning value-based priorities with treatment. The web-based program assists patients in identifying their health priorities as they complete t four online modules that help them to identify specific and actionable health goals and preferences. The final result can be printed and brought to the clinic or uploaded to the Electronic Medical Record to inform subsequent healthcare decision making. Unrecognized cultural preferences of AAs, including the important role of R/S beliefs and family-centered values, can interfere with adequate healthcare communication resulting in healthcare disparities and inequities."
48463414|NCT04541173|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
48463415|NCT04898816|PROCEDURE|closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive|Application of cyanoacrylate tissue adhesives over the surgical wound
48463416|NCT04898816|PROCEDURE|closure of wound using braided silk suture|suturing the surgical wound using braided black silk
48623675|NCT03137004|DRUG|Docetaxel|Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
48623676|NCT03137004|DRUG|S-1|S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
48623677|NCT04245163|BEHAVIORAL|Educational program|The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
48623678|NCT02043860|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
48623679|NCT02043860|PROCEDURE|Autologous Transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
48623680|NCT02043860|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant.
48623681|NCT02043860|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
48623682|NCT04993170|DIAGNOSTIC_TEST|Bleeding assessment tool|The standardized application of the questionnaire serves to identify patients at risk of bleeding at an early stage and to adapt and optimize perioperative coagulation management accordingly by initiating targeted diagnostics and therapy
48623683|NCT02186067|OTHER|Referral System|"Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
47935716|NCT03291301|OTHER|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
47935717|NCT00542451|DRUG|Paclitaxel|Every week for 12 weeks
47935718|NCT00542451|DRUG|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
48281557|NCT03097887|DEVICE|V-Loc|Sewing device to perform the anti-reflux sutures.
48281558|NCT03128463|DRUG|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
48281559|NCT04357171|PROCEDURE|Low anterior resection with protective loop ileostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.
47935719|NCT00463073|DRUG|Cetuximab|
47935720|NCT00463073|DRUG|Bevacizumab|
47935721|NCT00463073|DRUG|Irinotecan|
47935722|NCT01337687|DRUG|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
47935723|NCT01337687|DRUG|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
48463417|NCT02791958|DRUG|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
48463418|NCT02791958|DRUG|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
48463419|NCT02791958|DRUG|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
48623684|NCT05319704|OTHER|Test of effort on cycle on concentric or excentric mode|participants may receive 4 interventions sequentially during the protocol
48623685|NCT05319704|OTHER|Kinetics on concentric or excentric mode during test of effort|participants may receive 4 interventions sequentially during the protocol
47935724|NCT00539097|DIETARY_SUPPLEMENT|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
48623686|NCT03070145|OTHER|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
48623687|NCT06355349|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 21 days after administration
48623688|NCT04664296|OTHER|Review of medical patient file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
48623689|NCT04664296|OTHER|Phone call interview|less than 15 minutes phone call
48623690|NCT01710085|DEVICE|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
48623691|NCT06049342|BIOLOGICAL|NCR100 injection|Subjects will receive a one-dose intra-articular NCR100 injection.
48623692|NCT00954083|BEHAVIORAL|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
48463420|NCT01824576|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
48463421|NCT02037854|OTHER|Nutrient formulation|
48463422|NCT00822887|DRUG|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
48463423|NCT00822887|RADIATION|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
48463424|NCT01839539|BIOLOGICAL|dendritic and cytokine-induced killer cells|
48463425|NCT00640926|DRUG|Radezolid|300 mg/day, orally for 7-10 days
48463426|NCT00640926|DRUG|Radezolid|450 mg/day orally for 7-10 days
48463427|NCT00640926|DRUG|Radezolid|900 mg/day orally for 7-10 days
48623693|NCT00954083|BEHAVIORAL|Routine care|Routine care
48623694|NCT04399005|OTHER|after-each-case room disinfection|After-each-case room disinfection was defined as after completing each case.
48623695|NCT04399005|OTHER|daily room disinfection|Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
48623696|NCT03233217|BIOLOGICAL|QIV-HD by IM|IM, injected into the upper arm (deltoid area)
48623697|NCT03233217|BIOLOGICAL|QIV-SD by SC|SC, injected into the upper arm (posterior region)
48623698|NCT03233217|BIOLOGICAL|QIV-HD by SC|SC, injection into the upper arm (posterior region)
48623699|NCT01345799|DRUG|TRK-170|
47935725|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
48099215|NCT02396056|OTHER|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
48463428|NCT01523236|DRUG|Mometasone furoate|50 mcg/actuation Nasal Spray
48463429|NCT01523236|DRUG|Nasonex®|50 mcg/actuation Nasal Spray
48463430|NCT01523236|DRUG|Placebo|Nasal Spray
48463431|NCT01375309|DIETARY_SUPPLEMENT|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5\*10to9th bacteria per day
48623700|NCT01345799|DRUG|Placebo|
48623701|NCT04022694|BEHAVIORAL|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
48623702|NCT04022694|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
48623703|NCT06410547|OTHER|LLM|A LLM-based comparison between treatment and guideline will, if necessary, give treatment recommendations based on the guidline.
48463432|NCT01375309|DIETARY_SUPPLEMENT|Placebo contains dextrin|0.5 of dextrin
48463433|NCT02172469|DRUG|Tiotropium inhalation powder capsule|
48463434|NCT02172469|DRUG|Placebo Metered Dose Inhaler|
48463435|NCT02172469|DRUG|Ipratropium Bromide Metered Dose Inhaler|
48463436|NCT02172469|DRUG|Placebo inhalation powder capsule|
48623704|NCT05405712|BEHAVIORAL|Mobile Phone App|App-based peer support program, used in conjunction with standard outpatient treatment
48623705|NCT01334099|BIOLOGICAL|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
48623706|NCT01334099|RADIATION|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
48623707|NCT04894188|RADIATION|radiation therapy|Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
48281560|NCT04357171|PROCEDURE|Low anterior resection with protective loop transverse colostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
48463437|NCT02092701|DRUG|Cholecalciferol|
48463438|NCT01728987|DRUG|cholecalciferol|as in arm description
48463439|NCT01728987|DRUG|placebo|capsule looking identical to the cholecalciferol capsule
48463440|NCT00080613|DRUG|exemestane|
48623708|NCT04894188|DRUG|Goserelin 3.6 MG|Gosereline 3.6mg sc injection at week 1, week 5, and week 9
48623709|NCT04894188|PROCEDURE|radical prostatectomy|Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
48623710|NCT01599962|DRUG|Cinacalcet|single administration, 90mg
48623711|NCT01599962|DRUG|Placebo|single administration
48099216|NCT02396056|OTHER|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
48463441|NCT00080613|PROCEDURE|adjuvant therapy|
48281561|NCT05726591|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
48623712|NCT04733885|DEVICE|Experimental|Current application will be made in the frequency range of 20-50 Hz. The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh.ES applications will be performed in the supine position with head and knee pillow supported.
48623713|NCT04733885|DEVICE|Control|The Chattanooga (Intelect Neo) device with interfering current will be used for treatment, vacuum electrodes will be made in the form of 4 pole application. Two electrodes to the outside of the inguinal ligament, the other two electrodes will be placed on the upper inner part of the thigh. The same device used in ES application to the sham group will be attached to the patients, however, active ES will not be issued from the device and only vacuum will turn on. ES applications will be performed in the supine position with head and knee pillow supported.
48281562|NCT03979729|OTHER|Routine Screening Mammogram (3D + 2D)|Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
48463442|NCT00080613|PROCEDURE|aromatase inhibition|
48463443|NCT00080613|PROCEDURE|conventional surgery|
48463444|NCT00080613|PROCEDURE|endocrine therapy|
48463445|NCT00080613|PROCEDURE|hormone therapy|
48463446|NCT00080613|PROCEDURE|neoadjuvant therapy|
48463447|NCT00080613|PROCEDURE|surgery|
48463448|NCT01135940|DEVICE|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
48463449|NCT01135940|DEVICE|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
48463450|NCT03004157|PROCEDURE|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
48099217|NCT03404843|DRUG|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
48099218|NCT03404843|OTHER|Saline|100 mL saline bag.
48099219|NCT03060187|OTHER|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
48099220|NCT01356225|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
48463451|NCT06361654|OTHER|The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer|"The measurements will be taken during different climbing sessions, after the warm-up.~The study will include measurements on different climbers. Informed consent and personal data will be collected from the climbers before the measurements are taken. The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer."
48463452|NCT03195387|DRUG|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
48099221|NCT01356225|DRUG|Placebo|IN placebo
48099222|NCT04066751|DRUG|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
48099223|NCT04517994|BEHAVIORAL|Active Treatment|See arm description.
48099224|NCT04517994|BEHAVIORAL|Supportive Treatment|See arm description.
48099225|NCT05887323|DEVICE|Implantation of the Tendril 2088 lead in the LBBA|Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.
48463453|NCT05069974|DRUG|Linezolid 600 mg|After randomized to the experimental arm, the patient will take 1 tablet of Linezolid every 12hours during 10 days or 1 tablet of of Linezolid every 24hours during 5 days.
48623714|NCT05609227|OTHER|mobile application|The application, compatible with IOS and android systems for patients candidate for stem cell transplantation, could be applied whenever needed information relating to transplantation process.
48623715|NCT00200382|DRUG|PS-341 (Velcade-drug)|
48623716|NCT01922297|OTHER|Day Treatment MDFT-HIV|MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
48623717|NCT01922297|OTHER|Day Treatment SAU|Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall \& Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
48623718|NCT05037383|OTHER|Video recordings|The surgery of the patient will be recorded by cameras placed on the top of the displays used by the operating staff. The recordings will be only carried out while the patient is draped for the surgery, thus completely covered.
48623719|NCT02092935|DRUG|SMT19969|
48623720|NCT02092935|DRUG|Vancomycin|
47935726|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
48463454|NCT05069974|DRUG|Benzathine Penicilllin G|After randomized to the control arm, the patient will receive a single dose of intramuscular BPG.
48463455|NCT01611506|BIOLOGICAL|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
48463456|NCT01611506|DRUG|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
48463457|NCT01611506|DRUG|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
48463458|NCT02970149|OTHER|NA (observational)|
48463459|NCT01675115|DRUG|BNG-1|BNG-1 3 grams TID for 4 weeks
48463460|NCT01675115|DRUG|Aspirin|Aspirin 100 mg QD for 4 weeks
48463461|NCT02666482|BEHAVIORAL|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
48463462|NCT03596710|PROCEDURE|Image Guided Biopsy|Undergo image guided biopsy
48623721|NCT05415657|DRUG|Denosumab|Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
47935727|NCT01568788|BIOLOGICAL|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
48463463|NCT04763031|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
48463464|NCT01510509|DEVICE|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
48463465|NCT01510509|DEVICE|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
48463466|NCT05718180|OTHER|Transperineal imaging|To measure the difference between ultrasound parameters based on maternal position: to measure the variation of AoP (Angle of progression), MLA (Midline Angle), PAA(pubic arch angle expressed in grades) HSD (head-symphysis distance) HPD(head perineum distance) expressed in millimeters, in the supine position and kneeling squat position in the same woman during the expulsion phase, in the resting step and during the push.
48463467|NCT04025398|BEHAVIORAL|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
48623722|NCT05415657|DRUG|Placebo|Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
48623723|NCT01199770|OTHER|Control, small|control pasta, small portion
48623724|NCT01199770|OTHER|Experimental B, small|experimental pasta, small portion
47935728|NCT06142227|OTHER|Reading a Pictorial Storybook|The pictorial storybook by children will be chosen by child psychologists. The book will be read to children by researcher. The researcher has a fairy tale therapy certificate. The pictorial storybook reading will start 15 minutes before the dental treatment process and will be completed before the treatment process begins.. The pictorial storybook will be read to children only one time.
47935729|NCT00225043|DRUG|Epinephrine/phenylephrine|
48463468|NCT04025398|BEHAVIORAL|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
48623725|NCT01199770|OTHER|Experimental pasta C, small|experimental pasta C, small portion
48623726|NCT01199770|OTHER|control, medium|control pasta, medium portion
48623727|NCT01199770|OTHER|experimental pasta B, medium|experimental pasta B, medium portion
48623728|NCT01199770|OTHER|experimental pasta C, medium|experimental pasta C, medium portion
48623729|NCT01199770|OTHER|NL|no pasta, water only
48623730|NCT05540899|RADIATION|Hypofractionated Postoperative Radiotherapy|Hypofractionated Postoperative Radiation Therapy
48623731|NCT03388944|BEHAVIORAL|PCT group|In this group antibiotic therapy will be stopped based on serial PCT measurements starting from admission.
48623732|NCT02973620|DRUG|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
48623733|NCT00809198|OTHER|Sodium Hyaluronate|
47935730|NCT00461331|DRUG|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
48623734|NCT00809198|OTHER|Carboxymethylcellulose sodium|
48623735|NCT01792466|PROCEDURE|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
48281563|NCT03979729|OTHER|Routine Screening Mammogram (2D)|Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
48463469|NCT04151368|PROCEDURE|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
48623736|NCT04486144|OTHER|Proprietary extract of Nerium oleander|This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.
48623737|NCT06403059|DIAGNOSTIC_TEST|Cervical Length|trans vaginal ultrasound
48463470|NCT01899053|DRUG|TAK-228|TAK-228 Capsules
47935731|NCT00461331|DRUG|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
47935732|NCT03566836|DEVICE|Garmin Smart Watch|Garmin Smart Watch
47935733|NCT03566836|DEVICE|Garmin Chest Band|Garmin Chest Band
48281564|NCT03979729|OTHER|No Screening Mammogram|Subjects will participate in a one-time facilitated focus group.
47935734|NCT01751802|DRUG|Ecopipam|Antagonist of the dopamine D1 receptor
47935735|NCT01751802|DRUG|Placebo|Placebo for Ecopipam
47935736|NCT03826576|BEHAVIORAL|Multicomponent intervention|"The multicomponent intervention will be consist of:~1. Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~2. Nutritional and food allergen analysis of the menu of the restaurant~3. Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~4. Marketing campaign about healthy and food allergen adapted menus in the restaurants"
48281565|NCT00412529|DRUG|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
48281566|NCT00412529|DRUG|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
48281567|NCT05886998|DRUG|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
47935737|NCT04746872|DIAGNOSTIC_TEST|Alinity m HR HPV|A qualitative in vitro test that amplifies and detects HR HPV DNA in cervical tissue samples.
47935738|NCT05737771|DRUG|DWC202213|DWC202213
47935739|NCT05737771|DRUG|DWJ1563|DWJ1563
47935740|NCT05737771|DRUG|DWP16001|DWP16001
48463471|NCT01899053|DRUG|TAK-117|TAK-117 Capsules
48623738|NCT06403059|DIAGNOSTIC_TEST|Uterocervical Angle|by trans vaginal ultrasound
48623739|NCT02357433|DEVICE|High Doses CPFA|
48623740|NCT01526369|DRUG|Trastuzumab|
48623741|NCT01526369|DRUG|Paclitaxel|
48623742|NCT01526369|DRUG|Lapatinib|
48281568|NCT05886998|OTHER|Normal Saline|0.9% sodium chloride solution (normal saline)
48281569|NCT01033994|BIOLOGICAL|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
48281570|NCT00599768|OTHER|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
48281571|NCT02083276|DRUG|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
48623743|NCT01805050|PROCEDURE|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
48623744|NCT02098551|OTHER|SPT and APT|"All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone."
48623745|NCT02022527|DRUG|Acetyl Salicylic Acid|
48623746|NCT02022527|DRUG|Warfarin|
48623747|NCT02022527|DRUG|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
48623748|NCT00555191|BEHAVIORAL|diet restriction|each meal should contain less than 2 gm fructose
48623749|NCT05076929|DIAGNOSTIC_TEST|ultrasound|Ultrasonographic measurement of Inferior Vena Cava Collapsibility Index
48623750|NCT02602197|DRUG|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
48623751|NCT02602197|DRUG|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
47935741|NCT01063777|OTHER|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
47935742|NCT01063777|OTHER|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
47935743|NCT02551627|DIETARY_SUPPLEMENT|Test Product|MMN fortified beverage powder.
48463472|NCT02043392|DEVICE|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
48463473|NCT00668577|DRUG|Lactic acid (Dermacid)|
48463474|NCT00494741|DRUG|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
48463475|NCT00494741|DRUG|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
48463476|NCT02337322|DRUG|Dolutegravir|
48463477|NCT02337322|DRUG|Darunavir/r|
47935744|NCT02551627|DIETARY_SUPPLEMENT|Control|Isocaloric beverage powder without micronutrient fortification.
48623752|NCT01817478|OTHER|microbiologic sample|
48623753|NCT02082288|OTHER|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) \>35 (0) 30-35 (1) \<30 (2) No of retrived oocyte \<5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos \<2 (0) 2-4 (1) \>4 (2) No of good quality embryos \<3 (0) 3-5 (1) \>5 (2) No of embryos transferred -------- (0) ≤2 (1) \>2 (2)"
47935745|NCT02091674|DEVICE|Hyaluronic acid|Injected gel
47935746|NCT05725785|BEHAVIORAL|FOCUS participants|Participants using FOCUS will be given access to the FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
47935747|NCT02394145|DRUG|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
47935748|NCT02394145|DRUG|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
48281572|NCT01144273|PROCEDURE|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
48281573|NCT05139030|DRUG|bupivacaine liposome injectable suspension|Adductor canal block with EXPAREL
48281574|NCT05139030|DRUG|Bupivacaine Hydrochloride|Adductor Canal Block with bupivacaine HCl
48463478|NCT03792139|DRUG|LY3200882|Administered orally.
48463479|NCT03792139|DRUG|Itraconazole|Administered orally.
48099226|NCT02664376|OTHER|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~* Walking speed measurement~* Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
47935749|NCT01178255|DRUG|homeopathic q-potencies|individualised homeopathic medicines
47935750|NCT01178255|DRUG|Placebo|placebo
47935751|NCT01178255|OTHER|homeopathic case history taking type I|one special homeopathic technique for case history taking
47935752|NCT01178255|OTHER|homeopathic case history type II|another type of homeopathic case history taking
48281575|NCT03750500|DEVICE|Biofeedback device|12-week exercise program performed through the device
48281576|NCT03750500|BEHAVIORAL|Education on falls risk|Education on falls risk factors and how to minimize them
47935753|NCT04330196|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participant ingests 75g of glucose
47935754|NCT04330196|DIAGNOSTIC_TEST|Ingestion of placebo|Participant ingests 700mg of aspartame
47935755|NCT00791232|DRUG|extended-release (ER) OROS paliperidone|
47935756|NCT05953714|OTHER|incision side cleaning with antiseptic products|A pilot study was conducted with six pregnant women to clarify the use of the data collection tools and the implementation plan during the study process. After that, the data collection forms were finalized. In the 6 operating room, two different solutions (PI and CG) were applied, according to the preference of the physician, to clean the surgical field. The study was carried out by adding a CG shower application to the physician's preferred solution (for a total of 3 groups). Pregnant women who were admitted to the obstetrics clinic were informed about the purpose, scope, duration, and method of the study by one of the researchers. Follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications by the nurse researcher. At discharge, cultures were taken from the abdominal wounds of the participants
47935757|NCT00249288|DRUG|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
47935758|NCT00249288|DRUG|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
47935759|NCT02582255|BIOLOGICAL|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
47935760|NCT01919840|PROCEDURE|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
47935761|NCT01919840|OTHER|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
47935762|NCT00205829|DEVICE|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
47935763|NCT03295526|PROCEDURE|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
47935764|NCT05637593|BEHAVIORAL|Upper-limb movement training with the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to listen to the RAS sound, use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They should keep their movements consistent with the sound of the RAS, with one RAS sound corresponding to one pick-up movement.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
48099227|NCT04216823|DEVICE|perfusion index|perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
48099228|NCT06628583|OTHER|Magnetic Resonance Imaging with Contrast|The study was retrospective and did not set interventions
48463480|NCT02472834|DIETARY_SUPPLEMENT|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing \~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
48463481|NCT02834962|PROCEDURE|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
48463482|NCT02834962|PROCEDURE|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
48099229|NCT04167709|OTHER|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
48099230|NCT04564313|DRUG|Camrelizumab treatment|Camrelizumab (SHR-1210), 200mg, I.V., Q3W
48099231|NCT02416674|PROCEDURE|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
48281577|NCT03750500|OTHER|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
48463483|NCT01144845|PROCEDURE|Thoracic surgery|Thoracoscopy or anterior thoracotomy
48463484|NCT02757287|DRUG|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~- Quality of Life questionnaire the day after the bolus"
48463485|NCT00704249|DRUG|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
48463486|NCT00704249|DRUG|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
47935765|NCT05637593|BEHAVIORAL|Upper-limb movement training without the aid of RAS|"Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl is set at 30 cm. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.~Patients will be asked to use the right hand to take one bead at a time from the left target bowl to the main bowl, repeat this movement for the middle and right target bowls, and keep repeating this order. They are asked to execute the task as fast as possible.~Each daily training will consist of three rounds separated by two 5-minute breaks. Each round will consist of four consecutive sessions (for each session: 2-minute training followed by a 30-second break). The training will last for a total of 21 days."
47935766|NCT05130944|BEHAVIORAL|Entre Nosotras|"A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women."
47935767|NCT05130944|BEHAVIORAL|Doing What Matters in Times of Stress|The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
47935768|NCT00847171|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells."
47935769|NCT00847171|BIOLOGICAL|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
48099232|NCT02416674|DRUG|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
48281578|NCT03750500|DIAGNOSTIC_TEST|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
48281579|NCT00364793|DRUG|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
48099233|NCT06492031|DRUG|Icodextrin Peritoneal Dialysis Solution|The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
48623754|NCT03050567|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
48623755|NCT00393367|DRUG|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
48099234|NCT06492031|DRUG|Glucose Peritoneal Dialysis Solution|The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
48099235|NCT00310362|BEHAVIORAL|Use of Interactive Voice Response (IVR) system to improve adherence to GI appointments and prep procedures|Interactive voice response system (IVR) calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
48281582|NCT01329757|DRUG|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
48281583|NCT01329757|DRUG|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
48281584|NCT05196893|BEHAVIORAL|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
48281585|NCT02833025|DEVICE|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
48281586|NCT06401980|DRUG|Darolutamide|Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake
48281587|NCT06401980|OTHER|Standard of care|"* Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals."
47935770|NCT00847171|DRUG|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
47935771|NCT00847171|OTHER|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
48463487|NCT03396354|PROCEDURE|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
48463488|NCT03396354|PROCEDURE|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
48463489|NCT02579577|OTHER|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
48463490|NCT02579577|OTHER|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
47935772|NCT00847171|OTHER|immunoenzyme technique|
47935773|NCT00847171|OTHER|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
47935774|NCT00847171|OTHER|laboratory biomarker analysis|
48281588|NCT04432428|DRUG|Sufentanil Sublingual Tablet|"all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil"
48281589|NCT00327392|DRUG|AQUAVAN® (fospropofol disodium) Injection|
47935775|NCT00847171|OTHER|pharmacological study|
47935776|NCT00847171|PROCEDURE|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
47935777|NCT05897970|DIAGNOSTIC_TEST|Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
48281590|NCT00462423|DRUG|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
48281591|NCT00462423|DRUG|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
48463491|NCT02579577|OTHER|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
48281592|NCT04305392|DRUG|SHR4640|orally SHR4640
48463492|NCT00563394|DRUG|ofloxacin|400 mg twice a day for 14 days
48463493|NCT00563394|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
48463494|NCT00127166|DRUG|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
48463495|NCT00127166|DRUG|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
48463496|NCT00127166|DRUG|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
48463497|NCT00127166|DRUG|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
48463498|NCT00127166|DRUG|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
47935778|NCT05861531|BEHAVIORAL|Oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The oral stimulation program will be modeled after the protocol designed and studied for preterm infants and will be implemented for a goal of 10 consecutive days within a 14 day period. This includes 10 minutes of stroking the cheeks, lips, gums, and tongue, and the final 5 minutes consisting of mid tongue stroking, eliciting a suck with gloved finger, and sucking on a pacifier provided in the NICU. This will occur 15-30 minutes before a scheduled tube feeding when the infant is tolerating bolus enteral feeds of 120 ml/kg/day for at least 48 hours. This will occur behind a curtain to ensure blinding of staff and parents. Modifications will be made for infants that remain intubated and only 10 minutes of the stroking of the cheeks, lips, gums, and tongue will occur. Stimulation will cease if episodes of oxygen desaturation and/or apnea/bradycardia occur during the stimulation.
47935779|NCT05861531|BEHAVIORAL|Reading curriculum|Written packets with biweekly lessons. The first two lessons include how to begin to read and talk to their baby. The second two lessons include reading or talking about the day using infant directed speech. The final two lessons include continuing to engage with the baby through interactive reading.
47935780|NCT05861531|BEHAVIORAL|LENA recording|The LENA device provides 24 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
47935781|NCT05861531|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
47935782|NCT05861531|BEHAVIORAL|No oromotor stimulation|This will begin around 33 weeks corrected, the day following the first NTrainer measurements. The standard care group will not receive any stimulation but will have a study personnel present behind a curtain to ensure blinding of family, staff, and investigators. The study personnel will remain behind a curtain for 10-15 minutes prior to a feed for 10 days over a 14-day period beginning when the infant is tolerated 120 mL/kg/day for at least 48 hours.
48281593|NCT00934895|DRUG|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
48281594|NCT00934895|DRUG|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
48281595|NCT05060861|OTHER|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
47935783|NCT02048579|BEHAVIORAL|Behavior Therapy + Motivational Interviewing|
47935784|NCT02330328|OTHER|No Telemetry Monitoring|
48463499|NCT00003953|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
48463500|NCT00003953|DRUG|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
48463501|NCT00003953|DRUG|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
48463502|NCT00003953|DRUG|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
48463503|NCT00003953|DRUG|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
48463504|NCT00003953|PROCEDURE|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
48463505|NCT00003953|PROCEDURE|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
48463506|NCT00003953|RADIATION|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
48463507|NCT05963269|OTHER|Computer assisted intramuscular learning game|It is an educational game that can only be opened from the computer, with questions and answers and cases. The game is currently under development by the developers. The researcher will be able to see how many times the students entered the game and how many points they got.
48463508|NCT04249765|OTHER|Assessing grasping force, pinch force,|"Grip Strength The participants sat upright on a chair with their feet supported. The tested arm was positioned on a table with the shoulders slightly abducted and neutrally rotated, the elbow in 90° of flexion, the forearm in 0° between pronation and supination, and the wrist in neutral resting position. The participants were instructed to maintain that position during the test. The grip strength of both hands was measured using the Hand Dynamometer.~3. Pinch Strength Participants were seated at a table on which the dynamometers were positioned. The subjects were told to keep their elbow flexed without resting their arm or the grip handle of the dynamometer on the table."
48463509|NCT06533150|OTHER|multiomic profiling|2 aliquots of patients-derived bone tissue specimens (collected as surgical waste from routinely surgeries) will be collected and exploited from proteins and metabolites isolation according to standardized protocol. Then, samples will be digested using Filter-aided sample preparation digestion protocol and analysed by Liquid Chromatography Tandem Mass Spectrometry. Peptides will be loaded on the PepMap 100 C18 trap cartridge, and subsequently separated on an EASY Spray C18 analytical column. The mass spectrometer, equipped with a nanoESI spray source, operates in positive ion polarity and MS/MS mode. Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Obtained results will be analyzed by integrated pathway analysis (IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. The selected biomolecules will be then tested in patient cells using the developed bioink-nanoparticle complex.
48463510|NCT03730558|COMBINATION_PRODUCT|aflibercept + FOLFIRI|aflibercept + FOLFIRI
48463511|NCT02488057|DRUG|Liraglutide|Active comparator. See arm descriptions.
48463512|NCT02488057|BEHAVIORAL|Weight loss|Active comparator. See arm descriptions.
48463513|NCT06067789|PROCEDURE|neuraxial anesthesia|Intervention arm participants will be allocated to neuraxial anesthesia.
48463514|NCT01876758|BEHAVIORAL|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
47935785|NCT02330328|DEVICE|Telemetry Monitoring|
47935786|NCT02128360|DRUG|Letrozole, Gonadotropins|
47935787|NCT02128360|DRUG|Gonadotropins|
47935788|NCT03059446|DRUG|Cenicriviroc|Cenicriviroc immediate release tablets
47935789|NCT01234818|DEVICE|Mirena (LNG-IUS)|* General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
47935790|NCT04143529|BEHAVIORAL|Personalized acceptance-based mindfulness exercise|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
47935791|NCT04143529|BEHAVIORAL|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 seconds
47935792|NCT04945642|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR-BT
47935793|NCT04945642|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
47935794|NCT04946227|DRUG|Pembrolizumab 200mg +Paclitaxel 80mg/m2|Pembrolizumab 200mg +Paclitaxel 80mg/m2
47935795|NCT00848003|DRUG|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
47935796|NCT00848003|DRUG|Placebo|Strawberry flavored yogurt
47935797|NCT02837484|OTHER|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
48463515|NCT01876758|BEHAVIORAL|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
47935798|NCT04215133|OTHER|exercise therapy|inspiratory muscle training consists of strengthening exercise with threshold Inspiratory muscle training device and calf muscle training consist of isotonic and isometric strengthening exercise for calf muscle. All groups will receive compression therapy at the same time.
47935799|NCT01690338|DRUG|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
47935800|NCT01690338|DRUG|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
47935801|NCT01690338|DRUG|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
47935802|NCT00004727|DRUG|aspirin|
47935803|NCT00004727|DRUG|ticlopidine|
48099236|NCT06630923|DRUG|Human albumin|Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
48099237|NCT01740557|BIOLOGICAL|Aldesleukin|Given IV
48623756|NCT00393367|DRUG|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
47935804|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (\~140 mg tablet)
47935805|NCT03121339|BIOLOGICAL|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (\~275 mg tablet)
48099238|NCT01740557|BIOLOGICAL|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
47935806|NCT05583669|DRUG|DS-2325a|Subcutaneous injection (starting dose 300 mg)
47935807|NCT05583669|DRUG|Placebo|Subcutaneous injection
48099239|NCT01740557|DRUG|Cyclophosphamide|Given IV
48099240|NCT01740557|DRUG|Fludarabine Phosphate|Given IV
47935808|NCT00095680|DRUG|SCIO-469|two 30-mg capsules three times daily
47935809|NCT00095680|DRUG|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
48281596|NCT06657079|DRUG|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
48281597|NCT06657079|DRUG|Placebo|Saline inhaler
48623757|NCT00393367|DRUG|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
48623758|NCT00393367|DRUG|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
47935810|NCT03654742|PROCEDURE|tonsillectomy|removal of tonsil tissue as described in the study arms
47935811|NCT01541202|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
47935812|NCT01541202|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
47935813|NCT06289621|BEHAVIORAL|False Safety Behavioral Elimination Treatment (FSET)|5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)
47935814|NCT06289621|BEHAVIORAL|Enhanced Standard Care|Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.
48099241|NCT01740557|OTHER|Laboratory Biomarker Analysis|Correlative studies
48099242|NCT01740557|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
48099243|NCT01740557|OTHER|Quality-of-Life Assessment|Ancillary studies
48099244|NCT06187701|BEHAVIORAL|Co-Active Therapeutic Theatre (Co-ATT)|There will be one group drama therapy session per week, for a total of twelve weeks (i.e., total twelve sessions) followed by a single performance (with composition of the audience determined by unanimous agreement of the participants) of the dramatic work (script) produced by the participants during the course of the drama therapy intervention.
48099245|NCT05761509|DRUG|Doravirine|The study treatments will used during 28 days according to the routine care of each investigator center.
48099246|NCT04163484|OTHER|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
48099247|NCT01348087|DRUG|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
48099248|NCT01756287|OTHER|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
48099249|NCT00145002|DRUG|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
48099250|NCT00145002|DRUG|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
48099251|NCT06209359|DRUG|Ammonium Chloride|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
48099252|NCT06209359|DRUG|Placebo|Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
48099253|NCT00028301|DRUG|Atazanavir|
48099254|NCT00028301|DRUG|Lopinavir/Ritonavir|
48281598|NCT03751384|DIETARY_SUPPLEMENT|Möllers Omega-3 Ekstra Sterk|
48281599|NCT03751384|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|
48281600|NCT05379634|DRUG|Nipocalimab|Nipocalimab will be administered intravenously in double-blind period and LTE period.
48281601|NCT05379634|OTHER|Placebo|Nipocalimab matching placebo will be administered intravenously in double-blind period.
47935815|NCT06066801|PROCEDURE|Bedside blind bone biopsy procedure|It was performed in the patient's room under aseptic conditions. Pain relievers were given orally within the hour preceding the procedure. Superficial anesthesia was performed firstly subcutaneously and then on the periosteum, Inhaled anesthesia was started concomitantly. Following a short incision with a scalpel, the trocar inside a cannula was inserted through healthy skin at a minimum distance of 2 cm from the ulcer edge, close to the bone, preferentially on dorsal foot side. When the trocar was firmly inserted into the bone, it was pulled out from the cannula. Biopsy needle was then slipped into the cannula and twisted into the bone clockwise. Biopsy needle was then pulled out and the bone was pushed out with the ejector pin into a sterile surgical drape and divided in two parts.
47935816|NCT02016547|PROCEDURE|abciximab IV and thrombectomy|
48281602|NCT05379634|DRUG|Glucocorticoids|Prednisone or equivalent will be administered orally as Glucocorticoid.
48281603|NCT04756934|DRUG|HX008|HX008: 200mg, Q3W
48281604|NCT04756934|DRUG|LP002|LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
48281605|NCT00826748|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
47935817|NCT02016547|DRUG|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
48463516|NCT04621045|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
48463517|NCT04621045|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
48463518|NCT01430286|BEHAVIORAL|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
48463519|NCT01430286|BEHAVIORAL|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
48463520|NCT01188590|DEVICE|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
48463521|NCT03515044|DRUG|40 mg Rifaximin SSD once daily|SSD once daily (QD)
48463522|NCT03515044|DRUG|40 mg Rifaximin SSD twice daily|SSD twice daily (BID)
48463523|NCT03515044|DRUG|80 mg Rifaximin SSD once daily|SSD once daily (QD)
48463524|NCT03515044|DRUG|80 mg Rifaximin SSD twice daily|SSD twice daily (BID)
48463525|NCT03515044|DRUG|Placebo|Administered twice daily (BID)
48623759|NCT05920239|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI imaging is a diagnostic technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures. It provides high-resolution images of soft tissues, organs, and bones, allowing for the detection and evaluation of various medical conditions.Two experienced radiologists specializing in musculoskeletal imaging will evaluate the images obtained through conventional MRI. Cases demonstrating involvement, characterized by findings such as thickening exceeding 4 mm in the inferior glenohumeral capsuloligamentous complex, signal increase indicating edema on fluid-sensitive sequences, and a reduction in axillary recess volume (greater than 0.53 ml), will be included in the study.
48463526|NCT02121184|DRUG|Routine oxytocin|per regular oxytocin protocols
47935818|NCT01951859|OTHER|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
47935819|NCT06259500|OTHER|observational|Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia
48463527|NCT02121184|DRUG|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
48463528|NCT05642936|BEHAVIORAL|didactic health education control|didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
48463529|NCT05642936|BEHAVIORAL|Transcendental Meditation technique|a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
47935820|NCT00048841|DRUG|alendronate|
47935821|NCT05684432|OTHER|No intervention|No intervention
47935822|NCT04186689|OTHER|Routine Dental Examination|Routine dental examination for the pre-school children Questionnaire for their mothers
47935823|NCT05025540|DIAGNOSTIC_TEST|ultrasonic imaging|Two-dimensional ultrasound images of the patient's kidneys were obtained by ultrasound imaging.
47935824|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
48281606|NCT05931770|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference
48281607|NCT05931770|PROCEDURE|Parent (mother or father) selection according to parents' preference|Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
48281608|NCT02032524|DRUG|Avalglucosidase Alfa|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
48281609|NCT01409317|DEVICE|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
48463530|NCT03056144|DEVICE|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~1. st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~2. nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~3. th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~4. th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min \>5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
48463531|NCT02230267|OTHER|High intensity exercise and balance training|
48463532|NCT02230267|OTHER|Usual care arm exercise|
48463533|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
48463534|NCT04238195|DRUG|Moxifloxacin 400mg|Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
48463535|NCT04238195|OTHER|Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
48623760|NCT05920239|DIAGNOSTIC_TEST|Sonoelastography|Sonoelastography is a medical imaging technique that combines ultrasound imaging with elastography. It is used to assess the mechanical properties and stiffness of tissues in the body.The probe will be carefully positioned perpendicular to the anterior part of the glenohumeral capsuloligamentous complex (IGHCC), ensuring no pressure is applied and preventing anisotropy. It will be specifically oriented in the coronal plane towards the axillary recess. The grayscale examination will reveal irregularly thickened and heterogeneous structures at the axillary recess level in the patient group. On the other hand, in the control group, measurements will be taken from the anterior band of the normal, thin, smooth, and homogeneous structure of the IGHCC.
48623761|NCT01428141|DRUG|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
48623762|NCT05339074|DRUG|Ketamine Hydrochloride|60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
48623763|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; high dose
48623764|NCT05375305|DRUG|SHR8554 Injection|SHR8554 Injection; low dose
48623765|NCT05375305|DRUG|Saline Solution|Saline Solution
48623766|NCT05375305|DRUG|Morphine|Morphine
48623767|NCT04952896|DIAGNOSTIC_TEST|Synovitis diagnosis|
48623768|NCT00077194|DRUG|romidepsin|
48463536|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment B: Subjects receive TBPM-PI-HBr.
48463537|NCT06166862|OTHER|Action observation and motor imagery therapy for rehabilitation|"Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching."
48463538|NCT06166862|OTHER|Sham action observation and motor imagery therapy for rehabilitation|"Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions."
48463539|NCT02653235|BIOLOGICAL|Salmonella typhi vaccination|
48463540|NCT02653235|BIOLOGICAL|Placebo|
48463541|NCT00347048|DRUG|tacrolimus|oral
48463542|NCT00347048|DRUG|Placebo|oral
48463543|NCT02117141|DRUG|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
48623769|NCT02073617|RADIATION|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
48623770|NCT00048659|DRUG|YM598|
48623771|NCT04817982|DRUG|Perineural dexamethasone|Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.
48623772|NCT04817982|DRUG|Lidocaine|Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.
47935825|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
47935826|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
47935827|NCT01566760|DRUG|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
48463544|NCT02117141|DRUG|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
48463545|NCT02727192|DEVICE|PAP (CPAP or ASV)|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
48463546|NCT05643833|OTHER|no intervention|no intervention
48463547|NCT05336487|OTHER|Physical activity|2 hours of physical activity per day, 5 days per week, for the intervention period
48463548|NCT01628887|OTHER|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
48623773|NCT04817982|DRUG|Placebo|Saline will be added perineurally to an ulnar nerve block with bupivacaine.
48623774|NCT04817982|DRUG|Systemic dexamethasone|Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
48623775|NCT04864769|DIETARY_SUPPLEMENT|Krill protein hydrolysate|Ingestion of 35 g Krill protein hydrolysate
48623776|NCT04864769|DIETARY_SUPPLEMENT|Soy protein isolate|Ingestion of 35 g Soy protein isolate
48623777|NCT04864769|DIETARY_SUPPLEMENT|Whey protein isolate|Ingestion of 35 g Whey protein isolate
48623778|NCT04864769|DIETARY_SUPPLEMENT|Water|Ingestion of water (control)
48463549|NCT01251393|DRUG|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
47935828|NCT01566760|DRUG|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
48463550|NCT01251393|DRUG|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
47935829|NCT06171490|OTHER|NP2-4mg|NP2-4 mg is a new product containing tobacco-derived nicotine.
47935830|NCT06171490|OTHER|NP2-6 mg|NP2-6 mg is a new product containing tobacco-derived nicotine.
47935831|NCT06171490|OTHER|Loz-4mg|The Loz-4mg reference product is a commercially available 4mg nicotine lozenge.
47935832|NCT06171490|OTHER|Gum-4mg|The Gum-4mg reference product is a commercially available 4mg nicotine gum.
47935833|NCT02127398|BIOLOGICAL|fecal microbiota|fecal microbiota in capsule form
47935834|NCT05468736|BIOLOGICAL|Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) (or fractional dose if necessary) on Days 0 and 21 in the Initial Vaccination Period.
47935835|NCT05468736|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 201 and Day 229 for the participants originally randomized to placebo.
47935836|NCT05468736|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)|In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0
47935837|NCT05468736|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in the Initial Vaccination Period or on Days 201 or Day 229 in the Booster Vaccination Period
48463551|NCT05290519|OTHER|plant and animal protein|plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
48463552|NCT01151618|DEVICE|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
48463553|NCT03204851|DEVICE|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
48463554|NCT05189938|DIAGNOSTIC_TEST|HBA1c data and glucose levels|All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.
48463555|NCT00108030|PROCEDURE|Partial Body-weight supported Treadmill Training|
48463556|NCT00108030|PROCEDURE|PBWST + Power training|
47935838|NCT03119701|DRUG|Interferon Beta-1A|Lyophilisate for solution for injection.
47935839|NCT03119701|DRUG|Placebo|Lyophilisate for solution for injection as placebo.
47935840|NCT01381146|BEHAVIORAL|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
47935841|NCT01381146|BEHAVIORAL|TAU|have access to other jail programs and services
47935842|NCT01097798|DRUG|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
47935843|NCT01097798|DRUG|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
47935844|NCT03351985|DEVICE|quantitative electroencephalogram (qEEG)|the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
47935845|NCT04817527|DRUG|Edaravone Dexborneol|Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
47935846|NCT03625271|DEVICE|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
47935847|NCT03574324|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
47935848|NCT03574324|DRUG|CCRT+PF|Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
48463557|NCT00108030|PROCEDURE|"Usual physiotherapy care"|
48463558|NCT02698345|DEVICE|drug-eluting balloon (In.PACT Admiral, Medtronic)|
47935849|NCT05851001|OTHER|Progressive Muscle Relaxation exercise|This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.
48463559|NCT00327457|BEHAVIORAL|Help with physician office and patient management|
48463560|NCT00327457|BEHAVIORAL|Tailored physician recommendation letter|
48463561|NCT04417348|DRUG|Retinoic acid|To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
48463562|NCT04967950|DRUG|Secukinumab 300 MG|Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
47935850|NCT05851001|OTHER|Muscle relaxation exercise|The participant was asked to listen to relaxation music for 30 minutes in a private room.
47935851|NCT02206243|DRUG|Embozene Microspheres|Intraarterial application
47935852|NCT01561027|DRUG|CNV1014802|Administered as specified in treatment arm.
47935853|NCT01561027|DRUG|Placebo|Administered as specified in treatment arm
47935854|NCT01222403|BIOLOGICAL|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
47935855|NCT01222403|BIOLOGICAL|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
47935856|NCT00827580|DRUG|Eniluracil|
47935857|NCT05963893|BEHAVIORAL|Uni4Move to sit less and move more|Co-create and implement an action plan to move more and sit less in the university context
47935858|NCT05456945|OTHER|acupressure application|Acupressure will be applied to the UB32 point
47935859|NCT05456945|DEVICE|Shotblocher|Shotblocher will be administered during injection
47935860|NCT05915559|PROCEDURE|Tonsillectomy|Tonsillectomy
47935861|NCT05915559|OTHER|daily follow-up|daily follow-up of clinical parameters (pain, feeding) and analgesia adapted to the pain
47935862|NCT05419427|DRUG|Denosumab|Denosumab 60 MG/ML
47935863|NCT05419427|DRUG|Denosumab-Ref|Denosumab 60 MG/ML
47935864|NCT01057901|DRUG|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
47935865|NCT01057901|DRUG|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
47935866|NCT04410770|BEHAVIORAL|Mood tracker ratings|The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
47935867|NCT02607839|BIOLOGICAL|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
47935868|NCT03463876|DRUG|SHR 1210+apatinib|SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
47935869|NCT04240353|OTHER|COPD digital support service|Use of COPD digital services to record patient symptoms, integrate physiology monitoring, communicate with the clinical team and track interaction
48281610|NCT01409317|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
48463563|NCT04967950|DRUG|Secukinumab 150 MG|Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
47935870|NCT05342532|DRUG|Amoxicillin|1 g
47935871|NCT05342532|DRUG|Omeprazole|40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
47935872|NCT05342532|DRUG|Clarithromycin|500 mg twice daily
47935873|NCT04252833|DRUG|CT-044|CT-044 HCl is a reactive species decomposition accelerant
47935874|NCT02503995|BEHAVIORAL|Physical Exercise Participation|
47935875|NCT03702296|OTHER|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
47935876|NCT00907062|DIETARY_SUPPLEMENT|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
47935877|NCT02885168|DRUG|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
47935878|NCT02885168|DEVICE|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
47935879|NCT02885168|DRUG|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
47935880|NCT02885168|BIOLOGICAL|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
47935881|NCT04319679|DEVICE|Extracorporeal shockwave therapy|6 times during 2 weeks
47935882|NCT04319679|DEVICE|Sham therapy|6 times during 2 weeks
47935883|NCT01466595|DRUG|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
48281611|NCT06016712|DEVICE|SENSIMED Triggerfish Eye Lenses|Contact lenses used for measuring intraocular pressure.
47935884|NCT04869020|DEVICE|Otoband|Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
47935885|NCT04869020|DEVICE|Sham A|Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
47935886|NCT04869020|DEVICE|Sham B|Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.
47935887|NCT03477929|DRUG|Ganirelix Acetate|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
47935888|NCT03477929|DRUG|Cetrorelix Acetate|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
47935889|NCT03249220|DEVICE|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
48463564|NCT04967950|DRUG|Methotrexate|methotrexate
48463565|NCT04425096|OTHER|Skin to skin contact|Skin to skin contact
48463566|NCT00562718|DRUG|capecitabine|
48463567|NCT00562718|PROCEDURE|adjuvant therapy|
48463568|NCT00562718|RADIATION|radiation therapy|
48623779|NCT05557682|OTHER|composite restorative treatment|Restorative treatment using dental materials
48099255|NCT03985150|OTHER|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
48099256|NCT03985150|RADIATION|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
47935890|NCT01165567|DRUG|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
47935891|NCT03206957|DIAGNOSTIC_TEST|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
47935892|NCT03206957|DIAGNOSTIC_TEST|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
48099257|NCT01654705|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
48099258|NCT01654705|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
48099259|NCT04590651|PROCEDURE|Cataract surgery|Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
48623780|NCT01319370|DRUG|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
48623781|NCT01319370|DRUG|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
47935893|NCT03206957|DIAGNOSTIC_TEST|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes"
47935894|NCT03206957|DIAGNOSTIC_TEST|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
47935895|NCT03206957|DIAGNOSTIC_TEST|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
48623782|NCT00954135|DRUG|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
47935896|NCT04029532|DEVICE|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
47935897|NCT04029532|DEVICE|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
47935898|NCT04029532|DEVICE|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
47935899|NCT04029532|BEHAVIORAL|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
47935900|NCT04029532|BEHAVIORAL|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
47935901|NCT04029532|BEHAVIORAL|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
47935902|NCT04029532|BEHAVIORAL|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
47935903|NCT00706069|DRUG|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
47935904|NCT00706069|DRUG|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
47935905|NCT00602745|DRUG|S-1|oral administration
47935906|NCT00602745|DRUG|5-Fluorouracil|intravenous bolus
47935907|NCT02414139|DRUG|Capmatinib|"Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food."
48099260|NCT04590651|PROCEDURE|Cataract surgery with extra anterior chamber angle aspiration|Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
48099261|NCT05609578|DRUG|Adagrasib oral dose of 400 mg twice daily tablets|oral dose of 400 mg twice daily tablets
48099262|NCT05609578|COMBINATION_PRODUCT|Pembrolizumab|IV infusion once every 3 weeks
48623783|NCT00954135|DRUG|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
48623784|NCT04333498|BEHAVIORAL|Feedback on DBS Concentrations|The study team will examine the feasibility and acceptability of a feedback system based on DBS concentration amounts.
48099263|NCT05609578|COMBINATION_PRODUCT|Chemotherapy: Pemetrexed|IV infusion once every 3 weeks
48099264|NCT05609578|COMBINATION_PRODUCT|Cisplatin/Carboplatin|IV infusion once every 3 weeks
48099265|NCT03794804|DEVICE|ColdZyme|"ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap."
48099266|NCT03794804|DEVICE|ColdZyme Placebo|The placebo mouth spray solution has the following composition: ethanol (\<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
48099267|NCT06631989|DRUG|WSD0922-FU|"Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"
48099268|NCT06548490|DRUG|Semaglutide Pen Injector|Semaglutide will be provided using an injection pen
48099269|NCT06548490|DRUG|Placebo|Placebo will be a dry needle stick; no substances will be injected
48623785|NCT01001104|DRUG|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
48099270|NCT01107626|DRUG|Paclitaxel|Given IV
47935908|NCT00814879|DRUG|Raltegravir|400 mg BID
48623786|NCT01001104|DRUG|Placebo|Administered by SC injection, QW for 12 weeks.
47935909|NCT00814879|DRUG|Atazanavir|300 mg BID
48463569|NCT03386461|BEHAVIORAL|Exercise training|Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
48463570|NCT03386461|DIETARY_SUPPLEMENT|omega 3 supplementation|Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
48463571|NCT03386461|DIETARY_SUPPLEMENT|placebo|Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
48623787|NCT03831997|DRUG|Dextrose 5% W/ Sodium Chloride 0.225%|D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
48623788|NCT01191749|DRUG|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
47935910|NCT00814879|OTHER|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
47935911|NCT05475340|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
48463572|NCT05956717|DEVICE|Orthokeratology|The experimental group wore orthokeratology lenses
47935912|NCT00156702|BEHAVIORAL|Feedback and Motivational Interviewing|
47935913|NCT00156702|BEHAVIORAL|Smoking Prevention Video|
48463573|NCT01458886|DRUG|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
48099271|NCT01107626|DRUG|Carboplatin|Given IV
48099272|NCT01107626|BIOLOGICAL|Bevacizumab|Given IV
48099273|NCT01107626|DRUG|Pemetrexed Disodium Heptahydrate|Given IV
48463574|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
48463575|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
48463576|NCT01458886|DRUG|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
48463577|NCT04823533|DIETARY_SUPPLEMENT|Probiotic-placebo supplement|A probiotic formulation containing two well-documented probiotic strains. The finished product is a lyophilized powder packaged in single-dose sticks sachets Excipients used were as follows: xylitol, maltodextrin, plum flavor, and malic acid.
48463578|NCT04192032|OTHER|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
48463579|NCT04192032|OTHER|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
48463580|NCT04192032|OTHER|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
48099274|NCT02221700|PROCEDURE|Massage Therapy|Undergo massage therapy
48099275|NCT02221700|OTHER|Quality-of-Life Assessment|Ancillary studies
48463581|NCT04192032|OTHER|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
48463582|NCT04192032|OTHER|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
48623789|NCT02205021|OTHER|No intervention|
48623790|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
48623791|NCT01508897|DRUG|liraglutide|Single dose administered as subcutaneous injection
48623792|NCT03862885|DRUG|Avapritinib|Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles.
48623793|NCT04979013|OTHER|Smoking Abstinence|Smokers will be switched to smoking abstinence for 14 days
48623794|NCT02353741|DRUG|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
47935914|NCT01850602|DRUG|PA21|
47935915|NCT01850602|DRUG|Sevelamer hydrochloride|
48099276|NCT02221700|OTHER|Questionnaire Administration|Ancillary studies
48099277|NCT05483374|OTHER|observation|Not applicable, it is an observational registry
48099278|NCT02343744|DRUG|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
48463583|NCT05757609|DEVICE|Anodal tDCS combined with active physiotherapy|anodal tDCS over prefrontal cortex combined with active physiotherapy
48463584|NCT05757609|DEVICE|Sham anodal tDCS combined with active physiotherapy|Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
48463585|NCT03095950|OTHER|News items with spin|Interpretation of news items with spin
48623795|NCT02353741|RADIATION|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
48623796|NCT01692015|OTHER|Questionnaire on dietary history|
48463586|NCT03095950|OTHER|News items without spin|Interpretation of news items without spin
48463587|NCT04860349|OTHER|High Intensity Interval Training|4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
48463588|NCT05557656|DRUG|Regorafenib 40 MG|participants who received the treatment of Regorafenib
48463589|NCT03005834|OTHER|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
48463590|NCT01705002|DRUG|Promitil|2 mg/kg dose IV
48463591|NCT01705002|DRUG|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
48463592|NCT01705002|DRUG|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
48463593|NCT04513860|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
48463594|NCT03576053|DRUG|Lidocaine|Lidocaine intradermal injection
48463595|NCT03576053|OTHER|Histamine|Skin Prick Test with Histamine
48463596|NCT03576053|OTHER|Cowhage|Manually skin insertion of cowhage spicules
48463597|NCT03576053|OTHER|Heat stimulation|Short heat stimulation
48463598|NCT03576053|OTHER|Pre-heating|Mild skin pre-heating
48463599|NCT03576053|OTHER|Serotonin|Serotonin electrophoresis
48463600|NCT01552330|DRUG|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
48463601|NCT01552330|DRUG|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
48463602|NCT00453258|OTHER|Eye Examination|Subjects receiving eye examination
48463603|NCT01396655|DRUG|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
48463604|NCT05886127|DEVICE|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
48623797|NCT01692015|OTHER|Questionnaire on nosebleed severity|
48623798|NCT01692015|OTHER|One week food diary generated by weighing foods|
48463605|NCT06074640|OTHER|MET PIR with Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) MTrPs will be identified and located using flat or pincer palpation method in the Triceps Surae complex of the affected leg. The identified trigger points will be marked with a marker. Piston technique of dry needling is performed on the identified MTrPs in calf muscles. The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
48463606|NCT06074640|OTHER|MET PIR without Dry Needling|MET PIR Protocol: The subject will be asked to exert a small effort (20% of available strength) towards plantar flexion, against unyielding resistance, for 20 seconds. Once released, ankle will be dorsiflexed beyond the new range gained and stretched for up to 30 seconds. Rest period will be of 1 minute in between each repetition. (3 Repetitions, 1 Sets, 3 days per week, for 4 weeks consecutively.) The self stretches of Plantar Fascia and Calf muscles will be demonstrated. The stretch position will be maintained for 20 sec, followed by 20 sec rest and then repeated for 3 minutes. All stretches will be performed twice daily by patients for 4 weeks time period (3 Reps, 2 sets/day, for 4 weeks)
48623799|NCT01692015|PROCEDURE|Blood tests for full blood count, albumin, and indices of nutritional status|
48463607|NCT04266548|PROCEDURE|Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining|The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
48463608|NCT00493883|DEVICE|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
48463609|NCT04618172|OTHER|Exercise|30 minute long exercises twice a week
48623800|NCT04863521|OTHER|MHP|MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
48623801|NCT01094093|DRUG|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
48623802|NCT03090295|DEVICE|Palpation and Accuro|Identify placement for spinal
48623803|NCT03549260|BIOLOGICAL|LIB003|LIB003 or placebo
48623804|NCT04077398|DRUG|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
48281612|NCT05177484|DRUG|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
47935916|NCT03800303|BEHAVIORAL|Family-based treatment|2-week family-based treatment
47935917|NCT02605044|DRUG|Masitinib (AB1010)|
48463610|NCT04262180|OTHER|Base intervention-Fitbit with EHR integration|Every subject will start with a base intervention - Fitbit activity tracker with EHR integration including messages delivered via the EHR's patient portal
48463611|NCT04262180|OTHER|Coaching Calls|Non-responders to base intervention will be randomized to coaching calls.
48463612|NCT04262180|OTHER|Online Gym|Non-responders to base intervention will be randomized to online gym.
48463613|NCT01268839|DRUG|TMC278|25mg tablet once daily for 28 days
48623805|NCT03284554|DIETARY_SUPPLEMENT|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
48623806|NCT03284554|DIETARY_SUPPLEMENT|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
47935918|NCT02605044|DRUG|FOLFIRI|
48623807|NCT03284554|DIETARY_SUPPLEMENT|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
48099279|NCT04511663|COMBINATION_PRODUCT|Assertive community treatment|The intervention team consisted of psychiatrists, nurses, clinical psychologists, social workers, rehabilitation teachers. The specific services provided by the team include individual service plan. Each patient got a comprehensive evaluation within one month to establish treatment goals and individual intervention plan, rehabilitation training, family intervention peer support group, individual psychological counseling and crisis intervention.
48099280|NCT04511663|COMBINATION_PRODUCT|Basic public health services.|The control group received regular medical follow-up including symptom and medication evaluation, social function evaluation and physical examination after hospital discharge. The frequency was once a quarter.
48099281|NCT05791201|DRUG|VX-264|Allogeneic human stem cell-derived islets.
48099282|NCT05749029|BEHAVIORAL|Four Week Self-Compassion Course|"This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~1. The Foundations of Self-Compassion~2. Developing your Compassionate Self~3. Deepening the Compassionate Relationship with Yourself~4. Self-compassion in Everyday Life."
48623808|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intravenous infusion over 15 min
48623809|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 500 mg given by intramuscular injection
48623810|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 250 mg given by intramuscular injection
48623811|NCT04913675|BIOLOGICAL|sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 60 min
48623812|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 30 min
48623813|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab 2000 mg given by intravenous infusion over 15 min
48463614|NCT01268839|DRUG|TMC278|25mg tablet once daily for 14 days
47935919|NCT01633437|DRUG|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
47935920|NCT01633437|OTHER|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
47935921|NCT06150144|DRUG|5-Fluorouracil|The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
47935922|NCT06150144|OTHER|SURGERY|Total excision of the lesion
47935923|NCT02689687|BEHAVIORAL|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
48463615|NCT01268839|DRUG|Efavirenz|600mg tablet once daily for 14 days
48463616|NCT06265038|DEVICE|ReSpace TiCell Cage|"ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods."
48463617|NCT02664350|GENETIC|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
48463618|NCT02664350|BEHAVIORAL|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
48623814|NCT04913675|BIOLOGICAL|Sotrovimab|Sotrovimab up to 3000 mg given by intravenous infusion over 90 min
48623815|NCT00145067|BEHAVIORAL|Disease Management Assessment|
48623816|NCT01051804|OTHER|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
48463619|NCT02664350|BEHAVIORAL|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
48463620|NCT02664350|GENETIC|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
48463621|NCT01390051|DRUG|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
48463622|NCT01390051|DRUG|tinzaparin|Dose 4,500 IE daily
48463623|NCT03937791|BIOLOGICAL|E7 T Cell Receptor (TCR)|One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
48463624|NCT06338410|BEHAVIORAL|Kangaroo Mother Care|KMC is a care system for LBW and preterm infants at birth, based on skin-to-skin contact between the infant and the mother and exclusive breast feeding. The mother carries her Preterm infant for at least one hour per day. Urine collected before and after skin-to-skin contact.
48463625|NCT01617551|DRUG|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
48463626|NCT02786160|DIETARY_SUPPLEMENT|HMO|
48463627|NCT02786160|DIETARY_SUPPLEMENT|Dextropur|
48463628|NCT05274724|DIAGNOSTIC_TEST|No teleconsultation during the ambulance journey|Standard will be met according to the current institutional protocol, which does not include teleconsultation. Therefore, the call will be interrupted after guidance from the telemedicine on duty
48463629|NCT05274724|DIAGNOSTIC_TEST|Teleconsultation during the ambulance journey|"teleconsultation will receive a video call using the free WhatsApp application, made by one of the emergency workers of the Telemedicine Center, using an institutional smartphone. The teleconsultation can be done directly to the patient and/or with the companion who made the call. The telemedicine on-duty officer will then assess the condition during the time the ambulance travels. The ambulance team will contact the Telemedicine Center and inform the on-call person when the ambulance geolocation application informs 2 minutes of estimated time of arrival at the place of care. At this point, the on-call doctor will interrupt the teleconsultation and pass the information on to the ambulance team. The video call will be turned off upon arrival of the ambulance team."
48463630|NCT05227677|OTHER|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals in both groups. The anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
48463631|NCT05227677|OTHER|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals. Investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
48463632|NCT05771051|DEVICE|Headpulse measurements|Placement of headset on subject
48463633|NCT05962164|BEHAVIORAL|Passive Heat Therapy|The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
48463634|NCT05962164|BEHAVIORAL|Sham Immersion|The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
48463635|NCT01618513|DRUG|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
48463636|NCT01517919|BEHAVIORAL|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
48463637|NCT03508154|OTHER|Control Meal 1|carbohydrate test meal
48463638|NCT03508154|OTHER|Control Meal 2|carbohydrate test meal
48463639|NCT03508154|OTHER|Experimental Nutritional Product|ready to drink nutritional formulation
48463640|NCT00079495|DRUG|NBI-5788|
47935924|NCT02689687|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
47935925|NCT02689687|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
47935926|NCT02689687|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
47935927|NCT05158647|OTHER|normal saline|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
47935928|NCT05158647|DRUG|MgSo4|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
47935929|NCT01276197|OTHER|Story-Telling DVD|DVD will contain both informational and story-telling components.
47935930|NCT01276197|OTHER|Non-Storytelling DVD|DVD will contain only informational component.
48099283|NCT06481124|DEVICE|electrical impedance tomography|Measurement of ventilation and perfusion during mechanical ventilation with different positive end-expiratory pressure by electrical impedance tomography
48099284|NCT06629116|DRUG|Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).|Whether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
48463641|NCT06062160|OTHER|Therapeutic Touch|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
48463642|NCT04580615|DEVICE|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
48463643|NCT01931449|PROCEDURE|Modified method of digestive tract reconstruction|
48463644|NCT01931449|PROCEDURE|Routine digestive tract reconstruction|
48463645|NCT04941313|DRUG|3D229|3D229 is an investigational drug.
48623817|NCT01051804|OTHER|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
48623818|NCT04490915|DRUG|Crinecerfont|CRF1-receptor antagonist
48623819|NCT04490915|DRUG|Placebo|Non-active dosage form
48623820|NCT05202951|OTHER|questionnaires|Electronic case report form integrating questionnaires on chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used.
48623821|NCT04167670|DRUG|Vonoprazan|Over-encapsulated tablets administered orally.
48463646|NCT04941313|OTHER|Placebo|Matching placebo
48623822|NCT04167670|DRUG|Amoxicillin|Capsules administered orally.
48623823|NCT04167670|DRUG|Clarithromycin|Tablets administered orally.
48463647|NCT02190318|DRUG|Losartan|
48463648|NCT02190318|DRUG|spirolactone|
48463649|NCT02190318|OTHER|blank control|
48463650|NCT01285505|DRUG|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
48463651|NCT01285505|DRUG|alprazolam test sublingual tablet|0.5 mg tablet, single dose
48463652|NCT05428696|DRUG|ALXN2080|Powder-in-capsule
48463653|NCT05428696|DRUG|Placebo|Powder-in-capsule
48623824|NCT04167670|DRUG|Lansoprazole|Over-encapsulated capsules administered orally.
48623825|NCT00397241|DRUG|Drug: dorzolamide/timolol|
48623826|NCT00397241|DRUG|Drug: latanoprost/timolol|
48623827|NCT00397241|DRUG|dorzolamide/timolol and latanoprost|
48623828|NCT00397241|DRUG|placebo (artificial tears)|
48623829|NCT01369303|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
48623830|NCT04351971|OTHER|Intervention Group|The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.The patient's position is in the supine position. The therapist identifies the arches of the atlas and positions one hand at this level with the fingers extended. The other hand is located in the occipital region. Subsequently, the therapist makes a pressure with his shoulder assessing the movement and applies a pressure to the back. This technique is performed by mobilization cycles of 15 seconds and 3 seconds of rest for a total period of 5 minutes.
47935931|NCT03103815|DRUG|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
47935932|NCT04192227|BEHAVIORAL|EnHAncing BehavIors through wellness TreatmentS (HABITS)|Six 75-minute sessions via live video conference wherein participants will receive training in areas of health, wellness and quality of life. Classes will be supplemented with independent homework assignments and discussion on a closed social media forum with peers and facilitators.
47935933|NCT00971620|BIOLOGICAL|Botulinum toxin type A|Given as an intralesional injection.
47935934|NCT00971620|OTHER|Placebo|Given as an intralesional injection
47935935|NCT04253509|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Sequencing|Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.
47935936|NCT02448680|BIOLOGICAL|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
47935937|NCT00579085|DRUG|Ketamine|IV Ketamine .35mg/kg times ten days.
48463654|NCT00162968|DRUG|escitalopram|
48463655|NCT01941069|BEHAVIORAL|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
48463656|NCT01941069|BEHAVIORAL|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
48463657|NCT03113357|OTHER|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
48463658|NCT03113357|OTHER|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
48463659|NCT00380796|DRUG|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
48623831|NCT04351971|OTHER|Placebo group|The technique consists of placing the patient in the supine position, one hand is located in the arches of the atlas, the other hand is located in the occipital. The therapist's shoulder is located in the anterior region. This position is maintained for 5 minutes without exerting pressure.
48623832|NCT02222324|DRUG|Placebo|8 placebo tablets matching E2609
47935938|NCT00579085|OTHER|IV NSS|Placebo inactive ingredients
47935939|NCT00579085|OTHER|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
47935940|NCT03209453|OTHER|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
47935941|NCT05447221|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and pathologists|Pathologists and AI will assess the severity of intestinal metaplasia and judge the tumor area of whole slide images of gastric biopsy specimens independently. In addition, the pathologists can not see the diagnosis of AI.
47935942|NCT03042273|DIETARY_SUPPLEMENT|High Strength Cranberry|Softgel capsule
47935943|NCT03042273|DIETARY_SUPPLEMENT|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
47935944|NCT02218632|OTHER|lactose-free diet|standard diet
47935945|NCT02218632|DIETARY_SUPPLEMENT|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
47935946|NCT00821067|DIETARY_SUPPLEMENT|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
48463660|NCT05122858|PROCEDURE|EUS guided biliary drainage|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
48463661|NCT05122858|PROCEDURE|ERCP|A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
48463662|NCT01714284|BEHAVIORAL|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
48463663|NCT01714284|BEHAVIORAL|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
48463664|NCT02582554|BEHAVIORAL|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
48463665|NCT05002140|DRUG|XRD-0394|Single ascending dose
47935947|NCT00821067|DIETARY_SUPPLEMENT|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
48099287|NCT02078934|PROCEDURE|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
48463666|NCT05002140|RADIATION|Palliative radiotherapy|4 Gy × 5 daily fractions
48463667|NCT05276219|DRUG|Furosemide Injection|A diuretic (iv furosemide) strategy for decongestion in acute heart failure
48463668|NCT05276219|DRUG|Isosorbide Dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
47935948|NCT00589784|DRUG|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
48099288|NCT03114722|DRUG|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
48463669|NCT05276219|DRUG|Furosemide and isosorbide dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
47935949|NCT05530512|OTHER|electroacupuncture|acupuncture needling and stimulation are applied for 30 min
47935950|NCT02707159|DRUG|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
47935951|NCT02272387|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|
47935952|NCT02272387|OTHER|Placebo|
47935953|NCT04665882|PROCEDURE|Axillary surgery based on lymphedema prediction nomogram|Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
47935954|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
47935955|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
48463670|NCT03822858|DRUG|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
48623833|NCT02222324|DRUG|E2609|E2609 will be administered as 8 tablets
48623834|NCT02222324|DRUG|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
47935956|NCT02607566|BEHAVIORAL|Yoga|
48623835|NCT01326221|DRUG|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
47935957|NCT02607566|BEHAVIORAL|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
47935958|NCT05886517|DEVICE|Transfemoral transcatheter aortic valve implementation|ranscatheter aortic valve implantation, a percutaneous treatment for severe aortic valve stenosis, is increasingly performed worldwide. The pacemaker should be able to perform overdrive pacing which is essential to reduce cardiac output and transvalvular blood flow which are critical during balloon aortic valvuloplasty and valve deployment of the balloon- expandable valve. Minor adjustment may be needed for ideal positioning, but importantly this has to be done before valve implantation
47935959|NCT04080687|DEVICE|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
47935960|NCT00617643|DRUG|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
47935961|NCT00617643|DRUG|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
47935962|NCT01888887|OTHER|Cetaphil Daily Facial Cleanser|
47935963|NCT00817284|DRUG|bevacizumab and Irinotecan and radiotherapy|"* Bevacizumab 10 mg/kg is administered on days 1 and 15.~* Irinotecan:~* Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~* Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~* During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
47935964|NCT00817284|DRUG|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
47935965|NCT02780674|BIOLOGICAL|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
47935966|NCT02780674|BIOLOGICAL|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
47935967|NCT01653782|BEHAVIORAL|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
47935968|NCT01653782|BEHAVIORAL|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
48099289|NCT03114722|DRUG|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
47935969|NCT01653782|BEHAVIORAL|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
48099290|NCT02113163|DRUG|Metformin Eicosapentaenoate|
48623836|NCT01325441|DRUG|BBI608|
48623837|NCT01325441|DRUG|Paclitaxel|
47935970|NCT04174014|PROCEDURE|Recruitment manoeuvre|PEEP increment and decrement
47935971|NCT02317146|DRUG|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
47935972|NCT02012673|DEVICE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
47935973|NCT04506762|PROCEDURE|Regional analgesia|Insertion of bilateral ESP catheters
48623838|NCT05219890|DIETARY_SUPPLEMENT|Fish oil|They will consume the fish oil equivalent to 4.8 g/day of EPA and DHA for 3 months, followed by a one-month period without treatment.
47935974|NCT04862195|DEVICE|Attune™|Software as a medical device
47935975|NCT04862195|DEVICE|Cerena™|Software as a medical device
47935976|NCT05983146|DRUG|HRS-7053 Injection|HRS-7053 is administered by intravenous (IV) infusion once a week (QW) for one treatment cycle every 4 weeks
47935977|NCT04118582|OTHER|Body composition and resting metabolic rate analisys|
47935978|NCT01268371|DEVICE|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
47935979|NCT01268371|DEVICE|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
47935980|NCT02022176|OTHER|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
47935981|NCT02022176|OTHER|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
48099291|NCT02113163|DRUG|Metformin HCl and Vascepa|
48099292|NCT05731661|OTHER|Day hospitalization in support care with meeting with support care professionals and coordination of actions by the advanced practice nurse|During this day hospitalization, patients will meet with different specialized professionals depending on the support care needs identified.
48099293|NCT05731661|OTHER|Delivery of useful information according to support care needs, concerning support care professionals in the city|Delivery of useful information according to support care needs, concerning support care professionals in the city
48099294|NCT05731661|OTHER|Delivery of a personalized post-cancer plan|Delivery of a personalized post-cancer plan
48099295|NCT00140166|DRUG|niacinamide|
48099296|NCT00140166|DRUG|pyridoxine|
48099297|NCT00140166|DRUG|ascorbate|
48099298|NCT05735847|PROCEDURE|Total Knee Arthroplasty (TKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with TKA involves the replacement of both the medial and lateral compartments of the knee.
48099299|NCT05735847|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|The choice between TKA and UKA is based on the radiological presentation of the knee KOA on an x-ray. A surgery with UKA involves the replacement of one compartment.
48099300|NCT01019616|DRUG|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
48099301|NCT00673296|DRUG|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
48099302|NCT01249040|PROCEDURE|Physical therapy|
48099303|NCT01249040|PROCEDURE|steroid intraarticular injection|
48463671|NCT05697757|OTHER|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
48463672|NCT05697757|OTHER|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
48463673|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
48463674|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
48463675|NCT03215641|DEVICE|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
48463676|NCT03368391|DRUG|tetracaine HCl and oxymetazoline HCL|0.4 mL HCl and oxymetazoline HCl administered intranasally
48463677|NCT03368391|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
48463678|NCT03368391|DRUG|3% Mepivacaine with 1:100,000 epinephrine|2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
47935982|NCT02022176|OTHER|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
48463679|NCT03368391|DRUG|saline intranasal|0.4 mL intranasal saline will be administered as a placebo
48463680|NCT03368391|DRUG|saline infiltration|2.8 mL of saline will be infiltrated at anterior teeth as a placebo
48463681|NCT00926367|DRUG|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
48463682|NCT00926367|DRUG|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
48463683|NCT01525680|OTHER|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
48463684|NCT01525680|OTHER|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
47935983|NCT03918668|BEHAVIORAL|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
48099304|NCT05090891|DRUG|INCB000928|INCBG000928 will be administered QD orally.
48099305|NCT05090891|DRUG|placebo|placebo will be administered QD orally
48099306|NCT06628635|BEHAVIORAL|Exercise|Exercise involving aerobics, isometrics, and stretching
48099307|NCT06628635|BEHAVIORAL|Resting|Resting
48099308|NCT05776576|BEHAVIORAL|Evaluation|Within the scope of the evaluation, first of all, physical activity levels of children and adolescents with physical disabilities, barriers that prevent them from participating in physical activity, and motivators that can increase their participation will be determined, accompanied by an interactive roundtable meeting. Afterwards, posture analyzes of children and adolescents with special needs with physical disabilities will be performed by physiotherapists.
48099309|NCT05776576|BEHAVIORAL|Education|"In the education part, interactive informative seminars titled Physical Activity in Individuals with Special Needs will be given and after the objective posture assessments, postural disorders of children and adolescents with special needs will be determined and accordingly, posture and ergonomics training will be given to the participants individually."
48099310|NCT05776576|OTHER|Experimentation|In the experimentation part, group exercises, dance therapy programs and technology-supported exercise educations with various technological equipment will be implemented in the company of physiotherapists, taking into account the posture assessments.
48099311|NCT05189587|DEVICE|transcranial electrical stimulation (TES)|Transcranial electrical stimulation (tES) is a noninvasive brain stimulation technique that passes an electrical current through the cortex of the brain to alter brain function. The electrical current is applied to an individual's scalp usually via two or more electrodes, and whilst a large amount of the current is conducted between electrodes through soft tissue and skull (Vöröslakos et al. 2018), a portion of the current penetrates the scalp and is conducted through the brain, where it can alter neuronal excitability. By altering the activity of brain regions involved with a behaviour of interest, investigators can observe the resulting behavioral changes and so establish a causal link between the two (Reed et al. 2018).
48099312|NCT04675463|DRUG|BGF Inhalation Aerosphere|Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time
48463685|NCT01505049|DRUG|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
48463686|NCT00642811|DRUG|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
48463687|NCT00642811|DRUG|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
48463688|NCT00642811|DRUG|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
48463689|NCT01140607|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
48463690|NCT06316557|DEVICE|rTMS group|5Hz rTMS in lesion contralateral cerebellar hemisphere, once a day for a total of five days
48463691|NCT06316557|DEVICE|control group|shame rTMS in lesion contralateral cerebellar hemisphere, once a day for a total of five days
48463692|NCT04284007|DRUG|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
48463693|NCT04284007|DRUG|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
48463694|NCT04284007|DRUG|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
48463695|NCT01528293|DEVICE|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
48463696|NCT01528293|OTHER|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
48463697|NCT02570854|BIOLOGICAL|CSJ137|Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
48463698|NCT02570854|DRUG|Placebo|Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
48463699|NCT00521508|PROCEDURE|gene transcription and cytometry|samply of 30 ml of blood
48463700|NCT00928057|DEVICE|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
48463701|NCT00928057|DEVICE|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
48463702|NCT00928057|DEVICE|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
48463703|NCT00748787|DRUG|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
48463704|NCT00748787|DRUG|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
48463705|NCT02392689|OTHER|Procalcitonin|Procalcitonin guided antibiotic therapy
48463706|NCT01632423|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
48463707|NCT02837913|DEVICE|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
48463708|NCT01199653|PROCEDURE|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
48463709|NCT01199653|PROCEDURE|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
48463710|NCT06447285|DIAGNOSTIC_TEST|SensoDetect BERA technology|"All recruited participants are to be tested using SensoDetect's patented technology. All tests shall be performed in a quiet and darkened room. Participants will be asked to be comfortably seated in an armchair in a resting position (part 1 only). Surface electrodes will then be attached to the skin over the mastoid bones behind the left and right ear, with a ground electrode on one arm. Two reference electrodes will also be placed on the forehead. Before each test session, the procedure shall be fully explained to the test subject or parents.~The subjects will then be instructed to relax with their eyes closed and are permitted to fall asleep (with modifications in part 3). The test will require no active participation other than being subjected to sound stimulation. The subjects will be tested one at a time, and the duration of the testing procedure will be 15 min."
48463711|NCT00003906|DRUG|Raloxifene|60 mg/day plus placebo for 5 years
48463712|NCT00003906|DRUG|Tamoxifen|20 mg/day plus placebo for 5 years
48463713|NCT02832167|BIOLOGICAL|Nivolumab|Specified dose on specified days
48463714|NCT02898740|BEHAVIORAL|Structural exercise|Exercise instruction and encouragement
48463715|NCT02898740|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
48463716|NCT05521919|BEHAVIORAL|Sympathetic Nervous System Activation|Participants will complete a task that increases sympathetic nervous system activation.
48463717|NCT05521919|BEHAVIORAL|No-stress|Participants will complete a task that will not affect their sympathetic nervous system activity.
48463718|NCT00968916|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
48463719|NCT01513941|DRUG|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
48463720|NCT01513941|DRUG|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
48463721|NCT01513941|DRUG|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
48463722|NCT03366194|DEVICE|SkinStylus Sterilock System|Microneedling device will be used to treat ventral hypertrophic scars.
48463723|NCT06217276|OTHER|Respiratory muscle fatigue protocol|It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
48463724|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine|Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
48463725|NCT05056519|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
48463726|NCT04816851|PROCEDURE|OZAKI technique|an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
48463727|NCT03660787|DRUG|Seroguard|Seroguard 0.41 g/L solution
48463728|NCT03660787|DRUG|Placebo|Saline
48463729|NCT00588783|DEVICE|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
48463730|NCT00588783|DEVICE|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
48463731|NCT00061776|DRUG|Capsaicin Dermal Patch|
48463732|NCT02520193|PROCEDURE|Protocolized early mobilization in ICU|
48463733|NCT00622362|BIOLOGICAL|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
48463734|NCT00622362|BIOLOGICAL|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
48463735|NCT00622362|BIOLOGICAL|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
48463736|NCT00352807|DRUG|Brimonidine Purite|
48463737|NCT03670758|DIAGNOSTIC_TEST|Protein S activity|Intravenous blood sample
48463738|NCT04893096|DRUG|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
48463739|NCT02642809|DRUG|Pembrolizumab|
47935984|NCT04540939|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"There will be 8 sessions and these will be approximately 2 hours long. Over the 8-weeks participants will learn several mindfulness meditation techniques. Each session will involve group discussion and feedback. Participants will be asked to practice these techniques at home, and keep a log of mood, and stress ratings.~Audio files with exercises will be given to participants so that they can practice at home between sessions."
48463740|NCT02642809|RADIATION|Brachytherapy|
48463741|NCT02642809|PROCEDURE|Endoscopic biopsy|
48463742|NCT02642809|PROCEDURE|Computed tomography-guided biopsy|
48463743|NCT02642809|PROCEDURE|Peripheral blood collection|
48463744|NCT02296957|PROCEDURE|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
48463745|NCT02525263|BIOLOGICAL|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
48463746|NCT02174276|DRUG|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
48463747|NCT02174276|BIOLOGICAL|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
48463748|NCT00169130|DRUG|doxorubicin|
48463749|NCT00169130|DRUG|cyclophosphamide|
48463750|NCT00169130|PROCEDURE|Autologous stem cell transplantation|
48463751|NCT00913276|DRUG|Propofol|
48463752|NCT00913276|DRUG|Sevoflurane|
48463753|NCT00365053|DRUG|belinostat|Given IV
48463754|NCT00365053|OTHER|laboratory biomarker analysis|Correlative studies
48463755|NCT00510003|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
48463756|NCT01969864|BEHAVIORAL|HRSA Video Intervention|
48463757|NCT01969864|BEHAVIORAL|PI Video Intervention|
48463758|NCT01969864|BEHAVIORAL|CDC Health Website Intervention|
48463759|NCT05964049|DEVICE|active rTMS treatment|Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days. Individualized targets will be generated using the pBFS method.
48623839|NCT04867148|DEVICE|Inertial measurement unit sensor-based gait analysis system|Gait analysis was performed on 20-m long corridor to collect gait data on more than 23 strides. The gait protocol was performed with an IMU sensor-based gait analysis system (DynaStab™, JEIOS, South Korea) consisting of a shoe-type data logger (Smart Balance1 SB-1, JEIOS, South Korea) and a data acquisition system (DynaStab-Spotfire1, Tibco Spotfire 7.10). The shoe-type data logger included an IMU sensor (IMU-3000™, InvenSense, USA) that measured tri-axial acceleration (up to ± 6 g) and tri-axial angular 136 velocity (up to ± 500˚ s-1) along three orthogonal axes.12,16 The IMU sensors were installed in both shoe outsoles, and the data were transmitted wirelessly to a data acquisition system via Bluetooth®. Shoe sizes were adapted to each participant, with available sizes ranging from 225 mm to 280 mm. The local coordinate system for the IMU sensors included the 140 anteroposterior, mediolateral, and vertical directions.
48623840|NCT03180372|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
48623841|NCT01895998|DRUG|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
48623842|NCT01913184|DEVICE|AKITA|
48623843|NCT01644838|DRUG|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
48623844|NCT01644838|DRUG|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
48623845|NCT01151436|DEVICE|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
48623846|NCT00844519|DRUG|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
48099313|NCT04675463|DRUG|GFF Inhalation Aerosphere|Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
48099314|NCT03307980|BIOLOGICAL|PF-06838435 (formerly SPK-9001)|Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
48463760|NCT05964049|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
48463761|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
48463762|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
48463763|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
48463764|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
48463765|NCT05797740|DRUG|Mavenclad|This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.
48463766|NCT03236363|BEHAVIORAL|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
48463767|NCT03236363|BEHAVIORAL|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
48463768|NCT00001763|DRUG|Interleukin-12|
48463769|NCT06180915|BEHAVIORAL|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days.|The peer trainer will be subjected to assertiveness training based on dating violence and internalized misogyny by the researcher for 2 hours a day for 5 days. The peer educator will create a Whatsapp group with the experimental group participants and a name for the group will be found by mutual decision. The peer educator will schedule a time and date with the group. Each session will last approximately 60 minutes and the total training duration will be planned to be 3 weeks. One week and one month after the training is completed, the participants will fill out the scales again.
48463770|NCT01078350|PROCEDURE|tumor tissue aspiration|
48463771|NCT01078350|PROCEDURE|phlebotomy|
48463772|NCT05245955|DEVICE|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
48463773|NCT01236495|DRUG|spinal morphine 0.3 mg|spinal morphine 0.3 mg
48463774|NCT01236495|DRUG|spinal morphine 0.2 mg|spinal morphine 0.2 mg
48463775|NCT05696327|OTHER|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
48623847|NCT00844519|DRUG|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
48623848|NCT05962372|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
48623849|NCT05962372|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.
48623850|NCT04174261|DRUG|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
48463776|NCT05696327|OTHER|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
48463777|NCT05228717|DIAGNOSTIC_TEST|Point of Care Ultrasound|q48-72h point of care ultrasound of the lungs, heart, and IVC (inferior vena cava)
48463778|NCT01788709|OTHER|preparation cleaning solution|
48623851|NCT04174261|PROCEDURE|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
48099315|NCT06026189|DIAGNOSTIC_TEST|urine-first strategy|Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.
48623852|NCT04174261|DRUG|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
48623853|NCT00462462|DRUG|Ethanol 96% Gel|
48623854|NCT00462462|DRUG|Ethanol 98% Solution|
48623855|NCT03698149|DEVICE|PMT/Blackrock Combination Device|PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
48623856|NCT05708651|DEVICE|Investigational device [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep steady-state sedation \[I-II\] or procedural sedation according to SOC \[III-IV\].
48623857|NCT05708651|DEVICE|Comparator [I-IV]|Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock \[I-II\] or no device \[II-IV\]) in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterization \[IV\].
48623858|NCT02290093|DRUG|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
48623859|NCT02290093|DRUG|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
48623860|NCT02290093|DRUG|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
48623861|NCT00340483|BEHAVIORAL|Smoking cessation|
48623862|NCT00257452|DRUG|tiotropium 18 mcg or 54 mcg qd|
48623863|NCT00257452|DRUG|placebo matching tiotropium qd|
48623864|NCT00257452|DRUG|moxifloxacin 200 mg|
48623865|NCT04655872|DRUG|[14C]TPN171H|A single 10 mg oral dose of \[14C\]TPN171H containing approximately 100 microcurie of \[14C\]-TPN171H.
48623866|NCT01000714|DRUG|Psirelax|
48099316|NCT01048151|BIOLOGICAL|TNFerade™ Biologic|AdGVEGR.TNF.11D
48463779|NCT00904280|DRUG|Oxymorphone ER|Open label
48463780|NCT02756858|DRUG|ANAVEX2-73|
48623867|NCT02233257|DRUG|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
48623868|NCT01588509|DRUG|Romosozumab|Administered by subcutaneous injection
48623869|NCT00286455|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
48623870|NCT00286455|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
48623871|NCT00286455|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
48623872|NCT06203964|OTHER|No intervention|No intervention
48623873|NCT05460247|DIETARY_SUPPLEMENT|Protein|Participants will receive a diet supplemented by the above protein
48623874|NCT03987048|OTHER|Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.|"Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded."
48099317|NCT03879967|DEVICE|Allograft block graft|The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
48099318|NCT05586451|BEHAVIORAL|Traditional High Load Resistance Exercise (HLRE)|Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
48463781|NCT00796874|OTHER|active surveillance|Correlative Study
48463782|NCT00796874|OTHER|imaging biomarker analysis|Correlative Study
48463783|NCT00796874|PROCEDURE|biopsy|Tissue Removal
48463784|NCT00796874|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
48623875|NCT02311478|DEVICE|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
48623876|NCT04972630|BEHAVIORAL|Pal-Care|"Pal-Care intervention participants will receive a 6-month intervention based upon the WHO toolkit and it will be delivered by the community health workers (CHWs). The goal of this pragmatic clinical trial is to test and evaluate a home-based palliative care intervention for utilizing community health workers to facilitate the delivery of palliative care to cancer patients in rural India. More details provided in the intervention arms section. After the intervention, clinicians, CHWs and a purposefully selected set of patients/caregivers, who were involved in the Pal-Care will be interviewed to understand their experiences, needs, expectations, barriers, facilitators and strategies."
48623877|NCT04972630|BEHAVIORAL|Control-Usual Care|"The control group will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency."
48623878|NCT01400048|DIETARY_SUPPLEMENT|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
48623879|NCT01400048|DIETARY_SUPPLEMENT|Placebo control|60mg Ascorbic acid
48623880|NCT00927472|DRUG|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
48463785|NCT00796874|PROCEDURE|magnetic resonance imaging|Radiolical Medical Imaging
48463786|NCT00796874|PROCEDURE|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
48623881|NCT00927472|DRUG|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
48623882|NCT00694746|DRUG|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
48623883|NCT00694746|DRUG|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
48623884|NCT05104346|PROCEDURE|appendectomy|open or laparoscopic appendectomy
48623885|NCT03667716|DRUG|COM701|COM701 monotherapy.
48623886|NCT03667716|DRUG|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
48623887|NCT00539474|PROCEDURE|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
48099319|NCT05586451|BEHAVIORAL|Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)|Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
48099320|NCT05586451|BEHAVIORAL|Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)|Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
48281613|NCT05332444|DRUG|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
48463787|NCT03214523|BEHAVIORAL|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
48099321|NCT06628414|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation
48281614|NCT05332444|DRUG|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
48463788|NCT04513327|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to anterior cruciate ligament reconstruction post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 2 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 2 to 12 weeks post surgery."
48463789|NCT04513327|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
48463790|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement A|Oral administration of Supplement A
48463791|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement B|Oral administration of Supplement B
48463792|NCT00766493|DEVICE|GORE® Embolic Filter|Embolic protection during carotid stenting
48463793|NCT02871050|OTHER|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
48623888|NCT01381640|DRUG|Marketed paracetamol|marketed formulation
48623889|NCT01381640|DRUG|Experimental paracetamol formulation|Experimental formulation
48463794|NCT06375187|BIOLOGICAL|Engineering Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.
48623890|NCT00003090|BIOLOGICAL|aldesleukin|
48623891|NCT05619419|BEHAVIORAL|Mindfulness-enhanced positive affect induction|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the MPAI via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the MPAI to manage pain during the cold pressor test.
47935985|NCT04540939|BEHAVIORAL|Muscle Relaxation Therapy|Each MR session is approximately 2 hours. Over the 8-weeks you will learn how to relax your body using a step-by-step process in which you alternate between squeezing and relaxing your muscles. You will learn about your body's natural response to stress and how to use muscle relaxation during your everyday life. Each session will also involve group discussion and feedback. You will be asked to practice these techniques at home, and keep a log of your mood, and stress ratings. You will receive audio files with exercises so you can practice at home between sessions.
48623892|NCT05619419|BEHAVIORAL|Breathing Meditation|Participants will receive brief psychoeducation about biopsychosocial pain management and practice with the BM via guided audio recording. They will then listen to the audio recording a final time before beginning the cold pressor test for experimental pain induction. They will be instructed to continue using the BM to manage pain during the cold pressor test.
48623893|NCT02478788|DRUG|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
48623894|NCT02478788|DRUG|Placebo|Pills with no medication in it
48623895|NCT04675879|DEVICE|Shoulder arm bandage|Three different shoulder-arm bandage types
48623896|NCT05652842|BEHAVIORAL|Work-type|Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
48623897|NCT02325895|OTHER|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
48623898|NCT04039269|OTHER|Preoperative video information|
48623899|NCT02109224|DRUG|Ibrutinib|Given PO
48623900|NCT02109224|OTHER|Laboratory Biomarker Analysis|Correlative studies
48623901|NCT02109224|OTHER|Pharmacological Study|Correlative studies
48623902|NCT03672162|PROCEDURE|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
48623903|NCT00922389|PROCEDURE|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
48623904|NCT00922389|DRUG|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
48623905|NCT00922389|DRUG|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
48623906|NCT01076517|DEVICE|Therasphere|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
48623907|NCT04360720|DRUG|Antiplatelet Monotherapy|"All subjects randomized to Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to Monotherapy Group will be treated with ticagrelor or prasugrel alone until the end of the study, at Month 12."
48099322|NCT04332757|OTHER|Training intervention.|The investigators have designed a phased 18-week physical development programme to train both rehabilitative and performance enhancement elements of physical preparation. The rehabilitation element of the programme will specifically target pelvic floor function and core strength and stability (known collectively as Core Reconnection training) from weeks 6 to 24 postpartum, and the training element of the programme will contain resistance and high-intensity interval training (HIIT) from weeks 12 to 24 postpartum.
48099323|NCT06629688|DRUG|semaglutide|Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
48281615|NCT03642184|DRUG|Empagliflozin|Dosage adjustment based on glucose targets . Once daily
48463795|NCT05790460|OTHER|Telehealth|Enhanced synchronous telehealth nurse navigation, compared to usual care nurse navigation, to increase timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.
48463796|NCT04349696|DRUG|Mitiglinide|"Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)"
48463797|NCT05187884|DRUG|Darovasertib|Oral Darovasertib 300 mg tablets twice daily
48463798|NCT00307723|DRUG|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
48463799|NCT00307723|DRUG|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
48463800|NCT00307723|DRUG|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
48623908|NCT06090240|OTHER|MI-based ACP intervention|Motivational Interviewing on Advance Care Planning Intervention: Dyads of older adults and family caregivers will receive three MI-based ACP counselling sessions: (1) a preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions in weeks 2 and 3 will last 30-45 minutes each. Before each session, the nurse interventionist will first assess the dyad's readiness to engage in ACP based on the state of change algorithm. Participants who have never thought about ACP will be in the pre-contemplation state, those who are willing to discuss EOL care and preferences to be in the contemplation state, those ready to talk about EOL planning to be in the preparation state, and those in the action state have a confirmed action plan on signing up their ADs. Readiness-based ACP goals will be established, and state-matched MI counseling will be customized for each participant.
48281616|NCT03642184|DRUG|Linagliptin|Dosage adjustment based on glucose targets. Once daily
48463801|NCT00307723|DRUG|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
48463802|NCT00307723|PROCEDURE|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
48623909|NCT04689243|PROCEDURE|ALA-PDT|Low concentration ALA-PDT, 3 times a week.
48623910|NCT04689243|PROCEDURE|red light|red light, 3 times a week.
48623911|NCT04201600|DEVICE|Continuous Glucose Monitoring System (CGMS)|Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
48623912|NCT01697241|OTHER|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
48623913|NCT01697241|OTHER|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
48623914|NCT01620346|PROCEDURE|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
48623915|NCT01620346|PROCEDURE|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
48463803|NCT02288923|PROCEDURE|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
48463804|NCT02288923|PROCEDURE|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
48463805|NCT02288923|PROCEDURE|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
48463806|NCT02288923|PROCEDURE|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
48463807|NCT02288923|DRUG|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
48463808|NCT02288923|DRUG|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
48463809|NCT02288923|DRUG|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.
48463810|NCT02288923|DRUG|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
48463811|NCT02288923|DRUG|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
48463812|NCT02992548|DRUG|Pravastatin|
48623916|NCT00469729|DRUG|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
48623917|NCT02148627|DRUG|LY3041658 (SC)|Administered SC
48623918|NCT02148627|DRUG|LY3041658 (IV)|Administered as slow IV infusion
48623919|NCT02148627|DRUG|Placebo|Administered as slow IV infusion
48623920|NCT02403271|DRUG|Ibrutinib|BTK Inhibitor
48463813|NCT02740257|OTHER|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
48463814|NCT02324452|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
48463815|NCT01491464|DEVICE|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
47935986|NCT01467245|PROCEDURE|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
47935987|NCT01467245|PROCEDURE|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
48099324|NCT03503773|DRUG|Alcohol|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
48463816|NCT01491464|DEVICE|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
48463817|NCT01897441|DRUG|Cyclophosphamide|Given IV
48463818|NCT01897441|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48463819|NCT01897441|DRUG|Doxorubicin Hydrochloride|Given IV
48463820|NCT01897441|OTHER|Laboratory Biomarker Analysis|Correlative studies
48623921|NCT02403271|DRUG|Durvalumab|Anti PDL-1
48623922|NCT00002874|DRUG|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
48623923|NCT00002874|RADIATION|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
48623924|NCT00002874|DRUG|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
48623925|NCT01199614|DRUG|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
48623926|NCT02229604|OTHER|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
48281617|NCT04740957|OTHER|Distal limb reintroduction of ileostomy effluent|"Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma."
48281618|NCT06518629|OTHER|Photobiomodulation with low power laser|All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
48281619|NCT05173896|DRUG|Tadalafil 20 MG|Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.
48281620|NCT05173896|DRUG|Placebo|Daily dose of oral over-encapsulated placebo tablets for three months.
48281621|NCT03953105|DEVICE|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
48623927|NCT02229604|DRUG|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
48281622|NCT03953105|DEVICE|BT|usind the BT for weight estimation and suggestion of the defined parameter
48281623|NCT00661375|DRUG|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
47935988|NCT00572221|BEHAVIORAL|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
48099325|NCT03503773|OTHER|Sham control|endovascular, renal angiography
48281624|NCT01610921|OTHER|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
48463821|NCT01897441|DRUG|Paclitaxel|Given IV
48463822|NCT01897441|BIOLOGICAL|Trastuzumab|Given IV
48463823|NCT05909696|DRUG|rocuronium|Advanced intravenous injection of rocuronium before the succinylcholine injection
48463824|NCT02161549|DEVICE|Motus Gl CleanUp System|
48463825|NCT03750591|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
48463826|NCT03750591|PROCEDURE|Chuna manual therapy|"Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion."
48463827|NCT03750591|PROCEDURE|Bee venom pharmacopuncture|"Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea)."
48623928|NCT03822416|DRUG|Nicotine patch|Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
48623929|NCT03822416|DRUG|Nicotine lozenge|Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
48623930|NCT03822416|BEHAVIORAL|Therapy|In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
48623931|NCT03822416|OTHER|Information|Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
48623932|NCT00538538|DRUG|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
48623933|NCT00538538|DRUG|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
48623934|NCT05388175|DEVICE|Rigid catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
48623935|NCT05388175|DEVICE|Soft catheter|Participants will be invited to positioning a rigid catheter in the manikin's trachea for surfactant aministration
48623936|NCT01348698|PROCEDURE|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
48623937|NCT01348698|PROCEDURE|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
48623938|NCT04876183|OTHER|Selfapy for Binge Eating Disorder|Web-based intervention for Binge Eating Disorder with six mandatory weekly sessions covering topics related to eating behaviors, emotion regulation, and stress management, followed by an optional set of up to six modular specialization areas based on individual therapy goals. During the intervention, participants can access an online chat providing crisis management, answering questions concerning the exercises, and technical support. The chat does not include the opportunity to discuss individual topics and concerns about treatment.
48623939|NCT03474744|DRUG|Copanlisib|Solution for IV infusion
48623940|NCT03474744|DRUG|Rituximab|Solution for IV infusion
48623941|NCT06255548|OTHER|Immersive virtual reality group|The children in the IVR group were offered two video games from the Oculus Quest gallery. These games were Ocean Rift and Epic Roller Coaster-T-Rex Kingdom. Ocean Rift is the world's first VR water safari park. It has 12 different marine animals such as dolphins, sharks, and turtles and a habitat. Here one can visit a vibrant underwater world that extends all the way to the Arctic and Atlantis. Epic Roller Coaster-T-Rex Kingdom takes one on a roller coaster ride through the Age of Dinosaurs. There are more than 10 species of dinosaurs such as terrestrial, flying, herbivorous and carnivorous.
48623942|NCT06255548|OTHER|Music group|In musical interventions, it is recommended to play music chosen by individuals. Disposable ear pads were used for each child and the headphones were cleaned after each intervention.
48623943|NCT01449487|DRUG|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
48623944|NCT01449487|DRUG|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
48623945|NCT02469909|OTHER|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
47935989|NCT00572221|BEHAVIORAL|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
47935990|NCT00938964|DRUG|Lidocaine|Lidocaine versus placebo infusion for 48 hours
47935991|NCT00938964|DRUG|Placebo|Lidocaine versus placebo infusion for 48 hours
48463828|NCT03750591|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).
48463829|NCT03750591|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48463830|NCT03750591|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48463831|NCT03750591|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
48463832|NCT03750591|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
48463833|NCT05604651|OTHER|no intervention|no intervention
48463834|NCT04046562|BEHAVIORAL|PAW|Pain and Weight Treatment plus standard of care
48463835|NCT04046562|BEHAVIORAL|Pain Education|Pain Education plus standard of care
48463836|NCT04020445|OTHER|de-escalation of complex insulin regimens|complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist
48463837|NCT02036398|DEVICE|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
48463838|NCT02036398|DEVICE|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
48463839|NCT05588505|BEHAVIORAL|Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD|The intervention is 12 weeks long, made up of one 2- hour session each week. These sessions are designed to help the participants develop strategies to improve their executive functioning skills including self- care, time management and organizational skills. These skills will also be applied to specific academic tasks such as note-taking during reading and lectures, organizing and conducting research, and writing papers.
48463840|NCT03004508|DIETARY_SUPPLEMENT|Gingko Biloba Extract|120mg/day, twice a day, 6 month
48463841|NCT03004508|DIETARY_SUPPLEMENT|Placebo|120mg/day, twice a day, 6 month
48463842|NCT03709953|DRUG|Apatinib|500 mg，po，QD； 28 days every cycle
48463843|NCT04857333|DIAGNOSTIC_TEST|CT scan|For patients with low-risk pulmonary nodules, follow-up CT scan is recommended
48463844|NCT04857333|DRUG|Antibiotics|For pulmonary nodules with features of infectious disease, antibiotics is recommended
48463845|NCT04857333|PROCEDURE|Surgical Resection|For persistent high-risk pulmonary nodules, surgical resection is recommended
48463846|NCT00856622|DRUG|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
48623946|NCT02469909|OTHER|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
48463847|NCT00856622|DRUG|timolol 0.5% ophthalmic solution|one drop in the morning and evening
48463848|NCT00856622|DRUG|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
48463849|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle|the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
48281625|NCT00909272|PROCEDURE|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
48463850|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle|the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
48463851|NCT05777694|PROCEDURE|Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle|the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
48463852|NCT00404625|BEHAVIORAL|Risk factors for infections due to ESBL+ Enterobacteriaceae|
48463853|NCT00404625|BEHAVIORAL|Risk factors for inadequate initial antimicrobial therapy|
48623947|NCT02469909|OTHER|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
48623948|NCT02469909|PROCEDURE|immediate decannulation|the tracheostomy tube is removed at once
48623949|NCT02469909|PROCEDURE|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
48623950|NCT01948778|DEVICE|oXiris™ filter|
48623951|NCT01948778|DEVICE|Toraymyxin Filter|
48623952|NCT01948778|DEVICE|Standard of Care|
48623953|NCT03590002|DEVICE|Electronic ICU Medical Transfer Tool|Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
48623954|NCT01631253|PROCEDURE|Laparoscopic ovarian cyst enucleation|
48623955|NCT04890613|DRUG|CX-5461|150 mg sterile lyophilized powder containing 1% sucrose
48623956|NCT02724436|PROCEDURE|TACE|
48623957|NCT02724436|PROCEDURE|radioembolization with Y-90|radioembolization with Y-90
48281626|NCT00909272|PROCEDURE|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
48281627|NCT03293680|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
48463854|NCT00404625|BEHAVIORAL|Overall and 30-day mortality in bad first antibiotic therapy|
48463855|NCT03541239|DEVICE|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
48463856|NCT03241186|DRUG|Ipilimumab|1mg/kg
48623958|NCT06120972|DRUG|Olaparib tablet|Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
48623959|NCT02130141|DIETARY_SUPPLEMENT|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
48623960|NCT02130141|OTHER|Dietary counselling|Usual snacks are limited.
48623961|NCT03312166|DEVICE|Compression device|"interventions on patient are :~* surgical excision of ear lobe keloid~* application of compression device on sutured skin"
48623962|NCT03325439|DRUG|Brivaracetam (BRV) intravenous (iv)|"Exploratory Cohort:~Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment.~Confirmatory Cohort:~For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment."
48623963|NCT03325439|DRUG|Brivaracetam (BRV) oral|Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
48623964|NCT03043781|OTHER|Continuous epidural infusion|Continuous infusion, 5 ml/h
48623965|NCT03043781|OTHER|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
48623966|NCT04547920|DEVICE|Wearable Bladder Modulation System-1x per week|Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation
48623967|NCT04547920|DEVICE|Wearable Bladder Modulation System - 3x per week|Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation
48623968|NCT03122665|DRUG|Nefopam Low dose|Continuous intravenous infusion at 0.5 mg/ml for three hours.
48463857|NCT03241186|DRUG|Nivolumab|3mg/kg
48463858|NCT03241186|DRUG|Nivolumab|480mg
48463859|NCT02166801|BEHAVIORAL|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand \& Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
48623969|NCT03122665|DRUG|Nefopam High dose|Continuous intravenous infusion at 1.0 mg/ml for three hours.
48623970|NCT04416789|OTHER|Exercise programme|1 session of trampolining/dry sports (1.5 hours) and 1 session of supervised swimming (1.5 hours) per week for 10 weeks.
48623971|NCT05442931|DRUG|Pregabalin 150mg|The oral tablet half an hour preoperative 150 milligrams
48623972|NCT05442931|DRUG|Magnesium Sulfate|Intravenous administration half an hour preoperative 2 grams
48623973|NCT05442931|DRUG|Nitroglycerin|measure total dose of nitroglycerine in milligrams using a syringe pump
48623974|NCT05442931|OTHER|surgeon satisfaction|surgeon satisfaction measured according to Likert's scale
48623975|NCT01403584|DEVICE|AutoVPAP with addition of AutoEPAP|Implementation of automated algorithm for adjustment of conventional device parameter (EPAP0.
48623976|NCT01403584|DEVICE|AutoVPAP with EPAP manually selected|Conventionally applied Expiratory Positive Airway Pressure (EPAP)
48099326|NCT06101030|DEVICE|Signal On|InSee monitor patient signals are on.
48281628|NCT01146925|DRUG|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
48281629|NCT01146925|DRUG|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
48281630|NCT03711383|DIETARY_SUPPLEMENT|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
48281631|NCT03711383|DIETARY_SUPPLEMENT|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
48281632|NCT03711383|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before test day
48623977|NCT01680172|DRUG|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
48281633|NCT06657716|DEVICE|ANTERION investigational|"Device: ANTERION investigational~Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)"
48281634|NCT04377945|DRUG|Part 1, JM-010 component Group A|JM-010 component Group A
48281635|NCT04377945|DRUG|Part 1, JM-010 component Group B|JM-010 component Group B
48281636|NCT04377945|DRUG|Part 1, JM-010 component Group C|JM-010 component Group C
48281637|NCT04377945|DRUG|Part 1, Placebo Group|Placebo Group
48281638|NCT04377945|DRUG|Part 2, JM-010 combination Group A|JM-010 combination Group A
48281639|NCT04377945|DRUG|Part 2, JM-010 combination Group B|JM-010 combination Group B
48281640|NCT04377945|DRUG|Part 2, JM-010 component Group C|JM-010 component Group C
48623978|NCT01680172|DRUG|Placebo|Single dose of liquid placebo solution taken by mouth
48623979|NCT00898807|DRUG|citalopram|target dose 30mg daily for 9 weeks
48623980|NCT00898807|DRUG|placebo|daily for 9 weeks
48099327|NCT06629883|BEHAVIORAL|REPS w/BANDS|This theory-informed, one-arm proof-of-concept study provided participants (n=10) with an SHVD, exercise equipment (exercise bands, stability ball), and 2 supervised RE sessions per week for 12 weeks via the SHVD's video feature and incorporated strategies from self-determination theory to meet the psychological needs of autonomy, competence, and relatedness. Participants were randomly paired with a buddy.
48099328|NCT00283374|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
48099329|NCT00975806|DRUG|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
48281641|NCT04377945|DRUG|Part 2, Placebo Group|Placebo Group
48281642|NCT03714893|DEVICE|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
48281643|NCT04659993|BEHAVIORAL|Telemental Health Sessions, Support Groups and Questionnaires|Participants will complete initial online questionnaires lasting about 25-30 minutes as well as attend weekly support group meetings online. After 4 weeks, participants will complete seven online follow-up questionnaires that should take no longer than 30 minutes and again at the end of the study.
48281644|NCT06118528|DEVICE|Blur Obfuscation|Blurring is applied to the RGB images.
48281645|NCT06118528|DEVICE|Cartoon Obfuscation|Cartoonization is applied to the RGB images.
48281646|NCT06118528|DEVICE|Edge Obfuscation|A black background and simple outlines of objects/people are applied to the RGB images.
48281647|NCT06118528|DEVICE|No Obfuscation (raw)|No editing is performed on the RGB images.
48281648|NCT06187506|DRUG|Disitamab vedotin|2.0 mg/kg, administered intravenously every three weeks
48623981|NCT05044988|DRUG|HS-10342|HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
48623982|NCT03982654|DEVICE|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
48623983|NCT02142543|DRUG|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
48623984|NCT02142543|DRUG|Placebo Comparator|
48623985|NCT03155698|COMBINATION_PRODUCT|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~* After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
48623986|NCT03155698|RADIATION|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
48623987|NCT03210766|DRUG|Nabilone|
48623988|NCT03210766|DRUG|THC/CBD|
48623989|NCT00189670|PROCEDURE|6 TEC q 3 weeks|
48623990|NCT00189670|PROCEDURE|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
48623991|NCT00189670|PROCEDURE|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
48623992|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
48623993|NCT00667966|DRUG|Placebo|10/20 mg placebo in sequence in respective arm
48623994|NCT00667966|DRUG|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
48623995|NCT00635284|DRUG|ABI-009|nab-rapamycin
48623996|NCT04170933|PROCEDURE|Magnetic recanalization|"1. Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~2. Perform endoscopic sphincterotomy (EST).~3. Place one magnet above the stricture through the PTCD fistula.~4. Introduce another magnet below the stricture through the common bile duct with ERCP.~5. Place the magnets at the appropriate point to attract each other.~6. The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~7. A plastic stent will be placed in the bile duct for lasting support."
48623997|NCT05413642|DRUG|Recommended treatment schedule|Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
48623998|NCT05413642|DRUG|Usual care|Treatment regimens different from the recommended one according to family physician personal practice
48623999|NCT02777788|DRUG|JinFuKang|treated with chemotherapy
48624000|NCT02777788|DRUG|XingZaoRuanJian|treated with chemotherapy
48624001|NCT02777788|DRUG|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
48624002|NCT02763358|DEVICE|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
48624003|NCT01860404|DRUG|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
48624004|NCT01860404|DRUG|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
48624005|NCT03110276|DRUG|EYP001a|10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
48624006|NCT03110276|DRUG|Placebo|Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
47935992|NCT06313021|OTHER|Reliability and Validity Study|Reliability and Validity Study
47935993|NCT02283151|DIETARY_SUPPLEMENT|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake \< 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (\<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
47935994|NCT02283151|OTHER|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
48281649|NCT06187506|DRUG|Bacillus Calmette Guerin Vaccine|Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
48281650|NCT02603575|DRUG|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
48624007|NCT02296697|DEVICE|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
48624008|NCT02296697|DEVICE|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
48624009|NCT02296697|OTHER|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
48624010|NCT05220930|OTHER|Foot bath for heel warming|In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.
48624011|NCT05220930|OTHER|Ineffective heel warming with thermofor|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
48624012|NCT05518552|OTHER|Manual lumbar traction|Patient in the group were treated with manual traction
48624013|NCT05518552|OTHER|Prone traction|Patient in the group were placed on prone traction
48624014|NCT06342141|DRUG|Empagliflozin 25 milgrams (Mg)|Load dose
48624015|NCT06342141|DRUG|Empagliflozin 10 Mg|Maintenance dose
48624016|NCT01761188|PROCEDURE|Ablation|electrophysiology substrate mapping is the critical difference between both groups
48281651|NCT02603575|DRUG|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
48624017|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg"
48624018|NCT00153842|DRUG|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg"
48624019|NCT02931097|DEVICE|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
47935995|NCT01843478|OTHER|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
47935996|NCT01843478|OTHER|Usual Care|
47935997|NCT05846477|DEVICE|MySpine|patient specific guide for screw positioning
48463860|NCT02166801|BEHAVIORAL|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
48463861|NCT02957760|DRUG|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
48463862|NCT03428945|DRUG|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
48463863|NCT03428945|DRUG|Placebo|Placebo tablet identical to active drug
48463864|NCT03769636|DEVICE|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
48463865|NCT03673514|PROCEDURE|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
48624020|NCT02931097|DEVICE|Sham stimulation|
48624021|NCT00260442|BEHAVIORAL|Resistance Training|12 weeks, 3 times a week whole body resistance training
48624022|NCT00260442|BEHAVIORAL|Sedentary|Absence of physical activity
48624023|NCT06323993|PROCEDURE|Piezoelectric osteotomy|The piezoelectric technique, another window preparation procedure that does not use a round bur, was first introduced to LSFE in 2001 for its high accuracy of osteotomy and low rate of membrane perforation. Later studies demonstrated that the operation time, postoperative reactions, and perforation rate of this procedure are considered to be acceptable compared with rotary bur. Moreover, the piezoelectric technique allows for the lateral bone window to be cut and preserved relatively completely.
48624024|NCT00473499|DEVICE|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
48624025|NCT06091033|DIETARY_SUPPLEMENT|Fermented rice|1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks
47935998|NCT02749123|DRUG|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
47935999|NCT02749123|DRUG|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
47936000|NCT02749123|DRUG|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
48463866|NCT03323411|BEHAVIORAL|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
48463867|NCT01897077|DRUG|Peanut Dissolving Film|
48463868|NCT06367985|OTHER|Air Oxygen Concentration CAPA-IVM culture|"* Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
48463869|NCT06367985|OTHER|Low Oxygen Concentration CAPA-IVM culture|"* Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
48463870|NCT00017550|BIOLOGICAL|anti-thymocyte globulin|
48463871|NCT03814850|DEVICE|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
48463872|NCT03494933|PROCEDURE|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
48463873|NCT03494933|PROCEDURE|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
48624026|NCT06091033|DIETARY_SUPPLEMENT|placebo|1,000 mg of a placebo for 8 weeks
48624027|NCT01180777|DEVICE|etafilcon A (A)|Daily wear contact lens
48624028|NCT01180777|DEVICE|etafilcon A (B)|Daily wear contact lens
48624029|NCT01180777|DEVICE|etafilcon A (C)|Daily wear contact lens
48624030|NCT00306722|DRUG|AQUAVAN® (fospropofol disodium) Injection|
48624031|NCT04693728|BEHAVIORAL|Resilient Intrinsic Self-Regulation Strategies in Extremes|The manualized intervention covered resilience strategies organized into four modules: (1) engagement, (2) social relatedness, (3) transformation of pain and (4) building a good life. The modules were delivered in 8 weekly sessions of 90 minutes each.
48624032|NCT06473428|BEHAVIORAL|respiratory muscle training|Inspiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
47936001|NCT05500066|DEVICE|Aequalis Flex Revive Shoulder System|"The AEQUALIS FLEX REVIVE Shoulder System is intended for use as:~* A replacement of shoulder joints in primary anatomic or in primary reverse~* A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains.~The system also allows for conversion from anatomic to reverse shoulder prosthesis in case of revision."
47936002|NCT01484938|DEVICE|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
48624033|NCT06473428|BEHAVIORAL|Expiratory Muscle Training|Expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
48624034|NCT06473428|BEHAVIORAL|Placebo-Controlled Expiratory Muscle Training|Placebo-controlled expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
48624035|NCT01696968|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
48624036|NCT01696968|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
48463874|NCT01881737|DRUG|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
48463875|NCT01112462|DRUG|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
48463876|NCT01112462|DRUG|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
48463877|NCT03358147|DRUG|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
48463878|NCT03358147|DRUG|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
48463879|NCT03358147|DRUG|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
48463880|NCT03358147|DRUG|Placebo MDI|Placebo taken as 2 inhalations BID
48624037|NCT04882800|DEVICE|Lyric extended wear hearing aid device A|Current commercially available extended wear hearing aid
48624038|NCT04882800|DEVICE|Lyric extended wear hearing aid with fitting modification device B|Extended wear hearing aid with fitting modifications
48624039|NCT01251458|DRUG|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
48624040|NCT02346422|GENETIC|MYDICAR Phase 1|Single dose of MYDICAR
48624041|NCT02346422|GENETIC|MYDICAR Phase 2|Single dose of MYDICAR
48624042|NCT02346422|GENETIC|Placebo Phase 2 only|Single dose of placebo
48624043|NCT04656665|DRUG|Aspirin|For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
48624044|NCT00464464|BEHAVIORAL|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
48624045|NCT00766818|DRUG|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
48624046|NCT01917773|DRUG|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
48281652|NCT02603575|DRUG|Sulfanilamides|1.92g q8h
48281653|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin and flaxseed|2 capsules hesperidin and 30 g flaxseed
47936003|NCT04022161|DRUG|Nitrogen Gas for Inhalation|See arm description
47936004|NCT04022161|OTHER|Blood withdrawal|Blood samples will be collected over four time-points: (I) baseline (before surgery) (II) end of the surgery, (III) end of 24 hours of gas delivery and (IV) 24 hours from the gas suspension.
47936005|NCT04022161|DRUG|Nitric Oxide|See arm description
48281654|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin|2 capsules hesperidin
48281655|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: flaxseed|30 g flaxseed
48463881|NCT03358147|DRUG|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
48624047|NCT01917773|DRUG|Bisacodyl|
48624048|NCT03672825|DRUG|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
48624049|NCT05592197|DRUG|Lenvatinib|Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients \< 60 kg, and 12 mg qd for patients ≥ 60 kg)
48624050|NCT05592197|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
48624051|NCT05592197|RADIATION|External beam radiation (RT)|RT will be given within 4 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-6000 cGy in 25 fractions.
47936006|NCT04221243|DEVICE|3D printed space maintainer by NextDent Ortho Rigid|Biocompatible 3D printing material
47936007|NCT04221243|DEVICE|Conventional Band and Loop|metal space maintainer
47936008|NCT04369924|BEHAVIORAL|Unidimensional Measurement-Based Care|Youth and caregivers will complete a symptom rating scale every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
47936009|NCT04369924|BEHAVIORAL|Multidimensional Measurement-Based Care|Youth and caregivers will complete battery of questionnaires covering multiple process and outcome domains every session. Clinicians will receive feedback reports summarizing these data, including alerts indicating if the youth is on track for positive treatment outcomes. These feedback reports will be used to support clinical decision-making.
48099330|NCT00975806|DRUG|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
48281656|NCT03734510|OTHER|control|no supplementation
48281657|NCT02691000|DEVICE|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
48281658|NCT02691000|DEVICE|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
48463882|NCT03202251|OTHER|It's is a cohort|It is a prospective, observational, cohort study
48463883|NCT05995769|DRUG|Psilocybin|Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
48463884|NCT02511860|DIETARY_SUPPLEMENT|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
48463885|NCT02511860|DIETARY_SUPPLEMENT|Placebo|Methylcellulose (inert) tablet taken as placebo
48624052|NCT05699681|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"After induction of anaesthesia and stabilization of hemodynamics, transthoracic echocardiography will be done on a GE Vivid e9 workstation (GE Vingmed, Horton, Norway) with MS5 transthoracic probe with synchronized ECG.~From TTE the following views and measurements will be acquired :~* Apical four chamber (A4C) view~* Apical two chamber view (A2C) view~* Right ventricle (RV) focused A4C view~* Right ventricular systolic pressure (RVSP)~* Pulmonary arterial acceleration time (PAAT),~* Tricuspid annular plane systolic excursion (TAPSE),~* Tricuspid annular plane systolic velocity (s'),~* Right ventricular fractional area change (RV FAC)~* RV free wall strain,~* RV myocardial performance index (MPI),~* RV isovolumic relaxation time (IVRT),~* RV isovolumic acceleration time (IVA)~Invasive PA pressure measurement will be done after surgical exposure with a fine needle and a zeroed transducer by the Surgeon."
48624053|NCT02475447|DRUG|Asimadoline|kappa-opioid receptor agonist
48624054|NCT02475447|DRUG|Placebo|placebo-matched control
48624055|NCT01331434|DRUG|exemestane|25 mg tablet
48624056|NCT04790383|OTHER|Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).|Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.
48624057|NCT04790383|OTHER|Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona|Conventional Nanohybrid resin composite
48624058|NCT01287247|BIOLOGICAL|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
48624059|NCT01990781|DRUG|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
48624060|NCT01990781|DRUG|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
48624061|NCT01990781|DRUG|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
48624062|NCT01990781|DRUG|N: Normal saline (placebo)|Normal saline: 2ml
48624063|NCT03451968|OTHER|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
48624064|NCT01060176|DRUG|Tranexamic Acid|
48624065|NCT01060176|DRUG|Saline Solution|
47936010|NCT01936402|BEHAVIORAL|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
48624066|NCT01564407|DRUG|ICX-RHY-013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
48624067|NCT01771926|OTHER|potatoes|Daily intake of assigned treatment for 8 weeks
48624068|NCT01771926|OTHER|other carbohydrate|Daily intake of assigned treatment for 8 weeks
48463886|NCT05981716|OTHER|No intervention|This is an observational study. There is no intervention.
47936011|NCT05354804|DIAGNOSTIC_TEST|Troponin I (Siemens VTli) 0/1 hour algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
48463887|NCT04130685|DIAGNOSTIC_TEST|Allosure Test|Venous Blood Draw
48463888|NCT03789630|DEVICE|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
48463889|NCT05726162|DEVICE|biofeedback-based music program|The investigators will provide biofeedback-based music, which incorporates the patient's respiratory information. In a biofeedback-based music group, the patient performs an active respiratory intervention session, which induces a slow breathing pattern. If breathing has been slow enough, the automatic mode is activated to provide music based on patient's own breathing pattern. It automatically will be terminated 30 minutes after intervention.
48463890|NCT05726162|OTHER|Control|The investigators will provide noise-canceling earplugs to minimize bias from noise in the ward.
48463891|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing native palm olein|
48463892|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing interesterified palm olein|
48463893|NCT00530348|BIOLOGICAL|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
48463894|NCT00530348|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
48463895|NCT00310297|DRUG|Insulin Glulisine|
48463896|NCT00157066|DRUG|Ergocalciferol|
48463897|NCT00351117|DRUG|St. John's Wort|SJW in capsule form 300 mg PO TID
48463898|NCT00351117|DRUG|Lactose|lactose in gelatin capsule that same as St. John's wort
48463899|NCT02417571|DEVICE|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A\&D Company, Tokyo, Japan)
48463900|NCT01937689|DRUG|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
48463901|NCT01189656|BIOLOGICAL|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
47936012|NCT05354804|DIAGNOSTIC_TEST|Troponin T (Roche Diagnostics) 0/1 hour ESC algorithm|Patients will be investigated using the ESC 0/1 hour cTnT algorithm from ESC compared to a 0/1 hour algorithm utilizing the Siemens VTli POC instrument for cTnI.
48281659|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
47936013|NCT05860374|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
48281660|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
48281661|NCT01477450|DEVICE|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
48281662|NCT01477450|DEVICE|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
48281663|NCT01748383|PROCEDURE|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
48624069|NCT04926545|DRUG|Xiao Chai Hu Tang (XCHT)|"XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients."
48624070|NCT04926545|OTHER|Raloxifene|Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.
47936014|NCT01117051|DRUG|placebo|placebo
47936015|NCT01117051|DRUG|prucalopride|1 or 2 mg prucalopride once daily before breakfast
47936016|NCT02116478|PROCEDURE|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
47936017|NCT05636488|OTHER|No intervention|There is no intervention group in this study
48463902|NCT06381323|DRUG|Finerenone|All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
48099332|NCT05275686|DRUG|Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray|Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
48281664|NCT01748383|PROCEDURE|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
48281665|NCT01748383|PROCEDURE|stenting of IRA|The only stent implantation
48281666|NCT02622932|DRUG|Anlotinib and 14C-labeled Anlotinib|oral
48281667|NCT03444337|DEVICE|Catheter Ablation|
48281668|NCT04708912|OTHER|Observation|The study parameters will be obtained at the time of recuirement (Basal)
48281669|NCT06007612|BEHAVIORAL|Context Sensitivity in Emotion Regulation|Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
48281670|NCT01595217|DEVICE|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
48281671|NCT00318955|DRUG|Dexmedetomidine|
48281672|NCT00318955|DRUG|Propofol|
48281677|NCT03301857|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
48281678|NCT03040024|DRUG|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
48281679|NCT03040024|DRUG|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
48281680|NCT03040024|DEVICE|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
48281681|NCT06167161|DEVICE|Hearing aid|The hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and through a dedicated smartphone application
48463903|NCT02636673|PROCEDURE|Sigmoid Resection|
48463904|NCT02063815|PROCEDURE|Fissure sealant application|
48281682|NCT05436249|DEVICE|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
48281683|NCT05436249|BEHAVIORAL|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
48624071|NCT04926545|DRUG|FOLFIRI regimen|Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
48624072|NCT03572218|BEHAVIORAL|BWL|The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants \< 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that \>250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.
48281684|NCT05593432|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
48463905|NCT03824834|DRUG|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
48463906|NCT03824834|OTHER|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
48463907|NCT02930876|BEHAVIORAL|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
47936018|NCT06477809|DEVICE|ARIA Glasses ( Augmented Reality in Audio )|ARIA stands for Augmented Reality in Audio. The ARIA Device consists of Augmented Reality glasses connected by cord to a dedicated mobile phone that has the ARIA app installed. The glasses include cameras, speakers and an inertial measurement unit. The phone app uses artificial intelligence to convert camera vision from the glasses into a soundscape that includes words and unique sounds identifying specific objects nearby, and an audio rendering of depth that estimates the user's distance from solid matter. This soundscape is delivered to the user via an amplifier that enables volume control and switch-off. The soundscape is designed to augment rather than replace natural hearing, increasing the user's perceptual access to details in the nearby environment.
47936019|NCT03332550|PROCEDURE|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
47936020|NCT03332550|PROCEDURE|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
47936021|NCT04738929|OTHER|Extra virgin coconut oil or extra virgin olive oil|"Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil"
47936022|NCT05009082|DRUG|Carboplatin|Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
47936023|NCT05009082|DRUG|Paclitaxel|175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
47936024|NCT05009082|DRUG|Bevacizumab|7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year
48281685|NCT05593432|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
48281686|NCT04698187|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
48281687|NCT04698187|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
47936025|NCT05009082|DRUG|Niraparib|200 or 300 mg capsules once daily for up to a total of 3 years
47936026|NCT00746447|DRUG|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
47936027|NCT00746447|DRUG|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
47936028|NCT00746447|DRUG|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
48281688|NCT00533000|PROCEDURE|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
48281689|NCT04863716|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
48281690|NCT04863716|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
48463908|NCT01531790|DRUG|Carboplatin|d1, AUC 5, i.v.
48463909|NCT01531790|DRUG|Pemetrexed|d1, 500 mg/m2, i.v.
48281691|NCT01612234|DIETARY_SUPPLEMENT|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
48281692|NCT06261814|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
48463910|NCT01531790|DRUG|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
48463911|NCT01531790|DRUG|Centrum|1 tablet/day
48463912|NCT03699254|DRUG|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
47936029|NCT02573701|DRUG|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
47936030|NCT02573701|BEHAVIORAL|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
47936031|NCT02573701|DRUG|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
47936032|NCT02752555|OTHER|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
47936033|NCT01897376|PROCEDURE|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
47936034|NCT01897376|PROCEDURE|vertical skin incision|vertical skin incision at time of cesarean section
47936035|NCT06516445|RADIATION|SCRT|5×5Gy，5Gy/d，QD，D1-D5
47936036|NCT06516445|DRUG|Camrelizumab|200mg, D1, ivgtt, Q3W, C1-4
47936037|NCT06516445|DRUG|Fluzoparib|100mg, BID, PO, Q3W, C1-4
47936038|NCT06516445|DRUG|CAPEOX|Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4
47936039|NCT06477328|PROCEDURE|Telemedicine|Video calls were made with the telemedicine group.
47936040|NCT03721679|BIOLOGICAL|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
47936041|NCT03790007|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
47936042|NCT03091777|DRUG|GDC-229|GDC-229 is a vaginal gel.
47936043|NCT03091777|DRUG|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
47936044|NCT03091777|DRUG|Placebo|Inactive arm of the study
47936045|NCT03228199|OTHER|Intervention group|Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
47936046|NCT03228199|OTHER|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
47936047|NCT04628832|BEHAVIORAL|PMP Use Mandate Letter|A letter with reminders about the mandate to check the PMP when prescribing opioids.
47936048|NCT04628832|BEHAVIORAL|Prescribing Information Letter|A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.
47936049|NCT04628832|BEHAVIORAL|Prescribing Information + PMP Use Mandate Letter|A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.
47936050|NCT03934697|BEHAVIORAL|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
47936051|NCT05029570|DEVICE|Conduction System Pacing (pacemaker implantation)|Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
47936052|NCT02789579|DRUG|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
47936053|NCT02789579|DRUG|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
47936054|NCT02789579|DRUG|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
47936055|NCT05517460|OTHER|Auricular acupressure|The participant in Intervention period will receive acupressure on ear Shenmen point, ear Large intestine point, ear Rectumn point and ear San Jiao point.
47936056|NCT05517460|OTHER|health education|health education for self-care and medication adherence
47936057|NCT05519332|PROCEDURE|percutaneous vertebral-disc plasty|percutaneous vertebroplasty combined percutaneous cement discoplasty
47936058|NCT04507880|DEVICE|Reverse Total Shoulder Arthroplasty|The RTSA (GLOBAL UNITE Reverse Fracture System) from DePuy Synthes.
47936059|NCT04507880|DEVICE|Hemiarthroplasty|The shoulder hemiarthroplasty
47936060|NCT03809793|OTHER|Exercise Program|12-week walking based intervention (3 sessions per week)
47936061|NCT03809793|DIAGNOSTIC_TEST|DXA|Participants will undergo an assessment of body composition (DXA)
47936062|NCT03809793|DIAGNOSTIC_TEST|MRI|used to measure fat stored in the liver
48281693|NCT06261814|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
48624073|NCT03572218|BEHAVIORAL|BIAS|Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
48624074|NCT02907372|OTHER|neuropsychologic evaluation|
48624075|NCT02907372|OTHER|oncogeriatric evaluation|
48463913|NCT03699254|DRUG|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
48463914|NCT02838953|BEHAVIORAL|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
48624076|NCT05268289|DRUG|Iptacopan (part 1)|Taken for 52 Weeks
48624077|NCT05268289|DRUG|Iptacopan (part 2)|Taken for 52 Weeks
48624078|NCT05268289|DRUG|Placebo + standard of care|Taken for 52 Weeks
48624079|NCT05268289|DRUG|Iptacopan + placebo|Taken for 52 Weeks
48463915|NCT04153825|DEVICE|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
48624080|NCT05534672|OTHER|Rapamycin|Rapamycin in liquid administered orally
48624081|NCT05534672|OTHER|Placebo|Placebo in liquid administered orally
48624082|NCT02993900|DEVICE|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
48624083|NCT00475046|BEHAVIORAL|Motivational Interviewing|
48099333|NCT05275686|OTHER|Placebo Nasal Spray|The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
48281694|NCT06261814|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
48281695|NCT06261814|OTHER|Medical Chart Review|Ancillary studies
48463916|NCT04153825|DEVICE|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
48463917|NCT04153825|OTHER|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
48624084|NCT06047327|DIAGNOSTIC_TEST|EUS guided liver biopsy|Procedure will be performed by 19G Franseen needle.
48624085|NCT06047327|DIAGNOSTIC_TEST|Percutaneous Liver Biopsy|procedure will be done by 18G BioPince Needle
48624086|NCT03963388|OTHER|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
48624087|NCT00168298|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
48624088|NCT00168298|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
48624089|NCT00168298|OTHER|Sham Injection|Sham injection on Day 0.
48624090|NCT04755725|DEVICE|Epidural catheter|epidural catheter inserted pre induction
48624091|NCT04755725|DEVICE|rectus sheath catheter|The surgeon will place one hand inside the abdomen and with the other hand inserted the Tuohy needle through the skin and fascia. The surgeon will feel when the needle tip is just superfacial to interface between the peritoneum and muscle layer and avoid penetration of inferior epigastric artery. The procedure will be repeated on the contralateral
48624092|NCT06135259|DRUG|erythropoietin|erythropoietin solutions of 150, 300, and 500 IU/mL were mixed with trimethyl chitosan (M) solutions. glycerophosphate solution was then added to the mixture to obtain erythropoietin-loaded hydrogel comprising final concentrations of trimethyl chitosan(5%) and glycerophosphate (20%).
48624093|NCT06135259|DRUG|Triamcinolone acetonide|Each 0.1 mg triamcinolone acetonide in a dental paste containing gelatin, pectin, cream flavor, vanilla flavor and carboxymethylcellulose sodium in Plasticized Hydrocarbon Gel, a polyethylene and mineral oil gel base.
48624094|NCT04991584|DRUG|Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
48624095|NCT01970371|DRUG|plazomicin|
48624096|NCT01970371|DRUG|colistin|
48624097|NCT01970371|DRUG|meropenem|
48624098|NCT01970371|DRUG|tigecycline|
48624099|NCT01970371|DRUG|antibiotic of Investigator's choice|
48624100|NCT02602951|OTHER|Pilot MRI program|Pilot MRI program
48624101|NCT02602951|OTHER|MRI with 4D Flow sequence|MRI with 4D Flow sequence
48624102|NCT00653562|DRUG|zolpidem|Oral
48624103|NCT04611412|OTHER|Risk Factors|BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
48624104|NCT04731116|DRUG|Cannabidiol|Oral Cannabidiol 150 mg twice daily during 14 days
47936063|NCT03809793|DIAGNOSTIC_TEST|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (\>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
48463918|NCT04153825|DEVICE|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
48463919|NCT04153825|DEVICE|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
48463920|NCT01817595|OTHER|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
48463921|NCT01817595|OTHER|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
48463922|NCT00002727|RADIATION|radiation therapy|
47936064|NCT03809793|DIAGNOSTIC_TEST|VO2 Max|Assessment of maximum aerobic capacity.
47936065|NCT03809793|DIAGNOSTIC_TEST|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
47936066|NCT03809793|PROCEDURE|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
47936067|NCT03809793|DRUG|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
47936068|NCT01504061|OTHER|Mederma N&I|Topical gel applied three times a day for eight weeks.
47936069|NCT01504061|OTHER|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
47936070|NCT01483586|DRUG|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
47936071|NCT01483586|DRUG|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
47936072|NCT01987531|OTHER|left ventricular epicardial pacing lead|
47936073|NCT05894122|DIAGNOSTIC_TEST|DM-DIV MITRA®|Comparison of phenylalanine concentrations in the new device with those in the current device (blotter).
47936074|NCT06148389|DRUG|STSA-1301 subcutaneous injection|Subjects will receive the administration dose on Day 0 following protocol requirements.
47936075|NCT06148389|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements.
47936076|NCT03266198|OTHER|No intervention|No intervention
47936077|NCT06461429|DRUG|Erythromycin|Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
47936078|NCT06461429|DRUG|Amoxicillin and Erythromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
47936079|NCT06461429|DRUG|Azithromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
47936080|NCT06461429|DRUG|Caffeine citrate: Low dose|Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
47936081|NCT06461429|DRUG|Caffeine citrate: Medium dose|Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
47936082|NCT06461429|DRUG|Caffeine citrate: High dose|Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
47936083|NCT02569827|DRUG|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
47936084|NCT02569827|DRUG|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
47936085|NCT02569827|DRUG|Placebo|Placebo Q6H for 5 days
47936086|NCT02569827|DRUG|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
47936087|NCT05363943|PROCEDURE|double plating|open reduction and internal fixation by using lateral and medial plates.
47936088|NCT05363943|PROCEDURE|Distal femoral replacement|excision of the distal part of femur and replacement with distal femoral prosthesis
47936089|NCT02734433|DRUG|Pexidartinib|
47936090|NCT03098771|PROCEDURE|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
47936091|NCT03098771|DRUG|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
47936092|NCT06387433|BEHAVIORAL|mobile app use|The experimental group will use the mobile application while controlled group will not use mobile application. Investigators will assess the effectiveness of mobile application in ensuring medication adherence and self-management among diabetics in Pakistan
47936093|NCT03486145|DIETARY_SUPPLEMENT|fruit and vegetable juice supplement|"FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
47936094|NCT03486145|DIETARY_SUPPLEMENT|Placebo|"PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
47936095|NCT05184751|OTHER|colonoscopy|
48463923|NCT00562120|DRUG|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
48463924|NCT00562120|DRUG|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
48463925|NCT00562120|DRUG|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
48463926|NCT00562120|DRUG|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
48463927|NCT02260258|DRUG|Rocuronium|Neuromuscular Blockade
48463928|NCT02260258|DRUG|Normal Saline|Normal Saline
48463929|NCT02267408|OTHER|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
48463930|NCT02267408|OTHER|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
48463931|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
48463932|NCT04150549|BIOLOGICAL|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
48463933|NCT01098539|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
48463934|NCT01098539|DRUG|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
48463935|NCT04491734|DIETARY_SUPPLEMENT|maltosyl-isomalto-oligosaccharides (MIMO)|Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
48463936|NCT05616455|DRUG|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
48463937|NCT05616455|DRUG|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
48463938|NCT00005958|BIOLOGICAL|filgrastim|
48463939|NCT00005958|DRUG|docetaxel|
48463940|NCT00005958|DRUG|gemcitabine hydrochloride|
47936096|NCT00842452|DRUG|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
47936097|NCT00842452|OTHER|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
47936098|NCT05811533|OTHER|Spencer's MET with conventional therapy|Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
48463941|NCT01299779|DRUG|PEG-SD|"PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients."
48463942|NCT01299779|DRUG|PEG-ELS|"* 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
48463943|NCT03786770|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
48463944|NCT00965731|DRUG|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
48463945|NCT00965731|DRUG|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
48463946|NCT00965731|DRUG|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
48463947|NCT00924963|DEVICE|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
48463948|NCT00924963|DEVICE|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
48463949|NCT00924963|DRUG|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
48463950|NCT06481982|DIAGNOSTIC_TEST|MRI|MRI sequences
48463951|NCT03734458|OTHER|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
47936099|NCT05811533|OTHER|Post-Facilitation Stretch with conventional therapy|Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
47936100|NCT06523517|DRUG|Eliglustat Tartrate Capsules|The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
47936101|NCT01604109|DRUG|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
47936102|NCT01604109|DRUG|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
47936103|NCT00209651|DRUG|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
47936104|NCT00209651|DRUG|TS-1|80 mg/m2, PO (oral) on day 1\~14 of each 28 day cycle.
48463952|NCT03734458|OTHER|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
48463953|NCT03734458|OTHER|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
48099334|NCT04783181|BIOLOGICAL|AAV BBP-631|intravenous
48463954|NCT05237830|PROCEDURE|Use of Cell Salvage in revision of total hip arthroplasty|The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.
48463955|NCT01135264|BEHAVIORAL|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
48463956|NCT01135264|BEHAVIORAL|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
48463957|NCT04021160|DEVICE|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
48624105|NCT02441283|DRUG|ABT-493|ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
48624106|NCT02441283|DRUG|ABT-530|ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
48624107|NCT04874168|DEVICE|TAP block|bilateral ultrasound-guided TAP block was performed using a 12-4-MHz linear array transducer (ClearVue 350; Philips, Bothell, WA) placed transversely between the iliac crest and costal margin in the anterior axillary line and slid medial-lateral to visualize the external oblique, internal oblique, and trans-versus abdominis muscles; the most lateral (posterior) position obtaining a satisfactory ultrasound image was used
48624108|NCT00790933|DRUG|Vedolizumab|Vedolizumab intravenous infusion
48624109|NCT00169403|PROCEDURE|Deep brain stimulation|
48624110|NCT05621473|DEVICE|PICC|Tunnel PICC puncture technology is a perfect combination of ultrasound-guided puncture, ECG lead technology, PICC and subcutaneous tunnel. The valve conduction PICC is equipped with an integrated ECG lead Doppler ultrasound machine. Before the catheter is placed, in the yellow area, in the ultrasound mode, evaluate the blood vessel condition, measure the blood flow velocity, and correctly select the puncture site. When the catheter is pushed close to the superior vena cava, the electrocardiograph mode is switched to complete the precise positioning of the catheter according to the principle of ECG positioning technology. A subcutaneous tunnel was prepared in the green area, and the PICC at the puncture site in the yellow area was introduced to the green area and carefully bandaged. Whole-process integrated operation, simple and efficient operation.
48624111|NCT02212977|DEVICE|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
48624112|NCT02212977|PROCEDURE|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
48624113|NCT00102167|DRUG|gaboxadol|Duration of Treatment -1 day
48463958|NCT04021160|DEVICE|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
47936105|NCT06068920|OTHER|Distress evaluation|To evaluate the effects of psychological distress caused by living with a chronic disease such as rheumatoid arthritis.
48463959|NCT05136469|OTHER|NEURAL GLIDING|with Sciatic nerve gliding which is done by applying force on the proximal point and releasing the force distally and then reversing the process. This process was achieved for 30 seconds, 6 times on each leg for a total time of 3 minutes (360 seconds).
48463960|NCT05136469|OTHER|DYNAMIC STRETCH|The stretch force was applied on the ankle in downward direction which was held for 30 seconds and was repeated 5 times total of 2.5 minutes (150 seconds). Stretch was given on both legs one at a time. Treatment was given for 3 weeks with 2 sessions per week
48463961|NCT02319603|DRUG|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
48463962|NCT02319603|DRUG|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
48624114|NCT05455450|OTHER|Eye movement desensitisation and reprocessing therapy|Up to 16 EMDR sessions (minimum of 8 sessions), and 1-month follow-up session, as well as attending neuropsychiatric appointments (NPC). Participants will be given the choice of attending EMDR physically face-to-face or virtually via a video-consultation platform. Sessions will normally be attended weekly, with treatment completed within 6 months. Sessions will be 60-90 minutes long. EMDR will follow the standard 8-phase protocol, with additions so that it is tailored for FND presentations. The FND-specific EMDR therapy protocol has been developed for the trial by the chief investigator.
48624115|NCT05455450|OTHER|Neuropsychiatric care|Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.
48624116|NCT05893641|BEHAVIORAL|A regular training volume|Participate will maintain their training volume of 35 h/week
48624117|NCT05893641|BEHAVIORAL|A lower exercise volume group|Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)
48624118|NCT05893641|BEHAVIORAL|A longer rest group|Participate will maintain the 35 h/week of exercise training
48624119|NCT00551356|DRUG|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
48099335|NCT03962192|OTHER|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
48099336|NCT03690856|OTHER|inflammatory, neuropsychological and neuroimaging assessment|"Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)"
48099337|NCT05759819|DEVICE|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
48099338|NCT01564875|DRUG|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
48099339|NCT01564875|DRUG|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
48099340|NCT04596579|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody Analysis|10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
48099341|NCT04596579|DIAGNOSTIC_TEST|Weck-cel Swab Collection|A Weck-cel swab will be used to collect secretions from the mucosal epithelium
48099342|NCT04596579|BEHAVIORAL|Web Based Questionnaire|A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
48099343|NCT01575470|BIOLOGICAL|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
48099344|NCT05972239|OTHER|Standard pulmonary rehabilitation program|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
48099345|NCT05972239|OTHER|Balance training added on standard pulmonary rehabilitation|Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.
48099346|NCT01701154|OTHER|respiratory muscle strength training|
48463963|NCT06036550|DIAGNOSTIC_TEST|Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.
48463964|NCT02921516|BEHAVIORAL|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
48463965|NCT02921516|BEHAVIORAL|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
48463966|NCT02921516|BEHAVIORAL|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
48463967|NCT02279277|BEHAVIORAL|Supervised physical therapy program prior to total knee replacement surgery|
48463968|NCT02663661|PROCEDURE|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
48463969|NCT02663661|OTHER|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
48463970|NCT04474145|PROCEDURE|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
48099347|NCT00866996|DRUG|Methylphenidate extended-release; Atomoxetine|
48099348|NCT05911256|BEHAVIORAL|Pharmacist Only|Clinical pharmacists conduct encounters with patients by videoconferencing or phone. Pharmacists conduct a broad range of activities including ongoing evaluation of medication and lifestyle adherence, setting therapeutic goals, formulating a provider-approved plan of care, and documenting the plan in the electronic health record. Pharmacists propose medication changes based on algorithms and protocols derived from national guidelines under physician guidance.
48463971|NCT04474145|PROCEDURE|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
48463972|NCT06383949|DEVICE|Synergy Cervical Disc system|motion preservation disc
48463973|NCT00004105|DRUG|estramustine phosphate sodium|
48463974|NCT00004105|DRUG|paclitaxel|
48463975|NCT00004105|DRUG|vinorelbine ditartrate|
48463976|NCT03720548|DRUG|LY3372993|Administered IV.
48463977|NCT03720548|DRUG|Placebo|Administered IV.
48463978|NCT00724958|BIOLOGICAL|Infliximab|Not specified in the protocol.
48624120|NCT00551356|DRUG|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
48624121|NCT06403722|DIAGNOSTIC_TEST|Standard of care|No intervention. Clinical evolution was recorded, looking for perinatal complications.
48463979|NCT02269735|DRUG|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
48463980|NCT02269735|BIOLOGICAL|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
48463981|NCT02269735|DRUG|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
48463982|NCT02269735|BIOLOGICAL|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
48463983|NCT02269735|DRUG|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
48463984|NCT04554264|OTHER|questionnaire|Inventory of Complicate Grief (ICG) score in relative from patients who died in ICU after SARS-Cov2 infection. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score \> 25 indicate complicated grief.
48463985|NCT05634941|DEVICE|Active ON-tDCS|DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
48463986|NCT05634941|DEVICE|Sham ON-tDCS|For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
48463987|NCT01992094|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
48463988|NCT01992094|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
48463989|NCT01992094|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
48463990|NCT03328390|OTHER|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
48463991|NCT03328390|OTHER|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
48463992|NCT03610555|OTHER|new patient centered website|
48463993|NCT04834336|DEVICE|inspiratory muscle training device|Inspiratory muscle training will be performed with an inspiratory muscle training device.
48463994|NCT04834336|OTHER|Physical training|Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
48463995|NCT01710358|DRUG|Adalimumab|Administered SC
48463996|NCT01710358|DRUG|Baricitinib|Administered orally
48463997|NCT01710358|DRUG|Methotrexate|Administered orally
48624122|NCT05074147|DRUG|Reduction in the duration of antibiotic therapy 3 weeks or 6 weeks|"Drugs :~* Rifampin (IP an PO) : 10mg/Kg/12h~* Ofloxacin (PO) : 200Mg/8h~* Levofloxacin (PO) : 500mg ot 1g/ twice a day~* Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains~* Clindamycin : 600-900mg/8h~* Fusidic Acid : 500mg/8h~* Teicoplanin : 10mg/kg/12h for 5 dosis in combination, then in monotherapy.~* Ceftasidim : 2g/8h if Pseud spp ; 2g/12h for others Gram-negative bacilli strains~* Trimethoprim-sulfamethoxazole (800mg/160mg) : once per day if patient \< 80Kg ; one and a half per day if patient \> 80Kg.~* Doxycyclin : 200mg/day~* Minocyclin : 100mg/8h to 12h~* Ceftriaxon : 1g to 2g/day in IV, IM or SC~* Cefotaxim : 1g to 2g/day in IV~* Pristinamycin : 1g thrice a day"
48463998|NCT01710358|DRUG|Adalimumab Placebo|Adalimumab placebo administered SC.
48463999|NCT01710358|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally.
47936106|NCT03501771|OTHER|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
47936107|NCT00376714|DRUG|GSK233705|
47936108|NCT04084678|DRUG|Ralinepag|Oral ralinepag
47936109|NCT04084678|DRUG|Placebo|Matching oral tablets
47936110|NCT00116792|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
48464000|NCT00002936|DRUG|altretamine|
48464001|NCT00002936|DRUG|etoposide|
48464002|NCT00466531|BIOLOGICAL|therapeutic autologous lymphocytes|
48464003|NCT00466531|DRUG|cyclophosphamide|
48464004|NCT00709137|DRUG|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
48464005|NCT00709137|DRUG|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
48464006|NCT04080999|DEVICE|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
48464007|NCT04080999|DEVICE|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
48464008|NCT05648539|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
48464009|NCT00484991|DRUG|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
48464010|NCT02321839|DRUG|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
48464011|NCT00869713|BIOLOGICAL|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 \& 14, \& once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer \<1:40. Initial non-responders: Individual who has a PRNT80 titer \<1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 \<1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of \<1:40.
48464012|NCT02583191|DRUG|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
48464013|NCT02583191|DRUG|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily"
48464014|NCT03993080|DEVICE|Virtual reality relaxation|1-3.5 minute 360° videos
48624123|NCT06216366|DRUG|Sodium Chloride 0.9% Inj pre-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure
47936111|NCT02746003|OTHER|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
47936112|NCT05828771|PROCEDURE|THIN FREE FLAP|Flap design will be performed on the basis of the preoperative perforator mapping. Freestyle flap elevation will be performed under loupe magnification from one of the incisions until the perforators are reached
47936113|NCT04173793|DRUG|AK102|Administered by subcutaneous injection
48464015|NCT01092169|OTHER|No intervention|
48464016|NCT03447691|DRUG|Des (volatile anesthetic-desflurane)|Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
48464017|NCT03447691|DRUG|TIVA (Total intravenous anesthesia with propofol and remifentanil)|TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
48464018|NCT06381622|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
48464019|NCT06381622|DRUG|Lidocaine epinephrine|20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)
48464020|NCT06381622|DRUG|Ropivacaine 0.75% Injectable Solution|20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
48464021|NCT03254732|DRUG|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
47936114|NCT04173793|DRUG|Placebo|Administered by subcutaneous injection
47936115|NCT04173793|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
47936116|NCT05369390|DRUG|NNC0487-0111 A|Participants will receive NNC0487-0111 A tablet once daily.
48099349|NCT05911256|DEVICE|Continuous Glucose Monitor (CGM)|Patients will receive the Continuous Glucose Monitoring (CGM) system. The instruction on use of device is the intervention being tested, not the effectiveness of the device itself. Participants will receive instruction and training on how to use the device and will wear the device for 14 days.
48099350|NCT05911256|BEHAVIORAL|Community Health Worker (CHW)|Patients are connected to a community health worker(CHW). CHWs conduct home visits and facilitate 3-way Telehealth visits (Patients, pharmacists, and CHWs) via an iPad with cellular plan. Additional CHW activities include social determinants of health screening, health behavior education, problem solving, goal setting, and medication adherence support.
48464022|NCT03254732|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
48464023|NCT01869556|DRUG|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
48464024|NCT01869556|DRUG|Ergot|Ergot 0.25mg IV
48464025|NCT01869556|DRUG|Carboprost|Carboprost 0.25mg IM
48464026|NCT04502706|DRUG|GS-0189|GS-0189 will be administered intravenously.
48624124|NCT06216366|DRUG|Sodium Chloride 0.9% Inj post-exposure|Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure
48624125|NCT06216366|DRUG|Recombinant human plasma gelsolin pre-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure
47936117|NCT05369390|DRUG|NNC0487-0111 B|Participants will receive NNC0487-0111 B tablet once daily.
47936118|NCT05369390|OTHER|Placebo B (NNC0487-0111 B)|Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
48624126|NCT06216366|DRUG|Recombinant human plasma gelsolin post-exposure|rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure
48624127|NCT06216366|OTHER|Hyperbaric chamber|High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water
48624128|NCT05711147|PROCEDURE|Abutment removal|4 times healing abutment removal during prosthesis making (impressions, metal try-in, ceramic try-in, prosthesis loading)
47936119|NCT05369390|OTHER|Placebo A (NNC0487-0111 A)|Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
48624129|NCT05711147|PROCEDURE|Placement of definitive abutment|Placement of the final prosthetic abutment at the moment of implantation
48624130|NCT01947933|BIOLOGICAL|Mirikizumab- IV|Administered IV
48624131|NCT01947933|BIOLOGICAL|Mirikizumab - SC|Administered SC
48624132|NCT01947933|BIOLOGICAL|Placebo - IV|Administered IV
48624133|NCT03355456|PROCEDURE|Radiofrequency ablation|Ablation procedure to eliminate atrial fibrillation
48624134|NCT00407667|DEVICE|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
48624135|NCT01670006|DEVICE|Cochlear Nucleus Cochlear Implant System|
48624136|NCT00910390|OTHER|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
48624137|NCT00910390|OTHER|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
48624138|NCT00910390|OTHER|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
48624139|NCT01166334|BEHAVIORAL|WebQuit study group|Description withheld to protect integrity of study
47936120|NCT02446743|BIOLOGICAL|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
47936121|NCT04549974|OTHER|Heat exposure|Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.
47936122|NCT02835352|OTHER|Essential oils massages|
47936123|NCT02835352|OTHER|Oil massages|
47936124|NCT01307605|BIOLOGICAL|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
47936125|NCT01307605|DRUG|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
47936126|NCT04212143|OTHER|there is no intervention|There is no intervention in this study. It is observational only.
47936127|NCT01593462|PROCEDURE|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
48099351|NCT03744117|OTHER|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
48099352|NCT04278989|DRUG|Anti-tumor B|1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
48464027|NCT04502706|DRUG|Rituximab|Rituximab will be administered intravenously.
48464028|NCT01228552|DRUG|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
48464029|NCT01228552|OTHER|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
48464030|NCT04285073|DEVICE|Paclitaxel-eluting graft|Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
48464031|NCT01021501|DRUG|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
48464032|NCT04837664|DRUG|Curcumin|Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
48464033|NCT04837664|DRUG|Rose Bengal|Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
48464034|NCT04837664|DRUG|Nystatin|Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
48464035|NCT02810223|BIOLOGICAL|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
48464036|NCT00113919|DRUG|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin\* 10 mg/m, Continuous infusion 1-4 Adriamycin\*\* 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
48464037|NCT01124786|DRUG|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
48464038|NCT01124786|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
48464039|NCT02179151|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
48464040|NCT02179151|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
48464041|NCT01426334|DRUG|dasatinib|Given PO
48464042|NCT01426334|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
48464043|NCT01426334|OTHER|pharmacological study|Correlative studies
48464044|NCT01426334|DRUG|cyclosporine|Given PO
48464045|NCT02441985|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
48464046|NCT02441985|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
48464047|NCT02441985|OTHER|Fahn-Tolosa-Marin Tremor Rating Scale (TRS)|All participants will receive a clinical assessment of tremor severity by using the TRS test.
48464048|NCT02441985|OTHER|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
48464049|NCT02441985|OTHER|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
48464050|NCT02441985|OTHER|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
48464051|NCT02441985|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
48464052|NCT05748938|BIOLOGICAL|RD14-01|ROR1 Targeted CAR-T cells
48464053|NCT03910361|DRUG|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
48464054|NCT03910361|DRUG|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
48464055|NCT02360007|DRUG|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad"
48464056|NCT01541215|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
48464057|NCT01541215|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
48464058|NCT01541215|DRUG|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
48464059|NCT01712451|DRUG|salmeterol xinafoate, fluticasone propionate|LIPO-102
48464060|NCT01712451|DRUG|Placebo|Placebo
48464061|NCT01712451|DRUG|salmeterol xinafoate|Salmeterol
48464062|NCT04244643|OTHER|data collection|"Data collected from patient records~* Demographic data: date of birth, sex, city of birth~* Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~* Refraction~* Dry eye disease: Ocular Surface Disease Index (OSDI) score~* LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height"
48464063|NCT03174938|DIAGNOSTIC_TEST|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
48464064|NCT03174938|DIAGNOSTIC_TEST|[18F]-RO6958948|PET imaging of Tau aggregates
48464065|NCT03174938|DIAGNOSTIC_TEST|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
48464066|NCT03174938|DIAGNOSTIC_TEST|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
48464067|NCT00608634|DRUG|perillyl alcohol|Applied as topical cream
48464068|NCT00608634|OTHER|placebo|Applied as topical cream
48464069|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
48464070|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
48464071|NCT02937207|DRUG|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
48464072|NCT02937207|DRUG|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
48464073|NCT02937207|DRUG|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
48464074|NCT02937207|DRUG|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
48464075|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
48464076|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
48464077|NCT02937207|DRUG|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
48464078|NCT02937207|DRUG|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
48464079|NCT02937207|DRUG|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
48464080|NCT02937207|DRUG|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
48624140|NCT01166334|BEHAVIORAL|WebQuit control group|Identity and description withheld to protect integrity of study
48624141|NCT00534651|DRUG|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
48464081|NCT00153439|BEHAVIORAL|Motivational enhancements, parent training|
48464082|NCT04531527|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
48464083|NCT02377349|BIOLOGICAL|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
48464084|NCT02377349|DRUG|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
48464085|NCT01536249|DRUG|Dexpramipexole|Single Oral Dose
48464086|NCT01536249|DRUG|Cimetidine plus Dexpramipexole|Multiple Oral Doses
48464087|NCT04965831|DRUG|Furmonertinib|Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
48464088|NCT00504062|DRUG|budesonide|
48464089|NCT00504062|DRUG|fluticasone|
48464090|NCT05638035|DIAGNOSTIC_TEST|Ultrasonografi, Sarcopenia measurement, Zebris|"The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2."
48464091|NCT00963495|DRUG|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
48464092|NCT04428723|OTHER|Entry of demographic and medical history data into a deidentified database|Entry into repository for analysis.
48464093|NCT04428723|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
48464094|NCT04428723|DIAGNOSTIC_TEST|Stool sample for microbiome analysis|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
48464095|NCT04428723|DIAGNOSTIC_TEST|Mixed meal tolerance test|For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
48464096|NCT04428723|DIAGNOSTIC_TEST|Continuous glucose monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
48624142|NCT02341469|OTHER|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~* REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~* The training of nurses on IMCI and REC.~* A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~* A supervision system conducted implemented by district managers to provide support and guidance to health centres.~* A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
48624143|NCT02932943|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
48624144|NCT02932943|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
48624145|NCT01500096|DRUG|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
48624146|NCT01500096|DIETARY_SUPPLEMENT|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
48624147|NCT05644418|DEVICE|Flow Controlled Ventilation (FCV)|FCV is started with the same settings as PCV (PEEP, Ppeak, FiO2) and after 30 minutes FCV is optimized concerning the driving pressure and PEEP using the dynamic compliance. After a total of 60 minutes the flow is adjusted based on the arterial blood gas.
48624148|NCT05937282|DRUG|Dexmedetomidine|Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
48624149|NCT05937282|DRUG|Propofol|Patients will receive propofol infusion in the dose of 3 mg/kg/hr. 25 ml propofol 1% (10 mg /ml) in 50 ml syringe pump.
48099353|NCT05048355|DEVICE|Power Knee Mainstream Dynamic|Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
47936128|NCT01593462|PROCEDURE|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
48099354|NCT05048355|DEVICE|Passive microprocessor controlled knee|Any passive microprocessor controlled prosthetic knee on the market
48464097|NCT04428723|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
47936129|NCT01593462|BEHAVIORAL|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
48099355|NCT05057494|DRUG|Acalabrutinib|Dose formulation: Capsule or Tablet
48099356|NCT05057494|DRUG|Venetoclax|Dose formulation: Tablet
48099357|NCT05057494|DRUG|Obinutuzumab|Dose formulation: Injection
48099358|NCT03185663|OTHER|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
48099359|NCT03185663|OTHER|a pillow between the legs|setting up a pillow between the legs before the care
48464098|NCT04162197|DEVICE|GEO|Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
48464099|NCT04162197|DEVICE|GEO and HUNOVA|Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
48099360|NCT02279342|DRUG|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
47936130|NCT05368454|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.
48464100|NCT00307541|BIOLOGICAL|Pneumococcal (vaccine)|
48464101|NCT01688882|DRUG|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
48464102|NCT01688882|DRUG|Placebo|Placebo will be used to control for normal variability in disease severity.
48464103|NCT02656316|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
48464104|NCT02656316|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
48464105|NCT02465684|PROCEDURE|unicondylar knee arthroplasty|
48464106|NCT01151449|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
48464107|NCT01151449|OTHER|laboratory biomarker analysis|Correlative studies
48464108|NCT02331628|DEVICE|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~* Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\\52 from baseline until and including week 14\\52, one dose every two weeks ± 3 days), administered by the principal investigator.~* Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~* The energy flux density (EFD) will be 'high level'~* All participants will be supplied with headphones to reduce the noise level emitted by the machine."
48464109|NCT03074799|OTHER|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
48464110|NCT03074799|OTHER|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
47936131|NCT05368454|BEHAVIORAL|Standard of Care|All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
47936132|NCT01227564|BIOLOGICAL|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
47936133|NCT01227564|BIOLOGICAL|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
47936134|NCT01227564|OTHER|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
47936135|NCT00988767|BIOLOGICAL|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
47936136|NCT05962346|DEVICE|BALT GOLDBALL 2 detachable latex ballon|Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
47936137|NCT05962346|DEVICE|BALTACCIBDPE100 Microcatheter|Used to deliver the detachable balloon
47936138|NCT05962346|DEVICE|Storz fetoscopic operating sheath and miniature telescope/fetoscope|Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
47936139|NCT03830177|DRUG|Natural Treatment|The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.
47936140|NCT01629706|DEVICE|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
47936141|NCT01629706|DEVICE|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
47936142|NCT01629706|DEVICE|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
47936143|NCT01629706|DEVICE|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
48099361|NCT02329041|DEVICE|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
48099362|NCT02329041|DEVICE|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
48099363|NCT00691951|DRUG|budesonide and budesonide/formoterol|
48464111|NCT04881188|DIAGNOSTIC_TEST|Survey|Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
48464112|NCT00147693|BEHAVIORAL|Diagnosis of caregivers' problems|
48464113|NCT00147693|BEHAVIORAL|Professional service: treatment of problems by counseling or practical support|
48464114|NCT00000124|PROCEDURE|Brachytherapy|
48464115|NCT00000124|PROCEDURE|Eye Removal|
47936144|NCT01629706|DEVICE|Habitual lens care|Lens care per habitual use
47936145|NCT05877508|DRUG|AER002|Intravenous infusion of AER002
47936146|NCT05877508|OTHER|Placebo|Placebo infusion
47936147|NCT01994499|DEVICE|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
47936148|NCT01994499|DRUG|Medical drainage|Medical pleural drainage
48099364|NCT05872321|OTHER|Complication|whether or not complications occur
48099365|NCT06165731|BEHAVIORAL|Diaphragmatic Breathing Exercises|Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
48464116|NCT02190786|DRUG|KUX-1151|
48624150|NCT05937282|DRUG|Lidocain|Patients will receive lidocaine infusion in the dose of 2 mg /kg/hr.25 ml lidocaine 1% (10 mg/ml) in 50 ml syringe pump.
48624151|NCT05937282|DRUG|normal saline|Patients will receive infusion of 25 ml normal saline in 50ml syringe pump (control group).
48624152|NCT04565223|BEHAVIORAL|Cognitive behavioral therapy for insomnia|is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed
48624153|NCT01736059|DRUG|CD34+ bone marrow stem cells intravitreal|
48624154|NCT04076683|DEVICE|Algodrep|Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.
48624155|NCT06448286|PROCEDURE|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|Undergo CEST MRI
48624156|NCT06448286|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
48624157|NCT06448286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48624158|NCT06448286|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
48624159|NCT06448286|PROCEDURE|Surgical Procedure|Undergo surgical resection
48624160|NCT06448286|DRUG|Temozolomide|Given PO
48624161|NCT03155204|DRUG|tiotropium pMDI|inhalation
48624162|NCT04094805|DRUG|Rocaltrol|Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
48464117|NCT05223608|OTHER|ImmuCCo Cohort|Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
48464118|NCT03023137|BEHAVIORAL|Walking & dietary modification|"1. Daily walking at a moderate pace (4 km/h) \> 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding \>12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~2. At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
48624163|NCT04094805|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
48624164|NCT05383703|DRUG|Treatment of MNC-168 enteric-coated capsules as a single oral drug|Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
48624165|NCT00174668|DRUG|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
48624166|NCT00174668|DRUG|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
48624167|NCT00174668|DRUG|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
48624168|NCT01738178|DRUG|Caffeine|
48624169|NCT01738178|DRUG|Placebo|
48624170|NCT00515190|DRUG|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
48624171|NCT04051801|DRUG|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
48624172|NCT04051801|DRUG|Dose Escalation of Placebo|dose levels of the cohorts will be increased step wise
47936149|NCT01166243|BIOLOGICAL|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
47936150|NCT01166243|PROCEDURE|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
47936151|NCT00521911|BEHAVIORAL|Cognitive Behavioural Therapy|
47936152|NCT03636711|OTHER|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
47936153|NCT04789018|OTHER|Educational Intervention|Attend virtual genetics board
47936154|NCT04789018|OTHER|Survey Administration|Complete survey
47936155|NCT04789018|OTHER|Interview|Complete interview
47936156|NCT04581447|DRUG|Metformin|Metformin will start at dose of 850 mg once daily and, at one month increased to 850 mg twice daily
47936157|NCT04581447|OTHER|Standard Care|Standard Care
48624173|NCT01149967|DRUG|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
48624174|NCT05226377|DIAGNOSTIC_TEST|Atherogenic Index of Plasma|- The atherogenic index of plasma (AIP) is defined as the base 10 logarithms of the ratio of plasma triglyceride (TG) to high-density lipoprotein cholesterol (HDL-c) (17). AIP was employed as a predictor of cardiac risk (CR) with values of -0.3 to 0.1 are associated with low, values of 0.1-0.24 are associated with the medium, and values above 0.24 with high CR
48624175|NCT02851524|OTHER|posturography|
48624176|NCT02474368|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|
48624177|NCT02474368|DRUG|Cisplatin|
48624178|NCT02474368|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
48624179|NCT03208452|DRUG|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
48624180|NCT03208452|DRUG|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
48624181|NCT04575324|BEHAVIORAL|Telemedicine Linkage Intervention|Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
48624182|NCT02904343|DEVICE|domestic hemodialysis machine|WEGO, DBB-27C
48624183|NCT02904343|DEVICE|imported hemodialysis machine|Fresenius, 4008s
47936158|NCT04581447|DIETARY_SUPPLEMENT|Standardized meal|Measurements of metformin-induced enterohormones secretion will be done after standardized meal test in a subgroup of patients (ancillary study)
47936159|NCT01108978|DRUG|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
47936160|NCT01108978|DRUG|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
48464119|NCT05636891|BIOLOGICAL|Stimus|"* NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
48464120|NCT00688844|DRUG|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
48464121|NCT04220606|DRUG|Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)|
48464122|NCT00393705|DRUG|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
48464123|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
48464124|NCT00393705|DRUG|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
48464125|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
48464126|NCT00599105|PROCEDURE|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
48464127|NCT04847401|DIAGNOSTIC_TEST|H. pylori stool antigen|using H. pylori antigen kits in stool
48464128|NCT05762653|DIAGNOSTIC_TEST|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
48464129|NCT00772148|DRUG|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
48464130|NCT00772148|DRUG|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
48464131|NCT00403806|DRUG|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
48464132|NCT00403806|DRUG|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
48464133|NCT00403806|DRUG|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
48464134|NCT00403806|DRUG|Saline|Intravenous saline
48464135|NCT01158313|DIETARY_SUPPLEMENT|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
48464136|NCT03681587|OTHER|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
48464137|NCT03681587|OTHER|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
48464138|NCT00326326|DRUG|CP-778,875|
48464139|NCT03062787|DEVICE|Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)|Intra-articular injection
48464140|NCT03062787|DEVICE|Monovisc® (Sodium hyaluronate)|Intra-articular injection
48464141|NCT04267692|OTHER|HaRTC|HaRT-C participants will attend 8, virtual, adapted, low-barrier, weekly, closed-group Talking Circles-- named Harm Reduction Treatment Circles or HaRTC -- lasting approximately 2 hours each. During the HaRTC, the circle keeper will present the day's harm reduction topic, smudge the space, and allow participants to open themselves up to the circle. Topics presented by the Circle Keeper focus on harm-reduction and improving overall quality of health. Abstinence from alcohol use is not a requirement. We will not limit participants' access to treatment or services in either arm.
48624184|NCT03038139|OTHER|Cervical exercises|Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
48624185|NCT03038139|OTHER|Lumosacral exercises|Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
48099366|NCT06165731|BEHAVIORAL|Bladder Hygiene Education|Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
48099367|NCT03419780|BIOLOGICAL|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
48099368|NCT03921489|PROCEDURE|Subchondroplasty|Calcium phosphate mineral compound injected into the bone marrow lesions
48099369|NCT00370448|BEHAVIORAL|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
48464142|NCT01169038|DRUG|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
48464143|NCT01866644|DRUG|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
48464144|NCT01866644|DRUG|Saline|Bath saline transplanted liver
48464145|NCT05503992|OTHER|Intervention package|The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
48464146|NCT01812603|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
48464147|NCT00162929|BIOLOGICAL|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
48464148|NCT01567319|BIOLOGICAL|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
48464149|NCT01567319|BIOLOGICAL|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
48464150|NCT01567319|BIOLOGICAL|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
48464151|NCT04484740|DRUG|Gepotidacin|Single oral dose of 1500 mg gepotidacin
48464152|NCT03540160|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
48624186|NCT04137536|DRUG|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~* First 3 participants, twice weekly infusions of 10\^10 EGFR BATs infusions~* If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10\^10.~* If \>/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10\^9 per infusion~* If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10\^9 or 10\^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
48624187|NCT01281072|OTHER|vaccine|
48624188|NCT04023253|DRUG|Mirabegron|Mirabegron 25 mg
48624189|NCT04023253|DRUG|Solifenacin|Solifenacin 5 mg
47936161|NCT00618839|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
47936162|NCT00618839|PROCEDURE|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
47936163|NCT06256627|DRUG|recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine|"Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count."
47936164|NCT01724320|DRUG|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
47936165|NCT01565499|DRUG|Nab-paclitaxel|
48099370|NCT01311713|DRUG|CEP-9722|CEP-9722 will be administered per dose and schedule specified in the arm description.
48099371|NCT05476939|DRUG|Everolimus|Tablets of 2.5 mg or 10 mg. The prescribed dose is 5 mg/m²/day, orally, once daily. Dose will be capped at 10 mg once daily.
48099372|NCT05476939|DRUG|ONC201|Capsules of 125mg. The prescribed dose is 375mg/m², once daily at Day 1 and Day 2 of each week. Dose will be capped at 625 mg per dose.
48624190|NCT01857518|OTHER|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"* Visit V1: Diagnostic and clinical assessments~* Visit V2: psycho-behavioral assessment and neuroimaging~* Visit V3: Diagnostic and clinical assessments~* Visit V4: psycho-behavioral assessment and neuroimaging"
48624191|NCT00159809|DRUG|Viagra (Sildenafil citrate)|
48099373|NCT05476939|RADIATION|Radiotherapy|"All patients will be treated with 30 conventional single daily fractions of 1.8 Gy to a total of 54 Gy over a planned period of 6 weeks. Dose may be increased up to 60 Gy for adult patients with supratentorial ND-DMG. The clinical target volume will include all the areas of abnormality on T2/FLAIR sequences with a 1-cm margin.~Radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery. The study medication will be started at Day 1 (+3 days max) of radiotherapy. Reirradiation is permitted only at disease progression according to local practice.~In case of metastatic disease or intramedullary tumors, patients can be included in the study. In this situation, radiotherapy will have to start within a maximum of 4 weeks for DIPG, up to 6 weeks for other DMG H3K28-altered (ND-DMG), after the biopsy or last surgery while targeted treatment will start at the end of the irradiation."
48099374|NCT03031756|DEVICE|glycine powder air-polishing (Air-Flows)Perio Powder|
48624192|NCT05818033|DEVICE|CARE1.02|Participants in the intervention group will wear CARE1.02 and receive the follow-up checks.
48624193|NCT05818033|DEVICE|Single-vision spectacle lens|Participants in the control group will wear single-vision spectacle lens and receive the follow-up checks.
48099375|NCT03031756|DEVICE|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
48099376|NCT05993403|OTHER|Intercultural Sensitivity Education Program|The training program consists of three sessions. In the Intercultural Sensitivity training for nurses, it was aimed to develop the level of intercultural sensitivity, and it was aimed to provide proficiency in providing services to raise awareness and knowledge about intercultural sensitivity.
48099377|NCT06316674|BEHAVIORAL|sixth finger illusion|Participants will undertake the sixth finger illusion that is a body illusion which elicits the presence of an extra numerary finger due to visuo-tactile stimulation.
48624194|NCT03137368|DRUG|Exemestane Tablets|drug therapy
48624195|NCT03137368|OTHER|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
48624196|NCT03137368|GENETIC|CYP2D6*10 gene test|CYP2D6\*10 gene test
48624197|NCT03137368|DRUG|Tamoxifen|drug therapy
48624198|NCT01221909|DRUG|Tranexamic acid|Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
48624199|NCT01221909|DRUG|saline solution|5cc saline solution
48624200|NCT01055912|DRUG|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
48624201|NCT01055912|DRUG|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
48624202|NCT04167462|DRUG|BMS-986165|Specified dose on Specified Days
48624203|NCT04167462|OTHER|Placebo|Specified dose on Specified days
47936166|NCT04652180|PROCEDURE|Esophagectomy|In this monocentre randomized controlled trial, we compare robot-assisted thoracic approach with conventional open transthoracic Ivor Lewis esophagectomy.
47936167|NCT02155803|DRUG|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
47936168|NCT00277641|DRUG|Lamotrigine|25 mg or 100 mg
47936169|NCT00277641|DRUG|placebo|identical tablets to study drug
47936170|NCT02376283|DRUG|Prasugrel|
47936171|NCT02376283|DRUG|Clopidogrel|
47936172|NCT02376283|DRUG|ticagrelor|
47936173|NCT05235503|DRUG|Medicinal cannabis in combination with oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with oxycodon
47936174|NCT05235503|DRUG|Medicinal cannabis in combination with placebo oxycodon|The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
47936175|NCT01233687|DRUG|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
47936176|NCT00511225|DIETARY_SUPPLEMENT|cholecalciferol|10,000 IU weekly
47936177|NCT00511225|DIETARY_SUPPLEMENT|placebo|placebo capsule
47936178|NCT03083860|DEVICE|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
47936179|NCT04676360|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
47936180|NCT03706222|DRUG|elbasvir/grazoprevir|Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
47936181|NCT02139800|PROCEDURE|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
47936182|NCT02139800|PROCEDURE|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
47936183|NCT01254955|BIOLOGICAL|H1N1 vaccine Pandemrix|
47936184|NCT03312751|DRUG|Emapalumab|Emapalumab will be administered by intravenous infusion, twice weekly.
47936185|NCT06281301|OTHER|education tool|Participants will have 15 minutes to review the single sided card and then the survey will be administered. Participants will then be surveyed again within 1-2 weeks after initial completion to assess how well information was retained.
47936186|NCT06281301|OTHER|no additional information|Survey will be administered without reviewing the single sided card
47936187|NCT03475875|DEVICE|senofilcon A TEST Lens|senofilcon A with new UV blocker investigational process
47936188|NCT03475875|DEVICE|senofilcon A CONTROL Lens|senofilcon A with new UV blocker standard process
48464153|NCT05878132|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
48464154|NCT05878132|OTHER|Conventional therapy|The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
48464155|NCT02929927|PROCEDURE|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
48464156|NCT02929927|DEVICE|aPDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
48464157|NCT02929927|DRUG|1% iodine tincture|use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
48464158|NCT02929927|DRUG|2.5%NaClO|use 2.5% NaClO as irrigants
48464159|NCT02929927|PROCEDURE|root canal preparation|mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
48464160|NCT02929927|PROCEDURE|root canal obturation|filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
48464161|NCT05705791|DEVICE|QuiremSpheres|166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
48464162|NCT03235141|DRUG|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
48464163|NCT03235141|DRUG|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
48464164|NCT03748251|OTHER|the patients ate a pizza that fermented for 8 hours|Patients eat pizza prepared with controlled ingredients but fermented 8 hours
48464165|NCT03748251|OTHER|the patients ate a pizza that fermented for 24 hours|Patients eat pizza prepared with controlled ingredients but fermented 24 hours
48464166|NCT03886363|BEHAVIORAL|MBSR|Described previously
48464167|NCT02134639|PROCEDURE|68Ga-DOTATOC PET-CT Imaging|
48099378|NCT05550922|BEHAVIORAL|Healthcare Transition-Based Education|The goal is for asthmatic adolescents to take responsibility for their own disease, be prepared for transition to adult pulmonology services, increase their self-efficacy, and gain management skills as a result of health care transition education.
47936189|NCT01192243|DRUG|Gefitinib|250mg qd po d3-16
48464168|NCT00139815|DRUG|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
48464169|NCT00139815|DRUG|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
48464170|NCT03025451|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
48464171|NCT01780350|DEVICE|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
48624204|NCT06310629|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula
47936190|NCT01192243|DRUG|Pemetrexed|500mg/m2 venous infusion,D1,q3w
47936191|NCT01192243|DRUG|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
47936192|NCT04369170|DEVICE|prosthesis connected directly to the implants|dental prostheses connected directly to the dental implants
47936193|NCT04369170|DEVICE|Intermediate abutment|dental prostheses connected with an intermediate abutment to the implant
47936194|NCT03540498|DIETARY_SUPPLEMENT|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
48099388|NCT02742142|OTHER|water as placebo|topical application of water as a placebo in the control arm
48099389|NCT02742142|DRUG|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
48464172|NCT04846686|BIOLOGICAL|Placenta pathological examination|a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
48464173|NCT01118767|OTHER|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
48464174|NCT03232450|DRUG|Aspirin|Subjects will receive 81 mg enteric coated aspirin
47936195|NCT03540498|DIETARY_SUPPLEMENT|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
47936196|NCT02830269|DEVICE|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
47936197|NCT06484205|OTHER|WHO QualityRights e-training|WHO QualityRights training provides the necessary skills to support people with psychosocial disabilities in advocating for their rights. The QualityRights online course includes six main modules: 1) Human Rights; 2) Human rights, mental health and disability; 3) Legal capacity and the right to decide; 4) Stop coercion, violence and mistreatment; 5) Quality services and inclusion in the community; 6) Mental health, well-being and recovery and it will take approximately 8 hours for completion. QualityRights course modules can be completed at each participant's pace and needs. The training is considered concluded once the quizzes provided at the end of each of the six modules have been successfully completed and upon completion of the course it will be possible to download your official WHO certificate from the QR platform.
47936198|NCT06484205|OTHER|Emotional intelligence e-training|This course offers caregivers resources and knowledge so that they are able to manage their emotions and gain quality in the care they provide to others and in their own lives. The course duration is similar to that of the QualityRights online course and is intended for caregivers of people with disabilities and others interested
47936199|NCT03249389|BIOLOGICAL|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
47936200|NCT00996723|DRUG|vandetanib and dasatinib|Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
48464175|NCT03232450|DEVICE|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
48099390|NCT00106431|DRUG|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
48099391|NCT04682756|DIAGNOSTIC_TEST|The model of machine learning|Early diagnosis of NTEMI patients by machine learning model
48099392|NCT03273530|OTHER|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
48099393|NCT03603418|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.
48464176|NCT03232450|DEVICE|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
48464177|NCT00850551|OTHER|Early Intervention|Twice a week home spirometry and symptom assessment
48464178|NCT01160640|DRUG|Ceftriaxone|ceftrixone 250mg IM single dose
48464179|NCT01160640|DRUG|Doxycycline|Doxycycline 100 mg PO bid x 14 days
48464180|NCT01160640|DRUG|Metronidazole|metronidazole 500 mg PO bid x 14 days
48464181|NCT01160640|DRUG|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
48464182|NCT04022941|DRUG|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
48464183|NCT04022941|OTHER|Powdered table sugar as palcebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
48464184|NCT05778890|OTHER|Intervention Group: Physiotherapy program + home exercises program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.
48099394|NCT03603418|OTHER|Distilled water|Distilled water
48464185|NCT05778890|OTHER|Control Group : Physiotherapy program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
48464186|NCT00841620|PROCEDURE|Haemorrhoidectomy a.m. Milligan|Surgery
48464187|NCT00841620|PROCEDURE|Stapled anopexy|Surgery
48464188|NCT03171064|BEHAVIORAL|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
48099395|NCT01813903|BEHAVIORAL|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
48099396|NCT01813903|BEHAVIORAL|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
48624205|NCT06310629|DEVICE|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"|"Intrinseque Health Non-Rebreathing Mask (IHNRM)"
48464189|NCT02870686|PROCEDURE|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
48464190|NCT02870686|PROCEDURE|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
48464191|NCT01589835|BEHAVIORAL|Lifestyle changes|Green prescription with support from facilitator
47936201|NCT00708071|BIOLOGICAL|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
47936202|NCT03986632|BEHAVIORAL|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
47936203|NCT00821327|DRUG|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
47936204|NCT03869827|OTHER|necrotizing enterocolitis|Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
47936205|NCT05891964|DRUG|Secukinumab Injection|Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
47936206|NCT06020638|DEVICE|Experimental group|THE EFFECTS OF NASOPHARYNGEAL SUCTION POSITIVE PRESSURE
47936207|NCT06020638|DEVICE|control group|THE EFFECTS OF NASOPHARYNGEAL SUCTION NEGATIVE PRESSURE
47936208|NCT03784924|DIAGNOSTIC_TEST|MRI prostate|MRI and laboratory biomarkers
48464192|NCT01887795|DRUG|Erlotinib|
48464193|NCT01887795|DRUG|WBRT|
48464194|NCT05755854|BIOLOGICAL|allogeneic γ9δ2 T Cells|dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)
48464195|NCT05755854|DRUG|Fludarabine|Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
48464196|NCT05755854|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
47936209|NCT00084461|DRUG|romidepsin|Given IV
47936210|NCT00084461|OTHER|laboratory biomarker analysis|Correlative studies
48099397|NCT03532178|DRUG|"Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline"|"The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period."
48099398|NCT03532178|DRUG|"Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;"|"The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period."
48464197|NCT05755854|DRUG|Zoredronic acid|Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
48464198|NCT05456438|OTHER|İntervention 1|Group 1 applied coconut oil to the nipple
48624206|NCT06026306|BEHAVIORAL|Problem Management Plus (PM+)|PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session
48464199|NCT05456438|OTHER|İntervention 2|Group 2 applied tea tree oil to the nipple
48464200|NCT00784095|OTHER|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
48464201|NCT00784095|OTHER|Attention Control|Subjects will listen to a non-guided relaxation CD.
48464202|NCT00141258|DRUG|pregabalin|
48464203|NCT04117880|DRUG|Ataluren|Oral
48464204|NCT00769951|OTHER|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
48464205|NCT00769951|OTHER|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
48464206|NCT00769951|PROCEDURE|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
48464207|NCT00769951|PROCEDURE|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
48464208|NCT00769951|PROCEDURE|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
48464209|NCT05590390|DIAGNOSTIC_TEST|DXA|bone densitometry at lumbar and femoral site+ morphometry (DXA),
48464210|NCT05590390|DIAGNOSTIC_TEST|serum sample|serum samples for bone biomarkers ( eg. P1NP, CTX, Dkk-1, etc)
48464211|NCT05590390|DIAGNOSTIC_TEST|PROs|questionnaires to investigate patients reported outcome on quality of life
48464212|NCT05696548|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
48464213|NCT05696548|DRUG|Nivolumab|Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
48464214|NCT04161950|OTHER|Assessment of the safety and validity of echoendoscope|"1. Ultrasonic and endoscopic image quality assessment~2. Device controllability assessment~3. System safety assessment~4. System stability assessment"
48464215|NCT01044823|OTHER|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
48464216|NCT05491850|OTHER|Moderate Physical Activity for Peripheral Diabetic Neuropathy|Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
48464217|NCT05139394|PROCEDURE|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
48464218|NCT00007787|BIOLOGICAL|Cyclosporine|
47936211|NCT03963375|DRUG|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
47936212|NCT04041791|DRUG|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
47936213|NCT04041791|DRUG|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
47936214|NCT04041791|DRUG|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
48464219|NCT00007787|BIOLOGICAL|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
48464220|NCT00007787|DRUG|Tacrolimus|
48464221|NCT02842723|RADIATION|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
48464222|NCT04841967|BEHAVIORAL|TELL Tool Intervention|A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.
48464223|NCT04841967|BEHAVIORAL|eBook Attention Control|A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
48464224|NCT01427036|PROCEDURE|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
48464225|NCT01427036|PROCEDURE|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
47936215|NCT04041791|DRUG|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
47936216|NCT04041791|OTHER|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
47936217|NCT04041791|OTHER|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
47936218|NCT04041791|DRUG|Ampicillin|Ampicillin is a penicillin-type antibiotic.
48464226|NCT04149301|DIAGNOSTIC_TEST|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
48464227|NCT04149301|DIAGNOSTIC_TEST|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
48624207|NCT01597232|OTHER|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
48464228|NCT04698551|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
48464229|NCT00280930|DRUG|Letrozole|
48624208|NCT01597232|OTHER|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
48624209|NCT01597232|OTHER|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
48624210|NCT01764581|PROCEDURE|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
48624211|NCT03301714|BEHAVIORAL|Oral Health Education|Group-based oral health education vs Individual-based oral health education using motivational interviewing
48624212|NCT03205631|OTHER|Natural Frequency Patch|Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
48624213|NCT05594160|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of a University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers and physiotherapists.
48624214|NCT03795909|DRUG|Ruxolitinib|Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）
48624215|NCT03795909|DRUG|Dexamethasone|Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
48624216|NCT06310135|DEVICE|Filtered Eyewear|Filtered binocular viewing condition will be produced by eyeglasses frames with orange-tinted blue-blocking filter, eliminating all optical radiation for wavelengths shorter than 540 nm. For the filtered monocular condition, only the lens on the eyeglasses frame on the non-dominant eye will be tinted with the blue-blocking filter.
48624217|NCT06310135|DEVICE|Unfiltered Eyewear|For the unfiltered binocular, the subjects will wear transparent eyeglasses frames with no optical power. Unfiltered monocular vision will be produced by an opaque eyepatch occluding the non-dominant eye.
48624218|NCT06310135|OTHER|No Filters|Dim lights with no filters.
48624219|NCT00128427|DRUG|Colchicine (for 1 month)|
48464230|NCT00778453|OTHER|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
48464231|NCT00778453|OTHER|Hospital-based BIT|bilateral symmetric, repetitive arm training
48464232|NCT00778453|OTHER|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
48464233|NCT00778453|OTHER|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
48464234|NCT00778453|OTHER|Home-based BAT|bilateral symmetric, repetitive arm training
48464235|NCT00778453|OTHER|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
48464236|NCT03211351|DRUG|Liposic|one eye of the participant recieved Lipoic
48464237|NCT03211351|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
48464238|NCT01142908|BEHAVIORAL|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
48464239|NCT02196467|BIOLOGICAL|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
48464240|NCT02196467|PROCEDURE|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
48464241|NCT01833754|DRUG|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
48624220|NCT03353051|OTHER|Observational study|Observational study
48624221|NCT00661440|DRUG|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
48624222|NCT01498549|DRUG|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
48624223|NCT01498549|DRUG|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
48624224|NCT00031993|DRUG|erlotinib hydrochloride|Given PO
48624225|NCT00031993|OTHER|laboratory biomarker analysis|Correlative studies
48624226|NCT05217264|OTHER|Assesment|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
48624227|NCT03886623|PROCEDURE|4-day systematic oral hygiene|he intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
48624228|NCT03886623|OTHER|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
48624229|NCT02774083|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
48624230|NCT02774083|BEHAVIORAL|Adler Program|Social and emotional group program
48624231|NCT03135795|DRUG|Sufentanil|Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
48624232|NCT03135795|DRUG|dexmedetomidine|Patients received intravenous dexmedetomidine 1μg/Kg for induction.
48624233|NCT03135795|DRUG|propofol|Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
48624234|NCT03135795|DRUG|Rocuronium|Patients received intravenous rocuronium 0.6mg/Kg for induction.
48624235|NCT03135795|DRUG|sevoflurane|Patients received inhalation of sevoflurane (1-2%) for maintenance.
48624236|NCT03135795|DRUG|remifentanil|Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
48624237|NCT03135795|DRUG|Parecoxib|Parecoxib 40mg was given single intravenously before incision.
48624238|NCT02316613|DRUG|Rituximab|
48624239|NCT01003626|PROCEDURE|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
48624240|NCT01003626|DEVICE|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
47936219|NCT06335147|DRUG|Serplulimab, mFOLFOX6|Serplulimab，200mg，iv，q2w，d1； mFOLFOX6（Oxaliplatin: 85 mg/m2，LV ：400mg/m2，Fluorouracil： 400mg/m2 d1，2400 mg/m2 continuous intravenous drip for 46-48 hours；q2w）
48281696|NCT02725788|DEVICE|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
48281697|NCT02725788|DEVICE|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
48464242|NCT03922139|DRUG|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
48464243|NCT05440305|PROCEDURE|surgery type/exstirpation/debulking|Evaluation of benefit according to surgery
48464244|NCT04909970|OTHER|Self-hypnosis|Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
48464245|NCT04909970|OTHER|Control (Waiting list)|Usual practice during the first 16 weeks. At the end of study, the participant will practice Self-hypnosis training during 8 weeks and one daily self-hypnosis session during 8 weeks
48464246|NCT06476782|OTHER|Motor Relearning Program(MRP) and aerobic exercise|Participants of this group received training for a total of 8 weeks in the form of 3 sessions per week each session of 40 minutes, with a total of 24 sessions.
48464247|NCT06476782|OTHER|Motor Relearning Program(MRP)|the week 8 session was held in which patients were involved in 60-minute activities that involved practicing functional tasks without explicitly giving any type of relationship between those learned skills and the remedial tasks.
48464248|NCT00493727|DRUG|N-acetylcysteine(Mucomyst)|
48624241|NCT03881800|OTHER|titration- blood sample|Ceftazidime titration
47936220|NCT02484625|OTHER|Potato chips|Commercially available potato chips, 180 kcal
47936221|NCT02484625|OTHER|Greek yogurt|Commercially available Greek yogurt, 180 kcal
47936222|NCT02484625|OTHER|Cookies|Commercially available cookies, 180 kcal
47936223|NCT02484625|OTHER|Cheese|Commercially available cheese, 180 kcal
47936224|NCT02484625|OTHER|Milk|Commercially available milk, 180 kcal
47936225|NCT04309071|OTHER|Dietary intervention|Salivary insulin responses to a standardized mixed meal
47936226|NCT00264862|PROCEDURE|DynaCT|
48281698|NCT02256358|DRUG|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
48281699|NCT02256358|DRUG|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
47936227|NCT03778775|DIAGNOSTIC_TEST|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
48281700|NCT02031679|DRUG|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
48281701|NCT02031679|DRUG|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
48464249|NCT06227754|PROCEDURE|Angiography-guided PCI group|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
48464250|NCT06227754|PROCEDURE|Optical coherence tomography-guided PCI group|"\[Stent Optimization\]~1. Stent Expansion:~   Visually assess residual angiographic diameter stenosis \<10% AND~   ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area OR \>4.5 mm2~   ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM~2. Stent Apposition:~   No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall~3. Edge Dissection:~No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)"
48464251|NCT03343639|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
48464252|NCT03343639|DRUG|Matching Placebo Tablets|Placebo Tablets
48464253|NCT01476358|DIETARY_SUPPLEMENT|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
48464254|NCT00268164|DRUG|lactobacilus acidophilus & bifidobacterium animalis/lactis|
48464255|NCT00400634|DRUG|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10\^11 vg
48464256|NCT00400634|PROCEDURE|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
48464257|NCT03860025|OTHER|No intervention.|No intervention.
48464258|NCT03347019|OTHER|Accelerated rehabilitation|advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
48464259|NCT03347019|OTHER|Delayed rehabilitation|Patients were not allowed to start rehabilitation programme first three weeks after surgery.
48464260|NCT06334562|DRUG|SUGAMMADEX SODIUM 100 Mg in 1 mL|The dose of Sugammadex Sodium 100 Mg in 1 mL is 2mg/kg
48464261|NCT06334562|DRUG|Neostigmine|Neostigmine is 50 μg/kg
48464262|NCT00115869|BEHAVIORAL|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
48464263|NCT00265785|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
48464264|NCT02826395|DRUG|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
48464265|NCT01937767|DRUG|Remimazolam|
48464266|NCT01937767|DRUG|Propofol|
48464267|NCT01937767|DRUG|Sevoflurane|
48464268|NCT01937767|DRUG|Remifentanil|
48281702|NCT04036084|DIAGNOSTIC_TEST|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
48281703|NCT03449888|PROCEDURE|Regadenoson myocardial perfusion imaging stress test|Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
48281704|NCT03449888|PROCEDURE|Arm exercise electrocardiographic stress test|Published arm exercise score and best fit model of arm exercise ECG stress testing data.
48281705|NCT03449888|PROCEDURE|Treadmill electrocardiographic stress test|Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
48281706|NCT03449888|PROCEDURE|Coronary artery calcium score and cardiac computed tomographic angiography|Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease \> 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
48281707|NCT03754049|DRUG|TLC599|TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
48464269|NCT01937767|DRUG|Fentanyl|
48281708|NCT03754049|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
48281709|NCT00963807|DRUG|Cisplatin|Given IV
48281710|NCT00963807|PROCEDURE|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
48464270|NCT01937767|DRUG|Rocuronium|
48281711|NCT00963807|DRUG|Docetaxel|Given IV
48281712|NCT00963807|DRUG|FDG|Undergo FDG PET/CT
48281713|NCT00963807|DRUG|FLT|Undergo FLT PET/CT
48281714|NCT00963807|PROCEDURE|PET/CT|Undergo FDG PET/CT and FLT PET/CT
48624242|NCT02540304|BEHAVIORAL|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
48624243|NCT02011763|BIOLOGICAL|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
48624244|NCT06121674|PROCEDURE|Shaeer-II|"SHAEER-I targets ligation of the internal pudendal vein at the point where the vein exits Alcock's canal, and courses lateral to the ischial tuberosity.~Patient is oriented in the lithotomy position. The ischial tuberosity is marked. An incision is cut medial to the ischial tuberosity. Subcutaneous fat is dissected down to the neurovascular bundle harboring the internal pudendal vein. The vein is then ligated."
48624245|NCT06121674|PROCEDURE|PPI|Penile Prosthesis Implantation will be performed
48624246|NCT04093999|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
48624247|NCT00983970|BEHAVIORAL|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
48624248|NCT00983970|BEHAVIORAL|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
48464271|NCT03576040|DEVICE|Whole Body Dynamic 68Ga-DOTATOC PET/CT|"68Ga-DOTATOC PET-CT will be performed in the nuclear medicine department of the University Hospital of Brest on a Biograph mCT S64 machine (Siemens medical, Erlangen, Germany) Time of Flight system after intravenous injection of 150MBq of 68Ga-DOTATOC. In the usual conditions for performing this exam, the patient must remain at a strict rest for 60 minutes following the injection of the tracer and before a static 3D acquisition. For this protocol, a complementary 4D dynamic acquisition (15-60 minutes post-injection) will be performed during this usual rest period."
48464272|NCT04525898|DRUG|Methadone|The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
48464273|NCT04883333|DRUG|LEO 153339|LEO 153339
48464274|NCT04883333|DRUG|Placebo|Placebo
48464275|NCT00499824|BEHAVIORAL|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
48464276|NCT02169336|DRUG|Intranasal Dexmedetomidine|
48464277|NCT02169336|OTHER|Intranasal Placebo|
48281715|NCT00963807|PROCEDURE|Surgery|Undergo surgery
48464278|NCT04809714|DEVICE|Blood Flow Restriction with Delfi Tourniquet System Cuff|Postoperative rehabilitation will occur up to twice a day for 5 days a week for 2 weeks using a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of 60-100%. For each physical therapy session, participants will undergo therapy following a standardized protocol of 3-5 difference exercises each with 4 sets total in addition to NMES.
48464279|NCT04809714|OTHER|Routine Post-operative Physical Therapy|The control group with undergo a post-op therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. Participants will use a neuromuscular electrical stimulation device operating at a sub-therapeutic level.
48464280|NCT00569777|DEVICE|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
48464281|NCT00569777|DEVICE|Placebo Lens|contact lens without drug
48464282|NCT05770804|BEHAVIORAL|Face to face education|Face-to-face training was provided and supported by booklets.
48464283|NCT01073631|DRUG|voriconazole tablet|200 mg PO bid (orally, twice a day)
47936228|NCT04669288|DRUG|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
47936229|NCT04669288|DRUG|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
47936230|NCT00070733|DRUG|testosterone enanthate|
47936231|NCT00070733|DRUG|duastride|
47936232|NCT04333043|DIAGNOSTIC_TEST|audiological test, cognitive questionnaires|administration of cognitive and quality of life questionnaires and audiological test
48281716|NCT04751500|PROCEDURE|Outpatient hysteroscopy|Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
48281717|NCT04751500|BEHAVIORAL|Expectant management|Leaving the retained pregnancy tissue alone to pass by itself
48281718|NCT04751500|DRUG|Medical management|Giving medications to contract the womb to pass the retained pregnancy tissue
48281719|NCT04751500|DRUG|Antibiotic|Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
48281720|NCT04751500|PROCEDURE|Surgical management|Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
48281721|NCT05344547|DIAGNOSTIC_TEST|Cardiac risk ratio (CRR)|Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).
48281722|NCT03557021|DIAGNOSTIC_TEST|HIV Drug resistance testing|HIV Drug resistance testing by HIV pro DNA sanger sequencing
48281723|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
48281724|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
48281725|NCT03166800|DRUG|Placebo|This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
48281729|NCT01093495|DEVICE|CPAP|CPAP
48281730|NCT01093495|DEVICE|Nasal Cannula|Nasal Cannula
48281731|NCT03991247|BEHAVIORAL|Computerized behavioral therapy program delivered by internet for insomnia management|"The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm)."
48281732|NCT03991247|OTHER|Spa treatment|"Spa treatment is harmonized in the different stations. It consists in:~* a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~* an institutional follow-up: support, help and monitoring of patients during spa treatment~* Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C."
48281733|NCT01960686|BIOLOGICAL|Low dose RSV F Antigen|
48281734|NCT01960686|BIOLOGICAL|High dose RSV F Antigen|
48281735|NCT01960686|BIOLOGICAL|Dose 1 of Aluminum Adjuvant|
48281736|NCT01960686|BIOLOGICAL|Dose 2 of Aluminum Adjuvant|
48281737|NCT01960686|BIOLOGICAL|Dose 3 of Aluminum Adjuvant|
48281738|NCT01960686|BIOLOGICAL|Dose 4 of Aluminum Adjuvant|
48281739|NCT01960686|BIOLOGICAL|Placebo|
48281740|NCT01106638|BEHAVIORAL|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
48281741|NCT01106638|BEHAVIORAL|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
48281742|NCT06656741|BEHAVIORAL|Resting State|Resting state is a mental state and a research paradigm that people do nothing and idle as much as possible to show their baseline neuro signals. In this task, we instructed participants to rest with their eyes opened for 6 minutes. The VR environment of blue sky and swaying meadow was presented to the participants throughout this task.
48464284|NCT00579631|BEHAVIORAL|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
48464285|NCT04034277|OTHER|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
48624249|NCT01952860|OTHER|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
48624250|NCT01952860|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
48624251|NCT02189824|BIOLOGICAL|Partially HLA-matched unrelated donor cells|
48624252|NCT05177094|DRUG|LY3526318|Administered orally
48624253|NCT05177094|DRUG|Placebo|Administered orally
48624254|NCT01908244|OTHER|Music|Pentatonic music
48624255|NCT03125733|PROCEDURE|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:~1. Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~2. Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~3. Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~4. Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
48624256|NCT00112853|DRUG|tipifarnib|Given orally
48624257|NCT00112853|DRUG|etoposide|Given orally
48624258|NCT06077851|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment the first days after discharge. Monitoring will last for a maximum of three days.
47936233|NCT00704522|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
47936234|NCT00704522|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
48464286|NCT04034277|OTHER|Conventional Treatment|"speech rehabilitation protocol comprehend:~* Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~* Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
48624259|NCT03569462|BEHAVIORAL|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
48624260|NCT03569462|BEHAVIORAL|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
48624261|NCT01779362|DRUG|Metformin|Titrated to 1000 mg BID
48624262|NCT01779362|DRUG|Liraglutide|Titrated to 1.8 mg/day
48624263|NCT01779362|DRUG|Glargine|Titrated to target fasting glucose \<90 mg/dl
48624264|NCT01779362|DRUG|Placebo|Matching to metformin 1000 mg BI
48624265|NCT04027309|DRUG|Gilteritinib|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
48624266|NCT04027309|DRUG|Midostaurin|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
48624267|NCT05462678|BEHAVIORAL|Cognitive Rehabilitation|Each patient performed two weekly sessions of 45 minutes each, for 12 weeks
48624268|NCT05462678|BEHAVIORAL|Combined Rehabilitation|Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.
48624269|NCT05462678|BEHAVIORAL|Motor Rehabilitation|Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.
48624270|NCT02821559|DRUG|TOMOX|
48624271|NCT02821559|DRUG|Bevacizumab|Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
48624272|NCT01089595|DRUG|Nilotinib|Nilotinib 400 mg po bid
48624273|NCT01089595|DRUG|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
48624274|NCT06398691|DEVICE|Nazal CPAP|
48624275|NCT06398691|DEVICE|Heated humidified high-flow air support with nasal cannula|
48464287|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (before physical activity)|Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
48624276|NCT01766284|DEVICE|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
48624277|NCT00135655|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
48464288|NCT05302193|OTHER|Physical activity|Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
48624278|NCT05824585|DRUG|DZD8586|DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
48624279|NCT05469490|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT is specialize radiation that is effective for ablating tumors at primary and metastatic locations that increases antigen uptake/processing/presentation.
48624280|NCT05469490|DRUG|navoximod|A small molecule inhibitor with potent inhibition of IDO1 enzymatic activity as shown both in vitro and in vivo. As the main function of IDO1 is the regulation of acquired immune tolerance, and its expression in tumor- and dendritic cells in tumor draining lymph nodes negatively correlates with cancer prognosis and survival, navoximod-mediated IDO1 inhibition may restore immune reactivity towards tumors.
48624281|NCT05469490|DRUG|NLG802 (indoximod Prodrug)|An anti-tumor immunomodulator with the active ingredient of 1-methyl-D-tryptophan (NSC- 721782, 1-MT), which is an inhibitor of the indoleamine 2,3-dioxygenase (IDO) pathway that increases the bioavailability of indoximod by leveraging existing mechanisms of absorption, increasing the exposure of indoximod.
48624282|NCT00879853|BEHAVIORAL|Interpersonal Therapy|
48624283|NCT05710822|DEVICE|pulmonary vein isolation|pulmonary vein isolation utilizing the QDOT Micro ablation catheter
48624284|NCT00624260|OTHER|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
48624285|NCT00624260|OTHER|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
48624286|NCT06347588|OTHER|Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA|Blood sample at baseline, week 4, month 3, 6, 9,12.
48624287|NCT00850642|DRUG|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
48624288|NCT00850642|DRUG|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
48624289|NCT04632719|DEVICE|The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19|Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
48464289|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (after physical activity)|Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
48464290|NCT03682276|BIOLOGICAL|Ipilimumab|Ipilimumab is a monoclonal antibody given as an immunotherapy
48464291|NCT03682276|BIOLOGICAL|Nivolumab|Nivolumab is a monoclonal antibody given as an immunotherapy
48464292|NCT04808908|BIOLOGICAL|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
48464293|NCT06533215|OTHER|antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.|"The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml)."
48624290|NCT06275399|DIAGNOSTIC_TEST|OCT examination|OCT examination for precise evaluation of plaque morphology within the coronary stenosis.
48624291|NCT06275399|DIAGNOSTIC_TEST|Blood sampling|Blood sampling directly from coronary artery (proximal and distal segment) arteries
48624292|NCT06275399|DIAGNOSTIC_TEST|Assessment of vFFR and shear stress parameters|The procedure is based on non-invasive assessment of vFFR and shear stress parameters with dedicated software, deriving parameters directly from coronary angiography with the calculation based on the computational fluid dynamics
48624293|NCT03274089|DEVICE|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~* Collects patient information using patient-specific identification~* Prompts the user for answers to screening questions for acute conditions~* Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~* Triages patients based on responses to screening questions, physiological parameters and blood test results~* Provides recommendations to the patient on the care plan, self management and lifestyle choices"
48624294|NCT06189950|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
48464294|NCT05626348|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48464295|NCT05626348|DRUG|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48624295|NCT05186155|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
48624296|NCT05013775|DIAGNOSTIC_TEST|Computed tomography|Computed tomography to gauge response after preoperative chemotherapy cycles and excluded the development of interval metastases or irresectable disease
48624297|NCT05013775|DIAGNOSTIC_TEST|Diagnostic laparoscopy with peritoneal lavage|Diagnostic laparoscopy lavage to exclude (small-volume) metastases and determine local resectability
48624298|NCT01495247|DRUG|BEZ235|Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
48464296|NCT05626348|DRUG|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48281743|NCT06656741|BEHAVIORAL|Mindful Breathing|Mindful breathing is a state that people focus on their inner sensation. In this task, the meadow's motion in the VR environment corresponded to the participants' inhalation and exhalation, as detected by the respiration belt. The participants were instructed to focus mentally on their bodily sensations as they breathed, with the meadow's sway as a visual cue.
48464297|NCT05626348|DRUG|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48464298|NCT05626348|DRUG|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48464299|NCT01278641|BEHAVIORAL|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
48464300|NCT01278641|BEHAVIORAL|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
48464301|NCT02973906|OTHER|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
48464302|NCT02973906|OTHER|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
48464303|NCT02973906|OTHER|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
48464304|NCT03043040|BEHAVIORAL|Telephone follow up|Already described in previous page
48464305|NCT03043040|BEHAVIORAL|Treatment as usual|Already described in previous page
48464306|NCT03650751|OTHER|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
48464307|NCT04449341|DEVICE|Oculus Go headset with Ocean Rift application|Information already included in arm description
48464308|NCT03693950|BIOLOGICAL|BCD-066|BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
48464309|NCT03693950|BIOLOGICAL|Aranesp|Aranesp will be administered once a week intravenously in a dose 1 µg/kg
48464310|NCT02463019|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
48464311|NCT05471687|DEVICE|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
48464312|NCT05471687|DRUG|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
48464313|NCT01977456|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
48464314|NCT04315779|PROCEDURE|Salpingectomy|Patients will undergo removal of the affected tube
48464315|NCT02906917|DRUG|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
48464316|NCT02906917|DRUG|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
48464317|NCT02906917|DRUG|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
48464318|NCT06036927|DRUG|TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
48464319|NCT06036927|DRUG|TQC2731 matching placebo|It'a a placebo injection without active substances.
48464320|NCT05263505|DRUG|Baricitinib 2 MG [Olumiant]|Two tabs daily
48464321|NCT05263505|DRUG|Methotrexate|Target dose: 20mg weekly
48464322|NCT05263505|DRUG|Azathioprine|Target dose: 2mg/kg daily
48464323|NCT05263505|DRUG|Mycophenolate|Target Dose: 1g twice daily
48464324|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
48464325|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
48464326|NCT02860325|DEVICE|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
48464327|NCT02860325|DEVICE|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
48464328|NCT04138251|DRUG|Empagliflozin|oral administration of Empagliflozin
48624299|NCT01495247|DRUG|Paclitaxel|"The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts."
48624300|NCT01101048|DRUG|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
48624301|NCT01101048|DRUG|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
48624302|NCT00004055|BIOLOGICAL|filgrastim|
48624303|NCT00004055|DRUG|paclitaxel|
48624304|NCT00004055|DRUG|topotecan hydrochloride|
48624305|NCT02806999|DRUG|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
48624306|NCT02806999|DRUG|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
48624307|NCT02411136|DRUG|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
48624308|NCT02411136|DRUG|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
48624309|NCT03723954|DEVICE|ECG Holter SpiderFlash-t|"Record at visit V0 (day without match) and the competition days (Visit V1, V2 et V3) during the matches the heart rate of the golf fans.~SpiderFlash-t™ from MicroPort is a long-lasting event recorder set in walking position by the investigator the day of the record and it is activated by detecting rhythm anomalies. This recorder is a Class IIA medical device (according to European Economic Community Directive 93/42). It benefits from European Economic marking."
48624310|NCT03723954|DEVICE|Actigraph GT3Xp|"Record the study participant's physical activity while we record his heart rate.~The GT3Xp based activity monitors provide objective measurements of human activity and are used in many research and clinical applications. It includes a micro-electro-mechanical system (MEMS) based accelerometer and an ambient light sensor. It benefits from CE marking and FDA agreement (Class II medical device)."
48624311|NCT00675480|PROCEDURE|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
48624312|NCT00675480|PROCEDURE|Primary angioplasty|Standard primary angioplasty with stent implantation
48624313|NCT06265025|DRUG|GM103 (Part A)|dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days \[2 weeks\]).
48624314|NCT06265025|DRUG|GM103 (Part B)|dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease \[HNC, CRC\]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days \[2 weeks\]).
48464329|NCT04559841|OTHER|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
48478856|NCT05188183|BEHAVIORAL|Somatosensory Training|The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
48624315|NCT06265025|DRUG|GM103 and Pembrolizumab (Part C)|dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days \[3 weeks\]).
48624316|NCT03380572|DEVICE|Senhance Assisted Cholecystectomy|Cholecystectomy performed using Senhance surgical robotic system
48624317|NCT03380572|PROCEDURE|Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy
48624318|NCT00986141|PROCEDURE|Surgery|Selective Laser Trabeculoplasty for glaucoma
48624319|NCT00986141|PROCEDURE|Selective Laser Trabeculoplasty|Glaucoma Treatment
48624320|NCT02013414|DEVICE|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
48624321|NCT03341429|DRUG|Liraglutide Pen Injector [Saxenda]|Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (\<20%) after bariatric surgery and suboptimal GLP-1 levels.
48099399|NCT03593070|BEHAVIORAL|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
48099400|NCT00243334|OTHER|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
48281744|NCT06656741|BEHAVIORAL|Guided Breathing|Guided breathing refers to the breath training technique that trainees are guided to inhale and exhale according to a fixed tempo. In this task, meadow swayed in a fixed tempo of 4 seconds back and 6 seconds forth. The participants were instructed to synchronize their inhalation with the meadow's backward motion (lasting 4 seconds) and their exhalation with its forward motion (lasting 6 seconds).
48281745|NCT06656741|BEHAVIORAL|Breath Counting|Breath counting refers to the breath training technique that trainees mentally count the numbers of breath cycles they have finished in a certain period of time. In this task, similar to the mindful breathing task, the meadow's motion was synchronized with the participants' breathing patterns. During the 6 minutes, we instructed the participants to breathe naturally and mentally count their breathing cycles.
48281746|NCT04856761|DRUG|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
48281747|NCT04856761|DRUG|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
48624322|NCT03341429|DRUG|Placebo|Daily subcutaneous injection
48624323|NCT05011435|DEVICE|web-application for burnout|Use of burnout advisor web-application for detection of professional burnout
48624324|NCT05075772|DRUG|BI 765080|BI 765080
48464330|NCT06416449|OTHER|kinesiotape application|"In the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded. For the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~As implied by its name, cones are placed in a T-shape for the T-Agility Test, and the individual is required to touch the cones and return to the starting point as quickly as possible. In the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded. The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests."
48464331|NCT05791864|GENETIC|RGX-381|One time subretinal dose in study eye
48464332|NCT05094596|DRUG|Standart treatment group|Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
48464333|NCT05094596|DRUG|Montelukast sodium 10 mg treatment|Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment
48624325|NCT03542799|BIOLOGICAL|EGFR IL12 CART|EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
48464334|NCT05094596|DRUG|Montelukast sodium 20 mg treatment|Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
48624326|NCT05382728|DRUG|TY-9591|"The dose of TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
48624327|NCT05382728|DRUG|placebo Osimertinib|"The dose of placebo Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
48624328|NCT05382728|DRUG|Osimertinib|"The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
47936235|NCT00704522|BEHAVIORAL|Patient assistance program|"Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
47936236|NCT00457964|DRUG|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
47936237|NCT04647890|DRUG|FT011|Two x 100mg capsules once daily for 12 weeks
47936238|NCT04647890|DRUG|FT011|Two x 200mg capsules once daily for 12 weeks
47936239|NCT04647890|DRUG|Placebo|Two placebo capsules once daily for 12 weeks
47936240|NCT04644783|DIAGNOSTIC_TEST|Blood test assay|Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
47936241|NCT05415709|DRUG|Carboplatin|Given IV
47936242|NCT05415709|DRUG|Cisplatin|Given IV
48624329|NCT05382728|DRUG|placebo TY-9591|"The dose of placebo TY-9591 is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
47936243|NCT05415709|PROCEDURE|Cytoreductive Surgery|Undergo CRS
48624330|NCT02624089|DRUG|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
48624331|NCT02624089|DRUG|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
48624332|NCT03387046|DIETARY_SUPPLEMENT|D-aspartate|D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
48099401|NCT03641092|BEHAVIORAL|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
48099402|NCT03641092|BEHAVIORAL|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site \[when recruited families will be ineligible for CenteringParenting groups that will start in control sites\]. They will receive anticipatory guidance and handouts that are standard for the clinic.
48099403|NCT03220139|OTHER|fat intake|Observational study on fat intake and mortality
48099404|NCT05068713|OTHER|Usual Care + High Target of Mean Arterial Pressure|Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.
48099405|NCT05068713|OTHER|Usual Care|Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.
48099406|NCT00757718|DEVICE|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
48099407|NCT00757718|DEVICE|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
48281748|NCT04513145|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.
48281749|NCT04513145|DRUG|Saline Injection|Saline will be used as a placebo injection
48281750|NCT04513145|PROCEDURE|Total Knee Arthroplasty|All subjects participating in this study will undergo primary total knee arthroplasty
48281751|NCT01656642|DRUG|Atezolizumab|Atezolizumab will be administered q3w or q2w.
48281752|NCT01656642|DRUG|Cobimetinib|Oral repeating dose
48464335|NCT06423196|OTHER|Experimental group|In the development of the exercises, the players will mobilise dumbbells of different weights that will be estimated according to the calculation of 30% of 1 RM. This workload with dumbbells is based on previous work where blood flow restriction was used in healthy athletes.
48624333|NCT03387046|DRUG|Placebo|Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
47936244|NCT05415709|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
47936245|NCT05415709|DRUG|Paclitaxel|Given IV
47936246|NCT05415709|OTHER|Quality-of-Life Assessment|Ancillary studies
47936247|NCT05415709|OTHER|Questionnaire Administration|Ancillary studies
47936248|NCT03973801|OTHER|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
47936249|NCT02744937|DRUG|Aspirin|aspirin is continued by its regular dosing
47936250|NCT00375375|DRUG|Lactulose|
47936251|NCT00809029|OTHER|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
47936252|NCT01215864|DRUG|TCD-717|"Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m\^2"
47936253|NCT04050917|DEVICE|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
47936254|NCT04050917|DEVICE|no stimulation|The smartwatch generates no stimulation.
47936255|NCT03368573|DEVICE|QbTest|QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
47936256|NCT06422754|DEVICE|Becure GmbH|Becure Balance System
47936257|NCT03654430|OTHER|Echocardiography|Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
48099408|NCT01391442|BIOLOGICAL|blood and urine samples|58 ml of blood 120 ml of urine
48281753|NCT01656642|DRUG|Vemurafenib|Oral repeating dose, depending on arm/cohort
48281754|NCT00403104|DRUG|ONO-2506PO|1200 mg QD / 18 months
48281755|NCT00403104|DRUG|ONO-2506PO|0 mg QD / 18 months
48464336|NCT03733587|DRUG|GX-I7|GX-I7 25mg/ml/vial
48464337|NCT03733587|DRUG|Cyclophosphamide|Cyclophosphamide 500mg/vial
48464338|NCT00054834|DRUG|hLL2 (epratuzumab)|
48478857|NCT05188183|OTHER|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
48478858|NCT03296813|DRUG|Torsemide|Loop diuretic
48281756|NCT03212261|BEHAVIORAL|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
48624334|NCT03387046|BIOLOGICAL|IFN beta-1a|IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
47936258|NCT03882931|OTHER|Theta Burst Transcranial Magnetic Stimulation|Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
47936259|NCT03882931|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
47936260|NCT03882931|OTHER|Sham|The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
47936261|NCT02757950|BIOLOGICAL|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
48281757|NCT00372918|PROCEDURE|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
48281758|NCT03421548|DEVICE|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
48281759|NCT00673855|OTHER|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
48464339|NCT05564845|DIAGNOSTIC_TEST|MR scan of the brain|Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
48464340|NCT05564845|DIAGNOSTIC_TEST|Blood work|Lab work for current lab values and biobanking
48464341|NCT05564845|DIAGNOSTIC_TEST|Neurological examination|Classical neurological examination
48478859|NCT03296813|DRUG|Furosemide|Loop diuretic
48478860|NCT05002114|DRUG|Cannabidiol|Topical CBD cream - special formulation
48478861|NCT05002114|OTHER|Placebo|Not the drug
48624335|NCT03387046|DRUG|Methylprednisolone|Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
48624336|NCT06314971|OTHER|Tw1CE|A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
48624337|NCT04568109|BEHAVIORAL|Cognitive-behavior therapy|The manualized protocol (Gloster et al., 2011) comprise of 12 weekly sessions of CBT focusing on therapist-guided interoceptive and in-situ exposure exercises.
48624338|NCT05997589|BEHAVIORAL|Behavioral Intervention|Receive educational materials
48099409|NCT01391442|GENETIC|blood sample|11 ml of blood
48478862|NCT04225286|OTHER|Human breast milk|Intranasal human breast milk
48478863|NCT01030211|PROCEDURE|Platelet transfusion|4 units of platelets for patients with platelet count \<20x10\^3/uL
48478864|NCT01030211|OTHER|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
48478865|NCT03474029|DRUG|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
48624339|NCT05997589|OTHER|Educational Intervention|Attend financial health educational program
48624340|NCT05997589|OTHER|Questionnaire Administration|Ancillary studies
48624341|NCT04589767|BEHAVIORAL|CAPD scale|Two nurses will apply CAPD scale. One nurse will repeat the CAPD evaluation two minutes later
48099410|NCT01391442|OTHER|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
48099411|NCT01391442|OTHER|Stanislas ancillary study : MRI examination with GRICS technique|
48099412|NCT04616365|PROCEDURE|Semi-Elective Lung Transplantation|When suitable donor lungs become available for a consented recipient, the transplant procedure (anesthesia starting time) will be allowed to begin earliest at 6am with the lungs being preserved at 10°C cold static preservation upon organ arrival to our hospital using a specific incubator, regardless of when donor cross clamp occurs. The maximum time allowed between donor cross clamp and recipient anesthesia initiation will be 12h.
48099413|NCT06306859|BEHAVIORAL|Using m-health for monitoring and education provision|The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence
48099414|NCT06306859|OTHER|Standard care|The comparator group will be given standard and routine care
48099415|NCT02833155|DRUG|Entinostat|Given PO
48281760|NCT00673855|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
48281761|NCT00468715|DRUG|bicalutamide|
48624342|NCT03724344|OTHER|Cross section resaerch|Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
48624343|NCT01676662|DEVICE|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
47936262|NCT04163731|OTHER|DASI questionnaire|All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
47936263|NCT04172129|DEVICE|Total Hip Arthroplasty|
48281762|NCT00468715|OTHER|diagnostic laboratory biomarker analysis|
47936264|NCT01466140|OTHER|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
47936265|NCT00124397|DRUG|Atorvastatin|
47936266|NCT00003950|DRUG|cyclosporine|
47936267|NCT00003950|DRUG|CPT-11|
47936268|NCT00537901|RADIATION|First-Line Bevacizumab and Chemotherapy|Chemotherapy
47936269|NCT00537901|DRUG|Bevacizumab|Chemotherapy
47936270|NCT01685346|BEHAVIORAL|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
47936271|NCT06523374|PROCEDURE|Endoscopic brush cytology|A total of four brush samples will be taken during the endoscopy. Other minimally invasive interventions during this study are standard of care.
48099416|NCT02833155|DRUG|Exemestane|Given PO
48099417|NCT00469118|DEVICE|DRX9000™|Nonsurgical spinal decompression
48099418|NCT04802824|OTHER|PET/CT|18F-fluoropivalate PET/CT scan.
48099419|NCT02047461|DRUG|ORGN001 (formerly ALXN1101)|IV infusion
48099420|NCT01601314|DRUG|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
48281763|NCT00468715|OTHER|immunohistochemistry staining method|
48281764|NCT06286423|DRUG|Colchicine 0.6 mg|Colchicine treated subjects will take 0.6mg of drug 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of drug 1x per day (or every other day if kidney disease is present) for 76 +/1 days.
48281765|NCT06286423|DRUG|Control/Placebo group|Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
48281766|NCT03285815|DEVICE|Proton Therapy|
48281767|NCT03263806|DIAGNOSTIC_TEST|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
48464342|NCT05564845|DIAGNOSTIC_TEST|Neuropsychological assessment|"Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~* Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~* A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~  * Narrative memory~ * Word fluency~ * Route finding NEPSY-II~* World Fluency~* Additional Questionnaires (6-18 years):~  * Child Behavior Checklist (CBCL)~ * Teacher Report Form (TRF)~ * Youth Self Report (YSR)~ * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~ * Conners-3® • Additional Questionnaires (18+ years):~ * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70)~ * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70)~ * Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox"
48464343|NCT02355262|OTHER|Informational Intervention|Receive CATCH-UP intervention
48464344|NCT01148225|DRUG|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
48464345|NCT03324815|DRUG|Morphine|Pain Treatment
48464346|NCT03324815|DRUG|Methadone|Pain Treatment
48624344|NCT01676662|DEVICE|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
48281768|NCT03263806|DIAGNOSTIC_TEST|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
48464347|NCT06322251|BEHAVIORAL|Use of instrument to identify exposure to violence in close relationships|Use of instrument to identify exposure to violence in close relationships
48099421|NCT01601314|OTHER|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
48099422|NCT03354533|DRUG|L-fucose|Oral ORL-1F
48099423|NCT05397457|DEVICE|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
48099424|NCT02034149|BEHAVIORAL|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
48281769|NCT04716634|DRUG|Tislelizumab|Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
48624345|NCT05047380|BEHAVIORAL|Owstery Disability Scale for disability Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, VAS for pain, Pittsburgh Sleep Quality Scale for sleep quality|All assessments will be made using questionairres. The Oswestry Disability Index scale will be filled in to assess the severity of disability resulting from pain in the patient. Pain severity will be evaluated with the Visual Analog Scale (VAS). Depression and anxiety assessment will be made with Beck Depression Scale and Beck Anxiety Scale, respectively. Sleep quality will be evaluated with the Pittsburg Sleep Quality Index.
48464348|NCT04320576|DEVICE|Bulk-fill|Bulk-fill resin composite (bulk technique)
48464349|NCT04320576|DEVICE|Nano-fill|Nano-fill resin composite (layering technique)
48464350|NCT02795026|PROCEDURE|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
48464351|NCT02795026|PROCEDURE|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
48624346|NCT05494918|DRUG|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
48624347|NCT01360476|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
48624348|NCT01360476|DIETARY_SUPPLEMENT|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
48624349|NCT03790969|DEVICE|26 gauge needle|smaller gauge needle
48624350|NCT03790969|DEVICE|23 gauge needle|control group
48624351|NCT00344825|DRUG|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
48624352|NCT02911467|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
48624353|NCT02911467|DEVICE|MRI|MRI scan following the Pyruvate injection
48624354|NCT02015715|DRUG|RO6864018|A single oral ascending dose of RO6864018 capsules on Day 1.
48624355|NCT02015715|DRUG|Placebo|A single oral dose of placebo matching RO6864018 capsules on Day 1.
48624356|NCT00709670|PROCEDURE|MSCT and stress echocardiography|tests MSCT and stress echocardiography
48281770|NCT04716634|DRUG|Fruquintinib|Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
48281771|NCT06657066|DRUG|Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii|Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
48464352|NCT06223490|PROCEDURE|Cryolipolysis|To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
48464353|NCT02378909|DEVICE|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
48464354|NCT02885441|DRUG|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
48099425|NCT02034149|BEHAVIORAL|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
48099426|NCT02034149|BEHAVIORAL|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
48099427|NCT03455361|PROCEDURE|Stark Implant with low primary stability|
48099428|NCT03124108|DRUG|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
48099429|NCT03124108|DRUG|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
48099430|NCT03124108|DRUG|Placebo|Two coated tablets daily for 12 weeks
48099431|NCT04244318|BEHAVIORAL|Video-feedback ODISEA 3.0|Video-feedback intervention ODISEA 3.0 (Gómez \& Maureira, 2022), which incorporates an attachment theory framework. This intervention was constructed within the ODISEA's comprehensive and formative model of parenthood which was developed in Chile by Dr. Esteban Gómez Muzzio (Gómez, 2022).
48099432|NCT04244318|BEHAVIORAL|ODISEA-DTP: parental therapy|Parental Therapy (ODISEA-DTP, Gómez \& Maureira, 2022): is a parental therapy strategy that works over 5 sessions with the history of caregivers in a systematic way, allowing to explore their past, present and expected future concerning parenting, child rearing, attachment and child abuse, between other issues. The DTP is a protocolized model of parental therapy, each session is carefully designed to elicit memories, emotions and to stimulate reflective function (about the past and their own childhood) and parental reflective function (about the present with the child).
47936272|NCT06067659|OTHER|Extracorporeal shock wave therapy|ESWT (EMS Swiss DolorClast® Classic) application will be applied to patients in groups 1 and 3 with a frequency of 15 Hz, a 2000 shock wave and an energy density of 2.5 bar. In practice, patients will be asked to lie in the prone position and keep the knee and hip joints in a neutral position. By placing a towel roll under the ankle, the heel will be stabilized to be applied. Using the ultrasound gel as an intermediate, the ESWT device will be applied to the medial part of the calcaneus.
47936273|NCT06067659|OTHER|Kinesiology taping|The material used in the taping will be 5 cm wide and 0.5 mm thick Kinesio® Tape. In practice, the patients were placed in the prone position and the ankle would be dorsiflexed at 10 degrees, and the band would be divided into 4 equal parts on the metatarsals of the 1/3 of the foot from the cruis, starting from the calcaneus. Then, taping will be performed from the medial to the lateral of the calcaneus, passing over the area where the pain is intense. Patients will be asked not to remove the applied tape for 3 days.
47936274|NCT06067659|OTHER|Extracorporeal shock wave therapy+Kinesiology taping|Patients in this group will be treated with both extracorporeal shock wave therapy and kinesiotape.
47936275|NCT05967897|DIETARY_SUPPLEMENT|Blueberries|22 g freeze-dried blueberry powder mixed with water
47936276|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Whey Protein|22 g freeze-dried blueberry powder mixed with whey protein and water
47936277|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Pea Protein|22 g freeze-dried blueberry powder mixed with pea protein and water
47936278|NCT05967897|DIETARY_SUPPLEMENT|Blueberries and Hemp Protein|22 g freeze-dried blueberry powder mixed with hemp protein and water
47936279|NCT05769127|OTHER|Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)|DPP lifestyle intervention program DSMT education on diabetes and lifestyle changes
47936280|NCT05242315|DRUG|Envarsus Oral Product|as described in arm/group description
47936281|NCT05242315|DRUG|Prograf (SOC)|Prograf (SOC)
48099433|NCT04244318|BEHAVIORAL|Treatment as usual|"Psychosocial intervention (parental education, family counseling, home visits and school and Court coordination) for child abuse and neglect, implemented by six Family Therapeutic Programs (AFT) of the NGO Protectora de la Infancia"
48099434|NCT06632158|BEHAVIORAL|MindBoba|MindBoba is a smartphone app that uses strategies based on Problem-Solving Therapy to help decrease stress and anxiety, and teach new skills.
48099435|NCT06632158|BEHAVIORAL|Mindshift CBT|MindShift® CBT uses strategies based on Cognitive Behavioural Therapy (CBT) to help you learn to relax and be mindful, develop more effective ways of thinking, and use active steps to take charge of your anxiety.
48099436|NCT06118892|DEVICE|MISHA Knee System|The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
48099437|NCT05678296|DIAGNOSTIC_TEST|Diagnosis|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
48099438|NCT05678296|DRUG|Analgesic|Analgesics are prescribed for the patients for all groups.
48099439|NCT05678296|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
48464355|NCT05413512|OTHER|Acute psychological stress|Participants will undergo an acute psychological stress task that has been shown to elicit neural, cardiovascular, and psychological (feelings of stressfulness) responses.
48464356|NCT02752334|DRUG|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
48464357|NCT06110819|OTHER|control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
47936282|NCT05692973|BEHAVIORAL|Role of Knowledge Retrieval|Students will learn a new knowledge base to perfect mastery. Following the attainment of mastery students will read passages on the topic and answer questions that prompt the literal recall of key facts and the formation of inferences.
48624357|NCT06430528|DRUG|Osilodrostat|Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.
48624358|NCT00306072|DRUG|nutritional herbal extract from Salacia oblonga|
48624359|NCT03630601|PROCEDURE|Photoacoustic Imaging|Undergo PAI
48464358|NCT06110819|OTHER|Workgroup|"Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health."
48464359|NCT03344120|OTHER|Administration of USSQ Symptoms questionnaire after stent positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
48464360|NCT03206749|DRUG|VX-150|Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.
48464361|NCT03206749|DRUG|HB/APAP|Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.
48464362|NCT03206749|DRUG|Placebo|Participants received placebo matched to VX-150 and HB/APAP for 2 days.
48464363|NCT00000623|DRUG|Deferoxamine|
48464364|NCT00000623|DRUG|Deferiprone|
48464365|NCT00000623|DRUG|Arginine|
48464366|NCT00000623|DRUG|Sildenafil|
48464367|NCT00000623|DRUG|Decitabine|
48464368|NCT03315533|DRUG|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
47936283|NCT05692973|BEHAVIORAL|Inference Intervention|The intervention will pre-teach students a set of 20 essential facts about Egypt. Students will interact with expository and narrative texts. Students will practice using a text clue strategy to activate and integrate prior knowledge, will make in-text connections, connections across the 3 intervention texts, and connections between text and knowledge, and will make inferences about character motives and author intent. The tutor will ask students to justify connections and evaluate how these connections enhance understanding. Students will answer inference questions that require using text and background knowledge. A simple graphic organizer will support and scaffold inferencing. Throughout the intervention, students will practice retrieving the 20 essential facts about Egypt from memory using flash cards, completed in pairs with students providing each other feedback.
48281772|NCT06657066|DRUG|Control (Standard treatment)|The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
48281773|NCT06657300|DRUG|PRP|A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
48281774|NCT06657300|DRUG|Corticosteroid|A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
48464369|NCT03315533|DRUG|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
48464370|NCT03315533|DRUG|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
48464371|NCT01819064|DRUG|Atropine|intravenous atropine affect on heart rate
48464372|NCT04894409|DEVICE|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
48464373|NCT04894409|DEVICE|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
48464374|NCT02148744|BIOLOGICAL|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
48464375|NCT02148744|BIOLOGICAL|Placebo|
48464376|NCT04712734|DRUG|Iloperidone|oral tablet, long-acting injection
48464377|NCT01851876|DEVICE|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
48464378|NCT00343720|DRUG|VELCADE|
48464379|NCT00343720|DRUG|Alimta|
48464380|NCT03278041|PROCEDURE|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~* 1st step will be identify the facial artery and vein,~* 2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~* 3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
48464381|NCT03278041|DEVICE|maxillary obturator|immediate surgical obturator
48464382|NCT01282450|RADIATION|Radiotherapy|Radiotherapy
48099440|NCT05678296|BIOLOGICAL|Platelet Rich Fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
48464383|NCT06388733|DRUG|Niraparib|Participants will receive niraparib 200 mg orally once daily starting on Day 1 of RT. Following completion of RT, participants will continue niraparib adjuvant therapy orally once daily on Days 1 to 28 of each 28-day cycle until progression by BICR
48624360|NCT06095193|BEHAVIORAL|menopause education|Women will be taught the physiology of female reproductive organs, physiology of menopause, vaginal symptoms in menopause, sexual myths in menopause and practices that will support sexuality in menopause, in 50 minutes for 4 weeks.
48624361|NCT00313170|DRUG|Fulvestrant|intramuscular injection 250 mg \& 500 mg
48464384|NCT06388733|DRUG|Temozolomide|Participants randomized to the comparator arm (Arm B) will receive SOC TMZ 75 mg/m2 orally once daily with RT starting on Day 1 of RT. Following completion of RT, participants will complete a 4-week rest period, and then receive adjuvant TMZ 150 to 200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle until progression by BICR or for a maximum of 6 cycles.
48464385|NCT02219009|DEVICE|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
48464386|NCT04400292|OTHER|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
48464387|NCT04400292|DEVICE|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
48464388|NCT04400292|PROCEDURE|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
48464389|NCT02247687|DRUG|Protease inhibitor|"Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling."
48464390|NCT02247687|DRUG|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
48464391|NCT02247687|OTHER|Counseling arm|No change of antiretroviral treatment but only counseling
48464392|NCT00584103|DEVICE|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
48624362|NCT02273453|DRUG|Songha® Night|
48624363|NCT02273453|DRUG|Oxazepam|
48464393|NCT00584103|DEVICE|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
48464394|NCT01424020|OTHER|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
48624364|NCT02273453|DRUG|Placebo|
48624365|NCT06023407|OTHER|Water Immersion Heat Therapy|10-weeks of 3 days per week in 1 of the 2 arms
48624366|NCT04605913|COMBINATION_PRODUCT|Modified GCN+TTF treatment|The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
48624367|NCT05051839|PROCEDURE|Implant surgery and restoration|Implants with two different transmucosal neck configuration are placed.
48624368|NCT05072951|DIAGNOSTIC_TEST|Urine Biomarker for Kidney Transplant Rejection|Biomarker for active kidney transplant rejection.
48099441|NCT05678296|DRUG|Antibiotic|no systemic antibiotics are prescribed for the patients for all groups.
48624369|NCT00109369|OTHER|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
48624370|NCT03247244|DRUG|Cannabis|THC 10%, CBD \<0.5%
48099442|NCT02759744|DEVICE|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
48281775|NCT05786170|DIAGNOSTIC_TEST|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging
48281776|NCT06046482|DRUG|Pembrolizumab|Given by IV (vein)
48624371|NCT03247244|DRUG|Cannabis|THC 8.6%, CBD 8.6%
48099443|NCT04740359|OTHER|Functional training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min).
48099444|NCT04740359|OTHER|Routine training|The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.).
48281777|NCT06046482|DRUG|Magrolimab|Given by IV (vein)
48281778|NCT06046482|DRUG|cetuximab|Given by IV (vein)
48624372|NCT03247244|DRUG|Cannabis|THC 0.6%, CBD 14%
48624373|NCT06260293|BEHAVIORAL|exercise|"A total of 4 exercise interventions.~Twice In-patient exercise interventions: exercises on the ward at POD1, and POD2, and Recommended walking and stretching.~Twice home-based exercise interventions: post-discharge, Recommended 30 minutes of low to moderate-intensity walking and daily bodyweight exercises per day(150 minutes each week). and remote exercises 1 per week."
48624374|NCT02590315|OTHER|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
48624375|NCT02590315|DEVICE|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
48624376|NCT02590315|DEVICE|Conventional digital mammography.|Conventional digital mammography.
48281779|NCT06046482|DRUG|Docetaxel|Given by IV (vein)
48464395|NCT05774522|OTHER|Measurement of pharyngeal critical airway closing pressure|The Pcrit will be measured on an automatic controlled device specially designed by the engineers of the inserm neophen team capable of varying the pressures from +4 to -20 centimeters of water, by a nasal mask whose pressures are connected to a pneumotachograph. The measurements will be performed in supine position.
48464396|NCT05774522|OTHER|Acoustic pharyngometry|Acoustic pharyngometry is an non-invasive technique consisting of the propagation of an acoustic wave from the lips to the larynx providing information on the lengths, cross-sectional areas and volumes of the air spaces.
48464397|NCT05774522|OTHER|Upper airway ultrasound|Airway ultrasound is a non-invasive imaging allowing visualization and measurements of the tongue base and retrovascular fatty infiltration. Its main interest remains the evaluation of the tongue base which is clinically difficult.
48464398|NCT03367780|DEVICE|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
48464399|NCT02054754|DRUG|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
48464400|NCT02054754|DRUG|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
48464401|NCT02054754|DRUG|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
48464402|NCT02054754|DRUG|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
48464403|NCT02054754|DRUG|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
48464404|NCT02054754|DRUG|Placebo|
48464405|NCT00796796|DRUG|Temsirolimus|
48464406|NCT00796796|RADIATION|Radiation therapy|
48464407|NCT02759380|OTHER|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
48464408|NCT02015832|DEVICE|Coronary stent|
48464409|NCT02015832|RADIATION|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
48464410|NCT02015832|DEVICE|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
48464411|NCT02015832|DEVICE|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
48464412|NCT02015832|DEVICE|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
48464413|NCT01569113|DRUG|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
48464414|NCT01569113|DRUG|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
48464415|NCT00107016|DRUG|RAD001, Letrozole 2.5mg|
48464416|NCT00107016|DRUG|Letrozole 2.5mg|
48624377|NCT03881774|BIOLOGICAL|CAR-T cells|collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
48624378|NCT01592838|OTHER|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
48624379|NCT05730673|DRUG|700mg leronlimab weekly dose|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5
48624380|NCT05730673|DRUG|80mg Regorafenib at week 1|Regorafenib is a small-molecule multiple kinase inhibitor
48624381|NCT05730673|DRUG|120mg Regorafenib at week2|Regorafenib is a small-molecule multiple kinase inhibitor
48624382|NCT05730673|DRUG|160 mg Regorafenib at week 3|Regorafenib is a small-molecule multiple kinase inhibitor
48464417|NCT02070523|DRUG|VDCLD regimen|
48464418|NCT06467032|OTHER|superficial CO2 laser resurfacing|Application of the tested product and comparators on the laser treated side of the back
48464419|NCT06467032|OTHER|Laser untreated side|Application of the tested product and comparators on the laser untreated (control) side of the back
48464420|NCT00575601|DRUG|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
48099445|NCT02414230|DRUG|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
48099446|NCT03210727|BEHAVIORAL|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
48099447|NCT05700539|BEHAVIORAL|Internet-based cognitive behavioral therapy|A ten-week treatment based on cognitive behavioral therapy for ADHD, including two mandatory modules and at least four self-selected modules (out of ten available modules). The treatment consists of reading material and exercises to be completed each week.
48099448|NCT03332134|BEHAVIORAL|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
48099449|NCT04518930|OTHER|Peanuts or plain Greek yogurt|Two different types of dietary snacks
48099450|NCT03836417|DIAGNOSTIC_TEST|Microarray analysis|Microarray analysis to identify gene expression profiles that distinguish IPF from NSIP
48099451|NCT03742713|DRUG|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
48099452|NCT01636206|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year
48099453|NCT01636206|DRUG|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year
48099454|NCT00535067|BEHAVIORAL|Questionnaire|Questionnaires taking 60 minutes total to complete.
48464421|NCT00656539|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
48464422|NCT01072162|DRUG|Eltrombopag|25 mg tablet
48624383|NCT00038610|DRUG|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
48624384|NCT00038610|DRUG|Cyclophosphamide|300 mg/m\^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m\^2) for courses 1, 3, 5, 7.
47936284|NCT00849888|BIOLOGICAL|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects \>4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg \& serum free (SF) in other. After first 2 subjects \>10% naïve T cells, 3rd receives only SF thymus. After 3rd subject \>10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant \& thymus biopsy. Followed by immune evaluations.
48099455|NCT06264830|DEVICE|Alcon-NGENUITY®(NG)-system|During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation
48099456|NCT06264830|PROCEDURE|Standard cataract operation|Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
48281780|NCT05507424|PROCEDURE|Prone Positioning|Newborn will be prone position for 30-60 seconds during delayed umbilical cord clamping
48281781|NCT05507424|PROCEDURE|Supine Positioning|Newborn will be supine position for 30-60 seconds during delayed umbilical cord clamping
48464423|NCT01072162|DRUG|Eltrombopag|25 mg powder for oral suspension
48464424|NCT01652508|OTHER|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
48464425|NCT01652508|BEHAVIORAL|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
48464426|NCT00382187|BIOLOGICAL|MF59 adjuvanted H5N1 influenza vaccine|"* MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1"
48464427|NCT03920280|DEVICE|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
48464428|NCT03920280|DEVICE|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
48464429|NCT03920280|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
48624385|NCT00038610|DRUG|Doxorubicin|50 mg/m\^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
48624386|NCT00038610|DRUG|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
48099457|NCT02582411|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
48106917|NCT03342872|BEHAVIORAL|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
48281782|NCT03702725|DRUG|Ibrutinib|Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
48281783|NCT03702725|DRUG|Lenalidomide|Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
48464430|NCT05698316|DIAGNOSTIC_TEST|Collection of both retrospective and prospective data collection in 3 visits.|3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
48464431|NCT02340780|DRUG|Buparlisib|
48464432|NCT01847950|DIETARY_SUPPLEMENT|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
48464433|NCT01847950|DIETARY_SUPPLEMENT|Maltodextrin|
48464434|NCT05852873|DRUG|Nirmatrelvir/ritonavir|Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
48464435|NCT05852873|DRUG|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
48464436|NCT01513395|BEHAVIORAL|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
48464437|NCT02587143|DRUG|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
48464438|NCT02587143|DRUG|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
48464439|NCT06020040|DEVICE|Heterograft|Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
48464440|NCT01969760|BEHAVIORAL|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
48464441|NCT04013750|OTHER|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
48464442|NCT03292705|BEHAVIORAL|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
48464443|NCT03292705|BEHAVIORAL|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
48464444|NCT01828437|DRUG|Pyridoxine plus prednisolone|
48464445|NCT01828437|DRUG|Prednisolone|
48464446|NCT01909713|DRUG|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
48464447|NCT05171660|DRUG|Sintilimab Injection|Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses
48464448|NCT05171660|DRUG|Control Test|XELOX + Bevacizumab
48624387|NCT00038610|DRUG|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
48099458|NCT02582411|DEVICE|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
48099459|NCT03881657|BEHAVIORAL|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
48464449|NCT00547625|DRUG|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
48464450|NCT00547625|DRUG|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
48464451|NCT00268762|DRUG|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
48464452|NCT01471951|OTHER|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
48464453|NCT06291454|DIAGNOSTIC_TEST|Routine periodontal examination|In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
48464454|NCT00062296|BIOLOGICAL|rituximab|
48464455|NCT00062296|DRUG|epirubicin hydrochloride|
48464456|NCT00296530|DRUG|fluticasone propionate/salmeterol|
48464457|NCT00296530|DRUG|fluticasone propionate|
48281784|NCT03702725|DRUG|Dexamethasone|Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
48464458|NCT00296530|DRUG|montelukast|
47936285|NCT00849888|OTHER|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg \& serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, \>10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject \>10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy \& skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
47936286|NCT04672681|BEHAVIORAL|Play-based physical activity intervention|The intervention group will participate in a six-month play-based physical activity intervention starting from their initiated treatment. The intervention combines hospital and home-based physical activity. Three days a week, there will be 45 minutes of group-based physical activity at the hospital during admissions or appointments at the outpatient clinic, supervised by an exercise professional or pediatric physiotherapist. Children who are isolated during treatment are offered supervised individual 45 min. training sessions 3 times a week as a substitute. During the other four days a week, or on days where the family is at home, the parents administer the play-based physical activity. At inclusion, the parents receive education and supervision on conducting play-based physical activity with their child in the hospital room or at home. They will receive inspiration material containing numerous different plays, games, and activities in different intensities.
47936287|NCT04198818|DRUG|HH2710|HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
48464459|NCT00686764|OTHER|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
48099460|NCT03881657|BEHAVIORAL|Usual Care|Behavioral health services without primary care or integrated care services
48281785|NCT04859946|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
48281786|NCT04859946|DRUG|Busulfan|Given IV
48281787|NCT04859946|DRUG|Cyclophosphamide|Given IV
48281788|NCT04859946|DRUG|Fludarabine|Given IV
48281789|NCT04859946|DRUG|Itacitinib|Given PO
48281790|NCT04859946|DRUG|Tacrolimus|Given IV or PO
48281791|NCT04859946|DRUG|Thiotepa|Given IV
48281792|NCT05832307|OTHER|Existing Influenza Vaccination Practices|Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
48464460|NCT01507207|PROCEDURE|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
48464461|NCT04203823|DEVICE|Cloud-based Digital Twin and Meal Prediction algorithms|Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
48099461|NCT03646669|BEHAVIORAL|PEF Feedback|Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
48099462|NCT03646669|BEHAVIORAL|Asthma education|General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
48099463|NCT00284401|PROCEDURE|Evaluation of the placement of the Delta prosthesis|
48099464|NCT03877796|DEVICE|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
48099465|NCT04122807|PROCEDURE|Cardiac catheter ablation|Cryoablation
48464462|NCT00905008|PROCEDURE|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis \<30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
48464463|NCT00905008|DEVICE|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
48464464|NCT05909046|DIAGNOSTIC_TEST|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
48464465|NCT05909046|DIAGNOSTIC_TEST|Standard of care 4-12 week postpartum OGTT|Standard of care is 4-12 week outpatient postpartum OGTT
48464466|NCT00376740|DRUG|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
48464467|NCT02293616|DIETARY_SUPPLEMENT|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
48464468|NCT02293616|DIETARY_SUPPLEMENT|Placebo|
48464469|NCT06176885|DRUG|Camrelizumab|Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
48464470|NCT00193323|DRUG|Docetaxel|
48464471|NCT00193323|DRUG|Gemcitabine|
48464472|NCT00404053|DRUG|Clopidogrel|
48099474|NCT03105128|DRUG|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
48281793|NCT05832307|OTHER|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
48281794|NCT02176486|DRUG|Ixazomib|Ixazomib capsules.
48281795|NCT02176486|DRUG|Placebo|Ixazomib placebo-matching capsules.
48464473|NCT00951535|OTHER|questionnaire administration|
48099475|NCT03105128|DRUG|risankizumab IV|Risankizumab administered by intravenous infusion
48099476|NCT03105128|DRUG|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
48099477|NCT06629792|OTHER|Gentle Cleanser|The cleanser was instructed to be used twice daily over the course of 12 weeks
48099478|NCT06629792|OTHER|Facial Moisturizer|The Moisturizer was instructed to be applied to the global face twice daily over the course of 12 weeks.
48281799|NCT05648474|DIAGNOSTIC_TEST|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
48464474|NCT00951535|PROCEDURE|quality-of-life assessment|
48464475|NCT00951535|RADIATION|image-guided radiation therapy|
48099479|NCT06629792|OTHER|sunscreen SPF 30|The Sunscreen was instructed to be applied once daily in the morning, with re-application with extended sun exposure per FDA guidelines over the course of 12 weeks.
48281800|NCT04180605|OTHER|Additional support for preoperative planning of LAA closure procedures|"The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm."
48281801|NCT04180605|PROCEDURE|Left atrial appendage closure|Transcatheter device insertion to exclude the LAA from the cardiac circulation
48281802|NCT00157300|DRUG|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
48464476|NCT00951535|RADIATION|intensity-modulated radiation therapy|
48464477|NCT00951535|RADIATION|radiation therapy treatment planning/simulation|
48464478|NCT06195865|PROCEDURE|DIEP-flap|Breast reconstruction with a deep inferior epigastric perforator flap
48464479|NCT06195865|PROCEDURE|Implant|Breast reconstruction with an implant-based technique
48464480|NCT01015963|OTHER|laboratory biomarker analysis|Perform DNA sample analysis
48624388|NCT00038610|DRUG|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
48464481|NCT04517526|DRUG|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
48464482|NCT01239498|PROCEDURE|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%"
48099480|NCT03064074|DRUG|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
48281803|NCT01014884|OTHER|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
48281804|NCT01014884|OTHER|Multidisciplinary team bimonthly visits either in person or via telephone.|
48281805|NCT01014884|OTHER|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
48464483|NCT01239498|PROCEDURE|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
48464484|NCT06064149|BEHAVIORAL|CARE-PC Web-Based Application|The CARE-PC app is a pragmatic, patient-oriented, web-based application that enables the education of patients regarding cardiovascular (CV) risks and collects CV and prostate cancer-related risk variables and CV care access data from prostate cancer patients receiving ADT.
48464485|NCT05212987|DRUG|FCN-098|FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
48464486|NCT05924880|DRUG|durvalumab|Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.
48281806|NCT00528229|RADIATION|Computer Tomography|
48281807|NCT06477042|OTHER|Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score|Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.
48464487|NCT04492696|OTHER|Education|Education
48464488|NCT03135340|PROCEDURE|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
48281808|NCT06618313|DRUG|JCXH-213,an mRNA-LNP based in vivo CAR therapy|JCXH-213 infusion
48464489|NCT03135340|PROCEDURE|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
48464490|NCT03135340|DRUG|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
48464491|NCT03135340|DRUG|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
48464492|NCT03313713|DIETARY_SUPPLEMENT|Beta-glucans|Placebo consumption at breakfast (3 g per day)
48464493|NCT03313713|DIETARY_SUPPLEMENT|Placebo|Placebo consumption at breakfast (3 g per day)
47936288|NCT01221454|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
47936289|NCT01221454|DRUG|Conserved therapy|Oral or intravenous administration
48099481|NCT02419521|DEVICE|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
48099482|NCT04876781|DRUG|Tofacitinib XR|Tofacitinib XR 11mg
48099483|NCT00436137|BEHAVIORAL|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
48099484|NCT02197871|DIETARY_SUPPLEMENT|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
48281809|NCT06475404|BIOLOGICAL|verenafusp alfa 6 mg/kg|Single intravenous administration of 6 mg/kg of verenafusp alfa
48281810|NCT06475404|BIOLOGICAL|verenafusp alfa 9 mg/kg|Single intravenous administration of 9 mg/kg of verenafusp alfa
48281811|NCT06475404|BIOLOGICAL|verenafusp alfa 12 mg/kg|Single intravenous administration of 12 mg/kg of verenafusp alfa
48464494|NCT02824510|OTHER|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
48464495|NCT02824510|OTHER|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
48464496|NCT02824510|DRUG|Insulin aspart, glargine and detemir|
48624389|NCT00038610|DRUG|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
48624390|NCT00038610|DRUG|Mesna|600 mg/m\^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
48464497|NCT02986256|BEHAVIORAL|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
48624391|NCT00038610|DRUG|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
48624392|NCT02451475|DRUG|Amitriptyline|Amitriptyline 25 mg/day
48464498|NCT02986256|BEHAVIORAL|Visit at home|Home visit by the referring nurse every 15 days
48464499|NCT03467737|OTHER|Normal sorghum porridge, algal starch|Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
48464500|NCT03467737|OTHER|Normal sorghum porridge, algal dextrins|Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
48464501|NCT03467737|OTHER|Normal sorghum porridge, labeled flour|Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
48099485|NCT04018417|DRUG|Amphotericin B|Drug concentration: 0.255 μg/mL
48464502|NCT03467737|OTHER|Modified sorghum porridge, labeled flour|Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
48464503|NCT03467737|OTHER|Thinned sorghum porridge, labeled flour|Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
48464504|NCT03467737|OTHER|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
48464505|NCT04224948|DEVICE|PET MRI scan|"Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy"
48624393|NCT02451475|DRUG|Venlafaxine|Venlafaxine 75 mg/day
48624394|NCT02451475|DRUG|Paroxetine|Paroxetine 25 mg/day
48624395|NCT02495675|DEVICE|High flow nasal cannulas|Comparison of different flow levels
48624396|NCT02495675|DEVICE|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
48624397|NCT02602327|DRUG|Tas-102|Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
48624398|NCT02602327|DEVICE|SIR-Sphere|20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
48624399|NCT05673850|DRUG|NET or NCT|In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
47936290|NCT05262231|BEHAVIORAL|Online Breastfeeding Education|Breastfeeding education will be announced with a poster on social media. At the same time, mothers will be informed about the training in the institution where the institution permission is obtained. Postpartum period 4-8. A single-blind randomization method will be used per week. Pre-test will be applied to the mothers in the experimental and control groups. After the pre-test, online breastfeeding training will be given to the experimental group. The training consists of a single session. It will take about 40-60 minutes. The content of the training includes the benefits of breastfeeding for the mother, baby and society, breast problems and solutions, causes and solutions of breast rejection, breastfeeding positions, etc. consists of topics. After the training experimental group, the post-test will be applied. At the same time, the post-test will be applied to the control group who did not receive the training.
47936291|NCT02700087|DRUG|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
47936292|NCT02700087|DRUG|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
47936293|NCT00810927|PROCEDURE|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
47936294|NCT00810927|PROCEDURE|Laser Doppler flowmetry|Measurement of choroidal blood flow
47936295|NCT00810927|PROCEDURE|Measurement of intraocular pressure|
47936296|NCT04519177|BEHAVIORAL|Sleep Health Education Program (SHEP)|Sleep Health Education Program (SHEP) including screening for common sleep disorders
47936297|NCT06200194|DEVICE|MiyoSmart Spectacles|No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.
47936298|NCT06200194|DRUG|0.01% atropine|daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.
47936299|NCT02273609|DRUG|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor."
47936300|NCT00378079|OTHER|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
48281812|NCT03865472|OTHER|Questionnaire Administration|Ancillary studies
48624400|NCT02891330|BEHAVIORAL|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
48624401|NCT05842291|DEVICE|Active rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
47936301|NCT00378079|DRUG|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
47936302|NCT00378079|DRUG|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
48281813|NCT03865472|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
48281814|NCT03865472|PROCEDURE|Sham Intervention|Undergo sham rTMS
48281815|NCT05138419|OTHER|"CKD What You Need To Know Workbook System"|139 page Workbook including CKD Action Plan, Web-Based Resources, Interactive CKD Patient education material
47936303|NCT06254196|PROCEDURE|Telenursing interventions for monitoring Supportive Care Needs|"Use of the Intelligence2health platform, data collection forms on Google Forms, and dedicated telephone line for telenursing remote nursing monitoring interventions.~Based on the data, nurses will be able to implement patient education interventions aimed at preventing and monitoring healthcare support needs related to treatment."
47936304|NCT02904447|OTHER|x-ray and pedobar foot pressure mapping|
47936305|NCT06392945|DEVICE|Cognitive Treadmill Walking Training with Rhythmic Auditory Cueing (CTW+RAC) group|Participants in the CTW+RAC group participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. To increase adaptability to rhythmic auditory cueing prior to cognitive treadmill walking training, participants are required to keep stepping on their feet while listening to the auditory cueing using a metronome program (Metronome APP) for 5 minutes of warm up. Then they start walking on a treadmill with a target speed and perform a cognitive task concurrently while listening rhythmic auditory cueing. According to previous research, the target treadmill speed at week 1, week 2, week 3, and week 4 is gradually increased from 90%, 100%, 110%, to 120% baseline walking speed of comfortable walking on the ground. The beat of rhythmic auditory cueing using the Metronome APP on the smartphone is set at 110% of baseline cadence of comfortable walking on the ground based on a previous study in individuals with stroke.
47936306|NCT06392945|DEVICE|Cognitive Treadmill Walking Training (CTW) group|Participants in the CTW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed and perform a cognitive task concurrently without rhythmic auditory cueing. Same cognitive training and target treadmill speed will be used as the CTW+RAC group during cognitive dual-task treadmill walking. Three cognitive training programs will be the verbal fluency, arithmetic, and visual distinguish tasks. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the 10 meters walk test at week 4.
47936307|NCT06392945|DEVICE|Treadmill Walking Training (TW)|Participants in the TW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed only, without concurrent performing a cognitive task and no listening rhythmic auditory cueing. Same target treadmill speed will be used as the other two groups during treadmill walking. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the ground.
47936308|NCT04086875|BEHAVIORAL|Focus Group|Participate in focus group
47936309|NCT04086875|OTHER|Text Message|Receive text messages
48099486|NCT05955599|OTHER|ACL Injury Prevention Training|Supervised ACL injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
48099487|NCT05955599|OTHER|Control - Shoulder Injury Prevention Training|Supervised shoulder injury prevention training twice a week (2 x 15 minutes) over an 8-week period.
48099488|NCT00109174|DEVICE|3T and 7T device|3T and 7T device
48099489|NCT00486733|DEVICE|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
48099490|NCT03426072|OTHER|modified IHI breakthrough series|"There are five main elements to the intervention:~1. Establishment of the team and set up~2. Establishing baseline performance and knowledge~3. Ongoing developmental support~4. Learning sessions (3)~5. Action periods (3)~6. The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
48464506|NCT06037564|DRUG|DOR/DTG/3TC|Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
47936310|NCT04086875|OTHER|Best Practice|Receive usual care
47936311|NCT04086875|OTHER|Questionnaire Administration|Ancillary studies
48464507|NCT02798406|BIOLOGICAL|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
48464508|NCT02798406|BIOLOGICAL|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
48099491|NCT03127709|BEHAVIORAL|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
48099492|NCT03127709|BEHAVIORAL|Brief Test of Attention|Assesses auditory working memory
48281816|NCT05138419|OTHER|CKD Action Plan|Goals based on international guidelines that can protect kidney function (1 knowledge and 10 action goals) Patient education material used separately for control arm.
48281817|NCT05138419|OTHER|CKD Web-based Resource List|CKD Patient education material used separately for control arm
48281818|NCT05138419|OTHER|Food Label reading exercise|CKD Patient education material used separately in all arms.
48281819|NCT04152759|DRUG|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
48464509|NCT04795245|DRUG|afatinib|afatinib
48624402|NCT05842291|DEVICE|Sham rTMS with short inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 20 min for 5 days, using sham stimulation coils that comprehensively mimic the active condition. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
48624403|NCT05842291|DEVICE|Active rTMS with long inter-session interval|Participants in this group will receive ten sessions per day of 1800 pulses per session, at an inter-session interval of 50 min for 5 days. The individualized target will be generated using the personalized Brain Functional Sectors (pBFS) method.
48624404|NCT02310347|DRUG|dronabinol|
48298825|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
48464510|NCT05590676|DRUG|Metformin Hydrochloride|"Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg."
48464512|NCT00051805|BEHAVIORAL|Promotion of adherence to ARV medications|
48624405|NCT02310347|DRUG|Placebo|
48624406|NCT05742295|DRUG|Vitamin K|Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
47936312|NCT03616171|BEHAVIORAL|SLEEP-Extend intervention|"1. One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~2. Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
47936313|NCT03616171|OTHER|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
48464513|NCT00645944|DRUG|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
48464514|NCT00645944|DRUG|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
48464515|NCT03161236|OTHER|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
48464516|NCT03161236|OTHER|non exercise program|continue usual lifestyle
48464517|NCT05687448|DRUG|Apixaban 5 MG Oral Tablet|Patients treated with apixaban 5 mg twice daily (BID)
48464518|NCT05687448|DRUG|warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)|Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
48464519|NCT05589636|DIETARY_SUPPLEMENT|Bergamot Juice|Bergamot Juice (35% in water)
48464520|NCT01525628|DRUG|midazolam|CYP3A probe drug
48464521|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
48464522|NCT01525628|DRUG|tenofovir|nucleoside analogue
48464523|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
48464524|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
48464525|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
47936314|NCT04728672|OTHER|Kinesio Tape|Kinesio Tape
47936315|NCT04728672|OTHER|Micropore Tape|Micropore Tape
47936316|NCT03413943|OTHER|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
47936317|NCT04297657|OTHER|Counselling|o An appointment was made with the women in the experimental group at a time when they were available and a suitable environment was arranged in the hospital. The counselling programme of the experimental group was conducted in four sessions one week apart. In addition, each woman in the experimental group was given a counselling booklet and compact disc. The interviews lasted between 15- 45 minutes. The topics of interest among women were noted in the interviews and after the information on the subject was received, feedback was given to the relevant woman through a phone call.
47936318|NCT00307879|DRUG|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
48464526|NCT01525628|DRUG|midazolam|CYP3A probe drug
48464527|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
48464528|NCT01525628|DRUG|pegylated interferon|HCV treatment
48464529|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
48464530|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
48464531|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
48464532|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
48464533|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
48624407|NCT01246323|PROCEDURE|Spinal anesthesia with Fentanyl+ Morphine|Fentanyl 15 microgram Morphine 0.1-0.5 mg
48624408|NCT02984345|OTHER|Mycoprotein beverage|Mycoprotein protein beverage
48624409|NCT02984345|OTHER|Milk protein beverage|Milk protein beverage
48624410|NCT00189384|DRUG|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
48099493|NCT03127709|BEHAVIORAL|Symbol Span|Assesses visual working memory
48281820|NCT03754985|DEVICE|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
48281821|NCT04387292|PROCEDURE|Ophthalmologic exam|"* Visual acuity (ETDRS exam)~* Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~* Lipiview~* Eye pressure measurement (air tonometer)~* Wide field retinophotography~* Multicolor and auto-fluorescence retinophotography~* Indocyanine green retinal angiography~* Optical coherence tomography (OCT) B posterior pole scan~* OCT Angiography (OCT-A) of the optic nerve and posterior pole~* Adaptive optics~* Visual field (Humphrey)"
48281822|NCT01009294|DRUG|Ataluren|Oral powder
48281823|NCT01009294|DRUG|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
48281824|NCT05817045|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
48281825|NCT05817045|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
48281826|NCT05984927|GENETIC|NG101 AAV gene therapy|Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
48281827|NCT03818269|PROCEDURE|Subcutaneous pressure measurement|Subcutaneous interstitial measurement at D1 and D2
48281828|NCT03492164|DRUG|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
48281829|NCT01088425|OTHER|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
48281830|NCT01178021|DRUG|Chloroquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2
48464534|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
48464535|NCT01525628|DRUG|ribavirin|HCV treatment
48464536|NCT01525628|DRUG|ribavirin|HCV treatment
48464537|NCT01525628|DRUG|ribavirin|HCV treatment
48464538|NCT01525628|DRUG|pegylated interferon|HCV treatment
47936319|NCT00307879|PROCEDURE|collection of mobilized peripheral blood stem cells|
47936320|NCT00307879|PROCEDURE|Intracoronary infusion of mobilized cells|
48464539|NCT01525628|DRUG|ribavirin|HCV treatment
48464540|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
48464541|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
48099494|NCT03127709|BEHAVIORAL|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
48099495|NCT03127709|BEHAVIORAL|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
48464542|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
48099496|NCT03127709|BEHAVIORAL|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
47936321|NCT02779387|DRUG|Goserelin Acetate|
48099497|NCT03127709|BEHAVIORAL|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
48099498|NCT03127709|BEHAVIORAL|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
48464543|NCT01525628|DRUG|midazolam|CYP3A probe drug
48464544|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
48464545|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
48099499|NCT03127709|DIAGNOSTIC_TEST|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
48464546|NCT01525628|DRUG|ribavirin|HCV treatment
48478866|NCT03474029|DRUG|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
48624411|NCT01603914|DEVICE|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
48624412|NCT05136638|BEHAVIORAL|dCBTi|The dCBTi adopts a multi-module approach, consisted of 6 weekly modules including psychoeducational on sleep, insomnia, sleep hygiene, sleep restriction and prescription, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep.
48624413|NCT05136638|BEHAVIORAL|Virtual coaching|A virtual coach will be added to the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
48624414|NCT05136638|BEHAVIORAL|Non-therapist coaching|A research intern will answer questions and address concerns raised by the participant at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
48624415|NCT05136638|BEHAVIORAL|Therapist coaching|A clinical psychology trainee will provide therapeutic support to enhance the use and adherence to CBTi treatment strategies at the end of modules 1, 3, and 6 by phone. The contact time will be within 30 minutes on each occasion.
48624416|NCT05136638|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
48624417|NCT05227235|OTHER|3D Telemedicine|Clinical consultation with patient performed with 3D Telemedicine
48624418|NCT05227235|OTHER|2D Telemedicine|Clinical consultation with patient performed with 2D Telemedicine as standard of care
48624419|NCT00976898|RADIATION|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
48624420|NCT00500890|DRUG|Carboplatin|350 mg/m\^2 by vein, Over 2 Hours x 2 Days
48624421|NCT00500890|DRUG|Cyclophosphamide|1 g/m\^2 by vein, Over 1 Hour x 2 Days
48624422|NCT00500890|DRUG|Etoposide|100 mg/m\^2 by vein, Over 1 Hour x 5 Days
48624423|NCT00500890|DRUG|Vincristine|1.5 mg/m\^2 (by vein)IV Push Over 15 Minutes On Day 5
48624424|NCT00500890|RADIATION|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
48624425|NCT00877864|BEHAVIORAL|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
48624426|NCT00877864|BEHAVIORAL|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
47936322|NCT06051708|OTHER|standard AKI care bundle|AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.
47936323|NCT06051708|OTHER|standard care for hospitalized patients|this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
47936324|NCT03579654|BIOLOGICAL|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
48281831|NCT01178021|DRUG|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
48624427|NCT00877864|BEHAVIORAL|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
48624428|NCT00877864|BEHAVIORAL|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
48624429|NCT00877864|BEHAVIORAL|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
48624430|NCT00877864|BEHAVIORAL|Control|No exercise program provided by the study
48624431|NCT02302456|DRUG|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
48624432|NCT02302456|DRUG|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
48624433|NCT00312611|DEVICE|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
48281832|NCT05881993|DRUG|CBP-4888|siRNA therapeutic
48281833|NCT05881993|OTHER|Placebo|Normal Saline
48281834|NCT06060301|DRUG|sulfasalazine 500 MG|The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
48281835|NCT06060301|DRUG|corticosteroids|The patients will use topical corticosteroids 4 times per day.
48624434|NCT00992836|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
48624435|NCT04046653|DIETARY_SUPPLEMENT|Allin|Dietary supplement
48624436|NCT04046653|DIETARY_SUPPLEMENT|Sulforaphane|Dietary supplement
47936325|NCT00251160|PROCEDURE|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
47936326|NCT00251160|PROCEDURE|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
48624437|NCT04046653|DIETARY_SUPPLEMENT|Placebo|Dietary supplement
48624438|NCT01460472|BIOLOGICAL|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
47936327|NCT04148872|OTHER|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
47936328|NCT04148872|DRUG|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
47936329|NCT04148872|OTHER|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
47936330|NCT06516367|OTHER|Ain Shams University Screening Tool for Malnutrition, Sarcopenia, and Cachexia (ASUST-MSC)|25 items dichotomous questionnaire
48281836|NCT01978561|BIOLOGICAL|Post dosing with NT100|
48624439|NCT01460472|OTHER|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
48624440|NCT05981105|DEVICE|ambIT pump with catheter|0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.
48624441|NCT05981105|DEVICE|ambIT pump with sham catheter|sham catheter with no infusion
48624442|NCT00081458|DRUG|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
48624443|NCT00081458|DRUG|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
47936331|NCT04690205|OTHER|End of Life (EOL) Care at at Home|Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
48281837|NCT01978561|OTHER|Post dosing with Placebo|
48281838|NCT05220150|DEVICE|FFC-MRI scan|Undergo one FFC-MRI scan.
48281839|NCT04681092|BIOLOGICAL|AKS-452|s.c. or i.m. vaccination
48281840|NCT02284724|PROCEDURE|Dry Needling|
48624444|NCT00081458|DRUG|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
48624445|NCT06152354|DEVICE|rotary system|crown down technique using Kedo-SG file rotary system using endodontic motor
48624446|NCT06152354|DEVICE|Manual files|instrumentation were done by step back technique using K- file (Mani ) from size 15 to size 35 in quarter pull turn motion apically
48624447|NCT01143012|OTHER|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
48624448|NCT01143012|OTHER|Control group|The control group will not attend the group eczema education session.
48624449|NCT04370600|DRUG|beta hydroxybutyrate (BHB) ester|Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)
48624450|NCT04370600|DRUG|Placebo|Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
48624451|NCT01745510|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
48624452|NCT01745510|DIETARY_SUPPLEMENT|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
48624453|NCT04548128|DEVICE|HeartMate 3 Left Ventricular Assist System (HM3 LVAS)|This clinical trial investigates implant of the HM3 LVAS by techniques other than full median sternotomy.
47936332|NCT04484168|PROCEDURE|Terminal Interruption of the Reflux Source|Foam Sclerotherapy of veins in the immediate vicinity of the venous ulcer
47936333|NCT04484168|PROCEDURE|Axial Ablation|Endovenous ablation of venous reflux in the main superficial veins of the leg
47936334|NCT06028100|PROCEDURE|sacral erector spinae plane block|espb from bilateral sacral level 2 with 20 ml %0,25 bupivacaine
47936335|NCT02800876|OTHER|CT-acquisition|
48281841|NCT02284724|PROCEDURE|Sham Needling|
48281842|NCT01330290|DRUG|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
48281843|NCT05498272|DRUG|Olaparib|300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)
48281844|NCT05498272|DRUG|LHRH agonist|Total duration of therapy will be for 180 days with use of agent as per institutional standards
48298826|NCT04818450|DRUG|Gabapentin|Gabapentin 100-300 mg is given to the intervention group
48099500|NCT03127709|DIAGNOSTIC_TEST|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
47936336|NCT01383668|DRUG|sirolimus|Given PO
48624454|NCT05665998|DEVICE|ARC-BSI Cervical system|Unilateral implantation of a 64 channel - ECoG array over the sensory motor cortex combined with an implantation of 32 channel spinal cord stimulation system over the cervical region. The system decodes the motor attempts of the participant and translates those intentions into modulation of electrical stimulation.
48624455|NCT04058405|BEHAVIORAL|Observational|Cross-sectional observations
48624456|NCT04597450|DRUG|Lu AG06466|Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
48624457|NCT04597450|DRUG|Placebo|Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
48624458|NCT00002265|DRUG|Zalcitabine|
48624459|NCT02405962|BEHAVIORAL|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). The goal of ACT is to enhance the psychological flexibility of the parents, enabling them to (1) become aware of their thoughts and feelings regarding their child's asthma and its management, (2) accept and adapt flexibly to challenging situations, and (3) take actions to achieve valued goals in childhood asthma management.
48624460|NCT02405962|BEHAVIORAL|Control|One session of educational talk about pediatric asthma care, as the usual care. To ensure the equivalency of the assigned sessions between groups, after attending the talk in the first week, the parents in the Control group will receive three telephone calls, starting from the second week on a weekly basis. This arrangement can also minimize the interference of the usual care naturalistically available in the study setting.
48624461|NCT05855720|OTHER|FIT model project|Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
47936337|NCT01383668|DRUG|gold sodium thiomalate|Given IM
47936338|NCT01383668|OTHER|pharmacological study|Correlative studies
47936339|NCT01383668|GENETIC|RNA analysis|Correlative studies
48281845|NCT04224363|PROCEDURE|staining from cervical esophagus to esophagogastric junction|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
48624462|NCT03837834|OTHER|Functional Electrical Stimulation Leg Cycling Exercise|FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
47936340|NCT01383668|GENETIC|polymerase chain reaction|Correlative studies
48099501|NCT03127709|BEHAVIORAL|Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)|This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
48099502|NCT05664581|DEVICE|Rapid Acoustic Pulse|Subcutaneous Rapid Acoustic Pulse Treatments
48099503|NCT05290740|DRUG|Norepinephrine 5 mcg|norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
48099504|NCT05290740|DRUG|Norepinephrine 10 mcg|norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
48624463|NCT04898556|DRUG|Prasterone 6.5 MG|The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.
48624464|NCT04898556|OTHER|Placebo|Patients with a diagnosis of VVA who will not undergo treatment for 12 weeks.
48624465|NCT00178373|DRUG|Modafinil|
48624466|NCT00178373|DRUG|sugar pill|
48624467|NCT03033615|DEVICE|PixelShine|Machine learning algorithm
47936341|NCT06228911|DRUG|steroid (triamcinolone)|triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions
47936342|NCT03828370|BEHAVIORAL|B-SMART Intervention Group|The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
47936343|NCT03828370|BEHAVIORAL|Usual and Customary Information Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
48099505|NCT01549379|RADIATION|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
48099506|NCT01327469|DRUG|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
48099507|NCT01327469|DRUG|Albendazole 400mg|Albendazole 400mg
48099508|NCT01327469|DRUG|Mebendazole 500mg|Mebendazole 500mg
48624468|NCT03033615|DEVICE|Conventional processing|Iterative reconstruction software
48281846|NCT04224363|PROCEDURE|staining from esophagogastric junction to cervical esophagus|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
47936344|NCT01623986|DEVICE|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
47936345|NCT01623986|DEVICE|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
47936346|NCT01514370|DRUG|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
48099509|NCT01327469|DRUG|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
48099510|NCT01327469|DRUG|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
48099511|NCT00415675|PROCEDURE|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
48099512|NCT01939158|BIOLOGICAL|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
48099513|NCT01939158|BIOLOGICAL|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
48099514|NCT04411940|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
48624469|NCT06490315|BEHAVIORAL|OkeyMind intervention|The intervention group will receive a one-month mobile psychoeducation program (OkeyMind), which includes both psychoeducation and meditation components, with all content fully automated.
48624470|NCT06490315|BEHAVIORAL|Wait-list control|Participants in the waiting list control group will withhold access to the OkeyMind intervention until after the 3-month follow-up assessment.
48624471|NCT03731143|PROCEDURE|insertion of self retaining bicanalicular stent|"The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti"
47936347|NCT01514370|DRUG|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
48099515|NCT04411940|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
48099516|NCT01696721|OTHER|No intervention|
48099517|NCT05711498|OTHER|Transcutaneous spinal direct current stimulation (tsDCS)|tsDCS will be carried out using a direct current stimulator (DC-Stimulator Plus, neuroConn, Ilmenau, Germany), with one electrode placed above the thoracic spinal cord and the other electrode placed on the right shoulder. We will employ rectangular electrodes of 7 x 5 cm size (neuroConn, Ilmenau, Germany) covered by electrode paste (Ten20 Conductive Paste, Weaver and Company, Aurora, USA). Stimulation will consist of the following phases: a fade-in period of 15 seconds, a plateau period of 20 minutes (with stimulation at 2.5mA either anodally or cathodally) and a fade-out period of 15 seconds. Sham stimulation will follow the anodal montage with 15-second fade-in and fade-out periods, but only 45 seconds of plateau stimulation at 2.5 mA. Such a combination of stimulation and electrodes results in a current density of 0.071mA/cm2, well below thermal and histological limits for current density.
48099518|NCT05803967|BEHAVIORAL|Baduanjin exercising|baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
48099519|NCT03681691|DRUG|Estradiol patch|transdermal 17β-estradiol patch
48099520|NCT04037735|DEVICE|ATTUNE S+ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
48099521|NCT04037735|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
48099522|NCT05186545|DRUG|surufatinib + fulvestrant + chidamide|surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
47936348|NCT01514370|DRUG|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
47936349|NCT04373668|BEHAVIORAL|Hypnotic Medication Review|A training programme focused providing guidance on the review and withdrawal process of hypnotic drugs.
47936350|NCT04373668|BEHAVIORAL|Structured Sleep Hygiene|Training module on the principle of good sleep hygiene
48099523|NCT04858425|DRUG|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
47936351|NCT04373668|BEHAVIORAL|Night Time Care Activities Programme|Training and support package to assist in the development of a personalised night time care plan and support the implementation and dissemination of information within the care home environment
47936352|NCT05896579|BEHAVIORAL|Exercise training|Exercise training will include supervised high-intensity interval training for \~35 minutes 3x/week on an upright stationary bicycle and unsupervised continuous aerobic exercise for \~30 minutes 2x/week.
47936353|NCT05341388|DIAGNOSTIC_TEST|MOCA cognitive evaluation test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
48099524|NCT04858425|DRUG|Placebo|Matched placebo tablets 400 mg 3 times daily for 14 days
48099525|NCT00346931|PROCEDURE|Phacoemulsification, implantation of intraocular lens|
48099526|NCT00346931|PROCEDURE|Phacoemulsification, Implantation of IOL, trabeculotomy|
48099527|NCT01387256|DRUG|medical abortion|pregnancy termination with drugs
48099528|NCT05457491|BIOLOGICAL|Human platelet extract (cosmetic product)|A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.
48099529|NCT05457491|OTHER|Vanicream Gentle Facial Cleanser|A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks
47936354|NCT05341388|DIAGNOSTIC_TEST|BDNF levels|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
48281847|NCT05607134|OTHER|selected physical and occupational therapy program|The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
47936355|NCT05341388|OTHER|SF-36 test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
47936356|NCT05341388|DIAGNOSTIC_TEST|Geriatric depression test|Before starting their newly prescribed medication, we will apply MOCA and repeat it at the end of the trial.
47936357|NCT05313100|DRUG|sugammadex|At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
47936358|NCT02284971|BIOLOGICAL|CDX1127|
47936359|NCT02284971|RADIATION|SBRT|
47936360|NCT05805358|DRUG|Hyperpolarized 13C-Pyruvate injection|DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
47936361|NCT02197455|DRUG|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
47936362|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
47936363|NCT00206076|DRUG|mycophenolate mofetil|mycophenolate mofetil monotherapy
47936364|NCT03102840|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab will be performed in all participants
47936365|NCT03102840|DIAGNOSTIC_TEST|blood sampling|Blood sampling will be done by finger-prick in a sub-set of participants
47936366|NCT06361992|OTHER|Blue Cap Foam|Application regimen: Blue Cap foam 100 ml, Activated Piroctone Olamine (Foam, label 100 ml), Catalysis S.L. Madrid must be applied twice a day on all affected areas. The application is to be continued for 30 days, after which the patients stop using the foam until the final assessment at day 45.
47936367|NCT02764021|DIETARY_SUPPLEMENT|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
47936368|NCT02764021|DIETARY_SUPPLEMENT|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
47936369|NCT01609101|DEVICE|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
47936370|NCT01609101|DEVICE|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
47936371|NCT01609101|DEVICE|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
47936372|NCT01609101|DEVICE|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
47936373|NCT01609101|DEVICE|King Vision® videolaryngoscope|King Vision® videolaryngoscope
47936374|NCT01609101|DEVICE|Venner® videolaryngoscope|Venner® videolaryngoscope
47936375|NCT01609101|DEVICE|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
47936376|NCT00121797|PROCEDURE|urine culture|
47936377|NCT00121797|DRUG|antibiotics according to culture|
47936378|NCT01894815|DRUG|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
47936379|NCT01894815|DEVICE|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
47936380|NCT01894815|OTHER|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
47936381|NCT05853627|BEHAVIORAL|Memory reactivation procedures|In the Mismatch condition, a different, unexpected mismatch will be incorporated into the reactivation. In the Standard condition, the participant will read the narrative the same way each time.
48298827|NCT01969175|OTHER|Low-glycemic-load and milk-free diet|
47936382|NCT05853627|DRUG|Propranolol|Propranolol will be administered 60-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions.
48298828|NCT03255525|OTHER|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
47936383|NCT04533477|PROCEDURE|Reconstructing forked corpus spongiosum (FCS)|During the routine standardized surgery, the FCS should be cut off along both sides of the middle urethral plate before dissecting the glans wings and then dissected along the penile tunica albuginea closely from the near to the far side of the penis until the top of the penis head was reached. The corpus spongiosum on both sides will be reserved for the two wings of the glans. The two wings of the glans should be carefully expanded to at least the 3 o'clock and 9 o'clock positions of the penis. Some cases of small glans should be dissected to the 2 o'clock and 10 o'clock positions to close the two wings of the glans with no tension when performing glansplasty. Additionally, the original FCS on both sides should be combined at the coronal sulcus, thereby covering the surface of the new urethra.
47936384|NCT04533477|PROCEDURE|Routine standardized surgery|When the urethral plate can be preserved after degloving, the investigators chose the surgical method according to the width of the urethral plate. If the width of the urethral plate is ≥6 mm, tubularized incised plate (TIP) urethroplasty will be performed, whereas if the width of the urethral plate is \<6 mm, the onlay island flap (ONLAY) technique will be performed. When the urethral plate can not be preserved after degloving, transverse preputial island flap urethroplasty (Duckett) will be performed.
47936385|NCT04768985|DRUG|Treatment A: Acalabrutinib tablet|Participants will receive fixed single doses of acalabrutinib tablet in 2 treatment periods, under fasted conditions.
47936386|NCT04768985|DRUG|Treatment B: Acalabrutinib capsule|Participants will receive fixed single doses of acalabrutinib capsule in 2 treatment periods, under fasted conditions.
47936387|NCT04327960|DIAGNOSTIC_TEST|Cardiac troponin (cTn)|Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.
47936388|NCT01185431|DIETARY_SUPPLEMENT|Ficus carica (Fig paste)|Ficus carica paste 300g/day
47936389|NCT01185431|DIETARY_SUPPLEMENT|Placebo (Placebo paste)|Placebo composition 300g/day
47936390|NCT04307745|OTHER|Primary prevention|The primary prevention that the 4 groups put in place for the upper limp athletes
48298829|NCT03255525|OTHER|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
47936391|NCT05868889|DRUG|Trabectedin and PLD|The main treatment observed in this study is trabectedin in combination with PLD in elderly patients with platinum-sensitive relapsed ovarian cancer, according to the SmPC.
47936392|NCT05762770|PROCEDURE|PICSI|Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
47936393|NCT02017171|DRUG|Allopurinol|
47936394|NCT02017171|DRUG|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
47936395|NCT02548468|DRUG|Fludarabine|Given IV
47936396|NCT02548468|RADIATION|Total-Body Irradiation|Undergo TBI
47936397|NCT02548468|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
47936398|NCT02548468|DRUG|Cyclophosphamide|Given IV
47936399|NCT02548468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
47936400|NCT02548468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
47936401|NCT02548468|DRUG|Mycophenolate mofetil|Given IV
48099530|NCT05457491|OTHER|EltaMD UV Daily Broad-Spectrum SPF 40|A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.
48099531|NCT05457491|OTHER|EltaMD PM Therapy Facial Moisturizer|A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.
48099532|NCT05457491|OTHER|Vanicream Lite Lotion|Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.
48099533|NCT04378582|OTHER|risk factors|This is an observational study, so there are no interventions. Investigators will collect data about demographics, comorbidities, and other risk factors such as severity of disease at admission, need for advanced life support, need for invasive mechanical ventilation and ventilator parameters on day1 of mechanical ventilation or ICU admission as potentially association with survival
48099534|NCT04157712|DRUG|ALZ-801 or matching placebo|
48099535|NCT03737669|BIOLOGICAL|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
48099536|NCT03737669|BIOLOGICAL|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
48624472|NCT04543864|DEVICE|Electric intraoral welding device|welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally
48624473|NCT04543864|DEVICE|casting|casting the metal framework
48099537|NCT01286402|DRUG|Bupropion SR|"* 150mg, taken orally, taken daily for the 1st 3 days~* 300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
48099538|NCT01286402|OTHER|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
48099539|NCT06062017|DIETARY_SUPPLEMENT|Water and Potassium supplementation|All Participants will be given cases of water and instructed to drink at least an extra 1L per day. Additionally, participants will be given 2000 mg of potassium via potassium citrate powder.
48099540|NCT06504875|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
48099541|NCT06504875|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
48099542|NCT06504875|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
48099543|NCT06504875|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
47936402|NCT02548468|DRUG|Tacrolimus|Given IV
47936403|NCT05974501|DRUG|Dexamethasone|Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling
47936404|NCT05974501|DRUG|Acetaminophen|1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
47936405|NCT05974501|DRUG|Lyrica|Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively
47936406|NCT05974501|DRUG|Celebrex|200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively
47936407|NCT05974501|DRUG|Meloxicam|30mg administered via IV once postoperatively within 24 hours for pain and swelling
47936408|NCT05974501|DRUG|Oxycodone|5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively
47936409|NCT05974501|DRUG|Ropivacaine|20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
47936410|NCT05980793|PROCEDURE|PIP joint denervation|Surgical denervation of the PIP joint
47936411|NCT05980793|PROCEDURE|Patient education plus exercise|An education plus exercise program
47936412|NCT04895540|DIAGNOSTIC_TEST|ECG|All study subjects will undergo ECG recording.
48624474|NCT02789748|DEVICE|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
48624475|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
48624476|NCT00933933|DEVICE|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
48624477|NCT00461968|DRUG|Ezetimibe and Simvastatin|
48624478|NCT00876343|DRUG|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
48099544|NCT05233137|BEHAVIORAL|PA coaching|PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.
48298830|NCT03255525|OTHER|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
48464547|NCT01376596|BEHAVIORAL|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
48464548|NCT01376596|BEHAVIORAL|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
48464549|NCT02888743|BIOLOGICAL|Durvalumab|Given IV
48464550|NCT02888743|RADIATION|Radiation Therapy|Undergo radiation therapy
48464551|NCT02888743|BIOLOGICAL|Tremelimumab|Given IV
48624479|NCT00876343|DRUG|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
48624480|NCT00876343|DRUG|Placebo|administered orally once daily, 6 weeks
48464552|NCT06375915|RADIATION|radioembolization with Y-90|Radioembolization with Y-90 will be performed in nominal day 0
48464553|NCT06375915|DRUG|Durvalumab|Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
48464554|NCT06375915|DRUG|Cisplatin|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
48464555|NCT06375915|DRUG|Gemcitabine|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
48464556|NCT00526136|DRUG|Placebo|
48464557|NCT00526136|DRUG|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
48464558|NCT00869115|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
48464559|NCT00869115|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
48624481|NCT02983656|BIOLOGICAL|live attenuated varicella vaccine|
48624482|NCT05297760|BIOLOGICAL|Polvac Grass+Rye|Suspension of micro crystalline tyrosine with grass and rye pollen allergen
48624483|NCT05297760|DRUG|Saline 0.9%|Physiological saline solution for use as vehicle for the biological drug (Polvac Grass+Rye) or as placebo.
48624484|NCT01967953|PROCEDURE|EVLP Group|"EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy"
48464560|NCT00869115|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
48464561|NCT00869115|DRUG|Istaroxime|Placebo continuous i.v. infusion for 24 hours
48464562|NCT01145157|DEVICE|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
48464563|NCT01145157|DEVICE|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
48464564|NCT01145157|DEVICE|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
48464565|NCT05079230|DRUG|Magrolimab|Administered intravenously (IV)
48464566|NCT05079230|DRUG|Venetoclax|Tablets administered orally
48464567|NCT05079230|DRUG|Azacitidine|Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
48464568|NCT05079230|DRUG|Magrolimab Placebo|Administered intravenously (IV)
48464569|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
48464570|NCT00659815|DEVICE|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
48624485|NCT03139513|DRUG|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
48624486|NCT03139513|DRUG|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
48624487|NCT05759832|DEVICE|Modified HFNC oxygen therapy|In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.
48624488|NCT05759832|DEVICE|Face mask|In the face mask group, oxygen was delivered via a face mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen \> 90%.
48624489|NCT04959513|PROCEDURE|LPRF bone block|Guided bone regeneration using an L-PRF bone block (composite graft composed of a xenograft, a membrane from the patient's blood and a collagenous membrane) after a short healing period of 6 to 8 weeks after tooth extraction
48099545|NCT05233137|OTHER|Exercise training|"Each session will include at least the following components:~* Resistance training of the lower limbs: Exercises for 6 muscle groups using minimal (e.g. ankle weights or elastic resistance bands) or no (body weight) equipment are foreseen. Each exercise will be performed in 3 series of 8 repetitions.~* Functional training: Sit to stand exercise and stair climbing. During the first 2 weeks of the exercise training program, at least 3 strength exercises and 1 functional exercise will be performed each session.~Starting from the 3rd week of the exercise training program, whole body exercise training (interval training for walking, cycling, stair climbing and high knees) will be added. From this moment on, at least 1-2 whole body exercises and 2-3 strength and functional exercises will be performed during each physiotherapy session. By doing this, each session will consist of a minimum of 4 exercises in total."
48099546|NCT04692948|OTHER|Chimeric antigen receptor T cells (car-t)|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
48464571|NCT05327322|BEHAVIORAL|Glycemic load|Participants will be provided food to meet GL prescription for the duration of the trial.
48464572|NCT05327322|BEHAVIORAL|Calorie restriction|Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
48464573|NCT05327322|BEHAVIORAL|Behavioral support|All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
48464574|NCT05838716|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48099547|NCT06630754|OTHER|No Intervention: Observational Cohort|No intervention; observation cohort study
48624490|NCT02378181|BEHAVIORAL|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
48624491|NCT02378181|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
48624492|NCT02260622|DRUG|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
47936413|NCT04895540|DIAGNOSTIC_TEST|Echocardiography|All study subjects will undergo transthoracic echocardiography
47936414|NCT04895540|DIAGNOSTIC_TEST|Cardiac MRI|All ACM patients and SCD survivors will undergo cardiac MRI testing.
47936415|NCT04895540|DIAGNOSTIC_TEST|Ambulatory ECG recording|All ACM patients and SCD survivors will undergo 24-hour ambulatory ECG recording
47936416|NCT04895540|DIAGNOSTIC_TEST|Cardiac EP study|ACM patients and SCD survivors will undergo diagnostic cardiac Electrophysiology testing.
47936417|NCT04895540|GENETIC|All study subjects will undergo sample collection for genetic testing.|Blood samples and buccal swab will be collected from study subjects for genetic testing.
48464575|NCT05838716|DIETARY_SUPPLEMENT|D Vitamin|Given PO
48464576|NCT05838716|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
48464577|NCT05838716|DRUG|Placebo Administration|Given PO
48464578|NCT05838716|OTHER|Quality-of-Life Assessment|Ancillary studies
48464579|NCT05838716|OTHER|Questionnaire Administration|Ancillary studies
48464580|NCT03324217|OTHER|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
48464581|NCT02107469|DRUG|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
48464582|NCT02107469|DRUG|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
48464583|NCT02107469|DRUG|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
48464584|NCT02107469|DRUG|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
48464585|NCT02107469|OTHER|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
48464586|NCT02107469|OTHER|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
47936418|NCT06325930|DRUG|[14C]-HU6|\[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
47936419|NCT06331845|DRUG|Gemcitabine|1000 mg/m2 on Days 1 and 8
47936420|NCT06331845|DRUG|Cisplatin|a total of 80-100 mg/m2 for d1-3
47936421|NCT06331845|DRUG|Paclitaxel protein-bound|260 mg/m2 on Day 1
48099548|NCT06123988|BEHAVIORAL|Prolonged Overnight Fasting|"Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month.~Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions.~Participants will be provided with a notebook with information and support to encourage meeting the POF goals."
48099549|NCT06123988|BEHAVIORAL|Moderate-Intensity Exercise|"Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions.~Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise."
48624493|NCT02260622|DRUG|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
48624494|NCT00934882|DRUG|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
48624495|NCT00063622|DRUG|Pioglitazone|30 mg daily
48624496|NCT00063622|DIETARY_SUPPLEMENT|Vitamin E|800 IU daily
48624497|NCT00063622|DRUG|Matching placebo|Daily
48624498|NCT01860508|DRUG|pemetrexed /carboplatin|
48624499|NCT01044498|DRUG|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
47936422|NCT06331845|DRUG|Capecitabine|a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle
47936423|NCT06331845|DRUG|Tislelizumab|200 mg on Day 1
47936424|NCT02986880|DRUG|Botulinum toxin A|
48624500|NCT01044498|DRUG|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
47936425|NCT02986880|PROCEDURE|Placebo|Injection of sodium chloride (NaCl) 9/1000
48624501|NCT01595828|DRUG|Pitavastatin|
48624502|NCT03399084|DRUG|Ferric carboxymaltose|750 mg/15 mL
48624503|NCT01346683|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
48624504|NCT03419650|DRUG|ACTHar|Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
48624505|NCT01137760|DIETARY_SUPPLEMENT|Sucrose|5 g of sucrose daily for 8 weeks
48624506|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
48624507|NCT01137760|DIETARY_SUPPLEMENT|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
48624508|NCT03692806|DIETARY_SUPPLEMENT|Stablor|Stablor sachet
48624509|NCT03692806|DIETARY_SUPPLEMENT|placebo|placebo sachet
48624510|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
48624511|NCT00332397|DEVICE|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
48624512|NCT00332397|DEVICE|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
48624513|NCT03132389|OTHER|No intervention|All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
48624514|NCT03673358|BEHAVIORAL|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
47936426|NCT06268145|DRUG|ECC5004|A single dose tablet of 50 mg of the current tablet formulation (F1) or new tablet formulation (F2) administered orally.
47936427|NCT03787563|DRUG|Herbal Tea|All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
47936428|NCT03787563|DRUG|Placebo Tea|Similar looking inert placebo tea.
47936429|NCT05783882|DRUG|Prolgolimab|250 mg Q3W
47936430|NCT02895009|DEVICE|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
48624515|NCT04888104|PROCEDURE|Index or revision spine surgery for complex adult spinal deformity|Adult patients receiving minimum 5 level posterior spinal fusion with pedicle screw fixation supplemented at the proximal aspect of the construct with the VersaTie System.
47936431|NCT02895009|DEVICE|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
47936432|NCT00806507|PROCEDURE|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
47936433|NCT00806507|PROCEDURE|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
48624516|NCT02373072|DRUG|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
47936434|NCT00595777|BEHAVIORAL|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
47936435|NCT01744912|DRUG|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
47936436|NCT01744912|DRUG|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
48624517|NCT02373072|DRUG|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
47936437|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
48281848|NCT05607134|DEVICE|Radial Extracorporeal Shock Wave|The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
48624518|NCT02373072|DRUG|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
47936438|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
47936439|NCT00624702|DRUG|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
48099550|NCT06123988|BEHAVIORAL|General Health Education Sessions|Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
48099551|NCT05552547|DEVICE|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row at home.
48099552|NCT05552547|DEVICE|24-Hour Blood Pressure Machine|Participants will be asked to wear the machine for 24 hours.
48099553|NCT03640273|DRUG|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
48624519|NCT01618591|DRUG|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
48624520|NCT01618591|DRUG|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
48624521|NCT01618591|DRUG|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
48624522|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
48624523|NCT01618591|DRUG|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
48099554|NCT03640273|DRUG|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
48099555|NCT06631170|DRUG|Roflumilast Cream 0.15%|Roflumilast cream 0.15% is applied once daily for 4 weeks
48099556|NCT06631170|DRUG|Vehicle cream|Vehicle cream is applied once daily for 4 weeks
48624524|NCT06157567|DEVICE|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
48624525|NCT04415905|DRUG|Propofol|The participants in the group P are anesthetized with propofol
48624526|NCT04415905|DRUG|Sevoflurane|The participants in the group S are anesthetized with sevoflurane.
48624527|NCT02072044|DRUG|Anlotinib|Anlotinib p.o. qd
48624528|NCT02392910|DRUG|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
47936440|NCT00624702|DRUG|Placebo|
47936441|NCT03792425|PROCEDURE|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
48281849|NCT05607134|DEVICE|Peripheral magnetic stimulation|"The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity."
47936442|NCT04330820|DRUG|Venetoclax Oral Tablet|"This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3."
47936443|NCT03494348|DEVICE|Medial Congruent Polyethylene (MC)|One group receives the conventional CR surface and the other the new MC articular surface
48281850|NCT04919512|DRUG|TAR-200|TAR-200 will be administered.
48464587|NCT04358367|DRUG|Dexmedetomidine Injectable Product|Spinal anesthesia and intravenous dexmedetomidine (1μg/kg). The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
48464588|NCT04358367|DRUG|Saline|Spinal anesthesia and intravenous saline. The administrated drugs were slowly injected intravenously over 10 minutes then intrathecal block was achieved using 2-2.2 ml of hyperbaric bupivacaine (10 -12.5 mg) introduced at L3/4 or L4/5 interspace.
47936444|NCT02808572|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
47936445|NCT02808572|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
47936446|NCT02808572|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
47936447|NCT02514473|DRUG|VX-809|
48624529|NCT02392910|DRUG|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
47936448|NCT02514473|DRUG|Placebo|
47936449|NCT02514473|DRUG|VX-770|
47936450|NCT05438641|DRUG|BZDP-Sparing Protocol|BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA \> 15.
48464589|NCT02346149|OTHER|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
48464590|NCT03372317|DRUG|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
47936451|NCT05438641|DRUG|BZDP-Based Protocol|Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
47936452|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
47936453|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
47936454|NCT04143061|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine|Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
47936455|NCT04143061|BIOLOGICAL|Hepatitis A vaccine|Pharmaceutical form: Suspension for injection in prefilled syringe Route of administration: Intramuscular, 0.5 mL
47936456|NCT04143061|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine (MMR)|Pharmaceutical form: Lyophilized powder for injection Route of administration: Subcutaneous or Intramuscular, 0.5 mL
47936457|NCT04143061|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
48624530|NCT02615353|BEHAVIORAL|Intensive Lifestyle Intervention|6-months of lifestyle education
48624531|NCT02615353|OTHER|Usual Care Control|Medical visit and dietary counseling
47936458|NCT04143061|BIOLOGICAL|DTwP-HepB-Hib-IPV vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
47936459|NCT04143061|BIOLOGICAL|Varicella vaccine|"Pharmaceutical form: Sterile powder and diluent for injection in prefilled syringe Subcutaneous, 0.5 mL~Route of administration: Pharmaceutical form:"
47936460|NCT01425775|DRUG|vitamin D 25(OH)D|2000IU/day for 12 months
47936461|NCT01425775|OTHER|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
48099557|NCT05892913|DRUG|Slow dose preemptive Atropine|it will planned to administer 0.4 mg/4mL diluted atropine in 20 seconds(10mcg/kg), as a slow bolus as bradycardia would expected (10% reduction in peak heart rate after spinal anesthesia)
48281851|NCT04919512|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
48281852|NCT02160067|DRUG|Second generation BTDS patch|
48281853|NCT02160067|DRUG|First generation BuTrans patch|
48281854|NCT05280561|DIETARY_SUPPLEMENT|DHM|DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic
48281855|NCT05280561|DIETARY_SUPPLEMENT|Placebo|Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
48464591|NCT01447758|DRUG|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
48464592|NCT01447758|DRUG|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
48281856|NCT02626377|BEHAVIORAL|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
48464593|NCT02584166|BEHAVIORAL|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
48624532|NCT04163380|BEHAVIORAL|Resistance Training|Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
48624533|NCT05613868|DRUG|TPN-101|100 mg/ day up to 400mg/day of TPN-101
48624534|NCT01810952|DRUG|Glargine insulin|In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
48624535|NCT01810952|DRUG|Lispro insulin|In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
48624536|NCT01810952|DRUG|NPH Insulin|NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
47936462|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next|Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
47936463|NCT04510571|OTHER|Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files|Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
47936464|NCT05043285|BIOLOGICAL|SCTV01C|intramuscular injection
47936465|NCT05043285|OTHER|Placebo|Intramuscular injection
47936466|NCT03433027|DRUG|BB-401|BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
47936467|NCT04729478|DEVICE|Drug-induced sleep endoscopy|An intravenous bolus injection of midazolam 1.5 mg will be used to induce sleep. Maintenance of sedated sleep will be obtained by a target-controlled infusion of propofol (2.0-3.0 µg/mL).
48281857|NCT02626377|OTHER|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
48464594|NCT05692115|DIAGNOSTIC_TEST|stress ECG|stress ECG to patients suspected to be ischemic patients .
48624537|NCT03018730|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
48624538|NCT00775034|DRUG|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
48624539|NCT00775034|PROCEDURE|Drainage|Mesh repair for open incisional hernia repair with drainage
48624540|NCT01655160|BEHAVIORAL|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
48624541|NCT01655160|BEHAVIORAL|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
48624542|NCT01655160|BEHAVIORAL|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
48624543|NCT01655160|BEHAVIORAL|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
48624544|NCT03228576|COMBINATION_PRODUCT|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
48624545|NCT02639533|DRUG|Pregabalin|Pregabalin 150 mg PO, single dose.
48624546|NCT02639533|OTHER|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
48624547|NCT06134700|PROCEDURE|Laparoscopic Surgery|"* Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~* Port Placement~* Reflection of colon~* Isolation of ureterogonadal packet~* Upper pole dissection~* Hilar dissection~* Vessel clipping and division~* Dissection of kidney~* Delivery through either Pfannenstiel or iliac fossa incision"
48624548|NCT02667834|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
47936468|NCT04729478|DEVICE|Natural sleep endoscopy|Endoscopy during natural sleep.
47936469|NCT01739855|DRUG|Calciferol, calcium carbonate|
47936470|NCT00625482|BIOLOGICAL|OPV|
47936471|NCT00625482|BIOLOGICAL|OPV plus BCG|
47936472|NCT00625482|BIOLOGICAL|OPV|
47936473|NCT00625482|BIOLOGICAL|OPV plus BCG|
47936474|NCT05344638|DRUG|AGS (Experimental)|tid
47936475|NCT05344638|DRUG|AGU (Active Comparator)|tid
48281858|NCT01938183|PROCEDURE|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
48281859|NCT01938183|DRUG|Metronidazole tablet|750 mg metronidazole tablets
48281860|NCT01938183|DRUG|placebo gel|semi-solid suspension containing carbopol
48281861|NCT01938183|DRUG|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
48624549|NCT02667834|BEHAVIORAL|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
48624550|NCT02868528|GENETIC|chromosome screening with NGS technology|
48624551|NCT03611660|BEHAVIORAL|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
48624552|NCT03611660|BEHAVIORAL|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
48624553|NCT00895713|DRUG|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
48624554|NCT02520973|OTHER|Sputum sample|
48624555|NCT03785821|DIETARY_SUPPLEMENT|BMSO|BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.
48624556|NCT03785821|DIETARY_SUPPLEMENT|OO|Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
48624557|NCT01996995|DEVICE|Nd:YAG laser pulse therapy|
47936476|NCT06427915|OTHER|OLIPOP prebiotic soda|12oz serving containing Carbonated Water, OLISMART(TM) (Cassava Root Fiber, Acacia Fiber, Guar Fiber, Nopal Cactus\*, Marshmallow Root\*, Calendula Flower\*, Kudzu Root\*), Cassava Root Syrup, Apple Juice Concentrate, Lime Juice, Natural Cola Flavor, Alpinia Galanga Root\*, Stevia Leaf\*, Himalayan Pink Salt, Green Tea Caffeine\*, Natural Caramel Flavor, Natural Vanilla Flavor, Cinnamon\* (\*Extract)
48464595|NCT03242980|BEHAVIORAL|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
48624558|NCT01996995|DEVICE|Sham procedure|Sham procedure
48624559|NCT00574652|DRUG|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
48624560|NCT00113685|DRUG|Hypertonic Saline-Dextran Solution|
48624561|NCT00113685|DRUG|Lactated Ringer's Solution|
48624562|NCT03608969|OTHER|NOT-S|Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
48624563|NCT04648176|DEVICE|Moses technology|Using Holmium laser with Moses technology or conventional one
48624564|NCT05314725|DRUG|SGLT2 inhibitor|10 days of SGLT2 inhibitor after surgery
48624565|NCT05314725|DRUG|Placebo|10 days of placebo after surgery
48624566|NCT04837170|DRUG|Conventional therapy + S (+)-Ketamine|Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.
48624567|NCT04837170|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
48624568|NCT02468453|DEVICE|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
48624569|NCT03632330|DRUG|Dexmedetomidine|Dexmedetomidine group
48624570|NCT03632330|DRUG|Midazolam|Midazolam group
48624571|NCT03632330|DRUG|Propofol|Propofol group
47936477|NCT06427915|OTHER|Traditional sugar-sweetened cola|12oz serving containing carbonated water, high fructose corn syrup, caramel color, phosphoric acid, natural flavors, caffeine
47936478|NCT04440371|COMBINATION_PRODUCT|Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly|Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
47936479|NCT04440371|COMBINATION_PRODUCT|Calcipotriol/Betamethasone ointment plus NBUVB|Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
47936480|NCT06386731|OTHER|Intermittent Phototherapy|2-hour phototherapy application in the intervention group
48624572|NCT03632330|DRUG|Midazolam/Propofol|Midazolam/Propofol group
47936481|NCT04993222|DRUG|Amphotericin B liposome for injection|IV infusion
47936482|NCT04993222|DRUG|AmBisome®|IV infusion
47936483|NCT04590079|DEVICE|Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation|Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
47936484|NCT04934280|DIAGNOSTIC_TEST|sonohysterography|saline infusion transvaginally followed by 2D transvaginal ultrasound imaging
48099558|NCT05892913|DRUG|Ephedrine|For sympathetic blockade (SBP\<90) developed in patients in the ephedrine group, a bolus dose of 5 mg/mL ephedrine was used and repeated if necessary.
48099559|NCT04088188|DRUG|Cisplatin|Given IV
48099560|NCT04088188|DRUG|Gemcitabine|Given IV
48624573|NCT01124539|DRUG|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
47936485|NCT05551637|DIETARY_SUPPLEMENT|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
48099561|NCT04088188|DRUG|Ivosidenib|Given PO
48099562|NCT04088188|DRUG|Pemigatinib|Given PO
48099563|NCT03098030|BIOLOGICAL|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
48099564|NCT03098030|DRUG|Irinotecan|Irinotecan injection, IV infusion
48099565|NCT03098030|DRUG|Topotecan|Topotecan for injection
48099566|NCT06627907|OTHER|fluid challenge|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
48099567|NCT06627907|DIAGNOSTIC_TEST|end-expiratory occlusion test|"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M"
48099568|NCT05365139|OTHER|Structured clinical diagnostic interview for PGD (PGD-I)|"Participants were administered the Structured clinical diagnostic interview for PGD (PGD-I) and screened with clinical interviews for PTSD, anxiety and depression. Whether the Aarhus PGD-scale should be answered before or after the interview was randomized.~The PGD-I and self-report scale were readministered to 50 participants 7-14 days after the initial administration."
48099569|NCT01506843|BIOLOGICAL|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
48099570|NCT02882646|DEVICE|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
48099571|NCT06631365|DEVICE|PrEPsmart mobile app|"The PrEPsmart mobile app is an innovative and comprehensive app to support sexual minority men (SMM) using on-demand pre-exposure prophylaxis (PrEP) or daily PrEP. The PrEPsmart app consists of the following components:~1. PrEP 211 dosing/sex diary and reminders~2. Feedback on PrEP protection levels~3. Quick tips~4. Bi-directional secure messaging"
48099572|NCT06631365|DRUG|Truvada|Combination medication used in Human immunodeficiency virus (HIV) prevention, it blocks virus pathways to infection.
48624574|NCT02861976|OTHER|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
48624575|NCT02943759|DRUG|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
48624576|NCT02943759|DRUG|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
47936486|NCT00048087|DRUG|ZD1839|250 mg by mouth daily each day for 4 weeks.
47936487|NCT00048087|DRUG|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
47936488|NCT05156476|PROCEDURE|Genicular nerve block-iPACK group|Group 1: Genicular nerve block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
47936489|NCT05156476|PROCEDURE|Femoral triangle block-iPACK group|Group 2: Femoral triangle block-iPACK group (performed by anaesthesiologist) Method: Ultrasound and nerve stimulation guided injection Drug: a total of 30 ml of ropivacaine 0,5% (150 mg) will be used
48099573|NCT00015457|DRUG|Amlodipine plus Botulinum toxin|
48099574|NCT01943162|BEHAVIORAL|CPT|
48624577|NCT02482844|OTHER|pacemaker implantation|
48624578|NCT02482844|OTHER|holter implantation|
48624579|NCT03229811|OTHER|ESRD education + conservative kidney management and ACP education|Targeted conservative kidney management and advance care planning education delivered in person by trained healthcare providers
48624580|NCT06492694|DIETARY_SUPPLEMENT|Fish oil + wild orange essential oil supplement|This supplement contains fish oil and wild orange essential oil as its active ingredients.
48624581|NCT06492694|DIETARY_SUPPLEMENT|Fish oil supplement|This supplement contains fish oil as its active ingredient.
48624582|NCT03770455|DRUG|Avelumab|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
48099575|NCT00602589|DRUG|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
48099576|NCT06631898|OTHER|SaaTwae Bio-Natural Moisturizing Cream|A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
48099577|NCT02888431|DEVICE|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
48099578|NCT01766167|DRUG|MP-424|Low
48099579|NCT01766167|DRUG|MP-424|Middle
48464596|NCT04392934|PROCEDURE|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
48099580|NCT01766167|DRUG|MP-424|High
48624583|NCT03770455|DRUG|2nd generation ADT (abiraterone or enzalutamide)|2nd generation ADT (abiraterone or enzalutamide)
48624584|NCT04585542|DRUG|Polyethylene Glycol 3350|Nonspecific laxative comparison group.
48624585|NCT04585542|DRUG|Sodium Polystyrene Sulfonate Oral Suspension [SPS]|Potassium binder to treat hyperkalemia.
48099581|NCT01766167|DRUG|MP-424|Multiple
48099582|NCT05233527|PROCEDURE|Episiotomy Closure|indicated episiotomy with Novosyn® Quick after spontaneous vaginal delivery
48464597|NCT00105040|DRUG|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
48464598|NCT00105040|OTHER|Placebo (PB)|Oral tablets and oral solution
48464599|NCT02364258|DRUG|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
48099583|NCT03365609|DRUG|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
48099584|NCT03365609|DRUG|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
48099585|NCT03365609|DRUG|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
48464600|NCT02364258|DRUG|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
48464601|NCT02383706|DEVICE|ApneaLink Air|Overnight, home polysomnography device
48464602|NCT02383706|BEHAVIORAL|Berlin Quesionnaire|OSA screening questionnaire
48624586|NCT04585542|DRUG|Patiromer|Potassium binder to treat hyperkalemia.
48624587|NCT04585542|DRUG|Sodium zirconium cyclosilicate|Potassium binder to treat hyperkalemia.
48099586|NCT03365609|DRUG|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
48099588|NCT04579510|BIOLOGICAL|Novel monovalent oral poliovirus vaccine type 2 (nOPV2)|nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
48099589|NCT04579510|BIOLOGICAL|Bivalent oral poliovirus vaccine (bOPV)|The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).
48099590|NCT06286982|OTHER|Oral Symptom Assessment Scale|The Oral Symptom Assessment Scale is a patient-rated oral (or mouth) symptom assessment tool
48099591|NCT01871818|BEHAVIORAL|Combined program|Combined program with physiotherapy, endurance training and resistance training
48099592|NCT01871818|BEHAVIORAL|Physiotherapy in private practice|Physiotherapy in private practice
48099593|NCT01901770|OTHER|educational intervention|Receive HPV vaccination educational materials
48099594|NCT01901770|OTHER|educational intervention|Receive influenza vaccination educational materials
48099595|NCT06178315|PROCEDURE|EUS-guided celiac plexus block|Under EUS-guidance, celiac plexus block will be performed with injection of bupivacaine and triamcinolone into the area of celiac plexus.
48464603|NCT02383706|BEHAVIORAL|Epworth Sleepiness Scale|OSA screening questionnaire
48464604|NCT02383706|BEHAVIORAL|STOP-BANG questionnaire|OSA screening questionnaire
48624588|NCT00717080|PROCEDURE|IOL surgery|IOL surgery using capsular tension ring (AURORING)
48624589|NCT00717080|PROCEDURE|IOL surgery|IOL surgery without CTR
48624590|NCT01044667|BEHAVIORAL|GI and Quality of Life Assessment|
48464605|NCT02383706|OTHER|Physical exam|Physical exam of neck, mouth and upper airway
48624591|NCT05043870|DRUG|Infliximab and immunosuppressives|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
48624592|NCT05043870|DRUG|Infliximab|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
48624593|NCT02447029|DRUG|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
48624594|NCT02447029|DRUG|standard lidocaine paracervical block|1% lidocaine paracervical injection
48099596|NCT06178315|PROCEDURE|Sham procedure|Celiac plexus will not be performed in this arm.
48099597|NCT04655118|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.
48099598|NCT04655118|DRUG|Placebo|Placebo to match TL-895
48281862|NCT03190343|PROCEDURE|cholangio-pancreatoscopy|
48281863|NCT05268380|DIAGNOSTIC_TEST|Covid-19, TB and HIV diagnosis|GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
48099599|NCT04816890|DRUG|M1 Pram P037|Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
48099600|NCT04816890|DRUG|Insulin lispro|Subcutaneous administration of insulin lispro in combination with a basal insulin.
48099601|NCT06609928|BIOLOGICAL|FOLR1 CAR T-cells|Given IV
48099602|NCT06609928|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
48099603|NCT06609928|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48099604|NCT06609928|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48099605|NCT06609928|DRUG|Cyclophosphamide|Given IV
48099606|NCT06609928|PROCEDURE|Echocardiography|Undergo ECHO
48099607|NCT06609928|DRUG|Fludarabine|Given IV
48099608|NCT06609928|PROCEDURE|Pheresis|Undergo apheresis
48099609|NCT06609928|PROCEDURE|Positron Emission Tomography|Undergo PET
48099610|NCT02108054|DEVICE|7T MRI|Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
48099611|NCT05550480|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring for 50 days
48099612|NCT02777879|PROCEDURE|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
48099613|NCT02404454|PROCEDURE|Hysteroscopic metroplasty|
48099614|NCT02404454|DEVICE|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
48464606|NCT03930849|BEHAVIORAL|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
48281864|NCT02053805|OTHER|PSA|PSA. Serum \& plasma will be stored for future investigations
48281865|NCT02053805|OTHER|IPSS questionnaire|the validated International Prostate Symptom Score
48281866|NCT02053805|OTHER|DRE (Digital Rectal Examination )|physical examination for the prostate gland
48099615|NCT02404454|PROCEDURE|Office second look hysteroscopy|Second-look hysteroscopy after three months
48099616|NCT05495646|PROCEDURE|Central catheter insertion|The data will be obtained through the review of the medical records and the clinical follow-up of each patient to evaluate the technique of inserting the device, the possible risk factors of catheter-related infection, its clinical manifestations and the data microbiological.
48099617|NCT06028932|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
48099618|NCT06282835|DRUG|Eravacycline Injection|Eravacycline at the recommended dose and administration method according to the instructions: 1 mg/kg intravenous administration, every 12 hours. The intravenous infusion duration is approximately 60 minutes. For patients with severe liver impairment (Child-Pugh class C), administer 1 mg/kg of this product every 12 hours on the first day, followed by 1 mg/kg every 24 hours starting from the second day.
48099619|NCT05138172|DEVICE|"Forced Air Heating Temperature control Twinwarm II"|"For this purpose, we will use a device that is already routinely used in all operation rommss at MHH, the so-called warm air device Twinwarm, Generation III. This device has a valid CE mark and will be used according to its purpose pre-, intra- and postoperative maintenance of the normothermic body temperature of the patient. The device will be used strictly according to the existing in-house SOP Heat Management of 04/2021 of the Department of Anesthesiology and Intensive Care Medicine of the MHH.~Convective air heating has been shown to be effective in many studies and can be used flexibly with a variety of different ceiling models."
48099620|NCT03877471|GENETIC|Cell therapy|Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
48099621|NCT04312776|OTHER|none intervention|
48099622|NCT03722446|DEVICE|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
48099623|NCT03722446|DEVICE|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
48099624|NCT06545175|DRUG|Intracochlear application of VSF1.01|During cochlear implant operation, patients receive intracochlear VSF1.01 prior to insertion of the electrode array.
48281867|NCT02053805|OTHER|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
48281868|NCT02053805|PROCEDURE|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
48281869|NCT02053805|PROCEDURE|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
48624595|NCT00693459|DEVICE|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
48624596|NCT03888079|DRUG|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
48624597|NCT03888079|DRUG|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
48624598|NCT00947466|DRUG|Buprenorphine|Transdermal patch
48624599|NCT03144232|DEVICE|Active rTMS|rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
48624600|NCT03144232|DEVICE|Sham rTMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.
48624601|NCT02990377|BEHAVIORAL|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
48624602|NCT00954538|DRUG|[18F]MK-3328|IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
48624603|NCT02979288|DRUG|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
48624604|NCT02979288|OTHER|NO Intervention|NO Intervention
48624605|NCT01609972|DEVICE|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
47936490|NCT05156476|PROCEDURE|Local infiltration analgesia|Group 3: LIA (performed by surgeon) Method: Blind injection Drug: a total of 200ml of 0.2% ropivacaine will be used (400mg). Of this, 150ml of ropivacaine 0.2% will be mixed with 1mg of adrenaline.
47936491|NCT05998928|DRUG|Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells|"fludarabine 30 mg/m2 and cyclophosphamide 300 mg/m2 both on three consecutive days during D-7 to D-3~BCMA-GPRC5D CAR-T Cells on day 0"
47936492|NCT00782327|DRUG|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
47936493|NCT00782327|DRUG|Placebo|Daily placebo capsule
47936494|NCT00207571|BEHAVIORAL|Computer|
47936495|NCT06322290|DIAGNOSTIC_TEST|assessment of pathogens in blood specimens|Molecular diagnosis of Invasive bacterial diseases due to Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae
47936496|NCT05424237|BEHAVIORAL|App intervention|usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
47936497|NCT04014673|BEHAVIORAL|Behavioral : Characterization|Behavioral scales and neuropsychological tests; MRI, SPECT/PET
47936498|NCT05630300|DIAGNOSTIC_TEST|PMC Sure Status COVID-19 Antigen Test|COVID-19 professional use kit in out-patient departments
47936499|NCT05630300|DIAGNOSTIC_TEST|Acon Flowflex COVID-19 Antigen Home Test|COVID-19 self-test kits
47936500|NCT00184574|DRUG|biphasic insulin aspart|
47936501|NCT00184574|DRUG|metformin|
47936502|NCT00936091|DRUG|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
47936503|NCT00936091|DRUG|Placebo|125 children received placebo capsules
47936504|NCT03268473|OTHER|Experimental|Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis
47936505|NCT03268473|OTHER|Control|Control: Non-surgical periodontal therapy in Periodontitis
47936506|NCT00790257|DEVICE|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
47936507|NCT03397654|DRUG|Pembrolizumab|Pembrolizumab solution
47936508|NCT03397654|COMBINATION_PRODUCT|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
47936509|NCT00894374|DRUG|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
48624606|NCT05355207|DRUG|TRL1068|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
48624607|NCT01625182|DRUG|Fingolimod|Fingolimod 0.5 mg capsules
48624608|NCT01625182|DRUG|Placebo Comparator|Matching placebo capsules
48624609|NCT05301634|PROCEDURE|infraorbital block|the patients will receive bilateral infraorbital block
48624610|NCT05301634|PROCEDURE|topical intranasal bupivacaine|the patients will receive topical intranasal application of bupivacaine
48624611|NCT02736214|BEHAVIORAL|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
48624612|NCT03607084|BEHAVIORAL|School Health Worker Program|The intervention trains selected teachers to deliver health lessons to students, perform basic first aid, recognize common illnesses, refer student to skilled medical attention when needed. The intervention provides schools with basic medical supplies including pain relief medication, thermometers, bandages, antiseptics, and oral rehydration solution. Vitamin A supplementation and presumptive deworming medication are administered to students during biannual health screenings.
48624613|NCT02967029|DRUG|Esmolol Hydrochloride|the influence of brevibloc as a hypotensive agent on rSO2
48624614|NCT02967029|DRUG|Remifentanil Hydrochloride|the influence of remifentanyl as a hypotensive agent on rSO2
48624615|NCT03816917|OTHER|cutaneous parameters of psoriasis (exposure)|characteristic of the cutaneous domains of the psoriasis: age at start, disease duration, current and previous treatment PASI, BSA, nail involvement
47936510|NCT00894374|DRUG|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
47936511|NCT00215579|DRUG|Depot Risperidone Microsphere (Consta)|
47936512|NCT03926546|BEHAVIORAL|ERP for Individuals|Comparing Group vs. Individual ERP for OCD
47936513|NCT06115837|PROCEDURE|multivisceral resection|The prognostic factors were analyzed for pT4bN0M0 colorectal cancer after multivisceral resection
47936514|NCT04079569|BEHAVIORAL|Tobacco|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
47936515|NCT04079569|BEHAVIORAL|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
47936516|NCT02168426|PROCEDURE|Guardix|Applying 6g of guardix during abdominal surgery
47936517|NCT02168426|PROCEDURE|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
47936518|NCT03810820|DEVICE|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
47936519|NCT00983788|DRUG|Bezafibrate|3 x 200 mg/ day
47936520|NCT00983788|OTHER|Placebo|Placebo
47936521|NCT02884843|DEVICE|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
47936522|NCT02884843|DEVICE|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
47936523|NCT05739864|BIOLOGICAL|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
47936524|NCT05739864|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
47936525|NCT06265480|OTHER|FallFitness intervention group|Eight week group-based fallprevention intervention. A total of eight session (1-hour once a week).
47936526|NCT01213550|DRUG|Chlorhexidine gluconate|
48624616|NCT03816917|OTHER|comorbidity (exposure)|medical and medication history, current and previous comorbidity
48624617|NCT03816917|OTHER|family history (exposure)|Family history of PsC, PsA, IBD, AS, and uveitis
47936527|NCT01213550|DRUG|Placebo mouthrinse|
47936528|NCT00270829|DRUG|nesiritide|Drug given intrarenally or placebo
47936529|NCT01066442|DRUG|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
47936530|NCT01108289|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
47936531|NCT02166372|OTHER|Observation of natural course of Diabetes Mellitus Type 2|
48464607|NCT03930849|BEHAVIORAL|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
48624618|NCT03816917|OTHER|lifestyle (exposure)|"* Intoxications~* Lifestyle: occupation and injuries, sport and physical hobbies"
47936532|NCT04539145|DEVICE|Chocolate PTA Balloon|Chocolate PTA Balloon
47936533|NCT04539145|DEVICE|conventional balloon angioplasty|conventional bal-loon angioplasty
48464608|NCT02375750|DEVICE|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
48624619|NCT03816917|OTHER|patient reported outcomes (exposure)|VAS-score on fatigue, PsC severity, joint pain and general well-being
48624620|NCT03816917|OTHER|inflammatory markers (exposure)|Measurements of inflammatory and bone remodeling markers in serum and plasma
48624621|NCT03816917|OTHER|genetic (exposure)|Assessment of known HLA- and SNP-associations with PsA or PsA
48624622|NCT05297838|OTHER|Stationary Bike|Stationary Bike while hand is submerged in ice bath
47936534|NCT06385990|DRUG|UTD1|UTD1: 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles.
47936535|NCT02284672|DRUG|Dexmedetomidine|
47936536|NCT02284672|DRUG|Normal saline|
47936537|NCT00745225|DRUG|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
47936538|NCT00745225|DRUG|placebo comparator|1 capsule daily, 96 weeks.
47936539|NCT02069418|RADIATION|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
47936540|NCT02069418|RADIATION|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
47936541|NCT02943252|DRUG|Apatinib|apatinib 500 mg in tablet once daily
47936542|NCT02943252|DRUG|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
47936543|NCT00354900|DRUG|Aprotinin|
47936544|NCT04542538|OTHER|No intervention, observational study|
47936545|NCT01095471|BIOLOGICAL|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
47936546|NCT00613197|DRUG|Epanova|4g/day in divided doses
47936547|NCT04308798|PROCEDURE|Surgical glove changing|Changing surgical glove after draping and before cementation during total knee arthroplasty
48099625|NCT02652234|DRUG|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
48099626|NCT02652234|DRUG|Chemotherapy|
48099627|NCT04257851|DRUG|Theophylline Anhydrous Oral Tablet|Theophylline tablet (150 mg/12h)
48099628|NCT04257851|DRUG|Sumatriptan Succinate Oral Tablet|Sumatriptan tablet (25 mg/12h)
48281870|NCT06488781|DRUG|Azithromycin|Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
48464609|NCT02375750|OTHER|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
48464610|NCT03119896|OTHER|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
48464611|NCT02208336|OTHER|medical chart review|Ancillary studies
48464612|NCT00701194|BEHAVIORAL|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
48464613|NCT00185120|DRUG|Olmesartan medoxomil|
48281871|NCT06488781|DRUG|Placebo|Placebo given in place of other two active drugs
48281872|NCT01737775|PROCEDURE|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
48464614|NCT00185120|DRUG|Hydroclorothiazide|
48464615|NCT00185120|DRUG|Benazepril|
48464616|NCT00185120|DRUG|Amlodipine|
48624623|NCT05297838|OTHER|Virtual Reality (VR) Headset|VR headset containing gameplay
48624624|NCT05297838|OTHER|Ice Bath|Pain was elicited via a cold pressor test, which is an established method of producing controlled and repeatable painful stimuli in an experimental setting
48624625|NCT04938947|DEVICE|Blood Flow Restriction Cuffs|This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.
48624626|NCT04938947|OTHER|Low-Intensity Resistance Training|This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
48624627|NCT04938947|OTHER|High-Intensity Resistance Training|This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.
48624628|NCT02310594|OTHER|cytology specimen collection procedure|Undergo blood sample collection
48624629|NCT02310594|OTHER|laboratory biomarker analysis|Correlative studies
48624630|NCT02363660|BIOLOGICAL|GINI|
48624631|NCT00002940|DRUG|hydroxyurea|
48624632|NCT05485090|OTHER|Questionnaire : Adapted Safety Assessment Scale|Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
48624633|NCT04167800|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
48281873|NCT05149196|OTHER|Targeted hemodynamic management|"During anesthesia, hemodynamic managements include active hydration (\>10 ml/kg/h), use of inotropes (dobutamine), and forced diuresis; the targets are to maintain pulse pressure variation \<9%, mean arterial pressure ≥85 mmHg, and urine output \>200 ml/h (3ml/kg/h).~During the first 48 hours after surgery, systolic blood pressure is maintained ≥110 mmHg or within 20% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or vasoactive infusion."
48281874|NCT05149196|OTHER|Routine care|"During anesthesia, hemodynamic managements are conducted according to routine practice and usually include fluid infusion at a rate of 6-8 ml/kg/h without inotropics; the targets are to maintain mean arterial pressure ≥60 mmHg and urine output \>0.5 ml/kg/h.~During the first 48 hours after surgery, hemodynamic management is performed according to routine practice."
48281875|NCT01739595|DRUG|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
48281876|NCT01739595|DRUG|Placebo|Oral capsule taken one time daily for 3 months
48464617|NCT03853499|OTHER|No intervention (observational study)|No intervention (observational study)
48464618|NCT06471725|OTHER|combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound|The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
48464619|NCT02246296|DIETARY_SUPPLEMENT|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
48464620|NCT02246296|DIETARY_SUPPLEMENT|Modified F75 Milk|This is the experimental group
48464621|NCT06277076|PROCEDURE|Computer Implant guided Surgery|Dental implant placed using printed guide after a digital planification on a superimposed 3D surface scan and a 3D Cone Beam imaging of the jaw.
48464622|NCT06117241|BEHAVIORAL|IMAGINE HEALTHY|An anti-inflammatory nutrition program including cooking classes, physical activity, and stress reduction.
48464623|NCT05215054|DEVICE|Gana V®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
48464624|NCT05215054|DEVICE|Sculptra®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
48624634|NCT01651884|DEVICE|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
48624635|NCT01651884|DEVICE|Transcranial Direct Current Stimulation (Neuroconn)|
48624636|NCT06169670|DEVICE|Viality|"Viality is a lipoaspirate wash system designed to be used in the operating room in conjunction with, and attached to, a user-provided liposuction cannula, a vacuum source, and a waste canister.~Viality is to be used to filter and wash aspirated, harvested autologous adipose tissue for aesthetic body contouring. The system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is to be used without any additional manipulation. Viality is not intended to process autologous adipose tissue other than for aesthetic body contouring uses."
48099629|NCT05080192|DRUG|Fenofibrate|145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)
48624637|NCT03334097|OTHER|Prenatal education|"Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~1. St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~2. nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~3. rd: Puerperium.~4. rd :Breastfeeding~5. rd : Newborn care~6. rd :Positive parenting."
48624638|NCT03476642|DRUG|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
48624639|NCT03476642|DRUG|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
48624640|NCT00303797|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
48624641|NCT00303797|DRUG|sorafenib tosylate|
48624642|NCT00744835|PROCEDURE|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
48624643|NCT04398134|DRUG|ABI-H2158|3 X 100 mg tablets for oral administration
48624644|NCT04398134|DRUG|Placebo|Sugar pill manufactured to mimic the ABI-H2158 tablets
48624645|NCT04398134|DRUG|Entecavir (ETV)|0.5 mg tablet for oral administration
47936548|NCT01594385|BIOLOGICAL|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~* Two Seprafilm pieces between the liver and the anterior abdominal wall~* Four pieces over the exposed bowel surfaces anteriorly~* Two slightly staggered pieces of Seprafilm in each colic gutter~* Two pieces in the pelvic area.~* If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
48099630|NCT05080192|DRUG|Placebo|Matching placebo (once/day) for 10 days
48099631|NCT00725413|DRUG|etonogestrel implant (Implanon)|subdermal etonogestrel implant
48099632|NCT04663802|BEHAVIORAL|Default order set|With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.
48281877|NCT01014715|OTHER|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
48624646|NCT00487591|DRUG|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
48099633|NCT04663802|BEHAVIORAL|Physician-targeted accountable justification|When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
48099634|NCT04663802|BEHAVIORAL|Respiratory therapist (RT)-targeted accountable justification|If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.
48099635|NCT01167426|DRUG|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
48099636|NCT01167426|DRUG|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
48281878|NCT05227352|BEHAVIORAL|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
48281879|NCT01543750|DRUG|4-Aminopyridine|
48281880|NCT01543750|DRUG|Placebo|Placebo
48624647|NCT00487591|DRUG|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
48624648|NCT05031130|OTHER|Empowered program integrated with family support|The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
48099637|NCT03704311|PROCEDURE|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
48099638|NCT01004328|OTHER|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
48624649|NCT05067270|DRUG|Sodium Citrate|Administered SC infusion.
48099639|NCT02770859|PROCEDURE|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle \[esophagus\] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle \& sphincter of the LES for the treatment of achalasia
48099640|NCT04204408|DRUG|NNC0365-3769 (Mim8)|Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
48099641|NCT04204408|DRUG|Placebo (Mim8)|Mim8 placebo administered subcutaneously (s.c., under the skin)
48099642|NCT02454205|DRUG|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
48624650|NCT05067270|DRUG|Treprostinil|Administered SC infusion.
48624651|NCT05067270|DRUG|Humalog diluent|Administered SC infusion.
48624652|NCT05067270|DRUG|Magnesium Chloride|Administered SC infusion.
48624653|NCT03456323|BEHAVIORAL|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
48624654|NCT03456323|OTHER|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
48099643|NCT02454205|DRUG|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
48624655|NCT03620279|BEHAVIORAL|Magic camp intervention|Hand-arm bimanual motor skills training
48624656|NCT04247971|PROCEDURE|Blood draw|23 ml of blood collected
48624657|NCT04247971|PROCEDURE|Sputum collection|Induced sputum sample collected
48624658|NCT04247971|PROCEDURE|Pulmonary function test|Pulmonary function testing
48624659|NCT03044561|DRUG|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
48624660|NCT03044561|DRUG|matching placebo|orally, 4 times per day for 21 days
48624661|NCT03339453|DRUG|Nasal Glucagon|Administered nasally
48624662|NCT03339453|DRUG|Intramuscular Glucagon|Administered IM
48624663|NCT03340519|DEVICE|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
48624664|NCT01017250|RADIATION|Stereotactic Radiosurgery (SRS)|Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
48624665|NCT01017250|DRUG|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
48624666|NCT06018103|BEHAVIORAL|MBCT-vision|8-week mindfulness group learning course, using Mindfulness Based Cognitive Therapy customised for visual symptoms (MBCT-vision). Participants meet once weekly only, with daily home practice between sessions.
48624667|NCT02751905|DRUG|BIIB074|Administered orally as specified in treatment arm
48624668|NCT04687397|BEHAVIORAL|Rehabilitation|Multidisciplinary rehabilitation
48624669|NCT04925323|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
48624670|NCT04925323|BIOLOGICAL|surgical tissue samples|unused surgical tissue removed during plastic surgeries
48099644|NCT02454205|DRUG|Levofloxacin|750mg (\<50kg) 1000mg (\>50kg)
48099645|NCT02454205|DRUG|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
48099646|NCT02454205|DRUG|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
48099647|NCT02454205|DRUG|Ethionamide|15mg/kg (max 900mg)
48099648|NCT02454205|DRUG|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
48099649|NCT02454205|DRUG|Moxifloxacin|400mg po daily.
48099650|NCT02454205|DRUG|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
48099651|NCT04488250|OTHER|Robot Therapy|Robot Therapy
48624671|NCT02691338|OTHER|EEG|EEG analysis
48624672|NCT02691338|OTHER|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
48624673|NCT04729712|PROCEDURE|Anaesthesiologist-administered ultrasound guided Erector Spinae block with catheter insertion|Erector Spinae block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the erector spinae plane prior to surgical incision. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
48624674|NCT04729712|PROCEDURE|Surgeon-administered video-assisted Paravertebral block with catheter insertion|Paravertebral block: A bolus of 20 ml 0.375% Levobupivacaine will be administered into the paravertebral space after the thoracoscopic ports have been sited. A further bolus of 10 ml 0.25% Levobupivacaine will be given at skin closure if it has been greater than 1 hour after the first bolus of local anaesthetic medication. A continuous infusion of 0.125% Levobupivacaine will be commenced via the sited nerve catheter for postoperative analgesia. This will be started at 10 ml/hr and titrated to effect to a maximum rate of 15 ml/hr.
48099652|NCT06631404|DIAGNOSTIC_TEST|renal doppler|doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
48099653|NCT03315507|DRUG|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
48624675|NCT02622685|DRUG|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
48624676|NCT02622685|DRUG|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
48624677|NCT02622685|DRUG|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
48624678|NCT02622685|DRUG|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
48624679|NCT02315183|OTHER|This is an observational Study|THis study has no intervention
48624680|NCT00004059|DRUG|7-hydroxystaurosporine|
48624681|NCT00004059|DRUG|fluorouracil|
48464625|NCT02873260|BIOLOGICAL|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
48099654|NCT03870360|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
48464626|NCT02873260|BIOLOGICAL|rDEN3Δ30|Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
48624682|NCT05289882|BEHAVIORAL|PASS Program Condition:|Participants randomized to this condition will be invited to take part in weekly ball hockey games (once per week), that will last approximately 60 minutes, and will be followed by opportunities to socially connect afterwards. The results of our feasibility study indicated that the PASS program acted as an important conduit to direct participants to other support services and resources (e.g., counseling, career transition centre, employment, education). Military veteran men are often reluctant to access such supports, especially if they attach stigma to such services (e.g., mental health services). At each site, a military veteran will be trained as a facilitator to operate as a conduit to refer participants to the relevant support services and agencies.
48464627|NCT02873260|BIOLOGICAL|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
48464628|NCT04986254|OTHER|Blood sampling|During a single dosing interval, each participant will have 1 - 8 blood samples taken for each antibiotic. Blood samples (3 mL each) will be drawn from an existing arterial line or central venous catheter. Blood samples will be collected on 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
48464629|NCT04986254|OTHER|Epithelial lining fluid sampling|Epithelial lining fluid will be sampled using either a bronchoalveolar lavage (BAL) or mini-BAL technique, in accordance with the preferred procedure in participating sites. 3 BAL or mini-BAL samples will be collected over 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
48464630|NCT04986254|OTHER|Urine sampling|The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.
48624683|NCT02957448|DRUG|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
48624684|NCT02957448|DRUG|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
48624685|NCT00298857|DRUG|Valproic acid|
48099655|NCT03870360|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
48624686|NCT03784495|DRUG|Melatonin 1mg|1 mg/day 30 minutes before sleep
48624687|NCT03784495|DIETARY_SUPPLEMENT|Essential Aminoacids (eAA)|4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
47936549|NCT04648501|OTHER|Dual-task training|Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
47936550|NCT00171678|DRUG|Diclofenac Topical Sodium Gel 1%|
47936551|NCT02597816|RADIATION|Three dimensional ultrasound|
47936552|NCT04063527|DRUG|adjuvant chemotherapy|combination of paclitaxel and carboplatin
47936553|NCT01191879|OTHER|Blood test|Blood test
47936554|NCT00421291|BEHAVIORAL|Education|
48281881|NCT04172675|DRUG|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
48281882|NCT04172675|DRUG|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
47936555|NCT04195126|DEVICE|CytoSorb haemadsorption device|CytoSorb (Cytosorbents Inc.) aspecific blood purification device used in an extracorporeal circulation system without dialysis column. Anticoagulation is managed by siodium citrate-Calcium system, using the Gambro CVVHDF capable device.
47936556|NCT02730208|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
47936557|NCT02730208|DRUG|Ivacaftor|IVA 150 mg tablet.
47936558|NCT02730208|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
47936559|NCT02730208|DRUG|Placebo|Placebo matched to IVA tablet.
47936560|NCT04618887|PROCEDURE|pallidotomy|deep brain nuclei lesion of GPi
48099656|NCT03870360|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
48099657|NCT03870360|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
48281883|NCT04172675|DRUG|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
48624688|NCT03784495|COMBINATION_PRODUCT|Essential Aminoacids + melatonin|4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
48624689|NCT03784495|OTHER|Placebo|an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
48624690|NCT03188705|DRUG|Clopidogrel|Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
47936561|NCT04618887|PROCEDURE|deep brain stimulation|deep brain stimulation of GPi
47936562|NCT00469261|DRUG|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
48464631|NCT04986254|DRUG|Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam|Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
48464632|NCT06058806|OTHER|Multimodal Physical Therapy|Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
48624691|NCT03188705|DRUG|Aspirin|Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
48624692|NCT02071160|DRUG|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
47936563|NCT00469261|DRUG|Current medical therapy for AMI|Current medical therapy for AMI
47936564|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
47936565|NCT05544981|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
47936566|NCT03583242|DRUG|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
47936567|NCT03583242|DRUG|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
47936568|NCT04983953|DEVICE|cHS|Clinical decision support system for diagnosing intracranial haemorrhage
47936569|NCT03232073|DRUG|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
48099658|NCT03870360|BEHAVIORAL|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
48099659|NCT06253130|DRUG|IMP1734|PARP1 selective inhibitor
48099660|NCT04181931|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h+5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
48099661|NCT04181931|PROCEDURE|Surgery alone|hepatic resection remove the liver tumor and portal vein tumor thrombus
48099662|NCT05794022|OTHER|MRI|1 MRI at 1 month with gadolinium injection
48281884|NCT00543647|DRUG|Fenofibrate 160 mg tablet|
48281885|NCT00543647|DRUG|Placebo|
48281886|NCT04695977|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
48281887|NCT04695977|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
48281888|NCT06296394|OTHER|Parenthood|The intervention group will consist of participants who became first time parents to children under 5 years of age.
48281889|NCT04654507|DRUG|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
48281890|NCT04654507|DRUG|Placebo|Placebo
48464633|NCT06335186|DIAGNOSTIC_TEST|upper endoscopy|to detect esophageal or gastric varices
48464634|NCT01968031|DRUG|Istradefylline 40 mg|Istradefylline 40 mg and placebo
48464635|NCT01968031|DRUG|Istradefylline 20 mg|Istradefylline 20 mg and placebo
48464636|NCT01968031|DRUG|Placebo|Placebo
48464637|NCT05683808|DRUG|Apixaban|Open label
48464638|NCT05485051|OTHER|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
48464639|NCT05485051|OTHER|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
48464640|NCT03523650|DRUG|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
48464641|NCT03523650|DRUG|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
48464642|NCT00556699|DRUG|rituximab|Escalating intravenous repeating dose
48464643|NCT00556699|DRUG|SGN-40|Escalating intravenous repeating dose
48281891|NCT06286618|BEHAVIORAL|Psychosocial Intervention|Psychosocial intervention is an intensive behavioral therapy intervention to address dietary behaviors. Each intervention session is a one-on-one interaction that focuses on setting individualized dietary goals and following up on them and is delivered by trained personnel. Sessions are delivered in 3 modalities which include face-to-face, phone call, and telehealth delivery. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Face-to-face; Telehealth; Phone Call 2) Telehealth; Phone Call; Face-to-face 3) Phone call; Face-to-face; Telehealth.
48624693|NCT06327594|DIAGNOSTIC_TEST|ultrasound scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by ultrasound at multiple sites of the whole body, including muscle and fat.
48624694|NCT06327594|DIAGNOSTIC_TEST|CT/MRI scan|The patients with lung cancer who are scheduled to undergo radical resection of lung cancer are examined by abdominal CT/MRI.
48624695|NCT02818257|OTHER|Strip A|Adhesive strip A
48281892|NCT06286618|OTHER|Structural Intervention|The structural intervention is designed to supplement the diet with food resources via three modalities: voucher-based or F/V prescription, home meal delivery, or food bank box program. The voucher-based model includes a weekly $50 gift card with a prescription for having to eat more fruits and vegetables. The home meal delivery model includes a meal subscription that supplements the diet with two meals for two people each week (four total servings worth $65 including shipping). The food bank box program consists of participants picking up a box of food weekly from a food pantry located in the outpatient clinic. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Voucher; Meal Delivery; Food Box 2) Meal Delivery; Food Box; Voucher 3) Food Box; Voucher; Meal Delivery.
48281893|NCT06286618|OTHER|Traditional Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in a referral-based fashion in which participants will receive referral at enrollment visit.
48464644|NCT04387201|DRUG|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
48464645|NCT04387201|DRUG|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
48464646|NCT00987480|DRUG|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
48464647|NCT00987480|DEVICE|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
48464648|NCT01041495|DRUG|cyclobenzaprine ER (AMRIX)|active drug
48464649|NCT01041495|DRUG|placebo|matching placebo for AMRIX
48624696|NCT02818257|OTHER|Strip B|Adhesive strip B
48624697|NCT02818257|OTHER|Strip C|Adhesive strip C
48624698|NCT00679198|BEHAVIORAL|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
48624699|NCT05876494|DIAGNOSTIC_TEST|serum lactate|assessment of serum lactate and mean platelets volume
48281894|NCT06286618|OTHER|Integrated Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in an integrated fashion in which participants will receive immediate onboard at enrollment visit.
48624700|NCT03259308|DRUG|Ontamalimab|Participants will receive 1 mL of ontamalimab sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
48624701|NCT03259308|DRUG|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
48624702|NCT03591419|DEVICE|polymer clip|polymer clips will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
48624703|NCT03591419|DEVICE|endoloop|endoloop will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
48624704|NCT06165874|RADIATION|[68Ga]Ga-NOTA-RW102 PET Imaging|Intravenous injection of 1.8 MBq\[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RW102 in a single dose.
48624705|NCT06294353|DEVICE|WELT-ED (CBT based DTx)|The product delivers Cognitive Behavioral Therapy for Eating Disorders (CBT-ED) through a software interface (iOS and Android), designed to engage patients in a structured and interactive manner. It operates by analyzing patterns in the patient's lifestyle and eating data, identifying problematic behaviors associated with their eating disorder. Based on this analysis, the software sets daily learning objectives aimed at fostering positive cognitive and behavioral habits. By providing tailored guidance and support, the product seeks to assist patients in making sustainable changes, ultimately contributing to the improvement of eating disorder symptoms. This approach combines the principles of CBT-ED with the convenience and accessibility of digital technology, offering a personalized therapeutic experience to support patients in their recovery.
48099663|NCT05794022|BIOLOGICAL|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
48099664|NCT05794022|BEHAVIORAL|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
48099665|NCT03980964|DEVICE|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
48099666|NCT03685188|DRUG|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
48099667|NCT03685188|DRUG|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
48099668|NCT02756104|OTHER|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
48099669|NCT02756104|OTHER|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
48281895|NCT00278629|BIOLOGICAL|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
48099670|NCT05995574|BEHAVIORAL|avatar communication training|Avatar simulates a mother and a daughter for the pediatrician to practice communication about contraception.
48281896|NCT01175928|DEVICE|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
48281897|NCT01175928|DEVICE|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
48281898|NCT06121050|OTHER|Pet visit|Intensive care patients visited by their pets for 20 minutes
48281899|NCT06483477|OTHER|Standard skin care|From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
48281900|NCT06483477|DEVICE|Reminder App|In addition to standard skin care, patients are supported by a Reminder App. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. The patients may postpone each required care procedure for up to 2 hours. With each procedure, the patients are guided through the skin care with simple and self-explanatory illustrations. To increase the patients' motivation, they will additionally earn points for regular and punctual performed care procedures. The patients receive a hand-out including instructions how to properly perform skin care, but they can also find an information page within the application that includes similar instructions.
48281901|NCT02979314|DEVICE|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
48281902|NCT04122196|DRUG|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
48281903|NCT04122196|DRUG|Placebo oral tablet|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
48281904|NCT03969329|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
48281905|NCT03968965|DEVICE|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
48281906|NCT03968965|OTHER|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
48464650|NCT01924364|DEVICE|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
48464651|NCT01924364|PROCEDURE|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
48464652|NCT01223755|DRUG|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
48464653|NCT01223755|DRUG|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
48464654|NCT01954212|OTHER|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~1. Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~2. Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~3. Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
48464655|NCT03573336|DRUG|Vilaprisan (BAY1002670)|Intake orally, once daily
48464656|NCT03573336|DRUG|Matching Placebo|Intake orally, once daily
48464657|NCT00668395|DRUG|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
48464658|NCT02069262|OTHER|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
48464659|NCT06321055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Retrospective analysis.
48099671|NCT04697251|DIAGNOSTIC_TEST|FOT measurements in newborns and small infants|Measurements will be performed using the device TremoFlo N-100, at bedside, with the infant in the supine position during quiet natural sleep. After proper cleaning and decontamination, the face mask of the device will be preheated at 37oC (to avoid awakening) and will be placed on infant's face. The duration of each measurement will be predetermined at 10 s. At least 3 technically acceptable measurements will be performed per infant, with 30 s intervals between them. The validity of each measurement will be assessed according to the coherence function (automatically determined by the operating system of the device).
48099672|NCT06118736|PROCEDURE|Temporary Medial Hemi-epiphysiodesis of the proximal femur|Temporary Medial Hemi-epiphysiodesis of the proximal femur
48099673|NCT06110195|DRUG|Xevinapant|Given orally during study treatment on days 1-14 of a 21-day treatment cycles. It will be given continuously during treatment with carboplatin, paclitaxel, and radiation (chemoRT). After completely of the chemoRT dosing, an additional 3 cycles of Xevinapant along will be given.
48099674|NCT06110195|DRUG|Carboplatin|Given with radiation weekly for 7 doses.
48099675|NCT06110195|DRUG|Paclitaxel|Given with radiation weekly for 7 doses.
48099676|NCT06110195|RADIATION|Radiation Therapy|Radiation will be given together with paclitaxel and carboplatin for 7 weeks.
48281907|NCT02650011|OTHER|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
48281908|NCT06056973|DRUG|jinghua weikang capsule|Oral Jinghua Weikang Capsule, two capsules each time, three times a day
48099677|NCT04871607|BIOLOGICAL|Basiliximab|Given IV
48099678|NCT04871607|DRUG|Carmustine|Given IV
48099679|NCT04871607|DRUG|Cytarabine|Given IV
48099680|NCT04871607|DRUG|Etoposide|Given IV
48099681|NCT04871607|BIOLOGICAL|Genetically Engineered Hematopoietic Stem Progenitor Cells|Given via infusion
48099682|NCT04871607|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC or IV
48099683|NCT04871607|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
48464660|NCT01898598|DRUG|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
48099684|NCT00618319|DRUG|BIIB021|Dose, schedule, and duration specified in protocol
48099685|NCT06630702|DEVICE|SCS electrode stimulation 1|300Hz/300us
48099686|NCT06630702|DEVICE|SCS electrode stimulation 2|130Hz/300us
48099687|NCT06630702|DEVICE|SCS electrode stimulation 3|60Hz/300us
48281909|NCT00443508|DRUG|adding Certican to therapy|
48624706|NCT06294353|BEHAVIORAL|Standard Treatment|In the control group, from screening/baseline (Visit 1) to 8 weeks (Visit 5), counseling and support therapy will be conducted at all visits. Participants can continue taking SSRI medications and other antipsychotic drugs that they were already taking for the treatment of eating disorders during the trial period. However, the intake of any additional antipsychotic drugs, other than those already being taken (including SSRIs), is prohibited during the trial period.
48464661|NCT01898598|DRUG|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
48624707|NCT05781802|OTHER|Level of pressure support|"Patients will be evaluated in two different conditions sequentially. The first condition will be at a clinically selected level of pressure support under stable clinical conditions.~This condition will be labeled according to P0.1:~* In case of P0.1\<2, the clinically selected level of pressure support will be considered High Pressure support.~* In case of P0.1\>2, the clinically selected level of pressure support will be considered Low Pressure support.~After data collection at clinically selected level of pressure support, pressure support level will be transiently increased or decreased (i.e. from high to low/ from low to high) to the lowest/highest clinically tolerated level, aiming at the predefined P01 thresholds, and then kept for 20 minutes under stable clinical conditions. Data collection will be repeated and then the clinically selected level of pressure support restored."
48624708|NCT00494156|DRUG|heparin|
48624709|NCT00494156|DRUG|aspirin and clopidogrel|
48624710|NCT03991039|RADIATION|Gamma knife|Microvascular decompression
48624711|NCT03874962|OTHER|Routine oral cleaning and professional oral care group|Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
48624712|NCT04121013|OTHER|mothership|Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
48464662|NCT01388257|PROCEDURE|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
48624713|NCT05732714|BEHAVIORAL|Healthy lifestyle behaviors around the time of surgery|Healthy lifestyle choices, such as improving diet and beginning to exercise around the time of surgery and it's influence on an individual's long term risk of developing cardiovascular disease.
48624714|NCT03253822|OTHER|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
48624715|NCT01526382|DEVICE|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
48624716|NCT01526382|PROCEDURE|central venous catheter|patients in this arm can receive central venous catheter
48624717|NCT04085640|OTHER|Obturator nerve block with ropivacaine 0.2%.|20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
48624718|NCT04085640|OTHER|Obturator nerve block with isotonic saline|20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
48464663|NCT01388257|PROCEDURE|Simple seton drain removal|Patients are simply followed after seton drain removal.
48464664|NCT02105701|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
48464665|NCT02105701|DRUG|Ribavirin|200 mg capsule
48464666|NCT05121441|DRUG|ARD-101|Twice daily, oral administration
48464667|NCT05121441|DRUG|Placebo|Twice daily, oral administration
48464668|NCT06377007|DEVICE|IOLMaster 700 (Carl Zeiss Meditec AG)|Subjects will undergo measurements with the IOLMaster 700 device.
48464669|NCT06377007|DEVICE|Argos (Alcon Laboratories, Inc.)|Subjects will undergo measurements with the Argos device.
48464670|NCT06323616|PROCEDURE|MAC adjustment to PSI between 25 and 50|According to SedLine monitoring, the depth of anesthesia will be adjusted by changing the amount of sevoflurane so that the PSI median value is between 25 and 50.
48464671|NCT04380233|DRUG|Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome|The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
48099688|NCT06629636|DIETARY_SUPPLEMENT|NMN capsule|Total of 900mg/day for 8 weeks
48099689|NCT06629636|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
48099690|NCT05826444|DIAGNOSTIC_TEST|Echocardiography|Echocardiography with afterload change
48099691|NCT05826444|DIAGNOSTIC_TEST|Magnetic resonance imaging|Stress-MRI
48099692|NCT05826444|DIAGNOSTIC_TEST|Magnetocardiography|Magnetocardiography
48464672|NCT04380233|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
48464673|NCT02399891|OTHER|Quality Assurance Implementation|
48464674|NCT02399891|OTHER|Standard of Care|
48464675|NCT06103760|DRUG|Esketamine Nasal Spray [Spravato]|This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
48464676|NCT01715649|BEHAVIORAL|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
48099693|NCT05826444|DIAGNOSTIC_TEST|Histology|Histological analysis
48464677|NCT00964054|OTHER|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
48464678|NCT00964054|OTHER|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
48464679|NCT02059811|OTHER|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
48464680|NCT02059811|OTHER|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
48099694|NCT05826444|DIAGNOSTIC_TEST|Genetics|miRNA sequencing
48099695|NCT05826444|DIAGNOSTIC_TEST|calcium signaling|cardiomyocyte calcium signaling
48099696|NCT05826444|DIAGNOSTIC_TEST|IMR|Index of microvascular resistance measurement
48099697|NCT05826444|DIAGNOSTIC_TEST|Angio-IMR|Angiography derived post-processing index if microvascular resistance
48099698|NCT04293783|DIETARY_SUPPLEMENT|L.Reuteri|daily supplementation with two tablet for six months
48099699|NCT04293783|DIETARY_SUPPLEMENT|Placebo|daily supplementation with two tablet for six months
48281910|NCT00443508|DRUG|reducing Tacrolimus|
48464681|NCT03036592|BEHAVIORAL|Early OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
48464682|NCT03036592|BEHAVIORAL|Late OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
48099700|NCT02637544|OTHER|acupuncture|classical acupuncture therapy
48099701|NCT05891977|OTHER|Intervention A - Tomato paste|Participants will consume a daily amount of 0.5 g of tomato paste / kg of body weight following the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
48099702|NCT05891977|OTHER|Intervention B - Control|Participants will consume the regular diet plus consumption of low to moderate tomato or tomato-based products and lycopene containing foods
48099703|NCT06630884|BIOLOGICAL|Typhoid VI Polysaccharide Vaccine Injectable Solution|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
48099704|NCT06630884|OTHER|Saline Placebo (0.5mL injection)|The placebo injection will consist of 0.5mL of saline.
48099705|NCT05976243|DRUG|Remibrutinib|Remibrutinib treated groups and arms
48099706|NCT05976243|OTHER|Placebo|Placebo treated groups and arms
48099707|NCT06530030|DRUG|efanesoctocog alfa|All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
48099708|NCT00771667|DRUG|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
48099709|NCT00771667|DRUG|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
48099710|NCT00771667|DRUG|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
48281911|NCT05142709|DRUG|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
48478867|NCT03474029|DRUG|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
48099711|NCT00771667|DRUG|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
48099712|NCT00771667|DRUG|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
48099713|NCT00771667|DRUG|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
48099714|NCT00771667|DRUG|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
48099715|NCT00771667|DRUG|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
48099716|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
48281912|NCT06189820|DIAGNOSTIC_TEST|FAPI PET/CT|"In the department of Nuclear Medicine:~* Installation in a relax chair after weight and height control~* Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started.~* Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46"
48464683|NCT01003951|PROCEDURE|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
48464684|NCT03240120|DRUG|Dabigatran etexilate|Pradaxa 150 mg hard capsules
48464685|NCT03240120|DRUG|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
48624719|NCT01967277|DEVICE|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
48464686|NCT01713166|DRUG|plasmalyte solution|plasmalyte solution
48464687|NCT01713166|DRUG|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
48464688|NCT01402128|DIETARY_SUPPLEMENT|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
48464689|NCT01402128|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
48464690|NCT02263768|PROCEDURE|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
48624720|NCT01967277|DEVICE|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
48624721|NCT01525771|OTHER|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~* Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~* Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~* Cisplatin 60mg/m2 IV (D1) every 21 days"
48624722|NCT04681300|OTHER|Skin biopsy|a skin sample will be taken using a 4 mm punch biopsy in lesional skin
48281913|NCT02716376|DEVICE|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
48624723|NCT04681300|OTHER|Plastic surgery remnants|healthy skin from plastic surgery interventions
48624724|NCT01594684|DEVICE|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
48624725|NCT01594684|DEVICE|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
48624726|NCT01594684|DEVICE|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
48624727|NCT01594684|DEVICE|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
48281914|NCT05833880|BEHAVIORAL|Self-administered questionnaire|Self-administered questionnaire regarding complementary and alternative medicine use
48464691|NCT01616199|DRUG|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
47936570|NCT00733889|DRUG|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
47936571|NCT00738192|DRUG|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
48464692|NCT01616199|DRUG|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
48464693|NCT02761720|OTHER|No Intervention|
47936572|NCT00738192|DRUG|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
47936573|NCT00738192|DRUG|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
47936574|NCT00400114|DRUG|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
48281915|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 5mg QD
48281916|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD
48464694|NCT04685681|BEHAVIORAL|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
48624728|NCT00078494|DRUG|EBV-LMP-2|
48624729|NCT02737618|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
48624730|NCT02890186|DEVICE|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
48624731|NCT02890186|OTHER|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
48281917|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
48464695|NCT04685681|OTHER|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
48464696|NCT03152162|DEVICE|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
48464697|NCT00469898|DRUG|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion"
48464698|NCT00469898|DRUG|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
48624732|NCT06327061|BEHAVIORAL|Network overdose prevention|Participants are taught overdose prevention methods with network members.
48624733|NCT06327061|BEHAVIORAL|Standard of care health education|Participants will receive the standard of care for overdose prevention.
48624734|NCT05201001|DRUG|APX005M|adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
48624735|NCT03100747|PROCEDURE|Bilamellar 3 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
48624736|NCT03100747|PROCEDURE|Bilamellar 5 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
48624737|NCT03100747|PROCEDURE|Trabut 3 mm|Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
48624738|NCT00141921|DRUG|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
48624739|NCT02852044|BEHAVIORAL|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
48624740|NCT02852044|BEHAVIORAL|Exercise|One hour of cycling at 50% of maximal power output
48624741|NCT02852044|OTHER|Dorsal Hand Vein Cannulation (heated hand technique)|
48624742|NCT02852044|OTHER|Venous Cannulation|
48624743|NCT00287820|DRUG|Olanzapine|olanzapine 5-40 mg/day
48624744|NCT00287820|DRUG|olanzapine|olanzapine 5-40 ,mg/day
48624745|NCT00287820|DRUG|risperidone|risperidone 1-12 mg/day
48624746|NCT03535688|DRUG|D-cycloserine|200 mg twice daily
48624747|NCT03535688|DRUG|Placebo|twice daily
48624748|NCT04028505|DRUG|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
48281918|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 25 mg QD
48464699|NCT05575245|DEVICE|Drug-eluting Stent|Drug-eluting Stent angioplasty
48464700|NCT05575245|DEVICE|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
48464701|NCT04327336|DEVICE|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
48624749|NCT04831112|DRUG|Honey|Dressing of necrotizing fascitis wounds with honey.
48624750|NCT04831112|COMBINATION_PRODUCT|EUSOL|Dressing of necrotizing fascitis wounds with EUSOL.
48624751|NCT04248361|DIAGNOSTIC_TEST|TEM-PCR URI Panel|Target Enriched Multiplex Polymerase Chain Reaction (TEM-PCR™) is a breakthrough molecular multiplex technology that allows rapid DNA/RNA identification of multiple pathogens (i.e., bacteria and viruses) in a single sample, typically within one day of specimen receipt.
48624752|NCT04248361|OTHER|SOC/Empiric Diagnosis|The SOC for upper respiratory infection may include, but is not limited to, rapid strep testing, rapid influenza testing, and sputum cultures. In the event a lower respiratory infection is suspected a chest x-ray or CBC with differential may be performed.
48624753|NCT04183478|DRUG|K-001|K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.
48624754|NCT04183478|OTHER|placebo|Placebo which looks the same as K-001 in apparence
48624755|NCT02128750|OTHER|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
48624756|NCT03720847|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
48281919|NCT01608152|BEHAVIORAL|Focus Group|Attend a focus group
48281920|NCT01608152|OTHER|Internet-Based Intervention|Have access to the game
48281921|NCT01608152|BEHAVIORAL|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
48281922|NCT02195830|OTHER|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
48624757|NCT03720847|DRUG|Oral Micronized Progesterone|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
48624758|NCT03720847|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
48624759|NCT03720847|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
48624760|NCT02226900|PROCEDURE|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
48624761|NCT02226900|PROCEDURE|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
48624762|NCT03011853|PROCEDURE|Non-invasive and/or invasive mechanical ventilation|Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU
48624763|NCT00191100|DRUG|Gemcitabine|
48624764|NCT00191100|DRUG|Cisplatin|
48624765|NCT00191100|RADIATION|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
48624766|NCT00191100|RADIATION|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
48624767|NCT04611217|OTHER|Dietary fiber: 10-25g|10-25 g/day of fiber
48624768|NCT04611217|OTHER|Dietary fiber: 5g|5 g/day of fiber
48624769|NCT06075732|BEHAVIORAL|Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
48624770|NCT03426150|DRUG|CPP-ACP|The surfaces of specimens were pretreated with CPP-ACP for 3 min
48624771|NCT03426150|DRUG|Placebos|The surfaces of specimens were pretreated with deionized water for 3 min
48624772|NCT01181128|DRUG|Factor VIII (rFVIIIFc)|
48624773|NCT01181128|DRUG|Advate®|
48624774|NCT04649307|BEHAVIORAL|MI-CBT|Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
48624775|NCT02036918|DRUG|Sipuleucel-T|
47936575|NCT00400114|DRUG|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
47936576|NCT00400114|PROCEDURE|Radiation|Radiation 50 Gy (weeks 4-9)
47936577|NCT00400114|PROCEDURE|Surgery|Esophagectomy
47936578|NCT00400114|DRUG|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
47936579|NCT03706898|DRUG|Elpida®|Elpida® capsules, 20mg
47936580|NCT03706898|DRUG|Dolutegravir|Dolutegravir, film-coated tablets, 50mg
47936581|NCT03706898|DRUG|Sofosbuvir|Sofosbuvir, film-coated tablets, 400mg
48281923|NCT06657404|DRUG|use Amiodarone, Bisoprolol and Digoxin|"Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.~The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.~Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.~Digoxin 0.125mg qd orally."
48624776|NCT02036918|PROCEDURE|Lymph Node Biopsy|
47936582|NCT03706898|DRUG|Daclatasvir|Daclatasvir, film-coated tablets, 60mg
48464702|NCT04327336|DEVICE|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
48624777|NCT05311592|BEHAVIORAL|HERO Dads Program|The HERO Dads Program is a 4-week series of workshops for non-custodial fathers that focuses on improving parenting, offering job support, and financial counseling.
48624778|NCT01017315|DRUG|Baby talcum|50 grams apply locally prior cast application
48624779|NCT01108159|PROCEDURE|Blood Draw|
48624780|NCT01108159|PROCEDURE|Skin Biopsy|
48624781|NCT04753112|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor
48624782|NCT02329288|DRUG|Triamcinolone Acetonide|
47936583|NCT04539587|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
47936584|NCT02352584|BIOLOGICAL|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
47936585|NCT02352584|BIOLOGICAL|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
47936586|NCT02352584|BIOLOGICAL|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
47936587|NCT05090462|DEVICE|PICO dressing|Negative Pressure Wound Therapy device
47936588|NCT01562873|DRUG|Ruxolitinib|
47936589|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance|Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
47936590|NCT03931343|PROCEDURE|Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance|Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
48464703|NCT02401139|DRUG|Ketamine|
48464704|NCT02401139|DRUG|Placebo|
48624783|NCT02329288|DRUG|placebo|
48624784|NCT03297697|PROCEDURE|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
48624785|NCT03297697|PROCEDURE|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
48624786|NCT03297697|PROCEDURE|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
48624787|NCT03763383|PROCEDURE|Lateral Arm Flap|Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
48624788|NCT02321904|PROCEDURE|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
48624789|NCT02321904|PROCEDURE|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
48624790|NCT02321904|PROCEDURE|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
48624791|NCT02321904|PROCEDURE|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
48464705|NCT02614898|OTHER|Eculizumab|This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
48464706|NCT02509260|DEVICE|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
47936591|NCT05373615|DRUG|Cefiderocol|After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
48099717|NCT00771667|DRUG|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
48464707|NCT02509260|OTHER|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
48464708|NCT00908180|BIOLOGICAL|alemtuzumab|
47936592|NCT02728778|DRUG|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
48281924|NCT03614247|PROCEDURE|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
48464709|NCT00908180|BIOLOGICAL|donor lymphocytes|
48464710|NCT00908180|DRUG|carmustine|
48464711|NCT00908180|DRUG|cyclosporine|
48464712|NCT00908180|DRUG|cytarabine|
48464713|NCT00908180|DRUG|etoposide|
48464714|NCT00908180|DRUG|melphalan|
48464715|NCT00908180|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48464716|NCT00273130|PROCEDURE|transnasal endoscopy|
48464717|NCT00273130|PROCEDURE|transoral thin endoscopy|
48464718|NCT03968016|DEVICE|SYSMEX HLSCL|Diagnostic device
48464719|NCT04372641|DRUG|p97 Inhibitor CB-5339 Tosylate|Given PO
48464720|NCT01945580|PROCEDURE|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
48464721|NCT00881426|DRUG|Cefprozil 500 mg Tablets (Sandoz GmbH)|
48464722|NCT00881426|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
48464723|NCT02985749|DRUG|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
48464724|NCT00151255|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
48464725|NCT00151255|DRUG|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
48464726|NCT00151255|DRUG|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
48464727|NCT00151255|DRUG|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
48464728|NCT00151255|DRUG|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
48464729|NCT04411017|PROCEDURE|Endoscopy|Colonoscopy
48464730|NCT04385745|PROCEDURE|Biodegradable Intramedullary Nailing (BIN)|Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
48464731|NCT03729557|PROCEDURE|Nephrectomy|Unilateral nephrectomy
48464732|NCT00746486|DRUG|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
48464733|NCT00746486|DRUG|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
48464734|NCT03837171|BIOLOGICAL|Liberal Red blood cell transfusion|"Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians"
48464735|NCT03837171|BIOLOGICAL|Restrictive Red blood cell transfusion|Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
48464736|NCT03184649|DRUG|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
47936593|NCT02728778|PROCEDURE|Acupuncture|Application of acupuncture into the forehead
47936594|NCT05650554|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5413|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
47936595|NCT05650554|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular injection"
48099718|NCT06492356|DEVICE|Tripolar radiofrequency therapy|Twenty patients underwent weekly TriPollar RF treatment, using a new RF technology with three or more electrodes. Glycerin was applied to the treatment area before and after each session, with the procedure lasting 15 minutes. The technology uses a sequence of electrical modulation to prevent overheating and requires no active cooling of the electrodes or skin.
48099719|NCT06492356|DRUG|medical treatment|Twenty patients will receive medical treatment by dermatologist.
48099720|NCT03223883|DRUG|Curcumin|Oral supplement for 12 months
48464737|NCT03184649|DRUG|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
48464738|NCT03184649|DIETARY_SUPPLEMENT|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
48464739|NCT06095596|DRUG|Upadacitinib|Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.
48464740|NCT06095596|DRUG|Vedolizumab|Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
48464741|NCT04929730|OTHER|Nephrology care bundle|Nephrology care bundle
48464742|NCT01371617|DRUG|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
48464743|NCT02823327|GENETIC|Laboratory Biomarker Analysis|Correlative studies
48464744|NCT02823327|OTHER|Medical Chart Review|Medical chart review is performed
47936596|NCT05650554|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
47936597|NCT05650554|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular injection"
47936598|NCT03744000|PROCEDURE|Immediate stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
48099721|NCT03223883|OTHER|Placebo|Oral placebo for 12 months
48099722|NCT03965702|DEVICE|Use of a decision support system on the EV1000 monitoring (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
48099723|NCT03965702|OTHER|Manual application of the GDFT protocol (standard of care)|Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way. Blood pressure wil standardized in both group.
48099724|NCT02333630|OTHER|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
48099725|NCT02333630|OTHER|Asthma education|A website with links to written asthma education and videos
48099726|NCT05091164|PROCEDURE|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis|Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.
48099727|NCT00012987|BEHAVIORAL|Quality Improvement|
48099728|NCT03465488|DRUG|Albendazole Pill 400mg (GSK)|One single dose of 400mg Albendazole is provided at baseline.
48099729|NCT05564325|DEVICE|Deflectable guidewire|A deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
48099730|NCT05564325|DEVICE|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
48099731|NCT00300456|DRUG|ABT-335|135 mg, daily, 12 weeks
48464745|NCT02132624|BIOLOGICAL|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
48464746|NCT04481451|PROCEDURE|Erector spinae block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
48464747|NCT04481451|PROCEDURE|Quadratus lumborum block with ropivacaine 0.2%|Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.
48464748|NCT04481451|DRUG|Ropivacaine|ropivacaine 0.2% nerve block injection
48464749|NCT04621617|DRUG|Albumin|Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
48464750|NCT04621617|DRUG|Midodrine|Oral Midodrine will be given at a dose of 7.5 mg three times in a day
48464751|NCT04621617|DRUG|Standard medical therapy (SMT)|SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
48464752|NCT04450264|BEHAVIORAL|African Immigrant Breast Cancer Education Program|African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
48464753|NCT04668820|DIAGNOSTIC_TEST|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
48464754|NCT01732679|OTHER|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
48464755|NCT01337427|DRUG|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
48464756|NCT06105450|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
48464757|NCT01181830|DRUG|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
48464758|NCT01181830|DRUG|placebo|administration of 8.1 mmol bid of placebo
48624792|NCT02321904|PROCEDURE|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
48298831|NCT05650099|DEVICE|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
48624793|NCT05967468|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
48624794|NCT05967468|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|Parent-based bibliotherapy for treating anxiety disorders in youth
48624795|NCT05967468|OTHER|Relaxation and Mentorship|Relaxation based treatment
48624796|NCT05607043|DEVICE|Testing for SARS CoV2 RNA|Device: Testing for SARS CoV2 RNA- lab-based RNA RT-PCR testing
48624797|NCT00375297|DRUG|sildenafil|
48464759|NCT03573544|DRUG|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
48464760|NCT03573544|DRUG|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
48624798|NCT01280994|DRUG|Hyperpolarized 129Xenon Gas|Hyperpolarized 129Xenon Gas will be administered in multiple doses in volumes that are tailored to the subject's total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
48624799|NCT00367458|DRUG|Atorvastatin|80 mg atorvastatin oral daily
48624800|NCT00367458|DRUG|Placebo|patients will be administered placebo
48624801|NCT00447278|DRUG|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
48624802|NCT00447278|DRUG|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
48624803|NCT03439839|DRUG|iptacopan|iptacopan bid orally administered
48624804|NCT03439839|COMBINATION_PRODUCT|Standard of Care|Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.
48624805|NCT04072471|DRUG|Zurampic®|non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
48624806|NCT04072471|DRUG|Control group: xanthine oxidase inhibitor monotherapy|non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
48298832|NCT00876174|PROCEDURE|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
48298833|NCT00876174|PROCEDURE|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
48464761|NCT03573544|DEVICE|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
48624807|NCT04463706|OTHER|Predictors adverse evolution|Predictors adverse evolution in all hospital participant admitted patients
48624808|NCT04463706|OTHER|Predictors of health care provide|Predictors of death, unequity, variability in process of care, cost in all COVID positive patients form the Basque Country
48624809|NCT03956875|OTHER|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
48624810|NCT00923312|BIOLOGICAL|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
48624811|NCT02516436|DRUG|BEMA Buprenorphine NX|Buprenorphine with naloxone
48624812|NCT02516436|DRUG|Buprenorphine|Buprenorphine
48624813|NCT03070652|BEHAVIORAL|NBO, Newborn behavioral observation|
48624814|NCT03070652|BEHAVIORAL|Practice as usual|
48624815|NCT00126945|BIOLOGICAL|Meningococcal Vaccine|
48624816|NCT06217549|OTHER|ozone therapy|Medical ozone is a mixture of pure ozone gas (0.05-5%) and pure oxygen (99.95-95%). It is produced from pure medical oxygen by medical ozone generators. It is applied to the participants 10 sessions by the intravenous method.
47936599|NCT03744000|PROCEDURE|Deferred stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
47936600|NCT04600310|DEVICE|ULTRAPREP|ULTRAPREP device for reducing OR prep times.
47936601|NCT04600310|DEVICE|No Intervention|Conventional skin preparation technique
48099732|NCT00300456|DRUG|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
48298834|NCT01735110|PROCEDURE|transfemoral intervention (TFI)|
48298835|NCT01735110|PROCEDURE|Transradial intervention|
48298836|NCT00987051|PROCEDURE|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
48624817|NCT01651585|DRUG|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
48624818|NCT04205825|OTHER|The New Safety Checklist|Patients randomized in the New Safety Checklist intervention, nurses will use the New Safety Checklist, which we have named: INCARDIO-PASS (Interventional CARDIOlogy-Patient Safety System) checklist.
48099733|NCT00300456|DRUG|Placebo|Daily, 12 weeks, see Arm Description for placebo information
48464762|NCT02117505|DRUG|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
48464763|NCT02117505|DRUG|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5\*30 mg tablet=150 mg) in one of the treatment periods.
48464764|NCT00882245|OTHER|Vehicle ointment|Topical vehicle cream
48099734|NCT01335789|DRUG|Oxytocin|40 IUs
48099735|NCT01335789|DRUG|Saline|40 IUs
48099736|NCT00580801|DRUG|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
48099737|NCT00580801|DRUG|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
48099738|NCT00580801|DRUG|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
48099739|NCT00580801|DRUG|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
48281925|NCT03614247|PROCEDURE|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
48281926|NCT03614247|PROCEDURE|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
48298837|NCT03077945|BEHAVIORAL|heart rate variability biofeedback and cognitive reappraisal|
48298838|NCT03077945|BEHAVIORAL|control tasks|
48298839|NCT01116245|BIOLOGICAL|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
48464765|NCT00882245|DRUG|Ointment|SRD441 Ointment
48464766|NCT00283842|DRUG|DVS SR|
48099740|NCT00698802|DRUG|EX1000|Treat-to-target titration scheme, s.c. injection
48099741|NCT00698802|DRUG|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
48099742|NCT06388109|OTHER|Positive Peers mobile app|Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
48099743|NCT06631638|DEVICE|EMPHASYS Cup with VHN|Total Hip Replacement with EMPHASYS Acetabular shell and Non-Invasive Navigation
48099744|NCT00454662|DRUG|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
48099745|NCT00454662|DRUG|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
48099746|NCT02701361|BEHAVIORAL|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
48099747|NCT02701361|BEHAVIORAL|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
48099748|NCT02701361|BEHAVIORAL|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
48099749|NCT04348123|OTHER|Survey|Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators
48099750|NCT04348123|BEHAVIORAL|Education Session|After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
48099751|NCT05732428|DRUG|ARV-471|ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
48099752|NCT02246621|DRUG|Abemaciclib|Administered orally
48099753|NCT02246621|DRUG|Anastrozole|Administered orally
48099754|NCT02246621|DRUG|Letrozole|Administered orally
48099755|NCT02246621|DRUG|Placebo|Administered orally
48099756|NCT04163458|DRUG|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
48464767|NCT00283842|DRUG|Placebo|
48464768|NCT00844870|BEHAVIORAL|stabilization training|training of arm function with the trunk stabilized
48464769|NCT00844870|BEHAVIORAL|auditory training group|response to an auditory signal
48464770|NCT06099158|OTHER|HeartLogic|HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
48464771|NCT00651651|DRUG|budesonide/formoterol|
48464772|NCT00651651|DRUG|budesonide|
48281927|NCT03614247|PROCEDURE|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
48298840|NCT01116245|DRUG|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
48624819|NCT00140439|BEHAVIORAL|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:~1. Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.~2. Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.~3. Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
48099757|NCT04163458|DRUG|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
48624820|NCT01432327|DEVICE|SenseWear display|"Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals."
48624821|NCT01432327|DEVICE|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
48624822|NCT01432327|DEVICE|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
48624823|NCT01432327|BEHAVIORAL|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
48624824|NCT05118269|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/World Health Organization , Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary).
48624825|NCT05118269|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
47936602|NCT03981302|OTHER|Family nursing conversations|"The intervention is based on the concept family systems nursing developed by Wright \& Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation."
48624826|NCT03505775|DIAGNOSTIC_TEST|23Na magnetic resonance imaging|Imaging/diagnostic: Evaluation of the muscular and cutaneous sodium storage by 23Na magnetic resonance imaging. 23Na magnetic resonance imaging: 23NA-MRI protocol on a 3T scanner (Magnetom PRISMA, Siemens, Erlangen) implementing a 3D sequence.
48624827|NCT05422885|DRUG|Dasatinib|Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
48099758|NCT04163458|OTHER|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
48464773|NCT00651651|DRUG|formoterol|
48464774|NCT00422253|BEHAVIORAL|dietary intervention|
48464775|NCT04752527|DRUG|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
48464776|NCT01868243|DRUG|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
48464777|NCT01868243|DRUG|Warfarin|Warfarin adjusted-dose
48464778|NCT05021276|DRUG|Ruxolitinib|Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
48624828|NCT05422885|DRUG|Quercetin|Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
48624829|NCT01341041|BIOLOGICAL|chlorine dioxide|one time wash with 50ppm CD solution
48624830|NCT01341041|BIOLOGICAL|saline|one time wash with 50-100 cc normal saline
48624831|NCT00327327|DRUG|imexon|30-60 minutes IV, days 1,8,15 every 28 days
48624832|NCT00327327|DRUG|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
47936603|NCT00655135|DRUG|LDP-02|Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
48099759|NCT04163458|OTHER|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
48099760|NCT03015831|DRUG|Colchicine|Colchicine will be given to open heart surgery patients
48624833|NCT04529408|DEVICE|EarSats Pulse Oximeter Probe|Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
48624834|NCT04321499|GENETIC|lung cancer|PCR for SHOX2 and PTGER4
48624835|NCT01704079|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
48624836|NCT01704079|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
48624837|NCT04796896|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
48624838|NCT04796896|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48624839|NCT04796896|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
48624840|NCT01370915|DRUG|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
48624841|NCT01370915|DRUG|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
47936604|NCT00655135|DRUG|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
48099761|NCT03015831|DRUG|Placebo Oral Tablet|Placebo Oral Tablet will be given to open heart surgery patients according to randomization
48281928|NCT03614247|PROCEDURE|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
48464779|NCT04903340|PROCEDURE|PET/CT Exam|PET/CT image processing application of reconstruction parameters: scan time, respiratory gating, Q-clear
48464780|NCT05635630|OTHER|ctDNA and adjuvant therapy|Patients of ctDNA positive group receive individual adjuvant chemotherapy. The ctDNA status are evaluated every 2 months.
48464781|NCT05635630|OTHER|ctDNA|Patients of ctDNA negative group are monitored by ctDNA every 3 months.
47936605|NCT02934529|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
48099762|NCT04497961|DRUG|Lenalidomide|dose of 10mg oral lenalidomide on days 1-21 of each 28-day cycle.
48281929|NCT00509106|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
48281930|NCT00509106|DRUG|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
48281931|NCT00509106|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
48281932|NCT02886715|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
48281933|NCT02886715|DRUG|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
48464782|NCT03290807|DEVICE|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
48464783|NCT03021876|DRUG|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
48464784|NCT03021876|OTHER|usual intake|baseliner
48464785|NCT04194151|DRUG|Propofol Injection|1, 1.5 or 2 mg/kg of propofol according to the subgroup
48464786|NCT03136562|DIAGNOSTIC_TEST|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
48624842|NCT05587153|OTHER|perfusion index in all parturient recruited for the study|Using perfusion index and positional hemodynamic changes for the prediction of postspinal hypotension in all parturient recruited for the study
48624843|NCT04737694|DIETARY_SUPPLEMENT|Ketone ester|Oral ketone ester + glucose supplement
48624844|NCT04737694|DIETARY_SUPPLEMENT|Glucose|Glucose supplement
48624845|NCT03644732|PROCEDURE|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
48624846|NCT06294613|DEVICE|vitreoretinal surgery|Patients undergoing vitreoretinal surgery
48624847|NCT02738515|DRUG|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
47936606|NCT02934529|DRUG|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
47936607|NCT02934529|DRUG|5-FU|5-FU 400 mg/m² bolus day 1, q d15
47936608|NCT02934529|DRUG|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
48624848|NCT02738515|DRUG|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
48624849|NCT01136122|DEVICE|CPAP Treatment|Effective CPAP treatment for one month
48624850|NCT01107457|BIOLOGICAL|Ixekizumab|Administered subcutaneously
47936609|NCT02934529|DRUG|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
47936610|NCT02934529|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
48624851|NCT01107457|DRUG|Placebo|Administered subcutaneously
48624852|NCT03947723|DEVICE|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
48624853|NCT01748682|OTHER|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
48464787|NCT04666753|DIETARY_SUPPLEMENT|ImmunoFormulation|The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
48464788|NCT05970731|DRUG|Beclomethasone|84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
48464789|NCT05970731|OTHER|Placebo|Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.
48464790|NCT05970731|DEVICE|Microsponge|Drug delivery using chitosan-based biocompatible microsponge
48464791|NCT00973050|DRUG|Bicalutamide|50 mg Tablet
48464792|NCT00973050|DRUG|Casodex®|50 mg Tabelt
48464793|NCT01859936|DEVICE|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
48464794|NCT04473326|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
48464795|NCT04636541|BEHAVIORAL|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
48464796|NCT04636541|BEHAVIORAL|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
48464797|NCT05560139|DEVICE|a-tDCS|Transcranial direct current stimulation
48464798|NCT00026416|BIOLOGICAL|recombinant interferon alfa|
48464799|NCT00026416|DRUG|thalidomide|
48099763|NCT04497961|DRUG|Daratumumab|1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36
48099764|NCT04497961|BEHAVIORAL|Questionnaires|EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)
48464800|NCT00026416|PROCEDURE|adjuvant therapy|
48624854|NCT01957800|BEHAVIORAL|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
48624855|NCT01957800|BEHAVIORAL|Usual Care|Participants will record their weight and complete surveys online.
48099765|NCT04497961|OTHER|Dietary Intervention|The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by Daily Harvest. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
48099766|NCT00403884|PROCEDURE|Selective RPE laser treatment|interventional SRT laser treatment
48099767|NCT02974010|DRUG|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
48099768|NCT02974010|DRUG|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
48099769|NCT02974010|DRUG|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
48099770|NCT02974010|DRUG|Saline Solution Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
48624856|NCT03546543|PROCEDURE|Position change|Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
48464801|NCT05543395|BEHAVIORAL|Domestic Violence Questionnaire|Domestic Violence Questionnaire
48464802|NCT04260854|DRUG|Bupivacaine Hydrochloride|Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
48464803|NCT04260854|DRUG|Saline|Normal saline injections.
48464804|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~* Bifidobacterium animalis subsp. lactis BPL1,~* Lactobacillus rhamnosus BPL15,~* Lactobacillus rhamnosus CNCM i-4036~* Bifidobacterium longum ES1"
48464805|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
48464806|NCT04305535|DIETARY_SUPPLEMENT|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
48281934|NCT02886715|DRUG|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
48281935|NCT04681326|DEVICE|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
48281936|NCT01152853|DRUG|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
48298841|NCT03550716|PROCEDURE|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
48298842|NCT03550716|PROCEDURE|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
48624857|NCT01196611|BEHAVIORAL|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
48624858|NCT01196611|BEHAVIORAL|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
48624859|NCT04615507|DEVICE|JJVC Investigational Multifocal Contact Lens|TEST Lens
48624860|NCT04615507|DEVICE|Dailies Total 1® Multifocal Contact Lens|CONTROL Lens
48624861|NCT06364527|DEVICE|Aptar Digital Health respiratory disease management platform|The Aptar Digital Health respiratory disease management platform is a digital health tool that combines a Healthcare Professional portal (BreatheSmart Connect) and an associated patient mobile application (BreatheSmart mobile application). The Aptar Digital Health respiratory disease management platform is intended to be used in conjunction with compatible connected sensor devices that track medication adherence and for some, technique.
48624862|NCT05235607|BIOLOGICAL|Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration|subcutaneous administration
48298843|NCT03393845|DRUG|Pembrolizumab|Pembrolizumab 200mg IV, 21 day cycles
48464807|NCT00672217|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
48464808|NCT00672217|BEHAVIORAL|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
48464809|NCT04011787|DIETARY_SUPPLEMENT|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
48624863|NCT02095860|DRUG|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
48298844|NCT03393845|DRUG|Fulvestrant|Fulvestrant, 500mg IM, Loading dose: C1 D1 \& 15. Thereafter, Q4 wks
48298845|NCT02436486|DRUG|Placebo|Capsules, orally, single dose
48298846|NCT02436486|DRUG|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
48624864|NCT01771913|GENETIC|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
48298847|NCT02436486|DRUG|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
48298848|NCT02436486|DRUG|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
48464810|NCT04011787|DIETARY_SUPPLEMENT|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
48464811|NCT04011787|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
48464812|NCT04011787|DIAGNOSTIC_TEST|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
48464813|NCT04011787|RADIATION|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
48099771|NCT02680093|OTHER|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
48099772|NCT05283460|BEHAVIORAL|mandala|The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
48099773|NCT04455841|DRUG|INCB000928|INCB000928 will be administered at protocol defined dose.
48099774|NCT04455841|DRUG|ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
48099775|NCT04472767|DRUG|Nivolumab|Given IV
48624865|NCT01771913|GENETIC|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
48624866|NCT04498507|DIAGNOSTIC_TEST|HADS questionnaire|Patients will be asked to answer to 3 questionnaires about anxiety and depression, post-traumatic stress disorder and health-related quality of life
47936611|NCT02934529|DRUG|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
47936612|NCT02934529|DRUG|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
48099776|NCT04472767|DRUG|Ipilimumab|Given IV
48281937|NCT00742781|DIETARY_SUPPLEMENT|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
48464814|NCT05427994|OTHER|National Eye Institute Visual Function Questionnaire|National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
48464815|NCT05430815|BEHAVIORAL|Enhanced Postpartum Care System|The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
48464816|NCT04933240|DRUG|Tamoxifen Citrate 10Mg Tab|nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
48464817|NCT04933240|DRUG|Estradiol|estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
48281938|NCT05442385|OTHER|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
48281939|NCT04649385|DRUG|BGB-15025|Administered orally once or twice daily (QD or BID)
48281940|NCT04649385|DRUG|Tislelizumab|Administered 200 mg intravenous (IV) infusion
48281941|NCT00540215|OTHER|Glucagonlike peptide|450 nmol native form, synthetic
48464818|NCT04933240|DRUG|Placebo|A sugar tablet that does not contain any active medicine
48478868|NCT03474029|DRUG|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
48624867|NCT02722291|DEVICE|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
48624868|NCT05491889|BIOLOGICAL|trans arterial chemoembolization|trans arterial chemoembolization in patient with partial portal vein thrombosis
48624869|NCT00229528|DRUG|Paxil-CR|
47936613|NCT02934529|DRUG|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
47936614|NCT02934529|DRUG|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
47936615|NCT03242824|DRUG|Fluorine F 18 Fluorodopa|Contrast used in PET
47936616|NCT03242824|RADIATION|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
47936617|NCT03242824|PROCEDURE|Positron Emission Tomography|imaging test
47936618|NCT00415571|DRUG|Fispemifene (once daily for 8 weeks)|
47936619|NCT03221075|OTHER|Registry|There is no intervention.
47936620|NCT05807633|DEVICE|Novosyn®|Novosyn® for uterus closure in patients undergoing cesarian section
47936621|NCT02722096|DRUG|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
48099777|NCT04472767|DRUG|Cabozantinib|Given PO
48281942|NCT06379347|DIAGNOSTIC_TEST|POCUS performed on clinical indication|POCUS performed on clinical indication
48281943|NCT03458169|DEVICE|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
48281944|NCT03458169|DEVICE|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
47936622|NCT02722096|DRUG|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
48281945|NCT03458169|DEVICE|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
48464819|NCT04993118|OTHER|Integrated Neuromuscular Inhibition technique|Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
48281946|NCT05218213|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
48464820|NCT04993118|OTHER|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
48099778|NCT04472767|PROCEDURE|Transarterial Chemoembolization|TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
48464821|NCT04727554|DRUG|AMG 994|Administered as an intravenous (IV) infusion.
48464822|NCT04727554|DRUG|AMG 404|Administered as an intravenous (IV) infusion.
48464823|NCT06485518|BEHAVIORAL|The 5G RHS group receiving audio-video conferencing and effective data management for decision-making via augmented reality platform RealHealthcare System.|The 5G RHS group will receive audio-video conferencing and effective data management for decision-making via augmented reality platform. A total of 14 physicians from SRRSH will be participated in the study, offering remote consultations and instant guidance to the physician.
48464824|NCT05826093|PROCEDURE|Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)|US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
48464825|NCT05150405|DRUG|QLF31907|In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
48624870|NCT03318068|OTHER|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
48624871|NCT01139879|DEVICE|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
48624872|NCT03743818|DEVICE|dry needling|dry needling on the trigger point of the vastus medialis of the quadriceps
48624873|NCT03743818|OTHER|ultrasound|aply ultrasound on the knee
48624874|NCT03743818|DEVICE|hyauluronic acid|aply hyaluronic acid on the knee
47936623|NCT03262402|PROCEDURE|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
48099779|NCT03071497|DIAGNOSTIC_TEST|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
48099780|NCT03254329|OTHER|Assessment of human milk nutrient composition|Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
47936624|NCT02316873|BEHAVIORAL|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
47936625|NCT02316873|BEHAVIORAL|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
48281947|NCT06179472|DEVICE|BALT GOLDBAL2 Balloon|Placement and retrieval of the GOLDBALLOON Detachable Balloon for severe CDH
47936626|NCT04421807|OTHER|Scapulatoracic stabilization exercises|Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
47936627|NCT04421807|OTHER|Complex decongestive therapy (CDT)|In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
47936628|NCT03254368|DRUG|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
48281948|NCT06310369|RADIATION|radiation therapy|"Radiation therapy will be given in 20 fractions of 2.75 Gy covering the whole bladder over 4 weeks.~The use of a radiosensitizing agent is mandatory. Each recruiting center will have to choose 2 options of radiosensitizing agents."
47936629|NCT03254368|DRUG|Placebo|Placebo has the same excipients and appearance as ZGN-1061
48624875|NCT02806167|OTHER|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
48624876|NCT05574985|BIOLOGICAL|Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)|Injected one dose of research vaccine
48624877|NCT05574985|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero Cell)|Injected one dose of control vaccine
48281949|NCT03463330|BEHAVIORAL|Qigong exercise|The Qigong exercise is a series of mild exercise movements.
48281950|NCT03463330|BEHAVIORAL|Mild body exercise|Participants will be taught of series of similar movements to the Qigong exercise.
48624878|NCT03134807|OTHER|Observation prospective|No intervention
48624879|NCT04622956|DRUG|Methotrexate Injectable Solution|"Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial"
48624880|NCT00219271|DRUG|Zoledronic acid|
48624881|NCT00142753|BIOLOGICAL|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
48281951|NCT02262130|DRUG|Omalizumab|
48624882|NCT00142753|BIOLOGICAL|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
48624883|NCT00142753|BIOLOGICAL|Recombivax|Dosage at entry and week 24; non-responders ((\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
48624884|NCT00142753|BIOLOGICAL|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
48624885|NCT04505917|DRUG|dinoprostol|2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
48624886|NCT04505917|DRUG|misoprostol|2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
48624887|NCT04505917|DRUG|placebo|2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
48624888|NCT00554723|DRUG|NeuroAid|4 capsules 3 times daily, for three months
48624889|NCT00554723|DRUG|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
48624890|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Bioequivalence
48624891|NCT04230070|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Bioequivalence
48624892|NCT00565786|DEVICE|ArCom® Polyethylene|Argon packaged compression molded polyethylene
48624893|NCT00565786|DEVICE|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
47936630|NCT05635058|OTHER|The Reminisence Therapy|Reminiscence sessions were held in a meeting room in the nursing home and arranged in accordance with the interviews. In the reminiscence sessions, mnemonic materials selected specifically for the determined interview topic were used. The materials to be used in the reminiscence sessions were determined in accordance with the education level and cultural characteristics of the participants. In the sessions, topics such as childhood life, work life, religious holidays, national holidays, old songs, military ceremonies, wedding ceremonies, gardening and field work were shared. In the reminiscence sessions, the participants were encouraged to verbally express the feelings and thoughts they remembered about the mnemonics. The interviews were recorded by the researcher and each session lasted 45-60 minutes. At the end of the reminiscence session, the topics addressed in the session were summarized by the researcher, the following weeks topic was determined and the interview was concluded.
48281952|NCT00241267|DEVICE|Dedicated ultrasonographic probe during bronchoscopy|
48281953|NCT03001544|BIOLOGICAL|TS23|comparison of different doses
48624894|NCT03204825|DEVICE|Active TENS|TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
48624895|NCT03204825|BEHAVIORAL|Patient-Centred Education|Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking
48624896|NCT03204825|DEVICE|Placebo TENS|TENS device use with setting so that the stimulation delivered is ineffective
48624897|NCT02760888|DRUG|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
48624898|NCT02760888|DRUG|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
48624899|NCT02760888|DRUG|Placebo|Women will receive a Placebo 1 hour before the procedure
48624900|NCT01023321|DRUG|GLPG0555|single ascending doses, oral solution
48624901|NCT01023321|DRUG|placebo|single dose, oral solution
48281954|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
48281955|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
48281956|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
48281957|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
48624902|NCT01023321|DRUG|GLPG0555|multiple dose, oral solution, 7 or 14 days
48624903|NCT01023321|DRUG|placebo|multiple dose, oral solution, 7 or 14 days
48624904|NCT04359212|DRUG|thromboprophylaxis with low-molecular-weight heparin or fondaparinux|thromboprophylaxis with low-molecular-weight heparin or fondaparinux
48624905|NCT03543774|DRUG|Simvastatin 40mg|Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
48624906|NCT03543774|DRUG|Ezetimibe/simvastatin 10/20 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
48624907|NCT03543774|DRUG|Ezetimibe/simvastatin 10/40 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
48624908|NCT04625972|DRUG|AZD7442|Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.
48281958|NCT01753492|DEVICE|Ologen|
48624909|NCT04625972|DRUG|Placebo|Single dose (× 2 IM injections) of saline placebo on Day 1.
48624910|NCT00471120|OTHER|P2x7 assay|compare P2X7 assay to biopsy
48624911|NCT01381510|DRUG|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
48624912|NCT02557789|DRUG|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
48624913|NCT02317549|DRUG|LB1148|
48624914|NCT02317549|DRUG|Placebo|
48624915|NCT01125553|DRUG|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
48624916|NCT04621201|OTHER|observation and biopsy|biopsy
48624917|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), active condition.|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.
48624918|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), placebo condition|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
48624919|NCT04490356|BEHAVIORAL|Legacy Intervention|The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
48624920|NCT01784263|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
48624921|NCT01784263|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
48624922|NCT06009874|DRUG|Dapagliflozin 10mg Tab|patients will be treated with DAPA 10 mg once daily for three months
48624923|NCT06009874|DRUG|Placebo|patients will be treated with a placebo tab once daily for three months
48624924|NCT03997136|PROCEDURE|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
48099781|NCT06631456|OTHER|PRP injection|A total of 3 doses of intra-articular PRP were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
48281959|NCT06487351|BEHAVIORAL|The adapted PHBI|The adapted intervention is expected to be an online 60-minute video with an educational part about implicit racial bias, its consequences in healthcare inequalities, how to mitigate it, and seven case scenarios (5 minutes each) to train pharmacy interns on aspects related to cultural competency and how and when to use IBMS to reduce the impact of bias on prescribing PrEP for people of color.
48281960|NCT06487351|BEHAVIORAL|The NIH Implicit Bias course|The NIH Implicit Bias course consists of three modules designed to teach users what bias is, how to recognize it, and how to minimize its impact
48281961|NCT01442584|PROCEDURE|ovarian transplantation|ovarian transplantation
48281962|NCT00012610|PROCEDURE|Telepsychiatry|
48464826|NCT03059329|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
48464827|NCT01710696|DRUG|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
48464828|NCT01710696|DRUG|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
48464829|NCT00004162|BIOLOGICAL|sargramostim|
48464830|NCT00004162|DRUG|methotrexate|
48464831|NCT00004162|DRUG|pegylated liposomal doxorubicin hydrochloride|
48464832|NCT00004162|DRUG|vincristine sulfate|
48464833|NCT01242124|PROCEDURE|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
48464834|NCT01242124|PROCEDURE|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
48624925|NCT01374386|BEHAVIORAL|Exergaming|Participants will have access to Exergaming equipment (video games that require physical activity)
48624926|NCT06059859|PROCEDURE|Augmented reality robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
48624927|NCT06059859|DEVICE|Mixed reality intraoperative frozen section analysis|Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis
48624928|NCT06059859|PROCEDURE|Robot-assited radical prostatectomy|Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
48624929|NCT05249751|DIAGNOSTIC_TEST|Assessement of serum copeptin by ELISA technique|Assessement of serum copeptin by ELISA technique
48624930|NCT01761344|OTHER|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
48464835|NCT05756738|DIAGNOSTIC_TEST|Dried blood spot testing|To evaluate the efficacy defined as the rate of diagnostic tests against hepatitis C virus (HCV) performed with a dried blood spot test
48464836|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
48624931|NCT02041572|BEHAVIORAL|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
48624932|NCT04215770|DRUG|inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day|Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
48624933|NCT06023797|DRUG|Neoadjuvant immunochemotherapy|Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
48624934|NCT03893214|BEHAVIORAL|virtual reality exposure for acrophobia|"The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase."
48099782|NCT06631456|OTHER|Ozone therapy|A total of 3 doses of intra-articular ozone therapy were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
48099783|NCT05605743|BEHAVIORAL|breathing exercise|Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
48099784|NCT03573362|DEVICE|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
48099785|NCT03573362|DEVICE|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
48464837|NCT01139216|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
48464838|NCT01139216|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
48624935|NCT03893214|BEHAVIORAL|movie|Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
48624936|NCT02827968|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
48624937|NCT00000678|DRUG|Zidovudine|
48624938|NCT00000678|DRUG|Zalcitabine|
47936631|NCT01554969|DRUG|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
48464839|NCT04467619|DEVICE|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory \& motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
48464840|NCT04155840|DRUG|Copanlisib|Given IV
48464841|NCT04155840|BIOLOGICAL|Rituximab|Given IV
48624939|NCT03542409|OTHER|MR Perfusion Scan|MR perfusion scan before and during surgery.
48624940|NCT03542409|OTHER|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
48624941|NCT03542409|OTHER|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
47936632|NCT05419479|DRUG|ZIMBERELIMAB|Via IV on two days per cycle, dosage per protocol
47936633|NCT05419479|DRUG|DOMVANALIMAB|Via IV on two days per cycle, dosage per protocol
48099786|NCT03874156|DRUG|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
48099787|NCT03874156|DRUG|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
48099788|NCT06540196|DIAGNOSTIC_TEST|NodeAI|The ultrasound video and images of each LN will be analyzed by NodeAI, which will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
48099789|NCT06540196|DIAGNOSTIC_TEST|Surgeon|The ultrasound video and images of each LN will first be analyzed by the surgeon, who will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
48099790|NCT06628882|PROCEDURE|Infraclavicular Block|types of anesthesia used in upper extremity surgeries
48099791|NCT06628882|PROCEDURE|Wide-Awake Local Anesthesia with No Tourniquet|types of anesthesia used in upper extremity surgeries
48099792|NCT03201614|DEVICE|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
48099793|NCT03201614|DEVICE|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
48464842|NCT04155840|DRUG|Bendamustine|Given IV
48464843|NCT02082834|OTHER|abdominal MDCT examination|
48464844|NCT00003751|DRUG|penicillamine|
48464845|NCT00003751|RADIATION|radiation therapy|
48464846|NCT00850447|OTHER|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
48464847|NCT00850447|OTHER|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
48464848|NCT06357416|DEVICE|MV-POCT Sub-study|Point of care blood testing
48464849|NCT06357416|OTHER|Main Man Van Group Sub-study (MV-Eco)|Consent for long-term follow-up of patients
48464850|NCT06357416|OTHER|MV-QualQ Sub-study|Qualitative questionnaire and interview sub-study
48464851|NCT06357416|DIAGNOSTIC_TEST|MV-PRS Sub-study|Patients consenting to polygenic risk score testing
48464852|NCT06357416|OTHER|MV-DNA and MV-UctDNA Sub-study|Patients consenting to collection of DNA and urine for further study.
48464853|NCT06357416|OTHER|Man Van patients|All patients seen in Man Van
48464854|NCT06357416|OTHER|MV-SSI Sub-study|Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.
48464855|NCT06357416|OTHER|MV-TPP Sub-study|Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.
48464856|NCT06125002|DRUG|Diosmin750|The ingestion will occur orally, under monitoring by the responsible investigator.
47936634|NCT05419479|DRUG|APX005M|Via IV on two days per cycle, dosage per protocol
47936635|NCT05419479|DRUG|FOLFIRI|every two weeks through an infusion at a dose determined by physician
47936636|NCT03735173|PROCEDURE|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
47936637|NCT03735173|PROCEDURE|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
47936638|NCT03418571|BIOLOGICAL|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
47936639|NCT03418571|OTHER|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
47936640|NCT03804073|RADIATION|standard treatment|3000 cGy in 10 daily fractions
47936641|NCT03804073|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
48464857|NCT06125002|DRUG|Placebo|The ingestion will occur orally, under monitoring by the responsible investigator.
48464858|NCT03790241|PROCEDURE|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
48464859|NCT02052817|DEVICE|Optimal Medical Therapy Debridement + Toad Brace|
48464860|NCT02052817|OTHER|Optimal Medical Therapy - Debridement|
47936642|NCT01807702|DRUG|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
47936643|NCT05969418|DIAGNOSTIC_TEST|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter|Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter before and after ANTI-VEGF treatment
48464861|NCT03483350|DRUG|Granisetron|Ampoule
48464862|NCT03483350|DRUG|Midazolam|Ampoule
48464863|NCT06428149|PROCEDURE|Midline interproximal soft-tissue incision|Firstly, the marginal tissue will be elevated around the periodontal defect, through the tunneling of the tissues, entering through the gingival sulcus and the periodontal pocket of the teeth involved in the defect periodontal. Once the marginal tissues have been disinserted to full thickness, the soft supra-alveolar component of the defect to be reconstructed will be stretched, in a buccal direction, with a blunt instrument, applying pressure on the lingual aspect. Visualizing the midpoint of the interproximal tissue, the papilla will be dissected at its midpoint, entering through the mesial aspect, with the scalpel blade perpendicular to the central axis of the teeth.
47936644|NCT02388282|DEVICE|diaphragm ecography|recording of diaphragm ecography
47936645|NCT04577352|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
47936646|NCT04577352|DRUG|Placebo|Placebo will be administered per schedule specified in the arm.
47936647|NCT05249777|DRUG|TD0069 hard capsule|TD0069 hard capsule (800 ± 7.5% mg/capsule) contains 600 mg fine powder of mixed herbal medicines and 200 mg excipients.
47936648|NCT05249777|DRUG|TD0069 Placebo|TD0069 placebo (800 ± 7.5% mg/capsule) contains excipients
48099794|NCT03201614|DRUG|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
48464864|NCT06428149|PROCEDURE|Marginal approach by palatal incision|First, an incision will be made in the palatal aspect of the interproximal papilla, at the base of the papilla, parallel to the axis of the tooth until touching the palatine alveolar crest, in order to detach and move the papilla from its base, attached to the vestibular flap. From the palatal incision the interproximal tissue will be elevated towards the buccal until the buccal bone crest is exposed.
48464865|NCT06428149|PROCEDURE|Minimally invasive surgical technique|The defect will be accessed through an incision at the base of the papilla on the vestibular aspect. Depending on the anatomy of the interproximal space, two types of incisions will be made: simplified papilla preservation flap (SPPF) when the width of the interproximal space is equal to or less than 2 mm, or modified papilla preservation technique (MPPT) when the width is greater than 2 millimeters. The interproximal incision will extend intrasulcular on the lingual and buccal aspect of the teeth adjacent to the defect, and mesio-distally it will extend as necessary to allow access to the defect and its debridement. The papilla will move from its base towards the palatine.
48624942|NCT01027156|BEHAVIORAL|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
48624943|NCT05180058|OTHER|Wrapping + Breastmilk Group|Interventions applied during orogastric tube insertion
47936649|NCT02602977|OTHER|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
47936650|NCT02602977|OTHER|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
47936651|NCT02602977|BIOLOGICAL|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group \[n=10\], single-dose RIPC group \[n=10\] and control group \[n=10\]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
48099795|NCT06117254|BEHAVIORAL|Communication Counseling|Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.
48099796|NCT06117254|DEVICE|Hearing Aids|Hearing aids will be provided with amplification settings programmed specific to each participant's pure-tone hearing thresholds with subsequent adjustments based upon participant preferences. Standard noise cancelation and signal-to-noise ratio improvement strategies will be activated.
48099797|NCT06117254|DEVICE|Remote Microphones|Remote microphone systems will be provided for use with hearing aids.
48099798|NCT06631625|DRUG|Lidocaine Intravenous Infusion|Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
48281963|NCT06657261|PROCEDURE|The patient group receiving deep and superficial serratus anterior plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
48281964|NCT06657261|PROCEDURE|The patient group receiving a combination of deep serratus anterior plane block and transverse thoracic muscle plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
48281965|NCT02814773|OTHER|questionnaires|
48281966|NCT04232449|DRUG|PREDNISON Galepharm Tabl. 20 mg|5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
48099799|NCT06631625|DRUG|Lidocaine and ketamine|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
48099800|NCT06631625|DRUG|lidocaine and dexmedetomidine infusion|Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.
48281967|NCT04232449|DRUG|placebo tablets|5 daily- doses of placebo (2 tablets)
48281968|NCT06380244|OTHER|anesthesia without opioids|Opioid free general anesthesia
48281969|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
48281970|NCT00327444|DRUG|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
48281971|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
48281972|NCT05794529|OTHER|There are no interventions in the present study|There are no interventions in the present study
48281973|NCT03395522|DEVICE|iTind|device implanted for 5-7 days
48281974|NCT03893292|PROCEDURE|Total knee replacement|Patients will undergo total knee replacement surgery.
48281975|NCT03893292|DEVICE|COOLIEF|The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
48281976|NCT00373074|OTHER|Epidural Blood Patch|Use 15 cc of blood
48281977|NCT00373074|OTHER|Epidural Blood Patch|Inject 20 cc of blood into epidural space
48464866|NCT05724173|DEVICE|BrainGate Neural Interface System|Placement of the BrainGate2 sensor(s) into the speech-related cortex
48281978|NCT00373074|OTHER|Epidural Blood Patch|Inject 30 cc of autologous blood
48464867|NCT04491838|DRUG|Pozelimab|Single subcutaneous (SC) injection
48464868|NCT00516087|BIOLOGICAL|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2"
48281979|NCT00499707|DRUG|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
48281980|NCT04814537|DRUG|Bupivacaine Hydrochloride|Local Anesthetic Agent
48281981|NCT04246047|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
48281982|NCT04246047|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
48281983|NCT04246047|DRUG|Bortezomib|Proteasome Inhibitor
48464869|NCT01323127|PROCEDURE|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
48464870|NCT00582244|BEHAVIORAL|CBT and relaxation|Group A: CBT and relaxation.
48464871|NCT00582244|BEHAVIORAL|Physical activity|Group B: Physical exercise program.
48464872|NCT00582244|BEHAVIORAL|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
48464873|NCT00582244|OTHER|Control group|Waiting list control group
48464874|NCT04199416|DEVICE|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
48464875|NCT04199416|DEVICE|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
48464876|NCT03326167|OTHER|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
48464877|NCT01937806|DRUG|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
48464878|NCT01937806|DRUG|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
48281984|NCT04246047|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
48464879|NCT01021657|PROCEDURE|trabeculectomies, non penetrating deep sclerectomies|
48464880|NCT06173960|DEVICE|atherectomy|Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
48464881|NCT03380325|DRUG|Iloprost infusion|Iloprost is a stable prostacyclin analogue
48464882|NCT01634685|RADIATION|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
48464883|NCT01634685|DRUG|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
48464884|NCT01634685|DRUG|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
48464885|NCT03915977|BEHAVIORAL|Post ICU recovery program|Standardized follow up program
48624944|NCT02596672|BEHAVIORAL|The friendly walking group|A 12 week peer led walking group for adults and older adults (\> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
48624945|NCT04115228|DEVICE|Implantation and neuromodulation therapy|The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
48624946|NCT03934801|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
48624947|NCT03934801|OTHER|Ranking Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
48624948|NCT03934801|OTHER|Ranking Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
48624949|NCT03934801|OTHER|Ranking Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
48464886|NCT00844350|DRUG|letrozole , oxytocin,hCG,clomiphene citrate|
48464887|NCT03806491|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field. Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
48624950|NCT03412032|OTHER|assessment|different assessments in both arms
48464888|NCT03806491|BEHAVIORAL|Sleep Hygiene|Study therapists will review a one-page handout on sleep hygiene with all participants. This is the only intervention that participants assigned to the sleep hygiene condition will receive. This is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
48624951|NCT04075864|BEHAVIORAL|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
48624952|NCT05593458|DRUG|Oxaliplatin by arterial infusion plus S-1|3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
48464889|NCT03806491|BEHAVIORAL|Alcohol Use Disorder Treatment as Usual|CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
48281985|NCT05154474|OTHER|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
48464890|NCT02752854|OTHER|pain threshold measurement|pressure algometer
48464891|NCT02691676|DRUG|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
48464892|NCT02691676|DRUG|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
48464893|NCT03820258|DRUG|SOF/VEL/VOX|Administered once daily with food.
48464894|NCT00721955|DRUG|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
48464895|NCT00721955|DRUG|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
48464896|NCT00721955|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
48624953|NCT05593458|DRUG|SOX neoadjuvant|3 cycles of SOX neoadjuvant chemotherapy every 21 days.
48624954|NCT05593458|DRUG|Sintilimab neoadjuvant|3 cycles of neoadjuvant immunotherapy every 21 days.
48624955|NCT05593458|PROCEDURE|gastrectomy plus D2 lymph node dissection|All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.
48624956|NCT05593458|DRUG|SOX adjuvant, Sequential S-1|"3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation."
48624957|NCT05593458|DRUG|Sintilimab adjuvant|3 cycles of adjuvant immunotherapy every 21 days.
48624958|NCT00580398|BEHAVIORAL|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
48624959|NCT00580398|DRUG|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
48464897|NCT03454490|PROCEDURE|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
48464898|NCT03330496|OTHER|Pain Measurement|Measurement of infant responses (behavioral and physiological) during a painful procedure.
48624960|NCT06480357|PROCEDURE|laparoscopic adrenalectomy|laparoscopic transabdominal approach.
48624961|NCT01802047|PROCEDURE|milk expression with electric pump|
48624962|NCT05202405|DRUG|AD-221|AD-221 Oral Tablet
48624963|NCT05202405|DRUG|AD-221A and AD-221B|AD-221A Oral Tablet + AD-221B Oral Tablet
48464899|NCT03973151|DRUG|HL-085|HL-085 is one MEK inhibitor.
48464900|NCT05055687|DRUG|FL058|2500mg、3000mg
48624964|NCT06413329|BEHAVIORAL|preoperative physical activity level within 3 months|The exercise compliance criteria are moderate exercise of at least 150 minutes per week or high-intensity exercise of at least 75 minutes per week.
48624965|NCT01255020|DRUG|α-Keto Acid with restricted protein diet|"α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d"
48624966|NCT01255020|DRUG|Placebo plus restricted protein diet|"placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d."
48624967|NCT04249778|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Participants will receive 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
48624968|NCT04249778|DRUG|Placebo|Participants will receive a placebo to match 10 mg/day of dapagliflozin, beginning at hospital discharge, for 26 weeks.
48624969|NCT01674855|DRUG|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
48624970|NCT01674855|DRUG|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
48624971|NCT04358562|DRUG|Gefitinib|If persistence of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
48624972|NCT04358562|DRUG|Anlotinib|If clearance of plasma ctDNA EGFRm after 8 weeks of gefitinib first-line treatment
48624973|NCT04800796|OTHER|Audiovisual|Receive blended learning before and reading the Standard operating procedure
48624974|NCT00162734|DRUG|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
48624975|NCT06267404|OTHER|Iliopsoas Positional release therapy|Group A(Iliopsoas Positional release group) Patient supine, with both hips are fully extended .Find a Tender point in Iliopsoas muscle, at the initiation of pain Passively try combination of flexion Adduction/Abduction medial or lateral rotation at hip joint and stop where pain start to diminished. Hold this position of relief for 30 seconds until minimum of 75% of relief is achieved. Apply three times, than passively take lower limb in extension. Administered on both limbs.
48624976|NCT06267404|OTHER|Conventional exercises|Group B (conventional Physical therapy) For Ultra sonic therapy Patient prone lying, Aqua-sonic gel is applied to lumbosacral area and ultrasonic head is moved in circular motion. For TENS Electrodes are placed in crossed pattern, Paravertebral at L1 and L5 (Box Pattern)with circuit crossing at L3 and current is applied for 10 minutes, Hot pack which is kept in hydro-collateral at 70°C and 75°C is, wrapped in several towel layers, applied for 10 minutes.
48624977|NCT05508802|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
48624978|NCT05508802|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services they may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
48464901|NCT05055687|DRUG|Placebo|empty bottle
48464902|NCT05055687|DRUG|FL058|500mg、1000mg、2000mg
48464903|NCT05055687|DRUG|Placebo|empty bottle
48464904|NCT03438643|DIAGNOSTIC_TEST|Blood samples|Blood samples (42mL) will be taken before and during treatment.
48464905|NCT03438643|DIAGNOSTIC_TEST|skin biopsy|skin biopsy will be taken before and during treatment.
48464906|NCT03944057|DRUG|ATG-010|"ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)"
48464907|NCT05507996|DRUG|Recombinant adeno-associated virus administration|The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.
48464908|NCT00397254|DRUG|rizatriptan|10mg ODT 27 tablets
48464909|NCT00397254|DRUG|rizatriptan|10mg ODT 9 tablets
48464910|NCT01721772|BIOLOGICAL|BMS-936558 (Nivolumab)|
48281986|NCT02833311|BEHAVIORAL|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
48464911|NCT01721772|BIOLOGICAL|Placebo matching BMS-936558 (Nivolumab)|
48464912|NCT01721772|DRUG|Dacarbazine|
48464913|NCT01721772|DRUG|Placebo matching Dacarbazine|
48464914|NCT02980172|OTHER|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
48464915|NCT04483349|OTHER|Survey Administration|Complete survey
48624979|NCT00643253|BEHAVIORAL|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
47936652|NCT03565965|BEHAVIORAL|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
47936653|NCT03565965|BEHAVIORAL|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
47936654|NCT03490279|DIETARY_SUPPLEMENT|Lactoferrin CRX|Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
47936655|NCT03490279|OTHER|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
48099801|NCT05088226|DRUG|Ruxolitinib combined with Chidamide.|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
48099802|NCT01339702|OTHER|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
48281987|NCT02833311|BEHAVIORAL|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
48281988|NCT02833311|BEHAVIORAL|Contact Control Group|Participants are prescribed an exercise program and given information on healthy eating.
48281989|NCT04518384|PROCEDURE|colon or rectum resection|surgical procedure to resect the colon or rectum
48464916|NCT01887158|DRUG|Polyethylene glycol|
48464917|NCT01887158|DRUG|Bisacodyl|
48464918|NCT06176560|DRUG|Mesalazine|Oral Formulation
48464919|NCT00510419|DRUG|"InvestigationalAuto-injector (sumatriptan succinate)"|
48464920|NCT05568849|DIAGNOSTIC_TEST|OCTA measurements|OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
48464921|NCT05434091|DRUG|PF-07291177|PF-07291177 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
48464922|NCT05434091|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
48464923|NCT03258996|PROCEDURE|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
48464924|NCT03258996|PROCEDURE|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
48464925|NCT01610050|DRUG|LFA102|
48464926|NCT01361334|DRUG|Pazopanib|800 mg QD p.o.
48464927|NCT00776867|DRUG|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
48464928|NCT01710670|DRUG|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
48624980|NCT03073759|DEVICE|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
48624981|NCT03073759|DEVICE|Sham device|The device will administer a sham.
48624982|NCT03033836|DRUG|ARV treatment|Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
48099803|NCT03404336|BEHAVIORAL|Well-Being Therapy|Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
48099804|NCT03404336|OTHER|Control condition|Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
48464929|NCT01710670|OTHER|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
48624983|NCT05604950|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
48624984|NCT06290999|DIAGNOSTIC_TEST|multifrequential admittancemetry|"Every participant of the study have to complete an Ear, Nose and Throat examination included a conventional audiometry, and a multifrequential admittancemetry.~if radio-interventional venous stenting is not indicated, an multifrequential admittancemetry will also be performed 3 months after the procedure."
48624985|NCT03012776|DEVICE|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
48624986|NCT03012776|PROCEDURE|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
48624987|NCT02395770|OTHER|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching \& Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
48624988|NCT03270488|OTHER|Laser|Laser (power of 3.0w).
48624989|NCT03270488|OTHER|Placebo|Laser (power 0,0w)
48624990|NCT01859819|DRUG|Rituximab|
48624991|NCT01859819|DRUG|IT Cytarabine|
48624992|NCT01178931|DRUG|Oral dydrogesterone|oral-2x10mg
48624993|NCT01178931|DRUG|Crinone 8% gel|vaginal-1x90mg
48624994|NCT06357702|BEHAVIORAL|Physical Self Regulation Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes awareness and strategies for monitoring habits and 4 exercises to practice 5 times per day. Session 2 will be 2 weeks later and is a review of session 1 and an introduction to diaphragmatic breathing. Breathing is practiced for 15 minutes twice per day.
48624995|NCT06357702|BEHAVIORAL|Psycho-education Telehealth|2 sessions of an intervention delivered via telehealth. Session 1 includes discussing trigeminal nerve function, jaw and muscle anatomy, posture, pain referral patterns, and stress biology. Participants rate pain and jaw fatigue 5 times per day. Session 2 will be 2 weeks later and consists of checking on the homework and information from session 1,followed by a discussion of autonomic nervous system activity, and a discussion of sleep quality and sleep hygiene. Participants will be instructed to rate their stress levels, pain, and mood several times per day, similar to the times when participants in the PSR-TH condition would be practicing diaphragmatic breathing
48099805|NCT02165059|PROCEDURE|Surgical Full Thickness Biopsy|Eligible subjects will undergo a surgical full thickness biopsy of the stomach and/or proximal jejunum as part of their planned surgery.
48099806|NCT01068249|DRUG|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
48099807|NCT01068249|DRUG|RAD001 (Everolimus)|10 mg by mouth daily
48464930|NCT01710670|OTHER|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
48478869|NCT00601757|BEHAVIORAL|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
48624996|NCT04772235|DRUG|Repotrectinib|"Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib."
48624997|NCT04772235|DRUG|Osimertinib|"Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib"
48624998|NCT05862701|DRUG|Permethrin|5% permethrin cream
48624999|NCT05862701|DRUG|Sulphur|10% Sulfur ointment
48625000|NCT03558724|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
48464931|NCT01710670|OTHER|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
48464932|NCT00481169|DRUG|Bazedoxifene Acetate (TSE-424)|
48625001|NCT03558724|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
48625002|NCT05815927|DRUG|Pembrolizumab|Pembrolizumab: 400mg Q6W up to 2 years (i.e 17 cycles).
48625003|NCT05815927|RADIATION|stereotattic ablation radiotherapy (SABR)|Total dose and number of fractions will depend on the site of the disease. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments have to be completed within 10 working days.
48625004|NCT05007444|DRUG|P2Et (Caesalpinia spinosa extract)|Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
48625005|NCT05007444|DRUG|Placebo|After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
48625006|NCT02630654|OTHER|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
48625007|NCT03476577|DRUG|Ibuprofen|Patients are tested for their normal prescription ibuprofen medication
48625008|NCT02429739|BEHAVIORAL|Working memory Training|"The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.~Other name: Cogmed RoboMemo"
48625009|NCT04783948|OTHER|Brace Treatment|Compliance to brace compression used for the correction of pectus carinatum will be evaluated.
48625010|NCT04619537|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
48625011|NCT03685513|OTHER|BioHPP PEEK-based single posterior crowns|BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
48625012|NCT03685513|OTHER|Metal ceramic single posterior crowns|Standard metal coping veneered with glass ceramics
48625013|NCT00615316|DRUG|Guaraná|Guaraná extract 75mg/day
48625014|NCT00615316|DRUG|Placebo|Placebo 1tab/d
48625015|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
48625016|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
47936656|NCT01645722|PROCEDURE|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
48099808|NCT05805124|DIAGNOSTIC_TEST|Preop evaluation|"All preop evaluations prescribed in the preadmission clinic will be recorded, especially:~* renal function tests~* hematologic tests~* coagulation tests~* hepatic function tests~* ECG~* cardiac function tests~* pulmonary function tests~* endocrine function tests"
48099809|NCT00326027|DRUG|Pantoprazole|Efficacy of Pantoprazole
48099810|NCT02140554|GENETIC|lovo-cel|lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.
48464933|NCT00594503|DRUG|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
48464934|NCT00913536|OTHER|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
48464935|NCT05324891|DRUG|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
48464936|NCT05324891|DRUG|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
48464937|NCT04899076|DEVICE|Stool Processing Kit|The Stool Processing Kit is a centrifuge-free stool processing solution that allows preparation of stool samples for testing with the Xpert Ultra MTB/RIF assay
48464938|NCT06283888|DRUG|CYP2C19 Genotype Guided DAPT|Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd
48625017|NCT04602000|BIOLOGICAL|Placebo|Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
47936657|NCT02806193|PROCEDURE|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
48099811|NCT05025449|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST)|The Focused Assessment with Sonography for Trauma (FAST) exam is widely used and accepted as part of Advanced Trauma Life Support (ATLS) protocol. After consent, a baseline FAST exam will be performed and documented. This FAST will be distinct from the initial ATLS resuscitation FAST in order to avoid any interference in the trauma evaluation. The investigator will use a phased array or curvilinear transducer to record video of their baseline FAST exam.
48464939|NCT06283888|DRUG|Conventional DAPT|Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
48464940|NCT06369935|DRUG|Equecabtagene Autoleucel|Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
48464941|NCT01591915|OTHER|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
48464942|NCT01556906|DRUG|Lomitapide|Oral administration with escalating doses administered once daily
48464943|NCT06127186|DIAGNOSTIC_TEST|Swab test for viral antigens|No intervention except for a routine examination and viral testing is planned.
48464944|NCT03116776|PROCEDURE|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
48464945|NCT03116776|DRUG|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
48464946|NCT02416934|DRUG|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
48464947|NCT02416934|DRUG|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
48464948|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
48464949|NCT01342991|PROCEDURE|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
48464950|NCT04361838|BEHAVIORAL|prayer|receive prayers daily while in ICU
48464951|NCT00090753|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
48625018|NCT04602000|BIOLOGICAL|CT-P59|CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
48625019|NCT04602000|BIOLOGICAL|Placebo|Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
48625020|NCT00420264|DEVICE|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
47936658|NCT00576212|BEHAVIORAL|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
47936659|NCT03462069|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
47936660|NCT03462069|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
48464952|NCT00090753|DRUG|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
48464953|NCT00090753|DRUG|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
48464954|NCT00090753|DRUG|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
48464955|NCT05109520|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|Switch during standard routine care to Gla-300.
48625021|NCT04616521|PROCEDURE|Deep brain stimulation|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
48625022|NCT03380741|DIAGNOSTIC_TEST|Tumour markers detection|Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
48625023|NCT02558751|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
48625024|NCT02558751|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
48281990|NCT03982667|DIAGNOSTIC_TEST|PCT-guided group|In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and \<0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of \< 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
48281991|NCT00049127|DRUG|Imatinib Mesylate|Given PO
48625025|NCT05472298|BEHAVIORAL|self-management intervention|lifestyle modification, goal setting, coaching and peer support, problem-solving
48464956|NCT02174185|BEHAVIORAL|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
48464957|NCT01259830|DRUG|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
48464958|NCT01259830|DRUG|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
48625026|NCT01183637|DEVICE|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
48625027|NCT01183637|PROCEDURE|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
48625028|NCT02794805|DEVICE|¹³C-Octanoate Breath Test|Octanoate Breath Test to be performed on subjects with suspected HCC
48625029|NCT01159353|DRUG|Insulin glulisine|Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
48625030|NCT01159353|DRUG|Insulin aspart|Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
48099812|NCT05025449|DRUG|Bubble-Enhanced FAST (BEFAST)|Following the FAST exam and using the same machine, a BEFAST exam will be performed using a low mechanical index setting in contrast-specific imaging mode. A 2.4 mL IV dose of Lumason will be injected into the subject's IV, followed by saline flush. The contrast will be injected once for the right side of the body, and once for the left side of the body looking for disruptions in the normal enhancement pattern and evidence of active bleeding. To examine the right side of the body: the liver will be imaged first in arterial phase, followed by the right kidney, before returning to image the liver in venous phase. To examine the left side of the body: the pancreas will be imaged first, followed by the kidney and the spleen. The investigator will note evidence of solid organ injury, free fluid, or active extravasation on both sides of the body; lacerations will be graded by the American Association for the Surgery of Trauma (AAST) criteria.
48099813|NCT01249092|DRUG|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
48099814|NCT05644262|DRUG|T2:C100|"The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil. T2:C100 is a full spectrum oral solution with five non-reactive ingredients: delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a pharmaceutical grade medium chain triglyceride (MCT) oil, and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL study drug (T2:C100) twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL study drug twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks)).~Participants who enter the Open Label Extension will receive 1mL study drug (T2:C100) twice daily for Week 12 - Week 13 (approximately 1 week), and will then increase to 2mL study drug twice daily for the remainder of the Open Label Extension (Week 13 - Week 26 (approximately 23 weeks))."
48281992|NCT00049127|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48281993|NCT00049127|OTHER|Pharmacological Study|Optional correlative studies
48281994|NCT06021457|DRUG|RBT-1|Intravenous administration
48281995|NCT06021457|DRUG|Placebo|Intravenous administration
48281996|NCT01191593|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
48281997|NCT01191593|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
47936661|NCT03462069|DRUG|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
47936662|NCT03462069|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
47936663|NCT03833947|DRUG|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
47936664|NCT03833947|DRUG|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
47936665|NCT04450459|DIAGNOSTIC_TEST|ergospirometer test|ergospirometric test will be done before cardiac catheterisation and invasive measurement of FFR
47936666|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
47936667|NCT01017575|DRUG|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
47936668|NCT01017575|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
47936669|NCT01017575|DRUG|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
47936670|NCT01017575|DRUG|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
47936671|NCT01739400|DRUG|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
48625031|NCT01116843|DRUG|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
48099815|NCT05644262|DRUG|Placebo|"Matching placebo in a digestible oil. The placebo contains only three non-reactive ingredients: medium chain triglyceride (MCT) oil and two flavoring agents (lemon and peppermint).~During the double-blind treatment period, participants will receive 1mL placebo twice daily for Baseline - Day 7 (approximately 1 week), and then will increase to 2mL placebo twice for the remainder of the double-blind treatment period (Day 7 - Week 12 (approximately 11 weeks))."
48625032|NCT02090595|BEHAVIORAL|MBCT-C|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
48625033|NCT02090595|BEHAVIORAL|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
48625034|NCT06334198|DRUG|Naldemedine|Naldemedine is administered orally once daily in the morning in a dosage of 0.2 mg.
48625035|NCT06334198|DRUG|Placebo|Placebo is administered orally once daily in the morning.
47936672|NCT05599919|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
47936673|NCT05469685|DRUG|Vonoprazan|Potassium-competitive acid blocker
47936674|NCT05469685|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
48099816|NCT05903482|OTHER|None - observational|Observational
48099817|NCT05293301|DEVICE|Use of Periodontal Endoscope (Perioscopy®) to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using a Periodontal Endoscope or Perioscopy® for enhanced visualization, on teeth in one half of the mouth
48099818|NCT05293301|DEVICE|Use of traditional loupes to enhance magnification to enhance visualization while performing teeth deep cleaning|Deep cleaning or scaling and root planing (SRP) using tradional loupes for enhanced visualization on teeth, in the other half of the mouth
48099819|NCT06166719|OTHER|No intervention|No intervention
48099820|NCT03425604|PROCEDURE|Intrauterine insemination|
48281998|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
48281999|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
48464959|NCT00674908|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
48282000|NCT00257751|PROCEDURE|Aprotinine|
48625036|NCT06334198|DRUG|Tramadol|In both arms, tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200mg).
48625037|NCT01145222|DRUG|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
48625038|NCT01145222|DRUG|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
48625039|NCT01145222|DRUG|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
48625040|NCT01145222|DRUG|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
48625041|NCT05079087|PROCEDURE|Pericapsular nerve group blockade|The PENG-block will be administered under ultrasound (US) guidance with a low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease at the level of the anterior superior iliac spine. Scanning will be done with gradual caudal movement of the probe. After the anterior inferior iliac spine (AIIS) is visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of the superior pubic ramus is visible. The Psoas muscle with its prominent tendon will be identified just above the pubic ramus. The target is the plane between the 2 structures. While aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a 22 Go 10 cm needle will be introduced and 20 ml of anesthetic solution administered.
48625042|NCT05079087|DRUG|Midazolam Ketamine arm|Patients in the second group will undergo sedation and analgesic treatment with Ketamine and Midazolam titrated to the best Verbal Rating Score without respiratory and cardiovascular depressant effect.
48625043|NCT06418815|OTHER|Concept map group|The intervention group will create a concept map regarding neonatal toxic stress.
48625044|NCT02412657|DRUG|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
48625045|NCT02412657|DRUG|Normal Saline|
48625046|NCT01908842|DRUG|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
47936675|NCT02891616|DRUG|fludeoxyglucose F 18|
47936676|NCT02891616|DEVICE|Positron emission tomography-computed tomography|
47936677|NCT02891616|DRUG|18F-fluorothymidine|
47936678|NCT02891616|DEVICE|Positron emission tomography-magnetic resonance imaging|
47936679|NCT05303272|DRUG|Abatacept Prefilled Syringe|Abatacept (Orencia) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product. Combined with standard of care prednisone 10-40mg qd
48282001|NCT05718362|BEHAVIORAL|Ayres Sensory Integration Therapy|It is an intervention method whose effectiveness is questioned. It is a therapy program applied according to Ayres Sensory Integration Fidelity Measure.
48282002|NCT05718362|BEHAVIORAL|Home Program|These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.
48282003|NCT02732951|DRUG|BI 1026706|
48464960|NCT00674908|BIOLOGICAL|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
48464961|NCT00033150|BEHAVIORAL|Fast ForWord|
48464962|NCT00033150|BEHAVIORAL|Computer Assisted Language Intervention|
48625047|NCT01908842|DRUG|BNX sublingual film|Buprenorphine/naloxone sublingual film
48625048|NCT01908842|DRUG|Buprenorphine|Buprenorphine sublingual tablets
48625049|NCT02782104|DRUG|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
48464963|NCT00033150|BEHAVIORAL|Individual Language Intervention|
48625050|NCT01765491|OTHER|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
48625051|NCT01765491|OTHER|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
48625052|NCT01718067|DEVICE|VAKÜM system|15 minutes, twice a day.
48625053|NCT01718067|OTHER|conventional manual ELTGOL technique|20 minutes twice a day
48464964|NCT00033150|BEHAVIORAL|Academic enrichment|
48625054|NCT02850562|BEHAVIORAL|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
48625055|NCT02850562|BEHAVIORAL|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
48625056|NCT01233830|DRUG|AZD2423|oral solution
48464965|NCT04943822|OTHER|A new APP|A new APP for prevention and treatment of complications of intestinal peristomal skin
48625057|NCT01233830|DRUG|Placebo|oral solution
48625058|NCT04215575|DEVICE|glaucoma implant procedure (Baerveldt)|A 350 mm2 Baerveldt glaucoma implant was placed in the superotemporal quadrant in 25 patients randomized to BGI group. A limbus-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
48099821|NCT03570333|DIAGNOSTIC_TEST|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
48282004|NCT02732951|DRUG|Placebo|
48282005|NCT05290220|DRUG|HLX07|1500 mg
48625059|NCT04215575|DEVICE|glaucoma implant procedure (Ahmed)|A 184 mm2 Ahmed glaucoma implant was placed in the superotemporal quadrant in 56 patients randomized to AGV group. A fornix-based conjunctival flap was dissected, and the implant was sutured to sclera 10 mm posterior to the limbus. The Ahmed tube left patent and viscoelastic substance injected into anterior chamber. A scleral graft was used to cover the limbal portion of the tube, and the conjunctiva was closed.
48625060|NCT00690898|DRUG|Lanreotide autogel 120 mg|12 months
48625061|NCT01422447|OTHER|regular intervention|the subjects in the control group live in the used model
48625062|NCT01422447|OTHER|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
48625063|NCT03097315|DRUG|4 mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
48625064|NCT03404167|DRUG|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
48625065|NCT03279419|DIAGNOSTIC_TEST|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
48625066|NCT05124782|OTHER|Rheumatoid Arthritis Impact of Disease questionnaire|Rheumatoid Arthritis Impact of Disease questionnaire
48625067|NCT03429205|OTHER|No external heating used during surgery|Deviation from external heating for all surgery standard
48282006|NCT05290220|DRUG|HLX10|300 mg
48464966|NCT00522041|DRUG|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
48625068|NCT03429205|OTHER|External heating blanket used during surgery|Standard external heating plan used in all surgery types
48464967|NCT00522041|DRUG|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
48625069|NCT00546273|BIOLOGICAL|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
48464968|NCT02591849|DIETARY_SUPPLEMENT|Glucagon-like peptide-1 (GLP-1)|
48464969|NCT02591849|OTHER|Isotonic saline|
48464970|NCT02591849|OTHER|Hyperglycemic clamp|
48464971|NCT03196817|DRUG|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
48625070|NCT00546273|BIOLOGICAL|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
48282007|NCT05290220|DRUG|HLX04|15mg/kg
48464972|NCT03196817|DEVICE|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
48464973|NCT03685617|DEVICE|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
48625071|NCT00546273|BIOLOGICAL|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
48625072|NCT00546273|BIOLOGICAL|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
48625073|NCT00546273|BIOLOGICAL|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
48464974|NCT03685617|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
48625074|NCT04599218|OTHER|Prostate Biopsy|Standard of care
48625075|NCT04599218|OTHER|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.
48625076|NCT04599218|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
48625077|NCT01054248|DRUG|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
48625078|NCT01054248|DRUG|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
48625079|NCT01054248|DRUG|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
48625080|NCT02580071|DIETARY_SUPPLEMENT|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
48625081|NCT04182893|DIAGNOSTIC_TEST|ctDNA and Exosome Combined Detection|Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
48625082|NCT04705571|DEVICE|MorpheusV Applicator|1 treatment with the MorpheusV Applicator
48625083|NCT03727581|DIAGNOSTIC_TEST|Ultrasound guidance|Jugular vein is punctured with ultrasound guidance and guidewire is advanced. Right atrium and inferior vena cava junction is visualized by ultrasound using substernal view. Presence of guidewire in inferior vena cava or right atrium is confirmed. The procedure of catheter insertion is continued.
48625084|NCT06359522|DEVICE|NIRS monitor|NIRS monitoring data will be collected to determine organ perfusion.
48625085|NCT02355834|OTHER|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
48625086|NCT01492036|OTHER|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
48282008|NCT05290220|DRUG|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
48625087|NCT01492036|BEHAVIORAL|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
48625088|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|
48625089|NCT00922051|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Placebo
48282009|NCT02832271|DRUG|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
48282010|NCT02832271|DRUG|Placebo|Placebo
48282011|NCT03030040|BEHAVIORAL|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
48282012|NCT03016611|DRUG|Chewing Ticagrelor LD|180 mg Chewing Ticagrelor
48282013|NCT03016611|DRUG|Chewing Prasugrel LD|60 mg Chewing Prasugrel
48282014|NCT05718115|DIAGNOSTIC_TEST|CT scan|Biphasic CT scan including arterial phase and portal venous phase after intravenous injection of 80-100 mL of non-ionic iodinated contrast at rate of 4ml/s using pressure injector.
48282015|NCT00805207|DRUG|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
48282016|NCT00805207|DRUG|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
48282017|NCT00805207|DRUG|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
48282018|NCT00805207|DEVICE|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
47936680|NCT05303272|DRUG|Mycophenolate Mofetil 500Mg Tab|MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
48464975|NCT05311150|DEVICE|Narrow band imaging bronchoscopy guided endobronchial biopsy|Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
47936681|NCT06060821|OTHER|No intervention|No intervention
48464976|NCT05311150|DEVICE|White light bronchscopy guided endobronchial biopsy|Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
48464977|NCT02650973|DRUG|CHS-1701|
48464978|NCT02650973|DRUG|Pegfilgrastim|
48464979|NCT03407222|OTHER|Text messages|Text messages which encourage the increment of daily step count
48625090|NCT03357055|DRUG|Ketamine|IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
48625091|NCT03357055|DRUG|Normal saline|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
48625092|NCT00283582|DRUG|rhTPO|
47936682|NCT03002376|DRUG|REGN2810|REGN2810 treatment
47936683|NCT02794740|DRUG|X0002|External Spray
47936684|NCT02794740|DRUG|Placebo|External Spray
47936685|NCT00396747|DRUG|Infliximab, methylprednisolone, methotrexate|
47936686|NCT00396747|DRUG|Methotrexate|
47936687|NCT00396747|DRUG|Methotrexate + Methylprednisolone|
47936688|NCT00396747|DRUG|Methotrexate + Infliximab|
47936689|NCT02424214|OTHER|Artificial Oocyte activation|
47936690|NCT02424214|DRUG|Ca Ionophore|
47936691|NCT02424214|DRUG|Strontium Chloride|
47936692|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
48099822|NCT03244176|DRUG|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
48099823|NCT04742751|DRUG|Metformin|To begin week 12 for participants who remain prediabetic after 12 week lifestyle run-in. Dosage and Route of Administration: 500 mg dose/ day to be taken orally, increased to 1000 mg dose/ day at week 14 through week 24. The dose should be taken immediately following the evening meal and at approximately the same time daily
48282019|NCT00805207|DRUG|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
48282020|NCT00805207|OTHER|Control|No treatment with studies performed 31 to 72 days apart
48282021|NCT06225817|DIETARY_SUPPLEMENT|Open-label placebo pills|The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
47936693|NCT00623584|PROCEDURE|Corneal transplantation|Full thickness penetrating keratoplasty
48282022|NCT04438655|DRUG|Oral antibiotic drugs|"Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon."
48282023|NCT04438655|DRUG|Parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
48282024|NCT02696083|DEVICE|Provant Therapy System|
48282025|NCT01320228|DIETARY_SUPPLEMENT|Control|Alli treatment plus placebo (rice flour)
48282026|NCT01320228|DIETARY_SUPPLEMENT|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
48282027|NCT01320228|DIETARY_SUPPLEMENT|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
48282028|NCT01320228|DIETARY_SUPPLEMENT|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
48282029|NCT05386914|DRUG|Sirolimus|1 mg of Sirolimus taken orally once a day for 4 weeks.
48282030|NCT02017444|DRUG|AZD4017|
48282031|NCT02017444|OTHER|Placebo|Matched placebo (matched to AZD4017 arm)
48282032|NCT05847881|BEHAVIORAL|Self-guided at home activities|After the kick-off meeting participants will complete the cultural probe kit for 3 weeks. This kit is a design research tool, to prompt participants to document, map, journal, and reflect on various aspects of daily lives. Following this, participants will attend a facilitated workshop and then complete the next at-home kits.
48282033|NCT06623981|BEHAVIORAL|Enhanced Brief Interpersonal Psychotherapy|Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
48282034|NCT06623981|BEHAVIORAL|Supplemented Usual Care|Usual care for caregivers with PHQ-9 scores 10-27 involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
48464980|NCT05024487|DIAGNOSTIC_TEST|Clinical Examination|Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.
48625093|NCT01034423|DIETARY_SUPPLEMENT|Omega-3|Capsules with omega-3 fatty acids.
48099824|NCT04742751|BEHAVIORAL|Digital Intervention|"Lifestyle Change Digital Intervention - This is a digital platform that will include a core curriculum focused on diet, exercise, and behavioral strategies for goal setting and self-monitoring to improve diet including a weight loss On Day 1, participants will begin their digital lifestyle intervention using their smart-phone application with their lifestyle coach and peer group.~On day 14, participants will be contacted by phone (+/- 4 days, day 10 to 18) and adherence assessed using virtual pill counts via phone calls.~At weeks 4, 8, 16 and 20 a phone-based pill count for adherence and adverse event symptom log will be completed and study medication dispensed.~At week 12 (interim assessment) and 24 (study-end), the participant will return to St. Jude Children's Research Hospital (SJCRH) for an in-person assessment.~The digital lifestyle change program will complete at week 24."
48099825|NCT05227469|BEHAVIORAL|myofunctional therapy|In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
48099826|NCT00763282|BEHAVIORAL|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
48099827|NCT00763282|BEHAVIORAL|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
48099828|NCT00763282|BEHAVIORAL|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
48099829|NCT02104609|DRUG|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
48464981|NCT01524016|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
48464982|NCT03310593|DRUG|Cannabidiol|Cannabidiol as active intervention.
48464983|NCT03310593|DRUG|Placebo|Placebo intervention.
48625094|NCT01034423|DIETARY_SUPPLEMENT|sun flower oil|Capsules with sun flower oil.
48099830|NCT00768066|BIOLOGICAL|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
48282035|NCT03446677|OTHER|Postural Stability Testing|Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
48282036|NCT02183389|DRUG|Warfarin|
48282037|NCT02183389|DRUG|BI 1356|
48282038|NCT05760495|OTHER|blood sampling|Blood sampling for evaluation of oxidative stress markers
48282039|NCT06122077|DIAGNOSTIC_TEST|blood draw|Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.
48282040|NCT03394950|DRUG|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
48282041|NCT03394950|DRUG|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
48464984|NCT05546099|BEHAVIORAL|Self-management of BP medications|Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.
48464985|NCT05546099|BEHAVIORAL|Self-monitoring of home BP|Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
48464986|NCT04883788|OTHER|Pandemic period|Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
48464987|NCT00000708|DRUG|Flucytosine|
48464988|NCT00000708|DRUG|Fluconazole|
48464989|NCT00000708|DRUG|Amphotericin B|
48464990|NCT00292760|DRUG|Alemtuzumab|
48464991|NCT00292760|DRUG|Methyprednisolone|
48464992|NCT05192096|BEHAVIORAL|Train-the-trainer workshop|To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
48464993|NCT01802216|PROCEDURE|Scaling and root planing|non-surgical periodontal disease treatment
48464994|NCT01802216|DRUG|Minocycline|antibiotic microspheres
48464995|NCT03494686|PROCEDURE|LLETZ under local anaesthesia|Conization will be performed under local anaesthesia
48625095|NCT01601795|DRUG|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
48625096|NCT01601795|DRUG|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
48625097|NCT04889274|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
48625098|NCT04889274|BIOLOGICAL|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
48625099|NCT04889274|BIOLOGICAL|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
48625100|NCT05549245|DEVICE|high-flow nasal cannula oxygen therapy,|Patients were treated with high-flow nasal cannula oxygen therapy for three nights
48625101|NCT05549245|DEVICE|CPAP|Patients were treated with CPAP for three nights
48464996|NCT03494686|PROCEDURE|LLETZ under general anaesthesia|Conization will be performed under general anaesthesia
48464997|NCT02040961|DEVICE|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
48464998|NCT01207856|BEHAVIORAL|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
48464999|NCT01207856|BEHAVIORAL|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
48625102|NCT05146765|DEVICE|Mobile application|Device: Use of mobile application Participants will be instructed to use the speech therapy app for 30 minutes to one hour per day over a 4-week period.
48625103|NCT05146765|OTHER|Treatment as usual|The patients will follow the treatment as usual, including conventional stroke therapy if needed based on the medical guidelines.
48625104|NCT04807296|PROCEDURE|TFLEP|"Thulium fiber laser (TFL) is a novel laser technology that delivers a pulsed laser at a more optimal wavelength and a shallower depth of tissue penetration leading to better hemostatic properties. Patients will undergo thulium fiber laser enucleation of the prostate (TFLEP) at the Centre Hospitalier de l'Université de Montréal (CHUM) as a treatment for benign prostate hyperplasia. The surgeon performing TFLEP is experienced in TFLEP procedures.~Fifty (50) patients will undergo TFLEP."
48625105|NCT04807296|PROCEDURE|m-HoLEP|"The holmium: yttrium-aluminum-garnet (Ho: YAG) laser is the longest running and most studied laser used to perform this minimally invasive procedure. Holmium laser enucleation of the prostate reduces hospital stay and hemoglobin drop while improving IPSS and quality of life, as well as other positive postoperative outcomes compared to the historical gold standard, transurethral resection of the prostate (TURP). HoLEP has been found to have a better enucleation efficiency rate and may have better hemostatic properties when combined with the modulated pulsed laser energy featured associated with Moses technology (m-HoLEP). Patients will undergo m-HoLEP at the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île-de-Montréal as a treatment for benign prostate hyperplasia. The surgeon performing m-HoLEP is experienced in m-HoLEP procedures.~Fifty (50) patients will undergo m-HoLEP"
48625106|NCT05831072|BEHAVIORAL|Mindfulness-cognitive oriented group program|Mindfulness-cognitive oriented group program is a 4-week program based on the theory of mindfulness-based cognitive therapy (MBCT). The main elements of MBCT such as mindfulness breathing, raisin meditation for mindful eating, body scan and mindfulness walking are included. In addition to the weekly intervention, participants are also required to do the mindfulness practice at home.
48625107|NCT02406612|DEVICE|X-Seal 6F Vascular Closure Device|
48099831|NCT00768066|BIOLOGICAL|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
48099832|NCT00768066|BIOLOGICAL|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
48465000|NCT01207856|OTHER|no intervention|no intervention
48465001|NCT04371263|OTHER|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
48625108|NCT05331924|PROCEDURE|IPL therapy|Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.
48625109|NCT05331924|PROCEDURE|Punctal plugs|Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
48625110|NCT03360669|OTHER|Sequence: Clinical/Research|Participants will be assigned to a sequence of: research visit first/clinical visit second.
48625111|NCT03360669|OTHER|Sequence: Research/Clinical|Participants will be assigned to a sequence of: clinical visit first/research visit second.
48099833|NCT03797235|PROCEDURE|Dominant Arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
48625112|NCT02054949|DRUG|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
48625113|NCT05993143|DRUG|Ivermectin|Round and white tablets
48282042|NCT01538615|BEHAVIORAL|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
48625114|NCT05993143|DRUG|Placebo|Round and white tablets
48465002|NCT00150683|DEVICE|vibration and passive standing versus passive standing alone|
48625115|NCT04038398|PROCEDURE|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
48625116|NCT00742456|DIETARY_SUPPLEMENT|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
48625117|NCT00742456|DIETARY_SUPPLEMENT|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
48625118|NCT01963806|BEHAVIORAL|Smartphone-supplemented iCBT|"The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support."
48099834|NCT03797235|PROCEDURE|Non-dominant arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
48099835|NCT00831792|DRUG|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
48099836|NCT06620302|BIOLOGICAL|Bcl-XL Proteolysis Targeting Chimera DT2216|Given IV
48099837|NCT06620302|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48099838|NCT06620302|DRUG|Irinotecan (drug)|Given IV
48099839|NCT04598529|OTHER|A2 milk|a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
48099840|NCT04598529|OTHER|Conventional milk|cow's milk with a mixture of A1 and A2 beta-casein.
48282043|NCT01475955|DRUG|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
48282044|NCT01475955|DRUG|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
48282045|NCT01475955|DRUG|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
48282046|NCT01475955|DRUG|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
48282047|NCT01475955|DRUG|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
48282048|NCT01475955|DEVICE|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
48282049|NCT04813744|PROCEDURE|Atraumatic restorative treatment|
48465003|NCT02284139|DRUG|Arm EGF ointment 1ppm|EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
48465004|NCT02284139|DRUG|Arm EGF ointment 20 ppm|EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
48465005|NCT02284139|DRUG|Arm Placebos|EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
48465006|NCT03868631|DIETARY_SUPPLEMENT|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
48465007|NCT03868631|DIETARY_SUPPLEMENT|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
48465008|NCT04566549|COMBINATION_PRODUCT|Test group Probiotic Shampoo|Probiotic Shampoo
48465009|NCT04566549|COMBINATION_PRODUCT|Placebo group|Shampoo base
48465010|NCT05314062|DIETARY_SUPPLEMENT|FeSO4|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
48625119|NCT01963806|BEHAVIORAL|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
48625120|NCT01963806|OTHER|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
48625121|NCT02184117|DRUG|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
48625122|NCT02184117|DRUG|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
48625123|NCT02184117|DRUG|Resting conditions|Baseline measurement of aortic and coronary pressures
48625124|NCT06377085|DRUG|Placebo for the AZA 10mg/m^2|Placebo control group for the 10mg/m\^2, one-time subcutaneous injection without the active treatment.
47936694|NCT06551103|BEHAVIORAL|Intervention group trained in line with the Health Promotion Model|A literature review was conducted by the researchers within the scope of Health Promotion Model and a educational material was prepared. With this educational material, the patients in the intervention group were trained in four sessions lasting 25 minutes each.
48465011|NCT05314062|DIETARY_SUPPLEMENT|Ao iron|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
48465012|NCT01898845|DRUG|LEE011|
48465013|NCT02901730|PROCEDURE|532nm laser group|LPI with 532nm laser.
48465014|NCT02901730|PROCEDURE|561nm laser group|LPI with 561nm laser.
48465015|NCT01105182|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
48465016|NCT03920449|DRUG|Botulinum Toxins|In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
48282050|NCT04030130|BEHAVIORAL|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months).
48282051|NCT03319550|DIETARY_SUPPLEMENT|Casein|see experimental description
48282052|NCT03319550|DIETARY_SUPPLEMENT|Whey|see experimental description
48282053|NCT03319550|DIETARY_SUPPLEMENT|Leucine-enriched whey|see experimental description
48625125|NCT06377085|DRUG|Placebo for the AZA 20mg/m^2|Placebo control group for the 20mg/m\^2, one-time subcutaneous injection without the active treatment.
48625126|NCT06377085|DRUG|Placebo for the AZA 35mg/m^2|Placebo control group for the 35mg/m\^2, one-time subcutaneous injection without the active treatment.
48625127|NCT06377085|DRUG|Placebo for the AZA 75mg/m^2|Placebo control group for the 75mg/m\^2, one-time subcutaneous injection without the active treatment.
47936695|NCT05629104|OTHER|There is no intervention since it is an observational study patients are treated according to clinical praxis|No intervention
47936696|NCT02366598|OTHER|Hemp shake|Hemp protein shake
47936697|NCT02366598|OTHER|Soybean shake|Soybean protein shake
47936698|NCT02366598|OTHER|Control|Non-protein shake
48099841|NCT03780309|BEHAVIORAL|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
48099842|NCT03780309|BEHAVIORAL|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
48282055|NCT06347159|DRUG|EDG-7500|Liquid suspension formulation of EDG-7500
48282056|NCT06347159|DRUG|EDG-7500|Solid oral formulation of EDG-7500
48282057|NCT02039947|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
48282058|NCT02039947|DRUG|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
48282059|NCT03215914|DEVICE|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
48282060|NCT06656026|DRUG|ZSP1273 granules|Oral
48282061|NCT01574573|BEHAVIORAL|Self support, group sessions|Self support,group sessions
48282062|NCT00608140|PROCEDURE|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
48282063|NCT00608140|DRUG|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
48282064|NCT05664633|DRUG|Sugammadex|Sugammadex or G/N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist. The surgeon will typically do this at the time of putting the closing sutures.
48625128|NCT06377085|DRUG|5-Azacytidine 10mg/m^2|5-Azacytidine 10mg/m\^2, one-time subcutaneous injection
48625129|NCT06377085|DRUG|5-Azacytidine 20mg/m^2|5-Azacytidine 20mg/m\^2, one-time subcutaneous injection
48625130|NCT06377085|DRUG|5-Azacytidine 35mg/m^2|5-Azacytidine 35mg/m\^2, one-time subcutaneous injection
48625131|NCT06377085|DRUG|5-Azacytidine 75mg/m^2|5-Azacytidine 75mg/m\^2, one-time subcutaneous injection
48625132|NCT04767750|OTHER|Blood sample collection|"5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~* Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~* Total RNA extraction from PBMCs by Trizol reagent and spin column.~* Reverse transcription to cDNA.~* The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR"
48625133|NCT03843216|OTHER|observation|patients not treated
48625134|NCT03843216|OTHER|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
48625135|NCT03843216|DEVICE|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
48625136|NCT03510000|DRUG|Empagliflozin 25mg|Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
48625137|NCT03510000|DEVICE|Single hormone artificial pancreas|Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
48625138|NCT03510000|BEHAVIORAL|Meal strategies|Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
48465017|NCT03920449|PROCEDURE|Posterolateral internal sphincterotomy|In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
48625139|NCT03073447|OTHER|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
48625140|NCT06301152|DEVICE|high intensive laser|high-intensity laser ,three times in a week, for three weeks, 9 session
48625141|NCT06301152|DEVICE|extracorporeal shock wave therapy|extracorporeal shock wave therapy, once a week, for three weeks ,3 times,
48465018|NCT06226259|DIETARY_SUPPLEMENT|GABA supplement|Oral administration of GABA supplement once daily before sleep for 14 days.
48099843|NCT03627962|OTHER|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell \> 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
48099844|NCT05676294|DRUG|Olanzapine|5 mg of oral olanzapine one hour prior to ambulatory surgery
48099845|NCT05676294|DRUG|Placebo|oral matched placebo one hour prior to ambulatory surgery
48099846|NCT05462925|DEVICE|Functional electrical stimulation therapy.|Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
48465019|NCT06226259|DIETARY_SUPPLEMENT|placebo|Oral administration of placebo once daily before sleep for 14 days.
48465020|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
48465021|NCT01049282|BIOLOGICAL|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
48465022|NCT02783287|BEHAVIORAL|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
48465023|NCT02783287|BEHAVIORAL|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
47936699|NCT02385188|DRUG|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
47936700|NCT02385188|DRUG|paracetamol|
48099847|NCT00069459|DRUG|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
48465024|NCT02494505|DRUG|Mycophenolate Mofetil|2g/day per os
48465025|NCT02494505|DRUG|placebo|
48282065|NCT05157633|OTHER|Controls|questionnaire food scale: HME data collection of food survey
48625142|NCT06330025|OTHER|Children between 2 and 8 years, without medical treatments or pathologies impacting food intake and his parents|The group comprises 102 children aged between 2 and 8 years, hospitalized for at least 48 hours and their parents. The children's pathologies and medical treatments should not influence their food intake.
48625143|NCT04453683|DEVICE|Air-Q. ILA insertion of proper size|Success of fiberoptic guided intubation throuhgh Air Q supraglottic airway device
48099848|NCT02836665|PROCEDURE|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
48465026|NCT01096641|BEHAVIORAL|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
48465027|NCT01096641|BEHAVIORAL|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
47936701|NCT02385188|DRUG|lidocaine in Vaseline ointment|
47936702|NCT00260611|DRUG|Oxaliplatin|
47936703|NCT00260611|DRUG|Taxotere|
47936704|NCT00633867|DEVICE|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
48282066|NCT04903860|DEVICE|total hip replacement with single use ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
47936705|NCT00633867|DEVICE|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
47936706|NCT03329781|DIETARY_SUPPLEMENT|BCM-95|Consuming 1 capsule of BCM-95 per day.
47936707|NCT03329781|DIETARY_SUPPLEMENT|Placebo|Consuming 1 placebo capsule per day
47936708|NCT01859104|BEHAVIORAL|Use of smartphone app|
48282067|NCT04903860|DEVICE|total hip replacement with conventional ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
48282068|NCT03006783|PROCEDURE|Cross-face nerve graft|connecting the healthy facial nerve to the affected facial nerve
47936709|NCT04581135|OTHER|COVID-19|Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used.
48282069|NCT00762151|OTHER|Negative Control (Regular Toothpaste)|Regular Toothpaste
48282070|NCT00762151|OTHER|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
48282071|NCT00762151|DRUG|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
48282072|NCT00597649|DRUG|Bicifadine|SR dosage form of 400 mg bid or tid for one year
48282073|NCT03950323|RADIATION|MRI with Facial nerve tractography|MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
48282074|NCT04782622|DRUG|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
48282075|NCT01310738|DRUG|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
48282076|NCT01310738|DRUG|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
48282077|NCT01310738|DRUG|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
48282078|NCT01310738|DRUG|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
48282079|NCT01310738|DRUG|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
48282080|NCT04808687|DRUG|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
48282081|NCT04804215|PROCEDURE|Intraductal transanastomotic stent group|When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
48282082|NCT04804215|PROCEDURE|No stent group|Do not insert a stent into the bile duct during anastomosis of the bile duct.
48465028|NCT03900013|PROCEDURE|Injectable platelet rich fibrin combined with DFDBA|The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
48465029|NCT03900013|PROCEDURE|Demineralized Freeze Dried Bone Allograft|Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
48465030|NCT00712244|DEVICE|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
48465031|NCT00712244|DEVICE|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
48465032|NCT00712244|DEVICE|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
48465033|NCT00712244|DEVICE|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
48465034|NCT01686217|DRUG|ASP015K ER|oral extended release (ER) at three dosing levels
48465035|NCT01686217|DRUG|ASP015K IR|oral immediate release (IR)
48465036|NCT02244554|DEVICE|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
48465037|NCT04125134|DRUG|Preservative-free Refresh Optive Advanced Lubricant Eye Drops|over the counter artificial tear
48465038|NCT03461341|OTHER|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
48465039|NCT04711317|DEVICE|Nasal high flow oxygen|Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
48625144|NCT04453683|DEVICE|ILMA insertion of proper size|Success of fiberoptic guided intubation throuhgh ILMA supraglottic airway device
48625145|NCT05231967|OTHER|Cardioversion|In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
48625146|NCT04093076|DRUG|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
48282083|NCT04987203|DRUG|Tivozanib|Tivozanib will be administered orally.
48282084|NCT04987203|DRUG|Nivolumab|Nivolumab will be administered via intravenous infusion.
48282085|NCT04015765|PROCEDURE|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
48465040|NCT00397696|DRUG|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
48465041|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
48465042|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
48465043|NCT05522634|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
47936710|NCT02531334|DIETARY_SUPPLEMENT|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
48465044|NCT06269861|DEVICE|patient transfer scale|patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand
48625147|NCT04093076|DEVICE|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
48625148|NCT04093076|DRUG|Placebo|Placebo will be administered ID on Day 0 and Week 4.
48625149|NCT05875805|BEHAVIORAL|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
48625150|NCT05875805|OTHER|Education Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
47936711|NCT04352127|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
47936712|NCT03498001|DRUG|GLP-1 agonists|Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg
48478870|NCT00601757|BEHAVIORAL|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
48625151|NCT02260986|DRUG|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
47936713|NCT03498001|PROCEDURE|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides (\[TG\] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
48282086|NCT03550690|DEVICE|Large Volume Paracentesis|Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
48282087|NCT03550690|DEVICE|Rocket Indwelling Pleural Catheter|A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
48625152|NCT02260986|DRUG|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
48625153|NCT02260986|OTHER|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
48625154|NCT03923920|PROCEDURE|Biopsy|During clinically-scheduled spinal stenosis surgery, ligamentum flavum tissue (which may contain surrounding tissue and subcutaneous fat) that is removed during the procedure will be sent to pathology to be analyzed with amyloid-specific staining.
48625155|NCT00860925|DRUG|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
48625156|NCT00860925|DRUG|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
48625157|NCT00860925|DRUG|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
48625158|NCT00860925|DRUG|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
48625159|NCT03906994|OTHER|Video game Mario Kart Wii|Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
48099849|NCT02997618|BEHAVIORAL|Community based exercise programme|20 week community (home or gym based) exercise programme
48099850|NCT02997618|OTHER|Control|Usual care consisting of advice.
48625160|NCT01416051|DIETARY_SUPPLEMENT|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
48625161|NCT01416051|OTHER|Placebo|100% milk fat
48625162|NCT02530866|OTHER|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
48625163|NCT03188029|DIAGNOSTIC_TEST|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
48625164|NCT02397837|DRUG|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
48625165|NCT02397837|DRUG|Placebo|placebo match study drug
48625166|NCT06363500|OTHER|non applicable|Only blood sample collection
48625167|NCT04679246|BEHAVIORAL|Participatory intervention|Surveillance in compliance with the regulation of the sale of food in school buildings, according to official guidelines Training for the preparation of hygienic and healthy food for the personnel in charge of food sale Promotion of the consumption of simple water and healthy foods Reconditioning of the infrastructure for the consumption of simple water, free and healthy food, and the realization of physical activity Organization of events and support in the coordination of groups that promote physical activity at the community level Optimization of physical education classes at school sites Implementation of health promotion and care actions in the school context Development of skills in the school community for health care and generation of healthy school environments Creation and strengthening of health and nutrition committees in schools, with the participation of directors, teachers and parents to generate necessary and permanent conditions that favor healthy environments
48625168|NCT02233413|DEVICE|Active LLLT helmet application|LED helmet applied with light activated
47936714|NCT03498001|OTHER|Follow up by phone|at 2 and 4 mois
48099851|NCT00926939|BEHAVIORAL|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
48465045|NCT05219435|DRUG|Nivolumab|Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
48625169|NCT02233413|DEVICE|Non-active LLLT helmet application|LED helmet applied without light activated
48625170|NCT06157424|OTHER|Thread Embedding Acupuncture|Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.
48099852|NCT00926939|BEHAVIORAL|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
48099853|NCT04388488|DEVICE|CONNECT TF adaptable socket system|Prefabricated, adaptable socket system
48099854|NCT04388488|DEVICE|Any conventional handmade socket|Subjects current socket
48099855|NCT01549652|DRUG|Ondansetron|Ondansetron 8 mg oral tablet
48625171|NCT06157424|OTHER|Auricular acupuncture|Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
48625172|NCT06157424|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
48625173|NCT01955018|DEVICE|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
48625174|NCT03437954|OTHER|Diet modification|Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
47936715|NCT04571515|DRUG|MR-107A-01|Oral tablet
47936716|NCT04571515|DRUG|Placebo|Oral tablet
48099856|NCT01549652|DRUG|Placebo|Placebo to Match Ondansetron
48099857|NCT01549652|DRUG|Morphine|Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
48625175|NCT02927145|BIOLOGICAL|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
48625176|NCT03478878|DRUG|Vitamin A Palmitate|Provide vitamin A to participants with pre/post assessments of vision.
47936717|NCT03742908|DRUG|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
47936718|NCT05644249|DRUG|Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy|Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
48099858|NCT01549652|DRUG|Naloxone 0.4 mg/70 kg|Naloxone 0.4 mg/70 kg intravenous
48099859|NCT01549652|DRUG|Naloxone 0.8 mg/70 kg|Naloxone 0.8 mg/70 kg intravenous
48099860|NCT04238104|OTHER|no intervention|it's only observational study. No interventions.
48099861|NCT03132324|DRUG|INCB059872|INCB059872 tablets
48465046|NCT05219435|DRUG|Ipilimumab|Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
48465047|NCT01223027|DRUG|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
48465048|NCT01223027|DRUG|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
48625177|NCT06283108|DEVICE|Standard Child Life Preparation and Support + Meta Quest 2 VR headset with Gurney Journey (a mixed reality experience)|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental procedure. Child life specialist's will utilize Gurney Journey as part of their support for induction. Gurney Journey is a mixed reality experience, using the Meta Quest 2 VR headset that was designed to mitigate patient anxiety during transport from pre-admission rooms to the procedure room/operating room for surgical procedures.
48625178|NCT06283108|BEHAVIORAL|Standard Child Life Preparation and Support|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental procedure.
48625179|NCT03639389|DRUG|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
48625180|NCT03639389|DRUG|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
48625181|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) IV|Intravenous Injection
48625182|NCT06493799|DRUG|LAENNEC (Human Placenta Hydrolysate) SC|Subcutaneous Injection
48625183|NCT04519398|GENETIC|Complete thrombophilic profile testing by multiplex PCR|"Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:~* Factor V Leiden~* Factor V 4070 A\>G (Hr2)~* Factor II G20210A~* Methylenetetrahydrofolate reductase (MTHFR) C677T~* MTHFR A1298C~* Cystathionine β-synthase (CBS) 844ins68~* PAI-1 4G/5G~* Glycoprotein IIIa T1565C (HPA-1a/b)~* ACE-DEL/INS~* Apolipoprotein E (ApoE)~* AGT M235T~* Angiotensin II type 1 receptor (ATR-1) A1166C~* Fibrinogen - 455 G\>A~* Factor XIII Val34Leu"
48625184|NCT01807520|BIOLOGICAL|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
48625185|NCT01807520|BIOLOGICAL|Placebo|Placebo was provided in pre-filled 1 mL syringes.
48625186|NCT01725399|OTHER|Apple Juice|
48625187|NCT01725399|OTHER|Water|
48465049|NCT02069951|OTHER|Practice a procedural module on a simulator|
48465050|NCT02015351|DRUG|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
48625188|NCT01801332|DIETARY_SUPPLEMENT|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
48625189|NCT01801332|DIETARY_SUPPLEMENT|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
48625190|NCT04517799|DRUG|Epidiolex|"While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
48099862|NCT03552770|DRUG|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
48099863|NCT03653975|OTHER|no intervention|no intervention
48465051|NCT00605150|RADIATION|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
48465052|NCT00645827|OTHER|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
48478871|NCT06077734|OTHER|In vitro analyse|In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
48099864|NCT05376605|OTHER|assessment|Evaluations of the patients will be made with scales, questionnaires and physical tests.
48465053|NCT00645827|OTHER|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
48625191|NCT04517799|DRUG|placebo oral solution|"GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."
48625192|NCT04521140|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
48625193|NCT04521140|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
47936719|NCT05299788|OTHER|Active external warming|In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
48625194|NCT03161054|DRUG|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
48625195|NCT03161054|DRUG|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
48625196|NCT03161054|DRUG|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
48625197|NCT03161054|DRUG|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
48625198|NCT03161054|DRUG|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
48625199|NCT00849472|DRUG|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
48625200|NCT00849472|DRUG|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
48625201|NCT00849472|PROCEDURE|surgery|neoadjuvant surgery for breast cancer
48625202|NCT00849472|DRUG|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
48625203|NCT06116851|OTHER|MRI scan and laboratory visit|Prostate MRI scan is performed according to the protocol used in earlier studies (PMID 31158230). In addition to the PCa diagnostics, the scan will include abdominal imaging to body composition analysis (visceral and subcutaneous fat and psoas muscle). Baseline blood and urine samples are collected in Turku University Hospital laboratory.
48625204|NCT06116851|PROCEDURE|Prostate biopsies|The visit follows routine outpatient clinic protocol. The results from MRI and laboratory findings are discussed and the potential benefits and harms from prostate biopsies are evaluated. After a mutual decision, prostate biopsies are performed.
48625205|NCT06116851|PROCEDURE|Radical prostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Robotic assisted laparoscopic prostatectomy (RALP) is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
48625206|NCT06116851|PROCEDURE|TURP and blood, urine and tissue sampling|Baseline blood and urine samples are collected the time of surgery. TURP is performed according to normal protocol. Routine diagnostic histopathological procedures will be followed in the department of pathology. Additionally, tissue samples (a total of 10 resection chips) will be collected for study analyses. Due to the study, no additional tissue samples are removed, i.e. study samples are from the tissues removed as clinically indicated.
48625207|NCT06116851|PROCEDURE|Radical cystoprostatectomy and blood, urine and tissue sampling|Baseline blood and urine samples are collected at the time of surgery. Radical cystoprostatectomy is performed according to routine protocol. Routine diagnostic histopathological procedures will be followed, and study tissue samples are obtained in the department of pathology.
48625208|NCT03489564|BEHAVIORAL|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
48099865|NCT00061672|DRUG|ABT-510 - Thrombospondin-1 Mimetic|
48099866|NCT03568162|DRUG|ISB 830 - Part 1 Group 1|Subcutaneous injection (SC) every 2 weeks
48099867|NCT03568162|DRUG|ISB 830 - Part 1 Group 2|Subcutaneous injection (SC) every 2 weeks
48099868|NCT03568162|DRUG|ISB 830 - Part 1 Group 3|Subcutaneous injection (SC) every 2 weeks
48099869|NCT03568162|DRUG|Placebo - Part 1 Group 4|Subcutaneous injection (SC) every 2 weeks
48465054|NCT00053339|DRUG|tamoxifen|
48099870|NCT03568162|DRUG|ISB 830 - Part 2 Group 5|Subcutaneous injection (SC) every 2 weeks
48099871|NCT03568162|DRUG|Placebo - Part 2 Group 6|Subcutaneous injection (SC) every 2 weeks
48465055|NCT00053339|DRUG|trastuzumab|
47936720|NCT05299788|OTHER|Ice application|In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
48099872|NCT02337010|DEVICE|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
48099873|NCT02337010|DEVICE|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
48099874|NCT02337010|DRUG|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
48099875|NCT02337010|DRUG|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
48099876|NCT01530074|PROCEDURE|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
48099877|NCT00465985|DRUG|ACZ885|
47936721|NCT03523000|OTHER|Continuous intrathecal prognostic infusion test|The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
48465056|NCT01391650|PROCEDURE|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
48465057|NCT04305470|DRUG|Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)|One time oral dose on day of surgery (20 mg/kg bodyweight)
48099878|NCT00465985|DRUG|Placebo|
48099879|NCT00439933|BEHAVIORAL|low fat and polysaccharide rich diet|
48099880|NCT00439933|BEHAVIORAL|specific physical training program for obese children|
48465058|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
47936722|NCT03523000|DRUG|Bupivacaine|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
47936723|NCT03523000|DRUG|Fentanyl|Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
47936724|NCT03523000|DRUG|Placebo|Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
48465059|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
48465060|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
48465061|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
48465062|NCT01243151|BIOLOGICAL|PF-04950615 (RN316)|Infusion every week
48465063|NCT03910049|DRUG|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
48465064|NCT03901690|DRUG|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
47936725|NCT03523000|DEVICE|Intrathecal Drug Delivery System (IDDS)|40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
47936726|NCT04111952|DEVICE|CO2 laser|A single session of CO2 vaginal laser treatment
47936727|NCT04111952|DEVICE|Sham laser|A single session of sham laser treatment.
47936728|NCT02935374|DRUG|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
47936729|NCT02935374|DRUG|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
48099881|NCT04036162|BEHAVIORAL|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
48099882|NCT01213706|DEVICE|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
48099883|NCT01213706|DEVICE|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
48099884|NCT06275386|DEVICE|Paclitaxel Drug-coated balloon|Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.
48099885|NCT02431143|DRUG|Miltefosine|
48099886|NCT02785744|OTHER|Gaucher disease DNA mutation analysis|
48099887|NCT05082883|DIAGNOSTIC_TEST|Risk Assessment Cognitive Screening|Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
48099888|NCT03016130|OTHER|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
48099889|NCT02453724|DEVICE|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
48099890|NCT01839877|DRUG|HIA DEBIRI + systemic FOLFOX|
48099891|NCT04101123|OTHER|Non-Interventional|Non-Interventional
48099892|NCT02667730|DRUG|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
48099893|NCT02667730|DRUG|Naproxen|naproxen 500mg twice daily for 7 days
48099894|NCT02667730|DRUG|Celecoxib|celecoxib 100mg twice daily
48099895|NCT02667730|OTHER|physiotherapy only|physiotherapy only (no drug)
48625209|NCT03489564|BEHAVIORAL|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
48465065|NCT03901690|DRUG|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
48465066|NCT06204939|PROCEDURE|Randomizing for EPGB procedure|"Classic gastric bypass with 2 anastomoses but with an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
48465067|NCT06204939|PROCEDURE|Randomizing for OAGB procedure|"Gastric bypass with 1 anastomosis and an extended pouch of 12-15cm and a biliary limb of 150cm.~Patients will be single blinded randomized for one of the two procedures. 125 patients will undergo EPGB and 125 patients will undergo OAGB.~Pre-operatively, 6 months post-op and yearly post-op we will collect: weight, complications, revisions, comorbidities, blood samples and questionnaires."
48625210|NCT05129085|DRUG|Dexamethasone 4mg|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the ESI group, 8mg of dexamethasone (4mg/ml) added to 1 ml of normal saline will be given (total 3ml volume).
48625211|NCT05129085|PROCEDURE|epidural platelet rich plasma injection|For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the EPRP group, 3 ml of PRP will be injected. The total volume of injectate for both groups of patients is 3ml.
48625212|NCT02560805|PROCEDURE|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
48625213|NCT02560805|BEHAVIORAL|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
48625214|NCT02560805|PROCEDURE|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
48625215|NCT02560805|PROCEDURE|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (\~0-1°C) up to the wrist for 1 minute.
48625216|NCT02560805|DRUG|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
48625217|NCT02560805|DRUG|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
48625218|NCT02560805|DRUG|Losartan|Subjects will receive Losartan 25 mg once a day orally up to 12 weeks
48625219|NCT02560805|DRUG|Atenolol|Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
48625220|NCT01653886|OTHER|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
48625221|NCT01653886|OTHER|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
48625222|NCT01653886|OTHER|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
48625223|NCT04806451|DRUG|Crinecerfont|CRF1-receptor antagonist
48625224|NCT04806451|DRUG|Placebo|Non-active dosage form
48465068|NCT00498316|PROCEDURE|Cord Blood Infusion|Cord blood transplantation performed on day 0.
48465069|NCT00498316|DRUG|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
48625225|NCT02522182|BEHAVIORAL|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
48625226|NCT02522182|BEHAVIORAL|Usual Treatment|Information related to intervention description have been already included in arm/group description
48465070|NCT00498316|DRUG|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
48465071|NCT00498316|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
48465072|NCT00498316|OTHER|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
48465073|NCT00498316|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
48465074|NCT00498316|DRUG|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
48465075|NCT00498316|RADIATION|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
48625227|NCT02990962|DRUG|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
48625228|NCT02990962|DRUG|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
48625229|NCT05943704|DIETARY_SUPPLEMENT|beef broth|It indicates if the child has allergy of Beef or not.
48625230|NCT01363440|DRUG|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
48099896|NCT05616559|COMBINATION_PRODUCT|Treatment Package for First-Episode Depression|The outpatient 'treatment package' for first episode depression is a national uniform package designed by Mental Health Services in the Capital Region. The treatment package for first-episode depression is a program with manualized group CBT, psychoeducation of patients and relatives, and relapse prevention. Antidepressant medication and individual psychotherapy are available as needed.
48099897|NCT03538054|DRUG|Dextromethorphan|(1)10 mg, by mouth, twice daily every 12 hours.
48465076|NCT00498316|DRUG|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
48465077|NCT00498316|DRUG|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
48465078|NCT00498316|DRUG|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
48465079|NCT00498316|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is \> 2.5 x 109/L.
48625231|NCT01363440|PROCEDURE|Macular Laser Photocoagulation|Laser therapy
48625232|NCT01533220|DRUG|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
48625233|NCT01533220|DRUG|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
47936730|NCT02935374|DRUG|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
48625234|NCT00228852|DRUG|Busulfan, Fludarabine and ATG|
48625235|NCT02507284|DRUG|SRX246|
48625236|NCT02507284|DRUG|Placebo|
48625237|NCT05148507|DEVICE|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2001. PROKERA is considering it investigational for the study
47936731|NCT01390220|DRUG|USL261|
47936732|NCT01390220|DRUG|Placebo|
47936733|NCT05395273|DEVICE|Game Ready cryocompression|Cryotherapy on the coldest tolerable level and intermittend compression on the knee
47936734|NCT02653261|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
47936735|NCT02653261|DRUG|Placebo|An equal volume of saline
48099898|NCT03538054|DRUG|Placebo|1 capsule, by mouth, twice daily every 12 hours.
48099899|NCT03955445|DRUG|LNP023|LNP023 capsules
48465080|NCT05721469|BEHAVIORAL|Art therapy|Determining the mothers of children with eating disorders with the data obtained from the questionnaires and scales and separating them into randomized experimental and control groups, 8-12 sessions of 90 minutes of music, painting, ceramics, etc. were given to the mothers participating in the experimental group. Art Therapy Studies
48625238|NCT01965795|DIETARY_SUPPLEMENT|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
48625239|NCT01965795|DIETARY_SUPPLEMENT|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
48625240|NCT02145676|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
48625241|NCT02145676|DRUG|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
48625242|NCT01339013|DEVICE|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
48625243|NCT02617290|DRUG|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
48625244|NCT02617290|DRUG|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
48625245|NCT01098578|DRUG|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
48625246|NCT06300047|OTHER|Non-Medical Transition Coordinator|Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
48625247|NCT03624036|BIOLOGICAL|brexucabtagene autoleucel|CAR-transduced autologous T cells administered intravenously
48625248|NCT03624036|DRUG|Fludarabine|Administered intravenously
48099900|NCT05403307|BIOLOGICAL|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
48282088|NCT05182736|BEHAVIORAL|TRAIL intervention|The TRAIL program is comprised of a multi-tier system of strategies: Universal strategies impact the entire school via a school-wide social norms marketing campaign and school-climate change activities. School staff trainings and professional development activities focus on enhancing protective factors for students to reduce the effects of stressful life events and trauma, improving classroom management, linking students to resources, and improving the overall school climate for students and staff. Targeted strategies include an in-school curriculum and service learning component, which impact all ninth grade students at the intervention high schools and all eighth grade students at the intervention middle schools. Intensive strategies are intended for a subset of youth and their caregivers with identified increased risk-factors, and they include peer mentoring, after-school running/positive youth development programming, summer programming, and parent workshop support.
48465081|NCT02285049|OTHER|Urticaria Control Test|"* The patients get the 1st UAS28 form and four-week appointment to follow up.~* Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~* Then patients fill the 1st UCT and DLQI questionnaire by themselves.~* The patients get the 2nd UAS28 form and four-week appointment to follow up.~* At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
48465082|NCT04684511|DRUG|TRM-201 (Rofecoxib)|Eligible patients will be randomized to receive TRM-201 or placebo
48465083|NCT04684511|DRUG|Placebo|Matching Placebo
48465084|NCT01489605|DEVICE|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
48465085|NCT01489605|DEVICE|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
48465086|NCT01232049|DRUG|Multiple Oral Dose of|Pitavastatin 4mg
48465087|NCT01232049|DRUG|Multiple Oral Dose of|Valsartan 320mg
48465088|NCT05643105|PROCEDURE|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
48625249|NCT03624036|DRUG|Cyclophosphamide|Administered intravenously
48625250|NCT03286504|BEHAVIORAL|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
48625251|NCT05499936|DRUG|68Ga-FAPI|68Ga-FAPI were injected into the patients before the PET/CT scans
48625252|NCT00040638|DRUG|TLK286|
48625253|NCT05387525|DRUG|Tirbanibulin (Klisyri®) 10 mg/g ointment|Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).
48625254|NCT05387525|DRUG|Diclofenac Sodium 3% Gel|Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
48625255|NCT02487121|BEHAVIORAL|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
48625256|NCT02487121|BEHAVIORAL|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
48625257|NCT00897845|GENETIC|RNA analysis|
48625258|NCT00897845|GENETIC|microarray analysis|
48099901|NCT05403307|BIOLOGICAL|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
48099902|NCT03635567|BIOLOGICAL|Pembrolizumab|IV infusion
48099903|NCT03635567|DRUG|Paclitaxel|IV infusion
48099904|NCT03635567|DRUG|Cisplatin|IV infusion
48099905|NCT03635567|DRUG|Carboplatin|IV infusion
48099906|NCT03635567|BIOLOGICAL|Bevacizumab|IV infusion
48099907|NCT03635567|DRUG|Placebo to pembrolizumab|IV infusion
48099908|NCT06630429|OTHER|Biospecimen Collection|Undergo collection of blood and stool samples
48099909|NCT05702723|BEHAVIORAL|Smart-3RP|9 sessions of mind-body group treatment program via Zoom platform.
48099910|NCT05702723|BEHAVIORAL|Enhanced Usual Care|14-week group-based, online support group through CancerCare.org.
48282089|NCT02265913|DRUG|Acyclovir 5 percent (Perrigo)|
48282090|NCT02265913|DRUG|Acyclovir 5 percent (Reference)|
48625259|NCT00897845|OTHER|immunohistochemistry staining method|
48282091|NCT02265913|DRUG|Placebo cream|
48282092|NCT04074486|DEVICE|BrainScope Ahead 300iP-O|BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
48282093|NCT04074486|DIAGNOSTIC_TEST|SCAT5|Sports Concussion Assessment Tool 5
48478872|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
48478873|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
48625260|NCT00897845|OTHER|laboratory biomarker analysis|
48625261|NCT04856618|BIOLOGICAL|Massive Transfusion of Allogeneic Blood|Massive Transfusion of Allogeneic Blood, \> pRBCs
48099911|NCT02857283|OTHER|Ozone|Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
48099912|NCT02857283|OTHER|Filtered Air|Participants will be exposed to filtered clean air
48099913|NCT02857283|DEVICE|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
48099914|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Relative Risk|Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
48099915|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Metabolic Age|Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
48099916|NCT05427890|BEHAVIORAL|T2D Risk Communication Tool: Traffic Light|Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
48282094|NCT04074486|DIAGNOSTIC_TEST|Near Point Convergence|Manual ocular function measurement conducted only if electronic version on device fails
48625262|NCT06263491|DRUG|Rituximab|Given by PO
48625263|NCT06263491|DRUG|Pirtobrutinib|Given by PO
48625264|NCT02259322|BEHAVIORAL|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
48282095|NCT00491530|DRUG|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
48282096|NCT00491530|DRUG|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
48282097|NCT00491530|DRUG|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
48282098|NCT00491530|DRUG|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
48282099|NCT02561897|DRUG|Edoxaban|
48282100|NCT02561897|DRUG|Warfarin|
48282101|NCT05742386|BEHAVIORAL|Communication training|Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
48282102|NCT05742386|BEHAVIORAL|Communication training enhanced with standing orders optimization|"Clinics will host an AAT workshop, as in the other trial arm.~Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative."
48282103|NCT04622852|DEVICE|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
48282104|NCT00040534|DRUG|Farnesyl Protein Transferase Inhibitor|
48282107|NCT02607527|DEVICE|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
48282108|NCT02413658|DRUG|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
48282109|NCT02413658|DRUG|Sugar solution|
48625265|NCT02259322|BEHAVIORAL|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
48625266|NCT02259322|BEHAVIORAL|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
48625267|NCT01239680|DRUG|Glutamine|Intravenous 25 grams once over 6 hours
48625268|NCT01239680|DRUG|Ringer's Lactate|Intravenous 1 liter once over 6 hours
48625269|NCT01239680|DRUG|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
48625270|NCT06071988|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
48625271|NCT06071988|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
48625272|NCT02641353|DRUG|Apremilast Tablet|30 mg tablet
48099917|NCT02856711|BEHAVIORAL|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
48099918|NCT03514199|OTHER|Mediterranean-type diet|"Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa."
48099919|NCT03514199|OTHER|Low fat diet|Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
48099920|NCT00247143|DRUG|Kaletra (drug)|
48099921|NCT03049436|OTHER|Program of adapted physical activity|
48625273|NCT02641353|DRUG|Apremilast Oral Suspension|30 mg oral suspension
48625274|NCT05771870|OTHER|Peer mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After understanding about the study, two master's degree students from Karabük University Institute of Graduate Studies of Child Health and Diseases Nursing consented to participate on a volunteer basis and became peer mentors in the study. All postgraduate students are pediatric nurses with at least two years of clinical experience who have completed their undergraduate nursing program."
48625275|NCT05771870|OTHER|Nurse mentoring|"Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After providing information about the research to bachelor's degree nurses who have worked in the Children's Units of Karabuk Training and Research Hospital for at least two years, two mentors for the nurse mentoring group were chosen on a volunteer basis. Mentors were taught on the concept of mentoring, the roles of the mentor, interpersonal relationships, and communication skills prior to the study."
48625276|NCT01531153|DRUG|Galantamine|8mg or 16mg
48625277|NCT01531153|DRUG|Placebo|Placebo dose.
48625278|NCT04581512|DRUG|EP0042|EP0042 Oral 20 mg 50 mg capsules
48099922|NCT05949203|DRUG|Cabotegravir Injection|Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
48625279|NCT00136474|DRUG|Amifostine|Given 30-60 minutes prior to daily radiation therapy
48625280|NCT00136474|RADIATION|Radiation Therapy|Daily radiation therapy
48625281|NCT03247114|OTHER|Water|Water, 300 ml at room temperature
48625282|NCT03247114|OTHER|Glucose|Glucose, 50 grams in 300 ml water at room temperature
48625283|NCT03247114|OTHER|Fructose|Fructose, 50 grams in 300 ml water at room temperature
48099923|NCT03620929|DRUG|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
48099924|NCT04544995|DRUG|Niraparib|Niraparib will be administered as TfOS (Tablet for oral suspension)
48625284|NCT03247114|OTHER|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
48099925|NCT04544995|DRUG|Dostarlimab|Dostarlimab will be administered as IV infusion
48099926|NCT04544995|DRUG|Niraparib|Niraparib will be administered as tablet
48625285|NCT03247114|OTHER|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
48625286|NCT04289948|DRUG|Phage|The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
48625287|NCT00869180|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
48625288|NCT00869180|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
48625289|NCT01845857|BEHAVIORAL|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
48625290|NCT04307394|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
48625291|NCT04649723|DRUG|Rifampin|single oral dose, 600 mg, fasted.
48099927|NCT02772614|DRUG|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
48099928|NCT03994471|DRUG|XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght|XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
48099929|NCT03994471|DRUG|1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution|Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
48099930|NCT00968240|DRUG|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
48099931|NCT05773274|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48099932|NCT05773274|PROCEDURE|Computed Tomography|Undergo CT scan
48099933|NCT05773274|DRUG|Everolimus|Given PO
48099934|NCT05773274|DRUG|Lutetium Lu 177 Dotatate|Given IV
48099935|NCT05773274|OTHER|Quality-of-Life Assessment|Ancillary studies
47936736|NCT04687618|DEVICE|High Flow Nasal Cannula withAutomatic control of FiO2 using OAM|The target oxygen saturation (SpO2) value will to be determined and set by the clinician according to specific patient needs. The target SpO2 in preterm infants is 90-95% with alarm limits at 89-96%. In automatic control of oxygen, the OAM automatically increases or decreases the FiO2 (oxygen delivery) setting on the Vapotherm Precision Flow based on pulse oximetry readings of the OAM. The target saturation will be set at 93% and the FiO2 will be adjusted by OAM to maintain the target saturation. The automated FiO2 setting can be overridden for a clinician pre-set period of time (30-120 sec) by simply manually adjusting the FiO2 on the Precision Flow. Automated control resumes after the clinicians pre-set period of time (30-120 sec) based on the current SpO2 and FiO2. The OAM utilizes a feedback control algorithm that receives a patient's oxygen saturation value from a build in pulse oximetry device (Masimo SET OEM - normal sensitivity, averaging time window set at 8 seconds).
48099936|NCT05773274|OTHER|Questionnaire Administration|Ancillary studies
48099937|NCT04559724|DEVICE|Indego Therapy|Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
48099938|NCT04618913|DRUG|Apixaban|Anticoagulant
48099939|NCT04618913|DRUG|Rivaroxaban|Anticoagulant
48465089|NCT05702255|OTHER|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
48282110|NCT06657222|DRUG|TUB-030|A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
48282111|NCT03222271|DEVICE|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
48465090|NCT05702255|OTHER|Sham acuptressure|The same protocol as the active acupressure group.
47936737|NCT04687618|DEVICE|High Flow Nasal Cannula with manual control of FiO2|In manual control of oxygen all FiO2 adjustments will be done by the clinical staff to maintain saturations between 90-95%. The alarm limits will be 89-96%.
48282112|NCT05809310|PROCEDURE|Percutaneous intervention (stent) for PA stenosis|Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
48465091|NCT02214706|DRUG|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
47936738|NCT04110600|OTHER|Coffee effect on early gastric motility|this group 100ml coffee after two hours
48465092|NCT02214706|OTHER|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
47936739|NCT04110600|OTHER|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
48099940|NCT04618913|DRUG|Edoxaban|Edoxaban
48099941|NCT04618913|DRUG|Dabigatran|Dabigatran
48099942|NCT04618913|DRUG|VKA|Vitamin K antagonist
48465093|NCT02214706|DEVICE|Pulsed Dye Laser|
48099943|NCT04618913|DRUG|LMWH|Low Molecular Weight Heparin
48099944|NCT02885051|PROCEDURE|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
48099945|NCT00286689|DRUG|Growth Hormone|
48099946|NCT00286689|PROCEDURE|Whole body Protein turnover|
48099947|NCT00286689|PROCEDURE|DEXA scan|
48099948|NCT06487975|DIETARY_SUPPLEMENT|Bacillus Subtilis|Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)
48099949|NCT06487975|OTHER|Placebo|1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)
48099950|NCT02759029|DRUG|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~* concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~* bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~* levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
48465094|NCT03119662|DRUG|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
48282113|NCT05343390|BEHAVIORAL|Enhanced implementation package|Individual training with teaching and modeling (tablet-guided, \~8 hours) Small group training with practice and feedback (tablet-guided, \~16 hours) Ongoing continuous quality improvement sessions (tablet-guided, \~2 hours/month)
48465095|NCT03119662|DRUG|Placebos|100 mL saline, followed by a 10 mL saline flush.
48465096|NCT03093025|DRUG|TS-121 10 mg|Orally taken once daily
48625292|NCT04649723|DRUG|SHR1459|single oral dose, 200 mg, fasted.
48625293|NCT05302050|DEVICE|BT-001|"BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
48625294|NCT05302050|DEVICE|Control Mobile Application|The app asks patients brief questions about their health but does not include any behavioral therapy.
48625295|NCT05010967|OTHER|High intensity interval training|"HIIT 3 times a week for 8 weeks. For week 1 to 4 , Warm up 5 minutes jogging in place, 6 series of 30 seconds Burpees, 30 seconds recovery, 30 seconds skipping, 30 seconds recovery, 30 seconds lunge, 30 seconds recovery, 30 seconds 1-legged squats, 30 seconds recovery, 30 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.~For week 5 to 8 , Warm up 5 minutes jogging in place, 6 series of 45 seconds Burpees, 45 seconds recovery, 45 seconds skipping, 30 seconds recovery, 45 seconds lunge, 30 seconds recovery, 45 seconds 1-legged squats, 30 seconds recovery, 45 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches."
47936740|NCT03410264|BEHAVIORAL|CR-EXP|See arm/group descriptions
47936741|NCT03410264|BEHAVIORAL|EXP-CR|See arm/group descriptions
47936742|NCT03410264|BEHAVIORAL|Stress Management|See arm/group descriptions
47936743|NCT03094039|PROCEDURE|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
47936744|NCT03094039|PROCEDURE|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
48282114|NCT05343390|BEHAVIORAL|Standard implementation package|Individual training with teaching (facilitator-guided, \~2 hours) Small group practice (facilitator-guided, \~1 hour) Ongoing clinic support (facilitator-guided, \~30 minutes/month)
48465097|NCT03093025|DRUG|TS-121 50 mg|Orally taken once daily
48465098|NCT03093025|DRUG|Placebo|Orally taken once daily
48465099|NCT03985124|BEHAVIORAL|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
48465100|NCT04423003|PROCEDURE|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
47936745|NCT00000523|BEHAVIORAL|exercise|
47936746|NCT00056056|DRUG|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
47936747|NCT00056056|DRUG|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
47936748|NCT00056056|PROCEDURE|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
47936749|NCT05695664|DRUG|Ibuprofen 800 mg|Intravenous injection of ibuprofen 800 mg
48282115|NCT06257212|DRUG|BCG vaccine (Danish strain 1331)|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
48465101|NCT01578317|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
48465102|NCT01578317|BIOLOGICAL|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
48465103|NCT05355519|OTHER|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
48625296|NCT05010967|OTHER|Yoga Training|Yoga 3 times a week for 8 weeks. 30-50 minutes session, 5 minutes breathing, 15-35 minutes yoga poses (Cat-cow, child's pose, downward dog, plank, Cobra), followed by 10 minutes supine meditation.
48625297|NCT04386148|PROCEDURE|Obsidian ASG®|As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.
48465104|NCT05355519|OTHER|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
48465105|NCT02737462|DRUG|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
48465106|NCT00238615|DRUG|Docetaxel|20 mg/m2, 75 mg/m2 infusion
48465107|NCT00238615|DRUG|Carboplatin|AUC of 2 and 6 infusion
48282116|NCT06257212|DRUG|MMR Vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
48625298|NCT04242745|BEHAVIORAL|Intervention group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people."
48625299|NCT04242745|BEHAVIORAL|Control group|"The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes."
48625300|NCT04114370|DRUG|18F-fluciclovine|Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
48625301|NCT00652132|DRUG|cisplatin|
48625302|NCT00652132|DRUG|sodium thiosulfate|
48625303|NCT02393755|DRUG|Capecitabine|Given PO
48625304|NCT02393755|OTHER|Laboratory Biomarker Analysis|Correlative studies
48625305|NCT02393755|DRUG|Nintedanib|Given PO
48625306|NCT02393755|OTHER|Pharmacological Study|Correlative studies
48625307|NCT04569344|OTHER|Laboratory test positive for SARS-CoV-2 virus|Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2
48625308|NCT02905864|DRUG|Liraglutide 3 mg (Saxenda)|
48625309|NCT02905864|DRUG|Liraglutide 3 mg placebo|
48625310|NCT06225453|OTHER|Individualized perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at no less than -20% of the baseline values of each patient.
48625311|NCT06225453|OTHER|Conventional perioperative blood pressure management strategy|In this group, perioperative mean arterial pressure and systolic blood pressure are maintained at ≥65 mmHg and ≥90 mmHg, respectively, in all patients.
48625312|NCT00800514|DRUG|amantadine|amantadine twice daily
48625313|NCT00800514|DRUG|amantadine|amantadine 100 mg twice daily
48625314|NCT04384874|OTHER|Exercise therapy|A 12 week multi-stage exercise rehabilitation program
48625315|NCT02092103|PROCEDURE|Cord Milking|See description in cord milking arm.
48625316|NCT00665639|DRUG|micafungin|IV
48282117|NCT06257212|DRUG|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
48282118|NCT00099671|DRUG|Recombinant human interleukin-7|
48625317|NCT00665639|DRUG|caspofungin|IV
48625318|NCT03974009|OTHER|Calcaneal taping|Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.
48625319|NCT03974009|OTHER|Sham taping|Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.
48625320|NCT03974009|OTHER|Conventional therapy|Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward \& backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
48625321|NCT01334515|BIOLOGICAL|hu14.18-IL2 fusion protein|Given IV
48625322|NCT01334515|DRUG|isotretinoin|Given PO
48625323|NCT01334515|BIOLOGICAL|sargramostim|Given SC
47936750|NCT05695664|DRUG|Ketorolac Injection|Intravenous injection of Ketorolac 30 mg
48478874|NCT03151564|DIAGNOSTIC_TEST|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
48625324|NCT01334515|OTHER|laboratory biomarker analysis|Correlative studies
47936751|NCT02145507|DRUG|SOLX (Investigational)|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
47936752|NCT02145507|DRUG|AS-3 (Control)|AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
47936753|NCT03005171|DRUG|Bupivacaine|Thoracic epidural bupivacaine infusion
48625325|NCT03831724|DEVICE|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
48625326|NCT00620607|DRUG|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
47936754|NCT03005171|DRUG|Lidocaine|Intravenous lidocaine infusion
47936755|NCT00050687|DRUG|Gallium maltolate|
47936756|NCT01179997|DEVICE|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
47936757|NCT01179997|DEVICE|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
47936758|NCT02259790|DRUG|Telmisartan/amlodipine fixed-dose combination tablet|
47936759|NCT02259790|DRUG|Telmisartan|
47936760|NCT02259790|DRUG|Amlodipine|
47936761|NCT01230125|DRUG|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
47936762|NCT01230125|DRUG|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
48465108|NCT00238615|PROCEDURE|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
48465109|NCT00238615|PROCEDURE|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
48625327|NCT02140827|OTHER|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
48625328|NCT02315820|PROCEDURE|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
48282119|NCT06657339|PROCEDURE|Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)|"The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices~OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting.~Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach."
48465110|NCT01679431|DIAGNOSTIC_TEST|Doppler-echocardiography|
48465111|NCT01679431|RADIATION|Computed tomography|
48465112|NCT01679431|OTHER|Magnetic resonance imaging|
48465113|NCT01679431|BIOLOGICAL|Fasting blood sample|
48625329|NCT04086667|OTHER|Spinal manipulation|Spinal manipulation: The patient is placed in the side-position and a standard manipulation lumbar-roll technique will be applied at the indicated segment dependent on the subgroup indication.
48282120|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
48282121|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
48282122|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
47936763|NCT02312427|DRUG|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
48282123|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
48625330|NCT02314429|DEVICE|Vaginal ring releasing lactic acid (racemic mixture)|
48625331|NCT06161090|BIOLOGICAL|CM310|CM310 injection
48282124|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
48282125|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
48282126|NCT05553132|COMBINATION_PRODUCT|Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier|Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip. There are not enough cartilage cells to fill the defect so cartilage cells need to be mixed with MSCs. MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair. MSCs can be found in bone marrow and in the fatty tissues (i.e., area under the skin of the belly or breast) of patients. Fibrin glue is a product made from the naturally occurring compounds in blood which cause clotting. This glue hardens into a gel-like substance into which cells such as cartilage cells (chondrons) and AMSCs can be placed.
48282127|NCT02993237|DRUG|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
47936764|NCT02312427|DRUG|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
48282128|NCT02993237|DRUG|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
48282129|NCT04397276|DRUG|JNJ-70218902|JNJ-70218902 will be administered.
48465114|NCT04015024|DRUG|SKLB1028 150mg bid|150mg oral administration twice a day
48465115|NCT04015024|DRUG|SKLB1028 200mg bid|200mg oral administration twice a day
48465116|NCT04015024|DRUG|SKLB1028 300mg qd|300mg oral administration once a day
48465117|NCT06043375|DIETARY_SUPPLEMENT|Licorice Root Powder Capsule|Fresh licorice root will be obtained from local market of Lahore. The root will be washed and dried at room temperature. Then it will be converted into powder using grinder. After sieving the ground powder, it will be filled in capsules. One capsule will contain 1000mg of powder. Participants in experimental group will be instructed to consume one capsule per day.
48625332|NCT06161090|DRUG|Placebo|subcutaneous injection
48625333|NCT02520466|DIETARY_SUPPLEMENT|flavanol-rich drink vs flavanol-free drink|Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
48625334|NCT06218550|DRUG|Delta-9-THC|Acute self-administration of inhaled or oral ∆9-THC by healthy adult research volunteers
48625335|NCT06218550|DRUG|Delta-8-THC|Acute self-administration of inhaled or oral ∆8-THC by healthy adult research volunteers
48625336|NCT06218550|DRUG|Placebo|Consumption of a brownie or inhalation of ambient air through a cannabis vaporizer by health adult research volunteers
48625337|NCT02981251|BEHAVIORAL|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
48465118|NCT02711527|OTHER|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
48465119|NCT02711527|OTHER|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
48099951|NCT00598897|DRUG|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
48465120|NCT01877122|DEVICE|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
48465121|NCT01877122|DEVICE|Marlex® Mesh Implant|
48465122|NCT02328040|DRUG|Placebo and Insulin monotherapy via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
48465123|NCT02328040|DRUG|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
48465124|NCT03526562|BEHAVIORAL|Exercise|Exercise according to dose escalation
48465125|NCT06127745|DEVICE|Discure System|All subjects enrolled into the study will be implanted with the Discure System in a minimally invasive procedure.
48465126|NCT06241157|OTHER|Pediatric Quiz Game|"Investigator will start interacting with children upon their arrival and during their presence in the waiting room before entering the operating room. This will help to obtain better cooperation (frankl scale) and anxiety reductions (FIS and VPT) at different stages of the dental examination (e.g., entering the clinic, sitting on the dental chair, opening mouth, examination with mirror, probe, use of low-high-speed handpieces, ITR restoration). Pediatric Quiz is actually an ice-breaking quiz game developed for children, with the promise of a surprise gift at the end. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child among which the child would choose him/herself and answer the question easily."
48465127|NCT01833169|DRUG|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
48465128|NCT01638273|DRUG|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
48625338|NCT06285903|PROCEDURE|internal sinus lift surgery|surgery approach
48625339|NCT03483753|DRUG|Vasopressin|"Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min"
47936765|NCT02312427|DRUG|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
47936766|NCT02964403|DRUG|Cox-2|
47936767|NCT02964403|DRUG|Indomethacin|
47936768|NCT01816841|PROCEDURE|fluorescence imaging|Undergo DVFE
48625340|NCT03483753|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
48625341|NCT03869021|OTHER|3D printed surgical guide constructed|A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
47936769|NCT01816841|PROCEDURE|biopsy|Undergo scalpel biopsy
47936770|NCT01816841|PROCEDURE|examination|Undergo COE
47936771|NCT01816841|PROCEDURE|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
47936772|NCT01424202|DEVICE|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
47936773|NCT04914416|DIETARY_SUPPLEMENT|Verum T1|Verum T1 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
48099952|NCT06242964|BEHAVIORAL|Promoting Resilience in Stress Management - Social Needs (PRISM-SN)|The Promoting Resilience in Stress Management - Social Needs (PRISM-SN) intervention is a brief, skill-based psychosocial program. Five core sessions are delivered one-on-one, 1-2 weeks apart, in-person or via videoconference. Sessions teach evidence-based behavioral skills for managing stress, setting goals, reframing negative thoughts, meaning-making, and connecting with others. Each session lasts \<60 minutes and is supported by paper-and-pencil or mobile app-based worksheet(s) for learning and practice. A final review session may be completed individually or with a family member, caregiver, or significant other.
48099953|NCT02894307|DRUG|Rivaroxaban|In patients with mechanical valves and unstable INR
47936774|NCT04914416|DIETARY_SUPPLEMENT|Verum T2|Verum T2 is a 11500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
47936775|NCT04914416|DIETARY_SUPPLEMENT|Verum T3|Verum T3 is a 11500AAIU/g white kidney bean extract. Daily dosage is 565 mg in 3 capsules
47936776|NCT04914416|DIETARY_SUPPLEMENT|Verum T4|Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
47936777|NCT04914416|DIETARY_SUPPLEMENT|Verum T5|Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
47936778|NCT04914416|DIETARY_SUPPLEMENT|Verum T6|Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
47936779|NCT04914416|DIETARY_SUPPLEMENT|Verum T7|Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
47936780|NCT04914416|DIETARY_SUPPLEMENT|Verum T8|Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
48099954|NCT00140881|DRUG|MK0476; montelukast sodium|
48099955|NCT00140881|DRUG|Comparator: placebo|
48099956|NCT01964859|BIOLOGICAL|autologous skin fibroblasts|
48099957|NCT04570475|DRUG|Vitamin D|Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
48099958|NCT04570475|DRUG|multivitamin|Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
48099959|NCT04570475|DRUG|Placebo|Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
48099960|NCT01300832|PROCEDURE|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
48099961|NCT04729296|DRUG|Golimumab|For participants ≥45 kg, 50 mg of golimumab will be administered subcutaneously For participants \<45 kg, the dose of golimumab is 30 mg/m2 to maximum of 50 mg
48099962|NCT04729296|DRUG|Placebo|Inactive Drug
48282130|NCT06407856|OTHER|conventional therapy|The control group embarked on a conventional therapy regimen designed for patients with spastic diplegic cerebral palsy. This group will do 10reps of ROM exercises, 3 times stretching 30sec hold with 10sec rest and 5reps of strengthening exercises, standing , weight on one leg and raising the other leg to the side or behind, putting heel in front of your toe i.e., tandem stance, standing up and sitting down from a chair without using hands, walking while alternating knee lifts with each step.This group will do conventional therapy for 30 minutes a day, 3 times a week for 8 weeks
47936781|NCT04914416|DIETARY_SUPPLEMENT|Verum T9|Verum T9 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 1000 mg in 3 capsules
47936782|NCT04914416|DIETARY_SUPPLEMENT|Verum T10|Verum T10 is a polyphenol mix extract ( olive leaf, and blackcurrant extract). Daily dosage is 500 mg in 3 capsules
47936783|NCT04914416|DIETARY_SUPPLEMENT|Verum T11|Verum T11 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 900 mg in 3 capsules
47936784|NCT04914416|DIETARY_SUPPLEMENT|Verum T12|Verum T12 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and blackcurrant extract). Daily dosage is 600 mg in 3 capsules
47936785|NCT04914416|DIETARY_SUPPLEMENT|Verum T13|Verum T13 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 1000 mg in 3 capsules.
47936786|NCT04914416|DIETARY_SUPPLEMENT|Verum T14|Verum T14 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract. Daily dosage is 900 mg in 3 capsules.
47936787|NCT04914416|DIETARY_SUPPLEMENT|Verum T15|Verum T15 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, Zinc, and, black currant leaf extracts. Daily dosage is 1000 mg in 3 capsules.
47936788|NCT04914416|DIETARY_SUPPLEMENT|Verum T16|Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
48099963|NCT05876910|BEHAVIORAL|Speech Production Tasks|View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
48099964|NCT03595943|DIETARY_SUPPLEMENT|Low glycemic index, pulse-based diet|Diet that includes pulses (i.e. meals that contain chickpeas, lentils, beans, or peas)
48099965|NCT03595943|DIETARY_SUPPLEMENT|Moderate glycemic index hospital diet|Diet that is derived from a regular hospital menu for patients
48099966|NCT04084769|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: IM
48099967|NCT04084769|BIOLOGICAL|Meningococcal Group B vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
48099968|NCT04084769|BIOLOGICAL|Meningococcal group B vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
48099969|NCT06437002|BEHAVIORAL|Mental Motor Chronometry (MMC) Task Hands and Feet and Whole Body|"The MMC will be used as a measure of MI and it is adapted for use in hands, feet, and the whole body as well as for online experimentation. The task is comprised of two conditions, MI, and motor execution, in which respectively participants will be asked to imagine and execute a movement sequence with both hands and feet and the whole body.~Hand movements: index and thumb opposition; thumb extension from the fist; middle finger crossed on the index finger; and extension of the index and the little fingers.~Foot movements: foot internal rotation, foot external rotation, foot dorsiflexion, and foot plantarflexion.~Whole-body movements: take a small bow, lift arms over the head and stand on the tips of the toes (stretch), extend hands forward and lower the backside (squats) and a small jump.~The types of movements required to be executed by participants are simple and do not require much energy. Therefore, people affected by AN and BN should be able to perform them without problems."
48099970|NCT04332653|DRUG|NT-I7|Administered by intramuscular (IM) injection
48099971|NCT04332653|DRUG|pembrolizumab (KEYTRUDA®)|Administered by intravenous (IV) injection
48099972|NCT06529042|OTHER|Non-Interventional|Non-Interventional
48099973|NCT06343558|OTHER|Questionnaires, clinical scales and instrumental tests|Questionnaires, clinical scales and instrumental tests to collect a wide range of balance and gait measures.
48282131|NCT06407856|OTHER|Dual Task Training|Warming up exercise Supine Trunk and lower extremity ROM exercise Main exercise Sitting Base of support: balance cushion, ball Program: perform cognition task while maintaining balance (writing, drawing, puzzle etc.) Bench sitting (half ring P.) Base of support: balance pad Program: perform fine motor activities while maintaining balance (blocks assembly, scissoring, origami etc.) Standing Base of support: balance pad, balance cushion Program: perform eating while maintaining balance (drinking water, eat a snack etc.) Cool down exercise Supine Low extremity stretching \& deep breathing
48625342|NCT03869021|OTHER|free hand surgery|A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
48625343|NCT02957643|DRUG|Iron|oral treatment
48625344|NCT00870701|RADIATION|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
48625345|NCT00870701|OTHER|absence of radiotherapy|absence of radiotherapy
48625346|NCT02840565|DRUG|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
48625347|NCT02840565|DRUG|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
48625348|NCT03479151|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
48625349|NCT00166400|DRUG|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
48625350|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
47936789|NCT04914416|DIETARY_SUPPLEMENT|Verum T17|Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
47936790|NCT01542671|BEHAVIORAL|Intervention|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~* Monthly Motivational phone calls with Lifestyle Counselor for the first year~* 4 informational DVDs over the two year period~* Feedback on submitted food and exercise journals"
47936791|NCT01542671|BEHAVIORAL|Control|"* Lifestyle Counselor meetings at baseline, 6 months, and 12 months~* Structured eating plan~* 5 informational NIDDK mailings over the two year period"
48282132|NCT02039557|GENETIC|NiCord®/CordIn™ (omidubicel)|
48465129|NCT01638273|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
48465130|NCT04313296|DEVICE|Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)|The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
48465131|NCT03150901|DIAGNOSTIC_TEST|no drug|laboratory tests
48625351|NCT01311661|DRUG|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
48625352|NCT01311661|DRUG|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
48625353|NCT01311661|DRUG|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
48625354|NCT01311661|DRUG|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
48625355|NCT01311661|DRUG|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
48625356|NCT05516069|OTHER|Our Healthbox (smart vending machine or interactive dispensing system)|Our Healthboxes or interactive dispensing systems (IDS) will be placed in various locations across Canada and will house HIV self-test kits (provided by REACH), harm reduction supplies (provided by the provincial governments / local community based organizations; e.g. sterile drug use kits for safer injection, naloxone kits, syringes), other community determined needs (including but not limited to hats, mittens and/or socks, rapid Covid-19 antigen kits, KN95 masks). Individuals will be able to access the HIV self-test kits and harm reduction and other materials directly from the machine. Our Healthbox will also provide health information, and a support services directory for people to find the health care they need - in their community.
47936792|NCT03239028|BEHAVIORAL|Observational|
47936793|NCT02780219|OTHER|stable amino acid infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
48465132|NCT03391050|DRUG|APR-246|Intravenous infusion
48282133|NCT06644612|PROCEDURE|Light Weight Mesh|Participants will undergo abdominal hernia repair using light-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
48465133|NCT03391050|DRUG|Dabrafenib|Oral administration
48625357|NCT05548894|DEVICE|stabilization splint|upper acrylic splint rest on the maxillary teeth and had flat surface
48625358|NCT05548894|DEVICE|laser therapy|The laser apparatus had a hand piece on which either a specially designed optic prism was attached to transfer laser energy to the tip of the prism
48625359|NCT05548894|DEVICE|stabilization splint and laser therapy|the stabilization splint used in combination of treatment with laser therapy
48625360|NCT01723943|OTHER|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
48625361|NCT01723943|OTHER|counseling intervention|Undergo Helping Her Heal educational counseling program
48625362|NCT01723943|OTHER|educational intervention|Undergo Helping Her Heal educational counseling program
48625363|NCT01723943|OTHER|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
48625364|NCT02960685|PROCEDURE|Echocardiography|
48625365|NCT05965895|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Patients will receive US-guided SAP block with a bolus of 2 mg/kg levobupivacaine made up to a volume of 40 ml followed by an infusion of 0.125% levobupivacaine will be commenced at rate of 8 ml/hr for 48 hr.
48625366|NCT05965895|DRUG|intravenous dexmedetomidine infusion|Patients will receive initial loading dose of dexmedetomidine of 1 µg/kg over 30 min followed by a continuous infusion at a rate of 0.5 µg/kg/hr for 48 hr.
48465134|NCT01406639|DRUG|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
48465135|NCT00942734|DRUG|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
48465136|NCT00942734|DRUG|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
48465137|NCT04113616|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
48465138|NCT04113616|DRUG|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
48465139|NCT04113616|DRUG|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
48099974|NCT00885508|DRUG|Lenalidomide|"1. Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~2. Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~3. Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
48099975|NCT06293547|DRUG|Silver Diamine Fluoride|Silber Diamine Fluoride, a colorless, odorless alkaline solution, effectively halts carious lesions in various populations, including children and elderly patients, or those averse to invasive treatments. Its high fluoride content facilitates remineralization, caries arrest, and prevention. SDF application is simple, non-invasive, cost-effective, and does not stain intact enamel, making it suitable for treating dentin hypersensitivity. Its ease of use is advantageous for children, patients with special needs, and the elderly. Particularly beneficial for high-risk patients with salivary dysfunction or multiple carious lesions, SDF offers potential in pediatric dentistry and community oral health by streamlining procedures, requiring rapid application without sharp instruments or anesthesia.
47936794|NCT02780219|OTHER|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
47936795|NCT02780219|OTHER|24-hour post exercise amino acid infusion|stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
47936796|NCT00626054|DRUG|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
47936797|NCT00626054|DRUG|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
47936798|NCT02605837|DRUG|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
47936799|NCT02605837|DRUG|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
48099976|NCT04243343|DEVICE|Intervention + Standard of care|Acupuncture with electrostimulation plus standard of care prescribed home exercise program for treatment of plantar fasciosis.
48099977|NCT04243343|OTHER|Standard of care|Standard of care prescribed home exercise program for treatment of plantar fasciosis.
48099978|NCT03719677|BEHAVIORAL|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
48099979|NCT00555867|DRUG|Anastrozole|oral
48465140|NCT00000516|DRUG|enalapril|
48478875|NCT03395639|DRUG|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to \<18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
48625367|NCT04825899|OTHER||
48625368|NCT04288037|DIAGNOSTIC_TEST|fetal heart rate variability|observational study. no intervention
48625369|NCT02788045|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
48625370|NCT02788045|BIOLOGICAL|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5mL injection administered intramuscularly.
48099980|NCT05391048|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
48465141|NCT06348316|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
48465142|NCT06348316|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
48625371|NCT02788045|BIOLOGICAL|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
48625372|NCT02788045|DRUG|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
48625373|NCT02749890|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48625374|NCT02749890|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48625375|NCT02749890|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: Oral"
48625376|NCT02174172|DRUG|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
47936800|NCT02555241|BEHAVIORAL|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
47936801|NCT02555241|BEHAVIORAL|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
47936802|NCT02555241|BEHAVIORAL|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
48099981|NCT05391048|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
48099982|NCT05471167|BIOLOGICAL|BCG|Exposure is defined as having received the BCG vaccine during the first year of life.
48625377|NCT02174172|DRUG|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
47936803|NCT06505967|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+ is a novel dietary supplement, formulated to support the maintenance and enhancement of intracellular NAD levels.
47936804|NCT06505967|OTHER|Placebo|Rice flour
47936805|NCT05620641|DRUG|Ondansetron 8mg|50 patients will receive intravenous ondansetron 8 mg before the end of surgery.
47936806|NCT05620641|DRUG|Gabapentin|50 patients will receive 600 mg oral gabapentin 1 h before anesthesia.
47936807|NCT05929820|BEHAVIORAL|Protect Your Colon™|Protect Your Colon™ is an online decision aid focused on CRC screening. The site will first educate patients on the importance of CRC screening and offer information on the advantages and disadvantages of the available test options. Protect Your Colon™ will then present an interactive conjoint analysis-a quantitative survey technique that elucidates how individuals make complex decisions-to precisely determine individuals' latent preferences regarding CRC screening options. Afterwards, the app will generate a personalized report that rank orders the importance of each test attribute (e.g., accuracy, invasiveness, test frequency) in patients' decision making and identifies the screening modality that best matches their preferences. The report will also be shareable with physicians, enabling patients and providers to engage in shared decision making surrounding CRC screening in the clinic.
47936808|NCT00766961|PROCEDURE|Trans-catheter arterial embolization|Trans-catheter arterial embolization
48099983|NCT00906282|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
48099984|NCT00906282|DRUG|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
48625378|NCT02174172|DRUG|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
48625379|NCT02174172|DRUG|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
48625380|NCT02174172|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
48625381|NCT02174172|DRUG|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
48625382|NCT03222128|DEVICE|TAVR|Implantation of the SAPIEN 3
48625383|NCT04320875|OTHER|Transcranial direct current stimulation|Anode electrode -C3/C4 (International 10-20 electroencephalogram system), contralateral side of the most affected knee) Cathode electrode- contralateral supraorbital area. 2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
48625384|NCT04320875|OTHER|Conventional Physiotherapy|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
48625385|NCT01755637|DRUG|Albendazole|Albendazole tablets 400 mg
48625386|NCT02100631|BIOLOGICAL|PXVX0200|
48465143|NCT02834390|DRUG|Quizartinib|"\[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19."
48625387|NCT02100631|BIOLOGICAL|Placebo|
48625388|NCT04115722|OTHER|IBD ACTIVIT|Effect of IBD disease and activity of disease on coagulation parameters
48625389|NCT03255954|OTHER|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
48099985|NCT02794064|DEVICE|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
48099986|NCT05933655|BEHAVIORAL|Peer Coach|Peer coaching session to support shared decision making among patient with limited health literacy.
48099987|NCT05819450|PROCEDURE|Volumetric rejuvenation|Volumetric Rejuvenation with FDA-approved fillers on the skin of the dorsal hands
48099988|NCT00146978|PROCEDURE|intra-arterial treatment|
48625390|NCT05509621|OTHER|The Effect of Supine Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
48625391|NCT05509621|OTHER|The Effect of Prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
48625392|NCT05509621|OTHER|The Effect of left lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
48465144|NCT02834390|DRUG|Cytarabine|"\[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
48099989|NCT06628518|BEHAVIORAL|FAmily oriented Mindfulness informed Legal Education (FAMiLE)|The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a low-intensity intervention involving four sessions. The session will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The Family oriented component will include stress management, including coping techniques and problem-solving, positive communication, behaviour modification and parenting, and a session on consolidation including sustaining gains. The intervention will also incorporate positive parenting and interactions with children.
48099990|NCT02612584|DEVICE|Pinhole Soft Contact Lens apply for presbyopia|
48099991|NCT04826055|OTHER|biliary limb as fixed length|n all loop bypass procedures we will don't count the total length of small intestine and make the biliary limb as a fixed from total small intestine length as mentioned in literature
48465145|NCT02834390|DRUG|Idarubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2."
48465146|NCT02834390|DRUG|Daunorubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2."
48465147|NCT02090933|DRUG|Celecoxib|Given PO
48465148|NCT02090933|OTHER|Laboratory Biomarker Analysis|Correlative studies
48465149|NCT02090933|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
48625393|NCT05509621|OTHER|The Effect of right lateral Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
48625394|NCT05509621|OTHER|The Effect of Quarter prone Position on Physiological Parameters in Mechanically Ventilated Preterm Newborns|Preterm neonates who receive mechanical ventilation support and meet the study criteria will be provided with daily routine nursing care. Afterward, when it is time for positioning, the infant will be randomly placed in positions assigned according to the randomization. After positioning, data will not be collected for the first 30 minutes of each positioning in order to ensure the stability of the neonate. Starting from the 30th minute, the heart rate and oxygen saturation of the preterm neonate will be checked on the monitor at 15-minute intervals over the course of 90 minutes, and the respiratory rate will be counted and recorded for 1 minute by the researcher. For each position, the procedures will be repeated in the same way and the values will be recorded.
48099992|NCT04826055|OTHER|biliary limb as a percentage from small intestine length|in all loop bypass procedures we count the total length of small intestine and make the biliary limb as a percentage from total small intestine length rather than fixed length
48099993|NCT00425503|DRUG|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
48099994|NCT03377855|OTHER|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
48282134|NCT06644612|PROCEDURE|Heavy Weight Mesh|Participants will undergo abdominal hernia repair using heavy-weighted polypropylene mesh. Standard post-operative care and antibiotic prophylaxis will be provided.
48282135|NCT02730702|DEVICE|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
48465150|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
48465151|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
48465152|NCT02346825|BEHAVIORAL|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
48465153|NCT04422652|DRUG|Bupropion|Bupropion is an anti-depressant medication.
48465154|NCT04422652|BEHAVIORAL|Behavioral activation therapy|Brief behavioral activation treatments administered via video tele-conferencing.
48465155|NCT04422652|DRUG|Placebo|Double-blind placebo.
48465156|NCT04422652|OTHER|Clinical Management|Clinical management will serve as the attention control for the Behavioral Activation Therapy intervention.
48625395|NCT01901562|DEVICE|Ductoscopic papillectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
48625396|NCT01463345|OTHER|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 7.5 g/dl. Blood products should be given to maintain Hgb levels \>7.5 g/dl.
48625397|NCT01463345|OTHER|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures \< 9.0 g/dl. Blood products should be given to maintain Hgb levels \> 9.0 g/dl.
48625398|NCT03186365|DRUG|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
47936809|NCT00766961|PROCEDURE|Surgery|Surgery
47936810|NCT06536231|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
47936811|NCT05590221|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
47936812|NCT05590221|DRUG|Fludarabine|Administered according to package insert
47936813|NCT05590221|DRUG|Cyclophosphamide|Administered according to package insert
47936814|NCT01541345|DEVICE|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
47936815|NCT01541345|DRUG|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
47936816|NCT01541345|PROCEDURE|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
48099995|NCT06630520|COMBINATION_PRODUCT|Periarticular injection|"A 50ml periarticular injection was introduced intraoperatively before the time of closing. The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.~Before wound closure, periarticular cocktail was injected around the knee joint including the adductor canal from the hamstring harvest side in PAI group. All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery."
48465157|NCT00356096|DRUG|pramipexole|
48465158|NCT02093962|DRUG|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
48465159|NCT02093962|DRUG|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
48465160|NCT01301937|DRUG|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose"
48465161|NCT03786705|OTHER|Massive transfusion|Trauma patients who had received blood transfusion≥10 U
48465162|NCT03786705|OTHER|Non-Massive Transfusion|Trauma patients who had received blood transfusion\<10 U
48465163|NCT02835755|OTHER|Educational Intervention|Receive standard HPV and HPV vaccine information
48465164|NCT02835755|OTHER|Educational Intervention|Receive mHealth HPV vaccine intervention
48465165|NCT02835755|OTHER|Survey Administration|Ancillary studies
48465166|NCT01086969|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
48465167|NCT03013036|DEVICE|Ultrasonography|
48099996|NCT04226469|PROCEDURE|Tooth movement|The subject's canines will be retracted distally and crevicular fluid is collected
48465168|NCT03013036|DRUG|Sevoflurane|
48465169|NCT03013036|DRUG|intravenous midazolam|
48465170|NCT03013036|DRUG|Propofol|
48465171|NCT03013036|DRUG|fentanyl and rocuronium|
48465172|NCT05731024|DEVICE|close-loop synchronization controller with SPONT mode|One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
48465173|NCT05731024|DEVICE|Conventional synchronization settings with SPONT mode|One-hour period where the pressure support of spontaneous breath will be manually set.
48465174|NCT06536049|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48465175|NCT06536049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
48465176|NCT06536049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
48465177|NCT06536049|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
48465178|NCT06536049|BIOLOGICAL|Epcoritamab|Given SC
48465179|NCT06536049|DRUG|Ibrutinib|Given PO
48465180|NCT06536049|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48465181|NCT01947738|DRUG|VBY-891|Cathepsin S inhibitor
48465182|NCT01947738|DRUG|Placebo|
48465183|NCT04418167|DRUG|JSI-1187|JSI-1187 capsules for oral administration
48465184|NCT04418167|DRUG|Dabrafenib|Dabrafenib capsules for oral administration
48465185|NCT05736198|DRUG|Dexmedetomidine|dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
48465186|NCT05772858|OTHER|Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP)|An Innovative Web-based Tool to train mental health therapists in family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
48465187|NCT05772858|OTHER|Training on CIFFTA competencies using Training and Coaching as Usual (TCAU).|Therapists receive training using the traditional face to-face training method for 2.5 days followed by coaching.
48465188|NCT05772858|OTHER|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|CIFFTA has three major components: Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format. One session will typically be a family session which may include Family Therapy or Psychoeducational modules designed for the family or parents alone. The other session is typically with the adolescent alone which may include individual treatment or Psycho-educational modules designed for the adolescent.
48465189|NCT05772858|OTHER|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|The FTTIP agency readiness work begins with a pre-recorded FTTIP introduction webinar presented separately to each agency which presents overall goals of the project and the different FTTIP components, and key decisions agencies often make when seeking to sustain a new EBT.
48465190|NCT05772858|OTHER|Agency Engagement and Orientation as Usual|Work with the agency leaders will consist of the traditional engagement of the leadership so that they agree to collaboration with the study team, with the training team, and with the study procedures.
48465191|NCT05694117|BEHAVIORAL|self-determine sequence exercise program|The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
48478876|NCT03395639|DRUG|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
48099997|NCT00523731|PROCEDURE|Angiogenic Cell Precursors (ACPs) or Vescell TM|
48465192|NCT05694117|BEHAVIORAL|resistance training|The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
48465193|NCT05694117|BEHAVIORAL|Taichi exercise and resistance training|The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
48625399|NCT04714671|OTHER|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a small room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
48625400|NCT03997305|DEVICE|AltaValve|Transcatheter Mitral Valve Replacement
48478877|NCT01481870|DRUG|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
48478878|NCT01481870|DRUG|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
48625401|NCT04620538|DIAGNOSTIC_TEST|Breath Analysis|Participants will be asked to provide 500mls of exhaled breath which will be loaded on to thermal desorption tubes and analysed via Mass Spectrometry.
48625402|NCT02962557|DEVICE|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
48625403|NCT00000599|DRUG|colestipol|
48625404|NCT00000599|DRUG|niacin|
48625405|NCT00000599|BEHAVIORAL|diet, fat-restricted|
48625406|NCT00004897|BIOLOGICAL|recombinant interferon alfa|
48625407|NCT00004897|DRUG|cisplatin|
48625408|NCT00004897|DRUG|fluorouracil|
48625409|NCT00004897|DRUG|hydroxyurea|
48625410|NCT00004897|DRUG|leucovorin calcium|
48625411|NCT00004897|PROCEDURE|conventional surgery|
48625412|NCT00004897|RADIATION|radiation therapy|
48625413|NCT06118073|OTHER|Headspace|Headspace is a smartphone-based application that guides individuals through various mindfulness sessions and has been shown to reduce symptoms of depression, anxiety, and pain. Participants will be required to answer questions regarding anxiety levels and pain for 6 weeks after surgery.
48625414|NCT06118073|PROCEDURE|Total Knee Replacement|Participant will have total knee replacement surgery
48625415|NCT02245373|DRUG|Antidepressants|
48625416|NCT02245373|OTHER|Active Monitoring|
47936817|NCT03000127|DRUG|AndroGel 1 % Topical Gel|testosterone gel
47936818|NCT03000127|DRUG|Placebos|Placebo gel
47936819|NCT03709329|DEVICE|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
47936820|NCT03709329|DEVICE|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
47936821|NCT00652639|DRUG|Clonazepam|Tablets, 1 mg, single-dose
47936822|NCT00652639|DRUG|Klonopin|tablets, 1 mg, single-dose
48625417|NCT03570424|DIETARY_SUPPLEMENT|Nutrient support to HIIT|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).
48625418|NCT03570424|DIETARY_SUPPLEMENT|Placebo|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).
48625419|NCT04665232|DRUG|aqueous subcutaneous progesterone|25 mg/die of aqueous subcutaneous progesterone from the day of oocytes retrieval for two weeks.
48465194|NCT05694117|BEHAVIORAL|Randomly selected exercise program|Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
48625420|NCT05550181|BEHAVIORAL|intraoperative mechanical ventilation with hypocapnia (etCO2 < 35 mm Hg)|A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
48465195|NCT00338390|DRUG|Abacavir|Change tenofovir to abacavir
48465196|NCT00338390|DRUG|Didanosine|Increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.
48465197|NCT00338390|DRUG|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
48465198|NCT00943033|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
48465199|NCT01044433|DRUG|lapatinib ditosylate|Given orally
48465200|NCT01044433|DRUG|capecitabine|Given orally
48465201|NCT01773239|BEHAVIORAL|TARA computer-based exercises|
48465202|NCT03104231|OTHER|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
48465203|NCT01186562|DRUG|Sitagliptin|100 mg PO daily
48465204|NCT01186562|DRUG|Placebo|Placebo
48465205|NCT02107196|DRUG|Ibodutant 10 mg|Oral tablet, to be given once daily.
48465206|NCT02107196|DRUG|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
48465207|NCT04435054|DIAGNOSTIC_TEST|Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.|"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."
48625421|NCT05004285|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
48625422|NCT02370862|DRUG|Neostigmine and Glycopyrrolate|
47936823|NCT02195284|DEVICE|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
48625423|NCT01137812|DRUG|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
47936824|NCT02195284|DEVICE|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
47936825|NCT02195284|DEVICE|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
47936826|NCT02195284|DEVICE|TURBUHALER|Placebo inhaler containing lactose monohydrate.
47936827|NCT01058265|OTHER|Integrative|Integrative Medicine medical evaluation.
47936828|NCT01058265|OTHER|Standard|Standard general medical evaluation.
47936829|NCT03578770|DEVICE|Hot Axios stent|Hot Axios stent
47936830|NCT00272753|DRUG|budesonide/formoterol Turbuhaler|
47936831|NCT00272753|DRUG|formoterol Turbuhaler|
47936832|NCT00272753|DRUG|salbutamol|
47936833|NCT04849325|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with IBS Titan™.
47936834|NCT04849325|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Subjects in this arm will be treated with PTA device.
47936835|NCT02583243|BEHAVIORAL|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
47936836|NCT02583243|DRUG|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
47936837|NCT03117088|OTHER|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
47936838|NCT03117088|OTHER|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
47936839|NCT00823342|DRUG|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
47936840|NCT00823342|DRUG|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
47936841|NCT00823342|DRUG|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
47936842|NCT04255927|DRUG|Coated Vicryl plus|Vicryl plus (Coated Polyglactin 910 with Triclosan)
48625424|NCT01137812|DRUG|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
48625425|NCT01137812|DRUG|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
47936843|NCT04255927|DRUG|Coated vicryl|Vicryl (Coated Polyglactin 910 without Triclosan)
48465208|NCT04071613|DRUG|Tenecteplase|Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
47936844|NCT03924531|BEHAVIORAL|Mindful Awareness Program|2-hour mindfulness training for 6 weeks.
47936845|NCT03924531|BEHAVIORAL|Health Promotion Program|Health Promotion Program
48465209|NCT04071613|DRUG|Intravenous tissue plasminogen activator (tPA)|Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
48465210|NCT02465892|BEHAVIORAL|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
48465211|NCT04534140|DIETARY_SUPPLEMENT|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
47936846|NCT03159702|DRUG|Evomela|140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3
47936847|NCT03159702|DRUG|Fludarabine|40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
48465212|NCT04534140|OTHER|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
48099998|NCT05181579|OTHER|Manuel therapy|Some sacroiliac manipulation and mobilization techniques will be applied to patients by an experienced physiatrist. Patients in the manual therapy group will receive 5 sessions of sacroiliac joint manipulation once a week.
48625426|NCT01137812|DRUG|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
48625427|NCT01756001|DEVICE|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
47936848|NCT03159702|RADIATION|Total Body Irradiation|200 cGy on Day: -1
47936849|NCT03931668|DRUG|TPN-672|single dose of TPN-672 maleate tablet
47936850|NCT04862858|OTHER|Educational Intervention|The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
48099999|NCT05181579|OTHER|Sacroiliac joint injection|Corticosteroid (1 ml 40 mg methylprednisolone) and local anesthetic (1 ml 1% lidocaine) will be injected into the sacroiliac joint using a 22 G spinal needle, guided by fluoroscopy (C-arm fluoroscopy) by an experienced physiatrist. It will be applied just one time.
48625428|NCT01756001|BEHAVIORAL|Daily email, text message, or phone call reminders|
48625429|NCT01756001|BEHAVIORAL|Paid for adherence|
48625430|NCT03682640|DRUG|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
48100000|NCT02702674|DRUG|propranolol|propranolol 20 mg given before induction of labor
48100001|NCT02702674|DRUG|placebo|starch tablet containing no active drug material given before induction of labor
48465213|NCT03637127|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
48465214|NCT03637127|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
48465215|NCT05971524|DIETARY_SUPPLEMENT|6-BT|2,4 or 8mg of 6-BT once daily for 4 weeks
48465216|NCT05971524|DIETARY_SUPPLEMENT|Placebo|A placebo capsule once daily for 4 weeks
48465217|NCT02816684|BEHAVIORAL|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
48465218|NCT02816684|BEHAVIORAL|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
48625431|NCT03682640|DRUG|Insulin Lispro|Solution for intravenous or subcutaneous use
48625432|NCT03682640|BEHAVIORAL|Dietician support|Dietary advice
48625433|NCT05963230|OTHER|Ultrasound scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
48625434|NCT00221104|DRUG|Pravastatin|
48625435|NCT03233685|BEHAVIORAL|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
48625436|NCT03233685|BEHAVIORAL|Normal Training|Normal training routine
47936851|NCT00167466|DEVICE|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
47936852|NCT00167466|DEVICE|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
47936853|NCT01221103|DRUG|Combination of dexamethasone, ofatumumab and bendamustine|"* Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~* Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~* Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
47936854|NCT01452009|DRUG|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
47936855|NCT01452009|DRUG|TRAVATAN®|TRAVATAN® administered one drop once daily
48100002|NCT02702674|DRUG|Oxytocin|intravenous infusion of oxytocin
48100003|NCT02374333|BIOLOGICAL|huCART19|
48100004|NCT05266352|OTHER|Supervised exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises under control of the physiotherapist in the clinic."
48100005|NCT05266352|DIAGNOSTIC_TEST|Home exercise program|"A structured program consisting of range of motion, postural control, scapulothoracic strengthening, glenohumeral strengthening and dynamic stabilization exercises used in conservative treatment of rotator cuff tears will be performed for 8 weeks.~Patients will do the exercises at home. Patients will visit the clinic every 2 weeks and progression of exercise program will be made."
48100006|NCT06226987|DIAGNOSTIC_TEST|68Ga-DOTATATE PET/MRI|PET/MRI scanning
48465219|NCT00731367|DEVICE|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
48625437|NCT05484947|DIAGNOSTIC_TEST|Elisa HIV testing|HIV testing on a voluntary basis
48625438|NCT02038426|BIOLOGICAL|BLOOD SAMPLES|
48100007|NCT04878341|OTHER|Erector Spinae Plane Block|The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
48100008|NCT05187351|PROCEDURE|Percutaneous coronary intervention of the native coronary artery with Synergy|This is a registry study that will enroll patients with a 50-99% de novo SVG lesion SVG lesion and treated with percutaneous coronary intervention of the corresponding native coronary artery using a SYNERGY stent.
47936856|NCT04816201|OTHER|Electroacupuncture|Electroacupuncture at Xuanji (CV21), Danzhong (CV27), Qihai (CV06), Guanyuan (CV04), and bilateral Liangmen (ST21) and Zusanli (ST36).
47936857|NCT04513821|DRUG|Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter. Mino-Lok is made available through this expanded access protocol to patients who otherwise do not qualify for the phase 3 clinical trial (NCT02901717) Other Name: Standard of care antibiotics + Mino-Lok
47936858|NCT05656989|OTHER|Periodontal clinical measurements and GCF sampling|Periodontal clinical parameters measurements probing depth (PD), clinical attachment loss (CAL), the dichotomous recording (present/absent) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were recorded at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) per tooth, except the third molars using a manual periodontal probe. A sterile paper strip was gently placed into the gingival sulcus/periodontal pocket until mild resistance was sensed and left in place for 30 seconds.
47936859|NCT01258270|PROCEDURE|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
48100009|NCT03378739|PROCEDURE|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
48100010|NCT03360396|DEVICE|Endobronchial Coils|Endobronchial Coil implants
48100011|NCT03916926|DEVICE|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
48100012|NCT03916926|DEVICE|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
48100013|NCT02210702|DRUG|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
48625439|NCT02038426|DEVICE|Radiographs of the sacroiliac joints|
48625440|NCT02038426|DEVICE|Radiographs of heels|
47936860|NCT01258270|PROCEDURE|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
47936861|NCT01807832|OTHER|capsaicin challenge|
47936862|NCT05242861|RADIATION|Brachytherapy|Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
47936863|NCT02577432|DRUG|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
47936864|NCT02577432|DRUG|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
47936865|NCT02577432|DRUG|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
48100014|NCT02210702|DRUG|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
48100015|NCT04545606|BEHAVIORAL|In-Person CBT for insomnia in children with autism|"7 modules administered in-person~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
48100016|NCT04545606|BEHAVIORAL|Remote CBT for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares"
48100017|NCT04545606|BEHAVIORAL|Remote sleep hygiene and related education (SHARE) for insomnia in children with autism|"7 modules administered over telehealth/videoconferencing~1. Sleep Education~2. Sleep Architecture \& Parasomnias~3. Physical Activity \& Sleep~4. Nutrition, My Plate, \& Breathing during Sleep~5. Stress, Sleep, Dreams, \& Nightmares Connections~6. Mood, Self-Esteem, \& Sleep~7. Light \& Dark Cycle"
48100018|NCT01701609|BEHAVIORAL|Cognitive Remediation Therapy|
48100019|NCT05779514|DRUG|Mirabegron|Health Volunteers ：Mirabegron p.o. 28 days 100mg qd./ Tumor patients ：Mirabegron p.o. 28 days 100 mg qd or 200 mg qd.
48100020|NCT00712166|DRUG|AZLI 75 mg three times daily (TID)|
48625441|NCT02038426|DEVICE|SCAN|
48465220|NCT00731367|DEVICE|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
48465221|NCT05093686|BEHAVIORAL|RUBIES|RUBIES is an 8 module intervention that begins with foundational education on ASD (Session1), followed by introducing basic applied behavior analysis principles (Session 2). Instruction is then provided on strategies that can prevent problematic behaviors from occurring (Session 3 and 4). Reinforcement (Session 5) reviews the use of tangible and social reinforcers tools to promote new/desired behaviors while planned ignoring and functional communication training (Session 6) teaches that disruptive behavior can serve as a form of communication while ignoring disruptive communicative attempts. Sessions conclude with instruction on effective ways to deliver commands to promote compliance (Session 7) and targeting approaches to ensure positive behavior gains can maintain over time and strategies can be used across classrooms and staff (Session 8).
48465222|NCT05093686|BEHAVIORAL|Usual Care Training|Usual Care Training is an 8 module psychoeducation program that will provide foundational information on autism spectrum disorders, including the diagnostic criteria, appropriate educational services, common interventions, and how to promote social skills in the classroom.
48465223|NCT05758623|DEVICE|Device|The experimental group was treated with magnesium containing biodegradable polymer bone repair material produced by Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. Control group application β- Tricalcium phosphate bioceramics for treatment.
48625442|NCT03594552|DRUG|Arbaclofen_15|Single oral dose (15mg)
48625443|NCT03594552|DRUG|Arbaclofen_30|Single oral dose (30mg)
47936866|NCT02577432|DRUG|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
47936867|NCT00990275|OTHER|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
47936868|NCT01277042|BIOLOGICAL|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
47936869|NCT01277042|BIOLOGICAL|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
47936870|NCT00323869|DRUG|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
47936871|NCT00323869|DRUG|Gemcitabine|Nucleoside analog
47936872|NCT00323869|DRUG|Carboplatin|Alkylating agent
47936873|NCT04385407|DRUG|Sofosbuvir + Simeprevir + Ribavirin|
47936874|NCT00621400|DRUG|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
47936875|NCT00621400|DRUG|Melphalan|0,18mg/Kg/day from day 1- 4
47936876|NCT00621400|DRUG|Dexamethasone|40mg/day from day 1- 4.
47936877|NCT04509739|BEHAVIORAL|Music intervention|"At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study."
47936878|NCT05521776|PROCEDURE|First-trimester preeclampsia screening (FMF triple test)|"An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered."
47936879|NCT01314157|OTHER|Isostretching|12 interventions (two times per week) for 45 minutes
47936880|NCT00801671|PROCEDURE|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
47936881|NCT02766842|PROCEDURE|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
47936882|NCT02766842|PROCEDURE|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
47936883|NCT02766842|DEVICE|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
47936884|NCT02766842|DEVICE|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
47936885|NCT02942589|OTHER|Meal portion size|
47936886|NCT03636737|OTHER|pathology associated|list of pathology associated to Pyoderma gangrenosum
47936887|NCT04746742|PROCEDURE|Tunneled Femoral Catheter (TFC) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
48100021|NCT00712166|DRUG|Placebo three times daily (TID)|
48465224|NCT04947150|BEHAVIORAL|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
48465225|NCT04947150|BEHAVIORAL|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
48282136|NCT06258278|PROCEDURE|Arthroscopic-assisted lower trapezius tendon transfer surgery|The procedure, conducted under general anesthesia, starts with diagnostic arthroscopy followed by excision of the posterior bursa and preparation of the rotator cuff footprint. Attention then shifts to harvesting the low trapezius tendon, accessed through a 10cm incision over the spina scapula. The tendon is detached, dissected, and released from adhesions, ensuring not to damage its pedicle. A fascia lata graft is harvested from the ipsilateral thigh and sutured to the low trapezius tendon in a continuous, locking manner to aid fixation on the humeral head. A subdeltoid tunnel is formed, and the graft is shuttled into the subacromial space and fixed at the bicipital groove and tuberculum majus with knotless anchors. The stability of fixation and mobility of the low trapezius muscle are verified, and the graft and tendon are sutured together with tension, with the arm held in 90° abduction and maximum external rotation.
48282137|NCT03436264|OTHER|MRI|fMRI
48282138|NCT00938548|DRUG|Pregabalin|Pregabalin 75 mg orally
48282139|NCT00938548|DRUG|Vitamin Complex (placebo)|Vitamin Complex orally
48282140|NCT01035151|BEHAVIORAL|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
48282141|NCT01035151|BEHAVIORAL|Control|Written Cessation Materials
48282142|NCT03678974|BEHAVIORAL|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
48465226|NCT04947150|BEHAVIORAL|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
48478879|NCT05470829|DRUG|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
48625444|NCT03594552|DRUG|Placebo|Single oral dose placebo (oral tablet)
48625445|NCT03166956|DIETARY_SUPPLEMENT|Glutamine and vitamin C enteral supplement|Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
47936888|NCT04746742|PROCEDURE|Femoro-femoral Arteriovenous graft (FF-AVG) group|Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
47936889|NCT03687970|OTHER|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
47936890|NCT03687970|OTHER|Hospital Anxiety and Depression Scale|"* 14 item scale with even of the items relating to anxiety and seven relating to depression~* Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
47936891|NCT03687970|OTHER|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia \[pain provoked by light touch\]). Each of the parameters includes recall of the past 24 hours
47936892|NCT03687970|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
47936893|NCT03687970|PROCEDURE|Quantitative sensory testing|"* Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~* Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
47936894|NCT03687970|PROCEDURE|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
47936895|NCT03687970|OTHER|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
48282143|NCT06629389|DRUG|Cannabidiol 100 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
48465227|NCT04947150|BEHAVIORAL|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
48465228|NCT02133638|DRUG|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
48465229|NCT02133638|DRUG|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
48465230|NCT05796843|PROCEDURE|360 Degrees virtual reality-based mirror therapy|Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.
48465231|NCT05796843|PROCEDURE|Traditional mirror therapy|Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.
48465232|NCT05796843|PROCEDURE|Conventional Physical Therapy|Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
48465233|NCT04913545|DIAGNOSTIC_TEST|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
48465234|NCT02856776|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D provided in capsule form
48465235|NCT01361633|DRUG|d-cycloserine|single oral administration of 250 mg d-cycloserine
48465236|NCT01361633|DRUG|Sugar Pill|Single oral administration 250 mg Sugar Pill
48465237|NCT04346680|PROCEDURE|ADSC administration|The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
48465238|NCT04046094|DRUG|Ascorbic Acid|Ascorbic Acid Intravenous
48465239|NCT04598633|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
48465240|NCT04598633|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
48465241|NCT04664751|OTHER|Nil-per-Oral|NPO details
47936896|NCT04167956|DEVICE|ultrasound and CT|Experimental: ultrasound combined with CT guided Active Comparator: CT guided
47936897|NCT03010761|DRUG|escitalopram|antidepressant use for the betel-quid abstinence
47936898|NCT03010761|DRUG|Moclobemide|antidepressant use for the betel-quid abstinence
47936899|NCT03010761|DRUG|Placebo - Cap|Placebo - Cap
47936900|NCT03919877|OTHER|Dietary|Dietary counseling based on results of CGM analyses.
47936901|NCT05791370|DIETARY_SUPPLEMENT|A 12-week parallel dietary intervention|Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
48100022|NCT00031343|DRUG|highly active antiretroviral therapy (HAART)|
48625446|NCT01838811|BEHAVIORAL|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
48625447|NCT06005376|OTHER|Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive|The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
47936902|NCT01616134|OTHER|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
47936903|NCT01616134|OTHER|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
47936904|NCT04019418|DIETARY_SUPPLEMENT|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
47936905|NCT04019418|OTHER|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
47936906|NCT04019418|OTHER|Rest|30 minutes laying on a bed
47936907|NCT04019418|OTHER|Water|A drink containing 300ml of water
47936908|NCT04428437|DRUG|Lenvatinib|Prescribed by physician.
47936909|NCT01563146|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
47936910|NCT06423417|BEHAVIORAL|LifeHack|See arm description
48465242|NCT01125527|BIOLOGICAL|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
48625448|NCT00034866|DRUG|Protease inhibitor tipranavir|
47936911|NCT04910373|OTHER|Experimental Extensively Hydrolyzed Formula|experimental powder formula
47936912|NCT04910373|OTHER|Placebo Extensively Hydrolyzed Formula|placebo powder formula
47936913|NCT00391261|DRUG|Metformin|open-label, flexible dosing
47936914|NCT00002664|BIOLOGICAL|edrecolomab|
47936915|NCT00002664|BIOLOGICAL|sargramostim|
47936916|NCT06053008|OTHER|The relationship between pain perception, temporomandibular joint disorder severity and spine health|The relationship between pain perception, temporomandibular joint disorder severity and spine health
47936917|NCT04617535|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
47936918|NCT00349427|DRUG|Rosiglitazone 4 mg|
47936919|NCT02276573|BIOLOGICAL|buccal cavity sample|
47936920|NCT05968365|DEVICE|electronic Vision-aid Device|Electronic blind aid is a non-invasive electronic aid product for the visually impaired. The product converts visual signals into tactile signals. The Vision Pro is designed for people with poor or no visual perception. The product does not change the previous travel mode of the visually impaired, and provides additional external information for the visually impaired on the basis of their existing cognition. The product can provide the visually impaired person with additional external information based on the cognition in front of them. The product can feedback the environmental information within 2.52.5 meters in front of the visually impaired person in the form of electrical stimulation to the visually impaired person. The visually impaired person can be stimulated by the tongue current to help them identify obstacles and give early warning. Avoid obstacles and give early warning.
47936921|NCT02301988|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
47936922|NCT02301988|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion QW for 3 cycles.
47936923|NCT02301988|DRUG|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
47936924|NCT04075370|OTHER|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A\&B and COWA over time.
47936925|NCT00400530|DRUG|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
47936926|NCT00400530|DRUG|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
47936927|NCT03053765|OTHER|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
47936928|NCT06147973|BEHAVIORAL|Acceptance-based Treatment (ABT)|Participants will be provided with psycho-education, skill-builders, and other coaching to promote weight loss and healthy lifestyle changes.
47936929|NCT06147973|BEHAVIORAL|Health Education (HE) Comparison|Participants will be provided with psych-education and resources to promote weight loss and healthy lifestyle changes. They will not be provided with directives.
47936930|NCT05715801|PROCEDURE|hyperbaric oxygen therapy|The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.
47936931|NCT05715801|PROCEDURE|conventional oxygen therapy|Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
47936932|NCT00735059|DEVICE|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, \> 3 hours
48465243|NCT01125527|BIOLOGICAL|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
48465244|NCT06088095|OTHER|Mobility group|Patients will be mobilized in accordance with the gradual mobilization procedure 12 hours after the angiography procedure.
47936933|NCT00735059|DEVICE|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, \> 3 hours
47936934|NCT06234384|OTHER|Sarcoidosis diagnosis|Participants have been diagnosed with sarcoidosis.
47936935|NCT03512015|OTHER|The Lung Cancer App - LuCApp|The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care
47936936|NCT03512015|OTHER|Standard care|The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
47936937|NCT05261451|OTHER|Workshop|Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
47936938|NCT05769543|PROCEDURE|WATSU application|20-minute application of WATSU
47936939|NCT05769543|OTHER|Lecture|20-minute lecture on WATSU technique
47936940|NCT00912665|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
48100023|NCT05447013|BIOLOGICAL|Coronavirus-2-specific T cells|Coronavirus-2-specific T cells ex vivo expanded from selected COVID-19 recovered donors
48100024|NCT05447013|OTHER|standard of care (SOC)|standard of care (SOC)
48282144|NCT06629389|DRUG|cannabidiol 300 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
48100025|NCT02304822|DRUG|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
48100026|NCT02304822|DRUG|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
48465245|NCT01351363|DEVICE|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
48465246|NCT01351363|DEVICE|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
48100027|NCT02304822|DRUG|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
48465247|NCT03292263|DRUG|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
47936941|NCT00912665|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
47936942|NCT00912665|OTHER|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
47936943|NCT00912665|DEVICE|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
47936944|NCT04457219|DEVICE|Haemostatic Dressing|A Hemostatic Dressing is applied at the radial access site, following a transradial angiographic procedure. This is a mineral-based dressing with a hydrophilic polymer that works independently of the clotting cascade to seal the site, by accelerating topical hemostasis.
47936945|NCT04457219|DEVICE|Conventional Dressing|A Conventional Absorbent Dressing is applied at the radial access site, following the transradial angiographic procedure.
47936946|NCT04457219|DEVICE|120 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 2 hours. Prolonged time of compression may be required.
47936947|NCT04457219|DEVICE|60 Minutes External Compression|A radial compression device is applied at the radial access site to achieve patent hemostasis. The device remains in situ for 1 hour. Prolonged time of compression may be required.
47936948|NCT06179368|DIAGNOSTIC_TEST|hypothroidism|throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.
47936949|NCT06179368|DIAGNOSTIC_TEST|euothyroid|throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.
47936950|NCT00477074|PROCEDURE|bronchoalveolar lavage, blood analysis|
47936951|NCT06438627|DRUG|TPC combined with Apatinib and Camrelizumab|Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab
47936952|NCT06438627|DRUG|GP Combined With Camrelizumab|Gemcitabine, Cisplatin regimen Combined With Camrelizumab
47936953|NCT02586402|DRUG|pegol-Sihematide|
47936954|NCT02586402|DRUG|Epoetin Alfa|
47936955|NCT01179035|OTHER|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
47936956|NCT01179035|OTHER|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
47936957|NCT00768469|DRUG|Neratinib|Administered orally, continuous, once daily.
47936958|NCT00768469|DRUG|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
48100028|NCT05468333|OTHER|Cigarette trial|Per NIH Program Official, this is not an ACT and thus full protocol info is not required at this time (and would be detrimental to the study if details were disclosed during recruitment).
48465248|NCT03292263|DRUG|Nivolumab|iv infusion 100 mg on day -3, +17
48465249|NCT03292263|PROCEDURE|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
48465250|NCT03750357|DEVICE|Primary Relief v 2.0|To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
48465251|NCT05449080|DIAGNOSTIC_TEST|Karyotype|Patients were subjected to karyotype to determine their genotype
48465252|NCT05014880|BEHAVIORAL|ICR (Intensive Cardiac Rehabilitation)|Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.
48465253|NCT05014880|BEHAVIORAL|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
47936959|NCT02189954|PROCEDURE|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
47936960|NCT02189954|PROCEDURE|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
48100029|NCT01530009|DRUG|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
48100030|NCT01530009|OTHER|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
48100031|NCT01398930|OTHER|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
48465254|NCT06083623|BIOLOGICAL|TNM001|single dose intramuscular injection
48465255|NCT06083623|BIOLOGICAL|placebo|single dose intramuscular injection
48100032|NCT06146985|COMBINATION_PRODUCT|20 mg Famitinib & 1200 mg Adebrelimab|Famitinib is a novel multi-targeted tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. Adebrelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody that binds specifically to human PD-L1
48100033|NCT04691544|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Delivered by enema
48465256|NCT00633698|DRUG|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
48465257|NCT00633698|DRUG|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
48465258|NCT00000680|DRUG|Zidovudine|
48465259|NCT00000680|DRUG|Aldesleukin|
48465260|NCT03513224|OTHER|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
48465261|NCT00972231|OTHER|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
48465262|NCT03019016|PROCEDURE|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
47936961|NCT04387383|DEVICE|Acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into scalp acupuncture points (Baihui, Toulinqi) or straightly into body acupuncture points (Taichong, Zhangmen, Sanyinjiao, Zhongwan, Guanyuan, Tianshu, Zusanli). Electroacupuncture will be applied to the abdominal points at fast and dispersed waves through electric needle stimulator (ES-160 6-Channel Programmable Electro-acupuncture) for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
48100034|NCT02533167|OTHER|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
48100035|NCT00181909|BEHAVIORAL|Smoking cessation counseling delivered by telephone|
48100036|NCT00841958|PROCEDURE|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
48100037|NCT03181724|BEHAVIORAL|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
48100038|NCT01483287|DIETARY_SUPPLEMENT|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
48465263|NCT01480895|BEHAVIORAL|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
48100039|NCT04474925|PROCEDURE|Brain Surgery|Surgery to remove brain metastases
48100040|NCT04474925|RADIATION|Stereotactic Radiosurgery|SRS uses many focused radiation beams to treat tumors within the brain
48100041|NCT05905406|OTHER|Electrical estimulation|Electrical estimulation during the fatigue protocol. Frequency = 100 Hz, pulse duration = 500 µs, time ON = 20 s (including rise time = 1.0 s and descent time = 1.0 s) and off time = 20 sec
48100042|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
48465264|NCT03183141|BIOLOGICAL|SER-109|SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores
47936962|NCT04387383|DEVICE|Sham-acupuncture|Disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length) are inserted at the same way as in the acupuncture group but on sham-acupuncture points (Sham-Baihui, Sham-Toulinqi, Sham-Taichong, Sham-Zhangmen, Sham-Sanyinjiao, Sham-Zhongwan, Sham-Guanyuan, Sham-Tianshu, Sham-Zusanli). The sham points are non-acupuncture points nor located on meridians
47936963|NCT03300648|OTHER|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
47936964|NCT03300648|DRUG|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
47936965|NCT02599675|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
47936966|NCT02599675|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
47936967|NCT01915966|DIETARY_SUPPLEMENT|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
47936968|NCT01915966|DIETARY_SUPPLEMENT|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
48100043|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
48100044|NCT01320709|DRUG|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
48100045|NCT01320709|DRUG|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
48465265|NCT03599921|BEHAVIORAL|Family-based treatment|"Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness."
48625449|NCT03489525|BIOLOGICAL|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
48625450|NCT03489525|BIOLOGICAL|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
48625451|NCT04481282|DRUG|Terbutaline|2.5mg po tid for 12 weeks
48625452|NCT04481282|DRUG|Danazol|200mg po bid for 12 weeks
48625453|NCT05926531|DEVICE|CBTI online programe|20 MIN VR RELAX PROGRAME
47936969|NCT02374047|DRUG|CAT-2054|
48100046|NCT01898676|DRUG|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
48100047|NCT01898676|DRUG|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
48100048|NCT01720446|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
48282145|NCT06629389|DRUG|Cannabidiol 400 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
48625454|NCT00932854|PROCEDURE|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
48625455|NCT00226733|BEHAVIORAL|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
48625456|NCT00226733|BEHAVIORAL|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
47936970|NCT02374047|DRUG|Placebo|
47936971|NCT02374047|DRUG|CAT-2054-C|
47936972|NCT02374047|DRUG|Atorvastatin|
47936973|NCT01646060|DEVICE|CM-1500|Blood Volume Monitor
47936974|NCT02848053|OTHER|no intervention|
47936975|NCT00812487|DRUG|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
47936976|NCT00812487|DRUG|Subcutaneous insulin|4 injections of insulin/day
47936977|NCT05765981|DRUG|VGN-R09b|VGN-R09b will be injected into bilateral putamen by stereotactic surgery.（Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center）
47936978|NCT02960997|DRUG|Sirolimus, 2%|
47936979|NCT02960997|DRUG|Vehicle|
47936980|NCT00381953|DRUG|Peginterferon alfa-2a|
47936981|NCT00381953|DRUG|Interferon alfa-2a|
47936982|NCT00381953|DRUG|Ribavirin|
47936983|NCT00300118|DRUG|budesonide|9 mg
47936984|NCT00300118|DRUG|mesalazine|4.5 g
47936985|NCT05789394|BIOLOGICAL|Allogeneic Adipose-derived Mesenchymal Stem Cells|Receive IT
47936986|NCT05789394|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
47936987|NCT05789394|PROCEDURE|Craniotomy|Undergo craniotomy
47936988|NCT05789394|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47936989|NCT05789394|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir placement for collection of CSF
48625457|NCT06370975|DRUG|3% hypertonic Saline|"the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
48625458|NCT06370975|DRUG|Ringer's lactated solution|"the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
48625459|NCT06370975|DRUG|0.9% Normal saline|"the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100"
48625460|NCT02503930|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
48625461|NCT02503930|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
48625462|NCT02058277|DRUG|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
48625463|NCT05501379|OTHER|No intervention - observational study only|No intervention - observational study only
48625464|NCT01182961|OTHER|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
48625465|NCT01182961|OTHER|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
48625466|NCT01182961|OTHER|exercise group|standard of care exercise group to improve strength and balance
48625467|NCT02654509|BIOLOGICAL|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
48625468|NCT06036238|BEHAVIORAL|Healthy Living Intervention (HLI)|The Healthy Living Intervention (HLI) is a brief alcohol counseling intervention developed using the Information, Motivation, and Behavioral skills (IMB) model, a framework in which information, motivation, and behavioral skills are key determinants of health behavior. Participants initiating PrEP will be randomized to either HLI or standard of care alcohol counseling.
48625469|NCT06036238|BEHAVIORAL|Standard of Care|Participants who are randomized to the control arm will receive basic alcohol counseling through the Ministry of Health if it is provided as standard of care.
48625470|NCT00327132|DRUG|Omeprazole, Amoxicillin, Clarithromycin|
48625471|NCT05776719|BEHAVIORAL|Health & Wellness|PowerPoint slide decks will be shown via shared screen. The wellness group will be largely educational in nature and will encourage discussion, setting goals, and making healthy choices. Similar topics covered in this group have been used previously in health promotion classes.
48625472|NCT05776719|BEHAVIORAL|Warrior Renew|The group format includes warm-up community building exercises, psychoeducational presentation of material standardized by the use of PowerPoint slides, followed by discussion of the information and interactive exercises, and closes with exercises to improve affect management skills, such as mindfulness or guided imagery.
48625473|NCT04379180|DRUG|Bosentan Tablets|2mg/kg, bid
48625474|NCT04379180|DRUG|Sildenafil Tablet|1mg/kg, q6h/q8h
48625475|NCT04379180|DRUG|Tadalafil Tablets|1mg/kg, qd
48100049|NCT01720446|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
48100050|NCT01720446|DRUG|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
48625476|NCT00239291|DRUG|Gefitinib, radiotherapy|
48625477|NCT03306121|DRUG|TPF+CCRT|"Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
48625478|NCT03306121|DRUG|CCRT+ PF|"Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
48100051|NCT00540813|DEVICE|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
48100052|NCT01247558|OTHER|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for \>120 days
48100053|NCT01247558|OTHER|Not treated with Metanx®|Non-treated comparative cohort
48100054|NCT00516711|DRUG|Sevoflurane|
48100055|NCT01024205|DRUG|sunitinib malate|
48100056|NCT01024205|OTHER|laboratory biomarker analysis|
48100057|NCT01024205|PROCEDURE|adjuvant therapy|
48100058|NCT01024205|PROCEDURE|neoadjuvant therapy|
48100059|NCT01024205|PROCEDURE|therapeutic conventional surgery|
48100060|NCT03392558|OTHER|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
48100061|NCT03392558|OTHER|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
48100062|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
47936990|NCT02086279|DRUG|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
47936991|NCT00579007|BEHAVIORAL|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
47936992|NCT04186091|PROCEDURE|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction|correlation between baseline perfusion index and decrease in systolic blood pressure post spinal induction
47936993|NCT03723603|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
47936994|NCT03969992|DRUG|AeroFact|Aerosolized SF-RI 1
47936995|NCT03969992|OTHER|nCPAP|nCPAP (nasal continuous positive airway pressure) alone
47936996|NCT03538574|BEHAVIORAL|CBT-I|CBT-I is a behavioral treatment for insomnia
47936997|NCT03538574|BEHAVIORAL|MAP-I|MAP-I is a mindfulness meditation treatment for insomnia
47936998|NCT03067831|BIOLOGICAL|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
47936999|NCT04689438|DIAGNOSTIC_TEST|gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
48282146|NCT06629389|DRUG|Placebo|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
48465266|NCT03599921|BEHAVIORAL|Enhanced Cognitive behavioral therapy|"Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed."
48100063|NCT03907007|DEVICE|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
47937000|NCT03988959|PROCEDURE|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
48465267|NCT03599921|BEHAVIORAL|Family-based treatment modified for ARFID|"Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed."
48465268|NCT03599921|BEHAVIORAL|FBT + UP for ARFID|"Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses."
47937001|NCT04452929|DRUG|Erenumab|Subcutaneous injection of 140 mg erenumab.
47937002|NCT04452929|DRUG|Placebo|Subcutaneous injection of saline placebo.
47937003|NCT04452929|DRUG|Calcitonin gene-related peptide|Intravenous infusion of 1.5ug/min calcitonin gene-related peptide over 20 minutes.
47937004|NCT04452929|DRUG|Cilostazol|Oral intake of 200 mg cilostazol.
47937005|NCT05882721|DEVICE|Sofwave|"The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB"
47937006|NCT03914508|BEHAVIORAL|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
47937007|NCT06432881|DEVICE|RD SET Sensor|All subjects are enrolled into this arm and will have Sp02 measurements obtained.
47937008|NCT04722653|DRUG|NNC0194-0499|1 single dose administered subcutaneously (s.c. - under the skin)
48100064|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
48100065|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
48100066|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
48100067|NCT00556062|BIOLOGICAL|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
48100068|NCT01255033|DEVICE|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
48100069|NCT05583292|OTHER|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
48465269|NCT05991362|DRUG|GFH312 100 mg|Participants receive single dose of GFH312 100 mg orally
48100070|NCT05583292|OTHER|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
48100071|NCT05583292|OTHER|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
48465270|NCT05991362|DRUG|GFH312 200 mg|Participants receive single dose of GFH312 200 mg orally
48282147|NCT01480986|DRUG|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
48465271|NCT05991362|DRUG|GFH312 120mg|Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days
48465272|NCT05991362|OTHER|Placebo|Participants receive placebo matching with GFH312
48282148|NCT04109079|PROCEDURE|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
48282149|NCT04109079|RADIATION|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
48282150|NCT04109079|RADIATION|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
48282151|NCT05195606|OTHER|Auditory stimulus|Auditory stimulus will be applied to the patients in intervention group A. For the auditory stimulus, the sound recording of the relatives of the patients will be taken and the patients will be listened to with headphones.
48465273|NCT03275623|DRUG|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
48465274|NCT03275623|OTHER|Standard Prenatal Care|Continued surveillance of urinary cultures
48465275|NCT03774199|DEVICE|NightOwl|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
48465276|NCT02275754|BEHAVIORAL|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
48465277|NCT02275754|BEHAVIORAL|PN Only|Participants will be navigated by PN on request
48465278|NCT05767762|OTHER|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
48465279|NCT06204367|DIAGNOSTIC_TEST|Lung Ultrasonografisi|It is aimed to compare the agreement between lung ultrasonography and clinical score in the diagnosis and follow-up of newborn babies who are followed up in the neonatal intensive care unit due to bronchiolitis caused by frequently encountered RSV and other viral factors.
47937009|NCT04722653|DRUG|Placebo (NNC0194-0499 )|1 single dose administered subcutaneously (s.c. - under the skin).
47937010|NCT02265601|OTHER|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
47937011|NCT02265601|OTHER|standard care|paper/pencil living will form
47937012|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
47937013|NCT02809261|PROCEDURE|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
47937014|NCT02809261|DRUG|Normal Saline|Normal saline is safe for perineural injection.
48465280|NCT01482117|DRUG|Clopidogrel|single oral administration of 300mg of clopidogrel
47937015|NCT02809261|DRUG|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
47937016|NCT06519110|DRUG|Neratinib tablets|In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
47937017|NCT04420754|BIOLOGICAL|AIC100 CAR T Cells|Autologous CAR T cells directed against ICAM-1
48465281|NCT01482117|DRUG|Cilostazol|single oral administration of 100mg cilostazol
48465282|NCT01482117|DRUG|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
47937018|NCT00731432|DRUG|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
47937019|NCT00731432|DRUG|Placebo Patch|Identical in shape and texture to treatment patch
47937020|NCT05841121|DRUG|Dexamethasone|Antenatal dexamethasone will be given a course of four intramuscular injections of dexamethasone 6 mg (1.2 milliliter), 12 hours apart.
47937021|NCT02711345|DRUG|LTT462|ERK Inhibitor
47937022|NCT05742347|DEVICE|DriGo Skin Protectant Textile|All participants in this study will have the DriGo skin protectant textile applied to their skin fold condition. Erythema, denudation, maceration, odor, and moisture will be assessed following application of the SPT.
47937023|NCT00421447|DRUG|Anastrozole|Group of women with breast cancer
48625479|NCT05679505|DEVICE|Auricular transcutaneous vagus nerve stimulation|Transcutaneous vagus nerve stimulation (taVNS) was performed with an FDA-approved Vagustim stimulation device and an electrode-shaped earpiece. In the participants included in the study and randomized to two groups, i) left ear taVNS was applied to the first group and ii) double-ear taVNS was applied to the second group.
48100072|NCT06305988|DEVICE|Transcranial direct current stimulation|The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
48625480|NCT01092156|BEHAVIORAL|Education|Education on Infant-led latching
48625481|NCT05474677|PROCEDURE|closure of the abdominal fascia|The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.
47937024|NCT01205581|BIOLOGICAL|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
48282152|NCT05195606|OTHER|Tactile stimulus|Tactile stimulus will be applied to the patients in the intervention group B. The tactile stimulus will be performed by the researcher with a foot massage to be applied to the patient.
48282153|NCT04641286|OTHER|Body motion categorisation|All patients will receive passive motion categorisation monitoring
48282154|NCT04285918|PROCEDURE|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
48282155|NCT04910217|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation
48282156|NCT04910217|PROCEDURE|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
48465283|NCT04661280|DRUG|Donepezil|Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
48465284|NCT03400774|OTHER|Stair-climbing|Short bouts of moderate intensity stair-climbing
48465285|NCT01479062|BEHAVIORAL|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
48465286|NCT01479062|BEHAVIORAL|Usual Care|Placebo Control
48465287|NCT06348979|PROCEDURE|Fiber flowable (SFRC) support below hybrid nanoceramic endocrowns|restoration of endodontically treated teeth by endocrowns
48465288|NCT06348979|PROCEDURE|all ceramic Endocrowns (emax)|restoration of endodontically treated teeth by endocrowns
48465289|NCT03135080|OTHER|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
48465290|NCT03135080|OTHER|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
48465291|NCT00683592|DRUG|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
48465292|NCT00683592|DRUG|placebo|placebo
48465293|NCT01483820|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
48465294|NCT05889039|DEVICE|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
48465295|NCT05889039|PROCEDURE|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
48625482|NCT02385357|DIETARY_SUPPLEMENT|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
47937025|NCT01205581|BIOLOGICAL|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
47937026|NCT00244842|DRUG|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
47937027|NCT00244842|DRUG|Placebo|Placebo
47937028|NCT03750422|DEVICE|Picoway|1064/532nm picosecond laser
47937029|NCT03750422|OTHER|Stratacel|a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
47937030|NCT03750422|OTHER|Aquasonic|clear ultrasound gel
47937031|NCT02927067|DRUG|Maribavir|Participants will receive 400 mg of maribavir BID orally.
47937032|NCT02927067|DRUG|Valganciclovir|Participants will receive valganciclovir tablets orally.
48282157|NCT04910217|PROCEDURE|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
48465296|NCT05889039|PROCEDURE|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
48465297|NCT00591071|OTHER|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
48465298|NCT00591071|OTHER|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
47937033|NCT02927067|OTHER|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
47937034|NCT03194503|DEVICE|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
47937035|NCT02313454|DEVICE|Intranasal Tear Neurostimulator|Neurostimulation applied intranasally and extranasally.
47937036|NCT04646772|PROCEDURE|Multivisceral resection|Multivisceral resection for locally advanced colon cancer.
47937037|NCT01142128|DRUG|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
47937038|NCT01142128|DRUG|Placebo to Nexium|one capsule per day for one month
48282158|NCT05278390|RADIATION|Thoracic CT scan|Automated quantitative analysis of altered pulmonary volume
48282159|NCT03062501|DRUG|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
48282160|NCT03022422|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
47937039|NCT01142128|DRUG|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
48282161|NCT03022422|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
48282162|NCT02224950|DEVICE|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
48282163|NCT02224950|OTHER|Non-medicated Emollient plus Cotton Sleeve|
48282164|NCT02224950|OTHER|Placebo Sleeve|
48282165|NCT01879020|DRUG|TA-8995|Drug: TA-8995 1mg
48282166|NCT01879020|DRUG|TA-8995|Drug: TA-8995 2.5mg
48282167|NCT01879020|DRUG|TA-8995|Drug: TA-8995 5mg
48282168|NCT01879020|DRUG|TA-8995|Drug: TA-8995 10mg
48282169|NCT01879020|DRUG|TA-8995|Drug: TA-8995 25mg
48282170|NCT01879020|DRUG|Placebo|Placebo (TA-8995 1mg)
48282171|NCT01879020|DRUG|Placebo|Placebo (TA-8995 2.5mg)
48282172|NCT01879020|DRUG|Placebo|Placebo (TA-8995 5mg)
48282173|NCT01879020|DRUG|Placebo|Placebo (TA-8995 10mg)
48282174|NCT01879020|DRUG|Placebo|Placebo (TA-8995 25mg)
48282175|NCT00283010|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
48282176|NCT00283010|OTHER|Educational DVDs|
48282177|NCT06656351|DRUG|Tafenoquine 100mg|Tafenoquine
48282178|NCT06056284|BEHAVIORAL|Progressive relaxation exercises and sleep hygiene training|Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
48282179|NCT05240937|BEHAVIORAL|mindfulness-based self-compassion will be applied|A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
48282180|NCT00968734|DIETARY_SUPPLEMENT|colecalciferol|50.000UI single oral dose
48282181|NCT01413269|RADIATION|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
48282182|NCT04998006|DRUG|Alcohol and Cannabis vs. Alcohol only|Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
48282183|NCT04075643|DRUG|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
48100073|NCT04088513|DRUG|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
48100074|NCT04088513|DRUG|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
48100075|NCT06475807|DIETARY_SUPPLEMENT|High-fermented food|Step 1: patients will consume high-fermented food
48100076|NCT06475807|DIETARY_SUPPLEMENT|High fiber supplementation|Step 2: High fiber supplementation
48100077|NCT06063356|PROCEDURE|Intra-articular and extra-articular Dextrose Prolotherapy injection|In the prolotherapy group, 28 patients will receive intra-articular 5 cc 25% dextrose solution (4 cc 30% dextrose + 1 cc saline) and extra-articular 10 cc 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) in 3 sessions.Extra-articular Injection: Using a sterile syringe with a 27 gauge needle tip (Dental), the points previously found and marked with US (medial collateral ligament, lateral collateral ligament, patellar ligament and adhesion sites of coronary ligaments; pes anserine and superior patellar regions) perpendicular to the surface, using peppering technique, a total of 10 cc of 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) will be injected in small volumes (0.5cc-1cc) at each point.Injection applications will be done at weeks 0 - 3 - 6.
48100078|NCT06063356|PROCEDURE|Intra-articular and extra-articular Saline injection|In the saline group, 28 patients are planned to receive 3 sessions of intra-articular 5 cc saline and extra-articular 10 cc lidocaine-serum physiologic solution (5 cc saline + 5 cc 1% lidocaine).Injection applications will be done at weeks 0 - 3 - 6.
48100079|NCT03410667|BEHAVIORAL|Phase One: Exploration|"Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit."
47937040|NCT01142128|DRUG|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
47937041|NCT05004454|DIETARY_SUPPLEMENT|Bacillus subtilis BS50 spore preparation|Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
48100080|NCT03410667|BEHAVIORAL|Phase Two: Creation|Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.
48282184|NCT04075643|DRUG|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
48465299|NCT03530241|DIAGNOSTIC_TEST|Presence of bile duct stones|MRCP verified gall stones in the bile ducts
48465300|NCT03530241|DIAGNOSTIC_TEST|Non-presence of bile duct stones|MRCP without bile duct stones
48465301|NCT01288924|DRUG|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
48465302|NCT01288924|OTHER|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
48465303|NCT02575456|BIOLOGICAL|Ebola Vaccine|
48100081|NCT03410667|BEHAVIORAL|Phase Three: Reflection|This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.
48465304|NCT02575456|BIOLOGICAL|Placebo|control
48465305|NCT03617419|DEVICE|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
48100082|NCT03410667|BEHAVIORAL|Aim 3|This will be a large scale validation of the app, with assignment to standard care for the first year of enrollment.
48100083|NCT05790941|COMBINATION_PRODUCT|Latanoprost and Minoxidil|Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
48465306|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
48465307|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
48465308|NCT04997551|DRUG|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
47937042|NCT05004454|DIETARY_SUPPLEMENT|Maltodextrin|Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
48100084|NCT02359838|OTHER|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
48100085|NCT02359838|OTHER|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
48100086|NCT05741944|OTHER|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
48465309|NCT03845816|BEHAVIORAL|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
48465310|NCT03506841|DRUG|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
48465311|NCT00271973|DRUG|Oxycodone|
48465312|NCT04320745|DRUG|Androderm®|Androderm® transdermal dose.
48465313|NCT01452035|OTHER|Exercise|single session of exercise
48465314|NCT05885386|DRUG|Temozolomide|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
48465315|NCT00751023|DRUG|Modafinil|400 mg daily for four weeks
48465316|NCT00751023|DRUG|Placebo|Placebo 2 tablets daily for 4 weeks
48100087|NCT05741944|OTHER|standard care|All patients in control condition receive usual care.
48100088|NCT02751099|OTHER|transplanted patients|bone biopsy, echocardiogram, blood samples
48100089|NCT02000505|DEVICE|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
48100090|NCT02000505|DEVICE|Metronome|5 minutes chest-compression-only CPR, using a metronome
48100091|NCT02000505|DEVICE|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
48465317|NCT04551183|OTHER|Surgeons CT scan analysis|Surgeons extract diameter by hand (Gold Standard method) then realised a semi-manual segmentation of the images to extract volumes and diameters of the aorta (espacially AAA)
48465318|NCT04551183|DEVICE|PRAEVAorta CT scan analysis|CT scans are analysed by the software under investigation : PRAEVAorta. It will extract volumes and diameters of the aorta (AAA espacially)
48100092|NCT06423313|PROCEDURE|maintenance of anesthesia|Types used to maintain anesthesia
48100093|NCT06219603|OTHER|survey|questions around socio-demographic information, including age, sex, marital status, residency, education level, and employment status. After that, specific questions were asked to measure the level of knowledge and awareness about rheumatic diseases
48100094|NCT01539603|DEVICE|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
48465319|NCT01745887|DRUG|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
48465320|NCT06021106|OTHER|Breathing exercise application with virtual reality glasses|In adapting breathing exercises to virtual reality glasses; The exercise video was first shot by the researcher in front of a green screen. Then, a 3D background design was made by a software developer, a 360-degree printout was taken, and it was converted into a form that can be viewed with glasses. The exercise video is prepared as 20 minutes. Exercises were performed at patients' homes through home visits. A total of 24 sessions of exercises were performed three days a week.
48465321|NCT06021106|OTHER|routine treatment and care|routine treatment and care
48465322|NCT03531450|BEHAVIORAL|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
48282185|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 1 gram|after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
48465323|NCT01609582|DRUG|TAK-875|TAK-875 tablets
48465324|NCT01609582|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
47937043|NCT03490162|DRUG|DM1157|DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
47937044|NCT03490162|OTHER|Placebo|Placebo
47937045|NCT04872530|DIETARY_SUPPLEMENT|Pea-protein concentrate|Pea-protein concentrate
47937046|NCT04872530|DIETARY_SUPPLEMENT|Fava-bean protein concentrate|Fava-bean protein concentrate
47937047|NCT04872530|DIETARY_SUPPLEMENT|Chickpea protein concentrate|Chickpea protein concentrate
47937048|NCT04872530|DIETARY_SUPPLEMENT|Red lentil protein concentrate|Red lentil protein concentrate
47937049|NCT04872530|DIETARY_SUPPLEMENT|Non-essential amino acid blend|Non-essential amino acid blend
47937050|NCT04872530|DIETARY_SUPPLEMENT|Whey protein concentrate|Whey protein concentrate
47937051|NCT05503121|DIAGNOSTIC_TEST|3D motion analysis, muscle activation, biomarker analysis|Participants with nonspesific low back pain and control group will be analysed with 3D motion analysis sistem, sEMG and will be checked the biomarkers. Then the data will be compared.
47937052|NCT01781169|DIETARY_SUPPLEMENT|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
47937053|NCT04412993|OTHER|withdraw blood samples|withdraw blood sample from gorup O donors
47937054|NCT02749669|OTHER|Qualitative research|Semi-structured Interviews
47937055|NCT06515249|OTHER|Integrative medicine|Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient\&#39;s and staff\&#39;s choice
48100095|NCT01539603|DEVICE|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
48100096|NCT05850130|OTHER|Acupuncture intervention|"6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints.~After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist."
48100097|NCT05850130|OTHER|No acupuncture|The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is \<4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).
48282186|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 2 grams|after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
48282187|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 5 grams|after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws
48282188|NCT04463030|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 3 additional blood draws
47937056|NCT06110520|DEVICE|Violet Light Lamp|Medical grade lamps with Violet LEDs enabled
48282189|NCT02079727|DRUG|chondroitin sulfate|
48282190|NCT02079727|DRUG|celecoxib|
48282191|NCT02079727|DRUG|placebo|
48282192|NCT02591992|OTHER|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
48282193|NCT02591992|OTHER|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
48282194|NCT03517436|DEVICE|TAVR with CENTERA THV|TAVR with the Edwards CENTERA THV System
48625483|NCT04462679|OTHER|COMMIT mHealth application|We will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and youth living with HIV (YLWH).The tool will be used by community CHWs in Achham, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
48282195|NCT04039139|BEHAVIORAL|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
48625484|NCT02703363|DRUG|Minocycline|
48625485|NCT02703363|DRUG|Celecoxib|
48625486|NCT02703363|DRUG|Placebo|
48625487|NCT05350423|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
48625488|NCT05350423|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
48625489|NCT04987905|OTHER|Mindfulness|"In the study, for 60 minutes once a week for 8 weeks MIND-BE program will be applied to nurses. The program includes formal and informal practices of mindfulness (Getting started, Introduction to MIND-BE, Noticing the autopilot, Power of attention, Simple awareness, Eating awareness, Body awareness, Breath awareness, Sitting awareness, Stress and reactions, Vision awareness, Challenging emotions and situations in business life, Awareness in business life, Awareness and communication, Awareness and compassion, Developing your own practice)."
48625490|NCT00670384|BIOLOGICAL|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
48625491|NCT00670384|BIOLOGICAL|Placebo|Sublingual drops
48625492|NCT01227811|DRUG|Darifenacin|Single oral dose Darisec(R) 15.0 mg
48625493|NCT01227811|DRUG|Darifenacin|Single oral dose Enablex(R) 15 mg
48625494|NCT04106037|OTHER|Data extraction from medical files|Data extraction from medical files
48625495|NCT00474565|PROCEDURE|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
48465325|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
48465326|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
48465327|NCT01599689|OTHER|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
48465328|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
48282196|NCT04039139|BEHAVIORAL|Mind Body Intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
48282197|NCT06644183|DRUG|Roginolisib|Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.
48625496|NCT02687737|PROCEDURE|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
48625497|NCT02687737|PROCEDURE|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
48625498|NCT02687737|PROCEDURE|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
48625499|NCT02687737|BEHAVIORAL|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
48625500|NCT02022930|DEVICE|Hydros|
48100098|NCT06478680|BEHAVIORAL|Exoskeleton mediated gait training|"1 session of Forward Walking with EksoGT per week~1 session of conventional neurorehabilitation intervention per week~* Transfer training~* Gait training~* Balance (sitting/standing; static/dynamic)~* Strength~* Neuromuscular re-education~* Orthotics~* Positioning~* Caregiver education~* Assistive device~* Wheelchair assessment and mobility~* Endurance training"
48465329|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
48625501|NCT02022930|DEVICE|Hydros-TA|
48625502|NCT02022930|DRUG|Triamcinolone Acetonide|
48625503|NCT04400747|DRUG|Vitamin D3|one group will take weekly oral 50000 IU Vitamin D3, other group will take daily oral 6000 IU Vitamin D3.
48625504|NCT04328285|DRUG|Hydroxychloroquine|Hydroxychloroquine Oral Tablets
48625505|NCT04328285|DRUG|Placebo of Hydroxychloroquine|Placebo of Hydroxychloroquine Oral Tablets Placebo manufactured to mimic Hydroxychloroquine tablets
48625506|NCT04328285|DRUG|Lopinavir and ritonavir|LPV/r Oral Tablets
48625507|NCT04328285|DRUG|Placebo of LPV/r Tablets|Placebo of LPV/r Oral Tablets Placebo manufactured to mimic LPV/r tablets
48625508|NCT00466219|DRUG|Ribavirin|
47937057|NCT06110520|DEVICE|White Light Lamp|Standard bedside lamp with standard 4000K LED light bulb.
48100099|NCT06478680|BEHAVIORAL|High intensity gait training|"2 sessions of High-Intensity Gait Training at a target heart rate of 60-80% of the maximum heart rate or target RPE of 15-18~* Forward stepping practice~* Backwards stepping practices~* Sidestepping~* Stairs~* Balance and compliant surface training while walking~* Propulsion~* Lateral balance training~* Stability training~* Stance control training~* Limb advancement"
48100100|NCT04833192|DIAGNOSTIC_TEST|experimental group|DHEAS.24h-UFC,ACTH and cortisol are measured in the experimental group
48625509|NCT00466219|DRUG|Pegylated interferon alpha2a|
48625510|NCT03042637|DRUG|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
48625511|NCT01899885|PROCEDURE|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~1. standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~2. GDT-LiDCO fluid management pre-, per- and postoperative~3. Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~4. Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
47937058|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
47937059|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
47937060|NCT04265768|PROCEDURE|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
47937061|NCT00500305|PROCEDURE|Withhold standard INDO dose if BNP < 100 pg/ml|
47937062|NCT06515067|OTHER|back massage|back massage
47937063|NCT06515067|OTHER|no ıntervention|no ıntervention
47937064|NCT02741388|DRUG|selinexor|
48100101|NCT00282776|BEHAVIORAL|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
48100102|NCT00282776|BEHAVIORAL|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
48100103|NCT06628440|OTHER|oral condition assessment tool|Use of the Mat assessment tool by a nurse on the participant
48100104|NCT01208467|OTHER|Laboratory Biomarker Analysis|Correlative studies
48100105|NCT06189716|DEVICE|High flow oxygen through nasal cannula|High flow oxygen through nasal cannula and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions.
48100106|NCT04661670|DEVICE|occlusal stabilization splints|an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
48465330|NCT01980173|PROCEDURE|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
48465331|NCT01980173|DEVICE|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
48100107|NCT03213678|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
48100108|NCT03213678|PROCEDURE|Computed Tomography|Undergo CT
48282198|NCT06644183|DRUG|Venetoclax|B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.
48282199|NCT06644183|DRUG|Rituximab|Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.
48282200|NCT03431610|DRUG|SB414 2%|Twice daily
48282201|NCT03431610|DRUG|SB414 6%|Twice daily
48282202|NCT03431610|DRUG|Vehicle|Placebo comparator
48465332|NCT04282694|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|Early detection of lung cancer by LDCT and smoking cessation counselling
48465333|NCT03550196|OTHER|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
48465334|NCT00690027|PROCEDURE|Emergency portacaval shunt|
48465335|NCT00690027|PROCEDURE|Emergency and long-term endoscopic sclerotherapy|
48465336|NCT00564096|DEVICE|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
48465337|NCT00564096|DEVICE|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
47937065|NCT02741388|DRUG|Rituximab|
47937066|NCT02741388|DRUG|Dexamethasone|
47937067|NCT02741388|DRUG|Oxaliplatin|
48100109|NCT03213678|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
48100110|NCT03213678|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48100111|NCT03213678|DRUG|Samotolisib|Given PO
48282203|NCT03433066|PROCEDURE|Advanced platelet-rich fibrin mixed with biphasic alloplast|mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
48282204|NCT03433066|PROCEDURE|Biphasic alloplast mixed with saline|mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
48282205|NCT02112448|DRUG|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
48465338|NCT00108550|DRUG|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
48465339|NCT00108550|DRUG|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
48465340|NCT06299280|OTHER|dual task training|students will be given additional cognitive tasks while exercising in physical education class
48465341|NCT06299280|OTHER|single task training|students will exercise in physical education class, without additional cognitive tasks
48625512|NCT01107015|DEVICE|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
48282206|NCT02112448|DRUG|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
48282207|NCT02112448|DRUG|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
48282208|NCT02112448|DRUG|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
48282209|NCT06301854|DRUG|TPN171H|10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.
48465342|NCT00534430|DRUG|busulfan|
48465343|NCT00534430|DRUG|cyclosporine|
48465344|NCT00534430|DRUG|etoposide|
48465345|NCT00534430|DRUG|mycophenolate mofetil|
48465346|NCT00534430|PROCEDURE|allogeneic bone marrow transplantation|
47937068|NCT02741388|DRUG|Cisplatin|
47937069|NCT02741388|DRUG|Cytarabine|
47937070|NCT02741388|DRUG|Gemcitabine|
48100112|NCT03213678|PROCEDURE|X-Ray Imaging|Undergo x-ray
48100113|NCT01516892|BIOLOGICAL|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
48100114|NCT01180621|BIOLOGICAL|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
48100115|NCT01266044|PROCEDURE|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
48100116|NCT01266044|PROCEDURE|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
48100117|NCT01266044|OTHER|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
48100118|NCT01266044|OTHER|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
48282210|NCT05893134|OTHER|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
48282211|NCT03614390|BEHAVIORAL|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
48282212|NCT04062955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary counseling
48282213|NCT04062955|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
48282214|NCT04062955|OTHER|Questionnaire Administration|Ancillary studies
48282215|NCT05586334|BIOLOGICAL|Collection of vaginal secretions|In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
48465347|NCT00534430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48465348|NCT00534430|PROCEDURE|peripheral blood stem cell transplantation|
48465349|NCT00534430|RADIATION|total-body irradiation|
48465350|NCT02374216|PROCEDURE|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
48465351|NCT03911180|DEVICE|Proximal femoral nail with straight parallel blade|Petrochanteric fixation with Heracles proximal femoral nail
48465352|NCT04164758|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
48465353|NCT04164758|OTHER|Placebo|Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
48625513|NCT01107015|DEVICE|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
48625514|NCT01107015|DEVICE|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
48625515|NCT04529460|DIAGNOSTIC_TEST|COVID-19 antibody point of care test kit|A disponible point of care test that identifies the presence of antibodies to COVID-19
48625516|NCT05732545|BEHAVIORAL|enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure|There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
48282216|NCT05586334|BIOLOGICAL|Collection of the placenta and the membranes|In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
48282217|NCT05586334|OTHER|Administration of EPDS questionnaire|In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
48282218|NCT05895513|DRUG|Pimavanserin 34 mg|5HT-2a receptor antagonist
48465354|NCT04164758|DRUG|Quetiapine|Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
48465355|NCT03109041|DEVICE|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
48465356|NCT04273438|DEVICE|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
48465357|NCT04273438|DEVICE|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
48465358|NCT01363817|DRUG|BMS-906024|
48465359|NCT01363817|DRUG|Dexamethasone|
48100119|NCT05128305|DRUG|traditional Chinese medicine1 and traditional Chinese medicine 2|We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
48282219|NCT05895513|DRUG|Placebo|Inactive Comparator
48465360|NCT04427033|DEVICE|Bone Conduction Implant|Bonebridge system BCI 602
48465361|NCT04226586|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) group|Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
48465362|NCT04226586|DIETARY_SUPPLEMENT|Placebo|Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
48465363|NCT04432077|BEHAVIORAL|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
48465364|NCT06039774|DRUG|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
48465365|NCT06039774|DRUG|Placebo|Placebo
48465366|NCT00680524|OTHER|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
48465367|NCT04099680|PROCEDURE|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
48465368|NCT04099680|PROCEDURE|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
48465369|NCT04099680|DEVICE|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
48282220|NCT04544566|DEVICE|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
48282221|NCT04544566|DEVICE|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
48100120|NCT03719209|OTHER|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
48100121|NCT03719209|OTHER|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
48282222|NCT04544566|DEVICE|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
48465370|NCT04099680|PROCEDURE|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
48465371|NCT04099680|PROCEDURE|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
48465372|NCT04099680|PROCEDURE|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
48100122|NCT00640666|BEHAVIORAL|Exercise Behavior Change|Multidisciplinary
48100123|NCT05037266|BIOLOGICAL|COVID-19 Vaccine Janssen (Ad26.COV2-S)|one dose (0.5mL) at D1 and one dose (0.5mL) at D57
48100124|NCT05506709|DEVICE|Seawater nasal spray|Subjects will use the nasal spray (moderately hypertonic solution based on 100% natural sea water rich of marine trace elements with added manganese and calcium) at least once and up to 6 times as necessary per day during the 14-day test period. Each application is composed of two irrigating sprays per nostril for a total of 4 sprays per application.
48282223|NCT04925570|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
48282224|NCT04925570|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
48282225|NCT00275080|DRUG|vorinostat|Given orally
48282226|NCT00275080|DRUG|decitabine|Given IV
48282227|NCT04209738|OTHER|This is an observational study being conducted as a substudy of another trial.|This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
48282228|NCT01029561|DEVICE|CPAP|Treatment with Continuous Positive Airway Pressure
48282229|NCT01029561|BEHAVIORAL|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
48465373|NCT03519490|DEVICE|Hybrid Contact Lens|Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
48465374|NCT02464904|PROCEDURE|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
48465375|NCT02464904|OTHER|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
48465376|NCT02663856|OTHER|observational|Self assessment of ageing transition using a frailty index through MySAwH app
48465377|NCT04190706|OTHER|bioactive components fortified food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
48465378|NCT04190706|OTHER|control food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
48465379|NCT01746654|DRUG|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
48465380|NCT01746654|DRUG|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
48100125|NCT05528536|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
48100126|NCT05528536|OTHER|Art|To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
48100127|NCT05528536|OTHER|Exercise|An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
48100128|NCT05528536|OTHER|Treatment as usual|treatment as usual within their community centres
48100129|NCT05886335|DRUG|Cyclophosphamide|Time of administration
48100130|NCT04392349|DEVICE|Haag-Streit EYESTAR 900|The EYESTAR 900 is a new device developed by HAAG-STREIT AG which utilises Optical Coherence Tomography (OCT) for quantitative measurements of the geometry of the eye. As a successor to the LENSTAR 900, it represents the most recent in a series of successful biometry devices.
48465381|NCT01746654|DRUG|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
48465382|NCT01746654|DRUG|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
48465383|NCT00248092|DRUG|NRP104|
48465384|NCT04475315|DEVICE|Papillary Muscle Sling|The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
48100131|NCT04392349|DEVICE|Tomey CASIA 2|The CASIA2 is a testing application for Cataract / Glaucoma / Cornea Surgery already established on the market. It is a representative device for measurement of anterior and posterior corneal curvature (anterior and posterior corneal topography) by optical coherence tomography, and for measurement of crystalline lens tilt by optical coherence tomography.
48100132|NCT04392349|DEVICE|Oculus PENTACAM HR|The Pentacam HR is a high-resolution rotating Scheimpflug camera system for anterior segment analysis already established on the market. It is used as representative device for advanced anterior segment analysis such as anterior and posterior corneal topography and corneal pachymetry.
48100133|NCT04392349|DEVICE|Zeiss ATLAS 9000|ATLAS is a corneal topography system used as representative device for measurement of anterior corneal curvature (anterior corneal topography).
48100134|NCT01297972|BIOLOGICAL|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
48100135|NCT04675255|PROCEDURE|Frequently sampled glucose tolerance testing|Frequently sampled glucose tolerance testing
48100136|NCT04675255|PROCEDURE|abdominal subcutaneous adipose tissue biopsy|abdominal subcutaneous adipose tissue biopsy
48100137|NCT04675255|PROCEDURE|MRI scan to assess intrahepatic triglyceride content|MRI scan to assess intrahepatic triglyceride content
48100138|NCT05481294|OTHER|Transpersonal Supportive Coaching|Coaching is given for four months (two times a month) with a 45-minute duration per coaching by a professional coach
48100139|NCT05481294|OTHER|Standard Support|Standard support is given for four months using a support system provided by Peer Support Foundation
48100140|NCT05021419|OTHER|Streamlined protocol|A streamlined drug protocol for optimizing heart failure medication
48100141|NCT05021419|OTHER|Standard Protocol|Current standard optimization protocol as per NICE and ESC
48465385|NCT04475315|PROCEDURE|CABG surgery|Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
48465386|NCT01097694|DRUG|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
48465387|NCT01097694|DRUG|Placebo|Placebo
48282230|NCT04876339|DEVICE|"Gait rehabilitation with sonification"|The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).
48465388|NCT00851006|DRUG|Creatine Monohydrate|Creapure brand of creatine monohydrate
48465389|NCT04265287|OTHER|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
48465390|NCT03061903|DEVICE|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
48100142|NCT05198089|OTHER|Internet-Based Intervention|Use MyInspiration website
48100143|NCT00217711|DRUG|Capecitabine|capecitabine
48100144|NCT00217711|DRUG|irinotecan hydrochloride|irinotecan hydrochloride
48100145|NCT00217711|DRUG|oxaliplatin|oxaliplatin
48100146|NCT05288517|BEHAVIORAL|Lock to Live|Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
48100147|NCT04731610|OTHER|Radiotherapy|postoperative radiotherapy after complete resection of thymoma
48100148|NCT04731610|OTHER|Surveillance after resection|Surveillance after tumour resection
48100149|NCT05043818|OTHER||This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
48100150|NCT03697213|OTHER|Online study|20 hypothetical patient summaries
48625517|NCT03334266|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
48465391|NCT03061903|DEVICE|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
48625518|NCT03334266|OTHER|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
48625519|NCT03334266|OTHER|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
48625520|NCT06543732|OTHER|Return to work program|The eHealth modules focus on psychoeducation, perceptions of return to work based on a personal plan including problem-solving exercises, relapse prevention, and continuous monitoring. If needed, followed by the participatory approach, a stepwise, collaborative approach to analyse and solve bottlenecks to develop a consensus-based plan for return to work.
48625521|NCT05539508|BEHAVIORAL|Psychophysical evaluation|All participants will be required to perform a short experiment on a computer (15 minutes) where they will look at different photographs of scenes of different luminance and spatial frequencies. They will have to perform various tasks on these images using the keys on the keyboard.
48625522|NCT00764517|DRUG|Cladribine|Given IV
48625523|NCT00764517|OTHER|Laboratory Biomarker Analysis|Correlative studies
48625524|NCT00764517|BIOLOGICAL|Rituximab|Given IV
48100151|NCT02780362|DRUG|Prodactariv|1 tablet contains 60 mg Daclatasvir
48100152|NCT02780362|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
48100153|NCT06063330|COMBINATION_PRODUCT|RQ-001|"Drug product RQ-001 is the fully assembled device consisting of the vial containing RQ-01 and the actuator. Drug Product RQ-001 has been developed with an Aptar Bidose liquid nasal spray unit device (BDSI V3) capable of intranasally delivering a 200 uL total volume of drug product (specifically, 100 uL per nare, which delivers a 200 uL of total volume). The combination product comprises the drug constituent (RQ-01) and the assembly of commercially available, off-the-shelf device components.~Study staff will be responsible for assembling the drug product RQ-001 and subjects will self-administer under the supervision of study staff in the clinic."
48100154|NCT06063330|OTHER|Placebo|Matching placebo will be manufactured just as RQ-01 drug substance, with the active ingredient addition step omitted. Placebo will appear similar to RQ-01 drug substance as a clear to hazy, colorless to yellowish liquid. Matching placebo will be administered the same way as RQ-01
48625525|NCT00764517|DRUG|Vorinostat|Given PO
47937071|NCT04309747|PROCEDURE|nanosecond knife liver cancer ablation|This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
47937072|NCT04291378|RADIATION|Proton versus photon radiation therapy|The intervention is proton radiation therapy versus photon radiation therapy
47937073|NCT04643171|DEVICE|high intensity elliptical training|30 patients will receive 30 minutes of high intensity interval training on elliptical trainer, 5 times per week, for 12 week
48100155|NCT04989322|DRUG|Pembrolizumab|200 mg Q3W
48100156|NCT04989322|DRUG|Lenvatinib|8 mg daily
48100157|NCT04989322|DRUG|Pemetrexed|500 mg/m2 Q3W
48100158|NCT04989322|DRUG|Carboplatin|AUC5 Q3W
48100159|NCT05974072|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
48100160|NCT05974072|OTHER|PAINDOC Program|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of two parts: an education session called Empowered Relief (ER) and two pain neuroscience education (NDT) sessions.~* Psychotherapy: The psychotherapy part consists of one group session of one hour, face-to-face and with groups of up to 15 people, given by the psychologist of the pain unit.~* Mindfulness Meditation: The Mindfulness Meditation consists of one group session of one hour, face-to-face and with groups of up to 15 people. These are given by a nurse from the pain unit. T~* Therapeutic exercise: The therapeutic exercise module consists of three sessions of one hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
48100161|NCT06364033|BIOLOGICAL|serologic response evaluation|Blood samples collection
48100162|NCT01947179|BEHAVIORAL|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
48100163|NCT01670019|DRUG|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
48100164|NCT01670019|DRUG|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
48465392|NCT04011449|DEVICE|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
48465393|NCT03865225|OTHER|Biofeedback|9 x 10 minutes biofeedback sessions over period of three days
48100167|NCT04884399|DRUG|CMAB818|vascular endothelial growth factor (VEGF) inhibitor
48100168|NCT04884399|DRUG|Lucentis®|vascular endothelial growth factor (VEGF) inhibitor
48625526|NCT06449664|BEHAVIORAL|ADT-train|A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy
48282231|NCT04876339|OTHER|Standard gait rehabilitation (without sonification)|"The training will be carried out without any musical support. Exercises I Phase~1. Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~2. Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~3. Left foot swing (3 minutes exercise with a short break in the middle)~4. Right foot swing (3 minutes exercise with a short break in the middle)~5. March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed."
48282232|NCT01929252|DRUG|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
48465394|NCT03865225|OTHER|Sham-Biofeedback|9 x 10 minutes sham-biofeedback sessions over period of three days
48465395|NCT01872624|PROCEDURE|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
48465396|NCT06214637|DRUG|Melissa|The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
48465397|NCT06214637|DRUG|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
48100169|NCT05450029|DRUG|Sintilimab|6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
48100170|NCT05656092|DRUG|HIP0612|Test drug
48100171|NCT05656092|DRUG|HPP2202|Placebo drug
48282233|NCT01929252|DRUG|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
48282234|NCT00648986|DRUG|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
48282235|NCT03932240|DRUG|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
48282236|NCT03932240|DRUG|Cryoprecipitate|The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
48282237|NCT05087030|DRUG|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
48465398|NCT01580046|DRUG|iodixanol|"1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
48465399|NCT01580046|DRUG|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
48465400|NCT03112031|DRUG|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
48465401|NCT03112031|DRUG|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
48465402|NCT03112031|DRUG|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
48465403|NCT06440863|PROCEDURE|Total Knee Arthroplasty|Patients undergoing total knee arthroplasty
48465404|NCT06440863|PROCEDURE|Total Hip arthroplasty|Patients undergoing total hip arthroplasty
48465405|NCT03594617|BEHAVIORAL|Interaction Competencies with Children - for Caregiver|"Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children."
48625527|NCT03969537|OTHER|Telemedicine follow-up visit|Study participants will experience two telemedicine (live audio/video) visits.
48625528|NCT04518410|BIOLOGICAL|bamlanivimab 7000mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
48100172|NCT05656092|DRUG|RLD2204|Reference drug
48100173|NCT05656092|DRUG|HPP2201|Placebo drug
48100174|NCT01254981|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
48100175|NCT02750709|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
48100176|NCT02750709|DRUG|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
48100177|NCT02750709|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
48100178|NCT05822141|DIETARY_SUPPLEMENT|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
48100179|NCT05822141|DIETARY_SUPPLEMENT|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
48100180|NCT04795089|PROCEDURE|Shunt surgery|Patients are evaluated before and after shunt surgery which is a standard intervention in the clinical practice. HI do not undergo intervention.
48100181|NCT06353243|BEHAVIORAL|Bilateral alternating stimulation|positive touch intervention provided by parent to infant using alternating stimulation
48100182|NCT05191251|DIAGNOSTIC_TEST|HEMSTOP questionnaire|A HEMSTOP questionnaire is obtained during the anesthesia consultation.
48100183|NCT06629402|DRUG|PF614|Experimental oxycodone prodrug
48465406|NCT03757468|DEVICE|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
48465407|NCT04536506|OTHER|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
48465408|NCT04536506|OTHER|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
48465409|NCT06200376|DRUG|T3011|T3011 will be administered intraperitoneally twice a week.
48465410|NCT00569660|DRUG|Azacitidine|75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)
48465411|NCT04537520|DEVICE|Kerecis Omega3 Wound|Treatment of the wound with Kerecis Omega3 Wounds matrices
48465412|NCT04520243|DIAGNOSTIC_TEST|Visual acuity assessment by ETDRS charts|All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
48465413|NCT01407484|DRUG|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
48465414|NCT01407484|DRUG|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
48465415|NCT03854409|DRUG|Aripiprazole|Injection.
48465416|NCT05745636|DIETARY_SUPPLEMENT|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
48465417|NCT05745636|DIETARY_SUPPLEMENT|Placebo|2 capsules per day for 4 weeks.
48465418|NCT04814628|PROCEDURE|scenario 1 : pre-oxygenation with a face mask held by the anaesthetist|"the face mask is held by the anaesthetist (reference technique) to obtain effective pre-oxygenation for Oxygen Reserve Index (ORI) which has reached a plateau value for more than 10 seconds. All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
48465419|NCT04814628|PROCEDURE|scenario 2: one anaesthetist in charge, face mask held by the patient for pre-oxygenation|"one anaesthetist is in charge of the simulated patient (volunteer), face mask held by the volunteer for pre-oxygenation for ORI which has reached a plateau value for more than 10 seconds All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Face mask held by the patient for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
48465420|NCT04814628|PROCEDURE|scenario 3: one anaesthetist in charge, THRIVE used for pre-oxygenation|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. THRIVE for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
48465421|NCT04814628|PROCEDURE|scenario 4: one anaesthetist and one nurse anaesthetist in charge, the face mask is held by the anaesthetist or the nurse anaesthetist|"All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist or nurse anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop"
48465422|NCT05696509|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
48465423|NCT05696509|DRUG|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
48465424|NCT05696509|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
48100184|NCT06629402|DRUG|Placebo|Inactive medication
48100185|NCT06103734|COMBINATION_PRODUCT|Zavegepant 10 mg|4 doses of zavegpant 10 mg intranasal spray device
48100186|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 1|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
48100187|NCT06103734|COMBINATION_PRODUCT|Placebo - Control 2|3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
48282238|NCT05087030|DRUG|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
48100188|NCT01051583|PROCEDURE|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
48100189|NCT00469300|DRUG|Iontophoretic delivery of acyclovir|
48100190|NCT05765851|DRUG|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
48282239|NCT01567436|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
48465425|NCT06172439|OTHER|acupressure|Women in the intervention group will receive acupressure for 12 minutes.The acupressure pressure points related to the gynecologic surgery to be performed are named as the large intestine (LI4), stomach (ST36) and spleen (SP6) meridians, respectively. These points are determined by expert opinion and are used for pain control.
48465426|NCT04602741|BEHAVIORAL|A4i Intervention|6 months of the provision of A4i on the individual's own device.
48465427|NCT00414479|DRUG|praziquantl, iron, ACT|
48465428|NCT03493035|DIAGNOSTIC_TEST|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
48465429|NCT03493035|DIAGNOSTIC_TEST|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
48465430|NCT04162327|DRUG|IBI315|Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
48465431|NCT04162327|DRUG|IBI315|Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
48465432|NCT06076109|OTHER|Prone position|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.
48100191|NCT05765851|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
48465433|NCT06076109|OTHER|Standard treatment|Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.
48465434|NCT03294317|DEVICE|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
48465435|NCT05456022|DRUG|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying \< 4 % _ Purity (HPLC) \> 95 %"
48465436|NCT05456022|DRUG|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
48465437|NCT05456022|DRUG|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
48465438|NCT05360849|BEHAVIORAL|Practice Facilitation|Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
48625529|NCT04518410|BIOLOGICAL|BRII-196+BRII-198|1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
47937074|NCT04643171|DEVICE|electrocaupuncture|30 patients will receive 30 minutes of electroacupuncture on bilateral PC 4 and PC 6 for 5 times per week, for 12 week
47937075|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 1"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation."
48100192|NCT05251285|PROCEDURE|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
48625530|NCT04518410|BIOLOGICAL|AZD7442 (IV)|300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
48625531|NCT04518410|BIOLOGICAL|AZD7442 (IM)|Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
48625532|NCT04518410|DRUG|SNG001|1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
47937076|NCT04661553|DEVICE|"Mueller's polarimetric colposcopy Group 2"|"Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth."
47937077|NCT04197687|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine TPIV100|Given ID
47937078|NCT04197687|BIOLOGICAL|Pertuzumab|permitted at physician's discretion
47937079|NCT04197687|OTHER|Placebo Administration|Given ID
47937080|NCT04197687|BIOLOGICAL|Sargramostim|Given ID
47937081|NCT04197687|BIOLOGICAL|Trastuzumab|therapy are at the discretion of the treating physicians
47937082|NCT04197687|BIOLOGICAL|Trastuzumab Emtansine|at the discretion of the treating physicians.
48625533|NCT04518410|DRUG|Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
48625534|NCT04518410|BIOLOGICAL|BMS-986414 + BMS-986413|Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
48282240|NCT00484354|DRUG|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
48465439|NCT06113549|PROCEDURE|Knee Joint Distraction (KD)|Knee joint distraction (KJD) is a joint-preserving treatment for knee OA for younger patients, where the knee joint is temporarily fully unloaded by distraction of tibia and femur, using an external fixation frame.KJD treatment is performed according to the current approved concept NOV recommendations for clinical practice.
48625535|NCT04518410|BIOLOGICAL|SAB-185 (3,840 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
48465440|NCT06113549|PROCEDURE|Knee Prosthesis|A total or unicompartmental knee prosthesis
48465441|NCT05189691|BEHAVIORAL|walking exercise|Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
48465442|NCT05619822|BEHAVIORAL|TAU + A comprehensive third-generation intervention|This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
48465443|NCT05619822|BEHAVIORAL|TAU|Treatment as usual
48465444|NCT02725164|DRUG|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
48465445|NCT02725164|DRUG|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
48625536|NCT04518410|BIOLOGICAL|SAB-185 (10,240 Units/kg)|Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
48625537|NCT04518410|DRUG|CASIRIVIMAB + IMDEVIMAB|600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
48625538|NCT04518410|DRUG|Placebo for Bamlanivimab 7000mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
48625539|NCT04518410|DRUG|Placebo for Bamlanivimab 700mg|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
48625540|NCT04518410|DRUG|Placebo for BRII-196+BRII-198|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
48625541|NCT04518410|DRUG|Placebo for SNG001|Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
47937083|NCT03152422|DIAGNOSTIC_TEST|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
47937084|NCT01856023|DRUG|High Dose Interleukin-2|
48282241|NCT00484354|OTHER|Normal saline|IV Normal saline with volume given determined by patient weight
48282242|NCT00484354|OTHER|Bicarbonate|IV bicarbonate, dosed by weight
48282243|NCT00484354|OTHER|Placebo|Normal saline, with volume given based on patient weight
48282244|NCT04752280|RADIATION|Proton irradiation|proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
48282245|NCT04752280|RADIATION|Photon irradiation|proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
48282246|NCT01733355|RADIATION|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
48282247|NCT04084392|OTHER|Bridge Clinic|Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
48282248|NCT04084392|OTHER|Usual Care|Referral to an outpatient provider for addiction treatment.
48465446|NCT02725164|DRUG|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
48465447|NCT02725164|DRUG|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
48465448|NCT03481517|DRUG|Bupivacaine|Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
48465449|NCT02961205|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
48625542|NCT04518410|DRUG|Placebo for Camostat|200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
48625543|NCT04518410|DRUG|Placebo for SAB-185 (low dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
47937085|NCT01856023|DRUG|Ipilimumab|
48282249|NCT02500550|BIOLOGICAL|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
48100193|NCT05779007|DRUG|Pirfenidone|Pirfenidone
48282250|NCT02500550|PROCEDURE|Haploidentical hematopoietic stem cell transplantation (HSCT)|"CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)"
48282251|NCT02500550|PROCEDURE|TBI regime|"* Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
48282252|NCT02500550|PROCEDURE|Non-TBI regime|"* Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
48282253|NCT02421874|BEHAVIORAL|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
48282254|NCT02421874|BEHAVIORAL|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
48465450|NCT03670719|OTHER|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
48465451|NCT03670719|OTHER|Exercise|Exercises for the cervical spine
48465452|NCT05855824|OTHER|Applesauce Pouch|One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
48282255|NCT06027801|OTHER|Iron-fortified cookies|Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.
47937086|NCT01683773|BIOLOGICAL|AERAS-402|Intramuscular needle injection 1x10\^11 vp
47937087|NCT01683773|BIOLOGICAL|MVA85A|Intradermal needle injection 1x10\^8 pfu
47937088|NCT03310320|DRUG|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
47937089|NCT03310320|DRUG|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
48100194|NCT05779007|DRUG|Nintedanib|Nintedanib
48100195|NCT00308958|DEVICE|High frequency chest wall oscillator|
48282256|NCT06027801|BIOLOGICAL|Japanese encephalitis (JE) vaccine|All participants will be administered the live attenuated JE vaccine
48282257|NCT06027801|BIOLOGICAL|Typhoid Vi polysaccharide (Vi-PS) vaccine|All participants will be administered the typhoid Vi-PS vaccine
48282258|NCT06027801|OTHER|non-fortified cookies|Study cookies containing no iron
48282259|NCT05957640|COMBINATION_PRODUCT|Yttrium-90 carbon microspheres SIRT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
48465453|NCT05855824|OTHER|Fruit-vegetable puree blend|One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
48465454|NCT01613937|BEHAVIORAL|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
48465455|NCT04789187|PROCEDURE|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
48465456|NCT04789187|PROCEDURE|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
48465457|NCT02448563|BEHAVIORAL|Nutrition and physical activity education|Eight weekly in-person groups
48465458|NCT02625311|PROCEDURE|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
48465459|NCT02557217|DRUG|NP202|Active
48465460|NCT02557217|OTHER|Placebo|Placebo
48465461|NCT04789330|DRUG|Norepinephrine|Norepinephrine administered during anesthesia
48465462|NCT04789330|DRUG|Phenylephrine|Phenylephrine administered during anesthesia
48465463|NCT04667390|OTHER|total knee arthroplasty|total knee arthroplasty
48465464|NCT05358808|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
47937090|NCT02326311|DRUG|imatinib|Tyrosin kinase inhibitor
47937091|NCT02326311|DRUG|nilotinib|Tyrosin kinase inhibitor
47937092|NCT02326311|DRUG|dasatinib|Tyrosin kinase inhibitor
47937093|NCT03213353|DRUG|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
48100196|NCT04977128|DRUG|89Zr-KN035|Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
48100197|NCT03944343|OTHER|Cereal based products|The cereal products are made from common Swedish cereals.
48100198|NCT06285175|OTHER|Tele-REINVENT|Tele-REINVENT consists of EMG-biofeedback of the affected arm to control games on a computer screen.
48465465|NCT00762411|DRUG|LY450139|Administered orally once daily.
48465466|NCT00762411|DRUG|Placebo|Administered orally once daily.
48465467|NCT01353716|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
48465468|NCT05998980|PROCEDURE|Componeer prefabricated veneers|Individual Randomized Clinical Trial
48465469|NCT05998980|PROCEDURE|Essentia resin composite veneers|Individual Randomized Clinical Trial
48465470|NCT00363857|DRUG|Ropinirole|
48465471|NCT01661517|BEHAVIORAL|Motivational interviewing and referral to treatment|
47937094|NCT03213353|DRUG|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
48282260|NCT05191212|PROCEDURE|indocyanine green|Cervical indocyanine green injection for the detection of sentinel lymph node
48465472|NCT00840190|DRUG|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
48465473|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
48465474|NCT02907125|BEHAVIORAL|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
48465475|NCT02907125|BEHAVIORAL|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
48625544|NCT04518410|DRUG|Placebo for BMS-986414 + BMS-986413|Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
48625545|NCT04518410|DRUG|Placebo for AZD7442 (IV)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
48625546|NCT04518410|DRUG|Placebo for AZD7442 (IM)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
48100199|NCT03014102|DRUG|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
48100200|NCT03692520|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
48100201|NCT03317639|BEHAVIORAL|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
48100202|NCT06053788|DIAGNOSTIC_TEST|PocDoc|Point of care digital lipid test
48100203|NCT03631563|DRUG|Immunosuppressive Agent|ATG-Fresenius versus ATG
48100204|NCT04971018|DEVICE|Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
48100205|NCT04971018|DEVICE|Sham Auricular vagus nerve stimulation|Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
48100206|NCT03639441|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
47937095|NCT04877223|OTHER|No intervention|No intervention
47937096|NCT02151136|DRUG|24% sucrose|
47937097|NCT02151136|DRUG|Sterile water|
47937098|NCT02151136|OTHER|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
47937099|NCT02953158|OTHER|Haas Avocado|Hypocaloric weight loss diet
47937100|NCT02953158|BEHAVIORAL|Dietary Counseling|Dietary Counseling
48282261|NCT05797129|DEVICE|CEDM|Women underwent CEDM screening
48282262|NCT04885738|OTHER|no intervention|"For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD."
48282263|NCT03202654|OTHER|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
48282264|NCT03202654|OTHER|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
48282265|NCT03810989|DEVICE|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
48282266|NCT03810989|DEVICE|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
48282267|NCT03810989|DEVICE|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
48282268|NCT03698734|DRUG|Evening primrose oil(EPO)|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
48282269|NCT03698734|DRUG|Placebo - Cap|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
48282270|NCT03921112|DEVICE|lung ultrasound|bedside lung ultrasound will be done for patients
48282271|NCT03921112|OTHER|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
48625547|NCT04518410|DRUG|Placebo for SAB-185 (high dose)|Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
48625548|NCT04518410|BIOLOGICAL|bamlanivimab 700mg|Administered by single IV infusion. Participants are no longer being randomized to this intervention.
48625549|NCT01132755|PROCEDURE|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
48625550|NCT04208711|OTHER|biological sample|whole blood sample
48625551|NCT03722888|DEVICE|smokeSCREEN video game|smokeSCREEN video game is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
48625552|NCT02794779|DRUG|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
48625553|NCT00158730|DRUG|AmBisome|
48625554|NCT05141994|DRUG|2.5mg of BAT5906|Specification: 2.5mg of BAT5906
48625555|NCT05141994|DRUG|4mg of BAT5906|Specification: 4mg of BAT5906
48625556|NCT02018107|DIAGNOSTIC_TEST|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
48625557|NCT02018107|DIAGNOSTIC_TEST|PET scan|PET scan
48625558|NCT06240182|PROCEDURE|conventional surgery|Surgery performed using conventional rotary burs
48625559|NCT06240182|PROCEDURE|piezoelectric device|surgery performed using piezoelectric device.
48625560|NCT06044272|OTHER|Factors associated|Factors associated with the type of resistance by microorganisms.
48625561|NCT00408226|DRUG|MKC-1|capsules, twice daily for 14 days in 21 day cycle
47937101|NCT00805376|DRUG|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
48625562|NCT00408226|DRUG|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
48625563|NCT04278352|BEHAVIORAL|Mindfulness Based Relapse Prevention|The intervention is a group skills training program that is delivered once weekly for eight weeks. Content focuses on mindfulness and cognitive-behavioral relapse prevention skills, including psychoeducation, experiential exercises, and between session homework assignments.
48625564|NCT05548855|PROCEDURE|Heart Transplant|Patients who have undergone a heart transplant as standard of care (SOC) procedure
48625565|NCT05548855|DEVICE|Cardiac Assistive Device|Patients who have undergone a placement of a cardiac assistive device
48625566|NCT03692962|BEHAVIORAL|Sleep restriction|Time in bed will be restricted to 5 hours per night for 7 nights.
48625567|NCT03692962|OTHER|Acoustic stimulation|Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
47937102|NCT00805376|PROCEDURE|Tumor Removal|Surgical Tumor Resection
47937103|NCT04988828|DEVICE|Whole body vibration|vertical vibration platform with the frequency of 30Hz, amplitude of 4mm. The intervention will last for 5 weeks, twice /week.
47937104|NCT02278471|DRUG|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
47937105|NCT03549403|BEHAVIORAL|Patient-centered telephone education|The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
47937106|NCT03745430|DRUG|Ramucirumab|8 mg/kg (days 1 and 15, q4w) until disease progression
47937107|NCT04224883|PROCEDURE|Continuously feeding|Daily amount of feeding were continuously pumped for 24 hours. EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours. If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200mL were considered markers of good tolerance.Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
47937108|NCT04224883|PROCEDURE|16-hours feeding|Daily amount of feeding were continuously pumped for 16 hours.EN preparation pumping scheme was as follows: The initial pumping speed was average pumping volume of total enteral nutrition in one day, and gastric residual volumes is checked every 4 hours.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
47937109|NCT04224883|PROCEDURE|intermittent feeding|Daily amount of feeding were divided into four meals, each meal are pumped within 60mins or 120mins through stomach tube. EN preparation pumping scheme was as follows: If the volume of each meal is less than or equal to 250ml(≤250ml), pump in within 60min, if volume is greater than 250ml(\>250ml), pump in within 120min and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed. GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL. If GRV\>500mL, EN was stopped and reassessed after 4 hours.
47937110|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
47937111|NCT04638673|DEVICE|Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group|Participants will receive sham taVNS stimulation for weeks 1\&2 and active stimulation for weeks 3\&4 of the stimulation portion of this study.
47937112|NCT06108986|OTHER|tabata training|this include tabata training thrice a week for six weeks
47937113|NCT06108986|OTHER|plyometric training|this include plyometric training thrice a week for six weeks
48465476|NCT02578745|DEVICE|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (\~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
48465477|NCT02578745|OTHER|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
48465478|NCT05278858|COMBINATION_PRODUCT|MedJet Device with intralesional triamcinolone|A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
48100207|NCT03639441|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
48100208|NCT06411665|DRUG|Oliceridine|Patient-controlled intravenous analgesia with oliceridine for up to 3 days after surgery.
48100209|NCT06411665|DRUG|Morphine|Patient-controlled intravenous analgesia with morphine for up to 3 days after surgery.
48100210|NCT04622527|OTHER|Random assigned paradigm viewing order|Participants experience the paradigm in a random order
48100211|NCT03780790|DRUG|Bupivacaine|% 0,25
48100212|NCT06629129|DRUG|Latanoprost (0.005%)|MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT
48100213|NCT06049108|DRUG|[14C]-LY3871801|Administered orally
48465479|NCT02713139|DRUG|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
48465480|NCT02713139|DRUG|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
48465481|NCT02713139|DRUG|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
48465482|NCT03610386|OTHER|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...). One of the two biopsies will receive menthoxypropanediol topically.
48625568|NCT04628910|OTHER|Simulated Flotation Therapy|"The Zerobody is a new technology designed to simulate the effects of traditional Float-REST therapy, but without the contact with salt water. The system has a very thin membrane that cradles the body and provides a warm sensation, similar to that experienced in a traditional flotation tank. The system will be housed in a room that allows for significant reductions in light and sound to mimic the experience of a flotation tank. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks using the Zerobody, also termed dry floating, as one of the two interventions."
48282272|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Group (EBCM-G)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol.~Additionally, participants in the Group Intervention will be able to communicate with and respond to one another through the group chat rooms within the app."
48100214|NCT01090024|DRUG|BI 671800|BI 671800
48100215|NCT01090024|DRUG|Placebo|Placebo matching BI 671800
48100216|NCT01909232|DEVICE|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
48100217|NCT01909232|DEVICE|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
48100218|NCT06204796|DRUG|vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
48282273|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Individual (EBCM-I)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol."
48282274|NCT02587494|PROCEDURE|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
48282275|NCT05452564|DRUG|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
48282276|NCT05452564|DRUG|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
48282277|NCT06135337|DEVICE|Thioderm Elate|Test Device
48282278|NCT06135337|DEVICE|Juvéderm Ultra 3|Active Comparator Device
48282279|NCT06657378|OTHER|No Intervention|This is a non-interventional study.
48282280|NCT00527202|DRUG|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
48282281|NCT05241587|OTHER|Gum Group:|"Gum Group:~Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010)."
48282282|NCT05241587|OTHER|Mouth Spray Group:|"Mouth Spray Group:~The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request."
48282283|NCT06500741|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
48282284|NCT03343964|DIAGNOSTIC_TEST|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
48282285|NCT06657170|PROCEDURE|Pulmunary veins reconnection plus hidden slow conduction ablation|"Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms)."
48465483|NCT03610386|OTHER|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back ...). One of the two biopsies will not receive menthoxypropanediol.
48465484|NCT02838251|OTHER|No intervention|
48465485|NCT00806962|DRUG|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
48282286|NCT06657170|PROCEDURE|Pulmunary veins (PV) reconnection ablation only|Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
48282287|NCT00312013|DRUG|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
48465486|NCT00806962|DEVICE|placebo|intranasal, puff of air, 2 doses, 21 days apart
48465487|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
48465488|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
48465489|NCT01774058|DRUG|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
48465490|NCT01903057|DRUG|azithromycin|
48465491|NCT01903057|DRUG|ivermectin|
48465492|NCT01903057|DRUG|albendazole|
47937114|NCT00134537|DEVICE|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
47937115|NCT00134537|DEVICE|Conservative Care|Medication, exercise and spinal injections
47937116|NCT01488968|RADIATION|Standard Radiation Treatment|39 radiation treatments
47937117|NCT01488968|RADIATION|Hypofractionated radiation treatment|25 radiation treatments
48465493|NCT01903057|DRUG|placebo|
48465494|NCT02729207|DRUG|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
48465495|NCT03831490|DIAGNOSTIC_TEST|history|combining these 4 interventions will great an algorithm predicting preeclampsia
48465496|NCT04734704|PROCEDURE|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
48465497|NCT04734704|PROCEDURE|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
48465498|NCT02324335|DRUG|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
48465499|NCT02324335|OTHER|Placebo|
47937118|NCT00752544|DRUG|TMC435350|
47937119|NCT01198379|DRUG|aspirin|aspirin 100 mg qd for 3 years
48100219|NCT06204796|DRUG|Systemic prednisone|All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
48465500|NCT02896296|DRUG|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
48100220|NCT03826602|DRUG|Tucatinib|150mg administered orally twice daily
48100221|NCT03826602|DRUG|Metformin|850mg administered orally
48100222|NCT03826602|DRUG|Iohexol|1500 mg administered intravenously (IV)
48282288|NCT05194319|OTHER|All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)|The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
48465501|NCT01691612|BIOLOGICAL|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
48465502|NCT04381741|BIOLOGICAL|CD19-7×19 CAR-T plus PD1 monoclonal antibody|Three different doses of CD19-7×19 CAR-T (1×106/kg、2×106/kg、3×106/kg) plus 200mg Tislelizumab every 3 weeks for 6 times
48465503|NCT04848207|DEVICE|Digital impression technique|3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
48465504|NCT04848207|OTHER|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
48465505|NCT02581917|OTHER|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
48465506|NCT02581917|OTHER|Laboratory Biomarker Analysis|Undergo metabolic analysis
48100223|NCT05117450|DEVICE|Decrease per-dialytic heparin therapy|Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
48100224|NCT02148406|BEHAVIORAL|Yoga Skills Training (YST)|Undergo YST
48100225|NCT02148406|OTHER|questionnaire administration|Ancillary studies
48465507|NCT03092388|DIAGNOSTIC_TEST|Multi Frequency Bioimpedance Analysis (mfBIA)|Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
47937120|NCT01198379|DRUG|Placebo|
48100226|NCT02148406|OTHER|fatigue and depressive symptom assessment and management|Ancillary studies
48100227|NCT02148406|OTHER|psychological stress assessment|Ancillary studies
48100228|NCT02148406|OTHER|laboratory biomarker analysis|Correlative studies
47937121|NCT03210987|PROCEDURE|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
47937122|NCT03210987|PROCEDURE|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
47937123|NCT02772484|DEVICE|HS-1000|
47937124|NCT01171170|DRUG|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
47937125|NCT01171170|DRUG|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
47937126|NCT04650646|OTHER|Exercise-related hypoglycaemia|Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.
47937127|NCT04650646|OTHER|Hypoglycaemia under resting conditions|Hypoglycaemia induced by intravenous insulin during bed rest.
48100229|NCT02148406|OTHER|Attention Control|
48100230|NCT01254591|OTHER|18F-fluoromisonidazole|
48100231|NCT01254591|OTHER|fluorescence angiography|
48100232|NCT01254591|OTHER|laboratory biomarker analysis|
48100233|NCT01254591|PROCEDURE|infrared thermography|
48100234|NCT01254591|PROCEDURE|magnetic resonance imaging|
48100235|NCT01254591|PROCEDURE|therapeutic conventional surgery|
48100236|NCT01254591|RADIATION|[18F]-ML-10|
48100237|NCT01254591|RADIATION|fludeoxyglucose F 18|
48100238|NCT01254591|RADIATION|rubidium Rb-82|
48100239|NCT06629311|DEVICE|Autotransfusion device|Standard cardiac surgery using I-SEP and SAME™ autotransfusion device
48100240|NCT04672473|BIOLOGICAL|DC-CTL|DAC combined with Ag-CTL
48100241|NCT00000821|DRUG|Aldesleukin|
48625569|NCT04628910|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions twice a week for 3 weeks as one of the two interventions.
48625570|NCT00176137|PROCEDURE|preoperative radiochemotherapy|
48100242|NCT05920122|DRUG|2% Chlorhexidine gluconate with 70% alcohol|Patients will be prepared similarly using the appropriate number of 26mL Chloraprep sticks for their body surface area. The lever will be pinched to activate the ampoule and release the antiseptic. The solution will be given time to partially load in the sponge. The sponge will be pressed against the skin area where the incision is intended moving back and forth for 30 sec , then working up towards the upper edge of the surgical field and then working from below the incision sight to the upper thighs. The antiseptic will be given time to dry (3 min)
48100243|NCT05920122|DRUG|4% Chlorhexidine Gluconate aqueous solution|Patients will be scrubbed preoperative with an applicator that contain 4% chlorohexidine aqueous solution (3 consecutive applications) liberally over 2 minutes followed by drying with sterile towel. The area scrubbed will be the same as the chloraprep group.
48625571|NCT01458145|BEHAVIORAL|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
48625572|NCT03061643|DRUG|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
48625573|NCT03061643|OTHER|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
48100244|NCT04990401|BEHAVIORAL|Behavioral Activation Teletherapy|A total of 10 teletherapy sessions to be delivered over 12-14 weeks, designed to increase physical activity among depressed individuals.
48100245|NCT02992275|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
48100246|NCT02992275|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
48100247|NCT06316297|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form:Liquid suspension for injection-Route of administration:intramuscular
48100248|NCT06316297|OTHER|Placebo|Pharmaceutical form:Liquid solution for injection-Route of administration:intramuscular
48625574|NCT06549972|OTHER|Acute Ischemic Stroke|first-ever anterior circulation AIS (Acute Ischemic Stroke)
48625575|NCT00243061|DRUG|cediranib maleate|Given orally
47937128|NCT03230305|OTHER|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~* If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~* If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
47937129|NCT05872932|PROCEDURE|gastric balloon implantation|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed
48465508|NCT03092388|DIAGNOSTIC_TEST|Polysomnography/Polygraphy (PSG/PG)|Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
48465509|NCT03092388|DIAGNOSTIC_TEST|Capillary Blood Gas Analysis (CBGA)|CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
48625576|NCT06068400|BIOLOGICAL|BCMA/GPRC5D double CAR-T|BCMA/GPRC5D double CAR-T is a new type CAR-T cells therapy for patients with Multiple Myeloma.
48625577|NCT00013325|PROCEDURE|Cardiac Disease|
48625578|NCT04791826|BEHAVIORAL|On-screen electronic alert|On-screen computer-based alert notifying the provider that the patient is at an increased risk of developing HF based on the WATCH-DM risk score and associated guideline recommendation for preventive management of these patients.
48625579|NCT03988647|DRUG|Pembrolizumab|Pembrolizumab administered at 200 mg IV every 3 weeks
48625580|NCT03988647|RADIATION|Radiation Therapy|9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
47937130|NCT05872932|PROCEDURE|botulinum toxin A injection|After diagnostic endoscopy if there is no any gastric pathology that would be contraindication Botox injection and balloon placement, 200 U of Botox A will be injected to antrum and fundus. And 1 week later gastric balloon will be implanted
47937131|NCT02234856|PROCEDURE|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
48100249|NCT04371718|DRUG|JKB-122|JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
48100250|NCT04371718|OTHER|Placebo|A capsule has same component but active drug
48100251|NCT01611909|DRUG|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
48100252|NCT00950144|OTHER|medical chart review|
48465510|NCT03092388|DIAGNOSTIC_TEST|Tilting Table with Hemodynamic Monitoring|A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
48100253|NCT00950144|OTHER|questionnaire administration|
48100254|NCT00950144|OTHER|study of socioeconomic and demographic variables|
48625581|NCT03298061|DRUG|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
48625582|NCT03298061|DRUG|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
48625583|NCT04181645|DRUG|Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
48625584|NCT05276453|DEVICE|GMove Suit|12 week, home-based programme whereby participants are encouraged to use the GMove suit daily, for at least 30 minutes a day. Recommended activities include walking, sit-to-stand and step-ups
48625585|NCT05276453|BEHAVIORAL|Normal therapy|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 30 mins a day of physical activity and have active physical therapy (physiotherapy) sessions.
48625586|NCT06145074|DRUG|Propranolol|Oral administration.
48625587|NCT06145074|DRUG|Placebo|Oral administration.
48625588|NCT05226000|DRUG|Benaglutide Injection|All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
48625589|NCT06433063|DIAGNOSTIC_TEST|F-MISO PET|Evaluation of tumor hypoxia with F-MISO PET
47937132|NCT01695200|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
47937133|NCT03455049|OTHER|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
48465511|NCT06237101|DRUG|High dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
48465512|NCT06237101|DRUG|Medium dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
48625590|NCT01726686|DRUG|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
48100255|NCT00950144|PROCEDURE|quality-of-life assessment|
48100256|NCT05604274|OTHER|App to monitor stool consistency and symptoms|App to monitor stool consistency and symptoms
48625591|NCT01726686|DRUG|Placebo|
48625592|NCT03030209|PROCEDURE|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
48625593|NCT06188546|DRUG|Propofol|trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
48625594|NCT04267042|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
47937134|NCT03492775|DRUG|Obinutuzumab|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
47937135|NCT03492775|DRUG|Bendamustine|Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
47937136|NCT03930160|OTHER|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
48100257|NCT00387491|DRUG|MOA-728|
48100258|NCT03686813|DRUG|Sildenafil Citrate|Oral sildenafil, 50 mg
48100259|NCT03686813|DRUG|Placebo Oral Tablet|Placebo
48100260|NCT01269606|DRUG|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
48100261|NCT01269606|DRUG|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
48282289|NCT00135421|DRUG|Pexacerfont|Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
48465513|NCT02101073|BIOLOGICAL|ALX-0061|single dose, intravenous
48625595|NCT04267042|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
48625596|NCT04267042|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
47937137|NCT02632903|DRUG|Zoledronic acid|
47937138|NCT01825954|DEVICE|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
47937139|NCT00193193|DRUG|Paclitaxel|
47937140|NCT00193193|DRUG|Estramustine|
48465514|NCT02101073|BIOLOGICAL|ALX-0061|single dose, subcutaneous
48625597|NCT03240445|DRUG|ODM-203 (Period 1)|ODM-203 400mg as tablets taken 30 minutes after food
48625598|NCT03240445|DRUG|ODM-203 (Period 2)|ODM-203 400mg as tablets taken 1 hour before a light breakfast
48625599|NCT03240445|DRUG|ODM-203 (Periods 3-6)|ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
47937141|NCT00193193|DRUG|Carboplatin|
47937142|NCT00476801|DEVICE|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
48465515|NCT03581994|DIAGNOSTIC_TEST|DDI Test Report|Test results of simulated patients
48465516|NCT00362505|DRUG|Clevudine|
48465517|NCT04997720|OTHER|Training|"Each course will consist of:~1. Initial evaluation~2. Theoretical tutorial~3. Training with exercises of increasing complexity.~4. Final evaluation."
48100262|NCT01269606|DRUG|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
48100263|NCT01269606|DRUG|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
48465518|NCT00002923|DRUG|KRN5500|
48465519|NCT04153318|DEVICE|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
48625600|NCT02960789|OTHER|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
47937143|NCT01669707|DRUG|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2\*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
48100264|NCT05338242|DEVICE|Real-Time Exposure Feedback|Participants will receive real-time exposure monitors that continuously display real-time air concentration information and a color-coded designation for the current risk level.
48465520|NCT01632449|DRUG|Test product|Dimethyl Fumarate (BG00012)
48465521|NCT01632449|DRUG|Reference product|Dimethyl Fumarate (BG00012)
48100265|NCT05649098|DRUG|Dupilumab|The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
48100266|NCT05200650|COMBINATION_PRODUCT|TumoCure|TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
48100267|NCT02962336|DRUG|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
48100268|NCT02962336|DRUG|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
48100269|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
48100270|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
48100271|NCT01568996|DRUG|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
48465522|NCT04776005|OTHER|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
48625601|NCT02960789|OTHER|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
48625602|NCT02960789|DEVICE|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
48100272|NCT05139160|DIETARY_SUPPLEMENT|Protein quality|the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
48625603|NCT02960789|OTHER|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
48100273|NCT03879642|BEHAVIORAL|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
48100274|NCT02127476|DRUG|KHK6640|Single ascending dose and multiple ascending doses administration
48100275|NCT02127476|DRUG|Matching Placebo|Single ascending dose and multiple ascending doses administration
48100276|NCT04242758|DRUG|Dapagliflozin 10 MG|SGLT2-inhibitor: Diabetic oral drug with diuretic properties
48100277|NCT04242758|DRUG|Hydrochlorothiazide 12.5mg|Best known thiazide class diuretic.
48100278|NCT06629896|DIAGNOSTIC_TEST|Contrast Enhancement Mammography|In the experimental arm women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
48100279|NCT06629896|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) and digital mammography (DM)|women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.
48100280|NCT06630351|BEHAVIORAL|Behavioral Counseling|Participate in MCP-C
48100281|NCT06630351|OTHER|Discussion|Participate in virtual group discussions
48100282|NCT06630351|OTHER|Health Promotion and Education|Receive reading exercises and workbook materials
48100283|NCT06630351|OTHER|Interview|Ancillary studies
48100284|NCT06630351|OTHER|Questionnaire Administration|Ancillary studies
48465523|NCT03721887|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
48465524|NCT04391517|DIAGNOSTIC_TEST|SpHb measurement|All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
48465525|NCT03084562|OTHER|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
48625604|NCT02960789|DEVICE|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
48625605|NCT01719276|OTHER|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
48625606|NCT01719276|OTHER|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
48625607|NCT03349515|DRUG|Provodine-Iodine Solution|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
48625608|NCT03349515|DRUG|Group B will receive three drops in each eye of ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
48625609|NCT04810962|DRUG|APP13007, 0.05%|APP13007 eye drop, 0.05%
48465526|NCT03316976|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
48465527|NCT00170703|DEVICE|Cortical Electrical Stimulation|
48465528|NCT03397667|OTHER|ABC ANSWERS|Primary Care plus ABC ANSWERS
48100285|NCT03102242|DRUG|Atezolizumab|Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
48282290|NCT00135421|DRUG|Escitalopram|Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
48282291|NCT00135421|DRUG|Placebo|Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
48282292|NCT02468193|DRUG|Osilodrostat|Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
48465529|NCT03397667|OTHER|Control|Primary Care as usual
48465530|NCT04590339|PROCEDURE|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
48465531|NCT00660491|OTHER|exercise training|moderate intensity exercise group, and high intensity exercise group
48465532|NCT03895151|DIETARY_SUPPLEMENT|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
48625610|NCT04810962|DRUG|Matching Vehicle Placebo for APP13007, 0.05%|Matching vehicle placebo eye drop
48465533|NCT03895151|OTHER|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
48465534|NCT05819437|OTHER|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
48465535|NCT01489930|BEHAVIORAL|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
48465536|NCT01489930|BEHAVIORAL|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
47937144|NCT01669707|DRUG|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
47937145|NCT04694456|OTHER|cytokines dosage|Mesure of cytokines concentration in serum
48100286|NCT06629363|OTHER|biobank|"The following samples will be collected :~* Serum samples and plasma sample: inclusion visit and follow up visit~* Urines samples : inclusion visit and follow up visit~* blood DNA: inclusion visit~* Blood RNA: inclusion visit and follow up visit"
48100287|NCT01080131|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
48100288|NCT01080131|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
48282293|NCT03655028|BEHAVIORAL|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
48282294|NCT03655028|BEHAVIORAL|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
48282295|NCT05541315|DRUG|JNJ-88260237|JNJ-88260237 will be administered orally.
48282296|NCT05541315|DRUG|Placebo|Matching placebo will be administered orally.
48625611|NCT05316870|BEHAVIORAL|Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions|Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
48625612|NCT05316870|BEHAVIORAL|Conventional general practitioner management model|The current general practitioner anticoagulation management model was continued in the control group.
48465537|NCT01489930|BEHAVIORAL|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
48625613|NCT05341245|PROCEDURE|Graphene oxide and open flap debridement|Using Graphene oxide with open flap debridement in management of periodontal intrabony defects in dogs
48625614|NCT05341245|PROCEDURE|Open flap debridement|Using Open flap debridement in management of periodontal intrabony defects in dogs
48625615|NCT00548561|DRUG|Dexrazoxane|
48625616|NCT01245348|GENETIC|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
48625617|NCT04264585|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend \~15 mins. per week/per client.
48465538|NCT00828828|BIOLOGICAL|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
48625618|NCT04264585|BEHAVIORAL|Motivational Interviewing|Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
48625619|NCT04264585|BEHAVIORAL|Booster Session|"Clients assigned to the ICBT with Booster condition will receive access to a booster session one month after the end of the ICBT course. The booster session will include information about maintaining motivation, a review of the ICBT course content and skills, and information about structured problem solving. Clients will also have access to a Do-It-Yourself guide that summarizes the information in the booster session and includes worksheets for clients to practice the problem-solving skills described in the booster.~This booster session will be self-guided (ie. no therapist support is offered)."
48625620|NCT03601052|DRUG|Remlarsen|Intradermal injection at site of one excisional wound
48625621|NCT03601052|DRUG|Placebo|Intradermal injection at site of second excisional wound
48625622|NCT01424852|DIETARY_SUPPLEMENT|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
48625623|NCT04871945|DIAGNOSTIC_TEST|Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)|The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.
48625624|NCT04688788|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.
48625625|NCT04688788|DRUG|Ocrelizumab|Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.
48625626|NCT04688788|DRUG|Fexofenadine|Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
48625627|NCT04688788|DRUG|Paracetamol|Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
48625628|NCT04688788|DRUG|Methylprednisolone|Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
48625629|NCT04407520|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
48625630|NCT06368362|BEHAVIORAL|Benign cognitive bias modification for interpretation|Benign cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign rather than pain-related.
48465539|NCT04662476|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplement
48625631|NCT06368362|BEHAVIORAL|Pain-related cognitive bias modification for interpretation|Pain-related cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as pain-related.
48625632|NCT02588508|PROCEDURE|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
48625633|NCT02588508|PROCEDURE|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
48465540|NCT03546049|PROCEDURE|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
47937146|NCT04694456|PROCEDURE|test of walk|patient must walk during 6 minutes on a flat surface
47937147|NCT04694456|PROCEDURE|Manual muscular test|test performed to evaluate the patient muscular weakness
47937148|NCT04694456|PROCEDURE|Motrice fonction mesurement|scale allowing the evaluation of patient posture and upper body movements
47937149|NCT00937781|GENETIC|RNA analysis|
48625634|NCT04200924|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
48625635|NCT04200924|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
48625636|NCT06329310|DEVICE|aXess-E conduit|The aXess-E conduit is a sterile, regenerative biodegradable polymer-based vascular conduit, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess-E conduit is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
48625637|NCT04847921|DRUG|Dalbavancin|long-acting lipoglycopeptide antibacterial agent
48625638|NCT00672009|DRUG|Ixabepilone|Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.
48282297|NCT06489145|DEVICE|Technology-enhanced Rehabilitation|"Based on their individualized rehabilitation project, patients will undergo robot-assisted therapy (RAT) and/or virtual reality (VR)-based treatment.~RAT will consist of the use exoskeleton devices intended for the treatment of upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™) impairments.~VR-based rehabilitation will be conducted non-immersive VR devices: the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), and the Walker View™ (TechnoBody SRL, Italy).~Technology-enhanced treatment duration (number of sessions, minutes of use) will strictly depend on patients' rehabilitation needs and individualized rehabilitation program. Overall, part of the duration of the whole treatment will be dedicated to the use of the technological device, resulting in the same amount of rehabilitation for all participants."
48465541|NCT03546049|PROCEDURE|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
48625639|NCT04462146|BEHAVIORAL|Internet-based Self Applied Treatment Program|"It is a self-applied treatment for PGD through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is up to 8-10 weeks. A weekly support call will be made (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
48625640|NCT04462146|BEHAVIORAL|Videoconference treatment with a therapist|"It is a treatment for PGD applied by a therapist composed of 8-10 treatment sessions. Each session lasts approximately 60 minutes. No weekly support call will be provided.~The sessions will take place by videoconference. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention."
48625641|NCT04975230|BEHAVIORAL|Sleep Self-Management|Intervention delivered by a sleep coach will include 1) initial in-person 50 min consultation; 2) brief 5 min weekly follow ups in a format TBD; and 3) in-person 30 min booster sessions every 3 weeks (total 13 sessions).
48465542|NCT00999115|DRUG|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
48625642|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by IMBCAMS|Dosage form: 0.5mL/vial
48625643|NCT04223037|BIOLOGICAL|Japanese Encephalitis Vaccine produced by Liaoning Chenda|Dosage form: 0.5mL/vial
48625644|NCT03164707|DIAGNOSTIC_TEST|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
48625645|NCT02512419|BEHAVIORAL|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
48625646|NCT02512419|BEHAVIORAL|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
48625647|NCT02512419|DEVICE|Actigraph GT3X|
48465543|NCT04011098|DRUG|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
48465544|NCT04011098|DRUG|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
48465545|NCT02531490|DRUG|Labetalol|
48465546|NCT02531490|DRUG|Nifedipine|
48465547|NCT02531490|DRUG|Methyldopa|
48465548|NCT00163709|PROCEDURE|BNP test|
48625648|NCT00816270|PROCEDURE|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
48625649|NCT05710172|DEVICE|Auditory Mirror Therapy|21 days, up to 3 hours per day intervention
47937150|NCT00937781|GENETIC|gene expression analysis|
48625650|NCT05412420|OTHER|Patient Self-Reporting of Symptoms|"At baseline, clinical research staff will:~* verify the possibility of an internet connection at the patient's home~* help the patient to fill in the 1st questionnaire (baseline questionnaire - frailty)~Every two weeks for 3 months:~* patients complete questionnaires via app (toxicity; quality of life, medication adherence)~* responses are verified by clinical research staff~* In case of severe symptoms, the clinician contacts the patient and arranges for management.~At the end of the study :~- patients answer a satisfaction questionnaire"
48625651|NCT01327703|DRUG|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
48625652|NCT01327703|DRUG|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
48625653|NCT03965650|OTHER|Video coaching exercises|Patients will perform physical exercises following a specifical video coaching program during 6 months.
48625654|NCT03965650|OTHER|Routine exercises|"Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months."
48465549|NCT05953987|OTHER|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
48625655|NCT05957523|DEVICE|Remote ischaemic preconditioning|The participants rested in the supine position for 5 minutes, then turn on the ischaemic preconditioning apparatus and place the automatically programmed blood pressure cuff on both upper arms of the participant, pressurize to 200 mmHg, pressurize for 5 minutes, rest for 5 minutes, perform 4 cycles for a total of 40 minutes each time. The training for participants in group A will be performed once daily, while for participants in group B the training will be performed twice daily. And heart rate and blood pressure before and after each training will be recorded for 7 days.
48625656|NCT00914212|DRUG|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
48625657|NCT00914212|DRUG|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
48625658|NCT02661477|DRUG|pegylated interferon alfa 2|
48282298|NCT06489145|OTHER|Multidisciplinary Traditional Rehabiltiation|Patients will receive traditional treatment consisting of two daily one-hour session (4 weeks, 20 sessions) and including rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
48465550|NCT05953987|OTHER|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
48625659|NCT02661477|OTHER|Placebo|0,9% natrium chlorine solution
48625660|NCT04909255|DRUG|mirabegron|use beta-3 agonist for sjogren syndrome patient
48282299|NCT03010189|DEVICE|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
48282300|NCT03010189|DEVICE|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
48625661|NCT04909255|DRUG|oxybutynin, tolterodine, solifenacin|use anti-muscarinic agent for patient with overactive bladder syndrome
48625662|NCT02627807|RADIATION|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
48625663|NCT02627807|RADIATION|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
47937151|NCT00937781|GENETIC|microarray analysis|
47937152|NCT00937781|GENETIC|polymerase chain reaction|
48282301|NCT03010189|DEVICE|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
48282302|NCT04924322|DRUG|Enoxaparin|Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
48465551|NCT05953987|OTHER|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
48465552|NCT02250651|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
48465553|NCT02250651|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
48465554|NCT02250651|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
48465555|NCT02250651|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
47937153|NCT00937781|OTHER|immunohistochemistry staining method|
48282303|NCT00396396|DRUG|Acetylcysteine|
48465556|NCT00834236|OTHER|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
48625664|NCT02627807|DRUG|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
48625665|NCT02627807|DRUG|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
48625666|NCT02627807|DRUG|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
48100289|NCT01080131|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
48100290|NCT01080131|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
48100291|NCT03810482|DEVICE|Pedometer|A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.
48100292|NCT03810482|OTHER|6 minute walking test|Performed according to current recommendations during routine visits (baseline and \~90 days for the purposes of this study).
48282304|NCT00206570|DRUG|Estradiol|
48282305|NCT01059149|DEVICE|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
47937154|NCT00937781|OTHER|laboratory biomarker analysis|
47937155|NCT00123968|BIOLOGICAL|VRC-HIVDNA016-00-VP|1x10\^11 per unit vaccine administered intramuscularly via Bioinjector
48100293|NCT06529809|RADIATION|Hypofractionated external beam radiation|Central pelvis (20 Gy in 10 fractions), nodal basins (40 Gy in 15 fractions), with a simultaneous integrated boost to grossly positive lymph nodes (48 Gy in 15 fractions)
47937156|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
47937157|NCT00123968|BIOLOGICAL|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
47937158|NCT00123968|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
47937159|NCT03878186|OTHER|Usual Care (UC)|Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
48100294|NCT06529809|DRUG|Chemotherapy|Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
48100295|NCT06529809|RADIATION|Image-guided brachytherapy|HDR boost 7.3 Gy x 6 fractions
48100296|NCT00864682|DRUG|Saline|3.3 mL normal saline
48100297|NCT00864682|DRUG|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
48100298|NCT00864682|DRUG|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
48100299|NCT00546520|DRUG|Ciclesonide|
48100300|NCT02908620|COMBINATION_PRODUCT|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
48282306|NCT05004675|BIOLOGICAL|lerodalcibep|300 mg
48282307|NCT05004675|DRUG|Inclisiran|284 mg
48282308|NCT03240081|DRUG|50mcg estradiol cream|Use of study drug nightly applied to vulvar vestibule
48282309|NCT03240081|DRUG|100mcg estradiol cream|Use of study drug nightly
48282310|NCT04372238|BEHAVIORAL|RAPIDS Intervention|RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.
48465557|NCT00834236|OTHER|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
48465558|NCT01566851|OTHER|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
48465559|NCT01790308|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
48465560|NCT01790308|DRUG|Liraglutide|CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
48465561|NCT04477863|OTHER|Follow-up Interview|Non Applicable
48465562|NCT03835845|DEVICE|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
48465563|NCT00962494|BEHAVIORAL|Cancer: Thriving and Surviving Online Workshop|
48465564|NCT03929016|DRUG|DNDI-0690|capsules of 10, 100 and 200 mg
48465565|NCT03929016|DRUG|Placebo of DNDI-0690|capsules of matching placebo
48465566|NCT00379353|DRUG|Thalidomide|100 mg capsules orally, once a day for 14 days.
48465567|NCT00379353|DRUG|Placebo|Two placebo capsules orally, once a day for 14 days.
48465568|NCT05983627|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.
48465569|NCT04381481|BEHAVIORAL|Experimental Drink: Nutrition claim on fruit drinks|Fruit drink contains a nutrition claim (task 1)
48100301|NCT02908620|DRUG|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
48625667|NCT02627807|DRUG|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
48625668|NCT04557774|OTHER|Cognitive function test|"Laboratory and imaging test~* Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~* Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive"
48625669|NCT00576615|DRUG|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
48625670|NCT00576615|DRUG|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
48625671|NCT03740490|COMBINATION_PRODUCT|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
48625672|NCT03740490|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
48625673|NCT02086045|DEVICE|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
48625674|NCT05207358|DRUG|Rituximab|2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.
48625675|NCT05207358|DRUG|Mycophenolate Mofetil|Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
48625676|NCT05207358|DRUG|Cyclophosphamide|All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
48625677|NCT05207358|DRUG|Corticosteroids|3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.
48100302|NCT02908620|COMBINATION_PRODUCT|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
48282311|NCT04372238|BEHAVIORAL|Standard OEND|In the attention-matched control arm, participants will receive standardized overdose education and naloxone distribution (OEND) training, with attention-control visits at 1, 2, and 3 months. Participants will receive a naloxone kit after completion of the first session, and information regarding where to obtain additional naloxone at subsequent visits. They will have contact with study staff at month 6 and 12 follow-up visits to capture outcome and covariate data.
48282312|NCT05133986|OTHER|Onion Feeding|The intervention includes feeding individuals a 120g portion of onions (experimental condition).
48282313|NCT05133986|OTHER|Couscous Feeding|The intervention includes feeding individuals a 120g portion of couscous (control condition).
48282314|NCT05133986|OTHER|Onion Supplementation Period|Three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised.
48282315|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain with music|Such procedure may include sacroiliac joint (SI) steroidal injections, SI radiofrequency ablations, peripheral nerve stimulator implantations, caudal and laminar epidural steroidal injections, lumbar medial branch blocks, lumbar medial branch nerve radiofrequency ablations, spinal cord implantation of electro stimulators.
48282316|NCT06235996|PROCEDURE|Office-based procedure indicated for chronic pain without music|Office-based procedure indicated for chronic pain without music
48465570|NCT04381481|BEHAVIORAL|Control Drink: No nutrition claim|Fruit drinks does not contain a nutrition claim (task 1)
48465571|NCT04381481|BEHAVIORAL|Experimental snack: Text warning|The snack contains a text warning (task 2)
48465572|NCT04381481|BEHAVIORAL|Experimental snack: Graphic warning|The snack contains a graphic warning (task 2)
48465573|NCT04381481|BEHAVIORAL|Control snack: barcode label|The snack contains a neutral barcode label (task 2)
48625678|NCT00120718|DRUG|fasudil|
48625679|NCT00221325|DRUG|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
48625680|NCT03421561|DEVICE|"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"|"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
47937160|NCT03878186|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
47937161|NCT04315935|DRUG|Butorphanol and Propofol|The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
47937162|NCT04315935|DRUG|Fentanyl and Propofol|Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
47937163|NCT04814901|PROCEDURE|Curing small and medium sized oronasal fistula|"* Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures."
47937164|NCT00579436|DRUG|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
47937165|NCT00579436|DRUG|placebo|4 inert capsules daily by mouth for 12 weeks.
48282317|NCT02090543|DRUG|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
48465574|NCT02672761|BEHAVIORAL|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
48465575|NCT02672761|BEHAVIORAL|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
48100303|NCT02908620|DRUG|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
48282318|NCT02090543|DRUG|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
48282319|NCT06098079|DRUG|Naltrexone-Bupropion (NB) Combination|A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
48282320|NCT06098079|DRUG|Placebo|A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
48282321|NCT05049798|DRUG|Guselkumab|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
48465576|NCT02672761|BEHAVIORAL|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
48465577|NCT02672761|BEHAVIORAL|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
48465578|NCT03282539|DEVICE|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
48465579|NCT03282539|DEVICE|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
48465580|NCT04129944|DRUG|UBX0101|Investigational drug intra-articular injection
48625681|NCT03421561|DEVICE|EverCross™ 0.035 PTA Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
47937166|NCT00333203|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
47937167|NCT00333203|OTHER|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
48625682|NCT02197637|DRUG|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
48465581|NCT04129944|OTHER|Placebo|Placebo intra-articular injection
48465582|NCT00474188|DRUG|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
48465583|NCT00474188|DRUG|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
48465584|NCT01015287|DRUG|Placebo|Administered once orally
48465585|NCT01015287|DRUG|Prasugrel|Administered orally
48465586|NCT01279109|BEHAVIORAL|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
48465587|NCT01279109|BEHAVIORAL|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
48465588|NCT05595720|DEVICE|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215\&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
48465589|NCT00473616|DRUG|AZD7762|intravenous infusion
48465590|NCT00473616|DRUG|Irinotecan|intravenous injection
48282322|NCT05049798|DRUG|IL-17i|Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.
48465591|NCT02818894|DRUG|Lidocaine|Spinal anesthesia administered prior to participant's THA
48465592|NCT02818894|DRUG|Bupivacaine|Spinal anesthesia administered prior to participant's THA
48465593|NCT04501536|BEHAVIORAL|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
48465594|NCT06432140|GENETIC|VGN-R09b injection|Two levels of VGN-R09b will be injected into bilateral putamen in dose-escalating phase, and one dose level will be injected in dose confirming phase
48465595|NCT05212038|PROCEDURE|iliopsoas plane block group|Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml
48465596|NCT05212038|PROCEDURE|sham block group|Ultrasound-guided iliopsoas plane block with normal saline 10 ml
48625683|NCT03010865|DRUG|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
47937168|NCT05702853|DRUG|Cyclophosphamide injection|500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
47937169|NCT05702853|DRUG|Fludarabine Injection|30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
48465597|NCT01401296|BEHAVIORAL|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
48465598|NCT01401296|BEHAVIORAL|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
48465599|NCT03281096|DRUG|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
48465600|NCT03281096|DRUG|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
48625684|NCT03010865|DRUG|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
47937170|NCT05702853|BIOLOGICAL|CD19-CD34t metabolically programmed CAR transduced T-cells|Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
47937171|NCT04291261|DRUG|Uvadex|Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
47937172|NCT03380936|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
48100304|NCT04310579|DRUG|Oxycodone and Midazolam|"In one period subjects receive oxycodone 10-15 mg immediate release (IR) and placebo IV 1x per day.~In a second period (randomized cross-over), subjects receive midazolam 0.0375-0.075 mg/kg IV and oral placebo tablet 1x per day.~In a third period (randomized cross-over), subjects receive oxycodone 10-15 mg IR tablet and 0.0375-0.075 mg/kg midazolam IV 1x per day.~In a fourth period (randomized cross-over), subjects receive oral placebo tablet and placebo IV 1x per day."
48465601|NCT05807763|PROCEDURE|Laparoscopic paraesophageal hernia repair without fundoplication|"Patients undergoing laparoscopic paraesophageal hernia repair will be evaluated for risk of esophageal reflux using intra-operative impedance planimetry and endoscopic gastroesophageal valve grade. Patients deemed low risk for esophageal reflux will then be randomized to partial fundoplication or no fundoplication."
48465602|NCT03496298|DRUG|Efpeglenatide (SAR439977)|"Pharmaceutical form: Solution for injection,~Route of administration: SC"
48465603|NCT03496298|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: SC"
48465604|NCT01775722|DEVICE|Pulsed Dye Laser|port wine stain
48625685|NCT04992286|OTHER|questionnaire|questionnaire to evaluate fragility
48625686|NCT04992286|OTHER|accelerometer|To evaluate physical activity level
48625687|NCT02013427|DRUG|Naproxen|Take one 500mg naproxen capsule twice a day.
48625688|NCT02013427|DRUG|Placebo|Take one placebo capsule twice a day.
48625689|NCT02013427|DRUG|Omeprazole|Take one 20mg omeprazole capsule twice a day.
48465605|NCT01775722|DEVICE|Combined Bipolar Radiofrequency&Pulsed Dye Laser|Combined Bipolar Radiofrequency\&Pulsed Dye Laser Treatment
48465606|NCT01390948|DRUG|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
48465607|NCT01390948|RADIATION|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
48465608|NCT01390948|DRUG|Temozolomide (TMZ)|75 milligrams per square meter (mg/m\^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m\^2/day) x 12 cycles, 1st cycle 150 mg/m\^2/days 1-5, escalated to 200 mg/m\^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
48465609|NCT00897923|PROCEDURE|radionuclide imaging|
48465610|NCT00897923|RADIATION|indium In 111-labeled autologous peripheral blood mononuclear cells|
48465611|NCT00897923|RADIATION|indium In 111-labeled autologous polymorphonuclear leukocytes|
48465612|NCT04943549|DRUG|Bupivacain|Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
48465613|NCT05033145|DRUG|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
48465614|NCT05033145|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
48465615|NCT03306238|PROCEDURE|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
48106918|NCT03342872|BEHAVIORAL|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
48465616|NCT03306238|PROCEDURE|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
48465617|NCT06402227|OTHER|gamified instruction|"At the beginning, the speaker played the role of a laboratory rescue team, narrated the background story of the board game, and led the children into the game situation. Then, the speaker explained four types of pathogens, which the investigators defined them according to different types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker explained their characteristics and key points, representative diseases in real life, corresponding prevention methods and so on. The lecture lasted for 15 minutes, then the children were divided into different groups to play the board game for about 20 minutes. During the game, students were required to collect Prevention Method Cards made by the research team. Students must perform the correct behavior of infection control or answer questions related to the class content in order to obtain the card and win."
47937173|NCT03380936|OTHER|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
47937174|NCT06347679|OTHER|Aroma diffuser with single-note sweet orange essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note sweet orange essential oil into the aroma diffuser reservoir containing 120 ml of water.
47937175|NCT06347679|OTHER|Aroma diffuser with single-note tea tree essential oil|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of 100% concentration single-note tea tree essential oil into the aroma diffuser reservoir containing 120 ml of water.
47937176|NCT06347679|OTHER|Aroma diffuser with water|In a space of 3\*4\*2.6 cubic meters, positioned 10 cm away from the patient, add 4-6 drops (each drop being 0.05 ml) of water into the aroma diffuser reservoir containing 120 ml of water.
47937177|NCT02827565|OTHER|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
47937178|NCT02648321|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
47937179|NCT02648321|BEHAVIORAL|Health Education|General education about healthy lifestyle and diet.
47937180|NCT01094639|PROCEDURE|Scaling root planing|Deep gum cleaning with local anesthesia
47937181|NCT01094639|PROCEDURE|Supragingival Prophylaxis|Plaque removal
47937182|NCT00847119|BIOLOGICAL|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
47937183|NCT00847119|DRUG|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
47937184|NCT00847119|RADIATION|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
48625690|NCT05563974|OTHER|Family led postnatal care|"Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location."
48625691|NCT05312112|DRUG|Venetoclax|Observational study of venetoclax in AML
48625692|NCT05312112|DRUG|Gilteritinib|Observational study of gilteritinib in AML
48625693|NCT06053229|DEVICE|percussive massage|30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device
48625694|NCT06053229|COMBINATION_PRODUCT|Leg Immobilization|All subjects will have their left leg immobilized using an immobilization brace for 10 days
48625695|NCT01900314|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
48625696|NCT06119529|DRUG|LY3872386|Administered either IV or SC.
48625697|NCT06119529|DRUG|Prednisone|Administered orally.
48625698|NCT06119529|DRUG|Placebo|Administered either IV or SC.
48625699|NCT05639595|DEVICE|Web interface for health center staff and mobile application on smart phones for village health volunteers|The designated health center staff will receive a web interface that will allow them to offer job aid for supervision, including real-time information about VHSGs' performance in the form of process indicators and coverage of MCH services. The tool will also support health center staff in their daily tasks, such as high-risk patient tracking, low-supply-inventory alerts, supply chain management, electronic health records, vital events tracking, and automatic calculation of performance-based incentives and motivation for VHSGs. The mobile application will be offered to two female VHSGs from each of the 200 villages connected to their respective health centers in the intervention arm. The mobile application will provide job aid to VHSGs for scheduling home visit tasks, including ANC, home-based newborn care, reporting outcomes of pregnancies, and follow-up visits of complicated cases.
48100305|NCT04310579|DRUG|Oxycodone, Paroxetine, and Quetiapine|"In one period, subjects receive: oxycodone 10-15 mg IR tablet 1x per day and oral placebo 3x per day on Days 1 and 5; and oral placebo 3x per day on Days 2-4.~In a second period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, paroxetine 40 mg tablet 1x per day, and oral placebo 1x per day on Days 1 and 5; and paroxetine 40 mg tablet 1x per day and oral placebo 2x per day on Days 2-4.~In a third period (randomized cross-over), subjects receive: oxycodone 10-15 mg IR tablet 1x per day, quetiapine 50 mg tablet 2x per day, and oral placebo 1x per day on Day 1; quetiapine 100 mg (2x50 mg tablets) 2x per day and oral placebo 1x per day on Day 2; quetiapine 150 mg (3x50 mg tablets) 2x per day and oral placebo 1x per day on Day 3; quetiapine 200 mg (4x50 mg tablets) 2x per day and oral placebo 1x per day on Day 4; and quetiapine 200 mg (4x50 mg tablets) 1x per day and oral placebo 1x per day on Day 5."
48100306|NCT06630052|OTHER|adductor canal clinical examination|clinical examination of the adductor canal in patients with knee pain not matching the radiological changes
48100307|NCT03584295|DEVICE|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
48625700|NCT02210195|DRUG|aprepitant|125 mg daily for 8 weeks.
48625701|NCT02210195|DRUG|Placebo|Placebo daily for 8 weeks.
48100308|NCT03584295|OTHER|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
48100309|NCT04031417|OTHER|Hypoxia|
48625702|NCT02210195|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
48625703|NCT02204735|BEHAVIORAL|Eat majority of calories in the morning|
48625704|NCT02204735|BEHAVIORAL|Eat the majority of calories in the evening|
48625705|NCT03296683|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
48625706|NCT05188508|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
48625707|NCT05188508|COMBINATION_PRODUCT|Olaparib and Temozolomide|Olaparib and temozolomide will begin on cycle 3 day 1 and continue through cycle 11. Olaparib will be dosed 200mg orally twice a day (bid) days 1-7 each cycle. Temozolomide 50 mg/m2 will be administered orally days 1-7 each cycle.
48625708|NCT01584388|DRUG|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
48625709|NCT03783806|DIAGNOSTIC_TEST|Posturography measurements|Determination of functional status, Posturography measurements, postural tests
48625710|NCT05252754|DRUG|Tacrolimus capsule|Tacrolimus 5 mg PO, 1-2 hours prior to endoscopy
48625711|NCT05252754|DRUG|Placebo|Placebo PO, 1-2 hours prior to endoscopy.
48100310|NCT04031417|OTHER|Low Humidity|
48625712|NCT05252754|DRUG|Rectal Indomethacin|100 mg Rectal Indomethacin immediately after ERCP, in high-risk patients.
48625713|NCT01225744|DRUG|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA \> 2 m2 ."
48625714|NCT01225744|DRUG|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
48625715|NCT01225744|DRUG|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
48625716|NCT01225744|DRUG|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
48625717|NCT00784875|DRUG|LY2624803|1 mg, oral capsule, once nightly before bedtime
48625718|NCT00784875|DRUG|LY2624803|3 mg, oral capsule, once nightly before bedtime
48625719|NCT00784875|DRUG|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
48625720|NCT00784875|DRUG|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
48282323|NCT01275638|DRUG|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
48465618|NCT06402227|OTHER|conventional lesson lecture|The lecture was about 35 minutes. At the beginning, the speaker explained the terms to children, including infectious diseases, symptoms and pathogens. Next, the speaker introduced the components of the infection chain and how to make infection control behaviors for different parts of it. Then the speaker focused on the four types of transmission, including droplets, airborne, blood or body fluids, and fecal-oral. The speaker illustrated their characteristics and key points, representative diseases in real life, and corresponding prevention methods. In the end, the speaker led the students to practice infection control behaviors, such as the seven correct steps of washing hands, the right steps for wearing and taking off masks, and exercises that can be done to increase immunity.
48465619|NCT06340698|BEHAVIORAL|Resilience intervention|"Contents of the first session include:~1. Resilience. Know the concept of resilience.~2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.~3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.~Contents of the second session include:~1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.~2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.~3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing."
48282324|NCT05829057|BIOLOGICAL|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
48282325|NCT05829057|BIOLOGICAL|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
48465620|NCT06340698|BEHAVIORAL|Adherence intervention|"Contents of the first session include:~1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.~2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.~Contents of the second session include:~1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.~2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.~3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems."
48465621|NCT06209034|OTHER|Optic nerve sheath measurement|ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
48465622|NCT00425009|DRUG|Berberine|
48465623|NCT00425009|DRUG|Metformin|
48465624|NCT05793645|DEVICE|personalized care plan|Algorithm that defines personalized care plan
48465625|NCT04233866|DRUG|Fluorouracil|Given IV
48625721|NCT03791021|DIAGNOSTIC_TEST|draw a person (DAP)|the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.
48625722|NCT03791021|DIAGNOSTIC_TEST|Edinburgh Postnatal Depression Scale (EPDS)|measure of postpartum depression symptoms.
48625723|NCT03791021|DIAGNOSTIC_TEST|Beck Depression Inventory- II (BDI-II)|BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
48625724|NCT03791021|DIAGNOSTIC_TEST|Traumatic Events Questionnaire (TEQ)|The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
47937185|NCT01711879|DRUG|Aflibercept|Details covered in arm description
47937186|NCT03927599|OTHER|Data Collection|Colleciton of data from medical records only
47937187|NCT04639115|DRUG|Ozanimod|Ozanimod
47937188|NCT06004453|OTHER|Heart Failure medications|There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.
47937189|NCT04016740|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
47937190|NCT04016740|DRUG|Ketamine|Intraoperative infusion
47937191|NCT04016740|DRUG|Remifentanil|Intraoperative infusion
47937192|NCT04016740|DRUG|Dexmedetomidine|Intraoperative infusion
47937193|NCT04016740|DRUG|Rocuronium|Intraoperative intermittent bolus
47937194|NCT04016740|DRUG|Propofol|Intraoperative infusion
48465626|NCT04233866|DRUG|Gemcitabine|Given IV
48465627|NCT04233866|DRUG|Gemcitabine Hydrochloride|Given IV
48465628|NCT04233866|DRUG|Leucovorin|Given IV
48465629|NCT04233866|DRUG|Leucovorin Calcium|Given IV
48465630|NCT04233866|DRUG|Liposomal Irinotecan|Given IV
48465631|NCT04233866|DRUG|Nab-paclitaxel|Given IV
48465632|NCT04233866|OTHER|Quality-of-Life Assessment|Ancillary studies
48465633|NCT04233866|OTHER|Questionnaire Administration|Ancillary studies
48465634|NCT03256227|BEHAVIORAL|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
48465635|NCT03256227|BEHAVIORAL|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
48465636|NCT02546661|DRUG|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
48465637|NCT02546661|DRUG|MEDI4736|MEDI4736
48465638|NCT02546661|DRUG|Olaparib|MEDI4736 (durvalumab) + Olaparib
48465639|NCT02546661|DRUG|AZD1775|MEDI4736 (durvalumab) + AZD1775
48465640|NCT02546661|DRUG|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
48465641|NCT02546661|DRUG|AZD9150|MEDI4736 (durvalumab) + AZD9150
48465642|NCT02546661|DRUG|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
48465643|NCT00504179|PROCEDURE|Osteopathic Manipulative Treatment|
48465644|NCT05926245|DIETARY_SUPPLEMENT|Glutaryl Solution|Glutathione, ascorbic acid, cyclodextrin, potassium sorbate and radish root extracts
48465645|NCT05926245|DIETARY_SUPPLEMENT|Placebo Solution|Empty nanoparticles
48465646|NCT00559598|GENETIC|proteomic profiling|
48465647|NCT00559598|OTHER|medical chart review|
48625725|NCT02702310|OTHER|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
48625726|NCT02702310|OTHER|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 \& 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
48625727|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic injection will be made between the fascia and the muscle.
48625728|NCT05979597|PROCEDURE|Suprainguinal fascia iliaca block+dexamethasone|After the operation is completed, the fascia iliaca will be separated from the iliacus muscle. With ultrasound guidance, the local anesthetic+dexamethasone injection will be made between the fascia and the muscle.
47937195|NCT04016740|DRUG|Sevoflurane|Intraoperative inhaled as needed
47937196|NCT04016740|DRUG|Dexmedetomidine|Post-operative infusion
47937197|NCT04016740|DRUG|Propofol|Post-operative infusion
48100311|NCT05737550|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
48465648|NCT05820789|OTHER|Family support|Before the extubation procedure, the patient's relatives will be informed, and the patient will be allowed to enter the intensive care unit, and the patient will be able to express that he is with the patient by holding his hand and talking.
48465649|NCT05065346|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
48465650|NCT00434590|DRUG|Enteric coated mycophenolate sodium (Myfortic®)|
48625729|NCT02251392|OTHER|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
48625730|NCT02251392|OTHER|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
47937198|NCT04016740|DEVICE|EEG monitoring|Perioperative monitoring
47937199|NCT02125643|DRUG|Caffeine|
47937200|NCT02125643|OTHER|Flour|Flour will be administered as the placebo.
47937201|NCT02818491|DRUG|Placebo|Normal saline 0.9% in 2 mls
47937202|NCT02818491|DRUG|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
47937203|NCT02818491|DRUG|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
48465651|NCT03391622|DEVICE|Calibrated Automated Thrombogram|blood samples will be collected . Thrombin generation in platelet-poor plasma will be measured by means of the Calibrated Automated Thrombogram (CAT).
47937204|NCT02818491|DRUG|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
48465652|NCT03866928|DRUG|Stiripentol|1500 mg of stiripentol b.i.d.
48465653|NCT05228249|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
48465654|NCT05228249|DRUG|Carmustine|Given IV
48465655|NCT05228249|DRUG|Cytarabine|Given IV
48465656|NCT05228249|DRUG|Etoposide|Given IV
48465657|NCT05228249|BIOLOGICAL|Loncastuximab Tesirine|Given IV
48465658|NCT05228249|DRUG|Melphalan|Given IV
48465659|NCT04229914|OTHER|stroke patinets|3-m backwards walk test, timed up and go test, 10 m walk test, Berg BalanceTest, Functional Reach Test
48465660|NCT04606017|DRUG|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
48465661|NCT01214980|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
48465662|NCT01214980|OTHER|Standard of care|Standard of care provided per site-specific protocol
48465663|NCT00707187|DRUG|Cialis|35 pills of study medication (20 mg)
48465664|NCT01792453|OTHER|Spring water|
48465665|NCT00110734|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
48465666|NCT03908307|DRUG|OZURDEX|Implant 700 μg
48465667|NCT04962139|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
48465668|NCT04962139|OTHER|Vehicle Cream|ON101 Cream Placebo
48465669|NCT03336788|DEVICE|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
48465670|NCT03336788|DEVICE|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
48465671|NCT03680261|RADIATION|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
48465672|NCT03680261|DRUG|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
48465673|NCT04442854|OTHER|cognitive behavioral group therapy|A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
48465674|NCT02552082|DEVICE|Scorpio NRG posterior stabilized (PS)|
48465675|NCT02910596|DRUG|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
48465676|NCT02910596|DEVICE|early bladder training|early bladder training start on 3rd - 5thpostoperative day
48282326|NCT04246554|DRUG|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
48465677|NCT02910596|OTHER|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
48465678|NCT02910596|OTHER|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
48465679|NCT04485819|OTHER|Cleavage stage transfer|transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.
48465680|NCT04485819|OTHER|Blast stage transfer|transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
48465681|NCT00214864|DRUG|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8
48465682|NCT05535920|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
48465683|NCT01670643|BEHAVIORAL|Video camera magnifier|reading with video camera magnifier
48465684|NCT02745860|DRUG|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
48465685|NCT02745860|DRUG|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
48465686|NCT01309854|DRUG|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
48465687|NCT01309854|DRUG|pioglitazone|oral tablets, 30mg single dose per period
48465688|NCT01675739|BEHAVIORAL|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
48465689|NCT01675739|DRUG|polyethylene glycol (PEG)|"No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS"
48465690|NCT00006942|DRUG|bryostatin 1|Given IV
48465691|NCT00006942|DRUG|cisplatin|Given IV
48465692|NCT00006942|OTHER|laboratory biomarker analysis|Correlative studies
48465693|NCT01402934|PROCEDURE|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
48465694|NCT00499473|DRUG|sunitinib malate|Given orally
48465695|NCT00499473|OTHER|pharmacological study|Correlative studies
48465696|NCT02313662|DEVICE|NBI and PDD|
48465697|NCT00388063|DRUG|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
48465698|NCT02109458|DEVICE|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
48465699|NCT06331650|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
48282327|NCT04246554|DRUG|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
48282328|NCT00998738|DRUG|Calcium Gluconate|Given IV
48282329|NCT00998738|DRUG|Magnesium Sulfate|Given IV
48282330|NCT00998738|OTHER|Placebo|Given IV
48282331|NCT00998738|OTHER|Quality-of-Life Assessment|Ancillary studies
48282332|NCT00998738|OTHER|Questionnaire Administration|Ancillary studies
48282333|NCT00998738|DRUG|Ixabepilone|Given IV
48465700|NCT01956162|DEVICE|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
48465701|NCT01956162|DEVICE|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
48465702|NCT06074757|DRUG|Fulvestrant injection|phosphate ester of fulvestrant for test arm
48465703|NCT02986139|DRUG|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
48465704|NCT02986139|DRUG|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
48465705|NCT03742063|DRUG|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
48625731|NCT02251392|DRUG|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
48465706|NCT01360216|BEHAVIORAL|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
48465707|NCT03316157|DIETARY_SUPPLEMENT|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
48465708|NCT03316157|BEHAVIORAL|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
48100312|NCT02271607|DEVICE|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
48465709|NCT04090658|BIOLOGICAL|RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Subjects aged 60 to 80 years received 2 doses of the investigational adjuvanted RSV_PreF3 vaccine (GSK3844766A), at Day 1 and Day 61, by intramuscular (IM) injection into the deltoid region of the non-dominant arm preferably.
48100313|NCT00574886|BIOLOGICAL|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
48100314|NCT02534896|DRUG|Treatment I|Sunpharma1505 and Placebo
48100315|NCT02534896|DRUG|Treatment II|Sunpharma1505 and Placebo
48100316|NCT02534896|DRUG|Treatment III|Reference1505 and Placebo
48465710|NCT04090658|DRUG|Placebo|Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
48465711|NCT04476563|DIAGNOSTIC_TEST|Obtaining biological samples|Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
48465712|NCT05878899|DRUG|Enoxaparin|Prophylactic dose of enoxaparin once daily for 10 days after delivery.
48465713|NCT05486338|DEVICE|Hybrid Argon Plasma Coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
48465714|NCT06170034|BEHAVIORAL|Satisfaction questionnaire|Satisfaction questionnaire to assess how TIA patients feels about their medical care.
48465715|NCT06170034|OTHER|Medical care questionnaire|Recording appointments and results of examinations and consultations in TIA management
48465716|NCT05937724|OTHER|Family Caregiving|Family caregiving and sibling inclusive
48465717|NCT03332433|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
48465718|NCT00954603|DRUG|quetiapine|25-100 mg
48465719|NCT00954603|DRUG|haloperidol|0.5-2 mg
48465720|NCT03616691|DRUG|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
48465721|NCT03616691|DRUG|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
48465722|NCT03993639|DRUG|Pegfilgrastim|Single dose of SC administration
48465723|NCT00654641|PROCEDURE|Negative pressure wound closure|Applying negative pressure to primary wound closure
48465724|NCT00654641|PROCEDURE|Standard wound closure|Standard wound closure
48465725|NCT03381586|DRUG|ALT-803|Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
48625732|NCT02076841|DEVICE|interferon beta-1a|Administered as specified in the treatment arm
48625733|NCT04393428|OTHER|[TIMP-2]*[IGFBP-7]|\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
48100317|NCT01365403|DRUG|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
48100318|NCT01365403|DRUG|carbamazepine|multiple oral doses, Days 1-24 of study period 2
48100319|NCT02971306|DRUG|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
48100320|NCT02971306|DRUG|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
47937205|NCT02818491|DRUG|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
48100321|NCT02971306|DRUG|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
48100322|NCT02430181|DRUG|lonafarnib|antiviral farnesyl transferase inhibitor
47937206|NCT02818491|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
48100323|NCT02430181|DRUG|peginterferon alfa-2a|immunomodulator
48100324|NCT02430181|DRUG|ritonavir|CYP 3A4 inhibitor, lonafarnib booster
48106919|NCT02749045|RADIATION|SPECT imaging|myocardial perfusion imaging
48106920|NCT00155363|DEVICE|conventional artificial kidney (AK) vs. high flux AK|
48106921|NCT00544440|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
48625734|NCT03830606|DRUG|Nab-paclitaxel,S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)
48625735|NCT00594737|DRUG|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
48625736|NCT04289038|OTHER|Autogenic Relaxation|Autogenic relaxation
48625737|NCT04289038|OTHER|virtual reality game application|virtual reality game application,
48465726|NCT01071551|BEHAVIORAL|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
48465727|NCT01071551|BEHAVIORAL|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
48625738|NCT04289038|OTHER|kidney function narration|kidney function narration
48625739|NCT03407586|DIAGNOSTIC_TEST|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
47937207|NCT01362868|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
47937208|NCT05409820|PROCEDURE|use of different spinal anesthesia techniques|Comparison of spinal anesthesia with 5 mg hypobaric bupivacaine and 5 mg hyperbaric bupivacaine in outpatients
47937209|NCT00814801|DRUG|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
48465728|NCT06349096|DEVICE|Alma Harmony|The ClearLift is a class IIb medical device, High Power Q-switched (QS) 1064nm Nd:YAG laser module in the Harmony system. It has a targeted laser module for the non-invasive removal of various colored tattoos, as well as deep and superficial benign pigmented lesions, wrinkles, fine lines, and skin tightening.
48465729|NCT05327712|BEHAVIORAL|Control group|No outreach during the intervention period beyond an initial eligibility notice.
48465730|NCT05327712|BEHAVIORAL|Email only|Email reminders in addition to an initial eligibility notice.
48465731|NCT05327712|BEHAVIORAL|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
48465732|NCT05327712|BEHAVIORAL|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
48465733|NCT02308696|BEHAVIORAL|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
48465734|NCT02308696|BEHAVIORAL|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
48465735|NCT01653704|BEHAVIORAL|observational role|observational role in crisis scenario
48465736|NCT01653704|BEHAVIORAL|active role|active role in managing crisis scenario
48465737|NCT02223169|DIETARY_SUPPLEMENT|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
48478880|NCT05470829|OTHER|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
48625740|NCT01767285|DRUG|Etonogestrel implant|This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
48625741|NCT00120484|DRUG|Vitamin B12|
48625742|NCT05279079|DIAGNOSTIC_TEST|Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis|Panel of microRNA and pancreatic enzyme biomarkers
48625743|NCT00095771|DRUG|arsenic trioxide|
48625744|NCT00095771|RADIATION|radiation therapy|
48625745|NCT02811107|OTHER|Questionnaires|Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
48625746|NCT05569941|DRUG|ABI-4334 Tablet|ABI-4334 Tablet
48625747|NCT05569941|DRUG|ABI-4334 Placebo|Placebo to ABI-4334 Tablet
48625748|NCT01310283|OTHER|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
48625749|NCT00223431|DEVICE|all-ceramic fixed partial denture|
48625750|NCT04171076|PROCEDURE|Transcutaneous spinal cord stimulation|Theta burst stimulation at thoracic level (T5) over 2 minutes
48625751|NCT05105100|PROCEDURE|Biopsy|Tumor tissue collection
48625752|NCT05105100|PROCEDURE|Biospecimen Collection|Intravenously Blood draw
48625753|NCT00562341|OTHER|Bariatric Surgery|one time lapb-band gastric bypass surgery
48625754|NCT01755299|OTHER|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
48625755|NCT01755299|OTHER|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
48106922|NCT00544440|DRUG|Prednisone|Prednisone 5 mg tablet taken orally twice daily
48106923|NCT01412034|DRUG|CER-001|Biweekly infusion
48465738|NCT03391115|BEHAVIORAL|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
48465739|NCT03391115|BEHAVIORAL|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
48100325|NCT03537573|BEHAVIORAL|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
48465740|NCT04610580|DRUG|ALXN1840|ALXN1840 will be administered orally.
48100326|NCT03537573|BEHAVIORAL|Opioid Justification|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
48106924|NCT01568749|DRUG|Paracetamol|Paracetamol
48465741|NCT04334837|DIAGNOSTIC_TEST|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
48465742|NCT06147258|BEHAVIORAL|expressive writing|A typical session will begin with the teaching artist (i.e., writing coach) introducing a new writing theme. Participants will have at least 20 minutes to write, and each session will include post-writing reflections and sharing, an undirected supportive interaction among participants.
48465743|NCT03567460|BEHAVIORAL|Exercise|Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
48465744|NCT01731028|DRUG|Somatropin|Somatropin powder and solvent for solution for injection
48465745|NCT04587258|BEHAVIORAL|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
48465746|NCT00452543|DRUG|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
48465747|NCT00452543|DRUG|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
48465748|NCT00452543|BEHAVIORAL|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
48465749|NCT00452543|DRUG|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
48625756|NCT01755299|OTHER|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
47937210|NCT00814801|DRUG|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
47937211|NCT00814801|DRUG|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
47937212|NCT00337350|DRUG|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
47937213|NCT00337350|DRUG|placebo|matched placebo for rosiglitazone 4mg/day
47937214|NCT04085367|DRUG|MAL 16.8% cream|Day light photodynamic therapy with MAL 16.8% cream
48106925|NCT01568749|DRUG|Paracetamol formulation 1|Paracetamol
48106926|NCT01568749|DRUG|Paracetamol Formulation 2|Paracetamol
47937215|NCT04085367|DRUG|MAL Vehicle Cream|Day light photodynamic therapy with MAL vehicle cream
48106927|NCT01568749|DRUG|Paracetamol formulation 3|Paracetamol
48625757|NCT01755299|OTHER|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
48625758|NCT05644509|BIOLOGICAL|Oncolytic Virus Injection（Revottack）+PD-1|Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
48625759|NCT00195325|DRUG|TTI-237|
48625760|NCT04253730|OTHER|Cold Stress|60-90 mins of cooling via a liquid perfused suit circulating \~4-10°C liquid.
48100327|NCT03537573|BEHAVIORAL|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (\> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (\> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
48465750|NCT05125809|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
48100328|NCT06015594|DRUG|Metformin|Patients treated with metformin
48100329|NCT00590850|PROCEDURE|ORIF with Plate and Screws|ORIF with plate and screws
48100330|NCT00590850|PROCEDURE|Pin Fixation|Clavicle fixation with clavicle pin
48100331|NCT01432158|BIOLOGICAL|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
48100332|NCT01432158|BIOLOGICAL|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
48465751|NCT05125809|OTHER|Placebo|A 5% dextrose/glucose solution administered QM via IV infusion
48465752|NCT02914457|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
48465753|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
48465754|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
48465755|NCT01644422|OTHER|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
48465756|NCT03157349|OTHER|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
48465757|NCT03157349|OTHER|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
48465758|NCT00089973|DRUG|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
48625761|NCT05142059|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with Charcot-Marie-Tooth disease type 1A|The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter. A final analysis will be carried out at 1 year from the first according to the same methods as the initial assessment.
48625762|NCT02249780|PROCEDURE|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
48625763|NCT02249780|PROCEDURE|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
48106928|NCT01568749|DRUG|Paracetamol formulation 4|paracetamol
48465759|NCT04754555|OTHER|Arm Activity Measure (ArmA) in french|The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance
48625764|NCT02249780|PROCEDURE|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
48465760|NCT03365063|OTHER|Active Knowledge Translation|"1. Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~2. Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~3. Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids."
48465761|NCT01853540|DRUG|Sildenafil|
48465762|NCT04211480|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression
48625765|NCT02249780|DRUG|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
48625766|NCT04056429|COMBINATION_PRODUCT|BHA|BHA active ingredients include beta-tricalcium phosphate and a blood-derived component. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
48625767|NCT00879359|DRUG|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
48625768|NCT05330377|DRUG|Gilteritinib 40 MG Oral Tablet|Gilteritinib is an oral FLT3 inhibitor, and is active against both FLT3-ITD and FLT3-TKD mutations. Gilteritinib will be given orally according to the assigned phase I dose cohort starting day 6 until day 19. Participants will be given the daily dose with water as at the same time each morning. Gilteritinib should be taken at least 2 hours after or 1 hour before consuming food.
48625769|NCT05330377|DRUG|Cladribine|Cladribine is given intravenously at a dose of 5 mg/m2 I.V. over 2 hours once per day on days 1 to 5.
47937216|NCT02704910|BEHAVIORAL|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
47937217|NCT03158714|BEHAVIORAL|Couples Connecting Mindfully|
47937218|NCT03158714|BEHAVIORAL|ELEVATE|
47937219|NCT02886065|DRUG|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
48465763|NCT05939102|COMBINATION_PRODUCT|v-prep combined with RMGIC for bracket bonding|prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
48625770|NCT05330377|DRUG|Cytarabine|Cytarabine is given intravenously at a dose of 2,000 mg/m2 I.V. over 4 hours once per day on days 1 to 5, given second, 2 hours after cladribine.
48625771|NCT05330377|DRUG|Filgrastim|Filgrastim (GCSF) or biosimilar, will be given at a dose of 300 mcg S.C. once per day on days 0 to 5, started 24 hours prior to chemotherapy. If WBC is \> 20 × 109/L on day 0, the filgrastim dose on day 0 will be omitted.
48625772|NCT05330377|DRUG|Mitoxantrone|Mitoxantrone is given intravenously at a dose of 10 mg/m2 I.V. over 2 hours once per day on days 1 to 3.
48625773|NCT02487836|DEVICE|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
48625774|NCT02264041|DRUG|Cilobradine, low dose|
48100333|NCT06085820|BEHAVIORAL|Experimental (birth ball)|"It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions."
48100334|NCT06085820|BEHAVIORAL|Experimental (birth dance)|"Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman."
47937220|NCT02886065|DRUG|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
48100335|NCT03834493|BIOLOGICAL|Pembrolizumab|IV infusion
47937221|NCT02886065|DRUG|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
47937222|NCT02886065|BIOLOGICAL|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
47937223|NCT03207334|DRUG|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
47937224|NCT03207334|DRUG|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
47937225|NCT01083927|PROCEDURE|Rotational Narrow Strip Conjunctival Graft|Surgical technique
47937226|NCT01083927|PROCEDURE|Full Conjunctival Graft|Surgical technique
47937227|NCT01150331|DRUG|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
47937228|NCT01150331|DRUG|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
48100336|NCT03834493|DRUG|Enzalutamide|Capsules/Tablets
48100337|NCT03834493|DRUG|Placebo|IV infusion
48100338|NCT04944693|OTHER|Different ATS values.|"Observational, different ATS values were measured on MRI images and were regarded as interventions for different cohorts."
48100339|NCT03211325|PROCEDURE|Biopsy|
48100340|NCT02309567|OTHER|Blood Collection|
48100341|NCT05108896|DIAGNOSTIC_TEST|3-Screenings Protocol|The 3-Screenings Protocol is a modified bedside swallow exam (BSE) consisting of a study developed five-item decision tree algorithm including voice quality assessment and a 2-ounce water consistency assessment, the Yale Swallow Test, with a scored 3-ounce Water Swallow Test (3-WST), and the Toronto Bedside Swallowing Screening Test (TOR-BSST).
48465764|NCT05939102|COMBINATION_PRODUCT|Conventional bracket bonding technique|prepare the tooth with acid-etch, then bond a bracket using resin composite
48465765|NCT03803267|OTHER|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
48282334|NCT05738863|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
48282335|NCT05738863|DEVICE|Sham rTMS Protocol|"It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
48282336|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/p|solution for intramuscular injection, 0.5 ml
48282337|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/o/p|solution for intramuscular injection, 0.5 ml
48465766|NCT03803267|OTHER|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
48465767|NCT03803267|DRUG|Propofol|Propofol (2 mg/kg)
48465768|NCT03803267|DRUG|Fentanyl NCS|Fentanyl (1µg/Kg)
48465769|NCT03803267|DRUG|Atracurium Injectable Product|atracurium (0.5mg/kg)
48625775|NCT02264041|DRUG|Cilobradine, high dose|
48282338|NCT05308212|BIOLOGICAL|Ultrix [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
48282339|NCT02491541|BIOLOGICAL|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28"
48625776|NCT02264041|DRUG|Itraconazole|
48625777|NCT01019551|DRUG|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
47937229|NCT01315236|DRUG|Liposomal amikacin for inhalation (LAI)|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~* Subjects can continue with 84 additional days of dosing in the open label extension."
48282340|NCT02491541|BIOLOGICAL|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28"
48465770|NCT03803267|OTHER|Endotracheal intubation|endotracheal intubation
48465771|NCT03803267|DRUG|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
47937230|NCT01315236|DRUG|placebo|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are similar to LAI.~* Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
48465772|NCT03803267|DRUG|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
47937231|NCT00019110|BIOLOGICAL|human papillomavirus 16 E7 peptide|
47937232|NCT00019110|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
47937233|NCT03125291|BEHAVIORAL|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
47937234|NCT03055858|DEVICE|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
47937235|NCT05598827|OTHER|Tik Tok|The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
48465773|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
48625778|NCT01019551|BIOLOGICAL|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
48625779|NCT01324752|DRUG|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
48625780|NCT01324752|DRUG|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
48625781|NCT01324752|DRUG|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
48625782|NCT04691232|BIOLOGICAL|Regulatory T cells|Autologous, ex vivo expanded, regulatory T cells
48625783|NCT03399292|DRUG|Cationorm MD sine eye drops|studyparticipants receive lipidbased eye drops once only in the study eye
48625784|NCT00688779|DRUG|AZD8848|Concentrate for nasal spray,solution 60 mg/g
48100342|NCT05108896|DIAGNOSTIC_TEST|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
48465774|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
48100343|NCT05108896|DIAGNOSTIC_TEST|Tracheal Ultrasound|Ultrasound imaging of the trachea, measuring tracheal diameter and endotracheal tube (ETT) size ratio within 72 hours prior to extubation
48282341|NCT05021224|BEHAVIORAL|Rapidly prototype and test strategies|We will generate strategies for facilitating treatment initiation that address barriers and leverage facilitators, in partnership with a team of experts in behavioral science and implementation science. We will favor simple, established strategies with freely available resources (e.g., Caring Contacts templates) to promote scalability, but will also consider other potential strategies as indicated. We will explore both low- (e.g., manualized text messaging) and high-tech (e.g., electronic health record integrated patient messaging) strategies to maximize relevance across contexts. Next, prototype-strategy designs will be validated through rapid-cycle tests in this real world context and in a manner that is inexpensive and allows us to fail fast and learn quickly. After testing a given implementation strategy, the team will debrief and decide whether to refine or adjust it.
48465775|NCT00027417|DRUG|Liothyronine sodium/triiodothyronine|
48465776|NCT00027417|PROCEDURE|Cardiopulmonary bypass and cardiac surgery|
48465777|NCT05548920|OTHER|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
48465778|NCT05548920|OTHER|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
48465779|NCT03268096|DEVICE|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
48465780|NCT05187325|OTHER|no intervention|there is no intervention
48465781|NCT03161353|DRUG|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
48465782|NCT03161353|DRUG|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
48465783|NCT03161353|DRUG|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
48625785|NCT00688779|DRUG|Placebo|
48625786|NCT04711577|BEHAVIORAL|Track clinician-determined symptoms|Participants will track clinician-determined symptoms
48625787|NCT04711577|BEHAVIORAL|Track clinician-determined and self-determined symptoms|Participants will track clinician-determined symptoms and a self-determined symptom
48100344|NCT04766437|DRUG|Prasugrel 10mg|Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
48100345|NCT04766437|DRUG|Ticagrelor 90mg|Twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.
48625788|NCT00158457|DRUG|Tenofovir (TDF)|
48625789|NCT00158457|DRUG|Emtricitabine (FTC)|
48100346|NCT05848141|BEHAVIORAL|Exercise training|This is a single site center-based supervised exercise intervention.
48100347|NCT01234532|DRUG|entinostat|orally
48100348|NCT01234532|DRUG|anastrozole|Given PO
48100349|NCT01234532|OTHER|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
48625790|NCT00158457|DRUG|Efavirenz (EFV)|
48625791|NCT02941003|DEVICE|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
48625792|NCT02941003|OTHER|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
48625793|NCT02941003|DEVICE|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
48625794|NCT04976257|PROCEDURE|Angiogram|Undergo angiogram
48282342|NCT03415230|OTHER|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
48282343|NCT03415230|OTHER|Sham massage|Sham massage involves only light touch massage in a non systematic way
48282344|NCT00868387|OTHER|energy-restricted, CHO-restricted diet|carbohydrate content of the diet \< 40% Frequency: daily Duration: 12 months
48282345|NCT00868387|OTHER|energy-restricted, CHO-rich diet|carbohydrate content of diet \> 55% Frequency: daily Duration: 12 months
48465784|NCT03161353|DRUG|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
48465785|NCT03161353|DRUG|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
48465786|NCT03161353|DRUG|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
48465787|NCT03673592|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
48465788|NCT04532996|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in narrative coherence and affective dysregulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
48465789|NCT06289296|OTHER|Fatty acid intake in lean and obese males|Acute and chronic intake of MCT and LCT
48465790|NCT05909241|DRUG|BA1202|"BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B."
48465791|NCT04735887|OTHER|SADL-eM|The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
48282346|NCT04351659|OTHER|Blood donation from convalescent donor|Donation of 1 unit of blood or leukapheresis
48282347|NCT04445662|BEHAVIORAL|Financial incentives|Escalating financial rewards for saliva cotinine levels \<30 ng/mL, assessed 10 times over 12 weeks
48465792|NCT01421862|GENETIC|DNA methylation analysis|
48465793|NCT01421862|GENETIC|RNA analysis|
48465794|NCT01421862|GENETIC|gene expression analysis|
48465795|NCT01421862|GENETIC|microarray analysis|
48282348|NCT04445662|DRUG|Varenicline|"* Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement"
48282349|NCT04445662|BEHAVIORAL|Tobacco coaching|5 one-on-one tobacco cessation coaching sessions over 12 weeks
48465796|NCT01421862|GENETIC|mutation analysis|
48465797|NCT01421862|GENETIC|nucleic acid sequencing|
48465798|NCT01421862|OTHER|laboratory biomarker analysis|
48282350|NCT03486314|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
48282351|NCT03486314|DRUG|Rifampin|Rifampin capsules.
48282352|NCT03486314|DRUG|Docetaxel|Docetaxel intravenous infusion.
48282353|NCT03486314|DRUG|Carboplatin|Carboplatin intravenous infusion.
48282354|NCT03486314|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
48282355|NCT06071312|BIOLOGICAL|single FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
48625795|NCT04976257|PROCEDURE|Catheterization|Undergo prostatic arterial catheterization
48282356|NCT06071312|BIOLOGICAL|sequential FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
48282357|NCT01938859|DRUG|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
48282358|NCT01938859|DRUG|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
48282359|NCT01938859|DRUG|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
48282360|NCT06185920|OTHER|Description of severe infection|Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
48282361|NCT03007277|OTHER|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
48282362|NCT05877677|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
48282363|NCT05877677|DIETARY_SUPPLEMENT|Polygonatum kingianum extract drink|consume 1 bottle per day
48282364|NCT00892437|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
48625796|NCT04976257|DRUG|Gallium Ga-labeled PSMA-11|Given IV and IA
48625797|NCT04976257|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48625798|NCT00637897|DRUG|docetaxel|
48625799|NCT00637897|DRUG|ixabepilone|
48465799|NCT01220960|OTHER|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
48465800|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)|iTBS delivered to vmPFC for active treatment of spider phobia.
48625800|NCT00637897|DRUG|paclitaxel|
48625801|NCT00637897|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
48625802|NCT00637897|DRUG|paricalcitol|
48465801|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), vertex|iTBS delivered to vertex for placebo treatment of spider phobia.
48100350|NCT01234532|PROCEDURE|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
48465802|NCT00613041|PROCEDURE|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
48465803|NCT06459960|GENETIC|Hydrotherapy|Heated pool (32°C); Convention rehabilitation + Hydrotherapy
48465804|NCT06459960|GENETIC|Convention|Convention rehabilitation only
48465805|NCT06465979|BEHAVIORAL|Speech Manipulation|"The acoustic properties of speech sounds will be modified in two main ways. The first way is to introduce gradual changes to the perceived articulation of the target speech sound, such as changing from sh to s by various types of signal processing and filtering. The second type of change is to modify acoustic properties of the sounds that immediately precede the target speech sound, such as changing the speaking rate or its frequencies composition."
48465806|NCT06273709|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|(Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
48465807|NCT00950716|BEHAVIORAL|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
48625803|NCT01669850|DEVICE|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
48625804|NCT01669850|PROCEDURE|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
48625805|NCT06302036|OTHER|EFT|EFT
48625806|NCT02847767|PROCEDURE|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
48625807|NCT05252975|OTHER|Setup and Imaging for at CT radiation planning|Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
48625808|NCT00114777|DRUG|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
48625809|NCT00114777|DRUG|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
48625810|NCT00114777|DRUG|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
48100351|NCT02491931|DIETARY_SUPPLEMENT|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
48100352|NCT04808635|OTHER|no intervention, this is a cross sectional questionnaire based study.|no intervention, this is an observational cross sectional study
48100353|NCT03855709|DIAGNOSTIC_TEST|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
48100354|NCT06092931|DRUG|DC-806|Oral tablets
48100355|NCT06092931|DRUG|Midazolam|Oral syrup
48100356|NCT06092931|DRUG|Repaglinide|Oral tablets
48100357|NCT06092931|DRUG|Digoxin|Oral tablets
48100358|NCT06092931|DRUG|Rosuvastatin|Oral tablets
48100359|NCT02611232|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
48100360|NCT02611232|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
48100361|NCT05966389|OTHER|No interventions|No interventions
48100362|NCT00727584|RADIATION|radiation therapy|Patients undergo external beam radiotherapy
48100363|NCT01802229|PROCEDURE|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
48625811|NCT04270773|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|Vaccine administrated
48625812|NCT06349954|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
48625813|NCT06349954|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
48625814|NCT00869596|DRUG|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
48625815|NCT00869596|DRUG|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
48625816|NCT00869596|DRUG|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
48625817|NCT00869596|DRUG|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
48282365|NCT00892437|DRUG|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
48625818|NCT00446277|PROCEDURE|cataract surgery|
48282366|NCT00892437|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
48282367|NCT00892437|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
48465808|NCT00950716|BEHAVIORAL|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
48625819|NCT01379209|DRUG|RGI-2001|A single administration of RGI-2001 on Day 0 post AHSCT.
48625820|NCT01379209|DRUG|Calcineurin Inhibitors|GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
48625821|NCT01379209|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|According to institutional guidelines.
48465809|NCT03334045|RADIATION|PET/MR scans|Observations of glucose metabolism and dopamine binding potential
48465810|NCT04716829|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot allows the adaptation of movements during rehabilitation sessions according to the individually generated strength.
48282368|NCT00892437|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
48625822|NCT01379209|DRUG|Conditioning Regimen|Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
48282369|NCT00892437|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
48282370|NCT01241786|DRUG|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
47937236|NCT00522964|BEHAVIORAL|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
47937237|NCT03401853|OTHER|Laboratory Biomarker Analysis|Correlative studies
47937238|NCT03401853|BIOLOGICAL|Pembrolizumab|Given IV
47937239|NCT03401853|BIOLOGICAL|Rituximab|Given IV
48282371|NCT01241786|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
48282372|NCT05981950|DIAGNOSTIC_TEST|artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
48282373|NCT02248376|DRUG|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
48282375|NCT03959189|DRUG|ERX-963|Active medicine
48282376|NCT03959189|DRUG|Placebo|Comparator
48282377|NCT04960891|DRUG|Tebentafusp|Concentrate solution for intravenous infusion
48282378|NCT06528431|DRUG|Clinical tapering strategy|Clinical Tapering strategy : Adalimumab injections will be progressively spaced out according to DAS28 assessment every 3 months
48282379|NCT06528431|DRUG|Step Wedge trial|Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
48465811|NCT05788250|PROCEDURE|Subacromial spacer implantation|A biodegradable balloon implanted arthroscopically between the acromion and humeral head with tenotomy of long head of biceps.
48465812|NCT05788250|PROCEDURE|Rotator cuff repair|Rotator cuff repair with tenotomy of long head of biceps.
48625823|NCT01379209|PROCEDURE|Allogeneic Bone Marrow Transplantation|According to institutional guidelines
48625824|NCT01379209|DRUG|Methotrexate|
48625825|NCT01379209|DRUG|Mofetil Mycophenolate|
48625826|NCT01379209|DRUG|sirolimus|Administered for GVHD prophylaxis as per institutional guidelines
48625827|NCT01384409|DRUG|KW-3357|Intravenous infusion once a day
48625828|NCT03869437|DRUG|Cefiderocol|2 grams intravenously administered over 3 hours every 8 hours for a period of 5 to 14 days (dosage adjustment is necessary based on renal function).
48625829|NCT03869437|OTHER|Best Available Therapy|Standard of care was determined by the investigator
48625830|NCT00433537|DRUG|bortezomib|Given IV
48625831|NCT00433537|BIOLOGICAL|rituximab|Given IV
48625832|NCT00433537|DRUG|cyclophosphamide|Given IV
48625833|NCT00433537|DRUG|doxorubicin hydrochloride|Given IV
48625834|NCT00433537|DRUG|vincristine|Given IV
48625835|NCT00433537|DRUG|dexamethasone|Given IV
48625836|NCT00433537|BIOLOGICAL|filgrastim|Given SC
48625837|NCT00433537|BIOLOGICAL|pegfilgrastim|Given SC
48625838|NCT00433537|PROCEDURE|Autologous stem cell transplantation (ASCT)|
48625839|NCT00807872|BIOLOGICAL|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
48625840|NCT05823454|DRUG|Different drug dosage|Choice of Anesthesia
48282380|NCT05321186|PROCEDURE|minimally invasive spinopelvic fixation|"Bilateral percutaneous L4 and L5 pedicle screws will be placed under fluoroscopic guidance with Jamshidi needles, and these were will also be used the iliac fixation via percutaneous S2 alar iliac screws.~Cases presenting with significant instability, minimally invasive Transforaminal lumbar interbody fusion (MIS-TLIF) will be performed. Additionally, in cases with neurological deficit, posterior decompression will be performed."
48282381|NCT00683943|DRUG|Lithium Carbonate|
48465813|NCT02556853|DEVICE|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
48465814|NCT02556853|OTHER|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
48465815|NCT02297230|RADIATION|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
48465816|NCT02297230|DRUG|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
48282382|NCT04751643|OTHER|Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|"Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation"
48465817|NCT02297230|DRUG|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
48625841|NCT00562328|BIOLOGICAL|Alemtuzumab|"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."
48282383|NCT04751643|OTHER|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
48282384|NCT04490057|DRUG|Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler|Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
48282385|NCT04490057|DRUG|Varenicline or bupropion|Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
48625842|NCT00562328|BIOLOGICAL|Rituximab|"Weeks 2-5:~375 mg/m\^2 by IV once weekly"
47937240|NCT03401853|BIOLOGICAL|Obinutuzumab|Given IV
47937241|NCT03858231|DRUG|Norco 5Mg-325Mg Tablet|1 tablet up to 4 times per day for 7 days
48282386|NCT04490057|BEHAVIORAL|Contingency Management|Participants will be financially rewarded for abstinence to tobacco.
48282387|NCT02975128|DEVICE|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
48282388|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
48282389|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
48625843|NCT00562328|BIOLOGICAL|Sargramostim|"Week 1-6:~250 mcg subcutaneously three time as week"
48625844|NCT03442062|OTHER|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
47937242|NCT03858231|DRUG|Ibuprofen 600 mg|1 tablet up to 4 times per day for 7 days
47937243|NCT03858231|DRUG|Acetaminophen 325Mg Tab|1 tablet up to 4 times per day for 7 days
47937244|NCT01467427|DRUG|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
47937245|NCT01186497|DRUG|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
48625845|NCT03442062|OTHER|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
48282390|NCT03306537|DEVICE|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
48282391|NCT02886104|PROCEDURE|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
48625846|NCT03442062|OTHER|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
48625847|NCT00068848|BEHAVIORAL|Quick start oral contraceptive initiation|
48625848|NCT03568617|DEVICE|rTMS|The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
48625849|NCT00855478|DEVICE|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
48282392|NCT02886104|DEVICE|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
48625850|NCT04027621|DEVICE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
48625851|NCT04027621|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
48282393|NCT02649634|BEHAVIORAL|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
48282394|NCT02649634|BEHAVIORAL|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
48282395|NCT04108767|BEHAVIORAL|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
48625852|NCT05900245|OTHER|Index of consciousness+Anesthetic（propofol）+Muscle relaxant（Succinylcholine）|EEG monitoring is performed before induction of electrical shock anesthesia（propofol1.5mg/kg+Succinylcholine1mg/kg）, and the timing of electrical stimulation is determined based on the level of consciousness index 1 displayed on the EEG.
48625853|NCT00818844|DRUG|Nepafenac 0.1%|NSAID
48625854|NCT00818844|OTHER|BSS|BSS
48625855|NCT00315575|PROCEDURE|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
48625856|NCT00774748|DEVICE|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
48625857|NCT01088893|DRUG|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
48625858|NCT06208631|BEHAVIORAL|Gait retraining|Changing muscle coordination while walking
48625859|NCT02650557|PROCEDURE|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
48625860|NCT04841174|OTHER|Abdominal massage|The effect on gastric problems by applying abdominal massage to eligible participants in the study will be examined.
48625861|NCT01197027|BEHAVIORAL|Standard counseling|Standard HIV counseling
48625862|NCT05183620|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
48625863|NCT01699828|DRUG|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
48625864|NCT01699828|DRUG|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
48625865|NCT05827744|OTHER|Isokinetic evaluations|Peak torque and total amount of work of hip flexors and extensors will be determined by the Cybex 6000 model computer-aided isokinetic system.
47937246|NCT01186497|DRUG|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
48625866|NCT05827744|OTHER|Ultrasonographic evaluations|Ultrasonographic evaluations will be performed with a 5-12 MHz linear probe (Logic e portable; GE Healthcare, China). The thicknesses of the hip flexor (psoas major) and extensor (gluteus maximus) muscles will be measured while the patient is in the prone position, in accordance with the literature.
48625867|NCT02746939|BEHAVIORAL|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
48625868|NCT00258661|PROCEDURE|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
48625869|NCT00258661|PROCEDURE|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
48625870|NCT00395382|DRUG|Alendronate|70mg weekly orally
48625871|NCT00395382|DRUG|Placebo|weekly orally
48625872|NCT02858258|DRUG|R-CHOP/R-DHAP|Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
48625873|NCT02858258|DRUG|Ibrutinib (Induction)|Ibrutinib: only in cycle 1,3,5 on Day 1-19
48625874|NCT02858258|DRUG|ASCT conditioning|"ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)"
48625875|NCT02858258|DRUG|Ibrutinib (Maintenance)|Ibrutinib (Maintenance), daily 560 mg for 2 years;
48625876|NCT02019251|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
48625877|NCT02019251|DEVICE|MRI|
48625878|NCT04955925|DIAGNOSTIC_TEST|Ultrasound examination of the optic nerve sheath diameter|The optic nerve sheath diameter is examined using ultrasonography.
48625879|NCT04175756|DEVICE|Caiman 5 articulating Maryland|Laparoscopic colorectal surgery
48625880|NCT06109688|DIETARY_SUPPLEMENT|Bovine Lactoferrin|Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
48625881|NCT06109688|DIETARY_SUPPLEMENT|placebo|Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
48625882|NCT02842021|DRUG|S2G6T-1|Twice a day topical cream
48625883|NCT02842021|DRUG|S2G6T-2|Twice a day topical cream
48625884|NCT02842021|DRUG|S2G6T-3|Twice a day topical cream
48625885|NCT02842021|DRUG|S2G6T-4|Twice a day topical cream
48625886|NCT05206539|DRUG|Self-assembling peptide (P11-4)|"Prior to application, teeth are isolated by cotton rolls and gently air dried. The surface of the lesion is conditioned with a 2% sodium hypochlorite solution for 20 s and then rinse with water. Application of 35% phosphoric acid etching gel for 20 sec followed by rinsing with water-air spray for 30 sec. Drying the surface with compressed oil-free air for 60 sec. Curodont Repair is dissolve in 0.05 ml of distilled water and applied to the surface and allowed to work for about 5 min.~Participants will receive oral hygiene instructions."
48625887|NCT05206539|DRUG|CPP-ACFP|"Prior to application, teeth are isolated by cotton rolls and gently air dried. Application of fluoride varnish with a brush applicator on the surface of the teeth for 5 minutes. Patients is advising not to brush their teeth or chew food for at least 4 h after treatment.~Participants will receive oral hygiene instructions"
48625888|NCT05206539|DRUG|Resin infiltration|The validated ICON Vestibular (DMG) infiltration lesion infiltration protocol is applied. Icon Etch (DMG) etching gel containing 15% hydrochloric acid is applied for 120 seconds using an applicator. It is then removed by rinsing thoroughly with water-air spray for 30 seconds. Then follows application of pure alcohol - Icon Dry (DMG) for 30 seconds for complete drying of the lesion and additional drying compressed oil-free air for 40 sec. Application of Icon Infiltrant (DMG) using a microapplicator allows it to penetrate for 3 minutes, during which, if necessary, it is reapplied several times. Excess material is removed with dry microbrushes and followed by light curing for 40 seconds. Re-applying of the infiltrate for 1 minute, removal of excess material, light curing for 40 seconds. Participants will receive oral hygiene instructions
48625889|NCT05206539|OTHER|Control Group, No Treatment|Everyday oral hygiene instructions Subjects will receive non-prescription fluoride toothpaste (1400 ppm Fluoride, Elmex junior) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate and rinse.
48625890|NCT00229216|DRUG|Tinidazole|
48625891|NCT03406468|RADIATION|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
48625892|NCT05504278|DRUG|pemetrexed|500mg/m\^2, Q3W, day1, i.v.
48625893|NCT05504278|DRUG|cis-platinum|75mg/m\^2, Q3W, day1, i.v.
48625894|NCT05504278|DRUG|Sintilimab|200mg, Q3W, day1, i.v.
48625895|NCT05504278|DRUG|IBI351|recommended dose, po
48625896|NCT05504278|DRUG|carboplatin|AUC=5, Q3W, day1, i.v.
48625897|NCT05150288|OTHER|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
48625898|NCT03970512|DEVICE|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
48625899|NCT00433290|DRUG|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
48625900|NCT00433290|DRUG|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
48625901|NCT00985374|DRUG|RAD001|5mg or 10mg po daily
48625902|NCT00985374|DRUG|RG1507|16mg/kg iv every 3 weeks
48625903|NCT02636452|OTHER|cardiopulmonary exercise test|
48625904|NCT05594199|BEHAVIORAL|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
48625905|NCT02132468|DRUG|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
48625906|NCT00444249|PROCEDURE|White Alcon IOL|Implantation of white Alcon IOL
48625907|NCT00444249|PROCEDURE|Yellow Alcon IOL|Implantation of yellow Alcon IOL
48625908|NCT00444249|PROCEDURE|White Hoya IOL|Implantation of white Hoya IOL
48625909|NCT00444249|PROCEDURE|Yellow Hoya IOL|Implantation of yellow Hoya IOL
48465818|NCT02297230|DRUG|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
47937247|NCT01186497|DRUG|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
48100364|NCT01802229|PROCEDURE|Fascial suture|The port-site hole is closed with simple suture of the fascia
48100365|NCT03807102|BIOLOGICAL|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
48465819|NCT00879684|BIOLOGICAL|CVX-060|Weekly, intravenous dose
48465820|NCT01237080|DEVICE|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
48465821|NCT01237080|DEVICE|Fastrach|The Fastrach is an intubation laryngeal mask.
48465822|NCT02828280|DEVICE|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
48465823|NCT02828280|DEVICE|Traditional mask|A traditional air inflated facemark used to ventilate patients
48465824|NCT01656876|BEHAVIORAL|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
47937248|NCT01186497|DRUG|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
47937249|NCT01186497|DRUG|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
47937250|NCT04563676|BIOLOGICAL|blood test|covid19 infected patient will have a blood test in order to make an autoimmune assessment (antinuclear antibodies, soluble nuclear anti-antigen, ANCA, antiphospholipid antibodies, FT3, FT4 , TSH, antithyroid antibodies, ACTH cortisol, and creation of a serotheque).
47937251|NCT00896636|PROCEDURE|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
47937252|NCT00896636|OTHER|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
48100366|NCT06123585|OTHER|Invisalign® SmileView™|Pretreatment smiles were captured using the Invisalign® SmileView™ to simulate their new smiles before treatment was started.
48100367|NCT06123585|OTHER|Invisalign aligners|Patients were then treated using upper and lower Invisalign aligners with average treatment time of 12±3 months.
48100368|NCT06630910|PROCEDURE|Pancreaticojejunostomy without stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall without stenting or omental patch.
48282396|NCT04619407|DIAGNOSTIC_TEST|Nasopharyngeal swab|SARS-CoV-2 PCR
48282397|NCT04619407|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
48465825|NCT01656876|OTHER|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
48625910|NCT02193893|OTHER|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
48625911|NCT02193893|OTHER|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
48625912|NCT04002271|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. For induction, remifentanil 1mcg/kg and rocuronium 0.6 mg/kg will be given intravenously prior to intubation. Sevoflurane will not be given. Air and oxygen will be given, and FiO2 will be kept at between 35-50%. Similarly, to the GAS group, remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min and titrated according to the haemodynamic parameters stated for the GAS group. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. TCI propofol and remifentanil will be switched off at the end of the procedure. Reversal of muscle relaxation will be achieved as for the GAS group.
48625913|NCT04002271|DRUG|Sevoflurane|Patients in the GAS group will be induced with intravenous bolus propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6mg/kg for induction of general anaesthesia and intubation of patient. General anesthesia monitoring will be used. Maintenance of general anesthesia to be provided using sevoflurane, together with air and oxygen. FiO2 will be maintained between 35-50%. Bispectral (BIS) monitoring will be applied and level of anaesthesia will be maintained at a BIS value of 40-60. Remifentanil infusion will be given at between 0.1-0.2mcg/kg/min, to be titrated to maintain mean arterial blood pressure within 20% of baseline (blood pressure in ward before surgery as baseline) and heart rate between 45 to 100 bpm. Morphine sulphate to be given at a dose of 0.1mg/kg before skin incision. Sevoflurane and remifentanil infusion will be switched off at the end. Reversal of muscle relaxation to be achieved using intravenous neostigmine 50mcg/kg and atropine 20mcg/kg after the operation.
48625914|NCT04002271|PROCEDURE|Spinal anaesthesia|Patients in the SA group will receive intrathecal (L4-5, or L3-4 if failed at L4-5) administration of 2.2-2.4ml 0.5% heavy bupivicaine using a 25G Whitacare needle. No intrathecal opioid will be given during the procedure. Light sedation will be given during surgery with target-controlled infusion of propofol using the Marsh effect site model (0.3 -1 mcg/ml). Supplemental oxygen 2L/min will be given via the nasal cannula.
48625915|NCT02805998|BEHAVIORAL|Web-based CBT-I|
48625916|NCT02805998|OTHER|Treatment as Usual|
48625917|NCT03232944|DEVICE|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
48625918|NCT00180453|DEVICE|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
48625919|NCT00180453|DEVICE|Coronary artery stent placement|Coronary artery stent placement
48625920|NCT01056575|DRUG|OC000459|OC000459 100mg tablet, twice daily
48625921|NCT03033628|DEVICE|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
48465826|NCT01656876|BEHAVIORAL|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
48625922|NCT03033628|DEVICE|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
48625923|NCT05447832|DEVICE|Lung function monitoring equipment at home - 2 weeks|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once daily for 2 weeks.
48625924|NCT05447832|DEVICE|Lung function monitoring equipment at home - 4 months|The parent/carer setup the lung function monitoring equipment (Ventica®), and placed the WheezeScan® device on the child's chest at home before the child goes to sleep. This is performed once weekly for 4 months.
48625925|NCT05447832|DIAGNOSTIC_TEST|Inflammation and remodelling from clinical indicted bronchoscopy|For patients who are undergoing clinically indicated bronchoscopy, consent will be obtained to use any surplus clinical samples for this study. The samples to be collected are broncho-alveolar lavage and endobronchial biopsies. Both of these are taken from the airways during clinical bronchoscopy.
48625926|NCT03017261|DEVICE|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
48625927|NCT03399344|OTHER|MRI|In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
48625928|NCT03657953|OTHER|surgical approach|
48465827|NCT05863845|DRUG|Venetoclax|100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
48465828|NCT05863845|DRUG|Carmustine|300mg/m2 day -7, Given IV
48625929|NCT03734094|DEVICE|Ceramic barrier|The use of a ceramic barrier to induce bone formation during GBR
48625930|NCT03734094|DEVICE|Titanium Mesh|The use of a titanium mesh to induce bone formation during GBR
48625931|NCT03854227|DRUG|PF-06939999 dose escalation|PF-06939999 orally at escalating doses on a continuous basis
48465829|NCT05863845|DRUG|Cytarabine|100mg/m2/d, day -6 to day -3, Given IV
48465830|NCT05863845|DRUG|Etoposide|200mg/m2/d, day -6 to day -3, Given IV
48465831|NCT05863845|DRUG|Melphalan|140mg/m2, day -2, Given IV
48465832|NCT05863845|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
48625932|NCT03854227|DRUG|PF-06939999 monotherapy|PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
48625933|NCT03854227|DRUG|PF-06939999 in combination with docetaxel|PF-06939999 orally on a continuous basis in combination with docetaxel
48625934|NCT04095013|DRUG|Bupivacaine, fentanyl|Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
48625935|NCT04095013|DRUG|Bupivacaine, dexmedetomidine|Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
48465833|NCT04789733|OTHER|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
48465834|NCT04789733|OTHER|Routine pressure management|Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
48465835|NCT00535353|DRUG|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
48625936|NCT01129128|BIOLOGICAL|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
48625937|NCT01129128|BIOLOGICAL|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
48625938|NCT01129128|BIOLOGICAL|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
48625939|NCT03113955|DEVICE|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
48282398|NCT03949673|DRUG|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
48625940|NCT01932463|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
48282399|NCT03949673|DRUG|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
48625941|NCT01111669|DRUG|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
48625942|NCT01111669|DRUG|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
48625943|NCT03390660|OTHER|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
48625944|NCT01222351|DRUG|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
48282400|NCT03949673|DRUG|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
48625945|NCT00494312|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
48625946|NCT00494312|DRUG|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
48625947|NCT01402466|BEHAVIORAL|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
48282401|NCT03949673|DRUG|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
48625948|NCT01402466|BEHAVIORAL|Project Bridge|Arm 2
48625949|NCT05122819|PROCEDURE|Mandibular Molar Extraction Under Local Anesthesia|"Local Anaesthetic to be used: 2% Lidocaine in 1.8 ml cartridge (regularly used for dental anaesthesia regardless of the technique).~Pain on injection and local anaesthesia success will be checked by using numeric pain rating scale (NPRS)."
48625950|NCT00778414|DRUG|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
48465836|NCT00535353|DRUG|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
48465837|NCT01909115|DRUG|1000 IU of Vitamin D3|1000 IU of Vitamin D will be administered in capsule form, once daily.
48625951|NCT00918307|DRUG|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
48282402|NCT03949673|DRUG|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
48625952|NCT00918307|DRUG|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
48625953|NCT03346317|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
48625954|NCT03346317|PROCEDURE|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
48465838|NCT01909115|DRUG|4000 IU of Vitamin D3|4000 IU of Vitamin D will be administered in capsule form, once daily.
48465839|NCT00235560|DRUG|rapamycin|sirolimus
48465840|NCT06018064|DEVICE|Prone Positioner|An innovative device to allow for infants to be supported while in the prone position
48625955|NCT03346317|DRUG|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
48625956|NCT01350973|DRUG|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
48625957|NCT01350973|DRUG|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
48625958|NCT01774370|DRUG|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
48625959|NCT06111625|DRUG|blinatumomab|Blinatumomab was administered via a peripherally inserted central catheter (PICC) with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day, with a total dose of 175 μg, infused over 5 to 10 days. To mitigate the risk of cytokine release syndrome (CRS), dexamethasone at a dose of 20 mg was administered 12 hours before the onset of blinatumomab infusion.
47937253|NCT01163032|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
47937254|NCT01163032|DRUG|Placebo|Placebo capsules, PO daily for 6 months
47937255|NCT04325984|DRUG|Dexamethasone|To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
47937256|NCT00494845|BEHAVIORAL|Mindfulness|8-week mindfulness program will be compared to an education control group.
47937257|NCT00494845|BEHAVIORAL|Control: Health Education Class|8-week education program
48282403|NCT00212914|BEHAVIORAL|Reminder letter|
48465841|NCT02681588|PROCEDURE|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
48625960|NCT01942512|DEVICE|Endovascular treatment of intracranial aneurysm|
48625961|NCT04093284|DEVICE|The needle-free jet injector|Continuous insulin therapy for 9 days
48465842|NCT04985838|BEHAVIORAL|HEADS: UP (Helping Ease Anxiety and Depression)|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform. An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course. Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
48465843|NCT01954030|DRUG|CTO and Bevacizumab|
48625962|NCT00224796|DEVICE|V.A.C. ® System|
48625963|NCT02547935|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
48282404|NCT03417765|DRUG|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
48465844|NCT01954030|DRUG|CTO alone|
48465845|NCT01404962|BIOLOGICAL|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
48625964|NCT02547935|DRUG|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
48625965|NCT02547935|DRUG|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
48625966|NCT03331406|OTHER|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
48625967|NCT04832061|OTHER|Respiratory supports|The respiratory supports used in this patient population included conventional oxygen therapy (COT) via nasal cannula or face mask, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). NIV has three different methods, including high-flow nasal cannula (HFNC), bilevel positive airway pressure (BiPAP), and continuous positive airway pressure (CPAP).
48625968|NCT05428865|OTHER|correlation study|investigate the correlations between body mass index, spasticity, functional ability and isolated motor control in children with spastic diplegia.
48625969|NCT03121274|PROCEDURE|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
48625970|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily."
48625971|NCT04645108|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss|The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
47937258|NCT06142890|OTHER|No cooling (control)|Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.
48625972|NCT05909423|DRUG|Influenza vaccine|Intratumoral influenza vaccine treatment, administered via endoscopic procedure
47937259|NCT06142890|OTHER|Cooling with ceiling fan|Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
48100369|NCT06630910|PROCEDURE|Pancreaticojejunostomy with stenting and omental patch|A traditional pancreaticoduodenectomy with pylorus preservation was performed on each patient. A pancreaticojejunostomy was created by double-layered, end-to-side, duct-to-mucosa anastomosis between the primary pancreatic duct and jejunal wall, a nelaton stent 6f was inserted into the pancreatic duct and jejunum of each patient receiving PJ. The larger omentum was separated longitudinally over an avascular zone, and one or two omental branches of the gastroepiploic arteries were preserved using pedicle omental flaps. The omental flap was pushed between the posterior surface of PJ and the portal vein, then wrapped over the anterior surface of PJ. The omentum was rolled up and secured with a few PDS sutures.
48100370|NCT00923676|DRUG|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
48100371|NCT00923676|DRUG|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
48100372|NCT00923676|DRUG|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
48100373|NCT06550193|DEVICE|Ultrasound-guided procedure using AR/VR technology|Participants will receive the intervention, which involves utilizing AR/VR technology during ultrasound-guided procedures (e.g., regional anesthesia, line placement). All participants will receive standard pre- and post-block or line care as they normally would for the ultrasound-guided procedure.
48100374|NCT00762658|DRUG|AN2728 Ointment, 5%|
48100375|NCT00762658|DRUG|AN2728 Ointment, 2%|
48100376|NCT00762658|DRUG|AN2728 Ointment, 0.5%|
48100377|NCT00762658|DRUG|AN2728 Ointment Vehicle|
48100378|NCT00762658|DRUG|Betnesol®-V Creme, 0.1%|
48100379|NCT00762658|DRUG|Protopic® Ointment, 0.1 %|
48100380|NCT04542148|DRUG|Sliding Scale Insulin|After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
48625973|NCT05909423|DRUG|Pembrolizumab|Single dose pembrolizumab treatment
47937260|NCT00583479|OTHER|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
47937261|NCT00583479|OTHER|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
47937262|NCT04144465|DRUG|NORADRENALIN|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
47937263|NCT04144465|DRUG|PHENYLEPHRINE|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
47937264|NCT03506867|BEHAVIORAL|Life skills, training, education and work/volunteer opportunities|Intervention arm will receive proactive and sustained access to enhanced education and socio-economic supports (e.g. volunteer and/or work opportunities).
48465846|NCT02463630|PROCEDURE|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
48465847|NCT02285491|DRUG|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
47937265|NCT03506867|BEHAVIORAL|Standard Care|Usual care will receive information on locally available services.
47937266|NCT06017544|PROCEDURE|PCI|The T2DM affected by AMI will be referred for receiving PCI.
48100381|NCT04542148|DRUG|Up-Titration of Home Insulin|After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
48465848|NCT02285491|DRUG|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
48465849|NCT01754935|DRUG|VX-509|50 mg oral tablet
48465850|NCT01754935|DRUG|VX-509 matching placebo|0 mg oral tablet
48465851|NCT04703751|DEVICE|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
48465852|NCT00716625|DRUG|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
48465853|NCT02340962|DRUG|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
48465854|NCT02340962|DRUG|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
48465855|NCT02340962|DRUG|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
48465856|NCT00753350|DEVICE|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
48465857|NCT05543551|OTHER|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
48100382|NCT04542148|DRUG|Continuous Insulin Infusion|After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
48465858|NCT05543551|OTHER|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
48465859|NCT03417427|DRUG|Decitabine and Ara-C|Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.
48465860|NCT03417427|DRUG|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
48465861|NCT04894630|OTHER|antimicrobial treatment|Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.
48465862|NCT03485027|DRUG|the rechallenge regimen|XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
48465863|NCT03105297|DEVICE|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
48465864|NCT03105297|OTHER|No strip|
48465865|NCT04893590|BEHAVIORAL|Fatigue self-management SMS intervention|Participants will set up an initial goal for the SMS intervention related to fatigue management, and prior to beginning the intervention they will be trained to use the SMS system. Participants will receive text messages each day, providing tips and techniques to help self-manage fatigue. Weekly the participants will be asked to provide feedback regarding their fatigue levels and their patient activation will be re-assessed at the halfway point of intervention.
48465866|NCT02178891|DEVICE|extra short implant|
48465867|NCT01944553|DEVICE|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease"
48465868|NCT00362635|DRUG|Clevudine|
48465869|NCT04726215|DRUG|[18F]F AraG|PET imaging agent specific to activated T cells
48465870|NCT00003700|BIOLOGICAL|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC \> 5,000 uL after nadir: 7 day minimum for Courses I \& IV
48465871|NCT00003700|DRUG|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I \& IV
48465872|NCT00003700|DRUG|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
48465873|NCT00003700|DRUG|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, \& 3: Courses II \& V
48465874|NCT00003700|DRUG|daunorubicin hydrochloride|80mg/sq m (pts\<60y/o)OR 60mg/sq m (pts =/\>60y/o) IV infusion over 5-10 min Days 1,2,\& 3: Courses I \& IV
48465875|NCT00003700|DRUG|leucovorin calcium|"Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose"
48465876|NCT00003700|DRUG|mercaptopurine|60mg/sq m/d PO every day Course VII
48465877|NCT00003700|DRUG|methotrexate|15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
48465878|NCT00003700|DRUG|prednisone|60mg/sq m/day PO Days 1-21 (pts\<60y/o) OR Days 1-7 (pts \>/= 60y/o) Courses I \& IV and Days 1-5 of ea 4 cycle in Course VII
48625974|NCT06295952|DRUG|Pasireotide|Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
48625975|NCT06295952|OTHER|SF-36 and HADS|Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
48625976|NCT03600129|PROCEDURE|Qadratus Lumborum Block|Bilateral, ultrasound - guided Quadratus Lumborum Block
48625977|NCT03600129|DRUG|30 milliliters of 0.375% Ropivacaine|30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
48625978|NCT03600129|DRUG|30 milliliters of 0.9% NaCl|30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
48625979|NCT05249920|DRUG|Edaravone Dexborneol Concentrated Solution for injection|Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.
48625980|NCT05249920|DRUG|Edaravone Dexborneol placebo|Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.
48100383|NCT04542148|DEVICE|Dexcom G6 Professional Continuous Glucose Monitor|Masked Dexcom G6 Pro devices will be worn for 10 days.
48100384|NCT01881919|DIETARY_SUPPLEMENT|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
48282405|NCT06276387|BEHAVIORAL|Mindfulness Program|Participants will receive eight weekly 2.5-hour group sessions and one day-long silent retreat, delivered online. Intervention content will include the MBSR program, which has been extensively studied with many different chronic conditions, and augmentations for individuals with rheumatic diseases. Each MBSR session will include meditation practices (e.g., sitting meditation, body scan, gentle hatha yoga, walking meditation, mindfulness of daily activities, awareness of pleasant and unpleasant events) and review of home practice. Participants will complete daily home practices for about 45 minutes per day and log their practice.
48282406|NCT05018286|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
48282407|NCT04375800|DRUG|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
48282408|NCT04375800|DRUG|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
48465879|NCT00003700|DRUG|vincristine sulfate|2 mg total IV infusion Days 1,8,15,\& 22 Courses I \& IV and Days 1, 8, \& 15 Courses III \& VI, and Day 1 of ea 4 wk cycle in Course VII
48465880|NCT00003700|DRUG|Allopurinol|300mg PO q day Days 1-14 Course I
48465881|NCT05453708|OTHER|Survey|One 15-20-minute survey
48465882|NCT02571933|OTHER|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
48465883|NCT02571933|OTHER|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
48465884|NCT02571933|OTHER|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
48465885|NCT00296270|BEHAVIORAL|Memory for truth|
48465886|NCT00919711|DRUG|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
48465887|NCT00919711|DRUG|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
48465888|NCT01274962|DRUG|FOLFOX|"* Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days."
48465889|NCT01274962|RADIATION|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
48465890|NCT04785911|DRUG|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
48465891|NCT04629170|DRUG|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
48465892|NCT04629170|DRUG|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
48465893|NCT04952168|DRUG|Almonertinib|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
48465894|NCT04104360|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
48465895|NCT04104360|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
48465896|NCT02971787|DIETARY_SUPPLEMENT|Probiotics|Day 1-21: 2 capsules per day
48465897|NCT02971787|DIETARY_SUPPLEMENT|Salt|Day 8-21: 10 tablets à 600 mg per day
48465898|NCT00225849|DRUG|Aspirin|
48625981|NCT03615534|OTHER|Therapeutic Lifestyle Changes|Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
48282409|NCT06286722|OTHER|Progressive, individualized and structured exercise program|See description under Arms
48282410|NCT04243759|BEHAVIORAL|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
48282411|NCT04243759|BEHAVIORAL|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
48465899|NCT01402973|OTHER|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
48465900|NCT04918992|DIAGNOSTIC_TEST|Artificial Intelligence|investigators utilize a Artificial Intelligence (AI) supportive system to predict radiation proctitis for patients with pelvic cancers underwent radiotherapy
48465901|NCT02373839|OTHER|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
48465902|NCT04628975|DEVICE|transillumination dispositif|infrared light
48465903|NCT02773433|OTHER|Proportional Assist Ventilation|
48465904|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
48625982|NCT03615534|OTHER|Placebo|
48625983|NCT03615534|DRUG|Fenofibrate|
48625984|NCT03615534|DIETARY_SUPPLEMENT|Wax Matrix Extended Release Niacin (WMER Niacin)|
48625985|NCT04870203|DRUG|baricitinib treatment|4 mg daily during 12 months
48625986|NCT04870203|DRUG|adalimumab|40 mg every 2 weeks during 6 monts
48100385|NCT01881919|DIETARY_SUPPLEMENT|Control|Address: Fagron GmbH\&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
48465905|NCT03647917|BIOLOGICAL|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
48465906|NCT03045822|DRUG|Bioimpedance analysis|
48465907|NCT00428155|DEVICE|closure device placement|
48465908|NCT01886534|OTHER|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
48465909|NCT01886534|BEHAVIORAL|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
48465910|NCT01886534|OTHER|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
48465911|NCT01886534|OTHER|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
48465912|NCT01886534|OTHER|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
48465913|NCT02566096|DRUG|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
48465914|NCT05717387|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
48465915|NCT05717387|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
48465916|NCT00287053|DRUG|divalproex sodium|Divalproex sodium vs. placebo
48465917|NCT03794245|BEHAVIORAL|Men-Centered HIV Testing|The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
48465918|NCT03794245|BEHAVIORAL|Linkage to Care for HIV+ Men|Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
48465919|NCT03794245|BEHAVIORAL|Clinic-based HIV Testing|Individuals present to a clinic and request HIV counseling and testing
48465920|NCT03794245|BEHAVIORAL|Clinic Referral for HIV+ Men|Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
48465921|NCT00274495|DRUG|Rosiglitazone and Pegasys/Ribavirin|
48465922|NCT04740424|DRUG|FS222|Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
48465923|NCT04678063|OTHER|Exposure to Placebo|Patients are exposed to placebo in the EEC
48465924|NCT04678063|OTHER|Exposure to dose A and dose B of cat allergen|Patients are exposed to dose A and B for successive exposures in the EEC
48465925|NCT04678063|OTHER|Exposure to a single dose of cat allergen|Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
48625987|NCT04870203|DRUG|Placebo|40 mg every 2 weeks during 6 months
48625988|NCT03027934|DRUG|Ticagrelor|Ticagrelor, 90mg twice daily
48625989|NCT03027934|DRUG|Prasugrel|Prasurgrel, 10mg once daily
48625990|NCT02998112|DRUG|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
48625991|NCT02998112|DRUG|Saline|
48100386|NCT06629935|PROCEDURE|orthognathic surgery|Le Fort I surgery
48100387|NCT05835115|DIAGNOSTIC_TEST|A deep learning-based myopia and myopic maculopathy detection and prediction system|This deep learning system is capable of analyzing fundus images for myopia staging, myopic maculopathy detection, cycloplegic refraction estimation and prediction, and risk stratification of myopia and myopic maculopathy onset.
48282412|NCT04243759|BEHAVIORAL|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
48625992|NCT04719923|BEHAVIORAL|Children with autism spectrum disorders|Subjects affected by autism spectrum disorders
48625993|NCT03707730|DIETARY_SUPPLEMENT|AGY|oral AGY taken prior to meals
48625994|NCT03707730|OTHER|placebo|oral placebo taken prior to meals
47937267|NCT05740995|DRUG|neoadjuvant anti-PD-1 plus chemotherapy|"Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery."
47937268|NCT05278637|DRUG|Aspirin|Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
47937269|NCT05278637|DRUG|Ticagrelor|Ticagrelor 90mg BID x 4 weeks
47937270|NCT01070797|BIOLOGICAL|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10\^6 rCTLs/m2~Level Two: 1 x 10\^7 rCTLs/m2~Level Three: 2 x 10\^7 rCTLs/m2~Level Four: 5 x 10\^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
47937271|NCT04955860|OTHER|Dental model analysis|No interventional treatment intervention will be made for individuals. Digital dental models taken for orthodontic recording will be examined.
47937272|NCT05930704|DRUG|SHR-2017 injection|Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.
47937273|NCT05930704|DRUG|Placebo|Randomized participants will receive a single SC injection dose of matching placebo.
48282413|NCT05427630|DRUG|THC ~2.5%|Cannabis flower containing THC \~2.5%
48282414|NCT05427630|DRUG|THC ~5%|Cannabis flower containing THC \~5%
48282415|NCT05427630|DRUG|THC ~10%|Cannabis flower containing THC \~5%
48465926|NCT02199119|BEHAVIORAL|Exercise|30 min of moderate exercise on a treadmill
48465927|NCT02199119|BEHAVIORAL|TV viewing|watching TV (animated children's programming) for 30 min
48465928|NCT02199119|BEHAVIORAL|Sitting quietly|Sitting quietly for 30 min
48465929|NCT05569109|DEVICE|doppler ultrasound|doppler ultrasound on arteriovenous fistula in hemodialysis patients
48465930|NCT04598958|OTHER|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
48465931|NCT03370510|DRUG|Oxytocin|Oxytocin nasal spray.
48465932|NCT03370510|BEHAVIORAL|Pivotal Response Treatment|An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
48625995|NCT05788965|DRUG|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
48625996|NCT05658991|DIAGNOSTIC_TEST|Retinal electrophysiology|Retinal electrophysiology to assess retinal function before and with fasting during ramadan in both groups.
48625997|NCT04241731|DRUG|Raltitrexed|Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
48625998|NCT04241731|DRUG|Cetuximab|Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
48625999|NCT00993889|BEHAVIORAL|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
48626000|NCT00993889|BEHAVIORAL|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
48626001|NCT00993889|BEHAVIORAL|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
48626002|NCT02588287|OTHER|Blood draws for tenofovir PK, renal function|
48626003|NCT02857920|DRUG|Bevacizumab|7.5 mg/kg, i.v, once every 3 weeks (continuous)
48626004|NCT02857920|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfusion in 3 times, i.v.
48626005|NCT03248804|BEHAVIORAL|Soy group|
48626006|NCT03248804|BEHAVIORAL|Non-soy group|
48282416|NCT05427630|DRUG|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
48282417|NCT02363829|DRUG|Nelfinavir|
48282418|NCT02363829|BIOLOGICAL|Cisplatin|
48282419|NCT06656754|OTHER|Isometric Reaching|"The intervention of Isometric Reaching is the process of restricting the participant's hand movement in place, while using the forces they apply to the robot handle to drive a reaching arm simulation"
48282420|NCT05036785|OTHER|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
48282421|NCT04007276|DRUG|brimonidine tartrate ophthalmic solution 0.025%|Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
48282422|NCT04007276|OTHER|sterile balanced saline solution|Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
48465933|NCT03370510|DRUG|Placebo|Placebo nasal spray.
48465934|NCT05157750|OTHER|Recording of major clinical events|During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
48465935|NCT02451644|DEVICE|pedometer|patient will cary pedometer
48465936|NCT02697617|DRUG|Pioglitazone|Pioglitazone
48465937|NCT02697617|DRUG|Placebo|Placebo
48626007|NCT01615718|PROCEDURE|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
48626008|NCT01615718|PROCEDURE|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
48626009|NCT03698916|DRUG|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
47937274|NCT02050971|BIOLOGICAL|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
47937275|NCT02050971|BIOLOGICAL|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
48626010|NCT03589703|OTHER|Target ear points related to chronic low back pain (T-APA)|Light touch using vaccaria seeds on specific points of the ear.
48465938|NCT01611896|DIETARY_SUPPLEMENT|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
47937276|NCT01429038|BIOLOGICAL|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
47937277|NCT04798807|DIAGNOSTIC_TEST|Nutritional screening|
47937278|NCT06265779|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48465939|NCT01611896|OTHER|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
48282423|NCT00743886|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
48465940|NCT04374422|BEHAVIORAL|fsfi survey|sexual behavior Questionaire
48465941|NCT02913287|DIETARY_SUPPLEMENT|Aquamin/Aquamin MG|Marine-based nutraceutical
48465942|NCT02913287|OTHER|Maltodextrin Placebo|Maltodextrin Placebo
48465943|NCT05198635|DEVICE|local cerebral oxygen saturation|minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
48626011|NCT03589703|OTHER|Non-Target ear Points not related to chronic low back pain (NT-APA)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
48626012|NCT03589703|OTHER|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
48626013|NCT01025050|PROCEDURE|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
48626014|NCT05965934|DRUG|Direct Sodium Removal Infusate 2.0|Direct Sodium Removal via peritoneal ultrafiltration using Infusate 2.0 (30% icodextrin, 10% dextrose). Patients (if not yet on SGLT-2 inhibitors) will receive SGLT-2 inhibitors.
48626015|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
47937279|NCT06265779|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48282424|NCT00743886|DRUG|saline|injection of 6 cc of saline into injured area
48282425|NCT01875497|DIETARY_SUPPLEMENT|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
48282426|NCT00170976|DRUG|valsartan + amlodipine|
48465944|NCT02701608|DRUG|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
48465945|NCT02701608|DRUG|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
48465946|NCT02701608|PROCEDURE|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
48465947|NCT02312037|BIOLOGICAL|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~1. Mylotarg \<=9 mg/m2 as a single agent on Day 1 \& 14 of a 28-day cycle for a total of two cycles~2. Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~3. Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
48465948|NCT00544167|DRUG|Doxorubicin|
48626016|NCT02445560|DIETARY_SUPPLEMENT|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
48465949|NCT00544167|DRUG|Cyclophosphamide|
48465950|NCT00544167|DRUG|Paclitaxel|
48465951|NCT00544167|DRUG|Sorafenib|
48465952|NCT01652638|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
48626017|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
48626018|NCT02445560|DIETARY_SUPPLEMENT|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
48626019|NCT01303497|DRUG|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
48626020|NCT01303497|DRUG|Bevacizumab|"Bevacizumab until progression or inacceptable toxicity :~* During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~* After 6 cycles of chemotherapy : 15 mg/kg, IV"
48626021|NCT00382070|DRUG|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
48626022|NCT00382070|OTHER|Placebo|Placebo tablet taken orally once daily for 5 years
48626023|NCT05370482|DEVICE|Focal laser ablation|MRI-guided focal laser ablation for prostate cancer
48626024|NCT03791931|DIAGNOSTIC_TEST|oxidative stress measurement|oxidative stress measurement
48626025|NCT01789021|DEVICE|4 blood glucose monitoring systems|
48626026|NCT05419440|PROCEDURE|laparoscopic drainage of appendicular abscess|access to caecum and remove any adhesions with surrounding by sharp \& blunt dissection , then access to appendicular abscess by sharp and blunt dissection after complete separation of the appendix from surrounding \& complete drainage of pus \& removal of all necrotic tissue , removal of the remnant appendix , in cases with healthy base of appendix ,we closed the stump with endo-loop , in case with unhealthy base , we closed the stump by suturing by ethibond 2/0 in two layers in case with little edema \& inflammation of caecum ( sutures not cut through ) , in cases with marked edema and inflammation of caecum , we close the site of base by omental patch fixed by taking full thickness sutures in wall of caecum and pass through omental patch , we examine any leak by pressing on caecum and observe any fecal matter comes \& air leak test , in all cases we put large drain at pelvis
48626027|NCT03033706|PROCEDURE|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
48626028|NCT03033706|PROCEDURE|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
48626029|NCT03033706|PROCEDURE|Brain tumor excision|Brain tumor excision under general anesthesia
48626030|NCT00427596|DRUG|Solabegron|
48626031|NCT01935804|DRUG|Pioglitazone|30 mg/daily for 12 months
48626032|NCT01935804|DRUG|Metformin|850 mg/daily for 12 months
48626033|NCT04331405|BIOLOGICAL|Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions|"HUCBMCs samples were prepared for infusion in the specialized laboratory of Cord Blood Bank (CryoCenter Ltd) and transported to the clinic immediately within 2 hours in the Dry Shipper. All samples were chosen according to patients blood group and rhesus-factor.~All samples were examined for hemotransmissive infections and cell viability prior to the preparation.~Obtained samples were infused through the blood transfusion systems with additional filter after 3 tests for biological and individual compatibility and tolerance.~Each patient of the pilot group received 4 cell infusions (1 infusion per week) with 1 week interval during the in-hospital treatment."
48626034|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
48626035|NCT00541229|DRUG|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
48626036|NCT00541229|DRUG|Comparator: Placebo|sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
48626037|NCT04596423|DIAGNOSTIC_TEST|Fetal echocardiography|fetal heart examination by medical ultrasound
48626038|NCT00243321|PROCEDURE|high dose-rate brachytherapy|High dose-rate brachytherapy
48626039|NCT00243321|PROCEDURE|intensity-modulated radiation therapy|intensity-modulated radiation therapy
48626040|NCT03964129|PROCEDURE|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
48465953|NCT00570206|BEHAVIORAL|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
48465954|NCT00245986|PROCEDURE|Blood draw|
48465955|NCT05472415|OTHER|cognicise|"a combination of cognition and exercise training"
48465956|NCT05472415|DEVICE|arch support insoles|The FootDisc insole is designed with curEVA for shock absorption and motion reduction, poron for secondary heel and metatarsal protection, and dynamic arch support for returning energy for propulsion
48626041|NCT05503069|BEHAVIORAL|Interventions with social and cultural components|"Intervention Components~* Enrollment: We are expecting an enrollment rate of 20 participants per week, and completing enrollment in 6 weeks (n=120 participants)~* Baseline Data Collection~* Distribution of Educational Materials~* Lactation Training~* Dietary Literacy Training~* Follow Up Data collection: Infant's information on growth and development and Medical History of Infections, GI problems (diarrhea, constipation, colic, vomits, reflux) will be collected at 3, 6 and 12 months.~* Follow UP Surveys: Mothers will complete a short survey at 3, 6, and 12 months exploring their breastfeeding behaviors and challenges.~* Exit survey: Mothers will be asked to complete an exit survey on month 12 post-enrollment to explore their perception on the participation in the study."
48626042|NCT05854719|BEHAVIORAL|Speechreading training with an application|Optic Track application developed for this intervention will be used in speechreading training. The target is that, during the eight intervention weeks, it would be used for 15 minutes at least three times a week.
48626043|NCT06285604|PROCEDURE|Blood transfusion|Transfusion of designated red blood cell products to anemic neonates.
48626044|NCT02106273|DEVICE|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
48626045|NCT02106273|DEVICE|LMA-ProsealTM|
48626046|NCT02339207|DRUG|AL-335 matching placebo|
48626047|NCT02339207|DRUG|AL-335|
48626048|NCT04899206|DRUG|With an Antidepressant Drug|Current users of an antidepressant drug.
48626049|NCT04899206|DRUG|Without an Antidepressant Drug|Non-current users of an antidepressant drug.
48626050|NCT01197235|DRUG|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
48626051|NCT01197235|DRUG|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
48626052|NCT05166642|DEVICE|Bandgrip Micro-Anchor Wound Closure|This treatment group will utilize a suture closure technique for the deep dermal layers with Bandgrip being applied to the most superficial layer of the surgical incision
48465957|NCT04020016|DRUG|Nalbuphine ER|Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.
48626053|NCT05166642|DEVICE|Suture closure|This treatment gourd will utilize suture closure technique for all layers of the surgical incision.
48626054|NCT00356590|BIOLOGICAL|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
48626055|NCT02744768|DRUG|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
48282427|NCT04143022|DEVICE|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
48282428|NCT04472689|DRUG|Lidocaine|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
48626056|NCT02744768|DRUG|Blinatumomab|"Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
48626057|NCT05573360|OTHER|NGF5-A test formulation|One drop of investigational product instilled on the eye
48626058|NCT05573360|OTHER|NGF4-B test formulation|One drop of investigational product instilled on the eye
48626059|NCT05573360|OTHER|NGF6-B test formulation|One drop of investigational product instilled on the eye
48626060|NCT05573360|OTHER|NGF6-E test formulation|One drop of investigational product instilled on the eye
48626061|NCT05573360|OTHER|Systane eye drop|One drop of commercial product instilled on the eye
48626062|NCT03976128|BEHAVIORAL|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
48282429|NCT04472689|DRUG|Normal saline|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
48282430|NCT00816803|PROCEDURE|Autologous bone marrow transplant|
48282431|NCT00816803|PROCEDURE|Physical therapy|
48465958|NCT04020016|DRUG|Nalbuphine ER -|Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
48626063|NCT03976128|BEHAVIORAL|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
48626064|NCT03411538|OTHER|Collect data on clinical history|Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
48626065|NCT05743855|DIETARY_SUPPLEMENT|Nutritional Supplement|Nutritional Supplement + Chiropract sessions
48626066|NCT05743855|OTHER|Placebo|Placebo + Chiropractic sessions
48626067|NCT04441398|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
48626068|NCT04441398|DRUG|Placebo|Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
48626069|NCT05188794|PROCEDURE|lateral tap block|In the axial plane on the midaxillary line between the subcostal margin and the iliac crest with a linear probe using a 12 cm insulated nerve block needle is advanced in planely from skin, external, and internal oblique muscles to the target of fascial plane between the internal oblique and the transversus abdominis muscles.
48626070|NCT05188794|PROCEDURE|posterior tap block|In the axial plane on the midaxillary line a linear probe using a 12 cm insulated nerve block needle is advanced posteriorly to the most posterior limit of the TAP between the internal oblique and transversus abdominis muscles.
48626071|NCT04492514|DRUG|Mavrilimumab|treatment infusion
48626072|NCT04492514|DRUG|Placebo|Placebo infusion
48626073|NCT02879162|DRUG|Durvalumab|
48626074|NCT02879162|DRUG|Tremelimumab|
48626075|NCT02560766|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
48626076|NCT02560766|DRUG|HORIZANT 600 mg|HORIZANT 600 mg once daily
48626077|NCT02560766|DRUG|Placebo|Placebo once daily
48626078|NCT03860480|PROCEDURE|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
48626079|NCT03860480|PROCEDURE|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
48626080|NCT03403517|DRUG|Methylprednisolone|10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
48626081|NCT03403517|DRUG|Dexamethasone|Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
48626082|NCT04921163|DIETARY_SUPPLEMENT|sodium aluminium phospate (SALP)|1 pancake daily for 4 days
48626083|NCT04921163|DIETARY_SUPPLEMENT|Aluminium-free pancake|1 pancake daily for 4 days, without aluminium
48282432|NCT01018407|BEHAVIORAL|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen \& Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
48465959|NCT03171194|DRUG|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
48465960|NCT02248012|DRUG|Everolimus , temozolomide|
48465961|NCT00033527|DRUG|INS316|
48465962|NCT00033527|OTHER|sputum cytology|
48465963|NCT00260026|DRUG|Docetaxel|
48465964|NCT00260026|DRUG|Jin Fu Kang|
48465965|NCT01853176|DRUG|Liposomal Injection Bupivacaine (Exparel)|
48465966|NCT01853176|DRUG|Standard bupivicaine|
48465967|NCT00001191|DRUG|Pantoprazole|
48465968|NCT00001191|DRUG|Omeprazole|
48465969|NCT05505760|BEHAVIORAL|Quality-Based Digital Messaging|"The impact of MomConnect's models will be evaluated using a randomized controlled trial (RCT). Randomization will be at the individual level, where an individual refers to the unique user, which is defined by the unique phone number used at the time of registration to MomConnect at health facilities. Randomizing control and treatment allocations ensures that the study groups will be comparable in terms of observable and unobservable characteristics in expectation. Therefore, statistical inference can shed light on the likelihood that any differences in outcome variables at the end of the intervention were caused by the intervention as compared to chance. We will also study the treatment effects on different outcomes between the different arms of the experiment - comparing outcomes across different treatment arms or outcomes in the control to outcomes in treatment arms will help us answer the aforementioned research questions."
48465970|NCT03121079|DRUG|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
48626084|NCT03611270|DEVICE|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
48626085|NCT02122952|BIOLOGICAL|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
48465971|NCT02645487|RADIATION|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy \>1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy \>2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
48465972|NCT02189603|BIOLOGICAL|Recombinant (E. Coli) Hepatitis E Vaccine|
48465973|NCT00998595|OTHER|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
48626086|NCT01843881|DRUG|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
48626087|NCT01843881|DRUG|Placebo|A saline infusion will be given to match the study drug infusion.
48626088|NCT00005585|DRUG|cyclophosphamide|Given IV
48626089|NCT00005585|DRUG|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
48626090|NCT00005585|DRUG|daunorubicin hydrochloride|Given IV
48626091|NCT00005585|DRUG|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
48626092|NCT00005585|DRUG|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
48626093|NCT00005585|DRUG|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
48626094|NCT00005585|DRUG|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
48626095|NCT00005585|DRUG|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
48626096|NCT00005585|DRUG|thioguanine|Given orally
48626097|NCT00005585|DRUG|vincristine sulfate|Given IV
48626098|NCT04483037|DRUG|Bowklean|assigned intervention
48626099|NCT01640561|BEHAVIORAL|MISC|The Mediational Interventions for Sensitizing Caregivers
48626100|NCT01640561|BEHAVIORAL|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
48626101|NCT01105130|OTHER|Placebo|Given orally
48626102|NCT01105130|DRUG|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
48626103|NCT01105130|DRUG|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
48626104|NCT01653418|DRUG|Bortezomib|
48465974|NCT05960422|PROCEDURE|Popliteal Sciatic Nerve Block|Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue
48626105|NCT01653418|DRUG|Carmustine|
48626106|NCT01653418|DRUG|Etoposide|
48626107|NCT01653418|DRUG|Cytarabine|
48626108|NCT01653418|DRUG|Melphalan|
48626109|NCT01653418|PROCEDURE|Stem cell infusion|
48626110|NCT05017155|DRUG|Mexiletine|Mexiletine is a sodium channel blocker shown to be effective in reducing myotonia in a multi-centre randomised trial.
48626111|NCT05017155|DRUG|Lamotrigine 25Mg Oral Tablet, Extended Release|Lamotrigine is an alternative sodium channel blocker that has been shown to be effective in one randomised controlled trial. It is currently used as a licensed medication for other neurological conditions.
48626112|NCT03678662|OTHER|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
48626113|NCT03678662|OTHER|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
48100388|NCT06629415|DRUG|Indocyanine Green|"injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image"
48626114|NCT03678662|OTHER|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
48100389|NCT06629415|DRUG|Indocyanine Green Drug|1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
48626115|NCT01668537|BIOLOGICAL|LF formulation of IMVAMUNE®|
48626116|NCT01668537|BIOLOGICAL|FD formulation of IMVAMUNE®|
48626117|NCT02730130|DRUG|Pembrolizumab|
48626118|NCT02730130|RADIATION|Radiotherapy|
48626119|NCT05143775|PROCEDURE|Awake craniotomy|Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
48626120|NCT05030311|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
48626121|NCT05030311|DRUG|Placebo|Placebo
48626122|NCT05030311|DRUG|LOU064 (open-label)|LOU064 (open-label) active treatment
48100390|NCT06492889|DRUG|Levonorgestrel|Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
48626123|NCT05016336|OTHER|Social interaction combined with cognitive training based on mnemonic strategies.|In the first six sessions, participants in the experimental group learned and practiced six different mnemonic strategies: Story-Formation strategy, Face-Name strategy, Peg-Word strategy, Chunking strategy, Key-Word strategy and the Method of Loci. In the following six sessions, in order to assimilate the strategies they learned, participants practiced the same tasks.
48626124|NCT05016336|OTHER|Social interaction group|In the control group, each session also began with a conversation between the participants. The sessions then dealt with the content of interpersonal communication and the acquisition of tools for creating interpersonal relationships. Participants were asked to share the way they used the tools they acquired between sessions and received feedback from the other participants
48626125|NCT06298409|DEVICE|CapScan collection capsule|The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.
48626126|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (MDCK cells)|Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).
48626127|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (Chicken embryo)|Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).
48100391|NCT06492889|DRUG|Mifepristone|Participants in both groups will receive one tablet of 200 mg mifepristone
48626128|NCT06342349|OTHER|Phosphate buffer solution|Phosphate buffer solution without vaccine antigen(0.5ml/dose).
48626129|NCT02737059|DRUG|Naloxegol|25mg daily
48626130|NCT02737059|DRUG|Codeine|30mg 4 times daily
48626131|NCT02737059|DRUG|codeine placebo|4 times daily (placebo will be made to match the codeine)
48626132|NCT02737059|DRUG|naloxegol placebo|placebo will match naloxegol, given daily
48626133|NCT01673945|DEVICE|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
48626134|NCT02142621|OTHER|transpyloric feeding|
48626135|NCT02142621|OTHER|gastric feeding|
48626136|NCT00330096|DRUG|Hesperidin|
48626137|NCT00330096|OTHER|Placebo|
48626138|NCT04124796|OTHER|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
48626139|NCT04281719|OTHER|Mobile Application (working name: Bright Path)|The Bright Path web-based mobile application is designed to target co-occurring problems, enhance patient treatment engagement, and contribute to lasting improvements in teens' mental health. The central hypothesis is that developmentally tailored mobile applications that incorporate evidence-based treatment principles can facilitate increased patient engagement in and between sessions, thus, improving the efficiency, efficacy, and reach of treatments for this highly vulnerable population.
48626140|NCT00071331|DRUG|Tolvaptan|
48100392|NCT00759837|DRUG|Bosutinib|
48100393|NCT00012467|DRUG|Itraconazole|
48100394|NCT00012467|DRUG|Flucytosine|
48100395|NCT00012467|DRUG|Fluconazole|
48100396|NCT00012467|DRUG|Amphotericin B|
48100397|NCT00012467|DRUG|Interferon gamma-1b|
48100398|NCT02689349|DEVICE|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
48100399|NCT04882722|OTHER|Questionnaire|Self-questionnaire reported before the first PPFR session and after the last session
48100400|NCT05747599|BEHAVIORAL|Intervention with contingent incentives and text-based support|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
48100401|NCT05742984|DRUG|Linaprazan Glurate 25 mg|The participating subjects will receive 25 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.
48465975|NCT05960422|PROCEDURE|Adductor canal block|Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
48465976|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 subcutaneously.
48465977|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 intravenously.
48465978|NCT05848440|DRUG|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
48465979|NCT02897934|DRUG|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
48465980|NCT02048696|OTHER|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
48465981|NCT05553496|DRUG|Rituximab|Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
48465982|NCT05553496|DRUG|Dexamethasone|Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
48465983|NCT00769587|DRUG|thalidomide|
48465984|NCT01942278|OTHER|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
48465985|NCT02992457|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily.
48465986|NCT02992457|DRUG|Ribavirin|Ribavirin 1000-1200 mg daily
48465987|NCT02992457|DRUG|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
48465988|NCT02992457|DRUG|Simeprevir|Olysio once daily.
48465989|NCT02992457|DRUG|Daclatasvir|Dakla once daily for three months.
48626141|NCT03819699|DRUG|Lu AF20513|Lu AF20513 suspension for injection
48626142|NCT03819699|BIOLOGICAL|booster vaccine|booster vaccine (Cohort 2) - to be administered as per national recommendations
48626143|NCT04426162|OTHER|Multi-domain Intervention|Intervention includes neurofeedback, heart rate variability biofeedback, memory and cognitive training, and one-on-one coaching to encourage behavior change in diet, sleep, physical fitness, and stress reduction.
48626144|NCT05531097|DRUG|HSK31679|Single or multiple oral doses of HSK31679
48626145|NCT05531097|DRUG|Placebo|Matching placebo
48626146|NCT02507999|DEVICE|Flotrac|Flotrac guided intervention
48626147|NCT00377481|DRUG|darbepoetin alfa|30 micrograms sc weekly (2 doses)
48626148|NCT00377481|DRUG|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
48626149|NCT03466372|BEHAVIORAL|biofeedback|treadmill walking with biofeedback regarding propulsion and other gait parameters
48626150|NCT02587286|OTHER|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
48626151|NCT02011334|DRUG|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
48626152|NCT05349123|BEHAVIORAL|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
48626153|NCT05349123|BEHAVIORAL|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
48626154|NCT05713448|OTHER|No intervention|No intervention
48626155|NCT03104803|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
48626156|NCT01365611|DRUG|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
48626157|NCT01365611|DRUG|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
47937280|NCT06265779|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
47937281|NCT02376829|DEVICE|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
47937282|NCT05929755|DRUG|Depo-Medrol|steroid
47937283|NCT05929755|DRUG|Gel-Flow NT|hemostatic agent
47937284|NCT01369654|BEHAVIORAL|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
47937285|NCT01759485|DRUG|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
47937286|NCT01759485|DRUG|placebo|
47937287|NCT03777735|PROCEDURE|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
47937288|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and magnesium|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of 10% magnesium sulfate
47937289|NCT06520475|PROCEDURE|genicular nerve block using bupivacaine and normal saline|The patients will receive 13 ml of 0.5% bupivacaine and 2 ml of normal saline
47937290|NCT03555838|OTHER|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
47937291|NCT03555838|OTHER|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
47937292|NCT04733391|OTHER|Quality of life questionnaire|"Quality of life will be evaluated using the child version of the VSP-A questionnaire, for patients aged 8-10 years and the adolescent version for those aged 11-17 years."
48465990|NCT02992457|DRUG|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
48626158|NCT05309850|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
48626159|NCT02649699|OTHER|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
48626160|NCT03111732|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
48626161|NCT03111732|DRUG|Oxaliplatin|130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
48626162|NCT03111732|DRUG|Capecitabine|750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
47937293|NCT05167110|DIETARY_SUPPLEMENT|Placebo|Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
47937294|NCT05167110|DIETARY_SUPPLEMENT|Probiotic|Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
47937295|NCT03150667|DRUG|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
47937296|NCT03150667|DRUG|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
47937297|NCT01834482|DIETARY_SUPPLEMENT|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
47937298|NCT01834482|DIETARY_SUPPLEMENT|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
48465991|NCT02992457|DRUG|Sofosbuvir and Ledipasvir|Once daily for three months
48465992|NCT02992457|DRUG|Salvage therapy|three months in repeated treatment failure
48465993|NCT00748566|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
47937299|NCT05685628|OTHER|Cinnamon dressing|"Use of CINESTEAM® as a non-occlusive secondary dressing~CE marked medical device class I, secondary, absorbent, non-adhesive and composed of:~* Anti-odor upper part, adsorbent containing cinnamon powder.~* Weakly absorbent lower part intended to absorb excess exudates."
47937300|NCT05685628|OTHER|Charcoal dressing|"Use of ACTISORB® as a non-occlusive secondary dressing~CE marked medical device class IIb, without adhesive, consisting of a non-woven nylon envelope containing a layer of activated carbon. ACTISORB® can be applied as a primary or secondary dressing."
47937301|NCT03598634|PROCEDURE|administration of riboflavin for epi-off cross-linking|riboflavin 0.1% in 20% dextran solution
47937302|NCT03598634|PROCEDURE|administration of riboflavin for epi-on cross-linking|riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
48465994|NCT04952467|DRUG|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
47937303|NCT06097780|GENETIC|NestaCell®|Human Dental Pulp Stem Cells (hDPSCs).
47937304|NCT01247181|OTHER|Mobile phone text message|Weekly message with motivational content
47937305|NCT01247181|OTHER|Usual care|Usual care provided at clinic
47937306|NCT05607836|DEVICE|IntuBrite intubation|Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation
47937307|NCT05607836|DEVICE|Macintosh laryngoscope|Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
48465995|NCT00106106|PROCEDURE|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
47937309|NCT03953118|DRUG|Azithromycin Oral Product|Oral azithromycin dosed at 1 gram per week for 3 weeks
47937310|NCT03953118|DRUG|Placebo Oral|Oral placebo tablet
47937311|NCT02037152|BEHAVIORAL|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
47937312|NCT00558779|PROCEDURE|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
48100402|NCT05742984|DRUG|Linaprazan Glurate 50 mg|The participating subjects will receive 50 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.
47937313|NCT00558779|PROCEDURE|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
47937314|NCT06154200|DRUG|Testosterone gel 4.5%|Testosterone gel applied to eyelids twice per day
47937315|NCT06154200|DRUG|Vehicle gel|Vehicle gel applied to eyelids twice per day
47937316|NCT05497700|DRUG|Ephedrine|Bolus injection of 6 mg ephedrine to keep mean arterial blood pressure above 65 mm Hg
47937317|NCT05497700|DRUG|Norepinephrine|Bolus injection of either 6 mcg norepinephrine to keep mean arterial blood pressure above 65 mm Hg
48100403|NCT05742984|DRUG|Linaprazan Glurate 75 mg|The participating subjects will receive 75 mg doses of IMP, QD or BID for 14 days. After a drug holiday period (2, 4 or 6 days), linaprazan glurate will be given once more (QD or BID, on Day 16, 18 or 20). In total, 15 or 30 doses will be given.
48100404|NCT04286165|OTHER|Brief Peer Supported webSTAIR|The BPS webSTAIR program is an online platform where individuals are taught skills in emotion regulation. In this program they will learn how to recognize the emotions they are feeling by assessing their own body language, being attentive to their thought processes, and attempting to replace negative behaviors with positive. Throughout the platform they will engage in written exercises to help them solidify the lessons with their own life experiencing. They will also have the support of peers throughout the program to help them when they need clarification or having a difficult time applying the lesson(s).
48100405|NCT04206046|PROCEDURE|Spinal anaesthesia|Patients will receive a spinal anaesthetic
48100406|NCT04206046|PROCEDURE|General anaesthesia|patients will receive a general anaesthetic and a femoral nerve block
48100407|NCT04081506|OTHER|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
48100408|NCT02702024|PROCEDURE|Double uterine incision technique in uterus preserving surgery for placenta percreta|
48100409|NCT01605136|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
47937318|NCT02309463|DRUG|Endothelin receptor antagonist therapy|
47937319|NCT01742247|OTHER|Physiogel|Application of moisturizer on laser-treated area
47937320|NCT01742247|OTHER|Moisturizer|Application of moisturizer on laser-treated area
47937321|NCT04218123|DRUG|Venlafaxine|Daily oral intake 37.5 mg
47937322|NCT04218123|DRUG|Placebo oral tablet|Daily oral intake
47937323|NCT02177578|DRUG|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
47937324|NCT02177578|RADIATION|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
47937325|NCT02177578|RADIATION|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
47937326|NCT03792243|PROCEDURE|Complication|Readmission, reoperation
47937327|NCT02240173|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
48100410|NCT01605136|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months
48626163|NCT02658474|BEHAVIORAL|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
48465996|NCT00106106|DRUG|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
48465997|NCT04247841|OTHER|Visual Aid|The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
48465998|NCT04247841|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
48465999|NCT01581892|PROCEDURE|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
48626164|NCT04529174|DIETARY_SUPPLEMENT|CardioLux™HDL|"Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
48626165|NCT04529174|DIETARY_SUPPLEMENT|Placebo|"Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).~Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.~Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.~Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)"
48626166|NCT06293144|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
48626167|NCT04077359|DIAGNOSTIC_TEST|CT|the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
48626168|NCT03637829|OTHER|Control|Water
48626169|NCT03637829|OTHER|White chocolate|Experimental snack treatment
48626170|NCT03637829|OTHER|Dark chocolate 1|Experimental snack treatment
48626171|NCT03637829|OTHER|Dark chocolate 2|Experimental snack treatment
48626172|NCT01136915|DRUG|Iopamidol 370|one time administration for PCI
48626173|NCT01136915|DRUG|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
47937328|NCT02240173|DRUG|Haloperidol|Conventional drug normally used for psychotic problems
48466000|NCT04903652|DRUG|Pyrotinib Maleate|Pyrotinib p.o. 400 mg once daily
48466001|NCT04903652|DRUG|Vinorelbine|Vinorelbine p.o. 40 mg once every other day
48466002|NCT00867919|BEHAVIORAL|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~* parent-adolescent conflict~* adolescent development~* support and closeness~* behavioral activation~* response to adolescent negative affect~* relapse prevention~* suicide prevention, if necessary"
48466003|NCT00867919|OTHER|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
48626174|NCT04807530|DEVICE|TMS|The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
48626175|NCT02534961|DRUG|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
48626176|NCT00315822|OTHER|80% oxygen|Supplemental oxygen will be administered during surgery
48626177|NCT00315822|OTHER|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
48626178|NCT03870386|PROCEDURE|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
47937329|NCT01593722|DRUG|Diethylcarbamazine|single dose
47937330|NCT01593722|DRUG|Ivermectin|single dose
48626179|NCT03870386|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
48626180|NCT00019123|DRUG|thalidomide|
48626181|NCT04056026|BIOLOGICAL|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
48626182|NCT04235075|DEVICE|ECG/PCG and ultrasound signal acquisition|"The ECG - PCG signals are acquired over a 20-minute monitoring phase with passive non invasive sensors (abdominal and thoracic). The volunteer's abdomen is photographed when the electrodes and sensors are installed. An ultrasonography is also performed for 10 minutes.~The session is filmed for 5 volunteers accepting the video. Any distinctive elements will be removed from photos and videos to prevent the identification of participants."
48626183|NCT04061629|DEVICE|Cuffed ETT|Cuffed endotracheal tube.
48466004|NCT06111534|BEHAVIORAL|Holding|Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
48466005|NCT05456451|DEVICE|noninvasive vagus nerve srimulation|Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.
48466006|NCT02036749|PROCEDURE|nerve block|quadratus lumborum block
48466007|NCT06230380|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern.
48466008|NCT04439760|PROCEDURE|Superior Cervical Ganglion Block|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
48466009|NCT04733508|DRUG|111In-DTPA-exendin-4|Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography
48466010|NCT04733508|DRUG|IRDye800CW-exendin-4|Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy
48466011|NCT00013364|BEHAVIORAL|Talker variability|
48466012|NCT05103644|DRUG|Atorvastatin 80mg|patients received statin experimental group
48466013|NCT05103644|OTHER|placebo|patients received placebo control group
48466014|NCT06534164|DEVICE|Full/High Tech Telerehabilitation decision support system|"The TeleRehaB DSS intervention includes HOLOBalance balance rehabilitation programme delivered via an augmented reality hologram of a virtual physiotherapist. The system delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
48466015|NCT06534164|DEVICE|Basic/Low Tech Telerehabilitation decision support system|"The basic system does not inlcude exergames, a smartwatch, or a mobile phone for activity tracking.~It includes different multisensory balance and gait exercise, cognitive training and real-time feedback from motion sensors.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme."
48466016|NCT06534164|PROCEDURE|OTAGO Home exercise program|balance rehabilitation program
48466017|NCT06534164|PROCEDURE|Vestibular rehabilitation program|vestibular rehabilitation and dizziness program
48466018|NCT02314494|BEHAVIORAL|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
48466019|NCT02277951|DEVICE|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
48466020|NCT02277951|DEVICE|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
48466021|NCT02277951|DEVICE|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
48466022|NCT02277951|DEVICE|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
48626184|NCT03723070|DEVICE|The Cryterion Cardiac Cryoablation System|Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
48466023|NCT03668457|BEHAVIORAL|Intervention to Patients|"Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app."
48466024|NCT03668457|BEHAVIORAL|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
48466025|NCT03668457|OTHER|Control|Other: Usual care Usual care for depressive disorder received in mental health units
48466026|NCT02336308|DRUG|Ketamine|
48466027|NCT02336308|DRUG|Placebo, Normal Saline|
48466028|NCT06033586|DRUG|Open-label rusfertide|subcutaneous rusfertide
48626185|NCT05608655|DEVICE|DKutting LL balloon|After pre-dilation balloon is used (if any), DKutting LL balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
48626186|NCT05608655|DEVICE|Chocolate balloon|After pre-dilation balloon is used (if any), Chocolate balloon is used as final dilatation balloon before Stent implantation or Drug Coated Balloon deployment
48282433|NCT01018407|BEHAVIORAL|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
48282434|NCT06432777|OTHER|Characteristics of patients and Campylobacter bacteraemia episodes|Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
48466029|NCT01664039|DRUG|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
48282435|NCT03638011|DRUG|Exparel|Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
48282436|NCT05970887|BIOLOGICAL|bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine|The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
48100411|NCT05634317|BEHAVIORAL|Smartphone delivered Behavioral activation|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 Review the present use of time and use the monitoring form~Session 2 Brain-storm pleasant events and schedule pleasant activities~Session 3 Review scheduling of events and discuss how to improve~Session 4 Review modifications and consolidate gains on scheduling~Session 5 Review present social support and explore new sources of support~Session 6 Examine communication skills and explore new options~Session 7 Review new communications and discuss how to improve~Session 8 Review modification and consolidate gains on support"
48466030|NCT01664039|DRUG|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
48466031|NCT02227615|DIETARY_SUPPLEMENT|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
48466032|NCT02227615|DIETARY_SUPPLEMENT|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
48466033|NCT05414695|DEVICE|real acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm
48466034|NCT05414695|DEVICE|Placebo acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
48466035|NCT02409316|DRUG|[18F]FES|\[18F\]FES PET/CT scan
48100412|NCT05634317|BEHAVIORAL|Smartphone delivered Mindfulness|"Outline:~Session 0 45-minute psychoeducation on caregiving and depression~Session 1 The Raisin exercise (eating meditation) and12-min body scan~Session 2 Exercises on thoughts and feelings 12-min body scan~Session 3 Exercises focusing on unpleasant experiences, practicing seeing and hearing , sitting meditation, 3-min breathing space, and mindful stretching and breath meditation~Session 4 Practicing seeing and hearing, mindful communication, 3-min breathing space, and sitting meditation~Session 5 Mindful walking, 3-min breathing space, and sitting meditation~Session 6 Sitting meditation, exercises on thoughts and alternative viewpoints, and 3-min breathing space (responsive)~Session 7 Sitting meditation, activity and mood exercise, identifying habitual emotional reactions to difficulties, and 3-min breathing space (responsive)~Session 8 12-min body scan, exercise on looking forward, and exercise on preparing for the future"
48100413|NCT05187767|DIAGNOSTIC_TEST|cf DNA and ct DNA|Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
48466036|NCT00929006|DRUG|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
48466037|NCT00929006|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
48466038|NCT04547179|DRUG|Fremanezumab-Vfrm|Patients will receive three injections of Ajovy® if in the corresponding arm of the study.
48466039|NCT04547179|DEVICE|BLAfit®|Usage of the BLAfit device, a fixed orthotic appliance that allows users to tone facial muscles with one minute usage per day
48466040|NCT04547179|OTHER|Saline|Patients will receive three injections of saline if in the corresponding arm of the study. This is a placebo meant to simulate the Ajovy® injection.
48466041|NCT01115062|DRUG|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
48466042|NCT01115062|DRUG|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
48466043|NCT01115062|DRUG|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
48466044|NCT02141048|BEHAVIORAL|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
48466045|NCT02682134|DRUG|xylocaine|First group were given xylocaine
48466046|NCT02682134|DRUG|Dexamethasone|Second group were given Dexamethasone
48466047|NCT02682134|DRUG|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
48282437|NCT05970887|BIOLOGICAL|quadrivalent influenza vaccine|The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
47937331|NCT03340428|BEHAVIORAL|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
47937332|NCT06023524|DEVICE|Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points
48626187|NCT05804500|BEHAVIORAL|Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform|RecoveryPlus has developed an innovative CTR platform for patients with CVD that leverages: (1) video conferencing functionality (Zoom) for synchronous telehealth sessions of CR instruction for patients and licensed exercise physiologists (EPs), (2) a patient-facing mobile application delivering asynchronous exercise videos, and (3) a health care provider web portal for clinicians and EPs. The RecoveryPlus platform includes the ability for EPs and clinicians to monitor patient clinical data (e.g., heart rate) and input (e.g., rating of difficulty for individual exercises) and tailor individual patient regimens regularly for increased safety and optimal outcomes.
47937333|NCT06023524|DEVICE|Sham Laser Acupuncture and Standard Medication|Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
47937334|NCT05016284|OTHER|JW-100|Cosmetic CBD cream (JW-100)
47937335|NCT05016284|DRUG|Eucrisa|Topical EUCRISA®, Pfizer
48282438|NCT01073943|DRUG|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
47937336|NCT02187874|PROCEDURE|delayed umbilical cord occlusion|
47937337|NCT02187874|PROCEDURE|early umbilical cord occlusion|
47937338|NCT02187874|DRUG|Oxytocin|
47937339|NCT02043379|DRUG|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
47937340|NCT02043379|OTHER|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
47937341|NCT01856283|DRUG|Nilotinib 300mg BID|Nilotinib
48282439|NCT01073943|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
47937342|NCT01856764|DRUG|0.5% Roflumilast Cream|Roflumilast 0.5% cream
47937343|NCT01856764|DRUG|Vehicle Cream|Roflumilast formulation vehicle
47937344|NCT06515028|PROCEDURE|Group GA|Anesthesia induction will be performed preoxygenation with 3 minutes of 80% FiO2 , followed by intravenosus propofol 2-2.5 mg/kg and fentanyl 2 µg/kg. Rocuronium 0.6 mg/kg will be administered for neuromuscular blockade, followed by endotracheal intubation after 2 minutes of mask ventilation. Anesthesia maintenance will be achieved with inhalation of 2.5-3.3% sevoflurane with 50% oxygen and 50% air mixture, along with infusion of remifentanil at 0.1 micrograms/kg/min. ventilation will be performed using a volume-controlled.
48100414|NCT04504903|BEHAVIORAL|Cognitive Behavioral Therapy For Work Success (CBTw)|Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
48282440|NCT01073943|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
48282441|NCT05041335|OTHER|wet heparinzed suction|Needle flushed with 5000 Units in 10mL of heparin
47937345|NCT06515028|PROCEDURE|Group IB|infraclavicular brachial plexus block will be performed in supine position with the arm adducted and flexed at 90 degrees. A mixture consisting of 15 ml of 0.5% Bupivacaine, 15 ml of 2% Lidocaine, and 30 ml of saline solution will be prepared, with equal concentrations distributed into three different syringes of 20 milliliters each. The clavicular notch will be palpated, and an ultrasound linear probe covered with a sterile sheath will be positioned in the lateral sagittal plane over this area to visualize the median, lateral, and posterior cords of the brachial plexus surrounding the axillary artery. A special Stimuplex A 22G, 100 mm needle will be used for plexus anesthesia. local anesthetic injection will be sequentially performed around the posterior, median, and lateral cords under ultrasound guidance. After confirming sensory and motor block, the operation will be commenced.
47937346|NCT04679545|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of CBD.
47937347|NCT04679545|DRUG|Placebo|An inactive compound.
47937348|NCT04590742|DRUG|melatonin 6mg|6 weeks of melatonin (6mg) given to patient
48282442|NCT05041335|OTHER|Microsieve|A microsieve used for tissue preparation
48282443|NCT05041335|OTHER|No heparin flush|The needle not prepped
48282444|NCT05041335|OTHER|No microsieve|The tissue is placed into formalin
48466048|NCT04386213|DEVICE|coronary artery in-stent restenosis|treat the petients with coronary artery in-stent restenosis
48282445|NCT03842137|DEVICE|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
47937349|NCT04590742|DRUG|Placebo|Patient given 6 weeks of placebo tablet
47937350|NCT05628961|DRUG|HOPO 14-1|HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
47937351|NCT05246904|OTHER|Fitting algorithm|The best fitting algorithm will be selected by the audiologist (arm 1) or software.
47937352|NCT03825471|PROCEDURE|electrotherapy|Cranial electrotherapy stimulation
47937353|NCT03825471|DRUG|Opioid Anesthetics|consumption of opioids during general anesthesia
47937354|NCT03825471|PROCEDURE|colon cancer surgery|laparoscopic colon cancer surgery
47937355|NCT04621357|RADIATION|Brain MRI|Brain MRI will include differents sequences.
47937356|NCT04621357|BIOLOGICAL|Biological biomarkers|Biological biomarkers will include a set of systemic inflammatory markers
48282446|NCT03842137|DEVICE|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
48282447|NCT00942006|DRUG|doxycycline|100 mg bid, 14 days
48282448|NCT00942006|DRUG|ceftriaxone|2g x 1 iv, 14 days
48282449|NCT05144425|PROCEDURE|total knee arthroplasty with and without using pneumatic tourniquet|The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of\<8 g/dL or patient with symptomatic anemia.
48282450|NCT02863848|DIETARY_SUPPLEMENT|OraftiR inulin-type fructans|
48466049|NCT01603667|DRUG|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
48466050|NCT01603667|DRUG|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
48466051|NCT06394492|DRUG|SHR-A1921|SHR-A1921 dose 1
48626188|NCT02665936|DRUG|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
48626189|NCT02665936|DRUG|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
47937357|NCT03457233|DRUG|Gonadotropins|1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
47937358|NCT03457233|DRUG|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
47937359|NCT03457233|DRUG|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
47937360|NCT03457233|DRUG|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
47937361|NCT00265928|DRUG|bortezomib|
47937362|NCT00265928|DRUG|rituximab|
47937363|NCT00265928|PROCEDURE|antibody therapy|
47937364|NCT00265928|PROCEDURE|biological therapy|
48100415|NCT04504903|BEHAVIORAL|Psychoeducation|Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
47937365|NCT00265928|PROCEDURE|enzyme inhibitor therapy|
47937366|NCT00265928|PROCEDURE|monoclonal antibody therapy|
48282451|NCT02863848|DIETARY_SUPPLEMENT|Placebo|maltodextrin
48466052|NCT06394492|DRUG|Doxorubicin|Doxorubicin dose 2
48466053|NCT06394492|DRUG|Paclitaxel|Paclitaxel dose 3
48466054|NCT06394492|DRUG|Topotecan|Topotecan dose 4
48466055|NCT01763658|DRUG|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
47937367|NCT01631656|DRUG|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
47937368|NCT01631656|DEVICE|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
47937369|NCT04399174|DEVICE|US|
47937370|NCT05697744|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
47937371|NCT01765803|DRUG|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
47937372|NCT00708201|DRUG|Alvimopan|
47937373|NCT00708201|DRUG|Placebo|
47937374|NCT06004687|DRUG|acetaminophen mannitol|Intravenous acetaminophen was administered 30 minutes before anesthesia
47937375|NCT06004687|DRUG|Normal saline|Intravenous acetaminophen was administered 30 minutes before anesthesia
47937376|NCT02829944|DRUG|Ropivacaine|
47937377|NCT02829944|DRUG|Ketorolac|
47937378|NCT02829944|DRUG|Placebo|
47937379|NCT04049227|DRUG|Abemaciclib|Given PO
47937380|NCT04049227|DRUG|Letrozole|Given PO
47937381|NCT04049227|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care hysterectomy
47937382|NCT05684731|BIOLOGICAL|KM1|Administer via intraperitoneal infusion for 3 or 6 doses Q3D.
48466056|NCT01763658|OTHER|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
48466057|NCT04409054|OTHER|Cough and Valsalva effort|Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
48466058|NCT05307276|OTHER|Heliox|"Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved."
48626190|NCT02665936|DRUG|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
48626191|NCT02513199|RADIATION|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
48626192|NCT02513199|DRUG|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
48626193|NCT03310515|BEHAVIORAL|Risk reduction counseling|Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
48626194|NCT03310515|OTHER|Social harm interview|Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
48626195|NCT03310515|OTHER|Computer-Assisted Self Interviewing technique|Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
48626196|NCT02153827|OTHER|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
48626197|NCT02153827|OTHER|General Shoulder exercise|general exercise consisting of active shoulder movements
48626198|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
48626199|NCT03257397|DEVICE|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
48626200|NCT04464447|BEHAVIORAL|Acceptance and Commitment Therapy|"The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module."
48626201|NCT05480371|DEVICE|Conventional tracheal suctioning|"Group 1 allocated to conventional tracheal suctioning,all patiemts will be followed up until discharge from ICU or death~Tracheal suctioning will be performed following the American Association for Respiratory Care recommendations."
48626202|NCT05480371|DEVICE|Mechanical insufflation/exsufflation|Group 2 will be allocated to mechanical insufflation-exsufflation which will be performed with the which will be applied 5 times in 5cough cycles in automatic mode, with insufflation and exsufflation pressures of + 40/-40 cmH2O, respectively. The duration of each phase was 3 s, without pause. Hyperoxygenation (100% O2) will be performed for 1 min before applying each technique and a 20 s interval will be allowed between repetitions.
48626203|NCT00460798|OTHER|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
48626204|NCT00899275|OTHER|Cytology Specimen Collection Procedure|Correlative studies
47937383|NCT05684731|DRUG|Chemotherapy|"Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.~Administer beginning in Week 5 or Week 6."
48466059|NCT05307276|OTHER|Air|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
48626205|NCT02323334|DRUG|LY3202626|administered orally
48626206|NCT02323334|DRUG|Placebo (Part A, B, C)|administered orally
48626207|NCT02323334|DRUG|Itraconazole|administered orally
48626208|NCT02829814|DRUG|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
48626209|NCT02829814|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
47937384|NCT03007108|OTHER|blood withdrawal|
48626210|NCT03621670|BIOLOGICAL|Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)|Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
48100416|NCT04855188|DEVICE|YVOIRE Y-Solution 540|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
48466060|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
48466061|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
48466062|NCT02414464|OTHER|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
48466063|NCT01316432|DRUG|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
48466064|NCT01316432|OTHER|Placebo|Placebo will be administered as a 24-hour SQ infusion
48466065|NCT04753541|OTHER|no intervention|this is not an interventional study
48466066|NCT06347627|BEHAVIORAL|Group 1 (I x S x S x F)|Experimental message: Individual x Safety x Storytelling x Factual
48466067|NCT06347627|BEHAVIORAL|Group 2 (O x S x S x F)|Experimental message: Organization x Safety x Storytelling x Factual
48466068|NCT06347627|BEHAVIORAL|Group 3 (I x E x S x F)|Experimental message: Individual x Effectiveness x Storytelling x Factual
48466069|NCT06347627|BEHAVIORAL|Group 4 (O x E x S x F)|Experimental message: Organization x Effectiveness x Storytelling x Factual
48466070|NCT06347627|BEHAVIORAL|Group 5 (I x S x S x M)|Experimental message: Individual x Safety x Storytelling x Misinformation
48466071|NCT06347627|BEHAVIORAL|Group 6 (O x S x S x M)|Experimental message: Organization x Safety x Storytelling x Misinformation
48466072|NCT06347627|BEHAVIORAL|Group 7 (I x E x S x M)|Experimental message: Individual x Effectiveness x Storytelling x Misinformation
48466073|NCT06347627|BEHAVIORAL|Group 8 (O x E x S x M)|Experimental message: Organization x Effectiveness x Storytelling x Misinformation
48466074|NCT06347627|BEHAVIORAL|Group 9 (I x S x D x F)|Experimental message: Individual x Safety x Scientific data x Factual
48466075|NCT06347627|BEHAVIORAL|Group 10 (O x S x D x F)|Experimental message: Organization x Safety x Scientific data x Factual
48466076|NCT06347627|BEHAVIORAL|Group 11 (I x E x D x F)|Experimental message: Individual x Effectiveness x Scientific data x Factual
48466077|NCT06347627|BEHAVIORAL|Group 12 (O x E x D x F)|Experimental message: Organization x Effectiveness x Scientific data x Factual
48466078|NCT06347627|BEHAVIORAL|Group 13 (I x S x D x M)|Experimental message: Individual x Safety x Scientific data x Misinformation
48466079|NCT06347627|BEHAVIORAL|Group 14 (O x S x D x M)|Experimental message: Organization x Safety x Scientific data x Misinformation
48466080|NCT06347627|BEHAVIORAL|Group 15 (I x E x D x M)|Experimental message: Individual x Effectiveness x Scientific data x Misinformation
48466081|NCT06347627|BEHAVIORAL|Group 16 (O x E x D x M)|Experimental message: Organization x Effectiveness x Scientific data x Misinformation
48466082|NCT02976064|BEHAVIORAL|PreHabilitation|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~2. Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~3. Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~4. Work plan execution \& 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
48466083|NCT02976064|BEHAVIORAL|Rehabilitation in chronic stable patients in primary care|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~2. Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~3. Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk \& patients with mild disease."
48617827|NCT03003117|BEHAVIORAL|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), and lifestyle behaviors, consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets, kitchen utensils and cooking devices are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula, baby and family food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
48626211|NCT03621670|BIOLOGICAL|Prevnar13|Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
48626212|NCT03621670|BIOLOGICAL|Pediarix|Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
48466084|NCT02976064|BEHAVIORAL|Rehabilitation in mild chronic patients and citizens at risk|"1. Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~2. Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~3. Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~4. Work plan execution \& 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
48466085|NCT02811341|DRUG|Scopolamine Hydrobromide|
48466086|NCT02811341|DRUG|normal saline|
48466087|NCT03271996|PROCEDURE|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
48466088|NCT03271996|PROCEDURE|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
48466089|NCT02673086|OTHER|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
48466090|NCT02673086|OTHER|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
48466091|NCT01450800|DRUG|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
48466092|NCT01450800|DRUG|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
48466093|NCT02686762|DRUG|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
48466094|NCT02686762|DRUG|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
48466095|NCT02686762|DRUG|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
48466096|NCT01781117|PROCEDURE|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
48466097|NCT01781117|DEVICE|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
48466098|NCT00304434|DRUG|Oseltamivir|
48466099|NCT00304434|DRUG|Probenecid|
48466100|NCT03518723|OTHER|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
48626213|NCT03621670|BIOLOGICAL|Hiberix|Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
48626214|NCT03621670|BIOLOGICAL|Rotarix|Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
48626215|NCT03621670|BIOLOGICAL|M-M-R II|M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
48466101|NCT03518723|OTHER|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
48466102|NCT03043898|OTHER|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
48466103|NCT03043898|OTHER|Lung sound recording|Lung sounds are recorded using a sensor array.
48466104|NCT02641873|DRUG|BBI608|240 mg twice daily (480 mg total daily dose)
48466105|NCT02641873|DRUG|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
48466106|NCT02641873|DRUG|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
48466107|NCT02641873|DRUG|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
48466108|NCT02641873|DRUG|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
48466109|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered IM followed by Electroporation
48466110|NCT02464670|BIOLOGICAL|INO-4202|INO-4202 delivered IM followed by Electroporation
48466111|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered ID followed by Electroporation
48466112|NCT02464670|BIOLOGICAL|INO-4212|INO-4212 delivered IM followed by Electroporation
48626216|NCT03621670|BIOLOGICAL|Varivax|Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
48626217|NCT03621670|BIOLOGICAL|Placebo (saline water)|Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group.
48626218|NCT03621670|BIOLOGICAL|Prevnar 20|Prevnar 20 (PCV13) is to be administered intramuscularly as a booster dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
47937385|NCT05214846|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
48100417|NCT04855188|DEVICE|YVOIRE volume plus|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
48466113|NCT02464670|BIOLOGICAL|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
48282452|NCT03823729|DEVICE|Elosan Cabin|The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
48466114|NCT02464670|BIOLOGICAL|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
48466115|NCT01974362|DEVICE|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
48466116|NCT01974362|DEVICE|Monolithic Zirconia (MZ)|rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer
48466117|NCT01974362|DEVICE|Zirconia-Feldspathic (PVZ)|restore dental implants with a zirconia suprastructure and feldspathic veneers
48466118|NCT01974362|DEVICE|Monolithic Zirconia (FCMZ)|Full contour full arch zirconia rehabilitation
48466119|NCT04970498|DIAGNOSTIC_TEST|MRI|MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
48466120|NCT04970498|DIAGNOSTIC_TEST|blood routine test|The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
48282453|NCT02859038|PROCEDURE|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
48466121|NCT01467596|DEVICE|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
48626219|NCT00248547|DRUG|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
48626220|NCT00248547|DRUG|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
48282454|NCT02859038|PROCEDURE|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
48282455|NCT02258412|DRUG|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
48282456|NCT02258412|DRUG|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
48282457|NCT04630145|DRUG|Bedaquiline|Participants will receive BDQ tablets only/
48466122|NCT01219140|DIETARY_SUPPLEMENT|2 POMx Capsules|2 POMx Capsules daily
48466123|NCT01219140|DIETARY_SUPPLEMENT|2 placebo Capsules|2 placebo Capsules daily
48466124|NCT03635697|BEHAVIORAL|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
48466125|NCT05295524|OTHER|Kaftrio utilization in real life|daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
48466126|NCT01354301|DRUG|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
48626221|NCT00248547|DRUG|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
48282458|NCT04630145|DRUG|Clarithromycin|Participants will receive CAM 400 or 500 mg twice a day.
48466127|NCT01354301|DRUG|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
48466128|NCT01354301|DRUG|Basiliximabe|days 0 and 4, according to the package insert instructions.
48626222|NCT00248547|DRUG|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
48626223|NCT04118972|BEHAVIORAL|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
48626224|NCT06447051|OTHER|Kasai Surgery|As per institute treatment protocol
48626225|NCT01052415|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
48626226|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) and dentin (15sec) etching with phosphoric acid~4. Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~5. Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~6. Finishing and polishing"
48626227|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~4. Composite-resin application using a transparent cervical matrix and curing for 40sec~5. Finishing and polishing"
48282459|NCT04630145|DRUG|Ethambutol|Participants will receive 500 to 750 mg daily (maximum daily dose of 1.0 gram \[g\]) or 15 mg/kg once a day.
48100418|NCT06551922|COMBINATION_PRODUCT|Instrumental Soft Tissue Mobilization Technique with Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes will be positioned.~Frequency: 3 times per week. Duration: 90 seconds- 2 minutes on each muscle (Purbia, 2023). Technique: A therapist uses Ergon tools to apply gentle pressure and strokes along the targeted muscles and fascial tissues. Different IASTM techniques, like stroking, raking, and hooking, address specific tissue restrictions. The therapist should continue the IASTM technique for 5-10 minutes, or until the stiffness in the knee is reduced (Mubashar et al., 2022; Purbia, 2023).~Conservative Treatment: Stretching exercises for the hamstrings and quadriceps to improve flexibility and reduce tension. Affected iliotibialband. Hold for 30 seconds. Uncross your legs and stand up straight again. Repeat four more times (Mubashar et al., 2022)."
48282460|NCT04630145|DRUG|Rifampicin|Participants will receive daily dose is 450 mg (maximum 600 mg) RFP capsule once a day.
48282461|NCT04630145|DRUG|Rifabutin|Participants will receive daily dose of RBT 300 mg or 150 mg capsules once a day.
48282462|NCT01662999|DRUG|Saxagliptin|
48282463|NCT01662999|DRUG|Dapagliflozin|
48282464|NCT05523180|DIETARY_SUPPLEMENT|Probiotic|"Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
48282465|NCT05523180|OTHER|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
48626228|NCT04565938|PROCEDURE|Application of adhesive for the restoration of dental lesions with resin composite|"1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) etching with phosphoric acid~4. Application of AdheSE One and curing for 10sec~5. Composite-resin application using a transparent cervical matrix and curing for 40sec~6. Finishing and polishing"
48626229|NCT04232137|BEHAVIORAL|Postpartum coffee ceremony|The promise of a postpartum coffee ceremony
48626230|NCT04361175|DRUG|Letrozole|Each group will be followed up for ovulation by day 12 ovulation monitoring by Transvaginal ultrasound for mature griffian follicle and measure endometrial thickness and volume then day 21 test serum progesterone level to confirm ovulation and if pregnancy occurred confirm by serum pregnancy test at day 35 of the cycle and follow pregnancy till confirmed by fetal pulsation by ultrasound.
48626231|NCT04361175|DRUG|Clomiphine Citrate|Clomiphine Citrate
48626232|NCT05408221|DRUG|Rulonilimab+Lenvatinib|Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
48626233|NCT05408221|DRUG|Rulonilimab placebo +Lenvatinib|Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily
48626234|NCT05548374|DEVICE|Acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. Hwato-brand disposable acupuncture needles (size 0.30×40mm) will be inserted into the acupoints through the adhesive pads. Afterwards, the acupuncture will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance.
48282466|NCT06357221|DRUG|Cetaphil|Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
48282467|NCT00659295|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
48282468|NCT00986349|DEVICE|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
48466129|NCT01354301|DRUG|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
48466130|NCT01354301|DRUG|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
48466131|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
48100419|NCT06551922|COMBINATION_PRODUCT|Conservative Treatment|"TENS: Apply TENS for 10 minutes on the greater trochanter and the area just above the lateral knee joint line, adhesive electrodes will be positioned.~Stretching exercises with hold for 30 seconds. Uncross your legs and stand up straight again (Mubashar et al., 2022).~Quadriceps Strengthening: Perform exercises like straight leg raises, seated leg press and squats to strengthen (Lim \& Al-Dadah, 2022).~Hamstring Strengthening: Include exercises like leg curls to strengthen the hamstring muscles (Lim \& Al-Dadah, 2022).~Calf Strengthening: Perform calf raises to strengthen the calf muscles (Lim \& Al-Dadah, 2022).~Balance Exercises: Incorporate balance exercises like single-leg stands on a foam pad (Lim \& Al-Dadah, 2022).~Ice Therapy: Apply ice packs to the affected knee for 15-20 minutes (Lim \& Al-Dadah, 2022)."
48282469|NCT05026775|BEHAVIORAL|Initial Medication Adherence (IMA)|"The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals."
48282470|NCT05026775|OTHER|Usual care|Health professionals in the usual care group will prescribe medication and provide information as usual.
48466132|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
48466133|NCT02943096|DIETARY_SUPPLEMENT|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
48466134|NCT02943096|OTHER|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
48466135|NCT05193422|DIAGNOSTIC_TEST|Spirometry - baseline|"Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF.~Baseline spirometry will be performed before CPET in both study arms"
48466136|NCT05193422|DIAGNOSTIC_TEST|Spirometry - post CPET|Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms
48466137|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - baseline|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms"
48466138|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - post CPET|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms"
48466139|NCT05193422|DIAGNOSTIC_TEST|Oxygen saturation|Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms
48466140|NCT05193422|DIAGNOSTIC_TEST|Heart Rate|Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms
48466141|NCT05193422|DIAGNOSTIC_TEST|End-tidal CO2|Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms
48100420|NCT01025206|BIOLOGICAL|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
48100421|NCT01809808|PROCEDURE|Surgery for acromegaly|(non-experimental) standard procedure
48100422|NCT01809808|DRUG|Medications for acromegaly|(non-experimental) standard procedure
48100423|NCT01809808|DIAGNOSTIC_TEST|Total body magnetic resonance imaging|Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
48282471|NCT04288245|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
48466142|NCT05193422|DIAGNOSTIC_TEST|Respiratory rate|Continuous monitoring of RR using a Microstream capnograph, in both study arms
48466143|NCT05193422|DIAGNOSTIC_TEST|Temperature|Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm
48466144|NCT05193422|DIAGNOSTIC_TEST|Humidity|Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm
48466145|NCT05193422|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|"CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms"
48282472|NCT04288245|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
48282473|NCT01051739|PROCEDURE|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
48282474|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
48282475|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
48282476|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
48282477|NCT05124275|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
48282478|NCT06656169|DRUG|Subcutaneous polyvidone collagen|Use collagen-polyvidone at a dose of 0.2 ml, applied to the affected area of the hand.
48282479|NCT06656169|OTHER|saline solution|administer saline solution at a dose of 0.2 ml, applied to the affected area of the hand.
48282480|NCT01973283|DRUG|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
48466146|NCT05193422|DIAGNOSTIC_TEST|Discomfort level|"Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET."
48466147|NCT03807830|PROCEDURE|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
48466148|NCT02357927|BEHAVIORAL|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
48466149|NCT02357927|BEHAVIORAL|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
48466150|NCT01532908|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
47937386|NCT01847911|OTHER|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
48282481|NCT00594399|BEHAVIORAL|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
48282482|NCT03792503|DRUG|Apatinib|Apatinib 500 mg Po qd
48282483|NCT03792503|DRUG|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
48282484|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
48282485|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
48282486|NCT04321343|DRUG|PXL065|PXL065 oral tablet
48282487|NCT04321343|DRUG|Placebo oral tablet|Placebo oral tablet
48282488|NCT06448793|DRUG|Approved Non-small Cell Lung Cancer (NSCLC) therapies|As prescribed by treating physician
48282489|NCT04837612|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
48466151|NCT01532908|DRUG|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
48466152|NCT01532908|DRUG|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
48466153|NCT03457402|BEHAVIORAL|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
48466154|NCT02293486|DIETARY_SUPPLEMENT|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
48466155|NCT03319160|DEVICE|Defibrillation|Wearable Cardioverter Defibrillator
48466156|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
47937387|NCT01847911|OTHER|instructor training|a pre-validated OSCE neonatal resuscitation program
47937388|NCT00210171|PROCEDURE|Toxicity : Time to progression, 1 and 2 years survival|
48100424|NCT01809808|PROCEDURE|Adipose Tissue Biopsy|Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
48100425|NCT06479018|BIOLOGICAL|Blood sampling|Venous blood sampling will be carried out for each patient included in the study.
48100426|NCT06479018|BIOLOGICAL|Liquid bubble sampling|Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.
48282490|NCT05453799|DRUG|Vudalimab|Given IV
48282491|NCT05809687|DRUG|DKP21102_C|Placebo
48282492|NCT05809687|DRUG|DKP21102_B|Treatment
48282493|NCT05809687|DRUG|DKP21102_A|Active Control
48282494|NCT05086315|DRUG|SAR443579|Powder for solution for infusion; by IV infusion
48282495|NCT00444015|DRUG|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
48282496|NCT02082197|DRUG|ABT-SLV176|ABT-SLV176 administered daily
48282497|NCT04449692|DRUG|Dasiglucagon|Abdominal s.c. administration
48282498|NCT04449692|OTHER|Carbohydrate (dextrose tablets)|Oral administration
48282499|NCT01802359|DRUG|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
48282500|NCT02593929|DRUG|ruxolitinib|
48282501|NCT01856673|BEHAVIORAL|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
48282502|NCT01856673|BEHAVIORAL|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
48282503|NCT01856673|OTHER|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
48282504|NCT05008328|OTHER|Music therapy plus standard care during an SBT|If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
47937389|NCT03223636|DEVICE|TMS|We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.
48466157|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
48466158|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
48466159|NCT03998592|OTHER|Placebo|Placebo without active component
48466160|NCT03348527|DRUG|2-Hydroxyflutamide Depot|Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
48466161|NCT05862987|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
48466162|NCT05862987|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
48466163|NCT01435928|DRUG|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
48466164|NCT01435928|DRUG|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
48466165|NCT04438044|DRUG|ICP-022|ICP-022 The drug product is a white, round, uncoated tablet
48466166|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
48466167|NCT01367782|DEVICE|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
48466168|NCT00566722|BIOLOGICAL|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
48466169|NCT05997030|DEVICE|low intensity focused ultrasound (LIFU)|Subjects will undergo undergo a single LIFU of the target brain region
48466170|NCT06167330|OTHER|Progressive rehabilitation program|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
48466171|NCT06167330|OTHER|Stimulation devices|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
47937390|NCT03223636|DEVICE|MRI|MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
48466172|NCT00595140|DRUG|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
48466173|NCT00595140|DRUG|combination with somatostatin analogue octreotide|s.c., 100µg, one time
48466174|NCT00595140|DRUG|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
48466175|NCT01942616|OTHER|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
48466176|NCT01942616|OTHER|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
48466177|NCT01942616|OTHER|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
48466178|NCT04542915|OTHER|No intervention|No intervention.
48466179|NCT04085744|DRUG|Lidocaine 10% Spray|lidocaine will be apply on the cuff
48466180|NCT04085744|DRUG|Mometasone nasal spray|mometasone spray will be applied on the cuff
48466181|NCT06326424|DEVICE|Empatica EmbracePlus|wear a biosensor watch to passively collect biosensor data over 48 hours. The EmbracePlus will collect heart rate variability, accelerometry, and electrodermal activity.
48466182|NCT03192813|DEVICE|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
48466183|NCT03192813|DEVICE|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
48466184|NCT05692791|DIAGNOSTIC_TEST|Two-point Discrimination Test|Two-point discrimination (2PD) is the ability to discern that two nearby objects touching the skin are truly two distinct points, not one. It is often tested with two sharp points during a neurological examination and is assumed to reflect how finely innervated an area of skin is.
48466185|NCT05692791|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Semmes-Weinstein monofilament test is used to assess light touch sensations.
48466186|NCT00377156|RADIATION|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
48466187|NCT00377156|RADIATION|stereotactic radiosurgery|
48466188|NCT05129189|DRUG|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
48466189|NCT04109209|BEHAVIORAL|Psychosocial Intervention Group|The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
48466190|NCT04109209|BEHAVIORAL|Usual Care Group|"Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
48466191|NCT01978964|BIOLOGICAL|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
48466192|NCT03484234|DEVICE|Ultimaster stent|Percutaneous coronary intervention with Ultimaster stent for long lesion
48466193|NCT03484234|DEVICE|Xience alpine stent|Percutaneous coronary intervention with Xience alpine stent for long lesion
48466194|NCT00165516|DRUG|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
48466195|NCT00165516|DRUG|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
48466196|NCT01958476|DRUG|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
48466197|NCT01958476|DRUG|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
48466198|NCT01958476|DRUG|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally \>8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores \<8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
48466199|NCT03710551|OTHER|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
48466200|NCT03710551|OTHER|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
48626235|NCT05548374|DEVICE|Sham acupuncture|The acupoints of Shangyintang, Danzhong(RNl7), Jvque(RN14), Liangmen(ST21), Zhongwan(RNl2), Hegu(LI4), Waiguan(SJ5), Zusanli(ST36), Sanyinjiao(SP6), Taichong(LR3) are selected as main acupoints and used per treatment. The other three acupoints will be chosen one each session according to the syndrome differentiation: Taixi (KI3) for liver and kidney deficiency, Fenglong (ST40) for spleen deficiency and phlegm coagulation, and Xuehai (SP10) for qi-stagnation and blood-stasis. Sterile adhesive pads will be placed on the acupoints after skin disinfection. The needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
48626236|NCT06480955|DEVICE|Cryoablation system|Any cryoablation system from Boston Scientific that has received CE Mark and/or FDA clearance for the ablation of bone malignancies.
48626237|NCT04464460|DRUG|TAK-671|TAK-671 intravenous infusion.
48626238|NCT04464460|DRUG|TAK-671 Placebo|TAK-671 placebo-matching intravenous infusion.
48626239|NCT04575012|PROCEDURE|Deferred invasive strategy|PCI on 7 to 10 days after symptom onset
48626240|NCT04575012|PROCEDURE|Early invasive strategy|Primary PCI
48626241|NCT03750084|OTHER|questionary|The intervention consists of a digitally distributed questionary.
48626242|NCT04770974|OTHER|Biomarkers and proteomics|Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
48626243|NCT06532773|BEHAVIORAL|Nite2Day+|Mindfulness-based sleep strategies and cognitive-behavioral symptom coping skills.
48626244|NCT05362539|PROCEDURE|Cystoscopy|diagnostic cystoscopy for detection of any bladder lesions
47937391|NCT04658173|DRUG|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
48466201|NCT04771767|DRUG|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
48466202|NCT04771767|BEHAVIORAL|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
48466203|NCT05008120|OTHER|No intervention|No intervention
48466204|NCT03221205|DEVICE|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
48466205|NCT03221205|DEVICE|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
48626245|NCT05362539|DIAGNOSTIC_TEST|Computed tomography|Computed tomography for patients to exclude bladder lesions
48626246|NCT05362539|GENETIC|DNA hypermethylation assay|DNA hypermethylation assay of six genes (GATA4, P16, P14, APC, CDH1 and CD99)
48626247|NCT05362539|DIAGNOSTIC_TEST|Urine cytology|voided urine cytology for all patients
48626248|NCT05359068|DRUG|SPH3127 tablet|1 tablet
48626249|NCT05359068|DRUG|SPH3127 tablet|2 tablets
48626250|NCT05359068|DRUG|SPH3127 tablet|4 tablets
48100427|NCT06479018|PROCEDURE|Cutaneous biopsy|At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.
48626251|NCT05359068|DRUG|Valsartan|1 valsartan capsule
48626252|NCT05359068|DRUG|SPH3127 tablet|2 tablets
48626253|NCT05359068|DRUG|Valsartan|1 valsartan capsule
48626254|NCT06197282|PROCEDURE|Major surgery involving general anesthesia|EHR documented SAR-CoV-2 PCR nasopharyngeal swab results confirming Covid-19 status within one year of undergoing surgical procedure at Kern Medical Center.
48626255|NCT05399342|OTHER|No Intervention|Patients in the LAAOS III trial either had or did not have their left atrial appendage occluded at the time of surgery in that trial. No further intervention is required in this cohort, it is observational follow-up only.
48466206|NCT02262741|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
48466207|NCT02262741|BIOLOGICAL|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
48466208|NCT04158687|DRUG|CTP-692|Administered as powder for oral solution.
48466209|NCT04158687|DRUG|Placebo|Administered as powder for oral solution.
48466210|NCT02571309|DEVICE|Asthmatuner|Asthmatuner is an app for self-management of asthma.
48466211|NCT01291095|DRUG|CISPLATIN|"IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN"
48626256|NCT05098990|DRUG|Jinfukang oral liquid|Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
48626257|NCT05098990|DRUG|Platinum-based doublet chemotherapy|Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
48626258|NCT04994236|DRUG|Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)|The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
48626259|NCT00005774|DRUG|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
48626260|NCT00005774|DRUG|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
48626261|NCT01158586|DRUG|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
48626262|NCT00731198|DRUG|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
48282505|NCT05008328|PROCEDURE|Standard care during an SBT|The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
48466212|NCT01291095|RADIATION|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
48466213|NCT00905541|DRUG|simvastatin|40 mg/day
48466214|NCT00905541|DRUG|simvastatin|80 mg simvastatin acute-on-chronic
48466215|NCT00957762|OTHER|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
48466216|NCT00001864|DRUG|Atropine|
48466217|NCT00001864|DEVICE|Patch|
48466218|NCT04152356|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
48466219|NCT04152356|DRUG|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
48466220|NCT00016653|DRUG|Creatine Monohydrate|
48466221|NCT00016653|DRUG|Glutamine|
48466222|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
48466223|NCT03927495|RADIATION|palliative radiotherapy|3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
48466224|NCT03927495|DRUG|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
48466225|NCT01704534|DRUG|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
48466226|NCT05070754|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
48466227|NCT05070754|DEVICE|Cryotherapy|Cryotherapy refers to the application of liquid nitrogen using a cryospray device in order to freeze a lesion of interest. Treatment is repeated every few weeks until the lesion of interest has disappeared. It is considered SOC for the treatment of warts.
48466228|NCT05070754|DRUG|Canthardin Collodion|Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.
48466229|NCT01040273|DRUG|Bupivacaine|
48466230|NCT01040273|DRUG|Placebo|
48466231|NCT00438750|OTHER|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
48466232|NCT00438750|OTHER|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
47937392|NCT04658173|DRUG|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1 mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs，and alfentanil 5ug/kg when additional analgesia is needed
48466233|NCT05614115|DRUG|Empagliflozin|is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
48466234|NCT05614115|OTHER|Placebo|Placebo comparator
48466235|NCT00381849|DRUG|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
47937393|NCT05809739|DEVICE|STYLAGE Hydro|3 sessions of injections (J0, J14 and J28)
47937394|NCT01383512|DEVICE|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
48282506|NCT06491745|OTHER|ESWT+PT+corticosteroid injection, ESWT group|ESWT group. Patients in the ESWT group will receive ESWT, physical therapy, and both shoulder joint (glenohumeral joint, GHJ) and SASD bursa injection for 2 times in a 2-week interval. 3ml triamcinolone (1ml triamcinolone= 10mg) will be added to 3ml 1% xylocaine to make 6ml injectate. Among them, 4ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. After withdrawing the needle to subcutaneous layer, another 2ml injectate will be injected into the SASD bursa of the affected shoulder under US guidance.
48282507|NCT06491745|OTHER|Sham ESWT+PT+corticosteroid injection, SHAM group.|SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.
48282508|NCT00561353|DRUG|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
48282509|NCT00561353|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
48282510|NCT00561353|DRUG|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
48282511|NCT00561353|DRUG|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
48282512|NCT04681131|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
48282513|NCT04681131|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
48282514|NCT02426866|DRUG|Efavirenz|
48282515|NCT02148029|OTHER|Exercise|Upper and Lower extremity exercise
48466236|NCT00381849|DRUG|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
48466237|NCT05134571|DRUG|Laronidase|Solution for injection; Intravenous
48466238|NCT04498676|OTHER|CB-0002B|CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
48466239|NCT06045390|OTHER|App|"App features (App will be used during the office visit):~* Pictorial representation of drops (color-coded) and schedule.~* Quiz to assess understanding of the regimen.~* Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.~* Graphical print-out of the regimen."
48466240|NCT00833625|PROCEDURE|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
48466241|NCT00833625|OTHER|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
48626263|NCT00731198|DRUG|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
48626264|NCT03524378|BEHAVIORAL|Ergonomic and movement modifications|Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
48282516|NCT02148029|OTHER|Standard Care|anticoagulation, compression, and ad-lib ambulation
48282517|NCT03084523|DRUG|Ferumoxytol Injectable Product|Patients will be administered a single dose of ferumoxytol as an MRI contrast
48282518|NCT05065112|PROCEDURE|Pulmonary veins isolation + Cartofinder-guided ablation|The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.
48282519|NCT05065112|PROCEDURE|Pulmonary veins isolation|Wide area circumferential pulmonary veins isolation
48282520|NCT01769521|DEVICE|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
48282521|NCT00775164|DRUG|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
48282522|NCT00775164|DRUG|Metformin|Metformin XR; 1000 mg once daily
48282523|NCT02291159|DEVICE|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
48282524|NCT02291159|DEVICE|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
48282525|NCT01829048|DRUG|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
48282526|NCT01829048|DRUG|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
48282527|NCT01829048|DRUG|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
48282528|NCT01829048|DRUG|Placebo|Placebo Q12h
48282529|NCT04691258|BEHAVIORAL|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
48617828|NCT03003117|BEHAVIORAL|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
48626265|NCT02518269|PROCEDURE|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
48282530|NCT04691258|BEHAVIORAL|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
48282531|NCT01126229|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo daily for 12 weeks
48282532|NCT01126229|DRUG|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
48282533|NCT01126229|DRUG|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
48282534|NCT06201143|OTHER|BREATHING EXERCISE AND MOBILIZATION TRAINING|After cesarean mobilization and breathing exercise training, the number of breathing exercises performed and the duration of mobilization will be recorded. Thus, the effectiveness of the training will be examined in detail.
48282535|NCT06201143|OTHER|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING|It will be the first study to use kinesiotaping, breathing exercise and mobilization training together.
48466242|NCT06047626|OTHER|Fatigue Reduction Diet|Sessions will be \~15 minutes for 8 sessions. The FRD maintains participants on a diet with their typical caloric intake as assessed at baseline, and replaces some of their calories with the following foods on a daily basis: at least 50% of servings grains to be whole grains (these would replace non-whole grain foods); 5 servings of vegetables (1 leafy green, 1 tomato, and 1 yellow/orange); 2 servings of fruit (1 high in vitamin C), both fruit and vegetables would replace some of the carbohydrates from non-fruit and vegetable sources; 1 serving of fatty fish and or 1 serving of nuts and/or seeds (2 servings of nuts and/or seeds for vegetarians), both the fish, the nuts, and seeds will replace existing sources of fats and proteins in the diet.
48466243|NCT06047626|OTHER|General Health Curriculum|These sessions will be matched counseling method, time spent (\~15 minutes per session), for 8 sessions. Registered Dietitians will discuss general health topics with the participant, excluding topics of diet and food.
48466244|NCT05598164|OTHER|Botulinum toxin type A|"Patients of main group are treated with injection in internal sphincter botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter botulinum toxin type A."
48466245|NCT05040139|PROCEDURE|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
48626266|NCT05814835|DRUG|2-4 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
47937395|NCT01383512|OTHER|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
48282536|NCT05824910|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions
48282537|NCT02582515|DRUG|D-cycloserine|
48466246|NCT05040139|PROCEDURE|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
48466247|NCT00004416|DRUG|botulinum toxin type A|
48466248|NCT02684539|DEVICE|tilt table Erigo®|tilting table with onset of syncope
48466249|NCT02775058|DEVICE|synergoss Pxx|dental grafting
48466250|NCT03057535|DRUG|Sodium Bicarbonate|
48626267|NCT05814835|DRUG|4-6 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
48626268|NCT05814835|DRUG|6-8 mCi 68Ga/64Cu-FAPI-XT117|68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
48626269|NCT02690376|DEVICE|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
48626270|NCT03166254|DRUG|Pembrolizumab|-Pembrolizumab will be given intravenously over the course of 30 minutes
48626271|NCT03166254|BIOLOGICAL|NEO-PV-01 vaccine|-Generation of the vaccine is expected to take approximately 12 weeks
48626272|NCT03166254|PROCEDURE|Biopsy|-Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine
48626273|NCT03166254|DRUG|Poly ICLC|-NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.
47937396|NCT00413478|DRUG|5-Azacytidine|Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
47937397|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with inner side of the graft|Procedure: The tunnel technique for root coverage with CTG with inner side of the graft
47937398|NCT06366022|DEVICE|The tunnel technique for root coverage with CTG with outer side of the graft|The tunnel technique for root coverage with CTG with outer side of the graft
47937399|NCT04564118|DRUG|Retrospective analysis of assigned treatment|analysis of treatment assigned by physicians within routine clinical practice
48626274|NCT03166254|PROCEDURE|Leukapheresis|-Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
48626275|NCT03166254|PROCEDURE|Peripheral blood samples|-Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
48626276|NCT02752477|DRUG|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
48626277|NCT02752477|DRUG|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
48626278|NCT01617213|DRUG|Melphalan|200 mg/m2/IV
48626279|NCT01617213|DRUG|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
48626280|NCT05728229|DRUG|Supplement with SiderAl® Med|Nutritional supplementation with special purpose food
48466251|NCT03057535|DRUG|Sodium Chloride|
48466252|NCT05908617|OTHER|Video Discharge|Patient will watch a video discharge instructions in addition to the standard paper instructions. They will also take the pre and post test as the control group
48466253|NCT01159899|PROCEDURE|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
48466254|NCT00545116|OTHER|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
48466255|NCT04263233|OTHER|Analysis using descriptive statistics of patient clinical outcomes.|"Evaluation of the following:~* Laboratory values at admission, week 4, and day 90.~* Pre and post blood pressure at week one and week 4.~* Intradialytic hypotension at week one and week 4.~* Ultrafiltration rates at week one, week 4, day 90, day 180, and day 360.~* Target weight defined and achievement in week one and week 4 and changes between week one and week 4.~* Dialysis access type at week one and day 90.~* Hospitalization and mortality rates."
48626281|NCT04403282|DRUG|Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
48626282|NCT04403282|DRUG|Placebo Eflornithine Topical|Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
48626283|NCT04440384|OTHER|Functional evaluation|"Patients will complete these forms and tests :~Box and block test, Purdue peg board, Percival, Nine hole peg, T-GAP, EGF, MAHVIE, DASH, RAND36, CHQ-PF28, CHQ-CF45, CGI-S"
48626284|NCT02909426|DEVICE|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
47937400|NCT05068895|OTHER|liquid chromatography-mass spectrometry|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
48282538|NCT02582515|DRUG|Placebo|
48626285|NCT02909426|DEVICE|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
48626286|NCT03148340|DIAGNOSTIC_TEST|VIPS Monitoring|Bioimpedance asymmetry
48626287|NCT02286674|OTHER|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
47937401|NCT05728775|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia.
47937402|NCT05728775|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia.
48282539|NCT04634578|DRUG|Bevacizumab|"All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution."
48466256|NCT04263233|OTHER|Surveys with participants using validated survey tools.|Surveys will assess participants' Symptom index, Quality of Life, Patient Activation as well as satisfaction with the program.
48466257|NCT04263233|OTHER|Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.|Data will be collected using tracking tools throughout the program.
48282540|NCT00994617|DRUG|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
48282541|NCT00994617|DRUG|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
48466258|NCT01647997|OTHER|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
48466259|NCT02287220|DEVICE|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
48466260|NCT01056926|BEHAVIORAL|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
48466261|NCT01056926|DRUG|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
48626288|NCT05134818|OTHER|observer tool|comparison of the efficacy of an observer tool to enhance learning of technical skills of CVC insertion in anesthesiology residents The resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
48626289|NCT00968942|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
48626290|NCT00968942|DRUG|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
48466262|NCT01056926|DRUG|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
48626291|NCT03517215|BEHAVIORAL|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
47937403|NCT03816670|DRUG|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
47937404|NCT02331875|DRUG|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
48466263|NCT03511976|BEHAVIORAL|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
48466264|NCT03511976|BEHAVIORAL|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
48466265|NCT03511976|BEHAVIORAL|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
48466266|NCT03511976|DRUG|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
48466267|NCT01198873|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
48466268|NCT01198873|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
48466269|NCT04006873|DRUG|Tezacaftor/Ivacaftor + Ivacaftor|As per description in arms.
48466270|NCT04006873|DRUG|Placebo oral tablet|As per description in arms
48466271|NCT03512249|BIOLOGICAL|H56:IC31|5ug H56/500 nmol IC31
48466272|NCT03512249|BIOLOGICAL|Placebo|Sterile saline for injection
48466273|NCT02578641|BIOLOGICAL|autologous EBV specific Cytotoxic T cells|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
48466274|NCT02578641|DRUG|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
48466275|NCT01222364|PROCEDURE|Standard Cord Clamping|Immediate clamping (\<5 seconds) of the umbilical cord after delivery.
48466276|NCT01222364|PROCEDURE|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
47937405|NCT02331875|PROCEDURE|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
48466277|NCT00818220|PROCEDURE|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
48466278|NCT00818220|OTHER|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
48466279|NCT03563560|DRUG|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
48466280|NCT03563560|DRUG|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
48466281|NCT03563560|DRUG|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
48466282|NCT03563560|DRUG|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
48466283|NCT03563560|DRUG|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
48466284|NCT02973269|BIOLOGICAL|daxibotulinumtoxin type A|Intramuscular injection
48626292|NCT03517215|BEHAVIORAL|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
48466285|NCT02973269|BIOLOGICAL|Placebo|Intramuscular injection
48466286|NCT02849106|PROCEDURE|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
48466287|NCT01041209|BEHAVIORAL|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
48466288|NCT01041209|BEHAVIORAL|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
48626293|NCT05463770|DRUG|SEP-363856|SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
48626294|NCT00002470|BIOLOGICAL|recombinant interferon alfa|
48626295|NCT00002470|DRUG|fluorouracil|
48466289|NCT00491257|BIOLOGICAL|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
48466290|NCT04077125|DRUG|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
48466291|NCT05913817|BIOLOGICAL|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
48466292|NCT01507233|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
48466293|NCT01507233|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
48466294|NCT02319850|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
48466295|NCT03028155|DRUG|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
48466296|NCT03028155|DRUG|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
48466297|NCT04506567|DRUG|225Ac-J591|Single cycle of fractionated dose of 225Ac-J591
48466298|NCT04506567|DIAGNOSTIC_TEST|68Ga-PSMA-HBED-CC injection|68Ga-PSMA-HBED-CC PET/CT before and after treatment
48466299|NCT04506567|DRUG|225Ac-J591|Single dose of 225Ac-J591 every 6 weeks x 4
48466300|NCT03595241|DEVICE|Spinal cord stimulation by implanted device.|Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
48466301|NCT02771392|DRUG|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
48466302|NCT02771392|OTHER|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
48466303|NCT04926701|DRUG|ETD001 single dose|Single ascending doses of inhaled ETD001
48466304|NCT04926701|DRUG|Placebo single dose|Single doses of inhaled placebo
48466305|NCT04926701|DRUG|ETD001 multiple twice daily doses|Ascending doses of inhaled ETD001 administered twice daily
48466306|NCT04926701|DRUG|Placebo multiple twice daily doses|Doses of inhaled placebo administered twice daily
48466307|NCT04926701|DRUG|ETD001 multiple once daily doses|Doses of inhaled ETD001 administered once daily
48626296|NCT00743093|DRUG|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
48626297|NCT00743093|DRUG|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
48626298|NCT04706221|DEVICE|CM-1500|Blood volume monitor CM-1500
48626299|NCT04488185|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg administered s.c. (2 single-use prefilled syringes of 150 mg/mL), on Days 1, 8, 15, 22, 29, 57, 85.
48626300|NCT04488185|OTHER|Placebo|Placebo administered s.c. (2 single-use prefilled 1 mL syringes) on Days 1, 8, 15, 22, 29, 57, 85.
48466308|NCT04926701|DRUG|Placebo multiple once daily doses|Doses of inhaled placebo administered once daily
48466309|NCT01781234|DRUG|Intranasal Insulin|
48466310|NCT01781234|DRUG|Placebo|
48466311|NCT03449225|OTHER|Computer-Aided Genetic Education Module|Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
48617829|NCT00820378|OTHER|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
48617830|NCT00262379|DRUG|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
48626301|NCT04801693|DRUG|BI 1819479|BI 1819479
48626302|NCT04801693|DRUG|Placebo|Placebo
48626303|NCT01355367|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
48626304|NCT00126217|BIOLOGICAL|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
48466312|NCT05955326|DRUG|Sovateltide|Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
48626305|NCT03537456|DEVICE|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
48626306|NCT01870037|DRUG|Placebo (PBS-20% sucrose)|
48626307|NCT01870037|DRUG|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
48626308|NCT00361153|DRUG|Colesevelam hydrochloride|Welchol tablet 625mg
48626309|NCT00361153|DRUG|placebo|placebo
48282542|NCT02950506|DEVICE|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
48282543|NCT02950506|OTHER|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
48466313|NCT05955326|OTHER|Normal Saline|Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
48466314|NCT00003850|DRUG|thalidomide|
48466315|NCT03568604|DRUG|Prasterone|6.5 vaginal insert prasterone (dehydroepiandrosterone)
48466316|NCT00391534|DRUG|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
48466317|NCT00391534|DRUG|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
48466318|NCT02463487|DEVICE|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
48466319|NCT02463487|DEVICE|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
48626310|NCT03549195|PROCEDURE|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
48626311|NCT03549195|PROCEDURE|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
48626312|NCT03549195|PROCEDURE|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
48626313|NCT04640896|DRUG|Trigger point injection with bupivacaine|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
48626314|NCT04640896|DRUG|Trigger point injection with normal saline|Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
48466320|NCT05575557|PROCEDURE|Right heart catheterization|All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.
48466321|NCT00566657|BIOLOGICAL|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
48466322|NCT00566657|BIOLOGICAL|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
48466323|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
48466324|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
48466325|NCT05609695|DRUG|Immune checkpoint inhibitor|After signing the written informed consent form, patients begin to receive single or combined therapy with immune checkpoint inhibitor. The use of immune checkpoint inhibitors takes 3 weeks as a cycle, and the treatment dose for each cycle is carried out in accordance with the latest international authoritative guidelines.
48466326|NCT04237350|BEHAVIORAL|Video recording for behaviors|"A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded."
48626315|NCT04640896|DRUG|Lidocaine skin wheal|"Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection."
48626316|NCT02984137|OTHER|testing, evaluation, sampling|neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological \& neurocognitive status by using a predefined neuropsychological assessment battery.
48626317|NCT06040619|BEHAVIORAL|Therapy Together|8-week caregiver-led pediatric constraint-induced movement therapy program
48626318|NCT06040619|BEHAVIORAL|Usual Care|8 weeks of usual care received in an early intervention therapy program
48626319|NCT01618877|DRUG|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
48626320|NCT01618877|OTHER|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
48626321|NCT05919251|BEHAVIORAL|Ageless Grace|This unique program attempts to combine multiple aspects that easily fit together including music and a group setting for socialization. The use of music to improve cognition as has been shown in other research studies to improve participation in exercise program. By linking cognitive retraining, low intensity exercise, group activities and music, the researchers of this project can determine if a movement program with these attributes can benefit individuals as a program of wellness once their rehabilitation plans have been completed. The researchers are specifically interested in the effect on balance, activity and incidence of falls in people with chronic stroke. Additionally, the researchers will investigate the differences that this structured program will make on older adults who will act as a comparison group. This will bring insight into some of the additional challenges that people with stroke encounter on a daily basis.
48626322|NCT03651492|BEHAVIORAL|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
48626323|NCT05810662|OTHER|Lactated ringer and dextrose 5%|Fluid use perioperative
48626324|NCT01580644|DRUG|GLPG0187 prodrug|
48626325|NCT02635035|DRUG|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
48626326|NCT02635035|DRUG|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
48282544|NCT06001580|DRUG|BR101|BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study
48282545|NCT04837560|DEVICE|ElastiMed's SACS 2.0|A wearable medical device that improve circulation using smart materials
48282546|NCT02870673|DRUG|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
48282547|NCT02870673|DRUG|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
48626327|NCT03972228|COMBINATION_PRODUCT|Microdevice loaded with 19 chemotherapeutic agents|The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
48626328|NCT04600323|DRUG|Sodium Bicarbonate Tablets|Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
48626329|NCT04600323|DRUG|Placebo|Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
48626330|NCT05638984|DRUG|Decitabine Injection|Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
48626331|NCT05638984|DRUG|tirelizumab|10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
48466327|NCT06468514|OTHER|neural tensioning technique on radial nerve|the neural group tensioning technique: The test should be performed in approximately 10° of shoulder abduction. The examiner extends the elbow 2 seconds just to the range where the patient notices tension but no pain and then the elbow is flexed. Three sets of 6-8 swings are performed with 1 minute rest in between.
48626332|NCT02068599|DRUG|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
48626333|NCT02068599|DRUG|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
48626334|NCT06386549|BEHAVIORAL|tele-rehabilitation|Using the social networking tool WeChat, families of children with burns are educated and trained through texts, photos, voice messages, and live videos, twice a week for a total of 12 weeks
48626335|NCT04588272|DEVICE|DualGuard|DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.
48100428|NCT05998005|BEHAVIORAL|First Face Training Program|First Face for Mental Health is a culturally-appropriate community-based mental health training for lay persons and others that prepares learners to provide assistance to someone having a mental health crisis. The course takes approximately 8 hours to complete.
48626336|NCT06473818|DEVICE|Non-invasive monitoring|Non-invasive cardiac output monitoring
48626337|NCT06473818|DEVICE|Invasive monitoring|Invasive cardiac output monitoring
48100429|NCT05998668|OTHER|Genital hygiene training|In the first meeting with the women, 2 sessions of 45 minutes with a 10-minute break were held in the counselling rooms of the relevant family health centers. Two weeks after these sessions, a 45-minute session was held in order to reinforce the training with the same method.
48100430|NCT00782639|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
48100431|NCT00782639|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
48100432|NCT02186405|DRUG|LEVOTHYROXINE|administration of levothyroxine
48282548|NCT02870673|DEVICE|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
48282549|NCT02870673|DEVICE|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
48282550|NCT02224430|DEVICE|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
48466328|NCT06468514|OTHER|Sliding technique on radial nerve|The mobilization maneuver begins by identifying the first resistance and the range of extension associated with pain. Maintaining elbow extension within the elastic region of resistance free of pain and/or paresthesia the examiner increases elbow extension and simultaneously allows the wrist to extend as necessary for the radial nerve branches in the forearm to glide proximally. The physical therapist then flexes the wrist while allowing the elbow to flex to cause the radial nerve excursion distally in the forearm.
48466329|NCT04416854|PROCEDURE|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
48466330|NCT04416854|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
48466331|NCT04416854|DRUG|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
48466332|NCT04483895|PROCEDURE|Endotracheal tube insertion|ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
48466333|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
48617831|NCT04428489|OTHER|Observation and necessary supportive care|For patients with ICUS and CCUS, necessary supportive care could be given. No addtitional treatment is administrated.
48617832|NCT00548327|DRUG|Atomoxetine|Comparison between Atomoxetine and Placebo
48282551|NCT05413681|DIAGNOSTIC_TEST|a supra-maximal exercise test on a cycloergometer.|10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.
48282552|NCT05413681|DIAGNOSTIC_TEST|handgrip muscle activity test.|2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
48282553|NCT06557512|RADIATION|Hypofractionated Stereotactic Radiosurgery (SRS)|Undergo Hypofractionated Stereotactic Radiosurgery
48282554|NCT06557512|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
48282555|NCT06557512|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
48282556|NCT05125653|PROCEDURE|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
48100433|NCT06458127|OTHER|Tele-palliative care visit|Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.
48100434|NCT06249841|DEVICE|1.1mm flexible Cryoprobe SU|Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
48100435|NCT01724255|OTHER|questionnaire|
48282557|NCT05125653|PROCEDURE|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
48282558|NCT03025412|PROCEDURE|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
48282559|NCT03025412|BEHAVIORAL|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
48282560|NCT00046566|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
48282561|NCT00046566|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
48282562|NCT00046566|BEHAVIORAL|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
48282565|NCT02113293|DRUG|CyclASol®|Cyclosporine A Solution
48282566|NCT02113293|DRUG|Placebo (vehicle)|Vehicle Solution
48617833|NCT00548327|PROCEDURE|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
48282567|NCT06136858|DEVICE|Cuirass ventilation|We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
48282568|NCT01225354|DRUG|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
48282569|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|"2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)"
48282570|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
48282571|NCT00124306|DRUG|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
48282572|NCT00124306|OTHER|Placebo|Placebo will be dosed exactly as active arm.
48282573|NCT00125333|DRUG|NF-kappaB Decoy|
48282574|NCT00082082|DRUG|Thymalfasin (thymosin alpha-1)|
48282575|NCT00082082|PROCEDURE|Trans arterial chemoembolization (TACE)|
48617834|NCT00548327|PROCEDURE|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
48617835|NCT00548327|DRUG|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
48100436|NCT06103240|OTHER|Lacticaseibacillus rhamnosus LRa05|Bacterial count:100 billion CFUs Take one sachet per day for 4 weeks.
48100437|NCT04338165|DRUG|Evolocumab 140 MG/ML [Repatha]|3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
48466334|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation|The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
48466335|NCT02228889|PROCEDURE|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
48466336|NCT02228889|OTHER|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
48466337|NCT02228889|OTHER|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
48466338|NCT02228889|OTHER|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
48466339|NCT02228889|OTHER|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
48466340|NCT02228889|OTHER|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
48466341|NCT02228889|OTHER|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
48466342|NCT02228889|OTHER|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
48466343|NCT02228889|OTHER|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
48466344|NCT02228889|OTHER|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
48466345|NCT02228889|OTHER|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
48466346|NCT02228889|OTHER|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
48466347|NCT02228889|OTHER|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
48466348|NCT02228889|OTHER|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
48466349|NCT02228889|OTHER|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
48466350|NCT02228889|OTHER|Assess overall complications at 30 days postoperatively|
48466351|NCT02228889|OTHER|Assess overall complications at 1 year postoperatively|
48626338|NCT05461898|OTHER|Inpatient Rehabilitation|Standard inpatient rehabilitation program with a interdisciplinary team that included a physiotherapist who ensured muscle strength, balance, aerobic and functional training, an occupational therapist who provided training of basic and instrumental activities of daily living and education of energy conservation techniques and a a speech and language therapist for swallowing training.
48626339|NCT05461898|OTHER|Inspiratory muscle training|Inspiratory muscle training protocol during 6 weeks with a electronic-controlled valve device
48626340|NCT03837938|DRUG|Levopront® syrup 30 mg/5 ml|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).
48282576|NCT00460993|DRUG|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
48466352|NCT02228889|PROCEDURE|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
48466353|NCT02228889|DEVICE|Strattice|Strattice mesh
48466354|NCT02228889|DEVICE|XenMatrix|Xenmatrix mesh
48466355|NCT03350191|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48466356|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48466357|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48466358|NCT00003387|DRUG|carboplatin|
48466359|NCT00003387|DRUG|chemotherapy|
48466360|NCT00003387|DRUG|paclitaxel|
48466361|NCT00003387|RADIATION|radiation therapy|
48466362|NCT01234961|BEHAVIORAL|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
48466363|NCT01234961|OTHER|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
48466364|NCT05089890|DEVICE|Sorbact® Compress|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
48466365|NCT05089890|DEVICE|Sorbact® Gel Dressing|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
48617836|NCT02207608|DRUG|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
48617837|NCT02207608|DRUG|BCG (Immucist®)|Usual BCG treatment
48626341|NCT03837938|DRUG|Libexin®|The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.
48466366|NCT05089890|DEVICE|Sorbact® Ribbon Gauze|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
48466367|NCT03234309|DRUG|Ferumoxytol|Given IV
48466368|NCT03234309|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48466369|NCT04915222|OTHER|Natural apophyseal glides|Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
48466370|NCT04915222|OTHER|Cervical manual traction|Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
48466371|NCT02413008|DRUG|estriol|0.005% estriol vaginal gel
48466372|NCT02413008|DRUG|Placebo|placebo vaginal gel
48466373|NCT03349632|DEVICE|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
48466374|NCT03349632|DEVICE|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
48466375|NCT03349632|DEVICE|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
48466376|NCT03349632|DEVICE|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
48466377|NCT05525702|DEVICE|Virtual Reality Treatment|Patients wear virtual reality head-mounted displays and experience immersive virtual environments.
48617838|NCT00942851|DRUG|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
48626342|NCT01491165|PROCEDURE|stem cell transplantation through interventional procedures|one time interventional procedures
48626343|NCT01828684|OTHER|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
48626344|NCT01828684|OTHER|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
48626345|NCT02375997|OTHER|Palliative care|Early nutrition intervention and psychological intervention
48626346|NCT02158598|DRUG|Vitamin D chewable tablet supplementation|
47937406|NCT02331875|RADIATION|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
48100438|NCT01061229|DRUG|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
48626347|NCT02158598|DRUG|Vitamin D pill supplementation|
48626348|NCT03523351|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
48626349|NCT03523351|DRUG|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
47937407|NCT05012787|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.
47937408|NCT05012787|BIOLOGICAL|Havrix|Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.
47937409|NCT05012787|OTHER|Placebo; 0.9% saline|Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.
47937410|NCT02417948|OTHER|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
48626350|NCT04489056|GENETIC|Swabs for microbiome analysis|After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
48626351|NCT03729479|BEHAVIORAL|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
48626352|NCT03729479|BEHAVIORAL|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
48466378|NCT04346862|DRUG|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
48466379|NCT04346862|DRUG|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
48466380|NCT00476307|BIOLOGICAL|Fluarix™/Influsplit SSW® 2007/2008|
48466381|NCT06263114|DIAGNOSTIC_TEST|TruGraf® Liver gene expression panel (GEP)|Test done on blood sample collected during for cause or routine liver biopsy
48466382|NCT06358027|DIAGNOSTIC_TEST|lung ultrasound|The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.
48466383|NCT00967148|DRUG|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
48466384|NCT04707846|DEVICE|Bright Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
48466385|NCT04707846|DEVICE|Dim Blue Light Commercial AYO Light Therapy Device|"AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as exempt for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471)."
48466386|NCT04908540|PROCEDURE|Mini-screw Assissted Rapid Palatal Expansion|Mini-screw assissted RPE will be the main intervention in the two comparative groups. In the control (group A) will be used with its conventional activation protocol. While in experimental (group B) will be used with ALT-RAMEC protocol.
48466387|NCT04136067|DRUG|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
48466388|NCT04136067|DRUG|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
48626353|NCT03729479|BEHAVIORAL|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
48626354|NCT00003685|PROCEDURE|fatigue assessment and management|
48626355|NCT00003685|PROCEDURE|nausea and vomiting therapy|
48626356|NCT00003685|PROCEDURE|pain therapy|
48626357|NCT00003685|PROCEDURE|quality-of-life assessment|
48626358|NCT00003685|RADIATION|radiation therapy|
48100439|NCT01061229|OTHER|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
48100440|NCT04619654|PROCEDURE|Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold|Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent
48466389|NCT04781244|DEVICE|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
48466390|NCT04781244|DEVICE|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
48466391|NCT03033030|DIAGNOSTIC_TEST|Ultrasound|Ultrasound examination
48466392|NCT01156441|PROCEDURE|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers."
48466393|NCT00001217|DRUG|pre-surgical chemotherapy|
48466394|NCT02747680|OTHER|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
48466395|NCT05003882|OTHER|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
48282577|NCT04442607|DEVICE|artificial intelligence image processing|Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
48466396|NCT01282736|BEHAVIORAL|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
48466397|NCT01282736|BEHAVIORAL|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
48466398|NCT06405815|OTHER|tumor and peritumor radiomic feature|extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
48466399|NCT06188780|DIAGNOSTIC_TEST|urine/blood analysis with IA and LC-GCMS analysis|urine/blood analysis with IA and LC-GCMS analysis
48466400|NCT02941523|DRUG|NOX66|NOX66 administration
48466401|NCT02941523|DRUG|Carboplatin|Carboplatin administration
48466402|NCT06492551|OTHER|Trak exercise prescription protocol|Online treatment based on therapeutic exercise using the Trak software. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques to improve secretion management and respiratory mechanics will also be included.
48466403|NCT06492551|OTHER|Conventional rehabilitation plan in the gym|Treatment is based on therapeutic exercise following a conventional rehabilitation plan. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques will also be included to improve secretion management and respiratory mechanics.
48466404|NCT00158535|PROCEDURE|liver transplantation|
48466405|NCT03519438|OTHER|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
48466406|NCT04175860|BEHAVIORAL|The intervention with the patient (Chronic Patient Care Group and his family.)|"* Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~* Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~* Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
48466407|NCT05740215|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
48466408|NCT05740215|DRUG|Lenvatinib|Lenvatinib capsules
48466409|NCT06260982|RADIATION|18-FDG-PET|18-FDG-PET and neuropsychological tests (language, memory, visuo-spatial tests, etc.).
48466410|NCT05586386|OTHER|Cherry group|200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
48466411|NCT05586386|OTHER|Placebo group|200 mL of placebo juice twice/day
48282578|NCT04516681|DRUG|Ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
48466412|NCT02941939|OTHER|Hyperbaric chamber|
48466413|NCT02941939|OTHER|Ambient pressure|
48466414|NCT04715139|DEVICE|Products listed in Group/Cohort Description|Depending on approved indication per product
48466415|NCT02482558|OTHER|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
48466416|NCT02413034|DRUG|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
48466417|NCT02413034|OTHER|Control group|no antibiotic prophylaxis
48466418|NCT04204096|BIOLOGICAL|Vi-DT (Multi-dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~* Storage Conditions: +2 to +8°C"
48466419|NCT04204096|BIOLOGICAL|Vi-DT (Single dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~* Storage Conditions: +2 to +8°C"
48466420|NCT04204096|BIOLOGICAL|Control Vaccine|"* For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~* For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
48466421|NCT02336633|DIETARY_SUPPLEMENT|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
48466422|NCT02336633|OTHER|Placebo|
48466423|NCT00221520|DRUG|midazolam with 2 different levels of sedation scores|
48466424|NCT02532192|DRUG|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
48466425|NCT02532192|DRUG|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
48466426|NCT02532192|DRUG|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
48466427|NCT02532192|DRUG|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
48466428|NCT02532192|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
48466429|NCT02532192|DRUG|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
48466430|NCT02532192|DRUG|Fluconazole|100 mg by mouth daily for 10 days.
48617839|NCT00942851|DRUG|placebo|topical treatment NOT containing AH-8
48466431|NCT03335241|DRUG|Fludarabine and Pegylated liposomal doxorubicin|"Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks"
48466432|NCT03335241|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
48466433|NCT04482816|DEVICE|Physiological pacing|Pacing of the his bundle or the left bundle branch
48466434|NCT04482816|DEVICE|Right ventricular pacing|Conventional pacing; right ventricular pacing
48466435|NCT01633307|OTHER|Education|Teaching program
48466436|NCT02611323|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 milligrams (mg) via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
48466437|NCT02611323|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m\^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
48466438|NCT02611323|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
48466439|NCT02611323|DRUG|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
48466440|NCT01023061|DRUG|abiraterone acetate|Given PO
48466441|NCT01023061|DRUG|prednisone|Given PO
48466442|NCT01023061|DRUG|leuprolide acetate|Given via injection
48466443|NCT01023061|OTHER|laboratory biomarker analysis|Correlative study
48466444|NCT01023061|RADIATION|external beam radiation therapy|Undergo radiotherapy
48466445|NCT01023061|DRUG|goserelin acetate|Given via injection
48466446|NCT03092167|OTHER|Physical exercises|Physical exercises
48466447|NCT04175587|DRUG|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
48466448|NCT05483608|OTHER|Vertical climbing ergometer exercise|Exercise using the CLMBR, a vertical climbing exercise ergometer.
48466449|NCT05483608|OTHER|Recumbent cycling|Exercise using a recumbent cycle ergometer
48466450|NCT00020358|BIOLOGICAL|aldesleukin|
48466451|NCT00020358|BIOLOGICAL|gp100 antigen|
48466452|NCT00020358|BIOLOGICAL|incomplete Freund's adjuvant|
48466453|NCT00020358|BIOLOGICAL|tyrosinase peptide|
48466454|NCT00504634|DRUG|Bortezomib|1 mg/m\^2 IV On Days 1, 4, 8, and 11.
48466455|NCT04334850|PROCEDURE|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
48466456|NCT04334850|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
48466457|NCT02287636|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
48466458|NCT02287636|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
48466459|NCT02287636|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
48466460|NCT02287636|PROCEDURE|positron emission tomography|Undergo PET/MRI
48466461|NCT02287636|PROCEDURE|magnetic resonance imaging|Undergo PET/MRI
48466462|NCT00470691|PROCEDURE|plaster cast|complete circular plaster cast
48466463|NCT00470691|PROCEDURE|dorsal splint|dorsal plaster splint
48466464|NCT01802645|DRUG|Cetuximab|
48466465|NCT01802645|DRUG|Bevacizumab|
48466466|NCT01802645|DRUG|Irinotecan|
48466467|NCT01802645|DRUG|Oxaliplatin|
48466468|NCT01802645|DRUG|5-FU|
48466469|NCT01802645|DRUG|Folinic Acid|
48466470|NCT05842720|PROCEDURE|un-sedated colonoscopies|un-sedated colonoscopies in high risk patients with ASA\>=3
48466471|NCT06452758|OTHER|2000 meter ergometer test|Rowers will perform 2000m ergometer test. A 2,000-meter trial is a standard test used to assess performance in rowers.
48466472|NCT05667597|DIAGNOSTIC_TEST|Humoral immunity|determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).
48466473|NCT01970592|BEHAVIORAL|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
48466474|NCT00919516|PROCEDURE|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
48466475|NCT00595673|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
48466476|NCT06431776|DRUG|Molgramostim|Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.
48466477|NCT06441695|DIETARY_SUPPLEMENT|xumXR extended release caffeine|proprietary capsule for extended release of caffeine
48466478|NCT06441695|DIETARY_SUPPLEMENT|immediate release caffeine|immediate release caffeine capsule
48466479|NCT03942211|DRUG|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
48466480|NCT03942211|DRUG|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
48466481|NCT05717985|PROCEDURE|modified combined approach|A thin layer of epithelium will be excised from the harvested graft. This epithelium will be replaced at the donor site and sutured.
48466482|NCT05717985|PROCEDURE|de-epithelized gingival graft|Only dressing material will be placed at the donor site after graft harvesting
48466483|NCT01182792|DIETARY_SUPPLEMENT|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
48466484|NCT01182792|DIETARY_SUPPLEMENT|Placebo|1 month Placebo
48466485|NCT02335372|PROCEDURE|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
48466486|NCT02335372|DRUG|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
48466487|NCT02335372|DRUG|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
48466488|NCT02335372|PROCEDURE|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
48466489|NCT02004717|DRUG|DS-8895a|
48466490|NCT03565562|OTHER|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
48466491|NCT03565562|OTHER|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
48466492|NCT06449391|DEVICE|RAI|Immediate implantation
48466493|NCT06227520|OTHER|decellularized dermal matrix|Application of Wound bed
48466494|NCT06324305|PROCEDURE|Pars plana vitrectomy (PPV) and drainage of subretinal fluid|Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)
48466495|NCT01245491|OTHER|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
48466496|NCT05048862|DIAGNOSTIC_TEST|Neuromuscular ultrasound|Ultrasound will be performed with the Affiniti 70 (Philips Medical Instruments, Bothell, WA). all patients following standardized methods of our hospital. All the patient would be checked the skin surface temperature before the ultrasound examination. The image would be exported from the echo machine as DICOM format.
48466497|NCT05048862|DIAGNOSTIC_TEST|Muscle MRI|Muscle MRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject will lie in a supine position comfortably, supplied with ear plugs. A high resolution T1 weighted scan and Short-T1 Inversion Recovery series (STIR) of the four limbs muscle were obtained in axial and coronal plane. MR spectroscopy in interested muscle was also sampled to evaluate the composition of fat, water, lactate, and other studied molecules.
48466498|NCT05048862|DIAGNOSTIC_TEST|Nerve conduction studies and autonomic function tests|Nerve conduction study will be performed with a Nicolet Viking IV Electromyographer (Madison, WI) in all patients following standardized methods recommended by the Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Studied nerves include sural, peroneal, tibial, median and ulnar (motor and sensory) nerves.Autonomic functions will be assessed by the SSR and RRIV with established protocol by using Nicolet Viking IV Electromyographer (Madison, WI).
48466499|NCT05048862|DIAGNOSTIC_TEST|Quantitative sensory test|Quantative sensory test will be performed with a Thermal Sensory Analyzer and Vibratory Sensory Analyzer (Medoc Advanced Medical System, Minneapolis, MN). The procedure is the same as previously described 25. Briefly, the machine delivers to the patient a stimulus of constant intensity which is pre-set by the algorithm. By adjusting the intensity of stimulus (increase or decrease the intensity by a fixed ratio) according to the response of the subject (i.e. whether the subject perceives the stimulus or not), sensory thresholds of the warm, cold and vibratory modalities will be measured.
48466500|NCT05048862|DIAGNOSTIC_TEST|Skin biopsy|A skin specimen of 3 mm in diameter will be taken with a biopsy punch from the lateral side of the distal leg under 2% lidocaine local anaesthesia 26. No suturing is required, and the wounds are covered with a piece of gauze. Wound healing takes 7\~10 days, similar to a typical abrasion wound. Informed consent will be obtained from each patient before the skin biopsy. The intraepidermal nerve fiber density and sweat gland nerve innervation will be examined.
48466501|NCT05048862|DIAGNOSTIC_TEST|Muscle and nerve biopsy|Two muscle specimens with 5 x 5 x 5 mm were collected in an open muscle biopsy or needle biopsy at studied muscles under 2% lidocaine local anaesthesia. The wound was about 2-3 cm long, and suture was required. Would healing usually takes 10-14 days. First specimen was undergoing snap freezing fixation in a longitudinal axis perpendicular to the cork with the liquid nitrogen and isopentane. The second specimen was divided into two equiponderous tissues, and one was freezed in liquid nitrogen for DNA and protein analysis. The another one was treated with RNAlater solution in 4°C overnight for RNA analysis. Sural nerve biopsies or superficial peroneal nerve were obtained from a standard site posterior to the lateral malleolus under local anesthesia. The nerves were then fixed in 5% glutaraldehyde in 0.1 M phosphate buffer (PB) at 4 °C overnight. All samples were stored in the -80°C refrigerator for further analysis.
48626359|NCT05737147|DEVICE|Zero Heat Flux Thermometer|Comparison of the accuracy and precision of a Zero Heat Flux Thermometer (SpotOn) Versus Pulmonary Artery Temperature Measurement
48626360|NCT00849329|DRUG|lapatinib|1250mg lapatinib
48626361|NCT00849329|DRUG|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
48626362|NCT05023005|OTHER|Strain-Counterstrain treatment of piriformis muscle|Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.
48282579|NCT04516681|DRUG|FOLFOX Protocol|Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
48282580|NCT04516681|DRUG|Adebrelimab|20mg/Kg intravenously every 3 weeks
48282581|NCT05495464|DRUG|Acalabrutinib|Given by PO
48282582|NCT05495464|DRUG|Rituximab|Given by IV (vein)
48282583|NCT05495464|OTHER|Brexucabtagene Autoleucel|Given by IV (vein)
48282584|NCT05495464|DRUG|Cyclophosphamide|Given by IV (vein)
48282585|NCT05495464|DRUG|Fludarabine Phosphate|Given by IV (vein)
48282586|NCT02216565|OTHER|Hospitalization in specialized neuro-vascular unit|
48282587|NCT02216565|DRUG|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
48282588|NCT02216565|OTHER|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
48466502|NCT05048862|DIAGNOSTIC_TEST|Genomics, transcriptome, and proteomics|The DNA, RNA, and protein of the tissues (blood, muscle, nerve and skin) were retrieved and stored in the -80°C refrigerator. The next generation sequencing (whole exon sequencing or whole genome sequencing) and RNA-seq would be performed by NGS \& Microarray Core lab in National Taiwan University or another professional team. The protein analysis would be performed by the Proteomics \& Protein Function Core Lab in National Taiwan University.
48466503|NCT05048862|DIAGNOSTIC_TEST|Laboratory of blood chemical substances, metals and endocrine profiles|The methods of the measurement will follow the standards set by Department of Laboratory Medicine of National Taiwan University Hospital.
48466504|NCT05048862|DIAGNOSTIC_TEST|Contact heat evoked potentials|A contact heat evoked potential stimulator (Medoc, Ramat Yishai, Israel) will be used for delivering heat stimulation. Stimuli will be delivered repeatedly to the same stimulation site and the inter-stimulus interval will be randomly set to around 18\~22 s. CHEP will be recorded using a Nicolet Bravo evoked potential system (Nicolet Biomedical, Madison, WI). The recording electrode was placed at the Cz and P3 of international 10-20 system. The impendence of all recording electrodes was kept below 3 kΩ. The evoked potentials were filtered with a bandpass filter at 0.1\~30 Hz. Recording was triggered by the onset of each stimulus, and the sweep time was 1500 ms.
48466505|NCT05048862|DIAGNOSTIC_TEST|Nerve excitability study|Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at \>32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
48100441|NCT02837237|DRUG|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
47937411|NCT02417948|OTHER|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
48282589|NCT02216565|PROCEDURE|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
48282590|NCT02629705|DIETARY_SUPPLEMENT|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
48282591|NCT02629705|DIETARY_SUPPLEMENT|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
48282592|NCT05957276|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
48282593|NCT04972383|COMBINATION_PRODUCT|Platelet Rich Plasma|In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.
48282594|NCT04972383|COMBINATION_PRODUCT|Hyaluronic Acid|In the Hyaluronic group, 3mLHYAJOINT Plus was given.
48282595|NCT03061708|DRUG|AZD2014|mTOR inhibitor
48282596|NCT02351115|DRUG|A=Placebo|
48282597|NCT02351115|DRUG|B=Inhaled Alprazolam 0.5 mg|
48282598|NCT02351115|DRUG|C=Inhaled Alprazolam 1 m|
48282599|NCT02351115|DRUG|D= Inhaled Alprazolam 2 mg|
48282600|NCT02351115|DRUG|E=Placebo|
48282601|NCT01420133|OTHER|Regimen|regimen normal in salt and sugar
48282602|NCT01420133|OTHER|Standard regimen|with diet low in salt and sugar
48282603|NCT02560454|BEHAVIORAL|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
48282604|NCT02560454|BEHAVIORAL|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
48282605|NCT04833036|DRUG|Irinotecan|180 mg/m2, ivgtt d1，q2w
48282606|NCT04833036|DRUG|cetuximab|500 mg/m2, ivgtt d1，q2w
48282607|NCT00194350|PROCEDURE|Test for Factor V Leiden gene mutation|
48282608|NCT04339868|DRUG|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
48282609|NCT04339868|DRUG|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
48282610|NCT02765841|DRUG|Lomitapide|
48282611|NCT04604327|DRUG|Bemiparin sodium|Prophilactic vs full-dose for 10 days
48282612|NCT04771715|DRUG|Regorafenib|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
48282613|NCT04771715|DRUG|Nivolumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
48282614|NCT04771715|DRUG|Pembrolizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
48282615|NCT04771715|DRUG|Camrelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
48282616|NCT04771715|DRUG|Sintilimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
48282617|NCT04771715|DRUG|Toripalimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
48282618|NCT04771715|DRUG|Tislelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
48282619|NCT03384056|DEVICE|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
48282620|NCT03384056|DEVICE|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
48282621|NCT05627466|DRUG|Magrolimab|Administered intravenously
48282622|NCT01697345|DRUG|Testosterone|
48282623|NCT05695547|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
48466506|NCT05048862|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
48282624|NCT00204087|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
48282625|NCT00204087|BEHAVIORAL|Supportive Counselling (SC)|
48466507|NCT05048862|DIAGNOSTIC_TEST|fMRI acquisition and image analysis|fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
48466508|NCT02783326|OTHER|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
48466509|NCT01979146|OTHER|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
47937412|NCT03455764|DRUG|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
47937413|NCT03455764|DRUG|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
48282626|NCT04689308|DRUG|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
48282627|NCT06417515|DRUG|Xiao-Yao-San|Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
48282628|NCT06417515|OTHER|Weight loss class(WLC) group|Participants who attended the WLCs in our hospital and were willing to participate in our study were included in the WLC group (control group). Our WLCs consisted of 8 sessions of 2-hour dietary advice/exercise guidance and 1 session of weight-loss consultation in 3 months. The participants assessed their weights at the beginning, at 1.5 months, and after every class. They underwent pre-PSG tests in the beginning and post-PSG tests after 3 months of lectures.
48282629|NCT03560362|DRUG|Bupivacaine liposome|
48282630|NCT03560362|DRUG|Bupivacaine / Epinephrine|
48282631|NCT03198221|DRUG|Golytely|bowel preparation
48282632|NCT03198221|DRUG|Clenpiq|bowel preparation
48282633|NCT04331301|PROCEDURE|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
48282634|NCT04331301|PROCEDURE|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
48282635|NCT00736229|DRUG|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
48282636|NCT00155402|DRUG|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
48282637|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
48282638|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
48282639|NCT04034615|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
48282640|NCT03014648|DRUG|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
48282641|NCT05377632|PROCEDURE|Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)|laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.
48282642|NCT00397150|BEHAVIORAL|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
48282643|NCT03431012|OTHER|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch...') or the pandemic flu virus itself (VA: 'It can infect you when you touch...')
48282644|NCT03431012|OTHER|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
48282645|NCT02698410|DRUG|Lanreotide (Autogel formulation) and Temozolomide|
48282646|NCT05910827|DRUG|HMBD-001|HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
48282647|NCT05910827|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
48282648|NCT05910827|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
48282649|NCT06656234|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.
48282650|NCT06656234|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
48282651|NCT00900432|OTHER|immunoenzyme technique|
48282652|NCT00900432|OTHER|laboratory biomarker analysis|
48466510|NCT04045015|DIETARY_SUPPLEMENT|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
48466511|NCT03261817|BEHAVIORAL|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
48466512|NCT03261817|BEHAVIORAL|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
48282653|NCT04116671|DEVICE|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
48466513|NCT03390244|DEVICE|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
48466514|NCT03658434|RADIATION|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
48626363|NCT02999321|OTHER|aspartame|will be given 5mg aspartame or 15 mg aspartame
48466515|NCT00695045|DRUG|intra thecal morphine|100 mcg intrathecal morphine given once .
48466516|NCT00695045|DRUG|intra thecal morphine|200 mcg intrathecal morphine given once
48466517|NCT00695045|DRUG|intra thecal morphine|300 mcg intrathecal morphine given once
48466518|NCT02016235|DRUG|Phosphorus Supplement|250 mg po qid
48466519|NCT02016235|OTHER|Observation|Baseline blood and urine measurements only
48466520|NCT01067794|DRUG|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
48466521|NCT03740191|OTHER|EPIC questionnaire|The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.
48626364|NCT02999321|OTHER|water|control group
48626365|NCT04373070|COMBINATION_PRODUCT|CAir|The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 \[2017\], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.
48282654|NCT05999305|OTHER|Teaching the critical care nursing course with an Escape Room game|A teacher will begin with a 1.5-hour lecture, followed by an escape room game to reinforce learning through case studies for another 1.5 hours. The first section of the game will be a ten-minute pre-brief. The game will then begin promptly at a designated time and will be played in groups of six to seven students, with each group seated separately in a classroom. The game will last up to fifty minutes, during which all groups will be assisted to complete puzzles within the time limit. After the game, a fifteen-minute debriefing session will be held by the teacher, during which the students will reflect on their performance and what they learned about the cases and related topics. The teacher will finally provide feedback and support to the groups during this session.
48282655|NCT05999305|OTHER|Teaching the critical care nursing course with a case-based learning|Students in the comparison group will also receive a 1.5 hour lecture which is the same as those in the intervention group. Another 1.5 hour is a case-based learning session, with six sessions in total over six weeks. The case-based learning sessions will include a pre-brief, teamwork, and debrief, and will be facilitated by the same teacher and teaching assistant and will primarily be provided with paper-based case studies.
48282656|NCT00519077|DRUG|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
48282657|NCT03037216|OTHER|Exercise Intervention|10 Week aerobic exercise training
48282658|NCT01301326|DEVICE|subthreshold and threshold laser treatment|subthreshold laser treatment
48282659|NCT01301326|DEVICE|Threshold laser treatment|threshold laser treatment
48282660|NCT03397836|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
48282661|NCT03397836|OTHER|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
48282662|NCT05766956|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
48282663|NCT05766956|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
48282664|NCT00609609|PROCEDURE|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
48282665|NCT00609609|DRUG|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
48282666|NCT00460928|DRUG|intravenous immune globulin (IVIG)|
48466522|NCT03740191|RADIATION|kV x-ray images|After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.
48466523|NCT03740191|RADIATION|Conebeam CT|For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
48466524|NCT00651183|DRUG|Pramipexole immediate release|
48466525|NCT05337202|DEVICE|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
48466526|NCT03492476|DEVICE|Circaid|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~* Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
48282667|NCT04726306|DIAGNOSTIC_TEST|Otic Barotrauma Grading System|Otic Barotrauma Grading System Placards for TEED Score and the OGS grading system.
48466527|NCT03492476|DEVICE|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~* DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
48466528|NCT01913054|DRUG|Fentanyl Injection|
48466529|NCT01913054|DRUG|Etomidate Fat Emulsion Injection|
48466530|NCT01913054|DRUG|Propofol Injection|
48466531|NCT03110380|DRUG|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
48466532|NCT03110380|DRUG|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
48466533|NCT03110380|DRUG|DTG|50 mg tablet(s) administered orally once daily
48466534|NCT03110380|DRUG|DTG Placebo|Tablet(s) administered orally once daily
48466535|NCT03110380|DRUG|F/TAF Placebo|Tablet(s) administered orally once daily
48466536|NCT03110380|DRUG|B/F/TAF Placebo|Tablet(s) administered orally once daily
48466537|NCT00003615|BIOLOGICAL|denileukin diftitox|
48466538|NCT05662605|DEVICE|W-PPMA|"W-PPMA is a digital health tool designed specifically for the postpartum experience and is accessed through a mobile application which delivers evidence-based therapy through brief conversations with a fully automated relational agent called Woebot."
48617840|NCT00329108|DRUG|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
48466539|NCT04911205|OTHER|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
48466540|NCT02176616|PROCEDURE|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
48466541|NCT02176616|PROCEDURE|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
48466542|NCT03170739|DRUG|Dexmedetomidine|Dexmedetomidine given during surgery.
48466543|NCT03170739|DRUG|Dopamine|Dopamine given during surgery.
48466544|NCT03795441|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
48466545|NCT05619796|PROCEDURE|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin \& isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained \& the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points \& root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
48466546|NCT05619796|RADIATION|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
48466547|NCT05619796|OTHER|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
48466548|NCT06222229|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
48466549|NCT06222229|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended"
48466550|NCT05457868|DRUG|Salbutamol|Salbutamol claim is used as the exposure group.
48466551|NCT05457868|DRUG|LAMA|Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.
48466552|NCT03213548|PROCEDURE|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
48466553|NCT03213548|PROCEDURE|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
48466554|NCT00000449|DRUG|naltrexone (Revia)|
48466555|NCT00000449|BEHAVIORAL|cognitive behavioral therapy|
47937414|NCT03455764|DRUG|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
47937415|NCT05458726|DRUG|Osimertinib|Osimertinib or chemotherapy
48626366|NCT01324180|DRUG|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
48626367|NCT01324180|DRUG|Vincristine|1.5 mg/m\^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
48466556|NCT00000449|BEHAVIORAL|cue exposure treatment|
48466557|NCT03624777|BEHAVIORAL|Outdoor Fall prevention brochure|Participants in the wait list control group will initially receive written information only about preventing outdoor falls
48466558|NCT03624777|BEHAVIORAL|Stroll Safe outdoor fall prevention program|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/ problem solving, practice in strategy use, and action planning for safe community mobility.
48466559|NCT01493596|DRUG|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
48466560|NCT01493596|DRUG|Placebo|An equal volume of water mixed with juice will be administered.
48466561|NCT02305407|PROCEDURE|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
48466562|NCT02305407|OTHER|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
48466563|NCT06620757|DRUG|Single antiplatelet therapy (SAPT)|Observational study of effectiveness and safety of SAPT (either with acetyl-salycilic acid or clopidogrel) after LAAO with Lambre device in patients with high risk of bleeding
48466564|NCT03066895|DEVICE|BabyGentleStick|Experimental device.
48466565|NCT03066895|DEVICE|Standard Lancing Device|HMC standard of care.
48466566|NCT02919020|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
48626368|NCT01324180|DRUG|Dexamethasone|"* 10 mg/m\^2/day divided BID~* Take dexamethasone by mouth days 2-15"
48626369|NCT01324180|DRUG|PEG-asparaginase|"* 2500 IU's/m\^2/day~* Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~* If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~* Patients will receive Erwinase® 25,000 IU/m\^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
48626370|NCT01324180|DRUG|Doxorubicin|60 mg/m\^2/day IV over 15 minutes on day 2
48626371|NCT01324180|DRUG|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
48626372|NCT01938937|DEVICE|Transcranial bright light device|
48626373|NCT01938937|DEVICE|Transcranial sham device|
48626374|NCT01257542|DRUG|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
48626375|NCT01257542|DRUG|Placebo|A single 10 mL dose of matching placebo syrup
48626376|NCT00739219|DEVICE|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
47937416|NCT00906997|PROCEDURE|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
47937417|NCT00906997|PROCEDURE|Colonoscopy|Every 10 years, with sedation.
48626377|NCT04190095|DEVICE|Motion Tracking in VR|Participant will wear motion sensors and VR devices
48626378|NCT04190095|BEHAVIORAL|VR Interaction|Participant will perform VR interaction task
48626379|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
48626380|NCT02487199|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
47937418|NCT00597844|OTHER|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
47937419|NCT00597844|OTHER|undergo voice evaluation and fMRI prior|in approximately one month and six months
48466567|NCT02919020|OTHER|Resistance exercise|resistance exercise to strengthen lower limbs
48466568|NCT00508833|BIOLOGICAL|287615 containing HBsAg with adjuvants|
48466569|NCT00046839|DRUG|celecoxib|
48466570|NCT00046839|RADIATION|radiation therapy|
48466571|NCT06035211|OTHER|3D model pré-operative education|Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
48466572|NCT03127241|DEVICE|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
48466573|NCT03127241|DEVICE|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
48466574|NCT02297087|GENETIC|Standard of care based on target(s) identified via GWS.|
48466575|NCT05756465|DEVICE|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
48466576|NCT00695383|BEHAVIORAL|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
48466577|NCT00695383|BEHAVIORAL|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
48466578|NCT04468282|DRUG|VGB-ST|Single oral administration of 500 mg VGB-ST
48466579|NCT05595616|DEVICE|Insertion of tracheal thermometer and pulmonary artery catheter|Endotracheal intubation of endotracheal tube with thermometer (Human Endotracheal Tube, Insung Medical Co., Korea) and insertion of Swan-Ganz catheter
48466580|NCT00198536|DRUG|Ecabet 2.83%|
48466581|NCT00198536|DRUG|Ecabet 3.70%|
48466582|NCT00198536|DRUG|Vehicle|
48466583|NCT04084990|DEVICE|S9 VPAP Adapt|Auto-titrated positive airway pressure
48466584|NCT00748137|DEVICE|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
48466585|NCT00748137|OTHER|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
48466586|NCT04920058|DEVICE|Continuous Glucose Monitor|Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring
47937420|NCT04834765|OTHER|Mindfulness-based art therapy|The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.
48282668|NCT00356915|DRUG|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
48466587|NCT04920058|OTHER|<Active Comparator?>|\<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (\<50g/day) and associated education \>
48466588|NCT04661202|OTHER|multimodal exercise training|"A supervised moderate-intensity exercise training session, which will include aerobic exercise with a stationary exercise bike, resistance exercise using dumbbell, theraband band, or gym ball for each major muscle groups and core muscles (including pelvic floor muscle (PFM) training with biofeedback), and stretching exercise, twice a week for 8 weeks. All exercises will be individualized based on participant's heart rate reserve and Rate of Perceived Exertion (RPE). An oximeter and a sphygmomanometer will be used to monitor the heart rate, oxygen saturation and blood pressure of the participants to ensure safety.~A home exercise program will include a walking exercise for 30 minutes per day and a PFM training with the aim of completing 1\~3 sets of 8\~12 submaximal contraction of PFM by holding 6\~10 seconds with 12\~20 seconds of rest between each contraction, and it will end with 3 maximal PFM contractions by holding 1\~3 seconds 3\~6 seconds of rest between each contraction."
48466589|NCT02510872|OTHER|18F-FDG PET combined with CT with iodinated contrast injection|
48466590|NCT02510872|OTHER|18F-FDG PET combined with CT without injection|
48466591|NCT02907073|DRUG|BF4|Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F
48466592|NCT05544656|DRUG|Tolperisone Hydrochloride|Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
48466593|NCT05544656|DRUG|Placebo|matching placebo administered three times a day
48466594|NCT00635336|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
48466595|NCT00361387|DRUG|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
48466596|NCT00089427|DRUG|IL13-PE38QQR|
48466597|NCT00089427|PROCEDURE|Surgery for placement|
48466598|NCT00089427|PROCEDURE|Radiation therapy|
48466599|NCT00089427|DRUG|Temozolomide with radiation therapy|
48466600|NCT02876133|DEVICE|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
48466601|NCT02876133|DEVICE|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
48617841|NCT00329108|DRUG|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
48617842|NCT01373164|DRUG|Galunisertib|Administered orally
48617843|NCT01373164|DRUG|Gemcitabine|Administered intravenously
48617844|NCT01373164|DRUG|Placebo|Administered orally
48282669|NCT00356915|DRUG|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
48466602|NCT04509232|PROCEDURE|Silver diamine fluoride|"Group A~* Excavation of soft carious dentin will be done to minimize the staining.~* The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~* 38% Silver diamine fluoride will be applied to carious lesions by microbrush~* Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately ."
48466603|NCT04509232|PROCEDURE|Silver diamine fluoride and glass ionomer|"* 38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~* Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration."
48466604|NCT04453969|OTHER|COVID-19|Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
48466605|NCT01897064|BEHAVIORAL|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
48466606|NCT01897064|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
48466607|NCT04417439|OTHER|universal goniometer. evaluate the circumference measurement. The biochemical examination of CK (creatine kinase)|The joint range of motion within the affected areas of burn patients was assessed by a universal goniometer. A 7-mm-wide tape measure was used to evaluate circumference measurement in individuals. The biochemical analysis of CK (creatine kinase) was performed by an expert on blood samples taken from patients in the hospital laboratories.
48466608|NCT00240734|DRUG|Epoetin alfa|
48466609|NCT02780063|OTHER|Lenstar Biometer|uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
48466610|NCT00131716|DRUG|sulfadoxine-pyrimethamine|
48466611|NCT02627001|DEVICE|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
48466612|NCT02627001|DEVICE|Bag Valve Mask|Conventional bag valve mask
48466613|NCT04192929|DEVICE|Narrow band imaging|Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes
48466614|NCT04192929|OTHER|Chromoendoscopy|Indigo carmine will be sprayed during withdrawal phase of colonoscopy
48466615|NCT04192929|OTHER|High definition white light endoscopy|High definition equipment will be used to perform colonoscopy
48466616|NCT05523960|PROCEDURE|No MBP|No mechanical bowel preparation before operation
48466617|NCT04300998|BEHAVIORAL|Activities of Daily Living/ADLs|7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
48466618|NCT04300998|BEHAVIORAL|Instrumental Activity of Daily Living|8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
47937421|NCT04834765|OTHER|Art-only|The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.
47937422|NCT04834765|OTHER|Mindfulness-only|The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
47937423|NCT00876603|PROCEDURE|ACDF|Anterior cervical decompression and fusion
47937424|NCT00876603|PROCEDURE|Cervical laminoplasty|Cervical laminoplasty
48466619|NCT04300998|BEHAVIORAL|Timed Up and Go|Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (\<10 seconds, 10-20 seconds, \>20 seconds)
48466620|NCT04300998|BEHAVIORAL|Cognition|Mini-Cognition test: CDT and 3-word recall
47937425|NCT01727700|DRUG|Aripiprazole|Once-daily, tablet
47937426|NCT01727700|DRUG|Placebo|
47937427|NCT01997385|PROCEDURE|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
48282670|NCT00356915|DRUG|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
48282671|NCT02569515|DRUG|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
48282672|NCT03408132|DRUG|FE203799|FE203799 5 mg subcutaneous once weekly
48466621|NCT04300998|BEHAVIORAL|Geriatric Depression Scale|Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of \>/=1 is usually indicative of depression.
48466622|NCT04300998|BEHAVIORAL|Social Support|Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
48466623|NCT04300998|BEHAVIORAL|Brief Test of Attention|assess selective auditory attention.
48466624|NCT04300998|BEHAVIORAL|Trail Making Test|Assesses visual scanning, graphomotor speed, and set shifting.
48626381|NCT03782597|BEHAVIORAL|Semi-structured interviews or focus groups to explore families representations and strategies about their teenagers involved in radicalisation process|A sample of representative French families (parents, siblings, and persons identified as attachment figures) of adolescents or young adults (12-25 years old) involved in the radicalisation process will be asked to participate in semi-structured interviews or focus groups to explore their representations and strategies about radicalisation. It will be supplemented by genogram draw sociodemographic data.
48626382|NCT00106561|DRUG|Spironolactone|
48626383|NCT00106561|DRUG|Irbesartan|
48626384|NCT00554580|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
48626385|NCT00554580|PROCEDURE|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
48626386|NCT02709902|DRUG|Adapalene/BP gel, 0.3%/2.5%|Gel
48626387|NCT02709902|DRUG|EPIDUO® FORTE|Gel
48626388|NCT02709902|DRUG|Placebo|Gel
48626389|NCT02930447|DEVICE|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
48626390|NCT00560599|DRUG|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
48626391|NCT00560599|BEHAVIORAL|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
48626392|NCT00560599|DRUG|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen."
48626393|NCT04389138|OTHER|Physiotherapy Intervention|Physiotherapy intervention will include an assessment to identify individual areas that physiotherapy should target. Intervention will be based on the core areas recommended by the European Physiotherapy Guideline for Parkinson's Disease: physical capacity (muscle power, tone, joint range of movement, exercise tolerance and pain), transfers, manual dexterity, balance and gait. Posture is incorporated as part of these 5 core areas. The intervention will be delivered over 4 visits.
48626394|NCT02756468|OTHER|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
48626395|NCT01029821|DRUG|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
48626396|NCT00420836|DRUG|Tobramycin|
48282673|NCT04810052|BEHAVIORAL|Behavioral Intervention|Perform 1 nice thing
48282674|NCT04810052|BEHAVIORAL|Behavioral Intervention|Write a letter or note of gratitude
48282675|NCT04810052|BEHAVIORAL|Behavioral Intervention|Track daily activities
48282676|NCT04810052|OTHER|Interview|Ancillary studies
48282677|NCT04810052|OTHER|Quality-of-Life Assessment|Ancillary studies
48282678|NCT04810052|OTHER|Questionnaire Administration|Ancillary studies
48282679|NCT01946009|DRUG|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
48626397|NCT02018887|DRUG|LY2969822|Capsules administered orally
48626398|NCT02018887|DRUG|Placebo|Capsules administered orally
47937428|NCT01997385|PROCEDURE|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
48626399|NCT02113215|PROCEDURE|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
48626400|NCT02971904|OTHER|human milk collection|
48282680|NCT02372617|PROCEDURE|periacetabular osteotomy|
48282681|NCT00262704|BEHAVIORAL|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
48282682|NCT00262704|BEHAVIORAL|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
48282683|NCT05113940|DRUG|PF-07258669|PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
48282684|NCT05113940|DRUG|Placebo|Placebo will be administered as tablets; Q8H or Q12H over 14 days
48282685|NCT05113940|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
48282686|NCT00827489|DRUG|HTC-867|
48282687|NCT00827489|OTHER|Placebo|
48282688|NCT04447547|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
48282689|NCT05659732|DRUG|PEP07|PEP07 is a selective Chk1 inhibitor maleate drug which is supplied as a hard gelatin capsule. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
48282690|NCT04197713|DRUG|Adavosertib|Given PO
48282691|NCT04197713|DRUG|Olaparib|Given PO
48466625|NCT04300998|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency
48626401|NCT02250638|OTHER|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
48626402|NCT00441896|DRUG|Ganaxolone|
48626403|NCT00441896|OTHER|Placebo|
48466626|NCT04300998|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
48626404|NCT06415123|DEVICE|MagnetOs Flex Matrix|MagnetOsTM Flex Matrix is a resorbable and osteoconductive bone graft for the repair of bony defects.
48466627|NCT04300998|OTHER|Blood draw|collection of blood tests
48466628|NCT06249776|DEVICE|Supernova revascularization device|Mechanical Thrombectomy
48466629|NCT04320888|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and/or CT/MRI
48626405|NCT02505971|DRUG|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
48626406|NCT02505971|DRUG|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
48626407|NCT01905683|DRUG|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
48626408|NCT01511237|DRUG|Nevirapine, zidovudine, lamivudine|"* Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~  * NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~ * AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~ * 3TC syrup 2 mg/kg every 12 hours for four weeks."
48626409|NCT00157625|BEHAVIORAL|Automatic stop order|
48626410|NCT02904356|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
48626411|NCT03331081|OTHER|Bladder Training|The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
47937429|NCT00521001|DRUG|everolimus|
47937430|NCT00521001|DRUG|temozolomide|
48466630|NCT04320888|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
47937431|NCT01110070|DEVICE|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
48466631|NCT04320888|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
48466632|NCT04320888|PROCEDURE|Radionuclide Imaging|Undergo scintigraphy
47937432|NCT01110070|DEVICE|ChonDux|single use device
48282692|NCT01605474|OTHER|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
48282693|NCT01605474|OTHER|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
48466633|NCT04320888|DRUG|Selpercatinib|Given PO
48466634|NCT04320888|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
48466635|NCT06604195|PROCEDURE|Modified sciatic nerve mobility exercises|Each participant was made to lie down in a supine position on the treatment couch. The participant's leg was moved to about 30-45 degrees hip flexion with knee extension. The ankle was then moved to maximum dorsiflexion with inversion and hip internal rotation within the participant's tolerance, and this position was maintained for 30 seconds. While the therapist performed dorsiflexion with inversion and hip internal rotation in the supported straight leg raise position, the participant was instructed to actively flex the cervical spine slowly until they perceived a tolerable stretch sensation in the hamstring muscle and lower leg. The synchronous alternating movements were performed rhythmically for 10-15 repetitions. This maneuver was repeated 3 times in a single session, 3 days per week, and continued for 3 consecutive weeks.
47937433|NCT02889562|DRUG|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
47937434|NCT02889562|DRUG|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
47937435|NCT05743517|BEHAVIORAL|Fit4Treatment|This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
47937436|NCT00414427|PROCEDURE|Intraarticular steroids|
48282694|NCT02397252|DEVICE|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
48282695|NCT02397252|DEVICE|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
48282696|NCT02397252|PROCEDURE|Physician-collected sampling|Routine colposcopy sample collected by a physician.
48282697|NCT01295125|DEVICE|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
48282698|NCT01295125|PROCEDURE|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
48282699|NCT03246074|DRUG|Fostamatinib 100 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
48282700|NCT03246074|DRUG|Fostamatinib 150 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
48282701|NCT03246074|DRUG|Fostamatinib 200 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
48282702|NCT05647993|DRUG|Azithromycin Injection [Zithromax]|Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
48282703|NCT05647993|DRUG|Cefazolin|All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
48282704|NCT05647993|DRUG|Sodium Chloride 0.9% Intravenous Solution|For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
48282705|NCT05750940|DIAGNOSTIC_TEST|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
48282706|NCT00507715|DRUG|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
47937437|NCT04144023|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
47937438|NCT04144023|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
47937439|NCT04144023|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
47937440|NCT04144023|PROCEDURE|Echocardiography|Undergo ECHO
47937441|NCT04144023|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47937442|NCT04144023|PROCEDURE|Biopsy|Undergo biopsy
47937443|NCT03318718|DRUG|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
47937444|NCT03318718|DIAGNOSTIC_TEST|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
47937445|NCT03318718|DIAGNOSTIC_TEST|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
48282707|NCT00507715|OTHER|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
48282708|NCT03615092|PROCEDURE|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
48282709|NCT04915248|DRUG|Daratumumab|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
48282710|NCT04915248|DRUG|Bortezomib|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
48282711|NCT04915248|DRUG|Dexamethasone|"Induction phase planning one course (cycle 1) of daratumumab as single agent followed by 8 courses (cycles 2-9) of daratumumab in combination with bortezomib and dexamethasone (DVd regimen).~Patients achieving at least a SD after induction will be addressed to the maintenance phase, planning a maximum of 6 cycles (cycles 10-15) of daratumumab as single agent."
48282712|NCT00227357|DRUG|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
48282713|NCT00227357|DRUG|Off-site - methadone or no agonist|
47937446|NCT04403490|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
47937447|NCT04403490|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
47937448|NCT01718912|DRUG|metronidazole-nystatin oral rinse|
47937449|NCT06059118|DRUG|DFMO|Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
48466636|NCT06604195|PROCEDURE|Dynamic hamstring muscle stretching|"The participant was instructed to stand straight with the unaffected foot supported on the floor and the toes pointing forward. The heel of the testing leg was placed on an 18 high step with the toes directed upwards with knee extension. Once cued, the participant was asked to flex forward at the hip while maintaining the spine in a neutral position and reaching the arms forward. The knee joint remained fully extended as the participant continued to flex the hip until a gentle stretch was felt in the posterior thigh. Once the position was achieved, the participants were asked to hold it for 20-30 seconds. The same procedure was repeated 3 times daily, 3 days a week for three consecutive weeks."
48626412|NCT03331081|OTHER|TMAP|There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
47937450|NCT06059118|DRUG|testosterone cypionate|On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
48466637|NCT06539676|DEVICE|Nighttime Aligners|Nighttime aligners worn 10-12 hours per day or night during 2-8 months
48626413|NCT03331081|OTHER|Bladder Training + TMAP|Will perform the exercises of the bladder training group and the TMAP in an associated way.
48466638|NCT06539676|DEVICE|Daytime Aligners|Daytime aligners worn 20-22 hours per day or night during 2-8 months
48466639|NCT05068661|DRUG|Ropivacaine 0.1% Injectable Solution|DPE
48466640|NCT05068661|DRUG|Bupivacaine 0.25% Injectable Solution|CSE
48466641|NCT01107327|PROCEDURE|FDG-PET/CT|"The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer light up on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also lights up in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project."
48466642|NCT00856349|BEHAVIORAL|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
48626414|NCT02350205|BIOLOGICAL|Self assembled skin substitute (SASS)|All patients in Phase B will receive Self assembled skin substitute (SASS)
48626415|NCT05141747|DRUG|MRG002|Administrated intravenously
48626416|NCT06462872|OTHER|observational study|It is an observational study
48626417|NCT01873885|DRUG|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
48626418|NCT01873885|DRUG|Experimental: Single IV Infusion Vasomera (PB1046)|
48626419|NCT02846402|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
47937451|NCT06059118|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
48626420|NCT00330018|DRUG|Valganciclovir|Valganciclovir
48626421|NCT00330018|DRUG|Acyclovir|Acyclovir
48626422|NCT02024009|DRUG|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
47937452|NCT06059118|DRUG|Enzalutamide|Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
47937453|NCT05696860|DEVICE|Capnography Monitoring|Capnography monitoring
48626423|NCT02024009|RADIATION|60Gy in 30#|
48626424|NCT02024009|RADIATION|50.4Gy in 28#|
48626425|NCT02024009|DRUG|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
48626426|NCT02024009|DRUG|Capecitabine|Given in combination with gemcitabine, known as GemCap.
48626427|NCT02024009|DRUG|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
48626428|NCT02228122|DEVICE|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
47937454|NCT05202470|OTHER|TE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
48282714|NCT06488196|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) is a person-centered, goal-oriented psychotherapeutic intervention designed to enhance the recipient's motivation for and commitment to a target behavior or behavior change. MI's core action mechanisms include strengthening the recipient's change talk (e.g., assertions about desire and commitment toward the target behavior) and softening the recipient's sustain talk (e.g., statements about barriers). MI clinicians achieve these goals using specific micro-skills (e.g., reflective listening) that reflect MI's fundamental spirits (i.e. collaboration, acceptance, compassion, evocation.
48466643|NCT06249451|OTHER|Checklist-based phone calls|"The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB.~On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines.~The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines."
48626429|NCT03849989|PROCEDURE|Skin biopsy|"Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~* Skin desinfection with chlorhexidine digluconate 1% solution~* Local anaesthesia with lidocaine hydrochloride 1%~* Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~* Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~* Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~* Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~* In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage."
48626430|NCT01804335|DRUG|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
48466644|NCT01157598|DEVICE|bispectral index monitoring|parameter monitoring of bispectral index
48466645|NCT06232772|DIAGNOSTIC_TEST|α- Synuclein Ultrafine Fluorescence Detection Method|This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.
48466646|NCT06581601|OTHER|physiotherapy, exercises|An author's questionnaire will be used for participant selection, asking about the number and course of deliveries. Additionally, participants will log daily activities to calculate the physical activity level coefficient. Weight and height will be measured using a Tanita device to calculate BMI. The posture type and pelvic type will be assessed. Participants will be asked to complete the following questionnaires before and after the intervention: Pelvic Floor Disability Index (PFDI-20), Pelvic Floor Impact Questionnaire Short Form (PFIQ-7 SF), Sexual Satisfaction Scale (SSS-W-R15), Neck Disability Pain Index, Revised Oswestry Low Back Pain Disability Scale, Migraine Disability Assessment (MIDAS), Hospital Anxiety and Depression Scale (HADS), Short Form McGill Pain Questionnaire, CRANIA (Integrated Approach to Cranio Mandibular Neuroscience) questionnaire, IPAQ (International Physical Activity Questionnaire). Modified 1-Hour Pad Test. Execution of the Author's Training Program.
48466647|NCT05349240|DEVICE|C2 CryoBalloonTM Ablation System.|Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
48466648|NCT00114322|DEVICE|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
48466649|NCT00752076|OTHER|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
48466650|NCT05114668|DRUG|EVT801|"Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study."
48466651|NCT05317858|DEVICE|Blood Brain Barrier Disruption - Oncology|BBB opening via Exablate Type 2 system with microbubble resonators on the day of pembrolizumab infusion to treat brain metastases
48466652|NCT05317858|DRUG|Pembrolizumab|Pembrolizumab infusion
48466653|NCT00001239|DRUG|FLAC with GM-CSF|
48466654|NCT02061358|DRUG|UV-4B 3 mg|Oral solution, single dose
48466655|NCT02061358|DRUG|UV-4B 10 mg|Oral solution, single dose
48466656|NCT02061358|DRUG|UV-4B 30 mg|Oral solution, single dose
48466657|NCT02061358|DRUG|UV-4B 90 mg|Oral solution, single dose
48466658|NCT02061358|DRUG|UV-4B 180 mg|Oral solution, single dose
48626431|NCT00558883|DRUG|acarbose|oral application
48626432|NCT00819195|DRUG|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
48282715|NCT06488196|OTHER|Treatment As Usual|TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
48282716|NCT04057183|DIAGNOSTIC_TEST|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
48626433|NCT01452217|DRUG|Secretin|Secretin 1 IU/kg over 3 min
48626434|NCT00062504|DRUG|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
48626435|NCT02871427|DRUG|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
48466659|NCT02061358|DRUG|UV-4B 360 mg|Oral solution, single dose
48466660|NCT02061358|DRUG|UV-4B 720 mg|Oral solution, single dose
48466661|NCT02061358|DRUG|UV-4B 1000 mg|Oral solution, single dose
48466662|NCT02061358|DRUG|Placebo|Oral solution, single dose
48466663|NCT05419817|DRUG|pembrolizumab|Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle
48466664|NCT05419817|DRUG|Sitravatinib|A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
48626436|NCT06516848|OTHER|High Intensity Inspiratory Muscle Training Group (H-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 80% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
48466665|NCT02678780|DRUG|Lenvatinib|
48466666|NCT00361686|DRUG|tramadol|
48466667|NCT00361686|DRUG|remifentanyl|
48466668|NCT00361686|DEVICE|patient contolled analgesia|
48466669|NCT06381687|BEHAVIORAL|A multi-component, multi-level programme (MoviMusi)|"The MoviMusi program will be designed and implemented in each city by the 12 ECEC centres in the intervention group. In addition, the intervention programme will aim to address the main barriers and facilitators identified during the first year (baseline assessment) in relation to movement and music curricular practices. The programme will have three axes:~(1) Training. Educators and families will actively participate in a series of seminars and training workshops on the promotion of PA as a healthy behaviour and the use of music as a didactic resource to strengthen holistic education both inside and outside ECEC. (2) Participation. Each ECEC institution will be supported as they design a movement and music programme to offer children better opportunities to learn about the body, its possibilities of action, and musical skills.(3) Implementation. The specific actions of the MoviMusi Programme will be put into practice in each ECEC institution."
48466670|NCT05606328|BEHAVIORAL|Emergency Department Delirium Screening and Detection Program (ED-DDP)|Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses. No adaptations to the ED-DDP will occur between implementation sites and no data will be collected during implementation phases.
48466671|NCT05754528|DRUG|Standard of care administration of Endocrine therapy|Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
48466672|NCT05754528|DRUG|Dose-frequency escalation administration of Endocrine therapy|Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
48466673|NCT04580186|PROCEDURE|bladder exstrophy repair|primary complete bladder exstrophy repair
48466674|NCT00213005|DRUG|Carraguard (PC-515)|
48466675|NCT01940445|DEVICE|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
48466676|NCT01940445|DEVICE|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
48466677|NCT03837405|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
48466678|NCT03837405|BEHAVIORAL|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
48466679|NCT05653362|DEVICE|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
48466680|NCT05653362|DEVICE|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
48466681|NCT03108820|BEHAVIORAL|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
48466682|NCT03108820|OTHER|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
48466683|NCT05034185|DEVICE|Computer-aided diagnosis (CADx) support tool|"The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic."
48626437|NCT06516848|OTHER|Low Intensity Inspiratory Muscle Training Group (L-IMT)|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device. Initially, it will be worked out vigorously at 30% of the maximum inspiratory pressure determined by mouth pressure measurement. The load will be increased weekly.
48466684|NCT06086314|DEVICE|reactive exercise training with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
48466685|NCT06086314|DEVICE|reactive exercise training with co-contraction with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
48466686|NCT06086314|OTHER|neurorehabilitation program with functional reaching training without device.|Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Doing functional stretching to the anterior, right and left while standing.
48466687|NCT04863885|DRUG|Ipilimumab|Participants will receive Ipilimumab 3 mg/kg
48466688|NCT04863885|DRUG|Nivolumab|Participants will receive Nivoumab 1mg/kg
48466689|NCT04863885|DRUG|Sacituzumab govitecan|Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
48466690|NCT04326933|DRUG|Tyrosine kinase Inhibitors (Imatinib & Nilotinib)|Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)
48466691|NCT04973800|DRUG|Simvastatin 20mg|Simvastatin 20mg ON PO for 28-30 days
48466692|NCT04973800|DRUG|Placebo|Sucrose placebo ON PO for 28-30 days
48466693|NCT02586324|BIOLOGICAL|global medium|
48466694|NCT02586324|BIOLOGICAL|SSM|
48466695|NCT00001873|DEVICE|Isolex 300i plus MoAbs|
48626438|NCT02928432|DRUG|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
48626439|NCT06251427|DIETARY_SUPPLEMENT|Multiple micronutrient fortified maize with milk|The study product is a multiple micronutrient fortified maize pap with milk
48282717|NCT01590329|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
48282718|NCT01333189|OTHER|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
48282719|NCT01333189|OTHER|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
48282720|NCT02919306|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
48282721|NCT02919306|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
48282722|NCT02919306|DRUG|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
48282723|NCT03165396|DRUG|Propofol|Propofol is the most common clinical anesthetics.
48282724|NCT03165396|DRUG|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
48282725|NCT00245232|BEHAVIORAL|Cognitive Therapy|
48282726|NCT00245232|BEHAVIORAL|Cognitive Processing Therapy|
48282727|NCT00245232|BEHAVIORAL|Written Exposure|
48282728|NCT05908734|DRUG|Cetrelimab|Cetrelimab will be administered as IV infusion.
48282729|NCT05908734|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
48282730|NCT01904487|RADIATION|[11C]flumazenil|\[11C\]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
48282731|NCT01904487|DRUG|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
48282732|NCT05771428|DRUG|ABBV-552|Oral Capsule
48282733|NCT05771428|DRUG|Placebo for ABBV-552|Oral Capsule
48466696|NCT01634854|DRUG|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
48466697|NCT01634854|DRUG|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
48466698|NCT04581122|PROCEDURE|Lymphadenectomy|Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group
48466699|NCT00494351|PROCEDURE|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
48466700|NCT02894827|BIOLOGICAL|Blood sample|
48466701|NCT02894827|OTHER|Flow cytometry|
48466702|NCT02894827|OTHER|western blot|
47937455|NCT05202470|OTHER|CE|After the first meeting, diabetes education videos prepared in two parts a week will be sent to the mobile phones of the individuals. The video submission will be completed in a total of four weeks.
47937456|NCT02602847|BIOLOGICAL|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
48282734|NCT05248997|DRUG|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
48282735|NCT05248997|DRUG|Matching placebo|One dose of matching placebo
48282736|NCT03815890|DRUG|Nivolumab|2 courses 240 mg flat dose
48282737|NCT03815890|DRUG|Ipilimumab|single dose ipilimumab (1mg/kg) at day 1
48282738|NCT03815890|DRUG|Ipilimumab|two courses ipilimumab (1mg/kg) at day 1 and 21
48282739|NCT05418712|DRUG|Placebo|Placebo matched to VX-150 for oral administration.
48282740|NCT05418712|DRUG|VX-150|Solution or Suspension for oral administration.
48282741|NCT05478915|PROCEDURE|discectomy of the TMJ disc|removal of the TMJ disc
48466703|NCT00158925|DEVICE|EASYTRAK EPI lead|EASYTRAK EPI lead
48466704|NCT05530291|OTHER|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
48466705|NCT05467540|DEVICE|SPINERY|Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum
48466706|NCT01706809|OTHER|blood sampels from vena rectalis superior and vena cubiti|
48466707|NCT01888107|DRUG|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
48466708|NCT01888107|DRUG|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
48466709|NCT01888107|DRUG|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
48466710|NCT02018796|DRUG|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
48466711|NCT04409379|DIAGNOSTIC_TEST|Relative telomere length|Relative telomere length in peripheral blood cell
48466712|NCT02386761|DRUG|Single Ascending Dose (SAD)|
48466713|NCT02386761|DRUG|Multiple Ascending Dose (MAD)|
48466714|NCT01611415|DRUG|Ipragliflozin|Oral
48466715|NCT01611415|DRUG|Furosemide|Oral
48466716|NCT04158427|PROCEDURE|Faecal transplantation|Faecal transplantation from a healthy donor via colonoscopy
47937457|NCT00473746|DRUG|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
48282742|NCT05478915|PROCEDURE|TMJ discopexy|fixation of the TMJ disc
48282743|NCT01857895|DRUG|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
48466717|NCT04158427|PROCEDURE|Placebo faecal transplantation|Placebo faecal transplantation containing patient's own feces via colonoscopy
48466718|NCT01398787|DEVICE|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
48466719|NCT01398787|DEVICE|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
48466720|NCT02166606|DEVICE|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
48466721|NCT01812473|OTHER|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
48466722|NCT01500005|DRUG|Baby D3 drops|2000-4000 iu per day
48466723|NCT02229084|BIOLOGICAL|P10s-PADRE/ MONTANIDE™ ISA 51 VG|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions concurrent with chemotherapy.
48466724|NCT02229084|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
48466725|NCT02229084|DRUG|Cyclophosphamide|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
48466726|NCT02229084|DRUG|Docetaxel|"Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.~If docetaxel is not tolerated, paclitaxel (175mg/m2) may be used in its place."
48466727|NCT01256996|PROCEDURE|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
48466728|NCT02502331|BIOLOGICAL|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
48466729|NCT02502331|BIOLOGICAL|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
48466730|NCT03638596|BEHAVIORAL|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
48466731|NCT03638596|BEHAVIORAL|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
48466732|NCT05241314|BEHAVIORAL|Learning to BREATHE|A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
48466733|NCT05241314|BEHAVIORAL|After Deployment Adaptive Parenting Tools (ADAPT)|A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
47937458|NCT00473746|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
47937459|NCT00473746|DRUG|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
48282744|NCT05076422|DRUG|BI 3006337|BI 3006337
48282745|NCT05076422|DRUG|Placebo|Placebo
48466734|NCT02340624|BEHAVIORAL|Referral to SmokeFreeMoms, Quitline or Brief intervention|"1. SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.~2. The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.~3. Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
48282746|NCT04119050|DRUG|M281|M281 injection administered as intravenous infusion
48282747|NCT04119050|DRUG|Placebo|Placebo administered as intravenous infusion
48282748|NCT00658229|BEHAVIORAL|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
48282749|NCT04359966|DRUG|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
48282750|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
48282751|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
48282752|NCT04359966|DRUG|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
48626440|NCT05257187|DEVICE|Transcervical foley catheter|The foley catheter is inserted manually by an obstetric provider through the cervix and inflated with 60cc of saline. Once in the correct position, the catheter is inflated, which puts pressure on the cervix, allowing it to release hormones that soften the cervix and help the cervix to open. The foley catheter can be left in place up to 12 hours but typically will fall out when the cervix is dilated to 3-4 centimeters.
48282753|NCT01349738|DRUG|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
48282754|NCT04783207|DIETARY_SUPPLEMENT|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
48282755|NCT04783207|DIETARY_SUPPLEMENT|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
48282756|NCT02347293|OTHER|High levels of indigestible carbohydrates|
48626441|NCT06142552|DRUG|FRSW117|once a week, 50 weeks and as needed
48282757|NCT02347293|OTHER|Low levels of indigestible carbohydrates|
48466735|NCT00514150|DRUG|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
48466736|NCT00514150|DRUG|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
48466737|NCT02963064|BIOLOGICAL|Humanized anti-CD117 Monoclonal Antibody (JSP191)|Procedure: single intravenous infusion of JSP191 antibody
48626442|NCT02714738|PROCEDURE|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
48626443|NCT06194994|BEHAVIORAL|Parent Management Training|Behavioral parent training program aimed at increasing compliance and positive behaviours while decreasing disruptive behaviours
48626444|NCT06194994|BEHAVIORAL|Tuning Your Temper|Cognitive behavioural treatment for children focusing on arousal reduction, problem solving and cognitive restructuring.
48626445|NCT00968968|DRUG|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
48626446|NCT00968968|BIOLOGICAL|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
48626447|NCT02487706|DRUG|Dolutegravir|Dolutegravir 50mg/day per 5 days
48626448|NCT00197483|DRUG|Pergolide (drug)|
48626449|NCT03478995|DRUG|GX-I7|GX-I7 25mg/ml/vial
48282758|NCT03624569|OTHER|Bagel|A bagel will be consumed daily for 2 weeks.
48282759|NCT03624569|OTHER|Potato|A potato will be consumed daily for 2 weeks.
48282760|NCT04295902|DEVICE|C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.
48282761|NCT04295902|DEVICE|Direct laryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
48282762|NCT00109811|BIOLOGICAL|PSA:154-163(155L) peptide vaccine|Given subcutaneously
48282763|NCT00109811|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
48282764|NCT00109811|OTHER|laboratory biomarker analysis|Correlative studies
48466738|NCT00640393|DRUG|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
48466739|NCT00640393|DEVICE|nbUVB|
48466740|NCT05384457|OTHER|High intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
48466741|NCT05384457|OTHER|Moderate intensity training|Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
48626450|NCT00294788|BIOLOGICAL|Fluvax|
48626451|NCT00294788|DRUG|PCC® (Lactobacillus fermentum VRI 003)|
48282765|NCT04537442|DRUG|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
48466742|NCT02046317|DRUG|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
48626452|NCT00472381|DRUG|Insulin|Insulin
48626453|NCT03035539|OTHER|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
48626454|NCT03035539|OTHER|Standard treatment|Standard treatment
48626455|NCT03607058|OTHER|Kinect + Exercise Training|Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
48626456|NCT03607058|OTHER|Exercise Training|Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
48626457|NCT00046943|DRUG|atrasentan hydrochloride|
48626458|NCT01897389|DRUG|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
48626459|NCT01897389|DRUG|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
48626460|NCT01897389|DRUG|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
48626461|NCT01897389|DRUG|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
48626462|NCT01897389|DRUG|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
48626463|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
48626464|NCT01542099|DRUG|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
48626465|NCT06334900|OTHER|GAD patients|Describe the clinical and demographic characteristics of patients with anti-GAD65 antibody associated cerebellar ataxia.
48626466|NCT04650945|OTHER|isCGM group|As previously described
48282766|NCT04242030|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
48626467|NCT05230927|OTHER|Multidisciplinary Rehabilitation|All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
48626468|NCT04135651|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
48626469|NCT04135651|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
48626470|NCT02295449|DEVICE|biopsy sample performed after the SonoVue® injection|
48282767|NCT04242030|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
48466743|NCT02046317|DEVICE|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
48466744|NCT02046317|DEVICE|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
48466745|NCT02046317|DEVICE|Ultrasound|"The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles."
48466746|NCT01867190|BIOLOGICAL|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
48466747|NCT00131092|BEHAVIORAL|The Stanford Active Choices program|
48466748|NCT00131092|BEHAVIORAL|The TLC system|
48466749|NCT01386125|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
48466750|NCT01386125|DRUG|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
48466751|NCT04884334|DEVICE|VAC-Stent®|treatment with the VAC-Stent®
48466752|NCT02995187|DRUG|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
48466753|NCT06109805|OTHER|Gastric cancer|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
48466754|NCT04221048|OTHER|Retrospective observational|Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
48466755|NCT05396950|DEVICE|CPAP|CPAP in conjunction with radiotherapy
48466756|NCT04859140|OTHER|Psychometric ratings (Likert-scale)|Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
48466757|NCT04859140|BEHAVIORAL|Range of motion measures|Sit-and-reach and toe touch tests
48466758|NCT04859140|BEHAVIORAL|Mental calculation task|Iterated substractions (for 2 minutes)
48466759|NCT04859140|DEVICE|Resting-state electroencephalography|Alpha and beta oscillation power (4 minutes recordings)
48626471|NCT03637374|DEVICE|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
48626472|NCT03637374|DEVICE|Unitary Manifold|Endovascular stent graft system
48626473|NCT03637374|DEVICE|TAAA Debranching Stent Graft System|Endovascular stent graft system
48626474|NCT04510753|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform and blood pressure values.
48466760|NCT04859140|DEVICE|Resting-state galvanic skin resistance measures|Skin conductance during the resting state period
48282768|NCT04285723|OTHER|alpelisib|Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
48282769|NCT01167127|DRUG|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
48282770|NCT02904226|DRUG|JTX-2011|Specified dose on specified days
48282771|NCT02904226|DRUG|Nivolumab|Specified dose on specified days
48282772|NCT02904226|DRUG|Ipilimumab|Specified dose on specified days
48282773|NCT02904226|DRUG|Pembrolizumab|Specified dose on specified days
48282774|NCT06263712|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The Attempted Suicide Short Intervention Program (ASSIP) is a specific therapy for patients with a suicide attempt in their biography. The brief therapy ASSIP consists of three to four sessions of approximately 50 minutes each.~Session 1: A narrative interview is conducted, in which the patient is asked to tell her\*his personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behavior is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
48282775|NCT06263712|BEHAVIORAL|Standard of care plus resource interview group (STAR)|The standard of care plus resource interview group (STAR) will be offered a clinical interview, a risk assessment, and a non-specific resource focused intervention over three face-to-face sessions. In this resource focused intervention, the patient is asked to name her\*his resources, describe them, and give examples.
48282776|NCT01672892|RADIATION|Standard radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
48282777|NCT01672892|RADIATION|intensity-modulated radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
48282778|NCT03903471|DEVICE|22G-ProCore Endobronchial Ultrasound Needle|EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
48282779|NCT03903471|DEVICE|22G-Standard Endobronchial Ultrasound Needle|EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
48282780|NCT06656559|DRUG|Envafolimab and Surufatinib|Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd
48282781|NCT01773824|BEHAVIORAL|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
48282782|NCT01773824|BEHAVIORAL|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
48282783|NCT06169215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
48282784|NCT06169215|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48282785|NCT06169215|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48282786|NCT06169215|DRUG|Bortezomib|Given SC
48282787|NCT06169215|PROCEDURE|Computed Tomography|Undergo CT
48282788|NCT06169215|BIOLOGICAL|Daratumumab|Given SC
48466761|NCT00725764|DRUG|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
48466762|NCT02103101|OTHER|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
48282789|NCT06169215|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
48282790|NCT06169215|DRUG|Dexamethasone|Given PO
48282791|NCT06169215|DRUG|Lenalidomide|Given PO
48282792|NCT06169215|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48282793|NCT06169215|PROCEDURE|Positron Emission Tomography|Undergo PET
48282794|NCT06169215|DRUG|Selinexor|Given PO
48466763|NCT02103101|GENETIC|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
48466764|NCT01203917|DRUG|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
48282795|NCT02981290|DRUG|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
48282796|NCT02981290|DRUG|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
48282797|NCT02981290|DRUG|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
48282798|NCT02981290|DRUG|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
48282799|NCT00499265|DRUG|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
48282800|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
48282801|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
48282802|NCT04486560|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
48282803|NCT02484261|DRUG|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
48282804|NCT02484261|DRUG|Pravastatin|10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
48282805|NCT02081963|DRUG|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
48282806|NCT02081963|DRUG|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
48282807|NCT02195843|OTHER|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
48282808|NCT02195843|OTHER|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
48282809|NCT02195843|DEVICE|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
48466765|NCT00506012|DRUG|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
48466766|NCT01004510|DRUG|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
48466767|NCT02651064|OTHER|HIP|
48466768|NCT02545530|DRUG|transdermal clonidine|2.5mg/patch per week
48466769|NCT06338423|DEVICE|vacuum mattress|vacuum mattresses used to better positioning of the patient
48466770|NCT06338423|OTHER|Standard Mattress|Standard Mattress
48100442|NCT05218408|BIOLOGICAL|CYNK-001 systemic and Intra cavity administration|"Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a"
48100443|NCT06081803|DRUG|Repatha®|Repatha® 140mg x 3 pens subcutaneous injection
48282810|NCT01161225|BEHAVIORAL|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
48466771|NCT06030128|BEHAVIORAL|core stabilization exercise|All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
48466772|NCT04697316|DEVICE|Transcranial Direct Current Stimulation|To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
48466773|NCT04697316|DEVICE|Sham|For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
48466774|NCT03926416|BIOLOGICAL|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
48466775|NCT03926416|BIOLOGICAL|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
48466776|NCT01181531|DRUG|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
48466777|NCT01181531|DRUG|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
48466778|NCT05958433|BEHAVIORAL|Rehabilitation with stoma appliance|The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
48626475|NCT04510753|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
48626476|NCT04510753|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
48100444|NCT01841827|DRUG|Cilostazol|
48100445|NCT01841827|DRUG|Placebo|
48100446|NCT04272073|OTHER|High-Protein Mediterranean Diet|As in arm/group descriptions
48100447|NCT04272073|OTHER|Resistance Exercise|As in arm/group descriptions
48466779|NCT05588063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
48466780|NCT05588063|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
48466781|NCT02473055|OTHER|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
48466782|NCT06383091|BEHAVIORAL|Anterior Neck Manual Therapy|Manual massage applied to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
48466783|NCT06383091|BEHAVIORAL|Pain Neuroscience Education|Description of how the pain system works from a neurobiological level, discussing the biopsychosocial model that influences pain.
48466784|NCT06383091|BEHAVIORAL|Neck Stretches|Bilateral cervical side bending, cervical extension and bilateral rotational neck stretches held for 20 seconds x3.
48466785|NCT06383091|BEHAVIORAL|Scar massage|Digital manipulation of the scar itself in circles.
48466786|NCT06383091|BEHAVIORAL|Voice Exercises|Stemple Voice Exercises
48100448|NCT04272073|OTHER|Standard Dietary Advice|As in arm/group descriptions
48466787|NCT06383091|BEHAVIORAL|Placebo Anterior Neck Manual Therapy|Will apply extremely light manual contact to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
48466788|NCT06383091|BEHAVIORAL|Placebo Pain Neuroscience Education|Will discuss how pain will as a result of the surgical intervention.
48466789|NCT06383091|BEHAVIORAL|Placebo Neck Stretches|Will ask patient to look down as a neck stretch held for 20 seconds x3.
48466790|NCT02926755|PROCEDURE|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
48466791|NCT04884724|OTHER|Adaptive Dance Exercise Program|It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
48282811|NCT01161225|BEHAVIORAL|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
48466792|NCT03012893|DEVICE|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
48466793|NCT03012893|DEVICE|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
48466794|NCT03012893|PROCEDURE|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
48466795|NCT06678711|PROCEDURE|minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion|Make a 4.5 cm incision along the median line and then dissect the trapezius, splenius capitis, and semispinalis capitis muscle laterally 1.5 cm off the median line. Retract the obliquus capitis inferior muscle to expose the C1-C2 intra-articular space. Remove the articular cartilage, insert allogenic granular bone and 3D-printed cage. Place the screws and rod in the same positions as conventional surgery, and the operation is completed.
48100449|NCT04272073|OTHER|Standard Cardiac Rehabilitation Exercise|As in arm/group descriptions
48100450|NCT01545674|PROCEDURE|Blood Draw|Blood will be drawn from the mother and father
48282812|NCT02014948|OTHER|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
48466796|NCT06678711|PROCEDURE|Open atlantoaxial fixation and fusion|The Goel-Harms procedure will be used in the control group. Screws and rods are placed in the same position as in the experimental group, and a negative-pressure drain was placed until daily drainage was \<50 mL.
48466797|NCT06630897|OTHER|Text Messages|small amounts of digital support will be in the form of text messages
48466798|NCT06112743|DRUG|Mavacamten|Specified dose on specified days
48100451|NCT02633189|DRUG|Erlotinib|given orally 150 mg daily
48100452|NCT02633189|DRUG|Bevacizumab|15 mg/kg intravenously every 21 days.
48100453|NCT02893228|PROCEDURE|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
48282813|NCT06657209|PROCEDURE|Insulin resistance testing|Steady state Plasma Glucose test
48282814|NCT06657209|PROCEDURE|OGTT|Will collect 5 blood draws during the test to measure insulin secretion
48282815|NCT06657209|PROCEDURE|Fat biopsy|Needle biopsy to gather a sample of abdominal subcutaneous fat
48282816|NCT06657209|RADIATION|DXA scan|Whole body DXA scan
48282817|NCT06657209|PROCEDURE|MRI|Abdominal MRI
48282818|NCT06657209|PROCEDURE|1H-MRS|Spectroscopy of the abdominal region
48626477|NCT03941821|DRUG|Glecaprevir/Pibrentasvir|Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
48626478|NCT00207428|DRUG|Carbamazepine|
48626479|NCT00932802|DRUG|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
48626480|NCT02499315|DRUG|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
48626481|NCT02499315|DRUG|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
48466799|NCT02473237|DRUG|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
48466800|NCT02473237|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
48466801|NCT02940652|RADIATION|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
48466802|NCT00176891|PROCEDURE|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
48466803|NCT00176891|DRUG|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
48466804|NCT02825316|BEHAVIORAL|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
48466805|NCT02825316|BEHAVIORAL|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
48466806|NCT02017873|DRUG|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
48466807|NCT06505005|DEVICE|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT) Other Names:|Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT)
48466808|NCT06505005|DEVICE|Sham Patch without haptic vibrotactile trigger technology (VTT)|Sham Patch without haptic vibrotactile trigger technology (VTT)
48466809|NCT02521051|DRUG|Alectinib|
48466810|NCT02521051|DRUG|Bevacizumab|
48466811|NCT04338334|OTHER|Manual drainage & arm therapeutic exercise|See arm/group descriptions.
48466812|NCT04338334|OTHER|Cohesive bandaging & arm therapeutic exercise|See arm/group descriptions.
48466813|NCT02079363|OTHER|No interventions, this is an observational study|
48466814|NCT05953337|DEVICE|EYE90 Microspheres Treatment|Y90 glass microspheres
48466815|NCT04389645|DIAGNOSTIC_TEST|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
48466816|NCT06150079|PROCEDURE|Pes-Guided PEEP titration|Lung recruitment is performed at each time point, involving a switch from volume-controlled (VCV) mode to pressure-controlled (PCV) mode with a pressure setting of 20 cmH2O, RR of 15 bpm, I:E ratio of 1:1, FiO2 of 0.4, and PEEP of 5 cmH2O. During lung recruitment, PEEP is gradually increased in increments of 5 cmH2O, maintained for 5 respiratory cycles until PEEP reaches 20 cmH2O and airway pressure reaches 40 cmH2O, and then maintained for 10 respiratory cycles. After lung recruitment, ventilation is adjusted based on the target PEEP. Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability. PEEP is chosen to maintain a positive transpulmonary pressure at end-expiration (Ptp_ee = PEEP - Pes_ee). Each PEEP titration should ensure adequate muscle relaxation, volume status, and hemodynamic stability.
48466817|NCT04758390|BEHAVIORAL|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
48466818|NCT04758390|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
48466819|NCT00357955|BEHAVIORAL|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
48466820|NCT00357955|BEHAVIORAL|Interactive Education|interactive lectures with hands-on learning
48282819|NCT06657209|DRUG|Tirzepatide|16 weeks started at 2.5mg/week and increased to 5mg/week dose
48466821|NCT00357955|BEHAVIORAL|Role modeling|learning from peers with similar disease and problems
48466822|NCT00357955|PROCEDURE|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
48466823|NCT01475487|PROCEDURE|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
48626482|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if \<1500g b.w. or 4.0g/kg/d of enteral protein if \>1500g b.w. until 1 week before discharge
48626483|NCT01773902|DIETARY_SUPPLEMENT|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
48626484|NCT01773902|DIETARY_SUPPLEMENT|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
48626485|NCT04073576|DEVICE|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
48626486|NCT04073576|DEVICE|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
48626487|NCT02845388|DRUG|Sildenafil citrate|
48626488|NCT02845388|DRUG|estradiol valerate|
48626489|NCT03912636|BEHAVIORAL|Diaphragmatic breathing|Subjects will perform Diaphragmatic breathing after the test meal.
48626490|NCT03912636|BEHAVIORAL|Deep Slow Breathing|Subjects will perform Deep Slow Breathing after the test meal.
48626491|NCT03912636|BEHAVIORAL|Normal breathing|Subjects will perform Normal Breathing (as a control) after the test meal as a control.
48466824|NCT00483145|DEVICE|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
48466825|NCT00483145|DEVICE|Long-pulsed dye laser|
48466826|NCT00483145|DEVICE|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
48466827|NCT06574139|BEHAVIORAL|Unstained|Unstained is an individual-level, virtual intervention that involves three \~60-minute sessions delivered over a 3-6 week period. Each session includes watching two videos (six videos total), followed by a discussion facilitated by study coordinators.
48466828|NCT06574139|BEHAVIORAL|Like|Like is an hour-long film that discusses the impact of social media on the brain. Participants will receive a link to the film and will be asked to watch it independently. The film does not include information related to the outcomes of interest for the study.
48466829|NCT06678126|RADIATION|Prostate and Pelvic Nodes Radiotherapy|60 Gy prostate and 44 Gy pelvic nodes with 20 fractions
48626492|NCT03948386|DRUG|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
48282820|NCT06657209|DRUG|Pioglitazone|16 weeks at a 45mg/day dose
48626493|NCT03948386|DRUG|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
48100454|NCT02893228|DRUG|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
48100455|NCT06326866|DIAGNOSTIC_TEST|Otoacoustic emissions (non-invasive)|There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
48100456|NCT01846169|BEHAVIORAL|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
48282821|NCT00430534|BIOLOGICAL|EBV vaccine (268664)|
48282822|NCT02498652|DRUG|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
48466830|NCT04302935|OTHER|Global pain-assessment|Global pain-assessment, based on the ICF framework
48466831|NCT04274829|PROCEDURE|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
48466832|NCT02505035|BEHAVIORAL|Default ordering of palliative consult|
48466833|NCT00002244|DRUG|WF10|
48282823|NCT02498652|DRUG|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
48466834|NCT02412722|DRUG|Sapanisertib|Sapanisertib capsules
48466835|NCT02412722|DRUG|Paclitaxel|Paclitaxel injection
48466836|NCT00111137|DRUG|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
48466837|NCT00111137|DRUG|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
48466838|NCT05141474|BIOLOGICAL|NEXTGEN-TIL|"NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.~Each dose contains at least 5 x 10\^8 total viable lymphocytes, and a maximum of 1.11x10\^11. It will be administered IV on Day 0 (24h after the last dose of Fludarabine)."
48626494|NCT03948386|DRUG|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
48626495|NCT00498485|DRUG|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
48100457|NCT03269019|DIAGNOSTIC_TEST|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
48282824|NCT01818544|DRUG|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
48282825|NCT01818544|DRUG|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
48282826|NCT00475163|BEHAVIORAL|Behavior modification|
48282827|NCT05712824|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
48282828|NCT05011461|OTHER|Almond Oil|Almond Oil Pressed Cold
48626496|NCT00498485|DRUG|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
48466839|NCT05141474|DRUG|Non-myeloablative Lymphodepletion (NMA-LD) Regimen|Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
48626497|NCT03528850|OTHER|Telemedicine evaluation|Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
48626498|NCT02785042|DEVICE|Heidelberg Spectralis OCT|OCT imaging
48626499|NCT06475378|DEVICE|Moonbird|Moondbird is a technology-supported breathing exercise with a tactile breath pacer device
48626500|NCT06475378|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
48626501|NCT02960906|DRUG|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
48626502|NCT02960906|DRUG|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
48626503|NCT02960906|DRUG|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
48626504|NCT02960906|DRUG|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
48626505|NCT04498104|OTHER|Psychological assessment|Psychological assessment with the repertory grid technique (RGT) in order to quantify cognitive conflicts.
48626506|NCT00834938|OTHER|No intervention|No intervention
48626507|NCT04268511|PROCEDURE|Caudal epidural block group|The linear probe of ultrasound was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone. A 22 Gauge 50 mm echogenic block needle was advanced
48626508|NCT04268511|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
48626509|NCT00853047|DRUG|Telotristat etiprate|Telotristat etiprate capsules; orally 3 times daily.
48100458|NCT02162667|DRUG|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
48626510|NCT00853047|DRUG|Octreotide LAR Depot|A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.
47937460|NCT04441866|DIAGNOSTIC_TEST|Automated algorithms|Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
48100459|NCT02299921|OTHER|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
48100460|NCT03321539|DRUG|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
48466840|NCT05141474|DRUG|Interleukin-2|"Patients will receive sequential doses of 720,000 IU/kg IV IL-2 every 8-24 hours depending on patient tolerance. It will be administered on Days 0 to 2, starting between 3 and 24 hours after the completion of NEXTGEN-TIL infusion.~IL-2 doses may be skipped in case of toxicity. If 2 sequential doses or more than 2 non-sequential doses of IL-2 are skipped due to patient intolerance or the discretion of the investigator, IL-2 administration must be stopped."
48466841|NCT01910831|DRUG|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
48466842|NCT01910831|DRUG|Non-active placebo control|Non-active placebo control
48466843|NCT04231292|DRUG|RD01|RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
48466844|NCT04231292|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
48466845|NCT04231292|DRUG|placebo|placebo
48282829|NCT04871815|DRUG|sodium pyruvate nasal spray|Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
48282830|NCT02562729|PROCEDURE|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
48466846|NCT03844230|OTHER|Control - Inhibition|Taste and spit up water 10 minutes before drinking a glucose load
48100461|NCT03321539|DRUG|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
48100462|NCT05689268|DIAGNOSTIC_TEST|EUS-PPG and HVPG|"EUS-PPG and HVPG will be measured in all patients. Under deep sedation with propofol, an echoendoscopy will be performed. After identifying the left or middle suprahepatic vein, it will be punctured with a standard 22 G needle. The needle will be previously purged with heparinized saline and connected to a venous pressure monitor via an arterial pressure system, which will be calibrated to zero at the level of the axillary midline, at the level of the atrium. Subsequently, the left portal vein will be identified from the stomach or duodenum, repeating the procedure. From each vessel 3 measurements will be taken by flushing 1-2 ml of heparinized saline. The mean of the three measurements will be obtained.~On the same day or on successive days HVPG measurement will be performed."
48466847|NCT03844230|OTHER|Experimental I- Inhibition|Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
48466848|NCT03844230|OTHER|Experimental II- Inhibition|Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
48466849|NCT03844230|OTHER|Control- Stimulation|Taste and spit up water 10 minutes before drinking a glucose load
48466850|NCT03844230|OTHER|Experimental I- Stimulation|Taste and spit up sucralose 10 minutes before drinking a glucose load
48466851|NCT03844230|OTHER|Experimental II- Stimulation|Drink sucralose 10 minutes before drinking a glucose load
48466852|NCT03844230|OTHER|Sensory Evaluation|Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
48466853|NCT01922960|OTHER|micro-imaging|micro-imaging
48466854|NCT00939380|BEHAVIORAL|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
48466855|NCT00939380|OTHER|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
48466856|NCT00939380|OTHER|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
48466857|NCT00939380|OTHER|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
48466858|NCT03414073|DEVICE|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
48466859|NCT03414073|DEVICE|Conventional flossing technique|"The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
47937461|NCT04441866|DIAGNOSTIC_TEST|Standard technique|Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
48100463|NCT05511454|OTHER|Salivary and crevicular samples|The samples will be taken from patients in both groups who meet the selection criteria during consultations at the Montpellier University Hospital's Odontology Department. During these consultations, a sample will be taken after rinsing the oral cavity with a glass of water. The samples will be taken before the periodontal assessment in order to avoid bleeding.
48466860|NCT03414073|DEVICE|Conventional Interdental Brushing|The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
48466861|NCT02933892|PROCEDURE|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
48466862|NCT04917393|DEVICE|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
48466863|NCT04917393|OTHER|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
48466864|NCT02725619|BEHAVIORAL|CBT|
48466865|NCT02725619|BEHAVIORAL|PST|
48466866|NCT01058122|PROCEDURE|Collection of adverse drug events|
48466867|NCT00743860|DRUG|darapladib|experimental drug
48466868|NCT05799235|DEVICE|Telerehabilitation TAR program using a mobile application|Participants in this study arm will use a mobile application which allows participants to perform their home exercises with real-time feedback given, allowing for proper execution of exercises, on top of standard care.
48466869|NCT05799235|OTHER|Standard rehabilitation sessions|Participants in this control group will attend standard in person rehabilitation sessions with home exercise program given as per standard care.
48466870|NCT05123053|DRUG|Amifampridine|10mg tablet
48466871|NCT02786927|DRUG|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
48626511|NCT00853047|DRUG|Placebo|Placebo-matching telotristat etiprate capsules; orally 3 times daily.
47937462|NCT04094077|DRUG|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
48466872|NCT02786927|DRUG|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
48100464|NCT05022342|OTHER|alpelisib plus fulvestrant|Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.
48100465|NCT06469892|OTHER|Detect the expression level of miR-185 in salivary and plasma exosomes.|"Participants were instructed to refrain from eating, drinking, brushing their teeth, rinsing their mouth, or taking medications for one hour before saliva collection. They were then asked to bend over, lower their head, open their mouth, and allow saliva to flow naturally without chewing or spitting. Using a specialized container, 2 mL of unstimulated saliva was collected.~Participants fasted overnight before blood collection. Researchers used plasma tubes containing anticoagulant (EDTA) to obtain venous blood (4-5 mL) from the participants\&#39; upper arm. Subsequently, the blood was gently inverted to ensure optimal contact with the anticoagulant before centrifugation at 2000 rpm and 4°C for 10 minutes. Following centrifugation, the supernatant was extracted."
48466873|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
48466874|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
48466875|NCT02405793|DRUG|Meloxicam Test Capsules|
48466876|NCT02405793|DRUG|Meloxicam Test Capsules|
48466877|NCT02405793|DRUG|Meloxicam Tablets|
48466878|NCT05475548|DEVICE|powerscope|The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
48466879|NCT05438927|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
48466880|NCT05438927|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
48466881|NCT05438927|BEHAVIORAL|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
48466882|NCT05438927|BEHAVIORAL|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
48466883|NCT05438927|BEHAVIORAL|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
48466884|NCT05259956|BEHAVIORAL|Schroth based scoliosis specific exercise|The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.
48466885|NCT05259956|BEHAVIORAL|"3 plus 1 multidimensional exercise therapy"|The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
48466886|NCT01285076|OTHER|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
48466887|NCT01044134|BEHAVIORAL|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
48466888|NCT04550260|DRUG|Durvalumab|Durvalumab intravenous infusion
48466889|NCT04550260|DRUG|Placebo|Durvalumab matching placebo for intravenous infusion
48466890|NCT04550260|DRUG|cisplatin + fluorouracil|cisplatin + fluorouracil, as per Standard of Care
48466891|NCT04550260|DRUG|cisplatin + capecitabine|cisplatin + capecitabine, as per Standard of Care
48466892|NCT04550260|RADIATION|Radiation|50-64Gy in total
48466893|NCT06307626|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
48466894|NCT06307626|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
48466895|NCT05598398|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|"The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option."
48466896|NCT05598398|OTHER|Standard of Care (Wet-to-dry dressings)|Wet-to-dry dressings
48466897|NCT02361736|DRUG|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
48466898|NCT02361736|DRUG|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
48466899|NCT00073632|BEHAVIORAL|Acceptance Based Behavioral Therapy|
48466900|NCT05856760|DRUG|Sparsentan|Target dose of 400 mg daily
48466901|NCT00003725|DRUG|valrubicin|
48466902|NCT00003725|PROCEDURE|conventional surgery|
47937463|NCT05155137|DRUG|Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)|Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
48466903|NCT04394130|DRUG|ropivacaine 0.2%|continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
48466904|NCT05188417|DRUG|Tirofiban 0.05 MG/ML|intravenous injection of the drug according to different body weights and arms
48466905|NCT05188417|DRUG|0.9% sodium chloride solution|intravenous injection of the drug according to different body weights and arms
48626512|NCT05467202|DRUG|CLL1 CAR-T|A single infusion of autologous CLL1 CAR-T cells administered intravenously
48626513|NCT01666405|DEVICE|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
48626514|NCT06144801|DEVICE|CoolSense Group|Patients in the CoolSense group received a CoolSense device that had been pre-chilled in the freezer for a minimum of one hour. The cover of the CoolSense device was removed, and the arteriovenous fistula, whose metal tip had been cleaned with batikon, was brought into contact with the area where the arteriovenous fistula cannulation would occur. This contact was maintained for 5 seconds, involving circular movements, and the fistula cannulation took place promptly.
48100466|NCT02380742|DRUG|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
48626515|NCT06008002|PROCEDURE|M-TAPA block|ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (0.3 ml/kg , %0.25 bupivacaine) will be performed
48626516|NCT06008002|PROCEDURE|EXORA block|Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg , %0.25 bupivacaine) will be performed
48626517|NCT06008002|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
48626518|NCT05348694|DIETARY_SUPPLEMENT|Pendulum WBF-038|"All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
47937464|NCT05155137|BEHAVIORAL|Stroke Riskometer|the primary care units will be randomized to use Stroke Riskometer App together with health community workers to help in the lifestyle modifications
48282831|NCT05290467|BEHAVIORAL|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
48282832|NCT04810273|BEHAVIORAL|Early progressive mobilization|The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
48282833|NCT04017403|DRUG|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
48282834|NCT04017403|DRUG|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
48466906|NCT04511156|OTHER|Foundational Helping Skills|Each site will implement three waves of Foundational Helping Skills training. Each training will include 12 trainees each, with a minimum of 2 trainers per training. Each site will include pre and post research days, where they will collect primary and secondary outcomes with support from research staff (trained raters, actors, and qualitative researcher). Each site will qualitatively assess the training after the first wave to identify any areas for modification, and after the second and third waves to develop recommendations for future implementation.
48626519|NCT05348694|DIETARY_SUPPLEMENT|Pendulum Placebo|Pendulum placebo capsules containing magnesium stearate
48626520|NCT00910741|DRUG|Nanoplatin (NC-6004) and Gemcitabine|
48626521|NCT02786667|DRUG|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
48626522|NCT02786667|DRUG|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
48626523|NCT02473874|DEVICE|Skin Spect dermoscope|Skin imaging
48626524|NCT02473874|DEVICE|Spatially modulated quantitative|Skin imaging
48626525|NCT04649554|DEVICE|Exablate treatment|Ablation
48626526|NCT02417181|OTHER|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
48626527|NCT03274661|DRUG|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
48626528|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|Anthocyans
48626529|NCT00634387|OTHER|placebo|
48626530|NCT00634387|DIETARY_SUPPLEMENT|Anthocyans|
48282835|NCT06028438|DRUG|Placebo|Placebo will be administered intravenously.
48282836|NCT06028438|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
48282837|NCT06028438|DRUG|Certolizumab|Certolizumab will be administered subcutaneously.
48282838|NCT01160731|DRUG|cisplatin|
47937465|NCT00322153|DRUG|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
48282839|NCT01160731|DRUG|etoposide phosphate|
48282840|NCT01160731|DRUG|panobinostat|
48466907|NCT00384592|DRUG|Esomeprazole|
48466908|NCT00384592|PROCEDURE|Physical exam|
48626531|NCT05333744|DRUG|Prednisone|Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
48626532|NCT05333744|DRUG|Recombinant Human TPO|rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
48626533|NCT01431742|DRUG|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
48626534|NCT06553469|DEVICE|sacral neuromodulation|After screening according to the inclusion and exclusion criteria, the subjects were enrolled in the study. The sacral nerve regulation treatment was divided into two phases. Phase I was the testing phase, during which the sacral nerve stimulation electrode component was implanted. After the electrode was implanted, it was tested for 2-4 weeks. According to the urine diary and scale scores, if the symptoms improved by ≥ 50%, or if the patient requested to continue with Phase II and was evaluated by the researcher as suitable for implantation, Phase II (permanent implantation phase) treatment was performed, during which the sacral nerve stimulation pulse generator component was implanted
48626535|NCT02214810|DRUG|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
48626536|NCT01339182|DRUG|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
48626537|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
48466909|NCT00384592|PROCEDURE|Pregnancy test if applicable|
48626538|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
48626539|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
47937466|NCT00322153|DRUG|Placebo|Matching placebo oral administration once daily.
47937467|NCT03799172|DRUG|Echinocandin treatment|Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
47937468|NCT03799172|DRUG|Triazole treatment|"Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida."
47937469|NCT00566644|DEVICE|levonorgestrel-releasing intrauterine system|
48282841|NCT01160731|OTHER|laboratory biomarker analysis|
47937470|NCT00566644|OTHER|questionnaire administration|
47937471|NCT00566644|PROCEDURE|observation|
47937472|NCT00712556|RADIATION|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
48282842|NCT01160731|OTHER|pharmacological study|
48282843|NCT03797560|OTHER|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases"
48282844|NCT03797560|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
48282845|NCT00378846|PROCEDURE|infrared thermography|
48282846|NCT05180786|OTHER|Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned on.
48282847|NCT05180786|OTHER|No Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned off.
48466910|NCT05183451|PROCEDURE|En- masse retraction and LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs. LLLT will be applied on days 0,3,7,14 from extraction then repeated biweekly till the end of retraction."
48466911|NCT05183451|PROCEDURE|En- masse retraction without LLLT|"Retraction will start on a 0.019x0.025 Stainless steel wire using NiTi closed coils (force applied will be 200 g per side) extending between the crimpable hooks and the TADs."
48466912|NCT03031795|DRUG|Ketorolac|Oral Tablet
48466913|NCT03031795|DRUG|Placebo|Oral Tablet
48466914|NCT03947398|DEVICE|BLIMP balloon|Using BLIMP balloon to cross lesion
48466915|NCT03947398|DEVICE|Low profile balloon|using low profile balloon to cross lesion
48282848|NCT02845869|DEVICE|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
48282849|NCT02845869|DEVICE|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
47937473|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Convenctional TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Conventional TENS method).
47937474|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Pseudo-acupuncture TENS method).|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Pseudo-acupuncture TENS method).
48466916|NCT03545334|DIAGNOSTIC_TEST|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
48626540|NCT01339182|DRUG|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
48626541|NCT02466542|DRUG|Placebo group|Patients will receive regular general anesthesia
48626542|NCT02466542|DRUG|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
48626543|NCT03409458|DRUG|PT-112|"The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort.~For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15."
48626544|NCT03409458|BIOLOGICAL|avelumab|Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15.
48626545|NCT02748031|PROCEDURE|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
48626546|NCT00009893|DRUG|fluorouracil|
48626547|NCT00009893|DRUG|gemcitabine hydrochloride|
47937475|NCT04890743|OTHER|Kinesiotherapy combined with electrotherapy (Trabert ultrastimulation method)|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and electrotherapy (Trabert ultrastimulation method).
47937476|NCT04890743|OTHER|Kinesiotherapy combined with placebo electrotherapy|One of the four groups created during randomization will undergo a unified program of kinesiotherapy and placebo electrotherapy.
47937477|NCT06423729|DRUG|Nicorandil 10 MG|Patients will receive oral Nicorandil 10 MG twice daily in addition to 2nd generation sulfonylureas , for 3 months.
47937478|NCT05606146|DEVICE|IUB SEAD|The investigative device, the IUB SEAD™, is a novel spherical endometrial ablation device developed to allow for simple, office-based chemical EA to treat benign causes of the symptom of HMB
47937479|NCT00120354|PROCEDURE|Blood Testing|
47937480|NCT00120354|PROCEDURE|Percutaneous Liver Biopsy|
47937481|NCT00120354|PROCEDURE|Lamivudine Therapy|
47937482|NCT03705078|PROCEDURE|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
48282850|NCT00716443|DRUG|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
48282851|NCT00716443|DRUG|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
48466917|NCT04960761|OTHER|İntervention Group|"In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied."
48466918|NCT03264716|DEVICE|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
48466919|NCT04218487|DRUG|Xuefu-Zhuyu Capsule|treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
48466920|NCT04218487|DRUG|placebo|treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
48466921|NCT04218487|OTHER|conventional therapy|conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.
48466922|NCT02991313|DEVICE|Endocardial Ablation Procedure|
48466923|NCT05846256|OTHER|Sperm DNA Fragmentation|Sperm DNA Fragmentation analysis.
48626548|NCT00009893|DRUG|leucovorin calcium|
48626549|NCT00001647|PROCEDURE|White blood cell infusion|
48626550|NCT05390554|BEHAVIORAL|Buteyko Breathing Technique|"* The child was instructed to sit and take a relaxed posture in a vertical chair, relax his shoulders and lean his lower back against the back of the chair.~* Until conducting CP, the child was told to avoid alternate breathing, the child was asked to take a small breath in (two seconds), a small breath out (three seconds) and clutch the nose with empty lungs but not too clear on the 'out-breath. To prevent air from escaping through the airways, clutching the nose is necessary.~* The researcher estimates how many seconds the child can continue safely before the need to breathe in again,~* The child was told to hold their breath until the first need to breathe in was felt. Release the nose then and naturally breathe through it smoothly.~* The first intake of breath after the CP should be no higher than the breath before taking the measurement; the child should not hold the breath for too long as this could lead the child to take a major breath after measuring the CP."
48466924|NCT02379624|DRUG|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
48466925|NCT06579417|DIAGNOSTIC_TEST|RSI MRI|In ART-Pro-1, patients receive standard of care mpMRI, with addition of the RSI sequence, and subsets of the patients' images are read separately by two expert radiologists at the center, one of whom is the standard of care radiologist (Reader 1). Three research reports are generated using: bpMRI only (Reader 1), mpMRI (Reader 1), and bpMRI + RSIrs (Reader 2). The clinical report is submitted by Reader 1. Patients' future prostate cancer management will be recorded and used to evaluate the performance of the MRI techniques being tested.
48466926|NCT04348955|BEHAVIORAL|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized|"Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)"
48466927|NCT05413733|BEHAVIORAL|Digital care pathway|"Sessions of the digital neuropsychological program:~1. Subjective functional ability and goals~2. Fatigue after ABI~3. Attention and concentration~4. Memory~5. Memory strategies~6. Working memory and executive functions~7. Emotional reactions~8. Summary and future goals"
48466928|NCT05413733|BEHAVIORAL|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
47937483|NCT03705078|PROCEDURE|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
48626551|NCT04416542|DIAGNOSTIC_TEST|Home Sleep Testing|"Two-night Home Sleep Tests (HSTs) will be conducted using commercially available Home Sleep Test equipment. The HST will be ordered by the clinical center through a HIPAA compliant HST service that has been selected by the study sponsor.~The HSTs will be scored and interpreted according to AASM Guidelines by board certified sleep physicians affiliated with the HST service. The HST will be scored using the 4% oxygen desaturation rule."
48626552|NCT01113957|DRUG|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
47937484|NCT03488823|DIETARY_SUPPLEMENT|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
47937485|NCT03488823|DIETARY_SUPPLEMENT|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
47937486|NCT02571400|OTHER|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics \>90 days post-surgery
47937487|NCT05871983|DEVICE|MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM|"The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~* Nitinol stent frame~* Bovine pericardium~* Polyester skirt~* Anchoring system allows anchoring the frame to the annulus~* Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~* Transfemoral / transseptal access~* Self-expanding~* Dry pericardium (can be pre-loaded)~* No anchors~* 27 Fr delivery catheter (~* Sizes: 40/48/55mm~* Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems."
47937488|NCT02815774|DRUG|SP2086|all subjects were given SP2086 50mg only one time.
47937489|NCT01242397|DEVICE|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
47937490|NCT00882401|DRUG|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
47937491|NCT00882401|DRUG|Placebo|Matching placebo at same dose schedule as ergocalciferol
47937492|NCT00480974|OTHER|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
47937493|NCT03448081|DRUG|SNA-120|SNA-120 (0.5%) active ointment
48466929|NCT04384224|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
48626553|NCT01113957|DRUG|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
48626554|NCT01113957|DRUG|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
48626555|NCT02096536|DRUG|Vancomycin|vancomycin administration based on decision of treating physician
47937494|NCT03448081|DRUG|Placebo|Vehicle Ointment
47937495|NCT03448081|DRUG|Calcipotriene|Calcipotriene ointment (0.005%)
47937496|NCT04964284|BIOLOGICAL|rhTSH|rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH
47937497|NCT04964284|RADIATION|Radioiodine (131I)|Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
47937498|NCT00841373|PROCEDURE|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
47937499|NCT00841373|PROCEDURE|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
47937500|NCT05312047|PROCEDURE|Pelvic organ prolapse surgery|Vaginal surgery of any compartment for pelvic organ prolapse
47937501|NCT00482352|OTHER|laboratory biomarker analysis|Correlative studies
48626556|NCT04964232|DEVICE|Infrared Camera|The core-temperature is simultaneously measured by esophageal body temperature measurement methods, skin surface body temperature measurement methods, and thermal imaging camera.
48626557|NCT04964232|DEVICE|Esophageal Temperature Probe|In patients undergoing general anesthesia, the Esophageal temeperature parameters are measured using an Esophageal probe.
48466930|NCT01055834|DRUG|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting \>=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
48626558|NCT04964232|DEVICE|Skin temperature probe|In patients undergoing general anesthesia, the skin spot temeperature parameters are measured using an skin adhesive probe.
48626559|NCT06025461|OTHER|no intervention|no intervention
48626560|NCT01503801|DRUG|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
48626561|NCT01503801|DEVICE|respiratory support|Routine respiratory support.
48626562|NCT00005940|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
48282852|NCT05445193|BEHAVIORAL|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
48466931|NCT01055834|DRUG|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
48466932|NCT01083797|DRUG|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
48466933|NCT01083797|DRUG|Chloral Hydrate|Initial dose=50 mg/kg
48466934|NCT05965986|OTHER|Experimental: PREPS only|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative."
48626563|NCT00005940|DRUG|busulfan|Given PO
48626564|NCT00005940|DRUG|cyclophosphamide|Given IV
48626565|NCT00005940|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
48626566|NCT00005940|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
48626567|NCT00005940|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
48626568|NCT00005940|DRUG|cyclosporine|Given IV or PO
48626569|NCT00005940|DRUG|methotrexate|Given IV
48626570|NCT00005940|OTHER|laboratory biomarker analysis|Correlative studies
48626571|NCT05053828|DRUG|Antiplatelet Drug|Antiplatelet drugs and agents
48626572|NCT04942210|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
48626573|NCT04942210|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
48626574|NCT03474835|DIAGNOSTIC_TEST|ISCHEMIC HEART DISEASE diagnostic|ISCHEMIC HEART DISEASE diagnostic
48626575|NCT01859741|DRUG|OMP-59R5|OMP-59R5 administered intravenously
48626576|NCT01859741|DRUG|Etoposide|administered intravenously
48626577|NCT01859741|DRUG|Placebo|administered IV
48626578|NCT01859741|DRUG|Cisplatin or Carboplatin|administered intravenously
47937502|NCT04618770|DEVICE|Triathlon PSR Tibial Insert|The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
47937503|NCT04835467|DEVICE|Dual-modal OCT-FLIm|Intracoronary imaging using dual-modal OCT-FLIm catheter
48626579|NCT04919343|BEHAVIORAL|BBC Education Tiny Happy People videos|This intervention involves regular texting of BBC Education Tiny Happy People videos to parents
48626580|NCT04919343|BEHAVIORAL|Physical health control intervention|This intervention involves regular texting of publicly available videos about supporting infant physical and dental health to parents
48626581|NCT05130840|DIAGNOSTIC_TEST|MRI|MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks).
48626582|NCT05130840|DIAGNOSTIC_TEST|Lumbar puncture|LP at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA.
48626583|NCT02539693|DRUG|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
47937504|NCT01206673|OTHER|Blood sampling|One blood sampling is required for the research
48282853|NCT02820857|DRUG|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
48282854|NCT02820857|DRUG|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
48626584|NCT02539693|DRUG|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
48626585|NCT02539693|DRUG|Lidocaine|3 ml lidocaine 1% is injected at each block site
48466935|NCT05965986|OTHER|Experimental: PREPS and therapy|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative. In addition, participants will have a therapist call on week 2 and 4 of the program and then one week after surgery to check in and ensure the patient is meeting all milestones and answer any questions."
48466936|NCT04255849|BIOLOGICAL|9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Gardasil-9 HPV vaccine
48626586|NCT02539693|PROCEDURE|Pilonidal sinus|Removal of pilonidal sinus
48626587|NCT04668963|DEVICE|MIRROR THERAPY|patients were seated on a chair, with the mirror positioned between the upper limbs perpendicular to the subject's midline and with the unaffected upper limb facing the reflective surface. Following the physiotherapist indications, the patients observed the reflection of their unaffected limb while performing the following movements with the both arms, the affected one as good as possible: flexion and extension of the shoulder, elbow, wrist and finger, prone supination of the forearm.
48626588|NCT02811978|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
48626589|NCT02811978|DRUG|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
48626590|NCT02807090|OTHER|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
48466937|NCT04255849|OTHER|Saline Placebo|Saline Placebo
48466938|NCT01468688|DRUG|STI571|
48626591|NCT02807090|OTHER|Circular dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
48626592|NCT04983732|DRUG|FL-101-Intravenous|150 mg administered via the IV route
48626593|NCT04983732|DRUG|FL-101-Subcutaneous|150 mg administered via the SC route
48626594|NCT04607551|PROCEDURE|Prone positionning|4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours
48626595|NCT04607551|PROCEDURE|Supine position|Patients assigned to supine will remain in a semi-recumbent position.
48626596|NCT00158613|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
47937505|NCT06345664|OTHER|Diagnostics and intervention recommendations|All families get the same diagnostics and receive individual treatment recommendations.
47937506|NCT02503345|DRUG|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
47937507|NCT02503345|DRUG|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
48466939|NCT01468688|DRUG|BKM120|BKM120 combination therapy
47937508|NCT02503345|DRUG|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
47937509|NCT02503345|DRUG|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
48282855|NCT02689700|OTHER|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
48282856|NCT04874740|OTHER|No intervention|No intervention
48282857|NCT04322708|OTHER|Placebo|Placebo
48466940|NCT00777855|DRUG|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
48626597|NCT02328274|PROCEDURE|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
48626598|NCT03695835|DRUG|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
48626599|NCT03695835|DEVICE|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
48282858|NCT04322708|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
48466941|NCT00777855|DRUG|warfarin|warfarin 7.5mg po x 1
48466942|NCT05395416|DRUG|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
48466943|NCT05395416|DRUG|Placebo|administered orally once daily for 12 weeks
48626600|NCT01028391|DRUG|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
48626601|NCT01028391|DRUG|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
48466944|NCT03064867|DRUG|Venetoclax|"Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days"
48466945|NCT03064867|DRUG|Rituximab|"Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days"
48626602|NCT01028391|DRUG|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
48626603|NCT00692016|DRUG|Naproxen sodium|Administered under fasting condition
48626604|NCT00692016|DRUG|Naproxen sodium|Administered under fed condition
48282859|NCT05890703|DRUG|IMP2 (lidocaine-23%-tetracaine-7% gel)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
48282860|NCT05890703|DRUG|IMP1 (EMLA 5% cream)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
48282861|NCT04032366|DRUG|inhaled nitric oxide|using of inhaled nitric oxide
48282862|NCT04032366|DEVICE|PEEP|increasing PEEP or decreasing PEEP
48282863|NCT06116305|OTHER|No intervention|No intervention
48282864|NCT04237649|DRUG|KAZ954|KAZ954 will be administered in every arm.
48282865|NCT04237649|DRUG|PDR001|KAZ954 + PDR001
48466946|NCT03064867|DRUG|Ifosfamide|"Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle"
48282866|NCT04237649|DRUG|NIR178|KAZ954 + NIR178
48466947|NCT03064867|DRUG|Carboplatin|"Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle"
48466948|NCT03064867|DRUG|Etoposide|"Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle"
48466949|NCT06075849|DRUG|PB101|"Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator."
48466950|NCT05816655|DRUG|Fulvestrant plus AI plus ribociclib|Fulvestrant + AI + ribociclib +/- GnRH agonist
48626605|NCT03509584|RADIATION|hypofractionated radiotherapy|Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
48626606|NCT03509584|DRUG|nivolumab|administration of nivolumab
48626607|NCT03509584|DRUG|Ipilimumab|administration of ipilimumab
48626608|NCT06470464|DRUG|Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)|The oral dose of thalidomide is 1.5-2.5mg/kg/d daily (maximum 28g). Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
48626609|NCT01203371|DRUG|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
48626610|NCT01203371|DRUG|Tamsulosin|0,4 mg/day
48626611|NCT03695796|DIAGNOSTIC_TEST|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
48626612|NCT00408954|DRUG|UK-369,003|100 mg MR tablet once daily for 2 weeks
48626613|NCT00408954|DRUG|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
48282867|NCT04237649|DRUG|NZV930|KAZ954 + NZV930
48282868|NCT06657482|BEHAVIORAL|Delayed school start time|The intervention group will start school two hours later on Mondays (at 10.15 ± 15 min) and one hour later on Tuesdays (9.15 ± 15 min) and to ordinary school start time (8.15 ± 15 min) for the rest of the week
48466951|NCT05816655|DRUG|AI plus ribociclib|AI + ribociclib +/- GnRH agonist
48626614|NCT02184247|DRUG|anhydrous theophylline, 350 mg|
48626615|NCT02184247|DRUG|anhydrous theophylline, 300 mg|
48626616|NCT06163274|DEVICE|Placebo Intravaginal Ring A|Placebo Intravaginal Ring A consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 40A (Shore A hardness scale). The ring holds two blank grey cassettes.
48626617|NCT06163274|DEVICE|Placebo Intravaginal Ring B|Placebo Intravaginal Ring B consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 50A (Shore A hardness scale). The ring holds two blank grey cassettes.
48626618|NCT04913298|DEVICE|Cytosorb therapy|Start of Cytosorb therapy is at the discretion of the attending physician
48282869|NCT00753636|DRUG|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
48282870|NCT04847271|BEHAVIORAL|Physical activity on prescription (PAP)|The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
48282871|NCT03739970|DIETARY_SUPPLEMENT|Investigational Product (Silk Peptide)|"* Ingredient: Silk Peptide~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 9g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
48282872|NCT03739970|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Microcrystalline Cellulose~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 0g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
48282873|NCT04946318|DRUG|CSJ117|CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
48282874|NCT04946318|DRUG|Placebo|Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
48282875|NCT03451448|DIAGNOSTIC_TEST|PET/MRI|PET/MRI with USPIO contrast
48282876|NCT03451448|DIAGNOSTIC_TEST|MRI|MRI with USPIO contrast
48282877|NCT02420886|OTHER|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
48282878|NCT04820192|OTHER|Craniosacral Therapy|The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
48282879|NCT03806244|OTHER|Intraoperative acquisition (robotic c-Arm) of images|"Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform."
48282880|NCT01665638|DRUG|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
48282881|NCT01665638|DRUG|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
48466952|NCT05378958|OTHER|Individual interview|"Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion."
48466953|NCT00310115|BEHAVIORAL|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
48626619|NCT04924491|BIOLOGICAL|Autologous thyTreg|Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
48626620|NCT01522027|PROCEDURE|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
48626621|NCT02826499|DEVICE|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
48282882|NCT01665638|DRUG|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
48282883|NCT01665638|DRUG|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
48282884|NCT02528344|BEHAVIORAL|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
48282885|NCT06269523|OTHER|Kinesio taping, Lymphatic drainage|Kinesio tape, is an elastic cotton strip with an acrylic adhesive that is purported to ease pain and disability from athletic injuries and a variety of other physical disorders. The application of Kinesio Tex Tape facilitates the opening of microvalves due to a dynamic pressure variation due to alteration in skin density. This decompression activates lymphatics in the dermis and improves lymphatic flow. The end result is a tissue inflammation and swelling reduction.It has been applied at the end over every session after lymphatic dreinage (see below).
48466954|NCT00310115|BEHAVIORAL|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
48466955|NCT00310115|BEHAVIORAL|Counseling Intervention|2 in-person counseling sessions
48466956|NCT04485806|OTHER|GPS/LM|Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
48466957|NCT04485806|OTHER|SPL/LM|Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
48466958|NCT04485806|OTHER|GPS/PO|Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
48282886|NCT06269523|OTHER|Lymphatic drainage|Lymphatic drainage is a type of manual manipulation of the skin based on the hypothesis that it will encourage the natural drainage of the lymph, which carries waste products away from the tissues back toward the heart. The lymph system depends on intrinsic contractions of the smooth muscle cells in the walls of lymph vessels (peristalsis) and the movement of skeletal muscles to propel lymph through the vessels to lymph nodes and then to the lymph ducts, which return lymph to the cardiovascular system. Manual lymph drainage uses a specific amount of pressure and rhythmic circular movements to stimulate lymph flow.
48282887|NCT00189761|DRUG|Tacrolimus|
48282888|NCT02541630|BEHAVIORAL|Big Mind|mindfulness based intervention
48282889|NCT02499952|DRUG|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
48282890|NCT02972827|DEVICE|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
48282891|NCT02972827|OTHER|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
48282892|NCT05428371|DIAGNOSTIC_TEST|Multiomic analyses of blood and surgical specimens|"The following items will be evaluated:~* cell free dna length and integrity~* presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~* qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)"
48282893|NCT02365428|BEHAVIORAL|Physical activity text messages|
48282894|NCT02922764|DRUG|RGX-104|
48282895|NCT02922764|DRUG|Ipilimumab|
48466959|NCT04485806|OTHER|SPL/PO|Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
48466960|NCT02441322|DEVICE|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
48466961|NCT05493358|PROCEDURE|Laparoscopic distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
48466962|NCT00070239|DRUG|alvocidib|Given IV
48626622|NCT02826499|OTHER|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
48626623|NCT02004795|RADIATION|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
48282896|NCT02922764|DRUG|Docetaxel|
48282897|NCT02922764|DRUG|Pembrolizumab|
48466963|NCT00070239|OTHER|pharmacological study|Correlative studies
48466964|NCT00070239|RADIATION|fludeoxyglucose F 18|Correlative studies
48466965|NCT00070239|OTHER|fluorine F 18 fluorothymidine|Correlative studies
48100467|NCT02380742|DRUG|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
48282898|NCT02922764|DRUG|Carboplatin|
48282899|NCT02922764|DRUG|Pemetrexed|
48282900|NCT00763893|DRUG|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
48282901|NCT00763893|DRUG|Losartan|50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg
48466966|NCT00070239|PROCEDURE|positron emission tomography|Correlative studies
48466967|NCT06262503|DEVICE|Virtual Reality|Virtual Reality device is used for creating 3d avatar to engage the patient into a virtual world so he can overcome his pain
48466968|NCT06262503|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
48466969|NCT06262503|DEVICE|Mirroring Therapy|"Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb."
48282902|NCT03389672|PROCEDURE|spinal anesthesia|For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
48466970|NCT06262503|OTHER|Phantom Exercises|The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
48626624|NCT00372320|GENETIC|Gene Transfer|
48100468|NCT01559480|DRUG|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
48466971|NCT00279760|DRUG|Belatacept|
48466972|NCT00279760|DRUG|Abatacept|
48626625|NCT00372320|DRUG|AdhAQP1|
48282903|NCT03389672|PROCEDURE|epidural anesthesia|For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
48282904|NCT03389672|PROCEDURE|combined spinal-epidural anesthesia|For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
48282905|NCT05147246|BEHAVIORAL|ParentCorps-Professional Development (PD)|PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
48282906|NCT04427085|OTHER|Ultrasound assessment of optic nerve sheath diameter|Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
48282907|NCT04557059|RADIATION|Radiotherapy|Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
48282908|NCT04557059|DRUG|LHRHa|Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
48282909|NCT04557059|DRUG|Apalutamide|Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
48282910|NCT04899648|BEHAVIORAL|Behavioral Intervention Group|Behavioral intervention: (a) form groups and choose peer leaders; (b) train peer leaders on 16 core classes based on diabetes prevention program curriculum; (c) support and motivate peer leaders to lead intervention in their group; (d) monitoring of the interventions.
48282911|NCT00472303|DRUG|Tapentadol Extended Release|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
48466973|NCT06098313|DRUG|Cyclophosphamide|-Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
48466974|NCT05993754|OTHER|Non-pharmacological intervention|"The intervention consists of six main elements:~Correction of sensory deficits: Before surgery, the use of glasses, hearing aids and/or removable dental prostheses will be allowed, which will be removed before starting anesthesia in the emergency room. After surgery, they will be delivered back to the user.~Reorientation: In the postoperative period, the person will be informed where they are and the visit of the companion will be coordinated.~Early mobilization: A protocolized mobilization routine will be applied according to pain, state of consciousness, risk of thromboembolic disease and risk of falls.~Environmental management: You will be shown the time on a clock, it will reinforce the idea of the place where you are and that you can count on the team in case you need assistance.~Sleep protocol: The elderly person who does not want or cannot perform the mobilization routine, non-pharmacological sleep will be privileged.~Reduction of anticholinergic drugs"
48466975|NCT06594588|BEHAVIORAL|Aerobic exercise|Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy
48466976|NCT01120899|DRUG|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
48466977|NCT05386173|PROCEDURE|Fetal aortic balloon dilatation|Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
48466978|NCT01984606|DRUG|Empagliflozin|Empagliflozin once daily
48466979|NCT01984606|DRUG|Placebo|Placebo matching empagliflozin
48466980|NCT01984606|DRUG|Sitagliptin|Sitagliptin once daily
48466981|NCT01984606|DRUG|Placebo|Placebo matching sitagliptin
48466982|NCT03182751|DRUG|Tranexamic Acid (TXA)|Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
48466983|NCT03182751|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
48466984|NCT01350596|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
48466985|NCT01350596|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
48466986|NCT01529593|DRUG|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
48466987|NCT01529593|DRUG|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
48466988|NCT00387608|DRUG|veliparib|
48466989|NCT00387608|OTHER|pharmacological study|
48466990|NCT00387608|PROCEDURE|biopsy|
48626626|NCT03847077|BEHAVIORAL|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.
48626627|NCT03847077|BEHAVIORAL|Standard Counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
48626628|NCT01248975|DRUG|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
48626629|NCT01248975|DRUG|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
48626630|NCT01248975|DRUG|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
48626631|NCT01248975|DRUG|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
48626632|NCT01248975|DRUG|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
48626633|NCT01248975|DRUG|Placebo capsule (PM)|Placebo capsule (PM)
48626634|NCT01851512|DRUG|T-R (Test-Reference drug)|
48626635|NCT01851512|DRUG|R-T (Reference-Test drug)|
48466991|NCT05771935|PROCEDURE|ultrasound guided radial versus ulnar artery cannulation|"Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study."
48626636|NCT00183898|DRUG|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
48626637|NCT03295916|RADIATION|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
48626638|NCT01184807|DRUG|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
48626639|NCT04698486|OTHER|Hyperinsulinemic euglycaemic clamp|"Infusion of constant intravenous insulin to achieve hyperinsulinemia and concomitant infusion of glucose to maintain euglycemia (plasma glucose at 5 mM).~Infusion of palmitate and VLDL-triglyceride tracer. PET/CT scans of heart and liver, both in basal period and during intervention."
48626640|NCT02537470|DRUG|Biphasic Remogliflozin Etabonate|Experimental Drug
48626641|NCT02537470|OTHER|Placebo|Placebo Comparator
48626642|NCT03320369|OTHER|Elemental Diet Therapy|Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
48626643|NCT04177199|OTHER|TRIAGE HF Pathway|A new care pathway (Triage-HF Plus) for the remote monitoring and management of heart failure stability in a cohort of device patients at 3 hospital sites in North West England.
48626644|NCT01200355|DRUG|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
48626645|NCT01200355|DRUG|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
48626646|NCT04939389|DIAGNOSTIC_TEST|Orthelligent Pro|The sensor is attached to the knee of the participant and eight different movement exercises are performed
48626647|NCT01806792|DRUG|risedronate combine|
48466992|NCT00519103|OTHER|exercise|
48466993|NCT00865449|DRUG|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
48466994|NCT00865449|DRUG|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
48466995|NCT04016194|DIAGNOSTIC_TEST|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
48466996|NCT04712643|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
48626648|NCT01806792|DRUG|Risedronate|
48626649|NCT01806792|DRUG|Placebo(for Risedronate)|
48626650|NCT01806792|DRUG|Placebo(for risedronate combine)|
48626651|NCT03595891|OTHER|Non-Interventional|Non-Interventional
48626652|NCT05468307|BIOLOGICAL|Membrane Bound Cytokine Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.
48626653|NCT05084456|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
48466997|NCT04712643|DRUG|Becavizumab|Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
48466998|NCT04712643|DEVICE|Transarterial chemoembolization (TACE)|TACE will be performed by clinical demand.
48626654|NCT00996177|DRUG|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
48626655|NCT00996177|DRUG|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
48626656|NCT01122953|DRUG|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
48626657|NCT01122953|DRUG|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
48626658|NCT02927483|DIETARY_SUPPLEMENT|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
48626659|NCT02927483|DIETARY_SUPPLEMENT|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
48626660|NCT00152854|DRUG|Acetaminophen|acetaminophen 1g po qid
48626661|NCT00152854|DRUG|acetaminophen|acetaminophen 1g po qid for 7 days
48626662|NCT00152854|DRUG|placebo, sugar pill|
48626663|NCT00117000|DRUG|testosterone undecanoate|
48626664|NCT03185507|DEVICE|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
48626665|NCT05404841|DIETARY_SUPPLEMENT|CoffeeBerry Supplement|A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,
48626666|NCT05404841|DIETARY_SUPPLEMENT|Placebo|Placebo
48626667|NCT00768859|DRUG|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
48626668|NCT05564923|DRUG|there is no intervention|there is no intervention
48626669|NCT06329557|BEHAVIORAL|Intervention 1|Intervention 3
48626670|NCT03123588|DRUG|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
48626671|NCT03123588|DRUG|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
48626672|NCT03123588|DRUG|Placebo|Anagrelide-placebo administered orally BID
48626673|NCT03123588|DRUG|Placebo|Ruxolitinib-placebo administered orally BID.
48626674|NCT01937442|DRUG|Thalidomide Celgene™|200mg once daily and by mouth
48626675|NCT03148639|BEHAVIORAL|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
48626676|NCT03148639|OTHER|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
48626677|NCT01851369|DRUG|TRC102|Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
48626678|NCT01851369|DIAGNOSTIC_TEST|CT scan|CT scans will be performed at baseline, and repeat scans will be performed every 2 cycles (every 3 cycles for participants on study more than one year).
48626679|NCT01851369|OTHER|Lomotil|If diarrhea develops and does not have an identifiable cause other than study drug administration, anti-diarrheal's such as Lomotil (diphenoxylate hydrochloride (HCl) 2.5 mg + atropine sulfate 0.025 mg/tablet) dosed according to package insert or loperamide 4 mg by mouth (po) after the first unformed stool with 2 mg po every 2 hours as long as unformed stools continue (4 mg every 4 hours while asleep). No more than 16 mg of loperamide should be taken in during a 24-hour period.
48626680|NCT01851369|OTHER|Prochlorperazine|If a participant develops nausea/vomiting, an anti-emetic such as prochlorperazine may be given.
48626681|NCT01851369|OTHER|Metoclopramide|If a participant develops nausea/vomiting, an anti-emetic such as metoclopramide may be given.
48626682|NCT01851369|OTHER|5-HT3 antagonist|If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.
48626683|NCT01851369|OTHER|Aprepitant|If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.
48626684|NCT01851369|PROCEDURE|Biopsy|Tumor biopsies will be optional during the escalation phase.
48282912|NCT00472303|DRUG|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
48626685|NCT06259838|OTHER|no intervention|no intervention
48626686|NCT01286649|OTHER|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
48282913|NCT00472303|DRUG|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
48282914|NCT06656468|DEVICE|Pacemaker and defibrillator|Leadless pacemaker implantation procedure performed accordng to usual clinical practice. The indication for pacemaker implantation will be based on current guidelines.
48626687|NCT01286649|OTHER|Cell medium|Cell medium
48282915|NCT04203173|BEHAVIORAL|FINANCE-DM|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
48626688|NCT00009555|DRUG|Testosterone|
48626689|NCT04645706|OTHER|Characteristics of innate T cells|functional and phenotypic characteristics of innate T cells
48626690|NCT01951066|DRUG|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
48100469|NCT01559480|DRUG|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
48626691|NCT01951066|DRUG|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
48626692|NCT03402087|DRUG|Methotrexate|Specified dose on specified days
48626693|NCT03402087|DRUG|Leucovorin|Specified dose on specified days
48626694|NCT03402087|DRUG|BMS-986165|Specified dose on specified days
48626695|NCT00629239|DRUG|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
48626696|NCT00629239|DRUG|Placebo|
48626697|NCT00450749|OTHER|placebo|Given PO
48626698|NCT00450749|PROCEDURE|therapeutic conventional surgery|Undergo radical prostatectomy
48626699|NCT00450749|OTHER|laboratory biomarker analysis|Correlative studies
48626700|NCT00450749|DRUG|lycopene|Given PO
48626701|NCT01170130|DRUG|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
48626702|NCT06193967|BEHAVIORAL|Caregiver Praise|Caregivers will provide praise for child's engagement in dietary self-monitoring behaviors as a form of positive reinforcement
48466999|NCT06662617|OTHER|modified thoracoabdominal nerve block through perichondrial approach|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
48467000|NCT06662617|OTHER|Transversus Abdominal Plane block|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral TAP block application, USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline . After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
48467001|NCT02670785|DRUG|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
48467002|NCT02670785|DRUG|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
48467003|NCT02906813|DRUG|TAK-935 Tablets|Tablets
48467004|NCT02906813|DRUG|TAK-935 Oral Solution|Oral solution
48467005|NCT06374108|BEHAVIORAL|Progressive resistance training|The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.
48467006|NCT00112216|BIOLOGICAL|Melan-A analog peptide|
48467007|NCT00112216|BIOLOGICAL|FluMa peptide|
48467008|NCT00112216|BIOLOGICAL|Mage-A10 peptide|
48467009|NCT00112216|BIOLOGICAL|SB AS-2 adjuvant|
48467010|NCT00112216|BIOLOGICAL|Montanide adjuvant|
48467011|NCT01658995|DRUG|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
48467012|NCT01658995|DRUG|Placebo|Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
48467013|NCT04561713|PROCEDURE|Virtual reality task|Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.
48467014|NCT05691478|PROCEDURE|Bone Scan|Undergo bone scintography
48467015|NCT05691478|DRUG|Cabozantinib S-malate|Given PO
48467016|NCT05691478|DRUG|Cisplatin|Given IV
48467017|NCT05691478|PROCEDURE|Computed Tomography|Undergo CT
48467018|NCT05691478|DRUG|Doxorubicin Hydrochloride|Given IV
48467019|NCT05691478|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48467020|NCT05691478|DRUG|Methotrexate|Given IV
48467021|NCT05691478|PROCEDURE|Surgical Procedure|Undergo surgery
48467022|NCT05691478|PROCEDURE|X-Ray Imaging|Undergo X-ray
48467023|NCT00411333|DRUG|triamcinolone acetonide (Kenalog)|
48467024|NCT06678906|BEHAVIORAL|Intervention arm|All patients in the intervention group will benefit from the standard information phase on physical activity and sedentary behavior, as well as personalized support for behavior change in the form of a serious game and remote coaching.
48467025|NCT00298987|DRUG|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
48467026|NCT02753465|PROCEDURE|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
48467027|NCT02753465|PROCEDURE|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
48467028|NCT06678139|OTHER|physiotherapy|Bilateral gastrosoleus stretching, iliopsoas and hamstring stretching (if a shortness is detected), foot intrinsic and extrinsic muscle strengthening, lower extremity muscle strengthening and parkour walking training will be performed. Therapeutic exercises will be performed once a week for 12 weeks under the supervision of a physiotherapist. Parents will be asked to follow a 12-week home exercise program at home during the five days. The home exercise program will include the exercises performed in the pediatric physiotherapy and research laboratory. Parents will be instructed to perform each exercise twice a day at home. Children will be given a weekly exercise diary to increase adherence to the exercise program.
48467029|NCT05642130|OTHER|exersice program (Muscle energy technique)|Post isometric relaxation for upper trapezius and sternocleidomastoid muscles. the therapist moved the subject's head into the position that put each muscle in stretch, once resistance/ barrier was felt, that position was held and subjects were asked to isometrically contract the target muscle with 20% of maximal contraction for 5 sec against mild resistance from the therapist, relax for 5 sec followed by passive stretch until reaching a new barrier for 30 sec, 3 repetitions for each muscle, 3sessions /week over a period of 4 weeks, In addition to the program designed for control group
48467030|NCT05642130|OTHER|exersice program (stretching and strengthening exercises ) In addition to postural advices|static stretching exercise for upper trapezius and sternocleidomastoid . Repetitions: 3times/day, 3days/week over a period of 4 weeks, in addition to strengthening exercises of deep cervical flexors and scapular retractor muscles, 3sets of 12 repetitions with 6 sec hold. In addition to postural advices
48467031|NCT06105801|PROCEDURE|Endobronchial ultrasound with transbronchial needle aspiration|Participants will undergo Endobronchial ultrasound with transbronchial needle aspiration
48467032|NCT06105801|PROCEDURE|Bronchoscopy|Participants will undergo Bronchoscopy
48467033|NCT06105801|PROCEDURE|Cryobiopsy|Participants will undergo Cryobiopsy
48467034|NCT06094192|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
48467035|NCT03168906|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
48467036|NCT03168906|DRUG|Placebo|Saline bag
48467037|NCT01545739|DEVICE|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
48467038|NCT02594527|OTHER|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
48282916|NCT04203173|BEHAVIORAL|Active Comparator|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
48282917|NCT01898663|BIOLOGICAL|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
48282918|NCT00813995|DRUG|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
48467039|NCT06669754|DRUG|Deucrictibant|Deucrictibant 40mg extended-release tablet for once daily oral use
48467040|NCT06669754|DRUG|Placebo|Placebo
48626703|NCT06193967|BEHAVIORAL|Gamification|DSM logs will include gamification (points, levels, virtual pets) as positive reinforcement for child's engagement in dietary self-monitoring behaviors
48626704|NCT06277726|OTHER|Emotional freedom technique group|Emotional freedom technique will be applied to women in this group before intrauterine device application.
48626705|NCT06277726|OTHER|Music group|Women in this group will wear headphones and listen to music throughout the intrauterine device application.
48626706|NCT06277726|OTHER|Control group|No intervention will be applied to women in the control group.
48626707|NCT01078428|OTHER|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
48626708|NCT01078428|OTHER|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
48626709|NCT05967559|OTHER|Online Flipped Learning Group|The experimental group is the group that receives online flipped learning training.
48626710|NCT05967559|OTHER|Traditional learning Group|The control group is the group that received traditional learning training.
48626711|NCT00552162|PROCEDURE|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
48626712|NCT00552162|PROCEDURE|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
48626713|NCT04915300|DRUG|Apabetalone|Apabetalone 100mg p.o. (tablets) BID for 24 weeks treatment period.
48626714|NCT04915300|DRUG|Placebo|Placebo p.o. (tablets) BID for 24 weeks treatment period.
48626715|NCT02508064|DRUG|BMS-663068|BMS-663068
48626716|NCT03418974|DRUG|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
48626717|NCT03418974|DRUG|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
48626718|NCT03418974|DRUG|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
48626719|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
48626720|NCT01121926|DRUG|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
48626721|NCT02318979|DEVICE|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
48282919|NCT00813995|DRUG|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
48467041|NCT06449027|DRUG|T Leuprolide Injectable Emulsion|Arm 1 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
48467042|NCT06449027|DRUG|Leuprorelin Acetate Microspheres for Injection|Arm 2 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.
48467043|NCT04276012|OTHER|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
48467044|NCT03468296|DRUG|Intravitreal Aflibercept Injection 2mg|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
48467045|NCT02855840|OTHER|completion of the quality of life questionnaire|
48467046|NCT05832424|BEHAVIORAL|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
48467047|NCT05822726|DIAGNOSTIC_TEST|Prostate biopsy|"Targeted guided puncture biopsy guided by B-ultrasound will be performed (in addition to 12-needle system biopsy, if PSMA-PET/MRI or mpMRI indicates a positive lesion, puncture biopsy should be added at the lesion displayed on image, the 12-needle system biopsy+X scheme)."
48467048|NCT05681819|DRUG|SHR-1707|Multiple-ascending Dose
48626722|NCT02318979|DEVICE|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
48626723|NCT02318979|DEVICE|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
48626724|NCT00683384|DRUG|Etanercept (Enbrel)|
48626725|NCT01762189|PROCEDURE|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
48626726|NCT04981054|PROCEDURE|Cystocele repair|Repair of endopelvic fascia and anterior colporrhaphy
48626727|NCT01744821|DIETARY_SUPPLEMENT|Arm A: Vitamin D3 Group|
48626728|NCT01744821|DIETARY_SUPPLEMENT|Placebo|
48626729|NCT05132946|PROCEDURE|Nerve block|unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
48626730|NCT00845000|DRUG|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
48626731|NCT00845000|DRUG|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
48626732|NCT00845000|DRUG|Placebo|Placebo capsule, oral, at hour 0 of treatment period
48626733|NCT00845000|DRUG|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
48626734|NCT00845000|DRUG|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
48626735|NCT05706285|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
48626736|NCT00712049|DRUG|simvastatin|simvastatin 40 mg
48626737|NCT00712049|DRUG|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
48626738|NCT05278091|OTHER|None, pure observationnal study|None, pure observationnal study
48467049|NCT05681819|DRUG|SHR-1707 placebo|Multiple-ascending Dose
48467050|NCT00030511|DRUG|fluorouracil|
48467051|NCT00030511|PROCEDURE|conventional surgery|
48467052|NCT00030511|RADIATION|radiation therapy|
48467053|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
48467054|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
48467055|NCT04615494|PROCEDURE|Position|Pneumoperitoneum with Steep Trendelenburg position
48467056|NCT04660032|BEHAVIORAL|Nudge|An electronic prompt (nudge) will be sent to the participant's obstetric care provider. The provider will receive a staff message in Epic (Penn Chart) that his/her patient has an upcoming postpartum visit. The message will be sent 1 week before the scheduled visit. The message will have patient-specific information including hypertensive diagnosis, blood pressure medication(s), gestational diabetes diagnosis, and primary care provider as listed in the Epic banner. The message will also have dot phrases for recommended counseling and contact information for UPHS primary care and cardiology providers. There will be example text recommending follow-up with primary care or cardiology; counseling on risk of future CVD; and recommending aspirin in a future pregnancy.
48626739|NCT00456612|PROCEDURE|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
48626740|NCT01973400|DIETARY_SUPPLEMENT|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
48626741|NCT01973400|DIETARY_SUPPLEMENT|Placebo|Placebo
48626742|NCT03735342|OTHER|Audio Recording|All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
48626743|NCT03783884|DEVICE|Lungpacer Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
48467057|NCT02506205|BEHAVIORAL|Lee Silverman Voice Treatment (SVLT) LOUD|
48626744|NCT05015179|PROCEDURE|mixed reality technology in laparoscopic partial nephrectomy|All patients undergo contrast-enhanced computed tomography before surgery. DICOM files are converted to a 3D model. This model is then sent to HoloLens 2 smart glasses using HLOIA software
48626745|NCT01835756|DEVICE|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
48626746|NCT01835756|DEVICE|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
48467058|NCT02171897|PROCEDURE|Osteosynthesis|
48467059|NCT02171897|PROCEDURE|Total hip replacement|
48467060|NCT05828979|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
48467061|NCT04739423|DRUG|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
48467062|NCT04411251|BEHAVIORAL|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
48467063|NCT04411251|BEHAVIORAL|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
48467064|NCT00231582|DRUG|epirubicin|epirubicin
48467065|NCT00231582|PROCEDURE|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
48626747|NCT04234542|OTHER|Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be increased along with intensity as the stages progress.
48467066|NCT00231582|DRUG|paclitaxel|paclitaxel
48467067|NCT00231582|DRUG|etoposide|etoposide
48626748|NCT04234542|OTHER|Sham Low Level Laser Therapy|Each stage will follow this sequence of applications: (1) spine application (DUO-240 red and infrared array in a horizontal placement and 2 oblique placements bilaterally + LDR-100 laser probe + LDI-200 laser probe), (2) perineum application (DUO-240 red and infrared array in the surface of the perineum + LDR-100 probe) and (3) overlying branches of the pudendal nerve at the lateral perineum (LDI-200 probe). Parameters of frequency and duty cycle will be progressed, but power will always be set to 1%..
48626749|NCT04534946|OTHER|This is not an intervention study|This is not an intervention study
48626750|NCT00211939|DRUG|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
48626751|NCT00211939|DRUG|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
48467068|NCT00231582|DRUG|ifosfamide|ifosfamide
48467069|NCT00231582|DRUG|carboplatin|carboplatin
48467070|NCT02689817|DEVICE|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
48467071|NCT04656938|BEHAVIORAL|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
48467072|NCT04598607|DRUG|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
48467073|NCT04598607|DRUG|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
48467074|NCT03788876|OTHER|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.
48467075|NCT03788876|OTHER|Conventional care|Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
48467076|NCT01597349|DRUG|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
48467077|NCT01839838|RADIATION|Proton Therapy|
48467078|NCT01894009|PROCEDURE|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
48467079|NCT01894009|PROCEDURE|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
48467080|NCT01960608|OTHER|24_hours_urine_sodium|
48467081|NCT06148662|OTHER|No intervention (negative control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds."
48626752|NCT00211939|DRUG|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
48626753|NCT04368910|DRUG|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
48626754|NCT04368910|DRUG|Chloroquine|Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
48626755|NCT01312675|DEVICE|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
48626756|NCT02320396|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
48626757|NCT02320396|DRUG|Placebo|Placebo tablets
48626758|NCT02491450|DRUG|Heterosofir|1 tablet contains 400 mg sofosbuvir
48626759|NCT02491450|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
48626760|NCT05181657|BEHAVIORAL|COVID-19 education|This session will be completed within 45 minutes. The LinkUP intervention will be available in English and Spanish.
48467082|NCT06148662|OTHER|Water (positive control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds."
48467083|NCT06148662|DRUG|"Dental foam Biorepair PERIBIOMA"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
48467084|NCT06148662|DRUG|"Dental foam WATER:DENT"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
48626761|NCT02401295|DRUG|ATRA|
48626762|NCT02401295|DRUG|Celecoxib|
48626763|NCT02401295|DRUG|Itraconazole|
48626764|NCT05133570|DEVICE|vista care|Prospective, open-label, multi-centre study evaluating the performance of the VistaCare® wound healing device in routine practice.
48626765|NCT04278092|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, q21
48626766|NCT04278092|DRUG|Cetuximab|Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2
48626767|NCT04909788|BEHAVIORAL|a long-distance running (over 3 km)|Complete a long distance running（over 3 km） within the specified time (30 minutes)
48467085|NCT06148662|DRUG|"Dental spray BUCCOTHERM"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
48467086|NCT00163969|DRUG|ketamine|
48467087|NCT03867773|BEHAVIORAL|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
48467088|NCT06048887|DRUG|CRN04894 Oral Solution|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
48626768|NCT05031221|BEHAVIORAL|Yoga + behavioral weight loss|A 12-week, one-arm proof-of-concept and feasibility study will be conducted at the University of Colorado Anschutz Medical Campus (CU-AMC) to assess the processes critical for the success of future randomized trials including: a) Evaluating the feasibility and acceptability of adding a multi-component yoga program to a standard BWL intervention and b) Examining pre-post changes in relevant clinical/cardiometabolic, psychological, and energy balance/behavioral outcomes to inform the design of future trials. Participants will receive a comprehensive, group-based BWL intervention consistent with current guidelines for obesity treatment and a carefully designed multi-component yoga intervention delivered through pre-recorded videos delivered through a cloud-based platform that will be completed in-person and at-home (BWL+yoga).
48467089|NCT06048887|DRUG|Placebo Oral Solution|Placebo
48467090|NCT00685750|PROCEDURE|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
48467091|NCT05562648|OTHER|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
48467092|NCT05562648|OTHER|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
48467093|NCT04674228|OTHER|Electronic Health Record Review|Review of medical records
48467094|NCT04190927|BIOLOGICAL|Compounded topical estradiol and compounded topical progesterone in a carrier cream|Apply topical compounded estradiol and progesterone in the amount prescribed twice daily for each day of the 28 day lunar or menstrual cycle. Repeat each cycle month. Make note of any AE's so that modifications in dosing can be made.
48467095|NCT00159172|DEVICE|Motor cortex stimulation|
48467096|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 1: low intensity clinician training|"A booster of the established LSTDI implementation strategy. Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study. Online training options and when and how to complete goals of care conversations and documentation will be highlighted."
48467097|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 2: high intensity clinician training|"This includes two components:~1. Team facilitation to help the primary care team (advance practice provider, nurse, social worker) work together to create roles and responsibilities for accomplishing goals of care conversations with patients~2. A patient list trigger of patients potentially eligible for goals of care conversations (the patient study population) will be sent to the primary care clinicians."
48467098|NCT05001009|BEHAVIORAL|Low patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website.
48467099|NCT05001009|BEHAVIORAL|High patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
48467100|NCT01465113|DRUG|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
48467101|NCT01465113|DRUG|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
48467102|NCT01465113|DRUG|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
48467103|NCT01465113|PROCEDURE|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
48467104|NCT01465113|DRUG|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
48467105|NCT00063609|DRUG|zoledronic acid|
48467106|NCT06365320|OTHER|Single basketball training|Single basketball training session with fixed intensity and duration
48467107|NCT05453409|OTHER|No intervention|No intervention
48467108|NCT00111462|DRUG|Darbepoetin alfa|
48626769|NCT05165043|PROCEDURE|position change|The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
48626770|NCT03927391|DRUG|Enzalutamide|enzalutamide treatment
48626771|NCT02216409|DRUG|Hu5F9-G4|
48626772|NCT01484366|PROCEDURE|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
48626773|NCT01484366|PROCEDURE|plating|Surgical plating of both bonforearm fractures
48626774|NCT04008186|DRUG|Omaveloxolone|50 mg capsules
48626775|NCT04008186|DRUG|Midazolam oral solution|2 mg/mL oral solution
48626776|NCT04008186|DRUG|Repaglinide 1 MG|1 mg tablet
48626777|NCT04008186|DRUG|MetFORMIN 500 Mg Oral Tablet|500 mg tablet
48626778|NCT04008186|DRUG|Rosuvastatin|10 mg tablet
48282920|NCT05909891|OTHER|Patient training|"A training booklet will be created by scanning the literature on iron deficiency anemia. The training booklet will be evaluated in terms of content and readability, according to the DISCERN measurement tool, while obtaining expert opinion.~The training period will be at least 35-40 minutes, taking into account the educational status of the patient and explaining the importance of compliance with the treatment. After the training, when the patients come to the routine check-ups in the 1st and 2nd months, the level of compliance with the treatment and the fatigue of the patients will be evaluated."
48282921|NCT03500744|PROCEDURE|Erector spinae plane block|Ropivacaine 0.5% 20 mL at each site of ESPB
48467109|NCT06458751|OTHER|electrophysiological study|Antidromic sensory nerve conduction studies of median and ulnar nerves will be performed on both hands of 30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination., by using surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
48467110|NCT06458751|DEVICE|electromyograph|surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
48467111|NCT06030115|OTHER|Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)|Data collected on participants who completed the intensity recovery progression protocol program
48467112|NCT04188964|DRUG|Burosumab|Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
48467113|NCT00200655|DRUG|Pravastatin|
48467114|NCT00200655|DRUG|Placebo|
48467115|NCT05797870|COMBINATION_PRODUCT|Selective Internal Radiation Therapy with 188Re-SSS lipiodol|"The treatment with 188Re-SSS lipiodol SIRT requires two steps during the patient's hospitalization: the pre-treatment simulation step and the treatment step itself.~Pre-therapeutic simulation is performed during the screening phase, before definite patient inclusion, and is composed of two procedures: a diagnostic liver angiography and a liver perfusion scintigraphy (MAA scan and SPECT/CT).~The therapeutic stage is also composed of two procedures a therapeutic liver angiography with 188Re-SSS lipiodol and a 188Re-SSS lipiodol SPECT/CT."
48467116|NCT00799708|DRUG|Comparator: placebo|placebo capsule once daily for 7 days.
48467117|NCT00799708|DRUG|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
48467118|NCT00875082|DRUG|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
48467119|NCT00875082|DRUG|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
48467120|NCT01264198|BEHAVIORAL|Resistance Training|Supervised Resistance Training
48626779|NCT04008186|DRUG|Digoxin tablet|0.25 mg tablet
48626780|NCT04008186|DRUG|Gemfibrozil Tablets|600 mg tablet
48282922|NCT03500744|PROCEDURE|Sham block|Skin infiltration only
48282923|NCT02882477|DRUG|Deferiprone|
48467121|NCT06632054|BEHAVIORAL|Text Message Reminders|Text message reminders (instead of usual care - phone call reminders) to complete FIT for colon cancer screening.
48467122|NCT06670651|DEVICE|total knee arthroplasty device|total knee arthroplasty device with ultracongruent bearing surface
48282924|NCT02882477|DRUG|Acetylcysteine|
48282925|NCT02882477|DRUG|Sitagliptin and Metformin|
48467123|NCT06677190|DRUG|Belzutifan|A Hypoxia-Inducible Factor-2 alpha inhibitor, 40 mg immediate-release tablet, taken orally per protocol.
48467124|NCT05578794|OTHER|Straining types|Valsalva, spontaneous and natural strainings are supported in 2nd stage of labor. Duration of delivery, perineal trauma status and Apgar Scores were evaluated.
48467125|NCT03302949|DIETARY_SUPPLEMENT|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
48467126|NCT01380522|DRUG|Metronidazole|Capsules, single-dose, fed
48626781|NCT04008186|DRUG|Itraconazole capsule|100 mg capsule
48626782|NCT04008186|DRUG|Verapamil Pill|120 mg tablet
48626783|NCT00472641|DRUG|Ziprasidone/Geodon|Ziprasidone/Geodon
48626784|NCT01344200|DRUG|Celecoxib|In Phase I twenty (20) children will receive either celecoxib 14 or 7 mg/kg 120-180 minutes prior to lumbar puncture (LP). In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
48626785|NCT01344200|DRUG|Placebo|In Phase II forty-five (45) children will receive celecoxib 14 mg/kg, 7 mg/kg or placebo in one of 5 time intervals, 1-24 hours prior to LP.
48626786|NCT00169260|BEHAVIORAL|motivational counseling|behavioral motivational counselling
48626787|NCT00169260|BEHAVIORAL|placebo|
48626788|NCT01906164|DRUG|ALS-008176|
48626789|NCT01906164|DRUG|Placebo|
48626790|NCT04192344|DRUG|ABSK021|ABSK021 oral capsule
48626791|NCT01460771|DEVICE|TDCS (Transcranial Direct-current Stimulation)|active TDCS
48626792|NCT01460771|DEVICE|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
48626793|NCT04608864|PROCEDURE|varicocelectomy|microsurgical subinguinal varicocelectomy
48626794|NCT05019053|BEHAVIORAL|Coping Crew|Coping Crew consists of five 60-minute virtual intervention sessions coinciding with five weeks of EMI. Participants will receive psychoeducation, challenge cognitive biases or mythbust, and participate in behavioral exposure and behavioral experiments. An EMI component of this treatment will be included for the purpose of treatment monitoring and homework tracking. Participation in this EMI component involves the daily report of levels of anxiety, depression, stress, and loneliness. When participants endorse elevated levels on any of these constructs, they will receive a targeted message reminding them of the topics covered in COPING CREW. One month after the intervention session, COPING CREW participants will complete follow-up questionnaires and interview. Participants will also participate in a feedback session 3 months after the intervention.
48626795|NCT02219204|PROCEDURE|Acupuncture|
48626796|NCT02219204|OTHER|Herbal treatment|
48626797|NCT03472677|OTHER|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
48626798|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
48626799|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
48626800|NCT03472677|DRUG|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
48626801|NCT03472677|DRUG|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
48626802|NCT00277563|DEVICE|reduction of pain scores by magnetic energy|
48626803|NCT02803541|BEHAVIORAL|12 day mainstream summer camp experience|see arm description
48626804|NCT01142921|DEVICE|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
48467127|NCT01380522|DRUG|Flagyl|Capsules, single-dose, fed
48467128|NCT03563794|DRUG|CSII+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
48467129|NCT03563794|DRUG|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
48626805|NCT01142921|DEVICE|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
48626806|NCT06373939|DEVICE|Digital lung auscultation|"Two 30-second recordings will be made using CE-marked Littmann® CORE digital stethoscopes and the Pneumoscope at two bilateral lung positions on the posterior chest wall, focusing on the lower lobes. Spectral comparison and audio quality indices will be assessed between the Pneumoscope and the Littmann® CORE digital stethoscope.~Comparator: The Gold Standard Littmann® CORE picks up sounds, such as heart and lung sounds, from a patient's body. After amplification and filtering, the sounds are sent to the user through a binaural headset. The stethoscope chest piece is designed for use with adult, pediatric, and infant patients."
48626807|NCT06373939|DEVICE|Pulse oximetry measurement|"Pulse oximetry and heart rate will be measured using the CE-marked Masimo Rad-G® and iHealth® Air oximeters, as well as the Pneumoscope's built-in oximeter. Agreement between the Pneumoscope's oximeter and the reference oximeters will be evaluated. Measurement will take 30 second on the right index finger.~Comparators:~1. The Gold Standard Masimo Rad-G® sensor is indicated for the continuous noninvasive peripheral monitoring of arterial oxygen saturation (SpO2) and pulse rate. Its use consists in positioning the emitting window of the sensor attachment envelope on the top of the finger nail bed, while the detector is placed opposite the emitter on the other side of the same finger.~2. The Gold Standard iHealth® Air works by projecting two beams of light through a clip with a transmitter and a detector that is placed around a finger, nail side down and screen side up."
48626808|NCT06373939|DEVICE|Non invasive body temperature measurement|"Comparison of body temperature measurements between the Pneumoscope's built-in thermometer and Gold Standard thermometers (Terumo® C205 and VisioFocus Pro 06480).~Comparators:~1. The Gold Standard Terumo® C205 is an axillary thermometer. Its use consists in placing the probe in the armpit, then lowering the arm and holding the device firmly until the temperature is stabilised and the temperature is read and displayed on the thermometer screen.~2. The Gold Standard VisioFocus Pro 06480 is an infrared thermometer that detects the infrared radiation naturally emitted by the body and in particular from the human forehead. Its use consists in holding the thermometer close to the forehead but without direct contact with the skin. The temperature reading is then projected on the patient's forehead using a symbol system."
48626809|NCT02387918|DRUG|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
48626810|NCT02387918|DEVICE|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
48467130|NCT01956565|OTHER|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
48626811|NCT04560218|DRUG|sublingual Misoprostol|apply drug by Anesthesiologist
48626812|NCT04560218|DRUG|Intrauterine Misoprostol|apply drug by surgeon at uterine cornu
48626813|NCT00790036|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
48626814|NCT00790036|DRUG|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
48626815|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
48626816|NCT03087552|PROCEDURE|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
48626817|NCT05009420|OTHER|Avocado|avocado served with crackers as breakfast
48282926|NCT05574153|DIAGNOSTIC_TEST|Cardiac MRI|Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
48282927|NCT05334979|OTHER|Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic|"Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks."
48282928|NCT05888116|DEVICE|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
48282929|NCT05888116|DEVICE|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
48282930|NCT05463133|DRUG|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
48282931|NCT05463133|DRUG|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
48282932|NCT05463133|DRUG|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
48282933|NCT05463133|DRUG|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
48282934|NCT05463133|BIOLOGICAL|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
48282935|NCT05463133|DRUG|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
48282936|NCT05463133|DRUG|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
48282937|NCT05463133|DRUG|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
48282938|NCT05879133|BEHAVIORAL|Questionnaires|Survey
48282939|NCT05879133|OTHER|Fit Bit|measures physical activity
48282940|NCT06118879|DEVICE|Transcutaneous electrical stimulation|sensory level stimulation, one-leg standing and Y-balance training
48467131|NCT05568758|OTHER|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
48467132|NCT05568758|OTHER|Exercises (stretching and strenghtening )|"stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises"
48467133|NCT04909645|DIAGNOSTIC_TEST|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)\*80/CO.
48467134|NCT01085890|BEHAVIORAL|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
48467135|NCT06220526|DEVICE|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Transbronchial biopsy with Menghini-type or Franseen type Needle
48282941|NCT06360393|DEVICE|Smart spacer|Participants' inhalation medication adherence and inhalation technique will be monitored using a smart spacer. Their usual medication regime will be continued and they will not receive information about their adherence or inhalation technique measured by the spacer during the follow-up year (except for any interventions that will be done in standard care).
48282942|NCT00659438|DRUG|ZD6474 (Vandetanib)|300mg orally, once daily
48282943|NCT00659438|DRUG|Bicalutamide|150mg orally, once daily
48467136|NCT02301741|BEHAVIORAL|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
48467137|NCT04540692|DRUG|Docetaxel or Paclitaxel|Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
48467138|NCT04540692|DRUG|Cyclophosphamide + Doxorrubicin|Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
48467139|NCT04906876|DRUG|Gemcitabine|Gemcitabine as a 90-minute IV infusion
48467140|NCT04906876|DRUG|Docetaxel|Docetaxel as a 60-minute IV infusion
48467141|NCT04906876|DRUG|9-ING-41|9-ING-41 as an IV infusion over 1-4 hours twice weekly
48467142|NCT02259348|DRUG|Cyclophosphamide|Given intravenously (IV)
48467143|NCT02259348|DRUG|Fludarabine|Given IV
48467144|NCT02259348|BIOLOGICAL|G-CSF|Given IV or subcutaneously (SQ)
48467145|NCT02259348|BIOLOGICAL|Interleukin-2|Given SQ
48467146|NCT02259348|DRUG|Melphalan|Given IV
48467147|NCT02259348|DRUG|Thiotepa|Given IV
48467148|NCT02259348|DRUG|Rituximab|Given IV
48467149|NCT02259348|BIOLOGICAL|Natural killer cell therapy|Given IV
48467150|NCT02259348|BIOLOGICAL|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
48467151|NCT02259348|BIOLOGICAL|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
48467152|NCT05098951|DEVICE|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
48467153|NCT01118234|DRUG|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
48467154|NCT03890757|OTHER|ultrasound guided paravertebral or serratus anterior block|"Patients groups will be as follow:~Group (I): Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe ,Group (II): thoracic paravertebral block will be performed in the sitting position. The spinal level chosen for needle insertion will be two segments below the upper most fractured rib or midway between the upper most and lowest fractured rib, 2-2.5 cm distance from the midline in the same injury site"
48467155|NCT05061992|DRUG|Lactulose|"Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28."
48467156|NCT00096005|DRUG|tanespimycin|Given IV
48467157|NCT00096005|DRUG|bortezomib|Given IV
48467158|NCT00096005|OTHER|laboratory biomarker analysis|Correlative studies
48467159|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
48467160|NCT04402892|OTHER|35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)|Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
48467161|NCT01211262|DRUG|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
48467162|NCT02443285|DRUG|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
48467163|NCT02443285|DRUG|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
48467164|NCT06161701|OTHER|no intervention|no intervention
48467165|NCT05303948|DEVICE|Videolaryngoscopy / Direct Laryngoscopy|First pass success analysis
48467166|NCT01900457|OTHER|electromyography|
48467167|NCT01900457|OTHER|electroencephalography|
48467168|NCT01900457|OTHER|approaches from psychophysics|
48467169|NCT02241798|OTHER|oxygen|O2 by nasal prongs
48467170|NCT01256060|DRUG|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
48467171|NCT05285319|RADIATION|Prostate Only Radiation|Prostate Only Radiation for Intermediate and High Risk Prostate cancer
48467172|NCT05285319|RADIATION|Prostate and Pelvic Lymph Node Radiation|Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
48467173|NCT00239824|BEHAVIORAL|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
48467174|NCT00239824|BEHAVIORAL|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
48467175|NCT00379509|DRUG|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
48467176|NCT00379509|GENETIC|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
48467177|NCT00379509|GENETIC|gene expression analysis|Genetic analysis of tumor tissue.
48467178|NCT00379509|GENETIC|microarray analysis|Genetic analysis of tumor tissue.
48467179|NCT00379509|OTHER|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
48467180|NCT00379509|PROCEDURE|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
48282944|NCT00659438|DRUG|Placebo|orally, once daily
48282945|NCT06656897|BEHAVIORAL|FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)|FS-D is a multimedia behavioral intervention for use by family Caregivers (CG) of Persons with Alzheimer's disease or a related dementia (PwADRD) who are living at home and classified as at moderate to high risk for falls. FS-D will create, customize and support CG-provided daily multimedia sessions for PwADRD using structured learning techniques.
48282946|NCT06322381|PROCEDURE|Reinsertion achilles tendon|Prone position, tourniquet over the thigh, direct midline incision, 2.0 cm proximal the insertion of the Achilles tendon up to 4.0 cm prolonged distal to the insertion is recommended. This is followed by a totally disinsertion of TA. At least a debridement of inflammatory or necrotic tissue as well as the removal of bony tissue is performed. tendon is re-inserted by 2-4 anchors.
48467181|NCT00379509|RADIATION|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
48467182|NCT03563885|PROCEDURE|bariatric surgery|subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
48467183|NCT01385423|DRUG|Preparative Regimen|Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)
48467184|NCT01385423|BIOLOGICAL|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
48467185|NCT00842309|DRUG|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
48467186|NCT00842309|DRUG|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
48467187|NCT02435433|DRUG|Ramucirumab|Administered IV
48467188|NCT02435433|DRUG|Placebo|Administered IV
48467189|NCT03114345|OTHER|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
48467190|NCT03114345|OTHER|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
48467191|NCT00000564|PROCEDURE|oxygen inhalation therapy|
48467192|NCT02853539|DRUG|Denosumab|Subcutaneous injection of Denosumab
48467193|NCT02515487|OTHER|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
48467194|NCT04439331|DRUG|Defactinib Hydrochloride|Given PO
48467195|NCT02544139|OTHER|Chagas Detect Plus|
48467196|NCT02814708|BIOLOGICAL|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 binding Ab titer .
48626818|NCT02992379|DEVICE|pivot splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
48626819|NCT02992379|DEVICE|stabilizing splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
48467197|NCT02805517|DEVICE|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
48626820|NCT05419258|DEVICE|UPLUG Hemodialysis Connection Device|use of the device UPLUG during 1 month
48467198|NCT00067327|DRUG|Inosine|
48467199|NCT05581134|DEVICE|Virtual Reality intervention|Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.
48467200|NCT05581134|BEHAVIORAL|Control Group intervention|Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
48467201|NCT01200017|BIOLOGICAL|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
48467202|NCT01029509|DRUG|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
48467203|NCT00769496|DRUG|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
48626821|NCT01993758|PROCEDURE|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
48626822|NCT01993758|PROCEDURE|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
48626823|NCT04195412|DEVICE|tDCS + upper limb rehabilitation|Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
48626824|NCT04195412|DEVICE|Sham tDCS + upper limb rehabilitation|Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
48626825|NCT02852434|DRUG|Lidocaine Gel (2%)|
48626826|NCT02852434|DRUG|Lidocaine Paracervical Block (1%)|
48282947|NCT06322381|PROCEDURE|Zadek osteotomy|lateral position, under spinal anesthesia, tourniquet over the thigh, oblique lateral heel incision starting just anterior to the Achilles tendon, at a 45 angle to the long axis of the calcaneus posterior to the course of the sural nerve. A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
48467204|NCT00609154|DRUG|glucagon like peptide-1|GLP-1 1 pmole/kg/min
48467205|NCT00609154|DIETARY_SUPPLEMENT|glucose control|glucose without GLP-1
48467206|NCT06409858|OTHER|Pilates|Twice-weekly mat Pilates class for 8 weeks, either in person or online (depending on participant availability)
48467207|NCT06163937|OTHER|Glucose as reference food|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48467208|NCT06163937|OTHER|Orange juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48467209|NCT06163937|OTHER|Mixed fruit juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48626827|NCT00926120|DIETARY_SUPPLEMENT|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
48626828|NCT02463877|PROCEDURE|Minimally-Invasive Procedure|Laparoscopy
48626829|NCT06554236|OTHER|physical therapy and sensory training|Physical therapy standard of care and 5 minutes of sensory training.
48467210|NCT03038763|OTHER|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
48467211|NCT03038763|DIAGNOSTIC_TEST|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
48467212|NCT02630316|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
48467213|NCT02630316|DRUG|Placebo|Placebo administered four times daily
48467214|NCT01408888|BIOLOGICAL|LY2189265|Administered subcutaneously
48467215|NCT01408888|DRUG|Sitagliptin|Administered orally
48467216|NCT04560426|DEVICE|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
48626830|NCT05886023|DIETARY_SUPPLEMENT|High nitrate vegetables|Vegetable burger containing high nitrate vegetables
48626831|NCT05886023|DIETARY_SUPPLEMENT|Low nitrate vegetables|Vegetable burger containing to low nitrate vegetables
48626832|NCT02912377|BIOLOGICAL|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
48626833|NCT04517539|DRUG|rhGM-CSF，Peginterferon alfa-b2，radiation|"Radiation:~If there are two measurable lesions totally, One lesion received radiotherapy for 30 Gy in 5 fractions and rested for one week; If there are three measurable lesions totally, two lesion received radiotherapy for 30 Gy in 5 fractions separately.~drug: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy. Peginterferon alfa-b2 90 ug in d8 in each cycle.~And the 1 month after the end of all radiotherapy courses, 4 weeks as a course of treatment, once per course of treatment, each dose is 90μg until desease progress."
48626834|NCT01586182|RADIATION|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
48626835|NCT00577408|DRUG|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
48282948|NCT00702624|DRUG|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
48282949|NCT00702624|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
48282950|NCT00702624|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
48467217|NCT00250705|DRUG|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
48467218|NCT00501332|BIOLOGICAL|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
48467219|NCT03436316|DRUG|AZD8154|SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
48467220|NCT01562132|DRUG|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
48467221|NCT01562132|DRUG|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
48467222|NCT03969108|DRUG|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
48467223|NCT05655429|PROCEDURE|physical therapy|The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.
48626836|NCT00577408|DRUG|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
48626837|NCT00369759|OTHER|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
48626838|NCT06379126|DIAGNOSTIC_TEST|Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）|Test TAT, PIC, tPAI·C and TM of blood of SIC patients.
48626839|NCT05833932|DRUG|Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.
48626840|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - IR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total
48282951|NCT00702624|BIOLOGICAL|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
48282952|NCT00702624|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
48282953|NCT00702624|DRUG|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
48282954|NCT00702624|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
48282955|NCT00702624|BIOLOGICAL|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
48282956|NCT04721873|DRUG|Phentermine-Topiramate|Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --\> 7.5-46mg x 1 week --\> 11.25-69mg x 1 week --\> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
48467224|NCT05655429|PROCEDURE|arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy surgery procedure
48467225|NCT05155527|DRUG|Ivermectin Tablets|6 mg/tablet
48467226|NCT05155527|OTHER|Placebo|The placebo has same form as Ivermectin.
48467227|NCT05511441|PROCEDURE|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
48626841|NCT05791591|DIETARY_SUPPLEMENT|NUV001 - GR|Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total
48626842|NCT05791591|DIETARY_SUPPLEMENT|Placebo|Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)
48626843|NCT05987280|OTHER|eDelphi method|eDelphi method
48626844|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator|"Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
48467228|NCT03617120|DEVICE|Ergonomic Brace vs hard brace|"Visit 1:~1. Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~2. Pressure measurement of participant wearing their hard brace~Visit 2:~1. Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~2. 3D body scanning (before wearing the Ergonomic Brace)~3. Fitting of the Ergonomic Brace~4. Pressure measurement of participant wearing the Ergonomic Brace (instant)~5. Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~6. 3D body scanning (after wearing the Ergonomic Brace for 2 hours)~7. Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~1. Standing in-brace radiograph of the Ergonomic Brace~2. Doctor consultation"
48100470|NCT03991949|OTHER|Experimental Infant Formula|Formula fed Ad libitum
48467229|NCT03306927|DIETARY_SUPPLEMENT|Whole yellow pea chili|Chili containing whole yellow peas
48467230|NCT03306927|DIETARY_SUPPLEMENT|Split yellow pea chili|Chili containing split yellow peas
48467231|NCT03306927|DIETARY_SUPPLEMENT|Rice chili|Chili containing long grain white rice
48467232|NCT03869294|DRUG|GS|Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
48467233|NCT03368482|BEHAVIORAL|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
48467234|NCT03368482|BEHAVIORAL|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
48467235|NCT04345016|DEVICE|Once-daily remote foot temperature monitoring|Participants were provided a once-daily remote foot temperature monitoring mat (Podimetrics SmartMat; Podimetrics Inc., Somerville MA) which they used for one year or until dying, dropping out of the study, or disenrolling at a member of the health plan administering the study.
48467236|NCT00223938|DRUG|Oral Iron|Oral Iron
48467237|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 1
48467238|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 2
48100471|NCT02265731|DRUG|azacitadine|75 mg/m2 by IV infusion or subcutaneous dosing
48100472|NCT02265731|DRUG|venetoclax|Step-up doses of venetoclax to the designated cohort dose
48100473|NCT02265731|DRUG|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
48467239|NCT02751892|BEHAVIORAL|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
48467240|NCT05184803|DRUG|Docetaxel injection, oxaliplatin, S-1|As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
48467241|NCT00002367|DRUG|Saquinavir|
48467242|NCT00002367|DRUG|Lamivudine|
48467243|NCT00002367|DRUG|Zidovudine|
48467244|NCT02528045|PROCEDURE|Vitrectomy with scleral shortening|
48467245|NCT05917262|BEHAVIORAL|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
48100474|NCT02265731|DRUG|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
48100475|NCT05328076|DRUG|Indocyanine green|Indocyanine green is used to perform intraoperative angiography.
48100476|NCT05328076|DEVICE|SPY Portable Handheld Imaging (SPY-PHI)|The device is used to perform intraoperative angiography.
48282957|NCT04721873|DRUG|Placebo|Matching placebo, titrated as active intervention
48467246|NCT05917262|BEHAVIORAL|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
48467247|NCT05917262|BEHAVIORAL|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
48467248|NCT03414034|DRUG|Onvansertib|Onvansertib orally
48626845|NCT05054881|OTHER|sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator|"Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed."
48626846|NCT04779723|PROCEDURE|Comparison of two Techniques of bariatric surgery|We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
48282958|NCT01495026|DRUG|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
48282959|NCT01495026|DRUG|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
48626847|NCT05735496|DRUG|TQB2102 injection|TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
48282960|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
48282961|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
48626848|NCT04317027|DEVICE|New Fighting Clothing|VO2max test Clothing examination- 2-hour walk in 6 kph/4% elevation under 30 degrees Celsius and 60% relative humidity
48626849|NCT01540734|DRUG|Marketed paracetamol|Marketed formulation
48626850|NCT01540734|DRUG|Experimental paracetamol formulation|Experimental formulation
48626851|NCT01334853|OTHER|No drug will be used|Biomarker
48626852|NCT01334853|OTHER|No drug will be used|Biomarker
48282962|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
48467249|NCT03414034|DRUG|Abiraterone|Abiraterone orally
48467250|NCT03414034|DRUG|Prednisone|Prednisone orally
48626853|NCT05910398|DRUG|pyrotinib|an irreversible anti-HER2 tyrosine kinase inhibitor
48100477|NCT05994092|BEHAVIORAL|Voluntary Isocapnic Hyperpnea|The protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.
48282963|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
48282964|NCT01495026|DRUG|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
48282965|NCT01495026|DRUG|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
48282966|NCT01495026|DRUG|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
48467251|NCT03857724|PROCEDURE|prolapse surgery|prolapse surgery
48467252|NCT03645876|DRUG|SHR-1210|200mg
48282967|NCT00140803|DRUG|Visudyne|
48282968|NCT00140803|DRUG|Kenalog|
48467253|NCT03645876|DRUG|BP102|7.5mg/kg
48282969|NCT01173653|OTHER|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
48282970|NCT01173653|OTHER|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
48282971|NCT02646475|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
48467254|NCT03645876|DRUG|oxaliplatin|130mg/m2
48467255|NCT03645876|DRUG|capecitabine|1000mg/m2
48467256|NCT05760261|DRUG|Midazolam|Midazolam will be administered.
48467257|NCT05760261|DRUG|GSK3882347|GSK3882347 will be administered.
48467258|NCT05822674|DRUG|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
48626854|NCT05982119|DEVICE|ActiMyo/Syde|"The two watches can be worn as wristwatch or placed near the ankle and on the wheelchair.~* Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months.~* Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months.~* Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion.~* Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion."
48626855|NCT02845492|OTHER|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
48626856|NCT02845492|OTHER|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
48626857|NCT04035083|DEVICE|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
48626858|NCT04035083|DEVICE|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
48626859|NCT05551897|DRUG|Camizestrant|Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.
48626860|NCT05551897|DRUG|Itraconazole|Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.
48626861|NCT00890162|DRUG|Epinephrine|
48626862|NCT00890162|DRUG|Omalizumab (Xolair)|
48626863|NCT00890162|DRUG|Placebos|
48626864|NCT03182712|DIETARY_SUPPLEMENT|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
48626865|NCT03182712|DIETARY_SUPPLEMENT|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
48626866|NCT01721239|OTHER|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
48626867|NCT01789775|DRUG|Drug: CD07805/47 gel|
48626868|NCT01789775|DRUG|CD07805/47 gel Placebo|
48626869|NCT02584296|BEHAVIORAL|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, \~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
48626870|NCT02162433|DRUG|Normal Saline|to arms 2,4. Serves as the placebo.
48100478|NCT03459183|DEVICE|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
48282972|NCT02646475|DRUG|Saline|Normal saline will be used as a placebo comparator.
48282973|NCT01575912|OTHER|experimental pain tests|
48467259|NCT05822674|DRUG|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
48467260|NCT06677762|PROCEDURE|Irreversible electroporation|Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.
48626871|NCT02162433|DRUG|Dexmedetomidine|to arms 1,3
48626872|NCT02826551|DRUG|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
48626873|NCT02826551|OTHER|Ice|
48626874|NCT02826551|DRUG|Percocet|
48626875|NCT02826551|DEVICE|Knee Brace and Crutches|
48626876|NCT00032487|DRUG|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
48282974|NCT06540235|DEVICE|Otolith Device Active|The device will be providing different levels of stimulation hypothesized to affect the vestibular system
48282975|NCT06540235|DEVICE|Otolith Device Inactive|The device will be providing no stimulation to measure test-retest
48282976|NCT04745442|DRUG|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
48282977|NCT04745442|DRUG|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
48467261|NCT03179748|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
48467262|NCT04448041|OTHER|Malnutrition screening|Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
48467263|NCT02857387|BIOLOGICAL|blood sample withdrawn|
48467264|NCT03067935|DRUG|glembatumumab vedotin|
48626877|NCT00032487|DRUG|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
48626878|NCT00032487|DRUG|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
48626879|NCT00032487|DRUG|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
48626880|NCT01604031|BIOLOGICAL|B-CLL Vaccine|Patients will receive a fixed dose (2X10\^7) of IL-2 secreting B-cells together with (2X10\^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
48626881|NCT01604031|DRUG|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
48626882|NCT04639063|OTHER|Microscopic examination using H&E stained slides|Reexamination of the stained slides of the patients from the hospital archive and adding a CD10 stain when required
48626883|NCT04151498|BEHAVIORAL|Reengagement and Assessment Mobile Program|Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
48626884|NCT04151498|OTHER|Qualitative Interview|Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
48626885|NCT02820636|BEHAVIORAL|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual \& 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication \& trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
48626886|NCT02820636|BEHAVIORAL|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
48626887|NCT02843607|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
47937510|NCT05057910|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
48467265|NCT06588673|OTHER|Art Thrapy|Art therapy at Art Therapy Studio, a well-established recommended art therapy leader since 1967 with extensive experience in virtual therapy for patients with medical needs. Cheryl Pete, MA ATR-BC, a board-certified art therapist and the Clinical Director will complete the art therapy sessions. The art therapy will be a 1-hour sessions, once a week for a total of 8 weeks (or 8 sessions). Cheryl Pete's role will solely involve providing a service. Chery will complete the Art Therapy according to her standard practices. Cheryl's Art Therapy will not be altered in any way as a part of this research study. Cheryl will not collect any research data. As research participants are referred to Cheryl for the Art Therapy, the research participant's name and contact information will be shared.
48467266|NCT03605992|OTHER|Home-based Rehab|This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).
48467267|NCT03605992|OTHER|CentreRehab|This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
48467268|NCT00502658|BEHAVIORAL|Dietary supplement containing vitamins, minerals, and herbs|
48467269|NCT00502658|BEHAVIORAL|Shakes with nutrients and herbs|
48100479|NCT03459183|DEVICE|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
48467270|NCT00502658|BEHAVIORAL|Control dietary supplement|
48467271|NCT00502658|BEHAVIORAL|Isocaloric, isonitrogenous control shakes without herbs|
48467272|NCT00502658|BEHAVIORAL|Personal energy tracking tool|
48467273|NCT04937647|OTHER|collection of endoscopic images and videos|collection of endoscopic images and videos
48467274|NCT04734782|DIAGNOSTIC_TEST|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
48467275|NCT02394288|PROCEDURE|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
48467276|NCT00002228|DRUG|Enfuvirtide|
47937511|NCT03128151|BEHAVIORAL|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
47937512|NCT04512339|DRUG|Dupilumab|Dupilumab injections (blinded labels)
48626888|NCT02843607|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
48100480|NCT03459183|DEVICE|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
48626889|NCT04558827|OTHER|Low Carbohydrate Diet|Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.
48626890|NCT04558827|OTHER|Time Restricted Feeding|Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
48100481|NCT03459183|DEVICE|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
48100482|NCT03852758|BEHAVIORAL|Outdoor Exercise|2 outdoor exercise sessions per week
48100483|NCT03852758|BEHAVIORAL|Indoor Exercise|2 indoor exercise sessions per week
48467277|NCT05878041|DIAGNOSTIC_TEST|Molecular and genetic screening|Molecular and genetic screening
48467278|NCT06086353|DRUG|Tafamidis|Patients on tafamidis will be observed
48467279|NCT05258630|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
48626891|NCT01328119|OTHER|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
48626892|NCT01271738|PROCEDURE|Remove tumor only|No additional margins (tissue) removed at the initial surgery
48626893|NCT01271738|PROCEDURE|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
48467280|NCT05258630|BEHAVIORAL|Enhanced usual care|Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
48467281|NCT03711357|RADIATION|980 nm diode laser|980 nm high power diode laser device.
48467282|NCT03711357|OTHER|placebo|the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
48467283|NCT04540211|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
48626894|NCT00962650|DEVICE|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
48626895|NCT03587597|PROCEDURE|socket shield technique|socket shield technique with immediate temporization
48626896|NCT03587597|PROCEDURE|conventional immediate implant placement with immediate temporization|conventional immediate implant placement with immediate temporization
48626897|NCT04221152|DRUG|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
48626898|NCT05959291|OTHER|Discontinuation of Anti-HER-2 Maintenance Treatment|Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
48626899|NCT06101446|OTHER|Lavander Aromatherapy|Aromatherapy is one of the potential non-pharmacological methods. Lavender oil has been known to have calming properties and is one of the most effective aromatherapy oils. It reduces blood pressure and anxiety by stimulating the parasympathetic system
48626900|NCT05665842|OTHER|Music Application|The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
48626901|NCT05665842|OTHER|Sleep Hygiene Training|"After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ."
48626902|NCT03852576|DRUG|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
48626903|NCT01370538|DRUG|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
48626904|NCT06519149|DEVICE|Slow Wave UASD|An oral appliance for the treatment of OSA and snoring
48626905|NCT02412319|DRUG|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
48626906|NCT02412319|OTHER|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
48626907|NCT06280105|DRUG|Cadonilimab+regorafenib|cadonilimab: 6mg/kg iv D1 Q2W; regorafenib: 80mg QD oral; Eligible patients will receive cadonilimab combined with regorafenib, until disease progression or intolerable toxicity or death or withdrawal of informed consent, whichever occurred first
48467284|NCT04540211|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
48467285|NCT04540211|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
48467286|NCT04540211|DRUG|Cisplatin|Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
48467287|NCT04540211|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
48467288|NCT04540211|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
48467289|NCT03430635|PROCEDURE|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
48626908|NCT04561453|DIAGNOSTIC_TEST|Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring|All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
48626909|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
48626910|NCT00103506|DRUG|Bortezomib (VELCADE)|1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
48100484|NCT05644652|OTHER|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~* Flexibility exercises to restore joint mobility of soft tissues.~* Static and dynamic balance exercises~* Functional strengthening exercises.~* Functional gait training."
48467290|NCT05696704|OTHER|Behavioral: Mindfulness Based Cognitive Therapy|Individual tele-therapy 12 to 16 weeks
48467291|NCT05696704|OTHER|Behavioral: Behavior Activation|Individual therapy 12 to 16 weeks
48467292|NCT00949091|DRUG|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
48100485|NCT05644652|OTHER|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
48467293|NCT04802564|OTHER|regular hand therapy|edema control, scar management, stretching regimen, tendon gliding exercise, blocking exercise, muscle strengthening protocols
48467294|NCT03971734|DRUG|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
48467295|NCT03971734|DRUG|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
48467296|NCT03971734|DRUG|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
48467297|NCT03971734|DRUG|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
48626911|NCT00103506|DRUG|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
48626912|NCT03115970|PROCEDURE|capillary and venous lactate level measurement|capillary and venous lactate level measurement
48626913|NCT00920816|DRUG|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
48626914|NCT00920816|DRUG|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
48626915|NCT01053936|DRUG|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
48626916|NCT00016172|DRUG|pegylated liposomal doxorubicin hydrochloride|
48626917|NCT00016172|DRUG|picoplatin|
48626918|NCT01172301|DIETARY_SUPPLEMENT|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
48626919|NCT00424164|DRUG|lapatinib ditosylate|
48626920|NCT00424164|DRUG|tamoxifen citrate|
48100486|NCT03357224|DRUG|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
48626921|NCT00424164|OTHER|pharmacological study|
48626922|NCT04845971|DIETARY_SUPPLEMENT|Saisei Maf capsules|Dietary supplement name: Colostrum MAF, Saisei MAF immunomodulator. Formulation: 148 mg acid-resistant coated capsules, containing 2.3 mg of enzymatically treated bovine colostrum powder and supplementary ingredients The dietary supplement substances: Active ingredien: Enzymatically treated bovine colostrum powder 2.3 mg 1.6 % Supplementary ingredients: Lactase (Derived from yeast) 0,15 mg 0.1 % HPMC (Hydroxypropyl Methylcellulose) acid-resistant capsule 47 mg 31.8 % Microcrystalline cellulose (Derived from pulp) 98,4 mg 66.5 % Dosage for adults: 2 - 10 capsules daily (stronger version 9 capsules daily) Route of administration: oral Contraindication: allergy to dairy product components Precaution: pregnancy and lactation Storage: Can be stored in at + 5 to +25°C, on dry place for up to two years Manufacturer: Saisei Pharma, Osaka, MORIGUCHI city, OKUBO-cho, 3-34-8. Japan
48626923|NCT03459651|BEHAVIORAL|ANS training|In-home computer-based ANS training
48100487|NCT06165926|DRUG|15% hypertonic dextrose|"The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed."
48100488|NCT06165926|DRUG|Normal saline|The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
48467298|NCT03971734|DRUG|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
48467299|NCT03971734|DRUG|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
48467300|NCT03971734|DRUG|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
48467301|NCT05568173|OTHER|Boxing Training|"In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG."
48626924|NCT02428153|OTHER|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
48626925|NCT03908008|DRUG|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
47937513|NCT04512339|DRUG|Placebo|Placebo injections (blinded labels), matching the dupilumab injections in quantity and appearance
48626926|NCT03908008|DRUG|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
48626927|NCT03015701|DRUG|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
48626928|NCT03015701|OTHER|Placebo|placebo matching mifepristone
48626929|NCT03462147|DEVICE|Spinal cord stimulation|Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
48467302|NCT05568173|OTHER|Scapular Stabilization|"In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks."
48467303|NCT00344643|DEVICE|Silicone Hydrogel Soft Contact Lenses|
47937514|NCT02770261|DRUG|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
48467304|NCT04795466|BIOLOGICAL|Canakinumab|Biological sub-cutaneous injection
48467305|NCT04795466|OTHER|Placebo|Matching placebo subcutaneous injection
48467306|NCT00526162|DEVICE|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
48467307|NCT00178724|OTHER|No Treatment Given|Intervention is not given.
48467308|NCT06464874|PROCEDURE|Conventional ESD|Conventional ESD is the most suitable method for total resection, especially for large lesions. This method can complete the resection of early gastrointestinal cancer and precancerous lesions, while maintaining the integrity of digestive tract anatomy and physiological function.The operation difficulty of this technique is high, the equipment requirements are high, the operation time is long, and the complication rate is closely related to the technical level of the operator.
48467309|NCT06464874|PROCEDURE|Hybrid ESD|Hybrid ESD is a better choice, but only can remove the lesion in one piece, but also has a lower technical difficulty than conventional ESD
48626930|NCT04916249|DRUG|Tibetree Pain Relieving Plaster|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
48626931|NCT04916249|OTHER|Placebo|Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
48626932|NCT01312129|DRUG|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
48626933|NCT01312129|DRUG|Placebo|Placebo capsule x 3 doses 12 hours apart
47937515|NCT02770261|DRUG|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
48467310|NCT00759616|DEVICE|Oxford Partial Knee|Oxford Partial Knee
48467311|NCT05402917|PROCEDURE|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
48467312|NCT02881359|DEVICE|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
48467313|NCT00187265|DEVICE|Cardiac Resynchronization Therapy|
48467314|NCT02597049|DRUG|Dulaglutide|Administered SC
47937516|NCT02770261|DRUG|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
47937517|NCT02770261|DRUG|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
47937518|NCT02770261|DRUG|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
47937519|NCT02770261|DRUG|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
47937520|NCT05251428|PROCEDURE|Excision of the A1 pulley|Participants will undergo excision of the A1 pulley. Wounds will then be irrigated and closed in the standard fashion.
47937521|NCT05251428|PROCEDURE|Incision of the A1 pulley in the standard fashion|Participants will undergo incision of the A1 pulley in the standard fashion. Wounds will then be irrigated and closed in the standard fashion.
48467315|NCT02597049|DRUG|Placebo|Administered SC
48626934|NCT00296335|DRUG|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
48467316|NCT02597049|DRUG|SGLT2 inhibitor|Administered orally as standard of care for type 2 diabetes
48467317|NCT02597049|DRUG|Metformin|Administered orally as standard of care for type 2 diabetes
48467318|NCT03937206|DIETARY_SUPPLEMENT|NutriterraTM|Nutriterra 1000mg
48467319|NCT03937206|DIETARY_SUPPLEMENT|Placebo|Corn Oil 1000mg
48467320|NCT04129255|DRUG|Octreotide Acetate|administration every 28 days
48626935|NCT00296335|DRUG|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
48626936|NCT00031005|PROCEDURE|modified stem cell transplant|
48626937|NCT03475563|PROCEDURE|Coronary angioplasty with stent implantation|Coronary angioplasty with BiOSS LIM C stent implantation
48626938|NCT03414632|DRUG|99mTc-PYP|Radioisotope used in the SPECT/CT imaging
48626939|NCT03147287|DRUG|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
48626940|NCT03147287|DRUG|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
48100489|NCT06165926|OTHER|physical therapy|Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
48467321|NCT05426954|OTHER|Rehabilitation utilizing blood flow restrictive therapy|BFR therapy
48467322|NCT04000191|PROCEDURE|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
48467323|NCT04000191|OTHER|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
48467324|NCT03417206|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
48467325|NCT03417206|DEVICE|pupillary dilatation reflex|PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%
48467326|NCT03405064|DRUG|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
48467327|NCT03405064|DRUG|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
48467328|NCT05740553|DEVICE|ReTrieve Automated Stereognosis System|An automated tactile training system that may help patients recover lost tactile function after brain injury.
48467329|NCT02861833|OTHER|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
48467330|NCT01650155|DRUG|BI 1005273 s.c.|injection
48467331|NCT01650155|DRUG|BI 105273 i.v. Placebo|infusion
48467332|NCT01650155|DRUG|BI 1005273 s.c. Placebo|injection
48626941|NCT03147287|DRUG|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
48626942|NCT04582071|BEHAVIORAL|Psychotherapy|Psychotherapy is a term that we use to describe the use of the psychological method to understand and improve an individual's well-being and mental health. The Principal Investigator of this study, a clinical psychologist will be leading each of the sessions.
48626943|NCT00363467|DRUG|G-CSF|"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."
48626944|NCT00363467|DRUG|Leukapheresis|leukapheresis
48626945|NCT00363467|DRUG|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
48626946|NCT00363467|PROCEDURE|Stem cell reinfusion|autologous stem cell transplant
48467333|NCT01650155|DRUG|BI 1005273 i.v.|infusion
48467334|NCT02212236|OTHER|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
48467335|NCT02874196|PROCEDURE|Standard arthrography|
48467336|NCT02874196|PROCEDURE|Dual energy arthrography|
48467337|NCT02874196|PROCEDURE|Arthro-tomosynthesis|
48467338|NCT02874196|PROCEDURE|Arthro-tomography|
48626947|NCT03071744|DRUG|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
48626948|NCT02361931|DRUG|A hydrogel containing erythropoietin|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
48626949|NCT02361931|DRUG|Hydrogel (as a part of SOC)|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
48282978|NCT06640114|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The duration of hemoperfusion is from 2 to 6 hours through peripheral venous access, followed by follow-up for 4 hours. The rate of hemoperfusion is from 60 to 80 ml/min. Anticoagulation is systemic (heparin)."
48626950|NCT01837888|DEVICE|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
48282979|NCT02043574|BEHAVIORAL|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
48467339|NCT02874196|PROCEDURE|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
48626951|NCT06241443|OTHER|hybrid simulation|"During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices."
48626952|NCT06241443|OTHER|video-modeling|"The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance."
48626953|NCT04727749|BEHAVIORAL|Therapy Dog Team Visit|For the intervention group, patient interacts with the therapy dog, handler shares information about the therapy dog, asks about patient's pets, and offers a trading card of the therapy dog at the conclusion of the visit.
48626954|NCT01527669|DRUG|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
48626955|NCT01527669|DRUG|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
48626956|NCT02036723|DRUG|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
48626957|NCT02036723|DRUG|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
48100490|NCT04658342|DIAGNOSTIC_TEST|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
48626958|NCT04569370|PROCEDURE|Laparoscopic Cholecystectomy|Surgical removal of Gall bladder using laparoscopy
48626959|NCT00026338|DRUG|erlotinib hydrochloride|150 mg po daily
48626960|NCT00026338|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
48626961|NCT04652310|DEVICE|TFNA extended-short nail (235 mm)|The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)
48626962|NCT04652310|DEVICE|TFNA long nail (260-480mm)|The long version of the TFN-advanced proximal femoral nailing system (TFNA)
48626963|NCT00436709|BIOLOGICAL|bevacizumab|
48626964|NCT00436709|BIOLOGICAL|pegfilgrastim|
48626965|NCT00436709|DRUG|cyclophosphamide|
48100491|NCT04621682|OTHER|Non technical skills and checklist training in simulation|using structured debrifing, in three random medical simulation crises, training in non-technical skills will be carried out
48100492|NCT04621682|OTHER|Checklist training simulation|using structured debrifing, in three random medical simulation crises, training in checklist will be carried out
48626966|NCT00436709|DRUG|doxorubicin hydrochloride|
48626967|NCT00436709|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
48626968|NCT00436709|OTHER|flow cytometry|
48626969|NCT00436709|OTHER|immunoenzyme technique|
48626970|NCT00436709|OTHER|immunologic technique|
48626971|NCT00436709|OTHER|laboratory biomarker analysis|
48626972|NCT00436709|PROCEDURE|adjuvant therapy|
48626973|NCT00436709|PROCEDURE|immunoscintigraphy|
48626974|NCT03100292|OTHER|Sleeve gastrectomy or Roux-en-Y gastric bypass|
48626975|NCT00727064|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
48100493|NCT02903836|DRUG|Nafithromycin 800 mg 3 days|
48467340|NCT04857593|BEHAVIORAL|Melodies for Mums|"Classes start with a chat between mothers and the artist. The singing session will include welcome songs, introducing the babies and mothers to one another, and then involve a range of singing and music activities. These will include learning songs from around the world, ranging from short vocal exercises that use motherese style noises and sound effects (including sound baths where the mothers sang a sustained note providing a relaxation technique), to simple lullabies that can be picked up very quickly and sung in basic harmonies or rounds, to longer or more complex songs that will be learnt gradually over the weeks. Instruments such as guitar and ukulele will also be used by the artist for a small number of songs. Mothers will also work to write some of their own songs over the weeks, developing lyrics together about their babies or experiences of motherhood and creating simple melodies. Classes will be led by workshop leaders trained by Breathe, with support of assistants."
48467341|NCT01958060|DRUG|BI 1034020|intravenous part
48467342|NCT01958060|DRUG|Placebo to BI 1034020|intravenous part
48467343|NCT05005013|OTHER|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
48467344|NCT05005013|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
48467345|NCT05005013|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
48467346|NCT01087034|DEVICE|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
48467347|NCT01087034|RADIATION|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
48467348|NCT01087034|OTHER|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
48467349|NCT05074706|BIOLOGICAL|IgG antibodies to Sars-Cov-2|Samples will be collected between 30 and 60 days after second vaccine dose.
48467350|NCT05074706|BIOLOGICAL|QuantiFERON SARS-CoV-2 test|Samples will be collected within 9 months after completion of the vaccination series
48467351|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
48467352|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
48467353|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
48467354|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
48467355|NCT05167149|PROCEDURE|Carbon nanoparticles|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
48467356|NCT05167149|PROCEDURE|Indocyanine green|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
48467357|NCT03224767|DRUG|Vemurafenib|Given PO
48467358|NCT03224767|DRUG|Cobimetinib|Given PO
48467359|NCT03224767|OTHER|Laboratory Biomarker Analysis|Correlative studies
48467360|NCT03224767|OTHER|Quality-of-Life Assessment|Ancillary studies
48467361|NCT01129323|DRUG|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
48467362|NCT01702415|DRUG|Zoledronic acid|Single dose, intravenous solution 5mg
48467363|NCT01702415|DRUG|Placebo|
48626976|NCT00727064|DRUG|Venlafaxine Extended Release (VEN ER)|
48626977|NCT01793922|PROCEDURE|PD|pneumodilation
48626978|NCT01793922|PROCEDURE|POEM|peroral endoscopic myotomy
48626979|NCT03116815|OTHER|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
48100494|NCT02903836|DRUG|Nafithromycin 800 mg 5 days|
48467364|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.
48467365|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.
48626980|NCT00792480|BEHAVIORAL|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
48467366|NCT04791345|DRUG|Deflazacort|30 mg of deflazacort (1 pill) administered orally in a single dose.
48467367|NCT04791345|DRUG|Dexamethasone|4 mg of dexamethasone (1 pill) administered orally in a single dose.
48626981|NCT04433312|OTHER|Questionnaire|The questionnaire is developed based on a literature review and clinical experience. Initial testing of the questionnaire will be performed with 20 patients to assess the reliability and inter-rater variations. After initial testing, the final questionnaire will be formulated. The first sector of the questionnaire includes patient demographics and baseline characteristics; the second sector is regarding patient clinical condition, diagnosis, and scheduled surgery. The following sector examines the process of delivering the cancellation to the patient and requirements for re-scheduling. Patients will be classified into satisfied or dissatisfied according to the responses in this sector. The following sector addresses the course of care after cancellation and whether the patient conducted the surgery elsewhere or not. The last sector explores the impact of cancellation on patient health, career, and financial aspects.
48626982|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with Fluorescent Cholangiography|Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.
48626983|NCT04922528|PROCEDURE|Laparoscopic Cholecystectomy with White Light Imaging|As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.
48467368|NCT04791345|DRUG|Dexamethasone|2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.
48467369|NCT04792580|DRUG|Lifitegrast 5% Ophthalmic Solution|Used twice a day in both eyes for 4 weeks after a 2 week washout.
48467370|NCT04792580|DRUG|Placebo|Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
48467371|NCT04573309|DRUG|ALXN1840|Administered orally as tablets.
48467372|NCT00935623|BIOLOGICAL|Malaria Challenge|Malaria challenge
48467373|NCT05005637|DRUG|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 4RH (4 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
48467374|NCT05005637|DRUG|Prednisone tablet|Oral prednisone will be given at the dose of 1 mg/kgBW/day (max 60 mg/day) until the uveitis is controlled or up to 4 weeks of administration, after that the dose will be tappered off gradually.
48467375|NCT03944109|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
48467376|NCT03944109|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
48467377|NCT06060522|DIAGNOSTIC_TEST|CT, CBCT|"Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline."
48467378|NCT03417609|DEVICE|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
48467379|NCT03417609|PROCEDURE|Blood sampling|Blood sampling
48467380|NCT03417609|DIAGNOSTIC_TEST|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
48467381|NCT03417609|DIAGNOSTIC_TEST|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
48467382|NCT03417609|DIAGNOSTIC_TEST|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
48467383|NCT03417609|DEVICE|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
48467384|NCT03417609|DIAGNOSTIC_TEST|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
48467385|NCT05995873|DEVICE|unilateral transcranial photobiomodulation|An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
48467386|NCT03935737|DIAGNOSTIC_TEST|Full Dose Chest X-Ray|Full dose X ray at Day 1
48467387|NCT03935737|DIAGNOSTIC_TEST|Low Dose Chest X-Ray|Low dose X ray within 3 months from full dose
48100495|NCT02903836|DRUG|Moxifloxacin 400 mg|
48467388|NCT02664987|OTHER|Patients receiving cancer pain treatment|
48467389|NCT06070545|OTHER|Modified Supine Position|Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
48467390|NCT06222606|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
48626984|NCT00133354|DRUG|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
48626985|NCT00133354|DRUG|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
48626986|NCT00133354|DRUG|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
48626987|NCT02940379|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
48626988|NCT02940379|DRUG|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
48626989|NCT02940379|DRUG|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
48626990|NCT02162563|DRUG|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
48626991|NCT02162563|DRUG|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
48626992|NCT02162563|DRUG|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
48626993|NCT00331487|DRUG|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
48626994|NCT00331487|DRUG|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
48626995|NCT05644483|DRUG|Remimazolam|Remimazolam: loading (6mg/kg/hr) + continuous infusion (1-2mg/kg/hr)
48626996|NCT05644483|DRUG|Propofol|Propofol: target controlled infusion: 2-3mcg/mL
48626997|NCT02842099|DRUG|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
48626998|NCT02842099|DRUG|X|Capecitabine
48626999|NCT02472093|OTHER|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
48627000|NCT02472093|OTHER|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
48627001|NCT02472093|OTHER|Control group|The control group did brief educational sessions.
48467391|NCT00345033|DRUG|Aripiprazole|15-mg dose once a day for 8 weeks
48467392|NCT00345033|DRUG|Placebo|1 tablet placebo dose once a day for 8 weeks
48467393|NCT04681586|DEVICE|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
48627002|NCT04310228|DRUG|Favipiravir Combined With Tocilizumab|"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
48627003|NCT04310228|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
48282980|NCT02043574|BEHAVIORAL|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
48467394|NCT04681586|DEVICE|dim red light|using the same device as the active group, but with an installed filter that dims light to \<300 lux for 30min every morning for two weeks
48467395|NCT03623893|PROCEDURE|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
48467396|NCT02978651|DRUG|Pitolisant (BF2.649)|
48627004|NCT04310228|DRUG|Tocilizumab|The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
48627005|NCT00231933|BEHAVIORAL|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
48627006|NCT00231933|BEHAVIORAL|Community integration (CI)|CI includes recovery group sessions and community integration activities.
48627007|NCT00231933|BEHAVIORAL|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
48627008|NCT03339362|PROCEDURE|Active Procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint"
48282981|NCT00686127|DRUG|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
48282982|NCT00686127|DRUG|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
48627009|NCT03339362|PROCEDURE|Sham procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint."
48100496|NCT05386758|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
48100497|NCT00340613|DRUG|glargine insulin|
48282983|NCT03282396|DRUG|Ibrutinib|Given PO
48282984|NCT05430867|DRUG|Memantine Oral Tablet|Memantine 20mg once-daily
48282985|NCT05430867|DRUG|GV-971 capsule|GV-971 450mg twice a day
48282986|NCT02638246|BEHAVIORAL|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
48467397|NCT02978651|DRUG|Placebo Oral Tablet|
48467398|NCT06334016|PROCEDURE|Biospecimen Collection|Undergo blood collection
48467399|NCT06334016|DRUG|Cannabis sativa Extract|Vape THC
48467400|NCT06334016|DRUG|Nicotine|Vape active nicotine
48467401|NCT06334016|DRUG|Placebo Administration|Vape placebo nicotine
48467402|NCT06334016|OTHER|Questionnaire Administration|Ancillary studies
48467403|NCT04526080|DEVICE|TheraBionic Device|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
48467404|NCT04526080|DEVICE|Placebo Device|Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
48627010|NCT04041128|DRUG|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
48627011|NCT01481779|DRUG|Glargine|Administered by SC injection via a pen device.
47937522|NCT04650854|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
47937523|NCT01339026|DRUG|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
48467405|NCT06120660|OTHER|Music Therapy|Music Therapy
48467406|NCT02895841|OTHER|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
48467407|NCT02805309|BEHAVIORAL|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
48467408|NCT02805309|BEHAVIORAL|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
48467409|NCT02805309|BEHAVIORAL|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
48467410|NCT00867854|OTHER|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
48467411|NCT02976051|RADIATION|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
48467412|NCT00071539|DRUG|TP-38|Recombinant chimeric protein
48467413|NCT00071539|DRUG|TP38|recombinant chimeric protein
48467414|NCT05578469|PROCEDURE|surgical treatment of Marfan Syndrome with subluxation lens|different surgical treatment of Marfan Syndrome with subluxation lens
48467415|NCT03380130|DRUG|Nivolumab|An anti-programmed death 1 monoclonal antibody
48467416|NCT03380130|DEVICE|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
48467417|NCT02276625|BIOLOGICAL|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
48467418|NCT04229160|DEVICE|Noninvasive mapping (Cardioinsight® system)|Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure
48467419|NCT04229160|DEVICE|long-term cardiac monitoring (LINQ system)|long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure
48467420|NCT04229160|PROCEDURE|Atrial Fibrillation ablation procedure|Atrial Fibrillation ablation procedure is done with standard practice
48467421|NCT00325182|DRUG|Levetiracetam|
48467422|NCT00325182|OTHER|Historical controls|
48467423|NCT05632796|PROCEDURE|Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.|All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
48467424|NCT00160745|DRUG|Rosuvastatin|
48627012|NCT01481779|DRUG|LY2605541|Administered by SC injection with a pen device.
48627013|NCT01481779|DRUG|Insulin Lispro|Administered by SC injection with a pen device.
48627014|NCT05265676|DRUG|Enoxaparin Sodium (Venus Remedies Limited)|The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
48627015|NCT05265676|DRUG|Enoxaparin Sodium (Sanofi)|The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
48627016|NCT05573282|OTHER|Regorafenib combine with ICIs|Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
48627017|NCT03555786|OTHER|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
47937524|NCT01339026|DRUG|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
47937525|NCT02233946|BEHAVIORAL|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
48282987|NCT02638246|BEHAVIORAL|Internet-delivered, non-contingent incentives + Motivational Interviewing|
48282988|NCT02172118|DRUG|BI 1774 CL|
48282989|NCT04925752|DRUG|Oral Lenacapavir (LEN)|Tablets administered orally without regard to food
48282990|NCT04925752|DRUG|F/TDF|Tablets administered orally
48627018|NCT00915187|DRUG|CCS/C|Adjuvant to influenza vaccine
48627019|NCT00915187|BIOLOGICAL|Influenza Vaccine|Influenza vaccine
48627020|NCT00357604|DRUG|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
48627021|NCT00357604|DRUG|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
48627022|NCT03507283|PROCEDURE|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
48467425|NCT05194709|BIOLOGICAL|Anti-CAR-NK Cells|The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.
48627023|NCT05548504|RADIATION|Photon|50-66Gy/ 24 fractions, inhomogeneous dose distribution photon therapy
48467426|NCT01214239|DRUG|Placebo|once a day
48467427|NCT01214239|DRUG|Linagliptin|once a day
48627024|NCT05548504|RADIATION|Proton|50-66Gy/ 24 fractions, inhomogeneous dose distribution proton therapy
48627025|NCT04806425|DRUG|Intralipid|intralipid is given as a preconditioning drug during off bump coronary artery bypass grafting surgery to measure efficacy in decreasing post operative ischemia
48627026|NCT04806425|DRUG|Placebo|normal saline is given in same volume to normal saline group over the same duration
48627027|NCT02271542|DRUG|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
48627028|NCT04894240|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
48282991|NCT04925752|DRUG|Sub-cutaneous (SC) Lenacapavir (LEN)|Administered via SC injections
48467428|NCT01495715|DRUG|Idebenone|
48467429|NCT01495715|DRUG|Placebo|
48467430|NCT02568280|DRUG|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
48467431|NCT02568280|DRUG|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
48467432|NCT00176358|DEVICE|PTCA and Stent Implantation|
48627029|NCT01271972|DRUG|nesvacumab (REGN910/ SAR307746)|
48467433|NCT00176358|BEHAVIORAL|Exercise Training|
48467434|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
48627030|NCT04385992|DRUG|177Lu-Dotatate|Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
48627031|NCT00265291|DRUG|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
48627032|NCT03780062|BIOLOGICAL|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
48627033|NCT00611156|DIETARY_SUPPLEMENT|ginger|added to a brunch meal
48627034|NCT00611156|DIETARY_SUPPLEMENT|black pepper|Added to a brunch meal
48627035|NCT00611156|DIETARY_SUPPLEMENT|horseradish|Added to a brunch meal
48627036|NCT00611156|DIETARY_SUPPLEMENT|mustard|Added to a brunch meal
48627037|NCT00611156|DIETARY_SUPPLEMENT|placebo|Added to a bruch meal
48282992|NCT04925752|DRUG|Placebo SC LEN|Administered via SC injections
48282993|NCT04925752|DRUG|PTM F/TDF|Tablets administered orally
48282994|NCT04925752|DRUG|PTM Oral LEN|Tablets administered orally
48282995|NCT04925752|DRUG|F/TAF (for US participants only)|F/TAF tablets administered orally once daily
48467435|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
48467436|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
48467437|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
48467438|NCT01992874|DRUG|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
48467439|NCT02382822|OTHER|No intervention.|
48467440|NCT03602027|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
48467441|NCT03602027|DRUG|Gefitinib|Gefitinib 250mg orally daily for three weeks
48467442|NCT04979845|OTHER|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
48467443|NCT04979845|OTHER|Video exercise|Patients will receive video instructions for home based exercises
48627038|NCT01431846|BEHAVIORAL|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
48627039|NCT04893031|DRUG|Tocilizumab|400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
48627040|NCT03568903|OTHER|Comprehensive physical therapy|Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
48627041|NCT05554055|BIOLOGICAL|Anti Xa activity measurement.|Arterial blood samples of 3cc will be taken during the procedure at each ACT. Blood samples will be sent to the lab for anti Xa activity measurement.
48627042|NCT01656499|DIETARY_SUPPLEMENT|Arabinoxylanoligosaccharides|
48627043|NCT01656499|DIETARY_SUPPLEMENT|Maltodextrine|
48627044|NCT02299167|DRUG|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
48627045|NCT04688996|DIAGNOSTIC_TEST|Lateral Flow Assay for Pathogens of the Plague|A dipstick type of rapid test for antigens of the plague bacterium Yersinia pestis in samples from enrolled participants from both a known geography of plague activity (Madagascar) as well as samples from a geographically separated population of likely plague free status (US Naval Health Research Center, San Diego, CA).
48627046|NCT05946187|BEHAVIORAL|Apolo_Bari Stepped-care intervention|"Step 1 - Low-intensity intervention that will run on a private Facebook® group. Weekly, a subtopic and related activities are posted as short text/images. Patients are encouraged to participate by viewing publications, commenting, and posting their content.~Step 2 - Will consist of an adjusted version of the Cognitive Behavior Treatment (CBT) program developed by Conceição et al. (2016). The intervention will last for 12-months and be delivered online by Facebook's functionalities, namely chat and calls. The intervention offered includes three components: 1) a psychoeducational cognitive-behavioral-based self-help manual that consists of 12 different modules. Each month a different topic will be covered and divided into four weekly sub-topics, which are supported with a set of related CBT tasks; 2) interactive call sessions with a psychologist (30 min at the beginning of each month); 3) monthly monitoring of risk-behaviors responded every session."
48627047|NCT05946187|OTHER|Treatment as Usual for Bariatric Surgery|Treatment as Usual for bariatric surgery in portuguese public hospitals.
48627048|NCT01044199|BIOLOGICAL|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
48627049|NCT01044199|BIOLOGICAL|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
48627050|NCT06345820|DEVICE|Evolux|Evolux, enhanced monofocal IOL
48627051|NCT06345820|DEVICE|Tecnis Eyhance|Tecnis Eyhance, enhanced monofocal IOL
48627052|NCT02617862|PROCEDURE|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
48627053|NCT02617862|DEVICE|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
48467444|NCT05361408|DRUG|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
48467445|NCT05361408|DRUG|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
48467446|NCT06249893|OTHER|Point-of-care vascular ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to perform a pulsed-wave doppler measurement of blood flow during chest compressions and during pauses for rhythm and manual pulse checks.
48467447|NCT04203433|DRUG|DLX105-DMP|1mg applied to target lesion
48467448|NCT05472896|PROCEDURE|cTACE|transcatheter arterial chemoembolization with
48467449|NCT05472896|DRUG|Dicycloplatin (TP21)|the dosage of dicycloplatin was based on the body surface area (550 mg/m2) according to previous research. The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
48627054|NCT02617862|DEVICE|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
48627055|NCT00358280|DRUG|Ropivacaine|
48627056|NCT00358280|DRUG|Bupivacaine|
48627057|NCT04067310|OTHER|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
48627058|NCT04067310|OTHER|moisturizer Dnativ Revita derm|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
48467450|NCT05472896|DRUG|Epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
48467451|NCT06356987|PROCEDURE|Herniotomy|In Group A Laparoscopic assisted needle herniotomy was done
48467452|NCT00164918|DEVICE|nasogastric tube|
48467453|NCT04266431|BEHAVIORAL|EMPOWER|Behavioral weight loss intervention
48467454|NCT05497557|DRUG|Omeprazole|Omeprazole will be administered as an oral capsule.
48467455|NCT05497557|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
48467456|NCT06167850|PROCEDURE|Copenhagen plank|Performing Copenhagen adduction as prevention for adductor injury.
48467457|NCT01094262|DRUG|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
48467458|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
48467459|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
48467460|NCT01094262|DRUG|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
48467461|NCT02806791|DRUG|FILGRASTIM|
48467462|NCT02725996|BIOLOGICAL|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
48467463|NCT02725996|OTHER|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
48467464|NCT01961245|DEVICE|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
48467465|NCT04817995|BEHAVIORAL|FOREST|Intervention is going to take the form of an internet-based stress recovery intervention consisting of six modules. The themes include introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These themes were chosen after considering topics that might be the most useful for healthcare staff experiencing high levels of stress. Each module consists of psychoeducation and exercise parts. Psychologist provide individual feedback on completed exercises as well as can be reached on demand.
48467466|NCT01577173|DRUG|MEHD7945A|1100 mg iv every 2 weeks
48467467|NCT01577173|DRUG|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
48467468|NCT04761445|OTHER|Straumann Standard Plus implant and JDental care (JD) Octa implant|Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.
48467469|NCT00370851|DRUG|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
48467470|NCT03732833|DRUG|MT10109L|MT10109L will be injected into either the LCL, or both the LCL and GL.
48467471|NCT03732833|DRUG|Placebo|Placebo will be injected into either the GL, or both the LCL and GL.
48627059|NCT02762604|BEHAVIORAL|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
48467472|NCT03239145|DRUG|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
48467473|NCT03239145|DRUG|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
48467474|NCT03727763|DRUG|Vemurafenib|960mg po bid
48467475|NCT03727763|DRUG|Cetuximab|500mg/m2 iv gtt (14 days per course)
48467476|NCT03329209|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
48467477|NCT05920954|PROCEDURE|ERCP|Repeat ERCP
48467478|NCT00460850|DRUG|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
48467479|NCT04809844|OTHER|Concurrent chemoradiation|concurrent Paclitaxel and radiation therapy after Adjuvant doxorubicin and Cyclophosphamide chemotherapy for stage ll or lll breast cancer .
48467480|NCT00897676|DRUG|Exendin-(9-39)|100-500pmol/kg/min
48467481|NCT00897676|DRUG|placebo|placebo (0.9% NaCl)
48467482|NCT02359864|RADIATION|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
48627060|NCT02762604|BEHAVIORAL|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
48467483|NCT02359864|RADIATION|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
48467484|NCT03848858|BEHAVIORAL|EMDR plus TAU|The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
48627061|NCT05783219|DRUG|Lidocaine patch|4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
48467485|NCT00002633|DRUG|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
48100498|NCT00820118|DRUG|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day"
48100499|NCT00038103|DRUG|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
48100500|NCT00038103|DRUG|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
48100501|NCT03898986|BIOLOGICAL|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
48627062|NCT05783219|OTHER|Placebo|Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
48627063|NCT06354088|DRUG|Alpelisib 300 mg|All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.
48627064|NCT06354088|DRUG|Placebo|All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.
48467486|NCT00002633|DRUG|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
48627065|NCT06354088|DRUG|[1-13C] sodium acetate|All participants will receive continuous infusions of \[1-13C\] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
48467487|NCT00002633|DRUG|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
48627066|NCT06354088|DRUG|[6,6-2H2] D-glucose|All participants will receive continuous infusions of \[6,6-2H2\] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental)
48627067|NCT06354088|DIETARY_SUPPLEMENT|Nestlé BOOST Plus|All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental)
48627068|NCT05229081|BEHAVIORAL|vaccine education|The educational content was developed based on research and expert perspectives and included general information about immunization, pneumonia, and pneumococcal vaccines, as well as vaccine myths. This information was first conveyed to the patients verbally, and then booklets with the same material were handed to them. The Pneumococcal Conjugate Vaccine 13 (PCV13) vaccination was recommended based on Infectious Disease Society of America (IDSA), Advisory Committee on Immunization Practices (ACIP), and national adult immunization guidelines.
48627069|NCT05872919|OTHER|SMS reminder massages about adherence|SMS three-times per week in the first six weeks and twice per week in the second six weeks reminding the patient about adherence to prescribed medication
48100502|NCT03898986|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
48100503|NCT04335591|DRUG|75 mg linzagolix tablet|For oral administration once daily
48100504|NCT04335591|DRUG|200 mg linzagolix tablet|For oral administration once daily
48100505|NCT04335591|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
48100506|NCT04335591|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
48467488|NCT00002633|DRUG|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
48627070|NCT06102304|DEVICE|Focused Extracorpeal Shock wave|Focused Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band was applied as low energy 2 sessions per week for 4 weeks. (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus.
48627071|NCT06102304|DEVICE|Sham Extracorpeal shock wave|(EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus. The device will be used in the demo mood with no radiation or impulses applied.
48627072|NCT01292538|DEVICE|Erchonia GLS|532 nm green diode low level laser light device
48100507|NCT04335591|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
48100508|NCT04335591|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
48100509|NCT03753152|DEVICE|experimental|Neuramis® Deep Lidocaine
48100510|NCT03753152|DEVICE|comparator|YVOIRE® Volume Plus
48100511|NCT03121950|OTHER|Dance|The primary intervention is a dance class
48100512|NCT03121950|OTHER|Music|the secondary intervention is listening to live music
48627073|NCT01292538|DEVICE|Placebo laser|Sham light output with no therapeutic benefit
48627074|NCT06420583|PROCEDURE|MTA pulpotomy|"1. Application of rubber dam for isolation, then a standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level, bleeding control in the pulp chamber will be achieved by using 5% sodium hypochlorite.~2. gentle condensation of MTA mix in the pulp chamber will be done by a wet sterile cotton pellet and then the rest of the pulp chamber will be filled with Glass Ionomer restoration.~3. The tooth will be restored with a stainless steel crown."
48467489|NCT00002633|DRUG|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
48627075|NCT06420583|PROCEDURE|Extraction|After complete Anesthetic application in the affected area, non-surgical extraction will be done.
48467490|NCT00002633|DRUG|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
48627076|NCT04742179|OTHER|Manteinance and care intervention on the green areas.|Manteinance and care intervention on the green areas.
48627077|NCT05151614|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
48627078|NCT01253486|BEHAVIORAL|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
48467491|NCT00002633|PROCEDURE|orchiectomy|Optional orchiectomy
48467492|NCT00002633|RADIATION|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
48467493|NCT01889797|BIOLOGICAL|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
48467494|NCT01889797|BIOLOGICAL|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
48467495|NCT06099964|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
48467496|NCT06099964|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
48627079|NCT01253486|BEHAVIORAL|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
48467497|NCT02026362|BIOLOGICAL|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
48467498|NCT02026362|OTHER|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
48467499|NCT06353724|DEVICE|conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning|"Dosimetric analysis: the maxilla (area of the teeth), both parotid glands (ipsilateral and contralateral), the mandible, and the PTV were defined and contoured in computed tomography pre irradiation planning. The mean corresponding dose of each structure were acquired using a dose-volume histogram.~All patients will complete the radiotherapy sessions using the positional radiation prosthesis.~Mucositis assessment: The severity of mucositis will be assessed weekly from the beginning of RT to the end of the treatment (mean time, 7 weeks). It will be scored in accordance with the classification criteria of the National Cancer Institute.~PH of saliva measurement: Collection of saliva sample were done from each patient to measure salivary PH by digital PH meter before beginning of radiotherapy and the measurement will be continued weekly till the end of the treatment."
48467500|NCT06353724|DEVICE|Digital positioning stent|Digital positioning stent
48627080|NCT01253486|BEHAVIORAL|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
48627081|NCT02662920|OTHER|No Intervention|
48627082|NCT03470766|DEVICE|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
48627083|NCT01724190|DRUG|Vitamin D|
48627084|NCT01724190|DRUG|Placebo|
48627085|NCT03459586|OTHER|9zest app facilitated exercise|The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
48627086|NCT05130697|OTHER|eMPowEr App|A mobile app to support participants in the management of malignant pleural effusions at home
48467501|NCT03084458|BEHAVIORAL|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
48467502|NCT00052949|DRUG|imatinib mesylate|Given orally
48627087|NCT01910532|DRUG|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP \> 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
48627088|NCT00768677|DRUG|topiramate|
48467503|NCT00052949|OTHER|laboratory biomarker analysis|Correlative studies
48467504|NCT04068987|DIAGNOSTIC_TEST|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body
48627089|NCT02035293|OTHER|PEP|
48627090|NCT05574049|DRUG|Tetrahydrocannabivarin|The subjects will take once daily oromucosal strip with intervention drug for 90 days.
48627091|NCT05574049|OTHER|Placebo|The subjects will take once daily oromucosal strip with no drug on it for 90 days
48627092|NCT00088153|DRUG|Physiologic Estrogen/progesterone|Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
48627093|NCT00088153|OTHER|Placebo|Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
48467505|NCT05077501|DRUG|ACD856|Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
48467506|NCT05077501|DRUG|Placebo|Placebo oral solution
48467507|NCT05284552|DRUG|Tinzaparin Injectable Solution|Subcutaneous injection
48467508|NCT00411268|DRUG|OROS hydromorphone HCI SR (slow release)|
48467509|NCT04405908|BIOLOGICAL|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
48467510|NCT04405908|BIOLOGICAL|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
48467511|NCT04405908|BIOLOGICAL|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
48467512|NCT04405908|BIOLOGICAL|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
48467513|NCT04315272|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
48627094|NCT05586087|OTHER|Experimental group|The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (\>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
48467514|NCT04315272|DRUG|Placebo|Placebo
48627095|NCT05506254|DRUG|hLB-001|hLB-001 gene therapy
48627096|NCT05482789|DRUG|Exenatide|10 microgram injected sub-cutaneously once
48467515|NCT05869916|BEHAVIORAL|psychological first aid|The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
48627097|NCT03197155|DRUG|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
48627098|NCT00455455|DRUG|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
48627099|NCT00455455|DRUG|ReNu Multiplus Multipurpose Solution|lens care system
48467516|NCT02864524|OTHER|Manipulative and Massage Therapy|
48467517|NCT02864524|OTHER|Exercise Program|
48467518|NCT04219527|PROCEDURE|Dual-target injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
48467519|NCT05165654|DEVICE|Transcranial Electrical Stimulation|Transcranial electrical stimulation
48467520|NCT02710240|DRUG|Indocyanine Green (ICG)|
48467521|NCT02710240|RADIATION|Intraoperative near-infrared (NIR)|
48467522|NCT06678529|DEVICE|active tDCS|TDCS at 2 mA were received for 20 min, beginning with a 30-s current rise phase and ending with a 30-s current fall phase.
48467523|NCT06678529|DEVICE|sham tDCS|Subjects received only a 30-s current rise phase at the beginning of each session and a 30-s current fall phase at the end of each session without a constant current of 2 mA for 20 min
48467524|NCT05200364|DRUG|STRO-002|intravenous antibody drug conjugate
48467525|NCT05200364|DRUG|Bevacizumab|anti-VEGF agent
48467526|NCT04975724|DRUG|Liposom Forte|Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
48467527|NCT04975724|DRUG|Citalopram|The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
48467528|NCT04975724|OTHER|Placebo|Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
48467529|NCT01705483|DRUG|ASP9853|oral
48467530|NCT01705483|DRUG|Docetaxel|intravenous (IV)
48467531|NCT01705483|DRUG|Paclitaxel|Taxol
48467532|NCT03318289|BEHAVIORAL|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
48467533|NCT04167358|DRUG|Linerixibat|All participants will receive linerixibat.
48627100|NCT01981928|DRUG|ASP7962|Oral
48627101|NCT01981928|DRUG|Placebo|Oral
48627102|NCT02016508|DRUG|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
48627103|NCT04574505|DIETARY_SUPPLEMENT|Eufortyn Colesterolo Plus|Food supplement combination containing bergamot (Vazguard®) phytosomal polyphenolic fraction associated with standardized artichoke extract (Pycrinil®, Cynara Cardunculus L) and Cynara scolimus, associated with high coenzyme Q10 bioavailability(Q10 phytosome® Ubiqsome) and zinc.
48627104|NCT04574505|DIETARY_SUPPLEMENT|Placebo|Placebo
48282996|NCT05274438|DRUG|JS001+Imatinib mesylate|"This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered."
48627105|NCT03248895|DEVICE|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
48627106|NCT05852288|DIAGNOSTIC_TEST|Inflammatory markers|Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
48627107|NCT00729001|BIOLOGICAL|Human Rotavirus Vaccine - two different formulations|Two oral doses
48627108|NCT00729001|BIOLOGICAL|Prevnar|Three-dose intramuscular injection (US subjects only)
48627109|NCT00729001|BIOLOGICAL|IPOL|Two-dose intramuscular injection (US subjects only)
48467534|NCT05331625|BEHAVIORAL|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
48467535|NCT00604916|OTHER|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
48467536|NCT00604916|OTHER|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
48467537|NCT05772286|BIOLOGICAL|763SIP8/MPLA-5 vaccine|763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
48467538|NCT06673524|PROCEDURE|Group T (Transversus Abmoninis Plane Block)|TAP Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position, the ultrasound (USG) probe is placed in an oblique position lateral to the xiphoid process at the lower border of the rib cage. The rectus abdominis muscle and its posterior sheath are visualized above the transversus abdominis muscle. At this level, only the aponeurosis of the internal oblique muscle can be seen between the transversus and external oblique muscles. By applying some pressure and tilt to the probe, the image of the myofascial planes is better optimized. Using a 22-25G, 50-100 mm block needle, an in-plane technique is applied, advancing either medially to laterally or vice versa. In the fascial plane between the rectus abdominis and transversus abdominis or between the internal oblique and transversus abdominis muscles, 20 ml of 0.25% bupivacaine is injected. The same procedure is then applied to the opposite side.
48467539|NCT06673524|PROCEDURE|Group R (Rectus-Intercostal Fascial Plane Block)|Rectus-Intercostal Fascial Plane Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position and under ultrasound (USG) guidance, a linear probe is placed 2-3 cm lateral and caudal to the xiphoid process to visualize the rectus abdominis muscle and the 6th-7th costal cartilages. Using an in-plane technique, the needle is advanced from caudal to cephalad. After confirming the target by hydrodissecting between the ribs and the rectus abdominis muscle, 20 ml of 0.25% bupivacaine is injected into the interfascial plane between the 6th-7th ribs and the rectus abdominis muscle using a 22-G, 80 mm block needle. The same procedure is then applied to the opposite side.
48467540|NCT00907205|DRUG|SF1126|Dose Escalating with 3+ patients in each cohort
48467541|NCT06677658|DIETARY_SUPPLEMENT|Olive Oil|Group 1 included patients who consumed at least 20 ml of oral olive oil daily. Group 2 included patients who did not consume olive oil.
48627110|NCT00729001|BIOLOGICAL|Infanrix|Three-dose intramuscular injection (US subjects only)
48627111|NCT00729001|BIOLOGICAL|OmniHIB|Three-dose intramuscular injection (US subjects only)
48627112|NCT00729001|BIOLOGICAL|Pentacel|Three-dose intramuscular injection (Canada only)
48467542|NCT06677658|DRUG|Methylprednisolone|Both groups were diagnosed with Covid-19 pneumonia and were given pulse steroid ( methylprednisolone ) treatment at 250 mg/day for 3 days.
48627113|NCT05142085|DIETARY_SUPPLEMENT|nano-PSO|This active treatment will be delivered to 3 out of 5 patients
48627114|NCT05142085|OTHER|placebo|This treatment will be assigned to 2 out of 5 patients
48627115|NCT01264471|PROCEDURE|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
48627116|NCT01264471|PROCEDURE|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
48627117|NCT05396300|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
48627118|NCT06374290|DRUG|Naltrexone (Vivitrol)|At week 1 the Nurse Practitioner will administer extended-release naltrexone via intramuscular gluteal injection supplied as a standard single-use kit containing 380-mg vial of Vivitrol microspheres. Only one naltrexone injection will be administered over the course of the study
48627119|NCT06374290|DRUG|Bupropion|Oral bupropion will be titrated to 450 mg over the course of 3 days. One week's supply of the study medication will be dispensed at each visit. Cell-phone assisted remote observation of medication adherence (CAROMA) will be used to assess compliance. Following Week 3, participants will be provided with enough pills to titrate the dose of bupropion over a period of 4 days. Therefore, participants will receive bupropion pills 3 weeks plus 4 additional days to titrate down the dose.
48627120|NCT02867488|OTHER|Soybean oil in salad dressing|
48627121|NCT03600792|GENETIC|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
48627122|NCT03175588|OTHER|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
48627123|NCT00323544|DRUG|zidovudine and lamivudine (Combivir®)|
48627124|NCT00323544|DRUG|emtricitabine and tenofovir DF|
48627125|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
48627126|NCT03061019|PROCEDURE|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
48282997|NCT06657573|BEHAVIORAL|An AI-enabled chatbot tailored for influenza vaccine consultation|The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.
48467543|NCT06678659|DRUG|REC-1245|REC-1245 capsule 1mg, 5mg, 25mg
48467544|NCT04712916|BEHAVIORAL|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
48467545|NCT05377294|OTHER|Method of Levels therapy|MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.
48467546|NCT04970862|PROCEDURE|reversion surgery|reversion surgery
48467547|NCT03330860|OTHER|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
48467548|NCT03330860|OTHER|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
48467549|NCT01896492|DRUG|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
48467550|NCT05435833|PROCEDURE|bilateral ultrasound guided GPN block|a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
48467551|NCT05091632|PROCEDURE|Electroencephalography|Undergo EEG
48467552|NCT05091632|OTHER|Questionnaire Administration|Complete questionnaires
48467553|NCT05634707|DRUG|Fluoxetine|"Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~* Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~* Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6"
48467554|NCT05634707|DRUG|Temozolomide|Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
48467555|NCT04403945|DEVICE|Sidestream dark field(SDF) imagining|SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.
48467556|NCT05388474|OTHER|No ibalizumab or Pre-ibalizumab treatment|Patient registry
48467557|NCT05388474|BIOLOGICAL|On ibalizumab treatment|Patient registry
48467558|NCT06677983|OTHER|Bioflex Crowns|A preformed crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area.
48467559|NCT06677983|OTHER|Stainless steel crown|An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur ) to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement. Any excess cement will be removed, and proper occlusion will be verified.
48467560|NCT04337229|OTHER|Artifical intelligent|it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
48627127|NCT02949453|BEHAVIORAL|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~* first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~* second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
48627128|NCT03524144|OTHER|gastroscopy|Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
48627129|NCT02365129|OTHER|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
48467561|NCT06373263|OTHER|Plain-language summary|Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be 275-300 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.
48467562|NCT06373263|OTHER|Dissemination Tool (Infographic)|The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
48467563|NCT01609270|DEVICE|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
48627130|NCT05291481|BEHAVIORAL|CAPAS-yOUTH|11-week parent training intervention exclusively delivered to parents
48627131|NCT01011725|DRUG|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
48467564|NCT05099133|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
48467565|NCT05099133|DRUG|LEO 138559 Placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
48467566|NCT04624594|OTHER|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
48627132|NCT01011725|DRUG|Placebo|Placebo oral tablet b.i.d for 12 weeks
48627133|NCT00489268|DEVICE|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~\*\*\*\*\*\*Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
48627134|NCT03052673|DRUG|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
48627135|NCT03052673|DRUG|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
48627136|NCT00748800|BEHAVIORAL|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
48627137|NCT00748800|BEHAVIORAL|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
48627138|NCT03996213|OTHER|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
47937526|NCT03169751|DEVICE|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
47937527|NCT02063971|OTHER|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
47937528|NCT02596750|DEVICE|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
48467567|NCT04624594|OTHER|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
48627139|NCT03996213|OTHER|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
48627140|NCT00337194|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
48627141|NCT00337194|OTHER|placebo|Given IV
48627142|NCT00337194|DRUG|vinorelbine tartrate|Given IV
48627143|NCT00337194|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
47937529|NCT02596750|DEVICE|Sham microneedle Roller|Flat roller without microneedles
47937530|NCT02590302|OTHER|Implementation Phase|"Core Components of the implementation intervention include:~* Hospital and CMHA project commitment~* Site champion teams (from hospital and CMHA)~* Memorandum of Agreement between Hospital and CMHA~* Pre-intervention site visits~* Education sessions~* Posters/reminders~* Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
48467568|NCT05443724|DRUG|CVL-231 30 mg|Oral tablets
48467569|NCT04501094|DRUG|Bintrafusp alfa (M7824)|1200 mg administered intravenous (IV) every two weeks
48627144|NCT00337194|DRUG|gemcitabine hydrochloride|Given IV
48467570|NCT05164094|BIOLOGICAL|mRNA-1189|Sterile liquid for injection
48627145|NCT00337194|OTHER|laboratory biomarker analysis|Correlative studies
48627146|NCT00337194|OTHER|pharmacological study|Correlative studies
48627147|NCT02517229|OTHER|Parabolic flight|
48627148|NCT02517229|OTHER|balance control measurements|
48627149|NCT02517229|DEVICE|electromagnetic maneuverable postural platform|
48627150|NCT03967327|DRUG|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
47937531|NCT06111391|DEVICE|Osstell® device (Integration Diagnostics Ltd.).|After trans-mucosal abutments were removed and the smart pegs were attached to the fixtures, resonance frequency analysis was done to assess implant stability.The implant stability quotient (ISQ) was used to quantify stability via the Osstell® device (Integration Diagnostics Ltd.).
47937532|NCT01285960|DEVICE|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
47937533|NCT03650296|DEVICE|ePER vs PS vs PaedER|see detailed description of methods
48467571|NCT05164094|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48467572|NCT05611723|OTHER|Exposure to disability|Disability status assessed by functional measures
48467573|NCT06462118|DRUG|Astegolimab|Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
48467574|NCT03962868|PROCEDURE|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (\<1.5%)
48467575|NCT03962868|PROCEDURE|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
48467576|NCT06142292|BEHAVIORAL|Individual counseling|Individual counseling sessions with a licensed mental health counselor
48467577|NCT06142292|BEHAVIORAL|Group counseling|Group counseling sessions with a licensed mental health counselor
48467578|NCT06593405|COMBINATION_PRODUCT|occupational therapy interventions for low vision care|Occupational therapists utilize many different treatment strategies when caring for the client with low vision. Oftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. Interventions include task lighting, organizational strategies, smart apps, contrast, enlarged print, typoscopes and electronic magnification devices.
48627151|NCT03967327|DRUG|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
48627152|NCT00401115|DRUG|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
48627153|NCT00401115|DRUG|MS-R001 (rapamycin)|Intraocular injection in various dosages
47937534|NCT04969367|OTHER|Medical Device Usage and Evaluation|Wear activity monitor (Fitbit)
47937535|NCT04969367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47937536|NCT04969367|OTHER|Questionnaire Administration|Complete questionnaires
47937537|NCT04969367|OTHER|Quality-of-Life Assessment|Complete questionnaires
48100513|NCT01156116|DEVICE|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________"
48100514|NCT01156116|DRUG|Placebo|oral placebo tablet
48627154|NCT03805139|DIETARY_SUPPLEMENT|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
48627155|NCT03235414|DEVICE|MRI|Will receive a one time research MRI (MR elastography)
48627156|NCT03235414|DIAGNOSTIC_TEST|Blood draw|Will receive a one time blood draw to confirm healthy liver status
48282998|NCT04635176|DRUG|Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)|real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
48627157|NCT03463447|DEVICE|Electronic Dynamometer|Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
48627158|NCT03463447|DEVICE|Hydraulic dynamometer|Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
48627159|NCT02293499|BEHAVIORAL|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma \[LTAA\],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
48627160|NCT01566825|DRUG|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
48627161|NCT01566825|DRUG|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
48627162|NCT04325347|OTHER|Virtual Reality application|Virtual Reality application with a VR goggle
48627163|NCT04614779|DRUG|CN128 Tablets|Iron chelator, oral tablets
48627164|NCT01320566|DEVICE|AeriSeal System|Not applicable. Follow-Up study only.
48627165|NCT05586360|DRUG|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
48627166|NCT04401293|DRUG|Enoxaparin|Full Dose LMWH anticoagulation therapy
48627167|NCT04401293|DRUG|Prophylactic/Intermediate Dose Enoxaparin|Prophylactic/Intermediate Dose LMWH or UFH therapy
48627168|NCT01163656|DEVICE|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
48627169|NCT01163656|DEVICE|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
48627170|NCT04795323|DEVICE|TARA v3.1, only non-pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
48627171|NCT04795323|DEVICE|TARA v3.2, both non-pharmacological and pharmacological self-management support|Technology-Assisted Respiratory Adherence (TARA) is a digital behaviour change intervention (DBCI) intended to support patients with chronic obstructive pulmonary disease (COPD) in managing their condition by adopting and sustaining clinically recommended (evidence-based) self-management behaviours. TARA was used independently at home by patients via an internet-enabled device and was a fully online digital system that offered guidance on the self-management of COPD, targeting non-pharmacological self-management support (self-monitoring, pursed lip breathing, pacing and energy conservation, and adherence to prescribed rescue medication in TARA version 3.1 (v3.1). The study comprised a screening (pre-TARA) period (which included a 2-week run-in period), a 12-week intervention period (TARA study period), and a follow-up period (post-TARA).
48627172|NCT01972984|DRUG|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
48627173|NCT01719302|DRUG|Gemcitabine|1500 mg/m\^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
48627174|NCT01719302|DRUG|Docetaxel|50 mg/m\^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
48627175|NCT01719302|DRUG|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
48627176|NCT05413460|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.
48627177|NCT05285449|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|30 mg CBD in the form of 300 mg of 10% CBD isolate
48627178|NCT05285449|DIETARY_SUPPLEMENT|Matching Placebo Cannabidiol (CBD) powder formulation|Matching Placebo
48627179|NCT05179512|DRUG|Tiotropium|Tiotropium dispensing claim is used as the reference group.
48627180|NCT05179512|DRUG|salmeterol-fluticasone|Salmeterol/Fluticasone dispensing claim is used as the exposure group.
48627181|NCT03791372|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
48627182|NCT03791372|BIOLOGICAL|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
47937538|NCT01960387|DRUG|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
48627183|NCT06231121|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
48627184|NCT03595748|BEHAVIORAL|Peer mentorship|Participants randomized to this arm of the study will speak with their dialysis peer mentor once a week about fluid intake and adherence to dialysis.
48627185|NCT02274428|DRUG|pneumostem|human umbilical cord blood derived mesenchymal stem cells
48627186|NCT03853200|DRUG|QMix Root Canal Irrigant|Endodontic irrigant recommended for final irrigation
48627187|NCT03853200|DRUG|17%EDTA+2%Chlorhexidine|two endodontic irrigants will be used in this group in a sequential manner
48627188|NCT03853200|OTHER|EDTA|17% EDTA irrigation solution
48627189|NCT04241523|DRUG|Lenvatinib 4 mg Oral|"Planned doses of 8 mg of lenvatinib per day for patients with body weight \<60 kg, and 12 mg for those with body weight ≥60 kg.~In case of treatment-related adverse effects, interruption or reduction is allowed."
48627190|NCT03687255|DRUG|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
47937539|NCT01960387|DRUG|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
47937540|NCT02744001|OTHER|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
47937541|NCT03333733|BEHAVIORAL|HENRY|"HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in \~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children."
48282999|NCT04635176|DRUG|Sham iPACK block with 20ml normal saline|Sham iPACK block with 20 ml Normal saline
48627191|NCT03687255|DRUG|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
48627192|NCT00704834|OTHER|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
48627193|NCT00498732|DEVICE|CPAP|CPAP treatment for 4 weeks
48283000|NCT00575679|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
48100515|NCT00295867|DRUG|Zoledronic Acid|Zoledronic acid is a new, highly potent, heterocyclic nitrogen-containing third generation bisphosphonate that has demonstrated 40- to 850- fold greater potency than pamidronate in preclinical models of bone resorption. The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway
48283004|NCT01209858|DRUG|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
48467579|NCT05361343|OTHER|1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement|"1. Nutrition: intermittent fasting;~2. Physical activity: medium-intensity or high-intensity physical activity;~3. Hypoxic training (at least three per visit to the center);~4. correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~5. Individual motivational counseling."
48467580|NCT06570278|DIAGNOSTIC_TEST|WGS coupled with MCM|Whole genome will be screened and analysis will focus on pathogenic and likely pathogenic variants. The list of variants of interest will be recorded until examination and discussion during the MCM. MCM will edit a final synthesis concerning the pathogenicity of identified variants.
48467581|NCT01652963|OTHER|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
48283005|NCT01209858|DRUG|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
48283006|NCT06108284|DEVICE|Intervention Arm (Biphasic cuirass ventilation)|Patients in this arm will be placed on Biphasic cuirass ventilation
48283007|NCT04764188|DRUG|Alectinib|Participants will receive alectinib in accordance with local clinical practice and local labeling.
48467582|NCT05157048|OTHER|Charcoal-filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
48467583|NCT05157048|OTHER|Non-charcoal filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
48627194|NCT01111292|DRUG|Inositol|Given PO
48627195|NCT01111292|OTHER|Placebo|Given PO
48627196|NCT04834115|DRUG|Ivermectin Tablets|Oral ivermectin at a one time dose
48627197|NCT04834115|OTHER|Placebo|Oral placebo at a one time dose
48627198|NCT05577104|PROCEDURE|Negative pressure wound therapy (NPWT)|For patients in the NPWT group, the wound bed preparation was facilitated by vacuum-assisted closure (VAC).
48627199|NCT05577104|PROCEDURE|conventional moist dressings|For patients in the control group, the wound bed preparation was facilitated by conventional dressing change method (with alginates ).
48627200|NCT00694161|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
47937542|NCT04597372|DRUG|Tamsulosin|Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.
48283008|NCT05167201|DEVICE|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
48283009|NCT02609399|DRUG|Oseltamivir|Oral
48283010|NCT02609399|DRUG|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
48283011|NCT04462237|PROCEDURE|Root coverage procedures|Treatment of multiple adjacent gingival recession using a coronally advanced flap
48283012|NCT04954677|OTHER|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
48627201|NCT04617327|RADIATION|Hypofractionation|"Shorter radiation therapy means that a higher dose will be given on a daily basis. The goal is to target microscopic disease and decrease the chances of local recurrence.~Organs at risk (OAR) will receive doses following the constraints from the Timmerman tables used for reference when using 5 or more fractions of EBRT.~Treatment will be delivered every 2nd day, for a maximum of 3 fractions per week. Daily pretreatment Image Guided Radiotherapy Images (IGRT) (Cone-Beam CT - CBCT) will be co-registered with the CT simulation dataset to adjust patient position before each treatment by matching the bone adjacent to the planned tumour volume (PTV). Treatment will be administered if there is \<3 mm in any dimension, or rotation is \<3 degrees. If the isocentre set-up exceeds 3 mm at any given treatment session, the treatment couch will be translated to restore its planned position."
48283013|NCT06584279|DIAGNOSTIC_TEST|Biopsy of the prostate and pathological diagnosis|Whether the index-lesion-contralateral systematic biopsy was performed
48283014|NCT04410302|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue, blood, saliva, and urine samples
48467584|NCT02966730|DRUG|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
48627202|NCT04825977|OTHER|RISK STRATIFICATION USING AIMS65 SCORE AND RDW|Risk Statification of patients presenting with upper gastrointestinal bleeding to the emergency department using AIMS65 score and Red cell Distribution Width.
48627203|NCT00363168|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
48627204|NCT00363168|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
48627205|NCT04828525|DRUG|Dexamethasone|adjuvant dexamethasone treatment
47937543|NCT04597372|DRUG|Placebo|Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.
48100516|NCT04878796|DIAGNOSTIC_TEST|Serum collection, adverse events collection|Measuring Abs variation at different timepoints compared to baseline. LIAISON SARS-Cov-2 TrimericS IgG and Elecsys anti-SARS-Cov-2 tests will be adopted. The level of Abs will be evaluated at baseline and 30(±7), 180(±7),365(±7)days after the 2nd dose of vaccine
48467585|NCT02742701|OTHER|diagnosis|Measurement of glycosuria
48467586|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
48467587|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
48467588|NCT02563249|OTHER|Parabolic flight|
48467589|NCT02563249|OTHER|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
48467590|NCT01745094|DRUG|mirabegron|oral
48467591|NCT01745094|DRUG|solifenacin|oral
48467592|NCT05805527|DIAGNOSTIC_TEST|mobile health application named KANOPEE|Volunteers will undergo two clinical interviews, an in person clinician-led interview and a fully-automated interview administered via mobile phone
48467593|NCT04810533|DRUG|[14C] SH-1028|Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
48467594|NCT06049576|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
48467595|NCT06049576|PROCEDURE|Bone Scan|Undergo bone scan
48467596|NCT06049576|PROCEDURE|Computed Tomography|Undergo CT
48467597|NCT06049576|BIOLOGICAL|Ipilimumab|Given IV
48467598|NCT06049576|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48627206|NCT04828525|DRUG|normal saline|placebo
48627207|NCT04631276|DRUG|TS-091|Subjects received single-dose of 0.1, 0.2, 0.4, 1, 5, 12.5 and 25 mg of TS-091 (tablets or drug substance powder)
48627208|NCT06304571|DRUG|HC006|Specified dose on specified days
48627209|NCT05842980|OTHER|sepsis|collect 5ml blood from patient
47937544|NCT01795378|BIOLOGICAL|donor natural killer cell infusion|"* Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~* The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~* For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~* The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
48100517|NCT03429855|OTHER|trunk training|Bobath based trunk training
48100518|NCT03429855|OTHER|physiotherapy|conventional physiotherapy
48100519|NCT04547348|DRUG|Denosumab Injection|Injections made subcutaneously per standard description
48283015|NCT00652587|PROCEDURE|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
48283016|NCT00652587|PROCEDURE|hepatectomy|hepatectomy alone
48467599|NCT06049576|DRUG|Myrciaria dubia Prebiotic Supplement|Given PO
48467600|NCT06049576|BIOLOGICAL|Nivolumab|Given IV
48467601|NCT01298609|DEVICE|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
48467602|NCT04937998|PROCEDURE|Autologous PRP injection|Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
48467603|NCT04937998|PROCEDURE|HA injection|Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
48467604|NCT03976934|DRUG|Tamsulosin|administration of tamsulosin tablets
48467605|NCT03976934|DRUG|Placebo oral tablet|sugar pills
48467606|NCT06043713|DRUG|Bendamustine|Receive IV
48467607|NCT06043713|PROCEDURE|Biopsy|Undergo tissue biopsy
48467608|NCT06043713|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48467609|NCT06043713|PROCEDURE|Computed Tomography|Undergo CT
48467610|NCT06043713|DRUG|Cyclophosphamide|Receive IV
48467611|NCT06043713|PROCEDURE|Echocardiography|Undergo ECHO
48467612|NCT06043713|DRUG|Fludarabine|Receive IV
48467613|NCT06043713|PROCEDURE|Leukapheresis|Undergo leukapheresis
48467614|NCT06043713|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48467615|NCT06043713|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48467616|NCT06043713|PROCEDURE|Positron Emission Tomography|Undergo PET
48627210|NCT02474706|DRUG|Cefoxitin|
48627211|NCT02474706|DRUG|imipenem|
48627212|NCT06181851|OTHER|Analysis of microbiome and metabolomics|Analysis of microbiome and metabolomics through the assessment of blood and semen parameters
48627213|NCT04261166|DRUG|A1|Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
48627214|NCT04261166|DRUG|A2|Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
48627215|NCT04261166|DRUG|A3|Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
48627216|NCT04261166|DRUG|A4|Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
48627217|NCT04261166|DRUG|A5|Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
48627218|NCT04261166|DRUG|B1|Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
48627219|NCT04261166|DRUG|B2|Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
48627220|NCT04261166|DRUG|B3|Sublingual tablets. CBD 40 mg (1 tablet)
48627221|NCT04261166|DRUG|B4|Sublingual tablets. CBD 40 mg (1 tablet)
48627222|NCT01051167|DRUG|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
48627223|NCT03228407|PROCEDURE|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
48627224|NCT03228407|DIAGNOSTIC_TEST|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
48627225|NCT03228407|DIAGNOSTIC_TEST|Mucosal impedance (MI)|MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
48627226|NCT03321032|DEVICE|Polymer-free amphilimus-eluting stents|Cre8 Evo coronary stent system (CID, Saluggia, Italy)
48627227|NCT03321032|DEVICE|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
48627228|NCT05599425|BEHAVIORAL|Enhanced Healthy Living Education|24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change
48627229|NCT05599425|BEHAVIORAL|Basic Healthy Living Education|24-session healthy living education program
48627230|NCT05983055|DRUG|Dexamethasone 20mg|Periarticular dexamethasone injection
48627231|NCT04094389|OTHER|Orthotic continuous wear group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
48627232|NCT04094389|OTHER|Orthotic wear during waking hours only group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
48627233|NCT04094389|OTHER|Orthotic wear only while sleeping group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated"
48627234|NCT03240380|BEHAVIORAL|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
48283017|NCT01639183|DEVICE|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
48283018|NCT01639183|OTHER|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
48100520|NCT02458534|OTHER|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
48100521|NCT02458534|OTHER|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
48283019|NCT04925115|OTHER|Brisk walking|"* Warm up and cool down (10 minutes before physical activity)~* Brisk walking ( 30 minutes each session for 5 days in a week)"
48283020|NCT04420793|OTHER|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
48467617|NCT06043713|BIOLOGICAL|T-cell Receptor-engineered T-cells|Receive FHA11KRASG12V-TCR IV
48100522|NCT02458534|OTHER|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
47937545|NCT00543855|DRUG|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
48283021|NCT01284192|DRUG|ASP3026|Tablet
48467618|NCT04193579|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
48467619|NCT04193579|BEHAVIORAL|Control Treatment|Standard of Care
48467620|NCT05983523|DRUG|PEP07|PEP07 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
48467621|NCT01726257|DEVICE|Nellix System|Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
48467622|NCT04906941|DEVICE|MRI|"SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.~\* Sense 2 \* 2: 9min33s"
48627235|NCT03240380|BEHAVIORAL|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
48627236|NCT03242733|OTHER|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
48627237|NCT06072313|OTHER|Monopolar electrical diathermy plus therapeutic exercise|The Experimental Group will undergo two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device and one session of therapeutic neck exercise per week.
48627238|NCT06072313|OTHER|Therapeutic Exercise|The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Participants will be asked to focus on their posture, joint positions and muscle tension in each exercise posture.
48627239|NCT00303043|PROCEDURE|Mixed venous saturation monitoring|Mixed venous saturation monitoring
48627240|NCT01084720|DRUG|V0034 CR|
48627241|NCT01872936|DRUG|Miravirsen|
48627242|NCT01872936|DRUG|Telaprevir|
48627243|NCT01872936|DRUG|Ribavirin|
48627244|NCT02473744|OTHER|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
48627245|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
48627246|NCT01058824|DRUG|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
48627247|NCT02487485|DRUG|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
47937546|NCT00543855|DRUG|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
48100523|NCT02923128|DRUG|Dexmedetomidine|Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
48467623|NCT05973331|OTHER|Pancreatic Cancer Risk Model (PRISM)|A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
48467624|NCT01780467|BEHAVIORAL|Role of dopamine|
48467625|NCT05124496|DEVICE|Screening Device|Screening device comparing Rt-PCR positive and negative results to HyperDetector results
48467626|NCT00915434|DRUG|JNJ-31001074|
48627248|NCT02487485|DRUG|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
48627249|NCT02487485|DRUG|Placebo|Placebo oral dose
48627250|NCT02909595|DEVICE|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter \[Extractor Pro RX \[M00547000, M00547010, or M00547020\]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
48627251|NCT02909595|DEVICE|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V \[FG-V435P or FG-V425PR\]; Olympus Corp., Shang hai,China).
48627252|NCT01290731|DRUG|TMC435|100-mg capsule once daily for 12 weeks
48627253|NCT01290731|DRUG|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
48627254|NCT01290731|DRUG|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
48627255|NCT00152958|DRUG|Pramipexole|
48100524|NCT02923128|DRUG|Sufentanyl|Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
48283022|NCT00730236|DRUG|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
48283023|NCT03473873|OTHER|Measures of muscle function|The participants will be assessed with various measures of muscle function at baseline and at follow up including: Isokinetic knee muscle strength, Isometric strength of trunk and lower extremity, single-leg hop for distance (SLHD), side hop, postural orientation errors (single leg-squat, stair descending, forward lunge, SLHD), hip and ankle range of motion, and muscular activation patterns.
48283024|NCT06349551|BIOLOGICAL|Patients of intensive care unit|Patients of intensive care unit having an arterial catheter undergoing arterial blood sampling
48100525|NCT02923128|DRUG|Saline|Saline is used to dilute other drugs
48100526|NCT03096184|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
48100527|NCT03096184|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
48100528|NCT05899335|DEVICE|SmartCP (mobile phone app)|As described
48467627|NCT04316325|DRUG|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
48467628|NCT03225352|DRUG|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
48467629|NCT03225352|DRUG|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
48627256|NCT03309059|DEVICE|water and soap|Use of soap and water in the area and subsequent diaper placement disposable.
48627257|NCT03309059|DEVICE|zinc oxide|Use of soap and water sanitation and application of zinc oxide.
48467630|NCT03225352|DRUG|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
48627258|NCT03309059|DEVICE|Non-Irritant Barrier Film|Use of soap and water hygiene and application of Non Irritant Barrier Film.
48627259|NCT05708222|DEVICE|MEB-001|The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.
48627260|NCT02676427|PROCEDURE|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
48627261|NCT02605239|DRUG|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
48627262|NCT01575990|BEHAVIORAL|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.~1. Educational component~2. Values clarification exercise~3. Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider."
48627263|NCT01575990|BEHAVIORAL|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
48100529|NCT00329979|BEHAVIORAL|vascular access site|Randomized vascular access site
48100530|NCT03284749|OTHER|Copper impregnated wound dressing|Copper impregnated wound dressing
48100531|NCT03284749|OTHER|Normal wound dressing|Normal wound dressing
48100532|NCT03284749|OTHER|Copper impregnated maternity pads|Copper impregnated maternity pads
48100533|NCT03284749|OTHER|Normal maternity pads|Normal maternity pads
48100534|NCT02426320|OTHER|Sedation Interruption Protocol|
48100535|NCT02426320|OTHER|Standard Sedation Protocol|
48100536|NCT03545984|OTHER|Simulation-based learning|Simulation-based teaching involves using done on a mannequin to simulate actual conditions
48467631|NCT03225352|DRUG|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
48467632|NCT04370444|DEVICE|Phallus Length Reducer|Phallus Length Reducer
48467633|NCT04370444|OTHER|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
48467634|NCT05070962|OTHER|clinical population|or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.
48467635|NCT05395767|PROCEDURE|Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor|The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
48100537|NCT03545984|OTHER|interactive problem based learning|Standard teaching (problem based learning discussion) during cardiac/vascular rotation
48100538|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
48100539|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
48100540|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
48467636|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
48467637|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
48627264|NCT04094480|DEVICE|polymeric non absorbable clips|a method to secure appendicular stump
48627265|NCT04094480|OTHER|endoloops|a method to secure appendicular stump
48627266|NCT06494163|BEHAVIORAL|Exercise|The MICT and HIIT intervention groups will complete supervised virtual exercise sessions for 12 weeks using Zoom care or Microsoft Teams as a backup resource. The appointments will be scheduled and conducted 2 days per week. Initially, exercise intensity will be determined from participants' peak HR achieved during a baseline CPET.
48627267|NCT02957825|DEVICE|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
48283025|NCT05299892|DEVICE|Phonak Audeo P or Naida P hearing aid|"Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong"
48467638|NCT05306600|DIAGNOSTIC_TEST|whole exome and whole genome sequencing analysis|"Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer~Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer"
48467639|NCT01460030|DRUG|Cinacalcet HCl|Oral administration
48467640|NCT00880334|DRUG|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
48467641|NCT00880334|DRUG|vandetanib|taken orally once a day, every day
48467642|NCT00880334|DRUG|Placebo|Taken orally once a day every day
48467643|NCT00820599|DEVICE|Sapien XT™ transcatheter heart valve and delivery system|
48467644|NCT04815460|BEHAVIORAL|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
48467645|NCT04815460|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
48467646|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (10ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
48467647|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
47937547|NCT00543855|DRUG|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
48467648|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)|2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
48467649|NCT01872715|DRUG|Oracea|
48467650|NCT00050076|DRUG|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
48467651|NCT00050076|DRUG|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
48467652|NCT00050076|DRUG|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
47937548|NCT00543855|DRUG|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
47937549|NCT06260527|DRUG|ARTS-011|Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
47937550|NCT06260527|DRUG|Placebo|Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days.
47937551|NCT00988325|DRUG|Tamiflu|oral repeating dose
47937552|NCT02982785|BEHAVIORAL|Standard post-operative rehabilitation|
48100541|NCT00643708|PROCEDURE|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
48100542|NCT02899585|OTHER|Questionnaires|
48467653|NCT00050076|DRUG|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
48467654|NCT02051660|BEHAVIORAL|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
48467655|NCT02051660|BEHAVIORAL|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
48467656|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
48467657|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
48467658|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
48467659|NCT03389763|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
48467660|NCT02104258|OTHER|Physiotherapy ASPETAR|Standardized physiotherapy protocol
48467661|NCT02104258|OTHER|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
48467662|NCT01386034|DRUG|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
48467663|NCT03303417|DIAGNOSTIC_TEST|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
47937553|NCT02992561|BEHAVIORAL|FORNET (adapted version)|
47937554|NCT00333892|PROCEDURE|leukapheresis|pack of cells as per protocol
48467664|NCT03303417|OTHER|Kiwifruit|Kiwifruit
48467665|NCT03303417|OTHER|calorie-matched sugar drink|calorie-matched sugar drink
47937555|NCT00848575|DEVICE|Flexible Endoscope|
47937556|NCT03961074|OTHER|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
48100543|NCT02899585|OTHER|Score|
48467666|NCT01122316|DRUG|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
48467667|NCT05174754|BEHAVIORAL|Physician-prescribed Exercise Programme|A 20-week structured exercise programme derived and supervised by a Sports Medicine Physician following the FITT Principles
48467668|NCT05174754|DRUG|Best Medical Therapy|Best medical therapy with biologic agent or small-molecule therapy
48467669|NCT06504121|DEVICE|Septal Occluder Device|Transcatheter PFO closure with any commercially available septal occluder device
48467670|NCT00201136|BEHAVIORAL|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
48467671|NCT00201136|BEHAVIORAL|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
48467672|NCT05690035|DRUG|Tislelizumab & Fruquintinib|combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
48467673|NCT03941795|BIOLOGICAL|JS001(Toripalimab Injection)|"Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years."
48467674|NCT03941795|DRUG|Axitinib 1 MG [Inlyta]|Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death
48467675|NCT03941795|OTHER|JS001 and Axitinib|"Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years"
48467676|NCT01535911|OTHER|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
48467677|NCT06016153|OTHER|Software based feedback|Feedback is given by the data of a software (InnoMed CardioAid-1 Trainer AED, Innomed Inc., Budapest, Hungary).
48467678|NCT06016153|OTHER|Instructor feedback|Feedback is given by the opinion and observation of an experienced instructor.
48627268|NCT02188732|BEHAVIORAL|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
48627269|NCT02188732|BEHAVIORAL|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
48627270|NCT02188732|BEHAVIORAL|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
48467679|NCT03588260|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
48467680|NCT03737916|OTHER|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
48467681|NCT03737916|OTHER|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
48627271|NCT06174701|BEHAVIORAL|Problem Solving Therapy (PST)|PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
48627272|NCT05194488|DEVICE|Low level laser therapy|Patients will receive low-level laser therapy on the temporomandibular joint disc
48627273|NCT05194488|DRUG|Botulinum toxin type A|Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
48627274|NCT05194488|DEVICE|Anterior repositioning appliance|Patients will receive hard maxillary anterior repositioning appliance.
48627275|NCT03250195|DIAGNOSTIC_TEST|PET/MRI|PET/MRI scan
48627276|NCT05482243|DIETARY_SUPPLEMENT|Whey protein|Throughout 1 week (either in week 1 or 2), all participants will perform a 1-week resistance type exercise-training program, consisting of two different exercises. Leg press and leg extension exercise will be performed on regular weightlifting machines (Technogym, Rotterdam) at 3 days during the 1-week period (e.g. Monday-Wednesday-Friday). During the resistance exercise training protocol, participants will continue their habitual diet as usual. However, patients with CKD will be provided with a protein supplement following the exercise sessions.
48627277|NCT06512233|DRUG|LMW Heparin 5000 U/ML-Aspirin 75 MG|Arm 1
48627278|NCT06512233|DRUG|LMW Heparin 5000 U/ML|Arm 2
47937557|NCT04204785|BEHAVIORAL|Noise Reduction Education|OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
48283026|NCT04554368|PROCEDURE|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
48283027|NCT05772364|OTHER|Loading of low-calcium water first, then high-calcium water|All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium
48283028|NCT04915521|OTHER|erector spina plane block (ESPB) group|"An experienced anesthesiologist performed ESPB in all patients in sitting position bilaterally.~A linear ultrasound probe (6-13 MHz) was used for ultrasound guidance. Injection was done using in-plane technique. A 22G block needle (100mm, B-Braun, Germany) was inserted 3- cm lateral to the T9 spinous process and advanced in cranio-caudal direction. To separate erector spina muscle from the transverse process, initially 1-2 ml saline was injected; then 20 ml 0.5% bupivacaine and 5 ml 0.2% lidocaine were injected following separation. Diffusion of the drugs in erector spina plane at cranio-caudal line was ensured. No analgesic or sedative was used during the procedure."
48283029|NCT04720157|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
48283030|NCT04720157|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
48100544|NCT06062706|PROCEDURE|Donor hepatectomy|"Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach."
48283031|NCT04720157|DRUG|ARDT|Administered orally on a continuous basis as per package insert and guideline
48283032|NCT04720157|DRUG|ADT|ADT are administered as per physician order
48283033|NCT05661955|DRUG|BGB-A445|administered intravenously
48283034|NCT05661955|DRUG|Tislelizumab|administered intravenously
48467682|NCT03318757|DRUG|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
48467683|NCT03318757|DRUG|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
48467684|NCT02090231|DEVICE|rTMS, Magstim Rapid2|5 Hz rTMS
48283035|NCT00577590|DRUG|Metformin|Metformin is taken alone
48283036|NCT00577590|DRUG|Rosiglitazone|Rosiglitizone is taken with Metformin
48283037|NCT00577590|DRUG|Lovaza|Lovaza is taken with Metformin
48283038|NCT00006122|DRUG|cytarabine|
48283039|NCT00006122|DRUG|etoposide|
48283040|NCT00006122|DRUG|gemtuzumab ozogamicin|
48283041|NCT00006122|DRUG|idarubicin|
48283042|NCT00006122|DRUG|mitoxantrone hydrochloride|
48283043|NCT04646395|DRUG|Tafasitamab|200 mg powder for reconstitution with 5 ml water for injection
48283044|NCT04646395|DRUG|Acalabrutinib|100 mg hard gelatin capsules
48283045|NCT02624700|DRUG|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
48283046|NCT02624700|DRUG|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
48467685|NCT04055233|DRUG|Polihexanide; Serasept|"Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
48283047|NCT02624700|DRUG|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
48283048|NCT02624700|DRUG|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
48283049|NCT01144754|DRUG|Rituximab|Calculated per patient
48283050|NCT02456220|DEVICE|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
48283051|NCT01563601|DRUG|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
48283052|NCT01563601|DRUG|Carboplatin and Etoposide|"Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
48283053|NCT06657742|OTHER|SCIM-SR|SCIM-SR was a self-reported scale that evaluated the independence of patients.
48283054|NCT06197126|RADIATION|Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .|The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
48283055|NCT01870492|DRUG|Activase|Patients treated with Activase
48283056|NCT01870492|DEVICE|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
48283057|NCT03946267|DEVICE|Inverted inner limiting membrane flap technique for large full thickness macular holes|The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
48283058|NCT06498037|DRUG|Fentanyl|Administration of subcutaneously administered fentanyl loading boluses
47937558|NCT05440071|DEVICE|JX- XFINE lead|Pacemaker subjects implanted with one JX - XFINE passive pacing lead
47937559|NCT03686644|PROCEDURE|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
48100545|NCT05222750|OTHER|Pre-COVID-19|Pre-COVID-19
48283059|NCT04978623|OTHER|high frequency ultrasound|high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
48283060|NCT03437187|PROCEDURE|Cholecystectomy|Laparoscopic technique
48283061|NCT04538404|PROCEDURE|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
48283062|NCT01870635|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
48283063|NCT01870635|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
48467686|NCT04055233|DRUG|NaCl; saline|"Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
48283064|NCT00765765|DRUG|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
48283065|NCT00765765|DRUG|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
48283066|NCT04258618|BEHAVIORAL|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
48467687|NCT02128009|OTHER|osteoporosis|
48467688|NCT00497679|DRUG|AZD1152|7-day continuous intravenous infusion
48100546|NCT05222750|OTHER|COVID-19|COVID-19
48100547|NCT05222750|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out
48100548|NCT04460573|DEVICE|Boot|Smart boot in one of three configurations provided to participants
48283067|NCT04258618|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
48283068|NCT03723096|DRUG|CC-4047|CC-4047 will be administered orally
48283069|NCT05784090|OTHER|blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases|"Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation."
48283070|NCT04722718|DRUG|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
48467689|NCT01269645|BEHAVIORAL|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
48467690|NCT05967936|DRUG|Bupivacaine Injection|evaluation of pain by using two different types of local anesthesia
48467691|NCT01426087|DRUG|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
48627279|NCT05349500|BEHAVIORAL|OA CARE Intervention|"Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals."
48627280|NCT05349500|BEHAVIORAL|Usual Care control group|Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
48627281|NCT05775705|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
48467692|NCT01426087|PROCEDURE|endoscopic therapy|gastroscope plus EIS/EVL/HI
48467693|NCT03256994|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
48627282|NCT02646059|OTHER|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
48100549|NCT04423484|OTHER|Data collection|Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
48100550|NCT02438800|BEHAVIORAL|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
48467694|NCT03256994|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT-FR will incorporate a quality-of-life questionnaire. CIRT-FR will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
48100551|NCT00606866|DRUG|placebo|Placebo for four weeks
48100552|NCT00606866|DRUG|Sorafenib|Sorafenib 200 mg twice daily
48467695|NCT03269955|DRUG|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
48467696|NCT04457115|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level
48467697|NCT04457115|PROCEDURE|Erector spinae plane Block|Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
48467698|NCT00002976|DRUG|conjugated estrogens|
48627283|NCT02646059|OTHER|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
48627284|NCT04088955|OTHER|DigiMeds|Digitized Capecitabine
48283071|NCT04741464|DRUG|Tinzaparin|"Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT."
48100553|NCT00606866|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
48283072|NCT03834948|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
48627285|NCT03209960|DIAGNOSTIC_TEST|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
48627286|NCT03209960|OTHER|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
47937560|NCT03686644|PROCEDURE|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
47937561|NCT00434239|DRUG|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
47937562|NCT04211805|DRUG|Tenofovir Alafenamide 25 MG for arm (A)|Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.
47937563|NCT04211805|DRUG|Tenofovir Disoproxil Fumarate 300mg for arm (B)|Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
47937564|NCT01747018|BIOLOGICAL|Platelet-rich Plasma|
47937565|NCT01049477|OTHER|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
47937566|NCT01049477|OTHER|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
47937567|NCT04173364|DRUG|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
47937568|NCT04173364|DRUG|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
47937569|NCT00125684|DRUG|morphine|
48100554|NCT03994146|DRUG|Remifentanil|"Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
48283073|NCT03834948|DRUG|AO-176 + Paclitaxel|Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel
48283074|NCT03834948|DRUG|AO-176 + Pembrolizumab|Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
48283075|NCT01787071|OTHER|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
48283076|NCT02424149|DRUG|Phenazopyridine|
48283077|NCT04225598|DRUG|CAM2038|Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.
48467699|NCT04402606|OTHER|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
48467700|NCT03744286|DEVICE|Slip Training|-On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
48467701|NCT03208517|OTHER|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
48467702|NCT05505825|DRUG|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
48467703|NCT00032240|DEVICE|Shoe Insert|
48467704|NCT04677686|BEHAVIORAL|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
48467705|NCT03117205|OTHER|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
48467706|NCT03117205|OTHER|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
48467707|NCT01861249|DRUG|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
48467708|NCT03578809|BIOLOGICAL|MEDI6012|MEDI6012
48467709|NCT03578809|OTHER|Placebo|Placebo
48467710|NCT04609397|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
48627287|NCT04899037|OTHER|No intervention|This is an observational study of participants that either choose or not choose to utilize an OID. This is not an intervention prescribed study, however, participants may choose uptake of standard of care intervention and obtain and utilize an OID. An OID is an FDA-approved device commonly recommended to patients with conductive, mixed, or singled-sided hearing loss. There is no experimental intervention evaluated in this study.
48627288|NCT00502437|DRUG|GRANISETRON|
48627289|NCT03172000|DIAGNOSTIC_TEST|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
48627290|NCT00141375|DRUG|Pregabalin|
47937570|NCT01631955|DRUG|Ciprobay|Ciprobay (250mg, bid, oral)
48100555|NCT03994146|DRUG|Sodium Chloride 9mg/mL|"Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
47937571|NCT04449471|DRUG|Naproxen tablet|For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
47937572|NCT02755688|PROCEDURE|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
48467711|NCT04609397|DRUG|Hemay005|Hemay005 tables 45mg bid p.o
48467712|NCT04609397|OTHER|Placebo|placebo to Hemay005 tables bid p.o
48467713|NCT04972851|BEHAVIORAL|Self-Determined Learning Model of Instruction (SDLMI)|"SDLMI is a teaching model that enables providers to teach students to:~* make choices and decisions about setting a goal~* develop action plans for academic or other goals~* self-monitor and self-evaluate progress toward goal attainment~* adjust the goal or plan"
48467714|NCT05587023|PROCEDURE|stellate ganglion block|The experimental group was given 6ml ropivacaine for stellate ganglion block. In the control group, 6ml saline was used for stellate ganglion block.
48467715|NCT02870439|OTHER|Blood drawn|
48467716|NCT03765190|COMBINATION_PRODUCT|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
48467717|NCT00948909|DRUG|Placebo|Placebo intervention
48467718|NCT00948909|DRUG|ABT-126|Experimental intervention
48467719|NCT00948909|DRUG|donepezil|Active comparator intervention
48467720|NCT02922582|DRUG|DepoTXA|
48467721|NCT02922582|DRUG|Tranexamic Acid|
48467722|NCT05546398|DRUG|Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab|No study drug was administered during this study.
48467723|NCT05546398|OTHER|No study drug|No study drug was administered during this study.
48627291|NCT01124474|OTHER|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.
48627292|NCT03066076|DRUG|Antithyroid Drug|Antithyroid drug
48627293|NCT03066076|PROCEDURE|Total thyroidectomy|Operation
48627294|NCT00888849|PROCEDURE|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
48627295|NCT00888849|PROCEDURE|Suturing|Suturing
48627296|NCT00002246|DRUG|Stavudine|
48627297|NCT06505148|DRUG|Acetaminophen|administered alternatively with other drug
48627298|NCT06505148|DRUG|Ibuprofen|administered alternatively with other drug
48627299|NCT05702151|PROCEDURE|ESP Block|After induction of anesthesia in the operating room, the patient is positioned in lateral decubitus. Under strict aseptic conditions, and guided by ultrasound, an Erector Spinae Plane block is performed injecting ropivacaine 0.2% 20ml, and a catheter is placed. Ropivacaine 0.2% infusion at a 10ml/h rate is started during the surgery.
48627300|NCT05702151|DRUG|Morphine injection|Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
48627301|NCT00143520|DRUG|Rivoglitazone|
48627302|NCT00143520|DRUG|Pioglitazone|
48627303|NCT00143520|DRUG|Placebo|
48283078|NCT04225598|DRUG|Buprenorphine Sublingual Product|"COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD."
48467724|NCT01478516|PROCEDURE|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
48467725|NCT00110851|DRUG|rosiglitazone|
48627304|NCT01675700|DRUG|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
48627305|NCT05015023|BEHAVIORAL|Behavioral intervention|A cluster-randomized controlled trial will be conducted.
48467726|NCT00110851|DRUG|metformin|
48627306|NCT00766103|OTHER|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
48467727|NCT00110851|DRUG|PN2034|
48627307|NCT00471042|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
48627308|NCT04230239|DRUG|CPX-351|"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"
48627309|NCT03006120|PROCEDURE|Retroperitoneal hematoma due to cardiac catheterization|
48467728|NCT05337644|DRUG|Indocyanine green solution|"5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration."
48467729|NCT05385900|DRUG|Penpulimab combination with anlotinib and chemotherapy|Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
48627310|NCT04890990|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature two underage professionals (ages 16) acting as a simulated patient. All videos will focus on an empowered presenter with depression sharing her personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted her in overcoming symptoms of the illness. The actors will include a Black girl and a white girl.
48627311|NCT02034591|DRUG|Apixaban|
48627312|NCT02034591|DIETARY_SUPPLEMENT|Boost Plus|
48283079|NCT02490657|DRUG|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
48283080|NCT02490657|DRUG|normal saline (Saline 0.9%)|
48283081|NCT02807077|DRUG|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
48283082|NCT00193505|DRUG|Ifosfamide|
48283083|NCT00193505|DRUG|Carboplatin|
48283084|NCT00193505|DRUG|Etoposide|
48283085|NCT00193505|DRUG|Rituximab|
48283086|NCT00193505|DRUG|90Y Zevalin|
48283087|NCT05928143|PROCEDURE|Traditional corticotomy|A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
48283088|NCT05928143|PROCEDURE|Flapless corticotomy|Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
48283089|NCT05621668|DRUG|Cyclophosphamide|Given by IV (vein)
48283090|NCT05621668|DRUG|attIL2-T cells|Given by IV (vein)
48283091|NCT06604325|DRUG|Tranexamic acid injection|All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
48617845|NCT01171599|BEHAVIORAL|Fit4Life|As previously described, the purpose of this study is to develop a web and text message based weight loss intervention for childhood acute lymphoblastic leukemia survivors (ALL) survivor. The web and text message based intervention that is being developed will be evaluated in a separate ACS (American Cancer Society) funded trial randomized control trial. The web and text message based intervention (there are other intervention features that do not relate to the web \& text based platforms that were developed as part of this NIH funded study) is a 16-week program that includes:
48617846|NCT04167813|DRUG|Ondansetron 8mg or matched placebo tablets|"Participants will take one tablet daily in weeks 1 and 2, two tablets daily in weeks 3 and 4 and 3 tablets daily in weeks 5 and 6.~Dose escalation will be guided by tolerability, through telephone safety monitoring prior to each dose increase"
48283092|NCT06604325|DRUG|Placebo|All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
48283093|NCT04287153|DEVICE|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
48283094|NCT04644900|OTHER|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
48283095|NCT04644900|OTHER|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
48283096|NCT06221930|BEHAVIORAL|attexis|Participants will receive access to the digital health intervention attexis in addition to TAU.
48283097|NCT05992077|DRUG|Sofosbuvir/Daclatasvir|Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
48283098|NCT04140487|DRUG|Azacitidine|Given IV
48283099|NCT04140487|DRUG|Gilteritinib|Given PO
48283100|NCT04140487|DRUG|Venetoclax|Given PO
48283101|NCT04704180|BEHAVIORAL|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
48283102|NCT04026789|OTHER|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
48283103|NCT04026789|OTHER|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
48283104|NCT02999503|BEHAVIORAL|Nutritional education|Nutritional education trough a personal online nutritional consultant
48283105|NCT05041738|PROCEDURE|Intraoral Cryotherapy|small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
48283106|NCT05041738|PROCEDURE|Intracanal Cryotherapy|Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
48283107|NCT03547050|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
48467730|NCT02633241|DRUG|Dexmedetomidine bolus and high infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
48467731|NCT02633241|DRUG|Dexmedetomidine bolus and low infusion-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 0.5mcg/kg/hour. At the 5 minute point, propofol will be given (2-3mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
48627313|NCT06248203|BEHAVIORAL|Tealeaf-Mansik Swasta (Tealeaf) as adapted for Adolescents|"The investigators will test Tealeaf (Teachers Leading the Frontlines - Mansik Swastha \[Mental Health in Nepali\]) as adapted for adolescents. Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Created in Darjeeling, Tealeaf centers on training and supervising teachers to deliver education as mental health therapy (Ed-MH) to children (age 5-12). Ed-MH is the investigators' novel, task-shifting, therapy modality that minimizes the time teachers need to deliver care by fitting it into their work. In Ed-MH, teachers use evidence-based therapeutic techniques adapted for use in their existing interactions with students in need (e.g., while teaching) and streamlined for care for any diagnosis (transdiagnostic). Tealeaf-A's adaptation (inclusive of Ed-MH) is supported by a Doris Duke Charitable Foundation (DDCF), Fund to Retain Clinical Scientists (FRCS), Caregivers at Carolina COVID award."
48627314|NCT06248203|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment.
48627315|NCT05348330|PROCEDURE|Thoracic intervertebral foramen block|Under ultrasound guidance the continuous thoracic intervertebral foramen block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
48627316|NCT05348330|PROCEDURE|Mid-point to pleura transverse process block|Under ultrasound guidance the continuous mid-point to pleura transverse process block, will be provided to achieve analgesia in polytraumatic patients with rib fractures. A set for continuous peripheral nerve block will be used. The infusion rate of analgesic solution (levobupivacaine 0.25% combined with dexamethasone 16 mg) will be titrated to patient perceived pain. The block will be performed close, by considering the level of rib fractures.
48627317|NCT01068912|DRUG|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
48627318|NCT01068912|DRUG|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
48627319|NCT01068912|DRUG|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
48627320|NCT03915899|BEHAVIORAL|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
48100556|NCT03517579|DEVICE|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~* A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~* A cable that connects the collar unit to the Control Unit~* A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
48100557|NCT01649635|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
48100558|NCT01649635|DRUG|Prednisone|Pharmaceutical form: tablet Route of administration: oral
48283108|NCT03547050|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
48467732|NCT02633241|DRUG|Dexmedetomidine bolus only - Propofol|First, the investigators will begin by administering dexmedetomidine 1mcg/kg over 5 minutes. When this is completed, they will administer propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion which can also be titrated up or down to a maximum of 300mcg/kg/min to keep the blood pressure and heart rate within 30% of baseline levels.
48617847|NCT02348333|DRUG|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
48627321|NCT05664594|DEVICE|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
48283109|NCT04754087|DEVICE|Vivacit-E and Longevity (HXLPE) Liners|This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
48283110|NCT02940964|BEHAVIORAL|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
48283111|NCT02940964|BEHAVIORAL|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
48283112|NCT04653662|DEVICE|Earol|Treated with Earol on both ears and subsequent removal after 6 days of application
48283113|NCT01597869|DEVICE|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
48283114|NCT01564979|DRUG|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
48283115|NCT01564979|DRUG|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
48283116|NCT00278824|DRUG|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
48283117|NCT00278824|DRUG|Placebo Patch|Placebo patch applied every 3 days for 15 days
48283118|NCT02145130|BIOLOGICAL|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
48283119|NCT02145130|BIOLOGICAL|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
48283120|NCT01962142|OTHER|Assessment of activity capacities|
48283121|NCT01449825|DRUG|Pazopanib use|Treatment with pazopanib
48627322|NCT04937530|DRUG|RT001|RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
48627323|NCT04937530|DRUG|Placebo|Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
48627324|NCT02506036|OTHER|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
48627325|NCT01506076|DRUG|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
48627326|NCT01209468|DEVICE|monobloc oral appliance|one piece oral appliance
48100559|NCT01649635|DRUG|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
48283122|NCT01449825|DRUG|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
48283123|NCT00497224|DRUG|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
48283124|NCT01726361|BEHAVIORAL|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
48283125|NCT01726361|BEHAVIORAL|Treatment as usual|Other kinds of out of home placement
48283126|NCT06188832|DIETARY_SUPPLEMENT|glucomannan, inulin, and psyllium|the subjects recieved fiber supplement containing glucomannan, inulin, and psyllium
48100560|NCT01649635|DRUG|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
48100561|NCT00271258|DRUG|SODIUM DIVALPROATE|
48100562|NCT00455754|DRUG|Esomeprazole|
48100563|NCT03052946|PROCEDURE|Bulking agent|Filling bulking agent in the anal canal
48100564|NCT03052946|PROCEDURE|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
48283127|NCT06188832|OTHER|placebo|the subjects recieved placebo
48283128|NCT05391893|DRUG|Oral|Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
48283129|NCT05391893|DRUG|Intravenous drug|these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
48283130|NCT01810809|PROCEDURE|articular lavage with saline injection|Patients will receive articular lavage with saline injection
48283131|NCT01810809|DRUG|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
48283132|NCT01810809|DRUG|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
48283133|NCT01810809|DRUG|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
48283134|NCT02513446|DRUG|BI 1026706|Single dose of BI 1026706 on Day 1
48283135|NCT02513446|DRUG|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
48283136|NCT04802837|DRUG|Ridinilazole|Ridinilazole 200mg dosed BID for 10 days.
48283137|NCT04802837|DRUG|Vancomycin|Vancomycin 125mg dosed QID for 10 days.
48283138|NCT05126108|PROCEDURE|Thyroid and parathyroid surgery|Thyroid and parathyroid surgery
48283139|NCT05126108|OTHER|Recurrent nerves monitoring|Recurrent nerves monitoring
48283140|NCT04902287|BEHAVIORAL|Training Intervention for the Engagement of Families (TIES)|This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
48283141|NCT03445676|BEHAVIORAL|ABHR directly on gloves|HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
48627327|NCT01209468|DEVICE|twinblock oral appliance|two-piece oral appliance
48283142|NCT04307667|BIOLOGICAL|Whole lung antigen challenge (WLAC)|Whole lung antigen challenge with cat hair, house dust mite, or short ragweed allergen extracts.
48283143|NCT04307667|RADIATION|[18F]FEPPA|\[18F\]FEPPA is a radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.
48283144|NCT04880317|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|All enrolled patients will undergo a contrast-enhanced CMR examination for the assessment of extracellular volume
48283145|NCT04880317|DIAGNOSTIC_TEST|Additional CT acquisition|All enrolled patients will undergo an additional CT scan at 5 minutes post-contrast injection to evaluate myocardial relative enhancement
48283146|NCT04880317|DIAGNOSTIC_TEST|Blood tests|Patients will undergo blood tests to review hematocrit, Sars-CoV-2 antibody status and cardiac fibrosis biomarkers
48283147|NCT02065778|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
48283148|NCT06006078|DEVICE|Endoscopic Patient Facemask|A commonly used endoscopic patient facemask that is normally used for oxygen delivery during endoscopy will be tested in this trial as a potential intervention for decreasing particle aerosolization
48283149|NCT01937312|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
48283150|NCT01937312|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
48283151|NCT01937312|DRUG|Prostaglandin analogue|
48283152|NCT03885921|DRUG|Ezetimibe|oral tablet
48627328|NCT05791331|OTHER|Surfactant administration following lung mechanics assessment in addition to clinical assessment|Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O\*s /L
48627329|NCT05791331|OTHER|Surfactant administration following clinical assessment|Surfactant is administered following oxygenation-based criteria
48627330|NCT02478671|DEVICE|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
48627331|NCT03933033|DEVICE|Fractional Erbium Yağ Laser|Multiple sessions of Fractional Erbium Yağ Laser
48283153|NCT03885921|DRUG|Atorvastatin|oral tablet
48283154|NCT03885921|DRUG|Simvastatin|oral tablet
48283155|NCT01838057|DEVICE|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
48283156|NCT01838057|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
48283157|NCT05090241|DIAGNOSTIC_TEST|Instrumental measurement of balance and gait|The balance measurement was performed on a force platform. The walk test was carried out using sensors to analyze and retrieve data from the participant's walk (gait speed, step length, duration of the double support phase).
48283158|NCT02786641|DRUG|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
48283159|NCT02786641|DRUG|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
48283160|NCT02786641|DRUG|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
48283161|NCT02786641|RADIATION|IMRT|IMRT for all patients
48283162|NCT02786641|DRUG|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
48283163|NCT01965925|DRUG|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
48283164|NCT01965925|DRUG|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
48283165|NCT00351715|DRUG|Sublingual Methadone|
48283166|NCT00000312|DRUG|M-CPP|
48283167|NCT00824564|DRUG|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
48283168|NCT00824564|PROCEDURE|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
48283169|NCT05071339|DRUG|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
48617848|NCT02348333|DRUG|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
48617849|NCT03286790|OTHER|Data collection on pneumonia events|
48617850|NCT00846599|OTHER|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
48627332|NCT03933033|PROCEDURE|Platelet Rich Plasma|Multiple injections of Platelet Rich Plasma
48627333|NCT04373941|DRUG|Filgrastim|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
48627334|NCT02663167|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
48627335|NCT02819388|BEHAVIORAL|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
48627336|NCT02716285|DRUG|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
48283170|NCT06457126|BEHAVIORAL|Attention Training Technique|"Phase 1: Non-concurrent multiple baseline design A-B design where the ATT (B) is introduced sequentially across participants. ATT and baseline (A) will be alternated on a weekly basis.~Phase 2: Alternating treatment design where an active (B) and passive (C) version of the ATT are rapidly and frequently alternative within the same participant on a weekly basis (e.g., A-B-A-C-A or A-C-A-B-A)."
48467733|NCT03133728|DIAGNOSTIC_TEST|Alere Q Testing|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
48467734|NCT01326351|PROCEDURE|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
48467735|NCT01326351|PROCEDURE|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
48467736|NCT01326351|BEHAVIORAL|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
48617851|NCT00846599|OTHER|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
48617852|NCT02911116|DRUG|Ustekinumab|Subcutaneous Injection
47937573|NCT02755688|PROCEDURE|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
48100565|NCT01749761|OTHER|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
48100566|NCT01749761|OTHER|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
48100567|NCT00062062|DRUG|carboplatin|
48100568|NCT00062062|DRUG|gefitinib|
48100569|NCT00062062|DRUG|paclitaxel|
48100570|NCT00208104|BEHAVIORAL|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
48100571|NCT03997006|DRUG|IV Aminophylline|IV Aminophylline (100 mg/8h)
48100572|NCT03997006|DRUG|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/8h
48100573|NCT06409195|DRUG|SM-020 1% Gel|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to at least 1 and up to 5 Target Lesions (TLs) for 28 days.
48100574|NCT00533234|DEVICE|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
48100575|NCT06631157|DEVICE|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
48100577|NCT01450878|DRUG|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
48100578|NCT05169255|DRUG|Antibiotic administration|Individuals received either azithromycin or amoxicillin for 3 or 7 days
48100579|NCT05737784|DRUG|PRAX-222 - Initial Dose|PRAX-222
48100580|NCT05737784|DRUG|PRAX-222 - Initial Ascending Doses|Ascending doses of PRAX-222
48100581|NCT05737784|DRUG|PRAX-222 - Optional Ascending Doses|Escalation of PRAX-222 dose(s)
48100582|NCT05737784|DRUG|PRAX-222 - Fixed Doses|Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
48100583|NCT05737784|PROCEDURE|Placebo|Placebo procedure
48100584|NCT05590312|OTHER|general anesthesia|All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
48283171|NCT04459962|DIAGNOSTIC_TEST|Breath Test & Cheek Swab|Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
48283172|NCT00784407|DEVICE|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
48283173|NCT04636918|DRUG|Cyclosporine Ophthalmic|Prospective interventional study (single arm)
48283174|NCT01079767|DRUG|temsirolimus|
48283175|NCT05635565|OTHER|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
48283176|NCT05635565|OTHER|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
48627337|NCT02716285|DRUG|Placebo|Placebo capsule, containing microcrystalline cellulose
48627338|NCT02716285|DRUG|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
48627339|NCT01149538|DRUG|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
48627340|NCT01149538|DIETARY_SUPPLEMENT|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
48627341|NCT05371704|DIETARY_SUPPLEMENT|Multivitamin Supplementation|Participants will supplement daily with an over-the-counter oral multivitamin pill
48627342|NCT05371704|OTHER|Dietary Replication|Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial
48627343|NCT00152230|DRUG|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
48627344|NCT00152230|PROCEDURE|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
48283177|NCT00843986|DRUG|conivaptan|Premix bag
48627345|NCT02534480|DRUG|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
48627346|NCT02156661|DRUG|Oxytocin|
48627347|NCT00442689|DRUG|flutamide|250 mg twice daily
48627348|NCT00442689|DRUG|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
48627349|NCT00442689|OTHER|placebo|
48627350|NCT05697692|DRUG|Heparin sodium|Lung transplantation on central veno-arterial ECMO with standard additional heparin
48283178|NCT00843986|DRUG|placebo|Premix bag
48627351|NCT05697692|DRUG|Placebo|Lung transplantation on central veno-arterial ECMO without additional heparin
48627352|NCT06061159|DRUG|Remimazolam besylate|initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
48627353|NCT01692587|OTHER|Protein restrictive diet|To begin a reduced protein diet
48627354|NCT03802357|PROCEDURE|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
48283179|NCT01061489|OTHER|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
48283180|NCT01061489|OTHER|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
48283181|NCT00075881|DRUG|bortezomib|Given IV
48283182|NCT00075881|OTHER|laboratory biomarker analysis|Optional correlative studies
48283183|NCT02111538|OTHER|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
48627355|NCT00369083|PROCEDURE|Hospital at home treatment|
48627356|NCT03039725|OTHER|Observational|Retrospective chart review on vaccine compliance
48627357|NCT01060956|OTHER|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
48627358|NCT01060956|OTHER|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
48627359|NCT02536794|BIOLOGICAL|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
48627360|NCT02536794|OTHER|Laboratory Biomarker Analysis|Correlative studies
48627361|NCT02536794|OTHER|Pharmacological Study|Correlative studies
48283184|NCT00903084|DRUG|Tenofovir Disoproxil Fumarate|300-mg tablet
48283185|NCT02053688|DEVICE|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
48627362|NCT02536794|BIOLOGICAL|Tremelimumab|Given IV
48627363|NCT03004456|OTHER|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
48283186|NCT02053688|DEVICE|Toric Soft Contact Lenses|astigmatism correction using toric optics
48283187|NCT02125994|PROCEDURE|Interscalene nerve block|
48283188|NCT03747952|PROCEDURE|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
48283189|NCT03747952|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
48627364|NCT02609633|DEVICE|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
48627365|NCT02609633|DEVICE|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
48627366|NCT03812250|PROCEDURE|ERCP assisted trans-papillary drainage for malignant biliary obstruction|ERCP assisted trans-papillary drainage for malignant biliary obstruction
48627367|NCT03812250|PROCEDURE|EUS-guide biliary drainage for malignant biliary obstruction|EUS-guide biliary drainage for malignant biliary obstruction
48627368|NCT03543267|OTHER|MRI exam|MRI before and after resection surgery
48627369|NCT04330898|DEVICE|Biotronik peacemakers, implantable cardioverter-defibrillators and cardiac resynchronizers|Any of these Biotronik cardiac stimulation devices with the Home Monitoring function activated for the remote control of patients
48627370|NCT04661228|DIAGNOSTIC_TEST|Composite International Diagnostic Interview 5th version (CIDI 5.0)|Observational study assessing prevalence of mental and substance use disorders in the general population
48627371|NCT05121493|OTHER|Platelet Poor Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet free fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of white blood cells (WBC), red blood cells (RBC), and platelets when compared to the concentration before processing.
48627372|NCT05121493|OTHER|Platelet Rich Plasma Tear Drops|Participant blood will be drawn and processed by the University of Rochester Transfusion Medicine and Blood Bank. Processing will isolate the platelet fraction of the blood plasma. After processing, plasma should contain ≤ 5% concentration of WBC and RBC and 100 x 10³ μl or ≥ 50% recovery of platelets when compared to the pre-platelet count.
48627373|NCT02497755|BEHAVIORAL|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
48627374|NCT02497755|DEVICE|smartphone|
48627375|NCT02961725|BIOLOGICAL|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
48627376|NCT04408079|DRUG|TQB3558|TQB3558 is a kinase inhibitor of the TRK protein family.
48627377|NCT02037074|DRUG|Drug: EVP-6308|Arms 1, 2, 3
48627378|NCT02037074|DRUG|Placebo|Arm 4
48627379|NCT03016637|DEVICE|SharkCore (TM) FNB Exchange System|
48627380|NCT02383485|BEHAVIORAL|Exercise|Heart rate monitors worn by each child at each session
48627381|NCT02383485|BEHAVIORAL|After-school program|Supervised recreational program with token economy
48283190|NCT03360929|DRUG|AZD3759|Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
47937574|NCT02655393|DIETARY_SUPPLEMENT|Mitopure|
48100585|NCT01353638|DRUG|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
48100586|NCT01103973|BEHAVIORAL|Mind/Body Program|Ten week group mind/body program
48283191|NCT05476796|DRUG|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
48283192|NCT05476796|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
48467737|NCT02698930|DRUG|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
48467738|NCT02698930|DRUG|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
48627382|NCT01118091|BIOLOGICAL|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
48627383|NCT01118091|BIOLOGICAL|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10\^9 to 2x10\^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10\^8) and the administration of high-dose aldesleukin.
48467739|NCT04520061|BEHAVIORAL|Health Insurance Navigation Program|The program will be delivered via videoconferencing by a navigator over a 2-month period and will consist of 4 sessions. The navigation intervention sessions will be as follows: Session 1- Learning About Survivorship Healthcare Needs; Session 2- Learning About Your Plan in Relation to Policy; Session 3- Navigating One's Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs.
48467740|NCT02671877|PROCEDURE|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
48617853|NCT02911116|DRUG|Ustekinumab|Intravenous Infusion
48617854|NCT03052686|OTHER|Childbirth with uterine rupture|No intervention. Follow-up of women with rupture uterine at the childbirth.
48617855|NCT00068185|DRUG|Black cohosh|
48617856|NCT00929669|DRUG|pasireotide LAR|pasireotide LAR 80 mg IM once a month
48617857|NCT03695588|PROCEDURE|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
47937575|NCT01273376|DRUG|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
47937576|NCT01306877|DEVICE|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
47937577|NCT01306877|DEVICE|Endosurgery Proximate PPH03 Stapling Set|Surgical device
47937578|NCT00329940|DRUG|Letrozole|
48627384|NCT02473601|DRUG|Mivacurium Chloride|"Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%\~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 \~ 60. PetCO2 was 30 \~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
48627385|NCT04700605|BEHAVIORAL|Dual task balance test|Participants will be conducting two dual task tests; an 8m gait test and a Wii Balance Board test with simultaneous various cognitive tests.
48627386|NCT05664945|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
48100587|NCT01103973|BEHAVIORAL|Control|Spa gift certificates
48467741|NCT05625269|OTHER|Education|The first session of the individual training will be held for the patients in the intervention group on the first day of the service hospitalization, covering the issues related to the procedure and the hospital process. Afterwards, the second session of individual education will be held the day before discharge on issues related to the patient's home care, such as treatment site care, nutrition, exercise, medication and symptom management. In addition to the patients, their families will also participate in the training sessions. The training will be given face-to-face in a quiet environment to increase intelligibility in patients' rooms. The patients will be given a booklet and magnet prepared by the researcher in addition to the oral explanation.
48467742|NCT05934539|DRUG|ALG.APV-527|ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
48467743|NCT03311945|DRUG|Raltegravir|Raltegravir (1200 mg QD)
48467744|NCT03311945|DRUG|Lamivudine|Lamivudine (300 mg QD)
48467745|NCT00249990|DRUG|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
48467746|NCT03622229|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
48467747|NCT05492292|DIAGNOSTIC_TEST|Perfusion brain scintigraphy imaging|The cerebral perfusion scintigraphy via a SPECT examination aims to analyze the cerebral blood flow and detect possible lesions or inflammations.
48467748|NCT06052813|DRUG|BN104|Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
48467749|NCT01134198|DRUG|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
48467750|NCT01134198|DRUG|placebo|placebo
48467751|NCT02310503|PROCEDURE|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
48467752|NCT04249622|OTHER|Best Practice|Given standard of care pertuzumab-based chemotherapy
48467753|NCT04249622|OTHER|Questionnaire Administration|Ancillary studies
48467754|NCT04249622|DRUG|Rifaximin|Given PO
48467755|NCT00924586|DRUG|ONO-1101|Placebo for one minute IV
48467756|NCT00924586|DRUG|ONO-1101|0.125 mg/kg for one minute IV
48467757|NCT03562845|OTHER|NA-Observational only|NA-Observational only
48467758|NCT03581162|DIAGNOSTIC_TEST|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
48467759|NCT03045133|DRUG|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
48467760|NCT03045133|DRUG|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
48467761|NCT02118025|PROCEDURE|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
48467762|NCT02118025|PROCEDURE|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
48617858|NCT03695588|PROCEDURE|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
47937579|NCT05125887|OTHER|Questionnaire|Patients diagnosed positive for COVID on an outpatient basis will respond to a questionnaire by mail, at 24 month of diagnosis. This questionnaire will make it possible in particular to collect intercurrent events (hospitalization, emergencies, etc.).
48627387|NCT05664945|BEHAVIORAL|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
48627388|NCT05664945|BEHAVIORAL|Control|"Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation)."
48627389|NCT02549378|DEVICE|confocal microscopy|microvessel diameter measured by confocal microscopy
48627390|NCT02448082|OTHER|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
48627391|NCT02448082|OTHER|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
48627392|NCT01933425|DRUG|rocuronium|
48627393|NCT01933425|DRUG|sugammadex|
48627394|NCT01933425|DRUG|placebo|
47937580|NCT05818111|DRUG|steroid|triamcinolone 40mg 4cc
47937581|NCT05818111|DRUG|Xylocaine 2 % Injectable Solution|xylocaine 2% 4cc
48283193|NCT05476796|DRUG|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
48283194|NCT05476796|DRUG|Nivolumab|Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
48467763|NCT01422928|PROCEDURE|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~* GV.14~* LI.11 (bilateral)~* SP.6 (bilateral)~* SP.10 (bilateral)~* ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
48467764|NCT03930251|BEHAVIORAL|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
48467765|NCT03930251|BEHAVIORAL|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
48467766|NCT00721916|DRUG|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
48627395|NCT04040855|OTHER|Medication review|Multi-professional medication review
48627396|NCT01757847|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
47937582|NCT05818111|DRUG|Normal saline 2cc|normal saline 2cc
47937583|NCT05818111|DRUG|normal saline 12cc|normal saline 12cc
47937584|NCT01056380|DRUG|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
47937585|NCT01056380|DRUG|Placebo|Tablet, twice daily with food for 5 days
47937586|NCT01705782|BIOLOGICAL|E. coli endotoxin, US standard|
47937587|NCT02931266|DEVICE|PASS MIS®|Posterior mini-invasive osteosynthesis
48283195|NCT01486264|BIOLOGICAL|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
48467767|NCT00721916|DRUG|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
48467768|NCT05397301|PROCEDURE|Controlled sedoanalgesia|Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
48627397|NCT01757847|BEHAVIORAL|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
48627398|NCT01144806|BEHAVIORAL|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
48627399|NCT01144806|DIETARY_SUPPLEMENT|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
48627400|NCT00360204|BEHAVIORAL|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
48627401|NCT05573009|BEHAVIORAL|cognitive behavioral approach-based stress reduction program|"Five days lasting stress reduction program based on cognitive behavioral approach(each session will be an average of 60 minutes) will be initiated in the third day of hospitalisation to the intervention group.~Session main topics are:~Session 1 - Introducing the purpose and content of the program - Stress Psychoeducation Session 2 - Cognitive restructuring Session 3 -Behavioral coping Session 4 - Problem solving training Session 5-Upcoming parenthood"
48627402|NCT03719664|DRUG|Albuvirtide|Intravenous infusion of Albuvirtide
48627403|NCT03719664|DRUG|3BNC117|Intravenous infusion of 3BNC117
48627404|NCT03719664|DRUG|Baseline ART|Subjects continuing on baseline ART
48627405|NCT00918450|DRUG|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
48627406|NCT02723422|PROCEDURE|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
48627407|NCT02723422|PROCEDURE|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
48627408|NCT02448043|DRUG|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
48627409|NCT02448043|OTHER|Placebo: saline|Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
48467769|NCT02135991|BEHAVIORAL|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
48467770|NCT02135991|BEHAVIORAL|Project CHOICE|Sites will receive standard training for Project CHOICE.
48467771|NCT02939261|BEHAVIORAL|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
48467772|NCT02939261|BEHAVIORAL|Control|monthly emails with general health information
48467773|NCT05341856|DRUG|isosorbide mononitrate|insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
48467774|NCT05341856|DRUG|Placebo|insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
48627410|NCT04109963|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
47937588|NCT02433158|DRUG|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses.
48283196|NCT02913625|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
48467775|NCT04366284|OTHER|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
48627411|NCT05335018|DRUG|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
48100588|NCT06567743|DRUG|Cretostimogene Grenadenorepvec|Cohort A, Arm 1 and 2
48100589|NCT06567743|DRUG|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
48283197|NCT02913625|OTHER|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
48283198|NCT02502929|BEHAVIORAL|Social Services|
48283199|NCT02502929|BEHAVIORAL|Lifestyle|
48283200|NCT02502929|BEHAVIORAL|Lifestyle Plus Medication Therapy Management|
48283201|NCT06203002|DRUG|Placebo (blinded)|LX9211 matching placebo tablets
48283202|NCT06203002|DRUG|LX9211 (blinded)|LX9211 (blinded) tablets
48627412|NCT05478746|DEVICE|BioNourish, a component of the Flourish HEC kit|BioNourish is a vaginal moisturizing gel which obtained FDA 510k clearance in 2020. It is one component of the full system being tested. The main intervention is to use this kit to improve the vaginal microbiome.
48283203|NCT05837754|OTHER|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
48283204|NCT05837754|OTHER|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
48283205|NCT01855438|BEHAVIORAL|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
48467776|NCT04366284|OTHER|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
48467777|NCT04366284|OTHER|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
48467778|NCT04169555|PROCEDURE|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
48467779|NCT04169555|OTHER|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
48467780|NCT04496037|DRUG|Rituximab|See NCT03994783
48467781|NCT02005562|DRUG|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).
48283206|NCT03553173|OTHER|So-Lo-Mo|So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
48283207|NCT03553173|BEHAVIORAL|Psychological advice|Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
48283208|NCT03553173|DRUG|Bupropion Pill|Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
48467782|NCT02005562|DRUG|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
48627413|NCT05478746|OTHER|Control - no intervention|No intervention; participants only receive routine care.
48627414|NCT04257617|DRUG|ZL-1201|Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
48283209|NCT03553173|DRUG|Varenicline Pill|Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
48283210|NCT05078814|OTHER|Observational research|Observational research
48283211|NCT00795730|DRUG|NSA-789|
48283212|NCT00795730|OTHER|placebo|
48283213|NCT05272631|DEVICE|Retrograde Femoral Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with RFNA based on the surgeon's decision and the site's SOC.
48627415|NCT02944266|OTHER|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
48467783|NCT02005562|DRUG|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
48467784|NCT02005562|DRUG|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
48467785|NCT02005562|DRUG|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
48467786|NCT04832776|DRUG|Cetuximab|one group plus cetuximab
48467787|NCT04832776|DRUG|Bevacizumab|one group plus bevacizumab
48467788|NCT04832776|DRUG|FOLFOXIRI|FOLFOXIRI
48283214|NCT05272631|DEVICE|Tibial Nail Advanced|No drug will be given as part of this study. Participant will undergo surgery with TNA based on the surgeon's decision and the site's SOC.
48283215|NCT00201539|DRUG|single dose Morphine|
48283216|NCT00201539|DRUG|double dose Morphine|
48283217|NCT00201539|DRUG|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
48283218|NCT03080987|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
48627416|NCT03344393|DRUG|Ketamine Hydrochloride|intravenous ketamine infusion intraoperatively
48283219|NCT03080987|DRUG|JNJ-64179375 1.0 mg/kg|JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
48283220|NCT03080987|DRUG|JNJ-64179375 2.5 mg/kg|JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
48283221|NCT03080987|OTHER|Placebo|Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
48283222|NCT03080987|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined).
48467789|NCT05759156|DRUG|Tranexamic acid injection|The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
48467790|NCT00597428|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
48467791|NCT00597428|DRUG|Placebo|0 mcg capsules twice daily (BID)
48467792|NCT03996616|DEVICE|Head UP Position|"CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a \<10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
48627417|NCT03344393|DRUG|Normal saline|intravenous normal saline infusion intraoperatively
48283223|NCT01451515|DRUG|Prednisone|Given orally (PO).
48283224|NCT01451515|DRUG|Vincristine|Given intravenously (IV).
48283225|NCT01451515|DRUG|Daunorubicin|Given IV.
48283226|NCT01451515|DRUG|PEG-asparaginase|Given intramuscularly (IM) or IV.
48283227|NCT01451515|DRUG|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
48283228|NCT01451515|DRUG|Doxorubicin|Given IV.
48283229|NCT01451515|DRUG|Cyclophosphamide|Given IV.
48283230|NCT01451515|DRUG|Cytarabine|Given IV or IT.
48283231|NCT01451515|DRUG|Thioguanine|Given PO.
48283232|NCT01451515|DRUG|Clofarabine|Given IV.
48283233|NCT01451515|DRUG|Methotrexate|Given IV, IM or IT.
48283234|NCT01451515|DRUG|Mercaptopurine|Given PO.
48283235|NCT01451515|DRUG|Dexamethasone|Given PO or IV.
48283236|NCT01451515|DRUG|Hydrocortisone|Given IT.
48283237|NCT01451515|DRUG|Etoposide|Given IV.
48283238|NCT05069779|DRUG|Diazepam|Oral administration of 10 mg of diazepam
48283239|NCT02333708|OTHER|Blood sample|
48627418|NCT02094235|DRUG|E6005 0.05%|
48627419|NCT02094235|DRUG|Placebo|0.5 g placebo ointment
48627420|NCT02094235|DRUG|E6005 0.2%|
48627421|NCT02288871|RADIATION|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
48100590|NCT02677974|DEVICE|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
48100591|NCT00366353|OTHER|Sedation during SBT|
48100592|NCT00366353|OTHER|No sedation|
48283240|NCT04937270|DEVICE|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
48283241|NCT04937270|DEVICE|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
48283242|NCT04937270|DEVICE|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
48283243|NCT04937270|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
48283244|NCT04392414|BIOLOGICAL|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
48283245|NCT04392414|BIOLOGICAL|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
48283246|NCT00181298|DRUG|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
48627422|NCT03432962|OTHER|no intervention - recoding of food recall only|recoding of food recall
47937589|NCT01637987|PROCEDURE|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
48283247|NCT00181298|DRUG|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
48283248|NCT02670304|DRUG|letrozole|letrozole from the day of oocyte retrieval for 5 days
48283249|NCT02670304|DRUG|Aspirin|aspirin from the day of oocyte retrieval for 5 days
48467793|NCT03996616|DEVICE|Impedance Threshold Device|An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
48467794|NCT03996616|DEVICE|New Automated CPR|Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
48467795|NCT05830682|DEVICE|using a walking aid|The walking aid utilized for mobilizing patients in the intervention group during the study is a four-wheeled device that allows for movement in all directions. The height of the device can be adjusted according to the patients' height. It features a seat for resting when needed and a braking system that is controlled from the hand grips.
48467796|NCT01952691|DEVICE|kinesiotaping|correction method was used to align hallux.
48467797|NCT03038568|DIAGNOSTIC_TEST|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
48467798|NCT03255044|DRUG|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
48467799|NCT03255044|DRUG|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
48467800|NCT03255044|OTHER|guideline directed therapy|standard heart failure therapy
48467801|NCT05761743|DIAGNOSTIC_TEST|Urine and Blood Test|Urine N-telopeptide and serum osteocalcin
48467802|NCT04217538|OTHER|clinical exam|clinical oral examination
48467803|NCT03316040|BEHAVIORAL|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
48627423|NCT06063343|DRUG|KAND145|In Part 1 of the study, single ascending doses of KAND145 will be administered; in Part 2 of the study, multiple ascending doses (BID for 8 days) of KAND145 will be administered.
48627424|NCT06063343|DRUG|Placebo|Participants randomized to the placebo arms will receive placebo at the same dosing frequency as the experimental arms.
48627425|NCT01767389|OTHER|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
48627426|NCT01767389|OTHER|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
48627427|NCT01767389|OTHER|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
48627428|NCT02763995|BEHAVIORAL|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
48627429|NCT06025370|OTHER|Prone Position|"All healthy volunteers will be positioned in prone position, on a bed equipped with a mapping pressure system.~The volunteers will spend 5 minutes in each of the positions corresponding to the study groups."
48283250|NCT02271490|OTHER|Acrosome Reaction induction|
48283251|NCT02271490|OTHER|capacitation in incubation medium prior to ICSI|
48283252|NCT00995371|DEVICE|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
48283253|NCT00995371|DRUG|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
48283254|NCT04661696|DRUG|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
48283255|NCT06340711|DRUG|OBP-301|2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
48283256|NCT06340711|DRUG|Pembrolizumab|400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
48283257|NCT03243903|DEVICE|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
48283258|NCT03243903|DEVICE|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
48283259|NCT01252966|BEHAVIORAL|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
48283260|NCT01252966|BEHAVIORAL|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
48283261|NCT01186432|DRUG|PDS 1.0|
48283262|NCT00987844|DRUG|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
48467804|NCT03619876|DRUG|Abatacept|125 MG/ML subcutaneous injections
48467805|NCT03619876|DRUG|Adalimumab|40 Mg/0.8 mL Subcutaneous Kit
48283263|NCT05319964|BEHAVIORAL|Anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes anti-gravity treadmill sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
48283264|NCT05319964|BEHAVIORAL|Conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
48283265|NCT05319964|BEHAVIORAL|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
48283266|NCT03401749|DRUG|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
48467806|NCT04482933|BIOLOGICAL|Biological G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
48283267|NCT03401749|OTHER|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
48467807|NCT05856448|DRUG|GLPG3667|Capsule
48467808|NCT05856448|DRUG|Placebo|Capsule
48467809|NCT05367037|DEVICE|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
48467810|NCT05367037|DEVICE|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
48467811|NCT06407999|DEVICE|Expiratory Pressure Relief|EPR is a function used in CPAP intended to improve comfort by reducing delivered pressure during the expiratory phase. When EPR is not used, the patient receives true CPAP.
48467812|NCT06612827|OTHER|organoid etablishment|"Prior to initiation of 1st-line therapy:~* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)~* A blood test blood a for tumoroid realization and :~* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo~* Analysis of correlation between in vivo and ex vivo tumor characteristics~* Analysis of first- and second-line survival rates and overall survival"
48467813|NCT05761392|OTHER|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
48627430|NCT02129556|DRUG|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
48627431|NCT06529705|DEVICE|EkiYou V2|Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.
48627432|NCT03632447|DEVICE|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
48283268|NCT04905862|DIAGNOSTIC_TEST|Immune response|"1. Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated.~2. The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.~3. The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.~4. The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells."
48627433|NCT03632447|DEVICE|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
48283269|NCT04905862|OTHER|Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events|The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials. Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination. Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
48627434|NCT00945620|DRUG|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
48283270|NCT00957372|DRUG|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
48283271|NCT00957372|DRUG|placebo (Part I)|once daily placebo comparator
48627435|NCT00945620|DRUG|placebo|Placebo
48627436|NCT03650075|DRUG|MG-S-2525|The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
48627437|NCT02183974|PROCEDURE|Peptest|
48627438|NCT04914000|BEHAVIORAL|Self-help Materials|Self-help booklet targeted by cancer type to increase smoking cessation motivation
48627439|NCT04481659|PROCEDURE|Lap partial ISR|A direct laparoscopic surgery with completely abdominal approach laparoscopic partial intersphincteric resection
48467814|NCT03856034|DEVICE|Fetoscopy|Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
48467815|NCT06679218|OTHER|Activity Coaching Programme|The intervention will consist of individualized physical activity coaching sessions, which will take place twice a week for 8 weeks. These sessions will focus on encouraging progressive and personalized physical activity according to each participant's ability. The sessions will also include relaxation techniques, targeted ventilation and strategies to improve activity management.
48627440|NCT04481659|COMBINATION_PRODUCT|NCRT+Lap partial ISR|Preoperative radiation and chemotherapy + laparoscopic completely abdominal approach laparoscopic partial intersphincteric resection
48627441|NCT00582452|OTHER|Telephone survey|Telephone survey
48627442|NCT04622995|DRUG|Benzodiazepine|Benzodiazepine prescribing
48283272|NCT00957372|DRUG|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
48283273|NCT03681717|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
48283274|NCT04492410|OTHER|rapid serological test|screening using a rapid serological test with a drop of blood from a finger prick
48283275|NCT04866472|DEVICE|video-laryngoscope and GlideRite Rigid Stylet|Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.
48283276|NCT04866472|DEVICE|video-laryngoscope and TCI Articulating Introducer Device|In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
48467816|NCT06679218|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
48467817|NCT04155073|BEHAVIORAL|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
48467818|NCT04155073|OTHER|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
48467819|NCT01397266|PROCEDURE|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
48467820|NCT01397266|PROCEDURE|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
48467821|NCT00804999|DRUG|Clear Care|neutralized Clear Care
48467822|NCT00804999|DRUG|ReNu|overnight soak in solution
48467823|NCT00804999|DRUG|OPTI-FREE|overnight soak in solution
48467824|NCT00096239|DRUG|CP-547,632|
48467825|NCT02403973|OTHER|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
48467826|NCT05400798|DEVICE|Adipose Derived Regenerative Cells|single injection of adipose-derived regenerative cells (ADRCs) into the partial-thickness rotator cuff tear
48467827|NCT05400798|DEVICE|Corticosteroid|a single corticosteroid injection into the associated subacromial space
48467828|NCT02033317|DRUG|patiromer|15 grams/day (5 grams 3 times daily) administered orally
48467829|NCT04329676|PROCEDURE|Deep Brain Stimulation|Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
48467830|NCT01677650|DRUG|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
48467831|NCT02993705|DRUG|Trabectedin|Chemotherapy drug
48467832|NCT04395079|BIOLOGICAL|Durvalumab|Given IV
48467833|NCT04395079|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
48467834|NCT04395079|BIOLOGICAL|Tremelimumab|Given IV
48467835|NCT02964390|PROCEDURE|Balloon Pulmonary Angioplasty|
48467836|NCT05741502|DRUG|Clozapine|We will assess inflammatory/immune marker labs
48467837|NCT05741502|DRUG|Antipsychotics,Other (non-Clozapine)|We will assess monitor inflammatory/immune marker lab
48627443|NCT02668419|DEVICE|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
48283277|NCT03545243|DRUG|Pantoprazole 40mg|Peroral Pantoprazole 40mg once daily during 28 days
48283278|NCT03545243|OTHER|PPI withdrawal|PPI withdrawal for 8 weeks
48283279|NCT05466435|OTHER|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
48283280|NCT05466435|OTHER|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
48283281|NCT02427061|BEHAVIORAL|Intervention Program (Manhood 2.0)|
48283282|NCT02427061|BEHAVIORAL|Control Program (Job Skills Training)|
48283283|NCT03794986|BEHAVIORAL|Trauma-informed SGM affirmative care|"All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use)."
48283284|NCT03794986|BEHAVIORAL|Motivational Interviewing|"Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda"
48283285|NCT02464631|DRUG|Sofosbuvir + Ribavirin 1|
48283286|NCT02464631|DRUG|Sofosbuvir + Ribavirin 2|
48627444|NCT02668419|OTHER|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure \>15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as \>200 mmHg; 6) a rise in diastolic blood pressure during exercise \>110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
48467838|NCT06678802|OTHER|Blood sampling|blood sampling from peripheral vein
48283287|NCT02464631|DRUG|Sofosbuvir + Ribavirin 3|
48467839|NCT04178382|DIAGNOSTIC_TEST|PCR-CRISPR／Cas12a detection|Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
48467840|NCT00590694|DRUG|ranibizumab|0.5mg injection monthly according to protocol for one year
48283288|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
48467841|NCT05685472|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
48467842|NCT06408636|OTHER|Cardiac MRI|All selected patients completed a cardiac magnetic resonance examination without other interventions.
48467843|NCT02004691|DRUG|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
48283289|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
48283290|NCT02580162|BEHAVIORAL|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
48283291|NCT05527925|DEVICE|MRI|Brain testing of patients using MRI
48283292|NCT03103399|DRUG|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
48283293|NCT03103399|DRUG|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
48283294|NCT03103399|DRUG|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
48283295|NCT03103399|DRUG|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
48627445|NCT04055519|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
48627446|NCT04055519|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
48467844|NCT02004691|DRUG|Olipudase alfa|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
48467845|NCT05494632|DEVICE|Treatment-modifications to CI speech processor program|We will modify the CI speech processor program to reduce interaural loudness and pitch mismatches.
48627447|NCT04055519|DEVICE|Multi-purpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
48627448|NCT01677065|DRUG|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
48627449|NCT01677065|DRUG|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
48627450|NCT03306381|OTHER|Dietary intervention|Elimination of certain products.
48627451|NCT02460003|BEHAVIORAL|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
48627452|NCT02460003|OTHER|Home exercise program|Home exercise program
48627453|NCT05381870|BEHAVIORAL|Test Preparation-Reference preparation|Under fasting conditions, subjects randomly divided into TR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period.
48627454|NCT05381870|BEHAVIORAL|Reference preparation-Test Preparation|Under fasting conditions, subjects randomly divided into RT group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period.
48627455|NCT01452087|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
48283296|NCT00353977|BIOLOGICAL|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
48283297|NCT06150209|DEVICE|Vendaje|Dehydrated Human Amniotic Membrane
48467846|NCT02431624|DRUG|BTDS|
48283298|NCT02140125|DRUG|ASP2408|subcutaneous administration
48467847|NCT01367938|DEVICE|OMNI Apex Ultracongruent Knee Device|
48467848|NCT00779441|DRUG|Zolpidem 10mg tablets|
48467849|NCT04688515|BEHAVIORAL|Nutrition program developed using positive deviance approach|It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
48627456|NCT03608332|DEVICE|diaphragmatic ultrasound|Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
48283299|NCT02140125|DRUG|Placebo|subcutaneous administration
48627457|NCT00107588|BEHAVIORAL|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
48627458|NCT00107588|BEHAVIORAL|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
48627459|NCT00107588|BEHAVIORAL|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
48627460|NCT05232526|OTHER|Mental imagery (MI) and exercise program|Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
48627461|NCT05232526|DEVICE|Mental Imagery and Exercise program|Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
48627462|NCT00143351|DRUG|Ziprasidone|
48627463|NCT00307255|DRUG|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
48627464|NCT00307255|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
48467850|NCT03385954|OTHER|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
48467851|NCT03385954|OTHER|Control|will receive a lecture of 30 minutes.
48627465|NCT04339972|DEVICE|LIFUP|Low Intensity Focused Ultrasound Pulsation (LIFUP) is an interesting new form of brain stimulation that may be possible to stimulate non-invasively, safely, deep in the brain with focal precision.
48627466|NCT04339972|DEVICE|Sham LIFUP|The same as LIFUP but the device is not turned on and the subject does not receive any ultrasound.
48627467|NCT01227395|DRUG|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
48627468|NCT03888274|DEVICE|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
48627469|NCT02324322|DEVICE|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
48627470|NCT02324322|OTHER|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
48627471|NCT02324322|OTHER|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
48627472|NCT04692051|DRUG|Nab-paclitaxel + Cisplatin|Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
48627473|NCT04692051|DRUG|Gemcitabine + Cisplatin|Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
48627474|NCT01514175|DRUG|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
48627475|NCT01514175|DRUG|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
48627476|NCT03802110|DEVICE|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
48627477|NCT04758637|BEHAVIORAL|Overdose Notification|We will identify overdoses from state vital records and insurance claims data linked to emergency departments. We will use electronic health record data to identify prescriptions of scheduled drug to patients who experienced a non-fatal or fatal overdose within the health system. If randomized to the overdose notification group, physicians who prescribed the controlled substances to the deceased or surviving patient in the year prior to their overdose will be informed of the overdose via letter. The letters will alert prescribers to the patient's opioid-related overdose, recommend the use of the state-level PDMP, and list evidence-based interventions to lower opioid-related overdoses. The letters will increase the salience and availability of opioid-related harms, which may cause clinicians to be more wary of a future overdose when prescribing opioids, benzodiazepines, muscle relaxants, or sedative-hypnotics.
48627478|NCT00390351|DEVICE|optical coherence tomography|
48627479|NCT03712852|PROCEDURE|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
48627480|NCT03712852|PROCEDURE|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
48627481|NCT03712852|PROCEDURE|CAF treated patients|Patients will be treated by coronally advanced flap
48627482|NCT03819205|OTHER|kinesiotaping|The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
48627483|NCT04080284|DRUG|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
48627484|NCT00246207|DRUG|CONCERTA (OROS methylphenidate hydrochloride)|
48627485|NCT00754780|DRUG|Pirfenidone|Capsule 800 mg TID, oral
48627486|NCT03770975|PROCEDURE|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
48467852|NCT02883439|DRUG|MP29-02|local nasal application
48467853|NCT02883439|DRUG|Fluticasone propionate|local nasal application
48283300|NCT04990570|OTHER|Telemedicine in the form Virtual clinic via video consultation|"Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter."
48467854|NCT02603549|OTHER|Pituitary panel will be drawn pre-op and post-op for all patients.|
47937590|NCT01637987|PROCEDURE|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
48467855|NCT04141878|BEHAVIORAL|Aerobic Exercise|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.
48627487|NCT03770975|PROCEDURE|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
48627488|NCT00908778|DRUG|Vitreosolve|intravitreal injection
48627489|NCT00908778|DRUG|Vitreosolve|intravitreal injection
48627490|NCT00471354|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
48627491|NCT04411407|DEVICE|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order|PROM registration via the DANBIO WebApp and the outpatient touchscreen in a randomised order
48627492|NCT00295685|DRUG|Antacids|
48627493|NCT01746160|DRUG|C1 Implant|Patients treated with dental implants.
47937591|NCT01637987|PROCEDURE|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
48283301|NCT05288088|DIAGNOSTIC_TEST|No intervention|This is an observational study
48283302|NCT04710108|OTHER|Health Communication|Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
47937592|NCT04781777|DRUG|insulin|sonar guided insulin combined with dexamethasone and local anesthetics
47937593|NCT01469117|OTHER|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
48283303|NCT05394844|DEVICE|Dexcom G6|Dexcom G6 CGM device
48283304|NCT04519554|DEVICE|Endometrial sampling|Endometrial sampling with 2 different forceps
48283305|NCT04551443|BIOLOGICAL|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
48627494|NCT06034379|DEVICE|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
48627495|NCT06034379|DRUG|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
47937594|NCT06314620|DRUG|Heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing with heparin saline lock
47937595|NCT06314620|OTHER|Without heparin saline lock|Participants with intercostal chest catheter who underwent normal saline flushing without heparin saline lock
48283306|NCT04551443|BIOLOGICAL|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
48467856|NCT04141878|BEHAVIORAL|Diet Skills|Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
48467857|NCT01062334|PROCEDURE|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
48467858|NCT04307849|BEHAVIORAL|Adolescent Health Club|Sexual health/HIV-related evidence-based interventions
48627496|NCT01410604|DRUG|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
48627497|NCT01410604|DRUG|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
48627498|NCT01192698|DRUG|IV interferon|IV interferon 5MU during anhepatic phase
48467859|NCT04307849|OTHER|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
48467860|NCT05454085|DIETARY_SUPPLEMENT|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
48467861|NCT03782662|DRUG|Itraconazole|Itraconazole capsules
48467862|NCT03782662|DRUG|Verapamil|Verapamil tablets
48467863|NCT03782662|DRUG|Rifampicin|Rifampicin capsules
48467864|NCT03782662|DRUG|Midazolam|Midazolam oromucosal solution
48627499|NCT04398966|DEVICE|Prostatic Artery Embolization (HydroPearl® compressible microspheres)|Embolic material
48627500|NCT04508075|BIOLOGICAL|SARS-CoV-2 vaccine (inactivated)|SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
48627501|NCT04508075|BIOLOGICAL|Placebo|Placebo manufactured by PT. Bio Farma
48627502|NCT02492386|DEVICE|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
48627503|NCT01193985|DEVICE|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
48283307|NCT05085210|DEVICE|transcranial random noise stimulation (tRNS)|noninvasive current stimulation for 20 - 30 minutes stimulation on visual cortex (electrodes on surface of scalp, positioned O1 / O2 on EEG cap). 1mA max amplitude noise stimulation, frequencies from 100 Hz - 640 Hz.
48283308|NCT05085210|BEHAVIORAL|Computer Based Visual Training|Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center of screen during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
48283309|NCT05085210|DEVICE|Sham stimulation|20-30 minutes sham stimulation on visual cortex. Participants receive identical setup to real stimulation. The device provides a short ramp on period to simulate the feeling of real stimulation at the start but no current is delivered otherwise.
48283310|NCT05085210|BEHAVIORAL|Virtual Reality Based Visual Training|• Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center point within the VR headset during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
48283311|NCT03414879|DRUG|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
48283312|NCT03414879|DRUG|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
48283313|NCT00919659|DIETARY_SUPPLEMENT|parenteral nutrition|25kcal/kg bw with parenteral nutrition
48283314|NCT00200057|DEVICE|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
48283315|NCT05029622|DRUG|Triptorelin Pamoate|Triptorelin 6-month formulation for IM on day 1 and Month 6.
48467865|NCT03782662|DRUG|Placebo for RV521|Placebo for RV521 capsules
48283316|NCT02366962|BIOLOGICAL|ASP7374|subcutaneous
48467866|NCT03782662|DRUG|RV521|RV521 capsules
48467867|NCT04458961|PROCEDURE|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
48467868|NCT04458961|PROCEDURE|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
48467869|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).
48283317|NCT04439578|DRUG|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
48283318|NCT04068883|OTHER|Q collar|An externally-worn medical device that applies mild jugular compression
48467870|NCT04886154|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).
48467871|NCT04886154|COMBINATION_PRODUCT|Placebo|Placebo is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose_06 Group, ABCWY low dose_02 Group, ABCWY high dose_06 Group, ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding).
48627504|NCT01987674|DIETARY_SUPPLEMENT|Pre-meal protein drink|
47937596|NCT01165190|OTHER|pioglitazone|
48283319|NCT05363007|DRUG|nanoliposomal irinotecan|"Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)"
48467872|NCT04886154|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the deltoid region of the non-dominant arm, whenever it's possible, as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
48467873|NCT04886154|BIOLOGICAL|MenACWY vaccine|MenACWY vaccine is administered intramuscularly in the deltoid region of the dominant arm as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
48627505|NCT01987674|OTHER|Water drink|
48627506|NCT00785629|DRUG|Calcium acetate|
48627507|NCT00785629|DRUG|Lanthanum Carbonate|
48627508|NCT00785629|DRUG|Sevelamer Carbonate|
48627509|NCT00785629|DRUG|Placebo|
48627510|NCT04401774|DRUG|Nivolumab|Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
48627511|NCT03005756|DEVICE|Needle guiding robot|This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
48627512|NCT00051727|BEHAVIORAL|Bridges to High School Project|
48283320|NCT05363007|RADIATION|spleen irradiation|"Upfront SI (Arm A): upfront spleen irradiation (1 Gy/fx, day 1-4) in cycle 2~Add-on SI (Arm B): add-on spleen irradiation (1 Gy/fx, day 1-4) in cycle 1 following limited progression to prior nanoliposomal irinotecan + 5-FU/leucovorin"
48283321|NCT01147783|OTHER|CT, MRI|
48283322|NCT01451333|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
48283323|NCT01451333|DRUG|Efavirenz|400mg qd; 2 x 200mg
48627513|NCT00685282|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
47937597|NCT04706117|DEVICE|Self-retaining bicanalicular intubation stent|self-retaining bicanaliculs intubation setII(SRSII) which is the latest innovation in the field as these silicone stent segments traverse both canaliculi till the lacrimal sac. In which each end of this semicircular device has 2 stout angulated wings/flanges which pose no resistance while proceeding forward into the canaliculus, but once they get into open cavity (lacrimal sac), the flanges open up and give resistance to their removal against the common canalicular opening
48106929|NCT06116162|DEVICE|SVF-gel Filling and CO2 fractional laser|"SVF-gel preparation and filling:The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. Then the lipoaspirate was centrifuged at 1200g for 3 minutes to obtain Coleman fat in the middle layer. The Coleman fat was then transferred between two syringes until the Coleman fat converted into a uniform emulsion, and then processed by centrifugation at 2000g for 3 min. Finally, the remaining substance under the oil layer was SVF gel. We used a 22G sharp-tip injector to inject the SVF-gel into the dermis of acne scars, and the injected materials were diffusely distributed.~CO2 fractional laser treatment: After local anesthesia, Acupulse device (LUMENIS, US) was used to perform CO2 fractional laser. The laser was operated in DeepFX mode under the parameters of 20-25 MJ energy intensity, 5% coverage. Superficial mode under the parameters of 80-120 MJ energy intensity, 40-60% coverage."
48283324|NCT03319199|DIETARY_SUPPLEMENT|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
48283325|NCT03319199|OTHER|Placebo - water|for a duration of 16 weeks
48283326|NCT01000103|DEVICE|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
48283327|NCT01000103|DEVICE|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
48283328|NCT01671904|DRUG|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
48283329|NCT01671904|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams \[mg\]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
48283330|NCT01671904|DRUG|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.
48283331|NCT01671904|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
48283332|NCT00566306|OTHER|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
48283333|NCT05383820|DRUG|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
48283334|NCT01783834|DRUG|Gefitinib|compare progression free survivla rate and safety to both drugs
48283335|NCT01783834|DRUG|Pemetrexed|compare PFS rate, safety to both drugs
48283336|NCT03633331|DRUG|Palbociclib|Given PO
48283337|NCT03633331|DRUG|Letrozole|Given PO
48467874|NCT03157869|DEVICE|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
48467875|NCT03157869|OTHER|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
48627514|NCT06018168|OTHER|Skincare Routine|"Morning:~1. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face"
48627515|NCT06018168|DIETARY_SUPPLEMENT|MINDBODYSKIN Supplement|Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
48627516|NCT00607594|DRUG|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
48627517|NCT04740970|DRUG|JNJ-64304500|JNJ-64304500 injection will be administered subcutaneously.
48627518|NCT04740970|DRUG|Placebo|Matching placebo injection will be administered subcutaneously.
48627519|NCT05552131|DEVICE|T-wave coronary lithotripsy catheter system|Subjects who plan to receive possible interventional therapy meet all admission criteria and do not meet any exclusion criteria, and enter the screening stage of this clinical trial after signing informed consent. All subjects who sign the informed consent will be provided with a unique subject screening number. All subjects who met the inclusion criteria and did not meet the exclusion criteria were enrolled and lumen pretreated with a coronary shock catheter system followed by the implantation of drug-eluting stents.
48627520|NCT00890318|DRUG|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
48627521|NCT00890318|OTHER|ketoconazole|Tablet, see Arm Description for intervention information.
48627522|NCT00890318|DRUG|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
48627523|NCT04490655|BEHAVIORAL|Active somatosensory training|Patients in the experimental group will be required to move the robotic handle using their paretic arm from the start position to a visual target shown on screen. However, patients' paretic arm will be occluded from vision throughout the training session. They will make the reaching movement by depending on their proprioception of the arm position in space, without relying too much on the vision of their arm. Haptic guidance will be provided as somatosensory cues while participants are actively moving. Positive reinforcement will also be given for each successful movement that reaches the target in the form of a pleasant audio tone, visual feedback, and a running score. Assessment will be performed before and after the completion of the whole 15 training sessions.
48627524|NCT04490655|BEHAVIORAL|Motor-based training|Patients in the control group will also be required to propel the robotic handle using their paretic arm to a target location. This training covers the same centre-out reaching movements but without any emphasis on proprioception, where the view of the paretic arm will not be occluded. However, no haptic guidance will be provided during the reaching movement. Positive reinforcement will still be given to inform the participants of their trial outcomes. Assessment will be performed before and after the completion of the whole 15 training sessions.
48627525|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) 1 hour pre-exercise
48627526|NCT04862208|DIETARY_SUPPLEMENT|Whey supplement|whey (25g in 12 oz water) 1 hour pre-exercise
48627527|NCT04862208|DIETARY_SUPPLEMENT|Water|non-caloric control (12 oz flavored water) 1 hour pre-exercise
47937598|NCT04254042|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
48467876|NCT06424691|DIETARY_SUPPLEMENT|Tailored Recommendations|Based on the microbiome analysis, participants will receive personalized action plans. These plans include dietary, lifestyle, and supplemental suggestions to improve their infant's gut health.
48627528|NCT04862208|DIETARY_SUPPLEMENT|Maltodextrin supplement|maltodextrin (25g in 12 oz water) with no exercise
48627529|NCT05720247|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is a safe and effective test using ultrasound to measure liver elasticity and can detect early signs of liver disease even before a patient shows symptoms.
48627530|NCT05720247|BEHAVIORAL|Brief Intervention|Short counselling session to discuss drinking behavior, risks to health and available sources of treatment and support.
47937599|NCT04254042|DRUG|Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer|30 mg Zofenopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
47937600|NCT02346578|DRUG|Enzalutamide|
47937601|NCT02346578|DRUG|Flutamide|
47937602|NCT00491426|DRUG|Ampicillin|Drug prescribed per routine medical care.
48283338|NCT03633331|DRUG|Fulvestrant|Given IM
48467877|NCT06424691|BEHAVIORAL|Consult Call|Participants will have seven consult calls with a Gut Health Coach over the course of the study. These calls will provide guidance on the gut health reports, action plans, and any questions or concerns parents may have.
48467878|NCT06424691|BEHAVIORAL|Email Series|Parents will receive a series of educational emails covering topics such as the importance of gut health, breastfeeding benefits, the impact of C-section delivery on the microbiome, and tips for introducing solid foods.
48627531|NCT06114199|BEHAVIORAL|Produce Prescription Program (PPRx) Standard|Participants will receive biweekly deliveries of 20 lbs (\~50 servings) of fresh produce (8-10 different kinds of produce) plus standard nutrition education materials consisting of nutrition education infographics inside of the produce prescription boxes as well as online videos, recipes, and nutrition tips accessed via Quick Response (QR) code.
48627532|NCT06114199|BEHAVIORAL|Smartphone App|Participants will be given access to a smartphone app that allows women to interact with an artificial intelligence (AI) chatbot to obtain real-time cooking suggestions.
48467879|NCT05940233|DRUG|Letrozole|In the experimental group, we give the Letrozole 10 mg PO daily on the 4th day before Misoprostol 800 mcg SL on the 4th day. In the control group, we give Misoprostol 800 mcg SL on the 4th day.
48467880|NCT05257694|PROCEDURE|Surgery|hepatectomy
48467881|NCT05257694|PROCEDURE|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
48467882|NCT03900884|DRUG|Venetoclax|At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
48467883|NCT03900884|DRUG|Palbociclib|At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
48467884|NCT03900884|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
48467893|NCT04646694|DRUG|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
48467894|NCT04646694|OTHER|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
48467895|NCT04924751|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
48467896|NCT06182085|DRUG|PRI-002|Oral administration
48627533|NCT06154473|PROCEDURE|Open heart surgery group.|Patients undergoing open heart surgery.
48627534|NCT06154473|PROCEDURE|Percutaneous cardiovascular surgery group.|Patients undergoing percutaneous cardiovascular surgery.
48627535|NCT03608085|BEHAVIORAL|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~1. Online material for home self-study (10 contact hours);~2. Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~3. 1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~4. Monthly coaching conference calls/webinars with URI and Brown Faculty;"
48627536|NCT03608085|BEHAVIORAL|Patient Heart failure MTM intervention|"The baseline visit will take place \>= 7 but \<= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
48627537|NCT06159036|DEVICE|Inertial Strength training|Low speed strength training with classic movements, derived from Olympic lifting and jumping
48627538|NCT06545864|DRUG|Streptokinase Injection|250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
48283339|NCT03633331|OTHER|Questionnaire Administration|Ancillary studies
48283340|NCT03633331|OTHER|Quality-of-Life Assessment|Ancillary studies
48467897|NCT06182085|DRUG|Placebo|Oral administration
48467898|NCT01109849|BEHAVIORAL|behavior therapy|combination of individual and group parent training plus school consultation
48467899|NCT01109849|DRUG|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
48467900|NCT01109849|OTHER|monitoring|monthly weight, height and BMI checks
48467901|NCT01109849|OTHER|drug holiday|switch from seven day a week dosing to medication only on school days
48467902|NCT01109849|DIETARY_SUPPLEMENT|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
48467903|NCT00275639|DRUG|Cozaar|
48467904|NCT00973310|OTHER|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
48467905|NCT03755739|DRUG|Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy|vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
48467906|NCT02955940|DRUG|Ruxolitinib|5 mg BID
48467907|NCT02955940|DRUG|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
48467908|NCT02955940|DRUG|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
48283341|NCT02687308|PROCEDURE|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
48627539|NCT06545864|DEVICE|Penumbra System|"which comprised of several devices:~* RED Reperfusion Catheters~* Penumbra JET Reperfusion Catheters~* ACE Reperfusion Catheters~* MAX Reperfusion Catheters~* 3D Revascularization Device~* Penumbra ENGINE Aspiration Source~* Penumbra ENGINE Canister~* Aspiration Tubing"
48627540|NCT04038125|DRUG|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
48627541|NCT03090269|DRUG|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
48627542|NCT01635647|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation
48627543|NCT01635647|BIOLOGICAL|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
48467909|NCT01954901|DEVICE|Hyperbaric oxygen therapy|
48467910|NCT01954901|DEVICE|Hyperbaric room air|
48467911|NCT01346644|OTHER|Infant formula|Powder infant formula
48467912|NCT01346644|OTHER|Infant formula|Powder infant formula
48467913|NCT04134637|DEVICE|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
48467914|NCT04134637|DRUG|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
48467915|NCT02571634|DRUG|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
48467916|NCT03727139|DRUG|Rasagiline|Rasagiline Tablets
48467917|NCT04587245|OTHER|Online questionnaire and interviews|Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
48467918|NCT02375945|DEVICE|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
48467919|NCT02375945|DEVICE|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
48467920|NCT03864185|BIOLOGICAL|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
48627544|NCT04627753|DRUG|Rituximab, lenalidomide|Maintenance for 2 years
48627545|NCT06268119|OTHER|training nurses and caring for patients to prevent, diagnose, and intervene in postoperative delirium.|The intervention group received care in line with the postoperative delirium prevention, diagnosis and intervention protocol after the delirium training given by the researcher to intensive care unit nurses.
48627546|NCT03411551|PROCEDURE|regional anesthesia|The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
48627547|NCT02802722|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
48627548|NCT02802722|BIOLOGICAL|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
48627549|NCT02802722|RADIATION|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
48627550|NCT02802722|OTHER|Symptom questionnaire|Symptom questionnaire for recent symptom history
48627551|NCT02802722|OTHER|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
48627552|NCT06271980|OTHER|ENCORE|A panel of microRNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
48627553|NCT05426668|OTHER|No Intervention|No Intervention
48627554|NCT02000037|DEVICE|IR Reflexotherapy|"18 IR reflexotherapy sessions :~* Once a week for 12 weeks at the beginning of the study~* Once a week for 3 weeks, 9 months after the beginning of the study~* Once a week for 3 weeks, 15 months after the beginning of the study"
48627555|NCT02000037|BEHAVIORAL|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
48627556|NCT03792997|COMBINATION_PRODUCT|combination therapy for high peripheral NK cells|lipid emulsion \& prednisolone \& LMWH
48467921|NCT03864185|OTHER|Placebo|Administer placebo IV infusion once weekly for 4 doses.
48467922|NCT02957578|DEVICE|Solo TTD|Placement of tympanostomy tube with Solo TTD
48467923|NCT02214563|DIETARY_SUPPLEMENT|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
48467924|NCT02214563|DIETARY_SUPPLEMENT|Olive oil|
48467925|NCT00006434|BIOLOGICAL|tumor-pulsed dendritic cells|
48467926|NCT03448692|DRUG|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
48467927|NCT01066130|BEHAVIORAL|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
48467928|NCT01066130|BEHAVIORAL|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
47937603|NCT00491426|DRUG|Metronidazole|Drug prescribed per routine medical care.
47937604|NCT00491426|DRUG|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
48467929|NCT06435325|BEHAVIORAL|Precision diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
48467930|NCT06435325|BEHAVIORAL|Control diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
48467931|NCT02660541|DEVICE|Betafoam|Comparison between 2 medical devices
48467932|NCT02660541|DEVICE|Allevyn Silver Dressing|Comparison between 2 medical devices
48467933|NCT00093730|DRUG|BMS-59926|
48283342|NCT02687308|PROCEDURE|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
48283343|NCT05057728|BEHAVIORAL|Social-Emotional Prevention Program enhanced version|The intervention is provided for all children for whom parental consent is obtained. The intervention includes a classroom curriculum, teacher training and parent training.
48283344|NCT01960010|DRUG|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
48467934|NCT02058160|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
48467935|NCT02058160|DRUG|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
48467936|NCT02058160|DRUG|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
48467937|NCT05389241|OTHER|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
48467938|NCT05389241|OTHER|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
48467939|NCT00196820|DRUG|Capecitabine|
48467940|NCT01341405|DRUG|CG100649|once daily for 28 days
48467941|NCT01341405|DRUG|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
48627557|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
48627558|NCT03155477|DIETARY_SUPPLEMENT|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
48627559|NCT02782468|DRUG|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m\^2 intravenous infusion.
48283345|NCT01960010|DRUG|Vehicle|Vehicle dosed BID
48283346|NCT05361096|OTHER|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
48283347|NCT02143414|PROCEDURE|Biopsy|Undergo a biopsy
48283348|NCT02143414|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
48467942|NCT04619862|DRUG|Gabapentin|See arm descriptions
48467943|NCT04619862|DRUG|Placebo|See arm descriptions
48467944|NCT00757991|GENETIC|polymorphism analysis|
48283349|NCT02143414|BIOLOGICAL|Blinatumomab|Given IV
48283350|NCT02143414|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
48283351|NCT02143414|PROCEDURE|Computed Tomography|Undergo a CT scan
48283352|NCT02143414|DRUG|Dasatinib|Given PO
48627560|NCT02782468|DRUG|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m\^2 intravenous infusion.
48627561|NCT02782468|DRUG|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m\^2 intravenous infusion.
48627562|NCT02782468|DRUG|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m\^2 intravenous infusion.
48283353|NCT02143414|PROCEDURE|Echocardiography|Undergo ECHO
48627563|NCT02782468|DRUG|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
48627564|NCT06154174|DIETARY_SUPPLEMENT|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
48627565|NCT06154174|DIETARY_SUPPLEMENT|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
48627566|NCT06154174|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
48627567|NCT00267670|DRUG|Pentoxifylline|400mg PO TID
48627568|NCT00267670|DRUG|Placebo|1 pill PO TID
48627569|NCT02390375|DRUG|DW-0929|5/10mg
48627570|NCT02390375|DRUG|DW-0929|10/10mg
48627571|NCT02390375|DRUG|DW-0929|20/10mg
48467945|NCT00757991|OTHER|laboratory biomarker analysis|
48627572|NCT02390375|DRUG|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
48627573|NCT02390375|DRUG|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
48627574|NCT02390375|DRUG|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
48627575|NCT01131585|PROCEDURE|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
48627576|NCT01131585|DRUG|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
48627577|NCT01131585|DRUG|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
48627578|NCT01892852|PROCEDURE|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
48627579|NCT02305615|OTHER|Bevacizumab|Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
48627580|NCT02305615|COMBINATION_PRODUCT|Chemotherapy|Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil \[5-FU\] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
48627581|NCT04047472|DRUG|Brolucizumab 6mg|Subjects will receive Brolucizumab 3 x q4w up to Week 8 followed by q12w / q8w up to Week 40 or Week 44, depending on disease activity status.
48627582|NCT04047472|DRUG|Aflibercept 2 mg|Subjects will receive Aflibercept 3 x q4w up to Week 8 followed by q8w up to Week 40.
48627583|NCT01175720|PROCEDURE|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
48627584|NCT01008540|BIOLOGICAL|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
48627585|NCT01325766|OTHER|Yoga|Yoga 2 sessions per week for 8 weeks
48627586|NCT03938870|OTHER|L-Leucine 13C6|
48627587|NCT00396669|DRUG|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
48283354|NCT02143414|PROCEDURE|Lumbar Puncture|Undergo a lumbar puncture
48467946|NCT00757991|OTHER|questionnaire administration|
48467947|NCT03748095|DRUG|pipéracilline/tazobactam|There is not intervention description
48467948|NCT02376257|DRUG|250 mg DCS|Drug
48627588|NCT00396669|DRUG|Bupropion|Brain imaging after treatment with Bupropion
48627589|NCT05832983|BEHAVIORAL|Guided Meditation|In private exam room, the study registered nurse (RN) will read a prepared two minute guided meditation to patient.
48627590|NCT05832983|OTHER|Aromatherapy|In private exam room, study RN will first affix an Elequil Aromatab to patient's clothing on either their upper arm or chest (whichever the patient prefers and/or as clothing allows).
48467949|NCT02376257|DRUG|100 mg Modafinil|Drug
48467950|NCT02376257|DRUG|Placebo|Drug
48467951|NCT02199379|DRUG|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
48627591|NCT02551575|DRUG|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
48627592|NCT02551575|DRUG|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
48467952|NCT00939523|DRUG|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
48627593|NCT02551575|DRUG|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
48283355|NCT02143414|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48627594|NCT04663217|OTHER|Exercise|After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
47937605|NCT00491426|DRUG|Acyclovir|Drug prescribed per routine medical care.
48283356|NCT02143414|DRUG|Mercaptopurine|Given PO
48283357|NCT02143414|DRUG|Methotrexate|Given PO
48283358|NCT02143414|DRUG|Methotrexate Sodium|Given PO
48467953|NCT04122027|OTHER|Cerebral oximeter|Near infra-red spectroscopy, NIRS
48467954|NCT04933357|RADIATION|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
48467955|NCT04933357|RADIATION|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
48283359|NCT02143414|DRUG|Prednisone|Given PO
48467956|NCT05695651|DIAGNOSTIC_TEST|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln\[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2\].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
48467957|NCT03407729|OTHER|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
48467958|NCT03407729|OTHER|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
48467959|NCT06361472|OTHER|Standard Care|Standard Care includes exercises, mobilization, manual therapy, education, and Neck Wellness Home Care Guide (NWHCG). The rehabilitation program is based on current clinical practice guidelines aimed at reducing neck pain, improving range of motion, enhancing functionality, and promoting physical activity motivation. Each patient will receive active exercises and manual therapy techniques. Educational components will cover pain science, physical activity benefits, and return to normal activities , supplemented by a NWHCG. Treatment sessions will be conducted, featuring a one-to-one interaction between the participant and the physiotherapist. It will last 4 weeks, with two sessions per week, 45 minutes/session (8 treatment sessions).
48283360|NCT02143414|DRUG|Vincristine|Given IV
48283361|NCT02143414|DRUG|Vincristine Sulfate|Given IV
48283362|NCT02143414|PROCEDURE|X-Ray Imaging|Undergo an x-ray
48283363|NCT00388089|DRUG|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
48467960|NCT06361472|BEHAVIORAL|Contextual Factors|Bundle of contextual factors divided into three categories: professional, treatment, and healthcare setting features. Regarding the professional contextual factors, they include reputation, appearance, and positive attitudes. The treatment contextual factors encompass positive attitudes, verbal communication, non-verbal communication, empathetic therapeutic alliance, therapeutic touch, and the use of a mirror to show the patient what is being performed. Finally, the healthcare setting contextual factors feature a comfortable setting, adequate environmental conditions, and appropriate design.
48467961|NCT04795869|DRUG|Brentuximab Vedotin|Given IV
48467962|NCT04795869|BIOLOGICAL|Pembrolizumab|Given IV
48467963|NCT01008709|DEVICE|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
48467964|NCT01008709|DEVICE|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
48627595|NCT02056132|OTHER|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
48627596|NCT05796817|DEVICE|Ventilator modification|The ventilator modification will be fitted to a ResMed Lumis 150, Breas® Nippy 4+ or Vivo 1, 2 or 3 ventilator. The participants oxygen level will be measured with and without the modification in place at their baseline ventilation, and with 1, 2 and 3 litres oxygen extra to their baseline. the researcher will then leave the modification on and slowly reduce the oxygen going into the ventilator, maintaining the participants SP02 at an acceptable level (\>95%)
48627597|NCT04251494|DIAGNOSTIC_TEST|Carotid intima media thickness measurement (CIMT)|CIMT is a measurement of the thickness of the two inner layers of the common carotid artery wall. Using ultrasound, a linear array transducer is placed on the surface of the skin at the neck. Electrocardiogram(ECG) electrodes are placed on each wrist and one on the ankle. An image of the common carotid artery (CCA) is then produced in anterior, posterior and lateral views, and saved along with the ECG recording. The wall thickness can then be measured at the same point in the cardiac cycle using semi-automated detection software (Philips QLAB), which can reduce observer variability. The CIMT will be averaged across left and right CIMTs, as the control reference values use an average of both sides.
48627598|NCT04251494|DIAGNOSTIC_TEST|Pulse Wave Velocity measurement|The PWV measures the speed of a pulse wave travelling between two points in the vascular systems of known distance between them. PWV will be measured by the gold standard carotid-femoral PWV method which is a direct measurement of aortic stiffness. A 3-Lead ECG is connected alongside measurements of the blood velocity trace for the left CCA 2cm proximal to the bifurcation, and for the left common femoral artery origin.
48283364|NCT00388089|DRUG|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
48283365|NCT00388089|OTHER|flow cytometry|No description
48283366|NCT00388089|OTHER|immunoenzyme technique|No description
48283367|NCT00388089|OTHER|immunohistochemistry staining method|No description
48283368|NCT00388089|OTHER|laboratory biomarker analysis|No description
48283369|NCT00504257|DRUG|Avastin|Day 1, every 21 day cycle
48283370|NCT00504257|DRUG|Docetaxel|Day 1, 8, every 21 day cycle
48283371|NCT02659449|DEVICE|made to measure compression gloves|Patients achieve tests with compression glove
48283372|NCT02659449|DEVICE|Compression bandaging|Patients achieve tests with compression bandaging
48627599|NCT04251494|DIAGNOSTIC_TEST|Ankle-brachial pressure index (ABPI)|A blood pressure cuff is placed around the ankle and upper arm of the participant. A continuous wave Doppler probe is used over the surface of the skin to locate the artery distal to the cuff (such as the brachial artery in the arm, or the anterior tibial and posterior tibial arteries in the ankle). The cuff is then inflated, and the systolic pressure identified by listening cessation of the sounds produced by the probe corresponding to blood flow in the artery. The ABPI is then the ratio of the highest systolic ankle pressure divided by the highest systolic brachial pressure for the left and right sides of the body.
48283373|NCT02659449|OTHER|Free Hands|Patients achieve tests without device
48283374|NCT03752905|DRUG|PTR-01|Recombinant human collagen 7 (rC7)
48467965|NCT04305730|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
48283375|NCT03752905|DRUG|Normal saline|Saline control
48283376|NCT06338787|OTHER|FeSC|Iron/yeast complex
48467966|NCT04305730|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
48467967|NCT01680367|PROCEDURE|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
48283377|NCT02302495|DRUG|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
48283378|NCT03926403|OTHER|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36)."
48283379|NCT03926403|PROCEDURE|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
48467968|NCT01680367|PROCEDURE|wound care management|Receive native collagen wound dressing
48467969|NCT01680367|OTHER|questionnaire administration|Ancillary studies
48467970|NCT04258709|BEHAVIORAL|AME|Participants receive education on AME and feedback on technique with a remotely-based IBCLC via live streaming video.
48467971|NCT04258709|BEHAVIORAL|Video-based infant care education|Participants view a standard set of web-based streamed videos addressing evidence-based infant care, unrelated to feeding/breastfeeding.
48467972|NCT00113061|PROCEDURE|Exercise|
48467973|NCT01691586|DEVICE|Remote patient monitoring|Remote monitoring of ICD and heart failure data
48467974|NCT01691586|OTHER|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
48467975|NCT01425840|DRUG|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
48467976|NCT02559219|OTHER|Questionniares|
48467977|NCT02697708|DIETARY_SUPPLEMENT|Potassium control diet|No additional potassium.
48467978|NCT02697708|DIETARY_SUPPLEMENT|Potassium gluconate diet|1000 mg K from potassium gluconate.
48467979|NCT02697708|DIETARY_SUPPLEMENT|Potato Diet|1000 mg K from potatoes.
48627600|NCT04251494|OTHER|Diet questionnaire and diet diary|Dietary information will be collected in two formats. One will be a 14-item questionnaire (Martínez-González et al., 2012), which is a simplified version of a comprehensive food frequency questionnaire. This provides a quick measure of compliance to a Mediterranean dietary pattern and a rough measure of protective and adverse dietary factors that could affect individual CVD risk. The second will be a 3-day diet diary (3DDD). This will consist of participants recording the foods that they consume and the quantities, which will then be analysed for macro- and micronutrient composition once completed.
48283380|NCT03926403|PROCEDURE|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
48283381|NCT05911997|DRUG|MTC 01|Slurry to be administered via colonoscopy
48467980|NCT02697708|DIETARY_SUPPLEMENT|French Fries Diet|1000 mg K from French Fries.
48467981|NCT05248399|BEHAVIORAL|COVID-19 Group Problem Solving|The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a \~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe \& Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
48283382|NCT05911997|DRUG|Fecal Microbiota Transplantation (FMT)|Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
48467982|NCT05248399|BEHAVIORAL|Standard of Care|The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
48467983|NCT00084864|DIETARY_SUPPLEMENT|calcitriol|Given orally
48467984|NCT00084864|DRUG|dexamethasone|Given orally
48467985|NCT00084864|OTHER|clinical observation|No intervention before surgery
48627601|NCT04251494|OTHER|Routine blood samples|Blood samples will be taken from participants during their outpatient appointment. Patients routinely have blood samples taken during this clinic. The study will use the results from the routine blood tests, and also extra blood samples to collect data on other biomarkers. The laboratory facilities at Guy's and St Thomas Hospitals will be used to conduct analysis, no other laboratories will be used. Data will be collected on Phenylalanine levels, lipids, vitamin B12 and related biomarkers.
48467986|NCT02754492|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
48627602|NCT03174522|DRUG|REX-001|REX-001 is administered through an intra-arterial catheter.
48627603|NCT03174522|DRUG|Placebo|Placebo is administered through an intra-arterial catheter.
48627604|NCT02962466|OTHER|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
48627605|NCT05883878|GENETIC|PRS|genetic test for the evaluation of PRS cardiovascular risk
48627606|NCT05883878|DEVICE|Digital app and wearable device|a wearable device connected with its app
48627607|NCT00520468|DRUG|Erythropoietin|40,000 units injected under the skin (SQ) weekly
48627608|NCT00520468|DRUG|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
48627609|NCT00520468|DRUG|G-CSF|300 mcg injected under the skin (SQ) two times per week
48627610|NCT00520468|DRUG|Prednisone|60 mg per day for 7 days, taper over 1 month
48467987|NCT04256707|DRUG|Selinexor 100 mg|"100-mg 2 formulations:~* 5 × 20-mg tablets (Tablet A)~* 1 × 100-mg tablet (Tablet B)"
48627611|NCT05134844|OTHER|Hydrotherapy- Snoezelen|Multi sensory approach in water
48627612|NCT05134844|OTHER|Snoezelen|Multu Sensory approach on land
48627613|NCT05608707|BEHAVIORAL|Physical activity intervention|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
48627614|NCT05608707|DIETARY_SUPPLEMENT|Personalised nutrition intervention|Two Plant-based Protein and Fibre (PPF) product products have been selected from six initially developed, with best amino acid blend, taste, and bioavailability. Participants will be provided with the PPFs to consume daily as part of a personalised diet over 12 weeks.
48467988|NCT04256707|DRUG|Docetaxel|75 mg/m\^2 IV
48467989|NCT04256707|DRUG|Pembrolizumab|200 mg IV
48467990|NCT04256707|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m\^2~* Leucovorin 400 mg/m\^2~* 5-FU 400 mg/m\^2 bolus~* 5-FU 2400 mg/m\^2 IV"
48467991|NCT04256707|DRUG|Selinexor 40 mg|- 2 × 20-mg tablets (Tablet A)
48467992|NCT04256707|DRUG|Selinexor 80 mg|- 4 × 20-mg tablets (Tablet A)
48467993|NCT04256707|DRUG|Selinexor 60 mg|- 3× 20-mg tablets (Tablet A)
48627615|NCT05546528|DEVICE|Photobiomodulation|G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
48627616|NCT05546528|DEVICE|Photobiomodulation- Sham|G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
48627617|NCT02512159|PROCEDURE|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
48467994|NCT02955004|PROCEDURE|Electrical cardioversion|Transthoracic direct current electrical cardioversion
48467995|NCT00881231|DRUG|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
48467996|NCT00881231|DRUG|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
48467997|NCT01863433|BIOLOGICAL|Trivalent Influenza Vaccine|
48467998|NCT00099580|DRUG|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
48467999|NCT00099580|DRUG|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
48468000|NCT04194216|DRUG|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."|Treatment Arm A
48283383|NCT04609384|DEVICE|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
48468001|NCT04194216|DRUG|"Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days"|Treatment Arm B
48468002|NCT04850027|PROCEDURE|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
48627618|NCT02512159|PROCEDURE|Healing|"Were handled as follows:~1. Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~2. healing of skin ulcers were performed every 24 hours.~3. the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
48627619|NCT02619513|DRUG|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
48627620|NCT02619513|DRUG|Ropivacaine|Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
48627621|NCT02619513|DEVICE|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
48468003|NCT00623636|DRUG|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
48468004|NCT00623636|DRUG|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
48468005|NCT05289557|DRUG|Bonjesta|Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
48468006|NCT05289557|DRUG|Placebo|Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
48627622|NCT03343574|OTHER|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
48627623|NCT00745160|OTHER|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
47937606|NCT00491426|DRUG|Amphotericin B|Drug prescribed per routine medical care.
48283384|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
48283385|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
48283386|NCT05155098|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
48283387|NCT02363400|DRUG|MEP|Adjuvant Chemotherapy
48468007|NCT01928615|DRUG|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
48468008|NCT01928615|DRUG|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
48468009|NCT01928615|DRUG|Chemotherapy|Standard chemotherapy for early breast cancer.
48468010|NCT05892731|OTHER|with depression|age-related hearing loss with depression
48468011|NCT05892731|OTHER|without depression|age-related hearing loss without depression
48468012|NCT00117182|DRUG|Dry powder mannitol|
48468013|NCT00117182|DRUG|Budesonide 400mcg administered via turbuhaler|
48468014|NCT00117182|DRUG|Ipratropium bromide 80mcg|
48468015|NCT00117182|DRUG|Salbutamol 400mcg|
48468016|NCT03025776|BEHAVIORAL|Reaching|sitting reaching under various task conditions (size, speed, location)
48468017|NCT03025776|BEHAVIORAL|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many \& which hand to use, kinematic data collected
48468018|NCT04332211|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
48627624|NCT03899090|BEHAVIORAL|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
48468019|NCT04332211|DRUG|Pseudoephedrine 60 MG|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
48468020|NCT04332211|DRUG|Placebo oral tablet|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
48468021|NCT03501420|OTHER|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
48627625|NCT03899090|BEHAVIORAL|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
48627626|NCT03899493|OTHER|Observation|Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
48627627|NCT03432429|OTHER|REIMS iKnife|Use of REIMS iKnife in breast conserving surgery
48627628|NCT00514527|DRUG|oritavancin|Oritavancin as a single, infrequent or daily dose.
48468022|NCT03501420|OTHER|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
48468023|NCT03501420|OTHER|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
48468024|NCT03538795|COMBINATION_PRODUCT|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
48468025|NCT05995379|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|"Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed."
48468026|NCT01806311|DRUG|Candesartan32mg|
48468027|NCT01806311|DRUG|Amlodipine10mg|
48468028|NCT03552367|OTHER|Personalized structured exercise program|The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance
48468029|NCT03552367|OTHER|Non personalized non-structured exercise program|The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
48468030|NCT06447441|OTHER|Placebo|Enteral supplementation of placebo in 3 consecutive days within 96 hours after ICU admission.
48468031|NCT06447441|OTHER|Cholecalciferol|Enteral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days within 96 hours after ICU admission
48468032|NCT06168903|PROCEDURE|Ultrasound guided EOI block|"Before receiving general anesthesia, patients will be randomly assigned to one of the two study groups: the EOI block group or the ESPB group.~Using Ultrasound (Siemens ACUSON X300 Ultrasound System), guided blocks will be administered immediately after the induction of anesthesia and prior to surgical incision by consultant anesthesiologists who have experience in regional anesthesia and are familiar with the EOI and ESPB blocks"
48468033|NCT04729101|DRUG|Vonoprazan|Oral tablet
48468034|NCT04729101|DRUG|Lansoprazole|Oral capsule
48468035|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
48468036|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
48468037|NCT03639220|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
48468038|NCT01691430|DIETARY_SUPPLEMENT|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
48468039|NCT01691430|DIETARY_SUPPLEMENT|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
48627629|NCT00294398|OTHER|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
48627630|NCT00294398|OTHER|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
48627631|NCT03427281|BEHAVIORAL|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
48627632|NCT04913636|DEVICE|Treatment Gel|In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
48627633|NCT04913636|OTHER|Sham Control|Subjects will perform their regular denture cleaning routine.
48627634|NCT03107000|PROCEDURE|Trabeculectomy|Incisional surgery for glaucoma
48627635|NCT03107000|PROCEDURE|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
48627636|NCT04664088|PROCEDURE|Acupuncture|"Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary."
48627637|NCT04664088|DRUG|Venlafaxine|Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
48283388|NCT02375022|DRUG|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
48468040|NCT04664881|DEVICE|SmartHeart Device|A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
48627638|NCT00200824|DRUG|Soy Isoflavone Nutritional Supplements|
48627639|NCT00087412|DRUG|erlotinib hydrochloride|Given orally
48468041|NCT02180230|DEVICE|Shorty implants|Dental implant insertion to maxilla or mandible
48468042|NCT02393560|PROCEDURE|DECT scan|
48468043|NCT03448276|OTHER|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
48468044|NCT03448276|OTHER|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
48468045|NCT02890225|PROCEDURE|3 days after|in 3 days after RIRS.
48468046|NCT02890225|PROCEDURE|10days after|in10 days after RIRS.
48468047|NCT02890225|PROCEDURE|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
47937607|NCT00491426|DRUG|Ambisome|Drug prescribed per routine medical care.
48283389|NCT00326820|DRUG|ibandronate sodium|
48283390|NCT00326820|DRUG|zoledronic acid|
48283391|NCT00326820|DRUG|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
48283392|NCT02463942|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
48468048|NCT03506087|BEHAVIORAL|Advance care planning coaching session.|A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
48283393|NCT02463942|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
48468049|NCT03506087|BEHAVIORAL|Printed advance care planning materials|Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
48468050|NCT02197416|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
48627640|NCT00087412|OTHER|laboratory biomarker analysis|Correlative studies
48627641|NCT05492435|DEVICE|transcranial direct current stimulation|tDCS can regulate cortical excitability by influencing membrane polarity, where anodic current increases excitability and cathodic current reduces excitability. Therefore, in post-stroke patients when the anode is applied to the cerebral hemisphere ipsilesional to the lesion or the cathode to the contralesional hemisphere, the balance between the interhemispheres tends to be restored.
48627642|NCT00016302|DRUG|prednisone|Given orally
48468051|NCT04232540|DEVICE|MedViewer report|Results from the analysis of hair samples performed using the MedViewer
48468052|NCT02310841|DEVICE|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
48627643|NCT00016302|DRUG|vincristine sulfate|Given IV
48627644|NCT00016302|DRUG|daunorubicin hydrochloride|Given IV
48627645|NCT00016302|DRUG|asparaginase|Given IM
47937608|NCT00491426|DRUG|Anidulafungin|Drug prescribed per routine medical care.
48283394|NCT02463942|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
48283395|NCT01719757|DRUG|Oxycodone/Naloxone|Twice daily
48468053|NCT02257437|DIETARY_SUPPLEMENT|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
48468054|NCT02257437|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
48468055|NCT02257437|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
48468056|NCT02257437|DIETARY_SUPPLEMENT|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
48468057|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
48468058|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
48468059|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
47937609|NCT00491426|DRUG|Caspofungin|Drug prescribed per routine medical care.
47937610|NCT02891005|DEVICE|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
47937611|NCT02891005|DEVICE|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
47937612|NCT02710500|DRUG|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
47937613|NCT04485429|DRUG|Methylprednisolone|Methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.
48283396|NCT04515836|DRUG|Olaparib|Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
48468060|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
48627646|NCT00016302|DRUG|methotrexate|Given IT and orally
48627647|NCT00016302|DRUG|cyclophosphamide|Given IV
48627648|NCT00016302|DRUG|cytarabine|Given IV or SC
48627649|NCT00016302|DRUG|mercaptopurine|Given orally
48627650|NCT00016302|DRUG|leucovorin calcium|Given IV or orally
48627651|NCT00016302|DRUG|dexamethasone|Given orally
48627652|NCT00016302|DRUG|doxorubicin hydrochloride|Given IV
48627653|NCT00016302|DRUG|thioguanine|Given orally
48627654|NCT00016302|RADIATION|radiation therapy|Undergo cranial irradiation
47937614|NCT04485429|DRUG|Heparin|Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
48627655|NCT00016302|DRUG|nelarabine|Given IV
48283399|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
48283400|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
48283401|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
48468061|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
48468062|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
48468063|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
48468064|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
48468065|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
48627656|NCT00016302|DRUG|pegaspargase|Given IM
48627657|NCT00016302|RADIATION|radiation therapy|Undergo craniocervical radiotherapy
48627658|NCT00016302|OTHER|pharmacological study|Correlative studies
48627659|NCT00016302|OTHER|laboratory biomarker analysis|Correlative studies
48627660|NCT01251679|BEHAVIORAL|Hand washing|hand washing education and material
48627661|NCT01251679|DEVICE|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
48627662|NCT03419468|OTHER|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
48468066|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
48468067|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
48468068|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
48468069|NCT01898234|DEVICE|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
48468070|NCT01898234|DEVICE|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
48627663|NCT06422208|BIOLOGICAL|Autologous midbrain dopamine neurons|The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.
48627664|NCT04864392|DRUG|LNA043 Dosing Regimen A|Injection to the knee
48627665|NCT04864392|DRUG|LNA043 Dosing Regimen B|Injection to the knee
48627666|NCT04864392|DRUG|LNA043 Dosing Regimen C|Injection to the knee
48627667|NCT04864392|DRUG|LNA043 Dosing Regimen D|Injection to the knee
48627668|NCT04864392|DRUG|Placebo|Injection to the knee
48627669|NCT00676052|DRUG|GSK233705 12.5mcg|Once daily via dry powder inhaler
48627670|NCT00676052|DRUG|GSK233705 25mcg|once daily via dry powder inhaler
48627671|NCT00676052|DRUG|GSK233705 50mcg|Once daily via dry powder inhaler
48627672|NCT00676052|DRUG|GSK233705 100mcg|Once daily via dry powder inhaler
48627673|NCT00676052|DRUG|GSK233705 200mcg|Once daily via dry powder inhaler
48627674|NCT00676052|DRUG|Placebo|Once daily via dry powder imhaler
48627675|NCT03106805|PROCEDURE|early insertion|insertion at 4th postpartum week
48627676|NCT03106805|PROCEDURE|late insertion|insertion at 6th postpartum week
48627677|NCT02574208|PROCEDURE|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
48468071|NCT01898234|DEVICE|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
48468072|NCT01898234|DEVICE|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
48468073|NCT05645315|DRUG|TQB2618 injection and TQB2450 injection|TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
48627678|NCT02574208|PROCEDURE|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
48627679|NCT01732692|DRUG|MOVIPREP|MOVIPREP solution
48627680|NCT01852136|DEVICE|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
48627681|NCT01852136|DEVICE|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
48100593|NCT01532232|DRUG|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
48106930|NCT02015741|DEVICE|EEG monitoring with Bispectral Index and NeuroSENSE|
48468074|NCT03929328|PROCEDURE|High flow oxygen therapy in spontaneous breathing trial|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
48468075|NCT00387205|DRUG|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
48468076|NCT02111109|DEVICE|Side Stream Dark Field Microscopy|
48468077|NCT00002224|DRUG|Nelfinavir mesylate|
48468078|NCT00002224|DRUG|Stavudine|
48468079|NCT00002224|DRUG|Didanosine|
48468080|NCT00325312|DRUG|carbon dioxide, subcutaneous application|
48468081|NCT02864550|DRUG|Doxycycline|doxycycline 100mg orally daily
48468082|NCT02864550|OTHER|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
48468083|NCT00490321|DEVICE|VentrAssistTM Left Ventricular Assist Device|
48468084|NCT05513469|DRUG|Lutathera|regulair PRRT of 4 cycles with 7.4GBq
48627682|NCT01852136|DEVICE|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
48106931|NCT02015741|BEHAVIORAL|Clinical observation|Patients will be observed during awake periods and during natural sleep.
48106932|NCT03002844|DRUG|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
48106933|NCT03002844|DRUG|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
48106934|NCT03002844|DRUG|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
48106935|NCT00750750|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
48627683|NCT01913470|DRUG|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
48627684|NCT00778180|DRUG|furosemide 80 mg tablets|
48627685|NCT03559309|DIAGNOSTIC_TEST|Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing|Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
48627686|NCT03650270|DRUG|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
47937615|NCT03551340|DIAGNOSTIC_TEST|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
48468085|NCT04436133|BIOLOGICAL|Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
48468086|NCT04436133|BIOLOGICAL|9-valent HPV vaccine（Gardasil 9）|Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle
48468087|NCT01632306|DRUG|LY2090314|LY2090314 administered IV
48468088|NCT01632306|DRUG|FOLFOX|FOLFOX administered IV
48468089|NCT01632306|DRUG|Gemcitabine|Gemcitabine administered IV
48468090|NCT01632306|DRUG|Nab-paclitaxel|Nab-paclitaxel administered IV
48468091|NCT05878522|DRUG|sisunatovir|6 capsules administered Q12 hours for 5 doses
48468092|NCT05878522|DRUG|placebo|6 capsules administered Q12 hours for 5 doses
48468093|NCT05878522|DRUG|moxifloxacin|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
48468094|NCT05878522|DRUG|sisunatovir|7 capsules administered Q12 hours for 5 doses
48468095|NCT05580887|DRUG|mFOLFIRINOX|every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1 Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
48468096|NCT05580887|DRUG|Doxorubicin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
48468097|NCT05580887|DRUG|Cyclophosphamid|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
48468098|NCT05580887|DRUG|Paclitaxel|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
48468099|NCT05580887|DRUG|Carboplatin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
48468100|NCT05080140|DRUG|Ezetimibe 10mg|Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
48468101|NCT06292364|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
48468102|NCT06292364|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
48468103|NCT01307943|OTHER|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
48468104|NCT01307943|OTHER|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
48468105|NCT04912206|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
48468106|NCT01861990|DRUG|Valproic Acid|All participants enrolled on valproic acid arm.
47937616|NCT02359851|BIOLOGICAL|Pembrolizumab|Given IV
47937617|NCT02359851|OTHER|Laboratory Biomarker Analysis|Correlative studies
47937618|NCT05307939|DIAGNOSTIC_TEST|HPV ctDNA Assay|HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
48468107|NCT00794053|PROCEDURE|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
48468108|NCT03646162|DRUG|Veru-944|Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
48468109|NCT03646162|DRUG|Placebo|Placebo
48468110|NCT05747560|DIETARY_SUPPLEMENT|Buckwheat|Take buckwheat at a dose of 500 mg twice a day for 6 months.
48283402|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
48283403|NCT05939284|DRUG|Injection of Cetrorelix|Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
48283404|NCT05939284|DRUG|Oral insertion of dydrogeserone|Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
48283405|NCT05297565|BIOLOGICAL|Nivolumab/rHuPH20|Specified dose on specified days
48468111|NCT05747560|DIETARY_SUPPLEMENT|Astragalus extract|Take astragalus extract at a dose of 450 mg twice a day for 6 months.
48627687|NCT02846727|DEVICE|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
48627688|NCT01866592|DRUG|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
48627689|NCT06214715|DEVICE|Philips ultrasonography system|RRI will be measured by renal ultrasonography with a C5-1 convex probe using a Philips ultrasonography model device.
48627690|NCT03986268|DRUG|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
47914257|NCT01575626|DRUG|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
47937619|NCT05307939|DIAGNOSTIC_TEST|MRI Studies|Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.
48283406|NCT05297565|BIOLOGICAL|Nivolumab|Specified dose on specified days
48283407|NCT02490852|OTHER|Investigational infant formula|fed ad libitum
48468112|NCT05747560|DIETARY_SUPPLEMENT|Wolfiporia extract|Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
48468113|NCT00222040|RADIATION|Ultrasound|2-MHz, low intensity transcranial ultrasound
48468114|NCT00222040|DRUG|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
48468115|NCT01889550|BEHAVIORAL|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
48468116|NCT01889550|BEHAVIORAL|Access to the website www.ouh.dk|Access to the usual information from the hospital website
48627691|NCT03529149|COMBINATION_PRODUCT|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV\>37cm/s of （middle cerebral artery)MCA, PI \< 1.34cm/s, aMFV\>40cm/s of (basilar artery)BA, PI \< 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
48627692|NCT04149353|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
48627693|NCT02027194|DRUG|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
48283408|NCT02490852|OTHER|Active Comparator: Commercially available Infant formula|fed ad libitum
48283409|NCT02490852|OTHER|Active Comparator: Human milk|fed ad libitum
48283410|NCT06122584|DRUG|[18F]PSMA-1007|Diagnostic radiopharmaceutical for PET scan
48283411|NCT02748369|DRUG|Somatostatin|Somatostatin infusion to create a low insulin state.
48283412|NCT02748369|DRUG|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
48283413|NCT00451087|PROCEDURE|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
48283414|NCT00451087|PROCEDURE|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
48283415|NCT05812716|BEHAVIORAL|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
48468117|NCT03863041|OTHER|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
48468118|NCT01209988|DRUG|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
48468119|NCT01209988|OTHER|No medication|No medication
48468120|NCT03209167|BEHAVIORAL|Questionnaire|Two study-specific questionnaires
48468121|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
48468122|NCT05260008|DRUG|ATX-101|ATX-101 (bupivacaine) implant, one-time administration into the surgical site
48468123|NCT05260008|DRUG|bupivacaine hydrochloride without epinephrine|bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
47937620|NCT05307939|BEHAVIORAL|EORTC QLQ H&N 35 and C30|The EORTC QLQ H\&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
47937621|NCT05307939|BEHAVIORAL|MDADI-HN|The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
48468124|NCT02311517|DRUG|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
48468125|NCT02311517|DRUG|Normal Saline|
47937622|NCT05307939|BEHAVIORAL|COST-FACIT|Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.
47937623|NCT05307939|RADIATION|Intensity-Modulated Radiation Therapy (Arm A)|59.4-60 Gy in 1.8-2 Gy fractions: CTV_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck
47937624|NCT05307939|COMBINATION_PRODUCT|Chemoradiation (Arm B)|30 Gy in 2 Gy fractions: CTV_primary, CTV_node-positive neck, CTV_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons
48283416|NCT01288183|PROCEDURE|sham tDCS|"sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day"
48468126|NCT05761587|OTHER|Questionnaires|questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
48468127|NCT02156453|PROCEDURE|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
48468128|NCT05079841|DEVICE|Electric breast pump|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours
48468129|NCT05079841|DRUG|Exogenous oxytocin intravenous infusion without nipple stimulation.|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
48468130|NCT04742608|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48627694|NCT02027194|DRUG|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
48627695|NCT02027194|DRUG|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
48627696|NCT06140641|DIETARY_SUPPLEMENT|Probiotics|Bifidobacterium Longum BL21 or placebo for 8 weeks.
48627697|NCT04570579|DEVICE|Vivity Extended Depth of Focus Intraocular Lens|Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.
48627698|NCT05680701|OTHER|real tACS|The participant will receive one session of 10 Hz tACS for 20-minutes
48627699|NCT05680701|OTHER|sham tACS|The participant will receive one session of active-sham tACS for 20-minutes
48627700|NCT03112551|DRUG|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
48627701|NCT00602784|BIOLOGICAL|IC41|
48627702|NCT05176574|BEHAVIORAL|Questionnaire|A questionnaire will be developed via the Delphi method, will be pilot tested and implemented to assess physicians' perceptions and behaviors on physical activity and exercise in chronic, non-communicable diseases.
48627703|NCT01402700|DEVICE|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
48627704|NCT04685122|PROCEDURE|Phacoemulsification and intraocular lens implantation for cataract|Phacoemulsification and intraocular lens implantation for cataract
48627705|NCT00929032|RADIATION|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
48627706|NCT05081934|BEHAVIORAL|A-CRA|12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.
48627707|NCT05081934|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
48468131|NCT04742608|OTHER|Electronic Health Record Review|Medical charts are reviewed
48468132|NCT02342041|DRUG|SUVN-G3031|
48468133|NCT02342041|DRUG|Placebo|
48627708|NCT02451735|BEHAVIORAL|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
48627709|NCT02451735|BEHAVIORAL|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
48627710|NCT01995435|DEVICE|Telemedicine refraction|
48627711|NCT01995435|DEVICE|Traditional refraction|
48627712|NCT04359615|DRUG|Favipiravir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.
48627713|NCT04359615|DRUG|Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
48627714|NCT04721262|DEVICE|Hyperfine Portable MRI|The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
48468134|NCT03474393|OTHER|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
48468135|NCT06317402|OTHER|malnutrition questionary|At the patient's bed, using a questionnaire, evaluators take anthropometric measurements (weight, height, muscle strength) and collect biological data (albumin, pre-albumin, CRP, if available in the medical record) to establish nutritional status according to HAS criteria for undernutrition 2019-2021 and 2003-2007.
48468136|NCT01195116|DRUG|Dexmedetomidine|1 mcg/kg/hour
48468137|NCT01195116|DRUG|Normal Saline|1mcg/kg/hr
48468138|NCT03247699|OTHER|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
48468139|NCT03247699|OTHER|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
48468140|NCT04381013|DEVICE|Emergency Ventilator Splitter|Device to enable oxygen delivery to two patients independently from a single ventilator.
48468141|NCT04202458|DRUG|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
48627715|NCT00663351|DEVICE|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
48627716|NCT00663351|DEVICE|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
48468142|NCT01424098|BEHAVIORAL|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
48468143|NCT05540171|OTHER|Oral health education and instructions/training for self-oral care|Education intervention
48468144|NCT06458868|OTHER|salt water or tap water before UVA|Instead of using standard bath PUVA, this study investigates the efficacy of tap water or salt water with UVA in the treatment of palmoplantar psoriasis.
48468145|NCT06458868|OTHER|salt water or tap water before nbUVB|Instead of using standard nbUVB, this study investigates the efficacy of tap water or salt water with nbUVB in the treatment of palmoplantar psoriasis.
48468146|NCT04736394|DRUG|APL-1202|APL-1202 single-agent oral treatment
48468147|NCT04736394|DRUG|Epirubicin Hydrochloride|Epirubicin hydrochloride
48468148|NCT03473002|OTHER|Placebo|0.9% Sodium Chloride
48468149|NCT03473002|BIOLOGICAL|SeVRSV Vaccine|Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
48468150|NCT02132650|BEHAVIORAL|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
48468151|NCT02132650|BEHAVIORAL|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
48468152|NCT05366231|DRUG|Kesuting syrup|"Conventional treatment + Kesuting Syrup, take orally, 20 ml once, three times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later). Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
48468153|NCT05366231|DRUG|LianHuaQingWen Granules|"Conventional treatment + LianHuaQingWen Granules, orally, 1 bag at a time, 3 times a day.Conventional treatment refer to Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9 or later).Except for the test drugs, during the observation period, it is prohibited to use other Chinese and Western medicines for cough and phlegm elimination for treatment. If combined use is required, it shall be recorded truthfully."
48468154|NCT01787929|PROCEDURE|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
48468155|NCT04955015|PROCEDURE|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
48468156|NCT03941080|DIAGNOSTIC_TEST|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
48468157|NCT03941080|BEHAVIORAL|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
48468158|NCT03941080|DIAGNOSTIC_TEST|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
48468159|NCT04809662|DRUG|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for \~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
48627717|NCT02587364|DRUG|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
48627718|NCT02587364|DRUG|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
48468160|NCT00873834|DRUG|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
48627719|NCT02587364|DRUG|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
48627720|NCT02587364|DRUG|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
48627721|NCT02587364|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
48627722|NCT02587364|DRUG|Placebo|Placebo once daily (QD)
48627723|NCT02050295|PROCEDURE|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
48627724|NCT02050295|PROCEDURE|Sham washout|Infusion of saline to maintain catheter patency.
48283417|NCT01288183|PROCEDURE|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
48283418|NCT00537719|DRUG|GSK716155|albiglutide subcutaneous injection
48627725|NCT02050295|DRUG|Saline|
48627726|NCT05345587|OTHER|THESS monitoring|Consultation with the pharmacist to look for possible medication interactions between the oral therapy and the patient's usual treatments and to inform the patient about his treatment to improve QOL and compliance. Consultation and follow-up by a nurse. Weekly notification by THESS Application of the symptoms experienced by the patient over the last 7 days
48283419|NCT00537719|DRUG|Placebo|placebo injection
48283420|NCT00370344|PROCEDURE|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
48283421|NCT00370344|PROCEDURE|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
48283422|NCT02801175|PROCEDURE|Pulmonary vein isolation|
48468161|NCT00873834|DRUG|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
48468162|NCT05820919|BEHAVIORAL|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
48468163|NCT05820919|OTHER|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
48468164|NCT05554965|DRUG|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
48468165|NCT05554965|DRUG|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
48468166|NCT05736796|OTHER|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
48468167|NCT05736796|OTHER|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
48468168|NCT01550367|DRUG|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
48468169|NCT01550367|DRUG|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
48468170|NCT03293719|DEVICE|BPK-S Integration UC|Primary Knee Endoprosthesis
48627727|NCT05456217|OTHER|admission to ICU|admission to an intensive care unit or high dependency unit in Kenya
48627728|NCT01972178|DRUG|PRC-4016|
48627729|NCT01972178|DRUG|Placebo|
48627730|NCT01972178|DRUG|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
48627731|NCT05320588|DRUG|BIO-106|BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
48627732|NCT05320588|DRUG|Pembrolizumab|Programmed death receptor-1 (PD 1)-blocking antibody
48283423|NCT00304473|DRUG|Quetiapine fumarate|
48283424|NCT05459597|DRUG|antiepileptic drugs|phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
48283425|NCT00997074|DRUG|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
48283426|NCT00144170|DRUG|Tipranavir (with low dose ritonavir)|
48283427|NCT00144170|DRUG|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
48283428|NCT00337051|DRUG|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
48283429|NCT00337051|DRUG|Propofol|General anesthesia with propofol TCI
48283430|NCT02589977|DRUG|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
48468171|NCT01096602|BIOLOGICAL|DC AML Vaccine|Group 1: 2-3 doses of the vaccine at 4 week intervals
48627733|NCT02029547|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
48627734|NCT00516854|DRUG|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
48283431|NCT01710761|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
48283432|NCT01710761|DIETARY_SUPPLEMENT|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
48468172|NCT01112891|DRUG|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
48468173|NCT01112891|DRUG|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
48468174|NCT01112891|DRUG|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
48468175|NCT05975112|DIAGNOSTIC_TEST|Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge|Coagulation tests named earlier as well as SpHb
48627735|NCT04883853|PROCEDURE|Mild _moderate Ptosis tucking|A modified levator muscle tucking procedure.The level of sutures was determined according to the levator muscle function and the desired eyelid height. The middle (main) suture was taken first at the level of the medial part of the pupil and was tightened to keep the lid height at the superior limbus and the other two sutures (medial and lateral) were then adjusted. A spindle-shaped, horizontal part of the levator aponeurosis (2.5-3 mm wide and 0.5 mm deep) was excised at the site of insertion into the tarsus before tightening the central suture to induce strong fibrosis and adhesion between the tucked levator aponeurosis and the tarsus
48627736|NCT01799278|DRUG|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
48627737|NCT03850106|DIETARY_SUPPLEMENT|Placebo|Placebo
48627738|NCT03850106|DIETARY_SUPPLEMENT|Indus810|Active product
48627739|NCT00991432|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
47937625|NCT04589312|BIOLOGICAL|Standard of care vaccines|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance)
48468176|NCT01068704|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response
48468177|NCT01068704|DRUG|Lapatinib|Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
48468178|NCT01068704|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response
48468179|NCT01128868|DEVICE|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
48627740|NCT01272895|DEVICE|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
48627741|NCT01295892|DRUG|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
48627742|NCT04003571|BEHAVIORAL|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
48627743|NCT04003571|BEHAVIORAL|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
48627744|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
48627745|NCT02337946|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
48627746|NCT00731003|DRUG|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
48627747|NCT00731003|OTHER|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
47937626|NCT04589312|BIOLOGICAL|Boostagen, (BioNet-Asia)|Visit 1: Check tetanus immunisation status. Vaccination up to 25+ 6 weeks of pregnancy with Td; Visit 2: vaccination at least 4 weeks after visit 2 with either Tdap or Td (per randomisation and according to WHO guidance);
47937627|NCT00976573|BIOLOGICAL|bevacizumab|Given IV
47937628|NCT00976573|DRUG|carboplatin|Given IV
47937629|NCT00976573|DRUG|everolimus|Given orally
47937630|NCT00976573|DRUG|paclitaxel|Given IV
48283433|NCT06031753|BEHAVIORAL|Time restricted eating|Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
48283434|NCT05773456|OTHER|Sushi and wakame salad|One serving of mixed sushi and wakame salad
48283435|NCT00653315|DRUG|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
48283436|NCT00653315|DRUG|Ultracet|Tablets, 37.5mg/325mg
48468180|NCT01128868|DEVICE|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
48468181|NCT04212819|OTHER|Before Erythrocyte Suspension (ES)|ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.
47937631|NCT06330844|BEHAVIORAL|Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)|RBSEF-CCT-MCI differs from ME-CCT in that this intervention integrates psychoeducation and strategies for processing and coping with race/ethnicity-related stressors, as part of the larger conversation in ME-CCT regarding stress, and how stress interferes with attention, learning, and subsequently one's subjective sense of memory.
48468182|NCT04212819|OTHER|After Erythrocyte Suspension (ES)|Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
48468183|NCT05343273|DIAGNOSTIC_TEST|taking a blood sample|blood collection for routine biochemical analysis
48468184|NCT06551129|DRUG|Mavacamten|As prescribed by treating physician
48468185|NCT02646800|DRUG|Micafungin|Injection
48627748|NCT00731003|OTHER|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
48627749|NCT00731003|DRUG|Placebo capsule|Placebo for 5-HTP
48627750|NCT00429299|DRUG|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
48468186|NCT03609333|DEVICE|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
48468187|NCT03749915|DEVICE|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
48468188|NCT03749915|DRUG|Ametop|Tetracaine Hydrochloride Gel 4%
48627751|NCT00429299|BIOLOGICAL|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
48627752|NCT00429299|DRUG|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
48627753|NCT00429299|DRUG|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
48617859|NCT01710423|BEHAVIORAL|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
48627754|NCT00429299|DRUG|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
48627755|NCT00429299|DRUG|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
48106936|NCT00750750|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
48627756|NCT00191919|DRUG|Duloxetine Hydrochloride|
48627757|NCT00191919|DRUG|Placebo|
48627758|NCT02508207|DRUG|Tezacaftor/Ivacaftor|Tezacaftor/Ivacaftor FDC
48627759|NCT02508207|DRUG|Ivacaftor|
48627760|NCT02508207|DRUG|Tezacaftor/Ivacaftor matching placebo|
48627761|NCT02508207|DRUG|Ivacaftor matching placebo|
48627762|NCT06392126|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
48468189|NCT04666597|PROCEDURE|Modified CariesCare International management|"Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~1. D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~2. D-DETECT \& ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~3. D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~4. D-DO: Appropriate Tooth-preserving \& Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment."
48468190|NCT01176981|DRUG|High Dose Methotrexate|"Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days)."
48468191|NCT01618487|PROCEDURE|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
48468192|NCT01618487|PROCEDURE|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
48468193|NCT01618487|PROCEDURE|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
48627763|NCT06460129|OTHER|Brugger's Exercises|"1. The participant will sit upright and wrap an elastic resistance band around each hand, leaving the palms open. They will perform thumb and finger abduction and extension, wrist extension, and forearm supination. This will be followed by scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension, holding this position for 10 seconds.~2. In both sitting and standing positions, the participant will sit at the edge of a seat, naturally lifting the sternum, with legs spread at a 45-degree angle and feet slightly turned out. Shoulders should be relaxed, chin tucked, and elbows fully extended. The participant will keep their shoulders down, imagining the scapulae pressing together and downward into a V shape, with thumbs turned out, palms up, and fingers spread. This position is held for 10 seconds."
48627764|NCT06460129|OTHER|Kendal Exercise|"1. In a supine position, the participant will place a towel around their neck. With their head on the floor, they will tuck their chin and use the towel to apply gentle resistance, holding for 10 seconds to strengthen the deep flexor muscles of the cervical spine.~2. In a prone position, the participant will point their thumbs toward the ceiling and extend their arms fully while leaning forward, then return to the starting position. They will then extend their arms horizontally and hold for 10 seconds.~3. The participant will place both hands on the back of their head, lift their elbows upward, pull them back, and simultaneously spread their arms out to the side. This position will be held for 10 seconds before returning to the starting position."
48283437|NCT03723447|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
48468194|NCT01873339|DRUG|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
48627765|NCT03313193|OTHER|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for \~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
48627766|NCT00235313|PROCEDURE|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
48627767|NCT00235313|DRUG|nicotine patch|normal following with a nicotine patch
48627768|NCT01334775|PROCEDURE|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
48627769|NCT02950584|OTHER|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
48627770|NCT02950584|OTHER|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
48627771|NCT01370889|DRUG|resveratrol|Given PO
48627772|NCT01370889|OTHER|laboratory biomarker analysis|Correlative studies
48627773|NCT02517489|DRUG|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
48627774|NCT02517489|DRUG|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
48627775|NCT04915066|OTHER|Medical data collection|Collection of medical data from patients'medical records
48627776|NCT04332120|PROCEDURE|tubal sterilization|
48283438|NCT03723447|DRUG|Bupivacaine/epinephrine/dexamethasone|Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
48468195|NCT01873339|DRUG|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
48283439|NCT00013806|DRUG|131I-MIBG|
48283440|NCT06090474|DRUG|NDC-002|Combination of NDC-002B and NDC-002C
48283441|NCT04974307|DEVICE|OrCam MyEye 2|The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
48627777|NCT01484002|DEVICE|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
48283442|NCT05034679|BIOLOGICAL|Vcinated|Patients who were vacinated.
48627778|NCT00001818|DRUG|Hydroxyurea|
48283443|NCT03150940|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram used to demonstrate cardiac function
48283444|NCT03150940|DIAGNOSTIC_TEST|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
47937632|NCT06330844|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)|"ME-CCT focuses on:~1. Cognitive training, psychotherapeutic, and lifestyle techniques.~2. Incorporates CCT techniques designed to help patients manage problems with memory, attention, and executive functions (i.e., organization, planning, decision-making, and problem-solving).~3. Includes mindfulness-based stress reduction practice which has been shown to improve cognitive and neuropsychiatric function in various populations."
48283445|NCT01374698|DRUG|Aspirin|Aspirin 325 mg
48283446|NCT02678806|RADIATION|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
48283447|NCT02678806|DRUG|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 \~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
48468196|NCT06080698|DRUG|Intravenous Antibiotics|Participants will continue to receive intravenous antibiotics until the completion of the treatment course
48468197|NCT06080698|DRUG|Oral Antibiotics|Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
48468198|NCT02247076|BEHAVIORAL|Grazing|
48627779|NCT03812328|DRUG|SelK2|I.V., single-dose
48468199|NCT02247076|BEHAVIORAL|Time-restricted feeding (early eating)|
48468200|NCT01117844|RADIATION|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
48627780|NCT03812328|BIOLOGICAL|Enoxaparin|SC, QD for up to 10 ± 2 days
48627781|NCT04573530|BEHAVIORAL|We Walk Plus Intervention|The frequency and content of weekly personalized SMS are based on each participant's preference. Prior to implementation of intervention, the investigators will conduct focus groups to learn participants' social network activities and preferences, strategies that can be used to encourage engagement via a private Fitbit community network.
48627782|NCT01909401|DRUG|boceprevir|
48627783|NCT00621530|DRUG|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
48627784|NCT00621530|DRUG|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
48627785|NCT00769405|DRUG|fluorouracil|Given IV
48627786|NCT00769405|DRUG|leucovorin calcium|Given IV
48627787|NCT00769405|DRUG|oxaliplatin|Given during surgery
48627788|NCT00769405|PROCEDURE|hyperthermia treatment|Given intraperitoneally during surgery
48627789|NCT01846871|DRUG|Tivozanib|
48627790|NCT05840406|DRUG|Postoperative pain management with acetaminophen|During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
48627791|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine will be administered to the participant on each side.
48627792|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine and dexmedetomidine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine with the addition of 0,5 μg/kg dexmedetomidine will be administered to the participant on each side.
48627793|NCT05840406|DRUG|Postoperative pain management with tramadol|During the 24 hours postoperatively, participants will receive 500 mg tramadol + 500 ml 0,9% NaCl i.v. continuously 30ml/h.
48627794|NCT05840406|DRUG|Postoperative pain management with ketoprofen|During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
48627795|NCT05840406|DRUG|Postoperative pain management with ibuprofen|On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
48468201|NCT03485716|OTHER|running on a treadmill under normoxia or hypoxia|"* 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)"
48468202|NCT04673825|OTHER|Patient initiated care + telemonitoring|See arm/group descriptions.
48468203|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
48468204|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
48468205|NCT00999284|DRUG|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
48468206|NCT00070759|DRUG|Daclizumab|
48468207|NCT03879486|OTHER|Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy|The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
48468208|NCT04439123|DRUG|Capivasertib|Given PO
48468209|NCT01642563|PROCEDURE|Platelet transfusion|One dose of pathogen reduced platelets
48100594|NCT01532232|DRUG|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
48283448|NCT03095703|DRUG|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
48468210|NCT01642563|PROCEDURE|Platelet transfusion|One dose of standard platelets
48468211|NCT05714241|OTHER|Data extraction|"After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~1. MVA (evidence of CMD defined as any of abnormal CFR \[\<2.0\], IMR \[≥25\], or microvascular spasm);~2. VSA (CFR ≥2.0, IMR \<25 and epicardial spasm);~3. both MVA and VSA (evidence of CMD and epicardial spasm);~4. none/non-cardiac chest pain (CFR ≥2.0 and IMR \<25 and neither microvascular nor epicardial spasm)."
48468212|NCT05714241|OTHER|Blood sampling|At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
48468213|NCT05714241|OTHER|Clinical Follow-up|"All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected."
48468214|NCT06641154|DRUG|GT-UGT1A1-AAV8-02|Intravenous infusion, single dose
48468215|NCT05135377|OTHER|Observational|Not applicable - observational study
48468216|NCT03476681|DRUG|NEO-201 in combination with pembrolizumab|NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
48468217|NCT00250315|DRUG|Dobutamine|
48468218|NCT06361355|BIOLOGICAL|Post-change CMAB807|for subcutaneous injection only
48468219|NCT06361355|BIOLOGICAL|Prolia|for subcutaneous injection only
48468220|NCT04634630|GENETIC|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
48468221|NCT01337596|DRUG|LY2951742|Administered subcutaneously
48468222|NCT01337596|DRUG|Placebo|Administered subcutaneously
48468223|NCT00496067|DEVICE|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
48468224|NCT03310086|DEVICE|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
48468225|NCT03310086|PROCEDURE|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
48468226|NCT06232837|DEVICE|Direct laryngoscopy using Macintosh blade|Patients in operative room requiring direct laryngoscopy for endotracheal intubation
48468227|NCT02479477|OTHER|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
48468228|NCT02088333|BEHAVIORAL|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
48468229|NCT02088333|BEHAVIORAL|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
48468230|NCT05646537|BEHAVIORAL|Neuro-Linguistic Programming Techniques|"The new behavior creation technique of NLP is based on the argument that the imagination process and reality are recorded in the same way in the brain.~Using the Participant's eye movements and imagination . He will be asked to imagine himself while caring for the stoma. participient will then be asked to re-enact the process with the correct stages of stoma care and the jurals that must be adhered to in order to successfully care for it.~Questions will be asked about where he can find the support he needs to carry out this process successfully. At the end of this whole process, he will be expected to construct what life is like with a stoma.The technique will be applied to the patient once and will be instructed to remember this successful process every time he or she feels distressed about the stoma.~At the end of 6 months, the quality of life and compliance will be evaluated by asking the scale questions again."
48283449|NCT02561156|DRUG|TAK-653 Placebo|TAK-653 placebo-matching tablets.
48283450|NCT02561156|DRUG|TAK-653|TAK-653 tablets.
48283451|NCT04752787|OTHER|Online breastfeeding training|Online breastfeeding training will be provided to pregnant women expecting twin babies.
48283452|NCT04752787|OTHER|QR code supported online breastfeeding training|QR code supported online breastfeeding training will be given to pregnant women who are expecting twin babies.
48283453|NCT05749588|DRUG|A1: SHR-A1811|A1: an anti-HER2 antibody-drug conjugate (ADC)
47937633|NCT03498664|DEVICE|cap for mucosectomy|endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
48283454|NCT05749588|DRUG|A2: SHR-A1811 with Camrelizumab|"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
48283455|NCT05749588|DRUG|B1: TROP2 ADC|B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
48283456|NCT05749588|DRUG|B2: TROP2 ADC with Camrelizumab|"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
48283457|NCT05749588|DRUG|C1: SHR-A1811|C1: an anti-HER2 antibody-drug conjugate (ADC)
48283458|NCT05749588|DRUG|C2: SHR-A1811 with BP102|"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
48468231|NCT03712202|DRUG|Bleomycin|Given IV
48468232|NCT03712202|DRUG|Brentuximab Vedotin|Given IV
48468233|NCT03712202|DRUG|Dacarbazine|Given IV
48468234|NCT03712202|DRUG|Doxorubicin|Given IV
48468235|NCT03712202|BIOLOGICAL|Nivolumab|Given IV
48468236|NCT03712202|OTHER|Quality-of-Life Assessment|Ancillary studies
48627796|NCT01751685|BEHAVIORAL|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
48627797|NCT01751685|OTHER|Control|monthly educational lectures on various topics
48627798|NCT05196139|OTHER|retrospective study|vitrectomy performed in case of submacular bleeding
47937634|NCT03498664|DEVICE|standard snare for polypectomy|endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
47937635|NCT00470665|DRUG|Rapamune|
47937636|NCT05521529|OTHER|no intervention, as this is an observational study|no intervention
48283459|NCT05749588|DRUG|D1: TROP2 ADC|D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
48283460|NCT05749588|DRUG|D2: TROP2 ADC with BP102|"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
48283461|NCT05749588|DRUG|E1: SHR-A1811|E1: an anti-HER2 antibody-drug conjugate (ADC)
48468237|NCT03712202|DRUG|Vinblastine|Given IV
48468238|NCT06581081|BIOLOGICAL|Senl_B19 autologous CAR-T (S1904) treatment|Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment.
48468239|NCT00662896|DRUG|naproxcinod 375 mg bid|naproxcinod 375 mg bid
48627799|NCT05162911|BEHAVIORAL|Ask, advise, Assist and refer to the Quitline|A nurse will ask, advise, assist and refer patient to the Quitline
47937637|NCT03832244|DIAGNOSTIC_TEST|Sub-mental ultrasonography|Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
48283462|NCT05749588|DRUG|F1: TROP2 ADC|F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
48283463|NCT05749588|DRUG|G1: SHR-A1811|G1: an anti-HER2 antibody-drug conjugate (ADC)
48283464|NCT05749588|DRUG|H1: TROP2 ADC|H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
48468240|NCT00662896|DRUG|naproxcinod 750 mg bid|naproxcinod 750 mg bid
48468241|NCT00662896|DRUG|naproxen 250 mg bid|naproxen 250 mg bid
48468242|NCT00662896|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
48468243|NCT00662896|DRUG|ibuprofen 600 mg tid|ibuprofen 600 mg tid
48468244|NCT06677736|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
48468245|NCT06677736|RADIATION|Diode laser as adjunctive to conventional scaling and debridement|Diode laser as adjunctive to conventional scaling and debridement
48468246|NCT06679556|DRUG|Strength A Sublingual Minoxidil|One single dose of Strength A sublingual minoxidil
47937638|NCT01507454|DRUG|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
47937639|NCT03642093|COMBINATION_PRODUCT|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
47937640|NCT03642093|BEHAVIORAL|Physical Activity Intervention|Walking and Inspiratory Muscle Training
48468247|NCT06679556|DRUG|Strength B Sublingual Minoxidil|One single dose of Strength B sublingual minoxidil
48468248|NCT01600339|DRUG|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
48468249|NCT06462144|DRUG|IMPT-514 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
48627800|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor|A nurse will ask, advise, assist and refer patient to a counselor
48627801|NCT05162911|BEHAVIORAL|Ask, advise, Assist and referral to onsite counselor and NRT|A nurse will ask, advise, assist and refer patient to a counselor and provide nicotine replacement therapy in the form of gum
48283465|NCT01123889|BIOLOGICAL|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
48627802|NCT04613570|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy|"In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;"
48627803|NCT00189514|DRUG|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
48468250|NCT06678295|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly sessions of individual cognitive behavioral therapy
48468251|NCT01995968|OTHER|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
48468252|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autologous cartilage|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous auricular cartilage graft spacer.
48468253|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autogenous dermis graft spacer.|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous dermis graft spacer.
48627804|NCT00189514|DRUG|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
48627805|NCT02800252|DRUG|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
48627806|NCT02800252|DRUG|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
48627807|NCT02800252|DRUG|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
48468254|NCT06246734|BEHAVIORAL|Hasbro Joy for All robot pet companion|The robot pets are stuffed animals (dogs and cats) that have features that make them seem lifelike. For example, the animal toys turn their heads when petted, purr or make puppy sounds, feel warm, have a heartbeat, and go to sleep when they are ignored. They respond to attention and petting like a real pet. The robot pets do not collect information and do not require any maintenance, except a battery. Engagement with the device is at the discretion of participants.
48468255|NCT01630616|DRUG|Odanacatib|single oral dose, tablets, 10 or 50 mg
47937641|NCT01622127|DEVICE|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
47937642|NCT03764488|DRUG|Tofersen|Administered as specified in the treatment arm.
47937643|NCT03764488|DRUG|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
48100595|NCT03355053|DRUG|Dexmedetomidine|"Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL."
48100596|NCT03355053|DRUG|Placebo|"From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O."
48468256|NCT01630616|DRUG|Placebo|single oral dose, tablets
48468257|NCT05561257|DRUG|Vitamin C|Vitamin C
48468258|NCT04542707|PROCEDURE|joint manipulation|Thrust manipulation to the spine, hand, and foot
48106937|NCT00750750|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
48106938|NCT00750750|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
48106939|NCT02878915|DEVICE|Ultrasound guided femoral puncture|
48468259|NCT04542707|PROCEDURE|Exercise|Strength training, bike aerobic training, and yoga exercise
48468260|NCT04542707|DEVICE|Soft tissue massage|Graston tool
48468261|NCT05830162|DRUG|Placebo|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
47937644|NCT01203176|PROCEDURE|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
47937645|NCT04676555|DRUG|Ocrelizumab|There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
48468262|NCT05830162|DRUG|Bioclavid (Amoxicillin and Clavulanic acid)|We will evaluate how many women gets an infection and/or wound dehiscence after a second degree obstetric tear or episiotomy
48468263|NCT06290765|DRUG|Ropeginterferon alfa-2b|"Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), 250 µg at Day 1, 350 µg at Week 2, and target optimal dose of 500 µg at Week 4.~Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value."
48468264|NCT06290765|PROCEDURE|Phlebotomy and aspirin|Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.
48283466|NCT01123889|DRUG|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
48283467|NCT04930939|OTHER|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
47937646|NCT04676555|DRUG|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
48283468|NCT04575129|OTHER|No intervention will be applied|No intervention will be applied
48468265|NCT00006228|BIOLOGICAL|trastuzumab|Given IV
48468266|NCT00006228|BIOLOGICAL|aldesleukin|Given SC
48468267|NCT00006228|OTHER|laboratory biomarker analysis|Correlative studies
48468268|NCT00006228|OTHER|pharmacological study|Correlative studies
48468269|NCT02528409|DRUG|Vortioxetine|Medication currently approved for major depression.
48468270|NCT02528409|DRUG|Placebo|
48468271|NCT05675995|BEHAVIORAL|External Qigong|6 sessions of external qigong delivered in a group-based format once a week.
48468272|NCT00219986|DRUG|Potent HAART during acute or early HIV-1 infection|
48468273|NCT05533034|OTHER|Rehabilitation|"* 1 supervised session of rehabilitation, including a cardiac stress test (to define maximal intensity for aerobic activities), aerobic activity with interval training of moderate and progressive intensity (walking), and respiratory exercise using a volumetric spirometer, and strengthening exercises for lower and upper limbs.~* 3 months of self-managed home exercises. Patients will be asked to use a tracker activity when performing home exercises to self-monitor cardiac frequency and to assess their adherence."
48468274|NCT06309784|PROCEDURE|Drill Guidance System (DGS)|During a standard surgical procedure where a drill/k wire is being inserted the surgeon may choose (in advance) to supplement their drilling with use of the Drill Guidance System. This will be a supplement to normal practice. it is anticipated it will make surgery more accurate, swifter and safer. If however the surgeon is not finding the DGS useful it can be abandoned and standard drilling with X-ray guidance used
48627808|NCT06432426|BEHAVIORAL|Virtual reality training group|Participants will be given virtual reality games on Nintendo Wii Fit® and its peripheral Balance Board system. This equipment offers safe and engaging training protocols. Additionally, it ensures physical exercise in the three planes of movement (sagittal, frontal, and transverse) and with three difficulty levels, thus providing a linear progressive demand.
48627809|NCT06432426|BEHAVIORAL|Standard physical exercise group|Participants will be submitted to a standard physical exercise program based on the ACSM guidelines. Resistance training will involve exercises for arms and legs, using bodyweight self-loading and external weights. Balance exercises will include the three planes of movement.
48627810|NCT03453970|BEHAVIORAL|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
48627811|NCT00875459|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
48627812|NCT05016050|DEVICE|HPDT-DA-013|Digital program with therapeutic interventions based on Cognitive Behavioral Therapy (CBT).
48627813|NCT00727337|BEHAVIORAL|LACE-computer|Computerized Auditory Training
48627814|NCT00727337|BEHAVIORAL|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
48627815|NCT00727337|BEHAVIORAL|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
48627816|NCT00727337|BEHAVIORAL|Lace-DVD|DVD based Auditory Training
48283469|NCT05932732|DEVICE|HydraFacial Syndeo System|Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
48627817|NCT03126149|DRUG|PF-06667272|Single ascending dose of PF-06667272
48627818|NCT03126149|OTHER|Placebo|Single dose of placebo
48627819|NCT00689988|BEHAVIORAL|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
48627820|NCT00793065|OTHER|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
48627821|NCT00793065|OTHER|Medical Home redesign|Implementation of NCQA Level III Medical Home
48468275|NCT05133726|OTHER|Text4Support|Daily supportive text messages
48468276|NCT05133726|OTHER|Peer support|Meeting with peers who have lived experiences with similar diagnoses but are in recovery
48627822|NCT04947267|DRUG|3% Mepivacaine Hydrochloride|1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
48283470|NCT05932732|DRUG|ReGen-GF|The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
48468277|NCT04480307|DRUG|temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
48627823|NCT04947267|DRUG|2% Mepivacaine with 1:100,000 epinephrine|1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
48283471|NCT05932732|DEVICE|HydraFacial Elite MD System|Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
48283472|NCT01662089|DRUG|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
48468278|NCT04480307|DRUG|temelimab 36 mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
48468279|NCT04480307|DRUG|temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
48627824|NCT03634150|BIOLOGICAL|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
48627825|NCT00875901|RADIATION|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
48627826|NCT00875901|RADIATION|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
48627827|NCT00476541|DRUG|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
48627828|NCT04482790|PROCEDURE|Conventional celluloid matrix technique in management of black triangle|conventional restorative technique in management of black triangle
48627829|NCT04482790|PROCEDURE|Bioclear cervical matrix with injection molding technique|New restorative technique in management of black triangle restorative papilla regeneration
48468280|NCT04480307|DRUG|Placebo|Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
48468281|NCT03904147|DEVICE|TriClipTM Device|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
48468282|NCT05652309|PROCEDURE|spinal block and obturator nerve block|spinal block and obturator nerve block
48468283|NCT01733576|DEVICE|HD-tDCS|
48468284|NCT05222360|OTHER|Education|3 educational sessions about body image and nutrition
48468285|NCT05752435|PROCEDURE|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
48283473|NCT01662089|DRUG|Placebo drug supplement|Placebo drug instead of Zinc supplement
48468286|NCT05795439|BEHAVIORAL|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
48468287|NCT00125541|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
48468288|NCT01292837|DRUG|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
48468289|NCT03704974|BEHAVIORAL|Video-Based Parent Training Program|An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
48468290|NCT06676618|OTHER|Multimodal Exercise Training|"The exercise training consisting of aerobic, strengthening and balance exercises will be applied for 12 weeks/3days for 1hour. One day of the exercise training will be performed in a clinical environment with a physiotherapist, and the other 2 days of the week, participants will be asked to apply asynchronous video-based telerehabilitation over the internet in their own homes. The asynchronous video-based telerehabilitation application will be performed through an account created specifically for the participant on the www.telenororehab.com website. The exercise program will be created according to the individual's condition and progression will be provided every 3 weeks. Patients who do not attend 3 consecutive sessions will be excluded from the study."
48468291|NCT06676618|OTHER|Control Group|Participants in the control group will be placed on the waiting list after all evaluation methods have been applied and will be re-evaluated at the end of 12 weeks. After the evaluations, individuals in the control group will also be given multimodal exercise training.
48468292|NCT06474845|DEVICE|T-Control® catheter|Patients will be catheterized with T-Control® for 4 weeks
48468293|NCT06474845|DEVICE|Foley-type catheter|Patients will be catheterized with a conventional Foley-type catheter for 4 weeks
48468294|NCT04288076|OTHER|PEEP Titrated Mechanical Ventilation|Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
48468295|NCT04830241|DRUG|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
48468296|NCT05363982|DEVICE|Transcranial Photobiomodulation (tPBM)|"Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy.~Other Names:~Niraxx G1 Headband"
48468297|NCT05363982|DEVICE|Placebo/ Sham|The sham treatment will consist of applying all the procedures for the delivery of tPBM, but will not deliver light.
48468298|NCT00614276|BEHAVIORAL|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
48468299|NCT00614276|BEHAVIORAL|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
48468300|NCT00614276|BEHAVIORAL|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
48468301|NCT00614276|BEHAVIORAL|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
48468302|NCT00526435|BEHAVIORAL|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
48468303|NCT00526435|BEHAVIORAL|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
48468304|NCT01487499|DRUG|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
48468305|NCT04552028|OTHER|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
48468306|NCT02382601|RADIATION|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
48468307|NCT02382601|RADIATION|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
48283474|NCT03731793|BIOLOGICAL|Non-Animal Chondroitin Sulphate|Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
48283475|NCT03731793|OTHER|Placebo|Placebo
48283476|NCT02542995|OTHER|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
48283477|NCT00003554|BIOLOGICAL|rituximab|
48468308|NCT02382601|PROCEDURE|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
48468309|NCT02382601|BEHAVIORAL|Neurological Function Assessment|Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
48468310|NCT02382601|PROCEDURE|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
48468311|NCT02382601|PROCEDURE|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
48468312|NCT02382601|RADIATION|Pediatric heart ultrasound|Children will have ultrasounds of their hearts during follow-up visits.
48468313|NCT04201795|OTHER|Laser|laser with no emision will applied
48468314|NCT04201795|OTHER|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
48468315|NCT02414763|BEHAVIORAL|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
48468316|NCT03066934|OTHER|noninvasive ventilation respiratory support|
48468317|NCT04145245|DRUG|Levocarnitine|Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
48468318|NCT04763473|DIETARY_SUPPLEMENT|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
48468319|NCT04763473|DIETARY_SUPPLEMENT|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
48468320|NCT06048783|BEHAVIORAL|Program of systematic and periodic spiritual accompaniment and care|Systematic and periodic spiritual accompaniment and care
48468321|NCT06543446|PROCEDURE|ICD implantation|Surgical implant of ICD device
48468322|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
48627830|NCT05137145|DRUG|Linaclotide|The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
48627831|NCT05137145|DRUG|Compound Polyethylene Glycol Electrolyte Powder|The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
48627832|NCT04069520|OTHER|aNMT Biofeedback|"aNMT biofeedback is created by calculating kinematic and kinetic data in real-time from the athlete's own movements. These values determine real-time transformations of the stimulus shape the athlete views via augmented-reality (AR) glasses during movement performance. The athlete's task is to move so as to create (animate) a particular stimulus shape that corresponds to desired values of the biomechanical parameters targeted by the intervention. The aNMT biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks."
48627833|NCT04069520|OTHER|Sham Biofeedback|Sham biofeedback provides a similar phenomenological experience to aNMT biofeedback for athletes-both groups experience a shape that changes with their movements-but the sham biofeedback will not provide usable information to modify movement parameters during critical movement phases. The sham biofeedback occurs during neuromuscular training sessions. The neuromuscular training is a 18 session, pre-season training program occurring over 6 weeks.
48627834|NCT03175458|PROCEDURE|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
48468323|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
48627835|NCT03175458|PROCEDURE|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
48627836|NCT03418480|DRUG|BNT113|Intradermal vaccine
48627837|NCT03833258|BEHAVIORAL|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
48468324|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
48468325|NCT04432207|DRUG|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
48468326|NCT04432207|DRUG|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
48283478|NCT00003554|DRUG|melphalan|
48627838|NCT03188471|DRUG|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
48627839|NCT03188471|DRUG|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
48627840|NCT06216340|DRUG|Henagliflozin|10mg of Henagliflozin and diet-exercise therapy
48627841|NCT06216340|DRUG|Placebo|Placebo and diet-exercise therapy
48627842|NCT04227717|DIAGNOSTIC_TEST|MRI with custom MRI spine coil|Participants will undergo MRI with custom MRI spine coil
48627843|NCT01436500|DRUG|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
48627844|NCT01436500|DRUG|Placebo|Sterile water with 5% Dextrose
48627845|NCT01797185|DRUG|SPARC1104 modified dose regimen I|Subjects who exited study CLR_09_21
48627846|NCT01797185|DRUG|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
48627847|NCT01797185|DRUG|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
48627848|NCT05711407|GENETIC|Gene Polymorphisms of MMP-8|Saliva Samples
48627849|NCT04843904|DRUG|Venetoclax|Tablet, taken by mouth
48627850|NCT04843904|DRUG|Obinutuzumab|Given as an infusion into the vein (intravenous, IV).
48627851|NCT04843904|DRUG|Rituximab|Given as an infusion into the vein (intravenous, IV).
48627852|NCT03996460|DRUG|Placebo|"Fifteen (15) patients in group 1 will receive the sachet of matching placebo ( equivalent to a capsule of placebosugar pill) orally daily for 12 weeks (90 days) without food."
48627853|NCT03996460|DRUG|192 mg powder of K0706|Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
47937647|NCT04810572|DIETARY_SUPPLEMENT|Composition with Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
47937648|NCT04810572|DIETARY_SUPPLEMENT|Low-mineral composition without Silymarin|"Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation."
47937649|NCT05292404|DRUG|alirocumab|In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
47937650|NCT05292404|OTHER|conventional treatment|conventional treatment were given according to international uniformguidelines
47937651|NCT04127812|BEHAVIORAL|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
48627854|NCT03996460|DRUG|384 mg powder of K0706|Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
48627855|NCT01049828|OTHER|No intervention|No treatment for tinnitus will occur in this study.
47937652|NCT02070471|DRUG|Placebo|Placebo
47937653|NCT02070471|DRUG|LC28-0126 Dose A|LC28-0126 Dose A
48627856|NCT01346241|BEHAVIORAL|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
47937654|NCT02070471|DRUG|LC28-0126 Dose B|LC28-0126 Dose B
48627857|NCT04902144|OTHER|Electronic Health Record Review|Medical data collected
48627858|NCT04902144|OTHER|Questionnaire Administration|Complete questionnaires
48627859|NCT04902144|BEHAVIORAL|Behavioral Intervention|Receive coaching
48627860|NCT02233153|OTHER|Elder-Friendly Surgical Unit|
48627861|NCT00220714|DRUG|atypical antipsychotics:oral vs. long-acting route|
48627862|NCT00220714|BEHAVIORAL|Family Psychoeducation|
48627863|NCT03936127|PROCEDURE|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
48627864|NCT01684592|BEHAVIORAL|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
48627865|NCT01684592|BEHAVIORAL|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
47937655|NCT02070471|DRUG|LC28-0126 Dose C|LC28-0126 Dose C
47937656|NCT05897944|OTHER|COPD|A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
47937657|NCT03143491|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
47937658|NCT00293488|DRUG|polyamine analogue PG11047|
47937659|NCT00728078|DRUG|thalidomide|thalidomide 50mg tid for 6 months
48283479|NCT00003554|DRUG|prednisone|
47937660|NCT04258137|GENETIC|Liquid biopsy|Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
48283480|NCT04518371|OTHER|Reinforced composite for the fabrication of permanent, indirect restorations using a CAD/CAM grinding process.|Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments
48283481|NCT02764619|DRUG|Spironolactone|
48283482|NCT02764619|DRUG|Placebo|
48468327|NCT03460990|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
48627866|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
48283483|NCT03650504|PROCEDURE|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
48627867|NCT05880043|DRUG|GIC-102|GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
48468328|NCT03460990|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
48468329|NCT03460990|DRUG|IVA|Participants received IVA orally once daily in the evening.
48627868|NCT02989389|DRUG|LY3323795|Administered orally
48627869|NCT02989389|DRUG|Itraconazole|Administered orally
48627870|NCT02989389|DRUG|Placebo|Administered orally
48627871|NCT04803435|OTHER|Telemedicine Consultation|Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.
48627872|NCT04803435|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
48283484|NCT03650504|PROCEDURE|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
48283485|NCT02676258|DEVICE|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
48283486|NCT02676258|DEVICE|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
48283487|NCT04619576|BEHAVIORAL|Occupational health workers|Questionnaire online
48283488|NCT03460418|OTHER|Phone contact|Assessment of the different outcomes by means of a phone contact
48283489|NCT00761111|BEHAVIORAL|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
48283490|NCT01273818|DRUG|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
48283491|NCT01273818|DRUG|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
48283492|NCT01273818|DRUG|Gentamicin|80 mg gentamicin application intraoperatively
48283493|NCT01770184|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
48283494|NCT02281812|PROCEDURE|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
48283495|NCT01415388|DIETARY_SUPPLEMENT|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
48283496|NCT03067220|OTHER|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
48283497|NCT03067220|OTHER|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
48283498|NCT03099759|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D2/D3
48468330|NCT03460990|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
48468331|NCT03460990|DRUG|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
48468332|NCT02246348|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
48468333|NCT05443919|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'.
48468334|NCT00159419|DRUG|Alendronate|
48468335|NCT00159419|DRUG|Pamidronate|
48468336|NCT05001191|OTHER|Gentle Human Touch|Gentle human touch, which has a pain and stress-reducing effect, is a sensitive tactile stimulus applied to the skin, without caress or massage, which provides a kind of relaxation.
48468337|NCT00493792|DEVICE|X3 Polyethylene|Highly cross-linked polyethylene (HXLPE).
48468338|NCT00493792|DEVICE|N2Vac Polyethylene|Ultra-high-molecular-weight polyethylene (UHMWPE).
48100597|NCT05379127|OTHER|Patient-empowered follow up|"The patient-empowered follow-up protocol consists of patient-reported outcome measures (PROMs), self-assessment tools and clinical assessment including physical examination. Radiographs will only be taken when progression of the scoliosis (curve progression) or postoperative complications are suspected based on test results and based on the criteria of so called 'sense of alarm'.~Note: Sense of alarm ('niet pluis') is based on any deterioration on the above-mentioned PROMs, self-assessment tool, and clinician-based measurement instruments, which is a signal for the treating physician to consider when a radiograph is appropriate. Sense of alarm is described as any other concern by the orthopaedic surgeon, parent or child which warrants a radiograph. For both the Bunnell Scoliometer (clinical assessment tool) and the Scolioscoop (patient self-assessment tool) a threshold of ≥4° is used."
48100598|NCT05379127|OTHER|Standard follow-up|Routine radiographs are taken at each follow up visit during standard care (to detect possible curve progression or rule out postoperative complications).
48468339|NCT00290264|DRUG|Budesonide/formoterol|
48468340|NCT00005668|DRUG|Itraconazole oral solution|
48468341|NCT05338853|OTHER|Gongs mobilization|to deal adhesive capsulitis
48627873|NCT03150186|OTHER|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
48283499|NCT06198920|PROCEDURE|Stenting of the superficial femoral artery|Submitted to stenting of the superficial femoral artery for stenosis or occlusion causing intermittent claudication or critical limb ischemia
48468342|NCT05338853|OTHER|scapular mobilization|scapular mobilization
48283500|NCT03876587|DRUG|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
48283501|NCT03592862|DRUG|HTL0018318|Oral capsule
48283502|NCT03592862|DRUG|Placebo|Oral capsule
48283503|NCT01576211|GENETIC|DNA methylation analysis|
48283504|NCT01576211|GENETIC|RNA analysis|
48283505|NCT01576211|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
48283506|NCT01576211|GENETIC|gene expression analysis|
48283507|NCT01576211|GENETIC|nucleic acid sequencing|
48283508|NCT01576211|GENETIC|polymorphism analysis|
48283509|NCT01576211|OTHER|laboratory biomarker analysis|
48468343|NCT05608252|DRUG|VS-6766|Taken Orally
48468344|NCT05608252|DRUG|Abemaciclib|Taken Orally
48468345|NCT05608252|DRUG|Fulvestrant|Administered by intramuscular injection
48468346|NCT06044337|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
48468347|NCT01932190|PROCEDURE|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
48468348|NCT01932190|PROCEDURE|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
48468349|NCT00080795|BIOLOGICAL|filgrastim|
48468350|NCT00080795|DRUG|cisplatin|
48468351|NCT00080795|DRUG|doxorubicin hydrochloride|
48468352|NCT00080795|DRUG|gemcitabine hydrochloride|
48468353|NCT00080795|DRUG|ifosfamide|
48468354|NCT00080795|PROCEDURE|conventional surgery|
48468355|NCT00080795|PROCEDURE|neoadjuvant therapy|
48468356|NCT06678438|PROCEDURE|Ultrasound-guided brachial plexus block|The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block
48468357|NCT06678438|PROCEDURE|Standard anaesthesia|The type of analgesia will be according to local guidelines and clinical practices. It is expected that a haematoma block is the standard type of analgesia for closed reduction at most trial sites.
48100599|NCT05701592|PROCEDURE|DB-PCLR|DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
48283510|NCT05207267|DEVICE|driving pressure guided tidal volume|Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.
48283511|NCT04297644|OTHER|There is no intervention|There is no intervention
48100600|NCT03403699|BIOLOGICAL|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
48283512|NCT00005912|DRUG|Voriconazole|
48283513|NCT00783640|DRUG|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
48283514|NCT00605826|DEVICE|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
48283515|NCT00605826|DEVICE|Sham Injection|Sham injection at the start of the blinded phase.
48283516|NCT04113629|DEVICE|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
48283517|NCT00000889|DRUG|Aldesleukin|
48283518|NCT00524303|DRUG|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
48283519|NCT00524303|DRUG|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
48468358|NCT01731236|DIETARY_SUPPLEMENT|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
48468359|NCT01731236|DIETARY_SUPPLEMENT|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
48468360|NCT01731236|DRUG|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
48468361|NCT01731236|DRUG|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
48468362|NCT01731236|DRUG|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
48468363|NCT02802462|BEHAVIORAL|HIT|3-minute intervals at 40% and 80%VO 2max
48468364|NCT02802462|BEHAVIORAL|MCT|sustained 60%VO 2max
48468365|NCT03825744|DRUG|Hetrombopag Olamine+Standard Therapy|once daily
48468366|NCT03825744|DRUG|Placebo+Standard Therapy|once daily
48468367|NCT05622994|DRUG|Rimonabant|Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
48468368|NCT00040690|BIOLOGICAL|filgrastim|
48468369|NCT00040690|DRUG|cyclophosphamide|
48468370|NCT00040690|DRUG|cytarabine|
48100601|NCT02916719|DEVICE|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
48100602|NCT02391246|OTHER|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
48283520|NCT00524303|DRUG|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
48468371|NCT00040690|DRUG|doxorubicin hydrochloride|
48468372|NCT00040690|DRUG|etoposide|
48468373|NCT00040690|DRUG|ifosfamide|
48468374|NCT00040690|DRUG|leucovorin calcium|
48468375|NCT00040690|DRUG|methotrexate|
48468376|NCT00040690|DRUG|vincristine sulfate|
48468377|NCT00040690|RADIATION|radiation therapy|
48468378|NCT06616831|DEVICE|Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training|Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
48617860|NCT01116531|DRUG|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
48283521|NCT00524303|DRUG|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
48283522|NCT03427073|DRUG|ALM201|Drug: ALM201 administered subcutaneously
48283523|NCT05793567|DIAGNOSTIC_TEST|Coronary angiogram with coronary reactivity testing (CRT)|CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.
48283524|NCT03554512|OTHER|Telehealth virtual appointment|Appointment with NICU clinician via telehealth equipment.
48283525|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
48627874|NCT03150186|OTHER|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
48283526|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
48283527|NCT06270225|DRUG|Colchicine 0.5 mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
48283528|NCT04038840|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
48283529|NCT04038840|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
48283530|NCT03738956|DRUG|Tofacitinib|"The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment."
48468379|NCT06679764|PROCEDURE|Anterior quadratus lumborum block technique (AQLB)|"AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process.~A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane."
48283531|NCT03034941|DRUG|Metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
48468380|NCT06679764|PROCEDURE|Pericapsular Nerve Group (PENG) block|With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.
48468381|NCT06679764|DRUG|Control Group|Pataints received opioid analgesia with genaral anesthesia
48468382|NCT04628481|DRUG|Ladarixin|Oral ladarixin twice a day for 13 cycles
48468383|NCT04628481|DRUG|Placebo|Oral placebo twice a day for 13 cycles
48468384|NCT03102879|PROCEDURE|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
48468385|NCT03102879|PROCEDURE|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
48283532|NCT03034941|DRUG|Liraglutide + metformin|In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
47937661|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
47937662|NCT06010875|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
47937663|NCT05386628|OTHER|conventional physiotherapy|"A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises"
47937664|NCT05386628|OTHER|Manual lymphatic drainage|manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.
47937665|NCT05386628|OTHER|Myofascial relasing|it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.
48100603|NCT05641662|OTHER|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
48468386|NCT05857917|DEVICE|Virtual Reality|Virtual reality in PD catheter insertion surgery in the pre- and intraoperative setting.
48468387|NCT04386109|OTHER|No intervention - exposure is to COVID-19|No intervention - exposure is to COVID-19
48100604|NCT06629051|DRUG|Berberine Hydrochloride|post-intervention of berberine
48100605|NCT06629051|DRUG|Placebo|Looks the same as berberine
48100606|NCT02200952|DRUG|recombinant LH|recombinant LH twice/day for 10 days from pick up
48100607|NCT01119703|BIOLOGICAL|Tetanus & Diphtheria booster vaccine (Td)|Tetanus \& Diphtheria booster vaccine (Td), single intramuscular dose
48100608|NCT01119703|BIOLOGICAL|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM \[Hepatitis A Inactivated \& Hepatitis B (Recombinant) Vaccine\], intramuscular, two doses of standard three dose regimen (opposite arms)
48100609|NCT01119703|BIOLOGICAL|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
48100610|NCT03237936|DRUG|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
48468388|NCT02197208|PROCEDURE|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
48627875|NCT03150186|OTHER|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
48627876|NCT06459973|DRUG|intravenous (IV) infusion|YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
48100611|NCT06628570|DIAGNOSTIC_TEST|HRA + Biopsy|High-Resolution Anoscopy, or HRA, is a standard of care procedure for screening and detection of premalignant lesions of the anus. Using a small, thin round tube called an anoscope, the anal canal is examined with a high-resolution magnifying instrument called a colposcope. The application of a mildly acidic liquid on the anal canal facilitates the evaluation of abnormal tissue such as anal dysplasia. Biopsies for histological confirmation of disease will be taken. Biopsies' reporting will follow the terminology, criteria, and recommendations of the Lower Anogenital Squamous Terminology (LAST) project. Histology results will be reported as benign, condyloma acuminatum, AIN grades 1-3, or cancer. For the proposed project, aHSIL+ will be defined as AIN2 (p16 block-positive), AIN3, and cancer at the HRA encounter. All other cases will be classified as \<aHSIL, including benign, condyloma acuminatum, and AIN1
48100612|NCT06628570|DIAGNOSTIC_TEST|Anal Cytology|Anal cytology collection (swab samples) will be performed as part of the standard of care during this study. The collected cells, suspended in the SurePath liquid-based medium, will be placed on a slide and microscopically examined by a board-certified pathologist. The sample will then be interpreted using the Bethesda System: negative for intraepithelial lesion or malignancy (NILM), ASCUS, LSIL, ASC-H, or HSIL. Pathologists interpreting the anal cytology will be blinded from hrHPV testing and biopsy histology.
48627877|NCT03400189|DRUG|Sulthiame|Single dose (50, 100, 200 mg)
48627878|NCT05979077|OTHER|MyChart Questionnaire|Prior to clinic visits, families completing the MyChart Questionnaire will enter details about their current management and visit goals, automatically populating their electronic health record for subsequent review/revision by the health care team before and during the visit, reallocating clinic time previously used for data acquisition to individual patient priorities
47937666|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~1 hour, 3 times a week for six weeks."
47937667|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~1 hour, 3 times a week for six weeks."
48468389|NCT02197208|PROCEDURE|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is \>/= 17 mm and the endometrium measures \>/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
47937668|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
47937669|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (twelve weeks: 6 +6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
47937670|NCT03310827|BEHAVIORAL|Personalized Nutrition|Diet plan based on nutrition-related gene test results
47937671|NCT00399672|DRUG|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
47937672|NCT00399672|DRUG|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
47937673|NCT04415060|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
47937674|NCT04415060|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
47937675|NCT00242983|PROCEDURE|quality-of-life assessment|
48100613|NCT06628570|DIAGNOSTIC_TEST|Genotyping of anal hrHPV infection|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. To identify the infecting HPV genotype, DNA will be extracted from swab samples collected with the MagNA Pure LC DNA Isolation Kit III and an LC MagNA Pure system (Roche Diagnostics GmbH, Mannheim, Germany), followed by HPV typing using the TypeSeq assay, a laboratory prepared high-throughput next-generation sequencing assay developed by NCI will be performed as described. The assay uses three sequential PCR steps resulting in barcoded L1 amplicons sequenced and submitted to a bioinformatics pipeline for typing. This TypeSeq assay qualitatively detects and identifies 51 HPV genotypes (HPV types 3, 6, 11, 13, 16, 18, 26, 28, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, and 114), including 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)
48468390|NCT02197208|DEVICE|ultrasound|
48627879|NCT03888690|DEVICE|Virtual Reality Headset|Standardized procedures, with or without Virtual Reality Headset.
48627880|NCT05921500|DRUG|sodium peborate|Internal bleaching of discolored primary anterior teeth by using sodium peborate
48627881|NCT03520387|PROCEDURE|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
48627882|NCT03520387|PROCEDURE|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
48627883|NCT03520387|BEHAVIORAL|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
48627884|NCT03520387|BEHAVIORAL|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
48283533|NCT03328819|OTHER|Acupuncture|The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
48283534|NCT01982630|DRUG|MK-8521|
48100614|NCT06628570|DIAGNOSTIC_TEST|CINtec®PLUS|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. Dual immunostaining with p16/Ki-67 will be performed on the residual cytologic specimen by Roche MTM Laboratories (Heidelberg, Germany), using the CINtec®PLUS Kit according to the manufacturer's instructions. The anal cytology material will be stained with a mouse monoclonal antibody directed against human p16INKa (p16) protein (clone E6H4) and recombinant rabbit monoclonal antibody directed against human Ki-67 protein (clone 274-11AC3V1), using the BenchMark ULTRA instrument (Ventana Roche). Samples with insufficient cellularity will be excluded from the evaluation. A trained cytotechnologist will review all cases for cells staining positively with both markers. A slide will be considered positive if 1 or more squamous epithelial cell(s) stained positive for both p16 and Ki-67 and dual stain-positive cells will be semi-quantitatively assessed (0, 1, 2-5, 6-50, \>50).
48100615|NCT03370406|DRUG|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
48100616|NCT03370406|DRUG|Imiquimod 5% cream|Topical application of 5% cream over a 3 week period.
48100617|NCT05826834|DEVICE|ball-rolling (Myostorm ball)|the intervention group
48283535|NCT01982630|DRUG|Liraglutide|
48283536|NCT01982630|DRUG|Placebo|
48283537|NCT03214835|DEVICE|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
48283538|NCT04702711|OTHER|No intervention|No intervention
48468391|NCT04957719|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
48468392|NCT04957719|COMBINATION_PRODUCT|Placebo|"Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
48468393|NCT04608682|DRUG|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
48100618|NCT02716909|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
48100619|NCT00424216|PROCEDURE|DC Polarization|
48100620|NCT02089243|PROCEDURE|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
48100621|NCT02089243|PROCEDURE|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
48283539|NCT05732129|DRUG|Fluzoparib|150mg,orally, bid (days 1-7) every 2 weeks
48100622|NCT01424579|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
48100623|NCT01424579|OTHER|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
48283540|NCT05732129|DRUG|Irinotecan|30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
48283541|NCT03771625|RADIATION|radiotherapy|whole brain with/without spinal cord
48283542|NCT01810887|DRUG|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
48283543|NCT01810887|DRUG|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
48283544|NCT04520477|DIAGNOSTIC_TEST|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
48283545|NCT04520477|DIAGNOSTIC_TEST|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
48283546|NCT04520477|DIETARY_SUPPLEMENT|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
48283547|NCT04520477|DIAGNOSTIC_TEST|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
48468394|NCT04608682|DRUG|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
48468395|NCT03768817|OTHER|No Intervention|This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
48468396|NCT03614455|DRUG|Milademetan|Milademetan 100 mg capsule for oral administration
48468397|NCT03614455|DRUG|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
48468398|NCT03614455|DRUG|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
48468399|NCT01226524|DRUG|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
48468400|NCT05533151|DEVICE|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
48283548|NCT01078753|DRUG|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
48283549|NCT01078753|DRUG|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
48283550|NCT06389370|OTHER|HU-DBI questionnaire|a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.
48468401|NCT06183320|PROCEDURE|Restoration with Incremental Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
48468402|NCT06183320|PROCEDURE|Restoration with Bulk Fill Composite in Proximal Wall|Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
48283551|NCT01591980|DRUG|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
47937676|NCT04954170|DIAGNOSTIC_TEST|IRRTM|IRRT at maximal 90° abduction and maximal external rotation is performed with the shoulder at maximal 90° rotation and the elbow flexed to 90° (Fig. 2). The patient is then asked to resist the external rotation force applied perpendicular to the forearm by the investigator. The test is considered positive if the patient could not hold the position or if he or she showed weakness of resisted internal rotation compared with the other side. It should be noted the maximal 90° abduction and maximal external rotation is active range of motion. Passive motion may affect the result of the test because of severe pain.
48100624|NCT01424579|OTHER|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
48283552|NCT01591980|DRUG|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
48283553|NCT01591980|DRUG|placebo|Identical placebo capsules will be administered in the same way.
48100625|NCT05640596|DRUG|Betamethasone|
48100626|NCT03795740|DIAGNOSTIC_TEST|3-D CT scanning|For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
48100627|NCT00002896|DRUG|chemotherapy|
48100628|NCT00002896|DRUG|fluorouracil|
48100629|NCT00002896|DRUG|leucovorin calcium|
48627885|NCT02201576|DRUG|Bortezomib|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~3. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
48100630|NCT00002896|PROCEDURE|conventional surgery|
48283554|NCT04827238|DIAGNOSTIC_TEST|Standardized Invasive Hemodynamics|The SIH technique is a standardized, reproducible and efficient way of obtaining hemodynamic measurements.
48627886|NCT02201576|DRUG|Plasma exchanges and intravenous immunoglobulins|"1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
48627887|NCT02993341|DRUG|Tranexamic Acid|
48627888|NCT02993341|OTHER|Saline Wash|
48627889|NCT05404659|OTHER|Oscillatory Mobilization|conventional physical therapy treatment, postural correction and maitland's oscillatory mobilizitions.
48627890|NCT05404659|OTHER|Mckenzie Retraction Exercises|conventional physical therapy treatment, postural correction and Mckenzie retraction exercises.
48627891|NCT04404556|BEHAVIORAL|Diabetes Journey|Web-based telehealth intervention focused on adherence barriers and problem-solving
48100631|NCT00002896|RADIATION|low-LET cobalt-60 gamma ray therapy|
48283555|NCT04637451|PROCEDURE|Root coverage treatment|Gingival unit graft Connective tissue graft
48283556|NCT00385021|DRUG|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
48283557|NCT01687673|DRUG|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
48468403|NCT05378308|OTHER|Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)|Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability
48468404|NCT04487964|DIETARY_SUPPLEMENT|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
48468405|NCT03801317|DIETARY_SUPPLEMENT|BC/ egg|4.3 egg powder + 5.7 g bovine colostrum
48468406|NCT03801317|DIETARY_SUPPLEMENT|Control|15 grams corn-soya blend
48100632|NCT00002896|RADIATION|low-LET photon therapy|
48283558|NCT01687673|DRUG|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
48468407|NCT03801317|DIETARY_SUPPLEMENT|multiple micronutrient|multiple micronutrient sprinkle powder
48100633|NCT04855513|DRUG|Metformin|Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
48100634|NCT05163756|DRUG|DW1903|q.d. PO, DW1903 + Placebo of DW1903-R1
48100635|NCT05163756|DRUG|DW1903-R1|q.d. PO, Placebo of DW1903 + DW1903-R1
48283560|NCT01377493|DIETARY_SUPPLEMENT|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
48283562|NCT04396977|PROCEDURE|Histamine 10 mg/ml skin prick|Skin prick through 5 µL histamine diHCl (10 mg/ml)
48627892|NCT04404556|BEHAVIORAL|Enhanced Standard of Care|General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
48283563|NCT04396977|PROCEDURE|Placebo (saline) skin prick|Skin prick through 5 µL saline (0.9% NaCl)
48283564|NCT00006072|DRUG|Rituxan|
48283565|NCT03950986|OTHER|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
48627893|NCT02134028|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
48627894|NCT04491994|DRUG|HCQ|Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days
48627895|NCT04298203|DRUG|Phentermine-Topiramate|The study medication to be tested for this study is a combination of phentermine and topiramate.
48283566|NCT01264003|DRUG|sefazolin|In prophylaxis
48283567|NCT00054470|BIOLOGICAL|trastuzumab|
48283568|NCT00054470|DRUG|tipifarnib|
48468408|NCT06555263|DRUG|Luveltamab tazevibulin|intravenous antibody-drug conjugate targeting FOLR1.
48627896|NCT04298203|DIETARY_SUPPLEMENT|Meal Replacement Therapy|The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
48100636|NCT04923984|PROCEDURE|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
48100637|NCT00378677|DRUG|Cyclosporine A dry powder inhalation (Drug)|
48627897|NCT04298203|OTHER|Placebo|A pill that looks like Phentermine-Topiramate but has no active medication.
48627898|NCT02815956|DEVICE|percutaneous tibial nerve stimulation|
48627899|NCT02815956|DEVICE|Placebo|
48100638|NCT04647162|PROCEDURE|hematoma evacuation by craniotomy|The intervention method of hematoma evacuation is under craniotomy.
48100639|NCT04647162|PROCEDURE|hematoma evacuation by stereotactic puncture|The intervention method of hematoma evacuation is under stereotactic puncture.
48100640|NCT04647162|PROCEDURE|hematoma evacuation by neuroendoscopy|The intervention method of hematoma evacuation is under neuroendoscopy.
48100641|NCT04647162|OTHER|life support|The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
48100642|NCT00623922|BEHAVIORAL|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
48283569|NCT02835729|DRUG|Idarubicin|Chemotherapy
48283570|NCT02835729|DRUG|Cytarabine|Chemotherapy
48283571|NCT02835729|DRUG|Indoximod Freebase|IDO pathway inhibitor
48283572|NCT02835729|DRUG|Indoximod HCL F1|IDO pathway inhibitor
48283573|NCT02835729|DRUG|Indoximod HCL F2|IDO pathway inhibitor
48627900|NCT01377506|BEHAVIORAL|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
48627901|NCT01377506|BEHAVIORAL|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
48627902|NCT05049694|DEVICE|zirconia crowns|esthetic crowns for capping permanent molars with caries
48627903|NCT05049694|DEVICE|stainless steel crowns|stainless steel crowns for capping permanent molars with caries
48627904|NCT00950092|DEVICE|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
47937677|NCT04954170|DIAGNOSTIC_TEST|the lift-off test|The lift-off test is performed by placing the hand of the affected arm on the back (at the position of the midlumbar spine) and asking the patient to internally rotate the arm to lift the hand off the back \[9\]. The test is considered positive if the patient is unable to lift the arm posteriorly off the back or if he or she performs the lifting manoeuvre by extending the elbow or the shoulder. Weakness is also as a positive result.
47937678|NCT04954170|DIAGNOSTIC_TEST|the belly-press test|The belly-press test is performed with the arm at the side and the elbow flexed to 90°, by having the patient press the palm into his or her abdomen by internally rotating the shoulder \[3, 5\]. The test is considered positive (1) if the patient shows a weakness in comparison with the opposite shoulder or (2) the patient pushes the hand against the belly by wrist flexion, despite instruction to the contrary.
48627905|NCT03289000|DEVICE|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
47937679|NCT04954170|DIAGNOSTIC_TEST|the IRLS test|IRLS test is evaluated with the affected arm of the patient was held by the examiner at maximum internal rotation \[10\]. The back of the hand is then passively lifted away from the body until almost full internal rotation is reached. Then, the patient is asked to actively maintain this position. The test is considered positive when the patient fails to maintain the position and the hand lagged.
47937680|NCT04954170|DIAGNOSTIC_TEST|the bear-hug test|The bear-hug test is performed with the palm of one side placed on the opposite shoulder and fingers extended and the elbow positioned anterior to the body \[3\]. The patient is then asked to hold that position when the examiner tried to pull the patient's hand from the shoulder with an external rotation force applied perpendicular to the forearm. The test is considered positive if the patient could not hold the hand against the shoulder or if he or she showed weakness compared with the other side.
47937681|NCT04954170|DIAGNOSTIC_TEST|IRRT 0°|IRRT at 0° abduction and 0° external rotation is performed with the arm at the side and the elbow flexed to 90° (Fig. 1). The patient is then asked to resist the external rotation force applied by the investigator. The test is considered positive if the patient could not hold the position at the side or if he or she showed weakness of resisted internal rotation compared with the other side. The test is negative if patients only complain of pain.
47937682|NCT04954170|DIAGNOSTIC_TEST|Diagnostic arthroscopy|At the time of surgery, general anaesthesia was administered and the patient was placed in beach-chair position. A complete arthroscopic exploration of the glenohumeral joint and the subacromial space was performed through a standard posterior portal. The senior author performed a complete arthroscopic exploration. Arthroscopic evaluation of the rotator cuff was considered the gold standard for making the definitive diagnosis. Evaluation of the SSC was carried out with both a 30° arthroscope and a 70° arthroscope.
48100643|NCT04900155|DRUG|Atorvastatin 80mg|Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.
48100644|NCT04900155|DRUG|Atorvastatin-Ezetimibe|In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
48468409|NCT06678230|DRUG|Anlotinib|Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.
48627906|NCT03606070|DIAGNOSTIC_TEST|PET-MRI|"* a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~* a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
48627907|NCT00571090|PROCEDURE|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
48627908|NCT02885675|OTHER|blood sampling|sample no more than 3ml
48627909|NCT03971526|OTHER|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
48627910|NCT02838238|DRUG|Capecitabine|
48627911|NCT02838238|DRUG|Placebo|
48627912|NCT00986232|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
48627913|NCT00986232|BIOLOGICAL|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
48627914|NCT00986232|BIOLOGICAL|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
48627915|NCT03483220|DIAGNOSTIC_TEST|MRI brain|"1. Emotion Regulation Questionnaire (ERQ): A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale .~UPPS-P Impulsive Behavior Scale- Short form: The UPPS-P impulsivity scale is a 20-item scale designed to assess five distinct personality traits to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Positive Urgency and Sensation Seeking .~Magnetic resonance imaging examination:~The MR examination of brain was done using 1.5T MR scanner (Achieva, Philips Medical Systems, The Netherlands) with a 16 channel head coil without using any sedation."
48627916|NCT04545372|OTHER|aerobic exercise|
48627917|NCT01244282|PROCEDURE|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
47937683|NCT03020290|DEVICE|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
47937684|NCT04327479|DIAGNOSTIC_TEST|Assessment of cardiovascular diseases and cardiovascular risk factors|At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.
47937685|NCT05540080|DEVICE|BTL-899|Treatment with applicators C4/C5 to the BTL-899 system.
47937686|NCT04378985|DEVICE|Wearing a Wearable device (Fitbit inspire HR)|"'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'"
47937687|NCT05999942|DRUG|Liposomal Amikacin for Inhalation|Administered via the Pari LC STAR™ nebulizer.
47937688|NCT03137576|PROCEDURE|Paravertebral Block (PVB)|PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
47937689|NCT03137576|PROCEDURE|Erector Spinae Plane Block (ESPB)|ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
47937690|NCT06024733|DRUG|Sevoflurane|patient recieve propofol for induction and sevoflurane for maintenance
47937691|NCT06024733|DRUG|Target Controlled Infusion|target controlled infusion of propofol
47937692|NCT06024733|DRUG|Target Controlled Infusion and lidocaine|patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
47937693|NCT03583203|DEVICE|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
48283574|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
48283575|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
47937694|NCT03663153|OTHER|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
47937695|NCT03663153|OTHER|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
47937696|NCT05193357|DEVICE|home-based intermittent pneumatic compression (IPC) device|During the intervention, two programmed modes were used. The first mode, which mimics the MLD massage technique, begins with the inflation of the proximal chamber. After reaching the target pressure, the next chamber consecutively inflates while the initially inflated proximal chamber deflates. The inflation time of each chamber is 3 seconds with holding time of 1 second. The deflation and resting time of each chamber is 7 seconds (pressure setting: 40-60 mmHg). After 30 minutes of the first mode, the second mode, which is the conventional mode of sequential inflation from distal to proximal chambers while sustaining the pressure of the previously inflated chambers, was applied for 30 minutes (pressure setting: 80-100 mmHg, inflation time of each chamber: 6 seconds, holding time: 1 second, deflation time of each chamber: 7 seconds). Participants were instructed to use the IPC device with that 1-hour cycle twice a day for four weeks.
47937697|NCT02415855|DRUG|Dabigatran|
47937698|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
48283576|NCT00235157|DEVICE|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
48283577|NCT00548912|DRUG|Spironolactone|
48283578|NCT00608088|BEHAVIORAL|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
48468410|NCT00919334|DEVICE|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
48468411|NCT03142620|DRUG|Esomeprazole|40mg twice daily
48468412|NCT03142620|DRUG|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
48468413|NCT03142620|DRUG|Clarithromycin|500mg twice daily
48627918|NCT01659541|DEVICE|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
48627919|NCT01659541|PROCEDURE|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
48468414|NCT03142620|DRUG|Vitamin D3|5000IU
17358278|NCT06553599|DRUG|AZD5004|Active IMP daily during 36 weeks
48100645|NCT03837769|DEVICE|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
48627920|NCT02480361|DEVICE|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
48627921|NCT04352530|OTHER|Health Communication|Spoken word poems set to images performed by youth who wrote the poems. Videos were produced by The Bigger Project and were posted publicly to the Bigger Picture Project website and YouTube. Duration of videos ranges from 2 minutes to 6 minutes.
48627922|NCT03026725|OTHER|Tri-calcium Phosphate|A paste contains Tri Calcium Phosphate \& Fluoride
48468415|NCT05328700|OTHER|Kinesiotaping|Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
48468416|NCT05328700|OTHER|Tape|Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
48468417|NCT01318161|DRUG|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
48468418|NCT01318161|DRUG|Morphine|Morphine via PCA pump
48468419|NCT02176057|DRUG|Azithromycin|
48468420|NCT05750953|BEHAVIORAL|eHealth@Hospital-2-Home|At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
48468421|NCT03127306|DIAGNOSTIC_TEST|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
48627923|NCT03026725|OTHER|Placebo|paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
48468422|NCT06077929|OTHER|No intervention done|No interventions done
48468423|NCT04038606|OTHER|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
17358279|NCT06553599|DRUG|Placebo|Placebo daily during 36 weeks
48468424|NCT04390230|PROCEDURE|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
48468425|NCT04164030|BEHAVIORAL|Education and Exercise Program for Adults with Type 2 Diabetes|Eating Smart and Being Active program
48468426|NCT04164030|BEHAVIORAL|Nutrition Education plus Occupational Therapy plus Yoga|multimodal interdisciplinary approach
47937699|NCT04199598|DRUG|Abediterol (4.8 μg)|4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
47937700|NCT04199598|DRUG|Abediterol (2.4 μg)|2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
47937701|NCT04199598|DRUG|Abediterol (2.5 μg)|2.5 μg (nominal dose) abediterol via DPI, reference
47937702|NCT03027479|OTHER|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
48100646|NCT04659616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48100647|NCT04659616|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
48100648|NCT04659616|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiratie
48100649|NCT04659616|DRUG|Cytarabine|Given IV
48100650|NCT04659616|DRUG|Daunorubicin|Given IV
48468427|NCT02720549|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
48468428|NCT02720549|PROCEDURE|valvular surgery with bypass|valvular surgery with bypass
48283579|NCT00608088|BEHAVIORAL|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
48283580|NCT01814423|DRUG|Chloroquine-base 50 mg|
48468429|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
48283581|NCT01814423|DRUG|Chloroquine-base 70 mg|
48283582|NCT04146688|OTHER|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
48283583|NCT03183570|DRUG|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered
48283584|NCT02318004|OTHER|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
48283585|NCT00219908|DRUG|Mitoxantrone|
48283586|NCT01713062|DEVICE|Vitelene|THA
48283587|NCT01713062|DEVICE|XLPE|THA
48283588|NCT01773473|DRUG|Insulin Lispro Mix25|Administered SC
48283589|NCT01773473|DRUG|Insulin Lispro Mix50|Administered SC
48283590|NCT04815096|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
48283591|NCT05255757|BEHAVIORAL|Script Intervention|This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.
48283592|NCT05255757|BEHAVIORAL|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
48283593|NCT01733329|DRUG|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
48283594|NCT01733329|DRUG|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
48283595|NCT04609748|DRUG|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
48283596|NCT04609748|DRUG|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
48468430|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
48283597|NCT00002208|DRUG|Indinavir sulfate|
48283598|NCT00002208|DRUG|Lamivudine|
48283599|NCT00002208|DRUG|Stavudine|
48283600|NCT00002208|DRUG|Zidovudine|
48100651|NCT04659616|PROCEDURE|Electrocardiography|Undergo ECHO
47937703|NCT01608854|OTHER|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
47937704|NCT06479395|OTHER|Pediatric Endurance and Limb Strengthening (PEDALS) program|Participants will perform pediatric endurance and limb strengthening (PEDALS) program. The stationary cycling intervention will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. The longer session duration is designed to allow adequate rest intervals between set (1-3 minutes). A generalized stretching program will be performed prior to cycling for mental relaxation for 6-7 minutes. Ankle-foot orthosis if used for walking. Each 60 minutes cycling session will be divided into 2 phases: (1) lower-extremity strengthening and (2) cardiorespiratory endurance.
47937705|NCT06479395|OTHER|Task-Oriented Training (TOT)|The experimental protocol consists of task-oriented training program (TOT) .it will be performed 3 times per week, for a total of 24 sessions, within 8 weeks period. Before each training session, there will be a warm-up period with 5 to 10 minutes of dynamic activities (e.g., jogging). After training, there will be a cool down period with 5 to 10 minutes of dynamic stretching exercises. In addition to rest intervals. after training session, there will be a 48-hour rest interval to prevent muscle fatigue and injury.
48627924|NCT03589053|DEVICE|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
48627925|NCT03589053|DEVICE|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
47937706|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou probiotic flavored yogurt|Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.
47937707|NCT04375475|DIETARY_SUPPLEMENT|Bright Changyou lactobacillus flavored yogurt|Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.
47937708|NCT04375475|DIETARY_SUPPLEMENT|Bright flavored yogurt|Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
48283601|NCT04224623|BEHAVIORAL|Raising Well at Home|The Raising Well at Home intervention was delivered via 3 core home visits designed to be delivered every 4-6 weeks, with additional support via text or phone over 6 months. The home visits were designed to engage the whole family, build skills, and promote changes in the home environment to support lifestyle behavior change. These essential behaviors focused on reducing sugary beverage intake, promoting appropriate portion sizes, improving fruit and vegetable intake, increasing walking and reducing screen time/sedentary activity.
48283602|NCT00428363|DEVICE|Cataract surgery with implantation of an intraocular lens|
48283603|NCT05587881|BIOLOGICAL|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
48283604|NCT05587881|BIOLOGICAL|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
48283605|NCT05072405|DRUG|Simvastatin 20 mg (Zocor®, MSD)|Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
48283606|NCT05072405|DRUG|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
48283607|NCT00584662|DRUG|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
48283608|NCT01670201|DEVICE|Mepilex Transfer Ag|Silver dressing
48627926|NCT00003969|DRUG|tanespimycin|
48627927|NCT03268187|DEVICE|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
48627928|NCT03268187|BEHAVIORAL|Self-Alert Training|Self-Alert Training
48283609|NCT03716791|DIETARY_SUPPLEMENT|methylsulfonylmethane|3g per day
48283610|NCT03716791|DIETARY_SUPPLEMENT|placebo|white rice flour
48627929|NCT03268187|BEHAVIORAL|Relaxation Training|Relaxation Training
48627930|NCT01567085|DRUG|Eculizumab|
48627931|NCT03349047|BEHAVIORAL|Behavioral intervention group|Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.
48627932|NCT03349047|BEHAVIORAL|Education|The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
48627933|NCT04928586|DRUG|Pirfenidone|CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose
48627934|NCT04928586|DRUG|DMARDs|CTD-ILD patients treated with DMARDs according to the condition of the disease
48627935|NCT02595710|OTHER|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
48627936|NCT02595710|OTHER|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
47937709|NCT06184308|BEHAVIORAL|Home-based Physical Rehabilitation|Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.
48283611|NCT04226352|DRUG|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
48283612|NCT04747145|DEVICE|Radiation|60 Gy to be delivered over 30 daily treatments in six weeks. Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
48283613|NCT04747145|DRUG|Concurrent Chemotherapy (Temozolomide)|75mg/m\^2 x 42 days (concurrent chemotherapy with radiation). Chemoradiation is to start no sooner than 3 weeks after surgery and not later than 8 weeks.
48283614|NCT04747145|DRUG|Adjuvant Chemotherapy (Temozolomide)|Starting no sooner than 4 weeks after completion of chemoradiation, 150-200mg/m\^2, days 1-5 of 28-day cycle, for minimum of six cycles and up to 12 cycles.
48283615|NCT03116113|BIOLOGICAL|BIIB112|Administered as specified in the treatment arm.
48283616|NCT02858479|OTHER|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
48283617|NCT02858479|OTHER|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
48468431|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + venetoclax|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
48627937|NCT02595710|OTHER|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
48627938|NCT03828383|DEVICE|In-home technology|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.
48283618|NCT02858479|RADIATION|MRI scan|"2 sessions for 10 minutes :~* 11 controls stimulations for 6 s each spaced 20 s without stimulation.~* 11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
48468432|NCT04291859|DRUG|Lu AF28996|capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
48468433|NCT04994938|OTHER|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
48468434|NCT04994938|OTHER|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
48468435|NCT02629016|OTHER|Mindfulness|
48468436|NCT02629016|OTHER|Wellness|
48468437|NCT00152516|DRUG|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
48468438|NCT06094894|OTHER|sucralose|Food additive used to replace sugar providing a sweet taste without calories.
48627939|NCT03828383|DEVICE|Limited in-home technology|Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
48627940|NCT01331005|DRUG|nepafenac 0.1% drops|One drop three times per day for one year
48627941|NCT01331005|OTHER|Nepafenac Vehicle|Placebo
48627942|NCT00231192|DRUG|Repaglinide and Insulin|
48627943|NCT06043570|DEVICE|Remote Monitoring arm|Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
48100652|NCT04659616|DRUG|Pemigatinib|Given PO
48283619|NCT03702933|DIETARY_SUPPLEMENT|D-serine|dosage
48283620|NCT04619420|DRUG|JNJ-63733657|JNJ-63733657 low or high dose will be administered by IV infusion.
48283621|NCT04619420|DRUG|Placebo|Placebo matching to JNJ-63733657 will be administered by IV infusion.
48468439|NCT06094894|OTHER|placebo|Cornstarch without significant physiological effects
48468440|NCT04668274|DRUG|200 mg resveratrol as JOTROL|Low (first) dose of single ascending dose study
48468441|NCT04668274|DRUG|500 mg resveratrol as JOTROL|Second (intermediate) dose of single ascending dose study
48468442|NCT04668274|DRUG|700 mg resveratrol as JOTROL|Third (highest) dose of single ascending dose study
48283622|NCT06273163|OTHER|Medically tailored meals|Medically tailored meals are nutritious meals formulated for weight wellness.
48468443|NCT04668274|DRUG|500 mg resveratrol as JOTROL administered to assess influence of food|500 mg resveratrol as JOTROL administered to assess influence of food
48468444|NCT06660121|PROCEDURE|Electrochemotherapy with bleomycin|Electrochemotherapy (ECT) with bleomycin is a localized treatment approach used for managing desmoid fibromatosis, a benign but locally aggressive tumor. This technique combines electrical pulses with the administration of bleomycin, a chemotherapeutic agent, to enhance drug uptake into tumor cells. The electrical pulses create temporary pores in the cell membranes, allowing bleomycin to enter more effectively, leading to increased cytotoxicity. ECT is typically performed on patients who have not responded to conventional therapies or for whom surgery is not feasible. ECT can lead to significant tumor shrinkage and improvement in symptoms, making it a promising option in the multidisciplinary management of desmoid fibromatosis.
47937710|NCT06184308|BEHAVIORAL|Health Coaching|Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
48100653|NCT02434718|DRUG|Aducanumab|As described in the treatment arm
48100654|NCT02434718|DRUG|Placebo|IV administration of 0.9% sodium chloride
48627944|NCT03973593|BEHAVIORAL|Enhancing contraceptive counseling on method continuation and switching|Health care workers and Community Health Volunteers will be trained on a contraceptive counseling package that enhances information on method continuation and switching. This will be done in the ten intervention facilities prior to enrollment of clients into the cohort study.
48627945|NCT03157791|DRUG|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
48627946|NCT00693264|DIETARY_SUPPLEMENT|Hoodia Gordonii|750 mg capsule will be taken one time
48627947|NCT00693264|DIETARY_SUPPLEMENT|Placebo|Placebo capsule to be taken one time
48627948|NCT05367830|BEHAVIORAL|the Bone@BC app|The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
48627949|NCT02918799|BEHAVIORAL|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
48100655|NCT04993963|OTHER|Cycle Ergometery Training (Prehabilitation)|Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion \<13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
48468445|NCT01499160|DRUG|letrozole|Drug is are to be taken orally. 2.5 mg once daily
48468446|NCT01499160|DRUG|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
48468447|NCT01499160|DRUG|everolimus|Drug is to be taken orally. 5 mg once daily.
48468448|NCT03495206|DRUG|Y-2(Edaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
48468449|NCT05482425|OTHER|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
48468450|NCT01978691|DIETARY_SUPPLEMENT|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
48468451|NCT01978691|DIETARY_SUPPLEMENT|Polydextrose|Studied as a prebiotic
48468452|NCT01978691|OTHER|Placebo|Control
48100656|NCT04993963|OTHER|Control Standard Group|Breathing exercise 15 Reps and Walk (10-15 minutes)
48100657|NCT00404079|DRUG|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
48283623|NCT06273163|BEHAVIORAL|Noom®|Noom® is a subscription-based mobile application used to support healthy eating and exercise behavior change.
48283624|NCT06273163|OTHER|Usual care|Care is provided at the discretion of the individual provider (e.g., usual care).
48283625|NCT00663130|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
48283626|NCT00663130|DRUG|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
48283627|NCT02986373|BIOLOGICAL|risankizumab|Risankizumab administered by subcutaneous injection.
47937711|NCT05039827|OTHER|Mobilization with movement|Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
47937712|NCT05039827|OTHER|Soft Tissue Mobilization|Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
48627950|NCT06023537|BEHAVIORAL|Behavioral weight loss program|All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
48627951|NCT04324489|DRUG|DAS181|Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
48627952|NCT02471742|PROCEDURE|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
48627953|NCT02471742|PROCEDURE|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
48627954|NCT01272778|DRUG|Lorazepam|Oral capsule, 0.2 mg, single acute dose
48627955|NCT01272778|DRUG|Lorazepam|oral capsule, 0.5 mg, single acute dose
48627956|NCT01272778|DRUG|Lorazepam|oral capsule, 1.0 mg, single acute dose
48100658|NCT00404079|DRUG|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
48627957|NCT01272778|DRUG|Lorazepam|oral capsule, 2.0 mg, single acute dose
48627958|NCT01272778|DRUG|Placebo|oral capsule, single acute dose
48627959|NCT04379115|DEVICE|Active Comparator: Active tDCS + Active TUS|"Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes."
48627960|NCT04379115|DEVICE|Sham Comparator: Sham tDCS + Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes."
48627961|NCT03830411|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
48627962|NCT03830411|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
48627963|NCT03830411|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
48627964|NCT05860530|DRUG|The test olaparib tablet (T)|The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
48627965|NCT05860530|DRUG|The reference olaparib tablet (R)|The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
48627966|NCT06028373|DRUG|ATG-031|ATG-031 will be infused Q3W on Day 1 of each cycle, at the starting dose of 0.03 mg/kg and a maximum dose of 9 mg/kg in the Dose Escalation Phase, and the defined MTD if available or OBD in the Dose Expansion Phase. Based on the emerging PK, PDx, safety, and other relevant data, SRC may decide to explore alternative dosing schedules.
48627967|NCT00594555|DRUG|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
48100659|NCT00781690|DEVICE|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
47937713|NCT05463939|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
47937714|NCT00246688|DRUG|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
47937715|NCT02717845|DEVICE|Ellipse|diagnostic CT scan imaging
47937716|NCT02717845|DEVICE|Tomofix|diagnostic CT scan imaging
47937717|NCT02879240|OTHER|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
47937718|NCT02879240|OTHER|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
48100660|NCT04657991|DRUG|Encorafenib|Encorafenib
48100661|NCT04657991|DRUG|Binimetinib|Binimetinib
48100662|NCT04657991|DRUG|Pembrolizumab|Pembrolizumab
48100663|NCT04483843|OTHER|No intervention|No intervention will be performed while it is retrospective observational study.
48100664|NCT02973243|DEVICE|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
48100665|NCT03028363|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
48100666|NCT03028363|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
48100667|NCT04895007|BIOLOGICAL|Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine|Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.
48100668|NCT01178762|DRUG|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
48100669|NCT04033237|OTHER|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
48468453|NCT05214144|OTHER|PRO Instruments assessment questionnaire|"Patient Reported Outcome (PRO) questionnaire consisting of:~* PRO-CTCAE (approximately 11 questions plus free text)~* Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form (version 8c) (8 questions)~* PRO ECOG question (1 question)~* EORTC Quality of Life questionnaire (QLQ)-F17 questions (17 questions)~* Functional Assessment of Cancer Therapy-General version, rated on a 5-point Likert scale, (FACT-GP5) (single item global side effect bother question) (1 question)~* The Patient Global Impression (PGI)-C and PGI-S items (anchors for physical function) (2 questions)"
48283628|NCT03270722|DEVICE|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
48468454|NCT05214144|OTHER|Baseline Survey Clinician- reported (ClinRO) ECOG|Baseline Survey completed prior to initiation of chemotherapy
48100670|NCT00890786|DRUG|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
48468455|NCT05214144|DEVICE|Fitbit|wearable device
48468456|NCT05214144|OTHER|"Hugo Health (Hugo)"|an electronic platform that aggregates real world EHR data with patient's wearable and PRO data
48468457|NCT05214144|OTHER|6 Minute Walk Test (6MWT)|A comprehensive performance measure of exercise capacity, encompassing components of mobility, endurance, and functional capacity measure (PerfO)
48468458|NCT06604481|BEHAVIORAL|eCoaching for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills. This program is designed to operate individually on an e-platform. It consists of 6 weekly sessions, each lasting for less than 90 minutes. The content of the sessions focuses on teaching caregivers CBT techniques, lifestyle modifications to improve caregiving experiences, and effective communication strategies. In between each session, participants are assigned home practices to reinforce the skills learned further. All content will be included.
48627968|NCT00594555|DRUG|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
48627969|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
48627970|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
48283629|NCT03270722|PROCEDURE|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
48283630|NCT05994651|BEHAVIORAL|Tidal Model improvement model|"1. st interview Pre-assessment Application of measurement tools~2. nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process"
48468459|NCT06604481|BEHAVIORAL|eCoaching (need specific) for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills as in eCoaching I. However, eCoaching II will include content specified to carer's specific need.
48468460|NCT06604481|BEHAVIORAL|Control Intervention for Caregivers of Older Adults|The control group attends 6 weekly online sessions that primarily provide educational information about lifestyle factors and communication. These sessions aim to enhance the control group's knowledge and understanding of the factors that impact caregiving. Each session in the control group also lasts for 90 minutes. The focus of these activities will be on building practical caregiving skills and promoting overall well-being, rather than targeting any particular psychological or mental health-related factors directly.
48468461|NCT02153723|DRUG|Glatiramer Acetate|
48468462|NCT00963430|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
48468463|NCT06624371|DRUG|Atovaquone|"Atovaquone oral suspension (750 mg/5mL) will be administered with meals on an outpatient basis.~Patients 13 years and older will receive atovaquone 750 mg PO BID, the standard pediatric dosing for Pneumocystis Jirovecii Pneumonia (PJP) prevention and treatment.~For those aged 2-12 years, atovaquone will be dosed at 30mg/kg once daily. The maximum dose for children under 12 will be 1500 mg."
48468464|NCT06624371|RADIATION|Radiation Therapy|54-60 Gy in 1.8 Gy daily fractions of MRI-guided proton radiotherapy using intensity-modulated pencil-beam scanning technology to match the target will be used.
48468465|NCT01762228|DEVICE|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
48468466|NCT01762228|DIETARY_SUPPLEMENT|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
48468467|NCT03171324|DRUG|Iron Supplement|2 mg/kg/day elemental iron
48468468|NCT04139460|DEVICE|CRT-D|After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
48468469|NCT04139460|DEVICE|CRT-P|After randomization, devices will be implanted as soon as possible (within 2 weeks).
48468470|NCT00234780|PROCEDURE|pediatric nursing used in home to avoid hospitalization|
48468471|NCT04595032|DEVICE|3DCRT, IMRT, VMAT, SBRT|Radiation treatment
48468472|NCT05850234|BIOLOGICAL|GC012F (AZD0120)|GC012F (AZD0120) is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.
48468473|NCT06632236|DRUG|Amivantamab|Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.
48468474|NCT00024154|BIOLOGICAL|trastuzumab|Given IV
48468475|NCT00024154|DRUG|gefitinib|Given orally
48468476|NCT00024154|OTHER|laboratory biomarker analysis|Correlative studies
48468477|NCT06593418|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy, which delivers precise, high-dose radiation non-invasively to generate thermal scarring to myocardial targets causing VT
48468478|NCT04095624|BEHAVIORAL|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
48627971|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
48627972|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
48627973|NCT00785941|BIOLOGICAL|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
48100671|NCT00890786|DRUG|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
48627974|NCT00083707|DRUG|Thalidomide|
48627975|NCT04472741|DEVICE|difference between colonoscopes|patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
48627976|NCT05687565|DIETARY_SUPPLEMENT|Control group placebo|Dietary suplementation
48627977|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 1 lauric acid|Lauric acid 1.5 grams once daily
48627978|NCT05687565|DIETARY_SUPPLEMENT|Experimental group 2 lauric acid|Lauric acid 3 grams once daily
48100672|NCT00890786|DRUG|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
48100673|NCT02023372|OTHER|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
48100674|NCT01774994|OTHER|stable isotope infusion for measurement of metabolism|
48468479|NCT04095624|OTHER|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
48468480|NCT06676813|BEHAVIORAL|Alternate day fasting|Alternate day fasting
48468481|NCT01107028|OTHER|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
48468482|NCT00709514|DRUG|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
48468483|NCT00709514|DRUG|Placebo|Placebo
48468484|NCT06300086|BEHAVIORAL|Electronically delivered nudging letters to patients with CKD|"Patients in the active arm will receive a digital nudge letter as part of the study. The nudge letter will be delivered at baseline. Letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD randomized to not receive digital nudge letters (usual care)."
48468485|NCT06300086|BEHAVIORAL|Electronically delivered nudging letter to associated GPs of patients with CKD|"The associated GPs of the patients in the active arm will receive one digital nudge letter as part of the study. The nudge letter will be delivered at baseline. The letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD whose associated GP was randomized to not receive a digital nudge letter (usual care)."
48468486|NCT06004245|DRUG|RO7589831|RO7589831 will be administered orally and once daily (QD) in 3-week cycles.
48468487|NCT06004245|DRUG|Pembrolizumab|Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
48468488|NCT03826394|BEHAVIORAL|Exercise Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
48468489|NCT03826394|BEHAVIORAL|Dietary Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
48468490|NCT06678009|DEVICE|the isokinetic training group with blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
48468491|NCT06678009|DEVICE|the isokinetic training group without blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
48468492|NCT06556563|DEVICE|Optune® device|Optune® device delivering TTFields therapy at 200 kHz.
48468493|NCT06556563|DRUG|Temozolomide|Temozolomide per approved labeling.
48468494|NCT06556563|DRUG|Pembrolizumab|Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
48468495|NCT06556563|DRUG|Placebo|Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
48468496|NCT02725411|DRUG|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
48100675|NCT01396109|PROCEDURE|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA\* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
48100676|NCT01396109|PROCEDURE|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
48283631|NCT01901224|DRUG|Metformin 1000 mg|
48283632|NCT01901224|DRUG|Placebo|
48283633|NCT00142506|DRUG|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
48468497|NCT02725411|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
48468498|NCT02725411|BIOLOGICAL|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
48100677|NCT03025464|DEVICE|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
48283634|NCT00142506|DRUG|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
48283635|NCT03392233|RADIATION|Stereotactic Body Radiation Therapy|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
48627979|NCT05643690|DIAGNOSTIC_TEST|UriFind Bladder Cancer Assay|The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the Assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
48468499|NCT02725411|DRUG|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
48468500|NCT02725411|BIOLOGICAL|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
48468501|NCT06389838|DEVICE|Kranus Mictera|An app-based digital therapy program aimed at multimodal self-treatment for incontinence. The app is certified class I medical device (MDR).
48468502|NCT05076682|DRUG|Choline|Choline 300mg tid or 500mg bid, p.o
48627980|NCT04947280|RADIATION|Fractionated Stereotatic Radiation Therapy|Participants prescribed to receive 9 Gy x 3 or 10 Gy x3 image-guided fractionated stereotatic radiation therapy.
48627981|NCT05643508|DRUG|(D) DWC202206|Drug of DWC202206 A mg
48627982|NCT05643508|DRUG|(D) DWC202207|Drug of DWC202207 B/C mg
48627983|NCT05643508|DRUG|(P) DWC202206|Placebo of DWC202206 A mg
48627984|NCT05643508|DRUG|(P) DWC202207|Placebo of DWC202207 B/C mg
48627985|NCT02919332|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
48627986|NCT02919332|RADIATION|Fludeoxyglucose F-18|Given IV
48627987|NCT02919332|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
48627988|NCT06283030|DEVICE|Hypoglossal nerve stimulation|Device-mediated stimulation of the hypoglossal nerve
48627989|NCT03415269|DRUG|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
48627990|NCT06195605|DEVICE|Restylane-L|Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other
48627991|NCT06195605|DEVICE|Vehicle|Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
48627992|NCT04231006|RADIATION|High dose rate brachytherapy|High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT
48627993|NCT04034680|OTHER|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
48627994|NCT04034680|OTHER|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
48100678|NCT00686023|PROCEDURE|internal fixation (DHS - richard nail)|internal fixation
48100679|NCT00686023|PROCEDURE|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
48100680|NCT04399525|DRUG|Desloratadine Single Dose|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
48468503|NCT05076682|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
48627995|NCT02328729|PROCEDURE|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
48627996|NCT02328729|PROCEDURE|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
48283636|NCT04665102|OTHER|Image classification using deep learning algorithm|Image classification using deep learning algorithm
48283637|NCT03792958|DRUG|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
48283638|NCT02191748|PROCEDURE|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
48283639|NCT02191748|DRUG|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
48283640|NCT05337124|DRUG|LUPKYNIS|LUPKYNIS treatment per the approved US Prescribing Information
48283641|NCT03386240|DRUG|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
48283642|NCT03386240|OTHER|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
48283643|NCT06655883|DRUG|Suvorexant|Oral Tablet
48283644|NCT06655883|DRUG|Placebo|Oral Tablet
48283645|NCT05936086|DRUG|Cytoxan|Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
48283646|NCT05936086|DRUG|Etoposide|etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
48468504|NCT05076682|DRUG|Sodium Cromoglicate|Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
48468505|NCT05076682|DRUG|Efavirenz|Efavirenz 600mg qd, p.o
48627997|NCT02328729|PROCEDURE|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
48627998|NCT02328729|PROCEDURE|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
48283647|NCT05936086|DRUG|Dexamethasone|Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
48283648|NCT05936086|DRUG|Cyclosporine (CSA)|Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
48283649|NCT06657560|DRUG|HRS-9231|HRS-9231
48283650|NCT06279923|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
48283651|NCT02107664|RADIATION|Palliative RT for bone cancer pain|
48283652|NCT01917331|DRUG|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
48283653|NCT01917331|DRUG|Beclometasone/Formoterol|Active comparator
48283654|NCT04937023|DRUG|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
48283655|NCT01240070|OTHER|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
48283656|NCT03289689|DEVICE|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
48468506|NCT04775316|DEVICE|Leukomed T / Tplus skin sensitive treatment|Application of sterile wound dressing.
48468507|NCT06420297|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
48468508|NCT02400463|DRUG|Ruxolitinib|
48468509|NCT06245915|BIOLOGICAL|AB-2100|autologous T cell therapy
48468510|NCT02466087|DRUG|Mg Cl|Four supplements a day for 6 weeks.
48468511|NCT04546412|DEVICE|Vitrification and thawing|Vitrification using the Cryotop® - Open System followed by thawing
48468512|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
48468513|NCT01026649|PROCEDURE|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
48468514|NCT05126212|OTHER|User experience|User experience is assessed by validated scale
48468515|NCT06400225|PROCEDURE|Biopsy|Undergo biopsy
48468516|NCT06400225|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48468517|NCT06400225|PROCEDURE|Computed Tomography|Undergo CT scan
48627999|NCT02328729|PROCEDURE|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
48628000|NCT02328729|PROCEDURE|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
48628001|NCT05431790|DEVICE|Absorbable interface screws manufactured by Natong Biotechnology|Anterior cruciate ligament reconstruction uses absorbable interface screws manufactured by Natong Biotechnology.
48628002|NCT05431790|DEVICE|Absorbable interface screws manufactured by INION.|Reconstruction of anterior cruciate ligament using Inion Oy absorbable interface scews from INION, Finland
48628003|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
48628004|NCT01554813|BIOLOGICAL|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
48628005|NCT01554813|BIOLOGICAL|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
48628006|NCT02606253|DRUG|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
48628007|NCT02606253|DRUG|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
48628008|NCT02606253|DRUG|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
48628009|NCT02959762|DIETARY_SUPPLEMENT|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
48628010|NCT02959762|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
48468518|NCT06400225|PROCEDURE|Echocardiography|Undergo ECHO
48468519|NCT06400225|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48468520|NCT06400225|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
48628011|NCT02959762|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
48628012|NCT02015156|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
48628013|NCT02015156|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
48468521|NCT06400225|DRUG|Ulixertinib|Given PO
48628014|NCT01470807|DEVICE|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
48628015|NCT00949663|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
48628016|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
48628017|NCT00949663|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
48468522|NCT05134116|OTHER|Treatment as usual + cerebral oximetry monitoring the first 72 hours of life|SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants
48468523|NCT04682587|DRUG|Axitinib|Inlyta, axitinib
48468524|NCT04682587|DRUG|Avelumab|Avelumab, Bavencio
48628018|NCT00949663|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
48628019|NCT01284764|DRUG|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
48628020|NCT06261957|DRUG|Salbutamol HFA-134a|100 microgram (μg) (ex-valve) at 30-second intervals per actuation
48628021|NCT06261957|DRUG|Salbutamol HFA-152a|100 μg (ex-valve) at 30-second intervals per actuation
48628022|NCT01485835|DRUG|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
48628023|NCT01485835|DRUG|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
48628024|NCT01485835|DRUG|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
48628025|NCT03358953|DEVICE|Electron Cigarette|Blended Tobacco flavour, 18mg/ml
48628026|NCT03358953|DEVICE|Nicotine Replacement Patch|NiQuitin 21mg
48468525|NCT04682587|DRUG|Pembrolizumab|Pembrolizumab, Keytruda
48468526|NCT06137781|BEHAVIORAL|Six weeks of digital prehabilitation|All participants will be allocated to receive six weeks of digital prehabilitation via PreActiv's website, plus usual care.
48617861|NCT01116531|DRUG|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
48628027|NCT02280954|DRUG|Indocyanine Green (ICG)|
48628028|NCT01784185|PROCEDURE|virtual bronchoscopy guided transbronchial needle aspiration|
48283657|NCT03253640|OTHER|Exposure|Healthcare associated infection (HAI)
48283658|NCT01593982|OTHER|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
48283659|NCT03185676|OTHER|Bilberry|A bilberry based probiotic beverage
48283660|NCT03185676|OTHER|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
48628029|NCT01784185|PROCEDURE|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
48283661|NCT01925521|DRUG|Part1 : OPS-2071|single oral dose under fasted condition
48283662|NCT01925521|DRUG|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
48283663|NCT01925521|DRUG|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
48283664|NCT01925521|DRUG|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
48283665|NCT05381961|DEVICE|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
48283666|NCT03815292|DRUG|MMH-MAP|Oral administration
48283667|NCT03815292|DRUG|Placebo|Oral administration
48283668|NCT01774942|PROCEDURE|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
48283669|NCT02704429|DRUG|PRN1008|"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
48283670|NCT03520049|DRUG|Oseltamivir|
48283671|NCT03520049|DRUG|Placebo|
48283672|NCT06004661|DRUG|AAA617|Administered intravenously once every cycles (1 cycle = 6 weeks)
48283673|NCT06004661|DRUG|68Ga-PSMA-11|Single intravenous dose of approximately 150 MBq
48283674|NCT05282940|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Investigational Medicinal Product
48283675|NCT05282940|DRUG|Microgynon CD|Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
48283676|NCT03391869|BIOLOGICAL|Ipilimumab|Given IV
48283677|NCT03391869|PROCEDURE|Local Consolidation Therapy|Undergo radiation and/or surgery
48283678|NCT03391869|BIOLOGICAL|Nivolumab|Given IV
48283679|NCT03391869|OTHER|Quality-of-Life Assessment|Ancillary studies
48628030|NCT02346916|DRUG|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
48628031|NCT03605056|DRUG|chidamide|20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
48628032|NCT03605056|DRUG|lenalidomide|25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
48628033|NCT03605056|DRUG|dexamethasone|40mg weekly, will be administered orally or intravenously
48628034|NCT00446784|DRUG|CE-224,535|
48628035|NCT00446784|DRUG|Methotrexate|
48628036|NCT01427946|DRUG|IPI-504|
48628037|NCT01427946|DRUG|Everolimus|
48628038|NCT00176332|DRUG|rosuvastatin|
48283680|NCT03391869|RADIATION|Radiation Therapy|Undergo radiation
48283681|NCT03391869|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48283682|NCT05839132|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
48628039|NCT00478036|DRUG|Acular LS|Details covered in arm description
48628040|NCT00478036|DRUG|Pred Forte|Details covered in arm description
48628041|NCT00478036|OTHER|Refresh Tears|Placebo
48283683|NCT01440101|DRUG|Natalizumab (BG00002)|
48628042|NCT04808453|DRUG|CPI-300|CPI-300 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
48628043|NCT00132483|BEHAVIORAL|Instruction in physical training program|Instruction in physical training program.
48628044|NCT05639205|DIAGNOSTIC_TEST|Lateral Flow Device|Regular asymptomatic staff testing with a Lateral Flow Device including support payments if unwell.
48628045|NCT02478502|DRUG|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
48628046|NCT02753673|BEHAVIORAL|qualitative interviews with patients|
48628047|NCT02753673|BEHAVIORAL|questionnaires|
48628048|NCT05501405|OTHER|Electroencephalogram and eye-tracking recordings|"Participants will perform two tasks: recognize the expression (explicit recognition of the expression) or detect the change in color of the cross (implicit processing of the expression). Each participant will perform two tasks x 6 models x 5 expressions, i.e. 60 stimulations, for a stimulation duration of approximately 30 minutes.~Recognition of the emotional facial expression with a choice among 5 possibilities. Two neutral faces of the same person will be presented side by side. When the participant has looked at the central fixation cross for one second, one of the two faces will produce an expression. The participant will have to indicate as quickly as possible which expression it is, while his or her eye movements are recorded. Each participant will have to recognize 5 expressions x 8 models, i.e. 40 trials for a duration of approximately 5 to 10 minutes"
48283684|NCT01440101|DRUG|Placebo|
48628049|NCT03267589|DRUG|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
48628050|NCT06011226|OTHER|focus groups|A dozen patients with Chiari malformation and syringomyelia (n = 4) or isolated Chiari malformation (n = 4) or isolated syringomyelia (n = 4) will be brought together in at least two focus groups. Each focus group will include 5 to 8 patients and will last approximately 1 to 2 hours. The focus groups will be recorded (audio only, no personal data will be collected during these sessions) and will be conducted in the presence of a neurosurgeon and a psychologist, who will moderate the session.
48628051|NCT06011226|OTHER|questionnaire|developed questionnaire will be proposed to the patients in phase 2 and 3
48628052|NCT05628272|OTHER|Intravenous infusion of cord blood mononuclear cells|On the basis of the application of granulocyte stimulating factor, the research group was given intravenous infusion of umbilical cord blood mononuclear cells, each infusion ≥1×10\^8, once a week
48628053|NCT05628272|DRUG|application of granulocyte stimulating factor|application of granulocyte stimulating factor
48628054|NCT04217356|BIOLOGICAL|Hematopoietic stem cell transplant|Intravenous infusion of hematopoietic stem cells from a donor.
48628055|NCT04217356|DRUG|Ruxolitinib|Ruxolitinib is type of drug called a janus kinase (JAK) inhibitor. Ruxolitinib is taken orally (by mouth).
48628056|NCT04217356|DRUG|Hydroxyurea|Hydroxyurea is a type of drug called an antimetabolite. Hydroxyurea is taken orally (by mouth).
48628057|NCT01849809|PROCEDURE|Gamma Ventral Capsulotomy|
48628058|NCT01597362|PROCEDURE|laparoscopy|Trocar access in laparoscopy
48628059|NCT01597362|PROCEDURE|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
48628060|NCT01597362|PROCEDURE|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
48283685|NCT05293418|OTHER|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
48283686|NCT02286960|DRUG|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
48283687|NCT02286960|DIETARY_SUPPLEMENT|Lactose Pills|4 day course 2 x 20mg per da
48283688|NCT04599426|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15 ."
48283689|NCT06035718|DRUG|Probiotic Blend Capsule|By a probiotic blend capsule a specific product is intended which contains the following: Lactobacillus rhamnosus Lactobacillus plantarum Lactobacillus casei Lactobacillus helveticus Lactobacillus acidophilus Lactobacillus bulgaricus Lactobacillus gasseri Bifidobacterium bifidum Bifidobacterium lactis Bifidobacterium breve Bifidobacterium longum Streptococcus thermophile Fructooligosaccharides (FOS).
48283690|NCT06035718|DEVICE|tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp.
48283691|NCT06035718|DEVICE|Sham tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp. At this arm the electric current will be applied for a very short time (30 s) after which the device will turn off, thus providing the initial tingling sensation over the scalp but not interfering with the ongoing brain activity.
48283692|NCT00095121|DRUG|Placebo (PLB)|Matching placebo
48283693|NCT00095121|DRUG|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
47937719|NCT02910375|OTHER|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
48100681|NCT04399525|DRUG|Levocetirizine Single Dose|Levocetirizine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
48468527|NCT01966809|DRUG|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
48468528|NCT06638398|PROCEDURE|Computed Tomography|Undergo standard of care Computed Tomography
48468529|NCT06638398|DEVICE|Diagnostic Procedure|Receive a Virtual Nodule Clinic radiomic prediction score obtained in Optellum software.
48468530|NCT06638398|OTHER|Best Practice|Receive standard of care lung nodule management
48468531|NCT06638398|OTHER|Electronic Health Record Review|Ancillary Studies
48468532|NCT05459116|DEVICE|Placement of nasogastric balloon|A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients \>40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients \<40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
48468533|NCT05701124|DRUG|Ranibizumab (0.25 mg/0.025 mL)|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
48468534|NCT03827005|DIETARY_SUPPLEMENT|L-arginine|NOW Foods, Bloomingdale, IL
48468535|NCT03827005|DIETARY_SUPPLEMENT|Placebo|InHealth Specialty Pharmacy, Fargo, ND
48468536|NCT05006131|OTHER|Screening for pancreatic cancer|Screening for pancreatic cancer using EUS or MRI
48468537|NCT06428955|DEVICE|CT LUCIA 621P|The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
48468538|NCT06677697|DRUG|Ropivacaine 0,5%|Group B 30 patients recive 0.5% ropivacine
48468539|NCT06146660|DRUG|Mavacamten|According to approved product label
48628061|NCT01597362|PROCEDURE|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
48468540|NCT05107739|BIOLOGICAL|Drug Product De-TIL-0255|Autologous tumor-infiltrating lymphocytes
48468541|NCT06207253|DRUG|Diclofenac Sodium|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
48468542|NCT06207253|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
48468543|NCT06679595|OTHER|Pilot project paediatric transmural care|The implementation of pilot projects for transmural care for chronically ill children
48628062|NCT01787903|DEVICE|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
48628063|NCT06190119|OTHER|none intervention|This study has no intervention
48628064|NCT00164723|PROCEDURE|Capsule endoscopy|Capsule endoscopy and colonoscopy
48628065|NCT00901498|DRUG|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
48628066|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
48628067|NCT00901498|DRUG|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
48628068|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
48628069|NCT00901498|DRUG|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
48628070|NCT03510702|DIAGNOSTIC_TEST|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
48628071|NCT02603029|OTHER|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
48628072|NCT02603029|OTHER|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
48628073|NCT04836130|PROCEDURE|patient specific guide|patient specific guide reduction
48628074|NCT04836130|PROCEDURE|conventional technique|conventional anatomical reduction
48628075|NCT00272090|DRUG|Insulin glargine|
48468544|NCT04829448|DIETARY_SUPPLEMENT|Protein supplement|Protein supplement equivalent to Metagenics Ultrameal
48468545|NCT06599619|DRUG|Nivolumab|Nivolumab is a type of targeted therapy drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.
48468546|NCT06599619|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody and a type of immune checkpoint inhibitor that's used in cancer immunotherapy. It works by attaching to the PD-1 protein on the surface of T cells, which are immune cells. This prevents cancer cells from suppressing the immune system, allowing the immune system to attack and kill the cancer cells.
48100682|NCT04399525|DRUG|Desloratadine Fourfold Dose|Desloratadine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively
48283694|NCT00095121|DRUG|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration \>= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained \>= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
48283695|NCT06388057|DIAGNOSTIC_TEST|Intraoperative Small Bowel Ultrasonography|An intraoperative ultrasound study will be performed on the intestinal segment identified as the resection site
48283696|NCT06656598|DRUG|Carboplatin|Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
48468549|NCT06134440|DIETARY_SUPPLEMENT|Impact Oral®|All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
48468550|NCT04279847|DRUG|INCB057643|INCB057643 dose escalation and dose expansion.
48468551|NCT04279847|DRUG|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
48468552|NCT01978873|DRUG|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
48468553|NCT01978873|DRUG|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
48468554|NCT05900323|COMBINATION_PRODUCT|enteral nutrition guidelines|The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
48468555|NCT04038645|OTHER|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
48628076|NCT01386177|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
48628077|NCT01386177|DRUG|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
48628078|NCT01386177|DRUG|placebo|capsules identical to MDMA or doxazosin
48628079|NCT01275027|DIETARY_SUPPLEMENT|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
48628080|NCT01063582|OTHER|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
48628081|NCT01063582|PROCEDURE|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
48628082|NCT02049879|DRUG|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
48100683|NCT04399525|DRUG|Levocetirizine Fourfold Dose|Levocetirizine (H1-antihistamine): 2 oral tablets of 5 mg in the evening and 2 oral tablets of 5 mg in the morning, taken with 240 ml water, 14 and 4 hours prior to the histamine skin prick, respectively.
48100684|NCT03398811|DRUG|Depot medroxy-progesterone acetate|Injection every 3 months
48100685|NCT03398811|DRUG|Etonogestrel|68 mg implant
48100686|NCT03398811|DRUG|Desogestrel 75 µg|one pill every day for 28 days without pill-free interval.
48283697|NCT06656598|DRUG|Paclitaxel|Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
48283698|NCT06656598|DRUG|Cemiplimab|Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).
48283699|NCT06656598|RADIATION|Curative hypofractionated radiotherapy|Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
48283700|NCT06656598|DRUG|Cemiplimab (maintenance)|Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
48283701|NCT06463912|OTHER|Does not apply|A descriptive cross-sectional study will be carried out in the city of Armenia-Colombia. A total of 205 PWID, 18 years to 65 years old will be included. They will be selected through the implementation of the respondent-driven sampling (RDS).
48283702|NCT02711371|OTHER|fMRI|
48283703|NCT05779852|OTHER|self-hypnosis and dressing|self-hypnosis during dressing
48283704|NCT05779852|OTHER|dressing|dressing without self-hypnosis
48283705|NCT06392490|OTHER|Technology Based Asthma Program|Evaluate the impact of peer-led and adult-based technology-based education on the quality of life, asthma control, asthma knowledge and self-efficacy in adolescents diagnosed with asthma.
48283706|NCT02835495|BEHAVIORAL|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
48283707|NCT02835495|BEHAVIORAL|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
48283708|NCT01844076|DRUG|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
48283709|NCT01492673|DRUG|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
48468556|NCT04038645|OTHER|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
48283710|NCT03832387|DEVICE|Non-invasive mechanical ventilation|
48283711|NCT03832387|DEVICE|Continuous positive airway pressure|
48283712|NCT03832387|DEVICE|Venturi mask|
48283713|NCT03832387|DEVICE|Reservoir mask|
48468557|NCT06055309|DRUG|Cannabis (up to three doses)|a dose of cannabis will be baked into brownies
48100687|NCT06632093|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
48283714|NCT06153862|DIAGNOSTIC_TEST|Immuno analytical assay|The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
48283715|NCT04223089|DIAGNOSTIC_TEST|Near Infrared Spectroscopy|"The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of the following in superficial tissue:~* oxygen saturation (StO2),~* relative oxyhemoglobin level (HbO2), and~* relative deoxyhemoglobin (Hb) level~The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues."
48283716|NCT03206658|DRUG|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
48468558|NCT06679114|BEHAVIORAL|Acceptance and Commitment Therapy|The single-session ACT group intervention will involve a mixture of didactic instruction, discussion, metaphors, and experiential activities. ACT activities will help women notice and accept that negative thoughts, emotions, and experiences while being displaced by war are part of migratory and post-migratory life. ACT activities will also help them identify, reorient towards, and commit to values-consistent behaviors through effective goal-setting. The single-session will be approximately 3 hours long.
48468559|NCT06679114|BEHAVIORAL|Attention control|Usual care will be minimally enhanced by providing participants with an educational information session that provides information on health promotion.
48468560|NCT04499482|OTHER|Food|Soy-fiber containing food
48468561|NCT04614714|DRUG|Nicotinamide riboside chloride|Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
48468562|NCT04614714|DRUG|Placebo|Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
48468563|NCT04914247|DRUG|Selexipag|
48468564|NCT04323215|DEVICE|Support system|A support system named Provement will be used to provide behavioral treatment.
48468565|NCT03632694|BEHAVIORAL|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
48468566|NCT03632694|BEHAVIORAL|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
48468567|NCT06361693|OTHER|Auto-preoxygenation|"Management is not modified. Routine monitoring (ECG, BP, SpO2). As in care, the patient takes the mask and the respirator is started, delivering an inspired oxygen fraction of 100% (FiO2=1).~Monitoring of : inspired fraction of oxygen, expired fraction of oxygen and end-tidal fraction of carbon dioxide. The ventilator also provides the respiratory rate and tidal volume carried out by the patient.~The fresh gas flow is set by default and will be adjusted to 12l/min for patient comfort.After less than a minute, a normal capnia curve and the presence of an FeO2 value appear. Here, time is standardized to 1 min. In the absence of one of these elements, the caregiver always takes control of preoxygenation.Timer is started, it is T0 min. At T 3min, collection of values and decision-making :~* objectives achieved : end of this sequence.~* objectives not achieved, the caregiver takes control again for an additional 2 minutes in order to seek to achieve an FeO2\>90%."
48468568|NCT06361693|OTHER|APAIS scale|APAIS scale
48468569|NCT06361693|OTHER|Visual analog anxiety scale (VAS-A)|Visual analog anxiety scale (VAS-A)
48468570|NCT06361693|OTHER|Visual analog comfort scale (VAS-C)|Visual analog comfort scale (VAS-C)
48468571|NCT03211455|DRUG|Lidocaine|intravenous lidocaine versus placebo
48468572|NCT03211455|DRUG|isotonic saline|intravenous isotonic saline
48100688|NCT06632093|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
48100689|NCT05969860|PROCEDURE|Clinical Encounter|Receive treatment in clinic
48468573|NCT03297541|BEHAVIORAL|m-health approach|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981). Anthropometric and demographic data collected on children in the dyad only.
48100690|NCT05969860|OTHER|Home Health Encounter|Receive at-home treatment
48100691|NCT05969860|OTHER|Quality-of-Life Assessment|Ancillary studies
48100692|NCT05969860|OTHER|Questionnaire Administration|Ancillary studies
48100693|NCT01325870|DEVICE|ACD-CPR|
48100694|NCT01325870|DEVICE|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
48100695|NCT01325870|PROCEDURE|S-CPR|standard manual CPR
48100696|NCT01325870|DEVICE|Impedance Threshold Device (ITD)|
48283717|NCT03206658|DRUG|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
48283718|NCT06495710|OTHER|Blood pressure treatment algorithm|Single or combination antihypertensive therapy as needed: 1) amlodipine (2.5-10 mg), 2) telmisartan (20-80 mg) or losartan (25-100 mg), 3) chlorthalidone (6.25-25 mg), or 4) spironolactone (12.5-50 mg). a two-drug regimen with either amlodipine + chlorthalidone or telmisartan + chlorthalidone will be initiated following randomization. If a diuretic is contraindicated, amlodipine + telmisartan will be initiated. For those over 75 years, either amlodipine or telmisartan will be initiated at baseline if SBP is \<140 mmHg. In the standard treatment group (SBP goal of \< 140 mmHg), participants will either be prescribed amlodipine or telmisartan/losartan as initial therapy. If \>3 medications are necessary to reach the intensive goal and no first line options remain, potassium sparing diuretics or direct vasodilators will be considered.
48283719|NCT04497844|DRUG|Niraparib|Participants will receive Niraparib 200 mg once daily.
48283720|NCT04497844|DRUG|Abiraterone acetate (AA)|Participants will receive AA 1000 mg once daily.
48283721|NCT04497844|DRUG|Prednisone|Participants will receive prednisone 5 mg once daily.
48283722|NCT04497844|DRUG|Placebo for Niraparib|Participants will receive matching placebo for Niraparib once daily.
48283723|NCT00942409|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
48468574|NCT04776304|BEHAVIORAL|Art Therapy|"This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a visual voice, using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms."
48628083|NCT03526146|BEHAVIORAL|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
48628084|NCT00281801|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
48628085|NCT00281801|PROCEDURE|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
48628086|NCT06179875|DRUG|Intervention/Treatment|VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
48283724|NCT06146114|DIAGNOSTIC_TEST|Collect HER2 expression in prostate cancer patients|HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
48283725|NCT02936895|DRUG|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
48283726|NCT02936895|DRUG|Placebo|Placebo for 2 days
48283727|NCT04714112|DRUG|dexamethasone|Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
48283728|NCT00860470|DIETARY_SUPPLEMENT|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
48628087|NCT00202150|BEHAVIORAL|Application of a management action plan|
48468575|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients|"Completion by patients of a 28-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
48283729|NCT00860470|DIETARY_SUPPLEMENT|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
48468576|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients' life partner|"Completion by the patients' life partner of a 30-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
48468577|NCT00217334|BEHAVIORAL|Volunteer-led pharmacy sessions with feedback to physicians|
48468578|NCT04264819|DRUG|RTH258/Brolucizumab|Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
48468579|NCT01845753|OTHER|Observation|Observation
48468580|NCT05884255|DRUG|Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
48468581|NCT05884255|DRUG|long-acting Octreotide.|High-dose long-acting Octreotide.
48468582|NCT01160445|DRUG|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
48468583|NCT01160445|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
47937720|NCT02910375|OTHER|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
48468584|NCT06260891|DRUG|25 mg/day zinc|25 mg of zinc as zinc gluconate taken orally once a day
47937721|NCT04900168|DEVICE|Intracranial pressure monitoring|An invasive method to monitor the intracranial pressure of patient
47937722|NCT02565927|DEVICE|Traditional airway stent|process airway stenting
47937723|NCT02565927|DRUG|Iodine-125 seeds|process intraluminal brachytherapy
48468585|NCT06260891|DRUG|40 mg/day zinc|40 mg of zinc as zinc gluconate taken orally once a day
48468586|NCT01526135|DRUG|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
47937724|NCT05037188|BIOLOGICAL|Low dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
47937725|NCT05037188|BIOLOGICAL|High dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
48468587|NCT01526135|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
48468588|NCT02899312|DRUG|PSMA PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
48468589|NCT01276496|DRUG|Cilengitide|Given IV
48283730|NCT05435430|OTHER|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
48283731|NCT06236217|OTHER|Carotid Ultrasound|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
48283732|NCT06236217|OTHER|Electrical cardiometry|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
48283733|NCT01549990|DRUG|Sevoflurane|maintenance of general anesthesia with sevoflurane
48468590|NCT01276496|OTHER|Laboratory Biomarker Analysis|Correlative studies
48468591|NCT01276496|DRUG|Paclitaxel|Given IV
48468592|NCT01276496|OTHER|Pharmacological Study|Correlative studies
48468593|NCT00508898|DRUG|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
48468594|NCT00508898|DRUG|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
48468595|NCT06676449|DRUG|Immunotherapy|PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
48468596|NCT06676449|DRUG|chemotherapy: Paclitaxel/Cisplatin|Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.
48628088|NCT05838040|OTHER|General exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
48628089|NCT05838040|OTHER|General exercises with tranversus abdmoinis contraction|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. In addition to these exercises, the Back to Fitness Program includes the activation of the transverse abdominis muscle, which is an important stabilizing muscle in the core. The activation of this muscle is done through specific exercises and techniques, and is intended to improve core stability and reduce the risk of further back injuries.
48628090|NCT02428647|DIETARY_SUPPLEMENT|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
48628091|NCT02428647|DIETARY_SUPPLEMENT|preventive zinc supplement|7 mg zinc daily as dispersible tablet
48628092|NCT02428647|DIETARY_SUPPLEMENT|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
48628093|NCT02428647|DIETARY_SUPPLEMENT|preventive placebo supplement|dispersible daily placebo tablet
48628094|NCT02428647|DIETARY_SUPPLEMENT|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
48628095|NCT02428647|DIETARY_SUPPLEMENT|placebo powder|placebo powder
48283734|NCT01549990|DRUG|desflurane|maintenance of general anesthesia with desflurane
48283735|NCT00310310|BEHAVIORAL|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
48283736|NCT00310310|BEHAVIORAL|Usual care|Usual sleep apnea and cpap care
48283737|NCT06480734|OTHER|symptom-based scoring system (symptom-questionnaire, paper version)|The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital.
48283738|NCT03322800|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
48468597|NCT06676449|RADIATION|TDLN-sparing RT|TDLN-sparing radiotherapy 50.4Gy/28Fx.
48468598|NCT06679387|DRUG|Memantine-HCl|Memantine hydrochloride 20 mg once daily for 12 weeks.
48468599|NCT06679387|DRUG|Placebo Oral Tablet|A once daily matched tablet of placebo for 12 weeks
48468600|NCT00912522|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
48468601|NCT04433494|DRUG|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
48468602|NCT04067154|DIAGNOSTIC_TEST|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
48468603|NCT00574769|DRUG|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days"
48468604|NCT00652002|DRUG|budesonide/formoterol|
48468605|NCT00652002|DRUG|budesonide|
48283739|NCT03322800|OTHER|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
48283740|NCT03233399|DEVICE|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
48468606|NCT00652002|DRUG|formoterol|
48468607|NCT06646016|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
48283741|NCT03233399|DEVICE|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
48283742|NCT03233399|DEVICE|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
48283743|NCT02778698|DIETARY_SUPPLEMENT|Omegaven|
48283744|NCT00230763|PROCEDURE|GSS questionnaire|D0, D30 and D84
48283745|NCT00230763|PROCEDURE|IOP|D0, D30 and D84
48283746|NCT00230763|DRUG|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
48468608|NCT06646016|DRUG|Infliximab|Infliximab will be administered intravenously.
48468609|NCT06646016|DRUG|Vedolizumab|Vedolizumab will be administered intravenously.
48628096|NCT01457027|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
48628097|NCT03969420|DRUG|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
48628098|NCT03969420|DRUG|Alvocidib (flavopiridol)|Administered intravenously
48628099|NCT04033913|OTHER|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
47937726|NCT05037188|BIOLOGICAL|Low dose or high dose BCD-250 injection|A recombinant viral vector AAV5-RBD-S vaccine
47937727|NCT05037188|OTHER|Placebo injection|Placebo injection
47937728|NCT03268148|DEVICE|LaserPen|low level laser is used before heel-lancing for newborn screening
48283747|NCT00230763|PROCEDURE|Visual acuity|D0 and D84
48283748|NCT04914897|DRUG|THOR-707|Intravenous infusion: solution for infusion
48628100|NCT04781465|DEVICE|Immersive Virtual Reality|"Dedicated virtual reality sessions.~* Duration 20 minutes per session.~* The virtual reality session will be supervised by a health professional trained in this tool after 1.5 hours of training by the team responsible for the equipment (use of the equipment, and use of the 20 minutes of VR). This supervising professional may be a doctor, an occupational therapist, a caregiver or any other health professional trained in the tool under this protocol.~* The exercises proposed will be standardized virtual reality exercises with the same exercises for all, but adapted to the level and abilities of each patient."
47937729|NCT01180530|DEVICE|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
48283749|NCT04914897|DRUG|Pembrolizumab|Intravenous infusion: solution for infusion
48283750|NCT04554576|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
48283751|NCT04554576|BEHAVIORAL|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
48468610|NCT00705315|DRUG|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
47937730|NCT01846520|OTHER|educational intervention|Receive FCPCI home education sessions
47937731|NCT01846520|BEHAVIORAL|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
48468611|NCT00705315|DRUG|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
48468612|NCT00705315|DRUG|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
48468613|NCT03486938|DRUG|Placebo Oral Tablet|Placebo oral tablet
48468614|NCT03486938|DRUG|AGB101 220 mg tablet|220 mg AGB101 active compound
48628101|NCT03142750|DEVICE|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
48628102|NCT05375799|OTHER|Clinical Observation|"This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects )."
48283752|NCT04554576|BEHAVIORAL|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
48283753|NCT02420457|PROCEDURE|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
48283754|NCT02420457|DRUG|Epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
48468615|NCT02440555|OTHER|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
48283755|NCT05811351|DRUG|JNJ-81201887|JNJ-81201887 will be administered as intravitreal injection.
48468616|NCT00440115|BEHAVIORAL|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
48628103|NCT04344093|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
48628104|NCT06417671|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule per day.
48628105|NCT06417671|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule per day.
48628106|NCT05551988|OTHER|Retrospective observational study of diabetic foot ulcer|This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients
48628107|NCT05647304|DEVICE|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
48283756|NCT05811351|DRUG|Prednisone|Prednisone will be administered as oral capsule.
48628108|NCT05647304|DEVICE|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
48283757|NCT05811351|OTHER|Placebo|Prednisone matching placebo will be administered as oral capsule.
48468617|NCT00440115|BEHAVIORAL|Low intensity disease management|Health education mailings, one motivation interview/counseling
48283758|NCT05811351|DRUG|Triamcinolone|Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
48283759|NCT05811351|OTHER|Sham Procedure|Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
48283760|NCT06556108|BIOLOGICAL|ALPP CAR-T cells|T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells
48468618|NCT00440115|BEHAVIORAL|Comparison group|Health education mailings
48468619|NCT00440115|DRUG|Bupropion|Buproprion or Nicotine Replacement Therapy
48468620|NCT03837158|PROCEDURE|early loading|two TiZr implants on SLA surface
48468621|NCT03837158|PROCEDURE|immediate loading|four TiZr implants on SLA surface
48468622|NCT06214416|BEHAVIORAL|Abstention|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote abstention.
48468623|NCT06214416|BEHAVIORAL|Mediterranean alcohol-drinking pattern|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote the Mediterranean alcohol-drinking pattern.
48468624|NCT04317638|OTHER|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
48468625|NCT01427881|DRUG|cyclophosphamide|Given IV
48283761|NCT06556108|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
48468626|NCT01427881|DRUG|cyclosporine|Given IV
48468627|NCT01427881|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
48468628|NCT01427881|RADIATION|total-body irradiation|Undergo TBI
48468629|NCT01427881|DRUG|fludarabine phosphate|Given IV
48468630|NCT01427881|DRUG|busulfan|Given IV
48468631|NCT01427881|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
48628109|NCT05672069|PROCEDURE|Osteosynthesis|Foot pathologies
48628110|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
48628111|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
48628112|NCT00835978|DRUG|axitinib|axitinib 5mg BID (open-label)
48628113|NCT04595019|RADIATION|SBRT|Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
47937732|NCT01846520|PROCEDURE|quality-of-life assessment|Ancillary studies
48468632|NCT00640458|DRUG|Sildenafil 100 mg|
48468633|NCT00640458|DRUG|Placebo|
48628114|NCT02538198|DRUG|Lenalidomide|
48628115|NCT00432120|DRUG|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
48628116|NCT00074191|DRUG|cytarabine|
48628117|NCT00074191|DRUG|dexamethasone|
48628118|NCT00074191|DRUG|lomustine|
48628119|NCT00074191|DRUG|methotrexate|
48628120|NCT00074191|DRUG|procarbazine hydrochloride|
48628121|NCT02112552|DRUG|Paclitaxel|Given IV
48628122|NCT02112552|DRUG|Carboplatin|Given IP
48468634|NCT04906096|DRUG|PAXALISIB|Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
48468635|NCT03252717|BIOLOGICAL|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:~* Three 6 ml EDTA samples for proteomic and genomic work package~* One 6 ml dry sample for auto-antibodies analysis in the immunology work package~* Two 4 ml EDTA samples for DNA extraction in the immunology work package~* Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
48628123|NCT02112552|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
48468636|NCT00793234|DRUG|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
48468637|NCT00793234|DRUG|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
48468638|NCT01937117|PROCEDURE|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
47937733|NCT01846520|OTHER|questionnaire administration|Ancillary studies
48468639|NCT01937117|DRUG|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
48468640|NCT01937117|DRUG|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
48628124|NCT02112552|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48628125|NCT02112552|OTHER|Quality-of-Life Assessment|Ancillary studies
48628126|NCT02112552|OTHER|Laboratory Biomarker Analysis|Correlative studies
48628127|NCT02939781|DEVICE|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
48628128|NCT05849753|DEVICE|Advanced artificial pancreas closed-loop technology|Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
48628129|NCT03319121|DRUG|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
48628130|NCT03319121|DRUG|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
48628131|NCT02384460|DRUG|SD-101-6.0 cream|applied topically once a day for 90 days
48628132|NCT02384460|DRUG|Placebo (SD-101-0.0) cream|applied topically once a day for 90 days
48628133|NCT00608738|OTHER|informational intervention|
48628134|NCT00608738|OTHER|medical chart review|
48628135|NCT00608738|OTHER|questionnaire administration|
48628136|NCT00608738|PROCEDURE|assessment of therapy complications|
48468641|NCT04535193|DRUG|18F-mFBG for intravenous administration|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
48468642|NCT02647515|DRUG|ranibizumab|
48468643|NCT06519747|DEVICE|Cardiac monitoring device|Portable, up to 14 days of monitoring
48628137|NCT00608738|PROCEDURE|management of therapy complications|
48283762|NCT06556108|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
48283763|NCT02574221|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
48283764|NCT02574221|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
48628138|NCT04063020|BEHAVIORAL|Psychological monitoring|"Discussions with the psychologist PhD student before and after every surgery times : 3 discussions.~* Before the first surgery (about 1 month before) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)~* Before the second surgery (3 months later the first surgery) Clinical interview Drawing a person~* After the second surgery (15 months later the first surgery) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)"
48628139|NCT01433913|DRUG|metformin hydrochloride|Given PO
48628140|NCT01433913|OTHER|placebo|Given PO
47937734|NCT00005934|DRUG|5-Azacytidine|
47937735|NCT05680740|DRUG|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
47937736|NCT04985188|DIAGNOSTIC_TEST|Quantitative ultrasound (QUS) technique|Measurement of quantitative ultrasound parameter using clinical US machine (RS85)
48283765|NCT02277171|DEVICE|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
48628141|NCT01433913|OTHER|laboratory biomarker analysis|Correlative studies
48283766|NCT04935944|RADIATION|CBCT radiation|CBCT scanning
48283767|NCT05662644|PROCEDURE|Minimally Invasive Surgery for Esophageal Cancer|Assessment of minimally Invasive Surgery for Esophageal Cancer
48283768|NCT01154101|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
48468644|NCT06679725|DIETARY_SUPPLEMENT|Wild ginseng extract|This ginseng extract was manufactured and provided by the Korea Food Research Institute (sponsor). It is extracted from red ginseng. Red ginseng is generally considered to have greater biological effects and fewer side effects than white or fresh ginseng.
48468645|NCT06679725|DIETARY_SUPPLEMENT|Placebo|The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% Korean wild Ginseng Extract. This was achieved by incor-porating 0.25% scented ginseng and 0.06% caramel coloring
48468646|NCT02000115|DEVICE|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
48468647|NCT02000115|DEVICE|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
48468648|NCT03787017|DRUG|FDC(MP-513 20mg/Metformin XR 1000mg)|
48468649|NCT03787017|DRUG|MP-513 20mg|
48468650|NCT03787017|DRUG|Metformin XR 1000mg|
48628142|NCT00138294|BIOLOGICAL|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
48628143|NCT02997670|OTHER|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
48628144|NCT00154466|BEHAVIORAL|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
48628145|NCT00291915|DRUG|Adalimumab|
48283769|NCT01154101|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
48628146|NCT00291915|DRUG|Methotrexate|
48283770|NCT03050125|DEVICE|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
48628147|NCT00260390|DRUG|Testoviron|
48628148|NCT05729191|BIOLOGICAL|Anti Covid 19 vaccination campaign for pregnat women|Assessment of vaccine hesitancy and Covid-19 disease knowledge
48628149|NCT03312907|DRUG|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
48628150|NCT03312907|DRUG|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
48628151|NCT03312907|DRUG|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
48628152|NCT03312907|DRUG|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
48628153|NCT03312907|DRUG|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
48628154|NCT03312907|DRUG|Steroid Taper|Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
48283771|NCT03050125|DEVICE|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
48283772|NCT03050125|DEVICE|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
48283773|NCT00003937|DRUG|cisplatin|
48628155|NCT00552903|BEHAVIORAL|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
48628156|NCT02819375|DRUG|Propofol|1 mg/kg propofol
48283774|NCT00003937|DRUG|dexrazoxane hydrochloride|
47937737|NCT02651181|DEVICE|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
48283775|NCT00003937|DRUG|doxorubicin hydrochloride|
48283776|NCT00003937|DRUG|etoposide|
48283777|NCT00003937|DRUG|ifosfamide|
48283778|NCT00003937|DRUG|methotrexate|
48283779|NCT00003937|PROCEDURE|conventional surgery|
48468651|NCT00566280|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
48468652|NCT04096651|OTHER|gait recordings|gait recordings
48628157|NCT02819375|DRUG|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
48628158|NCT02819375|DRUG|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
48628159|NCT03983109|DEVICE|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
48628160|NCT03465605|DIAGNOSTIC_TEST|frailty test|questionnaire
48628161|NCT03395990|PROCEDURE|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
48628162|NCT03395990|PROCEDURE|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
48628163|NCT05527522|COMBINATION_PRODUCT|nutritional and educational intervention|individualized diet plus educational intervention with/without nutritional supplements
48628164|NCT05527522|OTHER|standard practice|The patients received the usual treatment and clinical practice
48628165|NCT02930941|DRUG|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
47937738|NCT04384588|BIOLOGICAL|Convalescent Plasma from COVID-19 donors|Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
47937739|NCT06217185|DRUG|Pyrotinib|Pyrotinib 400mg qd po continuously
47937740|NCT06217185|DRUG|Trastuzumab|For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg. It is to be used once every three weeks
47937741|NCT06217185|DRUG|Taxanes|Taxanes: Usual clinical dose is administered, in a 21-day cycle.
47937742|NCT06217185|DRUG|Capecitabine|Capecitabine: 650mg/m2 each time, given twice daily
47937743|NCT00879931|DRUG|Methylprednisolone|Methylprednisolone
47937744|NCT00879931|DRUG|Placebo|Placebo (NaCl 0.9%)
48283780|NCT03542188|BEHAVIORAL|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
48283781|NCT03542188|BEHAVIORAL|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
48283782|NCT03758937|PROCEDURE|volume-controlled ventilation|
48283783|NCT03758937|PROCEDURE|pressure-controlled ventilation|
48283784|NCT03361501|DRUG|CaPre|4 x 1 g capsules administered orally once daily for 26 weeks
48283785|NCT03361501|DRUG|Placebo|4 x 1 g capsules administered orally once daily for 26 weeks
48283786|NCT05393154|DEVICE|Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner|Microscopic viewing and imaging of Bronchoscopic Biopsy Specimens using Full Field Optical Coherence Tomography and Dynamic Cell Imaging
48283787|NCT05416892|OTHER|Pharmaclass® software|Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.
48283788|NCT06631287|DRUG|Baricitinib|4mg encapsulated, pre-formed tablet PO once daily for 24 weeks.
48283789|NCT06631287|OTHER|Placebo|Encapsulated, pre-formed tablet PO once daily for 24 weeks.
48468653|NCT04096651|OTHER|brain magnetic resonance imaging|brain magnetic resonance imaging
48468654|NCT04096651|OTHER|oculomotor movement recordings|oculomotor movement recordings
48468655|NCT01557751|GENETIC|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
48468656|NCT03395015|OTHER|VAS scale (from 1 to 10) esthetic assessment of facial 3-D images|The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
48468657|NCT06542250|DRUG|AZD5492|CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
48468658|NCT06293430|DEVICE|VERAFEYE System|VERAFEYE system guidance will be used on all patients undergoing AF ablation and/or LAAC procedures.
48468659|NCT04580420|DRUG|DCR-PHXC|Monthly dosing throughout study period
48628166|NCT02930941|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
48283790|NCT06137352|OTHER|Follow up|Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
48468660|NCT04099433|DIETARY_SUPPLEMENT|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
48468661|NCT04099433|OTHER|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
48468662|NCT06679166|OTHER|No intervention|No intervention
48468663|NCT00570128|DRUG|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (\>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).
48628167|NCT02801773|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
48628168|NCT02801773|OTHER|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
48283791|NCT04006769|DRUG|Entacapone|Entacapone tablet
48283792|NCT04006769|DRUG|Imatinib Mesylate|Imatinib Mesylate tablet
47937745|NCT04470921|PROCEDURE|Opportunistic Salpingectomy|An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.
48283793|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
48283794|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
48468664|NCT00570128|DRUG|Placebo|Liquid formulation matched to active treatment for oral administration.
48468665|NCT03528096|DEVICE|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
48468666|NCT03528096|OTHER|Sound|Sound of the moving bed was recorded and played back during the baseline night.
48468667|NCT01858922|DRUG|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
48628169|NCT05145114|PROCEDURE|THERAPEUTIC POSITIONS|Therapeutic positioning includes placing infants in prone (prone), supine, side (lateral) decubitus, using restraint devices to provide support, reassurance and physiological stability.
48628170|NCT05308693|OTHER|Education material - Patient Compatible Stoma Educational Material|It is an educational material made of rubber, similar to a stoma, that can be placed on the patient.
48628171|NCT02470572|OTHER|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
48628172|NCT02470572|OTHER|Conventional light microscope|Conventional light microscope
47937746|NCT04337385|BEHAVIORAL|Interrupting 3 hours of prolonged sitting with high intensity interval exercise|Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise
47937747|NCT04337385|BEHAVIORAL|3 hours of prolonged sitting|Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
47937748|NCT02235259|DRUG|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
47937749|NCT02235259|DRUG|Placebo|
47937750|NCT02102971|PROCEDURE|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
48283795|NCT05006612|PROCEDURE|Serratus Anterior Plane Block|"SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle."
48283796|NCT02240706|PROCEDURE|Best Supportive Care|At Discretion of the Investigator (Transfusions)
48283797|NCT02240706|DRUG|BI 836858|Monotherapy with BI 836858
48283798|NCT03530449|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
48283799|NCT03530449|DEVICE|Color Fundus Photography|Non-contact white light photography
48628173|NCT00012246|BIOLOGICAL|carcinoembryonic antigen peptide 1-6D|
48628174|NCT00012246|BIOLOGICAL|incomplete Freund's adjuvant|
48628175|NCT00012246|BIOLOGICAL|sargramostim|
48628176|NCT01140139|BIOLOGICAL|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
47937751|NCT06163469|DEVICE|Bladder instillation with Irrisept|9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
47937752|NCT01227148|OTHER|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
48628177|NCT04048083|BEHAVIORAL|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
48628178|NCT04048083|BEHAVIORAL|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
48628179|NCT04048083|BEHAVIORAL|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
48628180|NCT04048083|OTHER|No trainings|Healthy controls without any kind of training
48628181|NCT00906581|BEHAVIORAL|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
48628182|NCT04088253|PROCEDURE|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
48628183|NCT01392196|PROCEDURE|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
48628184|NCT04107051|DRUG|Nalmefene Hydrochloride Hydrate|Oral administration of nalmefene hydrochloride hydrate
48468668|NCT01858922|DRUG|DECA|"Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
48628185|NCT05496010|OTHER|Dry Needling and Ischemic Compression Technique|"For Group A, Dry needling will be applied into trigger points which are active and present in the muscles, efficiently and within the safe limits taking all the safety precautions.~For group B, Ischemic Compression Technique will be applied on trigger points.~The complete treatment session will be comprised of 3 sessions per week for two weeks followed by follow up after 1 month until the symptoms have been improved for both the groups."
48283800|NCT03530449|DEVICE|Optical Coherence Tomography|Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
48468675|NCT03008538|OTHER|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
48468676|NCT03008538|OTHER|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
48468677|NCT02230176|DRUG|Sunitinib|
48628186|NCT02271802|DIETARY_SUPPLEMENT|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
48628187|NCT02271802|DIETARY_SUPPLEMENT|NaCl|
48628188|NCT04234230|OTHER|Prevalence Survey|Questionnaire survey on self-management
48468678|NCT02230176|DRUG|177Lu-DOTA0-Tyr3-Octreotate|
48628189|NCT04914663|BEHAVIORAL|Exercise training|Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
48283801|NCT04438421|DRUG|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
47937753|NCT01227148|OTHER|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
48468679|NCT01221649|DEVICE|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
48283802|NCT04438421|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
48283803|NCT04438421|DRUG|Placebo|Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
48283804|NCT01861197|DRUG|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
48628190|NCT04267315|PROCEDURE|Trigger point injection|1mL injections of 1% lidocaine in the muscles identified active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
48628191|NCT04267315|PROCEDURE|Subcutaneous saline injection|0.2mL subcutaneous saline injections superficial to the muscles identified with active trigger points at the day of intervention (pectoralis major, serratus anterior, levator scapulae, latissimus dorsi, infraspinatus).
48628192|NCT04267315|OTHER|Comprehensive Rehabilitation program|Patients in both groups will undergo standard of care rehabilitation delivered by a Physiatrist, which may include Physical Therapy, Occupational Therapy, Exercise Physiologist, Rehabilitation Nurse, Psychologist, as per Physiatrist's prescription. Both the comprehensive rehabilitation program and pain medications will continue to be managed by participant's Physiatrist, who will be blinded to patient's allocation. The researchers will be responsible for TPI and for data collection.
48628193|NCT04656119|OTHER|there is no intervention in our study|there is no intervention in our study
48628194|NCT04393844|OTHER|turbo-ject PICC set|The turbo-ject PICC set, which will be used in this study, is the set for peripherally inserted central catheterization. In this study, we will see the difference according to the presence or absence of the hydrophilic coated stiffening obturator included in this turbo-ject PICC set.
48628195|NCT04713995|OTHER|Dietary recommendations|Dietary recommendations based on microbiome analysis of samples will be given and expected to receive and report in \~3 months survey after following recommendations.
48468680|NCT06241664|DEVICE|AEYE-DS Software|An Artificial Intelligence (AI) software device to be used as a diagnostic tool to assist healthcare providers in screening for diabetic retinopathy (DR) using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with DR.
48283805|NCT06488118|DRUG|R848|Inhaled R848 dose ranging from 0.1 to 100 μg/mL
48283806|NCT06488118|DRUG|Saline|Inhaled Saline control
48283807|NCT02631161|OTHER|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
48283808|NCT02631161|OTHER|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
48283809|NCT02688569|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
48283810|NCT05131971|DRUG|GSK3888130B|GSK3888130B will be administered.
48283811|NCT05131971|DRUG|Placebo|Placebo will be administered.
48628196|NCT00005790|OTHER|laboratory biomarker analysis|
47937754|NCT04243421|DEVICE|Implantation|Soft tissue aesthetics, marginal bone level on CBCT
47937755|NCT03813823|BEHAVIORAL|Fear tasks|All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
48283812|NCT01243593|PROCEDURE|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
48283813|NCT01243593|PROCEDURE|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
48283814|NCT03563534|DRUG|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
48468681|NCT02339740|DRUG|Arsenic Trioxide|Given IV
48468682|NCT02339740|DRUG|Cytarabine|Given IV
48468683|NCT02339740|DRUG|Dexamethasone|Given PO or IV
48468684|NCT02339740|DRUG|Idarubicin|Given IV
48468685|NCT02339740|OTHER|Laboratory Biomarker Analysis|Correlative studies
48468686|NCT02339740|DRUG|Mitoxantrone Hydrochloride|Given IV
48468687|NCT02339740|OTHER|Quality-of-Life Assessment|Ancillary studies
48468688|NCT02339740|OTHER|Questionnaire Administration|Ancillary studies
48468689|NCT02339740|DRUG|Tretinoin|Given PO
48468690|NCT06574191|DRUG|Topical Diclofenac gel 1%|Topical NSAID
48628197|NCT00005790|PROCEDURE|biopsy|
48628198|NCT00005790|PROCEDURE|magnetic resonance imaging|
48628199|NCT00005790|RADIATION|gadopentetate dimeglumine|
48628200|NCT02697422|OTHER|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
48628201|NCT03144206|DRUG|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
48628202|NCT02995889|DEVICE|FLT-PET|
48100697|NCT01565161|BEHAVIORAL|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:~1. In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~2. Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~3. Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
48468691|NCT03985046|DRUG|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
48468692|NCT01358253|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
48468693|NCT01358253|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
48468694|NCT01358253|DRUG|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
48468695|NCT01358253|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
48468696|NCT01358253|DRUG|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
48468697|NCT01358253|DRUG|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
48468698|NCT01358253|DRUG|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
48468699|NCT01358253|DRUG|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
48468700|NCT01358253|DRUG|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
48468701|NCT01358253|DRUG|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
48468702|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
48468703|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake and withdraw|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
48468704|NCT03646292|DRUG|Pioglitazone|The investigators will compare the degree of liver fat before and after pioglitazone monotherapy.
48468705|NCT03646292|DRUG|Empagliflozin|The investigators will compare the degree of liver fat before and after empagliflozin monotherapy.
48468706|NCT03646292|DRUG|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat before and after pioglitazone and empagliflozin combination therapy.
48468707|NCT03694938|DEVICE|Magnetic resonance imaging|Annually magnetic resonance imaging
48468708|NCT05876351|DRUG|Eculizumab|Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
48468709|NCT03447444|OTHER|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
48468710|NCT04547036|DEVICE|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
48468711|NCT06608355|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen of brain.
48283815|NCT03563534|DRUG|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
48468712|NCT04197258|OTHER|Peer support|"The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social."
48468713|NCT06663475|BEHAVIORAL|TTM-based health education videos about smoking cessation for expectant fathers|Tailored for expectant fathers, this smoking cessation health education information will be developed based on transtheoretical model to motivate a quit attempt and maintain abstinence by using videos.
48628203|NCT02736812|BIOLOGICAL|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of FLYP"
47937756|NCT03345342|DRUG|PP6M|Participants will receive intramuscular injection of PP6M.
47937757|NCT03345342|DRUG|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
47937758|NCT03345342|DRUG|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
47937759|NCT03345342|DRUG|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
47937760|NCT03345342|OTHER|Placebo|Participants will receive matching placebo.
47937761|NCT05837143|BIOLOGICAL|JV001|JV001 (AAV9/modTERT) will be delivered by a percutaneous method in the catheter laboratory. Dose: 2×10\^11vg/kg，or 6×10\^11vg/kg.
47937762|NCT02876640|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
47937763|NCT02876640|DRUG|Retinoid 9cUAB30|Given PO
47937764|NCT02876640|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection surgery
47937765|NCT01451268|DRUG|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
47937766|NCT01451268|DRUG|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
47937767|NCT04062318|DEVICE|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
47937768|NCT01993784|DRUG|nimotuzumab|
47937769|NCT05436340|DEVICE|The Effect Of Heel Protector In Intensive Care Units|In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
47937770|NCT05436340|DEVICE|Control group|Heel pads will not be used in the control group. Routine maintenance will be applied
47937771|NCT00846170|DRUG|co-biotic|give probiotic 2 t/day
47937772|NCT00846170|DRUG|placebo 2T/day|cross over of patients from study arm to placebo arm
47937773|NCT01043900|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
47937774|NCT04895800|DIETARY_SUPPLEMENT|Phytovive|Bacopa monnieri bacosides, Kaempferia parviflora methoxy flavones, pomegranate peel polyphenols, and Moringa oleifera leaf saponins)
47937775|NCT04895800|DIETARY_SUPPLEMENT|Placebo|Natural Flavors \[Chocolate, Caramel, Vanilla Cream\], Silica, Inulin, Sucralose)
47937776|NCT04895800|DIETARY_SUPPLEMENT|Caffeine|Caffeine (Green tea caffeine extract (170 mg; to deliver 34 mg caffeine \[20% natural caf-feine\])
48468714|NCT06663475|BEHAVIORAL|usual care treatment|general health education videos about hazards of smoking for expectant fathers in obstetric clinic
47937777|NCT03762538|DRUG|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
48283816|NCT06214728|PROCEDURE|Hyaluronic acid gel application|HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus. Patients were instructed not to eat, drink or brush their teeth for at least one hour. Subgingival application of HA was repeated 4 weeks after the first session.
48468715|NCT02474654|DRUG|Bupivicaine|15mg
47937778|NCT02598570|DRUG|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
47937779|NCT05904990|DEVICE|traditional exercise therapy only|50-minute program included a 10-minute warm-up phase (treadmill walking at a comfortable speed), 30 minutes of stretching exercises for (glutei, paraspinal muscles, hamstring, pectoralis, scalenus, intercostal muscles, and trapezius), and a 10-minute cool-down involving self-stretching and respiratory exercises
47937780|NCT05904990|DEVICE|HILT alongside traditional exercise therapy|YAG laser device (HIRO 3.0; ASA Laser, Arcugnano, Italy). This equipment delivers pulsed laser light at a wavelength of 1,064 nm, with a very high peak power of 3 kW and energy density ranging from 360 to 1,780 mJ/cm2. It operates with short pulse durations between 120 and 150 μs, at low frequencies of 10 to 40 Hz, and has a duty cycle of about 0.1%.
48283817|NCT06214728|PROCEDURE|Placebo gel application|The control group received placebo HA gel probe without rinsing. Placebo application was repeated 4 weeks after the first session.
48468716|NCT02474654|DRUG|Fentanyl|15mcg
47937781|NCT03691324|OTHER|Inhalation technique training and discharge service|Patient drug counselling one-to-one, focusing on inhalation drugs and technique
47937782|NCT01280955|DRUG|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
47937783|NCT04867434|DRUG|RZL-012|small synthetic molecule for submental fat reduction
47937784|NCT04867434|DRUG|Placebo|Placebo
47937785|NCT02022774|DRUG|Fimasartan|Fimasartan 60 \~ 120 mg/po take one tablet once a day
47937786|NCT06542263|DEVICE|CPAP|For the non-CPAP group, the intervention includes catheter ablation and conventional treatment for AF combined with OSA; For the CPAP group, the intervention includes catheter ablation and CPAP treatment for AF combined with OSA
47937787|NCT00926068|DRUG|HO/03/03 10µg|
47937788|NCT00926068|DRUG|Placebo|
48283818|NCT01779609|DRUG|Bosentan|
48283819|NCT01779609|DRUG|Placebo|
48283820|NCT01779609|BEHAVIORAL|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
48468717|NCT02474654|DRUG|Epimorphine|150mcg
48468718|NCT02474654|DRUG|Normal Saline|0.3 ml
48468719|NCT02474654|DRUG|Normal Saline|30ml
48468720|NCT02474654|DRUG|Normal Saline|100 ml
48468721|NCT02474654|DRUG|Ropivicaine|100 ml
48468722|NCT02474654|DRUG|Epinephrine|600 mcg
48468723|NCT02474654|DRUG|Ketorolac|30 mg
48468724|NCT02474654|DRUG|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
48628204|NCT02736812|BIOLOGICAL|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of Normale Saline Solution"
48468725|NCT01086930|DEVICE|ReJoyce Workstation|The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
48283821|NCT05698186|DRUG|Thero2-01S22|Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
47937789|NCT03064581|BEHAVIORAL|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
48283822|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
47937790|NCT00450112|DEVICE|Gel-200|Single Intra-articular Injection
48283823|NCT05698186|DRUG|Thero2-01S22|Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
47937791|NCT00728767|OTHER|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
47937792|NCT00728767|OTHER|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
47937793|NCT02283177|DRUG|crenolanib|
47937794|NCT02283177|DRUG|cytarabine|
48283824|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
48468726|NCT01086930|OTHER|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
48468727|NCT03275857|DRUG|Cisplatin|Weekly IV
48468728|NCT05127135|BIOLOGICAL|ThisCART7 cells|0.5-6 x 10\^6 CAR T cells per kg body weight
48468729|NCT05754918|DEVICE|TnoFs then TFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without fine structure coding then with fine structure coding
48628205|NCT05838599|DRUG|Imiquimod|5% cream applied topically 5 days/week for 6 weeks
47937795|NCT02283177|DRUG|daunorubicin|
47937796|NCT02283177|DRUG|idarubicin|
48468730|NCT05754918|DEVICE|TFS then TnoFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with fine structure coding then without fine structure coding
48468731|NCT05722249|BEHAVIORAL|Mindfulness and Sleep Hygiene|Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.
47937797|NCT06274905|DRUG|EMLA|EMLA cream
48468732|NCT05722249|BEHAVIORAL|Phyical activity and Sleep Hygiene|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
48468733|NCT05954910|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
48468734|NCT06177405|DRUG|genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors|drug therapy
48468735|NCT01279915|DRUG|ASP0456|oral
47937798|NCT06274905|DRUG|Ethyl chloride|Ethyl chloride
47937799|NCT06274905|DRUG|Aqueous cream BP|Aqueous cream
48468736|NCT01279915|DRUG|Placebo|oral
48628206|NCT05838599|RADIATION|Radiation Therapy|2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
47937800|NCT02909803|OTHER|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
47937801|NCT02909803|OTHER|White Bread|Participants will consume white bread on at least two different test days
47937802|NCT05562271|RADIATION|low-dose radiation therapy|low-dose radiation therapy to involved knee joint
47937803|NCT05562271|RADIATION|sham radiation therapy|sham radiation therapy to involved knee joint
47937804|NCT00957385|DRUG|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
47937805|NCT00005665|DRUG|interferon alpha|
47937806|NCT05000372|DRUG|68Ga-grazytracer|68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
47937807|NCT03095274|DRUG|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
47937808|NCT03095274|DRUG|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
47937809|NCT01358071|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
47937810|NCT01358071|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
47937811|NCT01358071|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
48468737|NCT03590834|BEHAVIORAL|Center-based Intervention|"1. Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~2. Staff training and technical assistance~3. Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~4. Health contests~5. Gross motor and physical activity program~6. Miranos! activity cards based on children storybooks"
48468738|NCT03590834|BEHAVIORAL|Home-based Intervention|"1. Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~2. Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~3. 16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~4. Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
48468739|NCT03590834|BEHAVIORAL|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
48468740|NCT04539808|DRUG|Capecitabine|Given PO
48468741|NCT04539808|DRUG|Fluorouracil|Given IV
48468742|NCT04539808|DRUG|Irinotecan Hydrochloride|Given IV
48468743|NCT04539808|DRUG|Leucovorin Calcium|Given IV
47937812|NCT00034749|DRUG|Risperidone|
47937813|NCT06302738|DIAGNOSTIC_TEST|polysomnography|patients will undergo a home sleep study to evaluate the presence of sleep disorders
47937814|NCT01860573|DRUG|Amino acids|
48468744|NCT04539808|DRUG|Losartan Potassium|Given PO
48468745|NCT04539808|DRUG|Oxaliplatin|Given IV
48283825|NCT06315010|DRUG|Repotrectinib|"Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid."
47937815|NCT00306332|PROCEDURE|T-cell and B-cell depletion|
47937816|NCT00088998|BIOLOGICAL|bevacizumab|
47937817|NCT00088998|DRUG|capecitabine|
47937818|NCT00088998|DRUG|docetaxel|
47937819|NCT05751616|OTHER|Laminate veneers with speed sintering|Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
47937820|NCT05751616|OTHER|Laminate veneers with conventional sintering|Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
47937821|NCT02710643|DRUG|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
47937822|NCT00876798|DRUG|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
47937823|NCT00876798|DRUG|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
47937824|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
47937825|NCT01055496|DRUG|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
48283826|NCT01357239|DRUG|AFQ056|
48468746|NCT04539808|RADIATION|Radiation Therapy|Undergo short-course or long-course RT
48468747|NCT04539808|PROCEDURE|Resection|Undergo surgical resection
48468748|NCT04539808|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
48468749|NCT04539808|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48468750|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
47937826|NCT05669001|BIOLOGICAL|TCD601|Investigational Product
47937827|NCT05669001|BIOLOGICAL|belatacept|Study Product
47937828|NCT05669001|DRUG|ATG|Comparator
48283827|NCT01357239|DRUG|Placebo|
48283828|NCT02135536|BIOLOGICAL|NGM282|NGM282
47937829|NCT05669001|DRUG|TAC|Comparator
47937830|NCT05669001|DRUG|MPA|Immunosuppression Therapy
47937831|NCT05669001|DRUG|Corticosteroids|Immunosuppression Therapy
47937832|NCT02355977|DRUG|minocycline|Periocline dental ointment
47937833|NCT02355977|PROCEDURE|surface and root planning|surface and root planning
47937834|NCT02625883|OTHER|Interview|Interview by validated Quality-of-life-questionnaire
47937835|NCT06164210|BEHAVIORAL|Snoezelen-Based Occupational Therapy Intervention Group|Snoezelen- Based Occupational Therapy Intervention Different from sensory integration interventions, Snoezelen-based interventions are environments with all sensory stimuli, such as auditory, visual, tactile, gustatory, olfactory, and vestibular stimuli, in the same environment and where therapeutic guidance and commands are not given to the individual. These interventions aim to reduce agitation, depression, and aggression in individuals and increase daily living activities, functional performance, and well-being. Psychiatric clinics, schools, rehabilitation centers, and occupational therapy clinics are some places where it is used. Some materials found in Snoezelen rooms are bubble tubes, fiber optic light cables, projectors, vibrating massagers, light tactile stimulation materials, aromatic scent emitting devices, music sets, and relaxing music and swings.
48283829|NCT05647213|BIOLOGICAL|iPSC-CL|Autologous IPSCL
48283830|NCT04112914|BEHAVIORAL|Post-concussion education for families|An educational intervention for families will be developed based on the CDC guidelines for returning to daily activities, school, and sports, adapted with stakeholder feedback to meet the learning needs of low health literacy parents.
48468751|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
48283831|NCT04754711|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|We will propose to the patients of group 1 several different oral nutritional supplements according to taste, and consistency of each child in order to optimize observance. Each of those different oral nutritional supplements will be adapted to the nutritional survey and the age of children without exceeding recommended intake of proteins, carbohydrates, lipids and micronutrients. Those patients will consume the Oral Nutritional Supplement during 12 months.
48283832|NCT03846947|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
47937836|NCT00002083|DRUG|Peptide T|
47937837|NCT04161300|OTHER|Foam Rolling (FR)|FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
47937838|NCT04161300|OTHER|Control Group (CG)|The CG did not receive any intervention.
48106940|NCT02372019|BEHAVIORAL|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 10 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
48283833|NCT01461525|PROCEDURE|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
48283834|NCT01461525|PROCEDURE|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
48283835|NCT00315302|DRUG|Atropine|Atropine 1% once each weekend day
48468752|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
48283836|NCT00315302|DEVICE|Plano Lens|Plano lens for the sound eye
48283837|NCT00044447|DRUG|Glimepiride|
48283838|NCT05854134|DIAGNOSTIC_TEST|Closed Chain|Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients
47937839|NCT04161300|OTHER|Orthopaedic Manual Physical Therapy Group (OMPT)|Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
48283839|NCT05854134|DIAGNOSTIC_TEST|Aerobic Exercise|Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients
48468753|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
48468754|NCT02413528|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
48468755|NCT02413528|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
48468756|NCT05274191|DRUG|Pyrotinib Maleate|Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
48468757|NCT05274191|OTHER|standard regimen|standard regimen
48468758|NCT04006119|BIOLOGICAL|Ad-RTS-hIL-12|"* intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection"
48468759|NCT04006119|DRUG|Veledimex|20mg/day 15 oral daily doses of veledimex
48468760|NCT04006119|DRUG|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
48468761|NCT04959032|DRUG|Lumateperone 42 mg|Lumateperone 42 mg capsules administered orally, once daily.
48468762|NCT04959032|DRUG|Placebo|Matching capsules administered orally, once daily.
48468763|NCT03388008|DRUG|Belatacept|Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
48468764|NCT03388008|DRUG|Tacrolimus|Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
48468765|NCT03388008|DRUG|ATG|Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
48468766|NCT03388008|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
48468767|NCT03388008|DRUG|Methylprednisolone|Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
47937840|NCT03845465|BEHAVIORAL|Positive Affect + Education|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
47937841|NCT03845465|BEHAVIORAL|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
47937842|NCT02403388|OTHER|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
47937843|NCT04499547|BEHAVIORAL|YouTube-delivered aerobic and muscle-strengthening physical activity intervention|Participants in the intervention group will receive two YouTube-delivered videos each week, for 8 weeks. In detail, on Monday, participants will receive an aerobic-based physical activity video with information and a workout to complete and on Thursdays, the participants will receive a video with muscle-strengthening physical activity information and a workout to complete.
47937844|NCT05920915|OTHER|non-interventional clinical research|This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
47937845|NCT03783247|PROCEDURE|Pericapsular nerve group block|The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
47937846|NCT03783247|PROCEDURE|Fascia Iliaca BLock|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
47937847|NCT04005989|BIOLOGICAL|Stromal Cells Injection|Adipose stromal cell
47937848|NCT05120843|BEHAVIORAL|Care coordination and motivational interviewing|Interventionist will engage participants in care planning, health education, health care navigation, screening for unmet health needs or social needs, and motivational interviewing. The final intervention is expected to be six months in duration. However during this single-arm open testing phase, some participants may receive only key components of the intervention in order to assess feasibility, reach, adoption, and fidelity of those components.
48283840|NCT04648371|OTHER|Cognitive Remediation and Transcranial Direct Current Stimulation|"Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode."
48283841|NCT01195025|DRUG|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
48283842|NCT01195025|DRUG|colloid|Infusion of starch 10 ml/kg over 30 min
48283843|NCT01195025|DRUG|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
48283844|NCT01195025|DEVICE|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
48283845|NCT05651087|DRUG|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
48628207|NCT03083379|DEVICE|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~* Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~* Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~* Incentive Spirometry therapy and monitoring session will last about 15 minutes"
48283846|NCT06564974|DRUG|Vamorolone|"Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week."
47937849|NCT05578157|DIAGNOSTIC_TEST|Feeling Hot sensor|The Feeling Hot sensor is a proof-of-concept system, which can measure overnight penile, thigh and air temperature.
47937850|NCT04703179|OTHER|Genetic test evaluation|Patients with rare and undiagnosed disease and their family members may be evaluated on a case by case basis. The research study may perform multi-omics testing to provide a diagnosis or to provide biomarker discovery.
47937851|NCT05994495|DIAGNOSTIC_TEST|nuclear acid amplification tests|The NAAT test will be performed with Bosch Vivalytic STI test. It is a qualitative Polymerase Chain Reaction-based assay for simultaneous detection of 10 common sexually transmitted pathogens: Herpes simplex virus 1 (HSV 1)- Herpes simplex virus 2 (HSV 2)- Chlamydia trachomatis (CT) - Haemophilus ducreyi (HD)- Mycoplasma genitalium (MG) - Mycoplasma hominis (MH) - Neisseria gonorrhoeae (NG) - Treponema pallidum (TP)- Ureaplasma urealyticum (UU) - Trichomonas vaginalis (TV)
47937852|NCT05994495|OTHER|Clinical Syndromic Approach|Physical examination
47937853|NCT03251677|PROCEDURE|Surgical procedure, Hysterectomy|Surgical removal of the uterus
47937854|NCT01208831|DRUG|LDE225|
47937855|NCT04426903|OTHER|webFitForAll|PT training participants use the webFitForAll exergaming computer platform as the physical training component (PT)
47937856|NCT04426903|OTHER|BrainHQ|CT training participants use the language adapted version of the BrainHQ program as the cognitive training component (CT)
47937857|NCT04499599|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
47937858|NCT04499599|OTHER|Fasting|Subjects in all groups will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1 and then fast overnight for approximately 15 hours.
48283847|NCT02441530|DIETARY_SUPPLEMENT|Vitamin D|
48283848|NCT02441530|DIETARY_SUPPLEMENT|Vitamin E|
48468768|NCT03388008|DRUG|Prednisone|Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
48468769|NCT02005939|DIETARY_SUPPLEMENT|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
48468770|NCT04347096|BEHAVIORAL|mHealth Intervention|"The mHealth Intervention will provide sedentary workers with evidence-based information on diet, physical activity and sedentary behavior, and tailored feedback on their responses to daily records. Key features of this intervention will include individualized feedback and multimedia presentation in the form of web app. The intervention group will also receive a reliable device for wireless physical activity tracking for monitoring step counts.~The web app will consist of seven major components: (1) daily healthy eating goals and records; (2) daily physical activity goals and records; (3) daily stand-up goals and records; (4) advice and reminder; (5) educational and motivational tools; (6) personal and team health ranking; and (7) online social network. In addition, the intervention will be enhanced with follow-up booster coaching calls bi-monthly at 2, 4, 6, 8 months after the 12-week intervention."
47937859|NCT04499599|OTHER|Study food|Study subjects will either continue to fast for 6 hours (Fast Group), consume either a breakfast (Breakfast Group) or a Fast Bar (Fast Bar Group).
47937860|NCT02895997|OTHER|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
47937861|NCT02914821|BEHAVIORAL|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
47937862|NCT05198700|DIETARY_SUPPLEMENT|Probiotic Formulation|Participants will be asked to take one sachet daily, containing 1 billion CFU of the probiotic formula. Sachets must be dissolved in warm water or mother's milk before consumption.
48283849|NCT02441530|DRUG|Ibuprofen|
47937863|NCT05198700|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take one sachet containing the placebo daily. Sachets must be dissolved in warm water or mother's milk before consumption.
48283850|NCT01706913|OTHER|Dermatology consult|
48283851|NCT03977779|DEVICE|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
48283852|NCT04725656|PROCEDURE|Smoking cessation counseling|Smoking cessation counseling at baseline, week 1, and week 4.
47937864|NCT05673460|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
47937865|NCT06260761|PROCEDURE|MIPO|minimal invasive surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
47937866|NCT06260761|PROCEDURE|Conventional|standard surgery with Volar locking plate fixation in isolated close fracture of distal radius under WALANT
47937867|NCT06421818|DRUG|Baitouweng Tang|Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
47937868|NCT06421818|OTHER|Placebo|The same volume and color as Baitouweng Decoction.
48283853|NCT04725656|OTHER|Open system vape device and nicotine salt e-liquids|Ad libitum use of nicotine salt e-liquids during three months.
48283854|NCT05087056|COMBINATION_PRODUCT|MenABCWY vaccine|Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
47937869|NCT03264170|DIAGNOSTIC_TEST|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
48283855|NCT05087056|COMBINATION_PRODUCT|Placebo|Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
48283856|NCT06033443|OTHER|Collaborative Learning Group|The experimental group is the group that receives nursing education based on collaborative learning.
48283857|NCT03643887|DRUG|FMT Capsule DE|30 capsule one-time oral dose
47937870|NCT02942576|DRUG|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
47937871|NCT02942576|DRUG|VKA-Based Regimen|Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
47937872|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
47937873|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in France.
47937874|NCT02942576|DRUG|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Spain.
47937875|NCT06239623|DRUG|JSI-1187|Use ERK inhibitor JSI-1187 to treat solid tumor
48468771|NCT04347096|BEHAVIORAL|Control Intervention|The control intervention group will receive educational tools, which will provide knowledge on benefits of physical activity and healthy eating, health risks of sitting and unhealthy diets, and recommendations on physical activity and a balanced healthy diet for good health.
47937876|NCT03989726|PROCEDURE|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
48468772|NCT05049668|DRUG|ATGAM plus CsA with or without Eltrombopag|Standard treatment with or without Eltrombopag
47937877|NCT05606718|DRUG|Dapagliflozin|dapagliflozin 10mg once daily for 3 months after randomization
47937878|NCT05606718|OTHER|guideline-directed medical therapy (GDMT)|guideline-directed medical therapy (GDMT)
47937879|NCT03791827|DRUG|Corticosteroid|corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
47937880|NCT03791827|DRUG|Hydroxychloroquine|Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
47937881|NCT03791827|DRUG|Cyclophosphamide|The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
47937882|NCT03791827|DRUG|Mycophenolate Mofetil|The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
48468773|NCT04669457|DRUG|Intra-nasal Dexmedetomidine|Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.
48468774|NCT04669457|DRUG|Oral Midazolam|Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.
47937883|NCT03791827|DRUG|Azathioprine|The recommended dose of azathioprine is 1.5 to 2mg/kg/d
47937884|NCT03791827|DRUG|Tacrolimus|The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
47937885|NCT03791827|DRUG|Cyclosporine A|The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
47937886|NCT03791827|DRUG|Rituximab|The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
47937887|NCT04024384|DRUG|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
47937888|NCT01203254|DRUG|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
47937889|NCT01203254|DRUG|Placebo|Placebo tablet: 3 times daily 2 tablets
47937890|NCT03442283|DIETARY_SUPPLEMENT|Vitamin mineral supplementation|supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
47937891|NCT03439527|OTHER|Muscle Precursor Cells (MPCs), ATMP|The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
48283858|NCT03643887|DRUG|Placebo oral capsule|30 capsule one-time oral dose
48283859|NCT06229509|DEVICE|Effective noninvasive ventilation|Noninvasive ventilation set to alleviate dyspnea Inspiratory aid set according to a preliminary test (aiming for a diminution of 2 points in Borg score)
48283860|NCT06229509|DEVICE|Sham noninvasive ventilation|Noninvasive ventilation set with an insufficient inspiratory aid to alleviate dyspnea
48283861|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
48283862|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
48283863|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
48283864|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
48283865|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
47937892|NCT00065364|BEHAVIORAL|Newborn Individualized Developmental Care Assessment Program|
47937893|NCT02730897|PROCEDURE|Central/Peripheral|Central versus peripheral location of the primary tumor
48468775|NCT03433703|DRUG|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
47937894|NCT04190303|OTHER|Pragmatic, multi-component package|This system-level intervention will be tailored to the needs and capacity of each hospital site, co-developed with policymakers and hospital staff
47937895|NCT03894592|OTHER|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
47937896|NCT04729946|DEVICE|Pure-Vu Cleansing Device|The Pure-Vu device attaches to the colonoscope and provides colonic cleansing during urgent colonoscopy without the need for a bowel preparation
47937897|NCT03231150|PROCEDURE|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
47937898|NCT03231150|PROCEDURE|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
47937899|NCT03231150|PROCEDURE|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
47937900|NCT06518694|DRUG|Βeta-Blockers discontinued (with tapering)|"The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation."
47937901|NCT05351398|DRUG|PDO group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. And they are treated with individualized neoadjuvant therapy under the guidance of a patient-derived organoid (PDO)-based drug sensitivity assay.
47937902|NCT05351398|DRUG|Traditional group|Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
47937903|NCT02997267|PROCEDURE|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
47937904|NCT04080076|DRUG|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 1042 x Week
47937905|NCT04080076|DRUG|Oral Tab Tacrolimus|Oral Tab Tacrolimus (1.0 mg PO BID) in combination with ACTHar 80 Units SQ 2 X week
47937906|NCT04176887|DRUG|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
47937907|NCT04176887|DRUG|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
47937908|NCT05958173|DIETARY_SUPPLEMENT|Capsaicin|Oral stimulation with natural TRPV1 agonist
47937909|NCT05958173|DIETARY_SUPPLEMENT|Piperine|Oral stimulation with natural TRPA1/V1 agonist
47937910|NCT05958173|DIETARY_SUPPLEMENT|Placebo|Oral stimulation with placebo solution
47937911|NCT05135312|DRUG|Etanercept|TNF-alpha inhibitors improve nail psoriasis.
47937912|NCT05135312|DEVICE|OCT|Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
47937913|NCT01489371|OTHER|Laboratory Biomarker Analysis|Correlative studies
47937914|NCT01489371|BIOLOGICAL|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
48283866|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
47937915|NCT01489371|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
47937916|NCT00442468|OTHER|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
48283867|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
47937917|NCT04041700|DEVICE|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
47937918|NCT05029973|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
47937919|NCT05029973|DRUG|Sintilimab|200mg IV d1,Q3W
47937920|NCT05029973|DRUG|Bevacizumab Biosimilar|7.5mg/kg IV d1,Q3W
47937921|NCT01168960|BEHAVIORAL|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
47937922|NCT03114059|DIAGNOSTIC_TEST|Glaucoma diagnostics|Heidelberg Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological examination
47937923|NCT04853303|DEVICE|Hypnosis VR|Children will be required to wear a VR gadget for hypnosis when they are experiencing chemotherapy-induced nausea and vomiting, sleep quality or pain. The duration is 15 minutes.
48283868|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
47937924|NCT04257097|DEVICE|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
47937925|NCT04257097|DEVICE|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
47937926|NCT03484260|DRUG|Testosterone Product|Men used testosterone product following prescription
48468776|NCT02797379|OTHER|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
47937927|NCT03406923|OTHER|Health literacy-psychosocial support|The intervention is based upon enhancing patient health literacy-related attributes by (1) addressing the barriers to patients' self-efficacy by working with the patient to minimize the barriers (2) clarifying the patient beliefs about diabetes and diabetes medications, and (3) developing personalized action plans. We will tailor the intervention to each patient, so, the details of the content of each session will depend on the individual's self-efficacy, beliefs in illness and medicines, and health literacy level obtained at baseline. In addition to the 45-minute scheduled sessions, patients will be able to call the clinical pharmacist on the phone during the 6-week session at their discretion, for patient-driven support for self-management of goals and skills.
47937928|NCT04896021|DIAGNOSTIC_TEST|Cardiovascular disease risk assessment|Intervention in which the addition of guideline-recommended absolute cardiovascular disease risk assessment is embedded into point-of-care blood collection services for cholesterol measurement and results (including risk score) are reported to referring doctors.
47937929|NCT04896021|DIAGNOSTIC_TEST|Usual care assessment|Usual care in which blood cholesterol results are reported to referring doctors
47937930|NCT02935543|BIOLOGICAL|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10\^7 CART19 cells, Day 2, 30% fraction: 3x10\^7-1.5x10\^8 CART19 cells, Day 3, 60% fraction: 6x10\^7-3x10\^8 CART19 cells
47937931|NCT04064567|BEHAVIORAL|PrEP-LINK|CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network \[TCN\]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.
47937932|NCT04064567|OTHER|Enhanced Standard of Care|Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
47937933|NCT00417482|DRUG|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
47937934|NCT00972855|DRUG|Bicalutamide|50 mg Tablet
48468777|NCT02656251|DRUG|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
48468778|NCT02656251|DRUG|placebo|Use of placebo every 12 hours for 04 days
48628208|NCT03083379|DEVICE|EzPAP® POSITIVE AIRWAY PRESSURE|"* A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~* Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~* EzPAP® therapy and monitoring sessions will last about 15 minutes"
47937935|NCT00972855|DRUG|Casodex®|50 mg Tablet
47937936|NCT04804501|DEVICE|Blue Light Glasses|Participants will be randomized into an experimental group (blue light glasses) or a control group (no glasses). Participants will perform a computer reading task while either wearing, or not wearing the glasses.
48468779|NCT02656251|DRUG|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
48468780|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
48468781|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
48468782|NCT05419505|DRUG|CCH-aaes|Administered by subcutaneous injection.
48468783|NCT05419505|DRUG|Antifibrinolytic Agent|Self-administered by participants enrolled in Cohort 7.
48468784|NCT00943813|BEHAVIORAL|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
48468785|NCT02721368|DEVICE|Neuramis® Volume Lidocaine|hyaluronic acid filler
48468786|NCT02721368|DEVICE|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
48468787|NCT02702986|PROCEDURE|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
48468788|NCT02702986|DEVICE|Laser|
48468789|NCT00176943|DRUG|Aldara Cream 5%|
48468790|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
48468791|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
48468792|NCT00190450|BIOLOGICAL|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
48468793|NCT02427399|OTHER|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
48468794|NCT02427399|OTHER|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
48468795|NCT02427399|OTHER|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
48468796|NCT02427399|OTHER|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
48468797|NCT03098628|BIOLOGICAL|PCV Vaccine|PCV vaccination
48468798|NCT05196815|OTHER|Ultrasound|Participants will have a routine ultrasound of the heart (echocardiogram) before the procedure. During this test we will take a few extra measurements, this will not add any significant time to the scan
47937937|NCT04804501|OTHER|Computer Reading Task|Participants will read on a computer until concussion symptoms increase by a score of 3 or more (reading task termination criteria). One or more points will be assigned for each increase in symptom severity, and one point will be assigned for each new symptom that appears.
47937938|NCT00814125|DRUG|Anastrozole (Arimidex)|1mg, orally, once daily
48468799|NCT05196815|PROCEDURE|Catheters|During the TAVI procedure 3 catheters (tubes) will be inserted into the blood vessels at the top of the participants legs as per normal standard care (there will be no extra skin punctures as part of the study).
48468800|NCT05196815|PROCEDURE|Soft study wire|Participants will have a soft study wire inserted to measure the pressure in the left ventricle. This step is in addition to standard care.
48468801|NCT05196815|RADIATION|X-ray|Participants will have chests x-ray when the soft study wire is inserted.
48468802|NCT05196815|DRUG|Dobutamine|Participants will be given a low dose infusion of dobutamine, to make the heart pump quicker and more vigorously.. This will last for approximately 5 minutes
48468803|NCT00982228|DRUG|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
48468804|NCT00982228|DRUG|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
48468805|NCT00982228|DRUG|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
48468806|NCT04070079|DRUG|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
48468807|NCT03646409|OTHER|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
48628209|NCT01026038|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
48628210|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing \<50 kg.
47937939|NCT00814125|DRUG|Tamoxifen (Nolvadex)|20mg, orally, once daily
47937940|NCT00814125|DRUG|Nolvadex placebo|
47937941|NCT00814125|DRUG|Arimidex placebo|
48100698|NCT01565161|BEHAVIORAL|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
48100699|NCT00001999|DRUG|Globulin, Immune|
48283869|NCT05293067|DIAGNOSTIC_TEST|high-sensitive troponin|Values of high-sensitive troponin would be measured as follows: 1) preoperatively - one day before the planned intervention and 2) postoperatively - 8 hours after the operation and the first day after the operation.
48628211|NCT01363076|DRUG|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
48628212|NCT03676829|DEVICE|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
48628213|NCT04761354|PROCEDURE|Unilateral adrenalectomy|
48628214|NCT02988388|PROCEDURE|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
48628215|NCT01320449|DRUG|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
48628216|NCT01320449|BEHAVIORAL|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
48628217|NCT01320449|OTHER|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
48628218|NCT03363035|DRUG|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
48628219|NCT03363035|DRUG|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
48628220|NCT03363035|DRUG|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
48628221|NCT02025036|DRUG|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
48628222|NCT02025036|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
48628223|NCT02025036|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
48628224|NCT05779644|DRUG|Liraglutide|Liraglutide is injected once a day.
48628225|NCT05779644|DRUG|Semaglutide|Semaglutide is injected once a week.
48628226|NCT05779644|DRUG|Metformin|Metformin is taken orally daily.
48628227|NCT02825459|BEHAVIORAL|Abstinence from e-cigarettes|Abrupt cessation for 6 days
48628228|NCT00448032|DRUG|PPM-204|
48100700|NCT00001999|DRUG|Ganciclovir|
48628229|NCT04253860|DEVICE|Transcutaneous electrical neurostimulation|Sessions of 30 minutes of TENS will be applied three times a week during 90 days
48628230|NCT04606719|PROCEDURE|Advanced Platelet Rich fibrin|Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes
48628231|NCT05319405|DEVICE|Sana Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
48628232|NCT00907114|DRUG|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
48628233|NCT00907114|DRUG|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
48628234|NCT01566162|DRUG|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
48628235|NCT06293950|BIOLOGICAL|WJMSC|- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
48628236|NCT02054195|BEHAVIORAL|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
48628237|NCT02054195|BEHAVIORAL|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
48628238|NCT03189953|RADIATION|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
48628239|NCT02887586|OTHER|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
48628240|NCT05103592|DIAGNOSTIC_TEST|Tartrate- resistant Acid Phosphatase marker|marker could be diagnostic for osteoporosis
48283870|NCT04543448|OTHER|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
48283871|NCT04543448|OTHER|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
48283872|NCT03340350|DRUG|Minocycline|Minocycline capsule
48468808|NCT04254809|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
48468809|NCT04254809|BEHAVIORAL|Healthy Social Living|To control for potential effects of time and presentation of educational material on study outcome variables, participants randomized to the control intervention will complete a computerized psychoeducation program regarding the benefits of social support networks. Across approximately 20 minutes of audiovisual slides, participants are informed of the ways in which social connections buffer against loneliness and facilitate social learning, provided tips for expanding and maintaining their social network, and administered a brief quiz to assess for comprehension.
47937942|NCT06271499|OTHER|Radial artery catheterization with USG|Radial artery catheterization with USG The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with the high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
47951367|NCT04046237|OTHER|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
47951368|NCT01232777|DRUG|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
48468810|NCT00260793|DRUG|Ropinirole Hydrochloride|
48468811|NCT05215938|DIAGNOSTIC_TEST|MRI examination|"The magnetic resonance imaging session will be performed in a clinical 3T MRI scanner (GE healthcare). A commercial human intent non-diagnostic RF coil (PulseTeq) will be used for 23Na MRI.~The scanner, coils and sequences are regularly used in research projects and validated for the same safety requirements as routinely used in the clinic. Nevertheless, the complete MRI session will be performed in research mode to use the advanced options (limits the usage to non-diagnostic purposes).~Participants will be placed in a supine position with coils covering the area of interest (AOF).~MRI examination will be performed by trained personnel."
48468812|NCT06679270|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
48468813|NCT00451490|DRUG|Agomelatine|
48468814|NCT00451490|DRUG|Fluoxentine|
48468815|NCT01261624|DRUG|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
48468816|NCT06439394|DRUG|Optive MEGA-3 (OM3)|Eye Drops
48468817|NCT06678763|PROCEDURE|CRS-HIPEC|Patients with uterine leiomyosarcoma who received unprotected morcellation were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with docetaxel and gemcitabine.
48468818|NCT04881513|DIAGNOSTIC_TEST|Narrow Band Imaging|Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)
48468819|NCT04881513|DIAGNOSTIC_TEST|Tongue sensitivity testing|testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
48468820|NCT04881513|OTHER|Qualitiy of life|Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire
48628241|NCT00649948|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
48468821|NCT04881513|DIAGNOSTIC_TEST|Threshold change|Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery
48468822|NCT04881513|DIAGNOSTIC_TEST|Taste|Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
48468823|NCT06033313|BEHAVIORAL|Negatively Framed text messages|Negatively Framed text messages delivered to participants three times per week for 8 weeks.
48468824|NCT06033313|BEHAVIORAL|Positively Framed text messages|Positively Framed text messages delivered to participants three times per week for 8 weeks.
47951369|NCT04564495|BEHAVIORAL|Seated exercise|Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
48468825|NCT04347330|DRUG|Intensive BP Control|Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
48468826|NCT04347330|DRUG|Standard BP Control|Participants in the Standard group has a goal of home SBP \<135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
48468827|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 1|Two doses of the non-adjuvanted HSV formulation 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468828|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 2|Two doses of the non-adjuvanted HSV formulation 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468829|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 3|Two doses of the non-adjuvanted HSV formulation 3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468830|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 1|Two doses of the HSV formulation 1 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468831|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 1|Two doses of the HSV formulation 2 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468832|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 1|Two doses of the HSV formulation 3 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468833|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 2|Two doses of the HSV formulation 1 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468834|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 2|Two doses of the HSV formulation 2 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468835|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 2|Two doses of the HSV formulation 3 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
48468836|NCT05298254|DRUG|Placebo|Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.
48468837|NCT05298254|BIOLOGICAL|HSVTI_F1|Two doses of the formulation of the HSVTI_F1 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
48468838|NCT05298254|BIOLOGICAL|HSVTI_F2|Two doses of the formulation of the HSVTI_F2 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
48468839|NCT02121717|DRUG|Chiglitazar|Take orally
48468840|NCT02121717|DRUG|Placebo|Take orally
48468841|NCT04293354|PROCEDURE|Serratus Plane Block|Serratus Plane Block was performed
48468842|NCT04293354|PROCEDURE|Control|No block was performed
48468843|NCT05538637|DIAGNOSTIC_TEST|Echocardiography|"Mitral velocity time-integral variability measurement before and after passive leg raising.~Mitral velocity time-integral variability measurement after fluid loading in preload-responsiveness patients."
48468844|NCT02248116|DRUG|Talsaclidine|
48468845|NCT04510792|OTHER|No intervention|No intervention
48468846|NCT06307613|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
48468847|NCT06307613|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
48468848|NCT01514513|DRUG|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
48468849|NCT01514513|DRUG|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
48468850|NCT00684944|DRUG|TRx0014|Gelatin capsule, tid
48628242|NCT00649948|DRUG|Glucophage XR 500 mg|500mg, single dose fed
48468851|NCT03755180|OTHER|Exercise Training|In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
47951370|NCT05742711|DEVICE|Primary Relief|Continuous neurostimulation with a set of pre-assigned stimulation parameters.
47951371|NCT05742711|DEVICE|Primary Relief - Sham Device|Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
47951372|NCT02149719|OTHER|Desensitisation using boiled peanut|
47951373|NCT02149719|OTHER|Desensitisation using boiled peanut (deferred start)|
47951374|NCT02096237|DEVICE|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
48468852|NCT03755180|OTHER|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
48283873|NCT05036278|BIOLOGICAL|Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).|"Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
48283874|NCT01217775|DRUG|PH80|PH80 intranasal spray 800 nanograms
48283875|NCT01217775|DRUG|Placebo intranasal spray|Placebo intranasal spray
48468853|NCT06068790|PROCEDURE|HoLEP Surgery|HoLEP will be performed per standard clinical care with the instruments assigned at randomization - 22Fr or 28Fr.
48468854|NCT06068790|DEVICE|28 French sized rigid sheath|The 28Fr is the standard of care sheath size used at this site.
48468855|NCT06068790|DEVICE|22 French sized rigid sheath|The 22Fr is the smaller, investigational sheath size to be used in this study.
48468856|NCT01097551|DRUG|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
48468857|NCT01097551|DRUG|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
48468858|NCT01097551|DRUG|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
47951375|NCT02400229|PROCEDURE|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
47951376|NCT02400229|PROCEDURE|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
48283876|NCT03456479|DIAGNOSTIC_TEST|skin prick test - specific serum IgE|The study will assess the diagnosis of Cow's milk protein allergy (CMPA) among infant and children in Assiut University Children Hospital using skin prick test and specificserumIgE
48283877|NCT00440323|DRUG|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
48283878|NCT00440323|DRUG|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
48283879|NCT00440323|DRUG|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
48283880|NCT02729129|OTHER|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
48283881|NCT02729129|OTHER|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
48468859|NCT01097551|DEVICE|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
48468860|NCT01590199|DRUG|RAD001|
48468861|NCT01590199|DRUG|SOM230|
48468862|NCT06222658|DEVICE|pharmaco-mechanichal thrombectomy|pharmaco-mechanichal thrombectomy in acute limb ischemia
48283882|NCT02998502|DEVICE|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
48468863|NCT00006467|DRUG|ISIS 2503|
48468864|NCT00006467|DRUG|gemcitabine hydrochloride|
48468865|NCT06580561|BEHAVIORAL|Personalized exercise coaching|"This is a 6-session personalized exercise coaching program (delivered over 8 weeks).~All participants will complete six 30-minute scheduled online or phone sessions with a health coach as part of a manualized personalized exercise program (once per week for the first four sessions and then once every two weeks for the remaining two sessions)."
47937943|NCT06271499|OTHER|Radial artery catheterization with smart glasses integrated UGG|The catheterization was performed by two anesthesiologist with different experience (Junior practitoner who has the experience of 20-50, and the senior practitioner who has the experience of \>50 radial artery catheterizations). Before the study, as practitioners had no previous experience with smart glasses, they performed 5 catheterizations with smart glasses integrated USG on model. The side to be catheterized was determined by modifie Allen test which was first performed on the nondominant hand. After general anesthesia induction, a 45° angle was given to wirst of selected side with a support. After skin asepsis, radial artery was vizualized 2 centimeter (cm) above the wrist in short axis with smart glasses integrated high-frequency linear USG probe. The radial artery puncture was performed while step by step monitoring the needle tip in short axis out-of-plane technique. Following the puncture, radial artery catheterized with a 3 French 8 cm catheter.
47937944|NCT03709732|OTHER|no intervention|observational study
47937945|NCT05205967|OTHER|MCED|Multi-cancer early detection (MCED) test
48283883|NCT04824261|DRUG|Clotrimazol solution 1%|50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
48283884|NCT04824261|DRUG|4%boric acid in distilled water|50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
48468866|NCT06580561|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|"This is a 6-week course of automated, digitally delivered cognitive behavioral therapy for insomnia delivered by the online program Sleepio. The weekly sessions will last approximately 15-20 minutes.~Session content comprises evidence-based cognitive and behavioral techniques including Stimulus Control Therapy and Sleep Restriction Therapy, sleep hygiene education, and relaxation exercises."
48468867|NCT06416371|DIAGNOSTIC_TEST|Fundus fluorescein angiography, with ultrawide field retinal imaging|Intravenous injection of sodium fluorescein for angiography of retinal blood vessels
48468868|NCT03696043|OTHER|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
48283885|NCT05305716|OTHER|Online Pilates Training|The group that received telerehabilitation and telerehabilitation-based pilates training.
48628243|NCT04508985|OTHER|Temporarily holding the RAAS inhibitor [intervention]|Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.
48628244|NCT04508985|OTHER|RAAS inhibitor [continued standard of care]|No intervention, Continuation RAAS inhibitor \[continued standard of care\].
48468869|NCT03696043|OTHER|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
48628245|NCT00280189|PROCEDURE|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
47937946|NCT05205967|OTHER|SOC|Standard of care cancer screening
47937947|NCT00192686|PROCEDURE|culture a.m. Kamme-Lindberg|
48468870|NCT03346850|DEVICE|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
48468871|NCT03346850|DEVICE|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
48628246|NCT00280189|BEHAVIORAL|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
48628247|NCT00280189|BEHAVIORAL|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
48468872|NCT06490770|DIAGNOSTIC_TEST|Gait analysis, Magnetic Resonance Imaging|Gait analysis and Magnetic Resonance Imaging to investigate the functionality and the pathological condition of the knee, respectively
48468873|NCT05550662|DRUG|129Xenon|There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.
48468874|NCT06390865|PROCEDURE|Biopsy|Undergo biopsy
48468875|NCT06390865|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48468876|NCT06390865|PROCEDURE|Computed Tomography|Undergo CT scan
48468877|NCT06390865|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48468878|NCT06390865|DRUG|Sapanisertib|Given PO
48468879|NCT06674356|BEHAVIORAL|chin tuck against resistance exercise|"Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises.~For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises."
48468880|NCT06527547|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagus nerve stimulation(taVNS) , as an emerging neuromodulation therapy, integrates China's traditional meridian and acupoint theory with transcutaneous electrical nerve stimulation technology, representing a non-invasive, simple alternative therapy. Electrical stimulation of auricular points (areas on the ear following the vagus nerve pathway) stimulates the parasympathetic system, leading to slow-wave sleep through activation of the reticular formation. Vagus nerve stimulation can also regulate sleep by altering concentrations of neurotransmitters such as gamma-aminobutyric acid (GABA), norepinephrine, and serotonin, making it a safe and effective method for treating primary sleep disorders. In rheumatoid arthritis (RA), studies have shown that vagus nerve stimulation can reduce disease activity and serum levels of inflammatory cytokines.
48468881|NCT06679634|DRUG|Chemoplaque also referred to as Episcleral Topotecan|Sustained Release Episcleral Topotecan
48468882|NCT02740907|PROCEDURE|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
48468883|NCT02738216|BEHAVIORAL|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
48468884|NCT02738216|BEHAVIORAL|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
48468885|NCT05793632|DRUG|Quetiapine|The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
48468886|NCT05753982|OTHER|Kinesiotape placement|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
48468887|NCT06266754|BIOLOGICAL|Oral polio vaccine|Standard oral polio vaccine
48628248|NCT04078399|DRUG|Azacitidine combined with interferon preemptive treatment|Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
47937948|NCT02130726|PROCEDURE|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
47937949|NCT02130726|PROCEDURE|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
48468888|NCT06266754|OTHER|Placebo|Saline 0.9%
48468889|NCT04721418|RADIATION|11C-UCB-J|11C-UCB-J PET scan
48468890|NCT03079427|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
48468891|NCT03079427|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
48628249|NCT05922085|OTHER|Ultrasound|performed within 3 hours prior to extubation
48628250|NCT05922085|OTHER|nasofibroscopie|performed within 24 to 36 hours after extubation
48628251|NCT05616897|BEHAVIORAL|Physiological responses during sustained CPR|
48628252|NCT05415111|PROCEDURE|Subepithelial connective tissue|Study specific intervention is the placement of a soft tissue autogenous graft (SCTG) in addition to bone grafting of periimplantitis-affected implants.
48628253|NCT05415111|PROCEDURE|Volume stable Collagen Matrix|Study specific intervention is the placement of a soft tissue substitute (VCMX) in addition to bone grafting of periimplantitis-affected implants.
48283886|NCT05305716|OTHER|Control group|The group who received breathing and relaxation exercises with a home program.
48628254|NCT05415111|PROCEDURE|No soft tissue augmentation|Study specific control intervention is the placement of a bone graft at periimplantitis-affected implants. No soft tissue grafts will be placed.
48628255|NCT00416949|DEVICE|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
48628256|NCT04869436|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
48628257|NCT02092428|OTHER|Image Quality|"The following procedures may be conducted as part of this study:~* Coronary MRI scan with no contrast~* Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~* MRI scan with an oral beta blocker (metoprolol)~* Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
48628258|NCT02092428|OTHER|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
48628259|NCT05206695|BEHAVIORAL|Multi-condition Pathway Intervention|See Experimental/Arm 1 description
48628260|NCT04137315|DEVICE|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
48628261|NCT05193396|DRUG|Hydrocortisone|hydrocortisone
48628262|NCT05193396|DRUG|Placebo|placebo tablets
48628263|NCT03410537|DRUG|Taurine|
48628264|NCT03410537|DRUG|Placebo|
48628265|NCT04968145|OTHER|Home To Stay Mobile Health Application|"Home to stay is an integrated discharge monitoring system with a mobile application. Features of the application include a Daily Health Check to report on post-operative recovery, picture taking capability to photograph incisions/wounds and educational information on post-operative care at home.~Patients will complete a Daily Health Check on post-discharge Day #1-14, #21 and #30. The Daily Health Check consists of a series of questions specific to colorectal surgery as well as the Quality of Recovery (QoR-15) questionnaire. After completion, the participant will receive a list of recommendations tailored to their responses including relevant education modules, to contact the surgical team or in urgent cases to go to the nearest emergency room. The participants' responses will be monitored daily via a secure web site. Any participants' responses in the extreme ranges are automatically red flagged and notify the health care team that a follow up telephone call is required."
48628266|NCT05474820|OTHER|Samples collection and ELISA analyses|"The serum and unstimulated saliva samples were taken from all patients between 8:00 and 10:00 in the morning. Saliva samples were centrifuged at 10,000 rpm (10 min) whereas venous blood samples were centrifuged at 4000 rpm for 10 min.~For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. All samples were run in duplicate, and values have been averaged."
48628267|NCT05474820|DIAGNOSTIC_TEST|Evaluating periodontal paramètres|The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient
48628268|NCT06282289|BEHAVIORAL|Magnetoencephalography (MEG)|Stimuli will be presented binaurally through headphones at 60 decibel sound pressure level (dB SPL). Conditions are presented in a pseudo-random order with an inter-stimulus interval of \~800 ms on average (range: 600 ms to 1000 ms). The duration of the stimuli is fixed: 2 seconds, in order to guarantee a minimum number of cycles.
47937950|NCT03312699|BIOLOGICAL|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
48283887|NCT01401569|BEHAVIORAL|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
48468892|NCT03467282|DIETARY_SUPPLEMENT|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
48468893|NCT03467282|DIETARY_SUPPLEMENT|Placebo|1g polydextrose/maltodextrin - twice day
48628269|NCT06282289|OTHER|Cognition development questionnaire|Computerised questionnaires completed by parents
48628270|NCT02919631|DRUG|Triheptanoin|Anaplerotic dietary oil
48628271|NCT02919631|DRUG|Placebo oil|Safflower oil
48628272|NCT01708837|DRUG|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
48628273|NCT03093870|DRUG|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
48628274|NCT03093870|DRUG|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
48628275|NCT03093870|DRUG|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
48628276|NCT01594268|DRUG|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
48628277|NCT01793935|DRUG|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
47937951|NCT03312699|BIOLOGICAL|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
47937952|NCT03312699|BIOLOGICAL|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
47937953|NCT03312699|BIOLOGICAL|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
48468894|NCT06677723|BEHAVIORAL|physical activity|moderate-intensity running
48468895|NCT05941611|DEVICE|Powered toothbrush|Oral-B powered toothbrush
48468896|NCT01485471|DEVICE|Diffuse optical spectroscopy imaging|ear exam imaging
48468897|NCT04410705|OTHER|Extracorporeal shockwave theraphy for hamstring tendinopathy|For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.
48468898|NCT04410705|OTHER|Extracorporeal shockwave theraphy for quadriceps tendinopathy|Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.
48468899|NCT04410705|OTHER|Extracorporeal shockwave theraphy for achilles tendinopathy|Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
48468900|NCT05281471|BIOLOGICAL|olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
48468901|NCT05281471|DRUG|Platinum chemotherapy: carboplatin (preferred) or cisplatin|Administered according to local practice
48468902|NCT05281471|DRUG|Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|Administered according to local practice
48468903|NCT05281471|DRUG|Bevacizumab (or biosimilar)|Administered according to local practice
48468904|NCT02254109|DRUG|BEA 2180 BR - rising dose|
48468905|NCT02254109|DRUG|Placebo|
48468906|NCT05511935|OTHER|professional development training for CHWs on dental health (GRIN)|multi module online training
48468907|NCT05920161|BEHAVIORAL|Socially Evaluated Cold Pressor Test|The SECPT is a brief validated laboratory-based stress induction containing both physical and social elements
48468908|NCT05920161|BEHAVIORAL|Control|This is matched to the SECPT but with warm instead of cold water
48468909|NCT06099639|DRUG|HER3-DXd|5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes
48468910|NCT02578290|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
48468911|NCT05535660|DIAGNOSTIC_TEST|Lipid panel|fasting blood draw to examine concentrations of lipids in maternal blood during pregnancy
48468912|NCT05603858|PROCEDURE|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
48468913|NCT05412121|DEVICE|Acupressure|"The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention."
48468914|NCT05002660|BEHAVIORAL|Group 1 (Intervention)|The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.
48468915|NCT05002660|BEHAVIORAL|Group 2 (Control)|Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
48468916|NCT04029454|BIOLOGICAL|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~* training on hepatitis B awareness and management~* training on EPI vaccination and cold chain~* training on the modalities for the birth dose administration~* the use of a monovalent unidose vaccine against Hepatitis B"
48468917|NCT06361550|OTHER|VENREDI group|Practical seminars aimed at improving the Mediterranean diet, guided by researchers.
48468918|NCT06361550|OTHER|Health education|Health education on Mediterranean diet
48468919|NCT00879541|BIOLOGICAL|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
48468920|NCT00879541|BIOLOGICAL|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
48468921|NCT00879541|BIOLOGICAL|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
47937954|NCT03312699|BIOLOGICAL|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
48283888|NCT01802944|DRUG|Intranasal Insulin|
48283889|NCT01802944|DRUG|Placebos|
48283890|NCT03021837|OTHER|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
48468922|NCT04832971|DRUG|ARO-ANG3|ARO-ANG3 Injection
48468923|NCT04832971|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
48468924|NCT04869137|DRUG|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
48468925|NCT04869137|DRUG|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
48468926|NCT05374915|COMBINATION_PRODUCT|REM-001 photodynamic therapy|Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
48468927|NCT03394716|RADIATION|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
48468928|NCT03843125|DRUG|Baricitinib|Administered orally.
48468929|NCT03843125|DRUG|Placebo|Administered orally.
48468930|NCT06678867|DRUG|5-ALA (Gliolan)|Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery
48468931|NCT06282406|OTHER|Transcutaneous Electrical Stimulation|Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.
48468932|NCT06282406|OTHER|Sham|Electrodes placed on the skin overlying putative sites of auricular vagal innervation but no current administered.
48617862|NCT01116531|DRUG|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
48283891|NCT04643041|BEHAVIORAL|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
48283892|NCT05548634|DRUG|TAVO412|Biologic
48283893|NCT02354950|DRUG|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
48283894|NCT06559501|BEHAVIORAL|Integrated case manager care|comprises 8 sessions delivered by case managers. Case managers will provide up to 6 low-intensity sessions in the hospital or the community (if the patient is discharged before completing the required sessions), with content and duration tailored to patient preferences. Post-discharge, patients will receive 2 follow-up sessions with case managers to ensure a smooth transition into the community.
48468933|NCT06673966|OTHER|Regular follow-up assessments without intervention.|Participants will receive a 3-month follow-up with clinical information, biological samples, and imaging data collected at baseline, 1st and 3rd months. The baseline assessment will include demographic information, medical history and previous medication use. At baseline and follow-up, patients' physical examination data (height, weight, waist and hip circumference, etc.), clinical symptom assessment scales (PANSS, SANS, SAPS, CDSS, CPSS, CGI, GAF, PSP, and SAS) and MCCB cognitive assessment data, blood and cerebrospinal fluid samples, MRI, and EEG data will be collected. Collection and store of blood and cerebrospinal fluid samples for routine laboratory tests and multi-omics including immunohistology, inflammation-related molecules, single-cell sequencing, extracellular vesicles, and other assays.
48468934|NCT06673966|OTHER|Cross-sectional assessment|Volunteers' physical examination data (height, weight, waist circumference, hip circumference, etc.), scale assessments (SCID, SCL-90, and CPSS) and MCCB cognitive assessment data, blood samples, MRI, and EEG data will be collected. Blood was collected and stored for exploring differences between patients and healthy individuals.
48468935|NCT06679647|BEHAVIORAL|Access to a trained ChatGPT|Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
48468936|NCT04898504|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution.
48468937|NCT04898504|PROCEDURE|Liver Transplantation|Patients randomized to this arm will be given 2nd line chemotherapy (regimen given at the discression of the treating oncologist) followed by liver-Tx
48468938|NCT05647291|DEVICE|extracorporeal Shock wave therapy|Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.
48468939|NCT05647291|DRUG|Corticosteroid injection|40mg/1ml methylprednisolone, two sessions once a week
48617863|NCT02171351|DEVICE|effect of neuromuscular electrostimulation (NMES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuromuscular electrostimulation (NMES).
48628278|NCT01793935|DRUG|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
48283895|NCT06435507|DRUG|IM-250 (50 mg)|Single dose
48283896|NCT06435507|DRUG|IM-250 (100 mg)|Single dose
48283897|NCT06435507|DRUG|IM-250 (200 mg)|Single dose
48283898|NCT06435507|DRUG|IM-250 (400 mg)|Single dose
47937955|NCT03312699|BIOLOGICAL|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm \[temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)\] drink on alternate days, e.g., days 1, 3, 5 and 7.
48283899|NCT05702021|BEHAVIORAL|Science to Service Laboratory|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
48283900|NCT00872066|DEVICE|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
48283901|NCT00872066|DEVICE|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
48283902|NCT00815308|DRUG|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)
48283903|NCT00815308|DRUG|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)
48283904|NCT00815308|DRUG|Cisplatin|Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)
48283905|NCT00815308|RADIATION|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
48283906|NCT03607227|DRUG|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
48468940|NCT05647291|DEVICE|Kinesiotaping|The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
48468941|NCT05177211|DRUG|Fedratinib Pill|Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.
48468942|NCT00466479|DRUG|brimonidine|
48468943|NCT00466479|PROCEDURE|laser trabeculoplasty|
48468944|NCT06401941|PROCEDURE|Hyperbaric Oxygen Therapy|HBO session includes three 20-minute inhalations of pure oxygen in a hyperbaric chamber utilizing specially fitted face masks for each patient. The session is conducted as follows: 10 minutes compression of up to 2.5 atm (0.25 MPa), inhalation of 100% oxygen for 20 minutes, a 5-minute break in the chamber without the mask (oxygen concentration up to 23%, constant temperature (room) and humidity), again 20 minutes inhalation of 100% oxygen, another 5-minute break (the same condition), the last 20 minutes inhalation of 100% oxygen, and finally a 10-minute decompression. The total duration of the session was 90 minutes.
48468945|NCT04601350|DRUG|remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia|remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
48468946|NCT04601350|DRUG|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
48468947|NCT06678113|DRUG|BSG005|Single arm dose escalation in patients with invasive fungal infection
48468948|NCT06677749|PROCEDURE|Eccentric resistance-exercise|Each participant will complete 300 repetitions of eccentric knee extensions using an isokinetic dynamometer after a baseline skeletal muscle biopsy is taken. Three hours following this, a second muscle biopsy will be taken to evaluate the changes in the dependent variables being measured (myokines).
48628279|NCT02700256|BEHAVIORAL|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
48628280|NCT02866383|DRUG|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
48283907|NCT03607227|DRUG|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
48468949|NCT03833427|DRUG|Selumetinib|Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.
48468950|NCT03833427|DRUG|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
48468951|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
48468952|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
48468953|NCT01026857|DRUG|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
48468954|NCT04188808|OTHER|Bypass surgery|All patients scheduled for elective surgery of PAA and PAD.
48628281|NCT02866383|DRUG|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
47937956|NCT04149392|DEVICE|Continuous Glucose Monitor|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
48283908|NCT02850796|BEHAVIORAL|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
48283909|NCT02850796|OTHER|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
48283910|NCT01682044|BIOLOGICAL|pegfilgrastim|Given SC
48283911|NCT01682044|BIOLOGICAL|rituximab|Given IV
48468955|NCT05934357|OTHER|Fiber|The intervention treatment will contain fiber.
47937957|NCT00060398|BIOLOGICAL|epoetin alfa|
48468956|NCT05934357|OTHER|Control|The control treatment will contain corn meal.
48468957|NCT00642057|DRUG|tetrabenazine|25 mg titrated to optimal dose per patient
48468958|NCT02169791|DRUG|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
48628282|NCT02866383|RADIATION|Radiotherapy|15 Gy x 1 fraction given on day 1
48628283|NCT05430295|PROCEDURE|phacoemulsification|cataract extraction followed by bilateral implantation of Eyhance intraocular lens in 10 patients and bilateral implantation of Tecnis 1 piece IOL in 10 patients
48283912|NCT01682044|OTHER|flow cytometry|Correlative studies
48283913|NCT01682044|PROCEDURE|biopsy|Correlative studies
48283914|NCT01682044|OTHER|immunohistochemistry staining method|Correlative studies
48283915|NCT01682044|GENETIC|western blotting|Correlative studies
48283916|NCT01503021|DRUG|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
48283917|NCT01503021|OTHER|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
48468959|NCT01104948|DRUG|DA-8031|
48468960|NCT01104948|DRUG|Placebo|
48468962|NCT06491979|DIETARY_SUPPLEMENT|Vitamin A treatment|Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks
47937958|NCT00060398|DRUG|dexamethasone|
47937959|NCT05034666|BEHAVIORAL|Before the education program|Before applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
47937960|NCT05034666|BEHAVIORAL|After the education program|After applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
47937961|NCT06235242|BIOLOGICAL|GT201 injection in combination with teraplizumab injection|GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
47937962|NCT01347580|DRUG|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
47937963|NCT01347580|DRUG|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
47937964|NCT01151098|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
47937965|NCT01076075|DRUG|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
47937966|NCT01076075|DRUG|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
48283918|NCT02988648|RADIATION|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
48283919|NCT01153490|BEHAVIORAL|Behavioral Intervention|Substance-related
48468963|NCT06491979|DIETARY_SUPPLEMENT|Monounsaturated fatty acid mixture|Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks
48468964|NCT06491979|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid mixture|Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks
48468965|NCT06491979|DIETARY_SUPPLEMENT|Fatty acid mixture|Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks
47937967|NCT01076075|DRUG|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
47937968|NCT01076075|DRUG|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
47937969|NCT01076075|DRUG|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
47937970|NCT01076075|DRUG|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
47937971|NCT01076075|DRUG|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
47937972|NCT02810678|OTHER|Latent Tuberculosis Infection program evaluation & diagnosis|
47937973|NCT05675605|DRUG|TY-1091|TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg
48283920|NCT03486236|DRUG|VX-440|VX-440 was administered in TC with TEZ and IVA.
48283921|NCT03486236|DRUG|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
48283922|NCT03486236|DRUG|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
48283923|NCT03486236|DRUG|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
48468966|NCT04854408|OTHER|healthcare workers with the coronavac vaccine|Health workers who are vaccinated will fill in the 20-question survey electronically.
48468967|NCT04600739|PROCEDURE|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
48468968|NCT05196789|DIAGNOSTIC_TEST|whole genome and transcriptome sequencing|To perform whole genome/transcriptome analysis of patients in a cohort of up to 350 Australian patients with IBMFS-RD
48283924|NCT06431373|DRUG|Brepocitinib PO QD|Brepocitinib PO QD
48283925|NCT06431373|DRUG|Placebo PO QD|Placebo PO QD
48283926|NCT04379583|DEVICE|HairDx Sample Collection Kit|Saliva collection using FDA OTC cleared sample collection device
48283927|NCT04603248|DRUG|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
48283928|NCT06656936|BEHAVIORAL|PharmFIT|The PharmFIT intervention involves the following components: referral notice to patient, FIT ready notification, FIT ready reminders, FIT distribution, FIT completion reminders, negative and positive results notification, patient navigation support.
48283929|NCT02288637|OTHER|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
48283930|NCT02288637|OTHER|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
48283931|NCT02288637|OTHER|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
48283932|NCT02175550|DEVICE|NR CC|
48283933|NCT02211339|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
48283934|NCT02211339|OTHER|Usual care|Staff-led social activity
48283935|NCT05918510|DIAGNOSTIC_TEST|Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx|The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
48283936|NCT01656239|DRUG|fedovapagon 1 mg|
48283937|NCT01656239|DRUG|fedovapagon 2 mg|
48283938|NCT01656239|DRUG|fedovapagon 4 mg|
48283939|NCT01656239|DRUG|Placebo ( sugar pill)|
48468969|NCT00368082|BIOLOGICAL|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10\^7 cells/m2 Day 14 2 x 10\^7 cells/m2~Group Two:~Day 0 6 x 10\^7 cells/m2 Day 14 6 x 10\^7 cells/m2~Group Three:~Day 0 1.5 x 10\^8 cells/m2 Day 14 1.5 x 10\^8 cells/m2"
48283940|NCT01797523|DRUG|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
48283941|NCT01797523|DRUG|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
48283942|NCT01797523|DRUG|Everolimus|10 mg by mouth once daily in a 28 day cycle.
48283943|NCT04614792|DEVICE|Transcranial direct current stimulation|Non-invasive brain stimulation or neuromodulation.
48283944|NCT01905956|DIETARY_SUPPLEMENT|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
48283945|NCT01905956|DIETARY_SUPPLEMENT|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
48468970|NCT06364072|DRUG|CT001|Intranasal
48468971|NCT03065699|DEVICE|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
47937974|NCT06422273|DRUG|Tranexamic Acid|Endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients
47937975|NCT06422273|OTHER|Saline (placebo)|Topical Saline (placebo) administered as endobronchial topical application prior to performing transbronchial biopsies in lung transplant recipients.
47937976|NCT05461807|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
48283946|NCT03748641|DRUG|Niraparib|Participants will receive niraparib 200 mg capsules or tablets once daily.
48283947|NCT03748641|DRUG|Abiraterone Acetate|Participants will receive AA 1000 mg tablets once daily.
48283948|NCT03748641|DRUG|Prednisone|Participants will receive prednisone 10 mg tablets daily.
48283949|NCT03748641|DRUG|Placebo|Participants will receive matching placebo once daily.
48283950|NCT03748641|DRUG|New Formulation of Niraparib and Abiraterone Acetate (AA)|Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily.
48283951|NCT05432544|DRUG|SHR-1918|Ascending dose
48283952|NCT05432544|DRUG|SHR-1918 placebo|Ascending dose
48468972|NCT03869424|OTHER|Active Placebo labelled as antidepessant|Participants receive an active nasal spray that is in fact a placebo.
48468973|NCT02998606|DRUG|Naloxegol|MOVANTIK™ 25 mg, daily
48468974|NCT02998606|DRUG|Placebo Oral Capsule|Placebo 25 mg, daily
48468975|NCT04413968|DIAGNOSTIC_TEST|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
48468976|NCT04413968|DIAGNOSTIC_TEST|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
48468977|NCT04413968|DIAGNOSTIC_TEST|Stool collection|Stool collection in children
48468978|NCT06559774|BEHAVIORAL|Hastiin Bidziil|Common Elements Treatment Approach (CETA) modified for cultural and gendered specific delivery for maximum community impact
48468979|NCT06559774|OTHER|Control condition - vehicle maintenance|Control condition was selected by the Community Research Council and includes five sessions on basic vehicle maintenance such as changing tire, checking fluid levels, and winterizing vehicles.
48468980|NCT04618939|BIOLOGICAL|BR-TD-1001|0.5 mL, IM
48468981|NCT04618939|BIOLOGICAL|Td-pur inj|0.5 mL, IM
48468982|NCT01591824|OTHER|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~* general column.~* lumbar muscles, and paraspinal muscles,~* sacral decompression oscillatory~* Opening by lateral vertebral lumbar rhythmic swing.~* Balancing and pelvic decompression~* Swing-lumbar vertebral rotation."
48283953|NCT02334709|RADIATION|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
48283954|NCT04291157|OTHER|CVD risk estimation incorporating the PRS and guideline based preventive interventions.|Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.
48283955|NCT04291157|OTHER|Standard GP care|Usual GP care (opportunistic CVD prevention)
48283956|NCT03368859|DRUG|Leucovorin|Intravenous
48283957|NCT03368859|DRUG|Fluorouracil - bolus|Intravenous
48283958|NCT03368859|DRUG|Bevacizumab|Intravenous
48283959|NCT03368859|DRUG|Fluorouracil - infusion|Intravenous
48283960|NCT03368859|DRUG|ABT-165|Intravenous
48283961|NCT03368859|DRUG|Irinotecan|Intravenous
48283962|NCT02677740|DEVICE|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
48283963|NCT02677740|DEVICE|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
48283964|NCT02638012|DRUG|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
48628284|NCT05430295|PROCEDURE|monofocal intraocular lens implantation|implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
47937977|NCT05461807|DRUG|Apixaban|Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data
47937978|NCT04025281|OTHER|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
48100701|NCT05193630|DIETARY_SUPPLEMENT|Milnutri Sure™|"Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water."
48100702|NCT02485834|PROCEDURE|FDG-PET|
48283965|NCT02638012|OTHER|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
48468983|NCT01591824|OTHER|column exercise group|"* paraspinal muscle stretching exercises~* postural correction~* mobilization exercises thoracic and lumbar~* Motor control exercises"
48100703|NCT02485834|PROCEDURE|surgery|
48100704|NCT02485834|DRUG|5-FU|200 mg/m\^2/day IV
48100705|NCT02485834|DRUG|capecitabine|oral 800 mg/m\^2 BID
48100706|NCT02485834|DRUG|docetaxel|30 mg/m\^2 IV
48100707|NCT02485834|DRUG|Irinotecan|50 mg/m\^2 IV
48100708|NCT02485834|RADIATION|3D-CRT|
48468984|NCT03434145|OTHER|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
48468985|NCT01224457|DRUG|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
48468986|NCT06072924|BEHAVIORAL|Isotonic Endurance Exercise|Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
48628285|NCT03390192|DEVICE|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
48628286|NCT03390192|DEVICE|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
48628287|NCT03545841|OTHER|HIT|Participants completed 6 weeks of HIT
48100709|NCT02485834|RADIATION|IMRT|
48100710|NCT01960803|RADIATION|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
48100711|NCT05407129|BEHAVIORAL|Family safety reporting intervention|Family safety reporting intervention for patients/families
48100712|NCT02741167|PROCEDURE|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
48100713|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
48628288|NCT03545841|OTHER|MICT|Participants completed 6 weeks of MICT
48628289|NCT03853837|DIAGNOSTIC_TEST|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
48283966|NCT06312306|DEVICE|transcranial direct current stimulation|Anodal tDCS applied using a direct current stimulator and two saline-soaked electrodes. The anode electrodes will be positioned approximately 2 cm anterior to Cz according to the International 10/20 EEG System. The cathode will be positioned over the inion. Stimulation intensity will be at 2.0 milliampere (as suggested to achieve excitation in the lower limb motor cortex areas)
48283967|NCT06312306|OTHER|Pilates based core training|The Pilates training program will last 30 min per session, Each action in the training will be repeated eight times these actions are at beginner level, considering the characteristics of stroke patients. The selected exercises will be given to all patients and progressed week-wise.
48283968|NCT06312306|OTHER|conventional physiotherapy program|"Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs"
48283969|NCT01724606|RADIATION|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
48283970|NCT01724606|DRUG|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
48283971|NCT01068561|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
48283972|NCT05289661|DRUG|Topical Ripasudil|To determine the effect of rho-kinase inhibitors on endothelial cell loss
48283973|NCT05289661|DRUG|Topical Placebo|topical Placebo
48283974|NCT04476264|PROCEDURE|Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection|The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
48468987|NCT06072924|BEHAVIORAL|Sham Exercise|Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day
48628290|NCT05993169|OTHER|Body Composition optimization visits|Patients who are selected into the body composition optimization (BCO) visits group will attend an extra one hour in-person check-up with Olivia Johnson as part of their regular clinic follow-ups. During their initial BCO visit, patients will complete a hard copy intake form. These BCO visits will take place in the same clinic as the regular visits. These visits will focus on individual concerns and goal-setting. These visits may be changed to online/video follow ups if the patients are finding it difficult to return to main campus that often.
48628291|NCT05786300|DEVICE|NMES+|"The Treatment Group will follow the rehabilitation protocol with the addition of the NMES+.~1st/2nd Week at 35 Hertz. 3rd/4th Week 50 Hertz. 5th/6th Week 70 Hertz."
48628292|NCT05786300|PROCEDURE|Rehab|"The Control Group will follow a protocol based on the latest available guidelines for the rehabilitation of the hamstrings lesions.~A weight-bearing protocol with a week by week progression on load, repetitions and sets."
47937979|NCT04025281|OTHER|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
47937980|NCT00511212|DRUG|intravenous immunoglobulin|
47937981|NCT00470184|DRUG|capecitabine|Oral
47937982|NCT00470184|DRUG|oxaliplatin|IV
47937983|NCT00470184|GENETIC|gene expression analysis|Correlative Study
47937984|NCT00470184|GENETIC|microarray analysis|Correlative Study
48468988|NCT06650124|DRUG|Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.|Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.
48628293|NCT05389787|DEVICE|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is \~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
48468989|NCT06650124|DRUG|Azathioprine + Prednisolone|In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.
48468990|NCT05333653|OTHER|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
48468991|NCT05333653|OTHER|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
48468992|NCT00808262|BIOLOGICAL|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
48468993|NCT04645186|DEVICE|bone graft substitute|Filling bone defects in current clinical practice
48468994|NCT06009588|DEVICE|self-expandable valves|patients undergoing TAVR use self-expandable valves
48468995|NCT06009588|DEVICE|balloon-expandable valves|patients undergoing TAVR use balloon-expandable valves
48468996|NCT06593067|OTHER|Ambient Heating|Description: Ambient heat stress (no higher than 47°C) with and without evaporative (water sprayed on the skin) and convective (electric fan) cooling i.e., no cooling, convective cooling, evaporative cooling, and convection + evaporative cooling.
48468997|NCT05184179|DRUG|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
48468998|NCT00653016|DRUG|norelgestromin; ethinyl estradiol|
48468999|NCT06506942|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
48469000|NCT02129062|DRUG|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
48469001|NCT02129062|OTHER|Laboratory Biomarker Analysis|Correlative studies
48469002|NCT00490503|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
48469003|NCT00490503|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
48283975|NCT04292938|DIETARY_SUPPLEMENT|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
48469004|NCT05857345|OTHER|Collection of breastmilk|Collection of breastmilk and other information about the participant
48469005|NCT06427044|DRUG|Anterior serratus block group|Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
48617864|NCT02171351|DEVICE|effect of neuro electrostimulation (NES)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of neuro electrostimulation (NES)
48628294|NCT03017287|DEVICE|GlucoMe App|Assessment of the the GlucoMe App
48628295|NCT05963919|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
48617865|NCT02171351|OTHER|effect of voluntary contractions (VC)|Each subject (type 2 diabetes and control) will be assessed with plethysmography during a single session of voluntary contractions (VC)
48469006|NCT06679491|OTHER|Resistance periodized training program (N-PF)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the follicular phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated based on the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are performed at a higher training load during both early and late follicular phases. The increased intensity leverages higher estrogen levels, which may support greater muscle strength and recovery during this phase.~Luteal Phase (Days 15-28): Training sessions are conducted at a lower training load during both early and late luteal phases to accommodate the hormonal shifts associated with elevated progesterone."
48469007|NCT06679491|OTHER|Resistance peioridized training program (N-PL)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the luteal phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated according to the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are conducted at a lower training load during both early and late follicular phases to accommodate the hormonal environment of this phase.~Luteal Phase (Days 15-28): Training sessions are performed at a higher training load during both early and late luteal phases. The increased intensity leverages the hormonal environment associated with elevated progesterone, which may affect muscle endurance and neuromuscular adaptations during this phase."
47937985|NCT00470184|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative Study
47937986|NCT00470184|PROCEDURE|adjuvant therapy|Metastatic growth control
47937987|NCT00470184|PROCEDURE|biopsy|Examination of tissue type
47937988|NCT00470184|PROCEDURE|conventional surgery|Tissue removal
48283976|NCT05330468|DEVICE|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
48469008|NCT06679491|OTHER|Continuous resistance training program (C)|"This intervention consists of a 13-week structured resistance training program with a continuous training intensity maintained throughout the menstrual cycle. Participants perform two resistance training sessions per week, each lasting 90 minutes, with a consistent training load applied across all phases.~Intensity Modulation:~All Phases: Training sessions are conducted at a steady training load regardless of menstrual phase. This continuous approach is designed to provide a baseline for assessing neuromuscular adaptations without the influence of phase-specific intensity adjustments."
48469009|NCT05798637|OTHER|Standard of care|No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
48469010|NCT00877994|BEHAVIORAL|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
47937989|NCT00470184|PROCEDURE|neoadjuvant therapy|Tumor shrinkage
48100714|NCT00611832|BEHAVIORAL|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
48617866|NCT01813175|OTHER|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
48628296|NCT05963919|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) by ATS/ERS criteria. Forced expiratory volume in 1 second (FEV1) and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
48628297|NCT05963919|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
47937990|NCT00470184|PROCEDURE|quality-of-life assessment|Correlative Study
47937991|NCT00470184|RADIATION|radiation therapy|Undergoing radiation therapy
47937992|NCT03289364|DEVICE|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
48100715|NCT04002128|OTHER|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
48100716|NCT02046616|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
48283977|NCT04382261|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
48100717|NCT02046616|DRUG|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
47951377|NCT01173939|DRUG|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
48100718|NCT02046616|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
48100719|NCT00988286|PROCEDURE|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
48283978|NCT03619785|DRUG|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
48283979|NCT03619785|DRUG|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
48469011|NCT00877994|BEHAVIORAL|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
48469012|NCT00465660|BEHAVIORAL|Progressive resistance training|
48469013|NCT05252234|OTHER|Observation of hemodynamic status and post operative pain|No intervention
48628298|NCT05963919|OTHER|Lower extremity muscle strength test|The 30-Second Chair Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving. The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart, and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand.
48628299|NCT01911325|DRUG|Buparlisib|
48628300|NCT01911325|DRUG|Buparlisib matching placebo|
47937993|NCT05852600|BEHAVIORAL|Parents and Adolescents Talking about Healthy Sexuality (PATHS)|"PATHS is an intervention delivered to parents of AMSM that aims to increase parent communication about sexuality and HIV, as well as other parent behaviors supportive of sexual risk reduction. PATHS can all be accessed online, is self-paced, and typically takes parents 40-60 minutes to complete. The toolkit is comprised of 7 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. One month later parents complete a refresher module that queries them about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact."
47937994|NCT05852600|BEHAVIORAL|Lead with Love (LWL)|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance. One month after watching LWL, parents return to the website to review refresher materials that summarize the most important lessons from the film."
48100720|NCT04299685|OTHER|Interview|Qualitative family interviews of 20 family units, or more until data saturation, of at least one parent and one adolescent (aged 10-19 year old) will be conducted based on deductive thematic approach. Each interview will last for about an hour, be conducted in Cantonese, and audio-taped for transcription in verbatim in Chinese.
48283980|NCT03224962|DEVICE|fluorescence camera|drug - diagnostic test
48283981|NCT06656949|PROCEDURE|injecting indocyanine green (ICG) dye Intraoperative|injecting indocyanine green (ICG) dye Intraoperative for patients with endometrial cancer
48283982|NCT06332443|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.
48283983|NCT06332443|PROCEDURE|Sedation epidural anesthesia|Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
48628301|NCT01911325|DRUG|Docetaxel|
48469014|NCT02156154|DRUG|Intravenous Acetaminophen|
48469015|NCT00722839|BIOLOGICAL|PADRE-CMV fusion peptide vaccine|Given subcutaneously
48628302|NCT00076609|DRUG|PHY906|
48469016|NCT00722839|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given subcutaneously
48469017|NCT00722839|DRUG|agatolimod sodium|Given subcutaneously
48469018|NCT04009876|DRUG|nal-IRI|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
48469019|NCT04009876|PROCEDURE|Surgical resection|Surgical resection of the tumour
48628303|NCT00076609|DRUG|capecitabine|
48628304|NCT06386120|OTHER|PEEP setting strategy|The attending physician selects different PEEP setting strategies
48628305|NCT03901209|DEVICE|Mid-face osteotomy|The mid-face osteotomy - typically according to LeFort I - is performed using a pulsed erbium-doped yttrium aluminium garnet (Er:YAG) laser driven by the CARLO robot arm.
48628306|NCT05756478|OTHER|Medication review|This is a feasibility study of implementing a pharmacist-led medication review using prescribing tools (e.g. STOPP/START, Beers Criteria)
48283985|NCT02051101|OTHER|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
48283986|NCT04048577|DRUG|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
48283987|NCT00290472|DRUG|temsirolimus|
48283988|NCT03607370|PROCEDURE|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
48469020|NCT04009876|OTHER|Watch-and-wait|No surgery approach
48469021|NCT04009876|DRUG|5-FU/LV|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
48469022|NCT04009876|DRUG|Oxaliplatin|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
48469023|NCT03850964|DRUG|Pazopanib|gel capsule, with 25mg-similar fills
48469024|NCT03850964|DRUG|Placebo oral capsule|identical gel capsule without active pharmaceutical ingredient
48469025|NCT00842816|DRUG|ST101|10 mg; administered once/day
48469026|NCT00842816|DRUG|ST101|60 mg; administered once/day
48469027|NCT00842816|DRUG|ST101|120 mg; administered once/day
48469028|NCT00842816|DRUG|Placebo|placebo tablets to match ST101 tablets
48628307|NCT04345432|DRUG|Gabapentin|"Gradually increasing doses of medication from 100 mg on day 1 to 300 mg twice a day on day 6. On day 7, the patient received a 300-mg dose from the day 7 envelope, about two hours after a light breakfast and 1 hour before data collection. The relatively low dose and gradual titration were selected to enhance compliance and reduce adverse effects, based on a rectal mechanosensitivity study."
48469029|NCT01115933|DEVICE|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
48469030|NCT06635876|BEHAVIORAL|Coaching Sessions|"The coach will use motivational interviewing techniques to:~1. To assist and guide the caregiver to establish a standby caregiver relationship~2. To assist and guide the caregiver as to how to use the EPT"
48469031|NCT05013723|OTHER|Surveys|Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)
48469032|NCT02845791|BEHAVIORAL|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
48469033|NCT04641403|PROCEDURE|The surgeon performed Laparoscopic-assisted TAP (LTAP) block|After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
48628308|NCT01050842|DRUG|bicalutamide|Given orally
48628309|NCT01050842|DRUG|raloxifene|Given orally
48628310|NCT01050842|PROCEDURE|quality-of-life assessment|Ancillary study
48283989|NCT02503891|DEVICE|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
48283990|NCT06264453|DRUG|KH001|topical applications of KH001
48469034|NCT06149286|DRUG|Odronextamab|Administered by intravenous (IV) infusion
48469035|NCT06149286|DRUG|Lenalidomide|Administered orally (PO)
48469036|NCT06149286|DRUG|Rituximab|Administered by IV infusion, or subcutaneously (SC)
48469037|NCT05017649|BIOLOGICAL|Blood sample|Blood sampling.
48469038|NCT02129517|OTHER|IMPACT intervention|Tailored, web-based educational short video clips
48469039|NCT02129517|OTHER|Online education materials|Online NCI-based educational materials
48469040|NCT02129517|OTHER|survey administration|Ancillary studies
48469041|NCT04905693|DRUG|Inhaled Treprostinil|Inhaled Treprostinil (6 mcg/breath) administered QID
48469042|NCT04905693|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
48469043|NCT01682187|DRUG|LY2157299|Administered orally
48469044|NCT01682187|DRUG|Lomustine|Administered orally
48283991|NCT06264453|DRUG|Placebo|topical applications of Water for Injection
48283992|NCT00133926|PROCEDURE|Treatment of periodontal disease|
48283993|NCT00588679|OTHER|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
48283994|NCT05846633|DEVICE|C mell treadmill|C Mell treadmill provides Virtual Reality environment for rehabilitation with obstacles and motivational assistance
48617867|NCT01813175|OTHER|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
48628311|NCT00266981|DEVICE|APOS - exercise component|
48628312|NCT06403501|DRUG|Clascoterone|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
48628313|NCT06403501|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
48628314|NCT01945242|DRUG|Alogliptin|Alogliptin tablets
48469045|NCT05514340|DRUG|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
48469046|NCT05514340|DRUG|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
48469047|NCT03422224|DIAGNOSTIC_TEST|Mixed lymphocyte reaction|Assessment of alloreactive T cell repertoire
48469048|NCT06677853|DRUG|Timolol Maleate Gel+Placebo|Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
48469049|NCT06677853|DRUG|Timolol Maleate Gel|Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
48100721|NCT00704756|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
48100722|NCT00704756|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (\<65 kg : 800 mg, 65 - 85 kg : 1000 mg, \>85 kg : 1200 mg) orally for up to 24 wks (Genotype \[G\] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
48100723|NCT02867046|DRUG|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
48100724|NCT04555044|DRUG|Clinolipid|Lipid injectable emulsion, USP 20%
48469050|NCT06677853|DRUG|Placebo|Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
48100725|NCT04555044|DRUG|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)
48100726|NCT06629727|OTHER|VR Group|the experimental group was shown a video through VRG during the lithotripsy procedure.
48628315|NCT02625740|DEVICE|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
48469051|NCT00826345|OTHER|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~- Active"
48628316|NCT02625740|DEVICE|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
48100727|NCT06629727|OTHER|Control group|Patients received standard care during the procedure
48100728|NCT00099437|DRUG|Fulvestrant|intramuscular injection
48100729|NCT03113487|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
48100730|NCT03113487|BIOLOGICAL|Pembrolizumab|Given IV
48100731|NCT04705857|COMBINATION_PRODUCT|"Histograft, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene"|gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 μg per 1.0 g of the OCP scaffold
48100732|NCT05709457|BEHAVIORAL|Cash transfer in prior study|Women were offered a cash transfer conditional on attending prenatal and postnatal visits and delivering in a facility
48100733|NCT06326463|DRUG|Fludarabine|40mg/m2, Day -4, -3 and -2
48100734|NCT06326463|DRUG|Cyclophosphamide|"Day -3 and Day-2~REST DAY, -1"
48100735|NCT06326463|DRUG|CD70-CAR T cell infusion (Autologous)|Day 0 or +1
48100736|NCT06326463|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
48100737|NCT04097899|OTHER|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~* Antibiotics cost.~* Appropriates of antibiotic use (initiation, duration \& time of discontinuation).~* Rate of resistance~* Clinical outcome, infection rate \&length of stay."
48100738|NCT03553446|DRUG|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
48100739|NCT04157257|DRUG|TDF tablet|TDF tablet 300mg QD
48100740|NCT04157257|DRUG|Entecavir Tablet|Entecavir tablet 0.5mg QD
48100741|NCT04157257|DRUG|QL-007|QL-007 tablets 200mg BID
48469052|NCT00826345|OTHER|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
48469053|NCT04640194|PROCEDURE|Standard of care|Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
48283995|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
48617868|NCT01813175|OTHER|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
48100742|NCT02932358|OTHER|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
48100743|NCT02932358|OTHER|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
48100744|NCT00247156|PROCEDURE|Acupressure treatments and NAET treatments|
48283996|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
48283997|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
48100745|NCT04800302|PROCEDURE|Continous Quadratum Lumborum Block III|Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum \& psoas major muscles with ultrasound guidance.
48100746|NCT04800302|PROCEDURE|Single dose Quadratum Lumborum Block III|Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.
48100747|NCT04800302|PROCEDURE|Intra-venous Morphine|Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.
48283998|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
48469054|NCT04640194|DRUG|Alteplase low dose|0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
48469055|NCT04640194|DRUG|Alteplase high dose|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
48469056|NCT03065231|DEVICE|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
48469057|NCT03065231|DEVICE|Lumbar Drain|
48469058|NCT01923818|DRUG|rivaroxaban|orally active direct factor Xa inhibitor
48469059|NCT01923818|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
48469060|NCT01923818|DRUG|placebo|
48628317|NCT02625740|DEVICE|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
48469061|NCT06679192|DEVICE|Milled thickness varied soft upper surface, based on plantar pressure measurement|"This custom made shoe insole is milled, with a thickness varied soft upper surface ranging from 0-6mm in thickness. The base of the insole is 45 shore Ethylene-vinyl acetate (EVA).~This intervention makes the insole from an individual foot scan, a plantar pressure measurement from the individual and the shoe model to mill a finished custom made shoe insole with a soft upper surface. It is difficult in clinical practice of making shoe inserts to create a thickness varied soft upper with different zones all over the insole. Furthermore, a soft upper requires a physical positive model to be made of the foot and staff must spend time to grind the insole to an acceptable shape. A milled version would be more effective since it require no physical foot model, little to no work grinding the insole and enables the use of thickness-variations. It also enables the use of data-based insole-manufacturing, such as data from plantar pressure measurements."
48469062|NCT06679192|DEVICE|3mm soft upper surface|This intervention has a 3mm soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
48469063|NCT06679192|DEVICE|No soft upper surface|This intervention has a no soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
48469064|NCT03797001|DRUG|Anakinra|100 mg subcutaneous injection, daily for 24 weeks
48469065|NCT03797001|DRUG|Placebo|subcutaneous injection, daily for 24 weeks
48469066|NCT01459198|BIOLOGICAL|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.
48469067|NCT01459198|BIOLOGICAL|Placebo vaccine|Given intranasally once at a baseline study visit
48469068|NCT05735028|DRUG|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
48100748|NCT05035225|OTHER|Survey|Multiple Pharmacy Use Survey
48100749|NCT04443452|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
48106941|NCT02372019|BEHAVIORAL|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
48283999|NCT02912871|OTHER|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
48284000|NCT02764879|DIETARY_SUPPLEMENT|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
48284001|NCT02764879|PROCEDURE|scaling and root planing|
48284002|NCT02764879|OTHER|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
48284003|NCT01462513|BIOLOGICAL|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
48284004|NCT01462513|BIOLOGICAL|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
48628318|NCT02625740|DRUG|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
48628319|NCT02625740|PROCEDURE|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
48628320|NCT02000271|PROCEDURE|Vaginal packing|
48628321|NCT02000271|PROCEDURE|No vaginal packing|
48628322|NCT01472835|DRUG|Midazolam|Used for anxiolysis
48628323|NCT01472835|DRUG|Fentanyl|Used for analgesia and as a sedative
48628324|NCT05592288|OTHER|PREDIABE-TR mobile app.|"* Module 1: Personal data Containing data on the participant's age, gender, telephone number, email and perception of his/her health (bad, so-so, good, very good).~* Module 2: Medical history of the participant In this module, the participants tick the items that apply to themselves or their first-degree relatives by marking the conditions in their medical history that may increase the risk of prediabetes. Additionally, in line with the recommendations of the Turkish Association of Endocrinology and Metabolism, this module contains the Finnish Diabetes Type-2 Risk Score (FINDRISK) which assesses an individual's risk of diabetes.~* Module 3: Healthy lifestyle behaviors The sub-sections of the module are devoted to nutrition, height-weight-body mass index (BMI) and physical activity."
48284005|NCT01583036|DRUG|Digoxin Alone|Single administration of digoxin 0.25mg
48284006|NCT01583036|DRUG|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
48469069|NCT05735028|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
48469070|NCT03205501|DRUG|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
48469071|NCT03205501|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
48469072|NCT01022255|BIOLOGICAL|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
48469073|NCT03887598|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
48469074|NCT01720849|DRUG|Fampyra|The will be given as per normal patient treatment plan
48469075|NCT05862844|BEHAVIORAL|Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )|The Intervention Arm involves a 90-minute educational session tailored to Muslim women. They will learn about HPV infection risks, cervical cancer risks, and benefits of early screening and HPV vaccination. Discussions cover transmission, consequences, risk factors (behaviors, infections, family history), and importance of early detection. The session provides information on screening methods, check-ups, and HPV vaccine safety. Participants actively engage in discussions, ask questions, and share thoughts. The session empowers women with knowledge to make informed decisions about their health, promoting cervical cancer prevention.
48469076|NCT06122610|DEVICE|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after first cycle of Lutathera® treatment
48469077|NCT06122610|DEVICE|Photon Emission Tomography / CT (PET/CT)|PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
48469078|NCT06122610|DRUG|64Cu-Dotatate|Standard of care administration of radioactive drug for PET/CT
48469079|NCT06122610|DRUG|177Lu-Dotatate|Standard of care administration of radioactive drug for PET/CT and SPECT/CT
48469080|NCT01995331|DRUG|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was \>1×109/L."
48469081|NCT03297151|DIETARY_SUPPLEMENT|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
48469082|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
48469083|NCT03297151|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
48469084|NCT01685216|BIOLOGICAL|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
48628325|NCT05788198|OTHER|Integrated care|"The intervention will be modelled based on the most frequently reported patient, family physician and specialist barriers in depression management. In this project, multiple interventions aiming to tackle these barriers will be set up, with the WHO Framework on Integrated People-Centred Health Services (IPCHS) serving as conceptual backbone to the study (Table 1). The IPCHS distinguishes five interdependent strategies supporting a shift in healthcare delivery, management and funding towards universal health coverage. These strategies are:~1. empowering and engaging people and communities;~2. strengthening governance and accountability;~3. reorienting the model of care;~4. coordinating services within and across sectors;~5. creating an enabling environment."
48469085|NCT00846898|DIETARY_SUPPLEMENT|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
48628326|NCT00705822|DRUG|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
48628327|NCT00705822|DRUG|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
47937995|NCT04335422|DEVICE|Robotic group (Upper extremity robot-assisted training plus routine physical and rehabilitation medicine program)|"Upper extremity robot-assisted training will include facilitated shoulder flexion-extension, internal-external rotation, abduction-adduction, elbow flexion-extension, forearm supination-pronation, wrist flexion-extension, ulnar-radial deviation, hand finger flexion-extension movements by means of visual feedback with a 3-dimensional virtual environment in which the patient is asked to perform various tasks such as object reaching, grasping, holding, dropping activities by playing computer games.~Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given."
47937996|NCT04335422|BEHAVIORAL|Control group (routine physical and rehabilitation medicine program)|Routine physical and rehabilitation medicine program including physical therapy and exercises, walking and balance training, and occupational therapy to improve daily living activities will be given.
48284007|NCT03175523|DEVICE|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
48284008|NCT03175523|DEVICE|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
48469086|NCT00470860|BEHAVIORAL|Participation in LOFTS online tutorial|
48469087|NCT04791371|BEHAVIORAL|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
48469088|NCT04386408|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
48469089|NCT04386408|COMBINATION_PRODUCT|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
48469090|NCT04873245|BEHAVIORAL|Intensive Behavioral Program|Participants randomized to this group will receive intensive behavioral therapy.
48469091|NCT04873245|DRUG|Semaglutide and Behavioral Program|Participants randomized to this group will receive semaglutide and behavioral therapy.
48469092|NCT04744428|BEHAVIORAL|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
48469093|NCT04744428|BEHAVIORAL|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
48469094|NCT01710605|BIOLOGICAL|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
48469095|NCT06677905|BEHAVIORAL|web-based spinal cord injury self-management program|"Peer health coaches will be recruited from the United Spinal Connecticut Chapter and SCI BC. They will be at least 5 years post-SCI and will be certified in brief action planning and in Mental Health First Aid.~Online coaching sessions are expected to cover a health-related topic (eg. bladder, bowel, skin, pain, healthy eating, physical activity or stress, anxiety and depression etc) and a self-management skill topic (eg.action planning, goal setting, problem-solving, mood management, navigating the health care system, communicating with health care providers). To ensure we meet the unique needs of participants, the coach and participant will determine jointly how many sessions to spend on a topic. In addition, coaches will be able to link relevant information and resources contained in the resource library to each session."
48469096|NCT06677905|BEHAVIORAL|Peer support|Existing peer support program from the United Spinal Connecticut Chapter or SCI BC
48469097|NCT02813382|DRUG|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
48469098|NCT02813382|DRUG|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
48469099|NCT02813382|DRUG|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
48617869|NCT03716960|OTHER|Pumpkin Seed Oil|This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
48628328|NCT04324697|PROCEDURE|Horizontal alveolar bone augmentation|Horizontal augmentation in anterior maxilla using allograft shell and autogenous chips with no need for a second surgical site
48628329|NCT00837330|DRUG|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
48628330|NCT03033693|OTHER|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
48628331|NCT03033693|OTHER|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
48469100|NCT00277043|DRUG|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
48469101|NCT00277043|DRUG|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
48628332|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.
48469102|NCT00096122|DRUG|cytarabine|Given IV
48469103|NCT00096122|DRUG|idarubicin|Given IV
48100750|NCT04443452|RADIATION|Radiographic Evaluation|Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
48628333|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.
48628334|NCT04828733|PROCEDURE|Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.|Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
48628335|NCT01011283|DRUG|decitabine|decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days
48628336|NCT01011283|DRUG|azacitidine|azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
48628337|NCT04270786|PROCEDURE|Early de-escalation|In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
48628338|NCT04270786|PROCEDURE|Standard|In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
48628339|NCT00854854|BIOLOGICAL|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
48628340|NCT04835753|DEVICE|shock wave|true radial ESWT.A rESW pneumatic device (SHOCK MED, Italy) was used to provide one session per week (for a total of 12-week)
48628341|NCT04835753|OTHER|traditional physical therapy program|lower limbs muscles stretch and strength in addition to balance and gait training
47937997|NCT04526990|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
48628342|NCT01770730|DEVICE|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
48628343|NCT00623376|DRUG|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
48628344|NCT00623376|DRUG|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
47937998|NCT04526990|BIOLOGICAL|Placebo|Intramuscular administration
47937999|NCT00393640|PROCEDURE|Early and regular breast milk expression|Breast pump given to be used on regular intervals
47938000|NCT03986762|DRUG|Clavulanic Acid|\~10 days of Clavulanic Acid
47938001|NCT05602311|DRUG|General anesthetic|Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
47938002|NCT04205097|DRUG|Neostigmine + glycopyrate|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
47938003|NCT04205097|DRUG|Sugammadex|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
48469104|NCT00096122|DRUG|tipifarnib|Given orally
48469105|NCT03722108|COMBINATION_PRODUCT|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
48469106|NCT03722108|DRUG|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
48469107|NCT02684396|DRUG|TAK-648|TAK-648 Solution
47938004|NCT04426578|DRUG|Perhexiline|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
48469108|NCT02684396|DRUG|TAK-648 Placebo|TAK-648 placebo-matching solution
48469109|NCT05475431|DRUG|The sequential therapy|Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days
48469110|NCT05475431|DRUG|The triple therapy|Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
48469111|NCT05475431|DRUG|The hybrid therapy|Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .
48469112|NCT05475431|DRUG|The concomitant therapy|Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days
48469113|NCT05475431|DRUG|Bismuth-based quadruple therapy|Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
48469114|NCT03278158|DRUG|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
48469115|NCT03278158|DRUG|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
48469116|NCT03278158|DRUG|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
48284009|NCT04684030|DEVICE|Continuous glucose monitoring system(CGMS)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
48469117|NCT03278158|DRUG|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
48469118|NCT03278158|DRUG|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
48469119|NCT03727945|OTHER|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
48469120|NCT03727945|OTHER|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
47951378|NCT01173939|DRUG|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
47951379|NCT05016219|DEVICE|Circadian-Effective Light|Narrowband blue light
48469121|NCT01566994|BEHAVIORAL|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
47951380|NCT05016219|DEVICE|Rhythmic Light|40 hertz (Hz) flicker
48284010|NCT04684030|DEVICE|Self-monitoring of blood glucose (conventional fingerpricking method)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
48284011|NCT00728338|DIETARY_SUPPLEMENT|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
48469122|NCT01566994|BEHAVIORAL|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
48469123|NCT01566994|BEHAVIORAL|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
48469124|NCT06667232|OTHER|Single-pulse stimulation|Investigators use single-pulse electrical stimulations at 1Hz to elicit cortico-cortical evoked potentials
48469125|NCT06667232|OTHER|Paired-pulse stimulation|The repetitive delivery of pairs of stimulation pulses is DES patten with a 5-50 ms interval between each pulse, constitutes repetitive paired-pulse stimulation.
48469126|NCT06667232|OTHER|Stepwise frequency stimulation|Stepwise incremental stimulation ranging from 5 Hz to 145 Hz following a cyclic pattern.
48469127|NCT06667232|OTHER|Burst stimulation|Burst stimulation pattern consisting of short bursts delivered once a second and an intraburst frequency of 50 Hz, 100 Hz, 150 Hz, 175 Hz and 200 Hz
48469128|NCT01174667|PROCEDURE|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
48469129|NCT01174667|OTHER|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
48469130|NCT05798338|DIAGNOSTIC_TEST|Blood sample|Analysis of plasma in order to quantify and characterize EVs
47951381|NCT05016219|DEVICE|Placebo Light|Narrowband red light
47951382|NCT05016219|DEVICE|Placebo Rhythmic Light|Random flicker for placebo rhythmic effect
47951383|NCT03178331|OTHER|Study questionnaires|filled by parents, school nurse and teacher
48284012|NCT00728338|DIETARY_SUPPLEMENT|Olive oil|7.5 g olive oil/day
48469131|NCT01470898|DEVICE|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
48469132|NCT04208490|OTHER|HN-STAR Intervention|The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
48469133|NCT03253744|DRUG|18F-DCFPyL|Participants will receive 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.
48469134|NCT03253744|RADIATION|Tumor Irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.
48284013|NCT05052203|OTHER|Exposure of interest: study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes|The primary objective is to study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge
48284014|NCT00820040|DEVICE|acellular porcine dermal collagen mesh|porcine mesh for hernia repair/ abdominal wall reconstruction
47951384|NCT05748197|BIOLOGICAL|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.
48284015|NCT06417632|OTHER|Graded Zirconia Crown|monolithic implant supported crown
48469135|NCT03253744|RADIATION|Prostate + tumor irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.
48469136|NCT03253744|RADIATION|Tumor Irradiation|External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.
48469137|NCT06678061|DEVICE|radiofrequency|block of neurolytic retrocrural celiac plexus block
48469138|NCT02498691|BIOLOGICAL|Biological collection|Blood and saliva samples, placenta and cord blood collection
48628345|NCT04113486|OTHER|Blood test|About 4 ml of blood draw
48628346|NCT00188838|BEHAVIORAL|Psychoeduction|
48628347|NCT00188838|BEHAVIORAL|Cognitive-Behavioral Therapy|
48628348|NCT05520047|BEHAVIORAL|COVID19-severe Patient|Behavioral and social test assessment
48628349|NCT05520047|BEHAVIORAL|family of COVID19-severe Patient|Behavioral and social test assessment
48628350|NCT05244837|DRUG|Tislelizumab 200 mg|Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
48628351|NCT05244837|DRUG|Carboplatin AUC 5|Carboplatin AUC 5 IV Q3W
48628352|NCT05244837|DRUG|pemetrexed 500mg/m2|Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
48628353|NCT05244837|DRUG|Paclitaxel 175mg/m2|Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
48628354|NCT05244837|DRUG|Nab-paclitaxel 260 mg/m2|nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
47951385|NCT05748197|DRUG|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
47951386|NCT01638767|DRUG|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
47951387|NCT01638767|DRUG|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
48284016|NCT06417632|OTHER|Conventional Zirconia Crown|monolithic implant supported crown
48469139|NCT01175473|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
48469140|NCT01175473|DEVICE|Pen auto-injector|
48469141|NCT01175473|DRUG|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
48469142|NCT01175473|DEVICE|Pre-filled pen injector|
48628355|NCT03699800|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
48628356|NCT02717715|BEHAVIORAL|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
48628357|NCT04717583|PROCEDURE|Intense pulsed light (IPL) treatment|"After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more."
48628358|NCT06501937|OTHER|Influencer marketing|Participants watched online survey-imbedded promotional videos featuring influencers
48628359|NCT04730375|DRUG|Dexmedetomidine Injection [Precedex]|two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
48628360|NCT01330524|DRUG|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
48628361|NCT01330524|OTHER|placebo|2mg placebo
48469143|NCT01175473|DRUG|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
48469144|NCT01067521|DRUG|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
48284017|NCT03268798|DEVICE|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
48284018|NCT04439734|DEVICE|Electromyostimulation|WB-EMS once per week 20 min for 16 weeks
48284019|NCT00800072|DEVICE|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
48284020|NCT05465135|DRUG|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
48284021|NCT02495363|PROCEDURE|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
48284022|NCT02495363|DRUG|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
48284023|NCT00489762|PROCEDURE|Installation of an energy efficient heater|
48469145|NCT01067521|DRUG|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
48469146|NCT06240065|OTHER|Green bean puree|Green bean puree as a proxy for fiber-foods
48469147|NCT05630014|BEHAVIORAL|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
48469148|NCT06581120|DRUG|Glucagon-Like Peptide-1 receptor agonists|GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
48628362|NCT05740592|PROCEDURE|micro-osteoperforations ,microincision|Patients in MOPs group will be subjected to minimal 6 MOPs 2mm apart and corticoperforation will be conducted by using drilling bure and only 1 or 2mm bicortical in the mid-palatal suture area. Patients with the piezocision group will be subjected to minimal 3 micro incisions spaced 4mm apart and a piezoelectric device with diamond surgical tip (size: 4 mm, thickness: 0.5mm) will be used.. The MARPE technique comprises the insertion of four bicortical miniscrews adjacent to the mid-palatal suture, being two mesial and two distal to the expanding screw. Each MARPE have two arms and will be fixed to molar band by soldering.
48100751|NCT04443452|PROCEDURE|Ultrasound-guided Aspiration|Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
48284024|NCT03836144|DIETARY_SUPPLEMENT|Potassium citrate|
48284025|NCT00040157|DRUG|ACH126-443 (Beta-L-Fd4C)|
48284026|NCT04680923|PROCEDURE|CPPLAI|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
48284027|NCT04680923|OTHER|Placebo|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
48284028|NCT04680923|DRUG|Bupivacaine 0.25%|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
48284029|NCT00602407|DRUG|Cilostazol|
48284030|NCT03884634|DEVICE|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
48284031|NCT04708990|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
48284032|NCT01878565|DRUG|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
48469149|NCT06581120|DIAGNOSTIC_TEST|Point of Care Gastric Ultrasound|A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
48469150|NCT05542849|DRUG|Acarbose Tablets 50mg|"Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals."
48628363|NCT01365572|DEVICE|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
48628364|NCT02217007|DRUG|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
48628365|NCT02449447|BEHAVIORAL|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
47951388|NCT04882046|OTHER|Blood collection|Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment
48100752|NCT04443452|DIAGNOSTIC_TEST|Muscle Strength Assessment|Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
48100753|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (A)|"The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial."
48284033|NCT01878565|DRUG|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
48628366|NCT02449447|OTHER|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
48628367|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
48628368|NCT00407030|DRUG|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
48628369|NCT00407030|DRUG|Placebo|Placebo
48628370|NCT03695094|DRUG|Padsevonil|Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
48628371|NCT03695094|DRUG|Oxcarbazepine|Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
48628372|NCT03695094|DRUG|Levetiracetam|Concomitant administration of levetiracetam (LEV) at therapeutic dosage
48628373|NCT03695094|DRUG|Lamotrigine|Concomitant administration of lamotrigine (LTG) at therapeutic dosage
47951389|NCT04882046|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
48469151|NCT06622486|DRUG|EGL-001|IV administration
48628374|NCT03695094|DRUG|Brivaracetam|Concomitant administration of brivaracetam (BRV) at therapeutic dosage
47951390|NCT05366517|DEVICE|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
47951391|NCT04004962|DEVICE|Infrared spectroscopy|Infrared spectroscopy
47951392|NCT00156897|DRUG|ATL-962|
47951393|NCT00156897|DRUG|Orlistat|
48284034|NCT01021111|DEVICE|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
48284035|NCT02371629|DRUG|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
48469152|NCT01875887|PROCEDURE|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
48469153|NCT05987332|DRUG|IDE196|Dosed orally, twice daily
47938005|NCT04426578|OTHER|Placebo|"All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count."
47938006|NCT00267618|BEHAVIORAL|FHP Pain|Evidence-based psychological and behavioural Intervention
47938007|NCT01687621|PROCEDURE|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
47938008|NCT05906238|BEHAVIORAL|STEREOBES Workshops|These workshops are designed to help patients develop appropriate behaviors to deal with stigmatizing situations. They will focus on three main areas: adapted physical activities, nutrition and mental well-being. They will include sessions on developing self-esteem, improving body image and managing emotions. The aim will be to deconstruct the myths and stereotypes surrounding obesity.
47938009|NCT05906238|BEHAVIORAL|Un Poids en moins|"Standard intervention proposed by La Vie la Santé"
47938010|NCT04099771|DRUG|Ketamine|Ketamine infusion
48106942|NCT02372019|BEHAVIORAL|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
48284036|NCT02371629|DRUG|Placebo|Placebo to NVA237
48284037|NCT02371629|DRUG|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
48284038|NCT01651923|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
48284039|NCT04793776|BEHAVIORAL|Manage Emotions to Reduce Aggression|MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
48469154|NCT05987332|DRUG|Crizotinib|Dosed orally, twice daily
48469155|NCT05987332|DRUG|Pembrolizumab|IV administration every 3 weeks
48469156|NCT05987332|DRUG|Ipilimumab|IV administration every 3 weeks for 4 Cycles
48628375|NCT03573856|BEHAVIORAL|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
48469157|NCT05987332|DRUG|Nivolumab|IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
48469158|NCT05987332|DRUG|Dacarbazine|IV administration every 3 Weeks
48628376|NCT03573856|OTHER|Health and Safety|Participants will be provided with education related to general health and safety topics.
48628377|NCT05150470|OTHER|prevention|dental digital fingerprinting
48628378|NCT01769365|DRUG|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
47938011|NCT03189771|PROCEDURE|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
48469159|NCT00691756|PROCEDURE|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
48628379|NCT01769365|DRUG|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
48284040|NCT04793776|BEHAVIORAL|Present Centered Psychotherapy|PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
48284041|NCT00877838|DRUG|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
48284042|NCT00877838|DRUG|Placebo|Gelatin capsules resembling the ones containing the active substance
48284043|NCT05449392|DRUG|Neosporin|Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
48284044|NCT05449392|OTHER|Vaseline|The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
48284045|NCT04339504|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
48469160|NCT00691756|PROCEDURE|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
48469161|NCT00440622|DRUG|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
48469162|NCT00440622|DRUG|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
48469163|NCT00440622|DRUG|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
48469164|NCT05955937|OTHER|Enhanced HF Clinical Care (Core-HF)|All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
48469165|NCT05955937|OTHER|Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)|A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
48284046|NCT04339504|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
48284047|NCT04339504|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
48469166|NCT06654752|OTHER|Immediate Oral Antibiotics|Increase airway clearance and start 14 days of preselected oral antibiotics right away
48469167|NCT06654752|OTHER|Tailored Treatment: Oral Antibiotics only if Additional Treatment needed|Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria
48628380|NCT01769365|DRUG|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
48628381|NCT03413917|OTHER|Analysis of genomic markers in uterine atony|No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
48628382|NCT03225222|DIAGNOSTIC_TEST|biopsy|prostate biopsy
48469168|NCT02438696|DRUG|BI 1060469, iFF, Test|
48469169|NCT02438696|DRUG|BI 1060469, iFF, Test|
48284048|NCT04444570|DEVICE|Continuous glycemia measuring device (Dexcom) implantation into the subcutaneous tissue|14 days before the date of the surgery and after the surgery patient will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
48469170|NCT02438696|DRUG|BI 1060469, TF1, Reference|
48628383|NCT05890820|OTHER|Preoperative nutritional assessment|Preoperative nutritional assessment and postoperative pulmonary complications
48284049|NCT05440825|DEVICE|VRelax|Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.
48284050|NCT05440825|OTHER|Relaxation exercises|Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
48284051|NCT05374941|DEVICE|Injectable and wearable neurostimulator for the hypoglossal nerve|Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
48284052|NCT02985801|DRUG|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
48469171|NCT02438696|DRUG|BI 1060469, TF2, Test|
48469172|NCT02438696|DRUG|BI 1060469, TF2, Test|
48469173|NCT02438696|DRUG|BI 1060469, iFF, Test|
48469174|NCT02438696|DRUG|BI 1060469, TF1, Reference|
48469175|NCT02438696|DRUG|BI 1060469, iFF, Test|
48469176|NCT02438696|DRUG|BI 1060469, iFF, Test|
48469177|NCT02438696|DRUG|BI 1060469, TF1, Reference|
48469178|NCT02438696|DRUG|BI 1060469, TF2, Test|
48469179|NCT02438696|DRUG|BI 1060469, TF1, Reference|
48469180|NCT02438696|DRUG|BI 1060469, TF1, Reference|
48469181|NCT02438696|DRUG|BI 1060469, TF2, Test|
48628384|NCT02331121|BEHAVIORAL|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
48284053|NCT02985801|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
48284054|NCT05771571|OTHER|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
48284055|NCT05771571|OTHER|Control|Refined olive oil
48469182|NCT02438696|DRUG|BI 1060469, TF2, Test|
48469183|NCT02438696|DRUG|BI 1060469, iFF, Test|
48469184|NCT02438696|DRUG|BI 1060469, TF2, Test|
48469185|NCT02438696|DRUG|BI 1060469, TF1, Reference|
48628385|NCT02331121|BEHAVIORAL|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
48469186|NCT06678893|DEVICE|Acupuncture Needle on an adhesive|This study utilizes acupuncture needs on small adhesives which will be placed according to the 5NP NADA Auricular Acupuncture Protocol.
48469187|NCT06678893|DEVICE|Adhesives|For those randomized to the placebo arm, adhesives without needles will be placed according to the 5NP NADA Auricular Acupuncture Protocol placement
48628386|NCT02669537|DEVICE|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
48628387|NCT06532916|OTHER|Experimental: Group1: Estelite Sigma Quick|Preheated conventional composite (Estelite Sigma Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Sigma Quick is a resin composite with the following composition (Silica-zirconiasupra-nano, monodispersingc spherica, Bis-GMA, UDMA, TEGDMA).
48628388|NCT06532916|OTHER|Experimental: Group 2: Estelite Flow Quick|Second group: Injectable flowable (Estelite Flow Quick, Tokuyama Dental Corp, Tokyo, Japan). Estelite Flow Quick is a resin composite with the following composition (Silica-zirconia, supra-nano monodispersing spherical, Bis-GMA, UDMA,TEGDMA).
48628389|NCT01927289|PROCEDURE|Proximal Brachial Plexus vs Distal Forearm Block|"Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach"
48284056|NCT00196885|DRUG|N-acetylcysteine|
48284057|NCT00987415|DRUG|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
48284058|NCT00987415|DRUG|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
48284059|NCT01175512|DRUG|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
48284060|NCT01175512|DRUG|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
48628390|NCT00780039|DRUG|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
48284061|NCT01071070|DRUG|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
48284062|NCT04363216|DRUG|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
48284063|NCT03013595|BEHAVIORAL|TRAM feedback|
48284064|NCT02104180|DEVICE|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
48284065|NCT02104180|DEVICE|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
48284066|NCT05745727|DRUG|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8
48284067|NCT05745727|DRUG|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
48284068|NCT01983865|OTHER|Exposure to birch pollen|
48284069|NCT04894383|DEVICE|Aetrex L420 Compete Orthotic|An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.
48284070|NCT04894383|DEVICE|Aetrex indoor comfort sandal with built-in arch support|An indoor comfort sandal with built-in arch support to be used at home. Provides extreme cushioning, shock absorption and durability. Arch support helps to stabilize and align feet and also helps to relieve common foot pain \& plantar fasciitis.
48284071|NCT00418288|DRUG|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
48284072|NCT00418288|DRUG|placebo|intravenous infusion of 1.2pmol/kg/min
48469188|NCT02075840|DRUG|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
48469189|NCT02075840|DRUG|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
48469190|NCT04225260|BIOLOGICAL|botulinum toxin neuromodulator|A dose of QM1114-DP will be injected in the GL area and in the LCL area.
48469191|NCT06655337|DEVICE|Smartphone Application for Post-Discharge Symptom Monitoring|This intervention involves the use of a smartphone application designed for symptom monitoring. The app enables participants to log daily health data, including symptoms and vital signs, for 7 days following discharge. It provides automated prompts and guidance for self-management, including when to seek medical assistance. The app does not provide direct medical intervention but facilitates remote symptom tracking to reduce readmissions and emergency hospitalizations. Follow-up consultations are conducted at day 7 and day 28.
48469192|NCT06121297|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
48469193|NCT03649945|DRUG|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
48469194|NCT03649945|DRUG|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
48469195|NCT03649945|DRUG|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
48469196|NCT06465875|OTHER|Reading a book|Individuals in the intervention group will be read a storybook for three nights.
48469197|NCT01784016|RADIATION|[11C]-PHNO|\[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
48469198|NCT06440278|BEHAVIORAL|Behavioral Activation for Health and Depression (BA-HD)|BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
48469199|NCT06440278|OTHER|Enhanced Usual Care|Patients will receive depression and heart disease education, as well as a list of local mental health resources.
48469200|NCT01302509|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
48469201|NCT02911935|DRUG|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
48469202|NCT02911935|DRUG|Placebo|Placebo suspension
48469203|NCT04631380|OTHER|PRAYER|THE PRAYER GROUP WILL RECEIVE ABSOLUTELY THE SAME CARE AS THE CONTROL GROUP PLUS PRAYERS
48469204|NCT05730452|BEHAVIORAL|Risk-stratified discharge and post-discharge care|"Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)"
48469205|NCT05065541|DRUG|CC-97489|Specified dose on specified days
48469206|NCT05065541|DRUG|[18F]T-401|Specified dose on specified days
48469207|NCT05065541|DRUG|[11C]MK-3168|Specified dose on specified days
48469208|NCT00002116|DRUG|Cidofovir|
48469209|NCT05585489|OTHER|Gait training with musical cue|Entraînement de 20 minutes de marche à vitesse confortable sur un parcours ovale de 20 mètres au laboratoire ARM avec la technique d'indiçage musical personnalisé de la longueur de pas.
48469210|NCT00568711|DRUG|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
48469211|NCT00568711|DRUG|rifampin|a 5-day course of daily 600-mg doses of rifampin
48469212|NCT06239428|BEHAVIORAL|i-TREAT|A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
48469213|NCT06239428|OTHER|Waitlist|A 12-week waitlist with access to online mindfulness material.
48469214|NCT03441139|OTHER|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
47938012|NCT05152914|DRUG|Cerliponase Alfa|Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
48469215|NCT03441139|DRUG|Medical Analgesics|Best analgesic therapy at investigator's discretion
48469216|NCT04994431|DRUG|Tamsulosin Hydrochloride|0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
48469217|NCT00348153|DRUG|Adalimumab|
48469218|NCT02497235|DRUG|TAK-935|TAK-935 oral solution.
48469219|NCT02497235|DRUG|[18F]MNI-792 (tracer)|\[18F\]MNI-792 injection.
48469220|NCT04233216|DRUG|ISL|ISL 0.75 mg capsule taken by mouth.
48469221|NCT04233216|DRUG|DOR|DOR 100 mg tablet taken by mouth.
48469222|NCT04233216|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC taken by mouth.
48469223|NCT04233216|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
48469224|NCT04233216|DRUG|Placebo to DOR|Placebo tablet matched to DOR taken by mouth.
48469225|NCT06678841|DEVICE|Personalized elevated cardiac pacing|Personalized elevated cardiac pacing treatment based each patient's height and baseline LVEF.
48469226|NCT03818386|DRUG|AGuIX®|"3 intravenous injection at 100mg/kg~* D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~* Fr1: AGuIX® injection before the first radiation session~* Fr6: AGuIX® injection before the sixth radiation session"
48469227|NCT03818386|RADIATION|Whole Brain Radiation Therapy|30 Gy in 10 fractions of 3 Gy over 2-3 weeks
48469228|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
48469229|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
48469230|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
48469231|NCT02833636|PROCEDURE|ACEF score|
48469232|NCT06678308|DEVICE|Embolisation with Magic Glue®|Magic Glue® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
48469233|NCT06678308|DEVICE|Embolisation with Embosphere®|Embosphere® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
48469234|NCT01763255|BIOLOGICAL|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
48284073|NCT03240640|PROCEDURE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
48469235|NCT01619956|DEVICE|SLA dental implants|Dental implant with surface modification.
48284074|NCT03240640|PROCEDURE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
48284075|NCT05856864|DRUG|Cadonilimab Injection|Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
48469236|NCT01619956|PROCEDURE|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
48284076|NCT05856864|DRUG|Ramucirumab Injection|Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
48284077|NCT05741203|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound
48469237|NCT01619956|PROCEDURE|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
48469238|NCT04995354|DRUG|EGF loaded Hydrogel|Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week
48469239|NCT04995354|DRUG|Hydrogel|Non-medicated self-healing hydrogel to be applied three times a day for 1 week
48469240|NCT06675890|DIAGNOSTIC_TEST|serum homocysteine|serum homocysteine is associated with atherosclerosis and vascular diseases.
48469241|NCT05316389|PROCEDURE|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
48469242|NCT04519879|OTHER|Clinical Observation|Undergo clinical observation
48469243|NCT04519879|OTHER|Patient Observation|Undergo active surveillance
48469244|NCT04519879|OTHER|Questionnaire Administration|Ancillary studies
48469245|NCT04519879|DRUG|White Button Mushroom Extract|Given PO
48469246|NCT05624762|DEVICE|Low-Intensity Focused Ultrasound (LIFU)|LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).
48469247|NCT05624762|DEVICE|Sham Low-Intensity Focused Ultrasound|Sham Low-Intensity Focused Ultrasound
48469248|NCT00564343|OTHER|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
48469249|NCT00212654|DRUG|ONO-1101|
48469250|NCT05332691|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
48617870|NCT03716960|OTHER|Placebo|This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
48628391|NCT00780039|DRUG|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
48106943|NCT00502372|DIETARY_SUPPLEMENT|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
48106944|NCT00502372|DIETARY_SUPPLEMENT|Juven|comparison of Juven with arginine only product in wound healing
48628392|NCT05946772|DRUG|Cyclosporine A|2.5mg/kg body weight Cyclosporine A as an intravenous bolus
48628393|NCT05946772|DRUG|Placebo|The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
48106945|NCT00844571|OTHER|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
48106946|NCT05712018|DRUG|Hydroxyethyl starch coload - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48106947|NCT05712018|DRUG|Hydroxyethyl starch coload - 5 ml/kg|5 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48284078|NCT04938648|BEHAVIORAL|Pharmacist-led deprescribing intervention|1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
48284079|NCT00430040|DRUG|Carvedilol Controlled Release (CR)|"lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80"
48284080|NCT00430040|DRUG|lisinopril|lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
48284081|NCT02957708|OTHER|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
48284082|NCT02957708|OTHER|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
48284083|NCT01664026|BEHAVIORAL|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
48284084|NCT01664026|BEHAVIORAL|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
48284085|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Amygdala|Low intensity focused ultrasound pulsation will be administered to the amygdala in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 10Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the amygdala and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
48284086|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Entorhinal Cortex|Low intensity focused ultrasound pulsation will be administered to the entorhinal cortex in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the entorhinal cortex and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
48284087|NCT04101812|DRUG|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
48284088|NCT04101812|DRUG|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
48284089|NCT03364998|DRUG|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
48284090|NCT03364998|DRUG|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
48284091|NCT00284115|DEVICE|Gait trainer|Mechanical gait repetitive training
48284092|NCT00284115|DEVICE|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
48284093|NCT04673838|OTHER|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
48617871|NCT00962767|DRUG|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
48617872|NCT00962767|DRUG|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
48617873|NCT05244096|OTHER|No intervention|Observational study
48617874|NCT03738215|DRUG|Cariprazine|Cariprazine supplied in capsules
48628394|NCT04957524|DEVICE|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
48628395|NCT00454402|DRUG|Alfuzosin|
48628396|NCT01691482|DRUG|Albuterol/salbutamol|Albuterol/salbutamol (daily)
48628397|NCT01691482|DRUG|Ipratropium|Ipratropium (daily)
48628398|NCT05444127|OTHER|Saliva samples|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
48628399|NCT05444127|OTHER|Questionnaire OHIP-14|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
48628400|NCT05444127|OTHER|Thorough dental examination|A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
48628401|NCT04240847|PROCEDURE|Skin incision|Skin incision on medial or lateral to tibial tubercle
48628402|NCT06421766|DEVICE|BAHS|Implantation of a percutaneous bone-anchored hearing system
48628403|NCT03161847|OTHER|Non-interventional study|Non-interventional study
48628404|NCT05225168|PROCEDURE|laparoscopic burch colposuspension operation|By pushing the urethra medially, two sutures are placed on the bladder at trigon level and midurethral and suspended on the bilateral iliopectineal ligament and colposuspension is supplied.
48628405|NCT05225168|PROCEDURE|minisling suburethral sling|A vertical vaginal incision is made 1 cm below the external urethral meatus. It is followed by minimal vaginal dissection from the inferior portion of the ascending ramus of the ischiopubic bone to the obturator muscle. The arms of the mesh are fixed on both sides of the obturator internus muscle with the help of a trocar. After leaving a 1-2 mm gap between the mesh and the urethra, the vaginal wall is closed by suturing.
48628406|NCT01622335|DRUG|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
48628407|NCT01622335|OTHER|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
48628408|NCT04453007|BEHAVIORAL|e-checkup to go|The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
48628409|NCT04453007|BEHAVIORAL|Feedback booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
48628410|NCT02591303|OTHER|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
48617875|NCT03738215|DRUG|Placebo|Placebo supplied in capsules
48617876|NCT00000142|DRUG|Cidofovir|"Three groups:~1. the deferral group, treatment deferred until retinitis progressed~2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
48628411|NCT02694250|DEVICE|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
48628412|NCT01168440|DRUG|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
48628413|NCT00000987|DRUG|Bleomycin sulfate|
48628414|NCT00000987|DRUG|Vincristine sulfate|
48628415|NCT00000987|DRUG|Doxorubicin hydrochloride|
48628416|NCT00000987|DRUG|Zidovudine|
48628417|NCT02817204|BEHAVIORAL|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
48100754|NCT04443452|DIAGNOSTIC_TEST|Function Assessment (B)|The 30-Second Chair Test is administered using a chair. The participant is seated in the middle of the chair with arms crossed at the wrists and held against the chest. The participant will practice a repetition or 2 before completing the test. If a participant must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand. The score is the total number of stands within 30 seconds (more than halfway up at the end of 30 seconds counts as a full stand). Incorrectly executed stands are not counted. The 30-second chair stand involves recording the number of stands a person can complete in 30 seconds rather than the amount of time it takes to complete a pre-determined number of repetitions.
48100755|NCT04443452|DIAGNOSTIC_TEST|Balance Assessment|Static balance and postural sway either in the medial-lateral or antero-posterior direction will be assessed using the RS Scan force plate. The participant will be asked to stand on the plate looking straight forward for 30 seconds in two conditions: first with their eyes open and then with eyes closed. Medial-lateral, antero-posterior and total sway will be recorded.
48100756|NCT00000433|DRUG|Anti-Tumor Necrosis Factor|
48628418|NCT02817204|BEHAVIORAL|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
48628419|NCT03508297|DIAGNOSTIC_TEST|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
48628420|NCT02386579|PROCEDURE|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
48628421|NCT01422902|OTHER|Plasticity-based Cognitive Training|
48628422|NCT01422902|OTHER|Non-plasticity-based Training|Computer games
48628423|NCT03536377|OTHER|very low calorie liquid diet|Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
48628424|NCT00409760|DRUG|valsartan+amlodipine combination, valsartan, amlodipine|
48628425|NCT03237091|OTHER|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
48628426|NCT03237091|OTHER|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
48628427|NCT03237091|OTHER|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
48628428|NCT03237091|OTHER|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
48628429|NCT03237091|OTHER|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
48628430|NCT00308282|DRUG|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
48628431|NCT00308282|DRUG|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
48628432|NCT02032784|DRUG|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
48628433|NCT02032784|OTHER|No Octreotide|No drug
48628434|NCT03269006|DEVICE|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
48628435|NCT03269006|DEVICE|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
48628436|NCT03269006|DEVICE|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
48628437|NCT03269006|DEVICE|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
48628438|NCT00990769|OTHER|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
48628439|NCT01446588|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
48628440|NCT00837460|OTHER|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
48628441|NCT03516500|DRUG|Iron Sucrose Injection|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
48628442|NCT06150443|OTHER|Osteopathic manipulative treatment (OMT)|Two osteopathic primary care physicians will performing osteopathic manipulative techniques with a minimum of three direct techniques focused on carpal tunnel. These techniques will include the interosseous membrane technique, the flexor retinaculum soft tissue technique, and the radiocarpal somatic dysfunction technique. They will also evaluate and treat the cervical spine, with particular attention to the C5-7 levels, all the way to the wrist and hand as they see fit based on the findings of their osteopathic structural exam.
48628443|NCT06150443|OTHER|Conservative treatment|Conservative therapy will be defined as including the use of splints, NSAIDs, opioids, and therapeutic injection of the carpal tunnel with steroids. Physical therapy will be excluded from the conservative therapy regimen.
48628444|NCT05581888|DEVICE|trifocal intraocular lens|Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
48628445|NCT00291226|DRUG|Glycine|Glycine 0.4 g/kg bid
48628446|NCT00291226|DRUG|Placebo|Placebo
48628447|NCT02686255|OTHER|complete blood count|complete blood count during follow up in the heart institute
48628448|NCT04732585|PROCEDURE|Physiotherapy or Surgery|"Physiotherapy: Guidelines suggest a tailored and progressive exercise program to improve muscle strength and control, joint mobility, and patient understanding of the problem and how to manage it. Additional interventions like tape or manual treatment can also be implemented but should not be exclusive~Surgery: ACL surgical reconstruction"
48628449|NCT02122523|PROCEDURE|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
48628450|NCT04179149|BEHAVIORAL|Environmental enrichment|The experimental group will participate in six modules that mimic and integrate the three hallmarks of EE: social interaction (more animals per cage = support group meetings, online support), novelty (toys and activities = exposure to new hands-on activities), and larger enclosures (larger cages = meetings in open environments). There will be 2 interventions per month, for three months, and a follow up 3 months after the end of the intervention
48628451|NCT04504760|DRUG|ONO-2910|Single ascending dose of ONO-2910 will be administered orally.
48628452|NCT04504760|DRUG|Placebo|Single dose of placebo will be administered orally.
47938013|NCT01005043|RADIATION|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
48628453|NCT04504760|DRUG|ONO-2910|Multiple ascending dose of ONO-2910 will be administered orally.
48628454|NCT04504760|DRUG|Placebo|Multiple dose of placebo will be administered orally.
48628455|NCT00557102|BIOLOGICAL|cetuximab|
48628456|NCT00557102|BIOLOGICAL|filgrastim|
48628457|NCT00557102|DRUG|fluorouracil|
48628458|NCT00557102|DRUG|irinotecan hydrochloride|
48628459|NCT00557102|DRUG|leucovorin calcium|
48628460|NCT06162234|OTHER|observational|none (observational study)
48469251|NCT06679335|OTHER|Lateralization Imagery Training|"Lateralization Imagery Training (LIE) is a form of implicit motor imagery that involves determining as accurately and quickly as possible whether an image of a body part belongs to the left or right side. It has been assumed that LIE performance differences reflect changes in central nervous system functioning, errors in judgment, and changes in bodily representations. It has been shown that LIE is a complex mental task that includes cognitive, sensory, motor and behavioral processes and can be associated with them. A study showed that there was a strong correlation between LIE and proprioception.~Within the scope of our study, 3 weeks of training will be provided; Lateralization imagery training will be given every day for the first 2 weeks, and imagery training will be given 3 days a week in the 2nd and 3rd weeks. A total of 20 sessions of treatment will be applied, including 14 sessions of lateralization and 6 sessions of visualization training."
47938014|NCT00510952|DRUG|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
47938015|NCT00510952|DRUG|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
47938016|NCT00367770|DRUG|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
48100757|NCT06630637|BEHAVIORAL|Glucose-Ketone Index (GKI) monitoring|Ketone and blood glucose monitoring with Abbott Optium Neo up to 10 times per day to observe GKI dynamics for gamification of adherence.
48469252|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
48469253|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
48469254|NCT00503113|DRUG|Alendronate|70mg per oral (po) weekly
48469255|NCT04158778|DRUG|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
48469256|NCT04158778|OTHER|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy.
48469259|NCT05079555|DEVICE|Robotic rehab|Patients using the robotic platform SWalker
48469260|NCT02332005|DRUG|diepalrestat choline|aldose reductase inhibitor
48469261|NCT02332005|DRUG|Placebo|Placebo
48469262|NCT06437028|OTHER|Dual-layer perinatal tissue allograft|The dual-layer perinatal tissue allograft is an amnion - amnion allograft
48469263|NCT06437028|OTHER|Three-layer fenestrated perinatal tissue allograft|The three-layer fenestrated perinatal tissue allograft is an amnion - chorion - amnion allograft
48100758|NCT06630637|BEHAVIORAL|Continuous Glucose Monitoring (CGM)|Monitoring with an Abbott Freestyle Libre to observe glucose dynamics for gamification of adherence.
48100759|NCT06630637|OTHER|Digital dynamometer|Grip strength measurements, right and left hand, up to 20 readings per day per hand.
48628461|NCT05858229|DRUG|RP1|Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-
48100760|NCT06630637|DEVICE|Wearables|All Apple Watch 9 and Whoop data daily \[heart rate variability (HRV), resting heart rate, cardio recovery, sleep duration, composition (stages of sleep) and analogous scores, potential maximum rate of oxygen consumption attainable during physical exertion (VO2 max), basal metabolic rate and potential respiratory rate\].
48100761|NCT06630637|DIAGNOSTIC_TEST|Blood tests|Pre- and Post-fast (48h) testing of lipid panel, ApoB, ApoA1, CRP, interleukin panel, omega 3:6 ratio, and autophagy analysis. Potential CBC, renal and liver panels to be taken where appropriate.
48628462|NCT00610038|DRUG|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
48628463|NCT04137887|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
48628464|NCT04137887|BIOLOGICAL|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
48628465|NCT00004032|BIOLOGICAL|ALVAC-hB7.1|Given IP
48628466|NCT00004032|BIOLOGICAL|recombinant interferon gamma|Given IP
48628467|NCT00004032|OTHER|laboratory biomarker analysis|Correlative studies
47938017|NCT05993975|DRUG|Bupivacain 0.5%|Bupivacaine hydrochloride was given without any adjuvant
48469264|NCT06437028|OTHER|Standard of care|Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.
48469265|NCT03826901|DRUG|delgocitinib|Cream for topical application
47938018|NCT05993975|DRUG|Dexmedetomidine Hydrochloride|Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
47938019|NCT06400927|OTHER|HF-guided VA|VA guided recommendation
47938020|NCT06400927|OTHER|Standard-of-care|Standard-of-care
48469266|NCT01310361|DRUG|Amoxicillin|
48617877|NCT04900272|BEHAVIORAL|VIPA and companion booklet|Participants will be asked to use the VIPA and accompanying second iteration of the instructional booklet focused on social-isolation. These participants will be surveyed over the phone for 16 weeks (baseline, 2 weeks, 4 weeks, 8 weeks, and 16 weeks) with outcomes measured at each time point.
48617878|NCT02084797|DRUG|V2R (Vasopressin 2 receptor)|All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
48628468|NCT05995366|DRUG|ABBV-903|Solution; Oral
48628469|NCT02298283|DRUG|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
48628470|NCT02298283|DRUG|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
48628471|NCT02298283|DRUG|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
48628472|NCT02298283|DRUG|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
48628473|NCT02298283|DRUG|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
48628474|NCT02298283|DRUG|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
48284094|NCT04673838|OTHER|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
48284095|NCT03314168|OTHER|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
48284096|NCT03314168|OTHER|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
48284097|NCT03999970|OTHER|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
48284098|NCT02626338|DRUG|Crenolanib|
48284099|NCT02626338|DRUG|Mitoxantrone|
48284100|NCT02626338|DRUG|Cytarabine|
48284101|NCT02626338|DRUG|Etoposide|
48284102|NCT02626338|DRUG|Fludarabine|
48284103|NCT02626338|DRUG|G-CSF|
48628475|NCT02298283|DRUG|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
48628476|NCT02298283|DRUG|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
47938021|NCT00912379|BIOLOGICAL|hemoglobin determination|laboratory and non invasive hemoglobin determinations
48284104|NCT02626338|DRUG|Idarubicin|
48284105|NCT00243737|DRUG|Artesunate-Mefloquine|
48284106|NCT02715271|PROCEDURE|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
48284107|NCT04352829|OTHER|VIDEO-TRAINING-SESSION ABOUT MDI USE|The steps were demonstrated with the brochure that illustrated correct inhalation techniques and were prepared by Turkish Respiratory Research Society-Inhalation Treatment Study Group in line with the literature and were described with a video that was designed by Turkish National Society of Allergy and Clinical Immunology (25). The video is provided with a free access on the webpage of Turkish National Society of Allergy and Clinical Immunology.The video included images that explained the steps about what to do before MDI use, how to use the device and the issues to which attention should be paid during the use of the device and focused on the skill-steps that should gradually be performed about MDI use.
48284108|NCT00366236|DRUG|Nitazoxanide|
48284109|NCT01091129|DEVICE|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
48284110|NCT03396081|BEHAVIORAL|PRADO-IC|"1. Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~2. Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure."
48284111|NCT03396081|BEHAVIORAL|No intervervention Usual Care|Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
48284112|NCT00337948|DRUG|Epoetin alfa|
48284113|NCT04057443|OTHER|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
48284114|NCT04057443|OTHER|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
48284115|NCT04057443|DRUG|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
48284116|NCT03783910|DRUG|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
48628477|NCT02298283|DRUG|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
48284117|NCT03783910|DRUG|Placebo|Placebo matching GRT9906 tablets
48284118|NCT05878509|OTHER|conducting questionnaires|The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.
48284119|NCT05878509|OTHER|assesment of the severity and pain|The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
48284120|NCT00576914|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
48284121|NCT02086773|BIOLOGICAL|Red blood cell transfusion|
48469267|NCT01310361|DRUG|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
48469268|NCT00559637|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
48469269|NCT04815434|OTHER|Interview|Interviews will be conducted.
48469270|NCT03022890|BEHAVIORAL|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
48469271|NCT03022890|BEHAVIORAL|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
48617879|NCT04575870|OTHER|waiting period|amount of time between clinical procedure and modified functional endoscopic exam of swallowing
48617880|NCT05743972|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
48100762|NCT06630637|DIAGNOSTIC_TEST|Stool tests|"15 g of stool will be collected from the subject pre- and post-fast for microbiome assessment and pre- and post- the first week (the three meal phase). After the first week, the maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast)."
48284122|NCT02054858|PROCEDURE|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
48284123|NCT05415579|OTHER|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
48284124|NCT03217760|PROCEDURE|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
48284125|NCT03217760|OTHER|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
48284126|NCT03217760|OTHER|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
48284127|NCT03217760|OTHER|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
48284128|NCT03217760|OTHER|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate \[HR\], systolic blood pressure \[SBP\], and diastolic blood pressure \[DBP\]) are monitored during each of the 6 steps.
48284129|NCT03217760|OTHER|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
48284130|NCT03217760|OTHER|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
47938022|NCT01466777|PROCEDURE|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
48284131|NCT03217760|OTHER|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
48284132|NCT03217760|OTHER|student preferences.|"When the treatment is complete the students are asked to report:~1. his/her level of satisfaction with the course of treatment,~2. whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~3. whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
48284133|NCT03754153|DEVICE|Balanced Binocular Viewing (BBV)|The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
48284134|NCT03754153|OTHER|Standard Therapy - Occlusion (patching) or blurring (atropine)|The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
48284135|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation A|
48469272|NCT04464603|DEVICE|InterFACE (mHealth tool)|"Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support."
48469273|NCT04464603|OTHER|Conventional methods|"Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool."
48469274|NCT06227091|DIETARY_SUPPLEMENT|Beetroot juice|acute dose of beetroot juice
48469275|NCT06227091|DIETARY_SUPPLEMENT|Placebo|depleted nitrate beetroot juice
48284136|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation B|
48284137|NCT05367661|DRUG|CHK336|Tablet
48469276|NCT06677684|DIETARY_SUPPLEMENT|Vitamin A|the intervention group received standard antibiotics plus adjunctive vitamin A supplementation (25,000 IU daily for two days)
48469277|NCT04984187|OTHER|high intensity laser plus exercise|high intensity laser plus exercise
48469278|NCT04984187|DEVICE|high intensity laser only|high intensity laser only
48469279|NCT04984187|OTHER|exercise|exercise only
48469280|NCT05540522|BIOLOGICAL|Quadrivalent influenza modRNA vaccine|Quadrivalent influenza modRNA vaccine (single dose)
48469281|NCT05540522|BIOLOGICAL|Quadrivalent influenza vaccine|Licensed quadrivalent influenza vaccine (single dose)
48469282|NCT05455164|DIETARY_SUPPLEMENT|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
48469283|NCT05958056|OTHER|Resistance exercise|The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.
47938023|NCT01466777|PROCEDURE|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
47938024|NCT02064075|DRUG|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
48284138|NCT05367661|DRUG|Placebo|Tablet
47938025|NCT02064075|DRUG|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
47938026|NCT05984849|BEHAVIORAL|vaccination games|Brief health games to promote two different vaccines among youth
48100763|NCT06630637|DIAGNOSTIC_TEST|Saliva tests|Saliva samples will be collected from the subject pre- and post-fast for microbiome assessment. Maximum number of tests is four per month (maximum of two fasts, with a pre- and post-fast test for each fast).
48100764|NCT06630637|BEHAVIORAL|Fitness intervention|90 minutes of strength and/or cardiovascular training for a minimum of 5 days per week.
48284139|NCT02063529|DRUG|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
48284140|NCT02063529|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
48284141|NCT02132221|BEHAVIORAL|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
48284142|NCT04151602|BEHAVIORAL|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
48284143|NCT05821543|DRUG|metformin+sibutramine|1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
48284144|NCT05821543|DRUG|sibutramine+ microcrystalline cellulose|1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
48284145|NCT04467112|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
48284146|NCT01999673|BIOLOGICAL|bavituximab|
48284147|NCT01999673|DRUG|Docetaxel|
48284148|NCT01999673|OTHER|Placebo (for bavituximab)|
48284149|NCT02515695|DRUG|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
48469284|NCT02520453|DRUG|Durvalumab|
48469285|NCT02520453|DRUG|Placebo|
48469286|NCT04850287|BEHAVIORAL|Digital Sensors for Population Awareness about Health Issues using Social Media|A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
48469287|NCT01560819|DRUG|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
48469288|NCT04355572|DRUG|Vitamin D 4000IU daily|Randomized to receive vitamin D 4000IU daily
47938027|NCT02925325|BEHAVIORAL|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
48284150|NCT01812525|DRUG|NaCl 3%|NaCl 3%: 4ml QID
48284151|NCT01812525|OTHER|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
48284152|NCT01940718|DRUG|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
48469289|NCT04355572|DRUG|Placebo|Randomized to placebo daily
48469290|NCT06218511|BIOLOGICAL|Peptide-based hepatocellular carcinoma vaccine IMA970A|IMA970A is a lyophilized multi-peptide vaccine consisting of 17 individual peptides (active pharmaceutical ingredients) and 2 excipients (Poloxamer 338 and Mannitol). All peptides have been chemically manufactured by well established solid phase peptide synthesis procedures. All peptides are composed of linear, unmodified L- amino acid chains with chain length in the range of 9 to 21 amino acids.
48469291|NCT06218511|COMBINATION_PRODUCT|Durvalumab|anti-PD-L1
48469292|NCT06218511|OTHER|Montanide (Adjuvant)|Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .
48100765|NCT06630637|BEHAVIORAL|Cold & heat intervention|"Cold plunge: at least 3 days per week, 2 sessions of maximum 5 minutes each (minimum 2 minutes between sessions) at a minimum of 6 degrees Celsius. Potential inclusion of GKI measurements before and after plunge.~Heat Therapy: maximum of 2 sessions of 20 minutes each of dry sauna blanket (minimum 5 minutes break between sessions) following the cold plunge intervention."
48469293|NCT06678217|OTHER|Stroop task|The Stroop task will be used as a mild, acute stressor since it has effects on anxiety and autonomic response. In each Stroop task condition, four coloured visual stimuli will be presented on a computer screen for 3 s with 7 s inter-stimulus interval. The stimuli will be coloured words naming the colour of the ink in the nonconflict task condition (e.g. GREEN written in green ink) and a different colour in the conflict task condition (e.g. GREEN written in red ink). The participants were asked to name the colour of the stimuli. The test will be administered using the online version of PsyToolKit (Stoet, 2021).
48469294|NCT06678217|OTHER|Cold pressor test|The participant lowers their hand in icy water to induce temporary tonic pain
48469295|NCT01923311|DRUG|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
48469296|NCT01923311|DRUG|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
48469297|NCT03845491|DEVICE|Mechanical Thrombectomy|Treatment of LVO with mechanical thrombectomy
48469298|NCT05312411|BIOLOGICAL|SCRI-E2CAR_EGFRtv1|Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
48469299|NCT05312411|DRUG|UB_TT170|Bispecific small molecule adapter formulated with phosphate buffered saline
47938028|NCT02925325|OTHER|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
47938029|NCT03549351|OTHER|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
47938030|NCT02274701|OTHER|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
47938031|NCT02142985|DRUG|Sodium Chloride 0.9% Intravenous|vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
47938032|NCT03302520|DEVICE|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
47938033|NCT03302520|DEVICE|PEEK cage|PEEK cage
48100766|NCT06630637|DEVICE|Airofit|"Airofit is a smart breathing training device designed to improve respiratory strength and efficiency. It is used for enhancing sport performance, well-being, and overall health. The device works by providing adjustable resistance to breathing muscles.~5-10 minutes of daily use."
48100767|NCT06630637|BEHAVIORAL|18h fasting|Minimum of 18 hours fasting per day, with feeding window to occur between 5pm-8pm or 12pm-3pm. The fasting procedures will occur only after the Three Meal Phase.
48100768|NCT06630637|BEHAVIORAL|48h fasting|48h fasting maximum twice monthly, at least one week apart. Multivitamin and electrolytes with water, and black coffee or tea (0-calorie drinks) will be consumed.The fasting procedures will occur the Three Meal Phase.
48469300|NCT01658358|DRUG|Lapatinib|"* dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily"
48469301|NCT01658358|DRUG|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
48469302|NCT04495959|DRUG|68Ga-HTK03149|PET/MRI scan with radiotracer 68Ga-HTK03149
48469303|NCT05610007|DRUG|Prilocaine|Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
48100769|NCT06630637|BEHAVIORAL|Three meal phase|During the first week of the study, the participant will follow a regime of three meals per day.
48469304|NCT03394833|OTHER|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
48469305|NCT04284553|OTHER|Order Entry|An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.
48628478|NCT02298283|RADIATION|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
48628479|NCT01374464|OTHER|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
48628480|NCT03780725|DRUG|BI 754111|Solution for infusion
48628481|NCT03780725|DRUG|[89Zr]Zr-BI 754111|Solution for infusion
48628482|NCT03780725|DRUG|BI 754091|Solution for infusion
48628483|NCT06021496|BEHAVIORAL|face to face health education|Face-to-face health education with home visit
48628484|NCT06021496|BEHAVIORAL|online health education|online health education with video call
48628485|NCT01617967|DRUG|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.
48628486|NCT06442969|OTHER|Education and resources provided by community health workers|The intervention will consist of implementing existing tools provided by EPA's Design for the Environment program, CalOSHA and NIOSH sector-specific guidance for agricultural workers, the Imperial County Department of Public Health and materials from California Department of Toxics Substances Control. The investigators will utilize and adjust existing educational tools such as the Heat Illness Prevention plan developed by CalOSHA. In addition to the educational materials, the investigators will give each farmworker cooling working gear to be worn during their work-shift with (specialized clothes that has been used in other occupational settings). The investigators will provide all participants with a low-cost fan filter, known as Corsi-Rosenthal box built jointly by the community health/research team to reduce chemicals at home, and a small A/C unit to reduce heat stress.
48628487|NCT04249635|DIETARY_SUPPLEMENT|DHA|Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
48628488|NCT02371252|DRUG|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
47938034|NCT03052933|DRUG|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
48628489|NCT03368430|DIETARY_SUPPLEMENT|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
48628490|NCT03368430|DRUG|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
48106948|NCT05712018|DRUG|Hydroxyethyl starch coload - 10 ml/kg|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48628491|NCT00000853|BIOLOGICAL|rgp120/HIV-1MN|
48628492|NCT04723069|DRUG|Control Group|metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
48628493|NCT04723069|DRUG|Test Group|metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
48628494|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
48469306|NCT04284553|OTHER|Open Encounter|An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
48469307|NCT04284553|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
48469308|NCT04284553|OTHER|Cold State outreach|An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
48628495|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
48628496|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
48628497|NCT00999206|BIOLOGICAL|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
48469309|NCT04284553|OTHER|Simplified|The alert language itself will be simplified.
48469310|NCT04284553|OTHER|Sign-off alert|An alert will display in the electronic health record when the medication is sent to sign-off for providers.
48469311|NCT04284553|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
48469312|NCT04284553|OTHER|Different Risks|Risks of the high-risk medications will be framed differently.
48469313|NCT04284553|OTHER|Standard Epic Basic Alert|This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
48469314|NCT04284553|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
48469315|NCT00781079|BEHAVIORAL|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
48469316|NCT00396955|DRUG|PLA-695|
48469317|NCT03772756|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
48469318|NCT03772756|RADIATION|chemoradiotherapy|Receive chemoradiotherapy
48469319|NCT04458467|DEVICE|Continuous Infusion|A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
48469320|NCT04458467|DEVICE|Automated Intermittent Boluses|Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
48469321|NCT00004188|BIOLOGICAL|filgrastim|Given IV
48469322|NCT00004188|DRUG|carboplatin|Given IV
48100770|NCT06630637|BEHAVIORAL|Mediterranean-inspired diet|"Regimen of Mediterranean-inspired nutrition comprised of Olive Oil, Olives, Leafy Green Vegetables, Lean Protein (Beef, Chicken, Lamb, Pork, Duck, Salmon, Tuna), Chia Seeds, Pecans, Macadamia, Pumpkin Seeds, Walnuts, Greek Yogurt, Salt, Pepper, Paprika, Cumin, Garlic powder, onion powder; Fruit: Blueberry, Grapefruit; Carbohydrates: Rolled Oats; Hydration: Water, Black Coffee, Black Tea, Coke Zero and 100 Zero sparingly, Ultima electrolytes.~Photographs of meals will be taken to create a visual record of the diet followed. Photographs of the devices will be taken to create a visual record of the blood glucose and ketone concentration results."
48284153|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
48469323|NCT00004188|DRUG|cisplatin|Given IV
48628498|NCT04614272|BEHAVIORAL|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
48628499|NCT04614272|BEHAVIORAL|Reading a poem|Reading is a distraction tool for pain management
48628500|NCT03977688|DEVICE|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
48628501|NCT00440024|DRUG|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
48628502|NCT00440024|DRUG|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
48628503|NCT00440024|DRUG|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
48628504|NCT03799120|DRUG|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
48469324|NCT00004188|DRUG|cyclophosphamide|Given IV
48469325|NCT00004188|DRUG|doxorubicin hydrochloride|Given IV
48469326|NCT00004188|DRUG|etoposide|Given IV
48469327|NCT00004188|DRUG|isotretinoin|Given IV
48469328|NCT00004188|DRUG|melphalan|Given IV
48469329|NCT00004188|DRUG|topotecan hydrochloride|Given IV
48469330|NCT00004188|DRUG|vincristine sulfate|Given IV
48469331|NCT00004188|PROCEDURE|autologous bone marrow transplantation|
48469332|NCT00004188|PROCEDURE|bone marrow ablation with stem cell support|
48469333|NCT00004188|PROCEDURE|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
48469334|NCT00004188|PROCEDURE|peripheral blood stem cell transplantation|
48469335|NCT00004188|RADIATION|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
48617881|NCT05743972|DIAGNOSTIC_TEST|Conventional ultrasound-guided core biopsy|Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
48617882|NCT02145858|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
48617883|NCT00593814|DEVICE|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
48628505|NCT03799120|OTHER|Placebo|Placebo
48617884|NCT02455193|BEHAVIORAL|Exercise|
48617885|NCT02455193|BEHAVIORAL|Diet|
48628506|NCT04484181|OTHER|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
48284154|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
48469336|NCT06492408|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
48469337|NCT00003404|RADIATION|Adjuvant Radiotherapy|Adjuvant radiation therapy
48469338|NCT06667141|DRUG|ACR-2316|ACR-2316 is an experimental drug
48469339|NCT05203146|DEVICE|PIMPmyHospital (mobile health tool)|Each participant will first be asked to retrieve a factious patient's laboratory results on the app when randomly made available, and then reach a colleague (role played by a study investigator) when asked to do so by a text message on the app.
48469340|NCT05203146|OTHER|Conventional method|Each participant will first be asked to retrieve a factious patient's laboratory results from the emergency department's computerized patient data system when randomly made available, and then contact a colleague (role played by a study investigator) when asked to do so (request made by a second study investigator).
48617886|NCT06027437|DRUG|Danicamtiv|Specified dose on specified days.
48617887|NCT00251472|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
48617888|NCT04179643|BIOLOGICAL|3 x 10e13vg NAN-101|There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
48628507|NCT04484181|OTHER|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
48628508|NCT03170921|OTHER|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
48628509|NCT03170921|OTHER|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
48628510|NCT03170921|OTHER|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
48628511|NCT01546298|OTHER|Patch tests|Patch tests for allergic reaction
48628512|NCT05998499|OTHER|Description|This study aimed to understand the situation of Latin American HIV-positive migrants seeking asylum in Spain and identify the challenges they encounter in getting HIV treatment. The main result measured was the proportion of participants with an HIV-1 RNA level of 50 copies/mL or higher at their first clinic visit
48628513|NCT04386837|OTHER|Turkish Aphasia Rapid Test|Same
48628514|NCT04116047|DRUG|Cisplatin|
48628515|NCT04116047|DRUG|Durvalumab|
48628516|NCT04116047|PROCEDURE|Radiotherapy|
48628517|NCT05540067|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
48284155|NCT02137668|DRUG|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
48628518|NCT05540067|OTHER|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
48628519|NCT01475500|PROCEDURE|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
48628520|NCT01475500|PROCEDURE|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
48284156|NCT06454968|DRUG|Orelabrutinib, obinutuzumab, lenalidomide|Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
48284157|NCT02975323|DRUG|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
48284158|NCT05646550|DRUG|CC-1 Infusion|Short term (3h) infusion of CC-1
48284159|NCT00003956|DRUG|fluorouracil|
48284160|NCT00003956|DRUG|leucovorin calcium|
48469341|NCT05352438|OTHER|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
48628521|NCT01475500|RADIATION|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
48628522|NCT01475500|OTHER|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
48628523|NCT01475500|PROCEDURE|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
47938035|NCT03052933|DRUG|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
48284161|NCT00003956|DRUG|lonafarnib|
48284162|NCT06091501|BEHAVIORAL|Lev Livet|"The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention."
48284163|NCT03783156|PROCEDURE|hot snare|polypectomy with hot snare
48628524|NCT01475500|PROCEDURE|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
48628525|NCT01475500|PROCEDURE|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
48628526|NCT01475500|PROCEDURE|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
48628527|NCT01475500|PROCEDURE|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
48628528|NCT01475500|PROCEDURE|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
48628529|NCT00398450|BIOLOGICAL|recombinant interferon alfa-2b|
48628530|NCT00398450|DRUG|azacitidine|
47938036|NCT03882775|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.
47938037|NCT03882775|DRUG|Heparin|heparin with or without gpi during emergency PCI.
47938038|NCT04732897|PROCEDURE|dynamic dressing|Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band
47938039|NCT02312882|DRUG|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
48106949|NCT04696250|DRUG|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
48628531|NCT03558672|DEVICE|Flexitouch system with Head and Neck Garments|Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed
48628532|NCT05008770|OTHER|No intervention|No intervention
48284164|NCT03783156|PROCEDURE|cold snare|polypectomy with cold snare
48284165|NCT00775567|DIETARY_SUPPLEMENT|Fructose powder|30g in 250ml water twice a day
47938040|NCT04710277|OTHER|Opioid-sparing multimodal pain management|Ice pack applied to abdominal incisions for 20 minutes every 2 to 3 hours for 24 hours after surgery and scheduled acetaminophen and NSAID for 96 hours after surgery. Narcotic pain medication for severe breakthrough pain.
48284166|NCT06411444|DEVICE|Grape Design Nasal Stent|Grape Design Nasal Stent
48284167|NCT03194425|DIAGNOSTIC_TEST|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
48284168|NCT00624338|DRUG|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
48284169|NCT00624338|DRUG|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
48284170|NCT00624338|OTHER|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
48284171|NCT04415138|DEVICE|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
48469342|NCT05352438|OTHER|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
48284172|NCT00404443|DEVICE|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
48469343|NCT00263627|BIOLOGICAL|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
48469344|NCT00263627|OTHER|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
48469345|NCT06002958|DEVICE|Horyzons USA|Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
48284173|NCT01152138|DEVICE|Open cells stent|Cobalt Chromium Stent with open cell design
48284174|NCT01152138|DEVICE|Closed Cells Stent|Cobalt Chromium stent with closed cell design
48284175|NCT03690791|DRUG|MediCabilis CBD Oil|50 mg of CBD: \<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.
48628533|NCT03238469|DEVICE|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
48628534|NCT06132997|PROCEDURE|Thoracoscopy procedure|is a minimally invasive endoscopic procedure utilized by pulmonologists to evaluate, diagnose, and treat pleural pathologies of the lung, mainly pleural effusions.
47938041|NCT04710277|OTHER|Usual care|Scheduled acetaminophen and NSAID for 24 hours after surgery. Narcotic pain medication for severe breakthrough pain.
47938042|NCT03030118|DRUG|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
47938043|NCT03030118|DRUG|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
48284176|NCT03690791|DRUG|Placebo Oil|Placebo will contain only hemp seed oil.
47938044|NCT01486485|DRUG|heparinized saline priming group|
47938045|NCT01486485|DRUG|nafamostat infusion after heparinized saline priming|
47938046|NCT05208307|BIOLOGICAL|Belantamab Mafodotin|Given IV
47938047|NCT05208307|DRUG|Dexamethasone|Given PO
47938048|NCT05208307|DRUG|Pomalidomide|Given PO
47938049|NCT05784961|DEVICE|tDCS|"tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6."
47938050|NCT03737851|DRUG|elezanumab|solution for infusion
47938051|NCT03737851|DRUG|placebo|solution for infusion
48284177|NCT03487224|DEVICE|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
48284178|NCT02680067|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
48284179|NCT02680067|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
48284180|NCT02320331|BEHAVIORAL|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
48284181|NCT03899740|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
48284182|NCT03899740|OTHER|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
48469346|NCT01093196|DRUG|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period \[different doses according to the age of patients (65-75 or \>75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
48469347|NCT01093196|DRUG|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
48469348|NCT01093196|DRUG|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
48469349|NCT04985955|DRUG|Tofacitinib|Tofacitinib tablet will be administered orally.
48284183|NCT03899740|OTHER|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
48469350|NCT06293391|PROCEDURE|cardiac indices in supine and trendelenburg position|Cardiac indices in supine and trendelenburg position in patients undergoing open or laparoscopic major cancer surgery
48628535|NCT06132997|PROCEDURE|Chest tube thoracostomy|Insert chest intercostal tube without thoracoscopy
48628536|NCT05520775|DRUG|Semaglutide|Semaglutide (subcutaneous)
48628537|NCT05520775|DRUG|Sham/placebo|Sham subcutaneous injection
48628538|NCT04076215|BEHAVIORAL|Stressogenic stimulus|Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
48628539|NCT04076215|DEVICE|Biobeat smart watch and adhesive biosensor patches.|Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
47938052|NCT04032574|COMBINATION_PRODUCT|Herbal Medicinal Product|
47938053|NCT04032574|OTHER|Placebo|
47938054|NCT01931670|OTHER|placebo|
48284184|NCT03899740|OTHER|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
48284185|NCT03832231|DEVICE|Shear Wave Elastography|Ultrasound technology to assess tissue stiffness
47938055|NCT01931670|DRUG|Elagolix|
47938056|NCT03571477|DEVICE|ApneaBand|Mesure of oxygen saturation (oximetry), pulse wave (photoplethysmography), electrodermal activity and movements (tri-axial accelerometer)
47938057|NCT01617148|DRUG|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
47938058|NCT01810965|PROCEDURE|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
48284186|NCT00221091|PROCEDURE|ventriculo-peritoneal shunt|
48284187|NCT04548310|OTHER|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
48284188|NCT00792766|DRUG|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
47938059|NCT02359162|DRUG|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
47938060|NCT02359162|DRUG|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
47938061|NCT02359162|DRUG|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
48284189|NCT00345111|PROCEDURE|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
48284190|NCT02237027|BIOLOGICAL|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
48284191|NCT02237027|BIOLOGICAL|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
48284192|NCT01006356|DRUG|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
48284193|NCT02339714|OTHER|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
48284194|NCT02339714|DRUG|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
48469351|NCT05312476|DRUG|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group)."
48469352|NCT02404857|DEVICE|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
48469353|NCT05922709|DRUG|CS12192 capsule|Participants receive CS12192 orally single or multiple doses
48469354|NCT05922709|DRUG|Placebo capsule|Participants receive placebo matching CS12192 orally single or multiple doses
48469355|NCT06679322|DRUG|Androtriol Injection (High-dose group)|Participants will receive 30 mL of Androtriol Injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
48469356|NCT06679322|DRUG|Androtriol Injection (Low-dose group)|Participants will receive 10 mL of Androtriol Injection combined with 20 mL of placebo (Hydroxypropyl Beta-Cyclodextrin Injection) per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
48469357|NCT06679322|DRUG|Hydroxypropyl-β-cyclodextrin injection|Participants will receive 30 mL of Hydroxypropyl-β-cyclodextrin injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be completed within 30±5 minutes.
48469358|NCT00260273|BEHAVIORAL|Cognitive Behaviour Therapy|therapy
48469359|NCT06468202|DRUG|Aspirin 81 mg|Participants will be assigned to 81mg Aspirin
48469360|NCT06468202|DRUG|Aspirin 162 mg|Participants will be assigned to 162mg Aspirin
48469361|NCT03278509|DRUG|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
48469362|NCT03278509|DRUG|Bisoprolol|Please see the section above.
47938062|NCT02359162|DRUG|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
47938063|NCT02359162|DRUG|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
47938064|NCT02359162|DRUG|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
47938065|NCT02359162|DRUG|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
47938066|NCT02359162|DRUG|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
47938067|NCT02359162|RADIATION|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
47938068|NCT03091972|PROCEDURE|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
47938069|NCT03091972|PROCEDURE|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
47938070|NCT03091972|PROCEDURE|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
48100771|NCT06630637|DIETARY_SUPPLEMENT|Supplements|Multivitamin (Centrum), Vitamin D (Up to 2000 IU per day), Creatine (Up to 2000mg), Fisetin (1 pill), Omega-3 (1 tablet), Turmeric, Pre-Probiotic, Blueberry Extract, Holy Basil Extract.
48284195|NCT04731064|PROCEDURE|HAL (Hemorrhoidal Artery Ligation) - RAR (Recto-Anal Repair)|The patient is operated on in the first perineal position, under general anesthesia or under locoregional or even local anesthesia, after rectal preparation by simple enema. The HAL equipment included a disposable transparent rectoscope fitted near its end with a centimeter window through which wire stitch ligatures will be made. A light source facilitating the exposure of the internal face of the rectum and a Doppler transducer secured to the base of the rectoscope containing the Doppler system. Everything is connected to a generator which transmits Doppler noises to the surgeon. A printer on the generator makes it possible to map ligatures and note the depth of linked arteries. Equipment includes needle holder, knot pusher, scissors and dissecting forceps. The material for HAL is identical, except for the disposable rectoscope which is more indented at its end and on one side.
48284196|NCT02655861|OTHER|Observation|
48284197|NCT04819828|PROCEDURE|Extracorporeal shock wave lithotripsy|A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
48100772|NCT06630637|BEHAVIORAL|Generative AI|Feeding ketone data, glucose data (from finger prick and/or CGM), any/all Apple Watch Data, and dietary images into a generative AI platform to convert data into images using any selected prompts, with the intent of the images serving as immediate, visual readouts as a function of activity and/or inactivity.
48284198|NCT04819828|DRUG|Diclofenac|Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
48284199|NCT04819828|DRUG|Tamsulosin|Oral tamsulosin (0.4 mg/day) for eight weeks.
48284200|NCT05088148|OTHER|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
48284201|NCT03304808|DEVICE|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
48284202|NCT03304808|BEHAVIORAL|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
48284203|NCT03540095|DRUG|Erector Spinae Plane Block|See arm description
48284204|NCT03540095|DRUG|Paravertebral Nerve Block|See arm description
48469363|NCT05974358|PROCEDURE|Kono-S anastomosis|Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis).
48100773|NCT06630637|OTHER|Interviews|Three interviews, of 30-60 minutes each one, at baseline, end of three meal phase and end of study, to gain insights into the participant's experience. Exploration of daily routines including diet, exercise and the use of technology and aspects of a healthy lifestyle.
48100774|NCT05547191|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
48100775|NCT04899284|OTHER|Early Intensive Bimanual Stimulation|Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
48106950|NCT00456274|PROCEDURE|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
48106951|NCT03450278|PROCEDURE|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
48106952|NCT00309452|BEHAVIORAL|Cognitive Behavioral Group Therapy|once per week
48106953|NCT00309452|BEHAVIORAL|Cognitive remediation|as needed
48106954|NCT00309452|DRUG|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
48106955|NCT00309452|BEHAVIORAL|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
48106956|NCT00309452|BEHAVIORAL|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
47938071|NCT06463678|DRUG|IVIEW-1201|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
47938072|NCT06463678|DRUG|NATACYN®|Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
47938073|NCT01212133|DRUG|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
48284205|NCT05539430|BIOLOGICAL|LB1908|Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells
48284206|NCT05294900|DRUG|paclitaxel/carboplatin|"Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5"
48284207|NCT04358393|DRUG|APG-115|APG-115 given once daily on day 1-5 of every 28 day cycle
48284208|NCT04358393|DRUG|5-azacitidine|5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
48284209|NCT01509027|BEHAVIORAL|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
48284210|NCT01509027|BEHAVIORAL|Standard care|standard care
48284211|NCT01509027|BEHAVIORAL|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
48284212|NCT02070432|DRUG|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
48284213|NCT02201823|DRUG|ABTL0812|ABTL0812. Five cohorts and one extension phase.
48284214|NCT03759652|BEHAVIORAL|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
48284215|NCT01928979|OTHER|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
48284216|NCT03972371|DEVICE|The ProVee Urethral Expander System|The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
48284217|NCT01587963|DRUG|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
48284218|NCT01587963|OTHER|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
48284219|NCT02473406|DRUG|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
48284220|NCT02473406|DRUG|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
48284221|NCT01956981|DRUG|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
48469364|NCT05974358|PROCEDURE|Conventional anastomosis for ileocolonicresection of Crohn's disease|conventional anastomosis for ileocolonicresection of Crohn's disease
48617889|NCT05232890|OTHER|Datterino tomato purée from hydroponic technology|Daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.
48469365|NCT05787392|BEHAVIORAL|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
47938074|NCT04073303|BIOLOGICAL|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
48469366|NCT01015417|DRUG|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
47938075|NCT04073303|OTHER|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
48469367|NCT01015417|OTHER|No medication|no postoperative antibiotics
48469368|NCT02573285|PROCEDURE|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
48469369|NCT02573285|PROCEDURE|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
48469370|NCT06678451|DRUG|Sugammadex|When T2 appeared, the sugammadex group was given 2mg/kg of sugammadex intravenously (adjusted body weight), the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
47938076|NCT06195761|PROCEDURE|computer guided modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide
47938077|NCT06195761|PROCEDURE|free hand modified ridge splitting technique in horizontal bone deficiency in posterior mandible|treatment plan includes manually harvesting and fixing the bone graft in posterior mandibular area without a surgical guide.
47938078|NCT00474682|DRUG|Micronized dispersible ferric pyrophosphate|
47938079|NCT00404703|DRUG|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
47938080|NCT00404703|DRUG|Platinum-based chemotherapy|As prescribed
47938081|NCT01010139|DRUG|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
47938082|NCT00660556|DEVICE|Archimedes Constant Flow Pump & System|Pump implanted in abdomen with intrathecal delivery (catheter) for pain.
47938083|NCT05504720|DRUG|Pembrolizumab|200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications
47938084|NCT05504720|DRUG|Trastuzumab|loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications
47938085|NCT05504720|DRUG|FLOT|Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
48284222|NCT01956981|DRUG|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
48284223|NCT03163342|BIOLOGICAL|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
48284224|NCT00308815|DEVICE|Automatic CPR machine|
48284225|NCT03469310|DRUG|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
48284226|NCT03469310|DRUG|Tylenol #3 Oral Tablet|Narcotic medication first
48284227|NCT03469310|DRUG|Tramadol|non-narcotic medication first with narcotic as second choice
48469371|NCT06678451|DRUG|Neostigmine|When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
48469372|NCT06347809|OTHER|Non-Interventional Study|Non-Interventional Study
48469373|NCT01150162|DRUG|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
48469374|NCT01150162|DRUG|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
48469375|NCT06608030|DRUG|Esketamine|A single dose of 0.3mg / kg esketamine during induction of anesthesia.
48628540|NCT02639026|RADIATION|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
48284228|NCT03540823|BIOLOGICAL|Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)|Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
48284229|NCT00650923|DRUG|ziv-aflibercept|Given IV
48284230|NCT00650923|PROCEDURE|radiation therapy|Undergo RT
48284231|NCT00650923|DRUG|temozolomide|Given PO
48469376|NCT06608030|DRUG|normal saline|Receiving the same volume of normal saline during induction of anesthesia.
48284232|NCT00650923|PROCEDURE|pharmacological study|Correlative studies
48284233|NCT00650923|PROCEDURE|laboratory biomarker analysis|Correlative studies
48469377|NCT06668116|DRUG|Ropivacaine 0,1%|"The study uses ropivacaine for nerve blocks, starting at 0.1% concentration and capped at 0.5% for safety. Concentration adjustments are made based on each participant's response 60 minutes post-injection:~* Increase by 0.025% if pain reduction is \<50%~* Increase by 0.025% if reduction is 50-75% without sensory/motor block~* Decrease by 0.025% if reduction is 50-75% with sensory/motor block~* Decrease by 0.025% if reduction is \>75%. Pain is assessed using a Numerical Rating Scale. The study employs Dixon's up-and-down method for five cycles to determine the optimal concentration for effective pain relief without significant numbness or weakness."
48469378|NCT06668116|OTHER|NaCl (placebo)|0.9 % NaCl solution (saline) injection
48469379|NCT04620941|DIAGNOSTIC_TEST|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
48469380|NCT02712294|OTHER|Neuromuscular Electrical Stimulation|
48469381|NCT06004934|DRUG|Avacopan|Administered orally.
48469382|NCT04340531|OTHER|Best Practice|Receive usual care
48469383|NCT04340531|OTHER|Survey Administration|Ancillary studies
48469384|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive referred to counseling session
48469385|NCT04340531|OTHER|Tobacco Cessation Counseling|Receive phone counseling
48469386|NCT04340531|OTHER|Training|Undergo training
48469387|NCT03482206|DEVICE|Automated extracranial internal carotid artery ultrasound sensor|The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
48628541|NCT02639026|DRUG|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
48469388|NCT05570630|BEHAVIORAL|VAX-MOM COVID-19 Intervention|The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
48469389|NCT05570630|OTHER|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
48469390|NCT02484430|OTHER|Laboratory Biomarker Analysis|Correlative studies
48469391|NCT02484430|OTHER|Pharmacological Study|Correlative studies
48628542|NCT02639026|DRUG|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
47938086|NCT06032481|PROCEDURE|surgery|Patients confirmed cervical cancer were undergone radical hysterectomy with pelvic lymphadenectomy
48284234|NCT05157425|DIETARY_SUPPLEMENT|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
48284235|NCT05157425|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
47938087|NCT06477224|OTHER|Scooter Board Activities|Participants in this arm engage in scooter board activities designed to improve neck control and address dysphagia. These activities include moving the scooter board in various directions using their hands or feet, maneuvering through obstacle courses, and engaging in playful tasks that require reaching or turning, which can enhance neck muscle strength and stability.
48284236|NCT06468579|DRUG|GT20029|Stage 1: GT20029 gel single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
48284237|NCT06468579|DRUG|GT20029 matching placebo|Stage 1: GT20029 gel matching placebo single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution matching placebo multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
48284238|NCT01517438|BEHAVIORAL|agitation|agitation score after desflurane anesthesia
48469392|NCT02484430|DRUG|Sapanisertib|Given PO
48469393|NCT06480604|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.
48469394|NCT06480604|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for the duration of the study (6 months).
48469395|NCT06078020|OTHER|Interview|Semi-structured interview to assess understanding and acceptability at 3+/-2 and 14+/-7 days after consent
48469396|NCT05473767|BEHAVIORAL|Family Check Up Heart|Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
48469397|NCT05473767|BEHAVIORAL|Family Check-Up|"The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being."
48469398|NCT06210685|DEVICE|Automatic Continuous Effusion Shunt implantation|The catheter pump chamber is placed with part of the chamber between adjacent ribs and part of the chamber under the skin and external to the ribs. The pump chamber is used to transfer pleural fluid into the peritoneal cavity.
48628543|NCT01433588|DEVICE|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
48628544|NCT01433588|OTHER|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
48284239|NCT03820115|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
48469399|NCT04687241|DRUG|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
48469400|NCT04687241|DRUG|Placebo Almonertinib|Placebo Almonertinib
48469401|NCT01207492|DRUG|nilotinib|Taken orally twice daily
48469402|NCT05642533|OTHER|No treatment given|No treatment given
48628545|NCT00454142|DRUG|pazopanib hydrochloride|Given PO
48628546|NCT00454142|OTHER|pharmacological study|Correlative studies
48628547|NCT00454142|PROCEDURE|computed tomography|Correlative studies
48628548|NCT03041870|DEVICE|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of \[11C\]DASB bolus.
48628549|NCT00440570|DEVICE|Low levels of amplitude-modulated electromagnetic fields|
47938088|NCT06477224|OTHER|Routine Physical Therapy|Participants in this arm receive traditional physical therapy interventions, which might include range-of-motion exercises, muscle strengthening, stretching exercises, and postural control activities. These exercises are aimed at improving overall motor function, with a focus on neck stability and control. Standard physical therapy equipment such as therapy balls, balance boards, and resistance bands may also be used.
48628550|NCT00440570|DEVICE|Emitter of low levels of amplitude-modulated electromagnetic fields|
48469403|NCT03710044|DRUG|Cyclosporine A|"Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks."
48469404|NCT06675227|DIETARY_SUPPLEMENT|electrolyte beverages|Using Electrolyte Beverages as replacement for water to dissolve PEG(2L plan) in bowel preparation process.
48469405|NCT03995550|DRUG|LEO 142397|A compound in development by LEO Pharma A/S
48628551|NCT02588534|DEVICE|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
48628552|NCT02588534|OTHER|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
48628553|NCT01398475|DRUG|LY3009104|Administered orally
48628554|NCT06447896|DEVICE|Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000)|"Cardiovascular autonomic reflex tests (CARTs) and heart rate variability analysis (HRV) are conducted with Cardiovascular Autonomic Nervous Function Multi-Parameter Evaluation System (Model: R6000). CARTs include five standardized tests, which are heart rate response to lying-to-standing, Valsalva maneuver, deep breathing, and blood pressure response to lying-to-standing and sustained isometric handgrip. These series of movements act as standardized stimuli to trigger hemodynamic changes in the body, altering vagal and sympathetic activity through mechanisms such as the baroreflex, thereby producing changes in heart rate and blood pressure. The sensor-monitoring interactive design of the device ensures the standardization of these maneuvers."
48100776|NCT06631703|OTHER|Group receiving Oral Colostrum Administiration|Description: Colostrum secreted in the first 3-5 days was oropharyngeal administered to the intervention group by withdrawing 0.2 ml of colostrum to be taken from the mother with the help of an insulin injector every three hours before each feeding meal in accordance with the literature.In the premature infants in the intervention group in which oropharyngeal colostrum was administered, the application was performed as follows: The oropharyngeal colostrum administration technique consists of slowly inserting a sterile 1 mL syringe without a needle with the tip of the syringe into the baby's mouth along the right buccal mucosa (0.1 mL) towards the oropharynx, then moving the syringe towards the inside of the cheeks and on the tongue, and repeating the same procedure on the left buccal mucosa (0.1 mL) without removing it (slow administration in approximately 1 minute). The routine feeding procedure was then continued
48100777|NCT02874261|DEVICE|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
48100778|NCT03333655|PROCEDURE|Biopsy|Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
48100779|NCT03761966|OTHER|Pregnant women|
48100780|NCT04747106|BIOLOGICAL|plasma exchange|when ADP inhibition \>30%, plasma exchange, once or twice a week, 1000-1500ml plasma was exchanged for each time
48469406|NCT03995550|DRUG|Placebo|Placebo
48469407|NCT03160079|DRUG|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
48469408|NCT03160079|DRUG|pembrolizumab|"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
48469409|NCT04413162|OTHER|Kinect motion tracking system|Kinect motion tracking system is used to measure shoulder range of motion compared to goniometric measurement.
48469410|NCT00402519|RADIATION|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
48628555|NCT06447896|DIAGNOSTIC_TEST|Conventional method of CARTs|Conventional method are conduced using blood pressure kit with manual sphygmomanometer and ECG machine. Conventional method and the investigated device are used simultaneously to record electrocardiograms. Conventional blood pressure taking are carried out in sequence with the investigated device. CARTs results from the conventional method are used as control.
48628556|NCT06447896|DEVICE|Ambulatory holter station Model i12 plus|Model i12 plus (manufactured by RENCARE) is an ambulatory holter station, which was approved by the Center for Medical Device Evaluation (CMDE), China National Medical Products Association (NMPA). It can analyze electrocardiogram and generate HRV indices, which include SDNN, RMSSD, NN50, pNN50, triangular index, average RR, deceleration capacity (DC), deceleration runs (DRs), VLF, LF, HF, LF/HF, and total power. Model i12 plus is used to analyzed the same ECG signals as the investigated device.
48469411|NCT00402519|RADIATION|External beam whole breast irradiation|Standard Whole breast irradiation
48469412|NCT02077881|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
48469413|NCT02077881|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
48617890|NCT05232890|OTHER|Datterino tomato puree from conventional cultivation|Daily intake of at least 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720 ml bottle.
48617891|NCT06028529|DEVICE|Exoskeleton|lightweight ground exoskeleton
48469414|NCT02077881|DRUG|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
48284240|NCT01152099|OTHER|Compression Bandaging|"Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
48469415|NCT01808248|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
48469416|NCT01808248|DRUG|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
48469417|NCT01808248|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
48469418|NCT06678399|DRUG|KELI-101|KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.
48469419|NCT06678399|OTHER|Vehicle (placebo)|Plasmalyte
48628557|NCT06358677|DRUG|Topical Tretinoin|Topical tretinoin will be applied to one half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
48469420|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for 7 days
48469421|NCT06641466|DRUG|Placebo Comparator|Matching placebo oral disintegrating tablets for 7 days
48469422|NCT06641466|DRUG|Standard of Care|Standard of care for acute treatment as needed
48469423|NCT06641466|DRUG|Rimegepant|Rimegepant 75 mg ODT for acute treatment as needed
48469424|NCT01362192|DEVICE|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~* Spot Size: 5 mm~* Fluence: 13-15 J/cm2~* Pulse Duration: 40 ms~* Epidermal contact-cooling: 5° Celsius"
48628558|NCT06358677|OTHER|Placebo|A placebo (topical moisturizer) will be applied to the other half of the face, either left or right side. The side the topical tretinoin will be applied to will be randomized.
48628559|NCT05025917|DIETARY_SUPPLEMENT|Shatavari|Shatavari root powder
48100781|NCT06473519|BIOLOGICAL|RSVpreF MDV|RSVpreF with 2-PE formulated in an MDV
48100782|NCT06473519|BIOLOGICAL|RSVpreF SDV|RSVpreF without 2-PE formulated in an SDV
48469425|NCT05874648|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
48469426|NCT04346654|DRUG|Eltrombopag|Eltrombopag is for oral use and comes in 25, 50 and 75 mg tablets. Prescribed dose is taken once daily.
48469427|NCT04346654|DRUG|Dexamethasone|Dexamethasone is for oral use and comes in 8 mg tablets. Prescribed dose is taken once daily.
48628560|NCT05025917|DIETARY_SUPPLEMENT|Magnesium stearate|Magnesium stearate powder
48628561|NCT00346528|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
48100783|NCT06631859|OTHER|Cosmetic products containing 0% Assam tea|Cosmetic products containing 0% Assam tea
48628562|NCT00346528|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
48628563|NCT04049565|DIAGNOSTIC_TEST|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
48628564|NCT05202496|DRUG|Calcitriol 0.25Mcg Cap|After orthodontic levelling and alignment, experimental group subjects are administered one capsule of calcitriol 0.25 mcg on a daily basis during the study period. Also, serum vitamin D levels are monitored at monthly intervals and rate of canine retraction is measured at monthly intervals
48469428|NCT00238563|DRUG|Triamcinolone injection, sub-tenon|
48469429|NCT04155827|OTHER|SIT|Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
47938089|NCT05408468|BEHAVIORAL|FAMCOPE-ICU|(1) FAMCOPE-ICU is a digital eHealth emotion regulation and coping intervention. FAMCOPE-ICU contains three digital modules representing the three interventional doses. Corresponding with Gross's Extended Process Model of Emotion Regulation, the three respective doses entail assessments, adaptive feedback, and interactive activities pertaining to understanding their affective experiences, learning strategies to regulate emotions and stress, and practicing these skills in a virtual decision-making task. Each dose of the intervention is expected to last 10-15 minutes
47938090|NCT03173534|DEVICE|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
48469430|NCT03400436|OTHER|No intervention in observational studies|No intervention in observational studies
48469431|NCT03981705|RADIATION|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
48469432|NCT02971813|BEHAVIORAL|Facebook|"1. Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~2. Participants will be given a baseline BREQ-3 survey and a PNSE scale.~3. Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~4. The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~   1. Educational posts will cover topics that will cover healthcare information.~  2. Provider support will be posted much like the educational posts.~5. The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~6. Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
47938091|NCT03173534|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
48469433|NCT00506116|BEHAVIORAL|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
48628565|NCT05202496|PROCEDURE|orthodontic treatment|experimental group subjects undergo orthodontic treatment after extraction of premolars
48100784|NCT06631859|OTHER|Cosmetic products containing 2.5% Assam tea|Cosmetic products containing 2.5% Assam tea
48100785|NCT03199417|DRUG|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
48100786|NCT03199417|OTHER|Placebo|An identically packaged placebo cream
48100787|NCT06454773|DIETARY_SUPPLEMENT|NCT/NFT|extract from black pepper and hemp hull
48100788|NCT04166682|BEHAVIORAL|Home-based cardiac rehabilitation|cardiac rehabilitation done at home
48100789|NCT04166682|BEHAVIORAL|Routine care|Routine care and followup
48100790|NCT06249633|DRUG|Nitric Oxide|Inhaled nitric oxide
48469434|NCT00506116|BEHAVIORAL|PME practice and record keeping (in diaries)|
48469435|NCT00506116|BEHAVIORAL|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
48469436|NCT00506116|PROCEDURE|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
48469437|NCT05659238|BEHAVIORAL|the effect on language development & attention|Tv \& other electronic devices effects onn children's language development \& attention
48628566|NCT06548243|BEHAVIORAL|Act with Nature Programme|The participants in the intervention group are offered a 12-week nature-based programme, which includes independent exercises and information on an online learning environment, as well as online or in-person group meetings.
48469438|NCT06677710|DRUG|IDP-023|NK cell therapy
48469439|NCT06677710|DRUG|Ocrelizumab|Anti-CD20 antibody therapy
48469440|NCT06677710|DRUG|Interleukin-2|Immune cytokine
48469441|NCT06677710|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
48469442|NCT06677710|DRUG|Fludarabine|Lymphodepleting chemotherapy
48469443|NCT06677710|DRUG|Mesna|Chemoprotectant
48469444|NCT06679257|DIAGNOSTIC_TEST|cell-free dNA|Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients
48469445|NCT01213407|DRUG|Trivax, Temozolomide, Surgery, Radiotherapy|"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
48617892|NCT02971826|DEVICE|REVIVETM SE thrombectomy|Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
48284241|NCT01152099|OTHER|Manual Lymph Drainage (MLD) and Compression Bandaging|"Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
48284242|NCT00513344|DIETARY_SUPPLEMENT|Dark Chocolate|1 portion
48284243|NCT00513344|DIETARY_SUPPLEMENT|Milk Chocolate|1 portion
48628567|NCT06420908|DRUG|Adebrelimab+TP/FP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage:~TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
48284244|NCT00513344|DIETARY_SUPPLEMENT|"Control (polyphenol-free) Chocolate"|one portion
48284245|NCT02580734|DIETARY_SUPPLEMENT|melatonin|Cross-over randomized clinical trials
48284246|NCT01923064|DRUG|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
48284247|NCT01923064|DRUG|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
48284248|NCT04133324|DIAGNOSTIC_TEST|C-reactive protein|C-reactive protein at postoperative days four and two.
48469446|NCT01213407|DRUG|Temozolomide, Surgery, Radiotherapy|"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
48469447|NCT03620617|DIETARY_SUPPLEMENT|Raspberry supplement|During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
48469448|NCT04288128|PROCEDURE|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
48469449|NCT04288128|OTHER|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
48469450|NCT04809506|BIOLOGICAL|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
48469451|NCT04012216|DEVICE|Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)|A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.
48284249|NCT05704530|OTHER|Blood sample|Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
48469452|NCT04012216|DEVICE|Gold standard: polysomnography|Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
48284250|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
48284251|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
47938092|NCT02398409|BEHAVIORAL|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
47938093|NCT02398409|OTHER|Control|8 week telephone usual care with education with nurse case manager
48100791|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of cochlear implant function|Because the subjects in the study will use CI devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of CI function. This will include perceptual tests of temporal discrimination and speech understanding.
48100792|NCT05554692|DIAGNOSTIC_TEST|Diagnostic tests of auditory function|The intervention here will be to carry out diagnostic tests of hearing. This will include perceptual tests of temporal discrimination and speech understanding.
48100793|NCT05632068|DRUG|Xian-Hua-Cha|Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
48100794|NCT04610294|DEVICE|Functioning Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status."
48100795|NCT04610294|DEVICE|Deactivated Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights."
48100796|NCT02771938|OTHER|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
48100797|NCT01985061|DRUG|BX2|
48100798|NCT01985061|DRUG|BX3|
48100799|NCT01985061|DRUG|BX4-Suspended|Suspended
48100800|NCT03778593|DRUG|5-Fluorouracil|D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
48284252|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
48284253|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
48284254|NCT05450068|OTHER|Mulligan's Mobilization with movement|The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
48628568|NCT06420908|DRUG|Adebrelimab+FP/TP+ radiation therapy|"Induction stage：~Adebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400 mg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;~Treatment stage: (switch to a different chemotherapy drug which not used during the earlier induction phase)~FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w Radiation therapy (50.4Gy-60Gy/28-33f);~Consolidation stage:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs."
48100801|NCT03778593|DRUG|Leucovorin|D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
48100802|NCT03778593|DRUG|Irinotecan|D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
48100803|NCT03778593|DRUG|Oxaliplatin|D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
48100804|NCT03778593|DRUG|5% dextrose water|mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
48100805|NCT05689047|DRUG|M5717 330 mg|Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
48100806|NCT05689047|DRUG|M5717 500 mg|Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
47938094|NCT00468767|DRUG|Vernakalant Injection 20 mg/mL|
48100807|NCT05689047|DRUG|M5717 660 mg|Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
48284255|NCT05450068|OTHER|Spencer's muscle energy technique|Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.
48284256|NCT05450068|OTHER|Conventional Therapy|Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
48284257|NCT05325112|DIAGNOSTIC_TEST|FFRCT|FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.
48284258|NCT04300725|OTHER|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
48284259|NCT01818349|OTHER|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
48469453|NCT05684796|DRUG|Anticoagulation|Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
48628569|NCT00663143|PROCEDURE|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
47938095|NCT06517108|PROCEDURE|Chuna therapy|"The chuna therapy group will receive chuna therapy based on the degree of displacement of the lumbar, ilium, sacrum, and cervical vertebrae. The type of weight or treatment is selected based on the clinical judgment of the Korean medicine practitioner (HVLA: high-velocity low-amplitude thrust, drop table manipulation, muscle energy techniques, myofascial release, etc.). The area and number of treatments performed are recorded separately. Thermotherapy is applied as an adjuvant treatment.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
47938096|NCT06517108|PROCEDURE|Physical therapy|"The physical therapy group will receive transcutaneous electrical nerve stimulation (TENS) for about 10 to 15 minutes, and the area and number of times it was administered will be recorded. Thermotherapy is applied as an adjuvant treatment, and the area and number of times it is applied are recorded separately.~The treatment will be administered between MCD 8 and MCD 28, twice a week during the 1st and 2nd cycle. The number of treatments can be adjusted depending on the patient's menstrual cycle and degree of displacement."
47938097|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
47938098|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
47938099|NCT00517803|DIETARY_SUPPLEMENT|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
48284260|NCT01818349|OTHER|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
48469454|NCT05684796|DEVICE|mechanical aspiration thrombectomy|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
48469455|NCT04124250|OTHER|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
48617893|NCT02598115|OTHER|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
48628570|NCT01641432|BEHAVIORAL|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
48628571|NCT01641432|BEHAVIORAL|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
48628572|NCT04726488|PROCEDURE|Periareolar Approach in Minimally Invasive Cardiac Surgery (PAMI Technique)|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
48628573|NCT04726488|PROCEDURE|inframammary approach|"To study the feasibility and safety of periareolar minimally invasive surgery protocol in patients undergoing periareolar minimally invasive surgery vs. Control group (inframammary approach)."
48628574|NCT01243424|DRUG|linagliptin|linagliptin tablets 5mg QD
48100808|NCT05689047|DRUG|Pyronaridine 360 mg|Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
48100809|NCT05689047|DRUG|Pyronaridine 360 mg|Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
48628575|NCT01243424|DRUG|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
48628576|NCT01243424|DRUG|linagliptin placebo|linagliptin placebo
48628577|NCT01243424|DRUG|glimepiride placebo|glimepiride placebo
48100810|NCT05689047|DRUG|Pyronaridine 540 mg|Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
48100811|NCT05689047|DRUG|Pyronaridine 720 mg|Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
48628578|NCT06165965|DRUG|SGLT2 inhibitor|SGLT2 dual inhibitor
48628579|NCT00940459|DEVICE|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
48628580|NCT00940459|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
48628581|NCT00940459|DEVICE|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
48628582|NCT00940459|DEVICE|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
48628583|NCT00940459|DEVICE|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
48284261|NCT01815398|BEHAVIORAL|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
48628584|NCT00940459|DEVICE|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
48628585|NCT04899128|DRUG|Pyrotinib|Pyrotinib-based therapy
47938100|NCT00517803|DIETARY_SUPPLEMENT|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
48628586|NCT03237663|BIOLOGICAL|The oral O1 / O139 cholera vaccine (enteric capsules)|
48628587|NCT03097471|DEVICE|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
48628588|NCT05298839|DIAGNOSTIC_TEST|Evaluation of core muscle endurance, hand grip strength, upper extremity functional performance, reaction time, agility performance and 3 minutes step test|"Core muscle endurance was evaluated with extensor muscle endurance test, flexor muscle endurance test and lateral muscle endurance test.~Hand Grip Strength was evaluated with Jamar hand dynamometer. Upper extremity functional performance was evaluated with health ball throwing test.~Reaction time was evaluated with Fitlight Trainer. Agility performance was evaluated with Pro-agility test. Cardiovascular endurance was evaluated with the 3-minute step test."
48628589|NCT05655988|DIAGNOSTIC_TEST|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
48284262|NCT01815398|BEHAVIORAL|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
48284263|NCT04421651|BEHAVIORAL|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
48284264|NCT00584350|OTHER|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
48284265|NCT00584350|OTHER|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
48284266|NCT00584350|OTHER|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
48284267|NCT02333838|DRUG|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
48628590|NCT02376335|BIOLOGICAL|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
48628591|NCT02376335|OTHER|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
48284268|NCT02333838|DRUG|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
48284269|NCT02333838|DRUG|IV Busulfan|(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
48284270|NCT02333838|DRUG|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
48617894|NCT02440867|DEVICE|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
48628592|NCT00490997|DRUG|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
48628593|NCT00490997|DRUG|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
48628594|NCT03787160|DIAGNOSTIC_TEST|initial VOC|Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
48617895|NCT02440867|DEVICE|Sham TBS|Sham stimulation
48617896|NCT04800627|BIOLOGICAL|Pembrolizumab|Given IV
48617897|NCT04800627|DRUG|Pevonedistat|Given IV
48617898|NCT01842204|DEVICE|Magnetic field therapy device|Therapy device for 1 week.
48617899|NCT01842204|DEVICE|Non magnetic field therapy device.|Non-active device for 1 week.
48617900|NCT03316105|DEVICE|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
48617901|NCT04542941|BIOLOGICAL|COVID Convalescent Plasma|Plasma collected from recovered COVID 19 individuals
48469456|NCT04334096|BEHAVIORAL|quality of life pathway|The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
48469457|NCT06298552|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
48628595|NCT03787160|DIAGNOSTIC_TEST|initial fecal microbiome|Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
48469458|NCT06298552|OTHER|Placebo IV|Intravenous infusion of placebo
48469459|NCT04848779|DRUG|Alglucosidase alfa GZ419829|"Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous"
48469460|NCT02245698|BIOLOGICAL|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
48469461|NCT02369354|BEHAVIORAL|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
48628596|NCT03787160|DIAGNOSTIC_TEST|initial pulmonary microbiome|Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
48628597|NCT03787160|DIAGNOSTIC_TEST|Maximum oxygen uptake|Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
48628598|NCT03787160|DIAGNOSTIC_TEST|Functional residual capacity|FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
48628599|NCT03787160|DIETARY_SUPPLEMENT|Probiotic treatment|CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
48628600|NCT03787160|DIAGNOSTIC_TEST|VOC probiotic|Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
48469462|NCT02369354|OTHER|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
48469463|NCT05103657|DRUG|BI 1358894|BI 1358894
48628601|NCT03787160|DIAGNOSTIC_TEST|Fecal microbiome probiotic|Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
48628602|NCT03787160|DIAGNOSTIC_TEST|Pulmonary microbiome probiotic|Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
48628603|NCT00535834|PROCEDURE|diagnostic procedure|
48628604|NCT00535834|PROCEDURE|molecular diagnostic method|
48469464|NCT05103657|DRUG|Placebo|Placebo
48469465|NCT03786354|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3DCRT
48469466|NCT03786354|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48469467|NCT00899535|GENETIC|DNA analysis|
48469468|NCT00899535|GENETIC|RNA analysis|
48628605|NCT00535834|PROCEDURE|protein expression analysis|
48628606|NCT00066937|DRUG|Nortriptyline Oral Capsule|Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
48628607|NCT00066937|DRUG|Benztropine Oral Product|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
48628608|NCT00066937|BEHAVIORAL|CBT|Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
48628609|NCT00066937|BEHAVIORAL|Disease MGT|Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
48628610|NCT03974958|GENETIC|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
48628611|NCT04935619|BEHAVIORAL|Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
48628612|NCT04935619|BEHAVIORAL|Non-Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
48628613|NCT04667429|OTHER|Food|HEC83518 40mg will be taken orally fasted or with food
47938101|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
48469469|NCT00899535|GENETIC|microarray analysis|
48628614|NCT04667429|DRUG|HEC83518|HEC83518 will be taken orally before sleep for 15 days
48628615|NCT04667429|DRUG|placebo|The placebo will be administered before sleep for 15 days.
48628616|NCT00981175|BIOLOGICAL|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
48628617|NCT00981175|BIOLOGICAL|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
48469470|NCT00899535|GENETIC|mutation analysis|
48469471|NCT00899535|GENETIC|polymorphism analysis|
48469472|NCT02587806|BIOLOGICAL|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
48469473|NCT02587806|OTHER|Liberation therapy|
48469474|NCT01843309|DRUG|Spironolactone 100mg|
48469475|NCT01843309|DRUG|Spironolactone 200mg|
48469476|NCT01843309|DRUG|Placebo|
48469477|NCT06223555|OTHER|Fixed Mixed Meal Test|a FIXED dose meal that will be 900 kcal of a liquid meal
48469478|NCT06223555|OTHER|Adjusted Mixed Meal Test|"a body weight ADJUSTED dose liquid meal.~(30% of total daily energy requirements)"
48469479|NCT01673841|PROCEDURE|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
48469480|NCT05891119|DIETARY_SUPPLEMENT|Caffeine|Oral liquid
48469481|NCT05891119|DRUG|Metoprolol|Oral tablet
48469482|NCT05891119|DRUG|Midazolam|Oral liquid
48628618|NCT00025311|DRUG|topotecan hydrochloride|
48628619|NCT04095936|DRUG|Romiplostim|Subcutaneous administration of 0 to 20ug/kg for 6 months
48628620|NCT01791296|DRUG|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
48284271|NCT06377189|OTHER|Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings|"The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases:~1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter.~2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions.~3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective."
48284272|NCT06377189|OTHER|Control Arm - Treatment As Usual (TAU)|PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
48469483|NCT05891119|DRUG|Warfarin|Oral tablet
48284273|NCT00812110|DRUG|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
48284274|NCT02571413|OTHER|score before teaching|score the check-point of correct INCS usage before teaching
48469484|NCT05891119|DIETARY_SUPPLEMENT|Vitamin K|Oral tablet
48284275|NCT02571413|OTHER|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
48469485|NCT05891119|DRUG|Omeprazole|Oral capsule
48469486|NCT05891119|DRUG|Rocatinlimab|Subcutaneous injection
48469487|NCT06359275|DRUG|PD-1|Toripalimab，240 mg/time，D1， Q3W
48469488|NCT06359275|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1，8, Q3W
47938102|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
48469489|NCT06359275|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，IV，D1，8，Q3W
48469490|NCT06359275|RADIATION|PULSAR|5-10 Gy per session, a total of 5 times.
48469491|NCT04439188|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
48469492|NCT01744964|DRUG|Apomorphine|1.5 mg Apomorphine
48469493|NCT03052855|OTHER|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
48617902|NCT01010100|DRUG|Acarbose (Glucobay, BAYG5421)|50 mg TID
48617903|NCT01010100|DRUG|Placebo|50 mg TID
48284276|NCT02571413|OTHER|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
48469494|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
48469495|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
48469496|NCT06386601|OTHER|Ergonomics Knowledge|Participants will participate in a lecture/module on surgical ergonomics
48469497|NCT06386601|OTHER|Ergonomics Feedback/Guided Practice|Participants will practice minimally invasive surgical skills while receiving feedback on ergonomic positioning/practice
48469498|NCT04957615|BIOLOGICAL|Nivolumab|Given IV
48469499|NCT02288351|OTHER|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
48469500|NCT02288351|OTHER|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
48469501|NCT02288351|OTHER|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
48469502|NCT02288351|OTHER|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
48617904|NCT05704712|BEHAVIORAL|Monetary Incentives|Monetary incentives, provided in the form of pre-loaded Visa debit cards are provided to encourage exercise.
48628621|NCT01791296|OTHER|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
48628622|NCT01028053|DRUG|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
48628623|NCT00856102|BEHAVIORAL|Exercise|Home-base walking program
48628624|NCT00856102|BEHAVIORAL|Control|Usual care
47938103|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
48284277|NCT05696340|OTHER|semi-structured interview|"Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation."
48284278|NCT01774916|GENETIC|blood samples|
48284279|NCT04847986|BEHAVIORAL|acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
48628625|NCT03827642|DRUG|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
47938104|NCT01920555|DRUG|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
47938105|NCT01920555|DRUG|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
47938106|NCT00003184|BIOLOGICAL|BCG vaccine|
47938107|NCT00003184|BIOLOGICAL|CD80 breast cancer vaccine|
47938108|NCT00003184|BIOLOGICAL|sargramostim|
47938109|NCT05806671|DRUG|Dalpiciclib|Dalpiciclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off
47938110|NCT05806671|DRUG|Pyrotinib|Pyrotinib 320mg/day orally continuously
48284280|NCT04847986|BEHAVIORAL|Control group|The control group will receive care as usual with psychoeducation materials provided.
48284281|NCT02900092|DRUG|Ganaxolone|Participants received ganaxolone
48469503|NCT02288351|OTHER|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
48469504|NCT02288351|DEVICE|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
48469505|NCT00344045|DRUG|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
48469506|NCT00344045|DRUG|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
48469507|NCT06257082|OTHER|Online Survey|Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.
48469508|NCT06336967|BEHAVIORAL|GUIDE|The GUIDE App is a wellbeing app designed for first responders and veterans that uses small group support, a learning management system, drivers of behavior change, and an anonymous member experience safeguarded by a leader in identity and login privacy, Okta (okta.com). It includes three main features: 1) Community, 2) Wisdom, and 3) Daily Practice. The Community feature connects app users with an online community of like folks, allowing for human support, encouragement, accountability and coaching. Online communities are moderated by GUIDE employees. The Wisdom feature includes tools and interactive media for personal growth. The Daily Practice feature includes simple, daily routines to maintain mental and emotional wellness.
48469509|NCT05795296|DRUG|Fruquintinib|Fruquintinib: 5mg po, d1-d14, q3w
48469510|NCT05795296|DRUG|Sintilimab|Sintilimab: 200mg ivgtt, d1, q3w
48469511|NCT00379158|DRUG|Micronutrient supplements|
48628626|NCT03827642|DRUG|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
48628627|NCT03827642|DRUG|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
48628628|NCT03827642|DRUG|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
48628629|NCT01149785|DRUG|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
48628630|NCT01149785|DRUG|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
48628631|NCT01149785|DRUG|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
48628632|NCT03878459|DRUG|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
48628633|NCT03878459|DRUG|Placebo|PATIENTS WILL RECEIVE PLACEBO
48628634|NCT00361244|DRUG|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
48628635|NCT00361244|DRUG|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
48628636|NCT00361244|DRUG|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
48469512|NCT05489796|DRUG|Fentanyl selector|Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
48469513|NCT05489796|DRUG|Fentanyl continuous|Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
48469514|NCT05489796|DRUG|Ketorolac continuous|Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
48628637|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
48628638|NCT02708173|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
48628639|NCT06257121|DEVICE|OSMS position management|Patient position management in real time during radiation using an optical Surface Management System (OSMS) (Vision RT)
48628640|NCT05100147|PROCEDURE|Uterine closure during Cesarean section|The uterotomy is sutured after the delivery of the fetus and the placenta with an appropriate delayed absorbable suture (number 1 polyglactin 910)
48628641|NCT01058005|DRUG|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
48628642|NCT01058005|DRUG|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
48628643|NCT01058005|DRUG|glatiramer acetate|20 mg subcutaneous injection once daily
48628644|NCT00025233|BIOLOGICAL|bevacizumab|Given IV
48469515|NCT06679205|BEHAVIORAL|Multidisciplinary and multimodal intervention|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of 2 parts: a 2-hour education session called Empowered Relief® and 2 1-hour pain neuroscience education sessions.~* Psychotherapy: The psychotherapy part consists of 1 group session of 1 hour, face-to-face and with groups of up to 15 people.~* Therapeutic exercise: The therapeutic exercise module consists of 3 sessions of 1 hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
48469516|NCT06679205|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
48469517|NCT05716100|DRUG|XEN1101|XEN1101 Capsules
48469518|NCT05716100|DRUG|Placebo|Placebo Capsules
48469519|NCT06628609|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
48469520|NCT06628609|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
48469521|NCT06628609|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
48469522|NCT06628609|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
48469523|NCT02833831|DRUG|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
48469524|NCT02833831|DRUG|Placebo|Matching Placebo will be administered.
48469525|NCT02833831|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
48469526|NCT06311019|DEVICE|Continuous glucose monitoring and use of connected insulinpen for bolus insulin|Continuous glucose monitoring (Abbott Freestyle Libre 2) and use of connected insulinpen (Novopen 6) for bolus insulin
48469527|NCT02867085|OTHER|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
48469528|NCT00008398|BIOLOGICAL|sargramostim|
48469529|NCT00008398|PROCEDURE|quality-of-life assessment|
48469530|NCT00008398|RADIATION|radiation therapy|
48469531|NCT00006034|BIOLOGICAL|keyhole limpet hemocyanin|Given intradermally and IV
48469532|NCT00006034|DRUG|doxorubicin hydrochloride|Given IV
48469533|NCT06256549|DRUG|GZR18|Titrated to low dose or middle or high dose
48469534|NCT06256549|DRUG|Semaglutide|Titrated to 1.0 mg once a week
48469535|NCT06679673|DRUG|SHR-1701|SHR-1701
48469536|NCT06679673|DRUG|BP102|BP102
48469537|NCT06679673|DRUG|SHR2554|SHR2554
48628645|NCT00025233|OTHER|laboratory biomarker analysis|Correlative studies
48469538|NCT02389595|OTHER|HIV positive subjects|This group will provide a blood sample.
48469539|NCT02389595|OTHER|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
48469540|NCT06069544|BIOLOGICAL|BNT165e|Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
48469541|NCT06069544|OTHER|Placebo|Isotonic NaCl solution (0.9%)
48469542|NCT00367536|DRUG|bazedoxifene/conjugated estrogens combination tablet|
48469543|NCT05440643|BIOLOGICAL|Peanut SLIT-tablet|Peanut extract
48469544|NCT05440643|OTHER|Placebo|Placebo
48469545|NCT00329160|DRUG|Rosuvastatin|2.5-20 mg
48469546|NCT00329160|DRUG|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
48469547|NCT05108259|DRUG|PBP1502|40 mg/0.4 mL single SC injection via PFS
48469548|NCT05108259|DRUG|EU-licensed Humira|40 mg/0.4 mL single SC injection via PFS
48469549|NCT05108259|DRUG|US-licensed Humira|40 mg/0.4 mL single SC injection via PFS
48469550|NCT05530850|BEHAVIORAL|Holistic Corrective Exercise Program|A holistic approach corrective exercise program including corrective exercises and postural perception training,
48469551|NCT05530850|OTHER|Thoracic exercise program|Thoracic region focused exercise program
48469552|NCT04817514|OTHER|Shoulder rehabilitation exercises and aerobic exercises|"SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines."
48469553|NCT03547830|DRUG|Plerixafor|Plerixafor for Conditioning before HSCT.
48469554|NCT03547830|DRUG|Gcsf|GCSF for Conditioning before HSCT.
48469555|NCT02874950|OTHER|office exercise training|The exercise group, did 6 months office exercise training.
48469556|NCT02874950|OTHER|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
48469557|NCT02874950|OTHER|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
48469558|NCT02874950|OTHER|Control|Control group did not do any exercise and did not follow any ergonomic modification.
48469559|NCT06513949|BIOLOGICAL|Atibuclimab|monoclonal antibody against human CD14
48469560|NCT06513949|OTHER|Placebo|Sterile normal saline for injection
48628646|NCT04964388|DRUG|GLP-1 receptor agonist|Diabetes medication
48628647|NCT03983005|PROCEDURE|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
48628648|NCT02063269|DRUG|Rivastigmine|9-18mg/rivastigmine for 52 weeks
48628649|NCT03745781|DRUG|Placebos|placebo pills
48628650|NCT02470767|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
48628651|NCT00890721|DRUG|SKY0402|During the operation, 30cc of SKY0402 are injected into the wound.
48628652|NCT00890721|DRUG|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
48628653|NCT00884598|DRUG|cilengitide|
48628654|NCT00884598|OTHER|pharmacological study|
48628655|NCT00884598|RADIATION|radiation therapy|
48469561|NCT01763554|DRUG|Lu-177 DOTA-TATE|The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
48469562|NCT01449409|OTHER|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
48628656|NCT00290238|DEVICE|Vertis Percutaneous Neuromodulation Therapy (PNT)|"* Ten PNT sessions in eleven weeks~* On average, one PNT session per week~* Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Continuous 50 Hz current~ * Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~ * Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
48628657|NCT00290238|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"* Ten TENS sessions in eleven weeks~* On average, one TENS session per week~* Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Current at 2 Hz-low frequency~ * Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~ * Intensity titrated according to subject's sensory threshold~ * To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
48628658|NCT01433770|DRUG|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
48284282|NCT01658800|BIOLOGICAL|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
48469563|NCT01559558|PROCEDURE|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
48469564|NCT03658148|PROCEDURE|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
48469565|NCT06429722|DRUG|NMRA-335140 80 mg|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
48628659|NCT05455866|DEVICE|central venous catheter|collection and descriptionof central venous catheter-related complications
48628660|NCT03422718|BEHAVIORAL|Healthy Behavior Texts|Participants receive motivational health behavior texts
47938111|NCT05806671|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle
48469566|NCT06429722|DRUG|Placebo|Placebo will be administered orally
48469567|NCT02593019|DRUG|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
48469568|NCT02861651|OTHER|DNA sequencing|
48469569|NCT06377449|DIAGNOSTIC_TEST|Ultrasound examination of the lungs|Experimental: Standard ultrasound examination of the lungs based on modified BLUE protocol Active Comparator: Standard ultrasound examination of the lungs based on modified BLUE protocol
48469570|NCT04837833|DIAGNOSTIC_TEST|ultrasound|Participants will undergo research ultrasound (rUS1) within three days of their routine CECT scan. A subset of participants (up to 10) will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT
48469571|NCT06230159|BEHAVIORAL|Non-menthol Cigarette Smoking|Smoke a non-menthol cigarette
48469572|NCT06230159|BEHAVIORAL|Menthol Cigarette Smoking|Smoke a menthol cigarette
47938112|NCT01525121|OTHER|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
47938113|NCT01997710|DEVICE|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
47938114|NCT01997710|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
48284283|NCT01419990|DRUG|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
48284284|NCT01419990|DRUG|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
48284285|NCT01419990|DRUG|Placebo|Placebo oral capsules, qd, 10 days
48628661|NCT03422718|BEHAVIORAL|No healthy behavior texts|Participants do not receive healthy behavior texts
48628662|NCT03422718|BEHAVIORAL|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
48628663|NCT03422718|BEHAVIORAL|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
48628664|NCT03422718|BEHAVIORAL|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
48284286|NCT06010667|DRUG|Envafolimab|With or without Envafolimab
48284287|NCT03669393|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
48469573|NCT06230159|BEHAVIORAL|Synthetic Cooling Agent Cigarette Smoking|Smoke a synthetic cooling agent cigarette
48469574|NCT06230159|BEHAVIORAL|Usual Brand Cigarette Smoking|Smoke usual brand cigarette
48469575|NCT06230159|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
48284288|NCT04373603|DRUG|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
48284289|NCT04373603|OTHER|Saline|sodium chloride and water for use as control
48469576|NCT06230159|OTHER|Questionnaire Administration|Survey questionnaires
48469577|NCT06230159|DIAGNOSTIC_TEST|Nasal Epithelial Lining Fluid|Nasal strip inserted into the nare to collect nasal epithelial lining fluid.
48469578|NCT01186016|BEHAVIORAL|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
48469579|NCT01186016|BEHAVIORAL|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
48469580|NCT06505122|BEHAVIORAL|Dyadic Life Review|DLR is an intervention that will promote relationship closeness, communication, and psychological distress in both older adults and caregivers.
48469581|NCT03201263|PROCEDURE|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
48469582|NCT03201263|PROCEDURE|Standard of care|Standard of care
48469583|NCT05676008|BEHAVIORAL|Microdosing of mindfulness|The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.
48469584|NCT05696041|OTHER|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
48469585|NCT05814393|DRUG|Treatment Period(JW0201)|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
48628665|NCT03422718|BEHAVIORAL|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
48284290|NCT04373603|DRUG|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
47938115|NCT03517488|BIOLOGICAL|XmAb20717|Monoclonal bispecific antibody
47938116|NCT05606653|OTHER|Measurement of critical airway closing pressure|Measurement of critical airway closing pressure
47938117|NCT05606653|OTHER|Respiratory function tests|CO2 response test
47938118|NCT05606653|OTHER|pharyngometry|measure of the pharyngometry
48284291|NCT04460703|OTHER|Control message|2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
48284292|NCT04460703|OTHER|Baseline message|3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.
48284293|NCT04460703|OTHER|Personal freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.
48469586|NCT05814393|DRUG|Treatment Period(Placebo)|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
48469587|NCT05814393|DRUG|Extension Period(JW0201)|JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
48469588|NCT06058039|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
48469589|NCT06058039|DRUG|Placebo|Placebo will be administered orally
48628666|NCT04352296|PROCEDURE|Individualized blood pressure|Individualized blood pressure management during mechanical thrombectomy with the administration of diluted norepinephrine (5-10 µg/ml) or nicardipine (1 mg/ml) or urpidil (5 mg/ml) to maintain the MAP within 10% of the first MAP measured in the angiography suit
48469590|NCT04619225|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
48469591|NCT04458168|BEHAVIORAL|Use of Purposeful app|"Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment."
48469592|NCT05829239|BIOLOGICAL|ADI-PEG20|Intramuscular injection weekly for 8 weeks
48469593|NCT05829239|OTHER|Placebo|Intramuscular injection weekly for 8 weeks
48628667|NCT04352296|PROCEDURE|Standard blood pressure|Standard blood pressure management based on international guidelines: Treatment of hypotension defined by a systolic blood pressure \<140 mm Hg, and treatment of hypertension defined by a systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>105 mm Hg) with usual treatments (norepinephrine, ephedrine or phenylephrine for hypotension; intravenous nicardipine or uradipil for hypertension).
48628668|NCT00092469|BIOLOGICAL|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
48628669|NCT06252337|OTHER|bioceramic sealer group|epoxy resin based + carrier based technique group. The sealer was inserted in the canal and the carrier was warmed in a dedicated oven (thermaprep) and inserted within 60 seconds.
48284294|NCT04460703|OTHER|Economic freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.
48284295|NCT04460703|OTHER|Self-interest message|1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
48628670|NCT04136301|OTHER|Informative Video group|Informative Video group before labor in nulliparous women
48628671|NCT05712382|BEHAVIORAL|Parent handbook|Handbook motivating parents to discuss alcohol use with their college student.
48628672|NCT05712382|BEHAVIORAL|Coping with negative emotions|Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
47938119|NCT00291733|DRUG|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
47938120|NCT00291733|DRUG|Placebo|Placebo tabl
48469594|NCT04587167|OTHER|Project ECHO|"Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice."
48284296|NCT04460703|OTHER|Community interest message|1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
48284297|NCT04460703|OTHER|Economic benefit message|1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.
48284298|NCT04460703|OTHER|Guilt message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.
48469595|NCT04587167|OTHER|Announcement Approach Training|Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.
48628673|NCT05712382|BEHAVIORAL|Problem-solving risky situations|Identifying and planning for barriers to change are encouraged.
48628674|NCT05712382|BEHAVIORAL|Recovering from slips|Peer and personalized techniques are discussed to facilitate resumption of moderate drinking after a heavy drinking episode.
48628675|NCT00622063|DRUG|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
48628676|NCT02669108|DEVICE|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
48628677|NCT01294072|DIETARY_SUPPLEMENT|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
48628678|NCT01294072|DIETARY_SUPPLEMENT|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
48628679|NCT01294072|OTHER|No intervention|no treatment
48628680|NCT00153920|DRUG|bortezomib|
48628681|NCT01276418|DEVICE|CO2 laser|Ablation and coagulation of soft tissue
48628682|NCT03915379|DRUG|JNJ-67571244|JNJ-67571244 will be administered.
48469596|NCT04587167|OTHER|Recall notices|Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
48469597|NCT05072821|DRUG|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
48469598|NCT05072821|DRUG|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
48284299|NCT04460703|OTHER|Embarrassment message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.
48469599|NCT05049772|BEHAVIORAL|Telerehabilitation-based motor imagery training|10 weeks of motor imagery training and stabilization exercises.
48469600|NCT05049772|BEHAVIORAL|Stabilization exercises group|10 weeks of stabilization exercises.
48469601|NCT06448754|DRUG|Volrustomig|Participants will receive volrustomig via intravenous (IV) infusion.
48628683|NCT04764253|BEHAVIORAL|Modified Sodium Watcher Program + Digital Self-Monitoring|Participants randomized to the experimental group will be asked to follow the modified Sodium Watchers Program intervention along with goal setting for low salt foods. Each participant will be registered to assign a unique ID in the Connected Health Platform developed by the Center on Smart and Connected Health Technologies at UT Health Science Center San Antonio and each account from the individuals' wireless and wearable devices (Fitbit and BP monitor) will be connected to his or her unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor. Through the Connected Health Platform, the Fitbit app and BP monitor will transmit the data of the intervention group to the research team.
48628684|NCT04764253|BEHAVIORAL|Usual care + Digital Self-Monitoring|Participants randomized to the control group will be asked to follow usual care which is based on their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium-restricted diet and take medications as prescribed. The participants will receive wireless and wearable devices (Fitbit wristband, BP monitor). Each participant will be registered to assign a unique ID in the Connected Health Platform at the baseline and each account from the individual's wireless and wearable devices (Fitbit and BP monitor) will be connected to their unique ID through this platform. Participants will be instructed to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
47938121|NCT03092804|PROCEDURE|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
47938122|NCT01887093|BEHAVIORAL|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
47938123|NCT06134609|BEHAVIORAL|Sexual intercourse|Sexual intercourse without barrier contraceptive at the evening/night after the embryo transfer
48469602|NCT06448754|DRUG|Carboplatin|Participants will receive carboplatin via IV infusion.
47938124|NCT01661816|BEHAVIORAL|interview|psychological, emotional, family and social parameters
47938125|NCT02430506|BIOLOGICAL|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
47938126|NCT02430506|BIOLOGICAL|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
47938127|NCT03895762|DRUG|Abstral Oral Disintegrating Tablet (ODT)|Opioid(Fentanyl)
47938128|NCT05803980|PROCEDURE|Fecal microbiota transplantation (FMT)|Single FMT infusion via colonoscopy
47938129|NCT04596553|DIETARY_SUPPLEMENT|Essential Amino Acid|Immediately following the exercise intervention participants will consume their assigned essential amino acid supplement
47938130|NCT04596553|DIETARY_SUPPLEMENT|Collagen Peptide|Immediately following the exercise intervention participants will consume their assigned collagen peptide supplement
47938131|NCT04596553|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Immediately following the exercise intervention participants will consume their assigned maltodextrin supplement
48469603|NCT06448754|DRUG|Pemetrexed|Participants will receive pemetrexed via IV infusion.
48469604|NCT04339595|BIOLOGICAL|Tildrakizumab|Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.
48469605|NCT01570231|DEVICE|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
48469606|NCT00005887|DRUG|efaproxiral|
48469607|NCT00005887|RADIATION|radiation therapy|
48469608|NCT00481026|DEVICE|transcranial direct current stimulation (tDCS)|tDCS
48469609|NCT00481026|DEVICE|active tDCS|Active tDCS
48469610|NCT02600208|BIOLOGICAL|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
48469611|NCT06393764|OTHER|Collection of biological samples|Collecte of blood and urine samples
48469612|NCT03206151|DRUG|CMAB009|for injection only
48628685|NCT03426007|PROCEDURE|Uterine lavage|embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
48628686|NCT04396275|OTHER|Food-1|Cooked whole navy beans (300 kcal)
48628687|NCT04396275|OTHER|Food-2|Cooked whole yellow split peas (300 kcal)
48628688|NCT04396275|OTHER|Food-3|Cooked rice considered as control (300 kcal)
48628689|NCT05872126|PROCEDURE|VATS-Surgical pleurodesis|VATS drainage and surgical abrasion.
48628690|NCT05872126|PROCEDURE|Tube Drainage|Tube drainage for malignant pleural effusion
48628691|NCT01456923|OTHER|Treatment with chemotherapy|
48628692|NCT01456923|OTHER|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
48628693|NCT01456923|PROCEDURE|surgery|
48628694|NCT04015687|DRUG|AG-881|Supplied as uncoated tablets.
48628695|NCT04015687|DRUG|Lamotrigine|Supplied as tablets of LAMICTAL® or generic equivalent.
48628696|NCT00477724|BEHAVIORAL|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
48628697|NCT00477724|OTHER|sedentary control group|control group with no specific training
48628698|NCT01941056|BIOLOGICAL|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
48628699|NCT01941056|OTHER|laboratory biomarker analysis|Correlative studies
47938132|NCT04633343|OTHER|Small volume breath and fast breathing rate for 5 minutes|Small volume breath and fast breathing rate delivered via mechanical ventilator.
47938133|NCT04633343|OTHER|Large volume breath and slow breathing rate for 5 minutes|Large volume breath and slow breathing rate delivered via mechanical ventilator.
47938134|NCT01943708|DEVICE|SPAP|Novel Auto-algorithm for Auto-CPAP device
48469613|NCT03206151|DRUG|Irinotecan|for injection only
48469614|NCT03206151|DRUG|Folinic acid|for injection only
48469615|NCT03206151|DRUG|5-fluorouracil|for injection only
48469616|NCT00623558|DRUG|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
48469617|NCT00623558|DRUG|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
47938135|NCT01943708|DEVICE|CPAP|Standard CPAP therapy
47938136|NCT00331253|PROCEDURE|Indocyanine Green-Mediated Photothrombosis|
47938137|NCT05314491|DEVICE|Multigen Plus CCK|Total Knee Arthroplasty
47938138|NCT05314491|DEVICE|AMF TT cones|To fill a proximal tibia or distal femur defect
48469618|NCT00623558|DRUG|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
48469619|NCT05002777|DRUG|rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
48469620|NCT05218109|DEVICE|tVNS|transcutaneous vagus nerve stimulation
48469621|NCT05218109|BEHAVIORAL|Mindfulness|Brightmind mobile mindfulness application
48469622|NCT05218109|DEVICE|sham tVNS|sham transcutaneous vagus nerve stimulation
48469623|NCT05218109|OTHER|Number Puzzle|Control number puzzle task delivered via mobile device
48469624|NCT05649722|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
48469625|NCT05649722|DRUG|Placebo|Oral placebo inhalation using a capsule-based dry powder inhaler device.
48469626|NCT01663467|DRUG|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
48469627|NCT01663467|BEHAVIORAL|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
48469628|NCT04505826|DRUG|OP-1250|Complete Estrogen Receptor ANtagonist (CERAN)
48469629|NCT04174118|DRUG|belcesiran|belcesiran will be administered subcutaneously (SC) at dose levels planned.
48469630|NCT04174118|DRUG|Placebo|Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
48628700|NCT02955927|DRUG|0.01% atropine eye drops|
48628701|NCT02955927|DEVICE|ortho-k|
48628702|NCT05391074|DIETARY_SUPPLEMENT|postbiotics (IGENH35.3A)|postbiotics to induce microbiota epigenetic factors
48628703|NCT05391074|DIETARY_SUPPLEMENT|vitamins (AREDS formulation and recommended daily dose)|vitamins (AREDS to prevent AMD progression
48628704|NCT01483651|DRUG|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
48628705|NCT01483651|DRUG|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
48628706|NCT03537677|BEHAVIORAL|Reduction in Sedentary Behavior|This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
48469631|NCT01921335|DRUG|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
47938139|NCT04688879|PROCEDURE|intra-arterial urokinase thrombolysis|Under local anaesthesia, the right femoral artery was punctured in accordance with the Seldinger technique, and a 6-Fr sheath, 10 cm in length, was implanted. Selective catheterization of the SMA was performed with 4-Fr catheter. The SMA angiography was performed to identify the filling defect. Thrombolysis was performed using a 5-Fr multiple-sideport infusion catheter (100cm with sideport of 7cm, 14 ports or 100cm with sideport of 15cm, 30 ports, Cook, Bloomington, IN, U.S.A). The tip of the microcatheter was embedded in the thromboembolism, which was fragmented at the time of thrombolysis. Thrombolysis was performed locally in the SMA with a bolus of urokinase
48100812|NCT05689047|DRUG|Pyronaridine-artesunate (Pyramax) 360 mg/120 mg|Participants with weight \>=24 to \<45 kg will receive dose of 360/120 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
48469632|NCT01921335|DRUG|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
48469633|NCT01921335|DRUG|Trastuzumab|6 mg/kg IV every 3 weeks
48469634|NCT05348395|OTHER|Experimental diet|Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
48469635|NCT06154837|DRUG|GSK3862995B|GSK3862995B will be administered.
48469636|NCT06154837|DRUG|Placebo|Placebo will be administered.
48469637|NCT06280417|DEVICE|Unreamed intramedullary tibial nail|Fixation of type IIIa tibial fractures by unreamed IMN
48469638|NCT04220775|DRUG|Bintrafusp Alfa|Given IV
48469639|NCT04220775|OTHER|Quality-of-Life Assessment|Ancillary studies
48469640|NCT04220775|OTHER|Questionnaire Administration|Ancillary studies
48469641|NCT04220775|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48100813|NCT05689047|DRUG|Pyronaridine- artesunate (Pyramax) 540 mg/180 mg|Participants with weight \>=45 to \<65 kg will receive 540/180 mg dose of Pyronaridine-artesunate (Pyramax) tablets under fasting condition.
48100814|NCT05689047|DRUG|Pyronaridine-artesunate (Pyramax) 720 mg/240 mg|Participants with weight \>=65 kg will receive 720/240 mg dose of Pyronaridine- artesunate (Pyramax) tablets under fasting condition.
48100815|NCT01802203|DEVICE|truFreeze Spray Cryotherapy|spray cryotherapy
48100816|NCT03817736|PROCEDURE|TACE|Procedure of TACE will be standardized.
48100817|NCT03817736|RADIATION|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
48469642|NCT04479735|DEVICE|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
48469643|NCT01831986|DIETARY_SUPPLEMENT|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
48469644|NCT01831986|OTHER|Placebo|Caps
48469645|NCT00838981|DRUG|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
48100818|NCT03817736|DRUG|Immune Checkpoint Inhibitor|An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
48469646|NCT00838981|DRUG|Sugar Pill|placebo, sugar pill will mirror active drug
48100819|NCT00942149|DRUG|Daptomycin|single dose of 6 mg/kg of daptomycin
48100820|NCT04346888|DRUG|HBM9161 Injection (680mg and 340 mg)|HBM9161 Injection (680mg and 340mg)
48100821|NCT04346888|DRUG|Placebos|Placebo, HBM9161 Injection (340mg)
48100822|NCT04346888|DRUG|HBM9161 Injection (340 mg)|HBM9161 Injection (340 mg)
48100823|NCT00432653|DRUG|rituximab|
48100824|NCT00076180|BIOLOGICAL|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
48100825|NCT00207844|DRUG|Selenium as sodium selenite|
48100826|NCT00764413|DRUG|methylprednisolone|1 gram intravenous a day for 3 days
48100827|NCT00764413|DRUG|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
48469647|NCT00838981|BEHAVIORAL|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
48469648|NCT00838981|DRUG|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
48469649|NCT00838981|BEHAVIORAL|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
48469650|NCT00838981|BEHAVIORAL|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
48628707|NCT01366105|DEVICE|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
48628708|NCT02441699|BEHAVIORAL|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
48628709|NCT05442892|PROCEDURE|Multicomponent exercise training programme|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
48628710|NCT03706352|PROCEDURE|tunneling epidural catheter|The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
48628711|NCT04520100|BEHAVIORAL|Clinical Hypnosis performed by the PI|The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
48628712|NCT04520100|BEHAVIORAL|Care by technician trained in empathic communication|The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
47938140|NCT06387160|DRUG|as per institutional protocol|This is an observational study. Treatment will be given to the patients as per institutional protocol
47938141|NCT00930982|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
48469651|NCT04302337|PROCEDURE|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
48469652|NCT04302337|PROCEDURE|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
48469653|NCT05683860|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
47938142|NCT00930982|DRUG|Placebo|Inhalation of matching placebo twice a day
48469654|NCT03023709|BIOLOGICAL|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
48469655|NCT03023709|BIOLOGICAL|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
48469656|NCT06428851|OTHER|Laser therapy|Shoulder girdle muscles were lasered for 5 minutes a day, 3 days a week, total of 4 weeks.
48469657|NCT06428851|OTHER|Neuromuscular electrical nerve stimulation|Neuromuscular electrical nerve stimulation was applied to the shoulder flexor and abductor muscles for 20 minutes a day 5 days a week, total of 4 weeks.
48469658|NCT06428851|OTHER|Control|Classical physical therapy exercises were applied according to the patient's needs and neurologic level. These exercises are determined by the physiotherapist according to the functional status of the patient and consist of passive, passive assisted, active range of motion exercises, stretching and strengthening exercises, mobilization exercises 5 days a week for 1 hour, total of 4 weeks.
48469659|NCT04021758|BEHAVIORAL|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
48628713|NCT03464838|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
47938143|NCT03494777|BEHAVIORAL|Incentivization based on high adherence|When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.
47938144|NCT03494777|BEHAVIORAL|Incentivization based on timely clinic visit|When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.
48628714|NCT03464838|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
48628715|NCT03934307|DRUG|ALN-AGT01|ALN-AGT01 will be administered by subcutaneous (SC) injection.
48628716|NCT03934307|DRUG|ALN-AGT01-Matching Placebo|Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
48469660|NCT05488119|BEHAVIORAL|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
48469661|NCT06678048|DRUG|Arsenous Acid plus Chemotherapy|Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine
48469662|NCT06001762|DRUG|Abemaciclib|CDK4 and CDK6 inhibitor, tablet taken orally
47938145|NCT03494777|BEHAVIORAL|Annual adherence prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.
48469663|NCT06001762|DRUG|Tamoxifen|Selective estrogen receptor modulator, taken orally per institutional standard of care
48469664|NCT06001762|DRUG|Anastrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
48628717|NCT03934307|DRUG|Irbesartan|Irbesartan will be administered orally.
48469665|NCT06001762|DRUG|Letrozole|Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
48628718|NCT03934307|DRUG|Irbesartan-Matching Placebo|Irbesartan-matching placebo will be administered orally.
48628719|NCT04291833|BEHAVIORAL|Intervention group 1|Protein supplementation BID, Vitamin D and calcium supplementation Vitamin D 2000 IU / d, calcium 1000mg/d, exercise 6 months
48628720|NCT04291833|BEHAVIORAL|Intervention group 2|Protein supplementation QD, Vitamin D and calcium supplementation Vitamin D 1000 IU / d, calcium 500mg/d, exercise 3 months
48628721|NCT04291833|BEHAVIORAL|Control group 0|no protein supplementation , no Vitamin D and calcium supplementation , no exercise
47938146|NCT03494777|BEHAVIORAL|Annual viral suppression-based prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.
48469666|NCT06001762|DRUG|Exemestane|Steroidal aromatase inhibitor, taken orally per institutional standard of care
48469667|NCT06001762|DRUG|LHRH Agonist|Luteinizing hormone-releasing hormone agonist), taken orally per institutional standard of care
47938147|NCT03494777|BEHAVIORAL|Year 2 booster|Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.
48469668|NCT06193200|DRUG|Dexamethasone sodium phosphate|Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
48469669|NCT06193200|OTHER|Placebo|Placebo encapsulated in autologous erythrocytes and administered via IV infusion
48628722|NCT02053116|DRUG|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
48628723|NCT02053116|DRUG|Placebo|Tablet, 0 mg, twice daily, 2 weeks
48628724|NCT02919605|DRUG|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
48628725|NCT02919605|DRUG|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
48628726|NCT02919605|DRUG|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
48628727|NCT05551221|DRUG|Silodosin Capsules|Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.
47938148|NCT03435640|DRUG|NKTR-262|"During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262."
47938149|NCT03435640|DRUG|bempegaldesleukin|"During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles."
48284300|NCT04460703|OTHER|Anger message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.
48469670|NCT05814068|DRUG|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
48469671|NCT06400238|PROCEDURE|Biopsy|Undergo biopsy
48469672|NCT06400238|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47938150|NCT03435640|DRUG|nivolumab|During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
47938151|NCT04568343|DEVICE|Capsule endoscopy|We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
47938152|NCT02394002|DRUG|Propofol|
48284301|NCT04460703|OTHER|Trust in science message|1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.
48469673|NCT06400238|PROCEDURE|Computed Tomography|Undergo CT scan
48469674|NCT06400238|DRUG|Copanlisib|Given IV
48469675|NCT06400238|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48469676|NCT05104502|BEHAVIORAL|Dietary Fasting|"The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed)."
48469677|NCT06679049|PROCEDURE|micromotion intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal tibial interlocking screw
48628728|NCT05551221|DRUG|Ningmitai capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
48469678|NCT06679049|PROCEDURE|standard intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal interlocking screw
48469679|NCT02094261|DRUG|AZD9291|Once daily tablet 80 mg
48469680|NCT06239844|OTHER|Experimental: Nav-Team|Participants in this arm will receive additional assistance related to asthma, log encounters, complete surveys.
48469681|NCT00702793|DRUG|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
48628729|NCT05551221|DRUG|Tamsulosin|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
48628730|NCT04145934|BEHAVIORAL|ADSTEP|ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
48628731|NCT01083472|DEVICE|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
48628732|NCT01083472|PROCEDURE|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
48628733|NCT06210295|COMBINATION_PRODUCT|Laboratory investigtions|To study causes of anemia in SLE in our environment and causes of refractory type and its relation to bone marrow affection and different drugs used in SLE
48628734|NCT06177353|OTHER|Sampling|Blood sampling Skin biopsy Collection of soiled bandages
48469682|NCT00676650|DRUG|Prednisone|5 mg BID, oral
48628735|NCT05265754|BEHAVIORAL|sujok therapy|sujok therapy
48628736|NCT02714959|DRUG|Proleukin|
48469683|NCT00676650|DRUG|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
48469684|NCT00676650|DRUG|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
48469685|NCT00676650|DRUG|Prednisone|5 mg BID, oral
48469686|NCT06029439|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
48469687|NCT00578838|OTHER|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
48469688|NCT00578838|OTHER|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
48469689|NCT03316222|DRUG|GNS561|Escalating doses to be administered 3 times a week.
48469690|NCT06591182|OTHER|Survey using a questionnaire.|Observational study, participants are not assigned an intervention as part of the study (Survey using a questionnaire).
48469691|NCT05442437|BIOLOGICAL|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
48469692|NCT02793713|PROCEDURE|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
48628737|NCT05758792|OTHER|Muscle Quality Index|Evaluations are applied to older adults to compare the results of muscle quality.
48469693|NCT06332092|DRUG|FID007|Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
48469694|NCT04172545|PROCEDURE|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
48469695|NCT06678815|OTHER|Emergency response|Those delivering or receiving emergency care from a CFR.
48469696|NCT01133236|DIETARY_SUPPLEMENT|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
48469697|NCT02010996|PROCEDURE|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
48628738|NCT03059342|PROCEDURE|single event multilevel surgery|
48284302|NCT04460703|OTHER|Not bravery message|1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
48284303|NCT06246682|PROCEDURE|Transcanal Endoscopic removal of atticoantral cholesteatoma|removal of the cholesteatoma presented in the atticoantral region by otoendoscope
48284304|NCT04087499|DEVICE|Acupuncture|acupuncture treatment on selected acupoint
48628739|NCT06060886|DRUG|Aripiprazole|Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
47938153|NCT03859206|OTHER|Medical thoracoscopy|• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken \& If no lesion, biopsy from parietal pleura was obtained from any sites.
48628740|NCT06060886|DRUG|Paliperidone|Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
48628741|NCT00222261|DRUG|aspirin|Aspirin 160 mg once daily for two years
48628742|NCT00222261|DRUG|clopidogrel|clopidogrel 75 mg once daily for two years
47938154|NCT00867477|PROCEDURE|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
48100828|NCT03321760|RADIATION|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
48284305|NCT04535063|BIOLOGICAL|COVID19 convalescent plasma infusion|intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
48284306|NCT01309516|BEHAVIORAL|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
48469698|NCT02010996|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
48469699|NCT04234061|COMBINATION_PRODUCT|ibrutinib and Tisagenlecleucel|Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
48469700|NCT02004067|DRUG|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
48469701|NCT02004067|DRUG|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
48469702|NCT01876953|DRUG|cytarabine|Given IV
48469703|NCT01876953|DRUG|idarubicin|Given IV
48469704|NCT01876953|DRUG|dasatinib|Given PO
48469705|NCT01876953|OTHER|laboratory biomarker analysis|Correlative studies
48469706|NCT06325124|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of hamstring and gastro-soleus. Frequency: 10 reps 3 times/week for 4 consecutive weeks Intensity starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
48628743|NCT00530075|DRUG|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
48628744|NCT01574560|BEHAVIORAL|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
48469707|NCT06325124|OTHER|Conventional PT|"They would be receiving treatment as follow:~Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
48469708|NCT00033436|DIETARY_SUPPLEMENT|niacinamide|
48469709|NCT00033436|DRUG|carbogen|
48469710|NCT00033436|RADIATION|radiation therapy|
48628745|NCT01574560|BEHAVIORAL|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
48628746|NCT06158880|BEHAVIORAL|Alcoholic Beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
48284307|NCT02997514|BEHAVIORAL|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
48628747|NCT06158880|BEHAVIORAL|Non-alcoholic Beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
48628748|NCT06158880|BEHAVIORAL|Partner Negative Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
48628749|NCT06158880|BEHAVIORAL|Partner Positive Mood Manipulation|Participants will engage in a laboratory task and will then report their own and their partner's emotions following the task.
48628750|NCT05301777|DEVICE|Computed tomography|Computed tomography
48628751|NCT00694122|DRUG|Lantus (glargine)|Described in Arm Description
48628752|NCT00298194|DRUG|Z-338|
48628753|NCT04948125|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
48628754|NCT04948125|DRUG|Apatinib Mesylate|250 mg qd
48628755|NCT03718000|DEVICE|Daily self-weighing (DSW)|DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
48628756|NCT01590615|DRUG|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
48628757|NCT00127010|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
47938155|NCT00867477|BEHAVIORAL|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
48469711|NCT04767087|DRUG|Honey|0.5 gm/Kg/day honey
48628758|NCT06139640|OTHER|Damask Rose Essential Oil|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
48628759|NCT02663505|PROCEDURE|Patients receiving the surgery planned for them|"For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient."
48628760|NCT02292225|DRUG|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
48628761|NCT02292225|DRUG|Obinutuzumab|1000mg/40mL single-use vials
48628762|NCT02810327|GENETIC|Genetic Sequencing|Sequencing of the SERPINA1 gene
48628763|NCT05331482|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
48628764|NCT05331482|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with conventional training protocol.
48628765|NCT04881721|PROCEDURE|Urethropexy|Suture based (Mesh-free) surgery to stabilize the urethra for the treatment of stress urinary incontinence
48469712|NCT04767087|DRUG|Nigella sativa seed|40 mg/Kg/day
48628766|NCT04071483|PROCEDURE|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
48628767|NCT03939832|OTHER|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
48628768|NCT03607695|OTHER|Gait training|Walking on a treadmill and receiving audio cues to improve gait
48628769|NCT03664141|DRUG|Cannabis oil|Treatment with cannabis oil
48628770|NCT03664141|DRUG|Placebo/ Regular Oil|Treatment with placebo (Regular Oil)
48628771|NCT02369692|DEVICE|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
47938156|NCT00867477|PROCEDURE|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
48100829|NCT00502593|BIOLOGICAL|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
48100830|NCT00502593|BIOLOGICAL|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
48469713|NCT04767087|OTHER|Placebo|empty capsule with sugar water
48469714|NCT00374166|DRUG|SSR149415|Oral administration (capsules of 50 and 100 mg)
48469715|NCT00374166|DRUG|Placebo|Oral administration (capsules)
48469716|NCT00374166|DRUG|Paroxetine|Oral administration (capsules)
48469717|NCT05955469|DEVICE|FS4 then TFS4 (cochlear implant)|Cochlear implant with default fitting then with tonotopy-based fitting
48469718|NCT05955469|DEVICE|TFS4 then FS4 (cochlear implant)|Cochlear implant with tonotopy-based fitting then with default fitting
48469719|NCT03509285|DRUG|Alprazolam Placebo|100 mg lactose tablets
48469720|NCT03509285|DRUG|Cenobamate placebo|Sugar pill manufactured to mimic cenobamate 100 mg tablet
48469721|NCT03509285|DRUG|Alprazolam|0.5 mg and 1.0 mg alprazolam tablets
48469722|NCT03509285|DRUG|Cenobamate|100 mg tablet
48469723|NCT06216574|OTHER|Internet-based Intervention|Receive access to SHINE modules
48469724|NCT06679751|BEHAVIORAL|ID-TOUCH|ID TOUCH is a multi-pronged intervention to increase HIV testing and PrEP linkage that includes jail-based HIV care process improvements with post-incarceration outreach and linkage to community services.
48469725|NCT05260034|OTHER|FAST Program|This program aims to teach how to effectively reduce impact forces during a sideways fall by 1) changing the trunk/knee angles during descent to decrease body acceleration, 2) using a rolling movement to allow for an optimal distribution of impact forces applied to any site along the contact path; and 3) tucking the chin to protect the head.
48469726|NCT05260034|OTHER|Otago Exercise Program|The Otago Exercise Program (OEP) was chosen, rather than no control intervention, to increase the level of evidence required to demonstrate efficacy, and because, similar to the safe fall training used here, it was designed to be performed individually or in small groups.
48469727|NCT05259709|DRUG|89Zr˗DFO˗REGN5054|Administered by intravenous (IV) infusion during Part A and B.
48469728|NCT05259709|DRUG|cemiplimab|Administered by IV infusion every 3 weeks (Q3W).
48469729|NCT05525676|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
48469730|NCT05525676|BEHAVIORAL|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 \& 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
48628772|NCT02673385|OTHER|Brazelton scale|
48628773|NCT04377386|DIETARY_SUPPLEMENT|1000 IU D vitamin|Participants in the intervention group will receive 105 DV doses of 1000 IU. The supplementation will be given by the Farma de Colombia laboratory, known commercially as Farma D, whose presentation is in soft gelatin capsules. It is recommended to take one dose per day at the same time and participants should record the daily intake time of the supplement for 15 weeks on a calendar.
48628774|NCT04377386|DIETARY_SUPPLEMENT|200 IU D vitamin|Participants in the control group will receive 105 DV doses of 200 IU. The supplementation will be given by the same laboratory; it will have the same characteristics and recommendations for the intake as for the intervention group.
48469731|NCT03097939|DRUG|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
48469732|NCT03097939|DRUG|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
48469733|NCT00464113|DRUG|XL228|1-hour IV infusion
48628775|NCT02079870|DRUG|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
48628776|NCT02079870|DRUG|placebo|Solution for subcutaneous (s.c. - under the skin) injection
48628777|NCT05698212|DIAGNOSTIC_TEST|MetriDx|Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
48628778|NCT02492919|DEVICE|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
48628779|NCT00021255|DRUG|Doxorubicin|
48628780|NCT00021255|DRUG|Cyclophosphamide|
48628781|NCT00021255|DRUG|Docetaxel|
48628782|NCT00021255|DRUG|Herceptin|
48628783|NCT00021255|DRUG|Carboplatin|
47938157|NCT01253330|OTHER|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
47938158|NCT01409759|PROCEDURE|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
47938159|NCT05022446|OTHER|Survey Administration|Complete survey
47938160|NCT03099070|BEHAVIORAL|Stress|Trier Social Stress Test
47938161|NCT03099070|OTHER|Fasting|12-hour fasting prior to study visit
48100831|NCT00731211|DRUG|Pazopanib|800 mg of pazopanib orally each day continuously
48100832|NCT00465751|DRUG|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
48100833|NCT00465751|DRUG|placebo capsules|placebo capsules containing mannitol tid po
48100834|NCT01879371|DRUG|Ibuprofen+caffeine FDC|oral dose
48100835|NCT01879371|DRUG|Ibuprofen (Nurofen Immedia®)|oral dose
48628784|NCT02909647|PROCEDURE|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
48628785|NCT02909647|PROCEDURE|Osteosynthesis|osteosynthesis using volar locking plate
48628786|NCT00875667|DRUG|Lenalidomide|"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
48628787|NCT00875667|DRUG|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
48469734|NCT06343688|OTHER|"Assessment of Balance and Lower Extremity Gross Motor Function with and without DAFO"|"Measurements will be conducted with the child's custom-made DAFO (Dynamic Ankle-Foot Orthosis) and barefoot."
48628788|NCT02407015|OTHER|Nintendo 3DS gameplay|
48628789|NCT02781701|DEVICE|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
48628790|NCT05771623|DEVICE|Iontophoresis drug delivery device|"Botulinum toxin type A (Botox Allergan ®, Irvine, CA, USA) is used. 100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 4 U/0.1 mL) is being administered once a month for a total period of three months.~The dose will be adjusted to 2.5 U/cm2 of the scar. The dose shouldn't exceed 100 units per session.~This can be done through the Iontophoresis drug delivery device. Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months)."
48628791|NCT05771623|BEHAVIORAL|Traditional physical therapy|Traditional PT: Stretching, deep friction massage and pressure therapy (2 times per week for 3 months).
48628792|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
48628793|NCT01104012|BIOLOGICAL|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
48628794|NCT03447795|PROCEDURE|Alveolar ridge preservation|grafting procedure using autogenous tooth.
48628795|NCT00299221|DRUG|Tacrolimus|tacrolimus
48628796|NCT00299221|DRUG|combination therapy|MMF
48628797|NCT02169999|OTHER|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
48628798|NCT05277259|DEVICE|Extracorporeal Shock Wave Therapy|Device named 'Elettronica Pagani,Italy' and will be used with radial probe.
48628799|NCT05277259|OTHER|Kinesiotaping|Elastic band to be used to stretch the upper trapezius muscle in the desired direction.
48628800|NCT05277259|OTHER|Conventional Physical Therapy|Conventional physical therapy will be consisted of hotpack, therapeutic ultrasound and tens applications.
48628801|NCT00232154|DRUG|Zithromax&#153; (azithromycin) 500mg tablets|
48628802|NCT00232154|PROCEDURE|Endoscopic Sinus Surgery|
48628803|NCT00232154|PROCEDURE|Blood sampling for hematology|
48628804|NCT00232154|PROCEDURE|Blood sampling for plasma chemistry profile|
48628805|NCT00232154|PROCEDURE|Serum pregnancy test (for women of child-bearing potential)|
48628806|NCT01903044|PROCEDURE|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
48628807|NCT04292886|DRUG|Tamoxifen and femoston|oral
48628808|NCT04292886|DRUG|Vitamin C and femoston|Vitamin C and femoston
48628809|NCT03203512|DIETARY_SUPPLEMENT|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
48628810|NCT03203512|DIETARY_SUPPLEMENT|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
47938162|NCT06007859|OTHER|section orientation|The patient was placed in a decubitus supine head back extension position to fully expose the cervical thyroid examination site. The instrument was adjusted appropriately to achieve optimal imaging quality, the suspicious nodule was located in conventional ultrasound mode, the SWE option in VT mode was selected, and the patient was instructed to hold his/her breath to minimize the effect of respiration, and elastograms of the nodule in transverse and longitudinal sections were obtained.
47938163|NCT00002576|DRUG|cyclophosphamide|
47938164|NCT00002576|DRUG|doxorubicin hydrochloride|
48628811|NCT05315258|DRUG|Tebentafusp|Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
48628812|NCT03679884|DRUG|Daridorexant 10 mg|Daridorexant 10 mg film-coated tablets
48628813|NCT03679884|DRUG|Daridorexant 25 mg|Daridorexant 25 mg film-coated tablets
48628814|NCT03679884|DRUG|Daridorexant 50 mg|Daridorexant 50 mg film-coated tablets
48628815|NCT03679884|DRUG|Placebo|Matching placebo film-coated tablets
48628816|NCT06248528|PROCEDURE|Liver resection|Patients in the intervention group received liver resection and postoperative adjuvant therapy
48628817|NCT06248528|PROCEDURE|Locoregional therapy|Patients in the control group received locoregional therapy and systemic therapy
48628818|NCT03870321|OTHER|Core training|"In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise."
48628819|NCT03033901|DEVICE|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
48628820|NCT03033901|DEVICE|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
47938165|NCT00002576|DRUG|mitoxantrone hydrochloride|
47938166|NCT00002576|DRUG|prednisolone|
47938167|NCT00002576|DRUG|vincristine sulfate|
48100836|NCT01879371|DRUG|Ibuprofen (Brufen®)|oral dose
48469735|NCT06605807|OTHER|Clinical Decision Framework for Managing older adults' chronic conditions during hospitalization.|All clinicians will attend an educational session where they will be provided a clinical decision framework for management of chronic conditions in hospitalized older adults, reviewing guiding principles for managing chronic disease in the hospital, and working through case-based hypothetical examples.
48469736|NCT05999240|DRUG|Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]|Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.
48628821|NCT03033901|OTHER|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
47938168|NCT00970866|DIETARY_SUPPLEMENT|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
48469737|NCT05999240|DRUG|Placebo|Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]
48469738|NCT04335188|OTHER|Prospective oberservational registry|Non interventional study.
48469739|NCT06015022|DRUG|Epigallocatechin gallate (EGCG)|EGCG is a green tea-derived catechin
48469740|NCT06015022|OTHER|Placebo|Placebo in the same capsule with the experimental agent (EGCG).
48628822|NCT02898506|DRUG|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
48628823|NCT02898506|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
48628824|NCT02677389|OTHER|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
48628825|NCT02677389|OTHER|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
48628826|NCT02677389|DEVICE|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
48628827|NCT02677389|OTHER|Quality-of-Life Assessment|Ancillary studies
48628828|NCT02677389|OTHER|Questionnaire Administration|Ancillary studies
48628829|NCT06135545|COMBINATION_PRODUCT|Bupivacaine Liposome SAPB|Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
48628830|NCT06135545|COMBINATION_PRODUCT|Traditional TPVB|The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
48628831|NCT00682838|BEHAVIORAL|Self-management|Self-management
48628832|NCT00682838|BEHAVIORAL|Telemonitored care|Telemonitored care
48628833|NCT02703025|DIETARY_SUPPLEMENT|GCB-70|green coffee bean extract
48628834|NCT02287519|BEHAVIORAL|Group Session|
47938169|NCT00970866|DIETARY_SUPPLEMENT|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
48469741|NCT05740696|PROCEDURE|ALF|Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
48469742|NCT05740696|PROCEDURE|SALF|The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
48469743|NCT05740696|PROCEDURE|ACLF|On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
48469744|NCT04738942|DRUG|Vedolizumab|Vedolizumab 300 mg, IV infusion
48469745|NCT05536531|DEVICE|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
48469746|NCT02726386|DRUG|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
48628835|NCT02287519|BEHAVIORAL|Telephone Coaching Session|
48628836|NCT02287519|BEHAVIORAL|Webinar|
48628837|NCT00902967|DRUG|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
48628838|NCT00902967|DRUG|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
48628839|NCT03050931|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
48628840|NCT00250718|DRUG|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
48628841|NCT00250718|DRUG|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
48469747|NCT06024343|PROCEDURE|MPD Exposure, Repair or Reconstruction|During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is injured due to its proximity or encasement by the tumor, MPD manipulation is performed. MPD manipulation is categorized into three scenarios: exposed but not injured; simple suture repair (using 5-0/6-0 PROLENE polypropylene suture); and suture repair/reconstruction following stent insertion. Using the F6 ventricular drainage catheter with 1-2 side holes trimmed as the stent, typically requiring 10 cm for passage through the duodenal papilla and 3-4 cm if not passing through. Following stent placement, intermittent suturing reconstructs the MPD, with one stitch securing the stent by passing through both the stent side wall and the MPD.
47938170|NCT00970866|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P\&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P\&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (\~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
48469748|NCT06669663|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Participants will receive Pimonidazole (non-CTIMP) prior to their surgery for OG cancer and then undergo intra-operative sampling.
48469749|NCT02684331|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
48469750|NCT02684331|OTHER|Echocardiography|Standard measurements and strain.
48469751|NCT02684331|OTHER|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
48469752|NCT05380050|BEHAVIORAL|Goal Management Training plus Attention Training|GMT is a Power Point directed interactive group training to use a five point strategy to plan and execute complex tasks. Attention Training utilizes Brain HQ attention modules and individualized attention goals.
48469753|NCT05380050|BEHAVIORAL|Brain Health Workshop and National Geographic Movies|BHW is a Power Point directed interactive training to learn about the brain and cognitive components. National Geographic Movies, participants select movies to watch with the therapists and answers questions regarding the content.
48469754|NCT02795676|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
48469755|NCT02795676|BIOLOGICAL|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
47938171|NCT04195737|PROCEDURE|Ossix volumax collagen matrix|Under LA horizontal incision is made.Split-full-split thickness flap is elevated.The remaining soft tissue of the anatomic interdental papillae deepithelialized.Coronal advancement of the flap obtained and closed using sling suture.
47938172|NCT04195737|PROCEDURE|Connective Tissue Graft|Under LA parallel incisions is made 1-2 mm first molar to canine.Graft incision 1 mm coronal to the horizontal flap incision.Through this incision designed graft thickness is obtained.The graft obtained between the two horizontal incisions has a 1 mm coronal strip that require depithelisation with a knife and closed using interrupted suture.
47938173|NCT01273285|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
47938174|NCT01266941|DRUG|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
47938175|NCT02314390|BEHAVIORAL|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
47938176|NCT02314390|BEHAVIORAL|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
47938177|NCT01196039|DRUG|MEMP1972A|Intravenous repeating dose
47938178|NCT01196039|DRUG|placebo|Intravenous repeating dose
48100837|NCT03126409|PROCEDURE|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
48469756|NCT03868111|DRUG|Sufentanil|The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
48469757|NCT03868111|DRUG|Remifentanil|The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
48469758|NCT01459757|OTHER|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
48469759|NCT03231345|PROCEDURE|US guided IJ|IV catheter placement
48469760|NCT03231345|DEVICE|Ultrasound|Ultrasound-guided Internal Jugular vein
48469761|NCT05502055|OTHER|Individual interviews|One on One interviews by Zoom video conferencing, \< 2 hours in duration
48469762|NCT05502055|OTHER|Focus Groups|Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration
48469763|NCT05502055|OTHER|National Survey|Survey conducted online and distributed nationally
48469764|NCT06678477|DEVICE|3D device|Use 3D machine to generate the 3D image
48469765|NCT05656690|OTHER|Exposure to disability|Disability status assessed by functional measures
48469766|NCT06283121|BIOLOGICAL|BioTTT001 intraperitoneal infusion|Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle
48469767|NCT06283121|DRUG|SOX regimen|Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
48469768|NCT06283121|DRUG|toripalimab|Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
47938179|NCT04561674|OTHER|Implementation of web-based patient education|Web-Based Patient Education on Colostomy and Ileostomy (WBPECI) was developed in accordance with the principles of the ADDIE instructional design. The web-based education was designed in line with these learning objectives determined. The content of the website was developed in light of the opinions sought from five subject experts. The WBPECI content includes a total of 7 videos, 1 animation with sound, 1 forum and 1 consultation page
47938180|NCT04812678|PROCEDURE|Fasciatherapy|Fasciatherapy, with manual therapy and/or gestual therapy.
48469769|NCT05260203|DEVICE|RITA (App)|"The RITA Remote Intelligence for Therapeutic Adherence application was designed, on the doctor's side, as a support for the management of the onco-hematological patient and, on the patient's side, as a first aid tool for the management of the most common problems, as well as an efficient and non-invasive means of communication with the doctor. The system also allows the caregiver and general practitioner to be included in the communication group.~The added value of the app consists in improving the relationship between the patient and the doctor, creating an effective communication channel, increasing the safety the patient has when facing his difficult path, reducing the number of visits to the facility and, in general, making those visits more efficient, thus creating savings both in terms of time and resources."
48469770|NCT06081010|BEHAVIORAL|Community Health Worker Intervention|Trained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems.
48469771|NCT04119557|DRUG|Placebo|Administered SC
48469772|NCT04119557|DRUG|LY3471851|Administered SC
48628842|NCT00250718|DRUG|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
48628843|NCT00250718|DRUG|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
48628844|NCT00250718|DRUG|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
48628845|NCT00150527|DRUG|Citalopram|40 mg, pill, single dose
48628846|NCT00150527|DRUG|Escitalopram|20 mg, pill, single dose
48628847|NCT00150527|DRUG|Dexamethasone|1 mg, pill, single dose
48628848|NCT00150527|BEHAVIORAL|Cold Pressor Test|single test
48628849|NCT00169325|PROCEDURE|Magnetic resonance imaging|
48628850|NCT02638441|OTHER|hospital anxiety and depression scale|Detection of infertility effect on emotional status
48628851|NCT01559623|PROCEDURE|retrospective data analysis|retrospective data analysis
48628852|NCT03631121|DRUG|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
48628853|NCT00504309|DRUG|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
48628854|NCT00504309|DRUG|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
48628855|NCT00504309|DRUG|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
48628856|NCT06103682|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
48628857|NCT02465970|DEVICE|STARSTIM|"Multifocal transcranial direct current stimulation.~* CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~* The stimulation is applied during a 60 min session"
47938181|NCT04812678|PROCEDURE|Physiotherapy|Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
47938182|NCT03023046|DRUG|Cyclophosphamide|Given IV
48628858|NCT02465970|DEVICE|sham TDCS|
48628859|NCT00580099|OTHER|assisted exercise|4 weeks of passive range of motion exercise
48628860|NCT00580099|OTHER|cuddle|cuddle infant for 20 minutes
48628861|NCT02705157|PROCEDURE|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
48628862|NCT02705157|RADIATION|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
48628863|NCT01442636|DEVICE|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
48628864|NCT01975480|DRUG|Desvenlafaxine|
48628865|NCT04740190|DRUG|Talazoparib|low dose whole brain radiation, followed by combination talazoparib and carboplatin
47938183|NCT03023046|DRUG|Dasatinib|Given PO
47938184|NCT03023046|DRUG|Doxorubicin|Given IV
47938185|NCT03023046|DRUG|Etoposide|Given IV
47938186|NCT03023046|DRUG|Imatinib Mesylate|Given PO
47938187|NCT03023046|OTHER|Laboratory Biomarker Analysis|Correlative studies
47938188|NCT03023046|DRUG|Prednisone|Given PO
47938189|NCT03023046|BIOLOGICAL|Rituximab|Given IV
47938190|NCT03023046|DRUG|Vincristine Sulfate|Given IV
48469773|NCT06665386|PROCEDURE|hypothermia|"Patients who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to either the control group or the IA-SCI group. Control group patients will receive BMM and EVT. IA-SCI group patients will receive BMM and EVT, and additionally a selective intraarterial cooling infusion. The specific method is as follows:~* Pre-recanalization: During the procedure, a micro-catheter used to deploy the stent retriever is threaded coaxially into the common femoral artery through the guide catheter. The microcatheter is advanced over a microguide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4℃) is infused into the ischemic territory at a rate of 10 mL/min via the microcatheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~* Post-recanalization: Following vessel recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL"
48469774|NCT06228248|OTHER|metagenomics|Feces used for metagenomic testing
48628866|NCT03805048|PROCEDURE|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
48628867|NCT01879657|DIAGNOSTIC_TEST|68Ga-DOTATATE injection and PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
48628868|NCT02783989|OTHER|white wine|A dietary beverage: a market white wine, 13º alcohol
48628869|NCT02783989|DIETARY_SUPPLEMENT|tyrosol|tyrosol in capsules
48628870|NCT01841853|BEHAVIORAL|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
48628871|NCT05665647|DRUG|Cohort 1: SIM0417/ritonavir and itraconazole|SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD
48628872|NCT05665647|DRUG|Cohort 2: SIM0417/ritonavir and rifampicin|SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD
48628873|NCT05665647|DRUG|Cohort 3: SIM0417/ritonavir and midazolam|SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
48100838|NCT03126409|PROCEDURE|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
48100839|NCT06479785|OTHER|Educational Intervention Program for machine workers|A detailed Educational Intervention Program for marble factory workers working on Machines.
48469775|NCT03693833|DRUG|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
48628874|NCT00131300|DEVICE|Synvisc (hylan G-F 20)|
48628875|NCT03501277|DRUG|Alogliptin|Alogliptin tablets.
48628876|NCT03501277|DRUG|Pioglitazone|Pioglitazone tablets.
48628877|NCT03501277|DRUG|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
47938191|NCT02337348|OTHER|Optical coherence tomography|Preintervention imaging
47938192|NCT02337348|RADIATION|Coronary angiography|Conventional coronary intervention
47938193|NCT02474888|OTHER|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
48284308|NCT02997514|BEHAVIORAL|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
48284309|NCT01841151|BEHAVIORAL|SCP training|
48469776|NCT03693833|DRUG|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
48469777|NCT05009056|DEVICE|Postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
48469778|NCT01781312|DIETARY_SUPPLEMENT|ProTectis|
48469779|NCT01781312|DIETARY_SUPPLEMENT|Gastrus|
48469780|NCT04139941|DIAGNOSTIC_TEST|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
48469781|NCT03874026|DRUG|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
48469782|NCT06678074|DRUG|Atibuclimab (IC14), 20 mg/kg intravenously, once|monoclonal antibody against CD14
48469783|NCT06678074|OTHER|Placebo, 150 mL intravenously, once|sterile normal saline for injection
48469784|NCT06448637|DEVICE|Drug Coated Balloon (DCB)|Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI)
48284310|NCT01841151|BEHAVIORAL|Live Z-score training|
48284311|NCT01841151|BEHAVIORAL|WM training|
48284312|NCT02189382|DEVICE|Potassium Oxalate|
48284313|NCT02189382|OTHER|Water|
48469785|NCT06448637|DEVICE|Drug Eluting Stent (DES)|Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI)
48100840|NCT06479785|OTHER|Educational Intervention Program for manual workers|A detailed Educational Intervention Program for marble factory workers working manually.
48469786|NCT05786417|OTHER|Clinician Discretion|Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
48469787|NCT05786417|DRUG|Beta blocker|Selection of the specific BB and initial starting dose will be determined by the treating clinician.
48469788|NCT05786417|DRUG|Calcium channel blocker|Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
48469789|NCT06024382|OTHER|twin block|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
47938194|NCT05095493|DIETARY_SUPPLEMENT|Zinc Acetate|50 mg tablet
47938195|NCT05095493|DIETARY_SUPPLEMENT|Placebo|Zinc Acetate matched placebo tablet
47938196|NCT06516601|OTHER|no intervention|observational study, the patients received corticosteroids according to the physician on duty
47938197|NCT00401141|PROCEDURE|Blood samples|
47938198|NCT04028245|DRUG|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
47938199|NCT04028245|DRUG|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
47938200|NCT01515007|DRUG|Ciprofloxacin dispersion for inhalation|
47938201|NCT01515007|DRUG|Placebo|
47938202|NCT02182648|DRUG|etomidate|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of etomidate at 2 minutes before anesthesia induction"
47938203|NCT02182648|DRUG|propofol|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of propofol at 2 minutes before anesthesia induction"
48284314|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT with post procedure curettage
48284315|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT without post procedure curettage
48284316|NCT02296346|DRUG|SoluMedrol|Infusion of drug subcutaneously, once a month.
48284317|NCT02296346|DEVICE|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
48284318|NCT02299934|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
48284319|NCT02299934|DIAGNOSTIC_TEST|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
48284320|NCT03616743|BEHAVIORAL|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
48284321|NCT03616743|BEHAVIORAL|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
48284322|NCT05736315|OTHER|Placebo dairy beverage|Placebo dairy beverage (placebo) is a sweetened dairy beverage.
48284323|NCT01676961|BIOLOGICAL|romiplostim|Given SC
48284324|NCT01121016|DRUG|Montelukast|10mg, qn, 4 weeks
48284325|NCT01121016|OTHER|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
48469790|NCT06024382|OTHER|twin block combined with low level laser|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
48469791|NCT02974647|DRUG|Ruxolitinib|
48284326|NCT05518149|DRUG|Aticaprant|Aticaprant 10 mg tablet will be administered orally.
48284327|NCT02320578|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
48284328|NCT02320578|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
48284329|NCT02894073|DEVICE|skin transilluminator|VeinViewer
48284330|NCT03203629|DEVICE|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
48284331|NCT03265691|OTHER|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
48284332|NCT03265691|OTHER|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
47938204|NCT02182648|DRUG|sevoflurane|"1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. inhale sevoflurane for anesthesia induction and maintenance"
48284333|NCT04712175|DIAGNOSTIC_TEST|Nasopharyngeal sampling|Swabs will be taken of nasopharyngeal samples for RT-PCR
48284334|NCT04712175|DIAGNOSTIC_TEST|Saliva sampling|A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
48284335|NCT06189443|OTHER|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
47938205|NCT00079014|DRUG|triapine|Given IV
47938206|NCT00079014|DRUG|doxorubicin hydrochloride|Given IV
48284336|NCT04652934|OTHER|Neurodynamic|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
48284337|NCT04652934|OTHER|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
48469792|NCT03296735|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
48469793|NCT03296735|PROCEDURE|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
48469794|NCT06589297|DIAGNOSTIC_TEST|Modified Rankin scale|Acute stroke patients will undergo modified rankin scale
47938207|NCT00079014|OTHER|laboratory biomarker analysis|Correlative studies
47938208|NCT00079014|OTHER|pharmacological study|Correlative studies
47938209|NCT03839927|OTHER|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
47938210|NCT05931588|OTHER|Pilates excercises, streching and breathing|international group receive Pilates exercises, stretching and breathing two times a week (30 min per session) perform 3 to 5 reps of Pilates exercises under supervision
47938211|NCT05931588|OTHER|stretching and breathing|control group guided with stretching and breathing home based program both group till 8 week both groups
48469795|NCT02749591|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
48469796|NCT02749591|OTHER|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
48469797|NCT02749591|OTHER|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
48628878|NCT00724503|DEVICE|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 \[Y-90\] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
47938212|NCT03730454|DEVICE|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
48469798|NCT02749591|OTHER|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
48469799|NCT04133675|DEVICE|BTL Emsella|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
48469800|NCT04133675|DEVICE|Sham BTL Emsella|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).
48469801|NCT05364606|DEVICE|Patient Specific Talus Spacer|Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
48469802|NCT05253430|PROCEDURE|Lymphadenectomy type|D1 vs D2 lymph node dissection
48628879|NCT00724503|DRUG|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
48628880|NCT06423027|BEHAVIORAL|Nature-Oriented Chatbots|Nature-oriented chatbots are an intervention with nature-based video delivered by self-developed chatbots
48628881|NCT04976972|DEVICE|NAVIO/CORI Surgical System|Total knee replacement with robotic assistance
47938213|NCT03730454|OTHER|No Transanastomotic Tube|No transanastomotic tube used during repair
47938214|NCT05262959|DRUG|Donafenib, PD-1|Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
47938215|NCT05262959|PROCEDURE|TACE|TACE will be performed by the investigator based on the patient's tumor status.
47938216|NCT01683227|BEHAVIORAL|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
48469803|NCT05194202|BEHAVIORAL|ED-HEART|Behavioral intervention that assesses 1) healthy and unhealthy relationship behaviors, 2) conversation with partners around boundaries within relationships, 3) harm reduction strategies, and 4) resources for Adolescent Relationship Abuse (ARA) and related concerns, including Point of Care (POC) Reproductive and Sexual Health (RSH) harm reduction resources.
47938217|NCT01683227|BEHAVIORAL|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
47938218|NCT02398227|BEHAVIORAL|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
47938219|NCT02398227|BEHAVIORAL|PCT|Present Centered Therapy for PTSD
48469804|NCT00860600|DRUG|PG2|500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
48628882|NCT04976972|PROCEDURE|Non-robotic conventional instrumentation|Total knee replacement with non-robotic conventional instrumentation
48628883|NCT04958590|RADIATION|whole spine X-ray|Group 1 underwent whole spine X-ray in standing and sitting positions.
48628884|NCT00770094|DEVICE|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
47938220|NCT02906969|OTHER|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
47938221|NCT02906969|OTHER|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
48469805|NCT02818296|BEHAVIORAL|Active IU CBM-I|
48469806|NCT02818296|BEHAVIORAL|Control CBM-I|
48469807|NCT06468722|BEHAVIORAL|Exercise-based rehabilitation|Patients performed regular physical exercise during inpatient rehabilitation
48469808|NCT03417739|DRUG|BVD-523|ERK1 and ERK2 inhibitor
48469809|NCT05887687|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
48469810|NCT00292591|DRUG|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
48469811|NCT00292591|DRUG|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
48469812|NCT06336356|DRUG|Baxdrostat|Baxdrostat will be administered orally once daily.
48628885|NCT00770094|DEVICE|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
48628886|NCT00770094|DEVICE|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
48628887|NCT04630730|DRUG|Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)|1 dose of VPM1002BC, live, 1-19.2 x 108 colony forming units (CFU) on day 1, 8 (+/- 1 day) and 15 (+/- 1 day)
48628888|NCT04630730|DRUG|Atezolizumab|Neoadjuvant immunotherapy with atezolizumab, 4 cycles 1200 mg fixed dose iv infusion on d1 q3w starting 4-16 weeks after date of surgery
48628889|NCT04630730|DRUG|Cisplatin|Neoadjuvant chemotherapy with cisplatin: 4 cycles 70mg/m2 iv infusion on d1 q3w (starting on d22)
48469813|NCT06336356|DRUG|Placebo|Placebo will be administered orally once daily.
48628890|NCT04630730|DRUG|Gemcitabine|Neoadjuvant chemotherapy with gemcitabine: 4 cycles 1000 mg/m2 iv infusion on d1 and d8 q3w (starting on d22)
48628891|NCT03033043|DEVICE|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
48628892|NCT01527981|BEHAVIORAL|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
48628893|NCT05678114|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol (4g/die)
48628894|NCT05752409|DRUG|The median dose of esketamine|1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
47938222|NCT05908318|BEHAVIORAL|olfactory training|In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
48628895|NCT05752409|DRUG|The high dose of esketamine|1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
48628896|NCT05752409|DRUG|Propofol|2mg•kg-1propofol for general anesthesia induction.
48628897|NCT04833608|DEVICE|Vktory insoles|Patients were randomized into either the Carbon fiber insole group or Morton's extension group.
48628898|NCT04833608|DEVICE|Morton's extension insoles|Patients were randomized into either the Vktory carbon fiber insole group or Morton's extension insole group.
48628899|NCT06091384|OTHER|Inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths per day at 75% of maximal inspiratory pressure, six days a week, during 6 weeks.
47938223|NCT00590460|BIOLOGICAL|CAMPATH-1H|Given intravenous on days -8, -7, and -6
47938224|NCT00590460|BIOLOGICAL|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
47938225|NCT00590460|DRUG|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
47938226|NCT00590460|PROCEDURE|Stem cell infusion|Stem cells are infused on day 0
47938227|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
48469814|NCT06678737|OTHER|CBIT +cTBS|10 daily sessions of CBIT plus cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
48469815|NCT06678737|OTHER|CBIT +sham cTBS|10 daily sessions of CBIT plus sham cTBS, with MRI, behavioral, and clinical assessments before and after treatment and at 1-, 3-, and 6-month follow-ups.
48469816|NCT03769532|DRUG|Pembrolizumab|Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses
48469817|NCT03769532|DRUG|Azacitidine|Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
48469818|NCT02875028|DRUG|Vorapaxar|10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
48469819|NCT02875028|DRUG|Placebo|
48469820|NCT02875028|OTHER|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
48469821|NCT06618638|BEHAVIORAL|Shared decision making model|Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.
48469822|NCT06618638|BEHAVIORAL|Usual Care|Usual care for ADPKD patients
48469823|NCT06149091|DRUG|Tranexamic Acid；|Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.
48628900|NCT04076137|OTHER|Targeted T-cell armed with bispecific antibody (Decitabine)|In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
48284338|NCT05367531|DEVICE|Autoinjector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
48469824|NCT06149091|DRUG|Adrenalin|In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.
48469825|NCT06149091|DRUG|Hemagglutinase|Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.
48469826|NCT02480608|DRUG|Imatinib|
48469827|NCT02480608|DRUG|Hydroxyurea|
48469828|NCT05972564|DRUG|Empagliflozin 25 MG|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes.
48469829|NCT05972564|DRUG|Placebo|Placebo consists of gelatin capsules.
48469830|NCT06036342|DIAGNOSTIC_TEST|MobiCARE test|7-days continuous electrocardiography monitoring using MobiCARE device
48469831|NCT05112991|DRUG|Envafolimab+Lenvatinib|"Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.~Lenvatinib: the recommended Phase 2 dose (RP2D) orally 20mg QD during each 28-day cycle."
48469832|NCT05112991|DRUG|Envafolimab|Envafolimab: 400mg envafolimab was administered once in D1 and D15 of the first treatment cycle and once in D1 of each subsequent 28 day cycle.
48469833|NCT03916562|BEHAVIORAL|Manipulation of spatiotemporal coordination during walking|A description of the intervention is included in the description of the study arms.
48469835|NCT02937506|DRUG|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
48628901|NCT02813720|RADIATION|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.~It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
48628902|NCT02827708|DRUG|semaglutide|Oral administration once daily.
48628903|NCT02827708|DRUG|placebo|Oral administration once daily.
48100841|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
48469836|NCT02937506|DRUG|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
48469837|NCT04633616|OTHER|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
48628904|NCT05863416|DRUG|Dexmedetomidine infusion|Intraoperative dexmedetomidine infusion
48628905|NCT03458091|DEVICE|THRIVE|Oxygenation during apnea using transversal humidified oxygen
48628906|NCT03458091|DEVICE|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
48628907|NCT03562507|DRUG|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
48628908|NCT03562507|DRUG|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
48284339|NCT05367531|DEVICE|Standard Injector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
48284340|NCT05367531|DEVICE|Prefilled|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
48469838|NCT04633616|OTHER|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
48469839|NCT01876368|DRUG|LCZ696|
48284341|NCT00655720|OTHER|infant formula|"1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics"
48284342|NCT01057121|DRUG|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
48284343|NCT05215522|DEVICE|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
48469840|NCT01876368|DRUG|Olmesartan|
48469841|NCT01876368|DRUG|Placebo of LCZ696|
48469842|NCT01876368|DRUG|Placebo of Olmesartan|
48469843|NCT00925873|DRUG|Active comparator (no fludarabine)|"1. Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~2. The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~3. Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
48469844|NCT00925873|DRUG|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
48469845|NCT06529133|OTHER|Evaluation of postural control|Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).
48469846|NCT03904836|DRUG|Tobramycin|5 milligrams per kilogram intravenous for one dose
48469847|NCT06674135|DRUG|biosimilar insulin glargine|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
48469848|NCT02118987|DRUG|Omalizumab|
48469849|NCT04229290|DRUG|Dolutegravir|Switch of virally suppressed participants to Dolutegravir
48469850|NCT05600023|DRUG|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
48469851|NCT05600023|DRUG|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
48628909|NCT01333566|BEHAVIORAL|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
48284344|NCT05500989|OTHER|Venepuncture|The only invasive procedure is a venepuncture where 100 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
48469852|NCT06678386|BEHAVIORAL|50% sugar reduction|Participants were advised by a dietitian to reduce their daily caloric intake from sugars by 50% for 12 weeks.
48469853|NCT04522245|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging."
48469854|NCT04522245|OTHER|Matched Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
48469855|NCT06678178|BEHAVIORAL|Control (QR) Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Control (QR) labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
48469856|NCT06678178|BEHAVIORAL|Warning High Climate Impact Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Warning High Climate Impact labels will be displayed beneath select items. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
48469857|NCT06678178|BEHAVIORAL|Traffic Light Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Traffic Light labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
48469858|NCT06678178|BEHAVIORAL|Climate Grade Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Climate Grade labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
48469859|NCT06678178|BEHAVIORAL|Numeric Carbon Footprint Labels|Participants will view a fast-food restaurant menu including main, side, dessert, and drink items. Each menu item will be displayed with an image of the item, name, price, and total calories. For main items only, Numeric Carbon Footprint labels will be displayed beneath each item. Participants will be instructed to select up to 4 menu items for a hypothetical meal order.
48469860|NCT03815409|OTHER|Treadmill with partial weight unload|10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
48284345|NCT03847311|DRUG|Sulfasalazine|This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
48100842|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
48469861|NCT03815409|OTHER|Traditional PT rehabilitation treatment|Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
48469862|NCT04505735|DRUG|11C-PiB|Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
48284346|NCT03847311|DRUG|Placebos|This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
48284347|NCT00687453|DRUG|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
48284348|NCT00687453|DRUG|NPH twice-daily|Addition of morning NPH to bedtime NPH
48284349|NCT06065046|DRUG|Baricitinib 4 MG|Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
48284350|NCT06065046|OTHER|Standard treatment|Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
48284351|NCT00000899|DRUG|Nelfinavir mesylate|
48284352|NCT00000899|DRUG|Lamivudine|
48284353|NCT00000899|DRUG|Filgrastim|
48284354|NCT00000899|DRUG|Stavudine|
48284355|NCT00000899|DRUG|Cyclophosphamide|
48284356|NCT03497299|DEVICE|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
48284357|NCT03497299|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
48469863|NCT06677632|OTHER|Palmitoylation Enzyme Expression Profiling Study|The expression of 23 zDHHC enzymes will be studied in human post-mortem hippocampi of AD patients and controls that have already been collected from UK brain biobanks. zDHHC enzymes will be analyzed at both mRNA and protein levels by Real Time PCR and Western blotting techniques, respectively
48469864|NCT06555744|DRUG|ZW191|Administered intravenously
48284358|NCT00375245|DRUG|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
48628910|NCT01333566|BEHAVIORAL|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
48628911|NCT05957341|DEVICE|active rTMS: 20min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 20 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
48628912|NCT05957341|DEVICE|active rTMS: 50min inter-session interval|Participants will receive active TMS, with 3 sessions per day, 1800 pulses/session, and 50 min inter-session intervals, lasting for 21 days. Individualized targets will be generated using the pBFS method.
48628913|NCT05957341|DEVICE|sham rTMS: 20min inter-session interval|The parameters in this group are the same as in the active rTMS: 20min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
48284359|NCT00375245|OTHER|Grapefruit Juice|Daily oral doses starting during the second week on study.
48284360|NCT00427414|DRUG|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
48469865|NCT04492397|DEVICE|Test Contact Lens|Subjects will be randomized to wear test lenses.
48469866|NCT04492397|DEVICE|Control Contact Lens|Subjects will be randomized to wear control lenses.
48469867|NCT04570735|DIAGNOSTIC_TEST|MRI|MRI
47938228|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
47938229|NCT00306202|DRUG|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
47938230|NCT01879527|DRUG|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
47938231|NCT01879527|DRUG|Sugar pill|containing placebo
47938232|NCT03260439|DRUG|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
47938233|NCT03260439|DRUG|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
48100843|NCT00706693|DIETARY_SUPPLEMENT|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
48100844|NCT06189105|OTHER|miss alice face it you love me serum|Facial serum with niacinamide, plant-based collagen and peptides will be applied by each participant to the treatment site according to randomization protocol every evening
48469868|NCT00139932|DRUG|formoterol fumarate|
48469869|NCT06188585|DEVICE|UI-EWD|Hemostatic powder administered at index endoscopy
48469870|NCT06188585|DEVICE|Conventional therapy|Conventional endoscopic therapy (bipolar electrocoagulation or clips, with or without epinephrine injection) administered at index endoscopy
48100845|NCT06189105|OTHER|No treatment (usual skincare rutine)|No treatment (usual skincare rutine)
48100846|NCT05484024|DRUG|Sintilimab|PD-1 inhibitor
48100847|NCT05484024|RADIATION|Short-course radiotherapy|Pelvic radiation
48100848|NCT05484024|COMBINATION_PRODUCT|CAPOX/mFOLFOX|chemotherapy regimen
48469871|NCT04946786|DIAGNOSTIC_TEST|Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis|"1. Complete history taking.~2. Thorough clinical examination :Assessing for buffalo hump, double chin, acanthosis nigricans, skin tags or acrochordon and xanthelasma and anthropometric measurements as measuring height m, weight Kg, waist circumference (WC) Cm, hip circumference (HC) Cm.~3. Pelvi-abdominal ultrasound. 4. Fibroscan examination will be done for all subjects to assess steatosis by measuring the CAP score.~5. Body composition analysis: to detect water, muscle and fat percentage in the body.~6. Laboratory investigations:All samples wil be analyzed for fasting blood glucose (FBG), and post-prandial (2hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST),alanine transaminase (ALT).~• Fasting insulin levels will be measured using ELISA kits"
48469872|NCT02415933|BEHAVIORAL|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~* Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~* Provision of seed grants to assist in business start-ups through microfinance loans;~* One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~* Trainings on financial planning and household livelihoods."
48628914|NCT05957341|DEVICE|sham rTMS: 50min inter-session interval|The parameters in this group are the same as in the active rTMS: 50min inter-session interval group. Stimulation was delivered by the same device as the active group fitted with a sham coil.
48628915|NCT04772131|DEVICE|Desara® One Single Incision Sling|Single incision sling
48284361|NCT05301244|OTHER|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
48284362|NCT05301244|OTHER|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
48284363|NCT05301244|OTHER|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
48284364|NCT05301244|OTHER|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
48284365|NCT05301244|OTHER|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
48469873|NCT02415933|BEHAVIORAL|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
48284366|NCT02719054|BEHAVIORAL|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
48284367|NCT02756871|OTHER|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
48284368|NCT01025635|DRUG|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
48284369|NCT01025635|DRUG|Vehicle foam|Applied topically twice daily for 12 weeks
48284370|NCT00679107|DEVICE|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
48284371|NCT04988230|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
48284372|NCT04988230|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
48284373|NCT00794287|OTHER|Taking blood samples|No intervention is done. Only blood samples are taken.
48284374|NCT03185130|DRUG|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
48284375|NCT03185130|DRUG|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
48284376|NCT03185130|DRUG|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push
48469874|NCT04200911|DRUG|Rapamune|Sirolimus 1mg capsules
48628916|NCT04772131|DEVICE|Desara® Blue Transobturator Sling|Standard mid-urethral sling
48284377|NCT03185130|DRUG|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
48284378|NCT02267928|OTHER|Check Symptoms|"Symptoms are Checked"
48284379|NCT02267928|OTHER|Uncheck Symptoms|"Symptoms are Un-checked"
48284380|NCT02267928|OTHER|Experienced|Focus of instructions is on symptoms the participant has experienced
48284381|NCT02267928|OTHER|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
48284382|NCT04802746|DRUG|Alprazolam|Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
48284383|NCT04802746|OTHER|Placebo|Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.
48284384|NCT02605577|PROCEDURE|new systemic nutrition management protocol|a new established systemic nutrition management protocol
48284385|NCT02015819|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
48284386|NCT02015819|DRUG|flucytosine|Given orally
48284387|NCT02015819|DRUG|leucovorin calcium|Given orally
48284388|NCT02015819|OTHER|pharmacological study|Correlative studies
48284389|NCT02015819|OTHER|laboratory biomarker analysis|Correlative studies
48628917|NCT03600428|BIOLOGICAL|Live Attenuated Influenza Vaccine (LAIV)|1 dose, 0.2 mL, intranasal administration
48628918|NCT03600428|BIOLOGICAL|Inactivated Influenza Vaccine (IIV)|1 dose, 0.5 mL, intramuscular administration
48469875|NCT00973089|OTHER|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
48469876|NCT03525340|BEHAVIORAL|Peer Navigation|Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
48469877|NCT06679374|DRUG|Placebo|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
48469878|NCT06679374|DRUG|Varenicline|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
48469879|NCT03222037|DEVICE|senofilcon A|Acuvue Oasys 1-Day
48469880|NCT03222037|DEVICE|Control|Trial Frame with best spherocylindrical refraction (SCR)
48469881|NCT04083534|DRUG|REGN5459|Administered by intravenous (IV) infusion
48469882|NCT02206009|DEVICE|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
48469883|NCT03298516|DRUG|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
48469884|NCT03298516|DRUG|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
48469885|NCT01610024|DIETARY_SUPPLEMENT|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
48469886|NCT01546727|BEHAVIORAL|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
48469887|NCT01546727|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
48469888|NCT06444165|DRUG|Lebrikizumab Pen|Injected into a practice pad.
48628919|NCT04086459|DEVICE|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
48628920|NCT00422435|DEVICE|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
48628921|NCT01509807|DRUG|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
48628922|NCT01509807|DRUG|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
48628923|NCT01699685|DRUG|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
48628924|NCT01699685|DRUG|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
48469889|NCT06674421|OTHER|Reliability Analyses|For the reliability analysis test-retest method will use. There will be a one-week break between the first test and the retest.
48469890|NCT00859040|DRUG|SOM230C|Injection in the buttocks every 28 days
48469891|NCT06678425|DEVICE|Peripheral magnetic stimulator|a non-invasive method of delivering a rapidly pulsed, high-intensity magnetic field to peripheral muscles
48469892|NCT06678425|DEVICE|Peripheral magnetic stimulator|The same coil as real rPMS, but in a position perpendicular to the skin
48469893|NCT00032916|DRUG|NS2359|
48469894|NCT02178124|DRUG|Donepezil|
48469895|NCT02178124|DRUG|placebo|
48469896|NCT00183196|DRUG|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
48469897|NCT00183196|DRUG|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
48469898|NCT00183196|OTHER|Inactive Placebo|Placebo
48284391|NCT02251743|DEVICE|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~2. Average voltage of theta waves~3. Average voltage of beta~4. Average ratio of theta to beta power (TBR)"
48284392|NCT02201940|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
48284393|NCT02201940|DRUG|Placebo|Tablet administered orally once daily
48284394|NCT05069038|DRUG|Palbociclib 125mg|Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
48284395|NCT04000035|OTHER|Health and work environment information and processes|see arm/group description
48284396|NCT00413751|DRUG|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
48284397|NCT01948752|OTHER|Nutrition information on menus|
48469899|NCT06450639|DRUG|Satralizumab|Satralizumab will be adminsitered SC in the abdominal or femoral region at a dose of 60 mg (participants weighing below 40 kg) or 120 mg (participants weighing more than or equal to 40 kg and less than or equal to 100 kg) on Day 1 and Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.
48469900|NCT06053840|DRUG|Chloral Hydrate|Participants will be involved in the trial for approximately 7-8 weeks, the first week to collect baseline data and complete screening and eligibility confirmation, the following two weeks they will administer IMP, and there will be a further 4 week observation period. All trial recruitment and follow-up procedures will be conducted remotely via telephone/video calls.
48469901|NCT02208973|DRUG|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
48469902|NCT02208973|DRUG|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
47938234|NCT01231308|PROCEDURE|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
48284398|NCT03746730|DEVICE|ultrasound|gray scale and doppler ultrasound
48469903|NCT06591572|PROCEDURE|Single-port robotic transanal total mesorectal excision|Rectal resection by transanal TME with single-port robotic surgery
48469904|NCT06591572|PROCEDURE|Laparoscopic transanal total mesorectal excision|Rectal resection by transanal TME with Laparoscopic surgery
48469905|NCT01734694|DRUG|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
48469906|NCT01734694|DRUG|Ceftaroline|"Dose based on package insert labeling~CrCL \> 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL \< 15mL/min: 200 mg q12h;"
48284399|NCT03802721|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
48469907|NCT01734694|DRUG|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL \< 30 mL/min: 6 - 10 mg/kg IV q48h"
48469908|NCT01734694|DRUG|Linezolid|600 mg IV/PO q12h
47938235|NCT01231308|BEHAVIORAL|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
48284400|NCT03802721|DRUG|Brussels sprouts before 50 ng dose|Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
48284401|NCT03802721|DRUG|DIM supplement before 50 ng dose|DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
48284402|NCT03267355|DEVICE|Endoscopic Ultrasound|Indication of EUS
48284403|NCT00049764|DRUG|Drotrecogin alfa (activated)|
48284404|NCT00049764|DRUG|Placebo|
48284405|NCT06059885|DRUG|Tislelizumab plus tyrosine kinase inhibitor|Lenvatinib, tyrosine kinase inhibitor (TKIs)
48469909|NCT03045627|DRUG|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
48469910|NCT03045627|DRUG|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
48469911|NCT03045627|DRUG|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
48469912|NCT03045627|DRUG|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
48469913|NCT01374945|DEVICE|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
48469914|NCT03066791|DIETARY_SUPPLEMENT|Turmeric tablets|
48469915|NCT03066791|DIETARY_SUPPLEMENT|Curcumin and Bioperine tablets|
48469916|NCT03066791|DIETARY_SUPPLEMENT|Placebo tablets|
48469917|NCT04681508|DIAGNOSTIC_TEST|Chest CT without contrast enhancement and chest X-ray|Chest CT without contrast enhancement and chest X-ray as supplement to diagnostic abdominal CT
48469918|NCT05491512|DIAGNOSTIC_TEST|18 F-FMISO PET/CT|The 18F-FMISO PET/CT Scan Protocol consists first of an IV bolus injection of approximately 5-10 mCi of the radiotracer. At between 150-180 mins post injection, 18F-FMISO images will be acquired.
48469919|NCT05491512|RADIATION|Radiation|Total Radiation Dose (over 3 weeks) 30Gy\*\* in 2 Gy per fraction
48469920|NCT05491512|DRUG|Cisplatin|Concurrent chemotherapy (2 cycles) will be given. At the start of week 1 of radiation, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2 ), typically on days 1 and 2, or as a single dose, typically on day 1.
48469921|NCT05491512|DRUG|Carboplatin|"If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).~(Cohort B to start carboplatin (AUC 1.5) and paclitaxel 45 mg/m2 at the start of RT)"
47938236|NCT03194490|OTHER|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
48469922|NCT05491512|DRUG|5-fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
48469923|NCT05956756|BEHAVIORAL|Health and resiliency programming|Students will engage in resilience programming as part of their regular coursework including mindfulness training, lifestyle medicine interventions, and creating a coping plan.
48469924|NCT04665739|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
48469925|NCT04665739|PROCEDURE|Computed Tomography|Undergo CT
48100849|NCT02214667|BEHAVIORAL|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
48469926|NCT04665739|DRUG|Everolimus|Given PO
48469927|NCT04665739|OTHER|Fludeoxyglucose F-18|Given FDG
48469928|NCT04665739|DRUG|Lutetium Lu 177 Dotatate|Given IV
48469929|NCT04665739|PROCEDURE|Positron Emission Tomography|Undergo PET
48100850|NCT02214667|BEHAVIORAL|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
48469930|NCT04665739|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
48469931|NCT02654015|DEVICE|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
48469932|NCT02654015|OTHER|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
48469933|NCT00693589|DRUG|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
48469934|NCT02221063|OTHER|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
48469935|NCT02221063|OTHER|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
48469936|NCT02221063|OTHER|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
48469937|NCT04552522|OTHER|shrimp allergy with intend to eat shrimp|shrimp allergy with intend to eat shrimp and treat with oral immunotherapy
48617905|NCT04926415|DEVICE|taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
48617906|NCT04926415|DEVICE|Sham taVNS|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
48628925|NCT01699685|DRUG|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
48469938|NCT04153786|OTHER|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
47938237|NCT03194490|OTHER|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
47938238|NCT01859585|DRUG|Parecoxib|Parecoxib 40 mg intravenous
47938239|NCT01859585|DRUG|Ketorolac|Ketorolac 30 mg intravenous
47938240|NCT00745615|DRUG|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
48469939|NCT06120530|DRUG|Bupivacaine|Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.
47938241|NCT00745615|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
47938242|NCT05937074|OTHER|Weight loss (%)|Change in body weight from cancer diagnosis to study enrollment
47938243|NCT05867342|DRUG|Epinephrin|Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
47938244|NCT05867342|DRUG|1% lidocaine with epinephrin 1:100,000|4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)
47938245|NCT05867342|DRUG|Saline|4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)
47938246|NCT03665415|BEHAVIORAL|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
47938247|NCT01210287|DRUG|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
48469940|NCT06120530|OTHER|Saline|Placebo
48469941|NCT00236145|DRUG|ACTIQ (Oral transmucosal fentanyl citrate)|
48469942|NCT04529876|DRUG|Tofacitinib|Tofacitinib claim is used as the reference group.
48628926|NCT04085003|PROCEDURE|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
48628927|NCT04067245|DEVICE|Tetrasodium EDTA catheter lock solution|Home parenteral nutrition patients who meets inclusion criteria is to receive tetrasodium edta catheter lock solution. Patient will receive standard catheter lock solution of heparin/saline for 1 month, followed by tetrasodium EDTA catheter lock solution using withdrawal method for 1 month and followed by tetrasodium EDTA catheter lock solution using flush method for 1 month. In total, patient will stay in the study for 3 months. A phone call will be conducted before the start of the study to give instruction to patient regarding the use of catheter lock solution. Time taken to connect and disconnect TPN will be recorded by patients, twice a month on first and last mondays of the month for 3 months. A survey regarding the ease of use of catheter lock solution will be conducted at the end of each month via phone by nurse coodinator.
48628928|NCT05188612|COMBINATION_PRODUCT|Observational (registry)|Observational (Patient Registry)
48628929|NCT03215615|PROCEDURE|Periodontal surgery|Coronally advanced flap for root coverage
48628930|NCT03215615|PROCEDURE|Total Etch adhesive|Total-etch adhesive system (two step)
48628931|NCT03215615|PROCEDURE|Universal Adhesive|One-step self-etching adhesive system
48628932|NCT03215615|PROCEDURE|Nanofilled Composite|Partial nanofilled-resin composite restoration
48628933|NCT03215615|PROCEDURE|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
48628934|NCT01127061|BEHAVIORAL|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
48628935|NCT04541654|GENETIC|Data and Specimen Collection|"* Provide research team and access to relevant medical records~* Answer short questionnaires periodically~* Consider consenting to other optional parts of the research such as:~* Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional).~* Provide a saliva sample (optional).~* Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional).~* Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional).~* Consider inviting relatives to join the study (optional)."
47938248|NCT04914507|DEVICE|Anterior Vertebral Body Tethering|Subject will receive anterior vertebral body tethering surgery.
47938249|NCT02878824|OTHER|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek \& Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr \& Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
47938250|NCT02878824|OTHER|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray \& Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
47938251|NCT03407300|DRUG|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
47938252|NCT03407300|DRUG|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
47938253|NCT05751096|DEVICE|Low-intensity Focused Ultrasound (LIFU)|repeat pulse application of low intensity focused ultrasound using a single element transducer to a selected neurological target for neuromodulation.
48469943|NCT04529876|DRUG|Abatacept|Abatacept claim is used as the exposure group.
47938254|NCT05751096|DEVICE|Sham Low-intensity focused ultrasound (LIFU)|Sham application of LIFU.
47938255|NCT05078502|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of vitamin D3(40000IU) weekly for 8 weeks
47938256|NCT02039440|OTHER|Blood draw|One-time blood draw
48284406|NCT06519929|PROCEDURE|ESP block with catheter using ropivacaine (bolus followed by continuous infusion)|A total of ropivacaine 75mg will be injected into the plane via the needle, followed by placement of a catheter 3-5 cm into the plane. A continuous infusion of ropivacaine 0.2% will be started at 8 mL/h and may be titrated up to a maximum of 10mL/h. Bolus doses of 5 mL using ropivacaine 0.2% will be permitted for breakthrough pain (pain score ≥ 7/10) and may be administered no more frequently than every 6 hours. Patients will be assessed for LAST twice daily by asking about tinnitus, perioral numbness, or metallic taste. Any patient who responds positively to these symptoms will have infusion stopped for 2 h and then restarted at a rate 2 mL/h lower. If the symptoms occur again, the catheter infusion will be stopped and the catheter removed. After the 72-hour study period the ESP catheter may remain in place if the patient has ongoing analgesia needs or if analgesia is controlled with oral medication the catheter may be removed at request of the treating team.
48469944|NCT04592419|DRUG|KSI-301|Intravitreal Injection
47938257|NCT03136731|DIAGNOSTIC_TEST|Celiac disease antibody screening|Observational parameters
48469945|NCT04592419|DRUG|Aflibercept|Intravitreal Injection
47938258|NCT05340907|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display (HUD) that allows users to interact with simulated environments and experience a first-person view (FPV). VR headsets replace the user's natural environment with virtual reality content, such as a movie, a game or a pre-recorded 360-degree VR environment that allows the user to turn and look around, just as in the physical world. Patient undergoing bronchoscopy will be given the device before and during the procedure.
47938259|NCT03119207|BEHAVIORAL|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
47938260|NCT00715169|DRUG|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
47938261|NCT00715169|OTHER|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
47938262|NCT03544476|BEHAVIORAL|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
48469946|NCT04592419|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
48469947|NCT04763447|OTHER|Attempt to withdrawal OMA treatment|Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
48469948|NCT04763447|DRUG|Continuation of OMA treatment|"Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care."
48469949|NCT01204125|DRUG|paclitaxel|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
47938263|NCT03544476|OTHER|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
47938264|NCT03463031|DRUG|GSP 301 NS|1 spray in each nostril twice daily for 14 days
47938265|NCT03463031|DRUG|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
47938266|NCT04807140|DRUG|Toripalimab, nab-paclitaxel, carboplatin|"Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
47938267|NCT04807140|DRUG|Toripalimab|"Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity."
47938268|NCT04807140|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
47938269|NCT01148797|DRUG|Canakinumab|
47938270|NCT01395862|DRUG|Salmeterol and Fluticasone|
47938271|NCT02186366|OTHER|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
47938272|NCT02186366|DRUG|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
47938273|NCT03122301|DRUG|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
47938274|NCT03122301|DRUG|Saline|sham injection with saline
48100851|NCT02214667|BEHAVIORAL|Jail and community-based behavioral health services|Existing behavioral health service programs
48100852|NCT02620072|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
48100853|NCT02620072|OTHER|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
48100854|NCT01367561|DRUG|Naloxone|
48100855|NCT01367561|DRUG|IV Methylnaltrexone (MNTX)|
48100856|NCT01367561|DRUG|Placebo|
48100857|NCT01429779|DRUG|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
48469950|NCT01204125|DRUG|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion~Route of administration :Intravenous"
48469951|NCT03455036|OTHER|Whole body vibration training|10 x 1 min whole body vibration exposure
48469952|NCT05547906|DRUG|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
48469953|NCT04304339|OTHER|Hypercapnic respiratory failure|Patients with hypercapnic respiratory failure will be followed without any additional intervention
47938275|NCT00147420|DRUG|Zhi Byed 11|
47938276|NCT04063098|OTHER|Oral glucose tolerance test|Oral glucose tolerance test (OGTT) after a 72-hours standardized diet. OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
48100858|NCT04758897|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
48100859|NCT04439513|DEVICE|Hemostasis|Compression device to achieve hemostasis.
48100860|NCT06477926|DRUG|ABBV-668 IR|• Oral Capsule
48100861|NCT06477926|DRUG|ABBV-668 ER|• Oral Tablets
48100862|NCT02615522|DEVICE|BPK-S Integration|
48106957|NCT00309452|OTHER|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
48469954|NCT05444543|DRUG|Fluticasone Propionate|Participants will cycle topical steroid in a three-months on three-months off fashion
48469955|NCT05444543|DRUG|Budesonide|Participants will cycle topical steroid in a three-months on three-months off fashion
48469956|NCT06073847|DRUG|Fedratinib|According to the approved label
48469957|NCT02240004|DEVICE|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
48469958|NCT01136928|DRUG|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
48469959|NCT06202534|OTHER||radiotherapy
48284407|NCT06519929|DRUG|Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h|A bolus of 1 mg/kg based on ideal body weight will be given over 10 minutes with a physician present and infusions will be started at 1 mg/kg/h based on IBW. Infusions will run continuously for the first 72 h and can be continued beyond that at the discretion of the treating team if pain persists. Patients will be assessed for LAST twice daily. Any patient with suspected LAST will have lidocaine infusion stopped and a lidocaine plasma level will be sent. If symptoms resolve, the lidocaine infusion can be restarted at a rate 25% lower. If pain is refractory to the lidocaine infusion and multimodal adjuncts, the infusion may be increased to a maximum of 1.5 mg/kg/h (during first 24 h only). The actual duration of the infusion as well as total lidocaine dose given in mg will be recorded. Stopping criteria for lidocaine will include the occurrence of new EKG changes for which an alternative explanation is not more likely as well as LAST symptoms.
48284408|NCT06066879|DRUG|Ketamine Hydrochloride|Pre-Operative Ketamine infusion
48284409|NCT03529487|DRUG|Oxymetazoline|Oxymetazoline gel applied intra-analy
48284410|NCT01826214|DRUG|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
48284411|NCT05813470|BIOLOGICAL|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
48284412|NCT05813470|BIOLOGICAL|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
48284413|NCT06057571|DRUG|TT-00420 (tinengotinib)|TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
48284414|NCT05326919|OTHER|Biobanking|For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
48100863|NCT06076434|OTHER|The Effect of Different Pressure Periods on Bruising and Pain After Subcutaneous Heparin Injection Applied to the Upper Arm Region|The injection site on the upper arm of each patient was cleaned with alcohol and after the alcohol was dried, 0.6 ml of subcutaneous heparin was injected into the tissue at a 90° angle with a 27 gauge needle. The heparin was injected in approximately 10 seconds without aspirating the syringe. After the injection, pressure was applied to the area with dry cotton for specified periods (10 second, 35 second and 60 second).
48469960|NCT06677619|DEVICE|intrusion by reverse curve wire in cervical position of twin slot bracket|intrusion of anterior teeth by putting reverse curve wire in incisal slot of twin slot bracket
48469961|NCT05138926|OTHER|Cervical Manipulation|high speed, low amplitude cervical manipulation
48469962|NCT05138926|OTHER|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
48469963|NCT05560451|BEHAVIORAL|Peer health coach intervention|Eligible participants will be randomly assigned to receive a telehealth delivered peer health coach intervention to promote health outcomes and behavior change among Veterans with multimorbidty.
48469964|NCT02266940|DRUG|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
47938277|NCT03115580|DEVICE|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
48100864|NCT04966156|BEHAVIORAL|CaRE-4-alloBMT plus usual care group|CaRE-4-alloBMT uses emerging eHealth technologies to reduce barriers to accessing and providing cancer rehabilitation which includes: 1) Individualized progressive exercise prescriptions that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials; 2) Individualized nutrition plans and stepped stratified care such as education, counselling, intervention based on nutritional status and delivered by registered dietitians; 3) On-line e-modules provide interactive education to promote self-management skills for stress management, nutrition, managing common symptoms, etc.; 4) Remote monitoring using FitbitTM devices to monitor patients physical activity, caloric intake, and sleep for duration of the program. CRS and alloBMT clinicians will have access to real-time Fitbit data through our clinical dashboard; 5) Remote clinical support: check-ins and health coaching sessions with a member of the CRS team (phone or MS Teams video).
48100865|NCT04472338|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or tissue samples
48100866|NCT04472338|OTHER|Laboratory Biomarker Analysis|Correlative studies
48284415|NCT05755789|DRUG|Loading bolus of cefoxitin|Cefoxitin \[2g\] before incision
48284416|NCT05755789|DRUG|Intermittent cefoxitin|Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
48284417|NCT05755789|DRUG|Continuous infusion of placebo|Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
48284418|NCT05755789|DRUG|Continuous infusion of cefoxitin|Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
48284419|NCT05755789|DRUG|Intermittent placebo|Additional bolus of placebo every 2 hours until the end of surgical closure
48469965|NCT02266940|DRUG|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
48469966|NCT05567887|DRUG|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
48469967|NCT02806609|OTHER|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
48469968|NCT02806609|OTHER|immersion in water at room temperature|immersion in water at room temperature
48469969|NCT02806609|OTHER|active recovery - running|active recovery
48469970|NCT02806609|OTHER|rest in the chair|rest in the chair
48469971|NCT03312400|DRUG|Danazol|Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
48628936|NCT04087590|DRUG|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
48284420|NCT00679861|BEHAVIORAL|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
48284421|NCT00679861|BEHAVIORAL|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
48284422|NCT06283706|OTHER|Tryptophan|There are 7 different tryptophan test levels ranging from 0.5, 2, 4, 6, 8, 10, 12 mg.kg-1.day.1
48284423|NCT05434546|DRUG|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
48284424|NCT05595525|DEVICE|1064NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
48469972|NCT01681862|BEHAVIORAL|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
48469973|NCT06678282|DRUG|JY231 Injection|The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.
48469974|NCT03684889|BIOLOGICAL|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
48469975|NCT03684889|BIOLOGICAL|SCRI-huCAR19v2|Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
48469976|NCT06488469|BEHAVIORAL|Psychological Interventions for children and adolescents|"Psychological Interventions for children and adolescents:~* Behavioral modifications using Functional Analysis and Parent Management Techniques~* Illness Management behavior - Motivational Interviewing, Cognitive Therapy to identify thinking errors posing challenges to self-management, Behavioral Modification to enhance self-management of illness, Solution focused therapy to manage identified barriers in illness -management~* Managing emotional problems- Cognitive Behavioral Therapy techniques~Psychological Interventions for Parents/ Caregivers:~* Parent management techniques- Identification of problem behaviors/deficit~* Education on Dysfunctional attitude and their effects Psycho-education for Children could be delivered best in Combined with Health Education and Nutritional education leading to dietary modifications.~* Individualized Treatment targets and Resetting targets"
47938278|NCT03115580|DEVICE|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
47938279|NCT03486704|BEHAVIORAL|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
47938280|NCT03486704|BEHAVIORAL|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
47938281|NCT03486704|BEHAVIORAL|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
48100867|NCT04472338|OTHER|Quality-of-Life Assessment|Ancillary studies
48100868|NCT04472338|OTHER|Questionnaire Administration|Ancillary studies
48100869|NCT00982254|DRUG|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
48100870|NCT00982254|DRUG|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
48284425|NCT05595525|DEVICE|755NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
48284426|NCT05041101|DRUG|Eribulin Mesylate|Given IV
48284427|NCT05041101|DRUG|Grapiprant|Given PO
48284428|NCT05467085|DEVICE|BX Pulsar 1002|Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
48284429|NCT03552783|BEHAVIORAL|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
48284430|NCT03552783|BEHAVIORAL|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~1. Personal responsibility~2. Personal responsibility to your child~3. Responsibility to your family and community"
48284431|NCT01715025|DRUG|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
48284432|NCT03216629|BEHAVIORAL|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
48284433|NCT03280329|OTHER|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
48284434|NCT03280329|OTHER|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
48284435|NCT00744289|OTHER|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
48284436|NCT05796661|OTHER|Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration|"Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow."
48284437|NCT04840667|DRUG|REPLAGAL|Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
48284438|NCT03808961|DIETARY_SUPPLEMENT|Niacin|100mg tablets twice daily
48284439|NCT03808961|DIETARY_SUPPLEMENT|Niacinamide|100mg tablets twice daily
48284440|NCT03808961|OTHER|Placebo|Placebo tablet twice daily
48284441|NCT05957081|DRUG|PMC-309 monotherapy|PMC-309 will be administered intravenously.
48284442|NCT05957081|DRUG|PMC-309 Dose Escalation in Combination with Pembrolizumab|Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.
48284443|NCT05957081|DRUG|PMC-309 Dose Expansion|"Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~* Cohort A: PMC-309 monotherapy therapy~  - PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~* Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab"
48284444|NCT01817257|DRUG|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
48100871|NCT06173570|DRUG|AZD0780|AZD0780 administered orally, once daily for 12 weeks
48100872|NCT06173570|DRUG|Placebo|Placebo administered orally, once daily for 12 weeks
48100873|NCT03172403|DIAGNOSTIC_TEST|Height and weight|Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
48100874|NCT03172403|DIAGNOSTIC_TEST|Blood samples|Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
48100875|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle force|Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
47938282|NCT03486704|BEHAVIORAL|Face to Face VRRS plus active tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
47938283|NCT03486704|BEHAVIORAL|Face to Face VRRS plus placebo tDCS and telerehabilitation|"Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
47938284|NCT04661020|DRUG|CD19 CAR-T cells|Each subject receive CD19 CAR T-cells by intravenous infusion
47938285|NCT02763761|DRUG|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
47938286|NCT02763761|DRUG|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
47938287|NCT00285467|DRUG|doxercalciferol|form of vitamin D that is already in active form.
47938288|NCT00285467|DRUG|Cholecalciferol|from of vitamin D that requires cells in the body to make active
47938289|NCT02923544|PROCEDURE|YUMI manipulator|
48284445|NCT01242111|DRUG|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
48284446|NCT03050684|PROCEDURE|vaginal lavage group|vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
48284447|NCT03050684|PROCEDURE|Control Group|vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
48284448|NCT04705454|BIOLOGICAL|Loncastuximab Tesirine|
48284449|NCT03980093|BEHAVIORAL|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
48284450|NCT03980093|BEHAVIORAL|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
48284451|NCT03335501|DEVICE|Insulin pump|The participant's insulin pump will be used to infuse insulin
48284452|NCT03335501|DEVICE|Continuous glucose monitoring system|The Dexcom G4 Platinum will be used to measure glucose levels
48284453|NCT03335501|OTHER|11-hour intervention with the single-hormone artificial pancreas|"Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes."
48284454|NCT03818035|DRUG|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
48284455|NCT03818035|DRUG|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
48284456|NCT00921921|DRUG|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
48284457|NCT00921921|DRUG|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
48284458|NCT05720312|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
48284459|NCT00934609|BEHAVIORAL|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
48284460|NCT04273945|DRUG|Macitentan 10 mg|Participants will receive macitentan 10 mg film-coated tablets orally.
48284461|NCT04273945|DRUG|Macitentan 37.5 mg|Participants will receive macitentan 37.5 mg film-coated tablets orally.
48284462|NCT04273945|DRUG|Macitentan 75 mg|Participants will receive macitentan 75 mg film-coated tablets orally.
48284463|NCT04273945|DRUG|Placebo|Participants will receive matching placebo film-coated tablets orally.
48284464|NCT04783155|DEVICE|POWERBreathe Plus®|Commercially available pressure-threshold device
48284465|NCT04783155|OTHER|Cardiopulmonary rehabilitation post lung transplant|Pulmonary function, lung diffusing capacity for carbon monoxide, inspiratory muscle strength, and diaphragm dimensions will be assessed in each patient. Each patient will also undergo a cardiopulmonary exercise test (CPET), 6 minute walk test, and an inspiratory muscle endurance test
48284466|NCT05951582|OTHER|Plyometric Exercises|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~1. Horizontal jumps over hurdle.~2. Standing long jump~3. Front cone hops~4. Forward-backward run~5. Double leg horizontal jump~6. Lateral jump over hurdle~7. Side to side sprint~8. Jumps over low hurdles~9. Split squat jump~10. Cone hops with change of sprint direction~11. Lateral jump over hurdle~12. Side to side slide and hops.~13. Lateral and horizontal jump~14. Cone hops with 180o turn~15. Vertical, Lateral, and horizontal jump~16. Lateral cone jump~17. Single leg lateral jump~18. Diagonal Jumps.~19. Standing long jump with diagonal sprint.~20. Single leg vertical jump~21. Cone hop with 1800 turn~22. Skipping over cone"
48284467|NCT05951582|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~1. Single Leg Squat/ Lunges~2. Modified Box Step Ups~3. Press Ups~4. Box Jumps~5. Shoulder Press~6. Standing Band Row~7. Band Butterfly Pills"
48284468|NCT00532259|DRUG|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
48284469|NCT02511210|BEHAVIORAL|regional anesthesia|preoperative anxiety
48284470|NCT02511210|BEHAVIORAL|general anesthesia|preoperative anxiety
47938290|NCT00014027|DRUG|Docosahexaenoic acid (DHA)|
48284471|NCT02418494|OTHER|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
48284472|NCT02418494|OTHER|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
48284473|NCT03184870|DRUG|BMS-813160|Specified dose on specified days
48284474|NCT03184870|BIOLOGICAL|Nivolumab|Specified dose on specified days
48284475|NCT03184870|DRUG|Nab-paclitaxel|Specified dose on specified days
48284476|NCT03184870|DRUG|Gemcitabine|Specified dose on specified days
48284477|NCT03184870|DRUG|5-fluorouracil (5-FU)|Specified dose on specified days
48284478|NCT03184870|DRUG|Leucovorin|Specified dose on specified days
48284479|NCT03184870|DRUG|Irinotecan|Specified dose on specified days
48284480|NCT00833859|DRUG|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
48284481|NCT00833859|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
48284482|NCT00937235|DRUG|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
48284483|NCT00937235|BEHAVIORAL|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
48284484|NCT00937235|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
48284485|NCT05432570|PROCEDURE|Group A - Muscle Relaxants Used|Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
48284486|NCT05432570|PROCEDURE|Group B - No Muscle Relaxants|Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
48284487|NCT02391610|OTHER|No intervention|
48284488|NCT01657123|OTHER|ergometry|ergometry measurements
48284489|NCT01657123|OTHER|ergometry|Ergometry measurements
48284490|NCT03978650|OTHER|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
48284491|NCT00363415|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
48284492|NCT00363415|DRUG|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
48284493|NCT00363415|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
48469977|NCT03504124|OTHER|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
48469978|NCT01355328|PROCEDURE|laser and radiofrequency|different laser and radiofrequency with different fluences
48469979|NCT04491916|DRUG|irone sucrose|drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
48469980|NCT06092827|BEHAVIORAL|Non weight-bearing physical activity program|12-week duration, 2 supervised trainings/week, 1 unsupervised home-based training/week Aerobic, resistance and flexibility exercises
48469981|NCT04585750|DRUG|PC14586|First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.
47938291|NCT00014027|DRUG|Eicosapentaenoic acid|
48284494|NCT06489288|OTHER|ERAS protocol|The ERAS process mainly includes removing the urethral catheter before the recovery of anesthesia, removing the abdominal drainage tube within 3 days after surgery, removing the nasogastric feeding tu
48284495|NCT01697332|DRUG|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
48284496|NCT04331899|DRUG|Peginterferon Lambda-1a|Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
48284497|NCT04331899|OTHER|Placebo|Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
48284498|NCT02682810|DEVICE|DNA PCR HIV diagnostic test|standard of care
48284499|NCT02682810|DEVICE|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
48469982|NCT04585750|DRUG|pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
48469983|NCT04618419|DIAGNOSTIC_TEST|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
48469984|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation A)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
48469985|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation B)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
48469986|NCT05186753|DRUG|Placebo Tablets|Placebo will be administered orally, once daily continuously for 28-day cycles
48628937|NCT01759641|DEVICE|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
47938292|NCT00462371|DEVICE|Insulin pump (CSII)|
47938293|NCT05038904|DRUG|Acalabrutinib|100 mg oral capsule
48469987|NCT06642675|DEVICE|Intermittent theta burst stimulation(iTBS)|By using the TMS Navigation System, the iTBS will be targeted at the left Supramarginal Gyrus.iTBS will be performed using Magstim Rapid² stimulator, parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 1800 pulses per session, intensity of 90% resting motor threshold(RMT), total duration of 10 minutes.
48469988|NCT06642675|DEVICE|Sham stimulation|Patients in sham group would receive the same intervention procedure as the active ITBS group, but the coil will be replaced with sham coil, which provides the sensation of TBS without enough magnetic energy to reach the cortex.
48469989|NCT02816424|BEHAVIORAL|Teens Exploring and Managing Prevention Options (TEMPO)|
48284500|NCT03431389|DEVICE|Tracheostomy tube|Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
48284501|NCT05952414|BEHAVIORAL|self-efficacy-based interventions|The intervention aims at increasing self-efficacy and consists of Cognitive Behavioural Therapy (CBT)-based exercises related to sources of self-efficacy beliefs: 1) mastery experiences, 2) vicarious experiences, 3) verbal persuasions, and 4) emotional and physiological states.
48284502|NCT05531240|PROCEDURE|Prostate Artery Embolization|Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.
48284503|NCT05531240|PROCEDURE|Transurethral Prostate Resection (TURP)|Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
48469990|NCT06531915|DRUG|Ciprofol|Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).
48100876|NCT03172403|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
48100877|NCT03172403|DIAGNOSTIC_TEST|Muscle biopsy|Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
48100878|NCT02584153|DRUG|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
48100879|NCT02584153|DRUG|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
48100880|NCT06225999|DRUG|Irinotecan liposome injection (S095013)|Irinotecan liposome injection (S095013) will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
48284504|NCT02485392|DEVICE|Da Vinci Single Site Robot-Assisted Cholecystectomy|
48284505|NCT02485392|DEVICE|Single Incision Laparoscopic Cholecystectomy|
48284506|NCT06657534|PROCEDURE|Push-pull technique|push-pull technique as described by McBride et al, J Infus Nurs 2018
48284507|NCT06657534|PROCEDURE|SOC (Standard of care)|Standard of care method to obtain blood with waste blood
48284508|NCT04578210|BIOLOGICAL|T memory cells and NK cells|Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
48284509|NCT01874483|DRUG|Placebo|placebo
48469991|NCT06531915|DRUG|Remimazolam|Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).
48628938|NCT03693898|OTHER|Observeational|No intervention, observational
48100881|NCT06225999|DRUG|Oxaliplatin|Oxaliplatin will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
48284510|NCT01874483|DRUG|BI 187004|BI 187004, dose 2
48284511|NCT01874483|DRUG|BI 187004|BI 187004, dose 4
48284512|NCT01874483|DRUG|BI 187004|BI 187004, dose 5
48284513|NCT01874483|DRUG|BI 187004|BI 187004, dose 6
48284514|NCT01874483|DRUG|BI 187004|BI 187004, dose 7
48284515|NCT01874483|DRUG|BI 187004|BI 187004, dose 1
48284516|NCT01874483|DRUG|BI 187004|BI 187004, dose 3
48284517|NCT01947270|OTHER|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:~* Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~* Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
48284518|NCT04945655|OTHER|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
48628939|NCT00139035|DRUG|cyclosporine A|
48628940|NCT02042001|DRUG|Immediate switch to TDF/FTC/RPV|
48628941|NCT02042001|DRUG|Switch to TDF/FTC/RPV after 24 weeks|Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
48100882|NCT06225999|DRUG|LLV (levoisomer form of leucovorin)|LLV will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
48100883|NCT06225999|DRUG|5- FU (5-Fluorouracil)|5-FU will be administered via intravenous (IV) infusion on days 1 and 15 of each 28-day cycle.
48100884|NCT05449002|BEHAVIORAL|Practicing the Opposite (PTO)|This 30-45-minute digital program is designed to help youths on the waitlist feel better prior to treatment and may also improve their treatment engagement and outcomes.
48100885|NCT05449002|OTHER|Usual Clinical Care|Usual care provided by participating youth mental health clinics in the United States.
48100886|NCT01547741|DRUG|Doxorubicin|
48100887|NCT01547741|DRUG|Cyclophosphamide|
48100888|NCT01547741|DRUG|Docetaxel|
48100889|NCT01547741|DRUG|Paclitaxel|
48100890|NCT03724370|BEHAVIORAL|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
48100891|NCT03724370|OTHER|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
47938294|NCT05314985|OTHER|Prehab intervention|Individual training program containing strengthening, sensori-motor, joint mobilisation and endurance exercises as well as educational inputs concerning perioperative procedure and instructions on e.g. how to walk with crutches.
47938295|NCT04105829|OTHER|Bond-a braid|Stainless steel lingual retainer application
48284519|NCT04945655|OTHER|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
48284520|NCT04945655|OTHER|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
48284521|NCT03456492|DIAGNOSTIC_TEST|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
48284522|NCT02849769|DEVICE|Implant of an MR-conditional Tachy device system|
48284523|NCT00883753|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
48284524|NCT00968266|BEHAVIORAL|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
48284525|NCT03864965|OTHER|Advance Care Planning|The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
48284526|NCT02389881|DRUG|TAK-058|TAK-058 Solution
48284527|NCT02389881|DRUG|TAK-058 Placebo|TAK-058 placebo-matching solution
48284528|NCT03446924|DIETARY_SUPPLEMENT|Phosphatidic Acid|To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
48284529|NCT03446924|DIETARY_SUPPLEMENT|Rice flour|Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
48284530|NCT04038333|OTHER|No intervention|This is an observational study without any interventions.
48284531|NCT00520026|DRUG|lithium|
48284532|NCT00520026|DRUG|placebo|
48284533|NCT00015548|DRUG|Olanzapine|
48284534|NCT00015548|DRUG|Quetiapine|
47938296|NCT04105829|OTHER|EverStick-Ortho|Fiber reinforced lingual retainer
47938297|NCT04105829|OTHER|Ribbond|Fiber reinforced lingual retainer
48284535|NCT00015548|DRUG|Risperidone|
47938298|NCT05152316|OTHER|Observational study|This is an observational study and no additional interventions will be done except for those that are standard care. Blood and tracheal aspirates will be taken to assess the surfactant protein levels and inflammatory markers including cell counts and cytokine levels.
47938299|NCT00336583|DRUG|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
47938300|NCT04935437|OTHER|Supervised rehabilitation program.|The program includes aerobic exercise, strengthening exercises, physiotherapy, psychological support and dietary advice.
48284536|NCT00015548|DRUG|Citalopram|
47938301|NCT04352231|DIETARY_SUPPLEMENT|High Fiber Diet Intervention|Plant-based diet with a targeted quantity of 35 g of dietary fiber per day, from a variety of fiber types. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
48284537|NCT02456623|BEHAVIORAL|Intervention|Home-based session targeting the parent
48469992|NCT01463891|DRUG|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
47938302|NCT04352231|DIETARY_SUPPLEMENT|Low Fiber Diet Intervention|Animal based diet (meat, dairy) with a targeted quantity of 10 g of dietary fiber per day. Each meal will be balanced to provide all essential nutrients and portions will be of adequate size to ensure participants are satiated. Participants on both diet interventions will be given multivitamin supplements in order to ensure they are receiving essential vitamins and minerals.
47938303|NCT05644782|OTHER|Open wheat challenge|Patients randomized to intervention diet group will have to follow a diet with elimination of wheat and cow's milk products for 2 months; after that they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
48284538|NCT02456623|BEHAVIORAL|Attention Control|Attention condition with newsletters and support phone calls
48469993|NCT00067132|PROCEDURE|Juven (nutritional), HMB (nutritional)|
48469994|NCT05881733|DEVICE|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
48469995|NCT01155102|DRUG|Anastrozole|1 mg tablet
48628942|NCT00408447|DRUG|Busulfan|Busulfan 4 mg/kg/d x 4d
48628943|NCT00408447|DRUG|Fludarabine|Fludarabine 30 mg/m2/d x 6d
48628944|NCT00408447|DRUG|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
47938304|NCT05644782|OTHER|Placebo challenge|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
47938305|NCT03784365|DRUG|One dose of Cefo-perazone Sulbactum|Antibiotic
47938306|NCT01322308|DRUG|pioglitazone|30 mg tablet QD (taken once daily)
47938307|NCT01322308|DRUG|placebo|tablet taken once a day
47938308|NCT00002398|DRUG|Levocarnitine|
47938309|NCT00002398|DRUG|Adefovir dipivoxil|
47938310|NCT01249118|DRUG|GDC-0973 IV Infusion|IV infusion.
47938311|NCT01249118|DRUG|GDC-0973 Oral Capsules|Oral dose.
48469996|NCT06678321|BEHAVIORAL|Mobil game|Participants in the intervention group will be asked to play the game and complete all parts.
47938312|NCT06353230|PROCEDURE|injection 5% phenol in almond oil|Group A were given 5% phenol in almond oil
48469997|NCT04246281|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
47938313|NCT06353230|PROCEDURE|injection 15% hypertonic saline|Group B were given hypertonic saline
47938314|NCT06353230|PROCEDURE|injection 50% dextrose water|group C were given 50% dextrose water
47938315|NCT04737057|PROCEDURE|SDF|Apply this topical medication through : 1)Dry with a gentle flow of compressed air to decayed tooth surfaces. 2) Bend micro sponge brush to remove excess liquid before application apply SDF directly to only the affected tooth surface. 3) Apply the SDF material 4)Dry with a gentle flow of compressed air for at least one minute. and Remove excess SDF with gauze
47938316|NCT04737057|PROCEDURE|Hall technique|this technique is performed through :1) Orthodontic separator being stretched between two pieces of floss, then placed between the contact points of primary molars (for five days.) 2)The correct size of crown will not impinge on the teeth on either side, and a slight 'spring back' will be felt when the PMC is gently pushed up to (but not through) the contact points and the PMC has been filled with a Riva self-cure capsule cement, extruded cement is quickly wiped away and the child is asked to keep biting on the crown for two minutes, until the cement is set, to prevent 'spring back' of the PMC from the fully seated position
47938317|NCT05170568|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
47938318|NCT06008834|PROCEDURE|First-day discharge protocol|Enhance Recovery after Surgery (ERAS) protocol consisting in perioperative mesures and first-day hospital discharge with domiciliary follow-up
47938319|NCT04387760|DRUG|Hydroxychloroquine|"400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
47938320|NCT04387760|DRUG|Favipiravir|"1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."
47938321|NCT04387760|OTHER|Routine care for COVID-19 patients|Supportive care according to local guidelines
47938322|NCT01417182|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
47938323|NCT04534465|DRUG|Polyethylene glycol (MiraLAX, BAY81-8430)|Oral solution, 17g polyethylene glycol, one time
47938324|NCT04534465|DRUG|Mannitol|Oral, 2g, 4g, 6g, 8g and 10g mannitol, one time
48100892|NCT04084288|OTHER|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
48100893|NCT04084288|DEVICE|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
48100894|NCT06417450|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
48469998|NCT04246281|PROCEDURE|Standard interventional management of low back pain|Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
48469999|NCT05724108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47938325|NCT05380999|DIAGNOSTIC_TEST|Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)|Up to 15 ml of peripheral blood will be collected from each subject, and the blood specimen will be processed to isolate mature red blood cells and extract the DNA and RNA from RBCs. DNA and RNA methylation will be tested by next-generation sequencing (NGS).
47938326|NCT03258177|OTHER|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
48100895|NCT06417450|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
48100896|NCT03072355|OTHER|Elastic Band|Localized muscle resistance test for shoulder
48100897|NCT03072355|OTHER|Isokinetic dynamometer|Localized muscle resistance test for shoulder
48100898|NCT02968004|DRUG|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
48470000|NCT05724108|PROCEDURE|Computed Tomography|Undergo CT
48470001|NCT05724108|DRUG|Lutetium Lu 177 Dotatate|Given IV
48470002|NCT05724108|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48284539|NCT02234037|DRUG|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
48284540|NCT02234037|BEHAVIORAL|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise \> 10 minutes of muscle strengthening, \> 10 minutes of aerobic exercise (treadmill walking or cycling), \> 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
48284541|NCT00551707|DRUG|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
48284542|NCT00551707|DRUG|prednisolone|prednisolone (2.7 mg)
48284543|NCT00551707|DRUG|dipyridamole|dipyridamole 360 mg
48284544|NCT00551707|DRUG|placebo|placebo
48284545|NCT00551707|DRUG|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
48470003|NCT05724108|DRUG|Triapine|Given PO
48470004|NCT06358001|DEVICE|EchoTip AcuCore|Using endoscopic ultrasound guided needle to collect biopsies
48470005|NCT06130969|OTHER|Cervical Retraction Exercise|Participants will hold cervical retraction for 10 s up to 10 times. A break of 5 s will be provided per one movement and 30 s per one set. A total of three sets will be conducted. Therefore, the total exercise time will be \<10 mints.
48470006|NCT06130969|OTHER|Diaphragmatic Breathing|The diaphragmatic exercise will be performed in a supine position with 40° trunk flexion while holding 2.5 kg on the abdomen in the first 5 sessions and then 5 kg in the second 5 sessions. Participants will perform 3 sets with 10 repetitions at a ratio of one second of inspiration to two seconds of expiration, three sets of 15 repetitions at a ratio of two seconds of inspiration to four seconds of expiration, and three sets of 20 repetitions at a ratio of three seconds of inspiration to six seconds of expiration. The rest between rests will be 60 s.
48470007|NCT06130969|OTHER|Baseline Treatment|"Hot fomentation will be given by applying cervical hot pack over the area in prone lying position for 10 mints and Isometric neck strengthening exercises (10 repetitions, each 5-second hold, 1 set) (20). • Nerve Stimulation (TENS) on the painful regions around the neck for 15 minutes with a TENS device. TENS parameters will be 150 μs square pulses with a frequency of 80 Hz.~The intensity of the current will be adjusted to produce no contraction.~• Posture education to keep upright posture during sitting."
48470008|NCT06679712|PROCEDURE|Transbronchial PDT lung tumor ablation|Transbronchial photodynamic therapy ablation for peripheral lung cancer
47938327|NCT04587180|PROCEDURE|Arthroscopic suture-bridge rotator cuff repair|Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
48100899|NCT02968004|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin using pre-filled pen device.
48100900|NCT04885595|PROCEDURE|Forceps biopsy and cryobiopsy|Once the nodule is visualized by radial EBUS, the position of the probe in relation to the lesion is noted. Routinely, forceps biopsy and cryobiopsy are used serially in each patient within the same session.
48100901|NCT05931107|OTHER|Stress ball practice group (Stress ball squeezing)|The stress ball is made of round, colorful, high-quality silicone. A stress ball of medium hardness and 6 cm in diameter (suitable for adult use) will be used in the research. When it is loosened, it returns to its original state. In the experimental group, the patients are required to squeeze the ball once after counting to three, inhale each time they squeeze the ball, exhale when they loosen their grip, and focus only on the ball. The experimental group has to squeeze the stress ball for 10-15 minutes every day for 4 weeks.
48100902|NCT06627426|OTHER|VR-based patient informed consent|"The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model first with demonstration of the technology and the model, afterwards the patient will be enabled to use the VR system by themselves. During the whole process the patient will be able to ask questions. Depending on the planned surgery, the surgical approach as well important anatomical structures will be explained."
48100903|NCT05757076|PROCEDURE|Blood test for ARR|Blood test for calculating aldosterone and renin ratio (ARR)
48100904|NCT03476109|DRUG|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
48284546|NCT04287530|DIETARY_SUPPLEMENT|Poly-unsaturated fatty acids supplementation|Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
48284547|NCT04287530|BEHAVIORAL|Neuropsychological intervention|"Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session."
48284548|NCT04287530|DIETARY_SUPPLEMENT|Placebo|Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
48284549|NCT05343195|OTHER|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
48284550|NCT05343195|OTHER|Control|Control intervention: conventional physiotherapy after hip replacement
48284551|NCT05164523|DIAGNOSTIC_TEST|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
48284552|NCT05164523|DIAGNOSTIC_TEST|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
48284553|NCT00820105|DRUG|ADX10059|oral administration
48284554|NCT00820105|DRUG|ADX10059|Oral administration
48284555|NCT00820105|DRUG|ADX10059|Oral administration
48284556|NCT00820105|DRUG|ADX10059 Matching Placebo|Oral administration
47938328|NCT03124238|OTHER|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
47938329|NCT00939757|DRUG|mirabegron|oral tablet
47938330|NCT05473182|OTHER|IndieTrainer system|The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
47938331|NCT02297282|BEHAVIORAL|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
47938332|NCT02857595|BEHAVIORAL|Online Behavioral Weight Loss program|
47938333|NCT02857595|BEHAVIORAL|Weight Loss Nomogram|
47938334|NCT02857595|BEHAVIORAL|Bite Counter|
47938335|NCT04661969|PROCEDURE|Surgery|(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
47938336|NCT03741127|DRUG|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
47938337|NCT01616082|BEHAVIORAL|Low Calorie Diet (LCD)|A Diet History Questionnaire was completed and subjects had dietary counseling and were provided shakes. The low calorie diet began, to continued for a period of 8 weeks.
47938338|NCT01616082|DRUG|Phentermine|"Individuals not on track to achieve their target weight by four weeks received the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects were given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~* Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~* Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
48284557|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
48470009|NCT06461442|PROCEDURE|Cryotherapy|Extremely cold liquid (liquid nitrogen) will used by a dermatologist to freeze and destroy abnormal cells in the treatment areas randomized to this treatment.
47938339|NCT03403270|OTHER|ENCOURAGE App|Users will have an opportunity to engage with the app as described for the duration of the study period.
47938340|NCT02380820|DEVICE|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
47938341|NCT02380820|DEVICE|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
47938342|NCT03364907|OTHER|HIPEC with flushing afterwards|flushing with saline fluid after HIPEC
47938343|NCT03364907|OTHER|HIPEC without flushing afterwards|NO flushing with saline fluid after HIPEC
47938344|NCT00179127|DRUG|glargine|0.3u/kg of glargine, subcutaneously, once
47938345|NCT00179127|DRUG|saline|0.3u/kg of saline, subcutaneously, once
47938346|NCT04908020|OTHER|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
47938347|NCT05715671|DRUG|esketamine|The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
47938348|NCT05439642|OTHER|Evaluation of health related quality of life|Evaluation of health related quality of life of boys with hemophilia with the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool and the Pediatric Inventory of Quality of Life
47938349|NCT00235001|DRUG|trandolapril/verapamil|180/2 mg QD
47938350|NCT04235010|DEVICE|Genius toothbrush|Patients brushed their teeth twice a day for 2 minutes. An integral timer was used in the genius toothbrush group.
47938351|NCT04235010|DEVICE|Manual toothbrush|Patients brushed their teeth twice a day for 2 minutes. During brushing, patients in manual group assigned to use their brushes were provided with a digital timer.
47938352|NCT00554112|BEHAVIORAL|Exercise|Exercise
47938353|NCT01729247|DEVICE|NIOX MINO® Instrument (09-1100)|
47938354|NCT01721707|DRUG|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
47938355|NCT01721707|DRUG|Latanoprost|1 drop in each eye, 1x/day, at 9PM
48100905|NCT03476109|DRUG|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
48284558|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
48470010|NCT06461442|DRUG|5Fluorouracil|Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
48470011|NCT05752552|DRUG|DO-2|Deuterated MET kinase inhibitor
48470012|NCT04393623|BEHAVIORAL|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
48470013|NCT04393623|BEHAVIORAL|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
48470014|NCT03110016|DEVICE|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
48284559|NCT02331264|OTHER|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
48284560|NCT03715543|PROCEDURE|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
48470015|NCT06466356|OTHER|Psychoeducational Course for Suicide Prevention|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
47938356|NCT06516159|DIAGNOSTIC_TEST|MBI-C Scale in French|"The original version has 34 items, divided into 5 areas:~* a reduction in motivation, interests and initiative~* the appearance of mood disorders~* dysregulation of impulse management~* loss of conventions and societal norms~* the abnormal development of strongly held beliefs and sensory experiences~The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.~This scale is completed by a member of the healthcare team on the basis of information collected from the relative (informant) either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.~The test lasts 10 minutes."
47938357|NCT04551391|OTHER|Blood and urine sampling|Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
47938358|NCT05532787|OTHER|Application of acute chest pain risk stratification scores (HEART and EDACS)|Collection of data elements for the HEART Pathway and EDACS-ADP assessments and calculation of scores to risk stratify patients into low risk or high risk
47938359|NCT05086068|DEVICE|Arthrosamid|Intra-articular hydrogel injection comprising of water and cross-linked polyacrylamide.
47938360|NCT03810404|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0.15-, 0.25-, 0.35- and 0.50 g/kgFFM (0.12-, 0.20-, 0.28- and 0.40 g/kgBM), respectively). SB (Alkala, SANUM, Poland) will be administered as dissolved form in a 750 ml of fluid (water + fruit juice). On testing days the SB will be taken before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
47938361|NCT03810404|DIETARY_SUPPLEMENT|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 750 ml of fluid (water + fruit juice). On testing days the PLA will be taken before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
47938362|NCT02129660|DRUG|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
47938363|NCT02129660|DRUG|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
47938364|NCT02129660|DRUG|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
47938365|NCT02129660|DRUG|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
48470016|NCT06466356|OTHER|Individual therapy session|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
47938366|NCT02129660|OTHER|Vehicle|Vehicle Topical Wipes
48100906|NCT01265758|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
48100907|NCT00941356|DIETARY_SUPPLEMENT|Bio-K+ CL1285|2 capsules per day before breakfast
48100908|NCT00941356|DIETARY_SUPPLEMENT|Placebo|2 capsules per day before breakfast
48100909|NCT04437056|PROCEDURE|Cognitive nerve transfers to spastic upper extremity muscles in stroke patients|Based on the fact that upper motor neuron syndrome after stroke is presented with variable clinical features, usually without affecting in the same way the entire upper extremity, we aim to investigate the efficacy of nerve transfers to spastic muscles after stroke using as donor nerves that innervate unaffected ipsilateral volitionally controlled muscles.
48100910|NCT00817635|DRUG|LCI699|LCI699 oral capsules
48100911|NCT00817635|DRUG|Eplerenone|Eplerenone oral capsules
48100912|NCT00817635|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
48100913|NCT00817635|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
48284561|NCT01725763|OTHER|Cardiac MRI|
48284562|NCT03196713|BEHAVIORAL|Early Intensive Behavioral Intervention|
48100914|NCT01489176|DRUG|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
48100915|NCT01762371|OTHER|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
48100916|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
48100917|NCT00099515|DRUG|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
48284563|NCT01617486|BEHAVIORAL|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
48470017|NCT06466356|OTHER|Treatment as usual|Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
48470018|NCT03973788|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
48628945|NCT00408447|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
48470019|NCT06602414|PROCEDURE|Conservative treatment|Conservative treatment instead of surgical repair
48470020|NCT04694703|DRUG|Covid-19 group|Routine COVID-19 treatment
48470021|NCT05499416|DRUG|Bimekizumab|Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
48470022|NCT06049654|DEVICE|NVT ALLEGRA TAVI System TF|Transcatheter aortic valve implantation of a NVT ALLEGRA TAVI System TF in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
48470023|NCT06049654|DEVICE|EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM|Transcatheter aortic valve implantation of an EDWARDS SAPIEN 3 SYSTEM in patients with severe haemodynamical valve deterioration of a biological aortic valve implanted surgically
48470024|NCT06412029|OTHER|Non-Interventional|Non-interventional study
48470025|NCT00020839|DRUG|temozolomide|
48470026|NCT00020839|RADIATION|radiation therapy|
48470027|NCT06629142|BEHAVIORAL|Default Order|A specialist PC consult is automatically ordered for patients meeting a certain threshold of 1-year mortality risk (dependent on arm). An EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
48100918|NCT04131829|DRUG|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
48628946|NCT01030575|DRUG|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
48470028|NCT06629142|BEHAVIORAL|Accountable Justification|An EHR-based Our Practice Advisory alert asks generalist clinicians to self-report whether they have provided primary PC by clicking which of 4 key PC domains they have addressed or to provide a brief justification as to why not.
48470029|NCT06629142|BEHAVIORAL|Standardized Usual Care|Moderately high-risk patients (e.g., with a 1-year mortality risk between 60% and 94%) will receive usual care. For very high-risk patients (e.g., with a 1-year mortality risk of ≥ 95%), an EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
48628947|NCT01030575|DRUG|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
48628948|NCT01030575|DRUG|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
48628949|NCT01030575|DRUG|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
48628950|NCT03556176|BEHAVIORAL|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
48628951|NCT03556176|BEHAVIORAL|Quiet rest|Quiet rest during 30 min
47938367|NCT00741962|DIETARY_SUPPLEMENT|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
48284564|NCT03338946|DEVICE|CIED interrogation|CareLink Express interrogation
48284565|NCT04935736|DEVICE|root canal sealer : CORTISOMOL SP|The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
48284566|NCT04935736|DEVICE|root canal sealer : SEALITE REGULAR|The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
48470030|NCT05685017|DIAGNOSTIC_TEST|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
48470031|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
47938368|NCT00741962|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
47938369|NCT03293511|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
47938370|NCT03293511|DRUG|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
47938371|NCT04564885|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
48470032|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
48470033|NCT03266055|DIETARY_SUPPLEMENT|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
48470034|NCT03266055|DIETARY_SUPPLEMENT|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
48470035|NCT00249717|BEHAVIORAL|Contingency management|Receive rewards (prizes) abstinence and attendance
47938372|NCT04564885|DEVICE|Mobi-C Cervical Disc|surgery
47938373|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TEA LIQUID PACKETS|JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.
47938374|NCT06522412|DIETARY_SUPPLEMENT|JING SI HERBAL TANG HENG POWDER DRINK|JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
47938375|NCT05110547|BIOLOGICAL|blood collection|2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
47938376|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
47938377|NCT00640835|DRUG|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
47938378|NCT00679055|DRUG|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
47938379|NCT00679055|DRUG|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
47938380|NCT00121888|BEHAVIORAL|Prolonged Exposure Therapy|
47938381|NCT00121888|DRUG|Paroxetine-CR|
47938382|NCT01728948|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
48470036|NCT02938442|BIOLOGICAL|P10s-PADRE with MONTANIDE™ ISA 51 VG|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
48284567|NCT04813510|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
48284568|NCT04813510|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
48470037|NCT02938442|DRUG|Doxorubicin|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
47938383|NCT01668927|DRUG|Proton Pump Inhibitor|
47938384|NCT01668927|DRUG|Bismuth|
47938385|NCT01668927|DRUG|Metronidazole|
47938386|NCT01668927|DRUG|Tetracycline|
47938387|NCT01668927|DRUG|Furazolidone|
47938388|NCT01668927|DRUG|Amoxicillin|
47938389|NCT00249158|DRUG|Risperidone|
47938390|NCT03937869|DRUG|Secnidazole|One dose
47938391|NCT01255787|DRUG|Vortioxetine|Vortioxetine tablets
47938392|NCT01255787|DRUG|Placebo|Vortioxetine placebo-matching tablets
47938393|NCT06520202|DRUG|rhPRG4 (450 µg/mL)|1-2 drops of rhPRG4 450 µg/mL solution in both eyes
47938394|NCT06520202|DRUG|Vehicle|Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.
48100919|NCT04131829|DRUG|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
48100920|NCT00518362|DRUG|TW|TW,120 mg/d
48470038|NCT02938442|DRUG|Cyclophosphamide|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
48470039|NCT02938442|DRUG|Paclitaxel|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
48470040|NCT03969641|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
47938395|NCT03249493|OTHER|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL"
47938396|NCT04447872|PROCEDURE|Timing of injectable gonadotropins|Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
47938397|NCT04219462|DEVICE|active extracorporeal shock wave|Ultrasound gel was used as a coupling agent, and the applicator of extracorpral shock wave therapy (ESWT) will be held perpendicular to the treatment surface throughout the treatment. Men in this group (n= 20) men receive ESWT twice weekly for 3 consecutive weeks and repeated after a 3-week rest period, for a total of 12 treatment sessions. The patients will receive ESWT for 15 minutes at an energy level of 0.09 and a frequency of 120 shocks/min (1800 pulses per session). Shockwaves were delivered to the distal, mid, and proximal penile shaft, as well as to the left and right crura + 5 mg sildnafil once daily for 3 months
47938398|NCT04219462|DEVICE|sham extracorporeal shock wave|twenty men will receive sham treatment underwent identical therapy with ESWT application with a similar appearance and sound as the active extracorporal shock wave therapy (ESWT), although shock wave propagation to the tissue wills be blocked by a metal plate that will inserted into the sham applicator + sildenafil 5mg once daily for 3 months.
47938399|NCT02049671|DRUG|Growth Hormone Therapy|
47938400|NCT02374086|BEHAVIORAL|Exercise training|
47938401|NCT00284622|PROCEDURE|Arthroscopy|HTO with pre-scope
47938402|NCT04082039|OTHER|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
47938403|NCT04082039|OTHER|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
47938404|NCT04609475|PROCEDURE|Osseodensification technique|Implant bed preparation will be performed according to the manufacturer's guidelines, densifying burs (Densah® Burs) will be used sequentially in densifying mode (counterclockwise drill speed 800-1500 rpm with copious irrigation) to achieve the planned osteotomy diameter and desired ridge expansion. The implant will be then placed in the prepared osteotomy
48470041|NCT03969641|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
48100921|NCT00637676|PROCEDURE|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
48100922|NCT00637676|PROCEDURE|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
48100923|NCT04231474|DEVICE|Urodynamic testing|All data were obtained using the MMS Alfa 4T by the same urologist with use of an 8 Charr catheter.
48100924|NCT02033096|DRUG|Stannsoporfin|No intervention was administered during this observational study
48100925|NCT02033096|DRUG|Placebo Control|No intervention was administered during this observational study
48470042|NCT05587257|DEVICE|Fractional CO2 laser|"Each patient will receive 6 sessions 2 weeks apart, after the laser treatment, a topical 5% minoxidil tincture will immediately applied.~All patients will advised not to use any other treatment during the study"
48100926|NCT02033096|OTHER|Phototherapy (as needed)|No intervention was administered during this observational study
48470043|NCT05587257|DEVICE|Derma pen|, will be treated by microneedling using dermapen ( automated Derma Pen, DR Pen Ultima A6, China) which under complete aseptic precaution with a cartridge containing 12 needles moved diagonally, vertically, and horizontally for 4-5 times in each direction with 1.5 mm depth and speed 4-5(new cartridge every session), the application has been extended 1-2 cm perilesionally. The pinpoint bleeding will be considered an endpoint. topical 5% minoxidil tincture will immediately applied. Each patient will receive 6 sessions 2 weeks apart.
48470044|NCT05587257|DRUG|Niosome minoxidil|The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.
48470045|NCT05587257|DRUG|Minoxidil Topical Spray|The patient of alopecia areata will be treated by topical minoxidil 5% preparation twice daily for 3 months with no other treatment.
48470046|NCT03842670|BEHAVIORAL|Cognitive Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein \& McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
48470047|NCT03842670|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz \& Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
48470048|NCT06679361|BEHAVIORAL|Motor Exercise Program|This program consists of wrist motor exercises focused on active range of motion (including flexion, extension, ulnar and radial deviation, and finger flexion) along with nerve mobilization exercises for the medial, radial, and ulnar nerves. The aim is to enhance motor function in the wrist and hand.
48470049|NCT06679361|BEHAVIORAL|Sensory Exercise Group|Arm Description: This group will engage in sensory exercises designed to enhance sensory awareness in the hand and wrist. Exercises will include interaction with varied textures (such as sand and sensory balls), different fabrics (fur, satin, linen), and multisensory foam gels. The goal is to improve sensory function and tactile discrimination.
48470050|NCT06679361|BEHAVIORAL|Combined Motor and Sensory Exercise Group|Participants in this group will perform both motor and sensory exercises as described for the first two groups. By combining motor and sensory interventions, this group aims to improve both motor skills and sensory awareness in the wrist and hand, potentially enhancing overall hand function more effectively.
48470051|NCT05271227|OTHER|Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.|VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
48470052|NCT05296941|PROCEDURE|Brush sampling|Brush sampling instead of surgical biopsy for control of reaccurance
48470053|NCT04648007|DIAGNOSTIC_TEST|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
48470054|NCT03945058|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
48470055|NCT03945058|DEVICE|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
48628952|NCT01297790|OTHER|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
48628953|NCT01297790|OTHER|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
47938405|NCT04609475|PROCEDURE|Motor driven expanders' technique|The technique consisted of preparing the implant bed by progressively increasing the size of the osteotomes until the desired expansion will be achieved. At the planned implant site, a pilot drill 1000 rpm with irrigation until the desired length, then expansion with the series of ridge spreaders and finally using the final drill. The implant will be then placed in the prepared osteotomy.
47938406|NCT06169631|DEVICE|Gen0b|The ultrasound will be administered to the brain region of interest.
48100927|NCT01003015|DRUG|BAY73-4506|160 mg BAY73-4506
48100928|NCT01419717|DRUG|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
48284569|NCT01695369|DEVICE|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
48284570|NCT01695369|DEVICE|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
48284571|NCT01091350|DEVICE|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
48284572|NCT01091350|DEVICE|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
48470056|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
48470057|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - targeted-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.
48284573|NCT02453841|DRUG|Oxymetazoline|
48284574|NCT02863263|DEVICE|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
48284575|NCT02863263|DEVICE|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
47938407|NCT02474225|DRUG|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
47938408|NCT01479985|OTHER|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
48284576|NCT01613092|DRUG|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
48284577|NCT01613092|DRUG|Cefazolin|Preoperative antibiotic
47938409|NCT02360605|BEHAVIORAL|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
48470058|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
48284578|NCT00996840|DRUG|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
48284579|NCT00996840|DRUG|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
48284580|NCT00996840|DRUG|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
48284581|NCT00996840|DRUG|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
48284582|NCT00996840|OTHER|Placebo|Placebo to match intervention
48284583|NCT02592564|BEHAVIORAL|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
48284584|NCT02490540|DRUG|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
48284585|NCT02490540|DRUG|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
48284586|NCT02490540|DRUG|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
48284587|NCT04510259|PROCEDURE|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
48284588|NCT03873597|BEHAVIORAL|Tele-coaching + Usual Care|The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
48284589|NCT04177498|DRUG|Rigosertib Sodium|given PO or 72 hour continuous infusion
48284590|NCT04177498|OTHER|Quality-of-Life Assessment|Ancillary studies
48284591|NCT02489370|DEVICE|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
48284592|NCT06114043|OTHER|Conservative treatment with orthopedic aid/wide shoe for participants with mild to moderate hallux valgus|60 participants will receive conservative treatment with orthopedic aid/wide shoe. Participants will be followed for 2 years.
48284593|NCT06114043|OTHER|Operation for mild to moderate hallux valgus|60 participants will receive the traditional operative treatment for the deformity. Participants will be followed for 2 years.
48284594|NCT05264337|OTHER|Self-reported lymphedema|Lymphedema as reported by LymQOL questionnaire.
48284595|NCT05264337|OTHER|Dielectric constant ratio|Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
48284596|NCT05264337|OTHER|Limb volume|Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
48284597|NCT06337201|DEVICE|Test of the application Min Memoria|Focus group interviews will be conducted to reach healthcare professionals' experiences using a written life story in daily care. Then, the information from the written life story will be transferred to the application, and the healthcare professionals will test a digital life story (the application) in daily care instead. Observation studies will be conducted to observe the use of the digital life story. What can be seen in the communication and the interaction, and in what situations is the digital life story used?
48284598|NCT00035893|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
48284599|NCT01854177|DRUG|Aprepitant|
48284600|NCT01854177|DRUG|Placebo|
48284601|NCT01794780|DRUG|LABA based treatment: indacaterol|LABA based treatment: indacaterol
48284602|NCT01794780|DRUG|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
48284603|NCT01794780|DRUG|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
48284604|NCT01794780|DRUG|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
48284605|NCT01794780|DRUG|theophylline based treatment|theophylline based treatment
48106958|NCT04679519|OTHER|Drop Jumps|Perform 100 drop jumps from 40 cm height. The protocol is divided into 5 sets of 20 repetitions. Between each repetition participants get 10 seconds, and between each set 2 minutes rest. Stand on the box, drop of the box and land with feet shoulder width apart. Then immediately bend knee to approx 45 degrees and jump straight up. Throughout each jump hands are placed on hips and should not move.
48284606|NCT01794780|DRUG|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
48284607|NCT00432198|DRUG|Zolpidem (Myslee®)|Oral
47938410|NCT02360605|BEHAVIORAL|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
48628954|NCT01297790|OTHER|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
48628955|NCT01642316|OTHER|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
48106959|NCT00762606|PROCEDURE|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
48284608|NCT00432198|DRUG|placebo|Oral
48284609|NCT01723306|GENETIC|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
48284610|NCT02803034|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number- SR15-60-Z15-030).
48284611|NCT02053974|DRUG|Spironolactone|Spironolactone
48284612|NCT02053974|OTHER|Placebo|Placebo
48284613|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
48284614|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
48284615|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
48284616|NCT02615301|DIETARY_SUPPLEMENT|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
48470059|NCT03716323|DEVICE|immediate premolar implant with xenograft and allograft|"* A peritome will be used for atraumatic extraction of remaining roots.~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~* Copious normal saline irrigation and curettage will be performed.~* In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~* In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
48470060|NCT02810249|OTHER|No intervention used|
48470061|NCT01309724|OTHER|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
48106960|NCT00762606|PROCEDURE|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
48284617|NCT03244371|OTHER|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
48628956|NCT01642316|OTHER|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
48628957|NCT02416141|DRUG|fast release oro dispersible tramadol 50 mg|idem arm 1
48284618|NCT05954039|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex|The study foresees the intake of 2 capsules per day during 84 days
48284619|NCT05954039|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
48284620|NCT05572099|DIAGNOSTIC_TEST|ExoDx Prostate|Observational only.
48284621|NCT04872725|BEHAVIORAL|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
48628958|NCT00465868|PROCEDURE|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
48628959|NCT01567800|OTHER|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
48628960|NCT01625767|BEHAVIORAL|AAT experiment|Smokers and nonsmokers complete AAT experiment
48628961|NCT04710433|DEVICE|Non-invasive Neuromodulation|Sacral nerve stimulation via two adhesive electrodes (single current).
48628962|NCT04710433|OTHER|Medical and Behavioral Therapy|Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
48628963|NCT03051009|DRUG|Desmopressin ODT 25 μg|
48628964|NCT03051009|DRUG|Desmopressin ODT 50 μg|
48628965|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
48628966|NCT00575302|DRUG|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
48628967|NCT00003720|DRUG|semaxanib|
47938411|NCT02360605|BEHAVIORAL|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
47938412|NCT01296243|DRUG|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
47938413|NCT03504670|PROCEDURE|Early Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
47938414|NCT03504670|PROCEDURE|Late Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
47938415|NCT00289718|BIOLOGICAL|Twinrix™ adult|Intramuscular administration
47938416|NCT03621618|DIAGNOSTIC_TEST|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
47938417|NCT03621618|DIAGNOSTIC_TEST|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
47938418|NCT04397627|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
47938419|NCT05983887|OTHER|Therapeutic Climbing|The protocol consists of using an in-door climbing wall as an complementary therapeutic intervention model.
47938420|NCT01011023|OTHER|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
47938421|NCT04431427|DEVICE|Biliary drainage with PC-SEMS|partially covered metallic biliary stent insertion during ERCP
47938422|NCT04431427|DEVICE|Biliary drainage with U-SEMS|Uncovered metallic biliary stent insertion during ERCP
48284622|NCT06244576|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
48284623|NCT04767880|DIETARY_SUPPLEMENT|Whey|Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))
48470062|NCT05167617|DRUG|Vit D|Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
48470063|NCT03762837|OTHER|Benigh gallbladder diseases|We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
48470064|NCT01137734|DEVICE|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
47938423|NCT04551144|DRUG|testosterone cypionate|intramuscular injection every 2 weeks. Dose will be titrated based on blood levels
47938424|NCT04551144|DRUG|Estradiol Valerate|intramuscular injection every week. Dose will be titrated based on blood levels
47938425|NCT02280473|DRUG|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
48284624|NCT04767880|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
48284625|NCT02357992|RADIATION|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
48470065|NCT01137734|DEVICE|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
47938426|NCT02280473|DRUG|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
47938427|NCT01091727|DRUG|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
47938428|NCT00952627|DIETARY_SUPPLEMENT|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
47938429|NCT00952627|DIETARY_SUPPLEMENT|Placebo|
47938430|NCT03626571|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
47938431|NCT03977428|OTHER|standard of care|No intervention, this a patient registry and is purely an observational study
47938432|NCT02515032|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|2 daily for 12 weeks
47938433|NCT02515032|DIETARY_SUPPLEMENT|Isocaloric placebo|2 daily for 12 weeks
47938434|NCT02029339|DEVICE|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
48284626|NCT02677584|DRUG|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
48284627|NCT02677584|DRUG|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
48470069|NCT00360490|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
48470070|NCT00360490|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
48470071|NCT02034448|PROCEDURE|Continuous Renal Replacement Therapy|
48470072|NCT03776929|BEHAVIORAL|Dialectical Behavioral Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
48470073|NCT02505724|BEHAVIORAL|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
48470074|NCT02505724|BEHAVIORAL|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
48470075|NCT00153257|DEVICE|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
48470076|NCT01598545|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
48470077|NCT02261220|BIOLOGICAL|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
47938435|NCT02029339|DEVICE|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
47938436|NCT05523440|DRUG|Bevacizumab|Bevacizumab infusion.
47938437|NCT05523440|DRUG|Niraparib|Niraparib oral capsule.
47938438|NCT01918722|DRUG|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
47938439|NCT01918722|DRUG|placebo|placebo herbal medicine, one dose,bid, for 10 days
47938440|NCT01918722|DRUG|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
47938441|NCT06168227|DRUG|Disitamb Vedotin|RC48-ADC based therapy
47938442|NCT00218127|DRUG|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
47938443|NCT00218127|DRUG|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
47938444|NCT00218127|DRUG|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
47938445|NCT04245371|DRUG|Lidocaine 1.8%|Topical Patch
47938446|NCT04245371|DRUG|Placebo|Matching Placebo Patch
48470078|NCT02261220|BIOLOGICAL|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
48470079|NCT04221594|PROCEDURE|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
48470080|NCT04221594|PROCEDURE|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate \~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
48628968|NCT00597675|BIOLOGICAL|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
47938447|NCT02801344|DIETARY_SUPPLEMENT|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
47938448|NCT02801344|DIETARY_SUPPLEMENT|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
47938449|NCT02801344|DIETARY_SUPPLEMENT|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
47938450|NCT02801344|OTHER|Controlled-diet|the diet containing 0.8 g protein /kg/day
47938451|NCT03703570|DRUG|KW-6356|Oral administration
47938452|NCT03703570|DRUG|Placebo|Oral administration
47938453|NCT04231318|DRUG|Cingal|Single intra-articular injection of Cingal into the knee.
47938454|NCT04231318|DRUG|Triamcinolone Hexacetonide (TH)|Single intra-articular injection of TH into the knee.
47938455|NCT04231318|DRUG|Placebo|Single intra-articular injection Placebo (0.9% Saline) into the knee.
47938456|NCT05074173|BEHAVIORAL|Text|These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure.
48284628|NCT04494165|OTHER|massage with frankincense and myyrh essential oil|In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
47938457|NCT01477203|DRUG|Escitalopram|2-4 weeks, 5-10mg, max 20mg
47938458|NCT06330688|PROCEDURE|percutaneous cholecystostomy|PC is a minimally invasive, nonsurgical, image-guided intervention that aims to drain and decompress the gallbladder by placing a pigtail catheter through the abdominal wall into the gallbladder lumen.
47938459|NCT04459767|DRUG|Vupanorsen|80 mg subcutaneous injection
47938460|NCT04459767|DRUG|Placebo|Subcutaneous injection
47938461|NCT01852357|OTHER|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
47938462|NCT01852357|OTHER|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
47938463|NCT01875003|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
47938464|NCT01875003|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
47938465|NCT01875003|DRUG|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
47938466|NCT02273518|DRUG|Asasantin ER, new formulation I|
47938467|NCT02273518|DRUG|Asasantin ER, new formulation II|
47938468|NCT02273518|DRUG|Asasantin ER, present commercial formulation|
47938469|NCT00644748|DRUG|gabapentin|"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
47938470|NCT04108676|DRUG|Fluzoparib|PARP inhibitor
47938471|NCT04108676|DRUG|Omeprazole|proton pump inhibitor
47938472|NCT06278220|DEVICE|placido-based topographer (wavelight allegro topolyzer vario) and scheimpflug -based (Oculus Pentacam )|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo pentacam and topolyzer examination to asses corneal high order aberrations before LASIK procedure.~Patients will be assigned to undergo LASIK. Follow up pentacam and topolyzer examination will be done 3 months after LASIK."
47938473|NCT03481660|DRUG|Brolucizumab|Intravitreal injection
47938474|NCT03481660|DRUG|Aflibercept|Intravitreal injection
47938475|NCT04165811|OTHER|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
47938476|NCT04165811|OTHER|Counselling|Only physical activity counseling will be given to the subjects in this group.
47938477|NCT04356976|DEVICE|Ventralex|Repair of hernia using Ventralex patch in sublay position
47938478|NCT04356976|OTHER|Stratafix|Repair of hernia without mesh. Defect closed with Stratafix suture.
47938479|NCT00660283|DRUG|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
47938480|NCT03949907|OTHER|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss \>10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
47938481|NCT03949907|OTHER|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
47938482|NCT01612728|OTHER|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine \& Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
47938483|NCT01612728|DRUG|Women with Arthralgia|
47938484|NCT00453388|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
47938485|NCT00453388|DRUG|Cyclophosphamide|Given IV
47938486|NCT00453388|DRUG|Cyclosporine|Given IV or PO
47938487|NCT00453388|DRUG|Fludarabine Phosphate|Given IV
47938488|NCT00453388|OTHER|Laboratory Biomarker Analysis|Correlative studies
47938489|NCT00453388|DRUG|Mycophenolate Mofetil|Given PO
47938490|NCT00453388|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
47938491|NCT00453388|RADIATION|Total-Body Irradiation|Undergo TBI
47938492|NCT03901898|BEHAVIORAL|Training, audit, and reminders|Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
47938493|NCT03901898|BEHAVIORAL|Intervention after 6 months (wait list)|After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
47938494|NCT06476964|PROCEDURE|skin biopsies|Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
48100929|NCT05408455|OTHER|EMST150 (Expiratory muscle training)|Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks
48100930|NCT05408455|OTHER|Sham EMST150 (Expiratory muscle training)|The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
48100931|NCT06221332|OTHER|% 0.25 bupivakain 20cc|Pregnant women in group S will be given 0.25% bupivacaine, 10 cc on each side.
48100932|NCT06221332|OTHER|20 cc saline|Pregnant women in Group K will be given 10 cc of saline on both sides.
48100933|NCT00186420|DRUG|Taxotere|
48100934|NCT02712866|DRUG|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
48100935|NCT05013606|DIETARY_SUPPLEMENT|Hydrogen water|This is an over the counter pill supplement that is dissolved in water.
47938495|NCT04290390|DRUG|Segesterone Acetate and Ethinyl Estradiol|Contraceptive Vaginal System
47938496|NCT04290390|DRUG|Rifampin|CYP3A inducer
47938497|NCT04290390|DRUG|Itraconazole|CYP3A inhibitor
47938498|NCT03850288|OTHER|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
47938499|NCT03850288|OTHER|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
47938500|NCT03026088|DRUG|Bisoprolol|Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
47938501|NCT00005851|DRUG|fludarabine phosphate|Given IV
47938502|NCT00005851|RADIATION|total-body irradiation|Undergo TBI
47938503|NCT00005851|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
47938504|NCT00005851|DRUG|cyclosporine|Given PO or IV
47938505|NCT00005851|DRUG|mycophenolate mofetil|Given PO or IV
47938506|NCT00005851|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
47938507|NCT00005851|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
47938508|NCT00005851|OTHER|laboratory biomarker analysis|Correlative studies
47938509|NCT02929784|DEVICE|Intervention|Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
47938510|NCT02929784|DEVICE|Sham|no meaningful stimulation will be given.
48284629|NCT04494165|OTHER|massage with carrier oil|In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
48284630|NCT01158612|DRUG|Growth Hormone|infusion of Growth hormone in the patella tendon.
48284631|NCT03155451|DIAGNOSTIC_TEST|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
48284632|NCT01760434|OTHER|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
48284633|NCT00604578|DRUG|Pioglitazone Hydrochloride|
48284634|NCT03853694|DRUG|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
48284635|NCT03853694|DRUG|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
48284636|NCT03853694|DRUG|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
48617907|NCT03946527|DRUG|Lanreotide|Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
48284637|NCT04582240|OTHER|no intervention|no intervention
47938511|NCT01049399|DRUG|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
47938512|NCT01049399|DRUG|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
47938513|NCT01049399|DRUG|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
47938514|NCT03893331|DEVICE|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
48284638|NCT02058121|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
48284639|NCT02058121|BEHAVIORAL|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
48284640|NCT02514538|DRUG|Non- effervescent Paracetamol kern|1g
47938515|NCT04801316|BEHAVIORAL|Steady Feet exercise programme|"Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature."
47938516|NCT04801316|BEHAVIORAL|Steady Feet Video|About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
47938517|NCT03858439|OTHER|Dietary|Low sodium, low protein dietary recommendation
48284641|NCT02514538|DRUG|Effervescent paracetamol termalgin|1 g
48284642|NCT03426046|PROCEDURE|Partial Pulpotomy|Partial removal of inflamed pulp tissue in cariously exposed teeth
48284643|NCT03426046|DRUG|Pulp Capping Agents|Biocompatible materials
48284644|NCT04269408|DRUG|Nicardipine|10 NicaPlant® implants releasing 4 mg nicardipine each.
48284645|NCT04269408|OTHER|Standard of care|Both arms receive the usual standard of care.
48284646|NCT01598181|DEVICE|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
48284647|NCT01598181|DEVICE|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
48617908|NCT01115270|OTHER|Non-invasive measures|assessment of cerebrovascular fluid movement
48617909|NCT06033378|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
48617910|NCT00576082|OTHER|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
47938518|NCT02140632|PROCEDURE|Local methylprednisolone acetate and lidnocaine injection|
47938519|NCT02140632|DEVICE|wrist splinting|
47938520|NCT04965558|OTHER|No intervention|No intervention
47938521|NCT03504930|OTHER|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
47938522|NCT02759978|OTHER|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
47938523|NCT04050371|DRUG|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|All study participants received daily observed therapy with FTC/TDF.
47938524|NCT00667420|DRUG|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
47938525|NCT00558376|DRUG|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
47938526|NCT00558376|DRUG|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
47938527|NCT06523751|DIAGNOSTIC_TEST|Trabeculopuncture|Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
48470081|NCT04221594|PROCEDURE|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
48470082|NCT03109327|DIAGNOSTIC_TEST|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
48470083|NCT02631252|DRUG|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
48470084|NCT02631252|DRUG|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
48470085|NCT02631252|DRUG|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
48470086|NCT00448227|DRUG|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
48470087|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 day before ablation|24 hours Holter EKG - 1 day before ablation
48470088|NCT06276296|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation using radiofrequency ablation
48470089|NCT06276296|PROCEDURE|Pulsed field ablation|Pulmonary vein isolation using pulsed field ablation
48470090|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 month after ablation|24 hours Holter EKG 1 month after ablation
47938528|NCT03950037|DRUG|Albendazole|Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
48470091|NCT03041532|PROCEDURE|Proximal retroflexion|The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
48470092|NCT03041532|PROCEDURE|Frontal view|The investigator explore twice right colon with frontal viewing
48470093|NCT02962089|DIETARY_SUPPLEMENT|Branched chain amino acids (BCAA)|
48470094|NCT02962089|DIETARY_SUPPLEMENT|Placebo|
47938529|NCT00318227|PROCEDURE|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
48470095|NCT01745081|DRUG|20% mannitol bolus administration|
48470096|NCT01745081|DRUG|Hypertonic saline 3% bolus administration|
48470097|NCT05327439|OTHER|Nicotine (electronic cigarette)|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
48470098|NCT05327439|OTHER|Nicotine (nicotine pouch)|Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
48470099|NCT02539368|DRUG|CT-P13|biosimilar infliximab
48470100|NCT02539368|DRUG|Remicade|infliximab
48470101|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
47938530|NCT03062410|OTHER|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
47938531|NCT02861989|OTHER|qualitative study|
47938532|NCT01410552|DEVICE|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
48470102|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
48470103|NCT06678607|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
48470104|NCT06678607|BIOLOGICAL|Placebo|One dose of 0.5 mL placebo is aluminum phosphate adjuvant (aluminum content 0.25mg/dose), sodium chloride, succinic acid, polysorbate 80, and water for injection except for antigen components in 24-valent pneumococcal polysaccharide conjugate vaccine
48470105|NCT01020617|DIETARY_SUPPLEMENT|Ls-33|10\~10 CFU/day
48628969|NCT00597675|BIOLOGICAL|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
48628970|NCT03554109|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
48628971|NCT03554109|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48628972|NCT03554109|DRUG|Aldoxorubicin HCl|albumin-binding prodrug of doxorubicin HCl
48628973|NCT03554109|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
48628974|NCT03554109|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
48628975|NCT03554109|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
48628976|NCT03554109|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
48628977|NCT03554109|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
48628978|NCT03554109|BIOLOGICAL|GI-6207|CEA yeast vaccine
48628979|NCT03554109|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
48628980|NCT03554109|DRUG|Avelumab|Avelumab
47938533|NCT00630474|DRUG|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
47938534|NCT00003171|DRUG|bryostatin 1|
48100936|NCT04138862|BEHAVIORAL|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
48470106|NCT04093349|GENETIC|SPK-3006|adeno-associated viral (AAV) vector
48470107|NCT02913755|BEHAVIORAL|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
48470108|NCT04674150|DEVICE|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
48470109|NCT04674150|DEVICE|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
48628981|NCT03554109|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48628982|NCT03554109|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
48628983|NCT03554109|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48628984|NCT03554109|DRUG|Doxorubicin HCL|Doxorubicin HCL
47938535|NCT01231230|DRUG|fluticasone|220- mcg once
47938536|NCT01231230|DRUG|placebo inhalation|placebo inhalation once
48100937|NCT06234280|DEVICE|Implantation of Eluvia stent|Implantation of Eluvia stent
48100938|NCT02496806|DIETARY_SUPPLEMENT|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
48100939|NCT06630728|BEHAVIORAL|Reduced Nicotine Content Cigars|Participants will complete 3 smoking sessions using a different product each session to examine each product's abuse liability
48100940|NCT06630728|BEHAVIORAL|Normal nicotine content cigar|Participants will smoke a normal nicotine content filtered little cigar
48470110|NCT02411149|DRUG|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
48628985|NCT03554109|DRUG|paclitaxel|paclitaxel
48628986|NCT02194491|OTHER|[11C]AS2471907|intravenous radiotracer
48628987|NCT02194491|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
48628988|NCT02194491|DRUG|ASP3662|oral
48628989|NCT02388789|OTHER|active movement|same as arm description
48628990|NCT01305343|PROCEDURE|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
48628991|NCT04995159|DRUG|Single anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Aspirin will be discontinued one year after surgery and clopidogrel will be continued until 5 years after surgery.
48628992|NCT04995159|DRUG|Dual anti-platelet therapy|Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first year after PCI. Patients continue to take dual antiplatelet (DAPT) drugs, including aspirin and clopidogrel, for 2 more years; then aspirin will be used alone from the 4th year to the 5th year.
48628993|NCT04545697|OTHER|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
48628994|NCT05340595|OTHER|Orthodontic retainer bonding|Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
48628995|NCT01119222|DRUG|Gabapentin|Capsule, single 1200mg dose
47938537|NCT01231230|DRUG|Salmeterol|50 mcg salmeterol once
47938538|NCT01231230|DRUG|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
47938539|NCT06398795|PROCEDURE|Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).|An innovative surgical approach, Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS), presents a unique dual-port endoscopic technique for thyroidectomy. DTS significantly reduces postoperative hospital stay, emphasizing its potential for accelerated patient recovery compared to COT.
47938540|NCT06398795|PROCEDURE|Conventional open thyroidectomy (COT)|open thyroidectomy with traditional collar incisions
47938541|NCT04552730|DRUG|Cenegermin-Bkbj|Topical Cenegermin-bkbj 6 times per day for 8 weeks.
48100941|NCT06630728|BEHAVIORAL|Usual brand cigar|Participants will smoke their usual brand filtered little cigar
48628996|NCT01119222|DRUG|Diphenhydramine|Tablet, single 50mg dose
48628997|NCT01119222|DRUG|Morphine|IV, single 10mg dose
48628998|NCT01119222|DRUG|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
47938542|NCT04980573|OTHER|Aromatherapy|The aromatherapy intervention consists of inhaling a fragrant oil extracted from citrus peels, plant resins, and leaves.
47938543|NCT04980573|OTHER|Placebo|The placebo intervention consists of inhaling an oil extracted from inert plant matter.
48470111|NCT02411149|DRUG|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
48470112|NCT02411149|DRUG|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
48470113|NCT02351635|OTHER|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
48628999|NCT03308643|DRUG|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
48629000|NCT03308643|OTHER|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
48629001|NCT00236431|DRUG|Galantamine hydrobromide|
48629002|NCT04607382|DRUG|LEP|LEP dosage up to the discretion of the treating gynecologists.
48629003|NCT04607382|DRUG|NSAIDs and/or Chinese medicine (CM)|Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Chinese medicine (CM) dosage up to the discretion of the treating gynecologists.
48629004|NCT05842707|DRUG|dualCAR-NK19/70 cell|Given by IV (vein)
47938544|NCT03614767|DIAGNOSTIC_TEST|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
47938545|NCT00002988|DRUG|carmustine|
47938546|NCT00002988|DRUG|irinotecan hydrochloride|
47938547|NCT05892861|BEHAVIORAL|cognitive stimulation|video education, board games, and 24-hour dietary recall record
47938548|NCT05892861|OTHER|as usual care|history taking, explain data, and discuss how to control healthy condition
47938549|NCT04686487|PROCEDURE|stereotactic ablative radiotherapy|stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
47938550|NCT03412071|DRUG|Oral Tinidazole|Please see description under arms
48470114|NCT05135273|BIOLOGICAL|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
48629005|NCT03219736|PROCEDURE|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
48470115|NCT05135273|BIOLOGICAL|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
48470116|NCT06015672|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will experience three accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
48470117|NCT01557686|BEHAVIORAL|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
48629006|NCT03219736|DEVICE|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
48629007|NCT03219736|PROCEDURE|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
48629008|NCT05571488|OTHER|Electronic surveys|Online questionnaires will be used to collect data, at recruitment and follow-up once a year
48629009|NCT05571488|OTHER|Qualitative Interviews|Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
48629010|NCT03738748|OTHER|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
47938551|NCT03412071|DRUG|Topical metronidazole|Please see description under arms
47938552|NCT03412071|DRUG|Topical Clindamycin|Please see description under arms
47938553|NCT03412071|DRUG|Topical Hydrogen Peroxide|Please see description under arms
47938554|NCT04570267|BIOLOGICAL|CSL324|Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection
47938555|NCT04570267|DRUG|Placebo|Sterile solution of CSL324 formulation buffer for injection
47938556|NCT04405427|PROCEDURE|head acupoints acupuncture|The participants will undergo GV20, EX-HN-1, GV21, GV22, GV23, GV24, GV29, and GB13 head acupoints aupunture treatment 3 times/ 1 week for 4 weeks.
47938557|NCT04405427|PROCEDURE|body acupoints acupuncture|The participants will undergo HT7, PC6, SP6, ST36, KI3, and LR3 body acupoints acupunture treatment 3 time/1 week for 4 weeks.
47938558|NCT02041442|PROCEDURE|Electrical mapping of the urinary bladder|
47938559|NCT03204786|DRUG|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
47938560|NCT03204786|DRUG|Placebo|Placebo Nasal Spray
47938561|NCT00785967|BIOLOGICAL|Various vaccines|VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
47938562|NCT06438146|DRUG|Liraglutide|"Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration"
47938563|NCT04757740|BIOLOGICAL|intra-articular Platelet rich fibrin and lidocaine|intra-articular injection of 3.5 ml of 1% lidocaine and PRF mixture.
47938564|NCT04757740|DRUG|methylprednisolone acetate and lidocaine|intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
47938565|NCT05765656|BEHAVIORAL|GP - pharmacist collaboration and pharmacist motivational interviewing|"1. Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~2. After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~3. Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR."
47938566|NCT04448782|DIAGNOSTIC_TEST|Asynchronies detection|Asycnhronies detection
47938567|NCT02865343|DEVICE|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
47938568|NCT02865343|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
47938569|NCT02012582|DRUG|VAS203|i.v. infusion
47938570|NCT02012582|DRUG|Saline|i.v. infusion
47938571|NCT05536505|GENETIC|Adjuvant treatment for MRD positivity|The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
47938572|NCT00278239|PROCEDURE|cognitive assessment|
47938573|NCT00278239|PROCEDURE|psychosocial assessment and care|
48470118|NCT06150599|DEVICE|Sacral neuromodulation|Interstim X, which includes an implantable pulse generator and lead, will be implanted surgically in a single-stage procedure.
48470119|NCT06003127|DEVICE|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation and measurement of related evoked potentials in the EEG.
48470120|NCT05953506|DRUG|HS-10506|HS-10506 will be administered orally once on Day 1.
48470121|NCT05953506|DRUG|HS-10506 Placebo|Matching placebo will be administered orally once on Day 1.
48470122|NCT05904262|OTHER|Foot Sole Sensation Evaluation|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
48470123|NCT06677944|RADIATION|Preoperative PBI|Preoperative PBI: 21 Gy \* 1 fraction Preoperative PBI is administered within 6 weeks of the patient's initial registration, and surgery is scheduled within 8 to 12 weeks after PBI.
48470124|NCT01411488|DEVICE|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
47938574|NCT00278239|PROCEDURE|quality-of-life assessment|
47938575|NCT03862040|DRUG|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
47938576|NCT03862040|DRUG|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
47938577|NCT02421003|PROCEDURE|heart surgery|
47938578|NCT02852772|BEHAVIORAL|Cognitive function tests|
47938579|NCT05550610|BEHAVIORAL|Mindfulness Based Attention Training (MBAT) and Yoga|Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
48629011|NCT03738748|OTHER|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
48629012|NCT04849832|DIETARY_SUPPLEMENT|SIC|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich
47938580|NCT04756674|OTHER|No intervetion will be used|No intervention will be used
47938581|NCT02881333|GENETIC|Blood samples|
47938582|NCT04131218|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
47938583|NCT02467335|DRUG|BMS-663068|BMS-663068
48100942|NCT06631742|OTHER|Exergaming on Dividat Senso|"The active dance video game is played with the Dividat Senso (Dividat \| Senso: cognitive-motor training). It consists of a dance disc with four arrows (up, down, left, right), and the game is played on a large screen (which is connected to the PC). The screen indicates which arrow the person should step on, thus controlling the game through body movements. The games give the person feedback in the form of auditory, visual, and somatosensory stimuli."
48470125|NCT06678880|BEHAVIORAL|Phase Advanced Intervention (PAI)|Phase-advanced restricted sleep (i.e., sleep 9pm-1am only) for 1 night, followed by morning bright white light for 30 min/day for 2 weeks.
48470126|NCT06678880|BEHAVIORAL|Phase Delay Intervention (PDI)|Phase-delayed restricted sleep (i.e., sleep 3am to 7am only) for 1 night, followed by evening bright white light for 30 min/day for 2 weeks.
48470127|NCT06310005|DRUG|BI 3006337|BI 3006337
48470128|NCT06310005|DRUG|Placebo|Placebo
48470129|NCT02767934|OTHER|Laboratory Biomarker Analysis|Correlative studies
48470130|NCT02767934|BIOLOGICAL|Pembrolizumab|Given IV
48470131|NCT00490932|DRUG|Hypo-osmolar ORS|
48470132|NCT02396927|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
48470133|NCT02396927|DEVICE|2D HD laparoscopy|Placebo
48470134|NCT00357539|DRUG|Azithromycin (T1225)|
48470135|NCT06679465|DRUG|Tiotropium (Spiriva®)|2 puffs tiotropium prior to allergen challenge
48470136|NCT06679465|DRUG|Placebo|2 puffs placebo
48470137|NCT06351592|DRUG|ALN-SOD|Administered by intrathecal (IT) injection
48470138|NCT06351592|OTHER|Diluent|Administered by IT injection
48470139|NCT06351592|DRUG|Placebo (PB)|Administered by IT injection
48470140|NCT06679400|BEHAVIORAL|Massage|"Participants will have one massage that will last 30 minutes and focus on the chest and shoulder of the side that received the cancer treatment. There will be certain techniques applied during the intervention (per protocol). The timing and order of each element will be varied based on tissue response and patient feedback.~All participants will have ultrasounds and complete surveys prior and after the massage."
48470141|NCT03981978|BEHAVIORAL|Physical Activity|Self-report questionnaires assessing physical activity level.
48470142|NCT06679426|DRUG|Conestat Alfa|See arm/group descriptions
48470143|NCT04489017|DIETARY_SUPPLEMENT|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day
48470144|NCT04489017|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day
48470145|NCT06275178|PROCEDURE|Medical thoracoscopy|The included particpants are the patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy.
48629013|NCT04849832|DIETARY_SUPPLEMENT|SIC + tea|Sodium Iron Chlorophyllin as prepared by the human nutrition laboratory, ETH Zurich with 2g of tea brewed for 5 minutes
47938584|NCT03986515|DRUG|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
47938585|NCT06468969|OTHER|Enhanced Follow-up|"Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)"
47938586|NCT00151853|DRUG|PPSB-SD|
47938587|NCT04148677|DIETARY_SUPPLEMENT|Protoves M1®|A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
48470146|NCT04181164|OTHER|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
48629014|NCT04849832|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate solution serves as a positive control - and whose absorption is well known.
48629015|NCT04849832|DIETARY_SUPPLEMENT|FeSO4 + tea|Ferrous sulfate solution given with 2g of tea brewed for 5 minutes - expected iron absorption inhibition
48629016|NCT03752931|DRUG|Celiprolol|receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
48470147|NCT04181164|OTHER|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
48470148|NCT04181164|BIOLOGICAL|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
48470149|NCT06122155|DEVICE|Transcranial direct current stimulation (Anodal)|20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
48470150|NCT06122155|DEVICE|Transcranial direct current stimulation (Sham)|20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
48470151|NCT06503003|DEVICE|Leonardo® Diode laser|The intervention involves non-ablative dual-wavelength diode laser therapy for treating Genitourinary Syndrome of Menopause (GSM). This includes three monthly sessions of the Leonardo® Diode laser (Biolitec®), with wavelengths of 980 nm and 1470 nm, delivering 8 pulses per centimeter along the vaginal canal, using local lidocaine gel as an anesthetic. Evaluations are conducted at baseline, 3 months, and 6 months post-treatment.
48617911|NCT05053490|OTHER|Static Stretching|Static stretches are those in which you stand, sit or lie still and hold a single position for a period of time.
48470152|NCT04310254|PROCEDURE|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
48629017|NCT03752931|DRUG|Diltiazem|receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
48629018|NCT06457932|BEHAVIORAL|Heart rate variability biofeedback training|An 8-week intervention based on daily 10-minute HRV biofeedback training at rest using the Pulse HRV smartphone application.
48100943|NCT06631742|OTHER|Usual Care|Standardised care with meal service, individual activities (e.g. hiking group, walking group, exercise group, handicrafts, gardening group, singing, painting or lunch) and customized care and support as required.
48100944|NCT00357396|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
48629019|NCT06457932|BEHAVIORAL|Guided meditation|An 8-week intervention based on daily 10-minute guided meditation sessions led by an instructor with over 20 years of experience in teaching meditation.
48629020|NCT00225030|DRUG|antihypertensive drugs according to current guidelines|
48629021|NCT03435419|DIAGNOSTIC_TEST|LoopampTM Leishmania Detection Kit|LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
48629022|NCT03435419|DIAGNOSTIC_TEST|CL DetectTM Rapid Test|CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
48629023|NCT01509924|OTHER|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
48629024|NCT02369926|PROCEDURE|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
47938588|NCT03580304|BEHAVIORAL|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
48629025|NCT02369926|PROCEDURE|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
47938589|NCT03580304|BEHAVIORAL|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
47938590|NCT03580304|BEHAVIORAL|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
47938591|NCT04735718|DEVICE|Cerviron|"Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations."
47938592|NCT02469038|DEVICE|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
48100945|NCT00357396|DRUG|busulfan|
48100946|NCT00357396|DRUG|melphalan|
48100947|NCT00357396|DRUG|thiotepa|
48100948|NCT00357396|PROCEDURE|allogeneic bone marrow transplantation|
48100949|NCT00357396|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48629026|NCT00809146|DRUG|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
48629027|NCT00809146|DRUG|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
48629028|NCT05795335|DRUG|CDK4/6 inhibitor|CDK4/6 inhibitors
48100950|NCT00357396|PROCEDURE|peripheral blood stem cell transplantation|
48100951|NCT02524444|DRUG|Mefloquine|Tabs Mefloquine 250mg
48100952|NCT02524444|DRUG|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
48100953|NCT05688956|DIETARY_SUPPLEMENT|Fortimel Advanced, Nutricia|Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine \& 10 µg Vitamin D.
48470153|NCT04310254|PROCEDURE|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
48617912|NCT05053490|OTHER|dynamic stretching|Dynamic stretching involves making active movements that stretch the muscles to their full range of motion.
47938593|NCT02469038|DEVICE|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
47938594|NCT03142061|PROCEDURE|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
47938595|NCT01725412|DIETARY_SUPPLEMENT|Thiamine 300mg PO once daily|
47938596|NCT01725412|DIETARY_SUPPLEMENT|placebo|
47938597|NCT04951232|DRUG|Cinepazide Maleate|The experimental group: guipiprazitel maleate injection (klingo): 320mg (4), dissolved in 500ml of normal saline, and injected in a medium vein at a rate of 100ml/h, once a day, and administered for 14 days.
47938598|NCT04951232|OTHER|Placebo|Placebo: 4 pieces, dissolved in normal saline 500ml, intravenous drip, the speed is 100ml / h, once a day, continuous administration for 14 days
47938599|NCT05585788|DEVICE|Addinex Device (ADX-27)|"The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized passcode for each dose that is loaded into a circular drum inside the device. The passcodes are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides passcodes on a request basis, while following instructions set by the treating physicians."
48100954|NCT05688956|OTHER|Resistance Exercise programme|Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
48284648|NCT05170737|DRUG|AEF0217|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD."
48284649|NCT05170737|DRUG|Placebo|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort."
48470154|NCT04310254|PROCEDURE|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
48470155|NCT06044727|PROCEDURE|Minimally invasive non surgical periodontal therapy|using Magnifying loupes
48470156|NCT06044727|PROCEDURE|Conventional subgingival instrumentation|Conventional subgingival instrumentation
47938600|NCT02771587|DIETARY_SUPPLEMENT|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
48470157|NCT04234555|DIAGNOSTIC_TEST|Corticomotor excitability to the pelvic floor muscles|Transcranial magenetic stimulation will be used to probe the excitability of cortical projections to the pelvic floor muscles. The outcomes of interest will include motor evoked potential amplitude and silent period.
48617913|NCT00596635|DIETARY_SUPPLEMENT|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
48617914|NCT00596635|DIETARY_SUPPLEMENT|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
48629029|NCT05904366|DIAGNOSTIC_TEST|MR Spectroscopy (MRS)|MR Spectroscopy (MRS)
47938601|NCT02771587|DIETARY_SUPPLEMENT|Alcohol|Multiple oral dose of alcohol
47938602|NCT02771587|DIETARY_SUPPLEMENT|Energy drink|Multiple oral dose of energy drink
47938603|NCT02771587|DIETARY_SUPPLEMENT|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
47938604|NCT04376892|OTHER|Quality of life measurement|Quality of life measurement by St. George Respiratory questionnaire
47938605|NCT05333783|BEHAVIORAL|Augmented Reality Exposure Therapy Based on ExposXR software|The ExposXR software is developed by The Stress Trauma Anxiety Research Clinic at Wayne State University, U.S.A. When it is used inside a Augmented Reality hardware such as Hololens, it renders artificial phobic objects into what the participants see. The treatment consist of a one-session treatment for cynophobia using Augmented Reality.
47938606|NCT04586361|COMBINATION_PRODUCT|RegenLab PRP|PRP preparations also improved functional outcome scores compared to hyaluronic acid and placebo in patients affected by knee osteoarthritis (OA). Based on previous studys, we can conclude that the PRP treatment is a safe and efficacious procedure which can provide functional benefit.
47938607|NCT04586361|COMBINATION_PRODUCT|hyaluronic acid|Few studies investigated the effects of HA+PRP combined treatment for knee osteoarthritis (OA). Numerous studies demonstrated the efficacy of HA injection therapy in knee OA for a clinical point of view, reducing the pain and improving the quality of life.
47938608|NCT04586361|OTHER|normal saline|In this study, we compare introperative PRP/PRP+HA/normal saline in ACL reconstruction patient.
47938609|NCT03639532|PROCEDURE|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
47938610|NCT03639532|PROCEDURE|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
47938611|NCT03762915|DRUG|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
47938612|NCT03600688|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair
47938613|NCT02272543|DIETARY_SUPPLEMENT|Fish surimi peptide|
48470158|NCT04234555|DIAGNOSTIC_TEST|Pelvic floor muscle response to pressure applied at the vulvar vestibule|Electromyography will be used to determine whether the pelvic floor muscles (PFMs) respond to pressure applied to the vulvar vestibule as anticipatory (i.e. PFMs are active before the pressure is applied) and as behavioural (i.e. PFMs are active after the pressure is applied) responses. The amplitude of the EMG responses will also be recorded.
48470159|NCT04234555|DIAGNOSTIC_TEST|Pressure pain threshold (PPS)|A custom vulvalgesiometer will be used to determine the mean pressure at which participants first report pain at the posterior vaginal fourchette.
48470160|NCT04234555|DIAGNOSTIC_TEST|Temporal summation of pain|A custom vulvalgesiometer will be used to apply the same pressure (rated as 4/10 duiring PPS testing as described above) to the vulvar vestibule across 10 repetitions. The difference in pain rated on the tenth application and that rated on the first application will be the outcome.
47938614|NCT02958189|BEHAVIORAL|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
47938615|NCT02958189|BEHAVIORAL|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
47938616|NCT01164384|DRUG|Baminercept|
47938617|NCT06245187|OTHER|GWTG Atrial Fibrillation program|Evidence based recommended therapies and counseling prior to hospital discharge.
48470161|NCT04234555|DIAGNOSTIC_TEST|Tonic, phasic and reflex activation of the pelvic floor muscles (PFMs)|Electromyography will be used to measure the mean smoothed, rectified activation amplitude across 1 second of complete rest, across three maximal effort PFM contractions, and across three attempts at a bearing down maneuver.
48470162|NCT02123524|DRUG|Rivaroxaban|
48470163|NCT02123524|DRUG|Placebo|
48470164|NCT05517174|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
47938618|NCT00812344|DRUG|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
47938619|NCT00812344|DRUG|Ketoconazole|tablets, orally, once daily for 3 days
48470165|NCT05517174|BIOLOGICAL|Standard-Dose Quadrivalent Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the Danish governmental influenza vaccine program may be used.
48470166|NCT06179563|OTHER|On-Demand Telemonitoring|Patients assigned to the on-demand intervention group do not have to use the app at set time intervals but will be asked to use the app at their own discretion, in case of symptoms. This implies that patients have full control over their monitoring activities. Patients have the option to reach out to the hospital whenever they feel the need.
47938620|NCT00812344|DRUG|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
47938621|NCT02554188|BIOLOGICAL|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
48470167|NCT04015180|DRUG|Eylea (Aflibercept, BAY86-5321)|Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.
48470168|NCT04015180|PROCEDURE|Laser photocoagulation|Treatment administered in 20090. Transpupillary conventional laser ablative therapy
48470169|NCT01345734|DRUG|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
48470170|NCT03583528|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|"Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
47938622|NCT02554188|OTHER|Diet|A 5-day low calorie fasting-mimicking diet
47938623|NCT05222243|DRUG|Direct pulp capping with calcium hydroxide|Capping exposed dental pulps during cavity preparation in primary teeth with calcium hydroxide
47938624|NCT05222243|DRUG|Direct pulp capping with MTA|Capping exposed dental pulps during cavity preparation in primary teeth with MTA
47938625|NCT05222243|DRUG|Direct pulp capping with Formocresol|Capping exposed dental pulps during cavity preparation in primary teeth with zinc oxide eugenol after medication with formocresol
47938626|NCT00622076|PROCEDURE|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
47938627|NCT02775201|PROCEDURE|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
47938628|NCT02775201|PROCEDURE|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
47938629|NCT06082271|DEVICE|Class III medical Hydrolyzed Collagen Peptides PEP-52 (Peptys)|Anti-inflammatory and regenerative effect, 5 mg/ml
47938630|NCT06082271|DRUG|Cortisone|DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
47938631|NCT04856865|BIOLOGICAL|Low dose ADP101|Active powder formulation
47938632|NCT04856865|BIOLOGICAL|High dose ADP101|Active powder formulation.
47938633|NCT04856865|BIOLOGICAL|Pooled Placebo|Placebo powder
48470171|NCT03583528|DIAGNOSTIC_TEST|18F-FDG PET/CT|"18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
48470172|NCT03312894|DRUG|TAK-653|TAK-653 tablets
48284650|NCT03237676|OTHER|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
48284651|NCT03237676|OTHER|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
48284652|NCT06225362|DEVICE|Quatera 700|Phacoemulsification device
48470173|NCT03312894|DRUG|Placebo|Placebo-matching tablets
48100955|NCT05688956|OTHER|Dietary advice|Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
48470174|NCT00166452|DRUG|Lenalidamide|
48470175|NCT02518607|DRUG|MGB-BP-3|Treatment of CDI
48470176|NCT02518607|OTHER|Placebo|Placebo
48470177|NCT00139438|BEHAVIORAL|Disease Management Assessment|
48470178|NCT03452007|DEVICE|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of \[5-6-5\]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
48470179|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
48470180|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
48470181|NCT06510504|DRUG|225 mg BNC210|225 mg BNC210
48470182|NCT06510504|DRUG|Placebo|Placebo
48470183|NCT01332968|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
48470184|NCT01332968|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
48470185|NCT01332968|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
48470186|NCT01332968|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
48470187|NCT01332968|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
48470188|NCT01332968|DRUG|Bendamustine|Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
48470189|NCT01332968|DRUG|Rituximab|Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
48100956|NCT00984282|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
48100957|NCT00984282|DRUG|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
48284653|NCT06225362|DEVICE|Centurion|Phacoemulsification device
48100958|NCT06630403|OTHER|Demographic Data|Demographic data (age, height, weight, BMI) will be collected verbally through an assessment form.
48100959|NCT06630403|OTHER|Disease History|The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned.
48470190|NCT04571502|OTHER|My PATI ( Person Assisted Touchscreen Interface)|My PATI was designed to support communication between PWD and their caregiver, and healthcare provide; promotes person centered care by giving the PWD their voice and specifically by supporting the PWD in expressing their experiences , needs, preferences in care activities (e.g., food choices, clothing), and entertainment ( personalized pictures, videos , and music). My PATI has multiple features including allowing the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the healthcare provider. The clinical trial evaluates the impact of the My PATI interface that relies on touchscreen technology ( two interfaces one for PWD that can be used independently or with assistance, and a 2nd caregiver interface for customization ). The comparison group will receive usual care.
48284654|NCT00658333|DRUG|Enteric-coated Mycophenolate Acid (EC-MPA)|
48284655|NCT00658333|DRUG|Mycophenolate Mofetil (MMF)|
48470191|NCT02255487|DEVICE|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
48284656|NCT00658333|DRUG|Placebo MMF|
48284657|NCT00658333|DRUG|Placebo EC-MPA|
48470192|NCT02255487|OTHER|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
48470193|NCT02212106|BIOLOGICAL|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
48470194|NCT02212106|BIOLOGICAL|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
48470195|NCT00000953|DRUG|Sorivudine|
48470196|NCT00000953|DRUG|Acyclovir|
48470197|NCT06520683|DRUG|Tislelizumab|- Tislelizumab 200mg (day 1 and day 22), administered after surgery
48470198|NCT06520683|DRUG|Adjuvant chemotherapy|"* Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine."
48470199|NCT00365690|BEHAVIORAL|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
48470200|NCT00365690|BEHAVIORAL|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
48617915|NCT03290768|DEVICE|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
48100960|NCT06630403|OTHER|Pulmonary Function Test|Pulmonary Function Test will be performed with a spirometer.
48100961|NCT06630403|OTHER|Reaction Time|Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test.
48100962|NCT06630403|OTHER|Functional Capacity|Functional capacity will be evaluated with 6 minute walk test
48629030|NCT05904366|DIAGNOSTIC_TEST|MR Elastography (MRE)|MR Elastography (MRE) with a device that induces shear waves in the body. This device is placed upon the abdomen of the subject and is hold in place by straps. The device will produce low-frequency vibrations (e.g. 30-60 Hz) which are not painful to the participant. A declaration of conformity and a safety document are provided in the study dossier.
48629031|NCT03096353|OTHER|Placebo|saline
48470201|NCT00365690|BEHAVIORAL|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
48470202|NCT01579006|DRUG|Tocilizumab|
48470203|NCT04217148|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
48470204|NCT04217148|DRUG|ATRA|ATRA, po,10mg bid, for 12 weeks
48470205|NCT02126657|DRUG|70% glycolic acid|
48470206|NCT00587249|BIOLOGICAL|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
48470207|NCT00587249|BIOLOGICAL|Alhydrogel|Aluminum hydroxide gel.
48470208|NCT06471179|DEVICE|Functional MRI|Functional Magnetic Resonance Imaging during rest for minutes and analysis of data obtained from resting fMRI
48470209|NCT04000945|DEVICE|BTL-899|Treatment with BTL-899 device, 3 therapies
48470210|NCT04000945|DEVICE|Sham|Sham treatment with BTL-899 device, 3 visits
48470211|NCT05805813|COMBINATION_PRODUCT|peritoneal rest|Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.
48470212|NCT04042402|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
48470213|NCT06595004|DRUG|HCP1004|Test Drug
48470214|NCT06595004|DRUG|RLD2401|Reference drug
48470215|NCT02336906|DRUG|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
48470216|NCT02336906|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
48470217|NCT02336906|BEHAVIORAL|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
48470218|NCT03432091|DRUG|melatonin|Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
48470219|NCT00610506|DRUG|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
48629032|NCT03096353|DRUG|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
48470220|NCT06616389|DRUG|ODX (Osteodex)|Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
48470221|NCT03943134|OTHER|Minimally Processed Human Umbilical Cord Membrane|Implantation of minimally processed human umbilical cord membrane at the time of surgery
48470222|NCT03943134|OTHER|Standard Surgical Procedures|Standard surgical intervention for at least one targeted acute upper extremity trauma
48470223|NCT06679348|OTHER|walking exercise on treadmill|The study included two intervention groups, consisting of participants who met the inclusion criteria and adhered to the experimental procedures. One group will do treadmill walking exercises, while the other will do treadmill walking exercises using virtual reality (VR). Both interventions were conducted in a single session, with each group participating in a 20-minute walking exercise session at a moderate intensity, as identified by other studies.
48617916|NCT03290768|DEVICE|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
48629033|NCT02553070|OTHER|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
48629034|NCT04503200|PROCEDURE|Double guidewire|After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.
48470224|NCT06679348|OTHER|Treadmill walking exercise using VR|Walking on the treadmill with the Free Run game on the Nintendo Wii allows users to walk at 5 miles per hour for 20 minutes. The user gets on the Wii Balance Board and starts walking in the virtual environment after running the application. The application detects the user's movements and controls the progress of the virtual character. During this experience, users increase their motivation by encountering various landscapes while tracking their performance and getting information about the calories they spend. This setup provides a fun, game-like atmosphere for a realistic walking experience.
48284658|NCT04298411|DEVICE|Falcon|The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
48284659|NCT00003248|BIOLOGICAL|rituximab|
48284660|NCT00003248|DRUG|fludarabine phosphate|
48470225|NCT06374654|OTHER|Home-based Exercise Protocol|The home-based eccentric exercise protocol is a do-as-tolerated variation on the protocol described by Alfredson et al. in 1998. The protocol includes doing a series of heel raises, twice daily. No equipment is necessary. Patients will be given handouts and video links that depict and describe the exercises and their prescribed frequency.
48470226|NCT06374654|OTHER|Formal Physical Therapy|Patients will be given a prescription for physical therapy consisting of 1-2 sessions per week for 6 weeks, with a renewal for another 6 weeks to be executed at the physical therapists' discretion. If an in-person visit is necessary for the renewal, or is requested by the physical therapist, the patient will be seen again in the office. Each patient will be given a release form to provide to his or her physical therapist. The release form will request a written record of all the treatment methods used by the physical therapist. Physical therapists who participate in the care of patients in this study will treat each patient using any and all methods that their professional experience deems clinically necessary.
48470227|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
48470228|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
48470229|NCT01757379|DIETARY_SUPPLEMENT|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
48470230|NCT01757379|DIETARY_SUPPLEMENT|Inulin|15 g of inulin dissolved in 200 ml of water
48470231|NCT02203578|DRUG|romidepsin|Given IV
48470232|NCT02203578|OTHER|laboratory biomarker analysis|Correlative studies
48470233|NCT04323722|PROCEDURE|Empty Bladder planning CT scan and CBCTs|Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
48470234|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
48470235|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
48470236|NCT00605176|DRUG|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
48470237|NCT03096067|OTHER|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
48470238|NCT03096067|OTHER|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
48470239|NCT00519506|OTHER|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
48470240|NCT05517096|OTHER|E-Health|In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
48470241|NCT03853096|DRUG|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
48100963|NCT06630403|OTHER|Dyspnea Perception|Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea
48284661|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Patients will receive 20 sessions of active HD-tDCS for a duration of 20min. Sessions will be delivered twice-daily over 2 weeks on the 5 consecutive working days. The number of electrodes used, electrode placement on the scalp (based on EEG 10/10), and the individual currents that need to be injected from each electrode will be determined based on the brain networks identified as involved in their hallucinations during a fMRI acquisition performed at baseline, and computed using a neurotargeting software that allows determining optimal electrode montages for achieving maximal brain current flow in the targeted brain region.
48100964|NCT06630403|OTHER|Quality of Life|"Quality of life will be assessed with the Quality of Life Scale for Children\&#34;"
48100965|NCT06630403|OTHER|Fear of movement|Fear of movement will be evaluated with Tampa Kinesiophobia Scale
48284662|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|Participants will receive 20 sessions of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS. However, stimulation will only be administered in the initial 30 seconds of the 20-minute period, with no further stimulation during the remaining duration. This approach aims to replicate the tingling sensation commonly associated with active stimulation.
48470242|NCT06458244|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
48470243|NCT06458244|DRUG|Chemotherapy|Chemotherapy for AML consolidation treatment
48470244|NCT00600873|DRUG|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
48470245|NCT04035954|OTHER|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
48470246|NCT04646525|DIAGNOSTIC_TEST|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
48470247|NCT01920750|BIOLOGICAL|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
48470248|NCT01920750|BIOLOGICAL|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
48470249|NCT01920750|OTHER|Mock Antigen|Physiological saline
48470250|NCT02822482|DRUG|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
48470251|NCT02822482|DRUG|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
48470252|NCT06677840|OTHER|probiotic (GKB7/placebo)|The objectives of this double-blind randomized placebo-controlled trial are to evaluate the tolerability, safety, and efficacy of the probiotic intervention with Clostridium butyricum GKB7 among 90 4-15-year-old children and adolescents with a clinical diagnosis of ASD according to the DSM-5
48470253|NCT06630260|DRUG|Avutometinib|Supplied as 0.8mg capsules.
48629035|NCT04503200|PROCEDURE|Transpancreatic precut|After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
48629036|NCT04995107|DEVICE|Electro Press needle|"Body acupoints will be stimulated by the press needles 0.25mm in diameter and 2mm in length and ear acupoints will be stimulated by the press needles 0.25mm in diameter and 0.9mm in length (all from ZhenXing Brand, Hangzhou Yuanli Medical Appliance Factory, China). After sterilization of the local skin, the needle will be pressed to the acupoints and the tape will be sticked to the skin. Then, the electric device (φ44×15.8mm Type ZXHPAMDZB-02C) together with the electrode patch will be sticked to the surface of skin (on top of the sticky tapes of the press needle) in the area of CV4 and bilateral EX-CA1, and bilateral SP6 respectively. The electric device will be switch to the mode of dense intermittent wave, and the current intensity will be increased gradually till the muscles around jumps slightly.All the needles on the body acupoints will be removed after each session, while those on the auricular acupoints can be kept for as long as 6 hours (removed before going to bed)."
48629037|NCT06125990|OTHER|Experimental: Study Group (SGr)|For 6 weeks, in addition to institutional conventional exercise 2 days a week, one day a week of home exercise, breathing exercises to increase lung volumes and 7 sets of video-based breathing exercises were applied, each set consisting of 2 minutes of performance and 1 minute of rest.
48629038|NCT06125990|OTHER|Sham Comparator: Control Group (CGr)|Only institutional conventional rehabilitation was implemented.
48629039|NCT05406895|DRUG|2% Lidocaine with 1:100,000 epinephrine|2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
48629040|NCT01138046|DRUG|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
48629041|NCT01890005|DRUG|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
48629042|NCT01890005|DRUG|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
48629043|NCT05556018|DEVICE|Electrical Activation Mapping Guided Cardiac resynchronization therapy|To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
48629044|NCT04527250|DRUG|ASC41|ASC41,1mg/table;5mg/table
48100966|NCT06630403|OTHER|Ability of Motor Imagery|Motor Imagery ability will be assessed by Movement Imagery Questionnaire-3 and Vividness of Movement Imagery
48100967|NCT06630403|OTHER|Cognitive Functions|Cognitive functions will be assessed with Trail Making Test and Stroop Test
48470254|NCT06630260|DRUG|Defactinib|Supplied as 200mg tablets.
48470255|NCT06630260|DRUG|Temozolomide|Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
48470256|NCT04949386|DRUG|S-1226 (8%)|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
48470257|NCT04949386|OTHER|Placebo|Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
48470258|NCT01189682|PROCEDURE|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
48470259|NCT02828566|DRUG|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
48100968|NCT00005813|BIOLOGICAL|bispecific antibody MDX447|
48284663|NCT04642144|OTHER|Yerba mate infusion|"Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate."
48470260|NCT02828566|DRUG|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
48470261|NCT02828566|DRUG|IN saline 0.9%|Intranasal 0.9% normal saline
48470262|NCT02828566|DRUG|IV saline 0.9%|Intravenous 0.9% normal saline
48470263|NCT03756701|BEHAVIORAL|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~1. Introduction and Drawings~2. Autogenic Training and Biofeedback~3. Guided Imagery~4. Meditation~5. Mobilizing, Transforming, and Celebrating Emotion~6. Genograms part 1~7. Genograms part 2~8. Mindful Eating and Healthy Nutrition~9. Spirituality~10. Closing Drawings and Ritual"
48470264|NCT05586724|DRUG|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
48470265|NCT05586724|DRUG|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
48470266|NCT04854213|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment
48470267|NCT00277030|DRUG|Surfactant|
48470268|NCT00277030|DEVICE|Nasal CPAP|
48470269|NCT06198647|PROCEDURE|Tui-na massage|Using Tui-na massage for the back muscles
48629045|NCT04527250|DRUG|ASC41 placebo|ASC41 placebo,1mg/table;5mg/table
48629046|NCT01814332|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
48629047|NCT01814332|DRUG|Placebo|Placebo compound treatment for comparison with IP
48284664|NCT04642144|OTHER|Carbohydrate meal|Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
48470270|NCT06198647|PROCEDURE|positional release technique|using positional release manual technique to relax the back muscles
48470271|NCT04509050|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
48629048|NCT02980653|DRUG|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
48629049|NCT02547987|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
48629050|NCT02547987|DRUG|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
48629051|NCT06195215|OTHER|Peer Counselling|7 weeks peer counselling process will be carried out.
48470272|NCT03712124|DRUG|CNSA-001|CNSA-001 Powder for Suspension
48470273|NCT03712124|DRUG|Placebo|Placebo Suspension
48470274|NCT04560439|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo METFIT program
48629052|NCT01101555|DRUG|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
48629053|NCT01101555|OTHER|Placebo|Placebo will be given to one member of each cohort.
48470275|NCT02371096|DRUG|MabThera (rituximab)|
48470276|NCT02371096|DRUG|RGB-03|
48470277|NCT04282239|PROCEDURE|PECS2 block|Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.
48470278|NCT04282239|DRUG|Ropivacaine 0.5% Injectable Solution|15 mL on each side of anterior chest for a total of 30mL
48470279|NCT04282239|DRUG|Lidocaine Epinephrine|10 mL on each side of anterior chest for a total of 20mL
48470280|NCT04282239|DRUG|Dexmedetomidine 0.004 MG/ML|10 mL
48470281|NCT03864458|DRUG|KHK7791|oral administration
48470282|NCT03864458|DRUG|Placebo|oral administration
48629054|NCT00266812|DRUG|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
48284665|NCT03157544|BEHAVIORAL|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
48470283|NCT03200535|OTHER|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
48284666|NCT01776268|OTHER|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
48470284|NCT03200535|OTHER|Bulk outreach|A bulk letter or email will be sent
48470285|NCT03200535|OTHER|Dietician call|Patients will receive a personalized call by a registered dietitian
48470286|NCT03754387|DRUG|Ceftazidime|Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
48470287|NCT03754387|PROCEDURE|appendectomy|APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
48629055|NCT00266812|PROCEDURE|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
48629056|NCT03594344|PROCEDURE|Hyperbaric oxygen therapy|Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
48629057|NCT00378859|BEHAVIORAL|Skim milk|
48629058|NCT00378859|BEHAVIORAL|Lean meat|
48629059|NCT05460988|PROCEDURE|Flap surgery|All the sites showing a residual pocket in a sextant allocated to surgery group will receive flap surgery. After the administration of oral local anaesthesia (Articaine 1:100000) an intrasulcular flap will be raised. In order to preserve interdental tissue the flaps will be designed accordingly the principles of papillary preservation flap. Toot root will be carefully debrided using both ultrasonic instruments and Grecey's curettes. Bone recontouring and ostectomy/osteoplasty will be avoided. Single simple sutures will be used to close the flap (Vicryl 5-0).
48629060|NCT05460988|PROCEDURE|Non surgical re-instrumentation|The sites showing remaining pockets (PD\>4mm), in the sextants allocated to re-instrumentation group, will be treated with subgingival debridement. The subgingival debridement will be performed after the administration of local oral anaesthesia (Articaine 1:100000) using a periodontal tip on ultrasonic instrument (EMS) and Gracey's curettes.
48629061|NCT05703776|BEHAVIORAL|Nordic Walking|Nordic Walking (NW) is an aerobic physical activity where regular walking is enhanced by the addition of the active use of specifically designed NW poles. The physical strain is distributed in a balanced way to various muscle groups of the whole body.
48629062|NCT00114478|DRUG|Epinephrine|
48629063|NCT00114478|DRUG|albuterol (salbutamol)|
48629064|NCT02200575|DRUG|Telmisartan|
48629065|NCT03837275|PROCEDURE|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement
48629066|NCT03837275|PROCEDURE|closed maxillary sinus lift|transdcrestal sinus lift and immediate implant placment
48629067|NCT00215956|DRUG|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
48470288|NCT03037424|DRUG|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
48470289|NCT03037424|DRUG|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
48470290|NCT04569058|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
48629068|NCT00215956|PROCEDURE|radiation|Preoperative radiation
48629069|NCT00215956|PROCEDURE|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
48629070|NCT00899457|GENETIC|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
48629071|NCT00899457|OTHER|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
48100969|NCT00005813|BIOLOGICAL|lymphokine-activated killer cells|
48100970|NCT00005813|PROCEDURE|conventional surgery|
48470291|NCT02064140|DRUG|Rocuronium|
48470292|NCT01418950|OTHER|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
48470293|NCT05567016|OTHER|Active case detection using molecular testing (ACDm)|In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
48284667|NCT04519528|OTHER|DENVER scale (under 2 years old) or Pediatric Cerebral Performance Category (PCPC) score (over 2 years old)|"The DENVER II is a measure of developmental problems in young children. It was designed to assess child performance on various age-appropriate tasks and compares a given child's performance to the performance of other children the same age. The instrument consists of 125 tasks, which broadly reflect the following areas: personal-social, fine motor-adaptive, language, and gross motor.~The target population corresponds to infants and pre-school age children.~The POPC and PCPC are global scales based on observer impressions. Scores include 1 for good, 2 for mild disability, 3 for moderate disability, 4 for severe disability, and 5 for vegetative state or coma (6 indicates death)."
48470294|NCT05567016|OTHER|Passive case detection using molecular testing (PCDm)|With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
47938634|NCT02845518|PROCEDURE|Cardiac magnetic resonance imaging (cMRI)|"Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9."
47938635|NCT02054468|DRUG|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
48470295|NCT05567016|OTHER|Control (standard of care)|With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
48470296|NCT00428818|DRUG|trimethoprim-sulfamethoxazole or doxycycline|
48470297|NCT00480324|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
48470298|NCT00480324|BIOLOGICAL|Placebo|Two-dose oral administration.
48470299|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
48629072|NCT00899457|OTHER|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
48629073|NCT00899457|PROCEDURE|bronchoscopy|Collection of breath condensate.
48629074|NCT00184509|BEHAVIORAL|integrated psychosocial treatment (behavior)|
48629075|NCT05935488|OTHER|EVOCs emulsion|Continuous breath sampling directly into SIFT-MS equipment. The instrument is equipped with a mouthpiece connected to the SIFT inlet where the subject blows in and the breath is analyzed in real-time
48629076|NCT06450561|OTHER|cardiovascular event|In this single group observational trial the exposure of interest is a cardiovascular event.
48629077|NCT03280030|DRUG|Midostaurin|Midostaurin 50 mg \[two 25 mg capsules\] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
48629078|NCT03280030|DRUG|Placebo|Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
47938636|NCT02054468|DRUG|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
47938637|NCT02054468|DRUG|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
48100971|NCT03702400|DRUG|Phenylephrine 100 mcg|Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
48629079|NCT04555148|BIOLOGICAL|GC5131|COVID19 Hyper-Immunoglobulin
48629080|NCT04555148|OTHER|Placebo|Placebo
48100972|NCT03702400|DRUG|Norepinephrine 5 mcg|Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
48100973|NCT01159158|DRUG|Nateglinide|Nateglinide Tablets 120 mg
48470300|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|10 mg as 1 x 10 mg film-coated tablet
48470301|NCT03941834|DRUG|Rimegepant|BHV3000 (rimegepant) 75mg tablet
48470302|NCT03941834|DRUG|Placebo|Placebo
48470303|NCT03480022|DRUG|Liraglutide Pen Injector [Saxenda]|daily sc injection of liraglutide with final dose of 3mg daily
48470304|NCT03480022|DRUG|Placebo Liraglutide Pen Injector|daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
48470305|NCT01080586|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
48470306|NCT03092414|PROCEDURE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
48470307|NCT03092414|PROCEDURE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
48470308|NCT05396417|PROCEDURE|cesarean delivery|Cesarean delivery under any form of anesthesia for any reason and for any indication
48470309|NCT02734524|BIOLOGICAL|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell \>1×10\^9，q28d\*4
48470310|NCT02734524|DRUG|Taxol|135-175mg/m2,q28d\*4
48629081|NCT00855582|DRUG|Tadalafil|tablet once daily by mouth for 12 weeks.
48629082|NCT00855582|DRUG|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
48629083|NCT02314247|DRUG|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
48629084|NCT06348212|DIETARY_SUPPLEMENT|Lactobacillus paracasei PS23|2 caps daily use
48629085|NCT06348212|DIETARY_SUPPLEMENT|microcrystalline cellulose|2 caps daily use
48284668|NCT04519528|OTHER|Pediatric Quality of Life Inventory™ (PedsQL)|"The PedsQL questionnaire is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The PedsQL Measurement Model integrates seamlessly both generic core scales and disease-specific modules into one measurement system. Twenty-three items divided into different functional areas are evaluated: physical (8 items), emotional (5 items), social (5 items) and school (5 items over 4 years old; 3 items before 4 y.o).~Child self-report and parent proxy report formats of the questionnaire allows self-assessment of child over 5 years old and parents' evaluations. Items can be reverse and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0) with higher scores indicating better quality of life."
48284669|NCT03068962|OTHER|beetroot Juice|Beetroot Juice
48284670|NCT03068962|OTHER|Buxton water|natural mineral water
48284671|NCT03068962|OTHER|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
48284672|NCT00760175|BIOLOGICAL|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
48470311|NCT02734524|DRUG|Carboplatin|AUC=5,q28d\*4
48470312|NCT06359340|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
48470313|NCT03527680|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
48629086|NCT01198548|DRUG|leucovorin calcium|Given IV
48629087|NCT01198548|BIOLOGICAL|bevacizumab|Given IV
48629088|NCT01198548|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
48629089|NCT01198548|DRUG|fluorouracil|Given IV
48629090|NCT01198548|DRUG|oxaliplatin|Given IV
48629091|NCT01198548|OTHER|pharmacological study|Correlative studies
48284673|NCT00025038|DRUG|tipifarnib|Given orally
48284674|NCT00025038|DRUG|isotretinoin|Given orally
48470314|NCT03527680|DRUG|Placebo - Cap|daily one capsule of placebo
48629092|NCT04452838|DRUG|Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)|4 mg administered under fasted condition.
48629093|NCT04452838|DRUG|Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)|4 mg administered under fasted conditions.
48470315|NCT04415047|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
48470316|NCT01122589|BEHAVIORAL|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
48470317|NCT01122589|OTHER|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
48629094|NCT04452838|DRUG|Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)|4 mg administered under fed conditions.
48629095|NCT04452838|DRUG|Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)|4 mg sprinkled on apple sauce administered under fasting conditions
48629096|NCT04452838|DRUG|Fesoterodine BIC SR4 fed (Treatment E in Part B)|4 mg administered under fed conditions
48629097|NCT02524678|DRUG|Placebo|
47938638|NCT02054468|DRUG|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
48470318|NCT04214288|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally.
48470319|NCT04214288|DRUG|Fulvestrant|Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
48470320|NCT01266603|DRUG|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
48470321|NCT01266603|BIOLOGICAL|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
48470322|NCT02970045|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
48629098|NCT02524678|DRUG|URC102|
48629099|NCT00308685|DRUG|Albuterol|Albuterol 90mcg
48629100|NCT00308685|DRUG|Placebo|Placebo
48629101|NCT00593255|DRUG|soluble human insulin|
48629102|NCT00593255|DRUG|insulin aspart|
48629103|NCT00593255|DRUG|insulin NPH|
48629104|NCT03238872|BEHAVIORAL|Cognitive Behavioural Therapy|
48629105|NCT03238872|OTHER|Treatment as usual|
48629106|NCT02261142|DEVICE|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
48629107|NCT04111783|DEVICE|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
48629108|NCT00726557|BIOLOGICAL|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
48629109|NCT00726557|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
48629110|NCT02117154|DEVICE|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
48629111|NCT00452257|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
48629112|NCT00549328|DRUG|Pazopanib (GW786034)|Pazopanib monotherapy
48629113|NCT01640106|DIETARY_SUPPLEMENT|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
48629114|NCT01640106|DIETARY_SUPPLEMENT|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
48470323|NCT02970045|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
48629115|NCT01716156|DRUG|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
48629116|NCT01716156|DRUG|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
48629117|NCT03622840|BEHAVIORAL|Cognitive Remediation|Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
48100974|NCT06343987|BEHAVIORAL|Physical Activity|12-week physical activity program with training 3 times a week. The training consists of high-intensity training such as weight-lifting and cardiovascular training, and low-intensity training such as relaxation and stretching.
48470324|NCT02970045|OTHER|Medical Chart Review|Review of medical chart
48629118|NCT03565653|OTHER|High dietary salt|\~4,000 mg Na+/day
48629119|NCT03565653|OTHER|Placebo|dextrose
48629120|NCT00775086|DRUG|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
48629121|NCT02112175|DRUG|Lenalidomide|
48629122|NCT04135001|BEHAVIORAL|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore \& Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
48629123|NCT04135001|OTHER|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
48629124|NCT03522168|DRUG|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
48629125|NCT03522168|DRUG|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
48629126|NCT00032760|BEHAVIORAL|Meditation|
48629127|NCT06543290|DRUG|Azithromycin Pill|Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm
48629128|NCT00541775|DRUG|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
48629129|NCT00541775|DRUG|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
48100975|NCT06141577|DRUG|UI059|take UI059 1cap/day for 7 days
48629130|NCT00541775|DRUG|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
48629131|NCT00541775|DRUG|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
48629132|NCT02843386|DRUG|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
48100976|NCT06141577|DRUG|UIC202201|take UIC202201 1cap/day for 7 days
48470325|NCT02970045|OTHER|Quality-of-Life Assessment|Ancillary studies
48470326|NCT02970045|OTHER|Questionnaire Administration|Ancillary studies
48617917|NCT03290768|BEHAVIORAL|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
48617918|NCT05266768|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
48284675|NCT00025038|DRUG|fludarabine phosphate|Given IV
48284676|NCT00025038|DRUG|cytarabine|Given IV
48284677|NCT00025038|RADIATION|radiation therapy|Undergo total body irradiation
48470327|NCT02959840|DEVICE|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
48470328|NCT02959840|DRUG|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
48470329|NCT02959840|DRUG|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
48470330|NCT04792489|BIOLOGICAL|zamtocabtagene autoleucel (MB-CART2019.1)|Chimeric antigen receptor (CAR) T cell therapy
48470331|NCT04792489|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
48470332|NCT04792489|DRUG|Fludarabine|Lymphodepleting chemotherapy
48629133|NCT02843386|OTHER|Intensive surveillance|"Intensive surveillance~* Total duration: 3 years.~* liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
48629134|NCT02974231|RADIATION|Intensity-modulated radiation therapy|
48470333|NCT04792489|DRUG|Bendamustine|Lymphodepleting chemotherapy
48470334|NCT02358551|DEVICE|Placement of electrode lead through axillary vein puncture|
48470335|NCT02358551|DEVICE|Placement of electrode lead through subclavian vein puncture|
48629135|NCT04855812|DEVICE|MyoMo|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
48629136|NCT04855812|OTHER|Myo-SB|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
48470336|NCT01053091|BEHAVIORAL|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
48470337|NCT05746052|PROCEDURE|Punch insturment|surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
48629137|NCT04855812|OTHER|Control|To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
48629138|NCT00514917|DRUG|Docetaxel|75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
48100977|NCT01245439|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
48100978|NCT00427557|DRUG|Fludarabine|30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).
48284678|NCT00025038|DRUG|cyclophosphamide|Given IV
48284679|NCT00025038|BIOLOGICAL|anti-thymocyte globulin|Given IV
48284680|NCT00025038|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
48284681|NCT00025038|PROCEDURE|double-unit umbilical cord blood transplantation|
48470338|NCT02990078|DRUG|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
48470339|NCT02990078|DEVICE|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
48284682|NCT00025038|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
48617919|NCT03832478|DEVICE|Virtual Reality Headset Given|Samsung Gear VR Headset with guided mindfulness meditation app
48100979|NCT00427557|DRUG|Melphalan|140 mg/m\^2 by vein for 1 Day (Day -7).
48100980|NCT00427557|PROCEDURE|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
48284683|NCT00025038|OTHER|laboratory biomarker analysis|Correlative studies
48284684|NCT05006443|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
48284685|NCT04878783|DIAGNOSTIC_TEST|CT scan|Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study
48284686|NCT00469508|DRUG|Modafinil|400mg pills taken orally daily for 12 wks.
48284687|NCT00469508|DRUG|Placebo|400mg pills taken orally daily for 12 wks
48470340|NCT02990078|OTHER|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
48629139|NCT00514917|DRUG|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
47938639|NCT02054468|DRUG|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
48284688|NCT04348903|BEHAVIORAL|Virtual Reality Distraction|The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
48284689|NCT04348903|BEHAVIORAL|Positive Pre-Visit Imagery Intervention|Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
48284690|NCT03289715|DEVICE|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
48284691|NCT03681860|BIOLOGICAL|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
48470341|NCT04647734|BEHAVIORAL|High intensity interval training|12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week
48470342|NCT04647734|BEHAVIORAL|Standard care|standard care after discharge from hospital (control group)
48470343|NCT05740748|DRUG|Tezepelumab|tezepelumab 210 mg sc q4wks for 20 weeks
48470344|NCT05740748|DRUG|Placebo|placebo sc q4wks for 20 weeks
48470345|NCT00297141|DRUG|Capecitabine|chemotherapy oral use
48470346|NCT00297141|DRUG|Oxaliplatin|chemotherapy intravenous use
48470347|NCT04863157|BEHAVIORAL|Survivor-SHIP|Parent/guardian education about healthy sleep practices to improve their child's sleep health.
48629140|NCT00514917|DRUG|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
48629141|NCT05290298|DIETARY_SUPPLEMENT|NITRATE|Multi-component nutritional formula
48629142|NCT05290298|DIETARY_SUPPLEMENT|PLACEBO|Placebo
48629143|NCT06389162|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation is a type of non-invasive brain stimulation that involves passing a weak current between two electrodes placed on the scalp.
48629144|NCT04042428|DRUG|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
48629145|NCT01185366|DRUG|Everolimus|10 mg by mouth once a day.
47938640|NCT02054468|DRUG|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
47938641|NCT02054468|DRUG|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
47938642|NCT02054468|DRUG|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
47938643|NCT02054468|DRUG|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
47938644|NCT00603421|OTHER|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
48470348|NCT03103828|BEHAVIORAL|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
48470349|NCT03103828|BEHAVIORAL|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
48470350|NCT03103828|BEHAVIORAL|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
48470351|NCT02102269|DEVICE|actimove sling|
48470352|NCT02102269|DEVICE|shoulderlift|
48470353|NCT06677788|DRUG|Roflumilast 500 Mcg Oral Tablet|Patients in this group received roflumilast 500 μg once daily for three months.
48470354|NCT06677788|DRUG|Vitamin E capsule|vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily
48470355|NCT02119052|DRUG|octeotride|
48470356|NCT02119052|DRUG|placebo|
48629146|NCT01185366|DRUG|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
48629147|NCT00368485|DEVICE|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
48629148|NCT02732730|DRUG|Truvada|400 women who accept to initiate PrEP
48629149|NCT03223194|GENETIC|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
48629150|NCT00487630|DRUG|recombinant alpha-galactosidase A|
47938645|NCT00603421|OTHER|treatment as usual|Treatment as usual
48470357|NCT06679010|OTHER|Online group counseling|The program progresses as one weekly group session over 10 weeks, each with its own topic. The core components of the program include psychoeducation, training self-compassion and acceptance, cognitive restructuring, interpersonal skills training, systems and management of daily life activities, prevention of conflicts, and the mother-baby relation. Participants will meet online as a group together with the instructor, a consultant from the ADHD Association, who will lead and facilitate the sessions. Before each session, there is a podcast episode that covers the topic of each session. The 10 podcasts feature interviews with clinicians, researchers, and women with ADHD, focusing on the themes from the program's sessions.
48617920|NCT06535659|DEVICE|VitaFlow Liberty™ Transcatheter Aortic Valve System|"Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System.~Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care."
48617921|NCT05082480|DEVICE|Hyaluronic acid (HA)|Hyaluronic acid (HA)
48617922|NCT05082480|DEVICE|Saline|Saline
48629151|NCT03736369|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
48629152|NCT03736369|DRUG|DWP14012 40mg placebo|DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
48629153|NCT03736369|DRUG|Esomeprazole 40mg|Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
48629154|NCT03736369|DRUG|Esomeprazole 40mg placebo|Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
48629155|NCT01895647|DEVICE|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
48629156|NCT03191201|DRUG|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
48629157|NCT03191201|DRUG|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
48629158|NCT00929097|OTHER|Implementation aids|"* Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~* Clinicians receive the guidelines and a risk communication tool, as well as education"
48629159|NCT00929097|OTHER|Control|Dissemination of guidelines
48629160|NCT06099379|DRUG|∆9-tetrahydrocannabinol|Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
48629161|NCT02612467|OTHER|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
47938646|NCT05391971|DRUG|Bupivacaine|At the C6 level, a total of 7cc of 0.5% bupivacaine will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of 0.5% bupivacaine.
47938647|NCT05391971|DRUG|Saline|At the C6 level, a total of 7cc of saline control will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of saline control.
47938648|NCT03823378|DRUG|Elsubrutinib|Elsubrutinib capsule will be administered orally.
48100981|NCT00427557|DRUG|Rituximab|375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
48629162|NCT02612467|OTHER|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
48284692|NCT03681860|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
48617923|NCT06157437|DEVICE|Focal Pulse field Ablation|Bidirectional block of the cavo-tricuspid isthmus (CTI) was performed with the novel focal pulse field ablation.
48100982|NCT00427557|OTHER|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
48100983|NCT04697576|BIOLOGICAL|Ipilimumab|immune checkpoint inhibitor
48100984|NCT04697576|BIOLOGICAL|Nivolumab|immune checkpoint inhibitor
48284693|NCT03681860|BIOLOGICAL|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
48617924|NCT05743907|DRUG|DA-2811|DA-2811 Group: DA-2811 + Forxiga placebo
48617925|NCT05743907|DRUG|Forxiga|Forxiga Group: Forxiga + DA-2811 placebo
48629163|NCT02164188|BEHAVIORAL|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
48629164|NCT01946854|BEHAVIORAL|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
48629165|NCT06094829|OTHER|Oral cytobrush|Oral epithelial cells will be collected during routine odontology appointments, upon documented non-opposition, via minimally invasive cytobrush sampling of the inner cheek
48100985|NCT04697576|BIOLOGICAL|Pembrolizumab|immune checkpoint inhibitor
48106961|NCT01641913|OTHER|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
48629166|NCT05145894|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
48629167|NCT01362270|DEVICE|Verum Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
48629168|NCT01362270|DEVICE|Sham Acupuncture|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
48629169|NCT05607758|BEHAVIORAL|StressProffen©™|An app-based program for stress management consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
48629170|NCT01258855|BIOLOGICAL|Aldesleukin|Given IV
48629171|NCT01258855|OTHER|Laboratory Biomarker Analysis|Correlative studies
48629172|NCT01258855|BIOLOGICAL|Ziv-Aflibercept|Given IV
48629173|NCT03342859|DRUG|Vilaprisan, BAY1002670|Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
48629174|NCT03342859|DRUG|Ulipristal|Daily single oral doses of 5 mg ulipristal over 8-12 weeks
48629175|NCT03234452|DIETARY_SUPPLEMENT|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
48629176|NCT03234452|DIETARY_SUPPLEMENT|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
48629177|NCT01214720|DRUG|bevacizumab [Avastin]|Intervenous repeating dose
48629178|NCT01237405|DRUG|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at \~1 minute) SPECT/CT of both knees; a late phase (at \~60 minutes) SPECT/CT image of both knees; and a late phase (at \~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
48629179|NCT05162274|DRUG|Lazertinib(G001)|Current formulation
48629180|NCT05162274|DRUG|Lazertinib(G002)|New formulation
48629181|NCT02614027|OTHER|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
47938649|NCT03823378|DRUG|Upadacitinib|Upadacitinib tablet will be administered orally.
47938650|NCT03823378|DRUG|Placebo for elsubrutinib|Placebo capsule for elsubrutinib will be administered orally.
47938651|NCT03823378|DRUG|Placebo for upadacitinib|Upadacitinib placebo tablet will be administered orally.
48629182|NCT02614027|OTHER|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
47938652|NCT02745067|BEHAVIORAL|enhanced cognitive behavioral therapy|
47938653|NCT01753739|DRUG|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
47938654|NCT01753739|DRUG|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
47938655|NCT03918681|OTHER|Therapeutic Intervention|Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
48100986|NCT04697576|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Given IM and intratumorally. For this protocol the U.S. F.D.A recently approved the use of recently expired influenza vaccine (only until new seasonal vaccine is available anticipated Sept 1). Use of expired vaccine will not exceed 4 months past June 30th expiry date (October 30th).
48100987|NCT04697576|PROCEDURE|Resection|Undergo surgical resection
48100988|NCT04697576|BIOLOGICAL|Nivolumab + Relatlimab|immune checkpoint inhibitor
48629183|NCT00065546|OTHER|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
48629184|NCT00065546|OTHER|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
48629185|NCT00065546|OTHER|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
48629186|NCT04657900|OTHER|Observational|Observational - no intervention given
48629187|NCT02679092|DRUG|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
48629188|NCT02679092|DRUG|Mifepristone|200 mg PO on the day prior to D\&E
48629189|NCT02679092|DEVICE|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
48629190|NCT00653757|DRUG|goserelin acetate|
48629191|NCT00653757|DRUG|leuprolide acetate|
48629192|NCT00653757|RADIATION|image-guided radiation therapy|
48629193|NCT00653757|RADIATION|intensity-modulated radiation therapy|
48470358|NCT04989569|DIETARY_SUPPLEMENT|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
48629194|NCT02898831|OTHER|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
48629195|NCT04626336|PROCEDURE|Cystectomy|Cystectomy
48629196|NCT01691313|DRUG|Vanoxerine|single oral dose
48470359|NCT04680780|OTHER|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
48629197|NCT01691313|DRUG|Placebo|single oral dose
48629198|NCT02097277|BIOLOGICAL|BMS-986036|
48629199|NCT02097277|BIOLOGICAL|Placebo (Matching with BMS-986036)|
48100989|NCT06435468|GENETIC|Blood sample for genetic analysis|genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
48100990|NCT06435468|OTHER|Blood sample for immunological response assessments|Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
48629200|NCT05752864|BEHAVIORAL|spine manual therapy|The manual treatment method applied to the sacroiliac joint used high-velocity, low amplitude (HVLA).
48629201|NCT05752864|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
48629202|NCT00907088|OTHER|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
48284694|NCT01927458|DEVICE|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
47938656|NCT06356701|DIETARY_SUPPLEMENT|Cancer nutritional treatment regimen (Spirulina Bifidobacterium Capsules, Fish Oil Grape Seed Blueberry Soft Capsules, Ganoderma Spore Oil Soft Capsules)|"Medication for Research :~* Spirulina Bifidobacterium Capsules~* Fish Oil Grape Seed Blueberry Soft Capsules;~* Ganoderma Lucidum Sporoderm Oil Soft Capsules; oral administration. non-squamous cell carcinoma Drug: Pemetrexed+Cisplatin (or carboplatin)~  * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion squamous cell carcinoma Drug:Paclitaxel+ Cisplatin (or carboplatin)~ * Sintilimab Injection/Camrelizumab/Tislelizumab/Atezolizumab Injection IV infusion"
48284695|NCT04387474|DEVICE|Brain-computer interface|brain-computer interface rehabilitation training.
48284696|NCT04387474|OTHER|Traditional rehabilitation|traditional rehabilitation training.
48284697|NCT04252378|PROCEDURE|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
48284698|NCT04252378|PROCEDURE|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
48284699|NCT04153630|BIOLOGICAL|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
48470360|NCT04680780|OTHER|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
48284700|NCT01059812|DRUG|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
48284701|NCT01059812|DRUG|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
48470361|NCT04680780|OTHER|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.
48284702|NCT06266637|OTHER|Conventional Physical Therapy Program|"Conventional Physical Therapy program:~trunk muscles strengthening exercises, trunk muscles endurance exercises, trunk proprioception exercises . postural correction exercises. Core exercise Spinal mobility exercises"
48470362|NCT02677662|OTHER|Diesel Exhaust|Dilute diesel exhaust
48470363|NCT02677662|OTHER|Filtered air|Filtered air
48470364|NCT00429624|PROCEDURE|Chiropractic manipulation|
48470365|NCT00429624|DRUG|acetaminophen|
48470366|NCT03674138|DIAGNOSTIC_TEST|DNA-guided choice of therapy|Buccal swab for DNA genotyping to identify best antidepressant therapy
48470367|NCT03674138|OTHER|Clinical management|Clinical management to identify best antidepressant therapy
48470368|NCT01247844|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
48617926|NCT00112957|BIOLOGICAL|rV-NY-ESO-1 vaccine|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10\^7 PFU) on Day 1.
47938657|NCT02048189|DRUG|LEVEMIR|
47938658|NCT02048189|DRUG|APIDRA|
48470369|NCT04245293|DEVICE|Ainara|Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
48470370|NCT04245293|DEVICE|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
48470371|NCT04030338|DRUG|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
48470372|NCT04030338|DRUG|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
48470373|NCT04030338|DIAGNOSTIC_TEST|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
48470374|NCT04931160|OTHER|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
48470375|NCT01891058|DEVICE|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
48470376|NCT04325516|BEHAVIORAL|Daily activities|"Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension"
48470377|NCT03964441|BIOLOGICAL|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
48470378|NCT03964441|BIOLOGICAL|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
48470379|NCT03964441|OTHER|Parent interviews (optional organizational study)|Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
48470380|NCT03964441|OTHER|parent questionnaire (optional organizational study)|To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
48470381|NCT03964441|OTHER|professional interviews (optional organizational study)|interview to understand how the decision is formed
48629203|NCT00907088|OTHER|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
47938659|NCT03589547|DRUG|Durvalumab|Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
47938660|NCT03589547|RADIATION|SBRT|"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~\*3 fractions are allowed for centrally located tumors"
47938661|NCT03570879|DEVICE|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
47938662|NCT03570879|PROCEDURE|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
47938663|NCT00112697|DRUG|cisplatin|
47938664|NCT00112697|DRUG|docetaxel|
47938665|NCT00112697|DRUG|fluorouracil|
47938666|NCT00112697|RADIATION|radiation therapy|
48470382|NCT03964441|OTHER|Focus group for professionals (optional organizational study)|interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
47938667|NCT03355118|OTHER|General anaesthesia and major surgery|The effect of general anaesthesia and surgery on oxygen transport and how it relates to outcome
47938668|NCT02106039|PROCEDURE|intensive monitoring|
47938669|NCT03111069|PROCEDURE|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
48100991|NCT06435468|OTHER|Blood sample to identify relevant biomarker of the disease|Research biomarkers for diagnosis, prognosis and monitoring of disease activity
48100992|NCT00258518|PROCEDURE|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
47938670|NCT03111069|DRUG|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation."
47938671|NCT03111069|RADIATION|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
47938672|NCT00057681|DRUG|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
47938673|NCT00057681|DRUG|Valproate|Titrated until blood level is 111 to 125 ug/mL
47938674|NCT00057681|DRUG|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
48470383|NCT01132417|DRUG|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
48470384|NCT04411173|DIETARY_SUPPLEMENT|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
48629204|NCT06388213|DEVICE|Gastric Ultrasonography|Evaluation of cross sectional area of the antrum by gastric ultrasonography in healthy patients and in patient treated by GLP-1 receptor agonists after a fasting period (6 hours for solid and 2 hours for clear liquids). For the GLP-1 receptor agonists group the gastric ultrasonochography will be repeated each 2 days during 7 days. In the non GLP-1 receptors agonists group the evaluation will be executed one time.
47938675|NCT03601000|DRUG|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
48470385|NCT06058364|DIETARY_SUPPLEMENT|Intervention 1 - Triglyceride|Triglyceride (1 softgel each morning with a glass of water)
47938676|NCT03601000|DRUG|Placebo|Placebo granules 5g given three times a day for up to 16 weeks.
48106962|NCT02321813|BEHAVIORAL|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
48106963|NCT02321813|OTHER|placebo control|Quality of life measurement
48106964|NCT00411996|DRUG|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
48629205|NCT06535737|DRUG|Cabozantinib|Cabozantinib (Cabometyx) 60, 40 and 20 mg
48629206|NCT06235541|DRUG|GENA-104A16|GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.
48629207|NCT02958670|OTHER|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
48629208|NCT05313464|OTHER|parent-pushed enteral feeding|skin-to-skin enteral nutrition pushed by the parent
47938677|NCT04529473|DIETARY_SUPPLEMENT|Eubacterium hallii|Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)
47938678|NCT04529473|OTHER|Placebo|Placebo capsules are identical to the active treatment
47938679|NCT00003301|DRUG|irinotecan hydrochloride|
47938680|NCT05053542|PROCEDURE|Enema|Patients in the PBP group underwent a cleansing enema procedure with a solution of monosodium phosphate and disodium phosphate (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before hemorrhoidectomy, whereas patients in the non-PBP group skipped the procedure.
47938681|NCT03649867|OTHER|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
47938682|NCT06352333|PROCEDURE|supraclavicular ultrasound guided brachial plexus block|two approaches of ultrasound guided supraclavicular brachial plexus block in upper limb surgery : the cornerpocket supraclavicular brachial plexus block and parasagittal supraclavicular brachial plexus block
48470386|NCT06058364|DIETARY_SUPPLEMENT|Intervention 2 - Placebo|Placebo (1 softgel each morning with a glass of water)
48629209|NCT05313464|OTHER|syringe-push enteral feeding|skin to skin nutrition with syringe pump
48629210|NCT02470377|DEVICE|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
48284703|NCT06266637|OTHER|Physiotherapeutic Scoliosis-Specific Exercise (Schroth)|It uses exercises customized for each patient to return the curved spine to a more natural position. The spine is addressed in all three anatomical planes - sagittal, frontal and transverse. The purpose of the method is to create spinal balance and stability by improving body mechanics and spinal stabilization to prevent further curve progression
48470387|NCT05683782|DRUG|Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
48470388|NCT05683782|DRUG|Split thickness Apically positioned flap without Erythropoietin application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
48470389|NCT01041235|DRUG|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
48106965|NCT01541358|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
48106966|NCT01541358|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
48470390|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique|"This is an innovative surgical method applied in proximal gastrectomy. By adding anti reflux structures such as false gastric fundus and false cardia on the basis of esophageal residual gastric anastomosis, the goal of anti reflux is achieved, while maintaining normal physiological channels and fully utilizing residual gastric function, reducing the difficulty of proximal gastrectomy surgery"
48617927|NCT00112957|BIOLOGICAL|rF-NY-ESO-1 vaccine|Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10\^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
48617928|NCT04857177|DRUG|CKD-701|CKD-701 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
48284704|NCT05059353|DEVICE|Digitally based multidomain intervention|"Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed."
48284705|NCT04634552|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression.
48470391|NCT06679244|PROCEDURE|Totally laparoscopic proximal gastrectomy with double-tract reconstruction|This is a traditional surgical method that has been widely used in proximal gastrectomy. After disconnecting the proximal stomach, performing Roux-en-Y anastomosis of the esophagus and jejunum firstly, followed by lateral anastomosis of the residual stomach and jejunum. Previous studies have confirmed its safety and effectiveness, but there are also issues of gastric channel disuse and high missed detection rate of residual stomach.
48470392|NCT00243152|DRUG|Lamotrigine|: 25mg and 50mg tablets
47938683|NCT02301585|PROCEDURE|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
48470393|NCT00243152|DRUG|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
47938684|NCT02301585|PROCEDURE|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
48106967|NCT00660478|DEVICE|Endeavor|Comparison of two different drug eluting coronary stents
48106968|NCT00660478|DEVICE|Cypher Select|Comparison of two different drug eluting coronary stents
48106969|NCT02981186|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
48470394|NCT06053749|DRUG|Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
48470395|NCT06053749|DRUG|Rebif (IFNβ-1-a, Merck Europe B.V.)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
48470396|NCT06053749|DRUG|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
48470397|NCT06053749|DRUG|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
48470398|NCT06053749|DRUG|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
48470399|NCT06053749|DRUG|MS disease modifying drugs (MSDMDs)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
48470400|NCT00399724|DRUG|Insulin glargine|
48470401|NCT02462486|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
48470402|NCT02462486|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
48470403|NCT02462486|OTHER|Sham Procedure|Sham injection.
48470404|NCT06347926|PROCEDURE|Questionnaires given before and after photobiomodulation|Questionnaires given at 1 month, 6 months and 12 months
47938685|NCT04891731|DRUG|AI or TAM|This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
48106970|NCT02981186|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
48106971|NCT02517307|DRUG|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
48106972|NCT02517307|DRUG|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
48106973|NCT02517307|DRUG|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
48106974|NCT02111148|PROCEDURE|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
48617929|NCT04857177|DRUG|Lucentis®|Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
48470405|NCT05553587|DRUG|Amara drops|"The investigational drug is approved with a reduced dossier without indication according to Art. 25 para. 1 KPAV (SR 812.212.24). This study follows the indication text licensed by Swissmedic: ... Weleda Amara-Drops can be used for digestive complaints such as heartburn, flatulence and bloating after meals, to stimulate the bile flow and for loss of appetite and nausea. The effect of Weleda Amara drops is based on a balanced mixture of medicinal plants with tonic (invigorating) and aromatic bitter substances, which are suitable for stimulating digestion. Further, no side effects have been reported in past studies so far. All these reasons lead us to the conclusion that this study is only associated with minimal risks and should be classified in risk category A."
48470406|NCT00164372|BEHAVIORAL|Peer Education Intervention|
48470407|NCT03091868|DRUG|Placebo oral capsule|Matching placebo capsules. Oral administration.
48470408|NCT03091868|DRUG|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
48470409|NCT03091868|DRUG|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
48629211|NCT02323061|PROCEDURE|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
48629212|NCT00086307|DRUG|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
48629213|NCT00086307|DRUG|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
48629214|NCT03641729|OTHER|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
48629215|NCT00294567|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
48629216|NCT00116909|DRUG|OSI 7904L|
48629217|NCT04370899|OTHER|lifestyle assessment|"A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco."
47938686|NCT03531073|DRUG|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
48470410|NCT03091868|DRUG|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
48470411|NCT03091868|DRUG|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
48470412|NCT05678517|DRUG|Anti-VEGF|intravitreal ranibizumab or intravitreal aflibercept
48629218|NCT00292994|BEHAVIORAL|Exercise|
48470413|NCT06678022|DEVICE|No Drone delivery|Usual ART delivery to landing sites
48470414|NCT06678022|DEVICE|Fixed Wing drones|Last Mile fixed wing drone delivery
48470415|NCT01505361|BIOLOGICAL|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
48629219|NCT00292994|BEHAVIORAL|Weight Loss|
48629220|NCT02416271|DRUG|Teriparatide|Administered SC
48629221|NCT02416271|DRUG|Alendronate|Administered orally
48629222|NCT02416271|DIETARY_SUPPLEMENT|Calcium|Administered orally
48629223|NCT02416271|DIETARY_SUPPLEMENT|Vitamin D|Administered orally
48470416|NCT01505361|BIOLOGICAL|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
48629224|NCT02416271|DRUG|Placebo-Oral|Administered orally
48629225|NCT02416271|DRUG|Placebo-SC|Administered SC
48629226|NCT01901588|DRUG|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
48629227|NCT01901588|OTHER|Placebo|intraoperative dose of intravenous placebo
48629228|NCT02745405|OTHER|Fat Suit|Participants wear a fat suit.
48629229|NCT02745405|OTHER|Control Condition|Participants wear same clothing as intervention, but in their own size.
48629230|NCT04151732|BEHAVIORAL|Physical activity, alcohol, tobacco|Physical activity, alcohol, tobacco - selfreported in the 1990's
48629231|NCT04151732|OTHER|Hormonal factors|Hormonal factors - selfreported in the 1990's
48629232|NCT04151732|OTHER|Cardiovascular disease|Cardiovascular disease - selfreported in the 1990's
48284706|NCT04427657|PROCEDURE|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
48470417|NCT00813345|OTHER|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
48629233|NCT04151732|OTHER|Anthropometric measures|Height, length, BMI
48629234|NCT04171999|OTHER|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
48629235|NCT00002051|DRUG|Thymopentin|
48106975|NCT02111148|PROCEDURE|Nitrazine|Nitrazine detection in vaginal wash
48470418|NCT00813345|OTHER|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
48470419|NCT00325104|PROCEDURE|Parathyroid hormone testing|
48470420|NCT00325104|PROCEDURE|Serum calcium testing|
48470421|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
48629236|NCT00689286|DEVICE|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
48629237|NCT05838872|DEVICE|Minuteful - Kidney Urine Analysis Test System|Urine samples were collected and tested by a lay user, using the Minuteful - Kidney test device. The lay user test results were compared to the results obtained by testing the same urine sample on the comparison device, the URiSCAN Optima.
48629238|NCT00038415|BIOLOGICAL|CLL vaccine using DNA plasmid vector|
48629239|NCT00236678|DRUG|Epoetin alfa|
48629240|NCT04630262|DEVICE|ATTUNE Cementless CR Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
48629241|NCT04630262|DEVICE|ATTUNE Cementless PS Fixed Bearing|Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.
48470422|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
48470423|NCT06388031|DRUG|Immune checkpoint inhibitor|"Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg."
48284707|NCT04427657|PROCEDURE|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
48470424|NCT00152906|PROCEDURE|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
48629242|NCT01281306|DRUG|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
48629243|NCT01281306|DRUG|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
48100993|NCT05541263|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
47938687|NCT04451642|PROCEDURE|Peripheral nerve block|Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
48100994|NCT01643291|PROCEDURE|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
48100995|NCT06526949|BEHAVIORAL|Reiki|To provide patients with a suitable environment during the intervention, screens will be lowered and earplugs will be used to ensure a quiet environment. The reiki practitioner will place his/her hands lightly on or above the patient's head and eyes, upper body from the neck to the pelvic area, arms and legs (standard reiki hand positions) for the duration of the therapy (30 minutes total duration).
48100996|NCT06526949|OTHER|(Sham Reiki)|In the sham (Sham Reiki) group, sham practitioners (not involved in the research) who have no experience in energy work will prepare a screen and headphones for the patients as in the intervention group. Then, they will place their hands gently on or above the patient's head and eyes, upper body from the neck to the pelvic region, arms and legs (standard reiki hand positions) for 30 minutes every other day for 2 days in a row or 2 times (Day 1 and Day 3) like the practitioner in the intervention group. Patient data will be recorded on forms before and after placebo administration as in the intervention group.
48100997|NCT04565249|DRUG|PLN-74809|PLN-74809
48284708|NCT03880396|RADIATION|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
48470425|NCT00006371|DRUG|aminoglutethimide|
47938688|NCT03362307|DEVICE|Low-Level Laser and Light-Emitting Diodes|Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
47938689|NCT03362307|DEVICE|Dental implant placement|A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
47938690|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
48284709|NCT05426343|BIOLOGICAL|MVC-COV1901|Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
48284710|NCT05426343|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
48284711|NCT04734873|DRUG|CPI-006 2 mg/kg + SOC|IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
48284712|NCT04734873|DRUG|CPI-006 1 mg/kg + SOC|IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
48284713|NCT04734873|DRUG|Placebo + SOC|IV placebo plus standard of care
48470426|NCT00006371|DRUG|ketoconazole|
48470427|NCT00006371|DRUG|therapeutic hydrocortisone|
48470428|NCT03458143|DRUG|Ketamine 150 ng/ml|conscious sedation in TCI-mode
48470429|NCT03458143|DRUG|Remifentanil|conscious sedation in TCI-mode
48470430|NCT03458143|PROCEDURE|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
47938691|NCT02808091|DRUG|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
48470431|NCT03458143|DRUG|Ketamine 200 ng/ml|conscious sedation in TCI-mode
48470432|NCT06678594|PROCEDURE|Calcium modification|"Patients will undergo one or more of the following procedures, subject to the algorithm:~Angioplasty Balloon Cutting Balloon Rotational Atherectomy Intravascular Lithotripsy"
48629244|NCT01281306|DRUG|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
48629245|NCT01281306|DRUG|Placebo|Placebo was supplied as tablets in blister cards.
48629246|NCT02756442|OTHER|Respiratory disorder assessment during sleep|
48629247|NCT02087592|BEHAVIORAL|Structured exercise training plus mediterranean diet|
47938692|NCT02808091|RADIATION|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
48284714|NCT05057351|OTHER|Isopentenyltheophylline 0.44% + Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
48470433|NCT04909112|OTHER|Evaluation of olfactory function|Evaluation of olfactory function using olfactory detection thresholds
48470434|NCT04909112|OTHER|Evaluation of taste function|Evaluation of taste function using taste detection thresholds
48470435|NCT04909112|OTHER|Evaluation of (intra-nasal and oral) trigeminal functions|Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
48470436|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|9-cis Rich Powder
48629248|NCT05376306|BEHAVIORAL|Stress Reduction: MBSR|Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.
48629249|NCT05376306|BEHAVIORAL|Stress Reduction : PMR|Progressively tensing and releasing each muscle group from head to toe in a specific order.
48629250|NCT06156267|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
48629251|NCT06156267|DRUG|mRNA tumor vaccines|neoantigen personalized mRNA vaccines
48629252|NCT01507389|DRUG|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
48629253|NCT03599466|DRUG|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
47938693|NCT02457273|DRUG|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
47938694|NCT00156572|PROCEDURE|Sodium supplementation|
48100998|NCT04565249|DRUG|Placebo|Placebo
48284715|NCT05057351|OTHER|Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
48284716|NCT05213169|DRUG|Apomorphine Hydrochloride 5mg/ml|Product administered using an external continuous subcutaneous infusion pump.
48284717|NCT05213169|OTHER|Sodium chloride 9mg/ml|Product administered using an external continuous subcutaneous infusion pump.
48284718|NCT00466505|BIOLOGICAL|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
48470437|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawill|9-cis Rich Powder
48470438|NCT01256697|OTHER|Sugar pill|Sugar pill
48470439|NCT04245358|DEVICE|Ainara|1g of gel per administration
48284719|NCT00466505|DRUG|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
48284720|NCT00466505|GENETIC|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
48284721|NCT00466505|OTHER|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
48470440|NCT06044584|OTHER|No intervention|Observational study with no intervention - Monitoring
48470441|NCT01992913|BEHAVIORAL|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
48470442|NCT01992913|OTHER|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
48470443|NCT01992913|BEHAVIORAL|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
48629254|NCT03599466|DRUG|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
48629255|NCT03720171|DEVICE|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
48629256|NCT00449007|DRUG|fluoxetine|6 months
47938695|NCT00156572|PROCEDURE|Fluid restriction|
47938696|NCT00008554|DRUG|Abacavir sulfate|
48470444|NCT05363579|OTHER|Physiotherapy|Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
47938697|NCT00008554|DRUG|Nelfinavir mesylate|
47938698|NCT00008554|DRUG|Lamivudine|
47938699|NCT00008554|DRUG|GW433908|
47938700|NCT00238537|DRUG|Alteplase t-PA|
48100999|NCT05972694|DIETARY_SUPPLEMENT|Freeze dried grape powder|46g/d freeze-dried grape powder
48106976|NCT02111148|DRUG|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
48106977|NCT00765492|DRUG|AZD8529|oral
48106978|NCT00765492|DRUG|Placebo|oral
48470445|NCT05363579|OTHER|Tuina therapy|Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
48470446|NCT05363579|OTHER|Physio and Tuina therapy|Physiotherapy mixed with Tuina
48470447|NCT02191124|DRUG|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
48470448|NCT02191124|DRUG|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
48617930|NCT03723824|DRUG|grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
48617931|NCT03426904|DRUG|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
48629257|NCT00449007|DRUG|bupropion|6 months
48629258|NCT01604200|BEHAVIORAL|focus group|key informant review
48629259|NCT00972257|DRUG|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
48629260|NCT00972257|DRUG|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
48629261|NCT01513928|DRUG|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
48470449|NCT06186219|DRUG|Rituximab|"Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) \< 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration."
48470450|NCT03803254|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48470451|NCT03803254|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
48470452|NCT03803254|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48470453|NCT03803254|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
48470454|NCT03259685|OTHER|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
48470455|NCT03259685|OTHER|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
48470456|NCT03259685|OTHER|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
48470457|NCT03723837|BIOLOGICAL|Inactivated Polio Vaccine (IPV)|Children receive one or two doses of IPV based on study arm they fall in
48470458|NCT03440333|DRUG|surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome
48470459|NCT06461377|DRUG|Glucagon-like peptide-1 receptor agonist：Semaglutide|The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
48470460|NCT05629702|DRUG|Nabiximols|Oromucosal spray
48470461|NCT05629702|DRUG|Temozolomide|Oral capsule
48629262|NCT01513928|DRUG|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
47938701|NCT02890290|DIETARY_SUPPLEMENT|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
47938702|NCT02890290|DIETARY_SUPPLEMENT|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
48470462|NCT05629702|DRUG|Nabiximols-matched placebo|Nabiximols-matched placebo oromucosal spray
48470463|NCT04485507|OTHER|Nature-VR|Viewing 360 degree nature pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
48470464|NCT04485507|OTHER|Urban-VR|Viewing 360 degree urban pictures delivered by a virtual reality headset for 10 minutes/day, 5 days/week for 4 weeks (total of 200 minutes).
48629263|NCT01513928|DRUG|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
48629264|NCT04869930|OTHER|specimen collection|participants will submit at minimum two of four required samples: fecal, urine, finger/toe-prick blood, and cheek swab, collected at home via commercially available kits
48629265|NCT03514225|OTHER|Metacognitive Therapy for Social Anxiety|The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
47938703|NCT02670343|DRUG|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
47938704|NCT02122731|DRUG|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
47938705|NCT04387825|DRUG|ADSVF application in the right hand|40 ml of fat was mixed with 2 ml of ADSVF and placed in 1-ml and 3-ml syringes. Using a 19-gauge blunt cannula (0.8 mm), 0.5 ml was applied to the radial and ulnar edge of each metacarpal phalangeal (MP) and interphalangeal (IP) joint in contact with each neurovascular digital pedicle and 3 ml was applied to each side of the metacarpal trapezius joint, together with 10 ml distributed subcutaneously throughout the palm of the hand and 10 ml evenly distributed on the back of the hand
47938706|NCT02194608|DEVICE|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
47938707|NCT01323738|BEHAVIORAL|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
47938708|NCT00877474|DRUG|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
48470465|NCT04306172|OTHER|An US Readmission Risk Prediction Model|Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
48617932|NCT03426904|DRUG|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
47938709|NCT03772860|OTHER|Pain stimulation|Pain will be simulated with an electric shock 25 mlAMP over the median nerve
48284722|NCT00466505|OTHER|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
47938710|NCT03772860|OTHER|Visual stimulation|Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
48470466|NCT04306172|OTHER|LACE+ score|The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
48470467|NCT04306172|OTHER|SQLAPE model|The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
48470468|NCT03818295|DRUG|[14C]-praliciguat|10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
48470469|NCT05119049|OTHER|Exercise guideline|The experimental group underwent 20 sessions with an aquatic exercise plan in the pool at the rehabilitation department. The control group did the same exercises in one of the rooms in the rehabilitation department, with the same number of sessions. Both groups were guided by a physiotherapist. The main outcome variables were assessed at the start of the study, at the end of the 20 sessions, and at 3 months after completing the sessions.
48470470|NCT02657005|DRUG|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
48470471|NCT03078257|DRUG|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
48470472|NCT03078257|DRUG|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
48629266|NCT04551924|DRUG|HR18034|HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
48470473|NCT03078257|DRUG|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
48629267|NCT04551924|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
48629268|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
48629269|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
48629270|NCT00127933|DRUG|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
48629271|NCT00127933|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
48629272|NCT00127933|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
48629273|NCT03688737|OTHER|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
48629274|NCT03688737|OTHER|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
48629275|NCT04803500|DRUG|Simvastatin|single injection of simvastatin gel in the gap around immediately placed implant
48629276|NCT04803500|DRUG|Placebo|single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
48629277|NCT06309758|OTHER|Breinzorg|"The BreinZorg multidomain lifestyle website comprises 16 domains, namely (1) physical activity, (2) healthy diet, (3) smoking, (4) alcohol, (5) sleep, (6) cognitive activity (7) social activity, (8) diabetes, (9) blood pressure, (10) cholesterol, (11) heart- and vascular diseases, (12) kidney diseases, (13) hearing damage, (14) obesity, (15) anxiety, and (16) depression. These 16 modules are separated into three big themes: mood, lifestyle, and body.~Each module consists of the following:~1. General information on the risk factor;~2. Tips on how to improve and decrease the risk;~3. Quiz questions about the risk factor, giving extra knowledge/ in a playful and interactive manner;~4. Examples of SMART goals fitting the risk factor (goal examples are given in a Specific, Measurable, Achievable, Relevant, and Time-Bound manner)."
48629278|NCT03406975|DEVICE|Overstitch Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
48629279|NCT03406975|BEHAVIORAL|Lifestyle Intervention|Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
47938711|NCT03772860|OTHER|Auditory stimulation|Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
47938712|NCT03772860|OTHER|Mental stress|A mathematical challenge will be displayed on a computer screen that must be quickly solved
47938713|NCT03915522|PROCEDURE|Single adductor canal block|The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
47938714|NCT03915522|PROCEDURE|Simulated adductor canal block|The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
48470474|NCT03078257|DRUG|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
48470475|NCT03078257|DRUG|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
48470476|NCT03078257|DRUG|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
48470477|NCT03078257|DRUG|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
48629280|NCT02061592|DEVICE|etafilcon A|
48629281|NCT02061592|DEVICE|etafilcon A|
48629282|NCT02443129|DEVICE|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
48629283|NCT01093885|DRUG|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
48629284|NCT02993302|DRUG|1α-D3|patients were given PTU and 1α-D3
48629285|NCT02993302|DRUG|Placebos|patients were given PTU and placebos
48629286|NCT02280499|DEVICE|standard PROMOS prosthesis|
48629287|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
48629288|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
48629289|NCT06299605|DRUG|Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days|Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
48629290|NCT04831554|PROCEDURE|single chest tube drainage|place single chest tube after surgery of PSP
47938715|NCT03474315|DIAGNOSTIC_TEST|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
47938716|NCT00062673|DRUG|Duloxetine|
47938717|NCT00062673|DRUG|Placebo|
48284723|NCT00466505|OTHER|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
48629291|NCT03171870|DIAGNOSTIC_TEST|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
48629292|NCT05084404|DRUG|Experimental: 4 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
48629293|NCT05084404|DRUG|Experimental: 8 mg/day of WY-8678 (guanabenz acetate)|Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
48470478|NCT03139240|DRUG|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
48629294|NCT00347945|PROCEDURE|Pencil Push-ups|
48629295|NCT00347945|PROCEDURE|Office-based Vision Therapy|
48629296|NCT00347945|PROCEDURE|Placebo Office-based Vision Therapy|
48470479|NCT03139240|OTHER|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
48629297|NCT01505335|DEVICE|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
48629298|NCT03968627|OTHER|Rehabilitative intervention|intensive multidisciplinar rehabilitation
48470480|NCT01042873|DRUG|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
48629299|NCT05901961|DRUG|Whitfield solution|The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
48629300|NCT05901961|DRUG|Zinc oxide nanoparticles solution|The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
48629301|NCT05901961|DRUG|Combined Whitfield and Zinc oxide nanoparticles solution|The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
47938718|NCT05427955|PROCEDURE|One-level Erector Spinae Plane Block|One-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 30 ml of 0.25% bupivacaine will be injected at the T5 level.
47938719|NCT05427955|PROCEDURE|Bi-level Erector Spinae Plane Block|Bi-level Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the lateral decubitus position. In applications, 15 ml of 0.25% bupivacaine at T4 level and 15 ml of 0.25% bupivacaine at T6 level will be injected.
47938720|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 14mg once daily|ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
47938721|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg once daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
48101000|NCT04242732|DIAGNOSTIC_TEST|CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.|The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.
48470481|NCT01514123|DRUG|VGX-100|VGX-100 will be administered by IV infusion once every week
48629302|NCT03298100|OTHER|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
48629303|NCT04224051|DRUG|Metformin|Metformin target dose 2 g daily
48629304|NCT04224051|OTHER|Standard care|Abdominal aortic aneurysm surveillance
48629305|NCT04705584|DRUG|Prednisolone (as Acetate)|Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.
48629306|NCT04705584|DRUG|CycloSPORINE Ophthalmic Suspension|This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.
48629307|NCT04705584|DRUG|LTacrolimus Topical|This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
48629308|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal brushing|Duodenal mucosal brushing will be performed at duodenal bulb.
48629309|NCT06326918|DIAGNOSTIC_TEST|Duodenal mucosal biopsy|Duodenal mucosal biopsy will be performed at duodenal bulb.
48629310|NCT02286830|DRUG|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
48629311|NCT02399800|PROCEDURE|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
48629312|NCT02399800|PROCEDURE|No Celiac Block|EUS but no celiac block performed
48629313|NCT02399800|DRUG|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
48629314|NCT01356810|OTHER|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
48629315|NCT01356810|OTHER|Standard Care|Delirium management by the attending physician's preferences.
48284724|NCT01379625|DRUG|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
48284725|NCT00319163|DRUG|levonorgestrel/ethinyl estradiol|
48284726|NCT05374343|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule orally (by mouth) on Day 1
48284727|NCT00201201|OTHER|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
48470482|NCT01514123|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
48470483|NCT02702869|PROCEDURE|cleft lip repair|
48470484|NCT02702869|PROCEDURE|cleft palate repair|
48470485|NCT02702869|PROCEDURE|oronasal fistula repair|
48470486|NCT02702869|PROCEDURE|pharyngoplasty|
48470487|NCT02702869|PROCEDURE|gingivoperiosteoplasty|
48470488|NCT02702869|PROCEDURE|LeFort-1 maxillary repositioning|
48470489|NCT02702869|PROCEDURE|rhinoplasty|
48470490|NCT02702869|PROCEDURE|myringotomy and tympanostomy tube placement|
48629316|NCT00589368|BEHAVIORAL|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
48629317|NCT04512872|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
48101001|NCT04242732|DIAGNOSTIC_TEST|Conventional CT scan|The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
48284728|NCT00201201|OTHER|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
48284729|NCT01627704|DRUG|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
48284730|NCT02789696|OTHER|Diagnosis of acromegaly|Biological analysis of IGF-1
48284731|NCT01011686|BIOLOGICAL|ANT-SM|autologous adipose-derived stem cell
48284732|NCT05898412|DRUG|Andexanet alfa|Patients treated with andexanet alfa
48284733|NCT03916068|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
48284734|NCT03916068|DRUG|Trental Pill|Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
48284735|NCT03916068|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
48470491|NCT02702869|OTHER|speech therapy|
48470492|NCT02702869|PROCEDURE|orthodontia|
48470493|NCT02702869|PROCEDURE|presurgical orthopedics|
48470494|NCT02702869|DEVICE|sound amplification for hearing|
48470495|NCT00272272|BEHAVIORAL|Music Therapy|Listening to Music while standing
48470496|NCT00416468|DRUG|Aliskiren|
48470497|NCT00416468|DRUG|Valsartan|
48470498|NCT00807209|DRUG|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
48284736|NCT00661765|DRUG|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
48284737|NCT00661765|DRUG|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
48284738|NCT00364260|DRUG|epoetin alfa|
48284739|NCT04942639|DEVICE|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
48284740|NCT05879263|OTHER|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
48470499|NCT00807209|DRUG|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
48470500|NCT00807209|DRUG|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
48470501|NCT00807209|DRUG|Fentanyl via PCA|Fentanyl via PCA
48470502|NCT00807209|DRUG|Bupivacaine via epidural|Bupivacaine via epidural
48470503|NCT00508040|DRUG|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
48470504|NCT00508040|DRUG|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
48470505|NCT06207292|RADIATION|Stereotactic Ablative Radiotherapy|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions"
48470506|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
48470507|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
48470508|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
48470509|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
48470510|NCT01877694|DRUG|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
48470511|NCT01877694|DRUG|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
48470512|NCT06394115|DEVICE|Ostomy pouch|Ostomy pouch coated with novel technology
48470513|NCT06679101|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
48470514|NCT06679101|DRUG|Lenalidomide|Lenalidomide will be administered.
47938722|NCT04778072|DIETARY_SUPPLEMENT|Ferrous sulfate 25mg twice daily|ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily
47938723|NCT03582644|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
48470515|NCT06679101|DRUG|Dexamethasone|Dexamethasone will be administered.
48470516|NCT06679101|DRUG|Daratumumab|Daratumumab will be administered.
48470517|NCT01776528|BIOLOGICAL|NGM282|
48470518|NCT01776528|BIOLOGICAL|Placebo|
48470519|NCT02995564|BEHAVIORAL|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
48470520|NCT00785681|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
48470521|NCT02594813|PROCEDURE|Biopsy, cold or hot snare polypectomy, or EMR|
48284741|NCT05879263|OTHER|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
48284742|NCT04341610|DRUG|Stem Cell Product|100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
48284743|NCT01835444|OTHER|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
48470522|NCT05335850|BEHAVIORAL|Isha Kriya|Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.
48629318|NCT04512872|BIOLOGICAL|EU-approved Prolia|60 mg/mL single dose, Solution for injection in PFS
48284744|NCT00904254|RADIATION|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
47938724|NCT05715879|DIAGNOSTIC_TEST|covid infection|patients with covid infection which was proved with positive test
47938725|NCT05715879|BIOLOGICAL|admission to hispital|patients with sever covid disease, who was admitted in hospital
48470523|NCT05335850|BEHAVIORAL|Nadi Shuddhi|Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
47938726|NCT05065775|DEVICE|Dexmedetomidine|Single intranasal dexmedetomidine dose of 100 µg. Intranasal dexmedetomidine will be administered shortly after induction of anesthesia using a mucosal atomization devise (LMA MAD Nasal™)
48470524|NCT05335850|BEHAVIORAL|Nada Yoga|Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.
48470525|NCT05335850|OTHER|Routine Daily Activity|"Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.~Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm."
48470526|NCT00971919|OTHER|questionnaire administration|
48470527|NCT00971919|PROCEDURE|assessment of therapy complications|
48470528|NCT00971919|PROCEDURE|psychosocial assessment and care|
48470529|NCT00971919|PROCEDURE|quality-of-life assessment|
48470530|NCT04546152|DEVICE|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
48470531|NCT05381896|OTHER|Conventional Scoliosis Exercise Program|Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.
48470532|NCT05381896|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
48470533|NCT01324544|DRUG|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
48470534|NCT03722862|DIETARY_SUPPLEMENT|Low fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
48470535|NCT03722862|DIETARY_SUPPLEMENT|Placebo|Participants will receive the placebo/dextrose.
48629319|NCT00033345|DRUG|Indole-3-carbinol|400 mg pill taken daily
48629320|NCT00033345|DRUG|Indole-3-carbinol|800 mg pill taken daily
48629321|NCT00033345|OTHER|Placebo|Placebo pill taken daily during run-in period
48629322|NCT00673829|BIOLOGICAL|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
48629323|NCT00673829|BIOLOGICAL|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
48284745|NCT06187818|DRUG|Crocin|According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
48629324|NCT01109381|DRUG|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
48629325|NCT00283569|OTHER|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
48629326|NCT00002619|BIOLOGICAL|filgrastim|
48629327|NCT00002619|DRUG|carboplatin|
48629328|NCT00002619|DRUG|thiotepa|
48629329|NCT00002619|PROCEDURE|autologous bone marrow transplantation|
48101002|NCT03701230|OTHER|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
48101003|NCT00508963|DRUG|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
48284746|NCT04881539|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|This group will receive an oral dose of CBD (Six Degrees Wellness).
48629330|NCT00002619|PROCEDURE|peripheral blood stem cell transplantation|
48629331|NCT01982227|DRUG|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
48284747|NCT05683132|BEHAVIORAL|Trauma-Informed CBT-I|5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
48284748|NCT05683132|BEHAVIORAL|PTSD Psychoeducation|5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
48629332|NCT04626362|OTHER|Cranberry juice|Cranberry juice cocktail will be provided by Ocean Spray Cranberries, Inc.
48101004|NCT00199641|DEVICE|enteral nutrition|
48284749|NCT04900701|OTHER|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
48284750|NCT01855230|DRUG|ASM-024|ASM-024 b.i.d for 14 days
48470536|NCT03722862|DIETARY_SUPPLEMENT|High fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
48284751|NCT01855230|DRUG|Placebo|Placebo b.i.d. for 14 days
48284752|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 1|Step 1 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 25% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
48284753|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 2|Step 2 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 50% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
48284754|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 3|Step 3 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 75% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
48284755|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 4|Step 4 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 100% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
48470537|NCT00786630|BEHAVIORAL|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
48629333|NCT04626362|OTHER|Placebo juice|Apple juice added with flavor and colorants will be provided by Ocean Spray Cranberries, Inc.
48629334|NCT06062069|DRUG|CT-868|CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
48629335|NCT06062069|DEVICE|CT-868 Pen Injector|The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
48629336|NCT06062069|DRUG|: CT-868 Pen Injector, Placebo|The placebo pen injector is identical and contains the same ingredients except for CT-868.
48629337|NCT03609840|DRUG|Thiotepa|Given IV
48629338|NCT06194669|OTHER|Blood and urine sample collection|One whole blood sample per individual (3 ml) will be collected. Up to 5 urine samples per individual will be collected
48629339|NCT04456283|BEHAVIORAL|Survival|5 year survival after Chemoradiation theraphy for Rectal Cancer
48629340|NCT06305546|DRUG|Chlorhexidine Gluconate|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
48629341|NCT06305546|DRUG|Metronidazole|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
48629342|NCT06305546|DRUG|combination gel (chlorhexidine and metronidazole)|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
48470538|NCT00786630|BEHAVIORAL|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
48470539|NCT06128187|OTHER|Control Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of virtual reality training will be given.
48470540|NCT06128187|OTHER|Study Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of dual-task training will be given
48470541|NCT00978887|OTHER|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
48629343|NCT06305546|DRUG|Placebo|For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
48470542|NCT00978887|OTHER|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
48470543|NCT06302348|DRUG|Sepiapterin|Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
48470544|NCT03668951|DRUG|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
48470545|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
48470546|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
48470547|NCT06038318|BEHAVIORAL|PRISM Program Video Coach|A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.
48470548|NCT06038318|BEHAVIORAL|PRISM Program Text Coach|A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.
48470549|NCT06038318|BEHAVIORAL|mPRISM Program App|6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.
48629344|NCT00723242|DRUG|Viraferon-peg and Rebetol|
47938727|NCT06521099|BEHAVIORAL|Evaluative Conditioning with positive stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social engagement (between none to high), experiences of the scenes (never to always) on Likert-scales. In the conditioning phase, the most negative and most positive social pictures perceived by each participant in their pre-conditioning phase will be selected and paired with positive stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
47938728|NCT06521099|BEHAVIORAL|Conditioning with neutral stimuli|In the pre-conditioning phase, participants will be exposed to pictures that vary in their emotional (negative, positive) and social (non-social, social) content. For each picture, they are required to indicate their immediate perceived valence (between negative to positive), degree of social engagement (between none to high), experiences of the scenes (never to always) on Likert-scales. In the conditioning phase, the most negative and most positive social pictures perceived by each participant in their pre-conditioning phase will be selected and paired with with neutral stimuli for trials in random order, for 6 sessions across 3 weeks. In the post-conditioning phase, participants will be asked to evaluate the valence of the stimuli again similar to that in pre-conditioning phase.
48101005|NCT04138771|DEVICE|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
48101006|NCT01407601|DIETARY_SUPPLEMENT|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
48470550|NCT05692154|DRUG|Fexofenadine|Fexofenadine oral tablet
48470551|NCT05692154|DRUG|Placebo|Fexofenadine matching placebo oral tablet
48470552|NCT06024031|DRUG|N-acetyl-L-cysteine|N-acetyl-L-cysteine (Yiweishi) capsules (Guangdong Renrenkang Pharmaceutical Industry) will be given orally 400mg three times a day from day 1 to day 28 after chemotherapy. In case of drug allergy such as nausea, vomiting, rash and bronchospasm, and disease relapse, to discontinue the drug immediately.
48470553|NCT04649697|DRUG|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
48470554|NCT04649697|DRUG|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
48470555|NCT04649697|DRUG|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
48470556|NCT01652586|DRUG|dexmedetomidine-remifentanil|
48470557|NCT01652586|DRUG|midazolam-remifentanil|
48470558|NCT01047033|BEHAVIORAL|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
48629345|NCT00881244|DRUG|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
48470559|NCT01047033|OTHER|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
48470560|NCT04515420|DRUG|noradrenaline|noradrenaline infusion
48470561|NCT05404451|DIAGNOSTIC_TEST|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
48470562|NCT05404451|DIAGNOSTIC_TEST|Mckenzie Exercises|Using Mckenzie Exercises
48470565|NCT05016882|DRUG|NNC0194 0499 50 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
48470566|NCT05016882|DRUG|Placebo (NNC0194-0499)|Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
48470567|NCT05016882|DRUG|Semaglutide 3 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
48470568|NCT05016882|DRUG|Semaglutide placebo|Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
48470569|NCT05016882|DRUG|NNC0174 0833 10 mg/mL|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
48470570|NCT05016882|DRUG|NNC0174 0833 placebo|Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
48470571|NCT00137202|DRUG|Ondansetron (Zofran)|
48470572|NCT00137202|DRUG|Diphenhydramine (Benadryl)|
48470573|NCT04724460|DRUG|Long DOAC|Administration of Rivaroxaban for 18 months
48470574|NCT04724460|DRUG|Short DOAC|Administration of Rivaroxaban for 6 months
48470575|NCT05072119|DEVICE|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
48629346|NCT01447771|BEHAVIORAL|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
48101007|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
48101008|NCT00702429|OTHER|Blood sampling|Analysis of the PNN, analysis of the monocytes
48470576|NCT02966496|BIOLOGICAL|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
48470577|NCT02966496|BIOLOGICAL|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
48470578|NCT06546995|DRUG|NMRA-323511|Participants will receive NMRA-323511 orally.
48470579|NCT06546995|DRUG|Placebo|Participants will receive matching placebo tablets orally.
48470580|NCT06321471|DEVICE|AeviceMD|AeviceMD is a remote patient monitoring system consisting of a wearable stethoscope, silicone patches, a docking station, and a mobile application.
48470581|NCT04625673|DEVICE|OsciPulse|OsciPulse device and standard IPC device
48470582|NCT00927251|DEVICE|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
48470583|NCT01848717|DEVICE|MINTLIFT®|
48470584|NCT06112054|DEVICE|Clotild Smart Guidewire System (CSGS)|In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure
48470585|NCT02595827|OTHER|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
48470586|NCT01863355|DRUG|B0 group: bolus 0.6mcg/kg without background infusion|
48470587|NCT01863355|DRUG|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
48470588|NCT01863355|DRUG|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
48470589|NCT03846063|OTHER|Home-based rehabilitation program|The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
47938729|NCT05796336|DEVICE|Lip taping|Steri strip tape and passive baby feeding plate Two methods of lip taping will be used with passive baby feeding plate. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
47938730|NCT02894632|DEVICE|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
47938731|NCT02391896|DEVICE|Dual energy and tomosynthesis xray|
47938732|NCT03734744|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
47938733|NCT03954652|GENETIC|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
47938734|NCT01905111|DRUG|BI 853520|BI 853520 once daily in a dose escalation schedule
48470590|NCT02923063|BEHAVIORAL|Combined Aerobic and Resistance Exercise via videoconferencing|Combined aerobic and resistance exercise session thrice weekly for 12 weeks
48470591|NCT04141644|DRUG|Ipilimumab|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
48470592|NCT04141644|DRUG|Osimertinib|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
48470593|NCT06676293|DRUG|Anti-PD1|Pembrolizumab 100mg in normal saline 100ml infusion over 30 minutes for every two month
48470594|NCT06676293|DRUG|asparaginase|The patients will receive asparaginase 10000IU/vail IM QD for three or five days.
48470595|NCT04305990|DEVICE|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
48470596|NCT04305990|DEVICE|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
48617933|NCT02362022|DRUG|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
48629347|NCT00222274|BEHAVIORAL|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J\&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
47938735|NCT00955383|DRUG|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
47938736|NCT00955383|DRUG|Placebo|Matching placebo
47938737|NCT05152264|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
47938738|NCT05152264|OTHER|Conventional analgesic treatment|Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
48101009|NCT04458831|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48101010|NCT04458831|DRUG|Pomalidomide|Pharmaceutical form: oral
48101011|NCT04458831|DRUG|Dexamethasone|Pharmaceutical form: oral
48101012|NCT04458831|DRUG|Carfilzomib|Pharmaceutical form: solution for infusion
48629348|NCT00222274|BEHAVIORAL|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J\&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
48629349|NCT00585650|BIOLOGICAL|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
48470597|NCT06678685|DRUG|.spironolactone|In the first week, the starting dose is 2mg/Kg per body weight once a day, taken with food at lunch every day, and subsequently adjusted according to the situation. If the patient's serum potassium is ≤5.0 mEq/L and the patient's serum creatinine is ≤2.5 mg/dL, treatment should be initiated with 25 mg spironolactone once daily. Increased to 100mg after remission. If the results are not obvious in the first month, increase the drug dose to 3mg/Kg.
48629350|NCT00585650|OTHER|Placebo injections|Placebo injections twice weekly for 12 weeks.
48629351|NCT05228964|DEVICE|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
48629352|NCT05099445|DRUG|INCB000928|INCB000928 200 mg will be administered on Day 1 of each treatment period.
48629353|NCT00668564|PROCEDURE|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
48629354|NCT00668564|DRUG|Cyclophosphamide|"Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours"
48629355|NCT00668564|DRUG|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
48629356|NCT00668564|DRUG|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
48470598|NCT01006967|DEVICE|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
48284756|NCT05097911|DRUG|MTL-CEBPA|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
48470599|NCT01006967|OTHER|Physical Therapy|Standard program of physical therapy for gait and balance
48470600|NCT04590781|BIOLOGICAL|XmAb18087|Monoclonal bispecific antibody
48470601|NCT04590781|DRUG|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
48470602|NCT04467099|OTHER|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
48470603|NCT04467099|RADIATION|X-ray|Standard x-ray of the foot.
48470604|NCT04467099|OTHER|Questionnaire|All participants will complete a questionnaire.
48470605|NCT05947084|OTHER|Infant Formula|Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period
48470606|NCT05425368|DRUG|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
48629357|NCT05212142|BEHAVIORAL|verbal education|Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
48629358|NCT05212142|BEHAVIORAL|verbal education, visual aids, and motivational interviewing|Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
48629359|NCT06131593|DRUG|TAPB with dexamethasone as an adjuvant to local anesthetics|patients will receive TAPB with dexamethasone as an adjuvant to bupivacaine and lidocaine local anesthetics
48470607|NCT05425368|DRUG|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
48470608|NCT06246669|BEHAVIORAL|Treadmill Walking|A treadmill will be used for participant to walk on. The frequency of exercise will be 5 times per week until they report symptom-free. The intensity will be determined via random group allocation (RPE of 13 or 9). The type of exercise is treadmill walking. The time of the intervention will depend on the the time it takes an individual to reach a specific caloric expenditure as a function of their weight and treadmill incline. This is based on the most recent American Congress of Sports Medicine's guidelines for estimating gross energy expenditure during common physical activities.
48470609|NCT03330132|BIOLOGICAL|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
48470610|NCT03330132|BIOLOGICAL|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
48470611|NCT03330132|BIOLOGICAL|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
48617934|NCT02689622|OTHER|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
48470612|NCT03330132|BIOLOGICAL|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
48470613|NCT06096350|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
48470614|NCT06096350|DIAGNOSTIC_TEST|hematochemical analysis|Blood samples of patients will be collected from patients in the early morning (7:30-9:00 a.m.) after an overnight fast at T0 and at T1. Sera samples will be separated by centrifugation (3,000 rpm, 10 min, and 4 °C), divided into 0.5 mL aliquots, and rapidly stored at -80 °C. Subjects' and reference samples were thawed just before the diagnostic test.
48470615|NCT06096350|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1), muscular force with hand grip
48470616|NCT06096350|DIAGNOSTIC_TEST|nutritional assessment, MNA,|nutritional status assessment will be performed by: body mass index measurements, (height and weight measurements at T0 and at T1); a Mini Nutritional Assessment survey will be administered to patients at admission; a food questionnaire will be administered to patients during from T0 to T1.
48470617|NCT06096350|DIAGNOSTIC_TEST|stool sampling|stool will be collected at T0 and at T1
48470618|NCT06096350|DIAGNOSTIC_TEST|urine sampling|the first morning urine will be collected at T0 and at T1
48470619|NCT06096350|DEVICE|indirect calorimetry analysis|indirect calorimetry analysis with K5 (COSMED, Italy) during six minute walk test or timed up and go test.
48470620|NCT05086770|DEVICE|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
48470621|NCT05086770|DEVICE|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
48470622|NCT02756949|OTHER|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
48470623|NCT02756949|DEVICE|Smartphone|
48470624|NCT06532968|DEVICE|Sham|Sham
48470625|NCT06532968|DEVICE|ORION spinal lamina cover|an artificial lamina coverage of the ORION spinal system
48470626|NCT05380219|OTHER|dual task strength training|strength training and dual task
48101013|NCT01369589|DRUG|P-552|P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
48101014|NCT01369589|DRUG|Placebo|Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
48101015|NCT00773435|BIOLOGICAL|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
48284757|NCT05097911|DRUG|Atezolizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
48470627|NCT04443569|DRUG|Lidocaine patch|Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management
48470628|NCT04443569|OTHER|Placebo patch|A placebo patch will be placed superior to the Pfannenstiel incision in the same manner as the lidocaine patch treatment group.
48470629|NCT05263713|OTHER|Suture Closure of Linear Wounds|Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
48629360|NCT06131593|DRUG|TAPB with methylprednisolone as an adjuvant to local anesthetics|patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
48629361|NCT05105971|DRUG|BAT6026|Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
48629362|NCT05777720|DEVICE|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
48629363|NCT05777720|BEHAVIORAL|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
48101016|NCT00773435|OTHER|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
48101017|NCT04467515|DRUG|CAM-H2|All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
48101018|NCT00431795|DRUG|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m\^2 IV every 4 weeks for 6 consecutive cycles
48101019|NCT00431795|DRUG|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles
48101020|NCT03566017|DRUG|pegunigalsidase alfa|Recombinant human alpha galactosidase A
48101021|NCT01137903|PROCEDURE|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
48101022|NCT01137903|DRUG|Ciprofloxacin|500 mg/ 12 hours during 90 days
48101023|NCT01137903|DRUG|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
48101024|NCT01137903|DRUG|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
48629364|NCT05777720|BEHAVIORAL|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
48629365|NCT00864513|DRUG|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
48470630|NCT06678633|DEVICE|T-Control® (experimental)|Patients will receive intravesical therapy (1-2 hours) through T-Control®, a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end, which has three positions.
48629366|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
48629367|NCT00327171|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
48629368|NCT01765621|OTHER|DDI+ System and Pharmacogenetic Data|
48629369|NCT06278168|OTHER|Awareness training with using Oculus.|"The protocol consists of 2 phases:one conducted in groups,one individually. In the first session, through interactive activities such as passing a wool ball while sharing passions and interests, and filling out personal cards, participants get to know each other and develop an atmosphere of mutual acceptance.~In the second session,participants explore neurodiversity through viewing videos, guided discussions and creating symbols representative of the group concept. Optical illusions are explored to understand differences in individual perception.In addition, issues of hypersensitivity and hyposensitivity are addressed,encouraging participants to reflect on their special interests and ways of presenting themselves. The second phase consists of 12 individual meetings to promote emotional well-being and self-awareness. During the meetings, the Oculus device will be used in which relaxation videos will be shown. In addition, heart rate will be detected with sensors placed in the chest."
48629370|NCT06278168|OTHER|Awareness training without using Oculus|The control group will carry out the same steps as the experimental group, heart rate will be taken through the use of sensors but in this case the Oculus device will not be used to watch relaxation videos.
48629371|NCT04545138|OTHER|cognitive training combine treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight), and ensures that patients can be cognitively trained at the same time. The cognitive training tasks will be projected on the screen and the participant have to answer the task orders during treadmill training simultaneously.
48470631|NCT06678633|DEVICE|Folysil® (control)|Patients will receive intravesical therapy (1-2 hours) through Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.
48629372|NCT04545138|OTHER|Treadmill training|Treadmill training includes warming up for 3 minutes, training for 25 minutes, and relaxing for 2 minutes. The speed of the treadmill during the warm-up and relaxation period is based on the participant's Borg's rating of perceived exertion (RPE) 7-9 points (very slight to very slight), and the RPE during the training period does not exceed 10\~12 points (slight).
48629373|NCT06468020|OTHER|The Gather.town gaming intervention|The online game-based learning intervention (oGBL): The investigator will develop the oGBL intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 5 sessions and plays a game through the Gather.Town platform.
48629374|NCT03372915|BEHAVIORAL|Standard Exposure|Exposure therapy conducted according to standard clinical care practices
48629375|NCT03372915|BEHAVIORAL|Exposure + Inhibitory Learning|Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
48629376|NCT05930470|OTHER|Magnetic Mitohormesis Therapy|The MMT device that will be used in the trial will be the QuantumTx BIXEPS Fitness and Wellness. The apparatus will provide pulsed electromagnetic fields at flux densities 1.5 mT. During the treatment period, participants will receive PEMF therapy during two ten-minute sessions each week for a total of 12 weeks. The treatment period will be preceded or followed by 12 weeks of twice-weekly sham treatments depending on randomization.
48629377|NCT00804479|OTHER|No intervention.|
48629378|NCT02347007|DIETARY_SUPPLEMENT|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
48470632|NCT05321875|DRUG|Candesartan|3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
48470633|NCT06012578|DRUG|ISM5411|Investigational Drug
48470634|NCT06012578|DRUG|Placebo|ISM5411 Matching Placebo
48470635|NCT06058013|DRUG|NMRA-335140|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
48470636|NCT06058013|DRUG|Placebo|Placebo will be administered orally
48284758|NCT05097911|DRUG|Bevacizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
48284759|NCT02045199|DEVICE|Tested product : V0111 cream|Application twice a day during 28 days
48284760|NCT02045199|DEVICE|Placebo|Application twice a day during 28 days
48284761|NCT01050621|DIETARY_SUPPLEMENT|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
48284762|NCT04642235|OTHER|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
48284763|NCT04642235|BEHAVIORAL|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
48284764|NCT04642235|OTHER|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
48284765|NCT05483127|DEVICE|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
48284766|NCT05483127|DEVICE|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
48284767|NCT01774448|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
48284768|NCT00932087|PROCEDURE|Blood sample|Blood sample for lipidomic study
48470637|NCT06678750|DEVICE|TKA using computer navigation|TKA using Exactech GPS Newton Knee protocol
48470638|NCT06678750|PROCEDURE|TKA|TKA using manual instrumentation
48470639|NCT04462744|OTHER|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
48470640|NCT03365791|BIOLOGICAL|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
48470641|NCT03365791|BIOLOGICAL|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
48470642|NCT01157234|DRUG|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of \< 140/ 90.
48629379|NCT02347007|DIETARY_SUPPLEMENT|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
48629380|NCT06520423|PROCEDURE|Urethral stent tube irrigation|During urethroplasty, a Fr3 ureteral catheter will be placed in the reconstructed urethra, with the proximal end extending approximately 2 cm beyond the urethral wound. The distal end will connect to an F6 single-lumen ureter and a urinary bag. On the second postoperative day, the urethra will be irrigated with 5 ml of saline twice daily. This irrigation routine will continue until the catheter is removed.
48470643|NCT01157234|DRUG|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure \< 140/90.
48470644|NCT03507686|DRUG|BIIB111|Administered as specified in the treatment arm.
48470645|NCT06343363|BEHAVIORAL|Early discharge protocol|Patients admitted for transcatheter edge-to-edge repair to either mitral or tricuspid valve and then discharged within 36 hours
48470646|NCT00964353|DRUG|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
48629381|NCT06520423|PROCEDURE|Urinary catheter drainage|During urethroplasty, intraurethral retention of urethral catheters is used to drain urine from the bladder.
48629382|NCT06132750|OTHER|No intervention|No intervention
47938739|NCT05596123|BEHAVIORAL|Therapeutic Chinese foot massage|Participants in the TCFM group will receive six weekly 25-minute TCFM sessions by a therapist. Each session will start with an assessment of the legs and toes of the affected extremity for broken skin and lesions, which the therapist will try to avoid. The participant will be positioned with support to their foot and legs, with the sole directed downward and the therapist directly in alignment with the soles of the foot. The therapist will sequentially perform the following four steps for each TCFM session.
47938740|NCT05596123|BEHAVIORAL|Placebo massage|The same therapist will give six weekly 25-minute placebo massage sessions to participants in the placebo massage group. These sessions will include assessing the affected extremity's legs and toes for lesions and broken skin in order to avoid them during the massage, as well as gentle foot and toe rubbing without any point stimulation or other TCFM techniques.
47938741|NCT04626466|OTHER|Biological investigations|(complete blood count, platelet count, renal function evaluation)
47938742|NCT01736384|PROCEDURE|Gastric bypass or cholecystectomy|
47938743|NCT01216995|BIOLOGICAL|Dose A|ADRC Dose A
47938744|NCT01216995|BIOLOGICAL|Placebo|Placebo Comparator
47938745|NCT00636883|DRUG|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
47938746|NCT04853381|OTHER|dietary treatment (low FODMAP)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
47938747|NCT04853381|OTHER|dietary treatment (gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
47938748|NCT04853381|OTHER|dietary treatment (low FODMAP+gluten free)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
47938749|NCT04853381|OTHER|dietary treatment (Traditional diet recommendations)|The aim of the study will be explained to the patients and the dietary treatment that will be recommended if they participate in the study will be told that they should be followed for 4 weeks. In addition, it will be notified that surveys will be conducted at the beginning and end of the 4-week period.
47938750|NCT03049527|BEHAVIORAL|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
48629383|NCT03487666|DRUG|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
47938751|NCT04907461|PROCEDURE|LAPTAP|Laparoscopic guided Transverse Abdominus Plane block
48470647|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
48470648|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
48470649|NCT06678620|BIOLOGICAL|Reinovax PCV24 formulation 3|One dose of Reinovax PCV24 formulation 1（0.5mL）
48470650|NCT06678620|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
48629384|NCT03487666|DRUG|Capecitabine|Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
48629385|NCT02792127|BEHAVIORAL|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
48284772|NCT00499915|BEHAVIORAL|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
48284773|NCT00499915|BEHAVIORAL|Asthma Education|Asthma education will be provided at NICU discharge.
48284774|NCT05990439|BEHAVIORAL|Baby-Feed|The Baby-Feed web application was developed by the researchers of this application at Florida International University. It was designed based on a validated infant food frequency questionnaire (FFQ) developed by our group. The Social Cognitive Theory (SCT) and the Health Self-Empowerment Theory (HSET) were used in the development of the different components. The main intervention component is showing automatic results on how well parents are feeding their infants, upon completion of the infant FFQ, showing results on which food groups are consumed at the recommended level, which are consumed above and which are consumed below. It also shows a growth chart showing how the baby is progressing when they add their baby's weight and length. The website also includes a tracking system with short questions asking about their weekly progress and the recommendations to review frequently, if needed.
48284775|NCT05990439|BEHAVIORAL|Limited access to the Baby-Feed web application|Limited access to the Baby-Feed web application, with only the options of completing the FFQ and inputing their baby's weight and length.
48470651|NCT06357156|RADIATION|CBCT|The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.
48470652|NCT00049296|DRUG|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
48470653|NCT00049296|DRUG|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
48470654|NCT01083862|BEHAVIORAL|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
48284776|NCT03877744|BEHAVIORAL|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
48470655|NCT01083862|BEHAVIORAL|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
48470656|NCT04564404|OTHER|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
48470657|NCT04533906|DEVICE|Coldamaris lozenges|sucking carageenan containing lozenge
48470658|NCT01117987|DRUG|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
48470659|NCT01117987|DRUG|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
48470660|NCT00024258|DRUG|arsenic trioxide|
47938752|NCT03500679|BIOLOGICAL|ExPEC4V|Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
47938753|NCT03500679|BIOLOGICAL|Placebo|Participants will receive placebo as an IM injection on Days 1 and 181.
47938754|NCT01469104|OTHER|3 day fast|Subjects will fast for 72 hours
47938755|NCT01469104|OTHER|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
47938756|NCT02680899|BEHAVIORAL|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
47938757|NCT00252629|OTHER|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
47938758|NCT01411072|DRUG|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
47938759|NCT01411072|DRUG|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
47938760|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
48470661|NCT03370822|DEVICE|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
48470662|NCT02596633|BEHAVIORAL|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
47938761|NCT00564720|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
47938762|NCT00564720|DRUG|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
47938763|NCT00564720|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
48284777|NCT03877744|BEHAVIORAL|live technician|parents will install car seat through guidance from a live certified technician who is present
48284778|NCT00368173|DRUG|rhIGF-I/rhIGFBP-3|
47938764|NCT02772679|BIOLOGICAL|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10\^6 cells. The second cohort will receive 20x10\^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
48284779|NCT05379595|DRUG|Amivantamab|Amivantamab will be administered as intravenous infusion.
48284780|NCT05379595|BIOLOGICAL|Fluorouracil|Fluorouracil will be administered as intravenous infusion.
48284781|NCT05379595|BIOLOGICAL|Leucovorin|Leucovorin will be administered as intravenous infusion.
48284782|NCT05379595|BIOLOGICAL|Oxaliplatin|Oxaliplatin will be administered as intravenous infusion.
48284783|NCT05379595|BIOLOGICAL|Irinotecan|Irinotecan will be administered as intravenous infusion.
48284784|NCT02180386|BEHAVIORAL|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
48284785|NCT03062917|DIAGNOSTIC_TEST|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
48470663|NCT06531876|DEVICE|Dreem 3S recording|Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.
48470664|NCT05766787|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
48470665|NCT05766787|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
48470666|NCT05766787|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
48629386|NCT02717962|DRUG|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
48629387|NCT00601237|BEHAVIORAL|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
48284786|NCT00813475|DRUG|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
48284787|NCT00813475|DRUG|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
48284788|NCT02366819|DRUG|Oxaliplatin|Given IV
48284789|NCT02366819|DRUG|Leucovorin Calcium|Given IV
48284790|NCT02366819|DRUG|Irinotecan Hydrochloride|Given IV
48470667|NCT00271557|DRUG|nesiritide|
48470668|NCT06599138|DEVICE|Ultrasound-guided maxillary nerve block|Suprazygomatic approach, ultrasound-guided infrazygomatic window, maxillary nerve block for injection of 2 - 5 ml of contrast
48470669|NCT03782480|DRUG|Intrarosa|Prasterone intravaginal inserts
48470670|NCT03782480|DRUG|Placebos|Placebo intravaginal inserts
48629388|NCT00601237|BEHAVIORAL|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
48629389|NCT06523946|BEHAVIORAL|Diabetes Prevention Program (DPP) (shortened)|The investigators will adapt the protocol of the 'Ohana project. The 'Ohana protocol was developed based on CDC's Diabetes Prevention Program (DPP) curriculum and designed to fit PcI's cultural background. It includes a 8-lesson curriculum delivered in 8 weeks (shortened from the original 16-lesson, 24-week core curriculum of DPP while retaining all original foci and behavior change strategies). Specifically, the first four lessons, delivered every week, focus on getting the participants started on increasing PA and improving diet (e.g., introduction; getting started on PA and diet; utilizing goal setting; making the process fun). The second four classes will be taught every other week and will focus on how to handle various challenges involved in maintaining healthy lifestyle behaviors. The investigators will deliver the curriculum in group settings of 15 people in a separate room in the National Tongan American Society.
48629390|NCT05242744|DRUG|[18F]FluorThanatrace|Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
48284791|NCT02366819|DRUG|Fluorouracil|Given IV
48284792|NCT02366819|PROCEDURE|Conventional Surgery|Undergo surgery
48284793|NCT02049567|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
48284794|NCT02049567|PROCEDURE|Cataract Surgery|Performed using standard microsurgical techniques
48284795|NCT02122289|DEVICE|Application of Smartphone|Weekly questionnaire on smartphone
48284796|NCT02122289|OTHER|No application Smartphone|No weekly questionnaire on smartphone
48284797|NCT02783781|PROCEDURE|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
48629391|NCT00263536|PROCEDURE|Interpersonal Psychotherapy|
48629392|NCT04764539|BEHAVIORAL|Video Assisted Speech Therapy (VAST)|Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).
48284798|NCT00705900|DRUG|LCD|2 applications / day for 12 weeks
48284799|NCT00705900|DRUG|calcipotriol|2 applications / day for 12 weeks
48284800|NCT01179295|DRUG|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
48284801|NCT01179295|DRUG|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
47938765|NCT03485469|BEHAVIORAL|Hypnosis|"There ar 10 hypnosis sessions :~* 1st session of hypnosis : relaxation and orientation towards emotional cleansing.~* 2nd session of hypnosis: oriented towards digestion, physical and psychological~* 3rd session of hypnosis: oriented towards the feeling of security.~* 4th session of hypnosis: self-esteem oriented.~* 5th hypnosis session: oriented towards emotional management.~* 6th hypnosis session: oriented towards self-confidence.~* 7th hypnosis session: oriented towards the completion of the projects.~* 8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis."
47938766|NCT03485469|BEHAVIORAL|Standard Care|The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
47938767|NCT00439465|BIOLOGICAL|Ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
47938768|NCT00259675|DRUG|carboplatin/gemcitabine, carboplatin/taxol|
47938769|NCT01759888|DRUG|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
47938770|NCT00043121|DRUG|oxaliplatin|Given IV
47938771|NCT00043121|DRUG|leucovorin calcium|Given IV
47938772|NCT00043121|DRUG|fluorouracil|Given IV
47938773|NCT00043121|DRUG|capecitabine|Given orally
47938774|NCT00043121|OTHER|pharmacological study|Correlative studies
47938775|NCT05235464|OTHER|Standard meal|Standard meal
47938776|NCT05235464|OTHER|High animal protein meal|Meal with high animal protein content
47938777|NCT05235464|OTHER|High plant protein meal|Meal with high plant protein content
48470671|NCT03230123|DIETARY_SUPPLEMENT|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
47938778|NCT05235464|OTHER|High plant protein meal with additional leucine|Meal with high plant protein content and additional leucine
47938779|NCT00190944|DRUG|Teriparatide|
48470672|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
48470673|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
48470674|NCT01085578|DRUG|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
48470675|NCT04773509|PROCEDURE|Paravertebral block|Randomly selected patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides.
47938780|NCT00190944|DRUG|placebo|
48470676|NCT03636087|PROCEDURE|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
48470677|NCT03636087|PROCEDURE|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
48470678|NCT03636087|PROCEDURE|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
48470679|NCT03636087|PROCEDURE|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
48470680|NCT03636087|PROCEDURE|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
48629393|NCT03122366|DIAGNOSTIC_TEST|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
48629394|NCT05992038|PROCEDURE|Osteotomy with putty|Synthetic ceramic putty
48629395|NCT05992038|PROCEDURE|Conventional osteotomy|conventional osteotomy
48629396|NCT03367702|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
47938781|NCT05345327|DRUG|Dapagliflozin|SGLT2 inhibitor
47938782|NCT05345327|DRUG|Metformin|Metformin
47938783|NCT06038474|DRUG|Descartes-08|Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
47938784|NCT04067583|OTHER|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
47938785|NCT01277081|DRUG|Paracetamol hot drink|Hot drink containing paracetamol
47938786|NCT01277081|DRUG|Paracetamol tablets|Paracetamol tablets
47938787|NCT01642654|OTHER|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
47938788|NCT01642654|OTHER|Educational lectures|Educational lectures
47938789|NCT06415851|DRUG|mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody|This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
47938790|NCT01912963|DRUG|Pertuzumab|
47938791|NCT01912963|DRUG|Trastuzumab|
48470681|NCT03636087|OTHER|Changing gloves before obturation|The treating dentist will change gloves before obturation
48470682|NCT03636087|OTHER|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
48629397|NCT03367702|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
48629398|NCT03959319|OTHER|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
48629399|NCT03959319|OTHER|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
48629400|NCT03316560|BIOLOGICAL|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
48629401|NCT01509105|BIOLOGICAL|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
48629402|NCT03682081|DEVICE|Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)|An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
48629403|NCT03682081|DEVICE|Biotene Oral Balance Gel|Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
48629404|NCT04607447|BEHAVIORAL|low intracranial pressure strategy treatment|"1. Supine position for 16h-18h daily, with head toward the affected side in most of the time, and 15-20 cm elevation of lower limbs.~2. Abdominal belt compression"
48629405|NCT04607447|DRUG|Atorvastatin plus Dexamethasone|Atorvastatin plus Dexamethasone
48629406|NCT02523638|DRUG|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
48629407|NCT01430884|OTHER|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
48284802|NCT01179295|DRUG|BAY86-9766|BAY86-9766 100 mg once a day (od)
48629408|NCT00321412|DRUG|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
48629409|NCT00512863|DRUG|Humira (adalimumab)|
48629410|NCT02196545|BEHAVIORAL|Exercise|
48629411|NCT00550004|DRUG|RP101|190 mg oral tablet
48629412|NCT00550004|DRUG|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
47938792|NCT01912963|DRUG|eribulin|
48284803|NCT01179295|DRUG|BAY86-9766|BAY86-9766 60 mg once a day (od)
48470683|NCT03636087|OTHER|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
48470684|NCT03636087|RADIATION|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
48470685|NCT03636087|RADIATION|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
48629413|NCT01834261|DRUG|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
47938793|NCT02545231|DRUG|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
47938794|NCT02545231|DRUG|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
47938795|NCT02545231|DRUG|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
48470686|NCT03957590|DRUG|Tislelizumab|Administrated at dose of 200 mg intravenously (IV)
47938796|NCT04805944|DRUG|Dolutegravir|Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
47938797|NCT04805944|DRUG|Bictegravir|Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
47938798|NCT04805944|DRUG|Dolutegravir|Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
47938799|NCT04805944|DRUG|Dolutegravir|Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
47938800|NCT04805944|DRUG|Bictegravir|Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
47938801|NCT05293964|DRUG|SIM0270|SIM0270 is an oral, selective estrogen receptor degrader (SERD)
47938802|NCT05293964|DRUG|Palbociclib|palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
48470687|NCT03957590|DRUG|Placebo|Placebo to match tislelizumab
47938803|NCT05293964|DRUG|everolimus|Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
48470688|NCT03957590|DRUG|Paclitaxel|Administered as 135 mg/m² IV injection
48470689|NCT03957590|DRUG|Cisplatin|Administered as 25 mg/m² IV injection
47938804|NCT00000977|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
47938805|NCT06423989|COMBINATION_PRODUCT|IVIG|treatment of subfertility
48629414|NCT01834261|DRUG|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
48629415|NCT01663831|OTHER|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
48629416|NCT02988557|PROCEDURE|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
47938806|NCT03978715|OTHER|No intervention-retrospective study|This is a retrospective study. No intervention
47938807|NCT00926588|DRUG|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
47938808|NCT03335917|OTHER|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
48470690|NCT03957590|RADIATION|Radiotherapy|Administered at a total dose of 50.4 Gy in 28 fractions
47938809|NCT03335917|OTHER|Exercise|Graded cycling exercise to volitional fatigue
47938810|NCT02240290|DRUG|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
47938811|NCT02240290|DRUG|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
47938812|NCT00054171|DRUG|aminolevulinic acid hydrochloride|
47938813|NCT00674778|PROCEDURE|Any percutaneous cardiovascular procedure|
48470691|NCT01513044|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
48470692|NCT01513044|DRUG|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
48470693|NCT02910024|DEVICE|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
48470694|NCT02910024|DEVICE|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
48470695|NCT01213836|DRUG|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
48470696|NCT01213836|DRUG|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
48470697|NCT01213836|DRUG|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
47938814|NCT00761748|DEVICE|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
47938815|NCT00761748|DEVICE|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
47938816|NCT05704296|PROCEDURE|Y-composite grafting|Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting
47938817|NCT05704296|PROCEDURE|Aortocoronary grafting|Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting
47938818|NCT00312403|PROCEDURE|Blood Sample|A single venous blood sample will be taken (10 ml).
47938819|NCT02582762|DRUG|Nail gel|apply nail gel on affected nails twice daily for 2 months
47938820|NCT02123628|DRUG|duration of the antibiotic therapy|
47938821|NCT01530347|DEVICE|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
47938822|NCT02828527|OTHER|Observational|
47938823|NCT00488878|PROCEDURE|Biospecimen Collection|Patients' residual tissue samples are collected
47938824|NCT00488878|OTHER|Electronic Health Record Review|Medical records are reviewed
47938825|NCT01019811|PROCEDURE|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
47938826|NCT00046891|DRUG|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
48101025|NCT04401917|DRUG|[18F]NOS|Participants will undergo approximately 60 minutes of dynamic whole-body scanning, including the brain, starting at approximately the time of injection of \[18F\]NOS. PET/CT imaging sessions will include an injection of ≤ 6.5 mCi (approximate range for most studies is anticipated to be 3.5-6.5 mCi) of \[18F\]NOS.
48470698|NCT01213836|DRUG|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
48470699|NCT03856606|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
48470700|NCT03856606|BEHAVIORAL|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
48470701|NCT03267927|DEVICE|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
48101026|NCT00586014|PROCEDURE|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
48470702|NCT03267927|DEVICE|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
48470703|NCT03267927|DEVICE|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
48470704|NCT04281524|DRUG|CSL312|CSL312 administered as an IV infusion
48470705|NCT04281524|DRUG|Placebo|Solution of 70% 0.9% saline / 30% CSL312 diluent
48470706|NCT06237348|DEVICE|Simeox|Daily airway clearance therapy at home during 2 months
48470707|NCT06237348|COMBINATION_PRODUCT|Control|Daily airway clearance therapy at home during 2 months
48470708|NCT03244605|OTHER|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
48470709|NCT03244605|OTHER|Rehabilitation Education|General health education
48470710|NCT03244605|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
48470711|NCT03244605|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
48470712|NCT06535464|DEVICE|Hypotension Prediction Index|Fluid management guided by Hypotension Prediction Index
48470713|NCT06535464|DEVICE|No Hypotension Prediction Index|Fluid management not guided by Hypotension Prediction Index
48629417|NCT02988557|DEVICE|treadmill|walking on a treadmill with a sloped surface
48629418|NCT04819620|DRUG|PN-232|Active Drug
47938827|NCT00046891|OTHER|Placebo|Patients will take 1 tablet BID
48101027|NCT05567952|DRUG|nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
48101028|NCT05567952|DRUG|ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
48101029|NCT05567952|DRUG|placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
47938828|NCT06206070|BEHAVIORAL|The Hong Kong version of Westmead Feeling Program 2|Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
47938829|NCT03347708|BIOLOGICAL|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
47938830|NCT03347708|DRUG|Saline Solution|Sodium Chloride Solution
48101030|NCT01771900|BEHAVIORAL|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
48101031|NCT01771900|BEHAVIORAL|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
48101032|NCT06460519|OTHER|Non-invasive blood pressure measurements|Non-invasive blood pressure measurements to the tension cuff three times in a row on each side (right arm and left arm)
48470714|NCT04053673|DRUG|RBN-2397|an oral PARP7 Inhibitor
48470715|NCT06270095|DIAGNOSTIC_TEST|Neurocognitive, neuromuscular and neurosensitive tests.|"At T0, the subject realizes a neurocognive test and an self-assessment of health symptoms autonomously on its professional digital tablet. They also realizes two self questionnaires on their state of fatigue (Samn-Perelli Fatigue Scale) and anxiety (Hospital Anxiety and Depression scale).~At T0 + 3 months, the subject follows a standardized medical examination carried out by a physician, assessing neuromuscular score using the Medical Research Council questionnaire and assessing neurosensitivity score using the Incat Sensory Sum Score. If necessary, the DN4 questionnaire for neuropathic pain is used. The same neurocognitive tests than T0, and Samn-Perelli Fatigue Scale and Hospital Anxiety and Depression scale are also repeated."
48470716|NCT06535763|OTHER|professional caregiver|"Care professionals will be questioned using a self-administered Quality of Life at Work scale, as well as a second scale (before and after training, with one test per day for 3 consecutive working days) asking about the number of work situations involving behavioral disorders in the residents under their care, and how they use the HAPNeSS method to deal with these situations.~The effects of the HAPNeSS method on caregivers' professional practices (actions taken, performance of tasks, relations with residents, etc.) and their feelings on the subject, will be collected in two semi-structured interviews (with half the participants selected at random) conducted before and after the training course by the research team's occupational psychologist."
48470717|NCT01110317|DRUG|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
48470718|NCT02710253|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48470719|NCT02710253|OTHER|Laboratory Biomarker Analysis|Correlative studies
48470720|NCT02710253|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48629419|NCT04819620|DRUG|Placebo|Matching Placebo
48629420|NCT00989027|DRUG|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
48629421|NCT00989027|DRUG|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
48629422|NCT00989027|DRUG|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
48629423|NCT00989027|DRUG|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
48629424|NCT00989027|DRUG|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
47938831|NCT03347708|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Vehicle
47938832|NCT02909179|OTHER|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
47938833|NCT04819022|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
47938834|NCT04819022|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
47938835|NCT04819022|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
47938836|NCT01818960|PROCEDURE|IRA-PCI|IRA only PCI at the time of Primary PCI
47938837|NCT01818960|PROCEDURE|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
48470721|NCT01655251|BEHAVIORAL|Intervention|
48629425|NCT01311583|BEHAVIORAL|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
48629426|NCT06367179|OTHER|Virtual reality and AI use|The experimental group will receive interventions of virtual reality and artificial intelligence wound detecting system.
47938838|NCT01298193|DRUG|Aprepitant|Efficacy phase (second cycle)
47938839|NCT06156475|PROCEDURE|Proprioception exercises|Patients trained for proprioception exercises.
48470722|NCT02608424|DEVICE|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
48470723|NCT02103582|OTHER|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
48470724|NCT04583150|PROCEDURE|Bariatric surgery|Bariatric surgery : sleeve gastrectomy or Roux-en-Y gastric bypass (RYGB)
48470725|NCT02714296|DRUG|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
48470726|NCT02714296|DIETARY_SUPPLEMENT|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
48470727|NCT01486108|PROCEDURE|dorsal column stimulator|test different settings of stimulation
48470728|NCT05925725|DRUG|• harpagozid • boswellin = LOXACON|Exercise therapy
48470729|NCT01010035|OTHER|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
48470730|NCT03824561|DRUG|Vedolizumab|Vedolizumab IV infusion
48470731|NCT04876937|DRUG|Dexmedetomidine|Dexmedetomidine is infused at a rate of 0.1-0.2 μg/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
48470732|NCT04876937|DRUG|Placebo (normal saline)|Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
48470733|NCT04655235|GENETIC|Genotyping|Genotyping of glutamatergic, GABAergic, dopaminergic and other CNS-related genes
48470734|NCT05774652|BEHAVIORAL|Lifestyle intervention Dietary advise and/or advise on physical activity|Lifestyle intervention Dietary advise and/or advise on physical activity
48470735|NCT05758909|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
48470736|NCT04646824|DRUG|Almonertinib Pemetrexed/Cisplatin|Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
48470737|NCT03642067|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
48470738|NCT03642067|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
48470739|NCT03642067|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
48470740|NCT03642067|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
48470741|NCT03607045|DEVICE|headless screw|headless screw group
48470742|NCT05043857|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~* CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~* CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy."
47938840|NCT06156475|PROCEDURE|Proprioception exercises with Electromyographic Biofeedback|Patients trained for Proprioception exercises with Electromyographic Biofeedback
47938841|NCT06156475|PROCEDURE|Wand Exercise|Patients were educated with wand exercises.
47938842|NCT05509946|DRUG|Single dose of celecoxib 400 mg and pregabalin 150 mg|Single dose of celecoxib 400 mg and pregabalin 150 mg
47938843|NCT05509946|DRUG|Repeated dose of celecoxib 200 mg and pregabalin 75 mg|Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery
47938844|NCT05509946|DRUG|Placebo|Placebo
48101033|NCT04311229|DEVICE|Negative-Pressure Wound Therapy group|The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.
48470743|NCT00334763|BIOLOGICAL|bevacizumab|
48470744|NCT00334763|DRUG|carboplatin|
48470745|NCT00334763|DRUG|chemoprotection|
48470746|NCT00334763|DRUG|paclitaxel|
48470747|NCT00334763|RADIATION|radiation therapy|
48470748|NCT01148524|BIOLOGICAL|No Vaccine|
47938845|NCT03458663|DEVICE|Prevena™ og ACTIV.A.C™ Therapy System.|A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
47938846|NCT02037581|BEHAVIORAL|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
47938847|NCT02037581|BEHAVIORAL|Standard Care|Standard care as being offered by private psychiatrists
47938848|NCT04674579|DEVICE|MRI|magnetic resonance imaging
47938849|NCT03216031|BEHAVIORAL|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
47938850|NCT04041739|DIAGNOSTIC_TEST|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
47938851|NCT04477239|BEHAVIORAL|Gluten (behaviour)|Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).
47938852|NCT04477239|BEHAVIORAL|Placebo (behaviour)|Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
47938853|NCT02691962|DEVICE|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
47938854|NCT02637128|DRUG|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
47938855|NCT02637128|DRUG|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
48101034|NCT04311229|OTHER|contol group|Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
48101035|NCT05132205|PROCEDURE|Radiofrequency Ablation|Radiofrequency Ablation using RFMedical device.
48101036|NCT06631248|OTHER|Coordinative exercise protocol|During the eight-week period, all children in the structured coordinative exercise intervention group participated in 30-minute sessions twice a week on the same day and time. The purpose-oriented basic movement patterns created in the coordinative exercise content were organised in a play-oriented manner suitable for the preschool age range.
48470749|NCT01148524|BIOLOGICAL|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
48470750|NCT06677801|BIOLOGICAL|Telitacicept 160mg|Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.
48470751|NCT02347319|DRUG|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
48470752|NCT02347319|DRUG|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
48470753|NCT02347319|DRUG|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
48470754|NCT02809768|DRUG|Avatrombopag|
48470755|NCT02809768|DRUG|Fluconazole|
48470756|NCT02809768|DRUG|Itraconazole|
48470757|NCT02809768|DRUG|Rifampin|
47938856|NCT03844477|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified."
47938857|NCT03844477|PROCEDURE|Placebo control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified."
47938858|NCT03155360|OTHER|Non interventional study|Non interventional study
47938859|NCT06000176|DEVICE|Optical coherence tomography angiography|diagnostic test OCTA macula and ONH
48470758|NCT02488824|PROCEDURE|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
48470759|NCT02123732|DIETARY_SUPPLEMENT|DbXell|
48470760|NCT02123732|DIETARY_SUPPLEMENT|Placebo|
48470761|NCT03031834|DRUG|Quinapril|
48470762|NCT05427045|OTHER|home - exercise program|Home exercise program
48470763|NCT00983528|BIOLOGICAL|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
48470764|NCT00983528|DRUG|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
48470765|NCT00005087|BIOLOGICAL|filgrastim|
48470766|NCT00005087|DRUG|cisplatin|
48470767|NCT00005087|DRUG|paclitaxel|
47938860|NCT05920928|RADIATION|Short course radiotherapy with concurrent capecitabine(825mg/m2)|Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)
48284804|NCT06294028|OTHER|Adverse events collection|Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
48284805|NCT06294028|OTHER|Quality of life questionnaire EQ-5D-5L|"Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100"
48284806|NCT06294028|OTHER|Medical-economic evaluation|"Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS)."
48470768|NCT00005087|PROCEDURE|conventional surgery|
48470769|NCT00005087|RADIATION|radiation therapy|
48470770|NCT02625337|DRUG|Pembrolizumab|
48470771|NCT02625337|DRUG|Dabrafenib|
48470772|NCT02625337|DRUG|Trametinib|
48470773|NCT02625337|PROCEDURE|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
48470774|NCT02625337|PROCEDURE|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
48470775|NCT00916695|DEVICE|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
48470776|NCT00055549|DRUG|Dextromethorphan|
48470777|NCT00055549|DRUG|Lorazepam|
48470778|NCT04581876|DRUG|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
48470779|NCT04581876|DRUG|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
47938861|NCT05920928|RADIATION|Long course radiotherapy with concurrent capecitabine(825mg/m2)|Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
47938862|NCT04537260|BEHAVIORAL|Educational Video|Those in the intervention arm were asked to watch the 3-minute educational video prior to the knowledge questionnaire and meeting their provider (midwife or obstetrician). The video shown to these participants is linked here: https://youtu.be/Pc9tcIV4Dm8.
47938863|NCT02775903|DRUG|Azacitidine|Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
48284807|NCT05611138|DIETARY_SUPPLEMENT|Protein supplementation|Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
48284808|NCT00041899|DRUG|CDB-2914|
48470780|NCT06057506|DEVICE|Paranix® Shampoo|well established medical device for the treatment of head lice infestation (osmolone based)
48470781|NCT06057506|DEVICE|Paranix® Lotion|well established medical device for the treatment of head lice infestation (dimethicone based)
48470782|NCT01192399|BIOLOGICAL|Eculizumab|
48470783|NCT02221817|PROCEDURE|Trochanter bursa injections|
48470784|NCT02221817|DEVICE|Ultrasound|
48470785|NCT00244829|DRUG|imatinib mesylate|
48470786|NCT00244829|PROCEDURE|adjuvant therapy|
48470787|NCT05950217|OTHER|Education|Nurse-led patient education
48470788|NCT06679621|BEHAVIORAL|Telehealth intervention|This telehealth intervention will be made using human centered design methods
48470789|NCT04934020|OTHER|Pre-pandemic stroke related metrics|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
48470790|NCT04934020|OTHER|Stroke related metrics during the pandemic|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
48470792|NCT02302716|DRUG|LY2963016|Administered SC
48470793|NCT02302716|DRUG|LANTUS®|Administered SC
48470794|NCT02302716|DRUG|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
48470795|NCT05393349|BEHAVIORAL|Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures|Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
48470796|NCT03212378|OTHER|percutaneous coronary interventions|Percutaneous coronary intervention.
48470797|NCT01185860|DRUG|danoprevir|oral doses
48470798|NCT01185860|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
48470799|NCT01185860|DRUG|placebo|oral doses
48470800|NCT01185860|DRUG|ribavirin|1000-1200mg/day po
48629427|NCT06367179|OTHER|Health education leaflet|The control group maintained the traditional pressure injury health education with oral introduction and health education leaflet.
48101037|NCT04235283|DEVICE|Primary total knee replacement by pinless navigation (Orthomap Express,Stryker, Michigan)|The varus/valgus, extension/flexion, thickness of distal cut of femur was determined and done by pinless navigation system. After cutting, the instant information of resection level can show on the display screen. If the alignment is satisfying, the anterior/posterior femoral cut, chamfer cut and box resection were done by conventional jig
48101038|NCT04235283|PROCEDURE|Primary total knee replacement by traditional jig and minimally invasive technique|The femoral alignment was determined by intramedullary guide. The femoral alignment jig was set to 5-7 degree valgus dependent on the preoperative radiograph. A bone plug is impacted into the entry hole of femoral medullary canal before prosthesis placement.
48284809|NCT00041899|DRUG|COB-2914|
48470801|NCT01185860|DRUG|ritonavir|oral doses
47938864|NCT02775903|BIOLOGICAL|Durvalumab|Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
48470802|NCT00124462|DEVICE|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
48470803|NCT00124462|DEVICE|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
48470804|NCT00355524|DRUG|TMC114|TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
48470805|NCT00355524|DRUG|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
48617935|NCT02689622|OTHER|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
47938865|NCT05956184|DEVICE|Intrauterine Device Insertion|All womens will be placed in a gynecological position and underwent a bimanual examination to better determine whether the uterus was in the anteverted or retroverted position. Subsequently, a speculum will be inserted, and the cervix will be disinfected with betadine. In the conventional method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and after entering the uterine cavity with a hysterometry the IUD is inserted. In the direct method: the anterior lip of the cervix is grasped and pulled with Pozzi forceps, and without using hysterometry the IUD is directly inserted. The strings will be cut approximately 2-3 cm after the cervix, and the Pozzi forceps and speculum will be removed. The accuracy of the IUD placement will be confirmed using pelvic ultrasound. The process will take about five minutes.
47938866|NCT03464695|DEVICE|O2matic|Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
48470806|NCT04593394|DIAGNOSTIC_TEST|Continous laryngoscopy exercise test|Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
48470807|NCT04593394|DIAGNOSTIC_TEST|Overnight respiratory polygraphy|Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
48470808|NCT02075034|DRUG|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
48470809|NCT03930069|DRUG|Misoprostol|prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
48470810|NCT03930069|DRUG|Vasopressin|one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
48470811|NCT02209116|OTHER|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
48470812|NCT04319458|BEHAVIORAL|Fotonovela|Secret Feelings/Sentimientos Secretos
47938867|NCT00568490|PROCEDURE|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
48470813|NCT04319458|BEHAVIORAL|Control|NIH Brochure: Depression: What You Need to Know
48470814|NCT04912986|BEHAVIORAL|Early Lung Rehabilitation Training|It is implemented in accordance with the Early Lung Rehabilitation Training Program for Adult Double Lung Transplant Patients. Establish multidisciplinary collaboration teams, including competent doctors, nurses, rehabilitation physicians, and psychologists.
48470815|NCT04912986|BEHAVIORAL|Routine treatment|Provide rehabilitation training as usual, without standard program
47938868|NCT00568490|PROCEDURE|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
47938869|NCT04128332|RADIATION|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
47938870|NCT05323565|DRUG|Dexmedetomidine|adjuvants to 0.25 bupivacaine in TAB block.
47938871|NCT00398489|BIOLOGICAL|trastuzumab|
48470816|NCT00689845|BIOLOGICAL|bleomycin sulfate|Given IV
48470817|NCT00689845|BIOLOGICAL|filgrastim|Given subcutaneously
48470818|NCT00689845|BIOLOGICAL|rituximab|given IV
48470819|NCT00689845|DRUG|cyclophosphamide|Given IV
47938872|NCT00398489|DRUG|anastrozole|
48101039|NCT00835016|BEHAVIORAL|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
48101040|NCT06418529|DRUG|tofacitinib|New index treatment of tofacitinib
48470820|NCT00689845|DRUG|cytarabine|Given subcutaneously
48470821|NCT00689845|DRUG|doxorubicin hydrochloride|Given IV
48470822|NCT00689845|DRUG|etoposide phosphate|Given IV
48470823|NCT00689845|DRUG|ifosfamide|Given IV
48470824|NCT00689845|DRUG|methotrexate|Given IV
48470825|NCT00689845|DRUG|prednisolone|Given orally
48470826|NCT00689845|DRUG|prednisone|Given orally
48470827|NCT00689845|DRUG|vincristine sulfate|Given IV
47938873|NCT00398489|DRUG|cyclophosphamide|
48470828|NCT00689845|DRUG|vindesine|Given IV
48470829|NCT00206180|DRUG|esomeprazole magnesium (oral medication)|
48470830|NCT01644149|DEVICE|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
48470831|NCT01644149|DEVICE|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
48470832|NCT01644149|BIOLOGICAL|2011-2012 Fluzone trivalent inactivated influenza vaccine|
48470833|NCT06353412|PROCEDURE|Lumbar puncture|Medical treatment Lumbar puncture Theco peritoneal shunt
48470834|NCT00040794|DRUG|paclitaxel|Given IV
48470835|NCT00040794|DRUG|carboplatin|Given IV
48470836|NCT00040794|DRUG|gefitinib|Given PO
48470837|NCT00040794|RADIATION|radiation therapy|Undergo radiotherapy
48470838|NCT00040794|OTHER|laboratory biomarker analysis|Optional correlative studies
48470839|NCT04205162|DEVICE|Verafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
48470840|NCT04205162|DEVICE|Etafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
48284810|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
47938874|NCT00398489|DRUG|docetaxel|
48101041|NCT06418529|DRUG|tumor necrosis factor inhibitors (TNFi)|New index treatment of TNFi
48470841|NCT01090817|DRUG|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
48284811|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
48629428|NCT06147154|OTHER|16S rRNA amplicon sequencing and untargeted metabolomics|"16S rRNA sequencing is a method for large-scale identification of community composition, expression abundance, and phylogenetic analysis by polymerase chain reaction (PCR) amplification of specific variable regions of 16S rRNA, combined with high-throughput sequencing and bioinformatics analysis. It also enables large-scale identification of the entire flora in a given habitat to study microbial diversity.~Untargeted metabolomics refers to the use of Liquid Chromatograph Mass Spectrometer (LC-MS), Gas Chromatograph Mass Spectrometer (GC-MS), and nuclear magnetic resonance (NMR) technology. The dynamic changes of small molecular metabolites in cells, tissues, organs or organisms before and after stimulation or disturbance were detected without bias. The differential metabolites were screened by bioinformatics analysis, and the pathway analysis of differential metabolites was performed to reveal the physiological mechanism of their changes."
48629429|NCT04180878|BEHAVIORAL|Intervention|Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.
48629430|NCT04180878|BEHAVIORAL|Intervention 2|Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
48629431|NCT05768464|DRUG|Toripalimab|240mg intravenously every 3 weeks
47938875|NCT00398489|DRUG|epirubicin hydrochloride|
47938876|NCT00398489|DRUG|goserelin acetate|
47938877|NCT00398489|DRUG|tamoxifen citrate|
47938878|NCT00398489|PROCEDURE|adjuvant therapy|
47938879|NCT00398489|PROCEDURE|conventional surgery|
48101042|NCT06418529|DRUG|abatacept|New index treatment of abatacept
48284812|NCT02171715|DRUG|BIBW 2992 MA2|powder for oral solution
48470842|NCT03027908|OTHER|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
48470843|NCT03027908|OTHER|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
47938880|NCT00398489|PROCEDURE|neoadjuvant therapy|
47938881|NCT00398489|RADIATION|radiation therapy|
48101043|NCT06418529|DRUG|tocilizumab or sarilumab|New index treatment of tocilizumab or sarilumab
48284813|NCT05164328|OTHER|No intervention|No intervention
48284814|NCT04893668|OTHER|Depression|Any participants who develop depression symptoms according to DSM 5 criteria
48284815|NCT04893668|OTHER|Anxiety|Any participants who develop anxiety symptoms according to DSM 5 criteria
48284816|NCT05150860|BEHAVIORAL|At-home COVID-19 testing|At-home over-the-counter (OTC) COVID-19 testing kits provided to middle school students and staff
48284817|NCT05150860|BEHAVIORAL|Family-based model|Making the COVID-19 testing program available to household/family members to increase participation of students and staff in the school COVID-19 testing program
48284818|NCT05150860|BEHAVIORAL|Onsite COVID-19 testing|Onsite COVID-19 testing for middle school students and staff
48470844|NCT04805385|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
48470845|NCT05268419|DRUG|Ethanol|Inhalation of 35%-ethanol spray
48470846|NCT05268419|DRUG|Water Distilled|Inhalation of water distilled spray
48617936|NCT02689622|OTHER|physical performance|Activities of Daily Living and physical performance
48629432|NCT05768464|DRUG|Axitinib|5mg orraly twice daily
48284819|NCT03064282|OTHER|Placebo|observation of skin changes if any
48470847|NCT06300606|DEVICE|NOL monitoring|Prospective observational study to assess pain during regional anesthesia for upper limb orthopedic surgery using NOL monitoring and the Algoplus pain scale
48470848|NCT05064267|DIAGNOSTIC_TEST|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
48470849|NCT01992341|DRUG|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
48470850|NCT01992341|DRUG|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
48470851|NCT04781322|DRUG|Alirocumab|Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
48470852|NCT04781322|OTHER|Placebo|Heavy drinking healthy volunteers
48470853|NCT06458257|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
47938882|NCT04967612|OTHER|Virtual implantation|Temporary placement of virtual optical lens in the crystalline lens plane.
47938883|NCT03778944|PROCEDURE|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
47938884|NCT03778944|PROCEDURE|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
47938885|NCT03778944|PROCEDURE|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
47938886|NCT01384643|DRUG|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
48284820|NCT03064282|DRUG|papaverine|observation of symptoms
48284821|NCT01615510|DRUG|Tapentadol immediate release|100 mg, single administration
48284822|NCT01615510|DRUG|placebo|placebo, single administration
48284823|NCT01370070|DRUG|MK-2206|200mg weekly repeated q 28 days
48284824|NCT05123287|DRUG|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
48284825|NCT00630032|DRUG|cyclophosphamide|500 mg/m² every 3 weeks
48284826|NCT00630032|DRUG|Docetaxel|100 mg/m² every 3 weeks
48284827|NCT00630032|DRUG|epirubicin hydrochloride|100 mg/m² every 3 weeks
48284828|NCT00630032|DRUG|fluorouracil|500 mg/m² every 3 weeks
48284829|NCT00630032|DRUG|ixabepilone|40 mg/m² every 3 weeks
48284830|NCT01938625|DRUG|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
48284831|NCT01938625|DRUG|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
48284832|NCT01938625|DRUG|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
48284833|NCT01938625|DRUG|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
48470854|NCT06458257|DRUG|Chemotherapy|Chemotherapy
48470855|NCT03878264|DRUG|CORT118335 Oral|CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
48470856|NCT03878264|DRUG|14C-CORT118335 intravenous|14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
48470857|NCT03878264|DRUG|14C-CORT118335 oral|14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
48470858|NCT01006954|DRUG|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
48470859|NCT01006954|DRUG|Flare up|Flare up protocol in poor responders for IVF/ICSI
48470860|NCT00894517|BIOLOGICAL|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
48470861|NCT00894517|DRUG|Placebo (saline)|Saline injected into the prostate on Day 1.
47938887|NCT03096145|BEHAVIORAL|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
48101044|NCT06631352|OTHER|Hepatopancreatoduodenectomy|Pancreatoduodenectomy with liver resection
48101045|NCT06234865|OTHER|Control Group|Patients in the control group will receive standard education plus a brochure education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The brochure education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
48101046|NCT06234865|OTHER|Video Education Group|Patients in the experimental group will receive standard education plus a video education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The video education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
48470862|NCT05831579|RADIATION|Proton GRID Radiotherapy|The proton GRID radiotherapy prescription dose is 20 Gy x 3 fractions to the tumor, with an integrated dose of 6 Gy x 3 fractions to the PTV. Treatment to multiple lesions within the PTV is allowed (ex. a dominant lesion plus satellites). Multiple proton GRID radiotherapy plans may be delivered on the same day or different days, but they cannot overlap.
47938888|NCT03096145|BEHAVIORAL|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
48470863|NCT05467982|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
47938889|NCT03096145|BEHAVIORAL|Health incentive|Smokers receive a $25 gift card if they call the quitline
47938890|NCT04276454|DEVICE|Flexitouch Plus system|A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
47938891|NCT01857310|DIETARY_SUPPLEMENT|5 mg folic acid and 30 mg elemental zinc|
47938892|NCT01857310|DRUG|Placebo Comparator: Placebo|
47938893|NCT06156540|OTHER|virtual reality glasses|Using virtual reality glasses, caregivers in the experimental group were shown 360-degree VR relaxing videos.
48470864|NCT05467982|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
48470865|NCT01294449|DEVICE|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
48470866|NCT01294449|DEVICE|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
48470867|NCT01959802|PROCEDURE|Vitrectomy|
48470868|NCT00647894|DRUG|Alprazolam Extended-Release Tablets 1 mg|
48470869|NCT00647894|DRUG|Xanax XR Tablets 1 mg|
48470870|NCT04692857|PROCEDURE|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
48470871|NCT03904901|DIETARY_SUPPLEMENT|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
48470872|NCT03904901|DIETARY_SUPPLEMENT|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
48470873|NCT05083754|DRUG|Retifanlimab|Anti-PD-1 Therapy
48470874|NCT05083754|DRUG|Temozolomide|Anti-PD-1 Therapy
48470875|NCT05083754|RADIATION|Radiation Therapy|Standard of Care
48470876|NCT04194554|DRUG|Niraparib|given PO per dose escalation schedule
48470877|NCT04194554|DRUG|Leuprolide|22.5 mg q3 month
48470878|NCT04194554|DRUG|Abiraterone Acetate|1000 mg daily
48470879|NCT04194554|RADIATION|Stereotactic body radiotherapy (SBRT)|5-6 fraction SBRT (total dose: 37.5-40 Gy)
48470880|NCT06679140|DRUG|ibuzatrelvir|ibuzatrelvir tablets
48470881|NCT06679140|DRUG|placebo|placebo tablets
48470882|NCT06398834|DRUG|Esketamine|In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).
48470883|NCT06398834|DRUG|Butorphanol|In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
48470884|NCT06031337|DIAGNOSTIC_TEST|ELISA|quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
48470885|NCT04429542|DRUG|BCA101|EGFR/TGFβ fusion monoclonal antibody
48470886|NCT04429542|DRUG|Pembrolizumab|anti-PD-1
48470887|NCT04290234|OTHER|fMRI assessment of cognitive and reactive fear|An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
48470888|NCT05425745|DRUG|Obicetrapib|10 mg Obicetrapib tablet
47938894|NCT03303482|BEHAVIORAL|Enhancing Trauma Awareness (Diane Wagenhals, MEd-Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
47938895|NCT05402020|DRUG|Tiotropium (Tio)|Tiotropium (Tio)
47938896|NCT05402020|DRUG|Inhaled corticosteroids (ICS)|Inhaled corticosteroids (ICS)
47938897|NCT05402020|DRUG|Olodaterol (Olo)|Olodaterol (Olo)
47938898|NCT05402020|DRUG|Long-acting β2-agonists (LABA)|Long-acting β2-agonists (LABA)
47938899|NCT02781519|DRUG|THC|Active THC (0.015mg/kg) administered over 10 minutes
48470889|NCT05425745|DRUG|Placebo|placebo tablet made to resemble active
48470890|NCT04888533|OTHER|EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool|EHSSA will be used to evaluate every patient for suicide risk.
48470891|NCT01352052|OTHER|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
48470892|NCT06678542|DRUG|GP681 tablet|GP681 tablet, 20 mg, single oral dose in each Group.
48470893|NCT06678542|DRUG|GP681 Powder for Oral Suspension|GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.
48470894|NCT06674694|DRUG|Brexpiprazole long-acting injection|A single injection was administered.
48470895|NCT05770557|BEHAVIORAL|survey|administration of a survey among healthcare workers
48470896|NCT01503333|BEHAVIORAL|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
48470897|NCT00003317|DRUG|carboplatin|
48470898|NCT00003317|DRUG|paclitaxel|
48470899|NCT00003317|RADIATION|radiation therapy|
48470900|NCT00003317|PROCEDURE|surgery|
48470901|NCT02510950|BIOLOGICAL|Personalized peptide vaccine|
48470902|NCT02510950|DRUG|Poly-ICLC|
48470903|NCT02510950|DRUG|Temozolomide|
48470904|NCT01723150|DRUG|Ciprofloxacin|
48470905|NCT01723150|DRUG|Ceftriaxone|
48470906|NCT01723150|DRUG|Trimethoprim/sulfamethoxazole|
48470907|NCT01723150|DRUG|Ertapenem|
48470908|NCT03594825|DRUG|Valsartan|Different time of taking medicine
48470909|NCT04874363|OTHER|no intervention|no intervention
48470910|NCT04834895|OTHER|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
48470911|NCT04834895|OTHER|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
48470912|NCT00006124|DRUG|celecoxib|Given orally
48470913|NCT00006124|DRUG|placebo|Given orally
48629433|NCT06033664|BEHAVIORAL|Fresh Funds|Participants will enroll in Instacart Fresh Funds program. Once enrolled participants will select foods that are eligible in the Fresh Funds to be delivered to their home each week for 12 weeks.
48470914|NCT04541680|DRUG|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
48470915|NCT04541680|OTHER|Placebo|Placebo
47938900|NCT02781519|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
47938901|NCT01805271|DRUG|Everolimus|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
48470916|NCT01696136|DEVICE|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
48470917|NCT00004441|DRUG|tauroursodeoxycholic acid|
48470918|NCT00004441|DRUG|ursodiol|
48470919|NCT06267183|DRUG|SV001|SV001 ： single-dose
48470920|NCT06267183|DRUG|Placebo|Placebo ： single-dose
48470921|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
47938902|NCT01805271|DRUG|Placebo|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
47938903|NCT00390234|DRUG|ziv-aflibercept|Given IV
48101047|NCT04977960|DRUG|Potassium Canrenoate|potassium canrenoate for 7 days in addition to maximal medical treatment
48470922|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
48470923|NCT01657526|BIOLOGICAL|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
48629434|NCT05442632|DRUG|Hetrombopag|The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
47938904|NCT03574480|BEHAVIORAL|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
47938905|NCT03574480|BEHAVIORAL|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
48470924|NCT04025294|DEVICE|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
48470925|NCT04025294|BEHAVIORAL|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
48470926|NCT00003822|DRUG|apomine|
48470927|NCT01669824|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
48470928|NCT05122351|DRUG|Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries|Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
48470929|NCT06435832|DRUG|Absorbable Gelatin|After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
48470930|NCT06435832|DRUG|Chlorhexidine|After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
48470931|NCT06435832|DRUG|Tranexamic acid|Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
48470932|NCT04767958|DIAGNOSTIC_TEST|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
48470933|NCT03485001|OTHER|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
48470934|NCT03485001|PROCEDURE|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
48470935|NCT04554914|BIOLOGICAL|Tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
48470936|NCT04100096|DRUG|Brexpiprazole|Tablet
48629435|NCT05442632|DRUG|Placebo|The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
48101048|NCT03136263|DRUG|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
48470937|NCT04100096|OTHER|Placebo|Tablet
48470938|NCT03904693|DRUG|FDC macitentan/tadalafil|Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
48470939|NCT03904693|DRUG|Macitentan 10 mg|Film-coated tablet with 10 mg macitentan, to be administered orally once daily.
48470940|NCT03904693|DRUG|Tadalafil 40 mg|Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.
48470941|NCT03904693|DRUG|Placebo FDC|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
48470942|NCT03904693|DRUG|Placebo macitentan|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
48470943|NCT03904693|DRUG|Placebo tadalafil|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
48470944|NCT00000243|DRUG|Buprenorphine|
48470945|NCT04899492|BEHAVIORAL|Motivational Interviewing (MI)|1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
48629436|NCT04777903|OTHER|collect date about all participants|a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.
48629437|NCT00476788|DEVICE|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
48629438|NCT05985551|OTHER|SLND or TAD by the magnetic technique (SPIO)|All patients will receive Radioisotope according to standard of care. They will also receive SPIO in a timeframe of clinical convenience, depending on whether primary response is planned by means of MRI. For patients that are ycN0, SLND or TAD will be performed. For those that convert from cN1 to ycN0, the index lymph node will be marked with a paramagnetic marker. Axillary surgery will be undertaken with the magnetic technique and each retrieved lymph node will be controlled for radiation. Upon the completion of the procedure, a background control will be performed with the radioactive signal as guide, to ensure standard of care best practice. Any palpable lymph nodes that are not sentinels with either tracer may be removed at surgeon discretion but will be reported seperately.
48629439|NCT04027946|DRUG|LMB-100|Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.
47938906|NCT00768937|DRUG|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
48101049|NCT03136263|DRUG|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
48101050|NCT01548391|DRUG|HX-1171|20mg, 200mg, 500mg
48470946|NCT04899492|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
48470947|NCT04899492|BEHAVIORAL|Hypnotherapy|About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
48470948|NCT04899492|DRUG|Nicotine Replacement Therapy (NRT)|All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
48470949|NCT02449616|DRUG|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
48470950|NCT03996837|OTHER|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
48470951|NCT05307562|OTHER|Interval training + analytical strength|Patients will receive a training program
48470952|NCT05307562|OTHER|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
48470953|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose in the fasting state.
48470954|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
48470955|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
48470956|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
48470957|NCT01531504|DEVICE|ViKY UP|laparoscopic-assisted hysterectomy procedure
48470958|NCT04148105|DRUG|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
48470959|NCT04148105|OTHER|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
48470960|NCT00784030|OTHER|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
48470961|NCT03799822|DRUG|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
48284834|NCT01938625|DRUG|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
48284835|NCT01237470|PROCEDURE|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
48284836|NCT01237470|PROCEDURE|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
48284837|NCT02957773|BEHAVIORAL|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
48470962|NCT03799822|DIETARY_SUPPLEMENT|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
48470963|NCT03799822|DRUG|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
48470964|NCT02798328|DEVICE|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
48470965|NCT04226339|PROCEDURE|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
48470966|NCT04226339|PROCEDURE|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
48284838|NCT02957773|BEHAVIORAL|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
48284839|NCT02957773|BEHAVIORAL|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
48284840|NCT02957773|BEHAVIORAL|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
48284841|NCT01389128|OTHER|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~* Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~* Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
47938907|NCT00768937|PROCEDURE|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
47938908|NCT06338761|BEHAVIORAL|Smoking cessation|Stop smoking
47938909|NCT06338761|BEHAVIORAL|Switching to E-cigarette|Switching to E-cigarette
47938910|NCT00102492|DRUG|GW679769|
47938911|NCT02524210|DRUG|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
48284842|NCT01389128|OTHER|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
48284843|NCT00768378|DEVICE|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
48284844|NCT00215150|DRUG|Ziprasidone|Sertraline augmentation with ziprasidone
48284845|NCT00215150|DRUG|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
48470967|NCT01830309|DRUG|CJ-12420 200mg|"Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition"
48470968|NCT02802215|DRUG|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
48284846|NCT03455543|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
48284847|NCT03455543|DEVICE|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
48284848|NCT04264104|OTHER|neural mobilization|This is a type of mobilization that uses a specific combination of joint movements
48470969|NCT02802215|DRUG|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
48470970|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
48470971|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
48470972|NCT03481855|DEVICE|Lower-body-low-pressure chamber|The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
48470973|NCT01287715|DRUG|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
48470974|NCT01287715|DRUG|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
48470975|NCT06215196|DIETARY_SUPPLEMENT|Fiber Supplement Group|Semaglutide (2.4 mg weekly). Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
48470976|NCT06215196|OTHER|placebo|Semaglutide (2.4 mg weekly). Three daily packets of placebo powder, taken 30 minutes before each main meal.
48470977|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
48470978|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
48470979|NCT02246764|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
48470980|NCT02246764|OTHER|Placebo|1 drop QD, AM, OU
48470981|NCT06502990|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
48629440|NCT04027946|DRUG|pembrolizumab|Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.
47938912|NCT02524210|DRUG|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
47938913|NCT02524210|DRUG|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
47938914|NCT01299701|DRUG|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
47938915|NCT01568307|DRUG|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
47938916|NCT01898494|PROCEDURE|Transoral surgery|Undergo transoral surgical resection
47938917|NCT01898494|RADIATION|intensity-modulated radiation therapy|Undergo standard-dose or low-dose IMRT
47938918|NCT01898494|DRUG|cisplatin|Given IV
47938919|NCT01898494|DRUG|carboplatin|Given IV
47938920|NCT03504579|OTHER|rt-fMRI neurofeedback|use of real time fMRI neurofeedback to achieve targeted brain changes
48470982|NCT05700136|BEHAVIORAL|MOMENT|Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
48470983|NCT04742894|BEHAVIORAL|Visual Feedback Training|Participants will be trained to work with a computer setup to control the position of a visual cursor on the screen using their speech while their auditory feedback is altered. The goal of the training is to help improve speech production and motor control ability.
48470984|NCT01287455|DRUG|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
48470985|NCT01287455|OTHER|placebo|drops, 70 placebo drops, once weekly for 6 weeks
48470986|NCT05568316|DIETARY_SUPPLEMENT|Preoperative Immunonutrition|"Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
48629441|NCT04027946|DIAGNOSTIC_TEST|Mesothelin Expression|Testing for mesothelin expression performed at screening
47938921|NCT01232218|OTHER|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
47938922|NCT01232218|OTHER|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
47938923|NCT03295461|PROCEDURE|SRP+ 10% Emblica officinalis irrigation|
47938924|NCT03295461|PROCEDURE|SRP + 0.2% Chlorhexidine irrigation)|
47938925|NCT03295461|PROCEDURE|SRP + 0.9% Saline irrigation|
47938926|NCT03295461|PROCEDURE|SRP +10% E. officinalis gel application.|
47938927|NCT03295461|PROCEDURE|SRP+ placebo gel application.|
47938928|NCT06011031|DEVICE|Novaloc attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
47938929|NCT06011031|DEVICE|Locator attachment|Each patient will be restored with 4 implants retained maxillary overdenture with the assigned attachment
47938930|NCT00559936|DRUG|Topical Avastin 1%|Avastin (bevacizumab) 1%
47938931|NCT05650567|DRUG|M5049 high dose|Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
47938932|NCT05650567|DRUG|Placebo|Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
47938933|NCT01082640|DRUG|Febuxostat|Febuxostat capsules
47938934|NCT01082640|DRUG|Placebo|Febuxostat placebo-matching capsules
47938935|NCT05857228|PROCEDURE|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
47938936|NCT03954522|OTHER|interview|"Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed"
47938937|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection )|Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
47938938|NCT04088604|DRUG|LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）|Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
47938939|NCT04088604|DRUG|Irinotecan Hydrochloride Injection（CAMPTO®）|Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
47938940|NCT05123599|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
47938941|NCT05123599|BIOLOGICAL|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
47938942|NCT05123599|DRUG|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
47938943|NCT05123599|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
47938944|NCT05123599|DRUG|TAF|TAF film-coated tablets will be administered orally.
47938945|NCT03316534|DRUG|Aspirin|Aspirin (100 mg once a day)
48629442|NCT04027946|DIAGNOSTIC_TEST|TrueSight Oncology 500|Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
48629443|NCT02580552|DRUG|Cobomarsen|
48629444|NCT00005795|DRUG|arsenic trioxide|
48629445|NCT02196909|OTHER|motor function and strength assessment|
48629446|NCT02196909|OTHER|NMR assessment|
48629447|NCT02196909|OTHER|24h urine and serum collection|
48629448|NCT00430859|DRUG|Alkaline Phosphatase|Intravenous over a period of 24 hours
48101051|NCT06064032|BEHAVIORAL|cognitive behavioral therapy|In control group there is 10 min session of PMR, 2 min deep breathing exercises,3 min training for life style modification which include use of planner, setting alarms breaking a task into parts positive reinforcement and communication.
47938946|NCT04048811|DRUG|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
48101052|NCT06064032|BEHAVIORAL|Motor Learning Techniques|In experimental group, participants will be given a 10 min PMR ,2 min deep breathing exercises, 3 min training for life style modification which include the use of planners setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with 3 min session of drawing a specific pattern with installing pegs on pegboard, 2 min session of balance board training, 3 min session of jigsaw puzzle training, 1 min session of squeezing a ball with maximum repetition and 1 min session of finding beads in puttey.
48284849|NCT03246438|BEHAVIORAL|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
48101053|NCT01935258|OTHER|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
48101054|NCT01935258|OTHER|care as usual|usual care of the general practitioner
48284850|NCT03246438|BEHAVIORAL|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
48284851|NCT03246438|BEHAVIORAL|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
48101055|NCT00631917|DRUG|Aliskiren|Aliskiren 300 mg once a day
48470987|NCT05568316|DIETARY_SUPPLEMENT|Perioperative Immunonutrition|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
48470988|NCT03111381|DRUG|Toradol|IV toradol
48470989|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A1|Suspension for injection. Route of administration: IM injection
48470990|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A2|Suspension for injection. Route of administration: IM injection
48101056|NCT00631917|DRUG|Ramipril|Ramipril 10 mg once a day
48101057|NCT00631917|OTHER|Placebo to Ramipril|Placebo capsules to match ramipril.
48101058|NCT00631917|OTHER|Placebo to Aliskiren|Placebo tablets to match aliskiren.
48101059|NCT01912495|DRUG|Boceprevir|
48284852|NCT01241539|DRUG|Dabigatran etexilate|150 mg capsule
48470991|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A3|Suspension for injection. Route of administration: IM injection
48629449|NCT00430859|DRUG|Placebo|Saline over a period of 24h
48101060|NCT06555029|BEHAVIORAL|EHR Changes|"Practice-Level:~Changes to the Epic EHR system will include the AAAC process to ask 5 oral health questions, advise for dental attendance, assess the type of referral, and connect with referral and resources"
48101061|NCT06555029|BEHAVIORAL|Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training|"Provider-Level:~Medical staff to complete EHR training and then deliver the ask, advise, assess, connect (AAAC) strategies to screen, refer, and provide resources for oral health.~Clinician will receive Common-Sense Model of Self- Regulation (CSM) and Social Cognitive Theory based education and skills training for the physician/nurse practitioner to communicate core OH facts to the patient and provide reinforcement of the importance of dental visits to overall health. Clinicians will also document the encounter in EHR."
48101062|NCT06555029|BEHAVIORAL|Standard ADA Oral Health Training|"Provider-Level:~Clinician only: Clinicians will receive standard American Dental Association (ADA) based oral health hygiene training (brushing, flossing, fluoridated water, cleaning dentures) and asked to follow their current oral health care with their patients. The usual care currently is to address oral health issues if the patient complains or has a question. The clinicians will not have skills training nor visual resources for the patient encounter."
48284853|NCT01241539|DRUG|Dabigatran etexilate|75 mg capsule
48284854|NCT01241539|DRUG|Dabigatran etexilate|110 mg capsule
48284855|NCT04861038|DEVICE|aerSleep II|Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar
48284856|NCT02602067|COMBINATION_PRODUCT|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
48284857|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
48284858|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
48284859|NCT00949338|PROCEDURE|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
48470992|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B1|Suspension for injection. Route of administration: IM injection
48470993|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B2|Suspension for injection. Route of administration: IM injection
48470994|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B3|Suspension for injection. Route of administration: IM injection
47938947|NCT04048811|DRUG|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
47938948|NCT04048811|DRUG|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
47938949|NCT02822391|OTHER|observation|
47938950|NCT03176758|DRUG|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
47938951|NCT03176758|DRUG|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
47938952|NCT03176758|DEVICE|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
48101063|NCT03916614|BEHAVIORAL|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,\[30\] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
48284860|NCT01358110|OTHER|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
48284861|NCT01358110|OTHER|Care as usual|Standard care as usual which may or may not include palliative care consultation
48470995|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C1|Suspension for injection. Route of administration: IM injection
48470996|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C2|Suspension for injection. Route of administration: IM injection
48629450|NCT05924230|OTHER|RL 10ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
48629451|NCT05924230|OTHER|RL 15ml/kg|Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
47938953|NCT06197399|PROCEDURE|Detethering Surgery|Detethering surgery, or cord untethering, is a conventional surgical approach for treating tethered cord syndrome (TCS). It involves releasing the spinal cord from its abnormal attachment. During the surgical procedure, once the tethered area is identified, careful microsurgical techniques are used to separate the spinal cord from the surrounding abnormal tissue. This operation aims to alleviate the symptoms of TCS by removing the cause of tension on the spinal cord.
48284862|NCT03390829|OTHER|semi-directed interviews|semi-directed interviews
48284863|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
48284864|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
48284865|NCT01154413|BEHAVIORAL|Intensive education of the doctor/nursing team on the protocol|
48284866|NCT00473694|DRUG|sugammadex|Administered as an intravenous (IV) infusion
48284867|NCT00473694|DRUG|neostigmine|Administered as an IV infusion
48284868|NCT00473694|DRUG|vecuronium|Administered as an IV infusion
48470997|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C3|Suspension for injection. Route of administration: IM injection
48470998|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 1|Suspension for injection. Route of administration: IM injection
48470999|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 2|Suspension for injection. Route of administration: IM injection
48471000|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 3|Suspension for injection. Route of administration: IM injection
48471001|NCT06583031|BIOLOGICAL|Monovalent RSV Vaccine|Suspension for injection. Route of administration: IM injection
48471002|NCT05386888|DRUG|GFH018|Administered as oral
48471003|NCT05386888|DRUG|Toripalimab|Administered as an IV infusion
48471004|NCT05386888|DRUG|Paclitaxel|Administered as an IV infusion
48471005|NCT05386888|DRUG|Carboplatin|Administered as an IV infusion
48471006|NCT05386888|DRUG|Cisplatin|Administered as an IV infusion
48471007|NCT05386888|DRUG|Pemetrexed|Administered as an IV infusion
48471008|NCT05386888|RADIATION|Thoracic Radiation Therapy (TRT)|Thoracic Radiation Therapy (TRT)
48471009|NCT05386888|DRUG|GFH018|Administered as an IV infusion
48284869|NCT00473694|DRUG|rocuronium|Administered as an IV infusion
48284870|NCT00473694|DRUG|glycopyrrolate|Administered as an IV infusion
48284871|NCT05176678|DIETARY_SUPPLEMENT|1 gram of a protein hydrolysate|After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
48284872|NCT05176678|DIETARY_SUPPLEMENT|2 grams of a protein hydrolysate|After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
48629452|NCT03390491|BEHAVIORAL|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack\>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
48284873|NCT05176678|DIETARY_SUPPLEMENT|4 grams of a protein hydrolysate|After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
48284874|NCT05176678|DIETARY_SUPPLEMENT|8 grams of a protein hydrolysate|After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
48284875|NCT01491958|DRUG|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
48284876|NCT01491958|DRUG|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
48471010|NCT00350987|BEHAVIORAL|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
48471011|NCT00987025|BEHAVIORAL|Telehealth|Use of telehealth blood pressure station every week
48471012|NCT00987025|BEHAVIORAL|Educational materials|Control
48629453|NCT03390491|BEHAVIORAL|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
48629454|NCT05161936|DRUG|Lumasiran|Lumasiran will be administered by SC injection.
48629455|NCT05161936|DRUG|Placebo|Placebo will be administered by SC injection.
48284877|NCT01491958|DRUG|methotrexate|Day +1, +3, and +6 and +11
48284878|NCT05190835|DEVICE|Optical scanner|During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
48284879|NCT06482879|DEVICE|Oxygen delivery|Oxygen is delivered with high flow nasal canula or simple nasal canula to prevent hypoxia during procedures under deep sedation.
48284880|NCT05462093|DEVICE|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
48284881|NCT05462093|DEVICE|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
48284882|NCT05462093|DEVICE|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
48284883|NCT01999829|DRUG|citrate of caffeine|
48284884|NCT01999829|DRUG|placebo|
48284885|NCT03744689|PROCEDURE|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
48471013|NCT02293460|DRUG|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
48471014|NCT04993131|PROCEDURE|Liver transplant|Liver transplant.
48471015|NCT00401154|OTHER|Stationary Cycling|Use of a stationary bicycle for exercise
48471016|NCT04469725|DRUG|KN046|KN046 5 milligram per kilogram, every 2 weeks
48471017|NCT05895578|DIETARY_SUPPLEMENT|Probiotic|1 capsule of probiotic (Lactobacillus CECT 9422 + Bifidobacterium CECT 30257) every 12 hours for 6-months.
48471018|NCT05895578|DIETARY_SUPPLEMENT|Probiotic + placebo|1 capsule of probiotic + 1 capsule of placebo per day for 6-months.
48471019|NCT05895578|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo every 12 hours for 6-months.
48471020|NCT04439110|BIOLOGICAL|Trastuzumab Emtansine|Given IV
48284886|NCT03744689|PROCEDURE|Sham block|Sham block will be done with serum physiologic.
48471021|NCT04299776|DEVICE|CirQPOD|CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
48284887|NCT03744689|DRUG|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
48284888|NCT03744689|DEVICE|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
48284889|NCT01684826|RADIATION|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
48284890|NCT01684826|RADIATION|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
48471022|NCT04299776|DEVICE|Standard airway management|Standard airway management during surgery (PEEP of +5 cmH2O)
48471023|NCT02365909|DRUG|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
48471024|NCT02365909|DRUG|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
48471025|NCT02370836|OTHER|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
48471026|NCT03885869|OTHER|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
48471027|NCT03885869|OTHER|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
48629456|NCT04970108|DRUG|Egito|EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
48629457|NCT04970108|DRUG|Empagliflozin + telmisartan|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
48629458|NCT02952677|BEHAVIORAL|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
48629459|NCT02952677|BEHAVIORAL|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
48629460|NCT02952677|OTHER|Control|Participants received usual care
48284891|NCT04632849|BEHAVIORAL|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
48284892|NCT04062812|OTHER|the same citrate dosification in both types|match concentrated and dilute citrate protocol
48284893|NCT02585544|PROCEDURE|day-care surgery|day-care surgery
48284894|NCT01334073|DRUG|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
48284895|NCT00708396|DRUG|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
48284896|NCT02305433|OTHER|Home-based physiotherapy (physical exercise)|Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
48471028|NCT03885869|OTHER|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
48471029|NCT03885869|OTHER|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
48471030|NCT03885869|OTHER|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
48471031|NCT03885869|OTHER|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
48471032|NCT00636324|DEVICE|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
48471033|NCT00636324|DEVICE|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
48471034|NCT04096339|OTHER|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
48471035|NCT04096339|OTHER|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
48629461|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) with the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw with the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
48471036|NCT06175715|PROCEDURE|carotid endarterectomy|carotid endarterectomy under local or general anethesia
48101064|NCT03916614|BEHAVIORAL|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
48284897|NCT04387279|OTHER|Interview|Surveys on medical use patterns and patient's perceptions about COVID-19
48284898|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling|Nutrition and Mental health counseling with a standardized format included in each session
48471037|NCT01474915|DRUG|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
48471038|NCT01474915|DRUG|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
48471039|NCT01474915|DRUG|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
48284899|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling with Nourish Carolina|Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
48101065|NCT03232684|DIAGNOSTIC_TEST|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
48101066|NCT02521844|DRUG|ETC-1922159|Oral administration
48101067|NCT02521844|DRUG|Pembrolizumab|IV administration
48471040|NCT01474915|DRUG|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
47938954|NCT06197399|PROCEDURE|Spinal Column Shortening Surgery|"Spinal column shortening surgery is an innovative surgical approach that involves reducing the tension on the spinal cord by shortening the spinal column, effectively untethering the spinal cord indirectly. The procedure primarily involves the thoracolumbar region.The choice of this region for intervention offers several advantages: it is a safe distance from the previous detethering surgery area; it is closer to the conus medullaris of the spinal cord, ensuring better treatment effectiveness; and the impact on spinal mobility is minimal after internal fixation at this region. This technique is designed to alleviate TCS symptoms while minimizing the risk of postoperative cerebrospinal fluid (CSF) leakage, which is a common complication in direct untethering procedures for recurrent cases. All procedures will be conducted by trained and experienced neurosurgeons following standardized protocols."
48471041|NCT06632483|DRUG|Vericiguat (Verquvo, BAY1021189)|Prescibed as per local label
47938955|NCT03856775|DEVICE|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
47938956|NCT05888571|PROCEDURE|prepectoral breast reconstruction|Patients receive immediate prepectoral breast reconstruction
47938957|NCT05888571|PROCEDURE|Tiloop Mesh implantation|Patients receive immediate prepectoral breast reconstruction with Tiloop Mesh
47938958|NCT03103061|DRUG|Lexiscan|Coronary vasodilator
47938959|NCT00955227|DIETARY_SUPPLEMENT|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
47938960|NCT00955227|DRUG|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
47938961|NCT05272215|PROCEDURE|Bariatric surgery|Pre- and post-bariatric surgery (3, 6, 12 months postoperative and yearly)
47938962|NCT05272215|PROCEDURE|Body contouring surgery|Pre- and post body contouring surgery (3, 6, 12 months postoperative and yearly)
47938963|NCT03425019|DEVICE|Soterix 1x1 tDCS mini-CT Stimulator device|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
47938964|NCT04518202|DRUG|lidocaine patch|5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.
47938965|NCT04518202|DRUG|Sham patch|Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
48471042|NCT03746535|DRUG|Elagolix|Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
48471043|NCT03321045|DRUG|[89Zr]-Df-Trastuzumab|\[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
48471044|NCT03321045|DIAGNOSTIC_TEST|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
48471045|NCT06631729|BEHAVIORAL|HRV-bio|participants will complete a HRV biofeedback task via the Elite HRV app. In this intervention, participants will learn how to use their HRV data that they will see in real-time via the Elite HRV app to improve their HRV by engaging in an app-guided diaphragmatic breathing exercise. They will complete this exercise twice daily (morning, night).
48471046|NCT06631729|BEHAVIORAL|ED-JITAI|"participants will be prompted to complete focused, guided body scan tasks that will be sent to them via the MindLogger app. These guided tasks will be sent to them in the form of 1 of 3 brief (3-5 minute) videos via the MindLogger app. The body scans will be designed to promote participants' connection with, vs.~distancing/distraction from, feared ED sensations (e.g., hunger, satiety, bloating).~Participants will receive prompts to complete the body scans at times when they report via EMA that they are experiencing worse interoception than usual. Worse interoception than usual will be defined as participants' EMA-reported interoception scores during the intervention period that fall 1 SD or more above their baseline EMA-reported interoception levels."
47938966|NCT05947643|DRUG|theophylline|capsules dissolved in intranasal irrigation
47938967|NCT05947643|DRUG|Placebo|identical-appearing lactose capsules dissolved in intranasal irrigation
47938968|NCT03758326|OTHER|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
48471047|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (rabbit)|
48471048|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (horse)|
48629462|NCT05328544|PROCEDURE|ACL reconstruction of the knee joint by arthroscopic technique, with the tibial fixation method using a bioabsorbable screw (Arthrex) without the use of autogenous cancellous bone grafts|Reconstruction of the anterior cruciate ligament (ACL) of the joint the knee stabilization method, a bioabsorbable screw without the use of an autogenous spongy bone graft taken during drilling of the tibial canal into the tibial canate before inserting the screw.
48471049|NCT00260689|DRUG|Cyclosporine|
47938969|NCT04365062|DEVICE|Excimer laser and drug coated balloon|Excimer laser and drug coated balloon
48471050|NCT00260689|DRUG|Alemtuzumab|
47938970|NCT04365062|DEVICE|Excimer laser and plain balloon|Excimer laser and plain balloon
48471051|NCT01755975|DRUG|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
48471052|NCT01755975|DRUG|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
48471053|NCT04755621|OTHER|Core stability training|Core stability exercises
48471054|NCT04755621|OTHER|Rocabado Exercises|Exercises for Temporomandibular Disorders
48471055|NCT04162587|OTHER|Carotid duplex+/- MRA neck|Carotid duplex and or MRA neck
48471056|NCT04162587|OTHER|brain MRA+/-CT angio on carotid and brain|brain MRA and or CT angiography on carotid and brain
48471057|NCT04162587|OTHER|MRI brain|MRI brain with diffusion to detect asymptomatic stroke
48471058|NCT04162587|OTHER|DSA (digital subtraction angiography)|DSA (digital subtraction angiography) in some cases to confirm diagnosis.
48471059|NCT01150006|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
48471060|NCT05476133|OTHER|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
48471061|NCT01588548|DRUG|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
48471062|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg|Administration: Inject intravenously single dose
48629463|NCT06544395|DEVICE|Non invasive neuromodulation therapy|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The intensity will be programmed in all sessions at Low, following the Arndt-Schulz law. The treatment was distributed in 3 phases: phase 1 of preparation, phase 2 to reduce fatigue and phase 3 to enhance autonomic improvement."
48629464|NCT06544395|OTHER|Manual therapy|Common manual therapy administered for said pathology by traditional physiotherapy and therapeutic exercise.
48629465|NCT06544395|DEVICE|Placebo with non invasive neuromodulation|"In the 4 studies, the intervention consisted of 15 sessions spread over 5 weeks.~Each intervention lasted 60 minutes. The treatment was carried out with the machine turned off."
48629466|NCT04077606|OTHER|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
47938971|NCT04365062|DEVICE|plain balloon and drug coated balloon|plain balloon and drug coated balloon
47938972|NCT03901118|DRUG|chiauranib|in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
47938973|NCT03901118|DRUG|etoposide|50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
47938974|NCT03901118|DRUG|paclitaxel|60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
47938975|NCT04152980|DRUG|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
47938976|NCT05961644|DRUG|Cladribine Subcutaneous Injection|Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
47938977|NCT05961644|DRUG|0.9% Chloride Injection Sodium|0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
48471063|NCT05276076|BIOLOGICAL|VM-001 3X10^6 cells/kg|Administration: Inject intravenously single dose
48471064|NCT05276076|BIOLOGICAL|VM-001 5X10^6 cells/kg|Administration: Inject intravenously single dose
48471065|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg two dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, two dose in total, weekly"
48471066|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg four dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, four dose in total, weekly"
48471067|NCT06125756|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
48471068|NCT06125756|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
48471069|NCT06125756|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
48471070|NCT06678672|BEHAVIORAL|Contingency Management (CM)|The participants will receive and be trained to use a CO monitor and iCO app to upload videos to verify smoking abstinence at a minimum of once per day, 5 times per week, over 5 weeks. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through remote CO monitoring. They will receive clinician feedback at the time of each CO reading, following the established VA CM protocol developed in the earlier phase of the project. Each CO reading during the weeks 2-5 will also be accompanied with a brief (5-minute) telephone or video feedback CM counseling session from the study clinician.
48471071|NCT06678672|BEHAVIORAL|Treatment as Usual (TAU)|Participants assigned to TAU will receive usual care at San Francisco VA Health Care System (SFVAHCS), i.e., referral to Tobacco Cessation Clinic and the VA Telequit Quitline. The SFVAHCS Tobacco Cessation Clinic is a consult service that calls patients proactively 3 times to offer 1:1 behavioral counseling for smoking cessation. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for up to 5 sessions per NCI Quitline guidelines. The smoker initiates the first call, and subsequent calls will be proactively made by Quitline staff.
48471072|NCT05521022|DRUG|AT-02|AT-02 via IV infusion
48471073|NCT05521022|OTHER|AT-02 (Placebo)|Normal saline solution via IV infusion
48629467|NCT04077606|OTHER|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
48284900|NCT01228773|BEHAVIORAL|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
48284901|NCT05219565|DEVICE|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
48284902|NCT06158698|DRUG|Colchicine|Colchicine 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
48284903|NCT06158698|OTHER|Placebo|Placebo 1 mg daily (or 0.5 mg daily il weight \<70 kg) from randomization for 180 days (6 months)
48284904|NCT02112968|PROCEDURE|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
48284905|NCT02112968|PROCEDURE|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
48284906|NCT02112968|PROCEDURE|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
48284907|NCT01052064|DEVICE|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
48284908|NCT01568411|DRUG|TD-1211|Period 1
48284909|NCT01568411|DRUG|TD-1211+ itraconazole|Period 2
48284910|NCT04002687|DRUG|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
48471074|NCT02845011|DEVICE|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
48471075|NCT02845011|OTHER|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
48629468|NCT01635179|PROCEDURE|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
47938978|NCT02148146|DRUG|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
48284911|NCT00542698|BEHAVIORAL|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
48471076|NCT06519760|DRUG|68Ga-C1|68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg
48471077|NCT03934060|OTHER|Exercise|specific strength training
48471078|NCT02528058|PROCEDURE|Vitrectomy with internal limiting membrane peeling|
48471079|NCT02979041|BEHAVIORAL|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
48471080|NCT02979041|OTHER|Standard Care|physiotherapy and medical care as provided currently
48471081|NCT06193187|DRUG|Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg|Test (T)
48471082|NCT06193187|DRUG|Entresto 50 mg|Reference (R)
48471083|NCT05948033|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3."
48471084|NCT03356106|DEVICE|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
48471085|NCT02226991|DRUG|Tipranavir|
48471086|NCT02226991|DRUG|Ritonavir|
48471087|NCT02226991|DRUG|Efavirenz|
48629469|NCT04753177|DRUG|Ribocyclib, fulvestrant, triptorelin|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
48629470|NCT04753177|DRUG|Doxorubicin, cyclophosphamide, paclitaxel|Neoadjuvant treatment will last 24 weeks in both groups. A follow-up examination will be carried out every 8 weeks. In the group of combined hormone therapy, repeate cor-biopsy of the tumor is planned to assess the Ki-67
48629471|NCT01556100|DRUG|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
48629472|NCT03811873|DIAGNOSTIC_TEST|Dual x-ray absorptiometry|DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
48471088|NCT01999894|DRUG|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
48471089|NCT02149394|OTHER|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
48629473|NCT03811873|OTHER|Vertebral Fracture Assessment|Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
48629474|NCT00004785|DRUG|dexamethasone|
47938979|NCT01858636|DEVICE|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
47938980|NCT05445934|DRUG|FB2001|FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
47938981|NCT05445934|DRUG|FB2001 placebo|Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
47938982|NCT00117065|DRUG|Aranesp®|
47938983|NCT00238511|DRUG|SPM 927|
47938984|NCT01599832|DRUG|pazopanib hydrochloride|Given PO
47938985|NCT01599832|OTHER|laboratory biomarker analysis|Correlative studies
47938986|NCT01599832|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
47938987|NCT01599832|OTHER|pharmacogenomic studies|Correlative studies
47938988|NCT06338605|OTHER|no intervention, observational study of AKI under CDK4/6 inhibitor treatment|no intervention
47938989|NCT01009281|DRUG|AIN457|
48471090|NCT02149394|OTHER|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
48471091|NCT00133367|DRUG|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
48471092|NCT00133367|DRUG|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
48629475|NCT00004785|DRUG|methylprednisolone|
48629476|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 5*10^10 vp|Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.
48629477|NCT03356561|BIOLOGICAL|Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.
48629478|NCT03356561|BIOLOGICAL|Placebo|Participants will receive placebo via IM route.
47938990|NCT03895242|BEHAVIORAL|Group 1:Supine-Prone|After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
47938991|NCT03895242|BEHAVIORAL|Group 2:Prone-Supine|After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
47938992|NCT04820127|BEHAVIORAL|personalized care preceded by a standardized assessment|"* personalized intervention plan (PIP) proposed to the patient/caregiver dyad to correct potentially reversible causes of psycho-behavioral symptoms. This PIP will be re-evaluated and adapted at each visit by the nurse in close collaboration with the GP;~* PIP implementation will be based on a close follow-up during the 18 months follow-up coordinated by the nurse (3 memory consultation visits, 3 home visits (with the GP) and 6 phone calls). This follow up will be enhanced with the use of a web platform (allowing teleconsultation, tele-expertise and telemonitoring);~* specific training on psycho-behavioral symptoms for caregivers at baseline and during follow-up will be performed. On line training on psycho-behavioral symptoms management for GP will be available;"
47938993|NCT03714737|BIOLOGICAL|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
47938994|NCT03714737|BIOLOGICAL|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
48284912|NCT03244098|BEHAVIORAL|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
48284913|NCT02635230|DRUG|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
48284914|NCT01106261|PROCEDURE|Metastasectomy|Pulmonary Metastasectomy
48284915|NCT01106261|PROCEDURE|Active monitoring|Active monitoring
48284916|NCT03291379|DRUG|BTG-002814|BTG-002814 containing 100 mg vandetanib
48284917|NCT03086850|BEHAVIORAL|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~* \<6000 steps/day: increase by 3000 steps/day~* 6000 - 10000 steps/day: reach 10000 steps/day~* \> 10000 steps/day: maintain or increase steps"
47938995|NCT03714737|BIOLOGICAL|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
47938996|NCT00226629|PROCEDURE|Endovascular vs Open Repair|
47938997|NCT05678049|DIAGNOSTIC_TEST|Synovial fluid analysis|"For patients with knee under tension at the joint level, the symptomatology often requires evacuation by puncture under ultrasound guidance. The intervention will be performed only for patients for whom this therapeutic indication exists anyway by their physicians.~After making the evacuation we will want to use this liquid for Microscopic and Spectrophotometric evaluation"
47938998|NCT00099645|DRUG|Mifepristone|
47938999|NCT05718544|DRUG|Esketamine|Esketamine 50 mg is included in the mixture for patient-controlled analgesia.
48284918|NCT03086850|OTHER|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
48284919|NCT01020331|DRUG|Memantine|
48284920|NCT05888259|OTHER|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
48284921|NCT02035943|DIETARY_SUPPLEMENT|Insulin separated|separate continuos infusion of insulin
48284922|NCT02035943|DIETARY_SUPPLEMENT|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
48284923|NCT05221190|PROCEDURE|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
48284924|NCT05221190|PROCEDURE|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
48284925|NCT00583401|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
48284926|NCT03015532|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), via instillation
48284927|NCT03015532|DRUG|Saline Placebo|Saline placebo via injection
48471093|NCT00133367|DRUG|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
48471094|NCT00133367|DRUG|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
48629479|NCT02324595|PROCEDURE|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
48629480|NCT03419871|OTHER|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
48629481|NCT03419871|OTHER|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
48284928|NCT03015532|DRUG|Bupivicaine HCl|Bupivacaine HCl without epinephrine
48471095|NCT00133367|DRUG|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
48471096|NCT00133367|DRUG|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
48471097|NCT00133367|DRUG|Melphalan|Given intravenously on day 2 before transplant.
48471098|NCT03310619|BIOLOGICAL|JCAR017|Gene modified autologous T cells
48471099|NCT03310619|DRUG|Durvalumab|Anti-PD-L1
48471100|NCT03310619|DRUG|CC-122|Pleiotropic Pathway Modifier
48471101|NCT03310619|DRUG|Ibrutinib|Ibrutinib
48471102|NCT03310619|DRUG|CC-220|CC-220
48471103|NCT03310619|DRUG|Relatlimab|Relatlimab
48471104|NCT03310619|DRUG|Nivolumab|Nivolumab
48471105|NCT03310619|DRUG|CC-99282|CC-99282
48284929|NCT03015532|DRUG|Ropivacaine|Ropivacaine, via injection
48471106|NCT04986124|OTHER|treatment as usual|No inervention. Treatment regime remains unchanged.
48471107|NCT05703841|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
48471108|NCT05187741|DEVICE|mobile health (mHealth)|"A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months)."
48471109|NCT04691700|DRUG|Goreisan|Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
48471110|NCT04691700|DRUG|Standard Treatment|Standard therapy without Goreisan
48471111|NCT05988424|OTHER|Left atrial mapping|Creation of a left atrial voltage map
48471112|NCT05310617|OTHER|Survey|Survey on the parental project and its realisation
48471115|NCT00175097|OTHER|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
48284930|NCT03896425|DEVICE|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
48471116|NCT00175097|OTHER|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
48471117|NCT00175097|OTHER|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
48284931|NCT04884828|DEVICE|external gas during NIV|The procedure was performed in the patient's room during his or her hospital stay to avoid additional visits for study participation. The patient was placed in the supine position, and the usual ventilator interface was placed in a single-limb system, along with the commercial ventilator to be studied. The ventilator model were evaluated at bedside in random order. The parameters of the ventilator were the same as those that the patients used at home (that is, unlike the bench study, the sensitivity of the trigger was not modified). A external polygraph was used to moritor the study, with the incorporation of thoracic and abdominal bands and parasternal electromyography, to better evaluate asynchronies, in addition to pulse oximetry control. The ventilation periods were 1 minute (without gas, gas, without gas). This sequence was performed twice in each group of established conditions.
47939000|NCT05718544|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
48284932|NCT00033735|DRUG|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
48284933|NCT00033735|DRUG|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
48629482|NCT04356443|DEVICE|AirGo Respiratory Monitor|AirGo™ is composed of a wearable, miniaturized recorder unit and a medical grade Holter worn over the floating ribs of patients both at rest and during normal activity. The recorder measures live circumference changes.
48629483|NCT00728923|DRUG|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
48629484|NCT03753542|OTHER|Multimedia education, booklet Providence and tele-nursing follow-up|Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
48629485|NCT02916329|OTHER|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
48629486|NCT03469973|PROCEDURE|Partial adenoidectomy|"The procedure will be completely visualized with a 45 degrees, 4- mm nasal endoscope; the upper part of the adenoid will be removed using the microdebrider, while the lower part will be preserves to maintain the velopharyngeal competence.~• Adenoid enlargement causing Obstructive Sleep-Disordered Breathing (OSDB) with velopharyngeal insufficiency (proved or suspected)."
48629487|NCT05480098|DRUG|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
48629488|NCT00313898|DRUG|sildenafil (viagra)|
48629489|NCT03006575|RADIATION|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
48629490|NCT03006575|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
48629491|NCT04663672|OTHER|Experimental Scent|Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
48629492|NCT04663672|OTHER|Control Scent|Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
48629493|NCT04663672|OTHER|No-Scent Control|Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser
47939001|NCT05718544|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
47939002|NCT01543373|DEVICE|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
48284934|NCT01936337|DRUG|DLX105 Hydrogel|topical administration on psoriatic plaque
48471118|NCT00175097|OTHER|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
48629494|NCT04663672|BEHAVIORAL|In-Vivo Exposure|Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
48629495|NCT02425488|BEHAVIORAL|Nursing therapeutics education|"Educational intervention will focus on~1. Appropriate lifestyles~2. Early recognition of signs/prodromal symptoms of HF~3. Early recognition of signs of inflammation of the ICD-pocket~4. Good management of the device~1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
48629496|NCT04680143|DRUG|Systemic erythropoietin injection|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
48629497|NCT06007443|OTHER|pain related variables assessment|Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
48629498|NCT00111332|BEHAVIORAL|Progressive resistance and aerobic training|
48629499|NCT04374552|DRUG|Hydroxychloroquine sulfate &Azithromycin|Drug - Hydroxychloroquine sulfate \&Azithromycin
48629500|NCT04374552|DRUG|Placebo|Drug - placebo
47939003|NCT01543373|DEVICE|Bare Metal Stent|Bare metal coronary stent
47939004|NCT05930041|PROCEDURE|Experimental CSP|Either CSP is performed for 10-19 mm nonpedunculated colorectal polyps.
48284935|NCT01936337|DRUG|Placebo|topical administration on psoriatic plaque
48284936|NCT03481530|DEVICE|Continuing Glucose Monitor System|glucose monitoring
47939005|NCT05930041|PROCEDURE|Active Comparator HS-EMR|Either HS-EMR is performed for 10-19 mm nonpedunculated colorectal polyps.
47939006|NCT04006782|DEVICE|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
47939007|NCT03911310|DIAGNOSTIC_TEST|[18F]PSMA-11|\[18F\]PSMA-11 PET/CT
47939008|NCT03911310|DIAGNOSTIC_TEST|[68Ga]PSMA-11|\[68Ga\]PSMA-11 PET/CT
47939009|NCT00633620|DEVICE|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
48471119|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
48471120|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
48471121|NCT01653795|DEVICE|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
47939010|NCT03156361|DRUG|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
47939011|NCT03156361|DRUG|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
47939012|NCT05577468|DRUG|Tegoprazan|tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
47939013|NCT06107231|OTHER|Honey|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)
47939014|NCT06107231|OTHER|Sucrose|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)
48629501|NCT00599313|DRUG|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
48629502|NCT00954655|GENETIC|mutation analysis|
48629503|NCT00954655|GENETIC|polymorphism analysis|
48629504|NCT00954655|OTHER|laboratory biomarker analysis|
48629505|NCT03018938|DRUG|Insulin Analog Mid Mixture|Administered SC
48629506|NCT03018938|DRUG|Basal Insulin Analog|Administered SC
48629507|NCT01098695|OTHER|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
47939015|NCT06107231|OTHER|Honey plus almonds|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
47939016|NCT06107231|OTHER|Sucrose plus almonds|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
47939017|NCT04766372|OTHER|Behaviour change|Using needs supportive, self-determination theory-based, components to improve the physical activity behaviours of adolescent girls.
47939018|NCT00260078|DRUG|Atazanavir|200 mg to 400 mg orally daily
47939019|NCT00260078|DRUG|Darunavir|300 mg or 600 mg orally twice daily
47939020|NCT00260078|DRUG|Efavirenz|Dosage dependent on participant
47939021|NCT00260078|DRUG|Nevirapine|Dosage dependent on participant
47939022|NCT00260078|DRUG|Ritonavir|50 mg or 100 mg orally twice daily
47939023|NCT00260078|DRUG|Tenofovir disoproxil fumarate|300 mg orally daily
47939024|NCT00260078|PROCEDURE|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
47939025|NCT00510874|BIOLOGICAL|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
47939026|NCT00510874|BIOLOGICAL|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
47939027|NCT04424524|OTHER|Direct-to-pharmacy oral PrEP refill visits|Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing
47939028|NCT01689961|BEHAVIORAL|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
47939029|NCT00000574|DRUG|ibuprofen|
47939030|NCT03116347|BIOLOGICAL|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
47939031|NCT03116347|BIOLOGICAL|KIOVIG|100 mg/ml solution for Immune Globulin Intravenous Infusion
47939032|NCT03116347|BIOLOGICAL|Cuvitru|200 mg/ml solution for Immune Globulin Subcutaneous Injection
47939033|NCT05323578|OTHER|Survey|Prevalence of safe caffeine consumption among anesthetists
48284937|NCT06513702|PROCEDURE|Transesophageal lung ultrasound (TELUS) guided recruitment maneuver|"1. Lung reinflation guided by transesophageal lung ultrasound (TELUS) after cardiopulmonary bypass weaning~2. TELUS guided recruitment maneuver with continuous positive pressure of 30cmh20 for 20 seconds and 40cmh20 for 20 seconds during sternal wiring"
48284938|NCT06513702|OTHER|Manual bag lung reinflation|"After weaning of CPB, Lung will be reinflated by 5 deep manual bag infaltion until full inflation observed by the anesthetist.~During sternal wiring, Lung ultrasound will be examine - LUNG ultrasound score will be taken- no recruitment maneuver will be done in this contro group (Basically this group of patient is a routine practice in cardiac surgery"
48284939|NCT00013884|DRUG|T-20|
48471122|NCT01653795|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
48471123|NCT04536792|DRUG|AG-946|AG-946, oral encapsulated coated-granules or tablets.
48471124|NCT04536792|DRUG|AG-946 Matched Placebo|AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
48284940|NCT05064241|OTHER|Access to Genetic Counselor for answering questions|A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
48284941|NCT00251797|DRUG|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
48284942|NCT00251797|DRUG|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
48471125|NCT04622930|DEVICE|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
47939034|NCT04707352|DRUG|Dapagliflozin|All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).
47939035|NCT01272284|DEVICE|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
47939036|NCT04985370|OTHER|Pain neuroscience education|Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.
47939037|NCT04985370|OTHER|Exercise|Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.
47939038|NCT03024437|DRUG|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
48471126|NCT05367635|DRUG|SKB315 for injection|SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.
48471127|NCT00669435|DRUG|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months"
48471128|NCT00669435|DRUG|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months"
48471129|NCT03847974|DRUG|LIB003|300 mg SC Q4W
48471130|NCT04979923|DRUG|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
48471131|NCT06679036|DRUG|HRS-2189|HRS-2189
48471132|NCT06679036|DRUG|Fluvustat|Fluvustat
48471133|NCT06679036|DRUG|HRS-8080|HRS-8080
48471134|NCT06679036|DRUG|HRS-6209|HRS-6209
48471135|NCT06679036|DRUG|HRS-1358|HRS-1358
48471136|NCT05801029|DRUG|Osimertinib|Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
48284943|NCT05778318|DRUG|The group of patients who received Lianhua Qingwen orally|Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
48284944|NCT05778318|OTHER|The group of patients who did not receive Lianhua Qingwen orally|The group of patients who did not receive Lianhua Qingwen orally.
48284945|NCT05654415|OTHER|Melatonin|Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
48284946|NCT05654415|OTHER|Deprivation|Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
48284947|NCT01025336|OTHER|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
48284948|NCT01025336|OTHER|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
48284949|NCT05288465|DRUG|Cerebrolysin|Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
48284950|NCT01967225|DRUG|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
48471137|NCT05801029|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
48471138|NCT03080376|OTHER|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
47939039|NCT03024437|DRUG|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
48471139|NCT03080376|OTHER|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
47939040|NCT03024437|DRUG|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
47939041|NCT03960021|RADIATION|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
48629508|NCT06470724|BEHAVIORAL|Structural visual approach|"The intervention comprised seven behavior approaches in this research defined as follows:~A successive approach: An approach to familiarization with the unfamiliar environment of the simulated dental office.~Tell-Feel-Show-Do (T-F-S-D): A dental approach explained to the patient's treatment by telling the patient what would happen, what he felt or did, and what had been done.~Visual pedagogy: Introduced dentistry to autistic children through visual media, such as pictures and photographs.~Audiovisual modeling: A learning process through audiovisual media, such as video and animation.~In-vivo modeling: Learning new activities by watching them in front of the model.~Behavioral trials: A learning strategy conducted through practicing the recent activity by him/herself.~Auto-modeling: A learning process following the activity of editing pictures during the prior visit of the patient."
48629509|NCT00552500|DRUG|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
48629510|NCT02966925|DEVICE|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
48629511|NCT03390153|OTHER|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
48284951|NCT01967225|DRUG|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
48284952|NCT05932433|BEHAVIORAL|Exercise|Each session (45 minutes aprox) is made by: mobility, endurance and final exercise to rest. The sesion is going to perform twice a week during 6 weeks.
48284953|NCT06221111|DRUG|Rimegepant 75 MG [Nurtec]|placebo controlled trial
48284954|NCT02354001|DRUG|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
48284955|NCT02354001|DRUG|Placebo|1 capsule daily for 12 week trial - lactose
48284956|NCT03322683|PROCEDURE|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
48471140|NCT03080376|OTHER|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
48471141|NCT03770793|PROCEDURE|Lung-sono guided|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible."
48471142|NCT06147414|BIOLOGICAL|Blood sample|"A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing."
48471143|NCT01341678|DRUG|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
48471144|NCT01341678|DIETARY_SUPPLEMENT|NeutraPhos|Diet will be supplemented with NeutraPhos
48471145|NCT01341678|OTHER|Diet Only|Diet containing 1500mg of phosphorus
48471146|NCT05540678|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
48471147|NCT05540678|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 6 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
47939042|NCT05072886|DRUG|AT193|Topical applied to affected areas daily
47939043|NCT00623116|DRUG|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
47939044|NCT00553865|DRUG|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
47939045|NCT05538819|DRUG|Glimepiride|Glimepiride 1-4 mg/day
47939046|NCT01596673|DRUG|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
47939047|NCT01596673|DRUG|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
48471148|NCT00037752|DRUG|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
48101068|NCT06007144|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only~Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
48101069|NCT03982199|BIOLOGICAL|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.
48101070|NCT03982199|BIOLOGICAL|Placebo|Participants will receive a single IM injection of placebo control on Day 1.
48101071|NCT06628726|DIAGNOSTIC_TEST|Liver biopsy|surgical biopsy from liver
48101072|NCT01155869|DRUG|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
48101073|NCT01155869|DRUG|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
48471149|NCT00037752|BEHAVIORAL|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
48471150|NCT02682108|DEVICE|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
48471151|NCT01889472|DEVICE|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
48471152|NCT04420624|DRUG|Colchicine|1 mg (or 0.5mg) tablet of colchicine taken once a day for 1 month
48284957|NCT03322683|PROCEDURE|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
48284958|NCT01400646|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
48284959|NCT01400646|DRUG|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
48284960|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
48284961|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
48284962|NCT01400646|DRUG|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
48284963|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
48284964|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
48471153|NCT06494826|OTHER|colonoscopy procedure|"Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only ."
48471154|NCT05303961|DRUG|SA001 240mg + Rebamipide 200mg or Placebo|Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
48471155|NCT05303961|DRUG|SA001 480mg or Placebo|Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
48471156|NCT05303961|DRUG|SA001 710mg + Rebamipide 600mg or Placebo|Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
48471157|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
47939048|NCT05091203|DRUG|Vitamin D|To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
47939049|NCT06070571|DRUG|Yarrow and moringa mixture|yarrow and moringa mixture nano particles loaded on buccal film
48101074|NCT02772315|OTHER|omics|diagnostic procedures applying omics results
48471158|NCT05303961|DRUG|SA001 360mg or Placebo|Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
48471159|NCT05303961|DRUG|SA001 720mg or Placebo|Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
48471160|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
48471161|NCT04721496|BEHAVIORAL|Power and Speed|"Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day."
48471162|NCT03566407|PROCEDURE|Colonoscopy|Colonoscopy will be required for all subjects at 6 months - Visit 3.
47939050|NCT00304369|DRUG|Metronidazole|
47939051|NCT00177476|BEHAVIORAL|behavioral weight loss|
48101075|NCT03070106|DIETARY_SUPPLEMENT|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
48101076|NCT02667418|DRUG|Fidaxomicin|200 mg PO twice daily for 10 days
48471163|NCT04271072|OTHER|No intervention|No intervention
48471164|NCT01445860|DRUG|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
48471165|NCT01074645|DRUG|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
48471166|NCT04728893|DRUG|Nemtabrutinib|Nemtabrutinib tablets administered PO QD.
48471167|NCT01487434|BEHAVIORAL|Check & Connect|Structured mentoring and case management
47939052|NCT01016561|RADIATION|intracavitary balloon brachytherapy|
47939053|NCT01016561|RADIATION|external beam radiation therapy|
47939054|NCT01016561|RADIATION|intensity-modulated radiation therapy|
47939055|NCT01016561|RADIATION|radiation therapy treatment planning/simulation|
47939056|NCT01016561|RADIATION|3-dimensional conformal radiation therapy|
47939057|NCT01016561|DRUG|Cisplatin|
47939058|NCT03565471|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography.
48471168|NCT05750706|OTHER|observation of invasive fungal infections|observation of invasive fungal infections during chemotherapy
48471169|NCT04937738|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
48471170|NCT04937738|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
48471171|NCT04937738|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
48471172|NCT04937738|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
48471173|NCT04937738|DRUG|Capecitabine|1000 mg/m² two times per day (BID), d1-14
48471174|NCT04937738|DRUG|Oxaliplatin|130 mg/m² d1 i.v. every 3 weeks
47939059|NCT03565471|DIAGNOSTIC_TEST|Right side catheterization|Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.
47939060|NCT03565471|DIAGNOSTIC_TEST|Exercise test|Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.
47939061|NCT03565471|DIAGNOSTIC_TEST|Holter monitor|Holter monitor worn for 2 whole days registering heart rate.
47939062|NCT03548090|OTHER|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
48471175|NCT02912767|BEHAVIORAL|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
48471176|NCT03769831|DRUG|SHR2285|Ascending dose oral adminstration
47939063|NCT03548090|OTHER|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
47939064|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
47939065|NCT03548090|OTHER|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
47939066|NCT03548090|OTHER|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
47939067|NCT03548090|OTHER|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
47939068|NCT03548090|OTHER|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
47939069|NCT03548090|OTHER|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
47939070|NCT05242523|OTHER|Bergamot scent|The scent of bergamot is fruity and citrusy, with floral hints and spice notes.
47939071|NCT05242523|OTHER|Natural wood scent|Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
47939072|NCT04163822|OTHER|no intervention|no intervention, only observation
47939073|NCT06259201|DEVICE|Vagus Nerve Stimulation|Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM \& PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.
47939074|NCT02383225|BEHAVIORAL|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
47939075|NCT02383225|BEHAVIORAL|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
48471177|NCT03769831|DRUG|Placebo|Ascending dose oral adminstration
48471178|NCT01737255|OTHER|Whole body MRI|Individuals will undergo whole body and brain MRI
47939076|NCT02383225|BEHAVIORAL|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
47939077|NCT01992978|PROCEDURE|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
48471179|NCT01737255|OTHER|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
48471180|NCT05220969|GENETIC|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
48471181|NCT03760016|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
48471182|NCT03760016|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
47939078|NCT01992978|PROCEDURE|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
48471183|NCT03754504|DIETARY_SUPPLEMENT|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
48471184|NCT03754504|DIETARY_SUPPLEMENT|Placebo|3 capsules/day of a placebo comparator
48471185|NCT00533806|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
48471186|NCT00533806|BEHAVIORAL|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
48471187|NCT06535711|RADIATION|Acute CT|Acute CT (a CT within 24 h)
48471188|NCT06535711|RADIATION|Deferred CT|Deferred CT (a CT within 3-4 weeks)
48471189|NCT04212728|BIOLOGICAL|Auotologous AMSCs plus autologous PRP|150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP.
48471190|NCT04212728|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
48471191|NCT03285464|OTHER|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
48471192|NCT05531617|PROCEDURE|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
48471193|NCT02460835|RADIATION|Adaptive Radiation Therapy|
48471194|NCT01517867|BEHAVIORAL|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
48471195|NCT01517867|BEHAVIORAL|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
48629512|NCT03390153|OTHER|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
47939079|NCT06309407|DEVICE|Hand Dosimeters|Participants were assigned to wear hand dosimeters in addition to the standard chest dosimeter worn by all participants
47939080|NCT06309407|DEVICE|Standard Practice|Participants only wore standard chest dosimeters
47939081|NCT05917509|DRUG|DTG/3TC|DTG/3TC FDC will be administered as an oral once daily tablet.
48471196|NCT01863186|DRUG|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
48471197|NCT01863186|DRUG|Placebo|Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
48471198|NCT01863186|DRUG|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
48471199|NCT02310763|BIOLOGICAL|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
48629513|NCT00038246|DRUG|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
47939082|NCT05917509|DRUG|Cabotegravir (CAB) LA|CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
48471200|NCT02310763|DRUG|Placebo|
48471201|NCT03542734|OTHER|multimodal magnetic resonance imaging|multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
48471202|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
48471203|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
48629514|NCT00038246|DRUG|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
48629515|NCT00038246|DRUG|Paclitaxel (Taxol)|100 mg/m\^2 by vein (IV) over 3 hours Day 3 and Day 10
48471204|NCT02642523|DRUG|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
48629516|NCT01263379|BIOLOGICAL|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
48629517|NCT06104293|OTHER|Grass Pollen Allergen Exposure|"After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations."
47939083|NCT05917509|DRUG|Rilpivirine (RPV) LA|RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
47939084|NCT03534453|DRUG|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
47939085|NCT01350518|DIETARY_SUPPLEMENT|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
48101077|NCT02667418|DRUG|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
48101078|NCT02667418|DRUG|Vancomycin|125 mg PO for times daily for 10 days
48101079|NCT05652530|DRUG|Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)|This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
48101080|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with occlusive or nonocclusive coronary artery disease who were treated invasive techniques (Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting)
48101081|NCT04763213|DIAGNOSTIC_TEST|Coronary Angiography|Patients diagnosed with oclusive or nonoclusive coronary artery disease who were treated medically
48101082|NCT01771887|BEHAVIORAL|education program|education program in 6 hours and monitoring phone every 15 days
48101083|NCT01506362|DRUG|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
48101084|NCT03852836|OTHER|ultra-rapid acquisition of bile ducts images|On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
48101085|NCT03862170|DRUG|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
48629518|NCT02664883|PROCEDURE|Computed Tomography|Correlative studies
47939086|NCT01350518|DIETARY_SUPPLEMENT|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
48101086|NCT03862170|DRUG|Cefazolin|
48101087|NCT02784704|DRUG|Eravacycline|
48101088|NCT02784704|DRUG|Meropenem|
48101089|NCT02784704|DRUG|Placebo|
48101090|NCT01025583|DIETARY_SUPPLEMENT|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
48629519|NCT02664883|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
48629520|NCT02664883|OTHER|Laboratory Biomarker Analysis|Correlative studies
47939087|NCT04448873|DRUG|Sirolimus|After at least 2 years of remission of KHE, we compare guided discontinuation with maintenance treatment in pediatric patients with KHE.
47939088|NCT01453192|DRUG|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
47939089|NCT03718299|DRUG|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
47939090|NCT05348135|OTHER|functional strength training|children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.
48101091|NCT01025583|DIETARY_SUPPLEMENT|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
48629521|NCT02664883|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
48101092|NCT04785066|DRUG|Administration of dornase alfa|Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous
48101093|NCT06629701|DEVICE|External support for vein grafts|Group A will consist of a group of patients who will be sutured with external support for vein grafts.
48284965|NCT02016807|DEVICE|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
48284966|NCT06172543|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants were assigned to ingest a single serving daily of either A) a 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb); or B) a 25-gram dose of Whey Protein Isolate + 25-gram dose of carbohydrate powder + 5-gram dose of creatine monohydrate (Creatine) for a 17-21-day period.
48284967|NCT06172543|DIETARY_SUPPLEMENT|Control|A 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb)
48284968|NCT01945892|DRUG|Ozurdex|"- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
48284969|NCT05671900|DRUG|Gemcitabine 1000 mg, Docetaxel 37.5g|6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
48284970|NCT02469246|DRUG|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
48284971|NCT02469246|DRUG|ABC/3TC|600/300 mg FDC tablets administered orally once daily
48284972|NCT02469246|DRUG|ABC/3TC Placebo|Tablets administered orally once daily
48629522|NCT01426451|OTHER|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
47939091|NCT05348135|OTHER|cognitive training|Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.
47939092|NCT05348135|OTHER|conventional physical therapy|including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
47939093|NCT01135576|DIETARY_SUPPLEMENT|non-fortified fruit juices consumed as part of the usual diet|
48101094|NCT03662399|DEVICE|Insoles|Orthotic Insoles
48101095|NCT03662399|OTHER|Standard shoe|Standard shoe
47939094|NCT01135576|DIETARY_SUPPLEMENT|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
47939095|NCT05956379|OTHER|exercise|Physical therapists will provide personalized aerobic exercise program prescriptions in the preparatory period based on the results of exercise-related assessments, and the training intensity is based on the results of the maximum exercise test, with moderate intensity for 24 weeks, \>=3 cardio workouts per week. The form of aerobic exercise can be carried out in the form of treadmill walking, walking, jogging, cycling, aerobic dance, ball games, swimming, rope skipping, stepping exercises, etc. When the exercise reaches the target intensity, we will adjust the training intensity process according to personal ability. The physical therapist will again adjust the content of the aerobic exercise program at week 12 based on the reassessment of the exercise capacity.
47939096|NCT00097851|DRUG|docetaxel|
48101096|NCT03152799|PROCEDURE|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
48101097|NCT03152799|OTHER|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
48101098|NCT03208062|OTHER|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
47939097|NCT00097851|DRUG|PI-88|
48284973|NCT02469246|DRUG|F/TAF Placebo|Tablets administered orally once daily
48284974|NCT02469246|DRUG|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
48284975|NCT03940885|PROCEDURE|Erector spinea plane block group|Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
48284976|NCT03940885|PROCEDURE|Transversus abdominis plane block|Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
48284977|NCT03940885|PROCEDURE|Control group|this group will receive only standard general anesthesia
48284978|NCT01439958|DRUG|Inhalation|Twice daily inhalation for a maximum of three years.
47939098|NCT02057627|BEHAVIORAL|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
47939099|NCT02057627|BEHAVIORAL|Placebo Comparator|Standard care plus depression monitoring by phone
48471205|NCT02642523|DRUG|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
48471206|NCT02642523|OTHER|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
47939100|NCT00586196|DRUG|donepezil|5 mg each day for 30 days
47939101|NCT00586196|DRUG|Placebo|Encapsulated cornstarch One capsule daily for 30 days
47939102|NCT00470912|DRUG|sunscreen RV 2547C|
47939103|NCT02959164|DRUG|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
47939104|NCT02959164|DRUG|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level"
47939105|NCT06087614|RADIATION|DE-HyART|The HSV delineation will be done for patients in arm 3 using baseline FMISO. The HSV will be contoured and adjusted according to the second FMISO scan done between the 4th - the 5th week of radiation treatment. A planning CT will also be repeated at the time for adjusting the HSV to account for temporal changes. The Biological Target Volume thus generated after adequate margins will be prescribed 30 Gy in 10 fractions over and above the standard fractination.
47939106|NCT06087614|RADIATION|Standard Arm|The prescribed radiotherapy dose will be 70 Gy in 2 Gy per fraction daily. The elective volume will be treated with 50 Gy in 2 Gy per fraction daily till the first 5 weeks. The entire treatment will be delivered in a phased mannered using sequential planning.
47939107|NCT06087614|DRUG|Cisplatin injection|Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
47939108|NCT06087614|RADIATION|Standard fractionation (Radiation Oncology preference)|Standard institutional practice is detailed before starting the patient. Doses 66-70 Gy over 6-7 weeks
47939109|NCT04351776|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora application
47939110|NCT04351776|OTHER|VR-Distraction|Participants will be instructed to use one of three applications
47939111|NCT04351776|OTHER|360 Video|Participants will be instructed which video to view
47939112|NCT03396393|DRUG|Dihydroartemisinin tablet|DHA tablet
47939113|NCT03396393|DRUG|Placebo tablet|Placebo tablet
47939114|NCT04850898|BIOLOGICAL|SAB-176|Treatment of influenza
47939115|NCT04850898|OTHER|Placebo|Placebo Control
47939116|NCT06072027|DIAGNOSTIC_TEST|cytology|Conventional cytology will be performed in parallel with VISIOCYT cytology in order to compare the two results.
48284979|NCT06254274|DRUG|RAY1225|Administered SC
48284980|NCT06254274|DRUG|Placebo|Administered SC
47939117|NCT03252184|DEVICE|Low level laser therapy - 1|In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
47939118|NCT03252184|DEVICE|Low level laser therapy - 2|In the phase 2, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Group 3 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
47939119|NCT03252184|DEVICE|Low level laser therapy - 3|In the phase 3, the low level laser therapy will be performed with the Thor DD2 (London, UK) and the cluster probe from the same manufacturer. For the interventions in groups G1 and G2 (photobiomodulation) will be used, respectively, the energy doses of 30J and 60J. A 810nm wavelength and an output power of 200mW will be used. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
48284981|NCT04025840|OTHER|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
48471207|NCT00776568|PROCEDURE|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
48471208|NCT00776568|DRUG|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
48471209|NCT06677827|DRUG|Bupivacaine|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral
48471210|NCT06677827|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
48471211|NCT04726852|DEVICE|Concurrent comparison|Concurrent comparisons at defined procedure events
48471212|NCT06569758|DRUG|GenSci098|subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.
48471213|NCT06569758|DRUG|GenSci098 Placebo|In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, GenSci098 and GenSci098 will be given on Day 1 and Day 85
48471214|NCT06319248|DRUG|Midodrine|Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
48629523|NCT01426451|OTHER|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
47939120|NCT06087315|OTHER|Multi-faceted oxygen systems strengthening interventions (different for each country)|The specific approaches are different in each country but broadly include efforts to: (1) strengthening policies, strategies, and governance of medical oxygen production, distribution, maintenance, and use; (2) building capacity of healthcare workers and technicians to use and maintain oxygen well, and (3) strengthening oxygen-related data acquisition and use for forecasting, budgeting, and monitoring.
47939121|NCT00350454|DEVICE|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
47939122|NCT00350454|DEVICE|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
48101099|NCT05012644|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + aromatase inhibitor
48101100|NCT05012644|DRUG|Aromatase inhibitor|Aromatase inhibitor
48101101|NCT03161691|PROCEDURE|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
48101102|NCT06242834|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48101103|NCT06242834|PROCEDURE|Computed Tomography|Undergo CT scan
48101104|NCT06242834|PROCEDURE|Echocardiography|Undergo echocardiography
48101105|NCT06242834|BIOLOGICAL|Pembrolizumab|Given IV
48101106|NCT06242834|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48101107|NCT06242834|DRUG|Tazemetostat|Given PO
48101108|NCT05283044|BIOLOGICAL|biopsy liquid|Patient performs a blood test at treatment baseline
48101109|NCT05460806|OTHER|Aerobic Exercise|Participants assigned to aerobic exercise training will walk on a treadmill (RodbyTM, RL 1600E, Enhorna, Sweden) for 40 minutes at an intensity of 60-75% of maximum heart rate (220-age formula) three times per week for 8 weeks. The heart rate of the participants will be measured with an electric heart rate monitor throughout the session.
48101110|NCT06114329|DRUG|AL01211|AL01211 is a novel, proprietary, selective GCS inhibitor with high potency against GCS with limited off target activity.
47939123|NCT00350454|DEVICE|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
48101111|NCT02135809|DEVICE|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
48101112|NCT05299333|OTHER|Exercise|High repetition muscle endurance and strengthening exercises Walking
48101113|NCT04044664|DRUG|Placebo oral capsule|Matching placebo capsules.
48101114|NCT04044664|DRUG|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
48101115|NCT04668183|PROCEDURE|Pudendal nerve block group|A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
48101116|NCT04668183|PROCEDURE|Dorsal penile nerve block group|Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
48101117|NCT00771849|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
48101118|NCT00771849|BIOLOGICAL|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
48101119|NCT04481906|PROCEDURE|Vaginal mesh for female cystocele|Vaginal mesh procedures (e.g. Perigee) were susgested for women with POP-Q stage III or more cystocele
48101120|NCT04118374|OTHER|Standard Carb Diet|Approximately 50% of caloric intake will come from carbohydrate consumption.
48284982|NCT04025840|DRUG|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
48284983|NCT04549012|DRUG|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
48101121|NCT04118374|OTHER|Low Carb Diet|Approximately 25% of caloric intake will come from carbohydrate consumption.
48284984|NCT04549012|DRUG|Oxytocin|Oxytocin
48284985|NCT00159484|DRUG|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
48284986|NCT03947294|DEVICE|Q-NRG®|Energy expenditure measurements
48284987|NCT04321863|OTHER|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
48471215|NCT06319248|OTHER|Standard of Care|Subjects will receive standard of care for sepsis treatment.
48101122|NCT00603356|DRUG|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
48471216|NCT05810857|DIAGNOSTIC_TEST|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
48471217|NCT05810857|DIAGNOSTIC_TEST|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
48471218|NCT01544517|DRUG|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
48471219|NCT03729518|RADIATION|Radiation Therapy (IMRT or IMPT)|"* Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~* Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~* Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
48471220|NCT04380545|DRUG|Fluorouracil|Given IV
48471221|NCT04380545|BIOLOGICAL|Nivolumab|Given IV
48471222|NCT04380545|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Given SC
48471223|NCT03033134|DEVICE|BSJ003W|BSJ003W implant
47939124|NCT00057122|DRUG|Isoniazid|300mg
47939125|NCT00057122|DRUG|Rifapentine|Rifapentine 900 mg
47939126|NCT00057122|DRUG|Rifampin|Rifampin 600 mg
47939127|NCT03405636|DEVICE|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
47939128|NCT01785095|DRUG|FSH (Follicle Stimulating Hormone)|
47939129|NCT02836600|DRUG|LY3039478|Administered orally
47939130|NCT06290973|PROCEDURE|surgery of varicose veins|including ablation with radiofrequency, phlebectomy and saphenectomy.
48101123|NCT03149406|OTHER|Comparing the expression of miRNAs|by PCR, in symptomatic and asymptomatic carotid plaques.
48471224|NCT04556916|DIAGNOSTIC_TEST|Blood sample|"Per patient 49 ml of peripheral blood sample :~* 21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~* 28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
47939131|NCT02723578|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
48471225|NCT03114358|OTHER|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
48471226|NCT06098651|DRUG|DCR-STAT3|DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion.
48471227|NCT03710096|DEVICE|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
48471228|NCT03710096|DEVICE|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
48471229|NCT02041858|OTHER|Altered Alarm Settings|An altered set of alarm parameter settings
47939132|NCT02723578|DRUG|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
47939133|NCT03925168|BEHAVIORAL|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
47939134|NCT04544969|DRUG|cisplatin-based chemotherapy|"GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.~TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.~PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.~Choice of chemotherapy regimen is decided by patient's doctor in charge."
47939135|NCT02819661|DEVICE|SOMNOTOUCH RESP|Ventilatory effort recorder
47939136|NCT02819661|PROCEDURE|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
47939137|NCT02819661|DRUG|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
47939138|NCT01757691|DRUG|Fingolimod 0.5mg/daily|
47939139|NCT01757691|DRUG|Placebo|
47939140|NCT06243744|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
48101124|NCT01353482|DRUG|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
48101125|NCT01353482|DRUG|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
48101126|NCT01353482|DRUG|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
48101127|NCT01353482|DRUG|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
48101128|NCT06628895|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Exercise training that consists of flexibility, aerobic, balance and strengthening regime. The exercise given three times a week, for 12 weeks.
48284988|NCT04321863|OTHER|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
48629524|NCT01018953|DRUG|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
47939141|NCT05829200|DEVICE|Transcranial Doppler (TCD)|All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
47939142|NCT06518902|DRUG|mesenchymal stem cells (umbilical cord) injection|Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
47939143|NCT02803762|DRUG|Pacritinib|400 mg \[14C\]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
47939144|NCT03503851|DEVICE|MitraClip implantation|Device to approximate the mitral valve leaflets
47939145|NCT02922491|DIETARY_SUPPLEMENT|vitamin E|daily intake of vitamin E
47939146|NCT02922491|DIETARY_SUPPLEMENT|starch|daily intake of starch (control)
47939147|NCT01630785|DEVICE|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
47939148|NCT01419821|DRUG|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
47939149|NCT01419821|OTHER|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
47939150|NCT05469204|DRUG|Midazolam oral solution|2 mg single-dose before and during estradiol treatment.
47939151|NCT05469204|DRUG|Digoxin Oral Tablet|0.25 mg single-dose before and during estradiol treatment.
48101129|NCT05192707|DIAGNOSTIC_TEST|TcPO2 measurement on the upper limb|Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.
48101130|NCT02013037|DRUG|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
48101131|NCT05502211|DRUG|Fentanyl|induction of anaesthesia using fentanyl
48101132|NCT05502211|DRUG|Lidocaine IV|induction of anesthesia using lidocaine
48101133|NCT02490176|DRUG|liraglutide|Liraglutide were taken daily for 7 days
48101134|NCT02490176|DRUG|placebo|Placebo were taken daily for 7 days
48101135|NCT02155829|DRUG|Riluzole|
48101136|NCT02155829|DRUG|Placebo (for Riluzole)|
48101137|NCT06161064|DRUG|Hyaluronic acid|hyaluronic acid is temporary material using for augmentation of vocal folds in patients with glottal insufficiency
48101138|NCT06629545|OTHER|irrigation activation with PUI|The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device. The power setting of the ultrasonic device was 30% (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 2.5% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 1 mm behind the working length without touching the canal walls.
48101139|NCT06629545|OTHER|irrigation with sonic activation|A suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) was inserted into the canal 1 mm short of the working length. 3 ml of 2.5% NaOCl solution was activated in three periods of 20 s (1 ml of 2.5% NaOCl in each cycle). Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
48284989|NCT04321863|OTHER|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
48284990|NCT02707757|DRUG|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
47939152|NCT05469204|DRUG|Acetaminophen Oral Tablet|500 mg single-dose before and during estradiol treatment.
47939153|NCT05469204|DRUG|Midazolam Injectable Solution|1 mg intravenous single-dose before and during estradiol treatment.
47939154|NCT03486717|DEVICE|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
48471230|NCT01436643|DRUG|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
48471231|NCT01436643|DRUG|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
48471232|NCT01436643|DRUG|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
48471233|NCT01436643|DRUG|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
48471234|NCT02459886|DRUG|BIIB054|IV infusion
47939155|NCT05718050|DIAGNOSTIC_TEST|Mandibular flexure evaluation|A mandibular silicon impression was taken, and a vacuum molded thermoplastic stent with radiopaque fiducial markers (steel ball bearings) on the facial side of the canines and molars was fabricated for each patient. Two Cone Beam Computed Tomographs (CBCTs) were made per patient with their radiographic stent in the mouth at the OVD and MO positions at the University Advanced Digital Diagnostic Center. The CBCT examination was performed without any stitching procedure using a computed tomography (SCANORA 3DX; Dexis LLC) set up at 90 kV, 4 mA and a field of view (FOV) of 140 and 100 mm in height and width respectively, to decrease the radiation dose without affecting the quality of the examination.
47939156|NCT03593161|BEHAVIORAL|Humor therapy|Clown visits
47939157|NCT01393015|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
47939158|NCT01393015|DEVICE|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
47939159|NCT02895633|OTHER|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
47939160|NCT02895633|OTHER|CT scan|With injection of Iomeron 400
47939161|NCT02895633|OTHER|MRI|With injection of gadolinium (Multihance)
47939162|NCT04638192|DEVICE|tACS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
48101140|NCT03456817|DRUG|Treatment Arm - high dose ATG|Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 \& -2, ATG will be infused after fludarabine \& busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 \& over at least 4 hrs on days -3, -2, -1 \& 0. Dose is based on actual body wt, \& rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in \>5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
48101141|NCT03456817|DRUG|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
48471235|NCT02459886|DRUG|Placebo|IV infusion
48629525|NCT06494956|PROCEDURE|Implant device|A subcutaneous tunnel was established under general anesthesia, the electrode was connected to the stimulator, and the pulse generator was implanted in the skull.
47939163|NCT05198778|DRUG|URC102|tablet
47939164|NCT05198778|DRUG|URC102|tablet
47939165|NCT01386112|DRUG|EUR-1100|Active oral medication
47939166|NCT01386112|DRUG|placebo|matching placebo
47939167|NCT01367119|DRUG|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
47939168|NCT01367119|DRUG|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
47939169|NCT00817583|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
47939170|NCT00817583|RADIATION|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
48101142|NCT02121418|DRUG|Cytarabine|Given IV
48101143|NCT02121418|DRUG|Decitabine|Given IV
48101144|NCT02121418|OTHER|Laboratory Biomarker Analysis|Correlative studies
48101145|NCT03093792|OTHER|Control|
48101146|NCT03093792|OTHER|American Heart Association plus exercise|
48101147|NCT03093792|OTHER|Curves Complete - I plus exercise|
47939171|NCT03800082|BEHAVIORAL|at heart (changed from HEARTPA♀N during usability testing)|An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease. The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
47939172|NCT05274659|DRUG|KJ103|Recombinant Immunoglobulin G Cleaving Enzyme
47939173|NCT05274659|DRUG|Placebo|Placebo
48101148|NCT03093792|OTHER|Curves Complete - II plus exercise|
48101149|NCT02711826|BIOLOGICAL|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.
48101150|NCT02711826|DRUG|Everolimus|
48101151|NCT02711826|DRUG|Tacrolimus|
48101152|NCT02711826|DRUG|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
48471236|NCT00081172|RADIATION|lutetium Lu 177 monoclonal antibody J591|
48629526|NCT03509597|BEHAVIORAL|Aerobic Exercise|Physical exercise training consisting of aerobic exercise and strength/resistance training.
48629527|NCT03509597|BEHAVIORAL|Cognitive Training|Cognitive remediation program using REHACOP rehabilitation program.
48629528|NCT03509597|BEHAVIORAL|Treatment as usual|Standard care for schizophrenia + Leisure and free time activities.
48629529|NCT03509597|BEHAVIORAL|Occupational Activities|Engagement in activities aimed to keep patients actively involved in demanding tasks.
48101153|NCT02711826|DRUG|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
48101154|NCT02711826|DRUG|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
48101155|NCT02711826|DRUG|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
48101156|NCT02711826|PROCEDURE|Biopsy, Kidney|
48284991|NCT02707757|DRUG|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
48284992|NCT05955742|DEVICE|Control|The operator prepared the glide path using a #15K-type stainless-steel hand file.
48284993|NCT05955742|DEVICE|ProGlider|The operator prepared the glide path using the ProGlider file.
48284994|NCT05955742|DEVICE|WaveOne Gold Glider|The operator prepared the glide path using the WaveOne Gold Glider file.
48284995|NCT02760628|BEHAVIORAL|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
48284996|NCT02760628|BEHAVIORAL|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
48284997|NCT04373525|OTHER|Genome analysis|Venous blood will be obtained for later genome analysis
48284998|NCT03909815|DEVICE|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
48284999|NCT03909815|DEVICE|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
48471237|NCT01275716|BEHAVIORAL|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
47939174|NCT05041530|DEVICE|REBUILD Bioabsorbable|REBUILD is an investigational medical device designed to be used with third-party suture to distribute suture tension in abdominal wall closures.
48101157|NCT02711826|PROCEDURE|Blood Draw|
48101158|NCT02711826|PROCEDURE|Leukapheresis|
48101159|NCT02711826|PROCEDURE|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
48101160|NCT04691778|PROCEDURE|CTO PCI with the first-choice Gladius guidewire|CTO PCI using antegrade wiring strategy with the first-choice Gladius guidewire
47939175|NCT05162040|DEVICE|Use of PedaleoVR|"All participants must undergo an evaluation of their motor skills through the application of physical assessment metrics performed by the physician. The metrics are the Timed Up-and-Go Test (TUG) and the 6-minute walk test.~Next, they must perform a pedaling exercise on a bicycle or stationary pedaling station synchronizing the physical activity with the visual feedback from the virtual reality application. Two pedalling sets of 10 minutes each are performed, with 5 minutes of rest between sets. Finally, the participant is asked to rate the usability: System Usability Rating Scale (SUS), activity credibility (Credibility and Expectancy Questionnaire, CEQ) and intrinsic motivation (Intrinsic Motivation Inventory, IMI) of the virtual reality application."
47939176|NCT01916967|DRUG|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
47939177|NCT01916967|DRUG|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
47939178|NCT02764125|DRUG|Stalevo|levodopa/carbidopa/entacapone
47939179|NCT02764125|DRUG|levodopa MR|levodopa MR/carbidopa/ODM-104
47939180|NCT04509765|RADIATION|Linac Based VMAT TBI|Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).
47939181|NCT00596362|DRUG|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
47939182|NCT02758977|PROCEDURE|ALPPS|For detailed information please refer to description of experimental arm
47939183|NCT02758977|PROCEDURE|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
47939184|NCT04756180|DRUG|Omega-3-acid ethyl ester or Placebo|Omega-3-acid ethyl ester 2 gm/day for first 4 week followed by 4gm/day for 8 week
47939185|NCT02448342|DEVICE|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
47939186|NCT03802747|DRUG|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
47939187|NCT03802747|DRUG|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
47939188|NCT03802747|DRUG|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
47939189|NCT03802747|DRUG|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
47939190|NCT04733612|OTHER|Informative messages|"In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months.~The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones."
47939191|NCT03231020|OTHER|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (\< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
47939192|NCT04455984|OTHER|Date collection|Retrospective data analysis
47939193|NCT00201331|DRUG|leucovorin+5-FU|
47939194|NCT05500547|OTHER|"US Public Health Service USPSH criteria for assessment of success of resin composite restorations"|"US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months."
47939195|NCT05731531|DEVICE|ELECTROGASTROGRAPHY|Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
47939196|NCT01954147|DRUG|GLP-1|GLP-1 therapy
47939197|NCT01954147|BIOLOGICAL|SC|Stem cell infusion
47939198|NCT01954147|OTHER|Standard Medical Treatment|Standard Medical Treatment
47939199|NCT05973396|OTHER|Physical Fatiguing Task only|Control group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] without mentally fatiguing task during low intensity effort pace
47939200|NCT05973396|OTHER|Physical and Mental Fatiguing Task|Experimental group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
47939201|NCT00254774|DRUG|quetiapine fumarate or valproate|
48101161|NCT04691778|PROCEDURE|CTO PCI without the first-choice Gladius guidewire|CTO PCI using standard antegrade wire escalation strategy
48629530|NCT01529216|DEVICE|DIAMOND System|Electrical stimulation to the fundus
48629531|NCT00694343|DRUG|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
48629532|NCT00694343|DRUG|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
47939202|NCT04968054|DRUG|Arm I (Propofol)|Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.
47939203|NCT04968054|DRUG|Arm II (Remimazolam)|Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.
47939204|NCT02140775|BEHAVIORAL|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
47939205|NCT05334511|OTHER|Functional Electrical Stimulation|functional electrical stimulation with Frequency 20 pps with Pulse width of 300 msec.
47939206|NCT04414332|OTHER|Data collection only|This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.
47939207|NCT03639571|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
47939208|NCT03639571|OTHER|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
47939209|NCT03508427|OTHER|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
47939210|NCT04061473|DRUG|Sitagliptin 100mg|"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
47939211|NCT04061473|DRUG|Empagliflozin 25 MG|2 tablets of empagliflozin 25 mg.
47939212|NCT04061473|OTHER|Placebo tablet|"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
47939213|NCT05453266|PROCEDURE|Application of Tranexamic acid in arthroscopic irrigation solution|Application of Tranexamic acid in arthroscopic irrigation solution
47939214|NCT05453266|PROCEDURE|No application of Tranexamic acid in arthroscopic irrigation solution|No application of Tranexamic acid in arthroscopic irrigation solution
48471238|NCT02435316|OTHER|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
48471239|NCT02435316|OTHER|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
48471240|NCT05614219|OTHER|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C \> 4 mmol/L in persons under the age of 40, or LDL-C \> 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
48471241|NCT04592653|BIOLOGICAL|Nemvaleukin alfa|IV infusion over 30 minutes
48471242|NCT04592653|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes
48471243|NCT05788432|DEVICE|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
48471244|NCT01134991|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
48629533|NCT00408915|DRUG|Continuous Subcutaneous Lisuride Infusion|
48629534|NCT06341283|DRUG|Abemaciclib and Letrozole/Anastrozole|Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.
48629535|NCT06341283|DRUG|Letrozole or Anastrozole|Take the treatment with Letrozole or Anastrozole.
48629536|NCT06341283|DRUG|Abemaciclib and Fulvestrant|Take the treatment with Abemaciclib and Fulvestrant at the same time.
48629537|NCT06341283|DRUG|Fulvestrant|Take the treatment with Fulvestrant only.
48629538|NCT01642966|DRUG|Prasugrel|Prasugrel 10mg/day for 15 days
48629539|NCT01642966|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
48629540|NCT00508846|BEHAVIORAL|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
48629541|NCT03851991|DRUG|Arbidol|oral
48629542|NCT03851991|DRUG|Placebos|controle
48629543|NCT03345004|BIOLOGICAL|Diamyd|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD65)
48629544|NCT03345004|DIETARY_SUPPLEMENT|Vitamin D|Oil suspension of Vitamin D
47939215|NCT00411931|DRUG|Multihance|0.5M administered as a single injection
47939216|NCT04024878|DRUG|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
47939217|NCT04024878|BIOLOGICAL|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
47939218|NCT04024878|PROCEDURE|Core Needle Biopsy|Surgical procedure
48285000|NCT02039154|BEHAVIORAL|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
48629545|NCT03345004|BIOLOGICAL|Placebo for Diamyd|Alhydrogel® only
48629546|NCT03345004|DIETARY_SUPPLEMENT|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
48629547|NCT01573377|DRUG|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
48629548|NCT01573377|DRUG|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
47939219|NCT02644200|DEVICE|Gelatin tannate|
47939220|NCT03972930|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
47939221|NCT01455376|DRUG|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
47939222|NCT05993182|DRUG|Ephedrine 5mg|Patients received 5mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
47939223|NCT05993182|DRUG|Ephedrine 10mg|Patients received 10mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
47939224|NCT05993182|DRUG|Ephedrine 15mg|Patients received 15mg bolus dose of ephedrine Intravenous after the first hypotension \[ Base line time or starting point is first hypotension\]
47939225|NCT01323842|PROCEDURE|EDTU|bedside ultrasound imaging by the treating emergency physician
47939226|NCT04336644|DEVICE|BodyGuardian Mini Plus|The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
47939227|NCT02610959|OTHER|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
47939228|NCT02610959|OTHER|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
47939229|NCT00046111|DRUG|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
47939230|NCT05760118|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
47939231|NCT02428985|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
48629549|NCT00927082|DRUG|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
48629550|NCT01708525|DEVICE|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
48629551|NCT01708525|OTHER|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
47939232|NCT04699253|DEVICE|SanaCoach Heart failure|Patients will be using the SanaCoach heart failure for at least 6 months during the study period. SanaCoach heart failure is a web application that will be guiding the patient through a regular, systematic assessment of patient's health and wellbeing as well as regular education sessions. The assessment frequency ranges from daily to monthly, based on the settings provided by the health care provider. Furthermore, it provides a repository for patient's care plan to give insight into the course and treatment of the disorder and offers the possibility to contact the health care provider through the web application.
47939233|NCT03080974|DRUG|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
47939234|NCT03080974|PROCEDURE|Irreversible Electroporation|Non-thermal ablation of tumor
47939235|NCT04807478|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|Dose, frequency and duration is a decision of the Investigator
48101162|NCT02577484|DEVICE|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
47939236|NCT01927302|BEHAVIORAL|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
47939237|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
47939238|NCT01927302|BEHAVIORAL|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
47939239|NCT01927302|BEHAVIORAL|No Treatment|No treatment will be administered.
48101163|NCT02577484|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
47939240|NCT05054244|OTHER|standard wound treatment|Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).
47939241|NCT05054244|PROCEDURE|Hyperbaric oxygenation (HBOT)|The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
47939242|NCT05868668|DEVICE|Focused shockwave|Storz Duolith SD-1 (Storz Medical, Tagerwilen, Switzerland)
47939243|NCT05868668|DEVICE|Radial wave|Zimmer enPuls Pro (Zimmer MedizinSysteme GmbH, Neu-Ulm, Germany)
48629552|NCT03963830|BEHAVIORAL|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
48629553|NCT06264622|DIETARY_SUPPLEMENT|Low dose|2 tablets per day during the morning for 12 weeks.
48101164|NCT06280209|DRUG|BMN 351|Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
48629554|NCT06264622|DIETARY_SUPPLEMENT|High dose|2 tablets per day during the morning for 12 weeks.
47939244|NCT05868668|DEVICE|Sham treatment|Handheld sham probe
47939245|NCT05411133|DRUG|Cabotamig (ARB202)|Cabotamig (ARB202), Atezolizumab
47939246|NCT04870736|PROCEDURE|Mout-to-mouth ventilation|Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.
47939247|NCT04870736|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
47939248|NCT03231982|DRUG|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
47939249|NCT03231982|DRUG|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
47939250|NCT00246779|PROCEDURE|Modified ultrafiltration|
47939251|NCT05280379|OTHER|no intervention will take place|no intervention will take place
47939252|NCT01375426|DRUG|Oral amoxicillin|
47939253|NCT06424418|DEVICE|Robotic Scope Cleaner|The device is used to clean the scope when it visualization becomes obstructed during a surgical procedure.
48101165|NCT00261547|DRUG|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
48101166|NCT02476773|BIOLOGICAL|Na-GST-1/Alhydrogel plus GLA-AF|
48101167|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
48101168|NCT02476773|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
48101169|NCT02476773|BIOLOGICAL|Sterile Saline Placebo|
48101170|NCT00019318|DRUG|romidepsin|
48629555|NCT06264622|DIETARY_SUPPLEMENT|Placebo|2 tablets per day during the morning for 12 weeks.
47939254|NCT01903525|DRUG|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
47939255|NCT01903525|DRUG|Placebo|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
47939256|NCT01812590|BEHAVIORAL|Exercise|
48285001|NCT02039154|BEHAVIORAL|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
48471245|NCT05301816|DEVICE|Spinal Cord Stimulator (SCS)|Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
48471246|NCT00603512|DRUG|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
48471247|NCT00603512|DRUG|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
48629556|NCT05676645|DRUG|Artemether-lumefantrine|National policy recommendation for treatment of uncomplicated malaria in Uganda
48629557|NCT01447472|DRUG|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
48629558|NCT03297827|OTHER|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic \& hemorrhagic stroke.
48629559|NCT01229553|DRUG|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
48471248|NCT00603512|DRUG|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
48471249|NCT00603512|DRUG|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
48471250|NCT00603512|DRUG|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
48471251|NCT05108844|PROCEDURE|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
48471252|NCT04056663|BEHAVIORAL|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
48629560|NCT03723239|DEVICE|TricValve® System|The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
48629561|NCT03828669|BEHAVIORAL|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
48629562|NCT03165903|BEHAVIORAL|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
48471253|NCT04172324|DEVICE|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
48471254|NCT04172324|OTHER|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
48471255|NCT04544852|BEHAVIORAL|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test."
48471256|NCT04544852|BEHAVIORAL|Targeted intervention programme|The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
48471257|NCT02700971|PROCEDURE|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
48471258|NCT02301533|BEHAVIORAL|Shikamana Intervention|See arm description
48629563|NCT03165903|BEHAVIORAL|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
48629564|NCT02931110|DRUG|CBL0137|CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
48629565|NCT05138640|OTHER|Not applicable. The study is designed as an observational cohort study|Not applicable. The study is desigend as an observational cohort study
48629566|NCT03753477|DRUG|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
48629567|NCT03753477|DRUG|Sevikar and Crestor|Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
48629568|NCT04667169|PROCEDURE|Haemorrhoidal Artery Ligation|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
48629569|NCT04667169|PROCEDURE|Laser Haemorrhoidoplasty|Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
48471259|NCT02301533|BEHAVIORAL|Standard Care|See arm description
48471260|NCT05317806|DRUG|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
48471261|NCT02274662|BIOLOGICAL|Cultured Thymus Tissue|"Subjects receive cultured thymus tissue which is implanted into the quadriceps muscle. Subjects may receive pre and/or post-implantation immunosuppression.~Potential subjects are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted into the subject's quadriceps muscle under general anesthesia in the operating room. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one year post-implantation. At year 2 post-implantation, subjects are contacted for data collection."
48471262|NCT02274662|PROCEDURE|Blood Draw|
48471263|NCT02274662|DRUG|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
47939257|NCT06071936|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
48471264|NCT02909517|OTHER|cSLO imaging|
48471265|NCT02488109|OTHER|Higher Calorie Refeeding|
48471266|NCT02488109|OTHER|Lower Calorie Refeeding|
48471267|NCT05712317|BEHAVIORAL|Exergame Intervention|8-week exergame-based intervention 3x per week
48285002|NCT04918693|DEVICE|Ultrasound scanning|All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
48285003|NCT06075940|DEVICE|MAGNITUDE BRS|Treatment with the MAGNITUDE Scaffold
48471268|NCT05712317|BEHAVIORAL|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise 3x per week
48471269|NCT02079233|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
48471270|NCT04685850|OTHER|sequela evaluation|clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance
48471271|NCT00057967|BIOLOGICAL|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
48471272|NCT00380588|DRUG|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
47939258|NCT06071936|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
47939259|NCT00920829|DRUG|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
48629570|NCT03995082|OTHER|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
48285004|NCT04265612|PROCEDURE|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
48285005|NCT04265612|PROCEDURE|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
47939260|NCT00920829|DRUG|Placebo|placebo
47939261|NCT03949491|PROCEDURE|3D medical models|Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
48285006|NCT03835663|DIAGNOSTIC_TEST|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
47939262|NCT02776371|DRUG|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
47939263|NCT02776371|DRUG|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
47939264|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
48285007|NCT02082691|DRUG|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
48285008|NCT04391140|OTHER|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
48285009|NCT03597906|PROCEDURE|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
48285010|NCT03597906|PROCEDURE|manifest refraction|using for ablation the exact manifest refraction
48285011|NCT03597906|PROCEDURE|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
48471273|NCT00380588|DRUG|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
48471274|NCT01272024|BEHAVIORAL|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
48471275|NCT01272024|BEHAVIORAL|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
48471276|NCT06204016|DRUG|Estradiol Valerate|To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)
48629571|NCT04951960|OTHER|Higher PEEP setting|PEEP levels are determined according to the higher PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
48285012|NCT03597906|PROCEDURE|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
48471277|NCT06204016|DRUG|Placebo|Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
48285013|NCT01531725|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
47939265|NCT00495131|DRUG|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
48285014|NCT06653166|DEVICE|bougie (S Guide)|bougie (S Guide)
48285015|NCT06653166|DEVICE|videolaryngoscopy|videolaryngoscopy hyperangulated or Macintosh
48285016|NCT05637450|DIETARY_SUPPLEMENT|Blue Whiting Protein Hydrolysate|25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
48285017|NCT05637450|DIETARY_SUPPLEMENT|Placebo|Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
48471278|NCT04118868|COMBINATION_PRODUCT|Pembrolizumab administered using the Sofusa® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
48629572|NCT04951960|OTHER|Lower PEEP setting|PEEP levels are determined according to the lower PEEP-FiO2 tables set plateau pressure less than 30 cmH2O. The duration of measurement at each PEEP levels is 1 hour.
48629573|NCT06469125|PROCEDURE|Endoscopic Prostate Interventions for Anatomic Enucleation|The intervention in this study involves performing anatomic endoscopic enucleation of the prostate (AEEP) using different energy sources. Following the enucleation, the resected prostate tissue will be morcellated within the bladder using various morcellators to remove the enlarged prostate tissue minimally invasively. The process will also involve evaluating and categorizing any resulting bladder injuries using the BICEP classification system.
47939266|NCT04777838|DRUG|Citalopram 10 MG|10 mg of citalopram every day
47939267|NCT04777838|DRUG|Amitriptyline|25mg of Amitriptyline every
47939268|NCT04777838|DEVICE|Bite Splint|Night use of occlusal splint
47939269|NCT06489379|DEVICE|high flow nasal cannula|humidified and heated oxygen
47939270|NCT06489379|OTHER|standard oxygen|oxygen delivery through Venturi mask
48285018|NCT02406664|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
48285019|NCT03489213|OTHER|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
48629574|NCT03739554|DRUG|CYC065|intravenous infusion
48629575|NCT03739554|DRUG|Venetoclax|oral capsule
48629576|NCT02120079|DRUG|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
48629577|NCT02120079|DRUG|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
48629578|NCT02120079|DIAGNOSTIC_TEST|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
48629579|NCT00179179|DRUG|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
48629580|NCT00179179|BEHAVIORAL|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
48629581|NCT01925820|DRUG|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
48629582|NCT00977184|PROCEDURE|50 HZ Repetitive TMS|
48629583|NCT00977184|PROCEDURE|Sham rTMS|
48629584|NCT05259293|OTHER|No intervention - retrospective study|This is a retrospective study. No intervention.
48629585|NCT04627584|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
48629586|NCT04627584|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
48629587|NCT03291015|DEVICE|radiographic|using plain x ray to determind the treatment plan
48629588|NCT03291015|DEVICE|arthroscopy|using wrist arthroscopy to determind the treatment plan
48629589|NCT00999011|PROCEDURE|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
48629590|NCT00999011|PROCEDURE|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
48629591|NCT03718260|DIAGNOSTIC_TEST|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with \[18F\]-DCFPyL PET/CT Scan (PSMA PET).
48629592|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule approximately 30 mcg daily 21 days
48629593|NCT00894920|DIETARY_SUPPLEMENT|biotin|capsule 300 mcg daily 21 days
48629594|NCT03461861|DRUG|AGB101 220 mg|AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
48629595|NCT03461861|OTHER|Placebo|Placebo, oral capsule given once-daily.
48629596|NCT03116269|DRUG|Cilostazol 100mg|
48629597|NCT03116269|DRUG|Aspirin|
48471279|NCT04219358|DRUG|Vehicle Gel Base|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water."
48471280|NCT04219358|DRUG|Imiquimod 5% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%."
48471281|NCT04219358|DRUG|Imiquimod 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form."
48629598|NCT02158507|DRUG|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
48629599|NCT01010620|BEHAVIORAL|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
48629600|NCT02027571|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( \> 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
47939271|NCT00062322|DRUG|cisplatin|
48471282|NCT04219358|DRUG|Imiquimod nanoencapsulated 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%"
48471283|NCT04219358|DRUG|Lip sunscreen 30 Sun Protector Factor (SPF)|Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
48471284|NCT04219358|DRUG|Dexpanthenol|"Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair."
48471285|NCT06467097|RADIATION|SBRT(Stereotatic Body Radiation Therapy)|Patients will receive treatment for one to two weeks, one to five times per region.
48471286|NCT00929058|DRUG|Bevacizumab|Intra-arterial infusion during 6 minutes
48629601|NCT03778333|BIOLOGICAL|Autologous mesenchymal stem cells|IV therapy with autologous bone-marrow derived mesenchymal stem cells
48629602|NCT03688113|BEHAVIORAL|Tinnitus application|Use of tinnitus application
48629603|NCT03925714|OTHER|life style|life sryle control only
48629604|NCT03925714|DRUG|Metformin|metformin twice daily
48629605|NCT03925714|DRUG|Nigetella salivata|NS twice daily
48629606|NCT04029051|OTHER|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
47939272|NCT00062322|DRUG|irinotecan hydrochloride|
47939273|NCT00062322|PROCEDURE|conventional surgery|
47939274|NCT00062322|PROCEDURE|neoadjuvant therapy|
47939275|NCT00062322|RADIATION|radiation therapy|
47939276|NCT03671473|DEVICE|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
47939277|NCT00218101|DRUG|Buprenorphine|
48285020|NCT03489213|BEHAVIORAL|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
48285021|NCT03489213|OTHER|Laboratory Biomarker Analysis|Correlative studies
48471287|NCT02329431|BEHAVIORAL|activation curriculum|psychosocial activation curriculum
48471288|NCT02329431|BEHAVIORAL|support group|parent directed support group
48629607|NCT05864014|DRUG|Hetrombopag|Hetrombopag
48629608|NCT05864014|DRUG|Hetrombopag plus Placebo|Hetrombopag plus Placebo
48629609|NCT05864014|DRUG|Placebo|Placebo
48629610|NCT05042882|DIETARY_SUPPLEMENT|Early enteral nutrition|Enteral nutrition via nasojejunal tube
48629611|NCT05535088|DEVICE|Virtual reality|Virtual reality consists for about a minute and a half 6 times per session. During the first and the second session, subjects will experiment virtual reality while sited. Moreover, during the third and the fourth session subjects will be standing with a side by side stand. During the last two experimental sessions subjetcts will be standing with a semi tandem stand.
47939278|NCT05875103|DIAGNOSTIC_TEST|linguistic processes|"Linguistic processes are assessed by performance score on the following tests:~* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)~* vocabulary test (Mill Hill - Deltour, 1993),~* repetition tests (Gremots - Bézy et al., 2016),~* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)~* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),~* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),~* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)"
47939279|NCT00920907|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
48285022|NCT03489213|DIETARY_SUPPLEMENT|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
48285023|NCT03489213|OTHER|Questionnaire Administration|Ancillary studies
48629612|NCT03821532|OTHER|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
48285024|NCT02203682|DRUG|Doxycycline hyclate|Tab. Doxycycline 50 mg PO per day for 12 weeks
48285025|NCT02203682|DRUG|Placebo|Tablet placebo for 12 weeks
48285026|NCT01089855|DRUG|Carbamazepine|
48285027|NCT01416311|DRUG|Eltrombopag|
48285028|NCT03554239|GENETIC|genotyping|Blood sample
48285029|NCT05008887|DRUG|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
48285030|NCT05008887|DRUG|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
48285031|NCT05008887|DEVICE|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
48285032|NCT03666767|OTHER|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
48471289|NCT06678464|OTHER|Moiz MM|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
48629613|NCT06449248|OTHER|Checking of appropriateness of OLP diagnosis|The above mentioned interventions will be carried out through the accurate analysis of patients' clinical records
48629614|NCT05903443|DIAGNOSTIC_TEST|ancillary tests|electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler
48629615|NCT01609192|DRUG|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
48629616|NCT03457584|PROCEDURE|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
48629617|NCT03457584|PROCEDURE|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
48629618|NCT04947787|BEHAVIORAL|Physical activity referral scheme (PARS)|Participants of the intervention group will receive brief physician advice and be referred to an exercise professional (e.g., physiotherapist, sports therapist) for a more intensive counseling intervention. The counseling intervention consists of an initial assessment, individual physical activity counseling (360'), a final assessment after 12 weeks, and a follow-up assessment after 24 weeks.
48285033|NCT03025581|OTHER|Nipple stimulation|For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
47939280|NCT00882700|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
47939281|NCT00882700|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
47939282|NCT04797897|DEVICE|CORI|unicondylar knee arthroplasty (UKA) treated with CORI
48285034|NCT02058381|DRUG|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
48285035|NCT02058381|DRUG|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
47939283|NCT04797897|DEVICE|Conventional|unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
48101171|NCT05457361|DRUG|VEN combined with azacitidine plus homoharringtonine|VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
48101172|NCT05457361|DRUG|VEN combined with azacitidine|The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
47939284|NCT00336180|BEHAVIORAL|HealthWise South Africa curriculum|18 classroom lessons
47939285|NCT01487473|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
47939286|NCT02663583|BEHAVIORAL|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
47939287|NCT02663583|BEHAVIORAL|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
47939288|NCT02663583|BEHAVIORAL|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
47939289|NCT05838235|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program will consist of a Personalized Training Program
47939290|NCT00145678|BEHAVIORAL|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
47939291|NCT00145678|BEHAVIORAL|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
48101173|NCT00731107|PROCEDURE|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
48101174|NCT00731107|PROCEDURE|laparoscopic surgery|Veress Needle laparoscopic entry
48101175|NCT06630442|OTHER|Educational Intervention|Attend a food safety educational training program
48285036|NCT02651610|BIOLOGICAL|Bavituximab|Biological: bavituximab
48285037|NCT02651610|DRUG|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
48285038|NCT01636037|DRUG|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
47939292|NCT00002178|DRUG|Ritonavir|
47939293|NCT00002178|DRUG|Nelfinavir mesylate|
47939294|NCT00002178|DRUG|Saquinavir|
47939295|NCT00002178|DRUG|Delavirdine mesylate|
47939296|NCT02961218|DRUG|ACZ885|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
47939297|NCT02961218|DRUG|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
47939298|NCT00107926|DRUG|Licarbazepine|
47939299|NCT00107926|DRUG|Placebo|
48101176|NCT06630442|OTHER|Questionnaire Administration|Ancillary studies
48101177|NCT06627205|BEHAVIORAL|Sleep Restriction Therapy|Therapist led sleep restriction therapy sessions.
48101178|NCT01954940|DEVICE|Whole Body Vibration Therapy|
48101179|NCT06631950|OTHER|Educational intervention|The educational intervention group will be provided with information that should allow them to correctly answer questions on fecundity knowledge and fecundity risks factors. The fecundity information will be provided through a short animated educational video (3 minutes) that will be sent out digitally. The control group is not receiving such information.
48101180|NCT02455687|DRUG|Hi-dose iv MgSO4|
48101181|NCT02455687|DRUG|Nebulized budesonide|
48101182|NCT02455687|DRUG|Std-dose iv MgSO4|
48101183|NCT02455687|DRUG|Nebulized normal saline|
48101184|NCT06494124|DEVICE|transcranial Alternating current stimulation (tACS)|It is a non-invasive brain stimulation technique that uses small, pulsed alternating current (1mA) to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
48471290|NCT06678464|OTHER|Moiz XL|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
48471291|NCT06678464|OTHER|Moiz LMF 48|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day or as often as needed Route of Administration: Topical"
48285039|NCT05523492|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|All clients will receive the Culturally Enhanced Wellbeing Course. The Course was originally developed at Macquarie University in Australia and was then culturally enhanced by the Online Therapy Unit in Saskatchewan Canada. The course is a trans-diagnostic Internet-delivered cognitive behaviour therapy intervention targeting symptoms of depression and anxiety. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in order over 8 weeks. Therapists will spend \~15 mins. per week/per client offering support via emails and or phone calls.
48285040|NCT05095389|DEVICE|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
48285041|NCT05095389|OTHER|standard care|standard care
48285042|NCT05095389|OTHER|Placebo|placebo
48285043|NCT05957874|OTHER|Combined package program|"Combined package program content:~* Training: A one-week sleep hygiene training will be given to the experimental group. The training will take an average of 30 minutes for three consecutive days and a training booklet will be provided. In addition, two posters will be prepared to hang in the classroom. In one of the posters, a sleep hygiene rule will be placed at each hour using the clock order. In the other poster, good and bad sleep habits will be placed in the form of do-do.~* Task Flower: Tasks that will facilitate the transition to weekly sleep will be given to the children of the experimental group. Tasks are applications to be done within 30-60 minutes before going to bed. After the tasks, the children will perform their daily sleep routine and go to sleep.~* Notifications: As part of using technology positively, reminders will be sent to families every day for two weeks via a social media tool. These warnings will include sleep hygiene principles."
48285044|NCT00565630|DEVICE|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
48471292|NCT05705973|DEVICE|Ultimaster Nagomi™|The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter
48471293|NCT05853783|OTHER|STRATICYTE™ Test|Assessment for risk of progression to oral cancer
48471294|NCT06613334|BIOLOGICAL|Blood test: measurement of plasma antipsychotic concentration|Four blood tests are prospectively realized per patient during the study to measure the plasma concentration of antipsychotics (primary treatment: risperidone/paliperidone, olanzapine or aripiprazole). These blood samples are taken at the inclusion visit, at the follow-up visits 2 and 4 months after the inclusion visit, then at the end-of-study visit 6 months after the inclusion visit.
48471295|NCT06613334|OTHER|Voice interviews and questionnaires carried out via the CALLYOPE application|"Voice interviews carried out via the Callyope application: they consist of a series of tests, divided into two parts: Structured tasks (same content for each participant) and Semi-structured tasks (content varies for each participant).~The simultaneous analysis of several speech tasks allows us to break down the different stages of speech production and the important factors that influence its achievement.~In addition, patients will complete self-questionnaires via the application. Finally, lifestyle habits (sleep duration and number of steps) will be recorded via the application.~These different tests will be carried out on the application at the inclusion visit (M0), then every month (M1, M2, M3, M4, M5) until the end of study visit (M6)."
47939300|NCT01606254|DRUG|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
48471296|NCT04429867|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
48471297|NCT04429867|DRUG|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
47939301|NCT06417073|BEHAVIORAL|Face-To-Face Task-orianted Training|In this study, face-to-face task-oriented station training is provided by trained occupational therapists to elderly nursing home residents. Each session involves structured activities that simulate real-world challenges designed to improve cognitive and hand functions. These include exercises to enhance fine motor skills, hand strength, coordination, and cognitive tasks such as problem-solving and memory exercises.
47939302|NCT06417073|BEHAVIORAL|Tele-Rehabilitation Task-orianted Training|This intervention utilizes video-conferencing technology to deliver task-oriented training to elderly nursing home residents, focusing on cognitive and hand function improvements.
47939303|NCT06417073|BEHAVIORAL|Home-based Task-orianted Training|"Home-Based Task-Oriented Training Intervention Description:~This home-based intervention involves a series of task-oriented activities specifically designed to improve cognitive and hand functions for elderly residents in nursing homes. Participants carry out prescribed activities independently, based on detailed guides provided by occupational therapists. The activities are tailored to stimulate cognitive processes and enhance fine motor skills, including tasks like sorting, assembling, and manipulative exercises that replicate daily challenges. Each participant follows a structured program of daily 45-minute sessions for two weeks, with periodic remote check-ins by therapists to assess progress and adjust the difficulty of tasks as needed. This format allows participants to engage in rehabilitation at their own pace, within the comfort of their own living spaces, fostering greater autonomy and adherence to the intervention."
48101185|NCT06494124|DEVICE|transcranial Direct current stimulation (tDCS)|It is a non-invasive brain stimulation technique that uses constant, low direct current to modulate lasting cortical excitability, producing facilitatory or inhibitory effects upon a variety of behaviours, with proven efficacy in various neuropsychiatric disorders.
48101186|NCT06494124|DEVICE|Sham controlled|1mA current will be applied for the first 30 seconds to provide the initial sensation of real stimulation, and then the current will be stopped, thus minimizing the stimulatory effects. It is known to have no effect on psychopathology/neuro-cognition and means to mimic the tDCS/tACS (in order to help blinding of the participants).
48101187|NCT04936789|DEVICE|IMES|Surgical implantation of IMES
48285045|NCT05187117|BEHAVIORAL|CAPABLE Family - Open Label Pilot|"As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations for cognitive decline will be made on a per-client basis as part of the open-label pilot. Topics of adaptations include problem areas addresses, care partner involvement, length/frequency of visits, types of assessments and questions asked, and brainstorming/action planning structure."
48285046|NCT05187117|BEHAVIORAL|CAPABLE Family - Randomized Control Trial|As in CAPABLE (NA_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
48285047|NCT02610283|DRUG|QPI-1002|IV injection
48285048|NCT02610283|DRUG|Placebo|isotonic saline
48285049|NCT03995771|OTHER|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
48285050|NCT00467844|DRUG|GTx-024|1 mg GTx 024
48285051|NCT00467844|DRUG|GTx-024|3 mg GTx-024
48285052|NCT00467844|DRUG|Placebo|Matching Placebo
48285053|NCT02923271|DEVICE|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
48285054|NCT00811629|OTHER|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
48285055|NCT01363050|DRUG|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
48285056|NCT01412242|OTHER|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
48285057|NCT05401071|OTHER|Short Regimen with Rifapentine 10mg/kg|rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
47939304|NCT00898378|GENETIC|gene expression analysis|gene expression analysis
48101188|NCT05775094|DRUG|Romosozumab|Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
48471298|NCT06630611|BIOLOGICAL|NMA-LD regimen|The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.
48471299|NCT06630611|BIOLOGICAL|Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion|On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.
48471300|NCT06630611|BIOLOGICAL|High dose IL-2|"Only for patients in Arm A.~IL-2 begins between 3 and 24 hours after the completion of the TIL infusion and is given as a bolus administration every eight hours (minimum interval) to 24 hours (maximum interval) with a maximum of six doses from the beginning of each administration."
48285058|NCT05401071|COMBINATION_PRODUCT|Standardized Regimen|"During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, \>71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, \>71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, \>71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, \>71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, \>50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally."
48285059|NCT05401071|OTHER|Short Regimen with Rifapentine 15mg/kg|rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
48285060|NCT05401071|OTHER|Short Regimen with Rifapentine 20mg/kg|rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
48471301|NCT06630611|BIOLOGICAL|IL-2 analog|"Only for patients in Arm B~ANV419 will be administered between 3 and 24 hours after the completion of the TIL infusion with a slow IV infusion over 15-30 minutes + 5 minutes once, at 243µg/kg."
48471302|NCT04998812|DRUG|Ocrelizumab|Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
48471303|NCT05294367|DRUG|Magnesium Chloride-based Lotion|Given topically
48471304|NCT05294367|OTHER|Quality-of-Life Assessment|Ancillary studies
48629619|NCT04947787|BEHAVIORAL|Physical activity advice (PAA)|Participants of the control group will only receive brief physician advice regarding the promotion of physical activity and as an information sheet with tips on how to adopt a more physically active lifestyle.
47939305|NCT00898378|GENETIC|polymerase chain reaction|polymerase chain reaction
47939306|NCT00898378|GENETIC|polymorphism analysis|polymorphism analysis
48101189|NCT04895566|BIOLOGICAL|Monoclonal antibody (Mab) sB24M|200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
48285061|NCT03247400|DRUG|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
48285062|NCT03247400|DRUG|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
48471305|NCT05294367|BEHAVIORAL|Special Diet Therapy|Consume magnesium rich foods
48285063|NCT05651646|OTHER|Intervention Arm (STIMFIX)|This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
47939307|NCT00898378|GENETIC|protein expression analysis|protein expression analysis
47939308|NCT00898378|GENETIC|proteomic profiling|proteomic profiling
47939309|NCT00898378|OTHER|gas chromatography|gas chromatography
47939310|NCT00898378|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
47939311|NCT00898378|OTHER|liquid chromatography|liquid chromatography
47939312|NCT00898378|OTHER|mass spectrometry|mass spectrometry
47939313|NCT00898378|OTHER|questionnaire administration|questionnaire administration
47939314|NCT03804034|DEVICE|Block of resin|
47939315|NCT03804034|DEVICE|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
48101190|NCT06629714|OTHER|Exposure: emotional distress status|The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.
47939316|NCT03395054|OTHER|cervical stabilization exercises|cervical stabilization exercises
48101191|NCT05714033|PROCEDURE|Ventilatory Strategy To Prevent Atelectasis|Given
48101192|NCT05714033|PROCEDURE|Lateral Decubitus Strategy (LADS)|Given
48101193|NCT06058182|DIAGNOSTIC_TEST|blood draws|Pre-procedure, post-procedure (12-24 h), 6-month, and 12-month blood draws
48101194|NCT02175537|BEHAVIORAL|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
48101195|NCT00452465|BEHAVIORAL|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
48101196|NCT05627557|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
48285064|NCT00094120|DRUG|MSI-1256F (Squalamine Lactate)|
47939317|NCT03395054|OTHER|conventional exercises|conventional exercises
47939318|NCT00436930|BIOLOGICAL|autologous tumor cell vaccine|Given subcutaneously
47939319|NCT00436930|BIOLOGICAL|sargramostim|Given subcutaneously
47939320|NCT00436930|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously
47939321|NCT01328171|DRUG|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
48285065|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
47939322|NCT01328171|DRUG|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
47939323|NCT00083096|DRUG|lonafarnib|
47939324|NCT00083096|DRUG|temozolomide|
47939325|NCT05022875|DEVICE|Healthcare CEO app- for experimental app intervention|The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q\&A
47939326|NCT05022875|DEVICE|Healthcare CEO app-for control app intervention|consists of 2 interfaces: CEO's profile, Health Tracking.
47939327|NCT04246255|DRUG|Xylocaine 10% Oral|"50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
47939328|NCT04246255|DRUG|Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul|"50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted."
47939329|NCT04758845|DIETARY_SUPPLEMENT|Cocktail|Subjects will consume 2B CFU once daily containing .5B CFU DE111, .5B CFU MIT411, .5B CFU CGI314, and .5B CFU CSI08 for 45 days.
47939330|NCT04758845|DIETARY_SUPPLEMENT|CGI314|Subjects will consume 1B CFU of CGI314 once daily for 45 days.
47939331|NCT04758845|DIETARY_SUPPLEMENT|CSI08|Subjects will consume 1B CFU of CSI08 once daily for 45 days.
47939332|NCT04758845|DIETARY_SUPPLEMENT|MIT411|Subjects will consume 1B CFU of MIT411 once daily for 45 days.
47939333|NCT00213408|PROCEDURE|Radiofrequency catheter ablation of typical atrial flutter|
47939334|NCT05581875|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
48101197|NCT05627557|DRUG|MMF|MMF will be administered as per schedule specified in the respective arm.
48101198|NCT05627557|DRUG|Prednisone|Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
48101199|NCT05627557|DRUG|Methylprednisolone|Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
47939335|NCT05581875|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
48471306|NCT06512519|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 ), cyclophosphamide (1g/m2/day, days -5 to -4)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)"
48629620|NCT04107363|PROCEDURE|Oropharyngeal aspiration before changing the position of the patient|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes. After the oropharyngeal aspiration was completed, the patient's position was changed."
48629621|NCT04107363|OTHER|Control group:|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
48629622|NCT02237274|OTHER|High altitude exposition|High altitude exposition
47939336|NCT05581875|DRUG|Pomalidomide|Pomalidomide will be administered per os.
47939337|NCT05581875|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
47939338|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
48471307|NCT06248151|BEHAVIORAL|Exercise session|Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups
48285066|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
48285067|NCT04884087|BEHAVIORAL|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
48471308|NCT06248151|BEHAVIORAL|Control session|Remain seated for 60 min
48471309|NCT05465096|PROCEDURE|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
48471310|NCT00212433|DRUG|Tagitol V, Lo So, Readi-Cat 2|
48471311|NCT01628549|DRUG|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
48471312|NCT01628549|DRUG|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
48471313|NCT01628549|DRUG|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
48471314|NCT05825768|DEVICE|Breast MRI|Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.
48471315|NCT05825768|DIAGNOSTIC_TEST|standard breast imaging|The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
48471316|NCT00263887|DRUG|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
48471317|NCT00263887|DRUG|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
48471318|NCT05318755|DRUG|GAHT for transgender men|Testosterone undecanoate
48471319|NCT05318755|DRUG|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
48471320|NCT06137807|DEVICE|TricValve® Transcatheter Bicaval Valve System|The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
48285068|NCT04884087|BEHAVIORAL|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
48285069|NCT03851861|OTHER|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
48471321|NCT06291090|BEHAVIORAL|OUD treatment intervention|Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
48471322|NCT05347394|DRUG|VX-708|Solution or suspension for oral administration.
48471323|NCT05347394|DRUG|Placebo|Placebo matched to VX-708 for oral administration.
48471324|NCT03710707|DRUG|DNL201|Oral repeating dose
48471325|NCT03710707|DRUG|Placebo|Oral repeating dose
48471326|NCT00198354|DRUG|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
48471327|NCT00198354|DRUG|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
48471328|NCT01866176|DEVICE|Stabilizing Knee Brace|Brace with no valgus action
48471329|NCT01866176|DEVICE|Valgus Knee Brace|Valgus brace with traditional three point bending system
48471330|NCT01866176|DEVICE|New Knee Brace|Brace with new mechanism to decrease the knee loading.
48471331|NCT03676790|OTHER|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
47939339|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
47939340|NCT02821910|DRUG|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
47939341|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
47939342|NCT02821910|DRUG|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
47939343|NCT02821910|DRUG|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
47939344|NCT00597337|BEHAVIORAL|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
48101200|NCT05627557|DRUG|Acetaminophen/ Paracetamol|Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
48101201|NCT05627557|DRUG|Diphenhydramine Hydrochloride|Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
48471332|NCT03676790|OTHER|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
48629623|NCT05210946|DRUG|Pemigatinib|"Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0."
48629624|NCT06024265|DRUG|ER2001 injection|The minimum initial dose is 0.04mg/kg, then escalate to 0.08mg/kg, 0.16mg/kg and 0.32mg/kg. The planned duration of the treatment is 14 weeks, and ER2001 will be administrated intravenously at the first day of weeks 1, 3, 4, 5, 6, 7, 8, and 14.
48629625|NCT02855983|PROCEDURE|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
48629626|NCT05615441|DEVICE|Analgesia Nociception Index monitor|Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor
47939345|NCT02640040|DEVICE|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
47939346|NCT02640040|DEVICE|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
47939347|NCT02640040|PROCEDURE|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
47939348|NCT05050682|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
48101202|NCT06628505|OTHER|Speech in Noise Training|The active controls will receive frequency discrimination training that uses the same visual landscape and basic task of controlling the wisp based on judgments about acoustic cues. The task requires participants to avoid obstacles by swiping upward or downward on the touchscreen to indicate whether a test frequency associated with the obstacle was higher or lower, respectively, than a target sound presented slightly before the test sound.
48106979|NCT06485427|PROCEDURE|Selective Intra-arterial Cooling Infusion (IA-SCI)|"Pre-recanalization: During the procedure, the micro-catheter is advanced over a micro-guide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4 ℃) is infused intro into the ischemic territory at a rate of 10 mL/min via the micro-catheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~Post-recanalization: After recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL/min for 10 min, repeated twice with a 10-minute interval between infusions."
48629627|NCT05615441|DEVICE|Standard monitoring|Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring
47939349|NCT05049733|DRUG|CBD 1mg/Kg|Participants will ingest soft gel tablets containing CBD 1mg/Kg
47939350|NCT05049733|DRUG|CBD 2mg/Kg|Participants will ingest soft gel tablets containing CBD 2mg/Kg
47939351|NCT05049733|DRUG|CBD 4mg/Kg|Participants will ingest soft gel tablets containing CBD 4mg/Kg
47939352|NCT05049733|DRUG|Placebo CBD|Participants will ingest soft gel tablets containing placebo for CBD
47939353|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
47939354|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
47939355|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
47939356|NCT01269788|DRUG|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
47939357|NCT01269788|DRUG|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
47939358|NCT01269788|DRUG|placebo|oral , daily 30 mins before breakfast, for 6 weeks
48629628|NCT03684057|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
48629629|NCT06476249|OTHER|without|without
48629630|NCT06203795|OTHER|Anticoagulation dosing|Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
48471333|NCT03676790|OTHER|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
48285070|NCT05087186|BEHAVIORAL|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~* Sessions 1 and 2: Guided imagery~* Sessions 3 and 4: FLASH technique~* Session 5: Refresher on guided imagery and FLASH technique"
48285071|NCT00189358|DRUG|ZD1839|
48285072|NCT00189358|DRUG|tamoxifen|
48285073|NCT03465956|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
48285074|NCT03920605|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
48629631|NCT06203795|OTHER|Blood sampling|Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
48629632|NCT06203795|OTHER|Duration of the dialysis session|Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
48106980|NCT02370563|DRUG|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
48285075|NCT03920605|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
48285076|NCT03920605|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
48285077|NCT05460208|DIETARY_SUPPLEMENT|Enriched spread|The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
48285078|NCT05460208|DIETARY_SUPPLEMENT|Control spread|The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.
48285079|NCT03668132|OTHER|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
48285080|NCT02173600|BEHAVIORAL|Group-level Intensive dietary Counselling|
48285081|NCT02173600|BEHAVIORAL|Individual-level Intensive Dietary Counselling|
48285082|NCT00844883|DRUG|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
48285083|NCT00844883|PROCEDURE|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
48285084|NCT04029337|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
48285085|NCT05752266|DIETARY_SUPPLEMENT|AMILI Probiotic pills|AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
48285086|NCT05752266|DIETARY_SUPPLEMENT|Placebo pills|Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
48285087|NCT03501576|BIOLOGICAL|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
48285088|NCT05169671|DRUG|ATH-1020|ATH-1020 in oral capsule form
48617937|NCT06141005|DIAGNOSTIC_TEST|Ultrathin bronchoscopy with intratumoral washing|Each subject suspected or diagnosed of lung cancer will undergo bronchoscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
48285089|NCT05169671|DRUG|Placebo|Placebo in oral capsule form
47939359|NCT03176875|OTHER|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
47939360|NCT03176875|OTHER|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
48629633|NCT06203795|DEVICE|Choice of the hemodialyzer|Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
47939361|NCT04522908|DRUG|Cabozantinib Oral Tablet|Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
47939362|NCT00095927|DRUG|Amifostine|Given subcutaneously
47939363|NCT00095927|DRUG|Carboplatin|Given IV
47939364|NCT00095927|DRUG|Paclitaxel|Given IV
47939365|NCT00095927|RADIATION|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
47939366|NCT05530876|OTHER|Telerehabilitation with virtual game|It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
47939367|NCT01933789|BEHAVIORAL|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
47939368|NCT02351986|PROCEDURE|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
47939369|NCT02351986|OTHER|ice pack|
48285090|NCT01896232|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
48285091|NCT01896232|DRUG|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
48471334|NCT03676790|OTHER|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
47939370|NCT05022264|DIAGNOSTIC_TEST|RIA-VS|Measuring vital signs with a new contactless camera technique
47939371|NCT02912988|DRUG|Letrozole|Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
47939372|NCT02524977|BEHAVIORAL|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
47939373|NCT02524977|BEHAVIORAL|Educational Intervention Only|Educational conference series
47939374|NCT05805488|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
47939375|NCT05805488|DIETARY_SUPPLEMENT|TCI904 sachet|consume 1 sachet per day
47939376|NCT01552473|BEHAVIORAL|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
48106981|NCT00003656|BIOLOGICAL|recombinant interferon alfa|
48106982|NCT00003656|DRUG|tretinoin liposome|
48285092|NCT01896232|DRUG|Oral Placebo|Administered orally once a day.
48285093|NCT01896232|DRUG|Intravenous Placebo|Administered intravenously (IV) three times per week.
48285094|NCT04335825|PROCEDURE|phacotrabeculectomy|combined antiglaucoma procedure: trabeculectomy with phacoemulsification
48285095|NCT04335825|PROCEDURE|ExPress antiglaucoma surgery combined with phacoemulsification|combined antiglaucoma procedure: ExPress device implantation with phacoemulsification
48285096|NCT06178640|DRUG|Simvastatin 40 mg film-coated tablet|Simvastatin 40 mg film-coated tablet
48285097|NCT06178640|DRUG|Zocor 40 mg film-coated tablet|Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
48285098|NCT01962662|OTHER|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
48285099|NCT01962662|OTHER|U/E exercise|strengthening and stretching
48629634|NCT01006408|PROCEDURE|Low Level Laser|Low Level Laser twice a week for 8 weeks
48285100|NCT01609283|BIOLOGICAL|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~* Group 1: single intrathecal dose of 1 x 107 cells~* Group 2: single intrathecal dose of 5 x 107 cells~* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~* Group 4: single intrathecal dose of 1 x 108 cells~* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
48285101|NCT00202540|DRUG|S18986|
48285102|NCT01358383|DRUG|naproxen|250mg, oral dose
48285103|NCT01358383|DRUG|esomeprazole|20mg, oral dose
48285104|NCT02591615|DRUG|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
48285105|NCT02591615|DRUG|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
48629635|NCT01006408|PROCEDURE|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
48629636|NCT02500355|PROCEDURE|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
48629637|NCT02500355|PROCEDURE|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
48629638|NCT02500355|PROCEDURE|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
48629639|NCT02500355|DEVICE|endoscope or an arthroscopic device|
47939377|NCT01552473|BEHAVIORAL|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
47939378|NCT01957527|DEVICE|Peripheral arterial tonometry (EndoPAT)|
48106983|NCT00839046|BEHAVIORAL|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
48285106|NCT02591615|DRUG|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
48285107|NCT02591615|DRUG|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
48285108|NCT03250741|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
48285109|NCT03250741|OTHER|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
47939379|NCT01948310|DRUG|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
48629640|NCT04209842|DEVICE|gastric balloon|non surgical weight loss via placement of gastric balloon
48629641|NCT00882388|DRUG|aspirin|aspirin 100 mg qd for 7 days
48629642|NCT00882388|DRUG|celecoxib|celecoxib 200 mg bid \* 7 days
48629643|NCT00882388|DRUG|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
47939380|NCT01948310|BEHAVIORAL|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
48285110|NCT04992026|PROCEDURE|robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection|Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.
47939381|NCT01948310|DRUG|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
47939382|NCT04733443|DEVICE|Biolimus|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the Biolimus treatment group
47939383|NCT04733443|DEVICE|SeQuent® Please Neo|140 patients who met the inclusion/exclusion criteria for in-stent restenosis were enrolled and assigned to the SeQuent® Please Neo treatment group
47939384|NCT05671328|OTHER|Biological examinations performed on blood and BAL|Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL
48629644|NCT00882388|DRUG|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
48629645|NCT00882388|DRUG|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
48629646|NCT02119000|DRUG|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
48629647|NCT02119000|DRUG|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
48285111|NCT04992026|DRUG|1.Abiraterone Acetate Tablets|1000mg(4 tablets, 250mg per tablet) daily for 6 cycles
47939385|NCT00000832|BIOLOGICAL|MF59|
47939386|NCT00000832|BIOLOGICAL|rgp120/HIV-1 SF-2|
47939387|NCT03889171|BEHAVIORAL|Behaviour|Comparison to psychological, medical and emotional Influencing communication and achievement factors to Oncogenetics tests
48101203|NCT06628505|OTHER|Spatial Hearing Training Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are given feedback about how their perceived location related to the actual sound location."
48285112|NCT04992026|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets
48285113|NCT04992026|DRUG|Luteinizing Hormone-Releasing Hormone Analog|Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.
48285114|NCT03604666|OTHER|Health care process with Nurse Navigator|"A Nurse Navigator will:~* Be present at the announcement consultation~* Give information on the outpatient circuit~* Offer assistance for patients over 75 years~* Complete onco-geriatric orientation questionnaires~* Take care of patients on the ambulatory circuit"
48285115|NCT00390832|DRUG|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
48285116|NCT00390832|OTHER|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
47939388|NCT02537574|DRUG|NTX/BUP|Daily doses
47939389|NCT02537574|DRUG|NTX/PBO-B|Daily doses
47939390|NCT02537574|DRUG|PBO-N/PBO-B|Daily doses
48629648|NCT03290729|PROCEDURE|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
48629649|NCT02216851|DEVICE|Restylane Perlane|Intradermal injection
48629650|NCT04145271|DEVICE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
47939391|NCT05783986|OTHER|randomly divided|500 patients of our hospital were randomly divided into testing group and internal validation group, and 100 patients in collabrative hospital were external validation group.
47939392|NCT05592834|BEHAVIORAL|positive deviance hearth strategy|"The PD-program is run for 3-months with 2 weeks (12 days) of nutrition education and rehabilitation sessions (NERS) conducted in each month. Each day session includes an half hour education session and a one and half hour peer led cooking session. Caretakers learn how to rehabilitate their malnourished children under the supervision and the support of caregivers who have well-nourished children (positive deviants). Children are nutritionally assessed by trained nutrition assistants or clinician on the 1st day of the NERS sessions and after three months.~During the rehabilitation sessions, caregivers learn how to prepare nutrient-rich meals for their children from locally available food identified during the positive deviance-inquiry, and actively practice good feeding and hygiene practices. Caregivers together prepare food menus based on the PD-inquiry good foods or what they can conveniently access but of equal nutritional value."
48471335|NCT03676790|OTHER|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~* 10 minutes warming-up (treadmill, ergometer bike or rowing machine);~* 30 minutes 2-3 sets with P-1, P-2 or P-3;~* 5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
48471336|NCT02318550|OTHER|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~* Normal operating mode~* SAR ≤ 2.0 W/kg per patient."
48471337|NCT05959616|BIOLOGICAL|Shigella sonnei 53G|Lyophilized S. sonnei 53G strain (Lot 1794)
48471338|NCT05959616|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin (500 mg orally twice daily for three days),
48471339|NCT03933267|OTHER|Cervical sensorimotor control training exercises|"Cervical sensory motor training exercises consisting of cervical position sense and cervical movement sense exercises with 3 levels of difficulty and 5 repetitions \* 3 sets for each exercise will be given. Some exercises are:~Head relocation with laser feedback:~head relocation to neutral and predetermined position with eyes opened (in horizontal / vertical direction) (5 reps x 3 sets) Head relocation to neutral, predetermined and to specific targets with eyes opened (in diagonal directions) (5 reps x 3 sets) Head relocation to neutral and predetermined position with eyes closed (in all directions)(5 reps x 3 sets) In addition to it conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility."
48471340|NCT03933267|OTHER|Conventional Exercises|conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility exercises will be given to patients.
48471341|NCT00602615|DRUG|Torsemide|
48471342|NCT06030544|DIETARY_SUPPLEMENT|OA-enriched functional olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a functional olive oil enriched in Oleanolic acid (equivalent dose 30 mg/day OA) Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494).
48471343|NCT06030544|DIETARY_SUPPLEMENT|commercial olive oil|Dietary intervention in diabetic patients. Oral intake of 55 mL/day of a commercial olive oil (blend of virgin and refined olive oils) chosen by its very low content of bioactive minor components.
48471344|NCT02519543|DRUG|Placebo|Placebo to be given twice daily, once with breakfast and once with supper
48471345|NCT02519543|DRUG|Metformin|Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
48471346|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
48471347|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
48106984|NCT00839046|OTHER|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
48285117|NCT03665155|DRUG|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
48629651|NCT04797728|DRUG|Elacestrant|Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
48471348|NCT02625376|DIETARY_SUPPLEMENT|Resvega|Dietary supplementation with Resvega BD
48471349|NCT02625376|DIETARY_SUPPLEMENT|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
48471350|NCT02625376|DIETARY_SUPPLEMENT|placebo|Dietary supplementation with a placebo BD
48471351|NCT03111667|BEHAVIORAL|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
48471352|NCT03111667|OTHER|Treatment as Usual|Referral to community resources
48471353|NCT03111667|BEHAVIORAL|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
48285118|NCT03665155|DEVICE|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
48471354|NCT03111667|BEHAVIORAL|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
48471355|NCT00691041|BEHAVIORAL|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
48471356|NCT00571480|OTHER|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
48471357|NCT00571480|OTHER|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
47939393|NCT05592834|BEHAVIORAL|Parent facilitator trainings|Primary caregivers of children with CP residing in the study setting are trained as parent facilitators by expert physical rehabilitation therapist . Trained parent facilitators then hold fellow caregiver workshops each lasting approximately two hours long and includes between 6-10 caregivers. To ensure quality and consistency of the workshops, the Parent Facilitators follow a detailed manual adapted from the Carer-2-Carer Programme translated into Lusoga, the local language. No expert therapists is involved in the parent facilitator training workshops. Parent facilitator training workshops involve 7 sessions that expose caregivers to understanding CP and how to improve body functioning: session1: what is CP? session2: CP as a way of life, Session 3: Getting my child's body ready to move, Session 4: Eating and drinking a healthy diet, Session 5: communication, Session 6: Play, and Session 7: Central visual impairment.
48471358|NCT00571480|OTHER|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
48471359|NCT00409461|DRUG|ATG-Sirolimus-Tacrolimus|
48471360|NCT02299687|DRUG|Omeprazole|
48285119|NCT03665155|OTHER|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
48285120|NCT01096667|DRUG|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
48285121|NCT01096667|DRUG|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
48285122|NCT01096667|DRUG|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
48285123|NCT01096667|DRUG|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
48471361|NCT06533072|OTHER|The group receiving infrared LED therapy|Patients in this group are the ones who will be exposed to IR LED light therapy, three times in total
48471362|NCT05694260|DRUG|Bempedoic acid|Once daily oral dosing with oral tablets or oral suspension.
48285124|NCT01096667|DRUG|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
48471363|NCT04086160|DEVICE|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
48471364|NCT05979441|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
48471365|NCT01999088|OTHER|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
48471366|NCT01999088|OTHER|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
48471367|NCT05063539|DRUG|LY3372689|given orally
48471368|NCT05063539|DRUG|LY3372689|given orally
48471369|NCT05063539|DRUG|Placebo|given orally
48471370|NCT06369610|DRUG|Abiraterone Acetate|Given abiraterone acetate
47939394|NCT05592834|OTHER|Control|This group will receive neither the PD nor the PFT interventions but care as usual
47939395|NCT05788978|OTHER|Scale development|Scale development
47939396|NCT02723253|RADIATION|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement \> 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
47939397|NCT02723253|DRUG|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
47939398|NCT05222490|DEVICE|Thermal Camera images acquisition - FeetSee|Thermal images will be collected according to the instructions for use of the Feetsee device.
47939399|NCT05222490|DEVICE|Thermal Camera images acquisition - Reference|After 15 minutes of resting, thermal images from the reference device will be collected according to their manufacturer
48285125|NCT01096667|DRUG|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
48471371|NCT06369610|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48471372|NCT06369610|PROCEDURE|Computed Tomography|Undergo CT
48471373|NCT06369610|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC or IM
48471374|NCT06369610|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48471375|NCT06369610|PROCEDURE|Positron Emission Tomography|Undergo PET
48471376|NCT06369610|OTHER|Questionnaire Administration|Ancillary studies
48471377|NCT06369610|RADIATION|Radiation Therapy|Undergo radiation therapy
47939400|NCT03149393|DRUG|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
47939401|NCT03149393|DRUG|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
47939402|NCT00198796|BIOLOGICAL|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
47939403|NCT03319290|GENETIC|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
47939404|NCT03241069|OTHER|Reference position|patient is put in a 30 degree supine position during 5 minutes
47939405|NCT03241069|OTHER|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
47939406|NCT03241069|OTHER|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
47939407|NCT03241069|OTHER|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.)
47939408|NCT02034422|DIETARY_SUPPLEMENT|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
47939409|NCT02034422|OTHER|Exercise rehabilitation|8 weeks of exercise rehabilitation
47939410|NCT05572190|DRUG|ETR028, ETR029, [ETR028 + ETR029] or HCBT|Hydrocodone prodrugs
47939411|NCT01962922|DRUG|LCP-Tacro|once-daily extended release tablet
47939412|NCT01962922|DRUG|Tacrolimus -IR|twice daily capsules
47939413|NCT02102360|DEVICE|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
47939414|NCT02102360|DEVICE|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
47939415|NCT00455910|DRUG|Thalidomide|
48285126|NCT01096667|DRUG|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
48471378|NCT04205838|BIOLOGICAL|Anakinra|Given SC
48471379|NCT04205838|BIOLOGICAL|Axicabtagene Ciloleucel|Given via infusion
47939416|NCT01661985|DRUG|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
47939417|NCT01661985|DRUG|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
47939418|NCT01661985|DRUG|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
47939419|NCT04975529|BEHAVIORAL|Game on Philly: Engaging Underserved Middle School Youth in Out-of- School Time Sports and Nutrition Education|Two-group quasi experimental intervention with schools assigned to intervention or comparison.
47939420|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for banking
47939421|NCT05770531|PROCEDURE|Computed Tomography|Undergo CT
47939422|NCT05770531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48285127|NCT04632199|DRUG|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
48285128|NCT04632199|DRUG|111In-IPN01087 High dose|Administered once via slow intravenous injection.
48471380|NCT04205838|DRUG|Cyclophosphamide|Given via infusion
48471381|NCT04205838|DRUG|Fludarabine|Given via infusion
48471382|NCT04205838|DRUG|Fludarabine Phosphate|Given via infusion
47939423|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for ctDNA evaluation
47939424|NCT05770531|BIOLOGICAL|Sacituzumab Govitecan|Given by IV
47939425|NCT04541160|DIAGNOSTIC_TEST|CR|Lung imaging evaluation performed with CR
47939426|NCT04541160|DIAGNOSTIC_TEST|ULDCT|Lung imaging evaluation performed with ULDCT
47939427|NCT06130306|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 45 minutes targeted the pudendal nerve, thrice weekly for a minimum of 8 weeks. The treatment plan remains ongoing until the patient opts to discontinue voluntarily.
48106985|NCT00839046|OTHER|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
48285129|NCT05417321|DRUG|HB0036|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
48285130|NCT02334267|DEVICE|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
48471383|NCT05715307|OTHER|Intensive training for endocrinologists in T2DM management|"One-week intensive experiential training for endocrinologists includes a 1-week hospitalization experience at Ruijin Hospital, involving health examinations, results interpretation, and integrated training courses for T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and participate in regular training sessions, including experience-sharing meetings."
47939428|NCT06130306|PROCEDURE|pelvic floor muscle training combined with transanal electrical stimulation|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system \[AM1000B; Shenzhen Creative Industry Co. Ltd, China\]) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB 4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible to get a PFM contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients also conducted 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks. If the patient is willing, the treatment plan can continue until the patient voluntarily decides to stop.
47939429|NCT02856893|DRUG|Osimertinib|Osimertinib 60 or 40 mg daily until progression
47939430|NCT02856893|DRUG|Gefitinib|Gefitinib 250mg daily until progression
47939431|NCT00792831|DRUG|ITF2357|Histone-Deacetylase Inhibitor
47939432|NCT01796496|OTHER|Manipulative Therapy Techniques|"* Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~* Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~* Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
47939433|NCT01796496|OTHER|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
48101204|NCT06628505|OTHER|Spatial Hearing Control Group|"Stimulus presentation and response measurement (Aim 2): Acoustic stimuli will be presented with a 360° speaker array that are fixed in place behind an opaque, nearly sound transparent, acoustic fabric curtain to avoid visual influences. Manual responses will be collected using a keyboard. Custom Matlab scripts control all relevant variables with millisecond precision. A webcam monitors the participant (not recorded) for the sole purpose of making sure the participant is always facing straight ahead.~Sound localization task and training: Participants will judge the location of a target white noise sound (1000 ms, 70 dB SLP, 10-10,000 Hz) by moving an auditory pointer that appears 2 seconds after the offset of the target sound.~The training group are NOT given feedback about how their perceived location related to the actual sound location."
48101205|NCT01609894|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
48101206|NCT01609894|DIETARY_SUPPLEMENT|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
48101207|NCT01760291|DEVICE|WATCHMAN LAA Closure Technology|
48101208|NCT05961670|DEVICE|Neer Infrared Spectroscopy|Premature infants will be studied with brain and lung NIRS before and after surfactant administration
48101209|NCT01211665|DRUG|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
48101210|NCT01211665|DRUG|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
48101211|NCT04301674|DEVICE|Breath Biopsy|ReCIVA breath sampler (Owlstone Medical, Cambridge, UK)
48101212|NCT04241653|PROCEDURE|Pressure Support Ventilation|Ventilator will be adjusted to administer pressure at 10 cmH2O.
48101213|NCT04241653|PROCEDURE|Unparalyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography.
48285131|NCT02334267|DEVICE|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
48285132|NCT03771872|DEVICE|Virtual Prism Adaptation Therapy|Hand trajectory will deviate to the right side in the virtual reality.
48285133|NCT03771872|DEVICE|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
48471384|NCT05715307|OTHER|Regular training for endocrinologists in T2DM management|"Regular training and communication are implemented by Ruijin Hospital under the guidance of T2DM management.~During the patient intervention period, endocrinologists will each manage approximately 10 T2DM patients, conduct regular follow-ups, and receive regular routine training."
48471385|NCT06019117|DIETARY_SUPPLEMENT|Probiotic K10|clinical trial using 90 days of probiotic K10
48101214|NCT04241653|PROCEDURE|Paralyzed Pressure Control Ventilation|Pressure controlled ventilation mode will be applied to obtain a volume of 8 ml/kg up to 20 cmH2O. The set respiratory rate will be 15 breaths/min then it is adjusted to achieve the end tidal CO2 levels between 35 and 40 mmHg as measured by capnography. Also, neuromuscular blockade will be achieved.
48101215|NCT04241653|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation; its size is chosen according to the body weight of the child.
48285134|NCT05954754|OTHER|Diaphragmatic Breathing Exercises|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
48285135|NCT00826514|DRUG|Tanezumab|Intravenous, 20 mg, single dose.
48285136|NCT00826514|DRUG|Placebo|Intravenous placebo, single dose
48285137|NCT02750410|DRUG|Dulaglutide|Administered subcutaneously (SC)
48285138|NCT02750410|DRUG|Placebo|Administered SC
48471386|NCT06019117|DRUG|Placebo|clinical trial using 90 days of placebo controlled
47939434|NCT01082380|DRUG|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
48471387|NCT03129776|DRUG|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
48285139|NCT02991612|DRUG|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
48471388|NCT03129776|DRUG|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
48471389|NCT04556734|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily
48285140|NCT05068804|PROCEDURE|Cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
48471390|NCT04556734|DRUG|Etrasimod|Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
48471391|NCT04556734|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily
48471392|NCT00133679|DRUG|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
48471393|NCT00133679|DRUG|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
48471394|NCT03267654|DRUG|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
48471395|NCT03267654|DRUG|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
48471396|NCT03267654|DRUG|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
48471397|NCT02077621|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
48471398|NCT02077621|DRUG|Placebo|500 mL normal saline
48471399|NCT03816436|OTHER|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
48471400|NCT00114595|DRUG|eicosapentaenoic acid|
48471401|NCT02458391|OTHER|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
48471402|NCT05824949|PROCEDURE|osseodensification drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.
48471403|NCT05824949|PROCEDURE|conventional drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
48471404|NCT01557920|DRUG|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
48471405|NCT01557920|DRUG|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
48617938|NCT02640560|OTHER|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
47939435|NCT02866487|PROCEDURE|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
47939436|NCT01949454|DRUG|Fluorometholone 0.1% ophthalmic solution|
47939437|NCT01949454|OTHER|Artificial tears (Placebo)|Artificial tears (Placebo)
47939438|NCT03257176|BEHAVIORAL|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
47939439|NCT01926665|DRUG|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
47939440|NCT01926665|DRUG|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
48101216|NCT04241653|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% will be titrated to achieve adequate depth of anesthesia to maintain immobilization of the eye.
48101217|NCT06632067|DRUG|sugammadex|sugammadex used for neuromuscular reversal
48101218|NCT06632067|DRUG|Neostigmine + Atropine|Neostigmine and Atropine used for neuromuscular reversal
48285141|NCT05068804|OTHER|control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
48285142|NCT01305369|DRUG|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
48285143|NCT06374810|BEHAVIORAL|Conscious Connected Breathwork|Participants were taught the Conscious Connected Breathwork Technique. 2 facilitators were monitoring and coaching the participants to ensure adherence to the technique
48285144|NCT06374810|OTHER|Placebo waitlist|Participants were told the study was full and that they were placed on a waiting list until the 1st cohort had completed the breathwork program
48285145|NCT00408681|DRUG|lithium carbonate|Given orally
48471406|NCT02277262|DEVICE|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
48471407|NCT02277262|PROCEDURE|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
48101219|NCT01536730|BEHAVIORAL|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
48101220|NCT05992064|OTHER|Measuring gait|"Measurements are performed by PA trackers. The measurements include:~* Lower limb 3D linear accelerations according to gait bouts collected and stored as time-series of linear accelerations with a frequency of 12.5 Hz.~* Details on the amount of time spent lying down, sitting, and standing, as well as the number of steps and sit-to-stands completed throughout the day. This information will be stored in 15-minute epochs and then summarized into daily summaries for analysis."
48101221|NCT04888585|DRUG|ABBV-154|Subcutaneous Injection
48285146|NCT00408681|OTHER|laboratory biomarker analysis|Correlative studies
48285147|NCT04267237|DRUG|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
48285148|NCT04267237|DRUG|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
48285149|NCT00186602|BEHAVIORAL|Peer counseling|
48101222|NCT04888585|DRUG|Placebo|Subcutaneous Injection
48285150|NCT06098014|DRUG|Thalidomide Capsules|To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
48285151|NCT06098014|DRUG|Placebo|compare with Thalidomide
48285152|NCT01137435|BIOLOGICAL|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
48471408|NCT01717040|DRUG|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
48285153|NCT03219125|DEVICE|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
48285154|NCT03219125|DEVICE|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
48285155|NCT05349461|PROCEDURE|Complete patellofemoral articular contact|The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
48285156|NCT05349461|PROCEDURE|Incomplete patellofemoral articular contact|The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
47939441|NCT04774120|DRUG|Propofol|Propofol will be started at a rate of 15-20 mg/kg/hr in patients \>65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
47939442|NCT03660488|DRUG|Cefixime 400 milligram Oral Capsule [Suprax]|The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
47939443|NCT03660488|DRUG|Benzathine Penicillin G|The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
47939444|NCT04113031|BEHAVIORAL|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (\~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
48471409|NCT01717040|DRUG|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
48471410|NCT01917084|OTHER|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
48471411|NCT05951751|OTHER|TRI-MOM intervention|"The TRI-MOM strategy includes 4 main activities:~1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)~2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests~3. Assessment and treatment of women positive for any of the 3 targeted infections~4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections"
47939448|NCT01931202|DRUG|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
47939449|NCT01931202|DRUG|Placebo oral tablet|Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
47939450|NCT01048281|PROCEDURE|Blood draw|
48285157|NCT03792009|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
48285158|NCT03792009|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
48285159|NCT03792009|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
48285160|NCT04713319|DRUG|Panavital|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
48471412|NCT04568577|OTHER|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
48471413|NCT04568577|OTHER|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
48471414|NCT04307381|DRUG|Donidalorsen|Donidalorsen administered SC
48471415|NCT03164187|DRUG|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
48471416|NCT05462717|DRUG|RMC-6291|Oral tablet once or twice a day
47939451|NCT01048281|PROCEDURE|Tissue tumor biopsy|
48285161|NCT04713319|OTHER|Placebo|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
48471417|NCT06679569|DRUG|rocuronium 0.2 mg/kg/hr continuous infusion|To maintain Train-of-four count 1 to 3 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.2 mg/kg/hr to achieve and sustain moderate neuromuscular blockade.
48471418|NCT06679569|DRUG|rocuronium 0.6 mg/kg/hr continuous infusion|To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
48471419|NCT03788369|PROCEDURE|Hybrid Coronary Revascularization|Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
48471420|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
48471421|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft|Transforaminal lumbar interbody fusion with local bone graft
48617939|NCT02640560|OTHER|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
48617940|NCT05991817|PROCEDURE|Surgery/general anesthesia|Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.
48285162|NCT04966221|DIAGNOSTIC_TEST|Lung MRI scan|Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
48285163|NCT03405103|BEHAVIORAL|Striving|
48285164|NCT03405103|BEHAVIORAL|Boning-Up|
48285165|NCT03405103|BEHAVIORAL|Personal Choice|
48285166|NCT04396457|DRUG|Pembrolizumab|Human PD-1 Monoclonal antibody
48101223|NCT05512949|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
48101224|NCT03795077|OTHER|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
48101225|NCT00409058|BEHAVIORAL|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
48101226|NCT06367413|DIETARY_SUPPLEMENT|Placebo|Participants will receive three servings of carbohydrate per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day).
48101227|NCT06367413|DIETARY_SUPPLEMENT|NAC|Participants will receive three servings of N-acetylcysteine per day during the 4-day experimental period. In specific, they will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day).
48285167|NCT04396457|DRUG|Pemetrexed|Antineoplastic antimetabolite
48285168|NCT04168086|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
48285169|NCT04168086|OTHER|Sham|The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
48285170|NCT04884243|DRUG|CBT-006|ophthalmic solution
48285171|NCT02332252|DEVICE|Scalpel|Skin incision performed with a scalpel during cesarean section.
48285172|NCT02332252|DEVICE|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
48285173|NCT02332252|PROCEDURE|Skin incision|
48285174|NCT00825071|DRUG|Dexamethasone|8 mg, Intravenous
48285175|NCT00825071|DRUG|Ondansetron|4 mg, intravenously
48285176|NCT00825071|DRUG|normal saline|2 ml, intravenously
48285177|NCT01554215|BEHAVIORAL|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
48285178|NCT01554215|BEHAVIORAL|Mom Power Attentional Control Group|at home control, weekly mailings
48285179|NCT03273621|PROCEDURE|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
48285180|NCT05059132|BEHAVIORAL|Tele-rehabilitation|The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
48285181|NCT05059132|OTHER|Education only|The education only arm will receive information on the importance of general exercise following lung cancer treatment.
48285182|NCT02509546|DRUG|8-Chloroadenosine|Given IV
48285183|NCT02509546|OTHER|Laboratory Biomarker Analysis|Correlative studies
48285184|NCT02509546|OTHER|Pharmacological Study|Correlative studies
48629652|NCT01305629|BEHAVIORAL|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
48471422|NCT01388998|OTHER|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
48471423|NCT04713982|DRUG|Deutetrabenazine|Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
48629653|NCT05178979|BEHAVIORAL|Training|This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
48629654|NCT00872157|DRUG|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
48285185|NCT05048472|DIAGNOSTIC_TEST|Abbott HIV-1/2 VL Point of care Device|Point of care viral load monitoring
48471424|NCT05940259|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
48471425|NCT04034654|OTHER|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
48471426|NCT02926170|DRUG|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
48471427|NCT02926170|DRUG|acenocumarol|Doses will be adjusted according to INR
48285186|NCT03359603|DEVICE|Electro-acupuncture|"Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments."
47939452|NCT06521840|DEVICE|Masimo RAD 67|This is an observational study of a non-invasive hemoglobin measurement device in a pregnant patient population. The current standard of care for anemia screening during pregnancy involves performing invasive venipuncture at two separate visits throughout the course of the pregnancy. The purpose of this research study is to compare the device performance with the gold standard hemoglobin measurement (venipuncture). The research team will use the Masimo Rad-67 handheld co-oximeter which has a reusable finger-tip sensor that enables spot-check monitoring measurements of both oxygen saturation and non-invasive hemoglobin measurement. At the time of a blood draw, the research team will place the pulse oximeter on the participant's finger. The devices requires 1-3 minutes for an accurate measurement. After the measurement is complete, the participant will be asked 2 questions on their satisfaction and comfortability with the device and 1 question regarding their skin tone.
47939453|NCT03624296|DEVICE|MRI 7T|MRI 7T
47939454|NCT03624296|OTHER|TEST EDSS|EDSS - Expanded Disability Status Scale
47939455|NCT03624296|OTHER|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
48471428|NCT01004445|DRUG|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
48101228|NCT06367413|DIETARY_SUPPLEMENT|NAC + Whey Protein|Participants will receive three servings of N-acetylcysteine + whey protein per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).
48101229|NCT01459549|PROCEDURE|Roux-en-Y choledochojejunostomy|Roux-en-Y choledochojejunostomy must be operated
48471429|NCT01004445|DRUG|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
48101231|NCT05555108|BEHAVIORAL|ACTCOM-I Intervention|ACTCOM-I s an individual treatment protocol based on Acceptance and Commitment Therapy (ACT) with targeted behavioral components for insomnia treatment and a specific focus on selfcompassion as a protector for sleep disturbance.
48101232|NCT05555108|BEHAVIORAL|Standard CBT-I Intervention|Standard CBT-I treatment for chronic insomnia. Treatment protocol adapted from Morin's protocol (1993)
48101233|NCT04859595|OTHER|Telephone follow-up|"Monthly follow-up by telephone from M1 to M6. The interview will unroll in 2 stages, a first stage of discussion during which the speech therapist will take news of the patient. The second, more formal phase will be the opportunity to collect the data necessary for the validation of the primary and secondary outcomes. To do this, the speech therapist will use the Functional Oral Intake Scale (FOIS) score, the DHI and an interview grid.~The interview will be conducted using an interview sheet previously written by the project team. The following elements will be discussed: the description of oral food intakes (TIMES), the perceived swallowing handicap (DHI), the instructions related to the diet and their daily application, ongoing rehabilitation follow-ups, notable events as well, then his emotional and psychological experience in relation to the disorder."
48101234|NCT00006413|PROCEDURE|Stem cell transplantation|
48101235|NCT00814281|OTHER|placebo|Placebo
48101236|NCT00814281|DRUG|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
48101237|NCT03152149|DRUG|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
48101238|NCT03152149|DRUG|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
48471430|NCT01004445|DRUG|Placebo|Two aerosol treatments per day (one treatment every 12hr)
47939456|NCT04873128|GENETIC|Multi-OMICS|Measurement of gene expression in immune cells (Human Peripheral Blood Mononuclear Cell (PBMCs) or total blood) using functional genomics, proteomics, metabolomics and lipidomics tools and compare the dynamics of immune response before and after vaccination against COVID-19.
47939457|NCT05571579|BIOLOGICAL|blood and/or csf collection|"blood and/or collection~Only once :~* 1 tube of blood of 4 mL on dry tube with or without gel,~* 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
47939458|NCT00095628|DRUG|ispinesib|Given IV
47939459|NCT00095628|OTHER|laboratory biomarker analysis|Correlative studies
47939460|NCT00095628|OTHER|pharmacological study|Correlative studies
48101239|NCT05765591|OTHER|Balneotherapy and aquatic exercises|Information has already been included in arm/group descriptions
48101240|NCT02242162|PROCEDURE|phrenic nerves magnetic stimulations|
48101241|NCT06408207|BEHAVIORAL|CGM Academy|Educational materials as well as online sessions with diabetes educators.
48285187|NCT02942498|DRUG|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
48471431|NCT01142661|DRUG|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
48471432|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gelatin capsule|Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
48471433|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene free form (PT)|Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
48471434|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule|Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).
47939461|NCT02902978|DRUG|E6130|
47939462|NCT02902978|DRUG|Placebo|E6130 matched placebo
48285188|NCT02942498|DRUG|Placebo|Placebo
48285189|NCT00004829|DRUG|tobramycin|
48285190|NCT04090723|BEHAVIORAL|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
47939463|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the experimental group will received functional electrical stimulation administered to surface electrodes attached to lower limb muscles (quadriceps, hamstrings, gluteus maximus and triceps). Electrical stimulation will be delivered appropriately to the muscle during cycling regarding the angle of the pedal by a stimulator (Motimove-8 de 3Fit Fabricando Faber).
47939464|NCT04841746|BEHAVIORAL|Physical therapy that include a standardized cycling training with no additional functional electrical stimulation|Immediately after the discharge of the intensive care unit, patient with a severe form of the COVID-19 will be admitted in the rehabilitation hospital. Rehabilitation will consist in physical therapy twice a day, 30 minutes, 5 days a week. One session will be dedicated to a standardized cycling training (TECHNOGYM RECLINE EXCITE 700). All participants will follow the same 4-week rehabilitation protocol representing a total of 1200 minutes. Participants randomized in the control group will received no additional functional electrical stimulation during cycling.
48471435|NCT06463119|OTHER|Collection of data in a registry|The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.
47939465|NCT01175837|OTHER|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
47939466|NCT01175837|OTHER|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
47939467|NCT01175837|OTHER|laboratory biomarker analysis|Correlative studies
48101242|NCT04550416|OTHER|ProMark Information and Test Results|Participants in the intervention arm will receive information (both print and webinar format) about ProMark in between Round 1 and Round 2 data collection, as well as appropriate ProMark test results for each of the vignette-based simulated patients that they care for in the second round of data collection.
48285191|NCT04655625|BIOLOGICAL|Group A (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 2-week intervals
48285192|NCT04655625|BIOLOGICAL|Group A (Placebo)|Placebo twice at 2-week intervals
48285193|NCT04655625|BIOLOGICAL|Group B (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 4-week intervals
48285194|NCT04655625|BIOLOGICAL|Group B (Placebo)|Placebo twice at 4-week intervals
48285195|NCT00217438|DRUG|melphalan|Given IV
48285196|NCT00217438|DRUG|amifostine trihydrate|Given IV
48285197|NCT00217438|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
48285198|NCT00217438|GENETIC|fluorescence in situ hybridization|Correlative study
48285199|NCT00217438|PROCEDURE|bone marrow ablation with stem cell support|Undergo transplant
48285200|NCT02721862|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
48285201|NCT02721862|DRUG|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
48285202|NCT02721862|RADIATION|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
48285203|NCT04400500|DIAGNOSTIC_TEST|Approaches to differential diagnosis and risk stratification|Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
48285204|NCT04411238|OTHER|interview|interview
48285205|NCT02596776|PROCEDURE|Fat biopsy|up to 16 biopsy samples will be taken from each subject
48471436|NCT04902911|DEVICE|COVID-19 SARS-CoV IgG/IgM antibody rapid test|Needle stick point of care and 3mL vial of blood will be collected and tested for individual without history of COVID-19 and immunization as well as a second group composed of individuals with history of COVID-19
47939468|NCT00929812|DRUG|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
47939469|NCT00929812|DRUG|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
47939470|NCT01915264|DRUG|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
47939471|NCT02721979|DRUG|Apalutamide|Given PO
47939472|NCT02721979|OTHER|Laboratory Biomarker Analysis|Correlative studies
47939473|NCT02721979|OTHER|Quality-of-Life Assessment|Ancillary studies
47939474|NCT02721979|OTHER|Questionnaire Administration|Ancillary studies
48471437|NCT04802213|OTHER|Rehabilitation exercise|Rehabilitation exercise use the methods that suggested by previous studies including finger wall climbing, pendulum exercise, and arms lifting.
48471438|NCT04802213|DEVICE|joint mobilization device treatment|The joint mobilization treatment used the mobilization device that developed in this research.It is a device developed by using the design of the vibration force generated by the vibration mechanism and the technologies to simulate the mobilization of the shoulder joint.When the subject uses the device, first sit on a seat that can be adjusted according to the user's body shape and buckle the shoulder fixation device. Then use the specially designed shoulder movement setting mechanism of the device to set the user's shoulder movement and movement angle.The next step is to set the direction and magnitude of the vibration force applied by the device to the shoulder joint in accordance with the joint mobilization technique (posterior, anterior, and inferior) that the therapist or user intends to perform to achieve the effect of simulating joint mobilization and increasing joint mobility.
48629655|NCT03423693|OTHER|No any intervention|No any intervention is applied to any groups in this study
48101243|NCT05312541|PROCEDURE|pre emptive local anaesthetic wound infiltration|Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
48101244|NCT04160689|BIOLOGICAL|implantology|placing of implant
48101245|NCT00744250|DRUG|Pancrelipase|PANCRECARB MS-16
48629656|NCT02326090|DRUG|cis-UCA ophthalmic solution 1.0%|
48629657|NCT02326090|DRUG|cis-UCA ophthalmic solution 2.5%|
48629658|NCT02326090|DRUG|Placebo ophthalmic solution|
48629659|NCT02802085|DEVICE|VEGA Knee|TKA
48101246|NCT00821925|PROCEDURE|bone densitometry|All patients do a bone densitometry after the inclusion.
47939475|NCT03704701|DIAGNOSTIC_TEST|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
47939476|NCT00170963|DRUG|valsartan/amlodipine|
47939477|NCT05522387|DRUG|XPro1595|Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
48101247|NCT03095911|OTHER|News items with spin|Interpretation of news items with spin
47939478|NCT03961854|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
47939479|NCT03961854|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
47939480|NCT02514317|PROCEDURE|percutaneous treatment|
47939481|NCT02514317|DEVICE|Ultrasound|
47939482|NCT05082532|OTHER|Interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) .|we here conduct a prospective study to evaluate the efficacy and safety of self- expandable nitinol stent especially interwoven supera stent (IW; Supera Veritas®; Abbott Vascular, Santa Clara, CA, USA) in femoropoliteal complex occlusive lesions.
47939483|NCT04673084|DEVICE|negative pleural suction|by comparing the effect of water seal alone of chest tube in one groups of trauma patients and the effect of both water seal and suction in other group
47939484|NCT05087849|BIOLOGICAL|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
47939485|NCT06287567|DRUG|Lusutrombopag Oral Tablet|Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg（2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
47939486|NCT05346835|DRUG|Cilta-cel OOS Therapy|Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) will be provided as a one-time administration as an intravenous infusion.
47939487|NCT06514443|OTHER|survey|survey exploring barriers and faciltiators for physical activity
47939488|NCT03192878|DRUG|Infliximab|infliximab biosimilar
48101248|NCT03095911|OTHER|News items without spin|Interpretation of news items without spin
48101249|NCT03059082|BEHAVIORAL|Recovery Navigator on an as needed basis up to 6 months|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit."
48285206|NCT02596776|DRUG|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
48285207|NCT02596776|OTHER|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
48285208|NCT06448156|DIAGNOSTIC_TEST|"cardiac arrest and sudden death"|"Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated"
48285209|NCT00292773|PROCEDURE|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
48285210|NCT00458471|DEVICE|Insertion of a urinary catheter coated with benign E. coli|
48285211|NCT02607215|DRUG|Vinorelbine|25 mg/m2, D1, D8
48285212|NCT02607215|DRUG|DDP|75 mg/m2, D1
48285213|NCT06283251|BEHAVIORAL|PediRISE Resource Program|A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits. Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.
48285214|NCT02947750|DRUG|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
48285215|NCT02947750|OTHER|6R-BH4 placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
48285216|NCT02947750|DIETARY_SUPPLEMENT|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
48285217|NCT02947750|OTHER|Exercise training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
48285218|NCT02947750|OTHER|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
48285219|NCT02947750|DIETARY_SUPPLEMENT|Histidine and beta-alanine supplementation|Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
48285220|NCT02947750|OTHER|Histidine and beta-alanine placebo|Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
48285221|NCT01691118|DRUG|Fimasartan|
48285222|NCT01691118|DRUG|Antihypertensive treatment|
48285223|NCT00336362|DRUG|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
48285224|NCT01985321|DRUG|ethanol/glycolic acid solution|ethanol/glycolic acid solution
48101250|NCT03059082|BEHAVIORAL|Recovery Navigator prior to hospital discharge|This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
48101251|NCT03059082|OTHER|No interaction with Recovery Navigator|This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
48285225|NCT01985321|DRUG|Placebo/Ethanol|ethanol solution
48285226|NCT01789879|DRUG|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
48285227|NCT01789879|DRUG|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
48285228|NCT01789879|DRUG|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
48285229|NCT03016234|DRUG|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
48629660|NCT04251156|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
48629661|NCT04251156|DRUG|Placebo (semaglutide)|Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
48629662|NCT04309630|PROCEDURE|intercostal block|pain control by intercostal block
48285230|NCT03016234|DRUG|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
48629663|NCT04309630|PROCEDURE|erector spina plane block|pain control by erector spina plane block
48629664|NCT01194700|DRUG|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
48629665|NCT01194700|DRUG|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
48629666|NCT01194700|DRUG|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
48629667|NCT01194700|DRUG|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
48629668|NCT01117545|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Six sessions of EFT
48629669|NCT02663440|RADIATION|Hypofractionated IMRT|Hypofractionated IMRT
48629670|NCT02663440|BIOLOGICAL|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
48629671|NCT02663440|DRUG|Temozolomide|Temozolomide
47939489|NCT04417543|DRUG|Memantine Hydrochloride|Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
47939490|NCT04417543|DRUG|Placebo|Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
48629672|NCT01609140|DRUG|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
48629673|NCT01609140|DRUG|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
48629674|NCT01609140|DRUG|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
48629675|NCT01609140|DRUG|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
48629676|NCT01609140|DRUG|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
48629677|NCT01609140|DRUG|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
48629678|NCT05916248|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
48629679|NCT00004201|DRUG|carboplatin|
47939491|NCT00107367|PROCEDURE|conventional surgery|
48629680|NCT00004201|DRUG|cisplatin|
48629681|NCT00004201|DRUG|gemcitabine hydrochloride|
48629682|NCT02968290|PROCEDURE|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
48629683|NCT02968290|DEVICE|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
48629684|NCT02968290|DEVICE|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
48629685|NCT03418675|DRUG|Rexulti|Atypical antipsychotic
48629686|NCT03418675|DRUG|Placebo|Pill that contains no medicine
48629687|NCT02933476|DEVICE|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
48629688|NCT04225143|PROCEDURE|urostim bilateral|Treatment by bilateral neurostimulation of the tibial nerve
48629689|NCT04225143|PROCEDURE|urostim unilateral|Treatment by unilateral neurostimulation of the tibial nerve
48471439|NCT04802213|DEVICE|laser acupuncture device treatment|The laser acupuncture treatment use the laser acupuncture device that developed in this research. A gallium-aluminium-arsenide (GaAlAs, infrared laser) continuous wave diode laser device with a wavelength of 850nm (invisible), a power output of 100 mW, and a spot area of 0.07cm2 was used for laser acupuncture.When performing laser acupuncture treatment, the laser emitted by the device is irradiated on the selected acupuncture points .The acupuncture points (GB 21, LI 4, LI 11, LI 14, LI15, LI 16, SI 9, SI 10, SI 11, TE 14, and TE 15) were determined according to the literature regarding acupuncture application in shoulder pain based on traditional chinese acupuncture.
48471440|NCT02150356|OTHER|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
48471441|NCT02150356|OTHER|Control|Diet based on refined cereal products for a period of 8 weeks.
48629690|NCT04329741|BEHAVIORAL|6-week basic dog obedience training course|The class focused on teaching owners how to better communicate with their dog and covered basic commands (e.g., sit, down, watch), loose leash walking, and polite greetings, among other skills. The importance of dog walking was implied, but not specifically emphasized. Classes were held once per week for 45 minutes, with 5-8 students per class.
48629691|NCT05268237|DRUG|Liraglutide|Sublingual or subcutaneous liraglutide
48629692|NCT05268237|DRUG|Placebo|Sublingual placebo
48629693|NCT01164969|DRUG|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
48629694|NCT01555931|DRUG|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
48629695|NCT02345343|DRUG|Apixaban|
48629696|NCT04229576|DEVICE|TENs|Assessing the efficacy of TENs in pain relieve during office hysteroscopy .
48629697|NCT01794975|DRUG|Ketamine|
47939492|NCT00107367|RADIATION|intraoperative radiation therapy|
48629698|NCT01794975|DRUG|Atomoxetine|
48629699|NCT01794975|OTHER|Cold pressor test|
48629700|NCT01794975|DRUG|Placebo|
47939493|NCT02499458|OTHER|None- observational study|
47939494|NCT04784104|DRUG|Bupivacaine HCl 0.5% Injectable Solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
47939495|NCT04784104|DRUG|Prilocaine HCl 2% Injectable solution|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
48471442|NCT05603936|OTHER|Questionnaire|"The original QOLISSY questionnaire was first developed in 2011, it is available as a patient reported and a parent reported instrument. It includes:~* QoLISSY questionnaire for children and adolescents (8-12, 13-18 yrs)~* QoLISSY questionnaire for parents of children with short stature (4-7, 8-12 and 13-18 yrs) The QoLISSY instrument can be used to assess the health-related quality of life in short stature youth regardless of its cause; however it was specifically developed for patients with GHD and ISS and their parents.The aim of the current study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective."
48471443|NCT00800618|DRUG|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
47939496|NCT04784104|DRUG|Adrenaline amp. 0.5 mg|30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
47939497|NCT04784104|PROCEDURE|Ultrasound guided supraclavicular block with coronal oblique method|The blocks will be performed by an experienced anesthesiologist with a USG guidence.
47939498|NCT04784104|PROCEDURE|Ultrasound guided lateral sagittal infraclavicular block|The blocks will be performed by an experienced anesthesiologist with USG guidence.
47939499|NCT05270421|DRUG|Furosemide 40 mg|Standard ESWL + Furosemide 40 mg
47939500|NCT05270421|OTHER|Conventional Treatment|Standard ESWL
47939501|NCT03353389|OTHER|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
48101252|NCT00731380|DRUG|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
48471444|NCT00800618|DRUG|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
48471445|NCT00800618|DRUG|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
48629701|NCT00601107|DRUG|Doxercalciferol|
48629702|NCT00601107|DRUG|Placebo|
48629703|NCT01482728|DRUG|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
48101253|NCT04258774|OTHER|Carbon Dioxide|The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
48101254|NCT01861678|PROCEDURE|High tie of IMA|Conventional technique
48101255|NCT01861678|PROCEDURE|Low tie of IMA|Technique for preserving left colic arterial perfusion
48106986|NCT05921526|DIAGNOSTIC_TEST|Point-of-care lung ultrasound|Participants assigned to the intervention group will receive POCLUS which will be performed by one of the trained pediatricians. The procedure involves 12 views: two anterior views, two lateral views and two posterior views on both chest walls
48629704|NCT01482728|DRUG|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
48629705|NCT00000975|DRUG|Itraconazole|
48629706|NCT05132452|DIAGNOSTIC_TEST|The Test of Mastication and Swallowing Solids (TOMASS) and the Timed Water Swallow Test (TWST)|Participants swallowed one cracker for the TOMASS. They swallowed 150 mL of water for the TWST.
48629707|NCT02804646|DRUG|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
48285231|NCT01548638|DRUG|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
48285232|NCT05182164|DRUG|Association of pembrolizumab + cabozantinib|"A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis."
48285233|NCT04902248|DEVICE|The OTSC® System Set|The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
48285234|NCT04902248|PROCEDURE|angiographic embolization|Transcatheter selective embolization to bleeding arteries
48285235|NCT04954846|DIETARY_SUPPLEMENT|OMNi-BiOTiC SR-9|"The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23"
48285236|NCT04954846|DIETARY_SUPPLEMENT|Placebo|The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
48285237|NCT03135093|OTHER|No intervention|No Intervention
48285238|NCT00849212|DRUG|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
48285239|NCT05505058|BEHAVIORAL|Audio-visual material|Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
48285240|NCT06453694|DRUG|Efgartigimod Alfa|"2,016 mg will be administered subcutaneously by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
48285241|NCT06453694|DRUG|Placebo|"Subcutaneous injection of placebo will be administered by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
48285242|NCT04074993|DRUG|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
48285243|NCT00001446|DRUG|thalidomide|
48285244|NCT03215277|DRUG|Bimekizumab|One bimekizumab dose will be administered.
48285245|NCT03215277|DRUG|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
48285246|NCT03215277|OTHER|Placebo|Placebo will be provided to maintain the blinding.
48285247|NCT04015557|DRUG|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
48285248|NCT04015557|DRUG|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
48471446|NCT00800618|DRUG|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
48471447|NCT00800618|DRUG|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
48471448|NCT04309994|OTHER|Myocardial protection system (MPS)|cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
48471449|NCT04309994|OTHER|Cardioplexol|cardioplegia solution
48471450|NCT05147740|DRUG|B/F/TAF|50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
48101256|NCT03380975|DRUG|Montelukast 10mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
48471451|NCT03904550|DRUG|Cisatracurium + Neostigmine|Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
48471452|NCT03904550|DRUG|Rocuronium + Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
48471453|NCT02476331|BEHAVIORAL|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
48471454|NCT04063670|OTHER|Video Intervention|Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
48471455|NCT04063670|OTHER|Control|Routine, Standard-of-Care
48471456|NCT06425055|DRUG|Vonafexor|"* One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24"
48471457|NCT04318080|DRUG|Tislelizumab|200 mg intravenously (IV) every 3 weeks (Q3W)
48285249|NCT06117592|OTHER|Education, training and assessment intervention|Staff competence assessment documents for acute oncology knowledge and skills
48285250|NCT01172314|DIETARY_SUPPLEMENT|EAA+LEU vs total AA|15 g as a bolus
48285251|NCT01172314|DIETARY_SUPPLEMENT|Total AA vs EAA+LEU|15 g as a bolus
48285252|NCT00232037|DRUG|Tegaserod|
48285253|NCT04375878|DRUG|MS1819|MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
48285254|NCT04375878|DRUG|Porcine PERT|Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
48285255|NCT05079438|DRUG|Dendrobium Huoshanense Suppository|1.7g rectal administration per day for 5 weeks
48285256|NCT03456115|DEVICE|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
48285257|NCT05382481|DIAGNOSTIC_TEST|Peak value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
48285258|NCT05382481|DIAGNOSTIC_TEST|Trough value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
48285259|NCT05382481|DIAGNOSTIC_TEST|Control Group|This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day. And will not detect the level of anti-Xa
48285260|NCT01919307|OTHER|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
48285261|NCT05115318|DRUG|Medical Cannabis|Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
48285262|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
48285263|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
48285264|NCT00396578|DRUG|aerosolized vancomycin or gentamicin|
48285265|NCT05700214|DRUG|Ropivacaine injection|30ml of 0.375% ropivacaine
48285266|NCT05700214|DRUG|Lidocaine IV|Before induction bolus of 1% lidocaine 1,5mg/kg IBW i.v., continuous infusion of 1% lidocaine intraoperatively rate 1 mg/kg IBW i.v.
48285267|NCT02261623|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
48285268|NCT02261623|DEVICE|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
48285269|NCT02261623|DEVICE|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
48285270|NCT03742427|DIAGNOSTIC_TEST|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
48471458|NCT04747184|OTHER|DNA extraction and 16S rRNA sequencing|DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
48471459|NCT04993417|OTHER|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
48285271|NCT00991900|DEVICE|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
48285272|NCT00391976|DRUG|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
48285273|NCT01612910|DRUG|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
48285274|NCT01612910|OTHER|laboratory biomarker analysis|Correlative studies
48285275|NCT01613105|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
48285276|NCT05267028|OTHER|AD-TAR|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
48285277|NCT05267028|OTHER|AD-Cognitive Stimulation|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
48285278|NCT00664170|DRUG|ANX-514|75 mg/m\^2
48285279|NCT00664170|DRUG|docetaxel|75 mg/m\^2
48285280|NCT01817010|BEHAVIORAL|Multi-Component Rehabilitation (CMC)|
48285281|NCT01817010|BEHAVIORAL|Control (CON)|
48285282|NCT03736044|DRUG|TNF-blockers suspension in patients with rheumatoid arthritis|in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
48285283|NCT01475201|BEHAVIORAL|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (\<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
48285284|NCT01475201|BEHAVIORAL|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
48285285|NCT00001923|PROCEDURE|Transcranial magnetic stimulation|
48285286|NCT04176510|BEHAVIORAL|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
48285287|NCT02220374|OTHER|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
48285288|NCT05917743|OTHER|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
48285289|NCT05917743|OTHER|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
48285290|NCT06388369|RADIATION|[177Lu]Lu-PSMA-617|2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals
47939502|NCT03353389|OTHER|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
48629708|NCT02804646|DRUG|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
48285291|NCT06388369|DRUG|Ipilimumab|4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
48101257|NCT01981356|BEHAVIORAL|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
48285292|NCT05897424|DRUG|INBRX-101|A1PI, Recombinant, Bivalent Fc Fusion Protein
48285293|NCT04184648|OTHER|no interventions|no intervention
48285294|NCT00138840|DRUG|STA-5326 mesylate|
48285295|NCT05914883|DIAGNOSTIC_TEST|Long-term continuous ECG monitoring|Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
48285296|NCT05797766|BEHAVIORAL|Fluid Distribution Timetable|a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
48285299|NCT04112758|OTHER|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
48285300|NCT03332888|DRUG|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
48629709|NCT03745456|DIAGNOSTIC_TEST|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
48629710|NCT06367114|BIOLOGICAL|ssCART-19|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
48629711|NCT06367114|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
48629712|NCT06367114|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
48101258|NCT01981356|OTHER|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
48101259|NCT01678196|BEHAVIORAL|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
48285301|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
47939503|NCT03353389|OTHER|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
47939504|NCT00076024|DRUG|Placebo|5 mg twice daily \[bid\] continuous dosing
47939505|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
47939506|NCT00076024|DRUG|AG-013736 (axitinib)|5mg twice daily \[bid\] continuous dosing
47939507|NCT00076024|DRUG|Docetaxel|Standard of care drug administration
47939508|NCT06383676|OTHER|Functional reaction balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
47939509|NCT06383676|OTHER|Functional balance training|The interventions will carried out two days a week and 40 minutes, for eight weeks.
47939510|NCT00221312|DRUG|Fosamax|
47939511|NCT04172662|BEHAVIORAL|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
48285302|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
48285303|NCT05128240|DIETARY_SUPPLEMENT|Placebo|1g corn oil capsules
48285304|NCT05128240|DIETARY_SUPPLEMENT|Ceto 10|1g capsules containing oil broad spectrum marine oil from north atlantic fish
48285305|NCT06278636|DIAGNOSTIC_TEST|Laparoscopi ultrasound examination|Analysis of feasibility and fellow surgeons learning curve in minimally invasive gynecological procedures
48285306|NCT03784378|DRUG|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
48285307|NCT04292600|DIAGNOSTIC_TEST|POCKiT diagnostics' algorithm for LVO detection|Measurement of blood biomarkers and integration within Pockit diagnostics' algorithm for LVO detection
48285308|NCT00016315|DRUG|carboplatin|
48285309|NCT00016315|DRUG|gemcitabine hydrochloride|
48285310|NCT00016315|DRUG|paclitaxel|
48285311|NCT00016315|RADIATION|radiation therapy|
48285312|NCT01409889|BEHAVIORAL|Diabetes Prevention Program|
47939512|NCT02701920|DEVICE|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
47939513|NCT02701920|DEVICE|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
47939514|NCT02701920|DEVICE|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
47939515|NCT02701920|DEVICE|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
47939516|NCT02701920|OTHER|parental feedback|Questionnaire
47939517|NCT02701920|OTHER|healthcare provider feedback|Questionnaire
47939518|NCT06115148|OTHER|Feeding|Nutrition beverages will be provided to meet the nutrient needs described in the Feeding Arm.
47939519|NCT06115148|OTHER|Fasting|Water will be consumed as described during the Fasting Arm.
47939520|NCT04445116|DEVICE|Action Video Game Treatment|Endeavor™ is a digital, non-drug investigational treatment that is delivered through an action video game and is designed to target cognitive deficits in adolescence and young adults with pediatric onset MS.
47939521|NCT00920205|DRUG|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
47939522|NCT05559333|PROCEDURE|class I restoration placement|zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
47939523|NCT02642874|DRUG|Methocarbamol|Methocarbamol twice daily
47939524|NCT02642874|DRUG|Calcium Carbonate|Calcium carbonate twice daily
47939525|NCT04350346|DRUG|Motilitone|"1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor."
47939526|NCT04350346|DRUG|Gasmotin|"1. Ingredient and content: mosapride citrate dihydrate 5.29mg (5mg as active ingredient)~2. Dosage method: Usually, an adult is orally administered 1 tablet 3 times a day before meals.~3. Pharmacological action: mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle"
48285313|NCT01409889|BEHAVIORAL|Healthy Living Program|
48285314|NCT03943381|DEVICE|Duplex US|Duplex US (Caliper, wave forms...)in evaluation of Pelvic Veins (namely left ovarian vein). in pelvic congestion syndrome
48285315|NCT02493179|DRUG|Serodase 5 mg|Serodase 5mg two tablets three times per day
48285316|NCT02493179|DRUG|Placebo|Placebo two tablets three times per day
48285317|NCT00296439|BEHAVIORAL|Behavior|
48285318|NCT04507815|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
48285319|NCT04507815|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
48101260|NCT01678196|OTHER|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
48285320|NCT01676116|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
48285321|NCT01676116|DRUG|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
47939527|NCT01887301|DRUG|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
47939528|NCT05268107|DRUG|Dupilumab|"Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16."
47939529|NCT03287583|BEHAVIORAL|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
47939530|NCT03287583|OTHER|Enhanced Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
47939531|NCT02009007|DRUG|dopamine|continuous infusion during operation
47939532|NCT02009007|DRUG|phenylephrine|continuous infusion of phenylephrine during operation
47939533|NCT04713657|OTHER|N-thymidine|15N-thymidine will be administered to patients in order to quantify cardiomyocyte proliferation. 15N-thymidine will be administered as 5 separate syringes. Each syringe will contain the recommended daily dose based on participants weight. Subjects will be given the labeled thymidine by mouth once a day for 5 consecutive days. The dosing will begin one week after starting the study drug.The caregiver (parent or nurse) will administer the labeled thymidine by mouth via a syringe once a day for 5 consecutive days. They will be provided with a diary to keep track of study drug dosing.
48285322|NCT01676116|DRUG|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
48285323|NCT00197860|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
48285324|NCT03578705|DEVICE|"Electrical Impedance Myography unit or EIM"|
48285325|NCT05621863|OTHER|Aim 1 Meal Challenge 1|A meal challenge will be provided that contains 1 serving of peaches and 2 servings of strawberries as a smoothie and 2 servings of tomatoes and 1 serving of carrot as a vegetable dish.
48101261|NCT06631508|OTHER|Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge|Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge
48101262|NCT06521892|BEHAVIORAL|social surveillance and health education interventions|"Social surveillance: In the intervention group retail pharmacies posted or hung signs antibiotics need to be purchased by prescription, if found without prescription sales, welcome to call 12315 hotline to report, to form social supervision intervention.~Health education: On-site training for retail pharmacy staff, inviting respiratory physicians and pediatricians to give health education lectures on disease diagnosis, treatment and medication."
48629713|NCT05675085|DIAGNOSTIC_TEST|Personalized screening protocol|"At the first screening round (recruitment) all participating women had the same tests;~* Two-view tomosynthesis of both breasts~* Calculation of volumetric breast density (VBD)~* Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~1. Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~2. Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~3. Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~4. Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~5. Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year."
48101263|NCT04878627|DRUG|Cannabidiol|patients receive cannabidiol at various doses for 3 weeks
48101264|NCT04878627|DRUG|Placebo|patients receive placebo for 3 weeks
48101265|NCT05415215|DRUG|Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
48101266|NCT05415215|DRUG|Pertuzumab IV|Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
48101267|NCT05415215|DRUG|Trastuzumab IV|Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.
48101268|NCT05415215|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
48101269|NCT05415215|DRUG|Investigator's Choice of Chemotherapy|Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
48285326|NCT05621863|OTHER|Aim 1 Meal Challenge 2|A meal challenge will be provided that contains 1 serving of banana and 2 servings of peaches as a smoothie and 1 serving of tomatoes and 2 servings of green beans as a vegetable dish.
48629714|NCT00815737|DRUG|rhubarb|14 days of rhubarb
48629715|NCT00815737|DRUG|Placebo|14 days of Placebo
48285327|NCT05621863|OTHER|Aim 1 Meal Challenge 3|A meal challenge will be provided that contains 2 serving of bananas and 1 serving of strawberries as a smoothie and 1 serving of green beans and 2 servings of carrots as a vegetable dish.
48285328|NCT05621863|OTHER|Aim 2 Typical American Diet|The diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. No bananas, strawberries, peaches, green beans, carrots, or tomatoes will be provided.
48285329|NCT05621863|OTHER|Aim 2 Typical American Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain refined grains and low amounts of fruits and vegetables, representative of the typical American diet. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts less than or equal to 1 serving per day each.
48285330|NCT05621863|OTHER|Aim 2 Dietary Guidelines for Americans Diet Plus Test Foods|This diet will provide sufficient calories for weight maintenance and will contain whole grains and high amounts of fruits and vegetables, representative of the Dietary Guidelines for Americans. Bananas, strawberries, peaches, green beans, carrots, and tomatoes will be provided in amounts greater than or equal to 1 serving per day each.
48629716|NCT01139372|OTHER|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
47939534|NCT04713657|OTHER|Urine Collection|Parents will be asked to keep a diary of the child's feeding and diaper changes during the administration of thymidine. To monitor how the labeled thymidine is processed in the body, investigators will analyze urine from the child's diapers. Each time a diaper is changed, a cotton ball will be placed in the diaper. At the next diaper change, this cotton ball will be removed from the diaper, placed in a Ziploc bag, and stored in the freezer. They will be collected and stored cotton balls starting with the first administration of thymidine until 24 hours after the last administration. The frozen cotton balls may be collected from the home by a nurse or brought by parent to the next clinic visit.
47939535|NCT04713657|PROCEDURE|Echocardiogram|On Study Day 1 to obtain baseline assessment of cardiac size. A second research dedicated echocardiogram will be done after being anesthetized for surgery. Echocardiography is routinely performed to determine right ventricle (RV) structure of the heart and function in ToF/PS and is non-invasive.
47939536|NCT04713657|PROCEDURE|Cardiac MRI|"A limited study protocol will be performed using the feed-and-bundle technique at the time of study enrollment, The feed and bundle technique is utilized so that the infant will be as comfortable as possible and asleep during the procedure. This is done to prevent the risk of sedation and allow for a more natural sleep. The baby is undressed, prepared with ECG-leads and an oxygen saturation probe, and fed. With this feed, swaddle, and sleep technique, scanning times of 30-60 minutes can be achieved, which provides the stillness needed for accurate visualization of the heart. A second CMR, with the same limited study protocol, will be performed under general anesthesia prior to surgical repair. It does not pose any risk of radiation exposure and will not require IV placement or contrast administration for a limited assessement of the right ventricle."
48101270|NCT05415215|PROCEDURE|Surgery|After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
48285331|NCT05230043|OTHER|Algometer test|The computerized pressure algometer, AlgoMed (Medoc, Ramat Yishai, Israel), will be used for mechanical pain stimulation to assess information about pain threshold and tolerance. A constant rate of pressure is delivered by the examiner, and the pressure is recorded in Kilopascal (kPa). The stimulation will be applied between the medial and distal joints of the phalanges of the dominant hand.
48285332|NCT05230043|OTHER|functional MRI|"* Two 8s sequences of spin echo field map with phase encoding AP and PA~* A 12:00min bold sequence for resting-state~* A 15:12min bold sequence for gambling task thickness=2mm, Matrix Size = 105×105, FOV=210×210mm2;~* A 6:38min T1w MPR sequence~* A 7:40min T1w MPR sequence~* A 5:57min T2w SPC sequence~* A 8:24min T2w SPC sequence~* A 8:32min FLAIR T2w sequence~* Two 8:26min Multi-echo GRE sequence~* A 8:29min high resolution multi-echo GRE sequence~* Two 6:46min multi-echo GRE sequence with and without magnetic transfer contrast~* Two 6:03min diffusion weighted images with phase encoding AP and PA"
48285333|NCT03271710|DEVICE|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
48285334|NCT04289883|COMBINATION_PRODUCT|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
48629717|NCT00311805|BIOLOGICAL|Autologous Stem Cells (CD34+)|Intramuscular Injections
48629718|NCT02633657|DRUG|HORIZANT 300 mg|HORIZANT 300 mg once daily
48629719|NCT05700838|BEHAVIORAL|Cough Skill Training - with Variable Practice|"Variable practice will involve three targets that reflect a range of cough airflows, including strong, moderate, and weak coughs."
48629720|NCT02381327|DEVICE|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
47939537|NCT04713657|DRUG|Propranolol Hydrochloride|For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
47939538|NCT04713657|DRUG|Placebo|For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
47939539|NCT04713657|PROCEDURE|Physical Exam|On Study Day 1; monthly until surgery in conjunction with patient's clinical cardiology appointment; and at the time of surgery. Will include vital signs.
47939540|NCT04713657|OTHER|Specimen Collection|On the morning of surgery, after IV access is obtained for anesthesia 2 ml of blood will be collected for analysis. A small piece of heart tissue and fat that has already been removed during surgery will be collected for analysis.
48101271|NCT05415215|RADIATION|Radiotherapy|After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
48101272|NCT00697411|OTHER|Syndrome cause identification|
48471460|NCT04993417|OTHER|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
48471461|NCT04759079|DEVICE|Acupuncture Needles|Acupuncture Needles placement at the PC6 in association to anti-emetic medication
48471462|NCT04759079|DRUG|Antiemetic Drug|Administration of Anti-emetic medication without acupuncture
48471463|NCT06212193|DEVICE|Trillium™|Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement
48471464|NCT00804245|PROCEDURE|needle biopsy|Biopsy of positive findings found on CT scan
48471465|NCT00804245|DRUG|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
48471466|NCT02569281|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
48471467|NCT02569281|OTHER|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
48101273|NCT03955640|DRUG|Olaparib|Given PO
48101274|NCT03955640|PROCEDURE|Hyperthermia Treatment|Undergo hyperthermia treatment
48101275|NCT03955640|OTHER|Questionnaire Administration|Ancillary studies
48101276|NCT03955640|OTHER|Quality-of-Life Assessment|Ancillary studies
48101277|NCT05112315|DEVICE|Predigraft|The Subject randomized to the Predigraft will benefit from Predigraft, a remote monitoring software that issues an alert to the investigator when the allograft survival prediction calculated by the iBox algorithm is decreasing. This follow-up is on top of the site's standard of care.
48101278|NCT06281821|BEHAVIORAL|mhealth-pc|Participants meet with an interventionist who explains the rationale for the mobile app. They complete video and survey-based intervention content each week for 8 weeks. App-based sessions are supplemented with brief chat-based coaching weekly.
48471468|NCT03601494|OTHER|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
48471469|NCT03601494|DRUG|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
48471470|NCT00735930|DRUG|Alvocidib Hydrochloride|Given IV
48471471|NCT00735930|DRUG|Lenalidomide|Given PO
48471472|NCT00735930|OTHER|Pharmacological Study|Correlative studies
48471473|NCT00735930|OTHER|Laboratory Biomarker Analysis|Correlative studies
48471474|NCT02128516|OTHER|oral powder in sachet|
48471475|NCT04784637|DEVICE|Web Simulation Tool (WST)|WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.
48471476|NCT04784637|DEVICE|Behavioral Adaptation Module (BAM)|BAM provides on-demand information to the participant primarily on glycemic risks.
48471477|NCT04784637|DEVICE|Auto Titration Module (ATM)|ATM provides recommendations to the participant to periodically update insulin parameters.
48471478|NCT04784637|DEVICE|Automated Insulin Delivery (AID) System|The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.
48471479|NCT00004906|BIOLOGICAL|filgrastim|
48471480|NCT00004906|DRUG|anastrozole|
48471481|NCT00004906|DRUG|carboplatin|
48471482|NCT00004906|DRUG|cisplatin|
48471483|NCT00004906|DRUG|cyclophosphamide|
48471484|NCT00004906|DRUG|docetaxel|
48471485|NCT00004906|DRUG|doxorubicin hydrochloride|
48471486|NCT00004906|DRUG|etoposide|
48471487|NCT00004906|DRUG|pamidronate disodium|
48629721|NCT02413346|DRUG|Sarecycline|Administered based on participant's body weight.
47939541|NCT02676466|DIETARY_SUPPLEMENT|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
47939542|NCT02676466|DRUG|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
48101279|NCT06214221|DEVICE|Signos System|The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.
48101280|NCT06214221|OTHER|Standard Lifestyle Education|"In the Standard Lifestyle Education arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight."
48285335|NCT04289883|COMBINATION_PRODUCT|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
48285336|NCT01759303|DRUG|pazopanib|"For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
48285337|NCT01984814|BIOLOGICAL|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
48285338|NCT06143410|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
48629722|NCT01701648|OTHER|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
48629723|NCT02450474|DEVICE|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
48629724|NCT02450474|DEVICE|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
48629725|NCT04494815|DRUG|SR419|Each participant will receive 1 dose of 20 mg SR419 oral suspension.
48629726|NCT04494815|DRUG|active control|Each participant will receive 1 dose of 300 mg active control capsule.
48629727|NCT04494815|DRUG|SR419 placebo|Each participant will receive 2 doses of SR419 placebo oral suspension.
48285339|NCT06143410|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
48285340|NCT06143410|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)
48285341|NCT06143410|PROCEDURE|gastroscopy|esogastroduodenoscopy
48285342|NCT03085069|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
48285343|NCT04847128|BEHAVIORAL|Chronic aerobic exercise|Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
48285344|NCT01987544|OTHER|Ergometer Training|
48285345|NCT01987544|OTHER|Motivation|
48629728|NCT04494815|DRUG|active control placebo|Each participant will receive 2 doses of active control placebo capsule.
47939543|NCT02676466|OTHER|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
47939544|NCT02676466|OTHER|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
47939545|NCT02250027|DRUG|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
47939546|NCT02250027|DRUG|Placebo|2 capsules at once, 3 times a day, for 7 days
47939547|NCT05992571|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 90 minutes of rest.
47939548|NCT05992571|DIETARY_SUPPLEMENT|β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 90 minutes of rest.
47939549|NCT03843112|DRUG|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
47939550|NCT03843112|DRUG|Placebo - Cap|Vaginal supplements
47939551|NCT00321061|DRUG|VRC-HIVDNA016-00, VRC-HIVADV014-00|
48101281|NCT06076759|DRUG|Intrathecal morphine or dexmedetomidine|Intrathecal injection
48471488|NCT00004906|DRUG|thiotepa|
48471489|NCT00004906|PROCEDURE|peripheral blood stem cell transplantation|
48471490|NCT05858775|DEVICE|Pregnolia System|Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
48629729|NCT03910946|DRUG|Tuberculin, Purified Protein 5Unt/0.1 mL Solution|Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
48629730|NCT02511158|PROCEDURE|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
48629731|NCT03362957|DEVICE|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
48629732|NCT03362957|DIAGNOSTIC_TEST|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
48629733|NCT00806026|DRUG|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
48285346|NCT06002685|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).
48285347|NCT06002685|OTHER|Home-Based Book-of-the-Week|The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
48285348|NCT03958201|COMBINATION_PRODUCT|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
48285349|NCT00731029|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
48629734|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
48285350|NCT00731029|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
48285351|NCT03707561|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
48629735|NCT00806026|DRUG|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
48629736|NCT00806026|DRUG|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
47939552|NCT02699216|DEVICE|Electrical Stimulation of the Retina|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
47939553|NCT05533476|BEHAVIORAL|Multi Sensory Stimulation and Priming|In the MuSSAP intervention group, the infant wears a multisensory stimulating wristband aiming at increasing attention for the affected upper limb and readiness to initiate a goal-directed movement. Parents are instructed to present a toy to their child if the child shows attention to the affected arm and hand. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
47939554|NCT05533476|BEHAVIORAL|Intensive Usual Care (Upper Limb)|The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
47939555|NCT01706679|DRUG|ATX-101 (10 mg/ml)|
48285352|NCT06062888|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Standard of Care + 2 units (400-500 ml) of fresh frozen plasma
48285353|NCT06133543|PROCEDURE|Robot-assisted ICG-guided sentinel lymph node biopsy|The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
48629737|NCT00806026|DRUG|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
48629738|NCT00806026|DRUG|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
48285354|NCT03663244|BEHAVIORAL|MBSR|Standardised stress reduction programme with established efficacy
47939556|NCT01706679|DRUG|ATX-101 (20 mg/ml)|
47939557|NCT01706679|DRUG|Moxifloxacin (400 mg)|
47939558|NCT01706679|DRUG|Placebo vehicle (PBS)|
47939559|NCT05864573|BIOLOGICAL|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
48285355|NCT03663244|BEHAVIORAL|LSR|Existing stress reduction programme in a Danish municipality
48285356|NCT06313216|PROCEDURE|duoteck membrane|the dehisced bone defect will be covered with duoteck membrane
48285357|NCT06313216|PROCEDURE|autogenous demineralized tooth graft|the dehisced bone defect will be covered with autogenous demineralized tooth graft
48285358|NCT06313216|PROCEDURE|autogenous demineralized tooth graft and plate|the dehisced bone defect will be covered with autogenous demineralized tooth graft combined with autogenous demineralized tooth plate
48285359|NCT02242279|DRUG|BEA 2180 BR|
48285360|NCT02242279|DRUG|Tiotropium|
48285361|NCT02242279|DRUG|Placebo|
48285362|NCT06210126|OTHER|local anesthetic injection|Ultrasound-guided pectointercostal fascial plane block group using 20 mL of 0.25% bupivacaine
48285363|NCT06210126|OTHER|Standard perioperative and postoperative analgesia protocol|postoperative IV morphine PCA and paracetamol will be given. If VAS is 3 or above, 75 mg dexketoprofen trometamol will be administered.
48285364|NCT03344835|OTHER|No intervention|
48285365|NCT03888495|BEHAVIORAL|Gender Socialization Training workshop|Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.
48285366|NCT03888495|BEHAVIORAL|Financial Literacy Training Intervention|Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.
48285367|NCT03888495|BEHAVIORAL|Family Planning Counseling and Services|Family planning counseling sessions and linkage to services.
48285368|NCT03595293|DEVICE|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
48285369|NCT03595293|DEVICE|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
48629739|NCT03831555|BEHAVIORAL|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~2. Information: knowledge about HCV treatment and one's own HCV disease status~3. Medication Adherence: current prescribed medications and adherence to them in the prior month~4. Self-efficacy: self-confidence about adhering to HCV treatment~5. Social Support and Stability: stability of financial, housing, and social support resources~6. Alcohol and substance use: alcohol and substance use behaviors and current treatment~7. Psychiatric Stability: current psychiatric status, previous and current treatment~8. Energy Level: sleep and fatigue~9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
48101282|NCT03012919|OTHER|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
48629740|NCT04429594|OTHER|blood sampling|blood sampling at J0, M6, M12, M24, M36, M48, M60
48629741|NCT00328809|DRUG|spironolactone|spironolactone administered to ESRD patients at low dose
48285370|NCT03457298|DEVICE|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
48285371|NCT03457298|DEVICE|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
48285372|NCT00242879|DRUG|Physician determined comparator PI + ritonavir|
48285373|NCT00242879|DRUG|GW640385 + ritonavir|
48285374|NCT02082561|BEHAVIORAL|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
48285375|NCT04773769|DIETARY_SUPPLEMENT|Tea Made of Graviola Leaves|"Graviola leaves will be supplied to the patient with instructions on how to prepare the tea which will consist of 10 guanabana leaves which the patient will boil in 1 liter of water for 3 minutes. Once boiled, the formulation will be stores in the refrigerator and once cool enough the patient will start drinking 100 cc two times per day.~The Treatment Period begins with Cycle 1 Day 1 dosing. Patients will take the tea continuously during a 28-day cycles, until there is an indication for treatment change based on response assessment."
48285376|NCT00358163|DRUG|PTK787/ZK 222584|Taken in tablet form daily
48285377|NCT00358163|DRUG|paclitaxel|Given as a 3-hour infusion once every 21 days
48285378|NCT02381158|DRUG|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
48285379|NCT02329925|DEVICE|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
48285380|NCT06346405|OTHER|Subthreshold Micropulse Laser Treatment|Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.
48285381|NCT01046318|DRUG|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
48285382|NCT05243771|PROCEDURE|Rectal resection with diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
48285383|NCT05243771|PROCEDURE|Rectal resection without diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
48285384|NCT05243771|PROCEDURE|Rectal resection with permanent colostomy|Patients in this group will receive a rectal resection and a permanent colostomy will be created
48285385|NCT00302692|DRUG|Esmolol|
48285386|NCT00302692|DRUG|Metoprolol|
48285387|NCT01642537|DEVICE|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
48629742|NCT05058456|DEVICE|Shockwave Medical Mini S Peripheral IVL Catheter|The Shockwave Medical Mini S Peripheral IVL Catheter is intended for lithotripsy-enhanced catheter dilatation of lesions, including calcified lesions found in the peripheral vasculature, such as the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. The Mini S IVL Catheter is not for use in the coronary or cerebral vasculature.
48629743|NCT01220154|DRUG|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
47939560|NCT00330798|DRUG|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
47939561|NCT00330798|OTHER|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
47939562|NCT02425644|DRUG|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
47939563|NCT02425644|DRUG|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
47939564|NCT06295978|DIAGNOSTIC_TEST|Biochemical marker assays|DOSAGE BIOMARKERS
47939565|NCT03557827|DRUG|Photodynamic Therapy with indocyanine green and diode laser|mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC
47939566|NCT03557827|PROCEDURE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
48285388|NCT06297304|BEHAVIORAL|Sedentary and physical activity behaviors|The intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: Week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to sedentary behaviors and the physical activity levels will be recorded to assess the progress of each student.
48285389|NCT05692349|DEVICE|MRI|MRI will be employed to assess muscle composition, evidence of degeneration or replacement by fat
48285390|NCT02826057|OTHER|Targeted temperature management (33 degree Celsius)|
48471491|NCT06474598|DRUG|MTX228|Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete
48471492|NCT06474598|DEVICE|DEXCOM G6|To monitor participants blood glucose levels continuously
48471493|NCT03853369|DRUG|Nifekalant hydrochloride|Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
48285391|NCT02951923|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
48101283|NCT03939572|BEHAVIORAL|Accurate step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
48101284|NCT03939572|BEHAVIORAL|Deflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
48285392|NCT02951923|DIETARY_SUPPLEMENT|Soy|
48285393|NCT04889677|DRUG|Danicopan|
48471494|NCT00264381|DRUG|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
48629744|NCT01220154|DRUG|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
48629745|NCT01220154|DRUG|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
48629746|NCT01381588|OTHER|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
47939567|NCT06159101|DRUG|HLX13|A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.
48285394|NCT04889677|DRUG|Placebo|
48285395|NCT03195140|DEVICE|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
48285396|NCT04071665|PROCEDURE|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
48285397|NCT01302275|DRUG|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
48285398|NCT02910778|DRUG|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
48285399|NCT02910778|DRUG|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
48285400|NCT02910778|DRUG|Ticagrelor|
48285401|NCT00607750|DRUG|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
48285402|NCT00607750|DRUG|Placebo|Placebo eyedrops, BID, 48 weeks
48471495|NCT01947686|DEVICE|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
48471496|NCT03597724|OTHER|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
48471497|NCT01504711|DRUG|fosaprepitant dimeglumine|Given IV
48629747|NCT05361759|DEVICE|Cardiac Implantable Electronic Devices|Description of Cardiac Implantable Electronic Devices
48285403|NCT00367809|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
48285404|NCT00367809|BEHAVIORAL|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
48285405|NCT00367809|BEHAVIORAL|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
48285406|NCT02007837|DRUG|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
48285407|NCT02007837|OTHER|Daily text reminder text messages|
48285408|NCT03394222|DRUG|preoperative budesonide inhalation|
48285409|NCT03394222|DRUG|preoperative normal saline inhalation|
47939568|NCT06159101|DRUG|CN-sourced ipilimumab|A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.
47939569|NCT06159101|DRUG|EU-sourced ipilimumab group|A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.
47939570|NCT06159101|DRUG|US-sourced ipilimumab group|A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
48101285|NCT03939572|BEHAVIORAL|Inflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
48101286|NCT03939572|BEHAVIORAL|Accurate feedback + mindset intervention|"After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets."
48285410|NCT05631028|DRUG|Dexmedetomidine|Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
48285411|NCT05631028|DRUG|Remimazolam tosilate|Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
48285412|NCT05707130|OTHER|gaze stabilization exercises|patients will perform gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
48285413|NCT05707130|OTHER|neck isometrics|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
48285414|NCT00388466|DEVICE|GALILEO|
48285415|NCT00274430|DRUG|dexamethasone 8 mg bid|
48285416|NCT00274430|DRUG|tadalafil 10mg bid|
48285417|NCT05277012|DRUG|Etrumadenant|Etrumadenant capsule and tablet formulations
48285418|NCT00628810|BIOLOGICAL|bevacizumab|
48285419|NCT00628810|DRUG|fluorouracil|
48285420|NCT00628810|DRUG|irinotecan hydrochloride|
48285421|NCT00628810|DRUG|leucovorin calcium|
48285422|NCT00465569|DRUG|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
48285423|NCT00465569|OTHER|Placebo|
48471498|NCT06326645|DRUG|Crofelemer Oral Product|Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)
47939571|NCT04516044|BEHAVIORAL|Video games|See arm description
47939572|NCT02480712|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
47939573|NCT00450775|DRUG|Dermatix Q|Dermatix Q applied twice daily
47939574|NCT01041729|DRUG|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
47939575|NCT01041729|DRUG|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
47939576|NCT03712254|DRUG|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
47939577|NCT03480867|DRUG|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
47939578|NCT03480867|RADIATION|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
48471499|NCT05648110|BIOLOGICAL|AZD5156 (Parent study Sentinel Safety Cohort)|"600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1"
48471500|NCT05648110|BIOLOGICAL|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo (3 mL + 2 mL) IM
48471501|NCT05648110|BIOLOGICAL|EVUSHELD™ (Parent study Main Cohort)|"600 mg EVUSHELD™/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL~2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181"
48471502|NCT05648110|BIOLOGICAL|AZD3152 (Parent study Main Cohort)|"300 mg AZD3152 at 150 mg/mL~1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181"
48471503|NCT05648110|BIOLOGICAL|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181
48471504|NCT05648110|BIOLOGICAL|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
48629748|NCT05663788|OTHER|E-learning module|"The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~* 10 modules, including theoretical knowledge and multiple exercises.~* 2 seminars with a tutor (after Module 5 and Module 10)~* feedback from the tutor on three cases recorded by the participant.~* 20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes."
48629749|NCT05192876|RADIATION|Radiotherapy|Outcomes and adverse events using radiation therapy
48629750|NCT00583804|DEVICE|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
48629751|NCT03476252|DIAGNOSTIC_TEST|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
48629752|NCT02301091|PROCEDURE|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
48629753|NCT02301091|PROCEDURE|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
47939579|NCT03679585|OTHER|Internet-Based Intervention|Undergo Talking Pictures social media intervention
47939580|NCT03679585|OTHER|Quality-of-Life Assessment|Ancillary studies
47939581|NCT03679585|OTHER|Questionnaire Administration|Ancillary studies
47939582|NCT00882219|DEVICE|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
48471505|NCT05648110|BIOLOGICAL|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
48471506|NCT05648110|BIOLOGICAL|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
47939583|NCT06331676|PROCEDURE|Tissue collection|Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
47939584|NCT06331676|OTHER|Data collection|Questionnaire on menstrual health and history of hormone treatments for the research purpose
47939585|NCT00423696|BIOLOGICAL|bevacizumab|
48471507|NCT02999698|OTHER|Observational|Observational
48471508|NCT02688387|DRUG|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
48471509|NCT02688387|DRUG|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
48471510|NCT02824185|DEVICE|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
48629754|NCT02301091|DRUG|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
47939586|NCT00423696|DRUG|capecitabine|
47939587|NCT00423696|DRUG|fluorouracil|
47939588|NCT00423696|DRUG|irinotecan hydrochloride|
47939589|NCT00423696|DRUG|leucovorin calcium|
47939590|NCT02207660|DRUG|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
47939591|NCT04864080|BEHAVIORAL|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
47939592|NCT04864080|BEHAVIORAL|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
47939593|NCT03243266|DIAGNOSTIC_TEST|CBC/Diff Reference Interval|Results will not be used to manage patients
48471511|NCT04855591|DRUG|SHR-1703|SHR-1703 will be administered subcutaneously
48471512|NCT04855591|DRUG|Placebo|Placebo of SHR-1703 will be administered subcutaneously
48471513|NCT02438540|DRUG|metformin|metformin tablet 500 mg
47939594|NCT02284178|OTHER|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
48285424|NCT00098059|DRUG|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
48285425|NCT05286294|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
48285426|NCT02588456|BIOLOGICAL|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
48471514|NCT02438540|OTHER|acupuncture|Electro body acupuncture and auricular acupuncture
48471515|NCT02998541|DRUG|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
48471516|NCT02998541|DRUG|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
47939595|NCT02284178|OTHER|Usual Care|Oral suction with suction swab every 4 hours
47939596|NCT03809923|DRUG|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
47939597|NCT03809923|DRUG|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
48285427|NCT03294304|DRUG|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
48285428|NCT03294304|DRUG|Cisplatin|Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
48285429|NCT03294304|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
48285430|NCT00288340|DEVICE|functional magnetic resonance imaging|
48285431|NCT00793923|DRUG|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
48471517|NCT02998541|OTHER|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
48471518|NCT04315324|DRUG|AKR1C3-activated Prodrug OBI-3424|Given IV
48471519|NCT04083443|OTHER|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
47939598|NCT03809923|DRUG|Lidocaine infusion|patients received an IV bolus infusion of lidocaine (2%) 1.5 mg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg made up to 20ml and 20ml normal saline every hour until 30 min before the end of operation, respectively.
48106987|NCT05921526|DIAGNOSTIC_TEST|Chest X-ray (digital images)|Participants assigned to the chest X--ray group will be sent to the Radiology department to get a CXR (digital) which will be performed by radio technicians like in routine care. Anteroposterior and/or posteroanterior chest images will be obtained. Reading/ reporting of the digital images will be done by both the radiologist and the enrolling pediatrician. The image/ clinical expert review panels (IERP/ CERP) will also have access to the images for review.
48106988|NCT05004272|PROCEDURE|Massage|20-minute manual full-body massage
48106989|NCT05004272|PROCEDURE|Gymnastics|20-minute moderate body workout
48106990|NCT05004272|OTHER|Lecture|20-minute lecture on medicinal herbs
48285432|NCT00793923|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
48285433|NCT01043640|DRUG|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
48285434|NCT01043640|DRUG|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
48285435|NCT01043640|DRUG|Busulfan|Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If \> 12 kg then 0.8 mg/kg/dose IV
48471520|NCT04608630|DRUG|Denosumab 60 MG/ML|Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
48471521|NCT04608630|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
48471522|NCT04608630|DRUG|Sodium Chloride 0.9% or 5% Dextrose Intravenous|Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
48471523|NCT04608630|DRUG|Sodium Chloride 0.9% Injection|Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
48285436|NCT01043640|PROCEDURE|Allogeneic stem cell transplantation|Administered \> 24 hours after last dose of busulfan.
48285437|NCT01043640|DRUG|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~* If body weight is ≤ 40 kg dosing will be 3 times daily~* If body weight is \> 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
48471524|NCT04922294|OTHER|Clinical decision support system|To develop a clinical decision support system based on a published cardiometabolic disease staging system.
48471525|NCT00843089|OTHER|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
48629755|NCT05122715|DEVICE|Additional PET/CT Scan|The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
47939599|NCT03809923|DRUG|Dexmedetomidine infusion|Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
47939600|NCT03127956|DRUG|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
48101287|NCT04666337|PROCEDURE|ultrasound-guided supraclavicular brachial plexus blockade|Ultrasound-guided supraclavicular brachial plexus block was done using an ultrasound machine (Philips; Model: OTD020, AcBel Polytech Inc., Taiwan) with a 5-10 MHz linear probe. The brachial plexus and its relation to the surrounding structures were viewed while the patient was supine and the head turned 45° to the contralateral side. In the supraclavicular fossa, the probe was placed in the coronal plane to visualize the subclavian artery and the brachial plexus in a transverse sectional view. After skin sterilization and local anesthetic administration, an insulated needle was then introduced lateral to the ultrasound probe and parallel to the long axis of the probe. Once the needle penetrated the brachial plexus cluster, the local anesthetic mixture was injected incrementally after negative aspiration for blood or air just next to the artery, then the needle was repositioned to inject on the upper pole of the artery.
48106991|NCT00579202|DEVICE|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
48285438|NCT01043640|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC\>500 x 10\^6 neutrophils/L x 3 days and chimerism \>90%), whichever is later.
48285439|NCT03636828|DIAGNOSTIC_TEST|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
48285440|NCT01444391|DEVICE|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
48285441|NCT01259466|DRUG|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
48285442|NCT02124850|DRUG|Motolimod|
48285443|NCT02124850|DRUG|Cetuximab|
48285444|NCT02124850|DRUG|Nivolumab|
48471526|NCT04802551|OTHER|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
48471527|NCT01736748|BEHAVIORAL|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
48285445|NCT02799381|DRUG|Optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
48285446|NCT02799381|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|Dose levels were individually optimized.
48285447|NCT02799381|DEVICE|CADD-Legacy ambulatory infusion pump|(manufactured by Smiths Medical)
48285448|NCT02799381|DEVICE|Percutaneous endoscopic gastrostomy tube|(PEG tube)
48285449|NCT02799381|DEVICE|Jejunal extension tube|(J-tube)
48471528|NCT01736748|BEHAVIORAL|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
48471529|NCT00324896|DRUG|eszopiclone|eszopiclone
48471530|NCT00324896|OTHER|placebo|matching placebo administered at night
48471531|NCT04884594|DRUG|AAV8-hCocH|2e12 vg/kg single infusion intravenous
48471532|NCT04884594|DRUG|AAV8-hCocH|6e12 vg/kg single infusion intravenous
48471533|NCT04884594|DRUG|AAV8-hCocH|4e12 vg/kg single infusion intravenous
47939601|NCT00766441|DRUG|Sitagliptin|tablet, 100mg, once daily, 4 weeks
47939602|NCT00766441|DRUG|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
47939603|NCT02517970|BEHAVIORAL|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
47939604|NCT04163718|DRUG|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
47939605|NCT01721473|OTHER|positron emission tomography scan|2-FA positron emission tomography scan
48285450|NCT05674773|PROCEDURE|Endoscopic or surgical resection|endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
48285451|NCT04165395|DEVICE|Five-layer foam dressing|Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
48285452|NCT04165395|DEVICE|Heelmedix boot|Heelmedix boot will be installed alternately from one foot to the other.
47939606|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
47939607|NCT00959335|DRUG|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
48285453|NCT01233726|DIETARY_SUPPLEMENT|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
48471534|NCT05551741|BIOLOGICAL|IBC-Ab002|An anti-PD-L1 monoclonal antibody
48471535|NCT05551741|OTHER|Placebo|Normal Saline
48285454|NCT01233726|DIETARY_SUPPLEMENT|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
48101288|NCT06630559|BIOLOGICAL|CT-P55|CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
48101289|NCT06630559|BIOLOGICAL|EU-approved Cosentyx|European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
48285455|NCT01233726|DIETARY_SUPPLEMENT|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
48285456|NCT02739139|DIETARY_SUPPLEMENT|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
48285457|NCT05762341|OTHER|PRESSURE INJURY PREVENTION TRAINING|PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING
48285458|NCT01519843|DEVICE|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
48285459|NCT01519843|DEVICE|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
48285460|NCT06097806|OTHER|low and high flow|low and high flow anesthesia are both being used. The effects of different gas flows will be evaluated.
48285461|NCT03455387|DIAGNOSTIC_TEST|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
48285462|NCT06443086|PROCEDURE|Radical operation and perioperative therapy|Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
48285463|NCT05824208|BEHAVIORAL|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
48285464|NCT03514147|OTHER|Experimental|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
48285465|NCT03514147|OTHER|Control|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
48285466|NCT05444244|OTHER|Relational Research Recruitment and Engagement Intervention|"* Specified recruiter/point of contact~* Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~* Resource matching (financial, transportation constraints)"
48285467|NCT05117801|DEVICE|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
48285468|NCT06433115|OTHER|Lean (93%) Grass-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
48285469|NCT06433115|OTHER|Lean (93%) Grain-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
48285470|NCT06433115|OTHER|Plant-Based Meat|Plant-based meat would be macronutrient matched to the same quantities of meat prescribed for a given energy level.
47939608|NCT00425633|DRUG|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
47939609|NCT04248803|OTHER|GLUMA (Kulzer GmbH, Germany) desensitizing agent|GLUMA desensitizer is used to reduce tooth sensitivity
47939610|NCT00117286|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
47939611|NCT00548106|DIETARY_SUPPLEMENT|partially hydrolyzed whey|Total infant feeding by study formula.
47939612|NCT00548106|DIETARY_SUPPLEMENT|Nan HA|Total infant diet by study formula.
47939613|NCT02129218|OTHER|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
47939614|NCT02129218|OTHER|laboratory biomarker analysis|Correlative studies
47939615|NCT02129218|BEHAVIORAL|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
48101290|NCT01735240|DRUG|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
48101291|NCT01735240|DRUG|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
48101292|NCT04373187|DRUG|CC-93538|one injection of 2mL
48285471|NCT03237780|DRUG|Atezolizumab|Given IV
48285472|NCT03237780|PROCEDURE|Biopsy|Undergo biopsy
48285473|NCT03237780|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48101293|NCT04373187|DRUG|CC-93538|two injections of 1.2mL
48285474|NCT03237780|PROCEDURE|Computed Tomography with Contrast|Undergo CT scan
48629756|NCT00368849|DRUG|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
48629757|NCT00368849|DRUG|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
48629758|NCT02154659|DEVICE|24hr pH monitoring|
48629759|NCT05967910|OTHER|chronic psychological stress|Chronic psychological stress includes symptoms of anxiety and depression.
48629760|NCT06169085|DRUG|Leritrelvir|Oral
48471536|NCT04073134|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
48471537|NCT04073134|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
48471538|NCT06450925|DRUG|Vitamin A|Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.
48471539|NCT06450925|OTHER|Placebo|Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.
48471540|NCT02655224|DRUG|Relugolix|Relugolix Tablets
48471541|NCT02655224|DRUG|Relugolix placebo|Relugolix placebo-matching tablets
48629761|NCT03491917|DEVICE|DBT plus S-View|DBT plus S-View images
48629762|NCT03491917|DEVICE|FFDM alone|FFDM alone images
48629763|NCT03331588|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
48629764|NCT03331588|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
48629765|NCT01846143|BIOLOGICAL|pBCAR3-phosphopeptide|
48629766|NCT01846143|BIOLOGICAL|pIRS2-phosphopeptide|
48629767|NCT01846143|BIOLOGICAL|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
48629768|NCT06139458|BEHAVIORAL|Cryotherapy|Participants will receive cryotherapy on both hands and feet
48629769|NCT06139458|BEHAVIORAL|Compression|Participants will receive compression on both hands and feet
48629770|NCT01160900|PROCEDURE|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
48629771|NCT02439619|OTHER|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
48629772|NCT04585477|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
48629773|NCT04585477|DRUG|Durvalumab|1500mg intravenous dose or 20mg/kg if weight is 30kg or less, manufactured by AstraZeneca
48629774|NCT04939584|DEVICE|MultiPulse Therapy|Electrical Stimulation
48629775|NCT02465047|OTHER|Self-help booklet|See Arm/Group Description
48629776|NCT06225752|DRUG|Probucol|Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
48629777|NCT06225752|DRUG|Placebo probucol|Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)
47939616|NCT02129218|BEHAVIORAL|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
47939617|NCT02129218|BEHAVIORAL|Low glycemic load|
47939618|NCT02129218|BEHAVIORAL|Medium Glycemic Load|
48629778|NCT06081062|BIOLOGICAL|Fabagal® (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
48629779|NCT06081062|DRUG|Active comparator (Agalsidase beta)|1 mg/kg every 2 weeks for 12 months
48629780|NCT02444377|BEHAVIORAL|Interval training|
48629781|NCT05327738|BIOLOGICAL|Atezolizumab|Given IV
48629782|NCT05327738|PROCEDURE|Biopsy|Undergo biopsy
48629783|NCT05327738|DRUG|Cabozantinib S-malate|Given PO
47939619|NCT05925218|RADIATION|Radiotherapy as per standard of care|Adjuvant Radiotherapy +/- systemic therapy as per standard of care
47939620|NCT00541463|DRUG|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
47939621|NCT00541463|DRUG|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
48101294|NCT00669461|DRUG|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
48106992|NCT00000878|DRUG|Lamivudine|
48106993|NCT00000878|DRUG|Stavudine|
48106994|NCT00000878|DRUG|Zidovudine|
48106995|NCT04910919|DIETARY_SUPPLEMENT|Honey|Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
48285475|NCT03237780|DRUG|Eribulin Mesylate|Given IV
48285476|NCT02162979|DRUG|sildenafil|sildenafil 50mg BID for 2 weeks
48285477|NCT02162979|DRUG|Placebo|
48285478|NCT00117767|DRUG|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
48285479|NCT00117767|DRUG|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
48285480|NCT01673061|DRUG|Lidocaine|See associated Arm Description
48471542|NCT04890964|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
48471543|NCT00022841|DRUG|Pamidronate|
48471544|NCT00083694|DRUG|Thalidomide|
48101295|NCT06628817|RADIATION|The Intensive Care Bundle with Mortality Reduction|a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
48285481|NCT01673061|DRUG|Vapocoolant|See associated Arm Description
48629784|NCT05327738|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
48629785|NCT00639379|DEVICE|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
48629786|NCT00639379|DEVICE|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
48629787|NCT01951027|DRUG|GX-G3 12.5 μg/kg or Placebo|Single SC injection
48629788|NCT01951027|DRUG|GX-G3 25 μg/kg or Placebo|Single SC injection
48629789|NCT01951027|DRUG|GX-G3 50 μg/kg or Placebo|Single SC injection
48629790|NCT01951027|DRUG|GX-G3 100 μg/kg or Placebo|Single SC injection
48629791|NCT03128060|OTHER|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
48285482|NCT06022770|DIETARY_SUPPLEMENT|Nutritional counseling，Enteral Nutrition|patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as the study objects for nutritional risk screening, malnutrition assessment and quality of life assessment. Randomly enter the nutrition consultation group (NC) and nutrition support treatment group (NST)
48285483|NCT03770143|OTHER|Feeding with palm olein formula|
48285484|NCT00482846|BIOLOGICAL|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is \>40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
48285485|NCT00482846|DRUG|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
48285486|NCT00482846|OTHER|questionnaire administration|Day -5 to Day +28
48285487|NCT00482846|PROCEDURE|autologous peripheral blood stem cell transplantation|Day 0
48285488|NCT00482846|OTHER|quality-of-life assessment|Day -5 to Day +28
47939622|NCT03458793|BEHAVIORAL|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
47939623|NCT00504582|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
47939624|NCT01467583|DRUG|Fondaparinux|2.5 mg every 48 hours
47939625|NCT05266274|DRUG|CD47 monoclonal antibody|patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
47939626|NCT03470571|DIAGNOSTIC_TEST|CMR|Outcome analysis of CMR features in suspected myocarditis patients
47939627|NCT04776044|DRUG|ATR-002|150mg tablets for oral intake
47939628|NCT04776044|DRUG|Placebo|matching tablets for oral intake
47939629|NCT05151601|DIETARY_SUPPLEMENT|Experimental|2 x sachets per day
47939630|NCT05151601|OTHER|Placebo|2 x sachets per day
47939631|NCT05542134|DIAGNOSTIC_TEST|P2Y12 Platelet Aggregation Inhibitor|Verify now PRU test
47939632|NCT05572554|OTHER|Foot Bath Group|The elderly were asked to soak their feet in the water in a marked plastic container with a depth of 10 centimeters and a temperature of 41-42°C for 20 minutes up to their ankles 50 minutes before normal sleeping hours every night for 8 weeks.
47939633|NCT03577171|DRUG|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
47939634|NCT03577171|DRUG|SOC ETV|Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
47939635|NCT03577171|DRUG|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
47939636|NCT00989690|DRUG|docetaxel|
47939637|NCT00989690|DRUG|erlotinib hydrochloride|
47939638|NCT00989690|DRUG|pemetrexed disodium|
47939639|NCT00989690|GENETIC|fluorescence in situ hybridization|
47939640|NCT00989690|GENETIC|mutation analysis|
48101296|NCT00133588|BIOLOGICAL|Trivalent split Inf|
48101297|NCT04732676|OTHER|Smartphone application|"Ecological Momentary Assessment (EMA)~: ambulatory assessment of behaviors/symptoms in real-time on smartphones"
48285489|NCT00424307|DEVICE|HiResolution Bionic Ear System|
48285490|NCT00206141|DRUG|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
48101298|NCT03943719|DIAGNOSTIC_TEST|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
48101299|NCT03426514|PROCEDURE|Three-port Laparoscopic Surgery|Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.
48101300|NCT03426514|PROCEDURE|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
48101301|NCT03329391|BEHAVIORAL|Nurse-led cognitive-behavioral-based group intervention|The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
48101302|NCT00149630|DRUG|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
48101303|NCT00149630|DRUG|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
48285491|NCT00174941|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
48285492|NCT00174941|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
48285493|NCT00174941|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
48285494|NCT05015712|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (\<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
48285495|NCT04227444|DIAGNOSTIC_TEST|Hologram|"Patient undergoing elective anatomical resection for lung cancer will receive standard preoperative CT scan of the chest (as usual); CT images will be subsequently elaborated by a Holographic computer to generate 3D images (holograms).Two radiologists and two thoracic surgeons will analyze CT images in a standard modality and report number of artery and vein branches for the lobe to be resected, moreover they will report every anatomical variation, according to the normal anatomy.~After that, the same two radiologists and thoracic surgeons will analyze 3D images by the use of Microsoft Hololens and perform the same analysis as quoted above.~For each review of the exam performed will be written a digitally signed clinical report to certify the timing of the evaluation and to be able to trace the analysis and any subsequent modifications of the interpretation of the CT images results."
48285496|NCT00291629|DRUG|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
48285497|NCT00291629|PROCEDURE|collection of mobilized peripheral blood stem cells|
48285498|NCT00291629|PROCEDURE|Intracoronary infusion of mobilized cells|
48285499|NCT03065530|DRUG|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
48285500|NCT03065530|DRUG|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
48629792|NCT03128060|OTHER|Enhanced usual care|"Usual primary care consists of: 1) appointment-based access to primary care providers (PCPs) as requested by the patient; 2) case management services; and 3) provider support through palliative care consultation. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.~These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
48629793|NCT04954820|DRUG|Lutathera|2 additional infusions of Lutathera®
48629794|NCT01732211|BIOLOGICAL|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
48629795|NCT01732211|OTHER|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
47939641|NCT00989690|GENETIC|proteomic profiling|
48285501|NCT03065530|DRUG|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
47939642|NCT00989690|OTHER|immunohistochemistry staining method|
47939643|NCT00989690|OTHER|laboratory biomarker analysis|
47939644|NCT00989690|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
47939645|NCT00989690|PROCEDURE|breath test|
47939646|NCT02207985|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|
47939647|NCT04812080|DEVICE|EXPLORER PET/CT|FDG PET Scans on the total body EXPLORER PET/CT scanner
47939648|NCT06482762|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
48471545|NCT00384124|DRUG|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
48471546|NCT03790137|DRUG|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
48471547|NCT00461669|PROCEDURE|ultrasound examination of the hip|
48471548|NCT02292550|DRUG|Ribociclib|CDK 4/6 inhibitor
47939649|NCT04124718|GENETIC|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
47939650|NCT00925171|BEHAVIORAL|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
47939651|NCT01181648|BEHAVIORAL|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
47939652|NCT00002585|DRUG|pyrazoloacridine|
47939653|NCT03325699|DEVICE|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
47939654|NCT03686826|PROCEDURE|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
48101304|NCT00149630|BEHAVIORAL|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
48101305|NCT00149630|OTHER|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
48285502|NCT03065530|DRUG|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
48471549|NCT02292550|DRUG|Ceritinib|ALK inhibitor
48629796|NCT02845349|DRUG|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
48629797|NCT02845349|DRUG|Placebo|A placebo comparator will be used in one subset of patients.
48101306|NCT01768143|BEHAVIORAL|unexperienced endoscopy nurses|
48101307|NCT01768143|BEHAVIORAL|Experienced endoscopy nurses|
48101308|NCT00545844|DRUG|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
48629798|NCT02487355|DRUG|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
48629799|NCT02487355|DRUG|Magnesium Sulphate|Magnesium Sulphate 50 mg
48629800|NCT02487355|DRUG|Bupivacaine|1ml/kg of 0.25%of bupivacaine
48629801|NCT02487355|DRUG|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
48471550|NCT04645940|DRUG|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
48471551|NCT04645940|DRUG|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
48471552|NCT02274558|DRUG|NBI-98854|NBI-98854 40 mg capsules
48471553|NCT02274558|DRUG|Placebo|NBI-98854 placebo capsules
48471554|NCT03721627|DRUG|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
48629802|NCT02014454|DRUG|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
48629803|NCT05507684|OTHER|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group for 9 times once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
48629804|NCT05135325|BEHAVIORAL|Patient portal message|Portal message encourages patients to donate blood
48629805|NCT05135325|BEHAVIORAL|Social responsibility|Message specifies that there is a shortage of the patient's blood type
47939655|NCT00910468|PROCEDURE|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
47939656|NCT02149615|OTHER|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
47939657|NCT06271655|DEVICE|SPOTFIRE R Panel|The intervention involves the use of a rapid point-of-care multiplex PCR test (Spotfire) to identify etiology of patients with ARI. Specimen samples will be collected by research staff at the time of ED presentation. Upon collection, the sample will be promptly prepared for testing on the SPOTFIRE R Panel device. The device will be in the ED to facilitate testing and accelerate delivery of diagnostic results to clinicians. The time when the provider receives the results will be recorded to evaluate the incorporation of results in clinical decision making.
47939658|NCT04941781|DRUG|PIPE-307|"Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging."
47939659|NCT04697381|BIOLOGICAL|somatropin - GH naïve pediatric cohort|somatropin 0.245 mg/kg/week
47939660|NCT04697381|BIOLOGICAL|somatropin - GH treated cohort|somatropin 0.084 mg/kg/week
47939661|NCT04697381|BIOLOGICAL|somatropin - adult cohort|somatropin 0.084 mg/kg/week
47939662|NCT04391413|DEVICE|Use of OCT to guide the angioplasty procedure|OCT will be performed and OCT data used to choose and/or modify procedural strategy. The OCT system used will be the Ilumien Optis system, and Dragonfly Optis probe.
48285503|NCT04118361|DIAGNOSTIC_TEST|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~* Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~* Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~* Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
47939663|NCT02457585|DRUG|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
48285504|NCT04118361|DIAGNOSTIC_TEST|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
48471555|NCT01030094|DRUG|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
47939664|NCT06240780|OTHER|Activated Incrediwear Products|Activated Incrediwear products incorporates semiconductor elements within the fabric that releases negative ions when stimulated by body heat. The negative ions activate cellular vibrations that increase blood flow and circulation.
47939665|NCT06240780|OTHER|Sham Incrediwear Products|Simple fabric Incrediwear products that do not include the semiconductor elements within the fabric.
47939666|NCT02800954|BIOLOGICAL|blood samples|
47939667|NCT02800954|BIOLOGICAL|Bone marow samples|
48471556|NCT01030094|DRUG|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
47939668|NCT00048711|DRUG|N-acetylgalactosamine 4-sulfatase|
48471557|NCT01030094|DRUG|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
48471558|NCT01030094|DRUG|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
48629806|NCT03471949|OTHER|CGM in a population with normal OGTT|The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
48629807|NCT01870570|OTHER|Reference Glucose|
48629808|NCT01870570|OTHER|Food Product A: Corn Flakes|
47939669|NCT03739840|DRUG|Padsevonil|Padsevonil in different dosages.
47939670|NCT03739840|DRUG|Placebo|Placebo will be provided matching padsevonil.
47939671|NCT03224546|BEHAVIORAL|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
48101309|NCT05085496|BIOLOGICAL|Atezolizumab|Given IV
48629809|NCT01870570|OTHER|Food Product B: Ginger Bread|
48629810|NCT01870570|OTHER|Food Product C:Sandwiched Breakfast Biscuit|
48629811|NCT01870570|OTHER|Food Product D: Crackers Nature|
48629812|NCT01870570|OTHER|Food Product E: Breakfast Biscuit|
48629813|NCT01870570|OTHER|Food Product F: White Bread|
48285505|NCT03826914|DIETARY_SUPPLEMENT|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
48629814|NCT02513082|PROCEDURE|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
48629815|NCT01371760|PROCEDURE|Venous PTA|PTA of the internal jugular and/or azygous vein
47939672|NCT02435069|DRUG|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-B'-C'-B1' withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
48285506|NCT03826914|DIETARY_SUPPLEMENT|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
48471559|NCT03046082|DRUG|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
48471560|NCT02009709|DRUG|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
48629816|NCT01371760|OTHER|Catheter Venography|The patients will undergo catheter venography but not PTA
48629817|NCT06485180|PROCEDURE|Active comparator|"Participants from conservative group were selected as uterine curettage (D\&C) cohort , hysteroscopy cohort, Uterine Artery Embolization (UAE) in Combination with D\&C, without MTX cohort, UAE in Combination D\&C with MTX cohort and UAE+ D\&C+hysteroscopy.~Participants from CSP excision plus hysterotomy closure group were selected as transvaginal CSP excision cohort, hysteroscopy-assisted laparoscopic CSP excision cohort and abdominal CSP excision cohort."
48471561|NCT02009709|DEVICE|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
47939673|NCT02435069|DRUG|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase B'-C'-B1' of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
48471562|NCT02009709|DEVICE|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
48471563|NCT02297841|DEVICE|Experimental: Novel lubricant Miami Fragrance|
48471564|NCT02297841|DEVICE|Experimental: Novel lubricant Miami no Fragrance|
48471565|NCT02297841|DEVICE|KY Liquid lubricant|
48629818|NCT06353516|DRUG|Propofol|delivered via intravenous route
47939674|NCT06222359|DEVICE|COMPASS|Digital CBT to treat psychological distress in Multiple Sclerosis (MS)
47939675|NCT02901639|OTHER|counseling|
47939676|NCT03824067|DIAGNOSTIC_TEST|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
47939677|NCT03824067|DIAGNOSTIC_TEST|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
47939678|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
47939679|NCT00772070|BIOLOGICAL|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
48471566|NCT02297841|DEVICE|Astroglide Gel lubricant|
48471567|NCT04636450|PROCEDURE|Rotatory technique pulpectomy|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
48471568|NCT04636450|PROCEDURE|Manual pulpectomy|Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
48471569|NCT05795348|DIAGNOSTIC_TEST|Personalised Musculoskeletal Modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
48471570|NCT04149535|DEVICE|Sentinel® Cerebral Protection System|cerebral embolic protection system
48471571|NCT01747577|DRUG|Solifenacin Succinate|Oral
48471572|NCT01747577|DRUG|Placebo|Oral
48471573|NCT06467201|DRUG|KSHN001126 150mg|6 subjects will receive single oral dose of 150mg
48471574|NCT06467201|DRUG|KSHN001126 300mg|6 subjects will receive single oral dose of 300mg
48629819|NCT06353516|DRUG|Sevoflurane|delivered via inhalation route
48629820|NCT00362323|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
48629821|NCT00362323|DRUG|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
48629822|NCT01610388|DRUG|500mg IV GSK1322322/placebo|500mg IV
48629823|NCT01610388|DRUG|1000mg oral GSK1322322/placebo|1000mg oral
48629824|NCT01610388|DRUG|1000mg IV GSK1322322/placebo|1000mg IV
48629825|NCT01610388|DRUG|1500mg oral GSK1322322/placebo dose|1500mg oral
48629826|NCT01610388|DRUG|1500mg IV GSK1322322/placebo|1500mg IV
48629827|NCT01610388|DRUG|2000mg IV GSK1322322J/placebo|2000mg IV
48629828|NCT01610388|DRUG|3000mg IV GSK1322322J/placebo|3000mg IV
48629829|NCT01610388|DRUG|1000mg IV GSK1322322J/placebo|1000mg IV
48285507|NCT05026073|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
48285508|NCT05026073|PROCEDURE|Blood and endometrial tissue sampling|"* All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
48285509|NCT05026073|PROCEDURE|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
48285510|NCT00260000|DRUG|5,6,7,8-tetrahydrobiopterin|
48285511|NCT01217749|DRUG|PCI-32765|420 mg PO daily
48285512|NCT01217749|DRUG|ofatumumab|per package insert as an IV infusion
48285513|NCT00522860|PROCEDURE|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
48285514|NCT00522860|PROCEDURE|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
48101310|NCT05085496|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48101311|NCT01022489|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
48285515|NCT03308630|BEHAVIORAL|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
48471575|NCT06467201|DRUG|KSHN001126 600mg|6 subjects will receive single oral dose of 600mg
48471576|NCT02502968|DRUG|Cytarabine|
48101312|NCT01022489|DEVICE|Placebo (sham coil) treatment|Sham coil treatment
48101313|NCT05939557|PROCEDURE|Jones technique|is a gentle soft tissue manipulation consisting of a passive procedure that positions the body in a position of comfort to release tissue that compresses or shortens the body structure (muscle contraction and joint dysfunction)
48101314|NCT05939557|DEVICE|Kinesiotape|KT has an S-shaped glue, which lifts the skin, thus improving blood and lymphatic circulation, with the intention of relieving pain and improving musculoskeletal diseases especially in sports
48106996|NCT04910919|OTHER|Standard of Care|The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
48106997|NCT04935489|DEVICE|Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form|The intervention is used regularly for patients with treatment resistant depression, however, in this trial it will be given multiple times per day and over less days than the usual protocol
48106998|NCT02476890|DRUG|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
48106999|NCT02476890|DRUG|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
48107000|NCT05573711|OTHER|assessments|Assessments, no specific intervention
48107001|NCT02156609|DEVICE|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
48107002|NCT01844544|OTHER|inspection of medical records|
48107003|NCT00092755|DRUG|MK0663, etoricoxib|
48107004|NCT00092755|DRUG|Comparators: ibuprofen and placebo|
48107005|NCT05404893|DIAGNOSTIC_TEST|Fecal calprotectin measurement|Stool samples will be collected and fecal calprotectin levels will be measured using an enzymatic immunoassay kit.
48107006|NCT03795428|DRUG|Pemziviptadil (PB1046) Injection|Once-weekly subcutaneous injection
48107007|NCT04286256|BEHAVIORAL|Motivational Interviewing|Participants/caregivers will receive several telephone-based and in-person motivational interviewing sessions along with specific oral health recommendations.
48107008|NCT05585567|BIOLOGICAL|V-01/V-01-B5|Contains 10μg of V-01 and 10μg of V-01-B5
48107009|NCT05585567|BIOLOGICAL|V-01-351/V-01-B5|Contains 10μg of V-01-351 and 10μg of V-01-B5
48107010|NCT05585567|BIOLOGICAL|V-01|Contains 10μg of V-01
48107011|NCT01818401|DEVICE|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
47939680|NCT01314911|DRUG|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
48285516|NCT04980547|DEVICE|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
48471577|NCT02502968|DRUG|BL-8040|
48471578|NCT02502968|DRUG|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
48471579|NCT01260337|BEHAVIORAL|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
47939681|NCT01314911|DRUG|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
47939682|NCT01336569|DRUG|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
47939683|NCT01575886|OTHER|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
47939684|NCT04847089|DEVICE|Motor imagery BCI training|Motor Imagery (MI)-BCI training, 2-3 hours, 3 times/week for 4 weeks.
47939685|NCT01187719|DRUG|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
47939686|NCT00135070|DRUG|Detemir|
48101315|NCT06629324|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cell Transfusion|Bone marrow was collected under general anesthesia from both anterior superior iliac crests, taking 15-20 minutes, with a maximum volume of 350 mL for older children. Mononuclear cells were isolated using Ficoll density gradient centrifugation and prepared for infusion. The infusion, performed in the L4-L5 spinal space, lasted about 30 minutes at a rate of 20 mL per hour. Cerebrospinal fluid (CSF) was withdrawn before infusion, with the amount based on the child's weight. Patients received Rocephin for infection prevention and pain relief with alternating doses of Ibuprofen and Efferalgan for 2 days post-procedure. Seduxen was given once on the first night after bone marrow collection.
48107012|NCT01818401|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
48107013|NCT00525850|OTHER|high fat diet|high saturated fat no starch diet
48107014|NCT00525850|OTHER|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
48107015|NCT05906225|PROCEDURE|EEG guided anesthesia|Monitoring of electroencephalogram via Sedline probe by MASIMO corporation. Adjust concentration of inhalational sevoflurane during anesthesia, according to component of slow\&delta wave and alpha wave, so that slow/delta oscillation (with or without alpha oscillation) is maintained.
47939687|NCT05808283|OTHER|preoperative anemia frequency|patients who applied to the outpatient clinic prospectively for 3 months
48629830|NCT05349266|BIOLOGICAL|ThisCART19A|each patient will receive a dose level per body weight(kg) for only once.
47939688|NCT04493879|OTHER|Bioptron Light Therapy (BLT)|BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
47939689|NCT06329089|PROCEDURE|Reoperative Sentinel Lymph Node Biopsy|Reoperative sentinel lymph node biopsy refers to a surgical procedure performed when there is a need to re-examine the sentinel lymph nodes (SLNs) in patients who have previously undergone breast cancer surgery. The sentinel lymph nodes are the first lymph nodes to which cancer cells are likely to spread from the primary tumor. During the procedure, the surgeon locates and removes the previously identified sentinel lymph nodes using techniques such as lymphatic mapping and injection of a radiotracer or dye. The removed lymph nodes are then examined by a pathologist to determine if there is any evidence of cancer spread.
47939690|NCT05641675|DIAGNOSTIC_TEST|right heart catheterization|Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
47939691|NCT03348384|RADIATION|[C-11]|Radiolabel
47939692|NCT03348384|DRUG|NOP-1A|Tracer
47939693|NCT02843308|BEHAVIORAL|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
47939694|NCT04008043|DRUG|Vicodin|In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
47939695|NCT04008043|DRUG|Dexamethasone|In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
48285517|NCT00526201|BEHAVIORAL|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
48629831|NCT00118794|DRUG|Chlorproguanil-dapsone (Lapdap)|
47939696|NCT01653028|DRUG|Alisertib|Given PO
47939697|NCT01653028|OTHER|Laboratory Biomarker Analysis|Correlative studies
47939698|NCT03320603|OTHER|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
47939699|NCT03320603|OTHER|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
47939700|NCT02201511|DRUG|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
47939701|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
47939702|NCT02201511|DRUG|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
47939703|NCT02201511|DRUG|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
47939704|NCT03882008|DRUG|Abatacept|All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
48285518|NCT00526201|BEHAVIORAL|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
47939705|NCT02059005|BEHAVIORAL|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
47939706|NCT02059005|BEHAVIORAL|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
47939707|NCT00989573|DRUG|Placebo|oral administration of placebo once-daily for 8 weeks
47939708|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
48285519|NCT03762980|OTHER|Bilateral training (BAT)|Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
48285520|NCT05751408|PROCEDURE|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
47939709|NCT00989573|DRUG|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
47939710|NCT03763227|DRUG|Intravitreal ranibizumab (IVR) injection|Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
47939711|NCT03763227|DRUG|Carbonic Anhydrase Inhibitor (CAI) therapy|Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
47939712|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
47939713|NCT03265327|DIETARY_SUPPLEMENT|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
48629832|NCT00118794|DRUG|Lumefantrine-artemether (Coartemether )|
48629833|NCT00842036|BEHAVIORAL|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
48629834|NCT00842036|BEHAVIORAL|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
48285521|NCT06231043|DRUG|Diclofenac/Tramadol|"Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse."
48285522|NCT06478836|OTHER|planter pressure|no intervention
48285523|NCT05475873|DRUG|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
48285524|NCT05475873|DRUG|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
48285525|NCT05475873|DRUG|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
48285526|NCT05223101|DRUG|Telminone 80 mg|Single administration of telmisartan 80 mg
48285527|NCT05223101|DRUG|Drug: Micardis 80 mg|Single administration of telmisartan 80 mg
48285528|NCT02888626|DEVICE|Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
48285529|NCT05076968|PROCEDURE|Complete denture fabrication|Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
48285530|NCT01186653|DRUG|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
48107016|NCT05906225|PROCEDURE|Conventional anesthesia|Adjust concentration of inhalational sevoflurane during anesthesia, according to vital signs, so that mean blood pressure and heart rate are maintained between 80% and 120% of baseline values measured at ward before anesthesia.
48107017|NCT02401919|BEHAVIORAL|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
48107018|NCT02667249|OTHER|clinical pathway|implementation of a standardized clinical pathway
48107019|NCT03313128|OTHER|Sanitation|Improved sanitation facility
48107020|NCT05496816|DIAGNOSTIC_TEST|CAC in septic patients|"Data collected included demographic parameters, comorbidities, vasopressors requirement, laboratory findings, in-hospital mortality scoring and diagnostic colagulation scores. Demographic parameters were taken on the day of admission, all other variables were taken on the day of admission to the ICU and on the day of initiation of invasive mechanical ventilation or on the day of discharge from the ICU.~Demographic parameters included age and sex of the patient, followed by comorbidities which was marked with Yes or No on the day of admission in the ICU. Mortality was assessed according to the qSOFA score and vasopressor requirements on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge. Laboratory analysis included analysis of platelets, neutrophils, lymphocytes, PCT, CRP, fibrinogen, D-dimer on the day of admission and on the day of initation of invasive mechanical ventilation or on the day of discharge."
48107021|NCT05097469|DEVICE|Carbon dioxide laser|3 consecutive sessions of carbon dioxide laser treatment
48107022|NCT05097469|DEVICE|Sham laser treatment|3 consecutive sessions of sham laser treatment
48107023|NCT05334758|DEVICE|Bio-Self COVID-19 Antigen Home Test|At home COVID-19 antigen test kit
48107024|NCT05334758|DEVICE|Standard of Care COVID-19 Test|Standard of care
48107025|NCT05334758|DIAGNOSTIC_TEST|RT-PCR Test|High Sensitivity RT-PCR COVID-19 Test
48107026|NCT00154791|DRUG|oxaliplatin|
48107027|NCT00154791|DRUG|gemcitabine|
48107028|NCT00154791|DRUG|5-FU/LV|
48107029|NCT04285762|OTHER|LVEEA|lymphaticovenous end-to-end
48107030|NCT04285762|OTHER|LVESA|lymphaticovenous end-to-side
48107031|NCT04285762|OTHER|LVSEA|lymphaticovenous side-to-end
48107032|NCT04040530|PROCEDURE|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
48107033|NCT04040530|PROCEDURE|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
48107034|NCT05097781|DRUG|PD-1 blocking antibody|All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
48107035|NCT03319017|PROCEDURE|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
48107036|NCT03329742|OTHER|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
48285531|NCT01186653|DRUG|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
47939714|NCT04246736|BEHAVIORAL|Bädda för Kvalitet|"A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts."
47939715|NCT02615925|OTHER|Psychiatry Consultation|Psychiatry Consultation
48285532|NCT01712360|DRUG|NAFT500 (pediatric)|Applied to both feet and groin area
48285533|NCT01712360|DRUG|NAFT600 (pediatric)|Applied to both feet only
48285534|NCT01712360|DRUG|NAFT500 (adult)|Applied to both feet and groin area
48285535|NCT01712360|DRUG|NAFT600 (adult)|Applied to both feet
47939716|NCT05223335|DRUG|Clopidogrel|75 mg/day
47939717|NCT05223335|DRUG|Prasugrel|60 mg bolus then 10 mg daily
47939718|NCT05223335|DRUG|Tricagrelor|180 mg bolus then 90 mg twice daily
47939719|NCT03361579|OTHER|Education|c.p. intervention description
47939720|NCT03518931|DIAGNOSTIC_TEST|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
47939721|NCT06515041|OTHER|brain well-being|Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.
47939722|NCT02872571|DRUG|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
47939723|NCT04374968|DEVICE|Blood flood restriction cuff|Blood flow restriction cuffs will be used as an augment to physical therapy
47939724|NCT01756300|DEVICE|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
47939725|NCT01600508|OTHER|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
47939726|NCT01278303|DEVICE|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
47939727|NCT05328115|BIOLOGICAL|ALZ-101|Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
47939728|NCT05328115|OTHER|Placebo|Intramuscular injections of adjuvanted placebo.
47939729|NCT05295797|BEHAVIORAL|Dance Program|Participants will take 2 in person dance classes led by peer dance instructors per week for 12 weeks
47939730|NCT02125474|RADIATION|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
47939731|NCT01684020|BIOLOGICAL|ARTISS human fibrin sealant|
47939732|NCT01362751|OTHER|No intervention|This study is an observational cohort study \> no interventions
47939733|NCT03663738|BEHAVIORAL|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
47939734|NCT02024438|DRUG|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
47939735|NCT02024438|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
47939736|NCT02001025|DEVICE|Absorb scaffold|
48285536|NCT05972187|OTHER|Temperature and Humidity|Temperature and Humidity of room changed
48285537|NCT00575796|DRUG|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
48285538|NCT01351662|BEHAVIORAL|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
48285539|NCT01187225|DRUG|Fibrinogen concentrate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
47939737|NCT02001025|DEVICE|Xience stent|
47939738|NCT01830075|BEHAVIORAL|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
47939739|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
47939740|NCT01278160|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
47939741|NCT01278160|DRUG|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
47939742|NCT00869843|PROCEDURE|RF Ablation|
47939743|NCT05373771|OTHER|Care pathway|Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
47939744|NCT04538196|OTHER|Resident education on documentation and coding|Surgery residents will receive education on documentation and coding at the beginning of a particular surgical rotation vs the control group who will receive no education on documentation
47939745|NCT02581943|DRUG|Carboplatin|Given IV
47939746|NCT02581943|OTHER|Laboratory Biomarker Analysis|Correlative studies
47939747|NCT02581943|DRUG|Paclitaxel|Given IV
47939748|NCT02581943|BIOLOGICAL|Pembrolizumab|Given IV
47939749|NCT02581943|OTHER|Quality-of-Life Assessment|Ancillary studies
48101316|NCT06629324|OTHER|Rehabilitation|Rehabilitation methods involve various therapies tailored to the patient\&#39;s mobility level. (1) Physical therapy focuses on exercises to control the head, neck, and trunk, manage muscle tone, and reduce spasticity. Patients gradually practice essential movements like rolling, sitting, crawling, standing, and walking, aligned with developmental milestones. (2) Occupational therapy aims to enhance fine motor skills and daily activities. Through hand function exercises, patients improve upper limb functionality, strengthen their ability to grasp and hold objects and refine coordination between both hands and hand-eye coordination. (3) Speech therapy improves communication, cognitive abilities, and chewing and swallowing functions. Specific exercises target lip and mouth movements, helping patients express and understand language better. Additionally, there are activities to strengthen jaw and facial muscles, which are essential for improving chewing and swallowing abilities.
48285540|NCT01187225|DRUG|Cryoprecipitate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
48471580|NCT01260337|OTHER|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
48629835|NCT00842036|BEHAVIORAL|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
47939750|NCT04490824|DEVICE|KELEA Excellerated Water|Water with increased kinetic activity as assessed by published methods of the PI
48471581|NCT00826137|DIETARY_SUPPLEMENT|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
48629836|NCT03780387|BIOLOGICAL|Felis Catus|Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
47939751|NCT04490824|DEVICE|Water Without an Elevated Level of KELEA|Bottled water without an elevated level of KELEA, as shown by proprietary testing will be provided as a control.
47939752|NCT00558571|DRUG|BI 10773 low dose|
47939753|NCT00558571|DRUG|placebo to BI 10773|
47939754|NCT00558571|DRUG|BI 10773 medium dose|
47939755|NCT00558571|DRUG|BI 10773 high dose|
47939756|NCT04183517|DRUG|PXS-5382A|Orally once daily or twice daily
47939757|NCT04401644|DIAGNOSTIC_TEST|Novel laser inferometry test for CORONA virus|detection of virus particles by light absorbtion patterns.
47939758|NCT01571024|DRUG|BKM120|BKM120 40 mg, orally, once daily.
47939759|NCT01571024|DRUG|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
47939760|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
47939761|NCT02896374|BEHAVIORAL|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
47939762|NCT03181373|OTHER|Cognitive rehabilitation program|Rehabilitation
47939763|NCT05407753|DIETARY_SUPPLEMENT|Ketone ester|Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.
47939764|NCT05407753|DIETARY_SUPPLEMENT|Placebo|Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
47939765|NCT03785288|RADIATION|HDR vaginal brachytherapy|HDR vaginal brachytherapy 7 Gy in 3 fractions or HDR vaginal brachytherapy 4 Gy in 6 fractions
48101317|NCT01877616|OTHER|diagnostic test|Polysomnography
48101318|NCT01877616|OTHER|Diagnostic test|overnight polysomnography
48101319|NCT05268198|DRUG|APR002|Active Investigational Product
48101320|NCT05268198|DRUG|Placebo|Placebo
48101321|NCT01191086|DRUG|USL255|
48285541|NCT02032953|DIETARY_SUPPLEMENT|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
48471582|NCT00826137|DIETARY_SUPPLEMENT|Placebo|Placebo is base powder of product with no oligosaccharides.
48471583|NCT01325038|PROCEDURE|Isometric exercise|Isometric exercise several times/week for three months
48285542|NCT02032953|DRUG|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
48285543|NCT05246410|DEVICE|Spot stent system|Spot stent system designed and produced by Acotec
48285544|NCT05246410|DEVICE|Self-expanding peripheral stent system|Self-expanding peripheral stent system designed and produced by Ev3, Inc
48285545|NCT04353947|DIAGNOSTIC_TEST|Mini Cognitive Examination (MCE)|This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
48101322|NCT03896828|DIETARY_SUPPLEMENT|Mixed-macronutrient meal|"Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be \~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches."
48101323|NCT03636451|DRUG|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
48101324|NCT03636451|DRUG|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
48101325|NCT05901558|BEHAVIORAL|Strategies for Toddler ASD with Remote-therapy (STAR)|The intervention strategies in STAR model are designed under the Naturalistic Developmental Behavioral Intervention (NDBI) framework which are implemented in natural settings targeting at improving social and communicational capabilities
48101326|NCT05901558|BEHAVIORAL|Community intervention|Regular community intervention
48107037|NCT03329742|OTHER|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
48107038|NCT05571358|DEVICE|Virtual Reality (Nature Trek)|"At the end of each session, participants will experience an immersive virtual landscape displayed by Nature Trek VR software (httpp://naturetreksvr.com/). First, participants will be placed in a sit down position and guided for their breathing control during 5 minutes (meditation Lotus option). After that, they will be encouraged to freely move around a relaxing virtual environment during 15 minutes taking special attention to soothing sounds of nature. The themes environment will be selected based on the preferences of the participants.~At the beginning of the study, advice is given on general care, in physical activity and issues concerning drug intake. Patients are advised to refrain from any other specific training during the intervention period. Any deviations from the adherence and practice of the VRi are recorded daily, noting any adverse incidents."
48107039|NCT04061902|OTHER|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
48107040|NCT04852146|PROCEDURE|Electronic feedback|Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.
48107041|NCT05207137|BEHAVIORAL|Telephone call about vaccination|Participants receive phone call from their family physician, where they are invited to ask questions about the COVID-19 vaccine.
48107042|NCT05037032|DRUG|Naltrexone Pill|50 mg PO one-time only
48107043|NCT05037032|DRUG|Placebo|Matching placebo for naltrexone
48107044|NCT04430426|OTHER|Controlled Diet|Participants will consume a controlled low oxalate diet for five days.
48107045|NCT04430426|OTHER|Glycolate Administration|Participants will come to the UAB Clinical Research Unit (CRU) and be administered a glycolate load via intravenous (IV) catheter.
48107046|NCT06233812|PROCEDURE|Simple interrupted suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
48107047|NCT06233812|PROCEDURE|Running suturing technique|Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
48107048|NCT01767259|DRUG|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
48107049|NCT01767259|DRUG|Valsartan|Valsartan alone
48107050|NCT01767259|DRUG|Hydrochlorothiazide|Hydrochlorothiazide alone
48107051|NCT02021799|DIETARY_SUPPLEMENT|Moringa and Lactobacillus rhamnosus GR-1|
48107052|NCT01787994|GENETIC|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.|
48107053|NCT00194623|DRUG|Botulinum Toxin A (Botox)|
48107054|NCT04298606|OTHER|Quality-of-Life Assessment|Ancillary studies
48107055|NCT04298606|OTHER|Questionnaire Administration|Ancillary studies
48107056|NCT04298606|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
48107057|NCT00444431|PROCEDURE|Pyeloplasty|
48107058|NCT00332436|DRUG|brimonidine/timolol fixed combination|
48107059|NCT05312866|PROCEDURE|Standard analgesia (paracetamol +fentanyl)|Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
48285546|NCT04353947|DIAGNOSTIC_TEST|Beck Depression Inventory-II (BDI-II)|This test evaluates the absence or presence of depressive symptoms.
48285547|NCT04353947|DIAGNOSTIC_TEST|Global Deterioration Scale (GDS)|This scale measures the level of deterioration of the subject.
48285548|NCT04353947|DIAGNOSTIC_TEST|Memory alteration test (M@T)|In this test different memory subtypes are evaluated.
48285549|NCT04353947|DIAGNOSTIC_TEST|Spanish-Complutense Verbal Learning Test (TAVEC)|This test is used to assess immediate memory, deferred memory and learning ability.
48285550|NCT04353947|DIAGNOSTIC_TEST|Barcelona test (BT)|"This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes."
48629837|NCT03366415|DRUG|gemcitabine and cisplatin (Induction and adjuvant chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.
48629838|NCT03366415|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor
48629839|NCT03366415|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.
48629840|NCT03366415|RADIATION|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4Gy to the primary tumor, concurrently with cisplatin 30mg/m² every week.
47939766|NCT03069118|BEHAVIORAL|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
47939767|NCT03069118|BEHAVIORAL|Control - Resource List|Tailored list of resources.
47939768|NCT01565837|DRUG|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
47939769|NCT01565837|RADIATION|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
47939770|NCT04639037|DEVICE|Automated adjustment of vasopressor|The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
47939771|NCT04639037|DEVICE|Manual adjustment of vasopressor|Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
47939772|NCT00403403|DRUG|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
47939773|NCT00403403|DRUG|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve \[AUC\]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
48101327|NCT00589212|DEVICE|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
48101328|NCT00728845|BIOLOGICAL|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
48101329|NCT00728845|DRUG|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
48101330|NCT00728845|DRUG|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
48285551|NCT04353947|DIAGNOSTIC_TEST|Rey-Osterrieth Complex Figure Test (ROCFT)|In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
48285552|NCT04353947|DIAGNOSTIC_TEST|Frontal assessment battery (FAB)|This test is a composite tool for assessing executive functions related to the frontal lobe.
48285553|NCT04353947|DIAGNOSTIC_TEST|Positive and Negative Affect Scale (PANAS)|It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
48285554|NCT04353947|DIAGNOSTIC_TEST|Auto-Assessment Manikins (SAM)|It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
48285555|NCT01113528|OTHER|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
48285556|NCT01113528|DRUG|Sugar pill|3 times daily
48285557|NCT00002523|DRUG|fluorouracil|
48285558|NCT00002523|DRUG|leucovorin calcium|
48285559|NCT00002523|PROCEDURE|conventional surgery|
48285560|NCT00002523|RADIATION|radiation therapy|
48285561|NCT00811226|DRUG|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
47939774|NCT00403403|DRUG|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
48285562|NCT01266096|DRUG|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
48285563|NCT03271489|OTHER|Elagolix Placebo|Tablets
48285564|NCT03271489|DRUG|E2/NETA|Capsules
48285565|NCT03271489|OTHER|E2/NETA Placebo|Capsules
48471584|NCT06504303|DEVICE|3D-printed socket|During the shape-capturing in-patient appointment, participants will be measured for the prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. The clinician will manually modify the positive plaster cast and digitally modify the scanned impression using OMEGA software. The manually-modified positive cast will be digitized by scanning the cast, then 3D-printed. The digitally-modified socket file will also be 3D printed. The research investigator will make a de-identified mark on each socket to differentiate between the two sockets after 3D printing, and will record the order in which the sockets are fit to the patient.
48471585|NCT02179593|OTHER|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
48471586|NCT02179593|OTHER|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
48471587|NCT01483625|DRUG|tiotropium|18mcg
48471588|NCT01483625|DRUG|Placebo|placebo
48471589|NCT03092596|BEHAVIORAL|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
48471590|NCT03092596|BEHAVIORAL|Patient health navigator-administered screening tool|patient health navigator-administered screener
48629841|NCT03462563|DEVICE|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
48629842|NCT03462563|DEVICE|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
48629843|NCT02923180|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
48629844|NCT05581264|BEHAVIORAL|Diabetes Self-Management Education Program|diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
48629845|NCT06163638|BEHAVIORAL|GRANDPACT Project|To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive and physical function, psychosocial well-being, quality of the family relationship due to the intervention, we compare the intervention phase (B) with a pre phase (A), a in between period (A) and another intervention period (B)
48101331|NCT00728845|DRUG|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
48101332|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). No Redon drainage system will be left in the subcutaneous tissue."
48285566|NCT03271489|DRUG|Elagolix|Tablets
48285567|NCT05187169|DRUG|VS-6766|Dual RAF/MEK inhibitor
48285568|NCT02396147|DRUG|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
48285569|NCT02396147|DRUG|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
48285570|NCT02396147|DRUG|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
48285571|NCT01447693|PROCEDURE|application of ointment (olive-omega 3 ointment)|
48285572|NCT01047787|OTHER|Polysomnography|examination for sleep disorders
48285573|NCT01336101|DEVICE|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
48285574|NCT01836315|OTHER|Observational Study|
48285575|NCT02306278|DRUG|gabapentin|gabapentin capsules 0.3g
48285576|NCT02306278|DRUG|vitamin capsules|vitamin B
48285577|NCT01218022|DRUG|Losartan Potassium Tablets|
48285578|NCT02657239|BEHAVIORAL|MOVE UP|Weight management behavioral program
48471591|NCT03092596|BEHAVIORAL|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
48471592|NCT04543331|DRUG|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
48471593|NCT02185963|DRUG|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
48471594|NCT01069614|DEVICE|TopClosure 3S System|
48471595|NCT05483270|BIOLOGICAL|the timing of embryo transfer in freeze-all cycles|"Immediate FET group Freeze-all embryo transfer will be carried out in the menstrual cycle immediately following oocyte retrieval.~Postponed FET group Freeze-all embryo transfer will be carried out during the second menstrual cycle to 6 months after oocyte retrieval."
48471596|NCT02937363|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
48471597|NCT02937363|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
48629846|NCT05787509|DRUG|Progesterone Sustained-release vaginal gel|the treatment time of vaginal progesterone
48629847|NCT03399123|OTHER|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
47939775|NCT03551353|OTHER|Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
47939776|NCT03551353|OTHER|Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
47939777|NCT01791010|OTHER|Inspiratory muscle training|
47939778|NCT01791010|OTHER|Training sham|Conducting fake training with the aim of blind the control group
47939779|NCT05817279|DIAGNOSTIC_TEST|Optical coherence tomography|"Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)"
47939780|NCT02942420|DRUG|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
47939781|NCT06271174|DRUG|Carbocaine|"After general anesthesia and before incision, patients will receive loco-regional analgesia.~Carbocaïne will be injected around the nerve responsible of the innervation of the operated area by echography guidance."
47939782|NCT06271174|DRUG|Profofol and/or Suxaméthonium and/or Sévoflurane|"General anesthesia~Anesthetic induction is performed on a full stomach using :~* Intravenous hypnotic Propofol 2-5 mg/kg~* A rapid-acting intravenous curare Suxamethonium 1 mg/kg~On an empty stomach :~- An intravenous hypnotic Propofol 2 to 5 mg/kg or/and an inhalatory hypnotic, Sevoflurane, as anesthetic co-induction by these 2 agents is generally used in pediatrics."
47939783|NCT04054570|OTHER|No intervention|No Intervention
47939784|NCT05324176|RADIATION|diaphragmatic ultrasound|diaphragmatic thickness will be measured on both sides during a deep breath in inspiration and during expiration.
47939785|NCT04653532|BEHAVIORAL|Exercise Programme and Counselling|A 6 month exercise and physical activity programme supported by an exercise specialist
47939786|NCT04653532|DEVICE|Polar Ignite and App|A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
47939787|NCT01799577|PROCEDURE|Laparoscopic surgery|Two methods will be compare
47939788|NCT01866722|BEHAVIORAL|Usual care|Participants will get a brief (\<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
47939789|NCT01866722|BEHAVIORAL|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
47939790|NCT01866722|BEHAVIORAL|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
47939791|NCT00655460|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
47939792|NCT02028871|DRUG|Intranasal Insulin|
47939793|NCT02028871|DRUG|Placebo|
47939794|NCT04148833|DRUG|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
47939795|NCT04148833|DRUG|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
47939796|NCT06025929|OTHER|Maitland's mobilization technique|Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.
47939797|NCT06025929|OTHER|Mulligan's mobilization techniques|Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.
48107060|NCT05312866|PROCEDURE|Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone|Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
48107061|NCT04498754|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|8 sessions of treatment for insomnia.
48107062|NCT04498754|BEHAVIORAL|Weekly phone contacts|Weekly calls to monitor insomnia symptoms.
48107063|NCT03673943|DRUG|64Cu-DOTATATE|Detection of somatostatin positive lesions in NET
48629848|NCT02797535|PROCEDURE|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
48629849|NCT00661219|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
48629850|NCT00661219|DRUG|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
48629851|NCT03808454|DRUG|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
48629852|NCT03808454|OTHER|Rehabilitation|strengthening ex, posture training,...
48629853|NCT03808454|COMBINATION_PRODUCT|PRP+Rehabilitation|combine PRP and Rehabilitation
48629854|NCT01406912|OTHER|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
47939798|NCT06025929|OTHER|Interferential Therapy (IFT)|Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
47939799|NCT04022343|DRUG|Cabozantinib|Given PO
48629855|NCT01406912|OTHER|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
47939800|NCT01658618|BIOLOGICAL|HP802-247|
48629856|NCT06516731|DIETARY_SUPPLEMENT|pH Balanced Cleanser|Participants will use the pH Balanced Cleanser daily during showers. The cleanser should be applied to the vulva with clean hands, gently worked into a lather, and rinsed clean. Participants will complete baseline and weekly questionnaires and vaginal pH tests over an 8-week period to evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
48629857|NCT03580187|DRUG|Morphine (+)|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still\> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still\> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization"
48629858|NCT00267319|DRUG|Glatiramer acetate|
48629859|NCT01309191|OTHER|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
48629860|NCT01309191|OTHER|Placebo|
48285579|NCT04807491|OTHER|Kabat Technique's|"As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises"
48285580|NCT04807491|OTHER|Neuromuscular Re-Education|"After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises"
48285581|NCT00964418|DRUG|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
48285582|NCT00964418|DRUG|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
48285583|NCT01090557|OTHER|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
48285584|NCT03478683|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
48285585|NCT03478683|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
48285586|NCT03478683|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
48285587|NCT03478683|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
48285588|NCT03478683|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
48285589|NCT03478683|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
48285590|NCT03478683|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
48285591|NCT03478683|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
48285592|NCT03478683|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
48471598|NCT02685696|DEVICE|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
48471599|NCT02685696|DEVICE|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
48629861|NCT06375720|BEHAVIORAL|Lower frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
48107064|NCT04630912|OTHER|Acceptance and Commitment Therapy|There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
48285593|NCT03478683|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
48285594|NCT00852930|PROCEDURE|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
48285595|NCT00852930|PROCEDURE|laser alone|The intervention is therapist administered laser
48285596|NCT00852930|PROCEDURE|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
48285597|NCT01401140|DRUG|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
48285598|NCT01401140|DRUG|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
48285599|NCT00968344|DIETARY_SUPPLEMENT|Leucine|3-4g Leucine added to daily meals
48285600|NCT00968344|DIETARY_SUPPLEMENT|Alanine|Powered amino acid
48285601|NCT02537860|OTHER|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
48285602|NCT02537860|OTHER|Placebo at T11 and L3|Two injections that contain saline are performed
48285603|NCT02537860|OTHER|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
48285604|NCT02537860|PROCEDURE|Herniorrhaphy|Unilateral inguinal hernia repair
48285605|NCT02537860|DRUG|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
48285606|NCT02537860|DRUG|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
48471600|NCT02327325|BEHAVIORAL|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
48471601|NCT02327325|BEHAVIORAL|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
48101333|NCT06220058|PROCEDURE|"Closure of the midline laparotomy using the small bites technique with an absorbable PP mesh"|"Closure of the midline laparotomy using the small bites technique will involve employing a monofilament polydioxanone suture with a gauge of 0 (PDS® II Ethicon, Bridgewater, NJ). A partially absorbable low-density polypropylene suprapubic mesh (Ultrapro®, Ethicon) will be added. Mesh fixation will be done with absorbable staples (Ethicon SecurestrapTM) +/- slow-absorbing resorbable sutures at the discretion of the surgical team.~In the case of a diverting stoma, the prophylactic mesh will not encircle it. A Redon-type drainage will be left at the subcutaneous tissue level. One or two drains will be left at the discretion of the surgical team. Closure of the subcutaneous tissue will be performed with 2/0 or 3/0 absorbable, multifilament, interlocking sutures."
48101334|NCT01181089|BIOLOGICAL|Placebo|
48101335|NCT01181089|BIOLOGICAL|Baminercept|
48471602|NCT02466334|DRUG|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
48471603|NCT02466334|DRUG|Placebo|40 ml of normal saline over 20 mins
48471604|NCT01623804|DEVICE|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
48471605|NCT01623804|DEVICE|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
48471606|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
48471607|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
48471608|NCT05850520|DRUG|Sham|Sham procedure will be given on visits when an active injection is not planned.
48471609|NCT05850520|DIAGNOSTIC_TEST|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
48471610|NCT04861740|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
48471611|NCT04861740|OTHER|Screening Intervention|Autism screening intervention only.
48471612|NCT01031992|DRUG|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
48471613|NCT01031992|DRUG|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
48629862|NCT06375720|BEHAVIORAL|Higher frequency, shorter period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 12 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
48471614|NCT06677931|PROCEDURE|Placebo Comparator:1565 non-ablative fractional laser combined with normal Saline|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply normal Saline.
48471615|NCT06677931|PROCEDURE|1565 non-ablative fractional laser combined with umbilical cord mesenchymal stem cell-derived exosomes.|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply exosomes.
48471616|NCT06678165|DRUG|YOLT-204|The intervention group will receive YOLT-204 on day0
48471617|NCT04290494|DRUG|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
48471618|NCT00957216|DRUG|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
48471619|NCT00957216|DRUG|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
48629863|NCT06375720|BEHAVIORAL|Lower frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
47939801|NCT05220410|DRUG|Psilocybin|Open-Label
48471620|NCT05496673|DIAGNOSTIC_TEST|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
48471621|NCT05496673|DIAGNOSTIC_TEST|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
48471622|NCT05496673|DIAGNOSTIC_TEST|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
48471623|NCT00153205|BEHAVIORAL|computerized physician order entry|
48471624|NCT04504006|PROCEDURE|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
48471625|NCT06678555|DRUG|Lorlatinib|Lorlatinib is an ALK/ROS1 tyrosin kinase inhibitor.
48471626|NCT06031220|OTHER|deep breathing exercise inform of diaphragmatic and costal breathing|deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
48471627|NCT05659329|DEVICE|Simplex HV|Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
48471628|NCT00545688|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
48471629|NCT00545688|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
48471630|NCT00545688|DRUG|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
48285607|NCT02454114|OTHER|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
48285608|NCT02454114|OTHER|Standard Hospital Care|"No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) \[performed twice in total\] - at recruitment (day 0) and 6 weeks~CAP-SYM \[performed 3 times in total\] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor."
48471631|NCT01540292|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
48471632|NCT00117806|BEHAVIORAL|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
48471633|NCT00117806|BEHAVIORAL|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
48471634|NCT05380726|BEHAVIORAL|Patient education|The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
48471635|NCT05958381|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
48107065|NCT01174199|DRUG|vorinostat|Given orally
48107066|NCT01174199|DRUG|temsirolimus|Given IV
48107067|NCT01174199|OTHER|laboratory biomarker analysis|Correlative study
48107068|NCT01174199|PROCEDURE|positron emission tomography/computed tomography|PET scan
48107069|NCT04210765|DRUG|Clomiphene Citrate|Clomiphene citrate used in incremental doses in nonresponsive cases.
48107070|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
48107071|NCT01247337|DRUG|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
48107072|NCT02114749|DEVICE|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
48107073|NCT02403323|DRUG|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
48107074|NCT05617586|OTHER|In-depth parental interview|A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.
48107075|NCT05617586|OTHER|Developmental Coordination Disorder Questionnaire (DCD-Q)|Parents will be asked to complete the DCD-Q. This will help us describe the sample.
48107076|NCT02931435|PROCEDURE|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
48107077|NCT02931435|PROCEDURE|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
48107078|NCT01983306|DRUG|SP-333 1 mg|Tablet
48107079|NCT01983306|DRUG|SP-333 3 mg|Tablet
48107080|NCT01983306|DRUG|SP-333 6 mg|Tablet
48107081|NCT01983306|DRUG|Placebo|Tablet
48107082|NCT05028712|BEHAVIORAL|Visual Information Training|Participants in this arm will receive training to improve the use of residual vision to enhance functional performance.
48107083|NCT05028712|BEHAVIORAL|Multimodal training|Participants in this arm will receive training in integrating input from different senses to enhance functional performance.
48107084|NCT02026258|PROCEDURE|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
48107085|NCT02026258|DEVICE|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
47939802|NCT04455360|OTHER|Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol|EMDR is a form of psychotherapy treatment whereby the client verbally relates a narrative of a traumatic episode or emotionally disturbing material in brief sequential doses while simultaneously focusing on an external stimulus. The EMDR Recent-Traumatic Events protocol (R-TEP) aims to enable an individual to process memories of the event in order to reduce psychological morbidity. EMDR R-TEP should be delivered within 3-months of the onset of a traumatic event.
47939803|NCT05547152|OTHER|massages|The experimental rehabilitation protocol includes massages
47939804|NCT05547152|OTHER|motor stimulation and stretching|motor stimulation and stretching
47939805|NCT05547152|OTHER|virtual reality|Patient watches an avatar of his face performing different movements on a screen, and will have to imagine performing these movements without actually doing them.
47939806|NCT02847468|OTHER|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
47939807|NCT02847468|OTHER|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
47939808|NCT03625206|BEHAVIORAL|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
47939809|NCT03625206|BEHAVIORAL|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
47939810|NCT03551483|DEVICE|ArtontheBrain|The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.
47939811|NCT03551483|DEVICE|Seniors Online Victoria|The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
47939812|NCT03722173|DRUG|Itraconazole|Oral solution
47939813|NCT03722173|DRUG|BI 894416|Tablet
47939814|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
47939815|NCT01070862|DRUG|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
47939816|NCT01070862|DRUG|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
47939817|NCT01070862|DRUG|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
47939818|NCT01070862|DRUG|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
47939819|NCT02914847|BEHAVIORAL|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
48101336|NCT04582357|BEHAVIORAL|Physical activity program|The physical activity program is a suite of several exercises which intend to improve muscular mass of targeted muscles.
48101337|NCT06554171|OTHER|Hippotherapy group|In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
48629864|NCT06375720|BEHAVIORAL|Higher frequency, longer period of Tai Chi Chuan|Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 5 sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard health education 0.5 hour/session, 2 sessions/month for 6 months.
48629865|NCT06375720|BEHAVIORAL|Standard Health Education|Participants would take standard health education 0.5 hour/ session, 2 sessions/month for 6 months.
48629866|NCT03693508|DRUG|Genvoya®|Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
48101338|NCT06554171|OTHER|Control group|In addition to conventional physiotherapy, the control group will be allowed to sit in the Hippotherapy Simulature for 15 minutes a day, 5 days a week for 4 weeks. However, the simulator will be kept in closed position to prevent oscillations.
48285609|NCT02111369|DRUG|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
48285610|NCT02111369|PROCEDURE|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
48285611|NCT03119649|DRUG|GLPG2222 50 mg|Oral tablet(s) containing GLPG2222
48629867|NCT05587647|OTHER|Transition to Adulthood Education Program|"YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~1. Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~2. Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~3. Coping with Stress"
48629868|NCT00837447|DEVICE|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
48629869|NCT00837447|DEVICE|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
48629870|NCT02396797|BEHAVIORAL|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
48629871|NCT02396797|BEHAVIORAL|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
47939820|NCT01511185|DRUG|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
47939821|NCT01511185|DRUG|placebo|A single dose administered subcutaneously in random order
48101339|NCT04769609|DEVICE|bioresorbable membrane|reconstructive surgical treatment of peri-implant bone defects
48285612|NCT03119649|DRUG|GLPG2222 100 mg|Oral tablet(s) containing GLPG2222
48629872|NCT04987970|DRUG|CKD-386(2)|QD, PO
48629873|NCT04987970|DRUG|D013, D326, D337|QD, PO
48629874|NCT01967875|DRUG|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
47939822|NCT04344288|DRUG|Prednisone|The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)
47939823|NCT04344288|OTHER|Control group|The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
47939824|NCT03753490|OTHER|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
48285613|NCT03119649|DRUG|Placebo|Matching oral tablet(s) containing placebo
48285614|NCT03119649|DRUG|GLPG2222 200 mg|Oral tablet(s) containing GLPG2222
47939825|NCT03753490|OTHER|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
48101340|NCT01125228|DRUG|Ziodovudine and Alpha Interferon|
48101341|NCT04238234|DEVICE|IVC Ultrasonography|Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.
48101342|NCT04238234|DEVICE|Plethysmographic variability index (PVI) and perfusion index readings (PI)|"The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= \[(PImax-PImin)/PImax\] x100"
48285615|NCT03119649|DRUG|GLPG2222 400 mg|Oral tablet(s) containing GLPG2222
48285616|NCT05446597|PROCEDURE|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
48285617|NCT05446597|OTHER|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
47939826|NCT00434343|OTHER|Global Therapeutic Massage (GTM)|
47939827|NCT00434343|OTHER|Myofascial physical therapy (MPT)|Connective tissue manipulation to all body wall tissues of the abdominal wall, back, buttocks and thighs that clinically were found to contain connective tissue abnormalities and/or myofascial trigger point release to painful myofascial trigger points
47939828|NCT04528771|DRUG|SNO|Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
48285618|NCT05446597|BEHAVIORAL|Multimodal Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
48471636|NCT05958381|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
48471637|NCT02822196|DRUG|Lidocaine|Local Anesthesia using 1% Lidocaine
48471638|NCT02822196|DRUG|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
48629875|NCT01967875|DRUG|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
48629876|NCT00748930|OTHER|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
48101343|NCT02841891|DEVICE|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
48471639|NCT00252447|PROCEDURE|Pre-Operative Conformal Radiotherapy|
48629877|NCT00943904|DEVICE|Interstim implant for SNS|stimulates third sacral nerve root
47939829|NCT04528771|DRUG|Nitrogen gas|Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
48285619|NCT03679221|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
48285620|NCT02512796|DRUG|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
48285621|NCT04345549|OTHER|Individualised Ayurveda|Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
48471640|NCT06338631|OTHER|Diet|Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
48471641|NCT02312479|DEVICE|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
48471642|NCT03354208|OTHER|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
48471643|NCT05947097|DRUG|HSK21542 Injection|1ug/kg bolus for 2min±5s
48629878|NCT05186298|DEVICE|AcrySof® IQ PanOptix®|The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
48629879|NCT05186298|DEVICE|Synergy®|The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
48629880|NCT05186298|PROCEDURE|Cataract Surgery|IOL implantation will be performed
48629881|NCT05995418|OTHER|There was no intervention as this was an observational study.|There was no intervention as this was an observational study.
48629882|NCT05311163|PROCEDURE|MitraClip|Transcatheter Mitral Edge-To-Edge Repair
48629883|NCT06378866|DRUG|Abiraterone|Given abiraterone
48629884|NCT06378866|DRUG|Apalutamide|Given apalutamide
48629885|NCT06378866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48629886|NCT06378866|PROCEDURE|Bone Scan|Undergo bone scan
48629887|NCT06378866|PROCEDURE|Computed Tomography|Undergo CT
48629888|NCT06378866|DRUG|Darolutamide|Given darolutamide
48629889|NCT06378866|DRUG|Degarelix|Given degarelix
48629890|NCT06378866|DRUG|Enzalutamide|Given enzalutamide
48629891|NCT06378866|DRUG|Goserelin|Given goserelin
48629892|NCT06378866|DRUG|Histrelin|Given histrelin
48101344|NCT02841891|PROCEDURE|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
48285622|NCT02894515|DRUG|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
48285623|NCT02894515|DRUG|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
48285624|NCT05415280|BEHAVIORAL|Mindfulness Based stress reduction|The aim of the psychological intervention to reduce the mental health problems of the participants.
48285625|NCT01975025|PROCEDURE|Short daily dialysis for 2 weeks|
48285626|NCT02139410|PROCEDURE|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
48285627|NCT03312855|DRUG|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
48471644|NCT05244317|DEVICE|cast|the cast of the upper limb from just below elbow joint to the knuckle of fingers
48471645|NCT05244317|DEVICE|splint|Removable splint
48471646|NCT02148354|BEHAVIORAL|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else...?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
48471647|NCT05414162|DIAGNOSTIC_TEST|Cardiac MRI|Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
48629893|NCT06378866|DRUG|Leuprolide|Given leuprolide
48629894|NCT06378866|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48629895|NCT06378866|OTHER|Patient Observation|Undergo watchful waiting
48629896|NCT06378866|PROCEDURE|Positron Emission Tomography|Undergo PET
48629897|NCT06378866|DRUG|Prednisone|Given prednisone
48629898|NCT06378866|OTHER|Questionnaire Administration|Ancillary studies
48629899|NCT06378866|DRUG|Relugolix|Given relugolix
48629900|NCT06378866|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48629901|NCT06378866|DRUG|Triptorelin|Given triptorelin
48629902|NCT06178913|OTHER|Exercise intervention|The exercise intervention method is a circuit training method that combines strength training and aerobic exercise forms and consists of a total of 12 movements. Performing movements 1 to 12 in order is 1 set. After completing the set, when the heart rate returns to the plateau (less than 59% of maximum heart rate), proceed to the next set, for a total of 3 sets.
48629903|NCT02722135|DRUG|Volasertib|
48629904|NCT01456338|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
48629905|NCT01456338|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
48101345|NCT03973424|BEHAVIORAL|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
48285628|NCT03312855|DRUG|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
48285629|NCT03312855|DRUG|Placebo|single dose, intravenous application of Placebo solution
48285630|NCT00542347|DRUG|Esomeprazole first|"* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
48285631|NCT00542347|DRUG|Generic omeprazole first|"* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
48285632|NCT04098380|PROCEDURE|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
48285633|NCT04098380|PROCEDURE|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
48285634|NCT05668156|OTHER|Consensus Decision Making|Consensus-based decision-making process, where experts are asked to comment definitions of terms used for fasting interventions
48285635|NCT05308108|PROCEDURE|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
48285636|NCT00206518|DRUG|Taxotere/Docetaxel|Taxotere
48285637|NCT00206518|DRUG|Adriamycin/Cytoxan|Adriamycin/Cytoxan
48285638|NCT00206518|DRUG|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
48285639|NCT05124769|BEHAVIORAL|Pain Allowing Program (PAllow)|Performing exercises considered to have a considerable supraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \> 40% MVC).
48285640|NCT05124769|BEHAVIORAL|Pain Avoiding Program (PAvoid)|"Performing exercises selected to have a minimal insupraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \<20% MVC).~These unloading exercises are performed for 6 weeks. In the second part of the exercise protocol, the loading exercises are applied, however without pain.~In case the patient still feels pain during the exercises in that period, the unloading exercises are continued."
48285641|NCT04880174|DIAGNOSTIC_TEST|serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
48285642|NCT04192604|OTHER|WMSDsQ|Work-related MusculoSkeletal Disorders Questionnaire
48285643|NCT02797561|OTHER|5 year Follow-up|
48285644|NCT02594592|OTHER|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
48285645|NCT03369847|DRUG|budesonide, beclomethasone|The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
48285646|NCT05060042|OTHER|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
48285647|NCT05060042|OTHER|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
48285648|NCT05545397|DRUG|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
48285649|NCT05545397|DEVICE|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
48471648|NCT04674826|DRUG|Tralokinumab administered as 1 × X mL with Device A|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
48285650|NCT01480180|DRUG|turoctocog alfa pegol|Administered i.v.
48285651|NCT02330991|DRUG|Temozolomide|
48285652|NCT06447792|OTHER|Loading protocol|The prosthetic restoration and functional loading of the dental implant.
48629906|NCT04056637|OTHER|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
48629907|NCT04056637|DEVICE|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
48629908|NCT04764604|DEVICE|Acapella Choice|3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
48629909|NCT04764604|DEVICE|Tube-in-water|3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
48285653|NCT05766735|BEHAVIORAL|Routine Care + Glycemic Excursion Minimization (RC+GEM)|In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.
48101346|NCT03973424|BEHAVIORAL|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
48285654|NCT05766735|OTHER|Routine Care (RC)|RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
48629910|NCT05632900|PROCEDURE|Endoscopic ultrasound guided drainage of walled off pancreatic necrosis|It is Therapeutic procedure to treat walled off pancreatic necrosis.
48629911|NCT00415259|DEVICE|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
48629912|NCT00415259|DEVICE|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
48629913|NCT06302361|PROCEDURE|Lymphovenous anastomosis (LVA)|Surgical procedure with supermicrosurgical anastomosis between distal lymph vessel and proximal venule.
47939830|NCT03486431|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
47939831|NCT03037268|DEVICE|Lytro Plenoptic Camera and 28D lens|"* visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~* screened and consented for study~* subjected to bilateral plenoptic ophthalmoscopy~* mydriatic, single-field fundus images obtained~* images reviewed for quality and diagnostic utility by a masked grader"
47939832|NCT02793193|DIETARY_SUPPLEMENT|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
48101347|NCT03178396|DIETARY_SUPPLEMENT|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
48101348|NCT03068611|BEHAVIORAL|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
48285655|NCT03222661|DIAGNOSTIC_TEST|Refraction|Refractive error measurement
48285656|NCT05004012|DEVICE|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
48285657|NCT01881555|PROCEDURE|invasive coronary angiography|
48285658|NCT01881555|PROCEDURE|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
48285659|NCT00459927|DEVICE|Floseal tonsillectomy|
48285660|NCT00459927|DEVICE|Coblation tonsillectomy|
48629914|NCT02410876|PROCEDURE|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
48629915|NCT02410876|PROCEDURE|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
48629916|NCT03189433|DRUG|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
48629917|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
48629918|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
48629919|NCT03593447|DRUG|non-cirrhotic subjects. low TG-2349+ low DAG181|Group 3: TG-2349 200 mg + DAG181 100 mg
48629920|NCT03593447|DRUG|non-cirrhotic subjects. high TG-2349+ high DAG181|Group 4: TG-2349 400 mg + DAG181 200 mg
48629921|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg_
47939833|NCT02793193|DIETARY_SUPPLEMENT|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
47939834|NCT02793193|DRUG|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
47939835|NCT02793193|DIETARY_SUPPLEMENT|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
47939836|NCT03923985|DIETARY_SUPPLEMENT|Probiotic containing Lactobacillus Crispatus|1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
47939837|NCT00174291|DRUG|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
48101349|NCT03068611|BEHAVIORAL|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
48101350|NCT03470987|PROCEDURE|Phase I Periodontal therapy|Oral hygiene instuction, scaling and root planning
48101351|NCT03470987|DIETARY_SUPPLEMENT|Metabolic control|Calorie restricted diet
48285661|NCT03370146|BEHAVIORAL|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
48629922|NCT03593447|DRUG|cirrhotic subjects. high TG-2349+ high DAG181|Group6: TG-2349 400 mg + DAG181 200 mg
48629923|NCT01395537|DRUG|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
48629924|NCT01395537|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
48629925|NCT01395537|DRUG|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
47939838|NCT03682575|OTHER|Enrollment|All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
47939839|NCT04014023|DRUG|DWP16001|DWP16001 tablets
47939840|NCT04014023|DRUG|Placebo|DWP16001 placebo-matching tablets
47939841|NCT01654796|DEVICE|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
47939842|NCT01654796|DEVICE|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
47939843|NCT05570201|OTHER|Control group|No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
47939844|NCT02916238|DRUG|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
48101352|NCT02877199|OTHER|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
48101353|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
47939845|NCT02916238|BEHAVIORAL|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
47939846|NCT04671173|DEVICE|Measurement of the Intra-Compartmental Pressure with the MY01 device|"All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device."
47939847|NCT04998682|PROCEDURE|Axillary Dissection|A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
47939848|NCT03665831|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
47939849|NCT00890188|DRUG|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
48101354|NCT01367912|DRUG|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
48285662|NCT03370146|BEHAVIORAL|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
48285663|NCT03370146|BEHAVIORAL|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
48285664|NCT05714371|DRUG|Nivolumab|Patients receiving nivolumab
48285665|NCT05714371|DRUG|Ipilimumab + nivolumab|Patients receiving ipilimumab + nivolumab
48285666|NCT05714371|DRUG|Pembrolizumab|Patients receiving pembrolizumab
48285667|NCT05714371|DRUG|Dabrafenib + trametinib|Dabrafenib + trametinib
48285668|NCT06374641|DIETARY_SUPPLEMENT|Mitochondrial Substrate Supplement|Mitochondrial Substrate supplement, 2xdaily 65 mL drink
48285669|NCT06374641|DIETARY_SUPPLEMENT|Placebo Supplement|Placebo supplement, 2xdaily 65 mL drink
48471649|NCT04674826|DEVICE|Tralokinumab administered as 2 × Y mL with Device B|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
48471650|NCT02951195|DRUG|VX-152|Tablet for oral administration.
48285670|NCT01561131|DIETARY_SUPPLEMENT|Whey protein|45g protein/d; Dosage 3x15g protein daily
48285671|NCT01561131|DIETARY_SUPPLEMENT|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
48471651|NCT02951195|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
48471652|NCT02951195|DRUG|IVA|Tablet for oral administration.
48471653|NCT02951195|DRUG|Placebo|Placebo matched to VX-152.
48285672|NCT01561131|DIETARY_SUPPLEMENT|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
48285673|NCT01561131|DIETARY_SUPPLEMENT|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
48285674|NCT03414359|DRUG|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
48285675|NCT03414359|DRUG|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
48285676|NCT02579603|DRUG|Nintedanib|Nintedanib 150mg bid
48285677|NCT02579603|DRUG|Pirfenidone|
48285678|NCT02189265|OTHER|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
48285679|NCT00000790|DRUG|Thalidomide|
48285680|NCT05059197|DIETARY_SUPPLEMENT|AP collagen peptide|Health functional food
48285681|NCT05059197|DIETARY_SUPPLEMENT|Placebo|placebo
48285682|NCT02408250|PROCEDURE|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
48285683|NCT05290870|DEVICE|Posterior-chamber intraocular lens|Implantation of a posterior-chamber intraocular lens to correct aphakia after removal of the crystalline lens
48285684|NCT04520789|DIAGNOSTIC_TEST|RPE cell collection and single cell heterogeneity study|Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
48285685|NCT04520789|PROCEDURE|Postoperative intervention|Early local steroids drug intervention in patients with severe postoperative PVR
48285686|NCT04520789|PROCEDURE|Conventional Surgery for Retinal Detachment|Conventional Surgery for Retinal Detachment
48471654|NCT02951195|DRUG|Placebo|Placebo matched to VX-152/TEZ/IVA triple combination (TC).
48471655|NCT02361814|PROCEDURE|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
48471656|NCT02562287|DRUG|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
48471657|NCT02562287|DRUG|Risperidone|Risperidone, in a flexible dosage
48471658|NCT02562287|DRUG|Olanzapine|Olanzapine, flexible dosage
48471659|NCT02562287|DRUG|Quetiapine|Quetiapine, flexible dosage
48471660|NCT02725060|DRUG|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
48471661|NCT02725060|DRUG|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
48471662|NCT02725060|RADIATION|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
48471663|NCT02725060|PROCEDURE|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
48471664|NCT02725060|PROCEDURE|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
48471665|NCT02725060|PROCEDURE|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
48629926|NCT03865251|DEVICE|Kinesiology tape|Application for 0%, 50%, and 100% of maximal KT stretch to the calf muscle during lying and standing positions
48471666|NCT02725060|PROCEDURE|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
48471667|NCT02725060|OTHER|Rebreathing test|Cardiac output will be measured using the rebreathing technique (Innocor)
48471668|NCT02725060|OTHER|Assessment of splanchnic capacitance|Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
48471669|NCT02725060|PROCEDURE|microneurography|microneurography will be measured in the peroneal nerve to assess sympathetic activity.
48471670|NCT00708682|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
48471671|NCT03788135|BEHAVIORAL|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
48471672|NCT02930135|PROCEDURE|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
48629927|NCT02739646|DEVICE|Functional MRI scan|7.0 Tesla functional MRI scan
48629928|NCT05236127|OTHER|Soccer Heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
48629929|NCT05236127|OTHER|Intermittent Fasting|The purpose of this study is to examine the effect of intermittent fasting on the acute neural responses to subconcussive head impacts. The study is designed to identify the effects of 20 controlled soccer headings in college-aged soccer players in one of four groups (fasted, pre-fasted, post-fasted, or control) through the use of neural-injury blood biomarkers, magnetic resonance spectroscopy, functional, and diffusion MRI, and ocular-motor function across 4 acute time points. Participants will be randomly designed to one of the four groups which consist of an 8 day fast, 5 day fast, 3 day fast, or the non-fasted control group.
48471673|NCT02486614|PROCEDURE|CRRT|citrate based continuous renal replacement therapy
48471674|NCT02413424|DIETARY_SUPPLEMENT|Sucralose|60 ml of 2mM sucralose
48629930|NCT05695482|OTHER|Neuromuscular training exercises|The 6-week exercise intervention consists of 25-minute group sessions of Neuromuscular training supervised by a researcher.
48101355|NCT01750554|OTHER|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
48101356|NCT05025124|DEVICE|Entia Liberty|Home monitoring system
48101357|NCT05821127|BEHAVIORAL|Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. In addition, 2 sessions of patient education will be provided with videoconference calls, and with the mobile application to be installed on the phones of the patients as non-immersive virtual reality support, it will be possible to practice median nerve and tendon gliding exercises in the form of 5 repetitions and 6 sets every day with video support for 16 weeks. In this application, the user will use the front camera of phone as a sensor to detect hand movements. A screen on which exercises will be played at the top of the screen and a virtual image of the user's hand in the lower half of the screen will be displayed in the field of view of the camera. Each exercise position will take 5 seconds. Patient education will include neuroscience, etiology, pathophysiology and treatment options of carpal tunnel syndrome, ergonomics and posture education.
48471675|NCT02413424|OTHER|Water|60 ml of water
48471676|NCT02413424|DIETARY_SUPPLEMENT|glucose load|
48471677|NCT02119962|BEHAVIORAL|Working memory training|
48471678|NCT02119962|BEHAVIORAL|Placebo training|
48471679|NCT02223286|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score
48471680|NCT02656654|OTHER|Whole-body compression|
48471681|NCT01805635|OTHER|No intervention|No intervention
48629931|NCT05695482|OTHER|Hip abductors muscular strength exercises|The 6-week exercise intervention consists of of 20-minute group sessions of progressive resistance training, supervised by a researcher.
47939850|NCT06326970|DIAGNOSTIC_TEST|99mTc-FAPI SPECT imaging|99mTc radionuclide is labeled to a HYINC-FAPI-04 probe as a tracer. SPECT imaging was performed 2 hours after 99mTc-FAPI intravenous injection into the subject, and image processing and quantitative analysis were performed using the Q.Volumetrix MI System software package.
48285687|NCT04621747|OTHER|Battery of neurophysiological explorations|"Visit 1: Biometry collection: gender, age, weight, height, eye colour.~* Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~* Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~* Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~* Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~* 48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~* 42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~* 12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness."
48285688|NCT01420185|GENETIC|RNA analysis|
48285689|NCT01420185|GENETIC|gene expression analysis|
48285690|NCT01420185|GENETIC|microarray analysis|
47939851|NCT03736707|DEVICE|Selective HFOV|Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
47939852|NCT03736707|DEVICE|CMV|CMV was delivered by time-cycled, pressure-limited ventilators
47939853|NCT06429007|DRUG|Metformin|Infants in the study will receive 50% of the target dose (12.5mg/kg) for the first 6 weeks of participation. At the 6 week visit, the patient will be assessed and if found still eligible, will receive the full dose (25mg/kg) for the remaining 6 weeks of participation.
47939854|NCT01480128|PROCEDURE|Single-port|Single-port laparoscopic colon resection
47939855|NCT01480128|PROCEDURE|Multi-port|Multi-port laparoscopic colon resection
47939856|NCT03929484|DEVICE|Nasal reservoir cannula|The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
47939857|NCT00916214|OTHER|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
47939858|NCT06016062|DRUG|RC148|RC148 is a bispecific antibody, targeting programmed death-1(PD-1) and Vascular endothelial growth factor(VEGF).
47939859|NCT02789332|DRUG|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
48285691|NCT01420185|GENETIC|reverse transcriptase-polymerase chain reaction|
47939860|NCT02789332|DRUG|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
47939861|NCT02789332|DRUG|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
47939862|NCT02789332|PROCEDURE|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
47939863|NCT02789332|OTHER|Stratification|Hormone-receptor status (HR+ vs HR-) Age \< 40 years vs \>= 40 years
48285692|NCT01420185|OTHER|laboratory biomarker analysis|
48285693|NCT02108730|PROCEDURE|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
48471682|NCT00172016|DRUG|Zoledronic acid|
48101358|NCT05821127|BEHAVIORAL|Neurodynamic Exercises and Patient Education with Traditional Method|A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. Patients will be asked to do the exercises in the form of 5 repetitions and 6 sets every day and to wear the night splint every night for 16 weeks. Each exercise position will take 5 seconds. A brief verbal education will be given to the patients under the same topics as the intervention group, as in the outpatient clinic.
48285694|NCT06231108|OTHER|Kinesio Taping|"Three different taping applications will be applied, namely ankle correction, quadriceps facilitation, and gluteus maximus facilitation.~1. Taping: Functional correction technique will be used to facilitate dorsal flexion movement.~2. Taping: Quadriceps Femoris (QF) Facilitation Technique - In taping to activate the QF muscle and regulate muscle tone, the patient will be placed in a supine position with hips and knees in neutral.~3. Taping: Gluteus Maximus (GM) Facilitation Technique - For taping to facilitate the GM muscle, a double-band application will be performed."
48285695|NCT03448835|DRUG|Atezolizumab|atezolizumab 1200 mg 5 cycles
48285696|NCT03448835|DRUG|Capecitabine|capecitabine 850 mg /m2 4 cycles
48285697|NCT03448835|DRUG|Oxaliplatin|oxaliplatin 100 mg/m2 4 cycles
48285698|NCT03448835|DRUG|Docetaxel|docetaxel 50 mg/m2 4 cycles
48285699|NCT02127762|BEHAVIORAL|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
48285701|NCT04942548|OTHER|Ketogenic Diet|Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.
48285702|NCT03409302|BEHAVIORAL|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
48285703|NCT03409302|BEHAVIORAL|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
48285704|NCT05678998|DRUG|WTX-330|Investigation Product
48285705|NCT01013727|RADIATION|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
48285706|NCT00201799|DRUG|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
48285707|NCT04050748|PROCEDURE|Achilles tendon repair|Patients will be undergoing achilles tendon repair
48285708|NCT04718090|PROCEDURE|PENG Block|Pericapsular nerve group block in shoulder surgery.
48285709|NCT03846362|OTHER|HSCT|allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2\>0,1% and initial intermediate risk
48285710|NCT02632825|DEVICE|Nasal High Flow|Nasal High Flow Therapy
48285711|NCT06380998|DIETARY_SUPPLEMENT|whey protien|Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
48285712|NCT02075164|DIETARY_SUPPLEMENT|Fructose|High oral Fructose challenge (150g per day for 56 days)
48285713|NCT02075164|DIETARY_SUPPLEMENT|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
48285714|NCT00474253|DRUG|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
48285715|NCT00474253|DRUG|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
48285716|NCT00474253|DRUG|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
48285717|NCT01626040|DRUG|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
48285718|NCT00256555|DRUG|Nutropin AQ|
48285719|NCT04763525|BEHAVIORAL|Pythagorean Self-Awareness Intervention(PSAI)|The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.
48285720|NCT01225406|DRUG|Tenofovir|
48285721|NCT00581607|DRUG|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
48285722|NCT00581607|DRUG|Placebo|Placebo twice a day
48285723|NCT00581607|DRUG|Bosentan|drug given for 16 weeks
48285724|NCT00581607|DRUG|Placebo|placebo
48285725|NCT05584826|DRUG|MDMA|On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
48285726|NCT05962307|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
48285727|NCT03047005|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
48285728|NCT03047005|OTHER|Placebo|Placebo
48285729|NCT04170140|OTHER|No intervention|Questionnaire
48285730|NCT03463317|DEVICE|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
48285731|NCT03463317|DRUG|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
48285732|NCT03463317|DRUG|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
48285733|NCT03463317|DRUG|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
48285734|NCT03463317|DRUG|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
48285735|NCT03463317|DRUG|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
48285736|NCT03463317|DRUG|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
47939864|NCT06181279|PROCEDURE|Individualized PEEP group|Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).
48285737|NCT03463317|DRUG|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
47939865|NCT06181279|PROCEDURE|Fixed PEEP group|After the same RM, PEEP is fixed at 8 cmH2O.
47939866|NCT05871996|OTHER|Palliative Care and Oncology Survey on Terminology (POST)|Each group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
47939867|NCT02886689|DRUG|TNF-alpha antagonist and other biotherapy|
47939868|NCT05396703|PROCEDURE|TOETVA|Completed procedure.
47939869|NCT00650234|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
47939870|NCT00650234|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
48285738|NCT03463317|DRUG|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
48285739|NCT02986451|DRUG|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
48285740|NCT02986451|DRUG|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
48285741|NCT02986451|DRUG|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
48285742|NCT01613612|PROCEDURE|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
48285743|NCT01613612|PROCEDURE|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
48285744|NCT03701503|BEHAVIORAL|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
48285745|NCT00189826|DRUG|tacrolimus|immunosuppression
48285746|NCT03578406|DRUG|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
48285747|NCT00582231|OTHER|Questionnaires.|Questionnaires.
48285748|NCT01674764|PROCEDURE|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
48285749|NCT01674764|PROCEDURE|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
48471683|NCT06678776|PROCEDURE|surgery|Explore the relationship between breast fascia development and surgical processes by repeatedly observing surgical videos of endoscopic mastectomy and reduction mammaplasty.
48471684|NCT01275976|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
48471685|NCT01275976|OTHER|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
48471686|NCT00261417|DRUG|Tesaglitazar|
48471687|NCT05038891|DIAGNOSTIC_TEST|Digital Cervical Exam|Standard Digital Cervical Exam by an experienced OB provider
48471688|NCT05038891|DIAGNOSTIC_TEST|Transperineal Ultrasound|Self-administered transperineal ultrasound after instruction by a health care professional
48471689|NCT05038891|DIAGNOSTIC_TEST|Transvaginal Ultrasound|Self-administered transvaginal ultrasound after instruction by a health care professional
48471690|NCT01198249|DRUG|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
48471691|NCT00930033|PROCEDURE|Nephrectomy|Current surgery
48471692|NCT00930033|OTHER|Sunitinib alone|Sunitinib alone without nephrectomy
48471693|NCT06230783|OTHER|TalkTracker|Participants will be asked to complete the speech collection procedures remotely/at home once per week for 8 weeks. The 8-week period of weekly remote speech collection will take place yearly for a total of 3 years. At the end of each 8-week study period for years 1-3, participants will complete a survey that asks questions about how easy/difficult the application was to use, how frustrated they felt using the application, and other usability questions.
48471694|NCT04462302|BEHAVIORAL|Internet-based pain coping skills program|The purpose of this study is to determine if an 8-session Internet-based pain management program can help you better manage your cancer-related pain.
48471695|NCT06051409|DRUG|Olverembatinib|Orally, once every other day (QOD).
48471696|NCT06051409|DRUG|Imatinib|Orally, once daily (QD).
48471697|NCT02083172|DEVICE|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
48471698|NCT02192294|DRUG|Oral Bosutinib|a single dose of 500 mg oral bosutinib
48471699|NCT02192294|DRUG|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
48471700|NCT01671592|BIOLOGICAL|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
48285750|NCT04598438|BEHAVIORAL|Music behavioral early intervention program|The program consists of carefully designed play-based enhancement strategies implemented in the form of hybrid online/in-person playgroups. Following a teach-model-coach-review approach, parents will learn to implement various skills that are expected to enhance infant's language and communication skills through singing and engaging in musical play with their child at home.
48285751|NCT04598438|BEHAVIORAL|Arts and crafts early enhancement program|The program follows the same general structure with the music intervention program. Parents will learn how to implement a series of arts and crafts activities at home, with an aim to enhance infant's visual-perceptual, motor, and sensory integration development.
48285752|NCT04987593|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
48285753|NCT04350203|PROCEDURE|Laparoscopic right colectomy with intracorporeal anastomosis (IA)|First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).
48285754|NCT04350203|PROCEDURE|Laparoscopic right colectomy with extracorporeal anastomosis (EA)|First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
48285755|NCT05681728|DRUG|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
48285756|NCT05681728|DRUG|Paclitaxel|On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
48285757|NCT05681728|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
48285758|NCT05681728|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
48285759|NCT03335124|DRUG|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
48285760|NCT03335124|DRUG|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
48285761|NCT03335124|DRUG|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
48285762|NCT03335124|DRUG|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
48285763|NCT00198705|BEHAVIORAL|Improved management of severe neonatal infections|
48285764|NCT00730743|PROCEDURE|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
47939871|NCT04471597|DRUG|normal saline 0.9%|5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
47939872|NCT04471597|DRUG|Bupivacaine Hydrochloride|5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
47939873|NCT00566501|DRUG|Donepezil|Donepezil SR 23 mg once daily orally.
48285765|NCT04429750|PROCEDURE|Immediate umbilical cord clamping|"In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping)."
48285766|NCT04429750|PROCEDURE|intact cord resuscitation|The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
48285767|NCT00193843|PROCEDURE|Post-operative chemoradiotherapy / accelerated radiotherapy|
48285768|NCT04382508|OTHER|Questionnaire|A weekly questionnaire will be filled in
48285769|NCT04844190|DIAGNOSTIC_TEST|EndoFLIP|During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).
48471701|NCT06678087|OTHER|motherhood preparation meditation training prepared with the thetahealing meditation method|"With Birth and Motherhood Preparation Meditation, all physiological and psychological reasons causing fear of birth will be addressed. How to do the meditation will be taught by the practitioner in the course.~The root belief analysis study for each topic is carried out with the questions of who, what, when, where, why and how. Then, the reprogramming work that allows the change of that belief, feeling, emotion will be done with methods specific to the technique.~The topics to be worked on during meditation each week are listed below. Each week, pregnant women will be given a 15-minute meditation homework per day until the next week regarding the topic worked on.~All meditations begin with relaxation and breathing exercises. In each meditation, the emotion and root-belief analysis related to the relevant topic will be done by the practitioner.~With this application, it is aimed to accelerate the change in the mind with positive language and regular repetition."
48471702|NCT06678087|OTHER|pregnancy school,|"In the pregnancy school, an informational support training is provided to pregnant women and their families to ensure that the pre-pregnancy, pregnancy and birth process is passed in a healthy and conscious manner.~The training content includes:~Reproductive organs and development, Nutrition during pregnancy and puerperium, Common problems during pregnancy, Physiological changes, Non-formological methods, Breathing techniques during birth, Anesthetic methods, Birth methods and techniques, Postpartum and baby care, Newborn Care / Problems, Home-Bag-Hospital preparation, Breast milk - Its importance - Breastfeeding, Family planning topics are given five days a week for 2 hours."
48471703|NCT05098132|DRUG|STK-012|pegylated alpha/beta-biased engineered interleukin-2
48471704|NCT05098132|DRUG|pembrolizumab|anti-PD-1 humanized monoclonal antibody
48285770|NCT04844190|DIAGNOSTIC_TEST|Antroduodenal Manometry|Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
48471705|NCT05098132|DRUG|pemetrexed|antifolate chemotherapy
48471706|NCT05098132|DRUG|carboplatin|platinum chemotherapy
48471707|NCT03815240|OTHER|No dressing|no dressing at sacrum
48471708|NCT03815240|OTHER|Mepilex® Border Sacrum|adhesive sacrum dressing
48471709|NCT03815240|OTHER|ALLEVYN Life Sacrum|adhesive sacrum dressing
48471710|NCT03815240|OTHER|Optifoam® Gentle Sacrum|adhesive sacrum dressing
48471711|NCT03793296|DEVICE|Percutaneous Device Closure: Vascular plug|percutaneous transcatheter approach into cardiac valve
48471712|NCT00333853|DEVICE|OneTouch(r) UltraSmart(r)|
48471713|NCT03380416|OTHER|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
48471714|NCT03380416|OTHER|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
48471715|NCT02402491|DRUG|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
47939874|NCT06084728|DIAGNOSTIC_TEST|Color Doppler ultrasonography|in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
48285771|NCT06319911|DEVICE|AETOS|The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
48285772|NCT02437669|DRUG|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
48285773|NCT02112110|DRUG|BMS-791325|
48471716|NCT02402491|DRUG|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
48471717|NCT02402491|DRUG|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
48471718|NCT02625506|DRUG|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
48471719|NCT02625506|DRUG|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
48617941|NCT03690544|DRUG|Apremilast 30mg|Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
48471720|NCT03169621|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
47939875|NCT00479895|DRUG|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
47939876|NCT05553951|BEHAVIORAL|Controlgroup|The control group and intervention group will receive daily text message reminders twice a week to take their medications and to rinse their nose.
47939877|NCT05553951|BEHAVIORAL|Intervention|Patients in the intervention group will receive systematic and structured nursing guidance regarding their adherence, which includes proper use of nasal irrigation once or twice daily, nasal steroid/drops, use of inhaled medications, follow-up of smoking status. The intervention group will receive guidance videos which have been prepared prior to the study and will be standard for the intervention group. Guidance videos will cover the correct use of nasal irrigation, inhalation steroid, and nasal steroid/drops.
48471721|NCT05931276|DRUG|Metoprolol Succinate|a dialyzable, beta-1 selective beta blocker
48285774|NCT02112110|DRUG|[13C]-BMS-791325|
48471722|NCT05931276|DRUG|Carvedilol|a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties
48471723|NCT01132261|OTHER|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
48471724|NCT00537017|DRUG|Preladenant|5 mg BID capsules
48471725|NCT00537017|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
48471726|NCT00537017|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
48471727|NCT03577886|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
48471728|NCT03577886|DRUG|Placebo|Phosphate Buffer Diluent oral solution
48471729|NCT02987634|OTHER|PeriActive|mouthwash
48471730|NCT03307811|OTHER|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
48617942|NCT01117870|OTHER|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
48285775|NCT05836961|OTHER|Benazir Nashonuma Program (BNP)|"Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
48285776|NCT03576027|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
48285777|NCT05632172|PROCEDURE|implant insertion|bone level dental implant insertion
48285778|NCT05374356|DRUG|Intrathecal bupivacaine and morphine|Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
48285779|NCT01104831|DEVICE|Cryotherapy|cooled sleeve placed over fracture site.
48285780|NCT01104831|DEVICE|Room temperature cuff|sleeve with room temperature water placed over fracture site.
48285781|NCT00308620|DRUG|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
48285782|NCT00308620|DRUG|Placebo|Placebo once daily for 8 weeks
48285783|NCT03560076|OTHER|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
48285784|NCT00467649|DRUG|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
48285785|NCT00467649|DRUG|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
48285786|NCT00467649|DRUG|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
48285789|NCT04453644|OTHER|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
48285790|NCT06075615|DRUG|dacomitnib|patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
48285791|NCT02730247|DRUG|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
48285792|NCT02730247|DRUG|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
48285793|NCT05914363|OTHER|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling
47939878|NCT06437990|PROCEDURE|Arteriovenous loop graft|Using saphenous vein graft to create an arteriovenous loop from the common carotid artery to the external jugular vein, providing vascular supply for a free functional gracilis muscle flap in patients with late-onset brachial plexus injury with concomitant subclavian or axillary artery injury.
48285794|NCT05914363|BEHAVIORAL|Behaviour change intervention|Support for behaviour change through 'floor clubs' and the provision of printed guides
47939879|NCT02524964|DRUG|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
48285795|NCT05914363|DRUG|Routine deworming|Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
48285796|NCT05914363|PROCEDURE|treatment for tungiasis|Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
48285797|NCT06196840|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
48285798|NCT06196840|BIOLOGICAL|Aflibercept intravitreal injection|Commercially available Active Comparator
48285799|NCT05316363|OTHER|OMT|"Suboccipital Release - Finger pads are placed onto suboccipital musculature and a smooth, gentle, and rhythmic laterocephalad traction is applied to reduce muscle tension.~Paraspinal Inhibition - Hands are placed under the patient's thoracolumbar spine and contract the erector spinae tissue to draw the thoracolumbar spine into extension and hold until relaxation is felt.~Rib Raising - Hands are placed under the subject's thorax and contact the rib angles with finger pads. Fingers are flexed while adding an anteriolateral traction directed at the rib angle while maintaining neutral wrists. Arms are used as a lever by leaning forward thus creating a fulcrum with the treatment table with a smooth, rhythmic motion. This motion is repeated several times throughout the entire thoracic region, unilaterally and then switch sides.~Diaphragm Release - Hands apply a gentle pressure until a barrier or point of ease of the fascia is felt and hold that position until tissue response is felt."
48285800|NCT04036760|BEHAVIORAL|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
48285801|NCT05324215|PROCEDURE|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
48285802|NCT05324215|DEVICE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
48285803|NCT01683500|DEVICE|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
48285804|NCT02795234|OTHER|Blood samples|
48285805|NCT00814710|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
48285806|NCT00814710|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
48285807|NCT00814710|BIOLOGICAL|Hiberix|Intramuscular injection, 3 doses
48285808|NCT00814710|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 3 doses
48285809|NCT04603378|OTHER|KB195|KB195 is a novel glycan
48285810|NCT04603378|OTHER|Polydextrose|Polydextrose is an oligosaccharide
48471731|NCT04799223|OTHER|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
48471732|NCT04799223|OTHER|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
48471733|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
48471734|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
48471735|NCT01040793|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
48471736|NCT01040793|DRUG|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
48471737|NCT01040793|DRUG|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
48471738|NCT05191511|RADIATION|Far- infrared|safety of far- infrared
48471739|NCT02269150|BIOLOGICAL|fecal microbiota transplantation (FMT)|
48471740|NCT02269150|OTHER|No fecal microbiota transplantation (FMT), routine management|
48471741|NCT05281172|BEHAVIORAL|Guided Self-Change therapy (GSC)|The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
48471742|NCT05281172|BEHAVIORAL|Psychoeducation program about healthy habits|The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
48285811|NCT04603378|OTHER|Pullulan|Pullulan is an oligosaccharide
48285812|NCT04603378|OTHER|Maltodextrin|Maltodextrin is a digestible carbohydrate
48285813|NCT05347823|DIAGNOSTIC_TEST|Hair analysis for drug concentration|Sample collection for the determination of treatment adherence
48285814|NCT02844738|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Days 7 and 14 \[PRP\]
48285815|NCT03285529|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
48285816|NCT03285529|DEVICE|VICRYL|Vicryl #1
48285817|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (800mg). Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
48285818|NCT05835401|DIETARY_SUPPLEMENT|Beetroot juice depleted in nitrate|The participant will intake beetroot juice depleted in NO3. Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
48285819|NCT01663649|BEHAVIORAL|Deprexis|web-based treatment program for depression
48285820|NCT01663649|BEHAVIORAL|Wait-list|the wait-list group receives Deprexis after 6 month
48471743|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction|Axillary Lymph Node Dissection with Immediate Lymphatic Reconstruction
48471744|NCT04241341|PROCEDURE|Axillary Lymph Node Dissection without Immediate Lymphatic Reconstruction|Current standard treatment at Memorial Sloan Kettering \[MSK\]).
48471745|NCT04241341|OTHER|quality-of-life questionnaires|Four validated patient reported outcome measures (PROMs): the Upper Limb Lymphedema-27 (ULL-27), the Quality of Life Measure for Limb Lymphedema (LYMQOL), the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R), and the Beck Anxiety Inventory (BAI). Study participants will undergo standard lymphedema measurements and quality-of-life questionnaires at baseline before ALND and postoperatively at 6 weeks (+/- 30 days) and at 6, 12, 18, and 24 months (+/- 30 days). If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them.
48471746|NCT04241341|OTHER|measured by arm volume|Bilateral arm volumes will be measured with sequential circumferential measurements with the truncated cone formula. If a patient cannot return to Manhattan for these assessments but is seen by a lymphedema therapist in a regional location or at an institution outside of MSK as part of their routine cancer treatment, this data can be used in the final analysis
48471747|NCT01710124|OTHER|Financial incentives|
48471748|NCT04815109|OTHER|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
48471749|NCT05626725|DEVICE|Automated insulin delivery system|This is an outpatient prospective observational study to evaluate the effect of DIY-AID use on maintaining glucose levels in physically active adult people living with T1D.
48471750|NCT03293771|OTHER|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
48471751|NCT03293771|DIAGNOSTIC_TEST|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
48285821|NCT03146312|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
48471752|NCT02672969|DEVICE|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
48471753|NCT03375749|BEHAVIORAL|Standing desk intervention|Standing desk converter
48471754|NCT03375749|BEHAVIORAL|Waitlist control|Control
48471755|NCT01324856|PROCEDURE|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
48471756|NCT01324856|PROCEDURE|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
48471757|NCT02023996|RADIATION|89Zr-DFO-trastuzumab|
48471758|NCT02023996|DEVICE|PET imaging|
48471759|NCT03604432|DEVICE|propylactic maze|Prophylactic limited left sided maze procedure for subjects in the treatment arm
48471760|NCT05721092|OTHER|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
48471761|NCT04975451|DRUG|Anlotinib|Anlotinib plus DCb
48471762|NCT02272894|PROCEDURE|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
48471763|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
48471764|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
48471765|NCT00307970|DRUG|HFA FP MDI|
48471766|NCT00307970|DEVICE|conventional chamber/mask; anti-static chamber/mask|
48471767|NCT00585312|DRUG|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
48471768|NCT00585312|DRUG|Placebo|Masked, placebo comparator
48285822|NCT03146312|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
48285823|NCT02573116|PROCEDURE|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
48285824|NCT05580289|OTHER|half-shower and hot pack|The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
48285825|NCT01565525|BEHAVIORAL|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
48471769|NCT04791956|DIETARY_SUPPLEMENT|Prebiotic|Daily intake of Inulin-type fructans from chicory
48471770|NCT04791956|DIETARY_SUPPLEMENT|Placebo|Daily intake of maltodextrin
48471771|NCT02751216|OTHER|EEG recording + pain protocol|
48471772|NCT01195220|BEHAVIORAL|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
48285826|NCT01565525|BEHAVIORAL|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
48285827|NCT01075425|DRUG|bortezomib|Given IV
48285828|NCT01075425|DRUG|belinostat|Given IV
48285829|NCT01075425|OTHER|laboratory biomarker analysis|Correlative studies
48285830|NCT01075425|GENETIC|western blotting|Correlative studies
48285831|NCT01075425|OTHER|pharmacological study|Correlative studies
48285832|NCT01075425|OTHER|flow cytometry|Correlative studies
48285833|NCT04506424|OTHER|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
48285834|NCT00738738|DRUG|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
48617943|NCT01117870|OTHER|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
48285835|NCT01733706|DEVICE|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
48629932|NCT05818787|BEHAVIORAL|Vestibular Perceptual Learning|The participants will be tilted and asked to indicate their perceived direction of self-motion (e.g., left or right). Feedback will be provided to promote learning (i.e., improved perception of motion). Feedback will only be provided after the subject response, and thus vestibular (i.e., self-motion) perception is required to judge the direction of the tilt stimulus. After each trial, a 3 second period of rest will be given. Each day of training will include three blocks of one-hundred trials each. Testing will take place in the dark (except for aims where a visual cue is provided). Subjects will be seated on a motion platform with a 5-point harness and the head restrained. Noise cancelling earpieces (along with a white noise signal) will be used to reduce external noise. Subjects will always be asked to make a decision (e.g. left versus right) by pressing buttons with their left or right hands. If not certain, subjects are instructed to provide their best guess.
48629933|NCT05818787|BEHAVIORAL|Placebo Intervention|The placebo (or control) task will consist of oculomotor exercises that the subject will complete at home (i.e., outside of the lab). The oculomotor exercises will include saccadic eye movements performed in the horizontal and vertical planes. All movements will be completed within a limited, comfortable range of motion with the head remaining stationary. As the control intervention will be performed with the head stationary and in a seated position, no change in self-motion perception or balance is expected to result from the control (i.e., placebo) task.
48629934|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 100 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 100 Hz, performed at a sub-motor threshold for 30 minutes.
47939880|NCT02524964|OTHER|control|equivalent volume of sodium chloride solution
47939881|NCT01551537|OTHER|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
48285836|NCT01733706|OTHER|Standard counseling|standard counseling
47939882|NCT01551537|OTHER|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
47939883|NCT01076816|DRUG|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
48285837|NCT04238845|DRUG|AQSP Administration|Three days treatment of all children with AQSP for SMC
48285838|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
48629935|NCT06274021|DEVICE|Transcutaneous spinal stimulation at 50 Hz|Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.
48285839|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
48285840|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Zinc|Daily supplementation with Zinc
47939884|NCT01076816|PROCEDURE|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
47939885|NCT01076816|PROCEDURE|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
47939886|NCT00573196|RADIATION|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
47939887|NCT01732003|DIETARY_SUPPLEMENT|Omega-3 Complete|
47939888|NCT01732003|DIETARY_SUPPLEMENT|Placebo Pill|
48285841|NCT00584064|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
48285842|NCT04627545|OTHER|2h exposure to sperm for IVF|Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination
48285843|NCT04627545|OTHER|overnight exposure to sperm for IVF|Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
48285844|NCT03744234|PROCEDURE|PRP|Autologous platelet-rich plasma
48285845|NCT03744234|PROCEDURE|Steroid Injection|Steroid injection
48617944|NCT03834090|DEVICE|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
48471773|NCT01195220|BEHAVIORAL|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
48471774|NCT01195220|BEHAVIORAL|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
48471775|NCT03442192|OTHER|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~* On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~* HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
48629936|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a single dose of baclofen, a centrally-acting muscle relaxant belonging to the class of gamma-aminobutyric acid (GABA) analogs. Its primary mechanism involves acting on the GABA receptors in the brain and spinal cord to decrease spasticity. Participants will receive baclofen orally at a single dose of 10 mg."
48629937|NCT06274021|COMBINATION_PRODUCT|Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine|"Transcutaneous spinal stimulation (TSS) is a non-invasive neuromodulation method that uses electrical currents to stimulate sensory fibers. The procedure involves placing surface electrodes midline on the lower back (T11-12 spinal processes) and on each side of the belly button. The stimulation frequency during the intervention is 50 Hz, performed at a sub-motor threshold for 30 minutes.~Study participants will receive a medication called tizanidine, which is an alpha-2 adrenergic agonist. This medication works by inhibiting presynaptic motor neurons, resulting in a reduction of muscle spasticity. It is commonly used to manage spasticity caused by neurological disorders. Each participant will be given a single oral dose of 4 mg of tizanidine as part of this trial."
48471776|NCT01334957|DRUG|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
48471777|NCT05333315|DIETARY_SUPPLEMENT|IP1|"IP1: 2 softchews 3 times a day before meals with 1-2 glasses of water for eight weeks.~OTHER: Placebo"
48629938|NCT06274021|DEVICE|Sham transcutaneous spinal stimulation|Sham Transcutaneous spinal stimulation (TSS) involves placing two surface electrodes midline on the lower back (T11-12 spinal processes). The stimulation frequency during the intervention is 50 Hz, performed for 30 minutes.
48629939|NCT01975584|BEHAVIORAL|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
48629940|NCT02423720|BEHAVIORAL|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
48629941|NCT03985995|DRUG|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
47939889|NCT01772511|BEHAVIORAL|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
47939890|NCT00806871|DRUG|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
47939891|NCT00806871|DRUG|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
47939892|NCT00806871|DRUG|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
47939893|NCT03245229|DRUG|Aprocitentan|Capsule for oral administration
47939894|NCT03245229|DRUG|Rosuvastatin|Tablet for oral administration
47939895|NCT00723203|DRUG|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
47939896|NCT00723203|GENETIC|gene expression analysis|Day 1 and day 28 samples
47939897|NCT00723203|GENETIC|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
48471778|NCT05333315|DIETARY_SUPPLEMENT|IP2|"IP2: One bag per day mixed in 200 mL of cold water or tea and consumed immediately, on an empty stomach, half an hour before breakfast for eight weeks.~OTHER: Placebo"
48471779|NCT05333315|DIETARY_SUPPLEMENT|IP3|"IP3: One bag per day in the morning, dissolved in a glass of warm water and three capsules per day with a glass of water or tea (one capsule at breakfast, one at lunch and one at dinner) for eight weeks.~OTHER:Placebo"
48471780|NCT05333315|DIETARY_SUPPLEMENT|IP4|"IP4: Twice a day 20 mL half an hour before breakfast and half an hour before dinner for eight weeks.~OTHER:Placebo"
48471781|NCT05333315|DIETARY_SUPPLEMENT|IP5|"IP5: Formula 1: One capsule per day at breakfast with a glass of water for eight weeks and Formula 2: Two capsules a day at breakfast and at dinner with a glass of water for eight weeks.~OTHER:Placebo"
48471782|NCT03735706|RADIATION|Radiation dose reduction|The radiation dose is is different between groups
48471783|NCT03735706|OTHER|Contrast media volume reduction|Contrast media volume is different between groups
48285846|NCT00636818|DRUG|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
47939898|NCT00723203|OTHER|laboratory biomarker analysis|Day 1 and day 28 samples
47939899|NCT04327310|DRUG|Meplazumab for Injection|humanized mAb against CD147
47939900|NCT04327310|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
47939901|NCT05610085|DRUG|Levetiracetam Injection|Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
47939902|NCT05610085|DRUG|Phenobarbital Sodium Injection|Standard of care for neonatal seizures
48285847|NCT02803216|DRUG|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
48471784|NCT03735706|RADIATION|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
48471785|NCT03735706|DIAGNOSTIC_TEST|Weight|A weighing scale is used to measure a patients body weight right before the scan.
48471786|NCT03561987|PROCEDURE|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
48471787|NCT04702035|DEVICE|Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)|All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
47939903|NCT03560830|OTHER|2 submaximal exercise stress tests|
47939904|NCT00953459|DRUG|sunitinib malate|
47939905|NCT00953459|OTHER|laboratory biomarker analysis|
47939906|NCT00953459|RADIATION|fludeoxyglucose F 18|
47939907|NCT05814497|OTHER|Multisensory Task|Reversing checkerboard, tones, and finger opposition.
47939908|NCT05814497|OTHER|Graphesthesia|Trace numbers on skin.
47939909|NCT05814497|OTHER|Divided attention|Divide attention between two noxious stimuli.
47939910|NCT02985203|DRUG|Vinorelbine Oral|Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
47939911|NCT03759288|DRUG|Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
48101359|NCT04495634|DEVICE|Stationary Head CT (s-HCT)|The system consists of a total of three x-ray sources and nine x-ray detectors with an estimation of approximately 150 projection angles per slice, with less than a minute per slice reconstruction. Radiation dose will be configured as to not exceed that of a conventional head CT, or 2 mSv. The subjects will be positioned on a medical procedure table that will move the subject through the scanning system at the rate of roughly 1 cm per second, during which the necessary x-ray projections will be acquired. The head will be positioned in a carbon fiber head holder from a clinical CT scanner that is secured to the table.
48471788|NCT00011609|DEVICE|Robotic Arm|
47939912|NCT03759288|DRUG|Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous Brazikumab on Day 85 and every 4 weeks through Week 48
47939913|NCT03759288|DRUG|Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
47939914|NCT03759288|DRUG|Placebo|Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 4 weeks through Week 48
47939915|NCT01626638|PROCEDURE|Confocal Micro Endoscopy|
47939916|NCT04476550|DRUG|Filgrastim|5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
47939917|NCT06183190|OTHER|No intervention|No intervention
47939918|NCT05596396|BEHAVIORAL|LifeHack|Participants assigned to LifeHack will follow a six week-guided online intervention with a fixed structure where the themes are delivered in a predefined order, and the contents get unlocked sequentially. The first mandatory module is the introduction module which also functions as a goal-setting module. Following this, students complete one mandatory module per week (and the optional modules if they choose to do so) delivered sequentially, starting with the theme of mood, studies, social life and finally, self-esteem. Students complete the themes one by one and the consecutive themes (and modules) are unlocked only after completing the main module of the assigned theme.
47939919|NCT05596396|BEHAVIORAL|LifeHack-C|Participants assigned to LifeHack-C will receive the same guided online intervention, but they can choose what theme they would like to start with, when to work on it and how many modules they wish to complete. After completing the introduction module, the participants will be advised to complete two modules per week and at least four in total. Therefore, the program's duration will be approximately two and six weeks. However, participants can follow the program at their own pace.
47939920|NCT04805827|DRUG|Gabapentin|1 tablet contains 600 mg Gabapentin
47939921|NCT04805827|DRUG|Neurontin|2 capsule contains 2\*300 = 600 mg Gabapentin
47939922|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
48101360|NCT05181449|BEHAVIORAL|Twin Precision Treatment|Combination of Artificial Intelligence algorithms based on daily sensor input and live nutrition, exercise, sleep and breath coaching to help treat type 2 diabetes
48285848|NCT02803216|DRUG|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
48285849|NCT02803216|DRUG|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
48285850|NCT04754373|DIETARY_SUPPLEMENT|GFA-918|Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
47939923|NCT01464983|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
47939924|NCT01464983|DRUG|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
47939925|NCT01464983|DRUG|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
47939926|NCT01464983|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
47939927|NCT00451139|DRUG|artemether/lumefantrine|
47939928|NCT00451139|DRUG|quinine|
48101361|NCT00320489|DRUG|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
48285851|NCT04754373|OTHER|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
48285852|NCT00715715|DRUG|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
48471789|NCT02760355|DRUG|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
48471790|NCT02760355|DRUG|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks.
48471791|NCT01333917|DRUG|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
48471792|NCT00630903|DRUG|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
48471793|NCT00630903|DRUG|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
48471794|NCT04659486|BEHAVIORAL|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
48629942|NCT03985995|DRUG|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
48629943|NCT00483392|DRUG|metformin, rosiglitazone|
47939929|NCT00451139|DRUG|atovaquone/proguanil|
47939930|NCT02016339|BEHAVIORAL|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
48101362|NCT00320489|DRUG|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
48101363|NCT03046290|PROCEDURE|circumcision|
48101364|NCT03046290|DRUG|Lidocaine|
48285853|NCT03400293|OTHER|Functional Assessment of HIV Infection|Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
48285854|NCT03400293|OTHER|Patient Satisfaction Questionnaire|Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
48285855|NCT03400293|OTHER|Symptom Distress Module|Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
48629944|NCT03675555|DRUG|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline \[NS\]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
47939931|NCT02016339|BEHAVIORAL|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
47939932|NCT00562744|OTHER|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
47939933|NCT03317132|BEHAVIORAL|IPS|One year of IPS Support
47939934|NCT03771053|DRUG|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
47939935|NCT03771053|DRUG|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
47939936|NCT02296944|OTHER|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
47939937|NCT06518525|OTHER|pilates-based tele-exercises|pilates-based tele-exercises
47939938|NCT01216267|DRUG|Lansoprazole|lansoprazole 30 mg HS x 7 days
47939939|NCT01216267|DRUG|lansoprazole|lanzoprazole 30 mg HS for 7 days
47939940|NCT00800748|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
48101365|NCT03046290|DRUG|Ropivacaine|
48471795|NCT03473067|BEHAVIORAL|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
48471796|NCT03473067|OTHER|Capacity Building|Schools will participate in teacher training and parent training.
48471797|NCT00136890|PROCEDURE|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
48471798|NCT01280227|BEHAVIORAL|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
47939941|NCT00800748|DRUG|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
48285856|NCT03400293|OTHER|Patient Health Questionnaire|Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
48285857|NCT03400293|OTHER|Internalized Stigma of AIDS Tool|Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
48471799|NCT01127776|DEVICE|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
48471800|NCT01127776|OTHER|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
48471801|NCT05970614|OTHER|Eye masks and ear plugs|Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
48471802|NCT01451996|DRUG|Claritin|Subject will be given 10mg Claritin tablet.
48471803|NCT05864924|BIOLOGICAL|Cohort A: 3.0x10^6 CAR-T cells/kg|Intravenous infusion
48471804|NCT05864924|BIOLOGICAL|Cohort B: 9.0x10^6CAR-T cells/kg|Intravenous infusion
48471805|NCT05864924|BIOLOGICAL|Cohort C:1.5x10^7 CAR-T cells /kg|Intravenous infusion
48471806|NCT06563583|OTHER|Group 1 will include patients aged 18-40 years|Group 1 will include patients aged 18-40 years.
48471807|NCT06563583|OTHER|Group 2 will include patients aged 40-64 years|Group 2 will include patients aged 40-64 years, and finally.
48471808|NCT06563583|OTHER|Group 3 will include patients aged 65-85 years|Group 3 will include patients aged 65-85 years.
48471809|NCT06112834|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
48471810|NCT01362296|DRUG|GSK1120212|Oral once daily
48471811|NCT01362296|DRUG|docetaxel|IV once every 3 weeks
48471812|NCT00441961|DRUG|methotrexate|methotrexate
47939942|NCT01539798|OTHER|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
48285858|NCT03400293|OTHER|Medication adherence visual analogue scale|Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
48285859|NCT05091346|DRUG|E7386|E7386 tablet.
48285860|NCT05091346|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
48471813|NCT03544840|OTHER|Physical Therapy Home Program|On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
48471814|NCT02495376|BEHAVIORAL|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
48471815|NCT06411392|RADIATION|Stereotactic Antiarrhythmic Radiotherapy|Patients with ventricular tachycardia will undergo cardiac stereotactic antiarrhythmic radiotherapy with a single fraction of 25 Gy to the arrhythmia substrate, as determined by electrophysiological cardiac mapping.
48471816|NCT04851067|OTHER|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
48471817|NCT04851067|OTHER|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
48471818|NCT05594641|OTHER|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
48285861|NCT05091346|DRUG|Lenvatinib|Lenvatinib capsule.
48285862|NCT03904615|DIETARY_SUPPLEMENT|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
48285863|NCT03904615|DIETARY_SUPPLEMENT|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
48629945|NCT03675555|DRUG|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
47939943|NCT01539798|OTHER|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
48285864|NCT03904615|DIETARY_SUPPLEMENT|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
48285865|NCT02152969|DRUG|Telmisartan|
48285866|NCT02152969|DRUG|Amlodipine|
47939944|NCT04132882|DRUG|Sodium Thiosulfate (STS)|
47939945|NCT01600118|DEVICE|Extracorporeal shockwave therapy|1000 impulses
47939946|NCT01600118|DEVICE|No extracorporeal shockwave|0 impulses, acoustic effect
47939947|NCT05032430|BEHAVIORAL|CCC|A mix of mindfulness-based stress reduction, mindful eating, and mindful parenting strategies.
48285867|NCT02152969|DRUG|Chlorthalidone|
48285868|NCT01305915|BEHAVIORAL|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
48471819|NCT05594641|OTHER|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
48471820|NCT01110044|BIOLOGICAL|251154 vaccine|Intramuscular, single dose
48471821|NCT01110044|BIOLOGICAL|Infanrix hexa™|Intramuscular, four doses
48471822|NCT01110044|BIOLOGICAL|Synflorix™|Intramuscular, four doses
48471823|NCT01110044|BIOLOGICAL|Rotarix™|Oral, two doses
48471824|NCT01843257|OTHER|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
47939948|NCT05032430|BEHAVIORAL|Enhanced Usual Care|Consists of strategies meant to enhance health and well-being (e.g., health education, strategies to get more physical activity) but does not include mindfulness as an active ingredient.
48101366|NCT03864484|DEVICE|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
48101367|NCT03864484|BEHAVIORAL|Usual rehabilitation|The control group receives usual rehabilitation.
48101368|NCT05337072|DIAGNOSTIC_TEST|Microbiome study|Investigation of the vaginal and endometrial microbiome
48101369|NCT03644537|PROCEDURE|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
48101370|NCT04182087|BEHAVIORAL|Cognitive tasks|Attention, language, memory, decision-making or executive functions
48101371|NCT05069935|DRUG|FT538|FT538 is an allogeneic natural killer (NK)-cell immunotherapy
48101372|NCT05069935|DRUG|Cyclophosphamide|Lympho-conditioning agent
47939949|NCT02824172|OTHER|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
48101373|NCT05069935|DRUG|Fludarabine|Lympho-conditioning agent
48101374|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Escalation|either avelumab, trastuzumab or cetuximab
48101375|NCT05069935|COMBINATION_PRODUCT|Monoclonal antibody - Dose Expansion|either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab
48285869|NCT02242396|DRUG|Telmisartan|
48285870|NCT02242396|DRUG|Telmisartan hydrochlorothiazide|
48285871|NCT05357183|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
48285872|NCT03932955|BIOLOGICAL|MC-19PD1 CAR-T cells|T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
48285873|NCT00555945|PROCEDURE|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
48471825|NCT01843257|OTHER|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
48471826|NCT04983524|DIETARY_SUPPLEMENT|propolis|resinous product of honeybees
47939950|NCT02824172|OTHER|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
47939951|NCT03861611|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
47939952|NCT03861611|DRUG|Ibuprofen|Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
47939953|NCT03861611|DRUG|Diclofenac|Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
48101376|NCT00996372|DRUG|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
48101377|NCT00996372|DRUG|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
48285874|NCT00555945|PROCEDURE|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
48285875|NCT05086237|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
48285876|NCT00377962|DRUG|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
48471827|NCT04983524|DRUG|Calcium Hydroxide|Gold standard control intracanal medicament
48471828|NCT00022555|DRUG|bryostatin 1|Given IV
48471829|NCT00022555|DRUG|vincristine sulfate|Given IV
48471830|NCT01398839|DEVICE|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
48471831|NCT01398839|DRUG|Riboflavin|Both treatment and sham groups will receive riboflavin
47939954|NCT03861611|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
47939955|NCT06313879|OTHER|online education|Description of hydrocephalus disease, treatment methods and ventriculoperitoneal shunt care training will be given.
47939956|NCT00430430|PROCEDURE|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
48285877|NCT00377962|DRUG|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
48471832|NCT03446599|DRUG|Hydroxocobalamin|One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
48285878|NCT00377962|DRUG|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
48285879|NCT00377962|DRUG|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
47939957|NCT00430430|PROCEDURE|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
47939958|NCT03593434|DRUG|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
47939959|NCT06063707|OTHER|Taking peripheral blood|Taking peripheral blood of no more than 3ml
47939960|NCT02746367|OTHER|Diagnostic test (LDT)|Proteomic assay
47939961|NCT04805320|PROCEDURE|Dental Extraction|Extraction
47939962|NCT02634710|RADIATION|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
47939963|NCT06079528|DEVICE|Electromagnetic device|"Health wave's generator (Manufactured with Simeds S.r.l. by Machiavelli, Italy, with serial number 11492.) with two separate emission channels and asynchronous operation was employed, along with 100 saved and storable programs that could be altered by the user (intensity, frequency and phase time). The different associated applicators are recognized automatically. Magnetic field strength up to 100 Gauss and output frequency from (1 - 100) Hertz are programmable."
47939964|NCT06079528|OTHER|visceral manipulation therapy|for the pelvic reproductive organs and their related structures (ligaments and fasciae) was applied one session/week for 12 weeks. Each patient was was advised to evacuate her bladder before starting the treatment session, mobility and motility testing of pelvic organs, together with the assessment of fascial tension, was then performed, with detecting restrictions, treatment was applied according to Hebgen
48471833|NCT03446599|DRUG|Methylene Blue|One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
48471834|NCT03446599|DRUG|Normal saline|200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
48471835|NCT03203642|DRUG|Tesevatinib|Pharmaceutical form: Tablet; Route of administration: orally
48471836|NCT03203642|DRUG|Placebo|Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
48471837|NCT06527638|BEHAVIORAL|Experimental Group: eHealth intervention for UI symptoms improvement|"The intervention was theoretically based on the HAPA model (including effective strategies in behaviour change, for example, action planning and coping with obstacles) and Common Sense Model of Self Regulation (beliefs, coping and appraisal), focusing on risk perception, planning, and self-efficacy.~The intervention consisted of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, were led by the psychologist responsible for the study, except the second session that was led by a physiotherapist. WhatsApp groups were created, to share experiences, knowledge, doubts and fears, and to create a sense of belonging, understanding and cohesion.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
48629946|NCT03675555|DRUG|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
48629947|NCT06001307|BEHAVIORAL|Program STARS (Supporting Trans Affirmation, relationships, and Sex)|See description to the left.
48285880|NCT03913910|PROCEDURE|Lipogems|Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
48285881|NCT00003029|DRUG|cisplatin|
48285882|NCT00003029|DRUG|fluorouracil|
47939965|NCT06079528|OTHER|General advice|were directed for both groups in term of the following: Perform pelvic floor exercises regularly ; avoid constipation and straining; treat the cause of any chronic cough and infection of urethra or bladder; stop smoking; maintain a healthy weight; drinking sufficient amounts of healthy fluids (water); decrease the caffeine intake; and decrease the amount of acidic and spicy foods.
48285883|NCT00730093|DIETARY_SUPPLEMENT|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
48285884|NCT01046149|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
48285885|NCT01046149|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
48285886|NCT01585649|DRUG|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
48285887|NCT05822856|OTHER|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
48285888|NCT03114761|RADIATION|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
48471838|NCT06527638|BEHAVIORAL|Control Group: Delivery of a Health Literacy single-leaflet|"A health literacy single-leaflet was delivered, by e-mail in the first week of the intervention. Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
48471839|NCT06143527|BIOLOGICAL|AlloRx|Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48629948|NCT06001307|BEHAVIORAL|Relaxation and Stress Reduction|See description to the left.
48629949|NCT02867826|DEVICE|Cap|Cap-assisted endoscopy
48285889|NCT06230796|DEVICE|FES-cycling|30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
47939966|NCT06079528|OTHER|pelvic floor muscle training|consisted of 24 sessions of 45-60 min each, twice a week, for 12 weeks. The PFMT was divided into four phases. Proprioceptive (3 weeks): where the woman has gained adequate perception of PFM and performed fast and slow contractions; Simple (3 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (3 week): where the exercise evolved into functional exercises of greater amplitude; and Power (3 week): where the maximum voluntary contraction of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and fast fibers
48629950|NCT01446653|BEHAVIORAL|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
47939967|NCT01247038|DEVICE|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
48285890|NCT06230796|DEVICE|SHAM-cycling|30 minutes of active leg cycling with SHAM FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
47939968|NCT01247038|DEVICE|Metal-on-Metal|Metal on Metal articulation
47939969|NCT02756065|OTHER|no intervention|no intervention is used
48629951|NCT01446653|BEHAVIORAL|Video|Video arm will provide information via documentary video
47939970|NCT00571376|OTHER|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
47939971|NCT06424327|OTHER|Patient-Reported Outcomes Measurement Information System|Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
48101378|NCT00639613|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
48285891|NCT00231478|DRUG|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
47939972|NCT03258138|BEHAVIORAL|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
48101379|NCT00639613|OTHER|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
48101380|NCT02989012|DRUG|GanMaoKangNing Granules|3 times a day, 2 bags each time.
48285892|NCT00231478|DRUG|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
48285893|NCT03306147|BEHAVIORAL|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
48285894|NCT00160927|DEVICE|local heating|
48285895|NCT00160927|DEVICE|iontophoresis|
48471840|NCT00198224|PROCEDURE|phlebotomy|
48629952|NCT01446653|BEHAVIORAL|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
48629953|NCT00581997|DRUG|QAX576|
48629954|NCT00581997|DRUG|Placebo|
48629955|NCT04479384|OTHER|Manual therapy - osteopathic techniques|"* HVLAT if any somatic dysfunction in T1-T5~* Stretch intrathoracic fascia x 3~* Recoil sternum x 3~* Cranial base release, 4 phases"
48629956|NCT05649774|PROCEDURE|Therapy|Only Myofascial Release will be provided
48629957|NCT05649774|PROCEDURE|Taping technique|Only Kinesiotaping will be provided
48629958|NCT05649774|PROCEDURE|Therapy with taping|Myofascial release will be provided followed by Kinesiotaping
48629959|NCT05649774|PROCEDURE|SHAM|Placebo Treatment will be given
48629960|NCT04631978|DIAGNOSTIC_TEST|Comprehensive ophthalmologic examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
48629961|NCT05254210|DEVICE|RF Device (Potenza™)|Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
48629962|NCT05797090|DRUG|Crystalloid Cardioplegic solution|To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
48629963|NCT06070532|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
47939973|NCT03258138|BEHAVIORAL|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
47939974|NCT03258138|BEHAVIORAL|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
47939975|NCT03258138|BEHAVIORAL|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
47939976|NCT03258138|BEHAVIORAL|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
48101381|NCT02989012|DRUG|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
48101382|NCT02989012|DRUG|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
48101383|NCT02989012|DRUG|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
48101384|NCT01611376|DEVICE|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
48101385|NCT06630845|DRUG|Fluorodeoxyglucose F18|Given IV as part of routine imaging
48101386|NCT06630845|PROCEDURE|Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)|Imaging procedure
48629964|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 3 Secs|3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
48629965|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 2 Secs|3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
48101387|NCT06630845|PROCEDURE|Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)|Imaging procedure done concurrently with PET/MRI
48101388|NCT06630845|DEVICE|General Electric (GE) SIGNA PET/MR|Imaging device
48101389|NCT06631300|DRUG|Prednisone|A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.
48101390|NCT06631300|DRUG|Placebo|A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
48101391|NCT02678104|PROCEDURE|Tooth extraction|Tooth removal
48101392|NCT02678104|DRUG|Chlorhexidine mouth wash|Chlorhexidine mouth wash
48101393|NCT02678104|DRUG|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
48101394|NCT05406180|BIOLOGICAL|VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular
48101395|NCT01648140|DRUG|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
48101396|NCT01648140|DRUG|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
48101397|NCT01648140|DRUG|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
48101398|NCT01648140|DRUG|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
48629966|NCT04011709|COMBINATION_PRODUCT|VR647 Inhalation System + VR647 Smart Card 4 Secs|3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
48629967|NCT01660685|BEHAVIORAL|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
48629968|NCT01660685|BEHAVIORAL|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
48629969|NCT01660685|BEHAVIORAL|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
48629970|NCT01660685|BEHAVIORAL|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
48101399|NCT01648140|DRUG|Telaprevir|375 mg film-coated tablet
48285896|NCT00160927|DRUG|actylcholine|
47939977|NCT02835560|DRUG|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
47939978|NCT02835560|DRUG|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
48285897|NCT00160927|DRUG|sodium nitroprusside|
48285898|NCT05998343|BEHAVIORAL|Intergenerational HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 19-39 years old who has received training to provide strength-based support sessions weekly for 12 weeks.
48285899|NCT05998343|BEHAVIORAL|Same-Generation Peer Support HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 60 years or older who has received training to provide strength-based support sessions weekly for 12 weeks.
48285900|NCT03605901|DRUG|Standard dosing of methadone|Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
48285901|NCT03605901|DRUG|Aliquots of methadone titrated to apnea|Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
48471841|NCT05013619|OTHER|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
48471842|NCT05013619|OTHER|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
48629971|NCT06236997|DRUG|Adebrelimab|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
48629972|NCT06236997|RADIATION|Radiation Therapy|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
47939979|NCT03469388|DIAGNOSTIC_TEST|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
47939980|NCT02216825|DIETARY_SUPPLEMENT|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
48285902|NCT00654927|DRUG|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
48285903|NCT00840463|DRUG|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
48285904|NCT00840463|OTHER|Placebo|Sugar pill
48285905|NCT06346912|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
48285906|NCT03379350|PROCEDURE|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
48471843|NCT05013619|OTHER|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
48629973|NCT06236997|DRUG|etoposide, carboplatin(EC)|Etoposide 100mg/m2 day1-3+carboplatin AUC 5 day 1(EC) combined with Adebrelimab（ PD-L1 inhibitor）1200mg day1 Q3w for 2 cycles, and the efficacy is evaluated 3 weeks after the treatment. If the efficacy evaluation is SD/PR/CR, concurrent radiotherapy(45Gy /3Gy/qd/3w) with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy+ Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.
48629974|NCT05523739|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
47939981|NCT02216825|DIETARY_SUPPLEMENT|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
48101400|NCT02351180|DRUG|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
48285907|NCT01647763|PROCEDURE|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.~In the area with the 3 largest knots a purse string suture will be placed."
48285908|NCT01647763|PROCEDURE|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
47939982|NCT05684523|DRUG|Valerian-Hop Extract|herbal drug
47939983|NCT05684523|DRUG|Placebo|Placebo
47939984|NCT00188799|PROCEDURE|daily Xray volume imaging for planning radiotherapy|
47939985|NCT00371501|DRUG|Rosuvastatin|10mg/day
47939986|NCT00371501|DRUG|placebo|one tablet/day
47939987|NCT00371501|DRUG|aspirin|80mg/day
47939988|NCT00371501|DRUG|placebo|placebo
48101401|NCT02351180|DRUG|Placebo|Placebo will serve as a control treatment
48101402|NCT06388941|DRUG|Iptacopan|LNP023 administered orally
48101403|NCT06388941|DRUG|Placebo|Matching placebo administered orally
48629975|NCT01713127|DRUG|remifentanil infusion|
48629976|NCT01713127|DRUG|Placebo|
47939989|NCT00144027|BEHAVIORAL|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
47939990|NCT01272661|BEHAVIORAL|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
48285909|NCT04278742|OTHER|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
48629977|NCT06381843|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
47939991|NCT01272661|BEHAVIORAL|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
48629978|NCT06381843|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
47939992|NCT01272661|BEHAVIORAL|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
47939993|NCT05403333|DRUG|utidelone|Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
47939994|NCT03902106|DRUG|salbutamol|subjects ingest salbutamol
48101404|NCT06388941|DRUG|Rituximab|Standard of care
48101405|NCT02286999|DRUG|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
48101406|NCT02286999|DRUG|Placebo|
48101407|NCT03416751|BIOLOGICAL|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
48101408|NCT03416751|OTHER|Placebo|Placebo enemas
48101409|NCT03960255|OTHER|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
48285910|NCT05480514|DEVICE|TEST LENS|etafilcon A with cosmetic pattern
48285911|NCT05480514|DEVICE|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
48629979|NCT02882984|DRUG|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
47939995|NCT03902106|OTHER|exercise|subjects undergo 6 weeks of endurance training (3 times weekly)
47939996|NCT02774733|DEVICE|spirometer;Intraocular pressure;Color doppler imaging|
47939997|NCT00186329|DRUG|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
48101410|NCT00929591|DRUG|cyclophosphamide|
48629980|NCT02882984|RADIATION|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
48629981|NCT02882984|RADIATION|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
47939998|NCT00590629|DRUG|Niaspan|1500 mg Niaspan for 16 weeks
48101411|NCT00929591|DRUG|doxorubicin hydrochloride|
48629982|NCT06131463|DEVICE|Electrocardiogram (ECG) feature in smart watches|A study participant that is randomly assigned to the experimental group should enable the ECG function on his or her smart watch and make sure that there is synchronization with a corresponding application on his or her mobile phone. The ECG function must stay enabled, and the participant should wear the smartwatch every day for 30 days.
48629983|NCT04453254|OTHER|Whole Food Meal|Isocaloric/ macronutrient whole food meal
48629984|NCT04453254|OTHER|Supplement Food Meal|Isocaloric/ macronutrient supplement food meal
48101412|NCT00929591|DRUG|endocrine therapy|
48101413|NCT00929591|DRUG|endocrine-modulating drug therapy|
48101414|NCT00929591|DRUG|fluorouracil|
48101415|NCT00929591|DRUG|tamoxifen citrate|
48101416|NCT00929591|RADIATION|brachytherapy|
48101417|NCT00929591|RADIATION|low-LET electron therapy|
48101418|NCT00929591|RADIATION|low-LET photon therapy|
48101419|NCT00929591|RADIATION|radiation therapy|
48101420|NCT04671108|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
48101421|NCT03523962|DRUG|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.
48101422|NCT03523962|DRUG|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.
48285912|NCT06481735|BIOLOGICAL|TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2 : dose of RP2D.
48285913|NCT06481735|DRUG|Fludarabine|Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.
48285914|NCT06481735|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
48285915|NCT00231140|DRUG|Thalidomide (drug)|
48629985|NCT00411658|DEVICE|Investigational Device|
48629986|NCT00411658|DEVICE|Experimental|
48629987|NCT00411658|OTHER|Cryopreserved|
48629988|NCT00834587|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
48629989|NCT00834587|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
48629990|NCT01155609|PROCEDURE|quality-of-life assessment|Ancillary studies
48629991|NCT01155609|PROCEDURE|management of therapy complications|Discontinue supplement; treat symptomatically
48629992|NCT01155609|DIETARY_SUPPLEMENT|L-lysine|Given PO
48629993|NCT00923702|BIOLOGICAL|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
48629994|NCT05428228|OTHER|TP1|Participants will be administered TP1 during one of the experimental visits.
48629995|NCT05428228|OTHER|TP2|Participants will be administered TP2 during one of the experimental visits.
47939999|NCT00708565|DRUG|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
47940000|NCT06165627|DEVICE|Lehfilcon A toric contact lenses|Commercially available soft contact lenses worn as indicated
47940001|NCT06165627|DEVICE|Comfilcon A toric contact lenses|Commercially available soft contact lenses) worn as indicated
47940002|NCT06165627|DEVICE|CLEAR CARE|Commercially available hydrogen peroxide-based solution for daily cleaning and disinfection of contact lenses used as indicated
47940003|NCT01657929|BIOLOGICAL|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
48285916|NCT06084780|PROCEDURE|Intestinal, Multivisceral or Modified Multivisceral Transplantation|"Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~* Isolated small bowel transplant (SBT): transplantation of the donor small intestine~* Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~* Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach"
48285917|NCT06084780|DRUG|Alemtuzumab|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
48285918|NCT06084780|DRUG|Tacrolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
48471844|NCT05013619|OTHER|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
47940004|NCT01657929|BIOLOGICAL|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
48471845|NCT00059709|PROCEDURE|Mediated Negotiation Training|
48471846|NCT00827840|DRUG|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
48471847|NCT00827840|DRUG|Risperidone|1 to 6 mg of risperidone once or twice a day
48471848|NCT04693221|OTHER|Choice of VNS set of parameters based on the lowest PLI|Vagal nerve stimulation according to PLI results.
48471849|NCT04693221|OTHER|EEG|Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
48471850|NCT05066568|DEVICE|Active Tracranial Direct Current Stimulation|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.
48471851|NCT05066568|OTHER|Hypnotic analgesia suggestion|The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
48471852|NCT05066568|BEHAVIORAL|Rest|The patient is asked to remain seated still for 20 minutes.
47940005|NCT01657929|BIOLOGICAL|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
47940006|NCT01657929|BIOLOGICAL|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
48471853|NCT05066568|OTHER|Active tDCS + Hypnotic analgesia suggestion|"Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Intervention time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.~The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance."
48617945|NCT03834090|OTHER|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
48617946|NCT02671968|DEVICE|Continuous Glucose Monitoring System|
48629996|NCT05428228|OTHER|Placebo|Participants will be administered placebo during one of the experimental visits.
48629997|NCT05438420|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
48629998|NCT05438420|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
47940007|NCT06326489|DEVICE|Switching to the Medtronic 780G insulin pump|Patients using a Medtronic 740G insulin pump will receive the 780G model for three months
47940008|NCT02987660|PROCEDURE|Topography Guided LASIK|Corneal surgery for refractive error correction
47940009|NCT02987660|PROCEDURE|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
47940010|NCT02987660|DEVICE|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
47940011|NCT02987660|DEVICE|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
47940012|NCT04663919|PROCEDURE|Bariatric surgery-RYGB|"After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis)."
47940013|NCT04663919|BEHAVIORAL|Dietary intervention|High-calorie medical nutrition program to ensure weight gain
47940014|NCT02931591|DRUG|Metformin|Metformin is administered as an oral solution
48629999|NCT00295776|DRUG|Lamictal in the treatment of Post-Herpetic Neuralgia|
48285919|NCT06084780|DRUG|Sirolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
48285920|NCT00861185|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
48285921|NCT00861185|DRUG|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
48471854|NCT05066568|OTHER|Sham tDCS + Hypnotic analgesia suggestion|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 0mA Intervention time: 20 min The current is turned off after 30 seconds. The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
48471855|NCT06679309|OTHER|Integrated care plan|Complex care plan facilitated by the integrated care lead with 90 day follow-up, 24/7 phone support and connection with resources and services
48471856|NCT01126606|DRUG|Dermacid Silver (Lactic acid)|Liquid soap, daily use
48630000|NCT02744547|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
48630001|NCT02546141|OTHER|skimmed milk (UHT)|
48630002|NCT02546141|OTHER|skimmed milk (pasteurized)|
48630003|NCT02546141|OTHER|skimmed yoghurt|
48630004|NCT02546141|OTHER|full-fat milk (UHT)|
48630005|NCT02546141|OTHER|non-homogenized full-fat milk (pasteurized)|
48630006|NCT02546141|OTHER|full-fat cheese (semi-matured)|
48630007|NCT02546141|OTHER|whey protein|
48630008|NCT02546141|OTHER|micellar casein|
48101423|NCT06188962|BEHAVIORAL|CBT-informed school-based counselling|Knowledge Insight Tools (KIT) is a CBT-based model of one-to-one therapy for secondary school pupils who are struggling with low mood and/or anxiety. KIT incorporates the key features of CBT (e.g., agenda setting, formulation around maintenance cycles, inter-session work involving exposure and/or behavioural activation) but is delivered in a semi-structured way that meets the young person's needs and pace of learning. Whilst there is an emphasis on symptom reduction, the primary focus is on the young person's goals for living and co-producing an understanding of how symptoms can interfere with these goals. Practitioners are encouraged to incorporate different therapeutic tools and modalities that complement the young person's strengths and ways of learning, including non-verbal forms of expression like arts and crafts, music, and dance. By being flexible, person-led, goal-focused, and integrative, KIT was designed to suit the needs of secondary school students.
48101424|NCT04075357|OTHER|Amniotic membrane transplantation|Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
48101425|NCT06059820|OTHER|rehabilitation treatment|3-month immobilization period, hyperextension braces for specific fractures, therapeutic exercises, and gradual activity restoration.
48101426|NCT06059820|PROCEDURE|Spine fusion|Pedicle screw fixation or fusion; anterior plate fusion
48101427|NCT02013986|DRUG|etomidate|0.3mg/kg IV only once during induction of general anesthesia
48101428|NCT02013986|DRUG|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
48101429|NCT02013986|DRUG|propofol|2mg/kg IV only once during induction of general anesthesia
48101430|NCT00270426|DRUG|Benazepril|
48101431|NCT00126009|DRUG|Amisulpride|
48101432|NCT04102449|DRUG|Apremilast|Single arm receiving Apremilast and ultrasound examinations
48285922|NCT03729180|PROCEDURE|Routine Elective Surgery- In patient or out patient elective surgery|Participants will be undergoing routine planned surgeries.
48285923|NCT03729180|DIAGNOSTIC_TEST|Blood test for genetic testing|Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
48285924|NCT03729180|OTHER|Drug-genetic Profile|Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
48285925|NCT01609933|DRUG|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
48285926|NCT01609933|DRUG|ABT-267|ABT-267 (tablets)
48471857|NCT01126606|DRUG|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
48471858|NCT03427801|DRUG|Erythropoiesis-Stimulating Agent|erythropoiesis-stimulating agent: Mircera or Darbepoietin
48630009|NCT01155323|DEVICE|etafilcon A|1-day soft contact lens
48630010|NCT01155323|DEVICE|omafilcon A|1-day soft contact lens
48630011|NCT01559285|DRUG|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
48630012|NCT01559285|DRUG|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
48630013|NCT01559285|DRUG|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
48630014|NCT05112588|BEHAVIORAL|Intervention|The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit accort´ding to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).
48630015|NCT02985281|DRUG|Sofosbuvir Oral Product|direct acting antiviral drug for HCV infection
48630016|NCT02985281|DRUG|Ribavirin|antiviral drug for HCV infection
48630017|NCT05942989|OTHER|Reiki implementation|Reiki is implied by putting hands on the patient and it is believed that energy is transferred to patients by hands.
48630018|NCT04546620|DRUG|R-CHOP|Arm A patients will receive R-CHOP alone.
48630019|NCT04546620|DRUG|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
48285927|NCT01609933|DRUG|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
48285928|NCT01609933|DRUG|Ribavirin (RBV)|Ribavirin (tablets)
48285929|NCT03572374|OTHER|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
48285930|NCT03572374|OTHER|Information Booklet|Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
48285931|NCT01719575|DRUG|Motilitone|
48285932|NCT01719575|DRUG|Placebo|
48285933|NCT06028815|BEHAVIORAL|Group music therapy|Music therapy intervention using active and receptive techniques, focusing on the technique of songwriting.
48471859|NCT02381197|DEVICE|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
48471860|NCT04599166|BEHAVIORAL|Who Would You Choose: Serious Fun|"Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay."
48471861|NCT01466036|DRUG|Cabozantinib|60 mg QD orally in cycles of 28 days
48471862|NCT01571817|BIOLOGICAL|Isolated Human Pancreatic Islets|
48471863|NCT01029392|DRUG|Vitamin D|2000iu once a day
48101433|NCT05409404|OTHER|Aerobic exercise + hot water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of hot water immersion at 40°C.
48101434|NCT05409404|OTHER|Aerobic exercise + thermoneutral water immersion|Light to moderate intensity aerobic exercise for 30 minutes, followed by 30 minutes of thermoneutral water immersion at 34°C.
48101435|NCT06628453|DEVICE|CGM|Real-time continuous glucose monitoring
48471864|NCT04623528|DIAGNOSTIC_TEST|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
48471865|NCT01142141|OTHER|manual therapy, kinesiotherapy|
48471866|NCT03439995|OTHER|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
48471867|NCT03439995|OTHER|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
48471868|NCT01341587|DEVICE|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
48471869|NCT02300987|DRUG|LEE011|
48471870|NCT02300987|DRUG|LEE011 Placebo|
48471871|NCT04523480|DRUG|Testopel 75mg Drug Implant|75 mg Testosterone pellets administered subcutaneously.
48471872|NCT04523480|DRUG|Testopel 100mg Drug Implant|100 mg Testosterone pellets administered subcutaneously.
48471873|NCT04523480|DRUG|Testopel 200mg Drug Implant|200 mg Testosterone pellets administered subcutaneously.
48630020|NCT00793611|BEHAVIORAL|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
48630021|NCT00793611|OTHER|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
48101436|NCT03971747|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
48471874|NCT00458159|DRUG|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.
48471875|NCT00458289|DRUG|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
48471876|NCT03934996|OTHER|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
48617947|NCT00937339|DEVICE|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
48630022|NCT00515593|DRUG|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
48630023|NCT02427217|BIOLOGICAL|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
48630024|NCT05608083|BEHAVIORAL|HEARTS classes|HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
48630025|NCT05608083|BEHAVIORAL|Online discussion group|A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
48285934|NCT02062086|DIETARY_SUPPLEMENT|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
48471877|NCT04286295|DRUG|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
47940015|NCT02931591|DRUG|Growth Hormone|Growth Hormone- no specific band
47940016|NCT02931591|DRUG|Placebo|
48285935|NCT03724708|DEVICE|IUD|IUD insertion
48285936|NCT06434168|BEHAVIORAL|Yoga intervention|Patients in the yoga group will receive a 60-minute session, twice per week over 12 weeks for a total of 24 sessions. Each yoga session consists of a warm-up, yoga postures standing or seated depending on the capability of the patient, and relaxation.
48285937|NCT06434168|BEHAVIORAL|Control condition|Patients in the control group will receive care-as-usual from their healthcare providers and will be asked to avoid engaging in yoga during their 3 months in the study.
48630026|NCT01902303|DRUG|Matching Placebo|Sublingual micro dosing of placebo for 7 days
48630027|NCT01902303|DRUG|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
48630028|NCT04920994|PROCEDURE|M-TAPA block|A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
48471878|NCT04286295|DRUG|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
48471879|NCT04286295|DRUG|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
48630029|NCT04920994|PROCEDURE|SCTAP block|A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
48471880|NCT00802373|DRUG|Solifenacin succinate|oral
48471881|NCT00802373|DRUG|Tolterodine|Oral
48471882|NCT02767947|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied per schedule specified in the arm.
48471883|NCT02767947|DRUG|Vehicle Cream|Vehicle cream will be applied per schedule specified in the arm.
48471884|NCT00932217|DRUG|filgrastim|subcutaneous filgrastim administration
48471885|NCT00932217|DRUG|lenograstim|subcutaneous lenograstim administration
47940017|NCT01216124|DRUG|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO\*6"
48630030|NCT04920994|DRUG|Bupivacaine Hydrochloride|20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
48630031|NCT03924297|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
47940018|NCT04376177|DIAGNOSTIC_TEST|Ultrasound|Echodoppler imaging of upper limbs performed by trained operators at rest and during provocative maneuvers for TOS diagnosis.
47940019|NCT04376177|DIAGNOSTIC_TEST|angiography|Angiography (arterial and/or venous) of upper limbs performed by trained operators at rest and during provocative maneuvers such for TOS diagnosis.
47940020|NCT04376177|DIAGNOSTIC_TEST|questionnaires|Use of standard questionnaires (MASC, DASH, SF36) for the evaluation of upper limb symptoms self-completed by the patients at admission.
48471886|NCT01817686|OTHER|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
48617948|NCT00937339|DEVICE|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
48617949|NCT04526054|DIAGNOSTIC_TEST|ENT exam|ENT examination of the nasal cavity: nasofibroscopy and anterior rhinoscopy.
48471887|NCT01817686|OTHER|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
48101437|NCT06631885|PROCEDURE|regenerative endodontic procedure using blood clot according to AAE|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using AAE protocol
48471888|NCT01817686|OTHER|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
48471889|NCT02564016|DRUG|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
48471890|NCT02564016|OTHER|Capped Epidural|epidural will be capped with no saline infusion.
48471891|NCT04408534|OTHER|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
48471892|NCT00347906|PROCEDURE|laser treatment|
48471893|NCT03934827|DRUG|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
48471894|NCT03934827|DRUG|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
48101438|NCT06631885|PROCEDURE|regenerative endodontic procedure using photo activated nanochitosan 2%|regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using photosensitized nanochitosan for root canal disinfection
47940021|NCT04376177|DIAGNOSTIC_TEST|Transcutaneous oximetry|Mesurement of transcutaneuos oxygen pressure on both forearms performed at rest and during provocative maneuversfor TOS diagnosis.
47940022|NCT04376177|DIAGNOSTIC_TEST|plethysmography|Photoplethysmography of the forearms or fingers performed at rest and during provocative maneuvers for TOS diagnosis
47940023|NCT04376177|DIAGNOSTIC_TEST|Electromyogram|Electromyography of the upper limbs with encoding of the physician for the presence or abnsence of signs of plexis compression (impairment of the response on C8 T1 erea
48101439|NCT00793806|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
48630032|NCT05434676|DEVICE|Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System M5 & S4|To assess the safety and effectiveness of IVL treatment used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries
48630033|NCT06407440|OTHER|control|There will be no interference ergonomics training
48630034|NCT06407440|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
48101440|NCT03223090|BEHAVIORAL|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
48101441|NCT03223090|BEHAVIORAL|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
48101442|NCT04285125|OTHER|cerebral MRI|Patients who agree to participate in the study will perform an MRI with ultra high resolution sequences added by the research MRI of control will be done at one year and two years
48101443|NCT01362491|DRUG|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
47940024|NCT04376177|DIAGNOSTIC_TEST|Standard X-Ray|Standard X-Ray performed for the research of apophysomegaly or additionnal cervical rib.
47940025|NCT05716503|DEVICE|Negative Pressure Wound Therapy (NPWT)|Patients Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.
48101444|NCT01362491|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
48101445|NCT01362491|DRUG|Placebo|Single-dose of placebo
48285938|NCT02411123|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
48630035|NCT04099420|BEHAVIORAL|Lifestyle counseling|An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
47940026|NCT05716503|OTHER|Ordinary dressings with antibiotic ointment and gauze|Patients will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting.
48285939|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose under fasted conditions
48630036|NCT02842671|OTHER|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
48285940|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
48285941|NCT06272214|RADIATION|Adjuvant radiotherapy|"The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area."
47940027|NCT01799031|OTHER|internet-based intervention|Receive access to the WISE web-based educational intervention
47940028|NCT01799031|PROCEDURE|management of therapy complications|Receive standard of care
47940029|NCT01799031|OTHER|educational intervention|Receive access to the WISE web-based educational intervention
47940030|NCT01799031|OTHER|questionnaire administration|Ancillary studies
47940031|NCT01799031|PROCEDURE|quality-of-life assessment|Ancillary studies
47940032|NCT04744038|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
47940033|NCT00637871|DRUG|Casodex|150mg once daily
48285942|NCT06272214|OTHER|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
48471895|NCT05264831|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
47940034|NCT00637871|DRUG|Tamoxifen|
47940035|NCT00813033|OTHER|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
47940036|NCT01795820|DRUG|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
48101446|NCT02925052|DEVICE|Gastric Tube Guide|
48101447|NCT02925052|DEVICE|Conventional placement|
48285943|NCT02818010|OTHER|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
48285944|NCT06163235|OTHER|Obemar platform|Online platform for education and follow-up
48471896|NCT05264831|PROCEDURE|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
48471897|NCT04322357|DRUG|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
48471898|NCT04322357|BEHAVIORAL|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
48471899|NCT04322357|DRUG|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
48471900|NCT01801917|DRUG|Placebo|Matching placebo tablet for oral administration
47940037|NCT01795820|DRUG|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
47940038|NCT04195139|DRUG|Nivolumab|Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
47940039|NCT04195139|DRUG|Temozolomide|Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
47940040|NCT04924205|DEVICE|FM2 Knee Brace|Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
48471901|NCT01801917|DRUG|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
48471902|NCT01030887|BEHAVIORAL|Exercise programme|Moderate intensity exercise
47940041|NCT05592522|OTHER|External oblique intercostal block|EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
47940042|NCT05592522|OTHER|Oblique subcostal TAP block|OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
47940043|NCT05592522|OTHER|Posterior Rectus sheath block|Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
48101448|NCT02823496|OTHER|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
48471903|NCT05045612|OTHER|Stop antibiotic therapy|Stop antibiotic therapy instituted by the admitting physician
48101449|NCT02823496|OTHER|Untreated skin|One site is patched without treatment as control
48101450|NCT06631976|DRUG|1ml of Depo-Medrol® injection|1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
48101451|NCT06631976|OTHER|Rehabilitation|Rehabilitation
48101452|NCT06631976|DRUG|Nerve block with 4ml of 2% lidocaine|Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
48101453|NCT06631976|DRUG|Tropocells® PRP injection|Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
48101454|NCT00683410|BIOLOGICAL|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
48285945|NCT02261740|BEHAVIORAL|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
48471904|NCT01594034|PROCEDURE|expired air|collection of expired air from ventilator
48617950|NCT04526054|DIAGNOSTIC_TEST|Olfactometry|Olfactometry test using odorous pens (Sniffin's stick test).
48630037|NCT03483090|DIETARY_SUPPLEMENT|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
48101455|NCT01329328|DEVICE|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
48101456|NCT03714750|PROCEDURE|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
48101457|NCT03714750|PROCEDURE|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
48101458|NCT05372094|DEVICE|Phonak Hearing Aid|Commercially available hearing aid with various noise reduction strengths
46887142|NCT06687642|OTHER|Free Generation of Associate Task|Free Generation of Associate Task (FGAT) measures participants' ability to generate creative ideas. The FGAT is a simple word-to-word generation task reflecting the ability to intentionally produce remote associations with the instruction to think creatively (FGAT-distant). A control condition (FGAT-First) involves giving the first word that comes to mind in response to a clue word.
46887143|NCT06687642|OTHER|Free Fluent Generation of Associates Task|"Participants receive the same instructions as for the FGAT, but instead of providing a single response for a clue word, they must verbalize each word that comes to mind, in one creative and two non-creative conditions."
46887144|NCT06687642|OTHER|Exploration of Associates Task|"Participants are asked to explore a virtual map on the screen (in an aesthetic design that might be similar to PacMan) in trial blocks, with instructions similar to those in the FGAT Distant condition, i.e. find a creative answer."
48101459|NCT04153344|OTHER|Electro-oculogram|Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
48285946|NCT04527757|PROCEDURE|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
48285947|NCT04527757|PROCEDURE|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
48617951|NCT04526054|DIAGNOSTIC_TEST|Brain MRI|Brain MRI focused on the olfactory bulbs (3 teslas).
48630038|NCT03483090|OTHER|Placebo|No therapeutic effect
48630039|NCT05403073|PROCEDURE|Ultrasound guided Suprainguinal Iliac Fascia Nerve Block.|Pain management at ER Department will be as usually with iv drugs and ultrasound guided Suprainguinal Iliac Fascia Nerve Block.
48630040|NCT00285675|DRUG|DN-101 (calcitriol) - Drug|
48630041|NCT02685865|DEVICE|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
48285948|NCT03052153|OTHER|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
48285949|NCT05740787|OTHER|No intervention|Observation only
48285950|NCT00793585|DRUG|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
48101460|NCT04153344|OTHER|Full-field electroretinogram|Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
48285951|NCT00793585|OTHER|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
48285952|NCT04778761|BEHAVIORAL|Home ACP Video|A video focused on Advance Care Planning and Hospice for patients with serious illness
48285953|NCT03476239|DRUG|Blinatumomab|"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."
48101461|NCT01419730|DRUG|Vitamin D3|Vitamin D3 50,000 IU
48471905|NCT03285919|DEVICE|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
48471906|NCT02823847|BEHAVIORAL|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
48471907|NCT02823847|DEVICE|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
48471908|NCT02823847|BEHAVIORAL|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation."
46887145|NCT06687642|OTHER|Sequential Choice of Associates Task|"Participants are presented with a clue word, followed by a series of potential responses (options) which they can either select (STAY) as a creative response (same instructions as in the remote FGAT: give the most creative response possible) or reject (SWITCH), to see another option screen."
48471909|NCT02823847|PROCEDURE|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
48471910|NCT02823847|PROCEDURE|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
47940044|NCT01858311|DIETARY_SUPPLEMENT|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
47940045|NCT01858311|OTHER|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
47940046|NCT01759134|OTHER|Post discharge formula|Babies will be given either materna sensitive or similac neosure
46887146|NCT06687642|OTHER|Emotional FGAT|We induce an emotional state in participants using video clips and sounds, during the FGAT. The task is similar to FGAT, with 124 trials, divided into a First condition and a Distant condition.
46887147|NCT06687642|OTHER|Rating|The Ratings task measures how the originality and appropriateness of responses are weighted in calculating the subjective value (satisfaction) that individuals attribute to the responses generated. Participants evaluate a set of responses from the FGAT (their own responses as well as responses given by others in the same task in previous laboratory experiments) by rating their originality, appropriateness and satisfaction (subjective value) using a pseudo-continuous rating scale (101 points) presented below the stimulus, with three reference graduations (not at all, neutral, very much).
46887148|NCT06687642|OTHER|Questionnaires|This task is a mini-battery of validated creativity tests.
46887149|NCT06687642|OTHER|Debriefing|The aim of the debriefing is to ask the participant how he or she felt about the experience, and to ensure that the instructions have been understood.
48101462|NCT01419730|BEHAVIORAL|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
48285954|NCT03476239|DRUG|Dexamthasone|Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
48285955|NCT03918993|DRUG|Tadalafil 5mg tablet|Once-a-day 5 mg dose of tadalafil for 8 weeks
48101463|NCT03437642|BEHAVIORAL|Short Term Psychotherapy|Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
48285956|NCT00221676|BIOLOGICAL|Alfarix|
48285957|NCT01069848|DEVICE|Vedera KXS|One treatment session with Vedera KXS
48285958|NCT01450137|DRUG|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
48285959|NCT01450137|DRUG|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
48285960|NCT05564130|DRUG|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
48285961|NCT05564130|DRUG|Sodium chloride|Sodium chloride 9 mg/mL
48285962|NCT01845077|DRUG|2x500 mg Metformin (Glumetza)|2 tablets
48285963|NCT01845077|DRUG|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
48285964|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
48471911|NCT02823847|PROCEDURE|Oral Biopsy|Premalignant and malignant oral lesions \[PMOL\]) still present 2 weeks after oral exam are biopsied.
48471912|NCT02889302|DRUG|KPS-0373|24 weeks
48471913|NCT02889302|DRUG|Placebo|24 weeks
47940047|NCT04213521|OTHER|Multisensory balance exercise|Multisensory balance training describes a balance exercise incorporating individual sensory manipulation of vision, vestibular, proprioception and sensory integration.
47940048|NCT04213521|OTHER|Conventional balance exercise|such as static and dynamic standing balance without altered sensory inputs.
48471914|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)|Marketed Drug
48471915|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)|Investigational Medicinal Product
48471916|NCT01950676|DEVICE|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
48630042|NCT02685865|DEVICE|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
47940049|NCT03415100|BIOLOGICAL|CAR-NK cells targeting NKG2D ligands|The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
47940050|NCT04447378|DRUG|Fondaparinux 2.5Mg/0.5Ml Inj Syr|post natal thromboprophylaxis
47940051|NCT00695578|DRUG|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
47940052|NCT00695578|DRUG|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
48101464|NCT00301509|DRUG|peginterferon and ribavirin|
48101465|NCT06548334|COMBINATION_PRODUCT|Advanced Physiotherapy|The physiotherapist used the regression techniques for 1 hour of session 2 times for 8 weeks. The caudal component involved the spinous process of the treated segment touching the therapist's hand and not applying force as though mobilising the segment at grade 2. These were applied if there is a suspected case of a posterolateral disc prolapse where the aim is to increase the diameter of the foramen and decrease the tension exerted on the nerve root. Applied posteroanterior was used to distract the anterior intervertebral end plate and to approximate the posterior end plates so as to pull back the protruded nuclear material by creating a negative pressure.
48285965|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
48285966|NCT01845077|DRUG|3x500 mg Metformin (Glumetza)|3 tablets
48285967|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
48285968|NCT01845077|DRUG|2 x 500 mg Metformin (Glumetza)|2 tablets
48285969|NCT01845077|DRUG|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
48285970|NCT01845077|DRUG|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
48285971|NCT02384720|OTHER|Age: 20-40years|
48285972|NCT02384720|OTHER|Age: 41-64years|
48285973|NCT02384720|OTHER|Age: ≥65years|
48471917|NCT00236886|DRUG|topiramate|
48471918|NCT06678646|PROCEDURE|Elbow ultrasound-guided surgery|Percutaneous Ultrasound-Guided Release of the Lacertus Fibrosus for Median Nerve Entrapment at the Elbow
48471919|NCT06024967|DRUG|PEG-somatropin|PEG-somatropin
48471920|NCT00681473|RADIATION|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
48471921|NCT04745949|DRUG|Brentuximab Vedotin|Given IV
48471922|NCT04745949|DRUG|Cyclophosphamide|Given IV
48471923|NCT04745949|DRUG|Doxorubicin|Given IV
48471924|NCT04745949|BIOLOGICAL|Nivolumab|Given IV
48471925|NCT04745949|DRUG|Prednisone|Given PO
48471926|NCT04745949|OTHER|Quality-of-Life Assessment|Ancillary studies
48471927|NCT04745949|BIOLOGICAL|Rituximab|Given IV
48471928|NCT01632163|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
48471929|NCT01632163|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
48471930|NCT03686215|COMBINATION_PRODUCT|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
48471931|NCT05868824|OTHER|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
48630043|NCT01956942|DEVICE|Micropulse Laser Trabeculoplasty|
48630044|NCT01956942|DEVICE|Selective Laser Trabeculoplasty|
48630045|NCT03485456|DRUG|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
48630046|NCT02846454|OTHER|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
48630047|NCT02846454|OTHER|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
48285974|NCT03384043|BEHAVIORAL|Smartphone Personal Assistant|Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
48285975|NCT03384043|BEHAVIORAL|Implementation Intention|Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
48285976|NCT05218629|DRUG|Anlotinib, PD-1 inhibitor|Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
48285977|NCT05671653|DRUG|PF-07081532|Experimental oral GLP-1 drug
48285978|NCT05671653|DRUG|Semaglutide|Approved and marketed GLP-1 drug for subcutaneous injection.
48285979|NCT00631462|DRUG|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
48285980|NCT00986336|DRUG|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
48285981|NCT00986336|DRUG|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
48285982|NCT00986336|DRUG|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
48285983|NCT00986336|DRUG|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
48471932|NCT01448148|OTHER|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
48471933|NCT01448148|OTHER|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
48471934|NCT02077335|RADIATION|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 \> 95%~* V150 30-35%~* V200 \< 15%~* D90 \> 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
48471935|NCT01463709|DEVICE|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
48471936|NCT03167216|DRUG|Cromolyn Sodium|Mast cell stabilizer
48471937|NCT03167216|DRUG|Cetirizine Hydrochloride|Histamine receptor antagonist
47940053|NCT01257802|DRUG|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
48285984|NCT02404506|DRUG|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
48285985|NCT03121690|DRUG|Prednisone|prednisone 40 mg/day for 7 days
48471938|NCT03604549|DRUG|Lipiodol UF|Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
48471939|NCT03604549|DRUG|Saline|Up to 10cc of saline will be infused via intrauterine catheter
48471940|NCT00197080|DRUG|Ropinirole Extended Release (XR)|
48471941|NCT03195673|DRUG|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
47940054|NCT01257802|DRUG|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
48285986|NCT03121690|DRUG|placebo|5ml saline / day for 7 days
48471942|NCT03195673|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
48471943|NCT03490409|DEVICE|Thigh compression stocking|Thigh compression stocking
48471944|NCT01970917|DEVICE|Olixia pure eye drops|
48630048|NCT06144307|PROCEDURE|plane block|injection of local anesthetic to the myofascial plane
48630049|NCT01108055|DRUG|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
47940055|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
47940056|NCT00797342|DRUG|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
48285987|NCT04252417|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
48285988|NCT01215630|BEHAVIORAL|Aerobic Interval Training|One interval training session
48285989|NCT00896519|BIOLOGICAL|rituximab|
48285990|NCT00896519|BIOLOGICAL|sargramostim|
48285991|NCT00896519|DRUG|cyclophosphamide|
47940057|NCT00797342|DRUG|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
48285992|NCT00896519|DRUG|doxorubicin hydrochloride|
48285993|NCT00896519|DRUG|prednisone|
48285994|NCT00896519|DRUG|vincristine sulfate|
48285995|NCT00896519|GENETIC|gene expression analysis|
48285996|NCT00896519|GENETIC|gene rearrangement analysis|
48285997|NCT00896519|GENETIC|polymerase chain reaction|
48285998|NCT00896519|OTHER|R-CHOP regimen|
48285999|NCT00896519|OTHER|laboratory biomarker analysis|
48286000|NCT04696549|BEHAVIORAL|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
48286001|NCT00847561|BEHAVIORAL|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
48286002|NCT00847561|BEHAVIORAL|Information Monitoring|Packet providing information on strategies for coping with anxiety
48286003|NCT05253131|DRUG|Selumetinib|"* Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer."
47940058|NCT02269826|DEVICE|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
48286004|NCT01998607|OTHER|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
48286005|NCT00167622|PROCEDURE|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
48286006|NCT00167622|PROCEDURE|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
48286007|NCT03842709|DRUG|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
48286008|NCT03842709|OTHER|Placebo|Administration of placebo
48286009|NCT03394495|OTHER|BCE Combination group|The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
48286010|NCT03018015|DRUG|Ibuprofen 400 mg oral powder|
48471945|NCT01970917|DEVICE|Placebo|0.9% physiological saline solution
48471946|NCT04362332|DRUG|Chloroquine Sulfate|cluster randomized
48286011|NCT03018015|DRUG|Ibuprofen 400 mg film-coated tablet|
48286012|NCT03018015|DRUG|Ibuprofen 400 mg soft capsule|
48286013|NCT03818815|COMBINATION_PRODUCT|OP0201|OP0201 20mg per day in two divided doses for 10 days
48471947|NCT04362332|DRUG|Hydroxychloroquine|cluster randomized
48471948|NCT04362332|OTHER|Standard supportive care|cluster randomized
47940059|NCT02269826|DEVICE|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
47940060|NCT05443971|BIOLOGICAL|Durvalumab|Given IV
48286014|NCT03818815|COMBINATION_PRODUCT|Placebo|Placebo 0mg per day in two divided doses for 10 days
48286015|NCT03818815|DRUG|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
47940061|NCT05443971|RADIATION|Radiation Therapy|Undergo grid therapy
48286016|NCT02693964|OTHER|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
48286017|NCT02654925|PROCEDURE|Adipose Tissue Biopsy|
48286018|NCT01926886|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
48286019|NCT02680288|DRUG|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
48286020|NCT02680288|DRUG|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
48286021|NCT02680288|OTHER|Oral Placebo|Oral inert treatment
48286022|NCT00393822|DRUG|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
48286023|NCT00393822|DRUG|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
48471949|NCT00601406|GENETIC|gene expression analysis|
48471950|NCT00601406|GENETIC|gene rearrangement analysis|
48471951|NCT00601406|GENETIC|polymorphism analysis|
47940062|NCT05443971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47940063|NCT03733340|DRUG|Imipenem|Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
47940064|NCT03384693|DRUG|Defibrotide|Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
48286024|NCT04560127|DRUG|Camrelizumab combination with Apatinib|Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
48286025|NCT00659672|DIETARY_SUPPLEMENT|Whey Protein|40 grams per day Whey Protein
48286026|NCT00659672|DIETARY_SUPPLEMENT|Soy Protein|40 grams per day soy protein
48286027|NCT00659672|DIETARY_SUPPLEMENT|Control (carbohydrate)|40 grams per day maltodextrin
48471952|NCT00601406|OTHER|laboratory biomarker analysis|
48471953|NCT00601406|RADIATION|radiation therapy|
48471954|NCT02722616|DEVICE|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
48617952|NCT00090428|BEHAVIORAL|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
48630050|NCT01108055|DRUG|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
47940065|NCT03001388|PROCEDURE|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
48286028|NCT01368068|DRUG|Tibolone|2.5mg/oral/daily
48286029|NCT01368068|DRUG|Escitalopram|10mg/oral/daily
47940066|NCT03370289|BIOLOGICAL|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
48286030|NCT01368068|DRUG|Natvia|serving size: 0.09g per tablet
48286031|NCT02182037|DRUG|Single rising doses of BIBT 1011 BS|
48286032|NCT02182037|DRUG|BIBT 1011 BS placebo|
48286033|NCT01901744|PROCEDURE|Cataract Surgery|
48286034|NCT01750918|DRUG|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
48286035|NCT01750918|DRUG|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
48286036|NCT01750918|DRUG|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
48471955|NCT02722616|DEVICE|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
48471956|NCT02722616|DRUG|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
48630051|NCT03750669|DRUG|AG regimen|Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2
48286037|NCT01750918|DEVICE|5-fluorouracil|5-fluorouracil-based chemotherapy
48471957|NCT00630578|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
48471958|NCT04604210|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
48286038|NCT02240134|BEHAVIORAL|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
48286039|NCT02240134|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
48286040|NCT02240134|DEVICE|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
48286041|NCT05495607|DEVICE|CARPEDIEN|Continuous renal replacement therapy
48630052|NCT03750669|DRUG|mFolfirinox|Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
48630053|NCT02614664|DEVICE|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
47940067|NCT04134351|OTHER|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
47940068|NCT01361854|DEVICE|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
47940069|NCT02769676|OTHER|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
47940070|NCT02769676|OTHER|usual care|Participants in the usual care arm will receive no additional interventions.
47940071|NCT05594043|DRUG|MK-6598|Oral tablet
47940072|NCT05594043|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
48286042|NCT03795350|DRUG|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
48286043|NCT00002103|DRUG|Trimetrexate glucuronate|
48286044|NCT00002103|DRUG|Leucovorin calcium|
48286045|NCT00023348|DRUG|Isoniazid|
48286046|NCT00023348|DRUG|Rifabutin|
48286047|NCT05465681|DRUG|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
48286048|NCT02865369|DRUG|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
47940073|NCT02633852|DRUG|Aflibercept|
48286049|NCT03918512|OTHER|nine online self-administered questionnaires|"patients will be invited to complete the following nine online self-administered questionnaires at baseline, 7 days and 3 months:~* Demographical and clinical characteristics at baseline~* Consolidated version of the CSS-48 questionnaire~* Lumbar pain numeric rating scale (NRS)~* Radicular pain NRS~* Zurich Claudication Questionnaire (ZCQ) (physical function subscale)~* Oswestry Disability Index (ODI)~* Fukushima LSS Scale 25 (FLS-25)~* 12-Item Short Form Health Survey (SF-12)~* Anchoring questions : 1 anchoring question about patient acceptable symptom state (at baseline, 7 days and 3 month) and 1 anchoring question about patient minimal clinically important difference (at 3 months)."
48286050|NCT04024696|DRUG|Abexinostat|Abexinostat Tosylate Tablets
48286051|NCT02911987|OTHER|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
48286052|NCT02911987|OTHER|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
48286053|NCT05232955|DEVICE|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
48286054|NCT04590612|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
48286055|NCT04590612|DRUG|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
48286056|NCT01645761|DRUG|Endonase|PPI- based triple therapy with endonase
48286057|NCT04248777|OTHER|standardised OCT-guided intervention|The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
48286058|NCT01584024|DEVICE|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
48286059|NCT01584024|DEVICE|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
48286060|NCT06370247|DIAGNOSTIC_TEST|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K will measure
48630054|NCT00791882|BEHAVIORAL|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
48630055|NCT00559715|DRUG|bevacizumab|1.25 mg intravitreally monthly/on demand
48630056|NCT00559715|DRUG|ranibizumab|0.5 mg intravitreally monthly/on demand
48630057|NCT00315315|PROCEDURE|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
48630058|NCT00315315|PROCEDURE|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
48630059|NCT00315315|PROCEDURE|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
48630060|NCT03808857|BIOLOGICAL|GB226|GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
48630061|NCT00668408|OTHER|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
48286061|NCT06198257|DEVICE|spider cage|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
48286062|NCT06198257|DEVICE|modified suits therapy|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
48286063|NCT02362373|DRUG|levonorgestrel IUS|placement of levonorgestrel intrauterine system
48286064|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
48286065|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
48471959|NCT02754128|BEHAVIORAL|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
48471960|NCT02754128|BEHAVIORAL|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
48630062|NCT00668408|OTHER|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :~* Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~* Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~* Beta-blockers~* Diuretics~* Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~* Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines."
48630063|NCT04616352|OTHER|Resistance to cefuroxime|Non susceptibility in vitro testing
47940074|NCT03869892|DRUG|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
47940075|NCT03869892|DRUG|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
47940076|NCT03869892|BIOLOGICAL|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
48286066|NCT01444716|BIOLOGICAL|Ofatumumab|Given IV
48286067|NCT02450357|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
48471961|NCT01263561|PROCEDURE|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
48471962|NCT01263561|PROCEDURE|trabeculectomy|trabeculectomy filtering surgery
48471963|NCT01857973|DEVICE|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
48471964|NCT05058768|DIAGNOSTIC_TEST|The lungs causes and extrapulmonary factors|Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
48471965|NCT03929809|DEVICE|Cochlear Implant|adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
48471966|NCT00297245|DRUG|cognitive function|
48630064|NCT03367585|DIETARY_SUPPLEMENT|Physical exercise + Vitamin D3|Strength exercise + Supplementation of vitamin D3 50,000 IU / week
47940077|NCT03869892|BIOLOGICAL|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
47940078|NCT05876260|BEHAVIORAL|Greek yogurt|Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise
47940079|NCT05876260|BEHAVIORAL|Carbohydrate-based study supplement|Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise
48286068|NCT02450357|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
48286069|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
48286070|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
48286071|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
48286072|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
48286073|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.2 Usage|Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
48286074|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
48286075|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
48286076|NCT03237403|OTHER|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
48286077|NCT01742923|BEHAVIORAL|Complex tailored intervention|
48286078|NCT01742923|BEHAVIORAL|Usual care|
48286079|NCT05502588|BEHAVIORAL|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
48286080|NCT05502588|BEHAVIORAL|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
48286081|NCT01057264|DRUG|HAI Abraxane|Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
48471971|NCT05193409|DRUG|225 mg BNC210|225 mg BNC210
48471972|NCT05193409|DRUG|675 mg BNC210|675 mg BNC210
48471973|NCT05193409|DRUG|Placebo|Placebo
48471974|NCT05671952|OTHER|Application of integrated intervention system programs|Application of integrated intervention system programs
48471975|NCT04936594|DEVICE|iTBS|1800 pulses of iTBS
48471976|NCT04936594|DEVICE|TMS|MagVenture MagPro x100 device. This will be used as the comparator.
48471977|NCT00109850|BIOLOGICAL|cetuximab|400mg/m\^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m\^2 maintenance dose, IV over 60 min, Days 8 \& 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
48471978|NCT00109850|DRUG|cisplatin|30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.
48471979|NCT00109850|DRUG|irinotecan hydrochloride|65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.
48471980|NCT00109850|RADIATION|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
48471981|NCT02773940|DEVICE|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
48471982|NCT00361478|BEHAVIORAL|Exercise and education|Weekly exercise and education program for 8 weeks
48286082|NCT01057264|DRUG|Gemcitabine|Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle
48286083|NCT01057264|DRUG|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
48286084|NCT01057264|DRUG|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
48286085|NCT03645187|DRUG|FOLFERI|FOLFERI regimen
48286086|NCT03645187|DRUG|Folferi and celecoxib|Folferi regimen and celecoxib
48286087|NCT05011552|BEHAVIORAL|Self-Compassion, Health, and Empowerment (SHE)|The SHE intervention includes 8 weekly sessions and 24-hour access to the intervener for any additional support needed. The first and last sessions will be delivered over the phone with the woman based on a brochure. The brochure describes the four major components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources. It will be discussed with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Session 2-7 focus on providing mental health self-care resources, which are deep breathing, progressive muscle relaxation, visualization, general introduction and overview of self-compassion, mindfulness, and loving-kindness.
48286088|NCT05011552|BEHAVIORAL|The Control Condition|Women randomized to the control group will be provided with the same brochure and mental health care resources.
48286089|NCT03167697|DIETARY_SUPPLEMENT|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
48286090|NCT03167697|OTHER|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
48286091|NCT04967690|DRUG|SI-053|SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
48286092|NCT01561638|PROCEDURE|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
48286093|NCT01561638|PROCEDURE|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
48286094|NCT01561638|PROCEDURE|Sham|will receive puncture for 4 minutes
48286095|NCT03586804|OTHER|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
48471983|NCT00361478|BEHAVIORAL|Education|Written educational material
48471984|NCT04753853|PROCEDURE|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
48471985|NCT03200145|OTHER|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~1. - Attention to the person based on:~   * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~  * Respect and acknowledge of the person.~  * Promotion of the autonomy.~  * Personalized treatment, with tailored attention and integrative cures~  * Protection of physical well-being, preventing damages and risks and promoting healthy habits.~  * Promotion of independence on daily activities.~  * Protection of privacy and personal matters~2. - Positive environment based on:~   * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~  * Social relationships, with proximity and collaboration with families.~  * Friendly organization, with empathetic professionals empowering users."
48286096|NCT03580447|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
48286097|NCT03580447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48286098|NCT05510986|DRUG|Fentanyl group|Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
48286099|NCT05510986|DRUG|Oxycodone Hydrochloride group|"Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes."
48286100|NCT03661385|DRUG|Nitric Oxide|Addition of nitric oxide 20ppm into bypass circuit
48286101|NCT00361530|DRUG|Statin|
48286102|NCT00098631|DRUG|lapatinib ditosylate|Given orally
48286103|NCT00098631|OTHER|laboratory biomarker analysis|Correlative studies
48286104|NCT03364218|DRUG|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
48286105|NCT06365359|OTHER|Blood sample for analysis of plasma of organochlorine pesticides concentration|A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the analysis of chlordecone and the following organochlorine compounds: p,p'-DDE, βHCH, γHCH, PCB 153. This analysis will be carried out at the Institut Pasteur of Guadeloupe (IPG).
48286106|NCT06365359|OTHER|Blood sample for cell collection|"A 20 mL blood sample will be taken up to 6 months after inclusion of the patient for the cell collection which will be kept at the CeRBiM.~This collection will be used for subsequent studies on the immunotoxicity of chlordecone, by studying the cytokine, apoptotic and autoreactive functions of PBMC (Peripheral Blood Mononuclear Cells)."
48286107|NCT02363205|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
48471986|NCT03019562|DRUG|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
48471987|NCT03019562|DRUG|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
48471988|NCT00142987|DRUG|Tegaserod|
48471989|NCT02129309|PROCEDURE|Forearm plethysmography|Dose response study
48471990|NCT02129309|PROCEDURE|Haemodynamic studies|Dose response study
48471991|NCT03895229|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
48630065|NCT03367585|OTHER|Physical exercise|Strength exercise
48630066|NCT04831385|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a first line therapy for insomnia
48286108|NCT03829761|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
48286109|NCT03829761|DEVICE|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
48286110|NCT01521845|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
48286111|NCT06206876|PROCEDURE|Biopsy|Undergo biopsy
48286112|NCT06206876|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48286113|NCT06206876|PROCEDURE|Computed Tomography|Undergo CT
48286114|NCT06206876|DRUG|DDX5 Degrader FL118|Given PO
48286115|NCT06206876|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48286116|NCT05129540|DEVICE|Custom-made foot orthosis|The foot orthoses for group A will be custom made using phenolic foam molds of the feet. They consist of a polypropylene layer of 3 mm from heel to just proximal to the metatarsal heads, and an upper sheet of 30 Shore A polyethylene foam.
48286117|NCT05129540|DEVICE|Placebo orthosis|"A flat insole made of the same material as the upper layer of the custom-made foot orthoses used for group custom-made foot orthosis."
48286118|NCT03551509|BIOLOGICAL|ArthroFLEX ECM scaffold graft|In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
48286119|NCT03551509|PROCEDURE|Control|This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
48286120|NCT03551509|BIOLOGICAL|Crossover|Patients randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
48286121|NCT02862795|PROCEDURE|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
48286122|NCT04824989|BEHAVIORAL|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
48286123|NCT04824989|BEHAVIORAL|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
48286124|NCT04824989|BEHAVIORAL|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
47940080|NCT05876260|BEHAVIORAL|Exercise|Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
47940081|NCT02750943|DRUG|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
48286125|NCT05394298|DRUG|Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included
48286126|NCT05394298|DRUG|Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
48286127|NCT02108457|RADIATION|[18F]Fluorothymidine (FLT) PET/CT Imaging|
48471992|NCT02434263|DEVICE|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
47940082|NCT02750943|DRUG|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
47940083|NCT05472454|OTHER|Ready-to-eat meals|Participant group to consume ready-to-eat meals in accordance with the DASH diet for a period of 4 weeks.
47940084|NCT05660798|BEHAVIORAL|heated tobacco - lifestyle intervention|Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
47940085|NCT02492581|DRUG|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
47940086|NCT02992210|GENETIC|4SCAR-GD2|
48286128|NCT02417623|BEHAVIORAL|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
47940087|NCT04759027|OTHER|subacromial distance measurement|distance between acromion and humerus
48286129|NCT06166771|DEVICE|Alma system|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
48286130|NCT05055908|DRUG|Pemetrexed plus Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
48286131|NCT05055908|DRUG|Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
48286132|NCT05055908|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
48286133|NCT02291341|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
48286134|NCT02291341|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
48286135|NCT05279378|RADIATION|lung ultrasonography versus CT|"chest CT will be done before admission and LUS within first 24 h from admission into the quarantine sector. In addition to 2 weeks after admission.~CT images will be reviewed by chest radiologist expert, who will calculate a CT severity score based on extension and distribution of GGOs and consolidations.~All CT scans will be performed in supine position at end inspiration without intravenous administration of contrast media.~Within 24 h from admission and CT scanning, bedside LUS will be performed by clinician who will be blind to chest CT findings.~Examinations will be performed with the patient in the sitting position, systematically scanning the front and the back side of each hemithorax.~Blood sample will be collected into 4 mL Vacuette containing EDTA. Samples will be stored on ice, processed within 30 min and plasma will be isolated by centrifugation at 2000g for 20 min at 4 °C. Plasma will be immediately frozen at - 80 °C in several aliquots."
48286136|NCT02350543|DRUG|Aspirin|
48471993|NCT04456933|PROCEDURE|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
48471994|NCT04456933|PROCEDURE|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
48471995|NCT02051595|OTHER|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
48471996|NCT05937581|DRUG|CSL040|IV Administration
48471997|NCT05937581|DRUG|Placebo|0.9% w/v NaCI, IV Administration
48471998|NCT03545399|DIETARY_SUPPLEMENT|Ulva Lactuca|The dose was taken with a glass of water during the evening meal once daily
48471999|NCT03545399|DIETARY_SUPPLEMENT|Placebo|The dose was taken with a glass of water during the evening meal once daily
48472000|NCT02588820|DRUG|Antiretroviral Therapy (Experimental)|"1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day"
48472001|NCT01267916|DEVICE|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
48472002|NCT01267916|DEVICE|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
48630067|NCT03873688|OTHER|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
48630068|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
48286137|NCT00216008|DRUG|docetaxel|
48286138|NCT00216008|DRUG|cisplatin|
48286139|NCT00216008|PROCEDURE|radiation|
48286140|NCT00216008|PROCEDURE|surgery|
48286141|NCT01860170|DRUG|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
48286142|NCT01860170|DRUG|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
48286143|NCT01860170|DRUG|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
48286144|NCT01064089|DRUG|HSP990|
48286145|NCT05816681|DRUG|DWJ1230|Daewoong Pharmaceutical
48286146|NCT05816681|DRUG|DWB2001|Daewoong Bio
48630069|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
48630070|NCT01363271|DRUG|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
48472003|NCT01267916|DEVICE|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
48472004|NCT01267916|DEVICE|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
48472005|NCT01267916|DEVICE|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
47940088|NCT01176344|DRUG|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
48286147|NCT05077514|BEHAVIORAL|Experimental: Cognitive Behavior Therapy|Participants assigned to Group A were asked to participate in a talking session with a psychologist regarding thoughts about treatment. This session is designed to explore thoughts about behavioral health therapy for suicidality. The session was administered by phone, initially and again one month later. Participants discussed current functioning and their thoughts about seeking help with the goal of modifying thoughts about treatment. This phone session lasted approximately 45 to 60 minutes.
48286148|NCT05077514|BEHAVIORAL|Active comparator: National Crisis Line|Participants assigned to Group B received information about the VA's National Crisis Line.
48286149|NCT03366714|DEVICE|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
48472006|NCT01267916|DEVICE|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
48472007|NCT06629181|OTHER|Education|"The researchers will conduct a 4-week intervention for the intervention group participants.~Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training"
48472008|NCT01257191|DRUG|Carbon Black|source: commercial
48472009|NCT01257191|DRUG|Diesel Exhaust Particles|source: diesel engine
48472010|NCT01257191|DRUG|Fine Concentrated Ambient Particles|source: concentrated ambient air
48472011|NCT01257191|DRUG|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
48472012|NCT01257191|DRUG|Saline|Saline solution
47940089|NCT01176344|DRUG|Placebo|Inert placebo capsules once monthly for 2 years.
48472013|NCT03883555|DEVICE|High flow nasal therapy (HFNT) : Optiflow™|"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"
48472014|NCT03883555|DEVICE|Non invasive ventilation (niv)|"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."
48630071|NCT01363271|DRUG|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
48630072|NCT04971824|PROCEDURE|Physiotherapeutic intervention|The physiotherapy consists in performing visceral manipulation of the pelvic and abdomen organs as well as doing special exercises (volunteers get a handout with instructions on how to exercise). The exercises include ones from the Mojzis´s method, Dynamic neuromuscular stabilisation, yoga or other therapeutic methods used by physiotherapists.
48630073|NCT01419925|BIOLOGICAL|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
48630074|NCT01419925|BIOLOGICAL|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
48630075|NCT01419925|BIOLOGICAL|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
48630076|NCT01419925|BIOLOGICAL|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
47940090|NCT00963677|PROCEDURE|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
48286150|NCT03366714|DEVICE|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
48286151|NCT05116969|DRUG|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
48286152|NCT02528695|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT
48286153|NCT02528695|DEVICE|euglycemic clamp|euglycemic clamp
48286154|NCT02528695|DEVICE|hypoglycemic clamp|hypoglycemic clamp
48286155|NCT06116383|DEVICE|NIRS|Renal perfusion will be evaluated with NIRS
48286156|NCT05425771|PROCEDURE|Anti Reflux Mucosa Ablation|Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
48286157|NCT06435715|OTHER|10 Repetitions of Deep Breathing Exercise|Respondents in the intervention group performed 10 repetitions of deep breathing exercises every 3 hours for 3 days.
48286158|NCT06435715|OTHER|3 Repetitions of Deep Breathing Exercise|Respondents in the control group performed 3 repetitions of deep breathing exercises for 3 days.
48286159|NCT00226642|DRUG|Sertralin|
48286160|NCT00226642|BEHAVIORAL|Cognitive-behavioral therapy|
48286161|NCT00226642|DRUG|Placebo|
48286162|NCT00226642|BEHAVIORAL|Non-specific supporting group therapy|
48286163|NCT04516902|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
48286164|NCT04516902|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
48286165|NCT04516902|OTHER|LSD Placebo|Pure alcohol instead of an alcoholic solution containing LSD
48286166|NCT04516902|OTHER|MDMA Placebo|Mannitol capsules instead of capsules containing MDMA
48472015|NCT03261024|DEVICE|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
48286167|NCT03868722|DRUG|Acalabrutinib|Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
48286168|NCT03868722|DRUG|Venetoclax|Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
48286169|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
48286170|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
48286171|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
48286172|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
48630077|NCT01558570|PROCEDURE|Blood Draw|One time blood draw
48286173|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
48286174|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
48286175|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
48286176|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
48286177|NCT03319628|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
48286178|NCT05283733|PROCEDURE|reverse conversion technique|converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
48286179|NCT01633060|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
48286180|NCT01633060|DRUG|BKM120|BKM120 100 mg once daily
48286181|NCT01633060|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
48286182|NCT00644579|DRUG|bLAC|bLAC high and low dose and placebo
48286183|NCT00644579|DRUG|Placebo|Placebo
48286184|NCT06127212|DRUG|Dapagliflozin 10 mg film-coated tablet|One tablet of the test drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
48286185|NCT06127212|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
48286186|NCT05758038|PROCEDURE|Radiofrequency ablation/Microwave ablation|thermal ablation by radiofrequency and Microwave
48286187|NCT05179395|OTHER|Brasthesis|Brasthesis is a harness that is integrated with an off the shelf sports bra
48286188|NCT01576471|BIOLOGICAL|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
48286189|NCT01576471|BIOLOGICAL|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
48286190|NCT05902793|DEVICE|Experimental: Investigational device: V.A.C. VERAFLO™ Dressing Kit|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation. The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit."
48286191|NCT05902793|DEVICE|Active Comparator: Dressing Name: Negative pressure wound drainage material|"Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1.~Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation. The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit."
48286192|NCT01570010|OTHER|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
48286193|NCT00564928|DRUG|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
48286194|NCT00121225|DRUG|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
48286195|NCT04933630|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
48286196|NCT00693186|BIOLOGICAL|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
47940091|NCT02579928|DRUG|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
47940092|NCT02579928|DRUG|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
47940093|NCT02169193|RADIATION|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
47940094|NCT01764425|DRUG|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
48286197|NCT00693186|BIOLOGICAL|Engerix B® 10 µg / 0.5 mL|10 µg
48286198|NCT05842798|DRUG|TNM002|TNM002, intramuscular injection
47940095|NCT00710437|DRUG|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
47940096|NCT03658707|OTHER|questionnaire|Shoulder questionnaire
47940097|NCT06229782|DIAGNOSTIC_TEST|Orbital Doppler ultrasonography|During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.
47940098|NCT06229782|DIAGNOSTIC_TEST|Transcranial Doppler ultrasonography|"During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus.~Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used."
47940099|NCT06229782|DIAGNOSTIC_TEST|Computed Tomography Angiography|Cranial Computed Tomography Angiography
48286199|NCT05842798|DRUG|Placebo|Placebo, intramuscular injection
48286200|NCT05309083|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
48286201|NCT00631319|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
48286202|NCT00631319|DRUG|Placebo|Placebo
48286203|NCT00444184|DRUG|Travoprost/timolol fixed combination, travoprost|
48286204|NCT05782088|PROCEDURE|Single Piezocision|Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.
48286205|NCT05782088|PROCEDURE|Repeated Piezocision|Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
48286206|NCT00759577|DRUG|Solifenacin|5mg and 10 mg, oral once daily
47940100|NCT03913546|PROCEDURE|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
48286207|NCT05154851|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
47940101|NCT03913546|OTHER|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
47940102|NCT00883584|DRUG|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
47940103|NCT00883584|DRUG|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
47940104|NCT06091787|DRUG|Ursodeoxycholic acid|Tablet Ursodeoxycholic acid 450mg per orally twice daily from Post operative day 1 to post operative day 10.
47940105|NCT06091787|OTHER|Standard Medical Treatment|Standard Medical Treatment
47940106|NCT03913442|DRUG|Colchicine 0.8 mg or 0.6 mg orally once daily|Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
47940107|NCT03913442|DRUG|Placebo oral capsule|Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
47940108|NCT00160966|DRUG|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
47940109|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
47940110|NCT00160966|DRUG|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
47940111|NCT04856202|BEHAVIORAL|Advance Care Planning interview|The facilitator will clarify the patients' preferences, asking specific questions regarding personal goals, including religious and cultural beliefs. The facilitator will discuss life supporting treatments that might be applicable to the patient and encourage the patient to weigh up personal benefits and burdens. Treatments may include: invasive therapy (such as chemotherapy or dialysis), hospitalization, resuscitation, ventilation, artificial nutrition or hydration and administration of antibiotics. The patient will also be encouraged to identify specific situations that are likely to improve or diminish his or her quality of life. The facilitator will assist the patient in documenting their wishes, including the assignment of a health care proxy.
47940112|NCT00995865|BIOLOGICAL|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10\^8 VE/0.5mL and Mid dose = 2.2 x 10\^7 VE/0.5mL
47940113|NCT00995865|BIOLOGICAL|Placebo|NaCl Injectable 0.9%
47940114|NCT03012516|BEHAVIORAL|PAP-treatment by physiotherapist|
47940115|NCT03012516|BEHAVIORAL|Ordinary PAP-treatment at the health care center|
47940116|NCT02091219|DRUG|Vitamin D|2400 IU/day by mouth for 16 weeks
47940117|NCT02091219|DRUG|25(OH)D3|20 micrograms/day by mouth for 16 weeks
47940118|NCT04211571|DEVICE|Theranova 400 dialyzer|Hemodialysis using Theranova 400 dialyzer
47940119|NCT04211571|DEVICE|High-flux dialyzer|Hemodialysis using high-flux dialyzer
48101466|NCT06548334|OTHER|Conventional Physiotherapy Techniques|In traditional physiotherapy, the patient underwent two sessions per week for eight weeks. Each session lasted one hour and included 20minutes of TENS treatment. The flexibility exercises consisted of hamstring stretches and single and double knee-to-chest stretches. The strengthening exercises were partial sit-ups, quadruped lifts, and double leg hold; pelvic tilts were performed with 10-15 repetitions, each held for 20-30 seconds and repeated three times.
48101467|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
47940120|NCT03237871|BEHAVIORAL|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
48101468|NCT01353092|DEVICE|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
48101469|NCT03080792|BEHAVIORAL|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
48101470|NCT01726140|PROCEDURE|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be \>200, the patient will stop the treatment.
47940121|NCT02072239|DEVICE|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
47940122|NCT00780390|OTHER|Autonomic Function Assessment|
47940123|NCT00586846|DRUG|Cisplatin|Cisplatin 120 mg/m\^2
47940124|NCT00586846|DRUG|Doxorubicin|75mg/m\^2
48286208|NCT00562419|DRUG|CT-322|IV solution, weekly
48286209|NCT00562419|DRUG|irinotecan hydrochloride|IV solution, biweekly
47940125|NCT00586846|DRUG|Methotrexate|Methotrexate 12g/m\^2
48286210|NCT00104507|DRUG|APD356|
48286211|NCT02599012|DRUG|Ferinject®|intravenous Ferinject 1000mg injection
48286212|NCT00187083|DRUG|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
48286213|NCT00187083|DRUG|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
48286214|NCT00187083|DRUG|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
48286215|NCT00187083|DRUG|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
48286216|NCT00187083|DRUG|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
48286217|NCT00187083|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
48286218|NCT06448377|PROCEDURE|Videolaryngoscopy|Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.
48286219|NCT06448377|PROCEDURE|FOB|Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.
48286220|NCT06448377|PROCEDURE|FOB+Aintree|Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.
48286221|NCT06448377|PROCEDURE|Classic intubation with laryngoscopy|Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.
48101471|NCT01726140|PROCEDURE|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be \>200, the patient will stop the treatment.
48101472|NCT01311180|DRUG|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
48101473|NCT01311180|DRUG|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
48101474|NCT01908634|DIETARY_SUPPLEMENT|Milk-based Strawberry Beverage without meal|
48101475|NCT01908634|DIETARY_SUPPLEMENT|Water-Based Strawberry Beverage without meal|
48101476|NCT01908634|DIETARY_SUPPLEMENT|Milk-based strawberry Beverage with meal|
48101477|NCT01908634|DIETARY_SUPPLEMENT|Water-Based strawberry Beverage with meal|
48101478|NCT03031444|DRUG|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
48101479|NCT03031444|DRUG|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
48101480|NCT05693155|BEHAVIORAL|Voluntary self-exclusion from gambling ('Spelpaus')|Voluntary self-exclusion from gambling, using the government-based, official service 'Spelpaus' (literally 'play break')
48101481|NCT03829410|DRUG|Onvansertib|Onvansertib orally.
48101482|NCT03829410|BIOLOGICAL|Bevacizumab|Bevacizumab intravenously.
48101483|NCT03829410|DRUG|FOLFIRI|FOLFIRI intravenously.
48286222|NCT06448377|PROCEDURE|Others|Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.
48286223|NCT01671410|DRUG|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
48286224|NCT01671410|DRUG|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
48101484|NCT00919763|DRUG|CD2027 Ointment 3 mcg/g, twice daily|Topical Ointment
48101485|NCT00919763|DRUG|Vehicle Ointment, twice daily|Topical Ointment
48101486|NCT05754281|DEVICE|2nd Gen LabPatch Glucose Sensing System|"I. The 2nd Gen LabPatch chip which lies in the center of a clasp unit. The chip measures approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact~II. A LabPatch clasp device~III. A wire that connects the clasp unit to a Windows tablet which will communicate with the clasp via an application. Each data point will be viewed on the tablet and the application will also have some limited graphing capabilities to view trends of previous measurements"
48101487|NCT04716933|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
48101488|NCT04716933|DRUG|Carboplatin|IV infusion Q3W
48101489|NCT04716933|DRUG|Cisplatin|IV infusion Q3W
48101490|NCT04716933|DRUG|Pemetrexed|IV infusion Q3W
48101491|NCT04716933|DRUG|Lenvatinib|Oral capsule once daily
48101492|NCT04716933|DRUG|Placebo matching lenvatinib|Oral capsule once daily
48101493|NCT00608348|PROCEDURE|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
48101494|NCT00608348|PROCEDURE|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
48101495|NCT02491736|DRUG|Ketoprofen|2.5% ketoprofen gel
48101496|NCT02491736|OTHER|Placebo|Placebo gel
48101497|NCT02805244|DRUG|JTZ-951, 14C-JTZ-951|
48101498|NCT01177852|DRUG|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
48101499|NCT01177852|DRUG|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
48101500|NCT01646775|DRUG|epidural fentanyl|withold epidural fentanyl
48101501|NCT00371020|DRUG|low molecular weight heparin, 5-FU|
48286225|NCT00567931|DRUG|1-methyl-d-tryptophan|Given orally
48286226|NCT00567931|OTHER|pharmacological study|Correlative studies
48286227|NCT00567931|OTHER|laboratory biomarker analysis|Correlative studies
48286228|NCT01094483|DRUG|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
48286229|NCT01094483|DRUG|ASA|Asprin 81 mg enteric coated tablet
48286230|NCT01094483|DRUG|Placebo|
48286231|NCT02131701|BEHAVIORAL|Physical activity|
48286232|NCT06024252|DRUG|TACE|TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
47940126|NCT06178328|BEHAVIORAL|Things You Do Course|Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
47940127|NCT00964080|DRUG|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
47940128|NCT04730167|OTHER|Neurological and neuropsychological assessments / MRI / PET scan / Video-oculography.|Essential data for this study are those collected during the concussion assessment, carried out as part of routine care at Princess Grace Hospital (medical background; history of sports practice and history of concussions; data extracted from clinical and neuropsychological evaluations, from imaging exams (MRI and PET-Scan) and from eye-tracking evaluation).
47940129|NCT04457973|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 milliampere (mA) will be applied for 20 minutes per session daily for 5 days via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and 5x7 cm saline-soaked surface sponge electrodes.
47940130|NCT04457973|DEVICE|Sham tDCS|The electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
47940131|NCT06336161|DRUG|Fentanyl|to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
47940132|NCT04830644|DRUG|Iguratimod|Iguratimod orally twice a day
47940133|NCT04830644|DRUG|Placebo|Placebo orally twice a day
48286233|NCT03992300|DEVICE|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
48286234|NCT06498388|OTHER|Stiffness measurement by visco-elastography|Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.
48286235|NCT04573959|DEVICE|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
48472016|NCT03261024|DEVICE|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
48286236|NCT05446298|DRUG|ONC-392|ONC-392 will be given by IV infusion, q3w.
48472017|NCT03968926|OTHER|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
47940134|NCT02306499|PROCEDURE|ICSI|Intracytoplasmic Sperm Injection
47940135|NCT05442775|DRUG|Reldesemtiv|Oral tablet
47940136|NCT04411524|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
48472018|NCT05302219|OTHER|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
48472019|NCT05302219|OTHER|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
48472020|NCT05302219|OTHER|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
48472021|NCT05290493|DRUG|NB-001|NB-001 is a non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs).
47940137|NCT04411524|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
47940138|NCT04411524|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
47940139|NCT04411524|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
47940140|NCT05468151|OTHER|Cold acclimation|The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.
47940141|NCT05468151|OTHER|Intervention Control group - volunteers with obesity|Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.
47940142|NCT05468151|OTHER|Acute cold exposure|All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.
47940143|NCT04354727|DRUG|APG-1252|infusion once weekly
47940144|NCT04354727|DRUG|Ruxolitinib|taken orally twice a day
48286237|NCT05446298|DRUG|Pembrolizumab|Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
48286238|NCT02466256|PROCEDURE|Intraocular lens implantation|Intraocular lens implantation
48286239|NCT02466256|DEVICE|Autosert Injector|Motorised injection device for intraocular lens implantation
48286240|NCT02466256|DEVICE|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
48286241|NCT02466256|DEVICE|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
48286242|NCT06602362|OTHER|Partnered sex involving choking|When a subject submits a survey indicating that they engaged in partnered sex involving choking, they will be asked to come in for data collection within 24 hours of survey submission.
48472022|NCT05290493|OTHER|Placebo|Matching, inactive placebo
48472023|NCT00565513|PROCEDURE|blood test|cord blood and maternal milk test
48472024|NCT01662024|DEVICE|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
47940145|NCT04490031|DRUG|Ketamine Hydrochloride|patient in Ketamine group will be given Ketamine as sedative agent
47940146|NCT02520128|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
47940147|NCT03786614|OTHER|Discontinuation of serotonergic antidepressants|Discontinuation of serotonergic antidepressants and possibly shift to other antidepressant categories that were proven to be effective in treating depression such as pramipexole, bupropion, quetiapine, lurasidone, brexpipazole. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
47940148|NCT03786614|OTHER|Continuation of serotonergic medications|Continuation of serotonergic medications which is the standard care of treatment. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
47940149|NCT05437835|DRUG|Ropivacaine|Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
47940150|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
47940151|NCT04147572|DRUG|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
47940152|NCT04147572|DRUG|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
47940153|NCT04147572|DEVICE|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
47940154|NCT04147572|DEVICE|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
47940155|NCT03248843|DRUG|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
47940156|NCT05821101|DEVICE|Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.|Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
47940157|NCT03226873|BEHAVIORAL|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
47940158|NCT05307731|DRUG|Fingolimod|0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
48101502|NCT06613074|DEVICE|Ali Pay intelligent navigation applet|"The intelligent navigation applet comprises of three function modules:~1. Stroke knowledge public education: information regarding prevention and emergency treatment of stroke would be push to users\&#39; mobile phones regularly;~2. Stroke recognition: questionaires, voice interaction, and facial recognition are employed to identify patients with AIS and large vessel occlusion;~3. Hospital recommendation: this module combines real-time traffic and average in-hopital delay of each stroke center nearby, recommending the stroke center in which patients are mostly likely to receive reperfusion therapy"
48101504|NCT05461547|DIAGNOSTIC_TEST|Lung Ultrasound|LUS will be performed and interpreted in real-time to guide acute management.
48286243|NCT06602362|OTHER|Partnered sex not involving choking|When a subject submits a survey indicating that they engaged in partnered sex that did not involve any choking, they will be asked to come in for data collection within 24 hours of survey submission.
48101505|NCT05461547|OTHER|Usual Care|Usual care to decide diagnosis and treatment
48101506|NCT00618280|DRUG|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
48286244|NCT04219371|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
48286245|NCT05947019|DEVICE|Myopic amblyopia comprehensive treatment instrument|Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.
48286246|NCT05947019|DEVICE|Glasses|Optometry with glasses as a routine treatment
47940159|NCT05307731|DRUG|guideline-based treatment for DM|guideline-based treatment for DM
47940160|NCT00006367|BIOLOGICAL|filgrastim|
47940161|NCT00006367|DRUG|busulfan|
47940162|NCT00006367|DRUG|cytarabine|
47940163|NCT00006367|DRUG|idarubicin|
47940164|NCT00006367|PROCEDURE|peripheral blood stem cell transplantation|
47940165|NCT01110655|OTHER|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
48101507|NCT03452306|DRUG|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
48286247|NCT06049316|OTHER|Scapular stabilization exercises|"In Scapular stabilization exercise, following treatment protocol will involve.~* In supine position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree. After this patient will raise his hand overhead with 90 degree flexion and elbow extension and also perform scapular retraction. (10 sec hold, 10 reps, 20 sec break).~* In quadrupled position with 120 degree flexion and shoulder abduction patient will lifted his hands. (10 sec hold, 10 reps, 20 sec break) TYI exercises will be administered~* T shape: Place both arms horizontal with thumbs up. (10 times, 5 sec hold, 3 sets)~* Y-shape: In prone lying place arms in 45 degree. (10 times, 5 sec hold, 3 sets)~* I-shape: In prone position patients will place his both arms overhead. (10 times, 5 sec hold, 3 sets).~These above exercises will perform 3 times a week for eight weeks."
48286248|NCT06049316|OTHER|Scapular functional exercises|"In Scapular functional exercises, following treatment protocol will involve~* Press-up (in a chair).~* Push-up plus, Grade 1, in oblique position exercise will be performed with the support of a table. After progression perform this in horizontal plane.~* Lateral pull down~* Horizontal pull apart~* Prone flexion: in prone position on plinth. Both arms placed overhead, and then raise arms towards ceiling.~* Prone rows: in prone position, with elbow straight, slowly raise arms towards ceiling while bending the elbows.~These all above exercises will perform by holding dumbbells in hands (20RM at first week, 10RM at last week) with 3 sets, 3 times a week for eight weeks."
47940166|NCT01110655|OTHER|Oral hypertonic saline|Oral 100mL bolus of 3% saline
47940167|NCT03894137|DIETARY_SUPPLEMENT|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
47940168|NCT03680430|RADIATION|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
47940169|NCT00844818|BEHAVIORAL|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
47940170|NCT06133738|OTHER|Standardized Exercise Program|"Participants will be asked to attend to the department for 8 supervised physiotherapy sessions designed to strengthen lower limb muscles. Eight sessions were chosen as this number should be able to achieve improvements in pain and function. Standardized exercises sessions will be held once weekly in the health center and will be supervised by the researcher. In addition, participants will be requested to perform the prescribed exercises 3 times per week at home, with 1-2 days rest interval between the exercise's sessions.~The program is comprised of a minimum of 4 and a maximum of 6 individualized lower limb exercises to be performed 4 times per week (once in the health center and 3 times at home). All exercise programs will include at least 2 knee extensor strengthening exercises, 1 hip abductor strengthening exercise, 1 hamstring strengthening exercise, 1 calf strengthening exercise, and 1 other exercise will be chosen based on assessment findings."
47940171|NCT06133738|OTHER|Internet based Cognitive Behavioral Therapy|"This intervention will be given to participants in intervention group. This is a link to access pre-recorded online sessions of CBT.~The iCBT link contained eight 35- to 45-minute sessions, designed to be completed weekly, each provided an explanation of a cognitive or behavioural pain coping skill. Session 1 provided an overview, including a therapeutic rationale of CBT, followed by training in progressive muscle relaxation. Sessions 2 through 7 taught brief relaxation skills, activity-rest cycling, pleasant activity scheduling, cognitive restructuring, pleasant imagery, and problem-solving. Session 8 consolidated the learnt and taught strategies for long-term skill use. Each session has to be completed within the same week where the physiotherapy session is given.~The researcher has developed a website that contained all the CBT materials."
47940172|NCT06133738|OTHER|Educational Materials|All participants will receive a link to access online educational material about chronic knee pain. This is a YouTube link that consists of 5 sessions, with each lasting for 5-7 minutes, and is comprised of general information about the following: healthy eating, osteoarthritis and X-Ray, physical activity, the full pain experience, and proper footwear. Participants will be encouraged to access the educational material at their own leisure and pace.
47940173|NCT06255210|DRUG|Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)|When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.
47940174|NCT04732156|BIOLOGICAL|Blood sample|Measurement of PHI Index
48101508|NCT03452306|DRUG|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
48101509|NCT03452306|DRUG|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
48101510|NCT03452306|DRUG|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
48101511|NCT02932293|DRUG|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
48101512|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the control arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
48101513|NCT05702294|DEVICE|Diary pod ( measuring vessel that automatically calculates voided volume)|Women in the Lower Urinary Tract Symptoms ( LUTS) arm of the study will be required to void in the measuring cup and write down their estimates on the paper diary and then transfer the voided volume to the diary pod provided (or vice versa).
48101514|NCT04912362|DEVICE|YAG iridotomy|YAG iridotomy was performed one week before operation, and then CO2 Laser-Assisted Sclerectomy Surgery was performed
48286249|NCT02088034|BEHAVIORAL|Promotora-led Intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
48286250|NCT02088034|DRUG|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
48286251|NCT02088034|OTHER|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
48286252|NCT06482060|DEVICE|Stabilization splint|Stabilization splint application is a treatment that improves the function of TMJ and masticatory muscles by creating a balanced, stable occlusion to reduce the effects of occlusal interference and parafunctional habits and eliminate associated pain.
48286253|NCT01558687|DRUG|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
48286254|NCT01558687|OTHER|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
48286255|NCT05075642|OTHER|Initial management of the urinary disorder/s identified during the screening phase|Intervention can be defined as the initial management of the LUTS identified during the screening phase; management lasts at least three months. As observation of routine clinical practice, no specific intervention is included, but any counseling/drug/rehabilitation included as first line management.
48286256|NCT05631951|PROCEDURE|bone transport through induced membrane|Debridement done followed by external fixator and cement application to be followed by removal of cement (after 6 weeks) and start bone transport
48286257|NCT05631951|PROCEDURE|bone transport|Debridement done then external fixator was applied then bone transport started.
48286258|NCT06013787|BEHAVIORAL|"Nuestras Historias"|"Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers."
48286259|NCT02859701|DRUG|AK002|IV AK002
47940175|NCT04732156|OTHER|Follow up questionnaire|3 years after inclusion
47940176|NCT04732156|DIAGNOSTIC_TEST|Human reading of prostate MR images (PI-RADSv2.1).|The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
47940177|NCT04854642|DRUG|Ladarixin|A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
48286260|NCT02859701|OTHER|Placebo|
48286261|NCT05176210|DRUG|PS1|PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
48286262|NCT05176210|DRUG|Placebo|Placebo will be provided as a 120 mg tablet.
48286263|NCT01099345|PROCEDURE|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
48286264|NCT01099345|PROCEDURE|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
48286265|NCT04663620|BEHAVIORAL|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
48286266|NCT04663620|BEHAVIORAL|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
48286267|NCT05747404|DIAGNOSTIC_TEST|Echocardiography|- Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
48286268|NCT05926206|DRUG|Devimistat|Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
48286269|NCT05926206|DRUG|Modified FOLFIRINOX|Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
48286270|NCT03648450|OTHER|Propeller EMD|Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
48286271|NCT06069063|DRUG|Zafirlukast|Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
47940178|NCT06166030|DIETARY_SUPPLEMENT|Nutritional blend (ImmuneRecov).|Effects of 30 days supplementation with ImmuneRecov on Peripheral and Respiratory Muscle Strength, on Lung Function and Immune Response.
47940179|NCT00815516|DRUG|micafungin|Administered by intravenous infusion
47940180|NCT00815516|DRUG|amphotericin B deoxycholate|Administered by intravenous infusion
47940181|NCT01165333|DRUG|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~* 240~* 480~* 720~* 1200~* 1800"
47940182|NCT01165333|DRUG|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
48101515|NCT04831684|DRUG|Placebo|Participants will be getting placebo for 8 days of dosing.
47940183|NCT01165333|RADIATION|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
47940184|NCT01165333|BIOLOGICAL|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
47940185|NCT01165333|BIOLOGICAL|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
47940186|NCT01165333|BIOLOGICAL|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
48101516|NCT04831684|DRUG|GET73|Participants will be getting GET73 for 8 days of dosing.
48101517|NCT04622826|BIOLOGICAL|immune plasma|immune covid 19 plasma infusion
48101518|NCT00886613|BIOLOGICAL|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
48101519|NCT00886613|BIOLOGICAL|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
48101520|NCT00886613|BIOLOGICAL|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
48101521|NCT00886613|OTHER|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
48101522|NCT00886613|OTHER|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
48101523|NCT04444180|DIAGNOSTIC_TEST|Virtual hand illusion (VHI)|Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
48101524|NCT05301556|OTHER|Experimental Product|"* Before the surgery: FSMP provides daily target energy needed by participants~* 1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. FSMP provides daily target energy needed by participants"
48286272|NCT01095861|DEVICE|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
48101525|NCT05301556|OTHER|Control Product|"* Before surgery: TPF-T provides daily target energy needed by participants~* 1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. TPF-T provides daily target energy needed by participants"
48101526|NCT06222619|PROCEDURE|Potal vein embilization|Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
48101527|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month pre-intervention visit
48101528|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month post-intervention visit
48101529|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 3-months post-intervention visit
48286273|NCT01095861|DEVICE|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
48286274|NCT01720771|DIETARY_SUPPLEMENT|probiotic tablet|Intake of one probiotic lozenge tablet per day
48286275|NCT01720771|DIETARY_SUPPLEMENT|sugar pill|one tablet daily
48286276|NCT03195101|PROCEDURE|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
48630078|NCT00852878|BEHAVIORAL|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
47940187|NCT02861131|DRUG|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
47940188|NCT02861131|DRUG|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
47940189|NCT04652232|OTHER|RV3466F lotion|"Code: RV3466F Formula: MF5354~Application modalities:~3 times per week, in the evening, on a dry scalp 10 sprays overall hair after having achieved hair rays in order that the product is in contact with the scalp. Then massage to promote penetration of the lotion. Don't rinse.~Shampoo should be avoided within the 2 hours after application"
48286277|NCT02852369|BEHAVIORAL|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
48286278|NCT03509506|BEHAVIORAL|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~* The vital signs show undesired readings~* The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
48286279|NCT04403867|PROCEDURE|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
48472025|NCT00875888|DEVICE|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
48472026|NCT04750668|OTHER|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
48472027|NCT05791734|OTHER|assessing preoperative skin cleanliness|2 skin swabs on surgical incision sites and direct skin visual observation by a nurse
47940190|NCT04652232|OTHER|Shampoo|"Associated neutral shampoo: Extra mild shampoo Ducray® Code: RD0057H Formula: VS4031~Application modalities:~as often as usual~For the treated group only : no shampoo within the 2 hours after lotion application"
47940191|NCT01575288|DRUG|Placebo|100g maltose 1/day
47940192|NCT01575288|DRUG|High-dose trehalose|100g 1/day
47940193|NCT01129570|DRUG|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
48472028|NCT00697801|DRUG|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
47940194|NCT00808431|BEHAVIORAL|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
47940195|NCT00568685|DRUG|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
48286280|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
48472029|NCT00697801|DRUG|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
48472030|NCT00697801|DRUG|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
48472031|NCT03882411|BEHAVIORAL|Electronic shared decision making (eSDM) tool|The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. In addition to education, providers will receive a patient preference report in real time with options for coordination of care
48630079|NCT00852878|BEHAVIORAL|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
47940196|NCT00568685|DRUG|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
48630080|NCT02123875|OTHER|Physiotherapy|
48630081|NCT02123875|OTHER|Control arm|Routine hospital based physiotherapy
47940197|NCT00568685|DRUG|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
47940198|NCT02085915|OTHER|strip Peri Screen|
47940199|NCT00033072|DRUG|Selegiline|
47940200|NCT04383899|OTHER|Questionnaire|All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
47940201|NCT05319093|DRUG|Ozanimod|Three-months, longitudinal observational period
47940202|NCT01159977|BEHAVIORAL|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
47940203|NCT01159977|BEHAVIORAL|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
47940204|NCT01159977|BEHAVIORAL|Usual practice|No protected time provided.
47940205|NCT04884776|DIETARY_SUPPLEMENT|Microbiome immunity formula|Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)
47940206|NCT04884776|DIETARY_SUPPLEMENT|Active placebo|Active placebo contains active vitamin
47940207|NCT03609580|DRUG|Tamsulosin - 1 week|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
47940208|NCT03609580|DRUG|Tamsulosin - 3 days|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
48286281|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
48286282|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
48286283|NCT03411070|DEVICE|Implanted Medical Device|Undergo SCOUT reflector placement
48286284|NCT03411070|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48472032|NCT01913717|RADIATION|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
48472033|NCT01616316|PROCEDURE|subfascial flap|subfacial dissection to thyroid
48472034|NCT01616316|PROCEDURE|subplatysmal flap|subplatysmal approach to thyroid
48472035|NCT03813225|OTHER|Bilateral serratus Intercostal plane Block|Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
48472036|NCT04117893|DRUG|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
48472037|NCT04117893|DRUG|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
48472038|NCT01182519|BEHAVIORAL|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
48472039|NCT05964673|DEVICE|bioptron light therapy|patients will receive patient education program and bioptron light therapy for four weeks
48286285|NCT05733481|DEVICE|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
48472040|NCT01849458|DEVICE|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
48472041|NCT03342235|PROCEDURE|Photorefractive Keratectomy (PRK)|Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
48472042|NCT03342235|OTHER|Patching 2 hours per day|Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
48472043|NCT03342235|DEVICE|Excimer Laser System|Excimer Laser System for use in photorefractive keratectomy.
48472044|NCT05592483|OTHER|None (Observational Study)|Not Applicable since observational study
48472045|NCT05345951|BEHAVIORAL|e-PBI+|The e-PBI+ is a preventive parent-based intervention emphasizing parent-teen communication on drinking/risks of alcohol abuse, with the addition of data-driven cannabis content to guide parent communications with their students (e.g., cannabis content focusing on the endocannabinoid system; acute and chronic cannabis use effects on the brain, cognition, and development; THC potency in present-day cannabis; cannabis use effects on mental and physical health, including psychosis, depression, and anxiety; respiratory/cardiovascular/sleep problems; cannabidiol (CBD) content, myths; and cannabis effects on psychosocial function). Together the goals are to reduce alcohol and cannabis use in college students.
48472046|NCT05345951|BEHAVIORAL|e-PBI|"The e-PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the e-PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
48472047|NCT04823130|DRUG|Dupilumab (SAR231893)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48472048|NCT00003350|DRUG|paclitaxel|Given IV
48472049|NCT00003350|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
47940209|NCT05464329|DRUG|Mosunetuzumab|Provided by Genentech.
47940210|NCT05464329|DRUG|DHAX|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
47940211|NCT05464329|DRUG|ICE|-Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
48286286|NCT00929292|OTHER|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
48286287|NCT00929292|OTHER|Modilac 1|Infant formula used for non breastfed children
48472050|NCT00003350|OTHER|laboratory biomarker analysis|Correlative studies
47940212|NCT01384279|DRUG|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
47940213|NCT03668366|DRUG|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
47940214|NCT00395538|DRUG|PTH 1-34|Given twice daily by subcutaneous
48286288|NCT02363647|OTHER|Tumor Genomic Analysis|"Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process."
48286289|NCT06329388|DIETARY_SUPPLEMENT|TruHeight Growth Protein Shake|Participants will be administered two scoops of TruHeight Growth Protein Shake, mixed with 12-16 fluid ounces of water, once daily, five times per week for six months. The supplement is intended to support growth patterns in children by providing essential nutrients that contribute to bone development and overall growth.
48286290|NCT00539721|DRUG|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
48286291|NCT00539721|DRUG|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
48286292|NCT00539721|DRUG|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
48286293|NCT00539721|DRUG|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
48286294|NCT00539721|DRUG|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
48286295|NCT00539721|DRUG|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
48101530|NCT04764019|DIAGNOSTIC_TEST|High resolution intestinal manometry|Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
48286296|NCT04037085|DRUG|Ketamine|Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
48286297|NCT05233995|PROCEDURE|Damage Control Surgery|Delayed anastomosis
48286298|NCT00789126|DRUG|VX-509|
48286299|NCT03503123|DEVICE|Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.|Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
48286300|NCT02001740|DRUG|Triamcinalone (steroid) and lidocaine|receive once
48472051|NCT00003350|PROCEDURE|quality-of-life assessment|Ancillary studies
48472052|NCT02496208|PROCEDURE|Biopsy|Undergo biopsies
48472053|NCT02496208|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48472054|NCT02496208|DRUG|Cabozantinib S-malate|Given PO
48286301|NCT02001740|OTHER|Lidocaine|receive once
48472055|NCT02496208|PROCEDURE|Computed Tomography|Undergo CT scan
48472056|NCT02496208|PROCEDURE|Echocardiography|Undergo echocardiography
48472057|NCT02496208|BIOLOGICAL|Ipilimumab|Given IV
48101531|NCT06611163|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter
48101532|NCT06611163|DRUG|Placebo|Placebo SC injection at Day 1 and Week 4
48101533|NCT05526911|DRUG|TBAJ-876|"* Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"
48472058|NCT02496208|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48472059|NCT02496208|BIOLOGICAL|Nivolumab|Given IV
48472060|NCT03785769|PROCEDURE|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
48472061|NCT03785769|PROCEDURE|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
48472062|NCT00683787|DRUG|docetaxel|Given IV once every 3 weeks
48472063|NCT00683787|DRUG|vandetanib|Oral vandetanib once daily
48472064|NCT00235118|DEVICE|Cordis AAA Bilateral Device|
48630082|NCT00365963|DEVICE|Comprehensive Health Enhancement Support System|computer based support and education
48101534|NCT05526911|DRUG|Midazolam|Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted
48472065|NCT01958515|OTHER|research blood draw and tissue biopsy|research blood draw and tissue biopsy
48472066|NCT01242618|BIOLOGICAL|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
48472067|NCT05478928|OTHER|Dynamic dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
48472068|NCT05478928|DEVICE|Fixed dose dynamic MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
48472069|NCT05478928|OTHER|Static Dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
48472070|NCT05478928|DEVICE|Fixed dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
48472071|NCT05478928|DEVICE|Algorithm-based dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
48472072|NCT05478928|OTHER|Placebo|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
48472073|NCT06614907|DRUG|QL2108 injection|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
48472074|NCT06614907|DRUG|Dupixent®|300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection
48472075|NCT01085669|DEVICE|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
48472076|NCT03438006|OTHER|Safety data collection (following routine vaccination)|"This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician."
48472077|NCT06678204|OTHER|Optimized illustrated pamphlets|Participants in the control group received traditional text-based pamphlets covering similar self-care information for RT. Pretests were administered before the start of treatment, and posttests were conducted two weeks after the completion of RT.
48472078|NCT05995990|DEVICE|Raman Spectrometry|Laboratory technique of Raman Spectrometry
48472079|NCT05531604|BEHAVIORAL|appetitive conditioning|The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm. The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
48472080|NCT03944161|DIETARY_SUPPLEMENT|Oral nutrition supplement|Hypercaloric and high protein supplement
47940215|NCT01600742|DRUG|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
47940216|NCT01600742|DRUG|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
47940217|NCT00246415|DRUG|Memantine|
48101535|NCT05526911|DRUG|Digoxin|Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
48101536|NCT06022536|DRUG|SSS40|Subjects injected with SSS40
48472081|NCT03944161|OTHER|Nutritional advice|Advice given by the clinician
48472082|NCT01717937|PROCEDURE|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
48472083|NCT00622687|DRUG|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
48472084|NCT00622687|DRUG|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
48472085|NCT00622687|DRUG|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
48472086|NCT04621656|COMBINATION_PRODUCT|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
47940218|NCT00881478|OTHER|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
47940219|NCT00881478|OTHER|Nutrition counseling|Nutrition counseling with registered dietician
47940220|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
48101537|NCT06022536|DRUG|Placebo|Subjects injected with Placebo
48472087|NCT02812654|DRUG|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
47940221|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
47940222|NCT03526731|OTHER|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
47940223|NCT00295828|OTHER|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
47940224|NCT00295828|PROCEDURE|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
47940225|NCT06198764|DRUG|Colistimethate sodium for injection|Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.
47940226|NCT06198764|DRUG|Meropenem for Injection|Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.
47940227|NCT06198764|DRUG|Coly Mycin M Injectable Product|Coly Mycin M is the originally marketed colistimethate sodium for injection.
47940228|NCT05346432|DIETARY_SUPPLEMENT|PS23|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
48286302|NCT02660554|OTHER|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
48472088|NCT02812654|DRUG|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
48472089|NCT02812654|RADIATION|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
48472090|NCT02758548|PROCEDURE|Blood sample|Fingerprick and venous
48286303|NCT01661647|DEVICE|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
48286304|NCT04392986|OTHER|Sunlight exposure|The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.\[15\] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
48472091|NCT02758548|DEVICE|POCT device|Investigational device
47940229|NCT03645018|DIAGNOSTIC_TEST|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
47940230|NCT00674167|DRUG|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
47940231|NCT00674167|DRUG|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
47940232|NCT00674167|DRUG|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
47940233|NCT00267189|DRUG|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
47940234|NCT00267189|DRUG|Calcineurin inhibitors (CNI)|
47940235|NCT00267189|DRUG|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
47940236|NCT00267189|DRUG|Steroids|
47940237|NCT03350984|DRUG|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.
48101538|NCT03960983|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
48472092|NCT00214812|DRUG|HEC placebo gel|
48472093|NCT04273087|OTHER|Observation|Clinical signs and symptoms
48472094|NCT04846439|BIOLOGICAL|CAR-T infusion|Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
48472095|NCT04731493|OTHER|Therapeutic Education Program|"* needs assessment~* educational group workshop~* specialized workshops by age group: child / adolescent / transition / adult / entourage / separated parents and in parallel~* socio-administrative workshop~* individual summary (accompanied or not by his entourage / family)~* satisfaction questionnaire"
48472096|NCT03145324|OTHER|Collection of vaccine histories|
48472097|NCT03761056|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
48472098|NCT03761056|DRUG|Fludarabine|Administered according to package insert
47940238|NCT03350984|DRUG|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
47940239|NCT00138411|DRUG|Ciprofloxacin 500 mg|
48101539|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
48101540|NCT03960983|RADIATION|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
48101541|NCT03960983|PROCEDURE|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
48101542|NCT02345200|PROCEDURE|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
48101543|NCT02345200|PROCEDURE|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
48101544|NCT02153606|DRUG|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
48101545|NCT02153606|OTHER|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
48101546|NCT00440986|PROCEDURE|Eritrocytoapheresis|
48101547|NCT02990858|DRUG|PRO 140 SC injections|
48101548|NCT03557385|DRUG|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~* Rate of 4 mL/sec, volume of 10 cc (left coronary system)~* Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
48101549|NCT03557385|DRUG|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
48101550|NCT03557385|DEVICE|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
48101551|NCT03557385|DEVICE|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
48101552|NCT03148938|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test"
48101553|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implant, Nanobone with PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* Alloplast bone graft material (Nanobone)~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
48101554|NCT02836678|BIOLOGICAL|Ridge splitting, immediate implantand PRF.|"* Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~* PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
48101555|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from whole goat milk|Infant formula and follow-on formula made from whole goat milk
48101556|NCT04599946|DIETARY_SUPPLEMENT|Infant formula and follow-on formula made from cow's milk ingredients|Infant formula and follow-on formula made from cow's milk ingredients
48101557|NCT00956449|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
48286305|NCT05953064|OTHER|DHA-NAT|Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
48286306|NCT05953064|OTHER|Placebo|Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
48286307|NCT00152256|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
48286308|NCT00152256|DRUG|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
48286309|NCT00152256|DRUG|Placebo|Placebo Tablet, oral Daily for 6 months
48472099|NCT03761056|DRUG|Cyclophosphamide|Administered according to package insert
47940240|NCT00138411|DRUG|ETI-204 (Anthim)|
47940241|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
47940242|NCT04020575|BIOLOGICAL|huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D|huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
47940243|NCT01902251|DRUG|Enzalutamide tablet|Oral
47940244|NCT01902251|DRUG|Enzalutamide capsule|Oral
47940245|NCT06130007|DRUG|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy|Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
48101558|NCT04760301|DRUG|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
48101559|NCT04760301|OTHER|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
48101560|NCT04760301|DRUG|IV 1 g tranexamic acid|IV 1 g tranexamic acid diluted in 100 ml saline
48472100|NCT01601691|DEVICE|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
48472101|NCT01937351|DEVICE|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
47940246|NCT03431311|BIOLOGICAL|Adoptive Cell Therapy (ACT)|T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
48472102|NCT05424250|BEHAVIORAL|occasional aversive imagination|During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.
47940247|NCT05455762|OTHER|Exercise|The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
47940248|NCT01237964|DRUG|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
47940249|NCT01643603|DRUG|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
47940250|NCT01643603|OTHER|laboratory biomarker analysis|Correlative studies
47940251|NCT03220529|DEVICE|Brillouin Ocular Scanner|
47940252|NCT02753218|DRUG|Midazolam|
47940253|NCT02753218|DRUG|LEO 32731|
47940254|NCT02285556|BEHAVIORAL|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
47940255|NCT02285556|BEHAVIORAL|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
47940256|NCT02285556|RADIATION|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
48101561|NCT04760301|OTHER|IV 1 g normal saline|IV 100 ml normal saline
48101562|NCT04175886|DRUG|Tofacitinib|Patients will be treated with tofacitinib
48101563|NCT02282527|BIOLOGICAL|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
48101564|NCT02282527|BIOLOGICAL|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
48101565|NCT01494662|DRUG|HKI-272|240 mg orally, once daily
48101566|NCT01494662|PROCEDURE|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
48101567|NCT01494662|DRUG|Capecitabine|750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
48101568|NCT01494662|DRUG|HKI-272|160 mg orally, once daily
48101569|NCT01494662|DRUG|Ado-Trastuzumab Emtansine|3.6 mg/kg IV every 3 weeks
48101570|NCT00470626|DEVICE|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
48101571|NCT05455346|DIAGNOSTIC_TEST|Ultrasound imaging|"Ultrasound B-mode images will be unilaterally collected from the biceps femoris muscle of the dominant limb for each participant using a commercial ultrasound system and linear array transducer. Standardized image locations will correspond to 33%, 50%, and 67% of the thigh length from the ischial tuberosity.~Three repeat longitudinal extended-field-of-view images of the entire biceps femoris muscle will be collected for offline analysis for fascicle length, muscle thickness, and pennation angle. Transverse extended-field-of-view images will be captured at the proximal, mid-belly, and distal locations to determine regional anatomical cross-sectional area of the biceps femoris long head muscle.~To determine changes in tissue stiffness via ultrasound shear wave speed, the same transducer will be placed in the same locations in a longitudinal view. Shear wave maps will be generated by the ultrasound system and shear wave speed measures extracted from the middle of the map."
48101572|NCT05455346|OTHER|Hamstring Eccentric Strength Testing|"Prior to each test, participants will perform a standardized 5-minute general warm-up followed by a task-specific warm-up including 3 sets of submaximal trials. Load increases (5-20%) will be added for each RDL 3-repetition maximum trial attempt until the participant cannot complete 3 repetitions through the full range of motion using proper technique. A 3-minute rest will be administered between all warm-up and testing sets to allow for full recovery.~Participants will kneel on a commercial device used to assess maximum eccentric knee flexor strength via uniaxial load cells with their ankles secured into fixed hooks. Participants will slowly lower their torso to the ground with arms crossed across their chest and without bending at the hips or spine. The maximal test will consist of 1 set of 3 maximal repetitions. If participants can control lower themselves to the ground, then they will hold barbell plates (5-10 lb increments) across their chest while performing the NHE."
48101573|NCT05455346|OTHER|Maximal 60 m Sprint|Following a standardized warm-up, inertial measurement units (IMUs) will be placed on the sternum, sacrum, and bilaterally on the thighs, legs, and foot. Each participant will perform a total of 3 maximal 60 m sprints from a standing position with 1.5-3 min rest in between each trial to minimize the effects of fatigue.
48472103|NCT05424250|BEHAVIORAL|Exposure|• All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
48472104|NCT01770002|PROCEDURE|Everted suture technique|
47940257|NCT02285556|RADIATION|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
47940258|NCT00164229|BEHAVIORAL|math|
47940259|NCT00164229|BEHAVIORAL|behavior regulation|
47940260|NCT03795610|DRUG|IPI-549|40mg by mouth (PO) every day (QD) for at least 14 days
47940261|NCT04572802|PROCEDURE|Coronary angiography|Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
47940262|NCT00586729|DEVICE|Vashe|Antimicrobial irrigant
47940263|NCT00586729|DRUG|Mafenide acetate|Antimicrobial solution
47940264|NCT05122676|BEHAVIORAL|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
47940265|NCT01171508|DEVICE|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
47940266|NCT01171508|DEVICE|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
47940267|NCT01171508|DEVICE|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
47940268|NCT01171508|PROCEDURE|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
47940269|NCT01171508|OTHER|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
48101574|NCT05455346|OTHER|Romanian Deadlift|The RDL intervention will be performed twice per week for 6 weeks. Participants will hinge at the hips lowering the bar to just below their patella before reversing the movement. The RDL will be performed with a 6 second eccentric component and returning to the start position with a maximal concentric hip extension.
48101575|NCT05455346|OTHER|Nordic hamstring exercise|The NHE will be performed twice per week for 6 weeks. Participants will be instructed to maintain their ankles in a dorsiflexed position, lower themselves as close to the ground as possible at a constant and controlled speed while maintaining a neutral position of the hips and trunk, and to cross their arms in front of their chest.
48101576|NCT06214468|COMBINATION_PRODUCT|Acetaminophen and Nicotinamide Riboside|Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
48101577|NCT06214468|DRUG|Acetaminophen|Collection of urine at different time intervals following ingestion of Tylenol only
48101578|NCT02696629|PROCEDURE|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
48101579|NCT02696629|DEVICE|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
48101580|NCT02696629|BEHAVIORAL|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
48101581|NCT06631599|OTHER|Physical training|The intervention consisted of physical exercise according to various protocols
48101582|NCT01913340|DRUG|Erythropoietin|1000 U/kg/dose IV x 5 doses
48101583|NCT01913340|DRUG|Normal saline|placebo: NS IV x 5 doses
48101584|NCT06629272|BEHAVIORAL|D-THIO (Deprescribing Thyroid Hormone In Older Adults)|"D-THIO consists of evidence-based pharmaceutical opinion letters to providers advising deprescribing for their patients 65 years and older with thyroid hormone overtreatment/misuse and EMPOWER (Eliminating Medications through Patient Ownership of End Results) brochures to their patients."
48286310|NCT04664491|BEHAVIORAL|Standardized COPD management|"In standardized management group, patients will receive a multifaceted and integrated disease management that follows recommendations in GOLD 2020 and China Guideline on COPD care. It contains the components below.~1. Maintenance therapy after initial treatment. In this study, patients' initial therapy is the prescribed inhalers at baseline. Maintenance therapy is the medications (LABA, LAMA, or ICS) prescribed for regular or long-term use after initial therapy.~2. Long-term follow-up and routine monitoring of symptoms measured by CAT, mMRC and SGRQ.~3. Regular pulmonary function testing for lung function monitoring~4. Strengthened COPD education~5. Behavioral modification, eg. encouragement of influenza/pneumococcal vaccination, providing smoking cessation counseling and pulmonary rehabilitation."
48286311|NCT04664491|OTHER|Routine COPD management|Patients will undergo usual care according to current clinical practice in study sites. Usual care is the routine care provided to patients. Prescription and dispense of medicine for COPD initial and maintenance therapy will be at the discretion of doctors.
48286312|NCT01457248|DEVICE|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
48286313|NCT01457248|DEVICE|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
48286314|NCT00980083|DRUG|Saline|
48286315|NCT00980083|DRUG|Exendin(9-39)amide|
48286316|NCT03669133|DRUG|Vitamin E|Vitamin E 800 IU/daily
48286317|NCT03669133|DRUG|Placebo|Matching placebo daily
48286318|NCT00714142|DRUG|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
48286319|NCT00714142|DRUG|15O-water|10-20 mCi, IV
48286320|NCT00714142|PROCEDURE|Positron Emission Tomography|PET Scan
48286321|NCT02724033|PROCEDURE|regional nerve block|regional nerve block
48286322|NCT02724033|DRUG|Antiemetic|Antiemetic
48286323|NCT05128617|DRUG|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
48286324|NCT05128617|DRUG|Paclitaxel|1 cycle of Paclitaxel
48286325|NCT05004467|OTHER|Mobilization With Movement Technique|The researcher explains cervical movements to the patient to be done while the technique is performed. This movements will be the painful and limited movements detected in goniometric intervention before the treatment and movements done actively and in all range of motion.
48286326|NCT05144061|DRUG|HRS2398 Tablets|Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.
48286327|NCT02997930|BEHAVIORAL|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
48286328|NCT02997930|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
48286329|NCT02997930|BEHAVIORAL|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
48101585|NCT06629272|BEHAVIORAL|Enhanced usual care|American Thyroid Association \[ATA\] provider guidelines, ATA patient brochure
48286330|NCT02997930|BEHAVIORAL|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
48286331|NCT02997930|BEHAVIORAL|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
47940270|NCT01171508|OTHER|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
47940271|NCT01171508|OTHER|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
47940272|NCT03230253|BEHAVIORAL|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
47940273|NCT03230253|BEHAVIORAL|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
47940274|NCT03230253|BEHAVIORAL|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
48286332|NCT02997930|BEHAVIORAL|General Depression Scale (GDS)|A measure of the of presence of depression.
48286333|NCT01655511|DRUG|Tafamidis|240 mg, solution, single dose
48286334|NCT01655511|DRUG|Tafamidis|480 mg, solution, single dose
48286335|NCT01655511|DRUG|Tafamidis|TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
48472105|NCT01770002|PROCEDURE|Non-everted suture technique|
48472106|NCT04396444|COMBINATION_PRODUCT|Aromastick|Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
47940275|NCT02298985|DRUG|Curcumin|3 g/day (3 capsules/day) for 6 months
47940276|NCT02298985|DRUG|placebo|3 g/day (3 capsules/day) for 6 months
47940277|NCT00687232|DRUG|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
47940278|NCT00687232|DRUG|Placebo|
47940279|NCT04948567|OTHER|split-dose of Magnesium Sulfate solution|purgative for bowel preparation
47940280|NCT04948567|OTHER|split-dose of PEG|purgative for bowel preparation
47940281|NCT03039972|DIAGNOSTIC_TEST|No intervention|No intervention
47940282|NCT02370771|PROCEDURE|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
47940283|NCT02370771|DEVICE|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
48286336|NCT05505422|DEVICE|Routine ECMO|Routine ECMO during lung tansplant
48286337|NCT05505422|DEVICE|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~2. Prolonged high dose pressor required to maintain adequate perfusion~3. A sustained drop in cerebral saturation \> 25% of baseline despite initial attempts at optimization~4. Inability to tolerate pulmonary artery clamping~5. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~6. Inadequate exposure to the surgical field"
48286338|NCT00986960|DRUG|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
48286339|NCT00986960|DRUG|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
48472107|NCT00245817|BEHAVIORAL|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
48472108|NCT00792207|OTHER|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
48472109|NCT00792207|OTHER|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
48617953|NCT00090428|BEHAVIORAL|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
48286340|NCT06041347|DIAGNOSTIC_TEST|Transvaginal ultrasound|Preoperative detection with TVUS of proximity or the involvement of the sacral nerve roots in women diagnosed with deep endometriosis or other benign or malignant pelvic tumors would also contribute to the safety of surgical interventions (e.g laparoscopy, tru-cut biopsy) It aslo provides correct counseling and select the appropriate surgical team and assess the likely operative complexity of the surgery. Until now the diagnosis was based on MRI.
48286341|NCT02429648|PROCEDURE|DCC first then PVI|DCC performed prior to PVI
48286342|NCT02429648|PROCEDURE|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
48286343|NCT02542345|PROCEDURE|magnetic resonance imaging|
48286344|NCT01277146|DRUG|OMP-59R5|IV infusion
48472110|NCT02452879|DEVICE|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
48472111|NCT02452879|DEVICE|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
48472112|NCT02452879|DRUG|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg / tablet
48472113|NCT01023776|BIOLOGICAL|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
48472114|NCT03460899|OTHER|Euglycaemic Clamp|All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
48472115|NCT03460899|OTHER|Hyperinsulinaemic/Hypoglycaemic Clamp|All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
48472116|NCT00292331|PROCEDURE|cyanoacrylate injection to treat gastric variceal hemorrhage|
48472117|NCT01264835|DEVICE|Slotted Anoscope|SA411
48286345|NCT04615871|DRUG|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
48286346|NCT04970680|PROCEDURE|glossopharyngeal nerve block|glossopharyngeal nerve block either blindly or using the ultrasonic technique
48286347|NCT00264277|DRUG|Vitamin K antagonist (Coumarin anticoagulants)|
48286348|NCT00224016|DRUG|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
48286349|NCT00224016|DRUG|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
48286350|NCT02519231|DRUG|Naproxen|Naproxen 440mg 1x pid
48286351|NCT02519231|DRUG|Placebo|Placebo tablet 440mg 1x pid
48286352|NCT00784758|DEVICE|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
48286353|NCT00784758|DEVICE|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
48286354|NCT01707875|OTHER|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
48472118|NCT00006009|BIOLOGICAL|visilizumab|
48286355|NCT01718717|OTHER|Thoracic Epidural Analgesia (TEA)|
48472119|NCT04976023|DRUG|Yupingfeng Powder granules|14.5 5 g twice daily for 8 weeks
48472120|NCT04976023|OTHER|Placebo|14.5 5 g twice daily for 8 weeks
48472121|NCT01764750|DRUG|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
48472122|NCT01764750|DRUG|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
48472123|NCT06453824|DRUG|MDI-2517|study drug
48472124|NCT06453824|OTHER|Placebo|matching placebo
48472125|NCT00535028|DRUG|AER 001|AER 001 25 mgs s.c. once daily for 28 days
48472126|NCT00535028|DRUG|placebo|sterile saline
48472127|NCT04423445|OTHER|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
48472128|NCT01758406|BIOLOGICAL|Intracoronary injection|stem cell transplantation
48472129|NCT01758406|BIOLOGICAL|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
48472130|NCT03992651|DEVICE|Measurements of capnia and tissue oxygenation by optical transcutaneous sensors|Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
48472131|NCT06179693|DIAGNOSTIC_TEST|Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.
48472132|NCT02721550|DRUG|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
48472133|NCT04651920|GENETIC|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
48472134|NCT00774241|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
48472135|NCT00774241|DRUG|docetaxel|75mg/m2 every 3 weeks for 18 weeks
48472136|NCT04066257|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
48472137|NCT04066257|DRUG|Metronidazole|Metronidazole 250 mg tablet
48472138|NCT04066257|DRUG|Tetracycline|Tetracycline hydrochloride 250 mg capsule
48286356|NCT01718717|OTHER|TEA followed by Intravenous morphine|
48286357|NCT03397186|PROCEDURE|Biopsy|Undergo biopsy
48286358|NCT03397186|OTHER|Laboratory Biomarker Analysis|Correlative studies
48286359|NCT03397186|DRUG|Trabectedin|Given as standard of care
48286360|NCT02452359|DEVICE|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
48286361|NCT00165737|DRUG|Donepezil Hydrochloride|
48286362|NCT04481100|DRUG|itraconazole|Oral administration of itraconazole twice daily concurrent with chemoradiation
48286363|NCT05446675|PROCEDURE|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
48286364|NCT05446675|PROCEDURE|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
48286365|NCT03466710|PROCEDURE|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
48286366|NCT03466710|OTHER|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (\>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (\</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or \>LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is \>/=CIN II. Results of \</=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
48472139|NCT04066257|DRUG|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
48472140|NCT02024594|DRUG|Nitrous Oxide-Oxygen conscious sedation|
48472141|NCT02024594|BEHAVIORAL|cognitive-behavioral therapy|
48472142|NCT04485416|DRUG|Eltrombopag|Eltrombopag is an orally administered small-molecule nonpeptide TPO-R agonist.
48472143|NCT00535080|DRUG|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
48472144|NCT06260501|OTHER|super-wet technique|Liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter
48472145|NCT02838940|PROCEDURE|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
47940284|NCT05169073|PROCEDURE|Virtual Reality training|In the Virtual Reality (VR) study arm, a VR software (Specto VRTM, version 4.0, Diffuse Ltd, Heimberg, Switzerland) will be used to display volumetric MRCP data using a tethered head-mounted display (HMD) prior to the operation. Specto uses volume rendering at 180 frames/sec to visualize the medical data in an immersive fashion in the VR environment and allows for viewing of the 3D reconstructed 3D imaging with 360° free movement. Each participant will perform a procedure with VR training and one with conventional preparation (MRCP).
47940285|NCT05169073|PROCEDURE|Conventional training|In the conventional study arm, the participants will view the preoperative MRCP.
47940286|NCT01910571|DRUG|P7435|
47940287|NCT01910571|OTHER|Placebo|
47940288|NCT01164540|DRUG|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
47940289|NCT01164540|DRUG|Placebo|Oral dose (od)
47940290|NCT06077708|DIETARY_SUPPLEMENT|Vitamin D3K2|Non-surgical periodontal treatment was applied to all individuals included in the study. 2 drops of the preparation containing 25 µg D3 \[1000 IU\] and 11.25 µg K2 in each drop were given per day to participants in the test group.
47940291|NCT06077708|OTHER|Saline Solution|Non-surgical periodontal treatment was applied to all individuals included in the study and saline solution (0.9% NaCl) was given as placebo, 2 drops per day to particiapants in the control group.
47940292|NCT01871857|DRUG|Hypertonic saline and epinephrine|
47940293|NCT01871857|DRUG|Normal saline and epinephrine|
47940294|NCT02038829|DRUG|Placebo|Placebo
47940295|NCT02038829|DRUG|SUN101 3 mcg|SUN-101 3 mcg bid
47940296|NCT02038829|DRUG|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
47940297|NCT02038829|DRUG|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
47940298|NCT02038829|DRUG|SUN-101 50 mcg|SUN-101 50 mcg bid
47940299|NCT02038829|DRUG|Aclidinium|Aclidinium 400 mcg bid
47940300|NCT04216914|DEVICE|Hand outline|A simple outline of a hand, to which the child tried to match their own hand on order to improve positioning.
47940301|NCT04601922|OTHER|Semi-structured interview|The interview will have the audio recorded, and will explore the ideas of each participant around long term cardiovascular care pathways
47940302|NCT06086691|OTHER|Strength Training with Caffeine|"The intervention protocol consists of 5 types of strength training exercises. The following exercises will be performed for the strength training group:~1. bench press (3 sets of 10 reps)~2. biceps curl (3 sets of 10 reps)~3. triceps pushdown (3 sets of 10 reps)~4. leg press (3 sets of 10 reps)~5. leg extension (3 sets of 10 reps)~Strength training would be performed in 3 sets of 10 repetitions with 2 minutes of rest between each exercise. This protocol will be performed in a 30-40-minute session. 10-15 minutes of light warm-up activities will be performed before the start of each exercise session. The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
48101586|NCT05241795|OTHER|Knee then Ankle rehabilitation protocol|"Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction.~Then, Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises"
48472146|NCT02838940|DRUG|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
48472147|NCT01501968|DRUG|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
48472148|NCT01501968|DRUG|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
48472149|NCT00491907|DRUG|folic acid 5mg/day|
48472150|NCT00142116|DRUG|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
48472151|NCT00142116|DRUG|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
48472152|NCT02114112|OTHER|NCPAP cycling|
48472153|NCT02114112|OTHER|NCPAP continuous|
48472154|NCT00588731|DRUG|Cannabidiol|Active Cannabidiol daily over 6 weeks
48472155|NCT00588731|DRUG|Placebo|Placebo
48472156|NCT01352364|OTHER|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
48472157|NCT01719562|PROCEDURE|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
48472158|NCT01719562|OTHER|Physical Activity|Tailored aerobic exercise program onsite and at home.
48472159|NCT01719562|OTHER|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
48472160|NCT01719562|DEVICE|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
48472161|NCT01719562|OTHER|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
48472162|NCT02418624|DRUG|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
47940303|NCT06086691|OTHER|Endurance Training with Caffeine|"The intervention protocol consists of 3 types of endurance training exercises. The following exercises will be performed by this group:~1. Cycling (15 min)~2. Running (20 min)~3. Rowing (10 min)~The intervention sessions would be carried out with a 3-5-day gap between the two intervention sessions."
47940304|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|2.5mg po daily
47940305|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
47940306|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
47940307|NCT00048061|DRUG|Ibandronate [Bonviva/Boniva]|150mg po monthly
47940308|NCT00048061|DIETARY_SUPPLEMENT|Calcium|500 mg/day
47940309|NCT00048061|DIETARY_SUPPLEMENT|Vitamin D|400 IU/day
48286367|NCT03466710|DIAGNOSTIC_TEST|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
48286368|NCT02117089|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
48286369|NCT04939493|OTHER|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
48472163|NCT00948337|BEHAVIORAL|Brochure of Secondary Cancer Screening|One kind of printed educational material
48472164|NCT02707887|BEHAVIORAL|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
48472165|NCT02707887|BEHAVIORAL|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
48472166|NCT02707887|BEHAVIORAL|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
48472167|NCT06453525|OTHER|intubation|Tracheal intubation using one of the three existing videolaryngoscopes
48472168|NCT02050035|OTHER|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
48472169|NCT00388037|DRUG|sunitinib malate|Given PO
48472170|NCT00388037|OTHER|laboratory biomarker analysis|Correlative studies
48472171|NCT00067717|BEHAVIORAL|Distance healing|
48472172|NCT05675358|BEHAVIORAL|Virtual Reality|Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
48472173|NCT04590196|DRUG|Longvida curcumin|longvida curcumin verdure sciences formulation
48472174|NCT04590196|OTHER|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
48101587|NCT05241795|OTHER|Ankle then Knee rehabilitation protocol|"Patients will start ankle exercises program that includes:~* Standing calf raises~* Foot lift~* Ankle eversion exercises~* Ankle Plantarflexion exercises~Then, Patients will start with knee exercise program that includes~* Partial Squats: The exercise will be performed as 3 sets of 10 repetitions each day.~* Toe Raises: The exercise will be performed as 3 sets of 10 repetitions each day.~* Stationary bike will be used (10-15 minutes /day) when the patients can bend their knees at least 100 degrees, as cycling is considered as an excellent conditioning and building exercise for the quadriceps muscles. As the patient's ability to pedal the bike with the operative leg improved, the therapist will increase the resistance.~* Hamstring exercises: After 6 weeks, the hamstring muscles will be exercised by the patient pulling the heel back producing a hamstring contraction."
48101588|NCT05754463|OTHER|The effect of plyometric training on balance and proprioception in athletes in different branches|Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
48472175|NCT05659758|PROCEDURE|Head up positioning during preoxygenation|patients will be preoxygenated in head up position
48472176|NCT05746117|DEVICE|Aktiia Device|The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
48472177|NCT05746117|DEVICE|Upper arm cuff|A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
48472178|NCT01989299|DEVICE|ILR implantation|
48472179|NCT00496028|DRUG|AZD0530|oral tablet
48101589|NCT04018118|BIOLOGICAL|Biological sample|Additional blood samples for biobanking
48101590|NCT05937906|DRUG|Phase I - Mirdametinib - Level 1|Mirdametinib 4 mg twice/day for 7 days per cycle
48101591|NCT05937906|DRUG|Phase II - Mirdametinib|For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
47940310|NCT02889276|OTHER|Functional Resistance Training|Supervised group-based Functional Resistance Training
48101592|NCT05937906|DRUG|Phase I - Mirdametinib - Level 2|Mirdametinib 4 mg twice/day for 14 days per cycle
48101593|NCT05937906|DRUG|Phase I - Mirdametinib - Level 3|Mirdametinib 6 mg twice/day for 7 days per cycle
48101594|NCT05937906|DRUG|Phase I - Mirdametinib - Level 4|Mirdametinib 6 mg twice/day for 14 days per cycle
48101595|NCT00064571|PROCEDURE|vocal fold medialization|
48286370|NCT04939493|OTHER|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
48286371|NCT04939493|OTHER|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
48472180|NCT00496028|DRUG|Carboplatin|intravenous infusion
48101596|NCT00064571|PROCEDURE|vocal fold reinnervation|
48472181|NCT00496028|DRUG|Paclitaxel|intravenous infusion
48101597|NCT03328117|DRUG|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
47940311|NCT02889276|BEHAVIORAL|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
47940312|NCT06379425|DRUG|Acetaminophen|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
47940313|NCT06379425|DRUG|Celecoxib|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
47940314|NCT06379425|DRUG|Gabapentin|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
48101598|NCT03328117|DRUG|Placebo oral capsule|Matching placebo oral capsule
48286372|NCT02623361|DRUG|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
48286373|NCT02623361|DRUG|Sham Block|Sham Block by saline injection
48286374|NCT03211247|BIOLOGICAL|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
48286375|NCT03211247|BIOLOGICAL|Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
48286376|NCT03211247|BIOLOGICAL|Placebo|Placebo patch, once daily
48286377|NCT01383122|DEVICE|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
48101599|NCT06441006|DRUG|Bedaquiline|Frequency: daily Route of administration: oral
47940315|NCT04300621|DRUG|OTF 1|Participants will receive (S)-ketamine administered sublingually through OTF 1.
47940316|NCT04300621|DRUG|OTF 2|Participants will receive (S)-ketamine administered sublingually through OTF 2.
48101600|NCT06441006|DRUG|Linezolid|Frequency: daily Route of administration: oral
48101601|NCT06441006|DRUG|Pretomanid|Frequency: daily Route of administration: oral
47940317|NCT04300621|DRUG|OTF 3|Participants will receive (S)-ketamine administered sublingually through OTF 3.
47940318|NCT04300621|DRUG|OTF 4|Participants will receive (S)-ketamine administered sublingually through OTF 4.
47940319|NCT04476823|OTHER|Activity|The questionnaire had requested information on the biosafety organization, impact of the COVID-19 crisis on the clinical and molecular pathology and the biobanking activity in thoracic pathology, on the research activity associated with the COVID-19, and on the educational and training organization. It requested the different needs planned by the different laboratories following the COVID-19 crisis and finally the consequence of this latter on the health and virological status of the staff members.
48101602|NCT06441006|DRUG|Moxifloxacin|Frequency: daily Route of administration: oral
48286378|NCT01383122|DEVICE|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
48286379|NCT01606722|DRUG|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
48286380|NCT03610412|OTHER|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
48286381|NCT03610412|OTHER|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
48472182|NCT02497079|DEVICE|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
48472183|NCT02497079|DEVICE|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
48617954|NCT01192815|DRUG|erlotinib hydrochloride|Given orally or via gastronomy tube
48286382|NCT05596825|DEVICE|Mandibular Advancement Device|"To analyze the phenotypic characteristics of different subgroups of patients with obstructive sleep apnea syndrome who respond better (complete responders) or worse (partial responders or non-responders) to treatment with mandibular advancement devices.~Responders will be defined as a post-treatment AHI of less than 10/h and at least a 50 percent reduction in their AHI. Partial responders will be defined as a post-treatment AHI greater than 10/hour but at least a 50 percent reduction in AHI, and non-responders as less than a 50 percent reduction compared to baseline."
48286383|NCT04075227|DRUG|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
48286384|NCT04075227|DRUG|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
48286385|NCT02303587|DRUG|methylprednisolone|
48286386|NCT02259231|DRUG|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
48286387|NCT02259231|DRUG|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
48472184|NCT02497079|DEVICE|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
48472185|NCT04397289|DRUG|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
48472186|NCT02324231|OTHER|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
48472187|NCT02324231|OTHER|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
48472188|NCT01011556|DRUG|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
48472189|NCT01011556|DRUG|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
47940320|NCT00063375|BEHAVIORAL|Computer Based Cognitive Behavioral Therapy|
47940321|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
47940322|NCT00764504|DEVICE|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
47940323|NCT00902161|DRUG|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
47940324|NCT00902161|DRUG|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
47940325|NCT00902161|DRUG|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
47940326|NCT01327911|BIOLOGICAL|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
48286388|NCT02259231|DRUG|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
48286389|NCT02259231|DRUG|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
48286390|NCT02259231|DRUG|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
48286391|NCT00104104|DRUG|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
48286392|NCT00378729|DRUG|Metformin and FSHr|treatment for infertility
48286393|NCT00378729|PROCEDURE|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
48286394|NCT06037655|DRUG|Total Neoadjuvant Treatment|Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
48286395|NCT01979744|PROCEDURE|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
48472190|NCT01997723|DEVICE|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
48472191|NCT01997723|OTHER|Polysomnography|One attended diagnostic sleep study.
48472192|NCT01997723|DEVICE|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
48472193|NCT01997723|DEVICE|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
48472194|NCT02145624|DRUG|Repevax|vaccine
48472195|NCT02145624|DRUG|Boostrix-IPV|vaccine
48286396|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
48286397|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
48286398|NCT01979744|PROCEDURE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
48286399|NCT04219267|BEHAVIORAL|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
48286400|NCT04219267|BEHAVIORAL|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
48286401|NCT06346275|PROCEDURE|Acupuncture|Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
48286402|NCT01519726|DRUG|Midazolam|
48286403|NCT05275413|BEHAVIORAL|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
48286404|NCT05275413|BEHAVIORAL|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
48286405|NCT05275413|OTHER|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
48286406|NCT05965570|DRUG|Brensocatib|Oral tablets.
48286407|NCT05965570|DRUG|Clarithromycin|Oral tablets.
48472196|NCT00248937|BEHAVIORAL|Positive affect and self-affect induction|
48472197|NCT04139031|DEVICE|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
48472198|NCT02896543|OTHER|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
48472199|NCT05452434|DRUG|mirabegron|mirabegron 50mg QD for 12 weeks.
48472200|NCT00650273|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fasting
48472201|NCT00650273|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fasting
48472202|NCT02000323|OTHER|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
48472203|NCT02000323|OTHER|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day."
47940327|NCT02352922|DRUG|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
47940328|NCT02352922|DRUG|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
47940329|NCT03200665|DIAGNOSTIC_TEST|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
47940330|NCT01520454|DRUG|Saline|IV saline at 0.83 mL/kg/hr for six hours
47940331|NCT01520454|DRUG|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
47940332|NCT01520454|DIETARY_SUPPLEMENT|Water|Water by mouth
47940333|NCT01520454|DIETARY_SUPPLEMENT|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
47940334|NCT01520454|DRUG|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
48101603|NCT06441006|DRUG|Control Arm FQ-S MDR/RR-TB regimen, designed according to latest WHO guidelines|The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 26 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest WHO guidelines and the local SOC.
48101604|NCT00343824|PROCEDURE|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
48101605|NCT05533866|COMBINATION_PRODUCT|APR-TD011|APR-TD011 wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician. Based on its product profile, APR-TD011 has been granted an FDA Orphan Drug Designation for epidermolysis bullosa.
48101606|NCT01626274|DEVICE|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
48101607|NCT01823341|DEVICE|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
48101608|NCT04397172|PROCEDURE|Study Arm|"First inpatient examination (within 24 hours after admission to ICU):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial function testing~* Neurophysiological examination (MVRC recording)~Follow-up inpatient examinations (day 2, 5 and 10 after admission):~* Clinical examination~* Laboratory tests, Biobanking, Mitochondrial functions testing~* Neurophysiological examination (MVRC recording)~* Day 10 only: Extended neurophysiological examination according to diagnostic criteria~* Day 10 only: Grading of muscle strength (Medical Research Council (MRC) system)~Follow-up outpatient examination (after discharge from intensive care):~* Clinical examination~* Grading of muscle strength (MRC)~* Modified Rankin Scale (mRS)~* Barthel Scale~* Questionnaires (Short Form (36) Health Survey, Essener Questionnaire for Coping with a Disease and Beck's Depression Inventory II)"
48101609|NCT03772964|DRUG|MetFORMIN Hydrochloride ER|Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
47940335|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention A|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
47940336|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention B|Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
47940337|NCT05086952|DRUG|Vericiguat (BAY1021189) - Intervention C|Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
47940338|NCT05086952|DRUG|Vericiguat (Verquvo, BAY1021189) - Intervention D|Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
47940339|NCT02179775|DRUG|propranolol|
48101610|NCT03772964|DRUG|Placebo|Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
48286408|NCT05080829|DIAGNOSTIC_TEST|Myeloid mutations measurement|Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
48286409|NCT02355340|OTHER|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
48286410|NCT02355340|OTHER|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
48472204|NCT03695211|PROCEDURE|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
48472205|NCT03695211|PROCEDURE|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
48472206|NCT02349074|PROCEDURE|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
48472207|NCT02330016|DEVICE|Voluma XC|Voluma XC
48472208|NCT04917627|DRUG|Vancomycin|one vial of vancomycin (1000 mg ) powder form.
47940340|NCT02179775|DRUG|Quince's oxymel|
47940341|NCT02179775|DRUG|placebo|
47940342|NCT03505671|PROCEDURE|Acupuncture Therapy|Undergo acupuncture therapy
47940343|NCT03505671|OTHER|Best Practice|Receive usual care
47940344|NCT03505671|OTHER|Quality-of-Life Assessment|Ancillary studies
47940345|NCT03505671|OTHER|Questionnaire Administration|Ancillary studies
47940346|NCT02519387|DRUG|Buprenorphine Transdermal Patch|
47940347|NCT01476644|OTHER|Clinical evaluation|Biomicroscopy (look at front of eye), ophthalmoscopy (look at back of eye), visual acuity, visual fields, intraocular pressure, spectral domain optical coherence tomography, Pelli-Robson and the Spaeth-Richman Contrast Sensitivity tests
47940348|NCT01476644|OTHER|Performance based measures|Compressed Assessment of Ability Related to Vision (CAARV) items include: 1) computerized motion detection; 2) recognizing facial expressions; 3) reading street signs; and 4) finding objects in a room
47940349|NCT01476644|OTHER|Subjective measures of vision-related quality of life|National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ-25) includes a series of questions pertaining to vision or feelings about a vision condition and the Modified Glaucoma Symptom Scale (MGSS) includes a series of questions pertaining to eye comfort.
47940350|NCT02343081|DRUG|Temozolomide|
47940351|NCT02343081|DRUG|Temozolomide|
47940352|NCT05075057|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
47940353|NCT05515666|DIAGNOSTIC_TEST|Wearable electrocardiogram|All participants will have their ECG monitored at home using a wearable ECG, and then be hospitalized for coronary angiography and quantitative flow fraction to confirm the presence of coronary artery disease.
47940354|NCT02594540|DEVICE|Mechanical Peripheral Stimulation (GONDOLA)|
48286411|NCT04191668|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
48286412|NCT04896177|DEVICE|Sirolimus drug-eluting coronary balloon catheter|Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
48472209|NCT06358963|DRUG|Receive 30 mg of Coq10|Group A received 30 mg of CoQ10, Group B was given 200 mg of Omega-3 daily supplements, and Group C did not receive any medication; after the two-month study period, teh clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
47940355|NCT01158508|PROCEDURE|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
47940356|NCT06088381|OTHER|Experimental Observation|Patients on the experimental arm will be under observation only.
47940357|NCT06088381|OTHER|Observation per Standard of Care|The low-risk group of patients will be observed per standard of care.
47940358|NCT06088381|RADIATION|Adjuvant Treatment per Standard of Care|The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)
47940359|NCT06088381|DIAGNOSTIC_TEST|Circulating Tumor DNA test (ctDNA test)|Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
47940360|NCT02898116|DRUG|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
47940361|NCT02898116|DRUG|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
47940362|NCT03251664|DIETARY_SUPPLEMENT|Food groups consumed|
47940363|NCT03905473|BEHAVIORAL|Accelerometer measurements|To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.
47940364|NCT01418027|OTHER|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
47940365|NCT01418027|OTHER|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
47940366|NCT05753631|PROCEDURE|non surgical periodontal treatment|"scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated."
47940367|NCT05695534|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
47940368|NCT00597701|DRUG|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
47940369|NCT00597701|DRUG|Placebo|Placebo
47940370|NCT00597701|DRUG|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
47940371|NCT03198039|BEHAVIORAL|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
47940372|NCT06187675|BEHAVIORAL|Nutrition and Exercise Lifestyle Intervention Program|Nutrition and Exercise components for pregnancy
47940373|NCT05310188|DIAGNOSTIC_TEST|pseudocholinesterease|blood samples
47940374|NCT00630695|DRUG|Lanreotide LP 90|Lanreotide LP 90
47940375|NCT00630695|DRUG|Placebo lanreotide|Placebo
47940376|NCT00423748|DRUG|ambrisentan|
48101611|NCT02540044|BEHAVIORAL|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
48101612|NCT02540044|BEHAVIORAL|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
48286413|NCT04896177|DEVICE|Paclitaxel drug-eluting coronary balloon catheter|Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
47940377|NCT01210573|DEVICE|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
47940378|NCT02262052|OTHER|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
47940379|NCT02172170|DRUG|BI 10773 single rising dose|
47940380|NCT02172170|DRUG|Placebo|
47940381|NCT00484718|DRUG|celecoxib|oral, 100 mg bid
47940382|NCT00484718|DRUG|Oxycodone|oral, 20 mg bid
47940383|NCT00484718|DRUG|placebo|oral bid
47940384|NCT00290979|DRUG|insulin glulisine|
47940385|NCT00107952|DRUG|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
47940386|NCT00107952|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
47940387|NCT00321724|DRUG|cediranib maleate|Given orally
47940388|NCT00321724|OTHER|laboratory biomarker analysis|Correlative studies
47940389|NCT01389518|DRUG|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
47940390|NCT01389518|DRUG|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
47940391|NCT02163122|PROCEDURE|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
47940392|NCT02163122|OTHER|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
47940393|NCT02163122|BIOLOGICAL|Cat allergen (FelD1)|
47940394|NCT02487823|DRUG|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
48101613|NCT06124118|RADIATION|carboplatin chemotherapy|"Concurrent chemoradiation will be given per standard of care within 24 hours of initiation of standard of care radiation therapy. Treatment will include a paclitaxel/carboplatin chemotherapy regimen administered during the radiotherapy course (over 6-7 weeks).~Paclitaxel (50 mg/m2) will be administered intravenous over 1 hour followed by Carboplatin AUC = 2 mg/min/mL intravenous weekly (every 7 days ± 3 days) during radiotherapy 11, NCCN Non-small cell lung cancer guidelines 2023).~If a patient has a hypersensitivity reaction to weekly paclitaxel, weekly nab-paclitaxel is allowed to replace paclitaxel at the discretion of the treating medical oncologist 37. The recommended starting dose of weekly nab-paclitaxel is 40 mg/m2 to 50 mg/m2 38 39. Standard premedications with steroids, diphenhydramine, H2 receptor antagonist, and 5-HT3 receptor antagonist antiemetics must be administered per individual institutional guidelines."
48286414|NCT05575518|DRUG|Optimised rifamycin|optimised dose rifampicin with or without moxifloxacin
48286415|NCT00203567|DRUG|carbamazepine ER|Active study drug, no comparator
48286416|NCT01283620|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
48286417|NCT01283620|OTHER|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
47940395|NCT02811601|PROCEDURE|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
47940396|NCT04300374|OTHER|The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively|routine remifentanil infusion during general anesthesia
47940397|NCT03487679|OTHER|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
47940398|NCT05638477|BEHAVIORAL|Free-viewing eye tracking|Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded
47940399|NCT04997590|BIOLOGICAL|Umbilical cord blood mononuclear cells|injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.
47940400|NCT04997590|DRUG|Staphylococcal Enterotoxin C|injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
47940401|NCT00021671|DRUG|Erythromycin|
47940402|NCT00021671|DRUG|Nevirapine|
47940403|NCT00021671|DRUG|Ampicillin sodium|
47940404|NCT00021671|DRUG|Metronidazole|
47940405|NCT03960554|DRUG|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
47940406|NCT03960554|OTHER|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
48286418|NCT02472483|BEHAVIORAL|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
48286419|NCT02472483|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
48286420|NCT04902885|DRUG|Trilaciclib, carboplatin, etoposide，or Topotecan|Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
48286421|NCT04902885|DRUG|placebo, carboplatin, etoposide，or Topotecan|placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
48286422|NCT00893607|DRUG|NRL001|10mg NRL001 was administered as a slow release suppository
48472210|NCT06358963|DRUG|Non-Medicare Drugs|and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
48472211|NCT04374799|DRUG|Heparin|two doses of heparin
48472212|NCT04374799|DRUG|Placebos|placebo
48472213|NCT01114997|DRUG|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
48472214|NCT01114997|DRUG|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
48472215|NCT01114997|DRUG|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
48472216|NCT06086496|DEVICE|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
48286423|NCT05937711|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG|"PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)"
48472217|NCT01989676|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
48472218|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
48472219|NCT01989676|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
48472220|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
47940407|NCT03640767|BEHAVIORAL|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
47940408|NCT04258189|DRUG|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
47940409|NCT03491189|DEVICE|Lag screw fixation|surgical fixation
47940410|NCT03491189|DEVICE|Helical blade fixation|surgical fixation
48286424|NCT05937711|DRUG|Duloxetine 30 MG|Duloxetine 30 mg p.o 1X1 (daily)
48286425|NCT04757363|DRUG|regorafenib|regorafenib (80 mg on days 1-21 of the 28-day cycle)
48286426|NCT04757363|DRUG|nivolumab|nivolumab (240 mg on days 1 and 15 of the 28-day cycle).
48472221|NCT06493409|DRUG|Repotrectinib|Specified dose on specified days
48472222|NCT06493409|DRUG|Voriconazole|Specified dose on specified days
48472223|NCT06493409|DRUG|Quinidine|Specified dose on specified days
48472224|NCT04755673|OTHER|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
48472225|NCT04171401|OTHER|In-patient stroke rehabilitation.|An in-patient multi-disciplinary stroke rehabilitation program was performed.
48472226|NCT01086228|DEVICE|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
48472227|NCT04868864|DIAGNOSTIC_TEST|CT scan|Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
48472228|NCT04868864|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
48472229|NCT04414033|DEVICE|Bubble: A New VR-AI Way of Treatment for Hot Flashes|Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
48472230|NCT03359720|OTHER|no intervention survey|survey
48472231|NCT03710317|DRUG|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
48472232|NCT03710317|DRUG|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
48472233|NCT03710317|DRUG|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
48472234|NCT03510338|DRUG|Sublingual sildenafil|100 mg biphasic sildenafil tablet
48472235|NCT03510338|DRUG|Oral sildenafil|50 mg oral sildenafil (Viagra)
48472236|NCT05907148|OTHER|Sensory integration training|"Sitting position:~1. Sit in a chair without a backrest while the feet on firm surface. without backrest while the feet on soft surface.~2. Sit on a ball while the feet on firm surface. while feet on soft surface.~3. Sit in a chair without a backrest with the feet on firm surface and perform sit-to-stand motion.~   without a backrest with the feet on soft surface and perform sit-to-stand motion.~4. Sit on a ball with the feet on the firm surface and perform sit-to-stand motion. with the feet on the soft surface and perform sit-to-stand motion.~5. Perform bipedal standing on a firm surface. on a soft surface.~6. Perform a semi-tandem stance on firm surface. on soft surface.~7. Walk forward on firm surface. on soft surface.~8. Walk forward on firm surface, cross obstacle, and continue to walk.~9. Walk forward on the soft surface, cross obstacle, and continue to walk."
48472237|NCT05907148|OTHER|Routine physical therapy|It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training
48472238|NCT05907148|OTHER|General coordination exercise|"In supine lying:~1. Patients are told to place heel of one leg on shin or knee of the other leg,~2. Patient bends one leg and extends the other leg like bicycling motion.~3. Flexing one leg while extending other leg~4. Flexing and extending of one leg while abduction and adduction of other leg.~In sitting:~1. Patient performs marching without backrest or back support,~2. Patient reaches forward and sideways with arms~3. Rotation of trunk with physioball in hand without back support.~4. Patient reaches with legs to marked point in sitting.~In standing:~Patient performs 10 repetitions of~1. Clock Reach~2. Side Leg Raises~3. Leg Swings and~4. Ball catch and throw"
48472239|NCT04431635|DRUG|Copanlisib|Copanlisib IV: day 1, 8, 15 every 28 days
48472240|NCT04431635|DRUG|Nivolumab|Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
48472241|NCT04431635|DRUG|Rituximab|Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
48472242|NCT00055809|BIOLOGICAL|PEG-interferon alfa-2b|Given SC
48472243|NCT00055809|BIOLOGICAL|bevacizumab|Given IV
48286427|NCT04757363|DRUG|FOLFOX chemotherapy with oxaliplatin|FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).
48472244|NCT00055809|OTHER|laboratory biomarker analysis|Optional correlative studies
48472245|NCT00784979|DRUG|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
48472246|NCT00272649|BIOLOGICAL|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
48472247|NCT03255434|DRUG|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
48472248|NCT03255434|DRUG|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
48472249|NCT04130217|PROCEDURE|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
48472250|NCT04130217|PROCEDURE|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
48472251|NCT05631821|PROCEDURE|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
48286428|NCT01416181|DRUG|natalizumab|Administered as specified in the treatment arm
48286429|NCT01416181|DRUG|Placebo|Matched placebo in part 1
48472252|NCT02537509|DRUG|Cholecalciferol|
48472253|NCT02537509|DRUG|Placebo of cholecalciferol|
48472254|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
48286430|NCT04155879|DRUG|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
48286431|NCT04155879|PROCEDURE|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
48286432|NCT05139524|OTHER|Evidence of past or recent RVF exposure|Detection of RVF exposure.
48286433|NCT01050777|DRUG|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
48286434|NCT01050777|DRUG|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
48286435|NCT01050777|DRUG|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
48286436|NCT01050777|DRUG|Placebo|Placebo
48286437|NCT02985346|BIOLOGICAL|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
47940411|NCT03935620|BEHAVIORAL|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
48286438|NCT01258439|DRUG|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
48286439|NCT01258439|DRUG|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
48286440|NCT04397679|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
48286441|NCT04397679|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
48286442|NCT04397679|DRUG|Temozolomide|Given PO
48286443|NCT04397679|DRUG|Chloroquine|Given PO
48286444|NCT04397679|PROCEDURE|Tumor Treating Fields Therapy (TTF)|Undergo TTF
48630083|NCT01320098|BEHAVIORAL|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~1. Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~2. Increasing the quality and quantity of positive interactions between you and your child~3. Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~4. Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
47940412|NCT02547285|OTHER|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
47940413|NCT02354482|BEHAVIORAL|Patient Communication and Care Management|"Received the following Transitional Care strategies:~1. Helpful Health Care Contact OR Symptom Management~2. Post-discharge Care Consultation~3. Patient Goal/Preference Assessment~4. Plain Language Communication in Hospital~5. Plain Language Communication at Home~6. Transition Summary for Patients and Family Caregivers"
47940414|NCT02354482|BEHAVIORAL|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Transition Team~2. Home visits~3. Plain Language Communication at Home~4. Promote Trust at Home~5. Referral to Community Services~6. Follow-up Appointment"
48286445|NCT00981435|DRUG|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
48286446|NCT00981435|DRUG|Ketorolac|Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
48286447|NCT00981435|DRUG|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
48286448|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
48286449|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
48286450|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
48286451|NCT00080327|DRUG|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
48286452|NCT03329872|OTHER|Data collection|data collection about symptoms without any specific clinical or biological intervention
48286453|NCT05782855|OTHER|Active Robot assisted physical training during acute hospitalisation|"Active training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the exercise movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform extension of hip and knee. The patient must use their muscular power to stretch the leg while ROBERT® provides resistance.~Training is defined as a minimum of three sessions before discharge."
48286454|NCT05782855|OTHER|Passive Robot assisted physical training during acute hospitalisation|"Passive training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform passive extension of hip and knee. ROBERT® moves the leg independently without the patient using any muscle power.~Training is defined as a minimum of three sessions before discharge."
48286455|NCT06499636|OTHER|other|other
48286456|NCT05057988|BEHAVIORAL|Empowered Relief class|The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
48286457|NCT03746197|DEVICE|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
48286458|NCT05041764|OTHER|NO INTERVENTION|No INTERVENTION
48286459|NCT03037905|DEVICE|SignatureSuite OR Integration System by STERIS Corporation|SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
48286460|NCT03652454|DEVICE|micro-osteoperforation|Propel device (ABD) using for regional acceleratory phenomenon
48286461|NCT03652454|OTHER|conventional fixed appliance treatment|conventional fixed appliance treatment
48101614|NCT06124118|DEVICE|NovoTTF-200T (TTFields) System|"The NovoTTF-200T (TTFields) System is an investigational medical device delivering 150 kHz TTFields to the thorax for the treatment of patients at the age of 22 years or older. The device is a portable, battery operated system which delivers TTFields at 150 kHz to the thorax by means of insulated Transducer Arrays. The NovoTTF-200T produces electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz to the thorax will be continuous for at least 11 hours a day on average, with a recommended duration of at least 18 hours a day. Subjects may take breaks for personal needs (e.g. showering, array exchange). TTFields may be continued as long as there is no disease progression per RECIST 1.1 or any of the treatment discontinuation conditions for subject withdrawal or termination."
48286462|NCT04416516|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
47940415|NCT02354482|BEHAVIORAL|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Identify High-Risk Patients and Intervene~3. Medication Reconciliation~4. Plain Language Communication in Hospital~5. Promote Trust in the Hospital~6. Transition Summary for Patients and Family Caregivers"
47940416|NCT02354482|BEHAVIORAL|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~1. Patient Goal/Preference Assessment~2. Identify High-Risk Patients and Intervene~3. Timely Exchange of Critical Patient Information among Providers~4. Patient/Family Caregiver Transitional Care Needs Assessment"
47940417|NCT02354482|BEHAVIORAL|Assessment and Teach Back|"Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Language Assessment~3. Teach Back for Information and Skills"
47940418|NCT02354482|OTHER|Standard of Care (Reference)|No specific Transitional Care Strategy
47940419|NCT04838197|OTHER|Questionnaires and Surveys|Quantitative questionnaires will measure and quantify the importance of the various factors (e.g., intensity of dependence, duration of care, health literacy, physical well-being, emotional well-being, social well-being, and financial well-being) that contribute to caregiver burden both preoperatively and postoperatively at 48 hours, 1 week, 2 weeks, and 1 month.
47940420|NCT00526877|DRUG|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
47940421|NCT05321160|DRUG|Esketamine|0.25 mg/kg esketamine for induction and 0.25 mg/kg esketamine at the beginning of surgery
47940422|NCT05321160|DRUG|Sevoflurane|4% sevoflurane for induction and 2-4% sevoflurane for maintain
48286463|NCT01390168|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
48286464|NCT01390168|BEHAVIORAL|Waitlist|active waitlist
48286465|NCT06487884|OTHER|escape games|A suitable day and time will be determined in the curriculum of the students in the intervention group and escape games consisting of various games involving intravenous drug administration will be played. Games will be played within the determined game guidelines. Each group will play the games at the stations respectively and get a clue at the end of each game. After completing the last game, the time it takes to find the password and complete the game will be recorded. After all groups complete the game, the group that completes the games in the shortest time will win the game and receive the prize in the chest.
47940423|NCT00560885|DEVICE|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
47940424|NCT00599781|GENETIC|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
47940425|NCT03193125|DIETARY_SUPPLEMENT|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
47940426|NCT03193125|DIETARY_SUPPLEMENT|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
47940427|NCT06210308|PROCEDURE|Data collection from gastric ultrasound|observational study
47940428|NCT05293015|OTHER|NP-Supported Multidisciplinary Diabetes Management|NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
47940429|NCT00739492|BEHAVIORAL|financial incentives|financial incentives based on attaining weight loss goals
47940430|NCT05812079|DIAGNOSTIC_TEST|skin biopsy examined by ELISA technique|skin biopsy examined by ELISA technique
47940431|NCT03590197|DRUG|Melatonin 3 mg|Melatonin 3 mg/ day with Valproate
47940432|NCT03590197|OTHER|Placebo|Placebo with Valproate
47940433|NCT02800902|DRUG|placebo|Oral prophylaxis followed by placement of placebo gel
47940434|NCT02800902|DRUG|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
47940435|NCT02800902|DRUG|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
48286466|NCT03499054|OTHER|Breathing exercises|During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
48286467|NCT03045146|OTHER|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
48286468|NCT02513381|OTHER|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
48286469|NCT02513381|OTHER|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
48286470|NCT02493751|DRUG|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
48286471|NCT02493751|DRUG|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
48286472|NCT04049825|DRUG|OPB-111077|OPB-111077+bendamustine
48286473|NCT04049825|DRUG|OPB-111077|OPB-111077+rituximab+bendamustine
48286474|NCT01772134|DRUG|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
48286475|NCT01772134|DRUG|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
48286476|NCT01772134|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
48286477|NCT01772134|DRUG|Placebo|Inhalation Powder, Placebo
48286478|NCT04093219|DRUG|IV acetaminophen|use of IV tylenol for pain
48286479|NCT04093219|OTHER|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
48286480|NCT02198144|OTHER|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
48286481|NCT02609477|DRUG|Istradefylline|Istradefylline 40, 80, 160 mg
48286482|NCT02609477|DRUG|Phentermine 45 mg|Phentermine 45 or 90 mg
48286483|NCT02609477|OTHER|Placebo|Placebo
48286484|NCT05814029|OTHER|Mobilization with movement for Ankle|The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a 3 set of 10 repetitions.
48286485|NCT03133715|PROCEDURE|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
48286486|NCT03133715|PROCEDURE|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
48286487|NCT05446844|OTHER|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~* Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~* Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~* Caring behaviors during psychological care included offering religious sound meditation.~* Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~* Caring behaviors during health teaching included providing health teaching for patients.~* Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
48286488|NCT05446844|OTHER|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
48472255|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
48101615|NCT06124118|DRUG|Durvalumab|Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
48101616|NCT02540135|OTHER|fluorescein|fluorescein and conventional neuro-navigation
48286489|NCT06102161|PROCEDURE|Wedge resection|Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.
48286490|NCT03895138|OTHER|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
48472256|NCT02476305|DEVICE|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
48472257|NCT03076749|OTHER|Creating models for the diagnosis of BL allergy|
48101617|NCT02540135|OTHER|intraoperative MRI|conventional neuro-navigation and iMRI
48472258|NCT03132311|BIOLOGICAL|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
48472259|NCT04118946|BIOLOGICAL|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
48472260|NCT05233787|PROCEDURE|Tailored use of defunctioning stoma after TME|"Tailored use of defunctioning stoma after TME based on a 2-step process:~i) to perform or not a defunctioning stoma according to the personalized risk of anastomotic leakage (defunctioning stoma only if Anastomotic Failure Observed Risk Score=\[2-6\]), ii) to perform an early stoma closure at day 8-12, according to clinical (fever), biological (CRP level days 2 and 4 postoperatively) and radiological postoperative assessment (CT-scan with colonic contrast retrograde enema day 7-8 postoperatively)"
48286491|NCT03895138|OTHER|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
48286492|NCT03957083|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
48286493|NCT01771302|DEVICE|Bio-Oss|It is a bone substitute of bovine origin
48286494|NCT01771302|DEVICE|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
48286495|NCT01215539|DRUG|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
48286496|NCT00276289|DRUG|Spironolactone|
48286497|NCT04077463|DRUG|Lazertinib|Lazertinib will be administered orally.
48286498|NCT04077463|DRUG|Amivantamab|Amivantamab will be administered as an intravenous (IV) infusion.
48472261|NCT05233787|PROCEDURE|Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 2-3 months after TME, according to French national and international guidelines
48286499|NCT04077463|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
48286500|NCT04077463|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
48286501|NCT03088579|DEVICE|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
48472262|NCT00812318|DRUG|GSK1265744 10 mg oral solution|GSK1265744
48472263|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
48472264|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
48472265|NCT05155579|BIOLOGICAL|R21/Matrix-M - single vial formulation|Adjuvanted malaria vaccine in a single vial formulation
48472266|NCT05155579|BIOLOGICAL|R21/Matrix-M - two vial formulation|Adjuvanted malaria vaccine in a double vial formulation
48472267|NCT05155579|BIOLOGICAL|Licensed vaccine - Measles-rubella|Licensed vaccine part of the EPI vaccination schedule
48101618|NCT05092906|OTHER|LP with complementary hypnoanalgesia|The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.
48472268|NCT05155579|BIOLOGICAL|Licensed vaccine - Yellow fever|Licensed vaccine part of the EPI vaccination schedule
48286502|NCT00666185|DRUG|Micafungin|IV
48286503|NCT00666185|DRUG|Fluconazole|IV
48286504|NCT00404729|DRUG|Citicoline|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
48286505|NCT05597566|PROCEDURE|modified electroconvulsive therapy|The patient underwent MECT therapy. The treatment instrument is Xingmaitong IV ECT multifunctional treatment instrument (USA, SOMATICS THYMATRON company), fasting for 6 hours before surgery, emptying urine. Routine preoperative preparations were made, followed by intravenous injection of atropine, propofol, and succinylcholine chloride injection, artificial respiration, placement of dental pads, and electroconvulsive therapy. The whole process is completed by an anesthesiologist and a therapist in cooperation with each other. The first 3 times are once a day, and the next 5 times are once every other day. A total of 8 courses of treatment.
48472269|NCT05155579|BIOLOGICAL|Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)|Licensed vaccine part of the EPI vaccination schedule
48472270|NCT05155579|BIOLOGICAL|Licensed vaccine - Oral Polio Vaccine (OPV)|Licensed vaccine part of the EPI vaccination schedule
48472271|NCT05155579|BIOLOGICAL|Licensed vaccine - Rotavirus|Licensed vaccine part of the EPI vaccination schedule
48472272|NCT05155579|BIOLOGICAL|Licensed vaccine - Pneumococcal vaccine|Licensed vaccine part of the EPI vaccination schedule
48472273|NCT05155579|BIOLOGICAL|Licensed vaccine - Inactivated Polio Vaccine (IPV)|Licensed vaccine part of the EPI vaccination schedule
48472274|NCT02304068|OTHER|Home monitoring|
48472275|NCT02304068|OTHER|Hospital assessment|
48472276|NCT06352203|DIETARY_SUPPLEMENT|Probiotic|1 dose of the probiotic every 24 hours, for 6-months.
48472277|NCT06352203|DIETARY_SUPPLEMENT|Placebo|1 dose of the placebo every 24 hours, for 6-months.
48472278|NCT04445233|DEVICE|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
48472279|NCT06207669|OTHER|Music therapy|Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
48472280|NCT05279638|DIAGNOSTIC_TEST|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
48472281|NCT00731991|OTHER|ART|ART to the levator scapulae.
48286506|NCT03864354|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
48286507|NCT03751202|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg|2 inhalations of Test and Reference product in each study period
48286508|NCT03751202|DRUG|ADVAIR DISKUS|2 inhalations of Test and Reference product in each study period
48286509|NCT01346800|DRUG|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
48286510|NCT01346800|DRUG|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
48286511|NCT05817721|DRUG|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
48472282|NCT00731991|OTHER|PNF|PNF to the levator scapulae.
48472283|NCT00731991|OTHER|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
48472284|NCT04066413|OTHER|Standard infant formula|Standard infant formula
47940436|NCT06447493|OTHER|Osteopathic Manipulative Treatment-Spencer's Technique (Modified)|Combination OMT approach utilizing Muscle Energy Technique (MET), Articulatory Technique (ART), and Myofascial Release (MFR). It is a series of direct OMT addressing the barrier of somatic dysfunction (SD) with the goal of restoring neurovascular balance and improved motion of the shoulder girdle and glenohumeral joint. Utilizing these three OMT techniques, the practitioner attempts restoration of glenohumeral joint motion using shoulder extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction, external rotation, internal rotation, and distraction in abduction. The study uses a modified version of the Spencer technique, done in the seated position for patient comfort, as well as adding to the treatment sequence: latissimus dorsi, pectoralis minor-major, serratus anterior, and rhomboid major-minor. Adding these muscles into treatment will help to address and correct sternoclavicular joint SD, acromioclavicular joint SD, and scapular SD.
47940437|NCT06447493|OTHER|Rest|10 minute rest period.
47940438|NCT00433654|DEVICE|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
47940439|NCT00433654|OTHER|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
48286512|NCT05817721|DEVICE|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
48286513|NCT06219538|DEVICE|DAISY Uterine Drain|Insertion of the DAISY Uterine Drain and connection to wall suction in women who have undergone a Caesarean Delivery.
48286514|NCT04964726|BEHAVIORAL|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
48286515|NCT03682796|DRUG|TRPH-222|administered by IV, 21-day Cycle
47940440|NCT02119091|DRUG|Moxifloxacin|
48286516|NCT05056714|OTHER|Questionaries|The patient will answer several questionaries
48286517|NCT00291343|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
48286518|NCT00291343|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
48286519|NCT00291343|BIOLOGICAL|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
48286520|NCT00452621|PROCEDURE|blood draw|
48286521|NCT00156728|DEVICE|Vitatron biventricular pacemaker|
48286522|NCT01458769|DRUG|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
48286523|NCT01458769|DRUG|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
48286524|NCT01458769|DRUG|C-10297|C-10297 200 mg, oral, single dose
48286525|NCT01458769|DRUG|C-10299|C-10299 200 mg, oral, single dose
48286526|NCT01458769|DRUG|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
48472285|NCT04066413|OTHER|Infant formula supplemented with HMO|Infant formula supplemented with HMO
48472286|NCT05078827|DRUG|Test Product (A): Fluorouracil Cream, 5% topical cream|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
48472287|NCT05078827|DRUG|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
47940441|NCT05497635|DRUG|STSA-1002 Injection|Intravenous injection
47940442|NCT05497635|DRUG|Placebo|Intravenous injection
47940443|NCT01546064|DEVICE|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
48630084|NCT01320098|BEHAVIORAL|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~1. Increasing the positive attention you give to your child.~2. Reducing the inappropriate use of commands, questions and criticisms.~3. Appropriate use of praise and physical attention (e.g., hugs) as rewards.~4. Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
47940444|NCT01546064|DEVICE|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
47940445|NCT04613453|DRUG|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
47940446|NCT04613453|DRUG|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
47940447|NCT01473056|DRUG|JTK-853|Tablets, twice a day for 3 days
48472288|NCT05078827|DRUG|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
48472289|NCT05240092|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
48472290|NCT03023189|DRUG|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
48472291|NCT03023189|DRUG|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
48472292|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
48472293|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
48472294|NCT02574338|DEVICE|Foley's Catheter|intracervical extraamniotic Foley's catheter
48472295|NCT02574338|DRUG|prostaglandin E1 analogue|intravaginal misoprostol
48472296|NCT01689155|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
48472297|NCT05155293|DRUG|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
48286527|NCT01458769|DRUG|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
48472298|NCT05155293|DRUG|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
48472299|NCT03124303|PROCEDURE|High Density-Electroencephalogram|EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
48630085|NCT01320098|BEHAVIORAL|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
48630086|NCT06122064|OTHER|Best Practice|Receive standard of care
48630087|NCT06122064|OTHER|Communication Intervention|Use shared decision-making conversation tool
48630088|NCT06122064|OTHER|Electronic Health Record Review|Ancillary studies
48630089|NCT06122064|OTHER|Survey Administration|Ancillary studies
48630090|NCT06122064|OTHER|Video Recording|Ancillary studies
48630091|NCT02313597|PROCEDURE|SETON|In seton treatment, initially Hydrogen peroxide will be applied to the external opening with a 10-cc syringe, and the internal opening will be located by direct visualization of the anal canal via proctoscope. A probe will be inserted into the external opening and carefully maneuvered through the internal opening. Silk 1/0 suture will be then tied to the tip of the probe, which will be then squeezed out of the external opening. The suture will be then tied around the sphincter and through fistula tract. Later, the seton will be tightened at four-week intervals under local anesthesia until the suture cut through the sphincter.
48630092|NCT02313597|PROCEDURE|VAAFT|Patients assigned to the VAAFT group will receive the following procedure. The external opening will be widened with a probe, and a fistulascope will be inserted to delineate the primary and secondary tracts and locate the internal opening. The internal opening will be then stitched with Vicryl™ (Polyglactin 910) 2-0 suture through the anal route with the help of a proctoscope. The tract of the fistula will be washed and debrided through the scope and cauterized. Finally, the external opening will be excised and will be sent for biopsy.
48630093|NCT00435721|BEHAVIORAL|Psychoeducation|
48630094|NCT05898373|DRUG|vedicitumomab (Edisil, RC48）|intravenously for 6-8 cycles before surgery and postoperative radiotherapy, followed by Treatment with injectable recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) until 1 year or disease progression or intolerable toxicity in locally advanced patients , and until disease progression or intolerable toxicity in metastatic patients .
48630095|NCT05898373|DRUG|vedicitumomab in combination with pyrrolizidine|vedicitumomab in combination with pyrrolizidine
48630096|NCT05898373|DRUG|RC48 in combination with a platinum-based chemotherapeutic agent|RC48 in combination with a platinum-based chemotherapeutic agent
48630097|NCT05898373|DRUG|RC48 in combination with teraplizumab|RC48 in combination with teraplizumab
48630098|NCT01120197|OTHER|Exercise group|Weekly exercises
48630099|NCT01120197|OTHER|Control Group|No Intervention, control group only
48630100|NCT00552058|BIOLOGICAL|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
48286528|NCT01458769|DRUG|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
48472300|NCT03124303|PROCEDURE|Magnetic Resonance Imaging|MRI scan of brain
48630101|NCT00552058|OTHER|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
48630102|NCT06136234|BEHAVIORAL|Caring Contacts|Caring Contacts are brief, periodic messages sent over 1 year that express unconditional care and concern
48630103|NCT06136234|BEHAVIORAL|Best Available Resources Alone|Participants will be offered information about best available resources and will receive an email summarizing the resources with links and contact information. These resources are tailored to best serve the participant based on information they share during the online survey or during conversations with study staff.
47940448|NCT01473056|DRUG|Dose 2 JTK-853|Tablets, twice a day for 3 days
48286529|NCT01458769|DRUG|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
48472301|NCT02215668|PROCEDURE|Physical exercise|Exercise muscle stretching and body warming.
48472302|NCT00080431|DRUG|Daclizumab|
48617955|NCT01192815|RADIATION|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
47940449|NCT01473056|DRUG|Dose 3 JTK-853|Tablets, three times a day for 3 days
47940450|NCT01473056|DRUG|Dose 4 JTK-853|Tablets, twice a day for 3 days
47940451|NCT01473056|DRUG|Placebo|Tablets, twice a day or three times a day for 3 days
48617956|NCT01192815|OTHER|pharmacogenomic studies|Optional correlative studies
48617957|NCT01192815|OTHER|gene expression analysis|Correlative studies
48286530|NCT02913807|PROCEDURE|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
48286531|NCT02913807|PROCEDURE|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
48630104|NCT05389839|DEVICE|Wechat program|The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
48630105|NCT05351034|DEVICE|Anorectal manometry|Anorectal manometry in diagnosis of Functional anorectal disorders
48630106|NCT04097184|DEVICE|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
47940452|NCT01435317|DEVICE|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
48630107|NCT00720200|BEHAVIORAL|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
48630108|NCT00720200|BEHAVIORAL|Usual Care|Family Members receiving usual care/clinical interaction
48630109|NCT02569983|OTHER|Observational cohort|No intervention - observational study
47940453|NCT02445391|DRUG|Capecitabine|Given PO
47940454|NCT02445391|DRUG|Carboplatin|Given IV
47940455|NCT02445391|DRUG|Cisplatin|Given IV
47940456|NCT02025517|OTHER|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
47940457|NCT02812407|DEVICE|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~* The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~* At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~* And at 20 cm"
48286532|NCT05498298|DEVICE|Biopotentials measurement with gtec device|A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
48630110|NCT00882765|DIETARY_SUPPLEMENT|genistein|Given orally
48630111|NCT04264962|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
48630112|NCT04264962|OTHER|Routine medical care|Routine medical care
47940458|NCT01863810|DRUG|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
47940459|NCT01863810|DRUG|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
47940460|NCT01863810|DRUG|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
47940461|NCT01863810|DRUG|Placebo of KW21052|Oral,once a day, for 8 weeks
47940462|NCT01863810|DRUG|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
47940463|NCT02425072|DEVICE|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
48286533|NCT06133010|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
48286534|NCT06133010|BIOLOGICAL|Placebo|Sterile liquid for injection
48286535|NCT00004415|DEVICE|Medlink spinal cord electrode|
48286536|NCT01756157|BIOLOGICAL|CINRYZE with rHuPH20|
48472303|NCT04091763|DRUG|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
48472304|NCT04091763|DEVICE|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
48472305|NCT06532409|DRUG|Amoxicillin/CA|Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
48472306|NCT06532409|DRUG|IV ceftriaxone|Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
48472307|NCT02902133|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
48472308|NCT06494098|PROCEDURE|Nasoalveolar Molding|presurgical orthopedics
48472309|NCT06494098|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch and nose
48472310|NCT04514133|BEHAVIORAL|Participating in Action Civics program|Students in school classrooms participating in Action Civics program
48472311|NCT03180255|COMBINATION_PRODUCT|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
48472312|NCT03180255|OTHER|Placebo|Ocular iontophoretic delivery of a placebo
48472313|NCT04849364|DRUG|Capecitabine|Capecitabine 1000 mg/m2 BID Orally 14 days on and 7 days off Cycle = 21 days; Total of 8 cycles
48472314|NCT04849364|DRUG|Talazoparib|Talazoparib Cycle 1: 0.75 mg then Cycle 2-8: 1 mg Cycle = 21 days; Total of 8 cycles
48472315|NCT04849364|DRUG|Pembrolizumab|Per standard of care.
48472316|NCT04849364|DRUG|Inavolisib|Inavolisib Cycle 1: 6 mg then Cycle 2-8: 9mg Orally 21 days on Cycle = 21 days; Total of 8 cycles
48472317|NCT03069417|BEHAVIORAL|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
48472318|NCT06471478|COMBINATION_PRODUCT|intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion|patients received intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion for decresing donor specific antibodies.
48472319|NCT05672745|DEVICE|WB-LIFE|WB-LIFE is a mobile application program grounded in validated psychotherapies (including cognitive behavioral therapy, interpersonal, and dialectical behavioral therapy), that enlists the relational agent Woebot to guide users in managing their mood. The user experience is driven by artificial intelligence and centers around mood tracking, evidence-based tools, and goal-oriented, tailored conversations.
48472320|NCT02798419|DRUG|DFD05 Cream|
48472321|NCT02798419|DRUG|Active01 Cream|
48472322|NCT00199901|BIOLOGICAL|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of NY-ESO-1 ISCOMATRIX® vaccine. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
47940464|NCT06515509|PROCEDURE|immediate implant placement with or without loading|immediate implant placement with or without loading
48286537|NCT03927040|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
48472323|NCT00199901|BIOLOGICAL|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® adjuvant~Each patient will receive four intramuscular injections of ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
47940465|NCT05515471|DRUG|SHR8058 eye drops|SHR8058 eye drops
47940466|NCT05515471|DRUG|saline eye drops.|saline eye drops.
47940467|NCT05611177|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
48286538|NCT05880914|PROCEDURE|miRNAseq analysis|Identify miRNA in serum and prepare a miRNA sequencing library for novel analysis.
48286539|NCT05880914|DRUG|Standard treatment for bone disorder|Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
48286540|NCT04630314|DEVICE|Percutaneus Coronary Intervention|Covered Stent
48286541|NCT01245712|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
48472324|NCT01811368|BIOLOGICAL|rituximab|Given IV
48472325|NCT01811368|BIOLOGICAL|ibritumomab tiuxetan|Given IV
48472326|NCT01811368|BIOLOGICAL|anti-thymocyte globulin|Given IV
48472327|NCT01811368|RADIATION|total nodal irradiation|Undergo TLI
48286542|NCT01245712|RADIATION|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
48286543|NCT01245712|OTHER|Quality-of-Life Assessment|Ancillary studies
48472328|NCT01811368|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
48286544|NCT02085577|DRUG|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
48286545|NCT02085577|DRUG|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
48286546|NCT02085577|DRUG|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
48286547|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
48472329|NCT01811368|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
48472330|NCT01811368|DRUG|cyclosporine|Given PO or IV
48472331|NCT01811368|DRUG|mycophenolate mofetil|Given PO or IV
48472332|NCT05135819|BEHAVIORAL|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
48472333|NCT03436953|DRUG|CX-8998|T-type calcium channel blocker
48472334|NCT03436953|DRUG|Placebo|Placebo comparator
48472335|NCT02856087|DRUG|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
48472336|NCT02856087|DRUG|Naloxone|naloxone infusion
48472337|NCT02856087|DRUG|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
48472338|NCT02856087|DRUG|Normal Saline|normal saline infusion
48472339|NCT01134341|DRUG|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
48472340|NCT01134341|DRUG|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met."
48472341|NCT01134341|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
48472342|NCT01134341|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
48472343|NCT01487629|DRUG|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
48630113|NCT02362932|OTHER|Sanitation|Shared sanitation
47940468|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
47940469|NCT00803218|DRUG|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
47940470|NCT03522753|DEVICE|Metal skin staples|Routine closure methods/material for surgical wounds
47940471|NCT03522753|DEVICE|Nylon sutures|Routine closure methods/material for surgical wounds
47940472|NCT00005863|BIOLOGICAL|filgrastim|
47940473|NCT00005863|DRUG|cytarabine|
47940474|NCT00005863|DRUG|daunorubicin hydrochloride|
47940475|NCT00005863|DRUG|etoposide|
47940476|NCT00005863|DRUG|fludarabine phosphate|
47940477|NCT00005863|DRUG|tretinoin|
48286548|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
48286549|NCT02085577|DRUG|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
48286550|NCT02085577|DRUG|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
48286551|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
48286552|NCT02085577|DRUG|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
48286553|NCT03028493|BEHAVIORAL|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
48286554|NCT03028493|BEHAVIORAL|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
48286555|NCT00004046|DRUG|exatecan mesylate|
48286556|NCT02924792|DEVICE|Reinfusion - Sternal IO needle|
48472344|NCT01487629|DRUG|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
48472345|NCT01784237|PROCEDURE|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
48630114|NCT05970211|DEVICE|Phonak Audeo Lumity Receiver in Canal Hearing Aid|bilateral receiver in canal hearing aids provided as part of a best practices hearing loss intervention including devices, hearing centered counseling, and self management skills training for hearing loss
48630115|NCT00771602|DRUG|Rituximab|375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
48286557|NCT02924792|DEVICE|Reinfusion - Intravenous needle|
48286558|NCT03983941|DRUG|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
48286559|NCT03251690|DRUG|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
47940478|NCT01120834|DRUG|azacytidine|"* Dose level 1: azacitidine 55 mg/m2 on days 1-5~* Dose level 2: azacitidine 75 mg/m2 on days 1-5~* Dose level 3: azacitidine 55 mg/m2 on days 1-5~* Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
48286560|NCT03251690|DRUG|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
48286561|NCT02270177|OTHER|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
48286562|NCT00691574|DIETARY_SUPPLEMENT|Melatonin|up to 3 mg, daily, for up to 1 year
48286563|NCT00691574|DEVICE|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
48630116|NCT00771602|DRUG|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
47940479|NCT01120834|DRUG|vorinostat|"* Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~* Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~* Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~* Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
48630117|NCT01027416|DRUG|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
48630118|NCT04769362|DRUG|Discontinuation of β-blocker|Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
48630119|NCT00937911|DRUG|YM150|oral
48630120|NCT04131192|DRUG|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
48630121|NCT04131192|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
47940480|NCT02068339|DRUG|Oltipraz 1 (90mg)|
47940481|NCT02068339|DRUG|Placebo|
47940482|NCT02068339|DRUG|Oltipraz 2 (120mg)|
47940483|NCT05633225|OTHER|Submax exercise test on a bicycle ergometer|"To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard)."
47940484|NCT02622750|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
47940485|NCT02622750|PROCEDURE|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
48286564|NCT02449330|DRUG|Teneligliptin|
48286565|NCT01606488|DRUG|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
48286566|NCT01606488|OTHER|no intervention|
48286567|NCT00003565|DRUG|docetaxel|
48286568|NCT04847115|PROCEDURE|Operative|Intramedullary screw fixation
48286569|NCT04847115|OTHER|Walking boot orthosis|Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
48286570|NCT04632979|PROCEDURE|Backwards running on a Treadmil with a negative slope|Running backward on a treadmill with a negative slope
48286571|NCT04163783|DRUG|[14C]-BGB-3111|20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,
48630122|NCT04249193|OTHER|Transfusion|pRBC and non-pRBC transfusions
48286572|NCT04163783|DRUG|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
48286573|NCT04674163|BIOLOGICAL|Blood sample and Cerebrospinal fluid (CSF) collection.|An additional blood sample (25 ml) and a cerebrospinal fluid (CSF) sample (2 ml) will be taken.
48286574|NCT02928419|DRUG|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
48286575|NCT02928419|OTHER|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
48630123|NCT06114966|OTHER|CADCAM|Milling of Final prosthesis over dental implants using CADCAM milling machine
47940486|NCT02641483|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
47940487|NCT03163810|DEVICE|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
48472346|NCT01784237|PROCEDURE|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
48472347|NCT03690089|DRUG|Atropine Sulfate|Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
48472348|NCT03690089|OTHER|Placebo|Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
48472349|NCT06461845|OTHER|Whole Body Vibration with conventional therapy|This group will be given WBV training session, by using a WBV platform was conducted to the study group. The wBV program comprises various positions such as the child stands in an erect position, sitting, and in kneeling position on vibrating platform. This platform vibrates horizontally at a frequency ranged from 10 to 25 Hz. The participants had to carry out each position for 2 min in the first month, and then it was increased to 3 min in the second month. The rest period between each position was 1 min in the first month, then it became half a minute in the second month. The duration of the vibration exposure was 10 min.
48630124|NCT04285684|DRUG|ketamine in lactation|2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
48630125|NCT05213390|OTHER|Dora|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
47940488|NCT03163810|DEVICE|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
48286576|NCT02928419|DRUG|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
48286577|NCT03906877|PROCEDURE|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
48286578|NCT03906877|BEHAVIORAL|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
48286579|NCT03906877|OTHER|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
48286580|NCT03906877|OTHER|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
48286581|NCT02453399|DEVICE|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
48286582|NCT02851446|OTHER|measure dyspnoea> Borg 7|
48286583|NCT03373786|DRUG|RG012|RG012 in 0.3% sodium chloride
48286584|NCT01400828|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
48286585|NCT01400828|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
48286586|NCT01400828|DRUG|Placebo|(encapsulated) Tablets QD/14 days
48286587|NCT02054650|OTHER|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
48286588|NCT02054650|OTHER|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
48286589|NCT04585763|DEVICE|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
48286590|NCT05488314|DRUG|Capmatinib|Capmatinib will be administered orally.
48286591|NCT05488314|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
48630126|NCT00428077|BIOLOGICAL|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
47940489|NCT04428775|DRUG|ALZT-OP1a (cromolyn)|"1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory"
47940490|NCT00965510|BEHAVIORAL|care coordination|patients receive care coordination to improve their type II diabetes
47940491|NCT05031598|OTHER|Long-term fasting according to the Buchinger Wilhelmi fasting program|the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
47940492|NCT05928871|DRUG|Misoprostol 200mcg Tab|60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)
48101619|NCT05092906|OTHER|LP with standard of care|"The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~* EMLA (Lidocain+Prilocain) Cream/Patch~* Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~* Nitrous oxide"
48286592|NCT05619848|DRUG|Rocuronium Bromide|0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
48286593|NCT02629393|DRUG|ORGN001 (formerly ALXN1101)|
48286594|NCT04188158|COMBINATION_PRODUCT|CAPECITABINE AND OXALIPLATIN|Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
48101620|NCT04742855|DIETARY_SUPPLEMENT|Probiotics|Study product is packaged as powders in a sachet. Participants and their parents will be instructed to dissolve the powder in water or milk, and to drink it in the morning and/or evening.
48101621|NCT06277622|DEVICE|PFUN|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
48101622|NCT06277622|DEVICE|PFNA|perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.
48101623|NCT01191788|BEHAVIORAL|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
48101624|NCT01191788|BEHAVIORAL|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
48101625|NCT02195479|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
48286595|NCT04244825|DRUG|BLD-2660|BLD-2660 - 150 mg capsules '00' size (PO) BID
48286596|NCT04244825|DRUG|Control: Placebo|Placebo - 150 mg capsules '00' size (PO) BID
48286597|NCT03858582|DRUG|pembrolizumab|pembrolizumab 200mg
48286598|NCT03858582|RADIATION|Radiation|52.8Gy/24Fx or 59.4Gy/27Fx
48472350|NCT06461845|OTHER|conventional therapy|This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexor;
48472351|NCT04608201|DRUG|Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|"Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)"
48472352|NCT04608201|DRUG|Placebo of NICOTINE Transdermal patch|Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
48472353|NCT05450991|PROCEDURE|Pull through|Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
48472354|NCT00105495|DRUG|Ferriprox (deferiprone)|
48472355|NCT00105495|DRUG|Desferal (deferoxamine)|
48472356|NCT03915561|DRUG|Parecoxib Injectable Product|Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.
48101626|NCT02195479|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
48101627|NCT02195479|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
48286599|NCT04442529|BEHAVIORAL|Mothers and Babies (MB)|Mothers and Babies is an evidence-based postpartum depression prevention intervention. It consists of 12 sessions which each last between 15-20 minutes. Intervention sessions are to be delivered either in person or by phone. The intervention is based on principles of cognitive-behavioral therapy (CBT).
48286600|NCT00649961|DRUG|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
48286601|NCT03461926|BEHAVIORAL|(SB-related planning + daily text messages)|Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
48286602|NCT02838030|DRUG|L-arginine|3 gr per day
48286603|NCT02838030|DRUG|Placebo (for L-arginine)|3 gr per day
48286604|NCT02838030|DRUG|acetylsalicylic acid|3 gr per day
48286605|NCT05614011|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.
48286606|NCT05614011|DIAGNOSTIC_TEST|Real-time PCR Test|Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.
48286607|NCT03466762|OTHER|Non applicable|Non applicable
48286608|NCT03077295|OTHER|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
48286609|NCT03077295|OTHER|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
48286610|NCT03376828|DEVICE|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
48286611|NCT03376828|DEVICE|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
48472357|NCT03915561|DRUG|Normal saline|Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
48472358|NCT02522780|DRUG|Mesalamine|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
48472359|NCT02522780|DRUG|Placebo|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
48472360|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC tablet for oral administration.
48472361|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration.
48472362|NCT00736398|PROCEDURE|Spinal fusion|Spinal fusion
48472363|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
48472364|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
48472365|NCT05563688|OTHER|Hypoxia exposure|"Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).~Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).~This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®)."
48286612|NCT02386423|DEVICE|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
48286613|NCT04109040|DEVICE|slit lamp|diagnostice device to examine anterior segment of the eye and for fundus examination
48286614|NCT00097266|DRUG|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
48286615|NCT00097266|DRUG|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
48286616|NCT00097266|DRUG|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
48286617|NCT04454814|OTHER|Protaper Universal instruments|Root canal treatment using Protaper Universal instruments
48286618|NCT04454814|OTHER|Reciproc Blue instruments|Root canal treatment using Reciproc Blue instruments
48286619|NCT04278573|DRUG|Vitamin D3|Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart
48286620|NCT04278573|DRUG|Placebo|0.3 ml injection of sterilized sesame oil with no active study ingredient
48286621|NCT01144637|BIOLOGICAL|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
48286622|NCT01144637|OTHER|Placebo|0.5 ml TBS
48286623|NCT05750914|DEVICE|Broadband Light|Broadband Light treatment using standard protocol
48472366|NCT05563688|OTHER|Sleep deprivation|"Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).~Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary."
48472367|NCT05563688|BEHAVIORAL|Cognitive tasks|"Participants will perform several cognitive tasks in the following conditions:~* in normoxia (FiO2 = 21%) after a night of usual sleep (\> 6 hours) ;~* in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (\> 6 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours)."
48472368|NCT01396694|OTHER|Questionnaire|Questionnaire
48472369|NCT04125615|BEHAVIORAL|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
48286624|NCT05859958|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
48286625|NCT06411626|OTHER|PNH-relevant therapies|This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
48286626|NCT04055649|DRUG|Akt/ERK Inhibitor ONC201|Given orally (PO)
48286627|NCT04055649|DRUG|Paclitaxel|Given IV
48286628|NCT04055649|OTHER|Questionnaire Administration|Ancillary studies
48286629|NCT01374282|DRUG|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
48286630|NCT00101088|DRUG|imatinib mesylate|Given orally
48286631|NCT00101088|DRUG|temsirolimus|Given IV
48286632|NCT00101088|OTHER|laboratory biomarker analysis|Correlative studies
48286633|NCT00893711|OTHER|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
48286634|NCT00893711|OTHER|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
48286635|NCT00893711|DIETARY_SUPPLEMENT|L.reuteri + Vit D|
48286636|NCT00893711|DIETARY_SUPPLEMENT|Vit D placebo|
48286637|NCT01959360|PROCEDURE|Direct lateral|Total hip replacement; direct lateral approach
48286638|NCT01959360|PROCEDURE|minimal invasive|Total hip replacement; minimal invasive approach
48286639|NCT01959360|PROCEDURE|modified minimal invasive|Total hip replacement; modified minimal invasive approach
48286640|NCT04732377|PROCEDURE|erector spinae block with bupivacaine|"Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5."
48286641|NCT04732377|PROCEDURE|erector spinae block with bupivacaine and dexmedetomidine|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
48286642|NCT03603132|DRUG|Hetrombopag Olamine|7.5mg in each cycle
48286643|NCT02488278|DEVICE|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
48472370|NCT06401954|DEVICE|High-intensity focused electromagnetic therapy|"High-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is set to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
48472371|NCT06401954|BEHAVIORAL|Foot core training|"Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks."
48286644|NCT01418872|OTHER|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
48286645|NCT05565924|OTHER|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
48286646|NCT05565924|OTHER|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
48286647|NCT05565924|OTHER|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
48472372|NCT06401954|DEVICE|Sham high-intensity focused electromagnetic therapy|"Sham high-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is unable to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
48472373|NCT04912856|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
48472374|NCT04912856|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
48472375|NCT00769314|DRUG|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
48101628|NCT02195479|DRUG|Daratumumab IV|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
48101629|NCT02195479|DRUG|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
48101630|NCT02195479|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
48101631|NCT05333887|BEHAVIORAL|PFC+|Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
48101632|NCT05206890|DRUG|fluzoparib monotherapy or combination therapy|patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
48101633|NCT02460484|BIOLOGICAL|Autologous Cord Blood Infusion|Intravenous infusion
48472376|NCT00769314|DRUG|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
48472377|NCT01626651|DRUG|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
48472378|NCT01626651|DRUG|Ketoconazole|Ketoconazole (400 mg \[2 x 200 mg\] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
47940493|NCT05928871|DRUG|Misoprostol Pill|"60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation)."
48101634|NCT02909699|OTHER|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
48101635|NCT00079664|BEHAVIORAL|Tai Chi|
48101636|NCT02735486|DIETARY_SUPPLEMENT|Ginger drink|300 ml ginger drink
48286648|NCT05565924|OTHER|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
48286649|NCT05565924|OTHER|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
48286650|NCT02624648|BEHAVIORAL|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
48286651|NCT02624648|BEHAVIORAL|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
48286652|NCT02624648|BEHAVIORAL|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
48286653|NCT02624648|DRUG|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
48286654|NCT02624648|DRUG|Placebo|They will receive a capsule of Placebo twice a day for 120 days
48286655|NCT00662155|DRUG|Zolpidem|sedative-hypnotic
48286656|NCT00662155|DRUG|Placebos|Placebo
48101637|NCT02735486|DIETARY_SUPPLEMENT|Placebo: Super pure water|Placebo: Super pure water
48101638|NCT04975243|DEVICE|GentleMax Pro Plus 755nm and 1064nm laser system|The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
48101639|NCT00684528|DRUG|Metformin 1500 mg daily|500 mg thrice daily
48286657|NCT00302640|DRUG|Alinia (nitazoxanide)|
48286658|NCT04295187|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
48286659|NCT04295187|OTHER|Physical development and General Health|Physical development and General health examination
48472379|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
48472380|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
48472381|NCT00756717|DRUG|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
48286660|NCT04295187|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
48472382|NCT06679023|DIAGNOSTIC_TEST|MolecuLight i:X and Wound blotting and Alcian blue biofilm detection kit|we will enroll patients with chronic wounds and quantify the biofilm severity by staining color of Wound blotting and Alcian blue biofilm detection kit, and by non-touched flourescent intensity of MolecuLight i:X.
48472383|NCT01376037|DEVICE|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
48472384|NCT01376037|DEVICE|inactive placebo laser device|non-therapeutic light application
48472385|NCT04869371|DRUG|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
48101640|NCT00684528|DRUG|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
48286661|NCT01421368|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
48101641|NCT00685893|BEHAVIORAL|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
48286662|NCT01421368|DRUG|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
48286663|NCT01421368|DRUG|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
48286664|NCT06070363|OTHER|Manual Acupuncture|Acupuncture Needle Insertion
48286665|NCT01777633|RADIATION|Palliative re-irradiation for progressive DIPG in children|
48286666|NCT05980026|DRUG|oral omega-3 fatty acids supplementation|oral omega-3 fatty acids supplementation
48286667|NCT05980026|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
48286668|NCT06487403|RADIATION|Standard of care external beam radiotherapy (single integrated boost)|70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
48472386|NCT04869371|DRUG|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
48472387|NCT04869371|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
48286669|NCT06487403|RADIATION|Standard of care external beam radiotherapy (two-phase treatment)|70Gy in 35 fractions, delayed 40 Gy in 20 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
48286670|NCT01914133|DRUG|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
48286671|NCT01914133|DRUG|Placebo|Placebo given prior to meal the standardized meal
48472388|NCT06286670|PROCEDURE|Single Implant Fixation|Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
48472389|NCT06286670|PROCEDURE|Dual Implant Fixation|Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
47940494|NCT05024318|DRUG|Pembrolizumab|Pembrolizumab 200 mg tobe administered as a 30 minute IV infusion every 21 days for 3 cycles
48101642|NCT00685893|BEHAVIORAL|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
48472390|NCT02583308|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
48472391|NCT02583308|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
48286672|NCT04008212|OTHER|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
48286673|NCT03977077|DRUG|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
48472392|NCT03852524|DRUG|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
48472393|NCT03852524|OTHER|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
48472394|NCT02026479|DRUG|Dexamethasone Phosphate|5mg; postauricular injection
48286674|NCT02830425|OTHER|No intervention|
48472395|NCT02026479|DRUG|Dexamethasone Phosphate|10mg; postauricular injection
48472396|NCT02026479|DRUG|Ginaton|40mg/pill, 3times/day,oral
48472397|NCT06163417|PROCEDURE|laparoscopic|laparoscopic
48472398|NCT04602585|BEHAVIORAL|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
48472399|NCT05509959|BEHAVIORAL|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
48472400|NCT05509959|BEHAVIORAL|Control|Single group session and access to website
48472401|NCT03525249|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume a capsule for eight weeks
48472402|NCT06442410|DEVICE|DTM™ spinal cord stimulation therapy delivered via Intellis™ neurostimulator system|Along with the appropriate Conventional Medical Management treatment made by the Investigator, the subject will be trialed and implanted with an Intellis™ neurostimulator system using DTM™ SCS programming parameters.
47940495|NCT05024318|RADIATION|Stereotactic Ablative Radiotherapy|42Gy delivered in 3 fractions
47940496|NCT05024318|PROCEDURE|Nephrectomy|Partial or total nephrectomy performed 9-12 weeks after first dose of Pembrolizumab
47940497|NCT04545359|BEHAVIORAL|Alpha-based neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
48472403|NCT06442410|OTHER|Conventional Medical Management (CMM)|The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
48286675|NCT01748760|BEHAVIORAL|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
48286676|NCT01748760|OTHER|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
48286677|NCT06402773|DEVICE|The Signati Separo™ Vessel Sealing System|Vessel Sealing System
48286678|NCT04222985|BIOLOGICAL|HSV 2 Formulation 1|Route of administration: Intramuscular
48472404|NCT03700645|DRUG|Allopurinol|Allopurinol
48472405|NCT05595122|DEVICE|EUS-CDS|EUS-CDS with FCSEMS through LAMS
48472406|NCT01859026|DRUG|MEK162|Treatment as outlined in study arms.
48472407|NCT01859026|DRUG|Erlotinib|Treatment as outlined in study arms.
48472408|NCT05539534|BEHAVIORAL|Training on suicide prevention|Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
48472409|NCT04751630|OTHER|Therapeutic Exercise|Online and structured exercise therapeutic program based on flexibility, strength, balance and aerobic exercises. The program have been supervised by an expert on the field and it participants will perform it under the supervision of an expert physiotherapist.
48472410|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
48472411|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
48472412|NCT02964650|DEVICE|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
48472413|NCT00063830|DRUG|Alicaforsen|
48286679|NCT04222985|BIOLOGICAL|HSV 2 Formulation 2|Route of administration: Intramuscular
48286680|NCT04222985|BIOLOGICAL|HSV 2 Formulation 3|Route of administration: Intramuscular
48472414|NCT06502210|PROCEDURE|Personalized surgical therapy of neuroblastoma|If the size of the tumor tissue is too large, the doctor gives the patient chemotherapy and then performs surgery to remove the tumor. In this study, the genotypes of children with neuroblastoma are screened by using Deep Sequencing Technology and Third Generation Sequencing Technology, and the treatment will be performed according to different therapeutic modalities.
48472415|NCT05629286|DEVICE|McConnell taping|non-stretch rigid McConnell tape will be applied
48472416|NCT05629286|DEVICE|Patella Stabilizer Brace|An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
48472417|NCT02514395|OTHER|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2\[32\] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
48472418|NCT05308368|DEVICE|Ultrasound Imaging|We will collect ultrasound images during the grasping motion for both groups
48472419|NCT05308368|DEVICE|Electromyography|We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups
48472420|NCT05308368|DEVICE|Inertial Measurement Units (IMU)|We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion
48472421|NCT05308368|DEVICE|Functional Electrical Stimulation (FES)|We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression
48286681|NCT04222985|BIOLOGICAL|HSV 2 Formulation 4|Route of administration: Intramuscular
48472422|NCT06148779|BEHAVIORAL|Digitally delivered first-line treatment for osteoarthritis|Digitally delivered first-line for osteoarthritis through the caregiver Joint Academy.
48472423|NCT06148779|BEHAVIORAL|Face-to-face first-line treatment for osteoarthritis|First-line for osteoarthritis delivered at a primary care clinic face-to-face with reported data to the BOA registry.
48472424|NCT06251960|PROCEDURE|socket preservation with completely demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
48472425|NCT06251960|PROCEDURE|socket preservation with partially demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
48286682|NCT04222985|BIOLOGICAL|HSV 2 Formulation 5|Route of administration: Intramuscular
48286683|NCT04222985|BIOLOGICAL|HSV 2 Formulation 6|Route of administration: Intramuscular
48286684|NCT04222985|BIOLOGICAL|Sodium Chloride 0.9%|Route of administration: Intramuscular
48286685|NCT05079035|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
48286686|NCT05079035|BIOLOGICAL|Saline|2 mL Sterile, preservative free 0.9% NaCl
48286687|NCT05598086|DRUG|Tranexamic acid|local infiltration of TXA or normal saline in the post-operation would
48286688|NCT02302911|BEHAVIORAL|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
48286689|NCT02302911|BEHAVIORAL|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
48286690|NCT02302911|OTHER|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
48286691|NCT03169283|OTHER|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
48286692|NCT03169283|OTHER|Cereal without B glucan|Cereal without B glucan
48286693|NCT05063370|DRUG|Levosimendan|Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
48286694|NCT05063370|DRUG|Standard Care|Patients will not receive Levosimendan and will receive standard care according to the institution protocol
48286695|NCT00345072|DEVICE|Web-based decision aid system|
48286696|NCT02343328|BIOLOGICAL|Fecal Microbiota Transplant|
48286697|NCT02343328|BIOLOGICAL|Placebo|
48286698|NCT03994640|COMBINATION_PRODUCT|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
48286699|NCT03994640|COMBINATION_PRODUCT|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
48286700|NCT00493389|DRUG|Adrenocorticotrophic hormone|
48286701|NCT00346515|DEVICE|FiberNet Emboli Protection System|
48286702|NCT05259475|OTHER|Lifestyle Advice|Maintain a weekly healthy diet and regular exercise.
48286703|NCT05259475|OTHER|Diet Intervention|Calorie-restricted meals (lunch and dinner)
48286704|NCT05259475|OTHER|OCFA Meal-Based Diet-Intervention|OCFA-containing food product
48286705|NCT04327648|DEVICE|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
48286706|NCT04327648|DEVICE|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
48286707|NCT04327648|OTHER|Routine treatment|Children in routine treatment group will keep the same initial treatment.
48286708|NCT03283215|DIAGNOSTIC_TEST|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
48286709|NCT05751005|DIETARY_SUPPLEMENT|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
48286710|NCT03426059|OTHER|No Intervention|No Intervention. This is an observational study.
48286711|NCT00117078|DRUG|Aranesp®|
48286712|NCT00946270|DRUG|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
48286713|NCT00946270|DRUG|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
48286714|NCT00946270|DRUG|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
48286715|NCT06058611|OTHER|Cognitive stimulation|Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
48286716|NCT06058611|OTHER|Stimulating leisure activities|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
48286717|NCT06421324|BEHAVIORAL|Health reccommendations|Patients are given recommendations according to their risk group, based on the model which already predicted health indicators. This information will be sent to the patient's treating physician so that treatment and recommendations are aligned with the clinical care practice based on the European Code of Cancer guidelines, the H. pylori best practices guidelines and European GIM guidelines
48286718|NCT05272514|OTHER|Hypoxia|Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
48286719|NCT02830373|DEVICE|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
48286720|NCT00241111|DRUG|zoledronic acid|
48286721|NCT02567695|DRUG|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
48286722|NCT04616586|DRUG|Siltuximab|11 mg/kg IV administered over 1 hour
48286723|NCT04616586|OTHER|Normal Saline|IV administered over 1 hour
48286724|NCT00509886|DRUG|Drysol|20% aluminum chloride hexahydrate
48286725|NCT00509886|DRUG|Drioff|1% aluminum acetate
48286726|NCT04914338|OTHER|Health Promotion|Participate in MDT-intervention
48286727|NCT04914338|OTHER|Quality-of-Life Assessment|Ancillary studies
48286728|NCT04914338|OTHER|Questionnaire Administration|Ancillary studies
48286729|NCT01576081|DEVICE|HEPHAISTOS|HEPHAISTOS unloading orthotic
48286730|NCT03883893|DRUG|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
48286731|NCT03883893|OTHER|Normal saline|Normal saline will given if randomized to this group.
48286732|NCT02875288|DRUG|liposomal bupivicaine|"1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration"
48286733|NCT00002700|DRUG|asparaginase|
48286734|NCT00002700|DRUG|cyclophosphamide|
48286735|NCT00002700|DRUG|cytarabine|
48286736|NCT00002700|DRUG|daunorubicin hydrochloride|
48286737|NCT00002700|DRUG|dexamethasone|
48286738|NCT00002700|DRUG|doxorubicin hydrochloride|
48286739|NCT00002700|DRUG|leucovorin calcium|
48286740|NCT00002700|DRUG|mercaptopurine|
48286741|NCT00002700|DRUG|methotrexate|
48286742|NCT00002700|DRUG|mitoxantrone hydrochloride|
48286743|NCT00002700|DRUG|prednisolone|
48286744|NCT00002700|DRUG|prednisone|
48286745|NCT00002700|DRUG|therapeutic hydrocortisone|
48286746|NCT00002700|DRUG|vincristine sulfate|
48286747|NCT00002700|PROCEDURE|allogeneic bone marrow transplantation|
48286748|NCT00002700|PROCEDURE|autologous bone marrow transplantation|
48286749|NCT00002700|RADIATION|radiation therapy|
48286750|NCT01581190|DIETARY_SUPPLEMENT|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
48286751|NCT05990530|BIOLOGICAL|YD02-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
48286752|NCT04507074|DEVICE|lumbar traction therapy|The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
48286753|NCT06255886|DRUG|Protein pump inhibitor. Continuing nutrition containing cows' milk protein.|1 mg/kg /day
48286754|NCT06255886|BEHAVIORAL|Mother or infant diet|Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed
48286755|NCT06255886|DRUG|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
48286756|NCT04537637|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
48286757|NCT05858008|BEHAVIORAL|Time-restricted eating|Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
48286758|NCT02450253|DRUG|Tadalafil|single dose, 20 mg capsule p.o.
48286759|NCT02450253|DRUG|Placebo|single dose, matching capsule p.o.
48286760|NCT02450253|BEHAVIORAL|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
48286761|NCT02450253|BEHAVIORAL|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
48286762|NCT02450253|OTHER|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
48286763|NCT02772380|DEVICE|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
48286764|NCT03905772|OTHER|Voluntary exercise|The participants will perform 36 maximal voluntary contractions, 3 times per week for 8 weeks.
48286765|NCT03905772|OTHER|Wide pulse responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in responder group in acute fase.
48286766|NCT03905772|OTHER|Wide pulse non responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in non responder group in acute fase.
48286767|NCT03905772|OTHER|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
48286768|NCT00200681|DRUG|Velcade|
48286769|NCT00852644|PROCEDURE|computed tomography|Standard CT scans
48286770|NCT00852644|RADIATION|fludeoxyglucose F 18|standard doses with CT scans
48472426|NCT04906330|DIAGNOSTIC_TEST|Oncoliq: test for early breast cancer detection.|Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
47940498|NCT04545359|BEHAVIORAL|Sham neurofeedback|"Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of an auditory sham neurofeedback with the Melomind device developed by myBrain Technologies (France). Sham feedback is based on the real feedback of the participants in the Experimental arm. Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions."
47940499|NCT00079534|BEHAVIORAL|Non-local/distant healing or prayer|
48286771|NCT00852644|RADIATION|hypofractionated radiation therapy|4 doses over 2 weeks
48472427|NCT04079452|DRUG|Doravirine|Doravirine 100 mg tablet
48472428|NCT04079452|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
48472429|NCT05524428|BEHAVIORAL|Implementation Science Strategy|The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
48286772|NCT00852644|RADIATION|stereotactic radiosurgery|CyberKnife radiosurgery
48286773|NCT03401606|DRUG|remifentanil|remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
48286774|NCT03401606|DRUG|Dexmedetomidine|dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
48472430|NCT06613269|DRUG|68Ga-NY104 PET/CT|"68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104."
48472431|NCT06613269|DRUG|18F-FDG PET/CT|18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
48472432|NCT06613269|RADIATION|Radiation Therapy|Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy.
48472433|NCT06613269|DRUG|Systemic therapy|Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
48472434|NCT02868996|DRUG|Recombinant human tissue kallikrein|Intravenous DM199
47940500|NCT00216554|DRUG|risperidone|
48286775|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|"Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2)."
48286776|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
48630127|NCT00428077|GENETIC|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
48286777|NCT05137938|DRUG|Intranasal Ketamine (IN)|A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
48101643|NCT00685893|BEHAVIORAL|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
48286778|NCT02786862|OTHER|independent ventilation|comparison conventional and independent 1:1 ventilation
48286779|NCT04673994|BEHAVIORAL|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
48286780|NCT00542984|DRUG|teriparatide 20 micrograms/day subcutaneous|
48472435|NCT01149434|DRUG|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
48472436|NCT01149434|DRUG|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
48472437|NCT04346563|OTHER|Kinesio tape, functional correction technique|According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.
48472438|NCT04346563|OTHER|Elastic band strengthening shoulder exercise|"The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week"
48472439|NCT05791747|OTHER|semi-structured interviews|This is an observational study Patients included in the study will conduct semi-structured interviews to discuss their knowledge and/or experience with supportive care, particularly hypnosis
48472440|NCT01738217|PROCEDURE|Fluobeam|
48472441|NCT06555289|DEVICE|Clareon PanOptix IOL|Spherical and toric T3
48472442|NCT00438659|DRUG|mometasone furoate|Applied to treatment area
48472443|NCT00438659|OTHER|placebo|Applied to treatment area
48630128|NCT04760457|PROCEDURE|Implant placement with flapped surgery|Four mini implants will be placed reflecting a flap.
48630129|NCT04760457|PROCEDURE|Implant placement with flapless surgery|Four mini implants will be placed without reflecting a flap.
48630130|NCT04760457|PROCEDURE|Implant immediate loading|Four mini implants will be immediately loaded.
47940501|NCT03708627|DRUG|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
47940502|NCT04494360|OTHER|No intervention|No investigational medicinal product will be administered as a part of this study.
47940503|NCT01351246|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
47940504|NCT01665612|DEVICE|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
47940505|NCT01182779|RADIATION|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
48286781|NCT00542984|DRUG|salmon calcitonin 100 IU/day subcutaneous|
48286782|NCT03645291|DIAGNOSTIC_TEST|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
48286783|NCT00404040|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
48286784|NCT00404040|DRUG|Lactulose|
48286785|NCT06064318|PROCEDURE|Revision|Any type of knee revision, excluding knee arthrodesis and femur amputation
48286786|NCT05375292|OTHER|PREHABILITATION|"Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~1. Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~2. Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~3. Cardio-respiratory endurance exercises."
48286787|NCT04453150|OTHER|Standard hypocaloric die|Standard hypocaloric diet
48286788|NCT04453150|OTHER|Intermittent fasting 16/8 (early fasting)|Intermittent fasting 16/8 (early fasting)
48286789|NCT04453150|OTHER|Intermittent fasting 16/8 (late fasting)|Intermittent fasting 16/8 (late fasting)
48286790|NCT04453150|OTHER|Alternate-day fasting|Alternate-day fasting
48286791|NCT04453150|OTHER|Ketogenic diet|Ketogenic diet
48286792|NCT02179398|BIOLOGICAL|Allocation to the Lab-score group|
48286793|NCT02179398|BIOLOGICAL|Allocation to the control group|
48286794|NCT05000801|BIOLOGICAL|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
48286795|NCT02838550|BEHAVIORAL|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
48286796|NCT02838550|BEHAVIORAL|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
48286797|NCT00330824|DRUG|antibiotic/steroid combination|1gtt, 4x/d, 15 days
48286798|NCT00330824|DRUG|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
48286799|NCT02330029|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
48286800|NCT02330029|DEVICE|Atractylodes|Atractylodes (\~10-15g)
48286801|NCT02330029|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
48286802|NCT02330029|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
47940506|NCT01182779|RADIATION|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
48286803|NCT02330029|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
48286804|NCT02330029|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
48286805|NCT02330029|DRUG|Radix curcumae|Radix curcumae (\~10g)
48286806|NCT02330029|DRUG|Fingered citron|Fingered citron (\~10g)
48286807|NCT02330029|DRUG|Tuckahoe|Tuckahoe (15g)
48286808|NCT02330029|DRUG|Placebo|Placebo is blindly given to patients.
48472444|NCT01835535|DEVICE|TIVUS|
48286809|NCT00716521|DRUG|placebo|single oral dose placebo
48630131|NCT04760457|PROCEDURE|Implant delayed loading|Four mini implants will be loaded after a 6-week healing period.
48286810|NCT00716521|DRUG|zolpidem|single oral dose, 5 mg zolpidem
48286811|NCT00716521|DRUG|zolpidem|single oral dose, 10 mg zolpidem
48286812|NCT01039168|BEHAVIORAL|Workplace dialogue|
48286813|NCT01039168|OTHER|Care as usual|
48286814|NCT05330520|PROCEDURE|"Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement"|when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
48286815|NCT05170191|BEHAVIORAL|Sleep Deprivation|The participants will stay awake for 24 hours.
48286816|NCT03946176|DIETARY_SUPPLEMENT|Symbiotic|HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
48286817|NCT03946176|DIETARY_SUPPLEMENT|Placebo|HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
48286818|NCT03946176|DEVICE|DVB cartridge|On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
48286819|NCT01600781|DIETARY_SUPPLEMENT|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
48286820|NCT00148239|BEHAVIORAL|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
48286821|NCT00148239|BEHAVIORAL|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
48286822|NCT00148239|BEHAVIORAL|Control|Participants given written educational materials at beginning of study; no treatment beyond this
48286823|NCT04668378|OTHER|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
48286824|NCT04668378|OTHER|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
48286825|NCT04418440|DIETARY_SUPPLEMENT|Souvenaid oral nutritional supplement (Nutricia)|Daily dose of a commercially available oral nutritional supplement based around the active compound recipe Fortasyn Connect, produced by Nutricia, Danone.
48286826|NCT00474227|BEHAVIORAL|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
48286827|NCT06251687|PROCEDURE|Transbronchial Cryobiopsy，TBLC|Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
48286828|NCT06251687|PROCEDURE|Transbronchial Lung Biopsy，TBLB|Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
48286829|NCT04555213|DRUG|NOX66|NOX66 Suppository
48286830|NCT01334112|DRUG|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
48286831|NCT06396481|BIOLOGICAL|Vγ9Vδ2 T cell|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
48286832|NCT03685656|OTHER|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
48286833|NCT03685656|OTHER|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
48286834|NCT04562324|DRUG|SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics|Medications to relieve anxiety
48286835|NCT04562324|DEVICE|Neurofeedback system|EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
48630132|NCT02747225|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
48630133|NCT02580344|DRUG|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
48630134|NCT00051506|DRUG|ALIMTA|
48630135|NCT00051506|DRUG|carboplatin|
48630136|NCT00051506|DRUG|cisplatin|
48630137|NCT00810745|PROCEDURE|starr|stapled transanal rectal resection
48286836|NCT00688038|PROCEDURE|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
48472445|NCT06535035|DEVICE|laser therapy After implant surgery, laser therapy (LLLT) was applied|After implant surgery, laser therapy (LLLT) was applied a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA)
48472446|NCT06535035|DEVICE|SHAM|After implant surgery, After implant surgery, laser therapy (LLLT) was applied in the same manner but without activating it
48472447|NCT03468712|PROCEDURE|Laparoscopic D2 distal gastrectomy|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
48472448|NCT04330495|DRUG|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
48472449|NCT04330495|DRUG|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
48472450|NCT05567627|BIOLOGICAL|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
48472451|NCT03105973|BEHAVIORAL|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
48472452|NCT00485004|DEVICE|Cutting balloon|Cutting balloon
48472453|NCT00485004|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
48472454|NCT01767727|PROCEDURE|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
48472455|NCT01016340|DRUG|MCS|MCS-5 Softgel 5 mg
48472456|NCT01057173|PROCEDURE|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
48472457|NCT01057173|PROCEDURE|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
48472458|NCT03426540|DRUG|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
48472459|NCT05445570|DIAGNOSTIC_TEST|Non-Interventional|This is an observational, non interventional study
48472460|NCT01109017|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
48472461|NCT04759534|BIOLOGICAL|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
48472462|NCT02087917|DRUG|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
48472463|NCT02087917|DRUG|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
48472464|NCT02683291|DRUG|sirolimus|
48472465|NCT02683291|DRUG|tacrolimus|
48472466|NCT02683291|DRUG|mycophenolate|
48472467|NCT02683291|DRUG|Prednisone|Prednisone 30mg/day
48472468|NCT02683291|DRUG|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
48472469|NCT02683291|DRUG|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
48472470|NCT00458445|DRUG|SPD465|
48472471|NCT00458445|OTHER|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
48472472|NCT05179161|DEVICE|Prone crawl positioning|Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
48472473|NCT02503813|PROCEDURE|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
48472474|NCT00091286|BIOLOGICAL|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
48630138|NCT01129895|BEHAVIORAL|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
48472475|NCT06452355|DEVICE|KOKO Device|The intrauterine rolling drain is extended into the uterus, where low pressure vacuum is applied to the uterus through the fabric intrauterine rolling drain. The KOKO™ device utilizes this vacuum to remove excess blood and compress the uterus reducing further blood loss.
48472476|NCT01948401|DRUG|LABA|long-acting beta-agonist treatment
48472477|NCT01948401|DRUG|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
48472478|NCT01948401|DRUG|prednisolone|additional 0.5 mg/kg orally for 7 days
48630139|NCT03990688|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
48472479|NCT01625117|BEHAVIORAL|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
48472480|NCT03779568|OTHER|Dose adjustment of bupivacaine|Spinal bupivacaine dose will be adjusted according to previous patient experience.
48472481|NCT01692886|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
48472482|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
48472483|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
48472484|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
48630140|NCT03990688|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
48630141|NCT01972971|OTHER|patient education|one by one patient education
48630142|NCT05025371|OTHER|Systemic immune-inflammatory markers|Systemic immune-inflammatory markers used in this study: total neutrophil count, total lymphocyte count, total monocyte count, total platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI)
48630143|NCT01774539|OTHER|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
48630144|NCT01408498|DRUG|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
48630145|NCT03648970|DRUG|Pravastatin|The participant will be given pravastatin 2 x 20 mg per oral daily
48630146|NCT06075290|BEHAVIORAL|internet plus model|Intelligent transcutaneous bilirubin meter and Internet plus model for neonatal jaundice monitoring at home and remote follow-up
48630147|NCT06075290|BEHAVIORAL|control|follow-up by conventional methods; hospital or community follow-up depending on arrangement
48286837|NCT00688038|PROCEDURE|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
48472485|NCT05523167|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
48472486|NCT05523167|OTHER|PBO|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
48472487|NCT02724826|BEHAVIORAL|Qigong therapy|Medical qigong
48472488|NCT02724826|BEHAVIORAL|Exercise therapy|Regular exercise
48472489|NCT05536908|BEHAVIORAL|Residential Written Exposure Therapy|Residential Written Exposure Therapy (resWET): TAU plus 5-individual WET sessions (40-60 min each; Marx \& Sloan, 2019) twice a week for two weeks and once a week for the final session, administered by WET trained psychologists, social workers, or postdoctoral residents. Treatment instructions are read, patients write for 30 minutes, and the writing is briefly processed. No formal written homework is required.
48630148|NCT02141724|OTHER|Positioning consultation|Assessment of pain,bedsores and postural troubles
48630149|NCT05800704|DIETARY_SUPPLEMENT|Nagasin|Lactobacillus, Lactococcus and Bifidobacteria strains with antimicrobial effect against C. difficile
48630150|NCT05800704|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin (placebo comparator)
48630151|NCT01421134|DRUG|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
48630152|NCT01421134|DRUG|Placebo|Placebo
48630153|NCT04677166|DEVICE|Negative pressure wound therapy coupled with instillation|Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.
48630154|NCT04677166|DEVICE|Standard Negative Pressure Wound Therapy|standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
48630155|NCT03509155|OTHER|National portion & IYCF counseling|Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
48630156|NCT03509155|OTHER|Adjusted portion & local food counseling|four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
48630157|NCT01763957|BEHAVIORAL|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
48630158|NCT01763957|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
48630159|NCT01842178|PROCEDURE|scratching|"Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control."
48630160|NCT04073407|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
48630161|NCT04073407|DIETARY_SUPPLEMENT|Placebo|placebo
48286838|NCT03929042|DEVICE|Posture correction girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
48286839|NCT00772967|DRUG|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
48286840|NCT00772967|DRUG|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
48286841|NCT00772967|DRUG|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
48286842|NCT02146781|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
48286843|NCT02146781|OTHER|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
48286844|NCT03879590|DRUG|Doxophylline|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
48286845|NCT03879590|DRUG|Budesonide|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
48286846|NCT01455727|OTHER|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
48286847|NCT01455727|OTHER|Usual care|Control patients received usual care directed by their physician.
48286848|NCT03445286|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Advantage Arrest) for the experimental group
48286849|NCT03445286|OTHER|Normal Saline|Normal Saline for the control group
48286850|NCT00077233|DRUG|cetuximab|IV
48286851|NCT00077233|DRUG|5-FU|IV
48286852|NCT00077233|DRUG|irinotecan|IV
48286853|NCT00077233|DRUG|leucovorin|IV
48286854|NCT00077233|DRUG|oxaliplatin|IV
48286855|NCT01586728|OTHER|Air - oxygen|"1. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~2. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
48286856|NCT01586728|OTHER|Oxygen - Air|"1. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~2. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
48286857|NCT01328873|OTHER|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
48286858|NCT04207710|DRUG|Gebauer's Pain Ease Top Aerosol Mist Spray|Topical refrigerant spray
48286859|NCT04207710|DRUG|Gebauer's Ethyl Chloride|Topical refrigerant spray
48286860|NCT05596981|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
48286861|NCT00802477|PROCEDURE|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
48286862|NCT00802477|PROCEDURE|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
48286863|NCT04046302|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
48286864|NCT04046302|DRUG|placebo|one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
48472490|NCT05536908|BEHAVIORAL|Treatment as Usual|Treatment as Usual (DOM SUD): The DOM SUD (TAU) is a 24-bed intensive SUD residential program with a typical 28-day length of stay. The program focuses on evidence-based treatments for SUD such as Cognitive-Behavioral Therapy, Motivational Enhancement Therapy, Medication Assisted Treatment, and Contingency Management therapy. Patients diagnosed with PTSD are typically referred to outpatient PTSD treatment following DOM SUD and often attend Seeking Safety during the program. Most of the programming is group-based though Veterans also have weekly individual case management appointments.
48472491|NCT03730740|DRUG|Lenalidomide 25mg|Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
48472492|NCT05385367|OTHER|Regional anesthetic|Patient having just the nerve block for surgery
48472493|NCT05385367|OTHER|General anesthetic|Patient having just general anesthetic ie. 'go completely under' for surgery
48101644|NCT00685893|BEHAVIORAL|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
48101645|NCT00685893|BEHAVIORAL|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
48286865|NCT06398392|DRUG|[18F]PBR111|\[18F\]PBR111 is a radiotracer produced at University Hospital of Geneva in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 10 mL (max) of formulated product, the maximal applicable dose being 200 MBq.
48286866|NCT06398392|PROCEDURE|PBR111 injection|\[18F\]PBR111 will be administered once, intravenously in the antecubital fossa at a dose of 200 MBq
48286867|NCT06398392|DEVICE|PET scan|Upon administration of the radiotracer, a 120-minute PET/CT scan will be initiated.
48286868|NCT06398392|RADIATION|PBR111 dosimetry|to establish the exposure of the organs/tissues to a standard radioactive dose (200 MBq) of \[18F\]PBR111
48286869|NCT02255838|DEVICE|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
48286870|NCT02255838|DEVICE|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
47940507|NCT03690323|PROCEDURE|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
47940508|NCT03690323|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
47940509|NCT03690323|DRUG|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
47940510|NCT03690323|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
47940511|NCT04705038|BEHAVIORAL|Patient Education|Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
47940512|NCT01016704|BEHAVIORAL|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
47940513|NCT02531243|BEHAVIORAL|CALMS|Family Therapy; Multi-user Biofeedback Videogames
47940514|NCT04348890|DRUG|Vamorolone 4% suspension for oral dosing|vamorolone 6 mg/kg/day orally once daily for 8 weeks.
47940515|NCT05263947|DRUG|Bevacizumab and Icotinib|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
48286871|NCT00540540|DEVICE|Diffuse Optical Spectroscopy|Breast properties scanning
48286872|NCT05600010|OTHER|Microplastics|Detection of microplastics as a yes/no value
48472494|NCT05385367|OTHER|Combined general anesthetic and regional anesthetic|Patient having a combination of a nerve block and general anesthetic for surgery
48472495|NCT02872051|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
48630162|NCT03383939|DRUG|Group A|one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
47940516|NCT01397812|DEVICE|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
47940517|NCT01397812|DEVICE|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
47940518|NCT00137865|GENETIC|EGEN-001 (phIL-12-005/PPC)|
47940519|NCT00002065|DRUG|Disulfiram|
48286873|NCT02837172|OTHER|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
48630163|NCT03383939|DRUG|Group B|10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
48630164|NCT00647023|DRUG|metformin|1000 mg metformin x 2 daily during 8 months
47940520|NCT03977454|PROCEDURE|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
48286874|NCT00964795|DRUG|Intravitreal Aflibercept Injection 2mg|
48286875|NCT05144165|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
48286876|NCT00292123|DRUG|Methadone|
48630165|NCT01370642|DRUG|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
48630166|NCT01370642|DRUG|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
47940521|NCT03977454|PROCEDURE|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
47940522|NCT03977454|DRUG|Ropivacaine|60 ml 0.2% ropivacaine
47940523|NCT03977454|DRUG|Dex|10 mg DEX/ 80 mg MPA
48472496|NCT02872051|OTHER|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
48286877|NCT00292123|BEHAVIORAL|Contingency Management|
48286878|NCT01872351|DRUG|Nutraceuticals|
48286879|NCT04937387|DRUG|FF/VI|FF/VI will be administered.
48286880|NCT04937387|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
48286881|NCT04937387|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
48286882|NCT02139189|DEVICE|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
48286883|NCT02437838|OTHER|No Intervention|No Intervention
48286884|NCT06070129|PROCEDURE|surgical pulmonary embolectomy|open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
48286885|NCT04909567|BEHAVIORAL|Optimisation|Defined optimisation
48286886|NCT05281315|OTHER|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.
48472498|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
48630167|NCT01370642|BIOLOGICAL|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
48630168|NCT01370642|DRUG|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
48630169|NCT02713841|DRUG|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
48630170|NCT02713841|DRUG|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
48630171|NCT04633876|BEHAVIORAL|Individual coaching|Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
48630172|NCT04633876|BEHAVIORAL|Group coaching|Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
48630173|NCT04633876|OTHER|Control group|Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
48101646|NCT04630457|DEVICE|Conventional ankle prosthesis|At the first visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using the conventional prosthesis that the patient had.
48286887|NCT04302272|DEVICE|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
48286888|NCT06427889|DRUG|Canoderm|humectant
48286889|NCT06427889|DRUG|Oviderm|humectant + antimicrobial
48286890|NCT06427889|DRUG|Decubal|Non-humectant
48286891|NCT05771922|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
48286892|NCT01325493|DRUG|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
48286893|NCT01325493|DRUG|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
48286894|NCT05422300|BEHAVIORAL|Fed|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine.
48286895|NCT05422300|BEHAVIORAL|Ex-Fed|"Participants will be subjected to a full-body resistance exercise protocol, consisting of an upper and lower body circuit. The upper body circuit will be a chest press and dumbbell row superset, whereas the lower body circuit will be leg press and leg extension (4 sets of 10 repetitions @ 75% of their 1 repetition max, respectively). The inter-set rest period will be 90 seconds.~Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine."
48286896|NCT02226068|DRUG|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
48286897|NCT02226068|OTHER|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
48286898|NCT00725738|GENETIC|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
48472499|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
48472500|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
48472501|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
48472502|NCT00131482|DRUG|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
48286899|NCT00820638|DEVICE|myomo e100|use of the myomo e100 in home
48286900|NCT02809248|DEVICE|ZES|stent implantation (zotarolimus eluting stent)
48286901|NCT02809248|DEVICE|BMS|stent implantation (bare metal stent)
48101647|NCT04630457|DEVICE|Meridium® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using Meridium®. For example, if visit 2 was evaluated using Meridium®, visit 3 was evaluated using RoFT®. In another example, visit 2 is evaluated using RoFT®, while Visit 3 is evaluated using Meridium®.
48101648|NCT04630457|DEVICE|RoFT® (Microprocessor ankle prosthesis)|There are two weeks apart between each visit. Depending on the group to which the patient belongs, at the second or third visit, 3D motion analysis, dynamic EMG analysis, energy consumption analysis, 6 minute walk test, Berg balance scale, Locomotor Capabilities Index, and Korean-Prosthesis Evaluation Questionnaire will be evaluated using RoFT®. For example, if visit 2 was evaluated using RoFT®, visit 3 was evaluated using Meridium®. In another example, visit 2 is evaluated using Meridium®, while Visit 3 is evaluated using RoFT®.
48101649|NCT00957086|DRUG|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
47940524|NCT02416310|DEVICE|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
47940525|NCT06130527|PROCEDURE|Nicardipine|Following the intubation, the infusion was initiated by using an infusion device (Orchestra Base Primea, Fresenius Kabi) with an i.v. dose of 1.0 µg/kg/min iv in Group N. The targeted MAP was determined as 50-65 mmHg and drug doses were increased until the targeted MAP was achieved In Group N. Nicardipine infusion will be increased by titration in groups with MAP above 65 mm/Hg for more than 5 minutes.
47940526|NCT06130527|PROCEDURE|Remifentanil|Infusion was administered i.v. using an infusion device (Orchestra Base Primea, Fresenius Kabi). In Group R, the dose will start at 0.05 µg/kg/min following intubation. The target MAP was determined as 50-65 mmHg and drug doses will be increased until the target MAP is reached. HR more than 120 seconds and less than 45 beats/min will be considered as bradycardia and the remifentanil dose will be reduced. If response is unsatisfactory, 0.5 mg Atropine i.v. will be implemented. Nicardipine and Remifentanil infusions in groups will be increased by titration if MAP rises above 65 mm/Hg for more than 5 minutes.
48101650|NCT00957086|DRUG|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
48101651|NCT02869958|OTHER|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
48101652|NCT02869958|OTHER|Written action plan|
48286902|NCT03590561|OTHER|High caloric diet|After dietary counseling, subjects will receive high caloric snacks for five days.
48286903|NCT02589587|PROCEDURE|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
47940527|NCT00355901|DRUG|Visilizumab (Nuvion®; HuM291)|
48286904|NCT02589587|OTHER|no intervention|lean control group
48286905|NCT05879939|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
48286906|NCT01955486|OTHER|flight simulation|
48286907|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
48286908|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
48286909|NCT03671044|DRUG|Taxotere® (100 mg/m2)|Docetaxel Injection Concentrate; 20 mg/0.5 mL
48286910|NCT04477122|OTHER|Manual therapy and extracorporeal radial shock waves therapy|25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
48286911|NCT00184990|DRUG|Aminoguanidine|
47940528|NCT00745576|DRUG|SAM-531|
47940529|NCT00281073|DEVICE|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
48286912|NCT00184990|DRUG|endotoxin|
48472503|NCT04287608|DRUG|dupilumab|No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
48472504|NCT05455606|OTHER|Best Practice|Receive usual care
48472505|NCT05455606|OTHER|Chart Abstraction|Ancillary studies
48472506|NCT05455606|OTHER|Educational Intervention|Physicians access genomic testing education materials
48472507|NCT05455606|PROCEDURE|Genomic Profile|Patients undergo genomic testing
48472508|NCT05455606|OTHER|Interview|Ancillary studies
48472509|NCT05455606|OTHER|Questionnaire Administration|Ancillary studies
48472510|NCT05455606|OTHER|Tumor Board Review|Patients undergo genomic tumor board review
48472511|NCT03396588|DRUG|Clonidine|1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
48472512|NCT03396588|DRUG|Morphine|Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
48286913|NCT04934735|PROCEDURE|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~1. Intake by a case manager~2. Referral to an occupational physician was within one week of the intake.~3. Charting an occupational rehabilitation program and timing the RTW date~4. Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~5. Provision of a guidance booklet for employers on the RTW of cardiac patients.~6. The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~7. Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
48630174|NCT03243188|OTHER|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
47940530|NCT00281073|DEVICE|Intracardiac Echo|Intracardiac Echo Viewmate
47940531|NCT00281073|DEVICE|ICE|ICE or TEE
48630175|NCT05064800|DRUG|Dabigatran|A single dose of Dabigatran on Day 1
47940532|NCT04250714|DEVICE|Boston Scientific Cardiac Cryoablation System|cryoablation of atrial fibrillation consisting in electrical isolation of the pulmonary veins
47940533|NCT00924417|BEHAVIORAL|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
47940534|NCT00924417|BEHAVIORAL|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
47940535|NCT04926727|OTHER|Survey|Observational study
47940536|NCT05831631|DIAGNOSTIC_TEST|Circulating leukocytes immunophenotype|Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype
47940537|NCT05831631|DIAGNOSTIC_TEST|Tumor sampling|Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
47940538|NCT05921318|COMBINATION_PRODUCT|Beijing protocol|"For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)~For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days)."
47940539|NCT02789228|BIOLOGICAL|Tumor associated antigen lymphocytes (TAA-CTL)|"This protocol is designed as a phase I dose-escalation study. In each treatment group (A and B), patients will be enrolled to one of the following TAA-T dose levels:~Dose Level One: 1 x 107 cells/m2 Dose Level Two: 2 x 107 cells/m2 Dose Level Three: 4 x 107 cells/m2"
47940540|NCT06424665|DRUG|FZ-AD005|Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
48472513|NCT05763849|BEHAVIORAL|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
48630176|NCT05064800|DRUG|PF-07321332/ritonavir + Dabigatran|PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
48286914|NCT05394077|DIAGNOSTIC_TEST|Active Release Technique|Using Active Release Technique
48630177|NCT05064800|DRUG|Ritonavir + Dabigatran|Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
48630178|NCT05316987|RADIATION|Narrow band ultraviolet B|48 sessions of narrow band ultraviolet
48630179|NCT00129558|DRUG|PT-523 for Injection|
47940541|NCT06168760|DIAGNOSTIC_TEST|Anthropometric Measurements|Anthropometric measurements of the hand were measured with a digital caliper. Anthropometric measurements were determined as hand length, width and finger lengths, taking into account previous studies. Manual dexterity was evaluated with the 9-Hole Peg Test.
47940542|NCT02812303|OTHER|Centralized support for population health management activities|
47940543|NCT00843726|RADIATION|Arm 1 stereotactic body radiation therapy|Patients undergo 1 high-dose fraction
47940544|NCT00843726|RADIATION|Arm II stereotactic body radiation therapy|Patients undergo 3 high-dose fractions
47940545|NCT04916782|OTHER|Quality of life Questionnaire|Quality of life questionnaire
47940546|NCT00894127|DEVICE|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
48101653|NCT05165030|GENETIC|Blood Sample|clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
48101654|NCT00169780|RADIATION|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
48286915|NCT05394077|DIAGNOSTIC_TEST|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
48630180|NCT05089175|DRUG|Low-dose aspirin|FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin \~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
48286916|NCT01910506|DRUG|RDEA3170 10 mg|
48286917|NCT06176703|DEVICE|mobile application|using mobile application along with standard treatment of diabetes mellitus
48286918|NCT04937257|OTHER|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
47940547|NCT06349070|BEHAVIORAL|Low Touch - Text Messaging Implementation Strategy|The low touch strategy is designed as a tool to distill and organize the most important information from the Starting Early Program (StEP) original evidenced-based intervention curriculum. Video links are sent to pregnant subjects via automated SMS messaging. Subjects will receive videos (20 videos total) at least weekly lasting 17 to 31 weeks and the duration is based upon the gestational age at enrollment into the study. Subjects will also receive SMS messages in between videos at least weekly to keep them engaged and reinforce the video content delivered. The StEP curriculum is guideline concordant and includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management, enhance prenatal breastfeeding support, and build social support. The StEP curriculum was adapted into brief videos (\<5 minutes), and an additional module on Sleep Health was added.
48101655|NCT01137292|DRUG|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
48101656|NCT02672813|PROCEDURE|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
48101657|NCT05658198|BEHAVIORAL|Counseling|Patients who first decline HPV vaccination receive a 3-5 minute counseling session on HPV and the benefits of the vaccine.
48101658|NCT03586544|DRUG|Albuterol Sulfate|Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
48101659|NCT03586544|BEHAVIORAL|Interval Warm-up exercise|Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
48101660|NCT01123083|BIOLOGICAL|Otelixizumab|infusion
48101661|NCT01123083|BIOLOGICAL|Placebo|Infusion
48101662|NCT05223192|BEHAVIORAL|Music Therapy Entrainment with Ocean Disc Intervention|The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
48286919|NCT04937257|OTHER|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
48286920|NCT04248166|DEVICE|Photoacoustic imaging|"1. Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~2. The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
48101663|NCT04333069|PROCEDURE|cataract surgery|cataract surgery in form of phaco emulsification or irrigation aspiration
48101664|NCT04312568|DRUG|Fadanafil|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
48101665|NCT04312568|DRUG|Placebo|Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
48101666|NCT06486818|PROCEDURE|Ablation of idiopathic monomorphic PVCs|3D carto ablation of idiopathic monomorphic PVCs
48286921|NCT02327650|PROCEDURE|The examinations for bones in joints of OA and RA patients|
48286922|NCT01457339|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
48286923|NCT01457339|DRUG|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
48630181|NCT05000437|OTHER|HIIT|3x/week high intensity interval training for 12 weeks
48630182|NCT02410174|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
48630183|NCT02571231|DEVICE|HFV + and - VG|High frequency ventilation with and without volume guarantuee
48630184|NCT06414018|DRUG|Alfentanil|alfentanil 10ug/kg is used for anesthesia induction
48101667|NCT03276039|DIAGNOSTIC_TEST|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
48101668|NCT04247711|BEHAVIORAL|OTCH|OTCH is structured in three phrases (i. engagement and initial needs assessment, ii. ongoing intervention and monitoring, and iii. transition to long-term services) and lasts an average of two years. OTCH will maintain the central characteristics of the OnTrack model, as well as its core principles, which include (1) Person-centered care, (2) Shared decision-making, (3) Recovery orientation, and (4) Culturally-competent care.
48101669|NCT04247711|BEHAVIORAL|Usual FEP Services|These include services such as psychiatric medication, psychotherapy, and psychoeducation for people with FEP and are usually provided at outpatient mental health clinics.
48101670|NCT05787444|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative and differential detection of nucleocapsid viral antigens from SARS-CoV-2, influenza A, and influenza B in an anterior nares sample (from both nostrils) collected by a healthcare professional for individuals aged 2 years and older. The test is authorized for individuals with symptoms of COVID-19, influenza A and B within the first 6 days of symptom onset.
48101671|NCT06386913|OTHER|Training|Measurement-Based Care Training
48101672|NCT02338739|BEHAVIORAL|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
48101673|NCT02338739|BEHAVIORAL|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
48101674|NCT02338739|BEHAVIORAL|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
48101675|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
48101676|NCT02338739|BEHAVIORAL|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
48101677|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
48472514|NCT05763849|BEHAVIORAL|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
48472515|NCT03877926|BIOLOGICAL|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
48472516|NCT03877926|BIOLOGICAL|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
48472517|NCT00002616|BIOLOGICAL|aldesleukin|
48472518|NCT00002616|BIOLOGICAL|filgrastim|
48472519|NCT00002616|DRUG|carboplatin|
48472520|NCT00002616|DRUG|cyclophosphamide|
48472521|NCT00002616|DRUG|thiotepa|
48472522|NCT00002616|PROCEDURE|peripheral blood stem cell transplantation|
48630185|NCT04822571|OTHER|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
48630186|NCT05080270|BIOLOGICAL|Tolerogenic Fibroblasts|administrating single dose of 100 million tolerogenic fibroblasts via intravenous infusion
48630187|NCT00309244|DRUG|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
48630188|NCT00309244|DRUG|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
48630189|NCT00501085|DEVICE|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
48630190|NCT01824004|DRUG|S-1|
48630191|NCT01332201|DRUG|Advagraf|oral
47940548|NCT06349070|BEHAVIORAL|High Touch - Community Health Worker (CHW) Implementation Strategy|The curriculum will be delivered by CHWs. Each subject will be asked to participate in 1-hour live sessions with a CHW. During the sessions, videos are interspersed with open-ended questions and pauses to discuss these open-ended questions. This results in an interactive session that employs principles of active learning. The curriculum includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management during pregnancy, enhance prenatal breastfeeding support, and build social support and are anchored by the same brief videos developed for the low touch strategy.
47940549|NCT05682248|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
47940550|NCT05682248|DEVICE|Sham Transcranial magnetic stimulation|Sham Transcranial magnetic stimulation
47940551|NCT06329843|DEVICE|Picterus Jaundice Pro (JP)|"Picterus Jaundice Pro photos will be obtained of enrolled subjects each time the patient has a serum bilirubin level obtained. Up to five paired measurements will be obtained per enrolled subject. The study nurse will place the proprietary calibration card over the subject's sternum and take six Picterus Jaundice Pro photos using a study iPhone within one hour of the serum bilirubin draw. This process takes less than one minute. After the study photos are obtained, the study nurse will record the serum and Picterus Jaundice Pro values in the data-recording log.~In the event an enrolled infant requires phototherapy, a light occlusive adhesive patch will be placed over the center of the chest before phototherapy initiation. When a serum bilirubin level is obtained, the research nurse will remove the patch for a brief moment to take Picterus Jaundice Pro pictures (within one hour of the serum value draw)."
47940552|NCT03217981|OTHER|Sepsis protocol|Adherence to the sepsis protocol
47940553|NCT00229918|DRUG|triamcinolone acetonide|
47940554|NCT01402895|OTHER|Exercise|Transversus abdominus exercise
47940555|NCT01402895|OTHER|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
48472523|NCT01745068|OTHER|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
48630192|NCT01332201|DRUG|Prograf|oral
48472524|NCT01321437|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48101678|NCT02338739|BEHAVIORAL|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
48472525|NCT01321437|OTHER|laboratory biomarker analysis|Correlative studies
48630193|NCT00177632|BEHAVIORAL|behavioral weight loss|
48472526|NCT01321437|DRUG|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
48472527|NCT01321437|OTHER|pharmacological study|Correlative studies
48472528|NCT05308823|PROCEDURE|Stent|The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
48472529|NCT02159287|DRUG|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
48472530|NCT02159287|DRUG|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
48630194|NCT01271166|DRUG|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
48630195|NCT05124678|DRUG|Isoniazid Tablets|High dose of isoniazid
48286924|NCT05850377|DRUG|5-Aminolevulinic Acid (5-ALA) Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
48286925|NCT05850377|PROCEDURE|Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)|During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.
48286926|NCT01163422|DEVICE|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
48286927|NCT04020432|BEHAVIORAL|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
48286928|NCT00954785|DEVICE|Ankle brace|Sports Stirrup ankle brace (Aircast)
48286929|NCT00954785|DRUG|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
48286930|NCT00954785|DRUG|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
48472531|NCT00069030|BIOLOGICAL|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
48472532|NCT04950686|BEHAVIORAL|Media Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults that uses a media literacy education (MLE) approach.
48472533|NCT04950686|BEHAVIORAL|Health Aware for Young Adults|Media Aware for Young Adults is a web-based sexual and relationship health promotion program designed for young adults.
48472534|NCT03241745|DRUG|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
48472535|NCT03514355|BEHAVIORAL|Mindfulness-Based Stress Reduction|8 weekly 2.5 h sessions plus one day of practice
48472536|NCT06535555|DEVICE|Investigational Safety and Feasibility|"Technical feasibility will be assessed based on a five-point rating scale assessing the ease-of-use, ureteral visibility, and time required to identify the ureter using ActivSight™. All images and video of the ureter will be recorded, but surgeon feedback will be used to assess technical success based on a five point scale, rather than these (subsequently de-identified) recordings.~Safety will be confirmed through clinical assessments and evaluation of adverse events intraoperatively and through a 28-day follow-up period using the criteria listed below. All adverse events will be adjudicated by the site's Principal Investigator (PI) to judge the relatedness of the adverse event to either the administration of riboflavin or the use of the prototype ActivSight™ device (or whether the adverse event was unrelated to either)"
48630196|NCT03043820|DRUG|Raloxifene|Oral selective estrogen receptor modulator (SERM).
48630197|NCT03043820|DRUG|Placebo|Tablets identical in form and color to intervention.
48630198|NCT03083041|BIOLOGICAL|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
48101679|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
48286931|NCT00006061|DRUG|phosphatidylcholine|
48286932|NCT05109390|DRUG|Danicopan|Oral tablet.
48286933|NCT05109390|DRUG|Cyclosporine|Oral capsule.
48286934|NCT05109390|DRUG|Tacrolimus|Oral capsule.
48630199|NCT03083041|DRUG|Apatinib|Apatinib tablet will be administered orally,once daily until progression
48630200|NCT03329248|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48286935|NCT05109390|DRUG|Calcium Carbonate|Chewable tablet.
48286936|NCT05109390|DRUG|Aluminum/Magnesium Hydroxide/Simethicone|Chewable tablet.
48286937|NCT05109390|DRUG|Omeprazole|Oral, delayed-release capsule.
48286938|NCT03531229|DRUG|Placebo|Placebo to Lu AF76432 oral solution
48630201|NCT03329248|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
48286939|NCT03531229|DRUG|Lu AF76432|Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
48286940|NCT02215265|DRUG|Cisplatin|Chemotherapy
48286941|NCT02215265|RADIATION|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
48630202|NCT03329248|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
48286942|NCT04721314|DEVICE|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF \>50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
48630203|NCT03329248|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
47940556|NCT00446589|DRUG|ibandronate|iv 1mg ibandronate monthly for one year
47940557|NCT00446589|DRUG|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
47940558|NCT01125501|DIETARY_SUPPLEMENT|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
47940559|NCT00084838|BIOLOGICAL|filgrastim|
47940560|NCT00084838|DRUG|cisplatin|
47940561|NCT00084838|DRUG|cyclophosphamide|
47940562|NCT00084838|DRUG|cytarabine|
48286943|NCT04721314|DEVICE|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
48286944|NCT02691273|BEHAVIORAL|cellular application treating diabetes using breathing technique|
48286945|NCT05713955|DEVICE|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
48286946|NCT06075056|OTHER|No Intervention|No intervention is planned as part of this study, this is a feasibility/pilot study
48286947|NCT03019549|DRUG|Lanabecestat|Administered orally
48286948|NCT03019549|DRUG|Rosuvastatin|Administered orally
48286949|NCT00365781|DRUG|ISIS 113715|
47940563|NCT00084838|DRUG|dexrazoxane hydrochloride|
48286950|NCT05136391|DRUG|XTR003|Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
48286951|NCT00648310|DRUG|Tolterodine 4 mg|
48286952|NCT00648310|DRUG|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
48286953|NCT04146545|BEHAVIORAL|"Community Rx-Dementia CRxD Caregiver Resources"|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
48286954|NCT03161418|DRUG|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
48630204|NCT03329248|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
48630205|NCT03329248|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
48630206|NCT03329248|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
47940564|NCT00084838|DRUG|doxorubicin hydrochloride|
47940565|NCT00084838|DRUG|etoposide|
47940566|NCT00084838|DRUG|leucovorin calcium|
47940567|NCT00084838|DRUG|methotrexate|
47940568|NCT00084838|DRUG|temozolomide|
47940569|NCT00084838|DRUG|therapeutic hydrocortisone|
47940570|NCT00084838|DRUG|vincristine sulfate|
48630207|NCT03329248|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48286955|NCT03161418|DRUG|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
48286956|NCT03138915|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
48286957|NCT03138915|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
48286958|NCT02621333|BIOLOGICAL|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
48286959|NCT02621333|DRUG|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
48286960|NCT05252520|DRUG|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
48286961|NCT06408090|OTHER|IDECIDE-HOSPICE|12-pg educational booklet detailing information about hospice including what hospice is, why someone would use hospice, who pays for hospice, and where hospice services are delivered
48286962|NCT00249561|BEHAVIORAL|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
48286963|NCT00249561|BEHAVIORAL|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg \& Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
48286964|NCT02655198|DRUG|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
48286965|NCT03935854|OTHER|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
48286966|NCT06011070|BEHAVIORAL|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
48286967|NCT01364415|DRUG|Pasireotide LAR|
48286968|NCT06052462|DRUG|[14C]-LY3556050|Administered orally
47940571|NCT00084838|RADIATION|radiation therapy|
47940572|NCT00084838|DRUG|Dactinomycin|
48286969|NCT02280811|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.
48286970|NCT02280811|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
48286971|NCT02280811|BIOLOGICAL|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
48472537|NCT04554147|BEHAVIORAL|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
48472538|NCT05167045|BEHAVIORAL|Brain Health PRO|The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
48472539|NCT02539784|DEVICE|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
47940573|NCT03961373|PROCEDURE|Gastrectomy with D2 lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
47940574|NCT03961373|PROCEDURE|Gastrectomy with D2plus lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
48286972|NCT02280811|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
48472540|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
48472541|NCT02224053|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
48472542|NCT02224053|DRUG|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
48472543|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
48472544|NCT01007019|DRUG|YH4808 30mg|YH4808 30mg (single dose)
48472545|NCT01007019|DRUG|YH4808 50mg|YH4808 50mg (single dose)
48630208|NCT03329248|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48630209|NCT03329248|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
48630210|NCT03329248|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
48630211|NCT03329248|DRUG|lovaza|Omega-3-acid ethyl esters
48630212|NCT03329248|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
48630213|NCT03329248|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
48630214|NCT05703412|BEHAVIORAL|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
48472546|NCT01007019|DRUG|YH4808 100mg|YH4808 100mg (single dose)
48472547|NCT01007019|DRUG|YH4808 200mg|YH4808 200mg (single dose)
48630215|NCT05703412|BEHAVIORAL|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
48630216|NCT05111769|DRUG|Recombinant human brain natriuretic peptide|1. To determine the effect of rhBNP on hemodynamics in sepsis based on PiCCO hemodynamic monitoring; 2. To collect and sort out the relevant data to determine the effects of rhBNP on cardiac function and kidney function, including cardiac ultrasound, kidney blood flow index and related laboratory tests. 3. To determine the effect of rhBNP on the final prognosis of patients, including ICU mortality and hospital mortality, ICU time, hospital stay, ventilator use time, kidney replacement therapy time, vasoactive drug dosage and time.
48630217|NCT00870155|DRUG|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
48630218|NCT00105508|DRUG|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
47940575|NCT01764035|BEHAVIORAL|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
48286973|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|
48472548|NCT01007019|DRUG|YH4808|YH4808 400mg (single dose)
48472549|NCT01007019|DRUG|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
48472550|NCT01007019|DRUG|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
48472551|NCT01007019|DRUG|YH4808 600mg|YH4808 600mg
48472552|NCT01007019|DRUG|YH4808 800mg (single dose)|YH4808 800mg (single dose)
48472553|NCT01007019|DRUG|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
48286974|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|
48472554|NCT01007019|DRUG|Placebo|10 volunteers will be administered matched placebo.
48472555|NCT01007019|DRUG|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
48472556|NCT01188226|DEVICE|Denture teeth|Denture teeth made of nano hybrid composite material
48472557|NCT03538925|BEHAVIORAL|AAC Generative Language Intervention|Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention
48472558|NCT03538925|BEHAVIORAL|Standard of Care / Business as Usual|Parent/Caregiver AAC App Operational Training
48472559|NCT04838379|DRUG|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB\&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block \& tap block was performed
48472560|NCT04139863|DIAGNOSTIC_TEST|aMMP-8 chairside test|No test
48472561|NCT01940263|DIETARY_SUPPLEMENT|Anthocyanin|
48472562|NCT01940263|DIETARY_SUPPLEMENT|Placebo|
48472563|NCT02091310|DRUG|Placebo|
48472564|NCT02091310|DRUG|GFT505|
48472565|NCT02091310|DRUG|Moxifloxacin 400 mg|
48472566|NCT04101695|DEVICE|tDCS|Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
48630219|NCT00105508|DRUG|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
48630220|NCT04162275|DRUG|Finamine tablets|taken Finamine tablets orally
48630221|NCT04162275|DRUG|Placebo tablets|taken Placebo tablets orally
48472567|NCT02476188|PROCEDURE|Sample of Blood|
48286975|NCT04243044|DEVICE|Transcutaneous spinal stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
48101680|NCT02338739|BEHAVIORAL|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
48101681|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
48101682|NCT02338739|BEHAVIORAL|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
48286976|NCT01211691|DRUG|KB004, Monoclonal Antibody|
48286977|NCT02765893|OTHER|No Foley|Patients will have Foley catheter removed 6 hours post-op.
47940576|NCT01764035|BEHAVIORAL|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
48286978|NCT01098968|BEHAVIORAL|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
48286979|NCT02185469|PROCEDURE|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
48286980|NCT02185469|PROCEDURE|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
48286981|NCT02185469|DRUG|sulfur hexafluoride (SF6)|
48286982|NCT02185469|DEVICE|5/8-in 25-gauge needle|
48286983|NCT02185469|DEVICE|laser|intraoperative laser retinopexy
48286984|NCT00677950|PROCEDURE|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
48286985|NCT02914626|DRUG|Intravitreal ranibizumab|Intravitreal ranibizumab injection
48286986|NCT00002042|DRUG|Epoetin alfa|
48286987|NCT03823638|DIETARY_SUPPLEMENT|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
48286988|NCT06388720|DRUG|Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml|Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml.
48286989|NCT00101361|DRUG|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
48472568|NCT06427187|DEVICE|an array of devices are used in thrombectomy. These include guide catheters, stent-retrievers, microcatheters, aspiration catheters, and aspiration pump systems|each patient with distal vessel occlusion subjected to mechanical thrombectomy using aspiration technique or stent retriever
48472569|NCT04674709|DRUG|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
48472570|NCT04674709|DRUG|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
48472571|NCT04674709|DRUG|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
48472572|NCT04674709|DRUG|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
48472573|NCT01069796|DRUG|Paclitaxel|80 mg/m² weekly
48286990|NCT00101361|DRUG|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
48472574|NCT01069796|DRUG|Bevacizumab|10 mg/kg d1 d15
47940577|NCT03845049|OTHER|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
48286991|NCT02225886|DRUG|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
48472575|NCT01069796|DRUG|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
48472576|NCT01012141|DIETARY_SUPPLEMENT|phytochemical|
48472577|NCT01012141|DRUG|Docetaxel|
48472578|NCT02735694|DRUG|Cycloserine|Capsule containing 250 mg of Cycloserine
48286992|NCT05593601|DRUG|Neomycin|Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
48286993|NCT00735423|DEVICE|No intervention|IDE used for outcome measurement not intervention
48286994|NCT03069638|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
48472579|NCT02735694|DRUG|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
48472580|NCT03423667|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
48630222|NCT01665378|DIETARY_SUPPLEMENT|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)\* 2800 Iron (mg)\* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
48472581|NCT03423667|DRUG|Lactose powder|Placebo comparator.
48472582|NCT00917735|DRUG|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
48630223|NCT01665378|DIETARY_SUPPLEMENT|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
48630224|NCT01665378|DIETARY_SUPPLEMENT|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
48630225|NCT03611127|OTHER|pulmonary rehabilitation|pulmonary rehabilitation standardized program
48630226|NCT02113566|DRUG|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
48472583|NCT00917735|OTHER|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
48630227|NCT00373087|DRUG|entacapone|entacapone
48630228|NCT00373087|DRUG|l dopa versus placebo|l dopa versus placebo
48630229|NCT02643784|DRUG|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
48630230|NCT02643784|OTHER|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
48630231|NCT01297114|DRUG|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
48472584|NCT01241682|BIOLOGICAL|DC + CTX|3x 50x10e6 DC + cyclophosphamide
48472585|NCT02550587|BEHAVIORAL|satisfaction|anesthesia satisfaction rates
48286995|NCT03069638|DRUG|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
48472586|NCT02658019|DRUG|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
48286996|NCT04402489|DRUG|Placebo|Placebo
48286997|NCT04402489|DRUG|MT-7117 Low Dose|MT-7117 Low Dose
48286998|NCT04402489|DRUG|MT-7117 High Dose|MT-7117 High Dose
48472587|NCT04093154|DEVICE|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
48472588|NCT00964873|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
48630232|NCT05838170|DRUG|Lotilaner Gel, 2.0%|Lotilaner Gel, 2.0% (TP-04) is an aqueous gel formulation of lotilaner, a member of the isoxazoline family of compounds and parasiticide that selectively inhibits parasite-specific gamma-aminobutyric acid (GABA)-gated chloride channels (GABA-Cls).
48630233|NCT05838170|OTHER|Vehicle control gel|Aqueous gel
48630234|NCT02528136|DRUG|Carbetocin|
48630235|NCT02528136|DRUG|Oxytocin|
48630236|NCT06296693|DEVICE|Pocket-size lung ultrasound for etiological definition of pneumonia and surveillance of complications in children hospitalized|The investigators will study the diagnostic accuracy of a pocket-size POCUS device vs. CXR for the etiological diagnosis of CAP, in paediatric age. During 1 year, all children aged \>12 months and \<18 years admitted to the Paediatric Department with the diagnosis of CAP on admission will be included. At least 76 participants will be required. Two investigators will perform, independently, a POCUS at admission, daily during hospitalization, 15 days and 1 month after discharge. All children will also undergo a CXR upon admission and whenever necessary. A third investigator will classify the CXR independently. It will be used the General Electrics Vscan AirTM®, with Bluetooth connection to smartphone/tablet. It will be collected the systematized description of POCUS and CXR, sociodemographic, clinical and therapeutic variables.
48630237|NCT02890888|OTHER|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
48630238|NCT05157763|DRUG|EscharEx 5% (EX-02 formulation)|EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
47940578|NCT03845049|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
48101683|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
48286999|NCT03283839|DIAGNOSTIC_TEST|Posturography|Evaluation of postural control and of orientation function
48287000|NCT02981472|DRUG|Apixaban|Specified dose on specified days
48287001|NCT02981472|DRUG|Vitamin K Antagonist (VKA)|Specified dose on specified days
48287002|NCT02981472|DRUG|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
48287003|NCT01300143|OTHER|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
48287004|NCT01300143|OTHER|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
48287005|NCT01435512|BEHAVIORAL|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
48287006|NCT00233779|DEVICE|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
48287007|NCT02734550|OTHER|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
48472589|NCT02927834|DRUG|6 day Prednisone|6 day prednisone burst
48630239|NCT04243837|DRUG|LYT-100 BCRL|BCRL patients will receive LYT-100 BID for 6 months
48472590|NCT02927834|DRUG|Augmentin|Antibiotic augmentin for 3 weeks
48472591|NCT02927834|DRUG|21 day Prednisone|21 day prednisone burst
48472592|NCT00249015|BEHAVIORAL|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
48472593|NCT05105919|DRUG|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
48472594|NCT00820508|DRUG|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
48472595|NCT01620281|DEVICE|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
48630240|NCT04243837|DRUG|Placebo BCRL|BCRL patients will receive Placebo BID for 6 months
48630241|NCT01328626|DRUG|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
48630242|NCT01420978|PROCEDURE|CSF Diversion|CSF drainage
48630243|NCT00425139|BEHAVIORAL|Re-Mission|
48630244|NCT00481104|DRUG|Tesofensine|
48630245|NCT01850940|DRUG|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
48630246|NCT01850940|OTHER|conventional thearpy|conventional therapy with salt limitation ,et al
48472596|NCT04878237|OTHER|Nasal Secretion Sampling|Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
48472597|NCT03095755|OTHER|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
48472598|NCT03095755|OTHER|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
48472599|NCT00359671|DRUG|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
48472600|NCT00359671|DRUG|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
48472601|NCT03627598|DEVICE|HFNC|patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
48472602|NCT03627598|DEVICE|standard|patients will receive low flow oxygen therapy at 1 to 4 liters per minute
48472603|NCT06056791|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.
48472604|NCT06190886|DRUG|PTX-912|Investigation Product Monotherapy
48472605|NCT05654194|DRUG|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
48472606|NCT05683691|DEVICE|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
48472607|NCT01405274|OTHER|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
48472608|NCT04980456|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
48472609|NCT04980456|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
48472610|NCT04980456|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
48630247|NCT04922762|BEHAVIORAL|Moderate Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 3 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
47940579|NCT03845049|DRUG|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
48472611|NCT00039910|DRUG|(PN-152,243)/ PN-196,444|
48472612|NCT05152615|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFA) Dietary Supplement|Butryate 1000 mg three times daily will be used in this study.
48472613|NCT05629923|DRUG|tixagevimab-cilgavimab(AZD7442, AstraZeneca)|In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
48472614|NCT00781430|DRUG|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
48472615|NCT03768349|DRUG|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
48472616|NCT03768349|DRUG|F-18 PSMA 1007|F-18 PSMA 1007 PET/CT for detection of tumor location
48472617|NCT01071850|DRUG|ipragliflozin|oral tablet
48472618|NCT01071850|DRUG|Metformin|oral tablet
48472619|NCT01071850|DRUG|Placebo|oral tablet
48472620|NCT02824887|OTHER|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
48472621|NCT02824887|OTHER|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
48472622|NCT02221440|DEVICE|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
48472623|NCT02221440|DEVICE|Low flow room air|Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
48472624|NCT06060184|GENETIC|Next-Generation Sequencing (NGS)|Sequencing of genomes (Long read NGS)
47940580|NCT03845049|OTHER|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
47940581|NCT00546468|PROCEDURE|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
48472625|NCT03730181|DRUG|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
48472626|NCT03730181|DRUG|Isoniazid|Isoniazid. 25mg/kg
48472627|NCT04650750|DRUG|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
48472628|NCT04650750|DRUG|Placebo|Similar placebo 4g twice a day for two months
48472629|NCT04356807|PROCEDURE|Reflex Locomotion Therapy|The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.
48287008|NCT02734550|OTHER|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
47940582|NCT00546468|PROCEDURE|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
47940583|NCT01155219|DRUG|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
47940584|NCT01155219|DRUG|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
48287009|NCT00131443|DRUG|Topiramate|
47940585|NCT03127787|DIAGNOSTIC_TEST|CMV Assay|Molecular diagnostic test to detect CMV
48287010|NCT04369339|OTHER|Colposcopy|
48287011|NCT01472237|OTHER|Nutritional intervention|Modification of diet
48287012|NCT00745030|DRUG|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
48287013|NCT00745030|DRUG|Placebo|Placebo 8 mg tablets
48287014|NCT01701700|PROCEDURE|portable electronic magnifier|
48472630|NCT04356807|PROCEDURE|Passive Joint Mobilizations|Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008
48472631|NCT04356807|PROCEDURE|Massage|Soft massage with soft pressures in limbs, tactile stimulation and no motion.
48472632|NCT03731728|BEHAVIORAL|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
48472633|NCT03731728|BEHAVIORAL|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
48472634|NCT01795235|DRUG|Saline|Saline s.c.
48472635|NCT01795235|DRUG|Glucagon|Glucagon s.c.
48472636|NCT01795235|DRUG|Placebo|Sugar Pill
48472637|NCT01795235|DRUG|Atenolol|Beta-1 receptor antagonist
48472638|NCT02510261|DRUG|Patisiran|Patisiran was administered IV.
48472639|NCT03164109|DRUG|GC4419 IV|50mg infused IV over 15 minutes
48472640|NCT03164109|DRUG|Placebo|Infused IV over 15 minutes
48472641|NCT03164109|DRUG|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
48472642|NCT02043158|BEHAVIORAL|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
48472643|NCT02043158|BEHAVIORAL|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
48472644|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
48472645|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
48287015|NCT01701700|PROCEDURE|optical aids|
48472646|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
48472647|NCT03355352|DRUG|Sufentanil|Sufentail sublingual 15ug nanopills
48472648|NCT00233155|DRUG|Capsaicin Dermal Patch|
48472649|NCT02913131|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
48472650|NCT02913131|DEVICE|MRI|MRI scan following the pyruvate (13c) injection
48617958|NCT01192815|RADIATION|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
47940586|NCT01732731|OTHER|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
47940587|NCT04640181|DRUG|Enoxaparin|Subcutaneous enoxaparin While hospitalized only.
47940588|NCT04640181|DRUG|Rivaroxaban|Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.
47940589|NCT02800759|DIETARY_SUPPLEMENT|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
47940590|NCT02800759|DIETARY_SUPPLEMENT|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
48287016|NCT00059761|DRUG|cisplatin|
48287017|NCT00059761|DRUG|irinotecan hydrochloride|
48287018|NCT00059761|RADIATION|radiation therapy|
48287019|NCT05741021|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
48287020|NCT05741021|DRUG|Pemetrexed|A chemotherapy medication used to treat a number of types of cancer.
48287021|NCT05741021|DRUG|Carboplatin|A chemotherapy medication used to treat a number of types of cancer.
48287022|NCT05741021|DRUG|Paclitaxel|A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
48287023|NCT06114082|PROCEDURE|IDA-TACE|Stable chemoemulsion will be produced by dissolving 10 mg of idarubicin powder (Zavedos; Pfizer, New York, NY, USA) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
48287024|NCT06114082|PROCEDURE|DOX-TACE|Stable chemoemulsion will be produced by dissolving 50 mg of doxorubicin powder (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Republic of Korea) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
48287025|NCT00133744|DIETARY_SUPPLEMENT|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
48287026|NCT00133744|DIETARY_SUPPLEMENT|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
48287027|NCT00133744|DIETARY_SUPPLEMENT|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
48287028|NCT06010810|DRUG|3 % Topical Tranexamic Acid|Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
48287029|NCT06010810|DRUG|4% Topical Hidroquinone|Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
48287030|NCT02851654|DEVICE|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
48472651|NCT04249596|DRUG|Tianeptine Sodium|At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
48472652|NCT00661921|BIOLOGICAL|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
48472653|NCT00661921|BIOLOGICAL|Placebo|AMG 108 volume matching placebo
48630248|NCT04922762|BEHAVIORAL|High Intensity, Normal Volume Exercise Training|"Week 1 3 days/week for 31 minutes/day 10 minute warm up at 50% of heart rate maximum 2 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 7 minute cool down at 50% of heart rate maximum~Week 2 3 days/week for 38 minutes/day 10 minute warm up at 50% of heart rate maximum 3 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 2 TIMES 7minute cool down at 50% of heart rate maximum~Weeks 3-10 3 days/week for 45 minutes/day 10 minute warm up at 50% of heart rate maximum 4 x 4 minute intervals 4 minutes at 90-95% of heart rate maximum 3 minutes at 70% of heart rate maximum REPEAT 3 TIMES 7 minute cool down at 50% of heart rate maximum"
48630249|NCT04922762|BEHAVIORAL|Moderate Intensity, High Volume Exercise Training|"Week 1 5 days/week for 20 minutes/day Performed at 70% of heart rate maximum~Week 2 5 days/week for 30 minutes/day Performed at 70% of heart rate maximum~Weeks 3-10 5 days/week for 45 minutes/day Performed at 70% of heart rate maximum"
47940591|NCT02800759|DIETARY_SUPPLEMENT|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
48472654|NCT06126328|DEVICE|Materna Prep Device|Subjects are treated with Materna Prep Device prior to vaginal delivery
48287031|NCT03118843|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
47940592|NCT02800759|DIETARY_SUPPLEMENT|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
47940593|NCT05922553|BEHAVIORAL|Active Ingredient Mukbang|Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.
47940594|NCT05922553|BEHAVIORAL|Common Mukbang|Common Mukbang videos made and uploaded by the famous Mukbang makers.
47940595|NCT05922553|BEHAVIORAL|General short videos|Short videos that don't contain any food cues.
48287032|NCT04135625|BEHAVIORAL|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
48287033|NCT04135625|BEHAVIORAL|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
48287034|NCT02608164|DIETARY_SUPPLEMENT|3000IU(75μg) vitamin D3|
48287035|NCT00168012|DRUG|Immunoglobulins Intravenous (Human)|
48472655|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization
48472656|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study
48617959|NCT01192815|OTHER|biopsy|Optional correlative studies
48287036|NCT06345040|BEHAVIORAL|Virtual-reality intervention|For the experimental condition, participants will receive seven individual sessions of Virtual Reality Therapy conducted by a therapist trained in both eating disorder psychotherapy and virtual reality-based therapy, including avatar therapy. In the initial stage of therapy participants create a virtual avatar embodying their eating disorder voice. This enables the person to engage in real time face to face dialogue with the eating disorder voice. The main goal of the intervention is to encourage participants to stand up to the negative comments and commands made by the eating disorder voice and hereby increase their power and agency in the context of the eating disorder voice.
48472657|NCT01894230|GENETIC|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele
48472658|NCT00476437|DRUG|biphasic insulin aspart|
48472659|NCT00476437|DRUG|biphasic human insulin|
48472660|NCT01465568|DRUG|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
48472661|NCT01465568|DRUG|bisphosphonates|continue present bisphosphonate treatment
47940596|NCT00286611|PROCEDURE|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
48472662|NCT01475786|BIOLOGICAL|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
48472663|NCT01475786|BIOLOGICAL|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
48472664|NCT01475786|OTHER|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
48472665|NCT03785145|DRUG|MT10109L|MT10109L will be injected into the LCL.
48472666|NCT03785145|DRUG|Placebo|Placebo will be injected into the LCL.
48617960|NCT01192815|OTHER|pharmacological study|Optional correlative studies
48617961|NCT01192815|OTHER|laboratory biomarker analysis|Optional correlative studies
48617962|NCT01192815|OTHER|questionnaire administration|Optional ancillary studies
48287037|NCT06345040|BEHAVIORAL|TAU - specialized treatment|The control condition encompasses treatment as usual comprising seven sessions of specialized treatment, such as individual or group psychotherapy and dietary guidance, provided by interdisciplinary health professionals.
48287038|NCT00638846|DEVICE|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
48287039|NCT00638846|DEVICE|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
48287040|NCT04964401|PROCEDURE|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
48472667|NCT01058928|OTHER|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
48472668|NCT05103449|OTHER|Video Coaching|Video-based coaching sessions after salpingectomy 1 and 2
48630250|NCT02382900|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
48287041|NCT05058378|DEVICE|perfusion index measurement|Clip will be attached to the patient's toe for perfusion index measurement
48287042|NCT00960557|DRUG|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
48287043|NCT01137630|DRUG|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
48472669|NCT05120791|DIETARY_SUPPLEMENT|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
48630251|NCT05756907|BIOLOGICAL|SON-1010|SON-1010 +/- Atezolizumab
47940597|NCT02908893|BEHAVIORAL|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
47940598|NCT04153071|DEVICE|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
47940599|NCT02097537|DRUG|Methacholine Chloride (SK-1211)|
48287044|NCT01137630|DRUG|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
48287045|NCT01137630|DRUG|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
48287046|NCT01652833|OTHER|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
48287047|NCT05952830|OTHER|ESWT group|subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
48287048|NCT05952830|OTHER|DN group|Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
48472670|NCT05120791|DIETARY_SUPPLEMENT|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
48472671|NCT05120791|DIETARY_SUPPLEMENT|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
48472672|NCT05120791|DIETARY_SUPPLEMENT|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
48472673|NCT04752319|DEVICE|BreEStim|BreEStim will be applied for 10 to 20 minutes per session for multiple sessions
47940600|NCT01850264|DEVICE|Application of quadripolar / bipolar LV electrodes|
48287049|NCT02424487|PROCEDURE|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
48287050|NCT03168061|DRUG|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
48287051|NCT02436239|DRUG|Vilazodone|Vilazodone tablets, once daily, oral administration
48287052|NCT06407518|DRUG|Midazolam oral solution|Each individual administers the midazolam oral solution nightly from enrollment to the surgry.
48630252|NCT04817579|DEVICE|Digital photography combined with eLABor_aid shade analyzing software|ELABor_aid is a new approach to objective shade communication and shade reproduction in dentistry, based on numeric quantification obtained from standardized RGB (red-green-blue) images, and the formulation of a patient personal shade recipe using trichromatic subtractive color mixing laws, thus abandoning the use of visual assessment and shade guides entirely. This approach is currently enjoying increasing popularity for its ease of use, reliability as well as for its practically oriented features like its imaging ability or the digital try-in.
48630253|NCT04817579|DEVICE|Spectrophotometer|Spectrophotometric measurement methods employing computer calculations, based on color science and theories, allow quantitative evaluation which is objective and appears to be more accurate.
48630254|NCT04817579|DEVICE|Conventional visual shade matching|Visual shade matching is the most common method, in which a color standard from a commercially available dental shade guide is compared to and matched with the target tooth.
48472674|NCT04752319|DEVICE|EStim|EStim will be applied for 10 to 20 minutes per session for multiple sessions
48287053|NCT06407518|OTHER|Placebo|Each individual administers placebo solution nightly from enrollment to the surgry.
48287054|NCT05614947|DIETARY_SUPPLEMENT|Powdered tart cherry|500 mg freeze-dried tart cherry per capsule
48287055|NCT05614947|DIETARY_SUPPLEMENT|Placebo|500 mg colored cornstarch per capsule
48287056|NCT04045912|OTHER|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
48287057|NCT04045912|OTHER|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
48472675|NCT03334149|OTHER|Self-Monitoring of Blood Pressure|"BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system."
48472676|NCT01139606|OTHER|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
48287058|NCT02260011|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
48287059|NCT02260011|DRUG|Atrovent® CFC inhalation aerosol|
48287060|NCT02260011|DRUG|Placebo|
48287061|NCT02904564|DRUG|MMP with 5-FU|MMP with 5-FU using tattoo device
48287062|NCT02904564|DRUG|MMP with Saline infusion|MMP with saline infusion using tattoo device
48472677|NCT01083238|DRUG|AZD5069|120mg single oral dose
48472678|NCT05054049|DEVICE|Interventional Diagnostic Device Arm|Point of care testing venous blood diagnostic device.
48472679|NCT05054049|OTHER|Usual care|Usual care provided to patient without use of point of care testing device
48472680|NCT05665517|DEVICE|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed."
48472681|NCT05898763|DRUG|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
48472682|NCT00145613|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
48472683|NCT00145613|DEVICE|Miltenyi Biotec CliniMACS|stem cell selection device
48472684|NCT00145613|DRUG|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
48472685|NCT00200317|BEHAVIORAL|Internet and print-based interventions|
47940601|NCT03395925|DEVICE|Celon Pro Surge|bipolar coagulation electrode intended for tissue heating
48287063|NCT00337532|DRUG|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
48287064|NCT00337532|DRUG|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
47940602|NCT02793466|DRUG|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
47940603|NCT00015938|BIOLOGICAL|filgrastim|
48472686|NCT02919189|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
48287065|NCT04776343|OTHER|telemedecine follow-up|weekly home-based follow-up of visual acuity on electronic tablet
48287066|NCT00405041|DIETARY_SUPPLEMENT|Dietary supplement GVG 2|2.670 g/day for 14 days
48287067|NCT01079923|DIETARY_SUPPLEMENT|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
48472687|NCT04712084|PROCEDURE|Positive pressure|Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
48472688|NCT06677879|RADIATION|Proton radiotherapy|"Lumpectomy group: The total dose was 40.05Gy (RBE) , 2.67Gy (RBE) per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy (RBE) , 2.66Gy (RBE) per fraction with 16 fractions. Once a day, five times a week."
48472689|NCT06677879|RADIATION|Photon radiotherapy|"Lumpectomy group: The total dose was 40.05Gy, 2.67Gy per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy, 2.66Gy per fraction with 16 fractions. Once a day, five times a week."
48287068|NCT01079923|DIETARY_SUPPLEMENT|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
48287069|NCT05942690|PROCEDURE|manual osteopathic intervention|The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
48287070|NCT04057963|OTHER|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
48287071|NCT04057963|OTHER|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
48287072|NCT03828292|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as an intravenous infusion.
48287073|NCT03828292|DRUG|Bortezomib|Bortezomib solution for injection will be administered subcutaneously.
48287074|NCT03828292|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally.
48287075|NCT03828292|DRUG|Pomalidomide|Pomalidomide capsules will be administered orally.
48472690|NCT01595841|DRUG|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
48472691|NCT04559750|BEHAVIORAL|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
48472692|NCT05392569|OTHER|Deep Brain Stimulation|"In addition to standard micro electrode recordings, we propose to measure:~1. surface potentials at the scalp (EEG) evoked by stimulation at the DBS electrode site~2. micro electrode potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~3. local field potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~4. surface EMG in the first dorsal interosseus and gastrocnemius muscles during stimulation at the DBS electrode site."
48287076|NCT05934760|OTHER|High intensity interval training (HIIT)|"Each HIIT session last 15 minutes. Participants will be asked to measure their own heart rate during their rest periods and provided with an estimated max heart rate which they should be aiming to achieve within the final 2 exercises. Participants will be provided with a logbook to record the heart rate achieved in each exercise. The regimen will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot"
48472693|NCT03245437|DRUG|Oxytocin nasal spray|nasal spray
48472694|NCT03245437|BEHAVIORAL|Social Cognition Skills Training|Group based training in social cognition skills
48472695|NCT03245437|BEHAVIORAL|Health Management|Group-based training in mental health management
48472696|NCT03245437|DRUG|Placebo nasal spray|placebo condition
48472697|NCT02166853|DRUG|sevoflurane|Sedation with inhaled sevoflurane
48472698|NCT02166853|DRUG|midazolam|Sedation with intravenous midazolam
48472699|NCT04709224|DRUG|Lumateperone Long-Acting Injectable|Lumateperone Long-Acting Injectable
47940604|NCT00015938|DRUG|docetaxel|
48472700|NCT05577494|OTHER|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
48472701|NCT05002881|OTHER|Moringa oleifera (E-HS-01)|One capsule to be taken stat
48472702|NCT05002881|OTHER|Placebo|One capsule to be taken stat
48472703|NCT02879773|RADIATION|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
48472704|NCT05226741|DEVICE|Head protection device|The participants are fitted with a form of head protection over the craniectomy and provide feedback on design, use, and comfort
48472705|NCT00942812|OTHER|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
47940605|NCT00015938|DRUG|vinorelbine|
48287077|NCT05934760|OTHER|Resistance based training (RET)|"Each RET session lasts an estimated 20minutes. Participants will be provided with a set of resistance bands to provide resistance to their workout, and a logbook to record the number of repetitions and band used.~Each session will include:~* 2 min warm-up jogging on the spot~* 2 sets of 12-15 repetitions of:~* Squats~* Hip flexion~* Hip extension~* Hip abduction~* Seated row~* Bench press~* Lateral raises~* 2 min jogging on the spot cooldown.~Each exercise will be separated by 1-minute rest, with participants encouraged to workout to mild fatigue on their final repetition in each set. If able to perform more than the allocated maximum of 15 repetitions prior to fatigue, then participants will be informed to increase the resistance by using a tougher resistance band."
48287078|NCT02309710|DEVICE|ShangRing|ShangRing administered to males seeking medical male circumcision
48287079|NCT03348683|DRUG|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
48287080|NCT03348683|DRUG|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
48287081|NCT02428140|DEVICE|Medtronic Reveal LINQ|
48287082|NCT02428140|DEVICE|Sorin Spiderflash-t|
48287083|NCT05542615|DRUG|Prolonged-Release Pirfenidone|1200 mg / day of Pirfenidone (KitosCell® LP)
48287084|NCT06513598|PROCEDURE|Major visceral surgery for gastrointestinal cancer|This is a longitudinal observational study of the patients undergoing major visceral surgery for gastrointestinal cancer. Biological samples will be collected to compare gastrointestinal and infection site metastases and develop biomarkers for postoperative infections.
48287085|NCT00077987|DRUG|SU011248|
48287086|NCT04652362|BEHAVIORAL|Growth Mindset Online Single-Session Intervention|During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.
48287087|NCT04652362|BEHAVIORAL|Supportive Therapy Online Single-Session Intervention (Control)|The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
48287088|NCT04230850|OTHER|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
48287089|NCT04230850|OTHER|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
48287090|NCT04230850|OTHER|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
48287091|NCT02715648|DRUG|Phenazopyridine|
48287092|NCT00442312|DRUG|Combigan Ophthalmic Solutiom|
48287093|NCT03008551|DRUG|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
48287094|NCT03008551|DRUG|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
48287095|NCT03038724|DIAGNOSTIC_TEST|Rapid HIV test|
48472706|NCT00942812|OTHER|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
48472707|NCT05735158|BIOLOGICAL|KB105|Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
48472708|NCT05735158|OTHER|Placebo|Visually matched excipient gel
48472709|NCT04187703|DRUG|5-azacytidine|5-azacytidine 50 mg/m\^2 Day 1 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
48472710|NCT04187703|DRUG|Decitabine|Decitabine 5 mg/m\^2 Day 4 every week ± G-CSF \~5 µg/kg (300µg vs 480µg)
48287096|NCT04924725|PROCEDURE|Endoscopic ultrasound-guided fine needle biopsy|Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
48287097|NCT02317731|OTHER|Straw|Bowel preparation ingestion with a straw
48287098|NCT03894540|DRUG|IPN60090|Oral capsules given daily
48287099|NCT03894540|DRUG|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
48287100|NCT03894540|DRUG|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
48472711|NCT04547933|DIAGNOSTIC_TEST|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
48472712|NCT02272309|PROCEDURE|EEG and EP measurement|
48472713|NCT03113435|OTHER|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
48472714|NCT02543151|PROCEDURE|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
48472715|NCT02887924|DEVICE|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
48472716|NCT00132834|DEVICE|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
48630255|NCT01413646|DIETARY_SUPPLEMENT|Walnut Supplementation|Eight weeks of walnut supplementation
48287101|NCT03894540|DRUG|IPN60090 single administration|Oral capsules given once
48287102|NCT05124938|DIAGNOSTIC_TEST|Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.|a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
48287103|NCT03928470|DRUG|EsoDuo Tab. 20/800mg|Nexium Tab. 20mg
48287104|NCT06316661|DIAGNOSTIC_TEST|stress perfusion cardiac magnetic resonance|stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment
48472717|NCT05229822|DIAGNOSTIC_TEST|LBP|Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
48472718|NCT05229822|DIAGNOSTIC_TEST|sCD14-ST|Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
48472719|NCT05229822|DIAGNOSTIC_TEST|16s rRNA|Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
47940606|NCT03071198|PROCEDURE|TME|"1. Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.~2. At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
47940607|NCT03071198|RADIATION|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
48287105|NCT06316661|DIAGNOSTIC_TEST|cardiopulmonary exercise test|bike exercise with ECG and non invasive respiratory gas exchange monitoring
48287106|NCT04652024|DEVICE|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
48287107|NCT02599389|DEVICE|Drug-coated balloons|
48287108|NCT02599389|DEVICE|Excimer Laser|
48287109|NCT04706546|OTHER|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
48287110|NCT04706546|OTHER|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
48287111|NCT00191529|DRUG|somatropin|
48287112|NCT02128568|BEHAVIORAL|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
48472720|NCT01291641|DRUG|HMG-CoA Reductase Inhibitor|"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
48472721|NCT01291641|DRUG|Probucol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
48617963|NCT01192815|OTHER|enzyme-linked immunosorbent assay|Optional correlative studies
48617964|NCT01192815|OTHER|polymorphism analysis|Optional correlative studies
48630256|NCT01413646|DIETARY_SUPPLEMENT|No walnut supplementation|Eight weeks without walnut supplementation
48630257|NCT04165980|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
48287113|NCT05191082|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
48472722|NCT01291641|DRUG|Cilostazol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
48472723|NCT01165476|DRUG|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
48630258|NCT04891653|DRUG|BR790|Subjects will receive oral administration of BR790.
48101684|NCT02338739|BEHAVIORAL|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
48101685|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
48472724|NCT00146796|DEVICE|Rapid diagnostic test for malaria|
48617965|NCT04908618|OTHER|digital impression for normal abutment|Accuracy of scan body impression
48617966|NCT04908618|OTHER|open tray impression|Accuracy of open tray impression
48101686|NCT02338739|BEHAVIORAL|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
48101687|NCT04395755|BEHAVIORAL|Generalized Anxiety Disorder-7 (GAD-7)|The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.
48101688|NCT04395755|BEHAVIORAL|Patient Health Questionnaire-9 (PHQ-9)|The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
48101689|NCT06421948|DRUG|Linperlisib and chidamide|A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.
48101690|NCT06421948|DRUG|cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone|A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
48101691|NCT02144350|PROCEDURE|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
48101692|NCT02144350|PROCEDURE|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
48101693|NCT03613129|DRUG|CT38|Infusion
48101694|NCT04875858|DRUG|ProDiax-23 (PPSV23)|diabetic old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed) and healthy old adults aged 70-75 years who received PPSV23 in previous 5-7 years (Persons 65-70 years old who have been inoculated with PPSV23 and 5-7 years have passed)
48101695|NCT03862833|DRUG|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
48101696|NCT03862833|DRUG|Zoledronic Acid|4 mg at day +15 post graft
48287114|NCT05191082|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
48287115|NCT05191082|DEVICE|Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
48287116|NCT05977543|OTHER|Functional crackers enriched with grape seed flour|The crackers was enriched with 10% grape seed flour
48617967|NCT04908618|OTHER|closed tray impression|Accuracy of closed tray impression
48617968|NCT06228989|PROCEDURE|Restorative therapy|Restorative treatment of first permanent molars affected with severe MIH
48617969|NCT06228989|PROCEDURE|Extraction therapy|Extraction treatment of first permanent molars affected with severe MIH
48630259|NCT00350506|DEVICE|64 Channel VCT|
48630260|NCT03640377|DRUG|Praziquantel|Praziquantel given as crushed tablets (40 or 80 mg/kg)
48630261|NCT02551107|DEVICE|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
48472725|NCT06441903|OTHER|Ultrasound|Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and extra-muscular connective structures of the muscle - Delto Pectoral Tendon (DPT) , Distal Pectoralis Major Tendon (PMT), Anterior Deltoid Tendon (ADT), Anterior Pretendinous Lamina of the Pectoralis Major (ALPM), Posterior Pretendinous Lamina of the Pectoralis Major (PLPM) and Deep Fascia of the Pectoral Major (DFPM) - constituting its connective skeleton, with particular attention to its distal portion near the humerus and on the search for this DPT tendon.
48472726|NCT00351351|DEVICE|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
47940608|NCT03071198|DRUG|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
47940609|NCT03071198|DRUG|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
47940610|NCT04353414|PROCEDURE|Transmuscular Quadratus Lumborum Block|Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
47940611|NCT04353414|PROCEDURE|Pericapsular injection|Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
47940612|NCT04353414|DRUG|Bupivacaine Hydrochloride|Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
47940613|NCT03580148|DRUG|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
47940614|NCT03580148|BIOLOGICAL|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
48287117|NCT05977543|OTHER|Functional crackers with 40% barley flour and enriched with β-glucans|The crackers consisted of 60% wheat flour, 40% barley flour and was enriched with β-glucans.
47940615|NCT05927324|BEHAVIORAL|CAVEAT|Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
47940616|NCT03508271|OTHER|Non-Interventional|Non-Interventional
47940617|NCT02826135|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
47940618|NCT04007432|OTHER|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
47940619|NCT00124488|DEVICE|Tomotherapy Treatment Planning|
48287118|NCT05710874|OTHER|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
48287119|NCT05710874|OTHER|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
48472727|NCT00351351|DEVICE|single probe ultrasonic|FDA-approved - single probe ultrasonic
47940620|NCT00010127|BIOLOGICAL|therapeutic autologous dendritic cells|
47940621|NCT00364130|DEVICE|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
47940622|NCT00364130|DEVICE|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
47940623|NCT03219879|BEHAVIORAL|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
47940624|NCT03219879|OTHER|Usual care|Usual care without any study-related intervention
47940625|NCT02525315|DEVICE|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
48287120|NCT05710874|OTHER|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
48472728|NCT02872350|DEVICE|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
48472729|NCT00224484|BIOLOGICAL|GSK208141|3 intramuscular doses
48472730|NCT00224484|BIOLOGICAL|Havrix (investigational formulation)|3 intramuscular doses
48472731|NCT00224484|BIOLOGICAL|Placebo|3 intramuscular doses
48472732|NCT00959569|DRUG|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
48472733|NCT00959569|DRUG|Placebo|normosaline (same ml of the study drug)
48472734|NCT00441233|DEVICE|Silicone hydrogel contact lens|
48472735|NCT03442569|DRUG|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
48472736|NCT03442569|DRUG|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
48472737|NCT03442569|DRUG|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
48472738|NCT06321354|DRUG|The diprospan plus ropivacaine group|The local infiltration solution containing 0.5ml diprospan and 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
48472739|NCT06321354|DRUG|The ropivacaine group|The local infiltration solution containing 15mg of 1% ropivacaine. The total volume is 30 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
48472740|NCT03002792|PROCEDURE|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
48472741|NCT00400582|DRUG|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
48472742|NCT02938013|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
48472743|NCT02938013|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
48472744|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
48472745|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
48472746|NCT00982501|DRUG|WS® 1442 900 mg/d|
48472747|NCT00982501|DRUG|WS® 1442 1800 mg/d|
48472748|NCT00982501|BEHAVIORAL|Nordic walking training 2 x 30 min/week|
48472749|NCT00982501|BEHAVIORAL|Nordic walking training 4x45 min/week|
48472750|NCT01739413|PROCEDURE|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
48630262|NCT02560792|BEHAVIORAL|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
47940626|NCT01218633|DRUG|saline infusion|saline infused at 30ml/hour
47940627|NCT01218633|DRUG|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
47940628|NCT01218633|DRUG|Exendin-9,39 at low dose|infused at 30pmol/kg/min
48287121|NCT05710874|OTHER|Conventional|Twice daily use of conventional toothpaste.
48287122|NCT01115712|DRUG|Placebo|Placebo (to match pioglitazone 30 mg) once daily
48287123|NCT01115712|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
48472751|NCT03756337|DEVICE|Neuro 1 & Neuro 2|participant common fitting map used for tests
48472752|NCT03756337|DEVICE|Neuro 2 & Neuro 1|participant common fitting map used for tests
48472753|NCT03070015|BEHAVIORAL|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI \> 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables \& no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch \& 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (\~50% kcal from carbohydrate,\~25% from protein,\~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
48472754|NCT03070015|BEHAVIORAL|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts \& sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day \& men ate 1500 kcal/day. Subjects with BMI \>40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
48472755|NCT04353258|BEHAVIORAL|Behavioral Economics intervention (BE mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth) that includes behavioral economics components.
48472756|NCT04353258|BEHAVIORAL|Standard mHealth intervention (mHealth)|Participants will receive a 12-month behavioral weight loss intervention delivered primarily via mobile phone (mHealth).
48472757|NCT06380257|OTHER|Observational study methods|Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.
47940629|NCT01218633|DRUG|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
48472758|NCT04629339|DRUG|INCB086550|INCB086550 will be administered orally twice a day.
48472759|NCT00862537|DEVICE|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
48472760|NCT01758133|BEHAVIORAL|Exposure to medical clown activities|
48472761|NCT06062550|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.
48472762|NCT00403949|DRUG|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
48472763|NCT00403949|DRUG|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
48472764|NCT00959439|DRUG|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
48472765|NCT00959439|DRUG|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
48472766|NCT00230594|DRUG|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
48472767|NCT00230594|DRUG|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
48472768|NCT03180528|DRUG|Remetinostat|Applied topically under bandage occlusion
48472769|NCT00089167|BIOLOGICAL|filgrastim|
48472770|NCT00089167|DRUG|dexamethasone|
48472771|NCT00089167|DRUG|melphalan|
48472772|NCT00089167|DRUG|thalidomide|
48472773|NCT05507320|BEHAVIORAL|Mechanisms of action perception and execution|Study the mechanisms of action perception and execution
48472774|NCT01456260|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
48472775|NCT01456260|DRUG|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
48472776|NCT01456260|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
48630263|NCT02560792|BEHAVIORAL|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
48630264|NCT02560792|BEHAVIORAL|Control Condition|Participants receive no information about affective response
48630265|NCT00523380|DRUG|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
48630266|NCT00523380|DRUG|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
48630267|NCT03022214|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
48630268|NCT03022214|DIETARY_SUPPLEMENT|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
48630269|NCT02874352|DEVICE|high resolution impedance manometry with Automated Impedance Manometry analysis|
48630270|NCT04286958|DRUG|Camrelizumab|Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)
48630271|NCT03842800|OTHER|MRI|Patients and volunteers will receive an MRI.
48630272|NCT03842800|DRUG|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
48630273|NCT02740010|DEVICE|EDOF Mini WELL Ready IOL|implant
48630274|NCT00696150|PROCEDURE|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
48630275|NCT00696150|PROCEDURE|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
48630276|NCT00696150|PROCEDURE|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
47940630|NCT00842764|PROCEDURE|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
47940631|NCT04672330|DRUG|Tislelizumab|Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) before surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）
48472777|NCT01456260|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
48472778|NCT01456260|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
48472779|NCT01456260|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
48472780|NCT01520987|DRUG|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
48472781|NCT01520987|DRUG|Placebo|once-daily
48630277|NCT02039570|OTHER|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
48630278|NCT03997201|PROCEDURE|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
48630279|NCT04366583|DEVICE|argon plasma coagulation|Olympus electrosurgical unit/argon plasma coagulation unit (PSD-60/Endoplasma, Olympus Corp., Tokyo, Japan)
48630280|NCT04366583|DEVICE|hemoclipping|clipping device (Olympus HX 110/610, Olympus Corp., Tokyo, Japan)
47940632|NCT00920231|DEVICE|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
48472782|NCT04977596|OTHER|No intervention|Retrospective study without intervention
48472783|NCT00498199|PROCEDURE|visual tests|
48472784|NCT04082806|DRUG|GHB|50 mg/kg GHB at one experimental night
48472785|NCT04082806|DRUG|Trazodone|1.5 mg/kg trazodone at one experimental night
48472786|NCT04082806|DRUG|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
48472787|NCT04568161|PROCEDURE|Physical Characteristics|Body weight, height and waist circumference
48472788|NCT04568161|PROCEDURE|Muscular Sympathetic Nervous Activity|Microneurography technique.
48472789|NCT04568161|DIAGNOSTIC_TEST|Cardiac Function|Echocardiography.
48472790|NCT04568161|DIAGNOSTIC_TEST|Heart rate|Electrocardiography
48472791|NCT04568161|DIAGNOSTIC_TEST|Blood pressure|Non-invasive photoplethysmography.
48617970|NCT06059144|DRUG|Peripheral intravenous norepinephrine|Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
48617971|NCT02598310|DRUG|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
48617972|NCT02598310|DRUG|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
48630281|NCT06293859|OTHER|Probiotic oat flakes|2 x 10\^9 cfu/g Lactococcus cremoris immobilized on oat flakes
48630282|NCT06293859|OTHER|Conventional oat flakes|Commercial oat flakes
48630283|NCT02246985|DIETARY_SUPPLEMENT|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
48630284|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
48630285|NCT02246985|DIETARY_SUPPLEMENT|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
48630286|NCT02246985|DIETARY_SUPPLEMENT|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
48472792|NCT04568161|DIAGNOSTIC_TEST|Blood Assessments|Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.
48630287|NCT02614014|BEHAVIORAL|Cognitive-behavior interventional program|
48101697|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
48630288|NCT02269449|DEVICE|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
48630289|NCT02269449|DEVICE|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
48630290|NCT02269449|PROCEDURE|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
48630291|NCT02269449|PROCEDURE|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
48101698|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
48287124|NCT01115712|DRUG|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
48287125|NCT01495819|DRUG|Saline|5cc's of saline give at least once.
48472793|NCT04568161|DIAGNOSTIC_TEST|Muscle blood flow|Venous occlusion plethysmography
48472794|NCT04568161|DIAGNOSTIC_TEST|Endothelium-dependent vascular function|Brachial ultrasound
48472795|NCT04568161|DIAGNOSTIC_TEST|Vascular intima-media thickness|Carotid ultrasound
48472796|NCT04568161|DIAGNOSTIC_TEST|Physical Capacity|Cardiopulmonary exercise test
48630292|NCT01121575|DRUG|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
48630293|NCT01121575|DRUG|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination \[PF-02341066 and PF-00299804\] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
48630294|NCT01121575|DRUG|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
48630295|NCT01121575|DRUG|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
48630296|NCT02130011|OTHER|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
48630297|NCT00792389|OTHER|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
48630298|NCT00792389|OTHER|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
48630299|NCT04488094|DRUG|[18F]FSPG|A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
48101699|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
48101700|NCT00973141|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
48101701|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
48101702|NCT00973141|DRUG|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
48101703|NCT01282437|RADIATION|Prophylactic Cranial Irradiation|"* 18 fractions of 2Gy~* 12 fractions of 2.5Gy~* 10 fractions of 3 Gy"
48472797|NCT04568161|DRUG|Anthracycline & Cyclophosphamide treatment scheme|Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
48630300|NCT04279262|OTHER|attendance by community first responders for medical emergencies|The investigators will purposively sample patients, relatives, and ambulance staff identified from records of patients who have been attended by a CFR in a rural location in the previous six months. Where possible the investigators will interview patients, relatives, CFRs and ambulance staff attending the same event. GPs will be purposively sampled from rural areas of the ambulance services involved. Investigators will recruit a maximum variation sample of patients (according to age, sex, condition, and ethnicity), ambulance staff (sex, experience, ethnicity and role), CFR (sex, ethnicity, length of experience, skill level) and CFR scheme leads (independent charity and ambulance trust overseen schemes).
48630301|NCT01479530|DRUG|Placebo|Once daily; tablet; orally; 16 weeks
48630302|NCT01479530|DRUG|Azilect®|1 mg daily; tablet; orally; 16 weeks
48630303|NCT02595554|RADIATION|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
48630304|NCT02595554|DRUG|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
48630305|NCT02595554|PROCEDURE|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
48630306|NCT02595554|DRUG|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
48630307|NCT01804907|BEHAVIORAL|Cognitive Behavioral Therapy|
48630308|NCT01804907|BEHAVIORAL|Behavioral Modification|
48630309|NCT04398914|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
48630310|NCT04398914|DRUG|Trastuzumab|"Trastuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4.~Adjuvant treatment: 8 mg/kg loading dose, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab"
48630311|NCT04398914|DRUG|Pertuzumab|"Pertuzumab IV infusion in 3-week cycles.~Neoadjuvant treatment: 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4.~Adjuvant treatment: 840 mg loading dose, followed by 420mg for remaining cycles till completion of 1 year pertuzumab"
48630312|NCT04398914|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
48630313|NCT04398914|DRUG|EC chemotherapy|Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)
47940633|NCT00920231|DEVICE|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
47940634|NCT05631288|GENETIC|Sampe collection|Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
48287126|NCT01495819|DRUG|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
48472798|NCT00655317|OTHER|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
48472799|NCT00655317|OTHER|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
48472800|NCT05331391|BEHAVIORAL|Brief mobile SMART Exercise Support Program|Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.
48617973|NCT05856487|DRUG|NVP-2203|Take it once daily for 8 weeks orally.
48617974|NCT05856487|DRUG|NVP-2203-R1|Take it once daily for 8 weeks orally.
48630314|NCT04398914|DRUG|Physician's choice|Physician decided chemotherapy for 0-4 cycles.
48630315|NCT04398914|DRUG|T-DM1|T-DM1 IV infusion in 3-week cycles. 3.6 mg/kg by intravenous (IV) infusion every 3 weeks for 14 cycles
48630316|NCT04398914|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
48630317|NCT06130202|DEVICE|Echocardiographic findings|Echocardiographic findings as Markers of Subclinical Cardiac dysfunction in Patients with Non-Alcoholic Fatty Liver Disease
48630318|NCT04193215|BIOLOGICAL|V114|IM injection
48630319|NCT04193215|OTHER|Pediatric vaccines|Standard of care vaccines administered according to the local recommended schedule.
48630320|NCT05309889|OTHER|no intervention|no intervention
48630321|NCT05331937|COMBINATION_PRODUCT|repetitive transcranial magnetic stimulation (rTMS)|rTMS (real versus sham) is used as adjuvant to ERP
48630322|NCT01952678|OTHER|DaTscan™ - Non-Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
48287127|NCT05858411|PROCEDURE|SRP+rhPDGF|The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.
48287128|NCT05858411|PROCEDURE|SRP+collagen sponge|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in saline solution.
48287129|NCT05858411|PROCEDURE|SRP alone|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
48287130|NCT00065910|BEHAVIORAL|Caregiver joint attention intervention|
48617975|NCT05856487|DRUG|NVP-2203-R2|Take it once daily for 8 weeks orally.
48617976|NCT05856487|DRUG|NVP-2203-R3|Take it once daily for 8 weeks orally.
48617977|NCT05856487|DRUG|NVP-2203 Placebo|Take it once daily for 8 weeks orally.
47940635|NCT02886156|DEVICE|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
47940636|NCT02886156|DIETARY_SUPPLEMENT|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
47940637|NCT03442387|OTHER|Frame of numerical information|Each group received only one frame of information.
47940638|NCT01514500|DRUG|somapacitan|Administered s.c. (subcutaneously, under the skin)
47940639|NCT01514500|DRUG|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
47940640|NCT03015883|RADIATION|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
47940641|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair|Arthroscopic massive rotator cuff repair without biceps tendon augmentation either partial or complete repair.
47940642|NCT05817071|PROCEDURE|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon|Arthroscopic massive rotator cuff repair with superior capsular augmentation using the long head of biceps tendon .
47940643|NCT04026581|BEHAVIORAL|Speech generating device (SGD) evaluation including BCI access|At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
47940644|NCT04026581|BEHAVIORAL|Training and treatment|Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
47940645|NCT04138888|DRUG|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
47940646|NCT04138888|DRUG|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
47940647|NCT01522586|DRUG|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
47940648|NCT01522586|DRUG|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
47940649|NCT02636842|DRUG|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
47940650|NCT03144024|DEVICE|band implantation|
47940651|NCT03144024|DEVICE|rigid ring implantation|
47940652|NCT02557438|PROCEDURE|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
47940653|NCT02557438|PROCEDURE|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
47940654|NCT02707809|DRUG|Dexmedetomidine|Dexmedetomidine infusion
47940655|NCT03703596|DRUG|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
47940656|NCT03703596|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
47940657|NCT04698265|BIOLOGICAL|Human amniotic suspension allograft (ASA)|Human amniotic suspension allograft (ASA) intra-articular injection.
47940658|NCT01464723|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
47940659|NCT02142010|DRUG|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
47940660|NCT05214378|DEVICE|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
48472801|NCT05478187|DEVICE|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
48287131|NCT03937986|DRUG|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
48472802|NCT05478187|OTHER|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
48472803|NCT05099510|BIOLOGICAL|NatrunixTM|The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
48472804|NCT05099510|BIOLOGICAL|Placebo|Placebo control for NatrunixTM subcutaneous injection.
48630323|NCT01952678|OTHER|DaTscan™ - Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
48472805|NCT03237299|OTHER|Collection of data|Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.
48101704|NCT05923255|PROCEDURE|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）|Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
48472806|NCT03237299|OTHER|No collection of data|The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
48472807|NCT05829850|DEVICE|SYNOLIS VA 40/80|Three 2mL injections of SYNOLIS VA 40/80, one week apart
48472808|NCT03574337|DRUG|Sugammadex|No additional information
48472809|NCT03574337|DRUG|neostigmine/glycopyrolate|No additional information
48472810|NCT05276687|DRUG|Betadine|Wound irrigation
48472811|NCT05276687|DRUG|Vancomycin|instillation in the wound
48472812|NCT03011060|PROCEDURE|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
48472813|NCT03011060|DRUG|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
48472814|NCT03698487|OTHER|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
48472815|NCT03710616|PROCEDURE|Surgeries|Surgical operations plus systematic lymphadenectomies
48287132|NCT03937986|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
48287133|NCT03937986|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
48287134|NCT01912040|DRUG|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
48472816|NCT05193773|OTHER|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
48472817|NCT00455962|DRUG|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
48472818|NCT00455962|DRUG|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
48472819|NCT03091257|DRUG|Dabrafenib|Administered Orally BID
48472820|NCT03091257|DRUG|Trametinib|Administered Orally once daily
48472821|NCT02725424|DRUG|S-1|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
48630324|NCT02760511|DIETARY_SUPPLEMENT|Anthocyanin|Capsules with different anthocyanin content
48630325|NCT02760511|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
48630326|NCT06318286|DRUG|Lenvatinib|Induction treatment: lenvatinib, 8 mg QD on Day 1 of a 21-day cycle for 4-6 cycles. Maintenance treatment: Lenvatinib, 20 mg QD may be given for up to a total of 35 cycles.
48472822|NCT02725424|DRUG|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
48472823|NCT02725424|DRUG|Oxaliplatin|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
48472824|NCT02725424|DRUG|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
48472825|NCT02997722|DRUG|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
48472826|NCT02997722|DRUG|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
48472827|NCT02289820|BIOLOGICAL|MEDI7510|RSV sF antigen plus adjuvant
48472828|NCT02289820|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
48472829|NCT04161573|BEHAVIORAL|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
48472830|NCT01899326|DRUG|Desipramine Hydrochloride|Given PO
48472831|NCT01899326|BIOLOGICAL|Filgrastim|Given PO
48472832|NCT01899326|OTHER|Laboratory Biomarker Analysis|Correlative studies
48472833|NCT06252207|DRUG|Desflurane|General anesthesia with desflurlane
48472834|NCT06252207|DRUG|Isoflurane|General anesthesia with isoflurane
48472835|NCT05120817|BEHAVIORAL|"Personal intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
48630327|NCT06318286|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 will be given by intravenous (IV) infusion on Day 1 of a 21-day cycle for 4-6 cycles.
48630328|NCT06318286|DRUG|Cisplatin/Carboplatin|Carboplatin (AUC 5 mg/mL/min) or Cisplatin (75 mg/m2) will be given by IV infusion on Day 1 of a 21-day cycle for 4-6 cycles.
48472836|NCT05120817|BEHAVIORAL|"Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
48101705|NCT05923255|PROCEDURE|TRH（Traditional Laparoscopic Right Hemicolectomy）|Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
48472837|NCT05120817|BEHAVIORAL|"Personal + Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
48472838|NCT04593303|PROCEDURE|Internal iliac artery ligation with cervicoisthmic compression suture|Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
48472839|NCT04593303|PROCEDURE|Cervicoisthmic compression suture without Internal iliac artery ligation|Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
48472840|NCT05597839|DRUG|DF9001|Immunotherapy agent targeting NK cells.
48472841|NCT05597839|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
48472842|NCT05597839|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
48472843|NCT02948426|BIOLOGICAL|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
48472844|NCT00785876|OTHER|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
48472845|NCT00943865|BEHAVIORAL|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
48472846|NCT00943865|BEHAVIORAL|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
48617978|NCT05856487|DRUG|NVP-2203-R1 Placebo|Take it once daily for 8 weeks orally.
48617979|NCT05856487|DRUG|NVP-2203-R2 Placebo|Take it once daily for 8 weeks orally.
48617980|NCT05856487|DRUG|NVP-2203-R3 Placebo|Take it once daily for 8 weeks orally.
48617981|NCT00872742|BEHAVIORAL|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
48630329|NCT06318286|DRUG|Pembrolizumab|Pembrolizumab, 200 mg will be given by IV infusion on Day 1 of a 21-day cycle for up to a total of 35 cycles.
48630330|NCT03661580|BEHAVIORAL|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
48472847|NCT00943865|BEHAVIORAL|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
47940661|NCT03470974|BEHAVIORAL|Self-titration strategy|The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
47940662|NCT01459848|BEHAVIORAL|block play|30 minutes of block play
48472848|NCT00943865|BEHAVIORAL|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
48472849|NCT00943865|BEHAVIORAL|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
48472850|NCT02001155|PROCEDURE|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
48472851|NCT04316195|DIAGNOSTIC_TEST|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
48472852|NCT04561336|DRUG|Avelumab|avelumab in combination with cetuximab
47940663|NCT01459848|BEHAVIORAL|baby dvd|30 minutes of dvd viewing
47940664|NCT03261180|OTHER|Best Practice|Receive regular diet
47940665|NCT03261180|OTHER|Laboratory Biomarker Analysis|Correlative studies
47940666|NCT03261180|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive Nestle Impact AR
47940667|NCT01982058|OTHER|communication intervention|
47940668|NCT01982058|OTHER|counseling intervention|
47940669|NCT01982058|OTHER|nutrition intervention|
48101706|NCT00380705|DRUG|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
48472853|NCT04561336|DRUG|Cetuximab|avelumab in combination with cetuximab
48472854|NCT04487288|DIAGNOSTIC_TEST|SONAZOID|CEUS using SONAZOID with fusion technique
47940670|NCT01982058|OTHER|questionnaire administration|
47940671|NCT03599401|OTHER|Scaling and root planing|"Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~."
47940672|NCT03431103|BEHAVIORAL|Exercise|12 week home exercise program
47940673|NCT02325856|DEVICE|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
47940674|NCT02325856|BEHAVIORAL|Clinical judgement|
47940675|NCT00002311|DRUG|Wobenzym|
47940676|NCT05471700|DRUG|Azacitidine|Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
48101707|NCT04732039|OTHER|Measurement of peak oxygen uptake|Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
47940677|NCT05471700|DRUG|Venetoclax|Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
48287135|NCT04394169|BEHAVIORAL|Intervention program|"Medical visits:~There will be three medical visits stipulated as follows:~* Visit 1 Intervention Group, four weeks after hospital discharge.~* Visit 2 Intervention Group, eight weeks after hospital discharge.~* Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~* Interview and physical examination.~* Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~* Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control."
48287136|NCT02308280|DRUG|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
47940678|NCT05616715|DEVICE|Peek device|Participants with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
48287137|NCT03962049|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
48287138|NCT04408456|DRUG|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
48287139|NCT04408456|OTHER|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
48287140|NCT03356132|DEVICE|Silimed® Textured Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
48287141|NCT03356132|DEVICE|Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant|Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
48472855|NCT01477424|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
48472856|NCT01477424|DRUG|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
48472857|NCT05290233|BEHAVIORAL|TRE + Exercise|"We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise"
48472858|NCT04099641|DRUG|Bavituximab|Bavituximab IV infusion
48472859|NCT04099641|DRUG|Pembrolizumab Injection|Pembrolizumab IV Infusion
48472860|NCT06199960|OTHER|Doustim protocol|In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
48472861|NCT04738838|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
48472862|NCT04738838|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
48472863|NCT00271024|DRUG|Naltrexone (drug)|50 mg q.d. for 13 weeks
48472864|NCT00271024|DRUG|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
48472865|NCT04379284|OTHER|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
48472866|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
48472867|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
48472868|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
48472869|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
48472870|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
48472871|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
48472872|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
48472873|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
47940679|NCT05616715|OTHER|Crown lengthening/gingivectomy|Participante with gummy smile will be recruited from the Dental Clinic of Instituto Universitário Egas Moniz
48101708|NCT03809299|OTHER|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
48472874|NCT02020109|RADIATION|splenic irradiation|
48472875|NCT01463982|DRUG|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14"
48472876|NCT03477383|DIAGNOSTIC_TEST|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
48472877|NCT04445701|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
48472878|NCT04445701|DRUG|AO-176 + Dex|Humanized mAb targeting CD47 plus dexamethasone
48472879|NCT04445701|DRUG|AO-176 + Dex + Bort|Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
48472880|NCT00055718|DIETARY_SUPPLEMENT|silymarin|
48472881|NCT06083987|BEHAVIORAL|Intersectionality and Identity|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of intersectionality and identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
47940680|NCT00775385|DRUG|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
48287142|NCT01805115|DRUG|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
48287143|NCT01805115|DRUG|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
48287144|NCT01805115|DRUG|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
48287145|NCT01805115|DRUG|Control|The control group was not given any cervical priming agents or placebo.
48287146|NCT01277575|DEVICE|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
48287147|NCT01277575|DEVICE|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
48287148|NCT04630015|OTHER|Survey Administration|Participants will complete study specific survey
48287149|NCT00651040|DRUG|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
48472882|NCT06083987|BEHAVIORAL|Confidentiality|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on Confidentiality for caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
48472883|NCT06083987|BEHAVIORAL|Educating Your Community|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of the education of family and friends about identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
47940681|NCT00775385|DRUG|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
47940682|NCT01455467|DEVICE|One iStent|Implantation of one iStent in conjunction with cataract surgery
47940683|NCT01455467|DEVICE|Two iStent|Implantation of two iStent in conjunction with cataract surgery
48287150|NCT00651040|DRUG|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
48287151|NCT03229577|BEHAVIORAL|Sudarshan Kriya Yoga|Yoga-based breathing program.
48287152|NCT03229577|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness program.
48287153|NCT03229577|BEHAVIORAL|Emotional Intelligence|Emotional Intelligence program.
48101709|NCT03809299|OTHER|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
48472884|NCT06083987|BEHAVIORAL|How to find Affirming Caregivers|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of finding affirming caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
48101710|NCT02770040|DRUG|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
48472885|NCT06083987|BEHAVIORAL|Control Group - No Interventions|Control Group - Will be given no interventions
48472886|NCT05434351|OTHER|vaginal dehydroepiandrosterone|the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
48472887|NCT02057536|OTHER|Arm A Directed exercise program|
48472888|NCT02057536|OTHER|Observation|
48472889|NCT03701126|PROCEDURE|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
48472890|NCT03701126|PROCEDURE|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
48472891|NCT03701126|DRUG|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
48472892|NCT03701126|DEVICE|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
48472893|NCT01376544|DEVICE|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
48472894|NCT05531851|OTHER|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
48472895|NCT01228227|DRUG|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
48472896|NCT01228227|DRUG|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
48101711|NCT00271765|DRUG|INO-1001|
48287154|NCT04526977|DIAGNOSTIC_TEST|Immune response study|"* ACE2 and CD26 receptor study~* Cytokine profile: Quantification of plasma cytokine levels~* SARS-CoV-2 CD4/CD8 T cell response~* TLR7/8 activation~* KIR characterization"
48287155|NCT05089565|DIAGNOSTIC_TEST|Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation|Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination
48472897|NCT00090116|DRUG|Neramexane|
48472898|NCT00480649|DRUG|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
48472899|NCT04736862|DEVICE|Continuous non-invasive blood pressure monitoring|In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
48472900|NCT04736862|DEVICE|Intermittent non-invasive blood pressure monitoring|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
48472901|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
48472902|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
48472903|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
48472904|NCT06010576|PROCEDURE|EUS-guided rendezvous|A linear array echoendoscope would be used to evaluate the common bile duct and left intrahepatic duct in order to identify the optimal route for biliary access by fine needle. Using a 19 gauge EUS needle, the dilated biliary tree will be accessed by either a transduodenal puncture to the common bile duct or a transgastric puncture to the left intrahepatic duct under direct EUS guidance. The optimal access route will be based on patient's anatomy after EUS assessment and left to the discretion of the investigator. Next, a guidewire would be advanced through the needle into the bile duct and out of the papillary orifice. The echoendoscope would then be exchanged to a duodenoscope for ERCP. The EUS rendezvous ERCP procedure will be completed by retrieving the rendezvous guidewire into the duodenoscope or by cannulation alongside the rendezvous guidewire to obtain biliary access.
48472905|NCT06010576|PROCEDURE|Early precut papillotomy group|The precut papillotomy would be performed with 1 of the following acceptable techniques per the usual practice of the study investigator and institution: 1) conventional precut papillotomy by needle knife, 2) precut fistulotomy by needle knife, or 3) transpancreatic precut papillotomy by papillotome
48472906|NCT00749411|DRUG|Placebo|matching placebo
47940684|NCT03381573|DRUG|Roflumilast|Roflumilast
47940685|NCT02903212|BIOLOGICAL|Autologous apoptotic cells injection|cells injection
48472907|NCT00749411|DRUG|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
48472908|NCT04313426|OTHER|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
48472909|NCT05757037|DEVICE|laser acupuncture|a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
48472910|NCT00209547|DRUG|fospropofol disodium|
48287156|NCT02739477|DRUG|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
48472911|NCT05231369|BIOLOGICAL|ChulaCov19 BNA159 mRNA vaccine|ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
48287157|NCT05893082|DEVICE|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
48287158|NCT02298244|PROCEDURE|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
48472912|NCT05344287|OTHER|Typical American Diet|Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
48472913|NCT05344287|OTHER|Plant-Based Diet|Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
48472914|NCT00003348|DRUG|O6-benzylguanine|
48472915|NCT00003348|DRUG|carmustine|
48472916|NCT06678958|PROCEDURE|Reconstruction of acetabular defect by trabecular metal augment|The augments were used in the flying buttress position
47940686|NCT02414672|BEHAVIORAL|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
48472917|NCT03777345|DEVICE|cobalt-chromium framework partial dentures|It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
48472918|NCT03777345|DEVICE|PEEK framework partial dentures|It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
48472919|NCT02690051|DEVICE|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
48472920|NCT01896505|DRUG|KCP-330|
48472921|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
48472922|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
48472923|NCT01706263|DRUG|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
48472924|NCT02885428|DEVICE|echography|
48472925|NCT04747132|OTHER|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
47940687|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
47940688|NCT01199900|DRUG|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
47940689|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
47940690|NCT01199900|DRUG|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
47940691|NCT01199900|DRUG|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
47940692|NCT01199900|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
48630331|NCT03661580|BEHAVIORAL|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
48630332|NCT05009550|PROCEDURE|Group ESP|Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group
48630333|NCT05009550|OTHER|Non-blocked Group|This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.
48630334|NCT06380608|PROCEDURE|Local anesthesia|Patients who will undergo a dental surgery under local anesthesia
48630335|NCT06380608|PROCEDURE|General anesthesia|Patients who will undergo a dental surgery under general anesthesia
48630336|NCT06324578|DIAGNOSTIC_TEST|AT Testing|Analysis of blood specimens and neck ultrasonography
48472926|NCT03434691|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
48472927|NCT03434691|DRUG|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
48472928|NCT01696565|DRUG|PG2|Injectable
48630337|NCT00057070|PROCEDURE|Smoking cessation information, collection, and dissemination|
48472929|NCT02285933|OTHER|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
48472930|NCT02285933|OTHER|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
48472931|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 350mg|
48472932|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 500mg|
48472933|NCT02930668|DIETARY_SUPPLEMENT|Placebo|
48630338|NCT04342585|DRUG|Micronised vaginal progesterone|A diary will be given to participants to ensure compliance.
48630339|NCT04342585|DEVICE|Vaginal pessary|The internal diameter size will be decided based on the clinical assessment of the cervix.
48630340|NCT04455295|DEVICE|Transdermal Vagus Nerve Stimulation (tVNS)|Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
48630341|NCT01298466|DRUG|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
48630342|NCT03989570|PROCEDURE|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
48630343|NCT03989570|PROCEDURE|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
48630344|NCT03989570|OTHER|control group|placebo
48630345|NCT01368770|OTHER|Coronary CTA|Coronary CTA using standard protocols
48630346|NCT01368770|OTHER|Stress MPI SPECT|Stress MPI using standard protocols
48287159|NCT02298244|PROCEDURE|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
48287160|NCT00670111|DEVICE|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
48287161|NCT01819961|DRUG|MCT/LCT and fish oil|
48287162|NCT01819961|DRUG|MCT/LCT|
48287163|NCT02277132|DRUG|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
48287164|NCT02277132|DRUG|Placebo|Placebo tablets three times daily orally from randomization until delivery
48287165|NCT02066662|DRUG|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
48287166|NCT00397956|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
48287167|NCT02158533|DRUG|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
48287168|NCT02158533|DRUG|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
48287169|NCT02158533|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
48287170|NCT02393092|BEHAVIORAL|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
48287171|NCT02393092|BEHAVIORAL|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
48287172|NCT02393092|BEHAVIORAL|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
48287173|NCT02273973|DRUG|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
48287174|NCT02273973|OTHER|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
48287175|NCT02273973|DRUG|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
48287176|NCT04632147|OTHER|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
48287177|NCT03338556|DRUG|PrEP-001|
48287178|NCT03338556|OTHER|Placebo|
48287179|NCT00480961|PROCEDURE|intramiocardiac autograft of autologous stem cells|
48287180|NCT02812680|OTHER|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
48287181|NCT01738035|DRUG|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
48287182|NCT01738035|OTHER|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
48287183|NCT02278978|DRUG|BIBF1120|BIBF1120 200 mg two times per day orally
48287184|NCT01450540|DEVICE|REMstar Auto A-Flex|Standard CPAP
48287185|NCT01450540|DEVICE|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
48287186|NCT05171530|DRUG|Lenvatinib plus taxane drugs|"* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA"
47940693|NCT01199900|DRUG|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
48287187|NCT00095303|BEHAVIORAL|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
48630347|NCT01452789|DRUG|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
48630348|NCT01452789|DRUG|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
48630349|NCT03299335|OTHER|Blood collection|assay of CPK and anti-cN-1A antibodies
48472934|NCT05460962|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
48472935|NCT05460962|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
48472936|NCT00557245|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
47940694|NCT05144204|BEHAVIORAL|Low FODMAP diet|Low FODMAP diet instruction to irritable bowel syndrome patients.
48472937|NCT00557245|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
48472938|NCT00557245|DRUG|Placebo|Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
48617982|NCT00872742|BEHAVIORAL|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
47940695|NCT02929251|DRUG|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
47940696|NCT02929251|DRUG|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
47940697|NCT02929251|DRUG|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
47940698|NCT00825851|DRUG|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
48617983|NCT02689960|DRUG|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
48617984|NCT02494011|OTHER|traditional exercise|mobilization stretching exercise
48617985|NCT02494011|OTHER|Russian current stimulation|stimulation to wrist flexors for 15 minutes
48630350|NCT04354571|PROCEDURE|Erector spinae plane block|An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.
48630351|NCT04354571|PROCEDURE|caudal block|caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
48630352|NCT03432689|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
48630353|NCT03432689|DRUG|Cycloserine|Cycloserine 100mg
48287188|NCT00095303|BEHAVIORAL|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
48287189|NCT01132014|BIOLOGICAL|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
48287190|NCT01405079|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
48630354|NCT03432689|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
47940699|NCT00825851|DRUG|Placebo patch|
48472939|NCT04232527|DIAGNOSTIC_TEST|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
48472940|NCT04232527|DIAGNOSTIC_TEST|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
47940700|NCT00825851|BEHAVIORAL|Smoking cessation|
48287191|NCT01405079|DRUG|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
48472941|NCT04232527|DIAGNOSTIC_TEST|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
48472942|NCT04232527|DIAGNOSTIC_TEST|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
48287192|NCT04887311|DRUG|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
48287193|NCT01004107|DEVICE|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
48287194|NCT02902809|BIOLOGICAL|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
48287195|NCT02462161|DRUG|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
48287196|NCT02462161|DRUG|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
48287197|NCT06232915|PROCEDURE|Mechanical ventilation|Mechanical ventilation during surgery
48287198|NCT05744986|DEVICE|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
47940701|NCT00825851|BEHAVIORAL|Continuous smoking|subjects smoke 20 cigarettes per day
47940702|NCT00997438|DIETARY_SUPPLEMENT|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
48287199|NCT05252312|BEHAVIORAL|Psycho-acoustic tests|"Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry"
48287200|NCT03615027|BEHAVIORAL|Dementia-specific advance care planning|see detailed description
48472943|NCT04232527|DIAGNOSTIC_TEST|S_CODS (change of direction speed) Test|S_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
48630355|NCT00064454|DRUG|OPC-6535 Tablets (drug)|
48630356|NCT04785807|OTHER|Post traumatic, Anxiety and depression evaluation|Family member of person or trust of patient who had a limitation or discontinuation of treatments will be identified and asked to fulfilled a hospitalized anxiety and depression scale and the revised Impact Event scale 7 and 30 days after the limitation or discontinuation of treatments announcement
47940703|NCT00901927|DRUG|Bendamustine|Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
47940704|NCT00901927|DRUG|Mitoxantrone|10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.
47940705|NCT00901927|DRUG|Rituximab|375 mg/m\^2 by vein over several hours on Day 1 of each cycle.
48287201|NCT01962454|DRUG|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
48287202|NCT01962454|DRUG|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
48287203|NCT01962454|DRUG|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
48287204|NCT01208181|DRUG|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
48287205|NCT01208181|DRUG|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
48287206|NCT01208181|DRUG|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
48287207|NCT01208181|DRUG|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
48287208|NCT00222079|DRUG|Esomeprazole (Nexium)|
48472944|NCT05357287|DEVICE|PREVENA incision management system|We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
47940706|NCT05860231|DEVICE|Foley catheter|"Silicone Foley catheters are transurethral balloon catheters used for the treatment of bladder emptying disorders, as well as for drainage of urine from the urinary tract, continuous fluid irrigation, and/or medication administration. Its use is suitable for a prolonged period of no more than 29 days and is used in Urology, Internal Medicine, Surgery, Obstetrics and Gynaecology Services.~For this study, conventional Foley-type catheters whose use is approved in Spain for routine use will be used. Silicone Foley catheters, usually available in 2- and 3-way, are made of silicone and consist of a body, drainage funnel, inflation funnel, irrigation funnel (if present, only on 3-way catheters) and balloon valve. The product is sterile and single use."
48101712|NCT05538091|DRUG|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
48472945|NCT05824858|DRUG|LY3537982|Administered orally.
48472946|NCT02711033|PROCEDURE|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
48472947|NCT02711033|PROCEDURE|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
48472948|NCT00075686|BIOLOGICAL|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles
48472949|NCT00075686|DRUG|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
48472950|NCT02991560|OTHER|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
48472951|NCT02991560|OTHER|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
48472952|NCT02991560|DEVICE|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
48472953|NCT02991560|DEVICE|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
48472954|NCT00792441|DEVICE|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
48472955|NCT06679231|BEHAVIORAL|Stress Ball|After the initial measurements of the participants assigned to the experimental group, the students involved in the project will accompany the patient and prepare the patient for the gynecological examination. To make the patient feel more comfortable during the gynecological examination, she will be given two stress balls. The patient will be asked to count each time she squeezes the stress ball during the examination. During the gynecological procedure, the participant will be administered the first EC-3. The stress ball intervention will help to reduce the participant's anxiety level and make the examination process more tolerable. In addition, the student's support to the patient will make the examination more comfortable and contribute to the participant's psychological well-being.
48472956|NCT02260635|DRUG|Evacetrapib|Administered orally
48472957|NCT02260635|DRUG|Placebo|Administered orally
48472958|NCT03675893|DRUG|Letrozole|Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
48472959|NCT03675893|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
48472960|NCT03675893|DRUG|LY3023414|LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
48472961|NCT03675893|DRUG|Metformin|Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.
47940707|NCT05860231|DEVICE|T-Control catheter|The T-control® catheter is a flexible, sterile silicone tube with an inflatable balloon at the distal tip, a polytetrafluroethylene membrane integrated into its body, and a sliding fluid control valve. The valve, built into the catheter, provides additional functions to the catheter, such as turning urine flow on and off after insertion (functions currently provided by accessories such as caps or valves) and controlling urination during the insertion process (function that is not provided by any other device). In this way, accidental loss of urine can be avoided from the first moment of use until its withdrawal. Additionally, it has a safety cap that reduces the possibility of accidental movements of the valve before use or during transport and fixing. The design has been developed in such a way that, once inserted, it facilitates autonomous use even for the elderly or patients with limited manual dexterity. The device is sterile and single use, like any conventional Foley catheter.
47940708|NCT01100736|DRUG|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
48287209|NCT00722605|PROCEDURE|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~* During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~* For all scans, an external monitor will be used to record your breathing.~* If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
48287210|NCT04891601|PROCEDURE|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
47940709|NCT01100736|DRUG|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
47940710|NCT01100736|DRUG|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
48287211|NCT00495846|DRUG|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
47940711|NCT01100736|BIOLOGICAL|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
47940712|NCT01483690|DRUG|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
47940713|NCT01483690|DRUG|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
48287212|NCT00495846|OTHER|Locoregional treatments|
48472962|NCT03675893|DRUG|Zotatifin|Zotatifin is a selective eukaryotic initiation factor 4A (eIF4A) inhibitor.
48472963|NCT05700396|BEHAVIORAL|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
48472964|NCT01439724|DEVICE|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
48472965|NCT01439724|DEVICE|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
47940714|NCT01483690|DRUG|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
47940715|NCT01483690|DRUG|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
47940716|NCT01483690|DRUG|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
47940717|NCT01483690|DRUG|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
47940718|NCT01483690|DRUG|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
47940719|NCT05501262|DEVICE|Cryoablation|Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
47940720|NCT05501262|PROCEDURE|Nerve block|Ultrasound and fluoroscopic guided nerve block.
47940721|NCT00193388|DRUG|Topotecan|
48287213|NCT04169477|DEVICE|CEFAR Primo Pro (TENS device)|"During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer."
47940722|NCT03793218|DEVICE|Latera Device|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
47940723|NCT03793218|PROCEDURE|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
48287214|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
48287215|NCT00831051|DRUG|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
48287216|NCT00831051|DRUG|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
48287217|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
48287218|NCT00831051|DRUG|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
48287219|NCT00831051|DRUG|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
48287220|NCT01259739|OTHER|Cocoa|dissolved in water twice-daily intervention
48287221|NCT06495151|DIAGNOSTIC_TEST|Mannose-binding lectin-associated serine protease-3 (MASP-3) Level|Measurement of venous blood serum and peritoneal fluid levels of MASP-3 level by ELISA method.
48287222|NCT06495151|DIAGNOSTIC_TEST|Adipsin Level|Measurement of venous blood serum and peritoneal fluid levels of adipsin level by ELISA method.
48287223|NCT06495151|DIAGNOSTIC_TEST|Properdin Level|Measurement of venous blood serum and peritoneal fluid levels of properdin level by ELISA method.
48287224|NCT06495151|DIAGNOSTIC_TEST|Complement Factor H (CFH) Level|Measurement of venous blood serum and peritoneal fluid levels of CFH level by ELISA method.
48287225|NCT06495151|DIAGNOSTIC_TEST|Cancer Antigen 125 (CA-125) Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
48287226|NCT00756002|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
48287227|NCT00756002|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
48287228|NCT04255134|DRUG|Abatacept Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
48287229|NCT04255134|DRUG|Adalimumab Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
48287230|NCT03530163|DEVICE|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
48287231|NCT03530163|DEVICE|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
48287232|NCT02852629|OTHER|observational study|
48287233|NCT01614457|DRUG|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
48287234|NCT01614457|DRUG|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
48472966|NCT04718649|DRUG|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
48287235|NCT03551886|BEHAVIORAL|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
47940724|NCT03052764|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
47940725|NCT03052764|DRUG|Placebo (saline)|Placebo (saline) injection into the bladder.
48287236|NCT03551886|BEHAVIORAL|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
48287237|NCT01513915|OTHER|Group cognitive behavioral intervention|A Group cognitive behavioral intervention _based on parent training component of FRIENDS program_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
48287238|NCT02570815|DRUG|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
48287239|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh no attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with no attachement of posterior mesh
48287240|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with the attachement of posterior mesh to vagina
48287241|NCT03556696|DEVICE|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
48287242|NCT03556696|DEVICE|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
47940726|NCT01020539|DRUG|Fludarabine|Conditioning Regimen
47940727|NCT01020539|DRUG|Busulfan|Conditioning Regimen
47940728|NCT01020539|DRUG|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
48630357|NCT00326495|DRUG|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
48630358|NCT00326495|DRUG|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
47940729|NCT01020539|DRUG|Gemtuzumab Ozogamicin|Dose Escalation
47940730|NCT01020539|DRUG|Anti-Thymocyte Globulin|Unrelated Donors only
47940731|NCT01020539|DRUG|Isotretinoin|JMML patients only
48287243|NCT03556696|DRUG|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
48287244|NCT03556696|DRUG|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
48287245|NCT03556696|DEVICE|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target"
48287246|NCT02916446|BIOLOGICAL|Viaskin Peanut 250 mcg|
48287247|NCT02916446|BIOLOGICAL|Placebo|
48287248|NCT02319772|DRUG|BCX4430|
48287249|NCT02319772|DRUG|Placebo|
48287250|NCT02283944|DEVICE|TMS|Pulsed non-invasive brain stimulation using electromagnets
48287251|NCT03050463|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
48287252|NCT03050463|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
48287253|NCT03050463|OTHER|Questionnaire Administration|Ancillary studies
48287254|NCT03968510|PROCEDURE|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
48287255|NCT00954577|BEHAVIORAL|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
47940732|NCT02933580|DRUG|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
47940733|NCT02933580|OTHER|Placebo|Participants will receive matching placebo tablets on Day 1.
47940734|NCT02495103|DRUG|Vandetanib|PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.
47940735|NCT02495103|DRUG|Metformin|Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib
47940736|NCT02495103|DRUG|Vandetanib/Metformin|Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
47940737|NCT06282848|DRUG|Atropine 0.05%|Topical application
48287256|NCT01900548|DIETARY_SUPPLEMENT|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
48287257|NCT01900548|DIETARY_SUPPLEMENT|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
48287258|NCT01900548|DIETARY_SUPPLEMENT|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
48287259|NCT01900548|OTHER|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
48287260|NCT00850512|DRUG|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
48287261|NCT00850512|DRUG|Zevalin|12-week safety period for Zevalin
48287262|NCT06123416|BEHAVIORAL|Expressive Writing|Caregivers complete three 20-min writing sessions in which they write about an assigned topic - emotional or non-emotional.
48287263|NCT03261869|OTHER|Cold application|
48287264|NCT03631329|DIAGNOSTIC_TEST|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
47940738|NCT06282848|DEVICE|DIMS lens|Spectacle wear
48287265|NCT05739708|OTHER|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
48287266|NCT01594723|DRUG|120 mg LY2784544|Administered orally
48630359|NCT03832088|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale performed for balance disorder
48630360|NCT03832088|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test for walking speed
48630361|NCT03832088|DIAGNOSTIC_TEST|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
48630362|NCT03832088|DIAGNOSTIC_TEST|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
48630363|NCT02783859|DRUG|Amoxicillin-clavulanic Acid|
48630364|NCT02783859|DRUG|Placebo (for Amoxicillin-clavulanic Acid)|
48630365|NCT03132272|DEVICE|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
47940739|NCT05302661|BEHAVIORAL|re-education|Contact patients by phone or wechat and guide them
47940740|NCT04867031|DIETARY_SUPPLEMENT|Milk|One portion of semi-skimmed cow's milk (approx. 450mL), providing \~140µg of iodine.
47940741|NCT04867031|DIETARY_SUPPLEMENT|Fish|One portion of cod (approx. 130g), providing \~140µg of iodine.
48101713|NCT05538091|DRUG|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
48101714|NCT02784327|DRUG|PRF110|
47940742|NCT04867031|DIETARY_SUPPLEMENT|Seaweed|One portion of dried seaweed sheets (approx. 6g), providing \~140µg of iodine.
48101715|NCT05067127|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
48101716|NCT05067127|OTHER|Placebo|Sterile solution of equal volume to active arm
48287267|NCT04837391|DEVICE|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
48287268|NCT04837391|DIAGNOSTIC_TEST|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
48630366|NCT02882516|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
48630367|NCT04757584|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
48630368|NCT01426646|DRUG|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
48630369|NCT01426646|DRUG|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1"
48630370|NCT05033457|PROCEDURE|unilateral biportal endoscopy technique or percutaneous endoscopic transforaminal discectomy|Treatment of lumbar intervertebral disc herniation with unilateral biportal endoscopy technique in unilateral biportal endoscopy technique group.Treatment of lumbar intervertebral disc herniation with percutaneous endoscopic transforaminal discectomy in percutaneous endoscopic transforaminal discectomy group.
48630371|NCT02852733|OTHER|end-of-life emergencies' management|
47940743|NCT04654884|OTHER|Auricular acupuncture (AA)|The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
47940744|NCT00075673|DRUG|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
47940745|NCT00075673|DRUG|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
48101717|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
48287269|NCT04837391|DIAGNOSTIC_TEST|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
48287270|NCT04837391|DIAGNOSTIC_TEST|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
48287271|NCT04349930|DRUG|Cannabidiol vaginal suppository|Cannabidiol vaginal suppository
47940746|NCT04643821|DRUG|N-acetylcysteine, NAC, and calcitriol|iv administration of antioxidant and active vitamin D
47940747|NCT02029599|DRUG|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
47940748|NCT02029599|DRUG|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
48101718|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
48101719|NCT00719823|DRUG|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
48630372|NCT02726269|DRUG|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
48630373|NCT02726269|DRUG|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
47940749|NCT02029599|DRUG|Methotrexate|7.5-15mg per week，All patients should be used
47940750|NCT02029599|DRUG|Acetaminophen tablets|Oral,0.5g, 1\~2 times a day, when vas=10
48630374|NCT05328232|OTHER|Olive oil|The parents of the babies included in the experimental group were asked to fill in the questionnaires. The infant's skin condition was assessed using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants. Each time the diaper was changed, the diaper area was cleaned with water and cotton wool and dried, 1-2 cc of natural extra virgin olive oil was applied, and the new diaper was fastened. At the end of each day, the diaper area was evaluated by the researcher and a nurse by using the Scale for Assessing the Severity of Uncomplicated Diaper Dermatitis in Infants.
48630375|NCT02619656|PROCEDURE|CO2 insufflation|Patients were randomized to insufflation with CO2.
48630376|NCT02619656|PROCEDURE|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
47940751|NCT03332771|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
47940752|NCT03332771|DRUG|Glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
48101720|NCT04227678|DRUG|Heparin|an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
48101721|NCT04227678|DIETARY_SUPPLEMENT|liquid meal|low fat meal: (500 mL, 898 Kcal, 13% fat, 20.3% protein and 62.3% carbohydrates) will be ingested over 20 minutes
48472967|NCT01166815|DIETARY_SUPPLEMENT|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
48472968|NCT01166815|OTHER|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
48472969|NCT02306837|DRUG|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
48630377|NCT05039385|OTHER|Exercise Program focused on resistance training|"The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise."
48630378|NCT00509600|DRUG|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
48630379|NCT00893295|OTHER|informational intervention|
48630380|NCT00893295|OTHER|medical chart review|
48630381|NCT00893295|OTHER|screening questionnaire administration|
48630382|NCT00893295|OTHER|study of socioeconomic and demographic variables|
47940753|NCT03332771|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
47940754|NCT03332771|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
47940755|NCT03332771|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
47940756|NCT03676985|DRUG|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
47940757|NCT03676985|DRUG|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
47940758|NCT03676985|DRUG|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
47940759|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
47940760|NCT01053949|DRUG|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
48101722|NCT04045743|DRUG|MABp1 (Bermekimab) OR Placebo|Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
48101723|NCT04045743|DRUG|MABp1 (Bermekimab)|Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
48287272|NCT04349930|DRUG|Placebo vaginal suppository|Placebo vaginal suppository
48630383|NCT00893295|PROCEDURE|barium enema injection|
48630384|NCT00893295|PROCEDURE|colon imaging study|
48630385|NCT00893295|PROCEDURE|screening colonoscopy|
48630386|NCT00893295|PROCEDURE|sigmoidoscopy|
48630387|NCT00108537|DRUG|bupropion and transdermal patch|
48630388|NCT00108537|DRUG|transdermal patch and nicotine inhaler|
48630389|NCT00140114|DRUG|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
48630390|NCT04984408|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"* The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
48630391|NCT04984408|BIOLOGICAL|influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)|"* The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius"
48630392|NCT05332795|DRUG|Metformin|gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
48630393|NCT05332795|DRUG|Placebo|gouty patients, will receive placebo tablets once daily for about 3 months.
48630394|NCT04997421|DEVICE|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
47940761|NCT00346944|PROCEDURE|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
47940762|NCT06468215|DRUG|Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.|Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.
47940763|NCT00398333|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
47940764|NCT03454321|OTHER|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
47940765|NCT03700879|RADIATION|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
47940766|NCT02851186|DEVICE|Acupuncture|
47940767|NCT02851186|DEVICE|Sham acupuncture|
48287273|NCT00907738|DRUG|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
48287274|NCT04260269|DRUG|Fluoropyrimidine|"This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up."
47940768|NCT01693302|OTHER|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
47940769|NCT00071266|DRUG|Niacin Extended Release and Lovastatin Tablets|
47940770|NCT05730634|DRUG|Atorvastatin 40 Mg Oral Tablet|Atorvastatin 40mg once daily for three months
47940771|NCT03416374|DRUG|Ixazomib|Ixazomib capsules
47940772|NCT03416374|DRUG|Bortezomib|Bortezomib injections
47940773|NCT03416374|DRUG|Carfilzomib|Carfilzomib intravenous infusions
47940774|NCT03416374|DRUG|Lenalidomide|Lenalidomide capsules
47940775|NCT03416374|DRUG|Dexamethasone|Dexamethasone tablets
47940776|NCT01063712|DEVICE|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
48101724|NCT05543811|DIETARY_SUPPLEMENT|Food for special dietary use|Food for special dietary use (spread) with modified ingredients' content will be included to the diet of 70 patients without significant organic pathology for 14 days receiving standard diet, modified by the inclusion of two portions of the spread, 20 grams each for breakfast and dinner
47940777|NCT03157323|BEHAVIORAL|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
48101725|NCT04304534|DRUG|BAY2433334|Tablet, taken orally once a day.
48101726|NCT04304534|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
48107086|NCT02228408|DRUG|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
48287275|NCT06481358|DIAGNOSTIC_TEST|Artificial intelligence|AI extract intestinal region and reconstruct into 3D image.
48287276|NCT02240628|DEVICE|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
48287277|NCT02240628|DRUG|Saline|Patients in arm 2 will receive Saline with the Propofol.
47940778|NCT02567552|DRUG|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
47940779|NCT02567552|DRUG|Intramuscular progesterone|intramuscular progesterone 50 mg/day
47940780|NCT02572193|PROCEDURE|POEM|To determine the feasibility of same-day discharge following a POEM procedure
47940781|NCT05425589|PROCEDURE|Adjustable strabismus surgery|Our objective was to assess the long-term success of adjustable suture strabismus surgery in terms of postoperative alignment and complications.
48287278|NCT02240628|DRUG|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
48287279|NCT04710030|DRUG|Valacyclovir hydrochloride 500mg caplet|Active Comparator
48287280|NCT04710030|DRUG|Placebo sugar pill caplet|Placebo Comparator
48287281|NCT05134623|DIAGNOSTIC_TEST|immunohistochemistry of tumors samples|routine resection of tumors, further analysis and immunohisochemical staining of the tissue slides.
48287282|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
48287283|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
48287284|NCT04698408|OTHER|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
48287285|NCT04698408|OTHER|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids \<10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
48287286|NCT02801357|DRUG|lofexidine administration in subjects seeking buprenorphine dose reduction|
48287287|NCT02660697|PROCEDURE|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
48287288|NCT04282577|DIAGNOSTIC_TEST|urinary nephrin and alpha one microglobulin|urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
48287289|NCT05045053|DRUG|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
48287290|NCT05337943|BEHAVIORAL|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
48287291|NCT05337943|DEVICE|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
47940782|NCT05569811|DRUG|Patritumab deruxtecan|HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
48101727|NCT06553573|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Parasternal Block and Recto-Intercostal Fascial Plane Block:Superficial PSB is performed bilaterally with the patient in the supine position using a high-frequency linear USG probe. The probe is inserted longitudinally 2cm lateral to the sternal border to visualize the T2T4 intercostal space and identify the pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is administered between the pectoralis major and intercostal muscle. Additionally, a Recto-Intercostal Fascial Plane Block is performed bilaterally with a high-frequency linear USG probe. The probe is inserted 2-3cm lateral to the xiphoid to visualize the rectus abdominis muscle and the 6th-7th cartilages. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique, and 1-2ml of saline is injected. After spreading to the target plane is observed, 20ml of 0.25% bupivacaine is administered.
48107087|NCT02228408|DRUG|Placebo|Placebo titration will mimic titration of active study arm
48287292|NCT04950738|OTHER|pess tack acupuncture|Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.
48107088|NCT05949554|OTHER|Ketamine infusion|"Continuous measurement of burst suppression (BS) (%) and 95% spectral frequency front (SEF95) on frontal EEG Sedline® Masimo Corporation, USA).~EEG recording will start 10 minutes before the beginning of infusion until the total amount of 10 milligrams of Ketamine has been infused.~The duration varies depending on patient's weight.~Each patient will receive a dose of 0,5 mg/kg over a period of time of 2 or 4 hours."
48287293|NCT04950738|OTHER|pess tack placebo|pess tack stickers without a needle
48630395|NCT04997421|DEVICE|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes|Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
48630396|NCT04080934|BEHAVIORAL|Swimming|Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
48630397|NCT02458300|OTHER|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
48630398|NCT02458300|OTHER|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
48287294|NCT03020511|OTHER|Ancient wheat flours|Ancient wheat flours will be administered in open label for 30 days
48287295|NCT02527304|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
48287296|NCT02527304|OTHER|Quality-of-Life Assessment|Ancillary studies
48287297|NCT02527304|OTHER|Questionnaire Administration|Ancillary studies
48287298|NCT02527304|RADIATION|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
48287299|NCT03848520|PROCEDURE|TKA|TKA performed in the past
48287300|NCT04385108|BIOLOGICAL|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
48287301|NCT04385108|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
48287302|NCT02551172|DRUG|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
48287303|NCT02551172|DRUG|HGP0816|Rosuvastatin
48287304|NCT02551172|DRUG|Placebo of HCP1105|Soybean Oil
48287305|NCT02551172|DRUG|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
48287306|NCT02601781|PROCEDURE|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
48287307|NCT02601781|DEVICE|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
48287308|NCT05777525|COMBINATION_PRODUCT|"application of cream La Chinata"|application of cream enriched with essential oil
48287309|NCT06216886|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
48287310|NCT06216886|DRUG|Sodium Chloride 0.9% for Injection, Preservative Free|intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
48287311|NCT05959499|DRUG|BR6002A|One tablet administered alone
48287312|NCT05959499|DRUG|BR6002B|One tablet administered alone
48287313|NCT05959499|DRUG|BR6002|One capsule administered alone
48287314|NCT00850499|DRUG|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
48472970|NCT01622660|DRUG|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
48472971|NCT01622660|DRUG|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
48472972|NCT03711396|BEHAVIORAL|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
48472973|NCT03559127|PROCEDURE|For the Group A. Applied Cryotherapy at 6 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
48472974|NCT03559127|PROCEDURE|For the Group B. Applied Cryotherapy at 2.5 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
48472975|NCT03559127|PROCEDURE|Control Group (CG). Applied irrigant at room temperature|Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
48472976|NCT02104869|BIOLOGICAL|Trivalent influenza vaccine (inactivated and fragmented).|
48472977|NCT04565496|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
48472978|NCT03537911|BEHAVIORAL|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
48472979|NCT02681406|BEHAVIORAL|ACHESS|Smartphone based additions focused application, encouraging social support
48472980|NCT02681406|BEHAVIORAL|TMC|Brief telephone monitoring and counseling
48630399|NCT02458300|OTHER|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
48287315|NCT00850499|DRUG|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
48287316|NCT00850499|DRUG|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
48287317|NCT05282212|DIAGNOSTIC_TEST|Ultrasound Scan|Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
48287318|NCT00989703|DRUG|placebo|oral solution, daily for 14 days
48287319|NCT00989703|DRUG|GLPG0259|oral solution
48287320|NCT00989703|DRUG|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
48287321|NCT02285010|DRUG|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
48287322|NCT02285010|DRUG|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
47940783|NCT05569811|DRUG|Chemotherapy|Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
48287323|NCT03590457|DEVICE|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
48287324|NCT04234438|DEVICE|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
48287325|NCT05666154|OTHER|Real diet|Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)
48287326|NCT05666154|OTHER|Sham diet|Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
48287327|NCT05666154|OTHER|Wheat exclusion diet|Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)
48287328|NCT05666154|OTHER|Soy exclusion diet|Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
48287329|NCT05006053|OTHER|Interviews/Focus groups|Qualitative study (no intervention delivered)
48287330|NCT05585853|OTHER|virtual reality|Virtual reality glasses application is a method without any side effects. Patients will be treated for an average of 10 minutes. Data will be collected before, during, immediately after the application, at the 15th and 30th minutes.
48472981|NCT06384482|DRUG|SNC115 injection|SNC115 Injection is DLL3 CART.
48617986|NCT02494011|OTHER|closed kinetic chain exercise|wall press exercise plyometric exercise
48630400|NCT02458300|OTHER|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
48630401|NCT02458300|OTHER|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
48630402|NCT02732145|DIAGNOSTIC_TEST|"Three Rings Vulvoscopy (TRIV)"|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme."
48630403|NCT02732145|PROCEDURE|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
48630404|NCT01646216|BEHAVIORAL|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
48630405|NCT02526394|BIOLOGICAL|Meningococcal vaccine|Meningococcal vaccination
48630406|NCT02526394|DRUG|Pertussis containing vaccine|Pertussis containing vaccination
48630407|NCT05683626|DRUG|Humira|subcutaneous injection
48287331|NCT06278259|OTHER|Telerehabilitation program bases aerobic and Baduanjin exercises|It is an interventional study in which 60 stroke patients estimated to enrol according to random allocation and divided into two groups. The study group participants involve in Telerehabilitation sessions is based on low-impact rhythmic movements, guided by video, according to the protocol of (Schachter et al., 2003). The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist
48287332|NCT06278259|OTHER|Telerehabilitation program bases aerobic exercises|The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.
48287333|NCT03328039|DEVICE|Garmin wearable device|Physiological data capture only
48472982|NCT00857818|DRUG|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
48630408|NCT05371197|DRUG|Neoadjuvant therapy with PD-L1 inhibitor|Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
48630409|NCT04505111|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
48472983|NCT00857818|DRUG|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
48472984|NCT02999984|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
48472985|NCT02999984|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
48472986|NCT02999984|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
48472987|NCT06325280|DIAGNOSTIC_TEST|Exercise cardiac MRI Assessment|Participants will undergo a standard cardiac MRI to assess resting ventricular structure and function then complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer.
48472988|NCT06325280|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Cardiopulmonary exercise testing will be performed using a cycle ergometer. Consistent with standard guidelines, workload will progressively increase (10W ramp protocol) such that peak oxygen consumption (VO2peak) is achieved within 8-12 minutes. VO2peak, VO2 at anaerobic threshold, peak power output (PPO), ventilation/carbon dioxide production (VE/VCO2) slope, peak heart rate (HR), and HR recovery at 1- and 3-minutes will be recorded. VO2peak will be converted to age-, weight, and sex-specific norms and a %predicted value.
48472989|NCT00005858|BIOLOGICAL|LMB-9 immunotoxin|
48472990|NCT03631173|PROCEDURE|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
48630410|NCT04505111|OTHER|Enhanced Recovery After Surgery|ERAS protocol
48630411|NCT05120232|BEHAVIORAL|Unified Protocol|A transdiagnostic, cognitive behavioral therapy.
48630412|NCT05120232|BEHAVIORAL|Modified Unified Protocol (UP+)|A transdiagnostic, cognitive behavioral therapy.
48630413|NCT02502071|DRUG|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
48630414|NCT03794063|OTHER|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
47940784|NCT05569811|DRUG|Letrozole|Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
48287334|NCT06117514|DRUG|Sudapyridine 30mg|Sudapyridine capsule 30mg, orally, single dose
48287335|NCT06117514|DRUG|Sudapyridine 100mg SAD|Sudapyridine tablet, 100mg orally, single dose
48287336|NCT06117514|DRUG|Sudapyridine 200mg SAD|Sudapyridine tablet, 200mg orally, single dose
48287337|NCT06117514|DRUG|Sudapyridine 200mg MAD|Sudapyridine tablet, 200mg orally once a day for 14 days
48287338|NCT06117514|DRUG|Sudapyridine 300mg MAD|Sudapyridine tablet, 300mg orally once a day for 14 days
48472991|NCT02251977|DRUG|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
48472992|NCT02251977|DRUG|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
48472993|NCT02251977|DRUG|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
48472994|NCT00664287|DRUG|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
48472995|NCT00664287|DRUG|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
48472996|NCT01728740|DRUG|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
48472997|NCT01728740|DRUG|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
48630415|NCT00651807|DRUG|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
48630416|NCT00651807|DRUG|Placebo|Every day one tablet up to 8 weeks
48630417|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
48107089|NCT01072357|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
48472998|NCT01728740|DRUG|Metformin|Metformin 500mg, oral, single dose
48472999|NCT04661592|DEVICE|NeuroCatch Platform|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
48617987|NCT03342768|OTHER|Smartphone-based messages|"For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research."
48630418|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
48630419|NCT00746720|DRUG|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
48630420|NCT00746720|DRUG|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
48630421|NCT03243890|DIETARY_SUPPLEMENT|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
48630422|NCT03243890|DIETARY_SUPPLEMENT|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
48630423|NCT03537430|PROCEDURE|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
47940785|NCT02123043|BEHAVIORAL|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
47940786|NCT02123043|BEHAVIORAL|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
47940787|NCT00315354|OTHER|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
47940788|NCT00315354|OTHER|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
47940789|NCT00315354|OTHER|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
47940790|NCT03385161|PROCEDURE|Botulinum toxin A|
47940791|NCT03385161|PROCEDURE|Ethanol|
47940792|NCT04862286|DRUG|Risankizumab|Subcutaneous (SC) injection.
47940793|NCT00560378|DRUG|Tacrolimus ointment 0.1%|Topical
47940794|NCT00092690|DRUG|MK0653A, ezetimibe (+) simvastatin|
47940795|NCT00092690|DRUG|Comparator: atorvastatin|
47940796|NCT02597634|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
47940797|NCT02597634|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
48287339|NCT06117514|OTHER|Placebo tablet SAD|Placebo tablet, 100mg orally, single dose
48630424|NCT03537430|PROCEDURE|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
48630425|NCT02147080|BEHAVIORAL|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
47940798|NCT01773772|DRUG|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those or = to 42 kg.
48107090|NCT01072357|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
48287340|NCT06117514|OTHER|Placebo 200mg SAD|Placebo tablet, 200mg orally, single dose
48287341|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 200mg orally once a day for 14 days
48287342|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 300mg orally once a day for 14 days
48287343|NCT03898570|BEHAVIORAL|Patient reported outcomes|"Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys"
48287344|NCT00002676|DRUG|carmustine|
48287345|NCT00002676|DRUG|cyclophosphamide|
48287346|NCT00002676|DRUG|cytarabine|
48287347|NCT00002676|DRUG|dexamethasone|
48287348|NCT00002676|DRUG|doxorubicin hydrochloride|
48630426|NCT02147080|BEHAVIORAL|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
48287349|NCT00002676|DRUG|methotrexate|
48287350|NCT00002676|DRUG|vincristine sulfate|
48287351|NCT00002676|RADIATION|low-LET cobalt-60 gamma ray therapy|
48287352|NCT00002676|RADIATION|low-LET photon therapy|
48287353|NCT01671670|OTHER|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
48287354|NCT01671670|OTHER|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
48287355|NCT01134510|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
48473000|NCT05976854|OTHER|Pain neuroscience education|The patients in the intervention group will receive, in addition to the prenatal educational content, the 12 Pain neuroscience education lessons in audiovisual format. Each lesson will last between 10-15 minutes. The contents of PNE will be an adaptation, focused on the context of a pregnant woman, of the Butler \& Moseley postulates. These contents have already been previously adapted according to the nature of the patients' pain, both in chronic pain and in acute pain. In summary, the participants will receive a detailed explanation about the biopsychosocial component of pain through the use of diagrams, metaphors and practical examples. In turn, the objectives of this program could be summarized as: (1) Reformulate erroneous beliefs about pain, (2) Inform about the biology and protective nature of pain and (3) Provide techniques to reduce kinesiophobia and, consequently, promote physical activity, with the beneficial effect it entails for patients with pain.
48473001|NCT02966340|DRUG|Prazosin|2mg Prazosin
48473002|NCT02966340|DRUG|Placebo|Placebo
48473003|NCT02010034|DRUG|Omegaven|Omegaven will be used in place of soy oil Intralipid
48630427|NCT01197898|BIOLOGICAL|Collagenase Santyl Ointment|Topical daily application
48630428|NCT01197898|OTHER|Placebo Comparator|Topical daily application
48630429|NCT02451319|PROCEDURE|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
48630430|NCT01245049|BIOLOGICAL|Boostrix PolioTM|Single dose, intramuscular administration.
48630431|NCT01245049|BIOLOGICAL|RepevaxTM|Single dose, intramuscular administration.
48630432|NCT01245049|BIOLOGICAL|PriorixTM|Single dose, intramuscular or subcutaneous administration.
48630433|NCT02172599|BEHAVIORAL|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
48630434|NCT01996540|OTHER|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
48287356|NCT01134510|DRUG|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
48287357|NCT04866836|COMBINATION_PRODUCT|Radiotherapy|Patients who meet the criteria for enrollment first receive radiotherapy, either IMRT or SBRT, and the relative biological effect dose is\> 40Gy. On the 7th day (±3 days) after radiotherapy, start to give tislelizumab 200 mg, IVD, q3w, and continue the treatment until disease progression, unacceptable toxic radiotherapy, death or meet the description in the protocol Any discontinuation criteria shall be subject to whichever occurs firs
48287358|NCT00704106|DRUG|Entecavir|0.5 or 1 mg dose qd
48287359|NCT00392873|BEHAVIORAL|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
48287360|NCT03429647|DIAGNOSTIC_TEST|visible light spectroscopy|Sigmoid perfusion was assessed using visible light spectroscopy
48473004|NCT03248986|OTHER|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
48473005|NCT05191745|DRUG|Parasternal blocks|Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
48287361|NCT04526587|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
48287362|NCT04526587|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48287363|NCT04526587|OTHER|Medical Chart Review|Patient's electronic health records are reviewed
48630435|NCT05047120|BEHAVIORAL|Hypnosis enhanced cognitive behavioral therapy|This therapy entails subjects being induced into a state of relaxation and the receiving cognitive behavioral therapy for pain associated with a new spinal cord injury.
48630436|NCT05047120|BEHAVIORAL|Pain Education|This therapy entails subjects learning about the causes, mechanisms, and ways to reduce pain associated with a new spinal cord injury.
48630437|NCT02368236|BEHAVIORAL|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
48473006|NCT05191745|DRUG|Standard of care|All standard management of postoperative pain, as per local protocols
48473007|NCT01263886|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
48630438|NCT00741949|DRUG|Propofol|Sedation in TCI with propofol
48630439|NCT00741949|DRUG|Placebo|Isotonic saline solution infusion
48630440|NCT03362593|DRUG|MEDI7219|Experimental Drug
48107091|NCT06055114|DIAGNOSTIC_TEST|Microscopic examination of vaginal discharge|Using gram-stained smears to detect vaginal secretions, and then the concentration and diversity of bacterial flora are observed using a microscope.
48107092|NCT00182936|BEHAVIORAL|Delirium Abatement Program|
48287364|NCT04107012|DEVICE|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
48287365|NCT03659435|DRUG|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
48473008|NCT01263886|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
48473009|NCT03935841|DIETARY_SUPPLEMENT|3-OHB salt (NaCl)|36 gram 3-OHB salt diluted in 500 ml sterile water
48473010|NCT01325506|OTHER|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
48473011|NCT05626387|DRUG|Mycophenolate Mofetil plus prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.
48473012|NCT05626387|DRUG|Prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms.
48473013|NCT02093923|DRUG|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
48287366|NCT03659435|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
48287367|NCT04459468|DRUG|Lipiodol|Lipiodol TACE procedure
48287368|NCT03456765|DIAGNOSTIC_TEST|Ultrasound|US will be made to assess kidneys
48287369|NCT01565486|DEVICE|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
48287370|NCT01565486|DEVICE|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
48287371|NCT02438930|BEHAVIORAL|Motivational interviewing intervention during HIV testing|
48287372|NCT02438930|BEHAVIORAL|Standard-of-care counseling during HIV testing|
48287373|NCT02606786|OTHER|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
48473014|NCT02093923|DRUG|Placebo|Participants will receive matching placebo subcutaneously.
48473015|NCT04594720|OTHER|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
48473016|NCT04594720|OTHER|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
48473017|NCT05607433|DEVICE|cook ®Airway Exchanger Catheter|A tube exchanger is a small calibre , flexible tube used to guide endotracheal intubation through a supraglottic device.
48630441|NCT03362593|DRUG|Placebo|Placebo
48473018|NCT04437277|DIAGNOSTIC_TEST|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
48630442|NCT03362593|DRUG|Formulation without Active Drug|Formulation without Active Drug
48630443|NCT00333307|DRUG|recombinant human relaxin|
48630444|NCT01495273|PROCEDURE|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
48630445|NCT01495273|PROCEDURE|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
48630446|NCT06309329|BEHAVIORAL|Strength at Home Parents|Strength at Home parents is an 8 week trauma-informed and cognitive behavioral tele-health group intervention that aims to improve parenting behaviors and overall parent-child and family functioning among U.S. military Veterans with post-traumatic stress disorder symptoms
48630447|NCT06309329|BEHAVIORAL|VA treatment as usual|VA treatment as usual includes referral to the online resources at veterantraining.va.gov/parenting .
48630448|NCT05257044|DRUG|Cannabigerol|Participants will ingest CBG and placebo in a double-blind randomized cross-over design
48630449|NCT05257044|OTHER|Placebo|Placebo
47940799|NCT01773772|DRUG|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
48630450|NCT04688944|OTHER|observation|observation the difference between two groups
47940800|NCT05866627|DRUG|Famotidine|Specified dose on specified days
47940801|NCT05866627|DRUG|Afimetoran|Specified dose on specified days
47940802|NCT03408002|BEHAVIORAL|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
48107093|NCT03725371|OTHER|No intervention was administered for the purpose of this study.|No intervention was administered for the purpose of this study. Observations were carried out for all participants.
48287374|NCT05207462|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
48630451|NCT05872399|OTHER|Attitudes Towards Psychiatry - 30|The participants will answer their beliefs in 30 statements about psychiatry and mental health.
48287375|NCT04893850|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
48287376|NCT04893850|BEHAVIORAL|Community Services as Usual Clinical Referral list|The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
48287377|NCT04676243|DRUG|Quizartinib|20 mg coated tablets, orally administered
48287378|NCT04676243|DRUG|Treatment according to Physician's Choice|Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
48287379|NCT04676243|DRUG|Standard of Care Chemotherapy|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
48287380|NCT04135781|DRUG|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
48287381|NCT04135781|DRUG|Tegafur|S-1 （\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
48287382|NCT04135781|DRUG|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
48287383|NCT04135781|DRUG|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
48287384|NCT01554202|BEHAVIORAL|assessment of memory|
48287385|NCT01554202|BIOLOGICAL|circulating tPA dosage|
48287386|NCT01554202|GENETIC|ApoE4|
48287387|NCT01554202|OTHER|Brain imaging examination MRI and PET examinations|
48287388|NCT03443024|BIOLOGICAL|Lebrikizumab|Sterile liquid solution administered subcutaneously.
48630452|NCT06329336|BEHAVIORAL|Social Emotional Competence for Children and Parents|This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
48287389|NCT03443024|DRUG|Placebo|Solution administered subcutaneously.
48287390|NCT01882725|DEVICE|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
48630453|NCT02070991|DRUG|Macitentan|oral tablet, 10 mg once daily
48630454|NCT02070991|DRUG|Placebo|matching placebo
48630455|NCT05753475|OTHER|renal transplantation|patients undergoing renal transplantation
48287391|NCT02821286|OTHER|Observational study|Blood sampling
48287392|NCT01731015|DRUG|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
48473019|NCT01370239|BIOLOGICAL|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
48473020|NCT02762994|DRUG|BCD-085|
48473021|NCT02762994|OTHER|Placebo|
48473022|NCT03860337|DIETARY_SUPPLEMENT|Alginate Sausage|Alginate sausage
48473023|NCT03860337|OTHER|Control Sausage|Control Sausage
48473024|NCT06157853|PROCEDURE|Radiofrequency Microneedling|A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
48473025|NCT06157853|OTHER|Facial Cleanser|Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
48630456|NCT02400736|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is the evidenced based model of supported employment.
48630457|NCT02400736|OTHER|Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)|Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
48630458|NCT06211790|DRUG|Anlotinib, Everolimus and Tislelizumab|Anlotinib (PO, QD), Everolimus (PO, QD) and Tislelizumab (IV, Q3W)
48630459|NCT04041518|PROCEDURE|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
48630460|NCT00949936|DEVICE|CAdisc™-L (Total Disc Replacement)|
47940803|NCT04974918|PROCEDURE|Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of large Lip defects post traumatic or post tumor resection.|A perforator near the defect was selected to accomplish a sufficient arc of rotation without tension. The flap was designed to cover the defect based on one perforator and to hide the donor site in the nasolabial fold. An incision on one side of the flap was made to the subcutaneous tissue. Undermining of the flap until the perforators were identified. After the perforators were identified, the flap was redesigned and an incision was made circumferentially. Dissection of the pedicle was performed until tension-free transposition was done to cover the defect, and the distal perforators were sacrificed to help flap movement.
47940804|NCT02034071|DRUG|DCCR|
47940805|NCT02034071|DRUG|Placebo|
47940806|NCT02715479|DRUG|Dolutegravir|Dolutegravir
47940807|NCT02715479|DRUG|BMS955176|BMS955176
47940808|NCT00419679|PROCEDURE|x-ray diffraction of human hair|
47940809|NCT05344885|BEHAVIORAL|DPT-Standard|The parent training intervention includes 7 modules, recommended to be completed within 7- to 10-weeks period. Module's content includes videos and texts guiding the parent through the training process; interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials, and a Q\&A section that contains frequently asked questions.
47940810|NCT05344885|BEHAVIORAL|DPT-Enhanced|DPT-Enhanced will include all the ingredients of DPT-Standard, but with additional features. The program itself is based on pre-defined decision rules that are either event or time based based on evidence based practice in promoting effective parental engagement. Each component includes a short learning phase, followed by a 1-2 week focusing phase. The focusing phase is designed to encourage and help parents to practice and acquire learned skills in their day-to-day lives, by making these skills more salient in their mind.
47940811|NCT05573386|DRUG|Filgrastim|human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
47940812|NCT05573386|DRUG|Pegfilgrastim|long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
47940813|NCT01669564|OTHER|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
47940814|NCT01669564|OTHER|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
47940815|NCT06156124|DIAGNOSTIC_TEST|Psychological tests and psychosocial questionnaires|Assessment of psychological functioning of adolescents (including occurrence of internalizing and externalizing problems, coping with adolescent crisis), family functioning (siblings relations, parental attitudes, parentification), functioning at school (school achievement, extracurricular activities), relations with peers (time spending with peers, number of friends, quality of relations). Further, the sociodemographic variables will be also measured.
47940816|NCT03206073|DRUG|Durvalumab|1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria
48630461|NCT03020888|DEVICE|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
47940817|NCT03206073|DRUG|Tremelimumab|300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1
47940818|NCT03206073|BIOLOGICAL|Pexa-Vec|3 x 10E\^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
47940819|NCT03206073|BIOLOGICAL|Pexa-Vec|1 x 10E\^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
47940820|NCT03300518|DRUG|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
48473026|NCT06157853|OTHER|Facial Moisturizer|Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
48630462|NCT01486394|OTHER|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
48630463|NCT02594878|DRUG|Pamidronatdinatrium|
48630464|NCT02594878|OTHER|Natrium chloride 9mg/ml|
47940821|NCT03300518|DRUG|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
47940822|NCT03300518|DRUG|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
48630465|NCT06304727|OTHER|clinical data review|Medical records review to gather and analyze demographic, clinical, care and virological data
48107094|NCT02957539|BEHAVIORAL|Financial rewards|Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.
48287393|NCT04844502|OTHER|Physical rehabilitation|Rehabilitation can be applied to the intervention group in two ways: in person or by home orientation. The face-to-face form will correspond to 5 weeks of intervention, 3 sessions per week, which should include: a) aerobic resistance training of 30 minutes in total, five minutes of cooling down); b) strengthening of peripheral muscles using 20-minute sessions of calisthenic exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups. The home-based intervention will correspond to three months of daily activities, monitored twice a week in the first month and once a week in the second and third months, by telephone or video conference, and will follow an exercise protocol that includes: a) aerobic resistance training for 15 uninterrupted minutes; b) anaerobic training to strengthen the peripheral muscles for 15 minutes at intervals with breathing exercises; and c) maintained active stretching, for 10 minutes, for the main muscle groups.
48473027|NCT06157853|OTHER|Sunscreen|Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
48473028|NCT01143831|DIETARY_SUPPLEMENT|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
48473029|NCT01942447|BIOLOGICAL|FMT|
48473030|NCT01942447|DRUG|Vancomycin|
48473031|NCT00462839|PROCEDURE|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
48473032|NCT03705871|DEVICE|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
48473033|NCT03705871|DEVICE|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
48473034|NCT02761603|BEHAVIORAL|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
48473035|NCT02761603|BEHAVIORAL|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
48473036|NCT02904538|DRUG|Dexamethasone|
48473037|NCT02904538|DRUG|isotonic saline|
48473038|NCT02588196|DRUG|Dexamethasone acetate|
48473039|NCT04253236|DRUG|RVT-1401 680 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
48473040|NCT04253236|DRUG|RVT-1401 340 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
48473041|NCT06106152|DRUG|WTX212A injection|The WTX212A infusion is given every 21 days
48473042|NCT06106152|DRUG|PD -1/PD-L1 monoclonal antibody|The PD -1/PD-L1 monoclonal antibody is given every 21 days
48473043|NCT05373667|PROCEDURE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) - High Frequency at 10 kHz
48473044|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
48630466|NCT01495728|PROCEDURE|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
48630467|NCT01495728|PROCEDURE|Sham Manipulation|Mid and Upper Thoracic Spine
48630468|NCT03336866|DRUG|Placebo|Normal saline
48630469|NCT03336866|DRUG|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
48630470|NCT01623284|DRUG|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of \[N-methyl-11C\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
47940823|NCT03300518|DRUG|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
47940824|NCT00127595|DRUG|gemcitabine, oxaliplatin|
48630471|NCT01623284|DRUG|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of \[18-F\]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
48630472|NCT01390935|OTHER|guideline adherence|guideline adherence of physician
47940825|NCT05825261|OTHER|voice sampling|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
47940826|NCT05825261|OTHER|capnometry|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
47940827|NCT03490968|BEHAVIORAL|Supervised Exercise|Subjects will have 3 visits per week for 12 weeks.
47940828|NCT03490968|BEHAVIORAL|Vascular Assessment|"Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated."
48473045|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
48473046|NCT03110796|DEVICE|Dressing without LU3103209|Dressing without LU3103209
48473047|NCT02928458|DRUG|Omnipaque|
48473048|NCT02928458|DRUG|MD-Gastroview|
48473049|NCT02735330|PROCEDURE|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
48473050|NCT02735330|PROCEDURE|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
48630473|NCT00805220|OTHER|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
48630474|NCT03897192|DRUG|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
48630475|NCT06222047|OTHER|breast milk|give breast milk before the OG catheter insertion
48630476|NCT06222047|OTHER|dextrose|give %20 dextrose before the OG catheter insertion
48630477|NCT06494813|DIAGNOSTIC_TEST|conventional pcr|conventional pcr to study matrix metalloproteinase -9 gene polymorphismin rheumatoid arthritis
48630478|NCT01877954|DRUG|Extra-fine hydrofluoroalkane beclometasone dipropionate|
48630479|NCT01877954|DRUG|Fluticasone propionate|
48630480|NCT03017664|OTHER|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
48630481|NCT03017664|OTHER|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
48630482|NCT02032212|OTHER|EVP unflavoured|
48630483|NCT02032212|OTHER|EVP flavoured|
48630484|NCT02032212|OTHER|Nicotine inhalator|15 mg nicotine Nicorette
48630485|NCT02032212|OTHER|Conventional cigarette|
47940829|NCT05685654|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of body temperature, oxygen saturation (SpO2), and pulse rate.
47940830|NCT00941382|DRUG|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
47940831|NCT00941382|DRUG|Sibutramine|15 mg per day for 180 days
47940832|NCT00941382|DRUG|Metformin|Metformin 850 mg per day for 180 days
47940833|NCT02973607|PROCEDURE|Nephrectomy|This is observational in design.
47940834|NCT01577654|DRUG|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
47940835|NCT01577654|DRUG|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
47940836|NCT01577654|DRUG|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
47940837|NCT01577654|DRUG|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
47940838|NCT03051646|DRUG|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
48630486|NCT00004485|DRUG|cyclosporine|
48630487|NCT00004485|DRUG|fludarabine|
48630488|NCT00004485|DRUG|mycophenolate mofetil|
48630489|NCT00004485|PROCEDURE|Bone Marrow Transplantation|
48630490|NCT04588363|OTHER|SARS-CoV-2 and/or MIS-C Exposure|This is an observational cohort study.
48630491|NCT01031615|BEHAVIORAL|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
48630492|NCT01031615|BEHAVIORAL|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
47940839|NCT03051646|DRUG|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
47940840|NCT01858584|DRUG|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~* Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~* Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
47940841|NCT01858584|DIETARY_SUPPLEMENT|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
47940842|NCT04119154|DIAGNOSTIC_TEST|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
47940843|NCT01936727|PROCEDURE|cataract surgery|
47940844|NCT00116662|DRUG|Resiquimod|
47940845|NCT03955380|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any exipients.
47940846|NCT05129891|DRUG|Semaglutide D|Tablet given orally
47940847|NCT05129891|DRUG|Semaglutide G|Tablet given orally
47940848|NCT05129891|DRUG|Semaglutide H|Tablet given orally
47940849|NCT05129891|DRUG|Semaglutide I|Tablet given orally
48473051|NCT02735330|PROCEDURE|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
48107095|NCT02957539|BEHAVIORAL|Non-Financial rewards|Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
48107096|NCT01013441|BIOLOGICAL|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
48473052|NCT00220727|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
48473053|NCT06396637|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride: 20mg/kg, qd
48473054|NCT05424731|COMBINATION_PRODUCT|DBV712 250 mcg|Daily epicutaneous delivery.
48617988|NCT05415878|DEVICE|RCW design form|"Tall RCW= a knee high removable cast walker with an offloading insole~Short RCW= an ankle high (extending up the leg just past the ankle) removable cast walker with an offloading insole, paired with an external shoe lift to be used with a diabetic shoe on the contralateral limb"
48630493|NCT05934253|DRUG|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
48630494|NCT00770484|DRUG|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
48630495|NCT00770484|DRUG|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
48630496|NCT05749185|DEVICE|radiofrequency high voltage|nvolved a high voltage PRF technique, where the voltage started at 65 V and could be adjusted up to 80 V based on patient tolerance. Both protocols involved two cycles of PRF application, with each cycle lasting 240 seconds and comprising alternating periods of current application and deactivation. The pulse rate frequency was set at 2 Hertz (Hz), resulting in two active phases/second (20 milliseconds (ms) of current application followed by 480 ms without stimulation)
47940850|NCT05129891|DRUG|NNC0385-0434 B|Tablet given orally
48287394|NCT05567328|DEVICE|Research FibroScan (FS)|"Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 \& 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 \& 191 to 230 Exams1\&2 Two consecutive Exploratory exams with the Research FS Exams3\&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1\&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS"
48287395|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 5g|Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
48287396|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 10g|Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
47940851|NCT05129891|DRUG|NNC0385-0434 C|Tablet given orally
47940852|NCT05129891|DRUG|NNC0385-0434 D|Tablet given orally
48630497|NCT05749185|PROCEDURE|standard RF|A standard voltage PRF technique, administering PRF at a fixed voltage of 45 volts (V)
47940853|NCT05129891|DRUG|NNC0385-0434 E|Tablet given orally
47940854|NCT02669277|DRUG|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
47940855|NCT02669277|DRUG|standard IVIG product|to compare efficacy and safety with the minipool IVIG
47940856|NCT02309866|GENETIC|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
47940857|NCT06482918|BEHAVIORAL|Cognitive Remediation|Computer-assisted top-down or bottom-up cognitive remediation using tablets
47940858|NCT05479773|DEVICE|Standard NIV mask|The hospital standered NIV mask
47940859|NCT05479773|DEVICE|Lumena NIV mask|aerosol-reducing mask
47940860|NCT03007901|BEHAVIORAL|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (\~30 min) relating to climate change, energy use, and carbon footprint.
48101728|NCT06553573|OTHER|Parasternal Block and Erector Spinae Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2cm lateral to the sternal border to identify the T2T4 intercostal space, pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is applied between the pectoralis major and intercostal muscle. Additionally, an erector spinae plane block is performed with a high-frequency USG probe. Erector spinae plane block is performed under general anesthesia, in the lateral position, under USG guidance, after sterilization, by inserting a needle between the deep surface of the erector spinae muscle and the transverse process with an in-plane approach in the craniocaudal direction. If no air or blood is seen in the aspiration, a 2mL serum test dose is applied to this area and a total of 20mL of 0.25% bupivacaine is injected bilaterally to perform an erector spinae plane block.
48287397|NCT03528681|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
48473055|NCT01520545|DRUG|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
48473056|NCT01520545|DEVICE|SynchroMed® II Programmable Pump|Intrathecal programmable pump
48473057|NCT02771028|BEHAVIORAL|Emotional Freedom Techniques|
48473058|NCT03656263|DIAGNOSTIC_TEST|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
48630498|NCT00588276|RADIATION|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
48101729|NCT00202358|DRUG|atenolol|
48287398|NCT06109909|DEVICE|Micro Current Neurofeedback Device using Low-Frequency Pulse-Based Transcranial Electrical Stimulation|The EEG interface device is a J\&J Engineering 1-330 C2 box. The software used to determine LIP-tES feedback patterns was developed by Neurogen High Performance Neurofeedback. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+,A-,B+,B-), with respect to the Common Neck Reference. During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scale to record EEG signals. All four (A+,A-,B+,B-) electrodes are involved in applying weak electrical pulses back to the brain (feedback process). The brief feedback pulse (\~100mV) is adaptive and determined based on the offset of the frequency spectrum recorded across the left and right hemisphere (A vs. B) electrodes in the time window immediately prior to stimulation.
48287399|NCT03903328|OTHER|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
48287400|NCT05042245|DRUG|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
48287401|NCT05042245|DRUG|Silymarin capsule|Silymarin capsules in the active comparator arm.
48287402|NCT05042245|DRUG|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
48287403|NCT05042245|DRUG|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
48287404|NCT00581503|DEVICE|diagnostic|oct imaging
48287405|NCT03844971|PROCEDURE|Computer assisted arthrocentesis of|Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
48287406|NCT02046135|DRUG|Sodium Bicarbonate|
48287407|NCT02046135|DRUG|Sodium Chloride|
48287408|NCT03304457|DRUG|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
48287409|NCT03304457|DRUG|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
48287410|NCT02990338|DRUG|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
48287411|NCT02990338|DRUG|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
48287412|NCT02990338|DRUG|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
48287413|NCT03358628|OTHER|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
48287414|NCT02646904|DRUG|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
48287415|NCT02646904|DRUG|CERCHIO 10 mg/ml OS|For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
48287416|NCT02788539|BEHAVIORAL|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
48287417|NCT02554643|OTHER|Diet|Nutrition intervention, once a week during 12 weeks
48287418|NCT02554643|OTHER|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
48287419|NCT02554643|OTHER|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
48287420|NCT06085157|OTHER|electronic diary|a smartphone application for self-documentation of drinking pattern
48287421|NCT01901328|DRUG|CB-5945|
48287422|NCT01901328|DRUG|Placebo|
48287423|NCT01403129|PROCEDURE|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
48287424|NCT01403129|PROCEDURE|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
48287425|NCT00110643|DEVICE|CoolTouch II laser|
48287426|NCT02109029|DRUG|Insulin Peglispro|Administered IV
48287427|NCT02109029|DRUG|Human Insulin|Administered IV
48473059|NCT00996424|DRUG|Acetylcysteine|Inhalation with N-Acetylcysteine
48287428|NCT05822869|PROCEDURE|EIT-guided mechanical ventilation strategy|During prone ventilation, the PEEP level is adjusted based on EIT monitoring. The optimal PEEP is the lowest sum of collapse and overdistension percentages
48287429|NCT05822869|PROCEDURE|Lung protective ventilation group|Lung-protective ventilation strategy during prone positioning that continues the supine position.
48287430|NCT03257046|DRUG|ITI-214|Oral
48287431|NCT03257046|OTHER|Placebo|Oral
48287432|NCT02803502|DEVICE|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
48287433|NCT02803502|DEVICE|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
48287434|NCT02803502|DEVICE|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
48287435|NCT04396912|PROCEDURE|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
48473060|NCT00996424|DRUG|normal saline|Inhalation with normal saline solution
48473061|NCT01462578|DRUG|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
48630499|NCT04686409|BIOLOGICAL|COVID-19 vaccines|Participants will be vaccinated with one of the approved COVID-19 vaccines
48101730|NCT00202358|DRUG|placebo|
48473062|NCT01348204|OTHER|quercetin|health food supplement
48473063|NCT03666325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
48473064|NCT03666325|DRUG|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
48473065|NCT02194140|OTHER|oral iodinated contrast material|diluted in water
48473066|NCT03695809|BIOLOGICAL|G9a protein|To assess G9a protein expression on vulvar cancer
48473067|NCT00269334|DRUG|Using Citalopram(drug) or Paroxetine(drug)|
48473068|NCT02820740|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
48473069|NCT04387617|DRUG|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
48473070|NCT04387617|DRUG|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
48473071|NCT03888534|DRUG|Ixazomib|Ixazomib intravenous injection in combination with reduction chemotherapy.
48473072|NCT03635983|BIOLOGICAL|NKTR-214|Specified dose on specified days
48630500|NCT00006215|BIOLOGICAL|filgrastim|
48630501|NCT00006215|DRUG|docetaxel|
48630502|NCT00006215|DRUG|vinorelbine tartrate|
48630503|NCT04197960|PROCEDURE|Microwave ablation|Use thermal energy to destroy tumor
48630504|NCT04197960|PROCEDURE|Surgical resection|Resect tumors
48287436|NCT01655407|DRUG|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
48287437|NCT01655407|DRUG|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
48473073|NCT03635983|BIOLOGICAL|Nivolumab|Specified dose on specified days
48287438|NCT00310505|DRUG|Amphotericin B deoxycholate given as daily administration|
48287439|NCT00934063|DRUG|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48287440|NCT00934063|OTHER|No treatment given|Control group not receiving treatment
48287441|NCT05222802|DRUG|ERAS-801|Administered orally
48287442|NCT00227461|DRUG|Wait first, then levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
48287443|NCT00227461|DRUG|Levetiracetam first, then wait|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
48287444|NCT03129438|DIAGNOSTIC_TEST|continuous EEG (cEEG)|differential use of continuous versus routine EEG
48630505|NCT03134638|DRUG|SY-1365 (Part 1)|"Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~* Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~* Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle."
48630506|NCT03134638|DRUG|Carboplatin|Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
48101731|NCT00030381|DRUG|4'-iodo-4'-deoxydoxorubicin|Given IV
48101732|NCT00030381|OTHER|pharmacological study|Correlative studies
48287445|NCT03129438|DIAGNOSTIC_TEST|routine EEG (rEEG)|differential use of continuous versus routine EEG
48287446|NCT00930410|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
48287447|NCT06509698|OTHER|virtual reality|STEP I: For the warm-up, the examiner will perform passive stretching exercises to maintain the range of motion. STEP II: The patient will receive the game instructions by the examiner. STEP III: The patient will play the Adventure games and Sport games including tennis, boxing and kicking. virtual reality (20 minutes) using Nintendo Wii®, Wii Fit game will be used to stimulate and reinforce the improvement of balance and gait and enhance the quality of life.(30) Balance game: Soccer Heading, Penguin Slides, Balance Bubble, Torso Twists, and Single Leg Stance. Motor function: Boxing, Kicking, Tennis and Bowling Aerobic Games: 2-P run, advanced step, Title city and Basic Run. Step IV: (cool-down): Same as step one.
48287448|NCT06509698|OTHER|Frenkel's exercise|Frenkel's activities, which included learning how to turn around, sit down, and get up using a variety of commonplace objects like chairs, beds, or traces drawn on the floor, as well as learning how to walk with upper limb coordination. This is a typical workout regimen used in testing and rehabilitation centers. Patients engaged in the following activities, each activity time is 1.5 minutes
48287449|NCT00294593|DRUG|folinic acid|
48473074|NCT02063217|DRUG|Sodium Oxybate|Sodium oxybate h.s.
48473075|NCT02063217|BEHAVIORAL|Sleep deprivation|36hr sleep deprivation
48473076|NCT00367016|DRUG|Omalizumab|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
48473077|NCT00367016|DRUG|Placebo|Placebo, given by subcutaneous injection.
48473078|NCT00076245|BEHAVIORAL|Light Therapy|Light therapy will involve exposure to bright light twice a day.
48473079|NCT00076245|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
48630507|NCT03134638|DRUG|Fulvestrant|Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
48101733|NCT03861221|DEVICE|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
48101734|NCT04164524|DRUG|Gentamycin|Gentamycin 160 mg spray applied over the mesh
48101735|NCT04465578|PROCEDURE|Sling tension adjustment by classic technique|We will adjust the tension of the sling by using the classic technique (2 fingers between the fascia and the knot)
48101736|NCT04465578|PROCEDURE|Sling tension adjustment by height of 4 cm|We will adjust the tension of the sling by using the height between the fascia and the knot of 4cm
48473080|NCT01065389|BEHAVIORAL|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
48473081|NCT01065389|BEHAVIORAL|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
48101737|NCT04564391|DIETARY_SUPPLEMENT|protein supplement|protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients
48101738|NCT04564391|DIETARY_SUPPLEMENT|placebo supplement|Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients
48101739|NCT01428895|PROCEDURE|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
48101740|NCT01428895|OTHER|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
48101741|NCT00946114|DRUG|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
48287450|NCT02426606|OTHER|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~* white rice or white rice combined with 1 of 3 different lentil varieties or~* white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
48287451|NCT00984451|BIOLOGICAL|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
48287452|NCT03381040|DEVICE|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
48287453|NCT03381040|DEVICE|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
48287454|NCT03177252|DRUG|Lidocaine|-2% lidocaine will be given
48287455|NCT03177252|DRUG|Sodium chloride|-Normal saline will be given
48287456|NCT03177252|DRUG|Bupivacaine|-0.5% bupivacaine will be given
48287457|NCT05784792|OTHER|Lugol -|Patients that undergo total thyroidectomy without Lugol solution pretreatment
48630508|NCT03134638|DRUG|SY-1365 (Cohort 2)|In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
48630509|NCT03134638|DRUG|SY-1365 (Cohort 5)|In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
48101742|NCT00946114|DRUG|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
48101743|NCT06259448|OTHER|urine self-sampling|urine self-sampling
48101744|NCT03608670|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
48101745|NCT02850055|OTHER|Conventional Physiotherapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home."
48101746|NCT02850055|OTHER|Specific Manual Therapy|"1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.~4. Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
48101747|NCT03219502|OTHER|Best Practice|Receive standard of care
48101748|NCT03219502|OTHER|Quality-of-Life Assessment|Ancillary studies
48101749|NCT03219502|OTHER|Questionnaire Administration|Ancillary studies
48101750|NCT03219502|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
48287458|NCT03933501|DRUG|amoxicillin and metronidazole|375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
48287459|NCT03933501|DRUG|Placebos|Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
48630510|NCT03134638|DRUG|SY-1365 (Part 2 Single Agent)|SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
48630511|NCT06258291|DEVICE|Hemosystem REBOOT|The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.
48630512|NCT03288831|DIETARY_SUPPLEMENT|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
48473082|NCT02106533|OTHER|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
48630513|NCT03288831|DIETARY_SUPPLEMENT|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
48630514|NCT04126668|DRUG|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
48630515|NCT00768638|DRUG|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
48630516|NCT00768638|DRUG|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
48630517|NCT01049672|DRUG|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
48630518|NCT01049672|DRUG|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
48630519|NCT00412451|DRUG|ocriplasmin|Intravitreal injection, single administration
47940861|NCT06040879|PROCEDURE|PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK|During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip
48101751|NCT03219502|PROCEDURE|Sham Intervention|Undergo sham rTMS
48473083|NCT02676960|OTHER|MRI without sedation|
48101752|NCT02414919|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
48287460|NCT06364748|DEVICE|Cellular enabled blood pressure cuff|Smart cuff
48473084|NCT06467578|DEVICE|Breezing Portable Indirect Calorimeter|Indirect calorimeter with face mask and smartphone compatible application
48101753|NCT02414919|DRUG|ParaGard|Copper T380A
48101754|NCT02414919|DRUG|Implanon/Nexplanon|Etonorgestrel contraceptive implant
48101755|NCT02526680|DEVICE|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
48287461|NCT06364748|DEVICE|Standard of Care Cuff|Standard blood pressure cuff
48473085|NCT05796596|BEHAVIORAL|Experimental: Virtual Reality (VR) distraction|Children in the VR distraction group will begin interacting with the virtual environment (VE) 2 minutes prior to the skin prick test and will continue playing throughout. The VR environment is a game in which the child draw a 360 degree image.
48617989|NCT01740206|DRUG|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
48630520|NCT00412451|OTHER|Sham injection|Sham intravitreal injection
48630521|NCT00645931|BEHAVIORAL|protein and calorie controlled diet and self-hypnotic relaxation|daily
48630522|NCT00997126|DRUG|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
48630523|NCT00997126|DRUG|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
48630524|NCT05639868|OTHER|Video-assisted CPR|Participants in V-CPR group get video-based (vocal and visual) instructions from the dispatcher.
48630525|NCT05639868|OTHER|Telephone-assisted CPR|Participants in T-CPR group get voice-based (vocal) instructions from the dispatcher.
48630526|NCT01346553|DEVICE|ESVV device|wearing the ESVV device for 6 hours
48630527|NCT01953237|BEHAVIORAL|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
48630528|NCT01953237|DEVICE|Smartphone|
48630529|NCT05849974|OTHER|Structural and fonctional phynotyping|"The additioan acts in this research are:~Fonctionnal phenotyping:Retinal sensitivity and fixation stability assessment using microperimetry, assessment of long-term fixation stability Structural Phenotyping: Anterior segment examination with OCT anterior Blood sample collection"
48630530|NCT01997255|DRUG|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
48630531|NCT04775134|DIAGNOSTIC_TEST|Lung biopsy|Biopsy of residuary material from a medically indicated pulmonary resection
48630532|NCT03251599|DRUG|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
48630533|NCT03251599|DRUG|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
48101756|NCT01267409|OTHER|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
48473086|NCT05796596|BEHAVIORAL|Active Comparator: Distraction by the book|In the book distraction group, the child will be invited to find and count animals in various landscapes. The book will be given 2 minutes prior to the skin prick test and continued reading throughout.
48473087|NCT00603395|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
48473088|NCT00878787|DEVICE|Transcranial magnetic stimulation|
47940862|NCT00440778|DRUG|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
47940863|NCT01828515|DRUG|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
47940864|NCT01828515|DRUG|Placebo|
47940865|NCT01828515|DRUG|Hydrocortisone|Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
47940866|NCT03973073|COMBINATION_PRODUCT|CapulinTM|camouflage
47940867|NCT03973073|OTHER|topical applications and NB-UVB|combination therapy of vitiligo
47940868|NCT03654027|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
48473089|NCT01123291|PROCEDURE|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
48473090|NCT01123291|PROCEDURE|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
48473091|NCT05148533|DRUG|TJ1133 Injection|TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
48473092|NCT03657238|DRUG|RD01|single S.C. dose of RD01 for subjects in test group
47940869|NCT03654027|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
47940870|NCT00749580|DRUG|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
47940871|NCT05288699|BEHAVIORAL|Aliento|Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
47940872|NCT05611125|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in our study.
47940873|NCT05128773|DRUG|Amcenestrant|tablet, oral
47940874|NCT05128773|DRUG|Tamoxifen|tablet, oral
47940875|NCT05128773|DRUG|Amcenestrant-matching placebo|tablet, oral
47940876|NCT05128773|DRUG|Tamoxifen-matching placebo|tablet, oral
48473093|NCT03657238|DRUG|Placebo|single S.C. dose of placebo for subjects in placebo group
48473094|NCT03901157|DIETARY_SUPPLEMENT|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
48630534|NCT02194686|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
48630535|NCT02194686|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
48630536|NCT02848352|OTHER|Placebo nasal spray|
48630537|NCT02848352|OTHER|Film Sequence|
48630538|NCT05876871|DIAGNOSTIC_TEST|Pelvic Binder Radiography|One series of radiographic exposures
48630539|NCT01016015|BIOLOGICAL|Cixutumumab|Given IV
48630540|NCT01016015|OTHER|Laboratory Biomarker Analysis|Correlative studies
48287462|NCT04541069|BEHAVIORAL|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
48287463|NCT05485103|DRUG|Polyethylene Glycols|Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
48287464|NCT00000249|DRUG|20% N2O|20% inhaled N2O
48287465|NCT00000249|DRUG|30% N2O|30% inhaled N2O
48287466|NCT00000249|DRUG|40% N2O|40% inhaled N2O
48287467|NCT01052285|PROCEDURE|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
48287468|NCT01052285|PROCEDURE|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
48287469|NCT01052285|PROCEDURE|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
48287470|NCT00920543|DRUG|Placebo|Twice daily dosing
48287471|NCT00920543|DRUG|FP 100mcg|Twice daily dosing
48287472|NCT00920543|DRUG|FP 500mcg|Twice daily dosing
48287473|NCT00920543|DRUG|FP 250mcg|Twice daily dosing
47940877|NCT04995796|OTHER|Surveys for Research Purposes|"VISIT #1:~1. Pre-Testing:~   * Pre Knowledge Test~  * Pre SURE (decisional conflict) test~2. Independent DSI/DA Interaction~3. Post-Testing:~   * Post Knowledge Test~  * Post SURE (decisional conflict) Test~  * Acceptability Index~  * Modified Single Item Literacy Screen~  * Additional Demographics~VISIT #2: Check-In Call 1 week later:~After viewing the DSI/DA and completing the post-test components above, the subjects will also complete a 5 minute debrief interview about 1 week later via phone or video conference with a team member to give feedback on their experience using the DSI/DA, including its strengths and weaknesses. This will allow for further improvement and refinement of the DSI."
48287474|NCT00920543|DRUG|FSC 100/50mcg|Twice daily dosing
48287475|NCT00920543|DRUG|FSC 250/50mcg|Twice daily dosing
48287476|NCT00920543|DRUG|FSC 500/50mcg|Twice daily dosing
48287477|NCT06059937|OTHER|Patient with pre-eclampsia|Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia
48287478|NCT00080210|DRUG|Puricase|
48287479|NCT05951127|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer and regional lymph nodes dissection.
48287480|NCT05815953|DEVICE|Polarstem|Stem used in total hip replacement. Manufacturer: Smith \& Nephew Orthopaedics AG, Baar, Switzerland.
48287481|NCT05815953|DEVICE|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
47940878|NCT00882973|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
48101757|NCT06065800|DEVICE|STEELEX® Sternum Set|Sternal Closure with stainless steel suture (STEELEX®) in patients undergoing cardiac surgery
48287482|NCT03644797|GENETIC|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
48287483|NCT04272606|DRUG|Tranexamic Acid|Antifibrinolytic Agent
48101758|NCT01280591|DRUG|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
48287484|NCT04272606|DRUG|Saline Solution|Placebo
48287485|NCT04272606|DIAGNOSTIC_TEST|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
48287486|NCT04272606|DIAGNOSTIC_TEST|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
48287487|NCT00090285|BIOLOGICAL|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
48287488|NCT00090285|BIOLOGICAL|Comparator: placebo (unspecified)|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
48287489|NCT05003245|DRUG|HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL solution at a 4-week interval for intravitreal injection
48287490|NCT05003245|DRUG|Lucentis|0.05mL solution at a 4-week interval for intravitreal injection
48287491|NCT00953121|DRUG|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
48287492|NCT00248677|BEHAVIORAL|Behavioral Family-Based Intervention|Behavioral family intervention
48287493|NCT00248677|BEHAVIORAL|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
48287494|NCT01845025|DRUG|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
48287495|NCT01845025|DRUG|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
48287496|NCT01845025|DRUG|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
48287497|NCT01845025|DRUG|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
48287498|NCT01845025|DRUG|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
48287499|NCT01953315|BIOLOGICAL|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
48287500|NCT02375776|OTHER|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
48101759|NCT01280591|DRUG|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
48287501|NCT03088150|PROCEDURE|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
48287502|NCT03088150|PROCEDURE|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
48287503|NCT04002323|DRUG|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
48287504|NCT04002323|DRUG|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
48287505|NCT02031900|DEVICE|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
48287506|NCT00933946|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
48287507|NCT02032875|DRUG|Daclatasvir|
48287508|NCT02032875|DRUG|Sofosbuvir|
48287509|NCT02032875|DRUG|Ribavirin|
48287510|NCT00782080|DRUG|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
48287511|NCT00782080|DRUG|Placebo|Placebo
48287512|NCT00233571|BIOLOGICAL|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
48287513|NCT04101110|OTHER|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
48287514|NCT03442803|DEVICE|Target-Controlled Infusion|Propofol Target-Controlled Infusion
48287515|NCT03348514|DRUG|CPX-POM - 30 mg/m^2|CPX-POM
48287516|NCT03348514|DRUG|CPX-POM - 60 mg/m^2|CPX-POM
48287517|NCT03348514|DRUG|CPX-POM - 120 mg/m^2|CPX-POM
48287518|NCT03348514|DRUG|CPX-POM - 240 mg/m^2|CPX-POM
47940879|NCT04991428|OTHER|Transcranial direct current stimulation|tDCS is a form of non-invasive brain stimulation. tDCS is an established research tool for non-invasive modulation of neuroplasticity. It uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential. Anodal tDCS has been shown to increase cortical excitability, reduce regional levels of GABA enhance LTP and synaptic plasticity.
48287519|NCT03348514|DRUG|CPX-POM - 360 mg/m^2|CPX-POM
48287520|NCT03348514|DRUG|CPX-POM - 600 mg/m^2|CPX-POM
48287521|NCT03348514|DRUG|CPX-POM - 900 mg/m^2|CPX-POM
48287522|NCT03348514|DRUG|CPX-POM - 1200 mg/m^2|CPX-POM
48101760|NCT01280591|DRUG|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
48287523|NCT02856737|OTHER|eye masks and earplugs|Materials similar to those offered on long commercial flights
48287524|NCT03484026|DIETARY_SUPPLEMENT|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
48287525|NCT04545307|BIOLOGICAL|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
48287526|NCT05431608|BIOLOGICAL|MCARH125|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
48287527|NCT05431608|BIOLOGICAL|MCARH109|MCARH109 and MCARH125 will be administered 2-7 days following the completion of conditioning chemotherapy. Each dose cohort will consist of 3-6 patients. MCARH109 and MCARH125 will be administered sequentially with 5-30 minutes between the two products.
48287528|NCT03777930|DRUG|Chemotherapy drugs|According to the NCCN Guidelines
48287529|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
48287530|NCT03777930|OTHER|optimal support treatment|Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
48287531|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
48287532|NCT04803812|OTHER|"Remote SMS (short message service, also known as text message) delivery"|Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.
48287533|NCT02236624|BEHAVIORAL|Aerobic exercise|
48287534|NCT04124367|DRUG|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
48287535|NCT04124367|DEVICE|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
48287536|NCT04124367|DRUG|Placebo|100 ml once daily 0.9% saline
48630541|NCT01016015|DRUG|Temsirolimus|Given IV
48287537|NCT04124367|DEVICE|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
48287538|NCT03767569|DRUG|Myo-inositol|Myo-inositol and Folic acid daily
48287539|NCT03767569|DRUG|Folic Acid|Folic Acid daily
48287540|NCT03317587|BEHAVIORAL|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
48287541|NCT01820910|DRUG|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
48287542|NCT05619926|DRUG|STSP-0601 for Injection|Intravenous Injection
48287543|NCT04377529|BEHAVIORAL|Local Champion|Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.
48287544|NCT01631162|OTHER|Breath sample in all patients|Breath sample will be collected by a special nylon bag
48287545|NCT00350064|BEHAVIORAL|Exercise Training|16 weeks of aerobic exercise training at two different intensities
48287546|NCT05036538|DEVICE|Intervention with natural sounds administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
48287547|NCT05036538|DEVICE|Intervention with natural sounds and binaural beats administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
48287548|NCT05036538|DEVICE|Intervention with natural sounds and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
48287549|NCT05036538|DEVICE|Intervention with natural sounds, binaural beats and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
48287550|NCT05726695|DIAGNOSTIC_TEST|microRNA test|Laboratory analysis for the detection of microRNA in blood samples.
48287551|NCT05726695|DIAGNOSTIC_TEST|Heart ultrasound examination|Heart ultrasound examination will be performed as a standard cardiology examination.
48287552|NCT06498908|DRUG|Nitrous oxide|Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
48287553|NCT06498908|DRUG|Oxygen|Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
48287554|NCT01954290|DRUG|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
48287555|NCT01954290|DRUG|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
48287556|NCT01954290|DRUG|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
48287557|NCT06085066|PROCEDURE|Conventional Ultrafiltration alone on Cardiopulmonary bypass|Conventional Ultrafiltration was used on Cardiopulmonary bypass for patients who underwent open heart surgery
48287558|NCT06085066|PROCEDURE|Conventional Ultrafiltration followed by Modified Ultrafitration on Cardiopulmonary bypass|Modified Ultrafiltration was used following the Conventional Ultrafiltration on Cardiopulmonary bypass for patients who underwent open heart surgery
48287559|NCT03525977|PROCEDURE|Fascia iliaca block arm|The fascia iliaca block will be performed by the anesthesiologist on call
48287560|NCT04154540|OTHER|Motion analysis|Gait and posture recording
48287561|NCT04284644|DRUG|Induction using propofol|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
48287562|NCT04284644|DRUG|Induction using sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
47940880|NCT00055471|DRUG|ZD4054 10 mg|1 x 10 mg oral tablets once daily
47940881|NCT00055471|DRUG|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
47940882|NCT00055471|DRUG|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
47940883|NCT05221827|DIAGNOSTIC_TEST|C2i Test|The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
48287563|NCT04284644|DRUG|Induction using propofol and sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
48617990|NCT01740206|OTHER|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
48473095|NCT03901157|DIETARY_SUPPLEMENT|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
48473096|NCT00000317|DRUG|Risperidone|Risperidone (4mg/day)
48287564|NCT04705480|DRUG|Pregabalin 50mg|Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
48287565|NCT04705480|DRUG|Gabapentin 300mg|Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
48287566|NCT04705480|DRUG|Neither Pregabalin nor Gabapentin|Patients will receive neither Pregabalin nor Gabapentin.
48473097|NCT00000317|DRUG|Placebo|Placebo
48473098|NCT00000317|BEHAVIORAL|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
48287567|NCT03671369|OTHER|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
48287568|NCT00680732|DIETARY_SUPPLEMENT|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
48287569|NCT00680732|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
48287570|NCT00680732|DRUG|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
48287571|NCT00680732|DRUG|Sulphadoxyne-pyrimethamine (SP)|Tablets
48287572|NCT05308147|DIETARY_SUPPLEMENT|First Reference product|Dextrose (containing 25 grams of carbohydrates)
48287573|NCT05308147|DIETARY_SUPPLEMENT|Second Reference product|Dextrose (containing 25 grams of carbohydrates)
48473099|NCT00460109|BIOLOGICAL|denileukin diftitox|
48473100|NCT00460109|BIOLOGICAL|rituximab|
48473101|NCT05263284|DRUG|8-Chloroadenosine|Given IV
48473102|NCT05263284|DRUG|Venetoclax|Given PO
48473103|NCT02569307|DRUG|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
47940884|NCT04534803|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
48287574|NCT05308147|DIETARY_SUPPLEMENT|Third Reference product|Dextrose (containing 25 grams of carbohydrates)
48287575|NCT05308147|DIETARY_SUPPLEMENT|First Concept product|Infant Formula (containing 25 grams of carbohydrates)
48287576|NCT05308147|DIETARY_SUPPLEMENT|Second Concept product|Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
48473104|NCT02569307|DRUG|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
48473105|NCT02569307|DRUG|Placebo|Placebo added to TAU
48473106|NCT02569307|DRUG|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
48473107|NCT04383717|DRUG|Levamisole and isoprinosine|oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
48473108|NCT04383717|DRUG|Azithromycin and hydroxychloroquine|oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
48473109|NCT01410760|OTHER|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
48473110|NCT00676494|DEVICE|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
48473111|NCT03936894|DRUG|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
48473112|NCT04012931|DRUG|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
48617991|NCT01865773|PROCEDURE|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
48287577|NCT05308147|DIETARY_SUPPLEMENT|Third Concept product|Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
48287578|NCT02217735|BEHAVIORAL|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
48287579|NCT06261528|DEVICE|Light therapy|Light therapy aimed at alleviating fatigue through circadian rhythm synchronization
48287580|NCT00986778|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
48287581|NCT00986778|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
48287582|NCT00986778|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
48287583|NCT04076566|DEVICE|alfapump system|active implantable device for treatment of malignant ascites
47940885|NCT04534803|OTHER|Placebo|.1 nL of diluent (saline) given intradermally at baseline
47940886|NCT01082731|DRUG|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
47940887|NCT01082731|DRUG|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
47940888|NCT04350398|OTHER|Hippotherapy|The horse is an excellent collaborator in situations of physical and mental disability, whether temporary or consolidated. It provides support to humans towards an impairment (anatomical or physiological), a disability, or a restriction of participation as defined by the WHO in 2001. Hippotherapy has a direct action on the sensorimotor capacities of the individual but also on their cognitive capacities, such as attention, memory, psychomotricity, emotions, perceptions, the sequencing of complex movements, or the experience of oneself and the functions of time. Overall, the strong demand from the sensitive, sensory and motor spheres promotes and interacts with the mechanisms linked to the execution of tasks in the cognitive domain (memory, attention, executive functions, speed of information processing, etc.) through the interactions of several neural networks.
47940889|NCT04350398|OTHER|Conventional therapy|Personalized care pathway after/during the cancer treatment takes into consideration all aspects of the disease, allowing to coordinate the intervention of the professionals that the patient might need in order to better preserve her quality of life while answering questions about cancer, prevention, treatments, or life after illness. The MIS mobilizes a chain of skills and support by providing patients: radiologists, pathologists, surgeons, oncologists, and radiation therapists, nuclear doctors, physiotherapists, cardiologists, psychologists, psychiatrists, nurses, social workers, nutritionists, dieticians, onco-geneticists, osteopaths, homeopaths, acupuncturists, sexologists, addictologists, algologists, and vascular physicians.
47940890|NCT01139840|DIETARY_SUPPLEMENT|vitamin D2|Study Supplement
48630542|NCT00133211|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation
48101761|NCT01280591|DRUG|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
48287584|NCT01574781|PROCEDURE|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
48287585|NCT01574781|PROCEDURE|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
48287586|NCT02489630|DRUG|Ketamine|0.1mg/kg ketamine IV
48287587|NCT02489630|DRUG|Normal Saline|1ml/kg normal saline placebo
48287588|NCT02489630|DRUG|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
47940891|NCT01139840|DIETARY_SUPPLEMENT|vitamin D3|Study Supplement
47940892|NCT00023192|DRUG|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
48101762|NCT02759731|DRUG|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg by mouth (PO) every day (QD)
48287589|NCT00553787|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
48287590|NCT00553787|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
48630543|NCT02565472|OTHER|White grape juice|
48630544|NCT02565472|OTHER|Apple juice|
48287591|NCT00553787|DRUG|VI-0521|placebo
48287592|NCT04562337|DRUG|SHR1316|Anti-PD-L1 antibody
48287593|NCT04562337|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
48287594|NCT04562337|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
48287595|NCT04562337|RADIATION|Radiation therapy|Thoracic radiation therapy ,TRT
48473113|NCT04012931|DRUG|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
48473114|NCT02301858|GENETIC|Genome analysis of tissue samples.|Genome analysis of tissue samples.
48473115|NCT02507817|OTHER|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein"
48101763|NCT00394381|PROCEDURE|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
48101764|NCT01407900|DRUG|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
48101765|NCT01407900|DRUG|5% Dextrose in Water|four hour infusion IV
48101766|NCT01805921|BIOLOGICAL|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10\^10 vp
48101767|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10\^8 pfu
48101768|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10\^10 vp
48287596|NCT04562337|DRUG|Cisplatin|Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
48287597|NCT05509244|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
48287598|NCT05509244|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
48287599|NCT00656214|DRUG|Lycopene|08 mg/day in two divided dosage
48287600|NCT00656214|DRUG|Placebo|Two divided dosage
48473116|NCT02045355|OTHER|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
48630545|NCT01958684|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
48630546|NCT01958684|DEVICE|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
48287601|NCT05864040|DEVICE|Bitrack System-assisted laparoscopic radical/simple nephrectomy|Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved. Abdominal wall incisions over 10mm are closed using a continuous suture. Skin incisions are closed using skin staplers.
48287602|NCT04215094|DIAGNOSTIC_TEST|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
48287603|NCT00117962|BIOLOGICAL|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
48630547|NCT06006221|BEHAVIORAL|Qi-gong relaxation exercise|Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
48630548|NCT06245707|DRUG|prednisone,methylprednisone and cyclophosphamide|In the first month, methylprednisolone 500mg/d was given intravenously for 3 days, and then prednisone 0.5 mg/(kg d) \* for 27 days. Oral cyclophosphamide 2.0 mg/(kg d) \* 30 days in the second month. After that, the first month and the second month plan were repeated twice.
48630549|NCT06245707|DRUG|Rituximab|The dosage of rituximab depends on peripheral blood B cells. After the treatment of rituximab, the peripheral blood B cells were in a clear state and then stopped. After monitoring the recovery of B cells, additional doses were given.
48630550|NCT03595722|DEVICE|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
48630551|NCT05575427|DRUG|Minocycline|The patients will receive minocycline oral between 7-28 days
48630552|NCT05575427|DRUG|Levofloxacin or Cotrimoxazole|The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
48630553|NCT05575427|DRUG|Placebo|Capsule without active compound
48630554|NCT03512158|OTHER|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
48630555|NCT05898880|OTHER|Self-acupressure|In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants
48630556|NCT05898880|OTHER|Acupressure by therapists|In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.
48630557|NCT05898880|OTHER|Control group|No intervention will be made in the control group.
48101769|NCT01805921|BIOLOGICAL|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10\^9 vp
48630558|NCT05022537|DEVICE|retrograde nephrostomy|this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.
48101770|NCT01805921|BIOLOGICAL|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10\^7 pfu
48101771|NCT01805921|BIOLOGICAL|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10\^9 vp
48287604|NCT00117962|DRUG|carboplatin|AUC = 5 q 21 days for 4 cycles
48287605|NCT00117962|DRUG|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
48630559|NCT05022537|DEVICE|antegrade nephrostomy|this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
48630560|NCT01309880|DEVICE|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
48630561|NCT01309880|DEVICE|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
48101772|NCT05245487|DIAGNOSTIC_TEST|DNA repair gene mutation analysis|Prospective monitoring of patients with next-generation sequencing for blood mutations
48473117|NCT05796518|OTHER|PREVENT Cardiovascular Health Assessment Tool|Participants will access a heart health information visualization tool online using a personal device or a study tablet computer using their e-mail address to log-in. Investigators will review participant lab results specifically related to their cardiovascular health (e.g. blood pressure, cholesterol) in order to personalize the heart health tool for participants. A brief survey before and after use of the tool will also be completed by participants.
48473118|NCT05796518|OTHER|Survey|A brief survey before and after use of the tool will also be completed by participants.
48473119|NCT05796518|OTHER|Interview Regarding Heart Health|Participants will be asked questions related to their heart health.
48473120|NCT00988468|PROCEDURE|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
48473121|NCT00988468|BEHAVIORAL|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
48473122|NCT00988468|BEHAVIORAL|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
48473123|NCT02776527|DRUG|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
48473124|NCT01218035|DRUG|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
48473125|NCT06292546|DRUG|Vonoprazan|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
48473126|NCT06292546|DRUG|Amoxicillin|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
48473127|NCT06292546|DRUG|Bacillus subtilis enteric-coated capsules|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
48473128|NCT05795231|DEVICE|Macintosh Laryngoscope Vs Video Laryngoscope|Evaluate incidence of first trial success and complications
48473129|NCT05504824|OTHER|Case-based education|"The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning."
48473130|NCT02351167|DRUG|Combination NRT (Nicotine patch, Nicotine lozenge)|
48473131|NCT02351167|DRUG|Varenicline|
48473132|NCT02351167|DRUG|Placebo|
48473133|NCT02351167|BEHAVIORAL|Intensive smoking counseling|
48473134|NCT04983342|DEVICE|Apollo Armband|The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
48473135|NCT00517192|DRUG|Tipranavir|
48473136|NCT00517192|DRUG|Darunavir|
48473137|NCT00517192|DRUG|Ritonavir|
48473138|NCT04208256|DIETARY_SUPPLEMENT|Energy Stimulus|Energy stimulus (energy surplus v. energy neutral) will be randomly assigned at the first brain imaging visit. At the second brain imaging visit, the participant will receive the alternate stimulus from what they received at the first brain imaging visit.
48473139|NCT00128817|RADIATION|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
48473140|NCT00128817|PROCEDURE|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
48473141|NCT02298387|DRUG|OMP-305B83|intravenous (in the vein) infusions
48630562|NCT05372900|OTHER|Test Product|Whey Protein Isolate with Mulberry leaf extract
48630563|NCT05372900|OTHER|Control Product|Wheat Protein Hydrolysate
47940893|NCT04793061|OTHER|blood sample collection|Blood is samples from peripheral vein during routine care
47940894|NCT05935722|BEHAVIORAL|Parenting Young Children|PYC is a home-based intervention programme involving weekly, one-hour sessions over a period of at least six months. The programme has two core modules (1) Parent-Child Interaction and (2) Child Care Skills and Safety. The Parent-Child Interaction module focuses on the parent-child relationship and interaction skills such as parents' responsiveness to the child's signals, giving the child attention and encouragement, and supporting prosocial behaviour. The Child Care Skills and Safety module targets safety at home and the parent's caring skills (e.g. food, health, and hygiene). Checklists are adapted to each parent in order to support the PYC practitioner and the parent. The programme is compiled in a manual that includes work tasks, instructions for how to perform the tasks, and teaching materials.
48287606|NCT00117962|RADIATION|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
48287607|NCT05366608|DIAGNOSTIC_TEST|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6 were estimated for all participants by ELISA.
48287609|NCT01823562|DRUG|lyophilized black raspberry confection|Given PO
48473142|NCT01829815|BEHAVIORAL|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
48630564|NCT03756935|PROCEDURE|All monitoring|Dicpleth and PI are obtained a posteriori from the PPG waveform reconstruction and blindly from ABP values. Dicpleth is defined as the ratio of the height of the dicrotic notch (from nadir point of the complex to the notch) to the height of the systolic peak (from nadir point of the complex to the pic), measured at end-expiratory time (average of 3 consecutive complex). PI is calculated as the ratio of the pulsatile component of the PPG signal and the continuous component.
47940895|NCT05935722|BEHAVIORAL|Treatment as Usual|TAU consists of a variety of interventions from the social services. The support will be logged and classified in accordance with the Swedish National Board of Health and Welfare's guidelines for classifications of its activities. TAU will be divided into the following five categories: 1) conversation counselling or emotional support, 2) practical support, 3) skills training, 4) compensatory strategies, and 5) other support. Support will also be classified based on whether it is home-based or given outside the home and whether it is individualised or in a group setting.
47940896|NCT02561624|BEHAVIORAL|Behaviour change communication via text message|
47940897|NCT00397566|DRUG|HIV Integrase Inhibitor (BMS-707035)|
47940898|NCT03583515|BEHAVIORAL|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
47940899|NCT03583515|BEHAVIORAL|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
47940900|NCT05091502|DIAGNOSTIC_TEST|Personalised musculoskeletal modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop personalised musculoskeletal models
48473143|NCT03313778|BIOLOGICAL|mRNA-4157|IM injection
48630565|NCT01953354|BIOLOGICAL|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
48101773|NCT05129982|DEVICE|whole body vibration|whole body vibration is a modality of physical therapy
48101774|NCT01102322|BEHAVIORAL|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
48287610|NCT01823562|OTHER|laboratory biomarker analysis|Correlative studies
48287611|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low polyphenol diet
48287612|NCT01823562|DIETARY_SUPPLEMENT|dietary intervention|Follow a low ellagitannin diet
48287613|NCT01823562|PROCEDURE|quality-of-life assessment|Ancillary studies
47940901|NCT05078918|OTHER|Comprehensive care program|Comprehensive care program includes education and re-evaluation process. Education using video-materials to help patients adapt to the new normal before and after surgery. And re-evaluation patient's needs 1 month after surgery and arrangement resources.
48107097|NCT05032937|DRUG|domestic polysaccharide superparamagnetic iron oxide nanoparticle|Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
48287614|NCT01823562|OTHER|questionnaire administration|Ancillary studies
48287615|NCT05347654|OTHER|Local treatment with silver sulphadiazine only|Local treatment with silver sulphadiazine and tulle from day 0 to day 8 (included). From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
48287616|NCT05347654|OTHER|Local treatment with silver sulphadiazine followed by URGOCLEAN® dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
48473144|NCT03313778|BIOLOGICAL|Pembrolizumab|Intravenous infusion
47940902|NCT05078918|OTHER|Usual care|Usual care includes encouraging deep breathing and exercise using inspirometer, postoperative early ambulation, giving information at discharge and follow up 1 month after surgery.
47940903|NCT02530567|PROCEDURE|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
47940904|NCT03247803|DEVICE|air-Q® SP|air-Q SP placement for airway maintenance,
47940905|NCT03247803|DEVICE|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
47940906|NCT03548571|BIOLOGICAL|Dendritic cell immunization|Intradermal injection
47940907|NCT03548571|DRUG|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
47940908|NCT00301821|BIOLOGICAL|epratuzumab|
47940909|NCT00301821|BIOLOGICAL|rituximab|
47940910|NCT00301821|DRUG|cyclophosphamide|
47940911|NCT00301821|DRUG|doxorubicin hydrochloride|
47940912|NCT00301821|DRUG|prednisone|
47940913|NCT00301821|DRUG|vincristine sulfate|
47940914|NCT01861171|DIETARY_SUPPLEMENT|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
47940915|NCT05337930|DEVICE|Happyr App|"The Happyr app offers three main areas:~(A) A mood diary in which a user can keep track of emotional wellbeing by answering three short questions.~(B) A pain diary in which a user and supporter can record headache attacks by answering a set of predefined questions whenever a user experiences or has experienced a headache attack.~(C) An overview section in which entries from the mood and pain diary are visualized for the user. In this section, a PDF document can also be exported with a summary of data from the symptom diary that can be taken to the clinician.~A standardized notification is sent to each user at 6pm local time to remind them about logging their mood and symptoms of a headache attack."
47940916|NCT01967758|BIOLOGICAL|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10\^7cfu
47940917|NCT01967758|BIOLOGICAL|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10\^8cfu
47940918|NCT01967758|BIOLOGICAL|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10\^9cfu
47940919|NCT01967758|DRUG|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
47940920|NCT03729973|DRUG|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
47940921|NCT03729973|DRUG|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
47940922|NCT03729973|DRUG|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
48473145|NCT03313778|BIOLOGICAL|SoC Treatment|Intravenous infusion
48473146|NCT02414373|DRUG|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
48473147|NCT02414373|DRUG|Bupivacaine|local anesthetics, which will epidurally administered
47940923|NCT03729973|DRUG|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
47940924|NCT05274139|DRUG|HD-MTX-Ara-C regimen|"HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine~1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles"
47940925|NCT05274139|DRUG|FTD regimen|FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 28 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
47940926|NCT03676335|DRUG|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
47940927|NCT03676335|DRUG|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
47940928|NCT03676335|DRUG|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
47940929|NCT04322214|DRUG|Cobicistat 150 MG|once daily cobicistat (150 mg QD) for 5 days
48107098|NCT02469467|DIETARY_SUPPLEMENT|VS-505|VS-505 is orally administered with meal for 8 weeks
47940930|NCT04322214|DRUG|Placebo|once daily lactose capsules (as aspect cobicistat capsules)
47940931|NCT04322214|DRUG|GHB|single oral dose of GHB (25 mg/kg) on days 5 and 17
47940932|NCT00775944|BEHAVIORAL|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
47940933|NCT00775944|BEHAVIORAL|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
47940934|NCT00775944|DRUG|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
48473148|NCT02414373|DEVICE|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
48473149|NCT02414373|DEVICE|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
48473150|NCT05348837|PROCEDURE|Deep brain stimulation|Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
48473151|NCT05765617|DRUG|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
48287617|NCT03078361|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
48287618|NCT03078361|BEHAVIORAL|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
48287619|NCT03078361|BEHAVIORAL|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
48287620|NCT00989326|OTHER|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
48287621|NCT02032628|BEHAVIORAL|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
48287622|NCT06382753|OTHER|Gingival inflammation|Patients were scored for their status of gingival inflammation using Gingival Index and Bleeding on Probing Scores
48287623|NCT04166396|DRUG|Resveratrol|500 mg resveratrol, BID
48287624|NCT04166396|DRUG|NR|500 mg NR BID
48287625|NCT04166396|DIETARY_SUPPLEMENT|Placebo|Placebo
48287626|NCT06091423|DRUG|XELOX combined with Fruquintinib and Sintilimab|XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
48287627|NCT03351673|DIAGNOSTIC_TEST|endometrial volume 2D TVS|calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
48287628|NCT05387161|OTHER|Nutritional intervention|The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
48287629|NCT05986656|PROCEDURE|Atlas-Standard method|Hardware acupressure of the suboccipital muscles according to the Atlas-Standard method for the reduction of chronic subluxation of the first cervical vertebra.
48287630|NCT02850198|DEVICE|scalp electroacupuncture|
48287631|NCT02850198|DEVICE|sham scalp electroacupuncture|
48287632|NCT03680677|PROCEDURE|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
48287633|NCT03680677|OTHER|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
48287634|NCT03680677|DIAGNOSTIC_TEST|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
48287635|NCT01532453|DEVICE|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
48287636|NCT01532453|OTHER|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
48287637|NCT06375850|OTHER|Sesame oil|"A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.~Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.~The sesame oil chosen for the project is Sesame bio - 100% pure vegetable oil from the Naissance brand.~To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air."
48287638|NCT06375850|OTHER|Saline solution|After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.
48287639|NCT03232112|DRUG|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
48473152|NCT05765617|OTHER|Placebo|Placebo give 2x1 per day for five day
48630566|NCT01953354|BIOLOGICAL|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
48287640|NCT03232112|DRUG|BD PosiFlush (saline)|Subcutaneous injection once-weekly
48287641|NCT03877406|DRUG|Empagliflozin 10 MG|addition of empagliflozin 10 MG
48287642|NCT03877406|DRUG|Hypoglycemics Oral|dose escalation of hypoglycemics oral
48287643|NCT05249595|DEVICE|Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
48473153|NCT06617416|DRUG|Cadonilimab (AK104)|AK104 ivgtt Q3W
48473154|NCT06617416|DRUG|Sugemalimab|1200mg Q3W
48630567|NCT00193986|DEVICE|Arbitrary Waveform Defibrillator|
48630568|NCT03055195|DRUG|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
48630569|NCT03055195|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
47940935|NCT03641885|BEHAVIORAL|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
48287644|NCT05249595|DEVICE|Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
47940936|NCT03641885|BEHAVIORAL|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
48287645|NCT05249595|DEVICE|Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
47940937|NCT03641885|BEHAVIORAL|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
47940938|NCT02208700|OTHER|Oxepa|Therapeutic nutrition with EPA, GLA\< and antioxidants
48287646|NCT00188448|DEVICE|MRI|
48107099|NCT03312335|DRUG|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
48287647|NCT01282814|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
48287648|NCT01282814|DRUG|Effexor® XR|150 mg Extended-Release Capsule
48287649|NCT03227861|DRUG|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
48287650|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
48287651|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
48287652|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
48287653|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
48287654|NCT00839163|DRUG|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
48630570|NCT05796973|BEHAVIORAL|Guided physical exercise|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions.
47940939|NCT02208700|OTHER|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
48107100|NCT05095675|BEHAVIORAL|psychological questionnaires|Participants have to fulfill psychological questionnaires in different time points during medical oncological treatment
48107101|NCT03624166|DRUG|Ketamine|patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
48287655|NCT03843580|DEVICE|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
48287656|NCT02024581|DRUG|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
47940940|NCT04735458|OTHER|Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
48473155|NCT04440709|DEVICE|Brain/neural hand exoskeleton (B/NHE)|The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
47940941|NCT02546115|DEVICE|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
48630571|NCT05796973|DRUG|Atorvastatin|Patients will be participating in guided physical exercise program regularly two times / week at a sports facility and guided by a professional trainer. They will participate in aerobic and resistance exercises during the sessions. In addition to the exercise program they will be given atorvastatin 40 mg QD medication.
47940942|NCT02546115|OTHER|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
47940943|NCT04913766|BEHAVIORAL|Problem Management Plus|Five session psychological intervention focusing on problem management skills.
47940944|NCT04913766|BEHAVIORAL|Services as Usual|Mental health services provided by a mental health specialists according to their standard practices of care
47940945|NCT03609151|PROCEDURE|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
47940946|NCT03609151|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
47940947|NCT05580510|DRUG|Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator."
48287657|NCT02024581|DRUG|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
48287658|NCT01272531|DRUG|Mood stabilizer treatment|lithium or valproate
48473156|NCT01897987|BIOLOGICAL|Pneumostem®|
48473157|NCT01897987|BIOLOGICAL|normal saline|
48630572|NCT05796973|OTHER|Independent exercise|The control group is advised of the benefits of physical exercise and they get an exercise program to follow. Participants in the control group exercise on their own.
48630573|NCT00604383|DRUG|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
48630574|NCT00604383|DRUG|placebo|1 tablet, orally, daily, up to 42 months
48630575|NCT03081923|DRUG|Durvalumab|anti-PD-L1 mono therapy
48630576|NCT03081923|DRUG|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
48630577|NCT04319536|OTHER|no intervention|self-sampling
48630578|NCT01926639|BIOLOGICAL|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
48630579|NCT03128086|PROCEDURE|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
47940948|NCT05580510|DRUG|Empagliflozin 10 MG OD|"This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug."
48287659|NCT00087295|DRUG|Depsipeptide|Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
48287660|NCT04154618|DEVICE|Continuous wireless vital sign monitoring|Infants will receive wireless vital sign monitoring throughout their birth hospitalization.
48287661|NCT01634347|DRUG|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
48287662|NCT01634347|DRUG|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
48473158|NCT01919541|OTHER|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
48630580|NCT02011464|DRUG|Exparel|Exparel is infiltrated into posterior compartment for pain control
48630581|NCT02011464|OTHER|Saline|Saline is infiltrated into posterior compartment for control
48630582|NCT06061055|DEVICE|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
48630583|NCT06061055|DEVICE|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
48630584|NCT02422901|DRUG|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
47940949|NCT00072176|DRUG|temsirolimus|Given IV
47940950|NCT00072176|OTHER|laboratory biomarker analysis|Correlative studies
47940951|NCT05819684|DRUG|SHR-4602 for injection|be administered via intravenous (IV) infusion
47940952|NCT06086626|DRUG|Cefiderocol|Administered via intravenous (IV) infusion
47940953|NCT06086626|DRUG|Standard of Care|Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards
47940954|NCT02075970|DRUG|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
48287663|NCT05928741|BEHAVIORAL|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
48287664|NCT04807946|PROCEDURE|lower third molar extraction|"All surgeries were performed by the same expert surgeon (RP), with the buccal approach using local anesthesia, and included the following maneuvers:~* luxation of the coronal portion of the tooth/root in an ipsilateral or parallel direction with respect to the IAN position and running, in order to minimize nerve compression;~* post-extraction residual bone cavity inspection using a Zeiss 4x300 magnification optical system to better identify intra-operative nerve exposure.~No material was inserted into the residual cavity, neither by regeneration nor by haemostasis.~After one week, sensitivity was tested on both sides with the tactile test using a 27-gauge needle tip and, if a difference was found, the patient was followed up once a week for the first month and every two weeks thereafter, until he/she reported to perceive the pin-prick test in the affected side the same way as the healthy side."
48287665|NCT02516930|BEHAVIORAL|crowdsourced video|video promoting condom use
48287666|NCT02516930|BEHAVIORAL|social marketing video|
48287667|NCT00440401|DRUG|fibrinogen (human) + thrombin (human)|
48287668|NCT00440401|DRUG|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
48287669|NCT02179632|BEHAVIORAL|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
48287670|NCT03563248|DRUG|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
48287671|NCT03563248|DRUG|Losartan|Losartan is a drug that is used to lower blood pressure
48287672|NCT03563248|DRUG|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
48287673|NCT03563248|RADIATION|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
48287674|NCT03563248|PROCEDURE|Surgery|definitive surgical resection
48287675|NCT00608465|DRUG|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
48287676|NCT00608465|DRUG|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
48287677|NCT01733563|PROCEDURE|Soft drink consumption|
48287678|NCT02364817|BEHAVIORAL|cognitive and psychiatric assessment|"Administered at baseline:~* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~* hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~* psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~* cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~* impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~* alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~* administered at week 12: ASRS"
48287679|NCT01158950|DRUG|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
48287680|NCT01158950|OTHER|Placebo|Placebo (200mg) administered at study visit
48287681|NCT03644576|DRUG|ozanimod|ozanimod
48287682|NCT03644576|DRUG|Pseudoephedrine|Pseudoephedrine
48287683|NCT03644576|DRUG|ozanimod placebo|ozanimod placebo
48287684|NCT01980446|PROCEDURE|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
48473159|NCT01919541|DEVICE|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
48473160|NCT01919541|DEVICE|hyperinsulinemic euglycemic hyperaminoacid clamp|
48287685|NCT05742620|DRUG|anlotinib+CAPEOX/SOX|"Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1."
48473161|NCT01919541|DIETARY_SUPPLEMENT|whey protein supplementation|
48473162|NCT01919541|OTHER|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
48473163|NCT06046326|BEHAVIORAL|virtual community of practice|The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
48473164|NCT01735786|DEVICE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
48473165|NCT02425501|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
48287686|NCT02533115|DRUG|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
48287687|NCT00542815|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
48287688|NCT00542815|DRUG|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
48287689|NCT04320095|DEVICE|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
48287690|NCT00161317|BEHAVIORAL|Living with Hope Program|
48287691|NCT01887444|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
48473166|NCT01785394|DRUG|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
48287692|NCT01887444|OTHER|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
48287693|NCT05361512|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
48287694|NCT05361512|DEVICE|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
48287695|NCT01887912|BIOLOGICAL|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
48287696|NCT01887912|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
48287697|NCT05780866|OTHER|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
48287698|NCT04562363|PROCEDURE|Suturing of a laparotomic wound with modified methods|Suturing the white line of the abdomen with the help of developed techniques aimed at preventing hernias and eventrations
48287699|NCT01508676|DRUG|Pennsaid|
48287700|NCT01508676|DRUG|Placebo (2.3% DMSO solution)|
48287701|NCT01341912|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
48287702|NCT04364217|DEVICE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
48287703|NCT05782296|DEVICE|TrueLabor|Non invasive monitoring device
48287704|NCT00293280|DRUG|lomustine|
48287705|NCT04595955|OTHER|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
48287706|NCT02515669|DRUG|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
48287707|NCT02515669|DRUG|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
48287708|NCT02215681|DEVICE|acupuncture|
48287709|NCT00834548|PROCEDURE|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
48287710|NCT01476930|PROCEDURE|cupping and serkangabin syrup|wet cupping serkangabin syrup
48287711|NCT01476930|DRUG|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
48473167|NCT06471491|OTHER|Driving pressure-guided positive end-expiratory pressure|Driving pressure-guided positive end-expiratory pressure during the surgical procedure
48473168|NCT05305950|OTHER|Patient population|Questionnaire, standard of care
48473169|NCT00206245|DRUG|AZD0865|
48287712|NCT03660501|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
48287713|NCT00583739|BEHAVIORAL|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
48473170|NCT06385288|OTHER|Blood and tissue collection for immunological studies, advanced imaging.|Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
48473171|NCT06385288|OTHER|neoadjuvant Therapy|neoadjuvant Therapy
48287714|NCT04323501|OTHER|Experimental treatment|"Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing"
48287715|NCT04323501|OTHER|Control group|Usual care
48287716|NCT04511299|OTHER|SMOFlipid 20%|Fish oil-enriched intravenous lipid emulsion
48287717|NCT04511299|OTHER|Lipofundin 20%|MCT/LCT standard intravenous lipid emulsion
48287718|NCT03032744|OTHER|Asthma Assessment & Management|Asthma Assessment \& Management based on NAEPP-EPR3 guidelines
48287719|NCT03032744|OTHER|Asthma Education|Asthma education on medications
48287720|NCT03032744|OTHER|Controller medication at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
48473172|NCT05916716|PROCEDURE|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
48473173|NCT05916716|PROCEDURE|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
48473174|NCT05916716|DEVICE|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
48473175|NCT05916716|DRUG|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
48630585|NCT05834153|DEVICE|kinesiotaping|"This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %"
48630586|NCT05834153|DEVICE|electrical muscle stimulation|"It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform"
48630587|NCT00947388|DRUG|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
48630588|NCT00947388|BIOLOGICAL|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
48630589|NCT03342794|PROCEDURE|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
48630590|NCT05929586|OTHER|"The combined C-it DU-it intervention: community data use for ANC"|"Combining data linkage (C-it) with work improvement teams for community data use (DU-it) to improve antenatal clinic uptake. Our short name C-it DU-it (pronounced see-it; do-it) is an acronym intended to convey 'seeing' linked data (C-it) and 'doing' or acting on the data (DU-it)"
48630591|NCT02662465|PROCEDURE|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
48630592|NCT05915169|OTHER|Topical haemoglobin wound care spray|It is a wound care spray used in the care of chronic wounds.
48630593|NCT01106950|BIOLOGICAL|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is \< or = 8 x 10\^7 nucleated cells/kilogram.
48287721|NCT02638181|PROCEDURE|trabeculectomy|
48287722|NCT00228371|DEVICE|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
48473176|NCT05916716|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
48473177|NCT00294892|DRUG|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
48473178|NCT00294892|DRUG|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
48473179|NCT05911919|DEVICE|brainQuant module of brainTale-care platform|brainQuant is a software module of brainTale-care medical device (a medical device software as a service (web platform) ) for the automatic processing of brain diffusion Magnetic resonance images and the provision of the diffusion regional standardised parameters.
47940955|NCT02075970|DRUG|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
48473180|NCT05695417|DRUG|OTX-TKI|Injection of OTX-TKI
48473181|NCT05695417|DRUG|Sham|Sham Injection of OTX-TKI
48473182|NCT01782287|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
48473183|NCT01782287|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
48473184|NCT05741931|DEVICE|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
48473185|NCT00559026|BIOLOGICAL|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
48473186|NCT00559026|OTHER|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
48473187|NCT04868565|DRUG|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
48473188|NCT06143462|DRUG|Usual care|Include anti-dizziness medications, diuretics, or hormone therapy.
48473189|NCT06143462|OTHER|Health Education|Include comprehensive health education, fall prevention and lifestyle adjustments.
48473190|NCT06143462|BEHAVIORAL|vestibular rehabilitation|Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
48473191|NCT05539716|DEVICE|PAP Therapy|Auto-PAP device (ResMed AirsenseTM Autoset) with a heated humidifier will be provided along with an appropriate mask and connecting hose for nightly use
48473192|NCT05539716|BEHAVIORAL|Lifestyle Counseling Intervention|Lifestyle intervention will include counseling on (a) education on nutrition and exercise; and (b) behavioral support for identifying lifestyle change strategies and problem-solving barriers to improve the regularity and duration of sleep. This will be conducted using brochures on weight loss and sleep hygiene
48473193|NCT03055741|DRUG|Donepezil|5mg or 10mg, once a day, 24 weeks
47940956|NCT01681797|DEVICE|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
48473194|NCT03055741|DRUG|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
48473195|NCT03055741|DRUG|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
48473196|NCT03676647|OTHER|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
48473197|NCT01432028|DRUG|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
48473198|NCT01432028|DRUG|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
48473199|NCT05462353|DRUG|2mg of ASC41|ASC41 tablet administered orally once daily.
48473200|NCT05462353|DRUG|4mg of ASC41 (2 tablets of 2 mg ASC41)|ASC41 tablets administered orally once daily.
48473201|NCT05462353|DRUG|Placebo|Placebo tablets administered orally once daily.
48473202|NCT01337882|OTHER|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin \[100, 300 \& 1000 pmol/min\]; acetylcholine \[5, 10 \& 20 µg/min\]) and -independent \[sodium nitroprusside \[2, 4 \& 8 µg/min\]; verapamil \[10, 30 \& 100 µg/min\]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
48473203|NCT05815368|DEVICE|REMO|REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
48473204|NCT05815368|OTHER|Task-Oriented Training|Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
48473205|NCT05817006|OTHER|Device|research of the long-COVID-19 in the children
48473206|NCT05858268|GENETIC|Whole-genome sequencing|Whole-genome sequencing
48473207|NCT04869839|OTHER|oral examination|examination done by dentist
48473208|NCT04736758|DRUG|GP681 tablet|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
48473209|NCT04736758|DRUG|GP681 Simulant|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
48473210|NCT03348488|PROCEDURE|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
47940957|NCT01043510|DRUG|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
47940958|NCT01043510|DRUG|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
47940959|NCT05220800|DRUG|Iron(III)isomaltoside|Weight-dependent dosage of iron(III)isomaltoside. See group descriptions
47940960|NCT05220800|DRUG|Placebo|Isoton saline infusion
47940961|NCT05806879|OTHER|Maternity Napkin|"Use of maternity napkin with the following specifications (followed for 4.5 months)~* Length is 230-240mm, to be able to provide adequate coverage.~* Width is 150-155mm with wings.~* Thickness is 3-5mm.~* The maternity napkin is curved to prevent leakage on the sides, has wings for secure attachment to the underwear and able to absorb 30-40 ml per minute."
48287723|NCT06265896|OTHER|Kinesio taping|Tape will be applied on rectus abdominis muscles using muscles facilitation technique from origin to insertion of muscle with a tension between 15-35%. Band will start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xiphoid process. Tape will be applied on the right and left external oblique muscles; the procedure will start without tension from bottom and of 6-12 ribs, then the hip will be placed in flexion and rotation to opposite direction and the tape will be attached to pubic bone with tension between 15-35%. Finally, the tape will be performed on the right and left internal oblique muscles; the procedure will start without tension from anterior superior iliac spine and then the hip will be placed in extension position and the tape will be attached to lower 4 ribs and linea alba with tension between 15-35%.
48287724|NCT06265896|OTHER|Pelvic floor exercise training|The intervention will be applied by a trained physical therapist. First of all, each participant will be instructed to relax thighs, bottom and abdomen musculature, then squeeze pelvic floor muscles 'focus on tightening without flexing abdomen, thighs or buttocks- avoid holding breath' 10 repetitions, 3 to 5 times a day (morning, afternoon, and night). Rest for 4 seconds and then repeat each contraction. Build up pelvic floor musculatures strength until each participant be able to do 10 slow contractions each time, holding them for 10 seconds each with rests of 4 seconds in between. Then do not hold your breath or tighten your stomach, bottom or thigh muscles at the same time. Will instruct participants to try holding each squeeze for a few seconds.
48287725|NCT04919564|DRUG|Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)|Furosemide 2 mg/hour infusion for 12 hours since induction
48287726|NCT04919564|DRUG|NaCl 0.9%|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
48287727|NCT02169076|DEVICE|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
48287728|NCT04596371|OTHER|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
48287729|NCT02662439|DEVICE|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
48287730|NCT03425383|DIAGNOSTIC_TEST|FMD and c-IMT|"The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position."
48287731|NCT00003789|DRUG|isolated limb perfusion|Undergo isolated limb perfusion
48287732|NCT00003789|DRUG|melphalan|Given via limb perfusion
47940962|NCT00832390|DRUG|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
47940963|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
48287733|NCT00003789|BIOLOGICAL|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
48287734|NCT00003789|OTHER|pharmacological study|Correlative studies
48287735|NCT00003789|OTHER|laboratory biomarker analysis|Correlative studies
48473211|NCT02419625|BEHAVIORAL|questionnaires|questionnaires , serum samples will be used
48630594|NCT01106950|DRUG|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
47940964|NCT04824729|PROCEDURE|Lower limb revascularization|French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
47940965|NCT03282851|DRUG|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
48473212|NCT04961567|DRUG|Litifilimab|Administered as specified in the treatment arm.
48630595|NCT01106950|DRUG|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
48630596|NCT01106950|DRUG|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
47940966|NCT03282851|DRUG|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
47940967|NCT03282851|DRUG|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
47940968|NCT02854410|DIETARY_SUPPLEMENT|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
48473213|NCT04961567|DRUG|Placebo|Administered as specified in the treatment arm.
48630597|NCT01106950|PROCEDURE|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
48630598|NCT01106950|DRUG|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
48630599|NCT00574951|DRUG|motesanib diphosphate|
48630600|NCT03126734|OTHER|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
48630601|NCT00066170|DRUG|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
48630602|NCT00066170|DRUG|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
48630603|NCT00066170|DRUG|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
48630604|NCT00066170|DRUG|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
47940969|NCT02854410|DIETARY_SUPPLEMENT|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
48107102|NCT03624166|DRUG|isotonic saline|patients will receive 3 ml of isotonic saline after spinal anesthesia
48107103|NCT02545062|OTHER|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
48107104|NCT03097016|DRUG|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
48287736|NCT05843201|DEVICE|The AquaPass System|The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
48287737|NCT00942682|DRUG|Sorafenib|Taken orally twice daily
48473214|NCT03840382|BEHAVIORAL|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
48107105|NCT00755118|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
48107106|NCT00755118|DRUG|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
48287738|NCT00942682|DRUG|RAD001|Taken orally once daily in the morning
48287739|NCT00377650|DEVICE|Percutaneous thrombectomy|
48473215|NCT02321124|OTHER|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
48287740|NCT03560440|OTHER|Plasma exposure vancomycin|Investigation of plasma exposure of vancomycin.
48287741|NCT03414125|OTHER|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
48287742|NCT03414125|OTHER|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
48287743|NCT05817201|DRUG|Toripalimab|Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.
48287744|NCT05817201|DRUG|Tegafur|Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.
48287745|NCT05817201|RADIATION|IMRT|PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W
48287746|NCT05434910|OTHER|Changes in mean arterial pressure|MAP set at 65 mmHg for 25 min by infusion of noradrenaline. MAP set at 80 mmHg for 25 min by infusion of noradrenaline. MAP set at 95 mmHg for 25 min by infusion of noradrenaline.
48473216|NCT02321124|BEHAVIORAL|life style advice|We will apply life style advice for four weeks.
48473217|NCT03209349|PROCEDURE|Water Exchange Sigmoidoscopy|See arm description.
48473218|NCT03209349|PROCEDURE|Air Insufflation Sigmoidoscopy|See arm description.
48473219|NCT03135899|DRUG|BI 443651|Three doses, each 12 hours apart
48287747|NCT06334133|DRUG|Cadisegliatin 800 mg QD|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
48287748|NCT06334133|DRUG|Cadisegliatin 800 mg BID|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
48630605|NCT04967703|PROCEDURE|Group A|Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks
48287749|NCT06334133|DRUG|Placebo|Placebo
48287750|NCT04685148|DRUG|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
48287751|NCT04685148|DRUG|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
48287752|NCT02123329|BEHAVIORAL|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
48287753|NCT02123329|OTHER|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
48287754|NCT02167061|DRUG|DA-1229_01|complex single administration
48287755|NCT02167061|DRUG|E+M|co-administration of 2 drugs
48287756|NCT02167061|DRUG|DA-1229_01 fast|
48473220|NCT03135899|DRUG|Placebo|Three doses, each 12 hours apart
48473221|NCT06113913|DRUG|Infliximab|Weekly administration of subcutaneous infliximab.
48473222|NCT06113913|DRUG|Infliximab|Bi-weekly administration of subcutaneous infliximab.
48473223|NCT06113913|DRUG|Infliximab|Optimized dosing schedule of intravenous infliximab.
48473224|NCT01451320|DRUG|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
47940970|NCT01293500|PROCEDURE|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
48473225|NCT01451320|DRUG|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
48287757|NCT02167061|DRUG|DA-1229_01 fed|
48287758|NCT05178537|OTHER|AAS users|no intervention
48287759|NCT03542214|COMBINATION_PRODUCT|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
48287760|NCT00262405|DRUG|zileuton|
48473226|NCT01451320|DRUG|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
47940971|NCT00276081|DRUG|Gabapentin, Estrogen and placebo administration|
47940972|NCT04223648|DRUG|tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy|"Subjects will receive 1 cycle of tremelimumab/durvalumab~* Subjects will undergo resection to obtain tumor for generation of autologous tumor infiltrating lymphocytes (TIL) cultures and blood draw to obtain peripheral blood mononuclear cell (PBMC)s~* TIL and PBMC will undergo immunoselection based on binding to an anti-programmed cell death 1 (PD-1) antibody and then will be expanded ex vivo.~Subjects will receive 3 cycles of ipilimumab/nivolumab~• Subjects will undergo staging with computer tomography (CT) chest/abdomen/pelvis and brain magnetic resonance imaging (MRI) or CT scan.~subjects with stable disease will continue with nivolumab monotherapy; Subjects with progressive disease will proceed to cell therapy."
47940973|NCT05625893|RADIATION|PBT and atezolizumab/bevacizumab|"Atezolizumab 1200 mg and bevacizumab 15 mg/Kg is administered IV infusion every 3 weeks.~Proton beam therapy 30 - 50 Gy/5 fractions to portal vein tumor thrombosis with or without main primary tumor after 1 week (+/- 7 days) of 2nd cycle of atezolizumab and bevacizumab~The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
48107107|NCT00755118|DRUG|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
48287761|NCT00262405|DRUG|azathioprine/prednisone|
48287762|NCT04248010|DEVICE|neuroConn DC-Stimulator MR|standard tDCS, active \& sham
48287763|NCT04248010|DEVICE|Soterix MxN HD-tES|HD-tDCS, active \& sham
48287764|NCT00800761|DRUG|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
48287765|NCT00800761|DRUG|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
48287766|NCT05051618|BEHAVIORAL|POWER-MS|"The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level."
48287767|NCT05051618|BEHAVIORAL|FLEX-MS|The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
48473227|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
48473228|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
48473229|NCT00542360|BEHAVIORAL|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
48287768|NCT04579861|OTHER|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
48287769|NCT02346448|PROCEDURE|endoscopic sphincterotomy|sphincterotomy during ERCP
48287770|NCT02346448|PROCEDURE|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
48287771|NCT02346448|PROCEDURE|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
48287772|NCT04302181|DRUG|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
48473230|NCT06353750|OTHER|Magnesium supplement|Intravenous magnesium supplement (10mmol).
48473231|NCT01391845|DRUG|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
48473232|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
48473233|NCT01391845|DRUG|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
48473234|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
48473235|NCT00825864|DRUG|diclofenac drops|one drop 4 times a day for 3 months
47940974|NCT02653404|OTHER|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
47940975|NCT04631302|BEHAVIORAL|Be Mindful|"Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises."
48107108|NCT00755118|DRUG|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
48473236|NCT00825864|DRUG|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
48107109|NCT00755118|DRUG|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
48107110|NCT00755118|DRUG|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
48473237|NCT03907917|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
48473238|NCT04458558|DRUG|Mifepristone|Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
48473239|NCT01589601|BEHAVIORAL|Usual heart failure care|Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
48473240|NCT01589601|BEHAVIORAL|Interdisciplinary palliative care|Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
48473241|NCT02512055|DRUG|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
48473242|NCT03699033|RADIATION|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
48473243|NCT03699033|DRUG|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
48473244|NCT03699033|DRUG|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
48473245|NCT01812629|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
48473246|NCT06494397|DRUG|VHX-896 and iloperidone|oral tablet
48473247|NCT06494397|DRUG|Iloperidone and VHX-896|oral tablet
48473248|NCT05541640|DRUG|normal saline group|normal saline infusion at the start of surgery
48473249|NCT05541640|DRUG|lidocaine group|lidocaine infusion at the start of surgery
48287773|NCT04237883|BEHAVIORAL|Standard communication email|This is the base communication that all physicians will receive.
48473250|NCT00673192|PROCEDURE|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
48473251|NCT03363698|OTHER|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
48473252|NCT01723917|DIETARY_SUPPLEMENT|PhytoSERM tablet|
48473253|NCT01723917|DIETARY_SUPPLEMENT|placebo|
48287774|NCT04237883|BEHAVIORAL|Social comparison Intervention|The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.
48630606|NCT04967703|PROCEDURE|Group B|Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A
48630607|NCT04967703|PROCEDURE|Group C|Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
48630608|NCT01498666|DIETARY_SUPPLEMENT|L. reuteri protectis|1 tablet once daily for 4 weeks
48473254|NCT03082651|OTHER|Alternating run training load|Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
48473255|NCT03082651|OTHER|Alternating footwear|Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
48473256|NCT03082651|OTHER|Constant training|Runners will be assigned identical training sessions over a 7-day period.
48473257|NCT03082651|OTHER|Constant footwear|Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
48473258|NCT00337558|DRUG|Solifenacin succinate|tablet
48473259|NCT00337558|BEHAVIORAL|Simplified bladder training|Instructions
48630609|NCT01498666|DIETARY_SUPPLEMENT|Placebo tablet|1 tablet once daily for 4 weeks
48630610|NCT04715100|OTHER|Observational group|The study dependent variables will be: pain (vas scale), joint status (Hemophilia Joint Health Score), perception of quality of life (SF-36 questionnaire), list of roles (Oakley questionnaire), performance of basic activities of daily life (Barthel index) and the performance of instrumental activities of daily living (Lawton and Brody scale).
48287775|NCT04237883|BEHAVIORAL|Leadership Training|Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
48287776|NCT05969210|OTHER|Toe strengthening exercise|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
48287777|NCT05969210|OTHER|Control Group|12 participants will be in control group they will do only there running training.
48287778|NCT01220219|DRUG|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
48287779|NCT01220219|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
48287780|NCT01220219|DRUG|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
48287781|NCT00947154|DRUG|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
48287782|NCT03619122|PROCEDURE|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
48287783|NCT00003323|DRUG|finasteride|5 mg/d PO
48630611|NCT06466265|DRUG|DNP002|Anti-CEACAM6 monoclonal antibody
48630612|NCT03640182|OTHER|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
48287784|NCT00003323|DRUG|flutamide|250 mg PO tid
48287785|NCT00003323|OTHER|quality-of-life assessment|Assessment survey administered at baseline, and 3 \& 6 months post initiation of treatment
48287786|NCT00075517|DRUG|docetaxel|
48630613|NCT00600782|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
48287787|NCT00075517|DRUG|gemcitabine hydrochloride|
48287788|NCT04946344|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
48287789|NCT04946344|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
48287790|NCT06079502|DEVICE|Neuromuscular Electrical Stimulation|A supervised program of intradialytic NMES of the quadriceps and calf muscles of both lower limbs with different phases, types and current intensity. The electrical stimulation program will included (total time, intensity, contraction-relaxation phase time): a toning program in the first two weeks.
48287791|NCT06079502|OTHER|resistive training program|"Part one: Warming up for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~Part two: The main part is the resistive training for quadriceps and calf muscles from supine position using weights in the form of sand bags for 20 min.~Part three: Cooling down for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~The training parameters:~The exercise training will be done during the first 2 hours of HD session using free leg weights. The patient will assume a supine lying position on the treatment plinth and perform the exercises for every lower limb separately while the other limb will be supported on the plinth by therapist or the patient himself. Resistance will be placed at the malleoli level in the distal third of the leg."
48287792|NCT03158584|DRUG|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
48287793|NCT04125745|DRUG|CXA-10|Each subject will receive oral CXA-10 at the dose of 300 mg once daily for 12 weeks
48287794|NCT00501319|BEHAVIORAL|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
48473260|NCT05930158|OTHER|Dual Task Exercises|Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.
48630614|NCT04599985|OTHER|star excursion balance training (SEBT)|The SEBT is aimed to be maintained the single limb stance on one leg while reaching farthest possible with the swing leg. An individual can reach farthest with the swing leg while maintaining the balance on the stance leg
48630615|NCT04599985|OTHER|Simplified star excursion balance training (SSEBT)|It is one of the training protocols, in a simplified way, with respect to star excursion balance test. It consists a series of reaching tasks for the lower limbs in three-directions i.e., anteromedial, medial and posteromedial.
48287795|NCT00501319|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
48287796|NCT02823912|DRUG|Capsaicin|
48287797|NCT02823912|DRUG|Magnesia calcinada|
48287798|NCT02820259|DRUG|Tacrolimus|
48287799|NCT05518786|OTHER|Exposure of interest: critical illness|Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae
48287800|NCT03435900|DRUG|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
48287801|NCT03435900|DRUG|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
48287802|NCT04304677|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI FFR pullback recording was done with conventional system~2. Automated algorithm to calculate delta FFR per unit time was developed~3. PCI was performed using 2nd generation DES"
48287803|NCT04403438|OTHER|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
48287804|NCT05689060|OTHER|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
48287805|NCT05689060|OTHER|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
48287806|NCT01466751|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
48473261|NCT05930158|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
48473262|NCT06025552|DRUG|TU7710|In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
48473263|NCT06025552|DRUG|Normal saline|Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
48630616|NCT06114550|OTHER|High intensity resistance training|The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.
48473264|NCT02093871|DEVICE|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
47940976|NCT04631302|BEHAVIORAL|Light exercise course|"The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness."
47940977|NCT00028275|DRUG|Gamma Interferon 1b|
47940978|NCT03775161|DEVICE|V-LAP™ System|Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
47940979|NCT02948283|OTHER|Laboratory Biomarker Analysis|Correlative studies
47940980|NCT02948283|DRUG|Metformin Hydrochloride|Given PO
47940981|NCT02948283|OTHER|Pharmacological Study|Correlative studies
47940982|NCT02948283|DRUG|Ritonavir|Given PO
47940983|NCT02948283|OTHER|Quality-of-Life|Ancillary studies
47940984|NCT02948283|OTHER|Questionnaire|Ancillary studies
48107111|NCT06554951|OTHER|Patients who are candidates for CAR-T cell therapy for hematologic malignancy|This study will include patients who undergo CAR-T cell infusion at participating centers during the 18-month duration of the enrollment period. A total of 100 patients are expected to be enrolled, including 80 patients for the prospective part and 20 for the retrospective part.
48473265|NCT00890279|DRUG|Cilnidipine|Cilnidipine up to 20 mg
48473266|NCT00890279|DRUG|Imidapril|Imidapril up to 10 mg per day
48473267|NCT05777382|OTHER|inquiry to postnatal mothers|structured questionnaires was asked to postnatal mothers
48473268|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 24 or 48 weeks
48473269|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 48 weeks
48473270|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
48473271|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 48 weeks
47940985|NCT00282542|PROCEDURE|Hepatocyte Infusion|
47940986|NCT05793437|BEHAVIORAL|permissive hypercapnia|Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg
47940987|NCT05793437|BEHAVIORAL|normocapnia|Tidal volume (8-10ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:35～45mmHg
47940988|NCT03280095|DRUG|co-codamol 15mg/500mg capsule|
47940989|NCT03280095|DRUG|co-codamol 30mg/500mg tablet|
47940990|NCT05034445|DIAGNOSTIC_TEST|Next generation sequencing|Extract DNA from sputum sample, minimum DNA amount should be over 50ng.
47940991|NCT02417844|DRUG|tamsulosin (Astellas)|
47940992|NCT02417844|DRUG|Tamsulosin HCL|
47940993|NCT01627171|DRUG|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
47940994|NCT01627171|DRUG|Polyethelene Glycol|280g reconstituted in 4 liters of water
47940995|NCT01627171|DRUG|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
47940996|NCT05202132|DIAGNOSTIC_TEST|Questionnaire|A 3 item validated questionnaire assessing masticatory function
48107112|NCT04189107|DRUG|Dexamethasone|High-dose dexamethasone peroperative and postoperative on day 2 and 4
48107113|NCT04189107|DRUG|Placebo|low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
48107114|NCT05535491|OTHER|Educational and Research Hospital|breathing exercise
48473272|NCT00869661|DRUG|RO5024048|1000mg bid for 24 weeks
48473273|NCT00869661|DRUG|RO5024048|500mg bid for 12 weeks
48473274|NCT00869661|DRUG|RO5024048|1000mg bid for 8 weeks
48473275|NCT00869661|DRUG|RO5024048|1000mg bid for 12 weeks
48473276|NCT05695391|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
48473277|NCT02666924|DIETARY_SUPPLEMENT|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
48630617|NCT06114550|OTHER|Low intensity resistance training|For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
48287807|NCT02126488|BEHAVIORAL|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
48287808|NCT02126488|BEHAVIORAL|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
48287809|NCT02126488|BEHAVIORAL|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
48287810|NCT02822365|PROCEDURE|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
48287811|NCT02822365|DEVICE|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
48287812|NCT02822365|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
48287813|NCT01843556|DRUG|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
48287814|NCT01969656|DRUG|2MD|
48287815|NCT01969656|DRUG|Calcitriol|
48287816|NCT01969656|DRUG|Placebo|
48287817|NCT00013052|BEHAVIORAL|Peer led classes. Led by trained veterans with a chronic disease.|
48287818|NCT01086683|BEHAVIORAL|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
48287819|NCT05088317|DIAGNOSTIC_TEST|Exercise capacity|The incremental shuttle walking test at increasing speed (ISWT) is one of the field tests used to evaluate exercise capacity. It has been shown that ISWT is a valid and reliable assessment tool that can be used to evaluate exercise capacity in obese individuals. This test is an exercise test in which walking between two cones 10 m apart at increasing speed for 12 minutes is counted as one sit-up for each 10-meter walk between the two cones. It is continued until the patient is unable to continue the test due to shortness of breath, the heart rate reaches 85% of the maximum expected heart rate, or completes the 12-minute test. In this test, the primary measure is the distance walked, and the result is calculated based on the number of shuttles completed.
47940997|NCT05202132|DIAGNOSTIC_TEST|Chewing gum test|The test is based on the ability of a subject of mixing a two colour chewing gum with 20 masticatory cycles. Mixing of the two colour chewing gum will be assessed as variance of hue in a scanned image of the flattened chewing gum. The method has been validated in independent studies.
47940998|NCT02999009|DEVICE|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
47940999|NCT05269251|DEVICE|Near Infrared Spectroscopy (NIRS)|After the brachial plexus block, the regional oxygen saturation (rSO2) was monitored for 30 minutes with the Regional Oximetry System (O3™, Masimo, Irvine, CA) and the radial artery diameter with ultrasound in the same period.
47941000|NCT06033508|OTHER|exercise with whole body vibration device|exercise with whole body vibration device
48287820|NCT06273904|DEVICE|Active transcranial focused ultrasound (tFUS)|Active non-invasive low-intensity focused ultrasound will be delivered using a proprietary head-worn device and control software from Attune Neurosciences. On an active stimulation day, focused ultrasound will be delivered to the brain region of interest using parameters from published research that are demonstrated to safely cause temporary changes in the activity in that brain area.
48287821|NCT06273904|DEVICE|Sham transcranial focused ultrasound (tFUS)|Non-active low-intensity ultrasound will also be conducted using a proprietary head-worn device and control software from Attune Neurosciences. On the sham stimulation day, the device will be activated in a manner that produces similar sensory effects (i.e., low-volume beeping-type noise from the device) but also prevents delivery of a focused ultrasound beam to the brain area of interest or any other brain area.
48287822|NCT05012696|DEVICE|Non-invasive ventilation (NIV)|Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
48287823|NCT05012696|DEVICE|High-flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
48630618|NCT05714397|DEVICE|Cingal|A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
47941001|NCT06033508|OTHER|placebo exercise|exercise without vibration on land
48287824|NCT02107144|DRUG|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
47941002|NCT04115540|DEVICE|TENS penile nerve stimulation|The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
47941003|NCT03932968|PROCEDURE|pH-metry during 24 hours|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
47941004|NCT05305027|BEHAVIORAL|Prompt diagnois pregnancy outcome|
47941005|NCT04073329|OTHER|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with \> 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as \< 1 mm step and \< 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
47941006|NCT02369562|PROCEDURE|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
47941007|NCT02186132|DRUG|Atropine 0.6 mg|Atropine 0.6 mg intravenous
47941008|NCT02186132|DRUG|Atropine 1.2 mg|Atropine 1.2 mg intravenous
47941009|NCT06420128|OTHER|Primary care team|Patients whose general practitioner is a member of a primary care team since at least 12 months
47941010|NCT05774977|OTHER|Aviation Noise Only (AN)|The aviation noise (AN) night will expose subjects to a pre-programmed recording of aviation noise during sleep from 2300-0700.
47941011|NCT05774977|OTHER|Pink noise, 50 dBA only (BN50)|The BN50 night will consist of exposure to continuous pink noise throughout the sleep period at a level of 50 A-weighted decibels (dBA).
48287825|NCT00674531|PROCEDURE|Artery resection|Artery resection
48287826|NCT05121740|DRUG|Plitidepsin 1.5 mg / day|Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
48287827|NCT05121740|DRUG|Plitidepsin 2.0 mg / day|Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
48287828|NCT05121740|DRUG|Plitidepsin 2.5 mg / day|Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
48287829|NCT02035384|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
48287830|NCT04132726|OTHER|Massage therapy|Massage therapy performed by a physiotherapist
48287831|NCT04132726|OTHER|non-effective treatment|non-effective treatment
48287832|NCT00527852|DEVICE|Flocked swab|
48287833|NCT01506791|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
48287834|NCT02213718|DRUG|Desflurane|desflurane (7%-8% end-tidal concentration)
48287835|NCT02213718|DRUG|propofol|propofol (TCI:3.5-4.0μg/min)
48287836|NCT02213718|DRUG|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
48630619|NCT05345314|PROCEDURE|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
48630620|NCT00812097|DEVICE|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
48630621|NCT02211157|DRUG|BIBR 796 BS|
48630622|NCT02211157|DRUG|Placebo|
47941012|NCT05774977|OTHER|Aviation noise plus earplugs (AN+EP)|The AN + EP night will consist of the aviation noise (AN) exposure with the addition of wearing earplugs overnight.
47941013|NCT05774977|OTHER|Aviation noise plus white noise 40 dBA (AN+BN40)|The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.
47941014|NCT05774977|OTHER|Aviation noise plus white noise 50 dBA (AN+BN50)|The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
47941015|NCT05774977|OTHER|Control Night (CTRL)|Control night (CTRL) without noise exposure and without earplugs.
47941016|NCT01002482|DEVICE|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
48287837|NCT02212418|OTHER|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
48287838|NCT02039388|PROCEDURE|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
48287839|NCT02446782|DRUG|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
48287840|NCT02446782|OTHER|saline|100 mL normal saline 15-30 minutes before the start of the procedure
48287841|NCT00863954|DEVICE|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
48287842|NCT05717322|BEHAVIORAL|TENS|apply TENS after orthognathic surgery
48287843|NCT05717322|BEHAVIORAL|sham TENS|apply non active TENS after orthognathic surgery
48287844|NCT05996744|DRUG|Obeldesivir|Tablet administered orally with or without food
48287845|NCT01919411|DRUG|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
48287846|NCT01919411|DRUG|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
48287847|NCT01318616|OTHER|Strength training of the hip adductors|Adductor strength training
48287848|NCT04677270|BEHAVIORAL|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
48287849|NCT03968146|PROCEDURE|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
48473278|NCT02666924|OTHER|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
48630623|NCT02211157|OTHER|high fat breakfast|
48473279|NCT03304431|DRUG|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
48630624|NCT03087357|OTHER|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
48630625|NCT00871000|BIOLOGICAL|Boostrix Polio™ 711866|Single dose, intramuscular administration.
48630626|NCT00871000|BIOLOGICAL|Priorix Tetra TM 208136|Single dose, subcutaneously.
48630627|NCT00871000|BIOLOGICAL|Tetravac TM|Single dose, intramuscular administration.
48630628|NCT03561740|DRUG|capecitabine|additional metronomic chemotherapy of capecitabine
48630629|NCT00249041|DRUG|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
48287850|NCT03968146|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
48287851|NCT03968146|DRUG|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
48101775|NCT05177341|OTHER|Determining Preferred Walking Speed|In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
48287852|NCT03968146|DRUG|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
48287853|NCT03968146|DRUG|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
48287854|NCT03968146|DRUG|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
48287855|NCT03968146|DRUG|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
48287856|NCT03968146|DRUG|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
48287857|NCT02047552|DRUG|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
48287858|NCT02047552|DRUG|Oxandrolone|10 mg PO Q12 hours for seven days
48287859|NCT02047552|DRUG|IV iron placebo|100 mL normal saline
48287860|NCT02047552|DRUG|Oxandrolone placebo|similar color and size sugar pill
48287861|NCT03069339|DRUG|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
48287862|NCT03069339|PROCEDURE|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
48287863|NCT01293669|DRUG|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
48287864|NCT01293669|DRUG|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
48287865|NCT00077454|DRUG|erlotinib hydrochloride|Given orally (PO)
48287866|NCT00077454|DRUG|temozolomide|Given PO
48287867|NCT00077454|OTHER|pharmacological study|Correlative studies
48287868|NCT00077454|OTHER|laboratory biomarker analysis|Correlative studies
48287869|NCT03321812|PROCEDURE|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
48287870|NCT03321812|PROCEDURE|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
48287871|NCT05174715|OTHER|BIA|nutritional status was evaluated using BIA
48287872|NCT02864303|OTHER|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
48630630|NCT00249041|DRUG|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
48630631|NCT00851136|DRUG|bevacizumab|Intravenous repeating dose
48287873|NCT00147771|DRUG|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
48287874|NCT04054310|DIAGNOSTIC_TEST|Liver Multi Scan|MRI to create cT1, T2\* and PDFF images of patients liver.
48287875|NCT03543865|BEHAVIORAL|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
48473280|NCT06330051|BEHAVIORAL|improvement acute reperfusion treatment quality for stroke through spatiotemporal computing|"1. Intelligent bracelet automatic positioning device and data feedback system based on spatiotemporal computing technology~2. Continuous in-hospital procedure improvement based on P-D-C-A cycle for AIS"
48630632|NCT00851136|DRUG|FOLFOX|Intravenous repeating dose
48630633|NCT00851136|DRUG|PRO95780|Intravenous repeating dose
48630634|NCT03197688|OTHER|Notapplicable|Not applicable as non-interventional study
48630635|NCT00977561|DRUG|figitumumab|Figitumumab (20 mg/kg)
48630636|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
48630637|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
48630638|NCT00977561|DRUG|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
48630639|NCT00977561|DRUG|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
48287876|NCT03543865|BEHAVIORAL|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
48287877|NCT03543865|OTHER|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
48287878|NCT01381107|DRUG|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
48287879|NCT01381107|DRUG|Placebo|Sublingual administration once daily for 7 consecutive days.
48287880|NCT02238613|DEVICE|radioactive stent|radioactive stent carrying seed iodine 125
48287881|NCT02238613|DEVICE|plastic stent|common plastic stent without carrying seed iodine 125
48287882|NCT02124798|DEVICE|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
48287883|NCT03331211|DRUG|TKIs|Dasatinib combined with Chematherapy
48287884|NCT01243931|DRUG|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
48287885|NCT00437905|PROCEDURE|angioplasty|
48287886|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
48287887|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
48287888|NCT01158898|DRUG|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
48101776|NCT03030950|DRUG|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
48287889|NCT01812304|OTHER|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
48287890|NCT01812304|OTHER|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
48287891|NCT03361670|OTHER|Observational Study|
48287892|NCT00936949|PROCEDURE|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
48287893|NCT00936949|PROCEDURE|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
48287894|NCT05162235|DEVICE|Augmented Reality-assisted localization of solitary pulmonary nodule|In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
48287895|NCT03014869|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
48287896|NCT02967523|DEVICE|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
48287897|NCT03636815|OTHER|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
48287898|NCT06070610|DRUG|BI 1015550|BI 1015550
48287899|NCT06070610|DRUG|Nintedanib|Soft capsules
48287900|NCT06070610|DRUG|Pirfenidone|Film-coated tablets
48287901|NCT03845283|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
48287902|NCT03845283|BEHAVIORAL|Physical Activity Intervention|An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
48287903|NCT03845283|BEHAVIORAL|Bite Counter|Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
48287904|NCT03845283|BEHAVIORAL|Virtual Reality|This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
48287905|NCT03845283|BEHAVIORAL|Virtual Meetings|Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
48287906|NCT00156078|DRUG|pregabalin|
48287907|NCT00011895|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
48287908|NCT00011895|DRUG|Efavirenz|
48287909|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
48287910|NCT04788563|DRUG|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
48287911|NCT04788563|OTHER|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
48630640|NCT06181500|OTHER|Home-based multicomponent exercise intervention program|A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).
48101777|NCT03030950|DRUG|Normal saline|to give normal saline to the other group as a placebo
48630641|NCT05930353|OTHER|COHORT|this evaluation includes a brief interview with perma profiler scale
48630642|NCT04250675|DEVICE|Intermittent pneumatic leg compressions|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.
48630643|NCT04250675|DEVICE|Sham|Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
48630644|NCT01783938|BIOLOGICAL|Nivolumab|
48630645|NCT01783938|BIOLOGICAL|Ipilimumab|
48630646|NCT02555098|DEVICE|Sapphire contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
48630647|NCT02555098|DEVICE|senofilcon A contact lenses|Each subject randomized to wear either the test or control contact lenses as a matched pair and cross over to the second matched pair
48630648|NCT05540275|DRUG|Tislelizumab plus Bevacizumab|200mg Tislelizumab plus 3mg/kg bevacizumab every 3 weeks
48630649|NCT02384343|DRUG|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
48630650|NCT02384343|DRUG|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
48630651|NCT00164866|DRUG|Omeprazole|
48630652|NCT02105142|BEHAVIORAL|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
48630653|NCT02105142|BEHAVIORAL|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
48630654|NCT02105142|BEHAVIORAL|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
48630655|NCT02774720|BEHAVIORAL|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
48630656|NCT02774720|BEHAVIORAL|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
48630657|NCT05452512|OTHER|Self monitoring|Self monitoring using smart clinical trial application
48630658|NCT05452512|OTHER|Smart watch assisted monitoring|Smart watch-assisted adherence monitoring
47941017|NCT01002482|DEVICE|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
47941018|NCT01911637|DRUG|VBY-036|Study drug VBY-036
47941019|NCT01911637|DRUG|Placebo|Placebo
48287912|NCT04788563|DRUG|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
48287913|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
48287914|NCT04788563|DRUG|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
48287915|NCT05325164|DRUG|Methadone|Methadone
48287916|NCT05325164|DRUG|Morphine|Morphine
48287917|NCT02843711|GENETIC|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
48287918|NCT01491945|DEVICE|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
48287919|NCT02234011|DRUG|Ketamine|
48287920|NCT02234011|DRUG|Placebo|
48287921|NCT03787069|DRUG|iv Lignocaine vs placebo|Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
48287922|NCT00982722|DRUG|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
48287923|NCT00982722|DRUG|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
48287924|NCT00262106|DRUG|PRO 2000/5|Gel
48287925|NCT00262106|DRUG|Placebo|Placebo
48287926|NCT00376688|OTHER|Laboratory Biomarker Analysis|Correlative studies
48287927|NCT00376688|DRUG|Temsirolimus|Given IV
48287928|NCT05987670|DEVICE|AI-stethoscope|"Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including~1. Delivery and setup~2. Smartphone app installation and login~3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice~4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines."
48287929|NCT04346225|DRUG|Hyperpolarized C13|Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
48287930|NCT04346225|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
48287931|NCT05126095|RADIATION|Radical radiotherapy|Intensity-modulated radiation therapy (IMRT)
48287932|NCT02723435|DRUG|Midostaurin|Given PO
47941020|NCT00162721|DRUG|doxorubicin, ifosfamide, cisplatin|
48287933|NCT04746521|DIAGNOSTIC_TEST|Multitest 6 color TBNK and BD Lyotubes|The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells
48287934|NCT04746521|BIOLOGICAL|genomicDNA extraction|Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
48473281|NCT04397640|DIAGNOSTIC_TEST|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
48630659|NCT05452512|DRUG|Vitamin D|Vitamin D self-administration for 3 months
48630660|NCT03854032|BIOLOGICAL|Nivolumab|Given IV
47941021|NCT00195871|DRUG|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
48287935|NCT05859815|BEHAVIORAL|Physical Therapy|As part of their normal care, participants will receive any combination of the following interventions to address their specific needs identified during the initial evaluation: cervical spine repeated movements (active range of motion), cervical spine stabilization exercise, aerobic exercise, motor control training, oculomotor/vestibular rehabilitation, stretching, soft-tissue mobilization, joint mobilization, and postural re-education activities.
48287936|NCT00662870|BIOLOGICAL|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
48287937|NCT00662870|BIOLOGICAL|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
48287938|NCT04837911|DEVICE|Spirobank Smart|Patients using the Spirobank Smart
48287939|NCT03040050|OTHER|rPCR results|Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
48287940|NCT03040050|OTHER|Control group|Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
47941022|NCT00195871|PROCEDURE|hematopoietic stem cell allograft|conventional procedures
47941023|NCT01778777|DEVICE|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
48287941|NCT01024244|DRUG|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
48287942|NCT01024244|DRUG|LY2599506|Administered po for 12 weeks
48287943|NCT00447421|DRUG|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
48287944|NCT00447421|DRUG|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
48287945|NCT00447421|RADIATION|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
48287946|NCT03984526|DRUG|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
48287947|NCT03984526|DRUG|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
48287948|NCT03984526|DRUG|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
48287949|NCT00998101|DRUG|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
48287950|NCT00998101|DRUG|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
48287951|NCT00998101|DRUG|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
48287952|NCT01784471|DEVICE|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
48287953|NCT00863668|DRUG|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
48287954|NCT00863668|DRUG|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
48287955|NCT00863668|PROCEDURE|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
48287956|NCT00863668|PROCEDURE|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
48287957|NCT04457921|OTHER|deep tissue massage|DTM was applied to participants in the experimental group twice (at the 10th and 22nd h) after cesarean
48287958|NCT04430348|DRUG|PTX-35|Monoclonal antibody PTX-35
48473282|NCT03498924|DIAGNOSTIC_TEST|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
48630661|NCT03854032|BIOLOGICAL|IDO1 Inhibitor BMS-986205|Given PO
48630662|NCT03854032|PROCEDURE|Therapeutic Conventional Surgery|Undergo Surgery
48287959|NCT03004846|DRUG|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
48287960|NCT03004846|DRUG|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
48287961|NCT00858832|DRUG|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
48473283|NCT00810706|DRUG|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
48630663|NCT03854032|OTHER|Questionnaire Administration|Ancillary studies
48630664|NCT02201082|PROCEDURE|Airway clearance technique|
48630665|NCT02201082|DRUG|Amikacin nebulization|
48287962|NCT04978753|DRUG|Anlotinib|"1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;"
48287963|NCT03580057|BEHAVIORAL|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
48287964|NCT03580057|BEHAVIORAL|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
48287965|NCT04439669|DEVICE|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
48287966|NCT04439669|DEVICE|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
48287967|NCT04606121|COMBINATION_PRODUCT|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
48287968|NCT01815684|DRUG|ASP3652|Oral
48287969|NCT01815684|DRUG|Placebo|Oral
48287970|NCT03020693|PROCEDURE|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
48287971|NCT03020693|PROCEDURE|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
48287972|NCT03728673|DRUG|Escitalopram Oral Capsules|Active capsules will contain 10 mg escitalopram oxalate.
48287973|NCT06023914|OTHER|STRENGTH EVALUATION WITH ELECTROSTIMULATOR|Evaluation of isometric strength using an electrostimulator.
48287974|NCT06023914|OTHER|STRENGTH EVALUATION WITHOUT ELECTROSTIMULATOR|Evaluation of isometric strength not using an electrostimulator.
48287975|NCT00871858|DRUG|anastrozole|Given orally
47941024|NCT01337271|PROCEDURE|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
48287976|NCT00871858|DRUG|fulvestrant|Given intramuscularly
48630666|NCT01676350|PROCEDURE|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
47941025|NCT01337271|PROCEDURE|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
47941026|NCT01596543|OTHER|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
48287977|NCT03193905|PROCEDURE|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
48287978|NCT03193905|PROCEDURE|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
48287979|NCT01226667|DRUG|Pregabalin|"Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly."
48630667|NCT00239980|DRUG|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
48101778|NCT06388707|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: max. three consecutive 10-minute FUS exposures with two 5-minute intermission intervals.
48287980|NCT01821963|DRUG|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
48287981|NCT01821963|DRUG|Ribavirin|Starting dose: 1,000 mg by mouth daily.
48287982|NCT01821963|DRUG|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
48287983|NCT03438422|DIETARY_SUPPLEMENT|Pollen extract|1 tablet a day
48287984|NCT00000110|PROCEDURE|magnetic resonance spectroscopy|
48287985|NCT00000110|DRUG|dietary fat|
48287986|NCT06114654|BEHAVIORAL|Physical Therapy|Specific physical tests to assess muscle strength, ankle stability and activation of the lower extremity musculature: Single Leg Stance Test, Hurdle Step test and Single leg vertical jump.
48287987|NCT03180762|DRUG|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
48287988|NCT03180762|DRUG|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
48287989|NCT03180762|DRUG|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
48630668|NCT06433726|DRUG|BY101921 tablets|An oral PARP7 Inhibitor
48630669|NCT06386042|OTHER|no intervention, observational study|no intervention, observational registry of the prescription of medical therapy according to the European Society of Cardiology Heart Failure guidelines (quality of care).
48630670|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
48630671|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
48630672|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
48630673|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
48287990|NCT03180762|DRUG|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
48287991|NCT03180762|DRUG|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
48287992|NCT03180762|DRUG|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
48287993|NCT03180762|DRUG|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
48287994|NCT03180762|DRUG|Placebo|Matching placebo will be administered.
47941027|NCT01292785|DRUG|Hormones|"FtM will receive~* 1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~* if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~* 50mg cyproterone acetate daily (Androcur®)~* estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is \> 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is \< 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~* 2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
48287995|NCT02984475|DRUG|Metformin|
48287996|NCT03322137|DRUG|SNA-120|Pegcantratinib ointment
48287997|NCT03322137|DRUG|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
48473284|NCT03911596|DEVICE|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
48630674|NCT04785885|DIAGNOSTIC_TEST|iStat Handheld Blood Analyzer|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
48630675|NCT04785885|DIAGNOSTIC_TEST|Hemochron|An easy-to-use blood analyzer that provides monitoring of heparin anticoagulation quickly for point-of-care testing. Testing will be done at baseline, 30s, 90s and 180s after heparin administration.
48630676|NCT01029483|OTHER|Low carbohydrate diet|Ad libitum low carbohydrate diet (\<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
48630677|NCT01029483|OTHER|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
48630678|NCT01029483|OTHER|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at \~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
48630679|NCT03630887|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
48630680|NCT03994120|OTHER|RTMS|Altering the connectivity of trans-synaptic pathways
48630681|NCT05662943|DRUG|Intravitreal aflibercept injection|Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
48630682|NCT04242602|DEVICE|Transcranial Doppler|Record flow velocity tracing of middle cerebral artery using a transcranial doppler.
48630683|NCT00369863|DRUG|Triamcinolone acetonide|
48630684|NCT00500929|DRUG|CMI X-11S|
47941028|NCT02135939|BEHAVIORAL|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
48287998|NCT05488054|PROCEDURE|Physical Therapy|Patients will undergo physical therapy following surgical intervention
48287999|NCT05488054|PROCEDURE|Monitored Work-out|Healthy volunteers will undergo a monitored workout for comparison of data
48288000|NCT05488054|DEVICE|Moxy Oxygen Sensor Device|Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
48288001|NCT06479005|DEVICE|Oura Ring|The Oura ring will remotely monitor the patients vitals at home continuously
47941029|NCT00689091|DEVICE|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
47941030|NCT00689091|DEVICE|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
47941031|NCT00883844|DRUG|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
48630685|NCT03294655|BEHAVIORAL|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
48630686|NCT00997815|DRUG|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
48630687|NCT00997815|DRUG|Normal saline injection|Using normal saline 2.5 ml injected in control side
48630688|NCT01879852|BEHAVIORAL|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
47941032|NCT00883844|DRUG|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
47941033|NCT03013127|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
47941034|NCT05730816|DRUG|Magnesium sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
47941035|NCT05730816|DRUG|Normal Saline|Intravenous infusion of normal saline.
47941036|NCT02631356|DRUG|Ringer's lactate solution|
47941037|NCT02631356|DRUG|Succinylated gelatin|
47941038|NCT03967678|DIETARY_SUPPLEMENT|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
47941039|NCT01999101|DRUG|Px-104|28 days treatment
47941040|NCT04140136|DIETARY_SUPPLEMENT|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
47941041|NCT04140136|DIETARY_SUPPLEMENT|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
47941042|NCT01462786|DRUG|ATX-101|2 mg/cm2 ATX-101
47941043|NCT05616806|BEHAVIORAL|iENDURE|"Two delivery modes: computer and text message. The intervention provides introductory strategies for managing physical and emotional distress associated with Long COVID through a computer-delivered session followed by 4-weeks of theoretically-informed text messages intended to promote distress tolerance (DT).~Computer - the initial intervention will be delivered online via the Qualtrics survey tool following informed consent. The intervention provides strategies to better tolerate emotional and physical discomfort to persist with behavioral goals. Text Message - The text message intervention will be delivered using Marigold Health (a HIPAA compliant platform for secure text messaging). Participants will receive daily text messages that focus on emphasizing adaptive strategies for tolerating physical and emotional discomfort in order to work toward behavioral goals. The text messages will be personalized and offer skills training (reminders of previously learned DT skills)."
47941044|NCT05350176|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
47941045|NCT05350176|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
47941046|NCT03531034|OTHER|Combined Exercise Training|The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
47941047|NCT02684318|DRUG|PM01183 + olaparib|
47941048|NCT02818647|PROCEDURE|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
47941049|NCT02561910|DEVICE|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
47941050|NCT06004908|DEVICE|MRI|a type of scan that uses strong magnetic field sand radio waves to produce detailed images of the inside of the body
47941051|NCT01314612|BEHAVIORAL|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
47941052|NCT01411930|DRUG|Intramuscular olanzapine, aripiprazole|"1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
47941053|NCT01411930|DRUG|Intramuscular aripiprazole, olanzapine|"1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
47941054|NCT05785104|OTHER|Myofascial release|Is Facilitation of mechanical and neurological adaptive capacity as integrated through the Myofascial system
48288002|NCT01309126|BIOLOGICAL|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
48288003|NCT01309126|DRUG|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
48288004|NCT01930071|DEVICE|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
48288005|NCT06402253|BEHAVIORAL|Music composition / edition|"Participants in this group will complete two 1-hour music composition training intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these music composition lessons has been developed specifically for this project, in collaboration and based on the educational music composition programs from the American Composers Orchestra (ACO).~Lessons review basic structural musical concepts, practicing active listening and music appreciation skills, teaching about the use of music-composition specific software (i.e., Soundtrap), and helping the students in expressing themselves / their identity through music, learning about musical story-telling through the creation of their own musical pieces from scratch."
48288006|NCT06402253|BEHAVIORAL|Photography composition / edition|"Participants in this group will complete two 1-hour photography/visual-arts composition/edition intervention sessions per week over the course of 3 months (24 sessions total). These sessions will take place in the participating schools\&#39; premises, during normal hours corresponding to their advisory period class; or in participating centers during extracurricular activities' periods.~The curriculum for these photography composition lessons has been developed specifically for this project, in collaboration and based on educational photography/film programs from Downtown Community TV Center (DCTV).~Lessons review basic structural photography/visual-arts concepts, practicing visual-arts appreciation skills, teaching about the use of photography edition specific software (i.e., Photoshop), and helping the students in expressing themselves/their identity through photography, learning about visual story-telling through the creation of their own photographical projects from scratch."
48630689|NCT01879852|BEHAVIORAL|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
48630690|NCT00523666|DRUG|Galantamine (Reminyl®)|8mg - 24mg
48630691|NCT00523666|DRUG|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
48630692|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
48630693|NCT01551823|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
48101779|NCT02949570|DRUG|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
48101780|NCT03795701|DRUG|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
48101781|NCT03795701|OTHER|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
48101782|NCT02328820|OTHER|Percutaneous coronary intervention (PCI)|For lesions with both FFR\<=0.8 and CFR\<2.0
48101783|NCT02328820|OTHER|Optimal medical therapy (OMT)|For lesions with FFR\>0.8 or CFR\>=2.0 or both
48101784|NCT03545789|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
48101785|NCT01250002|DRUG|Placebo|Placebo will receive the same volume of saline infusion.
48101786|NCT01250002|DRUG|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
48101787|NCT05039918|BEHAVIORAL|Affective touch|Gentle stroking at CT-optimal speed
48101788|NCT05623280|DRUG|Indocyanine green|Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
48101789|NCT00003790|GENETIC|polymerase chain reaction|
48101790|NCT00003790|OTHER|flow cytometry|
48101791|NCT06629571|OTHER|Education|Training for the patient before surgery
48101792|NCT04428554|RADIATION|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
48101793|NCT00134810|BIOLOGICAL|Botulinum toxin type A|
48101794|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution)|The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
48101795|NCT02577523|DRUG|ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD|The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
48288007|NCT01432639|OTHER|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
48101796|NCT05895760|OTHER|Multi-component physical exercise online intervention|"A multicomponent exercise program was implemented consisting of a combined program of endurance, strength, coordination, balance, and flexibility exercises depending on the level of functional capacity.~Three types of physical exercise programs were designed according to the physical performance level of each participant. The first type of exercise program training was performed for frail adults with an SPPB score of 4 to 6, the second was for the pre-frail adults with an SPPB score of 7 to 9 and the third for robust adults with an SPPB of 10 to 12."
48288008|NCT00411515|DRUG|Mycophenolate Mofetil 2x 1g|
47941055|NCT05785104|OTHER|Muscle energy technique|Is manual therapy procedure that involves alternating periods of resisted muscle contraction and assisted stretching
48101797|NCT02989662|DRUG|Mifepristone|Participants receive 6 doses.
48101798|NCT02989662|DRUG|Placebo - Cap|Participants receive 6 doses
48101799|NCT00567879|DRUG|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
48101800|NCT00567879|DRUG|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
48101801|NCT04995887|DEVICE|Jada® System|The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
48101802|NCT00076986|DRUG|IL13-PE38QQR|
48101803|NCT00076986|PROCEDURE|surgery and catheter placement (2 procedures)|
48288009|NCT04801914|PROCEDURE|Percutaneous biliary drainage|Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).
48288010|NCT05873530|OTHER|Grape|Reconstituted whole grape powder
48288011|NCT05417529|OTHER|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
48288012|NCT05417529|DRUG|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
48473285|NCT05108376|DEVICE|Visensia Safety Index (VSI)|Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
48473286|NCT01814358|DIETARY_SUPPLEMENT|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
48473287|NCT01814358|DIETARY_SUPPLEMENT|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
48473288|NCT04086524|OTHER|Binocular cartoon treatment at home|see arm description.
48473289|NCT04086524|OTHER|Patching|see arm description
47941056|NCT04123665|DRUG|Stannous fluoride|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
48101804|NCT00076986|DRUG|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
48101805|NCT00076986|PROCEDURE|surgery and wafer placement (1 procedure)|
48473290|NCT04086524|OTHER|Binocular cartoon treatment in office|see arm description.
47941057|NCT04123665|DRUG|Sodium monofluorophosphate|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
47941058|NCT03964844|OTHER|No intervention|No intervention
47941059|NCT03832075|DIAGNOSTIC_TEST|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
48101806|NCT03384537|COMBINATION_PRODUCT|Listerine total care zero|reducing intra-oral cariogenic microorganism.
48101807|NCT03384537|COMBINATION_PRODUCT|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
48101808|NCT02561403|BEHAVIORAL|EVO multitask video game|Participants will play a multitasking game for 4 weeks
48101809|NCT02561403|BEHAVIORAL|EVO words video game|Participants will play a word puzzle game for 4 weeks
48101810|NCT04716803|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
48101811|NCT04716803|DEVICE|Angel Concentrated Platelet Rich Plasma (cPRP) System|Aspiration of bone marrow will be collected from the patient's pelvic bone region and subsequently concentrated with the Angel Concentrated Platelet Rich Plasma (cPRP) System.
48101812|NCT03736005|OTHER|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
48101813|NCT03861949|OTHER|5 cmH2O CPAP|
48101814|NCT03861949|OTHER|head-up position|
48101815|NCT01850992|DEVICE|Active CPAP|Effective CPAP will be administered
48101816|NCT01850992|DEVICE|Sham CPAP|This is placebo CPAP
48101817|NCT04100044|OTHER|Exercise Counseling|Meet with physical therapist
48101818|NCT04100044|BEHAVIORAL|Exercise Intervention|Receive personalized home exercise intervention
48101819|NCT04100044|OTHER|Questionnaire administration|Ancillary studies
48288013|NCT03689231|OTHER|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
48288014|NCT02477098|DRUG|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
48288015|NCT02477098|DRUG|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
48288016|NCT02755636|BEHAVIORAL|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
47941060|NCT03832075|DIAGNOSTIC_TEST|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
47941061|NCT03832075|DIAGNOSTIC_TEST|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady \& balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
48288017|NCT02755636|OTHER|Usual care|Primary care as usual
48288018|NCT01588080|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
48288019|NCT01588080|DEVICE|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
48288020|NCT03501212|DRUG|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
48288021|NCT03501212|DRUG|Placebo|Placebo Cream 2.5gr applied to both wrist
48288022|NCT01088412|DRUG|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
48473291|NCT05555927|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
48630694|NCT04199039|OTHER|Effect on Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction|"When the study started, the first 43 patients were assigned to the control group and the following 43 patients were assigned to the study group in the CVS ICU. ET fixation in the control group was performed with plasters, which are routinely used in the ICU where the study was conducted. ET fixation of the patients in the study group was performed with an ET holder (AnchorFast Oral Endotracheal Tube Fastener, Hollister, Liberlyville, USA) when they arrived at the CVS ICU.~The patients' SBP, DBP, HR and SpO2 values, which were displayed on the bedside monitor (Nihon Kohden, Tokyo), were recorded on the Hemodynamic Parameters Form just before, during, and at the end of endotracheal suction, and in the following 5th and 15th minutes."
48630695|NCT02242006|OTHER|serial serum sampling for quantification of drug concentration|
48630696|NCT06450704|OTHER|Physical Exercise|"Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week.~Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes."
48630697|NCT05124860|DIAGNOSTIC_TEST|Indirect calorimetry|Measurement of metabolic rate (kcal/day) by respiratory gas analysis.
48630698|NCT03769974|BEHAVIORAL|Motor imagery|Two series of 30 seconds training of motor imagery in each manual engine gesture
48630699|NCT03769974|BEHAVIORAL|Action observation|Two series of 30 seconds training of action observation training in video format in each manual engine gesture
48630700|NCT03769974|BEHAVIORAL|Placebo intervention|Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
48288023|NCT04642664|DRUG|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
48101820|NCT04100044|OTHER|Quality-of-Life Assessment|Ancillary studies
47941062|NCT00004637|DRUG|Vitamin E|
48101821|NCT01511250|BIOLOGICAL|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
48288024|NCT04146558|DRUG|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
48288025|NCT04146558|OTHER|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
48288026|NCT03692273|PROCEDURE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
48288027|NCT03692273|PROCEDURE|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
48288028|NCT02950129|OTHER|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
48288029|NCT05249192|DEVICE|Immediate urinary catheter removal|Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
48288030|NCT05249192|DEVICE|Early urinary catheter removal|urinary catheter removal on the first postoperative day (6 a.m)
48288031|NCT02750566|PROCEDURE|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
48288032|NCT02750566|OTHER|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
48288033|NCT05413694|OTHER|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
48288034|NCT06067113|PROCEDURE|Supraaortic and transcranial duplex|Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
48473292|NCT04283370|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
48630701|NCT00393380|DRUG|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC\>2000/microL: PTH 100 mcg
48630702|NCT06466252|BEHAVIORAL|Psychometric Group|There are no interventions
48630703|NCT02004171|OTHER|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
48630704|NCT02004171|DRUG|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
48288035|NCT01863862|RADIATION|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
48288036|NCT02857712|DRUG|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
48288037|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 5mg
48288038|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 10mg
48630705|NCT01867476|OTHER|Automated Adherence Monitoring System|
48630706|NCT01453647|OTHER|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
48630707|NCT02372032|PROCEDURE|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
47941063|NCT02945787|BEHAVIORAL|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
48101822|NCT01511250|BIOLOGICAL|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
48288039|NCT05513976|DRUG|febuxostat tablet|febuxostat tablet 40mg or 60mg or 80mg based on prior medication
48288040|NCT05513976|DRUG|SHR4640 placebo tablet|SHR4640 placebo tablet 5 or 10mg
48288041|NCT05946330|BEHAVIORAL|NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).|The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
48288042|NCT05084547|OTHER|No intervention|No intervention
48630708|NCT02372032|PROCEDURE|ozone therapy|percutaneous intradiscal ozone injection
47941064|NCT02945787|BEHAVIORAL|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
48101823|NCT04138433|DEVICE|Real tDCS|Anodal tDCS 2 ma
48101824|NCT04138433|DEVICE|Sham tDCS|Sham tDCS 2 ma
48101825|NCT06630091|DRUG|Golidocitinib|150 mg once per day by PO
48101826|NCT06630091|DRUG|Cyclophosphamide|750 mg/m2 by IV
48101827|NCT06630091|DRUG|Doxorubicin|50 mg/m2 by IV
48101828|NCT06630091|DRUG|Vincristine|1.4 mg/m2 (max: 2 mg) by IV
48288043|NCT05927909|DIAGNOSTIC_TEST|Low Back Activity Confidence Scale (Lobacs)|Confidence Scale (LOBACS) is a self-report questionnaire designed to assess an individual's level of confidence in performing various physical activities involving the lower back region, to evaluate their perceived functional ability, and to assess the impact of low back pain on their daily life and functional performance.
48288044|NCT04956484|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg
48473293|NCT04283370|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
48288045|NCT04956484|DRUG|Standard of care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
48288046|NCT05780281|BIOLOGICAL|VIR-7831|VIR-7831 is a fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibody (mAb) derived from antibody S309 from a survivor of SARS-CoV-1.
48288047|NCT05780281|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
48473294|NCT00760786|DRUG|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
48473295|NCT00760786|DRUG|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
48288048|NCT05780281|BIOLOGICAL|Remdesivir|Antiviral agent
48288049|NCT00066781|DRUG|gemcitabine hydrochloride|Given IV
48288050|NCT00066781|DRUG|irinotecan hydrochloride|Given IV
48473296|NCT00760786|DRUG|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
48473297|NCT00760786|DRUG|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
48630709|NCT01279993|PROCEDURE|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
48630710|NCT06438952|PROCEDURE|Transforaminal steroid injection combined with lumbar sympathetic blockade|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance Lumbar sympathetic blockade will be made with 5 ml 0.5% bupivacaine + 6 mg dexamethason + 10 ml NaCl
48288051|NCT00986193|PROCEDURE|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
48288052|NCT00986193|PROCEDURE|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
48288053|NCT04146532|DRUG|Aspirin 500 MG|Single 500mg aspirin capsule.
48288054|NCT04146532|DRUG|Placebo|Single 500mg placebo capsule.
48288055|NCT06293092|DEVICE|leg pedaling cycling device|Intradialytic aerobic cycling exercise program ,each patient will receive the treatment program three times per week for three months.
48288056|NCT06293092|DEVICE|sand bags|Intradialytic resistive exercise program , each patient will receive the treatment program three times per week for three months.
48288057|NCT06293092|DEVICE|hemodialysis sessions|hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.
48630711|NCT06438952|PROCEDURE|Transforaminal steroid injection only|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance
48630712|NCT01684033|DEVICE|Opti-Free® PureMoist® MPDS|
48630713|NCT01684033|DEVICE|Biotrue™ MPS|
47941065|NCT03210181|OTHER|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
47941066|NCT03210181|OTHER|Placebo|Patients will receive an equivalent volume of normal saline
47941067|NCT03895021|BEHAVIORAL|Pisando Fuerte|"Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On \[SO\])."
47941068|NCT03660631|BEHAVIORAL|CVRS Intervention|"1. Evaluate gaps in therapy~2. Contact patients regularly by email, phone and/or text message~3. Assess and counsel for medication adherence, side effects, life-style behaviors~4. Develop an action plan and send recommendations to provider"
48101829|NCT06630091|DRUG|Prednisone|100 mg by PO
48101830|NCT05943795|DRUG|SI-B001|Administration by intravenous infusion
48101831|NCT05943795|DRUG|Docetaxel|Administration by intravenous infusion
48288058|NCT04468672|BEHAVIORAL|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
48288059|NCT00410891|DRUG|gatifloxacin|
48288060|NCT00203346|PROCEDURE|Greater Occipital Nerve Block|
48288061|NCT05300529|OTHER|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
48288062|NCT05300529|OTHER|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
48288063|NCT03951987|DRUG|4 ml CG5503|4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
48288064|NCT03951987|DRUG|5 g charcoal powder|Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
48630714|NCT01684033|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
48630715|NCT02726295|DRUG|E. coli Nissle 1917(Mutaflor®)|
48630716|NCT02726295|DRUG|Placebo|
48630717|NCT01371682|DRUG|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
48630718|NCT02353663|OTHER|Echocardiography|Echocardiography examination
48630719|NCT00005021|BIOLOGICAL|filgrastim|
48630720|NCT00005021|DRUG|carboplatin|
48630721|NCT00005021|DRUG|paclitaxel|
48101832|NCT04874012|DRUG|Active comparator Taurine|Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
48101833|NCT04874012|OTHER|Placebo Comparator|Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
48101834|NCT04201119|DEVICE|Oxiris|Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
48288065|NCT00861042|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
48288066|NCT03291327|DIETARY_SUPPLEMENT|Probiotics|Lozenges for Home use
48288067|NCT02700581|PROCEDURE|low PEEP conventional ventilation|
48630722|NCT00005021|DRUG|topotecan hydrochloride|
48630723|NCT00404300|DRUG|Optivate|Plasma-derived Factor VIII
48630724|NCT03818932|DRUG|Celecoxib|Post-Operative Non Opioid Pain Protocol
48630725|NCT03818932|DRUG|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
48630726|NCT03818932|DRUG|Ketorolac|Post-Operative Non Opioid Pain Protocol
48630727|NCT03818932|DRUG|Gabapentin|Post-Operative Non Opioid Pain Protocol
48630728|NCT03818932|DRUG|Acetaminophen|Post-Operative Non Opioid Pain Protocol
48630729|NCT03818932|DRUG|Diazepam|Post-Operative Non Opioid Pain Protocol
48630730|NCT02828085|BIOLOGICAL|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
48630731|NCT03786575|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
48288068|NCT02700581|PROCEDURE|moderate PEEP conventional ventilation|
48288069|NCT02700581|PROCEDURE|low PEEP protective ventilation|
48288070|NCT02700581|PROCEDURE|moderate PEEP protective ventilation|
48288071|NCT02850250|DRUG|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
48288072|NCT02817607|PROCEDURE|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
48288073|NCT05629962|DRUG|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
48288074|NCT05629962|DRUG|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
48288075|NCT03518515|OTHER|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
48288076|NCT03518515|OTHER|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
48288077|NCT03518515|OTHER|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (\~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
48288078|NCT04850950|DRUG|Tenofovir Alafenamide fumarate 25mg Oral Tablet|Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
48288079|NCT03490344|DRUG|Daratumumab|"* Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~* Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
48288080|NCT03490344|DRUG|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
48288081|NCT05101707|DEVICE|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
48288082|NCT05101707|OTHER|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
48288083|NCT02625038|DEVICE|EUDAMED CIV-14-03-011940|
48288084|NCT00550628|GENETIC|DNA methylation analysis|
48288085|NCT00550628|GENETIC|fluorescence in situ hybridization|
48288086|NCT00550628|GENETIC|gene expression analysis|
48288087|NCT00550628|GENETIC|polymerase chain reaction|
47941069|NCT06518889|PROCEDURE|Selective Dorsal Rhizotomy|Selective Dorsal Rhizotomy (SDR) is an irreversible neurosurgical procedure where 50-70% of the sensory nerve roots are cut at the spinal level. The procedure is used to reduce lower limb spasticity permanently and is augmented by intensive rehabilitation for at least two years after surgery to optimise outcomes.
48288088|NCT00550628|GENETIC|protein expression analysis|
47941070|NCT02260674|DRUG|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
48288089|NCT00550628|GENETIC|reverse transcriptase-polymerase chain reaction|
48288090|NCT00550628|OTHER|diagnostic laboratory biomarker analysis|
48288091|NCT00550628|OTHER|immunoenzyme technique|
48288092|NCT00550628|OTHER|immunohistochemistry staining method|
48630732|NCT01810107|PROCEDURE|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
48630733|NCT01123564|DRUG|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
47941071|NCT02260674|DRUG|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
47941072|NCT02260674|DRUG|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
47941073|NCT05100095|DRUG|Radiation therapy|Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
47941074|NCT01557894|OTHER|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
47941075|NCT01515540|DRUG|lidocaine|5% lidoderm patch
47941076|NCT01515540|DRUG|placebo|placebo
48288093|NCT00550628|PROCEDURE|biopsy|
48288094|NCT00550628|PROCEDURE|therapeutic conventional surgery|
48288095|NCT00550628|RADIATION|fludeoxyglucose F 18|
48288096|NCT03551899|OTHER|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
48288097|NCT00599651|DEVICE|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
48288098|NCT00599651|OTHER|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
48288099|NCT05968950|DEVICE|Thoracic ultrasound|The use of ultrasound to count ribs in order to surface mark the corresponding spinal level
48101835|NCT02441075|OTHER|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
48101836|NCT05716542|OTHER|Physical Activity Intervention|Fitbit wearable device, home exercise sessions, and telehealth appointments with physical therapist.
48288100|NCT04886765|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
48288101|NCT03675399|OTHER|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
48288102|NCT03675399|OTHER|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
48288103|NCT04723537|DRUG|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
48288104|NCT04723537|DRUG|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
48288105|NCT04723537|DRUG|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
48288106|NCT04723537|DRUG|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
48288107|NCT04775043|DIAGNOSTIC_TEST|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
48288108|NCT01296386|BIOLOGICAL|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
48288109|NCT03227926|DRUG|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
48288110|NCT03227926|DIAGNOSTIC_TEST|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
48288111|NCT01828827|DRUG|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
48288112|NCT03527043|DRUG|Escitalopram|10mg by mouth daily for 6 weeks
47941077|NCT01713387|DRUG|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
48101837|NCT00667693|DEVICE|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
48101838|NCT00667693|DEVICE|Pentax AWS|Intubation with Pentax AWS
48288113|NCT03527043|OTHER|Placebo|matched placebo control by mouth for 6 weeks
48288114|NCT03910699|DEVICE|Three-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.
48288115|NCT03910699|DEVICE|Two-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
48630734|NCT01123564|RADIATION|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
48101839|NCT05986149|BEHAVIORAL|Conversation about arts and culture|intergenerational conversation about arts and culture between older adults and international students who native language is not English.
48101840|NCT00946751|DRUG|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
48101841|NCT00946751|DRUG|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
48101842|NCT01345292|DEVICE|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
48101843|NCT01345292|DRUG|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
48288116|NCT01466114|DRUG|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
48288117|NCT01466114|OTHER|Placebo|4 capsules PO QD
48288118|NCT01466114|DRUG|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
48288119|NCT01466114|OTHER|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
48288120|NCT01836601|BEHAVIORAL|Family-centered nighttime communication bundle|
48288121|NCT03167619|DRUG|Olaparib Oral Product|olaparib 300mg twice daily
48288122|NCT03167619|DRUG|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
48288123|NCT01142648|DRUG|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
48288124|NCT01142648|DRUG|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
48288125|NCT00515125|BEHAVIORAL|Dietary Advice|Dietary Advice sheet
48288126|NCT00515125|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
48630735|NCT05285150|OTHER|Survey|It´s a survey
48630736|NCT04803903|DEVICE|Flotraq Sensor with EV1000 incorporating the HPI algorithm|"The HPI algorithm is only available on the EV1000, Hemosphere and Flotrac monitoring systems and requires the use of a Flotrac sensor connected to an arterial line (Edwards Lifesciences Corp., Irvine, CA, USA). The Flotrac sensor has a splitter which enables the splitting of the arterial blood pressure signal to facilitate a blood pressure signal on both the anesthesia machine monitor (standard care) and the HemoSphere monitor (study).~In the intervention arm we asked the anesthesiologist and anesthesia nurse to use the study treatment flowchart . If the HPI alarm goes off, which entails both a sound and a flickering light, we ask the anesthesiologist to act upon this alarm immedietaly. Use of the study treatment flowchart ensures that the anesthesiologist has to think about the underlying cause. The HemoSphere/EV1000 with HPI software has a second screen with variables that provide information about the underlying cause of the predicted hypotension."
48473298|NCT02116894|BIOLOGICAL|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
48630737|NCT06121232|DEVICE|Abbott® DRG / Abbott®/Medtronic® SCS|Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
48630738|NCT06121232|OTHER|Control Group|Participants will not receive any intervention
48630739|NCT05003999|DEVICE|HPC - SpeediCath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter
48630740|NCT05003999|DEVICE|Non-HPC - Self-Cath ®|The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
48630741|NCT02040220|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
48630742|NCT05777278|DRUG|Savolitinib|Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
48630743|NCT05777278|DRUG|Docetaxel|Docetaxel (60 mg/m2, ivgtt, q3w)
48630744|NCT02082483|OTHER|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
48101844|NCT01345292|DRUG|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
48101845|NCT03256344|BIOLOGICAL|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
48630745|NCT02456558|DRUG|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
48630746|NCT02456558|DRUG|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
48630747|NCT01651598|DRUG|Placebo to BI 144807|multiple dose (bid)
48630748|NCT01651598|DRUG|BI 144807|multiple dose (bid, low to high dose)
48101846|NCT03256344|BIOLOGICAL|Atezolizumab|A monoclonal antibody given by intravenous injection.
48101847|NCT04087044|DEVICE|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"1. Oculo-Motility and Positional Testing,~2. Caloric Testing"
48101848|NCT03735771|DRUG|Bupivacaine|0.25% bupivacaine plus fentanyl 8 mcg/ml
48630749|NCT03590327|DEVICE|Transcranial Magnetic Stimulation|rTMS
48630750|NCT00902525|DRUG|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
48630751|NCT01750281|DRUG|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
48630752|NCT01750281|DRUG|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
48630753|NCT01750281|DRUG|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
48630754|NCT01750281|DRUG|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
48630755|NCT05456893|PROCEDURE|Procedure: endoscopic biopsy|Per-endoscopic biopsies
48630756|NCT05456893|PROCEDURE|Blood sampling|Blood sampling
48630757|NCT05456893|PROCEDURE|stool sampling|stool sampling
48630758|NCT01090206|DIETARY_SUPPLEMENT|Vitamin D and calcium|Doses will be based on Vitamin D levels
48630759|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level -1|(1 x 10\^3 T cells/Kg)
48630760|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 1|(1 x 10\^4 T cells/Kg)
48630761|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 2|(1 x 10\^5 T cells/Kg)
48630762|NCT00586547|BIOLOGICAL|T-Cell Infusion Dose Level 3|(1 x 10\^6 T cells/Kg)
48630763|NCT00586547|BIOLOGICAL|T-Cell Infusion- Dose Level 4|(5 x 10\^6 T cells/Kg)
48630764|NCT00807404|PROCEDURE|histopathologic examination|
48473299|NCT02116894|DRUG|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
47941078|NCT02142114|DEVICE|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
47941079|NCT03315182|BIOLOGICAL|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
47941080|NCT03206255|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
47941081|NCT03206255|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
47941082|NCT00625742|BEHAVIORAL|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
48288127|NCT03385356|DRUG|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
48101849|NCT03677154|DRUG|Mosunetuzumab Intravenous (IV)|Participants in cohorts A and B will receive IV mosunetuzumab.
48101850|NCT03677154|DRUG|Mosunetuzumab Subcutaneous (SC)|Participants in Cohort C will receive SC mosunetuzumab.
48101851|NCT03677154|DRUG|Polatuzumab Vedotin|Participants in Cohort C will receive IV polatuzumab vedotin.
48101852|NCT03677154|DRUG|Tocilizumab|Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).
48101853|NCT04573374|PROCEDURE|Pulpotomy|Pulpotomy is the term for removal of the coronal pulp with the intent of maintaining the vitality of the remaining radicular pulp tissue.
48101854|NCT04744597|BEHAVIORAL|Real execution of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task
48101855|NCT04744597|BEHAVIORAL|Motor imagery of Fitts's law tasks|Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.
48630765|NCT00807404|PROCEDURE|optical coherence tomography|
48101856|NCT04744597|BEHAVIORAL|Skip counting|Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
48101857|NCT01779882|DRUG|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
48288128|NCT02011022|DRUG|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
48288129|NCT02011022|DRUG|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
48288130|NCT01070355|DRUG|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
48288131|NCT01070355|DRUG|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
48473300|NCT04584086|DEVICE|MRI 3 tesla|"1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~* During treatment when half of the prescribed dose has been delivered.~* 1 month after the end of the irradiation."
48630766|NCT01009697|DRUG|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
48630767|NCT02126202|PROCEDURE|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
48630768|NCT02990143|PROCEDURE|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
48630769|NCT02285972|DRUG|saline|before the anesthesia induction, 2mL saline iv injection
48630770|NCT02285972|DRUG|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
47941083|NCT00625742|BEHAVIORAL|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
47941084|NCT00625742|DRUG|Melatonin|20 mg by mouth (PO) Daily
47941085|NCT00625742|DIETARY_SUPPLEMENT|Juven|90 calories of Juven, twice a day.
47941086|NCT00625742|DRUG|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate \>110 beats/min) or resting energy expenditure (REE) \> 110% of predicted.
47941087|NCT00625742|DRUG|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
47941088|NCT02581839|DRUG|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
47941089|NCT02581839|DEVICE|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
47941090|NCT02581839|DRUG|Pre-Medication: Zofran|Zofran at 8mg orally. Given at the discretion of the treating physician
48101858|NCT01779882|DRUG|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
48101859|NCT03359031|OTHER|Patient education|This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
48101860|NCT06193785|OTHER|Hypnosis|hypnosis realised by expert practitioner, before and during the electromyogram procedure
48101861|NCT03265704|OTHER|AGA - Control group|Data processing from Patient Medical Files
48101862|NCT03265704|OTHER|SGA - Control group|Data processing from Patient Medical Files
48101863|NCT03265704|OTHER|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
48101864|NCT03265704|OTHER|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
48288132|NCT00754767|DRUG|L-carnitine L-tartrate|Given orally
47941091|NCT02581839|DRUG|Pre-Medication: Decadron|decadron at 8mg orally. Given at the discretion of the treating physician
48288133|NCT00754767|OTHER|placebo|Given orally
48288134|NCT02246270|DRUG|Intravesical Heparin|Heparin bladder instillation
48288135|NCT02246270|OTHER|Placebo|Intravesical saline
48101865|NCT04406168|PROCEDURE|urinary diversion|follow up outcomes of urinary diversion
48101866|NCT04300335|OTHER|Individual Exercise|Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
48101867|NCT04300335|OTHER|Group Exercise|Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
48101868|NCT02661035|DRUG|Allopurinol|300 mg/day (for peds -150 mg/m\^2/day), day -6 and continue through day 0 or longer if clinically indicated
48101869|NCT02661035|DRUG|Fludarabine|30 mg/m\^2 IV over 1 hour, day -6, -5, -4, -3 and -2
48101870|NCT02661035|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
48288136|NCT00960817|DRUG|Statin, aspirin|
48288137|NCT00960817|DRUG|Dipyridamole|
48288138|NCT05421754|DEVICE|ANNE Sleep|ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
48288139|NCT01224899|PROCEDURE|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
48288140|NCT00393458|DRUG|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
48288141|NCT00393458|DRUG|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
48630771|NCT02285972|DRUG|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
48288142|NCT00393458|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
48630772|NCT04934072|DRUG|FKS518|Participants will receive FKS518 via subcutaneous injection, every 26 weeks.
47941092|NCT00582283|DRUG|I124-NM404|I-124-NM404
47941093|NCT04399031|DRUG|E-cigarette e-liquid|Participants will self-administer an experimenter-provided e-cigarette.
47941094|NCT02660398|PROCEDURE|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
47941095|NCT01571297|DRUG|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
47941096|NCT01571297|DRUG|Placebo|Placebo given subcutaneously for 35 days
47941097|NCT00417573|DRUG|IV Gamunex 10%|
47941098|NCT05561179|PROCEDURE|Hyaluronic acid injection|"Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
47941099|NCT05561179|PROCEDURE|Sodium chloride injection (control group)|"Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms."
47941100|NCT05965297|DEVICE|DeltaFil|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
48288143|NCT00393458|DRUG|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
48288144|NCT03988712|DIAGNOSTIC_TEST|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
48288145|NCT05578521|DRUG|Cerebralcare pills|a dose of 2 packages, twice a day of Cerebralcare pills
48288146|NCT05578521|DRUG|Cerebralcare pills placebo|Cerebralcare pills placebo will be administrated at the same rate with experimental group
48288147|NCT04181281|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
48288148|NCT04181281|DIAGNOSTIC_TEST|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
48288149|NCT03160144|PROCEDURE|open lung approach|
48288150|NCT00084786|DRUG|docetaxel|
48288151|NCT00084786|DRUG|gefitinib|
48288152|NCT01898312|DRUG|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
48288153|NCT00283712|DRUG|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
48288154|NCT00283712|OTHER|Placebo Comparator|Placebo administered in place of infliximab for control group
48288155|NCT04047030|OTHER|None- Observational Study|No Intervention
48288156|NCT02952716|BIOLOGICAL|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
48288157|NCT02952716|OTHER|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
48288158|NCT02558023|DRUG|Urapidil|"Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
48288159|NCT02558023|DRUG|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
48288160|NCT03963544|DRUG|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
48288161|NCT04024410|OTHER|Evaluation of PEEP in prone position|Assessment of optimal Positive End-Expiratory Pressure (PEEP) in patients undergoing scheduled spine surgery in prone position.
48288162|NCT01824602|DRUG|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
48288163|NCT01824602|DRUG|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
48288164|NCT01824602|DRUG|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
48288165|NCT01824602|DRUG|Placebo|Placebo sugar pills
48288166|NCT06430255|OTHER|Global Postural Re-education|Program for treatment
48288167|NCT06430255|OTHER|Laser-guided Supervised Exercise|Program for treatment
48288168|NCT02708823|OTHER|CogCheck application|The application is administered once to all study participants.
48288169|NCT03785080|OTHER|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
48288170|NCT03785080|OTHER|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
48288171|NCT06184581|DRUG|Lithium Carbonate|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
48288172|NCT06184581|DRUG|Lamotrigine|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
48288173|NCT06345781|BEHAVIORAL|Abdominal Functional Electrical Stimulation|Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time.
48288174|NCT03703531|PROCEDURE|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
48288175|NCT05753111|DIETARY_SUPPLEMENT|PEA|PEA supplementation
48288176|NCT05753111|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin supplementation
48288177|NCT00298532|PROCEDURE|Advanced Life Support|
48288178|NCT05159765|DEVICE|Single vision contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
48288179|NCT05159765|DEVICE|Multifocal contact lenses|Wearing contact lenses during waking hours may alter the progression of myopia
48288180|NCT06508983|DRUG|SG301 Injection|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
48288181|NCT06508983|DRUG|SG301 placebo|Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
48288182|NCT06508983|DRUG|pomalidomide|Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
48288183|NCT06508983|DRUG|dexamethasone|Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
48288184|NCT00889356|DRUG|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
48288185|NCT00889356|DRUG|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
48288186|NCT02672956|PROCEDURE|Ten mm trocar|
48288187|NCT00506389|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
48101871|NCT02661035|DRUG|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
48101872|NCT02661035|RADIATION|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
48101873|NCT02661035|DRUG|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is \<40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~* Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~* Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
48101874|NCT02661035|DRUG|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, MMF will continue as long as clinically indicated."
48288188|NCT00506389|DRUG|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
48288189|NCT04207073|DEVICE|Mobilization of median nerve|Neural mobilization
48288190|NCT03502746|DRUG|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
48288191|NCT03502746|DRUG|Ramucirumab|8mg/kg, IV over 60 minutes.
48288192|NCT02448550|DRUG|Bivalirudin|
48630773|NCT04934072|DRUG|US-licensed Prolia|Participants will receive US-licensed Prolia via subcutaneous injection, every 26 weeks.
48288193|NCT02448550|DRUG|Unfractionated heparin|
48288194|NCT05852210|OTHER|Infrared Imaging|This study will use thermal forward looking infrared (FLIR) imaging to assess the severity of Complex Regional Pain Syndrome in newly diagnosed patients.
48473301|NCT04106817|BIOLOGICAL|Live, wild-type A/California/H1N1 2009 influenza virus|Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
47941101|NCT05965297|DEVICE|Riva Self Cure HV|Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
47941102|NCT01880047|DRUG|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (\> 50,000 and increase by \> 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (\> 50,000 and \> 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
47941103|NCT01880047|DRUG|Placebo|
48288195|NCT00142103|DRUG|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
48288196|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
48288197|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
48288198|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
48288199|NCT00142103|DRUG|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
48288200|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
48473302|NCT03880149|DIETARY_SUPPLEMENT|Omega-3|Each omega-3 capsule contains 600 mg, including 400 mg EPA + 200 mg Docosahexaenoic acid (DHA) and 400 IU of vitamin E for 5 omega-3 capsules. Omega-3 dosage: 1 g per 15 kg body mass
48473303|NCT03880149|OTHER|Placebo|Medium-chain triglyceride (MCT) and vitamin E
48473304|NCT00754871|DRUG|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
48630774|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
48288201|NCT03591822|BEHAVIORAL|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
48288202|NCT03591822|BEHAVIORAL|B : Systemic evaluation of the pain|A systematic evaluation of the pain
48288203|NCT00736281|OTHER|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
48288204|NCT04666883|OTHER|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
48288205|NCT01317849|DRUG|Folic Acid|0.8mg
48288206|NCT01317849|DRUG|Vitamin B6|10mg
48288207|NCT01317849|DRUG|Vitamin B12|500ug
48288208|NCT01317849|DRUG|placebo|0.8 mg
47941104|NCT00505882|DRUG|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
47941105|NCT00505882|DRUG|Glargine|
48288209|NCT01317849|DRUG|placebo|10mg
48288210|NCT01317849|DRUG|placebo|500ug
48630775|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
48630776|NCT00709800|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
48630777|NCT00709800|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
48630778|NCT00709800|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
48630779|NCT03902990|OTHER|Dual task|The patients in the dual task group received cognitive tasks during treadmill training sessions.
48630780|NCT03902990|OTHER|Treadmill Training|Standard treadmill training
47941106|NCT00505882|DRUG|Lispro|
47941107|NCT00505882|DRUG|Aspart|
48288211|NCT00949650|DRUG|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
48288212|NCT00949650|DRUG|BIBW 2992|BIBW 2992 once daily until progression
48288213|NCT00949650|DRUG|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
48288214|NCT03332953|OTHER|E-cigarettes with varying concentrations of nicotine & flavor|Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
48288215|NCT06511388|OTHER|Non-Interventional Study|Non-interventional study
48288216|NCT04913805|DRUG|Potassium Nitrate|Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
48288217|NCT04913805|DRUG|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside|Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
48288218|NCT04913805|OTHER|Potassium Chloride|Active control
48288219|NCT01121406|DRUG|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
48288220|NCT01121406|DRUG|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
48288221|NCT01121406|DRUG|Topotecan|Patients receive topotecan in 3 or 4 week schedule
48630781|NCT03902990|OTHER|Standard exercise programme|Standard exercise programme for Parkinson Disease
48630782|NCT00887588|DRUG|LCZ696|50 mg, 100 mg and 200 mg tablets
48630783|NCT00887588|DRUG|Valsartan|40 mg, 80 mg and 160 mg tablets
48630784|NCT00887588|DRUG|Placebo|matching placebo to LCZ696 and Valsartan
48630785|NCT05708378|OTHER|Rocker board training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
48288222|NCT01121406|DRUG|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
48288223|NCT01121406|DRUG|BI 6727|Patients receive BI 6727 infusion every 3 weeks
48288224|NCT00765583|DRUG|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
48473305|NCT00754871|DRUG|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
48101875|NCT02661035|BIOLOGICAL|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
48101876|NCT02661035|BIOLOGICAL|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10\^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
48473306|NCT00754871|DRUG|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
48101878|NCT00798772|DIETARY_SUPPLEMENT|Micronutrients and antioxidants|8 capsules twice daily for two years
48101879|NCT00798772|DIETARY_SUPPLEMENT|Multivitamins and minerals|8 capsules twice daily for two years
48101880|NCT03693755|PROCEDURE|In-plane Group|Placement of femoral nerve catheter under ultrasound control
48101881|NCT03693755|PROCEDURE|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
48101882|NCT05822609|DRUG|Semaglutide|1.0 mg
48101883|NCT05822609|OTHER|Placebo|Placebo
48473307|NCT00754871|DRUG|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
47941108|NCT04205994|DRUG|Tolcapone 200 MG|Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
47941109|NCT04205994|OTHER|Functional Magnetic Resonance Imaging (fMRI)|FMRI provides an indirect and noninvasive measure of brain activity.
47941110|NCT05293509|DRUG|Fludarabine|40 mg/m2/day i.v.- by vein
47941111|NCT05293509|DRUG|Dexamethasone|25 mg/m2/day i.v.-by vein
48288225|NCT06295926|DRUG|Serplulimab|Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
48288226|NCT01532661|OTHER|observational study|data collected by investigators
48288227|NCT04553887|DRUG|Almonertinib|single agent, 110mg p.o once daily until disease progressed
48288228|NCT03419702|DIETARY_SUPPLEMENT|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
48288229|NCT02604719|DRUG|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
47941112|NCT05293509|DRUG|Cyclophosphamide|100 mg/m2 IV-by vein
47941113|NCT05293509|DRUG|Bortezomib|Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
48288230|NCT04215549|OTHER|No intervention|cross sectional study，no intervention
47941114|NCT05293509|DRUG|Rituximab|Four doses of rituximab at a dose of 375 mg/m2- by vein
47941115|NCT05293509|DRUG|Busulfan|110 mg/m2 i.v-by vein
47941116|NCT05293509|DRUG|Cyclophosphamide (Cy)|by vein
47941117|NCT05293509|DRUG|Tacrolimus (or cyclosporine)|by vein
47941118|NCT05293509|DRUG|Mycophenolate mofetil (MMF)|given by PO
47941119|NCT05293509|DRUG|Rabbit ATG|by vein
47941120|NCT01709578|DRUG|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
47941121|NCT01709578|DRUG|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
47941122|NCT01709578|DRUG|hydroxychloroquine|Dispensed according to the local practice.
47941123|NCT01709578|DRUG|methotrexate|Dispensed according to the local practice.
48101884|NCT00683735|DRUG|Sitagliptin|100 mg once daily in the morning
48101885|NCT00683735|DRUG|Metformin|up to 2000 mg/day
48101886|NCT00683735|DRUG|Placebo|500mg 1-0-0-0
48101887|NCT00683735|DRUG|Placebo|100mg 1-0-0-0
48101888|NCT04385342|DRUG|FSH|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
48101889|NCT04385342|DRUG|HP-hMG|Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
48101890|NCT02212717|PROCEDURE|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
48101891|NCT02212717|PROCEDURE|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
48288231|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
48288232|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
48288233|NCT01850810|OTHER|Experimental Study Product|
48288234|NCT01850810|OTHER|Control Study Product|
48288235|NCT03672617|OTHER|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
48288236|NCT04611477|OTHER|Rice Hulk|Placebo
48288237|NCT04611477|OTHER|Synbiotic365 Ver 5|Active Comparator
48288238|NCT04611477|OTHER|Synbiotic365 Ver 7|Active Comparator
48288239|NCT06017323|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)
48288240|NCT06017323|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)
48288241|NCT06017323|DRUG|Proglumide Dose level 1|Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)
48288242|NCT06017323|DRUG|Proglumide Dose level 2|Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).
48288243|NCT02001012|DRUG|Artemether-lumefantrine combination|
48288244|NCT02001012|DRUG|Chloroquine|
48288245|NCT00184847|DRUG|acetylcholine|
48288246|NCT00184847|PROCEDURE|twenty minutes of forearm ischemia|
48288247|NCT00184847|PROCEDURE|three 5-minute periods of forearm ischemia|
48288248|NCT00184847|DRUG|adenosine|
48288249|NCT00184847|DRUG|caffeine|
48288250|NCT05838417|BEHAVIORAL|REDS survey|R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
48288251|NCT00678496|OTHER|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
48288252|NCT00678496|OTHER|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
48288253|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
48288254|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
48288255|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
48288256|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
48288257|NCT04909021|OTHER|Placebo (single-dose)|Single dose administered intranasally on Day 1
48288258|NCT04909021|OTHER|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
47941124|NCT01709578|DRUG|sulfasalazine|Dispensed according to the local practice.
47941125|NCT01709578|DRUG|leflunomide|Dispensed according to the local practice.
47941126|NCT00129818|DRUG|Famciclovir|
48288259|NCT04471220|DEVICE|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
48288260|NCT04236453|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
48288261|NCT04236453|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
48288262|NCT04236453|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
48288263|NCT04236453|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally on Day 1.
48288264|NCT04507217|DRUG|Tislelizumab, Carboplatin, Pemetrexed|"Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle"
48288265|NCT02884115|DRUG|benzathine penicillin|
48288266|NCT03767010|OTHER|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
48288267|NCT03767010|OTHER|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
48288268|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
48288269|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
48288270|NCT04711421|DEVICE|4 VIVOFIT-|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
48288271|NCT02526849|DRUG|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
48288272|NCT02526849|BEHAVIORAL|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
48473308|NCT05132439|DRUG|Metformin ER|Oral medication typically used for Type 2 diabetes with presumed anti-inflammatory properties
48288274|NCT05946252|OTHER|Motor imagery|"Motor imagery will be performed according to the PETTLEP (Physical,Environment,Task,Time,Learn,Emotion,Perspective) model for 15 minutes.~1. To imagine walking activity in different environments (seaside, beach, walking path).~2. The rest activity will be imagined by sitting on a bench.~3. Upper extremity strengthening exercises with dumbbells, lower extremity strengthening exercises with elastic band and trunk-oriented bridging, posterior pelvic tilt and table top stabilization exercises will be visualized.~4. The rest activity will be imagined by sitting on a bench.~5. Imagination will end with homecoming and domestic activities."
48288275|NCT05946252|OTHER|Diaphragmatic breathing|Diaphragmatic breathing will be shown to pregnant women in the supine position, eyes closed, with one hand on the chest and the other hand on the abdomen. This practice will last for five minutes.
48288276|NCT02896140|OTHER|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
48288277|NCT00810160|DIETARY_SUPPLEMENT|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
48288278|NCT00810160|DIETARY_SUPPLEMENT|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
48288279|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
48288280|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
48288281|NCT05863936|DRUG|Methylprednisolone Injectable Suspension|Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
48288282|NCT05863936|DRUG|Belimumab Injection|Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
48288283|NCT05863936|DRUG|Immunosuppressive Agents|"1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;~2. Tacrolimus, oral, 2-4mg per day."
48288284|NCT05355012|OTHER|5A organizational innovation|"This project is based on three strategic axes:~* A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~* Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~* Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
48288285|NCT00609271|BEHAVIORAL|low carbohydrate diet|\<40 grams carbohydrate/day
48288286|NCT00609271|BEHAVIORAL|low fat diet|\<30% fat, \<7% saturated fat
48288287|NCT03037294|DIETARY_SUPPLEMENT|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
48288288|NCT00539344|DRUG|ANG1005|IV infusion once every 21 days
48288289|NCT00486980|DRUG|Peramivir 150mg|
48288290|NCT00486980|DRUG|Peramivir 300mg|
48288291|NCT04073615|DRUG|Rivoceranib|Film-coated tablets
48288292|NCT04073615|DRUG|Trifluridine/Tipiracil|Film-coated tablets
48288293|NCT01690962|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
48288294|NCT01690962|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
48288295|NCT01649492|DIETARY_SUPPLEMENT|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
48288296|NCT02786537|DRUG|SOF/LDV (sofosbuvir/ledipasvir)|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
48288297|NCT02786537|DRUG|PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)|Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
47941127|NCT04867239|OTHER|A two-day education progra|During the camp, the multidisciplinary team provided disease information, lifestyle modification, nutrition, and exercise.
48288298|NCT02786537|DRUG|EBR/GZR (elbasvir/grazoprevir)|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
48288299|NCT02786537|DRUG|Ribavirin|200 mg pills (1-3 pills, 1-2 times per day)
48288300|NCT04265989|DEVICE|Single BMS|Single bare metal stent covered the coronary artery aneurysm
48288301|NCT04265989|DEVICE|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
48288302|NCT04265989|DEVICE|Single or Double BMS|Treated with single or double layer bare metal stents
48288303|NCT04265989|DEVICE|BMS+DES|Treated with bare metal stent combined with drug eluting stent
47941128|NCT00557401|DRUG|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
47941129|NCT00557401|DRUG|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
48473309|NCT05132439|DRUG|placebo|Matched to active study drug
48288304|NCT04610307|PROCEDURE|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
48288305|NCT04107220|DRUG|Sacubitril/Valsartan|Effect of Sacubitril/Valsartan on BNP and NT-proBNP
47941130|NCT00557401|DRUG|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
48288306|NCT03518957|BEHAVIORAL|Exercise|"Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home."
48288307|NCT00881829|DEVICE|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
48288308|NCT03792711|DIETARY_SUPPLEMENT|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
48288309|NCT00001081|DRUG|Nitazoxanide|
48630786|NCT05708378|OTHER|Stable surface training|Patients will perform 24 sessions (4 times per week over 6 weeks) and effects will be measured before treatment, at 3rd and after 6th week.
48630787|NCT04633304|DEVICE|EndoAVF System for endovascular AV fistula creation|AV fistula creation
47941131|NCT00557401|DRUG|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
47941132|NCT00557401|DRUG|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
48101892|NCT02628691|OTHER|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
48288310|NCT04064710|PROCEDURE|Vertebral Body Augmentation|Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
48288311|NCT04064710|DEVICE|Manual Surgical Instruments|Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
48288312|NCT01570491|OTHER|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
48288313|NCT01570491|OTHER|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
48288314|NCT04653415|DRUG|Gabapentin 300mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
48288315|NCT04653415|DRUG|Methylprednisolone 125 mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
48288316|NCT04653415|DRUG|Tablet|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
48288317|NCT04653415|DRUG|Normal Saline 10 mL Injection|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
48288318|NCT05511922|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
48288319|NCT03865342|BEHAVIORAL|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
48288320|NCT05399693|PROCEDURE|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
48288321|NCT02708511|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
48288322|NCT02708511|DRUG|Copper Cu 64-DOTA B-Fab|Given IV
48288323|NCT02708511|OTHER|Laboratory Biomarker Analysis|Correlative studies
48288324|NCT02708511|OTHER|Pharmacological Study|Correlative studies
48630788|NCT03519607|BEHAVIORAL|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
48630789|NCT00896233|PROCEDURE|MRE|"Part 1: Participants will have a screening visit, followed \~1 month later by two imaging visits over \~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed \~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
48630790|NCT05299450|DIETARY_SUPPLEMENT|Beet It shots|In addition to the procedures for the control group, women will be supplied with 84 Beet-It shots which they will be asked to take every morning with breakfast for 12 weeks. Women below 60kg will be advised to take a proportion of the 'shot' in order to comply with European Commission Accepted Daily Intake for nitrate, the active ingredient, of 0-5mg/kg. https://www.beet-it.com/product/beet-it-sport-shot/
48630791|NCT05299450|BEHAVIORAL|Exercise|In addition to the procedures for the control group, women will be supplied with gym membership for 12 weeks, 2 initial personal training sessions to design a personal exercise program followed by monthly personal training sessions.
48630792|NCT05299450|OTHER|Control group|Women will be supplied with a wearable device to measure physical activity, weighing scales and a home blood pressure monitor. They will be asked to record minutes of physical activity, exercise undertaken, resting blood pressure, resting heart rate and weight daily for 12 weeks.
47941133|NCT03269461|DEVICE|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
47941134|NCT01784393|RADIATION|chemoradiation|
47941135|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation A|Memantine HCl MR capsule formulation will be administered orally in a single dose
48288325|NCT02708511|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo PET/CT
48288326|NCT01843322|PROCEDURE|endoleak repair procedure (navigation technology )|
48288327|NCT00618956|DRUG|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily \[BID\]), oral administration.
48288328|NCT00618956|DRUG|Placebo|Placebo
48288329|NCT02188446|BEHAVIORAL|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
48288330|NCT01522495|DEVICE|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
48288331|NCT01522495|DEVICE|SPY Imaging|SPY Imaging to assess tissue perfusion
48288332|NCT05126615|DRUG|Auriculotherapy|Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
48288333|NCT05126615|BEHAVIORAL|Chronic Post-Surgical Pain evaluation|"Different questionnaires :~BPI : Brief Pain Inventory DN4"
48288334|NCT01744899|OTHER|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
48288335|NCT05667519|PROCEDURE|Additional guidance of lead implantation by transesophageal echocardiography|Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position
48288336|NCT06170255|BEHAVIORAL|Behavioral Activation (BA)|Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
48288337|NCT01189773|DRUG|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
48288338|NCT04014907|PROCEDURE|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
48288339|NCT00603044|DRUG|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
48288340|NCT01634243|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
48630793|NCT04275414|DRUG|Bevacizumab Injection|Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
48288341|NCT00051844|DRUG|Capravirine|
47941136|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation B|Memantine HCl MR capsule formulation will be administered orally in a single dose
47941137|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation C|Memantine HCl MR capsule formulation will be administered orally in a single dose
48288342|NCT03317808|DIAGNOSTIC_TEST|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
48288343|NCT05054946|PROCEDURE|Laparoscopic cystectomy|All surgeries will be performed under general anesthesia by laparoscopically.
48288344|NCT03808207|OTHER|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
48288345|NCT06512402|DRUG|Norepinephrine|patients will receive norepinephrine infusion at rate of 0.05 mcg/Kg/min
48288346|NCT06512402|DRUG|Epinephrine|patients will receive epinephrine infusion dose of 0.03 mcg/Kg/min
48288347|NCT04631718|RADIATION|Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)|"MRI-based QSM methods estimate the susceptibility of tissues based on measuring the magnetic field distortion produced by the tissues themselves.~Upon successful validation, MRI-based abdominal QSM will provide accurate, repeatable, and reproducible quantification of Liver iron concentration (LIC) that is independent of the distribution of iron and does not require calibration."
48288348|NCT03095105|DRUG|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
47941138|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation D|Memantine HCl MR capsule formulation will be administered orally in a single dose
47941139|NCT03468543|DRUG|Memantine Hydrochloride MR Prototype Capsule Formulation E|Memantine HCl MR capsule formulation will be administered orally in a single dose
48288349|NCT00244218|DRUG|tetrahydrobiopterin (BH4)|Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
48288350|NCT02449564|DRUG|sirolimus|sirolimus 1mg daily
48288351|NCT04883073|DEVICE|Use of Endo App|Use of Endo App
48288352|NCT04299269|OTHER|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
48288353|NCT03250520|DRUG|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
48630794|NCT05845190|OTHER|aerobic exercises|aerobic exercises in form of walking on treadmill
48630795|NCT05845190|OTHER|resistance exercises|60% of One-repetition maximum 3 sets ( 8 to 12 ) repetitions
48630796|NCT00811109|DEVICE|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
48630797|NCT00811109|DEVICE|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
48288354|NCT00765479|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
48288355|NCT00765479|OTHER|placebo|Given orally
48288356|NCT02556762|RADIATION|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
48288357|NCT02556762|RADIATION|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
48288358|NCT02556762|DRUG|PF|Chemotherapy: Cisplatin and 5fluorouracil
48288359|NCT02355093|PROCEDURE|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
48288360|NCT02355093|PROCEDURE|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
48288361|NCT02355093|DRUG|ropivacaine|
48288362|NCT06085391|OTHER|REThink Game|REThink Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of seven levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change, positive bias, distinction between useful and useless thoughts, problem solving and compassion.
48288363|NCT06085391|OTHER|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
48288364|NCT06085391|OTHER|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress."
47941140|NCT03468543|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
48288365|NCT01580475|OTHER|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
48288366|NCT04170621|DEVICE|Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
48288367|NCT04910750|DEVICE|Pulse oximetry|Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation
48288368|NCT04910750|DEVICE|Clinical Decision Support Algorithm|Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care
48288369|NCT01479725|PROCEDURE|HBOT|HBOT
47941141|NCT06404424|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of sepsis to improve hemodynamic function and abrogate septic shock.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
48288370|NCT02978014|DEVICE|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
48288371|NCT02677779|PROCEDURE|CO2 laser|Single session of CO2 laser debridement
48288372|NCT02677779|PROCEDURE|traditional surgery|Single session of traditional debridement
48288373|NCT03836638|DRUG|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
48288374|NCT03836638|DRUG|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
48473310|NCT05239182|DRUG|9-ING-41|9-ING-41 is a small molecule potent selective GSK-3β inhibitor
48288375|NCT06177613|PROCEDURE|Blank culture transfer|A maximum of 0.1 ml of gassed embryo culture medium preheated to 37°C is injected into the uterine cavity transcervically using an embryo transfer catheter placed just beyond the internal os, two to 3 days before transfer of the thawed embryo
48288376|NCT06177613|PROCEDURE|Sham transfer|An intermediate transfer step is added two or three days before the planned transfer of the frozen embryo but with an empty catheter.
48288377|NCT00565422|DRUG|Escitalopram|10 mg/day
48288378|NCT02723630|DRUG|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%"
48288379|NCT03426969|DRUG|Cyclophosphamide|Given IV
48288380|NCT03426969|BIOLOGICAL|Filgrastim|Given SC
48288381|NCT03426969|DRUG|Fludarabine Phosphate|Given IV
48288382|NCT03426969|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
48288383|NCT03426969|DRUG|Melphalan|Given IV
48288384|NCT03426969|DRUG|Mycophenolate Mofetil|Given PO
48288385|NCT03426969|DRUG|Tacrolimus|IV or PO
48630798|NCT00811109|DEVICE|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
47941142|NCT06404424|DEVICE|Efferon CT|"Efferon CT, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that adsorbs excessive cytokines via its intrinsic porosity.~This device is routinely used for extracorporeal therapy of cytokine storm syndrome in the course of severe SARS-CoV-2.~Plasma exchange procedures will be carried out with a replacement volume of 2 plasma volumes with fresh frozen plasma and albumin solution.~Each patient is scheduled to undergo two separate hemoperfusions lasting 8-10 hours within 48 hours.~60 minutes before the start of hemoperfusion, additional administration of antimicrobial drugs is performed, taking into account their elimination during plasma exchange and adsorption"
47941143|NCT03824028|DEVICE|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
47941144|NCT04107259|DIAGNOSTIC_TEST|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
47941145|NCT02133521|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
47941146|NCT02133521|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
48288386|NCT03426969|RADIATION|Total-Body Irradiation|Undergo TBI
48288387|NCT00753922|DEVICE|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
48288388|NCT00036790|DRUG|doxorubicin hydrochloride|
47941147|NCT00589485|DEVICE|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
47941148|NCT00589485|DEVICE|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
47941149|NCT02568982|OTHER|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
48288389|NCT00036790|DRUG|motexafin gadolinium|
48288390|NCT04373122|DEVICE|REBOA|Resuscitative Endovascular Balloon Occlusion of the Aorta
48288391|NCT00847717|PROCEDURE|Selective neck dissection|Level IIb preserving neck dissection
47941150|NCT05789108|DIAGNOSTIC_TEST|Blood sample and Ultrasound examination|"The ultrasound examination is a non-invasive procedure with no risks, adverse reactions, or discomforts associated with the examination. The study blood samples are mostly obtained at the same time as clinical blood sample collection in order to avoid unnecessary complications.~The inclusion and ultrasound examiniation is performed by the patient responsible physician at the Emergency Department. Blood samples during the study period are performed by trained study staff."
47941151|NCT02651714|DRUG|Tradipitant|
47941152|NCT02651714|DRUG|Placebo|
48288392|NCT00847717|PROCEDURE|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
48288393|NCT01923610|BIOLOGICAL|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
48288394|NCT06153381|OTHER|Chatbot|Rehabilitation program based on standard care, but assisted via an instant messaging application using a personal smartphone
48288395|NCT06153381|OTHER|Standard car|Rehabilitation program based on standard care, assisted with one education session plus informative brochure
48288396|NCT01864135|DEVICE|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
48288397|NCT01864135|DEVICE|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
48630799|NCT04331379|DEVICE|Nasal Elevator|A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
47941153|NCT03461510|PROCEDURE|Hyperglycemic clamp|Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at \~250 mg/dL during fMRI.
47941154|NCT03461510|PROCEDURE|Hyperinsulinemic Euglycemic clamp|Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
47941155|NCT04151342|DRUG|Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents.|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies for their cancer treatment.
47941156|NCT04151342|OTHER|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
47941157|NCT00477581|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
47941158|NCT00477581|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
47941159|NCT05196178|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565;Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
47941160|NCT00002898|BIOLOGICAL|dactinomycin|
47941161|NCT00002898|DRUG|carboplatin|
47941162|NCT00002898|DRUG|cyclophosphamide|
47941163|NCT00002898|DRUG|epirubicin hydrochloride|
48630800|NCT04331379|DEVICE|Taping Alone|Horizontal tape alone.
48630801|NCT05103735|DRUG|Propofol|awake neurosurgery under propofol-remifentanil sedation
47941164|NCT00002898|DRUG|etoposide|
47941165|NCT00002898|DRUG|ifosfamide|
47941166|NCT00002898|DRUG|vincristine sulfate|
47941167|NCT00002898|PROCEDURE|adjuvant therapy|
47941168|NCT00002898|PROCEDURE|conventional surgery|
47941169|NCT00002898|PROCEDURE|neoadjuvant therapy|
47941170|NCT00002898|RADIATION|brachytherapy|
47941171|NCT00002898|RADIATION|radiation therapy|
47941172|NCT03550651|OTHER|Licorice|Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.
47941173|NCT03550651|OTHER|Hypertonic salt solution|The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.
47941174|NCT03550651|OTHER|Essential oil|Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.
47941175|NCT03550651|OTHER|Chlorhexidine Gluconate|Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.
48473311|NCT05239182|DRUG|Retifanlimab|Humanized, hinge-stabilized, IgG4κ monoclonal antibody that recognizes human PD-1.
48473312|NCT05239182|DRUG|Gemcitabine|cytotoxic chemotherapy agent
48630802|NCT04279600|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1 gram of taurine powder, total dosage: 3 grams/day
48630803|NCT04279600|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 1 gram of starch powder, total dosage: 3 grams/day
48473313|NCT05239182|DRUG|Abraxane|cytotoxic chemotherapy agent
48101893|NCT03279666|OTHER|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
48473314|NCT00578968|DRUG|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
47941176|NCT03550651|OTHER|Distilled water|Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
47941177|NCT04827121|PROCEDURE|Fascial iliac compartment block|Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
48101894|NCT03692949|DRUG|LY3451838|One dose administered (IV)
48101895|NCT03692949|DRUG|Placebo|Administered IV
48630804|NCT04279600|OTHER|Exercise training|4 weeks of combined exercise training (alternating strength and aerobic exercise), with a frequency of 3 times/week with 55 min/day.
48630805|NCT06100445|BEHAVIORAL|Semi structured interviews|Gaining qualitative data
47941178|NCT04827121|PROCEDURE|Quadratus lumborum block|Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
48288398|NCT06459752|OTHER|visceral manipulation and noble technique|"First, the patient will lie face-up on a massage or exam table. Physiotherapists feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles. Physiotherapist manual poking, pressing, and massage actions do three things:~1. Reveals visceral adhesions.~2. Find tender spots.~3. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that makeup fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Minor adhesions may resolve after one session. Tough, stubborn adhesions may require several sessions plus self-manipulation between sessions"
48288399|NCT06459752|OTHER|noble technique|The patient is positioned in supine with both knees bent and feet flat on a firm surface. The patient then places her crossed hands over her abdomen to support and pull the rectus abdominis muscles towards the midline. Finally, the patient is asked to slowly raise her head until a slight contraction is felt in the abdomen, holding for 20 seconds and repeating the exercise up to 20 times a day
47941179|NCT05673564|PROCEDURE|Anatomical Resection|Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
47941180|NCT05320302|DRUG|[11C]-Lu AF88370|PET ligand in a single intravenous bolus injection
47941181|NCT02285660|PROCEDURE|4D PET-CT Scan|
47941182|NCT02285660|OTHER|No intervention|
47941183|NCT04263454|DRUG|Endotoxin, Escherichia Coli|Endotoxin is a purified lipopolysaccharide prepared from E. coli O:113 and vialed under good manufacturing practice guidelines.
47941184|NCT04263454|PROCEDURE|Magnetic Resonance Spectroscopy|MRI is a non-invasive imaging technique and does not utilize ionizing radiation.
47941185|NCT00494065|OTHER|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
47941186|NCT00494065|OTHER|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
47941187|NCT02616432|DEVICE|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
47941188|NCT05368532|OTHER|Temperature|The temperature will be reduced for approximately one hour.
47941189|NCT05045833|DRUG|SYN-020 Delayed Release Capsule|Oral administration (by mouth)
47941190|NCT05558917|PROCEDURE|PECS BLOCK 2|With the patient supine, the linear probe will be placed in the sagittal plane slightly lateral to the hemiclavicular line ipsilateral to the surgical site. Once both muscle planes of interest have been identified, in-plane needle insertion will proceed in the cranio-caudal direction. The first local anesthetic administration with Ropivacaine 0.5% will be 20ml between small pectoralis and serratus anterior. Coming out with the needle, 10ml of Ropivacaine 0.5% will then be injected between large and small pectoral.
47941191|NCT05558917|PROCEDURE|ESP BLOCK|Positioning yourself behind the patient, lying on her side with the surgical hemilateral on top, you place the linear ultrasound probe in the sagittal plane and find the lateral margin of the transverse process. At this point, the blocking needle is inserted in the caudocranial direction and 25ml of Ropivacaine 0.5% is injected, taking care to visualize the anesthetic spread in the cranial direction.
47941192|NCT04243109|DRUG|Pomalidomide + Cyclophosphamide + Dexamethasone|"Treatment Phase: Combination of Pomalidomide, Cyclophosphamide and Dexamethasone, days 1-21 every 4 weeks (28 day cycles), up to a total of 8 cycles:~* Pomalidomide: Treatment with Pomalidomide 4 mg / day 1-21 days in 28-day cycles is started. Dose reductions will be made based on the evaluation of hematological and non-hematological toxicity.~* Cyclophosphamide: Cyclophosphamide will be administered 15 mg / day, days 1-28 in 28-day cycles.~* Dexamethasone: Dexamethasone will be administered 40 mg / day, days 1, 8, 15 and 22 in 28-day cycles. In patients older than 75 years the dose will be reduced to 20 mg / day in the same previous schedule.~Maintenance Phase: Combination of Pomalidomide and Dexamethasone. The last doses prescribed in the previous cycle will be maintained."
47941193|NCT03945292|DRUG|Fazisiran Injection|solution for subcutaneous (sc) injection
47941194|NCT03945292|OTHER|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
47941195|NCT03751228|DRUG|BMS-986165|Swish and expectorate after tasting
47941196|NCT03751228|DRUG|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
47941197|NCT02090868|OTHER|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
48101896|NCT03692949|DRUG|Placebo|Administered SC
48101897|NCT03692949|DRUG|LY3451838|One dose administered SC
48101898|NCT04414878|DEVICE|VitaFlow™ II Transcatheter Aortic Valve System|VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
47941198|NCT01952470|DRUG|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
48288400|NCT03350711|OTHER|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~* Health history and physical examination~* Urinalysis~* Urine or serum pregnancy test~* Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~* Electrocardiogram (EKG or ECG)~* Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
48630806|NCT03592992|DRUG|Spinal Hydromorphone|75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
48630807|NCT03592992|DRUG|Spinal Morphine|150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
48630808|NCT03177850|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
48630809|NCT03177850|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
48630810|NCT01271829|DIETARY_SUPPLEMENT|Avocado supplement|Calories from avocados replace calories of the control lunch
48630811|NCT01271829|DIETARY_SUPPLEMENT|Avocado included|Calories from avocados will be added to calories from the control lunch
48630812|NCT04675281|OTHER|2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks|All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
48630813|NCT01535066|PROCEDURE|acupuncture therapy|Receive acupuncture
48630814|NCT01535066|PROCEDURE|sham acupuncture|Receive sham acupuncture
48630815|NCT02475057|DRUG|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
48630816|NCT02475057|DRUG|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
48630817|NCT02475057|DEVICE|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
48630818|NCT04517058|OTHER|psychology therapy|If the symptoms are mild, patients will get the psychology therapy. If it's necessary according to patients' willings, patients will be given SSRIs antidepressant therapy.
48101899|NCT05481502|PROCEDURE|Tumor biopsy|3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
48630819|NCT00800150|DRUG|fludarabine phosphate|
48630820|NCT00800150|DRUG|melphalan|
48630821|NCT00800150|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
48630822|NCT00800150|RADIATION|intensity-modulated radiation therapy|
48630823|NCT00800150|RADIATION|tomotherapy|
48630824|NCT00800150|RADIATION|total marrow irradiation|
48630825|NCT00800150|RADIATION|total nodal irradiation|
48630826|NCT03357705|PROCEDURE|alveolar ridge preservation with synthetic bone|after tooth extraction
48288401|NCT01430195|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
48288402|NCT01430195|PROCEDURE|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
48288403|NCT05315440|OTHER|graston tecnique|Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.
48288404|NCT05315440|OTHER|Conventional rehabilitation|30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
48288405|NCT05727774|OTHER|Water Biking in hot water condition|Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
48288406|NCT05727774|OTHER|Water Biking in neutral water condition|Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
48288407|NCT03403244|PROCEDURE|US-MR image fusion-guided PTED|patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
48288408|NCT03403244|PROCEDURE|fluoroscopy-guided PTED|patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
48288409|NCT00385333|PROCEDURE|Feasibility Study - Imaging System|
48288410|NCT00463970|BEHAVIORAL|Brief Intervention|Physical examination, education and follow up by a physiotherapist
48288411|NCT00463970|BEHAVIORAL|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
48288412|NCT00463970|DIETARY_SUPPLEMENT|Seal oil|20 capsules per day for 3 months
48630827|NCT03357705|PROCEDURE|alveolar ridge preservation with bovine collagen|after tooth extraction
47941199|NCT01952470|DRUG|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
47941200|NCT00000434|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
48288413|NCT00463970|DIETARY_SUPPLEMENT|Soy oil|20 capsules per day for 3 months
48288414|NCT01232725|DIETARY_SUPPLEMENT|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
48288415|NCT02429505|DRUG|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
48288416|NCT03689738|OTHER|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
48288417|NCT03689738|OTHER|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
48288418|NCT01030042|DRUG|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
48288419|NCT01030042|DRUG|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
48288420|NCT03260023|BIOLOGICAL|TG4001|PhIb: Dose escalation PhII: Established RP2D for TG4001
48288421|NCT03260023|DRUG|Avelumab|Anti PD-L1
48288422|NCT05098288|BEHAVIORAL|Multicentre Pain Monitor + Unified Protocol|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
47941201|NCT04087928|DEVICE|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
48288423|NCT02873221|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
48288424|NCT02873221|DRUG|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
48288425|NCT02873221|DRUG|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
48630828|NCT03019588|BIOLOGICAL|Pembrolizumab|IV infusion
48630829|NCT03019588|DRUG|Paclitaxel|IV infusion
48630830|NCT05845593|OTHER|Decision Support Test|LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
48630831|NCT01428128|DRUG|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
48630832|NCT04802785|DRUG|Citicoline|Citicoline 500 mg (Vitaae®) per os
48630833|NCT04802785|DRUG|Cytochrome C6|Cytochrome10 mg per os
48630834|NCT04802785|DRUG|Sodium Chloride Oral Product|Sodium Chloride (NaCl) 2.6 g. per os
48630835|NCT04802785|DRUG|Potassium Chloride Oral Product|Potassium Chloride 1.5 g per os
48630836|NCT04802785|DRUG|Sodium Citrate Oral Product|Sodium Citrate 2.90 g per os
48630837|NCT04802785|DRUG|Dextrose Oral Tablet, Chewable|Dextrose 13.5 g per os
48288426|NCT03654547|DRUG|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
48288427|NCT04599790|DRUG|TACE combined with lenvatinib and sintilimab|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
48630838|NCT04802785|DRUG|Domperidone Oral Product|Domperidone 1 tablet per os
48630839|NCT04802785|DRUG|Simethicone|3-4 capsules per os
48630840|NCT04802785|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 150 mg per os
48630841|NCT04802785|DRUG|Magnesium hydroxide|magnesium hydroxide 30 mg per os
47941202|NCT04087928|DEVICE|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
48101900|NCT05481502|PROCEDURE|Blood sample|7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
48630842|NCT04802785|DRUG|Probiotic Formula|1 capsule per os.
48630843|NCT04802785|DRUG|Melatonin 5 mg|Melatonin 5 mg per os.
48630844|NCT05125939|OTHER|Comparison of ADR|The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
48101901|NCT05481502|PROCEDURE|Bone marrow sample|If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
48101902|NCT02702921|DEVICE|Surgeon's 'standard of care' stapler|
48630845|NCT02453191|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
48630846|NCT02453191|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
48630847|NCT00620035|DRUG|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
48630848|NCT04574700|OTHER|knee joint mobilization and traction|"Grade 3 traction (Kaltenborn)from knee fully flexed to end of available Range of motion(ROM). Traction 30 sec, 10 sec rest period, 4reps, total 2 min of traction.3 sets for a total of 6 min of traction mobilization.Grade3 keltonborn tibiofemoral and tibiofibular anterior, posterior mobilization 3 sets10glides/set, 3 times/week on alternative days for 4 weeks.~TENS for 20 mins in sitting and strengthening exercises i.e. Quadriceps Setting10 reps, air Cycling 2 min for a bout, straight leg raise (SLR) with weight , Full arc extension 10 reps of each exercise will be carried per session except for full-arc extension and air cycling. Air cycling cont. for 2 min for 1 bout of exercise. Measurement will be taken at base level, after first and last session. Treatment will be given for 3 times/week on alternative days for 4 weeks"
48288428|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
48101903|NCT02702921|DEVICE|Ethicon Powered Vascular Stapler|
48288429|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
48288430|NCT00332657|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
48288431|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
48288432|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
48288433|NCT02846675|BIOLOGICAL|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
48288434|NCT02846675|BIOLOGICAL|Placebo|a Placebo treatment without SVF cells
48288435|NCT03607682|PROCEDURE|Tumor Treating Fields (TTF) Therapy|Undergo TTF therapy
48288436|NCT03607682|DEVICE|NovoTTF-200A Device|Undergo TTF therapy
48288437|NCT03607682|OTHER|Quality-of-Life Assessment|Ancillary studies
48288438|NCT00982605|PROCEDURE|EBUS_TBNA|EBUS during bronchoscopy
48630849|NCT04574700|OTHER|Post isometric relaxation|"Control group include Post isometric relaxation technique on hamstring muscle will be performed in supine lying, hip flexed to 90 degrees knee extended until the point of resistance 20% of maximum effort will be used by patient to create isometric contraction. Patient will be asked to breathe in and hold for 5 to 8 seconds and release both breath and effort then move to new barrier point and process was repeated three times per session~TENS and strengthening exercises as mentioned above.~This treatment regime will be given for 3 times/week on alternative days for 4 weeks."
48630850|NCT05507216|DRUG|ABX464|Administered once daily in the morning with food
48630851|NCT05507216|DRUG|Placebo|Administered once daily in the morning with food
48630852|NCT02813824|DRUG|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
48630853|NCT02813824|DRUG|Placebo (for Aspirin 300)|Daily dose during 4 years
48630854|NCT02813824|DRUG|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
48630855|NCT02813824|DRUG|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
48630856|NCT01279187|DRUG|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
48630857|NCT01279187|DRUG|Placebo|20ug per day, self administered injection, for 7 weeks
48630858|NCT01903200|DRUG|FK949E|Oral
48630859|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
48630860|NCT02692261|PROCEDURE|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
48288439|NCT02907944|BEHAVIORAL|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~* External Facilitator: Outside content expert who assists site~* Local Champion: Site stakeholder who promotes change~* Provider Education and Academic Detailing: Provision of unbiased peer education~* Stakeholder Engagement: Aligning goals of implementation and those impacted~* Tailor Program to Site: Addressing site specific needs based on Aim 1~* Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~* Formative Evaluation: Quant. and qual. determination of impact~* Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~* Program Marketing: Increase attention to availability of on-site addiction treatment services"
48288440|NCT01362322|BIOLOGICAL|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
48288441|NCT01362322|BIOLOGICAL|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
47941203|NCT02547714|DRUG|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
48101904|NCT06629909|DRUG|Secretome|3 ml Injection of secretome for 8 times two weeks apart
48101905|NCT02064569|GENETIC|GS010|
48101906|NCT01606384|DRUG|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
48101907|NCT01606384|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
48288442|NCT05447962|BEHAVIORAL|Community-to-Clinic Linkage Implementation Program in Barbershops (CLIP)|Multilevel intervention designed to mitigate adverse social determinants of health (SDoH) via linkage to care, health system navigation, and referral to social services.
48288443|NCT05447962|BEHAVIORAL|Barbershop-Based Facilitation (BF)|Trained and qualified facilitators assist community health workers (CHWs) to: 1) increase their confidence in delivering CLIP; 2) understand participants' concerns and beliefs about hypertension (HTN); and 3) develop skills in lifestyle counseling to help the men initiate lifestyle modification.
48288444|NCT04706390|BIOLOGICAL|covid-19 vaccine|vaccination
48288445|NCT04760548|OTHER|Observational study|
48288446|NCT05840705|PROCEDURE|Small curved incision with apex lateral|Small curved incision with apex lateral
48630861|NCT02148770|DEVICE|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
48288447|NCT06394063|BIOLOGICAL|Telitacicept|Telitacicept 160 mg SC every other week
48101908|NCT04103736|DIETARY_SUPPLEMENT|Beet It Sport Shot|Source of naturally occurring dietary nitrates
48288448|NCT06394063|DRUG|Placebo|Placebo to Telitacicept
48288449|NCT03623750|DRUG|EGFR-TK Inhibitor|Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
48288450|NCT03623750|BIOLOGICAL|EGF-PTI|"The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months."
48288451|NCT03623750|DRUG|Cyclophosphamide|Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
48288452|NCT01199341|DRUG|AZD1981|100 mg per oral, twice daily for 14 days
48288453|NCT01199341|DRUG|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
48288454|NCT01199341|DRUG|AZD1981|4 x 100 mg per oral, twice daily for 14 days
48288455|NCT02207387|DRUG|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
48288456|NCT02207387|BEHAVIORAL|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
48288457|NCT02207387|OTHER|Music|
48288458|NCT04761185|DRUG|Raltitrexed|Raltitrexed in HIPEC
48288459|NCT06329453|PROCEDURE|Colon Tissue Biopsy|Colonoscopy and colon tissue biopsy.
48288460|NCT01573468|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
48288461|NCT01573468|DRUG|Placebo|Placebo orally once on Day 1 of each cycle
48288462|NCT01573468|DRUG|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
48288463|NCT06411184|DRUG|Regulator T Cells|Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
48288464|NCT05065021|DRUG|Niraparib|Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
48288465|NCT05065021|DRUG|Dostarlimab|Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
48101909|NCT04103736|DIETARY_SUPPLEMENT|Nitrate-depleted placebo|Placebo
48288466|NCT05065021|DRUG|Bevacizumab|Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
48288467|NCT05065021|DRUG|Paclitaxel|Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
48288468|NCT04021472|BEHAVIORAL|Text message|Two months of daily text messages to support meeting a health goal
48288469|NCT01912885|DEVICE|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
48288470|NCT01912885|DEVICE|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
48288471|NCT01912885|DEVICE|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
48288472|NCT01912885|DEVICE|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
48288473|NCT01912885|DEVICE|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
48288474|NCT02506777|DRUG|metformin|
48288475|NCT02506777|DRUG|Fluoruracil|
48288476|NCT02506777|DRUG|Doxorubicin|
48288477|NCT02506777|DRUG|Cyclophosphamide|
48288478|NCT02506777|DRUG|melatonin|
48473315|NCT00578968|DRUG|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
48630862|NCT03970343|DEVICE|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~1. Optimizer Smart or Optimizer Smart Mini~2. Vesta Charger or Guardio Charger~3. Two commercially available intravascular leads"
48288479|NCT03707093|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
48288480|NCT01343615|PROCEDURE|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
48288481|NCT01343615|PROCEDURE|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
48288482|NCT03078491|OTHER|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
48288483|NCT00073944|DRUG|forodesine hydrochloride|
48288484|NCT05971329|DEVICE|Cervical Fusion (ZetaFuse™ Bone Graft)|Fusion of the C3-C7 cervical vertebral bodies
48288485|NCT02367612|DIETARY_SUPPLEMENT|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
48288486|NCT02367612|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48288487|NCT04066621|DRUG|Ceftriaxone Sodium and Sulbactam Sodium for Injection|daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
48288488|NCT04332549|DRUG|PICS (Reconstitution Method 1 or 2)|dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
48288489|NCT02728934|BIOLOGICAL|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
48473316|NCT01931345|BEHAVIORAL|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
48473317|NCT01931345|BEHAVIORAL|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
48473318|NCT05418634|OTHER|point of care EEG|For pocEEG, scalp electrodes are applied in five locations.
48473319|NCT03716635|PROCEDURE|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
48288490|NCT02728934|BIOLOGICAL|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
48288491|NCT02728934|BIOLOGICAL|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
48288492|NCT04329936|BEHAVIORAL|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
48630863|NCT05364255|DRUG|[14C]AZD9833 Oral Solution, 75 mg|Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
48630864|NCT05202431|BEHAVIORAL|Treatment adherence|The patients were reminded to take drug by patient training, telephone follow-up, and daily sms. It was determined that the effect of the training and telephone follow-up provided to the TB patients and contacts on the treatment adherence.
48288493|NCT00746538|DEVICE|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
48473320|NCT03716635|PROCEDURE|normal saline|a room temperature saline is used as a final flush after mechanical preparation
48473321|NCT05044494|PROCEDURE|non-prompt surgery|
48630865|NCT05593640|OTHER|biological samples|blood and synovial liquid will be sampled
48288494|NCT03163238|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
48288495|NCT03163238|DRUG|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
48288496|NCT03366311|PROCEDURE|holding position|two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
48288497|NCT00947102|OTHER|Observation|
48288498|NCT01939262|OTHER|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
48288499|NCT01939262|OTHER|Control|Participants assigned to the control group will be instructed to follow their usual diets.
48473322|NCT06076941|OTHER|Education|"Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated."
48473323|NCT05959486|DRUG|BR6002A|One tablet administered alone
48473324|NCT05959486|DRUG|BR6002B|One tablet administered alone
48473325|NCT05959486|DRUG|BR6002|One capsule administered alone
48473326|NCT00052520|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
48473327|NCT00052520|BIOLOGICAL|aldesleukin|Given SC
48473328|NCT00052520|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
48473329|NCT00052520|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
48630866|NCT04169659|DEVICE|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
48288500|NCT06106698|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive one dose of WMT for CDI. During follow-up, those who have non-response or CDI recurrence within 4-week post-WMT will receive rescue WMT.
48288501|NCT01538771|DRUG|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
48473330|NCT00052520|OTHER|laboratory biomarker analysis|Correlative studies
48473331|NCT00052520|GENETIC|gene expression analysis|Correlative studies
48473332|NCT00052520|OTHER|immunologic technique|Correlative studies
48473333|NCT00052520|OTHER|flow cytometry|Correlative studies
48473334|NCT00052520|GENETIC|polymerase chain reaction|Correlative studies
48473335|NCT00052520|GENETIC|cytogenetic analysis|Correlative studies
48288502|NCT01538771|DRUG|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
48630867|NCT04169659|DEVICE|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
48288503|NCT00652821|DRUG|Tramadol/ APAP|Tablets 37.5mg /325mg
48288504|NCT00652821|DRUG|Ultracet|Tablets, 37.5mg/325mg
48288505|NCT03145129|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
48288506|NCT04230538|DEVICE|DJO Walker|
48288507|NCT04230538|DEVICE|Traditional plaster cast|
48473336|NCT00052520|OTHER|staining method|Correlative studies
48473337|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
48473338|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
48473339|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
48473340|NCT02527330|OTHER|MR T2* imaging|Cardiac magnetic resonance imaging with T2\* imaging
48473341|NCT05352724|DIETARY_SUPPLEMENT|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
48473342|NCT04982367|DEVICE|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
48630868|NCT03650608|DRUG|Cohort 1: HL217 Ophathalmic Solution QD|Cohort 1 (Once a day)
48473343|NCT04982367|DEVICE|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
48473344|NCT00422045|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
48617992|NCT02320175|BEHAVIORAL|Patient and Family Centered I-PASS|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
48630869|NCT03650608|DRUG|Cohort 2: HL217 Ophathalmic Solution BID|Cohort 2 (Twice a day)
48288508|NCT03940105|BEHAVIORAL|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
48288509|NCT04926155|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
48288510|NCT01430247|OTHER|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
48288511|NCT01513018|OTHER|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
48288512|NCT01513018|OTHER|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
48288513|NCT02798523|DRUG|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
48288514|NCT02798523|DRUG|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
48288515|NCT03989063|BEHAVIORAL|Instructions to perform a motor task (external vs. internal focus instructions)|During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
48630870|NCT03650608|DRUG|Cohort 3: HL217 Ophthalmic Solution QID|Cohort 3 (Four times a day)
48630871|NCT03650608|DRUG|Placebo Ophthalmic solution|Placebo
48630872|NCT05769595|BIOLOGICAL|MK-2060|Lyophilized powder diluted in normal saline for IV infusion
48630873|NCT05769595|DRUG|Placebo|IV infusion
48288516|NCT02197962|DEVICE|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
48288517|NCT02197962|DEVICE|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
48288518|NCT00408278|DRUG|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
48288519|NCT00408278|DRUG|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
48288520|NCT00408278|DRUG|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
48288521|NCT00408278|DRUG|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
48288522|NCT02458976|DEVICE|PDL|
48617993|NCT03163966|DRUG|CR6086|oral CR6086 capsules
48617994|NCT03163966|DRUG|Methotrexate|oral Methotrexate tablets
48617995|NCT03163966|DRUG|Placebo|oral CR6086 Placebo capsules
48617996|NCT00750334|DRUG|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
48630874|NCT06328894|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48630875|NCT06328894|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48617997|NCT00750334|DRUG|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
48101910|NCT02646670|DRUG|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
48288523|NCT06513468|OTHER|Group education session by DESMOND Program|is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
48288524|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
48288525|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
48288526|NCT03228186|DRUG|Pevonedistat|25mg/m2 days 1, 3, 5
48288527|NCT03228186|DRUG|Docetaxel|75mg/m2 day 1
48630876|NCT06328894|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48630877|NCT02400580|DRUG|IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
48630878|NCT02400580|DRUG|placebo|The patients in the placebo arm will receive normal saline.
48630879|NCT00430664|PROCEDURE|Pleurodesis with either talc or iodopovidone|
48630880|NCT00002390|DRUG|Abacavir sulfate|
48630881|NCT00335621|DRUG|Inhaled Tiotropium|
48630882|NCT02738697|DRUG|Adjuvant chemotherapy|8\~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
48630883|NCT02738697|PROCEDURE|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
48630884|NCT06254690|DRUG|Pyrotinib dose escalation|Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
48288528|NCT03952286|DRUG|ED-Dispensing home and school supervision|"1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms."
48288529|NCT05335122|DRUG|OTX-TIC low dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
48630885|NCT06254690|DRUG|Pyrotinib dose normal|Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
48630886|NCT04218851|DRUG|Posaconazole IV|Posaconazole (POS) 6 mg/kg body weight by IV infusion
48630887|NCT04218851|DRUG|Posaconazole PFS|POS PFS 6 mg/kg body weight taken orally
48630888|NCT04218851|DRUG|Posaconazole tablet|POS tablet 300 mg taken orally
48630889|NCT05366842|DRUG|Stravix lyopreserved placental tissue (LPT)|Participants will undergo surgical implantation of Stravix lyopreserved placental tissue (LPT) during a standard of care radical prostatectomy.
48630890|NCT05366842|PROCEDURE|Radical prostatectomy|Standard care (no placement of tissue)
48101911|NCT02646670|DRUG|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
48101912|NCT02646670|DRUG|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
48288530|NCT05335122|DRUG|OTX-TIC high dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
48630891|NCT02974426|RADIATION|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
48630892|NCT02974426|RADIATION|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
48630893|NCT02974426|DRUG|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
48630894|NCT04469283|OTHER|caffeine and movement disorders|Caffeine efficacy on movement disorders in patients with ADCY5-related dyskinesia.
47941204|NCT01025765|DRUG|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
47941205|NCT01025765|DRUG|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
47941206|NCT01025765|DRUG|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
48288531|NCT05335122|DRUG|Durysta, Bimatoprost Intracameral Implant 10 µg|Durysta is injected into the anterior chamber of the eye.
48288532|NCT03572634|DRUG|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
48288533|NCT03572634|COMBINATION_PRODUCT|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
48288534|NCT03866551|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
48288535|NCT05387330|DIAGNOSTIC_TEST|ELISA kit|Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.
48288536|NCT06034730|DEVICE|Portable GC device for brath analysis|Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
48473345|NCT04459130|BEHAVIORAL|Child Obesity Program|"The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~* Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~* Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~* Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3."
48473346|NCT00442650|DRUG|Efalizumab|
48101913|NCT02646670|DRUG|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
48101914|NCT02063607|BIOLOGICAL|Peginterferon lambda|
48101915|NCT02478853|OTHER|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
48101916|NCT03603717|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
48101917|NCT03603717|BEHAVIORAL|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
48101918|NCT05086809|DEVICE|Device A|Participant wear Device A and evaluate the performance of the device.
47941207|NCT02003339|OTHER|Additional RMIs|
47941208|NCT00244166|DRUG|prednisolone|
48101919|NCT05086809|DEVICE|Device B|Participant wear Device B and evaluate the performance of the device.
47941209|NCT02433327|OTHER|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
48288537|NCT03455946|BEHAVIORAL|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
48101920|NCT01317134|DEVICE|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
48288538|NCT01859351|DRUG|WX-037|
48288539|NCT01859351|DRUG|WX-554|
48288540|NCT05295277|OTHER|Standard of care genetic testing group|N/A - no intervention as this is an observational study.
48288541|NCT02694029|DEVICE|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
48288542|NCT02694029|DEVICE|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
48288543|NCT05907915|DEVICE|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
48288544|NCT05907915|BEHAVIORAL|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
48288545|NCT05721885|BEHAVIORAL|nutrition management|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score \> 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
48288546|NCT01057303|GENETIC|RNA analysis|
48288547|NCT01057303|GENETIC|gene expression analysis|
48101921|NCT01317134|BIOLOGICAL|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
48288548|NCT01057303|GENETIC|reverse transcriptase-polymerase chain reaction|
48288549|NCT01057303|OTHER|laboratory biomarker analysis|
48288550|NCT02053246|DRUG|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
48288551|NCT04307966|BEHAVIORAL|The CIrCLE of Life Initiative|HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
48288552|NCT06513780|OTHER|Observation|No intervention were made.
48473347|NCT05387070|DRUG|TransCon PTH|TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.
48473348|NCT05387070|DRUG|placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
48473349|NCT05768178|DRUG|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg orally on a twice daily schedule throughout a 28-day cycle.
48473350|NCT05768178|DRUG|Cobimetinib|Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.
48473351|NCT06616519|DEVICE|BenQ Materials MSENCI soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
48473352|NCT06616519|DEVICE|Visco Oxypure Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
47941210|NCT02433327|OTHER|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
48288553|NCT05069363|DEVICE|Whole-Body Photobiomodulation Therapy|"* All participants entering the trial will receive a course of whole-body PBM therapy~* The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~* Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~* 18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~* The LED equipment delivers red and near infrared light therapy to the participant~* Session 1 = 6 minutes~* Session 2 = 12 minutes~* Sessions 3-18 = 20 minutes~* Timescale: 3 treatments/week for 6 weeks~* The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively"
48473353|NCT04042649|BEHAVIORAL|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
47941211|NCT00891111|BEHAVIORAL|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
48473354|NCT01921231|DRUG|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
48473355|NCT01921231|DRUG|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
47941212|NCT00891111|BEHAVIORAL|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
47941213|NCT03033446|RADIATION|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
47941214|NCT03033446|DRUG|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
47941215|NCT02187770|DEVICE|IMED-4|Non invasive recording electrode used to assess lung fluid
47941216|NCT04927000|DRUG|Tofacitinib|in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
47941217|NCT00272727|BEHAVIORAL|Dialog tool for caregivers|
47941218|NCT01384071|DEVICE|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
47941219|NCT01384071|DEVICE|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
47941220|NCT04896775|BEHAVIORAL|NiteCAPP CARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on sleep education, sleep hygiene, and stimulus control. Session 2 focuses on sleep compression, relaxation, and problem solving. Session 3 focuses on coping and stress management and cognitive therapy. Session 4 focuses on a review of skills and plan for maintenance of behavior change.
47941221|NCT04896775|BEHAVIORAL|NiteCAPP SHARES|Web-based intervention that will include 4 weekly sessions and 4 bimonthly boosters. Each session is to be completed individually by CG (with PWD to extent able) in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed. Session 1 focuses on expanded sleep education and sleep hygiene. Session 2 focuses insomnia education and sleep hygiene support. Session 3 focuses on targeted sleep education and sleep in dementia. Session 4 focuses on a review of skills and plan for maintenance of behavior change. Boosters review skills, encourage practice, and troubleshoot issues.
47941222|NCT01754909|DRUG|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
48101922|NCT03668327|OTHER||
48101923|NCT01803646|DRUG|AM-101|AM-101 gel for intratympanic injection
48101924|NCT01803646|DRUG|Placebo|Placebo gel for intratympanic injection
47941223|NCT01754909|DRUG|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
47941224|NCT00430651|DRUG|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
47941225|NCT00430651|DRUG|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
48101925|NCT04509713|BEHAVIORAL|Collection of odour samples|Samples of breath odours will be passively collected while participants wear the mask while breathing naturally, for at least 3 h. Skin odours will be passively collected by participants wearing the shirt and nylon socks for at least 12 h.
48101926|NCT01989637|DIETARY_SUPPLEMENT|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
48101927|NCT01989637|DIETARY_SUPPLEMENT|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
48473356|NCT00377572|BIOLOGICAL|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
48101930|NCT04958811|DRUG|Tiragolumab|600mg IV administered every 3 weeks.
48101931|NCT04958811|DRUG|Atezolizumab|1200mg IV administered every 3 weeks.
48101932|NCT04958811|DRUG|Bevacizumab|15mg/kg IV administered every 3 weeks.
48101933|NCT03437746|DRUG|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
48630895|NCT05386836|DEVICE|Pulse oximeter validation population|Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
47941226|NCT03711266|BEHAVIORAL|PE-PC|PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
48288554|NCT03154138|DEVICE|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
48288555|NCT03154138|DEVICE|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
48288556|NCT00005037|DRUG|temozolomide|
48288557|NCT00005037|DRUG|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
48288558|NCT05978869|OTHER|physical fitness training|Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
48288559|NCT05630144|BEHAVIORAL|HomeMed|The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
48288560|NCT05774470|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is a non-invasive monitoring device. The Sock secures the Sensor to the baby's foot. The Sensor measures the baby's SpO2, heart rate, and movement, and transmits the baby's readings to the Base Station. The Base Station records and monitors the baby's readings and can indicate prompts as needed based on the data sent from the Sensor.
48288561|NCT03048097|DRUG|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
48288562|NCT03048097|DRUG|Rubidium|used in PET scans
48288563|NCT03048097|DIAGNOSTIC_TEST|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
48288564|NCT04591288|OTHER|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
48630896|NCT00817102|PROCEDURE|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
48630897|NCT05659420|BEHAVIORAL|Cardiac rehabilitation comprised aerobic exercise on a treadmill accompanied by an electrocardiogram monitoring device and a blood pressure monitor|aerobic exercise on a treadmill (T7M, Motus, Paju, South Korea) accompanied by an electrocardiogram monitoring device (Q-Tel Rehabilitation Management System, Mortara Inc., Milwaukee, WI, USA) and a blood pressure monitor
48101934|NCT03437746|BIOLOGICAL|Blood samples|Blood samples (D0, D1, D2, D3, D4)
48288565|NCT04591288|OTHER|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
48288566|NCT04906005|DRUG|gadopiclenol|administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
48288567|NCT04906005|DRUG|Placebo|intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
48288568|NCT00939263|OTHER|assessment of disease activity using the EEsAI|disease activity index
48288569|NCT02569489|DRUG|HBI-8000|
47941227|NCT03028350|DRUG|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
48101935|NCT00290732|DRUG|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
48288570|NCT02569489|DRUG|Trastuzumab|
48288571|NCT02569489|DRUG|Paclitaxel|
48288572|NCT03392129|OTHER|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.
48288573|NCT03392129|OTHER|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
48288574|NCT02388230|DEVICE|Ultrasound imaging|
48288575|NCT05015361|DRUG|Remimazolam Tosilate|Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose
48288576|NCT05015361|DRUG|Propofol Injection.|Treatment group C: Propofol Injection.
48288577|NCT05418946|DRUG|Dapagliflozin 10mg|Treatment of T2D and cardio-renal prevention
48288578|NCT00764894|DEVICE|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
48473357|NCT00377572|BIOLOGICAL|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
48473358|NCT04544137|BEHAVIORAL|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
47941228|NCT03028350|DRUG|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
47941229|NCT02653885|OTHER|Red red cell distribution width|Results from hemogram
47941230|NCT06321627|RADIATION|Radiation therapy as curative treatment|Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
47941231|NCT05771168|DEVICE|Artificial urinary sphincter|Implantation of peri-urethral artificial urinary sphincter
47941232|NCT05771168|DEVICE|Male sling|Retrourethral implantation of male sling
48288579|NCT04336150|OTHER|Hypopressive exercises|See information included in arm/group descriptions.
48288580|NCT04336150|OTHER|Hypopressive maneuver|See information included in arm/group descriptions.
48288581|NCT04336150|OTHER|Hypopressive exercises plus pelvic floor muscle contraction|See information included in arm/group descriptions.
48288582|NCT04336150|OTHER|Hypopressive maneuver plus pelvic floor muscle contraction|See information included in arm/group descriptions.
48288583|NCT04885049|DRUG|Racecadotril|Anti secretary
48473359|NCT03026517|DRUG|Dabrafenib|
48473360|NCT03026517|DRUG|Trametinib|
48473361|NCT03026517|DRUG|Phenformin|
48473362|NCT00128141|BEHAVIORAL|Tactile stimulus|four times a day
48473363|NCT06106334|DRUG|S309309|Administered as oral capsules
48473364|NCT06106334|DRUG|Itraconazole|Administered as oral capsules
48473365|NCT06616441|DRUG|Bupivacaine|Group (A) only will receive intra-peritoneal 40 ml bupivacaine 0.2%, after laparoscopic procedure before removing trocars.
48473366|NCT06479278|BEHAVIORAL|Talk with Me Baby|Primary care providers will embed Talk With Me Baby (TWMB) within standard-of-care Well-Child Care visits for children ≤36 months of age. Children will receive usual care plus a brief language-promotion intervention (TWMB) in up to 4 consecutive Well-Child Care visits during their 12-month period.
48473367|NCT04912375|BEHAVIORAL|Priming intervention|The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
48288584|NCT04885049|DRUG|DiaResQ Children's Powder for Suspension|oral immunoglobulins
48288585|NCT02012816|OTHER|Peer-referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
47941233|NCT03376438|OTHER|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
47941234|NCT00209508|DRUG|GPI 1485|
47941235|NCT01578564|DRUG|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
48288586|NCT05457530|DRUG|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
48288587|NCT05457530|COMBINATION_PRODUCT|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
48288588|NCT05457530|DRUG|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
48288589|NCT03040583|OTHER|No intervention|Patients data will be collected during their disease follow-up
48288590|NCT05895851|RADIATION|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
48288591|NCT00064701|DRUG|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
47941236|NCT01111409|DEVICE|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
48288592|NCT00064701|DRUG|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
48288593|NCT00064701|DRUG|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
48288594|NCT00064701|DRUG|mycophenolate mofetil|Oral
48288595|NCT02424539|DRUG|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
48288596|NCT02424539|OTHER|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
48288597|NCT03489291|GENETIC|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
48288598|NCT02414477|DRUG|Deuterated NNN|Smokeless tobacco study product
48101936|NCT00290732|DRUG|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
48101937|NCT02680756|DRUG|Ferric Maltol|
48288599|NCT05121337|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 12-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.~Observation Phase:~For months 4-12 of the study, participants will be asked to continue following a DASH grocery shopping pattern without the provision of weekly groceries."
48288600|NCT05121337|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a monthly stipend at 4, 8, and 12-weeks of the intervention.~Observation Phase:~For months 4-12 of the study, participants will be asked to follow their typical shopping pattern without the provision of a monthly stipend."
48288601|NCT02660658|DRUG|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
48288602|NCT06342167|RADIATION|Radiotherapy|Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.
47941237|NCT01955980|DRUG|Budesonide|Inhalation
47941238|NCT01955980|DRUG|Budesonide|Nasal Spray
47941239|NCT03771547|DIAGNOSTIC_TEST|ERCP|
47941240|NCT04510974|OTHER|Spinal Cord Injury|Spinal Cord Injury
47941241|NCT05574166|DRUG|SP-8356|SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
47941242|NCT05574166|DRUG|Placebo|Placebo for SP-8356 powder
48101938|NCT02680756|DRUG|Ferric Carboxy Maltose|
48101939|NCT04554823|BEHAVIORAL|Health Education|Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
48101940|NCT04554823|BEHAVIORAL|Physical Exercise|Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
48107115|NCT05132686|BEHAVIORAL|IER+MED|Over a 6 month period follow a euenergetic Mediterranean diet 5 days per week and a 20% energy restriction over 2 contiguous days as a 70% energy restriction using the same macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
48630898|NCT00680173|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
48630899|NCT04249739|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Keytruda ™ (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
48630900|NCT05488353|DRUG|Disitamab Vedotin for Injection,Penpulimab Injection|"After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection."
48630901|NCT01164605|DRUG|Raltegravir|60 tablets (30-day supply)
48630902|NCT05337748|DEVICE|Lexie Self Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
48630903|NCT05337748|DEVICE|Lexie Professional Test and Fit Group|The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
48630904|NCT01590966|DRUG|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
48630905|NCT01590966|DRUG|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
48630906|NCT04411095|OTHER|Measuring thoracic rotation mobility|Measuring the thoracic rotation mobility with a goniometer, from a standardized position
48630907|NCT00182637|DRUG|bortezomib|
48630908|NCT00376506|DEVICE|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
48101941|NCT05602857|OTHER|Balance Training|"The BT program has multiple difficulty levels, and each child will progress at an individual pace tailored to their balance skills. Training sessions will emphasize top-down control of balance and contain a combination of dynamic and static balance exercises. Children and their parents will receive written step-by-step instructions, with photos, verbal and/or video instructions on their private OneDrive folder.~To monitor compliance, whether the exercises were done properly, and evaluate a child's progress, the parent/guardian will film the sessions, and upload the video to OneDrive, so we can score the child's performance and provide them with a progress tracking chart.~Every child will be given the equipment needed to do the balance exercises: two wooden beams that will make a 12-foot balance beam, four small wooden cubes that will raise the balance beam 5 inches off the ground, a wobble board, a hopscotch mat, one roll of painter's tape, one measuring tape, a bell, a small book."
48107116|NCT05132686|BEHAVIORAL|MED/DER|Over a 6 month period follow a Mediterranean diet 7 days per week with a 20% energy restriction 7 days a week using the macronutrient distribution of 45% carbohydrate, 25% energy from protein, and 30% energy from fat. For each participant a tailored diet plan is created based on sex, weight, height, and age. Complete a 1 hour walk five days per week.
48101942|NCT05602857|OTHER|Music Training|"Children assigned to MT will be asked what kind of music and what performers they like best, and what songs they like most. After those open-ended questions, they will be asked about specific songs, guided somewhat by the child's previous answers, and will watch short excerpts from music videos to see which the child would like to listen to and watch during Week 1 of the MT program. This is all to guide the selection of music videos the child will enjoy and might give some thought to.~They will receive 10 music videos per week, through the child's private OneDrive folder, from which they can choose 4 to watch every session. Children will be instructed to not do anything else, but simply watch the videos or listen with their eyes closed.~To monitor compliance, and to check if the child was paying attention to the music videos or just having them play in the background while doing something else, the parent/guardian will film the MT sessions, and upload the video to OneDrive."
48101943|NCT03691961|OTHER|Hair sampling|After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
48288603|NCT06342167|DRUG|Programmed Cell Death Protein 1 Inhibitor|200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
48288604|NCT06342167|DIETARY_SUPPLEMENT|Immunonutrition support|600-1600 ml of TPF-T per day according to the nutrition status evaluation
48288605|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
48288606|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
48288607|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
48288608|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
48288609|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
48288610|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
48288611|NCT05453253|BIOLOGICAL|Delayed second dose of oral cholera vaccine, Euvichol-Plus|The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.
48288612|NCT05453253|BIOLOGICAL|Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice|"Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.~In the control arm, participants will receive the Euvichol-Plus following the manufacturer recommendations: two doses administered orally 14 days apart for individuals aged ≥1 year."
48288613|NCT00071773|PROCEDURE|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
48288614|NCT00071773|PROCEDURE|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
48101944|NCT03691961|DIAGNOSTIC_TEST|Hair's drug concentrations|The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
48288615|NCT05178134|BIOLOGICAL|Etvax|"Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl)."
48288616|NCT05178134|BIOLOGICAL|Etvax|Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.
48288617|NCT04119908|DEVICE|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
48288618|NCT04119908|BIOLOGICAL|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
48288619|NCT02522377|DRUG|Ketamine|inter venous injections
48288620|NCT02522377|DRUG|Midazolam|inter venous injections
48288621|NCT04782739|OTHER|None - Descriptive study|Descriptive study
48288622|NCT04943211|DRUG|fluorodeoxyglucose (18F-FDG)|max 6 MGBq/kg, no more than 100
48288623|NCT03318367|OTHER|Educational Intervention|Complete virtual reality education module
48288624|NCT04208373|DRUG|JNJ-64417184|JNJ 64417184 tablets will be administered orally.
48288625|NCT04208373|DRUG|Itraconazole|Itraconazole capsules will be administered orally
48101945|NCT00864812|DRUG|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
48101946|NCT00864812|DRUG|tiotropium|COPD patients treated with tiotropium
48107117|NCT04008836|DEVICE|T-PLUS Meter|Blood Glucose Monitoring System (BGMS)
48288626|NCT04208373|DRUG|Etravirine|etravirine tables will be administered orally.
48288627|NCT06108479|DRUG|DF6215|Immunotherapy (cytokine) targeting effector cells.
48630909|NCT00376506|DEVICE|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
48630910|NCT03885388|DRUG|MTX|multicourse methotrexate chemotherapy
48288628|NCT04735029|DEVICE|Thermal gun|"Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
48288629|NCT04735029|OTHER|Heat pack|A hydrocollator heat pack used to simulate traditional thermal therapy
48288630|NCT01887210|BEHAVIORAL|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
48288631|NCT01887210|BEHAVIORAL|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
48288632|NCT06464406|BEHAVIORAL|Virtual Reality condition|Participants will watch a video on a virtual reality headset during the completion of the maximal cardiorespiratory exercise test.
48288633|NCT06464406|BEHAVIORAL|Control condition|Participants will complete the maximal cardiorespiratory exercise test under control conditions without video, music, or other distractions.
48630911|NCT03885388|DRUG|MTX+ACTD|combination use of methotrexate and actinomycin
48288634|NCT05921448|BIOLOGICAL|Vaxigripetra|Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
48288635|NCT05921448|BIOLOGICAL|Flumist|Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).
48288636|NCT03714841|OTHER|CRP|Knowledge of CRP value
48288637|NCT06439043|OTHER|EMDR Psychotherapy|EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
48288638|NCT06439043|OTHER|Online EMDR Psychotherapy|Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
48288639|NCT03900676|DRUG|VB-1953 - 2%|Topical Gel
48288640|NCT03900676|DRUG|VB-1953 - 0% (Vehicle)|Topical Gel
48288641|NCT00188994|DRUG|Insulin Cardioplegia|
48288642|NCT03490786|DRUG|GT-001|PK, PD Study to Determine Safety of Escalating Doses of GT-001
48288643|NCT06510842|OTHER|External drainage of intraventricular hemorrhage|An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
48288644|NCT04460027|OTHER|Woebot Substance Use Disorder|Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
48288645|NCT05641454|DIETARY_SUPPLEMENT|ElevATP supplement|ElevATP supplement containing apple and ancient peat extract
48630912|NCT02236767|DEVICE|Neurostar Transcranial Magnetic Stimulation Therapy System|Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
48630913|NCT05824676|DEVICE|Variable Angle LCP Patella Plating System|FDA approved device, 510K number of, K210408. The Variable Angle LCP Patella Plating System is a device that can be formed to a patients specific need with various anchoring points to best fix what is needed for fixation.
48101947|NCT06476925|PROCEDURE|sonar guided stellate ganglion injection|using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%
48288646|NCT05641454|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
48288647|NCT05634564|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
48473368|NCT04969354|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
48101948|NCT06476925|PROCEDURE|sonar guided stellate ganglion block|using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%
48288648|NCT05634564|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
48288649|NCT05634564|DRUG|Nab paclitaxel|Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
48288650|NCT05634564|RADIATION|Hypofractionated radiotherapy with simultaneous integrated boost|Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions.
48473369|NCT01347320|OTHER|Preoperative MRI|Preoperative staging
47941243|NCT04478331|BEHAVIORAL|Technology-based physical activity interventions|The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
47941244|NCT03267732|BIOLOGICAL|Pegilodecakin|Pegilodecakin Alone
48473370|NCT00464139|PROCEDURE|Laparoscopy|Laparoscopy
48473371|NCT02824731|RADIATION|Radiation with protons|
48473372|NCT02824731|RADIATION|Radiation with photons|
48473373|NCT03876028|BIOLOGICAL|Tisagenlecleucel|Infusion
48473374|NCT03876028|DRUG|Ibrutinib|Oral (tablets or capsules)
48288651|NCT00471380|DRUG|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
48101949|NCT00431808|BIOLOGICAL|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
48288652|NCT00471380|DRUG|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
48288653|NCT02739412|BIOLOGICAL|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
48288654|NCT04286308|OTHER|electrophysiological data collection|Electrophysiological data collection at the time of DBS surgery.
48288655|NCT04945993|DEVICE|Endomethasone N|Endomethasone N is a powder intended to be mixed extemporaneously with a eugenol-based liquid (i.e, Endomethasone Liquid) to obtain a permanent root canal sealer. After selection of dentists, they will screen consecutively and systematically eligible patients, will send them the Patient Information Letter and will enroll them in the clinical investigation if non opposition from the patient. Patient clinical data will be recorded in an electronic Case Report Form. Pseudonymized retro-alveolar radiographies at baseline consultation and at 5 and 10 years post-obturation consultations will be recorded in the e-CRF. These radiographies will be examined by 2 independent endodontists and the results of these examinations will be recorded in the e-CRF. Site data will be collected on a Site Questionnaire with Visual Analog Scales.
48288656|NCT05113524|OTHER|Dance|The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
48288657|NCT05113524|OTHER|No intervention|Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
48288658|NCT05255614|DEVICE|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device \& software at Swedan
48288659|NCT05255614|DEVICE|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
48288660|NCT01811030|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
48473375|NCT05827640|OTHER|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
48101950|NCT00431808|BIOLOGICAL|AMA1|50 micrograms of AMA1
48101951|NCT05825170|DEVICE|FASY L|Subjects will receive FASY L in lips at level of their scar.
48288661|NCT05412329|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
48288662|NCT03656887|DEVICE|Continuous interstitial glucose sensor|Installing and removing the sensor
48288663|NCT03656887|OTHER|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
48473376|NCT01878773|OTHER|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~--------------------------------------------------------------------------------"
47941245|NCT05350735|BEHAVIORAL|Intervention arm: SMS text reminders and medical card|This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
48101952|NCT01253499|DRUG|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
48101953|NCT02594215|DRUG|MK-7075 (miransertib)|MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
48107118|NCT00628719|DRUG|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
48288664|NCT03117933|DRUG|Olaparib|Tablet, 100mg and 150mg
48288665|NCT03117933|DRUG|Cediranib|Tablet 15mg and 20mg
48288666|NCT03117933|DRUG|Paclitaxel|Intravenous (IV)
48288667|NCT05066815|OTHER|Vita Enamic (Hybrid dental ceramic)|Vita Enamic (Hybrid dental ceramic) is provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology.
48630914|NCT05824676|DEVICE|Traditional Fixation|Traditional fixation methods for patellar fracture (screws, suture fixation, wire fixation, other plates).
47941246|NCT05625620|DEVICE|Active Transcranial Pulse Current Stimulation|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes.
47941247|NCT05625620|DEVICE|Sham Transcranial Pulse Current Stimulation|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anodal stimulation will be applied on the scalp over the cerebellum area (2 cm under the inion) and the cathode will be placed over the spinal lumbar enlargement (2 cm under T11). During anodal stimulation, a constant current of 2 mA will be applied for 20 minutes. Electric Current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
47941248|NCT04171427|OTHER|Lithium liposome|Cosmetic product
47941249|NCT04171427|OTHER|Placebo|Cosmetic product vehicle
48101954|NCT04954040|DRUG|Hydroxychloroquine Pill + Azithromycin Pill|"Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0"
48288668|NCT06477341|DIETARY_SUPPLEMENT|various available nutrition as those contain high protein content as ensure milk|note effect with usually prescribed suitable oral and parenteral nutrition for head and neck cancers receiving radiotherapy
48288669|NCT00085969|DRUG|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
48288670|NCT00085969|DRUG|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
48630915|NCT01769872|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
48630916|NCT04591132|DEVICE|kinematic analysis|motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
48288671|NCT00085969|DRUG|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
48288672|NCT00085969|DRUG|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
48288673|NCT00085969|DRUG|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
48288674|NCT00085969|DRUG|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
48288675|NCT04627350|OTHER|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
48288676|NCT05144022|BEHAVIORAL|Bungee jump|Bungee jump from a cran
48288677|NCT05370157|BEHAVIORAL|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
48288678|NCT03187379|DRUG|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
48288679|NCT03187379|DRUG|Bupivacaine|60cc Bupivacaine
48630917|NCT02981693|PROCEDURE|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
48630918|NCT00360854|DRUG|erlotinib hydrochloride|
48630919|NCT00360854|GENETIC|mutation analysis|
48630920|NCT00360854|GENETIC|polymorphism analysis|
48630921|NCT00360854|OTHER|laboratory biomarker analysis|
48630922|NCT00360854|OTHER|pharmacological study|
48630923|NCT00360854|RADIATION|radiation therapy|
48630924|NCT01197274|DEVICE|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
48630925|NCT02457286|DRUG|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
48630926|NCT02457286|BEHAVIORAL|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
47941250|NCT04491253|BEHAVIORAL|Social support for diabetes self-management|Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
48288680|NCT06244927|PROCEDURE|Replantation surgery|Surgery
48288681|NCT06375798|PROCEDURE|radiotherapy|If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.
48288682|NCT03183921|OTHER|No intervention|No Interventions
48288683|NCT00920309|DRUG|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
48288684|NCT00920309|OTHER|Standard of Care-Placebo|
48288685|NCT04655586|DRUG|rNAPc2|two dose levels of rNAPc2
48288686|NCT04655586|DRUG|Heparin|standard of care heparin per institution (therapeutic or prophylactic regimen)
48288687|NCT05012566|DEVICE|Juvederm|"* Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)"
48288688|NCT05012566|DRUG|Vistabex|Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
48288689|NCT01089777|DEVICE|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
48288690|NCT06513637|DIAGNOSTIC_TEST|12-Lead ECG and home sleep study (HST) diagnostics|"* 12-lead ECG hookup will be performed following standard placement procedures.~* The Home Sleep Study diagnostic device placement will be performed by study personnel following the manufacturer's instructions."
48288691|NCT03767738|DRUG|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
48288692|NCT04060992|DRUG|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
48288693|NCT02875210|PROCEDURE|Laximeter measurement|
48630927|NCT02457286|DEVICE|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
47941251|NCT04030455|DRUG|Carboplatin|Given IV
47941252|NCT04030455|DRUG|Cisplatin|Given IV
48288694|NCT05803564|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
48288695|NCT04831944|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
48288696|NCT02962635|DEVICE|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
48288697|NCT01826669|PROCEDURE|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
48630928|NCT03713788|OTHER|Cold pressor test|Participants placed their non-dominant hand into cold water for 2 minutes
47941253|NCT04030455|DRUG|Docetaxel|Given IV
47941254|NCT04030455|BIOLOGICAL|Pembrolizumab|Given IV
47941255|NCT05186428|OTHER|carrying out standard care|The adaptation of the diuretic treatment will be made according to the possible diuresis records and the weighing of the patient every 2 days.
47941256|NCT05186428|OTHER|adult diaper|the diuresis which will be calculated by making the difference between the weight of the soiled protection weighed and the weight of the dry protection
47941257|NCT00504036|DEVICE|inflatable intra-gastric balloon|inflatable intra-gastric balloon
47941258|NCT00371007|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
47941259|NCT00371007|DRUG|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
47941260|NCT03000270|DEVICE|Impella unloading prior to PPCI|Impella unloading prior to PPCI
47941261|NCT05143190|DRUG|PTR-01|Intravenous recombinant collagen 7
48630929|NCT06458400|DRUG|Tegileridine|single dose+PCA dose
48630930|NCT06458400|DRUG|Oliceridine|single dose+PCA dose
48630931|NCT06458400|DRUG|Morphine|single dose+PCA dose
47941262|NCT05023876|OTHER|IASTM+respiratory Exercise|Instrument assisted soft tissue mobilization
48630932|NCT04387214|OTHER|survey|online survey
47941263|NCT05023876|OTHER|Respiratory Exercise|Respiratory Exercise
47941264|NCT02687178|DRUG|Canrenone 50 vs canrenone 100 mg|
47941265|NCT05266027|DRUG|Nalbuphine Sebacate (Naldebain)|Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
47941266|NCT05266027|DRUG|Placebo medication|Placebo medication, Nalbuphine Sebacate not contained
48630933|NCT03930108|OTHER|SOFA score|Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
48630934|NCT04450875|DIETARY_SUPPLEMENT|Experimental group (with diet)|Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
47941267|NCT02902796|DEVICE|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
48630935|NCT03128164|DRUG|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
48630936|NCT03786055|BEHAVIORAL|Somatic Yoga and Meditation (SYM)|A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
48630937|NCT05104775|DRUG|GNC-035|Administration by intravenous infusion.
48630938|NCT03467945|DRUG|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
48630939|NCT03467945|DRUG|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
48630940|NCT03467945|DRUG|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
48630941|NCT02352142|OTHER|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
48630942|NCT02352142|BEHAVIORAL|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
48630943|NCT05787223|OTHER|Baseline Treatment|Control Group that will be provided with be given baseline treatment of static balance training (static exercise like standing on balance board, bounce on one foot, heel rises/toe rises, standing on one foot, jumping on trampoline)
48630944|NCT05787223|OTHER|Dynamic Training|Experimental Group that will be provided with base line treatment along with dynamic balance training (cross, side \&tandem walking, step up and down, jumping \&hopping on floor). Exercises Will be given the 40 minutes with 2 sessions per week over the period of 08 weeks
48630945|NCT04033536|RADIATION|Involved Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
48630946|NCT04033536|RADIATION|Elective Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
48630947|NCT01302171|DRUG|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
48630948|NCT01302171|PROCEDURE|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
48630949|NCT03024164|OTHER|Treatment following current guidelines|Treatment following current guidelines
47941268|NCT01496768|DIETARY_SUPPLEMENT|Leucine|7,2 g/day during 3 months
47941269|NCT01496768|DIETARY_SUPPLEMENT|Alanine|7,2 g/day during 3 months
47941270|NCT01408329|DEVICE|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
48101955|NCT04954040|DRUG|SOC|Acetaminophen or Metamizole. Antitussives if needed.
48630950|NCT05635864|PROCEDURE|Catheter ablation|Catheter ablation of atrial tachyarrhythmia (atrial fibrillation, atrial flutter)
47941271|NCT02015702|OTHER|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
48101956|NCT03518112|BIOLOGICAL|Blinatumomab|Given IV
48101957|NCT03518112|DRUG|Cyclophosphamide|Given IV
48101958|NCT03518112|DRUG|Cytarabine|Given IT or IV
48101959|NCT03518112|DRUG|Dexamethasone|PO or IV
48101960|NCT03518112|BIOLOGICAL|Filgrastim|Given SC
48101961|NCT03518112|OTHER|Laboratory Biomarker Analysis|Correlative studies
48101962|NCT03518112|DRUG|Leucovorin Calcium|Given IV
48101963|NCT03518112|DRUG|Mercaptopurine|Given PO
48101964|NCT03518112|DRUG|Methotrexate|Given IT or IV
48630951|NCT03927716|DRUG|SB206 12%|Topically once daily
48630952|NCT03927716|DRUG|Placebo|Topically once daily
48630953|NCT00335075|DRUG|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
48630954|NCT00335075|DRUG|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
47941272|NCT02015702|OTHER|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
47941273|NCT00757107|DEVICE|Taperloc Microplasty|primary total hip arthroplasty
47941274|NCT00757107|DEVICE|Taperloc standard|primary total hip arthroplasty
47941275|NCT02455141|DRUG|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w\*4 Cyclophosphamide: 600mg/m2, d1, q3w\*4
47941276|NCT02455141|DRUG|Taxanes|Paclitaxel: 80mg/m2, d1, qw\*12 or Docetaxel: 80-100mg/m2,d1,q3w\*4
47941277|NCT02455141|DRUG|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w\*4 Carboplatin AUC=2, d1,d8,d15, q4w\*4 or Docetaxel: 75mg/m2,d1,q3w\*4 plus Carboplatin AUC=5-6, d1, q3w\*4
47941278|NCT05587218|BEHAVIORAL|Self-production|After participants learn L2 lexical items via hearing or observing them paired with L1 translations, they are prompted to produce them themselves
47941279|NCT05693844|BIOLOGICAL|Pan-T booster co-expressing MSLN CAR T cell|Starting Dose: 1×10\^6 cells/kg
47941280|NCT05693844|DRUG|Albumin-bound paclitaxel|Administered intravenously at dose of 100-200mg/m2 on day -5
47941281|NCT05693844|DRUG|Cyclophosphamide|Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
47941282|NCT05693844|DRUG|Fludarabine|Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
47941283|NCT02990156|DEVICE|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
48101965|NCT03518112|BIOLOGICAL|Pegfilgrastim|Given SC
48101966|NCT03518112|BIOLOGICAL|Rituximab|Given IV
48101967|NCT03518112|DRUG|Vincristine Sulfate|Given IV
48101968|NCT01128530|DRUG|JNJ-32729463|250 mg tablet twice daily
48101969|NCT01128530|DRUG|linezolid|600 mg tablet twice daily
48101970|NCT01128530|DRUG|JNJ-32729463 placebo|1 placebo tablet twice daily
48101971|NCT01128530|DRUG|linezolid placebo|1 placebo tablet, twice daily
48288698|NCT01566838|DRUG|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
48617998|NCT06163859|BEHAVIORAL|Intervention Group|FCHVs will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. FCHVs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'.
47941284|NCT02990156|DEVICE|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
47941285|NCT04782960|DRUG|Iocal anaesthetic bupivacaine|Local anaesthetic Subconjunctival bupivacaine
47941286|NCT04782960|DRUG|Placebo|0.9 saline
47941287|NCT04099251|BIOLOGICAL|Nivolumab|Specified dose on specified days
47941288|NCT04099251|OTHER|Placebo|Specified dose on specified days
47941289|NCT01178073|DRUG|ambrisentan|ambrisentan (target dose: 10mg)
47941290|NCT01178073|DRUG|tadalafil|tadalafil (target dose: 40mg)
47941291|NCT02812355|DRUG|Heparin|
47941292|NCT00679744|DRUG|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
47941293|NCT00413166|DRUG|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
47941294|NCT00413166|DRUG|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
47941295|NCT00413166|DRUG|Idarubicin|"1. 12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~2. If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
47941296|NCT00413166|DRUG|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
47941297|NCT00773916|DRUG|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
47941298|NCT03841838|OTHER|Energy drink|Two 12 oz bottles of commercially available energy drink
47941299|NCT03841838|OTHER|Placebo drink|Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
47941300|NCT00234910|DRUG|Tenofovir DF|TDF 300mg QD for 72 wks
47941301|NCT00234910|DRUG|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
48101972|NCT00143689|DRUG|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
48101973|NCT06082076|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
48101974|NCT06082076|DRUG|Ketamine|Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia
48101975|NCT06082076|DRUG|Meperidine|If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine
48101976|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
48101977|NCT03582956|PROCEDURE|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
48107119|NCT00628719|DRUG|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
48288699|NCT01566838|DRUG|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
48288700|NCT01981187|DRUG|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
48288701|NCT00884507|DRUG|Placebo|po daily for 24 weeks
48288702|NCT00884507|DRUG|RO5313534|1mg po daily for 24 weeks
48288703|NCT00884507|DRUG|RO5313534|5mg po daily for 24 weeks
48288704|NCT00884507|DRUG|RO5313534|15mg po daily for 24 weeks
48288705|NCT00069121|DRUG|Capecitabine|1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
48288706|NCT00069121|DRUG|Oxaliplatin|130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
48288707|NCT00069121|DRUG|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
48288708|NCT00069121|DRUG|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
48288709|NCT05813821|BEHAVIORAL|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment \>7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
48617999|NCT06443827|DRUG|Amantadine Sulfate|intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
48630955|NCT02958527|DRUG|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
48630956|NCT04612621|DIAGNOSTIC_TEST|combination of diagnostic tests|capsule endoscopy, MRE , intestinal ultrasound, fecal microbiota, blood and serum biomarkers as described
48630957|NCT02941952|DEVICE|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
48630958|NCT04802915|PROCEDURE|Intraoperative ERM and ILM staining with their assessment and removal|ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM
48630959|NCT03331562|DRUG|Pembrolizumab|pembrolizumab solution for infusion
48630960|NCT03331562|DRUG|paricalcitol|Paricalcitol solution for injection
48288710|NCT03393351|OTHER|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~1. shared decision-making trainings for health care professionals,~2. individual coaching for physicians,~3. patient activation strategy,~4. provision of patient information material and decision aids,~5. revision of the clinics quality management documents, and~6. critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
47941302|NCT04682873|DRUG|Enisamium Iodide|"Capsule formulations of the active product (enisamium iodide 500 mg; Investigational medicinal product 1 \[IMP-1\]).~1 capsule Amizon® Max contains: enisamium iodide 500 mg.~Amizon® Max (active ingredient: enisamium iodide; IMP-1 will be administered as 1 capsule 4 times a day, every 6 hours (total dose 2,000 mg per day). Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-1 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
47941303|NCT04682873|DRUG|Placebo|"Capsule formulations of the reference product placebo Amizon® Max (IMP-2), will be identical in appearance (size, shape, and color), taste, and smell as the active formulation capsule.~1 capsule placebo Amizon® Max contains: placebo (no active substance).~Amizon® Max placebo (IMP-2), will be administered as 1 capsule 4 times a day every 6 hours. Capsule will be taken orally (swallowed whole), together with a sufficient amount of liquid (preferably water).~Treatment will start on Day 1 (randomization) and for up to 168 hours after the first dose administration i.e. Day 7 or Day 8. The site staff will ensure that the IMP (1 capsule) is taken every 6 hours by the study subjects.~For documentation purposes, the IMP-2 packs (empty blister / blister with unused capsules) will be kept at the site and drug accountability forms are completed."
47941304|NCT06409403|DEVICE|clinical application of robotic technique|effect of various surgical technique on clinical efficacy of TME
47941305|NCT05260970|PROCEDURE|Rectus muscle reapproximation at cesarean section|Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
47941306|NCT02855515|PROCEDURE|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
47941307|NCT00620789|DRUG|Escitalopram + CBT-I|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* CBT-I, four biweekly sessions during eight week Treatment phase."
47941308|NCT00620789|BEHAVIORAL|CBT-I plus placebo antidepressant medication|"* CBT-I, 4 biweekly sessions, eight week Treatment phase.~* Placebo,daily for duration of study(6 months)."
47941309|NCT00620789|DRUG|Escitalopram|"* Escitalopram, 10 mg daily for the duration of the study (6 months)~* SH, four biweekly sessions during eight week Treatment phase"
47941310|NCT01522729|DRUG|Fentanyl|Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
47941311|NCT01522729|DRUG|Placebo comparator|placebo \[NaCl\]
47941312|NCT00478374|DRUG|Sorafenib|Sorafenib 400mg bid
47941313|NCT00478374|PROCEDURE|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
47941314|NCT01545843|BEHAVIORAL|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
47941315|NCT01545843|DRUG|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
48288711|NCT03393351|OTHER|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
48288712|NCT02376439|OTHER|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
48288713|NCT03550339|PROCEDURE|SURG|bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
48288714|NCT03550339|BEHAVIORAL|DIET|dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
48618000|NCT04646278|DRUG|Hyperemic stimuli|Hyperemic simuli of coronary flow by adenosine or nicorandil injection
47941316|NCT03913325|OTHER|PREVSAM model|A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
47941317|NCT03913325|OTHER|Treatment as usual (standard treatment)|Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
47941318|NCT00727831|DRUG|glucarpidase|
47941319|NCT00727831|DRUG|leucovorin calcium|
47941320|NCT00727831|DRUG|methotrexate|
47941321|NCT00727831|OTHER|laboratory biomarker analysis|
47941322|NCT00727831|PROCEDURE|quality-of-life assessment|
47941323|NCT00727831|RADIATION|radiation therapy|
48101978|NCT03321955|DRUG|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5, 6 and 12 months.
48618001|NCT00937196|DRUG|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
48618002|NCT00937196|DRUG|Histaminum hydrochloricum globuli|
48630961|NCT03331562|DRUG|placebo|normal saline solution for injection
48630962|NCT06423703|DRUG|Cebranopadol|once daily for 3 days
48630963|NCT06423703|DRUG|Oxycodone IR|four times per day for 3 days
48630964|NCT06423703|DRUG|Placebo|three times per day 3 days (with cebranopadol), four times per day for 3 days (placebo arm)
48288715|NCT03550339|BEHAVIORAL|HAES|treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
47941324|NCT01387399|PROCEDURE|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
47941325|NCT05748665|DRUG|Remimazolam besylate|Using remimazolam for induction of general anesthesia
47941326|NCT05748665|DRUG|etomidate|Using etomidate for induction of general anesthesia
48288716|NCT02024464|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
48288717|NCT02024464|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
48288718|NCT02024464|PROCEDURE|Cataract removal and intraocular lens (IOL) implantation|Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects
48288719|NCT01215318|DEVICE|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
48288720|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
48288721|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
48288722|NCT04538950|DIAGNOSTIC_TEST|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
48630965|NCT03912805|BIOLOGICAL|botulinum toxin, Type A|topical liniment
48630966|NCT03912805|BIOLOGICAL|Vehicle|Vehicle Formulation
48630967|NCT06210633|OTHER|medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
48630968|NCT06210633|OTHER|endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
47941327|NCT04017247|DRUG|Oxytocin|Intermittent oxytocin Infusion
48630969|NCT02296801|DRUG|Letrozole|
47941328|NCT04017247|DRUG|Oxytocin|Continous oxytocin Infusion for 16 hours
47941329|NCT03858465|DRUG|Ephedrine|intravenous 25 mg of ephedrine
47941330|NCT03858465|DRUG|Phenylephrine|intravenous 0,3 mg of phenylephrine
48473377|NCT05999734|DRUG|Bupivacaine|Before skin incision, under complete aseptic precautions and sterilization, the patient will be placed in a lateral position. The spinous process of the fourth thoracic vertebra will be identified and marked. The ultrasound guided MTP block will be done by high frequency linear transducer will be placed in position just lateral to the spinous processes of thoracic vertebra target of the paravertebral space. A 50 mm 22-gauge echogenic needle will be inserted in an in plane technique from a caudal to a cephalad direction and will be advanced. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline will be injected. Once the needle tip has been confirmed and after careful aspiration to demonstrate the absence of air or blood, 0.5mL/kg 0.25% bupivacaine will be injected.
47941331|NCT02809521|OTHER|Activity Liking|
47941332|NCT03301974|PROCEDURE|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
47941333|NCT03301974|PROCEDURE|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
47941334|NCT03301974|PROCEDURE|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
47941335|NCT05512364|DRUG|Elacestrant|400mg QD orally on a continuous dosing schedule
48288723|NCT04538950|DRUG|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
48473378|NCT04154358|DIAGNOSTIC_TEST|HPV testing|will perform HPV testing with self-collected specimen
48473379|NCT00333476|DRUG|MSI-1256F (Squalamine Lactate)|
47941336|NCT05512364|DRUG|Tamoxifen|20 mg QD orally on a continuous dosing schedule
47941337|NCT05512364|DRUG|Letrozole 2.5mg|2.5 mg QD orally on a continuous dosing schedule
47941338|NCT05512364|DRUG|Anastrozole 1mg|1 mg QD orally on a continuous dosing schedule
47941339|NCT05512364|DRUG|Exemestane 25 MG|25 mg QD orally on a continuous dosing schedule
48473380|NCT04618484|OTHER|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
48630970|NCT02296801|DRUG|palbociclib|
48630971|NCT04549428|DRUG|Atezolizumab|Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.
48630972|NCT00471107|DEVICE|DC brain polarization|0.08 mA/cm2
48630973|NCT01891838|PROCEDURE|Volume controlled ventilation|
48630974|NCT01891838|PROCEDURE|Pressure-controlled ventilation|
48630975|NCT06460909|OTHER|Psychological support|An interview with the psychologist before surgery.
48630976|NCT04457778|DRUG|M6223|Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
48630977|NCT04457778|DRUG|Bintrafusp alfa|Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.
48630978|NCT04457778|DRUG|M6223|Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
48288724|NCT05429814|OTHER|Menthol Application|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
48288725|NCT01287117|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
48288726|NCT01287117|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
48288727|NCT01857986|DEVICE|AnapnoGuard 100 control unit|
48288728|NCT03340805|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
48288729|NCT03340805|DRUG|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
48288730|NCT03071432|DIAGNOSTIC_TEST|Paced breathing at 6, 10 and 15 breaths per minute|
48288731|NCT05594524|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
48288732|NCT02067312|OTHER|Thai massage|
48288733|NCT01519115|OTHER|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
48288734|NCT01519115|OTHER|usual care|one physical therapy visit in hospital following ACF surgery
48288735|NCT02708212|PROCEDURE|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
48288736|NCT00546351|DRUG|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
48288737|NCT01524289|DRUG|Anacetrapib|One oral tablet, orally once daily for 52 weeks
48288738|NCT01524289|DRUG|Placebo|One oral tablet once daily for 52 weeks
48630979|NCT03130322|OTHER|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
48288739|NCT04063683|DRUG|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"* anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
48288740|NCT02471963|DRUG|Empagliflozin|
48101979|NCT03321955|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline, 6 months and 12 months,
48101980|NCT03321955|DIAGNOSTIC_TEST|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
48101981|NCT06375356|BEHAVIORAL|Resistance Training|Strength exercises (3-4 sets each exercise) videos delivered electronically, participant self-tracks and self-progresses based on effort reported.
48630980|NCT03130322|OTHER|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).~Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
48630981|NCT03130322|OTHER|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
48101982|NCT04265378|DEVICE|anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
48101983|NCT04265378|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
48101984|NCT02593565|OTHER|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
48101985|NCT05054400|DRUG|F18 Fluciclovine|Given by IV
48101986|NCT05054400|OTHER|Standard of Care|Standard of care
48101987|NCT05703204|DRUG|QLF32101|The dose is given weekly and observed for 28 days(DLT observation period).Single agent treatment.
48101988|NCT03126084|DRUG|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
48101989|NCT03126084|DRUG|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
48101990|NCT03126084|DRUG|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
48101991|NCT03126084|DRUG|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
48101992|NCT03126084|PROCEDURE|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
48101993|NCT03126084|DRUG|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
48101994|NCT03703479|OTHER|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
48101995|NCT05171218|BEHAVIORAL|Music & Auditory Beat Stimulation|Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes
48101996|NCT05171218|BEHAVIORAL|Music Alone|Listening to calm music Participants listened to calm music for 24 minutes
48101997|NCT05171218|BEHAVIORAL|Auditory Beat Stimulation|Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes
48101998|NCT05171218|BEHAVIORAL|Pink Noise|Listening to pink noise Participants listened to pink noise for 24 minutes
48101999|NCT04348331|DIAGNOSTIC_TEST|Dual echo MRI sequence|new MRI sequences for imaging of joints
48102000|NCT06345612|BEHAVIORAL|hypoxia|eccentric training program conducted within normobaric hypoxic chamber
48102001|NCT06345612|BEHAVIORAL|normoxia|eccentric training program conducted within normoxic conditions
48102002|NCT06345612|DIETARY_SUPPLEMENT|creatine supplementation|5g of creatine per day
48288741|NCT02471963|DRUG|Placebo|
48288742|NCT05597267|DEVICE|MIRIA Laser|4-6 experimental treatments at 4-6 weeks intervals
48288743|NCT01666132|OTHER|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
48288744|NCT01666132|OTHER|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
48288745|NCT01666132|OTHER|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
48288746|NCT03952650|DRUG|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
48630982|NCT03130322|OTHER|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
48630983|NCT03130322|OTHER|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
48630984|NCT03889262|OTHER|Hippotherapy|Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.
48288747|NCT03952650|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
48288748|NCT03952650|DRUG|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
48288749|NCT03952650|DRUG|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
48288750|NCT03952650|DRUG|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
48630985|NCT03889262|OTHER|Neurodevelopmental Therapy|Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
48630986|NCT00529581|DRUG|C105|
48630987|NCT00852982|BEHAVIORAL|Exercise|Nordic walking, with walking poles, five hours per week during four months
48630988|NCT02588755|PROCEDURE|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
48630989|NCT02588755|PROCEDURE|TACE|TACE alone
48630990|NCT06217146|DRUG|Medical Cannabis|MediCane's medical cannabis oil
48630991|NCT06217146|DRUG|Placebo Oil|Placebo Oil
48630992|NCT04333459|BIOLOGICAL|Hataan DNA Vaccine/Puumala DNA Vaccine|Vaccine compared in High and Lose Doses.
48630993|NCT05932030|OTHER|Survey|Submission of a survey to solid organ transplant patients and health professionals working in transplantation to assess their knowledge and perception of the use of artificial intelligence in transplantation
48630994|NCT03813251|DEVICE|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
48630995|NCT01778985|DRUG|Premarin|
48630996|NCT01778985|OTHER|Placebo|
48102003|NCT06345612|DIETARY_SUPPLEMENT|no creatine supplementation|no creatine supplementation
48102004|NCT06165549|OTHER|Light therapy|The light therapy will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at 5000 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
48288751|NCT05146622|BEHAVIORAL|Workplaces in the World|Formative research activities to better understand attitudes and behaviors of outdoor workers with respect to UV safety.
48288752|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
48288753|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
48288754|NCT04068389|PROCEDURE|Pulmonary Tissue Collection|Pulmonary Tissue Collection
48288755|NCT05263843|DIAGNOSTIC_TEST|Biological markers of myocardial fibrosis|Blood sample for measurements of NET activation and collagen biomarkers
48288756|NCT00922935|DEVICE|Cresco|Cresco components loading 10 days post surgery
48288757|NCT00922935|DEVICE|Cresco|Cresco loading at 6-8 weeks post surgery
48630997|NCT03917264|PROCEDURE|Peri-implantitis debridement|Mechanical cleaning of titanium implants, peri-implantitis debridement.
48630998|NCT03917264|OTHER|Dental hygiene procedures|Titanium scalers and nylon brushed used for implant cleaning
48630999|NCT02344095|DRUG|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
48631000|NCT02344095|DRUG|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
48631001|NCT02344095|DEVICE|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
48102005|NCT06165549|OTHER|Light placebo therapy|The light placebo intervention will be administered by custom-made light boxes (LED) with adjustable brightness. The light intensity will be set at less than 200 Lux. The intervention will consist of daily exposure for 30 minutes in the morning. The whole intervention includes 14 days.
48102006|NCT06165549|OTHER|Emotion Bias Modification Training|The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, selecting a fixed word of the word-pair will be associated with a high probability (eighty percent) of getting a monetary reward and a low probability (twenty percent) of no reward, and probabilities will be reversed for the other word. Each training run will comprise 100 gaming picture trials and 100 healthy-activity picture trials, presented in a pseudo-randomized order. Participants will receive two training runs every day. The whole training includes 14 days.
48102007|NCT00125151|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|
48102008|NCT03874455|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
48631002|NCT01656746|PROCEDURE|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
48631003|NCT00358800|DEVICE|REMStar Auto with C-Flex|
48288758|NCT00922935|DEVICE|Straumann components|Straumann components loading 6-8 weeks post surgery
48288759|NCT02128490|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
48288760|NCT02128490|DRUG|Febuxostat XR|Febuxostat over-encapsulated capsules
48288761|NCT02128490|DRUG|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
48288762|NCT02128490|DRUG|Colchicine|Colchicine tablets
48288763|NCT02128490|DRUG|Naproxen|Naproxen tablets
48288764|NCT02128490|DRUG|Lansoprazole|Lansoprazole capsules
48288765|NCT01351519|DRUG|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
48288766|NCT06510478|BEHAVIORAL|Group Life Skill Intervention|This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
48288767|NCT06510478|BEHAVIORAL|Treatment as Usual for Control Group|Standard psychological interventions i.e. Debreathing, Meditation, supportive counseling, or psychoeducation.
48288768|NCT02307968|OTHER|insulin injection site|insulin injected site between inner thigh and out thigh
48288769|NCT04704076|OTHER|ESVS|Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
48631004|NCT00731536|OTHER|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
48288770|NCT04704076|OTHER|Exclusive breastfeeding|Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
48288771|NCT06334835|DIAGNOSTIC_TEST|lncRNA signature analyses|Evaluation of a signature of identified lncRNA in a cohort of childhood T-ALL patients in comparison with healthy subjects.
48288772|NCT04329949|DRUG|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
48288773|NCT04329949|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
48288774|NCT00149214|DRUG|pemetrexed|500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
48288775|NCT00149214|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
48288776|NCT00149214|DRUG|doxorubicin|60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
48288777|NCT00149214|DRUG|docetaxel|100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
48288778|NCT05763940|DIETARY_SUPPLEMENT|OmegaBoost|"An ultra-pure omega-3 fish oil supplement with no fishy aftertaste and no fish burps.~10x more omega-3 from fish oil than the leading omega-3 gummies. Gel bites have better absorption than ordinary, hard-to-swallow fish oil pills."
48288779|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (soft gel)|A commercially-available omega-3 soft gel formula
48288780|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (gummy)|A commercially-available omega-3 formula in gummy form
48288781|NCT03827876|DRUG|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
48288782|NCT02029430|DRUG|50 mg/m2 aldoxorubicin|
48288783|NCT02029430|DRUG|100 mg/m2 aldoxorubicin|
48288784|NCT02029430|DRUG|150 mg/m2 aldoxorubicin|
48288785|NCT01274897|BIOLOGICAL|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
48288786|NCT01274897|BIOLOGICAL|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
48288787|NCT03697239|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
48473381|NCT01245842|OTHER|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
48288788|NCT03697239|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
48288789|NCT03697239|DRUG|Cisplatin|25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
48288790|NCT03697239|DRUG|Gemcitabine|1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
48288791|NCT06040177|DRUG|Cadonilimab|Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
48288792|NCT06040177|RADIATION|Stereotactic radiotherapy|Radiation therapy: Stereotactic radiotherapy (5-8Gy\*5F) for portal vein thrombus within 21 days after entry
48288793|NCT06040177|DRUG|Renvatinib|Renvatinib: 8mg (weight \<60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
48288794|NCT05881850|OTHER|Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.|The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
48288795|NCT05358834|DIETARY_SUPPLEMENT|Melatonin|Oral melatonin administered as a single pill.
48288796|NCT05358834|DIETARY_SUPPLEMENT|Placebo|Oral placebo administered as a single pill.
48288797|NCT03952130|DRUG|LY900014|Administered SC
48288798|NCT03952130|DRUG|Insulin Lispro|Administered SC
48288799|NCT03952130|DRUG|Insulin Glargine|Administered SC
48288800|NCT03952130|DRUG|Insulin Degludec|Administered SC
48288801|NCT02650310|DEVICE|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
48473382|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
48473383|NCT00754052|DRUG|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
48288802|NCT03421223|OTHER|No intervention|No intervention
48288803|NCT01312155|OTHER|Intubation|Intubation, endotracheal
48288804|NCT05734937|OTHER|gastric assessment of gastric volume|ultrasound assessment of gastric volume is going to bel evaluted in the Preoperative and postoperative period while the patients lay in right lateral decubitus position.
48288805|NCT02455115|OTHER|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
48288806|NCT02455115|DRUG|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
48288807|NCT02455115|DRUG|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
48288808|NCT01912118|DRUG|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
48288809|NCT01912118|DRUG|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
48288810|NCT03389334|OTHER|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
48288811|NCT04063943|DEVICE|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
48288812|NCT00643539|DRUG|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
48631005|NCT05406999|DRUG|ADT|The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
48631006|NCT05406999|DRUG|Abiraterone Acetate|1000 mg (250 mg×4 tablets) once daily, orally
48631007|NCT05406999|DRUG|Prednisolone tablets|5 mg once daily, orally.
48631008|NCT05406999|DRUG|Enzalutamide|160 mg (40 mg× 4 tablets) once daily, orally.
48631009|NCT05406999|DRUG|Apalutamide|240 mg (60 mg×4 tablets) once daily, orally.
48288813|NCT00643539|DRUG|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
48288814|NCT04332419|DEVICE|PET/CT|Standard Imaging
48288815|NCT04332419|DEVICE|PET/MR|Additional Imaging
48288816|NCT04332419|RADIATION|SIRT with Y-90|SIRT with Y-90 for palliative treatment of the liver malignancy.
48288817|NCT02534337|DRUG|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
48631010|NCT05406999|DRUG|Darotamide|600 mg (300 mg × 2 tablets) twice daily, orally.
48631011|NCT05406999|DRUG|Rezvilutamide|240 mg (80 mg × 3 tablets) once daily orally
48288818|NCT02534337|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
48288819|NCT03312010|DEVICE|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
48288820|NCT03312010|DEVICE|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
48473384|NCT00754052|DRUG|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
48473385|NCT00065117|DRUG|ZD6126|
48473386|NCT00065117|DRUG|Placebo|
48631012|NCT05406999|DRUG|PARP inhibitor|The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
48288821|NCT04436913|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
48288822|NCT04436913|OTHER|Signal toothpaste|fluoride based toothpaste as a part of a caries preventive regimen
48288823|NCT04436913|OTHER|Signal toothpaste and fluoride varnish|application of fluoride varnish and using fluoride based toothpaste
48288824|NCT04853329|DRUG|CPO107|CD20-CD47 Bispecific Fusion Protein
48631013|NCT05406999|PROCEDURE|Robot-assisted radical prostatectomy|Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
48631014|NCT03072875|DEVICE|CAMS-RAS|
48631015|NCT01986751|DRUG|Clonidine|
48631016|NCT01986751|DRUG|ropivacaine|
48631017|NCT03338686|PROCEDURE|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
48631018|NCT03338686|PROCEDURE|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
48631019|NCT01760980|DRUG|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
48631020|NCT01760980|DRUG|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
48288825|NCT05691062|DEVICE|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
48288826|NCT05691062|DEVICE|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
48288827|NCT01571986|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation
48288828|NCT00003176|DRUG|carmustine|
48288829|NCT00003176|DRUG|temozolomide|
48288830|NCT03035812|DRUG|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
48288831|NCT04282928|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell
48288832|NCT04282928|PROCEDURE|Routine treatment|"According toInfluenza diagnosis and treatment plan (2019 version)"
48288833|NCT00824421|DRUG|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
48288834|NCT00824421|DRUG|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
47941340|NCT02013869|DEVICE|Flow-I, a modern anaesthetic machine without a bag/below/gas reservoir for compression of insufflation gas|Desflurane Dialed setting 18 % on the machine gas vaporized
47941341|NCT02013869|DEVICE|Asys, a anaesthetic machine with a bag/bellow for compression of gas to be insufflated|Desflurane dialed 18% on the machine gas vaporized
47941342|NCT06309537|DIAGNOSTIC_TEST|chemoreflex evaluation|the ventilatory response to carbon dioxide and hypoxia will be assessed in study participants
47941343|NCT04076527|DRUG|UDCA|Routine data is collected for UDCA therapy.
48102009|NCT05100472|BIOLOGICAL|Androgen deprivation therapy (ADT)|ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.
48102010|NCT05100472|RADIATION|Brachytherapy|After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.
48102011|NCT05100472|RADIATION|Hypofractionated pelvic External beam radiation|Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
48102012|NCT01949909|BIOLOGICAL|CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
48102013|NCT01949909|BIOLOGICAL|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
48288835|NCT00824421|DRUG|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
48288836|NCT00004081|DRUG|docetaxel|
48288837|NCT03750838|BEHAVIORAL|Text Messaging Intervention|The content for the text messaging Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
47941344|NCT04076527|DRUG|Ocaliva|Routine data is collected for OCA therapy.
47941345|NCT06336083|PROCEDURE|Doppler ultrasound|Participants will receive doppler ultrasound of the carotid arteries, and no other interventions studied
47941346|NCT00519298|DRUG|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
48102014|NCT01949909|BIOLOGICAL|TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
48288838|NCT02764866|OTHER|Sleep testing|Home sleep testing
48288839|NCT05631925|DRUG|propofol bolus|Propofol will be added in bolus doses of 0.5mg/kg.
48288840|NCT05631925|DRUG|propofol infusion|Propofol will be administered as 10mg/kg/hour infusion.
48288841|NCT03881163|DRUG|N-acetylcysteine (NAC)|Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
48288842|NCT00783289|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
48288843|NCT00783289|BIOLOGICAL|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
48288844|NCT00783289|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
48288845|NCT00783289|BIOLOGICAL|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
48288846|NCT00002187|DRUG|Fomivirsen sodium|
47941347|NCT00519298|OTHER|placebo|placebo
47941348|NCT00519298|DRUG|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
47941349|NCT06199037|DRUG|SHR-1707|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
47941350|NCT06199037|DRUG|SHR-1707 placebo|1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
48288847|NCT05426044|DRUG|Metformin|"To investigate whether metformin has a neuroprotective effect in patients with primary open-angle glaucoma by comparing the rates of change of average retinal nerve fiber layer ganglion cell inner plexiform layer (RNFL-GCIPL) thickness (primary outcome measure) between patients randomized to receive metformin versus those randomized to receive placebo.~To identify the risk factors associated with progressive RNFL-GCIPL thinning and progressive decline in visual field mean deviation in patients with glaucoma."
48288848|NCT05426044|DEVICE|Placebo|This study takes 24 months. Participants will have 12 visits within 24 months. All of the investigations will be carried out at Grantham Hospital and Hong Kong Eye Hospital. Patients will be randomly assigned in a 1:1 ratio to receive, twice daily, oral metformin 750mg (i.e. 1500mg/day) or identical-appearing oral placebo. The investigators and patients will be blinded to the treatment assignment. Participants will be followed up at 2-month intervals for 24 months.
48288849|NCT06394622|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
48288850|NCT05716451|DEVICE|Device-assisted mobilisation with the sit/stand stabilizer Liana|Non-invasive device-assisted mobilisation with LIANA
48288851|NCT00082823|BIOLOGICAL|ziv-aflibercept|
48102015|NCT01949909|BIOLOGICAL|TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
48102016|NCT01949909|BIOLOGICAL|TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
48102017|NCT01949909|BIOLOGICAL|TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
48102018|NCT01949909|BIOLOGICAL|TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
48102019|NCT00241423|DRUG|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
48102020|NCT00241423|DRUG|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
48102021|NCT03682328|PROCEDURE|vertebroplasty|Cement augmentation of the vertebral body
48102022|NCT03682328|PROCEDURE|kyphoplaty|Cement augmentation of the vertebral body
48102023|NCT03154944|DEVICE|Ostomy device 1|This device consists of a known adhesive and a new top film
48102024|NCT03154944|DEVICE|Ostomy device 2|This device consists of a new adhesive and a known top film
48102025|NCT03154944|DEVICE|Ostomy device 3|This device consists of a known adhesive and a new top film
48102026|NCT01117441|DRUG|PEG-L-asparaginase|see detailed protocol description
48102027|NCT01117441|DRUG|cyclophosphamide|see detailed protocol description
48102028|NCT01117441|DRUG|cytarabine|see detailed protocol description
48102029|NCT01117441|DRUG|daunorubicin hydrochloride|see detailed protocol description
48102030|NCT01117441|DRUG|dexamethasone|see detailed protocol description
48102031|NCT01117441|DRUG|doxorubicin hydrochloride|see detailed protocol description
48102032|NCT01117441|DRUG|etoposide|see detailed protocol description
48102033|NCT01117441|DRUG|ifosfamide|see detailed protocol description
48288852|NCT01813487|DRUG|HBsAg vaccine with Entecavir|
48473387|NCT00065117|DRUG|5-fluorouracil|
48473388|NCT00065117|DRUG|leucovorin|
48102034|NCT01117441|DRUG|mercaptopurine|see detailed protocol description
48102035|NCT01117441|DRUG|methotrexate|see detailed protocol description
48102036|NCT01117441|DRUG|prednisone|see detailed protocol description
48102037|NCT01117441|DRUG|thioguanine|see detailed protocol description
48102038|NCT01117441|DRUG|vincristine sulfate|see detailed protocol description
48102039|NCT01117441|DRUG|vindesine|see detailed protocol description
48102040|NCT01117441|DRUG|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
48102041|NCT01117441|DRUG|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
48102042|NCT01117441|RADIATION|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
48102043|NCT02793297|OTHER|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
48102044|NCT02793297|OTHER|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
48102045|NCT02793297|OTHER|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
48102046|NCT03241654|PROCEDURE|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
48102047|NCT06319664|PROCEDURE|retrosigmoid approach (RSA)|The skull base approach choice was fundamentally followed by the modified classification.
48102048|NCT06319664|PROCEDURE|subtemporal transtentorial transpetrosal approach (STTA)|The skull base approach choice was fundamentally followed by the modified classification.
48102049|NCT06319664|PROCEDURE|extended pterional transtentorial approach (EPTA)|The skull base approach choice was fundamentally followed by the modified classification.
48102050|NCT06319664|PROCEDURE|pretemporal trancavernous anterior transpetrosal approach (PTCA)|The skull base approach choice was fundamentally followed by the modified classification.
48102051|NCT06319664|PROCEDURE|presigmoid combined supra-infratentorial approach (PCA)|The skull base approach choice was fundamentally followed by the modified classification.
48102052|NCT06319664|PROCEDURE|inoperable|The skull base approach choice was fundamentally followed by the modified classification.
48102053|NCT00887640|DRUG|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
48473389|NCT00065117|DRUG|oxaliplatin|
48473390|NCT05841524|DIAGNOSTIC_TEST|Vector flow imaging measurement|Ultrasound measurement, using high framerate measurement techniques.
48631021|NCT03421080|BEHAVIORAL|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
48631022|NCT03421080|BEHAVIORAL|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
48102054|NCT00887640|DRUG|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
48631023|NCT03408145|DEVICE|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
48631024|NCT03408145|DEVICE|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
48102055|NCT03785782|DEVICE|Ultrasound|Breast ultrasound
48631025|NCT03408145|DRUG|Saline|Injection of Saline
48631026|NCT04786925|OTHER|Control diet|Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
48631027|NCT04786925|OTHER|Nutriprecision diet|Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
48631028|NCT01132690|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
48631029|NCT05639712|DRUG|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
48631030|NCT05639712|DRUG|Morphine 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
47941351|NCT04758910|DEVICE|High Flow Oxygen Therapy|A 30-minute spontaneous breathing trial using high flow oxygen therapy via tracheostomy.
47941352|NCT04758910|DEVICE|T-piece|A 30-minute spontaneous breathing trial using T-piece via tracheostomy.
47941353|NCT05503316|OTHER|Dynamic balance training|Participants will receive dynamic balance training while walking on the GRAIL device.
48102056|NCT05725668|BEHAVIORAL|dual-task tai ji quan|dual-task tai ji quan training
48102057|NCT05725668|BEHAVIORAL|standard tai ji quan|standard tai ji quan training
48102058|NCT05725668|BEHAVIORAL|stretching|stretching exercise
48102059|NCT03006341|DRUG|Dabigatran etexilate|observed upto 12 months
48102060|NCT03006341|DRUG|Warfarin|Observed upto 12 months
48473391|NCT06590350|OTHER|Clinical nutrition counseling|"In the first phase, all patients admitted to the Departmental Simple Operating Unit Admission Room of Policlinico Universitario A. Gemelli will be screened for NRS-2002 upon admission.~Only patients with NRS-2002 ≥ 3 will subsequently be tracked via the Foundation's computer system (TrackCare®).~The patients will be managed by caregivers who may spontaneously request nutritional counseling, as is currently the case.~Patient data (laboratory tests, medical history, reason for admission, any instrumental test reports) and clinical outcomes (average length of hospitalization, complications, antibiotic therapy use, intensive care admission, mortality, re-hospitalization within 30 days) will be obtained from the Foundation's computer system (TrackCare®) and recorded in a dedicated Excel® spreadsheet.~Costs related to hospitalization and management of any complications will also be assessed."
47941354|NCT05503316|OTHER|Traditional gait rehabilitation|Participants will receive traditional gait rehabilitation that also includes balance training while walking but not on the GRAIL device.
47941355|NCT04488107|DRUG|FCN-437c|- FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
47941356|NCT04488107|DRUG|Letrozole 2.5mg|"* Letrozole is the latest generation of aromatase inhibitor. Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.~* Letrozole is used to treat breast cancer in postmenopausal women. It is often given to women who have been taking tamoxifen (Nolvadex, Soltamox) for 5 years."
48473392|NCT01086345|RADIATION|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
48473393|NCT01086345|BIOLOGICAL|bevacizumab|Given IV
48473394|NCT01086345|DRUG|irinotecan hydrochloride|Given IV
48473395|NCT03981809|DIAGNOSTIC_TEST|"Diagnostic test (PainsCan) for the identification of the dominant pain mechanisms in cancer survivers with persistent pain"|Easy-to-use screening tool to identify the dominant pain mechanism by using quick clinical tests and compare their accuracy and validity with complicated reference tests.
48473396|NCT06390566|OTHER|calpaïnopathies|Identify and quantify the loss of strength of upper and lower limb muscle groups in patients with LGMD2A
48473397|NCT04540380|DRUG|Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab|Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin
48473398|NCT04540380|PROCEDURE|Combined bone marrow and kidney transplant|Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.
48473399|NCT00550888|PROCEDURE|suture techniques|
48631031|NCT05639712|DRUG|Morphine 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
48631032|NCT05639712|DRUG|Morphine 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
48631033|NCT05639712|DRUG|Oxycodone 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
48631034|NCT05639712|DRUG|Oxycodone 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
48631035|NCT05639712|DRUG|Oxycodone 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
48631036|NCT05639712|DRUG|Fentanyl 0.025 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
48631037|NCT05639712|DRUG|Fentanyl 0.05 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
47941357|NCT04702854|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy|Measure of cutaneous melanomas by ultrasound Biomicroscopy
48102061|NCT02107014|DRUG|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
48102062|NCT01495195|DRUG|High-dose donepezil|Donepezil titrated to 22.5 mg daily
48631038|NCT05639712|DRUG|Fentanyl 0.1 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
47941358|NCT03887403|BEHAVIORAL|Multimodal Intervention|
47941359|NCT03887403|OTHER|Usual care|
47941360|NCT04956770|PROCEDURE|Implantation surgery|"The intervention involves the implantation of:~* a neurostimulator: the Activa® RC from Medtronic~* a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic"
48102063|NCT01495195|DRUG|Low-dose donepezil|Donepezil titrated to 10 mg daily
48102064|NCT01495195|DRUG|Selegiline|Transdermal selegiline, 6 mg daily
48102065|NCT01495195|DRUG|Placebo|microcrystalline cellulose
48102066|NCT02404064|DRUG|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
48102067|NCT02404064|DRUG|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
48102068|NCT02404064|DRUG|Placebo|No perioperative antibiotics
48288853|NCT00848991|DRUG|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
48288854|NCT00848991|DRUG|Propofol|evaulation of propofol for emergence from anesthesia
48288855|NCT00288210|PROCEDURE|Primary angioplasty in acute myocardial infarction|
48288856|NCT03797287|DEVICE|Tensor Tunnler|Create the bone tunnels during the arthroscopic rotator cuff repair procedure
48288857|NCT03797287|PROCEDURE|Anchor Rotator Cuff Repair|The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
47941361|NCT02658058|OTHER|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
47941362|NCT02658058|OTHER|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
48102069|NCT06390891|OTHER|Persons with pancreatic resection in a hospital with at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with at least 50 pancreatic resections annually (observational)
48102070|NCT06390891|OTHER|Persons with pancreatic resection in a hospital not performing at least 50 pancreatic resections annually (observational),|Persons that have undergone a pancreatic resection at a hospital with not at least 50 pancreatic resections annually (observational)
48102071|NCT01514734|DRUG|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
48102072|NCT05147506|DEVICE|CNRM DTx|A mobile application intervention adapted from the CBT for Depression and CBT for TBI manuals.
48102073|NCT05147506|OTHER|Psychoeducation Comparison|A mobile application that consists of psychoeducational material regarding depression and brain injury.
48102074|NCT02023554|DRUG|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
48288858|NCT02203552|DRUG|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
48102075|NCT02023554|DRUG|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
48288859|NCT02203552|OTHER|placebo|Placebo given by mouth for 9 weeks
48102076|NCT00591838|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
48288860|NCT02203552|OTHER|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
48288861|NCT02203552|OTHER|Questionnaire administration|The CES-D and STAI will be administrated weekly.
48102077|NCT00127829|DRUG|Gefitinib|Oral tablet
48102078|NCT04319796|OTHER|Data set as defined by the ERN Research Workgroup of the European Commission|"The ERN-RND registry will be restricted to the minimum data set as defined by the ERN Research Workgroup of the European Commission. This includes the following data:~* Name of specialist center~* Pseudonym:~* Date of birth: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of birth~* Sex~* Date of death: For confidentiality reasons the ERN-RND registry will restrict this information to the Year of death~* Age of onset~* Orphacode for specific rare disease: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=DE~* Online Mendelian Inheritance in Man (OMIM) code as defined for genetic diseases: https://www.omim.org/~* Human Phenotype Ontology (HPO) terms for key features: https://hpo.jax.org/app/~* Agreement to be contacted for research purposes: Yes/No~* Biological samples (Yes / No)~* Link to a biobank (Link / No)~* Classification of disability (Disease group specific score)"
48107120|NCT05843136|OTHER|physiotherapy treatment|this is an interventional study of the use of 3 physiotherapy treatment techniques in order to evaluate the effectiveness of interferential current in relieving chronic low back pain
48107121|NCT00250562|DRUG|valsartan plus hydrochlorothiazide|
48288862|NCT00006812|DRUG|capecitabine|
48288863|NCT05347056|DIAGNOSTIC_TEST|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
48288864|NCT05347056|DIAGNOSTIC_TEST|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
48288865|NCT05347056|DIAGNOSTIC_TEST|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
48288866|NCT05347056|DIAGNOSTIC_TEST|Radiograph|spinal radiograph AP/Lateral
48288867|NCT05347056|BEHAVIORAL|SRS 22|SRS-22 Patient Questionnaire
48288868|NCT02167477|DEVICE|Macintosh laryngoscopy|Tracheal intubation
48288869|NCT02167477|DEVICE|Storz C-MAC, standard blade|Tracheal intubation
48288870|NCT02167477|DEVICE|Storz C-MAC, D-BLADE|Tracheal intubation
47941363|NCT02658058|OTHER|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
48102079|NCT03176030|DIETARY_SUPPLEMENT|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
48288871|NCT02097199|OTHER|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
48288872|NCT00248950|BEHAVIORAL|Positive affect induction and /or self affirmation induction|
48288873|NCT00388739|DRUG|Intervention: Budesonide|Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
48102080|NCT03138473|DIAGNOSTIC_TEST|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, creatinine clearance (CrCl) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of CrCl below 60 ml/min/1.73 m2 (1 point for CrCl between 59 and 50, 2 points for CrCl between 49 and 40 and 3 points for CrCl between 39 and 30 ml/min/1.73 m2). The CrCl is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
48288874|NCT00388739|DRUG|Usual care: albuterol + systemic steroids|All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
48288875|NCT05738980|BIOLOGICAL|Autologous RAK cells|Autologous RAK cells were treated by intravenous reinfusion
48631039|NCT05708235|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
48102081|NCT03138473|DIAGNOSTIC_TEST|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-\[rSS/bSS\]) ×100.
48102082|NCT05536219|DIAGNOSTIC_TEST|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
48102083|NCT00333541|BEHAVIORAL|Using internet/E-mail for follow-up|follow-up via email link to survey
48288876|NCT06046508|OTHER|blood samples collection|patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
48288877|NCT00298571|DRUG|.5% bupivacaine with epinephrine|
48288878|NCT02119130|DEVICE|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
48288879|NCT05000320|DIAGNOSTIC_TEST|Neuronal Injury Panel|A panel of neuronal and astroglial assays that may be a marker of brain injury.
48288880|NCT05321953|OTHER|Standard Physical Therapy Care|Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
48631040|NCT05708235|DRUG|Abemaciclib|Abemaciclib is an orally administered CDK4/6 inhibitor
48631041|NCT05708235|DRUG|Inavolisib|Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)
48631042|NCT00532857|DRUG|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
48631043|NCT03794323|DRUG|BI 764122|Tablet
48631044|NCT03794323|DRUG|Placebo|Tablet
48288881|NCT05321953|OTHER|Aerobic and Inspiratory Muscle Training|The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
47941364|NCT01325623|DEVICE|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
48288882|NCT06507020|BEHAVIORAL|Fall prevention knowledge education|"Frequency of Intervention: 4 sessions, 60 mins each, weeks 1, 3, 5, 8.~Intervention format：group intervention, 12-15 participants in one group.~Intervention content: Elderly fall risks, home safety improvements, community hazard identification, behavior modification.~Intervention tools: digital teaching PPTs.~Intervention deliverers: 2 members per community, one as leader for organizing health ed. activities (lectures, discussions, exercises, Q\&A), the other as assistant for support and participant safety during exercises."
48288883|NCT06507020|BEHAVIORAL|Exercise education|"Frequency of intervention: 4 sessions Duration of intervention: 30 minutes/session, once in each of the 1st, 3rd, 5th and 8th weeks of the intervention period.~Intervention format: group intervention, 12 people in a group (in principle, no more than 15 people).~Intervention content: The content of health education included (1) basic knowledge of exercise safety, 4 methods of balance function exercise (2) review 4 methods of balance function exercise(3) methods of exercising muscle strength (4) 2 methods of endurance exercise.~Intervention tools: accompanying teaching materials Intervention deliverers: same as before."
48288884|NCT06507020|BEHAVIORAL|Home hazard reduction education|"Intervention Time:~One home fall risk assessment and modification instruction at week 6 of health education.~Frequency of Intervention:~Single session.~Intervention Format:~Project staff conduct in-home fall risk assessments by appointment.~Intervention Content:~1. Evaluate fall risks in elderly living areas.~2. Provide personal guidance, complete two written forms-one for records, one for the participants.~3. Supply night lights, anti-slip mats, warning signs, and carpet mats; more services encouraged where possible.~Intervention Tools:~Utilize Elderly Home Fall Risk and Retrofitting Guide for detailed assessments and suggestions. Include tools like night lights, mats, and signs.~Intervention Deliverers:~Skilled community social workers or community health center staff."
48288885|NCT00650585|BEHAVIORAL|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
48288886|NCT02808715|OTHER|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
48288887|NCT00643045|DRUG|Safinamide|
48473400|NCT02148445|OTHER|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
48631045|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~Each patient will undergo a hypoxic test to assess the individual response to hypoxia. The minimum safe SpO2 value is 82%, and the maximum allowable heart rate increase during exercise is + 50% of the starting value. When these parameters are reached, an automatic switch to the supply of a hyperoxic gas mixture (35-40% oxygen) occurs till the SpO2 level is 100%. During each training session a hypoxic gas mixture is supplied to the patient in an intermittent mode, alternating with the supply of a hyperoxic gas mixture. On average, each workout includes 6 of the above cycles. The total time of inhalation of a hypoxic gas mixture during one procedure is 20-30 minutes."
48631046|NCT05379608|PROCEDURE|Intermittent hypoxic-hyperoxic training/control|"IHHT will be carried out using the ReOxy normobaric hypoxic therapy apparatus (Bitmos GmbH, Germany, 26790/10221, 04/10/2019).~A control group of 30 patients will undergo a simulated IHHT course (with the same exposure time and number of sessions as intervention group - 15 sessions, 40-minutes long each, 5 workouts per week for 3 weeks). Patients of this group will breathe normoxic gas mixture (ordinary humidified air is supplied through the mask) during the entire session."
48102084|NCT00470106|BEHAVIORAL|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
48102085|NCT00470106|BEHAVIORAL|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
48102086|NCT00470106|BEHAVIORAL|hybrid intervention|A combination of the two groups listed above.
48102087|NCT00470106|BEHAVIORAL|skills training|Skills training in how to identify symptoms of illness and medication side effects.
48102088|NCT04448717|DIAGNOSTIC_TEST|COVID-19 Antibody testing|COVID-19 Antibody testing in venous blood and/or saliva samples.
48107122|NCT01064804|DRUG|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
48473401|NCT02148445|OTHER|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
48473402|NCT02148445|DRUG|Nicotine replacement therapy|
47941365|NCT04349085|DEVICE|Effective PBMT/sMF|A cluster with 20 diodes, manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used: 4 diodes of 905 nm (1.25 average power, 50 W of peak power for each diode), 8 diodes of 850 nm (40 mW of average power for each diode) and 4 diodes of 633 nm (25 mW average power for each diode). Effective PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The effective PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 270 J for knee extensors/hip flexors, 180 J for knee flexors/hip extensors, and 60 J for plantar flexors.
48102089|NCT03315390|OTHER|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
48102090|NCT03315390|OTHER|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
48631047|NCT04216004|BEHAVIORAL|Controlled-Feeding Intervention|All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
48102091|NCT05929911|BEHAVIORAL|Trauma-focused psychodynamic psychotherapy|"This psychotherapy addresses disruptions in the ability to reflect and affective regulation by exploring the psychological meanings of symptoms and their relation to traumatic events. The therapist works to identify intrapsychic conflicts, intense negative affects, and defense mechanisms related to the PTSD syndrome using a psychodynamic formulation that provides a framework for intervention. The transference provides a forum for patients to address feelings of mistrust, difficulties with authority, fears of abuse, angry and guilty feelings, and fantasies.~This treatment will be provided in-person or over teletherapy as the public health situation demands."
48102092|NCT02286765|DEVICE|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
48102093|NCT03578523|OTHER|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
48102094|NCT03578523|OTHER|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
48102095|NCT03578523|BIOLOGICAL|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
48102096|NCT03578523|BIOLOGICAL|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
48102097|NCT06353958|DRUG|MiSaver|"MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered."
48102098|NCT02809300|BIOLOGICAL|blood collection|
48102099|NCT02501772|DEVICE|acupressure by ankle band|
48102100|NCT01193153|DRUG|Placebo|monthly by i.m. injection for 15 months
48102101|NCT01193153|DRUG|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
48102102|NCT06563375|DRUG|NP-101|Given by mouth
48102103|NCT02169102|OTHER|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
48102104|NCT02169102|RADIATION|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
48102105|NCT02169102|RADIATION|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
48102106|NCT02169102|RADIATION|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
48102107|NCT01724788|DRUG|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
48102108|NCT01724788|DRUG|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
48102109|NCT04249388|OTHER|No Intervention, just observation|No Intervention, just observation
48102110|NCT05603650|OTHER|Lumineux Oral Essentials rinse|mouthrinse
48102111|NCT05603650|OTHER|Listerine rinse|mouthrinse
48102112|NCT01556256|OTHER|Caregiver-Related Intervention or Procedure|Undergo TMV+P
48102113|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV
48102114|NCT01556256|PROCEDURE|Music Therapy|Undergo TMV+P
48102115|NCT01556256|OTHER|Quality-of-Life Assessment|Ancillary studies
48102116|NCT01556256|OTHER|Questionnaire Administration|Ancillary studies
48102117|NCT06630377|DIETARY_SUPPLEMENT|GOS|During the study period, subjects are instructed to take one pocket of galactooligosaccharide per day during the first week, followed by two pockets of galactooligosaccharide per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
48107123|NCT04630080|DEVICE|Scalp cooling|Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
48288888|NCT00643045|DRUG|Safinamide|
48473403|NCT00144079|PROCEDURE|external beam radiotherapy|
48473404|NCT05252247|OTHER|Immobilisation|Eight hours prior to attending the immobilisation session, a splint will be fitted to the hand of the participant and remain until the session start.
48473405|NCT05252247|OTHER|Exercise|Eight hours prior to attending the exercise session, the participant will be instructed to perform 150 ballistic finger movements every hour until the session start.
48473406|NCT01848210|DRUG|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
48102118|NCT06630377|DIETARY_SUPPLEMENT|Placebo|During the study period, subjects are instructed to take one pocket of placebo control per day during the first week, followed by two pockets of placebo control per day during the remaining 7 weeks. Aside from the dietary supplement provided, all participants are instructed to continue their normal routine and not make any changes to their dietary habits or physical activity.
48631048|NCT04216004|DIETARY_SUPPLEMENT|Non-dairy beverage|Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.
47941366|NCT04349085|DEVICE|Placebo PBMT/sMF|A cluster manufactured by Multi Radiance Medical® (Solon, OH, USA) with 20 diodes will be used: Placebo PBMT/sMF will be applied in direct contact with the skin and light pressure in: 4 sites in the knee extensor/hip flexor muscles, 3 sites in the knee flexor/hip extensor muscles and 1 site in the plantar flexor muscles. The placebo PBMT/sMF will be applied to both lower limbs. The dose used for applications will be approximately 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
47941367|NCT05612100|OTHER|Electronic Health Record Review|Ancillary studies
47941368|NCT05612100|OTHER|Questionnaire Administration|Complete alopecia questionnaires
47941369|NCT05612100|OTHER|Survey Administration|Complete alopecia surveys
47941370|NCT00569829|BEHAVIORAL|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
48102119|NCT04172948|DEVICE|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
48102120|NCT04172948|BEHAVIORAL|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
48102121|NCT01145456|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
48102122|NCT01145456|DRUG|gemcitabine hydrochloride|Given IV
48102123|NCT01145456|OTHER|pharmacological study|Correlative studies
48102124|NCT01145456|OTHER|laboratory biomarker analysis|Correlative studies
48102125|NCT04178343|RADIATION|tomotherapy|"1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF)."
48102126|NCT02021760|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
48102127|NCT05553145|DIAGNOSTIC_TEST|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
48102128|NCT00518557|PROCEDURE|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
48102129|NCT05035654|DRUG|LYR-220 Design 1|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
48102130|NCT05035654|DRUG|LYR-220 Design 2|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
48102131|NCT05035654|DRUG|Bilateral sham procedure control|Bilateral sham procedure control
48102132|NCT04277689|PROCEDURE|Brain signal data collection|Collection of speech related electrophysiological data at the time of DBS.
48102133|NCT03502733|PROCEDURE|Biopsy|Undergo tumor biopsy
48102134|NCT03502733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48102135|NCT03502733|PROCEDURE|Computed Tomography|Undergo CT scan
48102136|NCT03502733|DRUG|Copanlisib|Given IV
48102137|NCT03502733|PROCEDURE|Echocardiography|Undergo ECHO
48102138|NCT03502733|BIOLOGICAL|Ipilimumab|Given IV
48102139|NCT03502733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48102140|NCT03502733|BIOLOGICAL|Nivolumab|Given IV
48102141|NCT05324631|DRUG|SHR0302|SHR0302, oral, once daily
48102142|NCT05324631|DRUG|SHR0302 placebo|SHR0302 placebo, oral, once daily
48102143|NCT05054062|DIAGNOSTIC_TEST|Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
48102144|NCT04246697|DRUG|Tylenol|Used for both arms, scheduled
48102145|NCT04246697|DRUG|Oxycodone|Used for both arms PRN
48102146|NCT04246697|DRUG|Morphine|Used for both arms PRN
48102147|NCT04246697|DRUG|Gabapentin|Used for Arm B
48102148|NCT04246697|DRUG|toradol|Used for Arm B
48102149|NCT04246697|DRUG|Bupivacaine|Used for Arm B - anesthesia block
48102150|NCT02485626|PROCEDURE|2D tissue doppler echocardiography|
48102151|NCT02601053|OTHER|Dull movie|A dull movie (duration approximately 90 minutes)
48102152|NCT02601053|OTHER|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
48102153|NCT02601053|OTHER|Heart rate measurement|Heart rate measurement using a actiheart device
48102154|NCT00781612|DRUG|Docetaxel|Docetaxel will be administered as per local prescribing information.
48288889|NCT00643045|DRUG|Placebo|
48288890|NCT03466554|DEVICE|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
48288891|NCT01767233|PROCEDURE|ERCP and pancreatic stenting|
48288892|NCT03863938|DRUG|Tegoprazan 50mg|K-CAB
48288893|NCT01251523|BEHAVIORAL|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
48288894|NCT01251523|BEHAVIORAL|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
48288895|NCT03545516|DRUG|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
48288896|NCT03545516|DRUG|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
48288897|NCT03545516|DRUG|Placebo|Injection of a placebo into the surgical wound
48288898|NCT00003018|DRUG|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
48288899|NCT00003018|DRUG|fluorouracil|200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
48288900|NCT00003018|DRUG|leucovorin calcium|30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
48288901|NCT00003018|DRUG|mitomycin C|10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
48288902|NCT01172171|DRUG|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
48288903|NCT01172171|DRUG|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
48288904|NCT04446585|DEVICE|Automated External Defibrillator (AED)|Deployment of AEDs
48288905|NCT04446585|OTHER|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
48288906|NCT04446585|OTHER|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
48631049|NCT04216004|OTHER|Full-fat milk|3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
47941371|NCT01374711|DRUG|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
48288907|NCT02334969|DRUG|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
48288908|NCT02334969|DRUG|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
47941372|NCT01374711|DRUG|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
47941373|NCT01374711|OTHER|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
48288909|NCT06156202|OTHER|Comprehensive Rehabilitation|Subjects will be given the option to undergo the comprehensive rehabilitation program including speech therapy and physical therapy. Progression through the rehabilitation program will be personalized and designed based on impairments identified during the comprehensive baseline assessment and previous sessions. Subjects will undergo 12 one- hour sessions over the course of six weeks. The exercise program will be graded and targeted to the person's physical capacity with the goal of slowly advancing the exercise duration or intensity to effect physiological strengthening and increased physical function.
48473407|NCT01848210|DRUG|Placebo|Coumarin + troxerutin placebo-matching tablets
48631050|NCT04216004|OTHER|Fat-free milk|3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
48631051|NCT00710970|DRUG|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
48631052|NCT02496429|DEVICE|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
48288910|NCT06156202|OTHER|Augmented Usual Care|"Following randomization, subjects in the augmented usual care group will be given the results of their in-person baseline assessment as well as the WHO Guide Support for Rehabilitation Self-Management after COVID-19 Related Illness. This guide consists of ways to manage: breathlessness, difficulty with voice, eating, drinking and swallowing; problems with attention, memory and thinking clearly; limitations in activities of daily living, manage stress and mood dysfunction and advice for when to contact healthcare professionals. Follow-up interviews will assess process measures, including use of outpatient rehabilitation clinics, to examine possible contamination effects"
48631053|NCT00738517|DEVICE|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
48631054|NCT00319891|PROCEDURE|Computer-based Cognitive Training|
48631055|NCT05675696|OTHER|Esophageal Catheter|Newly designed external monitor that will capture esophageal pressure from a proprietary nasogastric tube combined with simultaneous pressure, flow, and volume measurements from the ventilator tubing.
48631056|NCT00126737|OTHER|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
48631057|NCT00126737|OTHER|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
48631058|NCT06500715|DEVICE|Acupuncture|Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
48631059|NCT01289587|BEHAVIORAL|Physical activity intervention|36 sessions of physical activity offered at different frequencies
48631060|NCT05316051|DEVICE|Inverted foot orthoses|Inverted functional orthoses will be used in this study based on Blake (1986) inverted orthotic technique. Two groups of foot orthosis will be fabricated with two different inverted angles: 25° inverted angle and 15° inverted angle.
48631061|NCT05486702|OTHER|Time Restricted Eating|Time restricted eating (TRE) can be divided into early TRE (eTRE) and late TRE (lTRE), depending on the time of day of the eating window.
47941374|NCT05290545|OTHER|PBSCs|PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.
47941375|NCT05290545|OTHER|Cord|The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.
47941376|NCT05290545|OTHER|BMSCs|BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.
47941377|NCT01704898|DRUG|Efavirenz 600 Test-Stocrin 600 Reference|
47941378|NCT01704898|DRUG|Stocrin 600 Reference-Efavirenz 600 Test|
48102155|NCT00781612|DRUG|Paclitaxel|Paclitaxel will be administered as per local prescribing information.
47941379|NCT00728052|DRUG|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
47941380|NCT00728052|DRUG|Placebo|Placebo capsules will be administered orally with water.
48102156|NCT00781612|DRUG|Pertuzumab|Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
48102157|NCT00781612|DRUG|Trastuzumab|Trastuzumab will be administered as per local prescribing information.
48102158|NCT00781612|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
48102159|NCT00781612|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
48102160|NCT04482348|OTHER|Explanation|Explanation provided to patients for more pain than expected
48102161|NCT02020018|DEVICE|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
48102162|NCT02020018|OTHER|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
48102163|NCT01680276|BEHAVIORAL|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
48102164|NCT01680276|OTHER|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
48102165|NCT02715063|BEHAVIORAL|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
48102166|NCT02715063|BEHAVIORAL|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
48102167|NCT02715063|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
48102168|NCT02715063|OTHER|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
48102169|NCT00356317|BEHAVIORAL|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
48288911|NCT04323189|DRUG|Sitagliptin 100mg|Sitagliptin will be administered daily for 7 days, with a study day on day 7.
48288912|NCT04323189|DRUG|Placebo Oral Tablet|Placebo will be administered daily for 7 days, with a study day on day 7.
48288913|NCT04596813|DEVICE|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
48288914|NCT03560895|DEVICE|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
48288915|NCT03560895|DEVICE|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
48288916|NCT03731715|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
48288917|NCT03309670|OTHER|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
48288918|NCT02395315|DEVICE|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
48288919|NCT02395315|DEVICE|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
48288920|NCT02620540|DEVICE|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
48288921|NCT03339427|OTHER|vitamin D|different doses of vitamin D supplementation
48288922|NCT03339427|OTHER|control|control group
48288923|NCT03530540|DEVICE|low-intensity extracorporeal shockwave therapy|Active shockwaves
48288924|NCT03530540|DEVICE|Placebo LI-ESWT|Placebo shockwaves
48288925|NCT03530540|DEVICE|Penile pump|both groups will be treated with a penile pump
48288926|NCT00219180|DRUG|aliskiren|
48288928|NCT04691661|DRUG|Radotinib HCl 50 mg|Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
48288929|NCT04691661|DRUG|Placebo|Placebo
48288930|NCT05065424|DRUG|IV Atropine and Fentanyl Premedication Arm|"Prior to the LISA procedure, the blinded bedside nurse will infuse IV Atropine, labelled as Atropine/Placebo, over 1 minute, followed by IV fentanyl, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After medication infusion, a primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
48288931|NCT05065424|DRUG|IV Normal Saline Placebo Arm|"Prior to the Less Invasive Surfactant Administration procedure, the blinded bedside nurse will infuse IV Normal Saline, labelled as Atropine/Placebo, over 1 minute, followed by a second infusion of IV Normal Saline, labelled as Fentanyl/Placebo, over 20 minutes in the presence of blinded respiratory therapist and primary team provider.~After Normal Saline infusion, primary team member will perform Less Invasive Surfactant Administration procedure. Infant vital signs, cerebral Near Infrared Spectroscopy values, pain scores will be monitored and recorded during and for 12 hours after the procedure. Level of respiratory support, oxygen requirement and subsequent need for intubation for 24 hours after the procedure will be obtained from the electronic medical record."
48102170|NCT00356317|BEHAVIORAL|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
48102171|NCT05452980|PROCEDURE|reestablishment of the acute angle of His|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
48288932|NCT06407362|DIAGNOSTIC_TEST|Cerebral Oxygen Saturation|We have designed this study to evaluate the accuracy of PVI, PI and rSO2 in both ventilation modes in patients undergoing septorhinoplasty operation under general anaesthesia
48288933|NCT05076708|OTHER|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
48288934|NCT04862416|BIOLOGICAL|R0.6C transmission blocking vaccine|Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
48288935|NCT04740866|RADIATION|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. (\[50Gy in 25 fractions conventional fractionation including tumor bed \& pelvic lymph nodes\]
48288936|NCT04121910|DRUG|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
48288937|NCT04121910|DRUG|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
48288938|NCT03047538|DRUG|Atorvastatin, Amlodipine, Perindopril|To compare free and fixed combination of atorvastatin, perindopril, amlodipine
48288939|NCT00718133|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
48288940|NCT02968030|OTHER|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
48288941|NCT01690832|DRUG|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
48288942|NCT01690832|DRUG|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
48288943|NCT01367743|DRUG|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
48288944|NCT01367743|DRUG|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
48288945|NCT04757337|DRUG|Doxorubicin|6 x 3-week cycles corresponding to a maximal duration of 18 weeks
48288946|NCT04757337|DRUG|Cyclophosphamide|Until progression up to 24 months
48288947|NCT04649853|OTHER|Standardized nursing care|All patients will receive standardized evidence based nursing care
48288948|NCT02024256|OTHER|Cold pads soaked in Magnesium sulfate solution|
48288949|NCT02024256|OTHER|Cold pads soaked in water|
48288950|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein preservation|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
48288951|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
48288952|NCT02403206|DEVICE|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
48288953|NCT02403206|PROCEDURE|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
48288954|NCT03444025|DRUG|Goserelin|Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
48288955|NCT00414440|DRUG|Placebo|placebo comparator
47941381|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
47941382|NCT01678937|PROCEDURE|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
47941383|NCT01678937|PROCEDURE|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
48288956|NCT00414440|DRUG|Everolimus|experimental
48288957|NCT01023529|RADIATION|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
48288958|NCT00487812|PROCEDURE|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
48288959|NCT05203627|OTHER|Best Practice|Receive standard nutritional support
47941384|NCT01678937|PROCEDURE|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
48288960|NCT05203627|OTHER|Questionnaire Administration|Ancillary studies
48631062|NCT01374789|DRUG|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
48107124|NCT00753168|DRUG|OT-730 ophthalmic solution|one eye drop twice daily
48288961|NCT05203627|OTHER|Telemedicine Visit|Receive telehealth sessions
48631063|NCT01374789|DRUG|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
48288962|NCT06511752|BEHAVIORAL|Psychosocial educational, support group and implementation of strategies|Psychosocial educational, support group and implementation of strategies
48288963|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
48288964|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
48288965|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
48288966|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
48288967|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
48288968|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
48288969|NCT00368368|DRUG|GK Activator (2)|100mg po
48288970|NCT06099054|DEVICE|Pigtail catheter|Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist
48288971|NCT06099054|DEVICE|Intercostal tube|Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
48288972|NCT00467883|DRUG|Liposomal Amphotericin B|high dosage
48288973|NCT03497689|DRUG|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
48288974|NCT02818634|PROCEDURE|Harvesting rib cartilage|
48288975|NCT03299504|OTHER|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
48288976|NCT00002993|DRUG|cisplatin|
48288977|NCT00002993|DRUG|doxorubicin hydrochloride|
48288978|NCT00002993|DRUG|mitomycin C|
48102172|NCT05452980|PROCEDURE|sleeve gastrectomy|A sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 15 mm lateral to the esophagus is respected to reduce the risk of high leak.
48288979|NCT02459171|OTHER|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
48288980|NCT02459171|OTHER|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
48288981|NCT02459171|OTHER|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
48288982|NCT02459171|OTHER|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
48288983|NCT03991637|DEVICE|Non-Invasive Comprehensive Metabolic Panel|The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
48288984|NCT00002445|DRUG|IM862|
48288985|NCT03618225|DRUG|Oral Duloxetine 60mg|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
48288986|NCT03618225|DRUG|placebo pill|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
48288987|NCT02293343|OTHER|blood profile|
48288988|NCT04219306|OTHER|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
48288989|NCT04923373|OTHER|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~1. initial training in hospital~2. physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
48288990|NCT04923373|PROCEDURE|standard physiotherapy|standard physiotherapy
48288991|NCT03542552|DRUG|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
48631064|NCT02164721|DEVICE|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
48102173|NCT04529993|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
48102174|NCT04490148|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
48288992|NCT03542552|DRUG|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
48288993|NCT04478422|OTHER|Muscle strengthening with vascular occlusion|The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.
48288994|NCT04478422|OTHER|Conventional muscle strengthening|The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
48631065|NCT00002226|DRUG|SU5416|
48288995|NCT01392690|BEHAVIORAL|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
48288996|NCT01541605|DRUG|methylphenidate|tablets for oral use
48288997|NCT01541605|DRUG|Placebo|tablets for oral use
48288998|NCT02215629|DRUG|VS-4718|
48288999|NCT04462042|RADIATION|Proton radiotherapy|Proton radiotherapy
48289000|NCT04462042|RADIATION|Photon radiotherapy|Conventional photon radiotherapy
48289001|NCT03738124|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
48289002|NCT01963637|DEVICE|gastric tomodensitometry with gas at 3 months and 12 months|
48289003|NCT02795598|PROCEDURE|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
48289004|NCT02795598|PROCEDURE|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
48289005|NCT05615714|OTHER|Paresthesia-free Peripheral Nerve Field Stimulation|High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
48289006|NCT05615714|OTHER|Sham stimulation|Stimulation will be turned off.
48289007|NCT00887081|DRUG|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
48473408|NCT04871009|BEHAVIORAL|Neurofeedback Intervention|"InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity."
48473409|NCT04871009|BEHAVIORAL|standard of care|trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
48473410|NCT00291473|DRUG|CHP-HER2, CHP-NY-ESO-1|
48631066|NCT02220556|PROCEDURE|Blood sampling|
48631067|NCT01168180|OTHER|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
48102175|NCT04490148|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
48289008|NCT03186469|BEHAVIORAL|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
48289009|NCT03186469|BEHAVIORAL|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
48289010|NCT06073314|DIAGNOSTIC_TEST|Quantitative MRI|Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
48289011|NCT06073314|DIAGNOSTIC_TEST|Reproducibility study|A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
48289012|NCT01240018|DIETARY_SUPPLEMENT|Probiotic|Parallel, randomized, controlled 2 arms study.
48289013|NCT00215501|DRUG|Capecitabine|Orally twice a day for 14 days (dosage will vary)
48631068|NCT01168180|OTHER|Ultrasound therapy and hot pack|
48102176|NCT04490148|BEHAVIORAL|Nurse Respiratory Health Coaching (NRHC)|"Nurse Respiratory Health Coaching - The NRHC intervention follows the teamlet model described by Bennett et al. \[Bennett2010\], made up of the research coordinator who performs respiratory testing, and the nurse practitioner who coaches using the GROW (goals, realities, options, wrap-up) model."
48289014|NCT00215501|DRUG|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
48289015|NCT00215501|DRUG|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
48289016|NCT00215501|DRUG|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
48289017|NCT00813839|OTHER|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
48289018|NCT02832492|BEHAVIORAL|pupil near response|
48289019|NCT03952364|OTHER|PredictSURE IBD™|To evaluate a test called PredictSURE IBD™ in the US population
48289020|NCT01344122|OTHER|KPI training only|See comparison arm description.
48289021|NCT01344122|OTHER|KPI plus OLI|See experimental arm description.
48289022|NCT03077048|DRUG|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
48102177|NCT06631560|DIAGNOSTIC_TEST|ELISA testing|Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
48102178|NCT04204837|DRUG|Nivolumab|Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
48102179|NCT04204837|DRUG|Nivolumab plus Relatlimab|Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
48102180|NCT05257733|OTHER|None, pure observationnal study|pure observationnal study
48102181|NCT05613257|DEVICE|Distal targeting jig|Patients in this arm will have an assistive targeting device used for interlocking screw placement. The targeting device is attached to the nail proximally or distally (for antegrade or retrograde nailing, respectively) to guide screw placement through the other end of the intramedullary device.
48102182|NCT05613257|PROCEDURE|Free-hand/perfect circles technique|"Patients in this arm will have no assistive targeting device use and the surgeon will use a free-hand technique for the placement of interlocking screws. With this technique, fluoroscopic images are taken such that the interlocking holes of the intramedullary device are perfect circles and indicate that a screw introduced in the same plane that the fluoroscopic image was taken would seat perpendicularly to the intramedullary device. This is the most commonly employed technique for interlocking screw placement through intramedullary devices."
48102183|NCT00221078|DEVICE|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
48102184|NCT06629662|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy with laparoscopic or robotic approach
48102185|NCT02722668|DRUG|Fludarabine|Both Arms: 30 mg/m\^2 IV over 1 hour Day -6 to Day -2
48102186|NCT02722668|DRUG|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
48102187|NCT02722668|DRUG|MMF|"Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (\>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC) ≥ 0.5 x 109 /L\]). If no donor engraftment, do not stop MMF."
48102188|NCT02722668|DRUG|Sirolimus|"Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m\^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
48102189|NCT02722668|RADIATION|TBI|Both Arms: 200 cGy on Day -1
48102190|NCT02722668|BIOLOGICAL|Umbilical cord blood cell infusion|Both Arms: Day 0
48102191|NCT02722668|BIOLOGICAL|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
48102192|NCT05541393|BEHAVIORAL|Active Intervention Group|The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
48102193|NCT01585038|DRUG|Efavirenz|600mg orally every evening
48102194|NCT01585038|DRUG|Rilpivirine|25mg orally once daily
48102195|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
48102196|NCT03107611|DRUG|Placebo Cream|
48102197|NCT03107611|DRUG|Pimecrolimus Cream, 1%|
48289023|NCT05195879|DIAGNOSTIC_TEST|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
48289024|NCT05645666|BEHAVIORAL|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
48289025|NCT04558008|BEHAVIORAL|Online MBSR|Described previously
48289026|NCT05669885|DRUG|Sildenafil|Study participants will be allocated to receive oral administration of 100 mg sildenafil.
48289027|NCT05669885|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
48289028|NCT01335646|PROCEDURE|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
48289029|NCT01335646|OTHER|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
48289030|NCT01855555|DRUG|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
48289031|NCT04296292|OTHER|In-depth interviews|In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
48289032|NCT00129714|OTHER|cervical collar|
48289033|NCT00129714|OTHER|physiotherapy|
48289034|NCT04665544|PROCEDURE|SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.|"The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques."
48289035|NCT02494908|BEHAVIORAL|Playing a computer game simulating a car race|Playing a computer game simulating a car race
48289036|NCT03054727|OTHER|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
48289037|NCT03054727|OTHER|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires."
48289038|NCT03275870|DRUG|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
48289039|NCT04503980|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
48289040|NCT06104683|DRUG|Placebo|Administered orally
48289041|NCT06104683|DRUG|Pirtobrutinib|Administered orally
48289042|NCT00974779|DEVICE|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
48289043|NCT00974779|DEVICE|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
48289044|NCT00722176|DRUG|BL-1020|10 mg
48473411|NCT03346954|OTHER|[11C]-Methionine PET/MRI|Implementation \[11C\]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The \[11C\]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
48473412|NCT01416116|DRUG|QUTENZA|topical
48289045|NCT00722176|DRUG|BL-1020 10-30 mg|BL-1020 10-30 mg
48289046|NCT00722176|DRUG|risperidone|risperidone
48473413|NCT01416116|DRUG|Lidocaine|topical
48473414|NCT01416116|DRUG|Tramadol|oral
48289047|NCT00950417|DRUG|Nimotuzumab|
48289048|NCT01462292|DRUG|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
48289049|NCT01462292|DRUG|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
48289050|NCT01462292|DRUG|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
48289051|NCT01462292|DRUG|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
48289052|NCT04419415|DIETARY_SUPPLEMENT|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
48289053|NCT04419415|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
48473415|NCT03889691|PROCEDURE|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
48107125|NCT00753168|DRUG|timolol maleate ophthalmic solution|one eye drop twice daily
48289054|NCT04419415|OTHER|Skipping breakfast|Participants will be asked to skip breakfast.
48289055|NCT00942708|DRUG|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
48289056|NCT06209697|DIETARY_SUPPLEMENT|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
48289057|NCT04977505|DEVICE|pushlock|The surgery procedure was performed with pushlock for fixation
48289058|NCT04977505|DEVICE|gryphon|The surgery procedure was performed with Gryphon for fixation
48473416|NCT02725645|OTHER|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
48473417|NCT02136706|PROCEDURE|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
48473418|NCT04219787|PROCEDURE|Long BPL LRYGB|LRYGB with an 180 cm BPL and an AL of 80 cm.
48102198|NCT01991912|PROCEDURE|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
48289059|NCT05070338|BEHAVIORAL|Guideline-Based (Injunctive Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amounts recommended by safety guidelines for these procedures.~For patient safety, Sutter Health recommends prescribing within the ranges below for these procedures. Doing so will also meet best-practice safety guidelines for post-operative opioid prescribing.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]"
48289060|NCT05070338|BEHAVIORAL|Peer-Based (Social Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amount prescribed by YY% of your peers for these procedures.~YY% of \[specialty\] surgeons at Sutter Health prescribe within the ranges below for these procedures.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]~The ranges of 5mg oxycodone tablets displayed will be the same as the ranges stipulated by the prescribing guidelines, but this nudge will not mention guidelines."
48289061|NCT00944944|BEHAVIORAL|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
48289062|NCT00944944|BEHAVIORAL|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
48289063|NCT01180725|DIETARY_SUPPLEMENT|Dried Plum|
48289064|NCT01180725|DIETARY_SUPPLEMENT|Metamucil|
48289065|NCT05032508|DRUG|Lidocaïne Aguettant 20 mg/ml|Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
48289066|NCT05032508|DRUG|NaCl 0,9%|Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
48473419|NCT04219787|PROCEDURE|Short BPL LRYGB|The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
48473420|NCT05688358|DIAGNOSTIC_TEST|serum levels of interleukin-17A in JIA|IL17 A by Enzyme linked immunosorbent assay method
48473421|NCT04238208|DRUG|Lidocaine 5% patch|5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
48473422|NCT04238208|DRUG|Capsaicin 8% Patch, Per 10 Square Centimeters|8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
48473423|NCT04522999|DEVICE|Photobiomodulation|The Valeda™ Light Delivery System
48473424|NCT04174573|OTHER|GTO|"1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
48631069|NCT00245570|DRUG|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
48631070|NCT00245570|DRUG|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
48631071|NCT00245570|DRUG|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
48102199|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
48107126|NCT00753168|DRUG|OT-730 placebo|one eye drop twice daily
48107127|NCT00484575|DRUG|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
48289067|NCT04889703|DRUG|15% Trichloroacetic acid peel|Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
48289068|NCT04889703|DRUG|30% Salicylic acid peel|Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
48289069|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
48289070|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
48289071|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
48289072|NCT03906695|DRUG|ASTX727|oral decitabine 20mg + cedazuridine
48289073|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
48289074|NCT02129764|DRUG|Prednisone|
48289075|NCT02129764|DRUG|Allopurinol|
48289076|NCT01593748|DRUG|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
48289077|NCT01593748|DRUG|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
48631072|NCT00245570|DRUG|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
48631073|NCT05695430|BEHAVIORAL|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
47941385|NCT01678937|PROCEDURE|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
48289078|NCT00014742|DRUG|collagenase|
48289079|NCT00502060|DRUG|AZD2171|
48289080|NCT00502060|DRUG|ZD1839|
48289081|NCT02517879|OTHER|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
48289082|NCT02517879|OTHER|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
48289083|NCT01645930|DRUG|Ixazomib|Ixazomib capsules
48289084|NCT01645930|DRUG|Lenalidomide|Lenalidomide capsules
48289085|NCT01645930|DRUG|Dexamethasone|Dexamethasone tablets
48473425|NCT04174573|OTHER|GT-tDCS|"1. Group therapy~   1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
48473426|NCT01956487|DRUG|Propafenone|Comparison of drug from 2 manufacturing sites
48473427|NCT02248714|DIETARY_SUPPLEMENT|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
48473428|NCT01561924|DRUG|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
47941386|NCT01678937|PROCEDURE|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~* Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~* Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~* HLA microchimerism \& HLA G"
47941387|NCT05977361|PROCEDURE|Resiting Epidural Catheter|After a UDP has occurred, epidural catheter will be re-sited in a different intervertebral space. Analgesia will be then maintained according to internal protocol, using PIEB (Programmed Intermittent Epidural Bolus) system. Catheter will be left in place for the first 24-36 hours.
48289086|NCT00337636|PROCEDURE|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
48289087|NCT00337636|DRUG|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
48289088|NCT03399890|DIAGNOSTIC_TEST|Neurological physical exam|Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
48289089|NCT02433249|BEHAVIORAL|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
48289090|NCT02433249|BEHAVIORAL|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
48473429|NCT05582109|DRUG|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
47941388|NCT05977361|PROCEDURE|Intrathecal Catheter Placement|After a UDP has occurred, an intrathecal catheter will be placed through the dural tap. Analgesia will be then maintained according to internal protocol, using PISB (Programmed Intermittent Subarachnoid Bolus) system. Catheter will be left in place for the first 24-36 hours. During this time, a continuous infusion of sterile saline at a rate of 2 mL/h will be maintained. Before removal, an additional bolus of 10 mL of sterile saline will be administered in the intrathecal catheter.
48289091|NCT02433249|BEHAVIORAL|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
48473430|NCT00612677|DRUG|Oxaliplatin|Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days
48473431|NCT00612677|DRUG|Pemetrexed|Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
48473432|NCT00889252|DEVICE|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
48473433|NCT00889252|DEVICE|contact lens|Placebo contact lens
48473434|NCT01659034|DRUG|Thienopyridine for 3 months|
48473435|NCT00000425|DRUG|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
48473436|NCT00000425|DRUG|Acetaminophen|
48473437|NCT04830982|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
48631074|NCT01845415|BEHAVIORAL|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
48631075|NCT01845415|BEHAVIORAL|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
48289092|NCT05013528|OTHER|Bal-A-Vis-X training|"Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~1. ball Rectangle~2. ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. ."
48289093|NCT05013528|OTHER|Aerobic Training Group|"Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed"
48289094|NCT04259710|BEHAVIORAL|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
48289095|NCT04259710|BEHAVIORAL|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
47941389|NCT02266043|DEVICE|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.~This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
48289096|NCT04259710|BEHAVIORAL|Pedometer only|the participant will be given a pedometer and instructed how to use it.
48102200|NCT00545376|PROCEDURE|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
48289097|NCT03045380|OTHER|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
48289098|NCT03045380|OTHER|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
48289099|NCT06326151|BEHAVIORAL|Interdisciplinary Psychoeducational Programme|This intervention is based on the principle of complementing and integrating both disciplines in order to meet the psychological needs of family carers and to train them in knowledge and strategies aimed at the correct performance of activities of daily living in order to promote the maximum autonomy and functionality of dependent people with cognitive impairment, and that this favours discharge, self-care, improvement of the affective state and quality of life of family carers.
48289100|NCT06326151|BEHAVIORAL|Health Education Programme|Upon discharge from the hospital, at the end of the baseline assessment, caregivers will receive instructions and recommendations for maintaining an active and healthy lifestyle. This will be done by encouraging self-care and good practices in caring for their dependent family member, as part of a health education programme. The benefits of an active lifestyle and general guidelines are emphasized.
48289101|NCT03157557|BEHAVIORAL|Lifestyle treatment|Lifestyle treatment
48289102|NCT02729961|DRUG|Brentuximab Vedotin|Given IV
48289103|NCT02729961|DRUG|Ceritinib|Given PO
48289104|NCT02729961|OTHER|Laboratory Biomarker Analysis|Correlative studies
48289105|NCT02729961|OTHER|Pharmacological Study|Correlative studies
48289106|NCT04804644|DRUG|Memantine Hydrochloride|Given PO
48289107|NCT04804644|OTHER|Neurocognitive Assessment|Ancillary studies
48289108|NCT04804644|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48289109|NCT04804644|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
48473438|NCT04830982|OTHER|Placebo|Placebo added to one liter of cardioplegia
48473439|NCT05028634|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tdap
48473440|NCT05028634|BIOLOGICAL|Pneumococcal polysaccharide vaccine|PPSV23
47941390|NCT04616027|DRUG|PF-06882961 20 mg|PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
48631076|NCT05565404|BEHAVIORAL|mobile health|Scaling and root planing, interdental brushing demonstration and regular text messages in type 2 embrasure patients.
48631077|NCT05565404|PROCEDURE|Scaling and root planing+Interdental aid|Scaling and root planing, interdental brushing demonstration in type 2 embrasure patients.
47941391|NCT03845374|DEVICE|Hyper-CL™ lens|Use of the Hyper-CL™
47941392|NCT00880685|DRUG|Memantine|10-30mg, daily for 8 weeks
47941393|NCT04561427|OTHER|Study of Sleep architecture in children with narcolepsy|Evaluate the cognitive performances, the effects of narcolepsy treatments on sleep architecture and the metabolic status of these children
47941394|NCT01564771|OTHER|Non Intervention|This Is A Non Interventional Study
48289110|NCT03147027|PROCEDURE|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
48289111|NCT03147027|OTHER|medication|medication to prevent sustained VT and ICD therapies
48289112|NCT05102201|DEVICE|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
48473441|NCT05028634|BIOLOGICAL|Seasonal influenza vaccine|Seasonal influenza vaccine
48473442|NCT03458364|DEVICE|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
48631078|NCT01928576|DRUG|Azacitidine|
48631079|NCT01928576|DRUG|Entinostat|
48631080|NCT01928576|DRUG|Nivolumab|
48631081|NCT01928576|DRUG|CC-486 300|
48631082|NCT01249443|DRUG|vorinostat|Given PO
48631083|NCT01249443|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
48631084|NCT01249443|OTHER|pharmacological study|Correlative studies
48631085|NCT01249443|DRUG|carboplatin|Given IV
48631086|NCT01249443|DRUG|paclitaxel|Given IV
48289113|NCT00302601|PROCEDURE|Scintigraphic interpretation|Not relevant
48289114|NCT05057624|OTHER|Placebo GC-MRT|Participants will hear music continuously throughout the trials, without regard to the faces they look at.
48289115|NCT05057624|OTHER|GC-MRT|Participants will hear music as a reward for looking at neutral faces and the music will stop when they focus on angry faces.
48289116|NCT05057624|OTHER|Exposure|Participants will hear music of their choice when they focus on angry faces, and when they look at neutral faces the music will stop.
48289117|NCT00432133|BEHAVIORAL|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
48289118|NCT00432133|BEHAVIORAL|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
48289119|NCT03307447|DRUG|Secukinumab|Secukinumab 300 mg subcutaneous injection
48289120|NCT02345161|DRUG|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
48289121|NCT02345161|DRUG|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
48289122|NCT02345161|DRUG|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
48289123|NCT02345161|DRUG|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
48289124|NCT02345161|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
48289125|NCT01564654|DEVICE|iTotal KRS|Total Knee Replacement System
48289126|NCT00645242|DRUG|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
48289127|NCT00004177|BIOLOGICAL|filgrastim|as prescribed by physician
48289128|NCT00004177|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks from treatment
48289129|NCT00004177|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
47941395|NCT00478881|DRUG|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
47941396|NCT00478881|DRUG|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
47941397|NCT04210323|DEVICE|ShotBlocker®|The injection area gripped with ShotBlocker®, released after the drug administration and then the ShotBlocker® was removed. After injection, light pressure was applied to the injection area with dry cotton.
48289130|NCT00004177|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
47941398|NCT04210323|DEVICE|Placebo group|The smooth surface (opposite side) of the ShotBlocker® was placed in the injection area just before administration by an experience registered nurse and the drug was injected by holding it on the skin surface during the injection. The process was managed by the researcher.
47941399|NCT03892473|OTHER|Community mental health teams (CMHT)|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
47941400|NCT03892473|OTHER|Care as usual (CAU)|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
47941401|NCT06402084|DIAGNOSTIC_TEST|abdominal ultrasound|abdominal ultrasound and lipid profile will be done
48289131|NCT00919022|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
48289132|NCT00295893|DRUG|cyclophosphamide|Given IV
48289133|NCT00295893|DRUG|docetaxel|Given IV
48289134|NCT00295893|DRUG|doxorubicin hydrochloride|Given IV
48289135|NCT00295893|BIOLOGICAL|Trastuzumab|Given IV
48289136|NCT00295893|DRUG|Carboplatin|Given IV
48289137|NCT00295893|DRUG|Paclitaxel|Given IV
48289138|NCT02997124|PROCEDURE|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
48289139|NCT02997124|PROCEDURE|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
48289140|NCT00994565|BEHAVIORAL|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
48289141|NCT03708692|BEHAVIORAL|Group F|After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
48289142|NCT01993355|OTHER|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
48289143|NCT01993355|OTHER|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
48289144|NCT01993355|BEHAVIORAL|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
48289145|NCT03205787|DIETARY_SUPPLEMENT|Trifolium pratense|Red Clover extract standardized to isoflavone content.
48473443|NCT03458364|DEVICE|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
48473444|NCT04469400|DIETARY_SUPPLEMENT|Low fat diet intensive intervention|education and Compound protein solid beverage
48631087|NCT03398382|DIETARY_SUPPLEMENT|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
48631088|NCT03398382|DIETARY_SUPPLEMENT|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
48631089|NCT03398382|DIETARY_SUPPLEMENT|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
48473445|NCT04469400|OTHER|Low-Carbon Water Diet Intensive Intervention|education and Nutrition bar
48473446|NCT01469741|BEHAVIORAL|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
48631090|NCT03398382|DIETARY_SUPPLEMENT|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
47941402|NCT00023244|DRUG|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
47941403|NCT00023244|DRUG|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
47941404|NCT00023244|DRUG|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
47941405|NCT00023244|DRUG|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
47941406|NCT00023244|DRUG|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
47941407|NCT00023244|DRUG|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
47941408|NCT00023244|DRUG|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
48102201|NCT00545376|OTHER|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
48473447|NCT04692584|BEHAVIORAL|The Lullaby Group|"Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration."
48473448|NCT01662934|DEVICE|I RUNE|
48473449|NCT01662934|DEVICE|sham|
48473450|NCT04072315|DRUG|PLN-74809|PLN-74809
48473451|NCT04072315|RADIATION|Knottin tracer|Radiotracer
48473452|NCT01706718|DIETARY_SUPPLEMENT|Bread|
48631091|NCT04375592|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute in tablet form (XPhe minis)|Intervention is a Phenylalanine-free protein substitute in tablet form. Subjects who currently take a concentrated second stage phenylalanine-free protein substitute will be recruited. Subjects will take the study product for 7 days and daily questionnaires will be completed. Subjects will replace some or all of their usual protein substitute with the new product. The amount of study product prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Daily acceptability and tolerance questionnaires will record information on ease of preparation and administration; how it is taken; and any problems or gastrointestinal effects. Additional questions at the beginning and end of the study will record information on taste, appearance, smell, presentation and packaging of the product. Routine weekly finger prick blood spots will be collected and analysed for phenylalanine and tyrosine as usual.
48631092|NCT04555369|GENETIC|ct-DNA|The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
48631093|NCT00311168|DEVICE|Intervention/treatment|"Device: VIP On~Device: VIP Off"
48631094|NCT06134414|DRUG|MY008211A tablets|dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
48631095|NCT05424809|BEHAVIORAL|Shared decision-making model|"The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation"
48631096|NCT04405388|DRUG|Placebo|Placebo will be given orally as capsule (same size and weight as Spermidine capula)
48473453|NCT02121041|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg
48631097|NCT04405388|DRUG|Spermidine|Spermidine will be given orally as capsule (4mg/day)
48631098|NCT02737787|BIOLOGICAL|WT1 Vaccine|
48631099|NCT02737787|DRUG|Nivolumab|Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
48631100|NCT02737787|BIOLOGICAL|NY-ESO-1 Vaccine|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
48473454|NCT02121041|DRUG|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
48102202|NCT06020651|DIAGNOSTIC_TEST|Arterial Doppler for Flow Mediated Reserve measurement|Arterial Doppler (ultrasound, no radiation, no contrast agent) and blood sampling twice for participants on ICIs
48473455|NCT02121041|DRUG|Losartan|Losartan 50 mg or 100 mg
48473456|NCT05637476|OTHER|Functional strength training of hip abductors|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Pelvic drop.~2. Single leg -bridge.~3. Side-lying hip abduction with hip internal rotation.~4. Lateral step-up.~5. Standing hip abduction on stance or swing leg with extra resistance ."
48473457|NCT05637476|OTHER|A selected physical therapy exercise program|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Strength dorsiflexors of the ankle-using rubber band.~2. Eccentric calf exercise (calf raise) .~3. Balance and proprioceptive exercise using wobble boards.~4. Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)"
48473458|NCT01104571|BIOLOGICAL|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery
48473459|NCT01104571|DRUG|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
48473460|NCT01104571|OTHER|laboratory biomarker analysis|
48473461|NCT01104571|PROCEDURE|adjuvant therapy|
48473462|NCT01104571|PROCEDURE|neoadjuvant therapy|
48102203|NCT05381701|PROCEDURE|Lung Ultrasound Score|Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
48102204|NCT04977271|DRUG|Venlafaxine|The Immediate Release generic formulation of this drug will be used due to its ability to be crushed for those patients who rely on parenteral administration of medications.
48102205|NCT04376814|DRUG|Favipiravir|Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days
48473463|NCT01104571|PROCEDURE|therapeutic conventional surgery|therapeutic conventional surgery
48473464|NCT04986098|DEVICE|TurboHawk|Directly remove the diseased plaque in the blood vessel to increase the effective lumen in the blood vessel
48473465|NCT04986098|DRUG|Paclitaxel|Paclitaxel
48473466|NCT06616077|DRUG|Micronized Progesterone 600 mg|Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.
48473467|NCT06616077|DRUG|mifepristone 200 mg|Post ovulatory single oral administration (LH+2, LH peak=LH+0)
48473468|NCT06616077|DRUG|Oral Placebo Tablet|Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
48473469|NCT06616077|DRUG|Placebo Vaginal|Cocoa butter
48473470|NCT01501110|DRUG|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
48473471|NCT03907241|DRUG|Octanorm 16.5%|Human normal immunoglobulin
48473472|NCT03077009|DRUG|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
48473473|NCT06160388|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
48473474|NCT05424380|DRUG|GSK3745417|GSK3745417 will be administered
48473475|NCT01910337|DEVICE|Use the Polar Cardiac rate meter|
48289146|NCT02646436|OTHER|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
48289147|NCT02646436|OTHER|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
48102206|NCT04376814|DRUG|Hydroxychloroquine|200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.
48289148|NCT01507246|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
48289149|NCT01507246|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
48289150|NCT03705923|PROCEDURE|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
48289151|NCT01804855|BEHAVIORAL|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
48289152|NCT01804855|DEVICE|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
48289153|NCT01174784|DEVICE|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
47941409|NCT06199050|OTHER|Questionnaire: SPIRIT|"T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document."
47941410|NCT06199050|OTHER|Questionnaire: HADS|Hospital Anxiety and Depression Scale, 14 questions likert scale
47941411|NCT06199050|OTHER|Questionnaire: QSC-R23|Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale
47941412|NCT06199050|OTHER|General questions|"* Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline"
47941413|NCT06199050|OTHER|Clinical data collected|"Clinical data in HIX:~* Age~* Gender~* Cancer type~* WHO status~* TNM"
47941414|NCT02905656|BEHAVIORAL|Brief Advice|Psychoeducation
47941415|NCT02905656|BEHAVIORAL|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
47941416|NCT02905656|BEHAVIORAL|Rate Reduction|Reducing the number of cigarettes consumed.
47941417|NCT02905656|DRUG|Pharmacological|Nicotine Replacement Therapy in the form of gum.
48289154|NCT01970150|DEVICE|rTMS real|
48289155|NCT04605679|PROCEDURE|Kidney Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive kidney graft
48473476|NCT00354562|DRUG|ABT-751|200mg ABT-751 daily for 14 days every 21 days
48473477|NCT00354562|DRUG|Placebo|Placebo daily for 14 days every 21 days
47941418|NCT02905656|BEHAVIORAL|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
47941419|NCT03491943|PROCEDURE|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
47941420|NCT03491943|PROCEDURE|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
48102207|NCT04376814|DRUG|Lopinavir / Ritonavir|Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
48473478|NCT00354562|DRUG|Docetaxel|Standard Docetaxel every 21 days
48473479|NCT03838341|DEVICE|AtriClip™ LAA Exclusion System|The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.
48102208|NCT04278820|DRUG|TQA3526|Tablet(s) administered orally once daily
48102209|NCT04278820|DRUG|Placebo to match TQA3526|Tablet(s) administered orally once daily
48289156|NCT00367471|DRUG|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
48289157|NCT00367471|DRUG|carboplatin|An alkylating agent used in the treatment of some cancers
48473480|NCT03838341|DRUG|Oral anticoagulation therapy|Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
48631101|NCT06243159|GENETIC|JY231|Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
48631102|NCT00505362|PROCEDURE|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
48631103|NCT01857154|DIETARY_SUPPLEMENT|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
48631104|NCT01857154|DIETARY_SUPPLEMENT|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
47941421|NCT04447612|DRUG|Durvalumab|Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy
47941422|NCT04447612|DRUG|Cisplatin|Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles
47941423|NCT04447612|DRUG|Gemcitabine|Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
47941424|NCT03871335|DIAGNOSTIC_TEST|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
48102210|NCT03143309|BEHAVIORAL|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
48102211|NCT03143309|OTHER|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
48631105|NCT01857154|DIETARY_SUPPLEMENT|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
47941425|NCT01900639|BEHAVIORAL|change time of intake of aspirin|
47941426|NCT04496310|PROCEDURE|Telemedicine|Telemedicine versus usual care (face to face visit)
47941427|NCT00001443|DRUG|indinavir (MK-0639)|
47941428|NCT04326075|DEVICE|CPAP treatment|CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
47941429|NCT01993251|DRUG|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
48102212|NCT04282980|DRUG|DCC-2618|Oral kinase inhibitor
48102213|NCT01726023|DRUG|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
48102214|NCT01726023|DRUG|metronidazole|Metronidazole 500mg/100ml solution for infusion
48102215|NCT01726023|DRUG|Meropenem|Meropenem powder for solution for infusion 1000mg
48102216|NCT00023725|DRUG|semaxanib|
48102217|NCT00023725|PROCEDURE|conventional surgery|
48102218|NCT00023725|RADIATION|radiation therapy|
48102219|NCT03108196|PROCEDURE|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
48107128|NCT00484575|DRUG|propofol|propofol given intravenously for sedation in control group
48289158|NCT00367471|DRUG|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
48289159|NCT00367471|DRUG|paclitaxel|A mitotic inhibitor used in cancer treatment
47941430|NCT01993251|DRUG|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
47941431|NCT01993251|DRUG|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
47941432|NCT01993251|DRUG|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
47941433|NCT05086744|DRUG|Iptacopan|Iptacopan 200 mg BID
47941434|NCT04942353|BEHAVIORAL|Home-based Exercise Rehabilitation.|Based on physical therapist or exercise physiologist assessment, subjects will receive an individualized exercise prescription for frequency, duration, and intensity of walking and strength training (including exercises using light-weight hand-weights and upper and lower body exercises using resistance bands). Research team will provide updated exercise prescription based on Garmin watch/Datos app activity data and Datos app data (including Borg scale).
48289160|NCT03548428|DRUG|Atezolizumab|1200mg IV every 3 weeks for 4 months
48289161|NCT03548428|RADIATION|SBRT|3 to 5 fractions depending on tumor size
48289162|NCT01809236|BIOLOGICAL|Conbercept|intravitreal injection of 0.5 mg Conbercept
48289163|NCT04036565|BEHAVIORAL|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
48289164|NCT01905735|DRUG|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
48289165|NCT01905735|DRUG|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
48473481|NCT00898768|PROCEDURE|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
47941435|NCT04942353|BEHAVIORAL|Usual Care|Patients receive a standardized recommendation to increase their walking activity to 30 minutes 5 days/week.
47941436|NCT00977808|DEVICE|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
47941437|NCT00977808|DEVICE|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
47941438|NCT04473625|OTHER|Stool Sample Collection|Subjects participating in the study will provide a stool sample within 30 days of enrollment.
47941439|NCT02686528|OTHER|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
47941440|NCT02686528|OTHER|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
47941441|NCT06480981|DRUG|Noribogaine|Noribogaine capsules
47941442|NCT06025851|DRUG|Anti-human CCL24 monoclonal antibody (CM-101)|Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)
47941443|NCT06025851|DRUG|Placebo|Placebo Comparator
47941444|NCT05236153|DIAGNOSTIC_TEST|Electroanatomic substrate mapping|Participants will undergo a sinus rhythm RV substrate map using the HD Grid catheter (Abbott) and the Ensite X electroanatomic mapping system (Abbott) prior to TPVR.
47941445|NCT01739673|OTHER|Ultraviolet-A and riboflavin|
47941446|NCT05916430|DIAGNOSTIC_TEST|EarliPoint Investigational Device|Infants will complete eye-tracking data collection at the age of 9 months on the EarliPoint Investigational Device. Eye-tracking video cameras will safely measure the movements of the child's eyes while they watch age-appropriate video scenes of other children playing together. Parents/Caregivers will complete screening forms and questionnaires about their baby's health and development. Parents/caregivers will complete surveys about their child's development. The surveys will be emailed, to be completed when the child is approximately 9, 12, 15, 18, 21, and 24 months old. If the child shows signs of developmental delay, the child will be asked to participate in a comprehensive developmental and diagnostic assessment.
47941447|NCT01610271|DEVICE|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
47941448|NCT00002567|BIOLOGICAL|filgrastim|
47941449|NCT00002567|DRUG|etoposide|
47941450|NCT00002567|PROCEDURE|peripheral blood stem cell transplantation|
47941451|NCT00002567|RADIATION|low-LET electron therapy|
47941452|NCT00002567|RADIATION|low-LET photon therapy|
47941453|NCT02545140|OTHER|No intervention|
47941454|NCT04461249|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
47941455|NCT04461249|DRUG|Travoprost 0.004% ophthalmic solution|Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
47941456|NCT04461249|DRUG|Tafluprost Ophthalmic 0.0015% Ophthalmic Solution|Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
47941457|NCT00992303|OTHER|biologic sample preservation procedure|
48102220|NCT03108196|PROCEDURE|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
48102221|NCT03737175|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting
47941458|NCT00992303|OTHER|medical chart review|
47941459|NCT00992303|OTHER|questionnaire administration|
48473482|NCT03143517|DIAGNOSTIC_TEST|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
47941460|NCT03381105|DIAGNOSTIC_TEST|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
47941461|NCT00526045|DRUG|AUY922 2 mg/m2|
47941462|NCT00950495|DEVICE|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
47941463|NCT00950495|DEVICE|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
47941464|NCT00950495|DEVICE|placebo|as a placebo, a thin (\< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
47941465|NCT05252065|OTHER|Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging|Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP are detected for cardiac biomarkers;echocardiography and cardiac magnetic resonance imaging are used to measure the functions of heart and vessels.
47941466|NCT01295931|DRUG|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
48289166|NCT04348721|OTHER|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
48289167|NCT00971321|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
48289168|NCT03990948|OTHER|Blood sampling|Blood sample collection
48289169|NCT04331704|DRUG|PrEP acronym (pre-exposure prophylaxis)|A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.
48289170|NCT04331704|BEHAVIORAL|Initial Web Survey|Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors
48289171|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) monitoring|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking
48289172|NCT04331704|BEHAVIORAL|Educational material on alcohol and sexual health behavior|Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.
48289173|NCT04331704|BEHAVIORAL|Interactive Voice Response (IVR) assessment with personalized information|Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses
48289174|NCT04331704|BEHAVIORAL|Personalized information based on web-based survey responses & standardized information|Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
48289175|NCT05606705|DIETARY_SUPPLEMENT|Baked Milk|Participants to regularly eat a baked milk muffin for 6 weeks
48289176|NCT02463591|DRUG|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
48289177|NCT03067311|BEHAVIORAL|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
48289178|NCT03067311|BEHAVIORAL|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
48289179|NCT01893177|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
48289180|NCT02048514|DEVICE|The Nellix® EndoVascular Aneurysm Sealing System|
48289181|NCT00380159|DRUG|Elvucitabine|Elvucitabine 10 mg in combination with background ART
48289182|NCT00380159|DRUG|Lamivudine|
48289183|NCT00380159|DRUG|Emtricitabine|
48289184|NCT00060892|GENETIC|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
48289185|NCT03719573|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
48289186|NCT02873546|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
48289187|NCT00124540|DRUG|misoprostol|
48473483|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10\^9 virus particles.
48473484|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10\^10 virus particles.
48102222|NCT03737175|PROCEDURE|Carotid Endarterectomy|Carotid Endarterectomy
48289188|NCT00124540|DRUG|placebo|placebo resembling misoprosotl
48289189|NCT01505062|DRUG|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
48289190|NCT02427581|BIOLOGICAL|Personalized synthetic long peptide vaccine (Poly ICLC)|
48289191|NCT02427581|DRUG|Poly ICLC|
48289192|NCT03887572|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
48289193|NCT01635569|BEHAVIORAL|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
48289194|NCT01635569|OTHER|Waitlist|Baseline and post-12 sessions
48289195|NCT01645163|BEHAVIORAL|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
48289196|NCT06498271|DEVICE|Personalized and automated digital coaching using a mobile application|Participants allocated to the experimental group will be invited to download a smartphone application which will appraise their motivation and automatically propose: 1) exercises to be performed at home and adapted to their pain levels; 2) audio recordings for pain management; and 3) educational and coaching content adapted to their motivation. In addition, the smartphone application enables users to plan their home exercises
48289197|NCT00749632|DRUG|oxybutynin|low dose oxybutynin administered daily
48289198|NCT00749632|DRUG|oxybutynin|middle dose oxybutynin administered daily
48473485|NCT01151319|BIOLOGICAL|pSG2.HIVconsv|DNA at 4mg per dose.
48473486|NCT01151319|BIOLOGICAL|MVA.HIVconsv|Attenuated poxvirus at 4x10\^8 plaque forming units per dose.
48473487|NCT01151319|OTHER|Placebo|Phosphate buffered saline
48473488|NCT01774630|DRUG|Nilotinib|300 mg/twice a day
48473489|NCT00671567|DRUG|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
48473490|NCT00671567|DRUG|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
48473491|NCT00671567|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
48473492|NCT05140317|PROCEDURE|Transcatheter heart valve implantation with or withour predilatatation|long term up to 5 years echographic and clinical follow up
47941467|NCT01295931|PROCEDURE|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
47941468|NCT00344240|BEHAVIORAL|Functional circuit training with lifestyle behavior|
47941469|NCT03480035|PROCEDURE|lightwand intubation|intubation using lightwand
47941470|NCT03766685|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
47941471|NCT00040261|DRUG|Memantine HCL|
47941472|NCT01427322|DRUG|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
47941473|NCT01427322|RADIATION|Radiation therapy|Standard radiation therapy
47941474|NCT02744469|OTHER|No intervention (observational study)|
47941475|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
47941476|NCT03480906|DRUG|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
47941477|NCT06479876|OTHER|HBCR|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
47941478|NCT06455839|BEHAVIORAL|Guided Resipiration Mindfulness Therapy (GRMT)|GRMT provides training in respiratory regulation, mindfulness and relaxation. The GRMT training will begin with a 15-minute introduction to the treatment model, followed by an hour of therapist-guided respiration (i.e., continuous rhythmic expansion of the chest, and relaxed exhalation involving release of all respiratory and peripheral musculature). The final 45 minutes will be used to discuss participant experiences during the GRMT training. GRMT training sessions will occur in-person and in a small group format (\<5 participants each).
47941479|NCT04949971|BEHAVIORAL|High volume group|Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
47941480|NCT02393690|RADIATION|Iodine I-131|Given PO
47941481|NCT02393690|OTHER|Placebo Administration|Given PO
47941482|NCT02393690|DRUG|Selumetinib|Given PO
47941483|NCT05537090|DRUG|BV100|Rifabutin for Infusion
47941484|NCT05537090|DRUG|Midazolam|Syrup for oral administration
47941485|NCT01640626|OTHER|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
47941486|NCT05938179|DRUG|HS-10353 30mg oral capsules|HS-10353 30mg oral capsules
47941487|NCT05938179|DRUG|HS-10353 50mg oral capsules|HS-10353 50mg oral capsules
47941488|NCT05938179|DRUG|Placebo for HS-10353 30mg capsules|Placebo for HS-10353 30mg capsules
47941489|NCT05938179|DRUG|Placebo for HS-10353 50mg capsules|Placebo for HS-10353 50mg capsules
47941490|NCT00737464|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
47941491|NCT02957565|BEHAVIORAL|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
47941492|NCT02957565|OTHER|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
47941493|NCT02957565|BEHAVIORAL|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
47941494|NCT06256757|PROCEDURE|fenestration|Thoracic EndoVascular Aortic Repair (TEVAR) with fenestrations
47941495|NCT04838392|DEVICE|RIGHTEST Continuous Glucose Monitoring System|RIGHTEST Continuous Glucose Monitoring System
47941496|NCT02966041|DRUG|Ondansetron|Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
47941497|NCT02966041|DRUG|Saline|Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
47941498|NCT01440062|DRUG|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
47941499|NCT01440062|DRUG|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
47941500|NCT00851760|PROCEDURE|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
47941501|NCT00851760|PROCEDURE|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
47941502|NCT03813771|DRUG|Benepali|Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
47941503|NCT03813771|DRUG|Sulfasalazine|Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
47941504|NCT03813771|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
47941505|NCT03813771|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
47941506|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
48107129|NCT00518726|BIOLOGICAL|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
48289199|NCT00749632|DRUG|oxybutynin|high dose oxybutynin administered daily
48631106|NCT05922280|OTHER|subtalar and talo-crural mobilization|"Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines."
47941507|NCT04808284|DEVICE|Transcranial direct-current stimulation|A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.
47941508|NCT04808284|DEVICE|Sham Transcranial direct-current stimulation|A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.
47941509|NCT06193577|DIETARY_SUPPLEMENT|Phaseolus Vulgaris L. Dry Extract|Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
47941510|NCT06193577|DIETARY_SUPPLEMENT|Placebo|The placebo control does not contain active ingredients.
47941511|NCT01158664|DEVICE|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
47941512|NCT01158664|DEVICE|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
47941513|NCT02616471|DIETARY_SUPPLEMENT|High-fat cheese|
47941514|NCT02616471|DIETARY_SUPPLEMENT|Low-fat cheese|
47941515|NCT02616471|DIETARY_SUPPLEMENT|No-cheese/carbohydrate|
47941516|NCT03256188|BEHAVIORAL|Active classroom|30 minutes of moderate-to-vigorous physical activity
47941517|NCT00573365|DEVICE|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
47941518|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
48289200|NCT03304951|DEVICE|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
48289201|NCT05033210|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a WHO developed support strategy that involves humane, supportive and practical help for individuals living in a serious humanitarian crisis. PFA does not necessarily involve a discussion of the event(s) that cause the distress but aims particularly at five basic elements that are crucial to promote in the aftermath of crises, i.e. a sense of safety, calm, self- and community efficacy, connectedness, and hope (Hobfoll et al., 2007). It consists of a conversation (approximately 30-45 minutes) that a helper has with a participant which can be provided remotely (e.g. videoconferencing or telephone). It has various themes; the helper provides non-intruding practical care and support, listen to needs and concerns, helps people to address basic needs (e.g. information), listens to people without pressuring them to talk, comforts people and helps them to feel calm, helps people to connect to information, services, and social support, and protects people from further harm (WHO, 2011).
48473493|NCT03408431|DEVICE|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
48631107|NCT05922280|OTHER|International Working Group of the Diabetic Foot care guidelines|"Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension"
48631108|NCT06021444|DEVICE|DKM420|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
47941519|NCT00573365|RADIATION|Radiation|Weekly radiation treatment
47941520|NCT01184131|OTHER|Mentor Training|Four 2 hour sessions of Mentor Training
47941521|NCT02730520|OTHER|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
47941522|NCT05315856|BIOLOGICAL|either BNT162b2 or ChAdOx1 vaccine|Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
48102223|NCT06630065|BEHAVIORAL|fMRI with emotional task and pupillometry|"Anatomical and functional magnetic resonance imaging (fMRI) imaging sequences with pupillometry (\~90 min)~A functional sequence - Task (\~20min):~* Emotional task in fMRI: Instructions: simply look images, then evaluate the emotions triggered at the end of each block; rating on a valence and intensity scale and intensity (arousal) scale.~* Experimental conditions: positive, negative and neutral~* Paradigm: block validated image banks: IAPS, GAPED, EMOPICS, OASIS, etc. Pupillometry: In order to collect objective data on emotional bias, we will use pupillometry (or eye-tracking) during functional MRI sequences."
48102224|NCT06630065|BEHAVIORAL|Behavioral task with emotional facial expressions|Description of the recognized emotion joy - sadness. Test to assess the hedonic value of an olfactory stimulus (10 min)
48102225|NCT06630065|GENETIC|Biological investigation|Standard biological assessment, immuno-inflammatory profile and the association of 8 mRNA editing variants
48102226|NCT03683628|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
48102227|NCT03683628|DRUG|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
48102228|NCT05313191|RADIATION|Pencil Beam Scanning Proton Therapy|Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
48102229|NCT04179227|OTHER|Questionnaire Administration|Ancillary studies
48102230|NCT04179227|OTHER|Survey Administration|Ancillary studies
48102231|NCT00159796|DRUG|Asenapine|Asenapine, 3 weeks
48102232|NCT00159796|DRUG|Olanzapine|Olanzapine, 3 weeks
48102233|NCT00159796|DRUG|Placebo|placebo, 3 weeks
48102234|NCT00424320|DRUG|Sodium bicarbonate|
48102235|NCT03935308|RADIATION|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
48102236|NCT01062880|BEHAVIORAL|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
48102237|NCT00522756|DRUG|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
48102238|NCT00522756|DRUG|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
48102239|NCT03775447|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
48289202|NCT05033210|BEHAVIORAL|Care as Usual (CAU)|In addition to PFA, both arms will be allowed to receive any usual care (CAU). CAU ranges from community care to specialised psychological treatments.
48473494|NCT03408431|PROCEDURE|neck extension|Patients' neck will be maximally extended (\~60°) during blind intubation.
48473495|NCT05507528|DEVICE|reborn treatment|Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
48631109|NCT06021444|DEVICE|Conjuran|A total of 3 doses will be applied at a dose of 2 mL over 3 weeks.
48289203|NCT05033210|BEHAVIORAL|Doing What Matters in Times of Stress (DWM)|DWM is based on the acceptance and commitment therapy (ACT), a form of cognitive-behavioural therapy, with distinct features (Hayes, Levin, Plumb-Vilardaga, Villatte \& Pistorello, 2013). ACT is based on the concept that ongoing attempts to suppress unwanted thoughts and feelings can make these problems worse, so instead it emphasises on learning new ways to accommodate these thoughts and feelings without letting them dominate. ACT has been shown to be useful for a range of mental health issues (Tjak et al., 2015) and has been used successfully in a guided self-help format (Hayes et al., 2013). DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, will be adapted for use on a smartphone or other device with internet access.
48289204|NCT05033210|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011). The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. In these 90-minute sessions participants may talk to trained non-professional helpers (who are supervised by registered (clinical) psychologists). PM+ has four core features: it is brief (five sessions); delivered by non-specialist helpers; transdiagnostic thereby addressing depression, anxiety, PTSD, stress and problems as defined by people themselves; and originally designed for people in low-income country communities but easily adaptable to different (vulnerable) populations, cultures and languages.
48289205|NCT03413644|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
48289206|NCT02424669|OTHER|ALS Functional rating Scale-revised (ALS FRS-R)|
48289207|NCT02424669|OTHER|slow vital capacity|
48289208|NCT02424669|OTHER|Blood sample|
48289209|NCT02424669|OTHER|Cerebrospinal Fluid (CSF) sample|
48289210|NCT03985137|OTHER|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
48289211|NCT00686751|DRUG|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
48289212|NCT00167908|DRUG|Ethyol (drug)|
48473496|NCT05061914|PROCEDURE|pericardial effusion drainage|tamponading pericardial effusion is a life threatenning condition , pericardiocentesis is performed for patients who are vitally unstable and with a massive amount of effusion to prevent cardiac tamponade, Surgical drainage of pericardial effusion was classically conducted by either open thoracotomy or subxiphoid pericardiectomy. Thoracoscopy has established itself as an alternative to open thoracotomy for the management of many pericardial, pleural and pulmonary disorders
48473497|NCT00932724|DRUG|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
48473498|NCT00932724|DRUG|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
48473499|NCT00558623|DIETARY_SUPPLEMENT|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
48473500|NCT00527917|DEVICE|placebo|bladder instillation
48473501|NCT00527917|DEVICE|Uracyst|20 ml sterile solution for weekly intravesical instillation
48473502|NCT00656968|DRUG|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
48631110|NCT04259242|PROCEDURE|SRP|scaling and root planing with ultrasonic scaler and manual instruments
48102240|NCT02156635|DEVICE|Transcranial direct current stimulation|
48289213|NCT06217406|DRUG|Intravenous acyclovir (ACYCLOVIR )|Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
48289214|NCT06217406|DRUG|Saline bags|Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
48289215|NCT03477916|BIOLOGICAL|FMT|fecal microbial transplantation (FMT)
48289216|NCT03477916|BIOLOGICAL|Placebo FMT|Placebo fecal microbial transplantation (FMT)
48289217|NCT03477916|DIETARY_SUPPLEMENT|Prebiotic Fiber|combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
48289218|NCT03477916|DIETARY_SUPPLEMENT|Cellulose|Cellulose
48473503|NCT00656968|DRUG|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
48631111|NCT03380988|OTHER|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
48631112|NCT03380988|OTHER|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
48631113|NCT00950924|DEVICE|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
48631114|NCT00950924|DEVICE|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
48102241|NCT02156635|BEHAVIORAL|Constraint-Induced Movement Therapy|
48102242|NCT02156635|OTHER|Placebo|
48102243|NCT02727764|GENETIC|ART-I02|Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
48102244|NCT01715909|DRUG|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams \[mg\]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for \</= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (\>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
48102245|NCT01205750|OTHER|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
48289219|NCT00690872|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
48289220|NCT00690872|DRUG|carboplatin|
48289221|NCT00690872|DRUG|gemcitabine hydrochloride|
48289222|NCT00690872|GENETIC|polymerase chain reaction|
48289223|NCT00690872|OTHER|fluorescence activated cell sorting|
48289224|NCT00690872|OTHER|immunoenzyme technique|
48289225|NCT03083912|DIETARY_SUPPLEMENT|Fortimel Complete|The residents included receive 2 bottle por day.
48289226|NCT05837260|OTHER|Sample collection only|Sample collection only
48289227|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 75 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
48289228|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 100 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
48289229|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 150 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
48289230|NCT00500071|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
48289231|NCT05460507|DRUG|Retreatment Rhenium Liposome|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
48289232|NCT04118556|BIOLOGICAL|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
48289233|NCT04118556|DRUG|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
48289234|NCT03235908|OTHER|Observation only|Observation only
48289235|NCT02682329|OTHER|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
48289236|NCT02682329|OTHER|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
48289237|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with hydroxyethylamide|The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
47941523|NCT06275581|DEVICE|Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)|Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
48289238|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)|The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
48289239|NCT02164565|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
48289240|NCT02164565|DRUG|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
48289241|NCT05284110|BEHAVIORAL|Physical activity|Multiple bouts of 3-min brisk walking, every 30 min, for 4 hours.
48289242|NCT00154505|DEVICE|Lateral trunk support of wheelchair seating|
47941524|NCT06275581|DEVICE|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)|Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
48289243|NCT04526522|OTHER|No intervention|No intervention
48289244|NCT06016543|PROCEDURE|osteopathic manipulative treatment (OMT)|Osteopathic manipulative treatment provided at the discretion of the treating physician and based on the patient's response to previous treatments.
48289245|NCT00870493|DRUG|Aliskiren|Aliskiren 300 mg daily oral
48289246|NCT00870493|DRUG|Placebo|starch tablet, 300 mg/day
48289247|NCT01268397|PROCEDURE|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
48289248|NCT01268397|PROCEDURE|closed reduction and plaster treatment|closed reduction, below elbow plaster cast, semicircular for 5 week
48289249|NCT01839994|RADIATION|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
48289250|NCT01839994|RADIATION|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
48289251|NCT01839994|DRUG|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
48289252|NCT03505242|DEVICE|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
48631115|NCT01232907|DRUG|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
48631116|NCT01784536|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
48102246|NCT01769781|DRUG|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
48102247|NCT01769781|DRUG|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
48289253|NCT03505242|DEVICE|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
48289254|NCT01101074|OTHER|This is non-intervention observational study|This is non-intervention observational study
48289255|NCT06067477|DIETARY_SUPPLEMENT|Vitamin D Supplement|Vitamin D Supplement
48289256|NCT03398772|BEHAVIORAL|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
48289257|NCT02062931|BIOLOGICAL|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
48289258|NCT03935646|DRUG|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
48289259|NCT03935646|DRUG|Placebo|Placebo
48289260|NCT04220892|DRUG|Pembrolizumab|200 mg intravenous (IV) every 3 weeks
48289261|NCT04220892|DRUG|Pemetrexed|900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
48289262|NCT04220892|DRUG|Abemaciclib|150 mg twice a day, by mouth.
48289263|NCT02265211|BEHAVIORAL|Self-Help App|
48289264|NCT03624998|OTHER|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
48631117|NCT05018819|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48289265|NCT03604328|DRUG|PA5108|single ocular implant, administered on day 1
48289266|NCT01652196|BIOLOGICAL|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
48631118|NCT00667589|DRUG|urea 40% cream|urea 40% cream applied twice per day to affected areas
48631119|NCT00667589|DRUG|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
47941525|NCT04240470|PROCEDURE|Thrombectomy|Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
48102248|NCT06328946|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
48289267|NCT01652196|DRUG|oxaliplatin|85 mg/m2 IV infused over 2 hours
48289268|NCT01652196|DRUG|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
48289269|NCT01652196|DRUG|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
48289270|NCT01652196|OTHER|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
48631120|NCT00667589|DRUG|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
48289271|NCT01652196|PROCEDURE|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
48289272|NCT01652196|RADIATION|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
48631121|NCT00667589|DRUG|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
48102249|NCT06328946|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48102250|NCT06328946|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48102251|NCT05357365|OTHER|questionnaire survey|Questionnaire survey about occupational, mental, physical factors on one's health.
48102252|NCT01570660|DRUG|Pioglitazone|12 weeks of pioglitazone treatment
48289273|NCT01652196|PROCEDURE|PET (positron emission tomography)|Correlative studies
48289274|NCT04957355|DEVICE|Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)|"Stance and Walk-Perturbation Training Protocol ActiveStep and Surefooted Protocol: Perturbation training protocol with and without FES Participants will be asked to perform a postural disturbance protocol in the stance position and walk in the form of 7 slips and 7 trips with two retention trials after the training using the ActiveStep treadmill system while fitted in a safety harness. All perturbations will be delivered at each participant's comfortable walking speed. Similar slip and trip training in walking will be conducted on the surefooted platform with and without FES.~Gait Training Protocol and Surefooted protocol Participants will be asked to perform a 10m walking test (walking for a distance of 45 feet) in a laboratory environment six times (three times with and without FES) and in an outdoor environment located in the parking lot of the Applied Health Science building (1919 W. Taylor St., Chicago, IL)"
48102253|NCT03594331|DRUG|Low-dose PvP001|Low-dose PvP001
48102254|NCT03594331|DRUG|Medium-dose PvP001|Medium-dose PvP001
48102255|NCT03594331|DRUG|High-dose PvP001|High-dose PvP001
48102256|NCT03594331|DRUG|Placebo|100 mL liquid with no drug
48102257|NCT03203018|BEHAVIORAL|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
48631122|NCT02606539|PROCEDURE|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
48102258|NCT05338905|OTHER|Palliative Therapy|Receive standard symptom management
48102259|NCT05338905|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
48102260|NCT05338905|OTHER|Questionnaire Administration|Complete quality of life questionnaire
48102261|NCT01544569|GENETIC|DNA analysis|
48102262|NCT01544569|GENETIC|fluorescence in situ hybridization|
48102263|NCT01544569|GENETIC|gene expression analysis|
48631123|NCT02606539|DRUG|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
47941526|NCT02962947|DRUG|Propranolol|80 mgR propranolol once daily
48102264|NCT01544569|GENETIC|gene mapping|
48102265|NCT01544569|GENETIC|microarray analysis|
48102266|NCT01544569|GENETIC|polymerase chain reaction|
48102267|NCT01544569|GENETIC|protein expression analysis|
48289275|NCT04373083|DRUG|Cemiplimab|Administered in 3-week intervals
48289276|NCT04373083|RADIATION|Involved-site radiotherapy (IS-RT)|Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
48289277|NCT02287246|DRUG|Extended-Release liposomal bupivacaine (Exparel)|20mL
47941527|NCT02962947|DRUG|Placebo|placebo once daily
48289278|NCT02287246|DRUG|Normal saline|20mL
48289279|NCT03396549|DEVICE|new sham tDCS|1 ch TCT transcranial stimulator
47941528|NCT05732987|OTHER|Analysis of samples|DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
47941529|NCT05732987|OTHER|Analysis of samples|RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
48289280|NCT03396549|DEVICE|real tDCS|1 ch TCT transcranial stimulator
47941530|NCT05732987|OTHER|Analysis of samples|Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.
47941531|NCT05732987|OTHER|Analysis of samples|Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
47941532|NCT04924179|DRUG|Tislelizumab plus Fruquintinib and SBRT|Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
47941533|NCT05507827|DRUG|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
48289281|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
48289282|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
48289283|NCT04837885|DRUG|LUTATHERA® by intra-arterial hepatic (IAH) injection|"One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations"
47941534|NCT05507827|DRUG|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
47941535|NCT01171664|DRUG|Placebo|Tablet, one BID
47941536|NCT01171664|DRUG|STAHIST|STAHIST in tablet form dosed one BID
47941537|NCT01721070|DRUG|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
47941538|NCT01721070|DRUG|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
47941539|NCT00006169|BEHAVIORAL|Behavioral Treatment|
47941540|NCT00069966|BIOLOGICAL|filgrastim|
47941541|NCT00069966|BIOLOGICAL|rituximab|
47941542|NCT00069966|DRUG|cisplatin|
47941543|NCT00069966|DRUG|cytarabine|
47941544|NCT00069966|DRUG|methylprednisolone|
47941545|NCT00069966|DRUG|pixantrone dimaleate|
47941546|NCT00069966|PROCEDURE|autologous bone marrow transplantation|
47941547|NCT00069966|PROCEDURE|peripheral blood stem cell transplantation|
47941548|NCT01071473|OTHER|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
47941549|NCT04048200|DRUG|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
47941550|NCT04048200|DRUG|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
47941551|NCT02783846|OTHER|normal saline|receive equal volume of normal saline
47941552|NCT02783846|DRUG|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
48289284|NCT04837885|PROCEDURE|Scan|Scans after completion of LUTATHERA® treatment injection
48289285|NCT03270787|DRUG|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
48289286|NCT03270787|DRUG|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
48289287|NCT02641704|BEHAVIORAL|Multidisciplinary program|Coordinated multidisciplinary program
48289288|NCT00377299|DRUG|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
48289289|NCT00377299|DRUG|Placebo|Placebo matching active medication in all other physical aspects
48289290|NCT00600002|BIOLOGICAL|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
47941553|NCT02783846|DRUG|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
47941554|NCT05710848|DRUG|STM-416|STM-416 monotherapy
48102268|NCT01544569|OTHER|laboratory biomarker analysis|
48102269|NCT01544569|OTHER|medical chart review|
48289291|NCT03540017|DRUG|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
48289292|NCT00201851|DRUG|Tamoxifen|20 mg po daily x 5 years
48289293|NCT00201851|PROCEDURE|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
48289294|NCT02486068|DEVICE|ABSORB scaffold|
48289295|NCT02486068|DEVICE|Xience|
48289296|NCT05329792|DRUG|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
48289297|NCT03868553|OTHER|No intervention|observational study
48289298|NCT00853905|DRUG|Triesence|At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
48289299|NCT00853905|DRUG|balanced salt solution BSS|At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
48289300|NCT00548314|OTHER|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
47941555|NCT04092569|BEHAVIORAL|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
48289301|NCT00548314|PROCEDURE|Split skin graft|
48289302|NCT00548314|DEVICE|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
47941556|NCT03830112|BEHAVIORAL|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
47941557|NCT03830112|BEHAVIORAL|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
48289303|NCT00025649|BIOLOGICAL|filgrastim|
48289304|NCT00025649|DRUG|busulfan|
48289305|NCT00025649|DRUG|carboplatin|
48289306|NCT00025649|DRUG|cyclophosphamide|
47941558|NCT01394718|DRUG|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
47941559|NCT01394718|OTHER|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
48473504|NCT03644043|DEVICE|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
48289307|NCT00025649|DRUG|doxorubicin hydrochloride|
48289308|NCT00025649|DRUG|etoposide|
48289309|NCT00025649|DRUG|melphalan|
48289310|NCT00025649|DRUG|vincristine sulfate|
48289311|NCT00025649|PROCEDURE|autologous bone marrow transplantation|
48289312|NCT00025649|PROCEDURE|conventional surgery|
48289313|NCT00025649|PROCEDURE|peripheral blood stem cell transplantation|
48289314|NCT03518840|DEVICE|SIJ Belt|Support Belts
48473505|NCT01625507|BEHAVIORAL|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
48473506|NCT06382506|DIETARY_SUPPLEMENT|Consumption of Cornbread with Hazelnut Bread|Cornbread was added to 15 grams and 30 grams of bread and consumed by the participants. Blood glucose levels were then measured. Obese and normal-weight individuals will be divided into two groups according to their anthropometric measurements.
48289315|NCT01165229|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
48289316|NCT01165229|BIOLOGICAL|Placebo|Intramuscular injection.
48289317|NCT00158977|DEVICE|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
48289318|NCT00640783|BEHAVIORAL|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
48289319|NCT00640783|BEHAVIORAL|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, \<30%).
48289320|NCT02696746|OTHER|Observation|No intervention
48289321|NCT04789785|DIAGNOSTIC_TEST|ultrasound|observation with usg
48289322|NCT03940573|DEVICE|Eclipse Insert|Rectal Control System.
48289323|NCT03863392|DRUG|Misoprostol|induction of labor
48289324|NCT00941980|BIOLOGICAL|Osteocel Plus|biologic
48289325|NCT02190591|DEVICE|Peanut Labor Ball|Peanut Labor Ball
48289326|NCT05114889|BIOLOGICAL|BSI-045B|BSI-045B will be administered weekly, subcutaneously
48289327|NCT05027269|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
48289328|NCT05027269|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
48289329|NCT03921372|DIAGNOSTIC_TEST|Isometric exercise|Squatting for 5 minutes
48473507|NCT04210349|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
47941560|NCT01836224|DRUG|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) \>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
48102270|NCT02470936|BEHAVIORAL|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
48289330|NCT02817438|BEHAVIORAL|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
48289331|NCT03854955|OTHER|iScribes|Device-based scribing service.
48289332|NCT02277886|DRUG|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
48289333|NCT02277886|DRUG|esomeprazole|40mg/tablet, one tablet once before breakfast
48289334|NCT00908297|DIETARY_SUPPLEMENT|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~* 300 mg for two weeks~* 600 mg for two weeks~* 1200 mg for two weeks~* 1800 mg for final two weeks"
48289335|NCT05981521|DIAGNOSTIC_TEST|Optimo prenatal screening test|Prenatal screening test done between weeks 11 and 13 of pregnancy to detect conditions such as trisomy 13, 18 and 21
48289336|NCT04169607|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|"Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT ."
47941561|NCT01836224|DRUG|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65
47941562|NCT01720212|DRUG|YM178|oral
47941563|NCT05428098|OTHER|education|Oral and written education according to the life model
47941564|NCT01057771|BEHAVIORAL|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
47941565|NCT01057771|BEHAVIORAL|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
48289337|NCT05212246|DRUG|5% Imiquimod cream|Topical 5% Imiquimod cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
48473508|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
48473509|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
48473510|NCT00631007|DRUG|INT131 besylate|Once-daily, oral
47941566|NCT06387537|PROCEDURE|Conventional physical therapy|Patients in this group will recieve hot pack, ROM exercises, strengthening exercises and Kaltenborn mobilizations. A total of 12 sessions, 3 sessions per week for 4 consecutive weeks. Sets and repetitions will be increased progressively.
48102271|NCT01524536|DRUG|prednisone|Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.
48473511|NCT00631007|DRUG|Pioglitazone HCl|Once-daily, oral
48473512|NCT00631007|DRUG|Placebo|Once-daily, oral
48473513|NCT03730779|DRUG|Hyperoxia|Patients will receive nocturnal normobaric hyperoxia therapy
48473514|NCT03431337|DRUG|Amoxicillin 875 mg|Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
48473515|NCT03431337|DIETARY_SUPPLEMENT|Placebo (lactase)|Placebo (in place of additional amoxicillin in experimental arm)
48473516|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with devices|Devices
48473517|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with no devices|No Devices
48473518|NCT02769650|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
48473519|NCT02769650|DRUG|Optimal medicamentous treatment|
48102272|NCT06631209|DEVICE|Transcranial Magnetic Stimulation (TMS)|Specifically, Continual Theta Burst Stimulation
48102273|NCT06631209|OTHER|Sham|Sham TMS
48473520|NCT02769650|PROCEDURE|Stress-MRI|A standard stress-MRI test with adenosine
48473521|NCT02979691|RADIATION|SIB-IMRT|
48473522|NCT02979691|DRUG|S-1|
48473523|NCT03029117|PROCEDURE|correction of rheumatic valve lesions|
48289338|NCT05212246|DRUG|Placebo Vehicle Control Cream|The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
48289339|NCT03954171|OTHER|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~* before treatment initiation (blood sample),~* during hospitalisation for surgery (blood sample),~* during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
48289340|NCT06126445|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
48289341|NCT06126445|DEVICE|Manual toothbrush|Device on plaque removal efficacy
47941567|NCT06387537|PROCEDURE|Scapular mobilization.|Scapular Mobilizations: Glides- superior, inferior, distraction, upward and downward rotation (5 sets, 10 reps, 30 sec break in 1 session).Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 consecutive weeks.
47941568|NCT02666534|DRUG|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
47941569|NCT02666534|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
47941570|NCT02666534|DRUG|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
48289342|NCT05561621|OTHER|Voice analysis|Voice analysis
48289343|NCT06304441|DRUG|Osimertinib|Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
48289344|NCT06304441|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
48289345|NCT01274377|BIOLOGICAL|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
48473524|NCT06331130|DIAGNOSTIC_TEST|Computed Tomography|Computed Tomography done according to Clinical Practice to assess mesenteric involvment
48473525|NCT04832334|OTHER|Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.|Imagery ability was determined.
48473526|NCT04832334|OTHER|Berg Balance Scale, Functional Reach Test|Balance level was determined.
48473527|NCT04832334|OTHER|Timed Up and Go Test, Functional Independence Scale|Functionality was evaluated.
47941571|NCT02666534|DEVICE|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
47941572|NCT03453411|OTHER|Non interventional study|Non interventional study
47941573|NCT05005520|DRUG|DTRI-031|Investigational drug
47941574|NCT05005520|DRUG|Placebo|Matching placebo to DTRI-031
48473528|NCT00785096|OTHER|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
47941575|NCT01762046|DRUG|Glipizide|
47941576|NCT01762046|DRUG|Metformin|
47941577|NCT01762046|OTHER|Oral Glucose Tolerance Test|
48289346|NCT03375710|DEVICE|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~1. myCordella™ Patient Management Portal~2. myCordella™ Hub~3. myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
48289347|NCT00793104|PROCEDURE|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
48102274|NCT06631014|DIAGNOSTIC_TEST|Early Rehab|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation.
48289348|NCT04132544|OTHER|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).
48289349|NCT04132544|OTHER|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home."
48289350|NCT04132544|OTHER|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
48289351|NCT04132544|OTHER|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health \[series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address."
48289352|NCT01755481|OTHER|Probiotic|
48289353|NCT01755481|OTHER|Whey protein concentrate|
48289354|NCT05643300|OTHER|Survey|Data collection from participants via questionnaire
48631124|NCT03907956|OTHER|Dry Needling with Fascial Winding Technique|"For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp."
48631125|NCT05539170|BEHAVIORAL|Immediate positive parenting feedback|Individual positive feedback concerning their parenting and their child's behavior.
48102275|NCT06631014|COMBINATION_PRODUCT|Delayed Rehab|The 2nd group of 25 patients that was fitted with Prosthesis after the time period of 6months after amputation. No physical rehab was done during this time period including physiotherapy and prosthetic treatment. Main aim was to check the significant impact of delayed rehabilitation.
48102276|NCT02891629|DEVICE|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
48102277|NCT05001906|BEHAVIORAL|Exercise group|The exercise program comprises static and dynamic breathing exercises, muscle stretching exercises and muscle strength exercises, exercises to strengthen the abdominal wall muscles, exercises to strengthen the thigh muscles - quadriceps femoris (lat. musculus quadriceps femoris), to strengthen gluteal muscles, exercises to increase pelvic mobility, exercise to improve circulation, as well as pelvic floor muscle training with relaxation techniques.
48102278|NCT01710514|DRUG|FE 999913 vaginal tablet|
48102279|NCT00233740|DEVICE|OPTEASE Vena Cava Filter|
48102280|NCT02580812|OTHER|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
48102281|NCT03755440|DRUG|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
48102282|NCT00057382|DRUG|T138067 intravenous|
48102283|NCT00057382|DRUG|doxorubicin intravenous|
48102284|NCT02294929|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
48102285|NCT04923139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Dosage at the discretion of the treating physician
48102286|NCT03835572|OTHER|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
48102287|NCT03835572|OTHER|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
48102288|NCT01145885|DRUG|BI 6727|PLK-1 inhibitor
48102289|NCT05236491|BIOLOGICAL|COVID-19 vaccine|Participants are to receive a booster dose of a COVID-19 vaccine.
48102290|NCT03658499|BEHAVIORAL|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
48289355|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.|1) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.
47941578|NCT03555773|PROCEDURE|Lipogems|After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
48631126|NCT00732459|DEVICE|Electro-acupuncture preconditioning|electro-acupuncture
47941579|NCT04199936|DEVICE|Electrical Muscle stimulation|Electrical muscle stimulation
47941580|NCT02178683|DRUG|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
47941581|NCT00611039|DRUG|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
47941582|NCT00611039|DRUG|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
47941583|NCT04232306|DRUG|Liposomal bupivacaine|Bupivacaine liposome injectable suspension
47941584|NCT04232306|DRUG|Bupivacaine HCl|Bupivacaine HCl surgical-site incision infiltration
47941585|NCT00427960|BEHAVIORAL|Dietary advice|
48289356|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.|2) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.
48631127|NCT01946802|DEVICE|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
47941586|NCT00427960|DRUG|rosuvastatin|rosuvastatin 5 mg
47941587|NCT00427960|DRUG|atorvastatin|atorvastatin 10 mg
47941588|NCT02136108|OTHER|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
47941589|NCT02136108|OTHER|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
47941590|NCT01177332|OTHER|exercise|2 hours cycling exercise at 50 % of maximal power output
47941591|NCT01812772|DEVICE|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
47941592|NCT01812772|DEVICE|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
47941593|NCT02406950|DRUG|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
47941594|NCT04121416|DRUG|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
48289357|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.|3) Sandwich with butter-like dairy product (40g milk fat) without MFGM.
48289358|NCT03856450|DEVICE|DTS|Subjects undergo wrist imaging using DTS.
48631128|NCT05409638|BEHAVIORAL|Cognitive Behavioral Therapy to manage cancer-related fatigue|Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
48631129|NCT00710554|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
47941595|NCT04121416|DRUG|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
47941596|NCT04356365|OTHER|Cross-sectional study investigating the association of NPIs with mental health|Cross-sectional study investigating the association of NPIs with mental health
47941597|NCT01309308|PROCEDURE|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
47941598|NCT01309308|OTHER|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
47941599|NCT00812747|OTHER|observation|
47941600|NCT04526301|DEVICE|Tablo Hemodialysis System|Home hemodialysis treatments \~4 times a week.
47941601|NCT00017238|DRUG|KRN5500|Given IV
47941602|NCT00017238|OTHER|pharmacological study|Correlative studies
47941603|NCT00847639|DRUG|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
47941604|NCT06166602|DRUG|PENG block with 0.25% bupivacaine.|Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
47941605|NCT04059198|DRUG|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
47941606|NCT04059198|DRUG|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
47941607|NCT05062278|DRUG|Vinblastine|Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).
47941608|NCT05062278|DRUG|Hydroxyurea capsules|Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.
47941609|NCT04526327|OTHER|exercise|the combination of aerobic and resistive exercise, three time a week
48289359|NCT03856450|DEVICE|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
48289360|NCT03856450|DEVICE|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
48289361|NCT01483573|OTHER|neural mobilization|stretch the nerve
48289362|NCT01483573|OTHER|straight leg raise|stretch the hamstring
48289363|NCT00208468|DEVICE|European Hip|A cementless femoral component for use in total hip replacement
48289364|NCT00208468|DEVICE|Zweymüller|A cementless femoral component for use in total hip replacement
48289365|NCT00208468|DEVICE|CLS Spotorno|A cementless femoral component for use in total hip replacement
48289366|NCT04751279|OTHER|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
48289367|NCT00072189|DRUG|7-hydroxystaurosporine|Given IV
48289368|NCT00072189|OTHER|laboratory biomarker analysis|Correlative studies
48289369|NCT00072189|OTHER|pharmacological study|Correlative studies
48289370|NCT04063761|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|Prospective, single center pilot study
48289371|NCT00863629|DRUG|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
48289372|NCT05431686|BEHAVIORAL|SMA visits|SMA visit once every 3 months over a 12 month period
48289373|NCT01674426|BEHAVIORAL|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
48289374|NCT00987766|DRUG|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
48289375|NCT00987766|DRUG|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
48289376|NCT00987766|DRUG|oxaliplatin|Given through a vein in the arm 1 time every other week.
48289377|NCT00987766|OTHER|laboratory biomarker analysis|Blood and tissue collection.
48289378|NCT02614846|DRUG|Hetrombopag Olamine|
48631130|NCT00710554|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
48289379|NCT01668069|DRUG|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
48289380|NCT00735332|DRUG|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
48289381|NCT02862210|DRUG|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
48289382|NCT02862210|DRUG|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
48289383|NCT04427592|DIAGNOSTIC_TEST|ultrasound|trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
48289384|NCT04427592|PROCEDURE|closure of uterine wall defect|uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
48289385|NCT05721261|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
48289386|NCT05721261|DEVICE|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
48289387|NCT03841877|PROCEDURE|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
48289388|NCT04273243|GENETIC|AT-GTX-501|No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
48289389|NCT05180669|OTHER|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
48289390|NCT05180669|OTHER|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
48289391|NCT01065480|BEHAVIORAL|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
48289392|NCT01065480|BEHAVIORAL|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
48289393|NCT05914779|OTHER|No use of antibiotics|Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
48289394|NCT05914779|OTHER|with antibiotics treatment|with antibiotics treatment
48289395|NCT03002493|DRUG|Eribulin mesylate|"Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate."
48289396|NCT03002493|DRUG|Eribulin mesylate|
48289397|NCT03002493|DRUG|Rifampicin|Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
48289398|NCT00887042|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, \& -6)
48289399|NCT02587403|DEVICE|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
48289400|NCT02587403|DEVICE|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
48289401|NCT03485612|DIAGNOSTIC_TEST|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
48289402|NCT01933984|DRUG|Bronchodilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
48289403|NCT05203965|DRUG|Mavoglurant (AFQ056)|Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.
48289404|NCT05203965|DRUG|Placebo|Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
48289405|NCT01415440|DRUG|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
48289406|NCT01415440|DRUG|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
48289407|NCT05738616|COMBINATION_PRODUCT|Lenvatinib combined with TACE and Camrelizumab|Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
48289408|NCT01237548|OTHER|Smoking Narghile for 30 min|No Other intervention will be used
48289409|NCT06476080|PROCEDURE|ultrasound guided erector spine block|Ultrasound guided thoracic erector spinae block
48289410|NCT06476080|PROCEDURE|Serratus anterior block|Ultrasound guided serratus anterior block
48289411|NCT00787735|BEHAVIORAL|Counseling compliance|Rates of attendance to call counseling session over specific time points
48289412|NCT05652660|DRUG|ARV-471|Experimental
48289413|NCT05652660|DRUG|Rosuvastatin|Probe substrate
48289414|NCT05568745|DEVICE|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
48289415|NCT05568745|DRUG|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose\*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
48289416|NCT05568745|DRUG|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
48289417|NCT06207344|DRUG|Dexmedetomidine and propofol|Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
48289418|NCT06207344|DRUG|Dexmedetomidine and desflurane|Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
48289419|NCT02446366|OTHER|Laboratory Biomarker Analysis|Correlative studies
48289420|NCT02446366|OTHER|Quality-of-Life Assessment|Ancillary studies
48289421|NCT02446366|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
48102291|NCT03658499|BEHAVIORAL|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
48289422|NCT03471910|DRUG|Diosmin|Diosmin 600mg tablet, once daily
48631131|NCT00508508|BEHAVIORAL|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
48289423|NCT03471910|DRUG|Diosmin / Hesperidin|Diosmin 900 mg / Hesperidin 100mg tablet, once daily
48631132|NCT00508508|BEHAVIORAL|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
48631133|NCT06260839|PROCEDURE|magnetic resonance neurography|preoperative magnetic resonance neurography and assisted design of surgical approach
48289424|NCT05599217|OTHER|Dietary and nutritional questionnaire|Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
48289425|NCT05599217|OTHER|Neurological function, cognitive function, and life quality assessment|Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
48289426|NCT05599217|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
48289427|NCT05599217|OTHER|Metabonomic test|Collect urine and stool samples from patients.
48289428|NCT05599217|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
48289429|NCT01380093|DRUG|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
48289430|NCT01380093|DRUG|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
48289431|NCT01380093|DRUG|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
48289432|NCT02584985|PROCEDURE|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
48289433|NCT02584985|PROCEDURE|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
48289434|NCT02559505|BIOLOGICAL|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
48289435|NCT02559505|OTHER|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
48289436|NCT02559505|BIOLOGICAL|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
48289437|NCT01535937|DRUG|Ketamine|0.5 mg/kg IV over 40 minutes
48289438|NCT01535937|DRUG|Midazolam|0.025 mg/kg IV over 40 minutes
48289439|NCT06512090|DIETARY_SUPPLEMENT|LGI steam bread|"LGI Steam bread called Mangusteam bread"
48289440|NCT06512090|DIETARY_SUPPLEMENT|Diabetic diet|the calorie intake of Diabetic diet will by recommended by nutritionist
48289441|NCT00001737|DRUG|Cyclosporin A Implant|
48289442|NCT04538352|DRUG|Semaglutide|Medication for type 2 diabetes management
48289443|NCT04538352|DRUG|Insulin Degludec|Medication for type 2 diabetes management
48289444|NCT04538352|DRUG|Insulin aspart|Medication for type 2 diabetes management (rapid-acting)
48289445|NCT03825042|DIETARY_SUPPLEMENT|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
48289446|NCT03825042|DIETARY_SUPPLEMENT|Placebo|Inactive compound in oral tablets
48289447|NCT02612714|DRUG|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
48289448|NCT04149522|DEVICE|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
47941610|NCT00845780|DRUG|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
48289449|NCT05975307|DRUG|Toripalimab|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively."
48289450|NCT05975307|DRUG|Gemcitabine|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles."
48289451|NCT05975307|DRUG|Cisplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
48631134|NCT06260839|PROCEDURE|no magnetic resonance neurography|Preoperative magnetic resonance neurography was not performed, and general minimally invasive surgery was performed
48102292|NCT03354169|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
48102293|NCT03897309|BIOLOGICAL|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
48102294|NCT03897309|BIOLOGICAL|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
48289452|NCT05975307|DRUG|Carboplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate \< 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
48289453|NCT05975307|RADIATION|Intensity-modulated radiation therapy|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions."
48631135|NCT02924116|DEVICE|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
48631136|NCT04784975|OTHER|No intervention|No intervention
48631137|NCT02839460|PROCEDURE|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
48631138|NCT01823887|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
48631139|NCT00832962|GENETIC|Genotyping|Whole blood sample
48631140|NCT00832962|OTHER|Usual prophylaxis|Prophylactic anti-RhD
48631141|NCT01296113|DRUG|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~* Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~* Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
48631142|NCT05431179|DRUG|Zilovertamab|After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
48631143|NCT05431179|DRUG|Ibrutinib|All participants will receive oral Ibrutinib (560mg) daily.
48631144|NCT05431179|DRUG|Placebo|After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
48631145|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
48631146|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
48631147|NCT05153486|PROCEDURE|Surgical ablation|Patients receive surgical ablation.
48631148|NCT02541487|DIETARY_SUPPLEMENT|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
48631149|NCT02205359|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
48631150|NCT02205359|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
48631151|NCT00397930|PROCEDURE|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
47941611|NCT05603663|GENETIC|Informing study subjects about their high CVD polygenic risk score|During a visit, the family physician will announce the value of the subject's polygenic risk for CVD (either at the start or end of the trial, depending on the group) and discuss what it means, calculate the subject's overall risk for CVD using the Kardiokompass tool, advise the subject on weight loss and physical activity, and, if necessary, commence preventive treatment. Between visits, a mobile application will be utilized to collect data about the subjects' level of physical activity and body weight as well as to send reminders to the subjects every two weeks regarding exercise and healthy lifestyle choices.
47941612|NCT02411760|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
48631152|NCT00397930|PROCEDURE|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
48289454|NCT03063073|DRUG|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]
48289455|NCT03063073|DRUG|Bupivacaine|
48631153|NCT00741221|DRUG|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
48631154|NCT00741221|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
48289456|NCT05429515|PROCEDURE|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
48631155|NCT05033535|DRUG|Sacubatril Allisartan medoxomil|Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension
48631156|NCT05033535|DRUG|Olmesartan Medoxomil|Efficacy for lowering blood pressure of Olmesartan medoxomil
48631157|NCT02046187|DIETARY_SUPPLEMENT|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
48631158|NCT02046187|RADIATION|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
48631159|NCT02046187|DRUG|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
48631160|NCT05078970|BEHAVIORAL|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
48631161|NCT05078970|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
48289457|NCT05429515|PROCEDURE|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
48289458|NCT05429515|DRUG|Chemotherapy|chemotherapy protocol will be made by hematologists.
48289459|NCT01373554|DRUG|Placebo|30mig/bid or 60mg/bid P.O
48289460|NCT01373554|DRUG|Oltipraz|30mig/bid or 60mg/bid P.O
48289461|NCT01968876|OTHER|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
48289462|NCT06143579|DRUG|FOLFOX-HAIC+Lenvatinib+Envolizumab|"FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW \< 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles."
48289463|NCT05922683|DRUG|Vivomixx|"Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks.~During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm."
48289464|NCT05922683|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
48289465|NCT05477771|PROCEDURE|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
48289466|NCT01318902|DRUG|Ixazomib|Ixazomib capsules.
48289467|NCT01318902|DRUG|Dexamethasone|Dexamethasone tablets.
48289468|NCT04901897|DEVICE|kalifilcon A|kalifilcon A daily disposable contact lens
48289469|NCT04901897|DEVICE|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
48289470|NCT04901897|DEVICE|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
48102295|NCT03897309|BIOLOGICAL|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
48289471|NCT05293938|DRUG|Obeticholic Acid 5 MG|once daily, oral administration
48289472|NCT05293938|DRUG|Obeticholic Acid 10 MG|once daily, oral administration
48289473|NCT05293938|DRUG|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
48289474|NCT03737864|BEHAVIORAL|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
48289475|NCT03737864|BEHAVIORAL|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
48289476|NCT01568944|DRUG|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
48102296|NCT01677104|DRUG|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
48102297|NCT01677104|DRUG|Placebo|
48289477|NCT01568944|PROCEDURE|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
48289478|NCT01165008|DRUG|Anakinra|
48631162|NCT05078970|BEHAVIORAL|Treatment As Usual|This assigned condition tracks the care received in typical circumstances.
48631163|NCT01968408|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
48631164|NCT01968408|DIETARY_SUPPLEMENT|Placebo|
48631165|NCT05877612|DEVICE|Implantable spinal cord stimulator|Spinal cord stimulation is possible thanks to implantable spinal cord neurostimulators. These are medical devices, which include a stimulation electrode and an implantable box, designed to deliver electrical stimulation for pain relief. The electrode is implanted in the epidural space in order to stimulate the posterior cords of the spinal cord through the dura mater, at the dorsal or cervical level.
48102298|NCT04386733|OTHER|no intervention, it was an observational study which looked at the reasons for surgical cancellations|the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
48102299|NCT06185400|DRUG|Disitamab Vedotin|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) in treatment naive NSCLC
48102300|NCT06185400|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
48102301|NCT06185400|DRUG|pyrotinib|RC48+pyrotinib after EGFR-TKIs progression
48102302|NCT00104754|DRUG|liposomal SN-38|
48102303|NCT06430125|DRUG|Nicorandil 10 MG Oral Tablet|Nicorandil 10 MG oral tablet twice daily
48102304|NCT06185192|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
48102305|NCT06315400|DRUG|Ingavirin®|60 mg/day for 5 days
48102306|NCT06315400|DRUG|Placebo|1 capsule/day for 5 days
48102307|NCT01985399|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing
48102308|NCT02452294|DRUG|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
48102309|NCT05528380|BEHAVIORAL|LPA + Fitbit Intervention|Participants will receive a Fitbit to track activity levels and participate in a 6-session lifestyle physical activity intervention over the course of 12 weeks. The intervention consists of 20-25 minute phone or video-delivered session to: (a) review PA progress and re-evaluate current step-count goals, (b) problem-solve barriers to incorporating PA into their daily lives, (c) address difficulties utilizing the Fitbit, (d) encourage the use of bouts of PA as a coping strategy, and e) engage the participant in brief discussions focused on increasing and maintaining PA.
48102310|NCT06554431|BEHAVIORAL|Self-Driven Repetitive Artmaking|Three (3) art kits which all use repetitive artmaking processes (e.g., materials for mandalas, stamp making kit, weaving kit)
48102311|NCT02480335|DRUG|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
48102312|NCT06552390|PROCEDURE|Cardiac Rehabilitation|"HRN4HTx is a phase 1 rehabilitation intervention protocol for post-heart transplant focused on the physical exercise component, and an educational plan regarding risk factors and safety criteria. The intervention protocol and its assessments are implemented by the team's rehabilitation nurses, always safeguarding the protective isolation required for these patients. The physical training protocol is divided into five stages of progressive levels of intervention. The protocol was defined following FITT parameters, international recommendations, and an integrated teaching program aimed at the therapeutic regimen exercise area. The frequency of intervention sessions is 7 days a week, twice a day (average of 13 sessions per week) throughout the hospitalization.~The intensity was defined according to Borg's modified scale of subjective perception of exertion (SPE), which must be maintained at less than 5."
48102313|NCT02814825|OTHER|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
48102314|NCT02503202|BIOLOGICAL|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
48102315|NCT02503202|BIOLOGICAL|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
48102316|NCT02503202|BIOLOGICAL|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
48102317|NCT02503202|BIOLOGICAL|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
48102318|NCT02503202|BIOLOGICAL|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
48102319|NCT05452993|DEVICE|Analysed Retinophotography|taking 2 retinophotographs per eye, and then analysed by AI software to detect Diabetic retinopathy
48102320|NCT00023218|DRUG|Lopinavir/Ritonavir|
48102321|NCT00023218|DRUG|Efavirenz|
48102322|NCT03467555|DEVICE|Class II correction using miniplates in zygomatic region|
48102323|NCT00140673|BIOLOGICAL|Rotavirus|
48102324|NCT01711307|PROCEDURE|operative|
48102325|NCT01711307|PROCEDURE|non-operative|casting within 48 hrs
48102326|NCT02653079|OTHER|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
48107130|NCT03908424|OTHER|Epidural Blood patch.|"An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura."
48289479|NCT01418755|BIOLOGICAL|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
48289480|NCT02987673|PROCEDURE|MGB/OAGB|
48289481|NCT02987673|PROCEDURE|LSG|
48289482|NCT00172380|DRUG|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
48289483|NCT01623466|DRUG|levonorgestrel|transdermal contraceptive delivery system
48289484|NCT04744415|OTHER|Epidemiology of admissions|Cardiology Intensive Care Unit admission
48289485|NCT03914547|BEHAVIORAL|REDCHiP|REDCHiP includes 10 telehealth sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
48289486|NCT03914547|BEHAVIORAL|ATTN|Provides a similar attention control. ATTN includes 10 telehealth sessions.
48107131|NCT01345838|PROCEDURE|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
48289487|NCT05265351|DIAGNOSTIC_TEST|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
48289488|NCT05265351|DIAGNOSTIC_TEST|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
48289489|NCT05285852|OTHER|Dry Needling|Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.
48289490|NCT05285852|OTHER|Placebo Dry Needling|Placebo Dry Needling only causes a pricking sensation
48289491|NCT03502135|DRUG|Tetracaine HCl and oxymetazoline HCl nasal spray|Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
48289492|NCT03431948|DRUG|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
48289493|NCT03431948|DRUG|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
48289494|NCT03431948|DRUG|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
48289495|NCT03431948|RADIATION|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
48289496|NCT01809366|PROCEDURE|seminal plasma insemination|
48289497|NCT05574543|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
48289498|NCT05574543|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
48289499|NCT02514057|OTHER|Questionnaire|Form filling only
48289500|NCT02862912|DRUG|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
48289501|NCT02862912|DRUG|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
48289502|NCT02862912|DRUG|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
48289503|NCT02862912|DRUG|Saline|Preservative free normal saline (0.3 ml) to bring the volume to \~ 2 ml
48289504|NCT06414122|OTHER|mid-frequency whole-body electromyostimulation (WB-EMS)|supervised group training sessions at least once and optionally twice a week, lasting 11-20 minutes, over 12 weeks, 12-24 training sessions in total
48289505|NCT06414122|OTHER|conventional exercise training|supervised group training at least once a week, optional additional home-based training once a week, lasting 40 minutes, over 12 weeks, 12-24 training sessions in total
48289506|NCT06414122|OTHER|nutritional therapy|conventional nutritional counselling with guidelines and digital nutritional coaching
48289507|NCT03942614|BEHAVIORAL|Nordic pole walking|
48289508|NCT00488943|DEVICE|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
48289509|NCT00211523|DRUG|MBI 226 Acne Solutions|
48473529|NCT05484609|OTHER|OUD scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
48289510|NCT03852212|OTHER|Manipulation|Thrust technique application
48631166|NCT02823561|DIETARY_SUPPLEMENT|Garcinia mangostana|
48107132|NCT05214235|DRUG|Hypoglycemic Drugs|Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
48289511|NCT04673903|OTHER|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
48289512|NCT04673903|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
48289513|NCT02007239|DRUG|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
48289514|NCT03088605|DRUG|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
48289515|NCT03088605|DRUG|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
48473530|NCT05484609|OTHER|Diabetes scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
48473531|NCT02105909|OTHER|GWAS|
48473532|NCT00559741|BIOLOGICAL|cetuximab|
48473533|NCT00559741|DRUG|fluorouracil|
48473534|NCT00559741|DRUG|irinotecan hydrochloride|
48473535|NCT00559741|DRUG|leucovorin calcium|
48473536|NCT00559741|OTHER|pharmacological study|
48473537|NCT05121168|DRUG|Active bupivacaine 0.25% via an erector spinae plane perineural catheter|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
48631167|NCT02823561|BEHAVIORAL|Control group|
48473538|NCT05121168|DRUG|Placebo normal saline via an erector spinae plane perineural catheter|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
48473539|NCT02102932|DRUG|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
48631168|NCT03280680|OTHER|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
48102327|NCT03854006|PROCEDURE|Cryoballoon pulmonary vein isolation|During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
48102328|NCT05046158|DEVICE|Transforming Powder Dressing|Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
47941613|NCT03903653|DRUG|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
47941614|NCT03903653|DEVICE|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
47941615|NCT05675982|OTHER|CAR-T cells monitoring|monitoring of circulating DNA by blood sample
47941616|NCT00234234|DRUG|Adalimumab|
48102329|NCT05046158|OTHER|Standard of care topical wound agents and dressings|Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
48102330|NCT04844957|DRUG|Vitamin D|Clinical Study
48102331|NCT04844957|DEVICE|Full automatic chemiluminescence measuring instrument|Chemiluminescence immunoassay
48102332|NCT01191463|OTHER|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
48102333|NCT01191463|OTHER|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
48102334|NCT01477619|DRUG|Tasimelteon|20mg single dose on Day 1
48102335|NCT01712594|DEVICE|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
48102336|NCT03645850|DEVICE|Vismed gel Multi 0.3% eye drops|Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
48102337|NCT03645850|DEVICE|Vismed Multi 0.18% eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
48102338|NCT04133974|BEHAVIORAL|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
48102339|NCT00280033|BIOLOGICAL|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
48102340|NCT00280033|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
48102341|NCT00280033|BIOLOGICAL|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
48102342|NCT00280033|DRUG|Placebo|Saline placebo.
48102343|NCT03198546|BIOLOGICAL|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
48102344|NCT04456920|OTHER|phone consultation|At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
48102345|NCT04456920|OTHER|e-PRO self-completed via connected objects (tablet/phone)|Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
48473540|NCT02102932|DRUG|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
48473541|NCT02102932|DRUG|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
48473542|NCT02102932|DRUG|850 mg metformin|850mg metformin tablet
48473543|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
48473544|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
48289516|NCT04076761|DRUG|Trifluridine/Tipiracil|FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
48102346|NCT04456920|OTHER|phone consultation|At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
48289517|NCT03505983|DEVICE|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
48289518|NCT03505983|DEVICE|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
48289519|NCT03505983|DEVICE|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
48289520|NCT02243176|DRUG|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
48289521|NCT02243176|DRUG|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
48289522|NCT02257606|OTHER|I-TRAVLE training|
48289523|NCT03120338|DIAGNOSTIC_TEST|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
48289524|NCT03328611|DEVICE|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
48289525|NCT02135640|DRUG|denosumab 60mg|solution
48631169|NCT03280680|OTHER|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
48631170|NCT03280680|OTHER|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
48289526|NCT02135640|DRUG|denosumab 120 mg|solution
48289527|NCT02135640|DRUG|placebo|solution
48289528|NCT01790061|PROCEDURE|Standardized FMT|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
48289529|NCT01790061|DRUG|Traditional treatments|Medications
48289530|NCT04306042|DRUG|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
48631171|NCT03300336|BEHAVIORAL|STRIDE|Implementation of STRIDE inpatient hospital mobility program
48631172|NCT05001503|DEVICE|Stability UO|STABILITY UO is a standalone software, based on a Bayesian model, which quantifies the risk of an individual patient developing severe oliguria (0.3mg/kg/hr for 6 hours). The model identifies at risk patients by predicting future urine output, using only previously recorded urine output values for that individual, allowing clinicians to see the predicted risk of a patient developing severe oliguria in real time.
48631173|NCT04679025|OTHER|Exposure - postoperative hyperglycemia|Postoperative hyperglycemia (blood or capillary glucose \> 10.0 mmol/L) within 72 hours of a surgical procedure
48107133|NCT02308137|DRUG|Domperidone|Simon-2-stage design for domperidone futility
48289531|NCT05295329|DRUG|Compound Danshen Dropping Pills|use Compound Danshen Dropping Pills
48289532|NCT05295329|DRUG|Placebo|use placebo
48289533|NCT00855712|DEVICE|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
48289534|NCT00855712|DEVICE|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
48289535|NCT04033679|OTHER|Active TDCS|Participants will receive active TDCS stimulation.
48289536|NCT04033679|OTHER|Sham TDCS|Participants will receive sham TDCS stimulation.
48289537|NCT01581411|DRUG|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
48289538|NCT02795156|DRUG|Afatinib|40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
48289539|NCT02795156|DRUG|Regorafenib|160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
48289540|NCT02795156|DRUG|Cabozantinib|60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
48631174|NCT01243125|DRUG|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
48631175|NCT01243125|DRUG|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
48289541|NCT00021866|BEHAVIORAL|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
48289542|NCT00021866|BEHAVIORAL|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
48289543|NCT02857465|DRUG|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
48289544|NCT02857465|DRUG|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
48289545|NCT02857465|DRUG|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
48289546|NCT02857465|DRUG|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
48289547|NCT01583647|DRUG|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
48289548|NCT01583647|DRUG|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
48289549|NCT00502710|DRUG|Placebo|Placebo po daily.
48289550|NCT00502710|DRUG|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
48289551|NCT01804595|OTHER|Sunscreen|
48289552|NCT01804595|BEHAVIORAL|Text-Message Reminders|
48289553|NCT01804595|OTHER|Sunscreen and Text Message Reminders|
48289554|NCT01804595|BEHAVIORAL|Education|
48289555|NCT00291304|PROCEDURE|MRI|pre-surgery
48289556|NCT06428773|OTHER|Exercise|Participants were randomly divided into two groups: the exercise group and the control group. The exercise group performed moderate-intensity aerobic exercise on a stationary bicycle ergometer for 30 minutes during hemodialysis sessions, three days a week over 12 weeks. Additionally, the exercise group engaged in walking exercise for 30 minutes, three days a week outside of hemodialysis sessions, maintaining the heart rate between 50-60%. The exercise group also performed isolated exercises to expand wrist vessels, including wrist and elbow flexion, extension, and rotation, repeated 10 times, 2-3 days a week outside of hemodialysis sessions.
48289557|NCT02218203|DRUG|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
48631176|NCT01283386|DRUG|Chlorambucil|10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
48289558|NCT02218203|DRUG|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
48289559|NCT02218203|DRUG|Placebo (Dextromethorphan)|0mg Dextromethorphan
48289560|NCT02218203|DRUG|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
48289561|NCT02977091|OTHER|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
48289562|NCT03941548|DRUG|CTP-543|Administered as 12 mg tablets.
48289563|NCT03941548|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
48289564|NCT03903055|DIAGNOSTIC_TEST|MDS group|patients diagnosed as MDS with high risk，aged 18-80，men/wemen
48289565|NCT03170284|DRUG|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
48289566|NCT04204681|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
48289567|NCT00002365|DRUG|LXR015-1|
48289568|NCT02214758|OTHER|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
48473545|NCT02102932|DRUG|850 mg metformin|850 mg metformin
48473546|NCT02102932|DRUG|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
48473547|NCT02102932|DRUG|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
48473548|NCT02102932|DRUG|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
48473549|NCT02102932|DRUG|500 mg metformin|500 mg metformin
48473550|NCT02102932|DRUG|500 mg metformin|500 mg metformin
48473551|NCT01275157|DRUG|LY2452473|Administered orally as a liquid suspension
48473552|NCT02582788|OTHER|Bathing Additive|
48473553|NCT03819920|BEHAVIORAL|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
48473554|NCT03819920|BEHAVIORAL|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
48473555|NCT00576303|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
48473556|NCT03902301|DIETARY_SUPPLEMENT|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
48473557|NCT03902301|DIETARY_SUPPLEMENT|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
48473558|NCT05463406|OTHER|The PLUS algorithm|Combination of a clinical prediction score and LUS, and if needed PCT measurement
48289569|NCT00707577|BEHAVIORAL|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
48289570|NCT04325815|DEVICE|CADDIE- Computer Aided (AI) Device used in Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
48289571|NCT04422587|OTHER|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
48289572|NCT00534846|DRUG|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
48289573|NCT00534846|DRUG|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
48289574|NCT05528276|PROCEDURE|Repair surgery|"1. a circumscribing skin incision was made 2 mm below the hypospadias meatus,~2. penile degloving,~3. the para-urethral plate incision was made,~4. A vertical midline incision of the urethral plate was made from within the hypospadiac meatus and extended up to the mid-glans.~5. The urethral plate was tubularised, beginning proximally, and closed in two layers using 6/0 polyglactin 910 suture.~6. The neomeatus was formed on a catheter 2 F larger than the urethral stent.~7. A flap was harvested from the prepuce to cover the neourethra and finally glanuloplasty.~8. A suitable urethral stent was left in situ for 7-10 days, with a compressive dressing applied.~   * Grafted tubularised incised-plate .~1.Same steps but adding a graft (dorsal inlay) , 2. The graft will be taken from the inner preputial skin . 3. The graft will be sutured to overlying plate incision line from the old meatus to the tip of the glans."
48289575|NCT05073289|BEHAVIORAL|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
48289576|NCT05073289|OTHER|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
48289577|NCT05508568|DIAGNOSTIC_TEST|ADXBLADDER|ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
48289578|NCT01197573|DRUG|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
48473559|NCT05463406|OTHER|Usual care|Management as usual
48473560|NCT00522990|DRUG|AT9283|Three weekly intravenous administration of AT9283
48473561|NCT06401434|DIAGNOSTIC_TEST|On-site radiologist|All participants in this arm will be screened by CXR. All CXR images will be interpreted by only an on-site radiologist. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
48631177|NCT01283386|DRUG|Cyclophosphamide|150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
48631178|NCT01283386|DRUG|Fludarabine|20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
48631179|NCT01283386|DRUG|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
48631180|NCT05916066|DIETARY_SUPPLEMENT|Nicotinamide|Tabletts of 500mg Nicotinamide (B3-vitamin)
48631181|NCT02170012|DRUG|PF-06743649|20 mg tablet once daily dosing for 14 days
48631182|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
48631183|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
48107134|NCT00732381|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
48631184|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
48631185|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
48631186|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
48631187|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
48631188|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
48631189|NCT02170012|DRUG|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
48631190|NCT02170012|DRUG|Placebo|Placebo tablet once daily dosing for 14 days
48631191|NCT01758081|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
48631192|NCT01758081|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
47941617|NCT01822496|RADIATION|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
47941618|NCT01822496|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
47941619|NCT01822496|DRUG|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
47941620|NCT01822496|DRUG|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
47941621|NCT01822496|DRUG|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
47941622|NCT01822496|DRUG|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
47941623|NCT01822496|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
47941624|NCT04984603|PROCEDURE|PLR in patients under VA-ECMO|After securing the VA-ECMO tubing, PLR is realized using an automatic bed elevation technique. The lower limbs are raised to a 45° angle while the patient's trunk is lowered in supine position
47941625|NCT01145612|DRUG|Losartan|Losartán dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
47941626|NCT01145612|DRUG|Atenolol|Atenolol dosage: 12.5 mg /day for patients \< 50 Kg or 25 mg/day for patients \> 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients \< 50 Kg
47941627|NCT04585373|OTHER|kinesio-taping with conventional therapy 24 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
47941628|NCT04585373|OTHER|kinesio-taping with conventional therapy 48 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
47941629|NCT04585373|OTHER|kinesio-taping with conventional therapy 72 hours|"standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa."
47941630|NCT00378586|PROCEDURE|Rectal biopsy|Rectal biopsy.
47941631|NCT00378586|PROCEDURE|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
47941632|NCT00378586|PROCEDURE|Measurement of rectal lactic acid|Equilibrium dialysis.
48631193|NCT01758081|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
48631194|NCT01758081|DIETARY_SUPPLEMENT|fish oil placebo|
48631195|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 10|One sentinel subject and 4 additional subjects will be assigned to COVID-19 vaccine HIPRA 10 µg
48631196|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 20|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 20 µg
47941633|NCT02829983|DRUG|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
47941634|NCT02829983|DRUG|Placebo|Use of placebo tablets twice a day for 3 days.
48631197|NCT05007509|BIOLOGICAL|COVID-19 vaccine HIPRA 40|One sentinel subject and 9 additional subjects will be assigned to COVID-19 vaccine HIPRA 40 µg
48631198|NCT05007509|BIOLOGICAL|Commercial COVID-19 vaccine|One subject in cohort 1 and 2 subjects in Cohort 2 and 3 will be assigned to Commercial COVID-19 vaccine
48107135|NCT00732381|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
48289579|NCT01197573|OTHER|No TPA Treatment|Standard of Care
48631199|NCT06376227|PROCEDURE|with or without Left Colic Artery Preservation|low ligation (LL) which with preservation of LCA and high ligation (HL) which without preservation of LCA
48631200|NCT00662701|PROCEDURE|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
48631201|NCT00662701|PROCEDURE|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
48289580|NCT01906840|DRUG|Turmeric|
48289581|NCT01906840|DRUG|placebo|
48289582|NCT01258829|OTHER|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
48289583|NCT01258829|OTHER|ECHO optimisation|Standard ECHO optimisation method
48289584|NCT02414295|DRUG|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
48289585|NCT05626491|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
48289586|NCT05626491|DEVICE|Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive sham treatment (no active stimulation) every other day via a headband.
48289587|NCT00091793|DRUG|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
48289588|NCT00091793|DRUG|Placebo|Placebo given at day 1, month 6, month 12 and month 18
48289589|NCT06209957|DRUG|Local corticosteroid injection|Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
48289590|NCT06209957|DRUG|Platelet-rich Plasma Local injection|Platelet-rich Plasma (From 2-step centrifugation of patient blood) Local injection.
48289591|NCT01112215|DRUG|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
48289592|NCT01112215|DRUG|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
48102347|NCT04456920|OTHER|visit|And at D10 (+/- 2 days), all patients will physically come to the Cancer center in the consultation of biopsy results announcement. At the beginning of this consultation, pain, anxiety and esthetical impact will be assessed using numeric scales. . The adverse events related to the breast biopsy will be collected as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy and its findings. Insomnia will be evaluated by the Insomnia Severity Index. If detected, pain or significative distress would be managed as usually in the center.
48102348|NCT05478772|DRUG|CTP-543|12 mg on Day 1 and Day 7
48289593|NCT04685603|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
48289594|NCT04707248|DRUG|DS-6000a|Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1
48289595|NCT04707248|DRUG|DS-6000a|Intravenous administration at RDE on Day 1 of Cycle 1
48289596|NCT02344940|DRUG|Toremifene|patients will take toremifene 60 mg qd.
48289597|NCT02344940|DRUG|Tamoxifen|patients will take tamoxifen 10 mg bid.
48289598|NCT04101422|BEHAVIORAL|Augmented Reality 1|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
48289599|NCT04101422|BEHAVIORAL|Augmented Reality 2|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
48289600|NCT04101422|BEHAVIORAL|Augmented Reality 3|Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
48289601|NCT04101422|BEHAVIORAL|Augmented Reality 4|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
48289602|NCT01916577|DRUG|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
48631202|NCT00350220|OTHER|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb \>13.0 g/dl
48289603|NCT00364910|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
48289604|NCT00364910|BEHAVIORAL|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
48289605|NCT04031014|DEVICE|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
48473562|NCT06401434|DIAGNOSTIC_TEST|CAD-based triage (with INSIGHT CXR software)|All participants in this arm will be screened by CXR. All CXR images will first be processed with the INSIGHT CXR CAD software (Lunit, South Korea) to identify the totally normal/clear CXR images; only those with the possibility of containing an abnormality (abnormality score ≥ 20) will be sent to the on-site radiologist for reading/interpretation. Participants with an abnormal CXR result from the radiologist will be indicated for follow-on diagnostic testing with the Xpert MTB/RIF Ultra assay.
48289606|NCT04031014|DEVICE|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
48631203|NCT00350220|OTHER|Low Hb transfusion group|RBCs will not be transfused unless the Hb \< 9.0 g/dl
48631204|NCT05481281|DRUG|Dexmedetomidine|I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion
48289607|NCT04336176|DEVICE|PulseFlow DF boot|Offloading boot
48289608|NCT04336176|DEVICE|Usual standard of care|Usual standard of care (offloading device)
48289609|NCT04336176|DEVICE|Sham|Sham shoe (closest to barefoot or baseline pressures)
48631205|NCT05481281|DRUG|Ketamine|0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion
48631206|NCT02869139|OTHER|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
48289610|NCT02187640|BEHAVIORAL|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
48289611|NCT02187640|BEHAVIORAL|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
48289612|NCT04952727|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
48289613|NCT04952727|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
48289614|NCT06313203|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution. The patients in this arm will also be given GemOX as systemic chemotherapy
48289615|NCT06313203|PROCEDURE|Selective Internal Radiation Therapy (SIRT)|Radioactive Yttrium 90 (Y-90) labeled particles are injected selectively into the feeding arteries of the tumour(s). This allows a high radiation dose in the lesions while limiting systemic side effects.
48289616|NCT06193148|DRUG|Jaktinib|Participants will receive Jaktinib orally for single dose
48289617|NCT06193148|DRUG|Placebo|Participants will receive Placebo orally for single dose
48289618|NCT03851601|OTHER|blood samples|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
48289619|NCT00813228|DRUG|Sitagliptin (Januvia)|
48289620|NCT05861947|DRUG|AUR106|Once or twice daily
48289621|NCT05417828|DEVICE|Emulation of Active Daily Living tasks with a robotic device (SPINDLE)|SPINDLE will provide an assistive and resistive force to aid in rehabilitating the subject's upper limb
48289622|NCT02221427|OTHER|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
48289623|NCT02221427|OTHER|Static labour progression curve (F)|
48289624|NCT05612997|OTHER|Dietary Assessment|Food Frequency Questionnaire and 24h Recalls.
48289625|NCT01611077|DRUG|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
48289626|NCT01611077|DRUG|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
48289627|NCT01611077|DRUG|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
48289628|NCT02510599|DRUG|solithromycin|
48631207|NCT02869139|OTHER|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
48631208|NCT04918797|BIOLOGICAL|COVAXIN|Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)
48289629|NCT02200107|BEHAVIORAL|self management education|
48289630|NCT02011503|PROCEDURE|Multi-layer compression therapy|Application of multi-layer compression therapy.
48289631|NCT02011503|OTHER|Application of dHACM|Application of dHACM to ulcer.
48289632|NCT04036266|PROCEDURE|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
48289633|NCT03550950|DRUG|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
48289634|NCT03550950|DRUG|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
48289635|NCT03550950|DRUG|Placebo|Matching placebo will be administered as IV infusion or SC injection.
48289636|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
48289637|NCT01815437|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
48289638|NCT01815437|DIETARY_SUPPLEMENT|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
48631209|NCT06468475|DRUG|Magnesium Sulphate infusion|Magnesium sulphate 24 hours apart by intravenous infusion at 250 mg/kg/dose (0.5 mL/kg/dose of injection magnesium sulphate 50% w/v diluted in 5 mL/kg of 5% glucose) over a duration of half an hour by an infusion pump
48631210|NCT03889795|DRUG|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
48631211|NCT03889795|DRUG|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
48631212|NCT03889795|DRUG|Digoxin|Digoxin oral pill will be taken once daily.
48631213|NCT04584983|DRUG|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
48631214|NCT04584983|DRUG|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
48289639|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Extract|Same quantity of mushroom extract in a capsule
48289640|NCT06351410|DEVICE|Eye Wearing Contact Lens|Each participant will be given 2 types of a different group of contact lenses for each eye and need to wear for 8 hours only. Measurements will be done pre and post wearing of lenses
48289641|NCT05702944|DRUG|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
48289642|NCT01207544|BEHAVIORAL|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
48289643|NCT01207544|BEHAVIORAL|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
48289644|NCT00299377|DRUG|Abciximab i.v.|
48289645|NCT00299377|DRUG|Abciximab i.c.|
48289647|NCT04628871|BIOLOGICAL|SB-318|No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
48289648|NCT04628871|BIOLOGICAL|SB-913|No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
48618003|NCT06215495|RADIATION|reduced target volume|"Delineate residual tumor(GTVp) and tumor bed(GTVtb) on enhanced contrast CT-MRI(T2 fluid attenuated inversion recovery, T2 FLAIR) fusion images. GTVtb and GTVp are expanded by 1cm to CTV_6000.~The clinical target volume_6000 cGy (CTV_6000) is partially reduced beyond the skull and midline. According to the CT-MRI(T2 FLAIR) fusion images, the edema area that cannot be seen on contrast-enhanced CT and only can be seen on MRI should be included.~If CTV_6000 includes thalamus, basal ganglia, brainstem or motor cortex, dose of these areas will be limited no more than 54Gy"
48631215|NCT04706403|BEHAVIORAL|Communication from a physician about the COVID-19 Vaccine|Participants who expressed hesitation about getting vaccinated against COVID-19 were randomized to receive one of five different versions of messages from a physician. The messages that participants in each group received varied slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns of those at risk for not being vaccinated.
48289649|NCT04628871|BIOLOGICAL|SB-FIX|No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
48289650|NCT03554590|BEHAVIORAL|carbohydrate counting|patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
48289651|NCT03554590|BEHAVIORAL|insulin therapy according to standard care|patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
48289652|NCT03094247|DRUG|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
48289653|NCT03094247|DIETARY_SUPPLEMENT|HO-RUTF|HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts
48289654|NCT03094247|DIETARY_SUPPLEMENT|D-HO-RUTF|D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts
48631216|NCT01016002|DRUG|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
48289655|NCT03094247|DIETARY_SUPPLEMENT|S-RUTF|S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts
48289656|NCT03867253|DRUG|ORY-2001 Low dose|0.6mg ORY-2001 capsule
48289657|NCT03867253|DRUG|ORY-2001 High dose|1.2mg ORY-2001 capsule
48289658|NCT03867253|DRUG|Placebo|Placebo capsule
48289659|NCT00477451|DRUG|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
48289660|NCT00477451|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
48289661|NCT00477451|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
48631217|NCT00991562|DRUG|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
47941635|NCT02829983|OTHER|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
48289662|NCT00477451|DRUG|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
48289663|NCT03237208|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
48289664|NCT03237208|DEVICE|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
48289665|NCT04205422|PROCEDURE|BIPAP|Biphasic Intermittent Positive Airway Pressure
48289666|NCT04205422|PROCEDURE|APRV|Airway Pressure Release Ventilation
48289667|NCT05734287|DIAGNOSTIC_TEST|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
48289668|NCT00213018|DRUG|Carraguard (PC-515)|
48289669|NCT03048448|DRUG|Fevipiprant|Single 450mg dose
48289670|NCT03887832|OTHER|SMBI digital app|Digital platform on the smartphone for the media package
48289671|NCT03887832|BEHAVIORAL|media package|The SMBI app contains a \<1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
48289672|NCT03887832|OTHER|standard newborn and infant care|Recommended standard pediatric primary care will be provided for infants up to 6 months.
48289673|NCT02467764|OTHER|Retrospective study|
48289674|NCT02312986|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
48289675|NCT02443844|PROCEDURE|Transurethral Resection|Endoscopic treatment of bladder cancer
48289676|NCT02443844|DRUG|Tamsulosin|Medical treatment for benign prostate hyperplasia
48289677|NCT03715257|DEVICE|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
48289678|NCT03715257|DEVICE|Tube changing catheter|"Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
48289679|NCT03653715|DEVICE|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
48631218|NCT01576965|DRUG|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
48289680|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
48289681|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
48289682|NCT03653715|DEVICE|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
48289683|NCT03901378|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
48618004|NCT06215495|RADIATION|EORTC (European organisation for research and treatment of cancer) target volume|delineate according to EORTC guideline
48618005|NCT06516471|DEVICE|Conventinal Navigation System Group|The preoperative planned model is projected onto the endoscopic display area in 3D using a mixed reality headset, accurately matching the actual anatomical structure and tissue displayed under the patient's endoscope to guide surgical resection of tumors.
48289684|NCT04201912|DIAGNOSTIC_TEST|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
48289685|NCT01738399|DIETARY_SUPPLEMENT|Coffee|
48289686|NCT01738399|DIETARY_SUPPLEMENT|Placebo|
48289687|NCT02340104|DRUG|Baricitinib|4 milligrams (mg) administered orally
48289688|NCT02340104|DRUG|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
48631219|NCT05192785|PROCEDURE|Incentive Spirometry Group|"The inspiration and expiration applications of incentive spirometry (IS) involved 10-20 breaths every one to two hours, depending on the tolerance of the patients.~During the inspiration application of IS, the head of the bed was elevated to a 45° angle, and the patient was placed in a long sitting position. The patient was requested to surround and fix the IS mouthpiece well, ensuring no gap was left between the lips. The patient was told to breathe slowly and deeply, and was asked to hold their breath for 2-3 seconds, and then to breathe normally with the IS mouthpiece in his/her mouth. The patient was advised to repeat the exercise 5-10 times, and to try to cough after every 5 exercises.~For the applied IS expiration technique applied in the study, which had not been previously encountered in literature, the patient was requested to turn the IS upside down (clockwise,180°) and to place the mouthpiece in his/her mouth and expiration application it."
48631220|NCT01084486|DRUG|Metformin|
48631221|NCT02959606|DRUG|Sarpogrelate SR 300mg|
48631222|NCT02959606|DRUG|Clopidogrel|
48631223|NCT05198310|DRUG|KPL-404|Humanized monoclonal antibody
48631224|NCT05198310|DRUG|Placebo|Matching placebo
48102349|NCT05478772|DRUG|Fluconazole|200 mg once daily on Days 3 through to Day 8
48102350|NCT03030924|DEVICE|Solace|Noninvasive physiologic monitor
48102351|NCT04567615|BIOLOGICAL|Nivolumab|Specified dose on specified days
48102352|NCT04567615|BIOLOGICAL|Relatlimab|Specified dose on specified days
48289689|NCT05585385|DEVICE|Backward Walking Training|The subjects in this group will receive BW training program on an electric treadmill. The subject will be asked to walk, arms beside, in a backward manner on a level treadmill, zero inclination, with a warming up and cooling down period (5 minutes for each period). The subject walks at his self-selected and comfortable walking speed. A warm-up and cool-down period, in form of light jogging on a treadmill, will be done at speed of 1-2 m/sec. The total training is 30 minutes, three times a week for six consecutive weeks.
48289690|NCT05585385|DEVICE|Balance Training|"Subjects in this group will receive balance training on Biodex Balance System for 3 sessions/ week, over 6 weeks period. Each subject will be instructed to stand with both legs on the locked platform. The researcher advances the platform to an unstable state while instructing the subject to focus on the visual feedback screen. Arms are free at the side of the body and not grasping handrails.~After selecting the stability training program (dynamic balance training), Stability levels are changed depending on the subject's ability to maintain balance, and subjects are instructed to maintain their Center of Pressure (COP) in the smallest concentric rings (balance zones) of the Biodex Balance System monitor, named A zone.~The stability level of the platform is set at level plate stability 8 (the most stable) for the first two sessions. After that, the plate stability is decreased by one level every two sessions to increase the difficulty in training."
48289691|NCT05585385|OTHER|Conventional treatment|Patients in this group will receive the traditional physical therapy program only for 3 sessions/ week, over 6 weeks period. The traditional physical therapy program is (evertors strengthening, short foot ex, heel raise ex, and calf stretch).
48289692|NCT05573685|DEVICE|DiNaMo Study App|Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
48289693|NCT05573685|DEVICE|Placebo App|Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
48289694|NCT05508152|DRUG|Wound irrigation with amoxicillin-clavulanate in saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes."
48289695|NCT05508152|DRUG|Wound irrigation with a saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes."
48289696|NCT02232438|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
48289697|NCT05313230|OTHER|CITRASATE SLED|Applying of CITRASATE SLED
48289698|NCT00609440|OTHER|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
48289699|NCT06244186|DIETARY_SUPPLEMENT|Probiotics|Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.
48289700|NCT06244186|DIETARY_SUPPLEMENT|Placebo|Placebo is provided by TCI CO., Ltd.
48289701|NCT00642616|DRUG|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
48289702|NCT00642616|DRUG|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
48473563|NCT04523246|BIOLOGICAL|SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.
48473564|NCT04523246|DRUG|Normal Saline|Sterile normal saline, inactive control.
48107136|NCT03684213|DRUG|Control (Norepinephrine)|This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
48289704|NCT00872898|DRUG|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
48289705|NCT00872898|DRUG|Placebo|Placebo capsules, once daily, oral administration.
48289706|NCT04361110|RADIATION|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
48289707|NCT03120910|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
48289708|NCT04512079|DRUG|Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
48289709|NCT04512079|DRUG|Apixaban|(5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
48289710|NCT01507194|DRUG|Ondansetron|Single IV dose
48289711|NCT01507194|DRUG|Vestipitant|Single IV dose
48289712|NCT00865501|DRUG|spironolactone|25mg per oral once daily
48289713|NCT00865501|DRUG|placebo|placebo
48289714|NCT02981212|DRUG|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
48289715|NCT02981212|DRUG|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
48289716|NCT02981212|DRUG|Corticosteroid|combination with Mycophenolate Mofetil
48289717|NCT02981212|DRUG|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
48289718|NCT01214512|OTHER|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
48289719|NCT02741531|OTHER|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
48289720|NCT02741531|OTHER|saline solution|Saline solution will be used to partially fill patients' bladders
48289721|NCT02214173|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
48289722|NCT02214173|DIETARY_SUPPLEMENT|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
48289723|NCT05783258|PROCEDURE|Periodontal surgery with CAF+tSCTG|Coronally advanced flap and subepithelial connective tissue graft harvested from the maxillary tuberosity area.
48289724|NCT05783258|PROCEDURE|Periodontal surgery with CAF+L-PRF|Coronally advanced flap and L-PRF membranes
48473565|NCT05042440|DRUG|Efanesoctocog alfa|Solution for injection Intravenous
48473566|NCT05042440|DRUG|Octocog alfa|Solution for injection Intravenous
48473567|NCT05042440|DRUG|Rurioctocog alfa pegol|Solution for injection Intravenous
48473568|NCT05298592|BIOLOGICAL|BMS-986406|Specified dose on specified days
48473569|NCT05298592|BIOLOGICAL|Nivolumab|Specified dose on specified days
48289725|NCT06510465|DRUG|utidelone|utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
48289726|NCT06510465|DRUG|Cisplatin|cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
48289727|NCT06510465|DRUG|Trastuzumab|Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
48289728|NCT06510465|DRUG|Pertuzumab|Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
48289729|NCT01938170|BIOLOGICAL|FluMist|Subjects receiving Flumist vaccine
48289730|NCT04150458|DRUG|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
48289731|NCT04623931|OTHER|Quality-of-Life Assessment|Ancillary studies
48289732|NCT04623931|OTHER|Questionnaire Administration|Ancillary studies
48289733|NCT04623931|RADIATION|Radiation Therapy|Undergo radiation therapy
48289734|NCT04623931|DRUG|Temozolomide|Given PO
48289735|NCT01122810|PROCEDURE|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
48473570|NCT05298592|DRUG|Carboplatin|Specified dose on specified days
48473571|NCT05298592|DRUG|Pemetrexed|Specified dose on specified days
48473572|NCT05298592|DRUG|Paclitaxel|Specified dose on specified days
48473573|NCT05310539|OTHER|assessment of the early recovery after wedge resection surgery|To assess the early recovery will be used 1 minute sit to stand, Numeric Rating scale to assess pain, incentive spirometer to assess vital capacity, Borg modified scale to assess dyspnea.
48473574|NCT04643002|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
48473575|NCT04643002|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
48473576|NCT04643002|DRUG|Pomalidomide|Pharmaceutical form: Capsule; Route of administration: Oral
48289736|NCT05368675|DRUG|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
48289737|NCT03267329|DRUG|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
48289738|NCT03267329|DRUG|Telmisartan|telmisartan 80mg
48289739|NCT03676309|DRUG|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
48289740|NCT03676309|DRUG|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
48631225|NCT00848315|BEHAVIORAL|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
48289741|NCT05899725|DRUG|Corticosteroids|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
48289742|NCT05899725|DRUG|Corticosteroids and Ruxolitinib|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
48289743|NCT02203370|DEVICE|NIRS - Near-infrared spectroscopy|
48289744|NCT05041543|DRUG|NTX-101|Eye drops, topical administration
48289745|NCT05041543|DRUG|Placebo|Placebo as eye drops
48289746|NCT05467735|OTHER|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
48289747|NCT01520922|BIOLOGICAL|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
48289748|NCT01520922|DRUG|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
48289749|NCT00676039|DRUG|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
48473577|NCT04643002|DRUG|Belantamab mafodotin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
48473578|NCT04643002|DRUG|Pegenzileukin|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
48473579|NCT04643002|DRUG|SAR439459|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
48473580|NCT04643002|DRUG|Belumosudil|Pharmaceutical form: tablet; route of administration: oral
48107137|NCT03684213|DRUG|Norepinephrine + Ascorbic Acid|This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
48289750|NCT00676039|DRUG|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
48289751|NCT00676039|DRUG|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
48289752|NCT00676039|DRUG|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
48289753|NCT01750021|DIETARY_SUPPLEMENT|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
48289754|NCT01750021|DIETARY_SUPPLEMENT|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
48289755|NCT04138667|OTHER|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
48289756|NCT04828876|BEHAVIORAL|Yoga practice|"Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received."
48289757|NCT01689506|DRUG|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
48473581|NCT04643002|DRUG|Evorpacept|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
48473582|NCT03227133|OTHER|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
48473583|NCT03227133|OTHER|Psychiatric interview|
48473584|NCT03227133|OTHER|Cardiovascular risk assessment|
48473585|NCT02608476|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
48473586|NCT02608476|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
48473587|NCT03327350|DEVICE|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
48618006|NCT05043935|PROCEDURE|L-PRF with antimicrobial photodynamic therapy|Application of L-PRF with antimicrobial photodynamic therapy in the defect
47941636|NCT04824183|OTHER|Music intervention|Three WhatsApp sessions will be delivered before the surgery. In the first session, participants will describe their experience with the diagnosis of breast cancer and acceptance. In the second session, participants will be educated on anxiety before their surgery, how anxiety is being managed in the hospital and self-care strategies for anxiety like MI, how to report preoperative anxiety. The third session will include postoperative pain education. The pain education will include information about the type of pain to expect after surgery, medications, pain reporting and MI for pain management. Telephone session; on the day of surgery and at 24 and 48 hours after surgery, a reminder will be sent to the participants by WhatsApp group chat. Face-to-face; MI delivery will involve the delivery of the MP3 to participants and monitoring of their use for 30 minutes both on the day of surgery and 24 and 48 hours after surgery.
47941637|NCT00154726|DRUG|Paclitaxel-HDFL|
47941638|NCT05027893|DRUG|Moxifloxacin 400 mg Oral Tablet|All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
47941639|NCT05027893|DRUG|Cefixime 400 mg Oral Tablet|All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
47941640|NCT05027893|OTHER|Placebo|All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
47941641|NCT02729675|OTHER|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F\&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F\&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F\&V fresh.
47941642|NCT02729675|BEHAVIORAL|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F\&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F\&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
47941643|NCT02729675|BEHAVIORAL|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
47941644|NCT03927807|DRUG|Misoprostol|"This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity."
48289758|NCT01689506|DRUG|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
48289759|NCT03863496|PROCEDURE|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
48289760|NCT05066893|OTHER|telehealth visits|intensive visits with doctor
48289761|NCT05960955|DRUG|Cadonilimab|IV infusion,Specified dose on specified days
48473588|NCT03327350|DRUG|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
48473589|NCT02853916|DIETARY_SUPPLEMENT|500 mg InSea2®|
47941646|NCT04082832|DRUG|Cu(II)ATSM|oral suspension
48289762|NCT05960955|DRUG|AK117|IV infusion,Specified dose on specified days
48289763|NCT05960955|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
48289764|NCT05960955|DRUG|Tegafur-gimeracil-oteracil potassium|Oral,Specified dose on specified days
48289765|NCT05960955|DRUG|Docetaxel|IV infusion,Specified dose on specified days
48289766|NCT05960955|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
48289767|NCT00463437|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
48289768|NCT00463437|BIOLOGICAL|Prevenar|Intramuscular injection, 1 dose.
48289769|NCT00463437|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
48289770|NCT00463437|BIOLOGICAL|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
48289771|NCT00463437|BIOLOGICAL|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
48289772|NCT00463437|BIOLOGICAL|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
48289773|NCT00463437|BIOLOGICAL|Meningitec|Intramuscular injection, 1 dose.
48289774|NCT00463437|BIOLOGICAL|NeisVac-C|Intramuscular injection, 1 dose.
48289775|NCT00463437|BIOLOGICAL|Menitorix|Intramuscular injection, 1 dose.
48289776|NCT05574972|DEVICE|Timing Carotid Stent|all the participants in this group will be performed with Timing Carotid Stent
48289777|NCT05574972|DEVICE|Carotid Wallstent|all the participants in this group will be performed with Carotid Wallstent
48289778|NCT03429556|BIOLOGICAL|Botulinum Neurotoxin Serotype E|Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
47941647|NCT04082832|DRUG|Placebos|oral suspension
48289779|NCT03429556|DRUG|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
48289780|NCT06148610|DEVICE|NewSpringForMe digital solution|Follow-up of transplanted patients for hematological diseases using the NewSpringForMe device as support of quality of life
48289781|NCT02937610|PROCEDURE|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
48289782|NCT01040832|DRUG|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
48289783|NCT01040832|DRUG|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
48289784|NCT06292312|OTHER|Craniosacral therapy|Craniosacral therapy is defined as an alternative, massage-like treatment approach using gentle manual force to address somatic dysfunctions of the head and the rest of the body.
48289785|NCT06292312|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises. Spasticity inhibition Balance and coordination exercises Walking training Stabilization exercises Breathing exercises
48289786|NCT03402763|BEHAVIORAL|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
48289787|NCT03402763|BEHAVIORAL|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
48289788|NCT00395785|DEVICE|Carotid Stent Implantation|
48289789|NCT00395785|DEVICE|Embolic Protection|
48289790|NCT06367270|DRUG|Pressured Intraperitoneal Aerosol Chemotherapy|PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.
48631226|NCT05492903|BEHAVIORAL|COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)|A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
48289791|NCT01073189|DRUG|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
48289792|NCT01073189|DRUG|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
48289793|NCT06483893|PROCEDURE|US-guided thyroid cartilage plane block (group TCPB)|Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
48289794|NCT06483893|PROCEDURE|US-guided traditional superior laryngeal nerve block (group traditional SLNB)|Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
48289795|NCT02372162|OTHER|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
47941648|NCT01352468|OTHER|Multifaceted cognitive training|Four computerized training tasks
47941649|NCT03219918|DEVICE|EndoRings II Distal Attachment|Colonoscopy cap
48107138|NCT03684213|DRUG|Norepinephrine + L-NAME|This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
48289796|NCT02372162|OTHER|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
48289797|NCT00009867|DRUG|arsenic trioxide|Given IV
48289798|NCT01737164|BEHAVIORAL|Aerobic Exercise|
48289799|NCT03537690|OTHER|Laboratory Biomarker Analysis|Correlative studies
48289800|NCT03537690|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
48631227|NCT02540434|DEVICE|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
48631228|NCT02540434|OTHER|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
48631229|NCT02540434|DRUG|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
48631230|NCT06509919|DIAGNOSTIC_TEST|Blood draw|Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.
47941650|NCT05899010|DRUG|Vaginal progesterone 600mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
48107139|NCT03684213|DRUG|Norepinephrine + L-NAME + Ascorbic Acid|This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
48107140|NCT01685788|OTHER|No intervention|
48107141|NCT00391833|DRUG|Panax Ginseng|
48473590|NCT02853916|DIETARY_SUPPLEMENT|250 mg InSea2®|
48473591|NCT02853916|DIETARY_SUPPLEMENT|Placebo|
48289801|NCT03537690|OTHER|Pharmacokinetic Study|Correlative studies
48289802|NCT05013060|DIETARY_SUPPLEMENT|Probiotics and microcapsulated sodium butyrate|The patients who give their consent to take part in this study, will receive an oral microencapsulated sodium butyrate and a mixture of probiotics formulation 2 times a day for a period of 12 weeks.
48289803|NCT05013060|DIETARY_SUPPLEMENT|Maltodextrin|The patients who give their consent to take part in this study will receive an oral maltodextrin as placebo 2 times a day for a period of 12 weeks.
48289804|NCT06513104|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
48289805|NCT06513104|DRUG|Levonorgestrel + Ethinylestradiol|Levonorgestrel + Ethinylestradiol will be administered orally.
48289806|NCT06513104|DRUG|Paracetamol|Paracetamol will be administered orally.
48473592|NCT02748655|OTHER|Alkaline ionized water|
48473593|NCT02748655|OTHER|Tap water|
48473594|NCT03561558|DRUG|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
48473595|NCT03561558|DRUG|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
48473596|NCT00676741|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48289807|NCT04103918|DEVICE|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
48473597|NCT00676741|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48473598|NCT00676741|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48473599|NCT02988271|OTHER|Interview|Participate in interview
48473600|NCT02988271|PROCEDURE|Meditation Therapy|Complete meditation therapy
48473601|NCT02988271|PROCEDURE|Quality-of-Life Assessment|Complete questionnaires
48473602|NCT02988271|PROCEDURE|Supportive Care|Receive supportive care
48473603|NCT01680016|BIOLOGICAL|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
48473604|NCT01680016|BIOLOGICAL|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
48473605|NCT04196348|PROCEDURE|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
48473606|NCT04196348|PROCEDURE|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
48473607|NCT00120315|DRUG|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
48631231|NCT03159949|OTHER|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
48289808|NCT04054713|DIAGNOSTIC_TEST|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
48289809|NCT04054713|DIAGNOSTIC_TEST|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
48289810|NCT04210570|DEVICE|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
48473608|NCT00120315|PROCEDURE|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
48473609|NCT01527838|BIOLOGICAL|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
48473610|NCT02252445|DRUG|Propofol|Propofol will be administered.
48289811|NCT04210570|DRUG|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
48289812|NCT02879500|OTHER|Diet beverages|
48289813|NCT00251069|DRUG|Glucosamine sulphate|
48289814|NCT05171738|DEVICE|skeletally anchored distal jet|used from day one and activated every month
48289815|NCT01893788|DRUG|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
48289816|NCT01893788|DRUG|Eplerenone|50 to 100 mg daily for 48 weeks
48289817|NCT02514070|DRUG|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
48289818|NCT02514070|DRUG|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
48289819|NCT06156098|OTHER|No Intervention|No Intervention
48289820|NCT06330753|OTHER|Trauma-informed Care Plan-|Per our IRB protocol patient participates will be consented for this study. A member of the healthcare team ( licensed nurse, social worker or doctor) will conduct the TICP with the patient. The TICP will be placed in the electronic medical record right below the patients name. The workflow is such is that if any plan of care placed on the Storyboard (under the patient's name) should be read first before engaging with a patient.
48473611|NCT02252445|DRUG|Sevoflurane|Sevoflurane will be administered.
48631232|NCT03159949|OTHER|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
47941651|NCT05899010|DRUG|Vaginal progesterone 800mg daily|If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
48289821|NCT06244966|DIAGNOSTIC_TEST|HIV diagnostic testing|Finger-prick capillary blood will be tested alongside venous blood
48289822|NCT03976856|DRUG|GB226|Geptanolimab, 210mg，q2w，ivgtt.
48631233|NCT06530095|OTHER|prone positioning|prone positioning
48631234|NCT05177263|OTHER|Placebo|Sterile Water
48289823|NCT03976856|DRUG|Fruquintinib|Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
48289824|NCT04705298|DIETARY_SUPPLEMENT|Prebiotic|Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
48289825|NCT04705298|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
48631235|NCT05177263|DRUG|10% Oral Dextrose Solution|10% Oral Dextrose Solution
48289826|NCT02545374|OTHER|Telemedicine|
48473612|NCT06617325|DRUG|DZP|Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
48473613|NCT06617325|OTHER|Placebo|Study participants will receive placebo at prespecified time-points.
48473614|NCT01223209|DRUG|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
48618007|NCT05043935|PROCEDURE|antimicrobial photodynamic therapy without L-PRF|application of antimicrobial photodynamic therapy without L-PRF in the defect
48631236|NCT05177263|DRUG|20% Oral Dextrose Solution|20% Oral Dextrose Solution
48631237|NCT05177263|DRUG|30% Oral Dextrose Solution|30% Oral Dextrose Solution
48289827|NCT02545374|OTHER|Control|
48289828|NCT01591590|OTHER|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
48289829|NCT01591590|OTHER|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
48289830|NCT01591590|OTHER|Blood samples (plasma preparation and CTC)|
48289831|NCT03388970|DRUG|Vitamin K 1|Research group use Vitamin K1
48289832|NCT03388970|DRUG|normal saline|Placebo group use normal saline
48618008|NCT00565461|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
48631238|NCT01127477|DRUG|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
48289833|NCT03248466|BIOLOGICAL|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
48289834|NCT06512480|PROCEDURE|colonic resection|colonic resection with the Hugo RAS robotic platform.
48289835|NCT02165540|OTHER|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
48289836|NCT00893789|DRUG|Armodafinil|Armodafinil 50 mg/day
48289837|NCT00893789|DRUG|Armodafinil|Armodafinil 150 mg/day
48289838|NCT00893789|DRUG|Armodafinil|Armodafinil 250 mg/day
48289839|NCT00893789|OTHER|Placebo|Placebo
48289840|NCT03758677|DRUG|Apatinib|30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
48289841|NCT03475394|OTHER|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
48289842|NCT03475394|OTHER|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket
48289843|NCT03475394|OTHER|Placebo|0.1 ml of Placebo gel was administered into the periodontal pocket
48289844|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
48473615|NCT01544439|PROCEDURE|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
48289845|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow-Sham|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
48289846|NCT00565955|DRUG|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; \> 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
48289847|NCT00565955|DRUG|Placebo|The patients will receive placebo tablets.
48289848|NCT00969722|BIOLOGICAL|MAb-3F8|
48473616|NCT01544439|PROCEDURE|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
48473617|NCT06613048|OTHER|Breathing exercise|"The researcher has a certificate in breathing exercises. Those who consent to participate in the study that meets the research criteria will be given training with a prepared training brochure about correct breathing technique, introduction and function of the diaphragm muscle, box breathing technique, diaphragm breathing technique and benefits of correct breathing before the exercise.~Box breathing technique will be applied in addition to standard treatment, 3 sets per day (morning, noon and evening) for 6 weeks, 10 repetitions in each set.~Diaphragm breathing exercise will be applied in addition to standard treatment, lasting 2 minutes in the first week, then increasing each week and reaching 12 minutes in the 6th week, as 3 sets (morning, noon and evening)."
48631239|NCT00215553|DRUG|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
48631240|NCT00215553|OTHER|B.3 SoC|Standard ARDS management and ICU care
48631241|NCT00215553|DRUG|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
48631242|NCT00215553|DRUG|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
48631243|NCT00215553|DRUG|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
48631244|NCT00215553|DRUG|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
48631245|NCT00215553|DRUG|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
48289849|NCT00969722|BIOLOGICAL|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
48289850|NCT00969722|BIOLOGICAL|13-cis-Retinoic Acid|
48289851|NCT01515072|OTHER|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
48289852|NCT05133427|DEVICE|TOOsonix system ONE-M|All selected BCC areas will be treated by high intensity focused ultrasound
48289853|NCT03425656|DRUG|Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide|Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
48631246|NCT04439409|DEVICE|Holter electrocardiogram|Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
47941652|NCT02464917|DEVICE|Device: simple facemask to administer supplemental oxygen|
47941653|NCT04623385|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone|"1. The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days~2. The infected patients will be treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation for 14 days"
47941654|NCT04623385|DRUG|The standard therapy|infected patients will receive the standard therapy for COVID-19 for 14 days
47941655|NCT00978432|DRUG|RAD001|10 mg/day for Part 1 of the trial
47941656|NCT00978432|DRUG|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
47941657|NCT00978432|DRUG|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
47941658|NCT05976438|DRUG|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.
47941659|NCT05976438|DRUG|Chlortalidone|Chlortalidone 25mg will be one of the study drugs the patients will receive.
47941660|NCT02438306|BIOLOGICAL|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
47941661|NCT02438306|OTHER|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
47941662|NCT05887648|BEHAVIORAL|SinDance|"One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise."
47941663|NCT05990998|DRUG|68Ga-DOTATATE and 68Ga-FAPI|Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
47941664|NCT01717144|BEHAVIORAL|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
47941665|NCT02172053|OTHER|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
48102353|NCT05139095|DRUG|Camrelizumab plus apatinib CohortA|Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
48102354|NCT05139095|DRUG|Camrelizumab plus apatinib Cohort B|Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
47941666|NCT02172053|OTHER|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
47941667|NCT02474680|GENETIC|Pharmacogenetic testing|Psychotropic genotyping panel
47941668|NCT05875467|OTHER|SE3 Game|A prototype online game designed to increase environmental health literacy
47941669|NCT04536831|DRUG|Vitamin D|Vitamin D will be given to group A selected by Lottery method
47941670|NCT04536831|DRUG|Normal saline|Vitamin D will be given to group B slected by Lottery method
47941671|NCT06217601|BEHAVIORAL|Digital intervention through Tablet|Web-based multi-domain lifestyle training intervention will be conducted to promoted and focus three lifestyles: nutritional advice, exercise and cognitive training; chat communication with research team, and personalized agenda on daily activities and an information library.
48473618|NCT03209024|OTHER|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
48631247|NCT02581423|DRUG|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
47941672|NCT04463511|OTHER|Polyethylene bag before the umbilical cord is clamped|"11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)"
47941673|NCT05023798|DEVICE|ATD (device test)|Medical device test (no intervention)
47941674|NCT00397410|DEVICE|Hip protectors|
47941675|NCT04456010|OTHER|Questionnaire|Eligible patients will be selected from our electronical database and invited via email to participate.
47941676|NCT04186481|DEVICE|MINITAC Ti 2.0 suture anchor|The MINITAC◊ Ti 2.0 Suture Anchor is intended to provide secure reattachment of soft tissue to bone in the foot and ankle as well as elbow, wrist and hand.
47941677|NCT04437953|DRUG|Avatrombopag|"Patients will receive an initial dose of Avatrombopag 60 mg on Day 1. Starting on Day 2, the dose will be Avatrombopag 20 mg daily. Once a patient has reached a platelet target of \> 100,000/mcL patients can initiate systemic cancer therapy. Avatrombopag will be continued as maintenance (subscript m) and titrated weekly with a goal to maintain a platelet count of ≥ 100,000/mcL during administration of systemic cancer therapy. Duration of maintenance therapy will be at least 12 weeks (indicated by Week 1m, Week 2m, ... 12m) starting from time of platelet correction and resumption of systemic cancer therapy. End of Treatment (EOT) is up to 15 weeks on study Week 12m."
47941678|NCT06483074|DRUG|Empagliflozin 10 MG|empagliflozin oral 10mg daily for 6 months
47941679|NCT01590992|BEHAVIORAL|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
47941680|NCT01590992|BEHAVIORAL|Relaxation therapy|Progressive muscle relaxation (Jacobson)
47941681|NCT00704808|PROCEDURE|Primary surgical treatment|Primary surgery for tumor resection.
47941682|NCT00704808|RADIATION|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
47941683|NCT00704808|DRUG|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
48102355|NCT03612804|BEHAVIORAL|Unsigned note to provider about cessation medication prescription|For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note for the provider about the recommended medication indicated by VA formulary guidelines.
48289854|NCT03471221|BEHAVIORAL|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~1. Specific treatment goals are not planned for each visit.~2. Volunteers and treatment providers are not required to take detailed notes.~3. Visit content and activities are spontaneous.~4. Visit length can be as long or as short as needed."
48289855|NCT04613011|DEVICE|Ultrasound|Checking vein width snd copression using US
47941684|NCT02435329|OTHER|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
47941685|NCT02399007|DEVICE|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
47941686|NCT02399007|DEVICE|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
47941687|NCT01244698|DRUG|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
47941688|NCT01244698|DRUG|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
47941689|NCT04295655|OTHER|Global Exercise intervention|The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
48102356|NCT03612804|BEHAVIORAL|Proactive Telephone Counseling from VA Quitline|Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
48102357|NCT04358328|OTHER|Comprehensive geriatric assessment (CGA) and care|Comprehensive geriatric assessment and care including geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions.
48102358|NCT04358328|OTHER|Standard care|Standard pre-, peri- and post operative care.
48102359|NCT02709174|PROCEDURE|blood draw|blood draw
48102360|NCT03526835|DRUG|MCLA-158|full-length IgG1 bispecific antibody targeting EGFR and LGR5
48107142|NCT05949125|OTHER|Cyclophosphamide (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
48289856|NCT02906046|DEVICE|Weight in Lower Limbs|
48289857|NCT04718064|DRUG|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
48289858|NCT04718064|DRUG|placebo|placebo once daily, for three consecutive days,
48289859|NCT02688855|DEVICE|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
48289860|NCT02688855|DEVICE|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
48289861|NCT00249262|DRUG|Taxoprexin|
48289862|NCT03114969|DEVICE|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
48289863|NCT03114969|DEVICE|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
48289864|NCT03114969|DEVICE|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
48289865|NCT03114969|DEVICE|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
47941690|NCT04295655|OTHER|Functional Electrostimulation Group|"The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103."
47941691|NCT04295655|OTHER|Standard treatment|Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
47941692|NCT04804020|PROCEDURE|NC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to the patients' uterus or adnexa. The second ultrasound will be performed on the sixth day of the cycle. Daily ultrasound and serum estradiol and LH level evaluation will be performed when the mean diameter of the dominant follicle of ≥14 mm. LH surge initiation is defined as a concentration of 180% above the latest serum value available in that patient with a continued rise thereafter9 to a level of 20 IU/l or more10 detected by the ECLIA method (Roche Cobas® E 801, Roche Diagnostics, Germany). Embryo transfer will be scheduled by the time of the initiation of LH and embryo stages.
47941693|NCT04804020|PROCEDURE|mNC|The first ultrasound scan will be performed on the second to the fourth day of the menstrual cycle to identify any problem related to patients' uterus or adnexa. A second ultrasound scan will be performed on the sixth day of the cycle; if there is at least one follicle with a diameter of ≥12 mm, an ultrasound scan will be performed daily. When the dominant follicle's mean diameter is ≥16 mm, human chorionic gonadotropin (Ovitrelle® 250 μg; Merck, Kenilworth, NJ, USA) will be injected to trigger ovulation. Embryo transfer will be scheduled by the time of the hCG injection and embryo stages.
48289866|NCT03114969|DEVICE|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
48289867|NCT03114969|DEVICE|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
48289868|NCT03114969|DEVICE|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
48289869|NCT03730389|DEVICE|External Physical Vibration Lithecbole (EPVL)|Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
48289870|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
48102361|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + Pembrolizumab|MCLA-158 in combination with pembrolizumab (non-IMP) will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.
48102362|NCT03526835|COMBINATION_PRODUCT|MCLA-158 + FOLFIRI|MCLA-158 in combination with FOLFIRI (non-IMPs) will be explored first in mCRC patients in the 2L setting.
48289871|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
48289872|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
48289873|NCT00482001|DRUG|donepezil|
48289874|NCT00482001|DRUG|Placebo (cornstarch)|
48289875|NCT01269034|DRUG|Exenatide|1.25 mcg before the boost sub-cutaneously.
48289876|NCT01269034|DRUG|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
48289877|NCT01269034|DRUG|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
48289878|NCT01745055|DRUG|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
48289879|NCT01745055|DRUG|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
48289880|NCT00196937|BIOLOGICAL|Cervarix|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
48289881|NCT01571271|PROCEDURE|Laser Lithotripsy|Laser Lithotripsy
48289882|NCT01571271|PROCEDURE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
48289883|NCT04740749|DEVICE|Compress Compliant Pre-Stress System|Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
48289884|NCT05190575|DRUG|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
48289885|NCT00488527|DRUG|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
48289886|NCT04240743|DEVICE|cephalomedullary nail|For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
48289887|NCT04240743|DEVICE|sliding hip screw|For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
48289888|NCT02316444|BIOLOGICAL|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
48289889|NCT04371510|OTHER|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
48289890|NCT00360022|OTHER|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
48289891|NCT03202121|OTHER|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
48289892|NCT03202121|OTHER|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
48289893|NCT03202121|OTHER|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
48289894|NCT00232570|DRUG|quetiapine|
48289895|NCT05127772|DRUG|HEC93077|Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
48289896|NCT05127772|DRUG|Placebo|Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
48289897|NCT05768906|OTHER|observational|Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians
48289898|NCT06128837|DRUG|Irinotecan hydrochloride liposome Injection|Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk
48289899|NCT06128837|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
48631248|NCT05742750|DRUG|Camrelizumab and Apatinib Plus GP|"Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason."
48631249|NCT05326100|OTHER|Conventional Therapy (CPT)|The exercises may include traditional vestibulo-ocular reflex (VOR) exercises, cervical musculoskeletal exercises, somatosensory exercises, habituation, gait exercises, and aerobic conditioning. The treating PT will modify specific exercises as appropriate based on the participant's symptoms.
48102363|NCT02057354|BEHAVIORAL|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
48107143|NCT05949125|OTHER|Fludarabine (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
48107144|NCT05949125|DRUG|R-TM123|Intravenous infusion over 20 days
48289900|NCT01217281|PROCEDURE|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
48289901|NCT03982225|DRUG|Polyene phosphatidylcholine injection|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
48289902|NCT03982225|DRUG|Placebo|Phosphate buffered saline placebo for injection
48289903|NCT04407507|DRUG|Ivermectin|ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
48289904|NCT04407507|DRUG|Placebo|Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
48289905|NCT02146846|DRUG|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
48289906|NCT04612088|BEHAVIORAL|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
48289907|NCT00003270|BIOLOGICAL|anti-thymocyte globulin|IV
48289908|NCT00003270|BIOLOGICAL|filgrastim|IV
48289909|NCT00003270|DRUG|busulfan|IV
48289910|NCT00003270|DRUG|cyclophosphamide|IV
48289911|NCT00003270|DRUG|cyclosporine|IV
48289912|NCT00003270|DRUG|methylprednisolone|IV
48473619|NCT03209024|DEVICE|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
47941694|NCT04804020|PROCEDURE|AC|The endometrium is prepared using oral estradiol valerate (Valiera®; Laboratories Recalcine) 8 mg/day, ranging from the second or fourth menstruation day. The endometrial thickness will be monitored from day six onwards, and vaginal progesterone (Utrogestan®; Besins) 800 mg/day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must be lasting for ≥9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages.
47941695|NCT02171702|DRUG|BIBW 2992|
48473620|NCT02371837|OTHER|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
47941696|NCT00925990|DRUG|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
47941697|NCT00925990|DRUG|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
47941698|NCT00925990|DRUG|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
47941699|NCT01387373|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
48102364|NCT02057354|BEHAVIORAL|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
48102365|NCT01921543|DEVICE|ITP Stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
48102366|NCT01921543|DEVICE|CI/BNST stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
48102367|NCT01921543|DEVICE|No stimulation|
48102368|NCT00440284|DRUG|conventional vs. flexible, intensive insulin therapy|
48102369|NCT00893373|DRUG|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
48102370|NCT00893373|DRUG|placebo|Standard AML chemotherapy plus placebo
48102371|NCT00603538|DRUG|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
48102372|NCT00006204|DRUG|naltrexone (Revia)|
48102373|NCT00006204|DRUG|fluoxetine (Prozac)|
48102374|NCT02181348|DRUG|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
48102375|NCT02181348|DRUG|placebo (edible oil)|
48102376|NCT00651378|DRUG|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
48102377|NCT00651378|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
48102378|NCT00651378|DRUG|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
48102379|NCT00728637|BEHAVIORAL|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
48102380|NCT00728637|BEHAVIORAL|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
48102381|NCT01360190|DRUG|fluoxetine|fluoxetine 20 mg. daily
48102382|NCT02957292|DRUG|Levonorgestrel (13,5 mg) intrauterine device|
48102383|NCT02957292|DEVICE|Cooper (380mm2) intrauterine device|
48102384|NCT04135209|DIAGNOSTIC_TEST|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
48102385|NCT00208507|DEVICE|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
48102386|NCT00208507|DEVICE|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
48102387|NCT02684565|DIETARY_SUPPLEMENT|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
48102388|NCT02684565|DIETARY_SUPPLEMENT|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
48107145|NCT05949125|DRUG|Allo-RevCAR01-T|A single dose of Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1. Allo-RevCAR01-T will not be administered again within this study.
48107146|NCT03504072|DRUG|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
48289913|NCT00003270|PROCEDURE|bone marrow ablation with stem cell support|IV
48289914|NCT00003270|PROCEDURE|umbilical cord blood transplantation|IV
48289915|NCT00003270|RADIATION|radiation therapy|High energy X-rays
48289916|NCT06005506|DIETARY_SUPPLEMENT|Prebiotic fiber|Moradyn active prebiotic fiber product
48473621|NCT05824494|DRUG|Cadonilimab|Cadonilimab 10mg/kg,every 3 weeks,IV infusion
48473622|NCT05824494|DRUG|Nab paclitaxel|Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
48473623|NCT03843515|DRUG|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
48473624|NCT02875041|DEVICE|Transcranial Magnetic Stimulation (TMS)|
48473625|NCT02875041|DEVICE|MAGSTIM Rapid2|
48289917|NCT06005506|DIETARY_SUPPLEMENT|Dietary fiber|Fibregum non-active fiber product
48289918|NCT06005506|DIETARY_SUPPLEMENT|Probiotic|Defense Plus probiotic complex
48473626|NCT03124134|DEVICE|Gelesis200|Encapsulated hydrogel
48473627|NCT03124134|OTHER|Water, only (placebo)|300 mL of water
47941700|NCT04597918|DRUG|Faricimab|A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
48102389|NCT06106659|DEVICE|Mini Midline|"The tube was placed in the upper arm in the test group and in the forearm in the control group. The veins were selected according to anatomical criteria (vein diameter and depth), and the puncture site was protected with a sterile cavity towel. The cannulation nurse wore sterile gloves and injected local anesthesia (1 mL of lidocaine) before venipuncture. Venipuncture was always performed using real-time ultrasound-guided visualization of the vein-guiding needle using an out-of-plane approach, and once the tip of the needle was visualized within the vein and the blood flowed back through the needle, a guidewire was introduced and the needle was removed. After the needle is removed, the cannula is advanced into the vein, the guidewire is removed, and the cannula is attached to an extension cord closed with a needleless connector."
48102390|NCT01632930|OTHER|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
48102391|NCT04539951|DRUG|Sertraline 200 milligram(mg)|All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
48289919|NCT04215692|DIAGNOSTIC_TEST|Pulmonary ultrasound|Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
48289920|NCT05248958|OTHER|Turkish Validity and Reliability of The CRAVE Scale|The aim of this study is to adapt the Cravings for Rest and Volitional Energy Expenditure (CRAVE) scale to Turkish society and to make its validity and reliability in Turkish.
48473628|NCT02086344|PROCEDURE|PBS|TLH plus PBS
48473629|NCT02086344|PROCEDURE|TLH _adnexal preservation|TLH without PBS
48473630|NCT03239496|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
48473631|NCT03239496|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
48473632|NCT05423093|BEHAVIORAL|Single-Session Virtual Group Psychoeducational Session about Postpartum Depression|Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
48473633|NCT03496987|DEVICE|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
48473634|NCT05141630|PROCEDURE|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
48473635|NCT01899196|BIOLOGICAL|blood sampling,|
48473636|NCT02361957|DIETARY_SUPPLEMENT|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
48631250|NCT05326100|DEVICE|CAREN Therapy|The CAREN, an FDA-registered exempted Class I device, is a VR-based system which includes a six degree-of-freedom motion platform with an embedded, instrumented treadmill surrounded by an immersive 180-degree screen. The CAREN can display a variety of virtual environments (VEs), where the difficulty level and task requirements can be easily modified by the treating clinician to target patient-specific needs.
48631251|NCT05326100|DEVICE|Augmented Reality (AR) Therapy|AR head-mounted displays are designed to provide immersive virtual environments similar to the CAREN, but with the portability to be used in most outpatient clinical settings and potentially for at-home therapy as well as significantly reduced cost compared to the CAREN. AR devices have integrated eye-tracking and inertial measurement units (IMUs) which can be used to objectively quantify characteristics of eye, head and body movement.
48473637|NCT02361957|DIETARY_SUPPLEMENT|Placebo|Placebo
48473638|NCT02913820|OTHER|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
48473639|NCT00831233|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
48473640|NCT00831233|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
47941701|NCT02389075|PROCEDURE|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
48631252|NCT00354211|DEVICE|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
48631253|NCT03004092|PROCEDURE|blood sample|Twice weekly blood sample, and at every outpatient visit
47941702|NCT02389075|PROCEDURE|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
47941703|NCT04177238|DIETARY_SUPPLEMENT|Fruit concentrate - either cherry or blueberry|Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
48289921|NCT05558345|BEHAVIORAL|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
47941704|NCT04005170|DRUG|Toripalimab|Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
47941705|NCT04005170|DRUG|Paclitaxel/Cisplatin|Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
47941706|NCT04005170|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
47941707|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
48473641|NCT00831233|DRUG|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
48473642|NCT05398835|BEHAVIORAL|Online interventions promoting HIV self-testing|1) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
48473643|NCT00117117|DRUG|Aranesp|
48473644|NCT02335957|RADIATION|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
48473645|NCT00332943|PROCEDURE|MR colonography with fecal tagging|
48473646|NCT00670033|DRUG|Travoprost ophthalmic solution (new formulation)|
48473647|NCT00670033|DRUG|Travoprost ophthalmic solution, 0.004%|
48473648|NCT00670033|DRUG|Vehicle|Inactive ingredients used as a placebo
48473649|NCT01938235|DRUG|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
48473650|NCT01938235|DRUG|Placebo|Intravenous bolus and 24-hour infusion of placebo
48473651|NCT00035555|DRUG|Belatacept|Solution, intravenous
48473652|NCT00035555|DRUG|Cyclosporine|Oral, capsule
48473653|NCT00035555|DRUG|Mycophenolate mofetil (MMF)|Oral, capsule
48473654|NCT00035555|DRUG|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
48473655|NCT04231409|DEVICE|Boston Scientific Spectra WaveWriter SCS System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
48473656|NCT02523794|OTHER|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
48473657|NCT02523794|OTHER|Placebo|Purified Drinking Water
48473658|NCT02206841|PROCEDURE|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
48473659|NCT02206841|DEVICE|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
48473660|NCT02206841|DEVICE|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
48473661|NCT02206841|DEVICE|Transient elastography|Transient elastography will be performed for evaluate fibrosis of liver.
48473662|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil|Ready to Use Therapeutic Food
48473663|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
48473664|NCT01593969|DIETARY_SUPPLEMENT|Standard RUTF|Standard formulation RUTF given according to National Guidelines
48473665|NCT06210945|DRUG|10 mg/kg CM-101|10 mg/kg CM-101
47941708|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
47941709|NCT01545453|DRUG|lebrikizumab|subcutaneous dose every 4 weeks
48473666|NCT06210945|DRUG|Placebo|Placebo
48473667|NCT02569541|DRUG|sodium fusidate|
48631254|NCT06413407|BEHAVIORAL|Tai Chi Exercise|Tai Chi Exercise will be applied to this group.
48289922|NCT05340400|OTHER|ROME IV Criteria|Collaborators will use Rome IV criteria for diagnosing IBS by the presence of the abdominal pain at least once a week in the last 3 months, in addition to at least two of the following: abdominal pain related to defecation, change in stool frequency, or shape.
48289923|NCT00749086|DEVICE|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
48289924|NCT00749086|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
48473668|NCT03088878|DRUG|Cirmtuzumab (2-16 kg/mg) plus Ibrutinib|Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
48473669|NCT03088878|DRUG|Cirmtuzumab (300mg) plus Ibrutinib|Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
48631255|NCT06413407|BEHAVIORAL|Receptive Music Therapy|Receptive Music Therapy will be applied to this group.
48631256|NCT06413407|BEHAVIORAL|Experimental|Tai Chi Exercise and Receptive Music Therapy techniques will be applied together to this group.
48631257|NCT02112227|OTHER|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
48631258|NCT04483947|DRUG|AZD2693|Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
47941710|NCT01545453|DRUG|placebo|subcutaneous dose every 4 weeks
47941711|NCT03388437|DEVICE|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
48289925|NCT02924753|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
47941712|NCT03388437|DEVICE|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
47941713|NCT03538678|OTHER|Kwit smartphone app|Kwit smarphone app
47941714|NCT06231836|DEVICE|High flow nasal cannula (HFNO)|O2 is administered by HFNO with flow 70L/min and the FiO2 is set at 40%,
47941715|NCT06231836|DEVICE|nasal cannula|O2 is administered by nasal cannula at 6L/min
47941716|NCT00001431|DRUG|gemcitabine|
47941717|NCT06448585|DRUG|Specific immunotherapy (SIT) treatment|Treatment with subcutaneous polymerized 100 specific immunotherapy (SIT) in its initiation phase with rapid (clustered) dosing, where the highest allergen concentration (0.2 + 0.3 mL) is administered directly, with an interval of 30 to 45 minutes between injections, in allergology consultations of the SES.
47941718|NCT06448585|DIETARY_SUPPLEMENT|Dietary Supplement: ABB C1|"Ingredients: betaglucanos, levadura Saccharomyces cerevisiae, selenio y zinc.~1 sachet/day; contains 3 grams"
47941719|NCT06448585|DIETARY_SUPPLEMENT|Mini-tablets with pork extract|Mini-tablets with pork extract containing the diamine oxidase enzyme (3 mini-tablets/day)
47941720|NCT04570722|OTHER|Ipsilateral peripheral IV insertion|Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur
47941721|NCT05419531|OTHER|prospective observational study - screening and follow up colonoscopy|Involves two visits and a colonoscopy. The first visit will be prior to the colonoscopy. 4-35 days after the colonoscopy, there will be a one time appointment to go over the results of the colonoscopy.
48289926|NCT02924753|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
48289927|NCT02924753|BIOLOGICAL|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
48473670|NCT03088878|DRUG|Cirmtuzumab (600 mg) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
48631259|NCT04483947|OTHER|Placebo|Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
48631260|NCT03514537|PROCEDURE|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
48631261|NCT03514537|DEVICE|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
48631262|NCT03514537|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
48631263|NCT03514537|DRUG|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
48631264|NCT03514537|DRUG|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
48631265|NCT02492776|DRUG|Omeprazole|20 mg oral capsules administered once daily for 8 days
47941722|NCT05191979|OTHER|Exercise regiment (aerobic exercise on bike)|Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
47941723|NCT02436642|DEVICE|AVERT Plus System|
48289928|NCT01166269|BIOLOGICAL|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
48289929|NCT01166269|BIOLOGICAL|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
48631266|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
47941724|NCT03606395|DRUG|NV-5138|single ascending dose
47941725|NCT03606395|DRUG|Placebos|Placebo liquid solution to mimic NV-5138
47941726|NCT05834413|DRUG|chemotherapy plus TCM 1&ICIs plusTCM2 placebo|"In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
47941727|NCT05834413|DRUG|chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo|"Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy."
47941728|NCT01244945|DIETARY_SUPPLEMENT|L. reuteri DSM 17938|L. reuteri will be administered at 1x10\^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10\^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10\^8 CFU/die) for 90 days.
47941729|NCT01244945|OTHER|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
47941730|NCT03694912|PROCEDURE|Partial or radical nephrectomy|The investigators perform partial or radical nephrectomy those diagnosed as RCC.
47941731|NCT04595240|DIAGNOSTIC_TEST|semen analysis|semen analysis
47941732|NCT04644445|DIETARY_SUPPLEMENT|Bariatric Full Liquid Diet|Patient's will receive a Bariatric Full Liquid Diet (standard bariatric clear liquid diet + protein shakes) to be started 4 hours after surgery
48289930|NCT01166269|OTHER|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
48289931|NCT02054832|DIETARY_SUPPLEMENT|Glycosade|
47941733|NCT05826184|BEHAVIORAL|Time restircted eating|8 hour time restricted eating alone
48289932|NCT02764840|OTHER|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
48289933|NCT02764840|OTHER|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
48289934|NCT05969080|BEHAVIORAL|Treatment for Self-Injurious Behaviors|Treatment for Self-Injurious Behaviors (T-SIB) incorporates evidence-based approaches to replace NSSI with behaviors that improve psychosocial functioning.
48289935|NCT05969080|OTHER|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
48289936|NCT04965714|BIOLOGICAL|Nivolumab|Given IV
48289937|NCT04965714|BIOLOGICAL|Pegargiminase|Given IM
48289938|NCT04965714|PROCEDURE|Resection|Undergo surgical resection
48289939|NCT05024760|DRUG|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
48289940|NCT05024760|DRUG|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
48631267|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
48631268|NCT00710788|DRUG|sevelamer phosphate-binders|1600 mg/day for 2 years
48631269|NCT00710788|DRUG|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
47941734|NCT05826184|BEHAVIORAL|Time restricted eating + prebiotic|8 hour TRE with a prebiotic supplement
47941735|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
47941736|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
47941737|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
47941738|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
47941739|NCT00666796|DRUG|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
47941740|NCT00666796|DRUG|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
48289941|NCT00315601|DRUG|Telithromycin|800 mg once a day for 5 days
48289942|NCT00315601|DRUG|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
48289943|NCT00315601|PROCEDURE|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
47941741|NCT00666796|DRUG|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
48289944|NCT00315601|DRUG|Telithromycin|Telithromycin 800 mg once a day
48289945|NCT05994625|DEVICE|Stream™ Platform|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage."
47941742|NCT00666796|DRUG|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
47941743|NCT02609698|DEVICE|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
48289946|NCT05994625|DEVICE|Stream™ Platform with Risk Score Omitted|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform."
48289947|NCT03993743|BIOLOGICAL|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
48289948|NCT01037712|DRUG|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
48289949|NCT01037712|DRUG|Placebo|placebo
48289950|NCT06481189|BIOLOGICAL|GNR-086|The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.
48289951|NCT06481189|BIOLOGICAL|Ilaris®|The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.
48473671|NCT03088878|DRUG|Cirmtuzumab (RDR) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
48289952|NCT05863429|BIOLOGICAL|Taking biological samples (blood) and keeping records with phone calls|Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
48289953|NCT05121246|DRUG|MB05 (Proposed palivizumab biosimilar)|Single IM dose of 3 mg/kg
48289954|NCT05121246|DRUG|EU-Synagis®|Single IM dose of 3 mg/kg
48289955|NCT05121246|DRUG|US-Synagis®|Single IM dose of 3 mg/kg
48289956|NCT02631187|DEVICE|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
48473672|NCT03088878|DRUG|Cirmtuzumab plus ibrutinib|Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
47941744|NCT02609698|DRUG|3 months DAPT|
47941745|NCT02609698|DRUG|6 months DAPT|
47941746|NCT02563132|PROCEDURE|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
47941747|NCT00701376|OTHER|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
47941748|NCT02025062|OTHER|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
47941749|NCT05933070|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent. INKumne is a replication-incompetent tumor cell line that does not require donor matching.
47941750|NCT04843852|DRUG|Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]|one 0.5ml intramuscular injection on day 0 and week 4.
48289957|NCT00419250|DRUG|lenalidomide|
48289958|NCT00419250|DRUG|lenalidomide|
48289959|NCT00419250|DRUG|lenalidomide|
48289960|NCT00419250|DRUG|lenalidomide|
48289961|NCT00419250|DRUG|lenalidomide|
48289962|NCT01145105|PROCEDURE|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
48289963|NCT01145105|PROCEDURE|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
48473673|NCT03088878|DRUG|Ibrutinib alone|Arm B: Participants will receive ibrutinib (420 mg) orally once daily
48473674|NCT04628845|DEVICE|Endo-perio therapy with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
48473675|NCT04628845|DEVICE|Endo-perio therapy without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
48618009|NCT00919672|DEVICE|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
48631270|NCT02971189|DEVICE|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
48631271|NCT01501513|DRUG|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
48631272|NCT01501513|DRUG|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
48631273|NCT01501513|DRUG|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
47941751|NCT04163679|PROCEDURE|Vaginal Preparation|"One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick."
48102392|NCT04539951|DRUG|Sertraline 300 milligram(mg)|In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
48102393|NCT04539951|DRUG|Fluvoxamine|Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
48102394|NCT04539951|DRUG|Venlafaxine|venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
48102395|NCT04539951|DRUG|Augment with Memantine|Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
48102396|NCT04539951|DRUG|Augment with Aripiprazole|Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
48102397|NCT04921423|BEHAVIORAL|Situational simulation teaching|The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
48102398|NCT03189134|DRUG|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
48289964|NCT03410147|DIAGNOSTIC_TEST|13C-octanoate breath test for gastric emptying|"The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations."
48289965|NCT02360943|OTHER|4 blood samples|PK and / or PD measurements during hospitalization
48289966|NCT03127020|DRUG|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
48289967|NCT03749642|DRUG|trazodone/gabapentin 2.5/25 mg|The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
47941752|NCT06271486|DRUG|Pregabalin 75mg|Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
48102399|NCT03189134|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
48102400|NCT05997199|DIETARY_SUPPLEMENT|Vitamin D replacement|Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
48102401|NCT03784963|DRUG|Omega 3 fatty acids|Patients will receive 4 grams fish oil once daily
48102402|NCT03784963|OTHER|Placebo|Standard of care
48618010|NCT04660383|DEVICE|Inspiratory Muscle Training|Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.
47941753|NCT06271486|BIOLOGICAL|An epidural blood patch (EBP)|Group B (EBP group) received active therapy in the form of an EBP
48107147|NCT03504072|DRUG|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
48107148|NCT05262270|DRUG|Extended-Release Naltrexone|XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
48107149|NCT05262270|DRUG|Extended Release Buprenorphine|Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
48289968|NCT03749642|DRUG|trazodone/gabapentin 5/50 mg|The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
47941754|NCT06271486|COMBINATION_PRODUCT|conservative treatment.|Group C (control group) received conservative treatment providing recommendations to the patients, including 24 hours of bed rest, stool softener, and consuming a minimum of 2.0 liters of fluid daily. Analgesics were permitted for pain relief depending on the patient's disease status.
47941755|NCT00351546|DRUG|Vildagliptin|
48289969|NCT03749642|DRUG|trazodone/gabapentin 10/100|The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
48289970|NCT03749642|DRUG|Gabapentin|"The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)"
48102403|NCT03076736|BEHAVIORAL|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
48289971|NCT03749642|DRUG|Placebo oral capsule|Two capsules, three times a day, for 8 weeks.
48289972|NCT03342443|DRUG|Memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
48631274|NCT04784494|DEVICE|Magnetic Seizure Theapy (MagPro XP MST)|"MST treatment will be administered over the frontal/vertex cortex using 100 Hz stimulation using the MagPro XP MST with Cool TwinCoil. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~MST treatments will be administered twice a week, for up to 16 treatments. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
48631275|NCT05565547|DEVICE|META|The META device is used for a comprehensive ophthalmic examination.
48631276|NCT05565547|DEVICE|Commercial devices|Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
48631277|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
47941756|NCT05637671|DRUG|oxybutynin ER|One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
47941757|NCT05637671|DRUG|Paroxetine CR|the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
47941758|NCT01218282|BEHAVIORAL|Home exercise training|20-30 min/day for at least 4 days/week
47941759|NCT01218282|BEHAVIORAL|NO Exercise Training|No intervention
47941760|NCT02237911|OTHER|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
47941761|NCT02237911|OTHER|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
47941762|NCT02285283|DRUG|Itraconazole|
47941763|NCT02285283|DRUG|Placebo|
47941764|NCT02765776|OTHER|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
47941765|NCT06143111|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
48102404|NCT03076736|BEHAVIORAL|Resource pack|Resource pack with information on living with aphasia and local community activities.
48102405|NCT01701713|DEVICE|DKI ED2011|
48102406|NCT01701713|DEVICE|Sham-TDCS|
48289973|NCT03342443|DRUG|Placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
48473676|NCT01592721|BIOLOGICAL|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
48473677|NCT03624855|OTHER|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
48618011|NCT05944796|OTHER|Diathermy|The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)
47941766|NCT06143111|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
47941767|NCT03324672|PROCEDURE|TRIGGER|only TRIGGER point will be included for the manual therapy
47941768|NCT03324672|PROCEDURE|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
47941769|NCT05618431|OTHER|NIPT|This research aims to develop and validate a new method for non-invasive prenatal testing
47941770|NCT00009061|DRUG|Ritonavir|
47941771|NCT00009061|DRUG|Abacavir sulfate|
48102407|NCT02235857|DEVICE|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
48289974|NCT01828125|PROCEDURE|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-\[6,6-2H2\] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-\[6,6-2H2\] glucose. A third catheter will be inserted for sampling. D-\[6,6-2H2\] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
48289975|NCT01828125|DRUG|Glucagon|
48289976|NCT04169828|DRUG|Methotrexate|Children in both the intervention and control group will receive Methotrexate dosed as prescribed by the attending rheumatologist
48289977|NCT04169828|DRUG|Ondansetron|"Children in the intervention group will be prescribed premedication with oral ondansetron.~Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate"
48289978|NCT04169828|DRUG|Folic/folinic acid|Children in both intervention and control group will receive folic acid or folinic acid dosed as prescribed by the attending rheumatologist.
48289979|NCT03176212|DIETARY_SUPPLEMENT|Milk fat globule membrane|
48618012|NCT05944796|OTHER|Placebo|The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)
47941772|NCT00009061|DRUG|Nelfinavir mesylate|
47941773|NCT00009061|DRUG|Lamivudine|
47941774|NCT00009061|DRUG|GW433908|
47941775|NCT03709641|DEVICE|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
48289980|NCT04318574|OTHER|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
48289981|NCT04096937|OTHER|Focus groups|Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
48289982|NCT02524080|PROCEDURE|Triage to optimal healthcare level|Triage to optimal healthcare level
48618013|NCT01772082|BEHAVIORAL|Internet mediated walking program|
48631278|NCT00684138|DEVICE|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
47941776|NCT04601337|PROCEDURE|Infrared Neural Stimulation|We will stimulate nerves identified for transfer or grafting over a range of simulation parameters (pulse width, spot size, energy per unit area, etc) to determine the stimulation threshold. Only portions of the nerve that are no longer functionally required will be stimulated optically. Successful INS events will be determined by visual muscle contractions. Stimulation thresholds will be determined by fitting the data to a cumulative distribution function. Stimulation sites on the nerve will be harvested and histologically examined for evidence of INS-induced damage.
47941777|NCT04689815|DRUG|Oral Arsenic Trioxide Formulation|Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day, from days 1 - 7 per cycle) plus azacitidine (75mg/m2 per day subcutaneously, from days 1 to 3 per cycle). Each cycle of oral-As2O3 plus azacitidine will be given once every 28 days. The total duration of treatment is 12 months (12 cycles). Treatment will be day-care and outpatient based. Reduction in the dosage and duration of oral-As2O3 is required if the subject is experiencing adverse events (AEs). In case of grade 3 or above toxicity, the dosage of oral-As2O3 will be reduced to 5mg per day.
48289983|NCT01678846|BEHAVIORAL|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
48289984|NCT02362438|GENETIC|scAAv9/JeT-GAN|scAAV9/JeT-GAN is a biological gene transfer reagent
48289985|NCT02388776|DEVICE|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
48289986|NCT01388400|OTHER|conventional occupational therapy|upper limb exercises
48289987|NCT01388400|DEVICE|video capture virtual reality|virtual reality delivered uppe limb exercises
48289988|NCT05552638|OTHER|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
48289989|NCT03255278|BIOLOGICAL|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
48473678|NCT03427476|DRUG|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
48473679|NCT01413763|DRUG|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
48473680|NCT01413763|DRUG|Placebo cream|placebo cream applied daily for 2 weeks
48473681|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
48473682|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
48631279|NCT05396781|DRUG|Proflavine|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
48631280|NCT05396781|DEVICE|Mobile, Augmented High Resolution Microendoscope|The marHRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
48631281|NCT05737732|DEVICE|Circadian Effective Lighting|Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (\<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, \<50lux at eye light level between 6:00PM and bedtime.
48631282|NCT05737732|DEVICE|Circadian Ineffective Lightning (CIL)|Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, \<50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
48631283|NCT04259489|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
48289990|NCT03255278|BIOLOGICAL|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
48289991|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
48631284|NCT02285309|PROCEDURE|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
48631285|NCT00383825|PROCEDURE|Anterior segment indocyanine green angiography|
47941778|NCT00575250|BEHAVIORAL|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
48289992|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
48289993|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
48289994|NCT01015443|BIOLOGICAL|Tecemotide|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
48289995|NCT01015443|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
48289996|NCT01015443|DRUG|Placebo|Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
48289997|NCT01015443|OTHER|Saline|A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
48289998|NCT01015443|OTHER|Best Supportive Care (BSC)|The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
48102408|NCT02380729|GENETIC|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
48289999|NCT00222846|BEHAVIORAL|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
48290000|NCT00222846|BEHAVIORAL|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
48290001|NCT04354025|BIOLOGICAL|Cytokine induced memory-like NK cells|-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
48290002|NCT04354025|DRUG|Fludarabine|-Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
48290003|NCT04354025|DRUG|Ara-C|-Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
48290004|NCT04354025|DRUG|G-CSF|-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
48473683|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
48473684|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
48290005|NCT04354025|DRUG|Interleukin-2|-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
48290006|NCT04354025|PROCEDURE|Leukapheresis|-Donor only
48290007|NCT01821677|DRUG|Danazol Capsules|
48631286|NCT02676622|DRUG|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
48631287|NCT02676622|OTHER|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
48290008|NCT01821677|DRUG|Placebo|
48473685|NCT04813562|BIOLOGICAL|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
48473686|NCT04813562|BIOLOGICAL|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
48473687|NCT04813562|BIOLOGICAL|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
48631288|NCT02676622|DRUG|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
48631289|NCT02676622|OTHER|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
48631290|NCT02676622|DRUG|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is \> 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
48102409|NCT02380729|GENETIC|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
48473688|NCT04813562|BIOLOGICAL|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
48473689|NCT05681416|DIAGNOSTIC_TEST|Panel sequencing, whole exome sequencing, whole genome sequencing|Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
48102410|NCT00128596|DRUG|arsenic trioxide|
48290009|NCT01426386|DRUG|FE 999049|
48290010|NCT01426386|DRUG|Gonal - F|
48290011|NCT03780517|DRUG|BOS172738|Oral capsules
48102411|NCT00365027|PROCEDURE|Delayed embryo transfer|
48102412|NCT02245854|DEVICE|Exacto™|Cold snare polypectomy
48102413|NCT04425434|OTHER|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
47941779|NCT00575250|BEHAVIORAL|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
48290012|NCT01210937|PROCEDURE|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
47941780|NCT04941963|DIAGNOSTIC_TEST|Chest ultrasound|Patients will undergo chest ultrasound scanning after obtaining parent's consent. each enrolled patient will have one chest ultrasound to assess diaphragmatic function and lung ultrasound severity score.
47941781|NCT01054807|DEVICE|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
48290013|NCT05585372|OTHER|CT guided opening mobilization of cervical intervertebral foreman|"1. the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~2. cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~3. Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~4. Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
48290014|NCT04403737|DEVICE|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
48290015|NCT04233346|DRUG|Ponatinib|CP-CML patients will be randomized into 30 mg and 45 mg dose groups at the ratio of 1:1,each group taken orally once daily. Other patients taken 45mg orally once daily.
48290016|NCT06512987|OTHER|technology-driven, interactive ICU diary|Through the diary platform, patients can share their feelings and needs, while family members can send supportive messages, pictures, and videos. Healthcare providers will use the platform to connect with families and monitor patient conditions.
47941782|NCT01054807|DEVICE|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
47941783|NCT01054807|DEVICE|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
47941784|NCT03964766|DEVICE|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
47941785|NCT03964766|DEVICE|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
47941786|NCT06104371|DEVICE|Magtrace|Sentinel lymph node tracer and metastatic lymph node clip
47941787|NCT06325904|PROCEDURE|Uniportal VATS|"* single port video-assisted thoracoscopic surgery in the 5th intercostal space~* performed under general anesthesia.~* pleural fluid/pus was drained~* pleural adhesions was removed"
47941788|NCT06325904|PROCEDURE|Tube thoracostomy|"* Chest tube is inserted in 5th mid-axillary line~* performed under local anaesthesia"
47941789|NCT00649415|DRUG|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
47941790|NCT00649415|DRUG|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
48290017|NCT06221644|DIAGNOSTIC_TEST|[18F]SynVesT-1 PET/CT|60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment
48290018|NCT00500097|DEVICE|Digital retina image|
48290019|NCT00500097|DEVICE|direct ophthalmoscopy|
48290020|NCT00500097|PROCEDURE|comprehensive eye exam|
48631291|NCT00513630|DRUG|Glipizide|
48631292|NCT00513630|DRUG|Metformin|
48631293|NCT04304378|BEHAVIORAL|Stabilization Techniques (ST)|The Stabilization Techniques intervention provides an opportunity to improve emotion/affect regulation and coping skills. The overarching goal of these sessions is to introduce different ways of managing emotional distress through imagery and stress reduction techniques. ST sessions focus on providing coping mechanisms for managing important symptoms of PTSD (i.e., hyperarousal, negative emotions, and physical symptoms).
47941791|NCT00182871|DRUG|testosterone|
47941792|NCT02495012|DRUG|placebo|Freeze-dried powder without snake venom will be dissovled in saline
47941793|NCT02495012|DRUG|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
47941794|NCT00392821|DRUG|Sorafenib|Sorafenib
47941795|NCT00392821|DRUG|RAD001|RAD001
47941796|NCT02236481|DRUG|Anakinra|
47941797|NCT02236481|DRUG|TNF alpha inhibitors|
47941798|NCT05447039|DRUG|Montelukast Sodium Tablets|intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
47941799|NCT02752971|DRUG|Bupivacaine|
47941800|NCT02752971|DRUG|Sodium diclofenac|
47941801|NCT06045169|PROCEDURE|Post Isometric Relaxation|Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
47941802|NCT00289484|DRUG|Omega-3 Polyunsaturated Fatty Acids|
47941803|NCT02480985|OTHER|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months~* Thyroid-stimulating hormone, free T4 and T3~* Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~* Adrenocorticotropic hormone stimulation test~* Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~* Demographic data~* Daily data (clinical exam, secondary brain injuries)~* Hormone levels on day 1, 3 and 7~* Biomarkers on day 1, 3 and 7~* Brain CT-Scan on day 1~* Pituitary MRI on day 7~Outcome measures at 6 and 12 months~* Neurological recovery (GOSe)~* Independent functioning (FIM)~* Quality of life (EQ-5D-5L)~* Life satisfaction (LISAT-11)~* Depression (PHQ-9)"
47941804|NCT06400979|DEVICE|Elequil aromatab|Aromatherapy impregnated tab utilized to dispense inhaled scent for the study
48290021|NCT02621385|DRUG|tradipitant|test agent
48290022|NCT02621385|DRUG|Midazolam|substrate for drug-drug interaction assessment
48290023|NCT02373930|DRUG|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
47941805|NCT03535376|DRUG|Valsartan|Patients are tested for their normal prescription valsartan medication
47941806|NCT01331941|DRUG|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
47941807|NCT01331941|DRUG|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
47941808|NCT05307978|DRUG|ALXN1910|Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
47941809|NCT05307978|DRUG|Placebo|Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
47941810|NCT04437849|DEVICE|Home Telemonitoring System|Home Telemonitoring System (HTS) The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
47941811|NCT05982431|OTHER|Traditional physical therapy program|60-minutes exercise program, three times a week on alternate days for 12 successive weeks
47941812|NCT05982431|OTHER|Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the kinesiology taping application
48290024|NCT02373930|DRUG|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
48290025|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
48290026|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
48290027|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
48290028|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
48290029|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
48290030|NCT05413447|COMBINATION_PRODUCT|Digital consult|Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
48290031|NCT01944215|DIETARY_SUPPLEMENT|Meal|effect of meal
48290032|NCT01944215|OTHER|Exercise|effect of exercise
48290033|NCT01944215|RADIATION|Sestamibi|reduce radiation dose
48290034|NCT01944215|DRUG|Caffeine Tablet|effect of caffeine
48290035|NCT01944215|OTHER|External Heating|Heating Pad and warm blanket robe
48473690|NCT00814606|DRUG|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
48290036|NCT02604966|DRUG|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
48290037|NCT02604966|DRUG|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
48290038|NCT03312946|DEVICE|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
48290039|NCT06353646|BIOLOGICAL|XH001|mRNA neoantigen cancer vaccine
48290040|NCT06353646|DRUG|Ipilimumab Injection|a type of immunotherapy that targets CTLA-4 protein on T cells
48290041|NCT06353646|DRUG|Chemotherapy|gemcitabine + capecitabine
47941813|NCT05982431|OTHER|placebo Kinsio taping|One full strip of kinesiology taping tape and one half-length strip were needed for the placebo kinesiology taping application
47941814|NCT03137771|RADIATION|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
47941815|NCT03137771|DRUG|Docetaxel|Given IV
47941816|NCT03137771|DRUG|Gemcitabine|Given IV
47941817|NCT03137771|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
47941818|NCT03137771|DRUG|Pemetrexed Disodium|Given IV
47941819|NCT03137771|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
47941820|NCT03137771|DRUG|Erlotinib Hydrochloride|Given PO
47941821|NCT03137771|DRUG|Pembrolizumab|Given IV
48107150|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-NTX|3 doses of intramuscular injections (Week 0, 3, 6)
48107151|NCT05262270|DRUG|Placebo (PLB) Injectable matched to XR-BUP|2 doses of subcutaneous injections (Week 0, 4)
48107152|NCT04752735|OTHER|endovascular treatment|all enrolled patients must receive endovascular treatment.
48290042|NCT03790735|DIAGNOSTIC_TEST|FISH|Targeted chromosomal aberrations detection
48473691|NCT00814606|DRUG|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
48473692|NCT00814606|DRUG|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
48473693|NCT05139758|DIAGNOSTIC_TEST|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
48473694|NCT00063258|DRUG|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
48473695|NCT00063258|DRUG|Paclitaxel|Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
48290043|NCT03420677|DEVICE|Application of tones|During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
48290044|NCT03420677|DEVICE|No application of tones|This is the sham-control intervention; The device will only record biosignals but will not play tones.
48290045|NCT02227407|DEVICE|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
47941822|NCT03492411|OTHER|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
48290046|NCT05484063|OTHER|Multicomponent, mobility-focused intervention|The intervention group will receive early therapist review (within one working day of admission to HOME unit), to be mobilised at least three times a day. They will also receive additional group exercise therapy sessions, as well as nurse screening for geriatric syndromes. Besides that, they will be screened for 4Ms (Mobility, Mentation, Medication, What Matters) by doctor on admission.
48290047|NCT04092036|DEVICE|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
48290048|NCT06449625|DRUG|Semaglutide Pen Injector [Ozempic]|Semaglutide active drug
48290049|NCT06449625|DRUG|Placebo|semaglutide placebo
48290050|NCT02435628|OTHER|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
48290051|NCT06163781|DEVICE|Blood culture prediction tool|Machine learning based predicition tool
48290052|NCT05421377|DIAGNOSTIC_TEST|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
48290053|NCT04440241|PROCEDURE|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
48290054|NCT05533125|DRUG|Rituximab|Rituximab 1000mg in 250ml NaCl 0.9% intravenously with usual premedication
48290055|NCT05533125|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously with usual premedication
48290056|NCT00479466|DRUG|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
48290057|NCT00479466|DRUG|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
48290058|NCT00479466|DRUG|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
48290059|NCT00479466|DRUG|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
48473696|NCT00063258|DRUG|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
48473697|NCT00313508|BIOLOGICAL|Autologous Dendritic Cells (DC)|Given intranodally
48473698|NCT00313508|DRUG|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
47941823|NCT02394548|RADIATION|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
47941824|NCT00326794|PROCEDURE|mobilisation (rehabilitation)|
48290060|NCT02726867|DRUG|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
48290061|NCT02726867|DRUG|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
48290062|NCT02726867|DRUG|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
48290063|NCT02726867|DRUG|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
48290064|NCT05153005|OTHER|examination methods|Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
48290065|NCT00385086|DRUG|TNF blocker|Treatment with TNF-alpha blocker
48473699|NCT00313508|BIOLOGICAL|Autologous Lymphocyte Infusion (ALI)|Infusion
47941825|NCT05670353|DRUG|Cannabis Derivatives|CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
48290066|NCT00385086|DRUG|Placebo|Treatment with placebo
48290067|NCT02348047|DEVICE|Hamilton T1|
48473700|NCT01618630|DIETARY_SUPPLEMENT|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
48473701|NCT01618630|DIETARY_SUPPLEMENT|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
48473702|NCT02363439|DRUG|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
48473703|NCT02056652|DEVICE|Bioteque cup pessary|
48473704|NCT01235442|DRUG|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
48290068|NCT04316481|DEVICE|AngelMed Guardian System|The AngelMed Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. The Guardian System is indicated as an adjunct to patient recognized symptoms.
47941826|NCT05670353|DRUG|Placebo|Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
47941827|NCT05670353|DRUG|Hormonal Contraceptive Agents|All participants will be given hormonal contraceptive.
47941828|NCT02518412|OTHER|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
48290069|NCT01596205|BEHAVIORAL|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
48290070|NCT01596205|BEHAVIORAL|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
47941829|NCT02518412|OTHER|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
47941830|NCT06115031|DRUG|Remimazolam|General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.
47941831|NCT06115031|DRUG|Propofol|General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.
47941832|NCT03354975|BEHAVIORAL|Experiential Training|Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
47941833|NCT03354975|BEHAVIORAL|Training-As-Usual|The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
47941834|NCT03358537|DIETARY_SUPPLEMENT|Clear Liquid Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
47941835|NCT03358537|DIETARY_SUPPLEMENT|Low-residue Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
47941836|NCT01149811|DRUG|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
47941837|NCT01149811|DRUG|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
47941838|NCT00438438|BEHAVIORAL|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
47941839|NCT02675101|OTHER|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
47941840|NCT02675101|OTHER|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
48107153|NCT05535530|DEVICE|Active PSIO|new designed active orthopedic appliance will be used. Impressions will be taken before starting the treatment (T1) and at the end of treatment (T2) three months later. The effectiveness of the two appliances will be assessed and measured on digital models of the maxillary arch before and after the treatment.
48290071|NCT04509089|DEVICE|Suremedix Device|Performing measurements using the Suremedix Device by applying gradually ascending air pressure to the subject lungs through a mouse piece while measuring respiratory chest motion, PPG and ECG.
48290072|NCT01972425|OTHER|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
48290073|NCT05767541|OTHER|Pilates exercises|The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.
48290074|NCT05767541|OTHER|Resistance exercises|Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
48290075|NCT01787591|OTHER|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
48290076|NCT01787591|OTHER|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
48473705|NCT01235442|DRUG|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
48107154|NCT00541749|DRUG|rhuMAb IFNalpha|Intravenous repeating dose
48290077|NCT01787591|OTHER|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
48290078|NCT01787591|OTHER|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
48290079|NCT01827501|DEVICE|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
48290080|NCT04875520|OTHER|Screening testing strategy|The intervention we are evaluating is the use of weekly screening testing among students and staff.
48290081|NCT04875520|OTHER|No screening testing strategy|a group of schools will not receive screening testing.
48290082|NCT01772979|DRUG|Trabectedin|
48290083|NCT06034223|OTHER|Proprioceptive training using head mounted laser|Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.
48290084|NCT06034223|OTHER|Conventional Physical therpay|Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
48290085|NCT01001585|DRUG|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
48290086|NCT04512729|DIAGNOSTIC_TEST|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
48290087|NCT04671680|DEVICE|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
48290088|NCT04837040|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
48290089|NCT04837040|DRUG|Placebo|Placebo, tablets, once daily by mouth
48290090|NCT05659615|OTHER|Study will not have intervention|Study will not have intervention
48290091|NCT03797443|DRUG|Ascorbic Acid|"Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid."
48290092|NCT03797443|DRUG|nab paclitaxel|30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
47941841|NCT02675101|OTHER|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
48107155|NCT01693419|DRUG|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14"
48290093|NCT03797443|DRUG|Cisplatin|60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
48290094|NCT03797443|DRUG|Gemcitabine|30 minute IV infusion on days 1 and 8 repeated every 21 days
48290095|NCT04720352|DEVICE|Active treatment|Active treatment delivers radiofrequency and cryogen
48290096|NCT04720352|DEVICE|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
48290097|NCT05191329|DIAGNOSTIC_TEST|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
48290098|NCT00634673|OTHER|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
48290099|NCT00310245|PROCEDURE|STI (structured Treatment Interruption)|
48290100|NCT04881877|DEVICE|Synthetic nitrite Condom|The condoms is composed of a synthetic nitrile rubber latex and 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and clear and colourless. It is manufactured by Karex Industries. It is currently experimental.
48290101|NCT04881877|DEVICE|Latex and graphene Condom|The condom is composed of a natural rubber latex with graphene. It is 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is greyish in colour. It is manufactured by Karex Industries. It is currently experimental.
48290102|NCT04881877|DEVICE|Standard latex condom|The condoms is composed of a natural rubber latex. It is 180 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is natural in colour. It is manufactured by Karex Industries. It has World Health Organisation (WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union, South African Bureau of Standards and US FDA approval
48290103|NCT00827203|DRUG|Elesclomol Sodium|Chemotherapy agent
48290104|NCT04654325|DIAGNOSTIC_TEST|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
48290105|NCT00483951|DEVICE|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
48290106|NCT00483951|DEVICE|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
48290107|NCT04865081|DEVICE|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
48290108|NCT00480194|DRUG|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
48290109|NCT05924477|PROCEDURE|Sulcus tube placement|GDD implantation surgery with tube placement in the ciliary sulcus
48290110|NCT05924477|PROCEDURE|Anterior chamber (AC) tube placement|GDD implantation surgery with tube placement in the anterior chamber
48290111|NCT05730608|OTHER|18F-FDG PET/CT|Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.
48290112|NCT01355432|OTHER|Observation|There is no intervention, this is an observational study.
48631294|NCT04304378|BEHAVIORAL|Stabilization Techniques with Behavioral Activation (ST+BA)|The Stabilization Techniques with Behavioral Activation intervention includes stabilization techniques as well as sessions targeted at increasing time engaged in physical activities during times outside of the intervention session. Preferred activities are selected by the participant. Strategies to foster engagement in the selected activities will include self-monitoring, structuring and scheduling daily activities, rating the degree of pleasure and accomplishment experienced during engagement in specific daily activities, exploring alternative behaviors related to achieving goals, and using role-play to address specific barriers. Establishing/maintaining routines and behavioral strategies to reduce avoidance and mange negative emotions are emphasized.
48631295|NCT04304378|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
47941842|NCT02770469|BEHAVIORAL|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
47941843|NCT02770469|BEHAVIORAL|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
47941844|NCT04158791|PROCEDURE|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
48107156|NCT04094155|DIAGNOSTIC_TEST|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
48107157|NCT05914506|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
48290113|NCT00334750|OTHER|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
48290114|NCT05441046|DRUG|Genakumab|genakumab plus tislelizumab 200 mg
48290115|NCT00163540|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
48290116|NCT00775307|DRUG|PAZOPANIB|400 mg/day (24 weeks)
48290117|NCT00775307|DRUG|Placebo|Placebo 400 mg/day (24 weeks)
48290118|NCT03029962|BEHAVIORAL|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
48290119|NCT02795910|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
48290120|NCT02795910|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
48290121|NCT02616822|DIETARY_SUPPLEMENT|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
48290122|NCT02616822|OTHER|Placebo|Used for placebo substance single dose
48290123|NCT05227573|PROCEDURE|Orthopedic surgery|Knee-, hip-, shoulder- and elbow surgery
48290124|NCT02778997|PROCEDURE|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
48290125|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
48290126|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
47941845|NCT00938223|BIOLOGICAL|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
47941846|NCT04520893|PROCEDURE|ventilator setting vcv with pause|ventilator setting vcv with pause
48290127|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
48290128|NCT01498991|DEVICE|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
48290129|NCT04012411|PROCEDURE|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
48290130|NCT04012411|PROCEDURE|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
48290131|NCT04012411|GENETIC|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
48290132|NCT04012411|OTHER|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
48290133|NCT01873950|DRUG|Ranolazine|
48290134|NCT01873950|DRUG|Dofetilide|
48290135|NCT01873950|DRUG|Verapamil|
48290136|NCT01873950|DRUG|Quinidine sulfate|
48290137|NCT01873950|DRUG|Placebo|
48290138|NCT02597595|OTHER|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
48290139|NCT04271163|DEVICE|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
48290140|NCT00881205|DRUG|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
48290141|NCT00881205|DRUG|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
48290142|NCT02669563|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
48290143|NCT02669563|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
47941847|NCT04520893|PROCEDURE|ventilator setting vcv|ventilator setting vcv without pause
48290144|NCT02669563|DRUG|[13N]ammonia|IV injection of \[13N\]ammonia
48290145|NCT02669563|DRUG|[11C]HED|IV injection of \[11C\]HED
47941848|NCT04520893|PROCEDURE|ventilator setting pcv-vg|ventilator setting with pcv-vg
47941849|NCT04211168|DRUG|Toripalimab plus Lenvatinib|"Toripalimab 240mg, every 3 weeks, intravenous infused, day 1, 6 weeks a cycle.~Lenvatinib 8mg (weight\<60kg) or 12mg (weight≥60kg), once a day, orally, day 2, 6 weeks a cycle. Dose reduction to 4mg/d or dose termination is allowed according to adverse events.~Number of cycle: until progression or unacceptable toxicity events develop."
47941850|NCT00006389|DRUG|bryostatin 1|Given IV
48290146|NCT02896725|DEVICE|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
48290147|NCT02896725|DEVICE|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
48290148|NCT05090345|OTHER|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
48290149|NCT03065673|PROCEDURE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
48473706|NCT03304717|DRUG|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
47941851|NCT00006389|DRUG|cisplatin|Given IV
48290150|NCT03065673|PROCEDURE|Placebo gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
47941852|NCT00006389|OTHER|laboratory biomarker analysis|Correlative studies
47941853|NCT00961766|DRUG|BG00010 (Neublastin)|Single dose, weight-based IV administration
48290151|NCT01488981|OTHER|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
48290152|NCT01488981|DEVICE|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
48290153|NCT00108810|DRUG|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
48290154|NCT00108810|DRUG|Placebo transdermal patch|12 hours application for 28 days
48290155|NCT06239311|DRUG|Methotrexate|Solution for injection in prefilled pen
48290156|NCT06239311|DRUG|Placebo|Solution for injection in prefilled pen
48290157|NCT04479761|BEHAVIORAL|Visual and Auditory Cues|Within each scene there will be 2 levels of visual input (static or dynamic) combined with 3 levels of sounds (static, none or dynamic). Postural responses to each combination will be evaluated in order to assess the role of generated and natural sounds in postural control and whether static sounds can improve balance within dynamic virtual environments.
48290158|NCT00476931|BIOLOGICAL|SB-509|60 mg dose
48473707|NCT03304717|OTHER|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
48473708|NCT03223909|DRUG|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
48473709|NCT03223909|DRUG|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
48473710|NCT03223909|DRUG|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
48473711|NCT03297086|PROCEDURE|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
48473712|NCT01953887|DRUG|EC905|Oral
48473713|NCT01953887|DRUG|solifenacin|oral
47941854|NCT00961766|DRUG|Placebo|Single dose IV matched placebo
47941855|NCT00018070|PROCEDURE|Angiography|
47941856|NCT00018070|PROCEDURE|Laser Treatment|
47941857|NCT01678027|DRUG|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
47941858|NCT01678027|DRUG|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
48290159|NCT00476931|OTHER|Placebo|Saline
48290160|NCT04352660|DRUG|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
48290161|NCT04352660|DRUG|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
48290162|NCT03507400|BEHAVIORAL|Introvision: mental and emotional self-regulation|Participants learn Introvision
48290163|NCT04541823|DRUG|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
48290164|NCT04541823|DRUG|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
48290165|NCT00675285|DRUG|montelukast sodium|one tablet 5 mg once/day for 4 weeks
48473714|NCT01953887|DRUG|tamsulosin|oral
47941859|NCT06484673|DRUG|Bosentan Dispersible Tablets|1 tablet of 32 mg Bosentan
47941860|NCT06484673|DRUG|Tracleer Tablet for Oral Suspension|1 tablet of 32 mg Bosentan
47941861|NCT03346707|DEVICE|10.5 Tesla|10.5Tesla MR scan
48290166|NCT00675285|DRUG|placebo|one tablet 5 mg once/day for 4 weeks
48290167|NCT02383394|OTHER|follow up antenatal care|ultrasound follow up of pregnancy
48290168|NCT04668846|OTHER|non-invasive sample collection of skin tissue|Both lesional and non-lesional skin will be sampled with up to 24 adhesive patches.
48290169|NCT03306771|DIAGNOSTIC_TEST|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
48290170|NCT05286398|PROCEDURE|Palatoplasty|Surgical closure of palatal defect
48290171|NCT05286398|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch
48290172|NCT02082184|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
48473715|NCT01543867|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
48473716|NCT06073886|DEVICE|Active cTBS|600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
48473717|NCT06073886|DEVICE|Inactive/Sham cTBS|600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
48290173|NCT02082184|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
48290174|NCT00623155|DRUG|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
48290175|NCT02021422|DRUG|anakinra|Dosage Route Administration 100 mg SC Every Other Day
48290176|NCT02021422|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
48290177|NCT02021422|DRUG|Irinotecan|Irinotecan 180 mg/m2 90 minutes
48290178|NCT02021422|DRUG|fluorouracil|fluorouracil 2400 mg/m2 48 hours
48290179|NCT06377995|OTHER|Placebo technique|The patient is in a supine position with a 90° knees flexion. The osteopath lies cephalad to the patient and places their hands on their shoulders.
48290180|NCT06377995|OTHER|Diaphragm protocol|The patient is in a supine position with a 90° knees flexion.To stretch the diaphragm, the osteopath stands at the head of the bed and places his hands on the lower edge of the ribcage and accompanies the lifting of the ribs during inhalation and maintains it during deep exhalation for up to 2 sets of 10 deep breaths separated by 1 minute. For the neuromuscular technique, the osteopath is positioned contralateral to the side to be treated and slides with the thumb under the lower part of the thorax, applying a force in the opposite direction.To inhibit the phrenic centre, the osteopath places one hand on the sternum in a caudal direction and the other in the projection of the phrenic centre in a cephalic direction.The participant inhales deeply and the osteopath presses in both directions during the expiratory phase for 10 respiratory cycles.
48290181|NCT01429649|PROCEDURE|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
47941862|NCT01236118|DRUG|LY2439821|Administered subcutaneously
48290182|NCT05102981|PROCEDURE|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
48290183|NCT03630068|PROCEDURE|Stereotactic percutaneous image-guided microwave ablation|Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
48290184|NCT01009775|DRUG|YM155|intravenous infusion
48290185|NCT01009775|DRUG|Docetaxel|intravenous infusion
48473718|NCT06073886|BEHAVIORAL|Imaginal exposure|Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
48473719|NCT00979212|DRUG|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
48473720|NCT00979212|DRUG|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
48473721|NCT00979212|DRUG|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
48473722|NCT00979212|PROCEDURE|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
47941863|NCT04160728|OTHER|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
47941864|NCT04160728|OTHER|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
48473723|NCT03561922|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
48473724|NCT03683329|OTHER|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
48473725|NCT03683329|OTHER|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
48473726|NCT00314782|DRUG|ZD4054 (Zibotentan)|oral tablet
48473727|NCT00314782|DRUG|Docetaxel|intravenous infusion
48473728|NCT00314782|DRUG|Placebo|
48473729|NCT00003467|DRUG|carmustine|
48473730|NCT00003467|DRUG|polifeprosan 20 with carmustine implant|
48473731|NCT00003467|PROCEDURE|surgical procedure|
48473732|NCT06166264|OTHER|Progressive resistance training|It consists of patients who will receive both Resistance exercise training sessions and aerobic training 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercises used in the resistance exercise 1)Standing chess press;(2)Strengthening back muscles in sitting position;(3)Standing strengthening abduction of both shoulders;(4)Standing strengthening flexion of both shoulders;(5)Standing strengthening flexion of both forearms;(6)Standing strengthening extension of both forearms;(7)Strengthening extension of both knees in sitting position;(8)Strengthening flexion of both knees in sitting position;(9)Strengthening dorsiflexion of both ankles in sitting position.
48473733|NCT06166264|OTHER|Control group|The participants will receive information regarding health education.
47941865|NCT04160728|OTHER|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
48473734|NCT05144464|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
47941866|NCT04160728|OTHER|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
47941867|NCT04160728|OTHER|Business as usual scenario|No interference with the usual work day of the participants
48102414|NCT05523258|BEHAVIORAL|Computerized cognition training|The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
48102415|NCT05523258|BEHAVIORAL|Basic training based on tablet computer|The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
48102416|NCT02906306|BEHAVIORAL|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
48102417|NCT02906306|BEHAVIORAL|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
48102418|NCT02116855|OTHER|according to the efficacy of AJBRs|
48102419|NCT03728738|PROCEDURE|Head of Bed Positioning|The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
48102420|NCT04097626|OTHER|nutrition education|The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
48102421|NCT04097626|OTHER|no nutrition education|This group will not receive nutrition education.
48102422|NCT06441656|PROCEDURE|Vitrectomy with ILM flap|In both groups, a single-layer ILM temporal flap of approximately 2 times the size of the optic disc was fashioned using an ILM forceps temporal to the macula. The nasal edge of the flap was not detached from the temporal MH edge. The flap was reflected nasally to cover the MH
48102423|NCT02199145|PROCEDURE|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
48102424|NCT00551772|DRUG|SB-742457|
48102425|NCT05880316|BEHAVIORAL|Intermittent Fasting|3:4 regime
48102426|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
48102427|NCT03045692|DIAGNOSTIC_TEST|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
48102428|NCT05245851|DEVICE|Opportunistic screening for low BMD|"Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~* This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD).~* This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician."
48102429|NCT02565056|OTHER|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
48102430|NCT01921140|DRUG|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
48102431|NCT01921140|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
48473735|NCT01908205|DRUG|Intranasal Oxytocin|
48473736|NCT01908205|DRUG|Placebo|
48473737|NCT00930241|DRUG|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
48473738|NCT00930241|DRUG|Prograf®|Prograf® (two daily doses of Tacrolimus)
48473739|NCT01668823|DRUG|HPPH|Given IV
47941868|NCT04160728|OTHER|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
47941869|NCT01755273|PROCEDURE|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
48473740|NCT01668823|DRUG|photodynamic therapy|Undergo photodynamic therapy with HPPH
47941870|NCT04944095|OTHER|Change in SARS-CoV-2 Antibody Levels|Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
47941871|NCT06138288|BEHAVIORAL|acupressure|The acupressure points to be used in the research are located on the inner side of the lower leg, 4 fingers above the ankle and on the spleen meridian behind the tibia (SP6), which was previously effective in reducing pain, and located three fingers above the wrist (in the middle of the 2nd metacarpal bone, on the dorsum of the hand, adjacent The points determined as P6 (located between the metacarpal bones) and LI4 located in the space between the thumb and index finger (between the 1st and 2nd metacarpal bones of the hand, in the middle of the 2nd metacarpal bone on the radial side) were applied by a certified researcher to women in the acupressure group. will be done
47941872|NCT02288143|DRUG|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm."
47941873|NCT03962309|OTHER|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
48102432|NCT01921140|OTHER|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
48102433|NCT01921140|OTHER|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
48102434|NCT02637908|BEHAVIORAL|Mindfulness training|6-weeks of group-based mindfulness training for parents
48102435|NCT03646331|DRUG|Imeglimin Reference product|Reference product
48102436|NCT03646331|DRUG|Imeglimin|Test product (new formulation tablet)
48102437|NCT03426696|BEHAVIORAL|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
48102438|NCT00773019|DEVICE|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
48102439|NCT02165891|DRUG|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
48102440|NCT02165891|PROCEDURE|primary video-assisted thorascopic surgery|
48102441|NCT00908947|DEVICE|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
48102442|NCT00005113|DRUG|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
48102443|NCT00005113|DRUG|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
48102444|NCT00005113|DRUG|Tacrolimus|dosage is in oral form titrated to target trough level
48102445|NCT03438487|BIOLOGICAL|Flucelvax Trivalent Influenza Vaccine|"Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
48102446|NCT03438487|BIOLOGICAL|Flucelvax Quadrivalent Influenza Vaccine|"Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
48102447|NCT01358916|OTHER|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
47941874|NCT01638819|BIOLOGICAL|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
48102448|NCT02512042|DRUG|Test-Brinzolamide 1% Ophthalmic suspension|
48102449|NCT02512042|DRUG|Reference-Brinzolamide 1% Ophthalmic suspension|
48102450|NCT01751724|DRUG|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
48102451|NCT01751724|OTHER|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
48102452|NCT05001919|PROCEDURE|GTR|intrabony defects treated by surgery and bone graft +collagen membrane
48290186|NCT00878228|DRUG|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
48290187|NCT00878228|DRUG|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
48290188|NCT04651777|DRUG|FF/UMEC/VI|The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
48290189|NCT04372329|BEHAVIORAL|CPAP4HealthySleep system|Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
48290190|NCT03488992|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 8 weeks
48290191|NCT03488992|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
48290192|NCT04697147|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
48290193|NCT06390618|OTHER|Aerobic Exercise (AE) Group|"A total of 24 sessions of aerobic exercise will be performed in 8 weeks, 3 days a week.~For aerobic exercise, a moderate intensity (50-60%) aerobic exercise program will be applied using the karvonen method. According to the aerobic exercise intensity karvonen method, the formula (Maximal Heart Rate (220-years) - Resting Heart Rate) x 50-60% + Resting Heart Rate) will be used. 1-4. week 50%, 5-8. Exercise intensity will be increased by 60% per week."
48290194|NCT06390618|OTHER|Combined Exercise (CE) Group|"In the combined exercise group, biopsychosocial exercise will be performed in addition to aerobic exercise.~In the combined exercise group, in addition to aerobic exercise (3, 8 weeks, 24 sessions of aerobic exercise per week), 16 sessions of biopsychosocial-based group exercise treatment will be performed 2 days a week for a total of 8 weeks.~BETY approach will be used in group exercise treatment."
48631296|NCT05586100|DRUG|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
48631297|NCT03364010|BEHAVIORAL|Evaluation of proprioception|Velocity perception and Position perception
47941875|NCT01638819|BIOLOGICAL|Placebo|Saline
48290195|NCT03446547|DRUG|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
48290196|NCT04570891|PROCEDURE|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
47941876|NCT04333771|DRUG|SHR0302|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
48290197|NCT04570891|PROCEDURE|Control|No regional block is provided at the end of surgery.
48290198|NCT01269567|PROCEDURE|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit \< 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
48631298|NCT03364010|BEHAVIORAL|Evaluation of motor learning|Motor accurancy and State Estimation with visual perturbations
48631299|NCT03364010|BEHAVIORAL|Evaluation of written language|Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
48631300|NCT02096224|DRUG|Sevoflurane|Sevoflurane will be used.
48631301|NCT02096224|DRUG|Desflurane|Desflurane will be used
48631302|NCT04268212|DIETARY_SUPPLEMENT|Bitter melon juice (100 ml)|Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
47941877|NCT04333771|DRUG|Placebo|The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
47941878|NCT04691388|DRUG|Amlotinib+Sindili|All patients will receive Sindelizumab combined with Antinib Hydrochloride capsule every 3 weeks
47941879|NCT02172066|BEHAVIORAL|Narrative Exposure Therapy (NET)|
47941880|NCT04594954|DIETARY_SUPPLEMENT|Diet|A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
48102453|NCT05001919|PROCEDURE|concentrated growth factor|intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
48102454|NCT03503630|DRUG|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
48102455|NCT03503630|RADIATION|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
48102456|NCT03503630|DRUG|mFOLFOX|Given every 2 weeks for 6 cycles
48102457|NCT03503630|PROCEDURE|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
47941881|NCT04594954|OTHER|FMT|"Stool Administration Procedure (ILBS FMT Protocol)~* 500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum \[(2 to 3 minutes per 50 ml).\]~* The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~* 100 mL freshly thawed sample will be given once in 15 days for 3 doses~* Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~* Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~* The patient will be allowed to consume liquid diet two hours after the procedure."
47941882|NCT04594954|OTHER|Physical Activity|"Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min."
47941883|NCT03282565|OTHER|Functional Resistance Training with Brace|A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
47941884|NCT03282565|OTHER|Control|A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
47941885|NCT03282565|OTHER|Functional Resistance Training with Elastic Band|An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
48102458|NCT01405235|DRUG|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
48102459|NCT01405235|DRUG|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
48102460|NCT03100162|DIETARY_SUPPLEMENT|Probiotic|
48102461|NCT03100162|DIETARY_SUPPLEMENT|Placebo|
48102462|NCT03469154|OTHER|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
48102463|NCT03469154|OTHER|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
48102464|NCT02315885|OTHER|Alcohol administration; Placebo administration|consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
48102465|NCT00587288|BIOLOGICAL|Reslizumab|
48102466|NCT00587288|OTHER|Saline|
48102467|NCT02865733|DRUG|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
48102468|NCT02865733|DRUG|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
48102469|NCT06037135|DRUG|dexmedetomidine|In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery. The research nurse, who did not participate in the study other than the management and preparation of the study medication, prepared 50mL of 0.9% normal saline for the control group and a mixture of dexmedetomidine 2 mL and 0.9% normal saline 48 mL (at a concentration of 4 μg/mL) for the dexmedetomidine group.
48102470|NCT06037135|DRUG|0.9% normal saline|In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
48102471|NCT02048709|DRUG|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
48102472|NCT03992495|OTHER|Exercise|All participants will be exposed to aerobic/strengthening exercises
48102473|NCT01944410|BIOLOGICAL|PRP injection|injection of PRP to traumatic bone cyst defect
48102474|NCT02785978|DRUG|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
48102475|NCT02785978|OTHER|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
48102476|NCT02785978|OTHER|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
48102477|NCT02785978|DEVICE|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
48102478|NCT02785978|OTHER|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
48102479|NCT04767828|DRUG|PYRROTINI|CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .
48102480|NCT04767828|RADIATION|Brain radiation therapy|Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.
48290199|NCT01269567|PROCEDURE|No pelvic drainage|no aspiration drain at the end of intervention
48631303|NCT04268212|BEHAVIORAL|Exercise|The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
48631304|NCT03428204|PROCEDURE|Balloon dilation during 180 seconds|Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
48290200|NCT04952012|DRUG|LT4|LT4 is used to improve the thyroid function of pregnant women.
48290201|NCT06661759|BEHAVIORAL|Clinic-based and technology-supported sleep intervention|CATS sleep intervention: The in-person sleep education and consultation will consist of 3 face-to-face, one-on-one sessions held 3 months apart during the child's routine clinic visit.The digital component of the sleep intervention will extend in-person education by providing ongoing support. Participants will receive one digital session per week for four weeks after the baseline, 3-month, and 6-month clinic visits, totaling 12 sessions.
48631305|NCT03428204|PROCEDURE|Balloon dilation during 300 seconds|Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
48631306|NCT02234180|OTHER|Placebo|Given PO
48631307|NCT02234180|DRUG|Regorafenib|Given PO
48631308|NCT05214950|DEVICE|ORI monitoring|Oxygen reserve index monitoring during the surgery
48102481|NCT00891618|OTHER|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
48102482|NCT04232592|BIOLOGICAL|Inject a solution of stem cell preparation|The control group was injected with a solution of stem cell preparation
48102483|NCT04232592|BIOLOGICAL|Inject stem cells|Three dose groups were designed: low dose group, medium dose group and high dose group.
48102484|NCT04300816|BEHAVIORAL|CBT for Uncertainty Tolerance|"Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis."
48102485|NCT04300816|BEHAVIORAL|Traditional CBT|Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
48631309|NCT02289378|DRUG|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
48631310|NCT02802475|BIOLOGICAL|vena punction|
48631311|NCT03927430|PROCEDURE|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
48631312|NCT01280500|BEHAVIORAL|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
48631313|NCT01280500|OTHER|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
48631314|NCT01280500|OTHER|usual care|No EMR
48631315|NCT01280500|OTHER|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
48102486|NCT02389192|DRUG|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
48102487|NCT00220350|DRUG|leuprolide acetate|
48102488|NCT06137846|DEVICE|Air-Polish|Dental implant will be cleaned with an airpolishing device
48290202|NCT04993742|BEHAVIORAL|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
48290203|NCT05205707|DIAGNOSTIC_TEST|ACE serum levels|Circulating ACE2 level will be measured
48290204|NCT04950231|OTHER|The questionnaire survey|Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.
48290205|NCT03533790|DRUG|DEP-Ru|"* Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone"
48290206|NCT01709877|PROCEDURE|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
47941886|NCT03901456|BEHAVIORAL|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.
48102489|NCT06137846|DEVICE|Ultrasonic|Dental implant will be cleaned with an ultrasonic device with a plastic tip
48290207|NCT04210973|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
48290208|NCT04210973|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
48290209|NCT01812720|DRUG|carfilzomib|Given IV
48290210|NCT01812720|DRUG|dexamethasone|Given PO
48290211|NCT01812720|OTHER|laboratory biomarker analysis|Correlative studies
48290212|NCT04661319|PROCEDURE|video editing training|"1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
48290213|NCT04819425|DEVICE|Elastic Adhesive Strips|Securement of Endotracheal tube with Elastic Adhesive Strips
48290214|NCT04819425|DEVICE|Lace in A Protective Sheath|Securement of Endotracheal tube with Lace in A Protective Sheath
48473741|NCT01668823|PROCEDURE|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
48473742|NCT00673764|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
48473743|NCT00673764|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
48473744|NCT05151393|DIAGNOSTIC_TEST|Measuring vitamin D3 level|Measuring vitamin D3 in both groups
48473745|NCT01405469|OTHER|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
48473746|NCT03241316|BEHAVIORAL|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
47941887|NCT03901456|BEHAVIORAL|Usual Care|"Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study."
48102490|NCT02882048|PROCEDURE|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
48102491|NCT02882048|OTHER|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
48102492|NCT02700867|DEVICE|NIO|Intraosseous access device NIO (Defibtech)
48102493|NCT00004367|PROCEDURE|Clinical vestibular tests|
48107158|NCT03156712|DIETARY_SUPPLEMENT|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
48290215|NCT04440917|DRUG|Camrelizumab|200mg, iv, on day 1, 15, 29, 43
48290216|NCT04440917|DRUG|Apatinib Mesylate|250 mg po, qd, 28 days as a cycle, 2 cycles in total
48290217|NCT01618955|DEVICE|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
48290218|NCT03611140|DIETARY_SUPPLEMENT|DP|a package containing a mix of functional foods
48473747|NCT00282581|BIOLOGICAL|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
48290219|NCT03611140|DIETARY_SUPPLEMENT|Placebo|a package containing maltodextrins and caseinate calcium to mimic the DP
48290220|NCT04115397|DRUG|Zoledronic Acid|Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
47941888|NCT05953376|DRUG|Calcium Gluconate|There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
47941889|NCT05493618|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
48290221|NCT04115397|DRUG|Placebo|Placebo
48290222|NCT00598130|BIOLOGICAL|Fleece|Fibrin Patch
47941890|NCT05493618|DRUG|Belantamab mafodotin|Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
47941891|NCT05493618|DRUG|Dexamethasone|Dexamethasone 40 mg IV q3 weeks (20 mg if patient \>75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
47941892|NCT01727908|OTHER|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
48290223|NCT00072969|DRUG|Daclizumab|
48290224|NCT04423939|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
48290225|NCT04298346|OTHER|no intervention|no intervention
48290226|NCT00444210|DEVICE|DL6049 (injectable poly-L-lactic acid)|
48290227|NCT01009112|BEHAVIORAL|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
48290228|NCT01009112|BEHAVIORAL|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
48290229|NCT04507750|DRUG|Camrelizumab|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
47941893|NCT04019587|DIAGNOSTIC_TEST|Fear of Falling Avoidance Behavior Questionnaire administration|The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
47941894|NCT01037322|DRUG|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
47941895|NCT01037322|DRUG|placebo in drops|olive oil containing no drug given in drops twice daily
47941896|NCT04179851|DIAGNOSTIC_TEST|Thermal imaging of neck veins|Thermal imaging of neck veins
47941897|NCT05395663|BEHAVIORAL|Community health worker|A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
47941898|NCT01232205|DIETARY_SUPPLEMENT|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
47941899|NCT01232205|DIETARY_SUPPLEMENT|Control|supplementation with milk
47941900|NCT01490788|DRUG|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
48290230|NCT06408792|DEVICE|Deepithelized graft and protection technique|To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.
48290231|NCT04493749|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG
48290232|NCT01667744|DRUG|Citalopram|10 mg/day
48290233|NCT06212440|DIAGNOSTIC_TEST|Identification rate of sentinel lymph node for each dual method|Direct comparison of identification rate between A arm and B arm, A arm and C arm.
48631316|NCT01280500|OTHER|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
47941901|NCT01490788|DRUG|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
47941902|NCT01490788|DRUG|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
47941903|NCT02156531|BEHAVIORAL|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
48290234|NCT04550507|BEHAVIORAL|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
48618014|NCT01529268|DRUG|DR cysteamine bitartrate capsule|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
48290235|NCT04550507|BEHAVIORAL|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory \& Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
48290236|NCT04374994|DRUG|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
48290237|NCT04374994|DRUG|Placebo oral tablet|lactose and maize starch, Egypt
48290238|NCT00637728|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
48631317|NCT04700462|BEHAVIORAL|Sm-EMA|Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e. COVID-19 preventative behaviors).
48631318|NCT02102737|DRUG|6-DIG|injection of 6-DIG
48631319|NCT02102737|PROCEDURE|clamp|hyperinsulinemic euglycemic clamp
48290239|NCT00637728|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
48290240|NCT06417684|DRUG|Amitriptyline|25 mg prescribed to be taken once daily for 90 days each evening.
48631320|NCT04530695|OTHER|Scaling and Root Planing|Periodontal treatment by scaling and root planing (SRP), deep cleaning
48631321|NCT01703221|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
48631322|NCT01703221|DRUG|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
48631323|NCT01703221|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
48631324|NCT01703221|DRUG|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
48631325|NCT00320580|DRUG|norelgestromin/ethinyl estradiol|
48631326|NCT02661373|DRUG|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
48631327|NCT02661373|DRUG|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
48631328|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
48631329|NCT00574899|OTHER|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
48631330|NCT00762788|DEVICE|senofilcon A|1 week extended wear contact lens
48631331|NCT00762788|DEVICE|lotrafilcon A|1 week extended wear contact lens
48631332|NCT00762788|DEVICE|lotrafilcon B|1 week extended wear contact lens
48631333|NCT00762788|DEVICE|balafilcon A|1 week extended wear contact lens
48631334|NCT00762788|DEVICE|comfilcon A|1 week extended wear contact lens
48631335|NCT00762788|DEVICE|etafilcon A|1 week extended wear contact lens
48631336|NCT00863460|RADIATION|cranial radiotherapy|40 Gy
48631337|NCT00863460|DRUG|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
48290241|NCT04820478|DIETARY_SUPPLEMENT|Beta Hydroxybutyrate Ester (KetoneAid KE4)|see arm/group description
48290242|NCT04820478|DIETARY_SUPPLEMENT|Placebo|see arm/group description
48290243|NCT03977532|OTHER|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
48290244|NCT05459805|DRUG|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
48290245|NCT05459805|DRUG|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
48290246|NCT02725177|DRUG|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
48290247|NCT02725177|DRUG|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
48290248|NCT02202681|DEVICE|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
48290249|NCT02097836|DEVICE|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
48290250|NCT02884466|BEHAVIORAL|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
48290251|NCT02273115|DRUG|Oxytocin|
48290252|NCT02273115|DEVICE|Transcervical Foley catheter|
48290253|NCT02718846|DRUG|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
48290254|NCT02718846|DRUG|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
48290255|NCT02759822|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
48290256|NCT02385123|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
48290257|NCT06672302|DIAGNOSTIC_TEST|ExoPred|Performing in vitro diagnostics with devices developed by EXoPERT
48290258|NCT01031095|OTHER|coronary intervention|elective coronary intervention
48631338|NCT00863460|DRUG|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
48631339|NCT03281915|PROCEDURE|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
48631340|NCT03281915|PROCEDURE|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
48290259|NCT00469235|DRUG|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
48290260|NCT05751525|DRUG|Sulfonylurea|Glibenlclamide / glyburide
48290261|NCT00180115|DRUG|Cytarabine Dosage|
48631341|NCT01968785|RADIATION|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
48631342|NCT01968785|RADIATION|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
48631343|NCT01111370|DEVICE|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
48290262|NCT00249886|DRUG|Citalopram|
48290263|NCT02984878|DEVICE|Revanesse Ultra|Nasolabial Fold correction
48290264|NCT00501852|DRUG|NVA237|single-dose dry-powder inhaler (SDDPI)
48631344|NCT02541903|DRUG|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
48631345|NCT04273789|DEVICE|Far infrared reflecting sleepwear|100% microlyocell sleepwear (shorts + shirt) with a ceramic print that reflects far infrared light (FIR, 5.6-1000 µm) emitted by the human body. Since FIR active garments are not powered, but reflect recycle light energy emitted by the body of the wearer, they have irradiances between 0.1-5 mW/cm\^2.
48290265|NCT00501852|DRUG|Placebo|single-dose dry-powder inhaler (SDDPI)
48631346|NCT04273789|DEVICE|Placebo sleepwear|100% microlyocell sleepwear (shorts + shirt)
48631347|NCT03443544|PROCEDURE|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
48631348|NCT05362019|DRUG|Compound Norethisterone Enanthate Injection|Combined injectable contraceptive use
48631349|NCT05362019|OTHER|One-to-one Service|"A mobile phone based service system will be used to pushing contraceptive knowledges, reminding injection, providing consultation on adverse reactions and ect."
48631350|NCT05362019|OTHER|Family Planning Service|routine family planning service and contraceptive service.
48290266|NCT00501852|DRUG|Tiotropium|Handihaler inhaler
48290267|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)"
48290268|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg"
48290269|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)"
48631351|NCT05708664|PROCEDURE|precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction|Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
48631352|NCT05378542|BEHAVIORAL|Mobile application usage|The implementation of the research was carried out in two stages. In the first stage, a mobile application was created, in the second stage, training and counseling was given to the experimental group with the mobile application, and no attempt was made to the control group.
48631353|NCT06005155|DRUG|Lithium|Sustained long-term exposure
48631354|NCT06288178|DIETARY_SUPPLEMENT|Bread consumption|There were four groups: whole wheat (WWB), buckwheat (BWB), corn bread (CB) and reference bread.
48631355|NCT05466253|PROCEDURE|Fixed Orthodontic treatment|All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
48631356|NCT04613869|DRUG|High-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
48290270|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
48290271|NCT05979012|BEHAVIORAL|MIndfulness Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.It is up to them if they want to listen to the daily recordings."
47941904|NCT02156531|BEHAVIORAL|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
47941905|NCT02469376|DRUG|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
47941906|NCT03839082|OTHER|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
47941907|NCT03839082|OTHER|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
47941908|NCT01806727|BEHAVIORAL|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
47941909|NCT01806727|BEHAVIORAL|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
47941910|NCT05868018|BEHAVIORAL|Education|This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
47941911|NCT00191646|DRUG|Gemcitabine|"1000 mg/m\^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m\^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
47941912|NCT00191646|DRUG|Paclitaxel|"175 mg/m\^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m\^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m\^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
47941913|NCT00191646|DRUG|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
47941914|NCT05844709|OTHER|IVH care Bundle|"The experimental group received bundle nursing care within 3 days after birth in addition to routine nursing care after consent was given and the informed consent form was signed.~IVH care Bundle: 1. Maintaining midline head position 2. Avoid prone, place in supine or side-lying position 3. Incubator tilted 15-30 degrees 4. Slow withdrawal and flushing for UAC, UVC, and PAL."
47941915|NCT01763671|DRUG|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
47941916|NCT01763671|DRUG|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
47941917|NCT01763671|DRUG|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
47941918|NCT03186885|BEHAVIORAL|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
48290272|NCT05979012|BEHAVIORAL|Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.They will have access to electronic audio recordings, with the order of listening labeled for each day. The recordings will increase gradually throughout the study, starting with about 10 minutes each day in the first week and reaching 30 minutes each day in the final week. The schedule is as follows: Week 1= 10 minutes, Week 2= 15 minutes, Week 3= 20 minutes Week 4= 30 minutes. It is up to them if they want to listen to the daily recordings."
48290273|NCT03288467|PROCEDURE|Root canal treatment with 5% NaOCl|
48290274|NCT03288467|PROCEDURE|Root canal treatment with 1% NaOCl|
48290275|NCT02153515|OTHER|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
48290276|NCT04293250|PROCEDURE|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
48290277|NCT02785757|OTHER|Thrombin Generation Assay|
48290278|NCT05431465|OTHER|Vita Ambria|onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)
48290279|NCT05431465|OTHER|IPs emax onaly|onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
48290280|NCT01998646|DRUG|ASP4058|Oral tablet
48290281|NCT01998646|DRUG|Placebo|Oral tablet
48290282|NCT02958137|PROCEDURE|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
48290283|NCT06082778|BEHAVIORAL|Fermented food intake above habitual level|Participants increase their habitual intake of fermented foods by three portions per day, compared to their habitual intake level at baseline.
48290284|NCT04494009|DRUG|INCMGA00012|INCMGA00012 (also known as MGA012) is a humanized, hinge-stabilized IgG4 monoclonal antibody against human PD-1, which blocks the interaction of PD-1 with PD-L1 and PD-L2, interrupting PD-1 signaling, enhances antigen-induced interferon-γ release, and has a favorable preclinical profile.
48290285|NCT04243369|DEVICE|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
48618015|NCT01529268|OTHER|DR cysteamine bitartrate placebo|"* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline"
48102494|NCT01071967|OTHER|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
48102495|NCT05885828|OTHER|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
48290286|NCT05537428|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
48290287|NCT01729832|PROCEDURE|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
48290288|NCT01729832|PROCEDURE|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
48290289|NCT01707147|DRUG|Trajenta tablet|Linagliptin
48290290|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method A|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
48290291|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method B|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
48631357|NCT04613869|DRUG|Low-dose Esketamine hydrochloride+Hydromorphone|By adding different doses of esketamine to the postoperative analgesic pump, and the control group without adding this drug to observe the postoperative pain, anxiety and depression indicators of the surgical patients
48102496|NCT05885828|OTHER|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
48102497|NCT05885828|BEHAVIORAL|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
48102498|NCT05885828|OTHER|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
48290292|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method C|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
48290293|NCT04930250|OTHER|Placebo Comparator: Minimally-processed oat bran (Positive Control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
48290294|NCT04930250|OTHER|Placebo Comparator: Readily-digestible carbohydrate (negative control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
48618016|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone and a cortical block|alveolar bone graft with cancellous bone only
48618017|NCT03883373|PROCEDURE|alveolar bone graft with cancellous bone only|alveolar bone graft with cancellous bone only
48631358|NCT04613869|DRUG|Hydromorphone|No esketamine added
48290295|NCT06316089|BEHAVIORAL|PrEPared for Release|A multilevel, behavioral and navigation intervention administered over two sessions to promote PrEP initiation, adherence and linkage to PrEP care in the community for incarcerated men with a history of injection drug use.
48290296|NCT03591952|PROCEDURE|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
48290297|NCT03591952|PROCEDURE|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
48290298|NCT03045484|DRUG|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
48631359|NCT03654079|OTHER|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
48631360|NCT00728182|DRUG|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
48290299|NCT03045484|OTHER|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
48290300|NCT01950884|DRUG|Ezetimibe|Ezetimibe tablets
48290301|NCT01950884|BEHAVIORAL|Lifestyle|lifestyle
48290302|NCT03450889|PROCEDURE|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
48290303|NCT00550238|DRUG|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
48473748|NCT04012073|DEVICE|Invasive Mechanical ventilation|"Volume-control ventilation with tidal volume will be set at 6 mL/Kg of predicted body weight, respiratory rate to maintain pH\>7.30 and PaCO2\<50 mmHg and FiO2 will be set to achieve a SpO2\>88-95%.~In case of hypercapnia with Ph\<7.30 despite a respiratory rate=30-35, an increase in tidal volume up to 8 ml/kg will be allowed.~In both groups, the assigned ventilation protocol will be followed for a minimum of 72 hours from randomization and any time fully controlled ventilation is deemed necessary by the attending physician up to 14 days from randomization. After 14 days from randomization, PEEP will be set according to the clinical practice of each institution.~After 72 hours from the study protocol, the PEEP setting protocol according to the assigned treatment will be resumed at any time within 14 days from enrolment if fully controlled ventilation is established, according to the decision of the attending physician in charge."
48473749|NCT04012073|DRUG|Neuromuscular Blocking Agents|All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
48473750|NCT04012073|PROCEDURE|Prone positioning|Prone positioning will be used in all enrolled patients as a standard of care: the decision about the timing and the duration of prone position sessions will be left to the attending physician and the time spent by the patient in the prone and in the supine position will be recorded: PEEP will be re-set according to the protocol of the allocated treatment anytime patient's position is changed.
48618018|NCT00025779|DRUG|methylphenidate|
48618019|NCT00025779|DRUG|guanfacine|
48631361|NCT00728182|DRUG|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
48631362|NCT03055507|DRUG|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
48631363|NCT03055507|DRUG|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
48631364|NCT03055507|DRUG|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
48631365|NCT03957057|DRUG|Iron Carboxymaltose|Intravenous iron carboxymaltose application
48631366|NCT03957057|DRUG|Iron Isomaltoside|Inravenous iron isomaltoside application
48290304|NCT05294042|OTHER|Navigation|The intervention in this study is a model of navigation for families seeking services at the two mental health agencies collaborating on this study. Navigators (PP and CM) will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
48290305|NCT05110586|OTHER|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
48290306|NCT00116311|BEHAVIORAL|allergen inhalation|
48290307|NCT00116311|BEHAVIORAL|withdrawal of medication|
48290308|NCT00116311|PROCEDURE|sputum induction|
48290309|NCT06274359|BEHAVIORAL|Digital storytelling|Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.
48290310|NCT05167292|OTHER|Observational study|Routine clinical care was provided to all AKI cases presenting to the TTM Hospital in Samoa. This prospective observational study reviewed incidence, aetiology and outcomes for these cases.
48631367|NCT03957057|DRUG|Ferrous sulphate|Oral ferrous sulphate application
48631368|NCT01557816|DRUG|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
48631369|NCT01557816|DRUG|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
48290311|NCT04430530|BIOLOGICAL|Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
48290312|NCT04696406|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
48290313|NCT03992235|OTHER|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
47941919|NCT03186885|BEHAVIORAL|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
47941920|NCT03186885|BEHAVIORAL|Control|Participants receive standard of care
48290314|NCT03992235|OTHER|Educational material|Exercise brochure with photos and explanations
48290315|NCT04847830|DEVICE|Er:YAG laser (Waterlase)|The WaterLase iPlus tissue cutting system is a unique device with diverse, hard- and soft-tissue dental applications. It utilizes advanced laser and water atomization technologies to safely and effectively cut, shave, contour, roughen, etch, and resect oral hard-tissue, and direct laser energy to perform oral soft-tissue removal, incision, excision, ablation and coagulation.
48290316|NCT04847830|PROCEDURE|root surface dbridement|root surface debridement under local anaesthesia
48290317|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in intervention group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
47941921|NCT00366015|PROCEDURE|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
47941922|NCT00366015|PROCEDURE|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
47941923|NCT06145906|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
47941924|NCT06145906|PROCEDURE|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus|PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
47941925|NCT03150485|DEVICE|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
47941926|NCT05050552|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
48290318|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
48290319|NCT03398408|BEHAVIORAL|Training|The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
48290320|NCT04419506|DRUG|BI 1015550|18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
48290321|NCT04419506|DRUG|Placebo|placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
47941927|NCT00815269|DRUG|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
48290322|NCT03705494|OTHER|Home-based peer counselling (web-based) intervention|The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
47941928|NCT00815269|DRUG|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
48102499|NCT05885828|OTHER|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
48102500|NCT03261596|DRUG|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
48102501|NCT01942967|OTHER|Echocardiography|"Measurement of:~* Left ventricular output (LVO).~* Right ventricular output (RVO).~* Assessment of the Mesenteric Artery Flow."
48102502|NCT01942967|OTHER|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
47941929|NCT00815269|DRUG|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
47941930|NCT00815269|DRUG|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
47941931|NCT00815269|DRUG|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
47941932|NCT01902433|PROCEDURE|Astym|
48290323|NCT01688648|DRUG|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
47941933|NCT05591846|BEHAVIORAL|Face-to-face training|Face-to-face training
47941934|NCT05591846|BEHAVIORAL|web-based training|web-based training
47941935|NCT02386969|DEVICE|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
47941936|NCT02386969|DEVICE|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
47941937|NCT05465746|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load
48102503|NCT03906630|DIAGNOSTIC_TEST|Telehealth clinical exam|This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
48102504|NCT03906630|DIAGNOSTIC_TEST|Standard clinical exam|This is a standard in-person clinical exam for patients presenting with shoulder pain
48102505|NCT05890521|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."
48290324|NCT01688648|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
47941938|NCT05465746|DIAGNOSTIC_TEST|Three-dimensional transthoracic echocardiography|Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
47941939|NCT01740843|DEVICE|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
48102506|NCT04894318|BEHAVIORAL|Low-fat and low-cholesterol diet|Low-fat (\<30% of total energy) and low-cholesterol (\<200mg/day) diet total of 12 weeks
48290325|NCT03768401|OTHER|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
48290326|NCT03768401|BEHAVIORAL|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
48290327|NCT02035423|DIETARY_SUPPLEMENT|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
48290328|NCT02035423|DIETARY_SUPPLEMENT|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
48290329|NCT02035423|DIETARY_SUPPLEMENT|Non-Fortified Milk|Daily consumption of non-fortified milk
47941940|NCT03632343|OTHER|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain \>3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
47941941|NCT03632343|OTHER|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
47941942|NCT03342521|DIAGNOSTIC_TEST|optical coherence tomography and VerifyNow|optical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow
47941943|NCT02799979|DEVICE|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
47941944|NCT03385083|BEHAVIORAL|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
47941945|NCT03385083|BEHAVIORAL|Step count monitoring without consultation|Subject counseled on step counts at initial visit
47941946|NCT03385083|DEVICE|Fitbit tracker|Fitbit tracker given to participant
48618020|NCT04213911|RADIATION|low-dose chest CT scan|The low-dose chest CT scan is now commonly used as a quick, painless, and non-invasive approach to screen for lung cancer. The radiation exposure from one low-dose CT scan of the chest (1.5 mSv) is comparable to 6 months of natural background radiation for a person living in the US.
48631370|NCT02255695|OTHER|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
48631371|NCT02785705|BIOLOGICAL|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
48631372|NCT02002208|DRUG|OC000459|Oral CRTH2 antagonist
48290330|NCT05819346|BEHAVIORAL|Lifestyle|Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after inpatient rehabilitation has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention (about one week post-rehabilitation) with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
48290331|NCT04097288|DRUG|Citalopram 40mg|Single dose
48290332|NCT04097288|DRUG|Reboxetine 8 mg|Single dose
48290333|NCT04097288|DRUG|Placebo oral tablet|Single dose
48290334|NCT04097288|DRUG|Placebo oral tablet|Single dose
48290335|NCT05452746|DEVICE|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
48290336|NCT05452746|OTHER|Treatment as usual|Inpatient psychiatric care for depression
48290337|NCT00187161|DRUG|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
48290338|NCT03701789|DRUG|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
48290339|NCT02690896|BEHAVIORAL|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
48290340|NCT02690896|BEHAVIORAL|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
48290341|NCT00114907|BEHAVIORAL|Consumption of black tea|
48290342|NCT04696744|BIOLOGICAL|CTC detection|"The collection and analysis of CTCs will be carried out in the following 6 steps: A blood sample will be taken: a maximum volume of 30 ml on 3 x 10 ml BD Vacutainer® EDTA tubes is required for the study.~CTCs will be enumerated and characterized by immunofluorescence after immunostaining with the following antibodies: anticytokeratin, anti-CD44, anti-N-cadherin and anti-PD-L1.~• - Secondary criterion(s) : Different tumor and clinical parameters will be analysed to find a correlation with CTC detection Gene expression profiles will be analyzed using the RNAseq single-cell at different times: before treatment, at interim times, and in case of relapse in order to establish correlations between patients at high risk of relapse and their molecular profiles"
48290343|NCT04512885|OTHER|Survey|Survey via questionnaire
48290344|NCT02365857|DRUG|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine \& Bupivacaine.
48290345|NCT02365857|DRUG|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
48290346|NCT03224533|DIAGNOSTIC_TEST|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
48290347|NCT02355912|DEVICE|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
48290348|NCT04814823|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
48290349|NCT00875420|DRUG|RAD1901|10 mg Oral once a day for 28 days.
48290350|NCT00875420|DRUG|RAD1901|25 mg Oral once a day for 28 days
48102507|NCT06631716|DEVICE|CVT|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is CVT.
48290351|NCT00875420|DRUG|RAD1901|50 mg Oral once a day for 28 days.
48618021|NCT04213911|DEVICE|insertion of esophageal balloon|The esophageal catheter is a flexible thin plastic tube with an air-filled balloon at the distal end. The tube will be placed through the nasopharynx after local anesthesia.
48290352|NCT00875420|DRUG|RAD1901|100 mg Oral once a day for 28 days
48290353|NCT00875420|DRUG|Placebo|Placebo Oral once a day for 28 days
48290354|NCT01821248|DRUG|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
48290355|NCT05901181|BEHAVIORAL|Laughter Yoga|"Laughter yoga is a childlike practice where group members make eye contact with each other.~It is a breath yoga practiced by imitating games and fake laughing. Brain the effects of real laughter on the body, as it cannot distinguish between fake and real laughter.~showing positive effects. It consists of sessions lasting at least 20 minutes and an average of 45 minutes."
48290356|NCT02333045|DRUG|Truvada qd|Truvada 1 tablet PO daily for 7 days
48290357|NCT02333045|DRUG|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
48290358|NCT00917410|BEHAVIORAL|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~1. Remember to take your preventive asthma medication (sent at 8.00 am).~2. Were you awakened during the night due to your asthma? Answer YES or NO.~3. How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~4. What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
48290359|NCT00671151|DRUG|Theophylline|Theophylline 100 mg bid for 3 months
48290360|NCT05632250|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
48290361|NCT05266638|OTHER|Data collection (radiological parameters, outcome information) from electronic patient files in hospital data system|Collection of medical data and medical images (MRI, radiographs) of the lumbar spine and pelvis of patients having received TLIF with degenerative spinal diseases from the years 2015-2020 and statistical analysis of the coded data.
48290362|NCT00035815|DRUG|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
48290363|NCT00035815|DRUG|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
48290364|NCT04730323|DRUG|Tocilizumab|"Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded."
48618022|NCT02674659|BEHAVIORAL|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session was held for around 30 minutes.
48618023|NCT02674659|BEHAVIORAL|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
48290365|NCT01331395|OTHER|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
48290366|NCT06510426|DRUG|Rebif 44 MCG Per 0.5 ML Prefilled Syringe|Rebif 44mcg per 0.5ml administered subcutaneously
48290367|NCT06510426|DRUG|Saline|0.5mL of saline administered subcutaneously
48290368|NCT02189330|DRUG|Tafamidis|20 mg of current commercial formulation.
48290369|NCT02189330|DRUG|Tafamidis|12.2 mgA free acid tablet.
48290370|NCT02189330|DRUG|Tafamidis|20 mg new soft gelatin capsule.
48290371|NCT02189330|DRUG|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
48290372|NCT02189330|DRUG|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
48290373|NCT00539786|DRUG|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
48290374|NCT04052958|DEVICE|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
48618024|NCT02941640|PROCEDURE|E group|The securing the base of appendix by endoloop.
48631373|NCT03237312|PROCEDURE|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
48631374|NCT03237312|BIOLOGICAL|Antimullerian hormone|"1. In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~2. In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
48631375|NCT01601977|DEVICE|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
48631376|NCT01601977|DEVICE|Usual care|Non-invasive ventilation with standard ventilator
48631377|NCT01183286|BEHAVIORAL|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
48631378|NCT01183286|BEHAVIORAL|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
48631379|NCT03398109|DEVICE|Customized toric IOL for post-DALK atigmatism|
48631380|NCT02665455|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
48631381|NCT03251105|DEVICE|supraglottic airway intubation|
48631382|NCT00762177|DRUG|Fluoride|Brush twice a day for 14 days
48631383|NCT00762177|DRUG|Fluoride, Triclosan|Brush twice daily for 14 days
48102508|NCT06631716|DEVICE|HFCWO|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is HFCWO.
48631384|NCT00762177|DRUG|Stannous Fluoride|Brush twice daily for 14 days
48631385|NCT02242110|BEHAVIORAL|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
48631386|NCT03418207|PROCEDURE|trans-perineal template-guided mapping biopsy|new super saturation of prostate biopsy technique
48631387|NCT00777673|DRUG|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
48631388|NCT03068520|DIAGNOSTIC_TEST|PET MR|PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals
48631389|NCT02822287|DRUG|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
48631390|NCT00387127|DRUG|Lapatinib oral tablets|Lapatinib is administered orally once daily.
48631391|NCT00387127|DRUG|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
48631392|NCT00387127|DRUG|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
48631393|NCT03123107|DRUG|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
47941947|NCT06413212|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.|Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
47941948|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
47941949|NCT00769574|OTHER|Biological analysis of biomarkers|Biological analysis of biomarkers
47941950|NCT06354257|DRUG|EE/LNG|One dose of EE and LNG is administered on Day 1 of treatment period 1 and one dose of EE/LNG co-administered with GSK3036656 DL 2 is given on Day 15 of treatment period 3.
48102509|NCT06631716|DEVICE|MetaNeb|During mechanical ventilation, patients with atelectasis confirmed by chest CT, chest X-ray or lung ultrasound should be treated with mechanical assisted sputum evacuation, and the mechanical assisted sputum evacuation equipment used is MetaNeb.
48618025|NCT02941640|PROCEDURE|S group|The securing the base of appendix by Stapler.
48618026|NCT02941640|PROCEDURE|H group|The securing the base of appendix by Hem-o-lok clip.
48618027|NCT02941640|PROCEDURE|DS group|The securing the base of appendix by DS clip.
48618028|NCT02941640|DEVICE|Endoloop|
48631394|NCT02708706|DRUG|hyaluronic acid (hyruan)|2cc hyaluronic acid
48631395|NCT02708706|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
48631396|NCT06017375|OTHER|Questionnaire based intervention|Three validated questionnaires amended from hepatitis B to D (Chronic liver disease questionnaire, self-stigma scale and HBV virus knowledge scale) will be used.
47941951|NCT06354257|DRUG|GSK3036656 Dose Level 1|A loading dose of GSK3036656 with DL 1 is administered on Day 4 of treatment period 2.
47941952|NCT06354257|DRUG|GSK3036656 Dose Level 2|One dose of GSK3036656 DL 2 is administered once a day from Day 5 to Day 14 of treatment period 2. In treatment period 3 a single dose of GSK3036656 DL 2 co-administered with EE/LNG is given on Day 15, then GSK3036656 DL 2 once a day from Day 16 to Day 17.
47941953|NCT03671993|PROCEDURE|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
47941954|NCT03671993|PROCEDURE|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
47941955|NCT05622370|DRUG|Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)|"Brivaracetam tablets (trade name: Briviact) Specification: 50mg/ piece Batch number: 34244 Content: 100.0% Date of purchase: September 2022~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach.~Expiry date: April 2025 Storage conditions: sealed, stored at 20-25℃, allowing short-term temperature deviation of 15-30℃ Manufacturer: Union Chimique Belge Pharm, UCB Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd."
47941956|NCT05622370|DRUG|Brivaracetam sustained-release tablets 100mg|"Brivaracetam sustained-release tablets Specification: 100mg/ tablet Batch number: 22081201 Content: 102.5% Date of production: August 12, 2022 Expiry date: August 11th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
47941957|NCT05622370|DRUG|Brivaracetam sustained-release tablets 50mg|"Brivaracetam sustained-release tablets Specification: 50mg/ piece Batch number: 22082501 Content: 100.0% Date of production: September 02, 2022 Expiry date: August 24th, 2024. Storage conditions: sealed and stored at 10-30℃ Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Taizhou Overseas Pharmaceuticals Co.,Ltd.~According to the random table, take test preparation A(T1) once (1 tablet/time) or test preparation B(T2) once (2 tablets/time) or reference preparation (R) twice (1 tablet/time, with an interval of 12 hours, before taking the medicine for the first time) on an empty stomach."
48631397|NCT03705611|DIAGNOSTIC_TEST|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
48631398|NCT03705611|BEHAVIORAL|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
47941958|NCT03239964|DRUG|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
47941959|NCT03239964|OTHER|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
47941960|NCT00797368|OTHER|Manual Therapy and Exercise|Manual Therapy and Exercise
47941961|NCT00797368|OTHER|Home exercises|Home exercises
47941962|NCT02314234|DRUG|sugammadex (Bridion)|single dose of sugammadex at skin incision
48618029|NCT02941640|DEVICE|Stapler|
48618030|NCT02941640|DEVICE|Hem-o-lok clip|
48618031|NCT02941640|DEVICE|DS clip|
48618032|NCT05994183|DRUG|Dexamethasone Oral|Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
48618033|NCT03636256|DRUG|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
48631399|NCT05991479|OTHER|Pilates exercises|"Pilates exercises:~The subjects will receive Pilates training (3 sessions/week) for 8 weeks. The Pilates training protocol will take 60 min per session, including 10 min of warm up prior to initiating the Pilates technique, 40 min for Pilates exercises and 10 min for cool down. The number of repetitions will be 10 times. The patient will perform the following Pilates exercises: (Hundred exercises, spine stretch, single leg stretch , double leg stretch, criss cross, swimming, one leg kick, side kick, clam, one leg circle, shoulder bridge, hip twist, roll up and down and standing footwork)."
48631400|NCT05991479|OTHER|Traditional physical therapy programme:|"All patients will receive a traditional physical therapy programme consisting of 45 minutes per session of a supervised and individualized exercise programme for three sessions per week for eight weeks which will include:~Stretching exercises for calf and hamstring muscles. Strengthening exercises for hip, knee, ankle, and foot muscles. Deep friction massage for scar management."
48631401|NCT02321501|DRUG|Ceritinib|Given PO
48631402|NCT02321501|DRUG|Everolimus|Given PO
48631403|NCT02321501|OTHER|Laboratory Biomarker Analysis|Correlative studies
48631404|NCT02321501|OTHER|Pharmacological Study|Correlative studies
48631405|NCT03061851|BEHAVIORAL|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
48290375|NCT06128941|OTHER|Repeated sprint|"* Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets."
48473751|NCT04012073|PROCEDURE|Resume of spontaneous breathing|"Assist/control and assist ventilation will be allowed after 72 hours from the enrolment if deemed appropriate by the attending physician.~During spontaneous breathing, PEEP will be set according to the decision of the attending physician and the practice of each institution: however, in order to standardize the treatments, moderate PEEP (10-15 cmH2O) will be encouraged in case of moderate hypoxemia (PaO2/FiO2\<150 mmHg) in control group, while PEEP close to the value set during controlled ventilation according to the treatment protocol but \<15 cmH2O will be suggested in the intervention group.~During assist/control and assisted ventilation, PEEP will never be higher than the last PEEP set according to the assigned protocol during controlled ventilation.~Fully controlled mechanical ventilation will be resumed any time during the study period if the patient meets the criteria described above or any time deemed necessary by the physicians in charge"
48473752|NCT04012073|PROCEDURE|Rescue treatments|Recruitment maneuvers, extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2-R) after randomization will be allowed in both groups as rescue therapies and according to the decision of attending physicians: any of these procedures will be accurately recorded on the case report form.
48631406|NCT03061851|OTHER|Maltose app|"1. Weekly diabetes-related science articles.~2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~5. Personalize the development of diet, exercise program.~6. different insulin and oral hypoglycemic drug medication time to remind.~7. hypoglycemic drug side effects query."
48631407|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
48631408|NCT02345577|OTHER|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
48631409|NCT04220281|DRUG|Propofol|propofol infusion during surgery
48631410|NCT04220281|DRUG|Nitroglycerin|nitroglycerin infusion during surgery
48631411|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh, vaginal flap and anterior colporrhaphy
48631412|NCT06494982|PROCEDURE|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy|Sacrospinous hysteropexy with the synthetic mesh and anterior colporrhaphy
48102510|NCT02952950|OTHER|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
48290376|NCT01425866|BEHAVIORAL|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
48631413|NCT04747002|DRUG|DSP-7888|Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
48631414|NCT05357079|DRUG|Tranexamic Acid|Topical application
48631415|NCT05357079|DRUG|Normal saline|Topical application
48631416|NCT06122493|DRUG|Tirelizumab|immunotherapy, 200 mg on day 1 per 3 weeks
48631417|NCT06122493|DRUG|Nab paclitaxel|chemotherapy, 175 mg/m² on day 1 per 3 weeks
47941963|NCT05912452|OTHER|Percussion Massage Therapy|Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.
48290377|NCT04392011|DRUG|Midazolam HCl|Oral syrup, 2 mg/mL
48473753|NCT04012073|PROCEDURE|Weaning from PEEP|"In order not to delay weaning from mechanical ventilation, when a patient is managed with assist/control or assist ventilation with PEEP higher than 8 cmH2O, a daily PEEP weaning trial will be performed whether PaO2/FIO2 ratio\>150 mm Hg and FIO2\<0.5: PEEP will be decreased to 8-5 cm H2O and arterial blood gas will be sampled after 20 -0 minutes. Previous ventilatory settings will be resumed if during the procedure transcutaneous oxyhemoglobin saturation decreases below 88%, PaO2/FIO2 falls below 150 mm Hg or if the patient experiences abnormal changes in respiratory rate or other clinical signs suggestive of respiratory distress.~When PaO2/FIO2 is no lower than 200 mm Hg at PEEP≤8 cmH2O, the patient will be considered to have acceptable gas exchange on 8-5 cmH2O of PEEP and will be deemed capable to tolerate this setting"
48473754|NCT04012073|PROCEDURE|Weaning from mechanical ventilation|"A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2\<88% or PaO2/FiO2\<150mmHg):~* improvement or resolution of the underlying cause of acute respiratory failure~* normal sensorium~* correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~* absence of fever (≥ 38 °C) or sepsis;~* blood hemoglobin concentration of 7 g/dL or more;~* hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~* respiratory rate \< 35/min,~* arterial oxygen saturation ≥ 90%,~* heart rate \< 120/min,~* systolic blood pressure \> 90 and \< 160 mmHg~* adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated."
48473755|NCT04012073|PROCEDURE|Extubation|"Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%\>SpO2\>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician."
48473756|NCT01314768|BEHAVIORAL|Brief intervention|Structured behavioural Brief intervention given by trained GPs
48473757|NCT01314768|OTHER|Business as usual|GPs to treat patient as they have until now based on best established practice
48473758|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
48473759|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
48473760|NCT00381823|BEHAVIORAL|Cognitive Behavioral Therapy|
48473761|NCT04167618|DRUG|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
48473762|NCT04703855|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
48473763|NCT02607137|BEHAVIORAL|Health Education|Information on healthy living style in relation to physical activity
48473764|NCT06070805|OTHER|depression|The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
48473765|NCT02902887|DEVICE|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
48473766|NCT04252287|DRUG|Canagliflozin 100 mg|Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
48473767|NCT04252287|DRUG|Placebo|Participants will receive matching placebo capsules orally once daily.
48618034|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
48631418|NCT06122493|DRUG|Carboplatin|chemotherapy, AUC=5 on day 1 per 3 weeks
47941964|NCT05912452|OTHER|Kinesiotaping|the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
47941965|NCT05912452|OTHER|Dynamic stretching|Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
47941966|NCT05708027|PROCEDURE|Thoracoscopic surgical ablation|Thoracoscopic surgical ablation is a minimally invasive procedure used to treat atrial fibrillation by creation Box Lesion Set using Radio Frequency Energy. Pulmonary veins isolation was performed using ablation clamps, whereas isolation of the posterior left atrium (box) was performed using a clamping Medtronic or a linear nonclamping AtriCure device.
47941967|NCT04146298|DRUG|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
47941968|NCT04146298|DRUG|Fludarabine|Fludarabine will be administered prior to cell infusion.
48290378|NCT04392011|DRUG|Dextromethorphan HBr|Oral liquid capsules, 15 mg
48631419|NCT06122493|RADIATION|Radiotherapy|Patients without disease progression after four cycles of chemoimmunotherapy receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy delivered over 28 fractions.
48631420|NCT02845427|DEVICE|closed suction drain|using closed suction drain system postoperative
48631421|NCT02845427|PROCEDURE|no suction drain|the surgical wound will be closed with no suction drain
48631422|NCT05282407|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
48631423|NCT05282407|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
48631424|NCT06398639|OTHER|Polygenic Risk Score (PRS)|"Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score."
48290379|NCT04392011|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
48473768|NCT05372497|OTHER|Intervention group (IG)|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~* Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~* Right / Left Discrimination Training~* Localization Training Level 1- Level 2 Training~* Visual imagination Training~* Visual Imagery Training~* Mirror Therapy~* Isometric and functional exercises"
48473769|NCT05372497|OTHER|Control group (CG)|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~* Electrotherapy~* Scapular mobilization~* Passive stretches~* Stick Exercises~* Pendulum Exercises~* Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
48473770|NCT00741754|OTHER|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
48473771|NCT02330744|BEHAVIORAL|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
48473772|NCT02330744|BEHAVIORAL|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
48618035|NCT03636256|OTHER|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
48290380|NCT03517722|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
48618036|NCT03636256|DRUG|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
48631425|NCT02773628|DEVICE|Acar'up system|
48631426|NCT02773628|DEVICE|Acar'up placebo system|
47941969|NCT04146298|BIOLOGICAL|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
48290381|NCT03517722|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
48290382|NCT03517722|DRUG|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
48631427|NCT03880890|PROCEDURE|sphenoidotomy versus sphenoid nasalisation|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
48290383|NCT01319760|DEVICE|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
48290384|NCT01319760|OTHER|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
48631428|NCT05099406|DEVICE|Transcranial electrical stimulation|"By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session."
48631429|NCT05496738|DRUG|PF-07264660 intravenous single ascending dose|PF-07264660 will be administered intravenously in single ascending doses
48631430|NCT05496738|DRUG|PF-07264660 subcutaneous multiple ascending dose|PF-07264660 will be administered subcutaneously in multiple ascending doses
48290385|NCT06274567|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
48290386|NCT06274567|DEVICE|Sham (placebo) TMS|Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
48290387|NCT05644730|DEVICE|Fusion closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
48290388|NCT04534894|DIAGNOSTIC_TEST|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
48290389|NCT03546556|DRUG|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
48290390|NCT01716169|DEVICE|Helicoll|Helicoll Collagen I Wound Dressing
48290391|NCT01716169|DEVICE|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
48473773|NCT04487899|DEVICE|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
48473774|NCT02111434|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
48473775|NCT03208673|DEVICE|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
48473776|NCT02292511|BEHAVIORAL|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
48473777|NCT01563458|DRUG|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
48473778|NCT01563458|DRUG|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
48473779|NCT01563458|DRUG|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
48473780|NCT00468338|DEVICE|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
48473781|NCT02124902|DRUG|Docetaxel|
48473782|NCT02124902|DRUG|Carboplatin|
48631431|NCT05496738|OTHER|Intravenous placebo|Placebo will be administered intravenously in single ascending doses
48290392|NCT03303430|DIAGNOSTIC_TEST|MRI|Diffusion weighted imaging 24 hours after revascularisation
48290393|NCT00787007|DRUG|S-equol|capsule, oral, single dose
48290394|NCT00787007|DRUG|Placebo|capsule, oral, single dose
48618037|NCT00112229|BIOLOGICAL|group 1|Melan-A analog peptide + CpG + Montanide
48631432|NCT05496738|OTHER|subcutaneous placebo|Placebo will be administered subcutaneously in multiple ascending doses
48631433|NCT04696770|BEHAVIORAL|Mindfulness|Mindfulness techniques will be taught to the participants
47941970|NCT04146298|DRUG|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
48290395|NCT01498510|BEHAVIORAL|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
48290396|NCT01850381|DRUG|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
48290397|NCT01850381|DRUG|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
48290398|NCT00055198|DRUG|daptomycin|
48290399|NCT02557503|DRUG|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
48290400|NCT01042301|OTHER|Blood samplings|
48473783|NCT02124902|PROCEDURE|FDG-PET/MR|"* Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study"
48473784|NCT03405857|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
48473785|NCT05907655|DRUG|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
48473786|NCT05907655|DIAGNOSTIC_TEST|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
48473787|NCT05907655|DIAGNOSTIC_TEST|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
48473788|NCT05907655|DEVICE|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
48631434|NCT01196234|DRUG|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
48631435|NCT01196234|DRUG|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
47941971|NCT05585164|BEHAVIORAL|Engage & Connect (E&C)|"Engage \& Connect, is a remotely-delivered extension of Engage psychotherapy. It is aimed to increase engagement in rewarding social activities and in turn, reduce postpartum depression. In each session, the therapist will work with the patient to develop action plans to pursue rewarding social activities of their choice with the goal of reducing social isolation."
48290401|NCT02928640|DEVICE|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
48290402|NCT00683189|DRUG|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
48290403|NCT04231981|DRUG|INCMGA0012|INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
48290404|NCT04508309|BIOLOGICAL|Cecolin®|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
48473789|NCT04847999|DIETARY_SUPPLEMENT|Dark chocolate|Dark chocolate
48290405|NCT04508309|BIOLOGICAL|Gardasil®|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
48290406|NCT06193083|OTHER|Semi-directed individual interviews|Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
48290407|NCT06193083|OTHER|The self-administered questionnaires, rPATD and BMQ|"rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal)~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief."
48631436|NCT00380523|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
48631437|NCT05756387|DEVICE|Non-invasive ventilation|NIV as in standard care
48631438|NCT04599257|DEVICE|BTL-899|The device applicator combines high-intensity focused electromagnetic procedure and radiofrequency energy to induce visible muscle contractions along with heating of the subcutaneous fat.
48631439|NCT03192020|PROCEDURE|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
48631440|NCT03192020|DRUG|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
48631441|NCT03192020|PROCEDURE|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
47941972|NCT05585164|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|SPR is a remotely-delivered intervention aimed to increase knowledge of postpartum depression and monitor mental health changes. In each session, the therapist will review the participant's symptoms and discuss information related to postpartum depression and changes after birth.
48290408|NCT06193083|OTHER|The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)|"FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations"
48290409|NCT00404768|DRUG|GSK221149A|6mg/h and 12 mg/h
48290410|NCT00404768|DRUG|Placebo|Matched Placebo to Drug
47941973|NCT05319769|PROCEDURE|Atrial fibrillation ablation|Pulmonary vein isolation
47941974|NCT01400685|DRUG|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
48290411|NCT04817540|DRUG|Herzuma|8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
48290412|NCT04677842|DRUG|ART Therapy|
48290413|NCT00236561|DRUG|topiramate, propranolol|
48473790|NCT00808717|DRUG|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
48290414|NCT03498872|DEVICE|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
48290415|NCT03498872|OTHER|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
48290416|NCT05992779|OTHER|Measuring the vocal audiometry of patients.|Measuring vocal audiometry at 6 months, 1 year and annually until the last date of follow-up
48290417|NCT05992779|OTHER|Measuring data loging|Measuring data loging at 6 months, 1 year and then annually until last date of follow-up
48290418|NCT01542372|DRUG|Medication augmentation|
48290419|NCT01542372|BEHAVIORAL|CBT|
48290420|NCT05719064|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
48290421|NCT05719064|BEHAVIORAL|Computer-Delivered Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
48290422|NCT05719064|BEHAVIORAL|Automated Text Reminders|Scheduled text reminder to take medication
48290423|NCT00002423|DRUG|Indinavir sulfate|
48290424|NCT00002423|DRUG|Abacavir sulfate|
47941975|NCT01400685|DRUG|Bendamustine|90 mg/m\^2 IV days 1-2 of each cycle for 6 cycles
47941976|NCT01400685|DRUG|Rituximab|375 mg/m\^2 IV day 1 (cycle 1), 500 mg/m\^2 day 1 (cycles 2-6)
47941977|NCT06179433|PROCEDURE|Root canal treatment|Two-visit root canal treatment will be performed.
48290425|NCT00002423|DRUG|Amprenavir|
48290426|NCT00002423|DRUG|Nelfinavir mesylate|
48290427|NCT00002423|DRUG|Lamivudine|
48290428|NCT04936880|DEVICE|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
48290429|NCT04936880|DRUG|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
48290430|NCT03541577|DEVICE|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
48290431|NCT03541577|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
48473791|NCT04398979|PROCEDURE|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
48473792|NCT05480306|DRUG|DKN-01|30 minute IV infusion (400mg) every two weeks with an additional loading dose in the first cycle of treatment
48618038|NCT00112229|BIOLOGICAL|group 2|Melan-A natural peptide + CpG + Montanide
47941978|NCT06179433|PROCEDURE|Regenerative endodontic procedure|Regenerative endodontic procedure with i-PRF and blood clot induction will be performed.
47941979|NCT03391531|PROCEDURE|Bilateral subcostal TAP block|Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
47941980|NCT05832827|DRUG|MK-3475|Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
47941981|NCT05832827|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
47941982|NCT05832827|DRUG|Carboplatin|Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
48290432|NCT00708877|PROCEDURE|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
48290433|NCT03450850|DEVICE|NOVOTTF-200A|NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
48290434|NCT02049528|DRUG|CC-122|CC-122
48290435|NCT02049528|DRUG|CC-122|CC-122
48290436|NCT02049528|DRUG|CC-122|CC-122
48290437|NCT02247830|OTHER|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
48290438|NCT02247830|DRUG|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
48290439|NCT01522651|DRUG|Ranolazine|Tablets administered orally twice daily.
48290440|NCT01522651|DRUG|Dronedarone|Capsule administered orally twice daily
48290441|NCT01522651|DRUG|Ranolazine placebo|Tablets administered orally twice daily.
48102511|NCT03533036|DEVICE|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D\&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
48102512|NCT04162366|DRUG|Aprocitentan 25 mg|Tablet, oral use once daily
48290442|NCT01522651|DRUG|Dronedarone placebo|Capsules administered orally twice daily
48290443|NCT05303675|OTHER|exercise and training|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
48290444|NCT00489983|DRUG|pemetrexed|
48290445|NCT00489983|DRUG|gemcitabine|
48290446|NCT02616653|PROCEDURE|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
48290447|NCT01231191|DRUG|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
48290448|NCT01231191|DRUG|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
48102513|NCT04162366|DRUG|Placebo|Matching placebo tablet, oral use once daily
48102514|NCT03910543|DRUG|Tofacitinib 5 mg twice daily|Tofacitinib will be administered at a dose of 5 mg twice daily
48290449|NCT06201299|OTHER|Standard Exercise Program|The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
48618039|NCT00112229|BIOLOGICAL|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
48290450|NCT06201299|OTHER|Chair-based Exercise Program|The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
48290451|NCT05337449|OTHER|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
48290452|NCT05337449|OTHER|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
48290453|NCT06449261|OTHER|Spinal Manual therapy used in Physiotherapy Practice|C5-C6 and thoracic spine mobilization with postural correction
48290454|NCT03976401|DRUG|EFX|Administered by subcutaneous injection
48290455|NCT03976401|DRUG|Placebo|Administered by subcutaneous injection
48290456|NCT04359953|DRUG|Hydroxychloroquine|Hydroxychloroquine 2 x per day during 14 days
48290457|NCT04359953|DRUG|Azithromycin|Azithromycin 2 x per day during 14 days
48290458|NCT04359953|DRUG|Telmisartan|Telmisartan 2 x per day during 14 days
48290459|NCT04155385|OTHER|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
48290460|NCT04155385|OTHER|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
48290461|NCT00673673|DRUG|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
48290462|NCT00673673|DRUG|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
48290463|NCT00443560|OTHER|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
48290464|NCT01928030|BIOLOGICAL|recombinant human hyaluronidase|Given SC
48290465|NCT05753306|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
48290466|NCT05753306|DRUG|Cisplatin|Given via HIPEC
48290467|NCT05753306|PROCEDURE|Computed Tomography|Undergo CT scan or PET/CT
48290468|NCT05753306|DRUG|Docetaxel|Given via HIPEC
48290469|NCT05753306|PROCEDURE|Gastrectomy|Undergo robotic gastrectomy
48290470|NCT05753306|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
48290471|NCT05753306|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48290472|NCT05753306|PROCEDURE|Positron Emission Tomography|Undergo PE/CT
48290473|NCT05753306|OTHER|Questionnaire Administration|Complete questionnaire
48290474|NCT01736683|DRUG|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
48290475|NCT04311905|DEVICE|Diode laser|Diode laser activated irrigation
48290476|NCT04311905|OTHER|Placebo|mock Laser activated irrigation
48290477|NCT02328716|PROCEDURE|Cytoreduction|Cytoreduction
48290478|NCT02328716|DRUG|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
48290479|NCT05446246|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
48290480|NCT00744367|DRUG|metformin|\>1500 mg/day or maximum tolerated dose (MTD)
48290481|NCT00744367|DRUG|pioglitazone|\>= 30 mg/day
47941983|NCT05832827|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
47941984|NCT01173861|BEHAVIORAL|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
47941985|NCT05060887|BIOLOGICAL|OVX836-003|One single administration intramuscularly at Day 1.
48290482|NCT00744367|DRUG|placebo|sc once weekly
48473793|NCT05480306|DRUG|FOLFIRI|90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
47941986|NCT05060887|BIOLOGICAL|Saline solution|One single administration intramuscularly at Day 1.
47941987|NCT02233062|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition Therapy|
47941988|NCT01859143|BIOLOGICAL|Trivalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
47941989|NCT01859143|OTHER|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
47941990|NCT04949685|PROCEDURE|plantar plate repair|surgical repair via dorsal approach of lesser metatarsophalangeal joint general anesthesia
47941991|NCT06182579|DRUG|RiMO-401|• Single intratumoral injection of RiMO-401 followed by palliative radiotherapy
47941992|NCT04840576|OTHER|Regular waterproof sterile dressing.|Waterproof sterile dressing OPSITE Post-Op Visible, Smith \& Nephew, UK
47941993|NCT04840576|OTHER|Prophylactic Negative Pressure Dressing|Negative wound pressure dressing: PICO-7, Smith \& Nephew, UK
47941994|NCT04562493|PROCEDURE|Transforaminal Epidural injection|Transforaminal injection will be performed under fluoroscopy guidance. The patient will be placed in the prone position and draped in the sterile manner. A 22-gauge, 3.5-inch spinal needle will be used. The selected patients will receive transforaminal epidural injection of the drug
47941995|NCT06434818|COMBINATION_PRODUCT|EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)|EDITOR includes a user-friendly cloud portal synced with the main device, providing a comprehensive training program for the orbitofrontal cortex (OFC). The main device stimulates the orbitofrontal cortex intensely, preventing habituation to smells and improving adaptability. This enhances neurobehavioral plasticity, benefiting Substance Use Disorder (SUD) outcomes. The device also features a 60% beta-caryophyllene scent for addressing issues like Alcohol Use Disorder and stimulant use disorders. With ten digital enhancements, it enables remote treatment and data collection, seamlessly transmitting information to healthcare providers through a secure, HIPAA-compliant portal.
47941996|NCT06434818|COMBINATION_PRODUCT|CBOT with olfactory stimulants & OFC tasks|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.
47941997|NCT06434818|COMBINATION_PRODUCT|CBOT Sham|CBOT Sham uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks
47941998|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc combined|Children \>= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
47941999|NCT00470158|DIETARY_SUPPLEMENT|iron and zinc on separate days|Children \>= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
48473794|NCT05480306|DRUG|Bevacizumab|90-min IV infusion (5mg)
48473795|NCT05480306|DRUG|FOLFOX|2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
47942000|NCT00470158|DIETARY_SUPPLEMENT|iron|Children \>= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
48102515|NCT05747313|DRUG|Chidamide|"Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal."
48102516|NCT04511806|OTHER|Registry|This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
48102517|NCT01229839|OTHER|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
48102518|NCT01229839|OTHER|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
48102519|NCT01229839|OTHER|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
48290483|NCT00744367|DRUG|taspoglutide|10 mg sc once weekly;
48290484|NCT00744367|DRUG|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
48290485|NCT03513380|BEHAVIORAL|Exergaming|free access to the exergame PedalTanks during 6 months
48473796|NCT02846233|DRUG|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
48473797|NCT02846233|DRUG|basal insulin|The participant will continue with the basal insulin.
48473798|NCT02846233|DRUG|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
48473799|NCT02846233|DRUG|Metformin|The participant will continue with metformin.
48618040|NCT00112229|BIOLOGICAL|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
48618041|NCT04464772|DEVICE|FreeStyle Libre 3|FreeStyle Libre 3 Continuous Glucose Monitoring System
48290486|NCT04230577|DEVICE|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
47942001|NCT00470158|DIETARY_SUPPLEMENT|Zinc|Children \>= 12 months received an average of 5mg zinc/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
48473800|NCT02857647|BEHAVIORAL|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
47942002|NCT00470158|DIETARY_SUPPLEMENT|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
47942003|NCT04766827|DRUG|albumin-bound paclitaxel|Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
47942004|NCT02044328|DRUG|Icotinib|Icotinib is administered 125 mg three times per day.
47942005|NCT00121173|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|recombinant DNA vaccine
47942006|NCT00606827|DRUG|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
47942007|NCT00606827|DRUG|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
47942008|NCT05337293|BEHAVIORAL|COPE-HF Partnership Intervention|Participants were trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems experienced in the home over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention was to move HF patients toward a positive problem orientation and use of rational problem-solving strategies that support greater HF self-care and reduce depression. The COPE-HF Partnership Intervention consisted of 1 home visit and 7 follow-up telehealth sessions led by a registered nurse interventionist.
47942009|NCT05337293|OTHER|Attention|Participants in the attention group received a sham intervention that consisted of scheduled telephone calls consistent with the timing of that received by the intervention group. During these calls, basic information was gathered on key areas of heart failure self-care management and the frequency of healthcare usage. No intervention or education was provided.
47942010|NCT02515812|DRUG|I-123-MIBG|
47942011|NCT02515812|DEVICE|CZT Camera (D-SPECT)|
48290487|NCT04230577|DEVICE|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
48290488|NCT02975648|BEHAVIORAL|educational model + follow up|Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
48290489|NCT02975648|BEHAVIORAL|usual care|Hospital health professionals offered orientation on care after discharge
48631442|NCT01776203|DRUG|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
47942012|NCT02515812|DEVICE|Anger Camera|
47942013|NCT04466228|DEVICE|non-invasive transcranial electrical stimulation|Non-invasive transcranial electrical stimulation across the prefrontal cortex.
47942014|NCT02147002|DIETARY_SUPPLEMENT|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
47942015|NCT05743621|DRUG|TVB-2640|TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
48290490|NCT01252329|PROCEDURE|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
48290491|NCT05581719|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
48290492|NCT05581719|DRUG|Nivolumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
48290493|NCT05581719|DRUG|Tislelizumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
48290494|NCT02420652|DRUG|Aspirin|Given PO
48290495|NCT02420652|OTHER|Laboratory Biomarker Analysis|Correlative studies
48290496|NCT02420652|DRUG|Metformin Hydrochloride|Given PO
48290497|NCT02420652|OTHER|Placebo|Given metformin hydrochloride placebo PO
48290498|NCT02420652|OTHER|Placebo|Given aspirin placebo PO
48290499|NCT02722577|PROCEDURE|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
48290500|NCT05539053|DRUG|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
48290501|NCT05539053|DRUG|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
47942016|NCT05743621|DRUG|Enzalutamide|160 mg daily PO
48290502|NCT01326962|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
48290503|NCT06450028|DRUG|10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine|Injection of 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine.
48290504|NCT06450028|DRUG|6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine|Injection of 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine.
48290505|NCT06273865|DIAGNOSTIC_TEST|Several assays|Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
48290506|NCT03320733|DIAGNOSTIC_TEST|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
48290507|NCT02250040|OTHER|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
48290508|NCT02250040|OTHER|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
47942017|NCT06256198|OTHER|measurement of serum lactate and procalcitonin and PCO2 gap|measurement of serum lactate, procalcitonin and PCO2 gap
47942018|NCT01194427|DRUG|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
48290509|NCT04048239|PROCEDURE|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
48102520|NCT03525041|PROCEDURE|CABG|CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
48102521|NCT03525041|PROCEDURE|mitral valve annuloplasty|Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
47942019|NCT00664469|DRUG|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
47942020|NCT00664469|DRUG|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
47942021|NCT00664469|DRUG|Comparator: Atorvastatin|Atorvastatin 20, 40 \& 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
47942022|NCT00664469|DRUG|Comparator: Rosuvastatin|Rosuvastatin 10, 20 \& 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
47942023|NCT06275607|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger.
48102522|NCT00315055|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
48102523|NCT00315055|BIOLOGICAL|DTaP-IPV//PRP~T combined|0.5 mL, IM
48102524|NCT00315055|BIOLOGICAL|Hepatitis B vaccine|0.5 mL, IM
48102525|NCT03245541|DRUG|Durvalumab|Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
48102526|NCT03245541|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR delivered as 6.6 Gy/fraction x 5 fractions given within two weeks will be administered weekdays and will begin D8.
48102527|NCT03001986|BIOLOGICAL|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
48102528|NCT02783157|DEVICE|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
48290510|NCT04048239|OTHER|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
48290511|NCT04048239|OTHER|electromyograph|electromyographic verification of the facial nerve
48290512|NCT06270992|DIAGNOSTIC_TEST|NCCN (National Comprehensive Cancer Network) diagnosis|For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
48290513|NCT06513221|DRUG|Chemotherapy, Bevacizumab, Adebrelimab|Adebrelimab: 1200mg，q3w Bevacizumab: 7.5mg/kg，q3w Fruquintinib: 4mg po d1\~d14, q3w Chemotherapy: XELOX/mXELIRI: conventional dose
48290514|NCT06358729|BEHAVIORAL|Typical Nipple|Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.
48290515|NCT06358729|BEHAVIORAL|Challenging Nipple|Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).
48290516|NCT05976737|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
48290517|NCT05976737|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
48290518|NCT01332032|BEHAVIORAL|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
48102529|NCT02783157|DEVICE|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
48102530|NCT03936829|DRUG|Cyclophosphamide|Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
48102531|NCT04313452|OTHER|the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged|to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
48290519|NCT01332032|BEHAVIORAL|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
48290520|NCT01332032|BEHAVIORAL|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
48290521|NCT05546788|PROCEDURE|scaling and root planing|subgingival Depridement
48290522|NCT05546788|DRUG|hydroxylated poly methoxy flavones|Received hydroxylated poly methoxy flavones extract solid dispersion incorporated into sodium carboxymethylcellulose gel
48290523|NCT05546788|DRUG|chlorhexidine|Received chlorhexidine gel
48290524|NCT05546788|DRUG|placebo|Received placebo gel
48631443|NCT01444170|DIETARY_SUPPLEMENT|dicreatinol sulfate|nutritional supplement
48631444|NCT01444170|DRUG|placebo sugar pill|
48631445|NCT01135056|DEVICE|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
48102532|NCT02860260|BIOLOGICAL|Blood samples|
48102533|NCT02860260|OTHER|Cerebral MRI|
48102534|NCT06249789|PROCEDURE|Spinal Anesthesia|Participants in this arm will receive single-shot spinal anesthesia with 12-15 mg of either 0.05% or 0.75% bupivacaine (iso or hyperbaric) once before surgery. Additionally, they will undergo an ultrasound-guided nerve block called the Fascia Iliaca Compartment Block (FICB ) in combination with spinal anesthesia.
48290525|NCT01327430|DIETARY_SUPPLEMENT|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
48290526|NCT01849848|DRUG|SyB L-0501|The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
48102535|NCT06249789|PROCEDURE|General Anesthesia|Participants in this group will be given a combination of general anesthesia and a nerve block. General anesthesia involves the use of a sedative called propofol, along with devices to ensure that the airway remains open during the procedure. Additionally, they will undergo an ultrasound-guided nerve block known as the Fascia Iliaca Compartment Block (FICB) in combination with spinal anesthesia.
48473801|NCT05393323|OTHER|conventional physical therapy with distraction technique|Distraction will be at suboccipital level and patients will ask to assume a supine position with the head on the plinth. The therapist will use fingertips in both hands from digits 2 through 5, and cups the suboccipital region of the patient and supports the posterior skull. The therapist provides a light distraction to the posterior skull. Distraction will be applied for 10 min with pull for 10 sec and5 sec will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 minute with total intervention period of 4 weeks with 5 sessions per week.
48473802|NCT05393323|OTHER|conventional physical therapy with traction technique|In cervical traction, patients will ask to lie supine on the treatment table. Head will cradle by physiotherapist from chin and the occiput, and then the physiotherapist will apply traction force in 25 degree neck flexion. Traction will be applied for 10 minutes with pull for 10 sec and 5 sec rest will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 min with total intervention period of 4 weeks with 5 sessions per week. All outcome measurements will be assessed before treatment and then reassessed at the end of 4th week.
48473803|NCT00432627|DRUG|Deferasirox|one dose of 20 mg/kg/day
48631446|NCT01135056|DRUG|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
48631447|NCT04464083|DIAGNOSTIC_TEST|IOP Measurment|To determine IOP readings before and after accelerated corneal collagen crosslinking (CXL)
47942024|NCT06275607|BEHAVIORAL|Emotional Discussion|General discussion of emotions; no therapy or training is offered.
48102536|NCT06366594|BEHAVIORAL|Authentic leadership training program|37 first-line nurse managers received authentic leadership training program
48290527|NCT00772395|DRUG|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
48290528|NCT00772395|DRUG|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
48290529|NCT01754896|OTHER|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
48631448|NCT00582829|OTHER|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
48290530|NCT01754896|OTHER|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
48631449|NCT00582829|OTHER|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
47942025|NCT00765024|DRUG|Ivermectin|single dose of 200 mcg/kg
47942026|NCT00765024|DRUG|ivermectin|two single dose of 200mcg/kg in 2 weeks
47942027|NCT00765024|DRUG|Albendazole|Albendazole 7 days
48102537|NCT02341924|OTHER|Portfolio of functional foods|
48102538|NCT02341924|OTHER|Control foods|
48290531|NCT01754896|OTHER|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
48290532|NCT01754896|OTHER|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
48290533|NCT00125203|DRUG|Botulinum toxin type B (Myobloc)|
48290534|NCT00125203|PROCEDURE|Injection of salivary glands|
48290535|NCT03191175|OTHER|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
48290536|NCT05082870|BEHAVIORAL|Supportive-expressive group therapy (SEGT)|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
48290537|NCT02796989|DIETARY_SUPPLEMENT|Wheat bran|20 g each day
48631450|NCT00582829|OTHER|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
48631451|NCT01316900|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
48631452|NCT01316900|DRUG|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
48631453|NCT01316900|DRUG|GW642444|25 mcg once-daily
47942028|NCT06048614|PROCEDURE|Saline Enema (SE)|"infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm"
47942029|NCT06048614|DRUG|Glycerin Suppository|"Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned."
47942030|NCT00239902|DRUG|FTY720|
48631454|NCT01316900|DRUG|tiotropium bromide|18 mcg once-daily
47942031|NCT05658003|DRUG|[177Lu]Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
47942032|NCT05658003|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
47942033|NCT05658003|DRUG|[68Ga]Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
47942034|NCT05658003|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
48473804|NCT00004241|DRUG|tanespimycin|Given IV
48631455|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
47942035|NCT05621551|DRUG|Dapagliflozin|The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
47942036|NCT02169973|DRUG|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
47942037|NCT02169973|DRUG|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
47942038|NCT05490238|PROCEDURE|Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)|Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
47942039|NCT00048451|DRUG|paricalcitol|
48290538|NCT02796989|DIETARY_SUPPLEMENT|Placebo|20 g each day
48290539|NCT02961764|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
48473805|NCT00004241|OTHER|pharmacological study|Correlative studies
48473806|NCT03747653|DRUG|ADVATE|Patients will be administered a single dose of ADVATE.
48473807|NCT03747653|DRUG|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
48473808|NCT01790230|DEVICE|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
48473809|NCT04194606|PROCEDURE|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
48473810|NCT04311944|OTHER|Early fast-track care|Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is \<200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA \<200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
48473811|NCT04311944|OTHER|Standard (deferred fast-track) care|Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is \<200 copies.mL, and they meet other eligibility criteria.
48473812|NCT01731886|PROCEDURE|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
48473813|NCT01731886|DRUG|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
48473814|NCT01731886|DRUG|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
48473815|NCT01731886|PROCEDURE|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is \>2500 x 109 cells/liter; platelet count is \>20 x 103/mm3.
48290540|NCT02961764|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
48290541|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.
47942040|NCT02593201|DRUG|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
47942041|NCT02593201|DRUG|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
47942042|NCT02506569|DEVICE|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
47942043|NCT02506569|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
48290542|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.
48290543|NCT01367132|PROCEDURE|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
48290544|NCT00345371|DRUG|Topiramate|
48473816|NCT01731886|DRUG|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
48473817|NCT01731886|DRUG|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
48473818|NCT01731886|DRUG|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
48473819|NCT01731886|DRUG|Mesna|Mesna will be provided with the cyclophosphamide.
48473820|NCT05283330|DRUG|²¹²Pb-DOTAM-GRPR1|²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
48290545|NCT00345371|DRUG|Placebo Oral Tablet|
48290546|NCT01848444|OTHER|Breastmilk|to measure levels of contaminants in human breastmilk samples
48473821|NCT04244006|DRUG|Dupilumab Prefilled Syringe|administration of dupilumab corresponding to dupilumab arm
48473822|NCT04244006|OTHER|Placebo Prefilled Syringe|administration of placebo corresponding to placebo arm
48473823|NCT02902055|DRUG|Neuromuscular Blocking Agents|Neuromuscular blockae
48473824|NCT02902055|DRUG|Isotonic saline|Placebo
48290547|NCT06223425|BEHAVIORAL|virtual reality Situation-Based Flipped Learning|Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
48290548|NCT01917825|DRUG|MDT-15|
48290549|NCT03959618|OTHER|dietary supplements questionary|Patient Questionary Patient to be carried out at the last cure
48290550|NCT00959244|OTHER|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
48290551|NCT00959244|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
48290552|NCT00959244|OTHER|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
48473825|NCT00047047|DRUG|gemcitabine hydrochloride|Given IV
48473826|NCT00047047|DRUG|tanespimycin|Given IV
48473827|NCT00047047|DRUG|cisplatin|Given IV
48473828|NCT00047047|OTHER|laboratory biomarker analysis|Correlative studies
48473829|NCT00823381|DIETARY_SUPPLEMENT|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
48473830|NCT00823381|OTHER|placebo|one placebo pill taken once a day with breakfast
48473831|NCT00823381|BEHAVIORAL|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
48473832|NCT02225106|DRUG|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
48473833|NCT00235417|PROCEDURE|Bone marrow transplantation|
48473834|NCT00006331|PROCEDURE|renal transplant|
48473835|NCT02695927|DEVICE|Computer rehabilitation glasses|
48290553|NCT00959244|OTHER|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
48290554|NCT02400346|DRUG|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
47942044|NCT06415734|DEVICE|rTMS|LF-rTMS of M1 contralateral to the brain lesion for 20 min, 1200 pulses, 120% RMT, treatment cycle of 5 days
47942045|NCT03812432|DEVICE|Near-infrared fluorescence cholecystocholangiography|Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
47942046|NCT03828773|DRUG|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients \>18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
48102539|NCT04555954|OTHER|surveys and questionnaires|The study practised the physical activity levels of healthy adults aged 18-65 years in Turkey during the novel type of coronavirus pandemic by the International Physical Activity Questionnaires-Short Form (IPAQ-SF). Communication with the participants of the study was conducted via online survey software (Google Forms) and social media communication application (WhatsApp).
48290555|NCT02400346|DRUG|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
48473836|NCT04015531|RADIATION|Conventional radiotherapy|50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.
48473837|NCT04015531|RADIATION|Hypofractionated radiotherapy|40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
48290556|NCT04876664|DEVICE|measuring blood pressure with noninvasive blood pressure device|To measure blood pressure in different circumstances with noninvasive blood pressure device
48290557|NCT05870475|DRUG|Ruxolitinib|Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
48290558|NCT05870475|DRUG|Pegylated interferon α-2b|Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
48290559|NCT01499576|PROCEDURE|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
48290560|NCT05621512|OTHER|Preventive sessions|Preventive sessions between the pregnant employee, her manager and a midwife.
48290561|NCT04936425|DEVICE|OTSC Stentfix|The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
48473838|NCT03662724|DRUG|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
48473839|NCT04619550|OTHER|High tibial osteotomy|Realignment surgery
48473840|NCT02546024|DRUG|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
48473841|NCT06467851|DRUG|Suanzaoren Decoction and Huanglian Wenda Decoction|Twice daily. Chinese herbal medicine includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
48473842|NCT01858350|OTHER|Active Music Therapy|
48473843|NCT01858350|OTHER|Passive Music Therapy|
48473844|NCT01858350|OTHER|Distraction Therapy|
48631456|NCT01623752|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
48631457|NCT00000446|DRUG|sertraline (Zoloft)|
48631458|NCT02279251|BEHAVIORAL|VÅG|Low-intensity CBT intervention
48631459|NCT02279251|BEHAVIORAL|CHILLED|Standard length CBT intervention
47942047|NCT03828773|DRUG|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
48290562|NCT03063255|DRUG|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
48290563|NCT03063255|DRUG|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
48290564|NCT04150432|DEVICE|Edmon|New device for exhaled propofol concentration measurements
48473845|NCT03847194|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
48473846|NCT06236412|BEHAVIORAL|Health education|Health education about the contents listed under each arm will be provided for the participants.
48290565|NCT05776459|DRUG|AC102 gel|Drug: AC102 Single intratympanic injection
48473847|NCT01594359|OTHER|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
48473848|NCT01594359|OTHER|BEAN|Placebo
48473849|NCT06123260|DIAGNOSTIC_TEST|renal function tests|BUN, eGFR , CBC , Electrolytes , Liver function tests
48290566|NCT05776459|DRUG|Prednisolone|Active comparator: Prednisolone Tablets taken daily by mouth
48473850|NCT03547817|DEVICE|Intermittent negative pressure device|Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
48473851|NCT00615849|PROCEDURE|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
48473852|NCT00715091|DRUG|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
48473853|NCT00715091|DRUG|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
48290567|NCT05776459|OTHER|Placebo Tablets|Placebo Tablets taken daily by mouth
48290568|NCT05776459|OTHER|Placebo gel|Placebo Single intratympanic injection
48290569|NCT02226016|DEVICE|FG-5000A|a measuring device for the assessment of levator muscle strength
48290570|NCT00148629|DRUG|multivitamin, mebendazole|
48290571|NCT00144300|DRUG|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
48290572|NCT00144300|DRUG|Requip|Standard marketed product dispensed according to manufacturer's guidelines
48290573|NCT02718677|DRUG|Refacto AF|Observational - Non-Interventional Study
48290574|NCT04920448|DRUG|N-Acetyl cysteine|Administered as specified in the treatment arm
48290575|NCT06282380|DEVICE|FibriCheck Mobile Application|PPG measurement with reference diagnosis
48290576|NCT04372355|DRUG|WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
48290577|NCT00602628|OTHER|questionnaire administration|
48290578|NCT00602628|PROCEDURE|adjuvant therapy|
48290579|NCT00602628|PROCEDURE|biopsy|
48290580|NCT00602628|PROCEDURE|computed tomography|
48473854|NCT01813435|DRUG|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
48290581|NCT00602628|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
48473855|NCT01813435|DRUG|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
48473856|NCT01813435|DRUG|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
48473857|NCT03126422|DRUG|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
48473858|NCT02427087|BEHAVIORAL|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
48473859|NCT02427087|BEHAVIORAL|Healthy Diet|Diet group (21) Recommendation for healthy diet.
48473860|NCT06285006|DRUG|Desmopressin|Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
48631460|NCT05839509|DRUG|GH001|GH001 administered via inhalation
48631461|NCT03614988|OTHER|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
48102540|NCT01928004|DEVICE|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
48102541|NCT01928004|PROCEDURE|Conventional reline|conventional reline of the existing mandibular complete denture
47942048|NCT02438527|BEHAVIORAL|Chart for CPR guidance|
47942049|NCT05940584|DEVICE|Tele-Reha provided with EvoPads|Exercises and cognitive training provided on an EvoPad
48102542|NCT03977116|DRUG|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
48102543|NCT03977116|DRUG|Placebo|These patients will receive placebo therapy after catheter ablation.
48102544|NCT02364518|PROCEDURE|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
48102545|NCT02771418|DRUG|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
48102546|NCT02771418|DRUG|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
48102547|NCT02771418|PROCEDURE|Elective carotid endarterectomy|
48102548|NCT00073138|DRUG|ABT-751|
48290582|NCT00602628|PROCEDURE|magnetic resonance imaging|
48290583|NCT00602628|PROCEDURE|therapeutic conventional surgery|
48290584|NCT00602628|PROCEDURE|ultrasound imaging|
48290585|NCT00602628|RADIATION|radiation therapy|
48290586|NCT01858883|DRUG|itacitinib|
48290587|NCT01858883|DRUG|Gemcitabine|
48290588|NCT01858883|DRUG|nab-paclitaxel|
48473861|NCT00730951|DIETARY_SUPPLEMENT|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
48631462|NCT03614988|OTHER|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
48631463|NCT02590510|DRUG|methotrexate|The quantity of methotrexate is different in the two groups.
48631464|NCT05085405|BEHAVIORAL|Clinician notification|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
48473862|NCT00730951|DIETARY_SUPPLEMENT|Corn Starch|500mg Capsulated Corn Starch
48473863|NCT04231331|DRUG|Ertugliflozin|Ertugliflozin 5mg qd for 12 months
48473864|NCT04231331|DRUG|Placebo|Placebo qd for 12 months
48473865|NCT04821739|DEVICE|AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.
48473866|NCT04769115|DEVICE|Alert for temperature delta|If alert for potential complications refer to appropriate specialist
48473867|NCT06503887|OTHER|Stool sample collection|Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
48473868|NCT02396290|PROCEDURE|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
48473869|NCT02396290|PROCEDURE|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
48473870|NCT00817141|OTHER|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
48473871|NCT05230823|BEHAVIORAL|CR with added BWLT|12 week outpatient cardiac rehab (CR) program consisting of twice-weekly supervised exercise and risk factor modification (e.g. smoking cessation, support with medication). Concurrently, the patients will attend a weekly behavioural weight loss treatment (BWLT). Weekly goal-setting facilitated by the interventionist will focus on behavioural changes in nutrition and moderate calorie reduction while also emphasizing physical activity consistent with an individualized CR exercise prescription. Patients will track caloric intake, weekly exercise, weekly weight, and success/challenges with other health goals (e.g., challenging negative thoughts, body image, mindful eating, etc.) using a daily health diary. ASPIRE-AF will be delivered virtually to small groups (8-12 patients) by senior PhD students with advanced training in cognitive-behavioural therapy and motivational communication principles.
48473872|NCT03480685|DEVICE|IVUS and OCT Imaging|Use of an imaging catheter
48473873|NCT05049031|OTHER|Questionnaire|A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
48631465|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~In this arm, patients receive no additional interventions beyond that provided during treatment as usual."
48290589|NCT01858883|DRUG|filgrastim|
47942050|NCT05940584|OTHER|Paper-based exercises with option to do tele-reha afterwards|Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
48102549|NCT03278288|DEVICE|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
48290590|NCT03324256|OTHER|energy drink|16 oz cold commercially-available energy drink
48290591|NCT03324256|OTHER|caffeinated drink|16oz cold commercially-available caffeinated drink
48290592|NCT03324256|OTHER|Energy gum|2 pieces of commercially-available energy gum
47942051|NCT05940584|OTHER|Only paper-based exercises|Same exercises and cognitive training as Group 2 provided on paper only.
48290593|NCT03324256|OTHER|placebo gum|2 pieces of commercially-available placebo gum
47942052|NCT02898155|OTHER|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
47942053|NCT00696683|OTHER|None, this is an observational study|
47942054|NCT03740867|OTHER|Pulmonary rehabilitation|Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
47942055|NCT03051854|BEHAVIORAL|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
48102550|NCT04765943|DEVICE|Implantable Loop Recorder implant|Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
48102551|NCT02906878|PROCEDURE|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
48102552|NCT05082649|OTHER|Face to Face Exercise|Face to face (in clinic) progressive spinal stabilization exercises.
48290594|NCT03324256|OTHER|Control drink|16oz cold control drink
48290595|NCT03324256|OTHER|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
48290596|NCT02440724|DEVICE|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
48290597|NCT02440724|DEVICE|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
48290598|NCT06671912|DRUG|Anastrozole|Given PO
48290599|NCT06671912|DRUG|Letrozole|Given PO
48290600|NCT06671912|DRUG|Exemestane|Given PO
48290601|NCT06671912|DRUG|Tamoxifen|Given PO
48290602|NCT06671912|PROCEDURE|Mammogram|Undergo mammogram
48290603|NCT06671912|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48290604|NCT06671912|BIOLOGICAL|Dual X-ray Absorptiometry|Undergo DEXA
48290605|NCT06671912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48290606|NCT06671912|OTHER|Questionnaire Administration|Ancillary studies
48290607|NCT03670862|OTHER|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
48290608|NCT04086134|OTHER|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
48290609|NCT05187195|OTHER|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
48473874|NCT01676129|PROCEDURE|Nocipoint Therapy|
48473875|NCT01676129|PROCEDURE|Physical Therapy|
48473876|NCT05596292|DEVICE|Immersive Virtual Reality glasses|The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
48473877|NCT05596292|OTHER|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
48473878|NCT03384433|BIOLOGICAL|exosome|allogenic mesenchymal stem cells derived exosome enriched by miR-124
48473879|NCT01883791|BEHAVIORAL|SBIRT|See above Arm description.
48473880|NCT01883791|BEHAVIORAL|Health Education|See Arm Description.
48473881|NCT00549341|DRUG|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
48473882|NCT00549341|OTHER|Physiologic saline|Single injection.
48473883|NCT02136238|DEVICE|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
48473884|NCT02136238|DEVICE|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
48473885|NCT00108628|BEHAVIORAL|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
48290610|NCT05187195|OTHER|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
48290611|NCT02770287|DEVICE|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
48290612|NCT05195359|BEHAVIORAL|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
48290613|NCT03241173|DRUG|INCAGN01949|In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
48290614|NCT03241173|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
48290615|NCT03241173|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
48290616|NCT00881920|BIOLOGICAL|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa"
48290617|NCT04980183|DEVICE|Arthroscopic surgical robot|The surgeon performs cruciate ligament bone canal positioning and ligament reconstruction with the assistance of an arthroscopic surgical robot
48290618|NCT04980183|DEVICE|Conventional arthroscopic cruciate ligament reconstruction|The surgeon performs conventional arthroscopic cruciate ligament reconstruction surgery without other auxiliary equipment
48290619|NCT03575468|BEHAVIORAL|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
48290620|NCT03575468|BEHAVIORAL|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
48290621|NCT04187001|OTHER|Content Validity|Use Delphi technique for achieve consensus
48631466|NCT05085405|BEHAVIORAL|Clinician Notification / Patient Activation|"An anticoagulation clinic nurse sends a templated letter to the patient's clinician and identifies the patient as high risk for upper GI bleeding, summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), provides a link to guidance on evidence-based use of antiplatelet therapy, and asks that the clinician manage any medication changes.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
48102553|NCT05082649|OTHER|Telerehabilitation|Remotely (with video) progressive spinal stabilization exercises.
48290622|NCT04187001|OTHER|Cultural adaptation|Adapt the content to the target population
48631467|NCT05085405|BEHAVIORAL|Clinician Notification with Nurse Facilitation / Patient Activation|"An anticoagulation clinic nurse sends an individualized letter to the patient's clinician which identifies the patient as high risk for upper GI bleeding and summarizes options for medication optimization (e.g., discontinuation of antiplatelet therapy or initiation of a proton pump inhibitor for gastroprotection), but in addition includes a summary of the patient's history of atherosclerotic cardiovascular disease and a concise guidance summary on appropriate use of antiplatelet therapy for relevant indications. The anticoagulation nurse will assist with order entry for any new medications and also provide education on medication changes to the patient upon request by the clinician.~Patient Activation:~An anticoagulation clinic nurse sends the patient an 8-page written guide, either through the patient portal or by mail. The guide provides education on upper GI bleeding risk and encourages patients to talk with their clinician about medication changes to reduce their bleeding risk."
48631468|NCT03181009|DRUG|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
48290623|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
48290624|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a lyophilized formulation
48290625|NCT00816972|DRUG|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
48290626|NCT00816972|DRUG|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
48290627|NCT00816972|DRUG|Placebo for Desloratadine 2.5 mg|Placebo BID
48290628|NCT00816972|DRUG|Placebo for Oxybutynin 2.5 mg|Placebo BID
48290629|NCT02263365|DRUG|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
48290630|NCT04180410|DEVICE|EIT|Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
48290631|NCT03911570|DRUG|Glucosamine Sulfate|Therapy with the prescription formulation of crystalline glucosamine sulfate
48102554|NCT01884389|OTHER|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
48102555|NCT01167036|DEVICE|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
48102556|NCT01167036|OTHER|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
48102557|NCT03094104|OTHER|News items with spin|Interpretation of news items with spin
48102558|NCT03094104|OTHER|News items without spin|Interpretation of news items without spin
48102559|NCT02057718|DRUG|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) oral dose up to twice a day (BID).
48102560|NCT02631499|PROCEDURE|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
48102561|NCT02631499|DRUG|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
48102562|NCT02631499|DRUG|lipiodol|lipiodol is a kind of embolization material used in TACE
48102563|NCT00087269|DRUG|erlotinib hydrochloride|Given orally
48102564|NCT00087269|PROCEDURE|therapeutic endoscopic surgery|Undergo surgical resection
48102565|NCT00087269|OTHER|laboratory biomarker analysis|Correlative studies
48102566|NCT03899818|DEVICE|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
48102567|NCT03899818|DEVICE|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
48102568|NCT00478855|DRUG|Tazocin (Piperacillin/Tazobactem)|
48102569|NCT05130060|BIOLOGICAL|Colorectal Cancer Peptide Vaccine PolyPEPI1018|Given SC
48102570|NCT05130060|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
48290632|NCT00247325|DRUG|Iodixanol(Drug)|
48290633|NCT01398254|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
48290634|NCT04171128|BEHAVIORAL|antibiotic stewardship efforts|The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.
48290635|NCT00117338|DRUG|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
48290636|NCT00117338|DRUG|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
48290637|NCT00520689|DEVICE|Silicone Hydrogel Contact Lens|use of lens over 2 days
48290638|NCT02997189|DRUG|OTO-104|12 mg dexamethasone administered intratympanically
48290639|NCT01373645|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
48290640|NCT00510692|DRUG|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
48290641|NCT00510692|PROCEDURE|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
47942056|NCT00660621|DRUG|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
47942057|NCT01771575|OTHER|Placebo device|Placebo device
48290642|NCT00510692|PROCEDURE|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
48290643|NCT00510692|DRUG|Placebo|2 x 500mg placebo capsules twice daily for 6 months
48290644|NCT05333562|OTHER|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
48290645|NCT05333562|OTHER|Motor control exercise with mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
48290646|NCT01959204|DRUG|Oxycodone|Pain
48290647|NCT01100021|DRUG|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
48290648|NCT01100021|DRUG|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
48290649|NCT03158545|DIETARY_SUPPLEMENT|Olive oil Placebo|olive oil
48631469|NCT03181009|DRUG|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
48631470|NCT02015936|BEHAVIORAL|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
47942058|NCT01771575|DEVICE|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance \& gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
48290650|NCT03158545|DIETARY_SUPPLEMENT|EPA-rich|EPA-rich omega-3 oil
48473886|NCT00108628|BEHAVIORAL|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
48473887|NCT01011335|BIOLOGICAL|Monovalent rAT|10, 25, 50 or 100 μg
48473888|NCT01011335|BIOLOGICAL|Monovalent rLukS-PV|10, 25, 50 or 100 μg
48473889|NCT01011335|BIOLOGICAL|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
48473890|NCT01011335|BIOLOGICAL|Placebo with adjuvant|Placebo with adjuvant
48631471|NCT02015936|OTHER|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
48631472|NCT06035198|OTHER|Stroke|No intervention
48631473|NCT02769052|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
47942059|NCT00426231|BEHAVIORAL|Navigation by a health worker|Help provided by health worker to navigate medication access programs
48290651|NCT03158545|DIETARY_SUPPLEMENT|DHA-rich|DHA-rich omega-3 oil
48290652|NCT02369510|DRUG|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
48290653|NCT02369510|DRUG|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
48290654|NCT02369510|DRUG|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
48290655|NCT00000681|DRUG|Bleomycin sulfate|
48290656|NCT00000681|DRUG|Vincristine sulfate|
48290657|NCT00000681|DRUG|Doxorubicin hydrochloride|
48290658|NCT00000681|DRUG|Zidovudine|
48290659|NCT00000681|DRUG|Sargramostim|
48473891|NCT01011335|BIOLOGICAL|Placebo|Placebo saline
48473892|NCT03160586|DIAGNOSTIC_TEST|Stuttering severity instrument-3|To measure of degree of stuttering in child
48290660|NCT01525394|DRUG|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
48290661|NCT01525394|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
48473893|NCT03160586|DIAGNOSTIC_TEST|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
48473894|NCT01847924|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
48473895|NCT01847924|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
47942060|NCT00426231|BEHAVIORAL|Information control|Information about medication access programs provided to the participant and their healthcare provider
48473896|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
48631474|NCT01598220|BEHAVIORAL|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
48473897|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
48473898|NCT03745417|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
48473899|NCT01367717|DIETARY_SUPPLEMENT|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
48473900|NCT01367717|DIETARY_SUPPLEMENT|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
48473901|NCT04674982|DEVICE|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
48473902|NCT02082249|DRUG|ABT-SLV187|Dose levels will be individually optimized
48473903|NCT06412211|DEVICE|Photoacoustic finder|Sentinel lymph node detector using photoacoustic signal
48473904|NCT01718730|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
48473905|NCT01718730|DEVICE|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
48473906|NCT03465150|OTHER|acne|Patient with acne
48631475|NCT01598220|OTHER|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
48631476|NCT06417411|DRUG|Aspirin 100mg|Daily use of low dose aspirin.
48631477|NCT02968394|DRUG|omalizumab|
48473907|NCT03668431|DRUG|Dabrafenib|"Dabrafenib will be taken twice a day for 28 consecutive days~."
47942063|NCT05535231|DIETARY_SUPPLEMENT|Turmeric test product|2 capsules of 490 mg Turmeric are taken with water once
48473908|NCT03668431|DRUG|Trametinib|Trametinib will be taken once a day for 28 consecutive days
48473909|NCT03668431|DRUG|PDR001|PDR001 will be administered IV every 28 days
48473910|NCT04973098|BIOLOGICAL|CT0181 Cells|5 dose levels each with or without lymphocyte clearance were tentatively determined.
48473911|NCT02966158|OTHER|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
47942064|NCT05535231|DIETARY_SUPPLEMENT|Turmeric comparator|2 capsules of 200 mg Turmeric are taken with water once
47942065|NCT04743518|OTHER|Aortic pulse wave velocity|Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness
47942066|NCT04743518|OTHER|carotid intima media thickness (CIMT)|carotid intima media thickness (CIMT)
47942067|NCT04520373|OTHER|Best Medical Management: Occupational and Physical Therapy|Observation while undergoing Occupational and Physical Therapy for 6 months
48473912|NCT04729608|DRUG|Batiraxcept|Batiraxcept is an experimental drug
48473913|NCT04729608|DRUG|Paclitaxel|Paclitaxel is the standard of care, background therapy
48473914|NCT04729608|OTHER|Placebo|Matching placebo
48473915|NCT00028379|PROCEDURE|Transcranial magnetic stimulation (TMS)|
48473916|NCT00493064|DRUG|Nicotinic acid|topical eye drops
47942068|NCT04520373|BIOLOGICAL|Autologous, Adipose Derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.
47942069|NCT00493376|PROCEDURE|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
47942070|NCT00493376|PROCEDURE|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
47942071|NCT00493376|PROCEDURE|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
47942072|NCT00493376|PROCEDURE|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
47942073|NCT06463574|OTHER|self-adhesive resin restoration|Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
47942074|NCT00003548|DRUG|aminocamptothecin colloidal dispersion|
48473917|NCT00493064|DRUG|Prednisolone acetate|topical eye drops
48473918|NCT06133309|BEHAVIORAL|Experiential Phenomenological Interview|"Consciousness fluidity of patients suffering from depressive disorder and treated with Esketamine will be evaluated thanks to Experiential Phenomenological Interview and EQFC Trait questionnaire"
48473919|NCT00288925|DRUG|Z-360|
48290662|NCT01525394|DRUG|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
47942075|NCT02291536|DRUG|tetrahydrocannabinol|
48290663|NCT01825434|DIETARY_SUPPLEMENT|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
48290664|NCT00683553|DRUG|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
48290665|NCT00683553|DRUG|Placebo|Single IV injection of saline
48290666|NCT02018250|DRUG|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
48290667|NCT02018250|DRUG|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
48290668|NCT02603640|DEVICE|MRI scanning|
48290669|NCT03939910|DEVICE|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
48290670|NCT00519532|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
48290671|NCT03784430|PROCEDURE|Immediate dental implant placement|Tooth will be extracted and a dental implant will be positioned at the same time.
48290672|NCT03784430|PROCEDURE|Immediate dental implant placement with CTG|Tooth will be extracted and a dental implant will be positioned at the same time with a connective tissue graft.
48290673|NCT04293848|OTHER|Vibroacoustic therapy|listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music
48290674|NCT04293848|OTHER|Only music (no vibrations)|listening to music, no vibrations
48290675|NCT02628730|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
48290676|NCT02628730|DEVICE|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
48290677|NCT04244045|OTHER|Suboccipital muscle inhibition|"The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot"
48290678|NCT02891993|OTHER|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
48473920|NCT06054477|DRUG|ALE.C04|Q3W
48473921|NCT06054477|DRUG|Pembrolizumab|200mg Q3W
48290679|NCT02891993|OTHER|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
48290680|NCT03033108|DRUG|Emixustat|Once daily, tablet for oral administration
48290681|NCT00503971|DRUG|Vorinostat plus Erlotinib|"Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
48473922|NCT01557062|OTHER|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
47942076|NCT02291536|DRUG|cannabidiol|
47942077|NCT02291536|OTHER|placebo|
47942078|NCT02787551|DRUG|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48290682|NCT01264315|DRUG|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count \>1x109/L without growth factors~* platelet count \>75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
48473923|NCT01557062|OTHER|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
48290683|NCT04222621|OTHER|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
48290684|NCT01607723|OTHER|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
48290685|NCT01607723|OTHER|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
48290686|NCT00693719|DRUG|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
48290687|NCT00693719|DRUG|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
48290688|NCT04568174|DRUG|PPSGG|an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
48290689|NCT04568174|DRUG|Placebo|A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
48290690|NCT02795767|DRUG|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
48290691|NCT02814214|DEVICE|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
48473924|NCT01557062|OTHER|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
48473925|NCT06617078|PROCEDURE|long-term oxygen therapy (LTOT)|Usual care with LTOT for 2 weeks
48290692|NCT00379730|DRUG|Prednisolone|
48290693|NCT05652192|RADIATION|SBRT|SBRT was added to systematic treatment (chemo+ PD-1 antibody)
48290694|NCT05115201|PROCEDURE|Scaling and root planing with antibiotics|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
47942079|NCT02787551|DRUG|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
47942080|NCT02787551|DRUG|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48290695|NCT05115201|PROCEDURE|Scaling and root planing only|Patients will be treated with scaling and root planing
48290696|NCT03876340|OTHER|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
48290697|NCT03876340|OTHER|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
48290698|NCT05841849|DRUG|Aprepitant|oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
48290699|NCT05841849|DRUG|Palonosetron|oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
48290700|NCT05841849|DRUG|Fosaprepitant|intravenous fosaprepitant 150mg for D1 before chemotherapy
48290701|NCT02864875|DRUG|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
48290702|NCT02067221|DEVICE|RIRS|"* RIRS arm~* Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
48290703|NCT02067221|DEVICE|MPCNL|"* MPCNL arm~* A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
48290704|NCT02875522|OTHER|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
48290705|NCT00152412|DRUG|Levocetirizine oral solution|
48290706|NCT00239460|DRUG|Tiotropium|
48290707|NCT05219643|DEVICE|NAVA|Nava level is set to maintain the target tidal volume: 6-10ml / kg (pbw). The trigger sensitivity is 0.5uv. The expiratory trigger sensitivity: the built-in software of the ventilator is set to 70% of the peak value of diaphragm electrical activity.
48290708|NCT05219643|DEVICE|PSV|According to the doctor's experience, maintain the target tidal volume: 6-10ml / kg (pbw); trigger sensitivity: 1.5-2l/min, expiratory trigger sensitivity: 30% inspiratory peak flow rate.
48290709|NCT02973672|DRUG|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
48290710|NCT04500288|DEVICE|LEFT Device|LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
48290711|NCT03000452|DRUG|DARATUMUMAB|DARATUMUMAB
48290712|NCT03000452|DRUG|DURVALUMAB|DURVALUMAB
48290713|NCT02214589|OTHER|Oral glucose, facilitated tucking, NNS|
48631478|NCT06214962|BEHAVIORAL|(multiple training modalities, MTM)|"1. Invite experts to discuss the course content of each unit of MTM, and then invite teachers to take pictures , and combine them into one course for the benefit of the elderly in the institution.~2. Select 3 units to try out in the dementia base, and make corrections based on the feedback of the elders and the base staff.~3. Continue to complete other units based on the experience of the first 3 units.~(2) In the Rizhao part, experts are mainly used to develop various course modules suitable for the elderly with dementia in Rizhao, and each module unit is tested on the elderly with dementia and then revised The planning task is mainly to establish a solution strategy. The method is to set up an activity course module planning or design group to develop various course modules suitable for Rizhao demented elders."
48290714|NCT02214589|OTHER|Oral glucose and NNS|
48631479|NCT05520177|DRUG|601 1.25mg|loading phase (6 months): 601 1.25mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
48631480|NCT05520177|DRUG|ranibizumab 0.5mg|loading phase (6 months): ranibizumab 0.5mg/eye/time, Intravitreal injection, administered once every 4 weeks for 6 consecutive doses
48290715|NCT02214589|OTHER|Facilitated tucking and NNS|
48290716|NCT06068725|BEHAVIORAL|Training videos|After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
48473926|NCT06617078|PROCEDURE|High Flow Nasal Therapy (HFNT)|High Flow Nasal delivered by myAirvo3 (4 hours minimum and during th 3-minute chair rise test, 30L/min, 34°C, identical O2 flow rate as LTOT) for 2 weeks
48473927|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 1|Low dose, approximately 10\^3 TCID50/mL
47942081|NCT02787551|DRUG|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
47942082|NCT02787551|DRUG|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
47942083|NCT02787551|DRUG|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48290717|NCT02551848|DRUG|Botulinum toxin type A|
48290718|NCT02641899|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
48290719|NCT02641899|DRUG|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
48290720|NCT02641899|DRUG|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
48290721|NCT02641899|DRUG|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
48290722|NCT02641899|DRUG|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
48290723|NCT02641899|DRUG|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
48473928|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 2|Medium dose, approximately 10\^4 TCID50/mL
48473929|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 3|High dose, approximately 10\^5 TCID50/mL
48473930|NCT03573817|DRUG|Revefenacin|Revefenacin is administered via a nebulizer.
48473931|NCT03573817|DRUG|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
48473932|NCT03573817|DRUG|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
48290724|NCT01415960|DRUG|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
48290725|NCT02574299|OTHER|E-learning|Management of auditory processing disorders with serious game (E-learning)
48290726|NCT02574299|DEVICE|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
48290727|NCT01300377|DRUG|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
48290728|NCT01300377|DRUG|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
48290729|NCT05534334|DRUG|Solu-Cortef|A vial sol. used for intra-mascular injection
48290730|NCT06510335|OTHER|Lavender essential oil-based product system|"Participants used the study products in a sequential, additive manner approximately 30-60 minutes before bedtime each night for 6 weeks. Usage consists of the following:~* 20 drops of essential oil blend in approximately 250 mL of water in a diffuser, which operated for 8 hours at nighttime.~* 3 x 6 swipes of the topical stick on the upper chest area, and 2 x 3 swipes on the inside of each wrist for topical application.~* 2 capsules of the dietary supplement.~Participants used the essential oil blend alone for 1 week, then added the topical stick for another 1 week. Finally, participants used the essential oil blend, the topical stick, and the dietary supplement for four weeks."
48290731|NCT06512766|DRUG|Hydroxychloroquine|Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
48290732|NCT06512766|DRUG|Methotrexate|This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
48290733|NCT06512766|DRUG|Cyclosporine A|Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
48290734|NCT06512766|DRUG|Retinoids|This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
48290735|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
48290736|NCT00856752|DRUG|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
48290737|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
48290738|NCT05835258|DIETARY_SUPPLEMENT|Melatonin with phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement with phenyl capsaicin
48290739|NCT05835258|DIETARY_SUPPLEMENT|Melatonin without phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement without phenyl capsaicin
48290740|NCT04072770|DIETARY_SUPPLEMENT|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
48290741|NCT04072770|DIETARY_SUPPLEMENT|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
48290742|NCT04151004|OTHER|Incremental cycling test (ICT)|Incremental cycling test to volitional exhaustion
48290743|NCT04151004|OTHER|Constant load cycling test (CET)|Constant load cycling test to volitional exhaustion.
48290744|NCT04151004|OTHER|Incremental respiratory muscle test (IncRMET)|Incremental respiratory muscle test to volitional exhaustion.
48290745|NCT04151004|OTHER|Incremental quadriceps muscle test (IncQMT)|Incremental quadriceps muscle test to volitional exhaustion.
48290746|NCT04151004|OTHER|Respiratory muscle training like interventions|Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
48473933|NCT03288402|OTHER|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
48290747|NCT03721328|COMBINATION_PRODUCT|vancomycin hydrochloride and tobramycin sulfate|vancomycin hydrochloride and tobramycin sulfate via local irrigation
48290748|NCT06058234|DRUG|Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease|FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
48290749|NCT05554900|PROCEDURE|preventive regenerative peripheral nerve interface reconstruction|Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
48290750|NCT01507545|DRUG|MORAb-004|MORAb-004 8mg per kg IV once a week
48290751|NCT01507545|DRUG|Placebo|Placebo - normal saline IV once a week
48290752|NCT01507545|OTHER|Best supportive care|Best supportive care to improve quality of life
48290753|NCT04674137|DRUG|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
48290754|NCT04674137|DRUG|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
48290755|NCT02511080|DEVICE|Spot-On|use of active hot measures
48290756|NCT05282706|DRUG|Lavender Oil|A hydrogel lavender oil infused aromatherapy patch
48290757|NCT05282706|DRUG|Mandarin Oil|A hydrogel mandarin oil infused aromatherapy patch
48290758|NCT05282706|DRUG|Peppermint oil|A hydrogel peppermint oil infused aromatherapy patch
48290759|NCT05282706|OTHER|Placebo|A placebo patch containing no aromatherapy oil
48290760|NCT05466110|DEVICE|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
48290761|NCT05466110|PROCEDURE|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
48290762|NCT03633643|DRUG|oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)|"five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital."
48290763|NCT03633643|DRUG|oral applications of Placebo|five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
48290764|NCT01105351|DIETARY_SUPPLEMENT|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
48290765|NCT01105351|DIETARY_SUPPLEMENT|folic acid|folic acid 400 µg
48290766|NCT01803802|BEHAVIORAL|Expressive writing|Five sessions of 30 minutes of expressive writing
48290767|NCT04786288|OTHER|massage with lavender essential oil mixed in a carrier oil|22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage
48290768|NCT04786288|OTHER|massage with odourless baby oil|odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
48290769|NCT02076672|DRUG|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
48290770|NCT00388752|PROCEDURE|Acupuncture|
48473934|NCT04502849|PROCEDURE|Bypass surgery|Creating a bypass with graft or vein.
47942084|NCT02787551|DRUG|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
47942085|NCT00255801|DRUG|Targretin® (bexarotene)|
47942086|NCT00255801|DRUG|pegylated liposomal doxorubicin hydrochloride|
47942087|NCT02594241|DRUG|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
47942088|NCT02594241|DRUG|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
47942089|NCT00132561|DRUG|Sulfadoxine/pyrimethamine and artesunate|
48290771|NCT03320629|COMBINATION_PRODUCT|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
48290772|NCT03320629|COMBINATION_PRODUCT|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
48290773|NCT04086043|DEVICE|Endovascular Denervation|multi-electrode catheter-based endovascular denervation
48290774|NCT04330625|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for four weekly doses
48290775|NCT01385696|DEVICE|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
48290776|NCT01385696|DEVICE|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
48290777|NCT00043147|DRUG|beclomethasone dipropionate|
48290778|NCT00043147|DRUG|methylprednisolone|
48290779|NCT00043147|DRUG|prednisone|
48290780|NCT02519764|OTHER|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
48290781|NCT02519764|OTHER|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
48290782|NCT01708564|BIOLOGICAL|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
48290783|NCT03424551|DEVICE|vibrator|Local or whole body vibration was applied at six different frequencies
48290784|NCT02282332|DRUG|Ticagrelor|
48290785|NCT00053820|BIOLOGICAL|aldesleukin|
48290786|NCT00053820|BIOLOGICAL|recombinant interferon alfa|
48290787|NCT00053820|DRUG|fluorouracil|
48290788|NCT06287047|PROCEDURE|Epidural analgesia|Epidural analgesia alone or with dural puncture with different sizes of spinal needles
48290789|NCT04685330|PROCEDURE|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
48290790|NCT04685330|DEVICE|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
48290791|NCT05216991|OTHER|TetraGraph on dominant hand|Using standard of care TetraGraph device on dominant hand
48102571|NCT06475170|PROCEDURE|proximal gastrectomy combined with 'λ+α' double-tract anastomosis|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. The jejunum is dissected 30 cm from the flexor ligament and the distal jejunum is lifted in an anterior colonic direction to the esophageal dissection.~4. Esophagojejunal anastomosis at 16 cm from the distal jejunal stump；~5. Residual gastrojejunostomy at 8 cm from the distal jejunal stump；"
48102572|NCT06164249|OTHER|strength training|Strength training, three times a week, during nine weeks.
48102573|NCT06632002|OTHER|DSF1|220 mL
48102574|NCT06632002|OTHER|DSF2|220 mL
48102575|NCT06632002|OTHER|Standard of Care (SOC)|Standard of care
48102576|NCT01109095|BIOLOGICAL|HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~* 1 x 10\^6/m\^2~* 3 x 10\^6/m\^2~* 1 x 10\^7/m\^2~* 3 x 10\^7/m\^2~* 1 x 10\^8/m\^2"
48102577|NCT03851237|DRUG|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
48102578|NCT03851237|DEVICE|PET/CT|-Standard of care
48102579|NCT03353467|PROCEDURE|Endoscopic surgery|Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
48102580|NCT03353467|RADIATION|Intensity-modulated radiotherapy|All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
48102581|NCT01451814|BEHAVIORAL|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
48102582|NCT01451814|DRUG|Nicotine polacrilex|8 weeks of nicotine patch
48102583|NCT01451814|BEHAVIORAL|Relaxation training|Instructions in progressive muscle relaxation
48102584|NCT01451814|BEHAVIORAL|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
48290792|NCT05216991|OTHER|TetraGraph on non-dominant hand|Using standard of care TetraGraph device on non-dominant hand
48102585|NCT04074551|DRUG|HCP1701|HCP1701
48102586|NCT04074551|DRUG|Losartan|Losartan
48102587|NCT04074551|DRUG|Amlodipine|Amlodipine
48102588|NCT04074551|DRUG|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
48102589|NCT00002290|DRUG|Zidovudine|
48102590|NCT00002290|DRUG|Acyclovir|
48290793|NCT02396407|BEHAVIORAL|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children \< 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
48290794|NCT02473653|BIOLOGICAL|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
48290795|NCT03940170|DEVICE|vistacam proof|Light fluorescence device
48290796|NCT03940170|OTHER|ICDASII|visual examination
48102591|NCT05380583|BEHAVIORAL|CRAFT-EP|CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks). The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps. The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services. Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
48102592|NCT05380583|BEHAVIORAL|TAU|Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
48102593|NCT03408860|OTHER|Countering Emotional Behaviors Module from Unified Protocol|This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
48102594|NCT05939648|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
48102595|NCT05939648|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
48102596|NCT02952755|DRUG|Co-administration of DWC20155/DWC20156|
48102597|NCT02952755|DRUG|DWC20162|
48102598|NCT00633412|DRUG|Esomeprazole|20mg oral daily
48102599|NCT00633412|DRUG|Ranitidine|150mg oral twice daily
48102600|NCT00633412|DRUG|Esomeprazole|40mg oral tablet daily
48102601|NCT03860220|DRUG|NEWSTATIN TS|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
48290797|NCT03940170|PROCEDURE|fissurotomy|histological validation
48473935|NCT04502849|PROCEDURE|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
48290798|NCT03787433|DEVICE|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
48290799|NCT06027983|DRUG|Chimeric receptor T-cells + Trastuzumab|Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
48290800|NCT06027983|DRUG|Fludarabine and Cyclophosphosphamide|3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
48290801|NCT02351037|DRUG|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
48290802|NCT02351037|DRUG|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
48290803|NCT02351037|DRUG|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
48290804|NCT04760132|BIOLOGICAL|COMIRNATY - BioNTech Manufacturing GmbH|Vaccination as part of the the Danish national government programme
48290805|NCT04760132|BIOLOGICAL|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Vaccination as part of the the Danish national government programme
48290806|NCT04760132|BIOLOGICAL|COVID-19 Vaccine AstraZeneca suspension for injection|Vaccination as part of the the Danish national government programme
48290807|NCT05101421|DIETARY_SUPPLEMENT|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
48290808|NCT03467022|DRUG|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
48290809|NCT02395679|BIOLOGICAL|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
48473936|NCT04502849|PROCEDURE|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
48473937|NCT04502849|DRUG|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
48102602|NCT03860220|DRUG|CADUET|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
48290810|NCT06227923|DEVICE|PRO-HOME intervention|Patients are transferred to the apartment inside the hospital setting and are evaluated and assessed also using technological devices
48290811|NCT04475094|DRUG|Rubidium-82|Consented subjects will undergo a rest/regadenoson stress myocardial perfusion PET study.
48290812|NCT04475094|BEHAVIORAL|Seattle Angina Questionnaire-7|Consented subjects will complete a SAQ-7.
48290813|NCT04475094|BEHAVIORAL|Rose Dyspnea Scale|Consented subjects will complete a RDS.
48473938|NCT04502849|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
48473939|NCT04502849|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
48473940|NCT04502849|DIAGNOSTIC_TEST|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
48473941|NCT00083434|DRUG|Epoetin alfa|
48473942|NCT03651908|PROCEDURE|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
48473943|NCT01195155|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
48473944|NCT02107222|DEVICE|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
48290814|NCT03115385|DIETARY_SUPPLEMENT|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
48290815|NCT03115385|DIETARY_SUPPLEMENT|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
48290816|NCT03977389|PROCEDURE|Total wrist denervation|Study of the files
48290817|NCT06443112|PROCEDURE|transvaginal cervical cerclage by Mc Donald technique|In the McDonald operation, a suture is is inserted around the exo-cervix as high as possible to approximate to the level of the internal os and thereby prevent second-trimester abortion.
48290818|NCT06485544|DRUG|Adebrelimab + Etoposide + Platinum-based Therapy|"Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
48290819|NCT06485544|DRUG|Etoposide + Platinum-based Therapy|"Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
48290820|NCT02893254|DRUG|IBI303|12 cycles. IBI303: 40 mg, iH
48290821|NCT02893254|DRUG|Adalimumab|12 cycles. Adalimumab: 40mg, iH
48290822|NCT05324943|GENETIC|FLT201|FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector. The vector is composed of a ss DNA genome packaged in an AAV-derived protein capsid.
48290823|NCT05519943|BEHAVIORAL|The Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
48290824|NCT05519943|BEHAVIORAL|TAU condition|A TAU waitlist condition during which participants received routine care services tailored to each child individually.
48290825|NCT01501344|DIETARY_SUPPLEMENT|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
48290826|NCT04590729|BEHAVIORAL|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
48290827|NCT04590729|BEHAVIORAL|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
48290828|NCT05089305|DRUG|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
47942090|NCT01733849|OTHER|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
47942091|NCT01733849|OTHER|Data collection|Log books
48102603|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
48102604|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
48290829|NCT02113748|OTHER|Downhill walking training|Walk on a treadmill with a negative inclination.
48290830|NCT02113748|OTHER|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
48290831|NCT04581187|OTHER|Quality of life assessment|Quality of life questionnaires
48290832|NCT03084159|BEHAVIORAL|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
48290833|NCT03320512|BEHAVIORAL|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
47942092|NCT01536288|DRUG|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
48290834|NCT03320512|BEHAVIORAL|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
48290835|NCT03320512|BEHAVIORAL|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
48290836|NCT04019496|DRUG|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
48290837|NCT03411603|OTHER|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
48102605|NCT00580437|PROCEDURE|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
48102606|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
48102607|NCT00000871|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
48290838|NCT05167786|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
48290839|NCT05167786|DEVICE|Noninvasive spinal stimulation|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation to subjects.
48473945|NCT00704496|DRUG|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
48473946|NCT03884725|DRUG|Fibrinogen Concentrate|Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
47942093|NCT01536288|DRUG|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
47942094|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)
48102608|NCT00000871|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
48102609|NCT00000871|BIOLOGICAL|rgp120/HIV-1 SF-2|
47942095|NCT04877106|DRUG|Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)|The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
47942096|NCT05250128|PROCEDURE|Catheterization|Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance
47942097|NCT03095443|OTHER|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
47942098|NCT03095443|OTHER|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
47942099|NCT03095443|OTHER|Attention Control|Participant receives an audio-book.
47942100|NCT03311620|PROCEDURE|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
47942101|NCT04581759|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.
47942102|NCT04581759|DRUG|foundational treatment|foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
47942103|NCT04637906|DIETARY_SUPPLEMENT|Bioarginina®|Food supplement based on 1,66 grams of L-arginine
47942104|NCT00000671|DRUG|Zidovudine|
47942105|NCT00000671|DRUG|Didanosine|
48102610|NCT04061408|RADIATION|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
48102611|NCT00391547|DRUG|Frio Oral Rinse|
48102612|NCT00778804|BEHAVIORAL|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
48102613|NCT01735474|OTHER|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
47942106|NCT03613597|DRUG|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
47942107|NCT03613597|DRUG|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
47942108|NCT02323932|BEHAVIORAL|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
47942109|NCT02841527|PROCEDURE|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
47942110|NCT02841527|PROCEDURE|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
47942111|NCT02841527|PROCEDURE|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
47942112|NCT00508768|DRUG|Oral SCIO-469 capsule|
47942113|NCT01528215|DEVICE|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
47942114|NCT01528215|DEVICE|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
47942115|NCT05120661|OTHER|food product|a food product containing 50 gram carbohydrates
47942116|NCT05355311|DRUG|Acetyl-l-carnitine|Acetyl-L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
47942117|NCT05355311|DRUG|Placebo|Matching placebo (sugar pill)
47942118|NCT06260098|BEHAVIORAL|Yoga with High Breath work & meditation; Low movement/postures|Participants will engage in an 8 week asynchronous yoga class focused on the internal and cognitive experience within the practice using breathing and meditation focused techniques.
47942119|NCT06260098|BEHAVIORAL|Yoga with Low Breath work & meditation; High movement/postures|Participants will engage in an 8 week asynchronous yoga class with a emphasis on the physicality and movements of the practice.
47942120|NCT05420727|DRUG|Ga-68-PSMA-11 PET/CT|Ga-68-PSMA-11 PET/CT imaging
47942121|NCT05420727|DRUG|Lu-177-ITG-PSMA-1|Lu-177-ITG-PSMA-1 treatment
48102614|NCT01735474|OTHER|Placebo|Usual care
48102615|NCT01014858|DRUG|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
48102616|NCT02260310|OTHER|Weizhong and Huantiao|
48102617|NCT02260310|OTHER|A-shi point|
48102618|NCT01616654|DRUG|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
48290840|NCT05167786|DEVICE|Conventional gait training|Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
48290841|NCT05167786|OTHER|Sham|Subject will not receive either transcutaneous electrical spinal cord stimulation or perform lower limb locomotor activities.
48290842|NCT05167786|OTHER|Exploratory Phase - Optimization of Gait Training and Spinal Stimulation|Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
48290843|NCT03210285|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing
48290844|NCT01483092|DIETARY_SUPPLEMENT|inulin|20g/day for 4 weeks
48290845|NCT01483092|DIETARY_SUPPLEMENT|maltodextrin|20g/day for 4 weeks
48290846|NCT05182515|DRUG|Therapeutic plasma exchange|"Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center."
48290847|NCT04154982|DRUG|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
48631481|NCT04361045|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning."
48631482|NCT05505890|OTHER|suprainguinal fascia iliaca block|Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.
48631483|NCT04294238|BEHAVIORAL|Aerobic exercise|The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
48290848|NCT00863187|BIOLOGICAL|rituximab|b cell depletion
48290849|NCT04569539|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
48290850|NCT03974178|DRUG|Fexinidazole|Adults and Children patients will receive fexinidazole tablets every day for 10 days
48290851|NCT00542828|BIOLOGICAL|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
48290852|NCT00030758|BIOLOGICAL|filgrastim|
48102619|NCT01616654|DRUG|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
48102620|NCT01616654|DRUG|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
48102621|NCT01616654|DRUG|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
48102622|NCT01616654|DRUG|Vehicle cream|Vehicle cream applied once daily
48290853|NCT00030758|BIOLOGICAL|pegfilgrastim|
48290854|NCT02241018|DRUG|CD25 monoclonal antibody|
48290855|NCT02241018|DRUG|calcineurin inhibitors|
48290856|NCT02241018|BIOLOGICAL|MSCs|
48290857|NCT01539629|DEVICE|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
48102623|NCT00866762|DRUG|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
48290858|NCT04932590|OTHER|End-expiratory occlusion test|The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
48631484|NCT04060745|OTHER|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
48631485|NCT04060745|OTHER|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
48631486|NCT03890939|DEVICE|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
48631487|NCT03890939|DEVICE|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
48102624|NCT02793427|BIOLOGICAL|blood sample collection|
48102625|NCT00139737|DRUG|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
48102626|NCT04173962|DRUG|Ketamine|administered 1 week prior to a laboratory-induced stress
48102627|NCT04173962|DRUG|Midazolam|administered 1 week prior to a laboratory-induced stress
48102628|NCT04538248|OTHER|Combined rehabilitation during hemodialysis|Combined rehabilitation during hemodialysis
48102629|NCT02931851|OTHER|ICU Families Website|Professionally developed website for relatives of ICU patients
48102630|NCT02931851|OTHER|Placebo|Standard Information provided online
48102631|NCT06609356|PROCEDURE|Study Visit 1|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
48102632|NCT06609356|DRUG|Placebo|"* T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies."
48102633|NCT06609356|PROCEDURE|Study Visit 2|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
48102634|NCT06609356|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).
48102635|NCT05341518|PROCEDURE|Subscapularis repair|To complete reverse total shoulder arthroplasty, the surgeon must cut through the subscapularis muscle. In this arm of the study, the muscle will be repaired, rather than left to heal itself.
48102636|NCT04290585|OTHER|Questionnaire Administration|Ancillary studies
48102637|NCT04290585|BEHAVIORAL|Telephone-Based Intervention|Receive text message reminders
48102638|NCT00048529|DRUG|T900607-sodium intravenous|
48102639|NCT06426303|DRUG|Naltrexone|12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
48102640|NCT05566587|OTHER|Mediteranean to Western to Mediteranean Diet|week 2-3 : Switching between Mediterranean diet and Western diet week 4-5 : Switching between Western diet and Mediterranean diet week 6-7 : Switching between Mediterranean diet and Western diet
48102641|NCT05566587|OTHER|Western to Mediteranean to Western Diet|week 2-3 : Switching between Western diet and Mediterranean diet week 4-5 : Switching between Mediterranean diet and Western diet week 6-7 : Switching between Western diet and Mediterranean diet
48102642|NCT00920686|DRUG|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
48102643|NCT00920686|DRUG|placebo|administered as 3 placebo hard gelatin capsules
48102644|NCT00920686|DRUG|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
48102645|NCT00163085|DRUG|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
48102646|NCT06629441|DIETARY_SUPPLEMENT|Probiotic group|taking 10 billion CFU probiotic one sachet one time, lasting 56 days.
48102647|NCT06629441|DIETARY_SUPPLEMENT|Placebo group|taking maltodaxtrin one sachet one time, lasting 56 days.
48102648|NCT00906035|DRUG|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
48102649|NCT00906035|DRUG|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
48102650|NCT00906035|DRUG|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
48102651|NCT03705819|DRUG|[11C]-NOP46|Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.
48102652|NCT03705819|RADIATION|PET/CT scan|After subjects receive a microdose of \[11C\]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
48290859|NCT04410783|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
48290860|NCT04410783|OTHER|Standard post intubation sedation practices|Usual care sedation provide in the ED
48290861|NCT01936246|DIETARY_SUPPLEMENT|Increased protein|
48290862|NCT01631357|BIOLOGICAL|CIK cell|CIK cell injection
48290863|NCT01631357|DRUG|Gemcitabine Injection|Gemcitabine injection
48102653|NCT03706963|OTHER|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
48102654|NCT01971892|OTHER|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
48102655|NCT01971892|OTHER|Standard oxygen therapy with facial mask|facial Venturi mask
48290864|NCT01631357|DRUG|Cisplatin injection|Cisplatin injection
48290865|NCT03411733|OTHER|Blood and stool samples collection|Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
48290866|NCT06513520|BIOLOGICAL|Blood sampling|Additional blood tube collection during routine blood sampling.
48290867|NCT06197607|OTHER|theraputty hand exercises|Theraputty hand exercises will be done in following manners: Finger flexion, Metacarpophalangeal joint flexion, Interphalangeal joint flexion, Finger grip strengthening, Finger abduction and Rolling putty into ball and pinching it between, thumbs and finger with both the hands. There will be 20 repetitions with one set of each
48290868|NCT06197607|OTHER|sensory stimulation|Sensory Stimulations (30 min) will be given following forms; All and single joint shaking, Multivariate sensory stimulations, Skin stretch in the muscular region, Fast stretch of the upper limb joints in different directions of motor action, brushing on the large muscles of arm and forearm, brushing on the fingers, Circular massage of the thenar and hypothenar area and pressing the tip of fingers.
48631488|NCT03890939|DEVICE|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
48631489|NCT00191152|DRUG|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
48631490|NCT00191152|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
47942122|NCT02758756|OTHER|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
48102656|NCT01714557|DRUG|Piperacillin|4.0g q8h 3-5 days
48631491|NCT00191152|DRUG|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
48631492|NCT03178942|DRUG|Permethrin Cream, 5%|Permethrin Cream 5%
48631493|NCT03178942|DRUG|Elimite™ Cream (permethrin) 5%|Permethrin Cream 5%
48102657|NCT01714557|DRUG|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
48290869|NCT05978895|OTHER|Targeted canteen menus|"The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population."
48290870|NCT01618656|DRUG|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
48102658|NCT02092844|BEHAVIORAL|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
48290871|NCT01618656|DRUG|Placebo|Sugar pill
48473947|NCT03884725|OTHER|control|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
48473948|NCT02172196|DRUG|BI 10773|
48473949|NCT02172196|DRUG|Sitagliptin|
48473950|NCT00164255|DRUG|sulfadoxine/pyrimethamine|
48473951|NCT00164255|DRUG|sulfadoxine/pyrimethamine plus artesunate|
48102659|NCT02888535|OTHER|Internal Medicine consultation|
48102660|NCT06279429|DIETARY_SUPPLEMENT|Sideral® Sucrosomial Iron|Sucrosomial Iron 30mg
48102661|NCT06279429|DIETARY_SUPPLEMENT|Iron chewable tablet|Iron chewable tablet 100mg
48473952|NCT03490916|DRUG|Acetazolamide|Administration of Acetazolamide
48473953|NCT03490916|DRUG|Placebo|Administration of Placebo
48631494|NCT01666613|DRUG|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
48631495|NCT01666613|DRUG|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
48631496|NCT01666613|DRUG|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
48631497|NCT01666613|DRUG|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
48290872|NCT04984135|PROCEDURE|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
48290873|NCT05047393|OTHER|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels \< 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
48290874|NCT03606746|BIOLOGICAL|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
48290875|NCT00942201|DRUG|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
48290876|NCT00942201|DRUG|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
48290877|NCT03042949|DEVICE|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
48290878|NCT03042949|DEVICE|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
48290879|NCT00687050|DIETARY_SUPPLEMENT|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
48290880|NCT00687050|DIETARY_SUPPLEMENT|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
48290881|NCT03320148|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"1. Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~2. Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~3. Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~4. Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
48290882|NCT03320148|OTHER|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
48290883|NCT02777463|OTHER|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
48290884|NCT05275829|OTHER|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
48290885|NCT02201810|BEHAVIORAL|Rate reduction intervention|
48290886|NCT02201810|BEHAVIORAL|Recycling Group|
48290887|NCT02201810|BEHAVIORAL|Choice Group|
48290888|NCT02201810|BEHAVIORAL|Proactive QL|
48102662|NCT02174562|BEHAVIORAL|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
48102663|NCT02174562|BEHAVIORAL|Enhanced Usual Care|Usual care enhanced with education and attention
48290889|NCT02612597|OTHER|Bedrest|
48631498|NCT03360487|RADIATION|Photobiomodulation in the sublingual region|In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
48290890|NCT02612597|OTHER|Exercise Training|
48290891|NCT04827537|DRUG|20-hydroxyecdysone Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
48290892|NCT04827537|DRUG|Metronidazole Oral|500 mg (one pill) x two times a day orally, 10 consecutive days
48290893|NCT04827537|DRUG|Placebo Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
48290894|NCT02347358|DEVICE|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
48290895|NCT02347358|DRUG|IV r-tPA|intravenous recombinant human tissue plasminogen activator
48290896|NCT05616234|PROCEDURE|Resistance Exercise|Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
48290897|NCT01341873|OTHER|educational intervention|Undergo APN FCI
48290898|NCT01341873|OTHER|psychosocial support for caregiver|Undergo APN FCI
48290899|NCT01341873|PROCEDURE|quality-of-life assessment|Ancillary studies
48631499|NCT03360487|RADIATION|Photobiomodulation in the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
48631500|NCT03360487|RADIATION|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
48631501|NCT05312060|DEVICE|PC Pneumatic compression|Pneumatic compression of the operated limb
48631502|NCT05312060|OTHER|AE Antithromboembolic exercises|Exercises for the edema
48631503|NCT05018559|BEHAVIORAL|BuG lesson|Participants of the intervention group in nursing care received a co-created setting-specific intervention to promote physical activity called BuG lesson. The BuG lesson comprises a weekly 90-minute lesson for apprentices of nursing care during regular school hours, covering physical activity and health in theory and practice. Previously, the nursing teachers voluntarily underwent a qualification process as physical activity instructors, enabling them to conduct the BuG lessons independently.
47942123|NCT02758756|OTHER|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
47942124|NCT04746716|OTHER|Phone call|Phone call to the patient to complete quality of life scales
47942125|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 before process changes 20 mg
47942126|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 after process changes 20 mg
47942127|NCT01843595|BEHAVIORAL|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
48102664|NCT00067639|DRUG|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
48290900|NCT01341873|OTHER|questionnaire administration|Ancillary studies
48290901|NCT04789824|BEHAVIORAL|eyelid hygiene|EH
48290902|NCT01050660|OTHER|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
48290903|NCT01050660|OTHER|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
48290904|NCT05067634|DRUG|Xcopri|Age groups 12 to \<18 will enroll once dosing data is received from Cohort I of the PK analysis of YKP3089C039 study. Age groups 6 to \<12 will enroll once dosing data is received from Cohort IIa of the PK analysis of YKP3089C039 study. Age groups 4 to \<6 will enroll once dosing data is received from Cohort IIb of the PK analysis of YKP3089C039 study. Age groups 2 to \<4 will enroll once dosing data is received from Cohort III of the PK analysis of YKP3089C039 study.
48290905|NCT03626051|DEVICE|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
48290906|NCT03626051|DEVICE|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
48290907|NCT00939172|DRUG|TTP607|3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
48290908|NCT01486238|DRUG|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
48290909|NCT03694522|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
48290910|NCT03694522|DRUG|Placebo|Administered by intravenous infusion over approximately 30 minutes
48290911|NCT03694522|DRUG|Modified FOLFOX6|"mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours"
48631504|NCT05018559|BEHAVIORAL|Tutoring system|Participants of the intervention group in automotive mechatronics received a co-created setting-specific intervention to promote physical activity called tutoring system. In the tutoring system, automotive mechatronics apprentices act as physical activity promotors for their fellow apprentices. In the sense of a peer-to-peer approach, apprentices voluntarily participate in a workshop to be qualified as tutors. Subsequently, the tutoring system takes place every two weeks for about ten to fifteen minutes during regular working hours, allowing the tutors to discuss the issues of physical activity and health among their peers.
48631505|NCT01149252|OTHER|Psoralait|Cream to be used as instructed.
48631506|NCT01149252|OTHER|Placebo cream.|Cream to be used as instructed
48631507|NCT05611424|GENETIC|FT-003|Administered via intraocular injection.
48631508|NCT04774354|DIAGNOSTIC_TEST|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
48631509|NCT05865249|OTHER|Spirometry decision support software (ArtiQ.Spiro)|ArtiQ.Spiro is a decision support software that combines two sub-components - one focussing on quality assessment (ArtiQ.QC), and one on spirometry interpretation (ArtiQ.PFT). It is intended to be used as an adjunct to spirometry to assist with the grading of spirometry quality and the interpretation of spirometry by providing the probability of six disease / or no disease categories.
48631510|NCT06455254|DRUG|Candonilimab (AK104)|Cadonilimab (AK104): 6mg/kg, i.v. q2w.
48631511|NCT06455254|DRUG|Regorafenib|Regorafenib: 80 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).
48631512|NCT01666314|DRUG|Orteronel|Orteronel tablets
48631513|NCT01666314|DRUG|Orteronel Placebo|Orteronel placebo-matching tablets
48631514|NCT01666314|DRUG|Prednisone|Prednisone 5 mg
48631515|NCT00211900|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
48290912|NCT05784389|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
48290913|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
48290914|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
48290915|NCT02066090|DEVICE|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
48631516|NCT05931900|DEVICE|moderate-severe or greater (MR ≥ 3+) functional mitral regurgitation (FMR) patients|Functional mitral regurgitation (FMR) is common in patients with myocardial infarction or dilated cardiomyopathy, and portends a poor prognosis despite guideline-directed medical therapy (GDMT).
48631517|NCT03423953|DEVICE|Comprehensive Nano|Patients requiring the Comprehensive Nano shoulder system.
47942128|NCT04226534|OTHER|Maximal effort test|Performing a maximal effort test on the treadmill
47942129|NCT00302198|BEHAVIORAL|ALS Registry|
47942130|NCT00678340|DEVICE|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
47942131|NCT00678340|DEVICE|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
48631518|NCT01926392|DRUG|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
47942132|NCT05331027|DRUG|Desflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
47942133|NCT05331027|DRUG|Sevoflurane|After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
48631519|NCT01926392|DRUG|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
48631520|NCT05311410|OTHER|Non-bloody dental procedures (control group)|Control group composed of 30 positive patients for SARS-CoV-2, from the same ICU, submitted to non-bloody procedures.
47942134|NCT00190515|DRUG|5FU+l-leucovorin|5FU+l-leucovorin
47942135|NCT00190515|DRUG|UFT+Leucovorin|UFT+Leucovorin
47942136|NCT04684290|PROCEDURE|Alcohol Septal Ablation|Participants will be treated with alcohol septal ablation.
47942137|NCT04684290|PROCEDURE|Surgical Septal Myectomy|Participants will be treated with surgical septal myectomy.
48631521|NCT05311410|PROCEDURE|Bloody dental procedures (study group)|Study group consisting of 30 patients who require open dental treatment and with a positive PCR test for SARS-CoV-2 prior and admitted to the Intensive Care Unit.
48290916|NCT02066090|DEVICE|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
48290917|NCT03477188|BEHAVIORAL|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
48290918|NCT03477188|BEHAVIORAL|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
48290919|NCT01703312|DRUG|QGE031|Drug administered by subcutaneous injection
48290920|NCT01703312|DRUG|omalizumab|Drug administered by subcutaneous injection
48290921|NCT01703312|DRUG|placebo|Drug administered by subcutaneous injection
48290922|NCT06457438|DIAGNOSTIC_TEST|Elecsys Anti-HEV IgG, IgM|Diagnostic test used to determine antibodies in blood and serum.
48290923|NCT05982977|OTHER|Acupuncture|The patient was placed in a supine position, selected Lianquan, Fengchi, and acupoints.
48290924|NCT05982977|BEHAVIORAL|Conventional rehabilitation|swallowing training included breathing training, masticatory muscle training, oral movement training and feeding training.
48290925|NCT01701791|OTHER|Computerized Decision Support System|
48290926|NCT04128098|OTHER|Evaluation|"* Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~* 3D analysis of locomotion and posture~* Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
48290927|NCT04128098|OTHER|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
48473954|NCT02315261|PROCEDURE|Elective Thoracic and Abdominal Surgery Patients|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection in Elective Thoracic and Abdominal Surgery Patients only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
48473955|NCT05814133|DEVICE|Thulium Fiber Laser|Thulium Fiber Laser will be used to break renal stones \< 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
47942138|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
48290928|NCT04128098|OTHER|Rehabilitation care program|"* Personalized global exercises (aerobics) on ergometers~* Muscle strengthening with resistance~* Balneotherapy~* Learning health skills related to their condition (therapeutic education)~* Personal and group motivational interviews~* Nutritional advice~* Relaxation session"
48290929|NCT01050062|DRUG|Telmisartan 80mg|Combination tablet
48290930|NCT01050062|DRUG|Telmisartan 40mg|Combination tablet
48473956|NCT02893280|DRUG|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
47942139|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
47942140|NCT01479504|DRUG|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
48290931|NCT01050062|DRUG|Hydrochlorothiazide 12.5mg|Combination tablet
47942141|NCT01479504|DRUG|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
47942142|NCT01451580|DRUG|Lipo-Dox|
48473957|NCT03547635|OTHER|AMNIOEXCEL Plus Amniotic Membrane|AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
48473958|NCT03547635|DEVICE|A Marketed Comparator|bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
48473959|NCT03547635|OTHER|Standard of Care|"* Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* An offloading boot (Pneumatic Short Leg Walker), as appropriate"
48473960|NCT03437057|OTHER|acetylsalicylic acid (below or equal to) 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
48473961|NCT00176540|DRUG|dextromethorphan hydrobromide|
48473962|NCT05775848|DRUG|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
48473963|NCT05775848|OTHER|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
48473964|NCT04491695|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
48102665|NCT00067639|PROCEDURE|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
48473965|NCT04491695|DRUG|Oral antiplatelet|Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
48473966|NCT00672776|DRUG|paroxetine|
48473967|NCT00672776|DRUG|placebo|
48473968|NCT00761176|DEVICE|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
48473969|NCT00745719|PROCEDURE|parathyroidectomy|total parathyroidectomy with forearm autografting
48473970|NCT03952988|DIETARY_SUPPLEMENT|Probiotic ice cream|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (\>10(exp7)/g) every day for 4 weeks
48473971|NCT03952988|DIETARY_SUPPLEMENT|Placebo ice cream|One portion (50g) of an ice-cream without probiotic every day for 4 weeks
48473972|NCT01322334|BEHAVIORAL|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
48473973|NCT04973813|BEHAVIORAL|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
47942143|NCT04284852|DRUG|Niraparib|PARP inhibitor
47942144|NCT04559919|OTHER|Seizure status|We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
47942145|NCT04559919|DIAGNOSTIC_TEST|Tests|We will collect results from imaging, electroencephalogram, and laboratory tests.
47942146|NCT04559919|OTHER|Epilepsy|We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
47942147|NCT04559919|OTHER|Demographics and psychosocial|We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
48102666|NCT01559506|DEVICE|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
48102667|NCT02377505|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
48102668|NCT02377505|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
47942148|NCT04559919|OTHER|Health care|We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
47942149|NCT03086278|DRUG|AST-008|AST-008 is a toll-like receptor 9 agonist.
48102669|NCT03121963|DRUG|Oxycodone|oxycodone tablet
48290932|NCT03540121|BEHAVIORAL|Video education + adherence contract|Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
48290933|NCT04663035|DRUG|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
48290934|NCT04663035|PROCEDURE|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
48290935|NCT00685178|DRUG|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
48290936|NCT00685178|BEHAVIORAL|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
48290937|NCT00685178|DRUG|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
48290938|NCT03665597|BIOLOGICAL|Pembrolizumab Dose C|SC injection
48290939|NCT03665597|BIOLOGICAL|Pembrolizumab Dose A|SC injection
48290940|NCT03665597|BIOLOGICAL|Pembrolizumab Dose B|IV infusion
48290941|NCT03665597|BIOLOGICAL|Pembrolizumab Dose D|IV infusion once every 6 weeks
48290942|NCT02525172|DRUG|Rituximab|
48290943|NCT02525172|DRUG|intravenous immune globulin|
48290944|NCT02525172|DRUG|Bortezomib|
48290945|NCT02525172|DRUG|Methotrexate|
48290946|NCT00479362|DRUG|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
48290947|NCT00479362|DRUG|Aspirin|Aspirin is continued without interruption prior to device implantation
48473974|NCT04973813|BEHAVIORAL|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
48473975|NCT04973813|BEHAVIORAL|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
48102670|NCT03121963|DRUG|Acetaminophen|acetaminophen tablet
48290948|NCT00479362|DEVICE|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
48290949|NCT00479362|DEVICE|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
48473976|NCT04973813|BEHAVIORAL|Guideline (G)|Web-based information about the national physical activity guideline.
48102671|NCT03121963|DRUG|Gabapentin|gabapentin tablet
48290950|NCT04779021|OTHER|Hospitalisation for SARS-COV2 infection|Patients hospitalized for SARS-COV2 infection
48290951|NCT04686890|PROCEDURE|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
48290952|NCT04686890|PROCEDURE|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
48290953|NCT05750667|BEHAVIORAL|Cascade screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
48290954|NCT01171521|DEVICE|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
48473977|NCT00317434|DRUG|lapatinib|
48473978|NCT01121107|DEVICE|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
48473979|NCT01121107|DEVICE|Patient Advisory Module|Handheld device that provides medication reminders
48102672|NCT03121963|DRUG|Celecoxib|celecoxib tablet
48102673|NCT03121963|DRUG|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
48102674|NCT05309980|OTHER|standard of care|retrospective study : standard of care
48290955|NCT02767570|OTHER|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
48290956|NCT02767570|OTHER|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
48473980|NCT05210712|DEVICE|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
48473981|NCT05562453|DEVICE|FlowOx 2.0|Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.
48473982|NCT05562453|DEVICE|FlowOx2.0 (Sham)|Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
47942150|NCT02594332|DRUG|Mepolizumab|100 mg SC every 4 weeks for 13 injections
47942151|NCT02594332|DRUG|Placebo|
48102675|NCT06309342|OTHER|PREVFUNKTION|Functional profile and advice concerning cardiovascular fitness level, strength, mobility, balance and posture. Motivational interview and support in goalsetting to make lifestyle changes.
47942152|NCT02092272|BEHAVIORAL|instructional exercise video source|instructional exercise video source
48473983|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
48473984|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
48473985|NCT03756883|DRUG|Placebo Inhalation Powder|No active content
48473986|NCT02251509|DRUG|Carvedilol|
48473987|NCT02251509|DRUG|Metoprolol tartrate|
48473988|NCT02498535|DRUG|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
48473989|NCT04014582|BEHAVIORAL|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
48473990|NCT04014582|BEHAVIORAL|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
48473991|NCT06013345|DRUG|Remimazolam|analgosedation without secured airway
48473992|NCT06013345|DRUG|Propofol|analgosedation with secured airway
48473993|NCT06013345|DRUG|Propofol|TIVA with secured airway
48473994|NCT02302937|PROCEDURE|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
48473995|NCT02302937|PROCEDURE|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
48473996|NCT03176433|DEVICE|Normothermic Machine Liver Perfusion|Liver Preservation Method
48473997|NCT03304340|DEVICE|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
48473998|NCT03304340|DEVICE|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device \& Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
48473999|NCT03304340|OTHER|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
48474000|NCT05930431|BEHAVIORAL|Physical activity variety intervention|The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
48618042|NCT03233256|PROCEDURE|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
48474001|NCT05930431|BEHAVIORAL|Physical activity consistency comparison condition|The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
48474002|NCT03527654|OTHER|Observational|Surveys, blood and urine collected prospectively over 24 months.
48474003|NCT03170102|OTHER|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
48474004|NCT00681018|OTHER|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
48474005|NCT00681018|OTHER|Powder human milk fortifier|Powder human milk fortifier added to human milk
48474006|NCT05831735|BEHAVIORAL|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
48474007|NCT05831735|BEHAVIORAL|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
48631522|NCT05050838|OTHER|Transcranial Doppler (TCD)|"TCD ultrasonography is based on the principle of the Doppler effect. According to this principle, ultrasound waves emitted from the Doppler probe are transmitted through the skull and reflected by moving red blood cells within the intracerebral vessels. The difference in the frequency between the emitted and reflected waves, referred to as the Doppler shift frequency, is directly proportional to the speed of the moving red blood cells (blood flow).~Cerebral blood flow (in cm/s) of the middle cerebral artery will be measured with TCD in blood-injured ARDS patients before and one hour after prone positioning (normal ranges: 48 to 72 cm/s)."
48631523|NCT00366535|DRUG|Placebo|4 tabs b.i.d.
48631524|NCT00366535|DRUG|Neurotropin|4 tabs b.i.d.
47942153|NCT00539669|DRUG|Docetaxel|
48474008|NCT04751045|PROCEDURE|EUS liver biopsy|Endoscopic ultrasound guided liver biopsy
47942154|NCT03912896|BEHAVIORAL|Taekwondo|Children will participate in a 7-week taekwondo program.
47942155|NCT04071587|DEVICE|Brain Computer Interface training|Training with RecoveriX system.
47942156|NCT04071587|BEHAVIORAL|Control|Standard physiotherapy and occupational therapy according to clinical routines.
48631525|NCT03184675|OTHER|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
48631526|NCT03184675|OTHER|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
48631527|NCT01960842|DRUG|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
48631528|NCT01960842|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
48631529|NCT01960842|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
48631530|NCT01960842|DEVICE|J-tube|jejunal tube
48631531|NCT04193527|DRUG|DaTSCAN™ Ioflupane (123I) Injection|All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
48631532|NCT04590183|DRUG|FK-506 (Drug)|Twice a day
48631533|NCT04590183|DRUG|Prednisolone Acetate 1% Oph Susp|Four times a day
48631534|NCT04108260|DRUG|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
48631535|NCT00194090|DRUG|celecoxib|
48631536|NCT06255587|OTHER|Screening|cross sectional
48631537|NCT01886157|PROCEDURE|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
48631538|NCT01886157|PROCEDURE|Corticosteroid injection|Standard trigger finger corticosteroid injection.
48631539|NCT05880030|DRUG|Cholecalciferol|cholecalciferol 10000 UI
48631540|NCT05880030|OTHER|placebo|sunflower oil
48631541|NCT05897554|DRUG|intra-arterial alteplase|For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
48631542|NCT00669331|DRUG|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
48631543|NCT00669331|DRUG|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
48631544|NCT05174507|DRUG|empagliflozin|Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
48631545|NCT05174507|DRUG|anakinra|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
48631546|NCT05174507|OTHER|saline subcutaneous (s.c.) (placebo)|Placebo for anakinra is 0.67 ml of sterile 0.9 % saline solution s. c. Treatment consists of a single subcutaneous injection of matched placebo (0.67 ml of 0.9 % saline) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
48631547|NCT05174507|OTHER|tablet per oral (p.o.) (placebo)|Placebo for empagliflozin is Winthrop P® (Zentiva, Frankfurt/Main) lactose tablet. Treatment consists of a single oral tablet of matched placebo two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
48631548|NCT00560404|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
48631549|NCT00560404|DRUG|Epoetin alfa|As prescribed
48631550|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
47942157|NCT01845883|PROCEDURE|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
47942158|NCT00276913|DRUG|STA-5312|
47942159|NCT05294536|DRUG|Liraglutide injection,RD12014|single dose, s.c. injection
48474009|NCT02426541|DRUG|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
48474010|NCT02426541|DRUG|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
48474011|NCT05667948|DRUG|Chemotherapy|different treatments based on the molecular analysis
48474012|NCT03680976|DRUG|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
48474013|NCT03680976|DRUG|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
48474014|NCT02709629|BEHAVIORAL|Individualized and adaptive computerized cognitive training|
48474015|NCT02709629|BEHAVIORAL|Active control|
48474016|NCT02105311|DEVICE|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
48474017|NCT02105311|DRUG|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
48618043|NCT06430489|DRUG|Nitrous oxide|inhaled nitrous oxide (1 hour at 50% concentration)
48618044|NCT06430489|DRUG|Medical air|inhaled medical air (1 hour)
48618045|NCT03772873|PROCEDURE|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
48618046|NCT05514119|DRUG|Fenofibrate|160mg once daily orally for 12 weeks
48631551|NCT01259882|DRUG|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
48618047|NCT05726253|DRUG|Supportive Care + Amoxicillin|Participants will be randomized to receive oral amoxicillin for a standard course (7 days)
48618048|NCT05726253|DRUG|Supportive Care + Placebo (no antibiotics)|Participants will be randomized to receive oral placebo for a standard course (7 days)
48631552|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
48631553|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
48631554|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
48631555|NCT01259882|DRUG|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
48631556|NCT02626351|OTHER|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: \[1\] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; \[2\] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; \[3\] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; \[4\] Follow up.
48631557|NCT02626351|OTHER|Baseline data collection (active comparator)|Endpoint data collection only
48631558|NCT05328895|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation with Betahistine|"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on the left ear was selected and stimulated with electronic acupuncture apparatus (Hwato, SDZ-IIB), with continuous wave, 25 Hz in frequency, 4 to 8 mA in intensity depending on patient's tolerance. The first 3 treatments were conducted in hospital, during which, the patients were trained to use the apparatus under the instruction of research staff. Afterwards, the rest treatments were exerted at home, twice a day, after every breakfast and dinner respectively, 30 min each time. The treatment was given from Monday to Friday a week, totally for 12 weeks.~Participants received betahistine mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day."
48631559|NCT04541342|PROCEDURE|initial arthroscopy with medial opening-wedge high tibial osteotomy fixed by a plate system then second look arthroscopy with plate removal|It is a joint preserving procedure especially preferred in young patients for whom arthroplasty is not desirable. The procedure promotes regeneration by causing lateral shift of the weight-bearing axis, thus decreasing load on the medial compartment and widening the medial joint space.Many of the patients complains of irritation through the plate and wish metal removal after healing of the osteotomy.All patients will undergo initial arthroscopy before high tibial osteotomy (HTO). During arthroscopy, debridement of the degenerate tissues and meniscal tears if present will be performed. Then opening-wedge high tibial osteotomy (OWHTO) will be performed and fixed by a plate system. Second-look arthroscopy will be conducted at the time of plate removal after healing of the osteotomy. This will be after about 6 months up to one year.
48631560|NCT01766089|DRUG|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
48631561|NCT01766089|DRUG|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
48631562|NCT05331833|RADIATION|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT under PET-CT guidance and the control group with CTV-delineated IMRT using a random number table.|
48631563|NCT00004859|DRUG|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
48631564|NCT00004859|DRUG|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
48631565|NCT00004859|DRUG|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
48631566|NCT00004859|RADIATION|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
48618049|NCT02265653|DRUG|BIIL 284 BS tablet C|
48618050|NCT02265653|DRUG|BIIL 284 BS tablet D|
48618051|NCT02265653|DRUG|BIIL 284 BS WIF tablet|
48631567|NCT04338997|DRUG|IZD174|Small molecule inhibitor of NLRP3
48474018|NCT02408120|DRUG|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
48474019|NCT02408120|DRUG|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
48474020|NCT02408120|DRUG|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~* BG \>141-180 mg/dL; 2-4 units of insulin aspart~* BG between 181-220 mg/dL; 3-6 units of insulin aspart~* BG between 221-260 mg/dL; 4-8 units of insulin aspart~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart"
48474021|NCT01435824|DRUG|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
48474022|NCT01435824|DRUG|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
48474023|NCT02283190|DRUG|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
48474024|NCT01572519|DRUG|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
48474025|NCT01572519|DRUG|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
48474026|NCT01572519|DRUG|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
48474027|NCT01572519|DRUG|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
48474028|NCT01572519|DRUG|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
48474029|NCT04047953|DRUG|Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1|Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA\>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
48474030|NCT01470417|DRUG|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
48474031|NCT01470417|DRUG|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
48474032|NCT03309917|OTHER|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
48474033|NCT03309917|OTHER|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
48474034|NCT03309917|OTHER|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
48474035|NCT00026923|PROCEDURE|Laparoscopic surgery|
48474036|NCT01619579|DEVICE|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
48474037|NCT05270486|PROCEDURE|Electromagnetic navigation system|The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
47942160|NCT05294536|DRUG|Liraglutide injection,Victoza|single dose, s.c. injection
47942161|NCT00096954|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
48631568|NCT05673655|DRUG|intraoral trigger point injection by botox|intraoral injection of trigger point of masseter muscle by botulinum toxin
48631569|NCT05673655|DRUG|transcutaneous trigger point injection by botox|transcutaneous injection of masseter muscle by botulinum toxin
48631570|NCT04981561|DRUG|GATE-251|Single dose of GATE-251
48631571|NCT04981561|DRUG|Placebo|Placebo
48631572|NCT04949295|DEVICE|ocular surface analyzer|Using ocular surface analyzer for Inspection
48290957|NCT05989880|DEVICE|SafeLM as a supraglottic airway device with video capability|The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
48290958|NCT05989880|DEVICE|SafeLM as a supraglottic airway device without video capability|The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
48290959|NCT05989880|DEVICE|SafeLM as a conduit for intubation using an endotracheal tube with video capability|The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
48290960|NCT05989880|DEVICE|SafeLM as a conduit for intubation using a bougie with video capability|The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
48290961|NCT00204386|DRUG|Topiramate|
48290962|NCT01478347|BIOLOGICAL|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
48290963|NCT01243476|DRUG|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
48290964|NCT01243476|OTHER|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
48290965|NCT03323307|DEVICE|OCT imaging|imaging of retina using OCT device
48290966|NCT03103750|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
48290967|NCT03103750|DRUG|PHNO|Used as a tracer for in vivo imaging.
48474038|NCT01134627|DRUG|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
48474039|NCT01134627|DRUG|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
48474040|NCT00688298|DEVICE|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
48474041|NCT00688298|DEVICE|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
48474042|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
48290968|NCT03103750|DIETARY_SUPPLEMENT|calcitriol|three 0.5 mcg capsules
47942162|NCT00096954|DRUG|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
48631573|NCT05789342|DRUG|GP681|GP681, tablet, oral
48631574|NCT05789342|DRUG|Rosuvastatin|Rosuvastatin, tablet, oral
48631575|NCT05789342|DRUG|Digoxin|Digoxin, tablet, oral
48631576|NCT05789342|DRUG|Itraconazole|Itraconazole, capsule, oral
48631577|NCT05789342|DRUG|Oseltamivir|Oseltamivir, capsule, oral
47942163|NCT03754673|DEVICE|MRI|MRI pulmonary with no contrast administration
47942164|NCT00145704|DRUG|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
47942165|NCT00145704|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
47942166|NCT00145704|DIETARY_SUPPLEMENT|Calcium|calcium supplement given to patients with growth hormone deficiency
48631578|NCT05381168|DIETARY_SUPPLEMENT|Calcium from fish bone|Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.
47942167|NCT04292392|OTHER|preop ACB, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
48631579|NCT05381168|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.
48631580|NCT05154929|BEHAVIORAL|Dietary and physical activity JITAI delivered through the myBPmyLife app|A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.
48290969|NCT03103750|DRUG|Placebo oral capsule|three 0.5 mcg capsules
48290970|NCT03103750|PROCEDURE|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
48290971|NCT03103750|DRUG|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
48631581|NCT05154929|OTHER|Control Group|Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
48631582|NCT05363800|DRUG|HRS-3738|HRS-3738 will be administrated per dose level in which the patients are assigned.
48631583|NCT02105870|DRUG|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
48290972|NCT05776537|DEVICE|Fibreoptic bronchoscopy|different endoscopies used for confirmation of diagnosis
48290973|NCT06020976|DIAGNOSTIC_TEST|liver biobsy|all pationt will be subjected yo liver biobsy to confirm diagnosis
48474043|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
48631584|NCT01435915|DRUG|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
47942168|NCT04292392|OTHER|preop ACB+IPACK block|Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block
47942169|NCT04292392|OTHER|preop ACB+IPACK block, followed by Intra-articular block during TKA surgery|"Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
48290974|NCT03453086|PROCEDURE|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
48474044|NCT04954690|BEHAVIORAL|Usual Care|Usual Care
48474045|NCT02317250|PROCEDURE|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
48631585|NCT00143143|DRUG|Pregabalin|
48631586|NCT06284837|OTHER|Access site|The SAFER-TAVI trial is randomized study comparing secondary access via a transradial versus transfemoral approach among patients undergoing transfemoral TAVI for aortic valve disease. Secondary access is gained along with primary access at the commencement of the TAVI procedure and is used for aortography before and after valve deployment and for assessment of the primary femoral access site after closure to confirm haemostasis. For patients assigned to radial access, the radial sheath will be removed using a radial band at the end of the procedure. For patients assigned to femoral access, the puncture site will be obtained under ultrasound guidance and fluoroscopic landmark identification. Unless contraindicated, the use of vascular closure devices will be recommended for all femoral cases. The choice of closure device is at the discretion of the operator. Catheters used in the access groups will be 5 or 6 French size at the discretion of the operator.
48631587|NCT01356485|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
48631588|NCT01356485|DRUG|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
47942170|NCT04265469|OTHER|Diabetic foot education|Give Diabetic foot education via mobile phone
48102676|NCT06309342|OTHER|Control|Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
48102677|NCT04538820|DRUG|Dexamethasone 4 mg IV-control|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
48290975|NCT02477865|DRUG|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
48102678|NCT04538820|DRUG|Dexamethasone 4 mg IV|dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
48474046|NCT02317250|PROCEDURE|FDG-PET|\[F-18\] FDG-PET brain scans are administered once to all arms.
48618052|NCT00747513|BEHAVIORAL|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
48631589|NCT05598307|DRUG|magnesium bolus followed by normal saline infusion|a bolus dose of magnesium will be followed by normal saline infusion
48631590|NCT05598307|DRUG|magnesium bolus followed by magnesium infusion|a bolus dose of magnesium will be followed by a magnesium infusion
48631591|NCT05598307|DRUG|normal saline bolus followed by normal saline infusion|a bolus of normal saline will be followed by normal saline infusion
48631592|NCT01836822|PROCEDURE|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
48290976|NCT02477865|DRUG|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
48102679|NCT04538820|DRUG|Dexamethasone 8 mg IV|dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
48618053|NCT05695287|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
48631593|NCT01836822|PROCEDURE|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
48631594|NCT01836822|PROCEDURE|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
48631595|NCT01836822|PROCEDURE|Bronchoalveolar lavage (BAL)|
48631596|NCT01836822|PROCEDURE|Endobronchial forceps biopsy|
48631597|NCT00512083|DRUG|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
48631598|NCT04772924|BEHAVIORAL|fasting|more than 12 hour of fasting as ceremony of Ramadan
47942171|NCT05802875|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
48102680|NCT04073914|BEHAVIORAL|Type 1 Teamwork Program|Psychoeducational web program
48102681|NCT04176458|DEVICE|Methacetin Breath Test (MBT)|The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
48290977|NCT02477865|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
48618054|NCT05695287|DRUG|Isoflurane|Isoflurane
48102682|NCT06502769|BEHAVIORAL|Therapeutic Exercise|A therapeutic exercise program will be carried out
48618055|NCT05695287|DRUG|Sevoflurane|Sevoflurane
48102683|NCT06502769|BEHAVIORAL|Pain Neurophysiology Education|A PNE program will be carried out
48102684|NCT00610688|DRUG|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
48102685|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
48102686|NCT00610688|DRUG|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
48290978|NCT02333539|BEHAVIORAL|Adherence behaviors and recommendations for improvement.|
48290979|NCT02333539|BEHAVIORAL|Adherence behavior that needs improvement is targeted|
48290980|NCT04918173|DRUG|Atenativ|Antithrombin concentrate
48290981|NCT02596880|DRUG|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
48290982|NCT02596880|DRUG|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
48290983|NCT02596880|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
48618056|NCT00977418|BEHAVIORAL|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
48631599|NCT04772924|BEHAVIORAL|not fasting|preferred not to take long term fasting
48618057|NCT00977418|OTHER|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
48618058|NCT00724945|DEVICE|balafilcon A|multifocal contact lens
48618059|NCT00724945|DEVICE|senofilcon A|multifocal contact lens
48618060|NCT00629577|GENETIC|microarray analysis|
48618061|NCT00629577|OTHER|flow cytometry|
48618062|NCT00629577|PROCEDURE|biopsy|
48618063|NCT00629577|PROCEDURE|colposcopy|
48618064|NCT06270615|OTHER|Ambispective validation of machine learning-based predictive model|Retrospective and prospective validation of a machine learning model to predict major haemorrhage in trauma patients compared to clinician prediction
48618065|NCT06045260|DRUG|177Lu-DOTATOC|Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.
48618066|NCT01934179|OTHER|cytology specimen collection procedure|Undergo blood sample collection
48618067|NCT01934179|OTHER|laboratory biomarker analysis|Correlative studies
48618068|NCT01934179|OTHER|questionnaire administration|Ancillary studies
48618069|NCT01692756|DRUG|Kenalog or placebo|
48618070|NCT01692756|DRUG|Kenalog then Placebo|
48618071|NCT01692756|DRUG|Kenalog|
48618072|NCT01692756|DRUG|Placebo|
48290984|NCT02935738|DRUG|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
48290985|NCT03852225|DIAGNOSTIC_TEST|Intra-arrest echocardiography|Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
48290986|NCT05624372|DIAGNOSTIC_TEST|hearing and cognitive assessment|psychiatric assessment, hearing assessment and brief cognitive assessment
48290987|NCT03378206|DEVICE|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
48290988|NCT03378206|DEVICE|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
48290989|NCT03949777|DEVICE|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
48290990|NCT01364610|DEVICE|Bravo|Bravo pH Monitoring System sited manometrically.
48290991|NCT01364610|DEVICE|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
48290992|NCT04214795|OTHER|Observational study. Postnatal variables are recorded|Postnatal evolution is analyzed in both groups
48290993|NCT01979510|DRUG|MK-0663B|MK-0663B once daily for 8 days.
48290994|NCT01979510|DRUG|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
48290995|NCT01979510|DRUG|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
48290996|NCT06203808|OTHER|COMPLETION OF QUESTIONNAIRES|Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.
48290997|NCT03730896|PROCEDURE|Dry needling|Dryneedling of the sternocleidomastoid muscles within a standard treatment approach of physical therapy
48290998|NCT02699775|OTHER|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
48290999|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
48291000|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
48291001|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
48291002|NCT05590403|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose administered intramuscularly at Day 1.
48291003|NCT05590403|DRUG|Placebo|One dose administered intramuscularly at Day 1.
48291004|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
48291005|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
48291006|NCT00003641|BIOLOGICAL|interferon alfa-2b|Given IV
48291007|NCT00003641|OTHER|observation|Patients undergo observation for 4 weeks.
48291008|NCT04901507|DEVICE|The Voutia System|Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
48291009|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
48291010|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
48474047|NCT03300908|BEHAVIORAL|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
48474048|NCT03300908|BEHAVIORAL|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
48474049|NCT00078741|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
48291011|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
48291012|NCT01525212|DRUG|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
48474050|NCT04640012|DRUG|DC371739|Participants received one of 6 dose levels of DC371739 administered as single oral doses.
48474051|NCT04640012|DRUG|Placebo|Placebo orally administered
48474052|NCT04649489|DRUG|Atezolizumab|atezolizumab 1200mg and bevacizumab 15mg/kg
48291013|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
48291014|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
47942172|NCT05802875|BEHAVIORAL|Progressive Muscle Relaxation|"Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS."
47942173|NCT03005938|PROCEDURE|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
47942174|NCT03005938|PROCEDURE|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
48291015|NCT05910593|DIAGNOSTIC_TEST|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
48291016|NCT05896176|DIAGNOSTIC_TEST|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
48291017|NCT03604614|DRUG|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
48291018|NCT03604614|DRUG|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
48291019|NCT06511661|PROCEDURE|Complete lymphadenectomy|At least 3 N1 stations and 3 N2 stations are examined during surgery, including station 7.
48291020|NCT06511661|PROCEDURE|Incomplete lymphadenectomy|Less than 3 N1 stations or 3 N2 stations are examined during surgery, or those without station 7 lymph node dissection.
48291021|NCT03442127|BEHAVIORAL|CaringGuidance™ After Breast Cancer Diagnosis|Web-based, psychoeducational, self-management tool
48291022|NCT02904967|BIOLOGICAL|Extra Blood Draw|
48291023|NCT01520792|DRUG|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
48291024|NCT02803372|OTHER|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP \> 95 mmHg, SVV \< 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
48291025|NCT02803372|OTHER|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output \> 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
48291026|NCT05335083|DEVICE|CPAP|A positive CPAP intervention
48291027|NCT05253807|DRUG|Pemigatinib|13.5 mg tablet
48291028|NCT03383367|BEHAVIORAL|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
48291029|NCT02291380|DRUG|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
48291030|NCT02291380|DRUG|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
48291031|NCT02435173|DRUG|CDZ173|CDZ173 10 and 70 mg capsules for oral administration.
48291032|NCT02435173|OTHER|Placebo|Placebo capsules for oral administration
48291033|NCT05932810|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
48291034|NCT05932810|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
48291035|NCT01718314|DRUG|Sublingual Misoprostol|
48474053|NCT04649489|PROCEDURE|Surgery|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
48474054|NCT02981316|BIOLOGICAL|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
48474055|NCT04542694|DRUG|Favipiravir|200 mg coated tablets
48474056|NCT04542694|DRUG|Standard of care|"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."
48474057|NCT03920306|DRUG|oral anti-acid treatment|This study investigates a bundle of three commonly used treatments
48474058|NCT01362673|DRUG|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
48474059|NCT01362673|DRUG|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
48474060|NCT01362673|DRUG|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
48474061|NCT01362673|DRUG|Placebo|Oral single dose as matching placebo
48474062|NCT01362673|DRUG|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
48474063|NCT01362673|DRUG|Placebo|Oral multiple doses as matching placebo for 12 days
47942175|NCT02128828|DRUG|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
48291036|NCT01718314|DRUG|Lidocaine pump spray|
48291037|NCT01718314|DRUG|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
48474064|NCT03890562|OTHER|Auricular acupressure|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
48291038|NCT01718314|DRUG|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
48291039|NCT06511726|DRUG|Cadonilimab|Induction chemotherapy and immunotherapy: Cadonilimab + cisplatin + albumin-bound paclitaxel, for a total of 2 cycles (cisplatin 75 mg/m² + albumin-bound paclitaxel 260 mg/m² q3w, Cadonilimab 10 mg/kg q3w).
48291040|NCT06671080|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|All of these tests planned to be used in the study will be applied to adolescent amateur soccer players who meet the inclusion criteria.
48291041|NCT00283829|DRUG|docetaxel|chemotherapy
48291042|NCT00283829|DRUG|IL2|immunotherapy
48291043|NCT03213639|DRUG|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
47942176|NCT03046173|OTHER|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
48102687|NCT05971355|DEVICE|LimpiAD cream 2,5% plus|A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome
48291044|NCT03213639|DRUG|Placebo Oral Tablet|once daily oral tablets
48102688|NCT05971355|OTHER|Vehicle|"Vehicle of LimpiAD cream 2.5 % plus which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus cream but without the HAc-40 component."
48102689|NCT05971355|OTHER|Emollient|Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
48102690|NCT00619645|DRUG|busulfan|
48102691|NCT00619645|DRUG|cyclosporine|
48102692|NCT00619645|DRUG|fludarabine phosphate|
48291045|NCT02952742|DRUG|Black Cohosh|Vital Nutrients Black Cohosh Extract
48291046|NCT02952742|OTHER|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
48631600|NCT05369156|OTHER|Chiropractic Care|The actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent and the duration of the thrust is always less than 200 milliseconds.
47942177|NCT03046173|OTHER|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
48102693|NCT00619645|DRUG|mycophenolate mofetil|
48291047|NCT03660904|BIOLOGICAL|home made vitrification & thawing kit|home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
47942178|NCT03012568|DEVICE|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
48102694|NCT00619645|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48102695|NCT00619645|PROCEDURE|peripheral blood stem cell transplantation|
48102696|NCT01549496|DRUG|Amlodipine|amlodipine 2.5 mg QD
48291048|NCT03660904|BIOLOGICAL|commercially made vitrification & thawing kit|commercially available vitrification \& thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
48291049|NCT01109706|OTHER|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
48291050|NCT01903434|DRUG|Evacetrapib|Administered orally
48291051|NCT02434887|DEVICE|KL029 Intimate Lubricant Gel|
48291052|NCT03613428|DRUG|Ruxolitinib|Dose escalation up to 80 mg administered orally
48291053|NCT03613428|DRUG|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
48291054|NCT03613428|DRUG|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
48291055|NCT01144546|PROCEDURE|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
48291056|NCT00565500|DRUG|celecoxib|celecoxib capsules 200 mg bid for 1 week
48102697|NCT01549496|DRUG|Diltiazem|diltiazem 120 mg qd
48102698|NCT00630513|DRUG|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
48474065|NCT04461340|DRUG|Sirolimus|oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
47942179|NCT02063880|OTHER|Urgent ART|Children will be started on HAART \<48 hours after enrollment.
47942180|NCT02063880|OTHER|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
48102699|NCT00630513|DRUG|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
48102700|NCT00111020|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
48102701|NCT00423007|DRUG|Bromfenac|
48291057|NCT00565500|DRUG|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
48291058|NCT00565500|DRUG|placebo|placebo capsules tid for 1 week
48291059|NCT03331341|DRUG|Dacarbazine|Given IV
48291060|NCT03331341|DRUG|Doxorubicin Hydrochloride|Given IV
48291061|NCT03331341|OTHER|Laboratory Biomarker Analysis|Correlative studies
48291062|NCT03331341|BIOLOGICAL|Pembrolizumab|Given IV
48291063|NCT03331341|DRUG|Vinblastine|Given IV
48618073|NCT06418867|BEHAVIORAL|Mindfulness|Mindfulness Practice including 6 sessions with 1 hour for each
48291064|NCT04777955|OTHER|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
48291065|NCT06246825|DIAGNOSTIC_TEST|Polysomnography|Patients with a high likelihood of having obstructive sleep apnea will undergo a polysomnography, as recommended by the guidelines
48291066|NCT04791969|DRUG|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
48291067|NCT04791969|DRUG|Placebo|Intermittent Oral Placebo
48291068|NCT04791969|BEHAVIORAL|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
48291069|NCT03966586|BEHAVIORAL|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
48291070|NCT03966586|BEHAVIORAL|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
48291071|NCT03966586|BEHAVIORAL|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
48291072|NCT03966586|BEHAVIORAL|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
48291073|NCT03966586|BEHAVIORAL|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
48291074|NCT03966586|BEHAVIORAL|Usual clinical care and counseling|Usual clinical care and counseling
48291075|NCT04706598|DRUG|Camrelizumab|Solution for Infusion (Intravesical)
48291076|NCT01009463|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
48474066|NCT05436132|BEHAVIORAL|VR and AR oral healthcare curriculum training|HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.
47942181|NCT03361267|DIAGNOSTIC_TEST|Helicobacter pylori PCR test|Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
47942182|NCT03361267|DIAGNOSTIC_TEST|CLO test|CLO test : negative --\> drop out CLO test : postive --\> bismuth containing quadruple therapy
47942183|NCT00964132|DRUG|NRX194204|Once Daily, Oral
47942184|NCT06552247|DIAGNOSTIC_TEST|Fundus Picture AI testing|G-Risk AI algorithm will assess the optic disc centered fundus picture and determine whether or not there is a need for referrable based on a pre-determined threshold (\>=0.73)
48474067|NCT05436132|BEHAVIORAL|traditional teaching methods oral healthcare curriculum|HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
48631601|NCT05369156|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
47942185|NCT01854931|BEHAVIORAL|Tai Ji Quan|single aim intervention
47942186|NCT02010827|BIOLOGICAL|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
47942187|NCT02010827|BIOLOGICAL|Oral glucose tolerance test, day A|
47942188|NCT02010827|BIOLOGICAL|intravenous iv glucose infusion, day B|
47942189|NCT04680676|DRUG|BI 730357|BI 730357
47942190|NCT04680676|DRUG|Placebo|Placebo
48102702|NCT00423007|DRUG|Placebo|
48102703|NCT03771846|DRUG|irinotecan, oxaliplatin , fluorouracil, and leucovorin|administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48102704|NCT03771846|DRUG|gemcitabine and oxaliplatin|administration of gemcitabine and oxaliplatin via vein
48631602|NCT05763316|OTHER|CRIB II|Calculate Clinical Risk Index for Babies II score
48291077|NCT01009463|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
48291078|NCT05107414|PROCEDURE|Total Knee Arthroplasty|Participants have previously undergone a total knee replacement surgery.
48291079|NCT05332899|BIOLOGICAL|Influenza Virus Type A H3N2 Challenge|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device or by natural exposure to infected participants. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
48291080|NCT06103552|BEHAVIORAL|Building Lifestyle Options for Orthopedic Mobility (BLOOM)|This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
48291081|NCT06498375|DIAGNOSTIC_TEST|Bioelectrical impedance|Fluid distribution measured by bioelectrical impedance Bodystat Multiscan 5000 Bodystat Ltd, Isle of Man, British Isles
48291082|NCT02413515|DRUG|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
48291083|NCT03060577|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
47942191|NCT02532530|DEVICE|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
47942192|NCT02452697|BIOLOGICAL|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
48102705|NCT06556069|OTHER|Peer-Support Enhanced Agitation Code Team (PACT)|"PACT will address systems challenges experienced by staff, safety threats to ED patients with mental illness and substance use disorders, and known structural biases against marginalized individuals during decisions in use of restraints for behavioral crises in the ED.~The PACT intervention includes a peer support service component to deliver patient-centered, trauma-informed, culturally sensitive care to patients presenting with behavioral complaints in the ED and experiencing distress."
48102706|NCT03787875|PROCEDURE|periodontal treatment|In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
48291084|NCT03060577|DRUG|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
48291085|NCT03811600|DIAGNOSTIC_TEST|PD1/PD-L1 exosomal expression|exosomal PD1/PD-L1 expression
48291086|NCT06070038|BEHAVIORAL|Integrated Behaviour Change Based Intervention Materials|The intervention will be delivered over a three-month period as a series of four zoom hosted workshops, online content, and a moderated social support group. Zoom workshops will last 45 minutes and will target key constructs from the integrated behavior change model. Main topics of the workshops are autonomy Supportive parenting (Week 1), goal setting and outcome beliefs (Week 3), physical activity norms (Week 5), and encouraging self-efficacy and maintenance (Week 8). Following each workshop, participants will receive links to online content that builds on workshop themes, such as messages, worksheets, and reflection tasks. Throughout the trial, participants will be able to participate in social support chat groups to discuss their progress with other members of the intervention group and intervention facilitators.
48291087|NCT03836521|DEVICE|Transcatheter aortic valve replacement|
48291088|NCT00200148|PROCEDURE|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
48631603|NCT05763316|OTHER|SNAP-II|Calculate Score for Neonatal Acute Physiology II
48631604|NCT05763316|OTHER|SNAPPE-II|Calculate Score for Neonatal Acute Physiology Perinatal Extension II
48631605|NCT05763316|OTHER|STOPS|Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score
48631606|NCT05763316|OTHER|MSNS|Calculate Modified Sick neonatal Score
48631607|NCT05763316|OTHER|nSOFA|Calculate neonatal sequential organ failure assessment
48631608|NCT00484900|DRUG|Co-Arinate FDC|
48631609|NCT00484900|DRUG|Coartem|
48631610|NCT06166823|OTHER|EMR alert|EMR alert for medication optimization
48291089|NCT00200148|PROCEDURE|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
48291090|NCT02162875|DRUG|Praziquantel|Six different treatment strategies with praziquantel
48291091|NCT01221298|DRUG|ABT-450|tablets
48291092|NCT01221298|DRUG|ABT-072|tablets
48291093|NCT01221298|DRUG|Ribavirin|tablets
48291094|NCT01221298|DRUG|Ritonavir|capsules
48474068|NCT04612530|DEVICE|Irreversible Electroporation (IRE)|Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
48474069|NCT04612530|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
48474070|NCT04612530|DRUG|Toll-Like Receptor 9|Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
48474071|NCT03003364|DRUG|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
48102707|NCT00145535|DEVICE|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, \~50 spots over 180°
48102708|NCT00145535|DEVICE|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, \~50 spots over 180°
48291095|NCT03650439|DIAGNOSTIC_TEST|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
48631611|NCT01270867|DEVICE|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
48102709|NCT00470743|DRUG|Ibuprofen|
48102710|NCT00470743|DRUG|Indomethacin|
48102711|NCT00370799|DRUG|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
48102712|NCT00370799|DRUG|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
48291096|NCT01916369|BIOLOGICAL|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
48291097|NCT04701086|DEVICE|Cationorm Pro|Eye Drops
48291098|NCT04701086|DEVICE|Vismed|Eye Drops
48291099|NCT06142747|DIAGNOSTIC_TEST|Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)|Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.
48291100|NCT04241003|DEVICE|SmartDrive Mx2+|Rear-mounted power assist
48291101|NCT01379586|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
48291102|NCT01379586|DRUG|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
48291103|NCT03987399|OTHER|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
48291104|NCT05515562|DRUG|Omadacycline Injection|All participants will receive Intravenous (IV) omadacycline
48474072|NCT03003364|DRUG|Placebo|Placebo in a blinded syringe
48474073|NCT01494103|BIOLOGICAL|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
48474074|NCT01494103|DRUG|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
48291105|NCT03668548|DIETARY_SUPPLEMENT|Leucine|192 mg/kg body mass/day
48291106|NCT03668548|DIETARY_SUPPLEMENT|Placebo|A taste and calorie-matched placebo
48291107|NCT00124423|PROCEDURE|Megavoltage CT scan|
48291108|NCT04248257|BEHAVIORAL|PeACE|3 session peer coaching intervention
48291109|NCT04248257|BEHAVIORAL|Community peer coaching|Peer coaching provided by community organizations that support the HBOC community
48291110|NCT05679726|BEHAVIORAL|massage|reflexology foot massage
48291111|NCT05056480|OTHER|Surveys|Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
48291112|NCT05941052|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
48291113|NCT00883194|DRUG|PRF-108|Ropivacaine
48291114|NCT00883194|DRUG|Placebo|PRF-108 Placebo
48291115|NCT00883194|DRUG|Ropivacaine|Solution
48291116|NCT00883194|DRUG|PRF-110|
48291117|NCT01924715|BEHAVIORAL|ISTDP|An emotion focused brief psychotherapy format.
48291118|NCT06474169|OTHER|1 blood sample for each participant|"Blood sample for cohort n°1 and n°2 (collection during a peripheral venous blood sample, part of the standard of care for this disease) :~1 blood sample for each patient 28mL of blood (4 tubes, 7mL per tube)~Blood samples for cohort n°3 (collection during blood donation at Etablissement Français du Sang) :~1 blood sample for each healthy donor 14mL of blood (2 tubes, 7mL per tube)"
48291119|NCT03741881|OTHER|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
48474075|NCT05790707|PROCEDURE|Atrial fibrillation ablation + antiarrhythmic drugs|"Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed."
48474076|NCT05790707|DRUG|Antiarrhythmic drug|Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
48474077|NCT04596397|OTHER|Inpatient setting|These women stay at the hospital.
47942193|NCT02452697|BIOLOGICAL|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
47942194|NCT04115644|DRUG|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
47942195|NCT04115644|DRUG|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
47942196|NCT04115644|DRUG|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
48102713|NCT00370799|DRUG|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
48291120|NCT00379483|DRUG|Deferasirox|
48291121|NCT00758615|BEHAVIORAL|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
48291122|NCT00243893|DRUG|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
48291123|NCT00243893|DRUG|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
48291124|NCT00552799|DRUG|Penicillin VK|Biconcave tablet 250mg oral, b.d.
48291125|NCT00552799|OTHER|placebo|biconcave tablet matching active comparator as much as possible in size and shape
48291126|NCT04624932|BEHAVIORAL|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
48291127|NCT04624932|BEHAVIORAL|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
48291128|NCT03504033|DRUG|Xenon|inhalation to maintain anesthesia
48291129|NCT03504033|DRUG|Desflurane|inhalation to maintain anesthesia
48291130|NCT02714205|DRUG|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
48291131|NCT02714205|DRUG|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
48291132|NCT03115255|DRUG|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
48291133|NCT01275248|DRUG|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
48474078|NCT04596397|OTHER|Outpatient setting|These women can leave the hospital.
48474079|NCT06087718|DEVICE|Maastro applicator|The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
48291134|NCT01275248|DRUG|Placebo|Oral tablet to match the experimental interventions
48291135|NCT05821504|BEHAVIORAL|High-Intensity Interval Training|The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
48291136|NCT03341468|DEVICE|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
48291137|NCT05659121|DEVICE|robotic exoskeleton training|robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
48291138|NCT06382688|DIETARY_SUPPLEMENT|NAD+ (nicotinamide adenine dinucleotide) IV|NAD+ enables cells to generate cellular energy from the food that one eats
48291139|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) IV|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.
48291140|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) oral|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.
48291141|NCT06382688|OTHER|Placebo|These individuals received a saline IV
47942197|NCT00589290|DRUG|Belinostat (PDX101)|1000 mg/m\^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
48291142|NCT06667505|BEHAVIORAL|Choice-ICD|The eHealth intervention theoretically driven, interactive and provides personalised information to patients and family members when and where they wish to access it. Five short (2-3 minutes) videos, involving patients, caregivers and professionals, are uploaded onto the APP, alongside animation clips and useful links to online resources. A discussion forum will be accessible for participants using the APP, which will be closely moderated by the researcher, who will ensure any concerning posts or dialogue are promptly removed, and the necessary action is taken. The diary function will allow patients to record and be reminded of future appointments. Patients and family members will engage with the intervention for 3 months.
48291143|NCT00883428|OTHER|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
48291144|NCT00943878|BIOLOGICAL|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
48291145|NCT00943878|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
48291146|NCT00943878|DRUG|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
48291147|NCT05761327|OTHER|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
48291148|NCT05761327|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
48291149|NCT05761327|DIETARY_SUPPLEMENT|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
48291150|NCT04441931|DRUG|LY3832479|Administered IV.
48291151|NCT04441931|DRUG|Placebo|Administered IV.
47942198|NCT00218725|BEHAVIORAL|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
48291152|NCT00169468|DRUG|Rituximab -CHOP plus Velcade|
47942199|NCT00218725|OTHER|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
47942200|NCT01865084|DRUG|Tadalafil|Administered orally
47942201|NCT01865084|DRUG|Placebo|
48291153|NCT04601272|BEHAVIORAL|Decision aid|Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
48291154|NCT00355589|DRUG|Ramipril and hydrochlorothiazide|
47942202|NCT02185846|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
48474080|NCT04889391|DRUG|[14C]-Danicopan|Liquid-filled capsules.
48474081|NCT04983602|OTHER|Comprehensive Geriatric Assessment arm|The intervention will involve a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.,
48474082|NCT04983602|OTHER|EDPLUS|EDPLUS involves a 6 week physiotherapy led community based intervention involving 3 home visits and weekly telephone support.
47942203|NCT02185846|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
48474083|NCT00320853|DRUG|Vitamin D|
48291155|NCT06399549|DIAGNOSTIC_TEST|Dead bug exercise|the participant in supine, lying on a mat with shoulders, hip joints and knees flexed to 90°. With the lumbopelvic region being maintained in the neutral position, the participant will be instructed to draw in the abdomen, lower two contra lateral limbs (opposite arm and leg) toward the floor, hold for the stipulated time, then return to starting position. The same movement will be repeated with the opposite limbs. In the DBG, both pairs of limbs will be moved an equal number of times withinthe stipulated time. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises.
48291156|NCT06399549|DIAGNOSTIC_TEST|The McGill Curl Up|"Lie down on your back. Extend one leg and bend the knee of the other leg. The Side Bridge. Lie on your side, with your forearm on the floor and elbow underneath your shoulder.~The Bird Dog. Assume a hands-and-knees position on the floor. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises. The exercise program includes a warm-up session of five exercises (awareness of the back, pelvic tilt, lumbar rotation, arm movements, whole-body movement in standing), well-known exercises targeting the muscles of the back extensors, abdominals, lateral buttocks, trunk rotators, posterior buttocks, leg muscles, oblique abdominals (e.g. the plank, diagonal arm and leg lift), as well as exercises for flexibility. The exercises will be taught to the patients at the end of the first session in both groups."
48291157|NCT05078034|DEVICE|Helmet Non-Invasive Ventilation (HNIV)|HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
48291158|NCT05078034|DEVICE|High Flow Nasal Oxygen|HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
48291159|NCT04382651|DRUG|MAS825|MAS825 liquid solution for intravenous infusion
47942204|NCT04856891|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8.
48291160|NCT04382651|OTHER|Placebo|Placebo liquid solution for intravenous infusion
48291161|NCT04382651|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
48291162|NCT04971811|OTHER|Snack with energy density less than 1.5 kcal/g|Snack meal with snack food having energy density less than 1.5 kcal/g
48291163|NCT04971811|OTHER|Snack with energy density greater than 1.5 kcal/g|Snack meal with snack food having energy density greater than 1.5 kcal/g
48291164|NCT00669773|DRUG|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
48291165|NCT00669773|DRUG|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
48474084|NCT02928978|DRUG|Ruxolitinib|tablet (taken by mouth)
48474085|NCT02928978|DRUG|Placebo (for Ruxolitinib)|tablet (taken by mouth)
48474086|NCT00513617|DRUG|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
48102714|NCT00370799|DRUG|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
48291166|NCT02289755|DRUG|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
48291167|NCT02552407|DEVICE|Manual Aspiration Thrombectomy|Thrombus aspiration
48291168|NCT04905329|DRUG|Empegfilgrastim|Extimia®
48291169|NCT01874704|BEHAVIORAL|Comparison of biomarkers of stress|
48474087|NCT00513617|DRUG|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
47942205|NCT04856891|OTHER|Placebo|Placebo
47942206|NCT06216834|OTHER|No intervention|No intervention
47942207|NCT00185770|BEHAVIORAL|Reducing television and other screen time (SMART curriculum)|
47942208|NCT04598789|OTHER|no intervention|no intervention, observational study
48102715|NCT00590382|DEVICE|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
47942209|NCT01157156|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
47942210|NCT02640469|OTHER|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
47942211|NCT02640469|OTHER|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
48291170|NCT02522481|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
48291171|NCT05738512|PROCEDURE|Medial Flap Coblation Turbinoplasty|Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
48291172|NCT05738512|PROCEDURE|Submucous Resection|Submucous Resection
48291173|NCT05292677|DRUG|Steroid/Anesthesia Mixture|Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
48291174|NCT05292677|DRUG|Placebo|2 mL of Normal Saline
48291175|NCT02813538|DRUG|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
48291176|NCT02813538|OTHER|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
48291177|NCT01434225|DRUG|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
48291178|NCT02586207|DRUG|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
48474088|NCT04643392|PROCEDURE|Complex decongestive physiotherapy|Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
48474089|NCT04028856|DRUG|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
48474090|NCT06077461|BEHAVIORAL|mandala painting|Patients in this group will be subjected to mandala painting.
48474091|NCT05310708|DIAGNOSTIC_TEST|Polysomnography|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
48474092|NCT03264664|DRUG|E7386|Oral immediate release tablets.
48474093|NCT05701618|OTHER|Psychologically Informed Education Video Series|A short three video series (5-8.5 minutes each) provides psychologically-informed education at an age-appropriate level to address kinesiophobia, pain catastrophizing, and fear-avoidance beliefs.30 Participants will view the three-part education video series on an iPad at their first visit (video 1), one week (video 2), and three weeks (video 3).
48474094|NCT05701618|OTHER|Anatomy and biomedical education videos|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
48291179|NCT02586207|DRUG|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
48291180|NCT02586207|RADIATION|Radiation|70 Gy fractionated over 35 days
48291181|NCT01363505|DEVICE|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
48291182|NCT04102891|OTHER|Microbiota modulation diet|The Collect\&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
48291183|NCT04425850|COMBINATION_PRODUCT|Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|Topical application in the nose and oral cavity
48291184|NCT04722978|DRUG|Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
48291185|NCT04722978|DRUG|Gemcitabine combined with carboplatin plus placebo|Standard chemotherapy (gemcitabine and carboplatin) plus placebo
48291186|NCT02634515|DRUG|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
48291187|NCT02634515|DRUG|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
48291188|NCT05810779|OTHER|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
48291189|NCT05810779|OTHER|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
48291190|NCT05344833|DRUG|Isatuximab|Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
48291191|NCT05344833|DRUG|Lenalidomide|Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.
48291192|NCT01381523|DRUG|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
48291193|NCT01381523|DRUG|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
48291194|NCT04522752|OTHER|Size and pathological type of benign epithelial gastric polyp|All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
48291195|NCT03976232|DEVICE|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
48291196|NCT03976232|OTHER|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
48291197|NCT03976232|OTHER|tDCS+ CST|This group will receive tDCS along with CST
48291198|NCT03406195|DEVICE|Transcranial magnetic stimulation (TMS)|TMS paradigm called theta burst stimulation
48291199|NCT06512974|BEHAVIORAL|NeuroTrainer|Virtual reality based cognitive training
48291200|NCT03584802|OTHER|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
48291201|NCT03584802|OTHER|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
48291202|NCT04946110|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
48291203|NCT03844438|DRUG|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
48291204|NCT05982873|DRUG|ABBV-400|Intravenous (IV) Infusion
48291205|NCT01019408|DRUG|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
48291206|NCT00199186|DRUG|imatinib|
48291207|NCT00199186|DRUG|vincristine|
48291208|NCT00199186|DRUG|cyclophosphamide|
48291209|NCT00199186|DRUG|cytosine arabinoside|
48291210|NCT00199186|DRUG|dexamethasone|
48631612|NCT00754286|OTHER|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
48291211|NCT00199186|DRUG|idarubicin|
48291212|NCT00199186|DRUG|methotrexate (intrathecal)|
48291213|NCT00199186|DRUG|AraC (intrathecal)|
48291214|NCT00199186|DRUG|dexamethasone (intrathecal)|
48291215|NCT02037945|PROCEDURE|18F-FCH PET Scan|
48291216|NCT02648230|DEVICE|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
48291217|NCT02648230|DEVICE|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
48291218|NCT02396862|DRUG|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
48291219|NCT03667131|DRUG|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
48291220|NCT03667131|DRUG|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
48291221|NCT02846077|OTHER|No intervention. Observation only|No intervention. Observation only
48291222|NCT02734732|DRUG|Trimethoprim/Sulfamethoxazole|
48291223|NCT02734732|DRUG|Ciprofloxacin|
48291224|NCT00205192|PROCEDURE|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
48291225|NCT02887144|DEVICE|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
48291226|NCT02887144|DEVICE|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
48291227|NCT04134845|DRUG|Dantrolene/Ryanodex|muscle relaxant
48291228|NCT04134845|DRUG|Placebo|Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
48291229|NCT02464319|DRUG|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
48474095|NCT06471127|BEHAVIORAL|Pseudoword learning paradigm task|Pseudoword learning is an experimental learning task by which participants view two novel objects (a target and a foil) and simultaneously hear an audio recording of the pseudoword name of one of the two objects. Participants must choose (via mouse click) which object corresponds to the word presented, immediately after which feedback is provided.
48474096|NCT01914016|OTHER|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
47942212|NCT02640469|OTHER|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
47942213|NCT02617784|DRUG|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
47942214|NCT04406610|BIOLOGICAL|GD2 CAR-T immunotherapy|Antigen-specific T cell therapy
48291230|NCT02464319|DRUG|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
48291231|NCT01902160|DRUG|Brentuximab Vedotin|Given IV
48291232|NCT01902160|OTHER|Laboratory Biomarker Analysis|Correlative studies
48291233|NCT01902160|DRUG|Temsirolimus|Given IV
48291234|NCT00465738|DRUG|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
48291235|NCT04020874|BEHAVIORAL|HuTT-2x|tackling and blocking training twice/week
48291236|NCT04020874|BEHAVIORAL|HuTT-4x|tackling and blocking training four times/week
48291237|NCT04701411|BIOLOGICAL|Darvadstrocel|Darvadstrocel perilesional injection.
48291238|NCT03299023|OTHER|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
48291239|NCT01765712|PROCEDURE|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
48291240|NCT01765712|BIOLOGICAL|Platelet Rich Plasma|
48291241|NCT00173953|PROCEDURE|immune response|
48291242|NCT02842814|OTHER|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
48291243|NCT02842814|DRUG|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
48474097|NCT04159194|OTHER|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (\~55% CHO) and the type and amount of ingested food will be recorded.
48474098|NCT04159194|OTHER|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
48291244|NCT02842814|DRUG|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
48291245|NCT03974919|OTHER|NO intervention required|NO intervention required
48291246|NCT03557372|RADIATION|Mathematical Model-Adapted Radiation Fractionation Schedule|"* Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~* Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~* Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
48291247|NCT03811951|DRUG|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
48291248|NCT00058799|BIOLOGICAL|Dose Level 1|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
48291249|NCT00058799|BIOLOGICAL|Dose Level 2|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
48291250|NCT00058799|BIOLOGICAL|Dose Level 3|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 4.2 x 10\^7
48291251|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, low dose
48291252|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, high dose
48291253|NCT04824872|DRUG|Placebo|placebo for dasiglucagon
48474099|NCT05470595|DRUG|Atezolizumab|Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
48474100|NCT06615999|PROCEDURE|Simple fracture Tension band wiring|OPS 5-793.27
48474101|NCT06615999|PROCEDURE|Simple fracture locked plate fixation|OPS 5-793.k7
48474102|NCT06615999|PROCEDURE|Multi-fragmented tension band wiring|OPS 5-794.17
48291254|NCT02956889|DRUG|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
48291255|NCT02956889|RADIATION|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
48631613|NCT00754286|OTHER|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
48291256|NCT05091710|OTHER|HF follow up care|The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.
48291257|NCT05091710|OTHER|HF Standard of Care (SOC)|SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
48631614|NCT01057940|PROCEDURE|DBE PEJ placement|One time procedure with follow-up telephone call.
48631615|NCT04079725|PROCEDURE|Combined trabeculotomy-trabeculectomy with mitomycin c|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
48291258|NCT02040246|DRUG|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
48291259|NCT02040246|DRUG|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
48291260|NCT02001350|OTHER|Ultrasonography|
48291261|NCT02806427|OTHER|Enteral Formula|
48291262|NCT05165394|DRUG|Placebo|Tablets for oral administration
48291263|NCT05165394|DRUG|NBI-1065846|Tablets for oral administration
48291264|NCT00521963|BIOLOGICAL|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
48631616|NCT00351104|DRUG|Ketoprofen Topical Patch 20%|
48291265|NCT00129077|PROCEDURE|plastic wrap over eye & lubrication applied q6 hrs|
48474103|NCT06615999|PROCEDURE|Multi-fragmented locked plate fixation|OPS 5-794.k7
48291266|NCT05712668|BEHAVIORAL|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
48291267|NCT05712668|BEHAVIORAL|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
48102716|NCT02454244|BEHAVIORAL|ART with Mindfulness|"1. Introduction of ART with Mindfulness. Visualization of 100% recovery~2. Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~3. The ART. Breaking the negative thoughts related to the illness. Walking meditation~4. Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~5. Mindfulness and self-compassion. Kindly awareness meditation~6. The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~7. Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~8. Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~9. The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~10. Return to regular life. Mindfulness practice"
48102717|NCT02454244|BEHAVIORAL|Mindfulness Compassion|"1. Introduction.Definition of Compassion~2. Self-Esteemed and Compassion~3. Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~4. Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~5. Love,affection and self-compassion.How participants connect with the suffering of others~6. Equanimity~7. Forgiveness~8. Interdependence. Gratitude.Affection to unknown people~9. Developing affection and empathy.Empathy and burn out~10. Review of the practices and meditations"
48102718|NCT02454244|BEHAVIORAL|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
48102719|NCT00117871|DRUG|Resiquimod|
48102720|NCT03643042|OTHER|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
48102721|NCT03540628|DIETARY_SUPPLEMENT|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
48102722|NCT01756417|DRUG|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
48102723|NCT01756417|DRUG|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
48102724|NCT04270734|PROCEDURE|EEG|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
48102725|NCT04270734|PROCEDURE|NIRS|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
48102726|NCT01859312|DRUG|Hydrocortisone (Solucortef)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
48102727|NCT01859312|DEVICE|Insulin pump (Medtronic)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
48102728|NCT04637750|BEHAVIORAL|Educational intervention|The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
48102729|NCT03723512|DEVICE|Non contrast-enhanced magnetic resonance imaging|Non contrast-enhanced magnetic resonance imaging
48291268|NCT01478750|DIETARY_SUPPLEMENT|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
48102730|NCT05292599|OTHER|Experimental|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
48102731|NCT05292599|OTHER|Control|CCFE will be performed with the patient in a supine position with both knees flexed at 45°. This exercise involves a craniocervical movement. The IFE will be performed with the patient in a supine position while the IEE will be performed in a prone position. Both exercises will activate cervical muscles. RFE and RRE will be performed with the patient in a sitting or standing position at the same time he resists with his hands on his head. ME the function of these exercises is to depress and stabilize the scapula.
48102732|NCT04577170|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography|Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
48102733|NCT06057220|OTHER|No intervention sample collection only|No intervention
48291269|NCT01478750|PROCEDURE|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
48291270|NCT03427775|COMBINATION_PRODUCT|multimodal perioperative pain protocol (MP3)|administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
48291271|NCT06673030|BEHAVIORAL|Using Kaleidoscope glasses during pulpotomy procedures|Kaleidoscope is an instrument that shows an infinite number of fascinating geometric shapes in the form of a flower, repeating and reflecting images of coloured goggle fragments in the front section in a prism mirroring the inner surface.
48631617|NCT05760677|DRUG|pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone|the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
48631618|NCT05760677|DRUG|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar|the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
48291272|NCT06673030|BEHAVIORAL|The Play-Doh Doctor Drill 'n Fill toy set|Consists of a plastic human head with slots into which Play-doh molded teeth can be inserted. A battery operated toy drill is used to drill into and clean the black, cavitated tooth model and filled with white Play-Doh compound to simulate cavity preparation and restoration using tooth colored cement.
48291273|NCT06673030|OTHER|Group 1 (Tell-Show-Do)|"In which Tell-Show-Do technique was done in three stages:~* Tell: The dental procedures were explained to the children using language and expressions appropriate for their age.~* Show: This began with showing the child the instruments and the topical anesthetic gel, high-speed handpiece and explaining the purpose of using the handpiece. and how the water removed using the suction device.~* Do: Performing the dental procedure immediately."
48291274|NCT02897908|PROCEDURE|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
48102734|NCT02098902|BEHAVIORAL|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
48102735|NCT00707590|DRUG|BMS-767778 or Placebo|
48102736|NCT04604873|OTHER|Hospital day care follow-up|Regular follow up every month in hospital day care
48291275|NCT02243566|DRUG|MicardisPlus®|
48291276|NCT00152373|DRUG|Levetiracetam|
48102737|NCT02396992|OTHER|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
48102738|NCT03143192|COMBINATION_PRODUCT|Micropulse Laser|Aflibercept injection with Micropulse laser.
48102739|NCT03143192|DEVICE|Sham Laser|Aflibercept injection with Sham Laser
48102740|NCT02551354|DEVICE|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
48291277|NCT05796089|RADIATION|Thoracic Radiotherapy|"Participants will receive thoracic radiotherapy to a dose of 30 Gray (Gy) in 10 fractions (3 Gy per day) concurrently with cycle 3 or 4 of chemo-immunotherapy (Group 1).~Participants who are unsuitable for concurrent radiotherapy may receive consolidation radiotherapy. Consolidation thoracic radiotherapy will be administered to a dose of 30 Gy in 10 fractions, following 4 cycles of chemo-immunotherapy (Group 2).~Treatment fractions will be delivered daily, where treatment should be completed within 15 days (9-10 fractions a fortnight)."
48102741|NCT02161653|DRUG|Prednisone plus Metadoxine|
48291278|NCT05796089|DRUG|Etoposide with Carboplatin or Cisplatin|"The chemotherapy in this study is a standard treatment for extensive-stage small-cell lung cancer (EC-SCLC). The combination of chemotherapy (etoposide + carboplatin or etoposide + cisplatin) which the participant will receive is dependent on what is standard at the treatment centre.~Chemotherapy will be administered via an intravenous infusion every 3 weeks (21 days) for 4 cycles."
48291279|NCT05796089|DRUG|Durvalumab|"The immunotherapy in this study is a standard treatment for ES-SCLC.~Participants will receive a dose of 1500 mg of Durvalumab via an intravenous infusion every 3 weeks (21 days) for 4 cycles, concurrently with chemotherapy.~A 1500 mg maintenance dose of Durvalumab will administered every 4 weeks after completion of chemotherapy (monotherapy)."
48291280|NCT06667440|OTHER|Cryotherapy|Women in the intervention group will apply cryotherapy on their hypogastrium with a coldpack
48291281|NCT01396525|DEVICE|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
48291282|NCT01845389|DEVICE|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
48291283|NCT01845389|DEVICE|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
48291284|NCT00190463|DRUG|Amphotericin B|
48291285|NCT04943900|DRUG|BMS-986416|Specified dose on specified days
48291286|NCT04943900|DRUG|Nivolumab|Specified dose on specified days
48291287|NCT04934202|OTHER|Teleconsultation|"Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:~* General signs: Anorexia, fatigue, new hospitalization, weight loss,~* Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge~* Neurological signs: headache, paraesthesia, anosmia, limb paralysis~* Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting~Edition 2021~◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties"
48631619|NCT04383015|OTHER|Exercise strategies|Strategies for exercise in type 1 diabetes to maintain glucose control
48631620|NCT02117817|DRUG|BKM120|
48102742|NCT02161653|DRUG|Pentoxifylline plus Metadoxine|
48102743|NCT03264456|DIAGNOSTIC_TEST|[18F] Fluciclovine PET/MRI|\[18F\] fluciclovine PET/MRI
48102744|NCT03264456|DRUG|[18F] fluciclovine|\[18F\] fluciclovine
48102745|NCT04656002|DRUG|Vactosertib|Take Baektoseotip (TEW-7197) twice a day for 5 days and take a break for 2 days (5D on/2D off). With this method, progression up to the 28th day is taken as one cycle. Take it with or without food every twelve hours
48631621|NCT02117817|DRUG|Nabpaclitaxel|Given IV
48631622|NCT03604627|OTHER|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
48631623|NCT01115010|DEVICE|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
47942215|NCT03497793|OTHER|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
47942216|NCT01143207|DRUG|Medroxyprogesterone acetate|Injectable hormonal contraceptive
47942217|NCT03205137|DRUG|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
47942218|NCT03205137|DRUG|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
47942219|NCT03205137|DRUG|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
47942220|NCT03205137|DRUG|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
47942221|NCT05204732|OTHER|Intonation training|The participants will receive intonation training (1h/week) for four weeks, aiming for more gender congruent intonation patterns.
47942222|NCT05204732|OTHER|Sham therapy + intonation training|The participants will first receive four weeks of sham therapy (with no expected effect on speech), during which information on voice functioning, voice surgery, voice hygiene, and transgender health care will be provided. In addition, during sham therapy, active intervention will be given around nonverbal communication. After four weeks of sham therapy, for ethical reasons, subjects in this group will also receive four weeks of intonation training (aiming for more gender congruent intonation patterns).
48102746|NCT04376385|BEHAVIORAL|GROw: An Internet based Self Applied Treatment Program for Prolonged Grief Disorder (PGD)|"It is a self-applied treatment through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is 8-10 weeks. A support call will be made a week (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided.~Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention"
48102747|NCT05996757|PROCEDURE|Wet clothing removal|The participants in the intervention group will have their clothing removed prior to insulation.
48102748|NCT03511885|OTHER|There is no intervention|
48102749|NCT00605904|DRUG|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
48102750|NCT00605904|DRUG|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
48102751|NCT00605904|DRUG|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
48102752|NCT00605904|DRUG|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
48102753|NCT03678116|DRUG|Sugar Pill (placebo)|Taken orally in capsule form
47942223|NCT04014309|OTHER|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
47942224|NCT04014309|OTHER|Usual care|Usual care
47942225|NCT00295971|BIOLOGICAL|anti-thymocyte globulin|
48102754|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
48102755|NCT03678116|DIETARY_SUPPLEMENT|Caffeine (plus Teacrine)|Taken orally in capsule form
48102756|NCT00006391|DRUG|oxaliplatin|
48102757|NCT00006391|DRUG|topotecan hydrochloride|
48102758|NCT01975467|DEVICE|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
48102759|NCT02454543|PROCEDURE|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
48102760|NCT02454543|DRUG|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
48102761|NCT02118935|OTHER|Previously marketed cow's mlik-based infant formula|
48631624|NCT01115010|DEVICE|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
48631625|NCT01115010|DEVICE|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
48631626|NCT01698008|OTHER|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
48631627|NCT01932580|DRUG|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
48631628|NCT01599676|DIETARY_SUPPLEMENT|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
47942226|NCT00295971|BIOLOGICAL|therapeutic allogeneic lymphocytes|
47942227|NCT00295971|DRUG|fludarabine phosphate|
48102762|NCT02118935|OTHER|Marketed cow's milk-based infant formula with prebiotics|
48102763|NCT05388344|OTHER|Booklet reading|Submission of the questionnaire before and after booklet reading
48102764|NCT02488174|OTHER|PROOFcheck|
48102765|NCT02488174|OTHER|Standard Care|
47942228|NCT00295971|DRUG|thiotepa|
47942229|NCT00295971|PROCEDURE|allogeneic bone marrow transplantation|
47942230|NCT00295971|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
47942231|NCT00295971|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
47942232|NCT00295971|RADIATION|total-body irradiation|
47942233|NCT03139097|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
47942234|NCT00428129|DRUG|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
48102766|NCT00825435|PROCEDURE|Coronary CT Angiogram|Coronary CT Angiogram
48631629|NCT01599676|DIETARY_SUPPLEMENT|Non essential amino acid|Non essential amino acid supplementation
48291288|NCT04934202|OTHER|Outpatient clinic|"During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.~* General clinical examination~* Assessment of the state of health~* Respiratory assessment~* Pulmonary CT assessment~* Cognitive evaluation~* Cardiological evaluation~* Renal assessment~* Immunological evaluation"
48291289|NCT05448534|DIAGNOSTIC_TEST|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
48631630|NCT00371631|BIOLOGICAL|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
47942235|NCT03512899|PROCEDURE|Right internal jugular access.|Implantation using percutaneous puncture.
48474104|NCT05164835|OTHER|pharmaceutical follow-up|"Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~* Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~* Extension of the duration of the usual interview by 10 minutes in order to collect the desired information."
48474105|NCT04810169|DEVICE|Smart inhaler|"* Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~* Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given"
48474106|NCT03969316|PROCEDURE|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
48474107|NCT01072799|BIOLOGICAL|Placebo|Two doses (Day 1 and Day 22); 0.5mL
48474108|NCT01072799|BIOLOGICAL|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 \& Day 22); 0.5mL
48474109|NCT03600181|DEVICE|RAD - 97 pulse co-oximeter|"non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)"
48474110|NCT04346940|OTHER|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
48474111|NCT04346940|OTHER|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
48631631|NCT04826614|OTHER|optimized treatment|early adjust dose or change drug
48102767|NCT02599844|DRUG|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
48474112|NCT05693831|OTHER|Cellworks Report|Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
48474113|NCT03513536|OTHER|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
48474114|NCT03513536|OTHER|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
47942236|NCT03512899|PROCEDURE|Left internal jugular access.|Implantation using percutaneous puncture.
47942237|NCT03512899|PROCEDURE|Right axillary vein access.|Implantation using percutaneous puncture.
47942238|NCT03512899|PROCEDURE|Left axillary vein access.|Implantation using percutaneous puncture.
47942239|NCT00642720|DRUG|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
47942240|NCT04351997|PROCEDURE|Cord clamping|Umbilical cord clamping after delivery.
47942241|NCT04338984|DRUG|General anesthetic|Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.
47942242|NCT04338984|DRUG|Ropivacaine 0.5% Injectable Solution|"Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia.~Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%."
48291290|NCT04820985|OTHER|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
48291291|NCT04820985|OTHER|Blood test|Blood sample to measure plasma dose of progesterone
48631632|NCT06480812|DIETARY_SUPPLEMENT|Synbiotic|"The proposed protocol will provide a simple but robust intervention study using a synbiotic (pre and probiotic combination) in order to improve our understanding of the mechanisms linking nutrition to health outcomes that are mediated by the gut microbiome.~This pilot study will comprise a controlled randomised intervention in which participants will be grouped into the active synbiotic arm or the control arm. The ratios will be 10g of the prebiotic supplement and 170ml of kefir. Randomisation will control for equal distribution of age and biological sex; characteristics that may confound between group comparisons and will be assessed by analysis of baseline data."
48631633|NCT03279965|DIAGNOSTIC_TEST|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
48631634|NCT00027443|DRUG|Muromonab-CD3|
48631635|NCT00027443|DRUG|Cyclosporine|
47942243|NCT00089284|DRUG|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
47942244|NCT00089284|DRUG|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
47942245|NCT00089284|DRUG|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
48474115|NCT03513536|OTHER|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
48631636|NCT01881295|DIETARY_SUPPLEMENT|Placebo control|
48474116|NCT03513536|OTHER|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
48631637|NCT01881295|DIETARY_SUPPLEMENT|Low dose potassium gluconate|
48631638|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potassium gluconate|
48631639|NCT01881295|DIETARY_SUPPLEMENT|High dose potassium gluconate|
48474117|NCT05157035|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
48474118|NCT01856387|BIOLOGICAL|high neutrophil to lymphocyte ratio|
48474119|NCT01856387|OTHER|normal neutrophil-to Lymphocyte ratio|
48631640|NCT01881295|DIETARY_SUPPLEMENT|Low dose potato|
48631641|NCT01881295|DIETARY_SUPPLEMENT|Medium dose potato|
48631642|NCT01881295|DIETARY_SUPPLEMENT|High dose potato|
48631643|NCT01881295|DIETARY_SUPPLEMENT|High dose French fries|
48631644|NCT01881295|DIETARY_SUPPLEMENT|Basal diet control|
48631645|NCT03473301|BIOLOGICAL|Infusion of allogeneic umbilical cord blood|Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.
48631646|NCT03473301|BIOLOGICAL|Infusion of MSCs|Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
48631647|NCT00943202|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
47942246|NCT05358015|PROCEDURE|vascularized bone graft for scaphois nonunion|vascularized bone graft for scaphois nonunion
47942247|NCT00751621|BIOLOGICAL|IgPro20|
48102768|NCT02599844|PROCEDURE|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
48474120|NCT00206596|DRUG|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
48474121|NCT00206596|DRUG|Placebo|Once daily via subcutaneous injection for up 22 weeks
48474122|NCT04055545|OTHER|HIIT|"* 5 min. warm up~* 10 × 60 seconds burst~* 60 seconds recovery after each burst~* Burst phase: HRR \>90%~* Recovery phase: HRR btw. 30-39%~* 5 min. cool down"
48631648|NCT00943202|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - \<36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
48631649|NCT01293877|PROCEDURE|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
48631650|NCT00917982|OTHER|vision therapy|
47942248|NCT01889940|BEHAVIORAL|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients \& families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
47942249|NCT01819376|OTHER|Facebook Status Update|
48474123|NCT04055545|OTHER|MICT|"* 5 min. warm up~* 20 min. continuous cycling: HRR btw. 40% - 59%~* 5 min. cool down"
48631651|NCT03022630|OTHER|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
48631652|NCT03022630|OTHER|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
47942250|NCT04647071|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion).
47942251|NCT04647071|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose
48102769|NCT02599844|PROCEDURE|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
48291292|NCT02628223|PROCEDURE|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
48291293|NCT02628223|DEVICE|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
48631653|NCT00629213|DRUG|acarbose|
47942252|NCT03547986|DIAGNOSTIC_TEST|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
47942253|NCT03547986|DIAGNOSTIC_TEST|IVUS with Intraarterial pressure measurement (IAP) if needed|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
47942254|NCT03686514|BIOLOGICAL|FLUARIX QUADRIVALENT|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two influenza A viruses and two influenza B viruses.
48102770|NCT02599844|PROCEDURE|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
48102771|NCT02599844|DRUG|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
48102772|NCT01872819|OTHER|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
48474124|NCT06495190|DIETARY_SUPPLEMENT|Blueberry|52 g/d blueberry powder supplement
48102773|NCT01872819|DRUG|chemotherapy|Patients receive 1 of 160 possible interventions
48291294|NCT01855789|DRUG|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).
48291295|NCT01855789|DRUG|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
48291296|NCT01855789|DRUG|Placebo (PBO)|PBO matching to MTX will be administered orally.
48474125|NCT06495190|BEHAVIORAL|Walking|Five 45-min walking sessions per week
48474126|NCT06495190|DIETARY_SUPPLEMENT|Placebo|52 g/d placebo powder supplement
48474127|NCT06495190|BEHAVIORAL|Stretching|Five 45-min stretching sessions per week
48474128|NCT05299567|DRUG|Azithromycin|Placebo with the same color and size than azithromycin tree days a wek for 6 months
48631654|NCT00629213|DRUG|placebo|
48631655|NCT01363830|BEHAVIORAL|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
48631656|NCT01363830|BEHAVIORAL|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
48474129|NCT01129739|OTHER|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
48474130|NCT01129739|OTHER|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
48474131|NCT03136406|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
47942255|NCT02722486|DEVICE|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
47942256|NCT02722486|OTHER|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
47942257|NCT05010408|OTHER|Flavored carbonated soft drink (CSD) at different sweetness levels|Beverage
47942258|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
48474132|NCT03136406|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
48474133|NCT03136406|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
47942259|NCT02462174|DRUG|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
48102774|NCT01872819|BIOLOGICAL|biological therapy|Patients receive 1 of 160 possible interventions
47942260|NCT02462174|DRUG|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
48102775|NCT06030908|PROCEDURE|Reconstruction of Achilles tendon insertion|knotless double-row anchor fixation of the achilles tendon insertion
48474134|NCT03136406|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48474135|NCT03136406|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
48474136|NCT03136406|DRUG|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
47942261|NCT02462174|DRUG|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
47942262|NCT02917473|BEHAVIORAL|In-person counseling|"In-person counseling~Sun protection"
47942263|NCT02917473|BEHAVIORAL|Written advice|Written advice
48102776|NCT05159128|DRUG|JNJ-75105186|JNJ-75105186 will be administered orally in Part 1 and 2.
48474137|NCT03136406|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
48474138|NCT03136406|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
48474139|NCT03136406|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48474140|NCT03136406|BIOLOGICAL|aNK for Infusion|NK-92 cells
48474141|NCT03136406|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
48474142|NCT03136406|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
48474143|NCT01231373|DRUG|polidocanol injectable foam, 0.125%|active placebo for blinding
48474144|NCT01231373|DRUG|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
48474145|NCT01231373|DRUG|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
48474146|NCT01231373|DRUG|Vehicle|injection of vehicle comparator
47942264|NCT02917473|BEHAVIORAL|Medical skin screening|Medical skin screening
47942265|NCT00000328|DRUG|Opioid-Related Disorders|
47942266|NCT02693392|DRUG|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents"
48102777|NCT05159128|OTHER|Placebo|Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.
48102778|NCT02930343|DRUG|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
48102779|NCT02930343|DRUG|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
48631657|NCT00442156|PROCEDURE|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
48631658|NCT01210209|OTHER|genome-wide association study|
47942267|NCT02693392|DIETARY_SUPPLEMENT|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
47942268|NCT00400790|DRUG|propofol|Propofol used as the primary anaesthetic agent
48291297|NCT05414968|DEVICE|Non-pharmacological Heat, Pressure, and Vibration|The innovation central to this approach is in the multifactorial combination of pressure, heat, and vibration stimuli to improve foot sensation. The heat stimuli will be provided with commercially available heating elements. The pressure stimuli will be provided via pneumatic garment. Lastly, the vibrotactile stimuli will be provided with commercially available vibrotactile motors. The non-pharmacological DPN device will be able to safely and consistently control temperature to 100-105°F within 1°F, control pressure to 50 mmHg within 5 mmHg at 0.25 Hz, and provide 5 distinguishable vibrational stimuli to 5 zones on the leg and foot.
48291298|NCT01079715|DRUG|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~* Atropine.~* Isoproterenol hydrochloride (isoprenaline.~* Terlipressin.~* Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
48291299|NCT03614624|DEVICE|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
48291300|NCT06673355|OTHER|dental implant prosthesis|patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon
48291301|NCT03331172|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
48291302|NCT00677261|PROCEDURE|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
48291303|NCT00677261|PROCEDURE|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
48291304|NCT00677261|PROCEDURE|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
48291305|NCT02640612|DRUG|BI 695501|
48291306|NCT00270920|BEHAVIORAL|Lactation counseling|
48291307|NCT02234622|BEHAVIORAL|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
48291308|NCT02234622|BEHAVIORAL|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
48291309|NCT04010422|DIAGNOSTIC_TEST|no intervention|no intervention
48291310|NCT03607734|DRUG|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
48291311|NCT01225068|DRUG|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
48291312|NCT01225068|DRUG|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
48291313|NCT00984789|DRUG|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
48291314|NCT00984789|DRUG|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
48291315|NCT03476850|PROCEDURE|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
47942269|NCT00400790|DRUG|desflurane|Desflurane used as the primary anaesthetic
48102780|NCT02930343|DRUG|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
47942270|NCT00225303|DRUG|TMC125|
47942271|NCT05661214|OTHER|Teaching|The intervention in this study is teaching. Researchers, will create a pressure injury teaching content and assess this effectiveness and also, intervention groups will use Clinical Decision Support System (CDSS) as a tool to plan nursing interventions.
47942272|NCT03456440|DIAGNOSTIC_TEST|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
47942273|NCT00003307|DRUG|amifostine trihydrate|
47942274|NCT00003307|RADIATION|radiation therapy|
48102781|NCT02930343|DRUG|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
48102782|NCT02930343|DRUG|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
47942275|NCT03488927|BEHAVIORAL|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
47942276|NCT03701321|DRUG|Bortezomib|Given SC
47942277|NCT03701321|BIOLOGICAL|Daratumumab|Given IV
47942278|NCT03701321|DRUG|Dexamethasone|Given PO
48102783|NCT02930343|DRUG|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
48291316|NCT03476850|PROCEDURE|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
48291317|NCT01563510|PROCEDURE|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
48291318|NCT01563510|PROCEDURE|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
48291319|NCT03427840|PROCEDURE|Procedure/Surgery: superior hypogastric block|superior hypogastric blockade during surgery
48474147|NCT02865148|BEHAVIORAL|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
47942279|NCT03701321|DRUG|Venetoclax|Given PO
47942280|NCT00000762|BIOLOGICAL|rgp120/HIV-1MN|
48291320|NCT03009695|DEVICE|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
48474148|NCT01321697|PROCEDURE|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
48474149|NCT05407818|DRUG|JNJ-63733657|JNJ-63733657 will be administered as an IV infusion.
48474150|NCT00595335|DRUG|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
47942281|NCT00000762|BIOLOGICAL|rgp120/HIV-1 SF-2|
47942282|NCT00000762|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
47942283|NCT04243785|DRUG|BTX-A51|Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.
47942284|NCT04243785|DRUG|Azacitidine|Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.
48474151|NCT00595335|DRUG|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
48474152|NCT00595335|DRUG|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
47942285|NCT02049320|DRUG|Remifentanil|
47942286|NCT02158260|BEHAVIORAL|Position changing|
48102784|NCT00013650|DRUG|Cyclophosphamate|
48102785|NCT04419181|DRUG|Docetaxel|Dose: 75 mg/m2 q3w
48102786|NCT04419181|DRUG|Carboplatin|Dose: area under the concentration-time curve \[AUC\] 6 q3w
48102787|NCT04419181|DRUG|Trastuzumab|Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
47942287|NCT04285099|DEVICE|Application of dual system in frequency A|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
47942288|NCT04285099|DEVICE|Application of dual system in frequency B|The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
47942289|NCT01500512|OTHER|Clinical Observation|Undergo observation
47942290|NCT04957095|DRUG|Apomorphine Injectable Solution|Apomorphine injected for therapeutic relief
47942291|NCT04957095|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
47942292|NCT05855070|DRUG|Intralesional treatment with Hyaluronic acid|Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid16 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
47942293|NCT05855070|DRUG|Intralesional treatment with Verapamil|Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.
48291321|NCT03009695|DEVICE|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
47942294|NCT05061745|DEVICE|Guided Meditation VR for Wellness|"Selected Modules of Commercially Available Guided Meditation VR presented on Valve Index Headset"
48291322|NCT03009695|DEVICE|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
47942295|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment A|Either MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP) or The NeuroStar® System will be used.
47942296|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment B|Either MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) or The NeuroStar® System will be used.
47942297|NCT03645031|OTHER|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
47942298|NCT03645031|OTHER|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
48291323|NCT03505866|BEHAVIORAL|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
48291324|NCT06320951|DRUG|Vericiguat 10 MG|The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
48291325|NCT06320951|OTHER|Placebo|The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
48291326|NCT06320951|OTHER|Insulin Sensitivity Test|An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
48474153|NCT01148069|PROCEDURE|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
48474154|NCT04223284|OTHER|D-Limonene|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
48474155|NCT04223284|OTHER|SLVO|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
48474156|NCT03989011|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
48291327|NCT06320951|OTHER|Resting Energy and Exercise Energy Expenditure Assessment|Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
48291328|NCT06320951|OTHER|White Adipose Tissue Biopsy|Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
48291329|NCT06320951|OTHER|MRI-PET Scan for Brown Adipose Tissue Volume Assessment|Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
48474157|NCT03989011|DIAGNOSTIC_TEST|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
48474158|NCT03662763|DRUG|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
48474159|NCT03662763|DRUG|Placebo oral capsule|
47942299|NCT01736020|DRUG|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
47942300|NCT01736020|DRUG|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
47942301|NCT01736020|DRUG|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
47942302|NCT01736020|DRUG|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
48291330|NCT03909685|BEHAVIORAL|Mobile Mental Health App|The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
48291331|NCT06394999|DRUG|Mifepristone 50 mg|Once-weekly oral mifepristone 50 mg
48291332|NCT00971646|OTHER|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
48291333|NCT00971646|OTHER|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
48291334|NCT00971646|OTHER|EuroQol-5D|This questionnaire grades the health condition of the subject.
48291335|NCT00971646|OTHER|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
48291336|NCT01675037|OTHER|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
48291337|NCT03478124|BEHAVIORAL|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
48291338|NCT06670482|DEVICE|Non-invasive ventilation (NIV)|Delivery of positive airway pressure to the lungs via an interface, such as a mask.
48291339|NCT05387590|BEHAVIORAL|Preventiometer device with wellness coaching|Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
47942303|NCT01736020|DRUG|Placebo|Placebo
48291340|NCT01407562|DRUG|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
48291341|NCT01407562|DRUG|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
48291342|NCT01407562|DRUG|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
48291343|NCT05296057|DEVICE|Participants Receiving VR-Exposure Therapy Treatment|In the baseline interview with an exposure therapy specialist and a member of the research team, participants will be presented with approximately three sets of possible exposure scenarios, each associated with approximately three different scenes that increase in severity level. Through discussion with the exposure therapy specialist, the participant will choose the exposure scenario (out of the three options) that most closely resembles their own epilepsy- or seizure-related fears. As the treatment, the participant will be exposed to the scenes that are associated with their chosen exposure set in a hierarchical manner using an immersive head-mounted display. The participant will work through the three levels of the chosen exposure scenario for approximately two weeks, ideally on each level for four days.
48474160|NCT04475250|DEVICE|Tetragraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
47942304|NCT01715714|DRUG|Statin Recapture Therapy|Given 12h and 2h before CABG
47942305|NCT01715714|DRUG|Placebo|Given 12h and 2h before CABG.
48102788|NCT04419181|DRUG|Pertuzumab|Dose: 840-mg loading dose, 420-mg maintenance dose q3w
48102789|NCT04419181|DRUG|Trastuzumab emtansine|Dose: 3.6mg/kg q3w
48291344|NCT06513169|PROCEDURE|Group 1: LEE|"Patients will be in supine position during induction with a 12 wedge placed at the level of the Achilles tendon (LEE)"
48474161|NCT06105021|DRUG|AFNT-211|Engineered TCR T-Cell
48474162|NCT06210204|OTHER|Telehealth follow-up|Patients to follow-up via phone after surgery
47942306|NCT04007211|DEVICE|ABT13107|Dose: 3mL, maximum 10mL
48102790|NCT02952053|DEVICE|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
47942307|NCT04007211|DEVICE|Hyalobarrier|Dose: 10mL
47942308|NCT04938479|BIOLOGICAL|blood sample|D-dimer measurement in blood sample
48102791|NCT02952053|DEVICE|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
47942309|NCT03004222|DRUG|Bupivacaine|20 ml of 0.5% Bupivacaine
47942310|NCT03004222|DRUG|Placebos|
47942311|NCT05778851|DEVICE|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
48102792|NCT06631495|OTHER|Observation|not available-observation study
48102793|NCT06155253|PROCEDURE|Erector spinae plane block|"ESP block is a paraspinal fascial plane block that involves injection of local anesthetic underneath the anterior fascia of the erector spinae muscles.~Local anaesthetic mixture (lignocaine 2% with adrenaline, bupivacaine 0.25%) will be delivered with insulated needle in bolus(es) to above-mentioned levels (L1 in 1ESP group, T12 \& L1 in 2ESP group)"
48102794|NCT01085279|DEVICE|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
48102795|NCT01085279|DRUG|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
48102796|NCT05518487|BIOLOGICAL|Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine|0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
48102797|NCT05655442|PROCEDURE|early APM|early APM within 3 and 6 month knee pain symptoms
48102798|NCT05655442|PROCEDURE|delayed APM|delayed APM within 6 and 12 month knee pain symptoms
48102799|NCT02116829|OTHER|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
48102800|NCT02116829|OTHER|Olive oil|
48102801|NCT02155686|DEVICE|Biosensors|Device: Biometric sensors; Home automation; telecare
48102802|NCT02155686|DEVICE|Home automation|
48102803|NCT00029523|DRUG|Intrathecal (injected into the spinal fluid) DepoCyt|
48102804|NCT00029523|DRUG|Intrathecal methotrexate|
48102805|NCT00029523|DRUG|Intrathecal cytarabine (also known as ara-C)|
48102806|NCT04463524|DEVICE|Personal ECG digital sensor|Patients in test group will receive personal ECG sensor and in control gropu will not.
48102807|NCT02313844|BIOLOGICAL|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
48102808|NCT05339971|OTHER|block perforation|The bone block used for lateral bone augmentation will be perforated several times.
48102809|NCT03360552|OTHER|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
48102810|NCT03360552|OTHER|Usual care|Usual clinical evaluation
47942312|NCT05541068|DEVICE|Bioimpedance analysis|Bioimpedance analysis to achieve assessments of fluid status, especially dry-weight, was performed with the portable Biomasc touch i8 (MaltronInternationl, Essex, UK).
48291345|NCT02405312|BEHAVIORAL|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
48291346|NCT00928915|DRUG|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
48291347|NCT04509856|BEHAVIORAL|Teach-back educational method|In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
47942313|NCT04703218|OTHER|olfactory rehabilitation|Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
47942314|NCT02986971|DEVICE|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
48291348|NCT04522102|DRUG|Start antiplatelet monotherapy|Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
48291349|NCT04714762|DEVICE|eMOM GDM application|"Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)"
47942315|NCT06344182|OTHER|Step Up and Down Test|Step Up and Down Test In the StUD test, the patient completes maximum number of step-up-down repetitions in 15 seconds. Starting from a standing position, the participant took a full step up, leading with the test leg, then the non-testing leg, until both knees were fully extended and both hips were at least in neutral extension. In order to stress the testing limb concentrically and eccentrically, the participant stepped off the step first with the non-testing limb, then the testing limb. The patient was asked to repeat for 15 seconds as quickly as possible. The physical therapist stood to the side of the step for safety and so that he/she could observe the technique and ensure that the participant came to a full step up and down during the test.
47942316|NCT00928798|DRUG|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
48631659|NCT04214236|DEVICE|ciNPT group|Closed-incision negative pressure therapy (ciNPT) will be applied for 7 day using continuous suction at 125 mmHg. To deliver ciNPT we will use a commercially available, FDA-approved device, used according to the manufacturer' indications (PREVENA™ Incision Management System (KCI, San Antonio, Texas, USA). After the first 7 post-operative days, subjects will discontinue the ciNPT and follow a standard wound care protocol.
48631660|NCT04214236|OTHER|Control group|Standard non-adherent surgical dressing (Vaseline petrolatum gauze) will be used for management of incisional wounds in the control group. Dressing changes will be performed per standard wound care protocol.
48102811|NCT00197015|BIOLOGICAL|Havrix®|2 doses administered intramuscularly
48102812|NCT00197015|BIOLOGICAL|M-M-R®II|1 dose administered subcutaneously
48102813|NCT00197015|BIOLOGICAL|VARIVAX®|1 dose administered subcutaneously
48102814|NCT04767230|OTHER|Dietary Intervention|A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
48102815|NCT04355130|DIETARY_SUPPLEMENT|Iron, vitamin B12 and acid folic supplementation|Vitamin and iron supplementation is administered one-two weeks before donation, and consist of iron supplementation (i.v. infusion of 20 mg/Kg ferric carboxymaltose in saline 100 ml), s.c. injection of 1 mg of vitamin B12 and acid folic 5 mg/die per os until day +15 post BM donation. BM collection is carried out by the transplant team and a maximal dose of 20-22 ml/Kg of the donor body weight is collected under general anesthesia (induction with fentanyl 1-3 mcg/Kg, Propofol 2-3 mg/Kg, rocuronium 0,6 mg/Kg and mantenaince with sevoflurane 0,8 MAC). Noninvasive cardiac output, blood pressure and hemoglobin monitoring are carried out during the entire procedure and in in the recovery room using the ClearSight™ system (Edwards Clinical) and the Radical Pulse co oxymeter (Masimo). After discharge from the hospital, donors will be revaluated on day + 7 after BM collection, and blood tests will be repeated in outpatient setting.
48102816|NCT02951117|DRUG|Venetoclax|Tablet
48102817|NCT02951117|DRUG|ABBV-838|Intravenous infusion
48102818|NCT02951117|DRUG|Dexamethasone|Tablet or intravenous infusion
48102819|NCT06279819|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|"The dietary intervention used the dietary intervention plan constructed in Phase 2, on the basis of which each study participant's individual dietary habits, food preferences and economic level were taken into account.~The dietary intervention was delivered by sending fresh ingredients. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings.~Ingredients will be delivered three times a week for a 12-week intervention period. The initial food items to be sent include: 90g of fish rich in omega-3 fatty acids; 300g of vegetables and/or legumes, and 200g of fruits; 30g of nuts; and a cup of probiotic yogurt.~Guided dietary follow-up was conducted through video viewing and WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance by sending videos every two weeks."
48102820|NCT06278064|OTHER|Gastric Cancer|Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
48102821|NCT06278064|OTHER|Esophagus Cancer|Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer
48102822|NCT00017004|RADIATION|External Beam Radiation Therapy|Undergo radiation
48102823|NCT00017004|DRUG|Cisplatin|Given IV
48102824|NCT00017004|RADIATION|Internal Radiation Therapy|Undergo radiation
48102825|NCT00017004|BIOLOGICAL|Epoetin Alfa|Given SC
48291350|NCT02894983|OTHER|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
48291351|NCT02894983|OTHER|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
48291352|NCT03682588|OTHER|Physical activity|The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
48291353|NCT00795626|BEHAVIORAL|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
48291354|NCT02447107|OTHER|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
48291355|NCT02447107|OTHER|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
48291356|NCT02195648|OTHER|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
48291357|NCT06289725|DRUG|antiviral treatment|The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
48291358|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
47942317|NCT00928798|DRUG|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
47942318|NCT03467607|PROCEDURE|tidal volume ventilation|low tidal volume ventilation
47942319|NCT01461278|DEVICE|iStent supra|Cataract surgery and implantation of one iStent supra
47942320|NCT01461278|PROCEDURE|Cataract surgery|Cataract surgery alone
47942321|NCT02939079|DRUG|Fingolimod|Produced by Osveh ® Pharm Company in Iran
47942322|NCT02939079|DIETARY_SUPPLEMENT|Fish Oil|produced by Zahravi ® Pharm Company in Iran
47942323|NCT02939079|DRUG|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
47942324|NCT02030054|DRUG|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
47942325|NCT02030054|DRUG|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
47942326|NCT04779931|BEHAVIORAL|Convoy-Pal|12 week mobile self-management intervention with palliative care resources.
47942327|NCT04235803|OTHER|Telemedicine follow-up|A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
48102826|NCT01379287|DRUG|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
48631661|NCT01034527|OTHER|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
48474163|NCT06421142|PROCEDURE|imaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI|"FAPI PET/MRI and FDG PET/MRI examination Data acquisition was performed using a GE Healthcare SIGNA PET/MR instrument. Enrolled patients were injected intravenously with 68Ga-FAPI or 18F-FDG tracer and underwent simultaneous PET and MRI scanning approximately 30-60 minutes after intravenous administration of the tracer at a dose of 1.85-3.7 MBq/kg.~MRI examination MRI examination was performed using a Skyra 3.0T MRI scanner from Siemens, Germany, with a 16-channel phased-array surface coil, and the scanning range was from the superior margin of the iliac wing to the inferior margin of the pubic symphysis."
48474164|NCT05377606|PROCEDURE|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
48474165|NCT05377606|PROCEDURE|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
48474166|NCT01601938|DIETARY_SUPPLEMENT|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
48474167|NCT01601938|DIETARY_SUPPLEMENT|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
48474168|NCT06233539|OTHER|Observational research without intervention|Observational research without intervention
48474169|NCT01272089|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
48474170|NCT02991352|DEVICE|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
48474171|NCT04266652|PROCEDURE|tooth block|tooth root blocks were used to increase the bone width
48474172|NCT04266652|PROCEDURE|autogenous bone block|autogenous bone block were used to increase the bone width
48102827|NCT00006369|DRUG|ERA-923|
48102828|NCT04878328|BEHAVIORAL|Onsite Point-of-care|Guided by Social Cognitive Theory, O-PoC will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.
48102829|NCT00296426|PROCEDURE|New technology - PAML|
48102830|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
48102831|NCT00444613|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
48618074|NCT05871476|BEHAVIORAL|Hospital Cohort Care Intervention at the hospital|There will be 3 different cohort groups for the patients: 1) Unknown CRE colonisation status with increased barrier precautions (all patients until screening results arrive will belong to this group unless there are available screening results from referral hospital), 2) CREpos, and 3) CREneg. CREpos patients (2) will be treated in one area of the ICUs by specially assigned nurses/personnel.
47942328|NCT01753804|OTHER|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
47942329|NCT05752981|DEVICE|multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS)|Participants will be monitored during surgery using the multichannel time-resolved (tr) functional near infrared spectroscopy (fNIRS) (tr-fNIRS). This study is observational in nature and no intervention will be applied based on the results of the tr-fNIRS device.
48102832|NCT00444613|DRUG|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
48102833|NCT04103671|PROCEDURE|Prompt panretinal photocoagulation|Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
48102834|NCT04103671|PROCEDURE|25G Pars-plana vitrectomy|Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
48102835|NCT02559258|DRUG|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
48102836|NCT02559258|DRUG|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
48102837|NCT02559258|DRUG|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
48102838|NCT02559258|DRUG|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
48102839|NCT02559258|DRUG|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
48102840|NCT02192034|BEHAVIORAL|Navigation|
48102841|NCT04590794|DIAGNOSTIC_TEST|Soluble Urokinase Plasminogen Activator Receptor|Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.
47942330|NCT05712876|DRUG|CK-0045|Interleukin-22 agonist
48291359|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
48291360|NCT02102230|BEHAVIORAL|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
48291361|NCT06442241|BIOLOGICAL|LYB005 low dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291362|NCT06442241|BIOLOGICAL|LYB005 middle dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291363|NCT06442241|BIOLOGICAL|LYB005 high dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291364|NCT06442241|BIOLOGICAL|LYB005 low dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291365|NCT06442241|BIOLOGICAL|LYB005 middle dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291366|NCT06442241|BIOLOGICAL|LYB005 high dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291367|NCT06442241|BIOLOGICAL|Placebo|0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291368|NCT06442241|BIOLOGICAL|Positive control|AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
48291369|NCT04075604|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
48291370|NCT04075604|DRUG|Anastrozole|Specified Dose on Specified Days
48291371|NCT04075604|DRUG|Palbociclib|Specified Dose on Specified Days
48291372|NCT06332963|BEHAVIORAL|Floatation-REST|Participants lay supine in one of two circular fiberglass pools that were custom-designed for research purposes. The floatation pools are 8 feet in diameter and contain 11 inches of reverse osmosis water saturated with \~1,800 pounds of Epsom salt (magnesium sulfate). This creates a dense saltwater solution with a specific gravity of \~1.26, allowing participants to effortlessly float on their back while the water hovers just above the ears. The temperature of the water and air is calibrated to approximate skin temperature (\~95.0 °F), helping to minimize the need for thermoregulation while reducing the boundary between air, body, and water. Clothing is usually not worn while floating since anything touching the body can generate somatosensory stimulation, detracting from the float experience. However, participants have the option to choose if they would prefer to float with a bathing suit or nude. During floatation-REST, visual, auditory, olfactory stimuli are minimized.
48291373|NCT06332963|BEHAVIORAL|IFT|Two ACT principles, contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the IFT condition, awareness and acceptance of bodily signals, thoughts, and emotions and being present with one's self (i.e., mindfulness focus is inward) are emphasized. All participants will engage in an introduction session. Followed by three IFT sessions. The experimental sessions are formatted the same for both conditions. Each begins with a clinician reviewing previous constructs and introducing a new skill. Then participants engage in their assigned condition intervention, followed by a debrief with a clinician. Practices in both conditions are matched as closely as possible for content. The mindful focus of IFT is internal toward thoughts, emotions, and body sensations. In the experimental sessions, participants will engage in a floatation-REST session while practicing acceptance and mindfulness-based skills presented to them.
48474173|NCT00176930|BIOLOGICAL|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
48474174|NCT00176930|DRUG|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
48474175|NCT00176930|RADIATION|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
48474176|NCT00176930|DRUG|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
48102842|NCT04586712|DRUG|Active CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).
47942331|NCT05712876|DRUG|Placebo|Matching placebo
47942332|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 1|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets.
48102843|NCT04586712|DRUG|Vehicle Control (Placebo)|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
48102844|NCT03659201|DRUG|Neosil complete|Oral, during 24 weeks.
48102845|NCT03659201|DRUG|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
48102846|NCT03659201|DRUG|Neosil|Oral, during only 12 weeks.
48631662|NCT05648916|OTHER|Celecoxib|Retrospectively comparing patients with and without heterotopic ossification who have been exposed to celecoxib and underwent cementless total hip joint replacement surgery.
48291374|NCT06332963|BEHAVIORAL|EFT|Two acceptance and commitment therapy modules contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the EFT condition, awareness and acceptance of thoughts and emotions and mindfulness of current experience are emphasized. The mindful focus of EFT is external, toward attending to experience as well as thoughts and emotions. During experimental sessions, participants will engage in a self-guided and computer-based practice of acceptance and mindfulness-based skills. These videos were created to ensure content was congruent with the material presented in the introduction sessions and represent skills that build from session to session.
48291375|NCT02233725|DEVICE|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
48291376|NCT04634669|DRUG|AXS-05 (dextromethorphan-bupropion)|- AXS-05 tablet, taken daily (up to 15 months)
48474177|NCT00176930|DRUG|Equine ATG (ATGAM)|UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
47942333|NCT05091671|OTHER|Free From Pain Exercise Programme Variation 2|Includes the initial 45-minute consultation + the exercise booklet + the 12 reasons to exercise leaflets + the 12 metaphor leaflets, and the 12 Zoom online sessions.
48291377|NCT02332915|BEHAVIORAL|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
47942334|NCT05036369|DEVICE|Vibrant capsule|Vibrant capsule - Administered twice a week (Monday and Thursday).
48291378|NCT00723658|BIOLOGICAL|rituximab|
48291379|NCT00723658|DRUG|bortezomib|
48474178|NCT00176930|BIOLOGICAL|CD4+/CD25+ cells|On days -2, patients will receive CD4+/CD25+ cells intravenously.
48474179|NCT01304186|BEHAVIORAL|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
48474180|NCT00311649|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|
48474181|NCT00378027|DRUG|Fondaparinux|Administer Fondaparinux Risk Stratify
47942335|NCT05036369|DEVICE|Placebo capsule|Placebo Capsule administered twice a week (Monday and Thursday)
47942336|NCT03088215|DEVICE|shock-waves|Application of shock-waves (radial and focused)
47942337|NCT01056328|DEVICE|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
48291380|NCT00723658|DRUG|carmustine|
48291381|NCT00723658|DRUG|cisplatin|
48291382|NCT00723658|DRUG|cyclophosphamide|
48291383|NCT00723658|DRUG|cytarabine|
48291384|NCT00723658|DRUG|dexamethasone|
48291385|NCT00723658|DRUG|doxorubicin hydrochloride|
48291386|NCT00723658|DRUG|etoposide|
48291387|NCT00723658|DRUG|melphalan|
48291388|NCT00723658|DRUG|thalidomide|
48291389|NCT00723658|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
48291390|NCT00723658|PROCEDURE|peripheral blood stem cell transplantation|
48291391|NCT03414918|DRUG|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
48631663|NCT02273466|DRUG|Desipramine tablet|
47942338|NCT01056328|DEVICE|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
47942339|NCT05788601|DRUG|Dapiglutide|GLP-1/GLP-2 receptor agonism
48474182|NCT06600100|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
47942340|NCT05788601|DRUG|Placebo|Placebo
47942341|NCT06087003|DRUG|Basiliximab Injection|As an induction treatment for kidney transplantation
47942342|NCT06087003|DRUG|rabbit ATG|As an induction treatment for kidney transplantation
47942343|NCT03508531|PROCEDURE|ESP Block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
48631664|NCT02273466|DRUG|Crobenetine infusion|
47942344|NCT03508531|PROCEDURE|OSTAP block|The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
48631665|NCT02273466|DRUG|Placebo infusion|
48631666|NCT05895500|DRUG|Injection for SC administration (120mg/syringe)|Injection
48631667|NCT05895500|DRUG|Tablet (50mg/tablet), oral|Tablet
48631668|NCT03528577|DRUG|Zero-dose|Treatment A
48631669|NCT03528577|DRUG|90 mcg of PROAIR® HFA|Treatment B
48631670|NCT03528577|DRUG|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
48291392|NCT03927976|BEHAVIORAL|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
48291393|NCT04083222|DRUG|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
48291394|NCT04083222|DRUG|ISIS 757456|ISIS 757456 administered as SC injection.
48291395|NCT01213810|BIOLOGICAL|Zostavax|Biological/Vaccine
48291396|NCT06658132|DRUG|0.5~1ug/kg/min remifentanil combined with 0.2~0.5mg/kg/h esketamine for the physiological testing phase of DBS surgery.|Throughout the first and third stages of surgery, all patients receive a traditional induction of anesthesia. Fifteen minutes before the second stage of surgery (MER and clinical assessment), when the burr hole is ready, the propofol and sevoflurane infusion is discontinued, and patients receive 0.5\~1ug/kg/min remifentanil combined with 0.2\~0.5mg/kg/h esketamine. On completion of the second stage of surgery, the interventional drug is discontinued and propofol combined with sevoflurane is resumed until the end of the third stage.
48291397|NCT04194931|BIOLOGICAL|Autologous BCMA CAR-T cells and CD19 CAR-T cells|Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
48291398|NCT06076330|BIOLOGICAL|20% Albumin|S. albumin \> 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr S. albumin \< 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr
48291399|NCT06076330|BIOLOGICAL|5% Albumin|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose In case of failure to attain a sustained MAP \>65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC.
48291400|NCT06076330|DRUG|Plasmalyte|Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
48618075|NCT05871476|BEHAVIORAL|, Household Education Communication Hygiene Intervention, Livestock Antibiotic Intervention|The intervention will focus on two main measurable outcomes: 1) Decrease feco-oral-animal transmission route to prevent in-HH and community spread of CRE +/- CoRE. 2) Decrease unindicated community use of ABs for humans and animals. This WP focuses on a one health intervention in collaboration with local health authorities, developing and implementing an HH Education Communication Hygiene Intervention (HECHI) to improve HH hygiene and health management and reduce the risk of transmission between humans and animals, a Provider Engagement Intervention (PEI) to improve case management of common infection and decrease unindicated AB, and and a Livestock AB Intervention (LAI) to reduce the use of AB in livestock through improved biosecurity conditions and animal husbandry.
48618076|NCT00107497|RADIATION|Radiation therapy|
47942345|NCT03508531|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
47942346|NCT00085124|BIOLOGICAL|oblimersen sodium|Given IV
47942347|NCT00085124|DRUG|cytarabine|Given IV
47942348|NCT00085124|DRUG|daunorubicin hydrochloride|Given IV
47942349|NCT00085124|OTHER|laboratory biomarker analysis|Correlative studies
47942350|NCT05012436|DRUG|YHD1119 75mg|A single oral dose
47942351|NCT06023225|BEHAVIORAL|Pain|Postoperative pain levels
47942352|NCT06023225|BEHAVIORAL|Opioid use|Postoperative opioid use
47942353|NCT03857906|DEVICE|Intra-Aortic Ballon Pump insertion|The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
48291401|NCT04729530|DEVICE|Dyson Pure Cool - Active Purifier|Free standing air purifier
48291402|NCT04729530|DEVICE|Dyson Pure Cool - Placebo purifier|Placebo air purifier
48291403|NCT01235533|DIETARY_SUPPLEMENT|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
47942354|NCT04167722|PROCEDURE|Robotic Radical Prostatectomy|Routine NHS Radical Prostatectomy
47942355|NCT00359697|DRUG|Hypertonic Saline, Mannitol|
47942356|NCT03183778|DRUG|Patiromer|Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.
47942357|NCT03183778|DIETARY_SUPPLEMENT|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
48291404|NCT06672380|OTHER|Remote Physical Exercise Program for Breast Cancer Survivors|Structured and remotely guided physical exercise program The participants in the intervention group took part in a remote physical exercise program for 12 weeks. The telepresence sessions, conducted three times a week via Google Meet®, lasted 60 minutes and consisted of three phases: warm-up (10 minutes), multi-joint functional exercises (40 minutes) and stretching (10 minutes). The exercises were progressively intensified over the weeks, using the Borg scale to monitor effort. The intensity was adjusted in three cycles: in the first 4 weeks (60 seconds of exercise/90 seconds of rest), in weeks 5 to 8 (75 seconds of exercise/60 seconds of rest) and in weeks 9 to 12 (90 seconds of exercise/30 seconds of rest).
48291405|NCT06672380|OTHER|Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance|Participants in the Ebook group received an illustrated manual containing detailed guidelines for practicing simple physical exercises at home, using only their body weight. The manual suggested a frequency of 3 to 5 times a week, with 30 to 60 minutes of activities such as stretching, squats and exercises for the upper and lower limbs. The participants were encouraged to follow these guidelines and, 30 days after receiving the ebook, an additional stimulus was sent by text message, reinforcing the importance of following the protocol.
48291406|NCT06672380|OTHER|Initial Incentive for Eating Habits in Women Surviving Breast Cancer|The control group only received general guidance on the importance of regular physical activity. The recommendations followed health guidelines, suggesting between 150 and 300 minutes of moderate-intensity physical activity per week.
48291407|NCT06667128|OTHER|Rapid Uptitration of Guideline-Directed Medical Therapy|Rapid up-titration of GDMT guided by protocol-specific guideline.
48291408|NCT06667128|DIAGNOSTIC_TEST|Elecsys® NT-proBNP - Roche Diagnostics|An assay provided by Roche (Elecsys® NT-proBNP - Roche Diagnostics) will be used to assess NT-proBNP levels in the Rapid Up-Titration GDMT Group with Point-of-Care (PoC) Monitoring, with the purpose of evaluating any differences in marker dosage between the indicated method and the monitoring by the hospital laboratory analysis.
48474183|NCT06600100|BEHAVIORAL|Placebo Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Here, three separate categories of non-food items (stationery, flowers and clothing) would be Go signal (associated with green 100%), No-Go signal (associated with red 100%) and control (50% red 50% green) respectively.
48474184|NCT02425384|BEHAVIORAL|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
48474185|NCT02425384|BEHAVIORAL|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
48474186|NCT02425384|OTHER|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
48474187|NCT05704673|DRUG|nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.|investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
48474188|NCT06327737|DIAGNOSTIC_TEST|Capnography|This is non-invasive follow-up method to the management of DKA and the reduction of the frequency of invasive procedures was investigated in patients diagnosed with diabetic ketoacidosis (DKA) in the pediatric emergency department and followed up with capnography.
48474189|NCT03630419|DIETARY_SUPPLEMENT|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
48618077|NCT03852511|BIOLOGICAL|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
47942358|NCT00446342|DRUG|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
47942359|NCT03335111|OTHER|Remote Ischemic Conditioning Equipment|BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
47942360|NCT03335111|PROCEDURE|Intravenous blood collection|Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
48102847|NCT00906620|OTHER|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
48474190|NCT03630419|OTHER|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
48474191|NCT05965817|DRUG|SGM-101 op top of ICG|SGM-101 op top of ICG
48474192|NCT04591652|DRUG|99mTc-MIRC208|99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
48474193|NCT03078478|DRUG|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
48474194|NCT03078478|DRUG|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
48474195|NCT00717782|PROCEDURE|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
48102848|NCT03673709|BEHAVIORAL|Antenatal Care|Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
48474196|NCT00717782|PROCEDURE|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
48474197|NCT06079255|DEVICE|IscAlert sensor(s) in patient with risk of acute compartment syndrome|of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
47942361|NCT02700022|DRUG|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
48102849|NCT03092557|OTHER|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
48102850|NCT00159354|DRUG|predisolone|
48474198|NCT06503354|DEVICE|Neural Sleeve and Zeno walkway|"A standard manual stopwatch will be used to record time. The Zeno pressure gait mat will be laid flat on the ground and used for all walking conditions. Overall, participants will perform four, 5-minute walking bouts while wearing the Neural Sleeve without electrical stimulation. Participants will not receive any intervention or treatment. Simultaneously, the Zeno walkway will be operated according to manufacturers instructions. Condition descriptions are as follows:~Condition 1 (normal walking speed): During this condition, participants will be asked to walk at their normal, comfortable pace for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course.~Condition 2 (fast walking speed): During this condition, participants will be asked to walk, covering as much distance as possible for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course."
48474199|NCT01332721|DRUG|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
47942362|NCT05273970|OTHER|Behavioral testing under intracranial monitoring|After standard of care surgery to implant the electrodes is complete and patients have have recovered satisfactorily from the procedure, they will be asked to perform some computer based tasks to answer questions about pretend financial decisions, pay attention to certain images, watch videos, look at images, listen to sounds, or move a joystick.
47942363|NCT02962154|RADIATION|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
48291409|NCT06667128|OTHER|Rapid Up-Titration GDMT Group with Hospital Monitoring|Rapid Up-Titration GDMT Group guided by protocol-specific guideline and hospital monitoring.
47942364|NCT02962154|OTHER|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
48102851|NCT04927143|DEVICE|App-Based Contingency Management|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
48102852|NCT04927143|BEHAVIORAL|Sham Control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
48102853|NCT06421090|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation，Intervention group25Hz，Control group1Hz
48102854|NCT02839330|BIOLOGICAL|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
48291410|NCT06512428|DRUG|simmitinib plus irinotecan liposome|simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
48291411|NCT06512428|DRUG|irinotecan liposome|irinotecan liposome 70 mg/m\^2 every 2 weeks
48291412|NCT06512428|DRUG|irinotecan|irinotecan 180mg/m\^2 every 2 weeks
48291413|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 100mg
48474200|NCT02800031|DEVICE|Transvaginal ultrasonography|
48474201|NCT02951936|DEVICE|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
47942365|NCT02962154|OTHER|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
47942366|NCT02962154|OTHER|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
47942367|NCT02962154|OTHER|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
47942368|NCT02962154|OTHER|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
47942369|NCT02962154|OTHER|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
47942370|NCT05538598|PROCEDURE|Intramuscular Dry Needling|The insertion of thin monofilament needles (without injectate) into a tight band of muscle. The needles will be inserted into the muscle for \~10 seconds.
47942371|NCT00237185|DRUG|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
47942372|NCT06433570|GENETIC|multiplex PCR|Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients using multiplex PCR
47942373|NCT02713204|DRUG|REGN910-3|
47942374|NCT02713204|DRUG|Intravitreal Aflibercept Injection (IAI)|
47942375|NCT00704912|DRUG|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
47942376|NCT00704912|DRUG|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
47942377|NCT00704912|DRUG|Combination of treatments|Medications will be administered as described for the other 2 arms.
47942378|NCT02126358|DRUG|Gemigliptin and/or Rosuvastatin|
47942379|NCT06317441|DIETARY_SUPPLEMENT|Probiotic|The intervention consists of a probiotic either with a low or high dosage
47942380|NCT03092024|OTHER|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
47942381|NCT02160353|DRUG|Abiraterone acetate, Prednisolone|
47942382|NCT06332248|DIETARY_SUPPLEMENT|Magnesium|The dietary supplement magnesium (375 mg) was given daily for up to 3 months (oral intake).
47942383|NCT06332248|DIETARY_SUPPLEMENT|Placebo|Placebo tablet, oral intake once a day for up to three months.
47942384|NCT01284530|DRUG|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
47942385|NCT05557435|OTHER|breast milk odor|"The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water."
48102855|NCT02839330|BIOLOGICAL|Placebo|Placebo: Saline injection
48102856|NCT00647205|DEVICE|QuantiFERON TB Gold In-Tube|
48291414|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 200mg
48631671|NCT03528577|DRUG|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
48102857|NCT00647205|DEVICE|T-SPOT.TB®|
48102858|NCT00578435|PROCEDURE|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
48291415|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 300mg
48291416|NCT01557010|DRUG|Control|Tablets, oral administration, Placebo
48291417|NCT00663858|DRUG|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
48291418|NCT00663858|DRUG|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
48291419|NCT00663858|OTHER|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
48631672|NCT03545581|OTHER|Experimental diet Fru rich diet|7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
48631673|NCT03545581|OTHER|Experimental low Fru diet|7 days (day 1 to day 7) with low-fructose diet (\<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
48474202|NCT02951936|DEVICE|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
48474203|NCT05709769|OTHER|There are no interventions.|There are no interventions.
48474204|NCT03589196|PROCEDURE|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
48474205|NCT03589196|PROCEDURE|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
48474206|NCT03589196|PROCEDURE|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
48474207|NCT03978416|BEHAVIORAL|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
48474208|NCT01858987|PROCEDURE|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
48474209|NCT01858987|PROCEDURE|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
48474210|NCT01858987|DEVICE|Ligasure|
48291420|NCT02908477|RADIATION|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
47942386|NCT05557435|OTHER|Placebo|Placebo
47942387|NCT06448182|DIETARY_SUPPLEMENT|Postbiotic|1 capsule of postbiotic daily in the morning
48291421|NCT02908477|DRUG|Docetaxel|15 mg/m2. Experimental arm only.
48291422|NCT02908477|DRUG|Cisplatin|40 mg/m2. Standard arm only.
48474211|NCT01858987|OTHER|vascular staple|
48474212|NCT03419104|DIAGNOSTIC_TEST|preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
48474213|NCT06308263|DRUG|M1774 [14C]M1774 microtracer|Participants will receive single oral dose of M1774 containing a \[14C\]M1774 microtracer solution on day 1 of period 1 under fasted conditions.
47942388|NCT06448182|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo daily in the morning
47942389|NCT01350154|DRUG|Sildenafil|20 mg in gelatine capsules, oral, three times daily
48291423|NCT03626467|BIOLOGICAL|HPV9v|Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
48291424|NCT01267435|PROCEDURE|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
48474214|NCT06308263|DRUG|M1774|Participants will receive a single oral dose of M1774 on Day 1 of Period 1, and daily single oral dose of M1774 for 2 weeks in 21 days cycle of Period 2.
47942390|NCT01350154|DRUG|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
47942391|NCT04731961|PROCEDURE|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
47942392|NCT04731961|PROCEDURE|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
47942393|NCT02942875|OTHER|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
47942394|NCT02942875|OTHER|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
47942395|NCT00070655|DRUG|SR34006 (idraparinux sodium) Injection|
47942396|NCT00070655|DRUG|vitamin K antagonist (warfarin or acenocoumarol) tablets|
47942397|NCT00003800|OTHER|immunohistochemistry staining method|
48291425|NCT00783510|BIOLOGICAL|adalimumab|As prescribed by treating physician
48291426|NCT00783510|DRUG|Methotrexate|As prescribed by treating physician
48291427|NCT06512883|DRUG|Benralizumab|Benralizumab will be administered as SC injection on Q4W.
48291428|NCT00396227|DRUG|vildagliptin|vildagliptin as add-on to metformin
48291429|NCT00396227|DRUG|thiazolidinedione (TZD)|TZD add-on to metformin
48291430|NCT02057237|DRUG|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
48474215|NCT02675374|DRUG|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
48474216|NCT02675374|DRUG|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
48474217|NCT05183711|BEHAVIORAL|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
48474218|NCT04467320|BEHAVIORAL|Teaching Recovery Techniques|Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
48474219|NCT04467320|BEHAVIORAL|Care as usual|In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
48474220|NCT04611594|BEHAVIORAL|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
48474221|NCT04478240|BEHAVIORAL|PeerLearning.net|"PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group."
48474222|NCT02095886|DRUG|BMS-955176|BMS-955176
48474223|NCT05767216|OTHER|Biological sampling|Blood, skin and stool samples for laboratory analysis
48291431|NCT00850772|DIETARY_SUPPLEMENT|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
47942398|NCT00003800|OTHER|laboratory biomarker analysis|
48474224|NCT05528861|DRUG|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
48474225|NCT05528861|OTHER|Placebo|Placebo
47942399|NCT00003800|PROCEDURE|radionuclide imaging|
47942400|NCT04396496|DRUG|Daratumumab Injection|"DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles."
48474226|NCT05429489|PROCEDURE|Bilevel erector spinae plane block|Bilevel erector spinae plane block at 3rd and 5th thoracic vertebral levels
48631674|NCT01391949|BEHAVIORAL|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
47942401|NCT01729260|DRUG|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
47942402|NCT06182280|BEHAVIORAL|PrEP4T|PrEP4T is an individualized TMSM-specific intervention adapted from The Fenway Model. PrEP4T consists of online one-on-one sessions between a peer and a participant using a strengths-based case management manualized curriculum. Peer navigators (PNs) share transmasculine community membership with participants and are trained to provide linkages. They use an individualized approach to navigate barriers, apply an assets-based frame to promote resiliencies, and pragmatically leverage these to improve biomedical HIV prevention outcomes. PNs utilize techniques from established behavior change models (e.g., Motivational Interviewing; Transtheoretical Model) in PrEP decision-making.
47942403|NCT06182280|BEHAVIORAL|LS4TM|LS4TM is a theory-based peer-delivered small group-based behavioral intervention to reduce HIV risk and address mental health-related effects of stigma for TMSM. Groups will be led by trained peer navigator staff and comprise no more than 10 participants per cohort.
47942404|NCT05961878|DIETARY_SUPPLEMENT|mediterranean diet with adequate protein intake|balanced mediterranean diet with 1.1 g/kg die protein intake
48631675|NCT01391949|BEHAVIORAL|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
48631676|NCT06444100|PROCEDURE|Impact of structural training on child abuse|"A focus group discussion to delve into teachers' perceptions of child abuse. Based on the findings, the training module will be modified as need-based.~Phase II: Randomly selected samples will be invited, with the researcher explaining the study procedures and obtaining verbal and written consent from teachers and assent from children. A dedicated room will be arranged for data collection, and participants will be instructed on how to respond to child abuse questions on tablets.~Phase-III A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. Teachers will also be educated on how to report instances of child abuse. A post-test will be administered using the same questionnaires two weeks after the training."
47942405|NCT06515522|OTHER|differential diagnosis|this is a retrospective observational study. no intervention has been or will be performed
47942406|NCT03092271|BEHAVIORAL|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
47942407|NCT03092271|BEHAVIORAL|Zero Suicide Quality Improvement|ZSQI
47942408|NCT02808871|DRUG|Pirfenidone|Pirfenidone three times daily (2403 mg) for 52 weeks
47942409|NCT02808871|DRUG|Placebo|Placebo three times daily for 52 weeks
48102859|NCT03651713|BEHAVIORAL|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
48474227|NCT05429489|PROCEDURE|Single level erector spinae plane block|Single level erector spinae plane block at 5th thoracic vertebrae
48474228|NCT05429489|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
48291432|NCT05386433|DRUG|Paxlovid|"Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir \[PF-07321332\] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus."
48291433|NCT05386433|DRUG|standard-of-care|standard-of-care of COVID-19
48291434|NCT04098614|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
48291435|NCT03210077|DEVICE|Monitoring|Monitoring
48291436|NCT05509608|DEVICE|RM Electrode|The RM Electrode is a corneal ERG electrode. The distinguishing features of the RM electrode are that it is a soft contact lens with a recessed electrode (i.e. no metal electrode makes direct contact with the eye). The RM Electrode also has an integral speculum to hold the wearer's eye lids open. The electrode is designed for superior positional stability on the eye during testing. These features work together to improve ERG signal quality.
48291437|NCT05509608|DEVICE|ERG Jet Electrode|The ERG Jet electrode is an FDA approved, commercially available corneal ERG electrode.
48291438|NCT05074784|DEVICE|IOPI Therapy|Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
48291439|NCT05074784|DEVICE|Tongue Depressor Traditional Intervention|Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
48291440|NCT05227846|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
48291441|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
48291442|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
48291443|NCT05134974|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
48291444|NCT05134974|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
48291445|NCT00004346|DRUG|chenodeoxycholic acid|
48291446|NCT00004346|DRUG|lovastatin|
48291447|NCT02202603|DRUG|Teriparatide|single oral tablet
48291448|NCT02202603|DRUG|Teriparatide|subcutaneous standard injection
48291449|NCT02202603|DRUG|placebo|Oral placebo
48291450|NCT05430659|OTHER|observational study|Retrospective observational study
48474229|NCT05799716|DRUG|IVIG|0.5g/Kg
48474230|NCT05118477|DEVICE|Ambulatory monitoring system|Patients will use AMS.
48291451|NCT03835338|DEVICE|Pulmonary Vein Isolation|Pulmonary Vein Isolation by RF Ablation
48291452|NCT03835338|DEVICE|LAA Isolation|LAA Isolation by RF Ablation
48291453|NCT03835338|DEVICE|LAA Occlusion|LAA Occlusion by implantation of the WATCHMAN LAAC Device
48291454|NCT00955110|DRUG|Oxymorphone ER|15mg or 30mg
48291455|NCT00955110|DRUG|Oxycodone CR|30mg or 60mg
48291456|NCT00955110|DRUG|Placebo|The placebo was a sugar pill.
48291457|NCT00955110|DRUG|Hydromorphone|8 mg
48291458|NCT04327570|OTHER|Patient sampling|Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable
48291459|NCT04370249|OTHER|pulmonary ultrasound|pulmonary ultrasound on admission
48474231|NCT05118477|DEVICE|Active alerting system|Clinical staff alerted if AMS detects deterioration
48474232|NCT06293352|DEVICE|All-cement articulating spacer|Two-stage intervention
48474233|NCT06293352|DEVICE|Durable, real-component articulating spacer|Single stage intervention
48474234|NCT06293352|DEVICE|Rigid Spacer|Observation intervention
48618078|NCT04858464|OTHER|Survey study|Patients will complete the mentioned questionnaires.
48618079|NCT05729958|DIAGNOSTIC_TEST|CT scan|CT scan of the involved ankle
48618080|NCT01605903|DRUG|Ibuprofen|Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
48618081|NCT01605903|DRUG|Acetaminophen|During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
48474235|NCT03882073|PROCEDURE|Modified amputation procedure|A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
48474236|NCT03882073|PROCEDURE|Standard amputation procedure|Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
48474237|NCT00699244|PROCEDURE|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
47942410|NCT05468138|DRUG|SOX|"Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1."
48474238|NCT00699244|PROCEDURE|Central placement of local anesthesia|Central placement of local anesthesia
48474239|NCT00784134|DRUG|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
47942411|NCT05468138|DRUG|XELOX|Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
47942412|NCT05468138|OTHER|Observation|follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
48474240|NCT00784134|OTHER|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
48474241|NCT04454528|RADIATION|Hypofractionated radiotherapy|Radiation boost (RT) 7 Gy x 1 fraction on Day -14/Day -7 (arm 1) or Day -7/Day -14
47942413|NCT05468138|DRUG|PD-1 antibody|Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
47942414|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
47942415|NCT00478699|DRUG|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
47942416|NCT00478699|DRUG|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
47942417|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
47942418|NCT00042367|DRUG|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
47942419|NCT00042367|DRUG|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
47942420|NCT00042367|DRUG|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC \< 500/mm3 or platelets (unsupported) \< 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
47942421|NCT00042367|DRUG|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
48102860|NCT03651713|DIETARY_SUPPLEMENT|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
48102861|NCT00877435|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
48102862|NCT01570751|DRUG|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
48102863|NCT01570751|DRUG|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
48102864|NCT00816829|DRUG|Placebo|Fenofibrate-matching placebo tablet
48474242|NCT04454528|DRUG|Pembrolizumab infusion|Pembrolizumab infusion flat dosing 200 mg delivered over 30 minutes.
48474243|NCT04454528|PROCEDURE|Blood and tissue sampling|Blood will be collected for laboratory studies and complete correlative studies to examine how the subject's immune system is responding to treatment. On day 0, samples of tumor and any lymph nodes removed from armpit will be analyzed by the UPenn Department of Pathology according to standard practice.
48474244|NCT05996406|DRUG|Venetoclax|Venetoclax 400mg po qd for 1 year
48102865|NCT00816829|DRUG|Fenofibrate|145 mg NanoCrystal tablet
48291460|NCT02542449|DIETARY_SUPPLEMENT|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
48291461|NCT02542449|DIETARY_SUPPLEMENT|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
48291462|NCT00705510|DRUG|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
48474245|NCT05996406|DRUG|Dexamethasone Oral|Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
48474246|NCT03355196|DRUG|LRX712|Ascending single dose on Day 1
48474247|NCT03355196|DRUG|Placebo|Ascending single dose on Day 1
48474248|NCT03328429|OTHER|Excision|Bartholin gland will be excised
48474249|NCT03328429|OTHER|Marsupialization|Bartholin gland will be marsupialised
48474250|NCT04228627|DRUG|Parentral Iron|Correction of Iron stores without anaemia
48474251|NCT04483531|DRUG|Odevixibat|A4250 is a small molecule and selective inhibitor of IBAT
48474252|NCT00512538|DEVICE|Bi-layered cell therapy (Apligraf)|
48474253|NCT05815849|DIETARY_SUPPLEMENT|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
48291463|NCT04224558|DRUG|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
48291464|NCT04224558|DRUG|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
48291465|NCT04224558|DRUG|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of \>1000/μL"
48474254|NCT05709782|PROCEDURE|Spine Radiosurgery|scan
48474255|NCT05709782|DEVICE|Magnetic Resonance imaging|scan
48474256|NCT05709782|RADIATION|MR-LINAC|scan
48474257|NCT01518335|PROCEDURE|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
48474258|NCT01518335|PROCEDURE|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
48474259|NCT01774682|PROCEDURE|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
48474260|NCT05051878|DEVICE|T-scan|occlusal analysis T-scan
48474261|NCT05051878|OTHER|articulating paper|articulating paper occlusal analysis
48291466|NCT04224558|PROCEDURE|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
47942422|NCT00042367|DRUG|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
47942423|NCT00042367|DRUG|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.~Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course~1."
48102866|NCT03467724|DEVICE|Fractional Radiofrequency (FRF)|Fractional radiofrequency will be delivered to the area of the surgical scar.
48474262|NCT01867606|BIOLOGICAL|serum-derived bovine immunoglobulin protein isolate|Given PO
48474263|NCT01867606|OTHER|placebo|Given PO
48474264|NCT01867606|OTHER|laboratory biomarker analysis|Correlative studies
48474265|NCT01867606|OTHER|quality-of-life assessment|Ancillary studies
48474266|NCT01867606|OTHER|questionnaire administration|Ancillary studies
48474267|NCT05598034|DEVICE|Left DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
48474268|NCT05598034|DEVICE|Right DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
48474269|NCT05598034|BEHAVIORAL|Cognitive task|Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
48474270|NCT06320158|OTHER|clinical evaluation of sarcopenic obesity|completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
48474271|NCT05103917|DRUG|X4P-001|CXCR4 inhibitor
48474272|NCT00413218|DRUG|Isavuconazole|Administered by intravenous infusion.
48474273|NCT00413218|DRUG|Caspofungin|Administered by intravenous infusion.
48474274|NCT00413218|DRUG|Voriconazole|Administered by intravenous infusion.
48474275|NCT02007668|OTHER|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
47942424|NCT00042367|DRUG|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is \< 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is \> 2000 on two consecutive days, post ANC nadir."
48291467|NCT04224558|PROCEDURE|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\^6 CD34+ cells/kg body weight.
48474276|NCT03667859|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
47942425|NCT00042367|DRUG|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
48474277|NCT03785691|DRUG|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
48474278|NCT03785691|DRUG|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
48474279|NCT03785691|DRUG|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
48474280|NCT05423587|PROCEDURE|Genicular Artery Embolisation|Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
48618082|NCT00435344|BEHAVIORAL|Pediatric Practice-Based Smoking Intervention|
48291468|NCT04224558|DRUG|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
47942426|NCT00042367|DRUG|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
48474281|NCT05423587|PROCEDURE|Genicular Artery Injection|Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
48474282|NCT02240186|DEVICE|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
47942427|NCT00042367|RADIATION|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.~8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
48474283|NCT02240186|DEVICE|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
48474284|NCT06248645|DRUG|Oxygen|High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
48474285|NCT06248645|DRUG|Placebo|High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
48631677|NCT06426576|OTHER|Standard one-off instruction using a scale|"The permitted weight is demonstrated to the patient once using a scale in the static position. The patient repeatedly places the foot with the permitted weight on a scale in order to develop a feeling for the load. After this exercise in the static position, the patient applies the perceived load to dynamic activities of daily living without receiving any feedback.~The instruction is given by a trained physiotherapist. Simultaneously with the instruction, the effective weight applied on the leg will be measured using instrumented insoles without any feedback."
48631678|NCT06426576|DEVICE|Plantar pressure insoles|The insoles are used in both static and dynamic conditions such as walking straight along the hallway or walking stairs if applicable. Initial instruction is given by a trained physiotherapist and will be continuously applied at home using the smartphone app for 5 out of 7 days per week during the first 2 weeks after surgery.
48631679|NCT06500728|DIAGNOSTIC_TEST|Fluorescein and Indocyanine green Angiography|The ophthalmologist frequently recommends fluorescein (FAG) and indocyanine green angiography (ICGA) at baseline (T0) to evaluate retinal and choroidal vascularisation. They can be repeated also after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4) or 26 ± 2 weeks (T5).
48631680|NCT06500728|DIAGNOSTIC_TEST|High-resolution Optical Coherence Tomography|The ophthalmologist often suggests performing HR-OCT initially (T0) to assess the width of the macula and optic nerve with potential signs of ischemic lesions in these areas. This assessment can also be repeated after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
48631681|NCT06500728|DIAGNOSTIC_TEST|Angio-Optical Coherence Tomography|The ophthalmologist often suggests OCT-A at the beginning (T0) to assess the retinal and choroidal vascularization. These tests can also be done after 48-72 hours (T1), 7 ± 2 days (T2), 4 ± 1 weeks (T3), 12 ± 2 weeks (T4), or 26 ± 2 weeks (T5).
47942428|NCT00945555|DRUG|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
47942429|NCT00900601|PROCEDURE|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
47942430|NCT01230710|DRUG|Erlotinib|Erlotinib was supplied as tablets.
47942431|NCT01012076|BEHAVIORAL|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
47942432|NCT01697358|DEVICE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
47942433|NCT01697358|DRUG|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
47942434|NCT03126877|DRUG|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
48474286|NCT05425342|DEVICE|Smartwatch ECG|Self-recorded 9-lead smartwatch ECGs
48474287|NCT00250133|PROCEDURE|Blood draws|
48474288|NCT04292015|DIAGNOSTIC_TEST|Optos ultra-widefield retinal imaging (Optos California)|retinal imaging device
47942435|NCT03126877|DEVICE|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
48291469|NCT04224558|DRUG|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
48291470|NCT04224558|DRUG|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
48291471|NCT04224558|DRUG|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
48474289|NCT04968106|DRUG|Doxorubicin|Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
48474290|NCT04968106|DRUG|Ifosfamide|Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
48474291|NCT04968106|DRUG|INCMGA00012|Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
48474292|NCT02613286|PROCEDURE|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
47942436|NCT02640716|BEHAVIORAL|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
48474293|NCT02613286|PROCEDURE|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
48474294|NCT02288208|DRUG|Antiviral Therapy (tenofovir or entecavir)|
48474295|NCT02288208|DRUG|Birinapant|
47942437|NCT02640716|BEHAVIORAL|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
47942438|NCT02378675|OTHER|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
48291472|NCT04224558|DRUG|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
48291473|NCT04224558|DRUG|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
48291474|NCT04224558|BIOLOGICAL|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
48291475|NCT04224558|DRUG|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
48474296|NCT02288208|DRUG|Placebo (for birinapant)|
48474297|NCT02682550|PROCEDURE|blood drawing|blood drawing
48474298|NCT04108832|DRUG|TCM OA2|Usage: 3g twice daily
48474299|NCT04108832|DRUG|PLACEBO|Usage: 3g twice daily
48474300|NCT05780996|DEVICE|QMODE +|Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)
48474301|NCT05780996|DEVICE|QMODE|Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
48291476|NCT00252863|DRUG|Symbicort, used twice daily (b.i.d) and as needed (prn)|
48474302|NCT01613794|DRUG|Rosuvastatin|20 mg od
48474303|NCT05016687|DRUG|CUR-N399|CUR-N399 will be administered as oral capsules.
48474304|NCT05016687|DRUG|Placebo|Placebo capsules matching CUR-N399 will administered.
48474305|NCT05472155|DEVICE|Bulb syringe|Suctioning with a bulb syringe
48474306|NCT05472155|DEVICE|Suction catheter|Suctioned with a suction catheter
48474307|NCT06207630|DEVICE|Dressing Device|Use of a dress at the end of surgery in the operating room, making sure not to stick it on the openings of the chest drains.
48474308|NCT01873781|DRUG|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
48474309|NCT02805413|OTHER|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10...). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9...). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
47942439|NCT02040285|DRUG|Bisacodyl & PEG-CS|"the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
48291477|NCT00252863|DRUG|Budesonide Turbuhaler 200 µg|
48291478|NCT00252863|DRUG|Fluticasone Discus 250 µg|
48291479|NCT00252863|DRUG|Formoterol Turbuhaler 4.5 µg|
48291480|NCT00252863|DRUG|Terbutaline Turbuhaler 0.5 mg|
48291481|NCT00252863|DRUG|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
48291482|NCT00252863|DRUG|Salmeterol Discus 50 µg|
48291483|NCT00252863|DRUG|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
48291484|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 250/50 µg|
48631682|NCT03434509|OTHER|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
48631683|NCT00464529|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
47942440|NCT02040285|DRUG|Iopamidol|"the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet"
47942441|NCT01600807|DRUG|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
47942442|NCT01600807|DRUG|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
48631684|NCT01232842|GENETIC|cytogenetic analysis|
47942443|NCT02889692|DRUG|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
47942444|NCT02889692|DRUG|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
48102867|NCT02560818|OTHER|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
48291485|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 500/50 µg|
48291486|NCT00252863|DRUG|Theophylline 200 mg|
48291487|NCT00252863|DRUG|Theophylline 300 mg|
48291488|NCT00252863|DRUG|Singulair 10 mg|
48291489|NCT04176822|OTHER|Educational animated movie group|Watching educational animation movie which were designed by the researcher before operation for fear and pain.
48631685|NCT01232842|OTHER|HUMARA assay|
48631686|NCT01232842|OTHER|fluorescence activated cell sorting|
48291490|NCT04176822|OTHER|Documentary movie group|Watching documentary movie about trees before operation for fear and pain.
48291491|NCT05283707|BEHAVIORAL|Paula Method Exercises|The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
48291492|NCT03453060|DRUG|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
48291493|NCT03453060|DRUG|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
48291494|NCT03453060|DRUG|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
48291495|NCT03453060|DRUG|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
48291496|NCT03453060|OTHER|Placebo|Participants received a single intravenous dose of placebo.
48291497|NCT02062177|DRUG|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
48474310|NCT02447887|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
48474311|NCT02447887|DRUG|Pegylated IFN-alpha 2b|Weekly injection
48291498|NCT02062177|DRUG|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged \> 70.
48291499|NCT02502630|DEVICE|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
48291500|NCT05564624|OTHER|Fasting mimicking diet (FMD)|The ProLon(TM) Fasting Mimicking Diet regimen is a meal replacement plan that mimics water only fasting. It consists of 100% natural ingredients, which are generally regarded as safe (GRAS). It is comprised of bars, soups, and beverages aiming to achieve consistent and effective short-term calorie restriction, while providing adequate micronutrients. The very low protein and very low sugar content are essential characteristics of the diet. Complex carbohydrates and polyunsaturated fatty acids are its main components.
48631687|NCT01232842|OTHER|laboratory biomarker analysis|
48631688|NCT01060111|DRUG|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
48631689|NCT01060111|DRUG|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
48474312|NCT01140737|DRUG|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
48474313|NCT00459823|DRUG|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
48474314|NCT04511572|PROCEDURE|embolization of the middle meningeal artery|The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed \[31\]. The procedure is performed under local anesthesia.
48474315|NCT02540837|DRUG|Bupivacaine|Obturator nerve block
48631690|NCT01060111|DRUG|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
48291501|NCT03534271|DEVICE|iPhone with Kenek Edge and Samsung S8|Smartphones with pulse oximetry and heart rate monitoring capabilities
48291502|NCT03830138|GENETIC|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
48291503|NCT01154725|BEHAVIORAL|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
48474316|NCT02540837|DRUG|Saline|Obturator nerve block with saline(placebo)
48631691|NCT02102828|DEVICE|extended compression|Home use of extended compression therapy and aspirin
48631692|NCT02102828|OTHER|Aspirin|standard therapy of aspirin
48631693|NCT02907827|OTHER|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
48631694|NCT03745469|DEVICE|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
48474317|NCT05860387|DIAGNOSTIC_TEST|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
48474318|NCT01388452|DEVICE|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
48102868|NCT02560818|OTHER|use of a previous blood collection for patients|
48102869|NCT01979913|DRUG|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
48102870|NCT04702503|DRUG|WP1220|Topical administration 2x daily for 84 consecutive days
48631695|NCT03057327|BEHAVIORAL|Improve awareness of checking moles|"Intervention:~1. Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~2. Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
48474319|NCT02972515|BEHAVIORAL|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
48474320|NCT02972515|DEVICE|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
48474321|NCT03345758|OTHER|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
48474322|NCT05008562|OTHER|COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|there is no interventions to the patients.
48631696|NCT03057327|OTHER|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
48631697|NCT03949231|DRUG|PD1/PDL1 inhibitor|Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.
48631698|NCT03904186|BEHAVIORAL|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
48631699|NCT03904186|BEHAVIORAL|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
48631700|NCT05399355|DEVICE|Active Pulsed Shortwave Treatment with BioElectronics Model 088|Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088
48631701|NCT05399355|DEVICE|Sham Treatment|Application of 7-30 days of a nonfunctional sham device(s)
48474323|NCT01473147|DRUG|Exenatide|Exenatide 5 microgram bid sc.
48631702|NCT03050489|PROCEDURE|On-Pump CABG.|Standard On-Pump CABG.
48474324|NCT01473147|DRUG|Normal saline|Normal saline 2 u bid sc.
48474325|NCT03001024|BEHAVIORAL|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
48474326|NCT03001024|BEHAVIORAL|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
48474327|NCT00004344|DRUG|leuprolide|
48474328|NCT00004344|DRUG|testosterone|
48102871|NCT03055767|DRUG|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
47942445|NCT02889692|DRUG|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
47942446|NCT02889692|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
47942447|NCT02889692|DRUG|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
47942448|NCT02889692|DRUG|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
47942449|NCT02889692|DRUG|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
48474329|NCT02898701|BEHAVIORAL|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
48474330|NCT05332886|BEHAVIORAL|MetaHealth Group|Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.
48631703|NCT03050489|PROCEDURE|Off-Pump CABG.|Standard Off-Pump CABG.
48631704|NCT03050489|PROCEDURE|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
47942450|NCT03162731|BIOLOGICAL|Nivolumab|Given IV
47942451|NCT03162731|BIOLOGICAL|Ipilimumab|Given IV
47942452|NCT03162731|RADIATION|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
47942453|NCT03162731|RADIATION|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
48291504|NCT01154725|BEHAVIORAL|habitual patient education|habitual patient education
48474331|NCT05332886|BEHAVIORAL|MobileHealth Group|The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
48474332|NCT00351286|DRUG|L-citrulline tablets, 1000 mg|
48474333|NCT00351286|DRUG|Placebo tablets matching L-citrulline tablets|
48474334|NCT00351286|DRUG|Background simvastatin at a stable dose of 40 mg qHS|
48474335|NCT02770144|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
47942454|NCT00953381|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
48474336|NCT02770144|BEHAVIORAL|Access to Referral to Social Services|
48631705|NCT02468375|DRUG|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
48631706|NCT03475043|BEHAVIORAL|Auditory training: temporal cues|Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
48631707|NCT04717180|BEHAVIORAL|aphasia rehabilitation using software program or conventional therapy|Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
47942455|NCT00953381|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
47942456|NCT00953381|DRUG|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
47942457|NCT00953381|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
47942458|NCT05152563|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8
47942459|NCT05152563|OTHER|Placebo|Placebo
47942460|NCT05998278|PROCEDURE|Personalized Optimization of Systematic Prostate Biopsy|Login the model based on our previous study (https://daringsky.shinyapps.io/prediction_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
48474337|NCT02958930|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
48474338|NCT01785615|DRUG|Atorvastatin|80mg
48474339|NCT01785615|OTHER|Placebo|80mg
48474340|NCT03559725|OTHER|VLN menthol cigarettes (A)|0.4mg nicotine / g tobacco king size filter menthol cigarette
48474341|NCT03559725|OTHER|Usual Brand Menthol Cigarettes (B)|Usual brand king size menthol cigarettes
47942461|NCT00135044|PROCEDURE|intravenous taurine in nutritional supplement|
47942462|NCT00410228|DRUG|AHT956|
48102872|NCT03055767|OTHER|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
48102873|NCT02959957|DRUG|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
48474342|NCT03559725|DRUG|Nicotine gum (C)|4 mg nicotine gum
48474343|NCT04550741|OTHER|telerehabilitation|After obtaining consent, the volunteers will be included in the study at the start of the 4th week and randomized into two arms: Experimental and Control group
47942463|NCT06202417|DRUG|Fruquintinib|an oral tyrosine kinase inhibitor (TKI)
47942464|NCT04343729|DRUG|Methylprednisolone Sodium Succinate|injectable solution at a dose of 0.5mg/kg
47942465|NCT04343729|DRUG|Placebo solution|injectable saline solution
47942466|NCT00348244|DRUG|Ketorolac, Prednisolone Acetate|
47942467|NCT01737450|DRUG|BKM120|
47942468|NCT02722525|PROCEDURE|Magnetic Resonance Imaging|Undergo treadmill stress CMR
47942469|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete treadmill exercise
47942470|NCT02722525|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
47942471|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete resistive lower extremity exercise
48102874|NCT02959957|DRUG|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
47942472|NCT02722525|PROCEDURE|Spectroscopy|Undergo skeletal muscle PMRS
48102875|NCT05356403|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
48102876|NCT05356403|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
48102877|NCT02966743|DRUG|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
48102878|NCT02966743|DRUG|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
48474344|NCT05783037|OTHER|New Organic Infant Formula|New organic infant formula fed daily ad libitum
48474345|NCT05783037|OTHER|Commercial Organic Infant Formula|Commercially available organic infant formula fed daily ad libitum
48474346|NCT03558139|DRUG|Magrolimab|Administered intravenously
48474347|NCT03558139|DRUG|Avelumab|Administered intravenously
48474348|NCT01017094|DRUG|silversulfadiazine|apply once a day
48474349|NCT05583877|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
48474350|NCT05583877|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
48474351|NCT00225563|DEVICE|Electronic Health Record|e-prescribing methods
48474352|NCT00627081|DRUG|remifentanil|dosage
48474353|NCT01074008|DRUG|ABT-450|50 mg capsules co-administered with ritonavir
48474354|NCT01074008|DRUG|ABT-072|50 mg tablet
48474355|NCT01074008|DRUG|ABT-333|400 mg tablet
48474356|NCT01074008|DRUG|Ritonavir|100 mg capsules co-administered with ABT-450
47942473|NCT02722525|OTHER|Laboratory Biomarker Analysis|Correlative studies
47942474|NCT02460458|DRUG|Von Willebrand Factor|Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
48631708|NCT06433011|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
48631709|NCT06433011|DRUG|r-tPA|Pulse spray and infusion
48631710|NCT02319083|PROCEDURE|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
48631711|NCT04694638|OTHER|Body position change|combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
48631712|NCT03338023|DRUG|LY2963016|Administered SC
48291505|NCT00519623|OTHER|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
48291506|NCT00639067|DEVICE|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
48291507|NCT00083824|DRUG|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
48291508|NCT00083824|DRUG|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
48474357|NCT01074008|DRUG|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
48291509|NCT00083824|DRUG|Placebo|2 pills/day QID for 3 years
48474358|NCT01074008|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
48474359|NCT01074008|OTHER|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
48474360|NCT04003818|DRUG|TEICOPLANIN|Pharmaceutical form:solution for oral administration Route of administration: oral
48291510|NCT04391868|DRUG|Viagra Tablet|50 mg tablet on Day 1 of each period
48291511|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
48291512|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
48291513|NCT06673004|PROCEDURE|Ovarian tissue allo-transplantation|Participants will receive donor ovarian tissue with immunosuppression
48474361|NCT03566238|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
48291514|NCT02035072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2
48474362|NCT03566238|DRUG|Placebo|Placebo identical in appearance to active drug (A4250).
48631713|NCT03338023|DRUG|Lantus®|Administered SC
48631714|NCT03338023|DRUG|Insulin Lispro|Administered SC
48631715|NCT00411541|DRUG|vincristine|
48631716|NCT00411541|DRUG|dexamethasone|
48631717|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Tobramycin Sulfate|Seven-day local antibiotic irrigation with tobramycin sulfate via the VT-X7 Knee or Hip Spacer.
47942475|NCT05080127|COMBINATION_PRODUCT|application of the allergenic food|a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
48291515|NCT02035072|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2
48291516|NCT02035072|RADIATION|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
48291517|NCT03096028|OTHER|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18\&28 weeks of pregnancy is the primary exposure of interest
48291518|NCT06659744|DRUG|New use of semaglutide injection|New use of semaglutide injection dispensing claim is used as the exposure.
48291519|NCT06659744|DRUG|New initiation of sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
48631718|NCT04662632|DRUG|Standard of Care|Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
48631719|NCT04662632|PROCEDURE|Two-stage exchange arthroplasty|Stage 1 consists of surgical removal of the infected prosthesis, debridement, and implantation of a temporary spacer. Stage 2 surgery consists of explantation of the temporary spacer, debridement, and implantation of a permanent prosthesis, followed by systemic administration of postoperative antibiotics for 42 days (inclusive) to 90 days (inclusive).
48631720|NCT04662632|COMBINATION_PRODUCT|VT-X7 Treatment System with Vancomycin Hydrochloride|Seven-day local antibiotic irrigation with vancomycin hydrochloride via the VT-X7 Knee or Hip Spacer.
48631721|NCT00485849|DRUG|Atomoxetine Hydrochloride|
48631722|NCT02857959|DRUG|Benzathine Penicillin G|
48631723|NCT00508300|PROCEDURE|Epidural analgesia|Thoracic epidural analgesia until day 2
48631724|NCT00508300|PROCEDURE|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
48631725|NCT01521364|DRUG|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
47942476|NCT00799110|DRUG|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
47942477|NCT00799110|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
48291520|NCT02224846|DRUG|Tadalafil|Administered orally
48474363|NCT00030641|BIOLOGICAL|oblimersen sodium|
47942478|NCT00799110|DRUG|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
48291521|NCT00545818|DEVICE|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
48291522|NCT00545818|DEVICE|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
48474364|NCT00030641|DRUG|docetaxel|
48474365|NCT06616896|DEVICE|vibration|Each participant will randomly receive four different vibration conditions (2 frequencies × 2 vibration modes = 4 conditions) in a different order. Considering that the current research range of local vibration frequency is 10 to 150 Hz the frequencies with low and high frequencies (30/60Hz) will be selected. The location chosen for this study is the quadriceps muscle belly. Two-minute vibrations will improve muscle strength without any fatigue side effects. Two vibration modes include providing a two-minute continuous vibration intervention and only providing vibration during the rest position before executing the functional test.
48474366|NCT02246088|PROCEDURE|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
48474367|NCT02246088|PROCEDURE|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
48474368|NCT05962268|OTHER|Video based education|The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
48474369|NCT05962268|OTHER|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
48631726|NCT04723368|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=5 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 14 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
48631727|NCT03782103|DRUG|ZuraPrep Clear Solution|Apply topically.
48631728|NCT03782103|DRUG|ChloraPrep|Apply topically.
48631729|NCT03782103|DRUG|ZuraPrep Vehicle|Apply topically.
48631730|NCT03120923|DRUG|Lidocaine 3 cc|
48631731|NCT03120923|DRUG|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
48631732|NCT03120923|DRUG|Triamcinolone Acetonide|
48631733|NCT04583826|DEVICE|CAVA|CAVA is a medical device containing 5 face-mounted ECG electrodes which are used to record the movement of the eyes.
48631734|NCT04624997|OTHER|biological sample|biological sample
48631735|NCT03737032|DEVICE|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
48631736|NCT03737032|DEVICE|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
47942479|NCT00402142|BIOLOGICAL|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
47942480|NCT00402142|BIOLOGICAL|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
47942481|NCT00402142|BIOLOGICAL|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
47942482|NCT00402142|BIOLOGICAL|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
47942483|NCT00402142|BIOLOGICAL|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
48291523|NCT05096169|DRUG|Clomiphene Citrate 25mg|clomiphene citrate at a dose of 25mg daily
48291524|NCT05096169|DRUG|Clomiphene Citrate 50mg|clomiphene citrate at a dose of 50mg every other day
48102879|NCT00580073|DRUG|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
48631737|NCT03737032|DEVICE|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
48631738|NCT01011296|DRUG|PF-04427429|Single 0.2mg dose of intravenous infusion
48631739|NCT01011296|DRUG|PF-04427429|Single 1mg dose of intravenous infusion
48291525|NCT04910412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
47942484|NCT03491306|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
48291526|NCT04567836|OTHER|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
48474370|NCT02012231|DRUG|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
48474371|NCT02719704|BEHAVIORAL|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
48631740|NCT01011296|DRUG|PF-04427429|Single 3 mg dose of intravenous infusion
48631741|NCT02569242|DRUG|Nivolumab|
48631742|NCT02569242|DRUG|Docetaxel/Paclitaxel|
48102880|NCT00580073|DRUG|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
48102881|NCT05599399|DIETARY_SUPPLEMENT|Gum acacia|25 grams of gum acacia powder is administered on daily-basis
48291527|NCT02439385|DRUG|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
48291528|NCT02439385|DIETARY_SUPPLEMENT|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
48631743|NCT01694394|DEVICE|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
48631744|NCT02998099|DRUG|Rivipansel|A single dose of IV rivipansel over 20 minutes.
48631745|NCT01801969|OTHER|Rehabilitation service|"* Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~* Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
48631746|NCT04853290|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
48291529|NCT00806117|RADIATION|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~* Lateral: 2 cm lateral to the bony margin of the pelvis~* Superior: Between L5 and S1~* Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
48631747|NCT04853290|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by the registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture protocol instituted in the hospital where the study will be conducted
48631748|NCT05890586|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
48291530|NCT00806117|OTHER|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
48291531|NCT00806117|OTHER|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135\~175mg/m2 over 3 hours Cisplatin 60\~75mg/m2
48291532|NCT05734872|DEVICE|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
48291533|NCT05734872|OTHER|Routine mental health course training|Conduct mental health education for patients by making a speech.
48291534|NCT01417286|RADIATION|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
48291535|NCT02412007|OTHER|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing"
48291536|NCT05569577|DRUG|Additional hCG injection|An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
48291537|NCT05569577|DRUG|estrogen and dydrogesterone|estrogen and dydrogesterone
48291538|NCT03725046|OTHER|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
48474372|NCT02719704|BEHAVIORAL|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
48631749|NCT05890586|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
48631750|NCT02369250|DRUG|Rosuvastatin|Rosuvastatin, is a statin group of drug.
48631751|NCT02369250|BIOLOGICAL|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
48631752|NCT00106535|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
48631753|NCT00106535|DRUG|Placebo|IV/month
48291539|NCT06513767|DEVICE|Zirconia Dental Ceramics|This investigation was conducted by enrolling subjects who met the enrolment criteria, using the investigational device (Zirconia Dental Ceramics) to perform dental prosthesess.
48291540|NCT00003995|BIOLOGICAL|trastuzumab|
48291541|NCT00003995|DRUG|irinotecan hydrochloride|
48291542|NCT05780840|OTHER|Dihydroxyacetone|Application of 10% dihydroxyacetone (2 mg per square cm skin)
48291543|NCT05780840|OTHER|Placebo|Application of lotion to the skin (2 mg per square cm skin)
48291544|NCT06508567|RADIATION|High Dose Rate Brachytherapy|2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).
48291545|NCT01330381|DRUG|prucalopride|"prucalopride~* subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~* subjects with weight \>50 kg: prucalopride 2 mg tablet once daily"
48291546|NCT01330381|DRUG|Placebo|Matching oral solution or oral tablets given once daily
48291547|NCT01330381|DRUG|PEG 4000|
48291548|NCT05650229|DRUG|KL1333|Twice daily
48291549|NCT05650229|DRUG|Placebo|Twice daily
48291550|NCT04111367|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
48291551|NCT04111367|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
48291552|NCT00564707|BEHAVIORAL|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
48291553|NCT00564707|PROCEDURE|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
48631754|NCT00106535|DRUG|Methotrexate|10-25 mg/week
48291554|NCT02990884|DRUG|ketamine|
48291555|NCT00234117|DRUG|Rabeprazole|
48291556|NCT01915875|OTHER|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
48618083|NCT05367999|DIAGNOSTIC_TEST|initial Paroxysmal Event Profile|The initial Paroxysmal Event Profile (iPEP) was derived from the paroxysmal event profile (PEP) and paroxysmal event observer (PEO) to provide a diagnostic tool aiming to differentiate between the most common underlying reasons for TLOC presentations: syncope, epilepsy, and dissociative seizures. The iPEP is a 35-item questionnaire developed from the PEP and PEO.5,25 The 5-point frequency scales used in response to each symptom in the PEP and PEO have been replaced with a binary 'present'/'not present' classification in recognition of the fact that the target patient group may have experienced only one or a few episodes of TLOC.
48618084|NCT05486169|PROCEDURE|Sleeve Gastrectomy|surgery of laparoscopic sleeve gastrectomy
47942485|NCT03491306|OTHER|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
47942486|NCT00736879|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
47942487|NCT00736879|DRUG|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
47942488|NCT02854176|PROCEDURE|Somatosensory electrical stimulation|
47942489|NCT02854176|PROCEDURE|Control|
48291557|NCT06292481|OTHER|Brunnstorm movement therapy|this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
48291558|NCT06292481|OTHER|Combined Brunnstorm Movement therapy and low level laser therapy|this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
48291559|NCT02441803|DRUG|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
48291560|NCT02441803|DRUG|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
48291561|NCT02441803|DRUG|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
48291562|NCT02441803|RADIATION|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
48631755|NCT04784403|DIAGNOSTIC_TEST|SARS-CoV-2 PCR and serology tests|Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
48631756|NCT05140980|OTHER|Data collection|evaluation of women's knowledge concerning sexuality
48631757|NCT05338580|DRUG|TJ271 Injection in Combination with Pembrolizumab|TJ271 Injection: 0.9% sodium chloride solution Pembrolizumab: 0.9% sodium chloride solution or 5% glucose solution
48291563|NCT02441803|DRUG|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
48631758|NCT03952741|BEHAVIORAL|Physical Therapy|
48474373|NCT05484791|OTHER|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
48291564|NCT02441803|BIOLOGICAL|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or \>3.0 X 108 marrow mononuclear cells/kg if bone marrow.
48291565|NCT02441803|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
48291566|NCT02441803|DRUG|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
48291567|NCT02441803|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
48474374|NCT01119586|GENETIC|DNA analysis|
48474375|NCT01119586|GENETIC|genetic linkage analysis|
48474376|NCT01119586|GENETIC|microarray analysis|
48474377|NCT01119586|GENETIC|nucleic acid sequencing|
48474378|NCT01119586|GENETIC|polymerase chain reaction|
48474379|NCT01119586|GENETIC|polymorphism analysis|
48474380|NCT01119586|OTHER|laboratory biomarker analysis|
48618085|NCT00941928|DRUG|Epratuzumab|360 mg/m\^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
48631759|NCT03767894|DEVICE|EMG Band|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.
48631760|NCT03767894|DEVICE|Shoulder harness|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
48631761|NCT02979158|PROCEDURE|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
48631762|NCT02979158|PROCEDURE|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
48631763|NCT02569905|DRUG|parecoxib sodium|parecoxib sodium 40mg
48631764|NCT02569905|DRUG|flurbiprofen|flurbiprofen 50mg
48631765|NCT02569905|DRUG|saline|normal saline
48291568|NCT02441803|DRUG|Decitabine|20 mg/m2 by vein on Days 1 - 5.
48291569|NCT02441803|DRUG|Cytarabine|1 g/m2 by vein on Days 6 - 10.
48291570|NCT02441803|DRUG|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
48291571|NCT05906446|OTHER|Multicomponent (Exercise + Protein Supplementation)|"* Exercises selected from a pre-specified list, reassessed weekly~* Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~* Participants will also be offered a protein supplement within 30 min of exercise.~* Sessions will be supervised"
48291572|NCT01589094|DRUG|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
48474381|NCT05420116|BEHAVIORAL|Cerdanya on Fitness|The intervention lasts 9 months. The participants will carry out group activities and will be followed individually by the different interdisciplinary professionals. Goals will be set for each visit. Before and after the training there will be an assessment of physical exercise, nutritional and positive mental health habits.
48474382|NCT06309914|DIETARY_SUPPLEMENT|Placebo|Subjects will consume one capsule of the Placebo twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
48474383|NCT06309914|DIETARY_SUPPLEMENT|Enovita Grape Seed Extract|Subjects will consume one capsule of Enovita twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
48474384|NCT06309914|DIETARY_SUPPLEMENT|Mirtoselect Bilberry Extract|Subjects will consume one capsule of Mirtoselect twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
48474385|NCT06309914|DIETARY_SUPPLEMENT|Virtiva Plus Ginko Biloba Extract|Subjects will consume one capsule of Virtiva Plus twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
48474386|NCT01537731|PROCEDURE|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
48474387|NCT05534048|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
48474388|NCT05534048|BIOLOGICAL|Comirnaty®|0.45 mL concentrate in a 2 mL clear multidose vial (type I glass) with a stopper (synthetic Bromo-butyl rubber) and a purple flip-off plastic cap with aluminum seal. Each vial contains 6 doses.
48474389|NCT01488240|PROCEDURE|pulsed dye laser|laser energy
48474390|NCT05116137|BEHAVIORAL|Circuit-based resistance exercise (CRT)|CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
48474391|NCT03700827|OTHER|Resistance Training|High-intensity Resistance Training Group
48474392|NCT03700827|OTHER|Aerobic Training|Aerobic Interval Training Group
48474393|NCT05120687|DRUG|noncorticosteroid systemic immunomodulatory therapy (NCSIT)|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
48474394|NCT00456482|DRUG|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
48291573|NCT01717612|DRUG|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
48291574|NCT01717612|DRUG|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
48291575|NCT02685150|DEVICE|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
48291576|NCT02685150|DRUG|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
48291577|NCT02685150|OTHER|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
48291578|NCT02599467|OTHER|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
48291579|NCT06585930|BIOLOGICAL|Blood sample|Additional 8.1 ml blood sample
48474395|NCT00456482|DRUG|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
48631766|NCT02370394|BEHAVIORAL|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
48291580|NCT05807828|PROCEDURE|VR simulation on basic THA skills|The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup and stem implantation before actual implantation.
48291581|NCT06316323|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
48474396|NCT01938352|BIOLOGICAL|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
48631767|NCT03868800|OTHER|SDM-DC|The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
48631768|NCT03777176|DRUG|Dasiglucagon|Glucagon analog
47942490|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
47942491|NCT00760214|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
47942492|NCT00760214|DRUG|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
47942493|NCT01516229|DRUG|somatropin|Prescription of somatropin at the discretion of the physician
48291582|NCT06316323|DRUG|Sodium fluoride|Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
48291583|NCT02732158|OTHER|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
47942494|NCT02173184|BIOLOGICAL|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
48291584|NCT04265534|DRUG|Telaglenastat|Oral Glutaminase Inhibitor
48474397|NCT01938352|BIOLOGICAL|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
48474398|NCT03788356|DEVICE|Inspiratory muscle training|Inspiratory muscle training with a device
48474399|NCT03788356|OTHER|Diaphragmatic breathing|Diaphragmatic breathing exercise
48474400|NCT03630094|DRUG|FEP-ZID|A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
48291585|NCT04265534|DRUG|Carboplatin Chemotherapy|IV infusion
47942495|NCT02173184|BIOLOGICAL|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
48291586|NCT04265534|DRUG|Pemetrexed Chemotherapy|IV infusion
48291587|NCT04265534|BIOLOGICAL|Pembrolizumab Immunotherapy|IV infusion
48291588|NCT04265534|DRUG|Placebo|Oral placebo
48474401|NCT00503230|BEHAVIORAL|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
48474402|NCT00503230|BEHAVIORAL|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
48474403|NCT02665884|OTHER|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
48474404|NCT02154802|BEHAVIORAL|video: community member|
48474405|NCT02154802|BEHAVIORAL|video: physician|
48474406|NCT02154802|BEHAVIORAL|video: choice of video|
48631769|NCT03777176|OTHER|Standard of Care|Standard of care according to site and/or country
48631770|NCT05610267|DEVICE|Retrospective chart review|The retrospective chart review will include the full consecutive series of patients between 22 years and 80 years old who underwent abdominal wall reconstruction for achart hernia with Integra Gentrix® Surgical Matrix during the time period between November 1, 2017, and present (90 days prior to the start of data collection).
47942496|NCT04885946|OTHER|Fecal microbiota transplantion (FMT)|Single donor, fecal microbiota transplantion (FMT) from healthy human donors.
47942497|NCT04885946|OTHER|Placebo|Food coloring, water, glycerol
47942498|NCT02779465|DRUG|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
47942499|NCT02923427|DEVICE|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
47942500|NCT02923427|DEVICE|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
48102882|NCT04163224|DEVICE|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
48102883|NCT02742896|OTHER|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
48102884|NCT05407142|BIOLOGICAL|"CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS"|"Subgroup 1 - 2100 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly at a dose of 0.5 ml and revaccinated at 6 months with one dose of the KoviVac vaccine (0.5 ml).~Subgroup 2 - 1400 volunteers who will be vaccinated with CoviVac vaccine three times at intervals of 21 days intramuscularly at a dose of 0.5 ml."
48474407|NCT03398590|BEHAVIORAL|self-regulation theory-based mHealth behavior intervention|Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
48474408|NCT01629537|PROCEDURE|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
48618086|NCT00941928|DRUG|Fludarabine|25 mg/m\^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
48618087|NCT00941928|DRUG|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
48618088|NCT00941928|DRUG|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
47942501|NCT03137030|DRUG|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
47942502|NCT03137030|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
47942503|NCT00688727|BEHAVIORAL|CBT|CBT, up to 12 sessions.
47942504|NCT00688727|BEHAVIORAL|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
47942505|NCT01483807|BEHAVIORAL|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
47942506|NCT01483807|BEHAVIORAL|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
47942507|NCT01991106|BEHAVIORAL|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
47942508|NCT01991106|BEHAVIORAL|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
48102885|NCT05407142|OTHER|The data from volunteers from the control group|Official data on the number of Covid-19 cases during the study period among 3,500 unvaccinated individuals.
48474409|NCT01629537|PROCEDURE|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
48474410|NCT01212549|PROCEDURE|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
48474411|NCT01212549|PROCEDURE|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
48102886|NCT04270604|OTHER|Biological sample collection|Biological sample collection for biobanking and research
48102887|NCT04180267|DEVICE|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
48102888|NCT04709744|DRUG|Vitamin D|Impact of serum vit D level in SLE patients with COVID-19 disease on severity of infection, duration of COVID-19 disease course, fatigue development as a complication for both SLE and COVID-19 and assess impact of prior chloroquine on COVID-19 disease outcomes
48102889|NCT04709744|DIAGNOSTIC_TEST|ELISA|Measure vitamin D level
48102890|NCT02165605|DRUG|HylaCare|cream
48102891|NCT02165605|DRUG|Placebo|placebo
48102892|NCT03709446|DRUG|Leflunomide|Single agent leflunomide
48102893|NCT00268606|BEHAVIORAL|cognitive-behavioral therapy|
48102894|NCT01550978|DEVICE|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
48102895|NCT01282840|DRUG|Tolterodine SR|Tolterodine SR 4 mg qd
48102896|NCT04814043|DRUG|PD-1 inhibitor|systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion
48102897|NCT05547750|DRUG|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
48102898|NCT05547750|DRUG|Placebo|Similar-looking placebo tablets
48474412|NCT02992613|PROCEDURE|total knee arthroplasty with ultra-congruent (UC) insert|
48474413|NCT02992613|PROCEDURE|total knee arthroplasty with posterior-stabilized (PS) insert|
48474414|NCT04046549|DRUG|Belatacept|Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.
48474415|NCT04046549|DRUG|VIB4920|"Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48."
48102899|NCT03702543|BEHAVIORAL|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
48102900|NCT04524832|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 16 weeks
48102901|NCT01916889|OTHER|RACY test|
48102902|NCT01469949|OTHER|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
48102903|NCT06335836|BEHAVIORAL|social isolation|social isolation (0≤LSNS-6≤12)
48102904|NCT03089346|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
48102905|NCT03089346|DIAGNOSTIC_TEST|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
48618089|NCT00941928|PROCEDURE|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
48102906|NCT04330469|PROCEDURE|Periodontal therapy|"Treatment will be performed by a periodontist.~1. Intensive removal of subgingival and supragingival calculus and plaque biofilm by scaling, root-planing and polishing. The procedures will be carried out with the use of hand scalers and a piezoelectric ultrasonic scaler with universal tips. Disclosing solution will be used to visualize the plaque for the clinician.~2. One to four sessions of subgingival scaling and root planing by quadrant, under local anesthesia as may be deemed necessary during the study period.~3. Subgingival irrigation using an antiseptic mouth rinse (chlorhexidine 0.12%).~4. Polishing of the coronal and radicular surfaces of the teeth."
48102907|NCT04330469|PROCEDURE|Oral hygiene advice|Oral hygiene advised by Periodontist
48102908|NCT01472536|BEHAVIORAL|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
48102909|NCT06632106|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
48474416|NCT04046549|DRUG|Thymoglobulin|"Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4."
48474417|NCT04046549|DRUG|Methylprednisolone|"Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit."
47942509|NCT01991106|DIETARY_SUPPLEMENT|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
47942510|NCT04608942|DEVICE|Jett Plasma Medical Lift|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
47942511|NCT04608942|PROCEDURE|Mechanical Debridement|Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
47942512|NCT02080858|DRUG|Ticagrelor + Apixaban + ASA|
47942513|NCT02080858|DRUG|Ticagrelor + Apixaban|
47942514|NCT05760573|BEHAVIORAL|Family Wellness Program (FWP)|The FWP will consist of the following general format: (1) 8 weekly 60-minute summer workshops; (2) 4 booster workshops throughout the year; and (3) 2-3 outreach text messages per week for 10 months.
47942515|NCT02780609|DRUG|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
47942516|NCT02780609|DRUG|Melphalan|Melphalan 100 mg/m\^2 IV over 30-45 minutes.
47942517|NCT02780609|DRUG|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
47942518|NCT02780609|PROCEDURE|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
47942519|NCT02780609|DRUG|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
47942520|NCT03911219|OTHER|eHealth system support for symptom management via CANKADO|Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.
47942521|NCT01468103|PROCEDURE|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
47942522|NCT01468103|PROCEDURE|Laser Iridotomy|alternative choice to surgical iridectomy
47942523|NCT02245204|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
47942524|NCT01765660|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
47942525|NCT01765660|BIOLOGICAL|Non-mesenchymal stem cells|Other second line drugs are taken.
47942526|NCT00934258|DRUG|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
47942527|NCT00934258|GENETIC|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
47942528|NCT00606944|BEHAVIORAL|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
47942529|NCT02875925|OTHER|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
48291589|NCT04265534|DIETARY_SUPPLEMENT|Folic acid 400 -1000 μg|Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
47942530|NCT04884932|DEVICE|30 kHz stimulation (Myomed 932, Enraf-Nonius)|"A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)"
47942531|NCT04884932|DEVICE|Sham stimulation (Myomed 932, Enraf-Nonius)|Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.
48291590|NCT04265534|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
48291591|NCT04265534|DRUG|Dexamethasone 4 mg|For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
48474418|NCT04699630|DRUG|U3-1402|All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.
48474419|NCT06404541|DRUG|Dexamethasone, tobramycin, netilimicin|Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
48474420|NCT05531682|OTHER|Placebo|Subjects will receive several injections of Placebo
48474421|NCT05531682|DRUG|HB0017|Subjects will receive HB0017 in different dosing regimens
48474422|NCT06093204|OTHER|Dietary evaluation|Comparative evaluation of the dietary consumption of ultraprocessed foods and ultraprocessed foods-derived compounds
48474423|NCT02863549|DEVICE|MitraClip in tricuspid valve|MitraClip in tricuspid valve
47942532|NCT01973543|BIOLOGICAL|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
48102910|NCT06632106|DRUG|Tyrosine kinase inhibitor (TKIs)|TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
48102911|NCT06632106|DRUG|Immune Checkpoint Inhibitors|ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
48291592|NCT01470339|DRUG|duloxetine|duloxetine 60mg once a day for 5 weeks
48291593|NCT06511609|PROCEDURE|double-flap technique（DFT）; double-tract reconstruction(DTR),|DFT (experiment group). Patients receive double flap technique after laparoscopic proximal gastrectomy. DTR (control group). Patients receive double-tract reconstruction after laparoscopic proximal gastrectomy.
48474424|NCT03245216|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
48474425|NCT03245216|BEHAVIORAL|rest|Seated rest before motor learning
48474426|NCT03245216|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
48474427|NCT00089076|BIOLOGICAL|ipilimumab|Given IV
48474428|NCT00089076|OTHER|laboratory biomarker analysis|Correlative studies
48631771|NCT05651737|BEHAVIORAL|Sui App (SRK)|"The Sui app contains the following chapters:~6 well-being chapters on: stress, sleep, resources throughout the day, chronic pain, emotion regulation, audio exercises 9 Swiss-specific information chapters on: housing, health (two sub-chapters), finances, asylum process, residence status, social integration, occupational integration, family reunification"
48631772|NCT00665886|DEVICE|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
48631773|NCT00665886|DEVICE|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
48474429|NCT05676983|OTHER|Spiky balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
47942533|NCT03723200|OTHER|Fibrinogen and blood products|Fibrinogen and blood products
47942534|NCT05386823|DRUG|HF1K16|HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
47942535|NCT05386823|DRUG|Placebo|Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
48102912|NCT01225939|DRUG|AZD8329|tablet
48102913|NCT01225939|DRUG|AZD8329|Solution
48102914|NCT06424977|DEVICE|Biomarker Targeted Stimulation (BTS)|Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.
48102915|NCT02306564|DRUG|Cabergoline|given to patients at high risk for OHSS
48474430|NCT05676983|OTHER|Pediatric neurodevelopmental therapy|Bobath therapy
48474431|NCT05676983|OTHER|smooth balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
48474432|NCT00883935|DRUG|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
48474433|NCT00883935|DRUG|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
48474434|NCT00883935|DRUG|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
48474435|NCT00883935|DRUG|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
48474436|NCT00384306|DRUG|prednisolone|
48618090|NCT00941928|DRUG|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
48618091|NCT03530293|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
48474437|NCT06378788|OTHER|Demographic information form|aims to collect basic demographic data( Age reported by years , weight and height will be combined to report Body Mass index (BMİ) in kg/m2, Smoking habit reported as smoker or non-smoker , Level of Education reported as illiterate, literate, Primary school, Middle school, High school, University or Post-graduate, Profession type, Significant medical records and Medications.
48474438|NCT06378788|DIAGNOSTIC_TEST|widespread pain index (WPI)|"The Widespread Pain Index is a 19-point checklist that assesses the presence of pain or tenderness (within the prior seven days) in 19 specific areas of the body; each affected area receives one point. The 19 regions on the WPI include the following:~Right and left jaw, Right and left shoulder girdle, Right and left upper arm, Right and left lower arm, Right and left hip/buttock Right and left upper leg Right and left lower leg Upper and lower back Neck Chest Abdomen A fibromyalgia diagnosis is confirmed if a WPI is ≥7 with an SS scale ≥5 OR a WPI range between 4-6 with an SS scale ≥ 9."
48474439|NCT06378788|DIAGNOSTIC_TEST|symptom severity scale (SSS)|SS scale score: Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The SS scale score sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.
48102916|NCT05777889|OTHER|Forward Looking InfraRed Camera|"Forward Looking InfraRed Camera:~1. We will use a FLIR T420 or T62101 camera with a resolution of 320\*240.~2. Each image will be captured perpendicularly with a 1-inch gap on all four sides.~3. A Myler blanket placed in the background will separate the feet from the background.~4. The camera will be normalized to a temperature range of 15°C to 40°C.~5. The images will be saved in radiometric JPEG format.~6. Once the images have been transferred to a computer, we will remove the background.~7. Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~8. The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~9. Those who improve by 30% or more are considered to have had a successful spinal cord stimulation."
48474440|NCT06378788|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
48618092|NCT03530293|DRUG|Placebo oral capsule|non-active dosage form
48618093|NCT00639509|BIOLOGICAL|cixutumumab|Given IV
48618094|NCT00639509|PROCEDURE|computed tomography|Undergo contrast-enhanced computed tomography
48102917|NCT04409210|BEHAVIORAL|Establishment of individual health records|Patients could upload self-test data (such as blood pressure, blood glucose, heart rate and weight) and medical institution examination data (such as blood lipids, ECG, echocardiography, etc.) through App. AND then the App can automatically generate health reports to reflect the dynamic changes of the data in the form of charts and whether the data is normal or not. It is convenient for patients to have a clear understanding of their health management, and if there are outliers, they can intervene in time.
48631774|NCT04799665|DIAGNOSTIC_TEST|Breast CT|This is a cross-sectional clinical study to determine the feasibility of breast CT for breast density assessment and association of CT-derived density measures with metabolic syndrome in overweight/obese Mexican-origin women in Southern Arizona. There is no intervention.
48631775|NCT00202995|DRUG|Glatiramer Acetate|20 mg s.c. daily
48102918|NCT04409210|BEHAVIORAL|Cardiovascular risk assessment|The China-PAR risk prediction tool can be used to stratify the 10-years atherosclerotic cardiovascular disease (ASCVD) risk. Those with predicted risks of \<5%, 5-10%, and ≥10% could be classified into categories of low-, moderate-, and high-risk for ASCVD, respectively. It is a risk prediction tool for Chinese developed by the team of Professor Gu Dongfeng of Fuwai Hospital of the Chinese Academy of Medical Sciences. When patients are aware of their risk of cardio-cerebrovascular diseases, it is helpful for patients to take the initiative to manage their cardio-cerebrovascular health.
47942536|NCT01482351|BEHAVIORAL|CPAP adherence intervention|Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.
47942537|NCT01482351|BEHAVIORAL|Attention control intervention|This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
47942538|NCT03557554|OTHER|Massage|A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
47942539|NCT05997472|DIAGNOSTIC_TEST|evaluation af mobility and balance|evaluation af mobility and balance Timed Up and Go Test Berg Balance Scale
47942540|NCT06136247|DIAGNOSTIC_TEST|Neurocognitive battery|The Penn Computerized Neurobehavioral Battery (CNB) consists of a series of cognitive tasks, measuring accuracy and speed of performance in major cognitive domains, including executive functions (i.e., abstraction, sustained attention, working memory), episodic memory (i.e., verbal, facial, and spatial memory), complex cognitive processing (i.e., language reasoning, nonverbal reasoning, spatial processing), social cognition (i.e., emotion identification, emotion intensity differentiation, age differentiation) and processing speed (i.e., sensorimotor and motor).
47942541|NCT06136247|DIAGNOSTIC_TEST|fNIRS|Functional near-infrared spectroscopy (fNIRS) is a noninvasive optical imaging technique that measures changes in oxygenated and deoxygenated hemoglobin (Hb) concentrations within the brain by means of their characteristic absorption spectra of the wavelengths range of 700-1000 nm \[35,36\].
47942542|NCT01302379|DRUG|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
47942543|NCT01302379|DRUG|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
47942544|NCT01302379|BEHAVIORAL|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
47942545|NCT01302379|BEHAVIORAL|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
47942546|NCT04360863|OTHER|Telephone survey|Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.
47942547|NCT02259218|OTHER|laboratory biomarker analysis|Correlative studies
48291594|NCT04959019|BEHAVIORAL|Supervised combined endurance and resistance training (CERT)|Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
48474441|NCT06378788|DIAGNOSTIC_TEST|Tender Point examination|Tender points are specific sites on the body that cause pain when pressed.. There are 9 pairs of tender points. Each pair has one point on each side of the body, for a total of 18 points.Prior to 2010, the diagnosis of fibromyalgia required at least 11 painful point of 18 but now tender points are no longer used as a diagnostic tool. The score will be reported as the number of tender points found with palpation.
47942548|NCT02531100|DEVICE|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
47942549|NCT02531100|OTHER|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
47942550|NCT04432337|PROCEDURE|The role of the activation of the NLRP3 inflammasome after cardiac surgery|Determine the effect on the inflammatory response post extracorporeal circulation mediated by the NLRP3 inflammasome, in patients after cardiac surgery
48474442|NCT06378788|OTHER|Muscle Architecture visualized with ultrasound|The three head of Quadratus femoris ( Vastus lateralis, Vastus Medialis and Rectus Femoris), Tibialis Anterior, the two heads of Gastrocnemius ( vastus Lateralis and vastus Medialis) ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.
48618095|NCT00639509|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
48631776|NCT00202995|DRUG|Betaseron|250 mg every other day
48102919|NCT04409210|BEHAVIORAL|Popularization of medical knowledge|Health education is divided into nine modules, such as introduction of cardio-cerebrovascular diseases, diet, exercise, sleep, psychology, medicine, cardiopulmonary resuscitation and cardiac self-rescue technology. The presentation of health education includes three modules: text, video and voice. Video and voice modules are more suitable for illiterates or people are inconvenient to read text. It mainly takes into account the fact that most of the high-risk population of cardio-cerebrovascular diseases are the elderly.
48631777|NCT00202995|DRUG|Rebif|44 ug 3 times a week
48631778|NCT03186924|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
48631779|NCT02227264|DRUG|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
48291595|NCT04959019|BEHAVIORAL|Delayed supervised combined endurance and resistance training (CERT)|After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
48291596|NCT02627950|DRUG|Morphinhydrochloricum|5 mg morphine intravenously
48291597|NCT02627950|DRUG|Metoclopramide|10 mg MCP intravenously
48291598|NCT02627950|DRUG|Ticagrelor|180 mg ticagrelor orally
48291599|NCT02627950|DRUG|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
48291600|NCT06077422|DRUG|bupivacaine liposome injectable suspension|Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
48291601|NCT06077422|DRUG|Bupivacaine Hydrochloride|Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
48291602|NCT05372705|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
48291603|NCT05000606|OTHER|A home visit program|A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
48291604|NCT02501356|DIETARY_SUPPLEMENT|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
48291605|NCT02501356|DIETARY_SUPPLEMENT|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
48291606|NCT01984112|DEVICE|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
48291607|NCT01984112|DEVICE|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
47942551|NCT05578703|PROCEDURE|Fundic Ablation Sequentially in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
48291608|NCT04893837|DEVICE|Standard care plus infrascans|Hourly infrascans to detect expanding intracranial hematomas
48291609|NCT01746602|DRUG|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
48291610|NCT01746602|DRUG|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
48291611|NCT01746602|DEVICE|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
48291612|NCT01746602|DEVICE|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
48291613|NCT01746602|DEVICE|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
48291614|NCT00358592|DEVICE|Mobius™ retractor|
48291615|NCT00358592|DEVICE|traditional metal retraction instruments|
48291616|NCT03049540|DRUG|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
48291617|NCT03049540|DRUG|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
48291618|NCT00004934|DRUG|carboplatin|
48291619|NCT00004934|DRUG|epirubicin hydrochloride|
48291620|NCT00004934|DRUG|paclitaxel|
48291621|NCT00004934|PROCEDURE|conventional surgery|
48291622|NCT02106208|OTHER|Cheese diet|
48291623|NCT02106208|OTHER|Butter diet|
48474443|NCT06378788|OTHER|Sarcopenia assessed by measuring isometric strengths of different parts of the body|Cervical Flexion (CF), Cervical Extension (CE), Right and Left Cervical Lateral Flexion (CLF R/L), Truncal flexion (TF), Truncal extension (TE), Shoulder flexion (SF), Shoulder extension (SE), Shoulder abduction (SAB), Shoulder internal rotation (SIR) and Shoulder external rotation (SER), Hip flexion (HF), Hip extension (HE), hip abduction (HAB), hip internal rotation (HIR), hip external rotation (HER), knee extension (KE), Knee Flexion (KF), Ankle Dorsiflexion (ADF) and Ankle Plantar flexion (APF) muscle strengths will be evaluated with hand held dynamometer
48291624|NCT02106208|OTHER|CHO diet|
48291625|NCT02106208|OTHER|MUFA diet|
48474444|NCT06378788|OTHER|Timed Up & Go (TUG)|The test will be used by investigators as a simple evaluative test used to measure participants functional mobility.
47942552|NCT05578703|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
47942553|NCT05578703|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
47942554|NCT01775462|DRUG|EDI200|3 or 10 mg/kg of EDI200
48291626|NCT02106208|OTHER|PUFA diet|
48291627|NCT05966701|DRUG|SSGJ-613|SSGJ-613 subcutaneous injection.
48291628|NCT05966701|DRUG|Placebo|Placebo subcutaneous injection.
48291629|NCT02725255|DIETARY_SUPPLEMENT|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
48474445|NCT05149924|DRUG|QL1012|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
48474446|NCT05149924|DRUG|Gonal-f ®|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
48474447|NCT05772572|OTHER|Questionnaires|"Questionnaires are completed only once and assess:~* recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~* psychiatric questionnaires for parents and patients on anxiety and depression~* behavior questionnaires for the parents and the patient: assessment of attachment~* questionnaires for the parents and the patient concerning the family context, the quality of life"
48474448|NCT05416099|PROCEDURE|laser|grid vs micropulse laser
48474449|NCT01004315|DRUG|KUC-7483|
48474450|NCT01004315|DRUG|Placebo|
48474451|NCT01004315|DRUG|Tolterodine|
48474452|NCT05095649|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of cluster of differentiation 25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.
48631780|NCT02227264|PROCEDURE|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
48631781|NCT02644811|DRUG|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
48631782|NCT02644811|DRUG|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
48631783|NCT02644811|PROCEDURE|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
48631784|NCT02644811|DRUG|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
48631785|NCT02644811|DRUG|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
48631786|NCT02644811|DEVICE|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
48631787|NCT02644811|DEVICE|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
48631788|NCT04055389|DRUG|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (\<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life \~4 days) at a weight-based dosage according to the following formula:~\[Desired level of AT (100%) - Subject level of AT (%)\] \* subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
48631789|NCT04055389|OTHER|Placebo|No study drug
48631790|NCT04623060|OTHER|Combination of Low-volume interval treadmill training and Resistance Training|"Low-volume interval training (LV-ITT) protocols included a 5 min warm-up (30%-50%VO2peak) up to 20min of LV-ITT and a 5 min cooling down (30%-50% VO2peak). The LV-ITT will repeat 60s bursts of fast treadmill walking at maximum tolerate speed (0% incline), alternate with pre-specified recovery periods about 4 minutes according to protocol. Each time the participants completed a burst successfully, treadmill speed will be increased by 0.1 mph for the next burst. The recovery periods will be 4 minutes. The intervention will be conducted for about 30 minutes.~Resistance training will be conducted by using a horizontal leg press machine. They are encouraged to focus on an explosive concentric movement and a controlled eccentric movement such that the time on each phase was in the ratio 1:2."
48631791|NCT05848375|PROCEDURE|Arthroscopic rotator cuff repair|The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.
47942555|NCT04000230|BEHAVIORAL|TCIT|"TCIT consists of the following:~* CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~* CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~* TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~* TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
48474453|NCT02339090|DRUG|Somavaratan|Somavaratan will be administered per dose and schedule specified in the arm description.
48474454|NCT02339090|DRUG|rhGH|rhGH will be administered per dose and schedule specified in the arm description.
48474455|NCT03631368|DRUG|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
48474456|NCT03554317|DRUG|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
48474457|NCT03554317|DRUG|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
48474458|NCT06073899|OTHER|Leg Extension Exercise|Participants will perform a concentric quadriceps contraction into terminal knee extension with weight equivalent to 65% of a1-repetition maximum.
48474459|NCT04066920|DRUG|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) \[ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 \], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
48474460|NCT01246713|DRUG|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
48291630|NCT02725255|DRUG|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
48474461|NCT01246713|DRUG|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
48474462|NCT05997940|DRUG|PENG block|The PENG block was performed with the patient in the supine position at preoperative waiting room. A curvilinear low-frequency ultrasound probe (2-5 MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22 gauge, 100 mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL
48631792|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.
48291631|NCT02725255|DIETARY_SUPPLEMENT|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
48291632|NCT02935881|DEVICE|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
48631793|NCT05848375|DRUG|naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)|Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
48631794|NCT05583058|OTHER|Hormone Overdose and Misuse|This is an observational study. Hormone Overdose and Misuse is an exposure.
48291633|NCT02935881|PROCEDURE|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
48291634|NCT01702012|DIETARY_SUPPLEMENT|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
48291635|NCT01702012|BEHAVIORAL|Group-Based Lifestyle Intervention|
48291636|NCT02886312|DEVICE|Supplemental Oxygen Delivery System|
48291637|NCT03205969|DEVICE|Functional mobile game|Functional mobile game for chemotherapy side effect education
48291638|NCT05728801|DIAGNOSTIC_TEST|Ageing|Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
48291639|NCT05176028|OTHER|conventional physiotherapy|For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.
48474463|NCT05530941|BEHAVIORAL|Online suicide prevention campaign|The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
48474464|NCT01987726|OTHER|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H\&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
48631795|NCT02545127|DRUG|Merotocin|Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
48631796|NCT02545127|DRUG|Placebo|Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
48291640|NCT05176028|OTHER|fascial release|Fascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the cervical, thoracolumbar and upper extremity areas until tissue loosening and releasing were felt.
48291641|NCT04245124|OTHER|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
47942556|NCT04000230|BEHAVIORAL|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
48291642|NCT04245124|OTHER|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
48291643|NCT04476771|BEHAVIORAL|Feliz-Mente (third generation psychotherapy)|The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
48291644|NCT03440112|DRUG|Clarithromycin (Not used as of 4/2020)|Clarithromycin (generic) capsule 250mg each
48291645|NCT03440112|DRUG|Placebo (Not used as of 4/2020)|Lactose in a gel capsule
48291646|NCT03440112|DRUG|Transdermal flumazenil (Added 4/2020)|Transdermal flumazenil 24mg/mL
47942557|NCT02312271|OTHER|enteral formula|standard tube feeding formulas
48291647|NCT03440112|DRUG|Placebo (Added 4/2020)|Transdermal placebo
48474465|NCT01987726|OTHER|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
48474466|NCT01205893|DEVICE|Neovasc Reducer|Implantation of the Reducer
48631797|NCT06093659|OTHER|Pulze device with heated tobacco sticks (Product A)|Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
47942558|NCT02804529|DEVICE|Veress needle|
47942559|NCT05553067|GENETIC|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.|Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.
47942560|NCT03022227|OTHER|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
47942561|NCT01338142|OTHER|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection"
47942562|NCT01338142|OTHER|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
48291648|NCT01713348|DEVICE|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
48291649|NCT01713348|DEVICE|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
48291650|NCT05221125|BEHAVIORAL|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
48291651|NCT06383403|DRUG|Elafibranor|Round and orange film coated tablet of 80 mg.
48291652|NCT06383403|OTHER|Placebo|Round and orange film coated tablet of placebo
48291653|NCT01220778|BEHAVIORAL|Exercise|
48291654|NCT00398528|DRUG|Glatiramer acetate, (Copaxone®)|
48291655|NCT00398528|DRUG|IFN-β-1a, (Avonex®)|
48631798|NCT06093659|OTHER|Pulze device with heated tobacco sticks (Product B)|Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
48631799|NCT06093659|OTHER|Pulze device with nicotine-infused heated herbal sticks (Product C)|Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
48631800|NCT06093659|OTHER|Pulze device with nicotine-infused heated herbal sticks (Product D)|Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
48291656|NCT05640986|BEHAVIORAL|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
48474467|NCT01205893|DEVICE|Control|Control - No device implanted
48474468|NCT00475917|DRUG|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
48474469|NCT00475917|DRUG|Gemcitabine|once-weekly 30-minute IV infusion
48631801|NCT06093659|OTHER|Conventional Cigarette (Product E)|Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.
48631802|NCT05096221|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
48631803|NCT05096221|GENETIC|placebo|Single IV infusion of matching placebo.
48291657|NCT05640986|BEHAVIORAL|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
48291658|NCT06229678|DRUG|Empagliflozin 25 MG Oral Tablet|Empagliflozin 25MG will be administered orally once per day for 3 months
48291659|NCT06229678|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
48291660|NCT06229678|DRUG|Acipimox 250 Mg Oral Capsule|subjects will be started on acipimox 250mg every 6 hours for 8 days while on continued empagliflozin/placebo therapy. This will be added at the end of 3 months after they finished baseline studies
48291661|NCT01914718|DRUG|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
48291662|NCT02927223|DRUG|Atropine|
48291663|NCT02927223|PROCEDURE|Exercise treadmill test|
48291664|NCT04483362|BEHAVIORAL|Complex physical activity intervention|"Structured weekly sessions with a Physiotherapist over an 8 week period, including:~* Evaluation of current levels of physical activity and physical function - including discussion of results~* Education regarding the importance of physical activity~* Supervised physical activity session with a physiotherapist~* Structured weekly sessions applying behavioural change techniques which aim to increase participation in physical activity. Sessions include: provision of activity monitor (Fitbit Inspire), goal setting, monitoring, collaborative problem solving and action plan implementation. Intervention includes additional time allowance of 1 hour per week to assist in implementing action plan items"
48291665|NCT06158672|BEHAVIORAL|Emotional freedom technique group|Menopausal women in the emotional freedom technique group will be administered the emotional freedom technique by the researcher a total of 4 times at one week intervals.
48474470|NCT05719337|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
48474471|NCT00774943|DRUG|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
48474472|NCT06347718|DRUG|anti-CD19 CAR T cell therapy|Single-dose
48474473|NCT05922488|PROCEDURE|Umbilical cord milking|Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
48474474|NCT05922488|PROCEDURE|delayed cord clamping|delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
48474475|NCT03966950|DIETARY_SUPPLEMENT|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
48474476|NCT03966950|DRUG|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
48474477|NCT03655275|BIOLOGICAL|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
47942563|NCT04323605|OTHER|"Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse"|"Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)"
48291666|NCT06158672|BEHAVIORAL|Sham emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will be administered sham emotional freedom technique by the researcher a total of 4 times with one week intervals.
48474478|NCT03655275|BIOLOGICAL|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
47942564|NCT01994590|DRUG|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
48291667|NCT04472104|BEHAVIORAL|MBCT-S|Group mindfulness treatment for sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
48291668|NCT04472104|BEHAVIORAL|SexEd|Group sex education on sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
48291669|NCT03211078|PROCEDURE|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
48474479|NCT01636934|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
48474480|NCT01636934|OTHER|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
48474481|NCT01636934|BEHAVIORAL|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
48474482|NCT02409329|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
48474483|NCT02409329|BEHAVIORAL|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
48474484|NCT02409329|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
48631804|NCT02440399|DRUG|Tramadol hydrochloride|Please see arm description
48631805|NCT02440399|DRUG|Morphine|Please see arm description
48631806|NCT02440399|DRUG|Paracetamol|
48631807|NCT02440399|DRUG|Diclofenac|
48631808|NCT02440399|DRUG|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
48291670|NCT04022369|BEHAVIORAL|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
48474485|NCT04048031|DIETARY_SUPPLEMENT|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
47942565|NCT01994590|DRUG|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
48291671|NCT00046826|DRUG|docetaxel|
48291672|NCT00046826|DRUG|estramustine phosphate sodium|
48291673|NCT00046826|DRUG|thalidomide|
48291674|NCT03598777|BIOLOGICAL|Botulinum toxin type A|Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
48291675|NCT03598777|DRUG|Placebo|The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
48291676|NCT00022711|DRUG|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
48631809|NCT05028088|DRUG|sugammadex|This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
48631810|NCT06040450|OTHER|Questionnaire survey|On outdoor sports practice activity, barriers to practice, impacts on well-being.
48631811|NCT02656342|DRUG|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
48631812|NCT02656342|DRUG|Placebo|Predicted to have no enhancing effect
48631813|NCT05628350|OTHER|No UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
48631814|NCT05628350|OTHER|Standard UPF controlled diet|Following a two-week eucaloric lead-in diet, participants will be provided and consume a diet maintaining usual UPF intake (59% energy). Diets will be eucaloric (50% carbohydrate, 35% fat, 15% protein), matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
48291677|NCT06092398|OTHER|PRP and PRFG in treatment of anal fistula|The tract fistula was cleaned with betadine 10% before PRP and PRFP were applied. Then, 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. The operation time was about 20-30 minutes, the clot formation usually takes about 8 minutes, but the anesthesia was extended to 20 minutes to make sure a complete clot in the place of fistula
48291678|NCT05460780|DEVICE|MATTISSE TEC|Tissue engineering chamber MATTISSE
48291679|NCT01534832|DEVICE|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
48291680|NCT02765412|OTHER|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
48474486|NCT04048031|OTHER|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
48474487|NCT02835963|OTHER|Data collection|Usual data collection
48474488|NCT03821792|DRUG|Abiraterone Acetate|Given PO
48474489|NCT03821792|DRUG|Apalutamide|Given PO
48474490|NCT03821792|DRUG|Prednisone|Given PO
47942566|NCT01994590|DRUG|Prednisone|5 mg by mouth twice daily.
47942567|NCT03642743|OTHER|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
47942568|NCT00923936|DRUG|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
47942569|NCT00923936|DRUG|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
48291681|NCT02765412|OTHER|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
48291682|NCT02765412|OTHER|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
48291683|NCT02765412|OTHER|Academic Detailing|All sites will be offered an academic detailing approach to implementation of Lung Decision Precsion. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
48291684|NCT00002669|BIOLOGICAL|aldesleukin|
48291685|NCT00002669|BIOLOGICAL|recombinant interferon alfa|
48291686|NCT00002669|DRUG|cisplatin|
48291687|NCT00002669|DRUG|dacarbazine|
48291688|NCT00940927|DRUG|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
48291689|NCT06511505|OTHER|TEMPUS AI-enabled ECG-based Screening Tool|The AI-enabled ECG-based screening tool, Tempus Next software, analyzes 12-lead ECG recordings to identify patients at increased risk for undiagnosed cardiovascular diseases, specifically atrial fibrillation (AF) and structural heart disease (SHD). Clinicians in the intervention group will receive a risk assessment for AF and SHD each time they order an ECG for their patients.
48291690|NCT03927729|DRUG|Methoxyflurane|Pain will be treated with inhaled methoxyflurane (Penthrox®).
48291691|NCT05372315|DRUG|Dextenza 0.4Mg Ophthalmic Insert|(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
48291692|NCT03709433|BEHAVIORAL|ACT groups and mobile app|See arm description.
48291693|NCT01910662|OTHER|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
48291694|NCT01910662|OTHER|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
48291695|NCT01910662|OTHER|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
48291696|NCT01910662|OTHER|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
47942570|NCT05547022|PROCEDURE|Endovascular revascularisation|Peripheral vascular angioplasty or stenting
48291697|NCT00294346|DRUG|AV608|
48291698|NCT00674934|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
48291699|NCT03401489|DEVICE|PACESETTER|Patients will be given a Viaca electronic pill tray \& blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational \& reinforcement messages guided by self-determination theory constructs of competence \& autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
48102920|NCT04409210|BEHAVIORAL|Personalized Reminders|"1. Abnormal data reminder App can automatically judge whether the data is normal. If abnormal data is found, it will inform the patient in red font and remind the patient to consult the doctor in time. Patients can consult their family doctors directly online through App or go to the hospital.~2. Medication reminder After patients upload their own medication information, the App will automatically generate a medication alarm clock to remind patients to take the drugs.~3. Follow-up reminder According to the clinical diagnosis and conditions of patients, make personalized follow-up time. Family physicians could use the App to remind patients to fill in the follow-up form or go to the hospital."
48102921|NCT04409210|DRUG|Routine treatment|Family physicians conduct the corresponding treatment and management according to the diagnosis and conditions of the patients.
48291700|NCT02104310|DRUG|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
48291701|NCT04024228|BIOLOGICAL|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
47942571|NCT00443612|DRUG|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
47942572|NCT00443612|DRUG|Irbesartan|Administration of irbesartan 150 mg/day
48291702|NCT04024228|BIOLOGICAL|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
48291703|NCT02005523|DRUG|RNS60|
48291704|NCT02005523|DRUG|Saline|
48291705|NCT06213701|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
48291706|NCT06213701|OTHER|Psychoeducation app|Psychoeducation app
48291707|NCT02758795|DIETARY_SUPPLEMENT|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
48291708|NCT02758795|DIETARY_SUPPLEMENT|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
48291709|NCT02725385|OTHER|Laboratory Biomarker Analysis|Correlative studies
48291710|NCT02725385|OTHER|Physiologic Testing|Undergo Trier Social Stress Test
48102922|NCT04451889|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
48291711|NCT02725385|OTHER|Questionnaire Administration|Complete questionnaire
48291712|NCT03566966|BIOLOGICAL|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
48291713|NCT03566966|BIOLOGICAL|Non-organ-specific Ab negative|direct-acting antiviral agents
48291714|NCT05099991|DEVICE|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
48291715|NCT05099991|DEVICE|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
48291716|NCT03928873|DEVICE|Low energy ESWT|1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
48291717|NCT03928873|DEVICE|High energy ESWT|1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
48291718|NCT03928873|DEVICE|Sham ESWT|sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
48291719|NCT04429932|OTHER|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
48474491|NCT04318431|DIAGNOSTIC_TEST|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
48474492|NCT03432273|DRUG|Nicotine lozenge|Nicotine mint lozenge, 2 mg
48291720|NCT04429932|OTHER|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
48291721|NCT04429932|OTHER|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
48291722|NCT04429932|OTHER|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
48291723|NCT04429932|OTHER|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
48474493|NCT03432273|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
48474494|NCT03862534|PROCEDURE|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
48474495|NCT03862534|PROCEDURE|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
48474496|NCT05373641|OTHER|Repeated feedback|Repeated feedback monthly based on previous month pain documentation audit results.
48474497|NCT05373641|OTHER|Pain documentation audit|Monthly pain documentation audit
48291724|NCT04429932|OTHER|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
48291725|NCT04429932|OTHER|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
48291726|NCT04429932|OTHER|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
48291727|NCT01533155|DRUG|Nektar 118|Oral 25 mg tablet
48291728|NCT01533155|DRUG|Quinidine|Oral 200 mg tablet
48291729|NCT01533155|DRUG|Quinidine placebo|Oral Tablet
48291730|NCT01533155|DRUG|Morphine|10 mg/ml, intravenously
48291731|NCT02409498|DRUG|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
48291732|NCT02409498|DRUG|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
48474498|NCT00866645|DRUG|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
48474499|NCT00866645|DRUG|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
48291733|NCT01938222|PROCEDURE|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
48291734|NCT00679562|DRUG|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
48291735|NCT00679562|OTHER|Distilled water|Application of patches containing distilled water for 24 hours
48291736|NCT02844608|OTHER|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
48291737|NCT04916197|DRUG|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
48474500|NCT03437330|DRUG|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
48474501|NCT03437330|DRUG|Insulin Glargine (Lantus®)|"insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)"
48474502|NCT03430011|BIOLOGICAL|JCARH125|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
48474503|NCT03430011|BIOLOGICAL|JCARH125 + anakinra|Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
48474504|NCT05917691|PROCEDURE|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
48474505|NCT05917691|DRUG|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
48474506|NCT05917691|DEVICE|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
48474507|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of Gpi|
48474508|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of STN|
48474509|NCT02827396|BEHAVIORAL|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
48474510|NCT02850172|BEHAVIORAL|Walk, Eat, & Breathe|"1. Walking exercise: 3 times per week, 20\~30 mins per section~2. Eat: nutritional assessment and advice weekly~3. Inspiratory muscle training: twice every day, 7 days a week, 6\~8 weeks before surgery"
48474511|NCT00864799|DRUG|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
48618096|NCT00434837|PROCEDURE|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
48291738|NCT04916197|DRUG|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
48291739|NCT02307526|DRUG|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
48291740|NCT02307526|DEVICE|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
48102923|NCT02118506|OTHER|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
48291741|NCT05376202|DRUG|Cetuximab-IRDye800CW|Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
48291742|NCT03046238|DRUG|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
48291743|NCT03046238|DRUG|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
48291744|NCT01594099|RADIATION|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
48291745|NCT01594099|DRUG|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
48291746|NCT01594099|DRUG|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
48291747|NCT06133777|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
48291748|NCT03662022|DRUG|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
48291749|NCT02185599|DEVICE|DySIS|Colposcopy performed with the DySIS digital colposcope
48291750|NCT00789204|OTHER|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
48291751|NCT00789204|OTHER|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
47942573|NCT01030627|DEVICE|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4\*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
47942574|NCT04811573|DRUG|EU-sourced Otezla®|Test product
47942575|NCT04811573|DRUG|US-sourced Otezla®|Reference product 1
48291752|NCT03882840|BIOLOGICAL|ITNK cell therapy|Infusion of ITNK/CAR-ITNK cells
48291753|NCT04159727|OTHER|stool and blood analysis|High throughput sequencing and quantitative PCR
48291754|NCT00841724|DRUG|Fludarabine, Busulfan, Thymoglobuline|
48291755|NCT03576872|OTHER|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
48291756|NCT02350829|OTHER|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
48291757|NCT05197244|BEHAVIORAL|Culinary Medicine Intervention|A 2-hour practical culinary medicine program facilitated by a culinary dietitian at a hospital-based teaching kitchen, followed by 3 virtual group follow-up sessions occurring monthly, each lasting approximately 30 minutes. The follow-up sessions will be facilitated by a culinary dietitian and will be conducted using a secure telephone/video conference platform.
48291758|NCT05185232|OTHER|Impact of gaps in care/loss to healthcare follow-up|There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
48291759|NCT04577768|DEVICE|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
48291760|NCT04577768|DEVICE|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
48291761|NCT04577768|DEVICE|HD-tDCS sham|sham stimulation of the right primary motor cortex
48291762|NCT02525224|DIETARY_SUPPLEMENT|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
48291763|NCT02756455|OTHER|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
48291764|NCT00579904|DIETARY_SUPPLEMENT|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
48291765|NCT00579904|DIETARY_SUPPLEMENT|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
48474512|NCT05386095|PROCEDURE|0.25%Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
48291766|NCT01722006|BEHAVIORAL|Pairing condition|
48291767|NCT01722006|BEHAVIORAL|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
48291768|NCT01410591|DEVICE|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
48291769|NCT01410591|DEVICE|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
48291770|NCT02247206|BEHAVIORAL|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
48474513|NCT05386095|PROCEDURE|0.19% Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
48474514|NCT05537467|OTHER|Music|Patients randomized to the music group will listen to upbeat music using headphones.
48474515|NCT02248506|OTHER|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
48474516|NCT06418997|BEHAVIORAL|CBI|CBI sessions follow a detailed manual to teach a group of peers cognitive and behavioral strategies that they may utilize in their daily lives, often based around the cognitive-behavioral model as a teaching tool. CBI aims to develop cognitive-behaviorally-based skills and habits in participants, such as behavioral activation, mood tracking, the identification and reframing of automatic thoughts, and assertion training.
48474517|NCT01590251|OTHER|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
48474518|NCT01590251|BEHAVIORAL|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
48474519|NCT06337513|OTHER|Rehabilitation intervention|"The intervention consists of a physiotherapist-coordinated (PT) interdisciplinary outpatient rehabilitation offer for 6-months.~The intervention encompasses 3 individual sessions with the PT, if needed individual sessions with the interdisciplinary team (PT, occupational therapist, OT, nurse, and social worker) (a maximum of 6 hours), and patient education in two group seminars."
47942576|NCT04811573|DRUG|Japan-sourced Otezla®|Reference product 2
47942577|NCT04733378|PROCEDURE|Peri-operative neurological monitoring|Pre- and post-operative cerebral MRI, standardized neurological examinations at 4, 12, 24 months and neuropsychological evaluation with a Bayley III test (Bayley Scale of Infant and Toddler Development, Third Edition) at 24 months.
47942578|NCT03472066|OTHER|Previous conization|a group of women who have been conized,
47942579|NCT03472066|OTHER|no previous conization|group with asymptomatic patients on routine second trimester echography
47942580|NCT00752115|DRUG|sildenafil|50mg, day1,8 and 15 in each cycle
47942581|NCT00752115|DRUG|placebo|1 tab, day 1,8 and 15 in each cycle.
47942582|NCT00752115|DRUG|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
47942583|NCT00752115|DRUG|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
47942584|NCT02554851|DRUG|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
47942585|NCT02554851|OTHER|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
47942586|NCT06010732|DRUG|0 ppm F (placebo, negative control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
47942587|NCT06010732|DRUG|1100 ppm F as sodium fluoride (positive control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
48474520|NCT06337513|OTHER|Usual care|Both the intervention and the control group will receive usual care.
48474521|NCT06227910|DRUG|Vedolizumab|Vedolizumab IV infusion.
48474522|NCT06227910|DRUG|Upadacitinib|Upadacitinib over-encapsulated tablets.
47942588|NCT06010732|DRUG|1100 ppm F as sodium fluoride Test Product|• Each subject will use this product during one of the three treatment periods in the crossover study design.
47942589|NCT04368273|DRUG|PD-1 antibody|a new treatment drug combined radical radiotherapy concurrent chemotharpy
47942590|NCT00006324|DRUG|Ethinyl estradiol/levonorgestrel|
47942591|NCT00006324|DRUG|Medroxyprogesterone acetate|
47942592|NCT03517124|OTHER|Ceramic tooth restoration|Dental restorations
47942593|NCT06426719|PROCEDURE|Alveolar ridge wideninig via applying osseodensification protocol using densah burs|alveolar ridge expansion using densah burs in horizontally deficient maxillary alveolar ridges prior to dental implants insertion
47942594|NCT06426719|PROCEDURE|Alveolar ridge widening via hand osteotomes|Alveolar ridge expansion using hand driven osteotomes in horizontally deficient maxillary alveolar ridges prior to dental Implant insertion
47942595|NCT02135159|DRUG|TDM1|administration of the TDM1 by IV perfusion
47942596|NCT02135159|RADIATION|Brain Sequential RT|local RT
48291771|NCT01709799|BEHAVIORAL|Exercise|"Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:~(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.~Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data."
48291772|NCT01709799|BEHAVIORAL|Exergames|"Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.~Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:~THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Polar Heart Rate monitors are used to measure THR and save resulting data."
48474523|NCT06227910|DRUG|Placebo|Upadacitinib matched placebo capsules.
48474524|NCT00129116|BIOLOGICAL|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
48474525|NCT00129116|BIOLOGICAL|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
48474526|NCT00129116|BIOLOGICAL|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
48474527|NCT00129116|BIOLOGICAL|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
47942597|NCT05276947|OTHER|position with peanut ball|The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
47942598|NCT02395510|DRUG|Vortioxetine|Vortioxetine 5-20mg
47942599|NCT05132868|OTHER|Educational video and pamphlet|The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.
47942600|NCT05132868|OTHER|Traditional genetic counseling|Patients will receive traditional genetic counseling
47942601|NCT05889572|DRUG|MaaT033|MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
47942602|NCT00122278|DRUG|Dexamethasone|Dexamethasone 10mg IV
47942603|NCT00122278|OTHER|Placebo|Placebo Dexamethasone 10mg IV
47942604|NCT04322981|BEHAVIORAL|Pharmacist-Led care|Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led
47942605|NCT04322981|BEHAVIORAL|Standard of Care (Hepatology)|Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
47942606|NCT03366779|DEVICE|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
48474528|NCT00129116|BIOLOGICAL|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
48474529|NCT03547414|OTHER|Nephrocheck test|A fresh urine sample was collected on inclusion (maximum 6 hours after starting catecholamines) through the urine collecting tube and frozen at -80°C. At the end of the study, urine samples were thawed and centrifuged as recommended by the manufacturer and the urinary TIMP2\*IGFBP7 concentration was determined using the Nephrocheck™ test. The Nephrocheck™ test simultaneously measures into the Astute 140™ meter (a bench top analyzer) the urinary concentrations of TIMP2 and IGFBP7 on 100 µl of urine mixed with 100 µl of buffer. The result is expressed as a single number corresponding to the product of TIMP2 and IGFBP7 concentrations.
48474530|NCT05680792|DRUG|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
48474531|NCT05680792|DRUG|Atazanavir/ritonavir|300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
48474532|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
48474533|NCT03259789|DRUG|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
48474534|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
47942607|NCT00814788|DRUG|Bicalutamide|50 mg oral tablet daily
47942608|NCT00814788|DRUG|Everolimus|10 mg oral capsule daily
47942609|NCT04686123|OTHER|Active Stretching or Self-stretching exercises|Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
47942610|NCT04686123|OTHER|Active strengthening Or Self-Strengthening exercises|Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
47942611|NCT06403631|OTHER|observational|Data will be gathered longitudinally from participants newly diagnosed with multiple sclerosis. Participants will fill in online questionnaires measuring flow, mindfulness, positive mental health, anxiety and depression. The questionnaires, including both scaled and open-ended questions, will be proposed at the project start (T1) and 6 months later (T2).
47942612|NCT03773380|COMBINATION_PRODUCT|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
47942613|NCT00145171|DRUG|apomorphine HCl injection|
47942614|NCT00426998|DRUG|Verteporfin|
47942615|NCT00426998|DRUG|Bevacizumab|
47942616|NCT00441454|DEVICE|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
48474535|NCT02345291|DRUG|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
48474536|NCT02345291|DRUG|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
48474537|NCT04328870|OTHER|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
48474538|NCT04328870|OTHER|General anesthsia|General anesthesia alone.
47942617|NCT00441454|DEVICE|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
47942618|NCT00608972|DRUG|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
48291773|NCT01709799|BEHAVIORAL|Cognitive Training|"Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28."
48291774|NCT01483846|DRUG|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
47942619|NCT00608972|DRUG|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
47942620|NCT00608972|DRUG|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
47942621|NCT05702866|DIAGNOSTIC_TEST|Transcutaneous oximetry|Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
47942622|NCT00557427|DRUG|hypericum|250mg tablets twice daily for 8 weeks
47942623|NCT00557427|DRUG|fluoxetine|20mg - 40mg daily for 8 weeks
47942624|NCT05753527|BEHAVIORAL|Progressive Relaxation Exercises|Deep abdominal breathing will be done three times and the breath will be given slowly. The fists will be clenched, keep the fists clenched in this way for 7-10 seconds, and then release them for 15-20 seconds. By opening the arms to the side and locking the elbows, the triceps muscle will be stretched and relaxed. The forehead muscles by raising the eyebrows The eyes will be closed and relaxed. The mouth will be opened and closed. The head will be stretched back and relaxed. The shoulders will be lifted and relaxed. Both hips will be tightened and relaxed by bringing them closer together. The thigh muscles will be tightened and relaxed.
47942625|NCT02938845|BEHAVIORAL|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
48474539|NCT02553655|PROCEDURE|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
48291775|NCT01483846|DRUG|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
48291776|NCT00466752|DRUG|sorafenib tosylate|Given PO
48291777|NCT00466752|GENETIC|microarray analysis|Correlative studies
48291778|NCT00466752|OTHER|immunohistochemistry staining method|Correlative studies
48291779|NCT00466752|GENETIC|gene expression analysis|Correlative studies
48291780|NCT00466752|PROCEDURE|needle biopsy|Correlative studies
48291781|NCT00466752|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
48474540|NCT02553655|PROCEDURE|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
48474541|NCT02553655|PROCEDURE|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
48474542|NCT03033524|DRUG|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
48474543|NCT03936218|DRUG|Inj. Goserelin (Test) Subcutaneously|10.8 mg, subcutaneously at every 3 month
48474544|NCT03936218|DRUG|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
47942626|NCT02938845|PROCEDURE|total laparoscopic hysterectomy(TLH)|
47942627|NCT02938845|PROCEDURE|total abdominal hysterectomy(TAH)|
47942628|NCT04157621|DEVICE|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
47942629|NCT04157621|DEVICE|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
47942630|NCT04723758|DEVICE|GI Genius-assisted diagnostic colonoscopy|Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
47942631|NCT04723758|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
47942632|NCT05043558|DRUG|beprostaglandin sodium|beprostaglandin sodium
47942633|NCT05970718|DRUG|REGN7544|Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
47942634|NCT05970718|DRUG|Matching Placebo|Solution for single ascending IV or SC administration per the protocol
47942635|NCT03053271|DRUG|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
48291782|NCT00466752|OTHER|laboratory biomarker analysis|Correlative studies
48291783|NCT00466752|GENETIC|western blotting|Correlative studies
48291784|NCT00466752|GENETIC|RNA analysis|Correlative studies
48291785|NCT03020186|OTHER|Physical activity|
48291786|NCT03020186|OTHER|Physical activity+ MED diet|
48474545|NCT00529217|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
48474546|NCT00828022|BIOLOGICAL|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
48474547|NCT04771247|PROCEDURE|Cardia Band Ligation|Patients will undergo cardia band ligation at the level of the GEJ.
48474548|NCT00179673|DRUG|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
48474549|NCT01752530|OTHER|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
48474550|NCT01752530|OTHER|Treatment as usual|Treatment as usual at the clinic
48474551|NCT00944684|DRUG|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
48474552|NCT00944684|DRUG|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg)
48474553|NCT00757549|BIOLOGICAL|cetuximab|
48474554|NCT00757549|DRUG|cisplatin|
48474555|NCT00757549|GENETIC|TdT-mediated dUTP nick end labeling assay|
48474556|NCT00757549|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
48474557|NCT00757549|OTHER|immunohistochemistry staining method|
47942636|NCT03053271|DRUG|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
47942637|NCT01298973|DRUG|Viscoat|One group will receive Viscoat for incision closure
47942638|NCT01298973|DRUG|Saline|One group will receive Saline to irrigate the wound
47942639|NCT00976170|DRUG|GC33(RO5137382)|IV administration at 6 escalating dose levels.
47942640|NCT00976170|DRUG|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
47942641|NCT04623398|DRUG|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
47942642|NCT04623398|DRUG|Placebo|Placebo
48291787|NCT03020186|OTHER|Physical activity+green MED diet|\*\*\*\*Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
47942643|NCT03576222|DEVICE|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
47942644|NCT03576222|DEVICE|MEPORE dressing|MEPORE dressing
47942645|NCT00841971|DRUG|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
48291788|NCT03636594|OTHER|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
48474558|NCT00757549|OTHER|laboratory biomarker analysis|
48474559|NCT00757549|RADIATION|fludeoxyglucose F 18|
48474560|NCT00757549|RADIATION|radiation therapy|
48474561|NCT03716739|DRUG|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
48474562|NCT03716739|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
47942646|NCT00841971|DRUG|Fluconazole|400 mg IV for 21 days
47942647|NCT00504985|BEHAVIORAL|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
47942648|NCT00662220|DRUG|ribavirin|25-29 mg/kg/day
47942649|NCT00662220|DRUG|ribavirin|12-15 mg/kg/day
47942650|NCT03368963|DRUG|Nanoliposomal Irinotecan|Given IV
47942651|NCT03368963|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
47942652|NCT00458068|DRUG|Oral administration of ferrous sulphate|
47942653|NCT06523283|OTHER|Natural Landscape Pictures Accompanied by Music|after data collection tools filled by participants , they will watch the video one time in hospital bed while breastfeeding , second time in their home while researchers is there and they will also receive the video link so they will contunie to watch video 8 more time. in total 10 sessions will be completed.
47942654|NCT00219167|DRUG|aliskiren|
47942655|NCT02606890|OTHER|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
47942656|NCT02869061|PROCEDURE|Liposuction|
47942657|NCT02869061|PROCEDURE|Transurethral bladder neck resection.|
47942658|NCT02869061|BIOLOGICAL|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
47942659|NCT02869061|OTHER|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
47942660|NCT03503071|PROCEDURE|Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
47942661|NCT02788474|DRUG|nintedanib|
47942662|NCT02788474|DRUG|placebo|
47942663|NCT04671485|OTHER|Standard care|Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
47942664|NCT04671485|OTHER|Autohypnosis|"The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
47942665|NCT04671485|OTHER|Musicotherapy|"the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
47942666|NCT01554228|OTHER|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
47942667|NCT04735575|BIOLOGICAL|EMB-06|EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.
47942668|NCT05199727|DEVICE|LI-ESWT|Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
47942669|NCT05199727|DRUG|Tadalafil 20Mg Oral Tablet|Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
47942670|NCT05984368|DRUG|BG136|Subjects injected with BG136 in Part 1 and Part 2
47942671|NCT05984368|DRUG|Placebo|Subjects injected with Placebo in Part 1 and Part 2
47942672|NCT01716325|OTHER|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
47942673|NCT01716325|OTHER|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
47942674|NCT01373307|BEHAVIORAL|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
47942675|NCT02761291|DRUG|Gemcitabine|Gemcitabine will be administrated 600\~1250 mg/m\^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m\^2. If no subject suffered the dose limit toxicity, 1000 mg/m\^2 and even 1250 mg/m\^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m\^2, the 600 mg/m\^2 will be started.
47942676|NCT02761291|DRUG|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
47942677|NCT02761291|DRUG|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and \< 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
47942678|NCT02552615|OTHER|body awareness therapy|
47942679|NCT02552615|OTHER|core stabilization exercises|
47942680|NCT02552615|OTHER|traditional exercises|
47942681|NCT00415454|GENETIC|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
48102924|NCT02118506|OTHER|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
48102925|NCT04628442|PROCEDURE|Sinonasal Debridement Procedure|This is a medical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
48474563|NCT04874896|DIETARY_SUPPLEMENT|Microbiota autotransplantation|Patients received microbiota autotransplantation in capsules (1g per day) for 6 months
48474564|NCT04874896|DIETARY_SUPPLEMENT|Control|Patients will not received microbiota autotransplantation in capsules and will received usual medical care
48474565|NCT05249972|DRUG|AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)|Topical cutaneous spray
47942682|NCT01158703|DRUG|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
47942683|NCT01158703|DRUG|sugar pill|sugar pill by mouth daily for 12 months
47942684|NCT01158703|DRUG|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
47942685|NCT00777205|BEHAVIORAL|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
47942686|NCT00777205|BEHAVIORAL|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
47942687|NCT01490970|OTHER|Database|Database
47942688|NCT06469398|DEVICE|Cutera Laser System|Subjects will receive up to 6 laser treatments
47942689|NCT04630639|DEVICE|Sparkle|The Sparkle device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
47942690|NCT00457366|DRUG|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
47942691|NCT00457366|DRUG|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
47942692|NCT00457366|DRUG|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
47942693|NCT00457366|DRUG|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
47942694|NCT00242073|PROCEDURE|MRI Prostate|
48474566|NCT05249972|DRUG|Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)|Topical foam
47942695|NCT04274478|DEVICE|Auditive cueing|Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
48102926|NCT04628442|PROCEDURE|Nasal Polyp Removal|This is a surgical procedure prescribed by the participant's physician that has been deemed necessary for patient care in order to address their chronic rhinosinusitis.
48102927|NCT04628442|PROCEDURE|Biopsy|A biopsy is optional and will remove a sample of inferior turbinate tissue from the nasal passage. It will be performed during a nasal polyp removal surgery already scheduled for patient care.
47942696|NCT05250089|OTHER|Simulation|Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
47942697|NCT05218265|DIAGNOSTIC_TEST|routine laboratory tests|Complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, and electrolytes), laboratory investigation to assess severity of COVID-19: lactate dehydrogenase (LDH), myocardial enzymes (CPK-MB), serum ferritin, D dimer and arterial blood gases analysis
47942698|NCT02759354|OTHER|Blood Sample|Blood sample at approx. 4 years of age
47942699|NCT03568084|OTHER|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
47942700|NCT03568084|OTHER|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
48102928|NCT06183710|BEHAVIORAL|Contingency management|Psychosocial intervention
48102929|NCT03037190|OTHER|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
48102930|NCT03610750|OTHER|psychiatric medications and evidence-based psychotherapies|Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.
48102931|NCT06442254|OTHER|Virtual Reality|In the application, which will be done with VR glasses, a video of walking on Istiklal Street in Istanbul's Beyoğlu district will be watched.
48102932|NCT00256243|DRUG|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
48102933|NCT00256243|DRUG|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
48102934|NCT00256243|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
48102935|NCT00256243|DRUG|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
48102936|NCT00256243|DRUG|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
48102937|NCT00256243|DRUG|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
48102938|NCT00699686|DRUG|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
48102939|NCT00699686|DRUG|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
48474567|NCT05249972|OTHER|Placebo|Placebo cutaneous spray
48474568|NCT01546519|DRUG|Vismodegib|oral repeating dose of 150 mg once daily
48474569|NCT04138784|OTHER|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
48291789|NCT06136338|BEHAVIORAL|Mindfulness training|Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
48291790|NCT06039917|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
48291791|NCT06039917|OTHER|Manually remind the patients|Medical staff remind patients to review manually.
48474570|NCT04138784|OTHER|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
48474571|NCT00575380|DRUG|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
48631815|NCT03958487|BEHAVIORAL|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
48291792|NCT06512324|DEVICE|Ampa One TMS System|Transcranial Magnetic Stimulation
48474572|NCT00575380|DRUG|Vigamox Eye Drops|One drop three times a day for seven days
48474573|NCT02203617|BEHAVIORAL|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
48474574|NCT02203617|BEHAVIORAL|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
48474575|NCT05739734|DRUG|CRIS100|local application of CRIS100
48474576|NCT02413294|DEVICE|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
48474577|NCT05918341|DRUG|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
48474578|NCT05647616|OTHER|Strengthening exercises|Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
48474579|NCT03770338|DRUG|Teriparatide|20ug dosage daily injection, 1-month preoperative
48474580|NCT05265299|DRUG|Aspirin 81mg|Aspirin 81mg once daily
48474581|NCT05265299|DRUG|Aspirin 162 mg|Aspirin 162 mg once daily
48474582|NCT05265299|DRUG|Aspirin 325mg|Aspirin 325mg once daily
48474583|NCT02247050|BEHAVIORAL|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
48474584|NCT00466843|DRUG|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
48474585|NCT00466843|DRUG|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
48474586|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
48474587|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
48474588|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
48474589|NCT05039476|DIETARY_SUPPLEMENT|Retinol face cream|Retinol face cream
48291793|NCT04095208|DRUG|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[80 mg\]."
48474590|NCT05039476|DIETARY_SUPPLEMENT|Placebo face cream|Placebo face cream
48291794|NCT04095208|DRUG|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\]."
48291795|NCT05081622|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|"Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~A one-day ICC-T refresher workshop aiming to refresh and re-emphasize the key aspects of the intervention is implemented about 6 to 12 months after the initial intervention."
48291796|NCT00846612|DRUG|Doxil|1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
48291797|NCT00846612|DRUG|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
47942701|NCT00596180|DRUG|HBOT|total body exposure to greater than atmospheric pressure oxygen
47942702|NCT04061382|PROCEDURE|Venepuncture|"One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2."
47942703|NCT04061382|PROCEDURE|Oral fluid swab|Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
48618097|NCT05486273|OTHER|interviews with coachs, semi-structured interviews and questionnaires|You will be offered 6 coaching sessions at a rate of one session per month and the first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12. Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
47942704|NCT01371370|OTHER|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
47942705|NCT01371370|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
47942706|NCT01371370|OTHER|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
47942707|NCT05588648|DRUG|Vactosertib|Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.
47942708|NCT00992329|DRUG|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
47942709|NCT05947578|DRUG|CLZ-2002|Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)
47942710|NCT02779712|PROCEDURE|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
47942711|NCT02779712|PROCEDURE|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
47942712|NCT05104554|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|IFA: Weekly regimen of one tablet containing iron (60 mg) and folic acid (2800 μg)
47942713|NCT05104554|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS)|MMS: Daily regimen of one multiple micronutrient tablet containing fifteen micronutrients in the United Nations International Multiple Micronutrient Preparation (UNIMMAP) preparation. Composition includes vitamin A (800 ug), vitamin D (5 ug), vitamin E (10 mg), vitamin C (70 mg), vitamin B1 (1.4 mg), vitamin B2 (1.4 mg), niacin (18 mg), vitamin B6 (1.9 mg), vitamin B12 (2.6 ug), folic acid (400 ug), iron (30 mg), zinc (15 mg), copper (2 mg), selenium (65 ug), and iodine (150 ug).
47942714|NCT00082927|DRUG|ibandronate sodium|
47942715|NCT04145479|BEHAVIORAL|physical activity|exercise
48291798|NCT00229840|PROCEDURE|Functional MRI, Diffusion Tensor Imaging|
48291799|NCT05314348|DEVICE|High-density surface EMG|High-density surface EMG for fasciculation detection
48291800|NCT05314348|DEVICE|Ultrasound|Ultrasound for fasciculation detection
48291801|NCT06320197|OTHER|In situ simulation assessment|Unannounced in situ simulation assessment during working hours
48291802|NCT00851110|PROCEDURE|stem cell reinfusion|hematopoietic stem cell reinfusion
48291803|NCT00851110|DRUG|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
48291804|NCT00005963|DRUG|carboplatin|
48291805|NCT00005963|DRUG|docetaxel|
48291806|NCT01601015|OTHER|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
48631816|NCT00753142|DRUG|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
48291807|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
48291808|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
48291809|NCT01601015|OTHER|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
48291810|NCT02903511|DRUG|Metformin|Monitoring of safety and tolerability
48291811|NCT02903511|DRUG|Placebo|Monitoring of safety and tolerability
48291812|NCT00621023|DRUG|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
48291813|NCT01450371|DEVICE|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
48291814|NCT01450371|DEVICE|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
48291815|NCT03855254|BEHAVIORAL|communication type|Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
48291816|NCT00178412|BEHAVIORAL|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
48291817|NCT00178412|BEHAVIORAL|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
48291818|NCT00335712|DRUG|ONO-5129|
48291819|NCT03247998|DRUG|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
48474591|NCT05670145|OTHER|PRECISE|"The target group is working pregnant women. Further, a smaller group of non-pregnant women from the same workplaces and with the same work tasks (colleagues) will be included. Around 95% of pregnant women in Denmark have a 1st trimester ultrasound scan.(17) To ensure a representative population, the recruitment to the project takes place at four obstetric departments. After giving informed written consent for participation, the pregnant women receive a baseline questionnaire followed by short weekly questionnaires by SMS until maternity leave.~Exposure to occupational standing/walking and bending are measured by use of triaxial accelerometers (Axivity sensors) worn on the back and thigh for 24 hours/day. Exposure to lifting is quantified through continuous observations during a workday with registration of number of lifts, weight of burdens, and number of person-liftings."
48474592|NCT06059417|OTHER|2x2 inch piece of 3M microfoam adhesive|"A 2x2 inch piece of 3M microfoam adhesive will be applied to the medial aspect of the subject's upper arm.~The adhesive will remain in place for 48 hours at which time an investigator will remove the adhesive and assess the study area. A numerical value will be assigned based on the Cutaneous Irritancy Scoring System (CISS). The study site will be compared to the contra-lateral upper extremity at the end of the 48 hour period."
47942716|NCT01741012|DRUG|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
48474593|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
48474594|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
47942717|NCT01456390|DEVICE|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
47942718|NCT06135415|DRUG|Tirbanibulin|Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
47942719|NCT06135415|OTHER|Vehicle ointment|Participants will apply vehicle ointment topically on the face or balding scalp with AK.
48291820|NCT03247998|DRUG|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
48291821|NCT06658808|BEHAVIORAL|Promoting Community Conversations About Research to End Suicide|Promoting Community Conversations About Research to End Suicide (PC CARES) trains local community health workers to facilitate a series of five 3-hour Learning Circles (LCs) over \~6 months to develop a 'community of practice' (CoP), whereby trusted adults of youth (a) learn about SPBPs; (b) tailor the SPBPs to their culture and community; (c) build cross-sector relationships (parents, teachers, etc.), and (d) do more to prevent suicide. Each session shares evidence-based, actionable ways to enhance social support, reduce harm/risk, and promote help seeking, which participants adapt and apply in their daily interactions with youth.
48291822|NCT00641940|BEHAVIORAL|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
47942720|NCT04166227|PROCEDURE|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
47942721|NCT04166227|PROCEDURE|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
47942722|NCT03179761|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine given intramuscularly
47942723|NCT03179761|OTHER|Laboratory Biomarker Analysis|Correlative studies
47942724|NCT03179761|BIOLOGICAL|Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine given intramuscularly
48291823|NCT00641940|BEHAVIORAL|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
48291824|NCT02081469|OTHER|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
47942725|NCT06243627|OTHER|Sunscreen C Color 2.0 SPF 70|Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.
47942726|NCT06243627|OTHER|Sunscreen C Color 3.0 SPF 70|Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.
47942727|NCT06243627|OTHER|Sunscreen M Very Light SPF 50|Sunscreen M very light SPF 50 will be applied topically on half of the face.
48474595|NCT02126384|DRUG|pneumovax vaccination|vaccination
48474596|NCT00587431|DRUG|GnRh (Leuprolide)|Leuprolide LUPRON
48291825|NCT04345939|DIAGNOSTIC_TEST|Detection method|Different methods for pathogen diagnosis
48291826|NCT02410369|DRUG|S-588410|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
48291827|NCT02410369|DRUG|Placebo|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
48291828|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
48474597|NCT00587431|DRUG|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
48474598|NCT00587431|DRUG|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
48474599|NCT04406194|DRUG|FAVICOVIR 200 mg Film Tablet|FAVICOVIR 200 MG FT is containing 200 mg favipiravir manufactured by Atabay, Turkey.
48474600|NCT04406194|DRUG|AVIGAN 200 mg Film Tablets|AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
48474601|NCT02369549|DRUG|Micro-particle Curcumin|as described in Arm
48474602|NCT02369549|DRUG|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
48474603|NCT02604576|DRUG|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
48474604|NCT02604576|DRUG|Bromopride 10 mg|Bromopride 10 mg
47942728|NCT06243627|OTHER|Sunscreen M Golden Color SPF 50|Sunscreen M golden color SPF 50 will be applied topically on half of the face.
48631817|NCT00753142|DRUG|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
48631818|NCT02548364|DRUG|Calcifediol|calcifediol treatment
47942729|NCT04425824|DRUG|Toripalimab combine with Rituximab|"Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC)."
47942730|NCT01780532|PROCEDURE|Photoacoustic Imaging (PAI)|Standard of Care
47942731|NCT02734420|DRUG|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
48291829|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
48291830|NCT00340327|DRUG|IMA-638|
48291831|NCT02679066|DEVICE|Sugar-tong splint|Plaster immobilization including the elbow
48291832|NCT02679066|DEVICE|Short forearm cast|Fiberglass immobilization with elbow free
48291833|NCT04095416|DEVICE|ACE compression wrap|Bilateral lower extremity ACE compression wraps
48291834|NCT00530699|DRUG|AZD1152|intravenous
48291835|NCT05051085|BEHAVIORAL|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
48291836|NCT04374903|DRUG|HCQ & AZ vs HCQ+SIR|Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
48291837|NCT06113666|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
48291838|NCT06113666|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
48291839|NCT02584569|DRUG|TAK-915|TAK-915 oral suspension
47942732|NCT02734420|DRUG|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
48102940|NCT02492464|DIETARY_SUPPLEMENT|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
48102941|NCT02492464|DIETARY_SUPPLEMENT|Placebo|
48291840|NCT05464277|OTHER|Oxygen|Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
48291841|NCT01625169|DRUG|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
48291842|NCT04805931|BEHAVIORAL|Behavioral economics|Tailored behavioral economic text messaging vs. standard text messaging
48291843|NCT01851473|DRUG|cocaine|25 mg IV on days 1, 5, and 10
48291844|NCT01851473|DRUG|quinine|80 mg orally on days 7-10
48291845|NCT01851473|DRUG|acetazolamide|15 mg orally on days 2-5
48291846|NCT01853228|DRUG|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
48474605|NCT06615856|OTHER|Questionnaire|"Two questionnaires will be provided to participants to complete before their routine tests (which they would already be having regardless of the study and are not affected by their participation in the study).~The questionnaires include: A Gastro-Oesophageal Reflux Symptom Questionnaire; and the ROME-IV Diagnostic IBS Module Questionnaire"
48474606|NCT02237547|BIOLOGICAL|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
48474607|NCT04979858|DEVICE|Focal Mask|The treatment group will receive and use the focal mask.
47942733|NCT02734420|DEVICE|Laser|
47942734|NCT00253500|BIOLOGICAL|pegfilgrastim|6 mg in a syringe
47942735|NCT00253500|DRUG|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
48102942|NCT06431035|DIETARY_SUPPLEMENT|caffeine|The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
48102943|NCT01664104|DRUG|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
48291847|NCT01853228|DRUG|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
48474608|NCT03990480|DRUG|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
48474609|NCT03990480|DRUG|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
48474610|NCT04783545|DRUG|VLX-1005|VLX-1005 infusion
48474611|NCT04783545|DRUG|Placebo|Placebo infusion
48474612|NCT01115855|DRUG|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
48474613|NCT01115855|DRUG|Placebo|Placebo once daily or every once daily
48474614|NCT02821949|BIOLOGICAL|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
48631819|NCT02548364|DRUG|Placebo|placebo control group
48474615|NCT01321177|BEHAVIORAL|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~* education about schizophrenia and its treatment for the participants and their family members~* medication for symptoms and preventing relapse that uses a computerized decision support system~* strategies for managing the illness and building personal resilience~* help getting back to school or work using a supported employment/education model"
48474616|NCT01321177|BEHAVIORAL|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~* medication for symptoms and preventing relapse~* psychosocial therapy which may include a range of behavioral treatments and supportive services~* Case management"
48474617|NCT03571659|PROCEDURE|Laser|
48631820|NCT04877639|DRUG|Esmketamine,Dexmedetomidine|Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
48631821|NCT02053584|DEVICE|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
47942736|NCT00253500|PROCEDURE|conventional surgery|to remove small piece of cancer
48474618|NCT00893451|DRUG|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
48474619|NCT00893451|DRUG|Placebo|Placebo orally twice daily
48474620|NCT02157363|PROCEDURE|Repositioning|
48474621|NCT02157363|PROCEDURE|Single positioning|
48474622|NCT00779220|DRUG|placebo|Intravenous repeating dose
48474623|NCT00779220|DRUG|methotrexate|Oral repeating dose
48474624|NCT00779220|DRUG|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
48102944|NCT02556034|OTHER|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
48474625|NCT00779220|DRUG|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
48474626|NCT00779220|DRUG|ocrelizumab 500mg|Intravenous repeating dose (500mg)
48474627|NCT05996692|OTHER|Evaluation of adherence to walking prescriptions|Adherence to walking prescriptions was evaluated according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.
48474628|NCT06348524|DRUG|Ferumoxytol injection|ferumoxytol will assess patency of coronary arteries
48474629|NCT03957694|DRUG|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
48474630|NCT03592329|BEHAVIORAL|Stress Reduction Training A|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
48474631|NCT03592329|DEVICE|active tVNS|non-painful electrical stimulation of the auricle
48474632|NCT03592329|BEHAVIORAL|Stress Reduction Training B|"twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions"
48474633|NCT03592329|DEVICE|sham tVNS|sham stimulation
48474634|NCT00037687|DRUG|rPAF-AH|
48474635|NCT04336332|COMBINATION_PRODUCT|Hydroxychloroquine Sulfate + Azithromycin|Given PO
48474636|NCT04336332|DRUG|Hydroxychloroquine Sulfate|Given PO
48474637|NCT02343354|BEHAVIORAL|Nutrition/physical activity intervention|Please see arm description
48474638|NCT06269354|DEVICE|3D printed prostheses|3D printed prostheses
48474639|NCT01009515|DRUG|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
48631822|NCT02053584|DEVICE|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
48631823|NCT06328231|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
47942737|NCT00542971|DRUG|Idarubicin|12 mg/m\^2 IV over 1 hour daily (days 1-3)
47942738|NCT00542971|DRUG|Sorafenib|Starting dose 400 mg by mouth for 7 days
47942739|NCT00542971|DRUG|Ara-C|1.5 g/m\^2 IV over 24 hours daily (days 1-4)
47942740|NCT01936077|DRUG|Recombinant LH (Luveris)|150 IU recombinant LH daily.
48102945|NCT06054269|BIOLOGICAL|FLUAD Quadrivalent|0.5 mL intramuscular dose of FLUAD Quadrivalent
48474640|NCT01947309|DRUG|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
48474641|NCT05934838|DRUG|Tazemetostat Pill|Participants will take 800 mg of tazemetostat twice a day starting 7 days before apheresis and continue to take tazemetostat until lymphodepletion, which is chemotherapy given prior to receiving the CAR T cells. Participants will stop taking tazemetostat after lymphodepletion until after CAR T cell infusion. Once lymphocyte counts increase, tazemetostat will be resumed and tazemetostat will be taken for 6 - 12 months, depending on participant response.
48474642|NCT01109576|BEHAVIORAL|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
48474643|NCT02464241|OTHER|only examination|
48631824|NCT04039438|OTHER|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
48474644|NCT05201638|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
48474645|NCT05201638|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
48474646|NCT05247268|DRUG|Megestrol Acetate 160 MG Oral Tablet|At a dosage of 160 mg/day
48631825|NCT04391907|PROCEDURE|IPL|Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
48631826|NCT02106559|DRUG|porfimer sodium|Given IV
48474647|NCT05247268|DRUG|Medroxyprogesterone Acetate 500 MG|At a dosage of 500 mg/day
48474648|NCT05247268|DRUG|Triprorelin Acetate|Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
48474649|NCT05247268|DRUG|Letrozole 2.5mg|At a dosage of 2.5mg/day and no more than 24 weeks
47942741|NCT05240287|DIAGNOSTIC_TEST|Navicular Drop Test|The researchers will measure the distance between the navicular tuberosity and the ground with a caliper with non-weight bearing in sitting. After that, the distance between the ground and the navicular tuberosity will be measured in standing while weight-bearing. The researchers will evaluate both sides and record the value in mm. According to Navicular Drop Test, the difference between weighted and unweighted measurements is considered normal (neutral) if it is between 5 and 9 mm, pronation (pes planus) if it is 10 mm or more, and supination (pes cavus) if it is 4 mm or less. In our study, individuals with a difference of 10 mm or more in both feet will be included in the pes planus, and individuals with a difference between 5-9 mm will be included in the control group.
47942742|NCT05240287|DIAGNOSTIC_TEST|Foot Posture Index|The index consists of six items in which the foot is evaluated observationally. In the evaluation, the individual is asked to stand in a comfortable and relaxed position. The researcher observes the medial longitudinal arch structure, the structure of the talonavicular joint region, the degree of abduction/adduction in the forefoot relative to the hindfoot in the front part of the foot. In the back foot, inversion/eversion of the calcaneus, talus head position, and curvatures above and below the lateral malleolus are evaluated. The total score is reached by scoring each criterion between -2 and +2 values. 0; neutral position, (+) values; pronation (pes planus), (-) values indicate supination (pes cavus). Individuals with +6 to +12 points from this index will be included in our study.
48102946|NCT06054269|BIOLOGICAL|FluQuadri|0.5 mL intramuscular dose of FluQuadri
48102947|NCT06628544|BIOLOGICAL|BCG vaccination|BCG vaccination
48474650|NCT03776578|PROCEDURE|swallow fuction and swallow training|nasogastric tube dependence rate
48474651|NCT00793117|PROCEDURE|packing|packing in middle meatus for duration of 5 day
48474652|NCT05239533|DRUG|177Lu-labeled-girentuximab|"The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. \>/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence."
48474653|NCT05239533|DRUG|Nivolumab|Nivolumab 240mg q2wk
48474654|NCT05239533|DIAGNOSTIC_TEST|89Zr-girentuximab PET/CT|All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
48631827|NCT02106559|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
48631828|NCT02106559|DRUG|photodynamic therapy|Undergo PDT
48631829|NCT02455180|DRUG|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
48631830|NCT01986322|BIOLOGICAL|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
48631831|NCT01986322|BIOLOGICAL|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
48631832|NCT04506710|BEHAVIORAL|Audio recording of the counseling conversation|The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
48102948|NCT06628544|DRUG|Metformin is administered on the day 0|Metformin is administered on the day 0
48102949|NCT06628544|OTHER|Placebo|Placebo
48102950|NCT06628544|DRUG|Metformin is administered on the day 9|Metformin is administered on the day 9
48102951|NCT06628544|DRUG|Metformin is administered on the day 85|Metformin is administered on the day 85
48474655|NCT05239533|DIAGNOSTIC_TEST|177Lu whole body (WB) planar and SPECT/CT scans|177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
48474656|NCT04359537|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described
48474657|NCT04359537|OTHER|Placebo|Control group will receive a Placebo tablet. Placebo 200mg will be given on Day 1 followed by Placebo 200mg every three weeks.
48474658|NCT04553835|BEHAVIORAL|Rhythmic auditory stimulation (RAS) for schizophrenia patients|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday."
48474659|NCT04553835|BEHAVIORAL|No RAS for schizophrenia patients|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
48618098|NCT05486273|OTHER|semi-structured interviews and questionnaires|The first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12.Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
47942743|NCT05240287|DIAGNOSTIC_TEST|Balance|Static and dynamic balance and stability limit values of individuals will be evaluated with the HUR Smart Balance (SME Inc, USA) balance measurement device. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals will be asked to place their feet on the marked places on the platform. The researchers will evaluate the balance in four different situations, 30 seconds each. In the first test, individuals keep the balance on firm ground with their eyes open. The second test performed on the firm ground with eyes closed, in the third test, on the soft ground with eyes open, and in the fourth test, on the soft ground with eyes closed. For dynamic balance, individuals will be asked to extend their body weight to the front, back, and sides with their feet in 4 different directions for 8 seconds.
47942744|NCT05240287|DIAGNOSTIC_TEST|Plantar Pressure Analysis|Plantar pressure analysis of individuals will be evaluated by measuring with the DIERS Pedoscan DICAM 3 v3.10.8 (2019) device. DIERS Pedoscan is a system integrated into the treadmill that measures the pressure distribution on the sole during stance. As a result of this evaluation, right-left and anterior-posterior weight transfer, left-right foot rotation, lateral mobility, the center of gravity movement, and swing area data will be recorded.
47942745|NCT05240287|DIAGNOSTIC_TEST|Gait Analysis|Gait analysis of individuals will be evaluated with the DIERS Leg Axis DICAM 3 v3.10.8 (2019) system. The system consists of a treadmill, computer, and cameras. Before the measurement, colored markers will be placed on the knee and ankle joints of the individual. For gait assessment, individuals will walk at their preferred comfortable walking speed. In the evaluation, joint angles, walking speed, step lengths are recorded. Evaluation time is approximately 5 minutes.
47942746|NCT04040868|DEVICE|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
47942747|NCT04040868|DEVICE|Freehand|conventional fluoroscopy-assisted
47942748|NCT00004017|PROCEDURE|conventional surgery|
47942749|NCT00004017|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
47942750|NCT00729599|DRUG|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
47942751|NCT02906371|DRUG|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
47942752|NCT02906371|DRUG|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (\~ Day -5 to -1) will follow the standard CRS Rx algorithm
47942753|NCT02906371|BIOLOGICAL|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of \~1.5 x107 - 5 x109 (\~3x105 - 1x108/kg) T cells.
47942754|NCT03657862|DEVICE|application of 38% silver diamine fluoride solution|SDF solution was painted onto the surface of the carious lesion of the tooth
47942755|NCT03657862|OTHER|application of a placebo (tonic water)|tonic water was painted onto the surface of the carious lesion of the tooth
47942756|NCT06405620|OTHER|Assistance robot|the child controls the robot at his parent's home from his room
47942757|NCT01674634|BIOLOGICAL|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent \[0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride\])
47942758|NCT01008631|DRUG|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
47942759|NCT02789878|DRUG|Goserelin|Androgen Deprivation Therapy
47942760|NCT02789878|DRUG|Prednisone|Corticosteroid
47942761|NCT02789878|DRUG|Abiraterone|CYP17 inhibitor
47942762|NCT02789878|DRUG|Apalutamide|Androgen-receptor antagonist
47942763|NCT05035641|DRUG|AND017|Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
47942764|NCT05035641|DRUG|Placebo|Orally, 3 times per week
47942765|NCT03524079|DRUG|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
48291848|NCT01853228|DRUG|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
48631833|NCT05750082|DEVICE|CCTA CT-FR CAG OCT|Per the protocol, patients will have a CCTA (coronary computed tomography angiography), CT-FFR (fractional flow reserve derived from CTA), ICA (invasive coronary angiography), OCT (optical coherence tomography).
47942766|NCT02701842|DEVICE|ImPACT Online/Paper Pencil Tests|
47942767|NCT02701842|DEVICE|ImPACT Online|
47942768|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% gel pump|
47942769|NCT00377000|DRUG|clindamycin 1% / benzoyl peroxide 5% tube|
47942770|NCT00001115|DRUG|Acyclovir|
47942771|NCT06135168|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
47942772|NCT06135168|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
47942773|NCT02698059|DEVICE|iNAP® Sleep Therapy System (iNAP)|The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
47942774|NCT02103049|DRUG|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
47942775|NCT04841915|DIETARY_SUPPLEMENT|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
47942776|NCT04841915|BEHAVIORAL|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
48291849|NCT06598397|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.
48291850|NCT06598397|BEHAVIORAL|Peer Mentoring|Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.
48291851|NCT06598397|BEHAVIORAL|Skills-based Text Messaging|NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.
48291852|NCT06598397|DRUG|Combination NRT|If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.
48291853|NCT05247177|DRUG|dexmedetomidine, ketamine co-administration with sevoflurane for general anesthesia|co-administration of sevoflurane, iv. dexmedetomidine and iv. ketamine to maintain a predefined EEG density spectrum array pattern for general anesthesia
48291854|NCT05247177|DRUG|Conventional general anesthesia by administration of sevoflurane alone|Administration of sevoflurane alone to maintain anesthesia with a bispectral index between 40-60
48102952|NCT06607731|OTHER|Collecting data from medical records|Data collected: clinical data (particularly pain), biological data, imaging.
48291855|NCT06513260|PROCEDURE|Surgical extraction of impacted lower third molars.|Surgical extraction of impacted mandibular third molars in the mesioangular position, according to the Tetsch and Wagner classification
48102953|NCT02271048|DEVICE|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
48102954|NCT00869037|DRUG|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
48102955|NCT00869037|DRUG|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
48291856|NCT06673290|DRUG|Sirolimus (RAPAMUNE)|Use of different doses of the same drug
47942777|NCT04841915|BEHAVIORAL|Weight loss|4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
47942778|NCT01982331|BIOLOGICAL|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
47942779|NCT01982331|OTHER|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
47942780|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
48291857|NCT01236885|OTHER|computer-assisted intervention|Undergo blood glucose management using Glucommander
47942781|NCT00974766|DRUG|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
47942782|NCT02913040|OTHER|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
47942783|NCT02913040|OTHER|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
48102956|NCT05699213|DIAGNOSTIC_TEST|Lung MRI|MRI of the lung
48102957|NCT05699213|DIAGNOSTIC_TEST|Blood Draw|Blood Draw
48102958|NCT02967016|BEHAVIORAL|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
48102959|NCT06052176|DRUG|Albumin Infusion|Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
48102960|NCT01306331|DRUG|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
48102961|NCT01306331|DRUG|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
48291858|NCT06187415|BEHAVIORAL|Mobile app to reduce harm of chemsex|Access to the mobile app which includes PrEP diary, demistification of chemsex urban legends, information on the location of needle and syringe services program, and alert sending to emergency contact.
48631834|NCT03563612|DEVICE|cpap|application of cpap to the non-dependent lung, during one lung ventilation
48631835|NCT02746380|DRUG|LBAL|Adalimumab
48631836|NCT02746380|DRUG|Humira®|Adalimumab
48631837|NCT00776997|DEVICE|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
48102962|NCT03183232|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
48102963|NCT03183232|BIOLOGICAL|γδ T cell|γδ T cells will be used against Lung Cancer
48102964|NCT03183232|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
48631838|NCT02792634|PROCEDURE|Sleeve-Gastrectomy, Roux en Y gastric bypass|
48631839|NCT02011997|PROCEDURE|patients undergo cVATS segmentectomy|
48631840|NCT02011997|PROCEDURE|Patients undergo cVATS lobectomy|
48631841|NCT03583866|DRUG|Candesartan|7 days of Candesartan (16mg/day)
48474660|NCT04553835|BEHAVIORAL|RAS for at-risk individuals|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day."
47942784|NCT03277521|OTHER|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
47942785|NCT02180269|DRUG|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
47942786|NCT02180269|DRUG|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
47942787|NCT02180269|DRUG|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
47942788|NCT02180269|DRUG|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
47942789|NCT01091337|DRUG|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
47942790|NCT01091337|DRUG|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
47942791|NCT03131453|DRUG|CNP520 50mg|50 mg capsule
47942792|NCT03131453|DRUG|CNP520 15mg|15 mg capsule
47942793|NCT03131453|OTHER|Matching placebo|Matching placebo for 15 and 50 mg capsules
47942794|NCT05183893|DIETARY_SUPPLEMENT|L-citrulline|5 g of L-citruline + 5 g of additives
48102965|NCT01357044|DIETARY_SUPPLEMENT|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
48102966|NCT01357044|DIETARY_SUPPLEMENT|Placebo|Tablets, two in the morning and two in the evening
48102967|NCT06118229|DEVICE|Wearable smart devices and PROs|Patients wearing wearable smart devices to monitor physiological data while regularly utilizing PROs to report subjective assessments of their own health status.
48102968|NCT03802786|DRUG|Imeglimin|Single administration dose of imeglimin
48291859|NCT02522910|DRUG|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
48631842|NCT03583866|DRUG|Placebo|7 days of Placebo
47942795|NCT05183893|DIETARY_SUPPLEMENT|Citrulline-malate|8g of citrulline-malate + 2 g of additives
47942796|NCT05183893|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrine
47942797|NCT00326573|BEHAVIORAL|Motivational Interviewing|
47942798|NCT04831957|DIAGNOSTIC_TEST|Assesment of thyroïd function|Blood sample for TSH, fT4, fT3, anti TPO, anti TG thyroid ultra sound Iodine urine sample
47942799|NCT05250752|DRUG|Dapagliflozin 10 MG [Farxiga]|Primary end-points are measure before (day 0), on treatment (day 1 and day 3) and after treatment (day 21)
47942800|NCT00533923|DRUG|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
47942801|NCT02449720|DRUG|Ropivacaine|Intraperitoneal instillation and infusion
47942802|NCT02449720|DRUG|0.9% Saline|Intraperitoneal instillation and infusion
47942803|NCT05384275|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
47942804|NCT01225536|DRUG|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
47942805|NCT05591742|DIETARY_SUPPLEMENT|FEMIDUR®|"Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin"
47942806|NCT05591742|OTHER|Placebo Z Cap V-3 Pla|Consist mainly of maltodextrin. One tablet a day.
47942807|NCT05080309|DIETARY_SUPPLEMENT|carbohydrate oral intake|During labor the women will have free access to water and 20 ml commercial fruit juice bricks containing between 430 or 660 kcal/l. Every 2 hours the midwife or the nurse will measure the fruit juice oral intake volume and will advise women to drink the planned volume (1 brick/2hours)
47942808|NCT05080309|OTHER|free water only|Women will have free access to water only
47942809|NCT05333081|OTHER|Consumption of rice for evaluation of the glycemic index|The test of each food was carried out for a maximum time of 120 minutes, by carrying out repeated measurements of the glycaemia of all subjects at a distance of 0, 15, 30, 45, 60, 90 and 120 minutes from the administration of the sample in order to obtain a glycemic curve for each sample considered.
47942810|NCT01490554|PROCEDURE|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
47942811|NCT02188342|BEHAVIORAL|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
48102969|NCT06145256|DEVICE|MRI brain, MSCT brain, Transcranial Ultrasound|MRI, MSCT and transcranial Ultrasound are an important diagnostic modalities in the assessment of severity and outcome of HIE
48102970|NCT02197299|DIETARY_SUPPLEMENT|L-carnitine|
48102971|NCT02197299|DIETARY_SUPPLEMENT|Placebo|
48102972|NCT04814940|OTHER|MENOPUR Cohort|"Non-interventional~All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place."
48102973|NCT04902586|DEVICE|TTFields|The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
48474661|NCT04553835|BEHAVIORAL|No RAS for at-risk individuals|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
48474662|NCT05853809|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement to guide anti-inflammatory asthma treatment
48631843|NCT04322695|BEHAVIORAL|Rehabilitation Education Care Program|The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
48631844|NCT01939275|RADIATION|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
48631845|NCT01939275|DEVICE|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
48631846|NCT01939275|OTHER|laboratory biomarker analysis|Correlative studies
48631847|NCT01939275|PROCEDURE|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
48631848|NCT04561531|OTHER|3%NaCl|Intervention is infusion of 3%NaCl which is defined in arms of experiment.
48631849|NCT00894725|PROCEDURE|laparoscopic left colonic resection|laparoscopic colonic resection
48631850|NCT00894725|PROCEDURE|open left colonic resection|conventional open colonic resection
48631851|NCT02755090|DRUG|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
48631852|NCT02755090|DRUG|IV Saline|
48631853|NCT03264950|DIAGNOSTIC_TEST|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
48631854|NCT03774472|DRUG|Hydroxychloroquine|Given PO
48631855|NCT03774472|DRUG|Letrozole|Given PO
48474663|NCT02771106|OTHER|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
48474664|NCT00603564|PROCEDURE|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
48474665|NCT05457634|OTHER|Combustible Cigarette|Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
48474666|NCT05457634|OTHER|blu Disposable A|Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
48474667|NCT05457634|OTHER|blu Disposable B|Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
48631856|NCT03774472|DRUG|Palbociclib|Given PO
48631857|NCT02822755|OTHER|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
48102974|NCT03629119|DIETARY_SUPPLEMENT|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
48102975|NCT02634216|DIETARY_SUPPLEMENT|Capros|250 mg BID
48102976|NCT05298111|OTHER|Formulation 3|Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
48102977|NCT05298111|OTHER|Control|Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
48102978|NCT00386204|DEVICE|Q-switched Ruby Laser|
48102979|NCT04370782|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5
48474668|NCT05457634|OTHER|blu Disposable C|Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
48474669|NCT05457634|OTHER|blu Disposable D|Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
48631858|NCT02917499|DEVICE|TMS|Transcranial magnetic stimulation
48631859|NCT05240885|OTHER|Stable tracer infusion in a postabsorptive state|Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids
48631860|NCT06124677|DRUG|Faricimab|The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
48631861|NCT03183440|DIETARY_SUPPLEMENT|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
48631862|NCT03183440|OTHER|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
47942812|NCT03613610|RADIATION|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
48474670|NCT05457634|OTHER|blu Disposable E|Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
48474671|NCT03123978|DRUG|Enzalutamide|Given PO
48474672|NCT03123978|DRUG|Niclosamide|Given PO
48631863|NCT01539889|RADIATION|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
48631864|NCT01014156|DRUG|epoprostenol|titration up to 4 ng/kg/min
48631865|NCT00145327|DRUG|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
48102980|NCT04370782|DRUG|Azithromycin|Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5
48102981|NCT04370782|DRUG|Zinc Sulfate|Zinc sulfate 220mg once daily for 5 days
47942813|NCT00296803|DRUG|clopidogrel|
48102982|NCT04370782|DRUG|Doxycycline|Doxycycline 200 mg once daily for 5 days
48102983|NCT04300933|BEHAVIORAL|Electroencephalogram-based neurofeedback|In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.
48102984|NCT02619266|OTHER|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
48102985|NCT02619266|OTHER|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
48474673|NCT06163092|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
48474674|NCT04381676|OTHER|Flipped Classroom Approach|In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
48474675|NCT00687882|OTHER|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
48474676|NCT00687882|OTHER|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
48474677|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
48474678|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
48474679|NCT03086135|DEVICE|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
48631866|NCT00145327|DRUG|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
48631867|NCT00284934|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
48631868|NCT00284934|DRUG|Tacrolimus|
48631869|NCT00284934|DRUG|Corticosteroids|At a dose of at least 5 mg/day.
48631870|NCT02361684|BEHAVIORAL|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
48631871|NCT02361684|OTHER|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
47942814|NCT06343389|DIAGNOSTIC_TEST|serum creatinine|to detect patients with Acute kidney injury
47942815|NCT05633004|DEVICE|Vivio|Non-invasive estimation of Left-Ventricular End Diastolic Pressure (LVEDP)
47942816|NCT05080660|DRUG|LY3526318|Administered orally.
47942817|NCT05080660|DRUG|Placebo|Administered orally.
47942818|NCT01511393|OTHER|No treatment given|None. Non-interventional study.
47942819|NCT03489551|DRUG|Haldol|
48102986|NCT02619266|DRUG|Megestrol Acetate|Megestrol Acetate 160mg tablet
48102987|NCT02619266|DRUG|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
48102988|NCT00098280|DRUG|Eculizumab|
48102989|NCT03631199|DRUG|canakinumab|canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)
48102990|NCT03631199|DRUG|canakinumab-matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
48102991|NCT03631199|DRUG|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
48102992|NCT03631199|DRUG|carboplatin|Area Under the Curve (AUC) 5 mg/mL\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\*min (squamous)
48102993|NCT03631199|DRUG|cisplatin|75 mg/m\^2 every 3 weeks (non-squamous)
47942820|NCT04549246|RADIATION|Spatially Fractionated Radiation (GRID) Therapy|Grid therapy allows for high doses of radiation to be delivered over several spatially distinct, small regions. This permits regions of very high dose to a large tumor away from critical structures, which could be beneficial in both palliative and definitive treatments. Additionally, allowing for high doses to be delivered could pose a benefit for radioresistant histologies.
47942821|NCT06184399|DRUG|Ivermectin 1.5 mg ODT|Oro-dispersible tablets of 1.5 mg ivermectin
47942822|NCT06184399|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
47942823|NCT06184399|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
47942824|NCT06184399|DRUG|Placebo IVM ODT|Placebo for ivermectin ODT
47942825|NCT05658666|BEHAVIORAL|Video feedback intervention (in Dutch: Video Interventie Ouderenzorg)|The video feedback trainer assesses the interaction between the person with dementia and the caregiver and acquires agreement from the caregiver on the goals of the intervention. Caregivers are trained during several feedback sessions using personal video footage of interaction between the person with dementia and the caregiver. The feedback focuses on basic interaction and attunement principles, and the team feeling competent. Recording starts with a nondemanding situation, enabling the caregiver to become aware of the principles they already apply and to learn how these principles can be used in more demanding situations. Subsequently, video footage is recorded in 1 to 3 situations, depending on the progress, of increasing difficulty, with about 4 weeks between 2 recordings. After each recording, a 1-hour feedback session is held. The intervention concludes with separate, 30-minute sessions for the formal and informal caregivers evaluating the intervention.
47942826|NCT03294473|BEHAVIORAL|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
47942827|NCT03294473|BEHAVIORAL|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
47942828|NCT03294473|BEHAVIORAL|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
47942829|NCT00846287|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
47942830|NCT00846287|DRUG|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
47942831|NCT00846287|DRUG|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
47942832|NCT02477267|DRUG|SL spray|
47942833|NCT02477267|DRUG|SL film|
47942834|NCT05832021|PROCEDURE|Open reduction and internal fixation (under WALANT)|Open reduction and internal fixation with volar Henry approach under WALANT.
47942835|NCT05832021|PROCEDURE|Open reduction and internal fixation (under peripheral nerve block)|Open reduction and internal fixation with volar Henry approach under peripheral nerve block.
47942836|NCT05659056|DRUG|Pyrotinib, trastuzumab, paclitaxel-albumin|pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
47942837|NCT03211962|OTHER|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
47942838|NCT05036720|BEHAVIORAL|LTP+Dads|"LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
48102994|NCT03631199|DRUG|paclitaxel|200 mg/m\^2 every 3 weeks (squamous)
47942839|NCT05036720|BEHAVIORAL|LTP+ Optional mother component|LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
47942840|NCT01504568|OTHER|Treatment|Adults: ≥40 kg:250mg every eight hours Children: \<40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
47942841|NCT04314310|DRUG|Tenoxicam|nonsteroidal anti-inflammatory drug (NSAID)
47942842|NCT04314310|DRUG|Placebo|equal volume of normal saline
47942843|NCT03611010|DRUG|Atorvastatin injection|statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
47942844|NCT03187756|DRUG|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
48102995|NCT03631199|DRUG|nab-paclitaxel|100 mg/m\^2 on Days 1, 8, and 15 of every cycle (squamous)
48102996|NCT03631199|DRUG|pemetrexed|500 mg/m\^2 every 3 weeks (non-squamous)
48102997|NCT03183024|BIOLOGICAL|benralizumab|open-label treatment
48102998|NCT03183024|BIOLOGICAL|placebo|sterile water to mimic benralizumab
48102999|NCT00325858|DRUG|Tramadol HCl ER|
48474680|NCT05050227|BEHAVIORAL|cCBT Enhanced Collaborative Care|"Computerized CBT (cCBT) will be delivered supported by a depression care manger who will facilitate access to cCBT, promote and monitor cCBT use, reinforce CBT concepts (during outside CBT session homework), and monitor mental health symptoms for each participant."
48631872|NCT02559960|DRUG|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
48631873|NCT02767245|DRUG|Thiamine|Thiamine IV 100 mg/day
47942845|NCT05883371|OTHER|Root-cause autoimmune treatment program|The AndHealth autoimmune treatment program combines validated and guideline-driven approaches along with emerging evidence-based modalities. The program includes a comprehensive assessment of disease severity, analysis of root causes and comorbidities, and an evaluation of the patient's readiness for implementing important lifestyle changes. This is followed by the development of an optimized and personalized plan to achieve and sustain clinical remission while monitoring their progress. Each patient participating in the AndHealth program receives a personalized care plan developed by the patient's medical provider in collaboration with a team of healthcare specialists. Helping a patient manage everyday lifestyle decisions can have a profound effect on their ability to achieve and maintain remission. The AndHealth Program has organized these into four basic groups of lifestyle behaviors: 1.) Dietary/Nutrition, 2.) Sleep/Circadian, 3.) Stress/HPA axis, and 4.) Physical Activity.
47942846|NCT03460600|OTHER|Optical Coherence Tomography (OCT)|Optical Coherence Tomography is a fairly new imaging technique in ophthalmology
47942847|NCT01437878|DRUG|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
47942848|NCT01437878|DRUG|Placebo|matching placebo
47942849|NCT05272839|DIETARY_SUPPLEMENT|Hypoglycemic food group|A booklet with 4 common food products, clinically validated against diabetes, with instructions for use will be presented to the diabetic patient. The selected food products have been assessed as anti-diabetic for humans through at least one fair randomized comparative clinical trial, with a follow-up of several weeks or months. While continuing to take his/her standard medication if any, the patient will be encouraged to follow his/her preferences within the established list of foods and spices: he is expected to choose 2 plants from the list and to consume each of them every day during the whole duration of the trial (12weeks).
47942850|NCT05272839|DIETARY_SUPPLEMENT|Control group|The control group will receive only lifestyle and dietary recommendations.
47942851|NCT02725853|DEVICE|tDCS|Application of 1.5 mA tDCS for 30 minutes
47942852|NCT02725853|DEVICE|sham tDCS|Application of sham tDCS for 30 minutes
47942853|NCT02725853|BEHAVIORAL|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
47942854|NCT02725853|BEHAVIORAL|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
48631874|NCT03428854|DRUG|LNG-IUS|Levnorgestrel containing IUD
47942855|NCT00937391|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
47942856|NCT01270061|BEHAVIORAL|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
47942857|NCT01270061|BEHAVIORAL|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
48103000|NCT05702710|OTHER|Surgery (PIRS)|"Laparoscopic procedure for repair of inguinal hernia as described in:~1) Thomas DT, Göcmen KB, Tulgar S, Boga I. Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric inguinal hernia: Experience with 250 cases. J Pediatr Surg. 2016 Aug;51(8):1330-5. doi: 10.1016/j.jpedsurg.2015.11.024. Epub 2015 Dec 11. PMID: 26777889."
48474681|NCT05050227|BEHAVIORAL|Usual Care|Primary Care Provider supported usual care typically includes medication prescription and referrals to specialty mental health, including Primary Care - Mental Health Integration services.
48474682|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
48631875|NCT02517138|OTHER|Parabolic flight|
48631876|NCT02517138|OTHER|Measurements of eye movements and perception|
48631877|NCT04333654|DRUG|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
48474683|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
48631878|NCT04333654|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
48631879|NCT02460380|DRUG|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
48631880|NCT02460380|OTHER|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
47942858|NCT01450111|DRUG|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
47942859|NCT01450111|DRUG|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
47942860|NCT01450111|DRUG|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
47942861|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
47942862|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
48631881|NCT01213771|PROCEDURE|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
48631882|NCT02493855|DRUG|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
48631883|NCT02493855|DRUG|Dasabuvir|Dasabuvir tablets
48631884|NCT02493855|DRUG|Ribavirin (RBV)|Ribavirin tablets
48631885|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
47942863|NCT01450111|OTHER|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
48474684|NCT06473051|OTHER|Original set|The original set of implementation strategies will include the same strategies as applied in the INTERCARE study by the research group but will be updated to fit the current practice field.
48474685|NCT06473051|OTHER|Adapted set|The adapted set of implementation strategies will contain similar implementation strategies that are expected to achieve the same outcomes as the first set, but with less resources required (for instance, by providing group coaching sessions rather than single sessions).
48474686|NCT06334276|OTHER|Drowning|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
48474687|NCT06350123|DRUG|Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
48474688|NCT06350123|DRUG|Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
48291860|NCT02137551|OTHER|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
48474689|NCT06350123|DRUG|Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
48474690|NCT01583634|DEVICE|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
48474691|NCT01583634|DEVICE|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
48474692|NCT04801719|DEVICE|Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK|Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
48474693|NCT03454282|OTHER|FMD|The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
48474694|NCT03170869|DEVICE|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
48474695|NCT01144403|DRUG|Cyclophosphamide|as prescribed, 6 cycles
48474696|NCT01144403|DRUG|Fludarabine|as prescribed, 6 cycles
48474697|NCT01144403|DRUG|Mitoxantrone|as prescribed, 6 cycles
48474698|NCT01144403|DRUG|Rituximab|375 mg/m\^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
48631886|NCT01002391|PROCEDURE|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
48631887|NCT00120848|BIOLOGICAL|HPV 16/18 VLP AS04|
48631888|NCT01208051|DRUG|Cediranib|Given PO
47942864|NCT00003173|BIOLOGICAL|filgrastim|
47942865|NCT00003173|DRUG|thiotepa|
47942866|NCT00003173|PROCEDURE|autologous bone marrow transplantation|
47942867|NCT00003173|PROCEDURE|peripheral blood stem cell transplantation|
47942868|NCT02992080|OTHER|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
47942869|NCT00048763|DRUG|Pletal|
47942870|NCT03718182|DIETARY_SUPPLEMENT|Cholecalciferol|vitamin D3 daily oral supplement
48103001|NCT06630546|DEVICE|first generation iStent (Glaukos, San Clemente, CA, USA) insertion|In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
48474699|NCT04227041|DRUG|Pyrotinib in combination with capecitabine|Pyrotinib in combination with capecitabine
48474700|NCT00003707|DRUG|gemcitabine hydrochloride|
47942871|NCT04082559|OTHER|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
48474701|NCT00003707|DRUG|tipifarnib|
48474702|NCT02360306|PROCEDURE|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
48474703|NCT01043926|DRUG|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
48474704|NCT05484141|OTHER|Rehabilitation with blood blow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
48474705|NCT05484141|OTHER|Rehabilitation without blood flow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
48631889|NCT01208051|DRUG|Cediranib Maleate|Given PO
48631890|NCT01208051|OTHER|Laboratory Biomarker Analysis|Correlative studies
48631891|NCT01208051|DRUG|Lenalidomide|Given PO
47942872|NCT04082559|OTHER|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
48103002|NCT06630546|DEVICE|phacoemulsification|A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
48631892|NCT05937100|DRUG|Formocresol|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
48631893|NCT05937100|DRUG|Biodentine|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
48631894|NCT05937100|DRUG|Hyaluronic acid gel|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
48631895|NCT04607590|OTHER|Best Practice|Receive usual care
48631896|NCT04607590|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
48631897|NCT04607590|OTHER|Questionnaire Administration|Ancillary studies
48631898|NCT04607590|PROCEDURE|Yoga|Participate in yoga sessions
48631899|NCT05364489|DRUG|Bevacizumab combined with Oxaliplatin and TAS-102|"Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug ."
48631900|NCT02712242|OTHER|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
48631901|NCT02712242|OTHER|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
48631902|NCT02712242|OTHER|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
48631903|NCT00739570|DEVICE|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
48103003|NCT06087432|OTHER|Rocabado's 6x6 Exercises|Rocabado's 6x6 program includes 6 basic components: tongue rest position, TMJ rotation control, cervical spine release, shoulder girdle retraction and rhythmic stabilization technique.
48103004|NCT06087432|OTHER|PNF Exercises|Proprioceptive neuromuscular facilitation (PNF) exercises will be applied to the neck and jaw with rhythmic stabilization (RS) and combined isotonic contraction (CIC) techniques. The RS protocol consists of alternating isometric contractions for 10 seconds and does not involve movement. The KIK technique involves combined concentric, isometric and eccentric contraction of the agonist muscle without rest, with each contraction lasting 5 seconds. KIK exercises consist of 5-15 repetitions per set, depending on the individual's tolerance. Between sets, a 30-second rest will be included. First, the RS protocol will be applied and after a 2-minute rest interval, the exercise will continue with the KIK protocol applications. The expected duration of exercise exercises is 30 minutes. Maximum performance will be requested from the individual in all repetitions and the necessary verbal commands will be given for appropriate movement.
47942873|NCT04082559|OTHER|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
47942874|NCT04082559|OTHER|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
48103005|NCT00677248|DRUG|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
48291861|NCT06664034|BEHAVIORAL|Multi-component reproductive health care intervention|"The multi-component reproductive health care intervention includes:~1. Young cancer patients presenting to oncology visits will complete a clinic-based reproductive health needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future and ii) need for contraception.~2. Reproductive health patient navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's reproductive health needs, ii) provide individualized patient education and counseling on a) infertility risk related to cancer type and treatment and b) screening and management strategies for reproductive health needs, iii) provide support with the goal of engaging in goal-concordant reproductive health care.~3. Telehealth reproductive health consultation will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
48291862|NCT04354051|DRUG|Sodium Nitrite|Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
48291863|NCT03163030|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
48291864|NCT04764032|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be undertaken by a range of appropriately competent practitioners including; intensive care clinicians, cardiologists and specialist echocardiographers. Imaging obtained will be in keeping with the protocol required for a Focused Intensive Care Echo (FICE) scan and should include ECG monitoring at all times. A focused dataset will be used to answer the primary outcome. If available and the echocardiographers competency and experience permit, further measures of RV function will be obtained at this time.
48291865|NCT02873715|BEHAVIORAL|Family-based treatment|Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
48103006|NCT00677248|DRUG|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
48291866|NCT02873715|BEHAVIORAL|Usual Care|Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
48291867|NCT00449059|DRUG|acute infusion of nitroglycerine into the pulmonary artery|
48291868|NCT06080750|GENETIC|Quantitative Real Time Polymerase chain reaction (qRT-PCR)|to study gene expression of NLRP3 inflammasome and IL-1B in blood
48291869|NCT06080750|DIAGNOSTIC_TEST|ELISA and colorimeter|IL-6 and total LDH
48474706|NCT02609516|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
48474707|NCT02833207|DRUG|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
48474708|NCT02833207|DRUG|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
48474709|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
48474710|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
48474711|NCT03964363|BEHAVIORAL|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
48474712|NCT03739216|DEVICE|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
48474713|NCT03186716|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
48474714|NCT03186716|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
48103007|NCT01842971|PROCEDURE|two stage hepatectomy|
48474715|NCT03584217|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
48474716|NCT03584217|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
48474717|NCT03584217|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
48474718|NCT06474481|DRUG|Zanubrutinib|Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
48103008|NCT00822913|DRUG|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
48103009|NCT04187157|DEVICE|Blue-light filtering intraocular lens|Bilateral implantation of blue light-blocking intraocular lens
48103010|NCT04187157|DEVICE|Conventional intraocular lens|Bilateral implantation of conventional intraocular lens
48291870|NCT01284556|DRUG|Phenobarbital|tablet
48291871|NCT01284556|DRUG|Placebo tablet|tablet
48291872|NCT05890391|OTHER|Time-Restricted Eating|They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
48291873|NCT05890391|OTHER|Energy-Restricted Diet|The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
48291874|NCT04977544|DEVICE|vert|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
48631904|NCT02985710|DEVICE|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
48291875|NCT04977544|DRUG|Sertraline|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
48291876|NCT02617121|DRUG|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
48631905|NCT02985710|PROCEDURE|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
48291877|NCT02617121|DRUG|Ramosetron|ramosetron 0.3 mg iv at end of surgery
48631906|NCT02985710|PROCEDURE|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
48474719|NCT06474481|DRUG|Obinutuzumab|Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
48631907|NCT01260792|OTHER|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
48103011|NCT03095209|DRUG|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
48474720|NCT06474481|DRUG|Prednisone|Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
48474721|NCT06474481|DRUG|Cyclophosphamide|Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
48474722|NCT06474481|DRUG|Vincristine|Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
48474723|NCT06474481|DRUG|Doxorubicin|Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
48474724|NCT05389709|DRUG|Iberogast (STW5-II, BAY98-7410)|Survey without any intervention assigned in the study.
48631908|NCT01260792|OTHER|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
48631909|NCT05102838|OTHER|Anti-virus treatment|Anti-virus treatment
48474725|NCT03079388|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
48474726|NCT03079388|DIETARY_SUPPLEMENT|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
48474727|NCT03079388|DRUG|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
48474728|NCT03079388|DRUG|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
48474729|NCT03079388|OTHER|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
48474730|NCT03079388|DRUG|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
48474731|NCT03079388|DRUG|Albendazole|Single dose albendazole 400mg given in the second trimester.
48474732|NCT03079388|COMBINATION_PRODUCT|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
48103012|NCT03095209|DRUG|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
48103013|NCT03095209|RADIATION|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
48291878|NCT02617121|DRUG|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
48291879|NCT04059809|DEVICE|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 \~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
48474733|NCT05201079|BIOLOGICAL|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
48474734|NCT05201079|DRUG|Dificlir|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
48474735|NCT00349401|DRUG|ketorolac|
48474736|NCT00349401|DRUG|morphine|
48474737|NCT02837133|BEHAVIORAL|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
48474738|NCT04987749|DEVICE|intermittent theta burst stimulation|stimulatory protocol
48618099|NCT01503047|DIETARY_SUPPLEMENT|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
48291880|NCT06260150|DEVICE|Intermittent Pneumatic Compression Devices|During use, the pressure is gradually reduced from large to small, and pressure is applied in steps, starting from the calf and moving up to the thigh. Every 30 minutes, the patient's skin color of the lower extremities is observed for any abnormalities, and the blood supply status of the distal ends of both lower limbs (palpation of the dorsalis pedis artery pulse) is noted. If any special conditions occur, the procedure must be immediately stopped.
48291881|NCT01038492|BEHAVIORAL|p16 Methylation and Lung Cancer Education|"* patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~* patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits."
48291882|NCT01187212|DRUG|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
48291883|NCT01187212|DRUG|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
48291884|NCT01067638|DRUG|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
48291885|NCT04701281|COMBINATION_PRODUCT|Intra-arterial LIOX + Capecitabine|5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
48291886|NCT02156700|PROCEDURE|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
48291887|NCT04272307|BIOLOGICAL|Blood samples|"At inclusion, at day 5, day 42 and at 3 months, one 2 ml EDTA blood tube will be collected for metabolomics.~Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method.~At inclusion, one 2 ml EDTA tube will be stored as a DNA collection."
48291888|NCT04272307|PROCEDURE|Stool samples|"One stool sample will be taken at baseline, day 5, day 42 and at 3 months and frozen at -80°C and divided in 2 aliquots.~One stool aliquot will be used for metabolomics. Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method. The other one will be used for microbiota analysis. Samples will be sent to the McGill University (Prof. SALEH's lab) for extraction and then, Génome Québec Innovation Centre (McGill University, Montréal, Canada) for sequencing of the V4 region of the 16S rRNA gene on Illumina MiSeq in paired-end mode."
48291889|NCT04272307|PROCEDURE|Colorectal biopsies|During routine flexible sigmoidoscopy, 6 biopsies will be collected with a 5 mm biopsy forceps at baseline and at 3 months. Biopsies will be placed into a sterile vial containing RNAlater (Qiagen, Hilden, Germany) and stored at -80°C. Two biopsies will be used for mucosal microbiome analysis in the same way as the stool sample. Four biopsies will be used for RNAseq. Samples will be shipped to Prof. SALEH's lab in Montréal for nucleic acid extraction. The McGill University and Génome Québec Innovation Centre (McGill University, Montréal, Canada) will provide library preparation and next generation sequencing. The average number of uniquely mapped reads per sequencing run will be 30 million reads per sample.
48291890|NCT05450861|OTHER|SF DNA extraction composition|the composition of small fragments of DNA from fish
48291891|NCT05450861|OTHER|Placebo|the scalp conditioning solution without SF DNA extraction composition
48291892|NCT00092911|DRUG|DVS-233 SR|
48291893|NCT03714412|DEVICE|Implantation|Implantation of the Cardiovalve transfemoral mitral valve replacement system
48291894|NCT00372164|PROCEDURE|American Society of Interventional Pain Physician Guidelines|
48291895|NCT01526226|DEVICE|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
48291896|NCT01526226|DEVICE|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
47942875|NCT04082559|OTHER|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
47942876|NCT04082559|OTHER|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
47942877|NCT04082559|OTHER|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
48291897|NCT00591383|DRUG|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
48291898|NCT00591383|DRUG|erlotinib|erlotinib taken at 150 mg every morning with food.
48291899|NCT01788085|DEVICE|Bravo pH monitoring procedure|Bravo pH monitoring procedure
48291900|NCT06668870|BEHAVIORAL|Supplemental Text Messaging|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information. Supplemental text messages will be sent to engage patients and deliver personalized reminders to complete monitoring tasks.
48291901|NCT06668870|BEHAVIORAL|Education and Training for Patient-Generated Data|Will receive education about the collection of patient-generated data, training in using the data collection tools, and guidance on the standard frequency for collection and sharing of information.
48291902|NCT06448780|DRUG|Caffeine citrate 20 mg/kg|Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
48291903|NCT06448780|DRUG|Caffeine citrate 30 mg/kg|Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
48291904|NCT01595204|PROCEDURE|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
48291905|NCT01500174|DEVICE|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
48291906|NCT01500174|DEVICE|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
48474739|NCT05212441|DEVICE|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
48618100|NCT01503047|DIETARY_SUPPLEMENT|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
48103014|NCT04511650|DRUG|Razuprotafib Subcutaneous Solution|Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
48103015|NCT04511650|DRUG|Placebo Subcutaneous Solution|Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
48631910|NCT04978831|DEVICE|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
47942878|NCT00005110|DRUG|Salmeterol|
48103016|NCT02276508|DRUG|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
48103017|NCT01673113|DEVICE|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
48103018|NCT06047262|DRUG|Dapansutrile|Patients receive investigational product.
47942879|NCT00005110|DRUG|Albuterol|
48103019|NCT06047262|DRUG|Placebo|Patients receive placebo.
48103020|NCT05252624|DRUG|placebo|Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
48103021|NCT05252624|DRUG|Henagliflozin 5Mg Tab|Single oral tablet
48103022|NCT05225935|DEVICE|image-guided VT ablation strategy|Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
48291907|NCT06517810|DEVICE|QUELIMMUNE (SCD-PED)|QUELIMMUNE device used as part of clinical practice.
48291908|NCT02625519|DRUG|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
48291909|NCT02625519|DRUG|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
48291910|NCT00928980|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
48291911|NCT00928980|DRUG|Optimal Medical Care|Therapeutic dose of antidepressant medication
48291912|NCT03000114|PROCEDURE|Percutaneous Needle Aponeurotomy|
48291913|NCT03000114|DRUG|XIAFLEX|
48291914|NCT01347684|BEHAVIORAL|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
48291915|NCT01347684|DRUG|Standard care using current drugs|Standard Drug therapy
48291916|NCT04634123|OTHER|Pulpotomy therapy by White Portland Cement|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement
48291917|NCT04634123|OTHER|Pulpotomy therapy by White MTA|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
48474740|NCT05212441|BEHAVIORAL|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
48618101|NCT03258242|DRUG|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
48618102|NCT03258242|DRUG|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
48618103|NCT06061419|OTHER|Huel Powder|Huel Powder v3.0 white, vanilla flavour
48103023|NCT05225935|DEVICE|conventional VT ablation strategy|Catheter ablation will be performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
48103024|NCT03828162|DRUG|Anticoagulants|
48103025|NCT00004192|BIOLOGICAL|filgrastim|
48103026|NCT00004192|BIOLOGICAL|pegfilgrastim|
48103027|NCT00004192|DRUG|cisplatin|
48103028|NCT00004192|DRUG|cytarabine|
48103029|NCT00004192|DRUG|etoposide|
48103030|NCT00004192|DRUG|methylprednisolone|
48103031|NCT04966572|DEVICE|Presurgical vacuum formed nasoalveolar molding aligners|at first visit, the infants will receive this appliance which is a maxillary vacuum plate incorporated with palatal screw, the infant's parents will be instructed to activate the screw and apply horizontal tap which will be placed at the base of nose in order to approximate lip segments and to change tape daily. After that, The infants will be recalled one week after the first visit to add the nasal stents into the appliance.
48103032|NCT04966572|DEVICE|Conventional Grayson acrylic formed nasoalveolar molding appliances|"at first visit, the infants will receive this appliance which is a maxillary acrylic plate without adding taping, the infants will be recalled bi weekly for activating the appliance.~When the cleft alveolar gap is reduced to 6mm or less, a pair of nasal stents will be added to mold the nasal cartilage. the infants will be followed up for 4-6 months."
48103033|NCT03966794|DEVICE|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
48103034|NCT03966794|COMBINATION_PRODUCT|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
48103035|NCT05542342|DRUG|Tislelizumab|200 mg IV once every 3 weeks
48291918|NCT00058370|DRUG|cisplatin|
48103036|NCT05542342|DRUG|Sitravatinib Malate|100 mg orally once daily
48103037|NCT00853424|PROCEDURE|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
48103038|NCT00853424|OTHER|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
48291919|NCT00058370|DRUG|lomustine|
48291920|NCT00058370|DRUG|vincristine sulfate|
48291921|NCT00058370|PROCEDURE|adjuvant therapy|
48291922|NCT00058370|RADIATION|iodine I 131 monoclonal antibody 3F8|
48291923|NCT00058370|RADIATION|radiation therapy|
48291924|NCT00298662|DRUG|Interferon beta-1b and Tacrolimus|
48291925|NCT05533554|BEHAVIORAL|Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students|Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre and post a month later) and 2 intervention sessions with a duration of 120 minutes each.
48291926|NCT04939896|OTHER|observation|Observed patients' compliance with rehabilitation at different time
48291927|NCT02553915|OTHER|Placebo|Soybean oil placebo
48291928|NCT02553915|DRUG|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
48291929|NCT02553915|DRUG|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
48291930|NCT02553915|DRUG|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
48291931|NCT04835272|PROCEDURE|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
48291932|NCT05202977|DEVICE|SinocrownTM Transcatheter Aortic Valve Replacement System|Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
48291933|NCT06257004|GENETIC|Saliva collection (screening of all participants)|All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis
48291934|NCT06257004|GENETIC|Bloodsampling|Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
48291935|NCT04368130|BEHAVIORAL|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
48291936|NCT06587568|BEHAVIORAL|Mobile chat messaging|A trained counsellor will interact with a participant individually and provide personalised alcohol reduction information and advice via a mobile instant messaging app in real time for 3 months from randomisation.
48291937|NCT06587568|BEHAVIORAL|Screening, brief intervention and referral to treatment|Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet
48291938|NCT02235285|PROCEDURE|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
48291939|NCT06365476|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.
48291940|NCT02021812|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
48291941|NCT00318838|DRUG|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
48291942|NCT00318838|DRUG|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
48291943|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
48291944|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
48291945|NCT00765869|OTHER|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
48291946|NCT03515980|DRUG|BMS-986231|Intravenous (IV) administration
48291947|NCT03341403|DIETARY_SUPPLEMENT|Probiotical®/Bactecal®|"Probiotical/Bactecal® is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill."
48291948|NCT03341403|OTHER|Placebo|pills containing placebo
48291949|NCT02498223|OTHER|experiment protocol|"the subjects will undergo the following experiment protocol:~1. recruitment and medical examination day.~2. physiological evaluation day- the subjects will perform twice\* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~3. biomechanical valuation day- the subjects will perform twice\* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~   * once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
48291950|NCT05396118|DRUG|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
48618104|NCT01768273|DRUG|Midazolam|
48618105|NCT01768273|DRUG|PA-824|
47942880|NCT05468385|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity of around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
48103039|NCT03679962|BEHAVIORAL|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
48103040|NCT03679962|BEHAVIORAL|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
48103041|NCT06027112|OTHER|musculoskeletal injuries|This research will be conducted to identify the factors that increase the risk of musculoskeletal injuries in university students,
48291951|NCT05396118|DRUG|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
48291952|NCT05396118|PROCEDURE|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.
48291953|NCT01370954|OTHER|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
48474741|NCT05212441|PROCEDURE|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
47942881|NCT05468385|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity of around 0.5mA via the earlobe in the left ear (based on participants' subjective reports), delivered with a pulse width of 0.5 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
47942882|NCT03953183|OTHER|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
47942883|NCT03953183|OTHER|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
47942884|NCT02669238|DEVICE|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
47942885|NCT02669238|DRUG|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
47942886|NCT03998813|DRUG|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
48291954|NCT01654575|DRUG|Methotrexate|Methotrexate 25mg/week for 16 weeks
48618106|NCT00484159|PROCEDURE|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
47942887|NCT03998813|DRUG|Ropivacaine|Tissue infiltration
47942888|NCT04208581|DRUG|Yiqi Huoxue Huatan granule|Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
47942889|NCT04208581|DRUG|Placebo Yiqi Huoxue Huatan granule|Placebo Yiqi Huoxue Huatan granule will be administered twice daily for five days a week for 52 weeks,Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks, Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks, Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks.
47942890|NCT05210231|OTHER|Transcranial Direct Current Stimulation|The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
48103042|NCT03762330|BEHAVIORAL|COPD structured self-management plan.|Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
48103043|NCT00578617|DRUG|Rate Control|Metoprolol 50-100mg
48103044|NCT00578617|DEVICE|Ablation Therapy|
48291955|NCT01654575|DRUG|Placebo|Placebo tablets once a week for 16 weeks
48291956|NCT05394545|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
48291957|NCT00002828|DRUG|fluorouracil|
48291958|NCT00002828|DRUG|raltitrexed|
48291959|NCT00400387|DRUG|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
48291960|NCT00400387|DIETARY_SUPPLEMENT|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
48291961|NCT04644107|DRUG|Marizomib|Marizomib will be administered via IV
48291962|NCT02642861|DRUG|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
48291963|NCT02642861|DRUG|Calcium Carbonate|Calcium carbonate for 2 weeks
48291964|NCT04370262|DRUG|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
48291965|NCT04370262|DRUG|SOC + Placebo|Standard of Care treatment plus IV placebo
48291966|NCT05483972|BEHAVIORAL|Whole Prediabetes Diet Intervention|Participants will be instructed by RDN on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled adults in the study, the goal is to maintain complete diet adherence during the two-week intervention. The focus for children/adolescents will be on encouragement and exposure of the diet by the index parent and any additional household parent/guardian/caregiver. Participants will receive groceries that are tailored specifically to the prescribed diet menus/recipes for each week. Foods will be distributed using either a grocery delivery service or via participant pick-up. Each household will receive enough groceries to feed a household of four-persons for each week of the intervention.
48291967|NCT05395169|OTHER|dietary supplement ,electronic treadmill ,DASH diet.|Control group Will be receive medical treatment for 12 weeks. Study group Will be receive the same medication as in control group in addition to DASH diet and aerobic exercise for 12 weeks.
48618107|NCT00484159|DRUG|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
47942891|NCT01195077|OTHER|seaweed, spirulina, seaweed + spirulina|"Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day."
47942892|NCT03702686|DEVICE|FEEDBACK System|Smart Nipple Shield and Monitor Unit
47942893|NCT00744458|OTHER|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
48291968|NCT00145340|DRUG|pioglitazone|30 Mg/day
48291969|NCT05657977|OTHER|nonpharmacologic intervention (swaddling)|Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
48291970|NCT03418246|DEVICE|GIC|tooth colored filling
47942894|NCT00744458|OTHER|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
47942895|NCT00744458|OTHER|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
47942896|NCT03979430|OTHER|Home spirometry|Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
47942897|NCT05561010|DRUG|Intra-articular injection of bupivacaine in the knee joint|25 participants will be allocated to the bupivacaine arm.
47942898|NCT05561010|DRUG|Intra-articular injection of placebo in the knee joint|25 participants will be allocated to the placebo arm.
47942899|NCT02981810|DEVICE|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55\* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
47942900|NCT02981810|PROCEDURE|tonsillectomy|
47942901|NCT03512990|PROCEDURE|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
47942902|NCT02104973|BEHAVIORAL|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
47942903|NCT01388920|DRUG|Tesamorelin|
47942904|NCT01388920|DRUG|Placebo|
48291971|NCT03418246|DEVICE|Biodentine|White filling -Biodentine
48291972|NCT04388735|BEHAVIORAL|Questionnaire|Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
48618108|NCT00484159|DRUG|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
47942905|NCT06150469|COMBINATION_PRODUCT|"Blend of ginger and lemon essential oils, Neutral oil"|Patients will be given aromasticks to inhale the blend of essential oils.
47942906|NCT03081221|DIAGNOSTIC_TEST|USG|
47942907|NCT02526836|PROCEDURE|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
47942908|NCT02526836|PROCEDURE|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
47942909|NCT01539317|DRUG|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
47942910|NCT01539317|DRUG|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
47942911|NCT03827837|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
47942912|NCT03827837|DRUG|Famitinib|a small-molecule multikinase inhibitor
47942913|NCT03952754|BEHAVIORAL|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
47942914|NCT03952754|BEHAVIORAL|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
47942915|NCT03415854|DRUG|Paricalcitol (Zemplar)|combination therapy
47942916|NCT03970213|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
47942917|NCT03970213|DRUG|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
47942918|NCT02131532|BEHAVIORAL|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
47942919|NCT02732080|DEVICE|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
47942920|NCT02732080|DEVICE|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
47942921|NCT02732717|OTHER|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
47942922|NCT06083935|DRUG|Daflon|Daflon; two film coated tablets 500 mg daily
47942923|NCT06083935|DRUG|Combined oral contraceptive|Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily
48618109|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
48618110|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
47942924|NCT06083935|DRUG|Metformin|Glucophage ® 500 tablets twice daily
47942925|NCT05386485|OTHER|None intervation|Observational Study
47942926|NCT03128645|DEVICE|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
48103045|NCT00578617|DRUG|Rate Control|Atenolol 50-100mg,
48103046|NCT00578617|DRUG|Rate control|Propranolol 40-80mg
48103047|NCT00578617|DRUG|Rate control|Acebutolol 200mg
48103048|NCT00578617|DRUG|Rate control|Carvedilol 6.25mg
48103049|NCT00578617|DRUG|Rate Control|Diltiazem 180-240mg
48103050|NCT00578617|DRUG|Rate Control|Verapamil 180-240mg
48618111|NCT00484159|PROCEDURE|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
47942927|NCT02636374|BEHAVIORAL|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
47942928|NCT00291538|DRUG|bortezomib|
48103051|NCT00578617|DRUG|Rate Control|Digoxin 0.125mg
48103052|NCT00578617|DRUG|Rhythm Control|Propafenone 450mg
48103053|NCT00578617|DRUG|Rhythm control|Flecainide 200mg
48103054|NCT00578617|DRUG|Rhythm control|Sotalol 240mg
48103055|NCT00578617|DRUG|Rhythm control|Dofetilide 500mcg
48103056|NCT00578617|DRUG|Rhythm control|Amiodarone 200mg
48103057|NCT00578617|DRUG|Rhythm control|Quinidine 600-900mg
48291973|NCT00318708|DRUG|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
47942929|NCT00405327|BIOLOGICAL|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
48618112|NCT00484159|PROCEDURE|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
47942930|NCT00405327|OTHER|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
47942931|NCT03866031|OTHER|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
47942932|NCT00261118|DRUG|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
47942933|NCT04926454|DRUG|Dexmedetomidine|"Patients will be monitored using standard monitoring (heart rate, non-invasive blood pressure, ECG and pulse oximetery) After the child is adequately anesthetized, intra-venous access with appropriate size cannula will be obtained Appropriate size LMA (2 and 2.5) will be inserted and patients will be allowed to breathe spontaneously.~patients will receive 0.25% Bupivacaine (0.3ml/Kg) with 1 μg/kg dexmedetomidine After general anaesthesia"
47942934|NCT02038452|DRUG|Depo-Medrone|Steroid Injection
47942935|NCT02038452|DEVICE|Wrist Splint|Simple wrist splint
47942936|NCT04465162|OTHER|Radiation Therapy|Undergo radiation therapy
47942937|NCT05684939|BEHAVIORAL|Questionnaire (patient reported outcome)|Online self-administered questionnaire exploring substance use, pain, chemotherapy-induced peripheral neuropathy, health-related quality of life, anxiety, depression, social and material deprivation, patients and oncological charactericitcs, and intercurrent pathologies
47942938|NCT03292211|BEHAVIORAL|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
47942939|NCT03292211|BEHAVIORAL|early standard intervention|Conventional early in-bed activities within three days after stroke
47942940|NCT05192915|DEVICE|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
47942941|NCT03149510|BEHAVIORAL|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
47942942|NCT05300633|BEHAVIORAL|Group-Based Community Reinforcement Approach and Family Training-Early Psychosis Intervention (CRAFT-EPI)|Behavioral therapy adapted for families of young people experiencing early psychosis delivered via telemedicine to groups following an individual orientation. Group session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, and problem solving. A happiness scale will be completed at each session. Will be provided in the context of an early psychosis intervention program that provides coordinated specialty care to 16- to 29-year-olds experiencing any diagnosis that can manifest as early psychosis.
47942943|NCT02826850|PROCEDURE|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
47942944|NCT02826850|PROCEDURE|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
47942945|NCT02570841|DRUG|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
47942946|NCT02570841|DRUG|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
47942947|NCT05360368|DRUG|HLX07|A Recombinant Humanized Anti-EGFR Monoclonal Antibody, HLX07 will be administered as a single intravenous (IV) infusion on Day 1 in each 3-week cycle
47942948|NCT05718999|DIAGNOSTIC_TEST|Not intervention|Not having intervention is an observational study
47942949|NCT02325661|OTHER|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
47942950|NCT00810381|DRUG|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
47942951|NCT00810381|DRUG|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
47942952|NCT00810381|DRUG|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
47942953|NCT00810381|DRUG|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
47942954|NCT05213000|BEHAVIORAL|Exercise|90 minute exercise session
47942955|NCT00700570|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
47942956|NCT00700570|DRUG|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
47942957|NCT00700570|DRUG|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
47942958|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 10 mg IV every 8 weeks
47942959|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 5mg IV every 8 weeks
47942960|NCT00744471|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
47942961|NCT00744471|BIOLOGICAL|Placebo|Placebo to match tanezumab IV every 8 weeks
47942962|NCT02171572|DRUG|Dabigatran etexilate low|
47942963|NCT02171572|DRUG|Dabigatran etexilate high|
48474742|NCT05212441|OTHER|Therapeutic Exercises|"1. Passive ROM (PROM).~2. Active ROM (AROM) \& Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~3. Stretching exercises: A low-load (low-intensity), long-duration stretch~4. Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
48474743|NCT04002869|DIAGNOSTIC_TEST|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
48474744|NCT02078011|DEVICE|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
48474745|NCT02142231|DEVICE|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
48474746|NCT02142231|DEVICE|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
48474747|NCT01708655|OTHER|Sweat Evaporimeter measurement|"1. The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~2. intracutaneous injection of 0.2 ml of atropine~3. Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~   1. Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~  2. intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~  3. intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
48474748|NCT03847363|PROCEDURE|epidural anesthesia|epidural anesthesia
48474749|NCT03847363|PROCEDURE|nerve block|paravertebral or serratus anterior plane block
48103058|NCT04147416|DRUG|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
48103059|NCT04147416|DRUG|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
48103060|NCT04168814|OTHER|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
48103061|NCT06261333|OTHER|Questionnaires|No Intervention
48103062|NCT05768932|DRUG|BAL0891|BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
48103063|NCT05768932|COMBINATION_PRODUCT|Carboplatin|Carboplatin is an Antineoplastic agent
48103064|NCT05768932|COMBINATION_PRODUCT|Paclitaxel|Paclitaxel is a natural product with antitumor activity
48291974|NCT00318708|DRUG|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
48291975|NCT00318708|DRUG|placebo clarithromycin|placebo clarithromycin twice daily
47942964|NCT00000656|DRUG|Zidovudine|
47942965|NCT00000656|DRUG|Didanosine|
47942966|NCT05869565|DRUG|Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1|Patients will be enrolled in the study and randomized into one of four arms
47942967|NCT02869997|DEVICE|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
47942968|NCT01631812|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
47942969|NCT03850665|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
47942970|NCT03850665|PROCEDURE|Anterolateral approach|Anterolateral approach surgery to replace the hip.
47942971|NCT03552458|DRUG|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
47942972|NCT03552458|DRUG|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
47942973|NCT03031236|BEHAVIORAL|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
47942974|NCT04621565|DRUG|Normal saline|No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
47942975|NCT04621565|DRUG|Hydrocortisone|"Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program."
47942976|NCT02188225|PROCEDURE|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
47942977|NCT02188225|DRUG|fluoxetine|10 mg/ daily
47942978|NCT04996641|PROCEDURE|Root canal treatment and crown|Pre-radiation one day root canal treatment and CAD/CAM chair side fabricated crowns for head and neck cancer patients
47942979|NCT01669096|BIOLOGICAL|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
47942980|NCT01925274|DRUG|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
47942981|NCT01925274|DRUG|irinotecan|90 minutes IV infusion of irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
47942982|NCT01925274|DRUG|Cetuximab|120 minute IV infusion of cetuximab 400mg/m\^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
47942983|NCT01925274|DRUG|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
47942984|NCT05255029|DEVICE|POD T 49P implantation experimental|The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
47942985|NCT05109052|DRUG|PXS-5505 and Atezolizumab and Bevacizumab|Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
48291976|NCT03831503|BIOLOGICAL|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
47942986|NCT00004347|BEHAVIORAL|diet|
47942987|NCT00686179|DRUG|AZD3480|Capsule, oral, single dose, 6 days
47942988|NCT00686179|DRUG|Moxifloxacin|Capsule(encapsulated), oral, single dose
47942989|NCT00686179|DRUG|PLACEBO|Capsule, oral, single dose
47942990|NCT01546012|DEVICE|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
47942991|NCT01546012|DEVICE|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
47942992|NCT05473884|DEVICE|lesion preparation devices|successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
47942993|NCT05473884|DEVICE|conventional balloon|Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
47942994|NCT01484054|DEVICE|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
47942995|NCT01484054|DEVICE|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
47942996|NCT04073368|DIETARY_SUPPLEMENT|AXA1957|Amino acids, food study
47942997|NCT04073368|DIETARY_SUPPLEMENT|AXA1125|Amino acids, food study
47942998|NCT04073368|DIETARY_SUPPLEMENT|Placebo|Amino acids, food study
47942999|NCT02857361|DRUG|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
47943000|NCT03161093|DRUG|Fasinumab|Solution for injection in pre-filled syringe
47943001|NCT03161093|DRUG|Naproxen|Pharmaceutical form: Capsule
47943002|NCT03161093|DRUG|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
47943003|NCT03161093|DRUG|Naproxen-matching placebo|Capsule
48103065|NCT05381662|BIOLOGICAL|CD19 CAR-T cells and CD19 positive feeder T cells|Detailed Description: Patients were divided into two groups, group 1 and group 2, and each group was enrolled in 5 patients. Group 1 patients did not receive any pretreatment, and group 2 patients received pretreatment with cyclophosphamide and fludarabine prior to reinfusion. Then Patients were given Chimeric Antigen Receptor T-Cell ( CAR-T) and CD19-positive T cells.
48103066|NCT00995709|DRUG|AIN457|
48103067|NCT00995709|DRUG|AIN457|
48103068|NCT00995709|DRUG|Placebo|
48474750|NCT00280969|DRUG|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
48474751|NCT00280969|DRUG|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
48474752|NCT06417437|DRUG|SSRI|Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
47943004|NCT04482712|DRUG|Rapamycin|Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
47943005|NCT04482712|DRUG|Placebo|Administration of investigational drug placebo for up to 4 weeks while hospitalized
47943006|NCT02537782|DEVICE|Cardiac resynchronisation therapy|
47943007|NCT02537782|OTHER|Echocardiography|
47943008|NCT02537782|OTHER|Magnetic Resonance Imaging|
48103069|NCT01805349|RADIATION|Hand X-rays|Hand X-rays to assess the digital arthrosis
48103070|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
48103071|NCT05946824|RADIATION|Daily-adaptive Stereotactic Body Radiation Therapy|Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
48103072|NCT05829096|OTHER|The COMBINED approach|"1. Patient-level intervention:~   * Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~  * Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~  * Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~2. Clinician-level implementation toolkit:~   * Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~  * Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~  * Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended"
48103073|NCT04703699|DEVICE|Myval Transcatheter Heart Valve Series|Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
48103074|NCT03999021|DRUG|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
48474753|NCT06417437|DEVICE|rTMS|Patients will be treated targeting either the traditional brain region or new region.
48474754|NCT06417437|BEHAVIORAL|Neuro-Feedback|Patients under 18 years old will first be considered this treatment before other methods.
48474755|NCT06417437|BEHAVIORAL|Game Regulation|Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
48474756|NCT05511649|DEVICE|continuous electronic monitor|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
47943009|NCT02537782|OTHER|Positron Emission Tomography|
48103075|NCT05671094|BEHAVIORAL|Prehabilitation|Physical, mental, stress reducing and dietary prehabilitation programme, 4 to 2 weeks before surgery
48474757|NCT00423709|PROCEDURE|Allogeneic Blood Stem Cell Transplantation|
48474758|NCT00423709|DRUG|Fludarabine|
48474759|NCT00423709|DRUG|Melphalan|
48474760|NCT05515107|DEVICE|Videolaryngoscope size 1 Miller blade|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
48474761|NCT04950894|DEVICE|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
47943010|NCT00835822|DRUG|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
47943011|NCT00835822|DRUG|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
47943012|NCT00111878|DRUG|MEDI-534|
48618113|NCT05112705|DIAGNOSTIC_TEST|Proximal lower limb ultrasound|Twice weekly proximal lower limb ultrasound
48618114|NCT02005796|OTHER|Dietary intervention|
48618115|NCT00956189|DRUG|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
48291977|NCT03831503|DEVICE|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
48291978|NCT03831503|DEVICE|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
48291979|NCT05182203|DRUG|biologic/targeted therapy|TNF inhibitors or the JAK inhibitors
48291980|NCT06508996|DIAGNOSTIC_TEST|Xpert HCV|Detection of HCV RNA by Xpert HCV test
48291981|NCT06673160|BEHAVIORAL|Pumping every 2 hours|The intervention will be pumping every 2 hours.
48291982|NCT06673160|BEHAVIORAL|breast pumping every 3 hours|The intervention will be pumping every 3 hours
48291983|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T4 dental implants in posterior mandible|Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
48291984|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T5 dental implants in posterior mandible|Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
48291985|NCT05712031|PROCEDURE|Insertion of 2 Nucleoss T4 dental implants posterior mandible|2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
48291986|NCT02492711|BIOLOGICAL|Margetuximab|15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
48291987|NCT02492711|BIOLOGICAL|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
48291988|NCT02492711|DRUG|Physician's choice of chemotherapy.|Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
48291989|NCT06630832|OTHER|Simulated work in the heat with no cooling during rest breaks|Young and older adults will not undergo cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
48291990|NCT06630832|OTHER|Simulated work in the heat with partial cooling during rest breaks|Young and older adults will not undergo partial cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
48291991|NCT06630832|OTHER|Simulated work in the heat with full cooling during rest breaks|Young and older adults will not undergo full cooling during rest breaks applied during the implementation of work-rest allocations over the duration of a 180-min work period following a continuous work bout to 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels).
48291992|NCT00077181|DRUG|cytarabine|Given IV
48291993|NCT00077181|DRUG|triapine|Given IV
48618116|NCT00956189|DRUG|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
48618117|NCT06004960|DRUG|[14C]CCX168|Administered orally.
48618118|NCT00756301|OTHER|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
48631911|NCT04978831|OTHER|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
48631912|NCT05509673|OTHER|Lipofilling (sublesional fat grafting)|
48631913|NCT02821000|BIOLOGICAL|Pembrolizumab|Intravenous infusion
48631914|NCT01186419|DRUG|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
48103076|NCT00588965|DRUG|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
48103077|NCT00588965|DRUG|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
48618119|NCT04023578|DEVICE|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
48631915|NCT04228653|DEVICE|Renishaw Drug Delivery System|Device that allows pharmaceuticals to be delivered into the brain is to be assessed over a period of time to inform of the long term safety of the implanted device.
48103078|NCT05289830|DRUG|Escitalopram|Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)
48291994|NCT00077181|OTHER|laboratory biomarker analysis|Correlative studies
48291995|NCT00907725|OTHER|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
48291996|NCT00907725|OTHER|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
48291997|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Ripple Mapping guided.|Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
48631916|NCT03020082|DRUG|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
48631917|NCT03020082|DRUG|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
48474762|NCT06276621|BEHAVIORAL|Family Bridge Program|The Family Bridge Program consists of 7 components, delivered by a trained lay navigator, the Guide. The program includes: (1) orientation to the hospital, unit, room, and hospital resources (e.g., toiletries, loaner phone chargers); (2)unmet social needs assessment, followed by connection to appropriate resources (e.g., food vouchers, community-based transportation); (3)communication and cultural preference assessment (eg, preferred language, comfort asking questions, and health-related cultural beliefs), which is communicated to the medical team and documented in the electronic health record;(4)communication coaching for parents/caregivers to help them clarify and practice asking questions of the medical team; (5)emotional support via daily check-ins during the hospital stay; (6)assistance with logistics ; and (7)one follow-up phone call, 2 days post-discharge, to address remaining questions and connect families to ongoing services if needed.
48474763|NCT06276621|BEHAVIORAL|Care as usual - resources only|Families randomized to the control arm will receive FBP written resources, which the Guide (and interpreter, as needed) will review with them over \~5-15 minutes one time. This includes information on hospital services (e.g., cafeteria coupons), community resources (e.g., food and housing support), the structure and roles of the medical team, and the daily hospital schedule. Parents will be informed that their child's nurse is available to help them.
48474764|NCT00115024|DRUG|Micronized 17B-estradiol|
48474765|NCT01401335|BEHAVIORAL|Questionnaires|questionnaires at entry, month 4, 8 and 12
48474766|NCT05926635|DEVICE|ATLAS 2030|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
48474767|NCT06490406|BEHAVIORAL|Multimodal intervention (communication and education simulations) for EG1|"In summary, students in EG1 received the following multimodal intervention flow: 1) Health communication training, 2) Structured educational simulation using standardized patients (SPs), and 3) simulation feedback and self-assessment using a systematic guide that included the health literacy practices."
48474768|NCT00952224|OTHER|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
48474769|NCT00709306|DEVICE|UV-Detect Photos|UV-Detect Photos
48474770|NCT00709306|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
48474771|NCT00709306|BEHAVIORAL|Education|Education
48474772|NCT06002178|DIAGNOSTIC_TEST|Neck ultrasound|A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
48474773|NCT02882269|DRUG|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
48474774|NCT02882269|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
48474775|NCT03357354|BEHAVIORAL|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
48474776|NCT05903339|DRUG|V3G CH848 Pr-NP1 60mcg|(60 mcg)
48474777|NCT05903339|DRUG|3M-052-AF 5mcg|(5 mcg)
48474778|NCT05903339|DRUG|Alum 500 mcg|(500 mcg)
48474779|NCT05903339|DRUG|V3G CH848 mRNA-Tr2 50mcg|(50 mcg)
48474780|NCT05903339|DRUG|ACU-026-001-1 2.0mg|(2.0 mg)
48474781|NCT05903339|DRUG|V3G CH848 Pr-NP1 100mcg|(100 mcg)
48474782|NCT01956708|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
48474783|NCT05872334|DEVICE|Monofix|a new absorbable barbed suture device
48474784|NCT05872464|OTHER|Artificial saliva containing cumin and ginger extract|Artificial saliva containing cumin and ginger extract in spray bottle
48631918|NCT03020082|DRUG|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
48103079|NCT05289830|OTHER|Placebo|Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
48103080|NCT02010619|BEHAVIORAL|Cognitive behavior therapy|
48103081|NCT02010619|BEHAVIORAL|Supportive therapy|
48474785|NCT05872464|OTHER|Placebo|Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
48474786|NCT01787110|DRUG|Oxygen|see arm description
48474787|NCT02118168|OTHER|No intervention|No intervention is foreseen in this Observational Study
48474788|NCT04212377|BIOLOGICAL|Dendritic Cells for endometrial cancer|Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
48474789|NCT02785627|OTHER|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
48631919|NCT03020082|DRUG|RBV|RBV administered orally 500mg (5 tablets)( body weight \<75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
48631920|NCT04868903|DIETARY_SUPPLEMENT|Vitamin D3|Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
48474790|NCT06230627|OTHER|Home-Based Rehabilitation rogram|The intervention is distinguished from others in that it applies to patients' homes and the trial was followed up in the middle of complex conditions of the COVID-19 Pandemic. Also, the challenge was represented by the HBRP applied to patients with SCIs after 4-5 years of rehabilitation interruption.
48631921|NCT03389750|DRUG|Intravenous Challenge Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
47943013|NCT01419639|DRUG|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
48474791|NCT01454440|DRUG|Eptifibatide|Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
48474792|NCT05628181|BEHAVIORAL|Educational nudge intervention|This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
48474793|NCT00891098|BEHAVIORAL|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
48474794|NCT00891098|BEHAVIORAL|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
48474795|NCT02618382|DRUG|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
48474796|NCT05902468|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 500 mg orally twice daily for 12 weeks
48474797|NCT03270592|OTHER|Service dog|Use of a individualized certified service dog
48631922|NCT03880409|DRUG|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
48631923|NCT03880409|DRUG|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
48631924|NCT05553210|BEHAVIORAL|FOREST+|The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
48103082|NCT04917432|PROCEDURE|intravascular ultrasound (IVUS)|Intravascular imaging using a specialized catheter delivered through intra-arterial approach to reach the coronaries to guide CTO-PCI procedure and optimize the results after wire crossing.
48103083|NCT04917432|PROCEDURE|Conventional CTO PCI (non-IVUS guided)|Non-IVUS guided CTO PCI for wiring but may be used for results optimization after wire crossing
48291998|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Conventional mapping guided.|Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
48291999|NCT05910463|OTHER|AXOMOVE Therapy Medical Device|Personalized exercise programs for the self-rehabilitation of low back pain patients
48292000|NCT04681664|OTHER|High fat diet|50 % fat
48474798|NCT01017939|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
48474799|NCT01017939|DRUG|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
48474800|NCT01017939|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
48474801|NCT01017939|DRUG|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
48474802|NCT04296201|DEVICE|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
48618120|NCT05290675|DIAGNOSTIC_TEST|Quantra QPlus System|Whole blood coagulation testing system
48618121|NCT02472405|DEVICE|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
48618122|NCT02472405|DEVICE|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
48618123|NCT02954341|DEVICE|CardioMEMS HF System|
48631925|NCT00540267|OTHER|No Intervention|No Intervention
48631926|NCT02368509|OTHER|Perform sensory tests|
48631927|NCT03879109|DRUG|Chemotherapy FOLFIRINOX, 6 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)"
48631928|NCT03879109|RADIATION|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
48474803|NCT04409587|DRUG|Aspart|"A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion."
48474804|NCT00108979|DRUG|Escitalopram|
48474805|NCT05919745|DRUG|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
48631929|NCT03879109|PROCEDURE|Surgery|"Surgery will be performed at:~* Arm A: 8 weeks (±1) after the end of treatment~* Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~* Total mesorectal excision (TME)~* Extended-TEM (e-TME)~* Pelvic exenteration (PE)"
47943014|NCT03376906|PROCEDURE|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
48474806|NCT05919745|DRUG|Placebo|Preoperative delivery of placebo per os.
48474807|NCT05919745|DRUG|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
48474808|NCT01604369|PROCEDURE|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
48474809|NCT02919111|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
48474810|NCT02319057|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
48474811|NCT02319057|DRUG|ORM-12741 IR|Immediate release formulation of ORM-12741
47943015|NCT03376906|PROCEDURE|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
47943016|NCT03376906|PROCEDURE|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
48474812|NCT02319057|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
48474813|NCT02968719|DRUG|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
48103084|NCT02762318|OTHER|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
48103085|NCT03967925|DRUG|Belimumab|Sub-cutaneous injection
48103086|NCT03967925|DRUG|Rituximab|IV infusion 1g x 2
48474814|NCT02968719|DRUG|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
48474815|NCT02968719|DRUG|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
48474816|NCT02968719|DRUG|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
48474817|NCT02968719|DRUG|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
48474818|NCT06274424|BEHAVIORAL|The Friends Program|A group CBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions.
48474819|NCT05528302|OTHER|Tech-CBT intervention|The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
48631930|NCT02263690|PROCEDURE|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
48631931|NCT02263690|PROCEDURE|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
48292001|NCT04600999|DRUG|Favipiravir|Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
48292002|NCT03720080|DEVICE|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
48292003|NCT03245476|OTHER|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
48292004|NCT03245476|OTHER|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
48292005|NCT02707094|DEVICE|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
48292006|NCT02707094|OTHER|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
48292007|NCT05617092|OTHER|Physiotherapy treatment|physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
48292008|NCT00105729|BEHAVIORAL|Intensive referral to 12-step self-help groups|
48292009|NCT05315310|DEVICE|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
48292010|NCT05720078|RADIATION|Adaptive, two-phase RT|Participants in this arm will be treated with an adaptive, two-phase radiation therapy approach
48292011|NCT00006669|BIOLOGICAL|rituximab|
48631932|NCT02263690|PROCEDURE|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
48631933|NCT02446938|PROCEDURE|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
48631934|NCT04926493|BIOLOGICAL|microbiological characterization|microbiological characterization of endotracheal tube biofilm
48631935|NCT01400633|DRUG|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
48631936|NCT01532375|DIETARY_SUPPLEMENT|Kochujang|Kochujang (32g/day) for 12weeks.
48631937|NCT01532375|DIETARY_SUPPLEMENT|placebo|placebo(32g/day) for 12weeks
48292012|NCT00006669|BIOLOGICAL|sargramostim|
48292013|NCT00006669|DRUG|EPOCH regimen|
48292014|NCT00006669|DRUG|cyclophosphamide|
48292015|NCT00006669|DRUG|doxorubicin hydrochloride|
48292016|NCT00006669|DRUG|etoposide|
48292017|NCT00006669|DRUG|prednisone|
48292018|NCT00006669|DRUG|vincristine sulfate|
48292019|NCT03391518|PROCEDURE|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
48474820|NCT05871333|DRUG|Losartan 50mg Tab|Losartan 50 mg oral tablets
48292020|NCT01883310|DEVICE|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
48292021|NCT01883310|DEVICE|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
48292022|NCT02602431|DEVICE|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
48292023|NCT02602431|DEVICE|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
48292024|NCT02602431|DEVICE|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
48292025|NCT02602431|DEVICE|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
48292026|NCT06509152|BEHAVIORAL|Theory of mind-based social competence group intervention|"The ToM-SCGI is designed as a group intervention, with 60-minute sessions held weekly, either once or twice, and led by trained therapists. Two caregiver meetings are conducted in the middle and end of the interventions.~The intervention process for each session is as follows:~1. Warm-up Activities(5-10 minutes): review the previous group session and prepare for the current group activities.~2. Theory of Mind Instruction(10-15 minutes): based on the developmental stage of the children's theory of mind, using thought bubbles to teach corresponding elements of theory of mind development.~3. Social Skills Group Games(30-35 minutes): design social scenario-based group games that allow children to practice applying the acquired theory of mind abilities into expressions and applications of theory of mind and social competence.~4. Summary(5-10 minutes): summarize the children's performance in the group and assign homework."
48292027|NCT01041573|BIOLOGICAL|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
48292028|NCT01041573|BIOLOGICAL|Havrix®720|0.5 ml im. at day 0 and month 7
48292029|NCT01041573|BIOLOGICAL|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
48474821|NCT01632384|BEHAVIORAL|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
48474822|NCT04440280|DRUG|N-acetyl cysteine (NAC) 10% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
48474823|NCT04440280|DRUG|N-acetyl cysteine (NAC) 20% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
47943017|NCT05653258|OTHER|Lifestyle Intervention|"1. Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.~2. Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)/American College of Cardiology (ACC) guidelines."
47943018|NCT05653258|DRUG|Dasatinib 100 MG|100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
47943019|NCT05653258|DRUG|Quercetin 1000mg|Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
47943020|NCT05653258|DRUG|Placebo|Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
47943021|NCT05653258|PROCEDURE|Abdominal adipose tissue biopsy|All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq
47943022|NCT00229151|BEHAVIORAL|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
47943023|NCT00229151|OTHER|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
48103087|NCT03967925|DRUG|Prednisolone|20mg prednisolone tapering dose
48103088|NCT02141347|DRUG|Tremelimumab|Tremelimumab administered intravenously
48103089|NCT02141347|DRUG|MEDI4736|MEDI4736 administered intravenously.
48474824|NCT04440280|DRUG|Visine Dry Eye Relief eye drops|Visine Tears Dry Eye Relief artificial tears ophthalmic solution
48474825|NCT00921284|DRUG|NaCl 9/00|Same volume as in the dexmedetomidine group
48103090|NCT04215198|DIETARY_SUPPLEMENT|Move3™ (NEM® brand eggshell membrane + KD PUR® brand fish oil)|Dietary supplement combination for the support of joint health.
48103091|NCT04215198|DIETARY_SUPPLEMENT|Placebo|Placebo
48474826|NCT00921284|DRUG|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
48474827|NCT03616002|OTHER|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
48474828|NCT06261619|DEVICE|Adult Sotair Device|Adult Sotair® device employs a flow limiting valve mechanism.
47943024|NCT06210581|OTHER|Supervised Exercise Program Group|The exercise programs will performed with the physiotherapist. The treatment programs of the patients will start with warm-up exercises and continue with aerobic exercises. Strengthening exercises will be performed in lying, sitting and standing positions. Body weight or free weight will be used for strengthening exercises. Balance exercises will be performed in sitting and standing positions and will be performed with or without support according to the patients conditions. The treatment sessions will be terminated by performing relaxation exercises combined with stretching and breathing exercises.
47943025|NCT06210581|OTHER|Internet Based Exercise Program Group|"Patients who are in the internet-based exercise program group will register cite ''https://www.telenororehab.com /'' which is web- based physiotherapy program for exercises. After the first evaluation patients will be given a username and password to log in to the system.~Before starting the exercise programs, the pages on how patients can log in to the system, how they can reach the physiotherapist through the system and how they can find individual exercise programs will be shown before the study. After logging in to their own pages, patients will be able to access video-based exercise programs that have been specially prepared for them. Patients in the Internet-based exercise program group will also be given the same exercise programs as the supervised exercise program group. The entry-exit times of patients to the system and the duration of maintaining exercise programs will be controlled from the administrator section on the system."
47943026|NCT00335920|DRUG|Dexamethasone-dihydrogenphosphate (4mg/ml)|
47943027|NCT05291026|OTHER|mobile phone-based health information|health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
47943028|NCT05055453|DEVICE|MyPhonak Junior App|The app is an accessory to the hearing aids which allows the user to make adjustments to their hearing aid in real-time. The hearing aid does not require the use of the app, but the objective of this study is to evaluate the effects of the user adjustments made via the app on the participant's speech intelligibility with the hearing aid.
47943029|NCT05055453|DEVICE|Phonak Sky hearing aid|A Behind-The-Ear hearing aid (BTE) fit to hearing impaired persons with mild to severe hearing loss.
47943030|NCT02793011|DRUG|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
47943031|NCT02793011|DRUG|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
47943032|NCT01052844|DRUG|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
47943033|NCT01052844|DRUG|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
47943034|NCT05437211|DEVICE|Virtual-reality (VR) Based Solution|VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
47943035|NCT05494320|DRUG|Folfox Protocol|Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
47943036|NCT04319731|BIOLOGICAL|Human Amniotic Fluid|Administration of amniotic fluid in SARS-CoV-2 positive patients
48474829|NCT05164913|OTHER|Achenbach Child Behavior Checklist （CBCL）scale|Use the Achenbach Child Behavior Checklist （CBCL）scale to assess children's behavior
48103092|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the diagnosis of hypospadias, as a part of routine care. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty and then, another sample in a 5 ml EDTA tube will be taken for DNA collection."
48474830|NCT02999451|DEVICE|snare-assisted POEM|"POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~4. The mucosal incision is closed with endoclips."
48474831|NCT02999451|DEVICE|knife-assisted POEM|"POEM is performed by using a conventional endoscopic knife.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~4. The mucosal incision is closed with endoclips."
48292030|NCT00934531|DRUG|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
48292031|NCT03699345|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
48292032|NCT05126225|BEHAVIORAL|Stigma reduction|The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator. The facilitator applies the principle of CBT and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques.
48103093|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the absence of hypospadias. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty."
48292033|NCT05662358|DRUG|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
48292034|NCT05662358|DRUG|Alendronate|oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
48292035|NCT05662358|DRUG|Placebo|oral placebo weekly
48292036|NCT03260738|DEVICE|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
48292037|NCT03260738|OTHER|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
48292038|NCT05418361|DRUG|ACE inhibitor ,angiotensin receptor blockers|patients taking ACEI or ARBs with cardiovascular disease
48292039|NCT04758793|OTHER|blood samples|3 citrated tubes and 3 EDTA tubes
48292040|NCT04758793|OTHER|biopsy of abdominal paroie|a muscle biopsy will be performed on the incision area
48292041|NCT05141526|OTHER|Non-restrictive satiating intervention|Diet group containing satiating foods
48292042|NCT05141526|OTHER|Conventional restrictive intervention + non-restrictive satiating intervention|Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase
48103094|NCT02205762|DRUG|Prednisone|Stratum I
48103095|NCT02205762|DRUG|Vinblastine|Stratum I
48103096|NCT02205762|DRUG|mercaptopurine|Stratum I
48292043|NCT05141526|OTHER|Control group|This group will receive minimal healthy guidelines
48292044|NCT00893503|PROCEDURE|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
48292045|NCT06141408|BEHAVIORAL|MPowerment Stigma-reduction Intervention|"In-person events will focus on five specific goals: Fostering a sense of community acceptance and social connection among Black sexual minority men (BSMM), promoting self-acceptance of sexual identity, teaching skills for coping with experiences of racism, reducing PrEP stigma, and providing education on HIV risk. In accordance with the MPowerment model, In collaboration with the PI, the BSMM core group and volunteers would lead the development, implementation, and evaluation of all intervention events. Both peer leaders and the primary investigator (all BSMM) will collaborate to develop specific events (M-Groups), guided by the findings in both the quantitative and qualitative studies. M-Groups will be held once every month. Events will be 2 hour in-person activities focused on the aforementioned goals."
48292046|NCT01538173|DRUG|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
48292047|NCT01538173|DRUG|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
48292048|NCT05816356|DRUG|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
48292049|NCT05816356|DRUG|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
48292050|NCT03134963|OTHER|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
48292051|NCT03134963|OTHER|Blood pressure monitoring|Continuous blood pressure recording
48292052|NCT03134963|OTHER|Heart rate monitoring|Continuous heart rate monitoring
48292053|NCT03134963|OTHER|End tidal CO2 monitoring|Continuous ETCO2 monitoring
48292054|NCT03134963|OTHER|Addenbrooke's cognitive examination|Performance of a memory test
48292055|NCT01757457|DRUG|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
48292056|NCT01757457|DRUG|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
48103097|NCT02205762|DRUG|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
48103098|NCT02205762|DRUG|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
48292057|NCT04044547|DRUG|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
48474832|NCT03098186|BEHAVIORAL|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
47943037|NCT05377203|DRUG|Quadruple combination of half doses therapy→Dual combination of standard dose therapy|"Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day."
48474833|NCT03098186|BEHAVIORAL|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
48474834|NCT02071368|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
48474835|NCT02071368|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
47943038|NCT05377203|DRUG|Dual combination of standard dose therapy→ Quadruple combination of half doses therapy|"Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day."
47943039|NCT02526173|PROCEDURE|RALP using full nerve sparing technique|RALP using full nerve sparing technique
47943040|NCT02526173|OTHER|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
47943041|NCT02210468|DEVICE|APIC-CF, 4 cc|
47943042|NCT02210468|DEVICE|APIC-CF, 2 cc|
47943043|NCT02210468|OTHER|Placebo Comparator: Saline|Placebo Comparator: Saline
47943044|NCT04068610|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
47943045|NCT04068610|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
47943046|NCT04068610|DRUG|FOLFOX|Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
47943047|NCT04068610|DRUG|Bevacizumab|Participants will receive IV infusion of bevacizumab as stated in arm description.
47943048|NCT00590798|BEHAVIORAL|Walking|Patient will walk within 30 minutes of vascular closure system procedure
48474836|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
48474837|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
47943049|NCT04866329|OTHER|Blood sample|Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)
47943050|NCT04866329|OTHER|Urine sample|Collection of the first urine in the morning on the day of the oocyte pick-up
47943051|NCT04866329|OTHER|Follicular fluid and granulosa cells sample|Collection of follicular fluid and granulosa cells during oocyte pick-up.
47943052|NCT04200859|OTHER|Cold application|cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
47943053|NCT04981821|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
47943054|NCT04981821|BEHAVIORAL|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
48103099|NCT02205762|DRUG|Cytosine Arabinoside|
48103100|NCT02205762|DRUG|2-chlorodeoxyadenosine|
48103101|NCT02205762|PROCEDURE|hematopoietic stem cell transplantation (RIC-HSCT)|
48103102|NCT02205762|BIOLOGICAL|Intravenous immunoglobulin|
48103103|NCT00942058|OTHER|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
48474838|NCT04117945|BIOLOGICAL|Cetuximab|Given IV
48474839|NCT04117945|DRUG|Irinotecan|Given IV
48474840|NCT04117945|BIOLOGICAL|Panitumumab|Given IV
48103104|NCT03949686|DRUG|Saline Solution|0.5 ml/kg saline
48103105|NCT03949686|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
48103106|NCT01063023|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
48474841|NCT04117945|DRUG|Regorafenib|Given PO
48474842|NCT01022684|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
47943055|NCT04505397|DRUG|SKL24741|An inhibitor of voltage-gated sodium channels and a possible activator of Big Potassium channels. Administered as an oral dose in the form of a capsule or tablet.
47943056|NCT04505397|DRUG|Placebo|Sugar pill manufactured to mimic SKL24741
48103107|NCT01063023|DRUG|BMS-650032|Tablets, Oral, 600 mg, BID
48103108|NCT05848323|BEHAVIORAL|4-week Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.
48103109|NCT05848323|BEHAVIORAL|4-week Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
48103110|NCT05848323|BEHAVIORAL|4-week Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
48103111|NCT02276131|DEVICE|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
48103112|NCT02945267|DRUG|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
48103113|NCT02945267|DRUG|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
48103114|NCT04324242|OTHER|abdominal hallowing maneuver|abdominal hallowing maneuver includes tucking navel in and up. To be able to control the effect of breathing it was instructed to start the maneuver at the end of the expiration. During the maneuver it was instructed to focus on increasing the thickness of TrA without increasing the thickness of IO and EO
48103115|NCT00394069|DRUG|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
48103116|NCT02930590|OTHER|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
48103117|NCT02930590|OTHER|Gel mattress|IsoGel, Stryker, USA
48103118|NCT02930590|OTHER|Basic foam|Standard hospital mattress
48103119|NCT04813393|OTHER|Questionnaire Development|To evaluate psychometric the properties of the Compliance of Parents of Children with Cerebral Palsy to Home Program Assesment Questionnaire (CPHP-Q), a caregiver-report for adherence and frequency of home program implementation of parents of children with Cerebral Palsy.
48103120|NCT04591301|DRUG|HEC113995 PA•H2O tablets|Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
48103121|NCT04591301|DRUG|Placebo tablets|Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
48103122|NCT02117843|DEVICE|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
48292058|NCT04044547|DRUG|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
48474843|NCT04688047|BEHAVIORAL|Nursing care based on the transtheoretical model|Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
47943057|NCT02911571|DEVICE|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
47943058|NCT03037801|DEVICE|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
47943059|NCT00234403|DRUG|gefitinib and fulvestrant|
47943060|NCT00389727|DRUG|Radiotherapy|Radiotherapy
47943061|NCT03036605|DRUG|Bupivacaine|%0.5 bupivacaine
47943062|NCT03036605|DRUG|Dexamethasone|8 mg Dexamethasone
47943063|NCT03182803|BIOLOGICAL|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
48292059|NCT03021525|PROCEDURE|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in \<15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
48292060|NCT03021525|PROCEDURE|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate \<100 bpm, mean arterial pressure \>65 mmHg, SpO2\>94%, and core temperature \>36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
48292061|NCT03910959|OTHER|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
48292062|NCT03910959|OTHER|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
48292063|NCT01525511|DRUG|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
48292064|NCT01525511|DRUG|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
48292065|NCT04194593|OTHER|PCR (Polymerase Chain Reaction)|"Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).~A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm."
48292066|NCT02481765|DEVICE|High definition transcranial direct current stimulation|
48474844|NCT01429831|DRUG|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
48474845|NCT02138981|PROCEDURE|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
48474846|NCT02138981|PROCEDURE|Immediate Resection|patients received immediate surgical resection.
48474847|NCT05746377|DRUG|Metoclopramide 10mg|IV Metoclopramide
48474848|NCT05746377|DRUG|Saline|Placebo
48474849|NCT04087863|OTHER|Not applicable(observational study)|Not applicable(observational study)
48103123|NCT05207982|BEHAVIORAL|Family Based weight management program|"Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two eating plan education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity."
47943064|NCT05436223|DRUG|Human CD19Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
48103124|NCT00639015|DRUG|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
48103125|NCT00639015|DRUG|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
48103126|NCT01142713|RADIATION|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
48103127|NCT02711982|PROCEDURE|Optic canal and optic nerve sheath decompression|within 5 days from trauma
48103128|NCT02711982|DRUG|methylprednisolone|within 5 days from trauma
48103129|NCT02955498|DRUG|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
48103130|NCT02955498|DRUG|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
47943065|NCT01199107|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
48631938|NCT05803954|OTHER|Sustained natural apophyseal glides (SNAGS)|SNAGS will be applied with the patient sitting comfortably on a stool. The therapist stand behind the patient and the medial border of one thumb's distal phalanx is placed on the articular pillar on the chosen side of the suspected site of lesion. The thumb nail slope at approximately 45 degree (in the direction of the eyeball). SNAGS mulligan will be given by active movement followed by passive overpressure based on the movement restricted by frequency of treatment will be three sets of ten repetitions. SNAG the anteroposterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s depending on response. A maximum of 6 repetitions will be given if there is a reduction in headache intensity at the time of the first application. A total of 20 oscillations (1 oscillation/1 second) will be given to each joint with a total duration of 15 minutes
47943066|NCT01199107|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
48631939|NCT05803954|OTHER|Neural mobilization|Neural mobilization will be applied with grade three neural mobilization and traditional therapy: Subjects will be placed in supine position and remained relaxed with the feet uncrossed. The patient will be slightly angled obliquely for easier access to the scapula. The therapist will be depressed the scapula with concomitant upper extremity joint positioning as per median nerve bias i.e., ULTT2 (shoulder abduction, elbow extension with forearm supination, wrist and fingers extended and ulnar deviated and thumb abduction). The wrist will be used as a tension factor and at the point where tension was felt by the therapist and perceived by the subject. Grade 3 oscillations were given rhythmically and slowly to each joint from proximal to distal. A total of 20 oscillations (1 oscillation/1 second) were given to each joint with a total duration of 15 minutes.
48631940|NCT05803954|OTHER|Traditional physical therapy|traditional therapy will be applied in the form of stretching for bilateral upper and middle trapezius muscles and bilateral neck rotators and isometric strengthening exercises for neck rotators, extensors, side bending muscles. Exercise was repeated for ten repetitions per session. In addition to hot pack was placed over the neck and upper part of shoulders musculature. This was being applied for ten min, over middle trapezius trigger Point itself.
48631941|NCT04579211|DIAGNOSTIC_TEST|urine lipoarabinomannan (LAM)|Investigate the utility of urine LAM as a test to identify individuals at very low risk for having a sputum culture positive for NTM.
48631942|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml + 1% lidocaine|Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain
48631943|NCT05302232|DIAGNOSTIC_TEST|depomedrone 40mg/ml+ 0.9% saline|Response to intra-articular injection of steroid only as a placebo
47943067|NCT01199107|BEHAVIORAL|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
47943068|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
48631944|NCT05302232|OTHER|painDETECT questionnaire|painDETECT questionnaire
48631945|NCT02585102|OTHER|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
48631946|NCT02585102|OTHER|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
48292067|NCT01460836|DRUG|Tobramycin solution for inhalation|
48292068|NCT01460836|DRUG|Aztreonam lysine for inhalation|
47943069|NCT00717444|BEHAVIORAL|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
47943070|NCT05542186|PROCEDURE|Kinesiotaping|Biomechanical correction for discogenic low back pain using kinesiotaping
48103131|NCT00914823|DRUG|kisspeptin 112-121|One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
48292069|NCT05301348|DEVICE|Photoacoustic Flow Cytometry|Detection of circulating blood clots
48292070|NCT06662539|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
48292071|NCT06662539|DRUG|Placebo|Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
48292072|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
48292073|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
48292074|NCT00758862|DRUG|2% TD1414 Cream|Application 3 times daily for 7 days
48292075|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
48292076|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
48292077|NCT00446394|BEHAVIORAL|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
48292078|NCT00446394|BEHAVIORAL|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
48292079|NCT05594992|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
48292080|NCT05965713|DEVICE|Neurolutions IpsiHand System|The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.
48292081|NCT05965713|OTHER|Standard of Care - Home Exercise Program for Upper Extremity|Subjects will receive a customized home range of motion exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks
48292082|NCT03741439|DEVICE|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
48292083|NCT03741439|DEVICE|Sham|Sham treatment
48292084|NCT02120586|OTHER|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
48292085|NCT02120586|OTHER|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
48292086|NCT03280550|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
48292087|NCT03280550|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
48292088|NCT02213757|DRUG|Premarin vaginal estrogen cream|
48292089|NCT02213757|DRUG|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
48292090|NCT03890224|DEVICE|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
48292091|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
48292092|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
48292093|NCT00153166|DRUG|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
48292094|NCT00153166|DRUG|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
48292095|NCT00153166|DRUG|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
48292096|NCT00153166|DRUG|placebo/placebo|placebo orally three times daily
48292097|NCT04250805|DRUG|Lidocaine|Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
48292098|NCT04250805|DRUG|Ropivacaine|Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
48474850|NCT03274037|DIAGNOSTIC_TEST|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
48474851|NCT01780376|PROCEDURE|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
48474852|NCT04615533|OTHER|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
48631947|NCT06493942|OTHER|BioCoat® by Premier®|BioCoat is a 56% filled resin formula that provides added strength and excellent long-term resistance to wear ؤomparable to flowable composites.
47943071|NCT04738851|OTHER|Therapy Mirror task|"The protocol has 3 conditions:~* A virtual TM task (TMV~* A classic TM task (TMC)~* A control task (TC)~The order of the 3 conditions will then be randomized to avoid potential biases linked to the sequence of conditions."
48292099|NCT06251388|DRUG|AK104|AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.
48292100|NCT00316901|PROCEDURE|computed tomography|
48292101|NCT00316901|PROCEDURE|positron emission tomography|
48292102|NCT00316901|RADIATION|fludeoxyglucose F 18|
48474853|NCT04083859|OTHER|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
48631948|NCT06493942|OTHER|UltraSeal XT™ plus by Ultradent|UltraSeal XT plus is a 58%-filled resin fluoride-releasing sealant. It is strong and has high wear resistant
48631949|NCT05451888|BEHAVIORAL|Spa treatment|A 40 minute period of lying in the spa treatment pool
48631950|NCT05484167|DRUG|Natesto Nasal Product|Nasal Gel used for 90 days then crossed over to placebo gel
48631951|NCT05484167|DRUG|Placebo|A nasal gel with no active ingredients
48292103|NCT06457048|OTHER|Stroke Unit|The stroke unit at the University Teaching Hospital is a 12-bed unit on the general medical wards staffed by neurologists and nurses specifically trained in stroke care. This intervention includes new protocols and clinical practice guidelines that were developed by multiple stakeholders in Zambia to standardize stroke care, with a focus on early and consistent mobilization of patients with stroke, minimizing use of urinary catheters, provision of deep vein thrombosis prophylaxis, formal assessment of swallowing and assignment of modified diets as needed, and appropriate initiation of secondary prevention medications for stroke. Nurses and doctors working in this unit were trained on the new stroke unit protocols and are asked to follow these protocols in caring for patients with stroke admitted to the Stroke Unit.
48631952|NCT01829165|DEVICE|rTMS Treatment|MRI-compatible TMS stimulator
48631953|NCT01829165|DEVICE|Sham rTMS Treatment|
48631954|NCT00626860|BIOLOGICAL|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
48292104|NCT02207192|OTHER|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
48474854|NCT04083859|OTHER|Lung health video|Web-based video about guideline recommended exercise for lung health
48631955|NCT04786574|DRUG|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
48631956|NCT05342688|BEHAVIORAL|Task-specific practice of upper extremity functions|The intervention will consist of training of items from the Wolf motor function test.
48631957|NCT06107673|DRUG|Dalpiciclib|Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
48631958|NCT06107673|DRUG|Aromatase inhibitor|AI: Take according to the instructions provided.
48631959|NCT06107673|DRUG|Docetaxel injection|Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
48631960|NCT06107673|DRUG|Epirubicin Hydrochloride Injection|Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
48631961|NCT06107673|DRUG|Cyclophosphamide injection|Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
48631962|NCT02491060|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
48631963|NCT02491060|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
48631964|NCT01191385|DRUG|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
47943072|NCT00154492|DRUG|activated recombinant human factor VII|
47943073|NCT02547948|BIOLOGICAL|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
47943074|NCT04990336|COMBINATION_PRODUCT|Dachaihu decoction compound|Dachaihu decoction compound includes Bupleurum, Rhubarb, Citrus aurantium, Scutellaria, Pinellia, White Peony, Jujube, Ginger.
48103132|NCT00914823|DRUG|GnRH|One or more IV doses of GnRH, and/or SC administration of GnRH
48103133|NCT04455009|DIETARY_SUPPLEMENT|Fitness Drink Formula|Single drink provided following baseline assessments
48103134|NCT00141830|DRUG|Methotrexate plus ERB-041 for 12 weeks|
48103135|NCT00141830|DRUG|Placebo for 12 weeks|
48103136|NCT03182036|DEVICE|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
48103137|NCT04806113|BIOLOGICAL|Moderna COVID-19 vaccine|Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
48631965|NCT03954730|OTHER|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
48631966|NCT03954730|OTHER|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
47943075|NCT04990336|DRUG|Rhubarb single medicine|Rhubarb single medicine
48103138|NCT06281080|PROCEDURE|En-Bloc Resection of Bladder Tumours|Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
48292105|NCT02859415|DRUG|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
48292106|NCT05328843|DRUG|PB119|"Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration."
48631967|NCT00924482|DEVICE|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
48631968|NCT04665791|BIOLOGICAL|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
48631969|NCT01993368|OTHER|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:~* T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~* Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~* Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
48103139|NCT00657280|DRUG|Sitagliptin|No one is blinded to the treatments.
48631970|NCT00205608|DEVICE|Positron Emission Tomography|camera is new
48103140|NCT00449813|DRUG|Pantoprazole|40 mg Pantoprazole
48103141|NCT06142240|OTHER|exercise programe|"The components of the exercise programe will be: muscle strength training and continuous-variable aerobic training or HIIT with loads between 70-90% of maximum heart rate. The aerobic training will last about 30 minutes and will then be completed with muscle training of the upper and lower limbs with loads determined according to the perception of effort (loads around 50-70%). The sessions will be monitored with pulse oximetry (heart rate and oxygen saturation), perception of fatigue and sensation of suffocation (Borg scale). The intensity of each component of the programme will be individualised according to the conditions of each subject.~Adherence to the programme will be recorded as successful when participation in the sessions is greater than 80% of the total number of sessions."
48103142|NCT02595398|DRUG|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), administered as a single injection at 2 timepoints
48103143|NCT02595398|DRUG|Sham Procedure|Sham procedure administered at 2 timepoints
48103144|NCT03532191|OTHER|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
48103145|NCT02305485|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
48103146|NCT02305485|DEVICE|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
48103147|NCT05803330|DRUG|Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma|Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma
48103148|NCT00678158|RADIATION|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
48103149|NCT04303182|PROCEDURE|Standard 3 port TEP|3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port
48103150|NCT04303182|PROCEDURE|LESS TEP|TEP inguinal hernia repair with one vertical skin incision under the umbilicus
48103151|NCT04258410|DRUG|Placebo oral soft chew|placebo identical to experimental drug contained in soft chew
48103152|NCT04258410|DRUG|Quercetin|experimental drug contained in soft chew
48103153|NCT03155152|OTHER|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
48103154|NCT03155152|OTHER|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
48103155|NCT00710307|PROCEDURE|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
48103156|NCT00710307|GENETIC|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
48103157|NCT06620614|COMBINATION_PRODUCT|0.5% Heavy Bupivacaine|There are two groups.
48103158|NCT06545708|OTHER|Patients|This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.
48103159|NCT06532760|OTHER|Blood sampling|Blood sampling to study sodium fragment kinetics
48103160|NCT03663218|RADIATION|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
48292107|NCT05398874|COMBINATION_PRODUCT|Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)|120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily
48292108|NCT05398874|COMBINATION_PRODUCT|placebo in addition to the standard treatment|placebo in addition to the standard treatment
48631971|NCT03220555|DEVICE|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
48631972|NCT03220555|DRUG|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
48631973|NCT00888082|DRUG|Goserelin acetate|3.6 mg depot injectable preparation
48474855|NCT06361095|BEHAVIORAL|Traditional Attention Bias Modification|Each ABM trial begins with a central fixation cross for 1500ms, followed by a pair of POFA or IAPS stimuli (see Figure 3). POFA pairs will be presented for 3000ms, while IAPS pairs will be presented for 4500ms (due to the increased image complexity of IAPS images relative to POFA images). Longer stimulus duration times were selected based on evidence that attention biases for sad stimuli are prolonged in depression. Following offset of the images, either a single or double asterisk probe appears in the location of one of the images and will remain until a participant response or 10,000ms. In active ABM, the probe had an 80% probability of appearing in the location of the neutral stimulus. Investigators selected 80% rather than 100% to allow for computing attention bias during training and to facilitate task engagement. At the end of each ABM session, participants are provided feedback regarding their task performance relative to their last five sessions in a visual format.
48474856|NCT06361095|BEHAVIORAL|Gamified Attention Bias Modification|Each trial consists of the fixation stage, facial cue stage, and response stage. At the fixation stage, an image appears (a colorful medallion) for 500 ms. The fixation appears randomly within a fixed rectangular field on the user's smartphone screen, and is always at the midpoint between the two face cues that will appear in the next stage. Next, after the cue disappears, two animated faces appear on the screen, one happy and one sad, with a 1000ms duration. Immediately after they disappear, a target probe (a trail) appears in the location of the happy face cue. The path remains (up to 3 seconds) until participants respond by tracing it starting from the point at which the face cue disappeared. They are instructed to quickly but accurately trace the path with their finger and receive visual and haptic feedback during tracing to indicate they are tracing accurately, followed by the path disappearing.
48474857|NCT06361095|BEHAVIORAL|Sham Attention Bias Modification|Sham attention bias modification designed to match the active ABM condition in all respects except for the shifting attention away from negative stimuli in active attention bias modification.
48474858|NCT06222593|DRUG|Bicalutamide in combination with Sunitinib|Antineoplastics, Antiandrogen; CYP3A4 Inhibitor
48474859|NCT05010824|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
48631974|NCT02635789|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
48631975|NCT02635789|DRUG|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
48631976|NCT01506375|BIOLOGICAL|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
48631977|NCT01506375|BIOLOGICAL|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
47943076|NCT04990336|COMBINATION_PRODUCT|Regular therapies|Regular therapies, such as fluid therapy, for acute pancreatitis
48631978|NCT03676725|DRUG|Lidocaine gel|Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
48631979|NCT03439514|DRUG|ARRY-371797 (PF-07265803)|400 mg twice daily (BID)
48631980|NCT03439514|OTHER|Placebo|BID
47943077|NCT06409351|BEHAVIORAL|Intervention group|Please refer to arm descriptions
48631981|NCT03815604|BEHAVIORAL|Independent Housing and Support (IHS)|Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
47943081|NCT05755737|DRUG|Ondansetron|Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
48292109|NCT04252807|BEHAVIORAL|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
48292110|NCT04252807|OTHER|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
48474860|NCT03088852|DRUG|Magnesium Citrate 100 MG|initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
48474861|NCT04211766|DIETARY_SUPPLEMENT|Dietary Fiber|Given fiber supplement
48474862|NCT04211766|DIETARY_SUPPLEMENT|Fish Oil|Given fish oil supplement
48474863|NCT04211766|OTHER|Comparator|Given fiber supplement placebo
48474864|NCT04211766|OTHER|Comparator|Given fish oil supplement placebo (corn oil)
48474865|NCT03028623|PROCEDURE|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
48474866|NCT03028623|PROCEDURE|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
48474867|NCT01085448|OTHER|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
48474870|NCT00607295|DRUG|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
48474871|NCT06351696|DIETARY_SUPPLEMENT|Bromlein|1500 mg/day
48474872|NCT06351696|OTHER|Placebo|Placebo (1500 mg/day)
48474873|NCT05785806|BEHAVIORAL|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
48474874|NCT05785806|BEHAVIORAL|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
48474875|NCT05785806|BEHAVIORAL|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
48474876|NCT05785806|BEHAVIORAL|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
48474877|NCT05785806|BEHAVIORAL|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
48474878|NCT00442351|DRUG|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
48474879|NCT00442351|OTHER|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
48103161|NCT02873884|BEHAVIORAL|Case-management|
48474880|NCT04760587|BEHAVIORAL|smart devices in adolescent weight control|The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
48474881|NCT03799848|DRUG|Vadadustat|Oral tablet
48103162|NCT05396976|BEHAVIORAL|Yoga and Muscle Relaxation Exercise Practices|Yoga and Muscle Relaxation Exercise Practices will be done two days a week for 10 weeks.
48103163|NCT06081231|DEVICE|open-source APS;|a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.
48103164|NCT01837641|BIOLOGICAL|LY3002813-IV|Administered IV
48103165|NCT01837641|BIOLOGICAL|LY3002813-SC|Administered SC
48103166|NCT01837641|DRUG|Placebo-IV|Administered IV
48103167|NCT06086899|PROCEDURE|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
48103168|NCT06086899|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
48474882|NCT04088747|DIAGNOSTIC_TEST|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
48292111|NCT03778229|DRUG|osimertinib|osimertinib (80 mg oral OD).
48292112|NCT03778229|DRUG|savolitinib|savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
48474883|NCT06235268|OTHER|Active systemic or non-systemic treatment (palliative or observation procedure)|The study includes medical visits and clinical-radiological re-evaluations according to clinical practice. The clinician will establish the number of visits necessary for each patient according to the needs encountered and depending on the treatment chosen.
48474884|NCT01417351|DIETARY_SUPPLEMENT|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
48474885|NCT01417351|DIETARY_SUPPLEMENT|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
48474886|NCT06360029|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
48631982|NCT03815604|BEHAVIORAL|Residential Care Settings and other Treatment as Usual (RCS/TAU)|Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
48631983|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
48631984|NCT01356888|DEVICE|Percutaneous Coronary Intervention (Orsiro DES)|stenting
48631985|NCT03324009|DIAGNOSTIC_TEST|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
48631986|NCT01089543|DRUG|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
48631987|NCT01089543|DRUG|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
48631988|NCT01089543|DRUG|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
48631989|NCT01089543|DRUG|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
48631990|NCT05224908|DEVICE|EOS|pelvimetry by EOS in standing and sitting position
48631991|NCT04228315|DRUG|Primaquine|radical cure dosing
48631992|NCT03168087|OTHER|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
48631993|NCT06195111|DRUG|Trifluridine/Tipiracil|This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
48631994|NCT06417307|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
48631995|NCT06417307|BEHAVIORAL|Control group|Maintain daily lifestyle until the end of the study. Receive no intervention/supplements.
48631996|NCT00290758|DRUG|placebo|Given orally
48631997|NCT00290758|DRUG|genistein|Given orally
48631998|NCT00290758|OTHER|laboratory biomarker analysis|Correlative studies
48631999|NCT04162314|DRUG|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
48632000|NCT04162314|DRUG|Placebos|Placebos
48632001|NCT01851304|DIETARY_SUPPLEMENT|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
48632002|NCT01851304|DIETARY_SUPPLEMENT|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
48632003|NCT01426659|BEHAVIORAL|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
48632004|NCT00468000|BIOLOGICAL|Ixmyelocel-T|IM injection
48632005|NCT00468000|BIOLOGICAL|Placebo|IM Injection
48632006|NCT03938415|PROCEDURE|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
48292113|NCT03778229|DRUG|placebo|placebo to osimertinib (oral OD)
47943082|NCT05755737|DRUG|Placebo|Matching placebo identical in appearance.
48292114|NCT00395122|DEVICE|Retinal nerve fiber layer and macular thickness measurements|
48292115|NCT03208192|PROCEDURE|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
48292116|NCT02471417|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
48292117|NCT02471417|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
48632007|NCT03938415|OTHER|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
47943083|NCT01847001|DRUG|Propranolol|Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
47943084|NCT01847001|OTHER|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
47943085|NCT01847001|DRUG|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
48632008|NCT00585585|DRUG|betahistine dihydrochloride|oral, 50-300 mg, daily
47943086|NCT01847001|DRUG|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
48632009|NCT03708770|DEVICE|everlinQ endoAVF System|
47943087|NCT01847001|DRUG|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
47943088|NCT01847001|DRUG|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
47943089|NCT01847001|DRUG|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
47943090|NCT01847001|DRUG|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
47943091|NCT01847001|PROCEDURE|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
47943092|NCT01847001|DRUG|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
47943093|NCT01847001|DRUG|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
47943094|NCT01847001|DRUG|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
48103169|NCT04308746|BEHAVIORAL|Online Individualistic Prime (statement writing)|Participants write 3 statements each about (1) themselves, (2) why they are not like others, and (3) why it is beneficial to stand out from others
48292118|NCT02946229|DEVICE|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
48292119|NCT06513715|DIETARY_SUPPLEMENT|Control|This intervention will be made with a placebo
48292120|NCT06513715|DIETARY_SUPPLEMENT|Jubanine|This intervention will be made with jubanine or prickly pear extract
48292121|NCT02413255|DRUG|TAK-020|TAK-020 oral solution
48292122|NCT02413255|DRUG|TAK-020 Placebo|TAK-020 placebo-matching oral solution
48292123|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
48292124|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
48292125|NCT04685473|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) Capsule
48292126|NCT05582837|DRUG|nortriptyline + topiramate|nortriptyline (7.5mg) + topiramate (10mg) taken 1x per day and escalate weekly as needed for 8 weeks
48292127|NCT05839548|DRUG|Mepivacaine 2% with epinephrine 1:100,000|Local Anesthesia
48292128|NCT05839548|DRUG|Articaine (4%) with epinephrine 1:100,000|Local Anesthesia
48292129|NCT03750162|DEVICE|VDW Ultra|supplementary disinfection technique
48292130|NCT03750162|DEVICE|AMD picasso|supplementary disinfection technique
48292131|NCT03750162|DEVICE|ProtaperNext X3 gutta-percha|supplementary disinfection technique
48292132|NCT03550144|BEHAVIORAL|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
48292133|NCT03550144|BEHAVIORAL|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
47943095|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS shear wave|"EUS Shear wave elastography (SWE) is a form of ultrasound elastography used in transabdominal ultrasonography. It measures tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI). The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals \[kPa\] or meters per second. Also, the dispersion slope or ultrasound shear wave dispersion (SWD) will be recorded. It is the measure of viscosity \[(m/sec)/kHz\] using SWE.~A first endoscopist will perform EUS over pancreas tissue. Without any elastography assessment (strain ratio/histogram) , the endoscopist will take ten shear wave measurements of pancreas tissue elasticity by generating shear waves inside the pancreas using the ARFI."
48292134|NCT06295783|OTHER|MDASI-HN|Given by Questionnaire
47943096|NCT05095831|DIAGNOSTIC_TEST|Pancreas EUS-elastography and EUS-guided biopsy|"Pancreas EUS-elastography measures the pancreatic tissue stiffness through strain ratio (SR) and strain histogram (SH).~A second endoscopist blind to pancreas tissue shear wave findings will perform EUS-elastography with corresponding SR and SH measurements. The SR/SH will be measured and documented. Finally, a pancreas tissue biopsy will be performed. The impossibility of biopsy is an exclusion criterion (except in control patients). Due to ethical purposes, a biopsy will not be performed on patients from the control group."
47943097|NCT03796832|DEVICE|Flat Flexible Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \<15 mm, (ii) shoe pitch \<10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight \<=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
47943098|NCT03796832|DEVICE|Stable Supportive Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \>30 mm, (ii) shoe pitch \>10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight \>300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
47943099|NCT03796832|OTHER|Exercise Therapy|The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
47943100|NCT02471976|OTHER|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
48103170|NCT04308746|BEHAVIORAL|Online Collectivistic Prime (statement writing)|Participants think about a social group and write 3 statements each about (1) their social group, (2) why they are like others, and (3) why it is beneficial to blend in with others
48103171|NCT04486729|OTHER|High PEEP with end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system with end inspiratory pause addition in volumen control ventilation
48292135|NCT06295783|OTHER|EORTC QLQ-C30|Given by Questionnaire
48292136|NCT06295783|OTHER|EORTC HN35|Given by Questionnaire
48292137|NCT05083208|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
48292138|NCT05083208|DRUG|Chidamide|"Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments."
48292139|NCT03756012|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
48292140|NCT01200511|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
48292141|NCT00686205|DEVICE|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
48292142|NCT05278793|DRUG|Ferrous fumarate|Ferrous fumarate 200mg oral
48292143|NCT02989948|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
48292144|NCT03388125|DRUG|Injection Sclerotherapy|5% ethanolamine oleate group
48292145|NCT03388125|DRUG|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
48292146|NCT02089737|DRUG|Panitumumab|Panitumumab for intravenous infusion
48292147|NCT06672679|BEHAVIORAL|Juntos|6 week family-based intervention
48292148|NCT06672679|BEHAVIORAL|Resource guide|Active control arm will receive a resource guide
48292149|NCT00018863|DRUG|Methylphenidate|
48292150|NCT02652429|DRUG|Inhaled Nitric Oxide|
48292151|NCT00231062|DEVICE|Sinuplasty|
48632010|NCT06482424|OTHER|intervention group|"Actions to be taken to the Intervention Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. The aromatic oil given to patients in the intervention group will be placed in 10ml dark glass bottles with droppers and a numbered label will be attached to the bottle.~Procedures to be Performed on the Placebo Group The researcher will record the state-trait anxiety scale and Pittsburg Sleep Quality Index score on the patient follow-up chart-researcher form at the patient's home at the beginning of the first week and at the end of the fourth week. Sesame oil given to patients in the placebo group will be placed in 10 ml dark glass bottles with droppers and a number two label will be attached to the bottle."
47943101|NCT02193451|PROCEDURE|Urodynamics|Diagnostic test for urinary storage and voiding function
47943102|NCT02193451|PROCEDURE|Usual care|
48292152|NCT03662464|OTHER|No intervention|develop and validate a specific tool to score the risk of escaping in Nursing Homes residents
47943103|NCT00116168|BIOLOGICAL|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
47943104|NCT00116168|BIOLOGICAL|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
48292153|NCT01471873|PROCEDURE|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
47943105|NCT00116168|BIOLOGICAL|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
47943106|NCT00116168|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
48103172|NCT04486729|OTHER|Low PEEP - FiO2 high|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 96-98%
48292154|NCT05565677|DEVICE|micro-computed tomography scanning of lung tissue specimens|Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
48292155|NCT01686503|DRUG|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
48632011|NCT05654207|BEHAVIORAL|WeCare|WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
48632012|NCT00356421|DRUG|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
48632013|NCT00356421|DRUG|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
48292156|NCT01977144|OTHER|Comprehensive Chromosomal Screening|
47943107|NCT01702831|DRUG|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
47943108|NCT01702831|DRUG|Melphalan|"I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2"
47943109|NCT01702831|DRUG|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
47943110|NCT00069433|PROCEDURE|Social skills and symptom management training|
48292157|NCT00984230|OTHER|BSF|feeding amount according to individual baby need
48292158|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
48292159|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
48292160|NCT00060086|DIETARY_SUPPLEMENT|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
48292161|NCT05491642|DRUG|BAY3283142|Oral administration
48292162|NCT05491642|DRUG|Placebo to BAY3283142|Oral administration
48292163|NCT04229147|RADIATION|Radiotherapy|Patients who received a total dose of 30 Gy
48292164|NCT02060825|DEVICE|Regional saturation monitor|
48292165|NCT00969618|DRUG|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
48292166|NCT01666522|DRUG|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
48292167|NCT01666522|OTHER|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
48292168|NCT03497962|PROCEDURE|Venepuncture|Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
48292169|NCT03497962|PROCEDURE|Bronchoscopy|Broncho-alveolar lavage to obtain alveolar macrophages
47943111|NCT00814151|OTHER|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
47943112|NCT06412575|PROCEDURE|JNT Guided OGT-overlap Oesophagojejunostomy|In the JNT group, the Joint Nasogastric Tube (JNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
48292170|NCT00446212|DRUG|Propofol|target controlled infusion of propofol
48292171|NCT00446212|DRUG|desflurane|Anaesthetic maintenance with desflurane
48292172|NCT05689827|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
48292173|NCT05689827|DRUG|Placebo|Placebo was used in the same way
47943113|NCT06412575|PROCEDURE|TNT Guided OGT-overlap Oesophagojejunostomy|In the TNT group, the Traditional Decompression Nasogastric Tube (TNT) was put into the oesophageallumen from the nose, to guide the cutting of a small enterotomy on the posterior oesophageal stump.
47943114|NCT03637179|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
47943115|NCT03637179|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
47943116|NCT00645684|PROCEDURE|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
47943117|NCT01012167|DRUG|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
47943118|NCT01012167|DRUG|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
48103173|NCT04486729|OTHER|High PEEP without end inspiratory pause|Applying a PEEP value 10 cmH2O higher than the lower inflection point of the pressure-volume curve of the respiratory system without end inspiratory pause addition in volumen control ventilation
48103174|NCT04486729|OTHER|Low PEEP - FiO2 low|Applying a PEEP value equal to the lower inflection point of the pressure-volume curve of the respiratory system with a FiO2 necessary to achieve a SpO2 88-92%
48103175|NCT03338218|DRUG|Volulyte 6%|Solution for infusion
48103176|NCT03338218|DRUG|Ionolyte|Solution for infusion
48292174|NCT00003820|DRUG|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
48292175|NCT02828319|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
48292176|NCT02417415|OTHER|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at \~44ºC continuously for 2 hr.
48292177|NCT02417415|OTHER|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
48292178|NCT01161836|DRUG|Iniparib|"Solution for infusion~60-minute intravenous infusion"
48292179|NCT04762355|DRUG|Palovarotene|ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
47943119|NCT01012167|OTHER|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
47943120|NCT01012167|OTHER|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
48103177|NCT06533878|DRUG|HY-209|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
48103178|NCT06533878|DRUG|HY-209 placebo|Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg
48103179|NCT00711646|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
48103180|NCT00711646|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
48103181|NCT05997654|DEVICE|MEDGEL ANTIAGE|The MEDGEL ANTIAGE is a medical grade silicone plate, biocompatible.
48292180|NCT04762355|DRUG|Vehicle|Placebo-to-match palovarotene ophthalmic solution vials
48292181|NCT06338449|BEHAVIORAL|Aerobic training (AT)|An exercise program was developed by a full-time physical education teacher, with all group exercises conducted at the outdoor track and field facility of Xuzhou Medical University. Participants in the aerobic training group, after completing a warm-up, were required to perform moderate-intensity aerobic running for 60 minutes per session, 4-5 times a week. The exercise intensity was set to reach 50%-70% of the maximum heart rate (Maximum heart rate = 220 - age). The exercise sessions were scheduled in the evening after dinner, from 17:30 to 19:00.All participants were continuously intervened for 8 weeks.
48292182|NCT06338449|BEHAVIORAL|Resistance training (RT)|Participants in the resistance training group were required to complete moderate-intensity resistance exercises 4-5 times per week. Each session included a warm-up, followed by exercises such as knee lifts with torso twists, knee-to-hand taps under the hips, jumping jacks, burpees, sit-ups, planks, and squats. The routine was structured to perform 5-6 exercises per session, with 6-8 repetitions for each set. There was a 30-second rest interval between sets, and the total exercise time was 60 minutes. The timing for these exercise sessions was the same as for the AT group, conducted in the evening after dinner.All participants were continuously intervened for 8 weeks.
48292183|NCT06338449|BEHAVIORAL|Combined aerobic and resistance training (AT + RT)|Participants in the combined aerobic and resistance training (AT+RT) group started their sessions with a warm-up, followed by 30 minutes of aerobic running. After the aerobic training, they engaged in resistance training. The resistance training regimen was the same as that for the RT group, except that the duration of the resistance training was shorter. The total duration of the exercise session was 60 minutes.All participants were continuously intervened for 8 weeks.
48292184|NCT05306678|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
48292185|NCT05306678|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
48292186|NCT04143971|OTHER|intermittent fasting diet|intermittent fasting diet
48292187|NCT04143971|OTHER|low calorie diet|continuous low calorie diet
48292188|NCT03133481|PROCEDURE|Adductor Canal Nerve Block|Adductor Canal never technique
48292189|NCT03133481|DRUG|Femoral Nerve Block|Traditional technique
48292190|NCT05942274|DIAGNOSTIC_TEST|We propose to validate these smartwatch ECG functions to support FDA submissions|1) Obtain a simultaneous recording of a Lead I (RA-LA) ECG from the Smartwatch and a clinical standard device (GE Cardiosoft ECG). Subsequent recordings will be acquired from the other models of the Smartwatch as well as a recording utilizing the FDA-cleared KardiaMobile.
48292191|NCT06511154|OTHER|Cognitive Rehabilitation|"Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied.~Core-based Upper Extremity Exercises~Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises"
48292192|NCT06511154|OTHER|Core-based Upper Extremity Exercises|Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
48292193|NCT02004990|PROCEDURE|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
48103182|NCT02887313|DRUG|mFOLFOX6|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4 cycles of mFOLFOX6 would be given before surgery.
48103183|NCT02887313|RADIATION|Radiotherapy|Patietns received preoperative radiotherapy, 1.8-2.0GY/23-25F
48103184|NCT04985487|OTHER|brolucizumab|Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
48103185|NCT04127058|DRUG|Iloperidone|Oral Tablet
48103186|NCT00597350|DIETARY_SUPPLEMENT|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
48103187|NCT01972152|DRUG|G-Pen(TM) 1 mg|
48103188|NCT01972152|DRUG|Lilly Glucagon(TM) 1 mg|
48103189|NCT01972152|DRUG|G-Pen(TM) 0.5 mg|
48103190|NCT05155371|OTHER|Titration of Optimal Positive End-expiratory Pressure|Titration of Optimal Positive End-expiratory Pressure with two different methods
48103191|NCT02954055|DRUG|Paclitaxel|Arm A
48103192|NCT02954055|DRUG|Cyclophosphamide|Arm B
48103193|NCT02954055|DRUG|Capecitabine|Arm B
48103194|NCT02954055|DRUG|Vinorelbine|Arm B
48103195|NCT01303835|DRUG|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
48103196|NCT01303835|DRUG|Placebo|Randomized patients received placebo to be taken every night before bed.
48103197|NCT01235949|BIOLOGICAL|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
48103198|NCT01235949|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
48103199|NCT01235949|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
48292194|NCT01269125|DRUG|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
48292195|NCT01269125|PROCEDURE|IVF|Assisted Reproduction Technique.
48292196|NCT03626415|DRUG|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
48292197|NCT00667277|DRUG|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
48292198|NCT02875548|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
48292199|NCT03526640|DEVICE|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
48292200|NCT06359249|BEHAVIORAL|change of habits|change of habits
48292201|NCT06359249|OTHER|change of habits + auto abdominal massage|change of habits + auto abdominal massage
47943121|NCT00753779|DRUG|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
48292202|NCT03538392|DEVICE|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
48292203|NCT04073212|OTHER|Dry Needling|Dry needling directly to the long head of the biceps tendon. The DN will be performed with disposable stainless-steel needles (.3 X 40mm; Seirin; Weymouth, MA) inserted into the skin over the most painful and/or thickened areas of the tendon, confirmed with palpation. Prior to insertion of the needle the overlying skin will be cleaned with alcohol. The needle will be inserted into the tendon. The technique will be a fast-in and fast-out technique described by Chiavaras et al.26 for 20-30 repetitions per session in up to 3 areas. An eccentric-concentric exercise program of the biceps muscle/tendon will follow each DN session and will be performed daily for the course of treatment and will be performed as described by McDevitt et al.
48292204|NCT04073212|OTHER|Heavy Slow Load Exercise|Eccentric exercise protocols have been found to be an effective treatment for tendinopathies of the upper and lower extremities and recent evidence supports heavy slow resistance training (including the addition of a concentric phase) as having better outcomes over eccentric exercise alone. Patients will use 1-5 pound weights to perform slow and controlled concentric and eccentric exercise to biceps muscle.
48292205|NCT04073212|OTHER|Rotator cuff and scapular stabilization exercise program|Both groups will be treated with a stretching and strengthening program. The rotator cuff and scapular stabilization strengthening and flexibility program used in this study has 3 phases and patients progress in phases based on their ability to perform a number of exercises using theraband or body weight resistance.
47943122|NCT00753779|DRUG|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
47943123|NCT01484132|PROCEDURE|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
48292206|NCT04073212|OTHER|Soft tissue mobilization|Both groups will receive soft tissue mobilization to the anterior shoulder.
47943124|NCT04245462|OTHER|No intervention|Cross-sectional
47943125|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
48103200|NCT01235949|DRUG|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
48292207|NCT04727216|DEVICE|Dorsal Root Ganglion Stimulation (DRG-S)|Dorsal Root Ganglion stimulation will be delivered with continuous dosing and 2 different ON/OFF periods to compare effects for each patient.
48292208|NCT01801397|DRUG|osteoanabolic therapy|
48292209|NCT01347164|BEHAVIORAL|RISE life coaching intervention|6 2-hour sessions
48292210|NCT01347164|BEHAVIORAL|HIV Counseling|Standard one-hour HIV counseling session
47943126|NCT01241084|DIETARY_SUPPLEMENT|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
48292211|NCT00123201|DRUG|Dronabinol MDI|
48103201|NCT01235949|DRUG|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
48103202|NCT02794948|OTHER|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province
48292212|NCT03667677|DRUG|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
48292213|NCT03667677|DRUG|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
48103203|NCT02794948|DIETARY_SUPPLEMENT|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical \&pharmaceutical limited company in Jiangsu province.
48292214|NCT03667677|DRUG|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
47943127|NCT01248481|DRUG|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
47943128|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
47943129|NCT02546635|DRUG|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
47943130|NCT04722549|DIETARY_SUPPLEMENT|Placebo|Cellulose
47943131|NCT04722549|DIETARY_SUPPLEMENT|Butyrate|Sodium butyrate
47943132|NCT04298372|DRUG|Lenalidomide 25mg|"As single arm study, patients will be treated as follows:~* Lenalidomide : D1\~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.~* Dexamethasone : D1\~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted."
47943133|NCT01483768|PROCEDURE|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
47943134|NCT05277961|RADIATION|Ultraviolet radiation|UV6 tubes
48103204|NCT02873676|BEHAVIORAL|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
48632014|NCT01905267|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
48632015|NCT02902315|OTHER|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
47943135|NCT04490811|OTHER|no intervention. observational cohort study|blood sampling is part of care
47943136|NCT05235139|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
47943137|NCT05235139|DEVICE|IOL implantation active comparator (Acrysof Vivity)|Implantation of EDOF IOL Acrysof Vivity
47943138|NCT02219347|DRUG|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
47943139|NCT02106910|DEVICE|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
48103205|NCT02873676|BEHAVIORAL|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
48474887|NCT06360029|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
48632016|NCT02902315|OTHER|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
48632017|NCT02902315|OTHER|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
47943140|NCT03860142|BEHAVIORAL|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
47943141|NCT06520670|DIAGNOSTIC_TEST|Urinary galectin-3 binding protein|Investigate urinary galectin-3 binding protein (G3BP) as a biomarker for lupus nephritis and indicator for disease activity.
48103206|NCT02873676|BEHAVIORAL|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
48103207|NCT02873676|BEHAVIORAL|control|The intervention involve dietary pattern modification and protein intake standardization
48103210|NCT00531518|DRUG|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
48103211|NCT00531518|BEHAVIORAL|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
48292215|NCT03667677|DRUG|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
48103212|NCT00531518|BEHAVIORAL|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
48103213|NCT06208696|OTHER|"Tomando control de su salud (Spanish Chronic Disease Self-Management)"|"Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management."
48292216|NCT02275572|PROCEDURE|Pharmacist Intervention|
48292217|NCT02031146|PROCEDURE|Lumbar puncture|
48292218|NCT00796783|DRUG|Cushing's syndrome confirmation|
48292219|NCT00090649|DRUG|DVS-233 SR|
48292220|NCT03877185|DIAGNOSTIC_TEST|Live birth rate|Live Birth Rate and Blastulation Rate according to the protocol of COS
48292221|NCT06123429|BEHAVIORAL|Mindfulness Based Stress reduction|"The MBSR course will consist of weekly sessions lasting two and a half hours, involving lecture, meditation, and self-reflection.~Mindfulness-Based Stress Reduction (MBSR) is a structured program designed to help individuals manage stress, increase self-awareness, and promote overall well-being. Developed by Dr. Jon Kabat-Zinn in the late 1970s, MBSR combines elements of mindfulness meditation and cognitive-behavioral techniques. MBSR is a comprehensive program that equips individuals with practical skills to better manage stress and enhance their mental and emotional well-being. Its emphasis on mindfulness, self-awareness, and the integration of these practices into daily life makes it a valuable resource for those seeking to reduce stress and improve their overall quality of life."
48292222|NCT06668363|BEHAVIORAL|Treat4All|An alcohol reduction evidence-based intervention integrated with HIV status-neutral counseling
48292223|NCT06668363|BEHAVIORAL|Standard of care (control arm)|Sexual risk reduction counseling
48292224|NCT06378710|PROCEDURE|Optimized PEEP|Optimized PEEP
48292225|NCT00941772|OTHER|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
48292226|NCT03148171|OTHER|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
48292227|NCT05237882|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
48292228|NCT02061995|DRUG|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
48474888|NCT06360029|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
48474889|NCT01102452|DIETARY_SUPPLEMENT|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
48632018|NCT02902315|OTHER|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
48632019|NCT04094636|BEHAVIORAL|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
48632020|NCT04094636|BEHAVIORAL|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
47943142|NCT05105022|DRUG|Propofol|Intravenous induction of general anesthesia in infants 3 months or less.
47943143|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using CIMBI-36 tracer|This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
48103214|NCT01544062|DRUG|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
48292229|NCT00728416|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
48292230|NCT00728416|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
48292231|NCT00492622|DRUG|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
48292232|NCT00492622|DRUG|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
48292233|NCT04227977|DEVICE|JuxtaFlow System|The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
48474890|NCT01102452|DIETARY_SUPPLEMENT|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
47943144|NCT05516732|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
47943145|NCT05516732|OTHER|Positron Emission Tomography (PET) scan using DASB tracer|To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
47943146|NCT05516732|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
47943147|NCT05516732|OTHER|Lumbar puncture|A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
47943148|NCT05993039|DRUG|Isoflurane Inhalant Product|1.5-2%
47943149|NCT05993039|DRUG|Sevoflurane inhalant product|1-2% adults 0.6-1.5% Children
47943150|NCT05993039|DRUG|Propofol injection|1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children
47943151|NCT05993039|DRUG|Remifentanil Injection|0.05-2ug/kg/min adults and children
47943152|NCT02207673|PROCEDURE|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
47943153|NCT01070043|DRUG|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
48632021|NCT01796444|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
48632022|NCT01796444|PROCEDURE|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
47943154|NCT01070043|DRUG|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
47943155|NCT00498524|DEVICE|ICD|Received an ICD
47943156|NCT00498524|DEVICE|ICD|Have not received an ICD
48632023|NCT01796444|PROCEDURE|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
48632024|NCT01796444|PROCEDURE|Pathological Evaluation|H\&E and IHC
48632025|NCT01796444|DRUG|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
47943157|NCT05337436|BIOLOGICAL|Lymphatic drainage|Biological determination in plasma:
47943158|NCT05337436|BIOLOGICAL|Total and ionized magnesium|Total and ionized magnesium
47943159|NCT05337436|BIOLOGICAL|Total and ionized calcium|Total and ionized calcium
47943160|NCT04960410|COMBINATION_PRODUCT|Types and exposure of different air pollutants|Types and exposure of different air pollutants in COPD patients' living and working environment
48632026|NCT01796444|RADIATION|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
47943161|NCT06410404|PROCEDURE|transversus thoracis plane block|with the patient lying in the supine position. After skin disinfection, a high frequency linear ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, different drugs according to the different groups will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
47943162|NCT06410404|DRUG|Dexmedetomidine|the dexmeditomedine group shall undergo bilateral transversus thoracis plane block with 15 ml of 25% levobupivacaine, and 0.05 ug/kg dexmeditomedine on each side of the sternum
47943163|NCT06410404|DRUG|Levobupivacaine|A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
47943164|NCT00603785|DRUG|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.
47943165|NCT00603785|DRUG|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
47943166|NCT05683223|BEHAVIORAL|Group CBT for Social Anxiety Disorder|Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.
48103215|NCT01544062|DRUG|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
48103216|NCT02774252|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - Y49-103)
48632027|NCT04682964|DRUG|Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.|Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.
48632028|NCT02403778|DRUG|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
48292234|NCT02242539|BEHAVIORAL|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
47943167|NCT05683223|DRUG|Sertraline|Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (\< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
47943168|NCT05683223|BEHAVIORAL|Individual CBT for Social Anxiety Disorder|Participants who show no or only partial response to the initial group CBT will continue with an individual, tailored form of CBT plus adjunctive SSRI. The format of CBT will include
47943169|NCT01788176|DRUG|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
47943170|NCT01788176|DRUG|Placebo|one single intravenous infusion of 100ml of saline.
48292235|NCT02242539|BEHAVIORAL|Community-based monitoring|"Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day."
47943171|NCT00683085|BIOLOGICAL|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
47943172|NCT01015053|PROCEDURE|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
47943173|NCT01015053|PROCEDURE|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
47943174|NCT02035501|DRUG|L-Tyrosine|
47943175|NCT02035501|DRUG|Placebo|
47943176|NCT05400915|DRUG|Variltinib, Paclitaxel|Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
47943177|NCT04912011|DRUG|Canrenoate Potassium|Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
47943178|NCT04912011|DRUG|Normal Saline|Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
47943179|NCT03918889|DRUG|Dexmedetomidine Injectable Product|dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1
47943180|NCT03918889|DRUG|Midazolam injection|midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
47943181|NCT04084327|OTHER|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
47943182|NCT03712631|PROCEDURE|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
47943183|NCT03828409|PROCEDURE|Short stitch|The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.
47943184|NCT03828409|PROCEDURE|Long stitch|Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
47943185|NCT01061632|PROCEDURE|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
47943186|NCT01061632|PROCEDURE|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
47943187|NCT02620007|DRUG|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
47943188|NCT02620007|DRUG|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
47943189|NCT02620007|DRUG|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
47943190|NCT02620007|DRUG|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
47943191|NCT03438318|DRUG|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
47943192|NCT03438318|DRUG|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
47943193|NCT03438318|RADIATION|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
47943194|NCT02353754|DRUG|Intrathecal morphine injection|0.2 mg
47943195|NCT02353754|DRUG|EXPAREL|266 mg
47943196|NCT05352490|DIAGNOSTIC_TEST|calculate LUS score|calculate LUS score
48474891|NCT04880226|DEVICE|Magnetic Resonance Imaging (MRI)|Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
48474892|NCT06616402|DEVICE|prototype prosthetic group|"These 3 sessions will commence only upon successful completion of the prosthesis safety and reliability tests conducted in the preceding sessions.~For each module combination, a session will be conducted to assess motor performance through the acquisition of spatiotemporal parameters and energy efficiency parameters of gait. Motor performance will be evaluated using functional assessment tests and data will be recorded during the following activities:~* parallel bar walking on flat ground~* parallel bar walking on an inclined surface~* treadmill walking with a safety harness~* stair climbing/descending with a handrail~* standing up and sitting down from a chair within parallel bars At the end of each session, satisfaction questionnaires (ad hoc questionnaire) will be completed. At the end of the experiment, a usability scale for the devices (ad hoc System Usability Scale) will be completed.~Each session is expected to last approximately 2.5 hours."
48474893|NCT00559364|DRUG|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
48474894|NCT00559364|DRUG|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
48474895|NCT00559364|DRUG|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
48474896|NCT00559364|DRUG|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
47943197|NCT02675712|OTHER|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
47943198|NCT00476359|DRUG|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
47943199|NCT03538431|DRUG|Buspirone|Buspirone is an atypical anxiolytic medication.
47943200|NCT04233463|DIETARY_SUPPLEMENT|Modulen|Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
47943201|NCT04233463|DRUG|Budesonide|Standard treatment for mild Crohn Disease patients
47943202|NCT00292318|BEHAVIORAL|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
47943203|NCT00292318|BEHAVIORAL|control group|Medical counseling and ano-sphinctal exercises.
47943204|NCT01459237|DRUG|Acthrel|Ovine Corticorelin
47943205|NCT00133393|DRUG|Pentoxifylline|
47943206|NCT04259554|DEVICE|OFC rTMS|repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
47943207|NCT01129674|DRUG|LY2140023|Administered orally, twice daily for 104 weeks
47943208|NCT01129674|DRUG|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
47943209|NCT01129674|DRUG|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
47943210|NCT01129674|DRUG|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
47943211|NCT01129674|DRUG|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
47943212|NCT01860781|DRUG|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
47943213|NCT03576365|BEHAVIORAL|VOICE Intervention Arm|"Introductory and background information about voice problems and psychosocial distress~* Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~* Information about perceived control and how improving perceived control can lead to decreased distress~* Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~* Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms"
47943214|NCT03576365|BEHAVIORAL|Information-Only Arm|"General introduction of the program and background on voice related information in an interactive manner~* Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~* Information on the anatomy of the voice and how the voice works~* Educational materials to help understand voice physiology and function~* Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)"
47943215|NCT01030328|DRUG|Placebo|2 sugar pills by mouth once a day.
47943216|NCT01030328|DRUG|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
47943217|NCT00664027|DRUG|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
47943218|NCT05994560|OTHER|With temporary occlusion|at the time of surgery the randomization table was consulted and if it was in the occlusion arm was performed
47943219|NCT05398926|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
47943220|NCT00890266|PROCEDURE|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
48292236|NCT05092581|DRUG|casirivimab+imdevimab|Single dose weight-based equivalent administered intravenously (IV)
47943221|NCT05736783|OTHER|plyometric exercises|"1. st week Wall touches 3x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4conesx10~2. nd week Wall touches 4x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4 cones x 30~3. rd week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30~4. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (20)~5. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (30)~6. th week Wall touches 6x30 s Split squat jumps 2x70 Lateral cone jumps 2x60 Cone hops with 180 turn 4 cones x 40 Drop jump 45.72 cm (40)"
47943222|NCT05736783|OTHER|strenghtening of quadriceps and hamstring|1st to 3rd week l 4th to 6th week Squat 2x12 3x8 l 3x10 4x6 Knee extension 3x12 3x8 l 2x10 2x6 Nordic hamstring 3x3 3x3 l 3x4 3x4
47943223|NCT02316912|DRUG|ATX2417|Randomised double blind parallel group ascending dose assessment
47943224|NCT02316912|DRUG|Placebo|Randomised double blind parallel group ascending dose assessment
47943225|NCT04559360|DEVICE|PRESTOapp|The intervention group will be asked to use the app for a period of 2 months.
47943226|NCT03024697|PROCEDURE|Pectoral Plane Block|
47943227|NCT03024697|PROCEDURE|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
47943228|NCT04177927|DEVICE|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
47943229|NCT04177927|DEVICE|Rutine monitoring|peripheric Oxygen saturation is monitored.
47943230|NCT06212427|DIETARY_SUPPLEMENT|HMO supplement|Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
47943231|NCT03654066|DRUG|Botulinum toxin type A|Botox injection in the LES
47943232|NCT03654066|DEVICE|Endoscope balloon dilator|Distal esophageal dilation
47943233|NCT03654066|OTHER|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
47943234|NCT03654066|DIAGNOSTIC_TEST|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
47943235|NCT04196751|OTHER|Clinical Supervision|After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6\&12 month with pre-specified tools.
48292237|NCT00427661|OTHER|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
48292238|NCT03288974|DRUG|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
48292239|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) with a goal inventory|Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool
48292240|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) without inventory|Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
48632029|NCT02403778|DRUG|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
47943236|NCT02705027|DEVICE|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
47943237|NCT03548233|BIOLOGICAL|bcg vaccine|live attenuated vaccine
47943238|NCT01413477|DRUG|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
47943239|NCT02712255|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
48103217|NCT01191619|PROCEDURE|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
48103218|NCT01761396|BEHAVIORAL|CBT|
48103219|NCT01761396|BEHAVIORAL|UC|
48292241|NCT05295160|BEHAVIORAL|weight loss by very low energy diet intake which may differ in protein or carbohydrate content|The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
48292242|NCT02252978|DRUG|ciprofloxacin|Given PO
48474897|NCT05359783|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension.
48292243|NCT02252978|OTHER|placebo|Given PO
48292244|NCT02252978|OTHER|quality-of-life assessment|Ancillary studies
48292245|NCT02252978|OTHER|laboratory biomarker analysis|Correlative studies
48292246|NCT00002056|DRUG|Pentamidine isethionate|
48292247|NCT00956644|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
48292248|NCT00956644|DRUG|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
48292249|NCT00798512|DEVICE|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
48474898|NCT01450241|OTHER|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
47943240|NCT02712255|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient."
48632030|NCT02825537|DEVICE|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
48632031|NCT02825537|OTHER|No use of compression stocking|No use of compression stocking
48632032|NCT01984060|OTHER|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
48632033|NCT01248390|BEHAVIORAL|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
48632034|NCT00443326|DRUG|AMG 714|Dosing Regimen is 6 Doses over 3 Months
48632035|NCT01477411|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
48632036|NCT01477411|DRUG|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
48292252|NCT00029796|DRUG|soy isoflavones|
48292253|NCT04334148|DRUG|Hydroxychloroquine|oral self administered tablet
48292254|NCT04334148|DRUG|Placebo oral tablet|oral self administered tablet
48292255|NCT05215210|OTHER|Bitter-gourd|12-week intervention of 3.6 grams of dried bitter-gourd supplements
48292256|NCT05215210|OTHER|Cucumber|12-week intervention of 3.6 grams of cucumber supplements
48292257|NCT01773395|BIOLOGICAL|GVAX|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
48632037|NCT04763408|DRUG|Lenvatinib|Oral capsules.
48632038|NCT04763408|DRUG|Sorafenib|Oral tablets.
48632039|NCT03685240|BEHAVIORAL|SafelyYou Fall Prevention System|Technology + Quality Assurance Services Provided by SafelyYou
48292258|NCT01773395|BIOLOGICAL|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
48292259|NCT01773395|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
48292260|NCT01773395|DRUG|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
48474899|NCT01450241|OTHER|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
48474900|NCT05229055|DRUG|Ketamine|giving ketamine intranasal
48474901|NCT05467826|DRUG|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
48632040|NCT01657500|OTHER|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
48632041|NCT01657500|OTHER|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
47943241|NCT02712255|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
47943242|NCT02712255|BEHAVIORAL|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
47943243|NCT03511118|DRUG|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943244|NCT03511118|DRUG|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943245|NCT03511118|DRUG|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943246|NCT03511118|DRUG|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48292261|NCT01773395|DRUG|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
47943247|NCT03511118|DRUG|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943248|NCT03511118|DRUG|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943249|NCT03511118|DRUG|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943250|NCT03511118|DRUG|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48474902|NCT05467826|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
48474903|NCT00432055|DRUG|Botulinum toxin type A (Botox)|
47943251|NCT03511118|DRUG|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943252|NCT03511118|DRUG|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48474904|NCT00432055|DRUG|placebo (saline)|
48292262|NCT01773395|DRUG|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
48292263|NCT01773395|DRUG|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
48474905|NCT03992547|OTHER|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
48474906|NCT00685035|DEVICE|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
48474907|NCT00685035|DEVICE|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
47943253|NCT03511118|DRUG|Ciprofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48292264|NCT03005535|OTHER|Vitaminized corn oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
48292265|NCT03005535|OTHER|Olive oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
48292266|NCT01964365|DRUG|Cresto 20mg|tablet, rosuvastatin 20mg
48292267|NCT01964365|DRUG|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
48292268|NCT01964365|DRUG|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
48292269|NCT04770155|DIETARY_SUPPLEMENT|Dietary Nitrates 400 mg|The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
48292270|NCT04770155|DIETARY_SUPPLEMENT|L-citrulline 3 g|Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
48292271|NCT04770155|DRUG|Sildenafil 100 mg|Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
48474908|NCT05999994|DRUG|Ramucirumab|Administered IV
48474909|NCT05999994|DRUG|Cyclophosphamide|Administered orally
48474910|NCT05999994|DRUG|Vinorelbine|Administered IV
48474911|NCT05999994|DRUG|Gemcitabine|Administered IV
48474912|NCT05999994|DRUG|Docetaxel|Administered IV
48474913|NCT05999994|DRUG|Abemaciclib|Administered orally
48474914|NCT05999994|DRUG|Irinotecan|Administered IV
48474915|NCT05999994|DRUG|Temozolomide|Administered orally
48474916|NCT00468208|DRUG|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~* 500 mg of abatacept for body weight less than 60 kg~* 750 mg of abatacept for body weight between 60 and 100 kg~* 1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
47943254|NCT03511118|DRUG|Doxycycline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943255|NCT03511118|DRUG|Levofloxacin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943256|NCT03511118|DRUG|Methylphenidate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943257|NCT03511118|DRUG|Sumatriptan|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943258|NCT03511118|DRUG|Citalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48632042|NCT03950388|BEHAVIORAL|Intervention|Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
48632043|NCT01104272|DEVICE|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
47943259|NCT03511118|DRUG|Cyclobenzaprine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943260|NCT03511118|DRUG|Furosemide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48292272|NCT04770155|DRUG|Bosentan 125 mg|Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
47943261|NCT03511118|DRUG|Gabapentin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48632044|NCT03928327|DRUG|TAK-788|TAK-788 Capsules
47943262|NCT03511118|DRUG|Hydrochlorothiazide|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943263|NCT03511118|DRUG|Hydroxyurea|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943264|NCT03511118|DRUG|Rosuvastatin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943265|NCT03511118|DRUG|Topiramate|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48632045|NCT03928327|DRUG|Itraconazole|Itraconazole Oral solution
47943266|NCT03511118|DRUG|Trazodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943267|NCT03511118|DRUG|Valganciclovir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943268|NCT03511118|DRUG|Venlafaxine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943269|NCT03511118|DRUG|Verapamil|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943270|NCT03511118|DRUG|Remdesivir|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48474917|NCT04576715|BEHAVIORAL|TEaM Intervention|"Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~* Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~* Management based on current best practices (however, may have additional education from the provider training)~* Return to school letters~* Primary Care Follow Up"
48474918|NCT04576715|BEHAVIORAL|Standard of Care|"Continue with CHOA current best practices for mTBI:~* No TEaM Provider training (but will be offered to all providers at end of study)~* Will not be trained on utilization and implementation of the concussion screening alert and eMR template"
48632046|NCT03928327|DRUG|Rifampin|Rifampin Capsules
47943271|NCT03511118|DRUG|Anakinra|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48474919|NCT01000688|DRUG|vildagliptin + acarbose|4 week treatment
47943272|NCT03511118|DRUG|Tocilizumab|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943273|NCT03511118|DRUG|Fluvoxamine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943274|NCT03511118|DRUG|Amoxicillin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943275|NCT03511118|DRUG|Bupropion|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943276|NCT03511118|DRUG|Duloxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943277|NCT03511118|DRUG|Hydrocodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943278|NCT03511118|DRUG|Levetiracetam|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48474920|NCT01000688|DRUG|acarbose + vildagliptin|4 week treatment
48474921|NCT00732160|DRUG|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
48474922|NCT00732160|DRUG|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
48474923|NCT00732160|OTHER|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
48474924|NCT00732160|OTHER|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
47943279|NCT03511118|DRUG|Paroxetine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
47943280|NCT03511118|DRUG|Buprenorphine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
48632047|NCT04799873|DRUG|AAT( Alpha 1 Antitrypsin)|AAT administration based on clinical indication
48632048|NCT02568254|DEVICE|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
48632049|NCT02568254|DEVICE|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
48632050|NCT02568254|DEVICE|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
47943281|NCT01222858|BEHAVIORAL|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
47943282|NCT01222858|BEHAVIORAL|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
47943283|NCT01840618|DEVICE|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
47943284|NCT00354471|PROCEDURE|Uterine Artery Embolization|
47943285|NCT03768570|DRUG|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
47943286|NCT00001095|DRUG|Indinavir sulfate|
47943287|NCT00001095|DRUG|Amprenavir|
47943288|NCT00001095|DRUG|Nevirapine|
47943289|NCT00001095|DRUG|Lamivudine|
47943290|NCT00001095|DRUG|Stavudine|
47943291|NCT00001095|DRUG|Zidovudine|
47943292|NCT05997758|OTHER|SEEG stimulation|Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
48632051|NCT05287100|DRUG|Midodrine Oral Tablet|Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued
47943293|NCT05997758|BEHAVIORAL|Adaptation task|Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
47943294|NCT04019431|DIETARY_SUPPLEMENT|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
47943295|NCT03622359|DIAGNOSTIC_TEST|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
47943296|NCT03622359|DIAGNOSTIC_TEST|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
47943297|NCT05932784|DEVICE|transesophageal echocardiography|Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
47943298|NCT03718871|BEHAVIORAL|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
47943299|NCT00721266|DRUG|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
47943300|NCT00932737|DRUG|Placebo|1-5 tablets per episode
47943301|NCT00932737|DRUG|HBB 20 mg|Active drug, one to five tablets per episode
47943302|NCT06190353|BEHAVIORAL|An internet-based self-help program with minimal telephone support utilizing Acceptance and Commitment Therapy for alleviating burnout among healthcare workers.|An eight module self help program
47943303|NCT02119169|DEVICE|Pigtail catheter|pigtail catheter for pleural drainage
47943304|NCT00003254|DRUG|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
47943305|NCT00003254|DRUG|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
47943306|NCT00881101|DRUG|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
47943307|NCT01869725|DRUG|gallium Ga 68-edotreotide|Given IV
47943308|NCT01869725|PROCEDURE|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
47943309|NCT01869725|RADIATION|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
47943310|NCT01869725|PROCEDURE|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
47943311|NCT01869725|PROCEDURE|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
47943312|NCT05816096|COMBINATION_PRODUCT|Hall technique|The child will be placed to them SSC on one of their HSPM affected teeth. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
47943313|NCT05816096|COMBINATION_PRODUCT|ART|The child will be restored to them one of their HSPM affected teeth by GIC. Pain during treatment will be assessed using the FLACC scale and satisfaction the child and parent will be evaluated using likert scale after the treatment immediately and after one month and evaluate the success restoration adapted from Innes et al. after 3_6_9_12 month.
47943314|NCT00596856|BEHAVIORAL|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
47943315|NCT04165642|OTHER|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
47943316|NCT05454904|BEHAVIORAL|Low fat diet|The low fat diet group will be counseled to consume a dietary pattern with fat restriction including food intake based in the following criteria: 1) \<3 teaspoons/day of olive or Canola oil and \<3 units/week of avocado, 2) removal of visible fat from meats before cooking or from cooked dishes before intake, 3) ≤1 serving per week fat-rich meats, hamburger, commercial ground meat, sausage, cured ham, bacon and salami, 4) daily consumption of low fat dairy products, 5) ≤1 serving/week of butter, margarine, lard, mayonnaise, milk cream, or milk- based ice cream, 6) ≤1 time/week intake of fatty fish or seafood, 7) ≤1 serving per week of commercial sweets or industrial bakery products (not homemade), and 8) ≤1 time/week consumption of nuts (including peanuts), potato chips, French fries, or commercial snacks. This intervention arm will be supplemented with powdered low fat milk (3 kgs/month) for daily use.
48103220|NCT04784013|PROCEDURE|Conventional CLOSE-guided pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
48632052|NCT05287100|OTHER|Standard Medical Treatment|"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"
47943317|NCT05454904|BEHAVIORAL|Mediterranean diet|The Mediterranean diet group will receive dietary recommendations as follows: 1) use of olive oil (\>3 teaspoons/day), 2) Canola oil as second fat source for cooking and dressing or \>3 units/week of avocado; 3) ≥3 daily servings of vegetables (at least one of them as fresh vegetables in a salad), 4) ≥2 daily servings of fresh fruits; 5) ≥2 weekly servings of legumes; 6) \>2 weekly servings of fresh, canned or frozen fish (at least one serving of oily fish)/seafood; 7) ≥2 weekly servings of nuts/seeds; 8) 4-8 servings/week of white meats (poultry or turkey without skin) instead of 9) fatty or processed meats (\<1 serving/week), 10) ≥2 daily servings of whole grains, 11) ≥1 daily/serving of low fat and fermented dairy products, 12) \<1 daily/serving of whole fat dairy products, 13) ≤1 daily/serving of sugary snacks, drinks or juices and \<4 teaspoons/daily of sugar, and 14) moderate (1-2 drinks/day) wine consumption with meals.
48632053|NCT04389671|DRUG|Lucinactant|Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
47943318|NCT05454904|BEHAVIORAL|Mediterranean diet plus psychological well-being support|This group will be subjected to the same Mediterranean diet pattern indicated previously as well as to a psychological well-being intervention that will include a variety of components/activities, embracing values, purpose, self-acceptance, character strengths, emotional regulation, dealing with negativity, goal-setting, mindfulness, savoring, gratitude, autonomy, relationships, social interactions, and prosocial behavior.
47943319|NCT06557174|DRUG|IMC-002|intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
47943320|NCT06557174|DRUG|mycophenolate mofetil， MMF|daily oral 0.2g
48632054|NCT03374904|BEHAVIORAL|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
48632055|NCT03374904|BEHAVIORAL|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
48632056|NCT00919490|DRUG|ABT-333|Tablet, see arms for interventional description
48632057|NCT00919490|DRUG|Placebo|Tablet, see arms for interventional description.
48632058|NCT01795937|DRUG|Itraconazole|twice daily
48292273|NCT06611605|BEHAVIORAL|Storytelling with metaphor toys|"There is evidence of the effectiveness of various methods such as using different types of balls as tactile stimulation and active distraction methods during the management of pain, anxiety, and fear, watching cartoons, using virtual reality (VR) as a method of distracting attention, and using virtual reality hypnosis (VRH). However, no scientific study has been found on storytelling with a metaphoric toy during venous blood collection.~Before the children in the intervention group start the blood collection process, the story will be told to the child by the researcher in the waiting room of Akdeniz University Hospital Blood Collection Unit. The child and the parent will be together during the story telling. Expert opinions were received from five academics who completed their doctorate in Child Health and Disease Nursing for the content of the story."
48292274|NCT03070132|DRUG|BIIB074|Administered as specified in the treatment arm
48292275|NCT03070132|DRUG|Placebo|Matched placebo
48292276|NCT02675517|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
48632059|NCT01795937|DRUG|Atorvastatin|single dose
48632060|NCT01795937|DRUG|Faldaprevir|once daily
48632061|NCT01795937|DRUG|Rosuvastatin|single dose
48632062|NCT01795937|DRUG|Faldaprevir|once daily
48632063|NCT04225832|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention for HIV-negative Latinx sexual minority men aimed at increasing HIV testing and prevention strategies.
48632064|NCT00218894|PROCEDURE|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
48632065|NCT04063904|DRUG|Mifepristone|One 200 mg pill (oral)
48632066|NCT04063904|DRUG|Misoprostol|Two 400 mcg pills (sublingual)
48632067|NCT04258098|DRUG|Oral antibiotics ( Streptomycin ,metronidazole )|Either polyethylene glycol or magnesium sulphate was adopted as laxative one day before surgery. Clyster was conducted on surgery morning. Streptomycin 1g plus metronidazole 0.2g was prescribed 3 times a day for 3 days before surgery in the OA+MBP group patients.
48632068|NCT04776876|BIOLOGICAL|Retifanlimab|Given IV
48632069|NCT04776876|DRUG|Telotristat Ethyl|Given PO
48632070|NCT00417729|DRUG|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
48632071|NCT01727154|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
48632072|NCT05290974|OTHER|Self exploring of available online material on supraclavicular brachial plexus block|Potential new method of learning a specific regional anesthesia technique
48632073|NCT05290974|OTHER|Conventional in-person teaching on supraclavicular brachial plexus block|Conventional method of learning a specific regional anesthesia technique
48632074|NCT00907868|RADIATION|partial breast irradiation|Patients undergo radiation tumor bed boost
48632075|NCT00907868|RADIATION|whole breast irradiation|Patients undergo whole breast irradiation
47943321|NCT00764491|DEVICE|Structural Allograft Spacer|Following disc space preparation the spacer is placed in accordance with cleared labeling and supplemental instrumentation is provided as an adjunct to fixation.
47943322|NCT00764491|DEVICE|OptiMesh 1500S|Following disc space preparation the OptiMesh is deployed and filled in accordance with study surgical technique and supplemental instrumentation is provided as an adjunct to fixation.
47943323|NCT00145600|DRUG|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
47943324|NCT00145600|DRUG|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
47943325|NCT00145600|DRUG|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
47943326|NCT00145600|DRUG|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
47943327|NCT00474838|DRUG|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
47943328|NCT00474838|DRUG|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
47943329|NCT06421207|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
47943330|NCT01295229|PROCEDURE|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
47943331|NCT01295229|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
47943332|NCT03246984|DEVICE|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
47943333|NCT04550910|RADIATION|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
47943334|NCT05342402|OTHER|Somatosensory Rehabilitation Program|Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
47943335|NCT05342402|OTHER|Educational Pain Management Program|Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
47943336|NCT03200158|OTHER|Endoscopy biopsy and blood|Medical operation
47943337|NCT04215588|DEVICE|Hemostasis Management System Plus|Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
47943338|NCT04215588|DEVICE|Activated Coagulation Timer System Plus|The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
47943339|NCT05800873|DRUG|EVER001|A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
47943340|NCT04409600|BEHAVIORAL|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
47943341|NCT04409600|BEHAVIORAL|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
47943342|NCT04409600|DRUG|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
47943343|NCT04409600|DRUG|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
47943344|NCT05773703|DRUG|PSMA-Targeted [In-111]-Labeled Trillium Compound|Radiotracer
48103221|NCT04784013|PROCEDURE|High power short duration pulmonary vein isolation|Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
48292277|NCT03245788|OTHER|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
47943345|NCT05773703|DRUG|PTI-122|Cytoprotective agent
47943346|NCT05690646|DRUG|Nirmatrelvir/ritonavir|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
47943347|NCT05690646|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 15mg/kg/day bid for5 days
48103222|NCT01644162|DEVICE|iVAPS ventilation|3 months of ventilation on iVAPS mode
47943348|NCT00788398|PROCEDURE|Saline Solution|Irrigation with Saline
47943349|NCT00788398|PROCEDURE|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
47943350|NCT00788398|PROCEDURE|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
47943351|NCT00788398|PROCEDURE|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
47943352|NCT00788398|PROCEDURE|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
47943353|NCT06418893|DRUG|Target control infusion propofol|target control infusion of propofol for target plasma concentration 2.5mcg/ml and BIS 40-60
47943354|NCT06418893|DRUG|Inhalational isoflurane|Inhalational Isoflurane at concentration 1-2%
47943355|NCT04840069|DRUG|Fluciclovine PET guided Radiotherapy|PET+MRI Based There is no GTV_5400. The GTV_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV_5400 will include the GTV_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV_5400 must also include the entirety of the GTV_6000. There is no CTV_6000. PTV_5400 is the CTV_5400 plus a geometric 3 mm expansion in all dimensions; PTV_6000 is GTV_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV_5400 must contain the PTV_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV_6000. PTV_6000 will be defined as GTV_6000 plus a geometric 3 mm expansion in all dimensions.
47943356|NCT05665023|DRUG|Bevacizumab + modified FOLFIRINOX|Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
47943357|NCT00869427|DRUG|vitamin C|vitamin C 1g bid for 1 year
48103223|NCT01228513|DRUG|ZK245186|Daily topical application
48103224|NCT01228513|DRUG|Placebo (vehicle without active ingredient)|Daily topical application
48103225|NCT06126536|PROCEDURE|Crestal Maxillary Sinus Floor Elevation using Osseodensification|Patients will be prepared for surgery with local anesthesia and thorough oral cavity disinfection. A full thickness crestal incision will be made slightly towards the palate to enhance the possibility of achieving primary wound closure. A conservative flap will be raised, extending slightly beyond the alveolar crest, to minimize flap-related issues. After preparing the osteotomy site using Densah burs and elevating the sinus to the desired height, the implant will be inserted into the osteotomy site.
48292278|NCT06673225|OTHER|Analysis of results|Analysis of previous imaging and/or laboratory tests, vital signs, body composition, pulmonary function, peripheral muscle strength, calf circumference, nutritional risk, quality of life, frailty level, and anxiety and depression. Screening for respiratory diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis, and other lung lesions, is based on spirometry and thoracic radiological images after the health professional's examination. After the multiprofessional procedures, patients will be evaluated by a physician to start specific treatment and/or perform complementary exams if necessary. Every year, they will be re-evaluated to record acute exacerbations of chronic respiratory diseases and assess disease progression through spirometry and thoracic radiological images.
48292279|NCT03016715|DRUG|Sirolimus 2%|
48292280|NCT03016715|DRUG|Vehicle|
48292281|NCT02094105|PROCEDURE|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
48292282|NCT00804440|DRUG|Ibuprofen Tablets, 800 mg|
47943358|NCT05110443|OTHER|D-WB PET/CT|"Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way."
47943359|NCT03708848|DRUG|Esomeprazole|Proton pump inhibitor
47943360|NCT03708848|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
47943361|NCT03708848|DRUG|Clarithromycin|antibiotic for H. pylori eradication
47943362|NCT03708848|DRUG|Metronidazole|antibiotic for H. pylori eradication
47943363|NCT03708848|DRUG|Levofloxacin|antibiotic for H. pylori eradication
47943364|NCT03708848|DRUG|Tetracycline|antibiotic for H. pylori eradication
47943365|NCT05041946|DRUG|Methylphenidate|Given PO
47943366|NCT05041946|OTHER|Placebo (Sugar Pill)|Given PO
47943367|NCT02828969|OTHER|Phone call or physical consultation|
47943368|NCT01050127|DRUG|ABT-436|See Arm Description for details.
47943369|NCT01050127|DRUG|Placebo|See Arm Description for details.
47943370|NCT01614600|DEVICE|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
48292283|NCT01819688|PROCEDURE|laparoscopic liver resection|
47943371|NCT02542982|DEVICE|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
47943372|NCT04542304|DRUG|Metolazone|Participants will be given a metolazone for the 1-week study period.
47943373|NCT04542304|DRUG|Placebo|Participants will be given a placebo for the 1-week study period.
47943374|NCT01555983|DRUG|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
47943375|NCT05201742|OTHER|Inspiratory muscle training|Threshold inspiratory muscle training was performed for 6 weeks with device.
48632076|NCT00986895|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
48632077|NCT02831036|OTHER|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
48632078|NCT02831036|OTHER|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
47943376|NCT05201742|OTHER|Incentive Spirometry|Incentive spirometry was performed for 6 weeks with device.
47943377|NCT05462470|PROCEDURE|Repeat Liver Surgery|repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
47943378|NCT05462470|PROCEDURE|Non-Repeat Liver Surgery|Systemic palliative chemotherapy
47943379|NCT01588249|DIETARY_SUPPLEMENT|Pasteurized maple syrup|
47943380|NCT01588249|DIETARY_SUPPLEMENT|Placebo|
47943381|NCT03031535|DRUG|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
47943382|NCT03031535|DRUG|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
47943383|NCT03031535|DIAGNOSTIC_TEST|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
48103226|NCT06126536|PROCEDURE|Lateral Maxillary Sinus Floor Elevation|A crestal incision with an anterior vertical releasing incision exposes the sinus's lateral wall. A mucoperiosteal flap is carefully reflected, revealing the sinus. A bony window is created using a Piezoelectric device, and after elevation, the sinus floor is carefully lifted with various curettes. Implant osteotomies follow standard placement protocol, with precautions against sinus membrane perforation. Nanobone is used as graft material, mixed with saline and gently packed into the sinus. A resorbable membrane is placed on the window's outer surface, secured with circumferential resorbable sutures, and the flap is sutured for closure.
48103227|NCT03543839|BIOLOGICAL|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
48292284|NCT02378753|BIOLOGICAL|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
48292285|NCT06430268|PROCEDURE|implant decontamination with titanium curette|Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implant, with and without flap elevation.
48632079|NCT02831036|OTHER|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
47943384|NCT03031535|DIAGNOSTIC_TEST|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
48292286|NCT06430268|DEVICE|implant decontamination with Air-Flow device|Air-polishing (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) will be carried out with AIR-FLOW powder PLUS (EMS) containing erythritol (sugar alcohol, 14 μm), amorphous silica and 0.3% chlorhexidine to decontaminate implants with and without flap elevation. The device will be adjusted to a power setting of 5 bar static pressure and a maximum level of irrigation with water.
47943385|NCT02313324|DEVICE|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
47943386|NCT02313324|DEVICE|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
47943387|NCT04741698|DRUG|Propranolol|Propranolol 2mg IV
47943388|NCT05495971|DEVICE|NaturalVue Multifocal|EDOF
47943389|NCT00761579|DRUG|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
47943390|NCT06033716|OTHER|Measurement correlation variable|resilience and anxiety and depression
47943391|NCT04502979|BEHAVIORAL|Responsive Feeding Training|Families will receive 4 monthly 1-hour sessions: (1) Signing with infants; (2) infant communication and responsive feeding; (3) nutrition, portion sizes, and neophobia; and, (4) infant intentionality.
47943392|NCT05868473|DIAGNOSTIC_TEST|Mobilization With Movement|Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
47943393|NCT05868473|DIAGNOSTIC_TEST|Kinesotaping|Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
47943394|NCT05102695|DIAGNOSTIC_TEST|Serum CRP , ferritine and d-dimer|Correlation between the results of the tests with outcome of the patient
47943395|NCT05044000|DEVICE|Deep propioceptive stimulation|Participants will start using the blanket (of the arm name), 30 days wash-out and 15d with the other blanket
47943396|NCT00126607|BIOLOGICAL|trastuzumab|Given IV
47943397|NCT00126607|OTHER|laboratory biomarker analysis|Correlative studies
48103228|NCT03543839|BIOLOGICAL|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
48103229|NCT03543839|OTHER|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
48103230|NCT04096144|DRUG|Neuromuscular Blocking Agents|Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
48103231|NCT01649791|DRUG|lenalidomide|Given orally
48103232|NCT01649791|OTHER|laboratory biomarker analysis|Correlative study
48103233|NCT01649791|PROCEDURE|lymph node biopsy|Correlative study
48103234|NCT01649791|PROCEDURE|bone marrow aspiration|Correlative study
48103235|NCT01649791|OTHER|pharmacological study|Correlative study
48103236|NCT01649791|OTHER|flow cytometry|Correlative study
48103237|NCT01019343|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
48103238|NCT01019343|DEVICE|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
48103239|NCT01019343|DEVICE|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
48103240|NCT01019343|OTHER|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
48474925|NCT06473402|DIAGNOSTIC_TEST|Muscle Strength Test|Hamstring muscle strength of the participants was measured with a dynamometer (Microfet 2, Hoggan Health Industries, HHD) with the knee flexed at 90 degrees. After the physiotherapist fixes and positions the dynamometer 5 cm proximal to the calcaneus with a belt, the participant will be asked to accelerate to maximum isometric strength by trying to bring his heel closer to his hip against this resistance. The isometric strength of the hamstring muscle will be measured in Newtons (N) by being asked to wait at maximum force level for three seconds. Measurements were made in 2 repetitions and the highest value was noted. There will be a 30-second rest period between attempts.
48632080|NCT04261595|OTHER|Dates fruit as functional Food|Two groups will receive Dates; The number per group is dependant on the child age. For children aged 3-6 years; they will receive the minimum numbers of dates (3 pieces). For children aged more than 6-12 years will receive 5 pieces of Dates the choice of the minimum numbers of dates (3 pieces) in this current trial is based on a study that was done by Al Jaouni and his colleagues, 2019 which proved the effects of three pieces of Ajwa on infection, hospitalization, and survival among 26 pediatric cancer patients in a university hospital; for which their treatment outcome was improved due to their intake of this amount of Ajwa during their standard treatment
48632081|NCT04261595|BEHAVIORAL|behavioral modification and stimulation|Behavioral modification applied to the autistic children that is based on applied behavior analysis (ABA), a widely accepted approach that tracks a child's progress in improving his or her skills. We use Positive Behavioral and Support (PBS)
47943398|NCT00287079|DRUG|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
47943399|NCT00287079|OTHER|No Treatment|No treatment for 96 weeks
47943400|NCT01867112|BEHAVIORAL|Physical Activity|Physical activity either by individualized program or general guidelines
47943401|NCT04768673|DRUG|CKD-393 formulation I|single, oral administration of 2 tablets under fed condition
48103241|NCT01019343|OTHER|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
48103242|NCT01019343|DEVICE|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
47943402|NCT04768673|DRUG|CKD-393 formulation II|single, oral administration of 2 tablets under fed condition
47943403|NCT04768673|DRUG|D501, D759, H053|single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
47943404|NCT05456919|OTHER|SFQ28 Questionnaire|SFQ28 Questionnaire
47943405|NCT00266773|BEHAVIORAL|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
47943406|NCT06288477|DRUG|A cotton pellet moistened with full-strength FC|A cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM (Intermediate Restorative Material).
48103243|NCT01019343|DEVICE|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
47943407|NCT06288477|DRUG|Neo-Putty|Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
47943408|NCT00000631|BIOLOGICAL|HIVAC-1e|
47943409|NCT00000631|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
47943410|NCT04408131|BIOLOGICAL|Blood sample|virological test
47943411|NCT04408131|BIOLOGICAL|Blood sample|serological test
47943412|NCT04104529|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
47943413|NCT04104529|OTHER|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
47943414|NCT02595970|DRUG|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
47943415|NCT02834377|OTHER|Treatment algorithm targeting individual cardiac output|
47943416|NCT01598168|DRUG|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
47943417|NCT00169884|BEHAVIORAL|cognitive-behavioural therapy|
47943418|NCT04152707|DEVICE|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
47943419|NCT01365065|DRUG|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
47943420|NCT02545595|DRUG|Sugammadex 1 mg/kg|
47943421|NCT02545595|DRUG|Sugammadex 2 mg/kg|
47943422|NCT02545595|DRUG|Sugammadex 4 mg/kg|
47943423|NCT04429360|PROCEDURE|pelvic reconstructive surgery|Pelvic reconstructive surgery
47943424|NCT01880216|DRUG|Bemiparin sodium|subcutaneous application daily for 7±2 days
47943425|NCT01880216|DRUG|Enoxaparin sodium|subcutaneous for 7±2 days
47943426|NCT04763174|BEHAVIORAL|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
47943427|NCT02068456|DRUG|Roflumilast|
47943428|NCT05564793|DEVICE|Pre-implantation planning|ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
47943429|NCT05564793|DEVICE|Post-implantation assessment|ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
47943430|NCT01712646|DRUG|Intranasal Oxytocin|
47943431|NCT02147912|OTHER|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
47943432|NCT02857582|BIOLOGICAL|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
47943433|NCT02857582|DRUG|Vancomycin|Active comparator to treatment with ACHIM
47943434|NCT02857582|DRUG|Metronidazole|Primary treatment for C diff in all treatment arms
47943435|NCT03139318|RADIATION|GRID radiotherapy|Patients will be treated with GRID radiotherapy
47943436|NCT03936322|DEVICE|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
47943437|NCT02778971|DRUG|[18F]Flutemetamol|amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management
47943438|NCT01556737|DIETARY_SUPPLEMENT|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
47943439|NCT01556737|DIETARY_SUPPLEMENT|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
47943440|NCT00608543|DRUG|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
47943441|NCT00892242|DRUG|Zoledronic acid|
47943442|NCT02694523|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
47943443|NCT02694523|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
47943444|NCT02694523|DRUG|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
47943445|NCT02694523|BIOLOGICAL|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
47943446|NCT04497207|OTHER|Scheimpflug Camera Corneal Tomography|Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
48103244|NCT01019343|DIAGNOSTIC_TEST|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
48103245|NCT01019343|DEVICE|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
47943447|NCT02988154|OTHER|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
47943448|NCT02988154|OTHER|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
47943449|NCT03048461|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
47943450|NCT03048461|DRUG|Placebo|intradermal injections to an area of alopecia
47943451|NCT00275964|DRUG|TMN-1|
47943452|NCT05324618|DRUG|Tacrolimus|0.03% topical tacrolimus ointment applied on the affected areas twice daily for 4 months.
47943453|NCT05324618|DRUG|Hydrocortisone|1% hydrocortisone cream applied on the affected areas twice daily for 4 months.
47943454|NCT02963831|BIOLOGICAL|ONCOS-102|ONCOS-102 was administered by intraperitoneal infusion at weekly intervals for 6 weeks.
48292287|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
47943455|NCT02963831|DRUG|Durvalumab|Durvalumab was administered by IV infusion once every four weeks for a total of 10 (Cohort A) or 12 four-week cycles.
47943456|NCT02963831|DRUG|Cyclophosphamide|A bolus dose of 300 mg cyclophosphamide (CPO) was administered IV 1 to 3 days before the first infusion of ONCOS-102.
47943457|NCT05389046|DRUG|Escitalopram|Escitalopram
47943458|NCT05389046|DRUG|Escitalopram+Aripiprazole|Escitalopram+Aripiprazole
47943459|NCT05389046|DRUG|Escitalopram+omega-3 PUFAs|Escitalopram+omega-3 PUFAs
47943460|NCT05389046|DRUG|Escitalopram+Aripiprazole+omega-3 PUFAs|Escitalopram+Aripiprazole+omega-3 PUFAs
47943461|NCT04407260|DEVICE|Oxygen Hood|High-Flow Oxygen Hood with neck dam and intake and exhaust tubing incorporating a Bacterial/Viral HEPA filter and optional PEEP attachment.
47943462|NCT05176509|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
47943463|NCT05176509|DRUG|YH001|YH001 will be administered intravenously over 60 minutes every 21-day cycle.
47943464|NCT05176509|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
47943465|NCT01954732|DRUG|metformin hydrochloride|Given PO
47943466|NCT01954732|OTHER|pharmacological study|Correlative studies
47943467|NCT03525093|BEHAVIORAL|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
47943468|NCT03525093|BEHAVIORAL|Health education|Participants receive a health education booklet on improving coping with stress.
47943469|NCT04738734|DEVICE|CellFX System Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
47943470|NCT04738734|DEVICE|Cryosurgery Liquid Nitrogen Sprayer|Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.
47943471|NCT00857415|DRUG|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
47943472|NCT00905216|DRUG|heparin sodium - Bergamo|5.000 UI/mL
47943473|NCT00905216|DRUG|heparin sodium - APP|5.000 USP
48292288|NCT02634164|DIETARY_SUPPLEMENT|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
48292289|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
48292290|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated barbed suture|Use of Triclosan-coated Polydioxanone barbed suture
47943474|NCT03238742|DRUG|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
47943475|NCT03238742|DRUG|normal saline|200ml normal saline every 12 hours for 5 days
47943476|NCT01672736|DRUG|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
47943477|NCT02922933|DRUG|entinostat|HDAC (histone deacetylase inhibitor)
47943478|NCT02922933|DIETARY_SUPPLEMENT|Omeprazole|Proton pump inhibitor
47943479|NCT02922933|DIETARY_SUPPLEMENT|Famotidine|Histamine-2 blocker
47943480|NCT03391310|OTHER|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
47943481|NCT06306053|COMBINATION_PRODUCT|tDCS+EuleriaLab|Home based: Non invasive Neuromodulation treatment + Motor Training
47943482|NCT06306053|DEVICE|tDCS|Non invasive brain stimulation
47943483|NCT06306053|OTHER|EuleriaLab|Home Motor Training
47943484|NCT04376879|OTHER|Data monitoring for 48h within the first 24 hours of admission for COVID-19|The admission variables and those constituting the predictive score (blood pressure, temperature, oxygenotherapy, biological analysis...) will be collected for 48 hours after enrolment (i.e within the first 24 hours of admission )
48292291|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated monofilament suture|Use of Triclosan-coated Polydioxanone monofilament suture
47943485|NCT05958732|OTHER|Somato-sensorial exercises therapy|It includes exercises, which is already mentioned in the arm description.
47943486|NCT05958732|OTHER|Conventional Therapy|It Includes routine exercises for the stroke patient the detail is already given in the arm description.
47943487|NCT00057876|DRUG|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m\^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m\^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
48292292|NCT03763279|DEVICE|Monofilament suture|Use of Polydioxanone monofilament suture
47943488|NCT00057876|RADIATION|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m\^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
47943489|NCT04771884|DRUG|meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid|The use of antimicrobial agents depends on the clinical practice
47943490|NCT04832087|DRUG|Teduglutide|Standard of care Teduglutide dosing
47943491|NCT03225274|OTHER|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
47943492|NCT05605431|DIAGNOSTIC_TEST|Polysomnography|over nightSleep study
47943493|NCT02666716|DRUG|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
48292293|NCT06510517|OTHER|Calculation of Mechanical Power.|"Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP)."
48292294|NCT06510517|OTHER|Measurement Diaphragmatic Excursion after first SBT|Chest ultrasound to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT. The DE at 0 min, 5 min, and 30 min of SBT was respectively named as DE0, DE5, and DE30. The variation of right DE between each time point was named as ΔDE30-5 and ΔDE30-0. (7)
48292295|NCT06671444|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
47943494|NCT02466373|DRUG|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
47943495|NCT06202456|DRUG|Huazhi Rougan granule|Huazhi Rougan granule
47943496|NCT03447184|DRUG|Androgen priming|"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"
47943497|NCT03264313|DEVICE|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
47943498|NCT01236014|DRUG|Eltrombopag|Eltrombopag \& standard of care
48103246|NCT01019343|PROCEDURE|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
48292296|NCT01070615|DRUG|Prucalopride|
48632082|NCT04261595|OTHER|nutritional Guidance|The nutritional education sessions are based on educating parents on providing their autistic children with a nutritious, balanced diet. Because children with ASD often have restricted diets as well as difficulty sitting through meal times, they may not be getting all the nutrients they need, particularly calcium and protein
47943499|NCT01236014|DRUG|Romiplostim|Romiplostim \& standard of care
47943500|NCT01236014|DRUG|Placebo|Placebo \& standard of care
47943501|NCT00831350|DRUG|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
47943502|NCT01654861|DRUG|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
47943503|NCT01550471|DRUG|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
47943504|NCT01550471|DRUG|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
48292297|NCT01919372|DEVICE|Telemedic assistance with a technological system|
48292298|NCT01919372|OTHER|Standard care|
48103247|NCT01019343|OTHER|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
48103248|NCT01019343|PROCEDURE|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).
48103249|NCT01019343|PROCEDURE|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
48103250|NCT01019343|PROCEDURE|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
48103251|NCT01019343|PROCEDURE|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
48103252|NCT01019343|PROCEDURE|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
48292299|NCT05331989|OTHER|patient group/ healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
48292300|NCT02278146|DEVICE|ParaPatch|A device for the treatment of urinary incontinence
48292301|NCT00517686|OTHER|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
48292302|NCT02277210|OTHER|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
48292303|NCT02940665|OTHER|ERAS|Patients in the ERAS group received the ERAS protocol
48474926|NCT06473402|DIAGNOSTIC_TEST|Hamstring Flexibility|The Sit and Reach Test will be administered to evaluate flexibility. Measurements will be made with a test stand with a length of 35 cm, a width of 45 cm and a height of 32 cm. The measurement of the participant who cannot reach the zero point of the sole of the foot on this tripod will be recorded as minus (-), while the measurement of the participant who can pass the zero point will be recorded as plus (+). Participants will be seated in a long sitting position with the soles of their feet resting on the testing apparatus, and the measurement will begin with their knee joints fully extended. While leaning his body forward, he will be asked to lie forward as far as he can, with his hands in front of his body, without bending his knees. The test will be repeated 2 times and the best value will be recorded in cm.
48474927|NCT06473402|DIAGNOSTIC_TEST|Knee Range of Motion|Joint range of motion measurement of the participants was made with a universal goniometer. Degree was used as the measurement unit. The measurement was made in the prone position. The pivot point of the goniometer is placed on the lateral epicondyle of the femur, and the fixed arm is kept parallel to the lateral midline of the femur, while the movable arm will follow the fibula. The joint range of motion of the participants was measured before and after manual therapy. AAOS (American of Orthopedic Surgeons) was taken as the reference value.
48474928|NCT06473402|DEVICE|Percussion Therapy|A percussion massage device was used in the study. Massage application was applied to the Hamstring muscle, adhering to optimal standards. During the application, a wide round head, which is the most preferred by clinical professionals, was used and 30 Hz, which is considered as the average application speed, was used. The application was applied for a total of 6 minutes, 2 minutes for each part of the muscle. Applications have been made many times on every part of the muscle, from the starting point to the ending point.
48474929|NCT06473402|OTHER|Manual Therapy Technique|Anterior and posterior innominate muscle energy techniques were performed on patients. In the anterior technique, the patient lay on their back with their leg on the diagonal shoulder. The clinician flexed the hip and knee, placed their hand on the back thigh, and instructed the patient to push, resulting in hip extension. After eight seconds, the patient inhaled and exhaled. The clinician then increased hip flexion and applied pressure against a new barrier. In the posterior technique, the patient lay on their side in the modified sims position. The clinician held the leg with their caudal hand and placed the hypothenar edge of their cranial hand on the right SIPS. The patient then pulled the leg towards themselves, applying equal counterforce for eight seconds before inhaling and exhaling. Finally, the clinician extended the leg and pushed it against a new barrier.
48474930|NCT06617143|OTHER|mindfulness-based cognitive therapy|In this study, it is planned to apply MBCT to asthmatic inpatients in the patient room in groups of 2 or 3. This application is planned to continue for one hour.
48474931|NCT06617143|OTHER|routine treatment and care|routine treatment and care
47943505|NCT01550471|DRUG|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
47943506|NCT01550471|DRUG|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
47943507|NCT01550471|DRUG|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
47943508|NCT01550471|DRUG|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
47943509|NCT02688712|DRUG|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
47943510|NCT02688712|DRUG|Capecitabine|Antimetabolite chemotherapy
47943511|NCT02688712|DRUG|Fluorouracil|Antimetabolite chemotherapy
47943512|NCT02688712|PROCEDURE|Tumor specific mesorectal excision|Tumor specific mesorectal excision
47943513|NCT05693727|DIAGNOSTIC_TEST|pleural markers|Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}
47943514|NCT03882788|DRUG|Isoflurane|Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.
47943515|NCT03882788|DRUG|Fentanyl (high dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
47943516|NCT03882788|DRUG|Fentanyl (low dose)|Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
47943517|NCT04842422|DRUG|Imiquimod 3.75% Cream|Imiquimod 3.75% Cream
47943518|NCT05910177|DRUG|Karelizumab combined with etoposide and cisplatin|Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w
47943519|NCT04223232|DRUG|[14C]-MD1003|single oral dose of 100mg \[14C\]-MD1003
47943520|NCT00290212|DRUG|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
47943521|NCT00290212|DRUG|Placebo capsules|
47943522|NCT04592744|DRUG|Angiotensin II|Angiotensin II infusion for Intraoperative management during liver transplantation
47943523|NCT04592744|DRUG|Norepinephrine|Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
47943524|NCT00139061|DRUG|Torcetrapib/Atorvastatin|
47943525|NCT00139061|DRUG|Fenofibrate|
47943526|NCT04749667|OTHER|MSCs|Autologous bone-marrow derived mesenchymal stem cells
47943527|NCT04749667|DRUG|Saline|Isotonic saline
47943528|NCT06498505|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
48292304|NCT01623687|DEVICE|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
47943529|NCT06498505|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
47943530|NCT04499976|DRUG|Isonicotinic Acid|Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
47943531|NCT04499976|DRUG|Placebo|Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
47943532|NCT04499976|DRUG|Misoprostol|Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
47943533|NCT01462227|DRUG|Naltrexone High Dose|Naltrexone 100mg for two administrations.
47943534|NCT01462227|DRUG|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
47943535|NCT03068598|DEVICE|PulseOn watch/Suunto Spartan Ultra watch|The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
47943536|NCT01941043|DRUG|CERC-301|
47943537|NCT01941043|OTHER|Placebo|
47943538|NCT04968379|DRUG|Ferric carboxymaltose|Intravenous
47943539|NCT01234207|DEVICE|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
47943540|NCT01234207|DEVICE|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
47943541|NCT02210273|DEVICE|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
48292305|NCT01623687|DEVICE|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
47943542|NCT02210273|DEVICE|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
47943543|NCT01297998|DRUG|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
47943544|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 6 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.
47943545|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 1 training session|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.
47943546|NCT05437159|BEHAVIORAL|Learning of novel multisyllabic nonwords|Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.
47943547|NCT05437159|DEVICE|Anodal tDCS|Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.
47943548|NCT05437159|DEVICE|Sham tDCS|Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.
47943549|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 8 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.
48292306|NCT01623687|DEVICE|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
48474932|NCT03888521|BEHAVIORAL|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
48632083|NCT00332098|BEHAVIORAL|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
48632084|NCT00332098|BEHAVIORAL|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
48632085|NCT00985790|BIOLOGICAL|Influenza vaccine GSK2321138A|Intramuscular injection
48632086|NCT00985790|BIOLOGICAL|Fluarix™|Intramuscular injection
48632087|NCT04495478|DRUG|Ramucirumab - IV|Administered IV.
48632088|NCT04495478|DRUG|Placebo - IV|Administered IV.
48632089|NCT04495478|DRUG|Ramucirumab - SC|Administered SC.
48632090|NCT04495478|DRUG|Placebo - SC|Administered SC.
47943550|NCT03599635|DRUG|liposomal bupivacaine|Experimental
47943551|NCT03599635|DRUG|Bupivacaine|Active Comparator
47943552|NCT00460369|DRUG|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake"
48292307|NCT01623687|DEVICE|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson \& Johnsson, USA).
48292308|NCT00177346|DEVICE|CAS with cerebral protection|
48474933|NCT02720133|BIOLOGICAL|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
48632091|NCT04299620|DEVICE|Digital Image Analysis|Analysis of images
48632092|NCT04299620|PROCEDURE|Radical Prostatectomy|Undergo standard of care radical prostatectomy
48632093|NCT04299620|PROCEDURE|Transrectal Ultrasound|Undergo transrectal ultrasound
48632094|NCT01467804|DRUG|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
48632095|NCT01467804|DRUG|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
48632096|NCT04055298|DEVICE|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
48632097|NCT03478787|DRUG|risankizumab|Subcutaneous (SC) injection
48632098|NCT03478787|DRUG|secukinumab|Subcutaneous (SC) injection
48632099|NCT04210245|BIOLOGICAL|aldafermin|aldafermin
48632100|NCT04210245|OTHER|Placebo|Placebo for aldafermin
48632101|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block|IV midazolam and propofol-based sedation combined with ultrasound-guided, left side TAP block
47943553|NCT00460369|DRUG|artemether-lumefantrine|"tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight"
47943554|NCT00460369|DRUG|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg"
47943555|NCT03583164|DRUG|Olorofim|30mg oral tablets
47943556|NCT00071578|BEHAVIORAL|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
47943557|NCT00071578|BEHAVIORAL|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
47943558|NCT04432272|BIOLOGICAL|COVID-19 convalescent plasma|Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit
47943559|NCT01681017|BEHAVIORAL|HBB/ENC Training and Equipment|See the detailed description section
47943560|NCT01681017|OTHER|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
47943561|NCT00372203|PROCEDURE|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
48474934|NCT01874977|BEHAVIORAL|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
48474935|NCT01874977|BEHAVIORAL|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
47943562|NCT04282512|OTHER|Sodium bicarbonate-rich mineral water|St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
47943563|NCT00689598|DRUG|Spironolactone|25 mg po qd 25 mg po bid
47943564|NCT00689598|DRUG|Placebo|Spironolactone 25 mg po qd
47943565|NCT00202176|DRUG|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
47943566|NCT03432156|BIOLOGICAL|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
48474936|NCT01874977|BEHAVIORAL|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
48474937|NCT00005086|DRUG|cisplatin|
48474938|NCT00005086|DRUG|docetaxel|
47943567|NCT02490410|DIETARY_SUPPLEMENT|protein supplement|
47943568|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed High Dose|26 gram flaxseed intervention
47943569|NCT01698112|DIETARY_SUPPLEMENT|Flaxseed Low Dose|13 grams flaxseed
47943570|NCT05025254|OTHER|Neurocognitive testing|"We are assessing several cognitive domains and have made minor adaptations (reducing the total number of trials or lengthening response windows) to several standard neuropsychology tests including measures of executive function, working memory, visuospatial function, declarative memory, reward processing, response inhibition.~Overall, the tests we use follow a standard set-up: participants are shown stimuli on the screen and are asked to provide a response using either a keyboard or a mouse, based on a specific set of instructions. We always provide a detailed set of on-screen instructions and a practice phase. In some cases, information about performance is provided in the form of points, in other cases, none is provided."
47943571|NCT01474369|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
47943572|NCT01474369|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
47943573|NCT01474369|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
47943574|NCT04288271|BEHAVIORAL|Adherence Intervention|"Intervention:~* Adherence Support Team (patient, parent or a significant other, Coach)~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Identification of adherence barriers, self-efficacy for medication-taking, and allocation of treatment responsibility~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~Device:~* Electronic pillbox monitoring with text message and/or audio/visual dose reminders and access to e-pillbox website~* Feedback of electronic monitoring data at increasing intervals between initiation of the intervention at 4-week and exit at 14-week."
48292309|NCT00177346|DEVICE|CAS without cerebral protection|
48474939|NCT00005086|DRUG|gemcitabine hydrochloride|
48292310|NCT02796144|DRUG|Lorcaserin|Max dose of 10 mg BID
48292311|NCT02796144|DRUG|Metformin|Max dose of 1,000 mg BID
48474940|NCT00005086|DRUG|methotrexate|
48474941|NCT03217526|OTHER|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
48292312|NCT02796144|DRUG|Placebo|Matching placebos will be administered for each drug.
48474942|NCT03776617|PROCEDURE|scalp block|Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
48474943|NCT04060134|OTHER|SimpliDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
48474944|NCT04060134|OTHER|AlloDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
48474945|NCT04060134|OTHER|AlloMax HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
47943575|NCT04288271|OTHER|Healthy living education intervention|"Intervention:~* Standardized educational videos on immunosuppressive medications, rejection, and improving adherence~* Healthy living topic discussion at increasing intervals between 4-wk and 14-wk visits~* 'Action-Focused Problem-Solving' to address barriers on healthy living topic selected by the patient~Device:~• Electronic adherence monitoring without dose reminders or feedback (enrollment to 14w)"
47943576|NCT00251355|DRUG|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
47943577|NCT00251355|DRUG|5-Fluorouracil|5-FU via continuous IV infusion.
47943578|NCT00251355|PROCEDURE|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
47943579|NCT03851471|DRUG|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
47943580|NCT04926623|DEVICE|FreeStyle Libre 24 weeks|FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
47943581|NCT04926623|OTHER|SMBG (22 weeks) and blind CGM (2 weeks)|Self-Monitoring of Blood Glucose and Continuous Glucose Monitoring
47943582|NCT05068024|DRUG|FWD1509 MsOH|FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
47943583|NCT03388515|BIOLOGICAL|SSS11|IV infusion for 60 min.
47943584|NCT03388515|OTHER|placebo|IV infusion for 60 min.
47943585|NCT02514603|DRUG|Prexasertib|Administered IV
47943586|NCT01248845|OTHER|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
47943587|NCT04095273|DRUG|Elimusertib (BAY1895344)|Study drugs will be administered as scheduled
47943588|NCT04095273|DRUG|Pembrolizumab (Keytruda®)|Study drugs will be administered as scheduled
48474946|NCT04060134|OTHER|FlexHD HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
47943589|NCT01121731|DRUG|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
47943590|NCT01121731|DRUG|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
48474947|NCT04060134|OTHER|DermACELL HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
48474948|NCT03144479|PROCEDURE|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
47943591|NCT01121731|DRUG|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
47943592|NCT06304038|DRUG|Flu Vaccine|Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
47943593|NCT05523297|DRUG|Octaplex|Prothrombin complex concentrate
47943594|NCT05523297|DRUG|Frozen Plasma Product, Human|If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
47943595|NCT00027937|BIOLOGICAL|aldesleukin|
47943596|NCT00027937|BIOLOGICAL|filgrastim|
47943597|NCT00027937|BIOLOGICAL|sargramostim|
47943598|NCT00027937|DRUG|busulfan|
47943599|NCT00027937|DRUG|cyclophosphamide|
47943600|NCT00027937|DRUG|melphalan|
47943601|NCT00027937|DRUG|paclitaxel|
48474949|NCT00170144|DRUG|Branchamin 4%|
47943602|NCT00027937|DRUG|thiotepa|
47943603|NCT00027937|PROCEDURE|bone marrow ablation with stem cell support|
47943604|NCT00027937|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
47943605|NCT05850312|DEVICE|Gamified Digital Intervention - Feasibility Analysis on MoM|In first round we aim to clinically analyze the game Militant of the Maze (MoM) as a vehicle for Exposure Theory, including, play, observation, and feedback from five clinicians.
47943606|NCT05850312|DEVICE|Gamified Digital Intervention|In the first phase of round 2 of the study, 5 clinicians will play the game to evaluate the revised game MoMG. In the next phase, 5 carefully-selected non-clinician participants will play the game. under real-time observation of clinicians, to ensure that subjects experience no harm, and that the gameplay is interesting and enjoyable.
47943607|NCT00691067|DRUG|mifepristone|200 mg po per day x 6 weeks
47943608|NCT00691067|DRUG|Placebos|placebo
47943609|NCT03587948|DIAGNOSTIC_TEST|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
47943610|NCT00284596|PROCEDURE|High tibial osteotomy|HTO
47943611|NCT04524169|DRUG|Thymosin Alpha1|Thymosin Alpha 1 will be subcutaneous injected to the participants twice per week for 4 weeks.
47943612|NCT06038981|DRUG|Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced|"The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)"
47943613|NCT02720237|BEHAVIORAL|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
47943614|NCT02720237|BEHAVIORAL|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
47943615|NCT02720237|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
47943616|NCT00463203|DRUG|Bevacizumab|10 mg/kg every 2 weeks
47943617|NCT00463203|DRUG|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
47943618|NCT06484491|RADIATION|Standard-dose intensity-modulated proton therapy (IMPT-60)|The standard care group will receive 60.0 Gy (RBE) to the whole clinical target volume
47943619|NCT06484491|RADIATION|Dose-escalated intensity-modulated proton therapy (IMPT-74)|Heterogeneous simultaneous integrated boost of 74.0 Gy (RBE) to primary tumor \>15mm away form mediastinal envelope, and 64.0 Gy (RBE) to primary tumor =\< 15mm away from mediastinal envelope. The rest of the clinical target volume, including affected lymph nodes, receives 60.0 Gy (RBE).
47943620|NCT06484491|DRUG|Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy|"Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days."
47943621|NCT06484491|DRUG|Immunotherapy: adjuvant durvalumab|"Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total."
48103253|NCT01019343|PROCEDURE|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
47943622|NCT03810339|DRUG|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
47943623|NCT00386607|DRUG|Aliskiren|Aliskiren 300 mg
47943624|NCT00386607|DRUG|Valsartan|Valsartan 320 mg
47943625|NCT00386607|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
47943626|NCT02738632|DRUG|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
47943627|NCT02738632|DRUG|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
47943628|NCT02738632|DRUG|Placebo for Hydrochlorothiazide|
48103254|NCT01019343|PROCEDURE|Trancutaneous spinal direct current stimulation (tsDCS)|Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
48103255|NCT04227990|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
48103256|NCT04227990|DRUG|Pegfilgrastim|Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
48474950|NCT02549846|DRUG|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
48474951|NCT02177552|DRUG|Carboplatin|
48474952|NCT02177552|DRUG|Docetaxel|
48474953|NCT02177552|DRUG|Capecitabine|
48474954|NCT02177552|DRUG|Epirubicin|
48474955|NCT02177552|DRUG|Oxaliplatin|
48474956|NCT02593344|DEVICE|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
48474957|NCT06287437|DRUG|HRS9531|HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
48292313|NCT06666296|BEHAVIORAL|Digital collection of recipes|The digital recipe collection is created for private use. This collection contains recipes for every meal of the day to ensure a Planetary Health Diet throughout the day. This includes digital weekly plans with corresponding dishes, including shopping lists, to simplify implementation in everyday life. This enables participants to make quick meal choices and simplify their shopping. Employees are encouraged to use this digital recipe collection to prepare their meals over a defined period of time. In addition, the kitchen management of the university hospital will be asked to assist with the creation of the recipes. The project benefits from the experience of the kitchen staff. Popular recipes can be used across projects.
47943629|NCT06223035|OTHER|Exercise|Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
47943630|NCT03948607|OTHER|Electroencephalography during sustained attention task.|"The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3."
47943631|NCT04840173|BEHAVIORAL|Music|During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
47943632|NCT03130491|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
47943633|NCT03130491|DEVICE|EMBLOK filter|Embolic Filter Protection System During TAVR
47943634|NCT02883166|DRUG|abiraterone|integested with a continental breakfast
47943635|NCT04973696|BEHAVIORAL|Toolkit for Optimal Recovery after Orthopedic Injury|The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.
48474958|NCT06287437|DRUG|HRS9531 placebo|HRS9531 placebo low frequency injection for 12 weeks.
48103257|NCT04227990|DRUG|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
48632102|NCT04878926|PROCEDURE|IV midazolam and propofol-based sedation with Local Anesthetic infiltration|IV midazolam and propofol-based sedation with Local Anesthetic infiltration
48474959|NCT04904484|DEVICE|iZephyr hood|Assessment of an aerosol containment device
48474960|NCT05468008|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection (ESD) is an outpatient procedure to remove deep tumors from the gastrointestinal (GI) tract
48632103|NCT05004298|OTHER|Animal Assited therapy|The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
48632104|NCT01898091|DRUG|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
48632105|NCT01898091|DRUG|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
48632106|NCT00384150|DRUG|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
48632107|NCT00272558|DRUG|Carboplatin and Vinorelbine|
48292314|NCT06666296|BEHAVIORAL|E-Mail-Newsletter|"The e-mail newsletter contains information on the Planetary Health Diet (background, urgency, goals, etc.). Regular contact by e-mail enables a fast, uncomplicated and personal exchange with the participants, uncomplicated and personal exchange with the participants. The e-mail support encourages participants to actively engage with the topic. The newsletter is supplemented by instructional kitchen videos (one person cooks a recipe from the recipe collection), checklists (e.g. How sustainable am I already acting?), tasks (e.g. three possible measures for a more sustainable diet) or food information (e.g. seasonal plan for fruit and vegetables). This provides participants with important information at regular intervals and ensures compliance."
48292315|NCT06666296|BEHAVIORAL|digital/hybrid teaching kitchen|Recipes, cooking techniques, shopping tips and recommendations for implementing the Planetary Health Diet are taught in the digital/hybrid teaching kitchen. The focus here is on fun, good taste and interesting experiences. A shared experience can be created through such cooking events. The teaching kitchen events can be supplemented by the participation of the kitchen management in order to benefit from their special cooking skills and wealth of experience. The positive aspect of the digital training kitchen is the easy access to information, as this does not have to be read, but is conveyed visually.
48292316|NCT06666296|BEHAVIORAL|Digital events (digital cafés)|"Events are planned that will be set up via the digital café for in-depth discussions and exchanges about the content. Fixed dates are planned at which the study participants can meet digitally. In this protected setting, the topics of the study will be discussed in a convivial atmosphere. The personal exchange enables a deeper examination of the topic. The online events give participants the opportunity to interact directly with the study coordinators and other participants in order to effectively and sustainably change the participants' perception and awareness of sustainable nutrition through the various intervention points."
48474961|NCT02690935|DRUG|2LALERG|Homeopathic drug
48292317|NCT06666296|BEHAVIORAL|Social-Media|A dedicated Instagram account for this project will be created for the center, where valuable content on the Planetary Health Diet will be shared regularly. The test subjects can also use this platform to exchange information.
48292318|NCT04535570|OTHER|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
48474962|NCT02690935|DRUG|Placebo|Placebo
47943636|NCT04973696|OTHER|Minimally Enhanced Usual Care (MEUC)|The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
47943637|NCT04407481|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
48103258|NCT06554067|DEVICE|Active transcranial direct current stimulation|Ten minutes of active transcranial direct current stimulation
48103259|NCT06554067|DEVICE|Active vagus nerve stimulation|Ten minutes of active vagus nerve stimulation
48474963|NCT00855764|DRUG|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
47943638|NCT04407481|DRUG|Iohexol Inj 300 milligrams per milliliter (MG/ML)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
47943639|NCT04407481|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
48474964|NCT03680716|DRUG|Ropivacaine injection|Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
48474965|NCT03680716|DRUG|Ropivacaine injection|Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
48474966|NCT05735418|DIETARY_SUPPLEMENT|GI Biome #7|It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10\^8 CFU/day.
48474967|NCT05735418|DIETARY_SUPPLEMENT|Placebo|The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
48632108|NCT01713140|OTHER|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
48632109|NCT02167360|DRUG|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
47943640|NCT01400815|DRUG|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
47943641|NCT01400815|DRUG|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
47943642|NCT02578771|DRUG|ZuraPrep with 70% IPA|Apply topically
47943643|NCT02578771|DRUG|ZuraPrep without 70% IPA|Apply topically. 0% IPA
47943644|NCT02578771|DRUG|ChloraPrep CHG/IPA Teal Tint|Apply topically
47943645|NCT02578771|OTHER|Normal Saline|Apply topically
47943646|NCT04857970|OTHER|Electronic HRQoL questionnaires with feedback to physicians|Use of the CHES software for HRQoL collection and graphical display of the patients' HRQoL scores to physicians
48103260|NCT06554067|OTHER|Sham transcranial direct current stimulation|Ten minutes of sham tDCS
47943647|NCT04857970|OTHER|Paper-pencil HRQoL questionnaires w.o. feedback to physicians|Use of paper-pencil HRQoL questionnaires, the results of which are not presented to physicians
48292319|NCT04372589|DRUG|Heparin|"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."
48292320|NCT01927562|DEVICE|Fractyl Duodenal Remodeling System|
47943648|NCT05030246|DRUG|Surufatinib/Toripalimab|Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
47943649|NCT01580514|DRUG|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
47943650|NCT01580514|DRUG|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
47943651|NCT05392517|OTHER|self-mobilization technique along with conventional therapy|"Group A will be treated with self-mobilization technique of thoracic spine with the frequency of 2 sets of 10 repetitions thrice per week for a total of six weeks and conventional treatment.~Self-mobilization technique will be comprised of self-mobilization technique using tennis balls and foam roller. The participant will be supine with knees in 90-degree flexion.~* Mobilization Technique 1: Cross your arms over your chest so that you are in slight flexion and then slowly begin to move your shoulders and head closer to the floor placing the mid back into extension over the balls joined to make mobilization device. Hold this position for 3 seconds and then return to the flexed position.~* Mobilization Technique 2: Lying lengthwise on the foam roller, clasp your hands together in front of you, above your chest with arms straight. Slowly move your arms above your head until you feel a good stretch. This exercise should be pain free. Hold stretch for 30- 60 seconds."
47943652|NCT05392517|OTHER|conventional therapy|Group B will be treated with the conventional treatment (heating pad, ultrasound, thoracic strengthening exercises
47943653|NCT01527318|DRUG|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
47943654|NCT00943124|DRUG|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
47943655|NCT00943124|DRUG|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
47943656|NCT00943124|DRUG|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
47943657|NCT06069648|BEHAVIORAL|printed screening decision aid|a booklet form of screening decision aid containing information of cervical cancer screening options
47943658|NCT06069648|BEHAVIORAL|a leaftlet|a leaflet containing information about healthy lifestyles
47943659|NCT06069648|BEHAVIORAL|mobile screening decision aid|a mobile app format of screening decision aid containing information of cervical cancer screening options
48292321|NCT03242759|DRUG|nintedanib|Drug
48292322|NCT03242759|DRUG|pirfenidone|Drug
48632110|NCT02622594|DRUG|Aminolevulinic Acid (ALA)|
48292323|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 10mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
48632111|NCT02622594|DEVICE|Environ Cosmetic Roller|
48632112|NCT02622594|DEVICE|BLU-U IIlluminator|
47943660|NCT03239158|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
47943661|NCT03239158|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
47943662|NCT00729924|DRUG|Raltegravir|400mg orally every 12 hours for 7 days
47943663|NCT02101203|DRUG|Placebo|
47943664|NCT02101203|DRUG|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
47943665|NCT01289457|DRUG|Clofarabine|"Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.~Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle."
48103261|NCT06554067|OTHER|Sham vagus nerve stimulation|Ten minutes of sham VNS
48632113|NCT00821821|DRUG|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
48292324|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 20mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
48292325|NCT02924675|DRUG|Pregabalin|150mg daily in three doses during three weeks
48292326|NCT02924675|DRUG|Placebo|Three doses daily with lactose
48632114|NCT00821821|DRUG|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
47943666|NCT01289457|DRUG|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
48292327|NCT02333955|DRUG|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
48292328|NCT01791439|OTHER|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
48292329|NCT01791439|OTHER|placebo|
48292330|NCT06097585|DRUG|SGLT2 inhibitor|case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter
48292331|NCT06211348|DEVICE|Genomic Sequencing|Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
48632115|NCT01163877|DIETARY_SUPPLEMENT|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
48632116|NCT04184908|DRUG|gel xerostomia|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
47943667|NCT01289457|DRUG|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
48292332|NCT06085365|DRUG|Immunonutrition （Su yusu)|Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
48292333|NCT06085365|DRUG|fluorouracil based chemotherapy regimens|fluorouracil based chemotherapy regimens
48292334|NCT02908802|DIETARY_SUPPLEMENT|Probiotic|Probiotic
48292335|NCT02908802|DIETARY_SUPPLEMENT|Placebo|Probiotics capsules without the active ingredient
48292336|NCT00816946|BEHAVIORAL|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI \& protection against ARI"
48292337|NCT06589986|DRUG|RO7790121|RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
48292338|NCT06589986|DRUG|Placebo|Placebo matching IV RO7790121. Placebo matching SC RO7790121.
48292339|NCT03358862|DEVICE|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
48292340|NCT00456937|DRUG|Escitalopram|
48292341|NCT04450914|BEHAVIORAL|CV Prevention Choice Tool|The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.
48292342|NCT04450914|BEHAVIORAL|Implementation Facilitation Strategies|During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
47943668|NCT01289457|DRUG|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
48292343|NCT03946306|DRUG|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
48292344|NCT03946306|DEVICE|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
48292345|NCT00360516|BEHAVIORAL|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
48292346|NCT03761953|DRUG|Oritavancin Injection|single 1200mg infusion of IV oritavancin.
48292347|NCT00772460|DEVICE|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
48292348|NCT01579201|DRUG|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
48292349|NCT04312997|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
48292350|NCT04312997|DRUG|Placebo|Sterile saline for inhalation
47943669|NCT02588937|DRUG|EntecaBell ODT. 0.5mg|
47943670|NCT02588937|DRUG|Baraclude Tab. 0.5mg|
48292351|NCT06669741|DEVICE|Placebo|One group will receive placebo therapy (identical shoulder brace and arm sleeve absent of semiconductor fabric)
48292352|NCT06669741|DEVICE|Shoulder Sleeve|One group will receive active therapy (active semiconductor embedded shoulder brace and arm sleeve)
47943671|NCT00543738|DRUG|MK0767|
48632117|NCT04184908|OTHER|gel placebo|Apply 2-3 cm of the gel on the tongue, gums and oral mucosa, at least three times a day, if necessary it can be applied at night
47943672|NCT05901792|OTHER|Virtual Reality Games|Six different Nintendo Wii Fit Plus games will be employed for six weeks, three days a week, for a total of 18 sessions ranging from 40 to 60 minutes. The games will be chosen from those that emphasize shifting the body's center of gravity. In addition, participants will be given basic correction exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the beginning of the study and instructed to practice them at home for six weeks.
47943673|NCT05901792|OTHER|Waiting List|As the control group, the cases on the waiting list will be evaluated. The control group will be given basic elements of corrective exercises (derotation, deflexion, basic tension, and lateral flexion 3\*3) at the start of the study and instructed to practice at home for six weeks.
48292353|NCT04696835|DIAGNOSTIC_TEST|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
48292354|NCT00450463|DRUG|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
48292355|NCT00450463|DRUG|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
48292356|NCT00450463|BIOLOGICAL|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
48292357|NCT00450463|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
48292358|NCT01092442|PROCEDURE|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
48292359|NCT01686984|OTHER|Altered breath|
48292360|NCT04021862|DRUG|Bermekimab Monoclonal Antibody|Bermekimab 400 mg or 800 mg will be administered subcutaneously.
48292361|NCT04021862|DRUG|Placebo|Placebo will be administered subcutaneously.
48292362|NCT02128581|DRUG|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
48474968|NCT05976724|OTHER|TENS, exercise|"TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily."
48292363|NCT02128581|OTHER|Saline|
48474969|NCT05976724|OTHER|Mulligan mobilisation|Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
48474970|NCT00500318|DRUG|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
48474971|NCT00500318|DRUG|Placebo|Dose matched placebo, once daily oral inhalation.
48474972|NCT05282108|DRUG|Carcemia|Generic Imatinib
48632118|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
48474973|NCT05282108|DRUG|Glivec|Imatinib
48474974|NCT05306197|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
48474975|NCT05306197|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
48474976|NCT05306197|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
48474977|NCT03167502|OTHER|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
48474978|NCT03167502|OTHER|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
48474979|NCT06013930|BEHAVIORAL|External Qigong|External Qigong will be facilitated by a seasoned Qigong practitioner. The Qigong practitioner will assist participants in learning how to use the healing powers of their bodies to decrease feelings of anxiety and/or depression
48474980|NCT06013930|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a meditation designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
48632119|NCT00302666|DRUG|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
48632120|NCT00250861|DRUG|Rituximab|
48632121|NCT00250861|DRUG|Aldesleukin|
48632122|NCT05510973|OTHER|Enhanced package for AHD care|The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis \[TPT and CPT\], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
48632123|NCT02415803|DRUG|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
48632124|NCT02415803|DRUG|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
48632125|NCT02415803|DRUG|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
48632126|NCT00858052|DEVICE|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
48474981|NCT06013930|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to managing anxiety and/or depression through a recorded presentation. Participants will learn about stress-management techniques to help reduce symptoms of anxiety and/or depression. They will also receive information on resources that could be helpful in treating anxiety and/or depression.
48474982|NCT03011879|OTHER|clinical pathway|
48474983|NCT05550831|PROCEDURE|Radiofrequency|Peripheral ablation of affected Morton´s Neuroma nerve endings by thermal dissipation by an electrode.
48474984|NCT05050981|DRUG|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
48474985|NCT05050981|DRUG|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
48474986|NCT02803931|DEVICE|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
48474987|NCT02803931|DEVICE|12-lead ECG|
48474988|NCT00625755|BIOLOGICAL|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
48474989|NCT01856439|DRUG|ProSavin|Long term follow up of patients who received ProSavin in a previous study
48474990|NCT01935648|DRUG|Ropivacaine|
48103262|NCT05122312|DRUG|Olinanoseal|it contains nanometer particles of fluoroapatite and calcium fluoride - guarantees the resistance to cracks and abrasion. At the same time insoluble nano-fluoroapatites fill all enamel microcracks and closes open dentinal tubules.
48474991|NCT01215903|DIETARY_SUPPLEMENT|Fish gelatin and omega-3 polyunsaturated fatty acid|
48474992|NCT01215903|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|
48474993|NCT00242229|DRUG|DVS-233 SR|
48474994|NCT03702634|BEHAVIORAL|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
48474995|NCT02451306|DRUG|Quetiapine|See information in arm description.
48474996|NCT02451306|DRUG|Placebo|See information in arm description.
48474997|NCT02463838|OTHER|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
48474998|NCT05287399|DRUG|ASC61 200 mg 1|200mg of ASC61 orally once daily for cycles of 28 days
48474999|NCT05287399|DRUG|ASC61 200 mg 2|200 mg of ASC61 orally twice daily for cycles of 28 days
48475000|NCT05287399|DRUG|ASC61 300 mg|300 mg of ASC61 orally twice daily for cycles of 28 days
48475001|NCT05287399|DRUG|ASC61 400 mg|400 mg of ASC61 orally twice daily for cycles of 28 days
48475002|NCT05287399|DRUG|ASC61 600 mg|600 mg of ASC61 orally twice daily for cycles of 28 days
48475003|NCT03629106|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
48475004|NCT00029211|DRUG|Echinacea|
48475005|NCT01758237|DEVICE|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
48475006|NCT01758237|PROCEDURE|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
48103263|NCT05122312|DRUG|Curodont D'senz|This agent contains p 11-4 peptide in addition to fluoride
48103264|NCT06628713|DRUG|Sebetralstat|Oral Plasma Kallikrein Inhibator
48103265|NCT03180905|DEVICE|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
48103266|NCT03180905|DEVICE|ImPACT Online|ImPACT Online will be administered at 2 time points.
48475007|NCT00536588|GENETIC|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
48103267|NCT00000634|DRUG|Nevirapine|
48103268|NCT02729272|PROCEDURE|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
48475008|NCT01731522|BEHAVIORAL|EF condition|
47943674|NCT00697073|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
48475009|NCT06366282|BEHAVIORAL|Caregiver Counseling for Childhood Traumatic Injury|Caregiver intervention will be provided by the counseling team that includes components of trauma narrative, psychoeducation, coping strategies, and resilience-building using, for burn patients.
48475010|NCT06366282|BEHAVIORAL|Standard of Care for Childhood Traumatic Injury|Control group receives the current standard of care provided by the counseling team
48475011|NCT05195177|DRUG|Anti-histamine cream 1 hour|At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.
48475012|NCT05195177|DRUG|Local anesthetic cream 1 hour|At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
47943675|NCT05345054|OTHER|no intervention|This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
47943676|NCT03139279|DRUG|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
47943677|NCT03139279|OTHER|Saline placebo|Intravenous saline/placebo
47943678|NCT03139279|DRUG|Propofol|Propofol titrated intravenous boluses
47943679|NCT04209348|BEHAVIORAL|Physical Activity Intervention|Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity). Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.
47943680|NCT04209348|OTHER|Wellness Education|The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin. No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
48475013|NCT01974076|DEVICE|Active tDCS + CBT|
47943681|NCT01008150|DRUG|Paclitaxel|
47943682|NCT01008150|DRUG|Trastuzumab|
47943683|NCT01008150|DRUG|Neratinib|
47943684|NCT01008150|DRUG|Doxorubicin|
47943685|NCT01008150|DRUG|Cyclophosphamide|
47943686|NCT00443105|DRUG|Tacrolimus 0.03% ointment (Protopic)|
47943687|NCT02857179|PROCEDURE|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,...)
47943688|NCT01843088|DRUG|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
47943689|NCT01843088|DRUG|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
47943690|NCT02378727|DEVICE|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
47943691|NCT02378727|DEVICE|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
47943692|NCT03276819|PROCEDURE|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
47943693|NCT03276819|BEHAVIORAL|Psychological and Sociological evaluation|Cohort B ....
48475014|NCT01974076|DEVICE|Sham tDCS + CBT|
48475015|NCT01339377|DEVICE|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
48475016|NCT06466005|OTHER|UnityPhilly app|UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
47943694|NCT03276819|BEHAVIORAL|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
47943695|NCT03276819|BEHAVIORAL|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
47943696|NCT01920009|BEHAVIORAL|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
48475017|NCT01857206|BIOLOGICAL|Mammalian cell based flu vaccine|
48475018|NCT01857206|BIOLOGICAL|Egg based flu vaccine|
48475019|NCT02466386|DRUG|SPD489|Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
47943697|NCT04685031|DRUG|Nitroglycerin ointment|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
47943698|NCT04685031|DRUG|Clobetasol Topical|after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
48103269|NCT02729272|PROCEDURE|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
48103270|NCT02729272|DEVICE|Monopolar ESD|
48103271|NCT02729272|DEVICE|Ultrasonic ESD|
47943699|NCT04585152|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
47943700|NCT02459652|DRUG|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
47943701|NCT02459652|RADIATION|Radiation Therapy|Radiation therapy is delivered with \>6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
47943702|NCT03880604|PROCEDURE|Triple tourniquets|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
47943703|NCT03880604|DRUG|TA|1-gram tranexamic acid (10 ml) in 100 ml saline infusion
47943704|NCT03880604|OTHER|placebo to TA|placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
47943705|NCT02294773|PROCEDURE|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
47943706|NCT02294773|DRUG|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
48475020|NCT05529368|BEHAVIORAL|Conventional Exercise and Tai Chi Exercise interventions|Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
48475021|NCT01309217|BEHAVIORAL|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
48475022|NCT01309217|OTHER|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
48475023|NCT00160888|DRUG|sodium nitroprusside, bradykinin, acetylcholine|
48475024|NCT01358396|OTHER|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
48475025|NCT05735626|COMBINATION_PRODUCT|Piperine 150μM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
48475026|NCT05735626|COMBINATION_PRODUCT|Piperine 1mM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
48475027|NCT05735626|COMBINATION_PRODUCT|Capsaicin 10μM + tDCS 2mA|2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
48475028|NCT02289937|DRUG|Ropivacaine|
48475029|NCT02289937|DRUG|Placebo|
48475030|NCT02289937|DEVICE|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
48475031|NCT02280187|PROCEDURE|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
47943707|NCT02294773|DRUG|Letrozole|Patient is to take letrozole during cycle days 3-7.
47943708|NCT02587039|PROCEDURE|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
47943709|NCT02587039|BEHAVIORAL|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
47943710|NCT01841307|DRUG|Cromolyn Sodium|
47943711|NCT01932073|DEVICE|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
47943712|NCT02616419|DEVICE|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
47943713|NCT02616419|DRUG|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
47943714|NCT03986151|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
47943715|NCT00486551|BEHAVIORAL|Anger control training|
47943716|NCT00570414|DEVICE|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
48103272|NCT00434278|DRUG|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
48103273|NCT00434278|DRUG|placebo|2.5 mg inhalation dose twice daily for 14±2 days
48103274|NCT04707417|OTHER|Home care|Advanced home care
48103275|NCT04074148|BEHAVIORAL|Diabetes Prevention Education Program|An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
48103276|NCT04074148|BEHAVIORAL|Diabetes Prevention Education brochure|An educational lifestyle modification brochure
48103277|NCT02000999|OTHER|brushing of bile duct strictures for cytology|
48103278|NCT03761784|DRUG|S6G5T-3|Once a day topical cream
48103279|NCT03761784|DRUG|S6G5T-8|Once a day topical cream
47943717|NCT00570414|DEVICE|Endotracheal tube|Airway management by the use of endotracheal tube
47943718|NCT03271229|BIOLOGICAL|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
47943719|NCT03271229|BIOLOGICAL|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
47943720|NCT05794971|DRUG|Regorafenib and DIBIRI|"Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer."
47943721|NCT05794971|DRUG|Regorafenib|Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)
47943722|NCT04307914|RADIATION|External beam radiotherapy|The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.
47943723|NCT04307914|PROCEDURE|MR-HIFU|MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
47943724|NCT00538564|DRUG|tadalafil|10mg oral tablets taken 3 times a week for 2 months
47943725|NCT00538564|DRUG|placebo|Placebo tablets taken orally 3 times a week for 2 months
47943726|NCT00853073|DRUG|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
47943727|NCT00853073|OTHER|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
47943728|NCT04515927|DRUG|JS002|Biological: JS002 Administered by subcutaneous injection
47943729|NCT01986907|DRUG|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
47943730|NCT03654443|DIAGNOSTIC_TEST|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
47943731|NCT05034133|DRUG|Durvalumab|Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
47943732|NCT03378375|OTHER|nutritional assessement|
47943733|NCT05621915|DRUG|Nadroparin|Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
47943734|NCT05357547|DRUG|Buspirone 20mg|Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism
47943735|NCT05357547|DRUG|Placebo comparator|Lactose-sucrose tablets in opaque capsule
47943736|NCT06259708|DEVICE|Low intensity focused ultrasound|Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
47943737|NCT04620655|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
48103280|NCT05094284|DEVICE|BioFreedom Ultra|this is a registry only
47943738|NCT05554523|DEVICE|Photoacoustic imaging|Photoacoustic imaging
47943739|NCT03727425|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
47943740|NCT05544370|BEHAVIORAL|Intensive high intensity intervallic training group|The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
47943741|NCT05544370|BEHAVIORAL|Extensive high-intensity intervallic training|The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
47943742|NCT02983396|DEVICE|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
47943743|NCT06411028|DIAGNOSTIC_TEST|Polymyography|We will measure muscle activity using surface electromyography and tremor using inertial measurement units while subjects perform rest, posturing and kinetic tasks.
47943744|NCT06411028|DIAGNOSTIC_TEST|Muscle ultrasound|We will obtain B-mode images and videos of upper extremity muscles of the most affected upper extremity.
47943745|NCT06411028|DIAGNOSTIC_TEST|(Functional) magnetic resonance imaging|Subjects will undergo (f)MRI scanning involving concurrent electromyography, accelerometry and functional magnetic resonance imaging.
47943746|NCT06411028|DIAGNOSTIC_TEST|Clinical assessment|We will assess tremor and dystonia severity using clinical scales.
47943747|NCT06411028|DIAGNOSTIC_TEST|Questionnaires|We will collect patient-reported outcomes.
47943748|NCT01354067|BEHAVIORAL|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
48103281|NCT00009984|DRUG|fludarabine phosphate|Given IV
48103282|NCT00009984|DRUG|thalidomide|Given orally
47943749|NCT01354067|BEHAVIORAL|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
47943750|NCT01606644|PROCEDURE|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
47943751|NCT06115668|OTHER|Positive end-expiratory pressure 5 (PEEP 5)|Fixed positive end-expiratory pressure of 5 cmH2O will be maintained throughout the duration of surgery
47943752|NCT06115668|OTHER|Individualized positive end-expiratory pressure (PEEPIND)|Patients will receive the individualized positive end-expiratory pressure. Titration process will be started after establishment of pneumoperitoneum: setting the initial PEEP to 5 cmH2O, then increasing positive end-expiratory pressure (PEEP)according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing positive end-expiratory pressure , until the calculated Cstat shows a downward trend, set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEPIND for this patient. The highest PEEP is limited to 20 cmH2O
47943753|NCT05044091|DRUG|PARP inhibitor|Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions
47943754|NCT04733144|DRUG|Prednisolone|7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
47943755|NCT04733144|DRUG|Dexamethasone|1,125 mg dexamethasone 4,5 mg dexamethasone
47943756|NCT03173027|DRUG|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
47943757|NCT05205954|BEHAVIORAL|Hepatology Home Hospital|The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
47943758|NCT01532973|DRUG|Elbasvir|Elbasvir was administered orally by tablet(s)
47943759|NCT01532973|DRUG|Placebo|Dose-matched placebo tablets were administered orally.
47943760|NCT03602729|OTHER|Breastfeeding education|Breastfeeding education in three different forms: written/verbal/video
47943761|NCT04069078|DRUG|Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
47943762|NCT04069078|OTHER|Normal saline|Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
47943763|NCT04152044|OTHER|Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy|Patinets undergoing surgery
47943764|NCT02145988|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
47943765|NCT02145988|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
47943766|NCT05663268|BIOLOGICAL|Infliximab-dyyb biosimilar|Remsima for subcutaneous injection is a biosimilar monoclonal antibody of infliximab-dyyb that inhibits the activity of tumour necrosis factor (TNF)-alpha.
47943767|NCT02583373|DRUG|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
47943768|NCT02583373|DRUG|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
47943769|NCT02583373|DRUG|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
48475032|NCT04928664|DRUG|Liposomal bupivacaine|Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
47943770|NCT01013298|DEVICE|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
47943771|NCT05854199|BEHAVIORAL|Telehealth solution|Telehealth nutrition education platform
47943772|NCT05231681|DIETARY_SUPPLEMENT|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer|Eye Concealer
47943773|NCT02312921|OTHER|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
47943774|NCT00051454|BIOLOGICAL|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
47943775|NCT00096083|DRUG|isolated perfusion|
47943776|NCT00096083|DRUG|melphalan|
47943777|NCT00240227|DRUG|Prazosin|FDA approved medication for hypertension
47943778|NCT00240227|DRUG|placebo|
47943779|NCT04944628|DIETARY_SUPPLEMENT|Probiotic|Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10\^9 cfu/day)
47943780|NCT03962855|DRUG|Ifetroban Sodium|Ifetroban sodium 250 mg capsule once daily for 4 weeks
47943781|NCT03962855|OTHER|Placebo|Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
47943782|NCT03656835|PROCEDURE|Molecular Nanotechnology|Undergo ILN biochip testing
47943783|NCT05521724|PROCEDURE|exercise|resistance and strengthening exercises will be applied to a randomized patient group.
47943784|NCT00558727|DRUG|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
47943785|NCT00362037|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
47943786|NCT06243224|OTHER|High intensity interval training|High intensity will be calculated based on load (watt) at % 75-85 of VO2 max analyzed during the CPET in HIIT group.Patients will perform 4 minutes of active high-intensity training with this load. Patients will perform for 1 minute each with a load (watt) of 50-60% of VO2 max in the interval phase.HIIT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
47943787|NCT06243224|OTHER|Moderate intensity continuous training|Moderate intensity will be calculated based on load (watt) at % 50-60 of VO2 max analyzed during the CPET in MICT group. Patients will complete their training sessions without changing this load determined during the treatment process.MICT program will be performed with a horizontal ergometric bicycle (Ergoline GmbH ergoselect5, Serial no:2020010104, Germany ) for 3 sessions per week, each session being 30 minutes, for a total of 12 sessions for 4 weeks in the cardiopulmonary rehabilitation laboratory.
47943788|NCT04953429|BEHAVIORAL|workload|Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
48292364|NCT06217159|DIETARY_SUPPLEMENT|Poikilocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will wear a specialized face mask and breathe room air for 60 min. The face mask will be attached to an automated gas-blender system; however, only room air will be delivered.
48292365|NCT06217159|DIETARY_SUPPLEMENT|Normocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will be outfitted with a specialized face mask and breathe air with a slightly higher concentration of CO2 to maintain PetCO2 to resting baseline values for 60 min. Gas will be continuously delivered by an automated gas-blender system.
48292366|NCT05788068|BEHAVIORAL|Cognitive behavior therapy|"Participants will receive CBT intervention for smoking cessation via wechat-based mini-program developed by a professional team."
48292367|NCT01170156|DEVICE|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
47943789|NCT04416308|DIAGNOSTIC_TEST|NG test|rapid diagnosis Covid 19
47943790|NCT04416308|DIAGNOSTIC_TEST|Blood test|sample
47943791|NCT04416308|BEHAVIORAL|Self-questionnary|behavioral survey
47943792|NCT01329484|BEHAVIORAL|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
47943793|NCT01329484|BEHAVIORAL|Cognitive training|Cognitive training using a computerized system
47943794|NCT01329484|OTHER|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
48292368|NCT06220344|BIOLOGICAL|Honey Dressing|Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
48292369|NCT06220344|DRUG|Iodine Dressing|Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
48292370|NCT00824694|OTHER|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
47943795|NCT01226043|DRUG|Insulin Glargine|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous"
47943796|NCT02808650|OTHER|Laboratory Biomarker Analysis|Correlative studies
47943797|NCT02808650|OTHER|Pharmacokinetic (PK) study|Correlative studies
47943798|NCT02808650|DRUG|Prexasertib|Given IV
47943799|NCT00956956|DRUG|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
47943800|NCT00956956|DRUG|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
47943801|NCT05588271|OTHER|Exposures|This study is an observational study.Exposure factors is patients with pressure injury.
47943802|NCT02690883|DRUG|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
47943803|NCT02690883|DRUG|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG \<10.0mmol/L.
48292371|NCT00824694|OTHER|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
48292372|NCT00824694|OTHER|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
48292373|NCT03989687|DEVICE|Fuji Triage|glass ionomer sealant
47943804|NCT02702063|OTHER|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
47943805|NCT02702063|PROCEDURE|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
47943806|NCT02702063|OTHER|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
47943807|NCT04966052|OTHER|No intervention|No intervention
47943808|NCT01200849|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
47943809|NCT02946320|DEVICE|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
47943810|NCT02946320|DEVICE|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
47943811|NCT02946320|DEVICE|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
47943812|NCT06228885|BEHAVIORAL|handwriting experiment and motor ability test|Participants will be instructed to participate in a handwriting experiment, which involves utilizing a Force Acquisition Pen (FAP) system and Near Infrared Spectroscopy (NIRS) to collect force data and cortical activation, respectively, during handwriting tasks. Children will be tasked with completing various assignments, such as tracing lines, writing numbers, and characters, among others. Additionally, assessments of motor ability and handwriting proficiency will be conducted using the Movement Assessment Battery for Children (MABC) and the Chinese Handwriting Evaluation Form (CHEF). The Pinch Holding Up Activity (PHUA) Test will also be administered to assess their sensorimotor ability.
47943813|NCT01798680|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
47943814|NCT01798680|OTHER|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
47943815|NCT02047149|DRUG|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
47943816|NCT02047149|DRUG|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
47943817|NCT02047149|DRUG|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
47943818|NCT02047149|DRUG|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
47943819|NCT01407744|OTHER|laboratory biomarker analysis|Correlative studies
47943820|NCT04317976|OTHER|paralaryngeal pressure|cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance
47943821|NCT04317976|OTHER|cricoid pressure|cricoid pressure by fingertips applied under ultrasound guidance
47943822|NCT05177133|DRUG|Capecitabine|PO Capecitabine
47943823|NCT05177133|DRUG|Oxaliplatin|IV Oxaliplatin
47943824|NCT05177133|DRUG|Retifanlimab|IV retifanlimab
48292374|NCT03989687|OTHER|isolation|rubber dam or cotton roll isolation
48292375|NCT01348178|PROCEDURE|Follow-up|Follow-up
48292376|NCT04756895|OTHER|Vancomycin dose adjustment using the Bayesian method|This intervention is the experimental method. The AUC/MIC target is 400-600 mg\*hour/L.
48292377|NCT04756895|OTHER|Vancomycin dose adjustment using the trough level method|This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.
48292378|NCT03211130|BEHAVIORAL|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
47943825|NCT02653027|DRUG|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
47943826|NCT02653027|OTHER|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
47943827|NCT00494273|BEHAVIORAL|Cognitive Behavioral and Standard Care with Healthy Living|
47943828|NCT03377114|PROCEDURE|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
47943829|NCT03377114|PROCEDURE|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
48632127|NCT05830643|BEHAVIORAL|Social skills group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
47943830|NCT03302195|DRUG|Heparin|Based on patient body weight (UI/kg)
47943831|NCT03302195|PROCEDURE|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
47943832|NCT01621503|DEVICE|NT-530P|intraocular pressure and central corneal thickness measurement
47943833|NCT04595344|OTHER|Listening to Pure Binaural Beats|"The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves."
47943834|NCT04595344|OTHER|Listening to classical music|The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.
47943835|NCT04595344|OTHER|No audio only headphone|The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
47943836|NCT01420653|DRUG|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
47943837|NCT01420653|DRUG|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
47943838|NCT01420653|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
47943839|NCT01420653|DRUG|Placebo|placebo, three tablets four times a day, with food for 48 hours
47943840|NCT00612183|DRUG|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
47943841|NCT03161821|OTHER|Observational|
47943842|NCT03975062|DRUG|dabigatran etexilate|150 mg twice daily (BID)
48103283|NCT01103219|DIETARY_SUPPLEMENT|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
47943843|NCT00004834|DRUG|imipramine|
47943844|NCT00004834|BEHAVIORAL|cognitive-behavioral therapy|
47943845|NCT04365257|DRUG|Prazosin|Participants in this arm will receive the study drug as outlined in the arm description.
47943846|NCT04365257|OTHER|Standard of care|Participants in this arm will receive standard of care.
47943847|NCT02071927|DRUG|CB-839|Single-agent CB-839
47943848|NCT02071927|DRUG|CB-Aza|CB-839 in combination with standard dose azacitidine
47943849|NCT02849665|OTHER|Kangaroo Position|
47943850|NCT00289367|DRUG|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
47943851|NCT00289367|DRUG|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
47943852|NCT03810144|GENETIC|Vectra MBDA Test|Vectra Guided versus Usual Care
47943853|NCT00644657|DRUG|Clopidogrel|All subjects will receive a 300 mg loading dose
48103284|NCT03412942|DEVICE|FISH SP|The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
48103285|NCT03677206|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
48103286|NCT03677206|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
48103287|NCT00029926|DRUG|2-deoxy-2 [F-18] fluoro-2-d-glucose|
48103288|NCT03208270|DRUG|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
48103289|NCT03208270|DRUG|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
47943854|NCT04522531|OTHER|Open cinetic chain shoulder exercise on unstabil ground|Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
48292379|NCT03211130|BEHAVIORAL|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
48292380|NCT02544984|DRUG|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
48292381|NCT02544984|DRUG|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
48292382|NCT05861583|OTHER|fat tissue|fat tissue sample collected while cosmetical liposuction
48292383|NCT05861583|OTHER|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
48292384|NCT05861583|OTHER|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
47943855|NCT03364530|DRUG|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
47943856|NCT03364530|PROCEDURE|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
47943857|NCT05058352|DRUG|HS269|Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.
47943858|NCT01549470|BIOLOGICAL|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
47943859|NCT01549470|BIOLOGICAL|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
48292385|NCT05861583|OTHER|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
48292386|NCT05286151|BEHAVIORAL|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
48292387|NCT02613572|DRUG|alpha lipoic acid|
48292388|NCT02613572|DRUG|Placebo|
48292389|NCT05346562|DIETARY_SUPPLEMENT|Cannabidiol|Cannabidiol tablets
48292390|NCT05346562|DIETARY_SUPPLEMENT|Placebo|Cannabidiol-matched placebo tablets
48292391|NCT00729430|DRUG|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
48292392|NCT00729430|DRUG|Placebo|Placebo tablets taken orally once per day for 6 months
48292393|NCT00390923|DRUG|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
48292394|NCT00390923|DRUG|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
47943863|NCT05272449|DEVICE|Sleep apnea diagnosis|Split-night
47943864|NCT04171284|DRUG|SCT-I10|200 mg, Q3W, maximum treatment up to six cycles
48632128|NCT05830643|BEHAVIORAL|Adult interest group psychotherapy|"Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim."
47943865|NCT04171284|DRUG|Docetaxel|70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
47943866|NCT04171284|DRUG|Placebo|200 mg, Q3W, maximum treatment up to six cycles
47943867|NCT03418623|DRUG|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
47943868|NCT03418623|OTHER|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
47943869|NCT01032902|DEVICE|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
47943870|NCT01781533|PROCEDURE|algorithm|
47943871|NCT05912660|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement (surgically or TAVI)
47943872|NCT03110731|BEHAVIORAL|Physical training|Physical training (2x / week) was performed for 12 weeks
48632129|NCT06088446|PROCEDURE|Supplementary anesthetic injections|Supplementary anesthetic injections after failed primary nerve block
47943873|NCT04473846|DRUG|PK general anesthesia|Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).
47943874|NCT04473846|DRUG|PFK combination|Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
47943875|NCT03802812|DEVICE|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
47943876|NCT03298776|DEVICE|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
47943877|NCT03298776|DIAGNOSTIC_TEST|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
47943878|NCT06459765|DEVICE|Mi2000 TICI|Cochlear Implantation
47943879|NCT02024529|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
47943880|NCT02024529|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
47943881|NCT05644444|DEVICE|Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
47943882|NCT05644444|DEVICE|Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)|"In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application."
47943883|NCT00054717|DRUG|Tipranavir|
47943884|NCT00054717|DRUG|Ritonavir(r)|
47943885|NCT00054717|DRUG|Comparator Protease Inhibitor (CPI)|
47943886|NCT02667327|DRUG|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
47943887|NCT02667327|OTHER|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
47943888|NCT00277797|DEVICE|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
47943889|NCT00277797|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
47943890|NCT06090357|OTHER|Plantar pressure|Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
47943891|NCT05820061|DIAGNOSTIC_TEST|upper endoscopy|data will be collected from the enoscopy archive files in Department of Tropical Medicine and Gastroenterology,Sohag University Hospital
47943892|NCT03784417|DEVICE|EUS-guided laser ablation|EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
47943893|NCT01907100|DRUG|Nintedanib|triple kinase inhibitor; 200mg starting dose
47943894|NCT01907100|DRUG|Pemetrexed|backbone chemo
47943895|NCT01907100|DRUG|Cisplatin|backbone chemo
47943896|NCT01907100|DRUG|Cisplatin|backbone chemo
47943897|NCT01907100|DRUG|Pemetrexed|backbone chemo
47943898|NCT01907100|DRUG|Placebo|Nintedanib matching placebo
47943899|NCT00005928|DRUG|Ramipril|
48103290|NCT06389318|DRUG|buccal midazolam +oral placebo syrup|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
48632130|NCT00756834|DEVICE|Screening|The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review
48292395|NCT06665568|DRUG|Intranasal ketamine hydrochloride|Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
48292396|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
48292397|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
48292398|NCT03469193|PROCEDURE|internal PUC implanted with mechanical ancillary|The control group consists of patients operated with a mechanical ancillary (reference surgery in our department). In this technique, bone sections are made with a standardized ancillary (manually adjusted bone cutting guides), according to preoperative radiological planning. The positioning of the implants is done manually and controlled by the placement of test implants.
48292399|NCT03469193|PROCEDURE|Internal PUC implanted with robotic assistance|Patients are operated by robotics (surgery that we want to develop systematically in our service). 3D modeling of the knee allows the operator to perform a dynamic planning taking into account the reducibility of the deformation and the model of the implant. The operator can position the implants in three dimensions of the space without difficulty. This makes it possible to visualize, before the bone resections, the angular correction obtained between 0 and 130° flexion and alignment of the prosthesis by visualizing the contact points between the two implants. Bone resections will be performed using a guided retro bone drill. The system retracts more or less the cutter according to the bone thickness to be removed. This technique requires the insertion of two threaded plugs in the tibia and two in the femur to position the sensors that will allow the acquisition of anatomical landmarks of the lower limb and then 3D modeling
48292400|NCT03524872|DEVICE|Original CAD/CAM prosthetic abutment|Original (Sweden\&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
48292401|NCT03524872|DEVICE|Compatible CAD/CAM abutment|Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
48292402|NCT03524872|PROCEDURE|Local anesthesia|Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
48292403|NCT03524872|DRUG|Painkillers|Patients will be prescribed ibuprofen 600 mg three times per day for five days
48292404|NCT03524872|DRUG|Mouthwashes|Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
48632131|NCT00000544|BEHAVIORAL|diet therapy|
48632132|NCT00003456|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48632133|NCT05669066|BEHAVIORAL|Mindful meditation|Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
48632134|NCT05121922|BEHAVIORAL|Metacognitive Therapy|Psychological treatment provided by the patient's regular general practitioner
48632135|NCT06064201|OTHER|Short-chain fatty acids (SCFAs)|The SCFAs mixture contains acetate, butyrate, and propionate in a ratio of 60:20:20, and the total daily amount of SCFAs is equivalent to the fermentation of 10g of arabinoxylan oligosaccharides. Participants will be asked to consume these capsules spread at four intervals throughout the day. The nursing staff will distribute the capsules to the participants individually, supervise their intake, and monitor adherence by capsule count.
48632136|NCT06064201|OTHER|Placebo|To serve as a placebo, microcrystalline cellulose will be included in the same type of CDCs.
48292405|NCT03524872|DEVICE|Implant placement|Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
48292406|NCT03453749|DIETARY_SUPPLEMENT|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
48292407|NCT00379938|BIOLOGICAL|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
48292408|NCT00379938|DRUG|Placebo|Saline control
48292409|NCT00379938|BIOLOGICAL|MF-59|Adjuvant
48292410|NCT05760625|DIAGNOSTIC_TEST|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
48292411|NCT02234401|DEVICE|Bi level pressure support|
48292412|NCT02234401|OTHER|Standard Care|
48292413|NCT06331585|RADIATION|low dose radiotherapy|LDRT (5Gy/5f) of oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy
48292414|NCT06319898|BEHAVIORAL|Lavender aromatherapy sticker|Lavender aromatherapy during procedure, music and dim lighting
48292415|NCT01183858|DRUG|Erlotinib [Tarceva]|Single daily oral dose
48292416|NCT06399081|OTHER|Observational|Observational
48292417|NCT00118170|DRUG|sorafenib tosylate|Given orally
48292418|NCT00118170|OTHER|pharmacological study|Correlative studies
48292419|NCT00770861|DRUG|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
48292420|NCT00770861|DRUG|Placebo|Matching placebo tablets, oral administration
47943900|NCT05716399|DEVICE|Transcutaneous electric stimulation pretreatment|Within 30 minutes before spinal anesthesia or 30 minutes after hypotension, TEAS (density wave 10/50Hz, one side of Neiguan and Quchi points connected to two electrodes on the same wire on the electroacupuncture instrument) was continuously performed on both sides of Neiguan and Quchi points, and the current intensity was only as high as the patient could comfortably tolerate (the electrical stimulation intensity was 2-3 times of the sensory threshold, for example, if the electrical stimulation intensity was 5 mA, 10-15 mA was used for stimulation), Record the specific value of current. FTEAS group pastes electrode piece, turns on the power, but there is no current output.
48632137|NCT02194088|DRUG|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
48632138|NCT02194088|DRUG|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
48632139|NCT00620802|DRUG|CGT-2168|(CGT-2168, one capsule each daily)
48632140|NCT00620802|DRUG|Plavix|(clopidogrel, 75 mg)
48632141|NCT03874403|PROCEDURE|DSA|The changes on DSA on NIVATS and VATS
48632142|NCT00973973|DRUG|Placebo|Matching placebo tablets taken orally once a day
48292421|NCT00045838|DRUG|VCR-HIVDNA006-00-VP|
48632143|NCT00973973|DRUG|Elagolix|Immediate release (IR) tablets taken orally once a day
48632144|NCT00069745|DRUG|Satraplatin|
48632145|NCT00069745|DRUG|Prednisone|
48632146|NCT06406816|COMBINATION_PRODUCT|Neoantigen Vaccine plus Capecitabine|"1. Capecitabine.Twice a day, 30 minutes after breakfast, swallow with water, continue for 2 weeks, then stop for 1 week, constitutes one cycle; three weeks make one cycle, lasting for 8 cycles.~2. Neoantigen Vaccine . Every 3 weeks, once every 21 days, for 4 to 8 cycles. The injection is administered on the first day after cessation of capecitabine. Treatment can last for up to 6 months without occurrences such as the researcher determining no further clinical benefit, intolerable toxic reactions, initiation of new anti-tumor treatment, withdrawal of informed consent, loss to follow-up, death, or other circumstances specified in the protocol that require treatment termination."
48632147|NCT03115658|BEHAVIORAL|Physical Activity|12 week print based intervention
48632148|NCT01438944|DRUG|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
47943901|NCT05716399|DEVICE|Transcutaneous acupoint electrical stimulation treatment|Transcutaneous acupoint electrical stimulation treatment
47943902|NCT05716399|DEVICE|Transcutaneous acupoint pseudo electric stimulation|Transcutaneous acupoint pseudo electric stimulation
48632149|NCT03722030|OTHER|Baseline Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
48632150|NCT03722030|BEHAVIORAL|Strength-Training|2 sessions per week (20-40 min), home-based resistance training
48632151|NCT03722030|OTHER|Mid-point Measures|Accelerometer (steps)
47943903|NCT02373722|PROCEDURE|Mohs Surgery|Undergo Mohs surgery
47943904|NCT02373722|OTHER|Internet-Based Intervention|Watch website application based educational video
48475033|NCT04928664|DRUG|Standard bupivacaine|Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
48632152|NCT03722030|OTHER|Post-Study Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
48632153|NCT02623270|DEVICE|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
48632154|NCT02623270|DEVICE|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
47943905|NCT02373722|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
47943906|NCT02373722|OTHER|Educational Intervention|Watch website application based educational video
47943907|NCT02373722|BEHAVIORAL|Exercise Intervention|Use Fitbit
47943908|NCT02373722|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
48103291|NCT06389318|DRUG|oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline|Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
48475034|NCT01660477|DRUG|Isavuconazole|oral
48475035|NCT01660477|DRUG|Lopinavir/ritonavir|oral
48475036|NCT00203320|DRUG|etanercept given by perispinal administration|
48475037|NCT02993419|DRUG|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
48475038|NCT02993419|OTHER|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
47943909|NCT02373722|OTHER|Questionnaire Administration|Ancillary studies
47943910|NCT02373722|OTHER|Survey Administration|Ancillary studies
47943911|NCT03619343|PROCEDURE|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
47943912|NCT06247800|DEVICE|Virtual Reality Device|A virtual reality headset is a heads-up display that allows users to interact with simulated environment.
47943913|NCT06247800|OTHER|Without virtual reality|Patients undergoing intercostal chest drain without the use VR device
47943914|NCT06143800|BEHAVIORAL|reactivation|During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.
47943915|NCT06143800|BEHAVIORAL|cognitive reappraisal intervention|"Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it."
47943916|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
47943917|NCT00674427|BIOLOGICAL|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
48632155|NCT04725643|DEVICE|Track bleeding patterns before and after implant|Participants will report if they had bleeding and the amount based on the Pictorial Blood Assessment Chart. Participants will also complete weekly surveys regarding their satisfaction with their bleeding. We will also ask participants to complete a survey regarding their satisfaction with their bleeding at end of month 2 and at the end of month 3 after replacement of their contraceptive implant.
48632156|NCT03876548|DEVICE|Cadexomer Iodine Gel|Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
48632157|NCT00666471|PROCEDURE|MICE|MICE
48632158|NCT00666471|PROCEDURE|SPA ligation|SPA ligation
47943918|NCT02884531|OTHER|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
47943919|NCT02884531|BEHAVIORAL|Patient Education|Patient education (1/2 day)
47943920|NCT02121990|DRUG|Paclitaxel,|
47943921|NCT02121990|DRUG|Bevacizumab|
47943922|NCT02121990|DRUG|Cisplatin|
48103292|NCT06391242|RADIATION|Standard Conventional Radiotherapy|20Gy in 5 fractions
48103293|NCT06391242|RADIATION|Stereotactic Body Radiotherapy|30 or 35Gy in 5 fractions
48475039|NCT01446224|DRUG|Pazopanib|Patients treated with pazopanib
48475040|NCT01446224|DRUG|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
48475041|NCT05780450|DEVICE|Transcranial Direct Current Therapy (tDCS)|"Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment."
48632159|NCT01837095|DRUG|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
48632160|NCT05071833|DIETARY_SUPPLEMENT|Peppermint oil.|Peppermint oil.
48632161|NCT05071833|OTHER|Placebo|Placebo
48632162|NCT02691377|DEVICE|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
48632163|NCT02691377|DEVICE|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
47943923|NCT02121990|DRUG|Olaparib|
47943924|NCT00975637|DRUG|70 mg SC|70 mg SC
47943925|NCT00975637|DRUG|210 mg SC|210 mg SC
47943926|NCT00975637|DRUG|140 mg SC|140 mg SC
47943927|NCT00975637|DRUG|280 mg SC|280 mg SC
47943928|NCT00975637|DRUG|Placebo|Placebo SC
47943929|NCT02966873|DRUG|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
47943930|NCT02966873|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
47943931|NCT02966873|DRUG|Inactive Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
47943932|NCT02966873|OTHER|Functional magnetic resonance imaging (fMRI)|Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
48475042|NCT05287087|BEHAVIORAL|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
48475043|NCT05287087|BEHAVIORAL|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~5. Thorough symptom explanations~6. Physical energy (focus on sleep, diet and activity)~7. Values and choices (focus on meaning and existential issues)~8. Emotional health (focus on emotion regulation)~9. Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
47943933|NCT02966873|OTHER|Proton magnetic resonance spectroscopy (MRS) Imaging|Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
47943934|NCT00423670|DRUG|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
47943935|NCT00423670|DRUG|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
47943936|NCT00423670|DRUG|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
47943937|NCT00423670|DRUG|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
47943938|NCT00877110|DRUG|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
47943939|NCT05800860|DRUG|GH001|GH001 administered via inhalation
48103294|NCT03256812|DEVICE|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
48103295|NCT03256812|DEVICE|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
48475044|NCT04323462|DRUG|Insulin Glargine|Three times bolus insulin with regular or Shorter acting insulin
48475045|NCT04323462|DRUG|Diabetic DM|Previously receiving OADs and/or basal insulin
48103296|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
48103297|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
48103298|NCT03490851|OTHER|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
47943940|NCT05800860|DRUG|Placebo|Placebo administered via inhalation
47943941|NCT03114488|DEVICE|tDCS|Transcranial electrical stimulator
47943942|NCT05215990|DRUG|MetFORMIN 500 Mg Oral Tablet|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
48475046|NCT05778240|BEHAVIORAL|Phone call|"Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions.~1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace?~2. What kind of transportation do you plan to take to come to the hospital at your appointment day?~3. At what time do you plan to leave home or work to come to the hospital?"
48475047|NCT05778240|BEHAVIORAL|Text message|Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.
48475048|NCT05778240|BEHAVIORAL|Control|Participants were given the vaccination appointment card.
48475049|NCT01280344|DRUG|Saline Solution for Injection|Intravenous (IV)
47943943|NCT05215990|DRUG|Placebo|studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
48475050|NCT01280344|DRUG|Ipamorelin|Intravenous (IV)
48632164|NCT06072261|OTHER|kinesio tape application|"Before the standard rehabilitation program, kinesio taping was applied to both upper extremities in the form of a Y tape from the medial epicondyle to the wrist flexors, with 15-20% tension, to the patients hospitalized in the orthopedic service after lower extremity surgery. The tape should remain on the patient's arm throughout the hospital stay"
48632165|NCT05628415|PROCEDURE|Non-powered AeonTM Endostapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the non-powered Aeon™ Endostapler (Lexington medical) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
48632166|NCT05628415|PROCEDURE|Echelon FLEX™ Powered plus Stapler (according to manufacturer medical device classification IIb)|Closure of the left and/or right side of the lung after bilateral or unilateral lung-volume-reduction- surgery is performed with the Echelon FLEX™ Powered plus Stapler (Ethicon) 60-mm and 45-mm. At the end of the operation, two 24F apical chest tubes are placed on each side and are systematically set at -10 cm H2O suction via the Medela- Topaz™ system. Air leak will be measured quantitatively in ml per minute by use of a Medela-Topaz™ system. Cessation of air leak is the case when a value of 0ml/min or two consecutive values under 30 ml/min by use of thoracic drainage Medela- Topaz™ system are read.
48632167|NCT02787798|DRUG|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
48475051|NCT01020526|DRUG|pregabalin|Oral capsule 75-450 mg/day
48475052|NCT03147924|OTHER|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
48475053|NCT03988101|DRUG|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
48475054|NCT03988101|DRUG|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
48475055|NCT01438476|PROCEDURE|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
48475056|NCT01438476|PROCEDURE|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
48632168|NCT02787798|DRUG|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
48632169|NCT02787798|PROCEDURE|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
48103299|NCT03490851|OTHER|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
48103300|NCT02987543|DRUG|olaparib|300 mg (2x 150 mg tablets) twice daily
48103301|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg capsules) once daily
48103302|NCT02987543|DRUG|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
48103303|NCT02987543|DRUG|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
48103304|NCT02987543|DRUG|enzalutamide|160 mg (4 x 40 mg tablets) once daily
48103305|NCT03612791|DRUG|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
48103306|NCT03612791|RADIATION|Radiotherapy|"* Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days."
48103307|NCT03612791|DRUG|Cisplatin|"* Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
48632170|NCT05129202|DRUG|immune therapy|The patient receives immunotherapy
48632171|NCT06404775|DRUG|mastalgia-oil, tamoxifen placebo|external mastalgia-oil 1 ml/d per breast plus oral tamoxifen placebo 10mg/d for 3 consecutive menstrual cycles
48632172|NCT06404775|DRUG|mastalgia-oil placebo, tamoxifen|oral tamoxifen 10mg/d plus external mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
48632173|NCT01580722|PROCEDURE|early reconstruction|patients underwent \< 8 weeks reconstruction after injury
48632174|NCT01580722|PROCEDURE|delay reconstruction|patients underwent \> 8 weeks reconstruction after injury
48632175|NCT02449577|OTHER|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
47943944|NCT06072248|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
48292422|NCT02805699|DRUG|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
48292423|NCT02805699|DRUG|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
48292424|NCT00302237|DEVICE|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
48475057|NCT01438476|BEHAVIORAL|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
48475058|NCT01438476|BEHAVIORAL|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
48632176|NCT02449577|OTHER|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
48632177|NCT02449577|OTHER|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
48632178|NCT02449577|OTHER|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
48632179|NCT02449577|OTHER|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
47943945|NCT06072248|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
47943946|NCT06072248|DEVICE|ventilator|ventilator
47943947|NCT02386306|DRUG|GC021109|
48632180|NCT02449577|OTHER|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
47943948|NCT02386306|OTHER|Placebo|
47943949|NCT02343133|BIOLOGICAL|HemaMax|
48292425|NCT01119040|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
47943950|NCT02343133|DRUG|Placebo|
47943951|NCT03965208|DRUG|Bivalirudin|titrated continuous infusion
47943952|NCT03965208|DRUG|Unfractionated heparin|titrated continuous infusion
48292426|NCT01596829|DIETARY_SUPPLEMENT|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
48475059|NCT03017352|DRUG|Exenatide|
48475060|NCT03017352|DRUG|Placebos|
48475061|NCT05787067|BEHAVIORAL|Health Belief Model-Based Mobile Online Training|Health Belief Model-Based Mobile Online Training
48475062|NCT03184012|DEVICE|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
48475063|NCT03184012|DEVICE|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
48632181|NCT02449577|OTHER|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
48632182|NCT02449577|OTHER|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
48632183|NCT02449577|OTHER|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
48632184|NCT02449577|OTHER|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
48632185|NCT02449577|OTHER|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
47943953|NCT03706131|OTHER|cervical mobilisation|manual therapy
47943954|NCT02374515|DEVICE|EndoCuff-assisted colonoscopy|Adenoma detection rate
47943955|NCT02374515|DEVICE|Standard Colonoscopy|
47943956|NCT00377975|DRUG|Ephedrine|
47943957|NCT00377975|DRUG|Pioglitazone|
47943958|NCT00377975|DRUG|Caffeine|
47943959|NCT00471016|BEHAVIORAL|Guided intervention|
47943960|NCT02355496|OTHER|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
47943961|NCT02002611|DRUG|Lobeglitazone|
47943962|NCT02002611|DRUG|Warfarin|
47943963|NCT02045173|OTHER|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
47943964|NCT02045173|DEVICE|Polysomnography/polygraphy|1 night polysomnography/polygraphy
48103308|NCT06028113|BEHAVIORAL|THRIVE 2.0|Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment \& responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines \& Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
48103309|NCT02287649|OTHER|blood sample|
48103310|NCT01043471|OTHER|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
48103311|NCT01043471|OTHER|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
48103312|NCT02980380|OTHER|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
48292427|NCT01596829|DIETARY_SUPPLEMENT|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
48292428|NCT02165852|PROCEDURE|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
48475064|NCT05939804|DEVICE|TENS|TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher.
48475065|NCT03072654|PROCEDURE|Thyroidectomy|Remove the nodular goiter on the neck by thyroidectomy (standard procedure)
47943965|NCT00506610|DRUG|T-62|
47943966|NCT06380829|OTHER|Questionnaire|Self-Care Assessment Scale for Children with CP aged 3-6 years - Parent Form (SPÇÖS-EF): A draft scale named SPÇÖS-EF was prepared by the researchers, using the literature, to determine the self-care status of children with cerebral palsy aged 3-6.
47943967|NCT01512056|DRUG|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
47943968|NCT03476668|OTHER|MIRT|4-week multidisciplinary intensive rehabilitation treatment
47943969|NCT05274165|DEVICE|Lyric Hearing Aid- Experimental Design|Extended wear hearing aid with a fitting modification that is currently not available
47943970|NCT05274165|DEVICE|Lyric Hearing Aid- Commercially Available|Extended wear hearing aid that is currently available
48103313|NCT04908982|DRUG|Aspirin 81mg|81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.
48103314|NCT06239948|OTHER|With Music|each subject was placed in a TMS laboratory with music for 20 minutes
48103315|NCT06239948|OTHER|Without Music|each subject was placed in a TMS laboratory without music for 20 minutes
48103316|NCT04973852|DEVICE|Ekso|Exoskeleton walking
48103317|NCT06421688|DRUG|Ascorbic acid|After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.
48103318|NCT06421688|DRUG|Saline|After participants underwent induction of anesthesia, 50 ml of saline was used and pumped using a micro pump at a rate of 25 ml/h.
48103319|NCT02471391|DRUG|ABT-199|
48103320|NCT02471391|DRUG|Ibrutinib|
48103321|NCT00629200|DRUG|Sodium Stibogluconate|400 mg/m\^2 IV daily on days 1-5.
48103322|NCT00629200|DRUG|Interferon Alpha-2b|3x10\^6 units subcutaneously three times weekly
48475066|NCT04766216|OTHER|Patient self-management|Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools
48475067|NCT04766216|OTHER|Usual care provided by anticoagulation providers|Normal care provided by anticoagulation providers
47943971|NCT00773929|DRUG|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
47943972|NCT04012918|DRUG|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
47943973|NCT04012918|DRUG|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
48103323|NCT04835038|DRUG|Sodium Bicarbonate Ringer's Injection|Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
48103324|NCT04835038|DRUG|Sodium Lactated Ringer's Injection|Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
48103325|NCT01194778|DIETARY_SUPPLEMENT|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
48103326|NCT01194778|DIETARY_SUPPLEMENT|vitamin K1|15 µg vitamin K1 per day during 12 weeks
48103327|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|15 µg vitamin K2 per day during 12 weeks
48103328|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|30 µg vitamin K2 per day during 12 weeks
48103329|NCT01194778|DIETARY_SUPPLEMENT|vitamin K2|45 µg vitamin K2 per day during 12 weeks
48103330|NCT06266858|OTHER|rehydration|The fasting patients in anaesthetised receive saline rehydration to maintain central venous pressure of 6-8 cmH2O when undergoing UCG.
48103331|NCT06266858|DIAGNOSTIC_TEST|UCG|UCG is the most common imaging modality to assess the mitral regurgitation in clinical and also is the primary modality recommended by guidelines. At the beginning of the study, the fasting patients receive UCG in the different situation such as pre-anaesthetic, post-anaesthetic and post-rehydration.
48103332|NCT06266858|DIAGNOSTIC_TEST|CMR|CMR may be more accurate than UCG in assessing MR severity. In another time, the patients receive CMR.
48103333|NCT06266858|OTHER|fasting|At the beginning of the study, the patients need to fast when receive UCG.
48632186|NCT01534403|BIOLOGICAL|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
48632187|NCT06235970|DEVICE|Transcranial electrical stimulation (tES) including SHAM|Transcranial electrical stimulation, known as tES, refers to a family of devices that utilize low-cost technologies and involve low-intensity currents which are safe for humans, and carry minimal risk of side effects or adverse events. Conventional approaches, which utilize fixed direct currents (tDCS) or alternating currents at a fixed oscillatory frequency (tACS), have been widely used as both a basic research tool and as a clinical intervention. In the current project, we use a custom-built device that enables near real-time current modulation triggered digitally, via software control, to allow for stimulation protocols guided by whole-brain individualized neural modeling.
48632188|NCT04743596|DEVICE|High-Definition Videobronchoscopy|Endoscopic inspection and endobronchial biopsy with standard forceps during high-definition videobronchoscopy.
48632189|NCT05223712|OTHER|Diagnostic Test: Chronic Kidney Diseases|The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
48632190|NCT05954689|OTHER|Femoral artery block|Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
48632191|NCT02945046|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
48632192|NCT02945046|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
48475068|NCT02824640|BEHAVIORAL|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
48475069|NCT02824640|BEHAVIORAL|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
48475070|NCT04376359|PROCEDURE|hyperbaric oxygen therapy|Hyperbaric oxygen therapy is the patient put in airtight oxygen tank, by increasing the air pressure in the environment (1.5 to 3.0) under atmospheric pressure, to give 100% oxygen, the patient treatment time is approximately 60 minutes to 120 minutes in this way, can achieve the purpose of greatly increase the oxygen partial pressure in the organization, so as to achieve reverse brain edema, reduce lipid peroxidation, inhibiting leukocyte hyperactivity, rebuild the blood brain barrier.
48475071|NCT06313060|DIETARY_SUPPLEMENT|Coca-cola|200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
48475072|NCT05751876|DRUG|Dienogest|Dienogest 2mg was prescribed once per day orally
48475073|NCT05091086|DRUG|Denosumab|Active comparator: persistent treatment of denosumab. Experimental: alternating treatment with zoledronate and denosumab
48475074|NCT02565017|BEHAVIORAL|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
48475075|NCT04374188|DRUG|Ciprofloxacin|drug adminstration to ameliorate sepsis incidence
48475076|NCT04374188|DRUG|Levofloxacin|levofloxacin pill
48475077|NCT02091349|OTHER|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
48475078|NCT02091349|OTHER|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
48475079|NCT05722028|PROCEDURE|hysteroscopy|Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
48475080|NCT00496262|BIOLOGICAL|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
48632193|NCT03074643|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
48632194|NCT03074643|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
47943974|NCT02831374|DRUG|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
48475081|NCT01422486|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
47943975|NCT02831374|PROCEDURE|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
48103334|NCT01188252|DRUG|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
48292429|NCT02165852|PROCEDURE|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
48292430|NCT04763265|BIOLOGICAL|"Botulinum toxin A BoNT/A-DP"|To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
48292431|NCT04763265|BIOLOGICAL|"Botulinum toxin A Botox Cosmetics"|To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
48292432|NCT04634643|OTHER|Usual diet and physical activity|Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD
48475082|NCT00426179|DRUG|Imatinib|
48475083|NCT02671682|PROCEDURE|Immunoadsorption|
48475084|NCT02671682|PROCEDURE|Plasmapheresis|
48475085|NCT00006102|DRUG|becatecarin|
47943976|NCT02831374|BIOLOGICAL|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
48475086|NCT06617663|BEHAVIORAL|EMDR|Eye Movement Desensitization and Reprocessing (EMDR) is a therapy designed to alleviate the distress associated with traumatic memories.
48475087|NCT06617663|BEHAVIORAL|ACT|Acceptance and Commitment Therapy (ACT) is an action-oriented approach to psychotherapy that stems from traditional behavior therapy and cognitive behavioral therapy. Clients learn to stop avoiding, denying, and struggling with their inner emotions and, instead, accept that these deeper feelings are appropriate responses to certain situations and should not prevent them from moving forward in their lives. The ACT Your Way method is specifically designed for young people.
47943977|NCT02831374|PROCEDURE|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
47943978|NCT02831374|PROCEDURE|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
47943979|NCT02831374|DRUG|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
48475088|NCT03123029|DRUG|Venetoclax|Venetoclax will be administered orally.
48475089|NCT06069856|DIETARY_SUPPLEMENT|Iron Folic Acid Tablets with 60 mg of iron|IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization
48475090|NCT06069856|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
48475091|NCT03655119|BEHAVIORAL|Parent toolkit|The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.
48475092|NCT03655119|BEHAVIORAL|Enhanced Care|PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.
48475093|NCT03655119|BEHAVIORAL|Caring Follow-Up Messages|Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
48475095|NCT05557370|BIOLOGICAL|Human Papilloma Virus vaccine (GARDASIL 9)|Patients will be scheduled to receive 3-dose 9vHPV vaccination (vaccination at enrollment \[time 0\], 2 months \[+ 6 weeks\], and 6 months \[+ 6 weeks\] per standard guidelines).
48475096|NCT06184867|DIAGNOSTIC_TEST|Relational Agent|Alex was developed as an interactive and personalized education and decision support intervention for smart devices, and guides participants through the key primary stages of assessing personal risk of hereditary cancer, providing genetic education, cancer family tree, patient testimonials, asks and answers questions and for those who choose, facilitates genetic testing, and streamlines disclosure of test results.
48475097|NCT06184867|OTHER|Clinical Letter|Letter will be signed by Dr. Toppmeyer and contain a recommendation to contact the Life Center for a cancer genetic risk assessment and to consider GT.
48475098|NCT04037982|PROCEDURE|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
48632195|NCT03074643|DIETARY_SUPPLEMENT|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (\~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
48632196|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
48632197|NCT03074643|DIETARY_SUPPLEMENT|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (\~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
48632198|NCT04064671|OTHER|Implantation of the Zephyr ZSI 475 FTM erectile implant|Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.
48632199|NCT02968875|DEVICE|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
48292433|NCT06668428|DEVICE|Virtual Reality Glasses|Pharmacological and non-pharmacological methods are applied in the management of pain and anxiety after cesarean section (Tetik \& Tekinemre, 2017). In addition to medical treatment during the post-cesarean care process, complementary and supportive non-pharmacological approaches can be used to address the woman holistically and provide multi-faceted contributions to the health of the mother and baby (Ali, 2022; Bayraktar, 2023). One of the non-pharmacological approaches, virtual reality glasses, is a device that provides two or three-dimensional environments to stimulate our senses by creating illusions of images (Appel et al., 2021). SGG creates a therapeutic effect by diverting attention, provides relaxation, and can thus be used in the management of pain and anxiety (Ayed et al., 2019). It has been determined that virtual reality glasses are an effective method in the management of pain and anxiety in the field of nursing (Akıncı \& Aydın Özkan, 2024).
48292434|NCT00757523|DRUG|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
48292435|NCT00757523|DRUG|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
48292436|NCT01965548|PROCEDURE|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:~* splenectomy~* splenic artery embolisation~* non-operative management~* any combination of the three treatments mentioned"
48292437|NCT03291002|BIOLOGICAL|CV8102|CV8102 alone
48292438|NCT03291002|BIOLOGICAL|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
48292439|NCT02848885|OTHER|Active TDCS|Participants will receive active tDCS stimulation.
48475099|NCT04037982|PROCEDURE|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
48475100|NCT02419833|PROCEDURE|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
48475101|NCT02419833|PROCEDURE|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
48475102|NCT02419833|DEVICE|Coronary artery stenting|Implantation of coronary stents
48475103|NCT06029582|DEVICE|VR headset|Virtual Reality Headset
48475104|NCT06613893|DRUG|TIVA|Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mg/kg/min) and fentanyl infusion (3-4.8 mic /kg/hour)(Ting 2019) that will be stopped 30 min before the end of the operation ,The heart rate and blood pressure will be maintained within the range of ±20% of the baseline
47943980|NCT01598675|OTHER|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
47943981|NCT01598675|OTHER|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
48292440|NCT02848885|OTHER|Sham TDCS|Participants will receive sham tDCS stimulation
48292441|NCT05823493|BEHAVIORAL|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
48475105|NCT06613893|DRUG|Inhalational anesthesia|Anesthesia will be maintained with inhaled isoflurane from (0.7 to 1.4%)(Hawkley, Preston, and Maani 2018) and fentanyl 0.35 to 0.5 mcg/kg supplementary dose will be given if needed to maintain the heart rate and blood pressure within the range of ±20% of the baseline
48475106|NCT05694130|DRUG|Prednisolone|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
48475107|NCT05694130|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
48103335|NCT01158196|DEVICE|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
47943982|NCT04624438|OTHER|Isometric training with electromyostimulation|"Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score."
47943983|NCT04624438|OTHER|Isometric training with voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
48292442|NCT05823493|DEVICE|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
48292443|NCT04697719|DRUG|Aspirin 81mg|81mg oral capsule
48292444|NCT04697719|DRUG|Aspirin 325mg|325mg oral capsule
48292445|NCT03955029|OTHER|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session).
48475108|NCT00935831|DRUG|GSK1278863A|50mg, 150mg
48475109|NCT00935831|DRUG|Placebo|matching placebo
48632200|NCT02968875|OTHER|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
47943984|NCT04624438|OTHER|Isometric training with combination of electromyostimulation and voluntary activation|Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
48103336|NCT03917329|OTHER|ACT and PBS group workshop|Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
48292446|NCT03955029|OTHER|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session)
48632201|NCT03686111|DIAGNOSTIC_TEST|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
48475110|NCT00775528|DRUG|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
48475111|NCT04569786|BIOLOGICAL|V590|Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).
48475112|NCT04569786|OTHER|Placebo|Placebo administered via IM injection.
48475113|NCT02095340|OTHER|Positive Interpretation Bias Training|
48475114|NCT02095340|OTHER|Neutral Interpretation Bias Training|
48475115|NCT06601751|OTHER|Neurobic Exercise Program|6 weeks to improve cognitive function, memory and overall brain health by introducing non-routine activities that require participants to utilise their multiple senses and remember sequences and patterns. Each activity would be performed 2-3 times/ session, for recalling the observation period set at 1 minute and at the end of the 9th week, the memory retention effect will be measured.
48475116|NCT06601751|OTHER|Traditional Brain Exercise|activities like calculation or memory games. These exercises will be conducted in 2 days/week for 60-minute sessions in 6 weeks. The memory retention effect will be measured at the end of the 9th week. It is intended to be the baseline for comparing the effectiveness of a neurobic exercise program.
48475117|NCT01344616|BEHAVIORAL|lifestyle support|computer-based lifestyle improvement support and clinician support
48475118|NCT03244982|DRUG|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
48632202|NCT05721027|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg PO every 8 hours as needed for 7 days
48632203|NCT05721027|DRUG|Dexamethasone Oral|Dexamethasone 16 mg PO during ED visit and next day
48632204|NCT05721027|BEHAVIORAL|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
48292447|NCT05739617|OTHER|Comprehensive Respiratory Training Exercise Program|This comprehensive respiratory training exercise program consists of four main components, including oropharyngeal muscle training, respiratory muscle training, aerobic exercise, and sleep hygiene education.
48292448|NCT05739617|OTHER|Sleep hygiene education|Sleep hygiene education
48292449|NCT00609128|DRUG|olopatadine|olopatadine one drop in one eye for one week
48292450|NCT05812508|DEVICE|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
48292451|NCT06148519|DIAGNOSTIC_TEST|2WIN-S portable refractor|All participants will be tested by 2WIN-S portable refractor without eye dilatation. If the 2WIN-S reports non-referral, participant will be tested visual acuity by optometrist. If the 2WIN-S reports referral, participant will be tested cycloplegic refraction by pediatric ophthalmologist, then tested by 2WIN-S again. The participant whose result is abnormal will be referred to the hospital for further management.
48292452|NCT01663740|DRUG|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
48292453|NCT01150110|DEVICE|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.~Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
48292454|NCT05010681|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48292455|NCT05010681|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48292456|NCT06281873|PROCEDURE|closure by PRF membrane|Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint
47943985|NCT03956056|BIOLOGICAL|Neoantigen Peptide Vaccine|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
47943986|NCT03956056|DRUG|Poly ICLC|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
48292457|NCT02119208|BEHAVIORAL|Intensity and timing of exercise|
48632205|NCT05545488|DEVICE|Virtual reality|I had the women wear virtual reality glasses and watch the video they wanted for at least 5, maximum 15 minutes during the examination.
47943987|NCT03956056|PROCEDURE|Blood for immune monitoring|-Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
48292458|NCT04832438|DRUG|9-ING-41|15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
48292459|NCT04832438|DRUG|Carboplatin|Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
48292460|NCT06021795|DEVICE|Sound Treatment|Customized sound audio track delivered via standard commercially available bone conduction headset
48292461|NCT03461289|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
47943988|NCT00666874|BEHAVIORAL|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
48292462|NCT05661136|DEVICE|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
48292463|NCT05661136|OTHER|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
48292464|NCT05101291|DRUG|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
48292465|NCT04950985|OTHER|Observational Study|Observational study
48475119|NCT03244982|DRUG|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
48475120|NCT02812771|DRUG|Efinaconazole|Solution
48475121|NCT00469053|DRUG|Buprenorphine|
48475122|NCT06189911|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
48475123|NCT02096822|BEHAVIORAL|Facilitated tucking + non-nutritive sucking|
48475124|NCT02096822|OTHER|non-nutritive sucking|
48475125|NCT00561171|DRUG|SPP635|oral once daily
48475126|NCT01469260|OTHER|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
48475127|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
48475128|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
48475129|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
48475130|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
47943989|NCT00666874|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
47943990|NCT01180166|DRUG|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
47943991|NCT06145607|DRUG|ABBV-CLS-7262|ABBV-CLS-7262
47943992|NCT02724150|DRUG|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
48475131|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
47943993|NCT02724150|DRUG|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
47943994|NCT04448054|OTHER|MRI|"Case 1: Routine care protocol not requiring injection~* Realization of the non-injected MRI protocol adapted to the indication~* + Addition of a 3D bFFE-Xd sequence (+ 2 min) The protocol will last the examination time usually provided by the current treatment according to the indication + 2 min of complementary sequence Case 2: Routine treatment protocol requiring an injection~* Realization of the injected MRI protocol adapted to the indication~* Before gadolinium injection:~* Addition of a 3D bFFE-Xd sequence (+ 2 min) before injection~* After gadolinium injection:~* Option 1: if olfaction disorder, addition of DCE perfusion sequence (T1-WI) which will be the 1st post injection sequence (+ 4 min 30)~* FABIR 0.9 3D sequence (+ 4 min)~* 3D sequence T1 TSE 0.7 (+ 2 min 30)~* FLAIR HR coronal sequence (+ 3 min 30)~* Option 2: if hearing / balance disorder, adding 3D FLAIR labyrinth sequence (+ 6min) which will be the 1st post injection sequence"
48475132|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
48475133|NCT06616974|DRUG|TX000045- Dose A|The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.
48475134|NCT06616974|DRUG|TX000045- Dose B|The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
48475135|NCT06616974|DRUG|Placebo|The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
48475136|NCT06449755|DIAGNOSTIC_TEST|Radiologic examination|Posoperative first week, month and third month On the x-ray of Hand AP view: metacarpal shortening On the x-ray of Hand 30 degree pronation view: dorsal angulation
48475137|NCT06449755|PROCEDURE|Grip Strength|Postoperative first month and third month grip streng compare with Cambry hand dinamometer.
47943995|NCT06157060|DIAGNOSTIC_TEST|circulating tumor DNA|blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
47943996|NCT02147028|RADIATION|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
47943997|NCT02147028|RADIATION|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
47943998|NCT05227144|DRUG|ORIC-533|ORIC-533 once daily in consecutive 28-day cycles
47943999|NCT01682668|PROCEDURE|Bilateral subthalamic stimulation|
47944000|NCT03732690|OTHER|Diet HP|"2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician."
47944001|NCT03732690|OTHER|Diet LP|2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
47944002|NCT05613803|DRUG|Fish oil|6g of EPA and DHA in a 1.3:1 ratio as six Omacor capsules manufactured by Provona Biocare (Olso Norway), or generic equivalent, taken once daily, or in divided doses, with food.
47944003|NCT05613803|OTHER|Placebo|Six capsules containing palm oil and soybean oil on an 8:2 ratio taken once daily, or in divided doses, with food.
47944004|NCT04860427|DEVICE|trapezoidal condylar plate|trapezoidal condylar plate open reduction and fixation
47944005|NCT04860427|DEVICE|two miniplates|two miniplates open reduction and fixation
47944006|NCT01024218|DEVICE|NovoFine® needle 8 mm|
47944007|NCT01024218|DEVICE|autocover needle|
47944008|NCT04622982|OTHER|Multidisciplinary treatment of obesity (diet + vitamin D + exercise + psychotherapy)|"Body weight reduction was induced by a low-energy mixed diet (55 % carbohydrates, 30 % lipids and 15 % proteins) providing 600 kcal less than individually estimated energy requirements based on the measured REE. The energy content and macronutrient composition of the diets adhered to the nutritional recommendations of the American Diabetes Association.~Patients were administered vitamin D supplement only if they presented a value of 25-hydroxyvitamin D (25OHD) \<30 ng/ml in blood tests at the beginning.~Patients were following an individualized physical activity plan within the hospital and were aided by a psychodynamic approach therapist."
47944009|NCT04761822|BIOLOGICAL|Moderna COVID-19 Vaccine|Intramuscular injection
47944010|NCT04761822|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|Intramuscular injection
48103337|NCT02082366|DEVICE|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
48103338|NCT02944955|DRUG|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
48103339|NCT06360042|DRUG|Adebrelimab plus Apatinib|Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
48103340|NCT06360042|DRUG|Adebrelimab plus Bevacizumab|Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
48103341|NCT06360042|DRUG|Camrelizumab plus Apatinib|camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
48475138|NCT06449755|OTHER|Quick DASH Questionnaire|Quick DASH is an 11-question questionnaire that assesses upper extremity functionality.
48475139|NCT04724499|BEHAVIORAL|High-Intensity Intervals Training|16 week exercise program with stationary bike.
48475140|NCT04724499|OTHER|Attention Control|16 week stretching program.
48475141|NCT02626208|DEVICE|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
48475142|NCT00147914|DRUG|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
48475143|NCT00147914|DRUG|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
48475144|NCT05794087|OTHER|Clean Air|Subjects will be exposed to clean air for 3 hours.
48475145|NCT05794087|OTHER|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
48475146|NCT00487929|DEVICE|nasal CPAP|Nocturnal
48475147|NCT00487929|DEVICE|Sham CPAP|Nocturnal
48475148|NCT05840276|DEVICE|Cryoneurolysis|The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
48632206|NCT04983498|DRUG|Ondansetron 4 MG|PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
47944011|NCT04761822|BIOLOGICAL|Placebo|Intramuscular injection
47944012|NCT01067976|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
47944013|NCT00614328|DRUG|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
47944014|NCT06045650|OTHER|baseline serum oxytocin levels|Both cases and controls will be assessed for their baseline serum oxytocin levels
48103342|NCT05731648|DEVICE|Intrathecal balofen pump|Management of spasticity
47944015|NCT06045650|OTHER|Emotional Sensitivity test|To assess the level of emotional sensitivity in the participant
47944016|NCT06045650|OTHER|Neuro-economical game|A game played to assess the trust-index of participants
47944017|NCT06045650|OTHER|Childhood Trauma Questionnaire|to assess childhood trauma score
47944018|NCT06045650|OTHER|Relationships Questionnaire|to assess attachment type
47944019|NCT06045650|OTHER|demographic questionnaire|To obtain basic data on demographics
47944020|NCT02935101|DRUG|Prednisolone|formulated for oral administration. encapsulated.
47944021|NCT02935101|DRUG|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
47944022|NCT03824171|DRUG|Raloxifene 60mg/Cholecalciferol 800IU|Raloxifene 60mg/Cholecalciferol 800IU tablet
47944023|NCT03824171|DRUG|AD-102|AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
47944024|NCT02922400|BEHAVIORAL|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
47944025|NCT05288413|DEVICE|3-compression Ultrasound scan with AutoDVT software integrated Ultrasound probe|The study coordinator, Miss Kerstin Saupe will perform a three-point compression ultrasound scan (USS) of the upper leg with the AutoDVT software. The AutoDVT software will store the results of the scan for retroperspective analysis and review. Effectiveness of AutoDVT as diagnostic tool will be evaluated in perspective to different patient groups, eg. patients with adipositas or maligner disease,
48103343|NCT00413868|PROCEDURE|LASIK|
48103344|NCT00413868|PROCEDURE|PRK|
48103345|NCT00413868|BEHAVIORAL|Small target contrast sensitivity and disability glare|
48103346|NCT02795650|DRUG|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
48103347|NCT02795650|DRUG|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
48103348|NCT01183533|DRUG|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
48103349|NCT05759585|BEHAVIORAL|person-centered lifestyle intervention|Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
48103350|NCT02499328|DRUG|AZD9150|AZD9150
48103351|NCT02499328|DRUG|MEDI4736|MEDI4736
48103352|NCT02499328|DRUG|AZD5069|AZD5069
48103353|NCT02499328|DRUG|tremelimumab (treme)|tremelimumab
48103354|NCT05507463|DRUG|KBP-7072|KBP-7072
48103355|NCT05507463|DRUG|Placebo|Placebo
48103356|NCT03593291|DIAGNOSTIC_TEST|Anti Xa|Levels of Anti Xa measure
47944026|NCT02910869|GENETIC|Pathway Genomics FIT test|
47944027|NCT05139082|DRUG|TQB3616 capsules＋ TQB2450 injection|"TQB3616 is a highly active CDK4/6 inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on the kinase activity of CDK4/6.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
47944028|NCT01368432|DRUG|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
47944029|NCT01368432|DRUG|Placebo|Sugar pill placebo
47944030|NCT05154201|DRUG|ORIN1001|Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
47944031|NCT03862716|DRUG|IDegLira|Dose is titrated to achieve fasting normoglycemia
48103357|NCT04565522|OTHER|Prospective observation|Prospective observation until one year follow-up
48103358|NCT05100329|DRUG|Mitoxantrone Hydrochloride Liposome injection|20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
48103359|NCT00151606|PROCEDURE|Reinforced isolation + Muciprocine|
48103360|NCT05098340|GENETIC|Quantitative Real-time polymerase chain reaction|Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).
48103361|NCT05425836|DEVICE|Standard oxygen therapy|nasal cannula
48103362|NCT05425836|DEVICE|HFNC|High flow nasal cannula
48292466|NCT02648815|PROCEDURE|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
48292467|NCT02648815|PROCEDURE|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
48292468|NCT03727711|OTHER|TPTNS|We will be comparing hospital treatment to TPTNS at home
48292469|NCT02509338|DEVICE|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
48292470|NCT05948878|DEVICE|Novel Taping Method|Subjects will be asked to have the novel taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
48292471|NCT05948878|DEVICE|BCH Emergency Department Taping Method|Subjects will be asked to have the BCH emergency department taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
48292472|NCT05948878|DEVICE|Chevron Taping Method|Subjects will be asked to have the Chevron taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
48292473|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
48292474|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
48103363|NCT02772653|OTHER|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
48292475|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
48292476|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
48292477|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
48292478|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
48292479|NCT01868269|DRUG|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
48292480|NCT01868269|DRUG|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
48292481|NCT01868269|DRUG|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
48292482|NCT01089725|BIOLOGICAL|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
48292483|NCT01089725|BIOLOGICAL|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
48292484|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
48292485|NCT01089725|BIOLOGICAL|Placebo IV|1 ml placebo administered IV every 8 weeks
48292486|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
48292487|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
48292488|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
48292489|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
48475149|NCT05840276|OTHER|Sham|A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
48475150|NCT04684680|DIETARY_SUPPLEMENT|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
48103364|NCT02772653|OTHER|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
48103365|NCT02772653|OTHER|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
48103366|NCT02772653|OTHER|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
48103367|NCT02772653|OTHER|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
48103368|NCT02772653|OTHER|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
48292490|NCT01089725|BIOLOGICAL|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
48292491|NCT01089725|BIOLOGICAL|Placebo SC|1ml placebo administered SC every 8 weeks
48292492|NCT05690633|DEVICE|Pulse oximetry|Noninvasive method of measuring the saturation of oxygen in the blood.
48632207|NCT04983498|DRUG|Lactated Ringers, Intravenous|Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
48475151|NCT04684680|DIETARY_SUPPLEMENT|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
48475152|NCT03039036|PROCEDURE|Amniotomy|Artificially rupturing membranes
48475153|NCT03039036|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
48475154|NCT03039036|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
48475155|NCT01853371|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
48475156|NCT01853371|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
48475157|NCT02389842|DRUG|Palbociclib + Taselisib / Pictilisib|
48475158|NCT06596499|DEVICE|CH-VAD|The CH-VAD pump is a fully magnetically levitated (maglev), centrifugal continuous-flow blood pump.
47944032|NCT03862716|DRUG|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
47944033|NCT03862716|DRUG|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
48475159|NCT00754494|DRUG|erlotinib hydrochloride|Given PO
48475160|NCT00754494|OTHER|placebo|Given PO
48475161|NCT00754494|OTHER|laboratory biomarker analysis|Correlative studies
48475162|NCT05753813|DRUG|Phexxi|intravaginal gel twice weekly for 4 weeks.
48475163|NCT06614751|DRUG|DAT-2645 tablet|The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
48475164|NCT06614751|DRUG|DAT-2645 tablet|The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
48475165|NCT02124473|OTHER|Homeopathy|
48475166|NCT02124473|OTHER|Placebo|
48475167|NCT04916613|DRUG|Darolutamide 300 mg|600 mg po, b.i.d.
48475168|NCT04916613|DRUG|Placebo|po, b.i.d.
48475169|NCT04916613|DRUG|Androgen deprivation therapy|Use according to local standard of care
48475170|NCT04779034|OTHER|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
48475171|NCT05708482|OTHER|Sling-Swing Position|The device is hammock which look likes a rope
48475172|NCT05527158|BEHAVIORAL|Yi Jin Jing exercise|Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
48475173|NCT04546269|PROCEDURE|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
48475174|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 100 mg
48475175|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 50 mg
48475176|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
48475177|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg
48475178|NCT00401245|DRUG|Placebo|Tapering placebo
48475179|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
48475180|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
48475181|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
48475182|NCT05080608|OTHER|Surgery|Treatment according to clinical practise
48475183|NCT06427369|OTHER|Radioconjugate|1241-hJAA-F11 IV administration
48475184|NCT06427369|PROCEDURE|Positron Emission Tomography|PET/CT Imaging
48475185|NCT06427369|PROCEDURE|Computed Tomography|PET/CT Imaging
48632208|NCT04983498|OTHER|Early Mobilization|Patient transferred up to the chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters and patient safety.
48632209|NCT04983498|OTHER|Early PO Intake|Patient will be offered PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters and patient safety.
48632210|NCT05476718|OTHER|Kinesio taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
48632211|NCT05476718|OTHER|placebo taping|Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
48475186|NCT06427369|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|FDG PET/CT Imaging
48475187|NCT06427369|PROCEDURE|Biospecimen Collection|Blood sample collection imaging
48475188|NCT00985231|DEVICE|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
48103369|NCT05738226|DEVICE|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
48475189|NCT00985231|DEVICE|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
48475190|NCT04906837|DIAGNOSTIC_TEST|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
48475191|NCT03263078|DRUG|Propofol|For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1
48475192|NCT03263078|DRUG|Sevoflurane|Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
48475193|NCT01301482|DEVICE|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
48475194|NCT03868826|PROCEDURE|Orthopaedic surgery and/or rehabilitation|The avulsion is repaired and hereafter the patient follows rehabilitation. Some are treated conservatively and only follow rehabilitation.
48475195|NCT03191838|OTHER|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
48620012|NCT04081181|PROCEDURE|Microwave ablation|CT_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
48103370|NCT03921684|DRUG|Capecitabine|Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
48103371|NCT03921684|RADIATION|Radiation therapy|1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine
48103372|NCT03921684|DRUG|mFOLFOX6|oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
48103373|NCT03921684|DRUG|Nivolumab|Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
47944034|NCT03862716|BEHAVIORAL|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
48475196|NCT06176755|OTHER|Treadmill training with weighted ankle cuffs|"Group A: Treadmill training and Ankle cuff.~Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently."
48475197|NCT06176755|OTHER|Treadmill training|Treadmill training only
48475198|NCT01177163|DRUG|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
48475199|NCT01177163|DRUG|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
48475200|NCT01177163|DRUG|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
48475201|NCT02405572|OTHER|infant formula|infant formulas
48475202|NCT00819767|DRUG|Aliskiren|Aliskiren was supplied in 150 mg tablets.
48475203|NCT00819767|DRUG|Valsartan|Valsartan was supplied in 160 mg capsules.
48475204|NCT00819767|DRUG|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
48475205|NCT00819767|DRUG|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
48475206|NCT05254158|DRUG|NNC0174 0833|Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
48475207|NCT02241109|OTHER|no intervention|progression monitoring by echocardiography
48475208|NCT00062101|DRUG|erlotinib hydrochloride|Given orally (PO)
48475209|NCT00062101|DRUG|celecoxib|Given PO
48475210|NCT00062101|OTHER|laboratory biomarker analysis|Correlative studies
48475211|NCT01816568|PROCEDURE|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
47944035|NCT01242683|BEHAVIORAL|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
47944036|NCT00954304|DRUG|HM30181AK 1mg|HM30181AK 1mg tablet
48475212|NCT01816568|PROCEDURE|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
48475213|NCT03134430|OTHER|Normal saline|Injection of Normal saline around peripheral nerve
48475214|NCT03134430|OTHER|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
48475215|NCT02784171|DRUG|Cisplatin|
48475216|NCT02784171|DRUG|Pemetrexed|
48475217|NCT02784171|DRUG|Pembrolizumab|
48475218|NCT06097702|DRUG|BX-001N Part 1|Dosage form- IV bolus Dosage- In the five cohorts, each participant receives a single IV bolus administration in one of the five doses based on body weight and followed up for 7 days.
48475219|NCT06097702|DRUG|BX-001N Part 2|Dosage form- IV bolus Dosage- In the three cohorts, each participant receives a single IV bolus administration for 7 sequential days in one of the three doses based on body weight and followed up for 14 days.
48475220|NCT06097702|DRUG|Placebo|Participants will receive matching placebo across Part 1 and 2 of the study.
48475221|NCT03767699|BEHAVIORAL|Medical Nutrition Therapy|MNT was offered every 2-4 weeks to all pregnant women with T2DM and GDM. Women. MNT is offered as a mandatory part of their prenatal visit and/or hospital stay. The MNT provides an individual food plan with the following recommendations: total calories should be calculated as 30 kcal/kg based on pregestational BMI for an ideal weight. Of the total energy intake 40-45% is provided by carbohydrates, a maximum of 40% is provided by lipids and the remaining percentage by proteins providing moderate-to-low glycemic index foods and fiber consumption, glucose self-monitoring, participating in 15-30 min of daily physical activity after prior authorization of the treating physician, and meeting the minimal energy requirements of pregnancy (never \< 1,500 kcal).
48475222|NCT05103709|OTHER|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
48475223|NCT05103709|OTHER|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
48475224|NCT06004180|DRUG|Lu AF28996|Hard capsule, orally, per schedule specified in the arm description.
48475225|NCT05091216|OTHER|Traditional Chinese Medicine mouthwash|The mouthwash used in this test is based on the records of past traditional Chinese medicine classics and the existing antibacterial experimental evidence. The selected medicinal materials are honeysuckle, scutellaria, peppermint, licorice, and rhizome.
48475226|NCT05091216|OTHER|Dilute 50 times of Traditional Chinese Medicine mouthwash|Dilute 50 times of traditional Chinese medicine mouthwash.
48632212|NCT03896360|BEHAVIORAL|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
47944037|NCT00954304|DRUG|HM30181AK 5mg|HM30181AK 5mg tablet
47944038|NCT00954304|DRUG|HM30181AK 15mg|HM30181AK 15mg tablet
47944039|NCT00954304|DRUG|HM30181AK 60mg|HM30181AK 60mg tablet
48475227|NCT04239495|OTHER|Observational study: range of clinical and lifestyle factors|Medical conditions and medications. Educational and occupational history. Lifestyle exposures, assessed using reduced Food Frequency Questionnaire, Rapid Assessment of Physical Activity questionnaire and objectively-measured physical activity levels over 7 days using a GeneActiv wrist-worn accelerometer (Activinsights, Cambridge, UK).
48475228|NCT04556578|PROCEDURE|High-flow extracorporeal CO2 removal|Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.
48475229|NCT03225014|DEVICE|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
48475230|NCT03225014|DIAGNOSTIC_TEST|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
48475231|NCT05305131|DRUG|cisplatin and gemcitabine|Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
48475232|NCT05305131|DRUG|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.|Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
48475233|NCT03670732|OTHER|continuous positive airway pressure|Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
48475234|NCT03670732|OTHER|nasal intermittent positive pressure ventilation|NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
48475235|NCT01035476|BEHAVIORAL|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
48475236|NCT05607563|DRUG|PM1009 injection|Participants receive PM1009 intravenously, every 2 weeks
48475237|NCT03082235|DRUG|E6742|gelatin capsules
48475238|NCT03082235|DRUG|Placebo|gelatin capsules
48475239|NCT00019734|BIOLOGICAL|aldesleukin|
48475240|NCT00019734|BIOLOGICAL|fowlpox virus vaccine vector|
48475241|NCT00019734|BIOLOGICAL|vaccinia-tyrosinase vaccine|
48475242|NCT00810628|BEHAVIORAL|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
48475243|NCT01363011|DRUG|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
48475244|NCT01363011|DRUG|COBI|COBI 150 mg tablet administered with food orally once daily
48475245|NCT01363011|DRUG|ATV|ATV 300 mg tablet administered orally once daily
48475246|NCT01363011|DRUG|DRV|DRV 800 mg tablet administered orally once daily
48475247|NCT01363011|DRUG|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
48475248|NCT02294448|DRUG|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
48475249|NCT03290313|DRUG|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
48475250|NCT03290313|DRUG|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
48475251|NCT03290313|OTHER|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
47944040|NCT00954304|DRUG|Loperamide 2mg|Loperamide 2mg capsule
47944041|NCT03775291|DIAGNOSTIC_TEST|Simultaneous assessment of sleep apnea by polysomnogram and wearable device|Characterization of sleep apnea by lab-based polysomnogram
47944042|NCT06428682|DRUG|Tranexamic acid|Experimental group will receive TXA intraoperatively (15mg/kg IV, once at beginning of case then re dose at 4hrs if operation goes longer) at the time of their surgery.
47944043|NCT06428682|DRUG|Placebo|Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
47944044|NCT04545554|DRUG|Romosozumab|Participants will receive multiple doses of romosozumab via a SC injection.
47944045|NCT04545554|DIETARY_SUPPLEMENT|Calcium|All participants will receive daily supplements of elemental calcium.
47944046|NCT04545554|DIETARY_SUPPLEMENT|Vitamin D|All participants will receive daily supplementation with vitamin D.
47944047|NCT01176331|PROCEDURE|20 and 23 gauge pars plana vitrectomy|
47944048|NCT06403670|DRUG|Dexmedetomidine|Group DP received 0.5 mcg/kg of dexmedetomidine IV for 30 seconds, then dexmedetomidine infusion was started at 0.1-0.7 mcg/kg/h. Propofol 1 mg/kg was administered after waiting for 5 minutes for adequate sedation to develop due to dexmedetomidine's delayed onset of action.
47944049|NCT06403670|DRUG|Remifentanil|Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
47944050|NCT02438657|PROCEDURE|median nerve block|
48103374|NCT01934829|DRUG|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
48475252|NCT01694082|BEHAVIORAL|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
48475253|NCT01694082|BEHAVIORAL|Brief brochure and assessment control|
48475254|NCT06535802|OTHER|Non-Interventional Study|Non-interventional study
48475255|NCT03645499|DRUG|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
48475256|NCT03645499|DRUG|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
48475257|NCT03645499|DRUG|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
48475258|NCT03645499|DRUG|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
48475259|NCT03645499|DRUG|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
48475260|NCT04622046|DRUG|ALXN2060|ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
48475261|NCT01269476|DRUG|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
48475262|NCT01269476|DRUG|Placebo|Same volumes and frequency as active.
48475263|NCT01529931|DEVICE|Hair2Go|Hair2Go treatment once a month for 6 months
48475264|NCT06617039|DRUG|Remifentanil and ciprofol|R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
48475265|NCT06617039|DRUG|esketamine 0.3mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.
48475266|NCT06617039|DRUG|esketamine 0.5mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.
48475267|NCT06617039|DRUG|Ciprofol|Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
48475268|NCT06616220|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
48475269|NCT06616220|DRUG|0.9%NaCl|0.9% NaCl
48475270|NCT03399006|DEVICE|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects
48632213|NCT03896360|BEHAVIORAL|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
47944051|NCT02439879|DRUG|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased \>3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
47944052|NCT02853344|BIOLOGICAL|Pembrolizumab|IV infusion
47944053|NCT06421051|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation
47944054|NCT01385007|BEHAVIORAL|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
47944055|NCT02504710|DEVICE|Kinematic Real Time Feedback|
48103375|NCT01363362|PROCEDURE|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
48620013|NCT00892255|DEVICE|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
48632214|NCT00120250|DRUG|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
48292493|NCT03925844|OTHER|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
48632215|NCT01242046|DIETARY_SUPPLEMENT|Caffeine|400 mg of caffeine in tablet form
48632216|NCT01242046|DIETARY_SUPPLEMENT|Placebo|Inert tablet
48632217|NCT01115621|OTHER|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
48632218|NCT05907499|DRUG|Decitabine|Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
48632219|NCT05907499|DRUG|Granulocyte Colony-Stimulating Factor|5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
48475271|NCT03399006|DEVICE|Doppler Ultrasound|"measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
48475272|NCT03399006|DEVICE|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
48620014|NCT06105437|OTHER|BE-EMPOWERed program|The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
48632220|NCT05907499|DRUG|Thrombopoietin Receptor Agonist|Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
48632221|NCT05907499|DRUG|Recombinant human erythropoietin|10000 U/day when hemoglobin ≤ 85 g/L
48632222|NCT03581747|DEVICE|Nevisense|Measurement of electrical impedance
48632223|NCT04767412|DEVICE|aerobic exercise training, inspiratory muscle training|All participants received 30 min of aerobic exercise training thrice per week for a period of 12 weeks, whereas the group B received an additional 30 min of IMT before each aerobic exercise session.
48632224|NCT00558493|DRUG|Clevudine|clevudine 30 mg qd for 24 seeks
48632225|NCT05683080|OTHER|Routine Clinical Care|Participants completing the research study will receive routine clinical care
48103376|NCT04905316|DRUG|Canakinumab|Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Intravenous Canakinumab (ACZ885) should start no sooner than 3 weeks after the last subcutaneous Canakinumab (ACZ885) injection. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
47944056|NCT02504710|OTHER|Traditional systems of manual therapy teaching|
47944057|NCT02684487|DRUG|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
47944058|NCT02684487|DRUG|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
47944059|NCT03324529|DEVICE|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (\<10 breaths/min) with prolonged exhalation.
47944060|NCT01842815|DEVICE|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
47944061|NCT01655680|DRUG|ABT-126|ABT-126 Middle Dose
47944062|NCT01655680|DRUG|ABT-126|ABT-126 Low Dose
47944063|NCT01655680|DRUG|ABT-126|ABT-126 High Dose
47944064|NCT01655680|DRUG|Placebo|Placebo
48632226|NCT03400553|DIAGNOSTIC_TEST|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
48632227|NCT02391584|DEVICE|XprESS|Balloon dilation of the Eustachian tube
47944065|NCT00486174|DRUG|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
47944066|NCT05598047|BEHAVIORAL|Executive Functioning Training|Those in the Executive Functioning Training Group will engage in exercises requiring one to set shift; that is, to maintain at least two sets of rules and decide which is appropriate to determine the response. In using these training exercises in the TOPS study, the effects size was quite large (d=-0.89). Dosage of 20 hours of training is considered an upper range on how much training is needed to produce an optimal therapeutic effect.
47944067|NCT04426201|DRUG|CYT107|IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
47944068|NCT04426201|DRUG|Placebo|Same number, volume and frequency of IM administration of saline
48475273|NCT06616467|BEHAVIORAL|Tummy Time for the prevention of childhood obesity|"A cognitive-behavioral intervention aimed at mothers of infants is presented that aims to increase the practice of TT and maintain a healthy weight in the infant, called \&#34;Tummy Time for the prevention of childhood obesity\&#34;, within the intervention modifiable variables are involved that directly impact the expected results such as: the knowledge and beliefs of the mothers, infant temperament, parental self-efficacy and self-efficacy for the practice of TT.~The intervention lasts 12 weeks from the first contact with the participants and consists of eight sessions broken down as follows: the first session is presented in a face-to-face format with expository, audiovisual and demonstrative means; sessions two, four, five and seven are provided through a text message with use WhatsApp® and the use of visual media. Sessions three, six and eight are delivered via telephone call with the aim of offering feedback on the doubts generated up to that point."
48475274|NCT03695055|DRUG|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
48632228|NCT02391584|OTHER|Control|Continued medical management
48632229|NCT05509374|DRUG|Carfilzomib 56 MG [Kyprolis]|Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
48632230|NCT05509374|DRUG|Pomalidomide|Pomalidomide 4 mg per os (Day1-21)
47944069|NCT06131723|BEHAVIORAL|Behaviorally informed tickler email|The email notification from patients' PCP office will inform patients that a new review of their records shows they are due for an important medical exam. This intervention harnesses behavioral principles related to importance (medical exam described as important), personalization (records described as belonging to participants), urgency (participants are asked to sign in and make the recommended appointment as soon as possible), timeliness (participants are told that there has been a new review of their records), source effects and accountability (participants are told that a message from their PCP's office is waiting for their response). To make it easier for patients to find and review the MAP letter, the email also contains a link that directs patients to the MAP letter on their patient portal.
47944070|NCT05346250|BEHAVIORAL|Non-exercise control|12 month lifestyle education
47944071|NCT05346250|BEHAVIORAL|Moderate intensity exercise|12 month moderate intensity exercise by brisk walk 30 min per day and more than 5 days per week.
47944072|NCT05346250|BEHAVIORAL|Vigorous intensity exercise|6 month vigorous intensity exercise on treadmill for 30 min per day and more than 5 days per week, and subsequent 6 month moderate exercise by brisk walk 30 min per day and more than 5 days per week.
47944073|NCT00537784|BIOLOGICAL|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
47944074|NCT00537784|BIOLOGICAL|no injection|
47944075|NCT02577562|DEVICE|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
48103377|NCT04905316|DRUG|Durvalumab|Patients will be treated with durvalumab either at a dose of 10mg per kilogram of body weight intravenously every 2 weeks or at a 1500 mg fixed dose administered every 4 weeks as consolidation therapy after completion of concurrent chemoradiation therapy, as per standard of care.
48103378|NCT04905316|RADIATION|Radiation therapy|Radiation therapy will be performed with external beam ionizing radiation as per standard of care in accordance with institutional practice. Intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist. Patients will be simulated in the treatment position with standard immobilization techniques for thoracic radiotherapy. The prescription dose will be 60 Gy (±10%) in 2Gy fractions to fields encompassing gross tumor and lymph nodes, as per institutional guidelines. The dose must satisfy institutional guidelines and minimize risk to adjacent organs at risk.
48103379|NCT04905316|DRUG|Chemotherapy|Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
48103380|NCT04604054|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
48103381|NCT04604054|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
48103382|NCT05513300|OTHER|Exercise intervention|12 weeks of exercise training, 3 times per week, \~1h long
48292494|NCT00652093|DRUG|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
48632231|NCT05509374|DRUG|Dexamethasone|Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
48632232|NCT01291875|PROCEDURE|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
48632233|NCT01291875|PROCEDURE|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
48475275|NCT05291351|OTHER|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
48475276|NCT05291351|OTHER|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
48475277|NCT05291351|OTHER|Porridge made with oat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
48475278|NCT03319069|RADIATION|Hypofractionated radiotherapy|"Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~."
48475279|NCT03319069|RADIATION|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
48475280|NCT05435976|DEVICE|CELLIS Dental (Porcine Acellular Dermal Matrix, PADM)|Biological membranes used in dental surgery
48475281|NCT00628979|BEHAVIORAL|CBT|cognitive- behavioral treatment for panic disorder.
48475282|NCT04703517|DIAGNOSTIC_TEST|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
48475283|NCT04157972|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
48475284|NCT04157972|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
48475285|NCT00658957|DRUG|gentamicin-collagen sponge|5 × 5 cm sponge
48475286|NCT00658957|DRUG|placebo collagen sponge|5 × 5 cm sponge
48475287|NCT03634059|DRUG|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
48475288|NCT02238132|DRUG|ATROVENT® inhalets|
48632234|NCT01856660|BEHAVIORAL|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to \> 40 min per day, 5 times/week.
48475289|NCT05990231|DRUG|Cadonilimab combined Anlotinib|Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
48475290|NCT03497819|BIOLOGICAL|CARTmeso CART19|Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
48475291|NCT05505305|BEHAVIORAL|Time-restricted eating and high-intensity interval training|Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
48475292|NCT04258280|BEHAVIORAL|Education and counseling|Education includes a workbook, counseling includes peer support.
48475293|NCT04258280|BEHAVIORAL|Education|Education includes a workbook.
48475294|NCT05197777|DEVICE|tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated functional task from an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. Elbow angles will be adjusted in a static position with a manual goniometer (60 degrees). The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes, undergoing repetitive movements. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat. The TCT - tDCS Stimulator Kit Research version, with 35 cm2 on M1 of the contralateral hemisphere for the rigth dominant hand. During the first 30 s of active tDCS, an initial period of ''ramping up'' is administered, in which the stimulator reaches the maximum programmed current (2 mA) to mimic cutaneous perceptions. A 2 mA intensity will be maintained during activity.
48475295|NCT05197777|OTHER|Conservative physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
48475296|NCT02969876|DRUG|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
48292495|NCT00652093|DRUG|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
48292496|NCT00652093|DRUG|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
48292497|NCT00652093|DRUG|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
48292498|NCT00652093|DRUG|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
47944076|NCT05262725|BEHAVIORAL|Values-based Behavioral Activation|Initially, patients complete a values assessment in which they identify personal values in various life domains. With the assistance of a clinician, patients set incremental behavior goals to move their daily actions to better align with their self-reported values. Goal completion allows the patient to achieve outcomes consistent with recovery, and they potentially experience enjoyment, self-efficacy, and confidence as they progress through the treatment.
48292499|NCT00652093|DRUG|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
48292500|NCT00537745|DRUG|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
48292501|NCT00537745|OTHER|Medication Management Therapy|Medication Management Therapy once a month.
48292502|NCT03921892|BEHAVIORAL|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
48292503|NCT06296810|DEVICE|aDBS|adaptive deep brain stimulation
48292504|NCT04967430|DRUG|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
48292505|NCT04967430|OTHER|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
48292506|NCT01645280|DRUG|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
48292507|NCT01645280|DRUG|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
48292508|NCT01645280|DRUG|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
48292509|NCT01645280|DRUG|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
48292510|NCT01645280|DRUG|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
48292511|NCT01738139|DRUG|Imatinib Mesylate|Given PO
48475297|NCT05968963|BEHAVIORAL|Mindfulness-based Music Therapy (MBMT)|Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
47944077|NCT03118973|PROCEDURE|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
48292512|NCT01738139|BIOLOGICAL|Ipilimumab|Given IV
48475298|NCT05968963|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.
48475299|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
48475300|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
48475301|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
48475302|NCT00328484|BEHAVIORAL|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
48475303|NCT00328484|BEHAVIORAL|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
48475304|NCT01015924|PROCEDURE|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
48475305|NCT01015924|PROCEDURE|ESIN|Elastiv stable intramedullary nailing
47944078|NCT05617443|DEVICE|stackable guide|different types of stackable guide
47944079|NCT01359007|DRUG|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
47944080|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
47944081|NCT00859183|DRUG|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
47944082|NCT00859183|DRUG|Placebo|Placebo oral
47944083|NCT02297243|DEVICE|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
48475306|NCT04108962|DRUG|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
48475307|NCT06535490|PROCEDURE|EUS-FNA|Puncture of pancreatic cystic lesion with a fine needle under EUS guidance
47944084|NCT03439943|DRUG|Lixisenatide|Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
47944085|NCT03439943|DRUG|placebo|Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
47944086|NCT01423149|DRUG|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
47944087|NCT02634281|DRUG|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
47944088|NCT02634281|DRUG|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
47944089|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
47944090|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
47944091|NCT00969813|DRUG|CP-690,550|Single 10 mg dose of CP-690,550
47944092|NCT04274283|OTHER|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
48292513|NCT01620996|BEHAVIORAL|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
48475308|NCT06535490|DRUG|ATBp|Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit
48475309|NCT06616324|DEVICE|Virtual Reality|Participants in the intervention group will undergo ESWL according to standard treatment but with the addition of Virtual Reality and ANC-headphones as a supplement.
48475310|NCT01230645|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
48475311|NCT01230645|DRUG|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
48475312|NCT02973581|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
48475313|NCT02973581|DRUG|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
48632235|NCT01856660|BEHAVIORAL|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
48292514|NCT01620996|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
48292515|NCT01620996|BEHAVIORAL|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
48292516|NCT04713345|OTHER|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
48292517|NCT04713345|OTHER|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
48292518|NCT04079777|DRUG|Clinical treatment|Liquid Resuscitation, Anti-infection
48292519|NCT00233636|DRUG|Iressa (Gefitinib)|
48292520|NCT00233636|PROCEDURE|Radiotherapy|
48292521|NCT04560101|DRUG|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
48292522|NCT02502422|DEVICE|Classic laryngeal mask airway|"1. measurement of head and neck~   * Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip\~sternal notch), modified mallampati classification under sitting position, thyromental distance.~2. laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~   * # 4.0 for female, #5.0 for male~  * initial cuff volume(air) : maximum volume recommended by the manufacturer~  * check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~  * remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
48292523|NCT03032887|BEHAVIORAL|voice prompts|voice prompts on disinfectant dispenser
48292524|NCT03032887|BEHAVIORAL|agitation|Education, reminders and optimising materials
48292525|NCT03670173|DRUG|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
48292526|NCT03953638|DIAGNOSTIC_TEST|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
48292527|NCT02167555|DIETARY_SUPPLEMENT|Active Comparator|Wild Blueberry Beverage
47944093|NCT04274283|OTHER|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
48292528|NCT02167555|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Beverage
48292529|NCT06104904|BEHAVIORAL|MAPP|Behavioral intervention based on exposure therapy strategies.
48292530|NCT02467114|DEVICE|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
48292531|NCT02467114|DEVICE|Sham coil stimulation|Stimulation with a sham coil as a comparison
48292532|NCT02467114|OTHER|Control without stimulation|
48292533|NCT04442620|OTHER|Physical activity and Mediterranean Diet (PA-MD)|Physical Activity plus caloric restricted Mediterranean diet
48292534|NCT04442620|OTHER|High meal frequency of Mediterranean Diet (HMF-MD)|High meal frequency of unaltered Mediterranean diet
48292535|NCT04442620|OTHER|Control diet (CD)|Control Diet
48292536|NCT05347732|DIAGNOSTIC_TEST|Successfull thrombolysis|Biomarker levels will be compared between patients with successful and failed thrombolysis.
48292537|NCT02887846|DEVICE|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH\> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.
47944094|NCT02291744|PROCEDURE|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
47944095|NCT02291744|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
47944096|NCT03242538|BEHAVIORAL|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
47944097|NCT00089856|BIOLOGICAL|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
48632236|NCT00612768|BIOLOGICAL|TRUE Test allergens Fragrance Mix and Thimerosol|"* Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~* Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~* Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~* Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
48292538|NCT00922545|OTHER|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
48292539|NCT00784069|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
48292540|NCT01986205|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen (USP oxygen \>99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
48292541|NCT01986205|COMBINATION_PRODUCT|Minimal pressure air|Room air delivered in a hyperbaric chamber with minimal pressurization.
48292542|NCT00990015|DRUG|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
48292543|NCT00990015|DRUG|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
48292544|NCT04859127|OTHER|effects of neck pain|Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
48292545|NCT03450772|DRUG|Creon® 25000|Experimental drug
48292546|NCT03450772|DRUG|Creon® 10000|Active comparator
48292547|NCT05197101|PROCEDURE|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
48292548|NCT04792996|OTHER|No intervention|No intervention. case - control design.
48292549|NCT01904461|DEVICE|Vacuum device|
48632237|NCT03920020|OTHER|the concentric isokinetic exercise group|concentric isokinetic exercises
48632238|NCT03920020|OTHER|the eccentric isokinetic exercise group|eccentric isokinetic exercises
48632239|NCT03920020|OTHER|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
48632240|NCT03666793|OTHER|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
48632241|NCT06289881|DRUG|Sildenafill-Test product|Test-Product: Sildenafil 100 mg tablets Manufactured by: Actigen Co., Ltd., Thailand
48292550|NCT01904461|PROCEDURE|Conventional surgery|
48292551|NCT06205134|DRUG|A: Epinephrine injection|Autoinjector for intramuscular, single-use, 0.3mg
48292552|NCT06205134|DRUG|B: FMXIN002 3.6mg|Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
48292553|NCT06205134|DRUG|C: FMXIN002 4.0mg|Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
48292554|NCT02236585|PROCEDURE|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
48292555|NCT02236585|PROCEDURE|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
48632242|NCT06289881|DRUG|Sildenafill-Reference product|Reference-product: Viagra 100 mg tablets Manufactured by: FAREVA AMBOISE, France
48632243|NCT03808909|OTHER|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
48292556|NCT03088241|OTHER|switch|switch to second-line ART
48292557|NCT03004014|OTHER|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
48292558|NCT01717846|DRUG|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
48292559|NCT01717846|OTHER|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
48632244|NCT04656548|DEVICE|HydroPICC|PICC lines
47944098|NCT00089856|DRUG|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
48292560|NCT04246229|DIAGNOSTIC_TEST|Transcutaneous bilirubinometry|use of transcutaneous bilirubinometry a non-invasieve measurement of skin bilirubin levels
48292561|NCT04246229|DIAGNOSTIC_TEST|Serum bilirubin|use of blood draws to measure serum bilirubin level
48292562|NCT02359123|OTHER|Cannabics capsules|Cannabis extract in an oil formulation
48292563|NCT02017249|DRUG|arginine in powder form|
47944099|NCT00136071|DEVICE|Transobturator tape-ARIS|
47944100|NCT00136071|DEVICE|TVT-O|
47944101|NCT05497518|OTHER|Observational study - registry|The Network is a longitudinal observational cohort study that collaborates with health systems to obtain both electronic healthcare records (EHR) and patient-entered data. Eligible people with a diagnosis of chronic kidney disease at any stage, age 18 years and above, are identified through EHR data review, referral by a provider, or are recruited through the NKF's outreach campaign. Patients self-enroll into the online registry and share their experiences and health data through a secure portal where they can also find education, tips, and support. Research partners can view aggregate data through a collaboration portal.
47944102|NCT02350673|DRUG|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
47944103|NCT02350673|DRUG|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
47944104|NCT00622973|OTHER|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
47944105|NCT00622973|OTHER|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
47944106|NCT05093348|DEVICE|Click2Print artificial eye|Digitally designed and manufactured ocular prosthesis
47944107|NCT05093348|DEVICE|Hand-made artificial eye|Hand-made artificial eye
47944108|NCT02853851|OTHER|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
47944109|NCT03084510|DEVICE|Lotus Edge™ Valve System|"• The Lotus Edge™ Valve System consisting of two main components:~* a bioprosthetic bovine pericardial aortic valve, and~* a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter."
47944110|NCT01046370|BEHAVIORAL|Amygdala Retraining Program|Mind-body intervention.
47944111|NCT02824965|DRUG|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
48292564|NCT02017249|DRUG|Silica and cellulose placebo powder|
48292565|NCT06511414|DEVICE|duramesh|Duramesh™ non-absorbable polypropylene suture is a hollow core, microporous, cylindrical suture made off in polypropylene filaments that are loosely braided and bonded to each other with heat and pressure
48292566|NCT06511414|DEVICE|Control|standard closure of fascia
48292567|NCT05217862|DIAGNOSTIC_TEST|PCR for COVID-19 testing|PCR for asymptomatic adult undergoing elective cataract surgery
48292568|NCT02439762|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
48292569|NCT02439762|BEHAVIORAL|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
48292570|NCT03412227|BEHAVIORAL|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
47944112|NCT02824965|BIOLOGICAL|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
47944113|NCT03422627|DRUG|Efavaleukin Alfa|"Phase 1: This study will be conducted as a multiple ascending dose (MAD) study. Each dosing cohort will consist of between 3 and 6 subjects who will receive efavaleukin alfa subcutaneously (SC) either every week or every 2 weeks plus protocol permitted background therapy for 52 weeks. At the discretion of the Sponsor, following discussion and agreement between the principal investigator and medical monitor, subjects responding to efavaleukin alfa (as assessed by the end of week 50), who wish to continue treatment, may continue to receive efavaleukin alfa treatment at their current dosing regimen for up to an additional 208 weeks through an extended dosing period. All subjects who continue to receive efavaleukin alfa during the extended dosing period will be reevaluated every 6 months for their response to treatment.~Phase 2: All subjects will receive the recommended phase 2 dose (RP2D) of efavaleukin alfa for 52 weeks."
48292571|NCT03412227|BEHAVIORAL|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, \& Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, \& LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b).
48292572|NCT03412227|BEHAVIORAL|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall \& Hedtke, 2006; Kendall, Choudhury, Hudson, \& Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
47944114|NCT00455767|DRUG|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
48292573|NCT03412227|OTHER|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
48292574|NCT03177577|DEVICE|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
48292575|NCT03177577|DEVICE|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
48292576|NCT02606773|DRUG|Ascorbic Acid|Ascorbic acid in different ways and doses
48292577|NCT04373369|DRUG|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
48292578|NCT04373369|DRUG|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
48292579|NCT02322307|OTHER|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
48292580|NCT02322307|OTHER|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
48475314|NCT02973581|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
48475315|NCT02973581|DRUG|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
48632245|NCT01306994|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
47944115|NCT00455767|DRUG|Placebo|Placebo
48292581|NCT04044638|OTHER|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).
48292582|NCT01251575|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
48292583|NCT01251575|DRUG|Cyclosporine|Given PO or IV
48292584|NCT01251575|DRUG|Fludarabine Phosphate|Given IV
48292585|NCT01251575|OTHER|Laboratory Biomarker Analysis|Correlative studies
48292586|NCT01251575|DRUG|Mycophenolate Mofetil|Given PO
48292587|NCT01251575|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
48292588|NCT01251575|DRUG|Sirolimus|Given PO
48292589|NCT01251575|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
48292590|NCT01441544|BEHAVIORAL|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
48292591|NCT06207877|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
48292592|NCT06207877|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
48475316|NCT04372784|DEVICE|Cryotherapy|Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture
48475317|NCT04372784|PROCEDURE|Esophagogastroduodenoscopy with Balloon Dilatation|This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
48475318|NCT03689894|DRUG|Ibrutinib|"Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events \>Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events \>Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily."
47944116|NCT01977651|DRUG|Enzalutamide|Participants received 4 capsules (40 mg each) of enzalutamide orally once a day, for a total daily dose of 160 mg. Treatment was given with or without food and as close as possible to the same time each day.
47944117|NCT00187759|DRUG|cephalexin|
48292593|NCT06207877|DRUG|Placebo|Placebo will be administered subcutaneously.
48292594|NCT01011062|PROCEDURE|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
48292595|NCT01011062|DRUG|Losartan|Acute administration of losartan 200mg total prior to clamp
48292596|NCT01011062|DRUG|Saline|Infusion of Saline as a volume control intervention
48292597|NCT04125823|BEHAVIORAL|Video game-based physical activity training|"Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
48292598|NCT04125823|BEHAVIORAL|Conventional physiotherapy program|"A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
48292599|NCT05065138|BEHAVIORAL|Standardized training on Helicobacter pylori eradication treatment|Standardized training on Helicobacter pylori eradication treatment
48292600|NCT02760602|DRUG|Solanezumab|Administered IV
48292601|NCT02760602|DRUG|Placebo|Administered IV
48292602|NCT00000637|DRUG|Zidovudine|
48292603|NCT00000637|DRUG|Didanosine|
48292604|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
48292605|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
48292606|NCT05112185|BEHAVIORAL|Healthy Drinks, Healthy Futures|The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
48292607|NCT06429631|DEVICE|mobile application on telephone|"when patient discharge from the hospital, mobile application downloaded their telephone. then researcher give feedback about patients CIC outputs.~also mobile application include 2 animations, videos, frequently asked questions and ask the expert section."
48292608|NCT06065722|DRUG|Akynzeo|OLANZAPINE
48292609|NCT04649710|BIOLOGICAL|BMS-986036|Specified dose on specified days
48292610|NCT04649710|OTHER|Placebo|Specified dose on specified days
48292611|NCT02065440|DRUG|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
48292612|NCT02065440|DRUG|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
48292613|NCT04982913|DRUG|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
48292614|NCT05798962|PROCEDURE|Biopsies|Biopsies from the pathological muscle and healthy, unaffected muscle
48292615|NCT01586663|DEVICE|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
48475319|NCT03689894|DRUG|Rituximab|Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
48292616|NCT01586663|DRUG|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
48292617|NCT00599586|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
48292618|NCT05437094|DRUG|CRD-740|CRD-740
48292619|NCT05437094|DRUG|Itraconazole|Itraconazole
48292620|NCT04646317|DRUG|Dexmedetomidine injection|Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
48292621|NCT04646317|DRUG|Normal Saline|0.9% as placebo
48292622|NCT06003816|BEHAVIORAL|Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI|The CHoBI7 program is during group sessions by a health promoter to those residing in a ring around a cholera patient reinforced through weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended water, sanitation, and hygiene behaviors.
48292623|NCT06003816|BEHAVIORAL|Standard message|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
48292624|NCT02194296|DRUG|Ambroxol hydrochloride - lozenge|
48292625|NCT02194296|DRUG|Ambroxol hydrochloride - syrup|
48292626|NCT06282172|DEVICE|Treatment with BTL-785-7|Treatment with BTL-785-7 delivering simultaneously radiofrequency (RF) and HIFES energy on the submental area
48292627|NCT00492921|DRUG|Cyclophosphamide|
48292628|NCT01982201|DRUG|Lesinurad 400 mg|
48292629|NCT01982201|DRUG|Tums 500 mg and 750 mg|
48292630|NCT01982201|DRUG|MINTOX 10 mL|
48292631|NCT03341104|DRUG|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
48292632|NCT05196932|DEVICE|Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies|"A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system."
48292633|NCT01348919|DRUG|CEP-18770|CEP-18770 will be administered per dose and schedule specified in the arm description.
48292634|NCT01348919|DRUG|Lenalidomide|Lenalidomide will be administered per dose and schedule specified in the arm description.
48292635|NCT01348919|DRUG|Dexamethasone|Dexamethasone will be administered per dose and schedule specified in the arm description.
48475320|NCT03466827|DRUG|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
48292636|NCT04986527|PROCEDURE|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
48292637|NCT04804852|OTHER|sarcopenia assessment|evaluation of sarcopenia by CT san at the C3 vertebrae
48292638|NCT06653634|DRUG|Methotrexate|Gradual withdrawal of the medication
48292639|NCT06653634|DRUG|TNF Inhibitor|Gradual withdrawal of the medication
48292640|NCT05781399|DRUG|JNT-517 Suspension|JNT-517 in on-site compounded suspension
48475321|NCT00230191|DRUG|RK-0202|
48292641|NCT05781399|DRUG|Placebo Suspension|On-site compounded placebo suspension
48292642|NCT05781399|DRUG|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
48292643|NCT05781399|DRUG|Placebo Tablet|Matching film-coated placebo tablet
48292644|NCT05687760|BIOLOGICAL|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
48292645|NCT05687760|DRUG|Calcium hydroxide|calcium hydroxide
48292646|NCT02721004|DRUG|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
48292647|NCT05488301|OTHER|chest physiotherapy|"chest physiotherapy session including:~* nasal ventilation~* decrease of respiratory rate without increasement of Tidal volume~* abdomino-diaphragmatic ventilation"
48292648|NCT01899144|DRUG|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
48292649|NCT01899144|DRUG|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
48292650|NCT01899144|DRUG|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
48292651|NCT05099601|COMBINATION_PRODUCT|Silymarin|The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
48292652|NCT05099601|PROCEDURE|Microneedling|Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
48292653|NCT03826953|OTHER|Nurse Led Allergy Clinic|Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
48292654|NCT05785338|DIAGNOSTIC_TEST|Posterior angle of the hard palate|Fetal ultrasound
48292655|NCT04736810|BIOLOGICAL|AK105|IV infusion
48292656|NCT04736810|DRUG|Cisplatin|IV infusion
48292657|NCT04736810|DRUG|Gemcitabine|IV infusion
48292658|NCT04736810|DRUG|Anlotinib hydrochloride|Oral administration
48292659|NCT02095730|DRUG|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
48292660|NCT02095730|DRUG|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
48292661|NCT02095730|DEVICE|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
48292662|NCT02095730|DEVICE|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
48292663|NCT04996576|PROCEDURE|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
48292664|NCT04996576|PROCEDURE|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
48292665|NCT01549847|DRUG|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
48292666|NCT01549847|DRUG|Placebo|Placebo PO BID
48292667|NCT02696512|DRUG|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
48292668|NCT02696512|DEVICE|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
48292669|NCT02696512|DIETARY_SUPPLEMENT|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
48475322|NCT01954914|DRUG|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
48475323|NCT01481857|OTHER|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
48292670|NCT02696512|OTHER|Standard of Care|Standard of Care treatment
48292671|NCT05522114|PROCEDURE|TMJ injection using patient specific guide|Prefabricated patient specific guide used to guide the needle into the superior joint space of TMJ while real time MSCT evaluate the accuracy of needle position. Sodium hyaloronate injected within the superior joint space.
48292672|NCT02292381|OTHER|Isometric exercise|
48292673|NCT00027131|BIOLOGICAL|Heat Shock Protein 70-peptide complexes (HSP70)|
48292674|NCT04333290|DRUG|[11C]MeDAS|PET radiotracer
48292675|NCT02517515|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
48292676|NCT02517515|DRUG|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
48292677|NCT03634072|PROCEDURE|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
48475324|NCT01481857|OTHER|Segmental trunk exercise|Segmental trunk exercise
48475325|NCT04225065|OTHER|Chlorhexidine|Chlorhexidine prep prior to surgery
48292678|NCT01419171|DEVICE|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
48292679|NCT02948595|OTHER|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
48292680|NCT02948595|OTHER|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
48292681|NCT06016621|BEHAVIORAL|Improvisational Music Therapy|The therapist engages with the child by playing and sharing musical instruments, and/or sings while being attuned to the child's behaviour and expression. Various improvisational techniques are employed to engage the child. There are opportunities for pulse, rhythmic, dynamic or melodic patterns, and timbre to be mirrored, reinforced, or complemented, which allows for moments of synchronization between the therapist and the child, giving the child's musical expressions a pragmatic meaning within this context. The therapist may also gently provoke the child by violating expectations or patterns that have been jointly developed in order to elicit specific social communication behaviours. Further, there are opportunities for the child to develop and enhance social communication skills such as joint attention, sharing affect, reciprocity, shared history, scaffolding, imitation and turn-taking. These have been shown to develop social competency and also resilience.
48292682|NCT00955240|BIOLOGICAL|cetuximab|
48292683|NCT00955240|DRUG|cisplatin|
48292684|NCT00955240|DRUG|fluorouracil|
48292685|NCT00955240|OTHER|laboratory biomarker analysis|
48292686|NCT00955240|RADIATION|radiation therapy|
48292687|NCT00875771|DRUG|Capecitabine+Irinotecan+Bevacizumab|"* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~* Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
48292688|NCT01342640|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
48292689|NCT02061137|DRUG|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
48292690|NCT01541254|DEVICE|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
48292691|NCT05073770|DEVICE|Titan Condom|"The test condoms have the following specifications throughout the study:~1. The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm.~2. The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
48292692|NCT04110834|DRUG|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
48292693|NCT04110834|DRUG|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
48292694|NCT04110834|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
48475326|NCT04225065|OTHER|Betadine|Betadine prep prior to surgery
48475327|NCT04184206|BEHAVIORAL|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
48292695|NCT04635644|PROCEDURE|Erector Spinae Plane Block|Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.
48292696|NCT04635644|PROCEDURE|Intrathecal morphine|Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
48292697|NCT00050713|DRUG|Sirolimus|
48292698|NCT02598713|DRUG|Aspiration Marker|Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
48292699|NCT05983302|DRUG|Platelet-Rich Plasma-Fibrin Glue|The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
48292700|NCT05983302|DRUG|Repairing Gel|The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
48475328|NCT04184206|BEHAVIORAL|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
48475329|NCT04184206|BEHAVIORAL|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
48475330|NCT06602492|DRUG|Lower nicotine e-liquid|A 3% nicotine concentration eliquid.
48475331|NCT06602492|DRUG|Higher nicotine eliquid|A 5% nicotine concentration eliquid.
48475332|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
48475333|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
48475334|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
48475335|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
48292701|NCT05983302|DRUG|Repairing Gel and Platelet-Rich Plasma-Fibrin Glue|The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
48632246|NCT01306994|PROCEDURE|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
48632247|NCT01306994|OTHER|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
48292702|NCT05983302|OTHER|Classical wound irrigation (control)|For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
48292703|NCT05450055|PROCEDURE|intraperitoneal lidocaine analgesic or normal saline as control|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
48292704|NCT04735900|PROCEDURE|Liquid biopsy sampling|Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
48292705|NCT00564629|DRUG|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
48292706|NCT00564629|DRUG|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
48292707|NCT00564629|BIOLOGICAL|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
48292708|NCT06302634|OTHER|Exercise-based cardio-oncology rehabilitation|Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
48292709|NCT00816218|DRUG|Pioglitazone|pioglitazone, 45 mg daily
48292710|NCT02720068|BIOLOGICAL|Favezelimab|IV infusion
48292711|NCT02720068|BIOLOGICAL|Pembrolizumab|IV infusion
48292712|NCT02720068|DRUG|Oxaliplatin|IV infusion
48292713|NCT02720068|DRUG|Irinotecan|IV infusion
48292714|NCT02720068|DRUG|Leucovorin (Calcium Folinate)|IV infusion
48292715|NCT02720068|DRUG|Fluorouracil [5-FU]|IV infusion
48292716|NCT02720068|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
48292717|NCT02720068|DRUG|Lenvatinib|Oral
48292718|NCT04596657|DIETARY_SUPPLEMENT|Vitamin D supplementation|Daily vitamin D3 supplementation (5000 IU)
48292719|NCT01319955|BIOLOGICAL|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
48292720|NCT06658899|DRUG|CRD-4730|Oral CRD-4730 in tablet form
48292721|NCT06658899|DRUG|Placebo|Placebo to match CRD-4730 in tablet form
48292722|NCT00375934|DRUG|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
48292723|NCT00375934|DRUG|Placebo|Oral placebo capsule, every 6 hours
48292724|NCT06480045|PROCEDURE|Performed PECS II block with AI integrated USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with AI-integrated USG.
48292725|NCT06480045|PROCEDURE|Performed PECS II block with conventional USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with conventional USG.
48292726|NCT03246035|BEHAVIORAL|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
48292727|NCT03246035|OTHER|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
48292728|NCT02176967|PROCEDURE|Biopsy|Undergo biopsy
48292729|NCT02176967|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48292730|NCT02176967|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48632248|NCT01306994|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
48292731|NCT02176967|DRUG|Carboplatin|Given IV
48292732|NCT02176967|OTHER|Clinical Observation|Undergo clinical observation
48292733|NCT02176967|PROCEDURE|Computed Tomography|Undergo CT
48292734|NCT02176967|DRUG|Cyclophosphamide|Given IV
48292735|NCT02176967|DRUG|Doxorubicin Hydrochloride|Given IV
48292736|NCT02176967|DRUG|Etoposide|Given IV
48292737|NCT02176967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48292738|NCT02176967|PROCEDURE|Ultrasound|Undergo ultrasound
48292739|NCT02281058|DRUG|Abatacept|self-injected subcutaneous biologic medication
48292740|NCT00641147|DRUG|Curcumin|Given PO
48292741|NCT00641147|OTHER|Laboratory Biomarker Analysis|Correlative studies
48292742|NCT00641147|OTHER|Placebo|Given PO
48292743|NCT01483404|PROCEDURE|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
48292744|NCT05186532|RADIATION|Dry Heat Application|50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
48292745|NCT05186532|OTHER|Moist Heat Application|included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
48292746|NCT00338936|DRUG|Valsartan + Hydrochlorothiazide|
48292747|NCT03679494|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
48292748|NCT01720251|DRUG|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
47944118|NCT04728867|OTHER|to compare the educational effectiveness of various educational tools|This prospective, randomized, blinded study is designed to compare the educational effectiveness of various educational tools including the surgical textbook, animation, and cadaveric videos in laparoscopic rectal surgery among board-certificated surgeons.
47944119|NCT02464371|OTHER|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
48103383|NCT05230680|DRUG|ACHOP|"1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total"
48103384|NCT04005313|DEVICE|vibroacoustic device|the participants will receive the vibroacustic device or music therapy
48103385|NCT03147456|DIETARY_SUPPLEMENT|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
48103386|NCT03147456|DIETARY_SUPPLEMENT|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
48103387|NCT04016818|DRUG|18F-FDG|Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
48103388|NCT04016818|DEVICE|Breast-dedicated PET camera|Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
48103389|NCT00198172|DRUG|Cisplatin plus Epirubicin|
48103390|NCT05728866|PROCEDURE|VR immersive therapy|Participants will be asked to participate in 5 consecutive, 1-hour, 1:1 therapy sessions focused on rehabilitation of their weakened arm. Each session will involve use of a Virtual Reality (VR) system to deliver an immersive environment to encourage movement of the arm. The system also relies on 6 body-worn sensors that will detect movements of participant's arms and trunk. VR use will encompass 30-minutes of the therapy session, the remainder of the session will involve working with the therapist in addressing the functional tasks that are most meaningful for the participant and that involve the upper extremities.
48103391|NCT03738137|DEVICE|Narotrend|Narcotrend motoring
48103392|NCT03738137|DEVICE|BIS|Bispectral index monitoring
48103393|NCT03738137|DRUG|Sufentanil|sufentanil is applied.
48103394|NCT03738137|DRUG|Lidocaine|Topical Anesthesia
48103395|NCT03738137|DRUG|Midazolam|midazolam is applied.
48103396|NCT00184561|DRUG|biphasic insulin aspart|
48103397|NCT01806714|OTHER|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
48103398|NCT01806714|OTHER|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
48103399|NCT00065390|DRUG|Pyrimethamine|
48292749|NCT01720251|DRUG|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
48292750|NCT01720251|DRUG|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
48292751|NCT04797975|BIOLOGICAL|KDS-1000|"Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose"
48292752|NCT04797975|OTHER|Placebo|0.9% Normal Saline
48632249|NCT01306994|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
48292753|NCT04661618|DEVICE|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
48292754|NCT03515798|DRUG|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
48292755|NCT03515798|DRUG|neoadjuvant EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
48292756|NCT02413983|PROCEDURE|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
48292757|NCT02413983|PROCEDURE|hepatectomy midline incision|
48292758|NCT02413983|PROCEDURE|hepatectomy transverse incision|
48292759|NCT06594406|DIETARY_SUPPLEMENT|creatine|The dosing schedule of creatine administration is 3 g daily for the first week and then 5 g daily for the remaining 7 weeks and administration of bifidobacterium placebo.
48292760|NCT06594406|DIETARY_SUPPLEMENT|Bifidobacterium|The dosing schedule of bifidobacterium administration is 1 billion colony forming unit (CFU) daily for 8 weeks.
48292761|NCT06594406|DIETARY_SUPPLEMENT|Bifidobacterium and creatine|The dosing schedule of creatine administration is 3 g daily for the first week and then 5 g daily for the remaining 7 weeks. In parallel, the dosing schedule of bifidobacterium administration is 1 billion CFU daily for 8 weeks and administration of creatine placebo.
48292762|NCT06594406|DIETARY_SUPPLEMENT|Placebo|Administration of creatine placebo and bifidobacterium placebo for 8 weeks,
48292763|NCT05347446|PROCEDURE|Hybrid ESD|Method of removing colon lesion
48292764|NCT05347446|PROCEDURE|Non-hybrid ESD|Method of removing colon lesion
48292765|NCT04430582|OTHER|Cognitive Assessment (not diagnostic)|Cognitive testing will assess premorbid intelligence, working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
48292766|NCT04430582|DIAGNOSTIC_TEST|ECG|ECG will take place during screening visit.
48292767|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
48292768|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
48292769|NCT04859491|DIETARY_SUPPLEMENT|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
48292770|NCT01363895|PROCEDURE|Percutaneous closure of LAA|Percutaneous closure of LAA
48292771|NCT01363895|PROCEDURE|Catheter ablation of AF|Catheter ablation of AF
47944120|NCT06458426|DEVICE|shock-absorbing prosthesis|the intervention will test the difference between rigid and shock-absorbing pylons, while the same prosthetic foot is applied in each condition.
48292772|NCT01768299|DRUG|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
48292773|NCT01768299|DRUG|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
48292774|NCT04855877|DRUG|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
48292775|NCT04855877|DRUG|Placebo|Oral administration of lactose tablet (placebo)
48292776|NCT05084989|BIOLOGICAL|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
48292777|NCT05084989|BIOLOGICAL|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
48292778|NCT05084989|BIOLOGICAL|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
48292779|NCT05084989|BIOLOGICAL|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
48292780|NCT03322657|DRUG|Neostigmine|Neostigmine injection
48292781|NCT03322657|DRUG|Glycopyrrolate|Glycopyrrolate injection
48292782|NCT03322657|DRUG|Sugammadex|Sugammadex injection
48292783|NCT06060080|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
48292784|NCT06511011|DRUG|Modified Suan ZaoRen Tang-TianWang BuXin Dan|Chinese medicine granules for 6 weeks
48292785|NCT06511011|DRUG|Placebo|Placebo granules for 6 weeks
48292786|NCT05930249|BEHAVIORAL|Personalized multidomain intervention|"1. Patients will complete personalized cognitive training based on baseline fNIRS on APP (20-30 mins/day, 3-4 days/week, 6 months).~2. Shared decision-making on risk factor of stroke between doctors and patients~3. Social support by grouping patients online to ensure close interaction with other patients in the same arm"
48292787|NCT05700240|DEVICE|orthokeratology|rigid contact lenses
48292788|NCT05700240|DEVICE|single-vision spectacle correction|simple wear of spectacle
48292789|NCT02633111|OTHER|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
48292790|NCT02633111|OTHER|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
48292791|NCT02633111|DEVICE|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
48292792|NCT03484533|BEHAVIORAL|HIV self-test kit|We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
48292793|NCT03484533|BEHAVIORAL|Standard of Care|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
48292794|NCT00252850|GENETIC|CERE-120: AAV2-NTN|
48292795|NCT00002516|BIOLOGICAL|dactinomycin|
48292796|NCT00002516|DRUG|cyclophosphamide|
48292797|NCT00002516|DRUG|doxorubicin hydrochloride|
48292798|NCT00002516|DRUG|etoposide|
48292799|NCT00002516|DRUG|ifosfamide|
48292800|NCT00002516|DRUG|mesna|
48292801|NCT00002516|DRUG|vincristine sulfate|
48292802|NCT00002516|PROCEDURE|conventional surgery|
48292803|NCT00002516|RADIATION|low-LET cobalt-60 gamma ray therapy|
48292804|NCT00002516|RADIATION|low-LET photon therapy|
48475336|NCT02230111|BEHAVIORAL|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
48632250|NCT01306994|OTHER|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
47944121|NCT03875118|BEHAVIORAL|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
48292805|NCT04640246|BIOLOGICAL|TBX-3400|Autologous transfusion
48292806|NCT00410371|DRUG|Lamotrigine|Lamotrigine
48292807|NCT00410371|DRUG|GI267119|25 mg ODT
48292808|NCT04350515|OTHER|Cyberball: Other Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.
48292809|NCT04350515|OTHER|Cyberball: Player Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.
48292810|NCT04350515|OTHER|Mindfulness: Emotion Regulation Task|In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.
48632251|NCT01306994|OTHER|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
48632252|NCT00636974|PROCEDURE|Combined spinal epidural anaesthesia|
48632253|NCT05459714|DEVICE|MCE for obese patients|Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
48632254|NCT05812495|PROCEDURE|Esophagogastric Side to Side Anastomosis|Esophagogastric Side to Side Anastomosis
48292811|NCT04350515|OTHER|Mindfulness: Word Recognition Task|"In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task."
48292812|NCT05346757|DIAGNOSTIC_TEST|miRFec test|The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
48292813|NCT02609893|OTHER|modified directly observed therapy (mDOT)|
48292814|NCT02609893|OTHER|unobserved dosing|
48292815|NCT02609893|OTHER|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
48632255|NCT05812495|PROCEDURE|Esophagogastric End to Side Anastomosis|Esophagogastric End to Side Anastomosis
48292816|NCT03914352|DRUG|PD-1 antibody|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
48292817|NCT03914352|PROCEDURE|TACE|In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
48292818|NCT00997685|DRUG|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
48292819|NCT00102037|DRUG|eptacog alfa (activated)|
48292820|NCT01105338|BEHAVIORAL|Green tea drink|Green tea drink
48292821|NCT01105338|DIETARY_SUPPLEMENT|green tea capsules|green tea capsules
48292822|NCT01105338|OTHER|Green tea placebo capsules|Green tea placebo capsules
48292823|NCT01105338|DIETARY_SUPPLEMENT|Lycopene capsules|Lycopene capsules
48292824|NCT01105338|OTHER|Lycopene placebo capsules|Lycopene placebo capsules
48292825|NCT01105338|OTHER|Tomato rich diet|Tomato rich diet
48292826|NCT00436670|BIOLOGICAL|AMG 317 75 mg|75 mg SC weekly injection
48292827|NCT00436670|BIOLOGICAL|AMG 317 150 mg|150 mg SC once weekly injection
48292828|NCT00436670|BIOLOGICAL|AMG 317 300 mg|300 mg weekly SC injection
48292829|NCT00436670|BIOLOGICAL|Placebo|Placebo SC once weekly injection
48292830|NCT03806569|BEHAVIORAL|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
48292831|NCT03806569|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
48292832|NCT06340594|PROCEDURE|Laproscopic cholecystectomy (LC)|Removal of gallbladder via laparoscopy
48292833|NCT06340594|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Removal of bile duct stones via endoscopy
48292834|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil|Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)
48292835|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide|Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
48292836|NCT06489678|DIAGNOSTIC_TEST|Robotic Assisted Bronchoscopy|Cone-beam computed tomography (CBCT) technology and robotic-assisted bronchoscopy (RAB) present promising methods to enhance biopsy accuracy and procedural safety through 3-dimensional reconstructions and increased bronchoscope tip flexibility. Additionally, the transfer of navigational data between CBCT and RAB may further improve diagnostic yield. Given their distinct approaches to enhancing diagnostic outcomes, two separate study arms are warranted for CBCT and RAB.
48292837|NCT01300286|DRUG|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
48292838|NCT01333618|DEVICE|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
48292839|NCT01333618|DEVICE|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
48292840|NCT00122499|DRUG|tadalafil|
48292841|NCT05627362|DRUG|Elafibranor 80 mg|Oral Tablet
48292842|NCT05627362|DRUG|Elafibranor 120 mg|Oral Tablet
48292843|NCT05627362|DRUG|Placebo Matched to Elafibranor 80 mg|Oral Tablet
48632256|NCT00676637|DRUG|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
48292844|NCT05627362|DRUG|Placebo Matched to Elafibranor 120 mg|Oral Tablet
48292845|NCT04536324|PROCEDURE|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
48292846|NCT04640597|DEVICE|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
48292847|NCT01920139|PROCEDURE|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
48292848|NCT01920139|PROCEDURE|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
48292849|NCT01920139|OTHER|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
48632257|NCT00676637|DEVICE|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
48292850|NCT02955186|DRUG|Saracatinib|Saracatinib 125 mg once per day for 8 days
48292851|NCT02955186|DRUG|Placebos|Placebo once per day for 8 days
48292852|NCT02917863|DRUG|L-Thyroxine (tablet, per os)|
48292853|NCT02917863|DRUG|L-Thyroxine (oral drops, solution)|
48292854|NCT02227212|DRUG|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48292855|NCT00945191|DRUG|CS-1008|CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
48292856|NCT00945191|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
48292857|NCT00945191|DRUG|Carboplatin|Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
48292858|NCT02562196|DEVICE|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
48292859|NCT03436589|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
48292860|NCT06074172|DRUG|Cannabidiol in Oral Dose Form|Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
48292861|NCT06074172|DRUG|Placebo in Oral Dose Form|Placebo press pills provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
48292862|NCT06669442|BEHAVIORAL|Guided Imagery|Guided imagery is a mindfulness based therapeutic technique that involves utilizing positive imagery allowing one to cultivate awareness of their mental state and shift their attention from ruminative thought patterns to the present moment. Evidence-based research shows that benefits of Guided imagery include relaxation, stress reduction, anxiety reduction, immune system enhancement, and overall well-being.
48292863|NCT03352856|OTHER|Barley starch|Highly purified barley starch
48292864|NCT03352856|OTHER|Maize starch|Maize starch
48292865|NCT04908072|DEVICE|Orbis-FundamentalVR MSICS Simulator|Cataract surgery training device, using virtual reality software combined with existing gaming technology for simulated surgery
48292866|NCT02348567|OTHER|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
47944122|NCT03875118|BEHAVIORAL|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
47944123|NCT02775604|BEHAVIORAL|Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
47944124|NCT02775604|BEHAVIORAL|Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)|A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
48292867|NCT02348567|OTHER|announced hospital surveys|
48292868|NCT05153395|OTHER|Carbon dioxide breathing|Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
48292869|NCT05153395|OTHER|Neurovascular Coupling|Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
48292870|NCT05153395|DRUG|Human insulin|Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
48632258|NCT06141681|OTHER|photoplethysmography|Photoplethysmography (BluePoint, Frankfurt, Germany) is the pulse wave measured by a pulse oximeter. It is obtained based on the absorbance of red/infrared light in a given tissue. The signal is made up of two components: 1) the alternating component (AC), which is the pulse wave itself, which is determined by the absorbance of pulsatile arterial blood. 2) The continuous component (DC), which represents the absorbance of venous blood and the rest of the tissues. Within these tests the investigators find vascular occlusion, elevation of the legs, raising or lowering the tested hand above/below the phlebostatic level, cold/heat test, etc. Each of them evaluates different aspects of circulation such as endothelial function, myogenic response to blood flow, perfusion pressure, autonomic reflexes, preload-dependence, or venous flow among other aspects of microcirculation.
48632259|NCT04832308|BEHAVIORAL|Exercise Therapy|This is a health coach driven exercise prescription for patients recommending 30 minutes or more of moderate effort walking 3-5 days a week with expected walk-rest-walk-rest intervals.
48632260|NCT05357170|OTHER|Human feces collection|Human feces collection and blood sampling
48632261|NCT02218268|DRUG|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
48632262|NCT02218268|DRUG|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
48632263|NCT05431751|DIETARY_SUPPLEMENT|Whole Algae|Whole Euglena gracilis algae, produced by proprietary fermentation.
48632264|NCT00122187|DEVICE|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
48632265|NCT05166928|DEVICE|carriere motion appliance|after finished treatment with carrirere motion appliance in the two group (group 1 have upper wisdom teeth ,group 2 have not upper wisdom teeth ) the pre and post casts will be scanned and superimposed to determine amount upper molar distalization
48632266|NCT00353574|DRUG|Darusentan|Darusentan capsules administered orally once daily
48103400|NCT04228055|BEHAVIORAL|CLIPP2|Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
47944125|NCT05116358|DEVICE|Phototherapy device|The active phototherapy device will emit light
48103401|NCT06630663|BEHAVIORAL|A Wearable Device and AI-Supported Diet and Exercise intervention|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
48103402|NCT06630663|BEHAVIORAL|standard care|The standard dietary education encompasses instruction on the calculation of total caloric intake and emphasizes the principles of the Mediterranean diet. Tailored dietary concepts are developed based on individual patient habits to give practical advice. Each participant who chose an extra wearable device downloaded the APP to connect with the health management platform. User interface of the health management platform collected data on the number of steps walked, distance, and heart rate spontaneously. Participants recorded a dietary diary every day with a smartphone APP. All collected information was uploaded to the health management platform, too. The well-trained case managers offered a platform to coach the participants to set-up a better self-managed lifestyle modification through strategies of emphasize reminders, tracking / monitoring/ feedback and goals / rewards.
48103403|NCT03557788|DRUG|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
48103404|NCT03888755|DRUG|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
48103405|NCT03103412|DRUG|TD-3504|TD-3504
48103406|NCT03103412|DRUG|15N2-tofacitinib|15N2-tofacitinib
48103407|NCT03103412|DRUG|Placebo|Placebo
48103408|NCT01612754|BEHAVIORAL|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
48103409|NCT01612754|BEHAVIORAL|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
48292871|NCT04724590|RADIATION|IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )|Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.
48632267|NCT00744419|DRUG|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose \[0.4 mg/kg (\< 44 wks PMA) or 0.8 mg/kg (44 wks to \< 1 yr)\] and the last 6 subjects in each age group will receive high dose \[0.8 mg/kg(\< 44 wks PMA) or 1.6 mg/kg(44 wks to \< 1 yr)\]
48632268|NCT01192360|PROCEDURE|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
48292872|NCT03809546|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
48292873|NCT03809546|DRUG|dextrose|We are administering dextrose to health volunteers for our placebo group
48292874|NCT03270085|DRUG|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
48292875|NCT03270085|OTHER|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
48292876|NCT06021743|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
48292877|NCT06021743|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
48632269|NCT01192360|PROCEDURE|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
48292878|NCT06021743|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
48292879|NCT06021743|DIAGNOSTIC_TEST|Measurement of inflammatory cytokines|A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.
48292880|NCT01292772|PROCEDURE|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
48292881|NCT01292772|RADIATION|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
48292882|NCT01292395|OTHER|Dietary Protein Intake|Protein intakes within the current recommendation
48475337|NCT02230111|BEHAVIORAL|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
48475338|NCT06267872|BIOLOGICAL|CD4BS CH505M5 Pr-NP1|A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered intramuscularly (IM).
47944126|NCT05407610|PROCEDURE|Conventional Radiofrequency ablation of the genicular nerves|Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.
47944127|NCT05407610|PROCEDURE|Cooled Radiofrequency ablation of the genicular nerves|Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.
47944128|NCT05407610|PROCEDURE|Sham procedure|Sham procedure with placing of needles subcutaneously.
47944129|NCT02860377|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
48103410|NCT01805414|OTHER|Modified Carbohydrate Breakfast|
48103411|NCT01805414|OTHER|Control Breakfast|
48103412|NCT04594330|DRUG|virgin coconut oil (VCO)|15 mL of VCO twice a day for 14 days
48292883|NCT01395485|DRUG|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
48292884|NCT06664567|BEHAVIORAL|Colorectal cancer screening test|delivery of colorectal cancer screening test by GP
48292885|NCT05343910|OTHER|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
48632270|NCT03757676|BEHAVIORAL|No Play|Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
48632271|NCT03757676|BEHAVIORAL|At Will Play|Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
48632272|NCT03757676|BEHAVIORAL|Goal Oriented Play|Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
48632273|NCT01899703|DRUG|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
48292886|NCT05770414|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
48292887|NCT04251312|OTHER|Oral Hygiene Education and Oral Hygiene Packets|Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
48292888|NCT00211822|PROCEDURE|fMRI|fMRI
48292889|NCT01644045|DEVICE|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
48475339|NCT06267872|BIOLOGICAL|CH505TF chTrimer|A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF gp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.
48475340|NCT06267872|BIOLOGICAL|3M-052-AF (labeled as AP 60-702)|An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
48475341|NCT06267872|BIOLOGICAL|Aluminum Hydroxide Suspension (Alum)|Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
48475342|NCT06267872|BIOLOGICAL|ACU-026-001-1 (labeled as empty LNP)|An AF consisting of 4 lipid components.
48632274|NCT01899703|DRUG|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
48632275|NCT01899703|DRUG|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
48632276|NCT03751787|OTHER|cranial osteopathy|two sessions at three weeks intervals
48632277|NCT03751787|OTHER|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
48632278|NCT02799290|BIOLOGICAL|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
48632279|NCT02799290|BIOLOGICAL|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
48632280|NCT04419350|PROCEDURE|Microneedling|One session of microneedling will be performed by using dermaroller 1.5 mm. The microneedling done from the edge of the normal skin towards the center of the hypopigmented lesion in all the directions (horizontal, vertical. diagonal).
48632281|NCT04607785|DRUG|Miswak mouthwash group|Twice daily for seven days for two months
48632282|NCT04607785|DEVICE|Chlorhexidine gluconate mouthwash|Twice daily for seven days for two months
48103413|NCT04594330|OTHER|placebo|15 mL of placebo twice a day for 14 days
48292890|NCT05916638|OTHER|blood sample|blood sample collection
48292891|NCT06667804|OTHER|Laughter yoga|Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). - The researcher is certified as an International Leader of Laughter Yoga. As a nursing intervention, patients with T2DM were made to do laughter yoga by the researcher. The laughter yoga program was conducted online (Google meet online) due to the ongoing COVID-19 pandemic at the time of the study. - The sessions were organized as follows: Monday-Thursday 10:00-10:45, Tuesday-Friday 10:00-10:45, Wednesday-Saturday 10:00-10:45. Participants participated in two sessions that were suitable for them within a week. A participant in a group was not allowed to change days in the following weeks.
48292892|NCT04301453|OTHER|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
48292893|NCT03921229|BEHAVIORAL|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
48292894|NCT06447922|OTHER|Metal ion level testing|Patients will undergo a pre- and post-operative blood draw to analyze metal ion levels (Cobalt, Chromium, Titanium and Nickel)
48292895|NCT03162718|BEHAVIORAL|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
48292896|NCT03988114|DRUG|Abemaciclib|Administered orally
48292897|NCT03988114|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
48292898|NCT01613235|OTHER|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
48292899|NCT02132338|BEHAVIORAL|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
48475343|NCT05440695|DEVICE|Continuous non-invasive arterial pressure (Infinity® CNAPTM, Dräger)|The basic working principle of CNAP is to keep the blood volume of the finger arteries constant by applying an exterior pressure to the vessel wall, that is done by an electronic system controlling the pressure inside a cuff around the finger. The pressure in the cuff, which is needed to keep the volume constant during arterial pulsation, corresponds to the AP.
48475344|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
48475345|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
48475346|NCT06340230|DRUG|SHR-A1811 Injection|Drug: SHR-A1811 Injection
48475347|NCT05806931|DRUG|TAS-102, oxaliplatin, irinotecan with bevacizumab|Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
48475348|NCT04991012|DEVICE|PDT Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
48475349|NCT04991012|DRUG|Triamcinolone (Substance) therapy side|th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
48475350|NCT01138345|GENETIC|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
48475351|NCT01138345|GENETIC|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
48292900|NCT02714946|DEVICE|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
48292901|NCT02714946|DEVICE|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
48292902|NCT04292847|OTHER|Referrals Recommendations|All participants will complete the geriatric assessment and receive Referral recommendations based on the assessment.
48292903|NCT02900677|BEHAVIORAL|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
48292904|NCT06663631|DRUG|chlorpromazine and promethazine|C+P were diluted to 50 ml saline solution and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
48292905|NCT06663631|DRUG|Placebo group|50 ml saline solution was set as placebo and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
48475352|NCT01138345|OTHER|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
48475353|NCT01138345|OTHER|medical chart review|perform medical chart review for all subjects
48475354|NCT01138345|OTHER|questionnaire administration|each cohort will be given the same questionnaire
48475355|NCT05085795|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
48475356|NCT05945810|DRUG|TLL-018 extended-release tablet|50mg TLL-018 extended-release tablet QD
48475357|NCT05945810|DRUG|TLL-018 immediate-release tablet|20mg TLL-018 immediate-release tablet BID
48475358|NCT06293443|OTHER|Lower extremity unilateral amputee|To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, Ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, Houghton scale and joint position sense evaluation tests.
48475359|NCT03993587|OTHER|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
48475360|NCT01737541|DRUG|Fluoxetine|
48475361|NCT01737541|DRUG|Placebo|
48292906|NCT06663631|PROCEDURE|endovascular thrombectomy|All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
48292907|NCT06663631|DRUG|rt-PA|All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
47944130|NCT02860377|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
47944131|NCT01242059|DIETARY_SUPPLEMENT|yellow pea protein|Served in a tomato soup
47944132|NCT01242059|OTHER|yellow pea fiber|Served in a tomato soup
47944133|NCT01242059|DIETARY_SUPPLEMENT|Control|Served in a tomato soup
47944134|NCT02260531|DRUG|Cabozantinib|
47944135|NCT02260531|DRUG|Trastuzumab|
47944136|NCT05521568|DIAGNOSTIC_TEST|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
47944137|NCT05521568|DIAGNOSTIC_TEST|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~* Swab #1 will be used to perform the rapid antigen detection test (see below)~* Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
47944138|NCT05521568|DIAGNOSTIC_TEST|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
47944139|NCT06081400|PROCEDURE|Cryoablation|Percutaneous imaging-guided cryoablation
47944140|NCT06081400|DRUG|Chemotherapy drug|"Either :~methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12, or vinorelbine 90mg/week (per os: 3x30mg, soft capsules) for 12 months."
48292908|NCT00306891|DRUG|Cediranib|45 mg oral dose
48292909|NCT00306891|DRUG|Cediranib 30 - 90 mg|oral tablet dose escalation
48292910|NCT02762864|OTHER|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
48292911|NCT02762864|DRUG|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
48292912|NCT02762864|DRUG|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
48475362|NCT05974449|DRUG|Vaginal Lactobacillus capsules|This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
48632283|NCT06323525|BIOLOGICAL|TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)|Phase 1 dose escalation (3+3): dose 1 (1 × 10\^6 cells/kg), dose 2 (3 × 10\^6 cells/kg), dose 3 (6 × 10\^6 cells/kg); Phase 2: dose of RP2D.
47944141|NCT02745210|DIAGNOSTIC_TEST|13C magnetic resonance spectroscopy|acquisition of 13C MR spectroscopy in the brain
48292913|NCT00006168|DRUG|Methotrexate|
48292914|NCT01616615|DRUG|Aspirin|150 mg/day oral use
48292915|NCT01616615|DRUG|placebo|1 capsule / day oral use
48292916|NCT01057628|DRUG|ipragliflozin|oral
48292917|NCT01057628|DRUG|placebo|oral
48292918|NCT01501149|DRUG|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
48292919|NCT01501149|DRUG|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
48292920|NCT06672094|DIETARY_SUPPLEMENT|NeuroQ|Two (2) capsules of NeuroQ taken once a day for 60 days.
48292921|NCT06672094|OTHER|Placebo|Two (2) capsules of placebo taken once a day for 60 days.
48292922|NCT05352217|DEVICE|Mobile app ovarian cancer followup (ePRO)|The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
48632284|NCT06323525|DRUG|Fludarabine|Intravenous fludarabine 25\~30 mg/m\^2/day on days -5, -4, and -3.
48292923|NCT04127136|BEHAVIORAL|Multi-disciplinary obesity management therapy|In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
48475363|NCT06267209|OTHER|Observational group|"After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
48475364|NCT01884064|DEVICE|rTMS|rTMS
48475365|NCT01884064|DEVICE|Sham rTMS|Sham rTMS
48475366|NCT03367936|BEHAVIORAL|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
48475367|NCT03367936|BEHAVIORAL|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
47944142|NCT05426798|DRUG|TQB2618 injection azacitidine, AZA decitabine, DAC|"Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation."
47944143|NCT01225887|DRUG|Nintedanib|Given PO
47944144|NCT02671773|DRUG|Inhaled corticosteroid dose/type|
47944145|NCT00730444|DRUG|Iobenguane I 123 Injection|1-10 mCi administered intravenously
47944146|NCT01370668|BEHAVIORAL|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
47944147|NCT01370668|BEHAVIORAL|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
47944148|NCT01370668|BEHAVIORAL|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
47944149|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
47944150|NCT00200161|DRUG|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
48292924|NCT01399827|DRUG|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
48475368|NCT03367936|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
48475369|NCT00668096|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
48475370|NCT00668096|DRUG|Placebo|Matching Placebo
48475371|NCT00098891|DRUG|entinostat|Given orally
48475372|NCT00098891|DRUG|isotretinoin|Given orally
48475373|NCT00637091|DRUG|Cetuximab, irinotecan|cetuximab, irinotecan
48475374|NCT00810602|PROCEDURE|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
48475375|NCT00810602|DRUG|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
48475376|NCT00810602|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
48632285|NCT06323525|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 250\~500 mg/m\^2/day on days -5, -4, and -3.
47944151|NCT03693170|DRUG|encorafenib|300 mg administered orally once daily (QD)
47944152|NCT03693170|DRUG|Binimetinib|Binimetinib 45 mg administered orally twice daily (BID)
48292925|NCT01399827|DRUG|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
48292926|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Synergy ZFR00).
48103414|NCT04622150|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE is comprised of a series of up to four treatment modules whose inclusion is determined based upon an individuals reasons for nonadherence (adherence barriers).The standardized modules are Psychoeducation, Modified Motivational Interviewing, Communication with Providers, Medication Routines. CAE participants will have a core series of approximately four sessions spaced about one week apart over a period of 4-6 weeks, and one booster in-person session 4 weeks after the completion of the four core sessions (total of approximately 5 sessions). Sessions 2-4 will be delivered remotely by the study interventionist. All participants will have the first session in-person. The final booster session will be conducted at the sites and will review all previously introduced materials. There will be a follow-up phone call with the study interventionist that will occur in the four-week time period between completion of four CAE core sessions and prior to initiation of the booster CAE session.
48292927|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Symfony ZXR00).
48292928|NCT04315363|BEHAVIORAL|Motivational MRI and Behavioral Intervention|Motivational messaging delivered during a functional brain MRI scan and with daily messaging
48292929|NCT04315363|BEHAVIORAL|Control MRI and Behavioral Intervention|Control messaging delivered during a functional brain MRI scan and with daily messaging
48292930|NCT06659289|DEVICE|Efferon LPS|"Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.~The hemoperfusion procedure is performed at the time of artificial circulation during cardiac surgery. The therapy (Efferon LPS hemoperfusion) is performed once. The duration of the procedure is limited by the time of artificial blood circulation."
48292931|NCT05980000|DRUG|Ramucirumab|Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.
48292932|NCT05980000|DRUG|Pembrolizumab|Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
48103415|NCT04622150|BEHAVIORAL|Enhanced Treatment as Usual (eTAU)|eTAU participants will receive monthly text messages (or phone calls for participants who prefer not to receive texts) to refill medications, fill eCAPs and brief general adherence promotion messages during the follow-up period.
48292933|NCT02798081|BEHAVIORAL|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
48292934|NCT05828940|DRUG|Losartan Potassium|oral tablet, over-encapsulated
48292935|NCT05828940|DRUG|Placebo|oral tablet, over-encapuslated
48292936|NCT04760652|BEHAVIORAL|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
48292937|NCT04975048|DIETARY_SUPPLEMENT|Egg yolks|Two egg yolks/day was designed for the study. However, uneven egg sizes during period 1 made the intervention unable to achieve the protocol's recommended cholesterol intake level, and the intervention was modified in period 2 to be 0.8 g egg yolk/day/kg body weight. This dosage was calculated by dividing the 35 g egg yolk with the lightest weight among the volunteers, which was 45 kg. This provides a more consistent cholesterol intake between persons as the egg yolk dosage is standardized for persons with different weights.
48292938|NCT04975048|DIETARY_SUPPLEMENT|Macronutrients equivalent control|The macronutrients equivalent control group was served 42 g egg white cooked with 10 g olive oil, designed to best imitate the energy and macronutrients of 35 g egg yolk (energy 119 kcal, protein 5 g, fat 10 g, carbohydrate 1 g) since the average weight of two large egg yolk was presumed to be 35 g. As an egg yolk dose of 0.8 g egg yolk per kg body weight per day was served during the intervention period 2, the macronutrients equivalent control was likewise adjusted as follow: subjects who weighed less than 55 kg were served 51 g egg white cooked with 12 g olive oil, which is equivalent to 40 g egg yolk; those who weighed from 55 kg to 65 kg were served 61 g egg white cooked with 14 g olive oil, which is equivalent to 48 g egg yolk; and those who weighed more than 65 kg were served 71 g egg white cooked with 17 g olive oil, which is equivalent to 56 g egg yolk.
48292939|NCT00165568|DRUG|Bevacizumab|
48292940|NCT05376111|DRUG|Venetoclax, Azacitidine|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
48292941|NCT04837404|PROCEDURE|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
48292942|NCT04837404|PROCEDURE|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
48292943|NCT05485012|DRUG|Marijuana|Double-blind administration of marijuana
48292944|NCT05485012|DRUG|Opioid|Double-blind administration of an opioid agonist
48292945|NCT05331365|OTHER|Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests|"Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8"
48292946|NCT06659679|DRUG|New use of oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
48292947|NCT06659679|DRUG|New initiation of sitagliptin|New use of sitagliptin dispensing claim is used as the reference.
48292948|NCT02944747|BEHAVIORAL|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
48292949|NCT02944747|BEHAVIORAL|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
48292950|NCT02944747|BEHAVIORAL|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
48292951|NCT00660140|DRUG|Gemcitabine|
47944153|NCT03693170|DRUG|Cetuximab|"Standard of care for the 28 first weeks(\*) and then every 2 weeks (\*\*) :~(\*) 400 mg/m2 administered as a 120-min infusion on Cycle 1 Day 1, followed by 250 mg/m2 administered as a 60-min infusion once weekly (QW) for the first 28 weeks. (\*\*) 500 mg/m2 administered as a 120-min infusion twice weekly (Q2W) from Week 29 (Cycle 8 Day 1) onward.~Following implementation of an Urgent Safety Measure on 26 Mar 2020 due to the outbreak of COVID-19 pandemic, cetuximab infusions could be administered Q2W regardless of the cycle number, after investigator's evaluation of the benefit/risk ratio for the subject, with regards to COVID-19 pandemic."
47944154|NCT00730197|DRUG|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
47944155|NCT00730197|DRUG|VoSpire® ER Tablets 8 mg|8mg, single dose fed
47944156|NCT03589014|DRUG|Propranolol|Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
47944157|NCT02947412|OTHER|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
47944158|NCT02860455|DEVICE|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
47944159|NCT02860455|DEVICE|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
47944160|NCT06191523|OTHER|Control Group|The control group will receive standard therapy and placebo.
47944161|NCT06191523|DRUG|Treatment Group|The participants in the treatment group will receive standard therapy and a single dose of oral melatonin 20 mg
47944162|NCT00181623|DRUG|Recombinant Human Prolactin|
47944163|NCT03120442|DRUG|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
47944164|NCT03120442|DRUG|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
47944165|NCT03120442|DRUG|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
47944166|NCT05174845|DRUG|1L PEG + ASCORBIC ACID|"* 2-Day Split-Dosing: The patient has taken the product in the evening before the scheduled colonoscopy and mandatory additional clear fluid. The patient has taken the second dose with mandatory additional clear fluids on the morning of the colonoscopy.~* Same Day: The patient has taken the first dose of the product on the day of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break, the patient has taken a second dose plus additional clear mandatory fluid."
47944167|NCT00443027|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
47944168|NCT03642665|DRUG|Natural cycle|no medication
47944169|NCT03642665|DRUG|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
47944170|NCT03642665|DRUG|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
48292952|NCT00660140|DRUG|Carboplatin|
47944171|NCT02897765|BIOLOGICAL|NEO-PV-01|Personal cancer vaccine
47944172|NCT02897765|BIOLOGICAL|Nivolumab|monoclonal antibody against PD1
47944173|NCT02897765|OTHER|Adjuvant|immune adjuvant
47944174|NCT03158987|OTHER|Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity
48103416|NCT03861169|DEVICE|Transluminal viscoelastic delivery and trabeculotomy|Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
48103417|NCT01175707|DRUG|Daptomycin|
48103418|NCT01175707|DRUG|Vancomycin|
48292953|NCT05738213|DEVICE|Thermal stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
48292954|NCT05738213|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
48292955|NCT05738213|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed.
47944175|NCT01003444|PROCEDURE|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
47944176|NCT03170856|OTHER|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 20 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
47944177|NCT02545075|DRUG|Ipilimumab|
47944178|NCT02545075|DRUG|Dacarbazine|
47944179|NCT00560469|OTHER|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
47944180|NCT01497327|DRUG|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
48632286|NCT01538407|OTHER|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
47944181|NCT01497327|DRUG|PSI-7977|PSI-7977 400mg QD for seven days
47944182|NCT05777018|PROCEDURE|conventional recruitment maneuvers|"The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings"
47944183|NCT05777018|PROCEDURE|ultrasound-guided recruitment maneuvers|"* Ultrasound guided maneuver will be performed at T2, T3 and T4.~* The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure."
47944184|NCT03011619|BEHAVIORAL|Usual Standard of Care|medication management, group therapy, and individual therapy.
47944185|NCT03011619|BEHAVIORAL|Cognitive Behavioral Therapy Condition (CBT)|CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
47944186|NCT04406285|OTHER|Standard protocol Leukemia|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
48632287|NCT01628809|BEHAVIORAL|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
47944187|NCT04406285|OTHER|Periodic Resistance Training Program Leukemia|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
48632288|NCT04986813|DRUG|Tranexamic acid injection|1 g of TXA in 100 ml of normal saline
47944188|NCT04406285|OTHER|Standard protocol Lymphoma|"* Bicycle ergometer endurance training for 5 minutes, with resistance individually adjusted based on the patient´s feedback (from 70% of maximum heart rate);~* Resistance exercises for muscle groups: hip flexors, knee extensors and ankle plantar flexors (10 repetitions, 1 sets);~* Resistance training for arms, using 0,5 kg or 1,0 kg dumbbels (10 repetitions, 1 sets)."
47944189|NCT04406285|OTHER|Periodic Resistance Training Program Lymphoma|"* Submaximal Ergometer tests with incremental load (from 85% of maximum heart rate or maximum effort related);~* 30-Second Chair Stand;~* Hand Grip Strength and submaximal arm effort using 0,5 kg or 1,0 kg dumbbels."
47944190|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
47944191|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
47944192|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
47944193|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
47944194|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
47944195|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
47944196|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
47944197|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
47944198|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
48632289|NCT04986813|OTHER|Normal Saline|100 ml
47944199|NCT01454115|DRUG|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
47944200|NCT01454115|DRUG|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
47944201|NCT01454115|DRUG|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
47944202|NCT02341105|PROCEDURE|Catheter ablation|Pulmonary vein isolation by catheter ablation
47944203|NCT02341105|DRUG|Amiodarone|antiarrhythmic therapy using Amiodarone
48292956|NCT05738213|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
48292957|NCT05738213|BEHAVIORAL|Conditioned pain modulation (CPM) response|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency. CPM testing includes the application of a test stimulus without conditioning (control run, pressure pain thresholds) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run, a 60 second of foot immersion in cold water). The CPM response is the difference in the pressure pain thresholds between the control and the conditioning runs."
48292958|NCT05738213|BEHAVIORAL|PedMIDAS (Pediatric Migraine Disability Assessment)|Adolescents with migraine will complete questions regarding their headache frequency. Migraine disability will be assessed using PedMIDAS (Pediatric Migraine Disability Assessment). This self-reported questionnaire assesses the number of days that headaches affect participant's daily activities. This is a widely used, reliable and validated tool to assess migraine disability.
47944204|NCT02783885|DRUG|immunotherapy|
47944205|NCT04095390|DRUG|Pyrotinib|400 mg
47944206|NCT04095390|DRUG|SHR6390|125mg
47944207|NCT04095390|DRUG|Letrozole|2.5mg
47944208|NCT04095390|DRUG|Capecitabine|500mg
47944209|NCT01229397|BIOLOGICAL|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
47944210|NCT01229397|BIOLOGICAL|Inflexal V|Inflexal V 0.5 mL administrated once only
47944211|NCT00604305|DEVICE|Acrysof|Monofocal IOL
47944212|NCT00604305|DEVICE|Acuity's AIOL|Accommodating IOL
47944213|NCT02310932|BEHAVIORAL|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
47944214|NCT05691907|DEVICE|THE therapy|"THE therapy consisting of:~* Heating Pad~* Interferential Therapy"
47944215|NCT05691907|PROCEDURE|Directional Preference Exercises|Directional Preference Exercises consisting of Mckenzie's extension protocol
47944216|NCT05691907|PROCEDURE|Motor Control Exercises|Motor Control Exercises consisting of External limb loading extension protocol
47944217|NCT04953052|DRUG|Imatinib Mesylate|An isotonic sterile solution of imatinib.
47944218|NCT04953052|DRUG|Placebo|An isotonic sterile solution
47944219|NCT00837928|DRUG|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
47944220|NCT00837928|OTHER|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
47944221|NCT00837928|PROCEDURE|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
47944222|NCT00837928|RADIATION|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
47944223|NCT05455385|OTHER|standard 12-week rehabilitation program|The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
47944224|NCT05455385|OTHER|extra session hydrotherapy|The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
47944225|NCT05455385|OTHER|extra session ground exercises|The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
47944226|NCT05123911|OTHER|Investigational Shampoo|Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.
47944227|NCT05123911|OTHER|Investigational Conditioner|Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.
47944228|NCT05123911|OTHER|Investigational Combing Cream|Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
47944229|NCT01163266|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
47944230|NCT01163266|DRUG|Placebo|Vortioxetine placebo-matching capsules
47944231|NCT01654627|DEVICE|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
47944232|NCT01654627|DEVICE|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
47944233|NCT05064904|DRUG|never received RAAS blockers or received RAAS blockers before AKI.|"Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge."
48632290|NCT05144282|PROCEDURE|intravitreal injection of anti VEGF|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF).
48292959|NCT05738213|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples (approximetly 2 tablespoons) will be collected for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone).
48292960|NCT05738213|OTHER|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-Wave 3 survey, which allows for differentiation between pre-, early-, late-, and post-pubertal status. Early puberty is defined as a score of 3 and no menarche, mid-puberty is defined as 4 and no menarche, late pubertal is defined as a score of 7 points or less and with menarche, and post pubertal is defined as a score of 8 and menarche. For boys, pubertal maturation status will be determined by the Physical Development Scale using the body hair growth voice change and facial hair questions. Early puberty is defined as a score of 4-5, mid-puberty is defined as a score of 6-8, late pubertal is defined as a score of 9-11 points, and post pubertal is defined as a score of 12.
48292961|NCT04772079|DRUG|Deucravacitinib|Specified dose on specified days
48292962|NCT04772079|OTHER|Placebo matching deucravacitinib|Specified dose on specified days
48292963|NCT06178510|DEVICE|INTELLiVENT-ASV.|INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs
48292964|NCT01355991|DRUG|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
48292965|NCT01355991|DRUG|Salmeterol|50mcg inhalation twice daily for two weeks
48632291|NCT05144282|PROCEDURE|laser photocoagulation|The treatment for ROP was either primary laser photocoagulation.
48632292|NCT00520442|DRUG|ibuprofen|
48632293|NCT00520442|DRUG|acetamin w codeine|
48632294|NCT01216280|DRUG|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
48632295|NCT01216280|DRUG|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
48632296|NCT01216280|DRUG|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
48632297|NCT04120675|DIETARY_SUPPLEMENT|Early Harvest Extra Virgin Olive Oil|Participants will take 3 tablespoons on a daily basis
47944234|NCT06415318|DRUG|Paclitaxel + Ifosfamide + Cisplatin & Toripalimab|Paclitaxel + Ifosfamide + Cisplatin \& Toripalimab
47944235|NCT00089323|PROCEDURE|Bone Marrow Aspiration|
48632298|NCT05713370|DIETARY_SUPPLEMENT|high fat meal|A high fat meal (milkshake) will be administered on the morning after the intervention of no exercise and no SR the night before.
48632299|NCT01864694|BEHAVIORAL|TLC-Diet|Participants receive diet intervention through an automated telephone system
48632300|NCT01864694|BEHAVIORAL|WEB-Diet|Participants receive diet intervention through a web-based system
47944236|NCT04547790|DIETARY_SUPPLEMENT|Psyllium|One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water
47944237|NCT04547790|DIETARY_SUPPLEMENT|Wheat Dextrin|One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
47944238|NCT02098824|DRUG|Galantamine|Single administration of capsule containing 16 mg of Galantamine
47944239|NCT02098824|DRUG|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
47944240|NCT02098824|DRUG|Placebo|Single administration of capsule containing placebo
47944241|NCT05129423|DRUG|MTPS9579A|MTPS9579A will be administered.
48292966|NCT03224637|PROCEDURE|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
48292967|NCT03224637|DRUG|Paracetamol (conventional)|
48292968|NCT03224637|DRUG|Ketorolac Tromethamine (conventional)|
48292969|NCT03264638|DRUG|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
48292970|NCT03264638|DRUG|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
48292971|NCT03264638|DRUG|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
48292972|NCT01466725|DRUG|CC-930|
48292973|NCT01466725|DRUG|Placebo|Placebo
48632301|NCT01864694|OTHER|Assessment-only control|Assessment-only control
48632302|NCT00729807|DRUG|pentamidine|
48103419|NCT04603014|COMBINATION_PRODUCT|Interdialytic peritoneal ultrafiltration with 10% dextrose solution|Interdialytic peritoneal ultrafiltration with incremental doses of a 10% dextrose solution, after hemodialysis twice weekly for three consecutive weeks
48103420|NCT06631846|OTHER|Music therapy|"Participants in the music therapy group (MTG) will be comfortably lying on the bed in a reclined position of 30-45 degrees. Using a headphone, participants will be instructed to select a volume that is comfortable to their ears and listen to the music titled as The Best Relaxing Piano and Flute Music Ever which will be played for 30-minutes every day for 1-week. Patients will be encouraged to focus on the music and let it fill their senses."
48103421|NCT06631846|OTHER|Mindfulness meditation|Mindfulness meditation group (MGT)will be listening to audio of Guided Mindfulness Meditation Series 1 by Jon Kabat-Zinn. Similar to MTG, participants in MMG will be lying on the bed in a reclined position of 30-45 degrees. A headphone to listen to the audio of guided MM will be provided to all the participants. Participants will begin with relaxation technique by focusing on deep breathing to help calm their body and mind. This will be followed by focusing on the present moment, letting go of any thoughts or distractions that come up. Participants can focus on their breath, bodily sensations, or a specific object in their environment. Finally, the session will end by expressing a gratitude for their body and mind and setting an intention to carry the feelings of relaxation and mindfulness with them throughout the day. Similar to MTG, MMG will engage in 30-minutes of MM every day for 1-week.
48103422|NCT06631846|OTHER|Music therapy and mindfulness meditation|Music therapy and mindfulness meditation group will be receiving both music therapy and mindfulness meditation in the same body position as MTG and MMG. Firstly, participants will listen to MT for 30-minutes followed by MM for another 30-minutes. In between the 2 interventions, a 15-minute of break will be provided to all participants. Intervention will be carried out every day for 1-week.
48292974|NCT06045572|DEVICE|VTM examination and breast biopsy|VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
48292975|NCT02768129|DEVICE|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
48292976|NCT02768129|DEVICE|sham transcranial direct current stimulation|sham stimulation
48292977|NCT01104389|DEVICE|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
48292978|NCT01278628|OTHER|exercise training|exercise class once a year
48292979|NCT06671535|DEVICE|Polymethylmethacrylate membrane|A polymethylmethacrylate hollow fiber membrane (PMMA membrane) has unique properties including the uniform structure and the adsorption property.
48292980|NCT06671535|DEVICE|polysulfone membranes|Dialyzers containing polysulfone membranes are widely used for modern dialysis therapies as they allow efficient removal of a broad spectrum of uremic toxins.
48292981|NCT02267785|OTHER|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
48620015|NCT04179214|OTHER|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
48292982|NCT02267785|OTHER|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
48632303|NCT03167710|OTHER|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
48632304|NCT03167710|OTHER|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
48632305|NCT04382079|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
48632306|NCT04382079|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
47944242|NCT05129423|DRUG|Placebo|Placebo matched with MTPS9579A will be administered.
47944243|NCT00990938|DRUG|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
47944244|NCT00990938|DRUG|Saline|Subcutaneous injection once per week for four weeks
47944245|NCT01107418|DRUG|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
48292983|NCT02267785|OTHER|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
48632307|NCT03830970|DIETARY_SUPPLEMENT|Canned beans of multiple varieties|Daily rotation of different varieties of canned beans including black, navy, pinto, red kidney and white kidney
48632308|NCT03830970|DIETARY_SUPPLEMENT|White Rice|Minute Rice Long Grain White Rice
48632309|NCT01567020|OTHER|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
48632310|NCT02232321|OTHER|PsA MDA|
48632311|NCT02334410|DEVICE|Whole body vibration (WBV)|Side-alternating WBV
48632312|NCT01647685|DRUG|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
48292984|NCT01481246|BEHAVIORAL|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
48292985|NCT01481246|BEHAVIORAL|Psychosocial and Psychoeducational Group training|Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.
48292986|NCT06131203|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
48475377|NCT00810602|DRUG|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher \[probably or definitely related to the drug\] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
48475378|NCT04299217|DIETARY_SUPPLEMENT|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
48475379|NCT04299217|OTHER|Placebo|Placebo comparator (carrier)
48475380|NCT00983476|BEHAVIORAL|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
48475381|NCT00983476|BEHAVIORAL|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
48475382|NCT03540849|DRUG|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
48632313|NCT01647685|DRUG|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
48632314|NCT01647685|DRUG|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
48632315|NCT04448080|DEVICE|Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT)|Intraocular pressure will be lowered by Micropulse Transscleral Laser Therapy for Glaucoma (MP-TLT) in patients with a diagnosis of glaucoma
48632316|NCT00666341|DRUG|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
48632317|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
48632318|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
48632319|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
48632320|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
48632321|NCT04640987|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
48632322|NCT04640987|DEVICE|CliniMACS Prodigy System|Device used for production of T-allo10 cells.
48632323|NCT04640987|DRUG|T-allo10 cells addback|T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
47944246|NCT01107418|DRUG|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
47944247|NCT01107418|DRUG|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
47944248|NCT01107418|DRUG|RO5185426|960 mg orally twice daily, from day 22 onward
47944249|NCT01107418|DRUG|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
47944250|NCT00073073|DRUG|Exemestane|exemestane 25 mg by mouth (PO) every day for two years
47944251|NCT00073073|DIETARY_SUPPLEMENT|Calcium carbonate|calcium carbonate 1200 mg PO every day x 2 years
47944252|NCT00073073|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 400 international units PO every day x 2 years
47944253|NCT03727399|OTHER|blood withdrawal|Blood withdrawal
47944254|NCT04776031|DEVICE|R:GEN Laser System|Laser Treatment
47944255|NCT01130103|DRUG|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
47944256|NCT01130103|BEHAVIORAL|Prolonged Exposure Therapy|Weekly for 10 weeks
47944257|NCT03375827|OTHER|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
47944258|NCT05546918|OTHER|survey, interviews and focus groups|"The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups"
47944259|NCT00063323|DRUG|Bupropion|
47944260|NCT05161871|DEVICE|Cathodal transcranial direct current stimulation|The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
48292987|NCT03838250|BIOLOGICAL|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
48292988|NCT04741243|DEVICE|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
48292989|NCT00677144|DRUG|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
48292990|NCT00677144|DRUG|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
48292991|NCT05174806|DRUG|Topical Pravibismane|Topical Pravibismane
48292992|NCT05174806|OTHER|Standard of Care|Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
48475383|NCT00835939|DRUG|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
48475384|NCT00835939|DRUG|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
48475385|NCT00835939|PROCEDURE|sclerotherapy|
48475386|NCT04915911|OTHER|cross-sectional study|cross-sectional study
48475387|NCT02421016|DEVICE|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
48475388|NCT02421016|DEVICE|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
48475389|NCT04449458|BEHAVIORAL|Positively Me|12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
48475390|NCT04449458|BEHAVIORAL|Positively Living|12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
48475391|NCT03379155|OTHER|Internet-based self-help program|The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem \& Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
48475392|NCT03546829|DRUG|Vancomycin|125 mg, 4x daily for 5 weeks
48475393|NCT03546829|RADIATION|Precision hypofractionated radiation|Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
48475394|NCT01124435|DRUG|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
48475395|NCT00084799|BIOLOGICAL|monoclonal antibody hu3S193|
48475396|NCT04857151|BEHAVIORAL|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
48475397|NCT00116493|DIETARY_SUPPLEMENT|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
48475398|NCT00116493|DRUG|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
48475399|NCT00116493|DIETARY_SUPPLEMENT|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
48475400|NCT00116493|DRUG|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
48475401|NCT05111886|BEHAVIORAL|Communication Skills Training|The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.
47944261|NCT05161871|DEVICE|Sham cathodal transcranial direct current stimulation|Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
47944262|NCT01583543|DRUG|Olaparib|400mg PO BID Continuous
47944263|NCT05830903|BEHAVIORAL|VR-assisted occupational training|VR-assisted occupational training
47944264|NCT00723216|DRUG|enoxaparin|20 mg twice a day
48292993|NCT04727112|DRUG|Usual care versus primary care|RCT study
48632324|NCT02277860|BEHAVIORAL|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
47944265|NCT00723216|OTHER|Physical prophylaxis|
48292994|NCT04710940|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
48292995|NCT04710940|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
48292996|NCT06162026|BEHAVIORAL|RACS app|risk assessment questions, symbol matching task, voice tasks
48292997|NCT06637917|DEVICE|OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System|The Nellcor™ N-600x Pulse Oximetry System with N-600X Pulse Oximeter and Nellcor™ Sensors and Cables with OxiMax technology is indicated for prescription use only for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin and PR. The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients during both no motion and motion conditions and for patients who are either well or poorly perfused, in hospitals, hospital-type facilities, intra-hospital transport, and home environments.
48292998|NCT06637917|DEVICE|LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter|The Masimo Rad-97™ and accessories are indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin, PR, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or acoustic respiratory rate (RRa). The Masimo Rad-97™ and accessories are indicated for use with adult, pediatric, and neonatal patients during both no motion and motion conditions, and for patients who are well or poorly perfused. In addition, the Masimo Rad-97™ and accessories are indicated to provide the continuous non-invasive monitoring data obtained from the Masimo Rad-97™ and accessories for functional oxygen saturation of arterial hemoglobin and PR to multi-parameter devices for the display on those devices.
48292999|NCT06637917|DEVICE|1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor|Market-released ECG monitoring system
48293000|NCT01954628|DRUG|AQX-1125|Synthetic SHIP1 activator
48293001|NCT01954628|DRUG|Placebo|Placebo control
48293002|NCT04666961|DRUG|Tamoxifen 20 mg|Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
48293003|NCT04666961|DRUG|Anastrozole 1Mg Tab|Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
48293004|NCT01799538|DRUG|albuterol inhaler|2 puffs of Metered Dose inhaler for Bronchodilation
48293005|NCT01799538|DRUG|albuterol nebulizer|Albuterol administered by nebulization will produce a greater increase in FEV1
48293006|NCT01799538|PROCEDURE|PFT|Breathing Test
48293007|NCT05677945|DRUG|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
48293008|NCT05677945|DRUG|3Mix: Modified triple antibiotic mix in propylene glycol|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
48293009|NCT01418222|DRUG|5-FU|Intravenous repeating dose
48293010|NCT01418222|DRUG|FOLFOX regimen|Intravenous repeating dose
48632325|NCT02474901|BIOLOGICAL|Quadrivalent Live Attenuated Influenza Vaccine|
48293011|NCT01418222|DRUG|Placebo|Intravenous repeating dose
48293012|NCT01418222|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
48293013|NCT01418222|DRUG|leucovorin|Intravenous repeating dose
48293014|NCT01418222|DRUG|onartuzumab [MetMAb]|Intravenous repeating dose
48293015|NCT05627193|OTHER|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
48293016|NCT05627193|OTHER|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
48293017|NCT05717920|DRUG|ADX-629 (Open-label)|ADX-629 (250 mg) administered twice daily for 90 days
48293018|NCT05391763|PROCEDURE|Fascia pectoralis preservation|A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
48293019|NCT06643481|BIOLOGICAL|VHB937|VHB937 solution for infusion
48632326|NCT03848351|BEHAVIORAL|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
47944266|NCT06488547|OTHER|Diaphragmatic breathing (DF)|Diaphragmatic breathing (DF), also known as belly or abdominal breathing, is a technique that can teach people how to use their diaphragm correctly while breathing, in order to activate the parasympathetic branch of the autonomic nervous system and to control stress.
47944267|NCT06488547|OTHER|Progressive Muscle Relaxation (PMR)|"Progressive Muscle Relaxation (PMR) is a technique that is helpful in the reduction of stress.~PMR by alternately tensing and relaxing different muscle groups in the body helps participants to become more aware of physical sensations and can be particularly helpful to muscle tension and relaxation."
48293020|NCT06643481|OTHER|Placebo|Solution for infusion
47944268|NCT04908657|DRUG|Sildenafil 20 MG|oral sildenafil 20 mg three times per day for 3 years
47944269|NCT01516528|PROCEDURE|Spirometry|Assessment of lung function by spirometry
47944270|NCT01225107|DIETARY_SUPPLEMENT|Cranberry Extract|500mg TID
47944271|NCT01225107|DRUG|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
47944272|NCT04490239|DRUG|Intranasal heparin sodium (porcine)|Intranasal heparin sodium
47944273|NCT00365144|BIOLOGICAL|bevacizumab|
47944274|NCT00365144|DRUG|erlotinib hydrochloride|
47944275|NCT00365144|OTHER|laboratory biomarker analysis|
47944276|NCT03263585|DEVICE|Spinal orthosis Spinomed|
47944277|NCT03263585|OTHER|Equipment training|
47944278|NCT05870293|BEHAVIORAL|nurse coaching|2 sessions of nurse coaching including the Walt Disney method will be applied to the participants.
48103423|NCT06631846|OTHER|Cardiac rehabilitation|Control Group will not receive any other therapy except the conventional post-operative cardiac rehabilitation. Other 3 intervention groups will also be participating in the usual cardiac rehabilitation program. Cardiac rehabilitation will be conducted during phase I, where rehabilitation will focus on early mobilization and ambulation of participants with a target heart rate of resting heart rate + 30 beats, with the non-strenuous exercises in the bed or at the bedside, focusing on a range of motion and limiting hospital deconditioning.
48103424|NCT03308487|DIETARY_SUPPLEMENT|vitamin D3 (1000 IU)|
48103425|NCT03308487|DIETARY_SUPPLEMENT|Vitamin D3 (2000 IU)|
48293021|NCT06438588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48293022|NCT06438588|OTHER|Dietary Intervention|Given FMD
48475402|NCT05111886|BEHAVIORAL|eHealth GenPMTO|The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).
47944279|NCT02164773|DRUG|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
47944280|NCT02164773|DRUG|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
47944281|NCT05220917|DRUG|SGLT2 inhibitor|Any SGLT2i dispensing claim
47944282|NCT05220917|DRUG|DPP-4 inhibitor|Any DPP-4 inhibitor claim
47944283|NCT05220917|DRUG|GLP-1RA|Any SGLT2i dispensing claim
47944284|NCT05220917|DRUG|2nd generation SU|Any 2nd generation SU claim
47944285|NCT02748473|OTHER|Pilates Exercises program|"The volunteers were divided in two groups:~Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.~The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.~Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.~After the 24 sessions, both groups were retested with the same measured methods of the baseline."
47944286|NCT02748473|OTHER|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
47944287|NCT02748473|OTHER|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
47944288|NCT05658536|BEHAVIORAL|6-Week Self-Management Group|The goal of the 6-session group-based intervention for patients with Post-COVID is to teach patients behavioral strategies known to be helpful in managing several common Post-COVID symptoms, including fatigue, memory and attention issues, poor sleep, breathlessness, coping with anxiety and uncertainty, and stress management. It is currently available to patients who are seen in the Post-COVID-19 Rehabilitation and Recovery Clinic at UW and the Post-COVID-19 Clinic in VAPSHCS Rehabilitation Care Services.
47944289|NCT01231854|DRUG|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
48103426|NCT03526081|OTHER|Chamomile Tea|Chamomile Tea in 300mL hot water
48103427|NCT03526081|OTHER|Parsley based drink|3.2 g dried parsley in 300mL hot water
48103428|NCT03526081|OTHER|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
48293023|NCT06438588|OTHER|Educational Intervention|Receive educational guidelines
48293024|NCT06438588|OTHER|Electronic Health Record Review|Ancillary studies
48293025|NCT06438588|OTHER|Interview|Ancillary studies
48293026|NCT06438588|OTHER|Nutritional Assessment|Receive nutrition counseling
48293027|NCT06438588|OTHER|Questionnaire Administration|Ancillary studies
48293028|NCT03553017|DEVICE|Binocular OCT|Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
48293029|NCT02673112|BEHAVIORAL|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
48293030|NCT02673112|BEHAVIORAL|Light stretching (LS)|Brief daily stretching routine.
48632327|NCT03848351|PROCEDURE|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
48632328|NCT03126266|RADIATION|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
48632329|NCT00520572|DRUG|AZD9056|
48632330|NCT00520572|DRUG|Etanercept|
48632331|NCT00520572|DRUG|Placebo|
48632332|NCT04852653|PROCEDURE|Supplementary blood samples collection during the normal follow up of the patients|Supplementary blood samples collection during the normal follow up of the patients
48632333|NCT04027387|BIOLOGICAL|TMB-365|An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
48293031|NCT00447954|DRUG|NT-501 implant|High Dose
48632334|NCT02521194|BEHAVIORAL|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
48632335|NCT04359680|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
48632336|NCT04359680|DRUG|Placebo|Placebo administered orally twice daily for six weeks
48632337|NCT04359680|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
48632338|NCT05562635|COMBINATION_PRODUCT|5% polymer gel with CBD application|Bilateral application of 5% polymer gel with CBD intraorally, on the masseter muscle
48632339|NCT05562635|COMBINATION_PRODUCT|10% polymer gel with CBD application|Bilateral application of 10% polymer gel with CBD intraorally, on the masseter muscle
48632340|NCT05562635|COMBINATION_PRODUCT|Placebo intervention|Application of placebo without CBD
48632341|NCT06494514|DRUG|nal-IRI+Oxaliplatin+5-FU/LV+PD-1|These drugs are given on d1, d15, 28 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
47944290|NCT01231854|DRUG|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
47944291|NCT03862859|DRUG|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
48103429|NCT03526081|OTHER|Apigenin|Apigenin capsule mixed with 300mL hot water
48293032|NCT00447954|DRUG|NT-501 implant|Low Dose
48293033|NCT00447954|OTHER|Sham Procedure|Sham Procedure
48293034|NCT00722059|PROCEDURE|Breast Tomosynthesis|3D breast imaging
48293035|NCT06617429|DRUG|GTX-102|antisense oligonucleotide
48293036|NCT06617429|PROCEDURE|Sham-LP|Small needle prick on the lower back at the location where the LP injection is normally made
48293037|NCT04693247|DEVICE|EQ103|Refraction device
48293038|NCT06361459|BEHAVIORAL|Stop smoking|Sine fuma program is offered. nicotine is checked in urine
48293039|NCT03940781|BEHAVIORAL|comprehensive rehabilitation|oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
48293040|NCT04467541|BIOLOGICAL|Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)|Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
48293041|NCT00475449|PROCEDURE|percutaneous coronary intervention|
48632342|NCT06494514|DRUG|Gemcitabine + albumin-paclitaxel+PD-1|These drugs are given on d1, d8, 21 days as one cycle. 6-6 treatment cycles. SBRT is performed in third cycles.
48293042|NCT00475449|PROCEDURE|coronary artery bypass grafting|
48475403|NCT05111886|BEHAVIORAL|Written Referral Process|"A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals."
48632343|NCT00559117|DRUG|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
48632344|NCT04759170|OTHER|Music therapy|The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
48632345|NCT00004015|DRUG|sodium borocaptate|
48632346|NCT00004015|PROCEDURE|adjuvant therapy|
48632347|NCT00406237|DRUG|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
48632348|NCT01471574|DRUG|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
48293043|NCT03235440|BEHAVIORAL|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
48293044|NCT05149755|DEVICE|Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)|Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).
48293045|NCT03551028|DEVICE|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
48293046|NCT03419234|DRUG|Abiraterone Acetate|Given PO
48293047|NCT03419234|DRUG|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
48293048|NCT03419234|DRUG|Cabazitaxel|Given IV
48293049|NCT03419234|OTHER|Laboratory Biomarker Analysis|Correlative studies
48293050|NCT03419234|PROCEDURE|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
48293051|NCT03419234|OTHER|Pharmacological Study|Correlative studies
48293052|NCT03419234|DRUG|Prednisone|Given PO
48475404|NCT05111886|BEHAVIORAL|One Session Education about Resources|"One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools."
48475405|NCT05111886|DIAGNOSTIC_TEST|Survey of Experience|Satisfaction with referral process
48632349|NCT01471574|DRUG|Ribavirin|Tablets; oral; for patients weighing \<75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing \>75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
48293053|NCT05653908|OTHER|StudentMood|StudentMood is an app that uses ecological momentary assessment method to asses mood and other mental health corelates. Participants will have to complete the application (the mood wheel, heart rate and other behavioral data as well as standardized scales) daily throughout the entire semester
48293054|NCT06095674|DRUG|Anti-PD-1 antibody balstilimab|Both antibodies will be neoadjuvantly administered around the cervical tumor.
48293055|NCT05385614|BEHAVIORAL|de:)press|Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
48293056|NCT04852887|OTHER|Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|"Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator."
48293057|NCT04852887|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
48475406|NCT06534931|PROCEDURE|High velocity low amplitude thoracic spine manipulation|Participants were supine on a treatment table. The chiropractor determined levels of apparent spinal dysfunction by means of static palpation. Participants were then asked to curl forward and bring their knees to their chest as the chiropractor placed a fist just inferior to the targeted level, anywhere between the T4 - T10 vertebrae. The participant was instructed to inhale and then exhale, at which point the chiropractor lowered the participant's torso back to the table and delivered a thrust using his body into his fist.
48475407|NCT06534931|PROCEDURE|Sham|A previously validated physiologically inert manual procedure to the thoracic spine
48632350|NCT01471574|DRUG|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
48632351|NCT03612700|OTHER|CPFA-rich foods|Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
48632352|NCT03760731|BEHAVIORAL|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
48632353|NCT03760731|BEHAVIORAL|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
48632354|NCT00353015|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
48632355|NCT00353015|DRUG|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
48293058|NCT03195790|BEHAVIORAL|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
48475408|NCT05845957|OTHER|Digital Education Group|Providing training on safe pediatric intravenous drug administration with digital storytelling method
48632356|NCT02499536|DEVICE|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
48632357|NCT06499649|DIETARY_SUPPLEMENT|IBSA Probiotics|Lactobacillus acidophilus and Bifidobacterium animalis Probiotic strains (LAC6; BLA8; BLC6).
48632358|NCT06499649|DIETARY_SUPPLEMENT|Placebo|The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.
48632359|NCT00850187|BIOLOGICAL|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
48632360|NCT04678310|OTHER|Support from the hospital palliative and end of life care volunteer service (developed for this study).|Hospital palliative and end of life care volunteer service: a volunteer service to provide support to patients dying in the hospital and their families. The volunteer service has been designed to provide presence and companionship to dying patients at the end of life, and their families.
48632361|NCT05538650|BEHAVIORAL|Mindfulness-Based Social Work and Self Care (MBSWSC)|MBSWSC is a unique mindfulness-based programme for social work and self-care which has been specifically developed for online delivery. The MBSWSC programme is embedded within key cognitive and emotion regulation, and stress coping theory. This programme combines mindfulness practices with psychoeducation with the aim of allowing participants to reduce any negative thinking about the past and future by learning skills that will allow them to focus on the present. It will also focus on how to effectively apply these newly acquired mindfulness skills in social work practice. The programme has been the subject of an initial RCT, which has helped to inform the current programme content and structure. The MBSWSC programme comprises 6x1.5 hour sessions, delivered weekly, over a 6 week period. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
48632362|NCT05538650|BEHAVIORAL|Mindfulness-Based Self-Care (MBSC)|MBSC is a modified, condensed Mindfulness Based Intervention; with a key focus on self-compassion/self-care. Key practices in this condensed programme were chosen for their relevance and utility to social workers. The MBSC programme comprises 3x1 hour sessions delivered over a 6 week period, with one session every two weeks. Homework, in the form of mindfulness practices, is given each week. This will take approximately 20-30 minutes to complete, on 6 out of 7 days, each week.
48632363|NCT04989738|BEHAVIORAL|THRIVE intervention|Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.
48103430|NCT03526081|OTHER|Parsley-based drink (II)|3.2 g dried parsley in 300mL hot water
48103431|NCT00897637|OTHER|laboratory biomarker analysis|Correlative studies
48293059|NCT01956643|OTHER|gum chewing|gum chewing
48293060|NCT01956643|OTHER|Control|Routine care during NPO
48293061|NCT05963698|DEVICE|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
48632364|NCT04989738|BEHAVIORAL|Active Control|Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
48632365|NCT03749863|PROCEDURE|Serial PRP injections|Autologous platelet-rich plasma will be injected into the vocal fold mucosa in a serial fashion, once per month for a total of 4 injections.
48293062|NCT02267499|OTHER|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
48103432|NCT03097237|OTHER|Wholegrain rye|Cereal products based on wholegrain rye
48103433|NCT03097237|OTHER|Refined wheat|Cereal products based on refined wheat
48103434|NCT00304980|DRUG|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
48475409|NCT00056381|DRUG|Anidulafungin|
48475410|NCT05931393|DRUG|Cabozantinib 80 MG|cabozantinib 80mg daily
48475411|NCT05931393|DRUG|Cabozantinib 40Mg Tab|cabozantinib 40mg daily
48475412|NCT05931393|DRUG|Nivolumab|nivolumab 480 mg IV every 4 weeks
48475413|NCT04226131|OTHER|Blood Draw|A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
48293063|NCT04765462|BIOLOGICAL|Allogeneic γδ T cells|"Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10\^6/kg, 1 x10\^7/kg to 5x10\^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients."
48293064|NCT06650163|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
48293065|NCT06650163|PROCEDURE|Brain Surgery|Undergo brain surgery
48293066|NCT06650163|OTHER|Electronic Health Record Review|Ancillary studies
48293067|NCT06650163|PROCEDURE|Immuno-Positron Emission Tomography Scan|Undergo immuno-PET
48293068|NCT06650163|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48293069|NCT06650163|PROCEDURE|Stereotactic Biopsy|Undergo stereotactic image-guided biopsy
48293070|NCT06650163|DIAGNOSTIC_TEST|Zirconium Zr 89 Crefmirlimab Berdoxam|Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
48293071|NCT06562816|DRUG|Trypsin-Chymotrypsin|100000 IU
48293072|NCT06562816|DRUG|Naproxen Sodium 550mg|550mg
48293073|NCT04939051|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48293074|NCT04939051|PROCEDURE|Esophageal Biopsy|Undergo esophageal biopsy, brushings and gastric aspirate
48293075|NCT04939051|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
48475414|NCT04226131|OTHER|Disease Activity (DAS-28) Assessment|Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
48632366|NCT03292978|DIETARY_SUPPLEMENT|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
48632367|NCT03292978|DIETARY_SUPPLEMENT|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
48632368|NCT04213339|BEHAVIORAL|Kegel Exercises|"Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~1. Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~2. Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~3. Squeeze the muscles in anus like holding a bowel movement focus penile area~4. Relax the pelvic floor muscles after each attempt.~5. Repeat this exercise 10 to 20 times.~6. While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises"
48632369|NCT03315559|DRUG|[14C]-GSK2269557 IV infusion|The \[14C\]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
47944292|NCT01021579|DRUG|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
47944293|NCT01021579|DRUG|Metfomin plus Simvastatin|
48103435|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
48103436|NCT03141658|DRUG|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
48293076|NCT04939051|PROCEDURE|Liver Ultrasonographic Elastography|Undergo liver ultrasound with elastography
48293077|NCT04939051|BIOLOGICAL|Obeticholic Acid|Given PO
48293078|NCT04939051|DRUG|Placebo Administration|Given PO
48293079|NCT04939051|OTHER|Questionnaire Administration|Ancillary study
48293080|NCT02933515|OTHER|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
48293081|NCT04049188|RADIATION|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
48293082|NCT06672887|OTHER|MiLES|The MiLES intervention is an open access website, accessible via an URL, but not traceable through any online search engine during the study period. Tailored for specific preferences and needs of different employees with cancer, the MiLES intervention consists of interactive videos, conversation checklists, tips and information regarding RTW guidance of employees with cancer, and an overview of involved stakeholders and relevant legislation. The MiLES intervention intends to optimize the RTW support the employer provides to the employee with cancer by enhancing the willingness and ability to implement the employer actions. The MiLES intervention focuses for example on fostering effective communication between the employer and employee, while disregarding assumptions based on previous experiences.
48293083|NCT03940144|DEVICE|the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device|Stroke volume variation (SVV)-guided fluid therapy
48293084|NCT06671236|BIOLOGICAL|Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)|Regulatory T cell therapy, intrathecal injection
48293085|NCT05227651|DRUG|AK104|IV infusion,Specified dose on specified days
48293086|NCT01690949|DRUG|PUR118|inhaled PUR118, BID
48103437|NCT03141658|DRUG|Placebo|Multiple doses of placebo once daily for 6 days
48293087|NCT06667336|PROCEDURE|intermittent suction|This suction was applied only as needed to clear secretions
48293088|NCT06667336|PROCEDURE|continuous suction|The suction catheter was inserted at the start of laryngoscopy and maintained in the oropharynx until the moment of ETT delivery.
48293089|NCT01304862|BEHAVIORAL|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
48293090|NCT01304862|BEHAVIORAL|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
48620016|NCT04179214|OTHER|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
48620017|NCT02875080|DRUG|OPC-34712|
47944294|NCT00336154|DRUG|tetracyclin|
48293091|NCT02398123|OTHER|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
48293092|NCT02398123|OTHER|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
48293093|NCT02398123|DRUG|Bupivacaine|
48293094|NCT00416767|DRUG|fluorouracil|
48293095|NCT00416767|DRUG|irinotecan hydrochloride|
48293096|NCT00416767|DRUG|leucovorin calcium|
48293097|NCT02797041|DRUG|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
48293098|NCT01359982|DRUG|RRx-001|Dose level 1 (10 mg/m2)
48293099|NCT01359982|DRUG|RRx-001|Dose Level 2 (16.7 mg/m2)
48632370|NCT03315559|DRUG|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
48632371|NCT03315559|DRUG|[14C]-GSK2269557 oral solution|The \[14C\]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving \[14C\]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
48632372|NCT04889651|DRUG|BR9004|BR9004: Abiraterone acetate 200mg, Boryung Pharmaceutical Co., Ltd.
48632373|NCT04889651|DRUG|BR9004-1|BR9004-1: Zytiga Tab. 500mg (Abiraterone acetate 500mg), Janssen Korea
48632374|NCT00335192|DRUG|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
48632375|NCT00335192|DRUG|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
48293100|NCT01359982|DRUG|RRx-001|Dose Level 3 (24.6 mg/m2)
48632376|NCT00335192|DRUG|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
48632377|NCT04428593|DRUG|Treamid 5 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
48632378|NCT04428593|DRUG|Treamid 15 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
48632379|NCT04428593|DRUG|Treamid 50 mg|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
48103438|NCT03141658|OTHER|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
48293101|NCT01359982|DRUG|RRx-001|Dose Level 4 (33 mg/m2)
48293102|NCT01359982|DRUG|RRx-001|Dose Level 5 (55.0 mg/m2)
48293103|NCT01359982|DRUG|RRx-001|Dose Level 6 (83 mg/m2)
48293104|NCT00015249|DRUG|Amantadine|
48293105|NCT06672848|DIAGNOSTIC_TEST|Numeretic rating scale (NRS)|NRS is a pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
48293106|NCT06672848|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|BPI is a chronic pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
48632380|NCT04428593|DRUG|Placebo|The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
48632381|NCT00795405|BEHAVIORAL|Exposure to sporting events|Exposure to sporting events
48632382|NCT00795405|BEHAVIORAL|No exposure to sporting events|No exposure to sporting events
48632383|NCT03008577|OTHER|Change in ambient operating room temperature|
48632384|NCT00513448|OTHER|Group wellness intervention|
48632385|NCT00513448|OTHER|Individualized physical rehabilitation|
47944295|NCT06087146|OTHER|Sauerkraut (Brassica oleracea v. capitata)|The research material is a donation from the company Eko Bio Zrnje, Vrbovec, Croatia. It's grated pickle cabbage produced by fermentation in a saline solution (NaCl) in which the fermentation was stopped by pasteurization and was packed in glass 500g jars. The nutritional and microbiological composition was tested by the laboratories of the Faculty of Food and Biotechnology, as well as by the cultural laboratory approach confirmed the presence of bacteria that produce lactic acid (4.82·103 (±2.31) CFU/mL)
48293107|NCT06672848|DIAGNOSTIC_TEST|The S-LANSS Pain Score|The Leeds assessment of neuropathic symptoms and signs (LANSS) Pain Scale is based on analysis of sensory description and bedside examination of sensory dysfunction, and provides immediate information in clinical settings. It was developed in two populations of chronic pain patients.
48293108|NCT06125210|BEHAVIORAL|early bedside rehabilitation|① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.
48293109|NCT06125210|DIETARY_SUPPLEMENT|nutrition program|(1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks
48293110|NCT06125210|PROCEDURE|tracheotomy|early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
48293111|NCT00668525|DRUG|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
48632386|NCT05231941|DRUG|Lidocaine IV|Bolus and infusion of lidocaine will be administered
48632387|NCT05231941|DRUG|Ropivacaine|Bilateral TAP block will be given to these patients
48632388|NCT00129896|DRUG|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
48632389|NCT00129896|DRUG|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
48632390|NCT00129896|DRUG|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
48632391|NCT00195052|DIAGNOSTIC_TEST|Intrinsic signal imaging of human cortex|Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
48632392|NCT03687697|BIOLOGICAL|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
48103439|NCT04034758|PROCEDURE|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
48632393|NCT02528305|OTHER|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
48293112|NCT00668525|DRUG|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
48632394|NCT06028737|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
47944296|NCT00185991|DRUG|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
48103440|NCT04034758|PROCEDURE|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
48103441|NCT02993471|DRUG|Drug Cocktail|Administered orally
48103442|NCT02993471|DRUG|Ixekizumab|Administered SC
48103443|NCT04299360|DEVICE|Cardiac Resynchronization Therapy device programming|Implanted CRT-D devices settings will be programmed based on the best acute hemodynamic response assessed non-invasively
48293113|NCT00668525|DRUG|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
48293114|NCT03897712|DEVICE|Custom Samfilcon B Contact Lenses|Contact lens
48293115|NCT03897712|DEVICE|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
48293116|NCT03897712|DEVICE|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
48293117|NCT03897712|DEVICE|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
48475415|NCT04226131|OTHER|Skeletal Muscle Mitochondrial Respiratory Capacity|Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
48632395|NCT06028737|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
48632396|NCT06028737|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
48632397|NCT06028737|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
48103444|NCT00920296|DRUG|GSK1265744|GSK drug
48103445|NCT04990791|DRUG|Aspirin 75mg|Aspirin 75mg OD for 14 days
48103446|NCT04990791|DRUG|Aspirin 20mg|Aspirin 20mg BD for 14 days
48293118|NCT03805880|DIAGNOSTIC_TEST|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
48632398|NCT02285244|DRUG|sotrastaurin acetate|Given PO
48632399|NCT02285244|OTHER|pharmacological study|Correlative studies
48632400|NCT02285244|OTHER|laboratory biomarker analysis|Correlative studies
48632401|NCT01321645|DRUG|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
48632402|NCT05189197|DRUG|Zanubrutinib + R-CHOP|"Zanubrutinib 160 mg BID administered by oral every day of each 21-day cycle. Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 (maximum total 2 mg) administered by IV infusion on Day 1 of each 21-day cycle.~Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle. After 6 cycles of zanubrutinib and R-CHOP combination therapy, patients achieved CR will continue to receive zanubrutinib 160mg BID for 1 year."
48632403|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA containing composite|Bonding materials of fixed lingual retainers applied with Bis-GMA containing composite
48632404|NCT05738889|DEVICE|Fixed lingual retainers applied with Bis-GMA-free composite|Bonding materials of fixed lingual retainers applied with Bis-GMA-free composite
48632405|NCT05738889|DEVICE|Vacuum-formed retainers|vacuum-forming machine and vacuum formed plates
48632406|NCT05738889|DEVICE|Hawley retainers|Acrylic based hawley retainers
48103447|NCT04990791|DRUG|Rivaroxaban 2.5 mg|Rivaroxaban 2.5mg BD
48103448|NCT05479539|BEHAVIORAL|Action observation therapy|Participants will watch 12-minute video-clips followed by 8 minutes of motor imagery. Video-clips observation and imagination will be focused un shoulder tasks occuring on the three planes of motion.
48103449|NCT00514332|PROCEDURE|stent|stent placement for colorectal cancer obstruction
48293119|NCT04770272|DRUG|Atezolizumab 840 MG in 14 ML Injection|840 mg Day 1 for two weeks
48293120|NCT04770272|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg Day 1 every 3 weeks for 8 cycles
48293121|NCT04770272|DRUG|Carboplatin|Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
48293122|NCT04770272|DRUG|Paclitaxel|Paclitaxel 80 mg/m² IV weekly x 12 cycles
48293123|NCT04770272|DRUG|Epirubicin|90 mg/m2, day 1 for 4 cycles (12 weeks)
48103450|NCT03838796|DRUG|lenvatinib|for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po
48293124|NCT04770272|DRUG|Cyclophosphamide|600 mg/m2, day 1 for 4 cycles (12 weeks)
48293125|NCT04770272|PROCEDURE|Biopsy Arm A|1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.
48475416|NCT04226131|OTHER|Muscle Biopsy|After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.
48475417|NCT04226131|OTHER|Body Composition|Body composition assessments include circumference measurements and the BOD POD®. Minimal waist circumference measurements will be taken using a tape measure.
48475418|NCT04226131|OTHER|Cardiopulmonary Exercise Test (CPET)|Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.
48475419|NCT04226131|OTHER|Strength Testing|Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests
48293126|NCT04770272|PROCEDURE|Biopsy Arm B|1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.
48475420|NCT04226131|OTHER|Questionnaires|Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.
48475421|NCT04226131|OTHER|Skeletal Muscle Biomechanical Property Assessment|Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.
48475422|NCT05768789|DIETARY_SUPPLEMENT|Buoy Electrolyte|Buoy intervention amount is 4% of total body weight given in 16 divided doses over 4 hours.
48475423|NCT05768789|DIETARY_SUPPLEMENT|Nuun|Nuun intervention given as 1L bolus and then free water in divided doses for a total of 4% total body weight.
48293127|NCT04770272|PROCEDURE|Surgery|After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
48293128|NCT02688010|BEHAVIORAL|Noise reduction and cycled light|Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
48293129|NCT03385668|DRUG|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
48293130|NCT01377467|DRUG|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
48293131|NCT03311685|DEVICE|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
48475424|NCT05768789|OTHER|Water|Water serves as a control
48475425|NCT06590467|DEVICE|Amplatzer™ Occlusion Devices|The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.
48475426|NCT06590467|DEVICE|Epic™ Surgical Tissue Heart Valve devices|The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
48475427|NCT06212674|PROCEDURE|PVI + LAAO|Treatment with a complex procedure of PVI + LAAO
48475428|NCT06212674|PROCEDURE|LAAO|Tratment with LAAO procedure
48475429|NCT06212674|DRUG|NOAC|NOAC treatment
48475430|NCT05889273|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
48475431|NCT06368024|OTHER|This is a retrospective analysis study of data collected with a diagnostic medical device|Transcranial Magnetic stimulation and Electroencephalogram
48475432|NCT01909739|DRUG|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
48475433|NCT01909739|DRUG|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
48475434|NCT01782755|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
48475435|NCT01782755|OTHER|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
48475436|NCT00387517|DRUG|Aliskiren/HCTZ|
48475437|NCT02630290|DRUG|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
48475438|NCT02630290|DRUG|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
48475439|NCT01754376|DRUG|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
48475440|NCT01754376|DRUG|Vemurafenib|Tablets given twice daily.
48475441|NCT00171340|DRUG|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
48475442|NCT00171340|DRUG|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
48475443|NCT03553563|DRUG|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
48475444|NCT03553563|DRUG|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
48475445|NCT04300023|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
48475446|NCT00003430|DRUG|L-778,123|
48293132|NCT03268174|OTHER|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
48293133|NCT03268174|OTHER|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
48103451|NCT03838796|PROCEDURE|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
48293134|NCT00839098|OTHER|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
48293135|NCT00839098|OTHER|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction \& Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
48293136|NCT03333356|RADIATION|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
48293137|NCT04418583|DIAGNOSTIC_TEST|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
48475447|NCT05598879|OTHER|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
48475448|NCT05545618|DIAGNOSTIC_TEST|CCTA and 18F-FDG-PET/CT|18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
48475449|NCT05049811|BEHAVIORAL|mini program|To design, construct, and test the mini program in patients managing cancer pain
48475450|NCT05049811|BEHAVIORAL|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
48475451|NCT05409521|OTHER|Kinesio taping|Kinesio taping with the mechanical correction technique will be applied on the thoracic region
48475452|NCT05409521|OTHER|Placebo taping|Placebo taping with no tension and technique will be applied on the arm
48475453|NCT02244073|DRUG|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
48475454|NCT06353308|BEHAVIORAL|Sexual Violence Prevention|The intervention included a game, five short videos, two posters, and five online quizzes, which were provided with a frequency of two posts per week and a final real-time online workshop. Materials included content on the spectrum of gender and sexual identities and orientations, gender and sexual roles, consent and communication, body positivity and self-acceptance, sexual pleasure and desire, as well as risky sexual behavior associated with dating app use and the legal issues and risks of sexual assault, such as precautionary steps and available resources.
48103452|NCT00461799|DRUG|orlistat|
48103453|NCT01912001|OTHER|Telephone follow-up|
48103454|NCT01912001|OTHER|Sympton Assessment|
48103455|NCT01227707|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
48103456|NCT01227707|DRUG|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
48293138|NCT01982110|BEHAVIORAL|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
47944297|NCT04609969|DIAGNOSTIC_TEST|RT-qPCR test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
47944298|NCT04609969|DIAGNOSTIC_TEST|COVID-VIRO® test|Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.
47944299|NCT01347307|RADIATION|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
47944300|NCT01347307|RADIATION|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
47944301|NCT04178473|PROCEDURE|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
47944302|NCT04178473|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
47944303|NCT01753102|DRUG|Estradiol|one tablet will be inserted daily for 14 days
47944304|NCT01675427|OTHER|Interleukin 28B testing|Blood sampling for ILB28 genotyping
47944305|NCT03668769|OTHER|Internet Mobile Technology|Use Quitting Schedule mobile smartphone app
47944306|NCT03668769|OTHER|Interview|Ancillary studies
47944307|NCT03668769|OTHER|Questionnaire Administration|Ancillary studies
47944308|NCT03668769|BEHAVIORAL|Smoking Cessation Intervention|Participate in individual smoking cessation program
48293139|NCT01982110|BEHAVIORAL|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
48293140|NCT00006246|DRUG|busulfan|
47944309|NCT02653534|BEHAVIORAL|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
47944310|NCT04865640|DIAGNOSTIC_TEST|Noninterventional and noninvasive|The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.
47944311|NCT03911154|DEVICE|Philips SmartSleep Technology--Continuous Fixed Interval modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
47944312|NCT03911154|DEVICE|Philips SmartSleep Technology--Block modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
47944313|NCT03911154|DEVICE|Philips SmartSleep Technology--In-Phase Adjustable modality|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~1. Continuous Fixed Interval~2. Block~3. In-Phase Adjustable~4. Sham: No auditory stimulation while wearing the SmartSleep headband"
47944314|NCT00620464|DRUG|Radiopaque Implanon|Radiopaque rod for 3 years
47944315|NCT00620464|DRUG|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
47944316|NCT04360590|DEVICE|pressure support ventilation versus neurally adjusted ventilatory assist|All patients underwent three mechanical ventilation modes, lasting 1 hour each: pressure support mode, neurally adjusted ventilatory assist and again pressure support ventilation
47944317|NCT01128751|PROCEDURE|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
47944318|NCT01128751|PROCEDURE|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
47944319|NCT01128751|PROCEDURE|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
47944320|NCT02413021|DRUG|Cytarabine|20 mg/m\^2 , SC, two times a day for 10 days every 30 days for 1 cycle
47944321|NCT02413021|DRUG|Deferasirox|20 mg/kg ,oral, per day
47944322|NCT05120609|DEVICE|Parkinson's Application|The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
48293141|NCT01204112|DRUG|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
48293142|NCT05523635|DEVICE|Gamma4 Nailing System|The Gamma4 Nailing System is is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).
48293143|NCT04319237|OTHER|Handgrip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles.
48475455|NCT06353308|BEHAVIORAL|Sexual health intervention|This general online sexual health education consisted of online videos, quizzes and game that covered a wide range of diverse topics on love, sex and relationships such as healthy and respectful relationships, body self-esteem, sexual identity and orientation, sexual rights and decision making, in addition to the conventional focus on sexual dysfunction and disease aversion.
48475456|NCT04743817|DEVICE|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
48632407|NCT05206097|DEVICE|Accelerometer|For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci \& Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
48632408|NCT04617223|PROCEDURE|Endoscopic sinus evacuation|Evacuation of the sinus by using endoscope
48632409|NCT02407977|OTHER|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
48632410|NCT04853537|DIETARY_SUPPLEMENT|intermittent fasting diet|intermittent fasting diet to obese pregnant women \>30 BMI and incidence of gestational diabetes
48632411|NCT04645056|OTHER|Stretching and Mobility exercises for neck and shoulder|9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
47944323|NCT05120609|DEVICE|Digital Placebo Application|The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
47944324|NCT03843827|DEVICE|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
48632412|NCT04582643|BEHAVIORAL|6P intervention|6P assessment targeting on diet, activity and mentality, along with education provided based on the 6P components. The 6P tool serves the functions to help the women to self-monitor and be aware of their negative lifestyle choices.
47944325|NCT03843827|DEVICE|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
48632413|NCT02357485|BIOLOGICAL|ADSC|Single injection of ADSC
47944326|NCT02413177|BEHAVIORAL|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
48475457|NCT06081140|DIETARY_SUPPLEMENT|Standard Process Hemp Oil Complex|10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
48475458|NCT03337217|PROCEDURE|Position during colonoscopy|Position during colonoscopy
48475459|NCT06319079|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
48475460|NCT06319079|OTHER|Powder milk|Commercial powder milk constitutes dehydrated commercially available cow's milk, which is fortified with Vitamins A and D by law.
48475461|NCT05284084|OTHER|Bed Head elevation, H2 blockers and mouth wash|Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.
48475462|NCT05284084|OTHER|Data collection for comparison|Data collection for comparison
48475463|NCT01182662|OTHER|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
48475464|NCT01182662|OTHER|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
48475465|NCT00908557|OTHER|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
48632414|NCT03197935|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab was administered as per schedule described in respective arm.
48632415|NCT03197935|DRUG|Placebo|Placebo matched to atezolizumab was administered as per schedule described in respective arm.
48632416|NCT03197935|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered as per schedule described in the arms.
48632417|NCT03197935|DRUG|Doxorubicin|Doxorubicin was administered as per schedule described in the arms.
48632418|NCT03197935|DRUG|Cyclophosphamide|Cyclophosphamide was administered as per schedule described in the arms.
48632419|NCT03197935|DRUG|Filgrastim|Filgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
48103457|NCT01227707|RADIATION|Radiation therapy|Total dose of 45 Gy over 38 days
48103458|NCT01227707|PROCEDURE|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
48103459|NCT01227707|DRUG|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
48103460|NCT01227707|DRUG|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
48103461|NCT01227707|DRUG|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
48293144|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|"The Wechsler Test of Adult Reading (WTAR) is a neuropsychological assessment tool used to provide a measure of Intellectual function. Participants are presented with 50 irregularly spelled words and prompted to pronounce each; the irregular grapheme-to-phoneme translations (such as the gh in the word tough) in the prompts make it difficult to pronounce without having previously learned the word. A high WTAR score is correlated with higher general intelligence as measured by the Wechsler intelligence scales."
48293145|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) consists of twelve subtests which give five scores, one for each of the five domains tested (immediate memory, visuospatial/constructional, language, attention, delayed memory).
48293146|NCT04319237|BEHAVIORAL|Neuropsychological Assessment - Color Trails|The Color Trails test measures sustained attention and sequencing. Numbered circles are printed with vivid pink or yellow backgrounds that are perceptible to color-blind individuals. Participants rapidly connect circles numbered 1-25 in sequence and rapidly connect numbered circles in sequence, but alternates between pink and yellow. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.
48293147|NCT04319237|BEHAVIORAL|Neuropsychological Assessment -Stroop Color and Word Test|The Stroop Color and Word Test is based on the observation that individuals can read words much faster than they can identify and name colors. The test-taker reads color words or names ink colors from different pages as quickly as possible within a time limit. The test yields three scores based on the number of items completed on each of the three stimulus sheets. An Interference score is useful in determining the individual's cognitive flexibility, creativity, and reaction to cognitive pressures.
48293148|NCT04319237|BEHAVIORAL|Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|The PROMIS-29 questionnaire assesses each of 7 domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities). A higher score equals more of the concept being measured.
48293149|NCT04319237|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-3) and the add-on EORTC QLQ Non-Hodgkin's Lymphoma (EORTC QLQ-NHL-HG29) module. All scales range from 0-100, a high scale score represents a higher response level. For example, a high functional score represents a high level of functioning.
48293150|NCT04319237|BEHAVIORAL|Quality of Life (EQ-5D-5L) Questionnaire|The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
48293151|NCT04319237|BEHAVIORAL|PROMIS Cognitive Function 4a Questionnaire|The PROMIS measures function, symptoms, behavior and feelings.
48475466|NCT00908557|OTHER|Control|information based on the classic informed consent document
48475467|NCT02020967|OTHER|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
48632420|NCT03197935|DRUG|Pegfilgrastim|Pegfilgrastim was administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
48632421|NCT02175758|DRUG|SOF|SOF administered orally once daily
48632422|NCT02175758|DRUG|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
48632423|NCT00315029|BEHAVIORAL|evidence based decision aid|evidence based decision aid
48632424|NCT00315029|BEHAVIORAL|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
48632425|NCT03156621|DRUG|Alirocumab|Alirocumab SC Q2W
48475468|NCT04405739|DRUG|EIDD-2801|Oral capsule of EIDD-2801
48475469|NCT04405739|DRUG|Placebo|Oral placebo capsule
48632426|NCT03156621|DRUG|Placebo|Matching placebo SC Q2W
48632427|NCT03587103|BEHAVIORAL|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
48632428|NCT03587103|BEHAVIORAL|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
48632429|NCT03587103|BEHAVIORAL|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
48632430|NCT05154162|DIAGNOSTIC_TEST|PSMA PET/CT|PSMA PET/CT (limited to the pelvis)
48293152|NCT04319237|BEHAVIORAL|Comprehensive Score for Financial Toxicity (COST) measure|The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
48293153|NCT03366844|DRUG|Pembrolizumab|checkpoint inhibitor
48293154|NCT03366844|RADIATION|RT Boost|The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
48293155|NCT03576677|DRUG|Levosimendan|"Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min."
48293156|NCT03576677|DRUG|Placebo|"The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group."
48293157|NCT05319535|OTHER|Implementation Strategy: Foundational REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Caregivers FIRST for context and provides tools for ongoing Caregivers FIRST evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully incorporate Caregivers FIRST into routine practice.
48293158|NCT05319535|OTHER|Implementation Strategy: Enhanced REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators posit that higher intensity strategies (defined as Enhanced REP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
48293159|NCT05105243|DRUG|CVN766|highly selective orexin-1 receptor (Ox1R) antagonist
48293160|NCT06436313|OTHER|Educational Sessions|"Two online educational sessions will be organized before DBS surgery. These will be scheduled between consultation with the neurologist and the consultation with the neurosurgeon. Each virtual session will last about 1 hour. Patients can login from home, together with their caregivers. The virtual sessions will be held on MS Teams virtual platform.~One of the sessions will include a DBS patient where patients will have the opportunity to ask peer-to-peer questions. The session includes testimonials from patient before and after their surgery.~The second session (about two weeks later) is a summary presentation, a quiz and time for Q\&A. During one of the sessions (first or second), a DBS patient (who has been implanted) can be invited to participate togive the attendees the opportunity to ask peer-to-peer questions. The quiz contains questions to assess the patients' knowledge of DBS."
48293161|NCT05721625|OTHER|Aerobic exercise|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
48293162|NCT05721625|OTHER|Connective tissue massage|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
48293163|NCT03425799|DRUG|Sodium Chloride 0.9% Inj|Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
48293164|NCT03425799|DRUG|Tranexamic Acid|Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
48475470|NCT03738787|PROCEDURE|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
48475471|NCT03738787|PROCEDURE|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
47944327|NCT02413177|BEHAVIORAL|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
47944328|NCT02496962|DRUG|Atorvastatin|atorvastatin were taken daily for 5 days
47944329|NCT02496962|DRUG|placebo|placebo were taken daily for 5 days
47944330|NCT04836312|BEHAVIORAL|Soft Commitment Device|Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.
48475472|NCT02621463|DEVICE|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
48632431|NCT05154162|PROCEDURE|Transperineal template prostate biopsy|Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
48293165|NCT04947566|DRUG|Comparison of Efficacy of Naproxen versus Ibuprofen|Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
48632432|NCT05154162|PROCEDURE|Transperineal targeted prostate biopsy|If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
47944331|NCT06198127|OTHER|combination of core stability exercises and kinesio-taping|the patient in the experimental group will receive the core stability exercises with kinesiology taping on trunk stabilizer muscles. the time of intervention was 30 minutes per day. The exercises such as Abdominal draw-in with a double knee to chest, Trunk twist while sitting on a medicine ball, Lying in a supine position on bed and rotating the trunk from side-to-side, Bridging exercises, the I-shaped elastic KT will apply to the four trunk muscles from their insertion to their origin: Kinesio-taping is used on global muscles such as Rectus abdominis, External obliques, Erector spinae, Quadratus lumborum. Kinesio-taping will 1 inch wide and apply on muscles for 1 to 2 days then remove for 24 hours then again apply a new one. The tension will be 10 to 15% and tape will apply on muscles which will be stretched by maintaining a posture.
48293166|NCT02928237|DEVICE|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
48293167|NCT00680420|PROCEDURE|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
48293168|NCT02368444|BEHAVIORAL|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
48475473|NCT04459676|DRUG|Standard of Care (SOC) + ANG-3777|Standard of Care (SOC) + ANG-3777
48475474|NCT04459676|DRUG|Standard Of Care (SOC) + Placebo|Standard Of Care + Placebo
47944332|NCT06198127|OTHER|Core stability exercises|After the baseline assessment, the patient in the control group will receive the core stability exercises with kinesio-taping on trunk stabilizer muscles. Time of rehabilitation will be 30 minutes per subject and four days per week. In first few minutes, the subject will be explained her/his task Subject will execute the exercises such as Abdominal draw-in with a double knee to chest 10- 15 times. Trunk twist while sitting on a medicine ball 10- 15 times. Lying in a supine position on bed and rotating the trunk from side-to-side 10- 15 times. Lying in a supine position on a mat and pulling upper and lower limbs upward 10- 15 times. Bridging exercises 10- 15 times, Deep Breathing and Wheelbarrow.
48475475|NCT01419899|BEHAVIORAL|Brief motivational intervention|A 20-30 minute motivational based discussion
48475476|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
48475477|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
48475478|NCT03928236|OTHER|Limited Intraoperative Benzodiazepine|policy for limited use of intraoperative benzodiazepine
48475479|NCT03928236|OTHER|Liberal Intraoperative Benzodiazepine|policy for liberal use of intraoperative benzodiazepine
48475480|NCT02288494|OTHER|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia \< 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
48475481|NCT03798340|OTHER|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
48475482|NCT03798340|OTHER|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
48475483|NCT03798340|OTHER|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
48475484|NCT05377125|BEHAVIORAL|Computerized cognitive training|This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
48475485|NCT05377125|BEHAVIORAL|Computerized placebo training|This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
48103462|NCT02797249|DRUG|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
48293169|NCT03693027|DIETARY_SUPPLEMENT|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
48293170|NCT03693027|DIETARY_SUPPLEMENT|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
48293171|NCT02965703|DRUG|Aspirin|Given PO
48293172|NCT02965703|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, stool, and rectal swab samples
48475486|NCT05783856|COMBINATION_PRODUCT|LiveSpo X-secret|In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
48475487|NCT05783856|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
48475488|NCT00031850|DRUG|goserelin acetate|
48475489|NCT00031850|DRUG|raloxifene|
48475490|NCT04296955|OTHER|Motivational interview as a new health communication intervention|Same as intervention name
48475491|NCT02023840|DRUG|metronidazole gel|
48475492|NCT02023840|PROCEDURE|ultrasonics|
48475493|NCT02023840|PROCEDURE|erythritol|
48475494|NCT02023840|DRUG|placebo|
48475495|NCT05966207|BEHAVIORAL|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation will be conducted by caregivers, with support by the research team. The intervention will span 12 weeks, consisting of three weekly sessions (30 minutes each session), totaling 36 sessions. Caregivers in this study will utilize a previously translated and validated version of Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers, specifically adapted for the European Portuguese population."
48475496|NCT00745134|DRUG|Capecitabine|Given PO
48475497|NCT00745134|DIETARY_SUPPLEMENT|Curcumin|Given PO
48475498|NCT00745134|OTHER|Laboratory Biomarker Analysis|Correlative studies
48475499|NCT00745134|OTHER|Pharmacological Study|Optional correlative studies
48475500|NCT00745134|OTHER|Placebo|Given PO
48475501|NCT00745134|OTHER|Quality-of-Life Assessment|Ancillary studies
48475502|NCT00745134|RADIATION|Radiation Therapy|Undergo radiation therapy
48475503|NCT01951287|OTHER|Acute beverage (water) consumption|Acute beverage consumption includes water.
48475504|NCT01951287|OTHER|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
48293173|NCT02965703|OTHER|Placebo Administration|Given PO
48475505|NCT01951287|OTHER|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
48475506|NCT01951287|OTHER|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
48475507|NCT01951287|OTHER|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
48475508|NCT01951287|OTHER|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
48475509|NCT03703453|DEVICE|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
48475510|NCT06460506|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
48293174|NCT02965703|OTHER|Questionnaire Administration|Ancillary studies
48475511|NCT06460506|DRUG|IVA|Granules for oral administration
48475512|NCT05321823|DEVICE|iBreast device|The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
48475513|NCT05321823|OTHER|Clinical Breast Examination|The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
48475514|NCT05321823|DIAGNOSTIC_TEST|Breast ultrasound|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
48293175|NCT02965703|PROCEDURE|Rectal Biopsy|Undergo rectal biopsy
47944333|NCT05597670|OTHER|traditional knee rehabilitation program|Patients in this group will receive a traditional therapeutic knee rehabilitation program in the form of mini-squatting exercise (up to 45 degree knee flexion measured by a universal goniometer) , strengthening of hip abductors and external rotators
47944334|NCT05597670|OTHER|proximal stabilization|the principles of proximal stability will be explained to patients before initiation of treatment and patients will be asked to comply with these principles during exercise. These principles include learning how to activate transversus abdominus by abdominal bracing without allowing pelvis tilting and ensure neutral spine and diaphragmatic breathing during exercise.
47944335|NCT02887573|DRUG|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
47944336|NCT02887573|DRUG|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
47944337|NCT02887573|PROCEDURE|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
47944338|NCT02887573|DRUG|2L PEG|2L PEG are laxatives for experiment group.
48103463|NCT02797249|OTHER|Blank|Routine examination during pregnancy.
48293176|NCT06268899|OTHER|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
48293177|NCT06602024|BIOLOGICAL|mRNA-1010|Intramuscular (IM) injection
48293178|NCT06602024|BIOLOGICAL|Fluarix®|IM injection
48293179|NCT06602024|BIOLOGICAL|Influsplit®|IM injection
48293180|NCT06384339|DIAGNOSTIC_TEST|CSIV, Social motive|The CSIV is a self-report measure and assesses interpersonal values using eight octant scales, which are aggregated into overall communion and agency scores, ranging from -4 to +4 .
48475515|NCT05321823|DIAGNOSTIC_TEST|Mammography|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
48475516|NCT00782561|DRUG|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
48620018|NCT03524209|DEVICE|Percutaneous instrumentation of the thoracolumbar spine|The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.
48632433|NCT05698628|PROCEDURE|Distal perfusion catheterization|Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
48632434|NCT00247793|DRUG|Oral Impact (preoperative enteral nutritional supplement)|
47944339|NCT02887573|DRUG|4L PEG|4L PEG are laxatives in the control group.
47944340|NCT02887573|DRUG|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
47944341|NCT02887573|DRUG|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
48632435|NCT00714272|DEVICE|Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1|6 treatments. One per week during the first six consecutive weeks.
48632436|NCT00714272|DEVICE|Treatment with a sham device, EXcorLab box 1.2|6 sham treatments. One treatment per week during the first six consecutive weeks.
48632437|NCT04317846|OTHER|Intravenous administration of vasodilatory drugs|Administration of the vasodilatory drugs in a different pattern than intra-arterially
48632438|NCT01895179|OTHER|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
48632439|NCT01895179|OTHER|Grazing|Grazing involves eating meals spread out over the course of the day.
48632440|NCT04017910|DEVICE|EchoMark/EchoSure|Each subject will have an EchoMark implanted at the time of arteriovenous fistula creation, and undergo EchoSure and duplex imaging follow-up.
47944342|NCT06317376|OTHER|MICT with Aerobic exercise on treadmill|MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
47944343|NCT06317376|OTHER|standard hospital protocol|standard hospital protocol
47944344|NCT03015545|DEVICE|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
47944345|NCT03015545|DEVICE|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
47944346|NCT03015545|DEVICE|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
47944347|NCT03015545|DEVICE|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
47944348|NCT05385185|DRUG|Camrelizumab or envafolimab|combine Camrelizumab or envafolimab with Recombinant human vascular endostatin
47944349|NCT02682407|BIOLOGICAL|OMS721 (narsoplimab)|Biological: OMS721 (narsoplimab)
48103464|NCT01521585|DRUG|SEN0014196|50 mg oral once daily tablet
48103465|NCT01521585|DRUG|SEN0014196|200 mg oral once daily tablet
48103466|NCT01521585|DRUG|Placebo|oral once daily tablet
48293181|NCT06384339|DIAGNOSTIC_TEST|Interpersonal messages and behavior|"The Impact Message Inventory - Circumplex (IMI-C) Brief Version is a self-report transactional inventory designed to measure a target person's interpersonal behavior on four octant scales dominance, hostility, submissiveness, and friendliness by assessing the covert responses or impact messages of another person. Each subscale consists of 7 items, with each item scored on a 4-point Likert scale from 1 (not at all) to 4 (very much so). The minimum score per scale is 7 and the maximum score is 28."
48632441|NCT02677285|OTHER|Different type of wound|
48632442|NCT00593073|BEHAVIORAL|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
48632443|NCT00593073|BEHAVIORAL|General Reminder Message|General CRC health education message and reminder to get screened.
48632444|NCT00494884|DRUG|vildagliptin|
47944350|NCT00116428|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
47944351|NCT00116428|DRUG|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
47944352|NCT03923738|DRUG|Tocilizumab|TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
48475517|NCT06616363|BEHAVIORAL|Questionnaires to be competed|"* The Pain Coping Questionnaire short form~* Functional Disability Inventory (FDI), the primary clinical outcome measure.~* COMPASS-31 and orthostatic hypotension modified for POTS.~* The Pain Response Inventory (PRI)PROMIS Depression~* GAD-7 for anxiety~* Varni/Thompson Pediatric Pain Questionnaire~* Child and Parent Reports of Post-Traumatic Symptoms (CROPS/PROPS)~* Pain Catastrophizing Scale (PCS-C)~* Detailed account of natural history and evolution of POTS and COPCs through MEDYSA (facilitates the assessment of specific syndromic diagnoses based on published criteria, rather than organ-based classification of symptoms)"
48475518|NCT06616363|BEHAVIORAL|Provide list of medication and lifetime events|Participants will provide a list of all medications taken at each visit time, lifetime history of infections, traumas, and other significant life events.
48475519|NCT06616363|BEHAVIORAL|Use phone App to record new life events|Subjects will also record new life events, minor traumas, entrance into a flare and menses in Ilumivu's EMA (Ecological Momentary Assessment) phone App
48475520|NCT06616363|DEVICE|Will wear an activity monitor|Participants will have an activity monitor loaned for the duration of the study to track their physical activity.
47944353|NCT00910988|DRUG|Olanzapine|olanzapine/Zyprexa
47944354|NCT00910988|DRUG|Ziprasidone|ziprasidone/Geodon
47944355|NCT02646254|OTHER|blood cardioplegia|
47944356|NCT02646254|OTHER|del nido cardioplegia|
48475521|NCT06616363|OTHER|Periodic 24-hour urine sodium check|POTS patients will have a periodic 24-hour urine sodium check to determine compliance to intake of salt.
48632445|NCT04100187|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
48632446|NCT02585167|PROCEDURE|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
48632447|NCT02585167|DEVICE|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
47944357|NCT04558281|DRUG|Active ropivacaine 0.3% erector spinae plane perineural administration|Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
47944358|NCT04558281|DRUG|Placebo erector spinae plane perineural administration|Normal saline administration via an erector spinae plane perineural catheter
48632448|NCT06151938|DRUG|Standardised allergen extract from house dust mites|Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
48475522|NCT06616363|DIAGNOSTIC_TEST|A fMRI scan|• Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.
48475523|NCT06616363|DIAGNOSTIC_TEST|A bedside tilt test will be performed|A bedside tilt test will be performed where blood pressure will be recorded supine and upright positions to confirm/exclude POTS.
47944359|NCT05607771|DEVICE|Manual Vitrification|Oocytes will be prepared for vitrification using the manual protocol
47944360|NCT05607771|DEVICE|Automated Vitrification|Oocytes will be prepared for vitrification using the DaVitri device
47944361|NCT06199232|DRUG|HAIC+targeted therapy+PD-1 inhibitor|"HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w."
47944362|NCT05530031|PROCEDURE|trabeculotomy ( angle glaucoma surgery )|a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
47944363|NCT05914922|OTHER|Educational Tool|20 MSK short case simulations were developed based on authentic patient experiences. Strategies to optimize learning of MSK conditions to prepare learners for real-world clinical encounters would be important for family medicine resident learners. To address this need, 20 case simulations of 15 minute duration were developed. This study will determine if an online educational tool may be impactful for determining competency of family medicine resident learners in developing skills and knowledge of 20 MSK conditions while also determining if the tool impacts patient care and satisfaction.
47944364|NCT03374631|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
47944365|NCT03374631|DEVICE|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
47944366|NCT00745173|DRUG|Premarin|
47944367|NCT00174811|DRUG|telithromycin (HMR3647)|
47944368|NCT00634400|DRUG|Candesartan|
47944369|NCT00634400|DRUG|Placebo|
47944370|NCT04723901|BIOLOGICAL|Dual target CAR-T cell therapy|CD19/CD22 dual target CAR-T cell therapy
47944371|NCT03436810|PROCEDURE|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
48103467|NCT04861610|BEHAVIORAL|Brief mindfulness based program|An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults
48475524|NCT06616363|OTHER|IV placed to collect blood samples|• An IV will be place for collection of 4 blood samples, about 12 mL of blood. For each position (lying and standing) the study team will draw 2 tubes each times with 3 mL of blood, for a total of 4 lab tubes (12 mL). Physical exams to assess the 18-tender points described by the American College of Rheumatology for the diagnosis of fibromyalgia and hypermobility/Ehlers-Danlos Syndrome (EDS) exam will be performed in all subjects.
48475525|NCT06616363|OTHER|Stool Sample|• Participants will provide a stool biospecimen sample at each in-person visit. Stool will be collected in a hat and sample will be swabbed with the swab placed directly into PrimeStore collection tube and the remainder of the sample discarded
48475526|NCT04204226|BEHAVIORAL|Social Worker|The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.
47944372|NCT03436810|PROCEDURE|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
47944373|NCT03436810|PROCEDURE|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
47944374|NCT03509610|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
48103468|NCT04861610|BEHAVIORAL|Psychoeducation|An intervention promotes the coping and problem solving in caregiving for the frail older adults
48103469|NCT00223054|DRUG|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
48103470|NCT00223054|DRUG|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
47944375|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
47944376|NCT00200551|DRUG|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
47944377|NCT01250288|OTHER|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
47944378|NCT02746068|DRUG|AXS-02|
47944379|NCT02746068|DRUG|Placebo|
48293182|NCT06384339|DIAGNOSTIC_TEST|CCS, Social motive|The CCS is a elf-report inventory, that measures tendencies towards competitiveness versus caring in social interactions. The minimum score for the two subscales competitiveness and caring are 9 and the maximum score is 90.
48632449|NCT01552889|BEHAVIORAL|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
48103471|NCT00223054|DRUG|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
48103472|NCT00223054|DRUG|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
48103473|NCT04035512|OTHER|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
48632450|NCT02734914|DEVICE|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
47944380|NCT06551636|OTHER|respiratory physiotherapy (AAD)|The AAD technique involves placing the physiotherapist's hands on the chest where the secretions are identified and applying pressure to the chest. The maneuver will last according to the patient's tolerance, in an average of approximately 10 min.
47944381|NCT00233428|PROCEDURE|Blood Draw|
47944382|NCT01243671|BIOLOGICAL|Adalimumab|
47944383|NCT00406094|DRUG|montelukast|10mg
48103474|NCT06555224|DEVICE|Systane Hydration MDPF eye drops|Systane Hydration MDPF eye drops 4x daily for 3 months additional to routine medication after cataract surgery
48103475|NCT05857358|PROCEDURE|lipoaspiration|"Adipose tissue harvest will be conducted by a surgeon under under local and intra-veinous sedation anesthesia. Once the patient is asleep and just before the laying of the operating drapes, the skin will be thoroughly disinfected, in order to avoid bacteriological contamination. Each entry point will be disinfected with betadine before and regularly during the procedure and will receive local anesthesia.~The lipoaspiration sites will be infiltrated using a closed system, thanks to a Khoury canula. Adipose tissue will be harvested after waiting at least 5 minutes, in order to limit hematoma and excessive blood harvesting. A 3mm incision will be made then the tissue collection will be performed using a canula, manually, by gentle aspirations into a syringe then directly transferred into a connected sterile bag.~The incision will be closed with 1 stitch of 6-0 absorbable and a paraffin gauze dressing. Then, patient will be awaken and transported to the recovery room."
48293183|NCT06405204|DRUG|Myoinositol|an enzymatic isoform of inositol and belongs to the vitamin B complex family
48293184|NCT06405204|DRUG|Co-Enzyme Q10|a lipid-soluble quinone, acting as an effective antioxidant,
48293185|NCT06405204|DRUG|Melatonin|an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
48293186|NCT06405204|DRUG|Folic acid|control
48293187|NCT05101213|BIOLOGICAL|Virus-specific Cytotoxic T-lymphocytes|Given IV
47944384|NCT00406094|DRUG|placebo|placebo
47944385|NCT04326959|BIOLOGICAL|Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium|Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
47944386|NCT04326959|BIOLOGICAL|Conditioned Medium|Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
47944387|NCT04326959|BIOLOGICAL|Triamcinolone Acetonide|Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
47944388|NCT04868058|DRUG|Ropivacaine injection|Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
48475527|NCT04204226|BEHAVIORAL|Autism Behavioral Health Navigation (ABHN)|The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.
47944389|NCT05067673|OTHER|Dry needling|The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.
47944390|NCT05067673|OTHER|Placebo dry needling|Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
47944391|NCT06345846|DEVICE|IFIOL|Implanted IFIOL
47944392|NCT06345846|DEVICE|SFIOL|Implanted SFIOL
48475528|NCT04204226|BEHAVIORAL|Social work + ABHN|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN
48632451|NCT02734914|DEVICE|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
48632452|NCT02171208|DRUG|dimethyl fumarate - Reference form|single dose 240 mg
47944393|NCT02197793|BEHAVIORAL|Community Mobilization Program|
47944394|NCT03543618|DEVICE|Sloped|Placement of implant with sloped design
47944395|NCT03543618|DEVICE|Control|Placement of implant with conventional design
47944396|NCT00412568|PROCEDURE|Photorefractive Keratectomy (PRK)|vision correction with PRK
47944397|NCT03988413|DRUG|25mg|SYHA1402 25mg or Placebo 25mg
47944398|NCT03988413|DRUG|50mg|SYHA1402 50mg or Placebo 50mg
47944399|NCT03988413|DRUG|100mg|SYHA1402 100mg or Placebo 100mg
47944400|NCT03988413|DRUG|200mg|SYHA1402 200mg or Placebo 200mg
47944401|NCT03988413|DRUG|400mg|SYHA1402 400mg or Placebo 400mg
47944402|NCT03988413|DRUG|800mg|SYHA1402 800mg or Placebo 800mg
47944403|NCT02586285|DRUG|S-Adenosyl Methionine|500mg-1000mg,iv,qd
47944404|NCT01360281|OTHER|Neuromuscular Electrical Stimulation|
48475529|NCT04204226|BEHAVIORAL|Social work + ABHN + CAP|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
47944405|NCT01360281|OTHER|ECR|Resisted exercises
47944406|NCT04663373|OTHER|Step counting|Patients are given a physical activity tracker (wrist band) that they are asked to wear for two weeks after discharge from percutaneous coronary intervention.
47944407|NCT04575844|DRUG|Liraglutide|24 weeks of Liraglutide
47944408|NCT04575844|OTHER|Exercise training|24 weeks of Exercise training
47944409|NCT04575844|DRUG|Liraglutide + Exercise training|24 weeks of Liraglutide + Exercise training
48475530|NCT01740791|DRUG|Velpatasvir|Tablets administered orally
48475531|NCT01740791|DRUG|Placebo|Tablets administered orally
48475532|NCT05409352|BEHAVIORAL|Self-administered acupressure|Participants will receive training of self-acupressure on the 5 standard acupoints by a trained traditional Chinese medicine (TCM) practitioner, have return-demonstration, be assessed by the practitioner with the use of a competency checklist, and be instructed to perform self-acupressure on the standard acupoints once a day. A follow-up visit will be conducted to reinforce learning, in which participants will demonstrate the acupressure technique while the practitioner observes and provides feedback, including suggestions for technique adjustments if necessary. The practitioner will recommend 2 additional acupoints from the list of optional acupoints based on the patients' sensitivity to acupoint stimulation and preference. Daily duration of self-practice will range from 8-10 minutes depending on the semi-individualized protocol (5 standard + 2 optional acupoints).
48620019|NCT03524209|OTHER|Brace|Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
48620020|NCT00254371|PROCEDURE|Androgen Replacement|
48632453|NCT02171208|DRUG|dimethyl fumarate - Test form|single dose 240 mg
47944410|NCT03423134|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive
47944411|NCT02534818|DRUG|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
47944412|NCT02534818|DRUG|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
47944413|NCT02263209|DEVICE|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
48632454|NCT06291207|DRUG|AD-224A|PO, Once daily, 8weeks
48632455|NCT06291207|DRUG|AD-224B|PO, Once daily, 8weeks
48632456|NCT06291207|DRUG|AD-224C|PO, Once daily, 8weeks
48632457|NCT06291207|DRUG|Placebo of AD-224A|PO, Once daily, 8weeks
48632458|NCT06291207|DRUG|Placebo of AD-224B|PO, Once daily, 8weeks
48632459|NCT06291207|DRUG|Placebo of AD-224C|PO, Once daily, 8weeks
48632460|NCT01084863|DRUG|CT-P6|CT-P6: administered every 3 weeks
48632461|NCT01084863|DRUG|Herceptin|Herceptin: administered every 3 weeks
48632462|NCT01084863|DRUG|Paclitaxel|Paclitaxel: administered every 3 weeks
48293188|NCT03854487|BEHAVIORAL|Mirror therapy|A mirror is placed at the midsagittal plane of the patient. The patients in the mirror therapy group watched the mirror illusion of the non-affected arm in the mirror and moved together with the affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
48293189|NCT03854487|BEHAVIORAL|Sham mirror|A transparent glass wall is placed at the midsagittal plane of the patient. The patients in the sham mirror group watched the movements of the affected arm through the transparent glass wall and moved together with the non-affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
48620021|NCT00347490|DRUG|Enoxaparine|
48620022|NCT00544271|BIOLOGICAL|INFANRIX|
48620023|NCT00544271|BIOLOGICAL|BOOSTRIX|
48620024|NCT00544271|BIOLOGICAL|HAVRIX|
48620025|NCT03436719|DRUG|Oral antibiotic|Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
48620026|NCT03436719|DRUG|Intravenous antibiotic|Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
48620027|NCT03436719|DRUG|Mechanical Bowel Preparation|Beginning of MBP at 4 p.m. in a day before surgery
48293190|NCT03854487|BEHAVIORAL|Covered mirror|A covered mirror is placed at the midsagittal plane of the patient. The patients in the control group watched the movements of the non-affected arm and moved together with the affected arm behind the covered mirror. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
48293191|NCT06249984|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48293192|NCT06249984|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
48293193|NCT06249984|BEHAVIORAL|Smokeless Tobacco Use|Use moist snuff
48293194|NCT06249984|OTHER|Survey Administration|Ancillary studies
48293195|NCT06307665|COMBINATION_PRODUCT|BDA MDI|Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
48293196|NCT06307665|COMBINATION_PRODUCT|AS MDI|Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
48293197|NCT01570725|BEHAVIORAL|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
48293198|NCT01570725|BEHAVIORAL|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
48632463|NCT03899597|DRUG|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
47944414|NCT02263209|DEVICE|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
48103476|NCT05857358|DRUG|Injection of the autologous adipose-derived stromal vascular fraction (AD-SVF)|"Autologous uncultured (AD-SVF) will be isolated by digestion and centrifugation of adipose tissue from lipoaspiration.~Then, AD-SVF will be injected in 6 sites :~* 2 for the accessory labial glands (0.5mL in the upper lip and 0.5mL in the lower lip)~* 2 for the sublingual glands (0.5mL for each gland)~* 2 for the inner face of cheeks (0.5mL for each side)~The volume of injection will be of 3 mL containing 30 millions of AD-SVF viable nucleated cells for the total safety dose."
48103477|NCT02718118|DEVICE|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
48103478|NCT02718118|DEVICE|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
48103479|NCT00281918|DRUG|Rituximab|Intravenous repeating dose
48632464|NCT03899597|OTHER|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
48632465|NCT00679601|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
48103480|NCT00281918|DRUG|Cyclophosphamide|Intravenous repeating dose
48103481|NCT00281918|DRUG|Fludarabine Phosphate|Intravenous repeating dose
48293199|NCT06671158|BEHAVIORAL|Psychotherapy|Individual psychotherapy for weekly 12-sessions
48293200|NCT01145391|OTHER|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
48293201|NCT03708003|DRUG|Ibrutinib|"Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
48293202|NCT03708003|DRUG|Venetoclax|"Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
48293203|NCT01901133|DRUG|MDV3100|Oral
48293204|NCT01486680|PROCEDURE|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
48293205|NCT01486680|PROCEDURE|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
48293206|NCT04722133|DRUG|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
48293207|NCT04278729|DRUG|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
48632466|NCT04242134|DEVICE|Drug-coating balloon|Provisional stenting technique with DCB
48632467|NCT02087683|OTHER|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
48103482|NCT00404794|DRUG|prednisolone and mycophenolate mofetil|
48103483|NCT00404794|DRUG|prednisolone and tacrolimus|
48475533|NCT05409352|BEHAVIORAL|Aerobic exercise|Participants will receive verbal and written information from a trained exercise specialist about the specific advice of the desired exercise frequency (3x/week), duration (30 min each time), and intensity (moderate determined by rating of 12 to 14 on the Borg Rating of Perceived Exertion scale). The exercise specialist will demonstrate how to perform walking at moderate intensity indoors and outdoors, followed by return-demonstration of the patient. Education on safety precautions and walk schedule planning will be provided. Competency check will be performed to assess participants' ability to self-monitor and self-regular exercise intensity using Borg Scale. One week after the start of the program, the exercise specialist will conduct a 1-hour follow-up visit to supervise the patient's walking session and assess whether there is any additional advice needed.
47944415|NCT05082831|BIOLOGICAL|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.
47944416|NCT02305888|DRUG|LEO 43204|Treatment of actinic keratosis
47944417|NCT04870034|DRUG|Binimetinib|Given PO
48103484|NCT04048304|DRUG|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
48103485|NCT04447768|DRUG|Obinutuzumab|"Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg"
48103486|NCT04447768|DRUG|Venetoclax|"Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily"
48103487|NCT06024564|DEVICE|Sonu Acoustic Resonance Therapy|Participants will receive Sonu treatment twice a day for 90 days
48103488|NCT02085356|BEHAVIORAL|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
48103489|NCT01006551|DRUG|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
48103490|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment|Compound level meeting
48103491|NCT02037243|BEHAVIORAL|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
48103492|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
48103493|NCT02037243|BEHAVIORAL|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
48103494|NCT03155490|BEHAVIORAL|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
48103495|NCT05811728|RADIATION|Low level laser therapy|The low-level laser applied will be a Diode laser\* emitting infrared radiation at a wavelength of 980 nm, in a continuous mode. On the experimental side, subjects will receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter, till the termination of the study period (3 months).
48632468|NCT02087683|OTHER|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
47944418|NCT04870034|DRUG|Palbociclib|Given PO
47944419|NCT04870034|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
47944420|NCT02892032|BEHAVIORAL|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
47944421|NCT02892032|BEHAVIORAL|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
47944422|NCT01539642|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
48103496|NCT05811728|OTHER|without beam emission|The laser tip will be held passively on the control side without beam emission, providing a placebo effect.
48293208|NCT06379295|OTHER|Questionnaire|Self-administered questionnaire to assess the participants risk factors, history of heart disease and medications.
48475534|NCT02746419|DEVICE|Vessix|Renal denervation using radio-ablation
47944423|NCT01539642|DRUG|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
48632469|NCT03865680|DRUG|CPP-ACP|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
48632470|NCT03865680|DRUG|Duraphat|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
47944424|NCT04535765|OTHER|early warm water sitz bath|The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
48475535|NCT04763278|DEVICE|Point Digit|The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
48475536|NCT06350617|DEVICE|High-Frequency, ipsilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
48632471|NCT06265805|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
47944425|NCT04535765|OTHER|Regular time warm water sitz bath|According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
47944426|NCT01133561|DRUG|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
47944427|NCT01133561|DRUG|actozone B|one tablet of vehicle without active ingredient pioglitazone
47944428|NCT02643329|DRUG|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
47944429|NCT02643329|DRUG|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
47944430|NCT05917769|OTHER|Rocabdo exercises|"The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises."
48475537|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
48620028|NCT01680796|DRUG|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
48475538|NCT06350617|DEVICE|High-Frequency, Lt. DLPFC|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: Lt. DLPFC~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
48632472|NCT06265805|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48632473|NCT06265805|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48632474|NCT00732693|DRUG|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
48632475|NCT00732693|DRUG|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
48632476|NCT00527878|DRUG|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
48632477|NCT00527878|DRUG|Placebo|
48475539|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
48632478|NCT04656431|DRUG|Hyperpolarized pyruvate (13C)|Given intravenously (IV) injection prior to imaging
48632479|NCT04656431|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
48632480|NCT03811405|DEVICE|Active biphasic pulse stimulation---Home Settings|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
48632481|NCT03811405|DEVICE|Active biphasic pulse stimulation---VIN Biphasic|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
48632482|NCT03811405|DEVICE|Active biphasic pulse stimulation---Stimulator Off|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
48632483|NCT04837742|DRUG|ESPB group|ESPB injection at T10 region with Chirocaine 100mg(20 cc)+ Omnipaque 10cc
48632484|NCT04837742|DRUG|Control group|ESPB injection at T10 region with Normal saline 20cc + Omnipaque 10cc
48632485|NCT04250974|OTHER|electroacupuncture|acupuncture with electricity
48632486|NCT01899287|BEHAVIORAL|group education|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
48632487|NCT05187637|DRUG|intravenous iron|One dose of intravenous iron carboxymaltose calculated according to ganzoni's formula. If after thirty days of the first dose, a second dose of 500mg will be administered if the patient continues to meet the inclusion criteria.
48103497|NCT06514105|OTHER|Physiotherapy program|All patients participating in the study will be included in the physiotherapy program. Physiotherapy program consist of hot-pack (for 15 minutes), ultrasound (Continuous ultrasound, for 5 minutes, 1-MHZ 1.5W/cm2, a 5-cm ultrasound head on the subacromial region),TENS (for 20 minutes with the BTL 4000 combined device) and exercise program (Stretching exercises for the rotator cuff, rhomboid muscles, levator scapula, serratus anterior and pectoaral muscles and strengthening the muscles around the shoulder with a resistance exercise band selected in a color appropriate to the patient's strength).
48632488|NCT00664040|OTHER|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
48103498|NCT06514105|OTHER|High intensity laser|High intensity laser will be applied using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area by making circular movements from the center to the outside for 100 seconds at a power of 10W and a dose of 10 J/cm2 (analgesic effect). The last 5 sessions will be applied to the painful area with linear movements at 4W power and 100 J/cm2 dose (biostimulation effect) for 10 minutes and 25 seconds.
48475540|NCT01957150|DRUG|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
48475541|NCT01957150|DRUG|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
48475542|NCT00412204|DRUG|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
48475543|NCT00412204|OTHER|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
48475544|NCT03471988|DRUG|AK1820|"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
48475545|NCT03471988|DRUG|Voriconazole|"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
48475546|NCT05792319|DIAGNOSTIC_TEST|24 hour copper in urine and liver function test|sampling 24 hour copper in urine and liver function test
48475547|NCT03446365|BEHAVIORAL|ASMAS|A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.
48475548|NCT03446365|BEHAVIORAL|Asthma education plus child health|Health educator led intervention focused on asthma education and other child health topics.
48475549|NCT02839798|DEVICE|NEST (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
48475550|NCT00418067|DEVICE|Endeavor|Zotarolimus-eluting stent
48475551|NCT00418067|DEVICE|Cypher|Sirolimus-eluting stent
48475552|NCT00418067|DEVICE|Taxus Liberte|Paclitaxel-eluting stent
48475553|NCT01222949|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
48632489|NCT00664040|OTHER|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
48475554|NCT04640779|DRUG|Choline Salicylate|Given PO
48475555|NCT04640779|DRUG|Selinexor|Given PO
48475556|NCT01007279|DRUG|ROSUVASTATIN|40 mg before procedure
48475557|NCT03974893|OTHER|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
48475558|NCT06387979|OTHER|Non-Interventional Study|Non-Interventional Study
48475559|NCT03462836|DRUG|IV ketamine/lidocaine/IV PCA apply|In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
48475560|NCT03462836|DRUG|IV PCA only apply|IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
48475561|NCT03164837|DRUG|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
48475562|NCT00399893|DRUG|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
48475563|NCT00399893|DRUG|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
48475564|NCT02310516|DEVICE|preoperative adequate explanations about awake surgery|
48475565|NCT02310516|OTHER|no preoperative explanation|
48475566|NCT06617065|DRUG|Addition of 1 mL of 50% dextrose solution to the usual local anesthetic solution of choice for each patient.|"The principal investigator will use a palpation-guided approach to select the injection sites. Injection solutions will be prepared by the assisting nurse. For each patient, 1 mL of a 50% dextrose solution (Pfizer Canada ULS, Kirkland, Québec) will be added to the usual local anesthetic solution of choice.~Solutions contain either 0.3% Ropivacaine, 1% Procaine, 0.5% Lidocaine, 0.25% Bupivacaine, or a mixture of 0.25% Bupivacaine and 2% Lidocaine in a 9:1 ratio."
48475567|NCT01834209|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
48475568|NCT01834209|DRUG|Prednisone or prednisolone|5 mg tablet taken orally once daily
47944431|NCT05917769|OTHER|Postural correction exercises|"* Posture correction exercises will be performed six times a day for six days.~* Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~* Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts."
48103499|NCT06514105|OTHER|Sham high intensity laser|In sham application, the patient will be positioned on the treatment stretcher and the device will be turned on. The guide light of the high-intensity laser device, which gives the same color as the laser light, will be applied to the subacromial region in circular movements from outside to inside and from inside to outside.
48475569|NCT05838456|DEVICE|Viz.AI software|Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
48475570|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 70%|The incubator will be set to an ambient relative humidity (RH) of 70%.
48475571|NCT06399861|DEVICE|Incubator ambient relative humidity (RH) of 90%|The incubator will be set to an ambient relative humidity (RH) of 90%.
48475572|NCT01075061|OTHER|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
48475573|NCT01075061|OTHER|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
48475574|NCT01075061|OTHER|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
48475575|NCT06616792|COMBINATION_PRODUCT|Dexamethasone phonophoresis|Ultrasound therapeutic device with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis.
48475576|NCT06616792|DEVICE|Laser Acupuncture|low level laser therapy placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint,
48475577|NCT06616792|OTHER|Traditional medication|Each participant in this group receive the traditional medication.
48475578|NCT04360408|OTHER|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
48475579|NCT03287687|DRUG|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
48475580|NCT03287687|DRUG|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
48475581|NCT00908882|BEHAVIORAL|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
48475582|NCT03588650|DRUG|HLX20|a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
48475583|NCT02429375|DRUG|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
48475584|NCT00703131|DEVICE|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
48475585|NCT04666688|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
48475586|NCT04666688|DRUG|Tislelizumab|anti-PD-1 monoclonal antibody
48475587|NCT04666688|DRUG|Gemcitabine/nab-paclitaxel|chemotherapy
48103500|NCT03068637|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
48103501|NCT01895517|OTHER|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
48103502|NCT01895517|OTHER|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
48103503|NCT03829267|BEHAVIORAL|eFIT Intervention|eFIT: social network accountability partners, a psychosocial intervention to increase physical activity in persons with multiple sclerosis
48475588|NCT05276505|OTHER|Lavender Aromatherapy Tablet|Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
48475589|NCT06120634|PROCEDURE|Open surgical method|After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.
47944432|NCT04660253|BEHAVIORAL|LTP Plus Dads|
48103504|NCT03829267|BEHAVIORAL|eJournal Intervention|1-hour online each week engaged in an active journaling activity
48620029|NCT01680796|DRUG|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
48620030|NCT01680796|DRUG|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
48620031|NCT06113978|PROCEDURE|Thoracoscopic sympathectomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.
48632490|NCT00664040|OTHER|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
48475590|NCT06120634|PROCEDURE|Plastibell method|The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
48632491|NCT00664040|OTHER|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
48632492|NCT05163405|DRUG|Bortezomib|Self-administration of subcutaneously Velcade.
48103505|NCT03829267|BEHAVIORAL|Treatment as usual|Participants in this condition will complete baseline and follow-up surveys with the same frequency as the active treatment groups, but will receive neither eFIT nor eJournal.
48103506|NCT04720781|DRUG|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
48103507|NCT04720781|DRUG|Esomeprazole|esomeprazole (20mg/day)
48620032|NCT06113978|PROCEDURE|Thoracoscopic sympathotomy|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.
48632493|NCT00776425|DRUG|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
48632494|NCT01691742|DRUG|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
48632495|NCT01691742|DRUG|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
48632496|NCT01691742|DRUG|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
48632497|NCT02287025|DRUG|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
48632498|NCT02287025|OTHER|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
48632499|NCT02287025|OTHER|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
48632500|NCT01494857|DRUG|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
48103508|NCT00480805|DRUG|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
48103509|NCT00480805|DRUG|Comparator : ramipril /Duration of Treatment : 8 Weeks|
48103510|NCT05302843|DRUG|BPI-28592|Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
48632501|NCT00190892|DRUG|olanzapine|
48632502|NCT00190892|DRUG|carbamazepine|
48632503|NCT04403893|OTHER|HANARO biliary stent placement|HANARO biliary stent placement
48632504|NCT01855568|PROCEDURE|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14."
48632505|NCT01855568|PROCEDURE|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
47944433|NCT02089854|DRUG|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
47944434|NCT03448055|DIETARY_SUPPLEMENT|Immunocal|cysteine-rich whey protein isolate
48103511|NCT01624636|DRUG|Placebo|
48103512|NCT01624636|DRUG|LFG316|
48103513|NCT01624636|DRUG|LFG316|
48293209|NCT03564249|DEVICE|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
48293210|NCT04752813|DRUG|BPM31510|Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.
47944435|NCT01743456|OTHER|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
48103514|NCT01227642|OTHER|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
48632506|NCT01558414|PROCEDURE|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
48632507|NCT01558414|PROCEDURE|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
48632508|NCT01558414|PROCEDURE|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
48632509|NCT02691663|DIETARY_SUPPLEMENT|Oral bicarbonate supplementation|
48632510|NCT02691663|DIETARY_SUPPLEMENT|Placebo|
48632511|NCT03868566|DRUG|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
48103515|NCT01227642|OTHER|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
48632512|NCT03868566|DRUG|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
48632513|NCT01769443|DRUG|bortezomib|Bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
48632514|NCT01769443|PROCEDURE|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m\^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
48632515|NCT04465149|PROCEDURE|Third Molar Germectomy|Surgical extraction of Third Molars that exhibits at least a third of its root in formation, with a periodontal ligament discernible on panoramic x-ray (defined as germectomy).
48632516|NCT04296682|PROCEDURE|Alveolar Ridge Preservation With Gingival Graft|Closure of the alveolus with the placement of a free gingival tissue graft removed from the individual palate.
48632517|NCT04090749|BEHAVIORAL|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
48632518|NCT03694652|BEHAVIORAL|PACE|Patient-centered Assessment and Counseling for Exercise \[PACE\] program
48632519|NCT03694652|BEHAVIORAL|Diet|Motivating healthy dietary habits
48632520|NCT03694652|OTHER|App|Using an app to deliver communication to the participant.
48632521|NCT03694652|OTHER|Face-to-face|Using in person meetings and/or phone communication with the participant.
48632522|NCT05983406|DEVICE|Doppler investigation|Doppler investigation
48632523|NCT00347087|DRUG|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
48103516|NCT01227642|OTHER|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
48103517|NCT04708743|DIAGNOSTIC_TEST|Automatic Tongue Diagnosis System|tongue image capture tongue images by Automatic Tongue Diagnosis System
48103518|NCT05869318|OTHER|ECIG own|Participants will vape using their own ecig device
48103519|NCT05869318|OTHER|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
48293211|NCT04752813|OTHER|Vitamin K1|Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg Intramuscularly prior to the beginning of each week of BPM31510 therapy.
48632524|NCT03494192|OTHER|Scapula Retraction Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up."
48103520|NCT03034915|DRUG|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
48293212|NCT04752813|DRUG|Temozolomide (TMZ)|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for additional 6 cycles post BPM31510 treatment.
48293213|NCT04752813|RADIATION|Radiation|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
48293214|NCT04257461|DRUG|Fluoropyrimidine|Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
48293215|NCT04257461|DRUG|Oxaliplatin|Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
48293216|NCT00001761|DRUG|Interleukin-10|
48293217|NCT02584621|BEHAVIORAL|Check Yourself App with Feedback|
48293218|NCT02021968|BIOLOGICAL|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
48293219|NCT02021968|BIOLOGICAL|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
48293220|NCT02021968|BIOLOGICAL|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
48103521|NCT03034915|DRUG|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
48103522|NCT03034915|DRUG|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
48103523|NCT03034915|DRUG|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
48103524|NCT03034915|DRUG|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
48293221|NCT03272477|DRUG|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
48293222|NCT03272477|DRUG|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
48293223|NCT03272477|DRUG|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
48293224|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
48293225|NCT03272477|DRUG|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
48293226|NCT03272477|DRUG|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
48293227|NCT03272477|DRUG|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
48293228|NCT03272477|DRUG|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
48293229|NCT03272477|DRUG|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
48632525|NCT03494192|OTHER|Scapula Retraction +Glenohumeral Rotational Exercise Group|"physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up"
47944436|NCT01563744|PROCEDURE|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
47944437|NCT01563744|PROCEDURE|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
47944438|NCT03337607|DEVICE|rESWT|"rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics"
47944439|NCT03337607|DRUG|Celecoxib|1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
47944440|NCT03337607|DRUG|Eperisone|3 x 50 mg per day for four weeks
47944441|NCT04766073|PROCEDURE|Niche prevention suture|This group will have the uterus sutured in two layers using a new technique.
47944442|NCT05942859|DIAGNOSTIC_TEST|Artificial Intelligence and Machine Learning technology|Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
47944443|NCT03711201|BEHAVIORAL|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
47944444|NCT01369615|DRUG|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
47944445|NCT01813110|DRUG|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
47944446|NCT01813110|DRUG|Placebo|olive oil
47944447|NCT04449510|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W. The device will be set at 10 watts for the study visits.
47944448|NCT05774548|OTHER|In-depth interviews (IDI)|In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.
47944449|NCT05774548|OTHER|Focus group discussion (FGD)|Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
47944450|NCT00949273|PROCEDURE|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
47944451|NCT02370277|OTHER|Cytology Specimen Collection Procedure|Undergo collection of stool samples
48620033|NCT06113978|PROCEDURE|Thoracoscopic sympathetic chain clipping|Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
47944452|NCT02370277|OTHER|Laboratory Biomarker Analysis|Correlative studies
47944453|NCT02370277|OTHER|Questionnaire Administration|Ancillary studies
47944454|NCT03139695|DIAGNOSTIC_TEST|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
47944455|NCT04373174|DEVICE|Regional oximetry probe|Regional oximetry probe will be placed in the frontal area of the head
47944456|NCT04373174|PROCEDURE|Thoracic Epidural block|Thoracic epidural block will be applied to the patients before the operation begins
47944457|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
47944458|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
47944459|NCT01425788|BIOLOGICAL|Osiris Phleum pratense|
47944460|NCT01137318|BEHAVIORAL|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
47944461|NCT00208299|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
47944462|NCT00208299|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
47944463|NCT04946461|DRUG|Dexamfetamine Sulfate 5 Mg Oral Tablet|The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.
48620034|NCT00662259|DRUG|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
47944464|NCT04946461|DRUG|Lisdexamfetamine Dimesylate|The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.
47944465|NCT04946461|BIOLOGICAL|blood samples|The blood samples will be taken at set times: 0, 2, 4, 6, 9 and 12 (hours)
48620035|NCT00662259|DRUG|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
48620036|NCT00619463|BEHAVIORAL|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
48620037|NCT00619463|BEHAVIORAL|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
48293230|NCT03272477|DRUG|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
48293231|NCT03272477|DRUG|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
47944466|NCT04704284|DIAGNOSTIC_TEST|Zero Echo Time Magnetic Resonance Imaging (ZTE MRI)|Magnetic Resonance Imaging (MRI) with zero echo-time (ZTE) that uses proton density differences rather than T2 relaxation time differences to achieve contrast.
47944467|NCT05266534|DRUG|Terlipressin|the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
48293232|NCT03272477|DRUG|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
48293233|NCT03272477|DRUG|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
48293234|NCT03272477|DRUG|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
48293235|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
48293236|NCT03272477|DRUG|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
48293237|NCT03272477|DRUG|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
48632526|NCT03492112|DEVICE|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
47944468|NCT05266534|DRUG|Carbetocin|the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
47944469|NCT05266534|DRUG|Saline|the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
47944470|NCT03014492|DEVICE|Q Collar|Collar designed to mitigate slosh in the brain
47944471|NCT01443273|OTHER|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
47944472|NCT03457688|DIETARY_SUPPLEMENT|prebiotic inulin-type fructans|
47944473|NCT03457688|DIETARY_SUPPLEMENT|placebo maltodextrin|
48293238|NCT03272477|DRUG|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
48632527|NCT03492112|DRUG|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
48632528|NCT03492112|DRUG|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
48632529|NCT02729168|BIOLOGICAL|Human rabies vaccine|
47944474|NCT04691401|DEVICE|Artificial Intelligence System (CAD EYE, Fujifilm Co.)|A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
48293239|NCT03272477|DIAGNOSTIC_TEST|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
48293240|NCT03272477|PROCEDURE|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
48293241|NCT02751307|DRUG|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
48293242|NCT02751307|DRUG|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
48475591|NCT05589259|PROCEDURE|Axillary Brachial Plexus Block plus Physiotherapy|"Participants will receive a single-shot axillary-approach brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm 21g Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will aspirate to ensure the needle is not intravascular. Once aspiration is confirmed negative, bupivacaine 0.25% 1.5mg/kg (lean body weight) will be injected in divided doses.~30 minutes after placement of the block, the standardized physiotherapy protocol will begin."
48632530|NCT04200209|OTHER|Implementation of a quality indicator feedback mechanism|"1. Audit and feedback: A summary of clinical performance and hospital safety culture over a specified period of time.~2. Benchmarking Achievable: benchmarks are calculated from the performance of all members of a peer group and represents a realistic standard of excellence attained by the top performers in that group (i.e. comparing to the top 10% of peers).~3. Educational outreach: A trained independent person or investigator will meet with health professionals or managers in their practice setting to provide information (e.g. feedback of quality indicators).~4. Action planning: The purpose of action planning is to support quality improvement efforts by identifying opportunities for improvement, strategies and steps to accomplish the work."
48632531|NCT02475837|DRUG|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
48293243|NCT04715750|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
47944475|NCT00562627|DRUG|ropivacaine|intraoperative and 1. postoperative day
47944476|NCT00562627|DRUG|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
47944477|NCT00562627|DRUG|ketorolac|intraoperative and 1. postoperative day
47944478|NCT00562627|DRUG|morphine|intraoperative
48103525|NCT06630143|OTHER|Combined Virtual and Clinical Simulation|Participants will complete a preeclampsia case scenario through virtual simulation first and then engage in a clinical simulation involving the same case. This sequential intervention is designed to reinforce knowledge and skills.
48293244|NCT06661265|PROCEDURE|adjuvant tomotherapy +- chemotherapy after the reconstructive surgery with flaps|adjuvant treatment in locally-advanced head and neck cancers submitted to upfront surgery with flap reconstruction, evaluation of toxicity and flap status performed at San Raffaele Hospital between December 2017-December 2022.
48475592|NCT05589259|PROCEDURE|Physiotherapy alone|"Participants in the EXP arm and the CON arm will complete the same physiotherapy program.~PHYSIOTHERAPY PROTOCOL The physiotherapy program will include manipulation with or without a block. The goal of manipulation is to break up adhesions, possibly overcoming microvascular dysfunction. After the manipulation, participants will take part in a 6-week program which will include a weekly one-hour session with a physiotherapist at the KHSC-CPC and a home exercise program (HEP). During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home."
48475593|NCT05118360|DRUG|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
48475594|NCT05118360|DRUG|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
48475595|NCT05118360|DRUG|Placebo|Matching placebo orally once daily for 52 weeks.
48475596|NCT04593147|OTHER|BBN|BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
48475597|NCT04593147|OTHER|Brand|Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
48475598|NCT03743610|OTHER|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
48475599|NCT03743610|OTHER|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
48475600|NCT02506231|DRUG|Folinic acid|
48475601|NCT02506231|DRUG|Placebo|
48293245|NCT02681887|DRUG|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
48293246|NCT02681887|DRUG|Placebo|placebo tablet identical to circadian
48293247|NCT06670027|OTHER|Family voice|Group A receives the family voice
48293248|NCT06670027|OTHER|Nature sound|Group B receives the nature sound.
48293249|NCT04065763|OTHER|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
48475602|NCT01497119|DRUG|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
48475603|NCT01497119|DRUG|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
48475604|NCT01497119|DRUG|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
48475605|NCT00487331|OTHER|Acupuncture|Acupuncture sessions 1-3 times per week.
48475606|NCT00487331|BEHAVIORAL|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
48632532|NCT02475837|DRUG|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
48632533|NCT00103753|DRUG|deferiprone|
48632534|NCT05182892|OTHER|Change of stimulation amplitudes in dopaminergic OFF drug state|Change of stimulation amplitudes during experiment in dopaminergic OFF drug state.
48632535|NCT02583009|DRUG|PAC-14028 cream 0.1%|Topical application
48632536|NCT02583009|DRUG|PAC-14028 cream 0.3%|Topical application
47944479|NCT00562627|DRUG|fentanyl|continuous postoperatively
47944480|NCT00562627|DRUG|bupivacaine|continuous postoperatively
47944481|NCT00856648|DEVICE|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
47944482|NCT03300531|BIOLOGICAL|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
47944483|NCT03300531|BIOLOGICAL|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
47944484|NCT03300531|DRUG|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
48103526|NCT06630143|OTHER|virtual simulation|Participants will complete the preeclampsia case scenario using the vSim® platform, allowing them to engage in virtual clinical decision-making.
48103527|NCT06630143|OTHER|clinical simulation|Participants will manage a preeclampsia case using a high-fidelity manikin in a simulated clinical setting, practicing hands-on skills and clinical decision-making.
48103528|NCT05115890|OTHER|Exercise training|Patients with HFpEF will undergo 8 weeks of exercise training.
48475607|NCT00232479|DRUG|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
48475608|NCT05365490|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
48475609|NCT05952089|DRUG|Danicamtiv|Specified dose on specified days
48475610|NCT05952089|DRUG|Midazolam|Specified dose on specified days
48632537|NCT02583009|DRUG|PAC-14028 cream 1.0%|Topical application
48632538|NCT02583009|DRUG|PAC-14028 cream vehicle|Topical application
48632539|NCT01038895|DRUG|Ramipril|tablet; 10 mg; od; 3 months
48632540|NCT01038895|DRUG|Experimental|tablet; 300 mg; od; 3 months
48632541|NCT03358706|DRUG|Ustekinumab IV Infusion|Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
48475611|NCT06308133|OTHER|apheresis procedure|collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)
48293250|NCT03228251|OTHER|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
48475612|NCT01622608|BEHAVIORAL|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
48475613|NCT02304978|BIOLOGICAL|Group CRC|blood samples
48475614|NCT02304978|BIOLOGICAL|Group control|Blood samples
48475615|NCT05746130|BEHAVIORAL|Plastic-free diet program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
48475616|NCT05746130|BEHAVIORAL|Plastic-free diet education program|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
48475617|NCT05746130|BEHAVIORAL|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
48475618|NCT02696941|DRUG|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
48632542|NCT03358706|DRUG|Ustekinumab SC Injection|Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
48632543|NCT03358706|DRUG|Midazolam 2 mg|Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
48475619|NCT02696941|DRUG|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
48620038|NCT03756675|OTHER|haplotype PBSCT|"haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system"
48632544|NCT03358706|DRUG|Warfarin 10 mg|Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
48632545|NCT03358706|DRUG|Vitamin K 10 mg|Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
48632546|NCT03358706|DRUG|Omeprazole 20 mg|Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
48632547|NCT03358706|DRUG|Dextromethorphan 30 mg|Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
48632548|NCT03358706|DRUG|Caffeine 100 mg|Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
48632549|NCT02830633|PROCEDURE|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
48632550|NCT02830633|PROCEDURE|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
48632551|NCT01529151|OTHER|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
48632552|NCT01529151|OTHER|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
48632553|NCT04419142|PROCEDURE|Total infrapatellar fat pad excision|Exposure for total knee arthroplasty (TKA) commonly includes total excision of the infrapatellar fat pad (IPFP). The rationale behind this is to obtain improved access to the lateral tibial plateau allowing a more accurate bone cut, baseplate placement and easier management of soft tissue interposition in the bone and cement interface. However, there is growing concern that as the IPFP is a highly vascularized and innervated fibrous adipose tissue filling the anterior compartment of the knee, its complete excision may have a detrimental effect on knee biomechanics and ultimately, TKA outcome. The reason for this effect has been suggested to be patellar tendon (PT) scarring and shortening via ischemic contracture following impaired vascularization, maintenance and biological repair of the tendon.
48632554|NCT04419142|PROCEDURE|Partial infrapatellar fat pad excision|It has been suggested in the literature that partial infrapatellar fat pad excision instead of total excision would diminish the potential negative effect on patellar tendon and knee biomechanics. However, there is only limited data in the literature and choice of total/partial infrapatellar fat pad excision in TKA remains debatable.
48632555|NCT04787458|DEVICE|abdomen binder (Sejung Korea, Seoul, Republic of Korea)|abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea)
48632556|NCT00195429|DRUG|Tacrolimus|
48475620|NCT04035382|PROCEDURE|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
48475621|NCT04313010|OTHER|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
48475622|NCT04313010|OTHER|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
48475623|NCT03102151|OTHER|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
48475624|NCT02376660|OTHER|Oats|
48475625|NCT00258505|PROCEDURE|Procedure: intracranial monitoring up to 9 days after injury|
48475626|NCT05294835|DRUG|Ketamine|ketamine infusion
48475627|NCT06402682|PROCEDURE|Right approach|Right approach of the management of esophageal atresia with a right aortic arch
48475628|NCT06402682|PROCEDURE|Left approach|Left approach of the management of esophageal atresia with a right aortic arch
48632557|NCT00195429|DRUG|Sirolimus|
48632558|NCT00195429|DRUG|prednisone|
47944485|NCT03815617|DIETARY_SUPPLEMENT|Zircombi|Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
47944486|NCT03815617|DIETARY_SUPPLEMENT|Placebo|Given as comparable packets. Same duration.
48293251|NCT04510727|DEVICE|Optical Coherence Tomography (OCT)|VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.
48293252|NCT04510727|PROCEDURE|Curettage & Desiccation (C&D) Procedure|Standard of care C\&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
48475629|NCT06616961|DRUG|Semaglutide Pen|"In this study, the intervention involves administering semaglutide (Fitaro) to participants for weight management. The treatment protocol includes the following steps:~Initial Dose: Participants will start with a subcutaneous injection of semaglutide at a dose of 0.25 mg once weekly for the first four weeks to allow for tolerance and adjustment.~Dose Escalation: After the initial period, the dose will be increased at four-week intervals as follows:~Week 5: Increase to 0.5 mg Week 9: Increase to 1 mg Week 13: Increase to 1.7 mg Week 17: Increase to a maximum dose of 2.4 mg, if necessary, based on individual weight loss response and tolerability."
48475630|NCT01368302|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
48475631|NCT06617754|BIOLOGICAL|Biologic drugs|Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies
48475632|NCT02184741|DRUG|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
48475633|NCT02184741|DRUG|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
48632559|NCT02887599|PROCEDURE|Blood collection|1ml of blood specimen collection
48632560|NCT02510482|OTHER|No intervention|
48632561|NCT03640026|DRUG|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
48632562|NCT06477510|PROCEDURE|non-surgical periodontal therapy|change in self perception of esthetics and clinical periodontal parameters will be assessed after non-surgical periodontal therapy.
48293253|NCT05205239|DIAGNOSTIC_TEST|Endoluminal image analysis by capsule endoscopy|Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
48293254|NCT03183635|PROCEDURE|Balance training|Improvement of balance ability in stroke patients
48293255|NCT06672185|DRUG|ARC101|ARC101 will be administered according to an assigned dose schedule.
48293256|NCT05886192|DRUG|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
48293257|NCT05886192|DRUG|Norepinephrine|norepinephrine
48293258|NCT01556919|PROCEDURE|Standard of care endoscopy|standard of care endoscopy
48293259|NCT05129839|DEVICE|lightened and musical baby mobile|Before going to sleep in the infant's room in the intervention group, a lightened and musical baby mobile was used.
48293260|NCT03032159|BEHAVIORAL|Text2Breathe Study Group|
48632563|NCT02266862|RADIATION|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
48632564|NCT01482286|DRUG|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
48632565|NCT01482286|BEHAVIORAL|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
47944487|NCT01607268|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
48293261|NCT02556086|DRUG|Daclatasvir|
48293262|NCT02556086|DRUG|Sofosbuvir|
48293263|NCT03796741|OTHER|Data collection on Stable Ischemic heart disease|No intervention only description of management and treatment
48293264|NCT06671782|OTHER|Kegel exercises|Kegel exercises without any formal training
48293265|NCT06671782|OTHER|Pelvic Floor Muscle Exercise Program with biofeedback|Patients in the intervention arm will undergo PFME training with a physical therapist 2 times before surgery (4-6 weeks \[in person\] and 3-4 weeks \[in person\], before surgery) (within ±1 week is considered acceptable to avoid protocol violations). Patients in the intervention group will also undergo 2 PFME training sessions after surgery (3 weeks and 1.5 months after surgery).
48293266|NCT06671782|OTHER|Questionnaires|All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.
48475634|NCT03936933|DRUG|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
48475635|NCT03936933|DRUG|ZOLADEX® 3.6mg Injection|3.6 mg, Subcutaneously at every 28 days
48475636|NCT05550792|DEVICE|optimizer smart|The CCM implantation procedure was performed in the right precordial region of the chest (the right subclavian area). Two active fixation Ingevity leads (Boston Scientific) were advanced via the right subclavian vein into the right ventricle (RV) and actively fixed to the right ventricular septum for ventricular sensing and delivery of CCM signals.
48475637|NCT03216109|BEHAVIORAL|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
48475638|NCT01226537|DRUG|Taurine|500 mg taurine capsules twice per day for 6 months
48475639|NCT03939949|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
48632566|NCT01482286|BEHAVIORAL|Exercise Training|"For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch."
47944488|NCT00168402|DRUG|Botulinum Toxin Type A|
47944489|NCT01986140|DEVICE|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
47944490|NCT01986140|OTHER|Control No treatment|No treatment to prevent hair loss
47944491|NCT05345873|BIOLOGICAL|SCTV01E|one dose of SCTV01E on D0, intramuscular
48293267|NCT06671782|OTHER|Interviews|A qualitative interview with each of the 15 patients in the intervention group to obtain information about the patient's experience. The interview will last for 30-60 min and will be conducted at 3-6 months after prostatectomy, when the patient has completed all 4 physical therapy sessions. It will cover topics related to patient involvement, satisfaction, and activation.
48293268|NCT02252952|OTHER|Beverage Consumption|
48293269|NCT03684083|PROCEDURE|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
48293270|NCT03691558|OTHER|Ketogenic diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
48293271|NCT03691558|OTHER|Western Diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
48293272|NCT06672562|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy|NECT-Y consists of 14 90-minute sessions over the course of 14 weeks. The intervention combines psychoeducation, cognitive therapy, narrative therapy, goal-setting and peer support. Each group meeting includes educational materials, reflections, and active exercises that participants are guided through to personalize the content to their experiences. Participants will be provided with a workbook which allows them to follow the activities easier.
48293273|NCT06672562|OTHER|Usual care|Standard usual care. No study-specific care, but participants will be provided with information on community resources and support, and will also be encouraged to speak to their clinician if they are interested in learning about other services.
48293274|NCT01172288|DRUG|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
48293275|NCT01172288|DRUG|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
48293276|NCT01786018|DRUG|Thiotepa|
48293277|NCT01786018|DRUG|Busulfan|
48293278|NCT01786018|DRUG|Fludarabin|
48293279|NCT01786018|PROCEDURE|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10\^7 CD3 cells/kg recipient weight and cryopreserved.
48293280|NCT01786018|RADIATION|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
48293281|NCT01786018|DRUG|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
48293282|NCT01786018|DRUG|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
48293283|NCT01786018|DRUG|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
48293284|NCT01786018|DRUG|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
48293285|NCT01786018|PROCEDURE|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
48475640|NCT03939949|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
48475641|NCT03939949|BEHAVIORAL|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
48475642|NCT05070390|DRUG|Enlicitide Chloride|10 mg capsule administered orally
48475643|NCT03825367|DRUG|Nivolumab|"The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg."
48475644|NCT03825367|DRUG|5-azacytidine|75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
48475645|NCT00610324|DRUG|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
48475646|NCT00610324|DRUG|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
48475647|NCT05685277|DRUG|Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg|Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
48293286|NCT02269319|DRUG|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
48293287|NCT02269319|DRUG|Linezolid|Oral linezolid 600mg given twice a day for 10 days
48293288|NCT02949661|PROCEDURE|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
48475648|NCT05685277|DRUG|Tritace® Plus tablet 10 mg/25 mg|Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
48475649|NCT06461793|RADIATION|Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients|this researcher performed biodegradable material injection during radical radiotherapy in combination with hormone therapy in high - risk prostate cancer patients. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
48475650|NCT06563245|DRUG|Brentuximab Vedotin for Injection|1.8mg/kg/dose (MAX 180 mg)
47944492|NCT05345873|BIOLOGICAL|mRNA-1273|one dose of mRNA-1273 on D0, intramuscular
47944493|NCT01699932|DRUG|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
47944494|NCT06333821|BIOLOGICAL|Nimotuzumab|Nimotuzumab 400mg
47944495|NCT06333821|DRUG|Cisplatin|Cisplatin 40mg/m\^2
47944496|NCT06333821|RADIATION|External Beam Radiotherapy (EBRT)|External Beam Radiotherapy (EBRT)
47944497|NCT06333821|RADIATION|Brachytherapy|Brachytherapy
47944498|NCT06333821|DRUG|placebo for Nimotuzumab|placebo for Nimotuzumab 400mg
47944499|NCT04378946|BEHAVIORAL|Intensive physical rehabilitation type training|Multiple reaching tasks aiming at increasing voluntary elbow range of motion
47944500|NCT04378946|DEVICE|Robotic system for supporting and monitoring arm motion|"Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training."
47944501|NCT04378946|DEVICE|Actigraph Activity Monitor|Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate
47944502|NCT04378946|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Done once before treatment (PRE)
47944503|NCT04378946|DIAGNOSTIC_TEST|Montreal Spasticity Measure (MSM)|Used to identify the actual spatial threshold (ST) prior to every training session
47944504|NCT02968511|BIOLOGICAL|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
47944505|NCT04533880|DEVICE|DBM|Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
47944506|NCT04533880|DEVICE|Calcium phosphate cement|Quickset, Arthrex, Naples, FL
47944507|NCT04533880|OTHER|Autologous bone graft|Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
47944508|NCT00414921|DRUG|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
47944509|NCT00414921|DRUG|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
47944510|NCT00414921|OTHER|placebo|inactive substance
47944511|NCT01690637|DRUG|Oseltamivir phosphate suspension|
47944512|NCT01690637|DRUG|Placebo|
47944513|NCT03052907|BEHAVIORAL|BSPAN|"1. Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~2. Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach \& Health Promotion and Delivery \& Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach \& Health Promotion component (Medium Capacity).~3. Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
47944514|NCT05660681|DRUG|glycerin 0.7%/PEG 400 0.3%|Eye drop with active agents from the OTC Monograph.
47944515|NCT05660681|DRUG|polyethylene glycol 400 0.4%/propylene glycol 0.3%|Eye drop with active agents from the OTC Monograph.
47944516|NCT00642473|DRUG|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
47944517|NCT00642473|DRUG|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
47944518|NCT00642473|OTHER|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
47944519|NCT05550649|PROCEDURE|embolization|Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
47944520|NCT03890952|DRUG|Nivolumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
47944521|NCT03890952|DRUG|Bevacizumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
47944522|NCT02394678|DEVICE|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
47944523|NCT00850161|DRUG|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
47944524|NCT00850161|DRUG|Nasulin™|100 IU(2 puffs in each nostril)
47944525|NCT03960931|OTHER|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
47944526|NCT03960931|OTHER|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
48293289|NCT02949661|PROCEDURE|Local wound infiltration|Patients will receive local wound infiltration
48293290|NCT00472927|DRUG|Premarin/MPA 0.45 mg/1.5 mg|
47944527|NCT03960931|OTHER|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
48293291|NCT01373905|PROCEDURE|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
48293292|NCT01373905|PROCEDURE|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
48293293|NCT02357277|DRUG|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
48293294|NCT02357277|OTHER|Placebo Inhaler|inhaled placebo
48293295|NCT04340869|OTHER|Theobromine|Natural extract from Cocoa
48293296|NCT04340869|OTHER|Remin Pro|Remin Pro
48293297|NCT02976467|DRUG|Fulacimstat (BAY1142524)|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
47944528|NCT00542568|BIOLOGICAL|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
48293298|NCT02976467|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
48293299|NCT02436798|DRUG|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
47944529|NCT01553032|DRUG|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
47944530|NCT01553032|RADIATION|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
47944531|NCT01570868|DRUG|Ponatinib|Starting dose: 45 mg by mouth once daily.
47944532|NCT00563420|PROCEDURE|Bronchoscopy|
47944533|NCT05318339|DRUG|Trastuzumab|"A loading dose of trastuzumab 8mg/kg IV over 90 minutes will be administrated on day 1 of week 1.~For all subsequent doses, trastuzumab 6mg/kg IV over 30 minutes will be administrated every three weeks.~Pyrotinib 400mg PO daily will be administrated at the same time."
47944534|NCT00567593|DRUG|Rosiglitazone|8mg tablet once a day for 14 days
47944535|NCT06048250|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47944536|NCT06048250|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
47944537|NCT06048250|PROCEDURE|Computed Tomography|Undergo CT
48103529|NCT06443021|DEVICE|PD cycler|"After a training phase and a run-in period of up to 6 weeks, depending on the PD cycler used prior to the study, the interventional phase will be initiated.~* Study phase A, variation of dwell duration: Duration of short cycles (cycle 1 and 2) 30 min, 60 min, 90 min, 120 min (and 150 min depending on the patient´s constitution and at the discretion of the treating physician)~* Study phase B, variation of dialysis fluid glucose composition: 1st cycle: 1.5% glucose concentration, 2nd cycle: 2.3% glucose concentration, 3rd cycle: 1.5% glucose concentration, 4th cycle: 2.3% glucose concentration; all following cycles to be applied as prescribed by the treating physician.~* Study phase C, variation of fill volume: 60% fill volume, 80% fill volume, 100% fill volume and 120% fill volume. (Volume of 120% will only be applied in case the patient tolerates these volumes according to the IPP."
48293300|NCT03115645|OTHER|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
48293301|NCT06331728|DRUG|IGNX001|IGNX001 given as a single subcutaneous dose on Day 1.
48293302|NCT06331728|DRUG|Placebo|Placebo to IGNX001 given as a single subcutaneous dose on Day 1.
48293303|NCT01095484|DRUG|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
48293304|NCT03333369|DRUG|200 mg levodopa/50 mg benserazide|
48293305|NCT03333369|DRUG|Dextrose|
48293306|NCT05295615|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
48293307|NCT02769871|BEHAVIORAL|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
48293308|NCT02769871|BEHAVIORAL|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
48475651|NCT06563245|RADIATION|response-adapted radiation|For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.
47944538|NCT06048250|BIOLOGICAL|Mezigdomide|Receive PO
47944539|NCT06048250|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
47944540|NCT04387721|OTHER|Kind of trifocal IOL|Patients will be divided between groups based on pre-surgery corneal astigmatism. Group FineVision is made up of patients with corneal astigmatism less than 1 D. Groups FineVision Toric is made up pf patients with corneal astigmatism more than 1.25 D
47944541|NCT03858478|DRUG|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
48632567|NCT06190665|DEVICE|DEB-TACE with visualable microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with visualable microspheres
48632568|NCT06190665|DEVICE|DEB-TACE with PVA microspheres|Drug-eluting Beads Transcatheter Arterial Chemoembolization(DEB-TACE) with polyvinyl alcohol microspheres
48632569|NCT00971503|PROCEDURE|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
48632570|NCT00971503|OTHER|Saline injection|Injection of saline solution for 5 days
48632571|NCT03024632|PROCEDURE|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
48632572|NCT02979054|DEVICE|T4020|
48632573|NCT02979054|DEVICE|Placebo|
48632574|NCT00513864|DRUG|Dextromethorphan|one time dose - 0.3mg/kg PO
48632575|NCT00513864|DRUG|Codeine|one time dose - 2mg/kg PO
48632576|NCT00513864|DRUG|Morphine|one time dose - 0.15mg/kg IV
48632577|NCT00142597|DEVICE|Acupuncture|"Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.~Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
48632578|NCT00142597|OTHER|Sham treatment|"Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
48632579|NCT00640432|DRUG|Diclofenac|75 mg oral capsule twice daily for 7 days
48632580|NCT00640432|DRUG|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
48632581|NCT01975649|DRUG|Tribulus Terrestris|patients will use 750 mg/day during 120 days
48632582|NCT01975649|OTHER|Placebo|patients will use placebo pills with the same shape of the drug
48632583|NCT04701320|DRUG|Conventional glass ionomer|Conventional glass ionomer with enhanced mechanical and esthetic proberties
48632584|NCT04701320|DRUG|Nano hydroxyapatite reinforced glass ionomer|Nanohydroxyapatite reinforced glass ionomer restorative material with enhanced mechanical proberties and chemical adhesion to tooth structure
48632585|NCT00504231|BIOLOGICAL|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
48632586|NCT04447066|OTHER|No intervention|No intervention - VHIT will be used but without intervention
47944542|NCT02328911|DEVICE|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
47944543|NCT02328911|DEVICE|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
48632587|NCT05515263|DIETARY_SUPPLEMENT|Intervention snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
47944544|NCT06252298|BIOLOGICAL|SCTC21C|SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
47944545|NCT04568889|BEHAVIORAL|A $10 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
47944546|NCT04568889|BEHAVIORAL|A $20 Survey Incentive|Individuals see a 10 dollar incentive on the flyers advertising the baseline survey.
47944547|NCT04568889|BEHAVIORAL|Emphasis of Government Involvement|Individuals see a message emphasizing the involvement of the government in the study,
47944548|NCT04568889|BEHAVIORAL|Emphasis of Academic Researchers Involvement|Individuals see a message emphasizing the involvement of academic researchers in the study,
47944549|NCT04568889|BEHAVIORAL|Cost-Benefit Frame|Individuals will see messaging that emphasizes the public health benefits of answering the survey questions in the baseline survey (cost-benefit frame).
47944550|NCT04568889|BEHAVIORAL|Duty Frame|Individuals will see messaging that emphasizes an individual's responsibility to their community in the baseline survey (duty frame),
48632588|NCT05515263|DIETARY_SUPPLEMENT|Control snack|To be eaten in replacement of usual snacks twice a day for 8 weeks.
48632589|NCT00441935|DEVICE|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
48632590|NCT04419974|DIAGNOSTIC_TEST|Molecular Diagnosis|Double-blind molecular diagnosis for the SCA3/MJD mutation.
48632591|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Baseline|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
48632592|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Baseline|"Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
48632593|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Baseline|Participants fill out 2 self-reported quality of life questionnaires.
48632594|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 12 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
48632595|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 12 months|"Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
48632596|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 12 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
48632597|NCT04419974|DIAGNOSTIC_TEST|Clinical Scales - Follow-up 24 months|SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
48632598|NCT04419974|DIAGNOSTIC_TEST|Blood Draw - Follow-up 24 months|"Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins"
48632599|NCT04419974|DIAGNOSTIC_TEST|Quality of Life Assessment - Follow-up 24 months|Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
48293309|NCT04530825|OTHER|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
48293310|NCT04530825|OTHER|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
48293311|NCT05609422|OTHER|Physical therapy program|"* Stretching exercises~* Strength Training Kneeling exercises~* Standing exercises~* Gait Training"
48293312|NCT05609422|OTHER|scooter board activities|"1. Scooter board bear walk.~2. Scooter board crab walk.~3. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~4. Cross sitting on scooter board, pulls along the rope using his/her hands~5. Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~6. Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items~7. Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8. Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~9. Supine flexion on scooter board, Clip clothespins to a rope hanging above."
48293313|NCT02975154|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
48293314|NCT04310137|BEHAVIORAL|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
48475652|NCT06563245|DRUG|Doxorubicin|25mg/m2/dose,
48475653|NCT06563245|DRUG|Etoposide|125 mg/m2/dose
48475654|NCT06563245|DRUG|Prednisone|20 mg/m2, BID, orally
48475655|NCT06563245|DRUG|Cyclophosphamide|600 mg/m2/dose
48475656|NCT06563245|DRUG|Dacarbazine|250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.
48475657|NCT06563245|DRUG|Tislelizumab Injection|3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
48632600|NCT02468700|DRUG|Dexamethasone|
48632601|NCT02468700|OTHER|Placebo Vehicle|
48293315|NCT04535011|BEHAVIORAL|PPKAY (brief intervention)|PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.
48632602|NCT04935515|DRUG|Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins|Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
48632603|NCT04935515|DRUG|Oral low dose steroid|Low dose oral methyl prednisolone was added.
48632604|NCT04935515|DRUG|Intravenous Antibiotics with Low dose steroid.|Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
48632605|NCT04935515|DRUG|Oral anti-coagulant|Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
47944551|NCT04568889|BEHAVIORAL|Racial/Ethnic Frame|Individuals will see messaging that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups in the baseline survey.
48475658|NCT06563245|DRUG|Bedamustine|180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
48475659|NCT04380649|DEVICE|New headset prototype|creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
48475660|NCT00973934|DEVICE|Magstim Theta|
48475661|NCT00973934|DEVICE|Thymatron System IV|
48475662|NCT02653729|BEHAVIORAL|cognitive behaviour therapy|
48475663|NCT02653729|DRUG|Espidone|
48632606|NCT02585492|OTHER|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
48632607|NCT02585492|OTHER|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
48632608|NCT01236807|PROCEDURE|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
48632609|NCT01236807|PROCEDURE|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
48632610|NCT01390584|DRUG|Doxorubicin|IV
48632611|NCT01390584|DRUG|Bleomycin|IV
48632612|NCT01390584|DRUG|Vinblastine|IV
48632613|NCT01390584|DIAGNOSTIC_TEST|PET|fludeoxyglucose F 18 Imaging exam
48632614|NCT01390584|RADIATION|INRT|selective external radiation therapy
48632615|NCT01390584|DRUG|Dacarbazine|IV
48632616|NCT01390584|DRUG|Etoposide|IV
48632617|NCT01390584|DRUG|Cyclophosphamide|May be given orally, IV push, or by IV infusion
48632618|NCT01390584|DRUG|Vincristine|IV
48632619|NCT01390584|DRUG|Procarbazine|PO
48632620|NCT01390584|DRUG|Prednisone|PO
48632621|NCT06235957|OTHER|Cast 3 weeks|patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks
48632622|NCT06235957|OTHER|Brace 1 week|patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
47944552|NCT04568889|BEHAVIORAL|No Messaging|Individuals will see no messaging in the baseline survey.
47944553|NCT04538573|DEVICE|Virtual Reality Distraction|Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.
47944554|NCT04538573|DRUG|Standard Treatment|"Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented."
48293316|NCT04535011|BEHAVIORAL|Standard Booster|After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.
48103530|NCT05266144|PROCEDURE|radiofrequency ablation|Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.
48293317|NCT04535011|BEHAVIORAL|Personalized Booster|After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
48293318|NCT00265941|DRUG|cetuximab|Cetuximab 400 mg/m\^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m\^2 IV weekly for 7 weeks
48293319|NCT00265941|DRUG|cisplatin|Cisplatin 100 mg/m\^2 IV on days 1 and 22
48293320|NCT00265941|RADIATION|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
48293321|NCT00265941|RADIATION|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
48293322|NCT00827268|BEHAVIORAL|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
48293323|NCT04927650|DIAGNOSTIC_TEST|HPV testing|Undergo collection of cervical samples for HPV testing
48293324|NCT04927650|OTHER|Questionnaire Administration|Complete questionnaires
48475664|NCT02653729|DRUG|Olepra|
48103531|NCT03313206|DRUG|Pembrolizumab|"Neo-adjuvant therapy :~* Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~* Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
48475665|NCT02653729|DRUG|Donu|
48103532|NCT03313206|PROCEDURE|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
48475666|NCT05181800|OTHER|Degarelix Cohort|Non-interventional
48475667|NCT02941588|PROCEDURE|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
48475668|NCT02037282|DRUG|Anti-influenza IVIG|
48475669|NCT01669031|OTHER|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
48475670|NCT01483014|DRUG|imatinib mesylate|
48475671|NCT02208752|OTHER|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
48475672|NCT03068845|DEVICE|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
48475673|NCT03068845|DEVICE|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
48103533|NCT03313206|RADIATION|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
48475674|NCT06082908|DIAGNOSTIC_TEST|Diagnostic test|Subjective and objective measurement will be performed in older adults.
48632623|NCT01496703|OTHER|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
48632624|NCT03479346|DRUG|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48475675|NCT06021470|BEHAVIORAL|Cognitive rehabilitation intervention|The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
48293325|NCT01088815|DRUG|Gemcitabine, nab-Paclitaxel, GDC-0449|"1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
48293326|NCT04624633|DRUG|Acalabrutinib|Oral, twice a day, predetermined dosage
48293327|NCT04624633|DRUG|Umbralisib|Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles
48475676|NCT03945799|DRUG|Anlotinib Hydrochloride|Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
48475677|NCT01783652|BEHAVIORAL|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
48475678|NCT02845726|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
48632625|NCT03479346|DRUG|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48632626|NCT01215240|DEVICE|Peritoneal dialysis|Prophylactic peritoneal dialysis
48475679|NCT03558035|DRUG|Induction CT+ CRT group|Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
48632627|NCT04867330|OTHER|Toxicities reduced treatment arm|Two cycles Toripalimab+docetaxel+cisplatin induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
48632628|NCT01717859|DRUG|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 \> 3.2, dosage will be escalated to 8 mg/kg.
48632629|NCT00055965|DRUG|carboplatin|
48632630|NCT00055965|DRUG|cisplatin|
48293328|NCT04624633|DRUG|Ublituximab|28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
48475680|NCT03558035|RADIATION|Concurrent CRT group|cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
48475681|NCT01469507|DEVICE|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
48475682|NCT01469507|DRUG|Hyaluronan|3 weekly injections
48632631|NCT00055965|DRUG|gemcitabine hydrochloride|
48632632|NCT06323720|OTHER|Quantitative Sensory Testing|Assessment of the heat and cold pain thresholds, temporal summation, conditioned pain modulation, pressure pain thresholds, electrical pain thresholds, and withdrawal reflex.
48632633|NCT02696577|DRUG|Low dose aspirin|
48632634|NCT02696577|DRUG|Omega 3|
48293329|NCT02973815|BEHAVIORAL|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
48293330|NCT02158221|DRUG|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
48293331|NCT01411540|DIETARY_SUPPLEMENT|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
48293332|NCT02742740|BEHAVIORAL|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
48293333|NCT00312351|DRUG|Pegaptanib sodium|
48293334|NCT01784549|DRUG|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
48293335|NCT06671028|DRUG|Ropivacaine and Lidocaine|Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL
48293336|NCT06671028|DRUG|Ropivacaine 0,5%|Popliteal sciatic block using ropivacaine 0.5% 20 mL
48293337|NCT02453412|DEVICE|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
48293338|NCT00149929|DRUG|Mycophenolate sodium (enteric coated)|
48293339|NCT05308485|OTHER|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
48293340|NCT03728361|BIOLOGICAL|Nivolumab|Given IV
48293341|NCT03728361|DRUG|Temozolomide|Given PO
48293342|NCT06509516|OTHER|Modified Sleeper-Stretch|Self-administered stretch in which the individual remains side-lying on the upper limb to be stretched, keeping the scapula stabilized by his/her own weight, and rolls the trunk 20-30º posteriorly, maintaining a 90º flexion in the shoulder and elbow. Using the opposite hand over the forearm of the limb to be stretched, the individual passively brings the shoulder to maximum internal rotation.
48293343|NCT06637540|DEVICE|RescueDoppler|Continous handsfree pulsed wave Doppler of the common carotid artery during cardiac surgery
48293344|NCT06637540|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the common carotid artery during cardiac surgery
48293345|NCT04656652|DRUG|DS-1062a|DS-1062a will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
48293346|NCT04656652|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
48293347|NCT03823768|DRUG|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
48293348|NCT03823768|DRUG|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
48293349|NCT02421380|DRUG|Hyperpolarized Pyruvate|
48293350|NCT02457052|DEVICE|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
48293351|NCT01276015|DRUG|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
48293352|NCT04913324|BEHAVIORAL|Virtual Care|Infants randomized at 4 months of age to the intervention arm will participate in virtual care visits for 16 weeks in addition to standard of care in-hospital visits.
48293353|NCT01084252|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48293354|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48293355|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
48293356|NCT03131297|PROCEDURE|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
48293357|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's polyp detection function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
48293358|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's quality monitoring function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
48293359|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy without the assistance of EndoAngel's any function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
48293360|NCT01418768|OTHER|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
48293361|NCT00749099|DRUG|pancrelipase|"The test drug (PANCRECARB® \[pancrelipase\] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
48293362|NCT00749099|DRUG|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
48475683|NCT04522804|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
48475684|NCT05481736|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
48475685|NCT05188924|DRUG|DKF-306|Active ingredients
48475686|NCT05188924|DRUG|Placebo|Placebo
48293363|NCT00887445|DRUG|SLV341|5 - 1000mg once daily
48293364|NCT00887445|DRUG|placebo|
48293365|NCT06673407|BEHAVIORAL|Group Exposure for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears.
48475687|NCT01885351|BEHAVIORAL|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
47944555|NCT03589781|DIETARY_SUPPLEMENT|Mikei Red Reishi Essence EX|Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.
47944556|NCT03589781|DIETARY_SUPPLEMENT|Placebo|Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
47944557|NCT05321927|DEVICE|Trancutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation produces an electrical current to stimulate the nerves for therapeutic purposes. continuous high frequency (≥ 50 Hz) stimulation for 5 minutes followed by high frequency (≥ 50 Hz) bursts with 9 pulses per burst for the last 5 minutes, with a stimulation/rest ratio of 1:2.
47944558|NCT05321927|OTHER|Strength training|Three training sessions for 10 minutes per muscle, per week, for four weeks in total.
48475688|NCT01885351|BEHAVIORAL|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
48475689|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
48475690|NCT04087317|DRUG|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
48475691|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
48475692|NCT04087317|DRUG|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
48475693|NCT04087317|DRUG|MIR|At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
48475694|NCT02190279|DRUG|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
48475695|NCT02190279|DRUG|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
48475696|NCT04080596|DRUG|Dorzagliatin|GKA for T2DM currently under clinical development
48632635|NCT03555045|PROCEDURE|conducting the slanted recession technique on the superior and inferior poles|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
48632636|NCT03555045|PROCEDURE|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
48632637|NCT05573737|OTHER|education|education about ubilical cord care
48632638|NCT03275610|GENETIC|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
48632639|NCT01277068|PROCEDURE|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
48632640|NCT02573467|DRUG|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
48475697|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment A|Single oral dose
48475698|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment B|Single oral dose
48632641|NCT02573467|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
48632642|NCT03886324|COMBINATION_PRODUCT|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
47944559|NCT05321927|DEVICE|Sham stimulation|Continuous stimulation at 1 Hz for 2 seconds, then no stimulation for 10 seconds. This will alternate for 10 minutes. The intensity equals the intensity that is just felt by the individual.
47944560|NCT03278782|BIOLOGICAL|Pembrolizumab|Given IV
47944561|NCT03278782|DRUG|Romidepsin|Given IV
47944562|NCT02273531|DRUG|Asasantin ER, new formulation|
48475699|NCT05944250|DEVICE|Spincare matrix|The Spincare device, developed by Nanomedic, is the first portable tool that delivers a non-invasive, non-therapeutic electrospun, nanofibrous matrix dressing to wounds to promote healing.
48475700|NCT02096588|DRUG|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
47944563|NCT02273531|DRUG|Asasantin ER, present commercial formulation|
47944564|NCT00118690|DRUG|Fluticasone propionate/salmeterol|
47944565|NCT02405754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
47944566|NCT04149873|PROCEDURE|MIE|MIE
47944567|NCT00232089|DRUG|Tegaserod|
48293366|NCT06673407|BEHAVIORAL|Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from our previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during our quality improvement project, that are designed to enhance compassion.
48293367|NCT06673407|BEHAVIORAL|Peer-Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
48475701|NCT02096588|DRUG|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
48475702|NCT00540358|DRUG|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
48475703|NCT00540358|DRUG|iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
48475704|NCT03532750|DEVICE|Particle|"1. 300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~2. 300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~3. Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~4. Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
48475705|NCT03532750|DEVICE|Coil|Ruby or Interlock detachable coils
47944568|NCT00005093|DRUG|gemcitabine hydrochloride|
47944569|NCT00005093|DRUG|tacedinaline|
48103534|NCT03313206|DRUG|Lenvatinib|up to 26 evaluable patients will be treated with pembrolizumab combined with orally lenvatinib at a daily dose of 20 mg for 6 weeks started on the day of the first anti-PD1 dose.
48475706|NCT03474328|DEVICE|AlcoChange|Smartphone app and breathalyser
48475707|NCT06035276|OTHER|Exposure to clean air|"Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest."
48475708|NCT06035276|OTHER|Exposure to urban air|"Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen."
48475709|NCT00193973|DRUG|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
48475710|NCT00193973|RADIATION|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
48475711|NCT05559463|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
48620039|NCT05702632|DEVICE|1- Reciprocal electrical stimulation|A specialized programmable electrical stimulation device was used (Uniphy is the manufacturer of Phyaction787; Uniphy, Eindhoven, the Netherlands). The device has two channels that can alternatively stimulate two opposing groups of muscles (reciprocate).
47944570|NCT00200096|PROCEDURE|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
48103535|NCT04898192|OTHER|questionnaire|questionnaire - the complex of 6 questionnaires aimed to recognize the fear of delivery, perinatal anxiety, depressive disorder, obsessive-compulsive disorder, general anxiety disorder, postpartal depression and domestic violence.
48103536|NCT06413940|BEHAVIORAL|Myofunctional Therapy|Oropharyngeal and tongue exercises : strengthening upper airway muscle 20 minutes
48103537|NCT06413940|BEHAVIORAL|Inspiratory Muscle Training|Respiratory muscle strengthening:inspiratory muscle strengthening by resistive loading of 50% maximum inspiratory pressure.
48103538|NCT06413940|BEHAVIORAL|Aerobic Exercise|Exercise intensity :40%-60% HRmax , 3-5 days/week
48293368|NCT06673407|BEHAVIORAL|Peer and Self-Compassion Enhanced Group Exposure Therapy for Social Anxiety|Group exposure therapy for social anxiety and public speaking fears plus piloted exercises from our previous studies among socially anxious undergraduates (Slivjak et al., 2022; Slivjak \&amp; Arch, in preparation), refined during our quality improvement project, that are designed to enhance compassion. These groups are facilitated by a pair of doctoral student and undergraduate student co-facilitators who explicitly use appropriate self-disclosure to establish the co-facilitators as individuals with lived experiences of social anxiety and public speaking fears.
47944571|NCT00200096|PROCEDURE|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
47944572|NCT00861536|DRUG|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
48293369|NCT06315881|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral mucosa sample collection
47944573|NCT00861536|DRUG|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
47944574|NCT00452478|DRUG|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
47944575|NCT02767505|OTHER|gastric bypass|Type of surgery: gastric bypass
47944576|NCT02767505|OTHER|Sleeve gastrectomy|Typ of surgery: sleeve gastrectomy
47944577|NCT04194346|PROCEDURE|Lung ultrasound|Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
47944578|NCT01825603|DRUG|ADH-1|Given IV
47944579|NCT01825603|DRUG|Cisplatin|Given IV
47944580|NCT01825603|DRUG|Gemcitabine Hydrochloride|Given IV
48293370|NCT06315881|DRUG|Cigarette|Smoke usual brand cigarette
48293371|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN R/S ONP
48293372|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN \> 99% S ONP
48293373|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high R/S ONP
48293374|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high FBN \> 99% ONP
48632643|NCT02298569|BEHAVIORAL|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
48632644|NCT01954173|RADIATION|3D conformal radiation therapy|Undergo conformal radiation therapy
47944581|NCT01825603|OTHER|Laboratory Biomarker Analysis|Correlative studies
47944582|NCT04228783|BIOLOGICAL|Ad26.ZEBOV|Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).
47944583|NCT04228783|BIOLOGICAL|MVA-BN-Filo|Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.
47944584|NCT04228783|BIOLOGICAL|Placebo|Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).
47944585|NCT02869438|DRUG|Benralizumab|Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
47944586|NCT02869438|OTHER|Placebo|Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
48103539|NCT00832884|DRUG|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
48103540|NCT05038969|DRUG|Stomopral|1 capsule contains 40 mg Esomeprazole
48293375|NCT06315881|DRUG|Smokeless Tobacco|Insert ST
48293376|NCT06315881|OTHER|Survey Administration|Ancillary studies
48293377|NCT06315881|OTHER|Text Message-Based Navigation Intervention|Receive text with a link to daily diary surveys
48293378|NCT05706467|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
48293379|NCT05706467|DEVICE|Non-invasive continuous positive airway pressure ventilation|Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
48293380|NCT02609711|DRUG|Candesartan cilexetil|
48293381|NCT00761124|BEHAVIORAL|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
47944587|NCT05863338|BEHAVIORAL|NURSING FOLLOW-UP BY PHONE|The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
47944588|NCT00808678|DRUG|ABT-143|once, see arm description for more information
48293382|NCT00761124|BEHAVIORAL|Printed Material|General prostate cancer pamphlet
48475712|NCT00337987|DRUG|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
47944589|NCT00808678|DRUG|ABT-335|once, see arm description for more information
47944590|NCT00808678|DRUG|rosuvastatin|once, see arm description for more detail
47944591|NCT04185870|DIAGNOSTIC_TEST|3D scan|All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
47944592|NCT04185870|DIAGNOSTIC_TEST|Standard photography|All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
47944593|NCT05299723|BEHAVIORAL|BLT Intervention|BLT will be administered via a Luminette 3 light therapy visor. The Luminette 3 is a visor worn above the eyes containing light emitting diode (LEDs) emitting a blue-enriched white light reflecting to the retina at 1,000 lux via a holographic system in order to ensure correct penetration into the eye without impeding vision. This range of light and intensity is sufficient to synchronize the circadian clock.
47944594|NCT05299723|BEHAVIORAL|BLB Intervention|BLB will be administered via orange lenses that filter out short-wavelength blue light, while allowing the other visible spectrum light to pass. The BLB lenses result in a reduction in melanopic irradiance (i.e., the light that affects sleep) of about 85%. The BLB lenses only make the overall light environment about 30% dimmer. Therefore, the BLB lenses are effective in blocking out most of the blue light in the visible environment that impacts sleep, but do not result in drastic overall dimming/darkening of the light environment.
47944595|NCT05299723|BEHAVIORAL|Sleep Hygiene Education|The sleep hygiene education will consist of watching a sleep education video (background on the regulation of sleep, the impacts of insufficient sleep on mental and physical health, etc.) and a sleep hygiene video (providing overview of sleep hygiene approaches).
47944596|NCT02407418|OTHER|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
47944597|NCT02407418|OTHER|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
47944598|NCT04758078|OTHER|Inhaled corticosteroids|Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
47944599|NCT04758078|OTHER|Placebo|Nebulized 0.9% saline will be given four times per day
47944600|NCT01485393|DRUG|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
47944601|NCT01485393|DRUG|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
47944602|NCT00950911|DRUG|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
47944603|NCT03029429|DRUG|Theophylline|oral theophylline
47944604|NCT03029429|DRUG|Placebos|oral placebo
47944605|NCT00892658|DRUG|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
47944606|NCT00438451|DRUG|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
47944607|NCT00438451|DRUG|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
48103541|NCT05038969|DRUG|Nexium|1 capsule contains 40 mg Esomeprazole
48103542|NCT04117451|OTHER|Propolis|Investigating the impact of propolis mouthwash on oral and cardiovascular health
48103543|NCT01693965|OTHER|sputum samples|
48293383|NCT04366271|BIOLOGICAL|Mesenchymal cells|1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
48293384|NCT04366271|DRUG|Standard of care|Best treatment option for COVID-19 according to investigator criteria
48475713|NCT00337987|DRUG|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
48475714|NCT02752386|BEHAVIORAL|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
48632645|NCT03833843|DIAGNOSTIC_TEST|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
48103544|NCT06191406|DIAGNOSTIC_TEST|6 minute walk test|Test for physical functions and cognitive functions
48103545|NCT04617717|PROCEDURE|Invasive cardiac electrophysiological study and ablation therapy|Invasive cardiac electrophysiological study with cathecholamine provocation and pacing procedures, as well as standard 3D mapping and PVC ablation
48103546|NCT04617717|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Standard ergometer bicycle test
48293385|NCT04247932|BEHAVIORAL|Active labor market intervention|Behavior change intervention
47944608|NCT00438451|DRUG|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
47944609|NCT03853343|DIETARY_SUPPLEMENT|Seaweed extract|1 capsule 3 times per day
47944610|NCT03853343|DIETARY_SUPPLEMENT|Placebo|1 capsule 3 times per day
48103547|NCT04617717|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with cine-imaging and late-gadolinium enhancement
48475715|NCT06274788|DRUG|Omegaven® (fish oil triglycerides) Injectable Emulsion|"Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator"
48475716|NCT00877617|BEHAVIORAL|QOL Questionnaire|Mailed survey.
48632646|NCT02347865|DRUG|AMG 162 - Prolia|500 patients
48632647|NCT02347865|DRUG|AMG 162 - Prolia|250 patients, one year later
47944611|NCT02517866|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
47944612|NCT04034082|DEVICE|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
47944613|NCT04034082|OTHER|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
48475717|NCT01776567|DEVICE|Everolimus eluting stents|
47944614|NCT02493582|BIOLOGICAL|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
48475718|NCT06472180|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
47944615|NCT02493582|DRUG|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
47944616|NCT06356090|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE)|SPACE is a parent-based treatment (parent-stand-alone treatment) for parents of youth with anxiety symptoms or OCD. The manualized treatment protocol contains 12 sessions, in which parents are taught to reduce family accommodation (FA) and to increase supportive responses to their child.
48475719|NCT06472180|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
48475720|NCT01376206|DRUG|Fluticasone|Collection of safety data
47944617|NCT00225446|DEVICE|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
47944618|NCT00093782|DRUG|temsirolimus|Given IV
47944619|NCT00093782|OTHER|laboratory biomarker analysis|Correlative studies
48475721|NCT06428695|BEHAVIORAL|one-hour dietary self-monitoring tool education session|access the impact of a one-hour dietary self-monitoring tool education session for participants in a calorie-restricted weight management program on their knowledge of the use of the tool to help them adhere to a calorie-restricted weight management program
48632648|NCT04873661|BEHAVIORAL|Hypnosis group intervention|See arm description
48632649|NCT04873661|BEHAVIORAL|Cognitive trance group intervention|See arm description
47944620|NCT01981759|DRUG|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
48103548|NCT04617717|DIAGNOSTIC_TEST|Holter monitoring|24h 5 lead or 12 lead ECG recording
48103549|NCT04617717|DIAGNOSTIC_TEST|Transthoracic echocardiography|2D echocardiography
48103550|NCT04617717|DIAGNOSTIC_TEST|Coronary angiography|Conventional invasive coronary angiography or CT angiography as indicated
48103551|NCT01376141|DRUG|Sumatriptan|
48475722|NCT02070757|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
48632650|NCT04873661|BEHAVIORAL|Meditation group intervention|See arm description
48632651|NCT05023655|DRUG|Tazemetostat|800mg po twice daily
48475723|NCT02070757|DRUG|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
48475724|NCT02305173|DRUG|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
48475725|NCT02305173|DRUG|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
48475726|NCT00646503|DRUG|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
48475727|NCT03237117|BIOLOGICAL|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
48632652|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - with Virtual Coach Botley|Bootle Boot Camp exercise sessions offered with movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the no feedback condition for a period of 4 weeks (4 sessions/week). Movement feedback will be guided by skeletal data captured by the 3D motion tracking camera and based on predefined movement acceptability criteria for each exercise. Feedback will take the form of visual markers, text/audio cues and rewards.
48632653|NCT05998239|OTHER|Bootle Boot Camp Home Exercise App - without Virtual Coach Botley|Bootle Boot Camp exercise sessions offered without movement tracking feedback will be provided for a maximum of two consecutive sessions before being alternated with the movement tracking feedback condition for a period of 4 weeks (4 sessions/week).
48632654|NCT01618708|DEVICE|Synvisc-One (hylan G-F 20)|6-mL IA injection
48293386|NCT06672276|DRUG|TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.
48632655|NCT01618708|DEVICE|Placebo|6 mL injection of phosphate buffered saline
48632656|NCT06469853|DRUG|MBF-015 16 mg oral capsules|MBF-015 oral capsules HDAC inhibitor
48632657|NCT04898465|OTHER|Social Paediatric Intervention|Family will meet the hospital's social-paediatrician and social worker. Together they will evaluate the need for social support, risk for neglect and refer families for local social services if needed. The visit will contain primary and secondary prophylaxis of child abuse and neglect.
48632658|NCT06309797|DEVICE|Interdental brush+HA|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm) +20 mL of 0.2% HA gel (Gengigel; Ricerfarma, Milan, Italy)
48632659|NCT06309797|DEVICE|Interdental brush|interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm)
48293387|NCT05595473|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV
48632660|NCT05199038|DRUG|Octreotide|Octreotide infusion for 2 days in patients with bleeding esophageal varices.
48632661|NCT00303628|DRUG|oxaliplatin|Given IV
48632662|NCT00303628|DRUG|fluorouracil|Given IV
48103552|NCT05392738|DEVICE|I-Stent implantation|I-Stent implantation
48475728|NCT01647958|DEVICE|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners
48475729|NCT01647958|DRUG|PPI|Control Arm participants will take maximum standard dose of PPI during Initial Study period
48293388|NCT05595473|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV
48293389|NCT05595473|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV
48293390|NCT05595473|DRUG|RZ-001 Dose 4|RZ-001 Dose 4 and VGCV
48475730|NCT04272476|OTHER|acupuncture and moxibustion|
48475731|NCT04272476|DRUG|Fluoxetine|
48475732|NCT05713227|DIETARY_SUPPLEMENT|White rice|185 g Jasmine (white) rice boiled in 356 g water
48475733|NCT05713227|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
48475734|NCT05987072|DRUG|Sisunatovir|Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
48293391|NCT04404400|DRUG|Investigational products administration|"Investigational products include:~* Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours, and~* 9 alpha fludrocortisone 50 μg: one tablet per day via a nasogastric tube.~All treatments will be stopped after 7 days or until the patient has left the intensive care unit (whichever occurs first) without tapering off."
48293392|NCT04404400|DRUG|Placebo administration|Placebos for hydrocortisone and for fludrocortisone, administered in same manner as the active drugs in the interventional arm, for 7 days.
48293393|NCT00779038|DRUG|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
48475735|NCT02488668|DEVICE|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
48475736|NCT01279382|BEHAVIORAL|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
48475737|NCT01279382|BEHAVIORAL|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
48475738|NCT01279382|OTHER|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
48475739|NCT00779402|OTHER|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
48632663|NCT00303628|DRUG|leucovorin calcium|Given IV
48632664|NCT00303628|DRUG|bevacizumab|Given IV
48632665|NCT02459925|BEHAVIORAL|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
48632666|NCT02459925|BEHAVIORAL|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
48632667|NCT02866266|OTHER|Retrospective database review|
48632668|NCT02342951|OTHER|Lung clearance index determination|Lung clearance index determination
48632669|NCT02197988|DRUG|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
48632670|NCT02197988|DRUG|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
48632671|NCT01572688|DRUG|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
47944621|NCT01981759|OTHER|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
47944622|NCT01981759|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
47944623|NCT03508739|DRUG|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
47944624|NCT03508739|DRUG|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
48632672|NCT01033227|DRUG|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
48632673|NCT00448357|BIOLOGICAL|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
48632674|NCT00448357|BIOLOGICAL|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
48632675|NCT00448357|DRUG|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
48632676|NCT00448357|DRUG|fludarabine phosphate|30 mg/m\^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
48632677|NCT00448357|DRUG|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
48632678|NCT00448357|PROCEDURE|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and maximum of 8 x 10\^6 cells/kg will be infused on day 0
48632679|NCT00448357|PROCEDURE|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on day 0
48632680|NCT00448357|DRUG|methotrexate|5 mg/m\^2 on days +1, +3 and +6
48632681|NCT03148925|BIOLOGICAL|SELA-070|Sub-cutaneous injection, multiple dose
48632682|NCT03148925|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
48632683|NCT05916287|BIOLOGICAL|Blood and urine samples|Blood and urine samples
48632684|NCT05916287|GENETIC|Blood samples|Blood samples
48632685|NCT05916287|OTHER|Cardiovascular assessment|Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).
47944625|NCT02908243|OTHER|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
47944626|NCT06558084|DRUG|CDK4/6 Inhibitor|CDK4/6 inhibitor in first and second lines
47944627|NCT04038931|OTHER|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
47944628|NCT04072562|DRUG|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
47944629|NCT00131508|DRUG|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
47944630|NCT00131508|DRUG|Placebo|Placebo
47944631|NCT00003927|BIOLOGICAL|filgrastim|
47944632|NCT00003927|DRUG|amifostine trihydrate|
47944633|NCT00003927|DRUG|cyclophosphamide|
47944634|NCT00003927|DRUG|doxorubicin hydrochloride|
47944635|NCT00003927|DRUG|paclitaxel|
47944636|NCT00003927|PROCEDURE|peripheral blood stem cell transplantation|
47944637|NCT04064385|DEVICE|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
48632686|NCT05916287|BEHAVIORAL|Dietary intake|Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire
48632687|NCT05916287|OTHER|Anthropometric parameters|Measurement of height, weight, abdominal circumference, hip circumference, arm circumference
48632688|NCT05916287|OTHER|Hemodynamic parameters|Systolic pressure index measurement
48632689|NCT05916287|OTHER|Hemodynamic parameters|Heart rate measurements, blood pressure measurements, orthostatic BP measurements
48632690|NCT05916287|OTHER|Hemodynamic parameters|"Blood pressure measurements by unattended BP monitor over 5 min"
48632691|NCT05916287|OTHER|Hemodynamic parameters|Electrocardiogram
48632692|NCT05916287|BEHAVIORAL|Assessment of compliance with antihypertensive treatments for treated participants|EVALOBS scale and compliance questionnaire
48632693|NCT05916287|OTHER|Ambulatory 24 hours measurment of blood pressure|For the first 100 patients willing to participate
47944638|NCT00130273|BEHAVIORAL|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
47944639|NCT00130273|BEHAVIORAL|Standard care|Participants will receive standard of care for 12 months.
47944640|NCT05923528|DEVICE|IPL|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter
47944641|NCT05923528|DEVICE|Heated eye mask|Heated eye mask will be used to assess its usefulness in dry eye signs and symptoms
47944642|NCT05923528|DEVICE|LipiFlow®|LipiFlow® can control the variables of temperature, pressure, and MG expression technique
47944643|NCT05923528|DEVICE|EyePeace®|The silicone-made flexible hand-held gadget applies regulated, vertical pressure to the closed eyelids.
47944644|NCT01953861|DRUG|EC905|Oral
47944645|NCT06058559|DIETARY_SUPPLEMENT|Sunflower lecithin|Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function
47944646|NCT06058559|DIETARY_SUPPLEMENT|Olive oil|Extra virgin olive oil
47944647|NCT02368704|OTHER|No intervention|
47944648|NCT05965778|DEVICE|T2769|T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
47944649|NCT05965778|DEVICE|Vismed® Multi|Hyaluronic acid
47944650|NCT04845373|OTHER|Mediterranean diet|Diet intervention:Mediterranean diet
47944651|NCT04845373|OTHER|Control diet: Low fat diet|Low fat diet
47944652|NCT02836353|DRUG|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
47944653|NCT02836353|DRUG|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
48103553|NCT05993949|DRUG|Dasatinib|3 pulses of oral dasatinib (100 mg daily) beginning on Day 4 (+up to 2 days) for 3 days (with 4 days off), repeated weekly. The weekly 3-day pulse schedule of dasatinib may continue for up to 3 months in subjects who continue to meet the dasatinib eligibility criteria and who do not meet off treatment/off study criteria
48103554|NCT00090298|DRUG|MK0653A, ezetimibe (+) simvastatin|
48103555|NCT00090298|DRUG|Comparator: Rosuvastatin|
48103556|NCT01250548|BIOLOGICAL|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
48475740|NCT00779402|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
48475741|NCT00240617|DRUG|sumatriptan succinate/naproxen sodium|comparator
48103557|NCT01250548|OTHER|Placebo|
47944654|NCT02747654|GENETIC|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
47944655|NCT01264016|DEVICE|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
47944656|NCT00046514|DRUG|ABI-007|
47944657|NCT04137224|BIOLOGICAL|IgPro20|Human normal immunoglobulin for subcutaneous administration
47944658|NCT04137224|BIOLOGICAL|IgPro10|Human normal immunoglobulin for intravenous administration
47944659|NCT00427271|DRUG|aspirin|
47944660|NCT03191240|DRUG|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
47944661|NCT03191240|DRUG|Normal saline|Placebo
48293394|NCT06671145|DIAGNOSTIC_TEST|catheter ablation|Catheter ablation after differentiating Atrioventricular Nodal Reentry Tachycardia from Orthodromic Atrioventricular Reentry Tachycardia during electrophysiological study.
48293395|NCT05025488|DRUG|Peptide-based vaccine|ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
48293396|NCT05025488|DRUG|Poly ICLC|ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
48293397|NCT05367804|DIETARY_SUPPLEMENT|Isolated pea protein|The subjects eligible to take part in this study will consume an isolated plant protein for 4 weeks (week 4 to 8), in each week the amount of protein supplementation will increase (0.25 to 1.0 g of protein per kg of body weight). The protein will be provided as a powder in opaque bags and participants will be instructed to dissolve the contained powder in liquids (as water) or on their food (e.g., yogurt, oat porridge). The baseline will consist of 4 visits (1 to 4) to see how stable are the baseline results.
48293398|NCT06027320|BEHAVIORAL|Brain Health Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
48293399|NCT06027320|BEHAVIORAL|Alzheimer Disease Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
48293400|NCT05138120|BEHAVIORAL|Common Elements Toolbox|An unguided online single-session intervention with four modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.
48293401|NCT02263339|BEHAVIORAL|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
48293402|NCT02263339|BEHAVIORAL|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
48293403|NCT02263339|BEHAVIORAL|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
48632694|NCT05916287|BIOLOGICAL|24 hours urinary collection|For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick
48293404|NCT04908137|DRUG|2-octyl cyanoacrylate|Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
48293405|NCT05400460|PROCEDURE|Anatomical single-bundle reconstruction（ASBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the ASBR group to receive anatomic single-bundle reconstruction.We used hamstring as an autograft in the operation, and we chose the anatomical footprint of the anterior cruciate ligament for the positioning of the bone tunnel.Arthroscopic ASB ACL reconstruction was conducted with AMP technique.
48475742|NCT00240617|DRUG|placebo|placebo to match
48632695|NCT05916287|OTHER|General questionnaires|Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)
48632696|NCT05916287|OTHER|Women specific questionnaire|Women specific questionnaire
48632697|NCT05916287|BEHAVIORAL|Women specific questionnaire|Women specific questionnaire
48632698|NCT05916287|DIAGNOSTIC_TEST|NYHA dyspnea questionnaire|Determination of NYHA class.
48632699|NCT05916287|BEHAVIORAL|Anxiety questionnaire|Assessment of anxiety
48632700|NCT05916287|BEHAVIORAL|Epworth Sleepiness Scale|sleep quality assessment
48632701|NCT05916287|OTHER|"A questionnaire on the perception of the management of cardiovascular risk factors"|Patient's evaluation of cardiovascular risk factors by the health system
48632702|NCT05916287|BEHAVIORAL|A questionnaire on eating behaviors|Assessment of eating behaviors
48475743|NCT05044663|OTHER|No intervention|This is an observational study
48632703|NCT05916287|BEHAVIORAL|A questionnaire on eating habits to determine consumer profiles|Assessement of eating habit to create a consumer profile
48632704|NCT05916287|DIETARY_SUPPLEMENT|A questionnaire on food supplements use|Evaluation od food supplements intake
48632705|NCT05916287|OTHER|SARS-CoV-2 Infection Questionnaire|SARS-CoV-2 Infection Questionnaire
48632706|NCT05916287|OTHER|Instantaneous expired air analysis|Carbon monoxyde analysis in expired air
48632707|NCT05916287|BIOLOGICAL|Capillary sampling|Capillary sampling for pollutant analysis (Optional)
48632708|NCT00003501|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48632709|NCT04595812|DRUG|Misoprostol 200mcg Tab vaginal|2 tablets vaginally 1 hour before surgery
48632710|NCT04595812|DRUG|Oxytocin|30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h
48632711|NCT04595812|DRUG|Carbetocin|100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute
47944662|NCT02344615|PROCEDURE|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
48632712|NCT04595812|PROCEDURE|pericervical hemostatic tourniquet|a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
48632713|NCT04127929|OTHER|Restoration of cavities using glass carbomer material (GCP Dental)|Detection of caries then restoration of cavities
48632714|NCT04127929|OTHER|Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)|Detection of caries then restoration of cavities
47944663|NCT02344615|PROCEDURE|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
47944664|NCT06550271|DRUG|Rapamycin|Rapamycin in 2 different dosage forms (compounded and generic)
47944665|NCT03098355|BIOLOGICAL|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
47944666|NCT03098355|DRUG|Interleukin-2|Interleukin-2 of 250,000iu/m\^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
48103558|NCT03728725|DEVICE|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
48103559|NCT04720599|DIAGNOSTIC_TEST|ExoDx Prostate(IntelliScore)|The ExoDx Prostate test result supports the biopsy decision process by stratifying patients based on risk for high grade prostate cancer
48632715|NCT05004168|OTHER|Day Gel-0120|Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with
48632716|NCT05004168|OTHER|P5 Reference Standard (SPF 35 reference)|The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.
48632717|NCT02866448|DRUG|Vehicle control|Described in arm
48632718|NCT02866448|DRUG|Isoquercetin|Described in arm
48632719|NCT02866448|DRUG|Aspirin|Described in arm
48632720|NCT02866448|DRUG|Isoquercetin plus Aspirin|Described in arm
48632721|NCT04714580|OTHER|Animal Fun Program|This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
48632722|NCT00999570|OTHER|Specialty training for knee surgeons|
48632723|NCT03941886|OTHER|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight \<40 Kg, from \<15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
48632724|NCT04769401|OTHER|Normal Progesterone group|Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).
47944667|NCT00597974|PROCEDURE|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
47944668|NCT00597974|DEVICE|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson \& Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson \& Johnson), Wallstent® (Boston Scientific Medi-Tech)
48293406|NCT05400460|PROCEDURE|Double-bundle reconstruction （DBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the DBR group to receive double bundle reconstruction.The hamstring autograft is still used for double-bundle reconstruction. The surgical approach is to treat the native ligaments as anteromedial bundles and posterolateral bundles and restore the structure of the two bundles of ligaments in the process of a
48632725|NCT04769401|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
48632726|NCT05113602|DEVICE|URGOnight|EEG dry electrodes portable device
48632727|NCT05113602|DEVICE|Enobio|EEG wet electrodes portable device
47944669|NCT00597974|OTHER|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
47944670|NCT00597974|PROCEDURE|Angiography|(non-experimental) Coronary angiography
47944671|NCT02788929|DEVICE|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
47944672|NCT03736694|BEHAVIORAL|Cognitive behavioural therapy for insomnia|CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, \& Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, \& Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, \& Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, \& Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, \& Meijer, 2015).
47944673|NCT03736694|BEHAVIORAL|Sleep hygiene education|SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, \& Daley, 2003).
47944674|NCT00602173|DRUG|Cilostazol|
47944675|NCT03420859|DIAGNOSTIC_TEST|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
47944676|NCT00198926|BEHAVIORAL|covert v overt nutrition labeling|
47944677|NCT00198926|BEHAVIORAL|varying meal nutrition manipulation|
47944678|NCT05770583|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"* FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~* FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98~* FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
47944679|NCT05770583|PROCEDURE|SpO2 (oxygen saturation)|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation≤%98
48293407|NCT05400460|PROCEDURE|Central axial single-bundle reconstruction（CASBR group）|"406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to CASBR group.Arthroscopic ASB ACL reconstruction was conducted with transtibial technique and using Hamstring as autograft.Single-bundle reconstruction is used in CASBR reconstruction surgery.~The footprint of the implant on the lateral femoral condyle was chosen to be the location of the AMB bone canal in DB reconstruction surgery while the footprint of the implant on the tibial plateau was chosen to be the location of the bone canal of the PLB in DB reconstruction surgery."
47944680|NCT03508375|BIOLOGICAL|blood samples|blood samples
47944681|NCT01047735|PROCEDURE|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
47944682|NCT01047735|PROCEDURE|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
47944683|NCT01047735|BEHAVIORAL|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
47944684|NCT04234451|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
48103560|NCT06221618|OTHER|High-frequency carotid arteries ultrasound, CCTA, Cranial MRA|CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines
48475744|NCT06165692|BIOLOGICAL|PRF|Post-operative PRF placement in the post-extraction socket after third molar surgery
48632728|NCT04078308|BIOLOGICAL|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 \& 3
48632729|NCT04078308|OTHER|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
48632730|NCT01761227|DRUG|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
48632731|NCT01761227|DRUG|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
48632732|NCT03158311|DRUG|QVM149|Indacaterol acetate / glycopyrronium bromide / mometasone furoate
48632733|NCT03158311|DRUG|Salmeterol/fluticasone plus tiotropium|Free triple arm of salmeterol / fluticasone plus tiotropium
48632734|NCT01783782|BEHAVIORAL|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
48632735|NCT01783782|DRUG|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
48632736|NCT01783782|DRUG|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
48632737|NCT00578058|OTHER|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
48632738|NCT05610839|BEHAVIORAL|Acceptance-Enhanced Behavior Therapy|8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
48632739|NCT00120874|BEHAVIORAL|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
47944685|NCT04234451|PROCEDURE|sham acupuncture|For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle. The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).
47944686|NCT00635791|DRUG|Sorafenib|Given by mouth
47944687|NCT00635791|DRUG|Vorinostat|Given by mouth
47944688|NCT05492110|DEVICE|Coronary sinus reducer|The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
47944689|NCT05492110|OTHER|Sham-procedure|Implantation procedure with no device implanted
47944690|NCT05492110|DIAGNOSTIC_TEST|Invasive coronary physiology|Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
47944691|NCT04176575|OTHER|Acupuncture|Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
47944692|NCT00739050|DRUG|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
47944693|NCT00739050|DRUG|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
47944694|NCT00398827|DRUG|Dexmedetomidine|
47944695|NCT00398827|DRUG|Placebo|
47944696|NCT00625794|DRUG|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
47944697|NCT00625794|BEHAVIORAL|Smoking cessation counseling|8 weeks or counseling
47944698|NCT03111173|DEVICE|Holter Device|MyECG E3.80 Holter Recorder
47944699|NCT05996874|DRUG|Semaglutide|Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
47944700|NCT03708185|DIETARY_SUPPLEMENT|Beta-alanine|N/A: see arm description
47944701|NCT03708185|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
47944702|NCT01104155|DRUG|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
47944703|NCT01104155|DRUG|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
47944704|NCT01284582|BIOLOGICAL|ATH03|4 vaccinations
47944705|NCT03221907|DRUG|GLA5PR GLARS-NF1|Pregabalin tablet
47944706|NCT03221907|DRUG|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
48103561|NCT05825079|BEHAVIORAL|Weight-Bearing Feedback|Feedback on how much weight patients are exerting on their crutch/injured lower extremity (measured via Smart Crutch Tip) will be delivered to their mobile phones.
48632740|NCT00120874|DRUG|Memantine|Patients receive 10 milligrams of memantine twice daily.
48632741|NCT04040673|PROCEDURE|thyroid lobectomy|routine surgical removal of thyroid for biopsy
48632742|NCT04040673|DEVICE|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
48632743|NCT00132912|DRUG|SCH 530348|
48632744|NCT02919345|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
48632745|NCT02919345|DRUG|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
47944707|NCT03221907|DRUG|Pregabalin|Pregabalin capsule
47944708|NCT03221907|DRUG|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
47944709|NCT05323110|DRUG|CBS001|Intravenously administered, humanised anti-LIGHT IgG monoclonal antibody.
47944710|NCT05323110|DRUG|Placebo|CBS001 matched placebo
47944711|NCT00060515|DRUG|RG2133 (2',3',5'-tri-O-acetyluridine)|
47944712|NCT01573351|DRUG|Asunaprevir|
47944713|NCT01573351|DRUG|Daclatasvir|
47944714|NCT01573351|DRUG|Peg-interferon Alfa-2a|
47944715|NCT01573351|DRUG|Ribavirin|
47944716|NCT03707054|DIAGNOSTIC_TEST|Study Arm|Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
47944717|NCT02866994|BEHAVIORAL|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
47944718|NCT02866994|BEHAVIORAL|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
47944719|NCT03949985|OTHER|Tests of biological hemostatic profile associated with contraceptives|Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
48632746|NCT06050993|OTHER|Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.|During the preoperative procedure scheduled at the Paul Brousse hospital, 3 additional blood tubes (total volume 12 ml) will be withdrawn in addition of samplings already done for the patient's standard of care.
48632747|NCT03246854|DRUG|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
48632748|NCT02965976|BIOLOGICAL|Botulinum Toxin Type A|Given IM
48632749|NCT02965976|PROCEDURE|Esophagectomy|Undergo esophagectomy
47944720|NCT01904058|DRUG|LUM001|
47944721|NCT01904058|DRUG|Placebo|
47944722|NCT01904058|DRUG|Ursodeoxycholic Acid|
47944723|NCT02595996|DRUG|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
47944724|NCT00600444|PROCEDURE|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
48103562|NCT05825079|DEVICE|Smart Crutch Tip|The device is attached to the crutch and measures how much weight-bearing load is exerted onto its axis. The device is capable of transmitting this data into the patient and physicians' user interface.
48103563|NCT02754011|DRUG|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
48103564|NCT03234816|DRUG|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
47944725|NCT00600444|PROCEDURE|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
47944726|NCT05432141|BIOLOGICAL|sIPV vaccine /DTaP vaccine|All subjects received 3 doses of sIPV vaccines and 3 doses of DTaP vaccines. Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
48103565|NCT03234816|DRUG|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
47944727|NCT05432141|BIOLOGICAL|sIPV vaccine /Hepatitis A inactivated vaccine /MMR vaccine|All subjects will receive 1 dose of sIPV and 2 doses of hepatitis A inactivated vaccine/or 1 dose of attenuated hepatitis A vaccine and 1 dose of MMR vaccine.Subjects recommended intramuscular injection. The best site for intramuscular injection is the anterolateral middle thigh for infants and the deltoid muscle for children.
47944728|NCT06236620|DIETARY_SUPPLEMENT|Processing of wheat|Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans
47944729|NCT05289531|PROCEDURE|Rectal Resection Patients|Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
48103566|NCT03234816|DRUG|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
48475745|NCT00660868|DRUG|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
48475746|NCT04701424|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
48475747|NCT04701424|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
48475748|NCT05678738|DIETARY_SUPPLEMENT|Antioxidant Berry Supplementation|Participants who opt-in will be instructed to consume 300mL of the bioactive (antioxidant berry) supplement every morning and afternoon during days of participation.
48475749|NCT05678738|OTHER|Acute and Chronic Exercise-Heat Stress|All participants (male and female) will be exposed to repeated bouts of exercise-heat stress.
48475750|NCT05678738|DIETARY_SUPPLEMENT|Placebo (non-juice) Supplementation|Participants who opt-in will be instructed to consume 300mL of the placebo (non-juice) supplement every morning and afternoon during days of participation.
47944730|NCT03854188|PROCEDURE|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
48475751|NCT00951951|PROCEDURE|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
48475752|NCT00951951|PROCEDURE|Posterior Approach|
48475753|NCT06184594|OTHER|eNav|The eNav toolkit is a digital navigation toolkit that includes a website and text messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).
48475754|NCT06184594|OTHER|Standard of Care|Standard of care procedures for selecting their CRC screening test.
48475755|NCT04526899|BIOLOGICAL|BNT111|IV injection
48475756|NCT04526899|BIOLOGICAL|Cemiplimab|IV infusion
48475757|NCT05310045|BEHAVIORAL|Personalised primary prevention intervention|"Personalised primary prevention intervention~1. Consultation 1~   * Assess caregiver's situation regarding their cancer risk factors~  * Explain the causal links between risk factors and cancer~  * Inform about national recommendations to prevent and limit cancer risk~  * Clarify informal caregiver situation with respect to national screening programs~  * Define a personalised primary prevention program~2. Implementation: personalised primary prevention program~   * Carried out by the informal caregiver~  * Supervised by the coordinating nurse~3. Consultation 2~   * Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program~  * Identify barriers and facilitators to their implementation whether actions or no actions have been done.~  * Adapt the personalised primary prevention program to informal caregiver needs."
48475758|NCT03146273|DIETARY_SUPPLEMENT|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
48475759|NCT02244931|DEVICE|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
48475760|NCT02244931|DEVICE|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
48475761|NCT02244931|DEVICE|Standard manual Wheelchair|Standard manual Wheelchair
48293408|NCT05400460|OTHER|rehabilitation training protocol|The rehabilitation program for all patients followed a standardized Process. The first day after surgery, quadriceps sets, straight-leg raises, and prone hangs were initiated. All of the patients were allowed to walk with crutches and braces but with no weightbearing. The range of motion (ROM) progressed from 0 to 90 degrees 3 to 7 days postoperatively and reached 115 degrees within fourth week. Closed kinetic chain exercises and full weightbearing were started in the sixth week. Patients progressed to running without braces at 4 to 6 months.
48632750|NCT02965976|OTHER|Quality-of-Life Assessment|Ancillary studies
48632751|NCT05900310|DIAGNOSTIC_TEST|Core Cognitive Evaluation (CCE)|The Linus Health Core Cognitive Evaluation (CCE) is an easy-to-use but powerful tool to augment and facilitate cognitive health assessment during a patient's visit to their PCP. As a digital assessment solution, the CCE combines objective insights into cognitive ability with patient-reported insights to detect early signs of cognitive impairment and reveal specific modifiable risk factors earlier than the existing status quo assessments. The CCE is an FDA-listed Class II 510k exempt software as a medical device. The CCE has two components: The Digital Clock and Recall (DCR™) test and the Life and Health Questionnaire (LHQ).
48632752|NCT04251936|BEHAVIORAL|Exercise training|The moderate-intense aerobic exercise training will involve supervised aerobicycle ergometer training for 30 min with 60-80% HRmax three times per week for 12 weeks.
48632753|NCT04251936|BEHAVIORAL|Smoking cessation group program|Participants of both groups will receive a 6-week standard cognitive behavioral therapy-oriented smoking cessation group program (SCP, one 60 min session per week).
48632754|NCT04849052|BEHAVIORAL|MASTERY|In MASTERY, participants will have interactive, two-way text message 'sessions' (5-10 minutes of two-way text communication with an automated text-message program) once weekly for 12 weeks. Furthermore, study trainers will conduct 4 brief calls with participants (Weeks 1, 4, 7, and 12) to introduce the program, assess progress, answer questions, and provide support.
48632755|NCT04849052|BEHAVIORAL|Attentional Control|Participants in the control condition will also receive text messages once per week. To ensure time matching, the program will have 4 phone check-ins (on physical activity) as in MASTERY.
48293409|NCT05400460|OTHER|Educate patients on return to sports and the importance of quadriceps strength|"Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve."
48632756|NCT05655897|DEVICE|GeminiOne Transcatheter Valve Edge-to-Edge Repair System|The transcatheter valve clamp system consists of a valve clamp, an adjustable bend mid-tube, and a manipulated inner tube. The adjustable bend introducer catheter consists of an adjustable bend outer tube and dilator. The valve clip is composed of nickel-titanium alloy, cobalt-chromium-nickel-molybdenum-iron alloy, and polyethylene terephthalate material and contains a closure clip, gripping tab, central mechanism, braid, and suture. The adjustable bend guiding catheter is used to provide access to the transcatheter valve clamping system and to reach the designated position. The adjustable curved mid-tube and manipulated inner tube are used to enable the delivery, gripping, and release process of the valve clips within the body.
48293410|NCT00312377|DRUG|Docetaxel|infusion
48632757|NCT04794998|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
48632758|NCT04794998|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family phisicians personal practice.
48632759|NCT05099276|DRUG|Tranexamic Acid Pill|1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
48632760|NCT05099276|DRUG|Placebo|Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
48632761|NCT03368560|OTHER|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
47944731|NCT02367131|DRUG|JARDIANCE®|JARDIANCE®
47944732|NCT01147588|DRUG|lansoprazole|60 mg (2x30-mg capsule), once daily
48293411|NCT00312377|DRUG|Vandetanib|oral
48293412|NCT06130566|DRUG|Amlitelimab|Injection solution SC injection
48632762|NCT05354258|DRUG|Albendazole|Anthelminthic drugs for the treatment of soil-transmitted helminths
48632763|NCT05354258|DRUG|Praziquantel|Anthelminthic drugs for the treatment of schistosomiasis
48632764|NCT05354258|DRUG|Amodiaquine|SMC partner drug
48632765|NCT05354258|DRUG|Sulfadoxine pyrimethamine|SMC partner drug
48632766|NCT06413771|DRUG|Letrozole 2.5mg|Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
48632767|NCT06413771|DRUG|Gonadotropin|Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
48632768|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
48632769|NCT02520440|DEVICE|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
48632770|NCT02520440|BIOLOGICAL|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
48632771|NCT01530256|BIOLOGICAL|ALD518|160 mg IV q 4 weeks for 4 doses
47944733|NCT01147588|DRUG|omeprazole|80 mg (2x40-mg capsule), once daily
48293413|NCT06130566|DRUG|Placebo|Injection solution SC injection
47944734|NCT01147588|DRUG|esomeprazole|40 mg (1x40-mg capsule), once daily
48632772|NCT01530256|BIOLOGICAL|ALD518|320 mg IV q 4 weeks for 4 doses
48632773|NCT01530256|BIOLOGICAL|ALD518|640 mg IV q 4 weeks for 2 doses
47944735|NCT01147588|DRUG|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
48632774|NCT04066244|DRUG|BLZ945|Investigational drug
48632775|NCT02793778|DRUG|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
48632776|NCT02793778|DRUG|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
48632777|NCT02003027|DRUG|BT injection|
48632778|NCT05516095|DEVICE|Transcranial magnet stimulation|Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.
48632779|NCT05516095|DEVICE|Sham Transcranial magnet stimulation|Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
48632780|NCT06310109|OTHER|PICU diary|.The PICU diary is a notebook with lined sheets located at the patient's bedside. In this diary parents, other caregivers, family members, healthcare professionals or other visitors can write thoughts, report events related to the child/adolescent's admission, attach drawings or photographs for the patient or related to the PICU admission.
48632781|NCT01023464|OTHER|FID114657|artificial tears
48632782|NCT01023464|OTHER|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
47944736|NCT04104334|DRUG|Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively|NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
47944737|NCT04104334|DRUG|Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices|Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
48103567|NCT03234816|DRUG|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
48103568|NCT06432842|OTHER|Laser Treatment|In the study group, low-dose laser treatment was applied in addition to conventional treatment. Chattanoga Group Therapeutic Laser device was used for laser treatment. Laser treatment was applied to 8 sensitive points around the knee for 1 minute, for a total of 8 minutes. Laser treatment was applied continuously, with a wavelength of 830nm and a power of 6J.
48103569|NCT00641472|DRUG|Budesonide inhalation suspension|0.5mg
48103570|NCT00641472|DRUG|Montelukast Sodium|4mg or 5mg
48103571|NCT01130064|BIOLOGICAL|QAX576|every 3 weeks via intravenous infusion
48103572|NCT01130064|DRUG|Placebo|every 3 weeks via intravenous infusion
48103573|NCT04263545|BEHAVIORAL|Group session with smoking cessation counsellor|Group session with smoking cessation counsellor
48103574|NCT04263545|BEHAVIORAL|Standard Care|standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit.
48632783|NCT02614768|DEVICE|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
48103575|NCT01695317|DRUG|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
48103576|NCT03360422|OTHER|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
48632784|NCT03513146|PROCEDURE|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
48632785|NCT03275272|DIAGNOSTIC_TEST|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
48632786|NCT02256878|DRUG|BIRT 2584 XX|
48632787|NCT02256878|DRUG|Amitriptyline|
48632788|NCT06093503|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
48632789|NCT06093503|DRUG|Osimertinib|Oral: Tablet
48632790|NCT06093503|DRUG|Cisplatin|IV Infusion
48632791|NCT06093503|DRUG|Carboplatin|IV Infusion
48632792|NCT06093503|DRUG|Pemetrexed|IV Infusion
48632793|NCT04201210|OTHER|TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation|Haploidentical 5+/10 HSCT from a relative, α/β T-depleted
48632794|NCT04201210|OTHER|Matched sibling donor transplantation|10/10 HSCT - matched family donor
48632795|NCT00007501|BIOLOGICAL|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
48632796|NCT00007501|BIOLOGICAL|Placebo|Placebo vaccine
48632797|NCT05428917|BEHAVIORAL|Simple task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform flexion / extension movements of the fingers of the left hand at 0.5 Hz."
48632798|NCT05428917|BEHAVIORAL|complex task|"The subject is seated on a chair facing a table, both hands resting on the table.~The subject is asked, for each block of 20 seconds, to perform an exercise based on the nine hole peg test"
47944738|NCT02568137|BEHAVIORAL|Smart-phone based technology|
47944739|NCT01460316|BIOLOGICAL|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
48632799|NCT04501575|OTHER|Osteopathic Consultation|A consultation including case history taking, physical assessment, osteopathic manual treatment, exercise prescription, and postural advice.
48632800|NCT04501575|OTHER|Sham Osteopathic Consultation|A sham treatment using light touch on bony structures, no diagnosis, advise or prescriptions
48632801|NCT03879577|DRUG|Docetaxel|Administered to all patients for a minimum of 4 cycles for 12 weeks.
48632802|NCT03879577|DRUG|Herceptin|Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
48632803|NCT03879577|DRUG|FEC|Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
48632804|NCT03879577|DRUG|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
48632805|NCT03879577|DRUG|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
48632806|NCT03879577|DRUG|LHRH agonist|Administered to all premenopausal patients.
48632807|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
48632808|NCT00115531|BIOLOGICAL|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
48632809|NCT05926193|DIETARY_SUPPLEMENT|Tailor Food Bags|The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
48632810|NCT06237127|DIETARY_SUPPLEMENT|Goji berry|Participants will be instructed to consume 28 grams of goji berries 5 days a week for 6 months
48632811|NCT06237127|DIETARY_SUPPLEMENT|Fiber|Participants will be instructed to consume the fiber supplements 5 days a week for 6 months
48632812|NCT00964678|DRUG|Carvedilol|twice daily oral treatment in escalating dose
48632813|NCT00185900|DRUG|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
48632814|NCT00185900|DRUG|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
48632815|NCT04612127|DIETARY_SUPPLEMENT|Dietary supplement consumption and physical exercise|"The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week."
48632816|NCT02322515|OTHER|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
48632817|NCT02322515|OTHER|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
48632818|NCT05955833|DIAGNOSTIC_TEST|89Zr-DFO*-trastuzumab PET scan|Patients will be administered 37 MBq 89Zr-DFO\*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
48632819|NCT03058016|OTHER|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
48632820|NCT01960478|BIOLOGICAL|(for each intervention)|
47944740|NCT01104701|DRUG|exenatide once weekly|subcutaneous injection, 2 mg, once a week
48632821|NCT01960478|OTHER|Blood test|
48632822|NCT06262373|DIAGNOSTIC_TEST|Ultrasound|Ultrasound based observational study
48632823|NCT04885712|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
48632824|NCT04885712|DRUG|Pioglitazone 15mg|Subjects take the investigational products once a day for 24 weeks.
48632825|NCT04885712|DRUG|Pioglitazone 30 mg|Subjects take the investigational products once a day for 24 weeks.
48632826|NCT04885712|DRUG|Pioglitazone 15mg Placebo|Subjects take the investigational products once a day for 24 weeks.
47944741|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
47944742|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
47944743|NCT01104701|DRUG|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
47944744|NCT03387150|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
47944745|NCT03387150|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9%; administered by IM injection
47944746|NCT00503516|DRUG|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
47944747|NCT00503516|DRUG|Placebo|1 sachet of 160 mg of placebo b.i.d.
48293414|NCT06051695|BIOLOGICAL|A2B694|Autologous logic-gated Tmod CAR T cells
48632827|NCT04885712|DRUG|Pioglitazone 30mg Placebo|Subjects take the investigational products once a day for 24 weeks.
48632828|NCT04885712|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
48632829|NCT04279678|PROCEDURE|Mitral valve repair|surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
48632830|NCT00581789|DRUG|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
48632831|NCT00284648|PROCEDURE|Surgical repair Achilles tendon rupture|
48632832|NCT00284648|PROCEDURE|Non-surgical repair Achilles tendon rupture|
48475762|NCT00876720|DEVICE|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
48632833|NCT00053742|DRUG|Modified Vaccinia Virus Ankara TBC-MVA|
48632834|NCT05911386|OTHER|study of biological samples and echocardiographic data and link with need of hemodynamic support|observational study : there is no intervention
48632835|NCT05036460|PROCEDURE|Ultrasonography|"The transducer will be placed over the anterior neck just above the suprasternal notch, in the transverse orientation. The position of the transducer could be adjusted to visualize both the esophagus and trachea. It will be considered as esophageal intubation if esophageal dilation or double-tract sign are noted."
48632836|NCT05036460|PROCEDURE|Direct visualization|While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
48632837|NCT01053052|DEVICE|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
48632838|NCT02715752|DIETARY_SUPPLEMENT|Gene-Eden-VIR/Novirin|
48632839|NCT02040064|DRUG|Gefitinib|Oral tablet
48632840|NCT02040064|DRUG|Tremelimumab|IV
48632841|NCT03591536|OTHER|Pentoxifylline|400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery
48632842|NCT03591536|OTHER|Placebo|oral placebo tablets from 3 days before surgery and on the day of surgery
48632843|NCT04697992|DRUG|vitamin c 20%|one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
48632844|NCT04697992|DRUG|Tranexamic acid 5mg/ml|one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
47944748|NCT03359239|DRUG|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 \[+/-2\] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
47944749|NCT03359239|BIOLOGICAL|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
48632845|NCT04311580|COMBINATION_PRODUCT|intravesical electromotive administration of mitomycin|
48632846|NCT01678690|DRUG|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
48632847|NCT01307618|BIOLOGICAL|NA17.A2 Peptide Vaccine|Given SC or ID
48632848|NCT01307618|BIOLOGICAL|Recombinant MAGE-3.1 Antigen|Given SC or ID
48632849|NCT01307618|BIOLOGICAL|Recombinant Interleukin-12|Given SC or ID
48632850|NCT01307618|BIOLOGICAL|MART-1 Antigen|Given SC or ID
48632851|NCT01307618|OTHER|Laboratory Biomarker Analysis|Correlative studies
47944750|NCT03359239|DRUG|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
47944751|NCT03359239|DRUG|Normal saline|0.19 mL
47944752|NCT00246896|BEHAVIORAL|care management|
47944753|NCT05770869|DEVICE|ALIBIRD mHealth platform|Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
47944754|NCT01502280|DRUG|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
47944755|NCT01502280|DRUG|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
48103577|NCT03360422|OTHER|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
48632852|NCT03521336|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
48632853|NCT03521336|DRUG|Placebo|Saline，Sham operation
48632854|NCT04648241|BIOLOGICAL|TBE vaccine 0.5 mL|TBE vaccine 0.5 mL (intramuscular injection).
48632855|NCT04648241|BIOLOGICAL|TBE vaccine 0.25 mL|TBE vaccine 0.25 mL (intramuscular injection).
48632856|NCT00787488|DEVICE|Hyperthermia|Every 3 weeks
48632857|NCT01935505|BEHAVIORAL|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
48632858|NCT01935505|DRUG|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
48632859|NCT01935505|BEHAVIORAL|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
48632860|NCT01935505|BEHAVIORAL|Consulting+Telephone+Drug intervention|Include all the above interventions
47944756|NCT02864719|OTHER|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
47944757|NCT04753307|DIAGNOSTIC_TEST|Laboratory measurements|Inflammatory and cardiac biomarkers will be measured before surgery, and on the first, second, third and fifth postoperative day
47944758|NCT00815243|PROCEDURE|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
48632861|NCT04757844|DEVICE|Functional Near-Infrared Spectroscopy (fNIRS)|The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
48632862|NCT00673114|BIOLOGICAL|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
48632863|NCT03572114|DIAGNOSTIC_TEST|3Tesla MRI|"1. A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~2. Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~3. 1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~4. conventional FLAIR sequence"
48632864|NCT03572114|BEHAVIORAL|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
48632865|NCT03572114|BEHAVIORAL|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
48632866|NCT03572114|BEHAVIORAL|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
48632867|NCT03572114|BEHAVIORAL|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
48632868|NCT02622022|DRUG|Morphine hydrochloride|
48632869|NCT02622022|OTHER|Placebo|
48632870|NCT05740384|DEVICE|Sonotubometry Assessment|"The exact order of the measurements will be randomised:~* Recording type 1: No sound applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Recording type 2: White noise applied, 10 seconds recording of baseline noise, followed by recording when the participant is asked to swallow 3 times.~* Ask for subjective feedback (did you hear a change in the sound in your ear on swallowing?) after each recording~* This is repeated using the contralateral ear and nostril. After successful recording, the microphone will be removed.~For comparison, tubomanometry measurements will be performed on each ear. Tubomanometry is an alternative method to assess the middle ear and Eustachian tube. Afterwards, the participant's involvement in the study will be complete. The entire involvement will take about 50 minutes."
48632871|NCT05752331|BEHAVIORAL|Physical activity behavioural modification|8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
48632872|NCT00295243|DRUG|Topotecan|
48632873|NCT05017636|DEVICE|shock wave therapy|The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.
48632874|NCT04289298|BEHAVIORAL|Engage-A|Therapist will encourage participants to engage in physical and social activities that are pleasurable or rewarding. Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
47944759|NCT00815243|PROCEDURE|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
47944760|NCT02193581|DEVICE|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
47944761|NCT04160962|PROCEDURE|lappg|Laparoscopic gastrectomy for pylorus preservation
47944762|NCT04615897|PROCEDURE|new tecnology intervention|"The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes."
47944763|NCT00098098|BIOLOGICAL|rBV A/B|
48632875|NCT04289298|OTHER|Training and utilizing Engage-A therapy|Therapist will be trained in Engage-A therapy and given supervision while utilizing this therapy.
47944764|NCT02129829|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
48632876|NCT06319443|DIETARY_SUPPLEMENT|Liquid vinegar|3.5 g acetic acid
48632877|NCT06319443|DIETARY_SUPPLEMENT|vinegar pill|0.022 g acetic acid
48632878|NCT02347956|PROCEDURE|Reduced port robotic distal gastrectomy|
48632879|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
48632880|NCT01112267|DRUG|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
48632881|NCT01112267|DRUG|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
48632882|NCT01112267|DRUG|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
47944765|NCT05382533|DIETARY_SUPPLEMENT|Menu plans|The study participants in group A and C receive defined personal nutritional counselling every two weeks and they are provided with daily menu plans (isocaloric) with optimized nutrient profiles and chosen study products (plant oils, nuts mixture etc.) over the study period of 10 weeks.
47944766|NCT03779360|DRUG|Erythromycin 4% topical gel formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
47944767|NCT03779360|DRUG|Clindamycin 1% lotion formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
47944768|NCT03779360|DRUG|Prednisolone tablet (0.5mg/kg; parallel comparison):|2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
48632883|NCT03560596|BEHAVIORAL|Adherence Intervention|9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
48632884|NCT03560596|BEHAVIORAL|Usual Care|standard hypertension treatment recommendations as determined by PCP
48632885|NCT05112068|OTHER|traditional skin care method|Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.
48632886|NCT05112068|OTHER|method using specialized gloves|"Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying."
48632887|NCT01712464|DRUG|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
48632888|NCT04264195|OTHER|Constraint-induced movement therapy: PEPS-MIT|"All participants of control and experimental groups received standard stroke rehabilitation. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~• Specific for the experimental group was that patients performed all manipulation tasks with forced use of the paretic hand/arm by wearing a soft-padded mitten at the non-paretic hand, preventing manipulation with that hand. Patients were encouraged to wear the mitten also for 3 hours/day at home, while performing ADL and learned exercises. Behavioural strategies included a treatment contract and daily use of the home activity checklist which was checked by patient's caregiver and signed by both patient and caregiver. Each treatment day the activity checklist was submitted to the therapist who gives feedback."
48632889|NCT04264195|OTHER|Bimanual manipulation exercises (PEPS-Bimanual)|"All participants of control and experimental groups received standard stroke. After regular office time, a 2 hours' peer group session was provided, 5 days/week, 4 consecutive weeks, to both groups. One patient 'leads' the group exercises under a therapist's supervision. The therapist is mainly helping and correcting patients during the various exercise tasks.~Specific for the control group was that patients performed all manipulation tasks bimanually, as they used to do in occupational therapy activities. Patients were also asked to document their 'at home' activities in an activity checklist that was regularly checked by the therapists."
48632890|NCT02629458|PROCEDURE|Treatment by Surgical resection|
48632891|NCT02629458|PROCEDURE|Stereotactic Ablative Radiotherapy (SABR)|
48632892|NCT03919266|PROCEDURE|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
48632893|NCT03919266|PROCEDURE|Control: usual antibiotic treatment|usual antibiotic treatment
48632894|NCT05343429|DRUG|Benzydamine hydrochloride|In BN group,15 ml of 0.15 % Benzydamine hydrochloride (BN) will be dissolved in 15 ml plain water in a sterile container and given to participants before anesthesia for surgery
47944769|NCT03779360|DRUG|Clobetasol propionate 0.05% topical formulation (crossover comparison):|"2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2."
48293415|NCT06051695|DIAGNOSTIC_TEST|xT CDx with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
48632895|NCT05343429|DRUG|Aspirin|In group AP, Aspirin (AP) 600 mg Aspirin tablets dissolved in 30 ml of plain water in a sterile container will be given to participants for gargling before anesthesia for surgery
47944770|NCT03779360|OTHER|Lipopolysaccharide|As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
47944771|NCT01601431|DEVICE|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
48293416|NCT00162877|DRUG|Rabeprazole vs. Esomeprazole|
48293417|NCT01666873|PROCEDURE|patients that undergo a total knee prosthesis|
48632896|NCT01643187|DIETARY_SUPPLEMENT|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
48632897|NCT01643187|DIETARY_SUPPLEMENT|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
48632898|NCT02355470|BEHAVIORAL|GIFTSS|Universal education and brief counseling regarding sexual violence
48632899|NCT02355470|BEHAVIORAL|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
48632900|NCT02247856|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
48632901|NCT02247856|DEVICE|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
48632902|NCT02247856|DEVICE|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
47944772|NCT01601431|DEVICE|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
48103578|NCT03360422|OTHER|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
48103579|NCT04268563|DRUG|placebo|Oral rehydration solution
48293418|NCT01720667|DRUG|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
48293419|NCT01720667|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
48632903|NCT02149160|DRUG|FRM-0334|
48632904|NCT02149160|DRUG|Placebo|
48103580|NCT04268563|DRUG|metformin|metformin tablet
48103581|NCT04268563|DRUG|Sitagliptin|Sitagliptin tablet
48103582|NCT04268563|DRUG|Sitagliptin/metformin|Sitagliptin/metformin tablet
48293420|NCT05759338|DEVICE|Revian Red All LED cap|"The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women."
48293421|NCT04320303|BIOLOGICAL|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
48293422|NCT00413569|PROCEDURE|cervical spine surgery|
48293423|NCT02614794|DRUG|tucatinib|300 mg orally twice daily
48293424|NCT02614794|DRUG|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
48293425|NCT02614794|DRUG|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
48293426|NCT02614794|DRUG|placebo|Oral dose twice daily
48293427|NCT06057129|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot|During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a supervisor (i.e., therapist or researcher). Minimally-supervised therapy means that participants try to perform therapy with the device by themselves, while the supervisor is still present but helps only in case participants encounter problems or if they have any questions. During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes.
48632905|NCT03304587|DIAGNOSTIC_TEST|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
48293428|NCT06057129|DEVICE|Unsupervised therapy|"After the familiarization phase, participants train without supervision at the clinic until discharge and then at home for six weeks.~If the therapist thinks that the participant have properly learnt how to use the device and can train with it safely, the participant can keep training with the device unsupervised (both at the clinic and at home).~If participants are not ready for unsupervised therapy with the device, they receive a booklet of exercises to perform without supervision (both at the clinic and at home). These exercises do not imply the use of the robot but are exercises discussed with the therapists and meaningful for the specific patient."
48293429|NCT02964104|DRUG|Insulin icodec|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
48293430|NCT02964104|DRUG|placebo|Administered once daily subcutaneously for 35 days
48293431|NCT02964104|DRUG|insulin degludec|Administered once daily subcutaneously for 35 days
48293432|NCT02964104|DRUG|placebo|Administered once weekly subcutaneously for 35 days
48293433|NCT05032976|BIOLOGICAL|Tozinameran 12 Years of age and older|BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
48632906|NCT03304587|DIAGNOSTIC_TEST|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
48632907|NCT03304587|OTHER|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
48632908|NCT03304587|OTHER|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
48632909|NCT03304587|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
48632910|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.
48632911|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
48103583|NCT06237062|OTHER|erenumab|This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.
48103584|NCT02989961|OTHER|Resticutis|Autologous, Activated-Platelets type of Preparation
48293434|NCT05032976|BIOLOGICAL|Tozinameran 5 to 11 Years of age|"BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age."
48475763|NCT00876720|DEVICE|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
48632912|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
48632913|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
48632914|NCT03304587|OTHER|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
48632915|NCT03304587|OTHER|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
48632916|NCT03304587|OTHER|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
48632917|NCT03304587|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
48632918|NCT03304587|OTHER|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue \& sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
48632919|NCT05892159|BEHAVIORAL|HRV biofeedback|An HRV biofeedback tool will be employed and utilized by individuals each day for the first 5 weeks during the intervention period.
48632920|NCT00635180|BEHAVIORAL|isometric exercise|
48632921|NCT05075681|DRUG|Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide|"Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;"
48632922|NCT04044287|DRUG|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
48632923|NCT04044287|DRUG|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
48475764|NCT01806610|DRUG|BPS804|Single dose BPS804 administration.
48632924|NCT03548415|DRUG|IONIS-GHR-LRx|IONIS GHR-LRx administered subcutaneously.
48632925|NCT03548415|DRUG|Placebo|Placebo administered subcutaneously.
48632926|NCT01978574|BEHAVIORAL|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
48475765|NCT01806610|DRUG|Placebo|Single dose placebo administration.
48475766|NCT04867811|OTHER|conventional therapy|conventional therapy
48475767|NCT04867811|OTHER|cupping therapy|cupping therapy
48632927|NCT01978574|BEHAVIORAL|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
47944773|NCT06253104|DIAGNOSTIC_TEST|BodyMetrix Body Composition Ultrasound|We will use a BodyMetrix Pro A-mode ultrasound device (BodyMetrix Pro, Intelametrix Inc., Livermore, CA) which is a lay imaging tool designed specifically to assess body composition. Images will be taken at two sites; the lateral thigh and bicep on the dominant side if able to identify, or else on the right side. On each visit, five images will be taken at each site (the lateral thigh and bicep). Participants will be measured 2-3 days from initiation in study, then 7 days after, and then weekly from the first measurement until time of advanced therapy, discharge, or death. This measurement sequence will then be repeated following advanced therapy up until discharge or death. Each measurement session will last about 20-30 minutes. This will be performed by the PI or members of the study team who have been trained by the research coordinator.
48293435|NCT05032976|BIOLOGICAL|Tozinameran 6 months to 4 years of age|"BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age."
48293436|NCT05032976|BIOLOGICAL|Riltozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
48632928|NCT00743262|DEVICE|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
48293437|NCT05032976|BIOLOGICAL|Famtozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
48293438|NCT05032976|BIOLOGICAL|Famtozinameran 5 to 11 Years of age|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
48293439|NCT05032976|BIOLOGICAL|Raxtozinameran 12 years of age and older|"BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.~For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine."
48475768|NCT04867811|DEVICE|TENS|transcutaneous electrical nerve stimulation
48475769|NCT04867811|OTHER|TENS and cupping therapy|TENS and cupping therapy
48475770|NCT04282655|OTHER|Treatment Guardian Milk Warmer (Medela TM)|Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)
48475771|NCT04282655|OTHER|Control|Standard warming procedure of breast milk in syringe prior to feeding.
48475772|NCT03749954|DIAGNOSTIC_TEST|Detachable string magnetically controlled capsule endoscopy|Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
48103585|NCT02989961|OTHER|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
48475773|NCT03397953|DRUG|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
48475774|NCT03934749|DEVICE|Non Invasive Ventilation|NIV using standard mode or Lowenstein mode
48475775|NCT05672199|DRUG|Efavaleukin alfa|Subcutaneous (SC) injection
48475776|NCT05672199|DRUG|Placebo|SC injection
48475777|NCT05630625|BEHAVIORAL|Drinking Dashboard|Day-level feedback on alcohol use and consequences
48475778|NCT05532488|DIETARY_SUPPLEMENT|Inulin 20 mg|Inulin can increase gut Bifidobacterium count. Bifidobacterium has beneficial effects on the metabolic profile and insulin resistance biomarkers.
48475779|NCT05532488|OTHER|Placebo|Placebo
48475780|NCT05135624|DRUG|SP16 (6mg)|SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
48475781|NCT05135624|OTHER|Placebo|Placebo will be administered as 2 concurrent, separate 2 mL s.c. injections of sterile water
48475782|NCT05135624|DRUG|SP16 (12 mg)|SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
48475783|NCT02419573|DEVICE|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
48475784|NCT02419573|DEVICE|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
48632929|NCT04313439|OTHER|Online cognitive therapy (I-CT)|"The treatment is an online cognitive therapy consisting of a structured self-help program over ten weeks, divided into eight modules, administered in an encrypted web platform. The program is based on the treatment manual The treatment of Obsessions by Stanley Rachman. In this treatment, the participant is recommended to perform daily exercises in order to identify and modify interpretations made about the importance of their obsessive thoughts. A designated therapist have email contact with the participant within the encrypted platform."
48632930|NCT02728726|DRUG|Sugammadex|Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
48632931|NCT02728726|DRUG|Placebo|Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
48632932|NCT05469308|OTHER|questionary|When the patients renew their treatment in community pharmacy, they have an adherence record with a pharmacist who calculates the PDC score, and perform questionaries on adherence to the DOACs, and collects data about clinical history and pharmacological information on the prescribed DAOCs, demography.
48632933|NCT02781194|DEVICE|3M™ Bair Hugger™|forced-air warming blanket
48632934|NCT02781194|DEVICE|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
48632935|NCT03662971|DRUG|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
47944774|NCT03875820|DRUG|VS-6766|"VS-6766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of VS-6766 and the inactive ingredients mannitol and magnesium stearate.~VS-6766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
48293440|NCT05032976|BIOLOGICAL|Raxtozinameran 6 months to 4 years of age|BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.
48293441|NCT04210713|DRUG|Minocycline|200 mg/day
48293442|NCT04210713|DRUG|Sugar pill|Matched placebo
48632936|NCT00517062|DRUG|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
48632937|NCT00517062|DRUG|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
48632938|NCT00047268|DRUG|cytarabine|
48632939|NCT00047268|DRUG|mercaptopurine|
48632940|NCT00047268|OTHER|laboratory biomarker analysis|
48632941|NCT00047268|PROCEDURE|allogeneic bone marrow transplantation|
48632942|NCT00047268|PROCEDURE|biopsy|
48632943|NCT00047268|PROCEDURE|peripheral blood stem cell transplantation|
48632944|NCT03597555|DRUG|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
48632945|NCT03597555|DRUG|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
48632946|NCT04772547|DRUG|Vigabatrin Only Product|enteral medication administration, serial blood draws, and outcome assessment
48293443|NCT01359540|DEVICE|OMNI Apex Modular™ Hip Device|
48293444|NCT01359540|DEVICE|OMNI Apex ARC™ Hip Device|
48632947|NCT01696214|DRUG|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
48632948|NCT01696214|DRUG|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
48632949|NCT01696214|DRUG|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
48632950|NCT01696214|DRUG|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
48632951|NCT03569007|DRUG|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
48632952|NCT03569007|DRUG|Matching Placebo|enteric-coated beads in gelatin capsules
48293445|NCT04397055|DIETARY_SUPPLEMENT|Cottonseed Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
47944775|NCT03875820|DRUG|Defactinib|"Defactinib is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to Defactinib, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive Defactinib orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
47944776|NCT04753476|BIOLOGICAL|Injection of Secretome-MSCs|"Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours"
47944777|NCT04753476|DRUG|Standard treatment of Covid-19|Patients will be given Standard treatment of Covid-19 which accordance with National protocol
47944778|NCT04565184|DRUG|Artesunate-amodiaquine combination|Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
48293446|NCT04397055|DIETARY_SUPPLEMENT|Olive Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
48293447|NCT02508714|DEVICE|Orsiro|stents will be implanted in case of significant coronary artery disease
48293448|NCT02508714|DEVICE|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
48293449|NCT03739983|DEVICE|Vaginal Renewal Program|Therapeutic vibrating wand.
47944779|NCT04565184|DRUG|Artemether, Lumefantrine Drug Combination|Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child
48103586|NCT05565196|BEHAVIORAL|Birth companions|The intervention will have the following components: 1) Orient facilities and providers to benefits of BC; 2) Develop/update formal standard operating procedures (SOP) for implementing BC and develop plans to implement SOP; 3) Assess data required for implementation and an audit and feedback cycle for tracking coverage; 4) Assess and carry out modest structural changes in facilities to facilitate BC; 5) Use human centered design to develop materials/resources and a means to distinguish/recognize the BC, taking into account common barriers and misconceptions; 6) Prepare providers to integrate BC into care team; 7) Orient ANC clients to BC rationale and selection; 8) Prepare BCs to support women; 9) Iterate model and track intervention/policies.
48103587|NCT02935218|BEHAVIORAL|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
47944780|NCT02611960|BIOLOGICAL|Pembrolizumab|IV infusion
48103588|NCT01679262|DEVICE|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
48293450|NCT05152446|OTHER|Infusion management scheme|"* To set up a pediatric intravenous infusion team;~* To form standardized procedures by carrying out a quality improvement program in collecting and sending samples for inspection once suspected CLABSI occurs (1 month for training and 3 months for continuous improvement ); providing infusion training curriculums to nurses in forms of lectures, group discussions, operation demonstrations, and scenario simulations, holding practice review meeting with them; providing elements to caregivers of educational leaflet, nurse-provided education during patients' infusion therapy( 6-month implementation);~* To observe the continued daily infusion practice in 6 months."
48293451|NCT03549624|OTHER|Standardised protocol for the perioperative management in patients in need of an acute laparotomy|A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
48293452|NCT05016128|DRUG|S-ketamine|S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
48293453|NCT05016128|DRUG|saline|saline is used for control
48293454|NCT03085732|DRUG|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
48293455|NCT04722172|DRUG|Acalabrutinib|Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.
48293456|NCT04722172|DRUG|Obinutuzumab|Obinutuzumab will be administered during Cycles 2-7.
48293457|NCT01859429|OTHER|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
47944781|NCT02611960|DRUG|Capecitabine|oral tablet
47944782|NCT02611960|DRUG|Gemcitabine|IV infusion
47944783|NCT02611960|DRUG|Docetaxel|IV infusion
47944784|NCT00943696|DIETARY_SUPPLEMENT|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
47944785|NCT01994928|DEVICE|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
47944786|NCT01994928|DEVICE|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
47944787|NCT01994928|PROCEDURE|Intubation|Intubation
48632953|NCT04037956|PROCEDURE|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
48632954|NCT04037956|PROCEDURE|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
48632955|NCT05045599|BEHAVIORAL|Capacity Building of Health care workers and providers to deliver integrated Family Planning and Maternal, Newborn and Child Health|Community engagement to improve awareness, and use of family planning products and services
48632956|NCT01260415|DRUG|Panitumumab, Oxaliplatin, 5-FU|"* Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours"
47944788|NCT02493387|OTHER|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
47944789|NCT02493387|OTHER|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
47944790|NCT00210132|DRUG|Ropivacaine|
48103589|NCT05652322|DRUG|Furosemide Pill 150% equivalent iv dose|change from intravenous to oral furosemide
48293458|NCT05567978|PROCEDURE|pupillometry index|Admission to the intensive care unit, measurement of pupillometry index every 4 hours for 7 days or at extubation of brain damaged patients
48632957|NCT00003008|DRUG|indinavir sulfate|
48632958|NCT00003008|DRUG|nelfinavir mesylate|
48632959|NCT00003008|DRUG|paclitaxel|
48632960|NCT00003008|DRUG|ritonavir|
48632961|NCT00003008|DRUG|saquinavir mesylate|
48632962|NCT03888482|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
48293459|NCT03698162|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo STAR DCE-MRI
48632963|NCT03888482|DEVICE|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
48632964|NCT02438085|OTHER|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
48632965|NCT01077895|PROCEDURE|CVVH|"CVVH is started using following parameters:~* Blood flow is started at 150 mL/min~* Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~* In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~* Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
48632966|NCT01077895|PROCEDURE|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~* Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~* Vasopressor or inotrope medication dose is increased by \> 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~* When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV \> 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~* If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
48632967|NCT01077895|PROCEDURE|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
48632968|NCT05888779|OTHER|Beverage One (Milk)|Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.
48632969|NCT05888779|OTHER|Beverage Two (Juice)|Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
48632970|NCT05511480|BEHAVIORAL|Interference through learning of a competing motor skill.|Interference through the learning of a competing motor skill.
48293460|NCT03698162|DRUG|Bevacizumab Injection|Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
48632971|NCT05511480|BEHAVIORAL|No interference|No interference through the continuation of learning same motor skill
47944791|NCT02138422|BIOLOGICAL|Xilonix|
47944792|NCT02138422|BIOLOGICAL|Placebo|
47944793|NCT05577871|DRUG|Dexmedetomidine|infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
47944794|NCT05577871|DRUG|normal saline|infusion of normal saline during the off pump coronary artery bypass grafting surgery
47944795|NCT02088242|DRUG|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
47944796|NCT02088242|DRUG|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
47944797|NCT06021665|OTHER|Fortetropin supplement|Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
47944798|NCT06021665|OTHER|Cheese protein|"The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g"
47944799|NCT01406925|DRUG|Placebo control|Placebo cream
47944800|NCT01406925|DRUG|NRL001 cream|Cream for single-dose intra-anal application
47944801|NCT04117139|DIAGNOSTIC_TEST|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
48103590|NCT05652322|DRUG|Furosemide Pill 200% equivalent iv dose|change from intravenous to oral furosemide
48103591|NCT05652322|DRUG|Furosemide Injection|change from intravenous to oral furosemide
48293461|NCT00929630|PROCEDURE|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
48632972|NCT03850587|DRUG|Celecoxib 200mg|comparator medication
48632973|NCT03850587|DRUG|Tramadol 37.5Mg+ Celecoxib 200mg|experimental medication
48632974|NCT03850587|DRUG|Tramadol 75mg+ Celecoxib 200mg|experimental medication
48632975|NCT03850587|DRUG|Tramadol 150mg+ Celecoxib 200mg|experimental medication
48632976|NCT02198131|PROCEDURE|laser therapy|Undergo pulsed dye laser
48632977|NCT02198131|OTHER|questionnaire administration|Ancillary studies
48632978|NCT00478140|BIOLOGICAL|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
48632979|NCT00478140|OTHER|laboratory biomarker analysis|Correlative studies
48632980|NCT06308445|DRUG|Rapamycin|This is a 2-dose rapamycin safety study, with a target through level of 3 to \<5 ng/ml for the first 3 months and 5-8 ng/ml for the next 3 months for each of the included patients. To avoid the possible cumulative effect, the two treatment phases will be separated by a 3-weeks wash-out period.
48632981|NCT00006457|DRUG|oltipraz|
48632982|NCT06391515|DIAGNOSTIC_TEST|Blood sample, CRF, thyroid ultrasound|Five visits were planned: at diagnosis (V0) and after 1, 3, 6 and 12 months (V1, V2, V3 and V4, respectively). At each visit, subjects were evaluated with anamnesis, physical examination, thyroid US and blood tests.
48632983|NCT02922660|DRUG|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
48632984|NCT02922660|PROCEDURE|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
47944802|NCT06166082|DEVICE|Active iTBS-DLPFC|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.
47944803|NCT06166082|DEVICE|Sham iTBS-DLPFC|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
48103592|NCT05515042|DRUG|Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)|As included in arm/group descriptions
48632985|NCT02922660|PROCEDURE|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
47944804|NCT00732797|BEHAVIORAL|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
47944805|NCT00732797|BEHAVIORAL|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
47944806|NCT04620395|DIAGNOSTIC_TEST|Punch biopsy|A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
47944807|NCT05599269|DEVICE|Examination of dentures with SR Phonares II teeth|The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
47944808|NCT02484690|DRUG|Faricimab|Faricimab will be administered as per the regimen specified in the individual arm.
47944809|NCT02484690|DRUG|Ranibizumab|Ranibizumab will be administered as per the regimen specified in the individual arm.
48293462|NCT00929630|PROCEDURE|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
48293463|NCT00929630|PROCEDURE|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
47944810|NCT02484690|DRUG|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
47944811|NCT03530566|OTHER|PnK® Method|A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
48293464|NCT00929630|PROCEDURE|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
48632986|NCT02922660|DRUG|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
48632987|NCT02922660|DRUG|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
48632988|NCT01035307|GENETIC|gene expression analysis|
48632989|NCT01035307|GENETIC|microarray analysis|
48632990|NCT01035307|GENETIC|proteomic profiling|
48632991|NCT01035307|OTHER|laboratory biomarker analysis|
48632992|NCT04657692|PROCEDURE|Anesthesia; general or regional|General anesthesia: general anesthesia with endotracheal tube Regional anesthesia: spinal anesthesia, epidural anesthesia, combined spinal epidural anesthesia
48632993|NCT04995926|PROCEDURE|Labial mucosal epithelium grafting for corneal limbus substitution|Labial mucosa epithelium grafting for corneal limbus substitution will be used to treat limbal stem cell deficiency by way of corneal surface re-epithelization
48632994|NCT01386320|PROCEDURE|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
48632995|NCT01386320|PROCEDURE|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
48632996|NCT01873833|DRUG|capecitabine|Given PO
48632997|NCT01873833|DRUG|cyclophosphamide|Given PO
47944812|NCT03530566|OTHER|standard diet|standard low calorie diet for weight loss
47944813|NCT03427112|DEVICE|Xin1 Humerus System|"Retrospective assessment of the surgical handling and performance of the X-ray-based tracking and navigation system Xin1 Humerus system evaluated from 10 proximal humerus plate fixations"
47944814|NCT01927341|DRUG|MEK162|Tablet for oral use, 45 mg (three 15 mg tablets), BID
47944815|NCT01927341|DRUG|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
48293465|NCT05437575|DRUG|Ketamine Hydrochloride|ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe
48293466|NCT05437575|DRUG|Fentanyl Citrate|fentanyl citrate 10mcg/ml packaged in pre-filled syringe
47944816|NCT03563287|DRUG|cocktail of nine CYP probe drugs|"Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules."
47944817|NCT04879277|BIOLOGICAL|Blood samples|Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
47944818|NCT00041821|PROCEDURE|Nasal irritation thresholds and irritant provocation|
47944819|NCT05068310|DEVICE|Cellular resolution full-field optical coherence tomography|Device: ApolloVue® S100 Image System
47944820|NCT05068310|DEVICE|Confocal microscopy|Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
47944821|NCT05068310|DEVICE|Optical coherence tomography imaging|Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
48103593|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
48103594|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
47944822|NCT05068310|DEVICE|Dermoscopy imaging|Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
47944823|NCT02321631|DIETARY_SUPPLEMENT|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
48103595|NCT03434392|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
48632998|NCT01873833|DRUG|lapatinib ditosylate|Given PO
48632999|NCT01873833|BIOLOGICAL|trastuzumab|Given IV
48633000|NCT01873833|OTHER|laboratory biomarker analysis|Correlative studies
47944824|NCT02321631|DIETARY_SUPPLEMENT|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
47944825|NCT04426708|DRUG|HMS5552|single dose of HMS5552 25mg
48633001|NCT03099356|DRUG|Cyclophosphamide|Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
47944826|NCT03182062|PROCEDURE|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
48633002|NCT03099356|DRUG|Sirolimus|Sirolimus 4 mg, PO, days 1-28
47944827|NCT03182062|PROCEDURE|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
47944828|NCT03182062|PROCEDURE|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
47944829|NCT05361785|BIOLOGICAL|FMT|FMT from healthy donor or placebo
47944830|NCT04627337|DRUG|Saccharomyces Boulardii 250 MG|Probiotic yeast in capsules
47944831|NCT04627337|BEHAVIORAL|Dietary advice following a low fermentation diet|Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
47944832|NCT02315573|PROCEDURE|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
48293467|NCT04799782|DRUG|Mirtazapine|15 mg dose before bed-time
48633003|NCT01133106|BEHAVIORAL|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
48293468|NCT04799782|DRUG|Placebo|One placebo pill before bed-time
48293469|NCT06180551|DIAGNOSTIC_TEST|DKK-3|DKK-3-Urine measurement
48293470|NCT00865462|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
48293471|NCT00865462|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
48293472|NCT05696366|DRUG|Sotagliflozin|Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
48103596|NCT05237804|OTHER|Patient component|Video, booklet, website
48103597|NCT05237804|OTHER|Organisational component|Coronarography, CT-scan, anesthesia...
48103598|NCT01560949|DRUG|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
48103599|NCT01560949|DRUG|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
48103600|NCT01560949|DRUG|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
48103601|NCT01560949|DRUG|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
48103602|NCT01560949|RADIATION|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
48103603|NCT02942290|DRUG|Azacitidine|Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.
48103604|NCT02942290|DRUG|Venetoclax|Oral; Tablet
48103605|NCT00853827|DRUG|Placebo|Placebo
48103606|NCT00853827|DRUG|Aliskiren|300 mg
48103607|NCT03700658|DRUG|TV-46046|TV-46046 will be administered per dose and schedule specified in the arm.
48103608|NCT03700658|DRUG|Depo-subQ 104|Depo-subQ 104 will be administered per dose and schedule specified in the arm.
48103609|NCT03700658|DRUG|TV-46046 Placebo|TV-46046 Placebo will be administered per schedule specified in the arm.
48293473|NCT05696366|DRUG|Volagidemab|Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
48293474|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Clarithromycin tablets|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.
48293475|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Cyclosporine softgels|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.
48293476|NCT06211049|DRUG|Vitex agnus-castus BNO 1095 (20 mg)|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
48293477|NCT06211049|DRUG|Placebo|1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
48293478|NCT05174637|DRUG|FDA018-ADC|FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
48103610|NCT03058783|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
48293479|NCT05658029|DRUG|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
48293480|NCT06431542|PROCEDURE|physician-applied Triamcinolone Acetonide Econazole Cream|The doctor applies the Triamcinolone Acetonide Econazole Cream onto a thin cotton swab and gently inserts it deep into the ear canal, evenly spreading the cream around the sides of the ear canal and on the surface of the eardrum.
48293481|NCT06431542|PROCEDURE|patient-applied Triamcinolone Acetonide Econazole Cream|The patient applies Triamcinolone Acetonide Econazole Cream in the external auditory canal at home using a cotton swab.
48293482|NCT02383329|DIETARY_SUPPLEMENT|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
48293483|NCT00042081|DRUG|CGT003 (E2F Duplex Decoy)|
48293484|NCT00857246|DRUG|Cetuximab|
48293485|NCT00857246|DRUG|Irinotecan|
48293486|NCT00857246|DRUG|Cisplatin|
48103611|NCT03058783|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
48103612|NCT06020131|PROCEDURE|Thoracic Mobility Rehabilitation|Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
48103613|NCT06020131|PROCEDURE|Lumbopelvic Stability Rehabilitation|Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
48103614|NCT06020131|PROCEDURE|Ankle Strengthening Home Exercises|Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
48103615|NCT04963049|OTHER|Protocol with Mask|Look at differences in group with facemask and no mask
48103616|NCT04582344|BIOLOGICAL|CoronaVac|Two doses at 14-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (each prefilled syringe of the vaccine contains 600 SU of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,14
48103617|NCT04582344|BIOLOGICAL|Placebo|Aluminium hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride 0.5mL/dose, two doses given 14 days apart.
48103618|NCT04224181|RADIATION|Cardiac PET|A scan examining blood flow to the heart
48103619|NCT04224181|RADIATION|99mTc-tilmanocept SPECT/CT|A scan to look at inflammation in the arteries
48293487|NCT00857246|PROCEDURE|Surgery|
48293488|NCT00857246|DRUG|5-FU|
48293489|NCT00857246|RADIATION|Radiation|
48293490|NCT04294784|DRUG|Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
48103620|NCT04224181|RADIATION|Contrast Enhanced Coronary and Aortic Computed Tomography Angiography|A scan of the heart and surrounding blood vessels
48103621|NCT04730999|DRUG|Etoposide|Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
47944833|NCT00731016|DRUG|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~* injection 1, S1: 0.0125 mg/kg of zoledronic acid~* injection 2, S6: 0.025 mg/kg of zoledronic acid~* injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
47944834|NCT05985005|OTHER|online simulation of high alert medication safety training|online simulation of high alert medication safety training
47944835|NCT04852497|PROCEDURE|Ventricular tachycardia ablation|patients having undergone ventricular tachycardia radiofrequency ablation using of pace mapping strategy to identify the critical isthmus
47944836|NCT05695196|BIOLOGICAL|nasal microbiota transplant (NMT)|nasal microbiota transplant
47944837|NCT05695196|BIOLOGICAL|Placebo|Placebo sterile saline
47944838|NCT02319837|DRUG|Enzalutamide|
47944839|NCT02319837|DRUG|Placebo (No longer applicable in Open Label study period)|Sugar pill to mimic enzalutamide
47944840|NCT02319837|DRUG|Leuprolide Open Label|
47944841|NCT02302534|DEVICE|MRI|MRI
47944842|NCT06091579|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a Plastiape capsule-based dry powder inhaler.
47944843|NCT06091579|DRUG|Placebo|Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
47944844|NCT05126498|OTHER|no intervention|no intervention was applied
48293491|NCT04294784|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
48293492|NCT05579626|DRUG|high-intensity statin arm|•high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
47944845|NCT01206868|PROCEDURE|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
47944846|NCT01206868|PROCEDURE|Control|Standard kidney transplantation
47944847|NCT04398251|DRUG|Febuxostat 40mg Tab|For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.
47944848|NCT04398251|BEHAVIORAL|Non-drug control group|All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly
47944849|NCT01511965|OTHER|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
47944850|NCT06529757|OTHER|Whole body cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to whole body skin wetting. Skin wetting will be performed by spraying water onto the whole body throughout the exercise bout.
47944851|NCT06529757|OTHER|Non-cooling|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modalities.
47944852|NCT04543825|DEVICE|Cardiopulmonary exercise testing|Subjects will perform cardiopulmonary exercise testing which consists of biking on a cycle ergometer (recumbant stationary bicycle) while breathing through a mouthpiece or mask to measure the oxygen and carbon dioxide in the subject's breath. We will also do impedance cardiography, an FDA-approved test to check how the heart functions during exercise. For this test we will attach 6 electrodes (total) to the chest and back (similar to an EKG), so that we can measure the quantity of blood coming out of the heart on every heartbeat. Each evaluation will also include cardiac testing looking for coronary artery disease (CAD).
47944853|NCT05760105|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
47944854|NCT03799211|BEHAVIORAL|Motivational Interviewing|Phone call using motivational interviewing technique
47944855|NCT03799211|BEHAVIORAL|Treatment as Usual|will receive a regular study phone call after three months
47944856|NCT00273910|DRUG|gp100:209-217 (210M)|
47944857|NCT00273910|DRUG|Montanide ISA-51|
47944858|NCT00273910|DRUG|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
47944859|NCT01632137|DRUG|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
47944860|NCT01632137|DRUG|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
47944861|NCT03274271|BEHAVIORAL|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
47944862|NCT03274271|BEHAVIORAL|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
47944863|NCT03274271|BEHAVIORAL|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
48103622|NCT04730999|DRUG|Carboplatin|Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.
48293493|NCT05579626|DRUG|low-intensity statin plus ezetimibe|•low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
48293494|NCT01221051|PROCEDURE|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
48293495|NCT01221051|PROCEDURE|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
48293496|NCT03399539|DRUG|Dexamethasone|Given PO
47944864|NCT03274271|BEHAVIORAL|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
47944865|NCT06076707|DRUG|bupivacain-tramadol|Comparing effectiveness of tramadol and bupivacaine for postoperative pain treatment and prevention for cesarian section
47944866|NCT00199069|DRUG|Asparaginase|
47944867|NCT00199069|DRUG|Vincristine|
47944868|NCT00199069|DRUG|Daunorubicin, Adriamycin|
47944869|NCT00199069|DRUG|Cyclophosphamide|
47944870|NCT00199069|DRUG|Ifosfamide|
47944871|NCT00199069|DRUG|Cytarabine|
47944872|NCT00199069|DRUG|Mitoxantrone|
47944873|NCT00199069|DRUG|Methotrexate|
47944874|NCT00199069|DRUG|6-Mercaptopurine|
47944875|NCT00199069|DRUG|6-Thioguanine|
47944876|NCT00199069|DRUG|VM26|
47944877|NCT00199069|DRUG|Dexamethasone / Prednisolone|
47944878|NCT00199069|PROCEDURE|CNS Irradiation|
47944879|NCT00199069|PROCEDURE|Mediastinal Irradiation|
48633004|NCT01133106|OTHER|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
47944880|NCT00199069|PROCEDURE|Stem Cell Transplantation|
47944881|NCT05774275|DRUG|Pegylated Liposomal Doxorubicin|In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
47944882|NCT05774275|DRUG|Doxorubicin|75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
47944883|NCT05774275|DRUG|Anti-PD-1 monoclonal antibody|200 mg, d1, q3w
48103623|NCT04730999|DRUG|Bevacizumab|"Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal."
48633005|NCT05560321|OTHER|Sani24|Disinfectant
48633006|NCT05560321|OTHER|Routine Disinfection|Routine disinfection at the study hospital
48633007|NCT02636322|DRUG|Cyclophosphamide|Given IV
47944884|NCT05774275|RADIATION|Radiotherapy|BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
47944885|NCT04598464|OTHER|Home based exercise|The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
47944886|NCT05075382|PROCEDURE|Elbow surgery for fracture|This group will undergo a surgery in order to fix a broken elbow.
47944887|NCT04756869|OTHER|COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology|Health care workers are on-study for 30 days, in which they wear a smart watch and temperature patches up to daily. Subjects also may provide nasal and saliva samples up to daily during the study period, and they may opt-in to blood samples lasting up to 1 year after study completion. Through a smartphone app, participants complete surveys at baseline and at study completion, as well as daily mood surveys and symptom-reporting surveys. Finally, exit interviews occur at the end of the study period, and follow-up interviews may occur at specified timepoints up to 1 year after study completion.
47944888|NCT06488313|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
47944889|NCT06016192|BEHAVIORAL|Aerobic Exercise Training|Physical activity performed as controlled aerobic exercise training on ergometer
47944890|NCT03054454|PROCEDURE|Podiatry|Podiatry treatments and care from the multidisciplinary team.
47944891|NCT04173234|OTHER|Aerobic Training|Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
47944892|NCT04173234|OTHER|Home exercise program|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
47944893|NCT05476536|BEHAVIORAL|self-management skills and healthy technology APP|self-management skills and healthy technology APP
47944894|NCT03509467|BEHAVIORAL|Personalized Information|Personalized information about ways that participants can protect themselves and their child from developing melanoma.
47944895|NCT03509467|BEHAVIORAL|Standard Information|Standard information about ways that participants can protect themselves and their child from developing melanoma.
47944896|NCT03509467|OTHER|DNA Extraction Determination of MC1R Genotypes|After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
47944897|NCT01931332|PROCEDURE|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
47944898|NCT01931332|PROCEDURE|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
47944899|NCT04870281|DEVICE|CRT-DX|Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
48103624|NCT04730999|DRUG|Atezolizumab|"Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit."
48103625|NCT03489265|DRUG|Eluxadoline 100 mg|100 mg capsule-shaped tablet by mouth taken twice per day
48293497|NCT03399539|DRUG|Ixazomib Citrate|Given PO
48293498|NCT03399539|OTHER|Laboratory Biomarker Analysis|Correlative studies
48293499|NCT03399539|DRUG|Venetoclax|Given PO
48293500|NCT01376739|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
48293501|NCT03047460|OTHER|multimodal evoked potentials|
48293502|NCT06673121|DRUG|Traditional Chinese Medicine|Received treatment with traditional Chinese medicine
48293503|NCT03849560|BIOLOGICAL|Grippol® Quadri|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).
48293504|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Yamagata lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
48293505|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Victoria lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
48293506|NCT06067646|BEHAVIORAL|Semistructured interview|Semistructured interview and validated quality of life assesment using EQ5-DL
48293507|NCT02231203|DRUG|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
47944900|NCT02378623|DRUG|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
48633008|NCT02636322|DRUG|Doxorubicin Hydrochloride|Given IV
47944901|NCT02378623|DRUG|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
47944902|NCT04447755|DRUG|Lenvatinib|Lenvatinib capsules administered orally at 14 mg/m\^2 QD
48103626|NCT03489265|OTHER|Placebo|Matching capsule-shaped placebo tablets taken by mouth twice per day
48293508|NCT02231203|DRUG|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
48293509|NCT06670924|PROCEDURE|Running suture for vesico-urethral anastomosis in open radical prostatectomy|The surgical technique of the RS followed the description of Van Velthovens, was applied with slight modifications. Two 3/0 absorbable monofilament (polydioxanone) sutures were used. The first needle is started from bladder neck at 3 o'clock, and terminated in the urethra at 9 o'clock. After completion of the posterior anastomosis, a transurethral catheter is placed. The second sutures' needle is passed from the bladder at 9 o'clock and ended in the urethra at 3 o'clock. The bladder neck and urethra are merged by gentle traction of the anterior and posterior sutures at 3 and 9 o'clock.
47944903|NCT01885871|DEVICE|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
48293510|NCT06670924|PROCEDURE|interrupted suture for vesico-urethral anastomosis in open radical prostatectomy|The technique described by Walsh for interrupted anastomotic suturing was applied with minor modifications. Six 3/0 absorbable monofilament (polydioxanone) sutures were placed at 1, 3, 5, 7, 9 and 11 o'clock to accomplish the vesicourethral anastomosis.
48293511|NCT01065129|DRUG|G-CSF|
48293512|NCT01065129|DRUG|Plerixafor|
48293513|NCT01065129|DRUG|Azacitidine|
48293514|NCT05592223|DRUG|BCG Vaccine USP|2x10\^6 cfu Tice® BCG (ID)
48293515|NCT05592223|DRUG|Isoniazid|INH in the dose of 300 mg for three days post BCG injection.
48293516|NCT05592223|DRUG|Rifampin|RIF in the dose of 600 mg for seven days post BCG injection.
48293517|NCT05905328|DRUG|CTO1681 10 μg|Administered 3 times daily for 15 days (initial cohort).
48293518|NCT05905328|DRUG|CTO1681 20 μg|Administered 3 times daily for 15 days (successive cohort).
48293519|NCT05905328|DRUG|CTO1681 30 μg|Administered 3 times daily for 15 days (successive cohort).
48293520|NCT01309425|DRUG|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
48293521|NCT01309425|DRUG|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
47944904|NCT00503438|DEVICE|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
47944905|NCT04924959|OTHER|Logistic Regression Analysis|Using logistic regression analysis to analyze the independent risk factors of PICC catheter displacement
47944906|NCT02999399|OTHER|Brussel Sprouts|Subjects are given \~150 g of Brussels sprouts once daily for 7 consecutive days.
48103627|NCT03426280|DEVICE|Apple Watch Series 1|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
48293522|NCT01309425|DRUG|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
48633009|NCT02636322|DRUG|Etoposide|Given IV
48633010|NCT02636322|DRUG|Ibrutinib|Given PO
48293523|NCT01309425|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
48633011|NCT02636322|DRUG|Lenalidomide|Given PO
48633012|NCT02636322|DRUG|Prednisone|Given PO
48633013|NCT02636322|BIOLOGICAL|Rituximab|Given IV
48633014|NCT02636322|DRUG|Vincristine Sulfate|Given IV
48633015|NCT03978208|DRUG|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
48633016|NCT03978208|OTHER|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
48633017|NCT03978208|DRUG|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
48633018|NCT03978208|DRUG|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
48633019|NCT03709589|OTHER|Modified Early Warning Score|Modified Early Warning Score
48293524|NCT05176847|BEHAVIORAL|Podcasts and tips of the day (within app)|Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
48293525|NCT05176847|BEHAVIORAL|mLIFE app (self-regulation features)|Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
48633020|NCT03926598|BEHAVIORAL|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
47944907|NCT02999399|DRUG|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
47944908|NCT02204007|DEVICE|3D imaging & surrogate bone model|3D imaging \& surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
47944909|NCT01354327|DIETARY_SUPPLEMENT|Limicol|3 tablets / day during 4 months
47944910|NCT01354327|DIETARY_SUPPLEMENT|Placebo|3 tablets / day during 4 months
47944911|NCT05424523|DRUG|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
48103628|NCT00001934|DRUG|Zenapax|
48103629|NCT01228851|OTHER|Balance Training|Group balance training sessions three times a week for 8 weeks
48293526|NCT05176847|BEHAVIORAL|mLIFE app (social support features)|"The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors."
48633021|NCT03926598|BEHAVIORAL|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
48633022|NCT03926598|BEHAVIORAL|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
47944912|NCT04253964|DRUG|Pembrolizumab|ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
47944913|NCT04253964|DRUG|Carboplatin|FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
47944914|NCT04253964|DRUG|Paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
47944915|NCT04253964|DRUG|Nab paclitaxel|FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
47944916|NCT04253964|OTHER|Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)|The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
47944917|NCT04253964|OTHER|QLQ-C30 Global Health/Quality of Life Questionnaire|30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
47944918|NCT04253964|OTHER|COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes|Dyspnea scale scores in patients with respiratory disease (particularly COPD) to establish baseline functional dyspnea burden (taken pre-study at Week 0 and Post Treatment at week 13)
48103630|NCT02280655|BIOLOGICAL|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
48103631|NCT02280655|BIOLOGICAL|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
48103632|NCT06313138|OTHER|The Individual and Family Enhancement Program|The program is a group-based intervention which will be developed by the researcher based on the Individual and Family Self-Management Theory (IFSMT) (self-management skills) and the principle of Medagogy (PITS model: Pathophysiology, Indications, Treatments, Specifies) to improve patients' and their families' understanding of disease-related information and self-management skills consisting of goal setting and action plan, self-monitoring, solving problems and decision-making, and emotional control.
48103633|NCT01890889|DIETARY_SUPPLEMENT|Ad-Chol-Pre|
48103634|NCT01890889|DIETARY_SUPPLEMENT|Half-dose Ad-Chol-Pre|
48103635|NCT01890889|OTHER|Defatted egg yolk without the active ingredient of the other two interventions|
48103636|NCT02875665|DEVICE|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
48633023|NCT03926598|BEHAVIORAL|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
48103637|NCT04667065|OTHER|Physical activity|Physical activity with the remotely guidance of physical activity teachers
48103638|NCT02163915|DRUG|TAK-137|TAK-137 tablets
48103639|NCT02163915|DRUG|TAK-137 Placebo|TAK-137 placebo-matching tablets
47944919|NCT04253964|DRUG|Pemetrexed|FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
47944920|NCT04553354|PROCEDURE|cortical resections|is the removal of the epileptic focus either temporal or extra temporal area
48103640|NCT02533206|PROCEDURE|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
48103641|NCT02533206|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
48103642|NCT03875248|DEVICE|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
48103643|NCT00117364|DRUG|SACCHACHITIN patch|
48103644|NCT06465667|BEHAVIORAL|Dashboard|The Dashboard intervention, representing current standard of care, will consist of a standard e-mail message with a link to the dashboard and text explanation. No performance data will be included in the e-mail, and links will not be monitored for clickthrough with repeat e-mail.
48633024|NCT03926598|BEHAVIORAL|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
48633025|NCT01052142|BIOLOGICAL|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
48633026|NCT00563212|DRUG|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
48633027|NCT03281720|PROCEDURE|TAD|the same intervention as listed in the arm description
48633028|NCT05666856|BEHAVIORAL|Community Reinforcement And Family Training|"Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior."
48633029|NCT05666856|BEHAVIORAL|We The Village Peer Community Forum|An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
48633030|NCT05221229|DRUG|Liraglutide plus upstream risk factors modification advice and consultation|Patients will be on treatment with daily injections of Liraglutide for a total of 65 weeks. During initial consultation for AF ablation, patients' BMI, risk factors status and baseline blood tests were performed and reviewed. Then the patients were discussed and encouraged to achieve optimal goal of risk factors modifications by non pharmacological and pharmacological measures.
48633031|NCT05349370|OTHER|Isotopically labeled lactate|A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
48633032|NCT03540940|OTHER|PEEP|7cmH2O positive end expiratory pressure
48633033|NCT03540940|OTHER|ZEEP|0 cmH2O positive end expiratory pressure
48633034|NCT04093700|DEVICE|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
48633035|NCT00713180|PROCEDURE|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
48633036|NCT00705276|DRUG|Lactic acid (Dermacyd Femina Delicata)|
48633037|NCT02358395|DRUG|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
48633038|NCT02358395|DRUG|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
48633039|NCT00299754|DRUG|Misoprostol|
48633040|NCT00499538|DRUG|SKI-606|
48633041|NCT00512044|PROCEDURE|Local anesthesia (pudendal block)|local anesthesia as indicated
48633042|NCT00512044|PROCEDURE|general anesthesia (spinal and general)|general according to guidelines
48633043|NCT04844346|DIETARY_SUPPLEMENT|Plant stanol mini drinks|Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
48633044|NCT04844346|DIETARY_SUPPLEMENT|Placebo mini drinks|Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
48633045|NCT04844346|BIOLOGICAL|COVID-19 vaccine|First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
48293527|NCT05176847|BEHAVIORAL|standard mLIFE app (social support features)|"The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members."
48293528|NCT03391011|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
48633046|NCT06456268|DEVICE|VibraCool mechanical stimulation and neuromodulatory therapeutic device|"Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors shut the gate on pain transmission, an inhibitory mechanism known as gate control. Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression."
47944921|NCT05873673|DRUG|Coenzyme Q10|cystic jaw defect filled with coenzyme Q10 gel
48633047|NCT06456268|DEVICE|Cryocompression (Game Ready, Bregs) device|Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.
48633048|NCT06456268|DEVICE|Standard ice packs|Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.
48633049|NCT02346370|DRUG|PEGylated recombinant human hyaluronidase PH20|
48633050|NCT02346370|DRUG|Docetaxel|
48633051|NCT04252118|BIOLOGICAL|MSCs|3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
47944922|NCT05873673|DRUG|control group|cystic jaw defect filled with placebo gel
47944923|NCT01135290|DRUG|Aquaphor|
47944924|NCT01135290|DRUG|HP828-101|
47944925|NCT01093638|BIOLOGICAL|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
47944926|NCT01093638|BIOLOGICAL|Placebo|Oral formulation of placebo fed concomitantly with infant formula
47944927|NCT04460456|DRUG|SBT6050|Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
47944928|NCT04460456|DRUG|pembrolizumab|400 mg IV
47944929|NCT04460456|DRUG|Cemiplimab|350 mg IV
47944930|NCT04863092|BEHAVIORAL|Educational Intervention|The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
48293529|NCT06195553|BEHAVIORAL|STEPPS plus Family Connections|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients and dialectical and behavior treatment using Family Connections for the families. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Main components Family Connections: psychoeducation, skills training and peer support.
48633052|NCT03506308|DEVICE|LUTONIX 035 Drug Coated Balloon PTA Catheter|All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
48633053|NCT06435845|DRUG|Anti-(integrin beta-3) human monoclonal antibody|human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody
48633054|NCT04322045|DIAGNOSTIC_TEST|multi-parametric MRI|Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
48633055|NCT03156452|DRUG|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
48633056|NCT03156452|DRUG|Prednisolone|5mg tablets for oral administration
48633057|NCT03826004|DRUG|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
47944931|NCT03767101|BEHAVIORAL|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
47944932|NCT03327454|BIOLOGICAL|Benepali|Administered as specified in the treatment arm.
47944933|NCT00881673|DRUG|AL38583 Ophthalmic Solution|Topical ophthalmic
47944934|NCT00881673|DRUG|Maxidex|Topical ophthalmic
47944935|NCT00881673|DRUG|Vehicle|AL38583 Vehicle
47944936|NCT01624051|OTHER|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
47944937|NCT01624051|OTHER|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
47944938|NCT05682235|OTHER|Therapeutic exercise AND pain neurophysiology education|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group and talks on healthy habits to the placebo group participants.
47944939|NCT05682235|OTHER|Sham|Talk about healthy habits
48293530|NCT06195553|BEHAVIORAL|STEPPS|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Waiting list group: Participant's relatives of this group will be able to receive the Family Connections intervention after the research end.
48293531|NCT04843111|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
48293532|NCT03733678|BEHAVIORAL|Price discounts for SARCs|SARCs are offered free to the client
48293533|NCT03733678|BEHAVIORAL|Price discounts for LARCs|LARCs are offered at lower prices to the client
47944940|NCT06392971|DRUG|Deep-sea fish oil|Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
48293534|NCT03733678|BEHAVIORAL|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
47944941|NCT06392971|OTHER|Placebo|Take a capsule made of food oil that looks like deep-sea fish oil at a dose of 1g po bid. Treatment is discontinued when patients develop acute radiation esophagitis.
47944942|NCT03470948|OTHER|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
48293535|NCT02961647|PROCEDURE|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
48293536|NCT05420012|DRUG|Vericiguat|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
48475785|NCT05388812|OTHER|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
48293537|NCT05420012|DRUG|Placebo|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
48293538|NCT03254667|BIOLOGICAL|Brodalumab|Brodalumab
48633058|NCT03826004|DRUG|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
48633059|NCT02223130|BEHAVIORAL|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
48633060|NCT03492268|BIOLOGICAL|BCMA-CART|After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
48633061|NCT01732523|DIAGNOSTIC_TEST|Contrast enhanced carotid ultrasound|
48633062|NCT02318277|DRUG|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
48633063|NCT02318277|DRUG|INCB024360|INCB024360: Oral daily dosing
48633064|NCT02885922|DRUG|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
47944943|NCT06365541|DRUG|Dapagliflozin|oral Dapagliflozin tablets 10mg/day for 6 months
47944944|NCT05285644|DRUG|AR 15512 Ophthalmic Solution|Topical ocular administration of one drop in both eyes BID for 90 days.
47944945|NCT05285644|DRUG|Vehicle|Topical ocular administration of one drop in both eyes BID for 90 days.
47944946|NCT03998878|BEHAVIORAL|Low-Carbohydrate Diet|Participants will be instructed to follow a low-carbohydrate diet.
47944947|NCT03998878|BEHAVIORAL|Intermittent Energy Restriction|Participants will be instructed to follow intermittent energy restriction.
47944948|NCT03998878|BEHAVIORAL|Hunger Training|Participants will be instructed to follow Hunger Training.
48293539|NCT03254667|DRUG|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
48293540|NCT06256575|COMBINATION_PRODUCT|Diosmin|A medical food of diosmin and alka4-complex
48293541|NCT06256575|OTHER|Placebo|Corn starch one (1) capsule twice daily
48293542|NCT02167204|PROCEDURE|Computed Tomography|Undergo 18F-FLT PET/CT
48633065|NCT01528774|OTHER|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
48633066|NCT05298501|OTHER|No intervention/exposure|No interventions/exposures will be administered or evaluated
47944949|NCT02463968|PROCEDURE|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
47944950|NCT02463968|PROCEDURE|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
47944951|NCT04710420|DEVICE|Endovascular therapy|Endovascular treatment for critical limb threatening Ischemia
47944952|NCT05077735|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
47944953|NCT05077735|OTHER|Questionnaire Administration|Ancillary studies
48633067|NCT03153293|DRUG|rAAV2-ND4|a Single IVT Injection
47944954|NCT05077735|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47944955|NCT05077735|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
47944956|NCT05803629|DIAGNOSTIC_TEST|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq(2-4 mCi) 68Ga-FAPI.
47944957|NCT05803629|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 7.4MBq/kg(0.2mCi/kg) 18F-FDG. 18F-FDG PET/CT is performed within one week from 68Ga-FAPI PET/CT scan.
47944958|NCT05787288|BIOLOGICAL|Extracellular Vesicles from Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cell-derived extracellular vesicle preparation; Specification: 5ml, with extracellular vesicle concentration of 1 × 109 particles/ml in the preparation;
48293543|NCT02167204|RADIATION|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
48633068|NCT05467137|DEVICE|MSOT|MSOT imaging (after ICG injection)
47944959|NCT04671524|OTHER|Exercise protocol|a combination of stretching, range of motion, and strengthening exercise.
47944960|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
47944961|NCT01464944|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
47944962|NCT01464944|DRUG|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
47944963|NCT01464944|DRUG|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
47944964|NCT01464944|DRUG|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
47944965|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
47944966|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
48633069|NCT00200083|DEVICE|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
48633070|NCT01111188|DRUG|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
48633071|NCT01111188|DRUG|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
48633072|NCT03434366|DRUG|ketamine and dexmedetomidine|intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
48633073|NCT03434366|DRUG|ketamine|intranasal ketamine for treatment for autism spectrum disorder
48633074|NCT03434366|DRUG|Saline|intranasal saline for treatment for autism spectrum disorder
47944967|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
48633075|NCT05449873|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes|Radiofrequency ablation will be performed by using triple cooled-wet electrodes. Two or three electrodes will be places around the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C.
47944968|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
47944969|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
47944970|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
47944971|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
47944972|NCT04107779|OTHER|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
47944973|NCT04107779|OTHER|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
47944974|NCT04107779|OTHER|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
47944975|NCT04107779|OTHER|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
47944976|NCT03985384|DRUG|Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Semaglutide 2 MG/1.5 ML Subcutaneous Solution
47944977|NCT03985384|DRUG|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
48293544|NCT02167204|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET/CT
48293545|NCT00863733|DRUG|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
48293546|NCT06274346|OTHER|Multiangular Isometric exercise|already were described in arm descriptions
48293547|NCT03851341|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
48293548|NCT03851341|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
48293549|NCT04148430|DRUG|Anakinra|100mg subcutaneous
48293550|NCT03078985|PROCEDURE|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
48293551|NCT03078985|DEVICE|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
48293552|NCT04988126|OTHER|Interventions|Observational study, not applicable
48293553|NCT06666361|OTHER|Experimental Group|"The experimental group participates in the Mobio Health Multimedia Hypertension Promotion Program, which includes a hypertension education manual and a mobile health (m-health) intervention aimed at enhancing participants' health literacy and promoting healthy behaviors. In the first week, participants receive the health-education manual on-site, with face-to-face explanations and guidance on using mobile resources, such as text messaging, provided by the Sub-Investigator.~The mobile health intervention transforms the manual's content into six video units, each covering a specific topic, and these videos are continuously pushed over a two-month period. Distributed through LINE@, the official LINE account of the nursing platform, participants can easily access information via the chat menu at the bottom of the screen. This setup improves accessibility, making it convenient for participants to locate and use essential health information directly from the chat window."
48293554|NCT06666361|OTHER|control group|The control group received one copy of the same health education manual as the experimental group. The sub-Investigator only explained how to use the manual, and afterwards, no face-to-face teaching or m-Health interventions were conducted. After the experiment concluded, the m-Health program used by the experimental group would be provided to the control group.
48293557|NCT00552539|OTHER|'educational video'|'educational video'
48633076|NCT01060969|DRUG|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
48293558|NCT00638066|DRUG|botulinum toxin|500 units of botulinum toxin for the second arm
48293559|NCT00638066|DRUG|botulinum toxin A|250 units of botulinum toxin A once
48293560|NCT05410145|DRUG|D3S-001|Oral
48293561|NCT05410145|DRUG|Pembrolizumab|Intravenous
48293562|NCT05410145|DRUG|Cisplatin|Intravenous
48633077|NCT01060969|DRUG|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
48633078|NCT03750227|PROCEDURE|Conventional Surgery|Undergo surgery
48293563|NCT05410145|DRUG|Carboplatin|Intravenous
48293564|NCT05410145|DRUG|Pemetrexed|Intravenous
48293565|NCT05410145|DRUG|Cetuximab|Intravenous
48293566|NCT02183298|DRUG|BI 1356 BS - intravenous|
48293567|NCT02183298|DRUG|BI 1356 BS - Tablet|
48293568|NCT02183298|DRUG|Placebo|
48293569|NCT01118143|BEHAVIORAL|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
48293570|NCT06249542|OTHER|Care Delivery Improvement Intervention|"KPWA clinical leaders and clinicians in each clinic implemented all aspects of the care delivery improvement intervention, including screening, assessment, and shared decision-making followed, as appropriate, by treatment. The implementation strategy, which was refined during the pilot phase, included:~1. Identification of a clinical champion and local implementation team~2. Participatory design~3. Training of primary care providers and medical assistants~4. Use of EHR clinical decision support tools~5. Weekly facilitated local implementation team meetings~6. Performance monitoring with feedback, including monthly meetings with the local implementation team and clinic leaders~7. Learning sessions for primary care providers during implementation~8. Social worker use of an EHR registry with weekly supervision~9. Use of a video and informational handouts to shift attitudes and reduce stigma associated with unhealthy substance use"
48293571|NCT03201653|PROCEDURE|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
48293572|NCT02558946|BEHAVIORAL|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
48633079|NCT03750227|OTHER|Quality-of-Life Assessment|Ancillary studies
48633080|NCT03750227|OTHER|Questionnaire Administration|Ancillary studies
48633081|NCT03750227|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
48293573|NCT02558946|BEHAVIORAL|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
48293574|NCT05775406|DRUG|KT-253|KT-253 will be administered intravenously per the defined protocol frequency and dose level.
48293575|NCT05736731|BIOLOGICAL|A2B530|Autologous logic-gated Tmod CAR T-cells
48293576|NCT05736731|DIAGNOSTIC_TEST|xT-Onco with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
48293577|NCT06556810|DRUG|Atibuclimab (IC14)|Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system
48293578|NCT06672614|OTHER|Post-Exercise Hot Water Immersion|Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max) followed by 30 minutes post-exercise hot water immersion (40oC) for 5 consecutive days.
48293579|NCT06672614|OTHER|Control Group|Participants will cycle for 60 minutes at 50% maximal oxygen uptake (VO2 max) for 5 consecutive days. There is no water immersion following the exercise.
48293580|NCT06248008|DRUG|ASC40|ASC40 tablets orally once daily
48293581|NCT06667089|OTHER|Povidone-Iodine|The povidone-iodine group will receive a 10% povidone-iodine solution or gel applied directly to the wound after gentle cleaning, with the treatment applied according to a set frequency, typically twice daily. This antiseptic will be left on the wound for a brief period to enhance its antimicrobial action.
48293582|NCT06667089|OTHER|Chlorhexidine|The chlorhexidine group will receive a chlorhexidine solution, usually at a concentration of 0.5% to 2%, applied similarly after cleaning the wound. This solution will remain on the wound according to protocol guidelines, also typically applied twice daily. Both groups will be monitored for adverse reactions, signs of infection, and the overall effectiveness of wound healing throughout the treatment period.
48293583|NCT01001494|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
48293584|NCT01001494|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
48633082|NCT00349076|DRUG|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
48633083|NCT00349076|DRUG|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
48633084|NCT05611736|OTHER|cold saline|After standard chemo-mechanical preparation of the root canal, final irrigation will be performed using 20 milliliters of cold (at 2.5 degrees Celsius temperature) saline solution.
48633085|NCT05611736|OTHER|saline|After standard chemo-mechanical preparation of the root canal, final irrigation of the root canal will be done using normal saline solution at room temperature
48633086|NCT03701178|OTHER|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
48633087|NCT05152095|OTHER|Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure|Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 \~ 3 hours, for 5 days.
48633088|NCT05152095|OTHER|Plain ear adhesive tape|Apply on Shenmen and Occiput without applying pressure for 5 days.
47944978|NCT00453518|DEVICE|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
47944979|NCT03164577|BEHAVIORAL|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
48293585|NCT01001494|DRUG|Placebo|Placebo twice-daily by inhalation for 24 weeks
48293586|NCT01223911|DRUG|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
48633089|NCT04640961|DEVICE|Cingal|Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
48633090|NCT02211742|DRUG|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
48633091|NCT05821595|DRUG|JYB1907|for injection
48633092|NCT00326040|DEVICE|Glaucoma Surgery|
48633093|NCT03428555|BEHAVIORAL|Integrated Care Pathway|The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
48633094|NCT03428555|BEHAVIORAL|Treatment As Usual|Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
48633095|NCT03719937|DEVICE|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
48633096|NCT06548958|PROCEDURE|Second Stem Cell Transplantation (SCT2)|"1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
48633097|NCT01266928|DRUG|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
47944980|NCT03164577|OTHER|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
48633098|NCT00003812|BIOLOGICAL|filgrastim|
48633099|NCT00003812|DRUG|carboplatin|
48633100|NCT00003812|DRUG|etoposide|
47944981|NCT00792077|DRUG|Lenalidomide|5 mg daily for 56 days.
47944982|NCT03347188|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
47944983|NCT03347188|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
47944984|NCT05391542|OTHER|aligning archwires|At the day of bonding, 0.016-inch archwire will be placed for the TuNT group. Eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. While, for the CuNT group, 0.014-inch archwire will be placed at the day of bonding and eight weeks later it will be replaced by the 0.018-inch archwire for another eight weeks. Archwires will be tied to the bracket by elastomeric modules which will be changed every 4 weeks. A good-quality alginate impression for the lower arch should be taken pre-treatment and after 4, 8, 12 and 16 weeks and a stone study model is obtained. Periapical X-ray for the mandibular central incisors will be taken pre-treatment and after 16 weeks. The participants will be provided by a visual analog scale (0-10) to record their pain perception during the first week after each wire placement.
47944985|NCT03946488|DEVICE|Functional electrical stimulation|Functional electrical stimulation of finger's muscles in order to open the hand
47944986|NCT02320318|DRUG|Ibodutant 10 mg|Oral tablet, once daily.
47944987|NCT02320318|DRUG|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
48633101|NCT00003812|DRUG|paclitaxel|
48633102|NCT00003812|DRUG|topotecan hydrochloride|
48633103|NCT00003812|RADIATION|radiation therapy|
48633104|NCT00355550|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
48633105|NCT00355550|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
48633106|NCT05130983|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
48633107|NCT04162483|DEVICE|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
48633108|NCT01086475|DRUG|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
48633109|NCT01086475|DRUG|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
48633110|NCT05033600|DEVICE|S.C.I.O.|The devices read, emit and entrain Electromagnetic waves of the body.
47944988|NCT03109054|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
47944989|NCT04449887|DRUG|Xiangsha Liujunzi granules|A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
47944990|NCT04008238|DRUG|Trabectedin|- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
47944991|NCT02672280|DEVICE|Medical Collagen Membrane with MSC|
47944992|NCT02672280|DEVICE|Medical Collagen Membrane|
47944993|NCT01667692|DRUG|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
47944994|NCT01667692|DRUG|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
47944995|NCT03060733|OTHER|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
47944996|NCT03420417|DEVICE|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
47944997|NCT02695875|PROCEDURE|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
47944998|NCT02695875|PROCEDURE|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
47944999|NCT04576624|BEHAVIORAL|Lifestyle Intervention|A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
47945000|NCT04576624|BEHAVIORAL|social activity|24 social gathering events
48293587|NCT01223911|DRUG|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
47945001|NCT00969904|DRUG|N-acetylcysteine|600 mg TID for 12 weeks
48293588|NCT06393114|OTHER|Fermented oat-based product|Participants will incorporate a novel fermented product into their habitual diet for three weeks. In addition, the consumption of dairy and plant-based dairy alternatives is restricted. Cereal product consumption, specifically bread and porridge, is slightly restricted to prevent gastrointestinal symptoms caused by the increased intake of dietary fibre. Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
48475786|NCT05388812|OTHER|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
48633111|NCT02926612|OTHER|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
48633112|NCT06138080|DIAGNOSTIC_TEST|Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography|We have no specific intervention. We investigate different diagnostic modalities of VUR.
48103645|NCT06465667|BEHAVIORAL|Precision Feedback Push|"The experimental intervention, precision feedback e-mail messaging, will consist of an e-mail with a link to the dashboard along with tailored information about a participant's performance in the quality process measure of interest. For example, e-mail subject lines may read You have room for improvement in stent omission, accompanied by a visual display in the body of the e-mail showing a participant's performance relative to a top performing peer. The behavior change intervention delivery component will also involve modifications to existing procedures. Namely, performance feedback will be reported directly in the e-mail as either plain text, or an embedded or attached image with graphed data."
48293589|NCT06393114|OTHER|Unfermented oat-based product|Participants will incorporate a novel unfermented product into their habitual diet for three weeks. Dietary adjustments and other guidance are consistent with those described during the fermented product intervention.
48293590|NCT03472534|DRUG|diacerein 1% ointment|diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
48293591|NCT06494176|BEHAVIORAL|neVR Fear the Dentist|neVR Fear the DentistTM comprises two major evidence-based interventions. First is a self-administered eHealth app for CBT/ psychoeducation with exposure therapy - delivered via a mobile tablet - that can be completed anywhere. Second is a 1-hr virtual reality exposure treatment (VRET).
48475787|NCT02508259|DRUG|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
48475788|NCT02508259|DRUG|Saline|50 ml IV over 30 minutes
48475789|NCT04688372|OTHER|Surge Index|See study description above
47945002|NCT00969904|DRUG|placebo|placebo tablet TID for 12 weeks
47945003|NCT02165709|PROCEDURE|Salpingectomy|
47945004|NCT02165709|PROCEDURE|Traditional sterilization|
47945005|NCT01465061|BEHAVIORAL|Online support group|Joining online support group
48475790|NCT04448496|DRUG|Dexamethasone implant|Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
48475791|NCT02926651|DRUG|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
48475792|NCT02926651|DRUG|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
48475793|NCT01588535|DRUG|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
48475794|NCT01588535|DRUG|placebo|placebo solution, five drops in affected ear canal each hour as needed
48475795|NCT00792584|DRUG|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
47945006|NCT06169228|DEVICE|mandibular advancement|The multidisciplinary sleep unit assessment and follow-up protocol will be followed for this group of patients based on the Spanish Clinical Practice Guideline of the Spanish Sleep Society (SES) on the use of mandibular advancement devices in the treatment of patients with obstructive sleep apnea
47945007|NCT02504996|DRUG|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
47945008|NCT02504996|DRUG|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
47945009|NCT02504996|DRUG|Placebo|Intravenous 100 ml normal saline
47945010|NCT00381251|DRUG|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
47945011|NCT05806723|DRUG|Atorvastatin 40 Mg Oral Tablet|daily drug intake during six months
48103646|NCT03551132|OTHER|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
48103647|NCT00464672|BIOLOGICAL|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
48293592|NCT02061007|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
48293593|NCT02061007|DRUG|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
48293594|NCT02061007|PROCEDURE|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
47945012|NCT00857402|DIETARY_SUPPLEMENT|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
48103648|NCT00464672|BIOLOGICAL|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
48293595|NCT00184054|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
48293596|NCT00184054|DRUG|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
48293597|NCT06387238|DIAGNOSTIC_TEST|PSMA PET/CT|pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.
48293598|NCT03015272|BEHAVIORAL|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
48475796|NCT00792584|DRUG|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
47945013|NCT00857402|DIETARY_SUPPLEMENT|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
48475797|NCT05426616|DEVICE|collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
47945014|NCT02827916|DEVICE|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
47945015|NCT02827916|DEVICE|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
47945016|NCT02827916|DEVICE|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
47945017|NCT03400644|DEVICE|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
47945018|NCT02891811|DRUG|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
47945019|NCT02891811|DRUG|Thalidomide|100mg orally on days 1-28 in patients \<75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
48620040|NCT05702632|DEVICE|TheraTogs orthotic treatment|A sleeveless top vest and two pairs of shorts with two thigh cuffs and limb cuffs each make up the TheraTogs strapping system which is applied to the children in the TheraTogs group. The TheraTogs suit is providing breathable, comfortable- Latex over the torso and thigh, as well as free toileting. For infection control and size fitting problems, participants are not allowed to share their TheraTogs with other patients. TheraTog's orthotic undergarment and strapping system were worn under their regular clothes, so it was neither distracting nor irritating.
48620041|NCT05702632|PROCEDURE|traditional physical therapy program|Facilitation of balance and gait training
48620042|NCT03004040|BIOLOGICAL|Flu Vaccine|
47945020|NCT02891811|DRUG|Lenalidomide|25mg p.o. on days 1-21 of each cycle
47945021|NCT02891811|DRUG|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
48293599|NCT03015272|BEHAVIORAL|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
48293600|NCT06166576|PROCEDURE|Ablative radioembolization|The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
48293601|NCT06380517|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
48293602|NCT06380517|OTHER|Eye Patch|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye
48293603|NCT06040567|OTHER|Validity and reliability of outcome measures in polyneuropathy|Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
48293604|NCT06040567|OTHER|Healthy controls|Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.
48293605|NCT03596125|DRUG|N-acetylcysteine|N-acetylcysteine supplementation
48293606|NCT03596125|DRUG|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
48293607|NCT00218244|OTHER|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
48293608|NCT00218244|OTHER|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
48293609|NCT04275310|BEHAVIORAL|Microeconomic Intervention|The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
48293610|NCT06038448|PROCEDURE|Urinary catheter balloon size|The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
48293611|NCT06672770|OTHER|Functional Inspiratory Muscle Training|"The functional inspiratory muscle training group will perform basic inspiratory muscle training in the first four weeks of the study and the following exercises with the Powerbreath device in muscle training in the following four weeks:~1. Diaphragmatic breathing exercises~2. Warm-up exercises~3. Trunk strength and lumbopelvic stability exercises~4. Dynamic trunk exercises~5. Postural control exercises~6. Cool-down exercises"
48293612|NCT06672770|OTHER|Basic Inspiratory Muscle Training|The basic inspiratory muscle training group will do muscle training with the POWERbreathe device for eight weeks.
48293613|NCT05743023|BEHAVIORAL|Ayurvedic lifestyle protocol|"Based on each participant's current mind-body imbalance determination, a personalized 12-week intervention lifestyle protocol will be given.~Each protocol will mainly address diet and daily routine, quality of food, food combinations, and living in harmony with natural rhythm for balancing the predominant imbalance based on Ayurvedic principles. In addition, the lifestyle protocol will also include stress-reducing methods and more specifically, participants will be recommended to learn and practice the Transcendental Meditation technique."
48293614|NCT03702257|PROCEDURE|bronchoscopy.|gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
48293615|NCT06275165|OTHER|acupressure|In the experimental group, routine nursing care and acupressure (Neiguan and Zusanli points) were performed from the 1st to the 5th day after the postoperative transfer from the ward to the hospital room. Twice a day, 3 minutes each time, 12 minutes in total.
48293616|NCT05857956|OTHER|Proper Wild energy shot|100% plant-based energy shot containing natural caffeine, L-Theanine, purified water, pineapple juice concentrate, natural flavors, kiwi juice concentrate, organic lemon juice concentrate, organic strawberry juice concentrate, monk fruit juice concentrate, pink himalayan sea salt.
48293617|NCT02989727|DRUG|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
48293618|NCT02989727|DRUG|Placebos|Placebo tablets
48293619|NCT02293681|DRUG|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
48293620|NCT02293681|DRUG|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
48293621|NCT02293681|DRUG|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
48293622|NCT03667651|DRUG|EpiCeram|Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
48293623|NCT01749735|DEVICE|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
48293624|NCT01749735|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
48293625|NCT01749735|DEVICE|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
47945022|NCT03819673|BEHAVIORAL|Intervention Group Care|children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
47945023|NCT00734370|BEHAVIORAL|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Virtual reality Exposure to agoraphobic situations and interoceptive exposure~* Relapse prevention"
47945024|NCT00734370|BEHAVIORAL|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Standard exposure in vivo to agoraphobic situations and interoceptive exposure~* Relapse prevention (according to the protocol of Craske \& Barlow)"
47945025|NCT00931736|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
47945026|NCT00931736|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
47945027|NCT03057379|OTHER|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
47945028|NCT06154538|DRUG|Cadonilimab|PD-1/CTLA-4 bi-specific antibody
47945029|NCT06154538|DRUG|FOLFOX regimen|FOLFOX chemotherapy
47945030|NCT05956873|DEVICE|REVAR|Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
47945031|NCT00004076|DRUG|mureletecan|
47945032|NCT03911713|DRUG|VX-561|VX-561 tablets for oral administration.
47945033|NCT03911713|DRUG|IVA|150-mg film-coated tablet for oral administration.
48103649|NCT05359913|BEHAVIORAL|Cervical cancer podcast for African American women|"The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
48103650|NCT01821586|OTHER|Modified ORS-1|
48103651|NCT01821586|OTHER|Modified ORS-2 (ReSoMal)|
48103652|NCT01821586|OTHER|Modified ORS-3 (Benefibre)|
48103653|NCT03872297|DIETARY_SUPPLEMENT|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
48103654|NCT03872297|DIETARY_SUPPLEMENT|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~* 2 blood tests :~* 2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~* 2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
48103655|NCT00711542|BIOLOGICAL|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
48293626|NCT02026271|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection or 1.0 x 10\^12 viral particles (vp) per injection~* one intratumoral injection of Ad-RTS-hIL-12"
47945034|NCT03911713|DRUG|Placebo|Placebo matched to IVA.
48103656|NCT00711542|BIOLOGICAL|placebo medium|intracoronary infusion of placebo medium
48103657|NCT01359371|BEHAVIORAL|Peer telephone cessation counseling|For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
48103658|NCT02176096|DIETARY_SUPPLEMENT|Glycosade|
48293627|NCT02026271|DRUG|veledimex|"* 4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~* 14 oral daily doses of veledimex~* 1 Expansion cohort at a single dose level at or below MTD"
48293628|NCT04224493|DRUG|Tazemetostat|"Stage 1 (Phase 1b):~Tazemetostat was escalated from a starting dose of 400 mg orally twice daily to 600 mg orally twice daily to 800 mg PO twice daily in 28-day cycles as tolerated in a standard 3 + 3 design. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
47945035|NCT03911713|DRUG|Placebo|Placebos matched to VX-561.
47945036|NCT01854203|DRUG|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
47945037|NCT01854203|DRUG|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
47945038|NCT01770652|DRUG|Deferiprone|Oral iron chelator
47945039|NCT04367883|DRUG|Antihistamine|No intervention is performed. We propose an observational study.
47945040|NCT04367883|DRUG|Amantadine|No intervention is performed. We propose an observational study
47945041|NCT04367883|DRUG|ACEI|No intervention is performed. We propose an observational study.
47945042|NCT04367883|DRUG|ARB|No intervention is performed. We propose an observational study.
47945043|NCT04367883|OTHER|Influenza vaccine and COVID|No intervention is performed. We propose an observational study.
47945044|NCT00447317|BEHAVIORAL|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
47945045|NCT00447317|BEHAVIORAL|Attention control|Standard peritoneal dialysis dietary education
47945046|NCT01607671|DRUG|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
47945047|NCT05216003|BEHAVIORAL|PATH4YOU|PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
47945048|NCT04945876|BEHAVIORAL|Digital follow-up|"Participants will receive:~One session of individual exercise and diet guidance focusing on goals and motivation.~An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise.~Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.~Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed."
47945049|NCT03566511|DRUG|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
47945050|NCT03566511|DRUG|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
47945051|NCT01933217|DRUG|Methylphenidate|
47945052|NCT01933217|DRUG|Placebo|
47945053|NCT05841901|DRUG|Huang-long Zhi-xiao Granule|The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
47945054|NCT05841901|DRUG|Huang-long Zhi-xiao Granule placebo|The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
47945055|NCT04802070|DRUG|Autologous CIK|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
47945056|NCT01241240|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
47945057|NCT01241240|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
47945058|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks from baseline
47945059|NCT04208464|DRUG|Baricitinib|4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
48107159|NCT01351272|DRUG|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
48107160|NCT01351272|DRUG|Placebo|
48620043|NCT04508816|DRUG|cetuximab (CTX) or nimotuzumab (NTZ)|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.
48620044|NCT03797729|DRUG|Tirofiban|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
47945060|NCT02680509|PROCEDURE|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
47945061|NCT02395783|DRUG|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
47945062|NCT02395783|DRUG|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
47945063|NCT02395783|OTHER|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
47945064|NCT01385631|DRUG|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
47945065|NCT01385631|DRUG|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
47945066|NCT02225509|PROCEDURE|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
47945067|NCT05780697|PROCEDURE|Surgery of Drainage of septic hip arthritis|Surgery for septic hip arthritis by anterior or lateral approach and inspection of femoral head
47945068|NCT04348461|DRUG|Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells|Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg
47945069|NCT05235477|PROCEDURE|Tube technique|"An excavator (smaller than the width of the defect; evaluated pre-surgically on a study model) is used to carefully reflect the papilla away from the alveolar bone and root surfaces on the buccal aspect to access the interproximal region to prepare the bed for the graft. The excavator is used to do the same on the palatal aspect. The amount of reflection should yield a very relaxed papilla flap that permits placement of the papilla at the new coronal position without tension. The recipient site at this time should resemble a tube with two openings; one on the buccal aspect at the mucogingival junction and one on the palatal aspect."
47945070|NCT04436211|PROCEDURE|Total Knee Arthroplasty|The common procedure of Total Knee Arthroplasty is investigated in order to compare the techniques of implantation (kinematic vs mechanical alignment)
47945071|NCT00766883|BEHAVIORAL|Problem Solving Education|
47945072|NCT01409395|DRUG|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
47945073|NCT01409395|DRUG|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
47945074|NCT01008397|DRUG|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
47945075|NCT00355654|BIOLOGICAL|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
47945076|NCT00355654|BIOLOGICAL|DT3aP-HBs-IPV|0.5 mL, IM
47945077|NCT05700318|DEVICE|neurostimulator|The ShiraTronics Migraine Therapy System
47945078|NCT04483323|PROCEDURE|Erector Spinae Plane Block|"The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected."
47945079|NCT04483323|PROCEDURE|Intraarticular Injection|Intraarticular injection of local anesthetic through the surgical port
47945080|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
47945081|NCT00945997|DRUG|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
47945082|NCT05732220|BEHAVIORAL|EMA assessment|Subjects will be asked to complete 3 waves of ecological momentary assessment (EMA) about smoking cues and smoking consumption via mobile phone at the first, second and third month after baseline (total 6 weeks)
48633113|NCT03286075|DEVICE|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
48633114|NCT03286075|DEVICE|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
47945083|NCT05732220|BEHAVIORAL|EMA-based cessation counselling|Subjects will receive tailored peer counselling based on the participants' EMA responses at 1-month and 3-month telephone follow-ups.
47945084|NCT05732220|BEHAVIORAL|Usual peer counselling|Subjects will receive peer counselling through telephone during follow-ups (usual care), in which the counsellor will apply the 5As model and motivational interviewing techniques.
47945085|NCT01887340|DRUG|Carboplatin|"- carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)"
47945086|NCT01887340|DRUG|Etoposide|100 mg/m2 D1 to D5
47945087|NCT01887340|DRUG|Cisplatin|20 mg/m2 de D1 to D5
48293629|NCT04224493|DRUG|Tazemetostat|"Stage 2:~Tazemetostat 800 mg administered orally twice daily in continuous 28-day cycles for 12 cycles. Tazemetostat will be administered as monotherapy at an 800 mg twice daily dose for up to 2 years after the initial 12 months of combination therapy."
48633115|NCT03286075|DEVICE|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
47945088|NCT02525276|BEHAVIORAL|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
47945089|NCT02525276|DRUG|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
47945090|NCT03722199|DIETARY_SUPPLEMENT|flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)|single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
47945091|NCT03722199|OTHER|Placebo|single intake of capsules with a placebo
47945092|NCT02597868|DRUG|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
47945093|NCT02597868|PROCEDURE|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
47945094|NCT06330454|DEVICE|I-ONE|Pulsed Electromagnetic fields joint therapy
47945095|NCT02616848|DRUG|Everolimus|
47945096|NCT02616848|DRUG|Eribulin|
47945097|NCT05041517|BEHAVIORAL|BOLT + PTC|BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
47945098|NCT03171051|DEVICE|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
47945099|NCT03171051|DEVICE|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
48107161|NCT02682446|DRUG|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen \[lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week\]
48475798|NCT05426616|DEVICE|titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
48475799|NCT04789967|BEHAVIORAL|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
48633116|NCT06461559|OTHER|ileostomy infusion|infusing patient's own ileostomy content into the diverted intestine
48633117|NCT00005596|DRUG|cyclophosphamide|
48633118|NCT00005596|DRUG|cytarabine|
48633119|NCT00005596|DRUG|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
48633120|NCT00005596|DRUG|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
47945100|NCT00585390|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|"* Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~* Docosahexaenoic acid fish oil concentrate at 1.6 grams"
47945101|NCT00585390|OTHER|Olive oil placebo|Olive oil capsules, 8 capsules per day
47945102|NCT00585390|DIETARY_SUPPLEMENT|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
47945103|NCT00585390|DRUG|Placebo|Olive oil capsule
48633121|NCT00005596|DRUG|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
48633122|NCT00005596|DRUG|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC \> 500/μL and platelets \> 75,000/uL
48633123|NCT00005596|DRUG|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
48633124|NCT00005596|DRUG|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; \> or = 1 day after the IT MTX
48633125|NCT00005596|DRUG|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC \> or = 500/ul and platelets \> or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
48633126|NCT00005596|DRUG|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
48633127|NCT06092983|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
48633128|NCT06092983|DRUG|HS-10383 Placebo|HS-10383 Placebo administered as one 50 mg, 150 mg, 300 mg and 450 mg capsule once daily, depending upon randomization.
48633129|NCT00624078|DRUG|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
48633130|NCT04213638|OTHER|Single Microneedle Radiofrequency therapy|Subjects are treated with three consecutive sessions of Single Microneedle Radiofrequency therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment. Each treatment session took approximately 30-60 minutes.
48633131|NCT04213638|OTHER|Photodynamic therapy|Subjects are treated with three consecutive sessions of Photodynamic therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment.
48633132|NCT04772430|RADIATION|snow globe|"Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure."
48633133|NCT05582603|BEHAVIORAL|CCT Long COVID|A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.
47945104|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
47945105|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
47945106|NCT01444352|BIOLOGICAL|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
47945107|NCT01444352|BIOLOGICAL|Placebo|0.5 mL, Intramuscular
47945108|NCT01356927|DRUG|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
47945109|NCT01356927|DRUG|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
47945110|NCT04708600|BEHAVIORAL|Pitch Elevation Therapy|"Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)"
47945111|NCT04708600|BEHAVIORAL|Articulation Resonance Therapy|"Goal: increase in lipspreading, forward tongue carriage, larynx elevation, forward resonance, precise articulation; 5 sessions Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory and visual discrimination of forward vs backed tongue carriage and lip spreading vs lip rounding)~* practice of technique on isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* practising larynx elevation through the twang technique, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* forward resonance, focusing on oral forward resonance rather than chest resonance, isolated vowels -syllables -mono and bisyllabic words - phrases - sentences and texts - conversation (generalization to spontaneous speech)~* clear, precise articulation and cork exercise"
47945112|NCT04708600|BEHAVIORAL|Sham therapy|"Goal: active sham treatment, 4 sessions Doses and duration: 4 one hour and 15 minutes sessions (5h), 4 weeks~Content:~* providing information about vocal function, vocal surgery, vocal hygiene, transgender health care~* discussing communication aspects and patterns, possible exercise contexts, communication partners, expectations of voice modification, conversational subjects~* active intervention on nonverbal communication (Kinesics, gestures and sign language, facial expression, haptics, proxemics, occulsics, and physical appearance)~* practising costo abdominal breathing patterns"
47945113|NCT00959712|BEHAVIORAL|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
47945114|NCT02629484|OTHER|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
47945115|NCT04081233|PROCEDURE|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
47945116|NCT04081233|PROCEDURE|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
48633134|NCT06302283|OTHER|Survey|Survey (online or paper) on caregiving burden and bereavement
48633135|NCT02832947|DRUG|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
47945117|NCT04648709|DIAGNOSTIC_TEST|ELISPOT|measure of immune response by ELISPOT
48103659|NCT03807557|OTHER|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
48633136|NCT04607616|BEHAVIORAL|Baseline sessions TAU|TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
47945118|NCT04648709|DIAGNOSTIC_TEST|QUANTIFERON|measure of immune response by QUANTIFERON
47945119|NCT05884710|OTHER|Foot core exercises|2 groups; First group is an intervention group who has contain foot core exercises and the other group is a control group.
47945120|NCT05884710|OTHER|Conventional Physiotherapy|Electrotherapeutic modalities and range of motion exercises
47945121|NCT01742936|DEVICE|CoaguChek|Hand held coagulation monitor.
47945122|NCT01742936|OTHER|Hospital Laboratory|Coagulation testing done by hospital laboratory.
47945123|NCT05685836|DRUG|Bevacizumab Zirconium Zr-89|See Arm description.
47945124|NCT02057393|DRUG|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
47945125|NCT02057393|DRUG|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
47945126|NCT02057393|DRUG|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
47945127|NCT01776047|DRUG|Exforge®|
47945128|NCT01776047|DRUG|G-0081|
47945129|NCT03360747|DRUG|AKCEA-ANGPTL3-LRx|AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
47945130|NCT00632073|DRUG|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
47945131|NCT05495087|DEVICE|IHT Treatment|IHT Treatment: IH exposure to 10% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
47945132|NCT05495087|OTHER|Sham-IHT Control|Sham-IHT Control: Exposure to 21% O2 for up to 5 min, interspersed with breathing room air recovery for up to 5 min, with up to 8 cycles/session, 3 sessions/week, for up to 12 weeks.
47945133|NCT04911413|DRUG|Tranexamic acid|The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
47945134|NCT03356054|COMBINATION_PRODUCT|R-DHAP|3 cycles q 3 weeks
47945135|NCT03356054|DRUG|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
47945136|NCT02499978|DRUG|Darunavir/Cobicistat|Fixed dose combination medication
47945137|NCT02499978|DRUG|Dolutegravir|single tablet medication
47945138|NCT02395016|DRUG|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
47945139|NCT02395016|DRUG|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
47945140|NCT02395016|OTHER|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
47945141|NCT06337422|DRUG|Celecoxib 200 mg capsule|Celecoxib 200 mg capsule
47945142|NCT04375618|DRUG|RhEGF|The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
47945143|NCT04375618|DRUG|Plain Collagen|A collagen membrane without FGF-2 will be used.
47945144|NCT00551044|DRUG|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
47945145|NCT04996381|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
47945146|NCT00950287|DEVICE|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
48293630|NCT04224493|DRUG|Placebo oral tablet|"Stage 2:~Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy."
48293631|NCT04224493|COMBINATION_PRODUCT|Lenalidomide|Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
48293632|NCT04224493|COMBINATION_PRODUCT|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
48293633|NCT05869344|DIETARY_SUPPLEMENT|Black bean protein hydrolysates (BPH)|Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
48293634|NCT05869344|OTHER|Commercial non-caloric beverage|Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
48475800|NCT04789967|BEHAVIORAL|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
48475801|NCT04789967|OTHER|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
48475802|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
48475803|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
48475804|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
48633137|NCT04607616|BEHAVIORAL|Interactive guidance therapy|"The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills."
48633138|NCT04607616|DIAGNOSTIC_TEST|Developmental and diagnostic assessments|MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
48103660|NCT03807557|OTHER|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
48475805|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
48633139|NCT04607616|BEHAVIORAL|Developmental assessment -Parental scales|Vineland II, IFDC, IDE
48633140|NCT04607616|BEHAVIORAL|Qualitative analysis|Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
47945147|NCT05554575|BIOLOGICAL|BT-007 CD7 CAR-T cells|T cells purified from the peripheral blood mononuclear cell (PBMC) of subjects or subjects' relatives which depend on their conditions, transduced with 4-1BB/CD3ζ lentiviral vector, expanded in vitro for future administration.
48293635|NCT04583865|OTHER|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
48293636|NCT02612090|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry
48293637|NCT02612090|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|Placebo
48293638|NCT03058458|DRUG|PIN201104|IV or SC administration
48293639|NCT03058458|DRUG|Placebo|IV or SC administration
48475806|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
48475807|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
48475808|NCT02672540|DRUG|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
48475809|NCT02672540|DRUG|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
48475810|NCT00000302|DRUG|Buprenorphine|
48475811|NCT06326528|DRUG|SGLT2 inhibitor|Dapagliflozin 10 mg or Empagliflozin 25mg
48475812|NCT01903564|DEVICE|magnetocardiography|recording of magnetic heart activity
48475813|NCT01903564|DEVICE|postnatal ECG|postnatal ECG
47945148|NCT05548309|DEVICE|HFNC|High flow nasal cannula (HFNC) was inserted through specific medium/large nasal prongs . FiO2 was continuously measured by a dedicated system (AIRVO™ 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) connected to the HFNC. Starting flow 35 L/min, temperature 31oc. The flow was titrated up to 60L/min with a target SpO2 of ≥94%.
47945149|NCT05548309|DEVICE|Oxygen face mask|Oxygen face mask was applied to patients postoperatively with starting flow 8L/min and titration of flow up to 10 L/min with target SpO2 of ≥94%
48103661|NCT02458599|DIETARY_SUPPLEMENT|Test product|Whey protein hydrolysate (20 g)
48475814|NCT01903564|DEVICE|fetal echocardiography|fetal echocardiography
48475815|NCT04079582|OTHER|Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
48475816|NCT04079582|OTHER|Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
48475817|NCT03808740|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day.
48475818|NCT03808740|DRUG|Placebo|sugar pill
48475819|NCT05305664|DRUG|Pelacarsen (TQJ230) 80 mg s.c.|Pelacarsen (TQJ230) 80 mg s.c. Q4W
48293640|NCT06672757|DEVICE|CV_AID|"Upon arrival at the scene, the paramedic utilizes a mobile app with an integrated camera to aid in conducting the National Institutes of Health Stroke Scale (NIHSS) assessment. The app assists in scoring the patient\&#39;s responses according to NIHSS criteria to determine the severity of stroke symptoms.~If the app assessment indicates a high likelihood of stroke, transport can be initiated without a conference with the neurovascular centre. The app shares the recorded NIHSS assessment and video of the patient with the neurovascular centre for review.~While en route, the paramedic confer with the neurovascular centre to discuss the patient\&#39;s condition and determine appropriate course of action. If the neurovascular centre decides not to treat the patient, transport can be diverted to the nearest hospital.~The paramedic documents all assessment findings, interventions, and communications related to the stroke patient in the patient care record. U"
47945150|NCT05689944|BEHAVIORAL|Dance-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 15 mn of body warm-up with taught contemporary dance exercises~* 15 mn of creative research based on dance improvisation on a given theme~* 15 mn of sharing for the elaboration of a choreography~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session if he/she wishes (e.g. think of a choreography, remember what was done etc. ....) in order to encourage the commitment to care. These sessions will be based on contemporary dance and dance improvisation techniques."
48293641|NCT02852694|DRUG|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
48293642|NCT02852694|DRUG|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
48103662|NCT02458599|DIETARY_SUPPLEMENT|Reference product 1|Iso-energetic carbohydrate (20 g)
48103663|NCT02458599|DIETARY_SUPPLEMENT|Reference product 2|Negligible energy placebo (20 g)
48103664|NCT03013348|DEVICE|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography \[EEG\] recordings) that are pathognomonic for PNES activity.
48103665|NCT02600442|OTHER|non interventional study|
48103666|NCT04726046|DRUG|Cefotetan|Cefotetan (as Disodium) 1 GM Injection before surgery
48293643|NCT02852694|DRUG|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
48293644|NCT00487279|DEVICE|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
48293645|NCT00487279|OTHER|Control|No Intervention
48293646|NCT01619618|GENETIC|mutation analysis|
48293647|NCT01619618|GENETIC|polymerase chain reaction|
48293648|NCT01619618|GENETIC|polymorphism analysis|
48293649|NCT01619618|OTHER|laboratory biomarker analysis|
48293650|NCT04689646|BEHAVIORAL|Mind Body Intervention 1|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
48293651|NCT04689646|BEHAVIORAL|Mind body intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
48633141|NCT05080543|DRUG|Albumin 20% and terlipressin|Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
48103667|NCT05178758|DEVICE|Virtual Reality (VR)|Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.
48103668|NCT01738867|DRUG|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
48103669|NCT01738867|DRUG|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
48103670|NCT01738867|DRUG|Placebo|Matching placebo capsules to GSK1521498 or NTX
48103671|NCT02414906|OTHER|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
48103672|NCT04621708|DEVICE|Repetitive transcranial magnetic stimulation|Left DLPFC iTBS rTMS
48103673|NCT00092716|DRUG|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
48103674|NCT00092716|DRUG|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
48103675|NCT03663101|DRUG|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
48103676|NCT03663101|BIOLOGICAL|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
48103677|NCT03663101|DRUG|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
48293652|NCT03072511|BEHAVIORAL|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
48475820|NCT05305664|DRUG|Corresponding Placebo|Placebo to Pelacarsen
48475821|NCT05472116|DEVICE|Mobile Health application (CapApp)|Mobile Health application (CapApp) will be used to measure capillary refill time in a healthy pediatric population and compared to two additional manual methods to include both human and computer annotation and mobile health application (Cap App).
48633142|NCT00559351|PROCEDURE|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
47945151|NCT05689944|BEHAVIORAL|Art-therapy|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 10 mn of discovery of a new technique (acrylic painting or collage).~* 35 mn of practice in a project fixed beforehand~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session (e.g. collecting plants for collage....) in order to encourage commitment to the treatment. The sessions will be based on acrylic painting or collage techniques."
47945152|NCT05689944|BEHAVIORAL|Yoga|"This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn welcome~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 50 mn of Vinyasa type yoga (warm-up, breathing, balance, strength and flexibility, relaxation)~* 5 mn of closing of the session~* At the end of the session, 5mn of self-evaluation of the pain thanks, the thymia, the fatigue and the level of appreciation of the session (VNS).~These sessions engage the body without entering into a therapy protocol turned towards art as in the two previous interventions."
47945153|NCT00957112|PROCEDURE|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
47945154|NCT00957112|PROCEDURE|standard follow-up care|Patients receive standard care
47945155|NCT05484778|PROCEDURE|Dual tasking paradigm|The dual task methodology is a testing model that requires one person to perform two tasks at the same time. The dual task is divided into two as motor-motor or motor-cognitive. Dual tasks provide an opportunity to examine the attention demands of both tasks and allow possible interference to be observed. The idea behind this design is that central processing capacity has a limit and must be distributed among concurrent tasks.
47945156|NCT03003611|PROCEDURE|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
47945157|NCT03003611|PROCEDURE|general anesthesia|Patient will be anesthetized with a classical general anesthesia
47945158|NCT03539354|DEVICE|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
47945159|NCT03539354|PROCEDURE|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
47945160|NCT03539354|DRUG|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
47945161|NCT05979285|DEVICE|N1-Headache App (by Curelator)|Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
48293653|NCT03072511|DRUG|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
48475822|NCT03822273|PROCEDURE|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
47945162|NCT00232167|DRUG|Indiplon|
47945163|NCT00232167|DRUG|Sertraline|
48103678|NCT03663101|DRUG|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
48103679|NCT01413113|DRUG|pazopanib hydrochloride|Given PO
48620045|NCT03797729|DRUG|Normal saline|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
48103680|NCT01413113|RADIATION|iodine I 131|Given IM
48103681|NCT06317688|DIETARY_SUPPLEMENT|Extra-Virgin Coconut Oil|Active ingredients act as a destructor of bacteria, viruses and fungus
48103682|NCT05015868|DIAGNOSTIC_TEST|Standard of care|"Enrollment of patients afferent to our Center with cryptogenic drug-resistant epilepsy with onset in pediatric age, subject to informed consent;~* acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data (previous negative brain magnetic resonance imaging);~* execution of a complete neuropsychological assessment for the classification of cognitive aspects and evaluation of executive functions;~* execution of genetic tests through Next generation sequencing epilepsies panel or exome sequencing"
48103683|NCT05015868|DIAGNOSTIC_TEST|Functional magnetic resonance imaging-Electroencephalogram combined analysis|"A functional brain magnetic resonance imaging is executed analysing blood oxygenation level dependent signal.~During the functional recording, a contemporary electroencephalogram is registered in order to analyse the space-time relationship between the epileptic discharges and the bold abnormalities."
48633143|NCT00559351|DRUG|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
48107162|NCT06429852|BEHAVIORAL|The DeST-ACT Trauma-Focused Acceptance and Commitment Therapy Program|The Trauma-focused psychosocial intervention program consists of 4 sessions online therapy.
48293656|NCT04728971|DRUG|Micafungin Sodium 50 MG Injection|Give Micafungin 150 mg/d within 24 hours after liver transplantation.
48293657|NCT04728971|DRUG|Caspofungin Acetate|Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.
48293658|NCT06468410|OTHER|long duration Hatha Yoga|60 min of Hatha yoga for 4 weeks. Week One:Participants begin with foundational breathing and yoga practicesOn the second day, Square Breathwork is introduced to foster calm and concentration. After a warm-up, the yoga flow focuses on heart openers to increase chest and shoulder flexibility, ending with a soothing cool-down. Week Two:Advanced breathing techniques and targeted yoga flows are introduced. The second session includes Nadi Shodhana to balance the nervous system. Week Three:The focus remains on heart openers with varied breathing exercises. The second day revisits Full Yogic Breath, followed by a warm-up and another heart opener sequence, concluding with a cool-down. Week Four:The final week integrates additional breathing techniques. The last session features Kapalabhati and Suddhi Pranayama to purify and energize the body. After a warm-up, participants engage in a well-rounded yoga flow combining various poses to enhance overall fitness, concluding with a final cool-down.
48293659|NCT06468410|OTHER|short duration Hatha Yoga|30 min of Hatha yoga for 4 weeks .
48293660|NCT06468410|OTHER|Control group|participants will receive information about physical activity guidelines but will not engage in any structured yoga exercise during the study period.
48293661|NCT06569537|DRUG|Lidocaine topical|4%
48293662|NCT06569537|DRUG|BLT|Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
48293663|NCT03766997|DRUG|Compound Betamethasone Injection|local injection
48293664|NCT03766997|DRUG|Hydrocortisone Butyrate 0.1% Cream|topical use
48293665|NCT06005493|DRUG|AZD5863|T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
48293666|NCT06671600|PROCEDURE|Osteopathic manipulative medicine|osteopathic manipulative treatment protocol will be applied to the cranial, cervical, thoracic, and ribcage regions. OMM procedures performed on the treatment group will consist of 1. suboccipital decompression/release, 2. base spread, 3. occipitoatlantal (OA) decompression, 4. venous sinus drainage, 5. compression of the fourth ventricle, 6. cervical myofascial (unilateral perpendicular stretch), 7. thoracic inlet release (direct or indirect), 8. Bilateral rib raising, 9. thoracoabdominal diaphragm doming (direct technique), and 10. pedal pump (Dalrymple lymphatic pump)
48293667|NCT06671600|PROCEDURE|Sham (No Treatment)|The sham group will serve as the control group and will receive a light touch-control procedure based on prior study utilizing light touch.
48293668|NCT01943630|DRUG|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
48293669|NCT01943630|DRUG|Vehicle|Administration of Vehicle once a day (overnight)
48293670|NCT00227877|BEHAVIORAL|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
47945164|NCT05229978|OTHER|Showing an existing Dynamic Consent (computer interface) as prompt|An existing Dynamic Consent interface will be shown as a prompt halfway through the focus group sessions.
47945165|NCT02457481|DEVICE|Embryo Culture medium|Two step sequential embryo culture medium system
47945166|NCT00135733|DRUG|Amevive (Alefacept)|
47945167|NCT00135733|DRUG|Placebo|
47945168|NCT05026723|BEHAVIORAL|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
48107163|NCT03601351|OTHER|ELISA for MOR-1 expression|To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
48293671|NCT00227877|BEHAVIORAL|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
48293672|NCT04853667|OTHER|Interview|Semi-structured interview, lasting a maximum of one hour
48293673|NCT04111822|DRUG|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
48293674|NCT04111822|DRUG|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
48293675|NCT00918723|DRUG|Fludarabine Phosphate|Given IV
48293676|NCT00918723|DRUG|Cyclophosphamide|Given IV
48293677|NCT00918723|BIOLOGICAL|Rituximab|Given IV
48293678|NCT00918723|DRUG|Vorinostat|Given PO
47945169|NCT05026723|BEHAVIORAL|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
47945170|NCT02200783|DEVICE|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
47945171|NCT02200783|DEVICE|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
47945172|NCT02200783|DEVICE|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
47945173|NCT02649114|BEHAVIORAL|Cognitive-Behavioural Therapy|
47945174|NCT02649114|BEHAVIORAL|Compassion-Focused Therapy|
47945175|NCT05907980|DRUG|ROSE12|ROSE12 as a IV infusion
47945176|NCT05907980|DRUG|Atezolizumab|Atezolizumab as a IV infusion
48293679|NCT06263166|BEHAVIORAL|Stress ball intervention|Women should squeeze and loosen the stress ball given to them during the vaginal examination and continue this process until the examination is completed.
48293680|NCT05132738|DRUG|Ripretinib treatment|"Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen."
48293681|NCT04003155|DRUG|fezolinetant|Oral Tablet
48293682|NCT04003155|DRUG|placebo|Oral Tablet
48293683|NCT02399878|DRUG|Inspiratory oxygen|
48293684|NCT05518591|BEHAVIORAL|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
48293685|NCT00573131|DRUG|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
48293686|NCT00573131|DRUG|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
48293687|NCT00573131|DRUG|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
48293688|NCT00573131|RADIATION|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
48293689|NCT00573131|PROCEDURE|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
48293690|NCT01183962|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 3000 IU daily
48293691|NCT01183962|OTHER|No medication|No intervention
48293692|NCT06673095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48293693|NCT06673095|PROCEDURE|Excision|Undergo narrow margin excision
48633144|NCT00559351|RADIATION|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
48633145|NCT05450120|OTHER|Functional Rehabilitation|Functional rehabilitation protocol
48633146|NCT05450120|OTHER|Neuromuscular Electrical Stimulation|Neuromuscular electrical stimulation protocol
47945177|NCT00801918|DRUG|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
48293694|NCT06673095|PROCEDURE|Excision|Undergo wide margin excision
48293695|NCT06673095|OTHER|Survey Administration|Ancillary studies
48293696|NCT06658002|DRUG|Cyclosporine A|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
48293697|NCT06658002|OTHER|Placebo Comparator: Placebo|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
48293698|NCT03711019|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
48633147|NCT01667614|DRUG|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
48633148|NCT01653262|DRUG|Brivaracetam|
48633149|NCT01117350|DRUG|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
48633150|NCT01117350|DRUG|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
48633151|NCT01117350|DRUG|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
48633152|NCT00452400|DRUG|BI 1744CL|
48633153|NCT01795131|DIETARY_SUPPLEMENT|Vitamin B12|
48633154|NCT01795131|DIETARY_SUPPLEMENT|Placebo|
48633155|NCT04416685|PROCEDURE|primary repair|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
48633156|NCT04416685|PROCEDURE|segmental resection|For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.
48633157|NCT04416685|PROCEDURE|graft reconstruction|Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
47945178|NCT00801918|DRUG|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
48293699|NCT03711019|DEVICE|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
48293700|NCT03711019|DEVICE|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
48293701|NCT02746679|OTHER|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
48293702|NCT06096194|DIETARY_SUPPLEMENT|vitamin D-enhanced egg|"In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks.~This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D"
48293703|NCT06096194|OTHER|Control|Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D
48293704|NCT05087823|DIETARY_SUPPLEMENT|Lipid Challenge|For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
48293705|NCT05087823|DIETARY_SUPPLEMENT|Glucose Challenge|For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
48293706|NCT05087823|DIETARY_SUPPLEMENT|Mixed Meal Challenge|For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
48293707|NCT06672510|DEVICE|ATC|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute P
48293708|NCT04660903|PROCEDURE|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
48293709|NCT05094440|BEHAVIORAL|Dialectical behavioral therapy skills training (DBT-ST)|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
48293710|NCT00148590|DRUG|Memantine|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
48293711|NCT00148590|DRUG|Placebo|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
48293712|NCT00659685|DRUG|Ondansetron|ODT, single-dose, fasting
48293713|NCT00659685|DRUG|Zofran ODT|
48293714|NCT05212532|DRUG|EOM613|peptide nucleic acid (PNA)
48293715|NCT05956574|BEHAVIORAL|Nutrigenomix, personalized dietary plan|Personalized dietary plan.
47945179|NCT00013468|PROCEDURE|Tinnitus|
48293716|NCT05956574|BEHAVIORAL|Physical Activity|Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.
48293717|NCT05956574|BEHAVIORAL|Behavioral counseling|Review behavioral counseling videos and participate in worksheets to assist with behavioral change.
48107164|NCT04980261|PROCEDURE|ORIF + autograft|Patients will undergo a standard open reduction internal fixation (ORIF) procedure with autograft implantation (from the iliac crest).
47945180|NCT04754243|DRUG|Gonadotropin|Giving patients gonadotropins and antagonist cetrotide
47945181|NCT04754243|DRUG|Standard protocol in IUI|Giving patients gonadotropins without antagonist cetrotide
47945182|NCT00596297|DRUG|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
48107165|NCT04980261|PROCEDURE|ORIF + FD BHA/Secretome|Patients will undergo an ORIF procedure and subsequently receive freeze-dried bovine hydroxyapatite/secretome composite implantation.
48293718|NCT05956574|BEHAVIORAL|Standard Dietary plan|Receive a standard dietary plan
48293719|NCT00806780|PROCEDURE|on table cholangiography|x-ray imaging of common bile duct
48293720|NCT05200351|BEHAVIORAL|Equine assisted Therapy (EAT)|15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
48293721|NCT05014282|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
48293722|NCT05014282|BEHAVIORAL|Counseling|Phone counseling with the state tobacco quitline.
48293723|NCT05014282|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
48293724|NCT05014282|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
48293725|NCT05760456|DRUG|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
48293726|NCT05760456|DRUG|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
48293727|NCT06513156|BEHAVIORAL|Integrated Infectious Diseases and Medication for Opioid Use Disorder Clinic (IC)|Integrated medication for opioid use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
48293728|NCT06513156|BEHAVIORAL|NavSTAR-CHOICE (NS)|Patient-centered social support intervention including motivational interviewing and patient navigation designed to overcome the barriers in accessing the recommended follow-up opioid use disorder treatment and medical care services for 6 months.
48293729|NCT02950623|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
48293730|NCT02950623|OTHER|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
48293731|NCT00259805|DRUG|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
48293732|NCT04634968|BEHAVIORAL|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
48293733|NCT04634968|BEHAVIORAL|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
48293734|NCT00307229|BIOLOGICAL|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
47945183|NCT00596297|PROCEDURE|pars plana vitrectomy|4 weeks after baseline
48103684|NCT05015868|DIAGNOSTIC_TEST|High density- electroencephalogram or 7 Tesla magnetic resonance imaging|"In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~* execution of High Density-electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~* 7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone (PI, italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
48103685|NCT02225600|DRUG|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
48293735|NCT06325709|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. The product is administered intravenously as a single infusion. This product is under an IND.
48293736|NCT06325709|DRUG|Busulfan|Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.
48293737|NCT06325709|DRUG|Palifermin|Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.
47945184|NCT03696173|OTHER|Non-Interventional|Non-Interventional
47945185|NCT03696173|OTHER|Non-Interventional|Non-Interventional
48103686|NCT02225600|DRUG|Placebo|Intranasal Placebo
48103687|NCT02225600|DRUG|24 IU intranasal Oxytocin|
48103688|NCT02605434|DRUG|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
48103689|NCT02605434|DRUG|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
48103690|NCT02605434|DRUG|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
48103691|NCT02605434|DRUG|Placebo- Sinemet|Placebo for Sinemet tables
47945186|NCT05753618|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
47945187|NCT05753618|DRUG|Omission of Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
47945188|NCT01833546|DRUG|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m\^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
48293738|NCT06325709|DRUG|Filgrastim|Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
48293739|NCT06325709|DRUG|Plerixafor|Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
48293740|NCT01665781|DRUG|Erythropoietin|
48293741|NCT03008512|DRUG|Genexol-PM|
48293742|NCT04815629|RADIATION|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
48293743|NCT03494725|DIETARY_SUPPLEMENT|Lpc-37|Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10\^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide
48293744|NCT03494725|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, magnesium stearate, silicon dioxide
48293745|NCT04263922|DRUG|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
48293746|NCT04263922|DRUG|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
48293747|NCT04561388|PROCEDURE|Electrocochleography|"Electrocochleographic responses will be evoked using different pure tone sounds delivered through an insert placed in the external auditory duct. The responses will be recorded with the electrodes of the cochlear implant connected to a dedicated interface.~Electrocochleographic responses will be collected continuously during the electrode-array insertion at the implantation surgery using 500Hz pure tone and after suturing with 250, 500, 750 and 1000Hz pure tones. Then, electrocochleographic responses to pure tones from 125 to 8000HZ (according to the subject residual hearing) will be recorded 2 weeks, 1 month, 2 months and 4 months after implantation."
48293748|NCT04561388|OTHER|Pure Tone Audiometry|"The perception thresholds to 125, 250, 500, 750, 1000, 2000, 4000 and 8000 Hz pure tones will be measured within the month preceding the implantation using the same insert t.~Pure tone audiometry with the same frequencies will be done 2 weeks, 1, 2 and 4 months after the implantation."
48293749|NCT04561388|OTHER|Speech audiometry|The speech perception will be assessed in silence and in noise in free field 1 and 4 months after implantation. The speech perception in silence will be assessed using monosyllabic words 60 dB SPL. Speech in noise will be assessed using an adaptative test with fixed noise level (60 dB SPL).
48293750|NCT05978284|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
48293751|NCT00538733|DRUG|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
48633158|NCT04887038|DRUG|SRT-015|Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 \& C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.
48633159|NCT04887038|OTHER|Matching Placebo for SRT-015|Matching Placebo
48293752|NCT00538733|DRUG|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
48293753|NCT00538733|DRUG|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
48293754|NCT00538733|DRUG|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
48293755|NCT06445335|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement.
48293756|NCT04449432|BEHAVIORAL|GROWell (Interactive Obesity Treatment Approach)|Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum
48293757|NCT04449432|BEHAVIORAL|Attention Support Control|Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
48293758|NCT03356847|DEVICE|Fitting of ocular implant|Removal of natural lens and replacement with a SISA monofocal intraocular implant
48293759|NCT06509100|DEVICE|Device: Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self- care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
48293760|NCT00906789|BEHAVIORAL|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
48293761|NCT02991950|DRUG|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
48633160|NCT05249400|PROCEDURE|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
48633161|NCT03922971|OTHER|Option 1: National comparison|Ability to view center's rate compared with all others.
47945189|NCT01833546|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
47945190|NCT05840718|DRUG|Thiamin|Patients in thiamine group received two daily dosis of 200 mg of thiamin diluted in 50 ml of 5% dextrose during 7 days
48293762|NCT03640897|DEVICE|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
48293763|NCT03640897|OTHER|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
48293764|NCT03640897|OTHER|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
48293765|NCT03690414|DRUG|Experimental BHVI2|Experimental BHVI2 eye drops
48293766|NCT03690414|DRUG|Atropine sulfate 0.02% eye drops|Atropine eye drops
48293767|NCT03690414|COMBINATION_PRODUCT|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
48293768|NCT00009594|PROCEDURE|Naturopathic Medicine|
48293769|NCT00009594|PROCEDURE|Traditional Chinese Medicine|
48293770|NCT00072722|DRUG|CC-4047|
48293771|NCT05868967|DRUG|[14C]DWP14012|Each subject will receive a single oral dose of \[14C\]DWP14012 suspension (containing approximately 40 mg/80 μCi \[14C\]DWP14012) under fasting conditions.
48293772|NCT06207175|BIOLOGICAL|Nonavalent HPV study vaccine|A 3-dose regimen administered at months 0, 2 and 6.
48293773|NCT06207175|BIOLOGICAL|GARDASIL® 9|A 3-dose regimen administered at months 0, 2 and 6.
48293774|NCT04533763|BEHAVIORAL|Technology-based Mindful Living program|The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
48293775|NCT04533763|BEHAVIORAL|Technology-based Healthy Lifestyles program|The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
48293776|NCT01411410|DRUG|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
48293777|NCT01411410|DRUG|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
48293778|NCT05018338|DEVICE|Brain shift monitoring|For use to monitor brain shift during craniotomy
48293779|NCT03088423|RADIATION|SBRT delivers high dose selective irradiation with millimeter precision to a small volume. The Cyberknife® is a robotic SBRT dedicated device that can deliver 100 to 200 photobeams to the target|Seven to ten days before the scheduled CT, 2-4 fiducial markers were implanted percutaneously 2 to 5 cm next to the lesion under sonographic guidance following administration of local anesthesia, thus allowing real-time tracking during treatment. The total dose delivered was 45 Gy on the 80% isodose, in three fractions over 10 days. Gross tumor volume (GTV) was defined as the tumor mass that could be discerned by diagnostic imaging. An isotropic margin of 5 mm was added to account for the microscopic extension (clinical target volume, CTV) and another 3 mm margin was added to compensate for uncertainties regarding the position (previsional target volume, PTV)
48633162|NCT03922971|OTHER|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
47945191|NCT04801173|COMBINATION_PRODUCT|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
48293780|NCT04760795|OTHER|PTSD Check List (PCL) scale|PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
48293781|NCT04760795|OTHER|Brief COPE scale|Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
48293782|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (during containment)|GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
47945192|NCT04801173|BEHAVIORAL|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
47945193|NCT01460589|PROCEDURE|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
47945194|NCT04012125|DEVICE|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
48293783|NCT04760795|OTHER|Analog scale|Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
48293784|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (post containment)|GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
48293785|NCT04760795|OTHER|Big Five Inventory (BFI) scale|Big Five Inventory (BFI) will be realized to evaluated personality.
48293786|NCT04760795|OTHER|Relationship Scales Questionnaire (RSQ)|Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
48633163|NCT01571609|OTHER|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes."
48293787|NCT02773992|BEHAVIORAL|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
48293788|NCT04260724|DEVICE|TMS|"* stimulation intensity : motor threshold 100%~* stimulation frequency : 1600 pulses for 20 minutes~* stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
48293789|NCT04260724|DEVICE|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
48293790|NCT00997412|DRUG|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
48293791|NCT00997412|DRUG|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
48633164|NCT01560988|DRUG|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
48633165|NCT01560988|DIETARY_SUPPLEMENT|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
47945195|NCT01155505|DRUG|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
47945196|NCT02289001|BEHAVIORAL|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
47945197|NCT03753269|DRUG|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
48103692|NCT04274543|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
48293792|NCT05111249|DRUG|Branaplam|messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.
48293793|NCT05111249|DRUG|Placebo|Matching placebo oral solution once weekly
48293794|NCT04399278|DIAGNOSTIC_TEST|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
48293795|NCT02850614|BEHAVIORAL|gaming application to encourage physical activity|
48293796|NCT02850614|DEVICE|FitBit|
48293797|NCT02521246|DRUG|Candesartan + Chlorthalidone|
48633166|NCT06539663|COMBINATION_PRODUCT|OmniLenz®|OmniLenz® applied for 1 week in all patients after development of corneal perforation
47945198|NCT03753269|DRUG|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
48293798|NCT02521246|DRUG|Candesartan + Chlorthalidone|
48293799|NCT02521246|DRUG|Losartan+hydrochlorothiazide|
48293800|NCT06672705|PROCEDURE|Biopsy|Undergo biopsy
48293801|NCT06672705|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48293802|NCT06672705|PROCEDURE|Computed Tomography|Undergo PET/CT
48293803|NCT06672705|BIOLOGICAL|Epcoritamab|Given SC
48293804|NCT06672705|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48293805|NCT03859999|DIAGNOSTIC_TEST|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
48293806|NCT04023422|BEHAVIORAL|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
48633167|NCT01146444|OTHER|UV A and B irradiation|UV irradiation
47945199|NCT03659786|OTHER|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
48293807|NCT04023422|BEHAVIORAL|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
48293808|NCT06365333|PROCEDURE|Fluoroscopic-guided air-enema reduction (FGAR)|A hand-held pump facilitated the delivery of atmospheric air, while pressure was monitored using a digital gauge. A two-way Foley's balloon catheter, ranging from 18oF to 24oF in diameter depending on age, was inserted rectally to introduce air. Following insertion, the balloon was filled with 10cc of saline to prevent air leakage, with patient immobilization ensured by leg straps and hand positioning above the head for abdominal exposure. Under intermittent fluoroscopy, the surgeon operated the pump with the right hand, inflating the catheter to 80 to 120 mmHg, simultaneously palpating the intussusceptum with the left hand, employing a deep gliding motion for deep and fixed cases. Successful reduction, indicated by air entry into the small bowel, was confirmed under fluoroscopy, with a subsequent brief rotating abdominal massage ensuring uniform air distribution throughout the small intestine, confirming complete reduction.
48293809|NCT01288378|DRUG|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
48293810|NCT00402350|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
48293811|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
48293812|NCT00402350|DRUG|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
48293813|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
48293814|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
48293815|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
48293816|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
48293817|NCT06633302|OTHER|Simulated multi-day heatwave exposure|Older adults exposed to a multi-day simulated heat wave exposure
48293818|NCT06672640|BEHAVIORAL|Remote Exercise Program|Participants in this group will engage in an eight-week exercise program conducted via video conferencing software. The sessions, which focus on balance, lower limb strength, and gait function, will be held twice weekly for 50 minutes each. Licensed physical therapists will supervise the sessions, and participants will exercise at home, with assistance from caregivers if necessary. The program aims to evaluate the effectiveness of remote exercise interventions in improving physical function and reducing the risk of falls in pre-frail older adults.
47945200|NCT05318937|DRUG|SAGE-718|Softgel capsules
47945201|NCT05318937|DRUG|SAGE-718-matching placebo|Softgel capsules
47945202|NCT02922595|DEVICE|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
48293819|NCT06672640|BEHAVIORAL|In-Person Exercise Program|Participants in this group will take part in an eight-week in-person exercise program at a senior welfare center. The sessions will be held twice weekly for 50 minutes and will be led by a licensed physical therapist. The exercise program, which includes balance, lower limb strength, and gait training, is identical to that of the remote exercise group, with the primary difference being the mode of delivery (in-person at the welfare center). This group aims to assess the effectiveness of direct supervision in a controlled environment.
48475823|NCT03822273|PROCEDURE|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz\]; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
48475824|NCT03822273|PROCEDURE|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
48475825|NCT05069233|OTHER|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
47945203|NCT02922595|DEVICE|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
47945204|NCT06152731|GENETIC|tests to determine HRD status|"Test Giscar AND test myChoice will be performed.~If one or two tests identifies a HRD status :~a PARP inhibitor treatment may be initiated according to current recommendations"
47945205|NCT05794412|OTHER|No intervention|No intervention
47945206|NCT03110744|DRUG|Palbociclib|application on 21 consecutive days of a 28 days cycle
47945207|NCT04701788|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.
47945208|NCT04171297|PROCEDURE|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
47945209|NCT04102670|DEVICE|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
47945210|NCT04102670|DEVICE|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
48633168|NCT04337255|OTHER|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
48633169|NCT04337255|OTHER|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
47945211|NCT04102670|DEVICE|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
47945212|NCT04102670|DEVICE|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
48633170|NCT00373711|DRUG|Iodine-124|2 mCi, oral
48293820|NCT06672640|OTHER|Physical Activity Education|Participants in this group will receive educational materials about physical activity, including a booklet and one educational session. They will not participate in any structured exercise program but will be encouraged to maintain their usual activities. The control group serves as a baseline to compare the outcomes of exercise interventions against no structured exercise, focusing on evaluating usual care versus targeted exercise programs.
48633171|NCT00373711|DRUG|Iodine-123|2 mCi, oral
48633172|NCT00373711|DRUG|F-18 FDG|10-15 mCi, iv
48293821|NCT03476551|DRUG|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
48633173|NCT01658735|DEVICE|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
48633174|NCT01658735|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
48633175|NCT01658735|DEVICE|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
48633176|NCT06190015|BIOLOGICAL|Advanced platelet rich fibrin (APRF) clots|15 minutes before surgery, phlebotomy will be performed and two vacutainers containing 10ml of blood will be placed in the centrifuge for 8 min and 200g. Acquired APRF clots will be placed in the extraction alveolus
47945213|NCT04102670|OTHER|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
47945214|NCT04252365|DRUG|Sintilimab|Given i.v.
47945215|NCT04252365|DRUG|Pembrolizumab|Given i.v.
48633177|NCT06190015|DEVICE|Enamel matrix derivative (EMD) group|After third molar removal, Pref Gel (EDTA) will be placed on the root surface for 2 min and then removed. Emdogain (EMD) will be placed on the collagen sponge (Botiss, Collacone) and then applied in the wound so that the side of the sponge which is covered with Emdogain is in contact with the root surface.
47945216|NCT03579576|DRUG|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
47945217|NCT06008028|DRUG|BR1015|One tablet administered alone
47945218|NCT06008028|DRUG|BR1015-1|One tablet administered alone
47945219|NCT06008028|DRUG|BR1015-2|One tablet administered alone
48293822|NCT00778323|PROCEDURE|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
48293823|NCT05590299|OTHER|Fish oral immunotherapy (codfish)|Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
48293824|NCT05590299|OTHER|Placebo oral immunotherapy|Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
48293825|NCT02077322|DEVICE|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
48293826|NCT02077322|DEVICE|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
48475826|NCT00151216|BIOLOGICAL|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
48475827|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
48293827|NCT03141801|DEVICE|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
47945220|NCT04637490|DEVICE|patellar component|patellar resurfacing
47945221|NCT02637336|DEVICE|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
47945222|NCT02637336|DEVICE|Aerobic exercise|aerobic exercise of moderate intensity
47945223|NCT02637336|DEVICE|Aromatherapy|inhalation of eucalyptus essential oil
47945224|NCT04447417|DRUG|Dupilumab SAR231893|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48293828|NCT03141801|OTHER|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
48293829|NCT03141801|OTHER|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
48633178|NCT00974233|DRUG|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
48633179|NCT00974233|DRUG|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
48293830|NCT02267512|DRUG|ATG-F|Intravenous (IV)
48293831|NCT02532543|BIOLOGICAL|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
48293832|NCT02532543|BIOLOGICAL|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
48293833|NCT02532543|BIOLOGICAL|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
48293834|NCT02532543|BIOLOGICAL|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
48293835|NCT01516801|OTHER|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
48633180|NCT00974233|DRUG|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
48293836|NCT06252714|DEVICE|Defecation Posture Modification Device|Patients will be asked to use the defecation posture modification device with each bowel movement for two weeks.
48293837|NCT05292391|BIOLOGICAL|Sm-p80|The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.
48293838|NCT05292391|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
48293839|NCT00010023|DRUG|capecitabine|
48293840|NCT00010023|DRUG|cisplatin|
48293841|NCT00988962|BEHAVIORAL|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
48293842|NCT02342171|OTHER|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
48293843|NCT04448249|BEHAVIORAL|APN intervention|"APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
48293844|NCT03133897|DRUG|Dexamethasone|experimental group will receive 2 day treatment
48293845|NCT03133897|DRUG|Prednisone|control group will receive 4 day treatment
48293846|NCT00598962|DRUG|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
48293847|NCT00598962|DRUG|Rifabutin/rifampin|
48293848|NCT01221545|DRUG|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
48293849|NCT01221545|DRUG|Placebo|Placebo
48475828|NCT00648245|DRUG|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
48475829|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
48475830|NCT00648245|DRUG|Placebo|Placebo given once daily for 21 days by nebulizer
48293850|NCT02827552|OTHER|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
48475831|NCT00648245|DRUG|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
48475832|NCT04024319|PROCEDURE|Genicular Nerve Block|4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
48475833|NCT02139618|DRUG|Methyl Aminolevulinate (MAL)|
48475834|NCT02139618|DRUG|Placebo|
48475835|NCT02073006|DIETARY_SUPPLEMENT|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
48475836|NCT04122781|DEVICE|Novel K-wire fixation devices|The patients received surgery using novel K-wire fixation devices
48475837|NCT02965664|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
48293851|NCT05537363|OTHER|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
48475838|NCT02965664|DRUG|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
48475839|NCT00914979|DEVICE|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
48475840|NCT03979833|GENETIC|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
48475841|NCT05886257|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
48475842|NCT05886257|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
48475843|NCT04395599|OTHER|Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.|Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
48475844|NCT01854255|DRUG|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
48475845|NCT04725591|DEVICE|Dexcom G6 Continuous Glucose Monitoring|Collection of glucose data
48475846|NCT04725591|DEVICE|MEDISAFE WITH External Insulin Pump|Insulin delivery
48475847|NCT04725591|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
48475848|NCT04725591|OTHER|Declaration of meals|Patient inputs related to meals
48475849|NCT04725591|OTHER|No declaration of meals|No patient inputs related to meals
48475850|NCT04725591|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
48633181|NCT03480516|DEVICE|SDF|38% silver diamine fluoride solution
48633182|NCT03480516|DEVICE|Fluoride varnish|5% sodium fluoride varnish
48633183|NCT06471166|DIAGNOSTIC_TEST|Amh hormone|Ovarian reserve
48633184|NCT05706402|DRUG|N-acetylcysteine|Patients will be randomized to receive oral N-acetylcysteine at 600 mg twice daily for 1 week. The randomization will be done via computer software with half of the patients randomized to receive NAC. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
48293852|NCT05537363|OTHER|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
48293853|NCT05537363|OTHER|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
48293854|NCT03057873|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
48293855|NCT03057873|DIETARY_SUPPLEMENT|Placebo|Dry powder to be mixed with 10 ounces of cold water
48293856|NCT04490954|DEVICE|brain biological electrical impedance tomography|Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
48293857|NCT04490954|DEVICE|MRI/CT|Patients diagnosed with brain supratentorial tumors through MRI/CT
48293858|NCT06602232|DRUG|DR-01|DR-01 will be administered via IV infusion.
48293859|NCT00750347|DRUG|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
48293860|NCT04281927|DEVICE|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
48293861|NCT06130384|DRUG|Use of bromfenac 0.09% to reduce intravitreal injection pain|The eyedrop (bromfenac) will be given to the assigned eye.
48293862|NCT06130384|DRUG|Use of artificial tears to reduce intravitreal injection pain|The eyedrop (artificial tears) will be given to the assigned eye.
48293863|NCT00818038|DRUG|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
48293864|NCT06480929|OTHER|Contrast TTE procedure, the SonoVue ultrasound agent|The intervention involved using contrast-enhanced transthoracic echocardiography (TTE) to improve the detection of left ventricular thrombus in patients with anterior ST-elevation myocardial infarction (STEMI).
48293865|NCT03482310|DEVICE|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
48293866|NCT03538873|BEHAVIORAL|Physical activity|
48475851|NCT05920330|OTHER|Nasal Plug|Please see the arm description for details.
48475852|NCT04615845|BIOLOGICAL|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
48475853|NCT01901172|DRUG|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
48475854|NCT01901172|DRUG|RO5503781|Daily for 5 days followed by 23 days rest per cycle
48475855|NCT01901172|DRUG|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
48475856|NCT01901172|DRUG|RO5503781|Single doses Days 1 and 11
48633185|NCT05706402|DRUG|Placebo|Patients will be randomized to receive placebo for 1 week. The randomization will be done via computer software with half receive placebo. Patients will also be given standard treatment for your COPD exacerbation and can continue the use of usual inhalers for COPD.
48293867|NCT00186238|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
48293868|NCT02769260|OTHER|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
48293869|NCT02747628|DRUG|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
48293870|NCT02747628|DRUG|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
48293871|NCT02747628|DRUG|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
48293872|NCT05134298|DRUG|Piperacillin/tazobactam, Meropenem|This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
48293873|NCT04664660|OTHER|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
48475857|NCT01901172|DRUG|posaconazole|Multiple doses Days 8-14
48475858|NCT03370107|DEVICE|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
48475859|NCT01709812|OTHER|individualized patient support program|individualized patient support with compliance supporting tools
48475860|NCT01709812|OTHER|Standard care|
48633186|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
48633187|NCT02816970|DRUG|Vildagliptin|1 tablet contains 50 mg vildagliptin
48293874|NCT06512220|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with or without risperidone 1 mg. It will also be administered in conjunction with supportive therapy.
48293875|NCT06512220|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with psilocybin 25 mg. It will also be administered with supportive therapy.
48293876|NCT04133753|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
48293877|NCT02749721|DRUG|vortioxetine|Open-label vortioxetine
48293878|NCT00230490|DRUG|pradefovir mesylate|
48293879|NCT00230490|DRUG|adefovir dipivoxyl|
48293880|NCT04489524|BEHAVIORAL|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
48293881|NCT04489524|BEHAVIORAL|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
48293882|NCT04489524|BEHAVIORAL|NRT|nicotine replacement therapy
48293883|NCT04635735|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
48293884|NCT03890276|OTHER|HMS EL&C training module|No additional information
48293885|NCT03890276|OTHER|Videos used to supplement live trainer|\[Cherrie to add\]
48293886|NCT00181688|DRUG|Iressa (ZD1839)|
48293887|NCT00181688|DRUG|Arimidex (Anastrozole)|
48293888|NCT00247481|DRUG|Gefitinib|
48293889|NCT00247481|DRUG|Docetaxel|
48293890|NCT04729127|BEHAVIORAL|Project ImPACT|Project ImPACT (Improving Parents As Communication Teachers) is an evidence-based parent-mediated intervention program based on best practices in early intervention. The program is designed for young children up to age six with social communication delays, including autism spectrum disorder. Project ImPACT focuses on social engagement, language, social imitation, and play. Project ImPACT is a naturalistic developmental behavioral intervention (NDBI).
48293891|NCT06511882|DRUG|Azacitidine|Standard of Care Intravenous (IV) infusion
48293892|NCT06511882|DRUG|Decitabine|Standard of Care Intravenous (IV) infusion
48293893|NCT06511882|DRUG|Venetoclax|Standard of Care PO (By Mouth)
48293894|NCT02377934|RADIATION|Cardiac Magnetic Resonance Imaging (MRI)|
48293895|NCT06611631|PROCEDURE|Hyaluronic acid pulpotomy|"1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown."
48293896|NCT06611631|PROCEDURE|mineral trioxide aggregate pulpotomy|"1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown."
48293897|NCT01952015|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
48293898|NCT03100331|OTHER|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
48293899|NCT00607360|BEHAVIORAL|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
48293900|NCT03546478|BIOLOGICAL|99mTc-ABH2|99mTc-ABH2 were injected into the patients before the SPECT/CT scans
48293901|NCT04952389|DEVICE|Acupuncture Therapy|Consists of two treatments per week for five weeks
48293902|NCT04952389|DRUG|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
48293903|NCT04952389|OTHER|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
48293904|NCT00455546|DRUG|A-002|
48293905|NCT06397261|DEVICE|LarynGuide|Artificial Intelligence assisted tracheal video intubation
48293906|NCT02743637|DRUG|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
48293907|NCT06246552|BIOLOGICAL|JTM201|"JTM201 20U in 0.5mL~: JTM201 will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
48293908|NCT06246552|BIOLOGICAL|Placebo|"Placebo 20U in 0.5mL~: Placebo will be injected via IM in 5 glabellar location 0.1mL (4U / 0.1mL) at each location"
48293909|NCT05484986|OTHER|A questionnaire with 47 items|A form consisted of questions on introductory characteristics (age, sex, and class, among others), Big Five Inventory (BFI) to evaluate personality traits, and Management of Workplace Violence Competence Scale for Nursing Students in Areas of Clinical Practice.
48293910|NCT04095910|BEHAVIORAL|Planet Nutrition program|"1. - Nutritional education sessions: The study team previously worked on the development of a handbook called Planet Nutrition which contains around 26 topics of nutrition and health. Interns from the Nutritional Sciences Degree of the University of Sonora implemented the sessions. 2 classes of 1 hour were given weekly, adding 18 sessions in total, during regular school hours. The program contemplates the establishment of different objectives.~2. - Physical activity: The classes were designed and implemented by interns from the Bachelor of Physical Culture and Sport from the University of Sonora along with a teacher from the study team. 3 weekly sessions of 1 hour were provided. The activities were held on the schoolyard court during normal school hours, independent of the physical activity classes of the school.~3. - Indirect family participation: Six information brochures with different nutrition and health topics were sent to parents."
48293911|NCT03686202|BIOLOGICAL|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
48293912|NCT03690518|OTHER|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
48293913|NCT04277702|DRUG|Montelukast 10mg|Oral administration of 10mg of montelukast daily for 12 months
48293914|NCT04277702|PROCEDURE|Endovascular treatment|Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries
48293915|NCT04277702|DRUG|Standard anti-platelet treatment|Standard antithrombotic treatment for patients undergoing endovascular procedures
48293916|NCT04275752|OTHER|Exercise Program|Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
48293917|NCT06672835|BEHAVIORAL|eBASIS|eBASIS is an online, optimized, and evidence-based practice agnostic implementation strategy that addresses the behavioral component often missing from standard evidence-based practice training and consultation. It relates to motivation before and volition after the evidence-based practice training and targets behavioral intentions by improving attitudes, subjective norms, and self-efficacy. The implementation strategy is designed to be designed to be delivered within the Preparation/Adoption phase immediately prior to the Action implementation in the EPIS model.
48293918|NCT06672835|BEHAVIORAL|eAttention Control|eAC is an online control for eBASIS. Providers assigned to eAttention Control (eAC) will receive pre- and post-training experiences designed to mirror those received in eBASIS. These training experiences will be delivered on the same platform and be approximately the same length as the eBASIS but will not contain any eBASIS content or mechanisms of change. The eAC pre-training experience will define, describe, and advocate for evidence-based practice implementation in schools. Content in eAC will be didactic similar to a typical professional development training for providers.
48293919|NCT02112266|OTHER|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
48293920|NCT02112266|OTHER|no mail support|follow-up without mail support
48293921|NCT01894282|PROCEDURE|Manual Therapy|Manual Therapy Arm
48293922|NCT01894282|PROCEDURE|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
48475861|NCT04372134|DEVICE|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (\>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
48475862|NCT00703976|DRUG|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
48475863|NCT00703976|DRUG|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
48475864|NCT00703976|DRUG|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
48475865|NCT00703976|RADIATION|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
48475866|NCT03767062|DRUG|Topamax|An antiepileptic agent used for migraine prophylaxis.
48293923|NCT03461692|DRUG|patients under 14 years of age using Reduning injeciton|To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
48293924|NCT06672393|DRUG|HS-10374 6mg tablets|Specified dose of HS-10374 tablets administered orally QD on specified days
48293925|NCT06672393|DRUG|HS-10374-matched placebo tablets|Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
48293926|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
48475867|NCT03767062|PROCEDURE|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
48475868|NCT02320162|BEHAVIORAL|Experiential learning oral health education|
48475869|NCT03195452|DRUG|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
48475870|NCT00801294|DRUG|BIBF 1120 and BIBW 2992|
48293927|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
48293928|NCT00336492|BIOLOGICAL|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
48293929|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
48475871|NCT05660863|DRUG|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
48633188|NCT03278145|GENETIC|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
48475872|NCT05660863|DRUG|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
48633189|NCT02655809|RADIATION|Fluoroscopic examination|
48633190|NCT02525432|BIOLOGICAL|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
48633191|NCT02525432|BIOLOGICAL|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
48633192|NCT03112850|DEVICE|Hearing aid|LOF hearing aid
48633193|NCT03112850|BEHAVIORAL|Auditory Training|
48475873|NCT00679250|DRUG|levocetirizine|5 mg once nightly before visit
48475874|NCT00679250|DRUG|placebo to levocetirizine|1 tablet once nightly before visit
47945225|NCT03652883|OTHER|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
48475875|NCT03844724|DEVICE|ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
48475876|NCT03844724|DEVICE|Peripheral Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
48633194|NCT00655746|DRUG|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
48633195|NCT01694771|DRUG|Tiotropium|Marketed dose
48633196|NCT01694771|DRUG|Placebo matching Olodaterol|One dose
48633197|NCT01694771|DRUG|Olodaterol|One dose
47945226|NCT03652883|OTHER|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
47945227|NCT04126551|OTHER|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
47945228|NCT04418284|OTHER|survey|online survey
47945229|NCT01043146|DRUG|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
47945230|NCT01043146|DRUG|placebo|intravenous 0.9 % NaCl
47945231|NCT03141073|DRUG|HMS5552|BID oral administration
47945232|NCT03141073|DRUG|Placebo|BID oral administration
47945233|NCT03507062|OTHER|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
47945234|NCT03507062|OTHER|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
47945235|NCT03507062|OTHER|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
47945236|NCT00886184|PROCEDURE|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
47945237|NCT00886184|PROCEDURE|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
47945238|NCT03072732|DEVICE|u-Cor System|Monitoring System
47945239|NCT03072732|DEVICE|ZOE Fluid Status Monitor|Monitoring System
47945240|NCT03308955|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
47945241|NCT03308955|PROCEDURE|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
48475877|NCT04186598|DEVICE|CPAP mask system|Intervention group will receive 15cm of H2O of positive end expiratory pressure
48475878|NCT04186598|DRUG|Nifedipine 30 MG|All participants will receive this intervention
48475879|NCT04186598|DEVICE|CPAP mask system without PEEP|Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
48475880|NCT02642237|BIOLOGICAL|Fluenz|intranasal inoculation with Fluenz
48633198|NCT01694771|DRUG|Tiotropium|Marketed dose
48633199|NCT00400088|DRUG|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
48293930|NCT06671990|DRUG|Vericiguat|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
48293931|NCT06671990|DRUG|Placebo|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
47945242|NCT03308955|PROCEDURE|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
47945243|NCT04504279|BIOLOGICAL|FB-401|Topical application
47945244|NCT04504279|BIOLOGICAL|Placebo|Vehicle
47945245|NCT01323946|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
47945246|NCT02022631|OTHER|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
48103693|NCT04274543|DRUG|Normal Saline|"Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions."
48475881|NCT02642237|OTHER|placebo|
48633200|NCT00400088|DRUG|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
47945247|NCT02022631|OTHER|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
47945248|NCT02528175|DEVICE|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
47945249|NCT02528175|RADIATION|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
47945250|NCT02528175|DRUG|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
47945251|NCT04539873|DRUG|Colchicine 0.5 MG|Patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. The duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.
48103694|NCT01803516|BEHAVIORAL|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
48103695|NCT03357341|DEVICE|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
48103696|NCT03357341|DEVICE|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
48103697|NCT03357341|DRUG|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
48103698|NCT03357341|DEVICE|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
48103699|NCT03357341|OTHER|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
48293932|NCT00225368|DEVICE|Insecticide treated bednets|
48475882|NCT02642237|OTHER|LPS|
48475883|NCT04417647|DEVICE|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
48475884|NCT04417647|PROCEDURE|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
48475885|NCT06377020|BEHAVIORAL|PACT2|Behavioral lifestyle intervention
48633201|NCT02239484|DRUG|Tadalafil|
48633202|NCT02239484|DRUG|Tamsulosin|
48633203|NCT02239484|DRUG|Tadalafil + Tamsulosin|
48103700|NCT03357341|OTHER|CAT|Subjects will be required to complete CAT monthly.
48475886|NCT01392326|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
48103701|NCT03357341|OTHER|ACT|Subjects will be required to complete ACT monthly.
48475887|NCT01392326|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
48475888|NCT01392326|DRUG|Placebo Comparator|Placebo Comparator
48475889|NCT06331117|DIAGNOSTIC_TEST|Diagnostic test|Multiomics profiling
48475890|NCT01100450|BEHAVIORAL|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
48475891|NCT04479748|DRUG|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
48475892|NCT04479748|DRUG|Prednisolone Acetate 1% Oph Susp|Topical steroid
48633204|NCT00452530|DRUG|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
47945252|NCT04539873|COMBINATION_PRODUCT|CONTROL GROUP|In this case, the centers where the patients are enrolled will adhere to the Colombian guidelines (Colombian Consensus of the Colombian Association of Infectious Diseases)
47945253|NCT04091009|DRUG|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
48633205|NCT00452530|DRUG|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
48633206|NCT00452530|DRUG|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
48633207|NCT00452530|DRUG|Apixaban-matching placebo|Oral tablet administered twice daily
48633208|NCT04549168|DRUG|Lemborexant|Lemborexant 10 mg tablet.
48633209|NCT04549168|DRUG|Placebo|Placebo tablet matched to lemborexant 10 mg tablet.
48633210|NCT05001412|DRUG|Camrelizumab; apatinib; carboplatin; etoposide|2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
48633211|NCT01260753|DRUG|UR-63325|UR-63325
47945254|NCT04091009|DRUG|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
47945255|NCT02385370|DRUG|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
48103702|NCT02685280|DEVICE|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
48633212|NCT01260753|DRUG|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
48633213|NCT01260753|DRUG|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
48475893|NCT01331577|BEHAVIORAL|Cognitive Behavioural Training|Two day seminar
47945256|NCT02385370|DRUG|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
47945257|NCT01589328|OTHER|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
47945258|NCT06058078|DRUG|RY_SW01 cell injection|Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
47945259|NCT06058078|DRUG|Basic treatment|Drugs for LN treatment
47945260|NCT01316354|OTHER|Bread types|Bread with 50 g available carbohydrate
47945261|NCT03773211|DRUG|Renaparin|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
47945262|NCT03773211|DRUG|Placebo|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
47945263|NCT02215031|DRUG|BI 44370|
47945264|NCT02215031|DRUG|Placebo|
47945265|NCT05273307|DIETARY_SUPPLEMENT|Miraculin|Given orally
47945266|NCT05273307|DIETARY_SUPPLEMENT|Miracle Fruit Placebo Cube|Given orally
48103703|NCT05580796|DRUG|KSH01 injection|TCR-T cell injection
48475894|NCT01331577|BEHAVIORAL|Integrative Kinesiology Intervention|Two day seminar
48475895|NCT04590768|OTHER|Fermotein based meals|various meal products: bread, soup and an occasional burgers
47945267|NCT00750386|DRUG|Paclitaxel|175 mg/m2, I.V, every 2 weeks
48475896|NCT04590768|OTHER|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
48475897|NCT04351230|DRUG|Abemaciclib|Given IV
48475898|NCT04351230|BIOLOGICAL|Trastuzumab Emtansine|Given PO
48475899|NCT04826068|BEHAVIORAL|Emotional Processing|Processing Emotions of others based on photographs of faces
48475900|NCT03294616|DEVICE|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
48475901|NCT02246686|DRUG|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
48475902|NCT02246686|DRUG|Placebo|Application over 12 weeks 20 drops three time daily
48475903|NCT05488886|DIETARY_SUPPLEMENT|Whole Aronia Berry Powder Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).
48475904|NCT05488886|DIETARY_SUPPLEMENT|Aronia Berry Extract Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).
47945268|NCT00750386|DRUG|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
48103704|NCT06027307|DRUG|Enavogliflozin|All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
48633214|NCT04632030|BEHAVIORAL|Tobacco power wall size and tobacco products displayed|The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
48633215|NCT02557893|BEHAVIORAL|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
48633216|NCT02557893|OTHER|Education|Bimonthly pregnancy education classes
48633217|NCT02557893|OTHER|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
48633218|NCT01428973|DRUG|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
48633219|NCT01428973|DRUG|Sirolimus|Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
48633220|NCT02372084|DRUG|osilodrostat|
48633221|NCT05597891|DEVICE|Hēlo PE Thombectomy System|Treatment with the Hēlo PE Thombectomy System for thromboembolectomy
48633222|NCT04315207|BEHAVIORAL|Telephone call|"All patients are informed that they will receive a telephone call between 08 AM and 5 PM on workdays, as soon as the results of invasive workup are available. This is expectedly 3 to 5 days after invasive workup. At the telephone call, patients are free to ask for a later call, to summon relatives, to turn on the loud speaker, and/or ask the physician to call one relative of choice to share the information.~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
48633223|NCT04315207|BEHAVIORAL|In-person meeting|"All patients are provided a written and verbal appointment date 5 workdays after invasive workup, and that they will receive a telephone call if 1) results are not available at the time of the meeting, and/or 2) if results need urgent action (such as small-cell lung cancer).~At the in-person meeting, patients are free to invite family and relatives (up to 4 persons, restriction due to space available).~Regardless of group, all patients are informed on the possibility of malignancy at every patient-physician encounter."
48633224|NCT00803907|DRUG|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
48633225|NCT00305279|OTHER|Dietary|Dietary
48633226|NCT00305279|OTHER|Dietary|Dietary
48633227|NCT00305279|OTHER|Dietary|Dietary
48633228|NCT02834442|DRUG|MT-7117|
47945269|NCT03847870|DIAGNOSTIC_TEST|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
47945270|NCT01291654|DRUG|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
47945271|NCT01291654|DRUG|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
47945272|NCT01291654|DRUG|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
47945273|NCT06174259|OTHER|intermittent fasting|16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
47945274|NCT04504773|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants will receive a single session of virtual reality exposure therapy that targets the participant's specific phobia stimuli.
48103705|NCT06027307|DRUG|Placebo|All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
48293933|NCT01134887|OTHER|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
48633229|NCT02834442|DRUG|Placebo|
48633230|NCT02294019|DRUG|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
48633231|NCT01032343|DIETARY_SUPPLEMENT|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
48633232|NCT01032343|DIETARY_SUPPLEMENT|Gelatine|One capsule daily for 3 months
48633233|NCT05343507|DRUG|Ketalar 50 MG/ML Injectable Solution|Intravenous solution (other info already provided)
48633234|NCT05343507|DRUG|Placebo|Saline Solution
48633235|NCT00445120|DRUG|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
48633236|NCT00445120|DRUG|placebo (sugar)|Placebo will be administered to patients once daily for six months
48633237|NCT01141790|OTHER|Music and voice message|
48633238|NCT00365820|DRUG|Tegaserod|
48633239|NCT03508453|BIOLOGICAL|IC14|Monoclonal antibody against CD14
48633240|NCT03508453|OTHER|Placebo|sterile normal saline for injection prepared to be identical to study drug
48633241|NCT02272010|OTHER|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
48633242|NCT02272010|OTHER|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
48633243|NCT05192083|BEHAVIORAL|Self-management and Support|A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
48293934|NCT01134887|BEHAVIORAL|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
48293935|NCT01134887|OTHER|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
48293936|NCT01134887|BEHAVIORAL|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor \[Coaching\]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
47945275|NCT06352658|DEVICE|Conventional mandibular advancement device|With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.
48293937|NCT01134887|OTHER|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
48293938|NCT02438072|DRUG|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
48293939|NCT01123304|DRUG|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
48293940|NCT06580119|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
48293941|NCT00002195|DRUG|Amprenavir|
48293942|NCT00002195|DRUG|Lamivudine|
47945276|NCT06352658|DEVICE|CAD CAM mandibular advancement device|"3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape).~Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by"
47945277|NCT06185127|DRUG|Dexmedetomidine|Dexmedetomidine solution of 1 μg/kg dissolved in 60 ml saline was administered over 15 minutes, followed by a maintenance dose of 0.5 μg/kg/h (continuous infusion).
47945278|NCT06185127|DRUG|Ketamine|A bolus dose of 50 mg ketamine dissolved in 10 ml saline was given 15 minutes after Dexmedetomidine initiation.
47945279|NCT06185127|DRUG|Midazolam|Bolus doses of midazolam (5 mg midazolam dissolved in 10 ml saline; 2 ml of the solution or 1 mg midazolam per bolus, premedication dose of 2mg, induction dose of 2 mg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 12 mg of midazolam were administered.
47945280|NCT06185127|DRUG|Fentanyl|Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
47945281|NCT03161132|DRUG|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
48103706|NCT01267838|PROCEDURE|PCI|PCI of bifurcation lesions with double stenting
48103707|NCT03872869|OTHER|Hip school or Tai CHi for arthritis|Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
48293943|NCT00002195|DRUG|Zidovudine|
48293944|NCT06410391|DEVICE|Ultrasound|"Gestational age, biparietal diameter and head circumference are measured. then 2 techniques are used according to the 2007 International Society of Ultrasound in Obstetrics and Gynecology guidelines for a US evaluation of the fetal central nervous system (CNS) (10) : 1- the axial transventricular technique including the posterior portions of the lateral ventricles, falx, CSP, and Frontal horn 2- the trans-cerebellar technique, including the cerebellum, cisternal magna, cerebellar peduncles, CSP, and FHs. CSP visualization and width, FH width, anterior horn width (AHW), center from the horn distance (CFHD), upside and downside measurement.~The corpus callosum is identified in the midsagittal plane. The image selected for CC measurement in addition to cerebellar vermis and cisterna magna"
48293945|NCT04776369|DRUG|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
48293946|NCT04776369|DRUG|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
47945282|NCT03161132|DRUG|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
48103708|NCT02327104|BEHAVIORAL|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
48293947|NCT04776369|DRUG|IV saline|Saline IV 50 ml
48293948|NCT00636623|OTHER|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
48103709|NCT02327104|OTHER|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
48103710|NCT00983164|DIETARY_SUPPLEMENT|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
48103711|NCT00092898|DRUG|MK0653, ezetimibe|
48475905|NCT05488886|DIETARY_SUPPLEMENT|Phospholipid-Polyphenol Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).
48475906|NCT05488886|OTHER|Low-Polyphenol Control Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.
47945283|NCT04266223|DEVICE|Mask-free surface monitoring|Mask-free headrest and couch for patient positioning for radiation therapy combined with a surface monitoring system
47945284|NCT00150540|DRUG|Lanthanum carbonate|
47945285|NCT01810211|OTHER|Horizontal Adduction Stretch and Pendulums|
47945286|NCT01810211|OTHER|Modified Sleeper Stretch and Pendulum|
47945287|NCT04342234|OTHER|data collection of palatal casts and palatal images of cleft patients routinely treated at the institution|data collection of palatal casts and palatal images of cleft patients, using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity
47945288|NCT03392077|PROCEDURE|Caesarean section|Caesarean section will be done to deliver the baby
47945289|NCT03392077|OTHER|cervical dilatation|Cervical dilatation will be done by double gloves digital dilatation postpartum
47945290|NCT03392077|OTHER|No cervical dilatation|after delivery of the baby cervix will be remain closed
47945291|NCT00690222|PROCEDURE|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
47945292|NCT04645888|PROCEDURE|Impacted tooth surgery|Surgical extraction of İmpacted tooth
47945293|NCT00411437|DRUG|Tolterodine ER|
48475907|NCT05486832|DEVICE|Cardiovalve TR valve replacement System|The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
48475908|NCT05141786|DRUG|MRG002|Administrated intravenously
48475909|NCT05352477|OTHER|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
48475910|NCT05352477|OTHER|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
48475911|NCT00544817|RADIATION|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
48475912|NCT00544817|DRUG|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
48475913|NCT00544817|DRUG|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
47945294|NCT00411437|DRUG|Oxybutynin ER|
48103712|NCT00092898|DRUG|Comparator: placebo|
48103713|NCT05288348|DRUG|Sufentanil 30 MCG Sublingual Tablet|30 microgram sublingual tablet administered using sublingual applicator
48103714|NCT05288348|DRUG|standard care pain treatment|standard care pain treatment given in Emergency Department
48103715|NCT05936892|OTHER|upper extremity aerobic training|upper extremity aerobic training \& baseline treatment will be given. Overall session time will be 40-45 minutes
48103716|NCT05936892|OTHER|upper extremity resistance training|upper extremity resistance training Overall session time will be 40-45 minutes
48103717|NCT00627874|DEVICE|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
48103718|NCT01043549|DEVICE|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
48103719|NCT01043549|DEVICE|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
48103720|NCT01958541|BEHAVIORAL|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
48103721|NCT01958541|BEHAVIORAL|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
48475914|NCT00602537|DRUG|Venlafaxine|75 to 375 mg
48475915|NCT00602537|DRUG|Lithium Carbonate|300 to 2400 mg
48475916|NCT04065061|DIETARY_SUPPLEMENT|Erinacine A-enriched Hericium Erinaceus Mycelia|
48475917|NCT04065061|DIETARY_SUPPLEMENT|Placebo|Placebo supplement was given to the participants.
48475918|NCT06386419|DRUG|inclisiran|Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively
48475919|NCT04152369|PROCEDURE|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
48475920|NCT01459263|DEVICE|ClariVein|Using the ClariVein device, the GSV will be occluded.
48475921|NCT00851409|DRUG|Recombinant Human C1 Inhibitor|"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."
48475922|NCT04051216|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention
48475923|NCT04051216|OTHER|Activity monitor|Participants will receive at least 1 of 4 activity monitoring devices
48475924|NCT04051216|OTHER|Interview|Participants will be interviewed about their experience using the device(s)
48475925|NCT04051216|OTHER|Survey Administration|Participants will receive surveys
48475926|NCT04051216|OTHER|Laboratory Biomarker Analysis|Correlative studies
48475927|NCT00406016|DRUG|ATI355|
48475928|NCT05600881|DRUG|Methylphenidate|Participants will take their regular medication or a placebo (vitamin C)
48475929|NCT04908280|DRUG|Ruxolitinib|1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
48103722|NCT04842669|OTHER|low level laser therapy|Endo-laser 422 with interchangeable laser probes will be used for the purpose. It is a 2-channel unit and is software operated. For treatment of small surfaces with mono laser there are diodes of 25, 100 and 500 milliWatt.Frequency will be adjusted to 500 Hz, dose 0.1/cm2 with time duration of 1-5 minutes.
48475930|NCT04975347|DRUG|Naloxone|One bolus and one infusion of naloxone
48633244|NCT06130904|BEHAVIORAL|Academic detailing|"Eligible dentists/oral surgeons will have one visit (30 minutes or less) at the dentist's office. During the initial visit, the detailers will discuss the evidence against routine opioid prescribing to adolescents and young adults for most common surgeries performed by dentists and oral surgeons, the harms of dental opioid exposure in adolescents and young adults, and the benefits and feasibility of relying on non-opioids as a first line option for routine dental procedures among adolescents and young adults. A survey will be completed to assess the satisfaction regarding the intervention. A professionally designed packet of information on reducing use of opioids for routine procedures will also be given.~There may also be a second optional follow-up visit conducted virtually for any participants that wish to discuss further with the detailer. The second visit may occur any time between the initial visit and March 31, 2024."
48633245|NCT00490412|DIETARY_SUPPLEMENT|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
48633246|NCT00490412|OTHER|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
48633247|NCT00899847|PROCEDURE|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
48633248|NCT00899847|PROCEDURE|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
48633249|NCT00899847|DRUG|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
48633250|NCT00899847|DRUG|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
48633251|NCT00899847|DRUG|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
48103723|NCT04842669|OTHER|Conservative treatment|(Topical ibuprofen gel) for muscle soreness will be provided
48103724|NCT01923948|DRUG|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
48103725|NCT01923948|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
48103726|NCT02889341|DIETARY_SUPPLEMENT|DHA|
48103727|NCT02889341|OTHER|Placebo|
48475931|NCT05861219|BEHAVIORAL|water immersion|mild physical activity then water immersion in tub
48475932|NCT01465932|OTHER|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
48475933|NCT01465932|OTHER|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
48475934|NCT02092337|OTHER|computer-assisted speech training|
48475935|NCT06422481|OTHER|Fluid administration|Patients will receive fluid administration (500 mL of saline over 30 minutes). The indication of fluid administration will be left to the discretion of the attending physician.
48475936|NCT06422481|OTHER|Norepinephrine administration or increase in norepinephrine dosage|Patients will receive norepinephrine or norepinephrine dosage will be increased if necessary to achieve the appropriate mean arterial pressure level. The indication of norepinephrine administration or increase in norepinephrine dosage will be left to the discretion of the attending physician.
48620046|NCT04019639|DEVICE|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
48633252|NCT00899847|DRUG|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
48633253|NCT00899847|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
48633254|NCT00899847|BIOLOGICAL|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
48633255|NCT00899847|DRUG|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
48633256|NCT00899847|DRUG|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
47945295|NCT00526604|BEHAVIORAL|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
48103728|NCT03317535|PROCEDURE|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
48633257|NCT00899847|DRUG|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
47945296|NCT02521766|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
47945297|NCT02521766|DEVICE|Commercially Available Intraocular Lens|IOL per investigator's standard of care
47945298|NCT02521766|PROCEDURE|Optic exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
47945299|NCT01066000|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
47945300|NCT04134052|DRUG|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
47945301|NCT02520661|BEHAVIORAL|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
47945302|NCT00206310|DRUG|CRESTOR|
47945303|NCT01056731|DRUG|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
47945304|NCT05833334|BEHAVIORAL|Public health infographic (AIM 3)|Standard public health infographic about home air radon testing, plus information about requesting a free home air radon test kit
47945305|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit
48103729|NCT03317535|PROCEDURE|Local anesthesia/concious sedation|Patients will be injected with propofol and remifentanil.
48103730|NCT03317535|PROCEDURE|Spontaneous breath|Patients will be kept spontaneous breath.
48103731|NCT03317535|PROCEDURE|Controlled ventilation|Patient will be kept with controlled ventilation.
48103732|NCT00770965|BIOLOGICAL|AIN457|
48103733|NCT00770965|BIOLOGICAL|Placebo|
48293949|NCT00636623|OTHER|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
48293950|NCT05198167|OTHER|Hyperoxygenated fatty acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
48633258|NCT00899847|DRUG|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
48633259|NCT00899847|DRUG|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
48633260|NCT03426488|BEHAVIORAL|VIP - Västerbotten Intervention Programme|Intervention on CVD (cardiovascular disease) and diabetes
48633261|NCT02452658|OTHER|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
48633262|NCT06419309|OTHER|Dietary intervention|"Four different dietary interventions are planned.~* Gluten-free, lactose-free diet,~* Diet enriched with Aronia Melanocarpa,~* Gluten-free, lactose-free and enriched with Aronia Melanocarpa diet,~* Healthy diet"
48633263|NCT04954443|PROCEDURE|Removing urinary catheter|Removing urinary catheter after vaginal surgery of pelvic organ prolapse
48293951|NCT05198167|OTHER|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
48633264|NCT04695626|PROCEDURE|The combination of bone marrow stimulation and modified suture bridge(Greenhouse tec)|According to the anteroposterior diameter of the injury, single or double high braided thread were used to suture the tendon in a modified Mason Allen way without knotting. Bone marrow stimulation was carried out in the footprint area of rotator cuff. A 2.0 mm diameter cone was created with a depth of 1 cm and a spacing of 5 mm. Six to eight holes were made due to the diameter of the tear of rotator cuff until blood and fat droplets exudate. Then the threads were passed through the locking eyelet of the lateral row anchor. After tightening the threads, the anchor was screwed in at the distal part of the gteater tuberosity. With this new technique, the rotator cuff was repaired by one lateral row anchor without medial row knotting.
48633265|NCT02305459|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
48293952|NCT01073072|PROCEDURE|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
47945306|NCT05833334|BEHAVIORAL|Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3)|Online health promotion intervention with messaging about home air radon testing tailored by the participant's stated smoking status, plus information about requesting a free home air radon test kit, plus reminder messages about home air radon testing sent over two months
47945307|NCT05833334|BEHAVIORAL|Focus group with educational overview (AIM 1)|90-minute online focus group discussion about home air radon testing, plus an educational overview about home air radon testing using a standard public health infographic
47945308|NCT04462510|PROCEDURE|Block/Local infiltration|One group received ILI/IHG Block and the other group received local anesthetic infiltration for pain relief
47945309|NCT03802227|DRUG|NKTR-181|A combination of NKTR-181 and oxycodone IR placebo
47945310|NCT03802227|DRUG|Oxycodone IR|A combination of oxycodone IR and NKTR-181 placebo
47945311|NCT04400942|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis
48103734|NCT05864482|OTHER|Psychosocial nursing intervention|The sessions were planned to be at least 45 minutes in a time suitable for the groups, with the bed curtains drawn if possible. Session 1: The purpose of this session; Brief CIS information will be provided. Session 2: The session starts with mood control of individuals. It is discussed whether they have experienced an event that occupies their minds and is likely to affect their illness. Session 3: It starts with mood control of individuals. They are asked if there is anything from the places where the guests are. Cognitive reviews are reviewed. It aims to describe recent stressful observations, negative automatic outcome descriptions, and evaluation of such experiences. 4.Session: The session starts with the mood control of the patient. It is discussed whether the patient has experienced an event that occupies his mind. Continuous analysis of negative thoughts and review of cognitive techniques and coping mechanisms are provided.
48103735|NCT04124263|OTHER|Educational short message texts|Educational messages for patient engagement
48103736|NCT04124263|OTHER|Adherence short message texts|Reminder messages of medication use time
48293953|NCT01073072|PROCEDURE|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
48293954|NCT06071286|PROCEDURE|Blood samples|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
48293955|NCT05260255|DRUG|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
48293956|NCT05260255|DRUG|Placebo|add on placebo ( 2 cap ) for 12 weeks
48293957|NCT04795180|DRUG|Irrigations trough the efferent limb of loop ileostomy|Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
48293958|NCT06522854|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
48633266|NCT02305459|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
48633267|NCT03204747|OTHER|Observational study : gait speed|No intervention, only propose water and wait for need to void
47945312|NCT04400942|BEHAVIORAL|Anamnesis|Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas
48633268|NCT04633720|OTHER|Changes in positive end-expiratory pressure and tidal volume|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
48633269|NCT01712074|DRUG|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
48633270|NCT01712074|OTHER|Placebo|Placebo QD
48633271|NCT03409146|DEVICE|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
47945313|NCT04400942|PROCEDURE|Operative hysteroscopy|Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
47945314|NCT00402272|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
47945315|NCT00573248|DRUG|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
48633272|NCT05569889|PROCEDURE|Anterior Cruciate Ligament reconstruction (ACLR)|A comparison between the two groups were done regarding the three following stages: (a) the preparation time of the trolley, which is the time taken by the CNOR to recover from the reserves all the single-packed sterile instruments (SPSI) necessary for the intervention or to recover the CST (b) the opening time of the instruments by the circulating nurse who opens the packages and gives them to the surgical nurse while respecting the sterility of the items, and by the surgical nurse who prepares the table for the intervention, and (c) the sorting time of the waste between plastic and paper at the end of the intervention.
48633273|NCT04900857|OTHER|Dry needle|Local twitch responses (LTRs) were obtained by multiple rapid insertions of the needle in and out of the point, similar to Hong's rapid-entry and rapid exit technique. Hong 1994). The needle was not removed from that site for the maximum stimulation time of 1 minute to 3 minutes after a local twitch response was obtained.
48633274|NCT04900857|DEVICE|Localize vibration|the vibration was applied with 110 Hz and 5.57 mm amplitude.
47945316|NCT00573248|OTHER|Placebo|Placebo Patch
47945317|NCT05718804|OTHER|Whether renal injury occurred and differences in intestinal flora|Whether renal injury occurred and differences in intestinal flora
48293959|NCT06522854|DRUG|Placebo Oral Tablet|Placebo tablet given orally every eight hours up to three times while mother is in labor
48633275|NCT01261377|DEVICE|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
47945318|NCT03235843|DEVICE|AAIR pacing|Rate adaptive pacing using a MV sensor.
47945319|NCT03235843|DEVICE|DDI-pacing|Rate adaptive pacing OFF
47945320|NCT02044835|DRUG|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
47945321|NCT05107427|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
47945322|NCT05107427|BIOLOGICAL|Avelumab 20 mg/mL Intravenous Solution (IV)|"Avelumab is an IV administered monoclonal antibody that blocks the interaction of programmed death ligand-1 (PD-L1) with its receptors PD-1 and B7.1 on T cells and antigen-presenting cells, and has been shown to activate adaptive and innate immune functions.~The study dosing regimen is 800 mg (four 20mL vials of 20mg/mL solution) for IV infusion once every two weeks"
48103737|NCT00608907|DRUG|bortezomib|1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
48103738|NCT00608907|DRUG|bortezomib, rifampicin|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
47945323|NCT03852004|OTHER|ostheopathy|standardized osteopathic treatment
47945324|NCT03852004|OTHER|simulated osteopathic treatment|standardized simulated osteopathic treatment
47945325|NCT01702571|DRUG|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
47945326|NCT04282278|DRUG|Camrelizumab/sintilimab+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
47945327|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）|Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
47945328|NCT04282278|DRUG|Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy|Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
47945329|NCT05792423|DEVICE|GE ultrasound system with increased acoustic output settings|We will perform liver stiffness measurements with standard settings and an increased acoustic output enhanced ultrasound system. Pre and post ultrasound LFTs will be collected to monitor unexpected liver tissue damage.
48633276|NCT01261377|DRUG|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
48293960|NCT06671951|OTHER|Focal Vibration|Focal vibration is a 3x3 electrode placed on the athlete's muscle belly, and emits a high frequency vibration (150Hz) to stimulate the muscle spindle and generate greater muscle activation.
48293961|NCT06671951|OTHER|Sham focal vibration|Is a focal vibration intervention but without conctact in the athelte's skin. Doing this we got a sham therapy
48293962|NCT05746780|PROCEDURE|Elective bilateral neck dissection in cN0 patients|Radical modified type 3 selective bilaterale elective neck dissection
48293963|NCT02355379|DRUG|LV5FU2 or capectitabine|
48293964|NCT02355379|DRUG|FOLFOX4 or XELOX|
48620047|NCT04019639|DEVICE|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
48633277|NCT01261377|DEVICE|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
48633278|NCT02610257|DEVICE|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
48633279|NCT01631929|OTHER|One bag|Infusion of dextrose and electrolytes using one bag
48633280|NCT01631929|OTHER|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
48633281|NCT06176131|OTHER|Telemedicine-based cross-sector collaboration for patient management|Telemedicine support from the hospital-based cardiology heart-failure team is provided on demand defined by the needs from Primary Care and from the patient rather than plain guideline-based targets
48633282|NCT04724200|DIAGNOSTIC_TEST|Echocardiogram|Echocardiography plays a crucial role in the diagnosis of HF; it is the standard of care imaging modality used to confirm the diagnosis, it permits real-time imaging of the heart and quantitative assessment of cardiac structure and function, crucial for diagnosis.
48633283|NCT00224354|BIOLOGICAL|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
47945330|NCT00014404|DRUG|celecoxib|
48103739|NCT00608907|DRUG|bortezomib, dexamethasone|bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
48293965|NCT02355379|OTHER|Observation|
48293966|NCT02355379|DRUG|LV5FU2 or capecitabine|
48293967|NCT02279329|OTHER|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
48293968|NCT00155285|PROCEDURE|computed tomography|
48293969|NCT03078725|DRUG|Glyburide|oral hypoglycemic agent
48293970|NCT03078725|DRUG|Metformin|oral hypoglycemic agent
48293971|NCT05882162|PROCEDURE|Coronectomy|Removal of crown part of the mandibular third molar
48620048|NCT05859698|DRUG|Valbenazine|Valbenazine capsules for oral administration
48633284|NCT00224354|BIOLOGICAL|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
48633285|NCT00224354|BIOLOGICAL|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
48633286|NCT00224354|DRUG|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
48633287|NCT00224354|BIOLOGICAL|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
48633288|NCT02046200|DRUG|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
48633289|NCT02046200|DRUG|Placebo|Matched placebo
47945331|NCT01646073|BIOLOGICAL|Adalimumab|adalimumab eow
47945332|NCT01646073|BIOLOGICAL|placebo|placebo
48293972|NCT05882162|PROCEDURE|Pulp Capping with calcium silicate|Application of a pulp capping material (BiodentineTM, Septodont, St Maur-des-Fosses, France) on pulp tissue to preserve the vitality of the residual pulp and prevent inflammation
48293973|NCT05652868|DRUG|MYTX-011|MYTX-011 will be administered as an intravenous infusion every 21 days.
48293974|NCT02278185|DRUG|Enzalutamide|Given PO
48293975|NCT02278185|DRUG|leuprolide acetate|Given SC or IM
48293976|NCT02278185|DRUG|goserelin acetate|Given SC or IM
48293977|NCT02278185|DRUG|histrelin acetate|Given SC or IM
48293978|NCT02278185|DRUG|triptorelin|Given SC or IM
48293979|NCT02278185|DRUG|degarelix|Given SC or IM
48293980|NCT02905773|OTHER|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
48293981|NCT02905773|OTHER|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
48293982|NCT00597558|DRUG|Egg white protein|Egg white protein powder
48293983|NCT03232723|DIAGNOSTIC_TEST|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
48633290|NCT02046200|DRUG|Alcohol|
48633291|NCT00398242|DEVICE|above or below elbow cast for the last 3 weeks of treatment|
48633292|NCT03416933|OTHER|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
48103740|NCT02929511|PROCEDURE|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
48475937|NCT06471309|DEVICE|Theta burst transcranial magnetic stimulation|The stimulation intensity of TBS was 80%RMT, with a total of 600 pulses, five times a week for two weeks. In the bilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the unilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the sham stimulation group, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. When giving sham stimulation, put the coil vertically so that the coil is perpendicular to the patient's skull surface , it will not produce real therapeutic effect.
48633293|NCT03832452|DRUG|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
47945333|NCT03929627|OTHER|Cortisol awakening response|Cortisol awakening response
47945334|NCT04650776|OTHER|Heat strain|The experimental procedure comprised 15 min baseline seated rest (23.2 ± 0.3°C, 24.5 ± 1.6% relative humidity), followed by 15 min seated rest and cycling in a climatic chamber (35.4 ± 0.2◦C, 56.5 ± 3.9% relative humidity; to +1.5◦C or maximally 38.5°C rectal temperature, duration 20-60 min), with a final 30 min seated rest outside the chamber.
48103741|NCT02929511|PROCEDURE|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
48103742|NCT02929511|PROCEDURE|Active comparator Protaper multi-file system|
48103743|NCT00909935|DRUG|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
48633294|NCT03832452|OTHER|Placebo|hard capsules for oral administration
48633295|NCT03832452|DRUG|Moxifloxacin|400 mg; film-coated tablets for oral administration
48633296|NCT03832452|DRUG|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
48633297|NCT03832452|DRUG|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
48633298|NCT04846257|OTHER|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is the acquisition of sequential images during the passage of a contrast agent within a tissue of interest.
48633299|NCT02944461|DRUG|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
47945335|NCT03866525|BIOLOGICAL|OH2 injection, with or without irinotecan or HX008|OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
48103744|NCT04347135|DRUG|F-18 FES|F-18 FES PET/MRI for detection of endometriosis.
48103745|NCT05708066|OTHER|Lavender Aromatherapy|"Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.~After the lavender patch has been in place for 5 minutes, the same VAS anxiety questionnaire will be provided"
48293984|NCT01452425|DEVICE|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
48293985|NCT01452425|DEVICE|INVOS assessment|Near Infraread spectroscopy, non invasive
48293986|NCT01452425|DEVICE|EMG assessment|Electromyography, non invasive
48293987|NCT00325572|DRUG|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
48293988|NCT00325572|OTHER|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
48293989|NCT00003530|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
47945336|NCT01672229|DRUG|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
48633300|NCT01205737|BIOLOGICAL|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
48633301|NCT01205737|BIOLOGICAL|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
47945337|NCT02644031|PROCEDURE|mtwo rotary system|post-treatment pain after using mtwo rotary system
47945338|NCT02644031|PROCEDURE|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
48293990|NCT06673342|BEHAVIORAL|Nutritional Counseling|Nutritional counseling based on Stephan's Curve. The Stephan's curve is a diagram that shows how the acidity of the oral cavity changes with consumption of food, specifically with added sugar. A laminated Stephan's curve will be used to show the drop of pH (acidity) based on the subject's reported daily consumption of food and snacks. Recommendations will be provided on a balanced diet according to the American Dental Association guidelines and recommendations on reducing the frequency of snacking.
48293991|NCT02240498|DRUG|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
48293992|NCT02240498|DRUG|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
48633302|NCT06137547|DEVICE|Hypotension prediction index (HPI)|The hypotension prediction index (HPI) is a value derived from the arterial pressure waveform. It was invented by Edwards Lifesciences through a machine-learning algorithm, and can be calculated with Acumen Hypotension Prediction Index software incorporated in HemoSphere advanced monitoring platform (EV1000). This value, ranging from 0 to 100, predicts the likelihood of a patient trending towards a hypotensive event, which is defined as mean arterial pressure below 65 mmHg for at least one minute.
48633303|NCT00147537|DRUG|CP-751,871|"Phase 2 Arm A:~CP-751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
48633304|NCT00147537|DRUG|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
48633305|NCT00147537|DRUG|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles"
48633306|NCT00147537|DRUG|CP-751,871|Phase 1b Dose Escalation/Expansion: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
48475938|NCT02807441|DRUG|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
48475939|NCT04540718|OTHER|Exercise|50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
48103746|NCT05708066|OTHER|Non-scented Tab|A non-scented tab will be placed on the participant's chest, according to manufacturer recommendations. Participants in this group will only receive the initial VAS anxiety questionnaire.
48103747|NCT01322958|DEVICE|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
48475940|NCT04540718|OTHER|Sauna|15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
48475941|NCT05470322|DEVICE|Er: YAG laser|Patients will be treated with laser for their HS scarring.
48475942|NCT00964106|DRUG|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
48475943|NCT00964106|DRUG|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
48475944|NCT00964106|DRUG|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
47945339|NCT02644031|PROCEDURE|hand files|post-treatment pain after using hand files
47945340|NCT04169100|DRUG|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
48103748|NCT00335023|OTHER|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
48103749|NCT03960619|BEHAVIORAL|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
48475945|NCT00964106|DRUG|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
48475946|NCT00964106|DRUG|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
48475947|NCT00964106|DRUG|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
48633307|NCT00147537|DRUG|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
48633308|NCT00147537|DRUG|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
48475948|NCT00964106|DRUG|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
48475949|NCT00964106|DRUG|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
48475950|NCT00964106|DRUG|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
47945341|NCT00586131|DRUG|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
47945342|NCT00586131|DRUG|Sodium citrate/citratic acid|dictated by pH
47945343|NCT00791310|DRUG|Flucis|FDG injected i.v
47945344|NCT03143881|BEHAVIORAL|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
47945345|NCT00591344|BEHAVIORAL|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
47945346|NCT00591344|BEHAVIORAL|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
48475951|NCT00964106|DRUG|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
48475952|NCT00964106|DRUG|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
48475953|NCT05945667|DRUG|Monural|1 sachet, only 1st day of trial
48475954|NCT05945667|DIETARY_SUPPLEMENT|UroNext|1 sachet per day for the first 7 days, followed by 7 days break Same scheme to be repeated for 3 months
48475955|NCT02678871|DEVICE|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
48475956|NCT02678871|DEVICE|WATCHMAN|LAA closure with the WATCHMAN device
48475957|NCT00867048|DRUG|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
48475958|NCT01164215|DRUG|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
48475959|NCT01164215|DRUG|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
48475960|NCT01164215|DRUG|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
48475961|NCT03705949|DRUG|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
48475962|NCT03705949|DRUG|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
48475963|NCT05390398|BEHAVIORAL|Behaviour change guided lifestyle intervention|Participants in the intervention group receive personalized coaching from a lifestyle coach on adhering to the World Cancer Research Fund cancer prevention guidelines. The lifestyle coach is specialized in behaviour change techniques and uses these as the core of the lifestyle coaching. For each participant behavioural determinants will be assessed and targeted with specific applicable behaviour change techniques.
48475964|NCT04938973|PROCEDURE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
48475965|NCT04938973|PROCEDURE|Open Transthoracic Esophagectomy (OTE)|Open Transthoracic Esophagectomy (OTE) is the current standard of care.
47945347|NCT01240876|DRUG|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
47945348|NCT01240876|DRUG|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
47945349|NCT05635071|DRUG|Nintedanib 100 MG [Ofev]|Nintedanib 100mg bid \*15 days orally after hysteroscopic surgery
47945350|NCT05635071|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg bid \*15 days orally after hysteroscopic surgery
47945351|NCT02584699|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
47945352|NCT01884623|DRUG|Cetuximab|
47945353|NCT01884623|DRUG|Methotrexate|
47945354|NCT02874287|DRUG|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
47945355|NCT02874287|DRUG|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
47945356|NCT03779958|OTHER|Mobile App|a mobile app that demonstrates hand therapy exercises
47945357|NCT02360111|DRUG|Cyclophosphamide|
47945358|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
48633309|NCT00147537|DRUG|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
47945359|NCT04151329|BIOLOGICAL|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
47945360|NCT01822704|DEVICE|Low intensity whole body vibration|
47945361|NCT01822704|DEVICE|High intensity whole body vibration|
48633310|NCT03733483|BEHAVIORAL|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
48633311|NCT05082155|DRUG|Bupivacaine 0.25%|Bupivacaine 0.25% will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
48633312|NCT05082155|DRUG|Normal Saline|Normal saline will be delivered as a basal infusion of 1 mL/h and an automatic intermittent bolus of 20 mL every 4 hours.
48633313|NCT02144818|DRUG|Ovitrel|Triggering of ovulation with Ovitrel
48633314|NCT02144818|DRUG|Decapeptyl|Triggering with GnRH agonist
48633315|NCT01128920|BEHAVIORAL|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
48633316|NCT01128920|OTHER|No intervention - assessment-only condition|No intervention is assigned in this condition
48633317|NCT01885234|OTHER|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
48633318|NCT01885234|OTHER|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
48475966|NCT04938973|DEVICE|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE)|Robotic Assisted Minimally Invasive Esophagectomy (RAMIE) will be performed using the Da Vinci Robotic Surgical Platform.
48475967|NCT02101788|DRUG|Letrozole|Given PO
48633319|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|Roux-en-Y
48633320|NCT00746161|PROCEDURE|Reconstruction after total gastrectomy|double tract reconstruction
48633321|NCT06122051|RADIATION|Dynamic chest x-ray|Group A and Group B- posterior-anterior dynamic chest x-ray film (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
48475968|NCT02101788|DRUG|Paclitaxel|Given IV
48475969|NCT02101788|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48475970|NCT02101788|OTHER|Quality-of-Life Assessment|Ancillary studies
48475971|NCT02101788|OTHER|Questionnaire Administration|Ancillary studies
48633322|NCT06122051|DIAGNOSTIC_TEST|Spirometry|Group A and Group B- Spirometry lung function test (Group A, This will represent an additional intervention not part of standard clinical care) (Group B, People with CF, already have this as part of their annual review process)
47945362|NCT01822704|BEHAVIORAL|Leg exercises|
47945363|NCT03143543|DRUG|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
48633323|NCT00312962|BEHAVIORAL|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
48633324|NCT00312962|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
48633325|NCT01512537|RADIATION|Narrowband UVB|UVB 3 times a week
48633326|NCT01512537|DIETARY_SUPPLEMENT|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
47945364|NCT03143543|DRUG|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
47945365|NCT03143543|OTHER|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
47945366|NCT03143543|OTHER|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
47945367|NCT02126371|DRUG|LEO32731|
47945368|NCT03436836|DRUG|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
47945369|NCT03436836|DRUG|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
48475972|NCT02101788|DRUG|Tamoxifen Citrate|Given PO
48633327|NCT00625378|DRUG|Sorafenib (Nexavar, BAY43-9006)|At the same dose and schedule as in the participants' original clinical trials
48633328|NCT05130021|DRUG|MAX-40279-01|MAX-40279-01 50mg/70mg
48633329|NCT05130021|DRUG|regorafenib|regorafenib
48633330|NCT05374993|DEVICE|3TBA|Induce third molar tooth bud agenesis
48633331|NCT00156130|RADIATION|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
48633332|NCT00156130|RADIATION|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
48633333|NCT04443777|OTHER|Resistance Training|Both groups will perform the resistance training protocol that will consist of a warm-up on the bench press and leg press, both with workload at 50% of 1-RM. After a 2-minute rest, the resistance training session will be started. It will consist of 4 sets of bench press and leg press exercises at 65% of 1-RM with maximum repetitions until concentric failure, with the execution speed of 2x2. The bench press exercises will be followed by the leg press exercises with no interval between them. A 2-minute interval will allowed after each series of exercises.
48633334|NCT00986583|DRUG|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
48633335|NCT04151641|DIETARY_SUPPLEMENT|MNGDPF|Standardized mangosteen extract in dry powder form
47945370|NCT03436836|DRUG|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
48475973|NCT02101788|DRUG|Topotecan|Given IV
48475974|NCT02101788|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
48475975|NCT05352282|PROCEDURE|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
48633336|NCT04151641|DIETARY_SUPPLEMENT|MNGEF|Standardized mangosteen extract in encapsulated form
48633337|NCT03810794|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
48633338|NCT03810794|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
48633339|NCT03028922|DEVICE|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
48633340|NCT04771871|DRUG|Epirubicin|Epirubicin is an antitumor antibiotics with good activity on breast cancer. It has less cardiotoxic effect than doxorubicin
47945371|NCT02562768|DRUG|LY3154207|Administered orally
47945372|NCT02562768|DRUG|Placebo|Administered orally
47945373|NCT02497612|DRUG|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
47945374|NCT02497612|DRUG|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
47945375|NCT02497612|OTHER|Placebo|Capsules. Placebo capsules were used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No participant received placebo only.
47945376|NCT00032032|DRUG|carboplatin|
47945377|NCT00032032|DRUG|paclitaxel|
47945378|NCT00032032|RADIATION|radiation therapy|
47945379|NCT03300323|DIAGNOSTIC_TEST|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
47945380|NCT01942473|DEVICE|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
47945381|NCT04302818|BEHAVIORAL|SKOLKONTAKT|N=21 participants are offered manualized and structured group training SKOLKONTAKT. The intervention includes 12 weeks, 3 sessions (50 minutes) per week.
48633341|NCT04771871|DRUG|Cyclophosphamide|Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
48293993|NCT02240498|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
48633342|NCT04771871|DRUG|Paclitaxel|Paclitaxel is a taxane chemotherapy agent indicated for the treatment of many cancers including breast cancer. It can be used alone or in combination with other drugs
48633343|NCT04771871|DRUG|Carboplatin|Carboplatin is a platinum compound indicated for the treatment of many types of malignancies including breast cancer
47945382|NCT04302818|BEHAVIORAL|Social activity group|N=21 participants. The active comparison group includes 12 weeks, 3 sessions (50 minutes) per week. Sessions will include socially oriented activities such as board games, sports or baking as well as a recommended, general agenda.
47945383|NCT02958501|DRUG|Colecalciferol|Drug
47945384|NCT00410202|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
48293994|NCT02240498|DEVICE|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
48293995|NCT02240498|DEVICE|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
48293996|NCT02240498|DEVICE|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
47945385|NCT00410202|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily
47945386|NCT00410202|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
47945387|NCT00410202|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
47945388|NCT06146881|DRUG|Diquafosol sodium 3%|Diquafosol sodium 3% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
47945389|NCT06146881|DRUG|Sodium hyaluronate 0.1%|Sodium hyaluronate 0.1% 4 times a day for 4 weeks before cataract surgery and 21 days after surgery
47945390|NCT00880373|DRUG|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
47945391|NCT00880373|DRUG|Placebo|Matching placebo three times daily for 4 days
48293997|NCT02240498|DEVICE|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
48293998|NCT02240498|DEVICE|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
48293999|NCT02240498|DEVICE|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
48475976|NCT05352282|PROCEDURE|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
48475977|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
48475978|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
48475979|NCT00051818|BEHAVIORAL|Treatment interruption/reinitiation schedule|
48475980|NCT06269913|OTHER|FeSC|Iron/yeast complex
47945392|NCT00880373|DRUG|Diamorphine or Morphine|Diamorphine or Morphine by PCA
48103750|NCT02886897|BIOLOGICAL|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
48294000|NCT02240498|DEVICE|Optical spectroscopy measurement|A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
48294001|NCT00530712|DEVICE|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
48294002|NCT00693381|DRUG|Tacrolimus|oral
48294003|NCT00693381|DRUG|Mycophenolate Mofetil|oral
48294004|NCT00693381|DRUG|methylprednisolone and prednisone|IV and oral
48475981|NCT03067740|DRUG|Bupivacaine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
48475982|NCT03067740|DRUG|Dexmedetomidine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
48475983|NCT03509662|DRUG|Vitamin C|Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).
48475984|NCT03509662|DRUG|Thiamine|All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
48475985|NCT03509662|DRUG|Placebos|One group receives a placebo.
48475986|NCT01374724|BEHAVIORAL|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
48475987|NCT01374724|BEHAVIORAL|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
48633344|NCT00005922|BEHAVIORAL|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
48633345|NCT00005922|DRUG|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
48633346|NCT00005922|OTHER|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
48633347|NCT00841074|DRUG|chlorhexidine|0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
47945393|NCT03561753|DRUG|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
48103751|NCT05818306|DRUG|BL-001|Live biological product BL-001
48103752|NCT05818306|DRUG|Placebo|Placebo
48103753|NCT03787706|OTHER|Dry Needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
48103754|NCT03787706|OTHER|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
47945394|NCT03561753|DRUG|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
48103755|NCT06553807|OTHER|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes.|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes. Pre-test and post-test will be applied to the participants after 4 weeks. Follow-up test data will be collected from the intervention and control groups after 3 months.
48103756|NCT03395353|DRUG|Duloxetine Hydrochloride|Administered orally
48103757|NCT05015517|PROCEDURE|Erector spinae plain block|Patients will be placed in the lateral position.Ultrasonography will be performed by an experienced anesthetist.The 4th lumbar vertebral level will be determined using the conventional method (imaginary line between two iliac crests). The low frequency convex probe (2-5MHz) will then be placed at the mid-vertebral line in the sagittal plane. It will be shifted from the midline, 3.5-4 cm lateral to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-plane technique a 22G/80-mm block needle will be advanced until it reaches the transverse process. After negative aspiration, 0.5-1 ml of the prepared local anaesthetic solution (20 ml bupivacaine 0.5%, 10 ml lidocaine 2%) and 10 ml normal saline will be administered for hydrodissection to confirm correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when injecting local anesthesia
48294005|NCT03356314|OTHER|MRI between 30-35 GA|MRI between 30-35 GA
48294006|NCT03356314|OTHER|Pediatric surgeon meeting|Pediatric surgeon meeting
47945395|NCT03838965|DEVICE|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
48294007|NCT03356314|OTHER|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
48294008|NCT03356314|OTHER|+/- prophylactic surgery|+/- prophylactic surgery
48294009|NCT01656616|DRUG|Cyanide antidote administration|
48294010|NCT01713400|DRUG|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
48294011|NCT01713400|DRUG|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
48294012|NCT01713400|DRUG|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
48294013|NCT01713400|DRUG|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
48475988|NCT01374724|BEHAVIORAL|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
48475989|NCT01374724|BEHAVIORAL|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
48475990|NCT03997786|DRUG|Tildrakizumab|Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
47945396|NCT03364790|PROCEDURE|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
48294014|NCT03656640|DRUG|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
48294015|NCT00933335|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
48475991|NCT03997786|DRUG|Placebo|(Weeks 0 to 16)
48475992|NCT03997786|DRUG|Tildrakizumab|(Weeks 16 to 52)
48475993|NCT03997786|DRUG|Tildrakizumab|at every 12 weeks in open label fashion till 5 years (240 weeks).
48475994|NCT03997786|DRUG|Tildrakizumab|(Weeks 0 to 16)
48475995|NCT03997786|DRUG|Etanercept|(Weeks 0 to 16)
48475996|NCT03997786|DRUG|Placebo|(Weeks 16 to 52)
48294016|NCT01003587|BEHAVIORAL|District health information package|"The intervention package consists of:~* A report on disease burden, disease control priorities and health system performance in India~* Condensed fact sheet based on the report~* District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~* Customized speech for district level officials detailing key actions to reduce deaths~* Reminder materials including poster version of the DRCs and video on key points and actionable messages"
48103758|NCT05015517|PROCEDURE|Fascia Iliaca block|"Patients will be placed in supine position. Ultrasonography will be performed by an experienced anesthetist using ultrasound device equipped with a low frequency (2-5 MHz) convex probe and an echogenic 21 G/ 10 cm needle will be used.~The probe will be placed in the inguinal crease. Scan will be started laterally from the femoral artery and nerve in the inguinal crease to identify the Sartorius muscle. The muscle will then be traced until its origin at the anterior superior iliac spine is identified and the shadow of the bony of iliac crest \& iliacus muscle will be seen. Injection will be performed at the plane deep to the fascia iliaca and above the lateral part of the iliacus muscle. After negative aspiration, the prepared local anaesthetic solution (15 ml bupivacaine 0.5%, 15 ml normal saline) will be injected incrementally, aspirating every 5 ml."
48103759|NCT01447914|DRUG|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
48103760|NCT01447914|OTHER|Diagnostic laboratory biomarker analysis|Correlative studies
48103761|NCT01447914|OTHER|Questionnaire administration|Ancillary studies
48103762|NCT01447914|PROCEDURE|Quality-of-life assessment|Ancillary studies
48103763|NCT05928364|PROCEDURE|Buccal mucosa for proximal ureter stricture|Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping
48103764|NCT02385669|DRUG|Ipilimumab|Checkpoint blockade inhibitor
48103765|NCT02385669|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
47945397|NCT03364790|PROCEDURE|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
47945398|NCT04478123|DRUG|Romiplostim|Romiplostim 3.0 mcg/kg SC on Day +1 and Romiplostim 2.0 mcg/kg SC on Day +8 after HDT-AHCT. Beyond Day +8, patients will be treated weekly until platelet count is \>50,000/mcL, without any platelet transfusions in the prior 48 hours. All doses after the second Romiplostim dose will be titrated as per Table 3, based on weekly CBC/platelet counts. Patients will receive a maximum of six weekly doses of romiplostim.
48103766|NCT01402271|DRUG|carboplatin|
48103767|NCT01402271|DRUG|paclitaxel|
48103768|NCT01402271|DRUG|pazopanib hydrochloride|
48294017|NCT06341712|DRUG|Cabozantinib|Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.
48294018|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
48294019|NCT06341712|OTHER|Best Supportive Care (BSC)|Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
48475997|NCT00161681|DRUG|Levonorgestrel/Ethinyl Estradiol|
48475998|NCT05621187|DEVICE|Pamira ICD lead family|Implantation, measurements and follow-up schedule
48475999|NCT03608306|OTHER|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
47945399|NCT04033198|PROCEDURE|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
47945400|NCT06150755|PROCEDURE|implant supported overdenture by ball|overdenture supported by two implant with ball attachment
47945401|NCT06150755|PROCEDURE|implant supported overdenture by bar|overdenture supported by two implant splinted by intraoral welding titanuim bar
47945402|NCT05237271|OTHER|Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)|Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.
48103769|NCT01402271|OTHER|laboratory biomarker analysis|
48103770|NCT01402271|OTHER|pharmacological study|
48103771|NCT04330430|DRUG|T-VEC|The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10\^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10\^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
48103772|NCT03899480|BIOLOGICAL|Haploidentical Natural Killer (NK) Cells|infusion with N-803 activated NK cells
48103773|NCT05984641|DEVICE|CONAN® Proctological Cream|The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
48103774|NCT05380505|BEHAVIORAL|Racially Congruent Ads|Facebook food ads that are racially congruent.
48294020|NCT06671522|OTHER|Survey|It is a qualitatative research. Only a survey.
48294028|NCT04542291|DRUG|Dapagliflozin|Dapagliflozin will be provided for this trial
48294029|NCT04542291|DEVICE|BIOSENSE meters|-Being used in this trial to evaluate utility for assessing breath ketones
48294030|NCT03634046|PROCEDURE|Percutaneous transforaminal endoscopic discectomy|The same as the descriptions in experimental group.
48294031|NCT03634046|PROCEDURE|Radiofrequency ablation|The same as the descriptions in active comparator group.
48294032|NCT06158841|DRUG|ABBV-383|Intravenous (IV) Infusion
48294033|NCT06158841|DRUG|Carfilzomib|IV Infusion
48294034|NCT06158841|DRUG|Pomalidomide|Oral Capsule
48103775|NCT05380505|BEHAVIORAL|Racially Incongruent Ads|Facebook food ads that are racially incongruent.
48294035|NCT06158841|DRUG|Elotuzumab|IV Infusion
48294036|NCT06158841|DRUG|Selinexor|Oral Tablet
48294037|NCT06158841|DRUG|Bortezomib|Subcutaneous or IV Injection
48294038|NCT06158841|DRUG|Dexamethasone|Oral Tablet or IV Infusion
48294039|NCT00267254|DRUG|torcetrapib/atorvastatin|
48294040|NCT00267254|DRUG|simvastatin|
48294042|NCT06029712|DRUG|Heart failure polypill|Copackaging of heart failure medications (beta blocker, SGLT2i, MRA, and ACE/ARB/ARNI) in an overencapsulated polypill. Individual tablets will be hand-packed into a single capsule at the level of the pharmacy. Specific medications and doses will be individualized to the participant.
48294043|NCT06029712|DRUG|Control Rx|GDMT delivered as individual tablets
48294044|NCT05115461|DEVICE|Biodex Balance System™ SD|Postural stability index values (anteroposterior, mediolateral and overall) will be measured for static and dynamic conditions.
48294045|NCT05115461|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
48294046|NCT01753518|DEVICE|Subcuticular suture|subcuticular Monocryl suture closure
48294047|NCT01753518|DEVICE|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
48294048|NCT04570449|DRUG|Fluoxetine|20 mg capsule
48294049|NCT04570449|DRUG|Placebo|fluoxetine placebo capsule
48294050|NCT01566344|OTHER|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
48294051|NCT01223248|RADIATION|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
47945403|NCT05237271|OTHER|Educational Materials on the CVD-T2D and Bundled Metabolic Panel|Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.
47945404|NCT04407052|DRUG|Double trigger|Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
47945405|NCT04407052|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
48103776|NCT05818800|DEVICE|digital solution|randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions
48294052|NCT01223248|RADIATION|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& within 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
48294053|NCT06671067|DEVICE|Remote dielectric sensing system|The remote dielectric sensing (ReDS) system is a non-invasive medical device that emits a low-power electromagnetic signal through the chest and lungs, which can accurately measure changes in lung fluid concentration.
48294054|NCT02564822|PROCEDURE|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
48476000|NCT03608306|OTHER|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
48476001|NCT01311427|BEHAVIORAL|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
48476002|NCT01311427|BEHAVIORAL|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
48476003|NCT05458037|PROCEDURE|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
48476004|NCT03187587|DEVICE|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
48476005|NCT03187587|DRUG|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
48476006|NCT04193319|DRUG|Fluzoparib|PARP inhibitor
48476007|NCT04193319|DRUG|Fluconazole|inhibitor
48476008|NCT05909969|OTHER|Pelvi-Fit app Training|This group will receive Pelvic Floor Muscle Strengthening exercises through software application.
48476009|NCT05909969|OTHER|Control|This group will receive Pelvic Floor Muscle Strengthening exercises through instructions and pamphlets describing exercises.
48476010|NCT01359748|DEVICE|Reference sphygmomanometer|\* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
48476011|NCT01359748|DEVICE|Sphygmomanometer under test|Electronic Oscillometric method.
48476012|NCT05549050|OTHER|interdialytic weight gain|interdialytic weight gain during hemodialysis
48476013|NCT01714739|DRUG|Lirilumab|Specified dose on specified days.
48476014|NCT01714739|DRUG|Nivolumab|Specified dose on specified days.
48476015|NCT01714739|DRUG|Ipilimumab|Specified dose on specified days.
48476016|NCT04105114|DRUG|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
48476017|NCT04105114|DEVICE|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
48476018|NCT04105114|DEVICE|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
48476019|NCT04105114|DEVICE|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
48476020|NCT04105114|DEVICE|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
48476021|NCT04105114|DEVICE|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
48633348|NCT00841074|DRUG|Placebo mouthwash|Placebo mouthwash spray application of \~1.3 ml twice a day.
47945406|NCT00003976|DRUG|indisulam|
48103777|NCT05818800|OTHER|Standard Care|randomised controlled trial where patients with hypertension will be randomised r to standard care
48476022|NCT00625326|DRUG|COL-121|75 µg/g COL-121 Ointment
48476023|NCT00625326|DRUG|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
48476024|NCT00625326|DRUG|Placebo|Placebo
48476025|NCT00625326|DRUG|COL-121|150 µg/g COL-121 Ointment
48476026|NCT00625326|DRUG|COL-121|300 µg/g COL-121 Ointment
48476027|NCT00680069|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
48476028|NCT05397795|DRUG|10000 IU hCG (Choriomon5000 IU; IBSA)|10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
47945407|NCT04844775|BIOLOGICAL|Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L|"1. Drep-HIV-PT1 The DREP-HIV-PT1 is a vaccine designed to elicit an immune response against human immunodeficiency virus-1 (HIV-1) and prevent infection by HIV-1 and/or disease caused by HIV-1. It is an alphavirus-based DNA replicon in which the sequences coding for the viral capsid and envelope have been replaced by the sequences encoding HIV-1 gp140 (96ZM651) antigen.~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
47945408|NCT04844775|BIOLOGICAL|DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)|"1. Drep-HIV-PT1 1mg (see above)~2. Drep-HIV-PT1 1mg (see above)"
47945409|NCT04844775|BIOLOGICAL|DNA-HIV-PT123 4mg and CN54gp140/MPLA-L|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef~2. CN54gp140/MPLA-L Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity."
47945410|NCT03424668|BEHAVIORAL|diet|lifestyle factors
47945411|NCT03572751|DIAGNOSTIC_TEST|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
47945412|NCT05074043|COMBINATION_PRODUCT|antiviral, surgical|surgical debridment
47945413|NCT00960739|DRUG|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
47945414|NCT00960739|PROCEDURE|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
47945415|NCT00960739|RADIATION|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
47945416|NCT00960739|RADIATION|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
47945417|NCT05199740|OTHER|in vitro analysis|in vitro analysis of mesoangioblasts from mtDNA mutation carriers
47945418|NCT05686954|OTHER|CSO LOW|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.
47945419|NCT05686954|OTHER|CSO MID|Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.
47945420|NCT05686954|OTHER|CSO HIGH|Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.
48294055|NCT05887856|OTHER|comprehensive educational program for reduction of Pre-Operative Anxiety|"BSEP 1 makes use of modern media and aims to educate patients and their carers through educational videos comprising of various aspect of surgical treatment.~1. Introduction to surgery by consultant surgeon, Patient to receive video of their own surgeon.~2. Introduction to Anesthesia.~3. What are different type of breast surgeries in cancer patients (General Video)~4. Specific video pertaining to the type of surgery patient is undergoing (Mastectomy, Breast Conserving Surgery, Breast Re Construction surgery)~5. Explanation of Methicillin-resistant Staphylococcus aureus Decolonization protocol~6. What to expect on Surgery Day~7. Virtual tour of Holding bay and Operation Room~8. Post-Operative care including wound care, drain management and common post-operative complications."
48294056|NCT04332692|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
48294057|NCT04332692|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
48294058|NCT04332692|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
48476029|NCT05397795|DRUG|Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)|GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
48476030|NCT04674683|DRUG|HBI-8000 in combination with nivolumab|Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight \< 40 kg, nivolumab will be dosed at specific doses on specific days.
48476031|NCT04674683|DRUG|Placebo in combination with nivolumab|Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
48476032|NCT01383850|OTHER|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
47945421|NCT05686954|OTHER|CONTROL|Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
47945422|NCT02301611|DRUG|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
47945423|NCT02301611|DRUG|Placebo|
47945424|NCT01848704|BEHAVIORAL|interpretation of the abstract|
47945425|NCT02929173|OTHER|Allceram|Pressed E-max coping veneered with E-max veneering system
47945426|NCT02929173|OTHER|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
47945427|NCT01641510|DRUG|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
48294059|NCT04332692|PROCEDURE|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
48294060|NCT04332692|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
48294061|NCT02140320|DRUG|RV1729 single dose|Safety and tolerability of single dose
47945428|NCT01641510|DRUG|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
48633349|NCT02282384|DRUG|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance \< 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
48633350|NCT02282384|OTHER|Placebo|
48633351|NCT00948207|BEHAVIORAL|My Living Story|"Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
48633352|NCT00948207|BEHAVIORAL|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
48633353|NCT02645708|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
48633354|NCT02645708|PROCEDURE|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
48633355|NCT00928005|BEHAVIORAL|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
48633356|NCT00928005|BEHAVIORAL|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
48633357|NCT05823077|OTHER|Bergamot|The affected knee will be massaged with Bergamot oil for 4 weeks, 2 sessions per week.
48633358|NCT05823077|OTHER|Placebo|The affected knee will be massaged with sweet almond oil for 4 weeks, 2 sessions per week.
48633359|NCT03532490|DRUG|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
48633360|NCT03532490|DRUG|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
48294062|NCT02140320|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single dose
48294063|NCT02140320|DRUG|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
48294064|NCT02140320|DRUG|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
48294065|NCT02140320|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
48294066|NCT02140320|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
48294067|NCT05888337|DEVICE|Contoura LASIK with Phorcides planning strategy|Bilateral treatment with topography guided LASIK
48294068|NCT05888337|DEVICE|Contoura LASIK with manifest refraction planning strategy|Bilateral treatment with topography guided LASIK
48294069|NCT02172222|DRUG|BI 10773|
48633361|NCT03863301|RADIATION|MR-guided single dose preoperative PBI|A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
48633362|NCT05689515|BEHAVIORAL|Mobile health app|A mobile app provided to participants to assess effectiveness in managing HIV
47945429|NCT02806973|DRUG|Nasal Glucagon|Administered intranasally.
47945430|NCT03174249|BEHAVIORAL|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
47945431|NCT02276404|BEHAVIORAL|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
47945432|NCT02276404|OTHER|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
47945433|NCT02005432|DRUG|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
48294070|NCT02172222|DRUG|Linagliptin|
48294071|NCT05701852|OTHER|reward learning task|during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.
48294072|NCT06293898|DRUG|BL-M07D1|Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.
48294073|NCT05384743|DRUG|Rituximab Monotherapy|Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
48294074|NCT04007029|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV
48294075|NCT04007029|DRUG|Cyclophosphamide|Given IV
48294076|NCT04007029|DRUG|Fludarabine Phosphate|Given IV
48294077|NCT04007029|BIOLOGICAL|Tocilizumab|Given IV
48476033|NCT01383850|OTHER|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
48633363|NCT00823888|DEVICE|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
48633364|NCT00874809|DEVICE|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
48294078|NCT06337370|BEHAVIORAL|Chronic Disease Self Management Program|"CDSMP is a group-based chronic disease self-management education intervention comprised of 2.5-hour sessions, including time for a break and snack. The maximum number of participants per session ranges from 12 to 16. In total the program consists of 6 sessions that take place once a week for a total duration of 6 weeks. The development of each of the sessions is standardized and scripted; two group leaders previously trained by a Master Trainer, who in turn was trained to train leaders with Stanford University, guide the sessions. In the case of the present study, the main researcher and a nursing professional with experience in health education will receive the training from a Master Trainer of the program. Participants receive the book Taking Control of Your Health at the beginning of the program."
48294079|NCT06337370|BEHAVIORAL|Conventional Care Group|"The conventional intervention consists of education provided by the nursing staff when the patient is admitted to the RA Clinical Care Center (C3AR); patients receive a pharmacological and allergy reconciliation form; the C3AR care pathway; an educational pamphlet and a disease diary. The education provided is oriented to the disease, pharmacological treatment, adherence, healthy lifestyles and guidance on administrative procedures. Group educational sessions are held twice a year with patients, family members and caregivers.~Follow-up is carried out either in person, virtually or by telephone to strengthen tools, agree on self-care goals, promote healthy lifestyles, improve adherence and mitigate risks related to the disease and its management at home."
48294080|NCT00891657|DEVICE|SprayShield™|Anti-adhesion barrier
48294081|NCT03403972|DRUG|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
48294082|NCT01496261|DRUG|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
48294083|NCT01496261|DRUG|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
48294084|NCT03295422|PROCEDURE|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
48294085|NCT03295422|PROCEDURE|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
48294086|NCT03215472|OTHER|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
48294087|NCT03215472|OTHER|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
48294088|NCT01056107|DRUG|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
48294089|NCT01056107|DRUG|Placebo|Placebo subcutaneous injection daily
48294090|NCT02094846|BEHAVIORAL|Voice messages|Voice messages reinforced with self-efficacy
48294091|NCT05635838|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
48294092|NCT05635838|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
48294093|NCT03798561|DRUG|ASN008 TG|ASN008 TG
48294094|NCT03798561|DRUG|Placebo TG|Placebo TG
48294095|NCT03763487|DIAGNOSTIC_TEST|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
48294096|NCT03763487|PROCEDURE|spleen volumetry|Ultrasound examination of spleen to scaled the size.
48294097|NCT02280005|DEVICE|WAK Treatment|Hemodialysis with WAK device.
48294098|NCT02996305|DRUG|OV101 Regimen 1|
48294099|NCT02996305|DRUG|OV101 regimen 2|
48294100|NCT02996305|OTHER|Placebo|
48294101|NCT02202811|BEHAVIORAL|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
48476034|NCT04480372|DRUG|Gemcitabine|Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).
48476035|NCT04480372|DRUG|Atezolizumab|Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
48633365|NCT03407911|OTHER|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
47945434|NCT02005432|DRUG|panfotocoagulation (PASCAL)|
47945435|NCT02005432|DRUG|panfotocoagulation (PRP) single shoot (ETDRS)|
48620049|NCT01188447|PROCEDURE|Canadian C-Spine Rule|Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
48620050|NCT01737086|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 and zinc sulphate|
48620051|NCT01737086|DIETARY_SUPPLEMENT|placebo|
48633366|NCT00977873|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
48633367|NCT00977873|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
48633368|NCT02725606|BIOLOGICAL|Pegylated Recombinant Human G-CSF|subcutaneous
48633369|NCT02725606|BIOLOGICAL|GW003|subcutaneous
47945436|NCT00093548|BIOLOGICAL|alpha fetoprotein adenoviral vector vaccine|
48633370|NCT03406052|BEHAVIORAL|Smartphone-Assisted MB-CBT|Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
48633371|NCT01442285|BEHAVIORAL|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
48633372|NCT05871489|DRUG|Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
48633373|NCT05871489|DRUG|Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
48633374|NCT05871489|DRUG|Bdq, Lzd, Lfx, Z, Dlm (9-12 months)|Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
47945437|NCT00093548|BIOLOGICAL|alpha fetoprotein plasmid DNA vaccine|
48633375|NCT01641783|DRUG|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
48633376|NCT06279403|DRUG|Toripalimab|Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
48633377|NCT06279403|PROCEDURE|Cytoreductive Nephrectomy|"Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia.~Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function.~Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively."
48633378|NCT06279403|DRUG|Axitinib|Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
48633379|NCT05243316|PROCEDURE|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
48633380|NCT05243316|PROCEDURE|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
48633381|NCT01992471|BEHAVIORAL|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
48633382|NCT01992471|BEHAVIORAL|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
48633383|NCT01992471|OTHER|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
48633384|NCT01992471|BEHAVIORAL|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
47945438|NCT00093548|BIOLOGICAL|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
47945439|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
47945440|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
47945441|NCT00395772|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
47945442|NCT00395772|DRUG|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
47945443|NCT05126953|DEVICE|samfilcon A Lenses with EPG01 Packaging Solution|samfilcon A Lenses with EPG01 Packaging Solution
47945444|NCT05126953|DEVICE|B+L Ultra Lenses|Commercially available Biotrue ONEday lenses
48294102|NCT06659718|DRUG|Oral semaglutide|New use of oral semaglutide dispensing claim is used as the exposure.
48294103|NCT06659718|DRUG|Sitagliptin|New initiation of sitagliptin dispensing claim is used as the reference.
47945445|NCT02058472|DRUG|G3041|
47945446|NCT02058472|DRUG|SEVIKAR®|
47945447|NCT01288027|BIOLOGICAL|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
47945448|NCT04920682|DRUG|Reversal of moderate neuromuscular blockade|Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4
47945449|NCT04920682|DRUG|Reversal of superficial neuromuscular blockade|Neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
47945450|NCT04920682|DRUG|Two-step reversal|Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
48294104|NCT02333331|DRUG|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
47945451|NCT04920682|DRUG|Placebo|0.9% saline solution (SF) when TOF = 3 and when TOF (T4 / T1)\> 0.4
47945452|NCT05173480|OTHER|Conventional rehabilitation|Exercise therapy through conventional rehabilitation training made by physiotherapists.
47945453|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS).
48633385|NCT01992471|BEHAVIORAL|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
48294105|NCT02333331|OTHER|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
48294106|NCT00005860|DRUG|floxuridine|
48633386|NCT04378088|OTHER|Validation of CEBuS|Validation of a new score for bubbles in the colon.
48633387|NCT00674232|DRUG|600 mcg misoprostol|single dose of misoprostol taken orally
48633388|NCT00674232|PROCEDURE|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
48633389|NCT05038514|OTHER|musıc therapy|After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
48633390|NCT01176994|DEVICE|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
48633391|NCT06109753|PROCEDURE|Robotically Assisted Laparoscopic Surgery|robotically assisted surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
48633392|NCT06109753|PROCEDURE|Conventional Laparoscopic Surgery|conventional surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
48633393|NCT00183391|DRUG|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
48633394|NCT00183391|DRUG|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
47945454|NCT05173480|DEVICE|Virtual Reality Rehabilitation System (VRRS)|Exercise therapy through a virtual reality rehabilitation system (VRRS) with sensors not connected.
47945455|NCT01087697|DEVICE|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
47945456|NCT04372797|DEVICE|Diagnostic test|A battery of oculomotor tests
47945457|NCT06551688|DIAGNOSTIC_TEST|Serum 25(OH)D level|The characteristics of 25 (OH) D3 are relatively longer half-life than 1.25 (OH)2 D3, stability, strong detection repeatability, and no biological activity. Generally, systemic levels of the more stable 25 (OH) D3 are considered to be the best index to reflect status of vitamin D in the individual patient
47945458|NCT00315159|PROCEDURE|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
47945459|NCT00215202|DRUG|Iressa (ZD1839)|
47945460|NCT04951440|DRUG|Nitrate ketone oxazine|Intervention group: 30min intravenous point. Drop qiu was given 1400 mg of injected sichuan nitrone I bed, and the drug was given 100 mL at day F Set 12 h, and at odds with another 7 days, that is, about 14 times in total.
47945461|NCT01428362|DRUG|VI-1121|
47945462|NCT01428362|DRUG|Placebo|
47945463|NCT01291433|DRUG|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
47945464|NCT01291433|DRUG|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
47945465|NCT01291433|DRUG|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
47945466|NCT01291433|DRUG|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
48294107|NCT00005860|DRUG|leucovorin calcium|
48294108|NCT00005860|DRUG|oxaliplatin|
48294109|NCT00231920|BIOLOGICAL|Fluzone|
48633395|NCT05296655|OTHER|Reflux Symptom Index Inventory (diagnostic survey)|Kazakh versions of the Reflux Symptom Index Inventory will be filled patients
48633396|NCT05296655|OTHER|Reflux finding score|laryngoscopy with a score RFS
48633397|NCT00002316|DRUG|Lobradimil|
47945467|NCT01291433|DRUG|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
47945468|NCT01291433|DRUG|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
47945469|NCT02004392|DRUG|EVP-6124|
47945470|NCT06350773|DRUG|tadalafil 20 mg then 40 mg if tolerated|Patients will receive tadalafil for 12 week follow up period, in addition to the conventional anti failure therapy.
48294110|NCT06411899|DRUG|Sonelokimab|Sonelokimab
48294111|NCT06411899|DRUG|Placebo|Placebo
48294112|NCT04853797|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
48294113|NCT04853797|DRUG|Ivabradine|15 mg oral Ivabradine.
48294114|NCT04853797|DRUG|Placebo|Oral placebo (calcium supplements).
47945471|NCT05819606|OTHER|Immunohistochemistry (IHC) analysis|Setting of the percentage amount of PSMA expression on the primary tumor cell surface on post-surgical samples by the Immunohistochemistry method (IHC)
47945472|NCT02091973|DRUG|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
47945473|NCT02091973|DRUG|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
47945474|NCT04737447|DEVICE|Whole Body Vibration Training|Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
47945475|NCT00341445|BEHAVIORAL|Effect of Cockroach Allergen|
47945476|NCT06239636|BIOLOGICAL|UP421|Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
47945477|NCT04163497|DEVICE|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
48103778|NCT05638204|BEHAVIORAL|Suicidal Crisis Intervention (SCI)|This study's experimental condition consisted of the Suicidal Crisis Intervention (SCI), developed by the Flemish Centre of Expertise of Suicide prevention. The SCI aims to provide tools for dealing with future suicidal crises for people after a suicidal crisis or suicide attempt. The intervention attempts to provide insight into the suicidal crisis by giving suicidality meaning within the life history. It aims to increase motivation for specialized care and therefore facilitate continuity of care. In addition, the method also wants to involve the close relative(s) of the suicidal person in the treatment. The SCI offers care providers a clear structure and handles to do this within a short period of time (4 sessions). Within the SCI are a number of crucial elements: the therapeutic relationship, involving loved ones, person-centred care, the Integrated Explanatory Model for Suicidal Behavior (Van Heeringen, 2007), the safety plan (Stanley \& Brown, 2012) and continuity of care.
48103779|NCT03311958|DRUG|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
48294115|NCT04641546|PROCEDURE|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
48294116|NCT04641546|PROCEDURE|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
48294117|NCT01103050|DRUG|QAV680 + Cetirizine Placebo|
48294118|NCT01103050|DRUG|QAV680 + Cetirizine|
48294119|NCT01103050|DRUG|Cetirizine + QAV680 Placebo|
48294120|NCT01103050|DRUG|QAV680 Placebo + Cetirizine Placebo|
48294121|NCT05717738|PROCEDURE|TACE|Procedure of TACE is standardized.
48294122|NCT05717738|DRUG|Lenvatinib|8mg; p.o.; q.d.
48294123|NCT05717738|DRUG|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
47945478|NCT04877743|OTHER|None (Observational study)|The main data sources for the study will be participants and their medical records. Vaccination details will be verified by a vaccination card, batch/lot number, and/or using a regional vaccination register. Participants will report all study outcomes using the study app, web portal, or call centre. Participants can also select a proxy to communicate on their behalf: a caregiver, family member, or other trusted individual. Participants will be asked for an emergency contact in case of death or incapacity.
47945479|NCT03722771|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
47945480|NCT03722771|OTHER|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
47945481|NCT03722771|OTHER|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
47945482|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
48294124|NCT05717738|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
48294125|NCT05717738|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
48294126|NCT05717738|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
48294127|NCT05717738|DRUG|Sorafenib|400mg; p.o. bid
48476036|NCT05934487|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)"
48620052|NCT02852759|PROCEDURE|Selective Cold|The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.
48633398|NCT00002316|DRUG|Amphotericin B|
48633399|NCT02176525|DRUG|BI 207127 NA|
47945483|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
48476037|NCT04602793|DIAGNOSTIC_TEST|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
48633400|NCT02176525|DRUG|Placebo|
48633401|NCT06355687|DRUG|Melatonin|Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
48633402|NCT06355687|DIETARY_SUPPLEMENT|Vitamin Supplement|Obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia.
48633403|NCT05248243|PROCEDURE|Recruitment assessment|"Intervention Details:~Construction of the P/V curve with subsequent measurement of HR and Vmax."
48633404|NCT02567292|OTHER|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants \<37 weeks PMA and/or or weight \<2,200g or PBCLN-002 for infants \>37 weeks PMA and/or weight \>2,200g)
48633405|NCT00576342|DRUG|AL-3862+timolol ophthalmic suspension|
48633406|NCT00576342|DRUG|Dorzolamide+timolol ophthalmic solution|
48633407|NCT05655572|OTHER|Action Observation Theraoy|After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks
48633408|NCT05655572|OTHER|Functional Training|after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
48633409|NCT02978508|DRUG|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
48633410|NCT02978508|DRUG|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
47945484|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
47945485|NCT03722771|DIAGNOSTIC_TEST|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
47945486|NCT05563844|DRUG|PM 8.4 mg/m2|1 case, Take the medicine once on D1,D 1-21.
47945487|NCT05563844|DRUG|PM 11.2 mg/m2|1 case, Take the medicine once on D1,D 1-21.
47945488|NCT00311662|DRUG|Tonabersat|Tablet 40mg daily for 12 weeks
47945489|NCT00311662|DRUG|Placebo|Tablet once daily for 12 weeks
47945490|NCT00674973|DRUG|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
48294128|NCT05717738|DRUG|Donafenib|200mg; p.o. bid
48476038|NCT01121588|DRUG|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
48476039|NCT04689893|DRUG|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
48476040|NCT04689893|DRUG|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
48476041|NCT02900274|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
48476042|NCT04039490|DEVICE|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
48476043|NCT06472271|DRUG|Polymyxin e|Increased starting colistin dose
48476044|NCT06097663|DRUG|MAS825|Active MAS825 single dose
48476045|NCT06097663|DRUG|MAS825 Placebo|MAS825 placebo single dose
48476046|NCT06097663|DRUG|DFV890|Oral tablet of DFV890 active once daily
48476047|NCT06097663|DRUG|DFV890 placebo|Oral tablet of DFV890 placebo once daily
48476048|NCT06495580|PROCEDURE|Optic Nerve Stimulation|Anterograde Stimulation of the Optic Neve.
48476049|NCT02676245|BEHAVIORAL|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
48294129|NCT05717738|DRUG|Regorafenib|160 mg; p.o.; q.d.
48294130|NCT05392322|OTHER|Self-help skills|Self-help skills were given to down's syndrome children 3 times per week upto 15 minutes.
48294131|NCT05392322|DEVICE|Virtual video reality gaming|Virtual video reality gaming was given to children with down's Syndrome 3 time per week upto 15 minutes.
48294132|NCT05934448|DRUG|Pembrolizumab|Pembrolizumab via iv, dosage and timing per protocol
48294133|NCT05934448|DRUG|Lymphodepletion Chemotherapy|Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
48294134|NCT05934448|DRUG|Chimeric Antigen Receptor (CAR) Therapy Infusion|Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
48476050|NCT02676245|BEHAVIORAL|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
48476051|NCT02443324|DRUG|Ramucirumab|Administered IV
48476052|NCT02443324|DRUG|Pembrolizumab|Administered IV
48476053|NCT00843830|RADIATION|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
48476054|NCT00843830|BIOLOGICAL|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
48476055|NCT05532007|DIETARY_SUPPLEMENT|Peanuts|2-3 ounces of peanuts to replace 20% of total daily energy intake
48476056|NCT05532007|OTHER|Habitual Diet|continue with habitual diet and abstain from eating peanuts
48476057|NCT02193607|PROCEDURE|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
48476058|NCT02193607|PROCEDURE|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
48476059|NCT01114581|DRUG|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
48476060|NCT01114581|DRUG|Placebo|Placebo given as 2 tablets
48476061|NCT04047563|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
48476062|NCT04047563|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
48476063|NCT03610828|OTHER|Vegetarian or Vegan Diets|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
48620053|NCT02852759|DEVICE|Electroacupuncture|Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
48620054|NCT01031290|DEVICE|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
48294135|NCT05934448|PROCEDURE|Leukapheresis|manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
48294136|NCT04272853|OTHER|Interview|Compilation of the interview concerning: demographic data, sports practice, habits on sleep, sexual habits, perception of the relationship between sexual habits and sleep, perception of the relationship between sexual habits and sports practice.
48294137|NCT02947139|DRUG|Co-administration of DWC20155/DWC20156|
48294138|NCT02947139|DRUG|DWC20161|
48294139|NCT02214979|DRUG|Telmisartan/Ramipril|fixed dose combination tablet
48294140|NCT02214979|DRUG|Telmisartan|
48294141|NCT02214979|DRUG|Ramipril capsule|
48294142|NCT02214979|DRUG|Ramipril tablet|
48620055|NCT02714647|BEHAVIORAL|Attentional prime|
48620056|NCT02714647|BEHAVIORAL|Sham prime|
47945491|NCT00674973|DRUG|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
47945492|NCT02034032|PROCEDURE|Regenexx SD|stem cell treatment
47945493|NCT02034032|BEHAVIORAL|Exercise Therapy|exercise therapy control
47945494|NCT03865134|DIAGNOSTIC_TEST|Snellen Test|Visual acuity measurement
47945495|NCT03865134|DIAGNOSTIC_TEST|Autorefractometer|Refraction measurement
47945496|NCT03865134|DIAGNOSTIC_TEST|Titmus Stereo Fly Test|Stereopsis measurement
47945497|NCT03865134|DIAGNOSTIC_TEST|Optical Kohlerans Tomography|Retinal development measurement
47945498|NCT03865134|BEHAVIORAL|Investigation of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
47945499|NCT03865134|BEHAVIORAL|Peabody Developmental Motor Scales - II|Evaluation of motor development
47945500|NCT03865134|BEHAVIORAL|World Health Organization Quality of Life - BREF|Assesment of quality of life
47945501|NCT03865134|BEHAVIORAL|State - Trait Anxiety Inventory|Assesment of anxiety
48103780|NCT04753463|OTHER|Survey|The on-line questionnaire which assess the subjective feelings of residents of pandemic impact on ophthalmology training programs
48103781|NCT00956982|DRUG|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing \< 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
48620057|NCT06238960|OTHER|Telerehabilitation|the patient will undergo 10 session of tele rehabilitation in continuity with traditional physiotherapy
48633411|NCT05335265|OTHER|Treatment training|"Face-to-face:Metered-DoseInhalerTraining gave 3 times on the 1st day, 2 times on the 2nd day, once on the 3rd day.During discharge, inhaler technical evaluation were done according to the Application Steps of Inhalation Techniques Evaluation Form checklist prepared by using the Patient's Booklet of the Turkish Thoracic Society (TTS).The people who is evaluate the patient's inhaler technique (IT) on the day of discharge was someone different from the health personnel who provided the training. In IT control, the patient's performance was evaluated simultaneously by 2 observers.~Video training:Training gave 3 times on the 1st day, 2 times on the 2nd day,once on the 3rd day.The TTS-Virtual Training Video were used.During discharge,inhaler technical evaluation was done same with face-to-face training.The person who is evaluate the patient's IT was someone different from the training personnel.In IT observation,it was used same method with face-to-face training."
48633412|NCT00507507|DRUG|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
47945502|NCT03585348|OTHER|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
47945503|NCT06003569|BEHAVIORAL|BACK-S|"BACK = Better Asthma Control for Kids:~The BACK -Standard package includes a tailor-and-adapt to context strategy of approaches necessary to implement BACK in schools based on our past work, operationalized as an implementation blueprint to coordinate with partner roles of child/family, schools, healthcare teams and community resource agencies. This includes a facilitation strategy to support problem-solving through regular learning collaborative meetings for asthma navigators (bi-weekly), school nurses (monthly to bi-monthly) and health care champions (quarterly)."
47945504|NCT06003569|BEHAVIORAL|BACK-E|The BACK-Enhanced package includes the BACK-Standard package plus an Enhanced strategy to develop interrelationships with students/family, schools, and community agencies providing resources to address social determinants of health.
47945505|NCT02791399|BEHAVIORAL|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
48103782|NCT01615835|OTHER|EnSite NavX System|EnSite NavX system is a 3D Mapping system
48103783|NCT05701111|BEHAVIORAL|Start with the Heart Students|The Start with the Heart curriculum includes psychoeducation, lessons, and activities, on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition to promote well-being. The curriculum will be taught in the classroom to students for 15-20 min per day for 6-8 weeks.
48633413|NCT00507507|DRUG|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
47945506|NCT02534220|DEVICE|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter \& Gamble, Cincinnati, OH
47945507|NCT02534220|DEVICE|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter \& Gamble, Cincinnati, OH
47945508|NCT03032133|PROCEDURE|Regional pain control|Regional pain catheter
47945509|NCT03032133|PROCEDURE|Local pain control|Local intraarticular pain catheter
47945510|NCT03521219|DRUG|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
48620058|NCT06238960|OTHER|Traditional rehabilitation|the patient will undergo 16 session of outpatient physiotherapy rehabilitation
48633414|NCT00507507|DRUG|Placebo|Placebo to match FTC taken once daily
47945511|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.25ml/vial)|Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
48294143|NCT06673394|DRUG|Complement protein C5 inhibitor|Investigational arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline). Terminal complement complex inhibition by eculizumab predisposes patients to infections by encapsulated bacteria, especially N meningitidis. Meningococcal vaccination will not be effective in this timeframe; instead, all enrolled patients will receive antibiotic prophylaxis against N meningitidis from the time of the first dose of the study drug to 8 weeks after the last administration.
48294144|NCT06673394|DRUG|IVMP|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
48294145|NCT05014074|OTHER|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
48294146|NCT00242177|DRUG|ACTOS (Pioglitazone)|
48633415|NCT01838889|BEHAVIORAL|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
48633416|NCT00944021|DRUG|PA-824|50mg
47945512|NCT05642078|BIOLOGICAL|Investigational Vaccine(0.5ml/vial)|Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
47945513|NCT05642078|BIOLOGICAL|Active compared Vaccine|Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
47945514|NCT03896685|DRUG|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
47945515|NCT03896685|DRUG|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
47945516|NCT03896685|DRUG|Clofazimine 100 MG Oral Capsule|Clofazimine: 100 mg QD
48633417|NCT00944021|DRUG|PA-824|100mg
48633418|NCT00944021|DRUG|PA-824|150 mg
48633419|NCT00944021|DRUG|Rifafour e-275 mg|275 mg
47945517|NCT03896685|DRUG|Linezolid 600Mg Tab|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
47945518|NCT03896685|DRUG|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
47945519|NCT00629174|BEHAVIORAL|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
47945520|NCT00629174|BEHAVIORAL|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
47945521|NCT02066220|RADIATION|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
48294147|NCT06106308|DRUG|Onvansertib|Oral capsule
48294148|NCT06106308|DRUG|FOLFIRI|FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
48294149|NCT06106308|DRUG|Bevacizumab|IV Infusion
48294150|NCT06106308|DRUG|FOLFOX|FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion
48294151|NCT04472429|DRUG|carboplatin|carboplatin will be administered intravenous on Day 1 of each 28 day cycle
48294152|NCT04472429|DRUG|paclitaxel|paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
48294153|NCT04472429|DRUG|retifanlimab|retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
48294154|NCT01252888|DEVICE|iStents|Implantation of two iStents through a small temporal clear corneal incision
48294155|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at T0|
48620059|NCT04238741|OTHER|Audio-recording of consent for anaesthesia for elective caesarean section|Antenatal women will be invited to attend 5-15 days before their caesarean section for an anaesthetic consent discussion with audio-recording. Participants will complete a questionnaire immediately following the recorded discussion and again within the 48 hours following their surgery, to establish their views on the process of audio-recording of consent and the potential usefulness/acceptability of the audio-recording.
48633420|NCT00944021|DRUG|PA-824|200 mg
48633421|NCT03907423|DRUG|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
48633422|NCT03907423|DRUG|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
48294156|NCT03123523|DIAGNOSTIC_TEST|Exercise test|
47945522|NCT02066220|DRUG|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
48294157|NCT03123523|BIOLOGICAL|Biological assays|Creatinin, hematocrit and BNP assays
48294158|NCT03123523|DEVICE|MRI with contrast agent injection|With injection of gadolinium
48294159|NCT03123523|DEVICE|MRI without contrast agent injection|Without injection of gadolinium
48294160|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at M24|
48294161|NCT00745316|DRUG|Tonapofylline|Oral Tonapofylline - 2 capsules bid
48294162|NCT00745316|DRUG|Placebo|Oral placebo - 2 capsules bid
48294163|NCT06092502|OTHER|Graded Motor Imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
48294164|NCT06092502|OTHER|Traditional Physiotherapy Program|This protocol included stretching and strengthening exercises
48294165|NCT05632497|BIOLOGICAL|Stool and blood samples|Stool and blood samples
48294166|NCT06235151|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
48294167|NCT06671691|RADIATION|SBRT level I|20Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
48294168|NCT06671691|RADIATION|SBRT level II|23Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
48294169|NCT06671691|RADIATION|SBRT level III|26Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
48294170|NCT06671691|RADIATION|SBRT level IV|28Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
48294171|NCT06671691|RADIATION|SBRT level V|30Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
47945523|NCT02066220|RADIATION|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
47945524|NCT02066220|DRUG|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
47945525|NCT02066220|RADIATION|WNT-HR < 16 years|Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Boost to macroscopic metastases - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
48294172|NCT04390815|DRUG|Insulin|Adding insulin to conventional wound treatment
48294173|NCT06563388|PROCEDURE|Stereotactic Ablative Radiotherapy|Radiation therapy begins after 3 months of Standard of care
48294174|NCT06563388|OTHER|Best Practice|Receive standard of care therapy
48294175|NCT02127112|PROCEDURE|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
48294176|NCT02127112|PROCEDURE|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
48294177|NCT00023907|DRUG|paclitaxel|
48294178|NCT03726216|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
48294179|NCT03345212|OTHER|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
48294180|NCT05440955|DEVICE|left fronto-temporal transcranial Direct Current Stimulation (tDCS)|"The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session."
48294181|NCT01962636|DRUG|Fludarabine|25 mg/m\^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
48633423|NCT02191397|DRUG|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
48294182|NCT01962636|DRUG|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
48294183|NCT01962636|RADIATION|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
48633424|NCT02191397|DRUG|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
48633425|NCT02191397|DRUG|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
47945526|NCT02066220|RADIATION|WNT-HR >= 16 years|Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 14.4 Gy in 8 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 50.4 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
47945527|NCT02066220|DRUG|Induction Chemotherapy|Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
47945528|NCT02066220|RADIATION|SHH-TP53 M0|"* with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks~* clinical target volume (CTV): safety margin along typical spread 10 mm: 23.4.Gy in 13 fractions to CTV.~* focal RT boost to tumour bed and residual tumour (GTV) (boost: 30.6 Gy in 17 daily fractions of 1.8 Gy)"
47945529|NCT02066220|RADIATION|SHH-TP53 M+ (germline)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 23.4 Gy in 13 daily fractions of 1.8 Gy Spine - 23.4 Gy in 13 daily fractions of 1.8 Gy Primary tumour boost - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (cranial) - 30.6 Gy in 17 daily fractions of 1.8 Gy Metastases boost (spinal) - 21.6 Gy in 12 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45.0 Gy in 25 daily fractions of 1.8 Gy
47945530|NCT02066220|RADIATION|SHH-TP53 (somatic)|craniospinal radiotherapy with boost to tumour bed, residual tumour and metastatic deposits with VCR 1,5 mg/m2 (max. 2mg), once weekly during radiotherapy, for a maximum of 6 weeks Brain - 36.0 Gy in 20 daily fractions of 1.8 Gy Spine - 36.0 Gy in 20 daily fractions of 1.8 Gy Primary tumour boost - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (cranial) - 18.0 Gy in 10 daily fractions of 1.8 Gy Metastases boost (spinal) - 9.0 Gy in 5 daily fractions of 1.8 Gy Total dose to primary tumour - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to cranial metastases - 54.0 Gy in 30 daily fractions of 1.8 Gy Total dose to spinal metastases - 45 Gy in 25 daily fractions of 1.80 Gy
47945531|NCT02066220|DRUG|Vinblastin Maintenance|Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
48294184|NCT01962636|DRUG|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
48633426|NCT02191397|DRUG|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
48633427|NCT00552838|BEHAVIORAL|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
48633428|NCT03246594|DEVICE|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
48294185|NCT01962636|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
48633429|NCT03246594|DEVICE|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
48633430|NCT05667402|DRUG|TBF regimen|The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.
48633431|NCT05667402|DRUG|modified BuCY2 regimen|The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
48633432|NCT05233059|BEHAVIORAL|FitEx|FitEx is an 8 week goal-setting, behavior tracking, physical activity intervention with a low dose of social support which will be delivered virtually.
48633433|NCT05233059|BEHAVIORAL|Weekly Yoga Sessions|30 minutes of optional guided yoga online led by a 500 hour yoga teacher once a week for participants in the walking plus yoga arm. Also accompanied by a yoga based newsletter.
48633434|NCT05233059|BEHAVIORAL|Weekly Movement Sessions|30 minutes of optional guided movement online led by a 500 hour yoga teacher once a week for participants in the walking arm. Also accompanied by a movement based newsletter.
48633435|NCT03696667|DEVICE|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
48633436|NCT02151604|DRUG|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
47945532|NCT00000188|DRUG|Selegiline|
47945533|NCT05052658|PROCEDURE|Neuraxial block placement|The time and ease of administering neuraxial blocks in high BMI patients,for the management of labor and delivery pain, will be assessed.
47945534|NCT02883842|BEHAVIORAL|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
47945535|NCT03630367|DRUG|Dexamethasone|Intramuscular injection 8 mg
47945536|NCT03630367|DRUG|L-Carnitine 1G/5mL Injection|slow intravenous injection
47945537|NCT05029700|OTHER|Combined exercise training|Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
47945538|NCT05029700|OTHER|Aerobic training|Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
47945539|NCT05403034|PROCEDURE|Muscle biopsy|Peroperative muscle biopsy will be performed during a planned shoulder surgery (arthrolysis and/or muscle transfer)
47945540|NCT03432312|DRUG|Nicotine lozenge|Nicotine mint lozenge, 4 mg
47945541|NCT03432312|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
47945542|NCT05191654|DIAGNOSTIC_TEST|evaluation of cardiopulmonary parameters, gross motor development and hand grip strength|Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer. Cardiopulmonary parameters values was evaluated with echocardiography.
47945543|NCT00537238|DRUG|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
47945544|NCT00537238|DRUG|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
47945545|NCT05049681|DRUG|Camrelizumab|SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
47945546|NCT05049681|DRUG|Apatinib|Apatinib 250mg, q.d.po
47945547|NCT06013475|DRUG|Apalutamide|Decision by the treating physician
47945548|NCT06013475|DRUG|Darolutamide (BAY 1841788)|Decision by the treating physician
47945549|NCT06013475|DRUG|Enzalutamide|Decision by treating physician
47945550|NCT06223919|BIOLOGICAL|LC16m8|"LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses"
47945551|NCT03361254|BIOLOGICAL|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
47945552|NCT03153956|DEVICE|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
47945553|NCT03153956|DEVICE|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
47945554|NCT01251744|PROCEDURE|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
47945555|NCT01251744|PROCEDURE|Cord blood sample|Cord blood sample taken at the time of delivery.
47945556|NCT01251744|PROCEDURE|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
47945557|NCT01251744|PROCEDURE|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
47945558|NCT01251744|PROCEDURE|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
47945559|NCT04708119|PROCEDURE|The follicular tissues were also excised after tooth extraction.|The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
48633437|NCT04017975|DRUG|Fluorescite|1 mL of Fluorescite will be diluted into 1L of saline. Up to 5mLs of the 1:1000 diluted solution will be applied topically to the cardiac tissue prior to imaging.
48633438|NCT04017975|DEVICE|Cellvizio 100 Series System with Confocal Miniprobes|The microscopy system will image cardiac tissue.
48633439|NCT03073057|DRUG|Budesonide/formoterol|2 inhalations as a single dose
47945560|NCT05241483|DIAGNOSTIC_TEST|mesure valition|Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
48633440|NCT03073057|OTHER|Charcoal|
48633441|NCT03073057|DRUG|Symbicort Turbuhaler|2 inhalations as a single dose
48633442|NCT03780322|DEVICE|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
47945561|NCT05413031|DEVICE|relative motion splint|splint with ability to move the fingers
47945562|NCT05413031|DEVICE|static splint|splint with immobility of wrist, and fingers
47945563|NCT06160076|DEVICE|Radiofrequency|Patient with atrial fibrillation ablated per catheter using radiofrequency energy
47945564|NCT06160076|DEVICE|Pulsed electric field|Patient with atrial fibrillation ablated per catheter using pulsed electric field
47945565|NCT01676727|DEVICE|CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
47945566|NCT00160173|DRUG|Estrogel|
47945567|NCT00160173|OTHER|Placebo|
47945568|NCT06339632|OTHER|Transcutaneous electrical phrenic nerve stimulation (TEPNS)|"The characteristics of the electrical current: biphasic waves, set at a stimulation frequency of 10 Hz, pulse width of 200 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. The application of TEPNS will initially be performed by defining the trajectory of the phrenic nerve in the cervical region. The negative pole (active point), a stick with a spherical tip for micro-current of 2 mm will be positioned with slight pressure in the region of the phrenic nerve pathway between the two heads of the sternocleidomastoid muscle. Additionally, at the positive pole (passive point), a self-adhesive electrode sized (2.0 x 2.0 cm) will be positioned on the skin in the shoulder region. The intensity, measured in milliamperes (mA), will be adjusted to the maximum tolerated by the patient. The total stimulation time will be 10 minutes, applied continuously in a single session."
47945569|NCT06339632|OTHER|Transcutaneous electrical diaphragm stimulation (TEDS)|The characteristics of the electrical current are: biphasic waves, set at a stimulation frequency of 30 Hz, pulse width of 400 μs, rise time of 1.0 second, on time of 1.0 second, fall time of 1.0 second, and off time of 2 seconds, resulting in 12 stimuli per minute. Two self-adhesive electrodes sized (5.0 x 5.0 cm) will be used, positioned in the bilateral parasternal region next to the xiphoid process and the other electrode in the intercostal space between the 6th and 7th ribs bilaterally, at the mid-axillary line. The intensity, measured in milliamperes (mA), will be adjusted to the maximum intensity tolerated by the patient until diaphragmatic contraction is observed with the naked eye, without contraction of other muscles in the abdominal region. The total stimulation time will be 10 minutes, applied continuously in a single session.
47945570|NCT04370431|DRUG|TTYP01 single ascending doses|TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
47945571|NCT04370431|DRUG|Placebo|Placebo control for Part A of the study
47945572|NCT04370431|DRUG|TTYP01, 60 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
47945573|NCT04370431|DRUG|TTYP01, 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
48103784|NCT05701111|BEHAVIORAL|Start with the Heart Teachers|Pure Edge Inc will train teachers to deliver the Start with the Heart curriculum. The training emphasizes the neuroscience of stress and educator self-care. The teachers will implement the training in their respective classrooms for 6-8 weeks.
48103785|NCT05701111|BEHAVIORAL|Cue Centered Therapy Counselors|The Early Life Stress and Resilience Program team members will train school counselors on Cue-Centered Therapy through self-paced online modules, virtual and in-person live training, and office hours as needed. Counselors will implement the intervention with eligible students for 15-18 weeks.
48103786|NCT05701111|BEHAVIORAL|Cue Centered Therapy Students|Students who report a threshold of PTSD symptoms will be offered participation in Cue-Centered Therapy with their school counselors. They will have one-on-one therapy that targets trauma experiences through cognitive behavioral tools, narrative therapy, exposure therapy, psychoeducation, and more. Their caregivers will be involved as needed. They will enroll in treatment for 15-18 weeks.
48476064|NCT04812574|PROCEDURE|Periurethral injection|Patients were in the lithotomy position for the procedure. After preparation, topical Lidocaine gel was instilled around the meatus and a 16 F probe was attached. The catheter balloon was inflated to localize the bladder neck and to ensure that injections were performed in the correct anatomical plane. Hypertonic saline (10% NaCl) was injected to the alignment of the urethral meatus in the order of 3-6-9-12 hours of the clock (5 cc to each site, totaling 20 cc). Syringes with 27 Gauge (0.40 mm) outer diameter were used to ensure controlled injection. Since the female urethra is about 4 cm in length, the needle was advanced about 3 cm. Due to the possibility of significant pain with hypertonic saline, 2 cc of Lidocaine hydrochloride was added into the solution.
48103787|NCT05701111|GENETIC|iSWAB-DNA|Eligible students will give DNA buccal swabs at 2-3 time points for later analysis of genetic markers.
48476065|NCT04812574|DRUG|Hypertonic (10%) saline|Periurethral hypertonic saline (10%)
48103788|NCT02655380|DRUG|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
48103789|NCT02655380|DRUG|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
48476066|NCT01530308|DRUG|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
48476067|NCT01530308|DRUG|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
48476068|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
47945574|NCT04370431|DRUG|Radicut® (ampoule), 30 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
47945575|NCT04370431|DRUG|Radicut® (bag) , 60 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
47945576|NCT04370431|DRUG|TTYP01, up to 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
47945577|NCT02809326|BEHAVIORAL|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
47945578|NCT02809326|BEHAVIORAL|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
47945579|NCT02809326|BEHAVIORAL|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
47945580|NCT00462540|DRUG|Formoterol Fumurate inhalation solution 20 mcg|
47945581|NCT00462540|DRUG|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
47945582|NCT00750880|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
47945583|NCT05560035|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
47945584|NCT05560035|OTHER|Normal saline (NS)|Patients are received equal volumes of saline intravenously until the end of the surgery
47945585|NCT00259454|BEHAVIORAL|In-home intervention|occupational therapy techniques to reduce caregiver stress
47945586|NCT03236831|OTHER|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~1. Avoidance of potentially nephrotoxic medications.~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Minimizing IV contrast exposure when appropriate~5. Treating severe anemia~6. Optimization of hemodynamics (Mean arterial BP\>65mmHg)"
47945587|NCT05861310|DRUG|Metronidazole 1% Cream,Top|Cream that has an active ingredient in the form of metronidazole with a content of 1%. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the participants were given metronidazole 1% cream which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
47945588|NCT05861310|DRUG|Placebo|Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
47945589|NCT03246620|DRUG|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
47945590|NCT03246620|DRUG|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
47945591|NCT03246620|DRUG|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
47945592|NCT03781544|DRUG|Tramadol|A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).
47945593|NCT03781544|DRUG|Paracetamol|A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).
47945594|NCT03781544|DRUG|Diclofenac|A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
47945595|NCT00471146|DRUG|AG-013736|oral administration, starting dose 5 mg twice daily \[BID\] every day until unacceptable toxicity or tumor progression.
47945596|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
47945597|NCT00471146|DRUG|Gemcitabine|intravenous administration at 1,000 mg/m\^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
47945598|NCT00471146|DRUG|placebo|placebo
47945599|NCT04604158|BEHAVIORAL|Elly Mobile Phone Application|The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
47945600|NCT03506061|DRUG|Trikafta|Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
47945601|NCT04878887|PROCEDURE|IP-DRA vs IP- PRA|Catetherization approach in plane : distal radial artery VS proximal radial artery
48633443|NCT03780322|OTHER|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~1. Upper extremity weight bearing exercises.~2. Approximation techniques on wrist, elbow and shoulder.~3. Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~4. Scapulothoracic joint mobilization.~5. Stretching of shoulder abductors and external rotators.~6. Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
48476069|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
48633444|NCT02408770|DRUG|ulipristal acetate|selective progesterone receptor modulator
48633445|NCT05130957|OTHER|Massage Application with clove oil|The experimental group is given a massage with clove oil,
47945602|NCT02484287|DEVICE|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
47945603|NCT02484287|DEVICE|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
47945604|NCT02484287|DEVICE|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
47945605|NCT02580903|RADIATION|Radiology|Only a small subsample will require CT and right heart catherisation
47945606|NCT00514423|OTHER|Psychoeducation by professonals|
47945607|NCT00514423|OTHER|Psychoeducation by peer-moderators|
47945608|NCT00514423|OTHER|Video-education|
47945609|NCT00514423|OTHER|Noneducational video group (control group)|
47945610|NCT00833716|DRUG|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
47945611|NCT03913403|PROCEDURE|ECHO|Echocardiogram at baseline and 24 hours later
47945612|NCT03913403|PROCEDURE|Blood Draw|Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later
48103790|NCT02655380|DRUG|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
48103791|NCT02846194|BEHAVIORAL|brief guided imagery|
48103792|NCT04586036|OTHER|ankle joint brace 1|The influence of ankle joint brace 1 on gait biomechanics
48476070|NCT00139906|DRUG|Bifeprunox|
48476071|NCT05655455|BEHAVIORAL|walking group: 1.group|In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
48476072|NCT05655455|BEHAVIORAL|dance and movement therapy group: 2.group|In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
48476073|NCT06422494|DRUG|hyperinsulinaemic hypoglycaemic clamp|Insulin will be infused at a continuous rate of 60 mU∙m-2 ∙min-1 and glucose 20% will be infused at a variable rate, aiming for stable plasma glucose levels of 5.0 mmol/L. The infusion rate of glucose will be adjusted by plasma glucose levels, measured at 5-minute intervals. After 30 minutes of stable euglycaemia, plasma glucose levels will be allowed to drop gradually to 2.8 mmol/L and will be maintained at this level for 60 minutes. Then, insulin infusion and adrenergic blockade infusions will be stopped. Glucose infusion will be increased and then tapered until stable euglycaemia plasma levels are reached.
48476074|NCT06422494|DRUG|Propranolol Hydrochloride 1 MG/ML|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
48476075|NCT06422494|DRUG|Phentolamine|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
48476076|NCT01847365|DEVICE|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
48476077|NCT01104428|DRUG|Placebo|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
48476078|NCT01104428|DRUG|"ziying granules"|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
48633446|NCT05130957|OTHER|Massage Application without any oil|The control group is given a massage without any oil as a standard midwifery care.
48103793|NCT04586036|OTHER|ankle joint brace 2|The influence of ankle joint brace 2 on gait biomechanics
48103794|NCT04586036|OTHER|ankle joint brace 3|The influence of ankle joint brace 3 on gait biomechanics
48633447|NCT00419432|OTHER|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
48633448|NCT00419432|OTHER|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
48633449|NCT01312077|DRUG|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
48633450|NCT01312077|DRUG|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
47945613|NCT04965909|OTHER|Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.|Online group therapeutic program (small groups), applied for 3 months.
48633451|NCT01230814|DRUG|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
48633452|NCT01230814|DRUG|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
48633453|NCT05285163|BEHAVIORAL|palliative care educatiom|The patients in the intervention group were presented palliative care training in addition to their usual care
48633454|NCT03942055|DEVICE|Sonosite Edge II Ultrasound|Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
48633455|NCT04784780|DRUG|Elobixibat 10mg|Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
48633456|NCT04784780|DRUG|Placebo|Patients with chronic constipation are administered placebo for 12 weeks
48633457|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with contegra|Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
48633458|NCT03348397|PROCEDURE|right ventricular outflow tract reconstruction with pulmonary homograft|cryopreserved pulmonary homografts
48633459|NCT00270075|DRUG|epoetin alfa|
48633460|NCT06274437|DRUG|BND-35|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
48633461|NCT06274437|DRUG|Nivolumab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
48633462|NCT06274437|DRUG|Cetuximab|Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
48633463|NCT01603511|DEVICE|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
47945614|NCT00935051|OTHER|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
47945615|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery without augmented reality|Minimally invasive gynecological surgery assisted by laparoscope.
47945616|NCT05930769|PROCEDURE|Gynecological laparoscopic surgery with augmented reality|Minimally invasive gynecological surgery assisted by laparoscope with the display of additional information through augmented reality.
47945617|NCT00390598|DRUG|PEG (solution given 4 L)|
47945618|NCT00390598|DRUG|senna glycoside 36 mg and PEG (solution given 2 L)|
48103795|NCT04586036|OTHER|ankle joint brace 4|The influence of ankle joint brace 4 on gait biomechanics
48103796|NCT04586036|OTHER|ankle joint brace 5|The influence of ankle joint brace 5 on gait biomechanics
48103797|NCT06182319|DRUG|Gastrografin|Administration of WSC (Gastrografin) 2 hours after placement of NGT.
48103798|NCT06182319|DRUG|Saline|Administration of Saline 2 hours after placement of NGT.
47945619|NCT00140634|BIOLOGICAL|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
47945620|NCT00002895|DRUG|chemotherapy|
47945621|NCT00470847|DRUG|Lapatinib|Orally twice daily
48103799|NCT06182319|PROCEDURE|SBO Treatment Without NG Tubes|Patients who decline to have NG tubes placed will be enrolled and followed with the same outcomes protocol as the other patients in the trial
48103800|NCT05493462|DRUG|Human FGF-1|Intranasal administration of human FGF-1
48103801|NCT01409512|PROCEDURE|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
48103802|NCT05420168|OTHER|Automatic tool to identify inappropriate antibiotic prescriptions|The system will identify inappropriate antibiotic prescriptions.
48103803|NCT00545324|DRUG|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
47945622|NCT00470847|PROCEDURE|Whole Brain Radiation|15 treatments over a period of 3 weeks
47945623|NCT00470847|DRUG|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
47945625|NCT03079180|OTHER|Strength training at 80% 1RM|Detailed in Arms section's
48294186|NCT01962636|BIOLOGICAL|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
48294187|NCT04086940|DRUG|Esmolol|preventive
48294188|NCT02008240|PROCEDURE|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
48294189|NCT02008240|PROCEDURE|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
48294190|NCT03334214|DRUG|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
48294191|NCT03334214|DRUG|Placebo|Saline 0.9%
48294192|NCT02652819|DRUG|FG-4592|
48476079|NCT04573296|DEVICE|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
48476080|NCT04573296|BEHAVIORAL|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
48476081|NCT01235715|DRUG|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
48476082|NCT06617572|GENETIC|Non-conforming afamitresgene autoleucel|Non-conforming afamitresgene autoleucel, suspension for intravenous infusion (NC afami-cel), single dose administration
48476083|NCT04030663|DRUG|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
48476084|NCT04030663|DRUG|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
48476085|NCT04030663|DRUG|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
48476086|NCT02274948|DRUG|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
48476087|NCT02274948|DRUG|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
48476088|NCT03359837|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
48476089|NCT03359837|DRUG|Insulin Glulisine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
48476090|NCT03359837|DRUG|Biphasic insulin aspart 30|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
48476091|NCT03359837|DRUG|Repaglinide|"Pharmaceutical form: tablet~Route of administration: oral administration"
48476092|NCT03359837|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
48476093|NCT03359837|DRUG|Metformin|"Pharmaceutical form: tablet or capsule~Route of administration: oral administration"
48476094|NCT03068884|DEVICE|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
48476095|NCT03068884|DIETARY_SUPPLEMENT|L-Tyrosine|Administration of 2 grams tyrosine
48476096|NCT03068884|DEVICE|Transcranial direct current stimulation (sham)|Sham tDCS
48476097|NCT03068884|DIETARY_SUPPLEMENT|Cellulose (placebo)|Administration of 2 grams cellulose
47945626|NCT03079180|OTHER|Strength training at 55% 1RM|Detailed in Arms section's
47945627|NCT00638807|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
47945628|NCT00638807|OTHER|Placebo|Matched oral placebo for 6 weeks
47945629|NCT02645721|BEHAVIORAL|Extended self-help program with guidance|See arm description for Experimental
47945630|NCT02645721|BEHAVIORAL|Briefer Self-help program, no guidance|See arm description for Active Comparator
47945631|NCT02645721|BEHAVIORAL|WL: Extended self-help program, choice of guidance intensity|See arm description for Waiting list.
47945632|NCT04810663|RADIATION|Radiotherapy|Adjuvant Radiotherapy in operated gastric cancer
47945633|NCT06253546|DRUG|TV-44749|"Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection"
47945634|NCT06253546|DRUG|Oral Olanzapine|"Pharmaceutical form:~tablet~Route of administration:~oral"
48294193|NCT02652819|DRUG|Placebo|
48294194|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
48294195|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
48294196|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
48294197|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
48294198|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
48294199|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
48294200|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
48294201|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
48294202|NCT01343719|DRUG|BI 661051|low dose tablet
48294203|NCT01343719|DRUG|Placebo|solution for administration
48476098|NCT02039063|DRUG|E6011 2 mg/kg|
48476099|NCT02039063|DRUG|E6011 5 mg/kg|
48476100|NCT02039063|DRUG|E6011 10 mg/kg|
48476101|NCT02039063|DRUG|E6011 15 mg/kg|
48476102|NCT06157463|RADIATION|Ga-68 FAPI|FAPI PET scans will be performed in addition to other staging/restaging work-up
48476103|NCT04325854|PROCEDURE|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
48633464|NCT06424535|OTHER|Chinese medicine for internal or external use、Acupuncture or Laser acupuncture pen treatment、Acupoint Tuina massage、Acupoint application of traditional Chinese herbal medicinal cake|"The treatment project a Chinese medicine practitioner based individual needs of the patient, and will be followed by a four-week treatment.~1. Traditional Chinese medicine for internal or external use: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them twice a week for 20 minutes each time.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint once a day~5. Nursing and health education and guidance~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes."
47945635|NCT04533633|PROCEDURE|Retrograde Percutaneous Coronary Intervention of Chronic Total Occlusion|Retrograde CTO-PCI using epicardial collateral connections
48103804|NCT00545324|DRUG|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
48476104|NCT06616584|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48476105|NCT06616584|BIOLOGICAL|Cemiplimab|Given IV
48476106|NCT06616584|PROCEDURE|Computed Tomography|Undergo CT
48476107|NCT06616584|DRUG|Dexamethasone|Given PO
48103805|NCT02907593|DRUG|Budesonide in Calfactant|Budesonide in Calfactant
48103806|NCT00414206|DRUG|Mecamylamine|
48476108|NCT06616584|DRUG|Docetaxel|Given IV
48476109|NCT06616584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48476110|NCT06616584|BIOLOGICAL|Ramucirumab|Given IV
48633465|NCT06424535|OTHER|Western medicine|Patients will receive routine Western medicine treatments as per individual patient's needs. The medications and bandages can vary due to the depth and size of the burn and scald.
48103807|NCT00414206|DRUG|Placebo|
48103808|NCT06116058|OTHER|Experimental: Group A: integrated neuromuscular inhibition technique|will receive integrated neuromuscular inhibition in addition to conventional treatment,INIT which included IC, SCS, and MET for the low back region for the quadratus lumborum( QL) and erector spinae (ES) muscles
48103809|NCT06116058|OTHER|Experimental: Group B :Instrument assissted soft tissue mobilization|IASTM performed on lumbar posterior muscle erector spinae (iliocostalis, longissimus), and quadratus lumborum(QL) The IASTM treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers being treated with the instrument at a 45° angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45° angle for an additional 20-seconds, resulting in a total treatment time of approximately 40 seconds.
47945636|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|CART22-65s are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD22 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
48103810|NCT06116058|OTHER|control group C conventional physical therapy|. The control group will applied general exercise. General exercise were applied with stretching exercises and stationary bicycling for 10-15 minutes14, 15) . Three sets of fifteen repetitions will performed, with rest times of 1 minute between sets during 4 weeks.
48294204|NCT01343719|DRUG|BI 661051|medium dose tablet
48294205|NCT02792777|OTHER|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
48294206|NCT02792777|OTHER|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
48294207|NCT04468750|DEVICE|kinesiotape|During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
48294208|NCT00003139|DRUG|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
48294209|NCT00003139|OTHER|Placebo|
48620060|NCT05604313|DEVICE|Ergonomic chinrest used with low shoulder rest (EC)|Participants will play the violin using the ergonomic chinrest with a low Kun Super shoulder rest (EC) for two weeks before the test day (crossover study), measuring upper body kinematic and muscle activity. The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
47945637|NCT05674175|BIOLOGICAL|Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)|HuCART19 cells are autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity for CD19 linked to an intracellular signaling molecule consisting of a tandem signaling domain comprised of the TCRζ signaling module linked to the 4-1BB costimulatory domain
47945638|NCT05921747|OTHER|Standard core stability exercise program|The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
47945639|NCT05921747|DEVICE|Off-the-shelf virtual reality system|HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.
47945640|NCT03213600|DEVICE|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
47945641|NCT05843760|OTHER|personal information form|undergraduate student(participants) will be asked; age, weight, height, smoking and alcohol use, and headache.
47945642|NCT05843760|OTHER|headache-specific questionnaires|ıd migraine test, numeric rate scale, hit-6 headache impact test, headache information form
47945643|NCT05843760|OTHER|Questionnaires for assessing biopsychosocial status|hospital anxiety depression, Discomfort Intolerance Test, pittsburgh sleep quality index, fatigue severity scale, self compassion scale, Body Awareness Questionarre, cervical range of motion, İnternational Physical Activity Questionnaire, 12-Item Short-Form Health Survey
47945644|NCT02325310|BIOLOGICAL|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
48294210|NCT00984659|DRUG|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
48620061|NCT02474641|RADIATION|Standard Radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
48633466|NCT01178411|DRUG|Tivantinib|Tivantinib 360 mg (3 x 120 mg tablets or capsules) twice daily by mouth.
47945645|NCT06558006|DRUG|Predimenol tablet|2 tablets of Predimenol (400 mg Predimenol) will be taken with 220 mL of water (one glass of water).
47945646|NCT06558006|DRUG|Predimenol tablet + Placebo tablet of Predimenol|1 tablet of Predimenol (200 mg Predimenol) + 1 tablet of placebo will be taken with 220 mL of water (one glass of water).
47945647|NCT06558006|DRUG|Placebo tablet of Predimenol|2 tablets of placebo tablet of Predimenol will be taken with 220 mL of water (one glass of water).
47945648|NCT03293797|BEHAVIORAL|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
47945649|NCT01572259|DRUG|Growth Hormone|
47945650|NCT01572259|OTHER|interruption of the traitment with growth hormone|
47945651|NCT03126903|DEVICE|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
48633467|NCT01178411|DRUG|Anti-Cancer Combination Therapy|Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the same dose and schedule in which they were administered in the original (previous) study.
48633468|NCT05234333|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccination
47945652|NCT03036306|DRUG|SCX-001|Nefopam cream formulation
47945653|NCT03036306|OTHER|Placebo|Cream formulation without Nefopam
48103811|NCT05577611|COMBINATION_PRODUCT|Basic chemotherapy + UCB transplantation|"The basic chemotherapy regimen was the same as that of the control group~UCB micro transplantation scheme:~Aza 100mg, 75mg/m2/d, IVGTT, D-10 to D-4~Ara-C 1000mg/m2/q12h, IVGTT, D-3 to D-2~Single non consanguineous umbilical cord blood (NC \> 1.5 \* 10 \^ 7 / kg), IVGTT, D0~Bone marrow aspiration smear, MRD and bone marrow chimerism were detected on D14, d30 and D60 after transplantation."
48294211|NCT00984659|DRUG|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
48294212|NCT00984659|DRUG|Placebo|Placebo DISKUS twice a day for 8 weeks
48294213|NCT04841668|DRUG|Metformin|Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
48294214|NCT00866294|DRUG|paroxetine IR 10mg tablet|1 or 2 tablets once a day
48294215|NCT00866294|DRUG|paroxetine IR 20mg tablet|1 tablet once a day
48620062|NCT02474641|RADIATION|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
48633469|NCT05508594|DRUG|CT001|Intranasal
48633470|NCT05508594|DRUG|Placebo|Intranasal
47945654|NCT04648254|DRUG|Q702|The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
47945655|NCT05573828|PROCEDURE|ICG angiography to show vascular map of parathyroid glands|Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
47945656|NCT06374771|DRUG|Melatonin 10 MG|10 mg of Melatonin will be given orally pre and post-operative
47945657|NCT06374771|DRUG|Vitamin C|1 gm of Vitamin C will be given orally pre and post-operative
47945658|NCT06517563|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
47945659|NCT06517563|DRUG|Rivaroxaban|FXa Inhibitor
47945660|NCT06517563|DRUG|UFH|Unfractionated Heparin
47945661|NCT06517563|DRUG|Enoxaparin|Low Molecular Weight Heparin
47945662|NCT05005754|DIETARY_SUPPLEMENT|Probiotics|During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
47945663|NCT05005754|DIETARY_SUPPLEMENT|Placebo control|During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
48476111|NCT06580327|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
48476112|NCT06580327|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
48103812|NCT02664337|OTHER|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
48476113|NCT06196944|BEHAVIORAL|Augmentative Alternative Communication|Traditional Method
48476114|NCT06196944|OTHER|Augmentative Alternative Communication Device|Augmentative Alternative Communication Device 3 session for 40 minutes
48476115|NCT02323802|BEHAVIORAL|educational group intervention|
48476116|NCT02323802|BEHAVIORAL|prescriptive diet|
48476117|NCT00116480|DRUG|Misoprostol|600 mcg of sublingual misoprostol
48476118|NCT00353652|DRUG|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
48476119|NCT00353652|DRUG|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
48633471|NCT05508594|DRUG|Sufentanil|Intranasal
48633472|NCT05508594|DRUG|Ketamine|Intranasal
48633473|NCT02182453|DRUG|BI 10773 - single rising dose|
48103813|NCT02664337|OTHER|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
48294216|NCT00866294|DRUG|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
48294217|NCT00866294|DRUG|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
48294218|NCT00866294|DRUG|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
48294219|NCT00866294|DRUG|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
48294220|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
48633474|NCT02182453|DRUG|Placebo|
48633475|NCT03838328|DRUG|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
48633476|NCT01953276|DEVICE|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
48294221|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
48294222|NCT05928026|BEHAVIORAL|Financial Support|A debit card will be loaded with $500 and can be used like a typical debit card.
48476120|NCT00353652|DRUG|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
48476121|NCT00353652|DRUG|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
48476122|NCT00353652|DRUG|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
48476123|NCT06616935|OTHER|Intervention group one, community activities.|"Intervention group one: participants will have a list of free activities in the community provided by third sector organisations to choose from. Participants will be referred to their chosen activities and expected to attend for six months.~Intervention group two: Participants will attend weekly online exercises and activities led by the researcher."
48476124|NCT06616935|OTHER|Intervention group two|Online exercises and activities
48476125|NCT02721706|OTHER|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h \<50%, serum albumin \<3 g/dl, body mass index \<18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
48476126|NCT04761471|DEVICE|TI transcranial electrical stimulation|"Participants will undergo transcranial electrical stimulation, which will be delivered with low current amplitudes (\<= 2 mA) established with international safety guidelines for electrical stimulation. Threshold for the current amplitude will be established by participants themselves, such that they cannot distinguish when stimulation is applied and not applied.~Duration of stimulation will not last longer than 30 minutes."
48476127|NCT05250206|OTHER|Myopia control lens|Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
48476128|NCT00981799|DRUG|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
48476129|NCT00981799|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
48476130|NCT00981799|DRUG|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
48476131|NCT00981799|DRUG|Methotrexate|"Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age"
48476132|NCT00981799|DRUG|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.
48476133|NCT00217724|DIETARY_SUPPLEMENT|glutamine|Given orally
48476134|NCT00217724|OTHER|placebo|Given orally
48633477|NCT02913859|RADIATION|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
48633478|NCT02913859|DRUG|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
48294223|NCT02365532|DRUG|GS-6615|GS-6615 tablets administered orally
48294224|NCT02365532|DRUG|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
48476135|NCT02741154|DRUG|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
48476136|NCT02741154|DRUG|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
48476137|NCT02741154|DRUG|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
48476138|NCT02741154|DRUG|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
48294225|NCT02365532|DRUG|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
48294226|NCT02365532|DRUG|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
48476139|NCT06172855|DEVICE|Electroacupuncture at ST36|Electroacupuncture at ST36, which located at the anterior aspect of the lower leg, 3 cun below ST 35, one finger-breadth (middle finger) from the anterior crest of the tibia. Twice or 3 times per week, for 6 weeks.
48476140|NCT00890331|BEHAVIORAL|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
48476141|NCT00890331|BEHAVIORAL|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
48476142|NCT01606228|DRUG|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
48476143|NCT00443482|DRUG|formoterol|
48476144|NCT06607718|OTHER|Resistance Training|Resistance training for elderly patients in the acute care unit.
48476145|NCT06607718|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|To receive two daily packs of a hypercaloric and hyperproteic oral nutritional supplement for 3 months.
48633479|NCT05754112|OTHER|B lymphocyte profiling|All individuals will undergo peripheral venous blood sampling and ultrasound-guided synovial tissue biopsy following a standardized procedure. B-lymphocytes will be sorted from PBMCs isolated by Ficoll gradient method using magnetic CD19-microbeads whereas tissue B-lymphocytes will be isolated from synovial tissue biopsies digested with Liberase. CD19 positive cells from PBMC will be incubated with pro-inflammatory molecules in presence or absence of Ubadacitinib. After stimulation, CD19 positive cells will be collected and processed for single cell RNA sequencing. Moreover, the impact of JAK-1 selective inhibition on B-lymphocyte cultures stimulation will be tested using ELISA method for the assessment of cytokines/chemokines production. Synovial tissue and synovial tissue B-lymphocyte subpopulations will be assessed through FACS analysis using IgD/CD27 classification. Finally, we will compare the transcriptomic profile of synovial tissue B lymphocytes from 5 subject groups.
48633480|NCT04134312|BIOLOGICAL|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
48633481|NCT00676754|PROCEDURE|Statens Serum Institut RT23 2TU tuberculin|
48633482|NCT00392275|DRUG|Ofloxacin 0.3%|
48476146|NCT06607718|OTHER|Control Group|No intervention
48476147|NCT01636817|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
48633483|NCT00392275|DRUG|Ciprofloxacin 0.3%|
48633484|NCT00392275|DRUG|Levofloxacin 0.5%|
48633485|NCT00392275|DRUG|Ofloxacin 400mg|
48633486|NCT00392275|DRUG|Ciprofloxacin 400mg|
48633487|NCT00392275|DRUG|Levofloxacin 250mg|
48476148|NCT01636817|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
48476149|NCT03381196|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6).
48103814|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)|During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.
48633488|NCT02077712|DRUG|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
48633489|NCT01297244|DRUG|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
48633490|NCT04331171|DEVICE|Web application users|questionnaire of comorbidity and symptoms completed by the patient on his smartphone
48633491|NCT02576366|DRUG|Voriconazole|
48633492|NCT02576366|DRUG|Rifampin|
48476150|NCT03381196|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).
48476151|NCT03381196|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
48633493|NCT02834897|RADIATION|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
48633494|NCT03079583|DIETARY_SUPPLEMENT|Intervention-group|Biofortified Rice is grown by foliar Zn application
48633495|NCT03079583|DIETARY_SUPPLEMENT|Control-group|Control Rice with normal zinc levels
48633496|NCT04347759|OTHER|Symptom Care at Home-Heart Failure|When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad. Based on symptom severity, intervention group will receive automated coaching messages. There will be a toll-free number for participants to call and a password to log into the system which will be stored on a secure and HIPPA-compliant sever. Calls can be personalized to allow the voice to greet the patient by name.
48633497|NCT04026516|DEVICE|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
48633498|NCT05373966|OTHER|Delphi Questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of robotic RNU. The Delphi questionnaire will be administered via Welphi.com.~In the first survey, panel members will outline the training program for robotic RNU.~In subsequent surveys, the expert panel will evaluate the modified criteria using a 1 to 5-point Likert scale with space provided for suggested edits and comments. Multiple rounds will be conducted until consensus is reached. After each round of Likert responses, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 80% in the first round or need further explanation, additional rounds of the survey may be performed."
48633499|NCT01898130|BIOLOGICAL|bevacizumab|Given IV
48633500|NCT01898130|PROCEDURE|quality-of-life assessment|Ancillary studies
47945664|NCT02284360|DRUG|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
47945665|NCT01385371|BIOLOGICAL|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
47945666|NCT01385371|BIOLOGICAL|Placebo for SCH 697243|One dissolving tablet sublingually once daily
48294227|NCT01691729|DEVICE|Ostomy accessory|Wearing each of the devices for 10 days each
48294228|NCT03997474|BIOLOGICAL|ATL001|ATL001 infusion
47945667|NCT02685514|DEVICE|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
47945668|NCT02714907|DEVICE|Cortrium C3 device|Data is read from Cortrium C3 monitor
48294229|NCT03997474|DRUG|Checkpoint Inhibitor|Nivolumab
48294230|NCT02732912|DEVICE|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
48294231|NCT02732912|DEVICE|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
48294232|NCT02732912|DRUG|Zopiclone|This night sedation will be given to any patient requesting it, in either group
48294233|NCT03488940|DEVICE|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
48294234|NCT03488940|DEVICE|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
48476152|NCT06132152|PROCEDURE|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
48620063|NCT03555929|DRUG|Dexamethasone|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
48633501|NCT01113814|DEVICE|FibroScan|
48633502|NCT01113814|DEVICE|Acoustic Radiation Force Impulse (ARFI)- Imaging|
48633503|NCT00003327|DRUG|paclitaxel|
47945669|NCT02714907|DEVICE|Holter device|Date is read from Holter device
47945670|NCT00094029|DRUG|Sutent|Sutent, 25, 37.5, or 50 mg daily
47945671|NCT04769856|OTHER|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
47945672|NCT04769856|OTHER|Satisfaction scale|Satisfaction scale
48103815|NCT05756998|DEVICE|Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)|During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.
48633504|NCT00330278|DRUG|Cefazolin|
48633505|NCT03476512|OTHER|Adherence Education|Patients were given adherence education to resolve the identified deficits
47945673|NCT01134315|DRUG|Paricalcitol|
47945674|NCT01134315|DRUG|Calcitriol|
47945675|NCT01826071|OTHER|Static Stretch|
47945676|NCT01826071|OTHER|Active Elongation|
47945677|NCT01310881|DRUG|NSI-189 Phosphate|Once daily oral administration
47945678|NCT06391346|DIAGNOSTIC_TEST|MSOT|Non-invasive transcutaneous imaging of muscle components via infrared and near-infrared laser pulses
47945679|NCT01279473|DRUG|Nilotinib|
47945680|NCT04594148|BEHAVIORAL|Weight-shift training|Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
47945681|NCT04290312|OTHER|Mastiha oil|After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing \~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
48476153|NCT06132152|PROCEDURE|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
47945682|NCT03188627|BIOLOGICAL|Bronchial basal cells|Transplantation of autologous bronchial basal cells
47945683|NCT00132639|DRUG|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
47945684|NCT00132639|DRUG|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
47945685|NCT04645420|PROCEDURE|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
47945686|NCT05729230|BEHAVIORAL|Questionnaire|"Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease.~Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients."
47945687|NCT03190369|DEVICE|Hylan G-F 20 (GZ402662/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
47945688|NCT03190369|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
47945689|NCT03090412|DRUG|HPPH|Given IV
47945690|NCT03090412|OTHER|Laboratory Biomarker Analysis|Correlative studies
47945691|NCT03090412|DRUG|Photodynamic Therapy|Undergo PDT
47945692|NCT03090412|OTHER|Quality-of-Life Assessment|Ancillary studies
47945693|NCT03090412|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
47945694|NCT02076633|DRUG|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
47945695|NCT04634890|BEHAVIORAL|Exercise intervention|Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
48476154|NCT04124029|DEVICE|No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|No intervention will be used.
47945696|NCT00351988|BEHAVIORAL|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
48476155|NCT04124029|PROCEDURE|No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.|No intervention will be used.
48633506|NCT03800628|OTHER|qualitative study|semi-structured interviews
48103816|NCT05756998|PROCEDURE|cesarian section|Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
48103817|NCT05095558|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
48476156|NCT05486845|OTHER|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
48476157|NCT00130234|DRUG|Xolair® (Omalizumab)|
48476158|NCT01765517|DIETARY_SUPPLEMENT|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
48476159|NCT01765517|DIETARY_SUPPLEMENT|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
48476160|NCT00531362|DRUG|Plain aspirin|Plain aspirin 75 mg or 150 mg
48476161|NCT03059485|BIOLOGICAL|DC/AML Fusion Vaccine|The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
48476162|NCT03059485|OTHER|Observation|Traditional care provided by the hospital.
47945697|NCT00351988|BEHAVIORAL|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
47945698|NCT00641303|PROCEDURE|acupuncture therapy|Given weekly for 8 sessions
48294235|NCT03488940|DEVICE|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
48294237|NCT04958564|DEVICE|DCP|"1. Dynamic compression plating to compress the fracture~2. Intramedullary device to share the load."
48294238|NCT01369693|PROCEDURE|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
48294239|NCT06298292|DIETARY_SUPPLEMENT|Zero minis (range of protein substitutes in tablet form)|Intervention: range of protein substitute tablets. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemias or alkaptonuria, homocystinuria, or MSUD will be recruited. Subjects will take the study product for 7 days. Daily questionnaires will be completed (ease of preparation,administration; any problems or gastrointestinal effects). Subjects will replace some or their entire usual protein substitute with the new product suitable for their diagnosed rare metabolic disease. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Additional questions at the beginning and end of the study will record information on organoleptic properties, presentation and packaging of the product. Routine weekly blood samples will be collected and analysed for amino acids typically for the metabolic control of the individual specified metabolic disorders as is usual clinical practice.
48294240|NCT06232122|DIAGNOSTIC_TEST|68Ga-FAPI-46|Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
48294241|NCT06232122|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 5-10mCi 18F-FDG
48294242|NCT06140407|DRUG|Cisplatin|Receive Cisplatin
48294243|NCT06140407|DRUG|Carboplatin|Receive Carboplatin
48294244|NCT06140407|DRUG|Etoposide|Receive Etoposide
48294245|NCT06140407|BIOLOGICAL|Pembrolizumab|Receive Pembrolizumab by IV
48294246|NCT06140407|PROCEDURE|Computed Tomography|Undergo Computed Tomography
48294247|NCT06140407|PROCEDURE|Positron Emission Tomography|Undergo Positron Emission Tomography
48294248|NCT06140407|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
48294249|NCT06140407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48294250|NCT06140407|RADIATION|Radiation Therapy|Undergo Radiation Therapy
48294251|NCT02831491|DRUG|Ramucirumab|Administered IV
48294252|NCT02831491|DRUG|Docetaxel|Administered IV
48294253|NCT04589494|DRUG|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
48294254|NCT05777811|PROCEDURE|Vertically coronally advanced flap combined with connective tissue graft.|The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.
48294255|NCT05777811|PROCEDURE|Free gingival graft|A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
48294256|NCT02297893|BEHAVIORAL|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
47945699|NCT00641303|PROCEDURE|sham intervention|Given weekly for 8 sessions
48294257|NCT02297893|BEHAVIORAL|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
48294258|NCT04416776|DRUG|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
48294259|NCT05495399|PROCEDURE|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
48294260|NCT05495399|RADIATION|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
48294261|NCT05873140|BEHAVIORAL|application LINE|Online lifestyle modification education for weight loss
48294262|NCT00126464|DRUG|fulvestrant|
48294263|NCT00126464|DRUG|tamoxifen citrate|
48294264|NCT00126464|PROCEDURE|conventional surgery|
48294265|NCT00126464|PROCEDURE|neoadjuvant therapy|
48294266|NCT02571179|DRUG|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
48103818|NCT00044928|DRUG|Piperacillin/Tazobactam|
48633507|NCT03461809|OTHER|Ocular acupuncture|Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
48633508|NCT00930787|DEVICE|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
48633509|NCT00930787|DEVICE|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
48633510|NCT02740582|DRUG|Tolcapone|
47945700|NCT05231044|DRUG|KX01 ointment 1%|The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
47945701|NCT05231044|DRUG|Placebo|Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
47945702|NCT04258514|PROCEDURE|Virtual Reality during vasectomy|Virtual Reality
48633511|NCT02740582|DRUG|Placebo|
48633512|NCT05612607|DRUG|Immunoglobulin replacement therapy (IGRT)|IGRT discontinuation will be dependent on participant's SMB levels. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.
47945703|NCT04258514|PROCEDURE|Standard Vasectomy|No Virtual Reality
47945704|NCT01222884|DRUG|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
47945705|NCT01222884|DRUG|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
47945706|NCT00794781|DRUG|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
48294267|NCT03176966|DRUG|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
48294268|NCT03176966|DRUG|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
48294269|NCT03176966|OTHER|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
47945707|NCT02938039|DEVICE|Ambu LMA|Ambu Laryngeal Mask Airways
47945708|NCT02938039|DEVICE|I-Gel LMA|I-Gel Laryngeal Mask Airways
48103819|NCT04074902|DEVICE|Ultrasonography|Mindray dp1100 plus.
48103820|NCT02082405|DRUG|bortezomib|Given SC or IV
48103821|NCT02082405|DRUG|cyclophosphamide|Given PO
48294270|NCT01202110|DRUG|Propranolol|
48294271|NCT00676559|DRUG|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
48476163|NCT00074750|DRUG|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
48294272|NCT00676559|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
48476164|NCT04201470|OTHER|Blood withdrawal|Measurement of serum neurofilaments light chain and GFAP
48476165|NCT04201470|OTHER|MRI|Cervical and cerebral MRI without contrast injection
48476166|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Patients|EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
48476167|NCT04201470|OTHER|Neurologic / neuropsychologic tests - Controls|NHPT, T25FW, CSCT
48476168|NCT00959322|DEVICE|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
48476169|NCT03746106|DRUG|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
48476170|NCT03746106|DRUG|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
48476171|NCT03746106|DIETARY_SUPPLEMENT|Vitamin B1|5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
48476172|NCT00700817|DRUG|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
48476173|NCT00700817|DRUG|sitagliptin|Tablets, 100 mg daily
48476174|NCT00700817|DRUG|metformin|Tablets, minimum 1500 mg daily
48476175|NCT00700817|DRUG|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
48476176|NCT04351347|DRUG|Ivermectin|ivermectin
48476177|NCT06396507|DRUG|Permethrin Solution|permethrin 5 % solution
48476178|NCT06396507|DRUG|Sulfur|Sulfur 10%+ vaseline 90 % ointment
48476179|NCT01279655|DEVICE|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
48476180|NCT01279655|BEHAVIORAL|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
48476181|NCT04314843|DRUG|Cyclophosphamide|Administered according to package insert
48476182|NCT04314843|DRUG|Fludarabine|Administered according to package insert
48476183|NCT04314843|BIOLOGICAL|Lenzilumab|Administered as an IV infusion
48476184|NCT04314843|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.
48476185|NCT03388502|OTHER|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
47945709|NCT02777736|DRUG|Methotrexate|i.v. or intrathecal CNS prophylaxis
47945710|NCT02521571|BEHAVIORAL|Resiliance Alliance|"The intervention is 6 months long \& is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs \& Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
48633513|NCT05866328|OTHER|Cognitive Rehabilitation and Individual Placement and Support|Cognitive Rehabilitation and Individual Placement and Support
48633514|NCT03946410|DIAGNOSTIC_TEST|Invitation to screening|Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
48633515|NCT04334811|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.
48633516|NCT01426555|OTHER|FES-Rowing|FES- Rowing Exercise
47945711|NCT02521571|BEHAVIORAL|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
47945712|NCT00915356|DRUG|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
47945713|NCT00915356|DRUG|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
47945714|NCT05399303|PROCEDURE|obturation|obturation using different types of sealers
47945715|NCT01977937|DRUG|Gabapentin 250mg/5mL NDC:59762-5025-01|
47945716|NCT01977937|DRUG|Simple Syrup|
47945717|NCT00600535|DRUG|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
47945718|NCT00600535|DRUG|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
47945719|NCT00600535|DRUG|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
48103822|NCT02082405|DRUG|dexamethasone|Given PO
48633517|NCT01426555|DRUG|Zoledronic acid|5 mg IV single dose
47945720|NCT00600535|DRUG|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
48103823|NCT02082405|OTHER|laboratory biomarker analysis|Optional correlative studies
48103824|NCT02082405|OTHER|quality-of-life assessment|Ancillary studies
48103825|NCT06003608|DEVICE|Fluid biopsy capsule|Ingestion of two SIMBA capsules
48103826|NCT06003608|DRUG|Levodopa-Carbidopa Immediate Release|Single dose, Levodopa-Carbidopa Immediate Release
48103827|NCT04559243|DIAGNOSTIC_TEST|Transthoracic Echocardiography|After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.
48103828|NCT05349097|DRUG|SAD IMG-004 30mg|Each participant will be randomized to receive a single oral dose of 30mg IMG-004
48103829|NCT05349097|DRUG|SAD IMG-004 100mg|Each participant will be randomized to receive a single oral dose of 100mg IMG-004
48103830|NCT05349097|DRUG|SAD IMG-004 200mg|Each participant will be randomized to receive a single oral dose of 200mg IMG-004
48103831|NCT05349097|DRUG|SAD IMG-004 400mg|Each participant will be randomized to receive a single oral dose of 400mg IMG-004
48633518|NCT05616780|OTHER|Physiological test|Lung volume measurements will be obtained using nitrogen washout and body plethysmography
48633519|NCT02931539|DRUG|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
48633520|NCT02931539|DRUG|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
48633521|NCT02931539|DRUG|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
48633522|NCT02931539|DRUG|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
48633523|NCT02931539|DRUG|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
48633524|NCT00170820|DRUG|Everolimus|
48103832|NCT05349097|DRUG|SAD IMG-004 600mg|Each participant will be randomized to receive a single oral dose of 600mg IMG-004
48103833|NCT05349097|DRUG|SAD Placebo 30mg|Each participant will be randomized to receive a single oral dose of 30mg matching placebo
48103834|NCT05349097|DRUG|SAD Placebo 100mg|Each participant will be randomized to receive a single oral dose of 100mg matching placebo
48103835|NCT05349097|DRUG|SAD Placebo 200mg|Each participant will be randomized to receive a single oral dose of 200mg matching placebo
48103836|NCT05349097|DRUG|SAD Placebo 400mg|Each participant will be randomized to receive a single oral dose of 400mg matching placebo
48633525|NCT00118859|BEHAVIORAL|Integrative care for low back pain|
48633526|NCT00118859|BEHAVIORAL|Conventional treatment for low back pain|
47945721|NCT00600535|DRUG|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
48294273|NCT03700892|OTHER|Cinnamaldehyde e-liquid|Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
48294274|NCT03700892|OTHER|PG/VG e-liquid|Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
48294275|NCT02727114|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
48294276|NCT04888221|DRUG|Tocilizumab|"Tocilizumab will be administered subcutaneously at a dose of 162mg/0.9mL weekly (each week, on the same day) from week 0 to week 24.~At the first injection (Baseline D0), a therapeutic education is provided for patients/caregivers who can carry out the injections themselves as part of their usual care."
48294277|NCT04888221|DRUG|Placebo|Placebo administered subcutaneously (SC) weekly during 24 weeks
48476186|NCT03388502|OTHER|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education \& teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
48476187|NCT02060045|OTHER|Bundle implementation|
48476188|NCT05569330|OTHER|Air purification|Aerosol particles are removed from room air by several methods
48476189|NCT02354911|BIOLOGICAL|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (\~10 million cells/injection).
48476190|NCT02354911|OTHER|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
48476191|NCT02076516|DEVICE|Drug-eluting stent: CORACTO®|
48476192|NCT06109701|PROCEDURE|Debridement with ultrasonic device and scaling with plastic curettes|Supragingival and subgingival debridement
48476193|NCT06109701|PROCEDURE|Debridement with erythritol based air-polishing powde|Supragingival and subgingival debridement
48476194|NCT00686244|OTHER|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
48476195|NCT05317195|OTHER|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
48476196|NCT05317195|OTHER|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
48476197|NCT05317195|OTHER|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
48476198|NCT05317195|OTHER|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
48476199|NCT05317195|OTHER|Velo-NP|Velo-NP; 10 mg nicotine;
48476200|NCT05317195|OTHER|Zyn-NP|Zyn-NP; 3 mg nicotine;
48476201|NCT04826289|RADIATION|X rays|Radiological assessment of vertical distance between medial and lateral malleolus in normal opulation
47945722|NCT00600535|DRUG|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
47945723|NCT00600535|DRUG|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
48103837|NCT05349097|DRUG|SAD Placebo 600mg|Each participant will be randomized to receive a single oral dose of 600mg matching placebo
48103838|NCT05349097|DRUG|MAD IMG-004 50mg|Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
48103839|NCT05349097|DRUG|MAD Placebo 50mg|Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
48476202|NCT05118516|DRUG|ASC43F|One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
48476203|NCT00663715|OTHER|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
48476204|NCT00067171|BEHAVIORAL|Behavior Therapy|
48476205|NCT05178576|DRUG|Gevokizumab|120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
48476206|NCT05178576|DIAGNOSTIC_TEST|Signatera test|ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
48476207|NCT02851732|BEHAVIORAL|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
48476208|NCT02010255|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
48476209|NCT02010255|DRUG|RBV|RBV tablets administered orally in a divided daily dose
48476210|NCT01575262|BEHAVIORAL|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
48633527|NCT02731859|DEVICE|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
48633528|NCT04559672|PROCEDURE|Cervical laminoplasty surgery|The posterior standard cervical laminoplasty procedure with ARCH mini-plate fixation
47945724|NCT00530101|DRUG|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
47945725|NCT05515172|OTHER|Mindfulness-based Intervention|"The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks."
47945726|NCT02632643|BEHAVIORAL|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
47945727|NCT00090051|DRUG|Rituximab|Intravenous repeating dose
47945728|NCT00090051|DRUG|Fludarabine Phosphate|Intravenous repeating dose
47945729|NCT00090051|DRUG|Cyclophosphamide|Intravenous repeating dose
47945730|NCT05113290|DRUG|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
47945731|NCT05113290|DRUG|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
47945732|NCT05591131|OTHER|genetic testing|Undergo genetic testing
47945733|NCT05591131|OTHER|Survey Administration|Complete survey
48103840|NCT05349097|DRUG|MAD IMG-004 150mg|Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
48103841|NCT05349097|DRUG|MAD Placebo 150mg|Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
48294278|NCT06663371|BEHAVIORAL|Basic Physical Fitness|The single module training paradigm followed a circuit-style format, with each training module consisting of 6 to 8 distinct exercise movements. Taking the INT training intervention on Mondays as an example, the training protocol involved completing one major module (e.g., plyometric exercises) before transitioning to another module (e.g., core stability exercises). Specific exercise methods, such as box jumps, were performed until all sets were completed before moving on to the next exercise (e.g., continuous depth jumps).
48476211|NCT01575262|BEHAVIORAL|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
48633529|NCT04559672|PROCEDURE|Cervical laminectomy and fusion surgery|The posterior standard cervical laminectomy and fusion surgery procedure with lateral mass screws fixation
48633530|NCT03142451|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
48476212|NCT04015960|OTHER|no intervention|qualitative research and patient reported outcome measure (PROm) development
47945734|NCT01886716|BEHAVIORAL|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
47945735|NCT01886716|BEHAVIORAL|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
47945736|NCT01886716|BEHAVIORAL|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
47945737|NCT05594810|BEHAVIORAL|TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)|A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.
47945738|NCT05594810|BEHAVIORAL|TAU only: Community Reinforcement Approach (CRA) + SCP|"CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded."
47945739|NCT04095832|PROCEDURE|Epidural anesthesia|Epidural anesthesia using standardized technique
48103842|NCT05349097|DRUG|MAD IMG-004 300mg|Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
48103843|NCT05349097|DRUG|MAD Placebo 300mg|Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
48103844|NCT05349097|DRUG|FE IMG-004 150mg|A single dose of IMG-004 at 150 mg dose level will be administered to the participants in fed and fasted states
48103845|NCT05252871|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
48103846|NCT05586230|DRUG|Pretomanid|Administered orally based on participant's weight
48103847|NCT05586230|DRUG|Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB|Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
48103848|NCT00325923|BEHAVIORAL|Decision aid|
48103849|NCT05126719|DRUG|MRG003|Administered intravenously
48476213|NCT00746291|OTHER|6 min walk test, Step climbing|walking for 6 minute and climbing steps
47945740|NCT01316471|BEHAVIORAL|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
47945741|NCT01316471|OTHER|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
48633531|NCT03142451|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
48633532|NCT04501445|BEHAVIORAL|Written Summary of Rounds|The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
48633533|NCT00375310|DRUG|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)"
48633534|NCT00375310|PROCEDURE|Radiotherapy|1.8 Gy CTV daily for 5 weeks
48633535|NCT01492803|DIETARY_SUPPLEMENT|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
48633536|NCT01492803|DIETARY_SUPPLEMENT|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
47945742|NCT03578757|BEHAVIORAL|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes...). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
48103850|NCT05126719|DRUG|Capecitabine tablets|Administered peros
48103851|NCT05126719|DRUG|Docetaxel injection|Administered intravenously
48103852|NCT01573858|OTHER|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
48294279|NCT06663371|BEHAVIORAL|Traditional Physical Training|In the fundamental strength training, a circuit training modality is employed, with each training segment comprising 5 to 7 exercise movements. For instance, a series of squat exercises is performed initially, followed by upper body strength training such as bench presses; each movement must be completed with the specified number of sets and repetitions before proceeding to the next exercise. Explosiveness training enhances the rapid contraction capabilities of the muscles through a series of jumping and throwing movements, while flexibility exercises improve the range of motion of muscles and joints through a combination of static and dynamic stretching.
48294280|NCT04886830|PROCEDURE|laparoscopic appendectomy using a single endoloop for appendiceal stump closure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
48294281|NCT04886830|PROCEDURE|laparoscopic appendectomy using two endoloops for appendiceal stump closure|laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
48294282|NCT04886830|PROCEDURE|laparoscopic appendectomy using a clip for appendiceal stump closure|laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
48633537|NCT05951842|DRUG|anesthetic method|Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
48633538|NCT01220063|RADIATION|Radiation|10 Gy for 4 times (total 40 Gy)
48633539|NCT01220063|DRUG|Irinotecan|40 mg/m² : Day 1 and day 8
48633540|NCT01524458|PROCEDURE|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
48633541|NCT01177488|BEHAVIORAL|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
48633542|NCT01894360|DRUG|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
48633543|NCT03466164|BEHAVIORAL|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
48633544|NCT06096948|DEVICE|NEXPOWDER-ENDOHS|Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
48633545|NCT00693108|DRUG|Transdermal testosterone|
48294283|NCT05370248|OTHER|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
48294284|NCT05370248|OTHER|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
48294285|NCT00296283|BEHAVIORAL|integrative behavior couples therapy|
48294286|NCT03891277|DRUG|Ferrous succinate|"Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks."
48294287|NCT06664515|PROCEDURE|Ciro Costagliola|invert flap tecnique
48294288|NCT02297217|DRUG|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
48294289|NCT02297217|RADIATION|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
48294290|NCT05157282|DEVICE|TESS|Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
48294291|NCT05157282|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
48294292|NCT05157282|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
48294293|NCT05157282|DEVICE|sham-TESS|Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
48294294|NCT04936139|BEHAVIORAL|Art Therapy|"During the 12 planned sessions, different artistic disciplines will be used: visual arts, music, play, narrative, dramatization, movement and body expression.~Each session is structured in 3 phases:~i. A first part of encounter and contextualization, to make contact with oneself, with the art therapist and with the group through a relaxation or meditation activity (35 minutes).~ii. A second part, where the session continues with the work of artistic elaboration and production with the different materials and the different artistic languages (50 minutes).~iii. A third part where the participants will be invited to make a closing, a moment to welcome and share whoever wishes, the experiences that have been experienced. A dialogue is created between Work-Patient-Art Therapist (35 minutes)."
48294295|NCT02463123|DEVICE|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
48294296|NCT03610971|DRUG|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
48294297|NCT03610971|DRUG|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
48294298|NCT03500107|DEVICE|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
48294299|NCT00418262|DRUG|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
48294300|NCT01948934|PROCEDURE|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
48294301|NCT02536482|DIETARY_SUPPLEMENT|Amix|Treat the children with cow's milk allergy for 5 months.
48294302|NCT06619990|BIOLOGICAL|XmAb942|Antibody
48294303|NCT06619990|DRUG|Placebo|Placebo
48294304|NCT02016742|DRUG|RDC5|
48294305|NCT00354068|DRUG|imatinib mesylate|
48103853|NCT01573858|OTHER|Acupuncture treatment 2|Needles will be inserted to a depth of \<5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
48294306|NCT00354068|DRUG|temozolomide|
48294307|NCT00354068|OTHER|pharmacological study|
48294308|NCT05014698|GENETIC|WGS|Whole Genome sequencing
48294309|NCT04375631|DRUG|Cladribine|Given IV
48294310|NCT04375631|DRUG|Cyclophosphamide|Given IV
48294311|NCT04375631|DRUG|Cyclosporine|Given IV then PO
48294312|NCT04375631|DRUG|Cytarabine|Given IV
48294313|NCT04375631|BIOLOGICAL|Filgrastim|Given SC
48294314|NCT04375631|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
48294315|NCT04375631|DRUG|Mitoxantrone|Given IV
48294316|NCT04375631|DRUG|Mycophenolate Mofetil|Given IV or PO
48294317|NCT04375631|DRUG|Mycophenolate Sodium|Given PO
48294318|NCT04375631|RADIATION|Total-Body Irradiation|Undergo TBI
48294319|NCT04375631|DRUG|Idarubicin|Given IV
48294320|NCT04375631|DRUG|Fludarabine|Given IV
48294321|NCT04375631|DRUG|Cytarabine|Given IV
48294322|NCT04375631|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48294323|NCT04375631|PROCEDURE|Echocardiography|Undergo ECHO
48476214|NCT02440035|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.
48476215|NCT02440035|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.
48476216|NCT02440035|DRUG|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
48476217|NCT03083977|OTHER|Safe and Sound Protocol|The intervention features music processed based on the resonating frequencies of the middle ear
48103854|NCT01573858|OTHER|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
48476218|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
48476219|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
48476220|NCT02576717|DRUG|RPC1063|
48476221|NCT05509088|DEVICE|high flow nasal cannula|Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
48476222|NCT01283646|DRUG|Apevitin BC|3.5 to 5 ml 3 times a daily
48294324|NCT04375631|PROCEDURE|X-Ray Imaging|Undergo x-ray
48294325|NCT04375631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
48476223|NCT01283646|DRUG|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
48476224|NCT02096367|OTHER|Gait analysis|
48476225|NCT02096367|OTHER|Kinematic gait analysis in lower limb|
48633546|NCT03274349|PROCEDURE|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
48633547|NCT03274349|PROCEDURE|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
48633548|NCT02320825|RADIATION|single-fraction SRS|
48633549|NCT02320825|RADIATION|high-dose hypofractionated SRS|
48294326|NCT04375631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspirate
48294327|NCT04375631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48294328|NCT03905434|GENETIC|miRNA sampling|Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
48294329|NCT03569514|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
48294330|NCT05783869|DEVICE|Echocardiography|echocardiographic study of both groups
48294331|NCT05131321|PROCEDURE|Primary ankle arthrodesis (fusion)|Primary arthrodesis: Subjects allocated to the fusion group will have insertion of a retrograde locked calcaneal nail. Tibiotalar joint preparation, bone grafting, subtalar preparation, and fibulectomy will not be performed unless deemed necessary by the treating surgeon.
48476226|NCT02096367|OTHER|Analysis of static posture|
48476227|NCT02096367|OTHER|Gait on treadmill|Treadmill during 2 minutes
48476228|NCT02096367|DEVICE|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
48476229|NCT03034434|DEVICE|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
48476230|NCT05628441|OTHER|Computer Aided Detection system for Barrett's neoplasia|CADe system running in the back, not directly interfering with patient care
48294332|NCT05131321|PROCEDURE|ORIF (open reduction and internal fixation)|ORIF: ORIF will be performed using modern techniques for timing and staging of fixation, soft tissue and fibula management, surgical approaches, reduction techniques, and plate choice.
48294333|NCT05131321|PROCEDURE|Intramedullary Fibular Nailing (IMFN)|Intramedullary Fibular Nailing: Participants allocated to the IMFN group will receive a locked fibular nail using a previously described technique.
48294334|NCT03799003|DRUG|ASP1951|Intravenously (IV)
48294335|NCT03799003|DRUG|pembrolizumab|Intravenously (IV)
48294336|NCT02194881|DRUG|CF patients with a G551D mutation and treated with Ivacaftor|
48294337|NCT00991627|DRUG|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
48294338|NCT00991627|DRUG|Morphine|200 µg of a 100 µg/ml solution, intrathecally
48294339|NCT00991627|DRUG|Lactated Ringer's solution|25 ml/min intravenously
48294340|NCT00991627|DRUG|Ephedrine, continuous infusion|37.5 mg/h intravenously
48294341|NCT00991627|DRUG|Ephedrine, bolus|"6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm."
48294342|NCT00991627|DRUG|Atropine|"0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values."
47945743|NCT05666622|OTHER|Only routine non-surgical periodontal treatment was applied to the patients.|The study included 70 systemically healthy individuals, as a test group of 35 patients with Stage 3, Grade A periodontitis and a control group of 35 individuals with no periodontal disease. Blood samples were taken for the examination of DNI, white blood cells (WBC), immature granulocytes (IG), procalcitonin, C-reactive protein (CRP), lymphocyte count and neutrophil count. For the patients with periodontitis, blood sample assays were repeated 3 months after non-surgical periodontal treatment
48633550|NCT02320825|BEHAVIORAL|Quality of Life Measures|
48633551|NCT01449994|DEVICE|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
47945744|NCT03496571|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
47945745|NCT03496571|OTHER|Placebo|Placebo
47945746|NCT00972088|DEVICE|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
47945747|NCT02193698|DRUG|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
47945748|NCT03424473|DRUG|Tucatinib|
47945749|NCT04940208|OTHER|Pain and neuropsychological questionnaires|Patient-reported outcomes, listed in the Secondary Outcome Measure Section
47945750|NCT04940208|DIAGNOSTIC_TEST|Quantitative Sensory testing|Summation pain threshold test and Heat pain threshold skin test
47945751|NCT01225796|DRUG|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
48476231|NCT03245892|DRUG|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
48476232|NCT03245892|DRUG|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
47945754|NCT02356315|OTHER|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
47945755|NCT05842876|DEVICE|Continuous Renal NIRS Monitoring|Renal oxygenation data collected every 6 seconds
47945756|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|q6 h BP, q6 h Pulse ox, Echo at 24-72h
47945757|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h
47945758|NCT05842876|OTHER|Satisfaction Survey|Survey to assess which method of monitoring is preferred
47945759|NCT02647437|DRUG|Levetiracetam|
47945760|NCT02647437|DRUG|Placebo|
47945761|NCT03048474|DRUG|nivolumab and ipilimumab|
48476233|NCT03245892|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery
47945762|NCT02639156|DIETARY_SUPPLEMENT|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
48103855|NCT01573858|OTHER|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
48476234|NCT03245892|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
48633552|NCT00083109|DRUG|Fluorouracil|Given IV
48633553|NCT00083109|OTHER|Pharmacological Study|Correlative studies
48633554|NCT00083109|DRUG|Suramin|Given IV
48633555|NCT02282033|DEVICE|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
48633556|NCT00002836|BIOLOGICAL|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
47945763|NCT05777343|OTHER|Experimental|Cognitive training combined with the recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
47945764|NCT05777343|OTHER|Exercise and PNE|Recommended non-pharmacological intervention (Exercise and Pain Neuroscience Education).
47945765|NCT05777343|OTHER|Cognitive training|Online sessions of cognitive training.
47945766|NCT01199731|DRUG|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
47945767|NCT01199731|DRUG|GSK2248761 200 mg once daily|2 100mg capsules OAD
47945768|NCT01199731|DRUG|Etravirine|2 100mg tablets twice daily
47945769|NCT04537455|DIAGNOSTIC_TEST|Ultra-high frequency electrocardiography|Patients will have an ultra-high frequency electrocardiography performed.
47945770|NCT02290327|DRUG|Pantoprazole|Proton pump inhibitor
47945771|NCT02290327|DRUG|Placebo|50 ml of 0.9% normal saline
47945772|NCT03215979|PROCEDURE|Platelet enriched plasma administration|It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
47945773|NCT03215979|PROCEDURE|Placebo Arm|5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
47945774|NCT04920422|OTHER|No intervention|Retrospective analysis using database without any intervention assigned in the study.
48294343|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
48633557|NCT00002836|DRUG|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
48633558|NCT00002836|DRUG|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
48633559|NCT00002836|DRUG|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
48633560|NCT00002836|DRUG|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
48633561|NCT00002836|DRUG|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
48633562|NCT00002836|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
48633563|NCT00964444|DEVICE|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
48633564|NCT00927186|DRUG|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
48633565|NCT00927186|DRUG|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
48633566|NCT05465876|BIOLOGICAL|EVUSHELD|EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
48633567|NCT01429623|DRUG|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
48633568|NCT01429623|DRUG|Placebo|Placebo comparator
48633569|NCT01133977|DRUG|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
48633570|NCT01133977|DRUG|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
48633571|NCT01133977|DRUG|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
48633572|NCT02875600|OTHER|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
47945775|NCT00756015|OTHER|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
47945776|NCT00756015|OTHER|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
47945777|NCT05401240|BEHAVIORAL|information reveal|the experimental group will be informed that there will be an important examination about his/her cardiopulmonary fitness condition at the outpatient department (OPD)
47945778|NCT03689673|OTHER|Data collection|
47945779|NCT04542044|OTHER|management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia|Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis
47945780|NCT01498601|OTHER|Enhanced oral care protocol|"* Changing mouth suction equipment every 24 hours~* Mouth assessment every 2-4 hours~* Cleansing mouth with toothbrush every 12 hours~* Cleansing oral mucosa with oral rinse solution every 2-4 hours~* Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~* Suction mouth and throat as needed~* Head of the bed elevated to a minimum of 30° during oral care"
47945781|NCT04058418|OTHER|Survey Administration|Completion of a short survey.
48633573|NCT04483232|BIOLOGICAL|Ear canal swab|Ear canal swab
48633574|NCT01282554|DEVICE|electrostimulation program (Rehab 400)|"electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months."
48633575|NCT05058638|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
48633576|NCT05664815|BIOLOGICAL|Human Amniotic Membrane|"After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges.~With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone.~For closure after hAM grafting : 2 options are possible:~Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa."
47945782|NCT02883192|DRUG|Ondansetron|Zofran 4 mg.
48633577|NCT05664815|OTHER|Conventional/Standard treatment|"Surgical procedure: Endo-oral approach:~* Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue)~* For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an apparently healthy bone (bone bleeding, clean appearance of the bone site)~* Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 silk thread type and round needle."
47945783|NCT02883192|DRUG|Placebo|Placebo
48633578|NCT02455011|BIOLOGICAL|REMD-477|
48294344|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
48294345|NCT01176851|DRUG|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
48476235|NCT00804024|DEVICE|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
48633579|NCT04981756|OTHER|observation|This observational study does not have any intervention.
47945784|NCT05997771|OTHER|Personal Nutrition Advisor|The study intervention will be the use of the PNA data analysis tool during remote nutritional counselling sessions delivered by certified dietitians, also referred to as PNA-assisted remote nutritional counselling.
47945785|NCT00467610|DRUG|Panhematin|
48476236|NCT03190772|OTHER|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
48476237|NCT03190772|OTHER|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
48476238|NCT06175247|OTHER|Low Glycemic Index Diet|A low glycemic diet will be initiated with dietician support and guidance.
48476239|NCT03551873|DRUG|Plecanatide|Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.
48476240|NCT03762746|DEVICE|Transcranial Magnetic Stimulation|A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
48476241|NCT03762746|DRUG|Control|The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
48476242|NCT00823199|DRUG|Allopurinal|300mg once daily by mouth for four weeks
48476243|NCT02031237|RADIATION|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
48476244|NCT02031237|RADIATION|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
48476245|NCT02031237|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
48476246|NCT02031237|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
48620064|NCT03555929|DRUG|Normal saline|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
48620065|NCT03983031|DRUG|Rituximab|Infusion
48633580|NCT04821011|DEVICE|electronic stethoscope|Record of maternal heart sounds (heartbeats) with an electronic stethoscope during 10 minutes.
47945786|NCT01094756|DIETARY_SUPPLEMENT|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
47945787|NCT06235632|BEHAVIORAL|Policy and Training Intervention|The intervention is a combination of a policy training and access to an in-depth training program to teach marijuana vendors the skills needed to refuse intoxicated customers
47945788|NCT06235632|BEHAVIORAL|Usual and Customary Policy and Training (UC-PT) (Control) Condition|The active control training that is already provided to marijuana vendors by the Oregon Liquor and Cannabis Commission
47945789|NCT05648760|BEHAVIORAL|Simulation training|Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
47945790|NCT00857428|DRUG|oxymorphone|Tablets
47945791|NCT00857428|DRUG|Oxymorphone|40 mg tablets
47945792|NCT06433401|BEHAVIORAL|Transitional care training with brochures, posters and slide training materials|Education at 3 and 6 months after the first interview
47945793|NCT03857035|OTHER|Piezosurgery group|Piezosurgery technique will be examined about impacted third molar surgery.
47945794|NCT03411915|BIOLOGICAL|XmAb18087|monoclonal bispecific antibody
47945795|NCT06170203|OTHER|Personalised Follow-up Pathway|Discharge from routine oncology Follow-Up 2 years following radical treatment for a head and neck cancer
48294346|NCT06671808|OTHER|Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB)|This meta-analysis examines the impact of HIV infection on the prevalence and outcomes of multi-drug resistant tuberculosis (MDR-TB) among affected populations. The analysis synthesizes data from multiple studies conducted across various countries, focusing on the correlation between HIV co-infection and MDR-TB rates, treatment outcomes, and demographic factors. The findings aim to enhance understanding of the complex interactions between HIV and MDR-TB, ultimately informing clinical practices and public health strategies.
48633581|NCT04821011|DEVICE|acoustic listening of mother's heartbeats|Each newborn included will have 20 minutes of an acoustic listening of their mother heartbeats previously recorded.
48633582|NCT04821011|DEVICE|Recording of the newborn's heart rate|"Recording of the newborn's heart rate: one hour before the acoustic listening, during the acoustic listening and one hour after the acoustic listening .~The variations of the autonomic nervous system will be analyzed.~An coupled Heart rate variability recording (ECG signal obtained from a Philips® IntelliVue MX700 monitor) and NIPΣ index of comfort (MDMS® NIPΣ monitor) will be used."
47945796|NCT02862899|DEVICE|Thermowire|
48633583|NCT00469027|BIOLOGICAL|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
47945797|NCT06281288|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive behavioral therapy
47945798|NCT06281288|OTHER|Exercise Training|Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
48633584|NCT04527731|DEVICE|Accelerometry|Participants are asked to wear an accelerometer during the day for a period of seven days.
48633585|NCT02278237|BEHAVIORAL|VME Group|Received inhaler education through VME (virtual education module)
48633586|NCT05688423|BEHAVIORAL|SIRI Team|"Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction"
48633587|NCT05688423|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
48633588|NCT03864549|DIETARY_SUPPLEMENT|Femina II|2 capsules per day until delivery
47945799|NCT01343927|BEHAVIORAL|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
48633589|NCT03864549|OTHER|Placebo|2 capsules per day until delivery
48103856|NCT06548880|OTHER|Structured exercise program|The intervention applied in this research has an online exercise training conducting with a structured exercise program including different types of exercise which are range of motion, stretching and low intensity aerobic exercises. The exercise program continued with sessions each lasting 60 minutes, once a week for 10 weeks.
48476247|NCT06615778|BEHAVIORAL|Motivated Social Emotional Learning|"MSEL arm consists of three intervention components: 1) CSEL, 2) the meaningful role tasks, and 3) the Secret Angel activity. First, participants in the MSEL arm will receive the same 6-session SEL as participants in the Curriculum-based Social-Emotional Learning arm.~Second, other than the CSEL, the second component is the Class Diploma tasks adopted from the pupil responsibilities intervention developed by Ellies et al. (2016). Participants will be provided with a list of meaningful roles and select the role they are willing to take based on their talents and interests. Each participant will take the role for two weeks, fulfilling the related duties and responsibilities. The third component is the Secret Angel, in which participants will anonymously recognize each other via the appraisal notes on Shout Out for Your Board."
48633590|NCT02552654|BEHAVIORAL|Stress Film|Film scene with severe physical and sexual violence.
48633591|NCT02552654|DRUG|Hydrocortisone|10mg
48294347|NCT00790296|DRUG|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
48294348|NCT00790296|DRUG|Placebo|Saline
48633592|NCT02552654|DRUG|Placebo|
48633593|NCT02477046|BIOLOGICAL|tOPV|administered per protocol
47945800|NCT01343927|BEHAVIORAL|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
47945801|NCT01343927|BEHAVIORAL|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
47945802|NCT02497300|DRUG|Spironolactone|
47945803|NCT02497300|DRUG|Amiloride|
47945804|NCT06556693|DEVICE|Dual Channel Stimulation|implant of dual channel stimulation device
47945805|NCT02159612|OTHER|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
47945806|NCT03002207|DEVICE|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
47945807|NCT03002207|PROCEDURE|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
48103857|NCT04009070|DEVICE|Acupuncture Pres Needle: 0.22x1.5 mm needle|Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
48294349|NCT05170945|OTHER|Early bowel preparation for colonoscopy|Early (\<24 hours) bowel cleansing prior to colonoscopy.
47945808|NCT03152032|BEHAVIORAL|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
47945809|NCT02199860|DRUG|SD I|
48633594|NCT02477046|BIOLOGICAL|bOPV|administered per protocol
47945810|NCT02199860|DRUG|SD II|
47945811|NCT02199860|DRUG|Placebo|
48103858|NCT04683159|DRUG|Brimonidine Tartrate 0.15% Oph Soln|1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
48103859|NCT04683159|DRUG|Brimonidine Tartrate 0.025% Oph Soln|1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
48103860|NCT04009356|PROCEDURE|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
48103861|NCT03746418|DRUG|Ultrasound Guided Bilateral single shot Erector Spinae Plane Block|Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit \[figure1(A)(B)(C)\] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
48103862|NCT01923857|DRUG|Androxal 25 mg|
48103863|NCT01190150|DRUG|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
48103864|NCT04722094|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
48103865|NCT04722094|OTHER|Saliva sampling|Saliva samples for miRNAs detection will be taken before starting the visit.
48633595|NCT02477046|BIOLOGICAL|IPV|administered per protocol
47945812|NCT04160481|DIETARY_SUPPLEMENT|FruitFlow|300mg tomato extract
48103866|NCT02465086|OTHER|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
48103867|NCT05582317|DRUG|Biodentine|Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
48103868|NCT05582317|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
48103869|NCT01762072|DIETARY_SUPPLEMENT|Fish oil|
48103870|NCT01762072|DIETARY_SUPPLEMENT|vitaminB12|
48103871|NCT00374699|DRUG|Velcade|
48103872|NCT01700790|DRUG|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
48294350|NCT04036136|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
48294351|NCT04036136|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
48294352|NCT01782599|OTHER|Dual nicotine patch and electronic cigarette|
48294353|NCT03704051|BEHAVIORAL|Mode of Feeding (breastfeeding versus bottle-feeding)|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
48294354|NCT06099873|DRUG|ZX-7101A|Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
48294355|NCT06099873|DRUG|Placebo|Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
48294356|NCT05673603|DRUG|Brensocatib|Oral tablet
48476248|NCT06615778|BEHAVIORAL|Curriculum-based Social Emotional Learning|"In the CSEL arm, 6-session SEL training will be delivered as the experimental component. The primary goal of the SEL training is to reduce traditional bullying and cyberbullying perpetration and victimization by enhancing students' social-emotional competence, which has been examined to be the protective factor for bullying-related behaviors.~Each session lasts 40 minutes and is delivered by the headteacher in each class weekly as an after-school workshop. The SEL curriculum is tailored to the social-emotional needs of primary school students, as suggested by CASEL (2013). Also, building on past literature highlighting the lack of SEC as a risk factor linked to bullying behaviors both in the physical and cyber world, specific topics such as self-appreciation (self-awareness), stress management (self-management), respect and acceptance (social awareness), and conflict resolution (relationship skills) incorporated into the curriculum design."
48476249|NCT01315028|OTHER|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley \& Schwannauer, 2006).
48476250|NCT01315028|OTHER|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
48633596|NCT01991574|DRUG|Calcium acetate|
48633597|NCT01991574|DIETARY_SUPPLEMENT|Iron Hydroxide Adipate|
47945813|NCT04160481|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48294357|NCT02185170|PROCEDURE|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
48294358|NCT02185170|DEVICE|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
48294359|NCT02185170|DEVICE|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
48294360|NCT00894530|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
48294361|NCT00894530|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
48294362|NCT04102839|OTHER|Interview|Qualitative Interview
48294363|NCT01277289|DRUG|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
48294364|NCT06547112|DRUG|Motixafortide|Dose = 1.25 mg/kg via subcutaneous injection
48294365|NCT06547112|DRUG|G-CSF|Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection
48294366|NCT04379518|OTHER|Best Practice|Receive standard of care
48103873|NCT03244436|PROCEDURE|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
48294367|NCT04379518|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
48294368|NCT04379518|DRUG|Rintatolimod|Given IV
47945814|NCT00572897|DRUG|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 \[given over 6 hours\], and 2 mg/kg on days -2 and -1 \[given over 4 hours\])"
48294369|NCT00330629|BEHAVIORAL|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
48294370|NCT00330629|BEHAVIORAL|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
48294371|NCT03023410|PROCEDURE|VERASENSE|Sensor-Assisted Revision TKA
48294372|NCT06583395|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
48294373|NCT04103372|DIAGNOSTIC_TEST|MRI scan|MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.
48294374|NCT04103372|OTHER|Radiologist training|Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.
48294375|NCT01615003|DRUG|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
48294376|NCT01615003|DRUG|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
48294377|NCT06421246|BEHAVIORAL|Staff-facing screen|Activity will be monitored before and after the introduction of a staff-facing screen
48294378|NCT01233219|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h)."
48294379|NCT06408194|DRUG|CD22CART infusion|CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
48294380|NCT06408194|DRUG|Tisagenlecleucel|All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
48294381|NCT06671886|BEHAVIORAL|E-trigger|The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned.
48294382|NCT01276847|DRUG|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing \> 100 kg on Day 1, and Weeks 4 and 16
48294383|NCT01276847|DRUG|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
48294384|NCT02211495|DEVICE|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
48476251|NCT06167473|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
48294385|NCT02211495|OTHER|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
48294386|NCT01248806|RADIATION|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
48294387|NCT01638689|DRUG|Escitalopram|20 mg p.o.
48294388|NCT01016483|DRUG|Pimasertib|
48294389|NCT01016483|DRUG|Gemcitabine|
48294390|NCT01016483|DRUG|Placebo|
48294391|NCT06028776|BEHAVIORAL|MS Ballroom Fitness|A personalized dance-based concept focusing on balance, walking capacity, and well-being.
48294392|NCT04067531|DRUG|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
48476252|NCT05540379|DEVICE|Virtual Reality Training|Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
48476253|NCT01082224|DRUG|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
48476254|NCT01082224|DRUG|motexafin gadolinium|motexafin gadolinium
47945815|NCT05374668|BEHAVIORAL|Video-based Yoga Exercises|They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
48294393|NCT02012972|BEHAVIORAL|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
48294394|NCT04652687|OTHER|VIA Disc NP (HCT/P)|VIA Disc NP - Allograft tissue injection
48294395|NCT04957498|BEHAVIORAL|Guided Self-Help for Family Based Treatment|A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
48476255|NCT01082224|OTHER|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
48476256|NCT04480801|OTHER|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
48476257|NCT04480801|OTHER|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
48476258|NCT02382367|OTHER|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
48633598|NCT01991574|DRUG|Placebo|methylcellulose capsules
47945816|NCT02031211|DRUG|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
47945817|NCT02031211|DRUG|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
47945818|NCT03885440|OTHER|Age|Age\<40 years old is chosen as the cutoff value.
47945819|NCT03885440|OTHER|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
47945820|NCT04918576|DRUG|Tranexamic acid|3 grams of tranexamic acid (30mL of 100 mg/mL solution) diluted in 10 mL of normal saline
47945821|NCT04918576|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
47945822|NCT02715973|DIETARY_SUPPLEMENT|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
47945823|NCT02715973|DIETARY_SUPPLEMENT|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
47945824|NCT04483167|DRUG|99mTccAbVCAM1-5 injection|intravenous injection of 99mTccAbVCAM1-5 with dose increase
48633599|NCT02636491|DEVICE|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
47945825|NCT05049369|DEVICE|Polysomnography|Polysomnography is performed one time overnight
48103875|NCT05663619|DEVICE|Virtual Reality Distraction during dental treatment of children.|One of the behavior management techniques used with children in dental clinics to allow for delivering quality dental treatment is the use of Virtual Reality distraction (VRD). Virtual reality distraction immerses the patient in an environment generated by a computer and works by simulating as many senses as possible: vision, hearing, and touch. In dentistry, VRD has exhibited great results in reducing anxiety and fear among children and adolescents compared to those who received no intervention or more conventional BMTs. VRD may allow the dentist to provide more efficient dental treatments, ranging from simple anesthesia to more advanced forms of dental treatment
48294396|NCT04957498|BEHAVIORAL|Family Based Treatment|Standard Family Based Treatment provided for up to 15 sessions.
48294397|NCT02831868|DEVICE|HAVAI|implantation of the HAVAI device to correct the IMA angle
48294398|NCT00370656|DRUG|Pregabalin|capsule, 150mg bd, 300mg bd
48294399|NCT00370656|DRUG|Duloxetine|Capsule, 60mg on, 60mg bd
48633600|NCT02636491|DEVICE|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
47945826|NCT03135626|DRUG|Biodentine|
47945827|NCT03135626|DRUG|ProRoot (Aggregate)|
47945828|NCT03135626|DRUG|MTA Plus|
47945829|NCT03135626|DRUG|Ferric Sulfate 20 % Dental Gel|
48294400|NCT00370656|DRUG|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
48294401|NCT02513940|DRUG|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
48294402|NCT02513940|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
48294403|NCT02513940|DRUG|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
48294404|NCT02513940|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
48294405|NCT02636790|PROCEDURE|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
48294406|NCT05888714|DEVICE|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
48633601|NCT04690647|OTHER|Opioid and non opioid postoperative analgesia.|Postoperative analgesia will be based on opioid and non opioid analgesics according to standardised protocol.
48633602|NCT04690647|OTHER|Fascia iliaca compartment block|Ultrasound guided suprainguinal fascia iliaca compartment block will be performed using 0.375% ropivacaine and 5ug/ml adrenaline according to standardised protocol.
47945830|NCT00978107|BIOLOGICAL|MVA-FCU1, flucytosine|"1. TG4023: single IT injection; possibility to re-administer once,~   * Percutaneous IT injections, under radiological or ultrasound imaging guidance~  * Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~  * MTD injected to up to 3 different lesions (Cohort #4)~2. 5-FC (5-fluorocytosine)/flucytosine~   * Dose and dosing schedule:~     * Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~    * Duration: 2 weeks.~  * Possible routes of administration:~     * PO: 500 mg tablets, qid~    * IV: 1% 250 mL vials, 45-minute infusions."
47945831|NCT00002121|DRUG|Diethylhomospermine|
47945832|NCT06379087|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.
48103876|NCT05663619|OTHER|Control: watching cartoon on screen as distraction during dental treatment of children.|"The American Academy of Pediatric Dentistry (AAPD) recommends a series of non-pharmacological behavior management techniques for managing children during dental care including distraction. Distraction is defined by AAPD as the technique of diverting the patient's attention from what may be perceived as an unpleasant procedure. It is widely used as it provides an effective and relaxing experience during treatment."
47945833|NCT06379087|DRUG|Tislelizumab Injection|Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody.
47945834|NCT06379087|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy Extent of radiotherapy: Primary lesion in the lung. Radiotherapy technique: IGRT. Radiotherapy delivery equipment: linear accelerator or TOMO accelerator or CyberKnife.
47945835|NCT01837732|OTHER|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
47945836|NCT01837732|OTHER|Relational:|Relational: 10 mn verbal patient's centered exchanges
47945837|NCT01736124|OTHER|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
47945838|NCT01736124|OTHER|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
47945839|NCT05145192|DEVICE|COSMED K5 CPET (Cardiopulmonary Exercise Test)|In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.
48103877|NCT00628940|RADIATION|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
48633603|NCT04690647|DRUG|Dexamethasone|Dexamethasone will be administered preoperatively in a dose of 0,1 mg/kg.
48633604|NCT03283995|OTHER|Cardiac Volume Monitoring VolumeView|hemodynamic measure
47945840|NCT05145192|DEVICE|ParvoMedics CPET|ParvoMedics CPET
47945841|NCT05746962|DEVICE|ScopeGuide Navigated Colonoscope|colonoscopes equipped with ScopeGuide
47945842|NCT05746962|DEVICE|Navigation screen|ScopeGuide's 3D visualisation screen
47945843|NCT05689697|DIETARY_SUPPLEMENT|PanTrek|administration of exogenouse keton body
47945844|NCT02427828|DEVICE|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
48103878|NCT00937846|DRUG|GSK1034702|Single oral 5 mg dose in liquid formulation
48294407|NCT05888714|DEVICE|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
47945845|NCT04155489|PROCEDURE|blood transfusion|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
47945846|NCT06130917|OTHER|Multisystem Exercise|"Proprioception: Seated ankle ball. Single leg stance with support and with extension of knees. Single leg stance (hip extension) with support and with extension' of knees.~Muscle strengthening: Seated alternate double knee lifts with weights, chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Training Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support.. Crossover with support Reaction time Seated alternate touches to front. Seated alternate touches to back. Seated alternate touches to side. Seated alternate touches to 3 steps (forward, side, backward)."
48103879|NCT03094767|OTHER|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
48103880|NCT03094767|OTHER|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
48294408|NCT05888714|OTHER|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
48633605|NCT03283995|DEVICE|echocardiography|hemodynamic measure
48633606|NCT00377806|DRUG|Diclofenac gel|
48633607|NCT04652843|PROCEDURE|Rectosignoidoscopy|Rectosignoidoscopy for colonic biospsies collection
48633608|NCT04652843|PROCEDURE|Coloscopy|Coloscopy for colonic biospsies collection
48633609|NCT04462250|DEVICE|Prescription Opioid Management App|Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
48633610|NCT02872142|BIOLOGICAL|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
47945847|NCT06130917|OTHER|Conventional Treatment|"ROM exercises Passive ROM exercise of hip. Passive ROM exercise of knee. Passive ROM exercise of ankle Muscle strengthening Seated alternate double knee lifts with weights. chair stands. Seated alternate kicks with weigh. Hip extension standing with support with weights.~Balance Seated alternate weight shifts. Seated calf and toe raise. Heel raise with support. Crossover with support Stretching exercises Stretching exercise of hamstring. Stretching exercise of quadriceps. Stretching exercise of calf muscle"
47945848|NCT04008823|OTHER|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
47945849|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
47945850|NCT01822678|DRUG|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
47945851|NCT01822678|DRUG|Placebo|Placebo
47945852|NCT00234390|DRUG|Pulmicort (budesonide) pMDI|
47945853|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
47945854|NCT00667602|BIOLOGICAL|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
47945855|NCT00667602|BIOLOGICAL|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
48294409|NCT04773041|PROCEDURE|Infinitome|All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
48294410|NCT01816646|DRUG|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
48476259|NCT05905796|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
48476260|NCT02151175|DEVICE|LIFUP|
48476261|NCT01998386|OTHER|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
48476262|NCT01998386|OTHER|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
48476263|NCT01998386|OTHER|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
48633611|NCT02872142|PROCEDURE|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
48633612|NCT03272165|DRUG|MEDI1341|Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
48633613|NCT03272165|DRUG|Placebo|Participants will receive IV infusion of placebo matched to MEDI1341.
48633614|NCT01282138|DRUG|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
47945856|NCT00667602|BIOLOGICAL|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
47945857|NCT00667602|BIOLOGICAL|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
47945858|NCT02271373|BEHAVIORAL|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
47945859|NCT05600738|DEVICE|RNS/DBS activation|This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
47945860|NCT03266523|OTHER|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
47945861|NCT00771316|DRUG|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
47945862|NCT00771316|DRUG|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
47945863|NCT00101712|DRUG|vildagliptin|
47945864|NCT00101712|DRUG|Vildagliptin Placebo|
48294411|NCT01816646|DRUG|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
48294412|NCT04385030|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY|The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
48294413|NCT05275218|PROCEDURE|Implementation of the KDIGO bundle)|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"
48294414|NCT02272205|OTHER|Retrospective analysis of records|
48294415|NCT01350700|OTHER|Scars assessment & QOL|Scar assessment and quality of life questionnaires
48294416|NCT00619541|DRUG|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
48294417|NCT00619541|DRUG|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
48294418|NCT00719810|DRUG|delafloxacin|300 mg intravenous every 12 hours
48294419|NCT00719810|DRUG|delafloxacin|450 mg intravenous every 12 hours
48294420|NCT00719810|DRUG|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
48294421|NCT03854162|DEVICE|SMART Guide|The device manufactured according to a digital plan based on patient anatomy. Guiding sleeves are used, through which bone drills are applied. These sleeves sit in a plastic template that is a negative of the patient's dentition, so that the guide is properly stabilized during the operation. The position of the sleeves is calculated from the surgical plan in a way that they guide the drills in the planned position.The material of the template is medical plastic, the sleeves are made of medical steel.The device is applied by the dentist during the implant surgery. The template is placed on the remaining dentition of the patient and stabilized this way. By this, the sleeves are also stabilized in their planned position. Access through the soft tissue can be prepared through the given sleeve with a circular trephine, but the system also supports flap surgery. As access has been established, the dentist performs the surgical protocol as planned.
48294422|NCT01635933|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
48294423|NCT01635933|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
48294424|NCT02004652|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
48294425|NCT02004652|DRUG|Placebo|Vitamin, 50mg, tablet.
48294426|NCT02698592|DEVICE|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
48294427|NCT02698592|DEVICE|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
48294428|NCT02698592|DEVICE|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
48294429|NCT00744055|DRUG|Prazosin|prazosin (16mg/day) 2 times a day
48294430|NCT00744055|DRUG|Placebo|Placebo
48294431|NCT05929326|DIAGNOSTIC_TEST|complete blood count, PT, aPTT, fibrinogen tests|Pregnant women who are eligible for the study will have their blood collected to run complete blood count, PT, aPTT, fibrinogen tests
47945865|NCT04350606|BIOLOGICAL|PF-06462700|PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
48294432|NCT00985452|OTHER|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
48294433|NCT00985452|OTHER|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
48294434|NCT01548664|OTHER|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
47945866|NCT05527405|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
47945867|NCT05237297|DRUG|Ilaprazole|Ilaprazole 10mg
48294435|NCT01548664|OTHER|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
48294436|NCT04153812|DEVICE|vagus nerve stimulation|Vagus nerve stimulation (VNS) is a new technique for stimulating the left cervical vagus nerve through implanted lead and a programmable pulse generator.
48294437|NCT04073823|DEVICE|Flexitouch Plus|Flexitouch Plus full arm and core treatment
48294438|NCT04073823|DEVICE|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
48633615|NCT01282138|OTHER|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
47945868|NCT05237297|DRUG|Naproxen|Naproxen 500mg
47945869|NCT05237297|DRUG|Aceclofenac|Aceclofenac 100mg
47945870|NCT05237297|DRUG|Celecoxib|Celecoxib 200mg
48633616|NCT00477217|DRUG|Zoledronic acid|
48294439|NCT05294848|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
48294440|NCT05294848|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
48294441|NCT05294848|BEHAVIORAL|Neutral Control|Dot-probe task using only neutral stimuli with no training toward threat
48633617|NCT04875273|DEVICE|Magnetic Tape® aplicación|Magnetic tape® is applied without creating any tension on the paravertebral skin of the lumbar spine
48633618|NCT04875273|DEVICE|Kinesiology Tape application|Kinesiology tape is applied without creating any tension on the paravertebral skin of the lumbar spine
48633619|NCT04348578|OTHER|QMix 2in1|In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
48633620|NCT05759377|DEVICE|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
48633621|NCT01666080|DRUG|Busulfan|0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
48633622|NCT01666080|DRUG|Fludarabine|40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.
48633623|NCT01666080|RADIATION|Total body irradiation|200 cGy on Day -1
48633624|NCT01666080|BIOLOGICAL|Stem cell transplant|stem cell infusion on day 0
48633625|NCT01666080|DRUG|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
48103881|NCT03890640|PROCEDURE|Ultrasound-guided TECI|When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
48103882|NCT06345833|DRUG|1%Tranexamic acid with standard local|1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.
48633626|NCT02227966|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48294442|NCT06100744|DRUG|Adalimumab|SC Injection
48103883|NCT06345833|DRUG|3% TXA|3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
48103884|NCT06345833|DRUG|1% TXA with local plus 3% TXA-soaked pledgets|1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
48103885|NCT03883438|PROCEDURE|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I\&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
48103886|NCT02375516|BEHAVIORAL|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
48103887|NCT03018041|DRUG|Omacor|"As described in Arms."
48294443|NCT06100744|DRUG|Risankizumab|Subcutaneous (SC) Injection
48294444|NCT03454139|PROCEDURE|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
48294445|NCT03873350|OTHER|Consumption of kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
48633627|NCT02227966|DEVICE|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
48633628|NCT00901563|DRUG|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
48633629|NCT00901563|OTHER|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
48633630|NCT05696158|DEVICE|MHNA-003|MHNA-003 is a self-guided digital program for people living with tinnitus
48633631|NCT00496327|BIOLOGICAL|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
48633632|NCT02978768|OTHER|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
48103888|NCT03018041|DRUG|Placebo Oral Capsule|"As described in Arms."
48103889|NCT00006450|DRUG|Phenylbutyrate|
48103890|NCT02614118|DRUG|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
48103891|NCT02614118|DRUG|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
48294446|NCT03873350|OTHER|Consumption of heat-sterilized kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
48294447|NCT04649281|DEVICE|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
48294448|NCT03370367|DRUG|13-cis retinoic acid|Taken daily.
48294449|NCT03370367|OTHER|Placebo|Placebo
48294450|NCT05279937|DRUG|Dextrose 50% Intravenous Solution|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
48103892|NCT02614118|DRUG|Placebo|placebo 45 minutes before root canal treatment
48103893|NCT05844748|OTHER|diabetes education with motivational interview technique|Techniques such as developing empathy, developing disengagement, turning with resistance, supporting self-efficacy, avoiding advice, a simple decision, importance-trust scale, open-ended questions, reflection and segmentation in motivational interviews.
48103894|NCT05640817|DRUG|Pentoxifylline 400 mg SR tablets|a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
48103895|NCT05640817|DRUG|cisplatin with standard hydration with normal saline|chemotherapy
48103896|NCT03433950|OTHER|No Intervention|Observational
48103897|NCT00921739|RADIATION|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
48294451|NCT05279937|DRUG|Lidocaine 1% Injectable Solution|10mL of 1% Lidocaine (Control)
48633633|NCT02978768|DEVICE|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
48103898|NCT00614406|DRUG|Celebrex|One 400mg tablet daily.
48103899|NCT00614406|DRUG|Placebo|One tablet daily.
48103900|NCT01876511|DRUG|MK-3475|MK-3475 10 mg/kg every 14 days
48103901|NCT05579886|DEVICE|Control Lens|Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks
48103902|NCT05579886|DEVICE|Test Lens|Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
48103903|NCT05465811|OTHER|Program of physical exercises and health education by telerehabilitation|"To carry out the telerehabilitation program, the Google Meet platform will be used in order to provide the synchronous service model. This will occur for a period of 16 weeks, three weekly sessions lasting 50 minutes, (total of 48 sessions). The sessions will be given by physiotherapists and students in their final year of graduation in physiotherapy, which will consist of the following phases: initial rest, warm-up, resistance exercises, stretching exercises, relaxation and final rest.~In addition, in exchange for the warm-up phase, every 12 sessions, the telerehabilitation program also will have an approach through health education, using presentations, digital booklets and direct conversation between therapist and participants. The themes exhibited (importance of physical exercise in the pandemic context, reduction of the risk of falls through changes in the home environment and physiological changes resulting from aging) will intend to make them aware of better lifestyle habits."
48103904|NCT04245319|DRUG|Acitretin|The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
48103905|NCT04245319|OTHER|Narrow band ultraviolet B|Patients receive nbUVB session 3 times per week
48294452|NCT04172831|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
48294453|NCT04172831|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
48294454|NCT06218589|DIAGNOSTIC_TEST|Velacur|Velacur is a liver ultrasound that measures hepatic fat and fibrosis through the propagation of a continuously, externally conducted shear wave. An enrolled participant may choose to do the ultrasound at the time of a clinic visit, or research visit or a scheduled radiology visit according to manufacturer's instructions by trained study staff. Fibrosis and steatosis measures will be collected from all scans.
48294455|NCT06218589|DIAGNOSTIC_TEST|MRI|Participants who have not had an MRI within the past two years will be offered a research MRI (no contrast or sedation will be used) to measure hepatic fat and hepatic stiffness (if required). Participants who have had an MRI or liver biopsy in the past two years will use historical data comparison data. MRI data will include the PDFF hepatic fat, any assessment of fibrosis and notes of other abnormalities.
48294456|NCT06218589|DIAGNOSTIC_TEST|Blood sample collection for biomarkers|Biomarkers are metabolic thumbprints of how the body is behaving to different health or disease processes, some of the biomarkers can be studied from plasma or serum combined with other demographics. A lipid profile and comprehensive metabolic panel (CMP), if not obtained clinically within 4 weeks, will be collected as a standard of care.
48294457|NCT06218589|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy data will be collected only if liver biopsy is done clinically when available and scored using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) approach.
48633634|NCT02978768|DEVICE|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
48633635|NCT06523816|DIAGNOSTIC_TEST|dermoscopy|Dermoscopy is a fast imaging technique that allows an excellent visualization of non-melanocytic skin tumors to diagnose them without invasive interventon.
48294458|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 35%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 35% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
47945871|NCT02035475|DEVICE|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
47945872|NCT01410539|DEVICE|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
48103906|NCT04059237|BEHAVIORAL|Web based decision aid intervention|Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
47945873|NCT01410539|DRUG|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
47945874|NCT02563990|PROCEDURE|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
47945875|NCT02563990|PROCEDURE|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
47945876|NCT04560790|DRUG|BD111 Adult single group Dose|3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
47945877|NCT05726734|DRUG|Vonoprazan|potassium-competitive acid blocker
47945878|NCT05726734|DRUG|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
47945879|NCT05726734|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
47945880|NCT05726734|DRUG|Esomeprazole|Proton pump inhibitor
47945881|NCT04234360|DRUG|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
47945882|NCT04234360|DRUG|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
48633636|NCT02405858|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
47945883|NCT02592122|DRUG|Salbutamol Aerosol|
47945884|NCT02592122|DRUG|No drugs|
48294459|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 6%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 6% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
48294460|NCT06672250|OTHER|CTCs/CTMs culture|Collect the thrombosis from participants underwent catheter-based thrombectomy.To characterized by cancer-specific surface markers successfully and identify within the culture
47945885|NCT06310044|OTHER|Root canal irrigant Commiphora Myrrh 50%|Root canal irrigant
48294461|NCT01108991|BEHAVIORAL|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
48294462|NCT01108991|OTHER|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
48294463|NCT06673082|DRUG|Oral zinc supplementation|Oral Zinc will be supplemented to the interventional group on a dose of 30 mg elemental zinc/day.
48294464|NCT06673082|OTHER|Placebo|Oral
48633637|NCT02405858|DRUG|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
47945886|NCT05627648|DRUG|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
47945887|NCT05627648|DRUG|Placebo|Intracordal injection, once per week, 3 weeks
47945888|NCT06098274|BEHAVIORAL|Motivational interviewing program based on transtheoretical model|It will be determined at which stage of change of the transtheoretic model the participants in the intervention group are. A varying number of motivational interviews will be held depending on the stage of change and a maximum of 6 motivational interviews. Those in the preparatory phase will be trained on smartphone addiction. Following completion of the motivational interviewing and training content, the study scales will be re-administered and the effectiveness of the motivational interviewing and training content will be evaluated by comparison with the baseline data.
47945889|NCT03206437|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
47945890|NCT03206437|BEHAVIORAL|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
47945891|NCT06058403|DIETARY_SUPPLEMENT|20g whey protein drink ingestion|Ingestion of a 300 mL drink containing 20g whey protein
47945892|NCT06058403|DIETARY_SUPPLEMENT|20g native canola protein drink ingestion|Ingestion of a 300 mL drink containing 20g native canola protein
47945893|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #1 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #1
47945894|NCT06058403|DIETARY_SUPPLEMENT|20g processed canola protein #2 drink ingestion|Ingestion of a 300 mL drink containing 20g processed canola protein #2
48294465|NCT06474793|OTHER|Aromatherapy Intervention Group-1|For four weeks, once a day, 30 minutes before going to bed, a mixture of 3% chamomile and 3% lavender oil, diluted with 2% jojoba oil, is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the right and left nose for 4 minutes. It is the group that massages the edges of the hole with the index finger in circular movements from top to bottom, and then drops 2 ml of the oil mixture into the palm of the hand, rubs the hands mutually, and gently massages the edges of the ear with the index finger in circular movements from top to bottom behind the right and left ears for 4 minutes.
48294466|NCT06474793|OTHER|Aromatherapy Intervention Group-2|For four weeks, once a day, 30 minutes before going to bed, 3% vetiver oil diluted with 2% jojoba oil is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the edges of the right and left nostrils from top to bottom with the index finger for four minutes. It is a group where massage is applied with a massager and then 2 ml of the oil mixture is dropped into the palm of the hand, the hands are rubbed mutually, and then a gentle massage is applied behind the right and left ears with circular movements from top to bottom for 4 minutes.
48294467|NCT06474793|OTHER|Aromatherapy Placebo Control Group|For four weeks, once a day, 30 minutes before going to bed, 2 ml of jojoba oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the edges of the right and left nostril with circular movements from top to bottom with the index finger for four minutes and apply jojoba oil to the palm again. It is a group in which 2 ml is dropped and the hands are rubbed together and then gently massaged behind the right and left ears with circular movements from top to bottom for 4 minutes.
48294468|NCT02617758|DRUG|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
48294469|NCT02617758|DRUG|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
48294470|NCT05004662|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
48294471|NCT05004662|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
48294472|NCT05004662|BEHAVIORAL|Counceling|Phone counseling with the Florida Quitline
48294473|NCT05004662|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
48294474|NCT03393962|BIOLOGICAL|OC-EIEs|2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
48294475|NCT02778880|DRUG|Ketamine|
48294476|NCT02778880|DRUG|Fentanyl|
48294477|NCT01823653|DEVICE|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
48294478|NCT03816163|DRUG|zolbetuximab|Administered as an intravenous infusion.
48294479|NCT03816163|DRUG|nab-paclitaxel|Administered as an intravenous infusion
48294480|NCT03816163|DRUG|gemcitabine|Administered as an intravenous infusion
48294481|NCT01842464|PROCEDURE|Anterior Sacro-Spinous|Anterior Sacro-Spinous
47945895|NCT04462185|DIAGNOSTIC_TEST|A genomic and transcriptomic landscape analysis|A genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.
47945896|NCT05232981|PROCEDURE|Ligation of the bilateral internal iliac arteries|"opening the posterior peritoneum overlying the bifurcation of the common iliac arteries. Then careful dissection of the internal iliac artery is carried out on each side and the anterior division of the internal iliac artery is ligated 4 cm below the bifurcation of the common iliac on both sides by single ligation procedure using Vicryl 1.0 .~Re-checking of the femoral pulsation of both sides is performed. Then, the placenta is removed manually in a piecemeal manner, any remaining bleeding points from the placental site are then controlled by hemostatic sutures ."
47945897|NCT05232981|PROCEDURE|Shehat's technique|"The three-step technique (Shehata's technique) entailed 3 steps, the first step is double bilateral ligation of uterine arteries before placental separation. Uterine artery ligation is made at 2 levels. First will be done at the isthmus and second will be done 1 cm above the cesarean incision. Regarding timing of ligation , we will apply the uterine artery ligation before placental separation to minimize blood loss at the attempt of placental separation.~Placenta is separated manually either totally or in piecemeal. If manual separation failed, placenta is removed by scissors.~Application of quadruple sutures is done at the lower uterine segment to compress and secure the neovascularization in the bed of placenta.~Insertion of triple way catheter is commenced from inside the uterine incision downwards using long artery forceps or uterine sound and the pulled by the assistant from below. The catheter balloon is inflated by 50 cc saline and left for 48 hours"
47945898|NCT02337738|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
47945899|NCT02337738|DRUG|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
47945900|NCT02337738|DRUG|Placebo|Placebo Tablets
48294482|NCT04331730|DRUG|AKST4290|Oral AKST4290
48294483|NCT04331730|DRUG|Placebo|Oral placebo
48294484|NCT04331730|DRUG|Aflibercept|Aflibercept intravitreal injection
48294485|NCT01253460|DRUG|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
48294486|NCT01253460|DRUG|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
48294487|NCT01253460|DRUG|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
48633638|NCT04250389|OTHER|Hemodynamic assessment (micro and macrocirculatory)|"Each of the variable related to macro- and microcirculatory will be evaluated before and one hour after start of MB infusion.~Macrocirculatory parameters will include :~* Mean, systolic, diastolic arterial, heart rate (HR)~* Cardiac output (CO), sequential vascular response (SVR) and stroke volume (obtained with transthoracic echocardiography or transpulmonary thermodilution catheter if available).~* A passive leg raising (PLR) test will be performed before and one hour after MB infusion. Patients will be classified as fluid responder if they had a CO of at least 10% after PLR.~Microcirculatory parameters will include :~* Cutaneous and gingival refill time~* Tissue oxygen saturation combined with vascular occlusion test (VOT)~* Video microscopy measurements of the sublingual microcirculation~* Metabolic variables: Arterial blood gases including arterial lactate and central venous blood gases."
48633639|NCT02619812|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
47945901|NCT03181893|DRUG|PF-06823859 low|A humanized immunoglobulin neutralizing antibody
47945902|NCT03181893|DRUG|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
47945903|NCT03181893|DRUG|PF-06823859 high|A humanized immunoglobulin neutralizing antibody
47945904|NCT04025983|DIETARY_SUPPLEMENT|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
47945905|NCT04025983|OTHER|Placebo|The placebo contains neither IgY nor L. johnsonii.
47945906|NCT04623307|DIAGNOSTIC_TEST|Non-contact DCS-Speckle multi-parameter imaging|The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
47945907|NCT01690429|DEVICE|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
47945908|NCT04064788|OTHER|Consecutive Modified Constraint-Induced Movement Therapy|Consecutive mCIMT group received 6 hours per day mCIMT sessions for consecutive 10 days. Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
48633640|NCT02619812|DRUG|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
47945909|NCT04064788|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
48633641|NCT02619812|OTHER|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
48633642|NCT01794169|DRUG|Azacitidine|
48633643|NCT01794169|DRUG|DA|
48633644|NCT05391087|OTHER|Mean arterial pressure based management|Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm
48633645|NCT05391087|OTHER|Cardiac index based management|Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration
48633646|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).
48633647|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|
48633648|NCT00093223|DRUG|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
48633649|NCT06469268|DEVICE|Epro software|EPRO software：patients with symptoms will fill in report forms via the software, when the data upload to the terminal, the doctor according to the results of the upload ePRO corresponding medical assessment,and give advises.
48633650|NCT00614341|DEVICE|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
48633651|NCT03277274|DRUG|TAK-954|TAK-954 intravenous infusion.
48633652|NCT00051350|OTHER|CARB|
48633653|NCT02663570|DRUG|Melatonin|
48633654|NCT05129384|DIETARY_SUPPLEMENT|B. infantis EVC001 or Lactose Placebo|Infant probiotic
48633655|NCT00003474|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48633656|NCT02476682|OTHER|blood or stool samples will be collected|blood or stool samples will be collected
48633657|NCT00394537|DRUG|Labetalol 10mg iv|
47945910|NCT04064788|OTHER|Intermittent Modified Constraint-Induced Movement Therapy|Intermittent mCIMT group received mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
47945911|NCT02269046|OTHER|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
48294488|NCT01458340|DRUG|TD-9855|Once daily
48294489|NCT01458340|DRUG|TD-9855|Once daily
48294490|NCT01458340|DRUG|Placebo|Once daily
47945912|NCT02269046|DRUG|Simvastatin|10mg/d,p.o,12 weeks.
47945913|NCT02269046|OTHER|Therapeutic Lifestyle Change|"* Reduced intakes of saturated fats (\<7% of total calories) and cholesterol (\<200 mg per day)~* Therapeutic options for enhancing LDL lowering~* Weight reduction~* Increased physical activity"
47945914|NCT00037960|PROCEDURE|Constrained Induced Therapy|
48294491|NCT03089567|DRUG|Sodium Fluoride|5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
48294492|NCT03089567|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
48633658|NCT02116062|DEVICE|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
48633659|NCT02116062|DEVICE|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
48633660|NCT02116062|DEVICE|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
48633661|NCT03517007|OTHER|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
48633662|NCT02544724|BIOLOGICAL|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
48633663|NCT03708289|RADIATION|DXA scan|total and hip and spine dual energy x-ray absorptiometry
48633664|NCT03708289|OTHER|Achilles bone US|
48633665|NCT03708289|OTHER|Medical body composition measurements|
48633666|NCT03708289|OTHER|Resting energy expenditure measurement|
48633667|NCT05420025|OTHER||
48633668|NCT02530073|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio \<25% (O/E LHR).
48633669|NCT00263562|DRUG|Steroid arm|Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
48633670|NCT00263562|OTHER|Placebo|Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
48633671|NCT03512886|OTHER|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
48633672|NCT03512886|OTHER|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
48633673|NCT03158779|COMBINATION_PRODUCT|SBRT and chemotherapy|Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
48633674|NCT05017402|DRUG|Alglucosidase Alfa|Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week.
48294493|NCT05859620|OTHER|Patient assessment and follow-up|There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.
48294494|NCT06671756|DIETARY_SUPPLEMENT|Fructose Ingestion|Participants will consume a beverage containing 75g of fructose dissolved in 225ml of water.
48294495|NCT06671756|DIETARY_SUPPLEMENT|Glucose Ingestion|Participants will consume a beverage containing 75g of glucose dissolved in 225ml of water.
48294496|NCT05616390|DRUG|Sintilimab|200mg IV d1,Q3W
48294497|NCT05616390|DRUG|Bevacizumab|7.5mg/kg IV d1,Q3W
48294498|NCT05616390|COMBINATION_PRODUCT|Liver Protective Support Therapy|Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy
48294499|NCT02325999|PROCEDURE|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
48294500|NCT04068103|DRUG|Capecitabine|Given PO
48633675|NCT00884065|OTHER|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
48633676|NCT00884065|OTHER|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
48294501|NCT04068103|DRUG|Fluorouracil|Given IV
48476264|NCT01998386|OTHER|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
48633677|NCT00500110|DRUG|Docetaxel|30 mg/m\^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
48633678|NCT00500110|DRUG|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
48633679|NCT00500110|DRUG|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
48633680|NCT00500110|DRUG|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
48633681|NCT04474379|BEHAVIORAL|Strategy Training (Time- and Event- Based)|In time-based training, strategic clock-checking behavior is taught by requiring participants to click a button to reveal the virtual time of day. Event-based training involves implementation intention methods.
47945915|NCT03250429|PROCEDURE|Sinus surgery|Standard Clinical Sinus Surgery
47945916|NCT05153473|DEVICE|Total Hip Arthroplasty Revision|Hip revision surgery is performed to repair an artificial hip joint (prosthesis) that has been damaged over time due to an infection, or due to normal wear and tear of the prosthetic hip. Revision surgery helps to correct the problem so the hip can function normally again.
47945917|NCT00227773|DRUG|octreotide acetate|
48476265|NCT02615184|DRUG|Dexlansoprazole|Dexlansoprazole capsules
48476266|NCT05110131|DEVICE|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
48476267|NCT01264913|BEHAVIORAL|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
48476268|NCT06609538|OTHER|Control Group|Receives standard preoperative instructions and propofol or ketamine infusion.
47945918|NCT00227773|DRUG|vatalanib|
47945919|NCT00227773|PROCEDURE|anti-cytokine therapy|
47945920|NCT00227773|PROCEDURE|antiangiogenesis therapy|
48294502|NCT04068103|DRUG|Leucovorin|Given IV
48294503|NCT04068103|DRUG|Leucovorin Calcium|Given IV
48294504|NCT04068103|DRUG|Oxaliplatin|Give IV
48294505|NCT04068103|OTHER|Patient Observation|Undergo active surveillance
48294506|NCT04129723|OTHER|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
48294507|NCT00053612|DRUG|Vitamin A|
48294508|NCT05914220|DEVICE|AI Insights Application|Predictive AI Model Risk score
48476269|NCT06609538|OTHER|Suggestion Group|Receives positive preoperative suggestions and propofol or ketamine infusion.
48476270|NCT01447225|DRUG|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
48294509|NCT02585804|DRUG|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
48294510|NCT02583750|BEHAVIORAL|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
48294511|NCT02583750|BEHAVIORAL|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
48294512|NCT06288386|DEVICE|GrandioSO Heavy Flow|Attachment will be performed with GrandioSO Heavy Flow.
48294513|NCT06288386|DEVICE|Filtek Z350XT Flowable|Attachment will be performed with Filtek Z350XT Flowable.
48294514|NCT03156153|DRUG|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
48294515|NCT03156153|DRUG|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
48294516|NCT05964738|DRUG|Diuretics withdrawal|Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
48294517|NCT05964738|DRUG|Diuretics maintenance|Any diuretic could be used
48294518|NCT04452526|OTHER|Best Practice|Receive usual care
48294519|NCT04452526|OTHER|Educational Intervention|Receive educational materials
48294520|NCT04452526|OTHER|Questionnaire Administration|Ancillary studies
48294521|NCT04452526|OTHER|Reminder|Receive reminder letter
48294522|NCT01212328|OTHER|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
48294523|NCT01212328|OTHER|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
48294524|NCT06671977|DRUG|DMT-Medium Dose|14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.
48294525|NCT06671977|DRUG|DMT-Low Dose|10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes
48294526|NCT06671977|DRUG|THC-Medium Dose|0.5 mg over 5 minutes and then 2 mg over and 55 minutes
48294527|NCT06671977|DRUG|THC-Low Dose|0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes
48294528|NCT06672328|PROCEDURE|Training with Action Observation Therapy|"AOT based mobility and balance exercises along with conventional therapy consisting of simple lower limb stretchings and strengthening.~The fun based activities inlcude reaching for objects, tower building and taking turns in various stances."
48294529|NCT06672328|PROCEDURE|Training without Action Observation Therapy|"Cerebral Palsy patients will receive balance and mobility training without action observation in various stances of sitting, standing and turning.~Activities are fun based and include reaching for objects, tower building and taking turns in different positions."
48294530|NCT00184639|DRUG|insulin detemir|
48476271|NCT01447225|DRUG|Carboplatin|administered at AUC 6
48476272|NCT01447225|DRUG|Pemetrexed|administered IV at 500 mg/m2
48476273|NCT01447225|DRUG|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
48476274|NCT01447225|DRUG|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
48476275|NCT01962649|BIOLOGICAL|ICG|
48476276|NCT01962649|DEVICE|Optical molecular imaging|
48476277|NCT01610609|BEHAVIORAL|Population Health Management Intervention|"This intervention includes:~* Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~* Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
48476278|NCT05811819|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
47945921|NCT00227773|PROCEDURE|biological therapy|
47945922|NCT00227773|PROCEDURE|endocrine therapy|
48294531|NCT02143271|DRUG|KHK7580|Oral administration
48294532|NCT04848974|DRUG|Cladribine|Given IV
48294533|NCT04848974|DRUG|Cytarabine|Given SC
48294534|NCT04848974|DRUG|Uproleselan|Given IV
48294535|NCT01690234|PROCEDURE|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
48294536|NCT01690234|PROCEDURE|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
48294537|NCT04763382|OTHER|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
48294538|NCT04763382|OTHER|Control gruop|Pre-test, post-test and urinalysis
48294539|NCT01464697|DRUG|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
48294540|NCT01464697|DRUG|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
48294541|NCT03648645|DEVICE|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
48294542|NCT06152601|PROCEDURE|anticipated bipedal standing position in the immediate post-operative phase|"Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position."
48294543|NCT06135818|DIAGNOSTIC_TEST|IRISA-TB|ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
48294544|NCT05077189|OTHER|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)"
48294545|NCT06673108|DEVICE|SoLa Pelvic Therapy|SoLa Pelvic Therapy laser emits near-infrared (810-980 nm wavelength) energy to the vaginal tissues. The device treats at 5-8 W for 3-6 minutes and delivers a fluence of 3,000 and 5,000 J/cm2 through a sterile vaginal probe. Specific treatment time is calculated based on vaginal length. Based on a code input, the device can cycle between emitting laser energy or sham which is visible light without focused laser energy.
48294546|NCT06290505|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
48294547|NCT02947451|OTHER|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
48294548|NCT02947451|OTHER|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
48294549|NCT04442581|DRUG|Cabozantinib S-malate|Given PO
48294550|NCT04442581|BIOLOGICAL|Pembrolizumab|Given IV
48294551|NCT03172650|DIAGNOSTIC_TEST|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
48294552|NCT04272125|BIOLOGICAL|CD123 CAR-T cells|A single infusion of CD123-CAR-T cells will be administered intravenously
48294553|NCT02138110|DEVICE|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
48294554|NCT04165265|DEVICE|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
48294555|NCT05337722|BEHAVIORAL|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
48294556|NCT05337722|BEHAVIORAL|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
48294557|NCT04618705|BEHAVIORAL|Smoking Cessation|Participants will start a smoking cessation program.
47945923|NCT00227773|PROCEDURE|enzyme inhibitor therapy|
48294558|NCT05597046|OTHER|Interview|Interviews
48294559|NCT04981340|BEHAVIORAL|Diaphragmatic breathing|Same as previously described
48294560|NCT04981340|BEHAVIORAL|Standard urotherapy|Same as previously described
48476279|NCT02966184|DRUG|preservative free albuterol|Preservative free albuterol for nebulization
47945924|NCT00227773|PROCEDURE|growth factor antagonist therapy|
47945925|NCT00227773|PROCEDURE|hormone therapy|
47945926|NCT00227773|PROCEDURE|protein tyrosine kinase inhibitor therapy|
47945927|NCT00227773|PROCEDURE|somatostatin analogue therapy|
47945928|NCT03234777|BEHAVIORAL|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
47945929|NCT03234777|BEHAVIORAL|Regular video|Developed by CDC
47945930|NCT04256954|BEHAVIORAL|Peer navigation intervention|A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
47945931|NCT04295473|PROCEDURE|Reduced port laparoscopic gastrectomy|The ports were reduced in the surgery of intervention arm.
47945932|NCT00990873|GENETIC|gene expression analysis|
47945933|NCT00990873|GENETIC|microarray analysis|
48294561|NCT05581576|DRUG|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
48294562|NCT05335525|DEVICE|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
48294563|NCT03199911|DRUG|Topical Antibiotic Product|Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
48294564|NCT03199911|DRUG|Topical Non-Antibiotic Ointment|Mineral oil/petrolatum-based artificial tear ointment.
48294565|NCT05182333|OTHER|Examination|History taking, examination of upper limb
48294566|NCT02163369|DRUG|Peppermint and Lavender Essential Oils|
48294567|NCT06263231|DRUG|INT230-6|INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.
48633682|NCT04307355|DEVICE|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
48294568|NCT06263231|DRUG|Eribulin|Eribulin IV
48294569|NCT06263231|DRUG|Trabectedin|Trabectedin infusion
48294570|NCT06263231|DRUG|Pazopanib|Pazopanib pill
48294571|NCT03074305|DEVICE|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy"
48294572|NCT06046443|DRUG|LB54640|Oral daily administration
48294573|NCT06046443|DRUG|Placebo|Placebo matched to LB54640
48294574|NCT05021614|DEVICE|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
48294575|NCT03886077|DRUG|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
48294576|NCT02858388|DEVICE|Sinuclean Nebules 45|Nebulization of solution
48633683|NCT03302936|DRUG|Phenazopyridine|to be given preoperatively
48633684|NCT05916924|OTHER|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting|Collection of clinical data including manual muscle test (MMT), range of motion (ROM), Fugl-Meyer assessment (FMA), berg balance scale (BBS) and kinetic data via video shooting
48633685|NCT05220995|GENETIC|protocol|ovarian stimulation protocols on euploid rates were compared.
48633686|NCT01347957|OTHER|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
48633687|NCT01347957|OTHER|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
48633688|NCT03486639|OTHER|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
48633689|NCT04616235|DRUG|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
48633690|NCT04616235|OTHER|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
48633691|NCT06106373|DEVICE|iotaSOFT Insertion System|robotic assistive technology for cochlear implant electrode insertion
48633692|NCT05873621|PROCEDURE|ICG-guided lymphadenectomy|Excision of ICG-fluorescent lymph nodes in addition to standard laparoscopic total mesorectal excision in rectal cancer patients after neoadjuvant chemoradiation
48633693|NCT03701087|DRUG|Vitamin D|2800 IU daily till 26 weeks of pregnancy
48633694|NCT04918628|DRUG|Sintilimab|A humanized anti-PD-1 monoclonal antibody
48633695|NCT05922735|BEHAVIORAL|Questionnaire|Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox
48633696|NCT02269488|DRUG|MEDI3250|MEDI3250
48294577|NCT02858388|OTHER|Saline solution|Nebulization of solution
48633697|NCT03125356|OTHER|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
48633698|NCT00492674|DEVICE|APOS biomechanical gait system|
48633699|NCT00492674|PROCEDURE|Physical Therapy|
48633700|NCT06253429|DRUG|Thioctic Acid 333 MG Oral Capsule|Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
48294578|NCT06672523|DRUG|BMS-986504|Specified dose on specified days
48294579|NCT06672523|DRUG|[14C]-BMS-986504|Specified dose on specified days
48294580|NCT03865069|OTHER|Mode of ventilation (Volume Guarantee)®|This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
48294581|NCT03865069|OTHER|Mode of ventilation (Volume control Ventilation)|Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
48294582|NCT04838912|BEHAVIORAL|Cool Kids (Chilled) Anxiety program adapted to children and youths with autism and anxiety disorders.|CBT program for anxiety in teenagers with autism
48294583|NCT01933672|DRUG|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
48294584|NCT01933672|DRUG|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
47945934|NCT00990873|GENETIC|reverse transcriptase-polymerase chain reaction|
48294585|NCT01933672|DRUG|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
48294586|NCT03340740|DRUG|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
48294587|NCT03340740|DRUG|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
48294588|NCT02367092|BEHAVIORAL|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
48294589|NCT00827619|DEVICE|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
48476280|NCT02507440|DRUG|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
48294590|NCT04872985|DRUG|Pyrotinib|400 mg orally once per day. Pyrotinib starts with a dose of 240 mg once daily for one week, followed by 320 mg once daily for the next week, before transitioning to 400 mg once daily as maintenance therapy.
48294591|NCT04872985|DRUG|Epirubicin|100 mg/m2,q3W\*4
48633701|NCT06253429|DRUG|Captopril 25Mg Tab|Oral angiotensin-converting enzyme inhibitors
48294592|NCT04872985|DRUG|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w\*4
48294593|NCT04872985|DRUG|Cyclophosphamide|600 mg/m2, q3w\*4
48294594|NCT04872985|DRUG|Docetaxel|100 mg/m2, q3w\*4
48294595|NCT04872985|DRUG|Nab paclitaxel|120mg/m2 qw\*12 or 260mg/m2 q3w\*4
48103907|NCT03107962|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
48294596|NCT04872985|DRUG|Placebo|400 mg orally once per day
48294597|NCT05730439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48294598|NCT05730439|DRUG|Nicotine Oral Pouch|Receive ZYN brand NP
48294599|NCT05730439|DRUG|Nicotine Oral Pouch|Receive Rogue brand NP
48294600|NCT05730439|OTHER|Questionnaire Administration|Ancillary studies
48294601|NCT05730439|DRUG|Smokeless Tobacco|Receive usual SLT
48294602|NCT03901183|OTHER|Plant-based Diet|Patients are guided to change their nutrition to a plant-based diet.
48294603|NCT02810002|DEVICE|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
48294604|NCT02810002|DEVICE|Control infantry boot|Training: infantry basic training in the control boots
48633702|NCT03066557|PROCEDURE|TACE and Apatinib|TACE and Apatinib 250mg po qd
48633703|NCT03066557|PROCEDURE|TACE|TACE
48294605|NCT06666855|DRUG|DE-117B Eye Drops|Investigational Product: 0.002% DE-117B Eye Drops
48633704|NCT05372939|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
48633705|NCT05372939|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
48633706|NCT05372939|COMBINATION_PRODUCT|Humira (adalimumab)|Humira comparator is administered subcutaneously, on Humira frequency schedule.
48633707|NCT04656080|BEHAVIORAL|CPET exercise testing|"* The cardiopulmonary exercise testing (CPET) is done.~* EKG testing will be done as part of the CPET test. Allosure testing will be done at baseline and then at 1 hr, 4 hrs, 1 day, 7 days after CPET."
48633708|NCT03309475|BEHAVIORAL|SocialMIND|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
48103908|NCT05318950|BEHAVIORAL|E-learning|8 lessons about nutrition and lifestyle
48103909|NCT05318950|DIETARY_SUPPLEMENT|Diet|Diet A: MedDASH diet (55% carbohydrates, 25% amino acids, 20% fatty acids) Diet B: MedDASHfat diet (10% carbohydrates, 25% amino acids, 65% fatty acids)
48294606|NCT06666855|DRUG|Latanoprost|Active Control: 0.005% Latanoprost Eye Drops
48103910|NCT00930813|DEVICE|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
48103911|NCT00930813|DEVICE|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
48294607|NCT06350162|DRUG|Serplulimab|4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
48294608|NCT06350162|RADIATION|Chest Radiation|30Gy-45Gy/QD/3Gy
48294609|NCT01483040|DEVICE|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
48294610|NCT00537823|DRUG|Cetuximab|
48294611|NCT00537823|DRUG|Bevacizumab|
48294612|NCT00537823|DRUG|Leucovorin|
48294613|NCT00537823|DRUG|Oxaliplatin|
48294614|NCT00537823|DRUG|Fluorouracil|
48294615|NCT03396471|DRUG|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
48294616|NCT03396471|RADIATION|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
48294617|NCT00163137|DRUG|lasofoxifene|lasofoxifene 0.25mg
48294618|NCT00163137|DRUG|raloxifene|raloxifene 60 mg/day
48294619|NCT00163137|DRUG|Placebo|0 mg/day
48294620|NCT04045223|OTHER|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
48294621|NCT05058872|DRUG|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
48294622|NCT05058872|DRUG|Placebo|Placebo comparator
48294623|NCT01803165|PROCEDURE|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
48294624|NCT00552305|DRUG|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
48294625|NCT01382069|DRUG|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
48294626|NCT01382069|DRUG|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
48294627|NCT05265013|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion
48294628|NCT05265013|BIOLOGICAL|pembrolizumab|200 mg every three weeks on days 1 and 22 of each 6-week cycle, 30 minute IV infusion
48294629|NCT06456723|DRUG|[18F]-FET-βAG-TOCA|Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA) - maximum injected dose of 370MBq - followed PET/CT imaging.
48294630|NCT00067522|BEHAVIORAL|User-independent contraception program|
48294631|NCT00067522|BEHAVIORAL|Future Planning Perspectives program|
48294632|NCT04408157|BEHAVIORAL|Self-management booklet (SWitCh: Stay well during COVID-19)|The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
48294633|NCT04692493|DRUG|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
48294634|NCT04692493|DRUG|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
48294635|NCT03527901|DIAGNOSTIC_TEST|GCF collection with aMMP-8 chair side test|
48294636|NCT03527901|OTHER|Saliva collection|
48294637|NCT06523621|DRUG|Nivolumab|2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
48633709|NCT03309475|BEHAVIORAL|Psychoeducational multicomponent intervention|The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
48633710|NCT03309475|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
48633711|NCT03309475|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
48633712|NCT05738252|DIAGNOSTIC_TEST|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
48633713|NCT05738252|DIAGNOSTIC_TEST|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
48633714|NCT00593645|DRUG|Clofarabine|
48633715|NCT00593645|DRUG|Cytarabine|
48294638|NCT04174963|BEHAVIORAL|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
48294639|NCT00870272|DRUG|Misoprostol|400mcg misoprostol taken sublingually or buccally
48294640|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
48294641|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
48633716|NCT00593645|DRUG|Thymoglobulin|
48633717|NCT00593645|PROCEDURE|Stem cell infusion|
48633718|NCT02892708|PROCEDURE|Surgery|partial or complete resection followed by radiotherapy
48633719|NCT02892708|RADIATION|radiotherapy|radiotherapy after a brain biopsy
48633720|NCT01451203|DRUG|Placebo|Subcutaneous (SC)
48633721|NCT01451203|DRUG|CZP|SC
47945935|NCT00990873|OTHER|laboratory biomarker analysis|
48294642|NCT02114203|DRUG|placebo for PDE9i|oral dose, every 12 hours for 28 days
48294643|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
48294644|NCT05283083|DRUG|Dexmedetomidine|A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
48294645|NCT03246269|DIAGNOSTIC_TEST|MoCA|
48294646|NCT02424370|PROCEDURE|TAVR|Percutaneous aortic valve replacement
48633722|NCT01451203|DRUG|methotrexate (MTX)|oral
48633723|NCT00801268|DRUG|tripterygium wilfordii|TW，60mg/d
48294647|NCT03988751|BEHAVIORAL|Ambulation|Variation in ambulatory intensity.
48294648|NCT02796950|DRUG|Acipimox|P.o. administration of 250 mg acipimox
48633724|NCT00801268|DRUG|Emodin|100mg/d
48633725|NCT02207179|DEVICE|LumaScan Image Guided Surgery|
48633726|NCT05253235|BEHAVIORAL|SAAF|A 7 session online intervention designed to augment protective processes associated with deterrence of substance use
48633727|NCT05253235|OTHER|Receipt of parenting book|Parents will receive a copy of the book, Parenting for Liberation: A Guide for Raising Black Children
48633728|NCT06413394|OTHER|environmental education|environmental education
48294649|NCT04089124|PROCEDURE|surgery of zone II cut flexor repair|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
48294650|NCT05308095|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
48294651|NCT05488457|DRUG|deuterated oxytocin (d5OT)|Subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their nonemergent cesarean delivery.
48294652|NCT00554294|BEHAVIORAL|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
48294653|NCT04983901|DRUG|Imipenem/Cilastatin/Relebactam|Given IV
48294654|NCT04983901|DRUG|Cefepime|Given IV
48633729|NCT03132259|DRUG|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
48633730|NCT03132259|DRUG|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
48633731|NCT02849223|DEVICE|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
48294655|NCT04983901|DRUG|Meropenem|Given IV
48633732|NCT02849223|DEVICE|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
48633733|NCT01574404|PROCEDURE|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
48633734|NCT02326246|OTHER|multi-parametic MRI|
48633735|NCT04212065|DRUG|buprenorphine|To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
48633736|NCT03385486|BIOLOGICAL|TBX-3400|Autologous transfusion
48294656|NCT04983901|DRUG|Piperacillin-Tazobactam|Given IV
48294657|NCT04983901|DRUG|Vancomycin|Given IV
48294658|NCT04983901|DRUG|Daptomycin|Given IV
48633737|NCT04950907|DIAGNOSTIC_TEST|vats|Use uniportal tubeless VATS to obtain the biopsy
48633738|NCT04950907|DIAGNOSTIC_TEST|CT-guided fine needle biopsy|Use CT-guided fine needle to obtain the biopsy
48633739|NCT00383851|DRUG|ATN-224|
48633740|NCT00383851|DRUG|Temozolomide|
48633741|NCT02056288|DRUG|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
48294659|NCT04983901|DRUG|Linezolid|Given IV or PO
48294660|NCT05017831|BEHAVIORAL|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
48294661|NCT05017831|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition. CRT is a behavioral treatment that presents tasks to participants in a standardized order within each session. Each task has a number of levels. Participants stay at the same task-based level until mastered. They then move up a level on that task. participants can be at different levels on different tasks within each session. After completion of tasks, participants are asked to reflect on their thought processes in solving the tasks. Standard prompts are used to guide the discussion.
48294662|NCT00006418|PROCEDURE|DNA collection|
48633742|NCT02056288|DRUG|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
48633743|NCT06251830|DIAGNOSTIC_TEST|MRI exam with Magnetic Resonance Fingerprinting|"Acquisition of MRI data with technique Magnetic Resonance Fingerprinting"
48633744|NCT02722603|DRUG|gabapentin|75 mg/ml gabapentin syrup
48633745|NCT02722603|DRUG|tramadol|100 mg/ml tramadol oral drops
48633746|NCT02722603|OTHER|placebo tramadol|placebo tramadol oral drops
48633747|NCT02722603|OTHER|placebo gabapentin|placebo gabapentin syrup
48633748|NCT06354842|DIAGNOSTIC_TEST|pilocarpine iontopheresis|Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
48633749|NCT02623439|DRUG|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
48633750|NCT03397758|DEVICE|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
48633751|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
48633752|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
48633753|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
48633754|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
48633755|NCT00398905|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
48633756|NCT00398905|DRUG|Enoxaparin|40 mg once daily (40 mg total daily dose)
48633757|NCT03691870|PROCEDURE|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
48633758|NCT03691870|PROCEDURE|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
48633759|NCT05162391|BEHAVIORAL|Contingency Management|Contingency management intervention with incentives tied to provision of urine samples with no detectable levels of methamphetamine (MA).
48633760|NCT01489358|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
48633761|NCT02131493|DRUG|S-1, Gemcitabine|
48633762|NCT00212355|DRUG|NPC-02|zinc acetate
48633763|NCT03849456|DRUG|GWP42006|Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
48294663|NCT03946566|PROCEDURE|Acupuncture|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
48294664|NCT05385705|DRUG|Cyclophosphamide|Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
48294665|NCT05385705|DRUG|Trastuzumab|Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
48294666|NCT05385705|DRUG|Pertuzumab|Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
48294667|NCT05385705|BIOLOGICAL|NK cells|NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.
48633764|NCT00112307|PROCEDURE|Brachytherapy|
48633765|NCT03391154|DRUG|levothyroxin|90 female received levothroxine
48294668|NCT05385705|DRUG|Interleukin-2|IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
48633766|NCT06401109|DEVICE|AquaPass|"The AquaPass system works by activating the body's natural sweating mechanism to remove excess fluid from the interstitial compartment. This process is achieved by wearing a garment that creates optimal microclimate conditions around the skin.~The system is controlled by a portable unit that delivers warm air to the wearable component while ensuring patient safety."
48633767|NCT02765971|OTHER|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
48633768|NCT02765971|DRUG|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
48633769|NCT02765971|DRUG|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
48294669|NCT03223727|DIAGNOSTIC_TEST|Blood tests|Blood tests for several bone markers (see summary)
48633770|NCT05329883|PROCEDURE|Double-J stent removal|Outpatient ureteral stent removal without antibiotic prophylaxis
48633771|NCT01121354|DRUG|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
48633772|NCT01121354|DRUG|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
48633773|NCT04787120|DEVICE|SQUIDperi|Liquid embolic delivery syringes and micro-catheter
47945936|NCT02556827|OTHER|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
48476281|NCT02507440|DRUG|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
48476282|NCT02507440|DRUG|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
48476283|NCT02612181|DRUG|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
48633774|NCT05471661|BIOLOGICAL|Pentavalent-specific T cells (penta-STs)|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
48633775|NCT04941911|DRUG|Octreotide Acetate|Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.
48633776|NCT04941911|OTHER|Placebo|Sodium chloride 0.9% w/v
48633777|NCT04728464|PROCEDURE|Periodontally Accelerated Osteogenic Orthodontics (PAOO)|Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
48633778|NCT03000751|OTHER|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
48633779|NCT03000751|OTHER|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
48633780|NCT03000751|OTHER|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
48633781|NCT01526746|DRUG|Tasimelteon|20mg capsule, once
48633782|NCT01526746|DRUG|Tasimelteon|20mg, once
48633783|NCT00289900|DRUG|MK-0524A|
48633784|NCT00289900|DRUG|Atorvastatin|
48633785|NCT00289900|DRUG|Simvastatin|
48633786|NCT03979989|DRUG|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
48633787|NCT03979989|DRUG|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
48633788|NCT02313272|RADIATION|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
48633789|NCT02313272|DRUG|Pembrolizumab|"Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase."
48633790|NCT02313272|DRUG|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a \> 10% change in weight.
48476284|NCT04489303|BEHAVIORAL|Caring Response App|Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
48476285|NCT04489303|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
48476286|NCT06028646|DEVICE|Dynamic Airway CT scan (DA-CT)|Patient will be asked to perform movements during the scan.
48633791|NCT03993678|DRUG|IP-001|Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.
48633792|NCT03993678|DEVICE|Thermal Ablation|"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"
48633793|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
48633794|NCT04082676|DRUG|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
48476287|NCT02452528|DRUG|ARC-520|
48476288|NCT02452528|DRUG|Placebo|
48476289|NCT02452528|DRUG|Entecavir|0.5 or 1.0 mg/day orally
48476290|NCT02452528|DRUG|Tenofovir|300 mg/day orally
48476291|NCT02452528|DRUG|diphenhydramine|50 mg orally as pretreatment antihistamine
48476292|NCT04924699|DRUG|MRG002|Administrated intravenously
48476293|NCT04924699|DRUG|Trastuzumab Emtansine for Injection|Administrated intravenously
48476294|NCT01355848|BEHAVIORAL|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
48633795|NCT03682393|DRUG|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
48633796|NCT03682393|DRUG|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
48633797|NCT05171335|DRUG|Lenvatinib|"Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time."
48476295|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
48476296|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
48633798|NCT05171335|PROCEDURE|Transcatheter Arterial Chemoembolization|Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
48633799|NCT02216877|DRUG|Mablet 360 mg|
48633800|NCT02216877|DRUG|Placebo|
48633801|NCT00177489|BEHAVIORAL|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
48633802|NCT00177489|OTHER|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
48633803|NCT06088628|DIAGNOSTIC_TEST|Facial expression; Electroencephalogram; MRI|Recording facial expressions of participants, EEG recordings, and MRI scans.
48633804|NCT00176254|RADIATION|Radiotherapy|80 centigray (cGy) on Day 1 \& 2 and 22 \& 23 of chemotherapy
48633805|NCT00176254|DRUG|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
48294670|NCT03397485|DIETARY_SUPPLEMENT|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
48294671|NCT03397485|DIETARY_SUPPLEMENT|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
48294672|NCT06565624|PROCEDURE|Cotton Swab Nasal Stimulation|Nostril probing for the purpose of producing reflex tearing
48294673|NCT02511574|DRUG|natural progesterone|
48294674|NCT02511574|DEVICE|cervical pessary|
48294675|NCT00824538|DRUG|sunitinib malate|
48294676|NCT00824538|OTHER|flow cytometry|
48294677|NCT00824538|OTHER|immunohistochemistry staining method|
48294678|NCT00824538|OTHER|laboratory biomarker analysis|
48294679|NCT04933097|DEVICE|Microfet2®|"Conducting a day hospitalization including analyses:~1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women)~2. Qualitative muscular analysis:~   * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~  * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~  * a walking test to assess the functional impact of sarcopenia and its severity"
48294680|NCT03873207|DEVICE|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
48633806|NCT00176254|DRUG|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
48633807|NCT03116087|DRUG|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
48633808|NCT03116087|DRUG|Placebo|Placebo patch
48633809|NCT01834651|DRUG|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
47945937|NCT02556827|DEVICE|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
48294681|NCT03873207|DEVICE|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
47945938|NCT02556827|DEVICE|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
47945939|NCT02556827|DEVICE|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
47945940|NCT01205815|OTHER|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
47945941|NCT02134197|DRUG|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
47945942|NCT00053365|DRUG|irofulven|Given IV
47945943|NCT00004198|BIOLOGICAL|keyhole limpet hemocyanin|
48294682|NCT02797366|RADIATION|Proton radiotherapy|
48294683|NCT02292134|DEVICE|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
48294684|NCT03288584|DRUG|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
48294685|NCT03288584|DRUG|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
48294686|NCT03288584|DRUG|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
48294687|NCT01364467|DRUG|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
48294688|NCT01364467|DRUG|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
48294689|NCT00570739|DRUG|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
48294690|NCT00570739|DRUG|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
48294691|NCT00570739|DRUG|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
48294692|NCT00570739|DRUG|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
48633810|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
48633811|NCT02882893|DRUG|Clostridium Botulinum A Toxin|
47945944|NCT00004198|BIOLOGICAL|sargramostim|
47945945|NCT00004198|BIOLOGICAL|tumor cell-based vaccine therapy|
48633812|NCT05362136|PROCEDURE|perforation of the sinus floor|perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation
48633813|NCT05362136|PROCEDURE|no perforation of the sinus floor|standard procedure for sinus floor elevation
48633814|NCT00502515|DRUG|SSR180575|Oral, once daily dosing
48633815|NCT00502515|DRUG|Placebo|Oral, once daily dosing
48103912|NCT06374056|DEVICE|Kintsugi Voice Device|"The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression.~The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs."
48103913|NCT04415333|DRUG|Sodium Butyrate 5 mmol|Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
48103914|NCT04415333|DRUG|Sodium Butyrate 80 mmol|Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
48103915|NCT03319589|DIETARY_SUPPLEMENT|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
48103916|NCT03275077|DEVICE|Thromboelastography|A viscoelastic test of coagulation
48103917|NCT04251143|PROCEDURE|corneal cross-linking|UV-A Irradiation and riboflavin
48103918|NCT04251143|DIAGNOSTIC_TEST|corneal topography and tomography|Detailed Information about corneal tomography is used for diagnosis
48476297|NCT00255151|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
48620066|NCT05073471|BEHAVIORAL|Patterned Sensory Enhancement (PSE)|"Patterned Sensory Enhancement (PSE) is one of Neurologic Music Therapy (NMT) techniques. NMT is a research-guided clinical model that is driven by advances in neuroscience and the understanding of the perception, production, and performance of music and how music can influence and change non-musical brain and behavior function.~PSE is a technique that uses the rhythmic, melodic, harmonic, and dynamic-acoustical elements of music to provide temporal, spatial, and. force cues for movements which reflect functional movements of activities of daily."
48633816|NCT02961582|DEVICE|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
48633817|NCT02961582|OTHER|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
47945946|NCT05280210|OTHER|PTC drug screening|PTC is an in vitro tumor model, which serves as a structural and functional unit recapitulating the original tumors in genotype, phenotype, and drug response. PTC will be used in drug screening.
47945947|NCT00884377|DRUG|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
47945948|NCT00884377|DEVICE|ThermoMed|ThermoMed heat treatment device, one treatment
48103919|NCT02716324|BEHAVIORAL|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
48633818|NCT01576393|BEHAVIORAL|Home-based Family Therapy|12 home-based family therapy sessions
48103920|NCT02716324|OTHER|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
48103921|NCT00694681|BEHAVIORAL|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
48294693|NCT05677789|DIAGNOSTIC_TEST|Medical observation|Likely suitable for home treatment
48294694|NCT05677789|DIAGNOSTIC_TEST|Supportive treatment (BSC)|Consider hospital supervised treatment
48294695|NCT05677789|DIAGNOSTIC_TEST|Intensive care management|Manage in hospital as severe pneumonia
48294696|NCT01852344|DRUG|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
48294697|NCT01852344|DRUG|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
48294698|NCT01852344|BEHAVIORAL|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
48633819|NCT01576393|BEHAVIORAL|office-based family therapy|12 office-based family therapy sessions
48633820|NCT01576393|BEHAVIORAL|WHE|12 Women's Health Education Sessions
48633821|NCT01457430|DRUG|Icatibant|30 mg subcutaneous dose of Icatibant
47945949|NCT04824365|DRUG|Sodium Pyruvate|Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
47945950|NCT04824365|OTHER|Saline|Subjects will use a saline nasal spray 3x daily for 14 days.
47945951|NCT04293731|DIETARY_SUPPLEMENT|Symbiter-Smectite|Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
47945952|NCT04293731|DIETARY_SUPPLEMENT|Placebo|Placebo
48294699|NCT01852344|BEHAVIORAL|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
48294700|NCT04144881|DIAGNOSTIC_TEST|coronary computed tomography|patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
48294701|NCT00602862|DRUG|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
48294702|NCT00602862|DRUG|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
48294703|NCT00602862|DRUG|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
47945953|NCT03964116|OTHER|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
48294704|NCT01748695|DRUG|V158866|
48294705|NCT01748695|DRUG|Placebo|
48294706|NCT04317222|DEVICE|eCRRT|"eCRRT was define as:~1. Initiated within the first 24 post-transplant hours;~2. High volume (35-50ml/kg) hemofiltration;~3. Continuous at least 12 hours per day for 3 days;~4. Standard treatment"
48294707|NCT05334589|DEVICE|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
48294708|NCT05804162|DRUG|Cagrilintide|Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
48294709|NCT05804162|DRUG|Cagrilintide Placebo|Participants will receive cagrilintide placebo subcutaneously once weekly.
48633822|NCT01663805|DRUG|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
47945954|NCT00000519|BEHAVIORAL|diet, reducing|
48294710|NCT05804162|DRUG|Moxifloxacin|Partcipants will receive a single dose of moxifloxacin orally.
48294711|NCT05804162|DRUG|Moxifloxacin Placebo|Partcipants will receive a single dose of moxifloxacin orally.
48294712|NCT06529185|DEVICE|The BREATHER|The BREATHER is Light/Medium resistance inspiratory muscle trainer which has significance role in increasing inspiratory muscle strength and endurance which could result in a decreased sensation of dyspnea
48294713|NCT06529185|DRUG|pharmacological treatment|patient will receive the usually pharmacological treatment.
48476298|NCT06428513|BEHAVIORAL|HCTP|10 weekly 1-on-1 30-minute tele-sessions via Zoom, delivered by a certified health coach. At baseline assessment including full medical history, medications, lifestyle practices, self-reported health status, psychosocial status, and other relevant information will be taken. At the first session, participants identify their health vision and 3-month health goals. At subsequent meetings, participants review their progress towards reaching the prior week's goals and identify goals for the next week. An individualized action plan will be formulated to help each participant achieve their goals. The action plan will focus on important lifestyle practices (physical activity/exercise training, correct nutrition, weight management, tobacco cessation, and stress management. Patients can request further health care advice felt necessary for their progress, and will be referred to health care professionals in the rehabilitation hospital that provide care for lung transplantation candidates.
48476299|NCT04944472|BEHAVIORAL|HDKQ questionnaire|Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
48294714|NCT05767957|OTHER|Rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist using conventional technique alone.
47945955|NCT00000519|BEHAVIORAL|exercise|
47945956|NCT00000519|BEHAVIORAL|diet, fat-restricted|
48294715|NCT05767957|OTHER|Cognitive-behavioral therapies in addition to rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies.
48294716|NCT02983292|DEVICE|PyroTITAN™ HRA|Humeral Resurfacing
48294717|NCT03751709|DRUG|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
48294718|NCT03751709|OTHER|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 \& Day 15
48294719|NCT05028023|BIOLOGICAL|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
48294720|NCT06515223|DEVICE|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation Mapping and Pelvic Floor Muscle Training
48294721|NCT02571361|DRUG|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
48294722|NCT02571361|DRUG|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
48294723|NCT02571361|DRUG|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
48294724|NCT02571361|DRUG|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
48294725|NCT02571361|DRUG|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
48294726|NCT00756977|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
48294727|NCT00756977|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
48294728|NCT05209243|RADIATION|SBRT|SBRT (all metastatic lesions)
48294729|NCT05209243|RADIATION|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
48294730|NCT06382493|DRUG|Tegoprazan-containing sequential H. pylori eradication therapy|tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
48294731|NCT06382493|DRUG|Esomeprazole-containing sequential H. pylori eradication therapy|Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
48294732|NCT01676376|DEVICE|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
48294733|NCT01676376|OTHER|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
48294734|NCT05958368|OTHER|Avocado|The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).
48294735|NCT05958368|OTHER|Other Fruit(s)|The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
48294736|NCT03947879|DRUG|L-glutamine|15 g of L-glutamine twice daily by mouth for 3 months.
48294737|NCT03947879|OTHER|No L-glutamine|The same patients will be given no L-glutamine for 3 months.
48294738|NCT04397133|OTHER|inspiratory muscle training|inspiratory muscle training will be done with Philips Respironics Threshold IMT device starting with resistance of % 50 of MIP value
48294739|NCT04397133|OTHER|sham intervention|in these group the patients will get sham intervention with Philips Respironics Threshold IMT device
48476300|NCT00003862|DRUG|cisplatin|
48294740|NCT06672913|BEHAVIORAL|skin to skin contact care|Early and regular skin to skin contact in NICU GA: \< 28 weeks: After the 72nd hour GA: 28 - 32 weeks: As soon as stabilization is ensured
48294741|NCT06671431|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy with or without radiotherapy
47945957|NCT04644991|OTHER|Kinesiology taping|Y-type kinesiology tape will be applied to the thoracolumbar fascia in experimental gruoup.
47945958|NCT04644991|OTHER|Six minutes walking test|Participants will be asked to walk as fast as they can for 6 minutes.
48294742|NCT06672107|BEHAVIORAL|Active Driver Training Intervention|simulated driver training focusing on practice of 4 specific driving skills including lane positioning, speed management, collision avoidance, and dashboard attention
48294743|NCT06672107|BEHAVIORAL|Control Intervention|pre-scripted familiarization with driving simulator controls in the absence of any complex driving scenarios, decision making requirements, or feedback pertaining to driving skills
48294744|NCT00399802|DRUG|ZA|Single ZA 4 mg IV infusion at the start of treatment
48294745|NCT00399802|DRUG|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
48294746|NCT00399802|DRUG|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
48294747|NCT00399802|DRUG|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
48294748|NCT04270851|DIAGNOSTIC_TEST|LiMAx test|The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.
48294749|NCT04270851|DIAGNOSTIC_TEST|HepaT1ca magnetic resonance scan|The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
48294750|NCT06672263|DRUG|TQB3911 tablets|TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.
48294751|NCT03512223|DRUG|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
48294752|NCT01354691|DRUG|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
48294753|NCT06146218|BEHAVIORAL|Contemplative-Based Resilience Training (CBRT)|The intervention is a 10-week program that will address mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing. The rationale for applying this mindfulness intervention to promote psychological resilience following the development of race-based traumatic symptoms is based on the notion that mindfulness promotes acceptance of complex thoughts and feelings, reduces rumination, and improves psychological function, cognitive flexibility, and coping processes.
48294754|NCT04174157|OTHER|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
48294755|NCT04174157|DRUG|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
48294756|NCT02418403|BEHAVIORAL|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
48476301|NCT00003862|DRUG|fluorouracil|
48476302|NCT00003862|DRUG|leucovorin calcium|
48476303|NCT00003862|DRUG|paclitaxel|
48476304|NCT00003862|PROCEDURE|conventional surgery|
48476305|NCT00003862|PROCEDURE|neoadjuvant therapy|
48294757|NCT02418403|BEHAVIORAL|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
48294758|NCT05113004|DRUG|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
48294759|NCT05113004|DRUG|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
48294760|NCT05113004|DRUG|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
48633823|NCT00799864|DRUG|Rilpivirine|Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged \>=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged \>=6 to \<12 years) or 25 mg once daily for up to 48 weeks.
48633824|NCT00799864|DRUG|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
48633825|NCT00799864|DRUG|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
48633826|NCT00799864|DRUG|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
48633827|NCT00799864|DRUG|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
48633828|NCT00799864|DRUG|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
48633829|NCT02330263|DIETARY_SUPPLEMENT|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
48633830|NCT04846478|DRUG|Talazoparib|capsule, taken by mouth, once a day
48294761|NCT05113004|DRUG|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
48294762|NCT05113004|DRUG|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
48294763|NCT05113004|DRUG|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
48294764|NCT03373812|PROCEDURE|Blepharoptosis repair|levator advancement or mullerectomy
48294765|NCT04309721|DRUG|Perampanel|Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
48476306|NCT00003862|RADIATION|radiation therapy|
48476307|NCT06425198|DRUG|BMS-986278|Specified dose on specified days
48633831|NCT04846478|DRUG|Tazemetostat|orally as a tablet twice daily.
47945959|NCT04644991|OTHER|Shame Kinesiology Tape|Sham kinesiology tape will be applied to the thoracolumbar fascia in sham gruoup.
47945960|NCT03208595|DIAGNOSTIC_TEST|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
47945961|NCT03012724|DEVICE|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
48476308|NCT03648879|DEVICE|Endoscope+Cellvizio(R) 100 microscope|Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
48476309|NCT05848258|DRUG|LY3871801|Administered orally
48476310|NCT05848258|DRUG|Placebo|Administered orally
48476311|NCT03457090|OTHER|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~* To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~* To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~* To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~* To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
48633832|NCT02334254|DRUG|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
48633833|NCT02334254|DRUG|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
48633834|NCT00002238|DRUG|Interferon beta-1b|
48633835|NCT00002238|DRUG|Zidovudine|
48633836|NCT01494974|DEVICE|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
48633837|NCT01494974|DEVICE|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
48633838|NCT03667729|BEHAVIORAL|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
47945962|NCT03012724|DEVICE|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
48633839|NCT02222181|OTHER|Pharmacotherapy Management|"* assessment of patient characteristics as alcoholic, smoker, food, drugs~* Pharmacotherapy follow-up~* to evaluated medication adherence~* Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention."
48633840|NCT04236466|DEVICE|hyrax appliance|Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
48476312|NCT04347525|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
47945963|NCT03276793|OTHER|MRI scan|Patients will undergo an MRI scan
47945964|NCT03276793|BEHAVIORAL|Behavioral testing|Patients will complete a series of cognitive tasks
47945965|NCT06173141|OTHER|low- to moderate-continuous intensity cycling exercises:|"aerobic exercise during dialysis using Pedal machine at low- to moderate continuous intensity rating from 11 to 13 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
48476313|NCT02860819|DRUG|Veliparib|Veliparib 250mg BID, continuously
48476314|NCT02860819|DRUG|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
48633841|NCT04236466|DEVICE|haas appliance|Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
47945966|NCT06173141|OTHER|moderate- to high-interval intensity cycling exercises|"aerobic exercise during dialysis using Pedal machine at moderate-to-high interval intensity rating from 12 to 15 on the Borg scale for 15-30 minutes.~warming up and cool down (approximately 10 minutes) in form of free active exercise of the lower extremities"
47945967|NCT06173141|OTHER|hemodialysis sessions only|hemodialysis sessions only
47945968|NCT04521777|BEHAVIORAL|Exercise Intervention|Participate in an 8-week home-based strengthening and walking program
47945969|NCT04521777|OTHER|Physical Performance Testing|Complete a physical function test
47945970|NCT04521777|OTHER|Questionnaire Administration|Ancillary studies
47945971|NCT02024282|DEVICE|Use of C-reactive protein (CRP) point of care test|
48294766|NCT04309721|DRUG|Placebo|Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
48476315|NCT02860819|DRUG|Carboplatin|Carboplatin AUC = 4, day 1
48476316|NCT06616805|DEVICE|treadmill|Treadmill JAGUAR treadmill:( T900, China) motorized treadmill model (T900) motor power (6.OHP) input voltage (AC220-240 V, 50Hz) speed range (1-20KM/H), inclination range (1-15%) was used for exercise treatment
48476317|NCT05405049|DRUG|Morphine hydrochloride|Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.
48633842|NCT04817800|DRUG|140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)|It will be nasaly administered
48633843|NCT02333968|BEHAVIORAL|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
47945972|NCT02024282|OTHER|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
47945973|NCT02024282|DEVICE|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
47945974|NCT02155569|PROCEDURE|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
47945975|NCT02155569|PROCEDURE|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
47945976|NCT00562029|PROCEDURE|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
48476318|NCT05405049|DRUG|Bupivacain|Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation
48476319|NCT04828434|OTHER|Virtual Individual Cognitive Simulation Therapy|Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
48476320|NCT02389699|RADIATION|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
48476321|NCT02389699|RADIATION|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
48476322|NCT03460145|OTHER|Lavender Oil on Nasal Strip (Lx)|Usage of Aromatherapy for Preoperative Anxiety
48476323|NCT03460145|OTHER|Strip without Lavender Oil (Px)|Strip without Lavender Oil (Px)
48476324|NCT03460145|DRUG|Propofol 1 % Injectable Suspension|Propofol 1% (10mg/mL)
48294767|NCT00304590|DRUG|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
48294768|NCT02044484|BEHAVIORAL|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
48294769|NCT04491396|BEHAVIORAL|Gentle Yoga and Yogic Breathing|"Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB."
48294770|NCT06533384|DRUG|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
48294771|NCT06533384|DRUG|9 cycles of Camrelizumab as adjuvant therapy.|9 cycles of Camrelizumab as adjuvant therapy.
48294772|NCT04438135|OTHER|Repeated open application test|parallel application of two different types of lotion with and without aluminium.
48294773|NCT02446652|DRUG|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
48476325|NCT05418985|BEHAVIORAL|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
48633844|NCT00474968|DEVICE|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector \[SoftPAP(R)\]
47945977|NCT06316115|OTHER|In Patıents Wıth Dıabetıc Foot Ulcer, Effect On Paın And Anxıety Of Stress Ball Use Durıng Sharp Debrıdement|Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
48294774|NCT02446652|DRUG|Placebo|Placebo (orally) starting 1 week before the first day of the QT
47945978|NCT03964805|OTHER|20% oxygen|culture excusively at 20% O2 (Day 0 to Day 6)
47945979|NCT03964805|OTHER|5% oxygen|culture excusively at 5% O2 (Day 0 to Day 6)
47945980|NCT03964805|OTHER|20 % and 5 % oxygen|culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
48294775|NCT02446652|DRUG|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
48294776|NCT02446652|DRUG|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
48294777|NCT02658656|DEVICE|ReWalk 6.0|Exoskeletal Assisted Walking Device
48294778|NCT06475274|DRUG|RMC-035|Protein, a recombinant variant of A1M. Concentrate for solution for infusion.
48294779|NCT06475274|DRUG|Placebo|Identical to RMC-035 intervention devoid of the active substance.
48476326|NCT02495532|OTHER|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
48476327|NCT02495532|OTHER|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
48476328|NCT01525654|BEHAVIORAL|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
48633845|NCT00474968|DEVICE|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
47945981|NCT04102956|DRUG|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
47945982|NCT05245253|RADIATION|Positron Emission tomography|Patients will be tested with PET-examination at 3 weeks, 3 months and 1 year after the trauma
48633846|NCT03499665|BEHAVIORAL|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
48633847|NCT03499665|BEHAVIORAL|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
48476329|NCT04116151|COMBINATION_PRODUCT|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
48476330|NCT04116151|COMBINATION_PRODUCT|Usual treatment|Application on the affected skin of the emollient and moisturizing substance
48294780|NCT05336370|BEHAVIORAL|Hypnosis|The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
48294781|NCT05336370|DEVICE|Vagus nerve stimulation|A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus \[36\]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds \[37\], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
48294782|NCT05336370|DEVICE|Sham control|Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
48294783|NCT00720707|PROCEDURE|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
48294784|NCT00720707|PROCEDURE|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
48476331|NCT02718287|BEHAVIORAL|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
48476332|NCT02718287|BEHAVIORAL|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
48476333|NCT05650086|DEVICE|Thermalytix|One-time Thermal imaging is performed for this cohort.
48476334|NCT06616480|DEVICE|BenQ Materials DSFNC1 soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
48476335|NCT06616480|DEVICE|Visco SiHy Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
48476336|NCT02146976|DRUG|propofol|introvenious infusion of propofol
48476337|NCT02146976|DRUG|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
48476338|NCT02806687|DRUG|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
48476339|NCT02806687|DRUG|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
47945983|NCT05568537|DRUG|Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)|Piflufolastat F18 will first be given intravenously over about 5 seconds.
47945984|NCT00315536|DRUG|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
47945985|NCT02218983|DEVICE|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
48476340|NCT01734135|OTHER|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
48476341|NCT03008837|DEVICE|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
48633848|NCT03499665|BEHAVIORAL|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
47945986|NCT02218983|OTHER|Usual care|
47945987|NCT05149599|DRUG|Saccharomyces cerevisiae|Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month
47945988|NCT03559673|DRUG|Lacosamide|Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
47945989|NCT01863238|OTHER|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
48294785|NCT05920096|OTHER|Diabetes specialist nurse-led multi-component smoking cessation intervention|"Aims to:~* inform participants on the association between smoking and diabetic complications;~* motivate and encourage smokers to quit;~* support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting."
48294786|NCT05920096|BEHAVIORAL|Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)|A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
48294787|NCT06673134|DRUG|enteral nutrition|exclusive enteral nutrition therapy or Partial enteral nutrition
48294788|NCT06673134|DRUG|Immunotherapy|Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc
48294789|NCT06673134|DRUG|biological agents|Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc
48294790|NCT06673134|DRUG|Glucocorticoids|Glucocorticoids treatments are given
48294791|NCT06673134|OTHER|fecal microbiota transplantation|Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc
48294792|NCT05509257|DRUG|Naltrexone|Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
48294793|NCT05509257|DRUG|Placebo|Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
48294794|NCT06672796|OTHER|Resisted Toe Spread Out Exercise|new resistance exercise phase in addition to the standard protocol
48294795|NCT06672796|OTHER|Toe Spread Out Exercise|Standart protocol of toe spread out exercise
48294796|NCT06672796|OTHER|Stretching exercise|Toe stretching
48294797|NCT06672016|DRUG|Transdermal system containing progestin|MR-130A-01 transdermal system, patch to be used for female contraception
48294798|NCT05348187|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
48633849|NCT03986541|DIAGNOSTIC_TEST|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
48294799|NCT04549038|OTHER|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
48294800|NCT05717907|DEVICE|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
48294801|NCT03910192|BEHAVIORAL|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
48294802|NCT03910192|BEHAVIORAL|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
48294803|NCT06575621|BEHAVIORAL|Support program|education, medical navigation, exercise
48294804|NCT06673056|DRUG|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
48294805|NCT06673056|OTHER|Placebo|Matching Placebo Sachet
47945990|NCT01863238|DRUG|Ivacaftor Exposed|
48294806|NCT04868240|BEHAVIORAL|Concurrent training program|"The experimental group will perform 16-weeks of exercise. The exercise sessions will occur three times/week.~The participants should conduct their daily activities as usual outside of the study and maintain the same diet."
48294807|NCT03546374|PROCEDURE|Surgical Ablation|In addition to the concomitant surgery, subjects are required to have amputation or closure (with sutures or ligation) of the left atrial appendage.The Cox Maze IV lesion set is required to be performed.
47945991|NCT04844619|DRUG|4mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
48294808|NCT03546374|DEVICE|Cardioblate and Cryoflex hand held devices|The Cardioblate hand held devices consist of the Cardioblate iRF and Cryo surgical ablation devices.
48294809|NCT01810991|DEVICE|Nd:YAG Laser|Nd:YAG 1440nm Laser
48294810|NCT05911958|DRUG|SHR-A1811 for injection|SHR-A1811 for injection
47945992|NCT04844619|DRUG|16mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
47945993|NCT00050271|DRUG|Acetyl-L-carnitine|
48294811|NCT05358886|DRUG|BPN14770/ zatolmilast|25mg BID BPN14770
48294812|NCT05358886|DRUG|Placebo|Placebo
48294813|NCT02195115|PROCEDURE|Laparoscopic Cholecystectomy|
48476342|NCT03008837|OTHER|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
48476343|NCT05762887|OTHER|Probiotic Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The probiotic group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
48476344|NCT05762887|OTHER|Placebo Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The placebo group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
48476345|NCT00706719|DRUG|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
48476346|NCT00706719|DRUG|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
48476347|NCT03424655|PROCEDURE|Twisted File Adaptive|Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
48476348|NCT03424655|PROCEDURE|Balance Force|Flex-R files sizes 15-45 taper .02 were used according to the technique
48476349|NCT03424655|PROCEDURE|WaveOne|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
48476350|NCT03424655|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
48476351|NCT02044250|DRUG|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
48476352|NCT02044250|DRUG|Aspirin|Aspirin 100\~200mg 1\~2tab P.O. daily
48476353|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a continuous treatment regimen
48476354|NCT04980495|BIOLOGICAL|Efgartigimod concentrate for solution for infusion 20 mg/mL|Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
48476355|NCT03548662|BIOLOGICAL|Platelet-Rich Plasma|Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA
47945994|NCT04925271|DEVICE|X-Tack|The mucosal or submucosal defect is closed with X-Tack.
47945995|NCT04925271|DEVICE|Overstitch|The mucosal or submucosal defect is closed with Overstitch.
48294814|NCT02195115|DRUG|amitriptyline|
48294815|NCT02195115|OTHER|low-fat and low cholesterol diet|
48294816|NCT02094469|DRUG|Cilostazol|Oral, Bid, 24 weeks
48476356|NCT03548662|DRUG|Hyaluronic Acid|Hyruan Plus Inj. produced by LG Life Sciences, Ltd.
48476357|NCT03548662|OTHER|Exercise|passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
48476358|NCT06437184|DIAGNOSTIC_TEST|ODP|se previously
48476359|NCT04476186|DRUG|Acyclovir|oral syrp
48476360|NCT04476186|DRUG|KOH 10 %|solution for local application
48476361|NCT00768352|OTHER|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
48476362|NCT02343965|OTHER|Touch-massage|
48476363|NCT04061577|DEVICE|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
47945996|NCT06422195|OTHER|Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA)|Ultrasound guided radial artery cannulation by Dynamic Needle Tip Positioning Technique in Short Axis Approach (DNTP - SA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. The ultrasound transducer is oriented transversely to the radial artery at the wrist, and the vessel appears as a circular anechoic structure in the ultrasound screen with gradual advancing of the needle till reaching the radial artery. Meanwhile, the ultrasound probe is being moved proximally in advance of the needle tip until it disappears from the ultrasound image. The cannula then advanced in the direction of the artery.
48294817|NCT05359627|DRUG|Polymyxin B|Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
48294818|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- ELISA|blood sample with ELISA
48294819|NCT05557474|OTHER|Early-stage lung cancer prognostic kit -- IHC|surgical tumor part with IHC
48294820|NCT05362162|PROCEDURE|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
48294821|NCT05045755|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
48294822|NCT00317070|DRUG|dimethyl sulfoxide|intravesical installation 50 ml
48294823|NCT00317070|DRUG|IC Cocktail|"* Heparin 10,000 units~* Gentamicin 80 mg~* Hydrocortisone sodium succinate (Solucortef) 100 mg~* Lidocaine hydrochloride 1% 10 ml~* Sodium Bicarbonate 8.4% 5 ml"
48294824|NCT05823558|DIAGNOSTIC_TEST|Lomber Muscle Thickness Measurement|Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
48294825|NCT00296348|DRUG|tacrolimus|immunosuppression
48294826|NCT00296348|DRUG|mycophenolate mofetil|oral
48294827|NCT00296348|DRUG|daclizumab|oral
48294828|NCT00296348|DRUG|steroids|oral
48294829|NCT04807569|OTHER|Peripheral magnetic neuromodulation|"Non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation"
48294830|NCT04807569|DRUG|Taking drug Tamsulosin|Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
48294831|NCT05416606|PROCEDURE|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
48294832|NCT05416606|PROCEDURE|open surgical transvesical prostatectomy|open surgical transvesical prostatectomy
48294833|NCT05826353|DRUG|Ripasudil|K-321 ophthalmic solution
48294834|NCT05826353|DRUG|Placebo|Placebo ophthalmic solution
48294835|NCT02958163|PROCEDURE|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
48294836|NCT02958163|DRUG|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
48294837|NCT02958163|RADIATION|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
48294838|NCT06672653|DRUG|"The monoterpenoid zinc tetra-ascorbo-camphorate (C14)"|The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.
48294839|NCT06672653|DRUG|Distilled water group|Instead of C14, distilled water will be administered in this group.
48294840|NCT04281537|DRUG|Enzyme Replacement Therapy (ERT)|ERT infusion every other week
48294841|NCT05695846|DEVICE|externally applied cricoid cartilage pressure|
48294842|NCT04652258|DRUG|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
48476364|NCT04251858|PROCEDURE|Dental Scaling|The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
48294843|NCT00450866|BIOLOGICAL|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
48294844|NCT04988607|DRUG|Osimertinib|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle
48476365|NCT04251858|OTHER|Oral hygiene instruction|Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
47945997|NCT06422195|OTHER|Long Axis Approach (LA)|Ultrasound guided radial artery cannulation in Long Axis Approach (LA) will be performed by an experienced anesthesiologist who has no subsequent role in the study. In the LA-IP approach, an ultrasound probe is placed parallel to the radial artery and the artery appears as a tubular anechoic structure in ultrasound.
48294845|NCT04988607|DRUG|Bevacizumab|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a
48294846|NCT04988607|DRUG|Osimertinib|Osimertinib is dosed orally at 80 mg once per day
48294847|NCT02016066|DRUG|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
48294848|NCT02016066|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
48294849|NCT02606877|DRUG|nintedanib|
48294850|NCT02606877|DRUG|pirfenidone|
48294851|NCT02523586|OTHER|Oxygen administration|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
48294852|NCT03278730|DRUG|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
48294853|NCT03278730|DRUG|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
48294854|NCT06453551|DRUG|TRN501 - Dose 1|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
48294855|NCT06453551|DRUG|TRN501 - Dose 2|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
48294856|NCT06453551|DRUG|TRN501 - Dose 3|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
48294857|NCT06453551|DRUG|TRN501 - Dose 4|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
48294858|NCT06453551|DRUG|TRN501 - Dose 5|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
48294859|NCT06453551|DRUG|TRN501 - Dose 6|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
48294860|NCT06453551|DRUG|TRN501 - Dose 7|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
47945998|NCT03211338|BIOLOGICAL|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
47945999|NCT03211338|BIOLOGICAL|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
48294861|NCT06453551|DRUG|TRN501 - Dose 8|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
48294862|NCT03424109|BEHAVIORAL|healthcare service utilization in the six months following the ED visit|The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
48294863|NCT00865254|BEHAVIORAL|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
47946000|NCT03211338|BIOLOGICAL|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
48476366|NCT04272489|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
48476367|NCT00931463|DRUG|raltegravir|400 mg raltegravir tablet taken every 12 hours
48476368|NCT00931463|DRUG|2N(t)RTI|2N(t)RTIs as prescribed
48476369|NCT00931463|DRUG|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
47946001|NCT03300310|OTHER|nursing visit|nursing visit at patient home
47946002|NCT03300310|OTHER|no nursing visit|the patient take his treatment without nursing visit
47946003|NCT03769298|DRUG|Envarsus XR|The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
47946004|NCT06298890|DEVICE|Artificial tears (sodium hyaluronate 0.2%)|Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.
47946005|NCT00013234|PROCEDURE|Teledermatology|
48294864|NCT00865254|BEHAVIORAL|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
48294865|NCT00865254|BEHAVIORAL|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
48294866|NCT03067558|DIAGNOSTIC_TEST|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
48294867|NCT03067558|DIAGNOSTIC_TEST|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
48294868|NCT02778776|DRUG|Metformin|Metfomin in tablet presentation of 500 mg
48476370|NCT01839695|DEVICE|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
48633850|NCT06433544|OTHER|6-week online mindfulness course|The experimental group received a 6-week online mindfulness course, once a week for 90 minutes each session.
48633851|NCT04425278|DEVICE|transcranial direct current stimulation with real current|transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons
48633852|NCT04425278|DEVICE|transcranial direct current stimulation with sham current|transcranial direct current stimulation with sham current is a placebo
48633853|NCT03520569|DRUG|Octreotide|we are using it to block insulin secretion from the pancreas
48633854|NCT03520569|DRUG|Insulin|we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
48633855|NCT03520569|DRUG|Dextrose 20% solution|We are using dextrose to maintain glycemia level
48633856|NCT05414773|OTHER|measurement of axial length and keratometry by sonographers with a topographic module|measurement of axial length and keratometry by sonographers with a topographic module
48633857|NCT00689052|DRUG|pramipexole ER|
47946006|NCT01889524|OTHER|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
47946007|NCT01889524|OTHER|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
48294869|NCT02778776|DIETARY_SUPPLEMENT|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
48294870|NCT02778776|OTHER|Placebo of agave inulin|Calcinated magnesia powder
48476371|NCT01162278|RADIATION|SBRT|Single fraction SBRT
48476372|NCT02710214|DRUG|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
48476373|NCT02710214|DRUG|Placebo|Once-daily dosing of placebo for 8 weeks
48476374|NCT05744401|DRUG|AL002|Administered via intravenous (IV) infusion
48476375|NCT05664217|DRUG|NKTR-255 at 1.5 µg/kg|NKTR-255 at 1.5 µg/kg
48476376|NCT05664217|DRUG|NKTR-255 at 3.0 μg/kg|NKTR-255 at 3.0 μg/kg
48476377|NCT05664217|DRUG|NKTR-255 at 3.0/6.0 μg/kg|NKTR-255 at 3.0/6.0 μg/kg
48476378|NCT05664217|OTHER|Placebo Comparator|Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
48633858|NCT00689052|DRUG|placebo|
48633859|NCT04132466|DEVICE|Defibrillation using the ASSURE wearable cardioverter defibrillator therapy delivered via a waveform delivery test system|defibrillation using a 170 joule biphasic truncated exponential waveform designed for the ASSURE wearable cardioverter defibrillator
48633860|NCT02307435|BIOLOGICAL|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
48633861|NCT00062959|BEHAVIORAL|Going Places: School program to prevent problem behavior|
48633862|NCT05377671|DIAGNOSTIC_TEST|IRM multimodale a ultra-haute camp|The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
48633863|NCT00440739|DRUG|etoricoxib|etoricoxib 120 mg
48633864|NCT00440739|DRUG|flavoxate|flavoxate 200 mg 3 times
48633865|NCT00440739|DRUG|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
48633866|NCT00440739|DRUG|placebo|placebo once and placebo 3 times
48633867|NCT01447147|DRUG|Placebo|Placebo capsules once daily
48633868|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
48633869|NCT01447147|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
48633870|NCT00001082|DRUG|Levocarnitine|500 mg tablet taken orally daily
48633871|NCT00001082|DRUG|Adefovir dipivoxil|120 mg tablet taken orally daily
48294871|NCT02778776|OTHER|Metformin placebo|Calcinated magnesia tablet
48633872|NCT00001082|DRUG|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
48294872|NCT02556879|BIOLOGICAL|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
48294873|NCT02556879|BIOLOGICAL|Serum bank|Additional samples for serum bank at each visit if possible
48294874|NCT02556879|BIOLOGICAL|DNA bank|Additional sample for DNA bank at inclusion visit if possible
48633873|NCT04267328|PROCEDURE|Elective Orthopedic Surgery|Patients having knee (unilateral primary osteoarthritis or bilateral primary osteoarthritis) surgery, hip (unilateral primary osteoarthritis or bilateral primary osteoarthritis) or shoulder (primary osteoarthritis) elective surgery.
48633874|NCT00621322|BIOLOGICAL|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
48633875|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
48294875|NCT02556879|PROCEDURE|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
48633876|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
48294876|NCT02556879|PROCEDURE|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
48294877|NCT01771094|BEHAVIORAL|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
48294878|NCT05536648|OTHER|Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial|To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
48294879|NCT02692053|BIOLOGICAL|blood sampling|additional blood sampling (volume: 18 mL)
48633877|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
48633878|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
48633879|NCT00621322|BIOLOGICAL|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
48633880|NCT06203665|DIAGNOSTIC_TEST|Recruitment Maneuver|The surgery would be performed under general anaesthesia according to the common practice using protective lung ventilation ( Vt= 6 ml /Kg ideal body weight , RR to maintain end-expiratory CO2 35-45 cmH2O and PEEP= 6- 8 cm H20). An incremental and decremental positive end-expiratory pressure alveolar recruitment maneuver would be performed after release of pneumoperitoneum.
48633881|NCT03511066|DRUG|CT-P27 90 mg/kg|Influenza A treatment drug.
48633882|NCT03511066|DRUG|CT-P27 45 mg/kg|Influenza A treatment drug.
48294880|NCT05638711|DEVICE|Built-in calculator to calculate Filtration fraction|A calculator built in electronic CVVH prescription system to calculate Filtration fraction
48294881|NCT06333951|DRUG|AMG 193|Administered PO
48633883|NCT03511066|DRUG|Placebo|Placebo.
48633884|NCT05365464|DRUG|Progesterone Pill|Orally active progesterone
48633885|NCT05365464|DRUG|hCG|Given by subcutaneous injection
48633886|NCT01301001|DRUG|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
48633887|NCT01301001|DRUG|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
48294882|NCT06333951|DRUG|Carboplatin|Administered IV
48294883|NCT06333951|DRUG|Paclitaxel|Administered IV
48294884|NCT06333951|DRUG|Pembrolizumab|Administered IV
48633888|NCT03951415|DRUG|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
48633889|NCT01623154|OTHER|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
48294885|NCT06333951|DRUG|Pemetrexed|Administered IV
48294886|NCT06333951|DRUG|Sotorasib|Administered PO
48294887|NCT01205243|DRUG|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
48294888|NCT05421897|DRUG|Dinutuximab with Chemotherapy|Rapid infusion of dinutuximab in 4 hours or less
48294889|NCT04308369|BIOLOGICAL|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
48633890|NCT04626778|DRUG|Peroxyl Mouthwash|Mouthwash
48633891|NCT04626778|DRUG|Placebo Mouthwash|Mouthwash
48633892|NCT02157337|DRUG|Atorvastatin|80 mg (PO) once daily for 6 days
48633893|NCT02157337|DRUG|placebo|80 mg (PO) once daily for 6 days
48633894|NCT01922661|DRUG|REGN1908-1909|
48633895|NCT01922661|OTHER|placebo|
48633896|NCT04014088|DEVICE|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
48633897|NCT06293287|DRUG|Subcutaneous enoxaparin sodium|Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily
48633898|NCT06293287|DRUG|Placebo|placebo (0.9% saline solution)
48633899|NCT02927314|DRUG|CF102|orally q12h
48633900|NCT02927314|DRUG|Placebo|orally q12h
48633901|NCT05719597|OTHER|PEP (Positive Expiratory Pressure)|Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
48633902|NCT05719597|OTHER|IS (Incentive spirometry)|Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
48633903|NCT03012945|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia. General anesthesia is performed as that in the general anesthesia group. Epidural anesthesia is performed with ropivacaine. Epidural analgesia is performed with a mixture of ropivacaine and sufentanil.
48294890|NCT01713985|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48294891|NCT01713985|DEVICE|Thermage|Radiofrequency treatment focusing radiofrequency energy
48294892|NCT06574828|DRUG|BIIB091|Administered as specified in the treatment arm.
48633904|NCT03012945|DRUG|General anesthesia|General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
48633905|NCT03346512|PROCEDURE|Cardiac surgery|Cardiac surgery
48633906|NCT02127515|PROCEDURE|Non Invasive Prenatal Testing|
48633907|NCT02127515|PROCEDURE|Invasive Prenatal Testing|
48294893|NCT06574828|DRUG|Moxifloxacin|Administered as specified in the treatment arm.
48633908|NCT01851226|PROCEDURE|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
48633909|NCT04211155|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
48633910|NCT04211155|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
48294894|NCT06574828|DRUG|BIIB091-matched Placebo|Administered as specified in the treatment arm.
48294895|NCT06574828|DRUG|Moxifloxacin-matched Placebo|Administered as specified in the treatment arm.
48294896|NCT06671704|OTHER|Genetic counseling months 4-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 4 to month 15.
48294897|NCT06671704|OTHER|Genetic counseling months 6-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 6 to month 15.
48294898|NCT06671704|OTHER|Genetic counseling months 8-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 8 to month 15.
47946008|NCT01889524|OTHER|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
47946009|NCT05839483|DIAGNOSTIC_TEST|CXCR4|Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET imaging.
47946010|NCT03402659|DRUG|neflamapimod|40 mg neflamapimod capsule
47946011|NCT03402659|OTHER|placebo|matching placebo capsule
48103922|NCT05424159|RADIATION|Carbon ion radiotherapy|Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
48294899|NCT06671704|OTHER|Genetic counseling at months 10-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 10 to month 15.
48294900|NCT06671704|OTHER|Genetic counseling at months 12-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 12 to month 15.
48294901|NCT06671704|OTHER|Genetic counseling at months 14-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 14 to month 15.
48294902|NCT05418608|DRUG|Radiotracer|A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
48294903|NCT06048731|DEVICE|Defibrillation using EV-ICD|Device: Defibrillation using the Extravascular ICD (EV-ICD)
48294904|NCT05269849|DRUG|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
48294905|NCT00414622|DRUG|DMXB-A|
48294906|NCT01380496|DRUG|doxycycline monohydrate|tablet, 100 mg, single, oral dose
48294907|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
48294908|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
48294909|NCT02499965|DRUG|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
48294910|NCT02499965|DRUG|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
48294911|NCT06439914|DRUG|[89Zr]Zr-DFO-emapalumab|Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
48294912|NCT01756976|DEVICE|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
48633911|NCT05960123|PROCEDURE|Tubularized Incised Plate (TIP) urethroplasty|tubularization of urethral plate with or without spongioplasty
48633912|NCT00655798|DIETARY_SUPPLEMENT|Placebo|plain yogurt and capsules containing cellulose
48633913|NCT00655798|DIETARY_SUPPLEMENT|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
48633914|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
48633915|NCT00655798|DIETARY_SUPPLEMENT|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
48633916|NCT04619030|OTHER|Augmented Reality|The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone
48633917|NCT04619030|OTHER|Traditional leaflet|Traditional leaflet with no Augmented Reality capability
48633918|NCT02256800|GENETIC|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
48633919|NCT02256800|GENETIC|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
48633920|NCT02256800|GENETIC|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
48633921|NCT02256800|GENETIC|UGT1A1 non-genotyping|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
48476379|NCT01620723|OTHER|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
48633922|NCT02256800|DRUG|bevacizumab (Avastin)|bevacizumab as target therapy
48633923|NCT02256800|DRUG|irinotecan|irinotecan as escalating dose according to UGT1A1 genotyping
48633924|NCT02256800|DRUG|Leucovorin|combined with 5-FU
48633925|NCT02256800|DRUG|5-FU|combined with irinotecan
48633926|NCT05676944|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
47946012|NCT04430829|DIAGNOSTIC_TEST|Weight-Bearing CT arthrography|A 20ml mixture of 5ml 0.5% ropivacaine, 5ml preservative-free sterile saline, and 10ml of non-ionic iodinated contrast media (e.g. iohexol 240) will be instilled into the knee joint of each patient prior to WBCTa imaging of the knee (LineUp, CurveBeam, LLC).
48294913|NCT06435156|DRUG|Sotagliflozin|Sodium-glucose Co-transporter inhibitor
48294914|NCT06435156|DRUG|Placebo|Matched placebo
48476380|NCT01620723|OTHER|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
48476381|NCT02551679|BIOLOGICAL|ACP-01|Injection into lower extremity
48633927|NCT04636944|OTHER|web-based COMPASS intervention|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these. This qualitative study will explore participants' perspectives on using COMPASS for managing depression and anxiety in heart failure.
48633928|NCT04143438|PROCEDURE|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
48476382|NCT02551679|BIOLOGICAL|Placebo|Injection into lower extremity
48476383|NCT01071031|BIOLOGICAL|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
48294915|NCT06602193|DRUG|BIIB122 225 mg|Administered as specified in the treatment arm
48294916|NCT06602193|OTHER|BIIB122-Matching Placebo|Administered as specified in the treatment arm
48294917|NCT06598007|DRUG|CT3001|CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
48294918|NCT03076008|OTHER|Observational|No intervention
48294919|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Active)|Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
48294920|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Sham)|Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
48294921|NCT04083144|DRUG|Varenicline|12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
48294922|NCT05243329|DRUG|Psilocybin|10 mg or 25 mg oral aqueous psilocybin solution
48294923|NCT05216263|DRUG|Atogepant|Oral Tablet
48294924|NCT05661565|OTHER|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
48294925|NCT03995407|DIETARY_SUPPLEMENT|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
48294926|NCT03995407|OTHER|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
48294927|NCT06671262|RADIATION|SBRT|Target the primary tumor region with a single dose of 8Gy, or deliver a dose of 3Gy to the axillary lymph nodes, administered once a day for three consecutive days.
48294928|NCT06671262|DRUG|Immuno-chemotherapy|Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.
48294929|NCT00354549|DRUG|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
48294930|NCT00354549|DRUG|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
48294931|NCT04645797|DRUG|APR003|This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
48633929|NCT05875077|DRUG|Dexmedetomidine|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
48633930|NCT05875077|DRUG|Propofol|compare the effects of dexmedetomidine infusion to propofol infusion during spinal anesthesia, on the incidence of postoperative nausea and vomiting in patients undergoing ureteroscopic procedures under spinal anesthesia.
47946013|NCT04430829|DIAGNOSTIC_TEST|Knee MRI|MRI will be acquired (in-plane 0.25mm x 0.25mm, and 1.00mm slab thickness/separation and In-plane 0.25mm x 0.25mm, and 2.00mm slab thickness/separation)
47946014|NCT02127723|DEVICE|Hyaluronic acid injection (Macrolane VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
47946015|NCT04319991|DIETARY_SUPPLEMENT|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
48294932|NCT06641765|DEVICE|Continous Glucose Monitoring|10 days of real time open access to Continous Glucose Monitoring - either at defined time intervals (Group 2) or continuously for 9 months (Group 3).
48294933|NCT04905914|DRUG|ATRN-119|ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
48294934|NCT03922399|PROCEDURE|Laser and Surgery|Laser and Surgery in patients with major burn scars Evaluating after three years treatment
48294935|NCT01818557|BEHAVIORAL|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
48294936|NCT06550050|BEHAVIORAL|Radiation|Standard of care
48294937|NCT03421847|DIAGNOSTIC_TEST|Rotatory vestibular test|We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
48294938|NCT05057312|OTHER|Enhancing Accessibility to Health Care|Receive enhanced access to vaccination
48294939|NCT05057312|OTHER|Informational Intervention|Receive standard CDC information
48294940|NCT05057312|OTHER|Informational Intervention|Receive video narratives
48633931|NCT00924651|BEHAVIORAL|exercise|home based walking and progressive resistance training exercise
48633932|NCT04356703|OTHER|Neuropsicomotor developmental test|Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
48633933|NCT02604667|OTHER|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
48633934|NCT02604667|OTHER|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
48633935|NCT05415787|OTHER|Blood sample|2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.
48633936|NCT05415787|OTHER|Urine sample|Urine sample is taken during the consultation carried out for the patient's care
47946016|NCT02450188|DRUG|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
48294941|NCT05057312|OTHER|Informational Intervention|Receive written narratives
48294942|NCT05057312|OTHER|Interview|Ancillary studies
48294943|NCT05057312|OTHER|Questionnaire Administration|Ancillary studies
48294944|NCT04085510|DEVICE|Contrast-enhanced mammogram|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
48294945|NCT06585670|OTHER|Calm Health - smartphone application|Participants randomized to the intervention arm of the study will be given free access to a mobile phone application called Calm Health, which they will use to engage in guided meditation and mindfulness modules for at least 10 minutes per day for 8 weeks.
48294946|NCT03130036|OTHER|[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan|A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study
48294947|NCT06265558|PROCEDURE|Negative pressure therapy (NPT)|Negative pressure therapy (NPT) involves placing the surface of a wound under a pressure lower than the ambient atmospheric pressure. To achieve this, a specially designed dressing is connected to a vacuum source and an exudate collection system.
48294948|NCT06265558|PROCEDURE|Dressing|Fatty dressing or hydrocellular dressing
48476384|NCT01071031|BIOLOGICAL|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
48476385|NCT01071031|BIOLOGICAL|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
48476386|NCT04493476|DRUG|Chinese herbal formula|Chinese herbal formula
48476387|NCT05371639|DRUG|Tian Ma Bian Chun Zhi Gan Tablets|Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
48476388|NCT05371639|DRUG|Placebo|Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
48476390|NCT01853241|PROCEDURE|Single Balloon|All patients in this group will undergo single balloon enteroscopy
48476391|NCT01853241|PROCEDURE|Spirus|All patients in this group will undergo Spirus Enteroscopy
48476392|NCT03691688|DRUG|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
48476393|NCT03691688|DRUG|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
48476394|NCT03754530|DRUG|Icotinib|orally three times per day
48476395|NCT03754530|RADIATION|WBRT or SRS|\>3 with WBRT;\<=3 with SRS
48476396|NCT04004845|DRUG|Cytotec|Misoprostol 25mcg vaginal
48476397|NCT04004845|DRUG|oxytocin|Oxytocin 10 IU/ml Solution for infusion
48476398|NCT04004845|DEVICE|Cervical Foley Balloon|Cervical Foley will be inflated to 80cc
48476399|NCT06616818|OTHER|DASH-FV|12weeks of fruit and vegetable delivery to the home
48476400|NCT06616818|OTHER|nutrition counselling only|nutrition counselling as part of standard of care
48476401|NCT05878431|OTHER|Foot Reflexology|"The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~* Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~* Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~* Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application."
48476402|NCT01953172|DIETARY_SUPPLEMENT|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
48476403|NCT01953172|OTHER|Placebo|Placebo
48476404|NCT03516487|DRUG|SYNB1618|SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
48476405|NCT03516487|DRUG|Placebo|Subjects receive placebo orally in a chilled buffered solution (100 mL).
48294949|NCT06671288|OTHER|Balloon-blowing exercises with abdominal & lumbar core muscle activation position.|"Patients in this group will recieve Balloon-blowing exercises with abdominal and lumbar core muscles activation position Total 4 weeks protocol will be followed in which 3 sessions per week will be supervised by physical therapist.~FREQUENCY: 3 times a week, INTENSITY : Moderate, TIME: 4 sets of balloon-blowing with 1 min rest (30 mins) TYPE: Balloon-blowing with abdominal \& lumbar core muscle activation position, DURATION : 4 weeks"
48294950|NCT06671288|OTHER|Diaphragmatic breathing exercise|Participants in this group will only be receiving diaphragmatic breathing exercise for 4 weeks. FREQUENCY: 3 times a week , INTENSITY: Moderate, TIME: 4 sets of diaphragmatic breathing with 1 min rest, TYPE: Diaphragmatic breathing, DURATION: 4 weeks
48294951|NCT05533242|DRUG|Lu-177 labeled 6A10-Fab-fragments|The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
48294952|NCT01847144|DRUG|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
48294953|NCT01847144|DRUG|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
48294954|NCT03807973|DRUG|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
48294955|NCT04116034|DEVICE|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
48294956|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
48294957|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
48294958|NCT04856462|BEHAVIORAL|Education Support|Structured education is provided every other week (biweekly) to family caregivers over the course of 12 weeks, along with facilitated video-teleconferencing group meetings.
48294959|NCT04856462|BEHAVIORAL|Phone Call|Participants will participate in an unstructored support group phone call
48294960|NCT04091867|DRUG|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
48294961|NCT04091867|DRUG|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
48294962|NCT04091867|RADIATION|Radiation Therapy|6930 cGy IMRT starting D15-D18
48294963|NCT05144542|PROCEDURE|Participants smoke their usual brand of cigarettes for 26 weeks.|Participants smoke their usual brand of cigarettes for 26 weeks.
48294964|NCT05144542|PROCEDURE|Participants will vape electronic cigarettes for 26 weeks.|Participants will vape electronic cigarettes for 26 weeks.
48294965|NCT05144542|DRUG|Nicotine Replacement|Smoke usual brand of cigarettes
48294966|NCT05144542|DRUG|Nicotine Replacement|Vape e-cigarettes
48633937|NCT06108336|PROCEDURE|TMS during sequence-demanding task|TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
48633938|NCT06108336|PROCEDURE|No TMS during sequence-demanding task|TMS is not administered during the execution of sequence-demanding task.
48633939|NCT06108336|PROCEDURE|TMS during non-sequence-demanding task|TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
48633940|NCT06108336|PROCEDURE|No TMS during non-sequence-demanding task|TMS is not administered during the execution of non-sequence-demanding task
48294967|NCT05144542|OTHER|Questionnaire Administration|Use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day.
48294968|NCT00318201|DRUG|Erythromycin|
48294969|NCT00318201|DRUG|Diltiazem|
48294970|NCT03631667|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
48294971|NCT03631667|DRUG|[14C]-benzo[a]pyrene plus phenanthrene|Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene
48294972|NCT04595604|PROCEDURE|Trimodal rehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
48294973|NCT04595604|PROCEDURE|ERAS + nutritional prehabilitation|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
48294974|NCT06065956|DRUG|Intravenous morphine|"Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation."
48294975|NCT06362798|OTHER|Financial Transfers|"Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a debit-card with a one-time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age."
48294976|NCT04745832|DRUG|Zandelisib|Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
48294977|NCT04745832|DRUG|Rituximab|Rituximab IV 375 mg/m2 for 6 cycles
48294978|NCT04745832|DRUG|Bendamustine|Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
48633941|NCT04394832|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
48633942|NCT05726279|DEVICE|NIRS based personalized blood pressure management|In lieu of predetermined blood pressure treatment thresholds, an optimal MAP range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
48633943|NCT06339762|BEHAVIORAL|Self-Compassion Training|Self-Compassion Training
48633944|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
48294979|NCT04745832|DRUG|CHOP|Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
48633945|NCT01783015|DRUG|Etanercept|Etanercept 50 mg once-weekly
48294980|NCT03300453|DRUG|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
48103923|NCT04897737|BEHAVIORAL|HIVST and enhanced adherence biofeedback|"The intervention includes the provision of an OraQuick HIV self-test (HIVST) for the woman and one test for each of her reported sex partners, along with instructions on how to use and interpret the results. Women were asked to report back within one month if their partner was able to test via a SMS, WhatsApp or by bringing in the test to confirm that he had tested.~Women then received adherence based feedback following the urine lateral flow assay (that measures recent tenofovir use in past 48 hours). Study counsellors requested that women provide a urine sample that was tested using the UrSure/Orasure test that provides feedback on the result in 2-3 minutes. Counselors provided counseling based on the results including how to improve daily adherence (for women without tenofovir present in their urine) and importance of condom use."
48294981|NCT05705401|RADIATION|Standard of Care Adjuvant Breast Radiation|adjuvant breast radiotherapy per the current standard of care
48633946|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
48633947|NCT01783015|DRUG|Placebo|Etanercept placebo once-weekly
48294982|NCT05705401|DRUG|Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation|participants are randomized to continue their standard of care systemic HER2-targeted therapy without adjuvant breast radiotherapy
48294983|NCT05895279|OTHER|Media Intervention|Watch MiCaP Research Digest video
48633948|NCT06535321|OTHER|vibration training|After modelling, when the vibration platform is closed, all participants of the control group completed the same action as vibration training.
48633949|NCT06535321|OTHER|vibration training|For the vibration group, vibration training was performed immediately after DOMS modelling.
48633950|NCT06535321|OTHER|Y-shaped kinesio taping|For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.
48103924|NCT04897737|DIAGNOSTIC_TEST|Orasure/UrSure test|See above
48294984|NCT05895279|OTHER|Media Intervention|Watch alternate video
48294985|NCT05895279|OTHER|Survey Administration|Complete survey
48294986|NCT02820610|DRUG|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
48294987|NCT02820610|DRUG|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
48294988|NCT02820610|DRUG|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
48294989|NCT00649298|PROCEDURE|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
48294990|NCT00770185|DRUG|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
48294991|NCT00770185|GENETIC|gene expression analysis|
48294992|NCT00770185|OTHER|immunohistochemistry staining method|
48294993|NCT00770185|OTHER|laboratory biomarker analysis|
48294994|NCT03110822|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
48294995|NCT03110822|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
48294996|NCT03110822|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
48294997|NCT03838848|DRUG|KN046|3mg/kg, Q2W, intravenous injection (IV)
48294998|NCT03838848|DRUG|KN046|5mg/kg, Q2W, intravenous injection (IV)
48633951|NCT06535321|OTHER|Combined vibration training and Y-shaped kinesio taping|For the combined group, the vibration group and kinesio group interventions were performed simultaneously.
48633952|NCT03969758|DRUG|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
48294999|NCT03838848|DRUG|KN046|5mg/kg, Q3W, intravenous injection (IV)
48295000|NCT03838848|DRUG|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
48295001|NCT03838848|DRUG|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
48295002|NCT03838848|DRUG|Ningetinib|Oral, QD
48295003|NCT05382338|DRUG|Cisplatin|Given IV
48476406|NCT04572204|OTHER|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
48633953|NCT03969758|DRUG|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
48633954|NCT04619173|OTHER|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
48633955|NCT04619173|OTHER|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
48633956|NCT03709095|OTHER|Sprint interval training|Participants utilized the arm ergometer for improving aerobic exercise capacity
48633957|NCT03709095|OTHER|moderate intensity continuous training|Participants utilized the arm ergometer for improving aerobic exercise capacity
48295004|NCT05382338|DRUG|Cyclophosphamide|Given IV
48295005|NCT05382338|DRUG|Lomustine|Given PO
48295006|NCT05382338|DRUG|Mesna|Given IV
48295007|NCT05382338|OTHER|Quality-of-Life Assessment|Ancillary studies
48295008|NCT05382338|RADIATION|Radiation Therapy|Undergo radiation therapy
48476407|NCT03917355|BEHAVIORAL|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
48633958|NCT01029964|BEHAVIORAL|Individually and in groups|During three year in a clinical setting.
48295009|NCT05382338|DRUG|Sodium Thiosulfate|Given IV
48295010|NCT05382338|OTHER|Survey Administration|Ancillary studies
48295011|NCT05382338|DRUG|Vincristine|Given IV
48295012|NCT05762822|DIETARY_SUPPLEMENT|3-OHB (KE4)|60 ml (30 g) of 3-OHB
48295013|NCT05762822|DIETARY_SUPPLEMENT|water|60 ml water (added bitter taste)
48295014|NCT00389077|DRUG|Perifosine|Perifosine 50 mg tablets
48295015|NCT03514472|DIETARY_SUPPLEMENT|Dried Moringa oleifera leaves|
48295016|NCT05864157|OTHER|Gait training without rhythmic auditory cues|Gait training on treadmill and overground without any rhythmic auditory cues
48295017|NCT05864157|OTHER|TRAC|Metronome set to 85% on treadmill and 115% when walking overground
48295018|NCT05864157|OTHER|dTRAC|Metronome set around 85% on treadmill and around 115% when walking overground
48295019|NCT01818375|PROCEDURE|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
48295020|NCT01818375|OTHER|Standard fluid therapy|
48295021|NCT05604131|DRUG|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
48295022|NCT05604131|DRUG|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
48633959|NCT00421733|DRUG|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
48633960|NCT00421733|DRUG|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
48633961|NCT00421733|DRUG|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
48633962|NCT01129284|DRUG|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
48633963|NCT03206385|RADIATION|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
48103925|NCT04943380|DIAGNOSTIC_TEST|Cxbladder|The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
48295024|NCT05196698|OTHER|High Flow Oxygen Therapy|"HFOT will be delivered validated medical devices and established as follow:~* Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.~* Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation \> 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa"
48295025|NCT05196698|OTHER|Long-term oxygen therapy|LTOT delivery will be performed according to French guidelines
48295026|NCT05377905|DRUG|Microneedle Array Doxorubicin (MNA-D)|The Microneedle array patch is loaded/prepared with a total dose of 50 micrograms of Doxorubicin and is applied to a single selected cSCC remnant for a period of 20 minutes for a total of 4 weekly applications
48295027|NCT00974662|DRUG|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 \& 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
48295028|NCT06014814|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation
48295029|NCT00401583|DRUG|GW786034 (pazopanib)|Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
48103926|NCT04369534|DRUG|Clopidogrel|Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI
48103927|NCT04369534|DRUG|Ticagrelor|Administration of standard dose of ticagrelor during 12 months after PCI
48295030|NCT00401583|DRUG|Probe drugs|probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
48295031|NCT02672839|DRUG|LGD-6972 Solution|15 mg of LGD-6972
48295032|NCT02672839|DRUG|LGD-6972 Capsules|15 mg LGD-6972
48295033|NCT02651662|DRUG|cemiplimab|Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
48295034|NCT02651662|DRUG|odronextamab|Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
48295035|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder.
48295036|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder.
48295037|NCT02662309|DRUG|MPDL3280A|Intravenous infusion
48295038|NCT05435248|DRUG|HS-10375|HS-10375 will be administered orally once daily in a continuous regimen
48295039|NCT04109443|BEHAVIORAL|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
48295040|NCT04109443|BEHAVIORAL|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
48295041|NCT00844298|DRUG|Nilotinib+mVPD|"1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT"
48295042|NCT00999752|DRUG|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
48295043|NCT00999752|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
48295044|NCT03069768|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
48295045|NCT03069768|DRUG|Chantix|For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
48633964|NCT03206385|RADIATION|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
48295046|NCT03418038|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
48633965|NCT00656812|DRUG|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
48633966|NCT00656812|DRUG|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
48633967|NCT06134128|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
48295047|NCT03418038|DRUG|Carboplatin|Given IV or PO
48295048|NCT03418038|DRUG|Cisplatin|Given IV or PO
48295049|NCT03418038|DRUG|Cytarabine|Given IV or PO
48295050|NCT03418038|DRUG|Dexamethasone|Given IV or PO
48295051|NCT03418038|DRUG|Etoposide|Given IV or PO
48633968|NCT00072579|BIOLOGICAL|sargramostim|
48295052|NCT03418038|DRUG|Gemcitabine Hydrochloride|Given IV or PO
48295053|NCT03418038|DRUG|Ifosfamide|Given IV or PO
48295054|NCT03418038|OTHER|Laboratory Biomarker Analysis|Correlative studies
48295055|NCT03418038|DRUG|Oxaliplatin|Given IV or PO
48295056|NCT03418038|OTHER|Placebo Administration|Given normal saline IV
48295057|NCT03418038|OTHER|Questionnaire Administration|Ancillary studies
48295058|NCT03418038|BIOLOGICAL|Rituximab|Given IV
48295059|NCT03418038|DRUG|Decitabine|Given IV
48295060|NCT03418038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48295061|NCT03418038|PROCEDURE|Core Biopsy|Undergo core needle biopsy
48295062|NCT03418038|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
48295063|NCT03418038|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
48295064|NCT03418038|PROCEDURE|Echocardiography|Undergo ECHO
48295065|NCT03418038|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48295066|NCT03418038|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48295067|NCT03418038|PROCEDURE|Central Venous Cannula Insertion|Undergo PICC placement
48295068|NCT03418038|PROCEDURE|Portacath Placement|Undergo portacath placement
48295069|NCT03418038|PROCEDURE|Computed Tomography|Undergo PET/CT
48295070|NCT01895010|DEVICE|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
48295071|NCT01895010|DRUG|tropisetron|only tropisetron 6mg before TACE
48295072|NCT03415074|BEHAVIORAL|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
48295073|NCT02147938|DRUG|Tacrolimus|oral
48295074|NCT05090540|DEVICE|Trancatheter Edge to Edge Repair|TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
48295075|NCT05090540|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
48295076|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie|Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
48295077|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie/Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
48295078|NCT04556604|BEHAVIORAL|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
48295079|NCT06671964|OTHER|Anthropometric measurements|Anthropometric measurements of the students, including weight, height, muscle mass, fat quantity, and waist circumference, were measured. The WHO BMI charts were utilized for classification. Stratified Random selection
48295080|NCT06671964|OTHER|Questionnaire|"The collection of data was performed using the Atlas questionnaire (Al-Hazzaa et al., 2011) and nutrition knowledge and healthy lifestyle behavior questionnaire (Kalender et al., 2011) with additional questions related to self-efficacy and dietary practices adapted from the literature (Becher, 2009; Voss et al., 2017; Kowalski et al., 2004). Stratified Random selection"
48295081|NCT06671964|OTHER|Educational sessions|The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.
48295082|NCT06671327|DRUG|Preemptive Dexmedetomidine injection|The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and after induction continue infusion 15min.
48295083|NCT06671327|DRUG|Sodium Chloride 0.9% Inj|The Placebo group was infused with equal amounts of isochronous normal saline.
48295084|NCT05536453|DEVICE|Lumbar Interbody Fusion Devices|Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease
48295085|NCT04923971|OTHER|Purdue Pegboard|Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
48295086|NCT00006452|DRUG|motexafin gadolinium|
48295087|NCT00006452|RADIATION|radiation therapy|
48295088|NCT02847611|DEVICE|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
48295089|NCT04211545|DRUG|Rabeprazole|Rabeprazole
48295090|NCT04211545|DRUG|CC-92480|CC-92480
48295091|NCT04830748|OTHER|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
48476408|NCT00932594|PROCEDURE|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
48476409|NCT00932594|OTHER|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
48295092|NCT04830748|OTHER|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
48295093|NCT02163408|OTHER|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
48295094|NCT05344092|BEHAVIORAL|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
48295095|NCT05247580|OTHER|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
48295096|NCT03953560|DIAGNOSTIC_TEST|dyspnea grade ≥ II according NYHA-WHO|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis"
48295097|NCT06392789|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Receive sleep education
48103928|NCT06256211|DRUG|Paracetamol|"All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study."
48295098|NCT06392789|OTHER|Internet-Based Intervention|Receive access to website content modules
48295099|NCT06392789|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
48295100|NCT06392789|OTHER|Questionnaire Administration|Ancillary studies
48295101|NCT06392789|OTHER|Text Message-Based Navigation Intervention|Receive sleep compression SMS conversations
48295102|NCT03964012|BIOLOGICAL|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
48295103|NCT03964012|BIOLOGICAL|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
48295104|NCT00217477|DRUG|gemcitabine hydrochloride|Given IV
48295105|NCT00217477|DRUG|paricalcitol|Given IV
48476410|NCT02371928|OTHER|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
48633969|NCT03460964|DEVICE|Adhesive glucose sensor|"Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat"
48295106|NCT04573777|DRUG|Repatha|140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
48476411|NCT02371928|OTHER|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
48476412|NCT03429049|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 injection
48476413|NCT03429049|DRUG|Placebo|Receiving Placebo injection
48476414|NCT05140668|DEVICE|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
48633970|NCT03460964|DRUG|Pilocarpine|Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
48476415|NCT03727698|DEVICE|MR Linac|MR guided radiotherapy treatment
48476416|NCT00014391|BIOLOGICAL|palivizumab|
48633971|NCT00699166|DRUG|DNK333|25 mg and 100 mg oral doses, each taken twice daily
48295107|NCT04185467|OTHER|Intervention (rehabilitation exercise)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
48295108|NCT01650779|BIOLOGICAL|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
48295109|NCT01196910|DEVICE|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
48295110|NCT01539265|DRUG|silodosin|
48295111|NCT01539265|DRUG|silodosin|
48295112|NCT01539265|DRUG|placebo|
48476417|NCT00014391|DRUG|ribavirin|
48476418|NCT06393660|DEVICE|CliniMACS® CD34 TCR Alpha/Beta|CliniMACS System uses an automated antibody/magnetic beads column system that allows efficient depletion of TCRαβ and CD19+ cells without relevant loss of cell viability. Hematopoietic stem cells are retained in sufficient numbers to permit engraftment and hematopoietic reconstitution. Humanitarian Exemption IDE approval has been obtained for CD34+ cell selection as a method of T-cell depletion.
48476419|NCT05260021|DRUG|Tirzepatide Dose 1|Administered SC
48476420|NCT05260021|DRUG|Tirzepatide Dose 2|Administered SC
48633972|NCT00930332|DRUG|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"
48633973|NCT00930332|OTHER|questionnaire administration|within 48 hours of registration
48633974|NCT00930332|PROCEDURE|management of therapy complications|if required
48633975|NCT03710733|RADIATION|Sequential boost|Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation
48633976|NCT03710733|RADIATION|Concomitant boost|Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
48103929|NCT04555265|DEVICE|Radiofrequency ablation or microwave ablation|Hepatocellular carcinoma treated by either radiofrequency ablation or microwave ablation
48103930|NCT01499654|DRUG|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
48476421|NCT05260021|DRUG|Placebo|Administered SC
48476422|NCT00339872|DRUG|IMA-638|
48476423|NCT04044560|BIOLOGICAL|blinatumomab|Continuous intravenous infusion
48476424|NCT05577806|DRUG|Dydrogesterone|progestin primed ovarian stimulation
48476425|NCT04614584|DRUG|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
48476426|NCT04614584|DRUG|Methamphetamine|Methamphetamine 30 mg IV once
48476427|NCT03647124|DRUG|Lenalidomide|Specified dose on specified days
48476428|NCT00328679|DEVICE|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
48633977|NCT04091438|DRUG|TAK-925|TAK-925 IV infusion.
48633978|NCT04091438|DRUG|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
48633979|NCT02340676|PROCEDURE|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
48633980|NCT02340676|DRUG|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
48633981|NCT04634903|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
48633982|NCT04634903|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
48633983|NCT04634903|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
48633984|NCT01319461|DEVICE|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
48633985|NCT01319461|DEVICE|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
48633986|NCT02216162|OTHER|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
48633987|NCT02216162|OTHER|No intervention|Usual clinical follow-up
48633988|NCT05485350|DRUG|Anlotinib Hydrochloride|12 mg/d, d1-14, q3w
48476429|NCT00004150|DRUG|fluorouracil|
48476430|NCT00004150|DRUG|leucovorin calcium|
48476431|NCT00004150|PROCEDURE|adjuvant therapy|
48476432|NCT05565261|DEVICE|complete denture|Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
48476433|NCT05554172|DEVICE|taVNS|Participants will receive vagal nerve stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
48476434|NCT05554172|DEVICE|Sham|Participants will receive sham stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
48476435|NCT02377180|PROCEDURE|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
48633989|NCT05485350|DRUG|penpulimab|200mg, ivgtt, d1, q3w
48633990|NCT05485350|RADIATION|SBRT|55-180Gy
48103931|NCT06026358|DRUG|Tirbanibulin|subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
48103932|NCT03646370|DRUG|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
48103933|NCT00741988|DRUG|Ixabepilone|ixabepilone 30 mg/m2
48103934|NCT00741988|DRUG|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
48295113|NCT06672874|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Fermented Papaya Preparation (FPP) is administered in this study as a dietary supplement aimed at assessing its potential benefits for cognitive function and driving performance in older adults. Participants consume FPP as a 3-gram powder dose taken orally three times daily (morning, afternoon, evening) for a total of 8 weeks. FPP is known for its antioxidant and anti-inflammatory properties, which may influence cognitive domains essential for safe driving, such as attention, memory, reaction time, and executive function. This intervention is specifically designed to explore FPP's potential impact on reducing driving errors and improving psychomotor skills in a high-fidelity driving simulation environment.
48295114|NCT04050007|OTHER|Preventive initiation of fluid removal|"Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
48295115|NCT04050007|OTHER|Curative initiation of fluid removal|"The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
48295116|NCT05477238|PROCEDURE|walking tasks|The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
48295117|NCT05062317|DRUG|Leucovorin|Given by PO
48295118|NCT05062317|DRUG|5-FLUOROURACIL|Given by IV
48295119|NCT05062317|DRUG|Oxaliplatin|Given by PO
48295120|NCT05062317|DRUG|Irinotecan|Given by IV
48295121|NCT05062317|DRUG|Capecitabine|Given by IV
48295122|NCT05062317|DRUG|Bevacizumab|Given by IV
48295123|NCT01435993|DRUG|GSK1223249|Intravenous infusion
48295124|NCT01435993|OTHER|Saline placebo|placebo intravenous infusion
48295125|NCT03370081|DEVICE|CAPNOGRAPHY|MONITORING OF CAPNOMETRY USING ETCO2 METHOD
48295126|NCT02432677|DRUG|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
48476436|NCT02377180|PROCEDURE|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
48476437|NCT02377180|PROCEDURE|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
48476438|NCT03105934|PROCEDURE|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
48476439|NCT00890942|DRUG|naloxone|naloxone 0.4mg.(1 ml) intramuscular
48476440|NCT00890942|DRUG|normal saline|normal saline 1 ml IM
48476441|NCT05062148|OTHER|Float-REST|Subjects receiving Float-REST will float for 60 minutes three times a week.
48633991|NCT00086463|DRUG|Iloprost or placebo|
48633992|NCT04928404|PROCEDURE|tongue base suspension using barbed suture|all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
48633993|NCT02454764|DRUG|Tenofovir + Interferon alpha 2b|
48633994|NCT02454764|DRUG|Tenofovir disoproxil Fumarate|
48633995|NCT03845673|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)
48633996|NCT03845673|DIETARY_SUPPLEMENT|Bowel recipe|consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
48476442|NCT05062148|OTHER|Photobiomodulation|Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
48476443|NCT02358733|PROCEDURE|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
48633997|NCT02074137|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
48633998|NCT02074137|DRUG|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
48633999|NCT02074137|DRUG|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
48634000|NCT05198362|OTHER|Placebo|Inactive comparator
48103935|NCT00741988|DRUG|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
48634001|NCT05198362|DRUG|Tesomet|Fixed-dose combination
48634002|NCT04492293|DRUG|ICP-192|ICP-192 is a white, round, uncoated table
48634003|NCT00482456|DRUG|Nitrous oxide|
48295127|NCT02432677|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
48634004|NCT05150886|DIAGNOSTIC_TEST|rox index|After HFNC during reassessment, the ROX Index can help suggest which patients will fail HFNC and need to progress to intubation for further ventilatory support.
48634005|NCT00562861|DRUG|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
48634006|NCT00562861|DRUG|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
48634007|NCT03164356|DEVICE|Bioimpedance monitor|Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
48634008|NCT04744532|DRUG|Bosutinib (Phase 1 part)|Subjects will receive 100 mg, 200mg, 300mg or 400 mg of bosutinib once daily, orally.
48634009|NCT04744532|DRUG|Bosutinib (Phase 2 part)|Subjects will receive 200mg/day or 300mg/day of bosutinib once daily, orally.
48634010|NCT05504421|OTHER|Sustainability education in nursing to be given with two different teaching methods|Sustainability education in nursing to be given with two different teaching methods (cooperative learning versus traditional learning) and the effects of two different teaching methods on the sustainability knowledge, attitude and skill acquisition of nursing students will be compared.
48634011|NCT02605616|DRUG|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
48634012|NCT02605616|OTHER|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
48634013|NCT04784871|BEHAVIORAL|5waysA Intervention|Web-based 10 week intervention, encouraging participants engaging in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
48634014|NCT04784871|BEHAVIORAL|5waysA Active wait-list control|Writing activity log in the waiting time. Then, after five months and the writing of activity log, the participants get the web-based intervention and SMS massages, which encourage the participants to engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
48295128|NCT02432677|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
48634015|NCT04784871|BEHAVIORAL|5waysA Inactive wait-list control|No activity while the participants wait. After five months of waiting, the participants get the web-based intervention and SMS messages, which encourage participants engage in five potential health promoting activities: 1. Be active, 2. Take notice, 3. Keep learning, 4. Connect and 5. Give.
48634016|NCT05543382|DEVICE|Axonics System|The Axonics System will be implanted as standard care
48634017|NCT00113126|DRUG|Treatment interruption|
48634018|NCT00153478|BEHAVIORAL|Brief Motivational Counseling|
48634019|NCT05439837|PROCEDURE|Infraclavicular and subomohoid block|Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve
48634020|NCT05439837|PROCEDURE|Paracoracoid subscapularis plane block|Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
48634021|NCT03437733|DEVICE|Radiofrequency Ablation|RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
48634022|NCT02827370|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary counseling
48634023|NCT03450135|BEHAVIORAL|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
48634024|NCT03450135|BEHAVIORAL|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
48634025|NCT03335566|DRUG|Sonazoid™|Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
48634026|NCT03335566|DRUG|SonoVue®|Single Dose of SonoVue® 2.4 mL as I.V. injection.
48634027|NCT04049084|BIOLOGICAL|autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)|ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
48295129|NCT02432677|DRUG|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
48476444|NCT02358733|PROCEDURE|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
48295130|NCT06132763|BEHAVIORAL|Hydration Intervention|"Teacher \& student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, \& update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning."
48295131|NCT06132763|OTHER|Control - Assessments Only|Assessments only
48295132|NCT04389801|DRUG|Desferal 500 MG Injection|iron chelating agent
48295133|NCT02408146|PROCEDURE|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
48295134|NCT02408146|DRUG|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
48295135|NCT02408146|PROCEDURE|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
48295136|NCT02408146|DRUG|fentanyl citrate+ ondansetron hydrochloride + normal saline|
48295137|NCT02408146|DRUG|celecoxib|
48634028|NCT01802671|OTHER|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
48634029|NCT01802671|BEHAVIORAL|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~* Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~* Cognitive restructuring techniques~* Behavioural therapy and activity pacing~* Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
48634030|NCT01802671|BEHAVIORAL|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
48295138|NCT02391727|BIOLOGICAL|SYN004|subjects who have received effective treatment for their cancers are eligible
48295139|NCT06031467|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
48295140|NCT06031467|DEVICE|Non-surgical mechanical therapy|Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
48634031|NCT02944825|DRUG|Ciprofloxacin|first line prophylactic oral antibiotic
48634032|NCT02944825|DRUG|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
48295141|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Nab-Paclitaxel|Given by IV, Given by PO
48634033|NCT02944825|DRUG|No Intervention|No intervention
48295142|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
48295143|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|Given by IV, Given by PO
48295144|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
48295145|NCT06449105|BEHAVIORAL|1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
48634034|NCT03967314|OTHER|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
48634035|NCT03967314|OTHER|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
48634036|NCT02739828|BIOLOGICAL|Adalimumab|Adalimumab
48634037|NCT04658147|DRUG|Nivolumab|Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.
48634038|NCT04658147|DRUG|Relatlimab|Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.
48295146|NCT06449105|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
48634039|NCT01067911|DIETARY_SUPPLEMENT|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
48634040|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
48634041|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
48634042|NCT01067911|DIETARY_SUPPLEMENT|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
48634043|NCT01524705|DRUG|Insulin Glargine|Glargine-injectable, variable, once daily (QD), 6 months
48634044|NCT01524705|DRUG|Metformin|Metformin-oral, up to 1000mg, twice daily (BID), 6 months
48634045|NCT01524705|DRUG|Prandial insulin|Aspart or glulisine or lispro
48634046|NCT01524705|DRUG|Exenatide|Injectable, 5mcg, twice daily (BID), 6 months
48634047|NCT03384485|DIAGNOSTIC_TEST|antiphospholipid syndrome|blood test for enzyme test,plasma and Lys-3-3 plasma
48634048|NCT00632970|DRUG|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
48634049|NCT00632970|DRUG|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
48634050|NCT00632970|DRUG|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
48634051|NCT00991003|PROCEDURE|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
48634052|NCT00991003|PROCEDURE|Conventional Colonoscopy|
48634053|NCT00961012|PROCEDURE|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
48634054|NCT01515527|DRUG|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
48634055|NCT01515527|DRUG|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
48634056|NCT01515527|DRUG|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
48634057|NCT01181765|BIOLOGICAL|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
48634058|NCT01420003|PROCEDURE|Bone Marrow Aspiration|3 per study
48634059|NCT01420003|PROCEDURE|Tonsil Biopsy|Optional upon completion of study
48634060|NCT04367935|DRUG|Pentoxifylline|Pentoxifylline tablets 400mg three times daily for 2 months
48634061|NCT00088101|DRUG|STA-5312|
48295147|NCT06449105|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
48476445|NCT00895037|DRUG|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
48476446|NCT00989209|DRUG|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
48476447|NCT00989209|PROCEDURE|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
48476448|NCT00497588|PROCEDURE|surgery|
48476449|NCT00497588|RADIATION|radiotherapy|
48476450|NCT00001554|DEVICE|intraoperative infrared (IR) neuroimaging|
48476451|NCT06357780|OTHER|close-loop synchronization controller with spontaneous mode|30 minutes period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during NIV mode.
48476452|NCT06357780|OTHER|Conventional|30 minutes period where the synchronization of pressure support of patient effort during NIV mode will be manually set.
48476453|NCT06276530|OTHER|EOS imaging for musculoskeletal disorder|The patients will have a low radiation 2D/3D biplane imaging of the rib cage, and spine before and after surgery.
48476454|NCT06276530|OTHER|Movement analysis by an optoelectronic camera.|Movement analysis by an optoelectronic camera before and after surgery.
48476455|NCT06276530|OTHER|Stabilometric measurement by strength platform|Stabilometric measurement by strength platform before and after surgery.
48476456|NCT02749760|OTHER|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
48476457|NCT02749760|OTHER|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
48476458|NCT00763555|DRUG|CD 2027|Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
48476459|NCT00763555|DRUG|Calcitriol Vehicle|Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
48476460|NCT03085368|DRUG|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
48476461|NCT00360737|BIOLOGICAL|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .
48476462|NCT04478708|BIOLOGICAL|maridebart cafraglutide|Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
48476463|NCT04478708|DRUG|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
48476464|NCT01945619|BIOLOGICAL|Trivirus-Specific CTLs|Patients will receive up to 2 x 10\^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
48476465|NCT01337726|BEHAVIORAL|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
48634062|NCT04225520|DEVICE|Cardiac resynchronization therapy ON|Implantation of a CRT device. Bi-ventricular pacing will be turned ON.
48476466|NCT01337726|BEHAVIORAL|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
48476467|NCT05906069|BEHAVIORAL|ICBT|The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
48476468|NCT01047891|DRUG|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
48476469|NCT05365035|DRUG|Cladribine|Given by Vein (IV)
48476470|NCT05365035|DRUG|Cytarabine|Given under the skin; subcutaneous injection (SQ)
48476471|NCT05365035|DRUG|Venetoclax|Given by PO
48476472|NCT05365035|DRUG|Azacitidine|Given by IV or subcutaneous injection (SQ)
48476473|NCT03806335|OTHER|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
48476474|NCT03806335|OTHER|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
48476475|NCT03806335|OTHER|General anesthesia|All patients will receive general anesthesia prior to infiltration
48476476|NCT03352375|DEVICE|Orotracheally intubation|Interventions used for airway safety and ventilation during surgical procedures
48476477|NCT03352375|DEVICE|Laryngeal Mask Airway|Interventions used for airway safety and ventilation during surgical procedures
48476478|NCT04865484|PROCEDURE|Surgical resection|Surgical resection of fibrostenotic area (\>4cm)
48476479|NCT04865484|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy of fibrostenotic area (≤4cm)
48476480|NCT04865484|PROCEDURE|Strictureplasty|Strictureplasty of fibrostenotic area (≤4cm)
48295148|NCT06449105|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
48295149|NCT06449105|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
48295150|NCT06449105|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
48295151|NCT06449105|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
48103936|NCT05073718|DRUG|Low-dose acetylsalicylic acid|In case of being positive for SARS-CoV-2 PCR or antigen test, she will be randomised 1:1 to receive daily LDASA (125 mg) or placebo, up to 36 weeks of pregnancy.
48634063|NCT04225520|DEVICE|Cardiac resynchronization therapy OFF|Implantation of a CRT device. Bi-ventricular pacing will be turned OFF.
48634064|NCT05996705|OTHER|Determining the relationship of fatigue with some parameters|Determining the relationship of fatigue with physical function, pain values at rest and in motion, gender, age, pain, disease activity, gender and disease duration in RA patients.
48634065|NCT00414609|DRUG|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
48634066|NCT00414609|DRUG|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
48634067|NCT03075631|OTHER|Questionnaire|Questionnaires
48634068|NCT03796130|PROCEDURE|Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
48634069|NCT00167947|DRUG|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
48295152|NCT06449105|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
48295153|NCT04072640|DRUG|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
48295154|NCT04072640|DRUG|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
48295155|NCT04072640|DRUG|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
48295156|NCT04678167|DIAGNOSTIC_TEST|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
48476481|NCT06090890|DRUG|Colchicine|Add 0.5mg QD orally and start using it within 48 hours after intervention.
48476482|NCT06090890|DRUG|Prednisone|0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
48476483|NCT06090890|DRUG|Aspirin|Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
48634070|NCT00167947|DRUG|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
48634071|NCT00167947|DRUG|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
48634072|NCT03055221|DRUG|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
48103937|NCT05073718|DRUG|Placebo|Placebo
48295157|NCT04678167|DIAGNOSTIC_TEST|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
48295158|NCT04678167|DIAGNOSTIC_TEST|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
48476484|NCT06090890|DRUG|P2Y12 Receptor Antagonist|Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
48634073|NCT02137356|RADIATION|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
48476485|NCT06090890|DRUG|Lipid-lowering drug|Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
48634074|NCT02137356|DRUG|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
48634075|NCT02137356|DRUG|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
48634076|NCT01450267|DRUG|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
48634077|NCT01450267|DRUG|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
48476486|NCT06610760|DRUG|Ursodeoxycholic Acid|Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
48476487|NCT06610760|DRUG|Placebo|Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
48476488|NCT01985464|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
48476489|NCT03480672|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
48476490|NCT03480672|OTHER|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
48476491|NCT03476031|DIAGNOSTIC_TEST|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
48476492|NCT06085937|DRUG|Ketamine|Patients will receive 0.2mg/kg of IV ketamine
48476493|NCT04451928|DIAGNOSTIC_TEST|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
48476494|NCT02518217|BEHAVIORAL|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
48476495|NCT02518217|BEHAVIORAL|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
48476496|NCT02518217|BEHAVIORAL|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
48476497|NCT06030856|DEVICE|STI test kits (NG, CT and TV) for home use|The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.
48476498|NCT06030856|BEHAVIORAL|Self Administered Behavioural Risk Assessment|Self Administered assessment to determine risk of HIV, STIs and pregnancy
48476499|NCT05065437|OTHER|Active (Virtual reality and spinal stimulation)|Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
48476500|NCT01317784|DEVICE|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
48476501|NCT01317784|DEVICE|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
48476502|NCT01317784|DEVICE|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
48476503|NCT01317784|DEVICE|HIV only|Choice of 4 different tests for HIV only.
48476504|NCT01265667|DRUG|CF101|orally q12h
48476505|NCT01265667|DRUG|Placebo|orally q12h
48476506|NCT05393128|PROCEDURE|Control group (Supine Position)|"In this group the patients will be given supine position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be given supine position.~3. The arms and the hands will be elevated and supported, the legs will be elevated and supported.~4. The patient will be covered.~5. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
48634078|NCT05380596|BEHAVIORAL|Telepharmaceutical Care|The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
48634079|NCT06015334|PROCEDURE|cataract surgery with implantation of intraocular lens|Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
48634080|NCT06013085|BEHAVIORAL|cognitive behavioral therapy|6 weeks cognitive behavioral therapy
48634081|NCT05682144|BIOLOGICAL|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
48634082|NCT00946036|DRUG|Sertraline Hydrochloride|
48634083|NCT04942873|OTHER|adherence|PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
48634084|NCT01818310|BIOLOGICAL|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
48295159|NCT04678167|DIAGNOSTIC_TEST|Alexander's degree of nystagmus|"there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left"
48295160|NCT04678167|OTHER|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
48295161|NCT04678167|OTHER|EEV questionnaire|European Vertigo Assessment Questionnaire
48295162|NCT04678167|OTHER|anxiety VAS|visual analog scale of anxiety
48476507|NCT05393128|PROCEDURE|Experimental Group (Right Lateral position)|"In this group the patients will be given right lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
48476508|NCT05393128|PROCEDURE|Experimental Group (Left Lateral position)|"In this group the patients will be given left lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
48476509|NCT04060914|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
48476510|NCT04060914|DRUG|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
48476511|NCT04060914|DRUG|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
48476512|NCT01491633|DRUG|Dasatinib|140 mg orally, daily in 28 day cycles
48476513|NCT03499366|DIAGNOSTIC_TEST|HFMS, MRC, ACTIVLIM, PedsQl-4.0|Clinical performance tests, quality of life, activity of daily life form.
48476514|NCT06616662|PROCEDURE|MAF|use mucosal advancement flap to treat PAF
48476515|NCT06616662|PROCEDURE|LIFT|use LIFT surgery for treating PAF
48476516|NCT05612139|DEVICE|JTIN implantation surgery|The JTIN is a self-extending intramedullary nail (telescopic rod) designed to provide fixation of femoral and/or tibial fractures, osteotomies, malunions and non-unions. The design of the JTIN includes a female and a male component, which are anchored to the proximal cortex and distal epiphysis through screw-type fixation. These two components slide from each other, allowing for extension of the JTIN as the bone structures remodel and patient growth occurs.
48476517|NCT00159835|DRUG|atorvastatin|
48476518|NCT00159835|DRUG|simvastatin|
48476519|NCT05673993|BIOLOGICAL|Telitacicept 80 mg|Telitacicept 80 mg subcutaneously once a week.
48476520|NCT05673993|BIOLOGICAL|Telitacicept 160 mg|Telitacicept 160 mg subcutaneously once a week.
48476521|NCT05673993|DRUG|Placebo|Subjects will be given subcutaneous placebo once a week.
48476522|NCT04228965|DRUG|Varenicline|Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
48476523|NCT04228965|BEHAVIORAL|Contingency Management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
48295166|NCT06673420|OTHER|No Interventions|This is an observational study
48295167|NCT03845998|PROCEDURE|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
48295168|NCT03845998|PROCEDURE|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
48295169|NCT06671652|BEHAVIORAL|Duyugoda igalenisodi (Starting again the right way)|Participants in the intervention arm will receive training and resources to build community resources and programming
48295170|NCT06652100|DIAGNOSTIC_TEST|ProNephro AKI (NGAL)|ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.
48295174|NCT04807582|OTHER|PET/MRI|18F-fluoropivalate tracer injection followed by PET/MRI scan
48295175|NCT06672588|DEVICE|Magnetic Seizure Therapy (MST)|MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
48295176|NCT06672588|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q or MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
48295177|NCT05552716|OTHER|School safety tactics and policies|A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
48634085|NCT01818310|BIOLOGICAL|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
48295178|NCT06671873|DRUG|100 µCi [14C] HMPL-306|D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose
48634086|NCT01818310|BIOLOGICAL|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
48295179|NCT06304272|PROCEDURE|Irrigating Traumatic Wound with Drinking Water|Irrigating Traumatic Wound with Drinking Water and Normal Saline
48295180|NCT03968445|DRUG|[18F]DPA-714-PET/MRI|\[18F\]DPA-714-PET/MRI
48295181|NCT04524741|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
48295182|NCT03562780|DRUG|Fortolin Tab 500mg|Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
48295183|NCT03562780|DRUG|Panadol Caplet 500mg|Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
48295184|NCT03152864|BEHAVIORAL|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
48295185|NCT00780000|DRUG|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
48476524|NCT04228965|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
48295186|NCT04552119|DEVICE|HEALICOIL Knotless PEEK|HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
48634087|NCT01818310|PROCEDURE|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
48634088|NCT04928066|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48295187|NCT04552119|DEVICE|HEALICOIL Knotless REGENESORB|HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
48295188|NCT06385496|PROCEDURE|Biopsy|Undergo biopsy
48295189|NCT06385496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48295190|NCT06385496|PROCEDURE|Computed Tomography|Undergo CT scan
48295191|NCT06385496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48295192|NCT06385496|DRUG|Sapanisertib|Given PO
48295193|NCT04304222|DEVICE|3D Printed Denture Framework|The Denture Framework is 3D printed from the digital image obtained from the denture mold.
48295194|NCT04709276|DRUG|Nivolumab|360 mg intravenously every 3 weeks
48634089|NCT04928066|DRUG|Tofacitinib|Tofacitinib,5mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48634090|NCT04928066|DRUG|Pred|Pred, 0-10mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response.
48634091|NCT00163735|DRUG|Administration of wine fined with potential food allergens|
48295195|NCT04709276|DRUG|Ipilimumab|1 mg/kg intravenously every 6 weeks
48295196|NCT04709276|DRUG|Carboplatin|"AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin."
48295197|NCT04709276|DRUG|Cabazitaxel|"20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel."
48295198|NCT06672666|DRUG|Hemp Derived Cannabidiol Extract|Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks
48295199|NCT06672666|DRUG|Placebo|Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
48295200|NCT02213003|BIOLOGICAL|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
48295201|NCT05020184|DRUG|Cimetidine|Oral Cimetidine 800mg twice daily.
48295202|NCT05020184|DRUG|Placebo|Placebo twice daily
48295203|NCT01770353|DRUG|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
48295204|NCT01770353|DRUG|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
48295205|NCT01441167|BIOLOGICAL|PfSPZ|
48295206|NCT04797286|DRUG|Sildenafil|Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
48295207|NCT04797286|OTHER|Placebo|Oral pill placebo.
48295208|NCT06184256|BEHAVIORAL|BfedBwell - Core Curriculum|12-week core nutrition education curriculum + 12-week tapered maintenance curriculum
48295209|NCT06184256|BEHAVIORAL|BfedBwell - 1:1 Counseling|Individual 1:1 counseling sessions with a registered dietitian
48295210|NCT06184256|BEHAVIORAL|BfedBwell - Behavioral Skills|Group-based behavioral skills development sessions
48295211|NCT06184256|BEHAVIORAL|BfedBwell - Group Support|Structured group support sessions
48295212|NCT06184256|BEHAVIORAL|Program delivery|Delivery and evaluation of one or more intervention components
48295213|NCT05422144|DEVICE|Antimicrobial Skin & Wound Cleanser (AWC)|BIAKŌS™ Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.
48295214|NCT05422144|DEVICE|Antimicrobial Wound Gel (AWG)|"BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~* Resists microbial colonization within the gel during shelf storage.~* Provides an amorphous gel covering.~* Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
48295215|NCT01687231|OTHER|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
48295216|NCT01804205|DRUG|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
48295217|NCT01804205|DRUG|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
48295218|NCT05917379|BIOLOGICAL|fecal microbiota|FMT utilizes stool from a healthy donor and puts them into capsules after processing
48295219|NCT05917379|OTHER|Placebo|Starch into the same outlook capsule with fecal microbiota
48295220|NCT05917379|DIETARY_SUPPLEMENT|synbiotics|Lactobacillus Helveticas+ Bifidobacterial longum + inulin(3g/day)
48295221|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: Virtual Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.
48295222|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: In-Person Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
48295223|NCT00607828|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
48295224|NCT06022679|OTHER|CBCT|CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
48295225|NCT05188235|DEVICE|Acoustical Resonance Device|"Infants will be studied for 15 min using an electronic tuning fork to transmit sound through the hip from a point on the skin while transmitted sounds FDA-approved stethoscope"
48295226|NCT02426086|DRUG|Imetelstat 4.7 mg/kg|Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
48295227|NCT02426086|DRUG|Imetelstat 9.4 mg/kg|Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
48295228|NCT01334125|DRUG|Metformin|Metformin 1000 mg once daily by mouth for 9 months
48634092|NCT04281771|PROCEDURE|cardiac MRI|"Patients are studied on a clinical 1.5 Tesla scanner with cardiac radiofrequency receiver coil centered over the heart, and ECG monitoring. The following parameters are assessed:~Functional imaging: ECG-gated cine Steady-state free precession (SSFP) MRI images are obtained during repeated breath holds in long axis and short axis orientations covering the entire left ventricle. Global systolic and diastolic function are assessed, and left ventricular mass is calculated.~Flow imaging: ECG-gated 2D flow measurements are assessed above the prosthetic valve, and at the level of the pulmonary trunk."
48634093|NCT02929121|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
48634094|NCT02929121|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
48634095|NCT01359280|BEHAVIORAL|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
48634096|NCT01359280|BEHAVIORAL|General Health Counseling|5 sessions of health improvement counseling
48634097|NCT01359280|BEHAVIORAL|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
48634098|NCT04578977|BEHAVIORAL|Functional assessment of surgical treatment of terrible triade injury of the elbow|Functional assessment of surgical treatment of terrible triade injury of the elbow
48634099|NCT01441414|BIOLOGICAL|PF-04856884|15 mg/kg/week intravenously \[IV\] until toxicity or disease progression
48634100|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
48634101|NCT01441414|DRUG|Axitinib (AG-013736)|5 mg PO BID
48634102|NCT01229111|DRUG|cediranib maleate|Given PO
48634103|NCT01229111|DRUG|oxaliplatin|Given IV
48634104|NCT01229111|DRUG|leucovorin calcium|Given IV
48634105|NCT01229111|DRUG|fluorouracil|Given IV
48634106|NCT05208632|OTHER|INTERSCALEN BLOCK APPLICATION WITH USG|40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
47946017|NCT02450188|BEHAVIORAL|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
47946018|NCT01848197|DRUG|paclitaxel|
47946019|NCT02670174|OTHER|Traditional training|
47946020|NCT02670174|OTHER|Separate kinetic chain training|
47946021|NCT02670174|OTHER|Integrated kinetic chain training|
47946022|NCT02575742|DEVICE|3D-Transit system|
48476525|NCT06001801|BEHAVIORAL|Diabetes Prevention Program|"The DPP group is led by the Community Health and Social Services Center (CHASS) community health workers (CHWs). For this study, the workers will deliver 16 weekly sessions (core phase) followed by two monthly sessions (maintenance phase). Each session lasts one hour plus the time required to weigh each participant and review food and activity logs.~This program will help participants make healthy lifestyle changes. Examples are improvements in eating and physical activity. The goal is that participants lose some weight and eat healthier food.~Sessions will be offered in-person in a room with video capacity to allow attendance of participants that cannot attend in person. For those participating virtually, the CHWs will briefly review with them what participants logged.~Participation in this project should last approximately 6-months."
47946023|NCT02549053|PROCEDURE|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
48295229|NCT01334125|DRUG|Placebo|2 capsules once daily by mouth for 9 months
48295230|NCT05090358|DIETARY_SUPPLEMENT|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
48476526|NCT06001801|BEHAVIORAL|INSPIRA|"This intervention will include the DPP plus additional interventions. The additional interventions include: participants to stay for an extra 30 minutes following the regular DPP sessions. In these INSPIRA sessions, participants will be trained in providing mutual peer support, be matched with a peer partner and asked to talk at least once a week, receive vouchers or gift cards, discuss participants action plans with the peer partner, and share challenges, successes, and tips from the CHW and others in the session.~CHWs will provide brief trainings on autonomy-supportive peer support approaches over the first three weeks of sessions.~Participation in this project should last approximately 6-months."
48476527|NCT01118026|DRUG|ABVD|doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV
48476528|NCT01118026|DRUG|BEACOPP|bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
48476529|NCT01118026|RADIATION|radiation therapy|
48634107|NCT05838313|BEHAVIORAL|Elective Induction of Labor Decision Support Tool|Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
48634108|NCT05615961|DIETARY_SUPPLEMENT|Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)|The intervention is a unique blend of probiotic cultures from a well-established manufacturer.
48634109|NCT05615961|DIETARY_SUPPLEMENT|Placebo|Placebo Tablets
48634110|NCT03180502|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|Undergo IMRT
48634111|NCT03180502|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
48634112|NCT03180502|DRUG|Temozolomide|Chemotherapy drug
48634113|NCT01687205|DRUG|1% Tenofovir Gel|
48634114|NCT00002370|DRUG|Itraconazole|
48295231|NCT05090358|DIETARY_SUPPLEMENT|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
48295232|NCT05090358|DRUG|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
48295233|NCT05090358|DRUG|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
48295234|NCT05090358|DRUG|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
48295235|NCT02819596|DRUG|Savolitinib|
48295236|NCT02819596|DRUG|MEDI4736|
48295237|NCT02819596|DRUG|Tremelimumab|
48295238|NCT06671847|DEVICE|THERABand resistance exercise bands|The training will be performed using THERABand resistance exercise bands.Participants will be instructed to perform the exercises twice per week at home, for the 24 weeks duration. Each exercise session will entail 1 set of 15 repetitions of 9 different exercises
48295239|NCT06248320|PROCEDURE|Sigh ventilation|Sigh breaths were delivered from intubation to extubation. Intervention primarily conducted in the following three stages: 1. From intubation to surgical opening of the chest cavity; 2. From the surgical closure of the chest cavity close and continue unit the operating room exiting; 3. From Intensive Care Unit (ICU) arrival to Spontaneous breathing trial (SBT) start.
48295240|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing high dose of the drug substance.
48295241|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing low dose of the drug substance.
48634115|NCT01795755|BEHAVIORAL|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
48634116|NCT01795755|BEHAVIORAL|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
48634117|NCT01219075|DIETARY_SUPPLEMENT|soy isoflavones|Given orally
48634118|NCT01219075|OTHER|placebo|Given orally
48634119|NCT01219075|OTHER|questionnaire administration|Ancillary studies
48634120|NCT01219075|PROCEDURE|magnetic resonance imaging|Correlative studies
48634121|NCT01219075|PROCEDURE|biopsy|Correlative studies
48295242|NCT05039515|DRUG|Placebo|Placebo will be supplied as powder filled hard capsules
48295243|NCT06438367|DRUG|[14C]TGRX-326|Healthy subjects will be given TGRX-326 60 mg orally on day 1.
48295244|NCT05327530|DRUG|Avelumab|Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
48295245|NCT05327530|DRUG|Sacituzumab Govitecan|Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
48295246|NCT05327530|DRUG|M6223|Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
48295247|NCT05327530|DRUG|NKTR-255|Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
48476530|NCT05105659|DIAGNOSTIC_TEST|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
48634122|NCT01219075|OTHER|immunohistochemistry staining method|Correlative studies
48634123|NCT01219075|OTHER|laboratory biomarker analysis|Correlative studies
48634124|NCT01219075|PROCEDURE|mammography|Correlative studies
47946024|NCT02549053|PROCEDURE|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
48476531|NCT05105659|DIAGNOSTIC_TEST|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
48634125|NCT01578720|DRUG|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
48634126|NCT01217515|DRUG|Diltiazem hydrochloride 4% cream|3 times daily
48634127|NCT01217515|DRUG|Diltiazem hydrochloride 2% cream|3 times daily
48634128|NCT01217515|OTHER|Placebo|3 times daily
48634129|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
48634130|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
48634131|NCT01829607|OTHER|Functional electrical stimulation of peripheral muscles|
48634132|NCT06547801|DIETARY_SUPPLEMENT|2'-Fucosyllactose|3 g/day of powder orally once daily
48634133|NCT06547801|DIETARY_SUPPLEMENT|Maltodextrin|3 g/day of powder orally once daily
48634134|NCT05783050|DEVICE|Wei Nasal Jet Tube|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
47946025|NCT06516484|DRUG|Romiplostim|Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
48295248|NCT06074510|DRUG|Piflufolastat F 18 Intravenous Solution [PYLARIFY]|Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
48295249|NCT04363307|DEVICE|AF Ablation|Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
48295250|NCT04363307|DEVICE|MRI|Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
48295251|NCT01477632|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
48295252|NCT01477632|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
48476532|NCT05105659|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
48476533|NCT05105659|DIAGNOSTIC_TEST|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
48634135|NCT05783050|DEVICE|Nasal Cannula Oxygen Support|The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
48295253|NCT01477632|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
48295254|NCT01410019|OTHER|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
48295255|NCT05153408|DRUG|BLU-701|BLU-701 for oral administration
48295256|NCT05153408|DRUG|osimertinib|Osimertinib tablets for oral administration
48295257|NCT05153408|DRUG|carboplatin|IV infusion of carboplatin
48295258|NCT05153408|DRUG|pemetrexed|IV infusion of pemetrexed
48295259|NCT05184764|BIOLOGICAL|AP-SA02|Bacteriophage administered via intravenous bolus infusion
48295260|NCT05184764|OTHER|Placebo|Inactive Placebo administered via intravenous bolus infusion
48295261|NCT04445077|OTHER|Dementia Competence Education for care home setting|The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.
48295262|NCT04445077|OTHER|Printed educational materials|The educational materials will be delivered to the participants in the control group for their self-study.
48295263|NCT02448823|OTHER|Mass media and Stylish Events|"1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~2. Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
48295264|NCT02448823|OTHER|Mass Media|1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
48295265|NCT03233594|OTHER|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
48295266|NCT03233594|OTHER|Healthy Control Group|Participants will not receive any interventions.
48295267|NCT05032833|DRUG|5-MeO-DMT|A single dose of 5-MeO-DMT will be administered intranasally
48295268|NCT05032833|OTHER|Placebo|A single dose of placebo will be administered intranasally
48295269|NCT04291014|DEVICE|SunRay Light Boxes|SunRay light boxes will be used to administer the light therapy.
48295270|NCT06080347|OTHER|Anti-inflammatory Diet|Dietary intervention
48295271|NCT06080347|OTHER|Healthy Diet|Dietary intervention
48295272|NCT05208112|DRUG|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
48295273|NCT01024465|DEVICE|ReShape Duo Balloon|ReShape Duo Balloon
48295274|NCT05945485|BIOLOGICAL|DCVC H1 HA mRNA vaccine|A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery
48295275|NCT05945485|BIOLOGICAL|Quadrivalent Recombinant Seasonal Influenza Vaccine|The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses, expressed using a baculovirus vector. These HA proteins are produced in a continuous insect cell line.
48295276|NCT05945485|OTHER|Sodium Chloride, 0.9%|0.9% Sodium Chloride Injection
48295277|NCT01479088|DRUG|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
48476534|NCT05105659|DIAGNOSTIC_TEST|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
48476535|NCT01879631|PROCEDURE|radial keratotomy|
48295278|NCT05829577|OTHER|Executive Function Strategies and Training|will be conducted by primary investigator and trained therapist ,EF strategies will be implemented during DLS and SI training and these strategies will target following area which proved by evidences within the context of functional training: Using monitoring system for each child , Improving sense of time, Externalize important information , Externalize Motivation, Provide consequences: Immediately, more frequently, Higher magnitude and more powerful, Richer degree of incentive, Rotated or changed more frequently, Personalize the command, praise, instruction, reprimanding, Process training, remediation and training on executive function skill
48295279|NCT05829577|OTHER|Daily Life skill training|each child will receive 25 minute of DLS training which will focus on training children on Grooming, feeding, dressing undressing, toileting and community reintegration tasks aligned with facilitation fine motor skills for children and Using several techniques for ADL training including : prompting, shaping, forward and backward chaining, and modeling ,training children based on level of independency identified by WeeFIM score
48295280|NCT05829577|OTHER|Sensory Integration /Processing training|each patient will receive 20 min of SI/SP training Manualized SI/SP intervention which will be used is based on the principles of sensory integration as outlined by Ayres ,such as deep pressure, brushing, weighted vests, and swinging will used , individually-tailored treatment activities might include activities such as using a carpeted scooter board while in the prone position to pull oneself up a ramp, then working to turn the scooter board around to ride down the ramp and land in a cushioned area of mats and pillows that are covered with various textures. Intervention is contextualized in play with active involvement of the child will be conducted in a large gym equipped with mats, a variety of suspended swings, large balls, a climbing wall, carpeted barrels, large inner tubes and foam blocks with opportunities for active, guided, sensory motor play.
48295281|NCT02719483|DEVICE|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
48295282|NCT02719483|PROCEDURE|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
48295283|NCT04575350|GENETIC|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
48295284|NCT04185610|OTHER|Qi Gong|Guided Qi Gong class
48295285|NCT04681287|DRUG|inetetamab and PD-1 inhibitor combined with chemotherapy.|"1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
48295286|NCT03863444|OTHER|Prenatal Preparation Education|Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
48634136|NCT05520450|BEHAVIORAL|Telematic support group|The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
48295287|NCT03863444|OTHER|Routine care|Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
48295288|NCT04283032|PROCEDURE|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
48295289|NCT03125642|DRUG|Etoposide|"BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
48634137|NCT04400955|DIAGNOSTIC_TEST|Audiometry tablet diagnostic tool and web-based test|as above
48634138|NCT01522547|DRUG|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
47946026|NCT02777710|DRUG|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
48634139|NCT06025383|DIETARY_SUPPLEMENT|L-Citrulline|2 weeks of L-Citrulline supplementation (6 grams/day)
48634140|NCT06025383|DIETARY_SUPPLEMENT|Placebo|2 weeks of microcrystalline cellulose supplementation (8 capsules/day)
48634141|NCT01769118|DRUG|Caffeine|Caffeine will be given according to departmental protocol
48634142|NCT06271070|OTHER|Non-intervention|Non
48634143|NCT01704560|OTHER|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
48634144|NCT05431907|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
48634145|NCT01971593|DRUG|Eplerenone|
48634146|NCT06436521|BEHAVIORAL|Positive Cognitive Behavioral Therapy|Positive CBT integrates brief Solution-Focused Brief Therapy with Positive Psychology techniques, within a cognitive-behavioral framework. It is considered a competency and strengths-based model.
48634147|NCT06436521|BEHAVIORAL|Traditional Cognitive Behavioral Therapy|Traditional cognitive behavioral therapy is a form of psychological treatment that emphasizes that psychological problems are based on faulty or unhelpful ways of thinking and the focus is to change thinking patterns.
48295290|NCT03125642|DRUG|BCNU|BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
48634148|NCT01991535|DEVICE|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.~Device model: Stellar 150® (ResMed, Australia)."
48634149|NCT01991535|DEVICE|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.~Device model: Stellar 150® (ResMed, Australia)."
48634150|NCT01991535|DEVICE|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.~Device model: Stellar 150® (ResMed, Australia)."
48634151|NCT01163500|DIETARY_SUPPLEMENT|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
48634152|NCT01163500|OTHER|Placebo|Placebo controlled (dextrin)
48634153|NCT04674800|BIOLOGICAL|MYL-1701P, a proposed biosimilar to Eylea|Open label and single arm
48634154|NCT00483509|DRUG|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
48634155|NCT00483509|DRUG|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
48634156|NCT02449928|DRUG|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
48634157|NCT02449928|DRUG|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
48634158|NCT01272856|DRUG|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
48634159|NCT03436420|DRUG|Gemcabene|Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
48634160|NCT01775709|DEVICE|PE tube with Duckbill Valve|PE tube with Duckbill Valve
48634161|NCT05718336|OTHER|Integrated care|multi-discipline care program
48634162|NCT00451984|BIOLOGICAL|Twinrix|
48634163|NCT00451984|BIOLOGICAL|interleukin-2|
48634164|NCT04557345|DIAGNOSTIC_TEST|Determination of cytokines|Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
48634165|NCT04557345|DIAGNOSTIC_TEST|Two-dimensional transthoracic echocardiogram|With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
48634166|NCT03114397|DEVICE|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
48634167|NCT03114397|DEVICE|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
48634168|NCT00198614|DRUG|Carvedilol versus Metoprolol|
48634169|NCT05788354|PROCEDURE|IUD insertion during cesarean section|placement of IUD during cesarean section after placental delivery
48295291|NCT03125642|DRUG|AraC|BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
48295292|NCT03125642|DRUG|Melphalan|BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
48295293|NCT03125642|PROCEDURE|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
48634170|NCT00003107|BIOLOGICAL|recombinant interleukin-12|
48634171|NCT03222609|DRUG|Ruxolitinib|Tablet; Oral
48634172|NCT03222609|DRUG|Navitoclax|Tablet; Oral
48634173|NCT04557137|DRUG|Somatostatin analog|120 mg ipstyl every 28 days
48634174|NCT04875845|BEHAVIORAL|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
48634175|NCT06090721|DRUG|DMT310|Topical Powder
48634176|NCT06090721|DRUG|Placebo|Placebo Topical Powder
48295294|NCT03125642|BIOLOGICAL|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
48295295|NCT03125642|DRUG|Cyclophosphamide|"CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
48295296|NCT03125642|RADIATION|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
48295297|NCT06667557|DEVICE|Superpulse Thulium Fiber Laser (sTFL) Treatment|The superpulse thulium fiber laser (sTFL) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
48295298|NCT06667557|DEVICE|Holmium:YAG Laser (Ho:YAG) Treatment|The holmium:YAG laser (Ho:YAG) was used as a minimally invasive surgical treatment for kidney and upper ureteral stones. All procedures were performed by experienced urologists using standard techniques for laser lithotripsy. Laser settings, such as pulse energy and frequency, were adjusted according to stone characteristics and the surgeon's judgment to optimize treatment efficacy and safety.
48295299|NCT04044534|DRUG|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
48295300|NCT04044534|DRUG|Placebo|Subjects in this arm will receive placebo.
48295301|NCT03902405|BEHAVIORAL|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
48295302|NCT03902405|BEHAVIORAL|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
48295303|NCT06077058|OTHER|Nicotine Replace Therapy (NRT) sampling|The intervention involves a Zoom/WhatsApp meeting or face-to-face session with a trained counselor who introduces NRT use, possible side effects, and patch dosage based on a previous RCT guide. An online intervention pack with a pamphlet and 1-week free NRT sample (14mg or 21mg patch) is mailed to participants. After 1 week, the counselor follows up. If participants need more patches, an additional pack is mailed, and they are advised to obtain further patches from smoking cessation services or pharmacies. NRT patch users may experience skin reactions, insomnia, or vivid dreams; if severe side effects occur, they are asked to stop using NRT.
48295304|NCT06077058|BEHAVIORAL|Simple exercise education (SEE)|All participants will be given a handgrip at study enrolment. The SEE includes a Zoom/WhatsApp meeting or face-to-face session including 1) watching a 5-minute video (www.youtube.com/watch?v=mZex2Wwy3fU) showing a chair professor of public health demonstrating the 10s-E, including the simple exercises with and without handgrip. The video also encourages participants to 1) follow the exercise instructions during the video demonstration; 2) perform the exercises whenever they experience craving or an urge to smoke during the quitting process; and 3) increase their exercise frequency and intensity as much as possible, which may also increase their grip strength. Participants will also receive a leaflet with exercise instructions and motivational messages.
48295305|NCT06077058|OTHER|Chat-based instant messaging|Participants will receive individualized chat-based encouragement and support messages about motivation and preparation for quit attempts using WhatsApp for 8 weeks. A trained smoking cessation counsellor will have real-time (synchronous), one-to-one interaction with the participants and provide personalized motivational, behavioural support according to the participants' needs. The conversation intensity will be flexible and depends on the participant. The conversation will also be integrated with brief advice using the Behaviour Change Techniques (BCTs) (18) and the AWARD (Ask, Warn, Advise, Refer, Do-it-again) intervention model (11). The intervention protocol will be similar as that in our previous RCT on CBIM (19). For participants who receive the SEE and NRTS, the trained counsellor shall follow-up on their compliance and provide adequate advice in adhering to these interventions.
48295306|NCT06077058|OTHER|Chatbot for smoking cessation|The information and access to the chatbot will be introduced to participants. Through the chatbot service, participants shall access to practical information on smoking cessation 24 hours at any time, such as details on cessation services and skills for tackling cravings. By using the second-generation chatbot, participants could receive personalized risk information and recommendations for smoking cessation, as well as reach to a counsellor through WhatsApp live chat for urgently needed advice.
48295307|NCT02575794|DRUG|Terameprocol|Given PO
48295308|NCT02575794|OTHER|Pharmacological Study|Correlative studies
48295309|NCT04962165|DEVICE|Mandibular Advancement Device|The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
48295310|NCT00417612|DRUG|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
48295311|NCT00417612|OTHER|Placebo|Placebo sugar pill
48295312|NCT04461847|PROCEDURE|subcutaneous mastectomy|Operating subcutaneous mastectomy
48295313|NCT04461847|PROCEDURE|endoscopic subcutaneous mastectomy|Operating endoscopic subcutaneous mastectomy
48295314|NCT00135434|DRUG|Atazanavir/Ritonavir/Lopinavir/ritonavir|
48295315|NCT06201572|OTHER|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared. The data management platform provides intelligent management of patients' out-of-hospital follow-up, and the dynamic physiological indicators and psychological assessment data of patients are mastered through the hospital port, so as to provide telemedicine guidance for patients, so as to improve the prognosis of hypertensive emergency patients.
48295316|NCT03699839|BIOLOGICAL|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
48295317|NCT03699839|BIOLOGICAL|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
48634177|NCT03189511|DRUG|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
48634178|NCT05344274|DIAGNOSTIC_TEST|Indocyanine Green Angiography|Erythrocyte Mediated Angiography with indocyanine green as well as conventional indocyanine green angiography will be conducted to determine retinal blood flow
48295318|NCT03699839|BIOLOGICAL|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
48295319|NCT00033839|DRUG|Civamide (Zucapsaicin)|
48295320|NCT01101724|BEHAVIORAL|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
48295321|NCT02226614|DEVICE|University of Edinburgh head cooling device|head cooling
48295322|NCT05342974|DRUG|Atorvastatin|Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.
48476536|NCT02063087|OTHER|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
48634179|NCT05344274|BIOLOGICAL|Isocapnic Oxygen|Investigators will evaluate retinal blood flow (RBF) in response to oxygen supplementation at a constant level of carbon dioxide (isocapnic hyperoxia) to isolate the vascular autoregulatory response to oxygen.
48634180|NCT05344274|DIAGNOSTIC_TEST|Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)|Investigators will image subjects with OCT as well as AO technology to determine retinal ganglion cell density, vessel density, and vessel flowrates
48634181|NCT02993432|DEVICE|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
48476537|NCT01380249|DRUG|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
48476538|NCT05890092|OTHER|Observation|Observing for disease prevalence - actual and self-reported
48476539|NCT01955044|DIETARY_SUPPLEMENT|LCPUFA supplement|
48476540|NCT01955044|DIETARY_SUPPLEMENT|placebo|
47946027|NCT02777710|DRUG|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
47946028|NCT04399837|DRUG|Spesolimab|Solution for injection
47946029|NCT04399837|DRUG|Placebo|Solution for injection
48476541|NCT01168687|DRUG|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
48476542|NCT01168687|DRUG|Placebo|
48476543|NCT03605524|OTHER|Sensory training|12 weeks sensory training
47946030|NCT06203574|RADIATION|[68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4|The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
48476544|NCT05021484|DRUG|Felzartamab|Intravenous infusion in regular intervals over 6 months
48634182|NCT02993432|DRUG|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
48634183|NCT02369159|DRUG|Peramivir|
48634184|NCT02369159|DRUG|Oseltamivir|
48476545|NCT05021484|DRUG|Placebo|Intravenous infusion in regular intervals over 6 months
48476546|NCT02215772|DRUG|BI 44370 BS|
48634185|NCT00276393|DRUG|Basal insulin|
48634186|NCT00393146|DRUG|GW856553|Study drug
48103938|NCT05644080|RADIATION|177Lu-PSMA I&T|Patients demonstrating a high tumor uptake of 68Ga-PSMA on the diagnostic PET/MRI examination in the screening part of the study are eligible for a standard of 3 cycles, with a possible extension to maximum number of 6 cycles, of 177Lu-PSMA radionuclide therapy sessions. SPECT/CT will be performed after each cycle of treatment for dosimetry calculations, while 68Ga-PSMA PET/MRI, quality-of-life schemes and clinical examinations will be used to monitor therapeutic effects during the therapy cycles and up to 1.5 year after treatment initiation. The main endpoints of the study are progression-free survival and overall survival.
48295323|NCT05342974|DRUG|Misoprostol|On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
48295324|NCT04204941|DRUG|Tazemetostat|400 mg, 600 to 800 mg of Tazemetostat will be administered twice daily.
48295325|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
48295326|NCT04204941|DRUG|Tazemetostat|800 mg administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.
48295327|NCT04204941|DRUG|Placebo|Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond
48295328|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
48295329|NCT00842517|BEHAVIORAL|Contingency Management|
48295330|NCT06512701|OTHER||This study is an observational study without any intervention measures.
48295331|NCT06094777|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
48295332|NCT05811572|DEVICE|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
48295333|NCT01726777|DIETARY_SUPPLEMENT|Control|Normal cheddar cheese
48295334|NCT01726777|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 supplemented cheddar cheese
48476547|NCT03207958|DRUG|Belimumab|-Given over 1 hour
48476548|NCT01997294|DRUG|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
48476549|NCT02462434|BEHAVIORAL|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
48476550|NCT02430207|PROCEDURE|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
48476551|NCT02430207|PROCEDURE|temporary pacing subclavian vein|
48476552|NCT03230734|DRUG|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
48476553|NCT03230734|DRUG|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
48476554|NCT06612034|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
48634187|NCT02173366|BEHAVIORAL|Change Club Intervention|
48634188|NCT01722734|BEHAVIORAL|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
48634189|NCT05877664|DRUG|ZG0895 Hydrochloride for Injection|The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
48295335|NCT02138578|RADIATION|SBRT|
48295336|NCT02138578|RADIATION|RFA|
48295337|NCT00664274|BEHAVIORAL|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
48295338|NCT00664274|GENETIC|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
48295339|NCT00001332|PROCEDURE|CHPP with cisplatin|
48295340|NCT05589181|DRUG|High Dose Buprenorphine|32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
48295341|NCT05589181|DRUG|Standard Buprenorphine Dose|12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
48476555|NCT06234748|RADIATION|Radiation|"Patients will undergo 2 phases of RT replanning:~1. Based on 2-week DCE-MRI low BV tumor subvolume, patients will have a PTVboost1 that will start to receive 2.5Gy/day with fraction 16. PTVboost1=(persistent lowBVsubvolume_2 wks+ MTV3_2 weeks)+ 3mm margin.~2. Based on 4-week FDG-PET MTV3, patients with have a PTVboost2 cone down that will receive 2.5Gy/day starting with fraction 23. PTVboost2=(LBV_2 wks + MTV3_4wks)+ 3mm margin~3. Thus, the tumor subvolumes that are included in the boost from fx16-35 will receive 86 Gy EQD2 (80Gy physical dose) and the FDG-avid subvolumes which start boost at 2 weeks but are not persistently avid at 4 wks will receive 76Gy EQD2 (74Gy physical dose)."
48476556|NCT06234748|DRUG|Platinum based chemotherapy|Standard of care therapy, weekly, with either Cisplatin or Carboplatin
48634190|NCT01062295|DEVICE|Siesta-System|
48634191|NCT01062295|DEVICE|Standard headrest|
48634192|NCT05270356|OTHER|MRI|Magnet Resonance Imaging of the Brain without Contrast
48634193|NCT03845868|OTHER|Dietary and environmental exposure (Observational study)|
48634194|NCT01922414|DEVICE|Laser|Patients will undergo laser lithotripsy durin PNL
48295342|NCT04442048|BIOLOGICAL|IMM-101|Three doses of IMM-101 on days 0, 14, and 45.
48634195|NCT01922414|DEVICE|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
48634196|NCT01593111|OTHER|Environmental Intervention|Home-based environmental intervention
48295343|NCT04442048|OTHER|Observation|No active treatment. Observation only
48295344|NCT02812030|OTHER|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
48295345|NCT02976831|DRUG|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
48295346|NCT02976831|DRUG|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
48295347|NCT03614715|DRUG|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
48295348|NCT01059604|DRUG|Sumatriptan|Sumatriptan
48295349|NCT01059604|DRUG|Naratriptan|Naratriptan
48295350|NCT01059604|DRUG|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
48295351|NCT01330446|DRUG|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
48295352|NCT01330446|OTHER|Placebo|1 by mouth every morning for a 28 day cycle.
48295353|NCT01330446|BEHAVIORAL|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
48295354|NCT00029315|DRUG|Recombinant Tissue Plasminogen Activator (rt-PA)|
48295355|NCT00950027|DRUG|povidone iodine|oropharyngeal decontamination every 4 hours
48295356|NCT00950027|DRUG|Placebo|oropharyngeal decontamination every 4 hours
48295357|NCT04097717|BEHAVIORAL|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
48295358|NCT04097717|OTHER|Usual Care|Usual medical care will vary among participants.
48295359|NCT03372954|DRUG|BMAC|retrograde administration on non-selected BMAC via coronary sinus
48295360|NCT04594694|DRUG|Obeticholic acid|5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
48295361|NCT04594694|DRUG|Bezafibrate 200 MG|200 mg IR tablet of Bezafibrate once daily for the remainder of the study
48295362|NCT04594694|DRUG|OCA Placebo|One tablet daily for the remainder of the study
48295363|NCT04594694|DRUG|Bezafibrate 200 mg Placebo|One tablet daily for the remainder of the study
48295364|NCT04594694|DRUG|Bezafibrate 400 MG|400 mg SR tablet of Bezafibrate once daily for the remainder of the study
48295365|NCT04594694|DRUG|Bezafibrate 400 mg Placebo|One tablet daily for the remainder of the study
48476557|NCT03860207|BIOLOGICAL|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.
48476558|NCT03860207|OTHER|Blood draw|In cycle 1, blood is drawn for PK studies.
48476559|NCT04309526|DRUG|NCO-48 Fumarate|NCO-48 Fumarate
48476560|NCT04309526|DRUG|Placebo|Placebo
48295366|NCT04594694|DRUG|OCA|OCA one tablet will be administered.
48476561|NCT05335382|BEHAVIORAL|Brief Interventions (BI)|'Brief Interventions' (BI) is a multitude of interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. The interventions within BI often have their foundation in CBT, ACT or Motivational Interviewing (MI), however interventions from other schools of therapy can also be used. The common theme is that they are principle-based rather than manual-based and focus on behavioural change in relation to a problem, rather than focusing on a specific diagnosis. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. A BI treatment usually consists of 1-4 appointments with several weeks apart and has an open ending, where the patient easily can schedule a new appointment. Clinicians delivering brief interventions will have had 3 days of training as well as regular supervision.
48295367|NCT04594694|DRUG|Bezafibrate|Bezafibrate one tablet will be administered.
48295368|NCT06267001|DRUG|Atezolizumab|Atezolizumab will be administered IV.
48295369|NCT06267001|DRUG|Tiragolumab|Tiragolumab will be administered IV.
48295370|NCT06267001|DRUG|Placebo|Placebo will be administered IV.
48295371|NCT01494038|DRUG|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
48295372|NCT01494038|DRUG|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
48295373|NCT03935477|DEVICE|WellBeing catheter|Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
48295374|NCT03271255|DRUG|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
48295375|NCT03271255|DRUG|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
48295376|NCT01704872|DRUG|ch14.18/CHO|
48295377|NCT01673880|DRUG|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
48295378|NCT01260181|DRUG|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
48295379|NCT04381000|OTHER|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
48295380|NCT06472570|RADIATION|Stereotactic radiotherapy boost|"A stereotactic radiosurgery boost is given in two cases:~* Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy).~* Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy.~Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively~Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment~Prescribed doses of stereotactic boost are in the range of 10-18 Gy"
48295381|NCT04163198|DEVICE|Insufflation|Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
48295382|NCT04163198|DEVICE|Exsufflation|Patients will receive different exsufflation pressures at fixed insufflation pressure.
48295383|NCT05874245|DRUG|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
48295384|NCT05874245|DRUG|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
48295385|NCT05874245|DRUG|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
48295386|NCT05506371|DRUG|Az+SRP|Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
48295387|NCT05506371|DRUG|SRP|Scaling and root planning (SRP) treatment of periodontitis
48476562|NCT05335382|BEHAVIORAL|Care As Usual (CAU)|Care As Usual includes the PCC's current routine care for patients with mental and behavioral problems. This can include a multitude of procedures and treatment, such as pharmacological treatment, supportive care, cognitive behavioural therapy (CBT) and psychodynamic therapy of varying lengths. Interviews with patients as well as medical journals will be used to categorise what type of care each individual patient has received.
48476563|NCT05685524|DIAGNOSTIC_TEST|DNA methylation test|Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
48476564|NCT06142669|DEVICE|EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert|Primary knee arthroplasty or a revision knee that requires a revision procedure.
48476565|NCT05929066|DRUG|Retatrutide|Administered SC
48476566|NCT05929066|DRUG|Placebo|Administered SC
48476567|NCT01991288|PROCEDURE|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
48476568|NCT01991288|PROCEDURE|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
48476569|NCT06616038|OTHER|Data collection|Given the observational nature of the study, the intervention is a simple data collection
48476570|NCT04248517|OTHER|mHealth Intervention|Participants will download the app onto their smartphone and complete ecological momentary assessements
48476571|NCT02087891|BEHAVIORAL|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
48476572|NCT02087891|BEHAVIORAL|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
48476573|NCT02087891|BEHAVIORAL|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
48634197|NCT01287429|OTHER|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
48634198|NCT00270569|DRUG|PhyxolTM, Cisplatin|
48634199|NCT04201405|DRUG|Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene|Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
48634200|NCT05403515|OTHER|foot massage|foot massage
48634201|NCT05403515|OTHER|Foot massage +Aromatherapy group|foot massage and lavender oil inhalation
48634202|NCT04430621|DRUG|Follicle Stimulating Hormone|FSH will be administered s.c. in the morning to male healthy subjects
48634203|NCT00395512|DRUG|Alogliptin|Alogliptin tablets.
48634204|NCT00395512|DRUG|Pioglitazone|Pioglitazone tablets.
48634205|NCT00395512|DRUG|Placebo|Matching placebo tablets.
48634206|NCT03044912|DRUG|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
48634207|NCT05560633|OTHER|No intervention|No intervention
48634208|NCT04725981|PROCEDURE|Total laparoscopic hysterectomy|Control group: colpotomy closure technique: 3 Z-sutures PDS 0 Intervention group: colpotomy closure technique: 3 Z sutures with PDS 0 and 1 continuous suture with V-Loc 2-0
48295388|NCT05506371|DRUG|No interventions|Diagnostocs to confirm the healthy state of the gingiva
48295389|NCT06035380|OTHER|placebo group|aromatherapy
48295390|NCT06035380|OTHER|mint oil group|aromatherapy
48295391|NCT06035380|OTHER|rose oil group|aromatherapy
48295392|NCT00878046|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
48295393|NCT01380756|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
48295394|NCT01380756|DRUG|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
48295395|NCT01863758|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
48295396|NCT02400112|DRUG|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
48295397|NCT06671470|DRUG|YZJ-1139 tablets|Oral dose 20 mg
48295398|NCT06671470|DRUG|Ticagrelor Tablets|Oral dose 90 mg twice daily
48295399|NCT05616949|BEHAVIORAL|Treatment as Usual (TAU) (Arm 1)|Treatment as Usual (TAU): The treatment and/or other services received as part of usual care while living in a recovery residence. This arm serves as the active comparator group for the study.
48295400|NCT05616949|BEHAVIORAL|Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)|Peer Recovery Support Services (PRSS) Intervention: The experimental group for this study that involves the implementation of the PRSS intervention. This study will test the preliminary efficacy of the PRSS intervention on Medications for Opioid Use Disorder (MOUD) retention by evenly randomizing N=50 individuals on MOUD living in recovery residences (RRs) to either a 24-week course of the experimental PRSS intervention layered on top of treatment as usual services
48295401|NCT00970294|BEHAVIORAL|Health Promotion Program|10 week health promotion program 3-4 times per week
48295402|NCT05468450|DRUG|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
48295403|NCT05468450|DEVICE|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
48295404|NCT06672367|PROCEDURE|Balance training group|"It includes participants receiving balance training for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously."
48476574|NCT05882734|DRUG|M1774|In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
48476575|NCT05882734|DRUG|Cemiplimab|Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
48476576|NCT06109857|OTHER|Non-Interventional Study|Non-interventional study
48476577|NCT00050882|DRUG|GM-611|
48476578|NCT05808166|BIOLOGICAL|Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).|Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
48476579|NCT05808166|OTHER|Isotonic Sodium Chloride injection|Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
48476580|NCT04676880|DEVICE|Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)|Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
48476581|NCT06617130|DIETARY_SUPPLEMENT|Corn soy bean blended flour porridge plus indispensable amino acid|"Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids."
48476582|NCT03215459|DEVICE|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
48634209|NCT03302663|DIAGNOSTIC_TEST|MRI scan|Addition of advanced imaging sequences for fetal MRI
48634210|NCT03296345|DRUG|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
47946031|NCT00940030|OTHER|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
47946032|NCT00940030|OTHER|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
48476583|NCT02270034|DRUG|Crizotinib|Crizotinib is added to Stupp method
48476584|NCT03259191|PROCEDURE|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
48295405|NCT06672367|PROCEDURE|Balance training combined with gaze stability exercises|"It includes participants receiving balance training combined with gaze stability exercises for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.~Gaze stability exercises~Visual tracking exercises"
48476585|NCT02399631|OTHER|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
48476586|NCT06596642|DRUG|Luspatercept|As per product label
48634211|NCT04621760|BEHAVIORAL|HIV Prevention Decision Support Tool (DST)|The tool is founded on principles of decision-science and developed in a systematic manner including pilot testing. The tool will present HIV prevention information through a tablet in the clinical setting. The decision support tool will address barriers to PrEP delivery, including 1) limited client knowledge about PrEP, 2) limited time to educate patients in busy clinics, 3) women's lack of knowledge of their own HIV vulnerability, and 4) hesitancy of women to initiate discussions about PrEP with providers due to judgmental attitudes and stigma. Also, the tool emphasizes the highly variable and individual nature of baseline risk.
48634212|NCT04621760|BEHAVIORAL|Standard Counseling|Participants in this arm will receive usual care.
48634213|NCT01283425|DEVICE|InsuPatch|Heaters for single use and a permanent control unit.
48634214|NCT00676962|BEHAVIORAL|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
48634215|NCT02659228|DEVICE|EEG recording|EEG recording with anesthetic (DIPRIVAN)
48634216|NCT02659228|DRUG|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
48634217|NCT03927755|OTHER|Education|Physicians will undergo training on how to rapidly obtain appropriate images.
48634218|NCT06407778|OTHER|High Intensity Strength Training|"* High-intensity workouts to strengthen the quadriceps and enhance knee function;~* Knee flexion and extension 10 lbs.~* 10RM of hip flexion and extension~* 10RM hip adduction and abduction~* Standing with feet aligned for one minute\*2, standing on one leg's forefoot and the other leg's heel for two minutes\*2, standing on one foot for three seconds\*15, and walking ten meters in a straight line for four minutes~* 4-week program; 3 days/week; Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
48634219|NCT06407778|OTHER|Muscle Energy Technique|"The Muscle Energy Technique (MET) to strengthen and flex your quadriceps and hamstrings.~* After maintaining an isometric contraction for ten seconds, a little stretch was maintained for thirty seconds.~* Four contractions every treatment, separated by three seconds of rest. Standing with feet parallel for one minute\*2, standing on one leg's forefoot and the other leg's heel for two seconds\*2, standing on the forefoot for three seconds\*15~* Move in a 10 m by 4 straight line.~* 4-week program; 3 days/week Conventional Treatment: Exercises for range of motion, mobility and weight bearing, muscle stretching, static quadriceps exercise, quadriceps exercise, and straight leg raising"
48634220|NCT03174275|DRUG|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
48634221|NCT03174275|DRUG|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
48634222|NCT03174275|DRUG|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
48634223|NCT03174275|DRUG|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
48634224|NCT03174275|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
48634225|NCT03174275|RADIATION|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
48634226|NCT02405065|DRUG|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
48634227|NCT04268966|DRUG|Brincidofovir|
48634228|NCT03368521|OTHER|Back pain screening test|The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
48634229|NCT00976391|BIOLOGICAL|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
48634230|NCT00976391|DRUG|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
48634231|NCT05427916|DEVICE|Avance Solo|Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.
47946033|NCT03003156|PROCEDURE|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
47946034|NCT03003156|PROCEDURE|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
48295406|NCT04207112|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
48295407|NCT04207112|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
48295408|NCT04207112|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
48295409|NCT04207112|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
48295410|NCT04207112|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
48295411|NCT04207112|DRUG|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
48295412|NCT03671083|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
48295413|NCT05033444|DRUG|PRV-002|"SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated."
48295414|NCT05033444|DRUG|Placebo|Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
48295415|NCT05476549|DIETARY_SUPPLEMENT|Lemon verbena|Lemon verbena supplement administered at an estimated daily dose of 15mg/kg
48295416|NCT05476549|DIETARY_SUPPLEMENT|Placebo|Placebo supplement containing carrier material only
48295417|NCT01894516|DRUG|GLPG0634|GLPG0634 capsules.
48295418|NCT01894516|DRUG|Placebo|Placebo capsules.
48295419|NCT05891743|DIAGNOSTIC_TEST|Patch Test|The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.
48295420|NCT05367960|DRUG|Zatolmilast/ BPN14770|25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
48295421|NCT00882713|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
48295422|NCT00933205|DRUG|Tipranavir|
48295423|NCT00797927|DRUG|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
48295424|NCT00797927|OTHER|no intervention|keep the original conventional antipsychotic agent for 28 days
48295425|NCT04805372|OTHER|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
48295426|NCT04805372|OTHER|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
48476587|NCT04350008|DEVICE|Renamic Neo programmer device, including software; PK-222-L ECG cable|Patients were enrolled either for implantation including subsequent pre-hospital discharge or for a follow-up visit only. ICM patients were included for follow-ups only. Implants were programmed and interrogated by using the investigational devices.
48476588|NCT03371329|BIOLOGICAL|MSC|bone marrow derived cultured MSC (mesenchymal stem cell)
48476589|NCT01662362|DEVICE|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
48476590|NCT03753776|DRUG|Placebo pills of Radium bromatum|Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
48476591|NCT03753776|DRUG|Radium bromatum pills|Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
48476592|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna placebo pills|Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
48476593|NCT03753776|DRUG|Radium bromatum/Apis mellifica/Belladonna pills|Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
48476594|NCT05004064|DRUG|Acalabrutinib|Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
48476595|NCT05004064|DRUG|Rituximab|Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
48476596|NCT00760526|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
48476597|NCT00760526|DEVICE|Home blood glucose monitor|Home monitoring 3 or more times a day
48476598|NCT04651595|PROCEDURE|Caudal block|caudal block with low dose bupivicaine 0.25% to preserve tone
48634232|NCT05427916|OTHER|Optifoam|Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
48634233|NCT05854264|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
48634234|NCT05854264|DIETARY_SUPPLEMENT|specialized nutrition|specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
48634235|NCT00901095|BEHAVIORAL|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
48634236|NCT04903509|DRUG|BI 1820237|BI 1820237
48634237|NCT04903509|DRUG|Placebo|Placebo
48634238|NCT04903509|DRUG|Saxenda®|Saxenda®
48634239|NCT04903509|DRUG|Paracetamol-ratiopharm®|Paracetamol-ratiopharm®
48634240|NCT01663987|DRUG|tiotropium bromide|18 mcg once a day (QD)
48634241|NCT01663987|DRUG|Placebo|once a day (QD)
48634242|NCT05548777|DRUG|Andexanet alfa|Andexanet alfa
48634243|NCT05548777|DRUG|4F-PCC|Four-Factor Prothrombin Complex Concentrate (4F-PCC)
48634244|NCT06427174|DRUG|Fascia iliaca block|For the group who will receive the fascia iliaca block .... After induction of the general anesthesia and before skin incision, fascia iliaca block will be performed in the patient while he is in the supine position
48634245|NCT06427174|DRUG|Caudal block|second group will receive the caudal block, we use bupivacaine 0.5 mg / kg.
48634246|NCT01008527|DRUG|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
48476599|NCT04651595|DRUG|Morphine|morphine to control pain and avoid using muscle relaxant
48295444|NCT02610023|OTHER|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
48295445|NCT02610023|OTHER|Laboratory Biomarker Analysis|Correlative studies
48295446|NCT02610023|DEVICE|Spectroscopy|Undergo resonance Raman spectroscopy
48295447|NCT04940468|OTHER|Diet Intervention|The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.
48295448|NCT06559137|DRUG|Ropivacaine 0.2% Injectable Solution|Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
48295449|NCT01455571|DRUG|HM781-36B|Q1DX14/2W for 3W HM781-36B
48634247|NCT01008527|BIOLOGICAL|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
48634248|NCT01008527|BIOLOGICAL|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
48295450|NCT05382676|DEVICE|Eyeswift Pro|assessment of visual function parameters
48295451|NCT00929578|DRUG|Fluphenazine|Intralesional injection of Fluphenazine
48295452|NCT00929578|DRUG|Placebo|Intralesional injection of placebo
48634249|NCT03276481|DIAGNOSTIC_TEST|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
48295453|NCT03488810|OTHER|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
48295454|NCT03488810|DRUG|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
48295455|NCT03488810|DRUG|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
48295456|NCT03488810|DRUG|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
48295457|NCT05462587|DRUG|AVTX-803 (L-Fucose)|L-fucose crystalline powder
48295458|NCT06004115|DRUG|Lorazepam|1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
48295459|NCT06004115|OTHER|Placebo|placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
48634250|NCT03276481|DIAGNOSTIC_TEST|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
48295460|NCT06572267|DRUG|Mepolizumab low dose group|Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
48295461|NCT06572267|DRUG|Mepolizumab middle dose group|Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
48295462|NCT06572267|DRUG|Mepolizumab high dose group|Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
48295463|NCT06572267|DRUG|Saline|Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.
48295464|NCT05365295|OTHER|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
48295466|NCT06673251|OTHER|motor and sensory assessments, surveys|It does not include any intervention. Only evaluation will be made.
48295467|NCT02406872|DRUG|Remimazolam Tosilate|IV pumping for anesthesia
48295468|NCT02406872|DRUG|Propofol|IV bolus for anesthesia
48295469|NCT06671405|DRUG|AZD0780|Dose 1
48295470|NCT06671405|DRUG|Itraconazole|"* Period 2 (itraconazole administration only).~* Period 3 (AZD0780 + itraconazole administration)."
48295471|NCT06671405|DRUG|Carbamazepine|"* Period 2 (carbamazepine administration only).~* Period 3 (AZD0780 + carbamazepine administration only)."
48295472|NCT06672003|DIAGNOSTIC_TEST|4 meter walking speed and hand grip strength|4 meter walking seconds are noteed for each of participants
48295473|NCT06110234|BEHAVIORAL|Episodic Specificity Induction|Recalling complex scenes using the Episodic Specificity Induction
48295474|NCT06110234|BEHAVIORAL|Associative Memory|Recalling word/picture pairs
48295475|NCT05519761|DEVICE|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
48295476|NCT02144220|OTHER|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
48295477|NCT03372057|DRUG|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
48295478|NCT03372057|DRUG|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
48295479|NCT03372057|DRUG|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)
48295480|NCT03635190|DEVICE|Orbital Circumferential Atherectomy|Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
48295481|NCT00107107|DRUG|pramlintide acetate|Syringe vial and Pen-cartridge
48295482|NCT01011205|DRUG|Advagraf|Capsule
48295483|NCT01011205|DRUG|Mycophenolate Mofetil|Solution for infusion
48295484|NCT01011205|DRUG|Basiliximab|IV infusion
48295485|NCT01011205|DRUG|Corticosteroids|IV bolus
48295486|NCT02399475|DRUG|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
48295487|NCT02399475|DRUG|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
48295488|NCT02399475|DRUG|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
48295489|NCT00000581|PROCEDURE|leukocyte transfusions|
48295490|NCT03177837|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
48295491|NCT03177837|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
48295492|NCT04251585|DRUG|Regular Novolin R|Intranasal insulin
48295493|NCT04251585|DRUG|Placebo|Intranasal placebo (0.9% saline)
48295494|NCT04388657|DIAGNOSTIC_TEST|Echo-Doppler|Utrasound Doppler of the lower limbs
48295495|NCT05611463|DRUG|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
48295496|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.
48295497|NCT06036108|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
48295498|NCT04086303|OTHER|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
48295499|NCT01179763|OTHER|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
48295500|NCT04001751|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
48295501|NCT01459107|PROCEDURE|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
48295502|NCT01459107|DRUG|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
48295503|NCT04520698|BEHAVIORAL|UPLIFT-AD|Access to palliative care needs screening, advance care planning conversations, palliative care consultations
48295504|NCT02475460|PROCEDURE|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
48295505|NCT02475460|DEVICE|HeartMate 3™|HM 3 LIS
48295506|NCT02369835|DRUG|Dakin's solution|Apply modified Dakin's solution (0.005 to 0.01%) topically
48295507|NCT02369835|OTHER|Placebo|Applied topically
48295508|NCT04164212|DRUG|Flumist Quadrivalent Nasal Product|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
48295509|NCT03336840|DRUG|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
48295510|NCT03336840|DRUG|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
48295511|NCT03336840|DRUG|1. Metformin tablets; 2. ProMetS probiotics powder|"1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
48295512|NCT06671834|DRUG|PF-07905428|Topical solution of PF-07905428 0.08% or PF-07905428 0.24%
48295513|NCT06671834|DRUG|Placebo|Topical solution of placebo
48295514|NCT02417220|BEHAVIORAL|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
48295515|NCT02417220|OTHER|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
48295516|NCT05707845|DRUG|Medical treatment.|Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
48295517|NCT05707845|BEHAVIORAL|weight reduction|weight reduction in the form low caloric diet program for 12 weeks.
48295518|NCT05707845|OTHER|exercise|aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
48295519|NCT02471131|DEVICE|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
48295520|NCT02119104|DRUG|Prevenar (13v)|Prevenar (13v)
48295521|NCT02444169|DEVICE|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
48295522|NCT02444169|DRUG|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
48295523|NCT02444169|DEVICE|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
48295524|NCT02444169|DEVICE|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
47946035|NCT05386576|DRUG|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
48476600|NCT04502498|DIAGNOSTIC_TEST|Lower limb duplex & doppler|Lower limb duplex and doppler one week before radical cystectomy
48476601|NCT03509571|OTHER|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
48476602|NCT03509571|OTHER|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
48476603|NCT01758341|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
48476604|NCT01758341|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
48476605|NCT01758341|DEVICE|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
48476606|NCT06616376|OTHER|Anti-Embolism Stocking|To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.
48476607|NCT02483338|BEHAVIORAL|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
48476608|NCT04235257|BIOLOGICAL|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
47946036|NCT03049618|OTHER|Laboratory Biomarker Analysis|Correlative studies
47946037|NCT03049618|BIOLOGICAL|Pembrolizumab|Given IV
47946038|NCT03049618|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
47946039|NCT01690026|BEHAVIORAL|Motivation interviewing based brief intervention|
47946040|NCT01690026|BEHAVIORAL|Standard Intervention|
48295525|NCT03311178|DRUG|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
48295526|NCT03870581|BEHAVIORAL|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
48295527|NCT03870581|BEHAVIORAL|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
48295528|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
48295529|NCT01272180|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
48295530|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
48295531|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
48295532|NCT03932136|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
48295533|NCT03932136|COMBINATION_PRODUCT|Placebo|The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
48295534|NCT03253198|DRUG|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
48295535|NCT03253198|DRUG|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
48295536|NCT05924360|OTHER|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
48295537|NCT05924360|OTHER|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
48295538|NCT05924360|OTHER|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
48295539|NCT05924360|DEVICE|TENS|TENS application will be administered for 20 minutes at 100Hz
48295540|NCT04501653|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
48295541|NCT04501653|DRUG|Methylphenidate|Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
48295542|NCT04507308|BEHAVIORAL|Single-session sleep intervention drawn from principles of the TranS-C youth protocol|We are providing participants psychoeducation on sleep and will be going over several handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth) to improve sleep.
48295543|NCT00052429|DRUG|cisplatin|
48295544|NCT00052429|DRUG|fluorouracil|
48295545|NCT00052429|PROCEDURE|adjuvant therapy|
48295546|NCT00052429|RADIATION|radiation therapy|
48295547|NCT00601289|DRUG|temozolomide|
48295548|NCT00601289|GENETIC|DNA methylation analysis|
48295549|NCT00601289|GENETIC|microarray analysis|
48295550|NCT00601289|GENETIC|protein expression analysis|
48295551|NCT00601289|GENETIC|proteomic profiling|
48295552|NCT00601289|OTHER|laboratory biomarker analysis|
48295553|NCT04002453|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
48295554|NCT02393651|DEVICE|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
48295555|NCT05297305|DEVICE|Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
48295556|NCT05297305|DEVICE|Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
48295557|NCT06671938|DRUG|exidavnemab|The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
48295558|NCT06671938|DRUG|Placebo Comparator|The trial medication will be administered as an intravenous (IV) infusion
48295559|NCT04797013|DRUG|rt-PA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
48295560|NCT04797013|DRUG|rhTNK-tPA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
48295561|NCT00391638|DRUG|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
48295562|NCT00391638|BIOLOGICAL|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
48295563|NCT06673303|BEHAVIORAL|Dynamic perceptual discrimination task|The study featured two task conditions, each of which required the integration of information from both stimulus dimensions. In each condition, participants viewed a stimulus containing motion and color information and were required to specify one of two possible responses. Within each condition, rules and the response mapping changed occasionally, but always by changing on a fixed feature dimension (ie. rightward/purple, leftward/orange). These uncued intra-dimensional shifts involved translational shifts in the learning boundary, requiring them to adapt their decision making within a familiar dimension. These shifts compelled participants to continuously adjust their learning strategies by focusing on the most relevant feature dimension.
48295564|NCT06673303|DIAGNOSTIC_TEST|fMRI|Participant brain imaging data will be collected concurrently while performing the perceptual discrimination task.
48634251|NCT03276481|DIAGNOSTIC_TEST|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
48634252|NCT03276481|BEHAVIORAL|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
48634253|NCT05853159|OTHER|Basic Laboratory investigations , Cerebrospinal fluid analysis|to detect severity and prognostic factors of Acute Necrotizing Encephalopathy
48295565|NCT01949493|DEVICE|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
48295566|NCT01949493|OTHER|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
48476609|NCT01556867|OTHER|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
48476610|NCT01556867|OTHER|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
48634254|NCT00800384|DEVICE|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
48634255|NCT06049277|OTHER|Mulligan techniques with manual traction|group A will be treated with Mulligan techniques with manual traction.16 patients in group A will be treated with Mulligan Techniques SNAGS in sitting, standing and prone position by applying Antero cranial glide in the direction of treatment plane over the spinous or transverse process and Spinal mobilization with leg movement at 6 to 8 repetitions per sessions and spinal mobilization with leg movement will be performed in side lying, patient facing the physiotherapist while the leg movement may assisted by another person (Physiotherapist/assistant). Sustained transverse glide is given on the desired spinous process with 10 repetitions of offending movement in first session while 10 reps in each of 3 sets in further sessions.
48634256|NCT06049277|OTHER|McKenzie extension exercises with manual traction|group B will be treated McKenzie extension exercises with manual traction.16 patients in group B will be treated with McKenzie active EEP in prone position with repeated movements along with standard protocols. McKenzie Extension Exercises performed actively in prone position. Extension exercises performed in three stages, initially patient instructed to be just lift the neck and look on front at the eye level, then progressed next and weight bearing on the elbow by lifting up the shoulder and then moved on third and final steps in which complete trunk extension is performed and weight bearing is on the hands.
48634257|NCT04464902|DEVICE|brace1|The brace1 can provide resistance when patients want to extend their knee.
48476611|NCT05981287|OTHER|Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
48476612|NCT05981287|OTHER|Gross motor task training and Conventional physical therapy (CPT)|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
48476613|NCT01363466|PROCEDURE|hysterectomy|
48476614|NCT03758573|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT)
48476615|NCT03758573|OTHER|Intensive Physiotherapy (IPT)|Intensive Physiotherapy (IPT)
48476616|NCT00560924|DRUG|estradiol, 25 mcg|
48476617|NCT05057793|DEVICE|geko|The geko device will be self-administered and deliver 12 hours of therapy daily.
48476618|NCT03992339|DRUG|ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
48476619|NCT04913519|DRUG|TDM-105795|TDM-105795 topical solution
48476620|NCT04913519|DRUG|Placebo|Placebo for TDM-105795 topical solution
48476621|NCT05062915|DIAGNOSTIC_TEST|HINTS|HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
48634258|NCT04464902|DEVICE|brace2|The brace1 can't provide resistance when patients want to extend their knee.
48476622|NCT04006938|BEHAVIORAL|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
48476623|NCT04006938|BEHAVIORAL|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
48476624|NCT05116787|DRUG|BCX9930 monotherapy|Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
48476625|NCT05116787|DRUG|Placebo|Administered orally twice daily
48634259|NCT04464902|OTHER|No Intervention|Control Group don't have any brace.
48634260|NCT05634928|OTHER|collection data|collection data
48634261|NCT04129801|OTHER|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
48295567|NCT04182191|DRUG|Tenoxicam|After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
48295568|NCT00363025|PROCEDURE|Two post-remission strategies|
48295569|NCT00363025|DRUG|Idarubicin versus daunorubicin|
48295570|NCT02619240|PROCEDURE|bronchoscopy|performance of bronchoscopy with BAL
48295571|NCT05913557|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
48295572|NCT00389415|DRUG|Vildagliptin|
48295573|NCT04383977|DRUG|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
48295574|NCT04383977|DRUG|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
48295575|NCT06079281|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
48634262|NCT04129801|OTHER|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
48634263|NCT03396458|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
48634264|NCT03396458|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
48634265|NCT00394472|DRUG|AZD3355|
48476626|NCT04449224|DRUG|Adalimuab, Etanercept, Tocilizumab, or Abatacept|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
48634266|NCT02383173|OTHER|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
47946041|NCT01086423|BIOLOGICAL|Infanrix-IPV/Hib™|Intramuscular, three doses
48634267|NCT02383173|OTHER|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
48634268|NCT05268120|DRUG|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
48634269|NCT05268120|DRUG|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
48634270|NCT00138970|DRUG|Zenapax®, CellCept® and prednisolone|
48634271|NCT00138970|DRUG|Sandimmun Neoral®, CellCept® and prednisolone|
48634272|NCT01713738|DRUG|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
48634273|NCT01404260|DRUG|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
48634274|NCT01404260|DRUG|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
48634275|NCT02681042|PROCEDURE|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
48634276|NCT02681042|DEVICE|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
47946042|NCT01086423|BIOLOGICAL|Infanrix Hib™|Intramuscular, three doses
47946043|NCT01086423|BIOLOGICAL|Poliorix™|Intramuscular, three doses
47946044|NCT01749774|BEHAVIORAL|Physical activity counseling|
47946045|NCT01131767|DRUG|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
47946046|NCT01969643|DRUG|ladiratuzumab vedotin|LV will be given into the vein (IV; intravenously)
47946047|NCT01969643|DRUG|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
47946048|NCT02422316|OTHER|Non-contrast Cardiac CT scan|
47946049|NCT01795638|DRUG|Sodium chloride|
47946050|NCT01795638|DRUG|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
48295576|NCT06079281|DRUG|Placebo|Placebo will be administered via SC injection.
48295577|NCT01206595|DRUG|SKY0402|Single dose of SKY0402 administered as a nerve block
48295578|NCT01206595|DRUG|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
48295579|NCT03792919|DRUG|Stop current treatment (anti-HBV neucleos(t)ides)|Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
48295580|NCT03792919|DRUG|Keep current treatment (anti-HBV neucleos(t)ides)|Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
48295581|NCT02151539|OTHER|medical chart review|Ancillary studies
48634277|NCT04516200|DEVICE|transcranial direct current stimulation and traditional physical therapy program|Transcranial stimulation will be applied only for the study group.
48634278|NCT04516200|OTHER|designed physical therapy program|sensory training and balance training
48634279|NCT06059079|OTHER|No Intervention|No Intervention
48634280|NCT01706380|BEHAVIORAL|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
48634281|NCT01706380|BEHAVIORAL|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
48634282|NCT04956965|RADIATION|Cardiac electro-mapping|Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
48634283|NCT00073047|DRUG|Daclizumab|
48634284|NCT05267002|PROCEDURE|Suture removal timing|Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
48634285|NCT05446155|DIAGNOSTIC_TEST|Imaging|Diagnostic and prognostic imaging, omics and machine learning methods will be applied
48634286|NCT06479057|OTHER|Supportive Care Pathway|All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
48295582|NCT02151539|OTHER|quality-of-life assessment|Ancillary studies
47946051|NCT04738409|OTHER|Lifestyle intervention|The purpose of the research is to evaluate the potential of a multidimensional lifestyle program for PCOS girls. The primary aim is to verify the effectiveness of a 16-week AID intervention vs. HCD (combined with PA\&T), in terms of improvement in androgens level and immune-metabolic risk parameters
47946052|NCT04738409|OTHER|Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls|The purpose of the intervention is to evaluate the effectiveness of the anti-inflammatory diet (AIDiet) among normal weight (N) and overweight/obese (Ov/Ob) women with PCOS.
48476627|NCT04449224|DRUG|Tofacitinib or Baricitinib|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
48634287|NCT06082544|OTHER|mini-screw implant|JEIL SCREW 1.6\* 8 MM 16-G2-008 or JEIL SCREW 1.6\*10 MM 14-G2-010
48634288|NCT06082544|DEVICE|removable partial denture|Acrylic removable partial denture
48634289|NCT02495935|DEVICE|OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
48634290|NCT02495935|DEVICE|Sham-OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
48634291|NCT05039593|OTHER|chlorhexidine|The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
48634292|NCT03952520|OTHER|Standard Approach (SA)|The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
48634293|NCT03952520|OTHER|Tailored Approach (TA)|The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
47946053|NCT04732169|DRUG|Active study drug ( oral CBD)|CBD in single dose syringes
48634294|NCT02965131|PROCEDURE|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
48634295|NCT03144635|DRUG|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
48295583|NCT06306638|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
48295584|NCT06306638|PROCEDURE|Computed Tomography|Undergo CT
48295585|NCT06306638|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo EBUS
48634296|NCT04167761|DRUG|Ertugliflozin|Consenting participants in the Ertugliflozen group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
48634297|NCT04167761|DRUG|Glipizide|Consenting participants in the Glipizide group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
48103939|NCT04302155|OTHER|balance-specific -games focusing on dynamic aspects of COP on Wii fit system.|"The participants were randomly assigned into two groups interventional and control. Total 18 minutes session was given to both groups wii fit group and traditional balance training group. All participants were given 3 sessions per week for 6.~Total 48 participants were initially accessed initially for eligibility , 13 participants were excluded because of having good balance and good balance age score on Wii fit assessment, 35 participants were recruited for balance training. These participants were randomly divided into Wii fit and traditional training group through sealed enveloped method 18 participants was recruited in Wii fit group and 17 in traditional balance training group. 3 participants drop out from Wii fit group and 2 from traditional balance training group.~Some examples include catching apples in a basket ,moving a golf ball around barriers towards a hole , popping rising balloons/bubbles and air hockey ."
48634298|NCT00795795|PROCEDURE|Preimplantation Genetic Screening|Preimplantation Genetic Screening
48634299|NCT00795795|PROCEDURE|IVF without PGS|IVF without PGS
48634300|NCT03555097|PROCEDURE|incremental pressure support|Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
48634301|NCT00797901|OTHER|Collaborative Care|
48634302|NCT03855371|DRUG|Decitabine|20mg/m2/d, intravenously, d1-d5, q4w
48634303|NCT03855371|DRUG|Arsenic Trioxide|0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
48634304|NCT04599335|DEVICE|2% HA|2% HA
48634305|NCT00962455|OTHER|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
48634306|NCT00962455|OTHER|usual practice|Usual practice regarding spirometry execution in family practice
48634307|NCT01433003|PROCEDURE|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
48634308|NCT02213991|DEVICE|Intraoperative radiotherapy using Intrabeam®|"Operation day~1. Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~2. Purse string suture pulles up tissues and wraps up the applicator.~3. Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~4. After IORT, applicator was out of the operative field, and usual wound closure will be done.~   * Postoperative period~     * Chemotherapy WBRT (46 Gy) for 4\~5 weeks~    * Endocrine therapy or target therapy"
48634309|NCT02099591|DRUG|Naloxegol|Opioid Antagonist
48634310|NCT05823883|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition"
48634311|NCT02792946|DRUG|Acebrophylline|
48634312|NCT02329275|PROCEDURE|Testicular biopsy|
48634313|NCT03148782|BEHAVIORAL|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
48634314|NCT04002557|OTHER|Interview-Questionnaire|Questionnaire
48634315|NCT03685435|OTHER|Bedside ultrasound|Checking for gastric content using bedside ultrasound
48634316|NCT04953260|OTHER|APRF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of APRF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of APRF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with APRF film
48634317|NCT04953260|OTHER|CGF|20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of CGF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of CGF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with CGF film
48634318|NCT04942509|BEHAVIORAL|Coloring as a brief mindfulness-based intervention|Participants watched an instructional video on mindful coloring at the beginning of the intervention and colored mindfully for at least 5 days or 100 minutes in total during a 10-day period. The intervention included a coloring booklet that contained mandala patterns for coloring.
47946054|NCT04732169|DRUG|matching placebo|Placebo made with sesame oil flavored with strawberry flavoring in single dose syringes
48634319|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline"
48634320|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
48634321|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
48634322|NCT01529112|DRUG|Lenvatinib|
48634323|NCT01529112|DRUG|Lenvatinib matched placebo|
48634324|NCT01529112|DRUG|BSC|
48634325|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing, externally chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the subgoal chosen by the study coordinator. Subgoals will gradually increase from the participant's baseline adherence up to 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
48634326|NCT05378607|BEHAVIORAL|End of year 1 adherence prize drawing|Participants will have a chance to participate in a prize drawing at the end of year 1 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on reaching 90% in the three months preceding the end of year 1.
48634327|NCT05378607|BEHAVIORAL|SMS motivational messages + reminder of prize drawing|Participants will receive weekly motivational messages with a reminder of their upcoming prize drawing throughout year 1 of the study.
48634328|NCT05378607|BEHAVIORAL|Year 2 re-allocation based on year 1 performance|In Year 2 of the study, participants who have reached 90% by the end of year 1 will no longer be given sub-goals and instead will be eligible for prize drawings if they maintain the fixed level of 90% or higher. Those who have not reached 90% by the end of year 1 will be allocated to the intervention group that showed the highest effectiveness in year 1.
48634329|NCT05378607|BEHAVIORAL|End of Year 2 viral suppression prize drawing|Participants will have a chance to participate in a prize drawing at the end of Year 2 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on achieving viral suppression by the end of Year 2.
47946055|NCT05137990|BEHAVIORAL|HIIT Exercise Intervention|Exercise trainers will provide encouragement and supervision for exercise prescription adherence and youth will select an age-appropriate music playlist from Spotify to enhance enjoyment throughout each session. Each exercise session consists of a 5-minute warm-up (10% HRmax), followed by a 20-minute HIIT protocol. The 20-minute HIIT protocol consists of seven bouts of 1-min high intensity exercise (90% HRmax) followed by 2-min of active recovery (10% HRmax). Participants will be encouraged to complete each exercise session with at least 24 hours of rest between each session.
48103940|NCT04302155|OTHER|mini trampoline and inflatable discs group|"High skipping and landing on a limb every time (2 repeats of 45 s each leg).Standing on one leg and try to catch the ball thrown at them in various directions by the researcher (2 repeats of 45 s each leg) Exercises in inFlated rubber hemisphere attached toa rigid platform (BOSU)~1. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance (2 repeats of 45 s each leg).~2. Standing on BOSU's round soft surface with one foot, in an attempt to maintain balance, while lifting the non-support leg forward and backward (2 repeats of 45 s each leg).~3. Standing on BOSU flat hard surface with both legs, in an attempt to maintain balance (3 minutes on both legs).~4. Standing on BOSUs flat hard surface with both feet, in an attempt to maintain balance, while trying to catch the ball thrown at them by the experimenter in various directions (3 minutes on both leg)"
47946056|NCT05137990|BEHAVIORAL|Stretching Intervention|This group will perform a home-based program of the same stretches utilized in the exercise group. The stretching protocol consists of one set of 4 static stretching exercises held for 30 seconds and performed 3 days/week. As flexibility exercises are low-intensity, low-impact and low-volume, minimal caloric expenditure is expected to be incurred. To increase compliance and aid in the standardization of the home-based stretching, participants will be provided a booklet of the flexibility exercises. Participants will be shown how to use the booklet and instructed in the stretching exercises by an exercise trainer prior to the intervention.
47946057|NCT02239627|DRUG|Epidural steroid|
47946058|NCT02239627|DRUG|Clonidine|
48103941|NCT00810550|OTHER|Carotid ultrasound|Measurement of intima-media thickness
48103942|NCT04715373|PROCEDURE|LISA|LISA administered in the DR after initial resuscitation or in the NICU after stepwise escalation of CPAP based on FiO2 ≥0.3. While maintaining infant on CPAP with binasal prongs/small nasal mask, a thin catheter (Hobart method) is inserted below the vocal cord using direct laryngoscopy. Poractant alfa (200mg/kg) is administered slowly over 2-3 minutes. Catheter is then withdrawn and infant is maintained on CPAP
48103943|NCT00198848|DRUG|Iron-folic acid supplement|
48103944|NCT03694678|BEHAVIORAL|Recovering Together|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
48103945|NCT03148990|BIOLOGICAL|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
48634330|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing self-chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the self-chosen subgoal. While self-chosen, subgoals are subject to a minimum threshold determined by baseline adherence working towards 90% adherence. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
48295586|NCT06306638|PROCEDURE|Interstitial Photodynamic Therapy|Undergo I-PDT
48295587|NCT06306638|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
48295588|NCT06306638|OTHER|Physical Performance Testing|Ancillary studies
48295589|NCT06306638|OTHER|Questionnaire Administration|Ancillary studies
48295590|NCT06306638|DRUG|Verteporfin|Given IV
48295591|NCT06306638|DEVICE|Laser: ML7710-PDT|Measuring tumor response
48295592|NCT03418662|DEVICE|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
48295593|NCT04953637|OTHER|Physiotherapy|Participants in the physiotherapy group will receive gait and balance focused physiotherapy at One Step Ahead Mobility physiotherapy clinic for 1-hour per day, 3 times/week for 8 weeks.
48295594|NCT00775372|DRUG|Clarithromycin 250mg/5mL|
48295595|NCT04844671|DEVICE|da Vinci Surgical Systems|The da Vinci Surgical Systems enable surgeons to perform delicate and complex operations through a few small incisions with robotic assisted surgery.
48634331|NCT05378607|BEHAVIORAL|Incentivization based on a fixed adherence goal|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000 or 10,000 Ugandan Shillings if adherence matches or exceeds the fixed adherence goal of 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
48295596|NCT04879446|PROCEDURE|Concentrated growth factor(CGF)|Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.
48295597|NCT04879446|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.
48295598|NCT04879446|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied.
48295599|NCT04879446|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied.
48295600|NCT04599816|DRUG|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
48295601|NCT04599816|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
48295602|NCT04599816|DRUG|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
48295603|NCT02221739|DRUG|Ipilimumab|
48295604|NCT02221739|RADIATION|Radiotherapy (IMRT or 3-D CRT)|
48295605|NCT06274489|DRUG|Setanaxib|Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4. It is a low molecular weight organic molecule and a member of the pyrazolopyridine dione chemical class.
48634332|NCT05378607|BEHAVIORAL|SMS motivational messages|The control group will also receive weekly motivational messages but without the reminder of the upcoming prize drawing.
48634333|NCT01520662|OTHER|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
48634334|NCT03724227|DRUG|ACE-011|ACE-011 will be administered subcutaneous injection
48295606|NCT06274489|DRUG|Placebo|Matching film-coated placebo tablets, containing only excipients
48295607|NCT06622109|BIOLOGICAL|20-valent Pneumococcal Conjugate Vaccine|Injection in the muscle or subcutaneous , 1 dose 0.5mL
48295608|NCT06012604|BIOLOGICAL|allogeneic mesenchymal stromal stem cells|mesenchymal stromal stem cells injection under ultrasound guidance into parotid and submandibular glands
48476628|NCT01293266|DRUG|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
48295609|NCT02050932|DIETARY_SUPPLEMENT|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
48295610|NCT01479049|DRUG|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
48295611|NCT01479049|DRUG|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
48295612|NCT01048515|DRUG|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
48295613|NCT06672068|DRUG|TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
48295614|NCT06672068|DRUG|TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
48295615|NCT04016493|PROCEDURE|Connective tissue graft|The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
48476629|NCT01722955|OTHER|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
48476630|NCT01722955|OTHER|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
48476631|NCT03701763|DRUG|Apremilast (CC-10004)|Apremilast (CC-10004)
48634335|NCT03422471|OTHER|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
48295616|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
48295617|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
48295618|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
48295619|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
48295620|NCT01174914|OTHER|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
48295621|NCT01174914|DRUG|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
48295622|NCT01174914|DRUG|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
48295623|NCT03116529|COMBINATION_PRODUCT|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as \>10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
48295624|NCT03178461|OTHER|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
48295626|NCT04874038|DRUG|Lidocaine 20mg/ml|Patients in the intervention group will receive an IV lidocaine infusion using a dosage regimen of 1.5 mg/kg bolus of a 2% lidocaine solution with induction of general anesthesia followed by a 2.0 mg/kg/hour infusion until the end of surgery (and up to 30 minutes into recovery room).
48295627|NCT04874038|DRUG|Placebo|Patients in the control group will receive a placebo bolus and infusion with normal saline (0.9% sodium chloride solution) until the end of surgery (and up to 30 minutes into recovery room).
48295628|NCT03507140|OTHER|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
48634336|NCT05436912|DRUG|Selpercatinib|Administered orally.
48295629|NCT05414123|DEVICE|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
48295630|NCT04238663|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
48295631|NCT04238663|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
48295632|NCT04238663|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
48295633|NCT02112604|DEVICE|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
48634337|NCT04250363|BIOLOGICAL|PfSPZ Challenge|Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
48634338|NCT04250363|DRUG|Palcebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
48295634|NCT02112604|DEVICE|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
48295635|NCT02112604|OTHER|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
48295636|NCT02112604|OTHER|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
48295637|NCT02112604|OTHER|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
48295638|NCT02112604|DRUG|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
48295639|NCT06573814|DIETARY_SUPPLEMENT|Bio Gelee Royale Forte|Two capsules of Bio Gelee Royale Forte will be taken in the morning on empty stomach once per day for 98 days.
48295640|NCT06573814|OTHER|Placebo|Two capsules of placebo will be taken in the morning on empty stomach once per day for 98 days.
48634339|NCT04250363|DRUG|M5717 30 mg|Participants received 30 mg single oral dose of M5717 capsule on Day 1.
48634340|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 1.
48634341|NCT04250363|DRUG|M5717 80 mg|Participants received 80 mg single oral dose of M5717 capsule on Day 1.
48634342|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 1.
48103946|NCT03148990|BIOLOGICAL|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
48103947|NCT00530335|DRUG|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
48103948|NCT05038072|DRUG|suprachoroidal injection of Triamcinolone Acetonide.|4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
48634343|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 1.
48634344|NCT04250363|DRUG|Placebo|Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
48634345|NCT04250363|DRUG|M5717 60 mg|Participants received 60 mg single oral dose of M5717 capsule on Day 5.
48634346|NCT04250363|DRUG|M5717 100 mg|Participants received 100 mg single oral dose of M5717 capsule on Day 5.
48634347|NCT04250363|DRUG|M5717 200 mg|Participants received 200 mg single oral dose of M5717 capsule on Day 5.
48634348|NCT00378560|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
48634349|NCT00378560|BIOLOGICAL|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
48634350|NCT05241210|DEVICE|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
48634351|NCT05936853|OTHER|Intravenous approach to anaesthetic maintenance|Anaesthetic agents given directly into the bloodstream via a cannula.
48634352|NCT05936853|OTHER|Inhalational approach to anaesthetic maintenance|Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
48634353|NCT00385229|DRUG|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
48634354|NCT04677036|OTHER|No intervention is given|No intervention given
48634355|NCT03598764|PROCEDURE|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
48634356|NCT03598764|PROCEDURE|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
48634357|NCT02975453|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
48634358|NCT00337961|PROCEDURE|Optic Nerve Sheath Fenestration|
48634359|NCT00908661|DEVICE|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
48634360|NCT03765021|DRUG|Tranexamic Acid|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
48634361|NCT03765021|DEVICE|Fractional CO2 laser|The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
48634362|NCT03090035|DRUG|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
48634363|NCT03090035|DRUG|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
48634364|NCT04643431|DIAGNOSTIC_TEST|Perflutren|The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
48634365|NCT00300495|DRUG|Amiodarone|Perioperative orally administered
48634366|NCT00300495|OTHER|Control arm, standard care|Control
48634367|NCT04626531|OTHER|Web-Based Education|Participants in the intervention group had unlimited access to the Web site, free of charge. The Web site was designed to run on personal computers and smartphones.
48103949|NCT01141933|OTHER|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
48103950|NCT01141933|OTHER|Usual care|This group receive the usual treatment only.
48295641|NCT03109951|DRUG|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
48634368|NCT04626531|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
48634369|NCT00585169|DRUG|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
48634370|NCT03883451|OTHER|Helmet Model|helmet model worn by football players
48634371|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
48634372|NCT00638079|DRUG|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
48634373|NCT04449809|BEHAVIORAL|Exercise program|3x per week group monitored group exercise sessions
48634374|NCT04303403|DRUG|Trametinib|Taken orally once daily
48634375|NCT04303403|DRUG|Ruxolitinib|Taken orally twice daily
48634376|NCT04992741|OTHER|education and motivational interview|The control group will remain subject to the routine process without any intervention.
48634377|NCT00862901|DEVICE|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
48634378|NCT03197272|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
48634379|NCT06197516|OTHER|Integrated Neuromuscular Inhibition Technique|After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.
48634380|NCT06197516|OTHER|Neuromuscular Reeducation Technique|Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required
48634381|NCT00936039|BEHAVIORAL|unloading|2 weeks of unloading of a single leg
48634382|NCT04604093|DEVICE|SMBG Meter|Self Monitoring Blood Glucose Meter
48634383|NCT04604093|DEVICE|FreeStyle Libre 2 System|The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
48634384|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
48634385|NCT00743080|PROCEDURE|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
47946059|NCT04048551|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
48634386|NCT00090402|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
48476632|NCT03701763|OTHER|Placebo|Placebo
48634387|NCT00090402|DIETARY_SUPPLEMENT|Lipoic Acid|Lipoic acid capsule
48634388|NCT00090402|OTHER|Fish Oil Placebo|Soybean oil placebo capsule
48634389|NCT00090402|OTHER|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
48634390|NCT04147741|DIETARY_SUPPLEMENT|Pre-Workout Supplement|"One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin."
48634391|NCT04147741|OTHER|Resistance Training|-Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
48634392|NCT04147741|OTHER|Endurance Training|- Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (\~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
48634393|NCT01275937|DRUG|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
48103951|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
48476633|NCT05029934|PROCEDURE|use of EndoClot|deployment of EndoClot adhesive spray
48103952|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
48295642|NCT00813956|DRUG|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
48295643|NCT06007170|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
48295644|NCT00717470|DRUG|Prograf®|oral
48295645|NCT00717470|DRUG|Advagraf®|oral
48295646|NCT00717470|DRUG|Mycophenolate Mofetil|oral
48295647|NCT00717470|DRUG|Simulect|oral
48295648|NCT00717470|DRUG|methylprednisolone / prednisone|oral
48295649|NCT02349230|OTHER|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
48295650|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
48295651|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
48295652|NCT00281411|PROCEDURE|Computed Tomography Angiography|Computed Tomography Angiography
48295653|NCT00281411|PROCEDURE|Magnetic Resonance Angiography|Magnetic Resonance Angiography
48295654|NCT02253875|DRUG|Tipranavir (TPV)|
48295655|NCT02253875|DRUG|Ritonavir|
48295656|NCT02253875|DRUG|Omeprazole|
48103953|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
48103954|NCT01372163|DRUG|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
48295657|NCT05725148|DEVICE|CART-I plus|CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
48295658|NCT03279237|DRUG|Irinotecan|May help shrink tumor before surgery.
48476634|NCT03747185|OTHER|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
48476635|NCT03747185|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
48476636|NCT03793920|OTHER|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
48634394|NCT01275937|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
48634395|NCT00274794|BIOLOGICAL|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
48634396|NCT00274794|BIOLOGICAL|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
48103955|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
48295659|NCT03279237|DRUG|Oxaliplatin|May help shrink tumor before surgery.
48295660|NCT03279237|DRUG|Leucovorin|May help shrink tumor before surgery.
48295661|NCT03279237|DRUG|5-Fluorouracil|May help shrink tumor before surgery.
48295662|NCT03279237|DRUG|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
48295663|NCT03279237|RADIATION|Radiation Therapy|May help shrink tumor.
48295664|NCT03279237|DRUG|Carboplatin|Carboplatin may stop cancer cells from growing.
48295665|NCT06671509|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
48295666|NCT03271827|DEVICE|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
48295667|NCT03942328|BIOLOGICAL|Atezolizumab|Given IV
48295668|NCT03942328|BIOLOGICAL|Bevacizumab|Given IV
48295669|NCT03942328|RADIATION|External Beam Radiation Therapy|Undergo high-dose EBRT
48295670|NCT03942328|PROCEDURE|Pheresis|Undergo apheresis
48295671|NCT03942328|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
48295672|NCT03942328|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given IT
48295673|NCT06671015|DEVICE|Airvo 3|Provides effective therapy for acute hypoxemic respiratory failure and post-extubation respiratory support for 24 hours post-extubation.
48295674|NCT02988986|DRUG|TAK-228|MTORC1/2 inhibitor
48295675|NCT02988986|DRUG|Tamoxifen|Non-steroidal anti-estrogen
48634397|NCT06199999|PROCEDURE|Erector Spinae Block|General anesthesia with Erector Spinae Plane Block
48295676|NCT00538603|DRUG|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
48634398|NCT06199999|PROCEDURE|Local infiltration with local anesthetic|General anesthesia with local infiltration of local anesthetic:
48634399|NCT01431547|DRUG|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m\^2, and escalated for successive cohorts of participants until MTD is found
48634400|NCT01431547|DRUG|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
48634401|NCT01431547|DRUG|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
48634402|NCT02620111|DIETARY_SUPPLEMENT|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
48634403|NCT02620111|DIETARY_SUPPLEMENT|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
48634404|NCT01666652|BIOLOGICAL|4 µg TDENV-PIV with Alum adjuvant|
48634405|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS03B1 adjuvant|
48634406|NCT01666652|OTHER|Phosphate buffered saline|
48634407|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
48634408|NCT01666652|BIOLOGICAL|1 µg TDENV-PIV with AS01E1 adjuvant|
48634409|NCT00374985|DRUG|Docetaxel, Oxaliplatin|weekly doses
48634410|NCT00374985|PROCEDURE|Radiotherapy|regular fractions
48634411|NCT01037465|DRUG|N-acetylcysteine|N-acetylcysteine
48295677|NCT00538603|DRUG|Paclitaxel & Carboplatin|Chemotherapy
48295678|NCT05822999|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
48295679|NCT05822999|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
48295680|NCT04795440|PROCEDURE|Testicular biopsy|Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
48295681|NCT05970640|DRUG|BI 3006337|BI 3006337
48476637|NCT06295094|DRUG|Cisplatin|10.5 mg/m2 body surface in 150ml saline
48476638|NCT06295094|DRUG|Doxorubicin|2.1 mg/m2 body surface in 50ml saline
48476639|NCT05987085|OTHER|Diet and exercise|Routine intervention included diet control and exercise
48476640|NCT01353248|DRUG|GS-5885|tablet, 30 mg QD
48476641|NCT01353248|DRUG|Tegobuvir|capsule, 30 mg BID
48476642|NCT01353248|DRUG|GS-9451|tablet, 200 mg QD
48476643|NCT01353248|DRUG|ribavirin tablet|(weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
48476644|NCT01353248|DRUG|GS-5885|tablet, 90 mg QD
48476645|NCT03417830|DRUG|GSK2315698 (CPHPC)|GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
48476646|NCT03417830|DRUG|GSK2398852 (unlabeled anti-SAP mAb)|Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
48476647|NCT03417830|DRUG|89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)|89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
48634412|NCT01037465|DRUG|Placebo|Placebo
48634413|NCT01827943|DRUG|Temsirolimus|Temsirolimus
48634414|NCT02360501|DRUG|Docetaxel|75mg/㎡,d1
48295682|NCT05970640|DRUG|Placebo matching BI 3006337|Placebo matching BI 3006337
48295683|NCT04291300|DRUG|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
48634415|NCT02360501|DRUG|Cisplatin|25mg/㎡,d1-3
48634416|NCT02360501|DRUG|Capecitabine|2000mg/㎡,d1-14
48634417|NCT04476485|OTHER|endocrine therapy|If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
48634418|NCT02111356|DEVICE|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
48634419|NCT00362609|DRUG|pantoprazole|
48634420|NCT00096408|PROCEDURE|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
48634421|NCT00096408|PROCEDURE|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
48634422|NCT01210443|DRUG|Sitaxentan|sitaxentan sodium 100 mg
48634423|NCT01975285|DRUG|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
48634424|NCT01975285|DRUG|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
48634425|NCT05395780|DRUG|MAX-40279|MAX-40279 capsule will be administered orally
48634426|NCT05320757|DRUG|Olaparib|a PARP inhibitor
48634427|NCT05688709|BEHAVIORAL|WhatsApp peer support group|YLHIVA assigned to the WhatsApp group will interact with each other and their peer counsellors through one-on-one private communications and on the group chat. The group chat will allow YLHIVA to ask questions, post comments, and reply to one another at any time. We shall share education videos once a week at a time agreed upon with study participants to optimize assimilation of information. In addition, peer counsellor will engage in private WhatsApp calls with youth once a week, to monitor psychosocial state, medication adherence, identify barriers to adherence and counsel YLHIVA. However, youth may initiate in more private communications' when need arises. The peer counsellor will also engage with YLHIVA daily through WhatsApp messages. We will tailor the messages to young people's treatment schedules, clinic appointments, and psychosocial state. Again, youth may text a peer counsellor whenever they wish to do so.
48634428|NCT06337409|DRUG|Generic empagliflozin 25 mg film-coated tablets|Empagliflozin 25 mg film-coated tablets
48295684|NCT01184989|DRUG|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
48634429|NCT03518203|DRUG|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
48634430|NCT01634750|DRUG|ManNAc|Single dose
48634431|NCT05737498|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
48634432|NCT03016403|BEHAVIORAL|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
48634433|NCT03016403|BEHAVIORAL|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
48634434|NCT04046575|RADIATION|Intensity Modulated Radiation Therapy|-15 fractions of treatment
48634435|NCT04046575|DRUG|Carboplatin|Begins on day 1 of radiotherapy
48634436|NCT04046575|OTHER|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
48634437|NCT04046575|OTHER|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
48634438|NCT04046575|OTHER|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
48634439|NCT04046575|OTHER|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
48634440|NCT04046575|OTHER|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
48634441|NCT04046575|PROCEDURE|Blood for ctDNA (optional)|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
48634442|NCT04046575|PROCEDURE|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
48634443|NCT04046575|DRUG|Paclitaxel|Begins on day 1 of radiotherapy
48634444|NCT02178189|OTHER|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
48634445|NCT02178189|OTHER|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
48634446|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
48295685|NCT02941731|DRUG|HIP1403|Oseltamivir 6mg/mL
48295686|NCT02941731|DRUG|HGP0919|Oseltamivir phosphate 6mg/mL
48295687|NCT02243124|DRUG|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
48295688|NCT02243124|DRUG|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
48295689|NCT04175912|DRUG|Carboplatin|Given IV
48295690|NCT04175912|DRUG|Paclitaxel|Given IV
48295691|NCT04175912|DRUG|Pevonedistat|Given IV
47946060|NCT04048551|BEHAVIORAL|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
47946061|NCT01567735|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
47946062|NCT03327597|OTHER|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
47946063|NCT03327597|OTHER|Mental Health and Quality of Life questionnaire|Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
47946064|NCT03327597|OTHER|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
47946065|NCT03327597|OTHER|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
47946066|NCT03327597|OTHER|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
47946067|NCT03327597|OTHER|Clinical follow-up control|Control clinical visit
47946068|NCT05482542|OTHER|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
47946069|NCT05482542|DRUG|Cyclophosphamide/ATG|Cyclophosphamide/ATG
47946070|NCT05482542|DRUG|Cyclophosphamide/Rituximab|Cyclophosphamide/Rituximab
48295692|NCT04735185|OTHER|Autologous stem cells|In this intervention participants will receive a 2 mL intradiscal injection into each affected disc of autologous bone marrow-derived mesenchymal stem cells from bone marrow aspirate of the posterior ilium.
48634447|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
47946071|NCT00586066|DRUG|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
47946072|NCT00586066|DRUG|Placebo|Inactive comparator. Placebo-matching memantine tablet.
47946073|NCT00876746|PROCEDURE|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
47946074|NCT00121264|DRUG|sorafenib tosylate|Given orally
47946075|NCT00121264|DRUG|tanespimycin|Given IV
48295693|NCT04735185|DRUG|Corticosteroid|In this intervention participants will receive a 1 mL intradiscal injection of the steroid methylprednisolone (40 mg/mL) into each affected disc.
48295694|NCT04735185|DRUG|Local anesthetic|In this intervention participants will receive a 1 mL intradiscal injection of the local anesthetic bupivacaine 0.5% into each affected disc.
48295695|NCT06507722|DIAGNOSTIC_TEST|Timing of OGTT|In Aim 1, timing of oral glucose tolerance test will be altered.
47946076|NCT00121264|OTHER|laboratory biomarker analysis|Correlative studies
47946077|NCT00121264|OTHER|pharmacological study|Correlative studies
47946078|NCT00121264|PROCEDURE|magnetic resonance imaging|Correlative studies
47946079|NCT05352399|OTHER|NeuViCare application|Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.
48476648|NCT06146855|PROCEDURE|Tunneling procedure with Amnion Membrane|Root Coverage by tunneling procedure with the addition of Amnion Membrane as a soft tissue substitute
47946080|NCT04899427|DRUG|orelabrutinib|Orelabrutinib will be given as 150mg per day orally, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
47946081|NCT04899427|DRUG|Sintilimab|Sintilimab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
47946082|NCT04899427|DRUG|Tislelizumab|Tislelizumab 200mg intravenous infusion d1, every 21 days for 1 cycle. The medicine will be given until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion.
47946083|NCT02998216|PROCEDURE|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
48103956|NCT01372163|DRUG|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
48103957|NCT01372163|DRUG|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
48295696|NCT06507722|BEHAVIORAL|Timing of Standardized Meal|In Aim 2, timing of a standardized meal will be altered.
48295697|NCT06672055|BIOLOGICAL|VXA-CoV2-3.1|Tablets for oral use.
48634448|NCT03435315|OTHER|Treadmill Exercise- behavioral approach|12-session, 6-week treadmill exercise program utilizing behavioral techniques while walking
47946084|NCT03265665|BEHAVIORAL|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive lifestyle physical activity intervention for African American (AA) women. There are 2 phases to the intervention: Adoptive (24 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. 1 Group session (maintenance): watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking, reinforce barriers and facilitators to walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks.
47946085|NCT03265665|OTHER|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, 24-weeks and 36-weeks."
48634449|NCT03435315|OTHER|Treadmill Exercise- traditional approach|12-session, 6-week traditional treadmill exercise program
48295698|NCT06672055|BIOLOGICAL|COMIRNATY®|Intramuscular (IM) injection.
48295699|NCT06335940|OTHER|Videoregulation|"To encourage the use of video-regulation, several measures will be taken to reinforce its use as much as possible:~* Posters visible to all in the dispatch room.~* Regular mailings to all dispatching physicians.~* On-site presence of interns and the study investigator to help doctors who are not used to video-regulation to get to grips with the computer tool.~* Involvement of ARMs to remind doctors to use video-regulation."
48295700|NCT00000711|DRUG|Zidovudine|
48295701|NCT00000711|DRUG|Sargramostim|
48295702|NCT03083951|PROCEDURE|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
48295703|NCT03083951|PROCEDURE|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
48295704|NCT06671002|DRUG|NSAID|"Once randomized to this group the surgical team will elect to prescribe 1 of the following treatment options for post-discharge pain:~* Ibuprofen 10 milligrams(mg)/kilogram (kg) (maximum 600mg) by mouth every 6 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)~* Celecoxib 6mg/kg (maximum 400mg) by mouth once then 3 mg/kg (maximum 200mg) every 12 hours around the clock for 2 days, then as needed for pain thereafter (40 doses)"
48295705|NCT06671002|DRUG|Opioid|"Once randomized to this group the surgical team will elect to prescribe for 1 of the following treatment options to be given post procedure for post-discharge pain:~* Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.~* Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses"
48295706|NCT06671002|DRUG|Acetaminophen|Participants will receive 15mg/kg up to 1000mg by mouth every 6 hours around the clock for the first 2 days after discharge from surgery then as needed thereafter (40 doses)
48295707|NCT06671002|DRUG|Ibuprofen|Ibuprofen 10mg/kg (maximum 600 mg) by mouth every 6 hours around the clock for 2 days after discharge from surgery then as needed thereafter (40 doses)
48295708|NCT06672120|BEHAVIORAL|Exercise training|Combined, home-based, supervised, video- assisted, endurance and resistance training
48295709|NCT03559985|DRUG|paracetamol|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
48634450|NCT03097159|PROCEDURE|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
48634451|NCT00388141|BEHAVIORAL|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
48634452|NCT02159404|BIOLOGICAL|Immunotherapy|
48634453|NCT05574400|DRUG|Dextrose Water|Dextrose 5% in water
48634454|NCT05574400|DRUG|Caffeine citrate|Low-dose caffeine citrate (1.5 mg/kg)
48634455|NCT05574400|DRUG|Caffeine citrate|High-dose Caffeine citrate (3 mg/kg)
48634456|NCT03975114|DRUG|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
48634457|NCT03975114|DRUG|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
47946086|NCT03024814|DRUG|Acetaminophen|"The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
47946087|NCT03024814|DRUG|Dextrose 5|"The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
47946088|NCT00287651|PROCEDURE|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
47946089|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
47946090|NCT00287651|PROCEDURE|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
47946091|NCT01119560|OTHER|Cytology Specimen Collection Procedure|Correlative studies
47946092|NCT01119560|OTHER|Laboratory Biomarker Analysis|Correlative studies
48295710|NCT03559985|OTHER|Placebo comparator|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
48476649|NCT06146855|PROCEDURE|Tunneling procedure with De-epithelialized Free Gingival Graft|Root Coverage by tunneling procedure with the addition of De-epithelialized Free Gingival Graft
47946093|NCT01119560|OTHER|Questionnaire Administration|Ancillary studies
47946094|NCT06359431|DEVICE|Novel Smart Speculum|"The examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
47946095|NCT06359431|DEVICE|Standard speculum|"he examiner will lubricate the intended speculum with a water-based lubricant then insert through the vagina. Immediately after the first speculum is inserted, and before the examiner attempts to expand the blades to visualize the cervix, the participant's comfort will be assessed using a modified version of the 0-10 Universal Pain Assessment Tool, which shows a series of faces ranging from happy face at 0, or no pain, to a crying face at 10, which represents worst pain possible. Her response will be recorded immediately.~Then the examiner will open the speculum adequately to visualise the cervix. At this point, the visual analogue scale will be given to the participant and told to indicate again the level of pain following manipulation of the speculum, using a scale of 0 (no pain) to 10 (the worst pain imaginable). Her response will be recorded immediately."
47946096|NCT05612698|BEHAVIORAL|Aerobic training|Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax. Due to any form of aerobic exercise involving large muscle groups and causes sustained increases in HR is likely to be beneficial, the type of aerobic exercise will be agreed with each group of patients, varying from 4 to 8 people. There will be a choice of ex-ercises and participants will be able to choose a combination of up to 2 different exercises. The participants' choice of the type of activity to be performed is expected to encourage greater adherence. The range of exercises will be brisk walking or running, swimming, and/or aerobic dancing.
47946097|NCT05612698|BEHAVIORAL|Aerobic training plus resistance training|Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action. In each session, between 5 and 10 exercises will be worked on, per-forming 10-15 repetitions, and progressing to 8-10 lifting as the weight increases, involving the major muscle groups from the core, lower body and upper body. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session.
48103958|NCT01711047|PROCEDURE|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
48103959|NCT01711047|PROCEDURE|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
48476650|NCT02636829|OTHER|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
48476651|NCT02636829|OTHER|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL \*.~\* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
48476652|NCT00688402|DRUG|AZD3355|Single dose
48634458|NCT03975114|DRUG|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
48295711|NCT02734121|BEHAVIORAL|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
48634459|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
48634460|NCT01327365|PROCEDURE|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
48634461|NCT01666600|DRUG|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
48295712|NCT00427388|DRUG|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
48295713|NCT00427388|OTHER|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
48634462|NCT01666600|RADIATION|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
47946098|NCT05612698|BEHAVIORAL|High intensive interval training|Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO. Starting with 4 intervals lasting 1 minute keeping in a range of 85-90% HRMax, separated by 1 minute of low intensity activity (no static) (4 × 1 min intervals.) A progression will be followed by increasing the number of circuits, up to 10 (10 × 1 min intervals) \[25, 78, 79\]. In all sessions there will be a 3-minute warm-up at the beginning of the session and a 2-minute cool-down at the end of the session. Although the target popula-tion is a sedentary population, we expect the HIIT approach, despite being high intensity, to be well received, due to its growing popularity, as demonstrated by a study in which 62% of inactive participants preferred HIIT to other types of exercise.
47946099|NCT01782911|DIETARY_SUPPLEMENT|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
47946100|NCT01782911|DIETARY_SUPPLEMENT|Placebo pills|The patients will take placebo for 40 days.
48295714|NCT01568580|DRUG|GreenGene|Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus
48295715|NCT01743027|DRUG|AL-4943A ophthalmic solution|
48295716|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
48295717|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.1%|
48295718|NCT01743027|DRUG|AL-4943A ophthalmic solution vehicle|
48295719|NCT05555069|OTHER|Menthol-flavored electronic cigarette|Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
47946101|NCT04574323|RADIATION|Curative radiotherapy|Standard curative radiotherapy
47946102|NCT04574323|OTHER|Paleolithic lifestyle intervention|This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
47946103|NCT04020328|DRUG|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR\<50ml/min
47946104|NCT06427759|PROCEDURE|arm aesthetic surgery|liposuction of arms brachioplasty of arms
48295720|NCT05555069|OTHER|Tobacco-flavored electronic cigarette|Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
48295721|NCT05074095|OTHER|retrospective analysis|
48476653|NCT00337974|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
48634463|NCT05803993|PROCEDURE|Fecal microbiota transplantation (FMT) Single FMT infusion|Single FMT infusion via colonoscopy
48634464|NCT06314035|OTHER|COPD Patient Decision Aid|Participants in this group will receive two 60-minute intervention sessions in one month. The COPD PDA consists of three main parts: The first component, clinical counselling, guides the participants in reviewing the common EOL scenarios. The second component, an evidence-based decision aid, is presented as an option grid in a booklet and a video to provide information about outcome probabilities of various treatment options and survival estimates in a balanced and unbiased manner. The information is presented in plain language for laypersons. The third component, decision coaching, introduces the concept of ACP and guides deliberation through value clarification.
48634465|NCT06314035|OTHER|General Health Coaching Intervention|The participants in the control group will receive two 60-minute health coaching sessions developed by the PI for another project as an attention placebo control. Trained research personnel will use the same amount of interaction time and similar formats to avoid threats to the study's internal validity. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes. The trained research personnel will give the guidebook consisting of general self-management advice to participants in this group.
48295722|NCT04634539|DRUG|Gemcitabine|Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
48476654|NCT00337974|OTHER|Educational DVDs|
48476655|NCT00267163|DRUG|donepezil|
48476656|NCT00267163|DRUG|Placebo|
48295723|NCT04634539|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
48295724|NCT04634539|DRUG|L-glutamine|The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
48295725|NCT05575804|DRUG|GQ1001+pyrotinib|GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
48295726|NCT05575804|DRUG|pyrotinib+capecitabine|pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
48295727|NCT06179212|DIAGNOSTIC_TEST|Exercise Tests|Patients will complete 4 different cardiopulmonary exercise tests in random order.
48634466|NCT03725735|BEHAVIORAL|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
48634467|NCT00652613|RADIATION|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
48634468|NCT00652613|RADIATION|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
48634469|NCT04867590|DEVICE|Endorotor|"The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis."
48634470|NCT04867590|DEVICE|Radiofrequency|"Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required."
48634471|NCT00567112|DRUG|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
48634472|NCT00567112|DRUG|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
48634473|NCT00567112|DRUG|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
48295728|NCT04591665|OTHER|swallowing examination|patients received swallowing examination, including high resolution impedance manometry and Video-Fluoroscopic swallowing study.
48634474|NCT00567112|DRUG|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
48634475|NCT04678297|BEHAVIORAL|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
48634476|NCT04678297|BEHAVIORAL|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
48634477|NCT00202852|OTHER|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
47946105|NCT02366858|PROCEDURE|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
48295729|NCT06403345|BEHAVIORAL|Green Activity Program|See arm description.
47946106|NCT02366858|PROCEDURE|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
48103960|NCT01516788|OTHER|Phototesting|Single MED dose on Day 2
48103961|NCT02904707|OTHER|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
47946107|NCT03500471|PROCEDURE|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
47946108|NCT03500471|PROCEDURE|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
47946109|NCT06369623|OTHER|Monetary Incentive Delay Task|The Monetary Incentive Delay functional Magnetic Resonance Imaging task is well-characterized and commonly utilized in research settings to measure neural activation between win and loss conditions, as well as between phases of anticipation and consummation/outcome. A recent meta-analysis indicates that the task has been used in over 80 studies and 5,000 subjects as of Year 2022. The task is also valid and appropriate for use in children and adolescents, as demonstrated by its inclusion in National Institute on Drug Abuse ABCD study. The task is utilized for its short-lived, reversible, and/or benign effects on brain activation (e.g., brief processing of a reward cue).
47946110|NCT01262209|DEVICE|portable CCTV|This is a small handheld mini screen intended to improve reading.
48634478|NCT00202852|DRUG|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
48634479|NCT00202852|BIOLOGICAL|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
48634480|NCT00202852|DRUG|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
47946111|NCT01262209|DEVICE|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
47946112|NCT01262209|DEVICE|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
47946113|NCT04890431|DRUG|Oxygen|oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)
47946114|NCT04890431|DRUG|Placebo|ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
47946115|NCT00810524|DRUG|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
47946116|NCT00810524|DRUG|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
47946117|NCT00810524|DRUG|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
47946118|NCT00810524|DRUG|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
48103962|NCT06631872|BEHAVIORAL|Tele-prehabilitation education session: Surgery School|Online telehealth education program using videos and a live clinician facilitator
48476657|NCT05911087|BIOLOGICAL|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
48476658|NCT05911087|BIOLOGICAL|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
48476659|NCT05911087|BIOLOGICAL|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
47946119|NCT06207968|DEVICE|Knee surgery with FH Ortho devices|"This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons."
48634481|NCT05003336|DRUG|Xiangshao Granules|dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
48634482|NCT05003336|DRUG|Xiangshao Granules Placebo|Xiangshao Granules Placebo
48634483|NCT00063037|BEHAVIORAL|Behavioral modification - nutrition education|
47946120|NCT05550844|RADIATION|Chest HRCT|A chest HRCT to identify emphysema
48634484|NCT01665105|DEVICE|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
47946121|NCT05550844|GENETIC|blood analysis|If emphysema is identified, a blood analysis will be performed to exclude known causes of emphysema (Alpha-1 antitrypsin deficiency, PTPN6 mutation)
48103963|NCT06631872|BEHAVIORAL|Individualised Inspiratory Muscle Training and Walking Program|An individualised inspiratory muscle training and walking program delivered by a Physiotherapist using telehealth.
48103964|NCT06631872|OTHER|Usual Care|Usual care alone. Usual care will be reviewed every four months during the trial and site leads will be asked to provide information about any changes to usual hospital and medical care at their site.
47946122|NCT05550844|OTHER|Lung function tests|Lung function tests will be performed in accordance with ATS/ERS technical standard
47946123|NCT04461288|BEHAVIORAL|Social media-based education, counseling, and support|This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.
47946124|NCT04461288|OTHER|Nicotine replacement therapies (NRT)|"Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette."
47946125|NCT04461288|OTHER|Gamification|Gaming elements designed to encourage participation in the program and behavior change.
47946126|NCT00518973|DRUG|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
48103965|NCT05823181|DEVICE|laparoscopy|laparoscopic exploration of common bile duct
48103966|NCT03724838|DRUG|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day
48103967|NCT03724838|DRUG|Sildenafil Citrate|Patients will take Sildenafil Citrate 40mg every 8 hours
48103968|NCT03724838|DRUG|Placebo to Esomeprazole|Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
48103969|NCT03724838|DRUG|Placebo to Sildenafil Citrate|Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
48103970|NCT04026620|BEHAVIORAL|Informational Pamphlet|The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
48295730|NCT06105957|BEHAVIORAL|Core|The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals. Weekly tips and discussion board postings invite participants to apply skills introduced in the modules and prompt interaction and social support within the closed group which starts the program simultaneously.
48103971|NCT04026620|BEHAVIORAL|Brief Motivational Enhancement Therapy (MET) Session|The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
48103972|NCT06175923|BIOLOGICAL|Collection of EDTA (disodium salt of ethylenediaminetetraacetic acid) tubes of marrow during routine care|When bone marrow is collected as part of a patient's care (diagnosis, follow-up, suspected AML/MDS hemopathy), one or two additional EDTA tubes of marrow are collected. Certain hematological data (NFP, genetic and molecular characteristics) will be collected in anonymized form and correlated with the BMP pathway alterations measured.
48103973|NCT02934035|DRUG|Antidepressant|
48476660|NCT05911087|BIOLOGICAL|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
48476661|NCT04683588|OTHER|Nursing Coaching|Different strategies, methods and training techniques are used in the implementation of preoperative and postoperative nursing care of surgical patients scheduled for total knee arthroplasty surgery. One of them is patient coaching. Coaching is a method that increases the quality of nursing care.While the coaching strategy contributes more to the recovery process of the patient with the role of the case manager of the nurse, it provides a reduction in the problems related to surgery (pain, nausea-vomiting, mobilization problems), reduction in repeated hospitalizations and positive contributions to the cost.
48476662|NCT04424966|DRUG|Infigratinib|The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
48476663|NCT00781092|OTHER|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
48634485|NCT03791697|OTHER|Telehealth 2 week postoperative visit|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)"
48634486|NCT02027493|DRUG|Reiferon R|subcutaneous injection of 100 μg/m2
48634487|NCT02027493|DRUG|Ribavirin|15 mg/kg daily on two divided doses
48634488|NCT01801605|PROCEDURE|rTMS|Active session with stimulation and placebo session with fictive stimulation
47946127|NCT00518973|DRUG|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
48295731|NCT06105957|BEHAVIORAL|Facilitated Weekly Group Sessions|Participants will receive 24 facilitated online video-conference-based weekly group sessions. These groups will be 60 minutes long and will be facilitated by a trained professional, who reinforces the information and behavioral strategies introduced in the weekly modules, elicits the experiences of participants in applying behavioral skills to establish new diet and exercise habits, and guides problem solving. Group cohesion to offer social support is promoted.
48295732|NCT06105957|BEHAVIORAL|Counselor Crafted Feedback|Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message. The emailed feedback will provide positive reinforcement for successful goal achievement, identify possible areas for improvement, and suggest possible strategies for identified challenges.
48476664|NCT00781092|OTHER|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
48476665|NCT02807779|DRUG|Dexamethasone infusion|Participants will receive dexamethasone infusion following plain balloon angioplasty
48476666|NCT02807779|DEVICE|Drug coated balloon|Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
48476667|NCT02807779|DEVICE|Plain balloon angioplasty|Participants will receive plain balloon angioplasty only
48476668|NCT04916275|OTHER|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
48476669|NCT04413032|DEVICE|DreaMS|The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.
48476670|NCT02253069|DEVICE|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
48476671|NCT02253069|DEVICE|Applying Placebo to tie-over dressings|Placebo control
48476672|NCT00546910|DRUG|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
48476673|NCT00546910|DRUG|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
48476674|NCT01685359|DRUG|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
48476675|NCT03610919|DRUG|Nasal Sprays|Intranasal administration of 24 international units per dose.
48476676|NCT01765270|DRUG|Saxagliptin|one 5-mg saxagliptin tablet daily
48476677|NCT01765270|DRUG|Placebo|5mg placebo tablet daily
48476678|NCT01471834|DEVICE|BAROSTIM NEO System|
48476679|NCT01471834|DRUG|Medical Management|
48476680|NCT06573970|DRUG|Atomoxetine|Atomoxetine is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD), and executive dysfunction. Dispensing of blinded medication (40mg to 80mg ATX or placebo) will begin at randomization and will be dispensed at weeks 2, 4, 8, and 12. The initial dose of ATX is 40mg or placebo and will be given for one week, the dose will be titrated to 80mg if tolerated in the second week through week 12.
48476681|NCT06573970|DRUG|Placebo|placebo pill appears like real atomoxetine pill but has no therapeutic ingredient and benefit. The same schedule to distribution as Atomoxetine arm.
48634489|NCT05574244|PROCEDURE|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
48634490|NCT05574244|PROCEDURE|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
48634491|NCT02542579|GENETIC|16S rRNA pyrosequencing analysis|Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
48476682|NCT00653159|DEVICE|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
48476683|NCT00653159|DEVICE|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
48476684|NCT02546050|DRUG|Metformin|
48476685|NCT06613087|OTHER|Foot bath|In the foot bath application, the feet will be kept in water at a constant temperature of 38-40 °C for about 20 minutes. During this time, the water temperature will be checked with a thermometer at intervals. Foot bath applications will be performed for 3 days, on the 2nd, 3rd and 4th days of hospitalization.
48634492|NCT00000839|DRUG|Didanosine|
48634493|NCT00250575|DRUG|Clozapine|
48634494|NCT05259540|DRUG|compound kushen injection combined with pabolizumab|compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
48634495|NCT03053830|DRUG|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
48634496|NCT03295448|OTHER|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
48634497|NCT03295448|OTHER|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
48103974|NCT02767219|DRUG|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
48103975|NCT02767219|DRUG|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
48103976|NCT02767219|DRUG|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
48634498|NCT03295448|OTHER|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
48634499|NCT04718389|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
48103977|NCT00432029|PROCEDURE|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
48634500|NCT04718389|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided in a single-use PFS.
48103978|NCT00432029|DEVICE|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
48103979|NCT04322643|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over 30 minutes every 3 weeks
48103980|NCT04322643|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes)
48103981|NCT04322643|DRUG|Durvalumab|Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.
48103982|NCT04322643|DRUG|Nivolumab|Nivolumab 480mg IV over 30 minutes every 4 weeks
48103983|NCT04322643|DRUG|Avelumab|Avelumab 800 mg IV over 60 minutes every 2 weeks
48103984|NCT05000450|GENETIC|ALLO-605|ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
48103985|NCT05000450|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
48295733|NCT06105957|BEHAVIORAL|Individual Coaching Calls|Participants will receive 3 online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss. The first call will emphasize amplifying motivation and promoting early treatment engagement by establishing rapport, exploring personal reasons for weight loss and lifestyle change, and reinforcing and expanding change talk, and it will occur prior to starting the core program. Subsequent calls will use a motivational interviewing-informed approach to problem solve barriers to self-monitoring, particularly dietary self-monitoring because of the strong role it plays in promoting better weight loss and will occur during the first half of the program, reflecting the critical role of early engagement in the treatment program on long term weight loss success. Coaching calls will be of approximately 30 min duration and will follow a semi-structured interview format.
48634501|NCT04718389|BIOLOGICAL|Benralizumab|Benralizumab will be provided in a single-use PFS.
48634502|NCT04718389|BIOLOGICAL|Placebo|Placebo will be a sterile liquid formulation.
48634503|NCT04718389|DRUG|Standard of care (SoC)|Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
48476686|NCT04027257|BEHAVIORAL|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
47946128|NCT04867057|DRUG|Trichomylin for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
48103986|NCT05000450|DRUG|Fludarabine|Chemotherapy for lymphodepletion
48103987|NCT05000450|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
48103988|NCT04680702|DIAGNOSTIC_TEST|Sims Score|Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity
48476687|NCT02033135|PROCEDURE|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
48476688|NCT02033135|OTHER|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
47946129|NCT04867057|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
48634504|NCT04718389|DEVICE|Pre-filled Syringes (PFS)|PFS will include glass barrel with pre-staked needle and plunger.
48103989|NCT03168191|DRUG|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
48103990|NCT03168191|OTHER|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
48103991|NCT03168191|OTHER|Menthol Flavor|Menthol flavored e-cigarette for lab session
48103992|NCT04417270|DEVICE|Freestyle Libre 14 day CGM system|The FreeStyle Libre 14 day system is a continuous glucose monitoring system consisting of a handheld reader and a sensor worn on the back of the upper arm.
48103993|NCT04417270|DEVICE|Accuchek Inform II platform|The Accu-Chek Inform II system is designed to deliver data with speed and efficiency, helping to provide optimal care. Wireless meter quickly transfers data. The Accu-Chek Inform II system is the first point-of-care blood glucose device to offer truly wireless technology at the meter level.
48103994|NCT01221337|OTHER|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
48476689|NCT02033135|DEVICE|Zilver PTX|
48476690|NCT03677219|OTHER|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
48476691|NCT06267794|DRUG|Pirfenidone 1200 mg|1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
47946130|NCT04867057|DRUG|Trichomylin for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
47946131|NCT04867057|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
47946132|NCT04850313|DEVICE|ProProKera Plus®|ProKera® is a sutureless form of CryoTek amniotic membrane that is clipped into a dual polycarbonate ring system with the epithelial side up when in contact with the ocular surface.
47946133|NCT00968318|PROCEDURE|Excision of strip of deep fascia|operative technique to excise deep fascia.
47946134|NCT01632046|DRUG|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
47946135|NCT04108442|BEHAVIORAL|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
47946136|NCT04108442|BEHAVIORAL|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
47946137|NCT03971071|DRUG|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
47946138|NCT03971071|DRUG|Erenumab 140 mg|Erenumab once every 4 weeks. Subcutaneous injection.
47946139|NCT03971071|DRUG|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
47946140|NCT03588871|OTHER|Dental bleaching with PaintOn Plus VivaStyle|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
47946141|NCT03588871|OTHER|Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle|Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
47946142|NCT03588871|OTHER|Dental bleaching with Opalescence GO|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
47946143|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence GO|Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
48476692|NCT06267794|DRUG|Pirfenidone 1800 mg|1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
48476693|NCT06267794|DRUG|Placebo|0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
47946144|NCT03588871|OTHER|Dental bleaching with Opalescence PF|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
47946145|NCT03588871|OTHER|Dental Bleaching impact in quality of life with Opalescence PF|Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
48103995|NCT06629675|DEVICE|Music walking application BeatClearWalker (BCW)|The music walking application (BCW) is a smartphone application that can monitor the walking pace and allow individuals to listen to music and give immediate feedback so they can correct their walking pace to match their target walking speed, as prescribed by the healthcare professional. The application provides real-time audio feedback in the form of music; the music sound quality will reduce whenever the walking speed drops below or exceeds the participant\&#39;s target walking speed. Simply, the application will work to supervise service users while exercising walking. The investigators are trying to assess the feasibility of this application with service users during their Pulmonary Rehabilitation programme (at the hospital/ home) to find out how participants interact with listening to music while exercise walking and how well they're able to keep to their target speed.
48634505|NCT03861507|DEVICE|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
48634506|NCT05627661|DEVICE|Biosensor|Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days
47946146|NCT01296360|BIOLOGICAL|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
48103996|NCT05578352|OTHER|Add oral hyppoglycemia drug|Oral hypoglycemic drugs with insulin sensitization effect are added, reduce insulin dose according to blood glucose
48103997|NCT05578352|OTHER|Add GLP-1 receptor agonist|Add GLP-1 receptor agonist and reduce insulin dose according to blood glucose
48476694|NCT01779388|PROCEDURE|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
48476695|NCT00398684|DRUG|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
48476696|NCT00398684|DRUG|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
48476697|NCT00398684|DRUG|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
48634507|NCT01734928|DRUG|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
47946147|NCT01296360|BIOLOGICAL|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
47946148|NCT03793868|DRUG|Perampanel|Oral tablet
47946149|NCT03793868|OTHER|Placebo|Placebo (not drug)
47946150|NCT01147172|DEVICE|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
48103998|NCT05578352|OTHER|Change insulin|Change premix insulin to long-acting insulin
48103999|NCT00882635|DRUG|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance \< 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
48634508|NCT01734928|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
48634509|NCT01734928|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\>75 years old\] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
48634510|NCT04886037|OTHER|sestrin|Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.
48634511|NCT00257855|DRUG|Lamotrigine|
48634512|NCT01691807|DRUG|ofatumumab|treatment for NHL
48634513|NCT01691807|DRUG|bendamustine|treatment for NHL
48634514|NCT06213805|PROCEDURE|Minimally invasive microsclerostomy|"MIMS is a filtering glaucoma surgery, which consists of creating a sclero-corneal drainage channel, to allow the flow of aqueous humor and therefore the reduction of intraocular pressure.~This surgery is extremely quick, lasting 3 to 5 minutes, according to recent MIMS studies, in contrast to the duration of a trabeculectomy, the classic glaucoma surgery, which varies between 20 and 60 minutes."
48634515|NCT02325453|PROCEDURE|Robotic Surgery|Surgical procedure performed with a robotic system.
48634516|NCT02325453|PROCEDURE|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
48634517|NCT02325453|PROCEDURE|Open Surgery|Traditional approach for gastric cancer.
48634518|NCT05756309|DEVICE|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
48634519|NCT04026451|DEVICE|Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor|Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.
48634520|NCT04026451|BEHAVIORAL|Sedation guided by SAS scale (1-2)|Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
48634521|NCT04026451|DRUG|Deep sedation with propofol andfentanyl|Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
48634522|NCT04026451|PROCEDURE|Mechanical Ventilation|Critically ill patients will be ventilated mechanically following the clinical indication.
47946151|NCT02808377|OTHER|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
47946152|NCT04228393|DRUG|6-mercaptopurine|6-mercaptopurine was administered orally to patients once daily.
47946153|NCT04228393|PROCEDURE|Standard treatment|The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.
47946154|NCT04228393|PROCEDURE|Individualized treatment|The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.
47946155|NCT02586051|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
47946156|NCT02586051|DRUG|Intravenous Immunoglobulin|High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
47946157|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day screener|See descriptions
47946158|NCT06235333|BEHAVIORAL|Gambling Disorder Screening Day information sheet|See descriptions
48634523|NCT04935294|DRUG|Danicopan|Oral tablet.
48634524|NCT02746731|OTHER|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
48634525|NCT02746731|OTHER|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
47946159|NCT05577403|BEHAVIORAL|Mulligan's mobilization with movement MWM added isometric strength training|"Mulligan's mobilization with movement added isometric exercise:~the participants in the experimental group will receive a Mulligan's mobilization with movement added isometric exercise.~Treatment will be given for the period of three weeks, for five days a week in both groups.~Data will be collected before intervention and after 2nd \& 4th week of intervention."
47946160|NCT02963935|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
47946161|NCT02963935|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
47946162|NCT02963935|BEHAVIORAL|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
47946163|NCT00723931|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
47946164|NCT01439568|DRUG|LY2510924|Administered subcutaneous injection
47946165|NCT01439568|DRUG|Carboplatin|Administered intravenously
47946166|NCT01439568|DRUG|Etoposide|Administered intravenously
48634526|NCT04113980|OTHER|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
47946167|NCT04587544|BEHAVIORAL|Cold Water Immersion|The participants maintained their daily activities during the intervention. When daily activity ended, the intervention was begun. CWI therapy by immersed the whole part of inflamed target joints in the water at 20-30C for 20 minutes/day. The intervention was continued for four weeks. The researchers work together with the nurses of community health services to give the intervention.
47946168|NCT05533216|OTHER|Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.
47946169|NCT00781508|DRUG|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
47946170|NCT00781508|OTHER|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
48104000|NCT00882635|DRUG|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
48634527|NCT04113980|OTHER|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
48634528|NCT04113980|OTHER|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
48104001|NCT02943993|DRUG|Edoxaban|Prescribed according to approved label
47946171|NCT03575897|DIAGNOSTIC_TEST|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
47946172|NCT04792515|DRUG|Camrelizumab combined with SOX/ or apatinib|"Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing."
47946173|NCT05726916|DRUG|Soliris®|Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
47946174|NCT05726916|DRUG|Renin angiotensin system blockers|Blood pressure control with renin angiotensin system blockers
47946175|NCT04629885|DRUG|Oxytocin 400 IU vaginal gel|
47946176|NCT04629885|DRUG|Placebo|Matching placebo gel with identical appearance to the test product, used as reference treatment.
47946177|NCT00063193|DRUG|minocycline|
48104002|NCT01187576|BEHAVIORAL|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
48476698|NCT00265772|DRUG|MODULEN IBD (R) (specific Enteral Nutrition)|
48476699|NCT00265772|DRUG|prednisolon|
48476700|NCT00727519|DIETARY_SUPPLEMENT|Pomegranate juice|
48476701|NCT00727519|DIETARY_SUPPLEMENT|Placebo|
48476702|NCT02173652|DRUG|BI 1356, high dose|
48476703|NCT02173652|DRUG|BI 1356, low dose|
48476704|NCT04134754|OTHER|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
48476705|NCT04880382|DRUG|ICI treatment discontinuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
48476706|NCT04880382|DRUG|ICI treatment continuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
48476707|NCT00535041|DRUG|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
47946178|NCT00063193|DRUG|creatine|
47946179|NCT04453228|OTHER|Classification statistics|We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
47946180|NCT04190173|DRUG|Prucalopride|1-2 mg once daily enteral feeding for 5 consecutive days
47946181|NCT04190173|DRUG|Placebo|1/2-1 tablet once daily enteral feeding for 5 consecutive days
47946182|NCT00739999|DRUG|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
47946183|NCT00739999|DRUG|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (\<3.35 mmol/L) after 4-week treatment.
47946184|NCT01649609|DRUG|Tacrolimus|Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
48295734|NCT06105957|BEHAVIORAL|Pre-Scripted Feedback|Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring within each of the following domains: dietary monitoring, physical activity monitoring, and self-weighing, as well as on weekly module completion. Feedback is automatically generated based on decision algorithms and will be sent from program staff.
48295735|NCT05151744|DRUG|Vamikibart|Vamikibart will be administered by IVT injection in the study eye.
48634529|NCT05747547|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.
48634530|NCT05747547|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
48634531|NCT05747547|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
47946185|NCT01649609|DRUG|Mycophenolate acid|Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
47946186|NCT01649609|DRUG|Sirolimus|mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
47946187|NCT05843162|DRUG|Telmisartan|Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
47946188|NCT05843162|DRUG|Losartan|Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
47946189|NCT01267656|DEVICE|Lubricating and Rewetting Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
47946190|NCT01267656|DEVICE|AMO Blink Contacts Lubricant Eye Drops|Instill 1-2 rewetting drops in each eye at least QID (4 times per day) for one week.
47946191|NCT04798495|OTHER|Multimodal interdisciplinary rehabilitation programme (HAPPY)|A 6-month multimodal interdisciplinary rehabilitation programme abbreviated HAPPY was tested. The programme consisted of motivating interviewing technique, individual dialogues with fixed subjects, individual supervised physical exercise training, relaxation exercises, nutritional counselling, and group sessions (a combination of topics and exchange of experiences) with patients and relatives. To reach patients at home, the team phoned patients, who were also given tablets with access to the project's homepage and a digital physical exercise programme.
48634532|NCT05747547|DIAGNOSTIC_TEST|Retinal oximetry|Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.
48634533|NCT05747547|DIAGNOSTIC_TEST|Optical coherence tomography and angiography|Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).
48634534|NCT04909411|OTHER|OPHTHALMOLOGICAL ASSESSMENT|assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
48634535|NCT04909411|OTHER|NEUROPSYCHOLOGICAL ASSESSMENT|completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
47946192|NCT04072575|DRUG|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
48295736|NCT05151744|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
47946193|NCT04072575|DRUG|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
48295737|NCT05151744|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
48295738|NCT03693365|PROCEDURE|PEEP trial|Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
48476708|NCT02074267|DRUG|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
48634536|NCT02706548|BEHAVIORAL|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
48634537|NCT02706548|BEHAVIORAL|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association \& American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
48634538|NCT04679818|DRUG|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
48634539|NCT04679818|DEVICE|PMD-200 Nol-guided opioid administration|PMD-200 Nociception level (NOL) values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
48634540|NCT03847805|OTHER|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
48634541|NCT03847805|OTHER|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
48634542|NCT02516111|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
48634543|NCT02516111|BIOLOGICAL|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
48634544|NCT02516111|DRUG|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
47946194|NCT04664244|COMBINATION_PRODUCT|Combination of nimotuzumab and radiotherapy|Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
47946195|NCT05274685|PROCEDURE|haemodialysis|continuous venovenous hemodiafiltration (CVVHDF) at a prescribed dose of 30-35 mL/kg/h of effluent and with regional citrate anticoagulation
47946196|NCT00068783|DRUG|imatinib mesylate|Given orally
47946197|NCT00068783|OTHER|laboratory biomarker analysis|Correlative studies
47946198|NCT02761434|OTHER|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
47946199|NCT02761434|OTHER|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
47946200|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
47946201|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
47946202|NCT01456507|DRUG|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
47946203|NCT04329442|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|30 day supply of 200mg tablets
47946204|NCT05002283|OTHER|patient specific guide|harvesting palatal free gingival graft using the patient specific guide
47946205|NCT02818231|OTHER|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
48104003|NCT01187576|BEHAVIORAL|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
48295739|NCT06395311|OTHER|COPD psychological well-being assessment|Patients will complete the following questionnaires: Hospital Anxiety and Depression Scale (HADS), COPD Assessment Test (CAT), State Shame and Guilt Scale (SSGS), Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE), Brief Fear of Negative Evaluation Scale (BFNE), Self-Compassion Scale Short Form (SCS-SF). Dyspnea will be evaluated with the mMRC scale, and functional capacity will be assessed with the six-minute walking test (6MWT).
48295740|NCT05805969|OTHER|Accommodating variable-resistance training|"The training was conducted twice weekly for six successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
48295741|NCT05805969|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with juvenile idiopathic arthritis (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
48295742|NCT06341569|OTHER|Respiratory breathing techniques group|"Target group: subjects in the respiratory breathing techniques group. Program duration: the program lasts for 14 weeks.~Breathing techniques: the program includes various breathing exercises, including:~Diaphragmatic breathing teaches participants to breathe deeply, engaging the diaphragm muscle, which can improve lung capacity and relaxation.~Pursed-lips breathing: this technique involves inhaling through the nose and exhaling slowly through pursed lips, which can help slow down breathing and manage shortness of breath.~Alternate nostril breathing: this technique involves closing one nostril while inhaling and exhaling through the other nostril alternately.~Relaxation techniques: the program incorporates progressive muscle relaxation techniques. This involves progressively tensing and relaxing different muscle groups.~Medical education: topics like the anatomy of the respiratory system, the importance of proper breathing, potential benefits of specific breathing exercises."
48476709|NCT02074267|DRUG|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
48476710|NCT03543709|DIAGNOSTIC_TEST|fibromyalgia 2013 criteria|Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
48476711|NCT03543709|OTHER|Behcet's disease current activity form|Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
48634545|NCT02516111|DRUG|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
48104004|NCT00585455|DRUG|sertraline|open label 25-50 mg daily as tolerated
48476712|NCT04836351|OTHER|Concentrated rehabilitation for patients with persistent symptoms post COVID-19|3+ 1-2 days concentrated rehabilitation for patients with persistent symptoms post COVID-19 with a mobile application follow-up and physical consultations at 3 months post intervention.
48634546|NCT06378255|DEVICE|Polycation-based new dentinal desensitizer|Dental desensitization treatment
48634547|NCT06378255|DEVICE|GLUMA desensitizer|Dental desensitization treatment
48634548|NCT01259024|DEVICE|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
48634549|NCT00318864|BEHAVIORAL|Cognitive behavioral therapy|
48634550|NCT05670340|DEVICE|Switched Prosthetic Profile|The implant will be rehabilitated with a switched emergence profile
48634551|NCT05670340|DEVICE|Matched Prosthetic Profile|The implant will be rehabilitated with a matched emergence profile
47946206|NCT04923815|DEVICE|THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter|THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
47946207|NCT03654859|OTHER|cardiopulmonary resuscitation|no pre-specified
48476713|NCT06224855|DRUG|DXC006|"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."
47946208|NCT04709354|DIAGNOSTIC_TEST|Dermoscopic examination|The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
48104005|NCT02114840|PROCEDURE|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
48104006|NCT02114840|PROCEDURE|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
48104007|NCT02114840|PROCEDURE|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
48476714|NCT02073136|OTHER|Diet with phosphate containing additives|
48476715|NCT02073136|OTHER|Diet without phosphate containing additives|
48634552|NCT02072993|DRUG|AZD1979|Single dose, oral solution administration
48634553|NCT02072993|DRUG|Placebo to match|Single dose, oral solution administration
48634554|NCT01414829|PROCEDURE|Gastroscopy|The reason for gastroscopy will be not related to the study
48634555|NCT02269605|OTHER|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
48634556|NCT02269605|DRUG|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
48634557|NCT02269605|DRUG|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
48295743|NCT05590949|OTHER|Physical Evaluation|Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
48295744|NCT05590949|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scans|Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
48634558|NCT02454582|DEVICE|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
48634559|NCT00676689|DEVICE|SAPIEN Transcatheter Valve Implantation|Device Implantation
48295745|NCT05590949|DIAGNOSTIC_TEST|Trabecular Bone Score|TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
48295746|NCT05067777|PROCEDURE|Massage Therapy|Receive SMT
48295747|NCT05067777|OTHER|Questionnaire Administration|Ancillary studies
47946209|NCT04603716|OTHER|Eccentric Muscle Energy Technique|"Conventional Treatment given to both groups (Hot pack for 15 minutes, Mobilization, AROM Exercises 10 sets x 3days in a week)~Reciprocal inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) causing relaxation, patient force is minimal towards maximal therapist force, 5-7 repetition for 2-4seconds 3 days in a week up to 6 weeks.~Muscle is taken from shortened to lengthened position."
47946210|NCT04603716|OTHER|Concentric muscle energy technique|"Group B: Concentric Muscle Energy Technique: (Autogenic inhibition of target muscle (i.e. levator scapulae ,pectoralis major, upper trapezius) patient force is greater than therapist force, 5-7repitition for 3-4seconds)Muscle is taken from lengthened to shortened position.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 1st 3rd and 6th week"
48295748|NCT05067777|PROCEDURE|Sham Intervention|Receive light touch control procedure
48295749|NCT00759473|DRUG|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
48295750|NCT00759473|DRUG|Placebo|
48634560|NCT00992394|DRUG|etanercept|etanercept 50 mg once weekly as requested.
48634561|NCT00992394|DRUG|etanercept|etanercept 25 mg or 50 mg as requested.
48634562|NCT06468917|BEHAVIORAL|1st day removal of abdominal drain|once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed
48634563|NCT02303938|BEHAVIORAL|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
48634564|NCT02916771|DRUG|Ixazomib|Oral, proteasome inhibitor
48634565|NCT02916771|DRUG|Lenalidomide|Oral, immunomodulatory agent
48634566|NCT02916771|DRUG|Dexamethasone|Oral, steroid
48634567|NCT02051283|OTHER|RFA|RFA
48634568|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
48634569|NCT00281580|DRUG|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
48634570|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
48634571|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
48634572|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
47946211|NCT03751644|OTHER|Electrical stimulation|Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
47946212|NCT04727931|BEHAVIORAL|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
47946213|NCT02047227|DRUG|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
48295751|NCT06672354|PROCEDURE|Otago Exercise Program|"1- Otago Exercise Program: i) This exercise program will consist of strengthening, balance exercises and walking plan. The OEP will be performed according to the following: 5 min warm-up, 10 min resistance training and 15 min balance exercises.~ii) The strength training protocol targets, on hip abductors, knee flexors, knee extensors, plantarflexors, and dorsiflexors.All exercises will be performed for 10 repetitions. This protocol recommends strength training 3 days per week.~iii) The balance retraining protocol incorporates various exercises. The exercises progress in difficulty through four levels, with Level 1 being the easiest and Level 4 the most challenging. Balance exercises will progress from holding onto a stable supporting structure such as heavy furniture to perform the exercises independent of the support. The protocol recommends participants to carry out balance exercises 3 days a week.~iv) Participants will be instructed to walk at their usual pace for 30 minutes, twice"
48634573|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
48295752|NCT06672354|PROCEDURE|Non-Immersive Virtual Reality Training|In this interventional group, VR training exercises will be performed by using Xbox Kinect, which includes a Kinect sensor.-The monitor or Tv screen will recognize the movements of participants via camera and infra-red motion sensors.-In order to perform simulated exercises in each session, the participant will be positioned at 1.5-2 meter from the monitor or TV screen.-The virtual reality training exercises will include Kinect Adventure games (Rally Ball, 20,000 leaks, Reflex Ridge) and Sports pack 1 games (Super Saver, Target Kick, Body ball).-Exercises will be continued for 30-45 minutes each session, for 3 alternate days per week for a total period of 12 weeks.
48295753|NCT03633071|OTHER|Web-knee brace|Web -Knee Brace
48295754|NCT00950781|PROCEDURE|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
48634574|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
48634575|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
48634576|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
48634577|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
48634578|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
47946214|NCT02047227|DRUG|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
48295755|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy of the lesion that is suspected to be osteosarcoma in a patient with localized disease (Group 1)
47946215|NCT02047227|DRUG|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
47946216|NCT00877201|DRUG|CDR2|
48476716|NCT05148078|OTHER|PROMISE (Pediatric Radiation Oncology with Movie Induced Sedation Effect)|Pediatric Radiation Oncology with Movie Induced Sedation Effect (PROMISE) is an interactive, incentive-based movie system that integrates with a video surveillance gating module (VisionRT) to help keep a child's attention and prevent him or her from moving during radiation treatment. This technology is being studied as an alternative sedation solution for pediatric patients needing radiation treatment. As part of the trial, patients will be attempted to have CT simulation scan and first radiation treatment(s) using PROMISE, with general anesthesia on standby should PROMISE be unsuccessful. If PROMISE is unsuccessful for a given patient, then standard of care general anesthesia will be used for that patient's radiation treatment and PROMISE will be reattempted at physician discretion with anesthesia on standby.
48634579|NCT00281580|DRUG|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
48634580|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
48634581|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
48634582|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
48634583|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
48634584|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
48295756|NCT06064682|OTHER|standard of care biopsy|Image-guided or surgical biopsy or excision of the lesion that is suspected to be recurrent or metastatic osteosarcoma (Group 2).
48295757|NCT06095284|OTHER|Pre-Extraction Phase|This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire
48295758|NCT06095284|OTHER|Extraction Phase|Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire
48295759|NCT06095284|OTHER|Post-Extraction Phase|Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
48295760|NCT02162745|DRUG|Isotonic solution (NaCl 0.9%)|
48295761|NCT02162745|DRUG|Hypertonic solution (NaCl 3%)|
48634585|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
48295762|NCT00100555|DRUG|zoledronic acid|
48295763|NCT00974077|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
48295764|NCT00974077|OTHER|Waiting List Control|Patients receive MBCT with a delay of 6 months.
48295765|NCT04681846|PROCEDURE|Staged approach using antibiotic-cement impregnated PMMA spacer|It will be prepared in the following manner. the cement will be mixed with vancomycin in a ratio of 2 gm to each 40 gm of the spacer. The spacer should be shaped into a cylinder before its solidification. The spacer should be as big as possible to fill the whole defect, without compromising the soft tissue and skin closure. Also, cement should wrap the two ends of bone extremities on 2 or 3 centimeters.
48295766|NCT06139380|DRUG|Ketamine|This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
48295767|NCT06139380|DRUG|Sterile water|Intranasal sterile water was administered via syringe.
48295768|NCT00063648|BIOLOGICAL|EBV-specific autologous CTL|
48295769|NCT00036218|DRUG|sumanirole|
48295770|NCT00036218|DRUG|ropinirole|
48295771|NCT02688075|OTHER|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
48295772|NCT01546220|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
48295773|NCT06513793|BEHAVIORAL|Roots and Shoots|Four-week intervention involving a self-help guidebook to improve mental wellbeing.
48295774|NCT06513793|BEHAVIORAL|Waiting list|Four-week waiting list period involving treatment as usual.
48295775|NCT05326893|OTHER|Femoral nerve neurodynamic mobilization|The mobilization was carried out with the patient lying on the non-dominant side in a total flexion position, and the therapist performed the hip extension movement with the knee joint kept in flexion till the patient felt soreness or pain. This position was held for three seconds and then released. This tensioning maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
48295776|NCT05326893|OTHER|Femoral nerve placebo neurodynamic mobilization|The individual was asked to lie on his non-dominant side and keep his head in the midline. In this position, while the pelvis was stabilized, the upper leg, which was in full knee extension, was grasped and the hip was abducted for 3 seconds. This maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
48295777|NCT05043610|BIOLOGICAL|Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
48295778|NCT05043610|OTHER|Conventional Treatment|Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
48295779|NCT00001542|DRUG|fluconazole|
48295780|NCT06377098|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
48104008|NCT04747457|DEVICE|Research FibroScan|"After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~1. Standard examination \[Reference CE-marked FibroScan\]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~2. Standard examination \[Research FibroScan\]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~3. Exploratory examination \[Research FibroScan\]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver)."
48295781|NCT06377098|DRUG|Placebo Oral Tablet|Placebo table given orally every eight hours up to three times while mother is in labor
48295782|NCT03461965|BEHAVIORAL|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
48634586|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
48634587|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
48634588|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
48634589|NCT00281580|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
48634590|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
47946217|NCT05109845|DIAGNOSTIC_TEST|Spheres & Shield Maze Task|"A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards."
47946218|NCT05844397|DEVICE|WaveLight EX500 Excimer Laser System|LASIK Refractive Surgery Using Contura with Phorcides
47946219|NCT05844397|DEVICE|VisuMax Surgical Laser|SMILE Refractive Surgery
47946220|NCT04926077|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
48634591|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
48634592|NCT00281580|DRUG|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
48634593|NCT00281580|DRUG|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
48634594|NCT00281580|DRUG|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
48634595|NCT00281580|DRUG|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
48634596|NCT00281580|DRUG|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
48634597|NCT00642265|PROCEDURE|osteosynthesis|operative treatment
48634598|NCT00642265|OTHER|sling|conservative treatment
48634599|NCT02560415|DEVICE|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
48634600|NCT02560415|BEHAVIORAL|Comparator|Treatment as usual
48634601|NCT01629862|DEVICE|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
48634602|NCT01629862|DEVICE|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
48634603|NCT03850431|BEHAVIORAL|Social Norms + Behavioral Instructions|A letter with two types of nudges. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
48634604|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patient. One highlights a potential negative consequence for others if the patient no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
48634605|NCT03850431|BEHAVIORAL|Caring + Consequences for Self + Behavioral Instructions|A letter with three types of nudges. One suggests that the institution cares about the patients. One highlights potential negative consequences for the patient if s/he no-shows. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
48634606|NCT03850431|BEHAVIORAL|Caring + Consequences for Others + Consequences for Self + Social Norms + Behavioral Instructions|A letter with all types of nudges combined. One suggests that the institution cares about the patients. One highlights a potential negative consequence for others if the patient no-shows. One highlights potential negative consequences for the patient if s/he no-shows. One points out the common behavior of attending appointments. And one provides clear, specific instructions for making appointment changes. The appointment reminder also includes usual care (basic appointment information on date, location, and phone number(s) for scheduling changes).
48634607|NCT01942980|RADIATION|Radiation therapy Brain metastasis in breast cancer|Radiation
48634608|NCT00372515|DRUG|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
48634609|NCT04557761|DEVICE|microMend®|microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
48634610|NCT04557761|DEVICE|Closure with Sutures|The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
48634611|NCT01762462|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
48634612|NCT04309448|BEHAVIORAL|Perturbation-based balance training with functional electrical stimulation|The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
48634613|NCT05811975|DRUG|KSX01-TCRT injection|individualization TCR-T cell injection
48634614|NCT03281538|DRUG|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
48634615|NCT05733533|DRUG|HRS-2261 oral tablet|HRS-2261 oral tablet, oral, BID
48634616|NCT05733533|DRUG|Matching placebo to HRS-2261|Matching placebo to HRS-2261, oral, BID
48634617|NCT01777529|BIOLOGICAL|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
48634618|NCT03997838|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
48634619|NCT03997838|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
48634620|NCT01852214|DRUG|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
48634621|NCT01852214|DRUG|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
47946221|NCT02517216|OTHER|parabolic flight|
48295783|NCT03461965|BEHAVIORAL|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
48295784|NCT05718076|PROCEDURE|cataract surgery|Phacoemulsification combined trifocal lens implantation
48295785|NCT01347697|PROCEDURE|Reconstruction with an acellular porcine dermal collagen implant (biological mesh)|Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.
48295786|NCT01347697|PROCEDURE|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
48295787|NCT02232789|DRUG|Mephedrone|Single oral dose mephedrone
48295788|NCT02232789|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
48295789|NCT02232789|DRUG|Placebo|Single oal dose placebo
48295790|NCT06567106|OTHER|Ultrasound application|Apply ultrasound to the participant within a safe range.
48295791|NCT06567106|OTHER|No ultrasound application|No ultrasound application to the participant.
48295792|NCT01651260|OTHER|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
48295793|NCT02117050|DRUG|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
48295794|NCT06511856|DEVICE|ARROW|Patients included in the study are patients operated with one or more shoulder medical device fabricated by FH ORTHO. Medical devices of interest are CE marked and include ARROW and ARROW prosthesis, Telegraph Evolution humeral nail and STRAPFLEX strapping system.
48295795|NCT02660580|DRUG|MSB11022|Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
48295796|NCT02660580|DRUG|Humira®|Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.
48295797|NCT01968044|DRUG|Gemigliptin|
48295798|NCT01968044|DRUG|Placebo to Linagliptin|
48295799|NCT03952923|BIOLOGICAL|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
48295800|NCT06671561|DEVICE|Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS)|Observational data collection
48295801|NCT06465329|DRUG|Cemiplimab|Intravenous (IV) infusion administration
48295802|NCT06465329|DRUG|Platinum-based chemotherapy|IV infusion
48295803|NCT06465329|DRUG|REGN7075|IV infusion
48295804|NCT05535673|DRUG|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
48295805|NCT01742351|BEHAVIORAL|Guided internet-based cognitive behavior therapy|
48295806|NCT00722540|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48476717|NCT06331234|OTHER|Vena cava inferior diameter|he VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
48634622|NCT03614780|BEHAVIORAL|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
48295807|NCT00722540|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48295808|NCT00722540|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48295809|NCT00722540|DRUG|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48295810|NCT00722540|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48295811|NCT00722540|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48295812|NCT00722540|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48295813|NCT00722540|DRUG|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48295814|NCT00722540|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48295815|NCT00722540|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48295816|NCT03304483|OTHER|246-km running|Spartathlon 2017
48634623|NCT01412983|DEVICE|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
47946222|NCT02517216|DEVICE|MRI|
48295817|NCT00258154|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
48295818|NCT00258154|BIOLOGICAL|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
48295819|NCT00258154|BIOLOGICAL|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
48295820|NCT01947673|OTHER|Mindfulness Meditation|
48295821|NCT01947673|OTHER|Health Education|
48295822|NCT05032157|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
48295823|NCT05032157|DRUG|Placebo|Placebo
48295824|NCT05032157|DRUG|LOU064 (open-label)|LOU064 (open-label) active treatment
48476718|NCT04675775|OTHER|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
48476719|NCT04675775|DIETARY_SUPPLEMENT|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
47946223|NCT02477969|DRUG|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
47946224|NCT02477969|DRUG|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
48476720|NCT04675775|BEHAVIORAL|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
48476721|NCT02853864|DRUG|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
48476722|NCT02853864|DRUG|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
48476723|NCT02853864|DRUG|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
48476724|NCT02853864|DRUG|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
48476725|NCT02853864|DRUG|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
48476726|NCT04593342|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
48476727|NCT04593342|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
48476728|NCT04651192|OTHER|Combat Exposure|Soldiers will be exposed to combat as part of their routine military service. The ROTC students will not be exposed to combat.
48476729|NCT02277431|DIETARY_SUPPLEMENT|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
48476730|NCT02277431|DIETARY_SUPPLEMENT|placebo|
48476731|NCT04529395|OTHER|Blending of essential oils|The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
48476732|NCT04529395|OTHER|Apricot vegetable oil|The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
48476733|NCT06365294|PROCEDURE|Rescue extracranial stenting|Rescue extracranial stenting in tandem occlusions
48476734|NCT00700245|BEHAVIORAL|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
48476735|NCT00700245|BEHAVIORAL|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
48634624|NCT01412983|DEVICE|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
48634625|NCT01573793|BEHAVIORAL|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
48634626|NCT01573793|BEHAVIORAL|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
47946225|NCT02477969|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
47946226|NCT02477969|DRUG|Metformin|0.5mg,oral,tid.
47946227|NCT03848442|OTHER|'Uptime' participation|The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
47946228|NCT02326675|OTHER|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
47946229|NCT02326675|OTHER|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
47946230|NCT04945031|OTHER|cannabis|This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.
47946231|NCT01998815|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass surgery|
47946232|NCT01814618|DRUG|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
47946233|NCT01330706|DRUG|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
48476736|NCT00700245|BEHAVIORAL|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
48476737|NCT03946917|DRUG|JS001|JS001 3 mg/kg, iv drip, d1, d15, q4w
48476738|NCT03946917|DRUG|regorafenib tablet|80/120/160 mg, po, d1-d21, Q4w.
48476739|NCT05866718|BEHAVIORAL|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
48476740|NCT05866718|BEHAVIORAL|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
48476741|NCT01477099|DEVICE|Toothbrushing with a manual brush|Toothbrushing with a manual brush
48476742|NCT01936311|BEHAVIORAL|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
48476743|NCT02107079|DRUG|Melatonin|swallowing 1 piece, collecting saliva afterwards
48476744|NCT06617507|OTHER|Group 1|The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.
48476745|NCT06035484|OTHER|Seat height|Seat height of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
48476746|NCT06035484|OTHER|Seat inclination|Seat inclination of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
48476747|NCT01099631|BIOLOGICAL|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.
48476748|NCT02326363|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
48476749|NCT02326363|BEHAVIORAL|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
48476750|NCT06193369|BEHAVIORAL|Digital Peer Navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for cancer. Participants will be matched through a digital app with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Patients will communicate with their peer navigator through digital direct messaging, videoconference or by telephone. Participants will also have access to a health resource library on the digital app that contains local and national resources about cancer.
48476751|NCT05883397|OTHER|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.
48476752|NCT05883397|OTHER|Hippocampal training|Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
48476753|NCT02704195|PROCEDURE|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
47946234|NCT03451942|DRUG|FLOT regimen chemotherapy|FLOT regimen chemotherapy
47946235|NCT03451942|PROCEDURE|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
48104009|NCT06480123|DRUG|Skin drug prepared with exome originated from stem cell|Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
47946236|NCT06288009|PROCEDURE|Running locking suture|In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.
48634627|NCT03987607|DEVICE|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
47946237|NCT06288009|PROCEDURE|Standard running suture|In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.
47946238|NCT02602899|PROCEDURE|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
47946239|NCT04571008|OTHER|Placebo|Intervention will last at least 16 weeks in the form of two capsules.
48104010|NCT03651531|DRUG|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
48104011|NCT03651531|DRUG|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
48634628|NCT01727427|DRUG|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
48634629|NCT04062604|OTHER|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
48104012|NCT00917358|DRUG|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
48104013|NCT00199589|DRUG|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
48634630|NCT03169972|BIOLOGICAL|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
47946240|NCT04571008|DIETARY_SUPPLEMENT|Treatment|Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).
47946241|NCT01722773|DEVICE|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
47946242|NCT06087406|DRUG|Imvotamab|Administered intravenously
47946243|NCT06087406|DRUG|Placebo|0.9% sodium chloride administered intravenously
47946244|NCT03710876|BIOLOGICAL|rAd-IFN|Adenovirus-Delivered Interferon Alpha-2b
47946245|NCT03710876|DRUG|Celecoxib Oral Product|400 mg twice daily
47946246|NCT03710876|DRUG|Gemcitabine|1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
47946247|NCT06221917|OTHER|Face-to-face|FTF group are participants who will learn simple sutures physically present with the instructor in the same room.
47946248|NCT06221917|OTHER|Live-streaming|One general surgeon (FH) will teach the participants how to do simple sutures on a mannequin, starting by explaining, then doing a live-demo step-by-step of simple wound suturing. The instructor uses a GoPro Hero 8 device on her head which is connected to the internet and produced live-streaming video, which will then be watched by LS group.
47946249|NCT05715333|BIOLOGICAL|CM326|CM326 Injection
47946250|NCT05715333|OTHER|Placebo|Subcutaneous injection
47946251|NCT03745950|DRUG|Olaparib Oral Capsule|- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
48634631|NCT02639559|DRUG|BL-8040|
48634632|NCT02639559|PROCEDURE|Leukapheresis|
48634633|NCT02639559|PROCEDURE|Hematopoietic cell transplant|
48634634|NCT06479083|OTHER|New Intervention form including|The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.
48634635|NCT06479083|OTHER|Standard treatment|The standard treatment which all compulsory insured patients get.
48634636|NCT04924452|PROCEDURE|Laser conditioning and Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 µm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm2; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
48634637|NCT04924452|PROCEDURE|Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
48634638|NCT04924452|DEVICE|Er:YAG laser therapy|Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.
48634639|NCT04924452|PROCEDURE|Conventional therapy|Conventional rotary instruments will be used for caries removal - high-speed and low-speed dental handpieces. Restoration with compomer.
48634640|NCT01466231|DRUG|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
48634641|NCT03570138|DEVICE|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
48634642|NCT03570138|DEVICE|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
48634643|NCT03817515|DRUG|ABI-009|Sirolimus Albumin-bound Nanoparticles
48634644|NCT04168138|DRUG|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
48634645|NCT05686252|OTHER|Held Position|Change in angle of held position during kangaroo mother care to alternative angle
47946252|NCT03745950|DRUG|Placebo oral capsule|- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
48476754|NCT02704195|PROCEDURE|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
48476755|NCT00493779|PROCEDURE|Blood Collection|4 weeks
48476756|NCT04224194|COMBINATION_PRODUCT|Adalimumab|Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
48476757|NCT04580849|OTHER|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
48476758|NCT02506218|DIETARY_SUPPLEMENT|10 + 20 g protein consumption|whey isolate
48476759|NCT02506218|OTHER|30 g protein breakfast|30 g mixed meal breakfast
48476760|NCT02506218|OTHER|10 g protein breakfast|10 g mixed meal breakfast
48476761|NCT01794754|OTHER|Care as usual|
48476762|NCT01794754|OTHER|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
48476763|NCT04157478|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
48476764|NCT04157478|RADIATION|Radiation therapy|Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
48476765|NCT04157478|DRUG|Temozolomide|Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
48476766|NCT00521482|DRUG|Temozolomide|
48476767|NCT00521482|DRUG|Temozolomide plus Thalidomide|
48476768|NCT04546048|BEHAVIORAL|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
48476769|NCT01489618|BIOLOGICAL|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
48476770|NCT01489618|BIOLOGICAL|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
48476771|NCT00707564|DEVICE|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
48476772|NCT00707564|DEVICE|Gauze with pressure|Gauze with pressure
48634646|NCT02577380|BEHAVIORAL|IPV/GBV HTC|Participants will be interviewed after receiving their services.
48104014|NCT01927965|DRUG|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
48476773|NCT03012659|BEHAVIORAL|Contraceptive Counseling Training|"Intervention sites will receive:~1. In person training: All staff at an intervention health center will participate in a one-day counseling training.~2. On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~3. Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
48634647|NCT01407133|DEVICE|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
48634648|NCT01407133|DEVICE|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
48634649|NCT06281002|DEVICE|conventional impression stone casts digitization|"Nine conventional physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs to act as a reference comparator.~Impressions will be digitized to reference STL files."
48634650|NCT06281002|DEVICE|digital scanning with coupled scanning aiding device|Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.
48634651|NCT06281002|DEVICE|Digital Implant Model assessment of accuracy|The nine STL files of optical scanning will serve as reference data for comparison with the digitized DIMs to evaluate the accuracy of representation of the actual position of implants in the software.
48295825|NCT06425744|OTHER|self-myofascial release combined reformer Pilates|"The self-myofascial release combined reformer Pilates group performs 10 minutes of self-myofascial release using the BALLance© method before beginning 20 minutes of Reformer Pilates. The 6-week program includes warm-up and breathing, main supine exercises 1 and 2, and movements targeting the sacroiliac and hip joints.~All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants attend twice a week for 6 weeks, for a total of 12 sessions.~And all participants performed home exercise program follows the guidelines of Geroge et al (2021) and includes myofascial release and Pilates Reformer exercises, as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
48634652|NCT01951456|BEHAVIORAL|Resistance training|
48476774|NCT01719887|DEVICE|Conservative treatment|Conservative treatment with functional brace.
48476775|NCT01719887|PROCEDURE|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
48634653|NCT01951456|BEHAVIORAL|Health and Wellness|
48634654|NCT06307444|PROCEDURE|Ultrasound-Guided Stellate Ganglion Block|high frequency (6 to 13 MHz) linear transducer will be placed perpendicular to the tracheal axis at the cricoid cartilage and will be moved inferiorly until the superior aspect of the thyroid gland is visualized. Later, the transducer should be relocated laterally to visualize the anterior aspect of the Chassaignac's tubercle on \[\]the C6 transverse process. The carotid artery, internal jugular vein, thyroid gland, trachea, Longus colli, and Longus capitis muscle, prevertebral fascia, the root of C6 spinal nerve, and transverse process of C6 can be identified. Color Doppler will be used to detect the position of the vessels. With an in-plane approach, 22 to 25 gauge echo-enhanced needle is placed beside the trachea with a lateral to medial direction.
48634655|NCT06307444|PROCEDURE|T2 T3 (High Thorathic) ESP Block|We will count the laminae in the cephaled-to-caudal direction, starting from the C7 using the US to determine the exact vertebral level where the needle will be inserted. A linear high-frequency ultrasound probe will be used to perform the blocks. After the determination of the needle insertion site, the US probe was placed over the spinous processes of the vertebrae at the midline in the longitudinal plane. The US probe will then slid laterally from the spinous processes to visualize the transverse process. The needle will be advanced posterior-to-anteriorly, in the caudal to cephalic direction using the in-plane orientation within paraspinal muscles, targeting the transverse process. When the tip of the needle reaches and contact the transverse process, the local anesthetic drugs(0.2-0.3ml/kg(11) of bupivacaine 0.25% 8mg Dexamethazone) will be administered
48634656|NCT03043937|OTHER|registry|
48634657|NCT03843970|DRUG|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
48634658|NCT03843970|DRUG|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
48476776|NCT01719887|OTHER|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
48634659|NCT00736476|BIOLOGICAL|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
47946253|NCT05405413|OTHER|Treatment recommendations made by Molecular Tumor Board.|"Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing"
48104015|NCT02347163|DRUG|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
48476777|NCT01305876|BEHAVIORAL|yoga intervention|yoga session 2 x week over 3-1/2 months
48476778|NCT00368563|DRUG|Helioblock SX|
48104016|NCT00646451|DRUG|pregabalin (Lyrica)|75 mg bid to 300 mg bid based on per subject tolerability
48104017|NCT00646451|DRUG|placebo|up to 4 capsules bid as tolerated
48476779|NCT02340689|OTHER|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
48476780|NCT05247333|OTHER|Minor ailment service|The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
48295826|NCT06425744|OTHER|Reformer Pilates|"The reformer Pilates group will do 30 minutes of Pilates on the Reformer. All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants also attend twice a week for 6 weeks, for a total of 12 sessions.~The home exercise program follows the guidelines of Geroge et al (2021) as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
48295827|NCT03991624|DIAGNOSTIC_TEST|cognitive assessment|"* MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease"
48295828|NCT03991624|OTHER|Inhibition evaluation|"* Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~* Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
47946254|NCT06681415|DRUG|Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution|"Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion."
48104018|NCT05386446|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
48104019|NCT00365638|DRUG|simvastatin|
48295829|NCT03991624|OTHER|Assessment of mental flexibility|"* a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~* a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
48476781|NCT06616558|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
48476782|NCT06616558|OTHER|Sunscreen SPF 70|On the randomized side of the half-face, the product will be applied by a qualified technician
48476783|NCT06443255|DRUG|Cociane hydrochloride 4%|2 mL of 4% cocaine
48476784|NCT06443255|DRUG|Lidocaine 4%|1.5 mL of 4% lidocaine
48476785|NCT06443255|DRUG|Xylometazoline 0.1%|0.5 mL of xylometazoline 0.1%
48476786|NCT06443255|DRUG|Saline 0.9%|2 mL of saline 0.9%
48476787|NCT04063319|OTHER|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
48476788|NCT05025631|DRUG|Fruquintinib|Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
48476789|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily from the time of randomization until delivery.
48476790|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
48476791|NCT06079918|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization until delivery.
48476792|NCT00968019|DEVICE|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
48476793|NCT04654897|DRUG|[14C]-NT-814|120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) \[14C\].
48476794|NCT02219308|PROCEDURE|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds"
48476795|NCT02219308|PROCEDURE|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds"
48104020|NCT03669562|DRUG|Alprostadil Liposome for Injection|intravenous infusion Alprostadil Liposome
48104021|NCT03669562|DRUG|Placebo|intravenous infusion liposome control
48295830|NCT03991624|OTHER|Evaluation of the update|"* an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~* an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
48295831|NCT03991624|OTHER|working memory|"* the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~* the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~* the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
48295832|NCT03991624|OTHER|episodic memory|- A recognition task with a Remember/Know paradigm
48295833|NCT04134104|PROCEDURE|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
48634660|NCT00736476|BIOLOGICAL|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
47946255|NCT06273293|DIAGNOSTIC_TEST|Fractional Flow Reserve|"Agreement measurements between the different post-ICP functional values (cFFR+NTG and FFR) will be performed at the end of the intervention on the treated vessels. The study protocol consists of 4 sequential steps (separated by at least 30 sec):~1. Determination of FFR with contrast and NTG: cFFR +NTG will be calculated with the lowest ratio after the infusion of 0.2 mg bolus of intracoronary NTG and pushed with contrast.~2. Determination of distal pressure between basal aortic pressure: The Pd/Pa will be obtained after about 30-60 seconds of the NTG bolus in step 1.~3. Determination of the diastolic dPR index: the average value (2-3 determinations).~4. Determination of fractional flow reserve with adenosine: The FFR will be obtained after continuous peripheral venous infusion with adenosine or with intracoronary boluses according to the protocol of each center."
47946256|NCT01296438|DRUG|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
47946257|NCT01296438|DRUG|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
47946258|NCT00912678|DRUG|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
47946259|NCT00912678|DRUG|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
48295834|NCT02295891|DEVICE|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
48295835|NCT01056523|DRUG|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
48295836|NCT01056523|DRUG|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
48295837|NCT05046210|BEHAVIORAL|LHA intervention|The participants in the EG received 4 lessons from a LHA over 4 weeks. Four lessons were taught one-on-one once a week by a certified LHA at the participants' homes. The lessons including understand oral structure, learn oral self-care skills and oral function promotion, understand the status of oral self-care and the relationship between oral diseases and systemic diseases, understand swallowing dysfunction and safe eating skills and review.
48295838|NCT05046210|BEHAVIORAL|Oral exercise intervention|Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
48295839|NCT00828386|PROCEDURE|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
48295840|NCT01747330|DRUG|Pancreatin|Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
48634661|NCT02473263|DRUG|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
48295841|NCT05734781|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
48295842|NCT02172612|OTHER|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
48295843|NCT03403101|DRUG|S1|"Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle."
48295844|NCT03403101|DRUG|Oxaliplatin|"Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle"
48634662|NCT02473263|DRUG|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
48634663|NCT02473263|DRUG|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
48634664|NCT02473263|DRUG|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
48634665|NCT01168479|RADIATION|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
48634666|NCT01168479|RADIATION|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
48634667|NCT00635583|OTHER|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~* 8 oz milk~* 6 oz yogurt~* 1.5 oz cheese"
48634668|NCT04295265|DEVICE|smartphone message|Receive daily whatsapp/ SMS message to remind the drug intake
48634669|NCT05879172|DEVICE|electric tubular anastomotic device|"The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery.~Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment."
48634670|NCT05879172|DEVICE|traditional anastomotic device|Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.
48634671|NCT02818062|BIOLOGICAL|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
48634672|NCT04791852|DIAGNOSTIC_TEST|Donor-derived Cell Free DNA|We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification
48634673|NCT06221254|BEHAVIORAL|COBMINDEX digital application|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.
48634674|NCT06221254|BEHAVIORAL|Human therapist (Control)|COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.
48634675|NCT02021604|DRUG|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
48634676|NCT03305211|OTHER|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
48634677|NCT00712075|BEHAVIORAL|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
48634678|NCT00712075|BEHAVIORAL|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
48634679|NCT00712075|BEHAVIORAL|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
48634680|NCT04102644|OTHER|Observation|Documentation of course and outcome of hospitalization, labor, delivery, and postpartum period
48295845|NCT03403101|DRUG|Irinotecan|"Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle"
48295846|NCT00425438|DRUG|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
48634681|NCT03008096|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
48634682|NCT02571244|BEHAVIORAL|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
48634683|NCT00597792|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
48634684|NCT01496443|DRUG|TAK-875 and Glimepiride|
48634685|NCT02234986|DRUG|ENMD-2076|250 mg oral dose, QD for 28 day cycles
48104022|NCT04761562|DRUG|Platelet- and extracellular vesicle-rich plasma|PVRP will initially be applied to the gelatine sponge without prior exogenous activation, which will first be inserted into the middle ear cavity to support the reconstructed tympanic membrane. The remainder of the PVRP will then be exogenously activated with calcium chloride. Gel rich with platelets and extracellular vesicles will be created and applied on top of the reconstructed tympanic membrane. Finally, the external auditory canal will be filled with pieces of gelatine sponge soaked with PVRP.
48295847|NCT00425438|DRUG|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
48295848|NCT00425438|DRUG|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
48634686|NCT04808895|DRUG|Acetylsalicylic acid|administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
48295849|NCT00425438|DRUG|Cyclophosphamide|0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
48295850|NCT04128657|DIAGNOSTIC_TEST|MA_LARS|Validation of the MA_LARS and MA_Wexner
48634687|NCT04808895|DRUG|Placebo|administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
48295851|NCT04322682|DRUG|Colchicine|Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
48295852|NCT04322682|DRUG|Placebo oral tablet|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
48295853|NCT06672315|DIAGNOSTIC_TEST|transesophageal echocardiography|Confirmation of chest compression positioning via transesophageal echocardiography (TEE)
48476796|NCT00876356|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
48634688|NCT05643144|DEVICE|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
48634689|NCT01392495|DRUG|Imatinib|200 mg or 400 mg qd
48476797|NCT00876356|DIETARY_SUPPLEMENT|Olive oil|Olive oil 4.5g/day x 12 weeks
48476798|NCT06226077|BEHAVIORAL|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
48476799|NCT06226077|BEHAVIORAL|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
48476800|NCT05882045|DRUG|Retatrutide|Administered SC
48476801|NCT05882045|DRUG|Placebo|Administered SC
48476802|NCT04690569|DIAGNOSTIC_TEST|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
48634690|NCT02563431|DEVICE|SYSTAM - SP-ED|"* Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~* Daily passive mobilisation of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
48476803|NCT00043576|DRUG|calcitriol|
48476804|NCT00043576|DRUG|docetaxel|
48476805|NCT01221831|DRUG|estetrol, P 1 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day"
48295854|NCT06672029|OTHER|combining pattern-specific manual therapy, Schroth Best Practice exercise, and Gensingen brace application|"* The pattern-specific manual therapy: It was developed by our author. This therapy was done immediately before each SBP (Schroth Best Practice) exercise session, targeting both the spine and extra-spinal regions.~* The Schroth Best Practice exercises: It contains following 6 components: The physio-logic® program for sagittal profile correction, education on activities of daily living (ADLs), the 3D made easy program, the new Power Schroth program, the rehabilitation of walk, and neuromobilization.~* The Gensingen brace application: it was made according to the patients' Lehnert Schroth Classifications. the investigators recommended the patients to wear the brace for 21-23 hours per day during the first year. As the bone maturation reached Risser 4 to 4.5, the daily brace wearing time was gradually reduced."
48295855|NCT02468089|DRUG|Carbepenem|
48295856|NCT02468089|DRUG|Albumin|
48295857|NCT02468089|DRUG|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
48295858|NCT05026658|DEVICE|Visibly Digital Acuity Product|"The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:~1. V1, E, V2~2. E, V1, V2~3. V2, E, V1~4. E, V2, V1~Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.~The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences."
48295859|NCT01475292|DRUG|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
48295860|NCT01475292|DRUG|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
48295861|NCT01475292|DRUG|Placebo|Placebo administered via a nebuliser once daily for 14 days
48295862|NCT00184912|DRUG|caffeine|
48295863|NCT00184912|DRUG|Technetium-TC99m-labeled Annexin A5|
48295864|NCT00184912|PROCEDURE|ten minutes forearm ischemia|
48295865|NCT00184912|PROCEDURE|ischemic forearm exercise|
48634691|NCT02563431|DEVICE|Ultrasling ER 15°Donjoy - 4P-ED|"* Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~* A training of the patient and members of family on pathology, risk, use of material~* Daily passive mobilization of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
48634692|NCT05366647|PROCEDURE|canaloplasty|canaloplasty ab interno with tensioning suture
48634693|NCT05366647|PROCEDURE|Gonioscopy-assisted Transluminal Trabeculotomy|Gonioscopy-assisted Transluminal Trabeculotomy ab interno
48634694|NCT02472951|OTHER|Low carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%"
48634695|NCT02472951|OTHER|Standard carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%"
47946260|NCT05885542|DRUG|Cannabidiol oral solution|Double-blind cannabidiol oral solution 800 mg administered once
47946261|NCT05885542|DRUG|Placebo|Double-blind placebo oral solution administered once
47946262|NCT06613867|OTHER|Wakobotikodro|Wakobotikodro : an intervention combining (i) training matrons to identify and monitor high-risk pregnancies, (ii) integrating them into the healthcare system and (iii) using a digital decision-support application installed on a smartphone and adapted to their profile, could improve the identification and monitoring of high-risk pregnancies.
48295866|NCT05808088|OTHER|Hypnotherapeutic sound-files|The participants have access to hypnotherapeutic sound files which they can use as the please.
48295867|NCT00864227|BIOLOGICAL|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide: 50 mg/kg IV on Day -6~* Total body irradiation: 200 centigray (cGy) on Day -1"
48295868|NCT00864227|BIOLOGICAL|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~* Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~* MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm\^3 for three consecutive measurements, each on different days."
48295869|NCT05829720|DIETARY_SUPPLEMENT|a2 Full Cream Milk|Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
48476806|NCT01221831|DRUG|estetrol, P2 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day"
48476807|NCT01221831|DRUG|Estradiol valerate, dienogest and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day"
48634696|NCT01423890|GENETIC|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
47946263|NCT06680154|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current was delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) were used throughout the stimulation. Before placing the electrodes on the head, the subject's hair was moved to the side
48476808|NCT03795389|DRUG|DM199|Single SC dose
48634697|NCT02301429|DEVICE|Model 20105|implant and follow-up of study device
47946264|NCT06680154|DEVICE|Theta burst stimulation|the intermittent theta burst stimulation (iTBS) which is regarded as safe for high-frequency neuromodulation. Compared to classical rTMS, where pulses are applied repeatedly at a fixed frequency, iTBS consists of bursts of pulse triplets. In the classical protocol, the bursts are applied for two seconds in 5Hz intervals followed by an eight-second break, before the next bursts are applied. This pattern is repeated for 190 seconds resulting in 600 pulses per protocol.
48295870|NCT05829720|DIETARY_SUPPLEMENT|Conventional Milk (Weidendorf)|Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
48295871|NCT04408092|DRUG|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
48476809|NCT06165445|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm) or via more than two but smaller round electrodes over the target regions.
48476810|NCT06165445|DEVICE|multichannel transcranial direct current stimulation (tDCS)|In multichannel tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through more than two and smaller round electrodes over the target regions.
48476811|NCT00939627|BIOLOGICAL|cetuximab|Given IV
48476812|NCT00939627|OTHER|placebo|Given orally
48476813|NCT00939627|DRUG|sorafenib tosylate|Given orally
48476814|NCT00939627|OTHER|laboratory biomarker analysis|Correlative studies
48476815|NCT00939627|PROCEDURE|quality-of-life assessment|Ancillary studies
48476816|NCT00172068|DRUG|Zoledronic acid + Calcium/Vitamin D|
48476817|NCT05123781|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the test product was administered orally with 240 ml of water
48476818|NCT05123781|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orally with 240 ml of water
48476819|NCT02013531|DRUG|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
48295872|NCT06570954|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.
48476820|NCT05332054|BIOLOGICAL|Allogeneic CAR-T therapy|N/A this is an observational study
48476821|NCT04768634|DIAGNOSTIC_TEST|Provocative electrophysiology study|Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
48476822|NCT06192641|DRUG|Melatonin 3 MG|patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
48476823|NCT00374049|DRUG|MUC_1|Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
48634698|NCT01630811|DRUG|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
48634699|NCT01630811|OTHER|Placebo|Placebo will be given once daily for 7 days.
48476824|NCT03858127|OTHER|Collection of urine sample|Collection of urine sample for measurement of LH and FSH
48476825|NCT03858127|OTHER|Examination of genitalia|Examination of genitalia
48476826|NCT03858127|OTHER|Video messaging|Short video of infant recorded at home by the parents
48476827|NCT03766217|COMBINATION_PRODUCT|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
48476828|NCT03766217|COMBINATION_PRODUCT|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
48634700|NCT02813512|DRUG|ADSCs|Autologous ADSCs
48295873|NCT05604105|OTHER|Questionnaire|The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
48295874|NCT02310633|BEHAVIORAL|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
48634701|NCT05932680|OTHER|Off Drug Surveillance|After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.
48634702|NCT02636036|BIOLOGICAL|enadenotucirev|
48634703|NCT02636036|BIOLOGICAL|nivolumab|
48634704|NCT02229292|DRUG|Tranexamic Acid|"Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
48634705|NCT02229292|DRUG|Saline|"Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
48295875|NCT02310633|BEHAVIORAL|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
48295876|NCT02310633|BEHAVIORAL|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
48295877|NCT01408537|BIOLOGICAL|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
48295878|NCT01696409|DIETARY_SUPPLEMENT|400 IU vitamin D3|Take 400 IU once/day for 2 months
48476829|NCT04333381|OTHER|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~1. The educational intervention will consist:~   Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~2. The organizational intervention will consist:~   * Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~  * Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~  * Review organizational strategies and definition of new improvement measures~  * Audit the delays in STEMI~  * Periodic multi-disciplinary update sessions"
48634706|NCT02203786|DRUG|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
48634707|NCT02203786|DRUG|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
48634708|NCT02203786|DRUG|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
48634709|NCT02203786|DRUG|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
47946265|NCT06680154|DEVICE|Sham (No Treatment)|In the case of sham TMS, two different sham coils (double 70mm pCool-SHAM coil, Mag\&More GmbH, Munich, Germany) will produce audible clicks at the decibel intensity corresponding to an active coil without the induction of an electromagnetic pulse. Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
48634710|NCT02203786|BEHAVIORAL|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
48295879|NCT01696409|DIETARY_SUPPLEMENT|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
48295880|NCT01963052|DRUG|AGS15E|intravenous (IV) infusion
48295881|NCT05334784|DEVICE|Impella ECP|Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
48295882|NCT03964415|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
48295883|NCT03964415|BIOLOGICAL|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
48295884|NCT03964415|BIOLOGICAL|Placebo|Participants will receive matching placebo.
48295885|NCT00048906|DRUG|DRX005B|
48295886|NCT00277472|DRUG|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
48295887|NCT00277472|DRUG|HCTZ|25 mg taken once daily orally
48295888|NCT00196495|DEVICE|Polypropylene Mesh|
48295889|NCT05336227|BEHAVIORAL|Virtual Reality Exergaming|The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
48295890|NCT04904042|DEVICE|Use of plasma of neutral argon|"Evaluation of the mesentery or peritoneum area infiltrated by miliary implants that is going to be treated. Determination of the PCI. Collection of several samples of the mesenteric peritoneum or parietal peritoneum with tumor involvement (implants between 1-2.5mm of diameter).~It will established a matrix which will be divided into 12 quadrants where the tissue with implants will be placed and it will be treated according to specific power (80-100%), and for an action time of 2-4 seconds or until macroscopic tumor destruction. For each power, application of Plasmajet at 1, 2 and 3 cm from the target tumor tissue.~The in-vivo effect will be evaluated with the use of ball-tip in terms of damage to the serosa or vascularization of the mesentery."
48295891|NCT00631722|DRUG|Quatiapine Fumarate|600-750mg/day
48295892|NCT00631722|DRUG|Haloperidol|12-20mg/day
48295893|NCT00751881|DRUG|Placebo|"Film-coated tablet~Oral administration"
48295894|NCT00751881|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
48295895|NCT03807765|DRUG|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
48295896|NCT03807765|RADIATION|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
48295897|NCT01134484|DRUG|Velcade|"* INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~* REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
48295898|NCT01134484|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
48295899|NCT01134484|DRUG|Dexamethasone|"* INDUCTION THERAPY~  1. VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~ 2. TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~* AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~  1. VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~ 2. TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
48295900|NCT01134484|PROCEDURE|Peripheral Blood Stem Cell (PBSC) collection|"* Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~* G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
48295901|NCT01134484|PROCEDURE|First Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
48295902|NCT01134484|PROCEDURE|Second Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
48295903|NCT05757999|DRUG|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
48295904|NCT05757999|DRUG|Saline|The patients will be pretreated with an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min before induction of anesthesia.
48295905|NCT00751101|DRUG|Nicotine patch|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
48476830|NCT04333381|OTHER|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
48476831|NCT04819373|DRUG|BDB001|BDB001 is an immunotherapy agent.
48476832|NCT00671073|DRUG|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
48476833|NCT00671073|DRUG|Placebo|Placebo, oral administration, once daily for 12 weeks
48476834|NCT00671073|DRUG|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
47946266|NCT04450836|DRUG|Regorafenib then Trifluridine/Tipiracil|"REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle."
48295906|NCT06671925|BEHAVIORAL|Strengthening COnnections to Overcome Pain (SCOOP)|Each week for 7 weeks, SCOOP intervention group participants will watch a brief video on the study website teaching a pain management or social connectedness skill and have a session with a community health worker, where they will receive support with behavioral goal-setting related to pain management and/or social connections. Participants will be screened for unmet social needs and connected to appropriate resources.
48295907|NCT06483100|DRUG|Elrantamab|"- Elranatamab will be dosed in 28-day cycles as follows:~* C1D1: 12 mg SC priming dose~* C1D4: 32 mg SC priming dose~* C1D8, C1D15, C1D22: 76 mg SC~* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15"
48295908|NCT06483100|DEVICE|clonoSEQ|FDA approved MRD testing
48295909|NCT05930925|DRUG|[phenyl-14C]ARV-471|Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
48295910|NCT05930925|DRUG|[oxoisoindolin-14C]ARV-471|Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
48295911|NCT06448247|DRUG|SPY001-001|Experimental
48295912|NCT06448247|OTHER|Placebo|Placebo
48295913|NCT03623269|PROCEDURE|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
48295914|NCT04300218|BEHAVIORAL|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
48295915|NCT04300218|OTHER|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
48295916|NCT04183257|DRUG|oral vitamin D|oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
48295917|NCT06369324|OTHER|Pain education|It consisted of holding information sessions on each of the days that the subjects were scheduled for treatment. These sessions will be supported by supplementary material in the form of brochures, posters and videos which briefly explain interesting knowledge about spondyloarthropathies.
48295918|NCT06369324|OTHER|Exercise supervised by external focus|This therapeutic exercise involves proprioceptive training with external feedback to enhance exercise execution and promote optimal postural control, particularly for individuals with back pain. The method, based on research by Abdollahipour et al. and Chiviacowsky et al., focuses on automatic control, reducing the cognitive load during exercises and improving movement retention. The Motion Guidance Clinician Kit will be utilized, consisting of a panel and laser guide for precise cervical movement. Exercises progress in difficulty over 12 sessions, targeting cervical and lumbopelvic stabilization, flexion-extension, rotations, and lateral flexions. Sessions start with seated exercises and progress to standing, with increasing distance between laser targets to expand cervical range of motion. Thoracic and lumbar exercises involve 10 repetitions each. The entire program lasts around 20 minutes and follows Tidier recommendations for intervention.
48476835|NCT00671073|DRUG|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
48634711|NCT05507892|DRUG|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
48476836|NCT00099957|DRUG|vildagliptin|
48476837|NCT00523289|DRUG|Bupivacaine|Dosage: 150mg at once for anesthesia induction
48476838|NCT00523289|DRUG|Ropivacaine|Single dose of ropivacaine, 150mg
48295919|NCT06369324|OTHER|Therapy by means of electrical stimulation (electro-massage)|This technique combines manual therapy (massage) with interferential current. Following a supervised therapeutic exercise program, this intervention targets the spine for 15 minutes. Using a Sonopuls 692® device, a bipolar current mode with specific frequencies is applied. The physiotherapist moistens sponges with warm water and administers the current through them while performing manual soft tissue therapy on the neck, shoulders, scapulae, thoracic, lumbar, and sacral areas. The intensity is adjusted to provide a strong but comfortable tingling sensation, without muscle twitching. The therapy sequence includes superficial stroking, deep gliding movements, trapezius kneading, muscle stretching, and deep rubbing on the thoracic and lumbar areas. The electro-massage protocol lasts 14 minutes.
48295920|NCT05894993|DEVICE|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
48295921|NCT03551418|BEHAVIORAL|Watching a video|Watching a video of an adult with DS washing his hands
48295922|NCT03622411|DEVICE|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
48476839|NCT05799196|PROCEDURE|Microfracture|Microfracture was made in the non-weight bearing chondral to provide the release of MSC and growth factor.
48295923|NCT03622411|DEVICE|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
48295924|NCT03622411|BEHAVIORAL|aphasia therapy|language exercises provided by the speech therapist in hospital
48295925|NCT00000530|DRUG|nifedipine|
48295926|NCT00000530|BEHAVIORAL|biofeedback (psychology)|
48295927|NCT00000530|PROCEDURE|electromyography|
48295928|NCT00336193|BEHAVIORAL|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
48476840|NCT06444321|BEHAVIORAL|INTERCARE-HF|Develpent of an individualized treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level as well as the patients' symptoms and needs.
48476841|NCT00519974|OTHER|counseling intervention|
48476842|NCT00519974|OTHER|study of socioeconomic and demographic variables|
48476843|NCT00519974|PROCEDURE|management of therapy complications|
48476844|NCT00519974|PROCEDURE|psychosocial assessment and care|
48476845|NCT05773534|DIAGNOSTIC_TEST|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
48476846|NCT01131962|PROCEDURE|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
48476847|NCT03041207|BEHAVIORAL|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
48476848|NCT02269631|BEHAVIORAL|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
48476849|NCT02269631|BEHAVIORAL|Control diet group|no legumes in lunch or dinner meals
48476850|NCT02269631|DEVICE|Smartpill|to assess how long food takes to pass through the digestive system
48476851|NCT02269631|OTHER|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
48476852|NCT02176668|DRUG|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
48476853|NCT02176668|DRUG|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
48476854|NCT02176668|DRUG|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
48476855|NCT02176668|DRUG|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
48295929|NCT06671613|DIETARY_SUPPLEMENT|FMD|Plant-based diet program
48476856|NCT03321474|PROCEDURE|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
48476857|NCT05274048|DRUG|Neratinib Pill|Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
48476858|NCT05274048|DRUG|Fam-Trastuzumab Deruxtecan-Nxki (TDxD)|standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
48476859|NCT05523570|DRUG|HNC364|2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
48476860|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
48295930|NCT06671613|COMBINATION_PRODUCT|Regular Diet Plus FMD|Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6
48295931|NCT05585437|PROCEDURE|gastric cancer specialist training program|The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
48634712|NCT05507892|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
48634713|NCT02441257|PROCEDURE|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
47946267|NCT04450836|DRUG|Trifluridine/Tipiracil then Regorafenib|"TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off."
47946268|NCT01516073|DRUG|Fluticasone Propionate|FP BID for 12 weeks
47946269|NCT05727462|OTHER|Manual Therapy with TECAR|"The following myofascial release techniques will be applied:~Myofascial release of the upper trapezius Gross stretch, vertical gross stretch, and focused stretch of the upper trapezius Myofascial release at the cranial base Gross release of the sternocleidomastoid muscle~Additionally, the following ischemic compression technique will be applied:~Ischemic compression on the upper trapezius muscle Manual therapy manipulations will be administered in combination with a capacitive conventional electrode and two special electrode bracelets that turn the therapist's hands into anti-static electrodes. High-frequency currents will be applied at frequencies of 300 kHz, 500 kHz, and 1 MHz, with a flexible self-adhesive grounding electrode placed on the thoracic spine for reference."
48476861|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
48476862|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
48634714|NCT02441257|PROCEDURE|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
48295932|NCT02159092|BEHAVIORAL|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
48634715|NCT03255590|BEHAVIORAL|Configuration task|Training the impaired hand on a configuration task
48634716|NCT00271570|DRUG|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
48634717|NCT00271570|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
48634718|NCT01391871|DEVICE|OCT|Optical coherence tomography
48634719|NCT01391871|DEVICE|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
48634720|NCT01383824|DEVICE|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
48634721|NCT06100835|OTHER|Complex intervention involving physical activity and behaviour change techniques|"The intervention protocol derives from a previous, extensive, co-creation phase involving end-users as well as relatives, experts, professionals working working with older adults, university students and researchers.~It will be based on a structured group-based PA programme supervised by trained professionals, tailored to participants' needs to include joyful components combined with self-management strategies to encourage behaviour change also beyond the sessions. All participants (including end-users but not only) will also be encouraged to join virtual communities of practice (VCoP) for further support and knowledge exchange."
48634722|NCT03202550|DRUG|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
48634723|NCT03202550|DRUG|Placebo Comparator|Placebo oral pills
48634724|NCT03160807|DRUG|Levofloxacin|Levolet 500 mg OD for 5 days
48634725|NCT03160807|DRUG|Levofloxacin|Levolet 500 OD for 10 days
48104023|NCT04761562|PROCEDURE|Control group|Edges of the tympanic membrane perforation will be refreshed and the tympanomeatal flap raised. Under the tympanic membrane perforation, a guide (fascia of the temporalis muscle, perichondrium, cartilage or fat) will be placed. An absorbent gelatin sponge will be placed under the guide and on the outer surface of the reconstructed tympanic membrane.
48634726|NCT03053999|OTHER|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
48634727|NCT03053999|OTHER|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
48634728|NCT04867070|DIAGNOSTIC_TEST|NAS score|Participants will be recorded according to the NAS and W-BAS pain scores
48634729|NCT03744975|DRUG|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
48634730|NCT03744975|DRUG|Placebos|Participants will receive 1oral Placebo capsule
48634731|NCT01889563|OTHER|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
48634732|NCT05280314|DRUG|IO102-IO103|IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).
48634733|NCT05280314|DRUG|Pembrolizumab KEYTRUDA®|Pembrolizumab KEYTRUDA® administered intravenously
47946270|NCT05727462|OTHER|Manual Therapy without TECAR|Participants in this group will follow the same manual protocol as the first group, without the application of high-frequency current. Each manual therapy session will begin with a ten-minute preparation involving light massage and stretching. The massage will include the effleurage technique, followed by petrissage and kneading, focusing on the cervical and thoracic areas, particularly the upper trapezius, suboccipital region, and cervical paraspinal muscles. Stretching will be applied to the upper trapezius, levator scapulae, and sternocleidomastoid muscles.
47946271|NCT05952037|DRUG|BGB-11417|Administered orally as a tablet.
48476863|NCT06416852|DRUG|18F-Alfatide Injection|A single dose of (0.1\~0.15）±0.015 mCi/kg IV injection of 18F-Alfatide. The patients will be intravenously injected with 18F-Alfatide Injection and undergo PET/CT scan at 60 min±10 min after the injection.
48634734|NCT05807750|OTHER|Post-discharge income supplement|$300 income supplement
47946272|NCT05952037|DRUG|Zanubrutinib|Administered orally as a tablet.
48295933|NCT05259046|DIETARY_SUPPLEMENT|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
48476864|NCT06416852|DRUG|18F-FDG Injection|A single dose of 5～10mCi IV injection of 18F-FDG. The patients will be intravenously injected with 18F-FDG Injection and undergo PET/CT scan at 40 min±10 min after the injection.
48476865|NCT06616701|BEHAVIORAL|Follow up call|As part of the standard of care, caregivers of youths who present to the hospital with suicidal risk receive a follow up call approximately 5-10 business days after the hospital discharge to assist them with any challenges they may encounter in accessing mental health care, including medication access. The intervention group will receive a call 5 days after discharge. The non-intervention group will receive a call 10 days after discharge.
48634735|NCT05807750|OTHER|Enhanced care planning|Enhanced care planning provided by a nurse care manager
48634736|NCT03313765|BEHAVIORAL|Motivational interviewing (MI)|Brief MI intervention
48634737|NCT03313765|OTHER|Standard-of-care|Standard-of-care education and counseling
48634738|NCT06344377|DIETARY_SUPPLEMENT|Betaine|Betaine supplemented for 8 weeks
48295934|NCT05259046|DIETARY_SUPPLEMENT|Placebo tablet|One placebo tablet per day
48476866|NCT06204575|OTHER|Data collection|Data collection
48634739|NCT06344377|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
47946273|NCT03603054|OTHER|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
47946274|NCT03603054|OTHER|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
47946275|NCT05063890|PROCEDURE|Muscle Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
48104024|NCT03478696|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
48104025|NCT03478696|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
48104026|NCT03478696|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
48104027|NCT03478696|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
48634740|NCT05137613|OTHER|One visit root canal retreatment|The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
48476867|NCT02555982|DRUG|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
48476868|NCT02555982|DRUG|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
47946276|NCT05063890|PROCEDURE|Movement Specific Post Isometric Relaxation MET|3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
47946277|NCT05063890|PROCEDURE|unilateral postero-anterior glide|3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
47946278|NCT05063890|PROCEDURE|Heating and TENS|Heating and TENS for 10 minutes
47946279|NCT03698331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
47946280|NCT03698331|DRUG|Placebo oral capsule|non-active dosage form
47946281|NCT03939156|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
47946282|NCT06680986|OTHER|Clinical cardiac parameters (Arterial pressure, number of anti-hypertensive medications, and the NT-proBNP measurements)|The degree of severity of the hypertension will have been previously diagnosed for each patient with the help of the blood pressure measurements, the number of antihypertensive treatments and the NT-proBNP measurement which is correlated with the left intraventricular pressure and the mass of the left ventricle. This information will be used (i) to guide the structuring of the pathology representation space during the learning phase from a sub-population (a portion of the collected database that will be used for training algorithms); (ii) to serve as an endpoint from a test sub-population (the remaining portion of the database collected).
47946283|NCT01609231|DRUG|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
47946284|NCT01609231|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
47946285|NCT01609231|DRUG|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m\^2 followed by weekly infusions of 250 mg/m\^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
47946286|NCT06390319|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
48104028|NCT03478696|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
48295935|NCT04523792|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
48476869|NCT05896215|DRUG|KNP2002|Dairy topical administration for 12 weeks
48476870|NCT05896215|DRUG|Placebo of KNP2002|Dairy topical administration for 12 weeks
48634741|NCT05137613|OTHER|Two visit root canal retreatment|The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
47946287|NCT06390319|DRUG|Vincristine|Given IV.
47946288|NCT06390319|DRUG|Daunorubicin|Given IV.
47946289|NCT06390319|DRUG|Calaspargase pegol|Given IV.
47946290|NCT06390319|DRUG|Dasatinib|Given PO
47946291|NCT06390319|DRUG|Venetoclax|Given PO (ETP, near-ETP, and MPAL only).
47946292|NCT06390319|DRUG|Bortezomib|Given IV (T-LLy only).
47946293|NCT06390319|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Given Intrathecal (IT), Age adjusted.
47946294|NCT06390319|DRUG|Cyclophosphamide|Given IV.
47946295|NCT06390319|DRUG|Cytarabine|Given IV or IT.
47946296|NCT06390319|DRUG|Mercaptopurine|Given PO.
47946297|NCT06390319|DRUG|Nelarabine|Given IV
47946298|NCT06390319|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
47946299|NCT06390319|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
48104029|NCT03478696|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
48104030|NCT03478696|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
48104031|NCT03478696|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
48634742|NCT01096186|DRUG|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
48634743|NCT01096186|DRUG|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
48634744|NCT01096186|DRUG|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
48634745|NCT01096186|DRUG|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
48295936|NCT02273310|BEHAVIORAL|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
48634746|NCT01531803|DRUG|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
48634747|NCT01531803|DRUG|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
47946300|NCT05936268|DRUG|Genakumab for injection|150 mg/1ml/bottle
47946301|NCT05936268|DRUG|Colchicine|0.5mg/table
48104032|NCT03478696|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
48295937|NCT06665672|DEVICE|Wrist worn vibro-acoustic device|The Apollo device is a wrist worn device that is similar to a typical wristwatch. It emits a vibration pattern based on settings selected on a designated mobile app.
48295938|NCT03090737|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
48295939|NCT02430792|BEHAVIORAL|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
48295940|NCT03955848|BIOLOGICAL|Alloreactive NK cell infusion|Alloreactive NK cell infusion
48295941|NCT01810159|OTHER|Integrated collaborative care|
48295942|NCT01810159|OTHER|Education and Resources|
48295943|NCT04516616|DRUG|Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)|PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
48295944|NCT02446639|OTHER|Blood collection|
48295945|NCT06339229|OTHER|proteinuria|dipstick proteinuria values negative, trace, 1+, and ≥2+
48476871|NCT06494800|DIAGNOSTIC_TEST|True cut needle biobsy|The biobsy procedure done at the radiology department and the cores are examined by the pathology department, the patient lie prone, supine or in lateral decubitus according to the location of the lesion. A thoracic CT scan was performed first to evaluate the needle pathway and distance from the puncture site to the lesion. The needle pathway was selected to avoid bone, visible vessels, bullae, and fissures. The puncture site was chosen by the CT gantry laser lights and landmarks using a homemade radiopaque grid on the patient's skin. Local anaesthesia was induced with 5 mL of 2% lidocaine. An 18-G coaxial needle was used to puncture the lung, and a repeat CT scan was performed to evaluate the site of the needle. When the needle tip reached the lesion, the specimen was obtained by pressing the trigger of the needle. The specimen was reviewed by the pathologist.The specimen was placed in 10% formaldehyde for pathological examination.
48476872|NCT02632175|BIOLOGICAL|Adalimumab|every other week or weekly subcutaneous injection
48476873|NCT02344745|OTHER|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
48476874|NCT02344745|OTHER|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
48476875|NCT00981227|DRUG|Eslicarbazepine acetate|Scored tablets
48476876|NCT00981227|DRUG|Placebo|oral route
48476877|NCT00472953|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
48476878|NCT00472953|DRUG|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
48476879|NCT03282149|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
48476880|NCT05445609|DRUG|VLP-encapsulated TLR9 Agonist CMP-001,|Given SC or IT
48476881|NCT05445609|BIOLOGICAL|Nivolumab|Given IV
48476882|NCT06276699|PROCEDURE|1.Isometric exercise 2.combined conservative treatment|Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.
48476883|NCT03074864|DRUG|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
48476884|NCT00131755|DRUG|diazoxide|
48476885|NCT01350934|DRUG|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
48476886|NCT01350934|DRUG|Calcitriol|0.25 μg once daily orally
48104033|NCT03478696|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
48295946|NCT00843622|DRUG|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
48634748|NCT05020522|DIAGNOSTIC_TEST|Luminal Index MRI (LI-MRI)|Multiecho T2 sequence; eventual biopsy of lesion(s) detected with LI-MRI only.
48634749|NCT05020522|DIAGNOSTIC_TEST|LI-MRI targeted prostate biopsy|Biopsy targeted to suspicious lesions detected with LI-MRI only
48634750|NCT05020522|DIAGNOSTIC_TEST|Plasma methylation signature (ctMethSig)|Blood sample.
48634751|NCT05020119|DRUG|Neoantigen-expanded cell therapy.|Infusion of personalized neoantigen-expanded T (CIK) cells
48634752|NCT00465283|DRUG|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
48634753|NCT02382263|DRUG|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
48295947|NCT00843622|OTHER|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
48295948|NCT06443281|DIAGNOSTIC_TEST|Neurophysiology|Pain-related evoked potentials and nerve conduction studies
48295949|NCT06443281|DIAGNOSTIC_TEST|Cardiovascular test|Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability
48295950|NCT06443281|DIAGNOSTIC_TEST|Experimental pain paradigms|Temporal summation of pain, conditioned pain modulation
48295951|NCT06443281|DIAGNOSTIC_TEST|Quantitative sensory testing|Thermal and mechanical sensory testing
48295952|NCT06443281|DIAGNOSTIC_TEST|Clinical pain phenotype|Pain drawings, plus and minus signs of pain
48295953|NCT02901717|DRUG|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
48295954|NCT02901717|DRUG|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
48295955|NCT01175239|GENETIC|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
48476887|NCT01350934|DIETARY_SUPPLEMENT|Calcium 500 mg|one 500 mg tablet once daily
48295956|NCT00091390|RADIATION|High Dose brachytherapy boost|19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
48295957|NCT00091390|RADIATION|External beam radiotherapy|45 Gy as 1.8 Gy five days a week for five weeks.
48476888|NCT05840471|DRUG|Tranexamic acid injection|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
48476889|NCT05840471|OTHER|Glucose water 5%|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
48476890|NCT03980301|DIAGNOSTIC_TEST|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
48476891|NCT06227117|DRUG|Disitamab Vedotin Injection （18 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
48476892|NCT06227117|DRUG|Toripalimab （18weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
48476893|NCT06227117|DRUG|Carboplatin|AUC 3 Q2W or AUC1.5 QW intravenous infusion
48476894|NCT06227117|DRUG|Disitamab Vedotin Injection （12 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
48476895|NCT06227117|DRUG|Sequential Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
48476896|NCT06227117|DRUG|Sequential CTX|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
48476897|NCT06227117|DRUG|Toripalimab （12weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
48476898|NCT02994290|DRUG|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
48634754|NCT02382263|DRUG|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
48634755|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle
48634756|NCT02382263|DRUG|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
48634757|NCT01451788|DEVICE|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
48634758|NCT03611465|OTHER|Pace-mapping|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
48295958|NCT04933812|BEHAVIORAL|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
48295959|NCT05050136|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
48295960|NCT05050136|DRUG|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
48295961|NCT03279510|DEVICE|hearing aids|Subjects are fit with hearing aids.
48295962|NCT06443879|OTHER|Axillary brachial plexus nerve block: loss and return of sensation|Evaluating loss and return of sensation after axillary brachial plexus nerve block
48295963|NCT03873129|BEHAVIORAL|mobile health app (mHealth)|A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
48295964|NCT02817542|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
48295965|NCT05497505|DEVICE|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
48295966|NCT06649344|DRUG|HRS9531 Injection|HRS9531 injected subcutaneously once weekly.
48295967|NCT06649344|DRUG|Semaglutide Injection|Semaglutide injected subcutaneously once weekly.
48295968|NCT01070303|BIOLOGICAL|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
48295969|NCT05574101|DRUG|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
48295970|NCT05574101|RADIATION|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
48295971|NCT00562510|DRUG|Raltegravir|Raltegravir 400 mg BID added to stable HAART
48295972|NCT00562510|DRUG|Placebo|Placebo BID added to stable HAART
48295973|NCT06672692|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA RSV viral RNA, and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
48295974|NCT01277224|BEHAVIORAL|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
48295975|NCT04912128|DRUG|Anlotinib|"Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases"
48295976|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
48295977|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
48295978|NCT03344159|DRUG|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
48295979|NCT03344159|DRUG|Placebo|Placebo daily for a total of duration of 12 weeks
48295980|NCT03344159|RADIATION|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
48295981|NCT03344159|DIAGNOSTIC_TEST|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
48295982|NCT02442999|OTHER|Screening for obstructive sleep apnea|
48295983|NCT02442999|DEVICE|CPAP - continuous positive airway pressure|
48295984|NCT04151563|BIOLOGICAL|nivolumab|Specified dose on Specified days
48295985|NCT04151563|BIOLOGICAL|ipilimumab|Specified dose on Specified days
48295986|NCT04151563|DRUG|cabozantinib|Specified dose on Specified days
48295987|NCT04151563|BIOLOGICAL|docetaxel|Specified dose on Specified days
48295988|NCT04151563|BIOLOGICAL|ramucirumab|Specified dose on Specified days
48295989|NCT04151563|DRUG|lucitanib|Specified dose on Specified days
48295990|NCT03641300|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
48295991|NCT03641300|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
48295992|NCT06532383|DRUG|PF-07940369|Bulk powder for extemporaneous preparation for oral solutions.
48295993|NCT06532383|DRUG|Placebo|Bulk powder for extemporaneous preparation for oral solutions
48295994|NCT05154747|DRUG|Cabotegravir, Rilpivirine Drug Combination|"Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (\<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock."
48295995|NCT05154747|DRUG|TLD|Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
48295996|NCT00623012|DRUG|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
48295997|NCT00623012|DRUG|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
48295998|NCT00364546|DRUG|CG 5503;tapentadol|
48295999|NCT04579393|DRUG|Placebo|Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
48296000|NCT04579393|DRUG|fostamatinib|The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
48296001|NCT03595215|DEVICE|TENS|Transcutaneous electrical nerve stimulation
48296002|NCT04018287|OTHER|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
48296003|NCT01203462|OTHER|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
48296004|NCT01203462|OTHER|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
48476899|NCT02994290|BEHAVIORAL|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
47946302|NCT06380179|DEVICE|THOR3 training + Photobiomodulation Therapy (PBMT)|"PBMT will be delivered at 32-40W (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.~PBMT will be delivered by a trained study team member using the LightForce® XLi 40W device with the Smart Hand Piece technology, which has a built-in accelerometer in the hand piece that controls the speed of light delivery to the treatment area. The trained team members will use the Smart Hand Piece technology, which assesses the operator's speed and provides real-time visual and sensory feedback calibrated to shut-off when moving too slowly and warns the operator when moving too quickly by vibrating. Treatment is delivered through a flexible optical fiber threaded through the hand piece, which contains a rolling glass massage ball."
48296005|NCT03975972|OTHER|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
48296006|NCT06660212|DEVICE|Photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. Doses will increase from 40%-100% power over the course of the intervention
48296007|NCT06660212|DEVICE|Sham photobiomodulation|The laser therapy will be delivered in progressively higher doses, based on individual participants tolerance. Each stage will follow this sequence of applications: (1) perineum application (DUO-240 red and infrared array in the surface of the perineum) and (2) LDR-100 probe on the vestibula more generally. . Doses will always be set to 1% power over the course of the intervention
48296008|NCT06660212|PROCEDURE|Multimodal physiotherapy|A total of 10 sessions of multimodal physiotherapy interventions will be provided to each of the participants in the multimodal physiotherapy (mPT) and multimodal physiotherapy combined with photobiomodulation treatment (mPT+PBM) groups. In general, each session will take place in the following order:1) Subjective assessment of the condition and screening for adverse effects or deterioration of the condition, 2)Education, 3) Relaxation Techniques, 4) Pelvic Floor Muscle Exercises, 5) Manual techniques, 6) exercises with accommodators, 7) Global exercises, 8) Assessment of the post-treatment condition and 9) adjustment of the weekly exercise program to be done at home. Each of these 9 treatments will be adjusted and tailored to each participant and progressed based on individual preference and response to treatment under the discretion of the study physiotherapist.
48296009|NCT04561817|DRUG|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
48296010|NCT04561817|DRUG|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
48634759|NCT03611465|OTHER|Standard pace-mapping examination|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
47946303|NCT06380179|DEVICE|THOR3 training + sham PBMT|Sham PBMT will be provided by a trained study team member. Sham PBMT will be delivered in the same manner as indicated for the PBMT process above, but the device will stay in standby mode (i.e., the treatment mode will not be turned on). As infrared light is invisible to the naked eye, the only visible difference between treatment and standby modes is the presence of a few tiny amber lights (these lights are on during treatment mode).
48296011|NCT04362267|OTHER|self-administered questionnaire|Every14 days, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
48476900|NCT01675076|DRUG|Dabigatran|NOAC
47946305|NCT06327659|DEVICE|30 mL syringe manual thrombectomy catheter|30 mL syringe manual thrombectomy catheter
47946306|NCT06327659|DEVICE|50 mL syringe manual thrombectomy catheter|50 mL syringe manual thrombectomy catheter
48296012|NCT04362267|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every14 days, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
48296013|NCT03384511|DRUG|Apatinib|Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
48296014|NCT05187533|OTHER|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
48296015|NCT04914130|OTHER|Study specific testing procedures|Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
48476901|NCT01675076|DRUG|Rivaroxaban|NOAC
48476902|NCT01675076|DRUG|Apixaban|NOAC
48476903|NCT04474431|OTHER|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
48476904|NCT02654587|BIOLOGICAL|OSE2101|
48476905|NCT02654587|DRUG|Docetaxel|
48476906|NCT02654587|DRUG|Pemetrexed|
48634760|NCT05493345|BEHAVIORAL|Bridge-building between municipality-based lifestyle programs and community-based physical activities|Four co-created bridge-building activities has been implemented in the municipality of Odsherred, including (1) A digital portal for information and sharing of knowledge, (2) Visits between municipal rehabilitation programs and community-based physical activities, (3) Co-created teams for the target group, and (4) a 'Bridge builder' coordinator.
48634761|NCT03412890|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
48634762|NCT03412890|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
48634763|NCT04849000|DRUG|SHR-1209|SHR-1209
48634764|NCT04849000|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
48634765|NCT04088357|DRUG|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
48634766|NCT04088357|DRUG|Topical Vehicle Gel|TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
48296016|NCT05804110|OTHER|Mindful Caring Education Program|A four-session education plan was prepared under the nature of action research. The Theory of Unitary Caring Science is transferred to practice through Caritas processes. In this context, ten Caritas processes and caring-healing modalities (meditation, reflection, etc.) were used in the study. The pilot study was carried out with six nurses face-to-face. The education program was conducted on an online platform. Each education took approximately 2.30-3 hours. The evaluation process in action research is an essential part of the change.
48296017|NCT04408521|OTHER|NEUROFEEDBACK|EEG recording during alpha-related TV viewing
48476907|NCT02614833|BIOLOGICAL|IMP321 (eftilagimod alpha)|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
48296018|NCT04408521|OTHER|CONTROL|EEG recording during passive TV viewing
48296019|NCT05069558|DEVICE|Investigational PFO Closure Device|Occlutech Flex II PFO Closure Device
48476908|NCT02614833|DRUG|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
48476909|NCT02614833|DRUG|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
48476910|NCT01355302|DRUG|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
48476911|NCT01355302|DRUG|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
48476912|NCT01355302|DRUG|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
48476913|NCT04475276|DRUG|Placebo|Lifestyle modification with placebo for 12 weeks
48476914|NCT04475276|DRUG|Alphalipoic acid|Lifestyle modification with Alphalipoic acid for 12 weeks
48476915|NCT01961258|OTHER|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
48476916|NCT02497131|DRUG|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
48476917|NCT06013111|BIOLOGICAL|Intravenous infusion anti-CEA-CAR-T cell|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10\^7 CAR-T cells/kg, 1×10\^7 CAR-T cells/kg, and 3×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
48476918|NCT03129230|PROCEDURE|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
48476919|NCT00528268|DRUG|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
48476920|NCT03209609|DEVICE|VEST|External support for vein grafts, cobalt chrome braid
48476921|NCT03209609|PROCEDURE|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
48476922|NCT04167384|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
48476923|NCT04167384|OTHER|Product B|Nicorette® Mint 4 mg nicotine lozenge
48476924|NCT04167384|OTHER|Product C|CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
48476925|NCT04167384|OTHER|Product D|CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
48476926|NCT04167384|OTHER|Product E|CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
48476927|NCT04167384|OTHER|Product F|CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
48476928|NCT04167384|OTHER|Product G|CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
48634767|NCT03839680|PROCEDURE|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
48296020|NCT05069558|DEVICE|Standard of Care PFO Closure Device|Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
48296021|NCT06497985|DRUG|Tucidinostat|30mg orally BIW
48296022|NCT06497985|DRUG|Sintilimab|200 mg intravenously (IV) Q3W
48296023|NCT06497985|DRUG|Bevacizumab|7.5mg/kg intravenously (IV) Q3W
48296024|NCT06497985|DRUG|Fruquintinib|5mg orally QD
48296025|NCT05319951|DRUG|Oral Rehydration Salts power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
48476929|NCT04167384|OTHER|Product H|CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
48476930|NCT04244799|BEHAVIORAL|Behavioral nudges|"Behavioral nudges include the following:~1. Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~2. Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~3. Sticker of a pair of eyes placed above the handwashing station~4. Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap"
48476931|NCT04244799|BEHAVIORAL|National WASH policy|"The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion."
48476932|NCT03579134|DEVICE|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
48476933|NCT03579134|OTHER|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
48476934|NCT03485846|DRUG|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
48476935|NCT03485846|DRUG|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
48634768|NCT02186171|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection once a month.
48634769|NCT02186171|DRUG|Placebo|Administered by subcutaneous injection once a month.
48634770|NCT03307096|PROCEDURE|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
48634771|NCT03307096|PROCEDURE|FURS|Parents are treated by FURS
48476936|NCT03485846|DRUG|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
48476937|NCT00692952|DRUG|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
48296026|NCT05319951|DIETARY_SUPPLEMENT|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
48296027|NCT05319951|DIETARY_SUPPLEMENT|water|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
48296028|NCT06472726|BEHAVIORAL|IONA Mind app|The IONA Mind app is a smartphone app that delivers mental health support.
48296029|NCT01707823|DRUG|acetylsalicylic acid|Given PO
48296030|NCT01707823|OTHER|laboratory biomarker analysis|Correlative studies
48476938|NCT00692952|DRUG|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
48476939|NCT02861027|PROCEDURE|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
48476940|NCT02861027|PROCEDURE|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
48476941|NCT05583682|OTHER|Dental restoration|Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
48476942|NCT06456424|BIOLOGICAL|Phage therapy|Bacteriophage cocktail consisting of phages BP13 and J1P3
48476943|NCT06207123|DRUG|LP-118|LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
48476944|NCT06207123|DRUG|Ponatinib|Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).
48476945|NCT06207123|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.
48476946|NCT06207123|DRUG|Dexamethasone|Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)
48476947|NCT06207123|DRUG|Methotrexate|Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
48476948|NCT00190489|DRUG|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
48476949|NCT00190489|DRUG|Docetaxel 60mg/m2 every 21 days for 6 cycles|
48476950|NCT00190489|DRUG|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
48476951|NCT02045524|OTHER|Deep muscle injection|
48476952|NCT02045524|OTHER|Sub-Q Injection|
48476953|NCT06470334|DRUG|Ropivacaine|Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
48476954|NCT06470334|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
48476955|NCT02001051|PROCEDURE|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
48476956|NCT02001051|OTHER|Observation|Observation for 6 months prior to surgery
48476957|NCT01159106|OTHER|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
48634772|NCT03096990|DRUG|apremilast|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
48296031|NCT03390231|COMBINATION_PRODUCT|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
48296032|NCT01388010|OTHER|1-Fermented Probiotic Dairy Product (test)|
48296033|NCT01388010|OTHER|2-Milk-based non-fermented dairy product(control)|
48296034|NCT06671340|DRUG|Dorzagliatin|chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral)
48296035|NCT01048125|DEVICE|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
47946307|NCT00775216|BEHAVIORAL|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
47946308|NCT02648269|DRUG|SEL-110|
47946309|NCT02648269|BIOLOGICAL|SEL-212|
48634773|NCT03428269|OTHER|simulation by gaming (LabForGames Warning)|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
48634774|NCT03428269|OTHER|traditional education|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
47946310|NCT02648269|BIOLOGICAL|SEL-037|
47946311|NCT03589469|DRUG|Loncastuximab tesirine|intravenous infusion
48296036|NCT01048125|BEHAVIORAL|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
47946312|NCT05895071|DRUG|5%potassium hydroxide|. In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
47946313|NCT05895071|DRUG|Liquid nitrogen|in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
47946314|NCT02027038|DEVICE|Pelvic belt application|
47946315|NCT06310915|DRUG|Navelbine oral,Pembrolizumab|Oral vinorelbine was administered three times weekly, and pembrolizumab was administered every 3 weeks
48296037|NCT01048125|DRUG|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
48296038|NCT01048125|OTHER|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
48296039|NCT01048125|DEVICE|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
48476958|NCT01159106|OTHER|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).~The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
48476959|NCT04143282|DRUG|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
48476960|NCT04143282|DRUG|Chemotherapy|standard chemotherapy
47946316|NCT05821673|PROCEDURE|Argon plasma pre-treated abutment insertion|abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. In order to restrict any post-treatment contamination; abutments were inserted immediately after the end of the plasma process. The reactor was set at 75 W of power and -10 MPa of pressure for 12 min.
47946317|NCT05821673|PROCEDURE|abutment insertion|the abutments assigned to the control group were screwed onto the implants without receiving argon plasma pretreatment
47946318|NCT04045795|DRUG|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
47946319|NCT04045795|DRUG|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
48476961|NCT01295086|DRUG|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
47946320|NCT04045795|DRUG|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
47946321|NCT04045795|DRUG|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48296040|NCT04806568|OTHER|Cognitive Training|The cognitive training treatment is a Greek adaptation of BrainHQ developed by Posit Science Corporation. The intervention will target speed, attention, working memory, and executive function through the visual and auditory domains via a set of 15 exercises. Each daily training session consists of four exercises chosen from an active set of six. Participants will be instructed to train for one hour per day, three days per week, over 12 weeks via a tablet. Each subject will receive at least 29 sessions of computerized cognitive training.
48296041|NCT04806568|DEVICE|Monitoring of daily activity|Monitoring of daily activity via Fitbit Charge 4 smartwatch.
48296042|NCT03562221|OTHER|Gluten free diet|Controlled gluten free diet
48296043|NCT03562221|DIETARY_SUPPLEMENT|Probiotics|Capsules
48296044|NCT03562221|DIETARY_SUPPLEMENT|Placebo|Capsules
48296045|NCT02133014|PROCEDURE|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
48296046|NCT02133014|DRUG|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
48296047|NCT00170157|DRUG|Bicalutamide|Given orally
48296048|NCT00170157|DRUG|Flutamide|Given orally
48296049|NCT00170157|DRUG|Goserelin Acetate|Given SC
48296050|NCT00170157|DRUG|Ipilimumab|Given IV
48296051|NCT00170157|DRUG|Leuprolide Acetate|Given IM
48296052|NCT00170157|OTHER|Pharmacological Study|Correlative study
48296053|NCT01411397|OTHER|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
48296054|NCT01411397|OTHER|mesh repair|mesh repair of strangulated hernia without resection
48296055|NCT02777840|DEVICE|face mask oxygen|oxygen given by face mask as per routine practice
48296056|NCT02777840|DEVICE|High flow oxygen|High flow oxygen given via optiflo machine / device
48296057|NCT06128512|OTHER|Auricular acupuncture|Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.
48296058|NCT06128512|OTHER|Sham Auricular acupuncture|Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
48296059|NCT04806581|DRUG|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
48296060|NCT06513325|OTHER|Canadian Occupational Performance Measure|It is a semi-structured scale that helps to identify problematic areas of performance experienced by individuals and to measure their perceived occupational performance and satisfaction. This scale assesses the level of performance of self-care, productivity and leisureoccupations and satisfaction with these performances as perceived by the individual.
47946322|NCT04045795|DEVICE|Investigational injector device|Subcutaneous administration
48296061|NCT03495505|DEVICE|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
48296062|NCT00320671|DRUG|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
48296063|NCT00320671|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
48296064|NCT00759512|OTHER|Therapeutic Touch|
48296065|NCT06513195|PROCEDURE|endoscopic ultrasound-guided portal pressure measurement|The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
47946323|NCT02562833|DEVICE|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
47946324|NCT02562833|DEVICE|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
48296066|NCT05222906|DRUG|Venglustat|tablet; oral
48296067|NCT05222906|DRUG|imiglucerase|sterile lyophilized product; intravenous
48296068|NCT02948231|DEVICE|Mistral implantation|Mistral Implant is implanted in the Mitral valve
48296069|NCT01868087|DIETARY_SUPPLEMENT|Boost Plus®|
48296070|NCT01868087|DIETARY_SUPPLEMENT|Impact Advanced Recovery®|
47946325|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
47946326|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
47946327|NCT04483778|DRUG|Pembrolizumab|SCRI-CARB7H3(s)x19 plus pembrolizumab
47946328|NCT06680947|DRUG|610|Subcutaneously injection.
47946329|NCT06680947|DRUG|610|Subcutaneously injection.
47946330|NCT06680947|DRUG|Placebo|Subcutaneously injection.
47946331|NCT05314478|DEVICE|Continuous laryngoscopy during exercise test using the HALOS headgear|"The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~1. The headgear is prepared for use.~2. The headgear is fitted onto the participant's head.~3. The endoscope is inserted into the participant.~4. The endoscope is fitted onto the headgear.~5. The CLE test is carried out.~6. The endoscope is removed from the headgear.~7. The endoscope is removed from the participant.~8. The headgear is removed from the participant.~9. The headgear is cleaned and stored."
48476962|NCT01295086|DRUG|Oxaliplatin|100 mg/m² day 1 every 3. week
48296071|NCT03515538|DRUG|RRx-001|RRx-001 for injection
47946332|NCT06679985|DRUG|Casdozokitug|Solution for infusion
47946333|NCT06679985|DRUG|Toripalimab|Solution for infusion
47946334|NCT06679985|DRUG|Bevacizumab|Solution for infusion
47946335|NCT06309667|DRUG|PG-102(MG12)|GLP-1 and GLP-2 fusion protein
48476963|NCT01295086|DRUG|Capecitabine|1250 mg/² continuously
47946336|NCT06309667|DRUG|Placebo|Placebo drug of PG-102(MG12)
47946337|NCT04963231|DRUG|Setmelanotide|SC injection
47946338|NCT04963231|DRUG|Placebo|SC injection
47946339|NCT03987776|BEHAVIORAL|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
47946340|NCT03987776|BEHAVIORAL|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
48296072|NCT03515538|DRUG|Cisplatin for injection|Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
48476964|NCT01295086|DRUG|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
48476965|NCT00504478|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
47946341|NCT01209923|DEVICE|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
47946342|NCT05327959|DEVICE|Clavicle open reduction and internal fixation|Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
48476966|NCT00504478|OTHER|high complex carbohydrate diet|
48476967|NCT03336918|DRUG|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
48476968|NCT00004079|DRUG|SarCNU|Given PO
48476969|NCT00004079|OTHER|pharmacological study|Correlative studies
48476970|NCT00004079|OTHER|laboratory biomarker analysis|Correlative studies
48476971|NCT02577068|DRUG|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
48476972|NCT02577068|DRUG|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
47946343|NCT00005602|DRUG|carboplatin|
47946344|NCT00005602|DRUG|cereport|
47946345|NCT00005602|RADIATION|radiation therapy|
47946346|NCT04457154|DEVICE|Inspire Upper Airway Stimulation System|Implant of the Inspire Upper Airway Stimulation System
47946347|NCT06470763|DRUG|ANV600|ANV600 administered by intravenous (IV) infusion
47946348|NCT06470763|DRUG|ANV600 + pembrolizumab (KEYTRUDA®)|ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion
47946349|NCT06328036|BIOLOGICAL|Atezolizumab|Given IV
47946350|NCT06328036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47946351|NCT06328036|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47946352|NCT06328036|PROCEDURE|Surgical Procedure|Undergo surgical resection
47946353|NCT06328036|BIOLOGICAL|Tiragolumab|Given IV
47946354|NCT00904306|DIETARY_SUPPLEMENT|Sugar Pill|placebo oral tablet taken once per day
47946355|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|1000 ug/day chromium picolinate for 6 months
47946356|NCT00904306|DIETARY_SUPPLEMENT|chromium picolinate|600 ug/day chromium picolinate
47946357|NCT04119310|OTHER|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
47946358|NCT04119310|OTHER|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
47946359|NCT00140478|DRUG|Mifepristone|200mg orally once daily
47946360|NCT00509392|DEVICE|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation \& ClosureFAST catheter
47946361|NCT00509392|DEVICE|Endovenous Laser|laser catheter
47946362|NCT03821207|BEHAVIORAL|The exercise group|The students will make exercise during the first three days of the menstrual period
47946363|NCT03821207|BEHAVIORAL|The abdominal massage group|The students will make abdominal massage during the first three days of the menstrual period
47946364|NCT03821207|BEHAVIORAL|Control Group|The students will nor massage or exercise
47946365|NCT02130024|DRUG|Ranibizumab 0.5 mg|Administered as an intravitreal injection
47946366|NCT02130024|DRUG|Aflibercept 2.0 mg|Administered as an intravitreal injection
48104034|NCT02323386|DEVICE|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
48104035|NCT02081898|DIETARY_SUPPLEMENT|LCD|approximate 100 kcal/d caloric deficit
48476973|NCT03389087|DRUG|Apatinib and Etoposide Capsule|Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
48476974|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
48476975|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
48476976|NCT03802617|DRUG|MR13A9|Intravenous administration
48476977|NCT03802617|DRUG|Placebo|Intravenous administration
48476978|NCT01961687|DEVICE|Resorbable Mesh|Phasix Mesh
48476979|NCT04726189|OTHER|Standard exercises|Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
48476980|NCT04726189|OTHER|Standard exercises plus Early progressive exercises|This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
48476981|NCT02388698|PROCEDURE|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
48296073|NCT03515538|RADIATION|Radiation Therapy|Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
48296074|NCT06528691|DRUG|Entrectinib|Given orally (PO) or enterally
48476982|NCT02388698|RADIATION|PET-CT|PET-CT will be completed 3 month post chemoradiation.
48476983|NCT02388698|BIOLOGICAL|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
48476984|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing placebo|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
48476985|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing 250mg of Urolithin A (Mitopure)|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
48476986|NCT04270006|BIOLOGICAL|adipose derived stem cells exosomes|they are small extracellular vesicles
48476987|NCT04845516|OTHER|Efficacy of apheresis|Efficacy of apheresis
48476988|NCT06617780|RADIATION|X-ray (wrist)after 3 months and CT (wrist) the day after closed reduction|One addition x-ray and on addition CT scan of the wrist
48476989|NCT02775578|PROCEDURE|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
48476990|NCT02775578|PROCEDURE|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
48476991|NCT02775578|PROCEDURE|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
48476992|NCT00348816|DRUG|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
48476993|NCT00348816|DRUG|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
48476994|NCT00348816|PROCEDURE|Radical prostatectomy|Radical prostatectomy as part of standard care
48296075|NCT06528691|DRUG|Cyclophosphamide|Given intravenous (IV)
48296076|NCT06528691|DRUG|Etoposide|Given IV
48296077|NCT06528691|DRUG|Carboplatin|Given IV
48296078|NCT06528691|BIOLOGICAL|G-CSF|Given subcutaneous (SQ) or IV
48634775|NCT02994277|DEVICE|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
48634776|NCT00057577|BEHAVIORAL|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
48634777|NCT00057577|DRUG|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
48634778|NCT01292473|DRUG|Placebo|Placebo was supplied lyophilized in vials.
48634779|NCT01292473|DRUG|Omalizumab|Omalizumab was supplied lyophilized in vials.
47946367|NCT01039974|DRUG|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
48296079|NCT06528691|BIOLOGICAL|Pegfilgrastim|Given SQ as part of recommended Bridging Therapy instead of G-CSF.
48476995|NCT00348816|RADIATION|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
48476996|NCT05823896|DRUG|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
48476997|NCT05823896|DRUG|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
48476998|NCT00418522|DRUG|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
48476999|NCT00418522|DRUG|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
48477000|NCT05368558|DRUG|Cariprazine|Oral Capsule
48477001|NCT05368558|DRUG|Placebo|Oral Capsule
48477002|NCT02176278|OTHER|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
48477003|NCT02176278|OTHER|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c\<7%, BP\<130/80 mmHg, LDL-C\<1.8 mmol/l, triglyceride\<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
48477004|NCT02176278|OTHER|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
48477005|NCT01013428|OTHER|Ultrasound|Ultrasound will be used to evaluate tendons.
48477006|NCT02759549|BEHAVIORAL|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
48634780|NCT05611892|COMBINATION_PRODUCT|18F-FDS PET/CT|20 millicurie (mCi) of 18F-FDS in adult patient age group and 2.5 mCi in children (age 12-18 years old) followed by a PET/CT scan.
48634781|NCT00553475|DRUG|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
48634782|NCT00553475|DRUG|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
48634783|NCT00553475|DRUG|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
48634784|NCT04692688|DRUG|APX3330|APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
47946368|NCT01039974|DRUG|Ketoconazole|400 mg
48296080|NCT06528691|PROCEDURE|Surgery|A gross total resection or significant debulking may become possible if a response to entrectinib is seen.
48296081|NCT03238248|DRUG|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
48296082|NCT03238248|DRUG|Pevonedistat Infusion|20 mg/m2
48296083|NCT03238248|PROCEDURE|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
48296084|NCT00978575|DRUG|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
48296085|NCT00978575|DRUG|Ferrosulfate|200mg daily for 12 weeks
48296086|NCT00978575|DRUG|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
48296087|NCT06671275|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
48296088|NCT01312792|OTHER|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
48296089|NCT01312792|OTHER|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
48296090|NCT06510816|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT injection
48296091|NCT06510816|OTHER|Sham Administration|Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).
48296092|NCT02917486|OTHER|blood sample|
48296093|NCT03237845|DRUG|Rimegepant|75 mg tablet QD
48296094|NCT03237845|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
48296095|NCT05955027|DRUG|ZX-7101A|a drug to treat influenza, oral
48296096|NCT05955027|DRUG|Placebo|placebo control, oral
48296097|NCT04108195|DRUG|Daratumumab|Participants will receive daratumumab.
48296098|NCT04108195|DRUG|Talquetamab|Participants will receive talquetamab.
48296099|NCT04108195|DRUG|Teclistamab|Participants will receive teclistamab.
48296100|NCT04108195|DRUG|Pomalidomide|Participants will receive pomalidomide.
48296101|NCT01527604|OTHER|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
48296102|NCT01527604|OTHER|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
48296103|NCT05972967|DRUG|OMS906 Study Drug - 3 mg/kg|All patients will receive 3 doses of OMS906 of 3 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.
48296104|NCT05972967|DRUG|OMS906 Study Drug - 5 mg/kg|All patients will receive 3 doses of OMS906 of 5 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.
48296105|NCT05972967|DRUG|Ravulizumab|Participants must be on prescribed stable dose of ravulizumab (IV dose per approved summary of medicinal product characteristics) for at least 2 doses (4 months) prior to baseline. During the Run-in period - ravulizumab only. During the Treatment period all patients will receive 3 doses of ravulizumab at 8-week intervals. Clinical responders at Week 24 will not receive additional ravulizumab. Incomplete responders may receive an additional 3 doses of ravulizumab with OMS906 at 8-week intervals. Non responders will return to treatment with ravulizumab or standard of care.
48296106|NCT02985125|DRUG|LEE011|Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
48296107|NCT02985125|DRUG|Everolimus|Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
48296108|NCT02307305|DRUG|Duloxetine|"1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)"
48296109|NCT02307305|DRUG|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
48296110|NCT06667284|PROCEDURE|Roux en y procedure|subtotal gastrectomy en bloc with Roux-en-Y reconstruction, using TA 90 and GIA staplers. The length of the biliopancreatic limb was 50 cm, while the alimentary limb was 80 cm
48296111|NCT06667284|PROCEDURE|Omega brown procedure|Gastrojejunal anastomosis with jejunojejunal anastomosis
48296112|NCT06649747|DRUG|AFA-281|A small molecule, orally available
48296113|NCT06399705|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
48296114|NCT06399705|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
48296115|NCT00855530|DRUG|amibegron (SR58611A)|oral administration of 300 mg twice daily
48296116|NCT02175667|PROCEDURE|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
48296117|NCT05546996|DEVICE|FlowSense|"Patients will have one or more existing external ventricular drains (EVDs). Phase B patients will additionally have an accessible (shaved) region of skin \>3 cm x 3 cm overlaying the EVD tubing.~Clinical data to be collected include: 1) total drainage volume1 over the 20-minute measurement period; 2) handheld ultrasound measurement of skin thickness2 over the EVD; and 3) an ICP waveform from a standard-of-care transducer, 4) dimensions (inner diameter and outer diameter) of tunneled catheter. Single patients may be measured multiple times during their admission; each measurement will be considered independent for analysis."
48477007|NCT02759549|OTHER|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
48634785|NCT04692688|DRUG|Placebo|Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
48634786|NCT00667979|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
48634787|NCT00667979|DRUG|Placebo|Matching placebo
48634788|NCT00625729|BIOLOGICAL|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
48634789|NCT00625729|BIOLOGICAL|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
48634790|NCT00625729|BIOLOGICAL|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
48634791|NCT00625729|DRUG|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
48634792|NCT00625729|DRUG|fludarabine phosphate|Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
48634793|NCT03377127|BEHAVIORAL|Pharmacy Managed Diabetes Clinic (PMDC)|The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
48634794|NCT03377127|OTHER|Standard of Care (SOC)|Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
48634795|NCT00270166|DRUG|epoetin alfa|
48634796|NCT03638167|BIOLOGICAL|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
48104036|NCT04163471|DEVICE|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
48296118|NCT06671639|DEVICE|da Vinci Xi Robotic Surgery System|"The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.~The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system."
48634797|NCT00715897|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
48634798|NCT04983511|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
48634799|NCT05945758|PROCEDURE|Injectable resin composite technique.|A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.
48634800|NCT05945758|PROCEDURE|Conventional layering technique|the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
48477008|NCT02759549|BEHAVIORAL|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
48296119|NCT01797029|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
48477009|NCT02268539|PROCEDURE|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
48634801|NCT02916914|OTHER|Q2 feeding|Infants are going to be fed every 2 hours
48477010|NCT05486299|PROCEDURE|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
48634802|NCT04941365|DIAGNOSTIC_TEST|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
48634803|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)
48634804|NCT00159874|DRUG|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg
48634805|NCT00159874|DRUG|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
48634806|NCT02916433|DRUG|Octreotide|
48634807|NCT01718106|DEVICE|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
48634808|NCT01681303|DRUG|AST-120|
48634809|NCT01354535|PROCEDURE|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
48634810|NCT01354535|PROCEDURE|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
48634811|NCT03854981|BEHAVIORAL|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
48296120|NCT01797029|BIOLOGICAL|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
48296121|NCT00362388|PROCEDURE|Intramyocardial injection of autologous bone marrow cells|
48296122|NCT00695994|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
48296123|NCT00695994|DRUG|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
48296124|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
48296125|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
48477011|NCT01270620|DRUG|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
48477012|NCT01270620|DRUG|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
48477013|NCT00697840|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 doses
48477014|NCT00697840|BIOLOGICAL|HBV-MPL 208129|Intramuscular injection, 2 doses
48477015|NCT00697840|BIOLOGICAL|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
48477016|NCT00458419|DRUG|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
48477017|NCT00458419|DRUG|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
48477018|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
48296126|NCT00632034|OTHER|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
48296127|NCT06498102|OTHER|Intermittent Fasting: Time Restricted Feeding During 6 Weeks|Thirty-one healthy, young males (age: 27.5±6 years, body mass: 76.5±8.4 kg, and maximal oxygen uptake \[V̇O2max\]: 43.9±6.6 mL/kg/min) were randomly assigned to either TRF (n=14) or control group (n=17). TRF group followed an 16:8 intermittent fasting diet program for 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the diet program.
48477019|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
48477020|NCT04958252|DRUG|BI 1569912|BI 1569912
48477021|NCT04958252|DRUG|Placebo|Placebo
48477022|NCT06384794|DEVICE|Sperm capacitation through the ZyMōt®Sperm Separation Device®|This chip based on microfluidic properties will help us to separate and recover the semen sample with improved sperm quality. It is composed of two microwells, one initial and one final, and a porous membrane through which the sample will be filtered and the capacitated spermatozoa with better motility will be selected. Syringe 850µL of the initial seminal sample into the first well and 750µL of seminal wash medium into the second well. The device is incubated at 37°C for up to 30 minutes. During this incubation, the sample will travel by microfluidic properties from the first well through the porous membrane to the second well. This membrane will filter those spermatozoa with a higher motility. Thus, at the end of the established incubation time, the medium with the selected spermatozoa from the second well (final well) will be collected with a syringe. After this, the sample will be processed and ready for the following procedures.
48477023|NCT06384794|PROCEDURE|Swim-up|The swim-up is a sperm capacitation technique in which the motile spermatozoa of the seminal sample, after centrifugation and incubation, move to the upper part of the medium. In this way, spermatozoa with good progressive motility will remain in the supernatant.
48477024|NCT03991442|DRUG|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
48634812|NCT03854981|PROCEDURE|Standard Care|Standard preoperative care of bariatric surgery
48634813|NCT00360100|DRUG|Zmax|
48296128|NCT05839626|DRUG|SAR445514|Powder for solution for injection. Sub Cutaneous administration.
48296129|NCT06544863|OTHER|Data collection and blood sample|In addition to collecting medical data, additional blood samples will be collected in order to create a biological collection and identify biomarkers associated with the occurrence of cirrhosis-related complications, progression to TH and follow-up.
48104037|NCT04940676|DRUG|Huzhangxiefei Decoction|Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
48296130|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; low dose
48296131|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; middle dose
48296132|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; high dose
48296133|NCT06672172|DRUG|HRS-7535 placebo tablet|HRS-7535 placebo tablet
48296134|NCT06663046|BIOLOGICAL|Single dose injection of certain dose of UWD-00B|Eligible participants will undergo FC lymphodepleting chemotherapy preconditioning after signing an informed consent form, followed by a one-time injection of certain dose of universal UWD-00B cells
48477025|NCT04287868|BIOLOGICAL|PDS0101|PDS0101 will be administered on Day (D)1, D15, D29 followed by booster vaccines every 4 weeks for up to a year. Subcutaneous 1.0mL (2.4mg of total peptide and 3 mg of R-DOTAP) injection.
48477026|NCT04287868|BIOLOGICAL|M7824|M7824 will be administered at a flat dose of 1,200 mg intravenous (IV) (over 1 hour) once every 2 weeks.
48477027|NCT04287868|BIOLOGICAL|NHS-IL12|NHS-IL12 will be administered at as dose of potentially de-escalating doses by subcutaneous (SC) injection every 4 weeks.
48477028|NCT04010916|OTHER|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
48477029|NCT04010916|OTHER|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
48477030|NCT04010916|OTHER|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
48104038|NCT04940676|DRUG|10% Huzhangxiefei Decoction|10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
48104039|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
48296135|NCT00803244|DRUG|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
48296136|NCT00803244|DRUG|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
48477031|NCT03710902|DIAGNOSTIC_TEST|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
48296137|NCT04965012|BEHAVIORAL|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
48296138|NCT04965012|BEHAVIORAL|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
48296139|NCT04354753|OTHER|No Intervention|No intervention
48296140|NCT06672978|DRUG|Meropenem-Vaborbactam|Administered as specified in the treatment arm
48296141|NCT06672978|DRUG|Antibiotics|Administered as prescribed by the study physician in accordance with the local marketing authorizations
48296142|NCT00703807|DRUG|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
48296143|NCT00703807|DRUG|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
48296144|NCT01810367|DRUG|ABX Combined With Cisplatin|
48296145|NCT01810367|DRUG|Gemcitabine Combined With Cisplatin|
48634814|NCT02783937|BIOLOGICAL|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
48104040|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
48104041|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
48104042|NCT05235789|OTHER|Rational-Emotive-Behavioral Therapy|"The structure of the REBT sessions includes the following points:~1. Determine specific goals that explain what the participant want to achieve through the content of the session.~2. Explain the level of skills to be achieved in each session.~3. Development of the session, reminder of the previous session, review of homework (from the second session to the 8th). Irrational beliefs and disruptive thoughts will be worked on together with the participant in order to achieve an improvement in their emotional state. Key messages with healthier alternatives that make your daily life easier.~4. Establishing homework. Using the REBT Toolbox with Key Messages.~5. Individual psychosocial work will be recorded in the computerized medical history."
48104043|NCT05235789|OTHER|Control Group usual care|In the control group, for each center , the depression is treated as usual with the conventional treatment, according to national and international guidelines.
48104044|NCT01040741|OTHER|Non-intervention observational study|Non-intervention observational study
48104045|NCT05358197|OTHER|yoga|laughter yoga
48104046|NCT00751491|DRUG|Adenosin|Intracoronary Adenosin 50 microg;
48104047|NCT00751491|OTHER|placebo|no intervention
48634815|NCT02783937|DRUG|Saline|Injection of saline SC injection twice daily for five consecutive days
48634816|NCT02113046|PROCEDURE|pancreatico-jejunal anastomosis|
48634817|NCT02113046|PROCEDURE|traditional anastomosis|
48104048|NCT00751491|DRUG|Clopidogrel|Clopidogrel 300/600 mg
48104049|NCT01740570|DRUG|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
48104050|NCT02009358|OTHER|mental health promotion|
48104051|NCT00922675|PROCEDURE|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
48104052|NCT00922675|PROCEDURE|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
48104053|NCT05857306|DIETARY_SUPPLEMENT|Olvanil|"Nutritional recommendation along with 4 mg Olvanil (1 capsule daily)~Subects within the Intervention group will be provided with a nutritional recommendation along with Olvanil capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 4 mg Olvanil and 255 mg soy lecithin as excipient"
48104054|NCT05857306|DIETARY_SUPPLEMENT|Placebo|"Nutritional recommendation along with 255 mg soy lecithin (1 capsule daily)~Subects within the placebo group will be provided with a nutritional recommendation along with placebo capsules. Subjects will be asked to consume one capsule per day. Every capsule contains: 255 mg soy lecithin"
48104055|NCT01906060|DEVICE|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
48296146|NCT02752308|DRUG|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
48296147|NCT02752308|PROCEDURE|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
48296148|NCT02752308|DRUG|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
48634818|NCT02316132|DRUG|Stress|Corticotropin-Releasing Hormone
48634819|NCT02316132|DRUG|Control|Saline 0.9%
47946374|NCT04710056|DRUG|REGN4461|
48634820|NCT02903381|DRUG|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
48634821|NCT02903381|DRUG|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
48634822|NCT02903381|DRUG|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
47946375|NCT04573998|PROCEDURE|LSG|bariatric surgery
48296149|NCT02752308|DRUG|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
48634823|NCT05605080|DEVICE|Gelfoam|Use Gelfoam as a hemostatic agent after anal surgery.
48296150|NCT02752308|DRUG|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
48296151|NCT02752308|DRUG|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
48296152|NCT02752308|PROCEDURE|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
48296153|NCT02018510|BIOLOGICAL|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
48477032|NCT03710902|OTHER|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
48477033|NCT01713088|OTHER|Multisystemic therapy|
48477034|NCT01713088|OTHER|YOT (usual services)|
48477035|NCT06115863|OTHER|Early Cognitive Stimulation Interventions|early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.
48477036|NCT00278174|BIOLOGICAL|recombinant interferon alpha-1b|
48477037|NCT06617793|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
48477038|NCT06533371|DIAGNOSTIC_TEST|Relationship between lung ultrasound and computed tomographic scan|"Ultrasonographic findings will be obtained with clinical machines. Additionally, US scans as acquired with the Ula-Op open research platform will also be gathered. For both scanners, 10seconds videos will be recorded and stored in each landmark.~To correlate LUS artefactual patterns with peripheral parenchymal changes evaluated by HRCT of the chest, all chest CT findings will be analysed by an image processing platform designed to provide visualization and quantification of areas with abnormal CT tissue density indicative of emphysema and air trapping. Post-processing image analysis will be performed on images by using automated detection of potential emphysema systems."
48477039|NCT04944316|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet
48477040|NCT04944316|BEHAVIORAL|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
48477041|NCT04027881|BEHAVIORAL|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
48477042|NCT02751827|OTHER|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
48477043|NCT00757679|DRUG|Milnacipran|capsules
48477044|NCT00757679|DRUG|Placebo|capsules
48477045|NCT00552149|DRUG|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
48477046|NCT02866591|OTHER|mammography according to an auto-compression procedure|
48477047|NCT02866591|OTHER|mammography according to a standard procedure|
48477048|NCT02866591|OTHER|questionary|
48477049|NCT04599621|DIAGNOSTIC_TEST|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
48477050|NCT01672047|DRUG|Vitamin D2|25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， \>116.75nmol/L stopped.
48477051|NCT06557278|BIOLOGICAL|AlloStim|experimental immunotherapy to prime for checkpoint inhibitor
48477052|NCT06557278|DRUG|Bavencio|anti-PDL1 checkpoint inhibitor
48477053|NCT06615934|OTHER|Aerobic and resistance exercise|"From the first day of transplantation in the ICU until 10 days after transfer to the ward or discharge from the hospital, if needed, the patients of the group will undergo respiratory physiotherapy once a day. The process of this program includes patient assessment, clinical decision-making, and implementation of therapeutic interventions.~The interventions of the therapeutic exercise group are divided into three phases:~1. From the time the patient enters the ICU until the time of extubation;~2. From the time of extubation to the time of transfer to the ward;~3. Duration of the patient's stay in the ward."
48634824|NCT05605080|OTHER|Bosmin gauze|Use bosmin gauze as a hemostatic agent after anal surgery.
48634825|NCT01429935|DRUG|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
48296154|NCT02018510|BIOLOGICAL|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
48296155|NCT02018510|BIOLOGICAL|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
48296156|NCT02018510|BIOLOGICAL|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
48296157|NCT02018510|BIOLOGICAL|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
48296158|NCT02018510|BIOLOGICAL|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
48296159|NCT03464097|DRUG|Ozanimod|Specified dose on specified days
48296160|NCT03464097|OTHER|Placebo|Specified dose on specified days
48634826|NCT01429935|DRUG|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
47946376|NCT05906173|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
47946377|NCT06599697|BIOLOGICAL|Intravenously administered pooled human immunoglobulin (IVIG)|IVIG 2g/kg every 4 weeks for 12 weeks (3 doses)
48296161|NCT02177669|OTHER|quick Contrast Sensitivity Function test|
48296162|NCT06258837|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
48477054|NCT06615934|OTHER|Respiratory physiotherapy|The participants of this group will receive respiratory physiotherapy daily after transplant until discharge.
48477055|NCT02241694|OTHER|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
48477056|NCT01223235|BIOLOGICAL|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
48477057|NCT04421976|PROCEDURE|PEEP|"Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
48477058|NCT03766139|BIOLOGICAL|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
48477059|NCT03766139|BIOLOGICAL|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
48477060|NCT03022539|RADIATION|Repeat CT scan|
48477061|NCT00860743|DRUG|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
48477062|NCT03823287|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
48477063|NCT03823287|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
48477064|NCT03823287|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
48477065|NCT05340192|DRUG|Octreotide 1 MG/ML|100 mcg (1 ml) of Octreotide
48477066|NCT01099306|OTHER|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
48477067|NCT06368141|DRUG|Serplulimab|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
47946378|NCT06431737|DRUG|Amoxicillin|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid or 500 mg qid, clarithromycin 500 mg bid for 14 days
48296163|NCT06258837|PROCEDURE|Adenotonsillectomy|Tonsil and/or adenoid removal
48477068|NCT06368141|DRUG|Capecitabine|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
48477069|NCT06368141|DRUG|Oxaliplatin|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
48477070|NCT03105817|DEVICE|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
48634827|NCT01429935|OTHER|placebo|capsules contain starch
48634828|NCT06405425|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
48634829|NCT06405425|DRUG|PD-1|Administration by intravenous infusion for a cycle of 3 weeks.
47946379|NCT02795793|DRUG|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
48634830|NCT06218784|DRUG|iN1011-N17 HCl Suspension (Part 1)|Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
48634831|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 1)|Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
48634832|NCT06218784|DRUG|Placebo Capsule (Part 1)|Dose: b.i.d for 7 days
48634833|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 2)|Dose: 400 mg QD
48634834|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 2)|Dose: 400 mg QD
48634835|NCT06218784|DRUG|iN1011-N17 HCl Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
48634836|NCT06218784|DRUG|iN1011-N17 Mesylate Capsule (Part 3)|Dose: 400 mg b.i.d for 14 days
48634837|NCT06218784|DRUG|Placebo Capsule (Part 3)|Dose: b.i.d for 14 days
48634838|NCT00013299|DEVICE|Prevention of Diabetic Ulcers|
48634839|NCT00652652|DRUG|nesiritide, furosemide|
48634840|NCT03065738|OTHER|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
48634841|NCT02801227|DRUG|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
48634842|NCT02801227|DRUG|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
48634843|NCT06244251|PROCEDURE|TU-LESS|TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy
48634844|NCT06244251|PROCEDURE|MPLS|Patients with uterine who plan to receive MPLS for myomectomy
48634845|NCT05383950|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
48634846|NCT04595578|DEVICE|Cerebellar repetitive transcranial magnetic stimulation|rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.
48634847|NCT02571855|DRUG|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
48634848|NCT02571855|DRUG|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
48634849|NCT02571855|DRUG|Placebo|Placebo capsules matching the ACT-541468 formulations
48634850|NCT03315689|DRUG|Vehicle|Vehicle Topical Solution
48634851|NCT03315689|DRUG|ATI-50002|ATI-50002 Topical Solution
48634852|NCT00682435|DRUG|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
48104056|NCT02301221|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
48634853|NCT00002482|BIOLOGICAL|antibody therapy|
48634854|NCT00002482|BIOLOGICAL|biological therapy|
48634855|NCT00002482|BIOLOGICAL|muromonab-CD3|
48634856|NCT00002482|DRUG|cyclophosphamide|
48634857|NCT01206270|DRUG|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
48634858|NCT01206270|DRUG|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
48634859|NCT00829478|BEHAVIORAL|Decision Aid for Atrial Fibrillation|Single contact educational session
48634860|NCT00829478|OTHER|Usual Care|Usual Care
48634861|NCT02541201|DIETARY_SUPPLEMENT|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
48634862|NCT02541201|DIETARY_SUPPLEMENT|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
48634863|NCT01436292|DRUG|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS."
48634864|NCT04781985|PROCEDURE|cystoscopy|extraction of the bladder stone via suprapubic incision
48634865|NCT02563210|OTHER|airway resistance measurement|assessment of airway resistance
48634866|NCT00325585|BEHAVIORAL|Couples HIV counseling and testing|
48634867|NCT00325585|BEHAVIORAL|Women's relationship-focused HIV counseling and testing|
48634868|NCT00004931|DRUG|leucovorin calcium|Given IV
48634869|NCT00004931|DRUG|fluorouracil|Given IV
48634870|NCT00004931|DRUG|oxaliplatin|Given IV
48634871|NCT00004931|OTHER|laboratory biomarker analysis|Correlative studies
48634872|NCT06329297|DEVICE|CGM monitor|blood glucose sensor used to monitor interstitial glucose
48634873|NCT01433874|PROCEDURE|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
48634874|NCT01433874|PROCEDURE|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
48634875|NCT01433874|PROCEDURE|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
48104057|NCT02301221|DRUG|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
48104058|NCT00927823|DRUG|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
48104059|NCT05629364|DRUG|KIO-101|Randomized, Controlled
48634876|NCT01433874|PROCEDURE|Control group|Co2 was removed by passive exsufflation through the port site.
48296164|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Flexible Negative Pressure Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Flexible Negative Pressure Ureteral Access Sheath (UAS) that allows access to the stone site and enables negative pressure suction for stone removal.
48296165|NCT06667466|DEVICE|Super Pulsed Thulium Fiber Laser (sTFL) + Conventional Ureteral Access Sheath (UAS) Intervention|The intervention combines a Super Pulsed Thulium Fiber Laser (sTFL) with a power setting of 0.8J and a frequency of 12 - 20Hz for stone fragmentation and a Conventional Ureteral Access Sheath (UAS) used for access to the upper ureter or ureteropelvic junction for stone treatment.
48634877|NCT06539377|PROCEDURE|Living donor liver transplantation|"Liver transplantation from living donor donation (SII/III as left-lateral donation during a two stage-procedure or left lobe donation or right lobe donation) in patients with unresectable intrahepatic cholangiocarcinoma."
48634878|NCT01148420|DRUG|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
48634879|NCT01148420|DRUG|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
48634880|NCT04346238|OTHER|Reuse of existing data from patients' medical records|Reuse of existing data from patients' medical records
48634881|NCT00003151|DIETARY_SUPPLEMENT|bismuth subcitrate|
48634882|NCT00003151|DRUG|amoxicillin|
48634883|NCT00003151|DRUG|clarithromycin|
48634884|NCT00003151|DRUG|metronidazole hydrochloride|
48634885|NCT00003151|DRUG|omeprazole|
48634886|NCT00003151|DRUG|tetracycline hydrochloride|
48634887|NCT01733693|DRUG|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
48634888|NCT01733693|DRUG|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
48634889|NCT00510562|PROCEDURE|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
48296166|NCT04691596|BEHAVIORAL|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
48634890|NCT00510562|PROCEDURE|Sham/Placebo|A laying on of hands with no treatment being performed.
48634891|NCT03796975|DRUG|Combination of Pioglitazone and Metformin Tablets|15mg/500mg, oral, 2/day
48634892|NCT03796975|DRUG|Metformin Hydrochloride Tablets|Oral metformin 850mg, 2/day in the control group
48634893|NCT03656575|BIOLOGICAL|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
48634894|NCT03439878|DIETARY_SUPPLEMENT|Galactose|Co-ingestion of d-galactose with a high-fat meal
48634895|NCT03439878|DIETARY_SUPPLEMENT|Glucose|Co-ingestion of d-glucose with a high-fat meal
48634896|NCT01166945|DRUG|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
48634897|NCT01166945|DRUG|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
48104060|NCT01414231|DRUG|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
48104061|NCT02791750|OTHER|questionnary of quality of life|
48104062|NCT00361517|BEHAVIORAL|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
48104063|NCT00361517|OTHER|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
48104064|NCT00361517|OTHER|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
48104065|NCT00361517|DRUG|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
48104066|NCT00361517|OTHER|blood test|Blood will be tested twice a week for the presence of Galactomannan.
48104067|NCT00361517|OTHER|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
48634898|NCT01636544|PROCEDURE|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
48634899|NCT00747071|DRUG|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
48634900|NCT02245386|RADIATION|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
48634901|NCT01720602|DRUG|vorinostat|Given PO
48634902|NCT01720602|DRUG|anastrozole|Given PO
48477071|NCT02491996|BEHAVIORAL|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
47946380|NCT02795793|PROCEDURE|Appendectomy group (Operative management, OM)|
47946381|NCT06206265|DRUG|TRYP-0082|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
47946382|NCT06206265|BEHAVIORAL|Psychotherapy|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
47946383|NCT05435209|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|Gardasil
47946384|NCT03298373|DRUG|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
47946385|NCT03298373|DRUG|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
47946386|NCT00055224|DEVICE|Threat of shock|During threat, a participant could receive a shock. During safe, a participant could not receive as shock. Participants selected their highest tolerable level of shock.
47946387|NCT05221307|OTHER|exercises|Group 1 will be given MPEs for 45 minutes, 3 days a week for 8 weeks. In the second group, traditional Neurodevelopmental Treatment (NGT-Bobath) approach will be applied for 45 minutes a day, 3 days a week for 8 weeks. Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment.
47946388|NCT01367431|DIETARY_SUPPLEMENT|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
47946389|NCT05449769|BEHAVIORAL|eNutriCardio personalised nutrition advice|eNutriCardio is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutriCardio Team, including a registered dietitian and registered nutritionist, are in line with UK dietary guidelines (primarily the EatWell Guide), and promote a Mediterranean-style diet (in line with NICE guidance). Therefore, the advice builds on the generalised advice given during the usual NHS CR programme.
47946390|NCT00058487|DRUG|epirubicin hydrochloride|
47946391|NCT00058487|DRUG|thalidomide|
48477072|NCT04030013|OTHER|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
48477073|NCT05762484|PROCEDURE|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
47946392|NCT06402643|PROCEDURE|Pterygium Excision|Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
47946393|NCT00815399|DRUG|Pioglitazone|15-45 mg/die
47946394|NCT00815399|DRUG|Metformin|500-2000 mg/die
47946395|NCT04704843|DRUG|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
47946396|NCT04704843|DRUG|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
47946397|NCT06161571|DRUG|Efruxifermin|Administered by subcutaneous (SC) injection
47946398|NCT06161571|DRUG|Placebo|Administered by SC injection
47946399|NCT05490771|PROCEDURE|Biopsy|Undergo tumor biopsy
48477074|NCT05762484|DRUG|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
48477075|NCT00076531|DRUG|Leuprolide Acetate for Injectable Suspension 22.5 mg|
48634903|NCT01720602|DRUG|letrozole|Given PO
48634904|NCT01720602|DRUG|exemestane|Given PO
47946400|NCT05490771|PROCEDURE|Computed Tomography|Undergo CT
47946401|NCT05490771|DRUG|Copanlisib Hydrochloride|Given IV
47946402|NCT05490771|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47946403|NCT06604520|DRUG|Vortioxetine|Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine
47946404|NCT04724980|DRUG|PRGN-2012|"In the Phase 1, 3+3 dose escalation clinical trial evaluating PRGN-2012 at two dose levels (1x10\^11 and 5x10\^11 particle units (PU)) administered as adjuvant therapy prior to standard-of-care debulking surgery.~In the Phase 2 segment, PRGN-2012 is evaluated at the RP2D."
47946405|NCT06511050|DIETARY_SUPPLEMENT|Lumbrokinase|Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.
47946406|NCT05880654|PROCEDURE|Scaling & root planning|Non Surgical periodontal therapy
47946407|NCT00497276|PROCEDURE|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
47946408|NCT04367129|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram
48296167|NCT04691596|BEHAVIORAL|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
48296168|NCT04691596|BEHAVIORAL|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
48634905|NCT01720602|PROCEDURE|positron emission tomography|Correlative studies
47946409|NCT06403046|DRUG|intraarticular injection|all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space in the (Tx group) and Meloxicam injection among the patients of (Mx group).
47946410|NCT06681597|DIETARY_SUPPLEMENT|Raspberry ketone|Human consumed 500mg of raspberry ketone
48296169|NCT04691596|BEHAVIORAL|App use instructions|Received a basic training with the StepUp app
48296170|NCT03475407|DRUG|Ozurdex intravitreal injection|"1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~2. AC paracentesis at 6 wk~3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
48296171|NCT02192710|PROCEDURE|electronic tab|classic use of an electronic tab with age specific games
48296172|NCT02192710|DRUG|Midazolam oral intake|
48296173|NCT03327922|DEVICE|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
48296174|NCT05632939|DRUG|ASKB589 +CAPOX+Sintilimab|"Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years.~ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years."
48296175|NCT03671863|OTHER|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
47946411|NCT03189485|DRUG|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
47946412|NCT06087458|BIOLOGICAL|VOY-101|VOY-101
47946413|NCT05115578|DRUG|Remifentanil 1 MG Injection [Ultiva]|Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
47946414|NCT05115578|DRUG|Midazolam 1 MG/ML Prefilled Syringe|Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
47946415|NCT05115578|DRUG|Saline solution|Group III Control
47946416|NCT05115578|DEVICE|Algometry|The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.
48296176|NCT03671863|OTHER|Prenatal management|Prenatal management
48296177|NCT06106425|DIAGNOSTIC_TEST|EEG|diagnostic tool
48296178|NCT06352216|DIAGNOSTIC_TEST|Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)|Each subject is examined for the presence of synovitis using the aforementioned diagnostics.
48296179|NCT04160403|OTHER|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
48296180|NCT03312673|OTHER|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
48296181|NCT05114863|OTHER|Product A1|Usual Brand (UB) filtered, non-menthol cigarette
48296182|NCT05114863|OTHER|Product B|40007388, A Non-Combusted Cigarette Variant and product use Mode A
48296183|NCT05114863|OTHER|Product C|40007388, A Non-Combusted Cigarette Variant and product use Mode B
48296184|NCT05114863|OTHER|Product D|40007386, A Non-Combusted Cigarette Variant and product use Mode B
48477076|NCT03829215|DEVICE|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
48634906|NCT01720602|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
48634907|NCT01720602|RADIATION|fludeoxyglucose F 18|Correlative studies
48634908|NCT01720602|OTHER|laboratory biomarker analysis|Correlative studies
47946417|NCT06381466|DRUG|AZD0233|Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)
47946418|NCT06381466|DRUG|AZD0233 Placebo|Randomized participants will receive matching placebo orally as a SAD or MAD.
47946419|NCT01281137|GENETIC|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
47946420|NCT01281137|OTHER|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
47946421|NCT01281137|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
47946422|NCT02435147|DRUG|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
47946423|NCT03029273|DRUG|Cyclophosphamide and Fludarabine|Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
47946424|NCT03029273|BIOLOGICAL|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
47946425|NCT03169309|DEVICE|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
47946426|NCT06593106|PROCEDURE|Cryosurgery|Undergo cryodevitalization
47946427|NCT06593106|PROCEDURE|Robotic Bronchoscopy|Undergo standard of care robotic bronchoscopy with biopsy
47946428|NCT06593106|PROCEDURE|Bronchoscopy with Biopsy|Undergo standard of care robotic bronchoscopy with biopsy
47946429|NCT06593106|PROCEDURE|Resection|Undergo standard of care surgical resection
47946430|NCT06593106|PROCEDURE|Chest Radiography|Undergo chest x-ray
47946431|NCT06593106|PROCEDURE|Computed Tomography|Undergo Computed Tomography
47946432|NCT06593106|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
47946433|NCT06593106|OTHER|Electronic Health Record Review|Ancillary studies
47946434|NCT03383471|BIOLOGICAL|Invossa K Inj.|Invossa K Inj.
47946435|NCT03383471|DRUG|Placebo|Placebo control
47946436|NCT03599245|DRUG|Ocrelizumab|Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
47946437|NCT06019429|BEHAVIORAL|HiRO|"HiRO consists of weekly lessons. The lessons are aimed to promote social-emotional development. More specifically, lessons are designed to develop and enhance 1) trust, 2) collaboration, 3) respect, 4) self control, 5) resilience, 6) discipline, 7) joy. The annual program consists of four phases:~Phase 1 \& 3: Fundamental phase (6 weeks) Engaging with the values through movement. In these phases, group formation and establishing behavioral expectations are central. In the Fundamental phase, one value is addressed school-wide each week. The entire school starts with trust and ends with discipline.~Phase 2 \& 4: Theme weeks (12 lessons) A customized series of Experiential lessons for each class. Experiential learning is the guiding principle of the program, with a strong foundation based on the values upheld in judo. The learning cycle forms the basis for each experiential lesson within HiRO, and focusses on concrete experience, reflective observation, conceptualization, and practice."
47946438|NCT06019429|BEHAVIORAL|HiRO +judo|In the condition HiRO with judo, students receive the same treatment as offered in the HiRO condition. In addition, they receive physical judo classes that are designed to translate the above-mentioned values to the behavioral level.
47946439|NCT06019429|BEHAVIORAL|School as usual|Any amount of classes offered to promote social-emotional development
47946440|NCT05388396|OTHER|PIMS-TS diagnostic a treatment|PIMS-TS diagnostic a treatment
47946441|NCT02266914|DEVICE|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
47946442|NCT00719095|DRUG|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
47946443|NCT00719095|BEHAVIORAL|Behavioral therapy|
47946444|NCT01670604|DRUG|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
47946445|NCT01670604|DRUG|Tetraspan, B. Braun, Melsungen, Germany|
47946446|NCT02209831|DEVICE|BIBR 796 BS|single dose
47946447|NCT02209831|DRUG|Pantoprazole|5 days
47946448|NCT00849537|DRUG|Triamcinolone|Injection of intravitreal Triamcinolone
47946449|NCT05639465|BEHAVIORAL|JoH-C19|Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum
47946450|NCT05639465|BEHAVIORAL|Switch off Get Active|Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
47946451|NCT05398640|BIOLOGICAL|OOS AMTAGVI|Patients will undergo preparative lymphodepleting chemotherapy. Infusion of lifileucel is then given and is followed by administration of IL-2.
47946452|NCT06680336|DIAGNOSTIC_TEST|Mulit-componant neuropsychological assessment|Multi-component cognitive assessment including following domains: attention \& information speed, executive functioning, verbal memory, language, visuospatial-construction and orientation.
47946453|NCT06680336|DIAGNOSTIC_TEST|Multimodal MRI|Structural MRI (e.g., MPRAGE, DTI) and functional MRI (introducing a modified working memory task for stroke patients)
47946454|NCT06679075|PROCEDURE|Full pulpotomy using propolis and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and bioceramic putty as a dressing material
47946455|NCT06679075|PROCEDURE|Full pulpotomy using Propolis and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and MTA as a dressing material
48104068|NCT02029664|DEVICE|Visual distortion increment based on the gait pattern|
48104069|NCT01387113|OTHER|Computed tomography perfusion imaging|As per standard of care at CPMC
47946456|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and bioceramic putty|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and bioceramic putty as a dressing material
47946457|NCT06679075|PROCEDURE|Full pulpotomy using sodium hypochlorite and MTA|Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using sodium hypochlorite (NaOCl) as a hemostatic agent and MTA as a dressing material.
47946458|NCT06383767|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
47946459|NCT06383767|DRUG|Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)|Eribulin, capecitabine, gemcitabine or vinorelbine
47946460|NCT06477133|DRUG|Magnesium sulfate|Pre-mixed solution of 2 grams of magnesium sulfate dissolved in 20 mL sterile water
47946461|NCT04469075|DRUG|Clindamycin Phosphate|phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
47946462|NCT04469075|DRUG|Triamcinolone Acetonide|triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
47946463|NCT03583723|RADIATION|Radiotherapy Group|Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
47946464|NCT00209768|DEVICE|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
47946465|NCT02161029|DEVICE|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
48104070|NCT05725018|BIOLOGICAL|EB-101 Surgical application of RDEB wounds|"EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7~Other Names:~• LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]"
48296185|NCT05114863|OTHER|Product A2|Usual Brand (UB) filtered, menthol cigarette
48296186|NCT05114863|OTHER|Product E|40007385, A Non-Combusted Cigarette Variant and product use Mode A
48296187|NCT05114863|OTHER|Product F|40007385, A Non-Combusted Cigarette Variant and product use Mode B
48296188|NCT05114863|OTHER|Product G|40007387, A Non-Combusted Cigarette Variant and product use Mode B
48296189|NCT05114863|OTHER|Product H|40007386, A Non-Combusted Cigarette Variant and product use Mode B
48296190|NCT05114863|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
48296191|NCT04100070|BEHAVIORAL|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~* visits with the diabetologist/pediatrician~* contacts with the service provider (nurses' visits) (more in intensive group)~* personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
48296192|NCT03074175|RADIATION|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.
48296193|NCT04726267|DEVICE|Wide-field optical coherence tomography|Merged 4 images of wide-field optical coherence tomography, 2 images of vertical scan and 2 images of horizontal scan.
47946466|NCT02161029|DEVICE|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
47946467|NCT02810977|DEVICE|Ultrasound|Ultrasound assessment of gastric content and volume
47946468|NCT01663168|DRUG|Rifabutin|
47946469|NCT06680895|OTHER|FeNO Observation|FeNO was observed and measured among patients with advanced respiratory support
48477077|NCT02931292|PROCEDURE|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
48477078|NCT02377388|DRUG|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
47946470|NCT04920981|OTHER|atezolizumab|observational
47946471|NCT06469164|DRUG|BNT331|Vaginal insert
47946472|NCT06469164|OTHER|Placebo|Vaginal insert
48104071|NCT02272400|OTHER|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
48296194|NCT03088904|BIOLOGICAL|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
48296195|NCT03088904|BIOLOGICAL|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
48296196|NCT02563873|DEVICE|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
47946473|NCT04665180|DIAGNOSTIC_TEST|Primary knee arthroplasty|Patients who return to work after primary knee arthroplasty
47946474|NCT06431204|OTHER|Obstetric comorbidity index|Obstetric comorbidity index score
48296197|NCT00062738|DRUG|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
48296198|NCT00062738|DRUG|Nortriptyline|nortriptyline 25 - 75 mg q hs
48634909|NCT04594083|DEVICE|Palm Stimulator|The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
48634910|NCT04594083|DEVICE|ShotBlocker|ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
47946475|NCT02896244|OTHER|no intervention|
47946476|NCT00224848|BEHAVIORAL|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
47946477|NCT00924079|DRUG|nalbuphine|oral dosage form, 66 mg, single dose
47946478|NCT02069132|DRUG|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
47946479|NCT02685046|DRUG|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
47946480|NCT05276154|OTHER|thermoviscous bulkfill composite (Viscalor)|a relatively new product of composite resin which is transformed from high viscosity to low viscosity by the action of head produced by a heating device.
47946481|NCT00326677|BEHAVIORAL|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
47946482|NCT00326677|BEHAVIORAL|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
47946483|NCT04780581|DRUG|Dexamethasone|6 mg/24h - 10 days
48296199|NCT00062738|OTHER|placebo|matching placebo
48296200|NCT02251730|BEHAVIORAL|Smoking cessation|Refer for smoking cessation
48296201|NCT06410287|OTHER|ArtSpective|ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.
48296202|NCT04908189|DRUG|Deucravacitinib|Specified dose on specified days
48296203|NCT04908189|OTHER|Placebo|Specified dose on specified days
48296204|NCT04908189|DRUG|Apremilast|Specified dose on specified days
48296205|NCT00649519|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
48296206|NCT00649519|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
48296207|NCT01094899|RADIATION|Radiography|Radiography, microscanner, osteodensitometry
48296208|NCT01094899|OTHER|Urine and Blood sampling|mainly dosage of bones metabolism
48296209|NCT01094899|OTHER|Echography|body bones echography
48477079|NCT02377388|DRUG|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
48477080|NCT04187924|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
47946484|NCT04780581|DRUG|Methylprednisolone|250 mg/ 24h - 3 days
47946485|NCT05441761|DRUG|liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: gemcitabine (1000 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: dexamethasone (40 mg) will be administered on day 1-4 of each 21-day cycle.~Drug: cisplatin (75 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle."
47946486|NCT04343300|OTHER|Pilates|Intervention of12 weeks of Pilates
47946487|NCT04343300|OTHER|exercise without Pilates|exercise without Pilates
47946488|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent BRIX3000® in group (1A)"|"In group(1A), the chemomechanical caries removal agent BRIX3000® was used for caries removal in primary molars."
48634911|NCT02742974|DEVICE|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
47946489|NCT05427591|PROCEDURE|The traditional surgical treatment in group (1C)|In group(1C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
47946490|NCT05427591|PROCEDURE|"The chemomechanical caries removal agent Carie-CareTM in group (2B)"|"In group(2B), the chemomechanical caries removal agent Carie-CareTM was used for caries removal in primary molars."
47946491|NCT05427591|PROCEDURE|The traditional surgical treatment in group (2C)|In group(2C), the traditional surgical method (high-speed and low-speed air-rotors) was used for caries removal in primary molars.
47946492|NCT02028312|DRUG|Loteprednol etabonate|
47946493|NCT02028312|DRUG|Artificial Tears|
47946494|NCT02028312|DRUG|Restasis|
47946495|NCT00074438|DRUG|methotrexate|Oral or parenteral repeating dose
47946496|NCT00074438|DRUG|rituximab|Intravenous repeating dose
47946497|NCT00074438|DRUG|corticosteroids|Intravenous repeating dose
47946498|NCT00074438|DRUG|placebo|Intravenous repeating dose
48477081|NCT04187924|DEVICE|SIMEOX + Autogenic drainage|SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
48634912|NCT02983942|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
48634913|NCT02983942|DIETARY_SUPPLEMENT|Routine diet|Routine diet is given without blood ketone requirement
48634914|NCT04341662|BEHAVIORAL|E-MOTIVE intervention|"The E-MOTIVE intervention consists of three elements: 1) a strategy for early detection of PPH, which allows triggering of the 'first response' treatment bundle; 2) a 'first response' bundle called MOTIVE, based on the WHO guideline recommendations and consisting of uterine Massage, Oxytocic drugs, Tranexamic acid, IV fluids and Examination \& Escalation; and 3) an implementation strategy, focusing on simulation-based training with peer-assisted learning, local E-MOTIVE champions, feedback of actionable data to providers, calibrated drape with trigger line, and MOTIVE emergency trolley and/or carry case."
47946499|NCT06015971|DIETARY_SUPPLEMENT|omega-3|Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
47946500|NCT06015971|DIETARY_SUPPLEMENT|Standard|Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
47946501|NCT02783677|PROCEDURE|Percutaneous balloon angioplasty|
47946502|NCT01348607|DRUG|methylphenidate hydrochloride|Given orally
47946503|NCT01348607|DRUG|modafinil|Given orally
47946504|NCT01348607|DRUG|placebo|Given orally
48634915|NCT04341662|BEHAVIORAL|Usual care|Health facilities will continue to follow usual care as per the baseline period for the remainder of the intervention phase.
47946505|NCT06415942|OTHER|Maternal Outcome Monitoring and Support system|The Maternal Outcome Monitoring and Support system is a mobile health application that allows participants to choose symptoms they may be having that are warning signs of pregnancy related death. They then receive decision support about when they should seek medical care (call their provider or go to an emergency room).
47946506|NCT02423772|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
47946507|NCT04986644|DEVICE|Hioxifilcon A standard hydrogel contact lens with Hyaluronic Acid (HA)|Daily disposable contact lens wear for 1 week
47946508|NCT06174064|DEVICE|Broadband Light treatment|While shielding the eyes, multiple passes of broadband light will be applied to the upper cheeks and eyelids after applying topical lidocaine.
48634916|NCT04601909|DRUG|FX-322|active comparator
48634917|NCT04601909|OTHER|placebo|placebo
48634918|NCT04116697|OTHER|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
48634919|NCT04116697|OTHER|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
48634920|NCT04813874|DRUG|Nitrous Oxide|Nitrous Oxide Inhalational Agent
48634921|NCT04813874|PROCEDURE|Neuraxial analgesia|Epidural Labor Analgesia Placement
48634922|NCT05092503|DRUG|JINZHEN Granules for Oral Solution|JINZHEN granules will be dissolved in drinking water and administered orally.
47946509|NCT06174064|DEVICE|Sham broadband light treatment|The light will be occluded on the usual BBL device so that no treatment is delivered but the preparation and procedure will otherwise be the same.
47946510|NCT00895856|OTHER|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
47946511|NCT06376331|DRUG|washed microbiota transplantation|The prepared microbiota suspension was infused into the participates' lower gut.
48634923|NCT05092503|DRUG|Placebo|Placebo granules will be dissolved in drinking water and administered orally.
47946512|NCT01570920|BEHAVIORAL|physical training|walking many times a week
47946513|NCT03150160|DRUG|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
47946514|NCT03150160|DRUG|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
47946515|NCT03150160|DRUG|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
47946516|NCT05449522|DIETARY_SUPPLEMENT|Vitamin D|High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube
47946517|NCT05449522|DIETARY_SUPPLEMENT|Placebo|Medium-chain triglyceride (MCT)
47946518|NCT01436916|DRUG|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
47946519|NCT01436916|DRUG|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
47946520|NCT06131398|DRUG|AMG 355|Short-term intravenous (IV) infusion
48104072|NCT04841733|OTHER|Foam Roller (FR)|Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
48104073|NCT04841733|OTHER|Stretching (STR)|Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
48477082|NCT04823507|DEVICE|BIOFLEX DUO+|"* Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~* Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~* Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~* Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
48477083|NCT02079337|DRUG|Rocuronium|
47946521|NCT06131398|DRUG|Pembrolizumab|Short-term IV infusion
48477084|NCT02079337|DRUG|sugammadex|
47946522|NCT04192591|DEVICE|Superion™ IDS device|The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
47946523|NCT06324630|OTHER|Produce Prescription Delivery|Fruit and vegetable box delivery
47946524|NCT06324630|OTHER|Healthy Meal Kit Delivery|Ingredients to cook healthy meals delivered to home
47946525|NCT06324630|OTHER|Produce Prescription Mobile Market|Voucher to purchase fruits and vegetables at a mobile market
48477085|NCT02079337|DRUG|placebo|
48477086|NCT04897191|OTHER|Age|Determination of age-dependence
48477087|NCT03176784|DRUG|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
48477088|NCT03176784|DRUG|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
48477089|NCT03176784|OTHER|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
48477090|NCT03176784|OTHER|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
47946526|NCT04576104|PROCEDURE|Biopsy|Undergo biopsy
47946527|NCT04576104|DRUG|Extended Release Metformin Hydrochloride|Given PO
47946528|NCT04576104|DRUG|Megestrol Acetate|Given PO
47946529|NCT04576104|OTHER|Questionnaire Administration|Ancillary studies
47946530|NCT04844073|DRUG|TAK-186|TAK-186 IV infusion.
47946531|NCT01927627|DRUG|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
48477091|NCT01566526|DRUG|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
48477092|NCT05415124|DEVICE|HemoPill|The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
47946532|NCT01529684|DRUG|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
47946533|NCT01529684|DRUG|OSI-906|Part B: oral tablets OSI-906
47946534|NCT03815643|DRUG|Avelumab|Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
47946535|NCT04099342|DEVICE|FEAST|FEAST with standard electrode configuration and current flow
47946536|NCT04099342|DEVICE|FEAST RP|FEAST with standard electrode configuration and reversed current flow
47946537|NCT05365581|DRUG|ASP2138|Intravenously or Subcutaneously
47946538|NCT05365581|DRUG|Pembrolizumab|Intravenously
47946539|NCT05365581|DRUG|Oxaliplatin|Intravenously
47946540|NCT05365581|DRUG|Leucovorin|Intravenously
47946541|NCT05365581|DRUG|Fluorouracil|Intravenously
47946542|NCT05365581|DRUG|Ramucirumab|Intravenously
47946543|NCT05365581|DRUG|Paclitaxel|Intravenously
47946544|NCT05365581|DRUG|Irinotecan|Intravenously
47946545|NCT05908110|BEHAVIORAL|Health Communication Message|The health communication message is a single infographic developed iteratively with input from stakeholders (parents and providers). This image informs the parent that their child may have OSA, lists common nighttime symptoms parents may observe (e.g., snoring, apnea) and common daytime symptoms (e.g., hyperactivity, sleepiness) that can result from OSA. Parents are then encouraged to speak to their child's primary care provider if they observe these symptoms in their child.
48104074|NCT04841733|OTHER|Cold-Water Immersion (CWI)|Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
48104075|NCT00241540|DRUG|Esomeprazole|
48477093|NCT02040311|DRUG|Topiramate 96 mg daily|
48477094|NCT02040311|DRUG|Topiramate 192 mg daily|
48477095|NCT02040311|DRUG|Placebo|
48477096|NCT05852925|OTHER|Traditional Venipuncture|Traditional blood collection is performed and the necessary amount of blood is collected into the collection tubes (either SST or Lithium Heparin tubes based on the biomarker being tested).
47946546|NCT04814732|DRUG|Surufatinib|HMP-012
48477097|NCT05852925|DEVICE|Tasso+|The Tasso+ is the blood self-collection device used in the study and this device enables the collection of microliter capillary whole blood samples into compatible reservoirs. In this study, the reservoirs utilized include either SST or Lithium Heparin microtainers based on the biomarker being tested.
48477098|NCT04266873|DEVICE|AffloVest|Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
48477099|NCT03257215|DRUG|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
48477100|NCT03257215|DRUG|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
48477101|NCT03257215|DRUG|Stoss placebo|A single 1.5 mL dose administered on Day 1
48477102|NCT03257215|DRUG|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
48477103|NCT04751474|OTHER|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
48477104|NCT06216860|BEHAVIORAL|Laughter Yoga|In Laughter Yoga Practice; each session will last approximately 30 - 45 minutes and will consist of four parts. These parts are: warm-up exercises, deep breathing exercises, childlike games and laughter exercises.
48477105|NCT01684527|OTHER|Respiratory secretions obtained|
48477106|NCT03702049|BEHAVIORAL|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
48477107|NCT04664868|PROCEDURE|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
48477108|NCT00002787|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
48477109|NCT00002787|BIOLOGICAL|sargramostim|Given SC
48477110|NCT00002787|BIOLOGICAL|aldesleukin|Given SC
48477111|NCT00002787|OTHER|laboratory biomarker analysis|Correlative studies
47946547|NCT05417243|OTHER|Trauma life support training|Clusters are randomised for their residents to be trained in one of two trauma life support training programs or to continue providing standard care.
47946548|NCT05472324|DRUG|TQC2731 injection|TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
47946549|NCT05472324|DRUG|Placebo|The drug is a placebo Comparator.
47946550|NCT03409068|PROCEDURE|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
47946551|NCT03409068|PROCEDURE|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
47946552|NCT05231785|DRUG|ALN-APP|ALN-APP will be administered intrathecally (IT)
47946553|NCT05231785|DRUG|Placebo|Placebo will be administered IT
47946554|NCT05030818|DRUG|Polypill of acetylsalicylic acid, ramipril and atorvastatin|Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more
48477112|NCT01684059|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
48477113|NCT00101842|DRUG|Pemetrexed|
48477114|NCT00101842|DRUG|Gemcitabine|
48477115|NCT00101842|DRUG|Platinol|
48477116|NCT02668094|DRUG|Lidocaine|
48477117|NCT02668094|DRUG|Pregabalin|
48477118|NCT02668094|DRUG|propofol|
48477119|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Baseline|Measurement of rubella IgG antibody levels at baseline
48477120|NCT05923970|DIAGNOSTIC_TEST|Serology to assess cell mediated immune (CMI) response - Baseline|Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
48477121|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Post third dose of MMR vaccine|Measurement of rubella IgG antibody levels post third dose of MMR vaccine
48477122|NCT05923970|DIAGNOSTIC_TEST|Serology to assess CMI - Post third dose of MMR vaccine|Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
48477123|NCT01257581|DRUG|creatine|creatine monohydrate powder
48477124|NCT01257581|DRUG|tamoxifen|Tamoxifen citrate capsules
48477125|NCT05644886|BEHAVIORAL|FP Training and Technical Support|Same as in Intervention arm description
48477126|NCT04238637|DRUG|Durvalumab|Durvalumab IV (intravenous Infusion)
48634924|NCT00063232|DRUG|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
48634925|NCT06270394|DRUG|68Ga-Fibroblast activation protein inhibitor|Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
48634926|NCT05280808|DEVICE|Experimental phone app used for self-fitting of hearing aids|This software allows participants to set up hearing aids as appropriate for their hearing loss
48634927|NCT04287556|DIAGNOSTIC_TEST|In vitro contracture test (IVCT)|In vitro study of muscle contraction after exposure to different substances (caffeine and halothane).
48634928|NCT04287556|DIAGNOSTIC_TEST|In vitro test of hypermetabolism in B lymphocytes|In vitro study of the activation of lymphocytes B after being incubated with a cocktail of primary antibodies and measuring the acidification in response to the RyR1, 4-CmC agonist, using ryanodine as a positive control.
48634929|NCT04287556|DIAGNOSTIC_TEST|Genetic test|Analysis of genes related to MH (CACNA1S and RYR1).
48634930|NCT04017468|DRUG|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
48634931|NCT02697929|DRUG|sugammadex|
48634932|NCT02697929|DRUG|Neostigmine|
48296210|NCT03063385|BEHAVIORAL|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
48296211|NCT03063385|BEHAVIORAL|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
48296212|NCT05740007|DRUG|IW-3300 rectal foam|IW-3300 rectal foam administered daily for 12 weeks
48296213|NCT05740007|DRUG|Placebo|Placebo rectal foam administered daily for 12 weeks
48296214|NCT00803088|DEVICE|The Alair System|Treatment of airways with the Alair System
48634933|NCT00480311|OTHER|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
48634934|NCT05822271|PROCEDURE|Orthognathic Surgery|Type of surgery performed to correct skeletal malocclusions
48634935|NCT02255279|BIOLOGICAL|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
48634936|NCT02255279|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
48634937|NCT01217138|DEVICE|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
48296215|NCT06322433|DIAGNOSTIC_TEST|no drugs used for this study|tomographic, angiographic and clinical follow up
48296216|NCT04842344|DEVICE|ECCO2R|extracorporeal carbon dioxide removal
48296217|NCT02465034|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 hertz (Hz)) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
48477127|NCT04238637|DRUG|Tremelimumab|Tremelimumab IV (intravenous Infusion)
48634938|NCT04424680|BEHAVIORAL|Advanced Care Planning program of health decisions|Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
47946555|NCT05030818|DRUG|Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin|Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill
47946556|NCT00464269|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg, 10 mg and 25 mg~* Route of Administration: Oral use"
48634939|NCT05014490|DRUG|Exib 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
47946557|NCT00464269|DRUG|Brivaracetam 2.5 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use"
47946558|NCT00464269|DRUG|Brivaracetam 10 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg~* Route of Administration: Oral use"
47946559|NCT00464269|DRUG|Brivaracetam 25 mg|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 25 mg~* Route of Administration: Oral use"
47946560|NCT01933958|DRUG|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
47946561|NCT06680934|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
47946562|NCT06162429|PROCEDURE|Flexible Bronchoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy
47946563|NCT06162429|PROCEDURE|Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent medical thorascopy using semi-rigid pleuroscopy
47946564|NCT04562610|DRUG|Intravenous Infusion group|The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
47946565|NCT04562610|DRUG|All oral administration group|Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
47946566|NCT06516822|PROCEDURE|CPVI-MLA|The details include: (1) EI-VOM procedure: An 8.5-French-long sheath is inserted into to the CS via the femoral vein. A JR4 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a guide wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated at 6-8 atm pressure in the VOM. Ethanol is infused into VOM from distal to proximal with 3ml each time within 1-2min. After the distal EI-VOM, the balloon is deflated and adjusted to the middle part of VOM. The EI-VOM procedure in the proximal and middle part of VOM should be the same as that in the distal. After three times of EI-VOM, the contrast is injected into VOM to make it permeable and dispersed to observe the effect of alcohol ablation. (2) After EI-VOM, radiofrequency ablation is performed to achieve bilateral PVI, PWI, bidirectional block of MI and CTI, disappearance of LAI-CS potential and SVCI. (3) Any organized AT observed during the procedure is targeted as well.
47946567|NCT06516822|PROCEDURE|CPVI only|After reconstructing the left atrial geometry, CPVI is performed. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia for PVI to achieve a wide PVI ring. The mapping catheter PentaRay will be used to confirm the complete isolation of the PV antrum when all PV potentials within each antrum are abolished. If the AF persists after CPVI, direct current cardioversion is then be conducted to restore sinus rhythm. If spontaneous AFL/AT occurs during ablation, ablation is performed targeting the focal or critical isthmus under the guidance of high-density activation mapping. The endpoint of CPVI is to achieve complete entrance and exit block of all PV antra as recorded by PentaRay during sinus rhythm or CS pacing.
47946568|NCT06202690|PROCEDURE|Single-port robotic-assisted thoracic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the SP robotic system.~A 4-cm single incision will be made below the subcostal margin. A chest tube will be inserted in same incision."
48634940|NCT05014490|DRUG|Arcoxia® 120 mg etoricoxib film-coated tablets|Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
48634941|NCT03947021|RADIATION|Computed tomography (CT) scan|A CT scan of thorax and heart will be performed in the CT+BSPM group.
48634942|NCT03947021|DEVICE|Body-surface potential mapping|Measurement of 256-lead body-surface electrocardiogram
48634943|NCT04455750|DRUG|Enzalutamide|Given PO
48634944|NCT04455750|DRUG|Rucaparib camsylate|Given PO
48634945|NCT04455750|DRUG|Placebo|Given PO
48634946|NCT04455750|DRUG|Leuprolide Acetate|Given IM
48634947|NCT04455750|DRUG|Goserelin Acetate|Given SC
48634948|NCT04455750|DRUG|Degarelix|Given SC
47946569|NCT06202690|PROCEDURE|Single-port video-assisted thoracoscopic surgery|"All patients : 145 patients Single-port anatomical pulmonary resection(segmentectomy, lobectomy) with a complete mediastinal lymph node dissection will be performed using the VATS.~A 4-cm single incision will be made at 5th intercostal space. A chest tube will be inserted in same incision."
47946570|NCT03225729|DEVICE|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots \<6 mm which are previously selected by the investigator team.
47946571|NCT03225729|DEVICE|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots \<6 mm a small amount of nitrogen liquid.
48634949|NCT04455750|OTHER|Quality-of-Life Assessment|Ancillary studies
48634950|NCT04455750|OTHER|Questionnaire Administration|Ancillary studies
48477128|NCT03081728|DEVICE|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
48634951|NCT01142687|DIETARY_SUPPLEMENT|dihydrocapsiate capsule|"* Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
47946572|NCT06508944|DRUG|vaginal 17 beta-estradiol|"* Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
47946573|NCT06508944|DRUG|Placebo|"* Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
47946574|NCT06508944|BEHAVIORAL|Behavioral modifications|Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.
48477129|NCT03081728|DRUG|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
48477130|NCT01701973|DRUG|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
48477131|NCT01701973|DRUG|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
48477132|NCT01701973|DRUG|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
48477133|NCT01701973|DRUG|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
48477134|NCT01701973|DRUG|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
48477135|NCT03176524|DRUG|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
48477136|NCT03176524|DRUG|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
48477137|NCT03176524|DRUG|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
48477138|NCT00992095|DRUG|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
48477139|NCT06318871|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells|Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.
48477140|NCT06318871|DRUG|Interleukin-2 (IL-2)|Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
48477141|NCT04552912|BEHAVIORAL|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
48477142|NCT03451604|OTHER|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
48477143|NCT02249117|DRUG|BIWH 3|
48477144|NCT02249117|DRUG|Placebo|
48477145|NCT01304381|OTHER|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
48477146|NCT01304381|OTHER|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
48477147|NCT02404077|DRUG|Clonidine|
48477148|NCT06355830|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).
48477149|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
48477150|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
48477151|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
48477152|NCT02182167|DRUG|IV N-acetylcysteine (NAC)|
48634952|NCT02845596|DRUG|cyclosporine|cyclosporine
48634953|NCT02845596|PROCEDURE|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
48634954|NCT02845596|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
48634955|NCT02845596|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
48634956|NCT02845596|DRUG|methotrexate|methotrexate
48634957|NCT02845596|DRUG|fludarabine|fludarabine
48634958|NCT02845596|DRUG|cyclophosphamide|cyclophosphamide
48296218|NCT02465034|DEVICE|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
48296219|NCT02465034|DEVICE|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
48296220|NCT02465034|DEVICE|Corticocortical Paired Associative Stimulation|Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
48296221|NCT02465034|DEVICE|Sham Paired Associative Stimulation|The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
48296222|NCT05878444|DIETARY_SUPPLEMENT|Probiotic|Resistant gastrointestinal capsules will be provided daily to the participants.
48296223|NCT05983367|DRUG|Ompenaclid|Ompenaclid (RGX-202-01)
48296224|NCT05983367|DRUG|Placebo|Placebo
48296225|NCT05983367|DRUG|Bevacizumab|Bevacizumab
48296226|NCT05983367|DRUG|FOLFIRI regimen|FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
48296227|NCT04892446|DRUG|Magrolimab|Administered IV
48296228|NCT04892446|DRUG|Daratumumab|Administered either SC or IV
48296229|NCT04892446|DRUG|Pomalidomide|Administered orally
48296230|NCT04892446|DRUG|Dexamethasone|Administered orally
48296231|NCT04892446|DRUG|Bortezomib|Administered either SC or IV
48634959|NCT02845596|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
48634960|NCT02845596|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
48634961|NCT03915054|DRUG|AREG-TRIGGER|"Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media."
48634962|NCT03915054|DRUG|CONTROL-TRIGGER|"Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)"
48634963|NCT02455323|OTHER|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
48296232|NCT04892446|DRUG|Carfilzomib|Administered IV
48634964|NCT02455323|OTHER|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
48634965|NCT02455323|OTHER|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
48296233|NCT03590847|BEHAVIORAL|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
48296234|NCT06495996|DEVICE|Percutaneous mechanical thrombectomy (PMT)|Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus.
48296235|NCT05896189|BEHAVIORAL|Arm 1: Computerized Cognitive Training-Global Stimulation Games|The program will includes 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku. These games are well matched for time on task, novelty, and progression across levels. These are strategy-based games without adaptive, speeded, or accuracy-based algorithms underlying their personalization.
48477153|NCT02182167|DRUG|Water|
48477154|NCT01992016|DRUG|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
48477155|NCT04596124|DEVICE|fitostimoline plus|randomized controlled multicentric study
48296236|NCT05896189|BEHAVIORAL|Arm 2: Computerized Cognitive Training-Neuroplasticity Games|Cognitive training exercises include Double Decision (targets visual speed of processing and useful field of view), Target Tracker (targets visuospatial working memory capacity), Visual Sweeps (targets speed of processing), Syllable Stacks (targets auditory memory), Eye for Detail (targets eye movement speed and visuo-spatial working memory), Mind Bender (targets mental flexibility), Divided Attention (a shape-color-pattern inhibitory control exercise that focuses on rapidly determining whether flashing colors, shapes, or patterns meet a pre-specified rule), Right Turn (targets spatial reasoning).
48634966|NCT02455323|OTHER|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
48634967|NCT01807104|PROCEDURE|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
47946575|NCT06629207|DEVICE|PET/CT with 18-FDG|FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.
47946576|NCT06629207|DEVICE|SPECT : 123 I-FP-CIT (DATSCAN)|DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.
47946577|NCT06629207|DEVICE|MRI|MRI examination to exclude structural brain anomalies.
47946578|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
48296237|NCT00005592|BIOLOGICAL|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
48296238|NCT00005592|BIOLOGICAL|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
48296239|NCT00005592|RADIATION|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
48296240|NCT01900275|OTHER|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
48296241|NCT06672159|DEVICE|Two defibrillators|DSED procedure consists of pads placed in anterior-lateral position, and in anterior-posterior position. Defibrillations will be given in rapid sequence, less than a second apart. All other aspects of resuscitation in accordance to existing guidelines.
48296242|NCT06672159|DEVICE|One defibrillator|Standard OHCA treatment according to existing guidelines.
48477156|NCT01396382|RADIATION|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
48477157|NCT03643926|PROCEDURE|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
48477158|NCT03643926|PROCEDURE|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
48477159|NCT02917252|OTHER|3-hydroxybuturate|Drink of ketone bodies
48477160|NCT02917252|OTHER|Placebo|Drink of saline
48634968|NCT01807104|PROCEDURE|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
48634969|NCT03092037|PROCEDURE|Blood draw|The Investigators will collect serum and whole blood from participants.
48634970|NCT04461535|DRUG|Adrenocorticotropic hormone|Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
48296243|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist|anti-IL6 alone
48296244|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist and corticosteroids|anti-IL6 + corticosteroid combination
48634971|NCT00884000|DRUG|Genotropin|
48634972|NCT00884000|DRUG|Zomacton|
48296245|NCT04486521|DRUG|corticosteroid alone|"dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent"
48296246|NCT00707018|DEVICE|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
48634973|NCT01819480|PROCEDURE|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
48634974|NCT06500897|DEVICE|VEST|External MEsh Support for safein vein
48634975|NCT05362799|DRUG|Letrozol (Femara, Novartis)|Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
48634976|NCT05362799|DRUG|Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)|Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
48634977|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
48634978|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
48634979|NCT03150797|DRUG|Melatonin|Melatonin
48296247|NCT00707018|DEVICE|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
48296248|NCT00746772|DRUG|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
48296249|NCT00746772|DRUG|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
48296250|NCT03796169|BEHAVIORAL|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
48634980|NCT03150797|DRUG|Placebo oral capsule|Placebo
48296251|NCT03796169|BEHAVIORAL|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
48296252|NCT03796169|BEHAVIORAL|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
48634981|NCT03856177|BEHAVIORAL|Emotion Induction|Described in arm
48634982|NCT04890171|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
48634983|NCT04890171|PROCEDURE|Surgery|Gastrectomy with lymph node dissection by a surgeon
48634984|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
48634985|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
48634986|NCT00345592|DEVICE|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
48296253|NCT04606511|DIAGNOSTIC_TEST|Circumference tape measurements|centimeter and volume criterias
48296254|NCT04606511|DIAGNOSTIC_TEST|Indocyanine green lymphangiography|Presence of dermal backflow
48296255|NCT04606511|DIAGNOSTIC_TEST|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
48296256|NCT04606511|DIAGNOSTIC_TEST|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
48296257|NCT01177215|PROCEDURE|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
48296258|NCT05941182|OTHER|online questionnaires|Before and after online questionnaires
48296259|NCT02713750|OTHER|reversible contraceptive methods|"1. Consistent male condom use only~2. Consistent female condom use only~3. Hormonal contraception, combined oral contraceptive pills and male/female condom~4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~5. Hormonal contraception , progestin only hormonal implant and male/female condom~6. Intrauterine device and male/female condom"
48296260|NCT02261480|OTHER|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
48296261|NCT02261480|OTHER|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
48296262|NCT04034979|BEHAVIORAL|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
48296263|NCT05218889|DRUG|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
48296264|NCT05218889|DRUG|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
48296265|NCT00205972|DEVICE|Humerus Nail or LC Plate|
48296266|NCT06372639|DEVICE|Trans-Cranial Magnetic Stimulation|Brain stimulation by the TMS device will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, the target area will be determined based on an fMRI scan in the resting state of the subject.
48296267|NCT06672952|DIETARY_SUPPLEMENT|400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.
48296268|NCT06672952|DIETARY_SUPPLEMENT|Placebo|The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.
48296269|NCT06672952|DIETARY_SUPPLEMENT|200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.
48296270|NCT01599351|RADIATION|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
48296271|NCT05834959|OTHER|An Educational and Training Program|Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
48296272|NCT02318394|BIOLOGICAL|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
48296273|NCT05634512|DRUG|Laronidase therapy and a stem cell transplant|To identify key differences leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH. There will be 12 samples per patient (6 pre-transplant and 6-post-transplant). Laronidase will be administered IV per protocol using standard dosing (0.58 mg/kg intravenously on a weekly basis), and six (n=6) blood samples will be collected over 24 hours for the determination of mononuclear cell lysates and plasma laronidase concentrations for a total of 18mL. The second PK monitoring will be obtained using the same PK design but following complete or near-completedonor derived myeloid engraftment which is evaluated at different time pointspost-HCT (day 30, day 42, day 60). The standard is to continue ERT through 8 weeks post-transplant.
48296274|NCT01125891|DRUG|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
48296275|NCT01125891|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
48296276|NCT05067660|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.
48296277|NCT05067660|RADIATION|Current standard template-based salvage therapy|In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.
48296278|NCT03991377|BEHAVIORAL|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~1. Patient history.~2. Patient preparation.~3. Patient assessment.~4. Memory desensitization.~5. Installing the positive cognition.~6. Body scan.~7. Closure.~8. Reevaluation."
48634987|NCT01169909|DRUG|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
48634988|NCT03364686|BIOLOGICAL|Biotin-Labeled Red Blood Cells|We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
48634989|NCT03683498|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
47946579|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in PA, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
48477161|NCT06130787|BIOLOGICAL|Blood and bone marrow sample|"Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36"
48477162|NCT05661461|DRUG|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
48477163|NCT00707447|BEHAVIORAL|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
48477164|NCT00707447|BEHAVIORAL|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
48477165|NCT06425367|DIAGNOSTIC_TEST|Antibiotic susceptibility testing|antibiotic susceptibility testing is performed on MHR-SIR or MH medium depending on randomization
48477166|NCT04403399|DRUG|Varenicline|Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
48477167|NCT04403399|DRUG|Placebo|Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
48477168|NCT03224520|BEHAVIORAL|Recommender CTHC|Enhanced Messaging
48477169|NCT03224520|BEHAVIORAL|Standard CTHC|Standard Messaging
48477170|NCT03224520|OTHER|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
48477171|NCT03224520|OTHER|Standard Online Recruitment|Search Engine and Social Media Advertisements
48477172|NCT05699291|OTHER|Sentinel node detection technique|Patients cared for by a surgeon for histologically proven breast cancer and for whom an indication for detection of the sentinel lymph node is posed.
48477173|NCT03572842|OTHER|quantiferon monitor test|different blood test with quantiferon monitor
48477174|NCT02970552|DRUG|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
48477175|NCT02970552|DRUG|Placebo|Indistinguishable placebo vaginal suppository
48477176|NCT02333188|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
48477177|NCT02333188|DRUG|Leucovorin Calcium|Given IV
48477178|NCT02333188|DRUG|Irinotecan Hydrochloride|Given IV
48477179|NCT02333188|DRUG|Fluorouracil|Given IV
48477180|NCT02333188|OTHER|Laboratory Biomarker Analysis|Correlative studies
48477181|NCT03684681|BEHAVIORAL|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
48477182|NCT03684681|BEHAVIORAL|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
48477183|NCT05983159|DRUG|Alpelisib|Oral alpha-specific PI3-kinase inhibitor
48477184|NCT05983159|DRUG|Mirdametinib|An investigational oral MEK inhibitor
48477185|NCT02384291|DEVICE|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
48477186|NCT02384291|DEVICE|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
48477187|NCT05556226|DRUG|ABBV-154 Dose Formulation A|Subcutaneous Injection
48477188|NCT05556226|DRUG|ABBV-154 Dose Formulation B|Subcutaneous Injection
48477189|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops|
48477190|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops placebo|
48477191|NCT03715686|PROCEDURE|wire localization|Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
48477192|NCT01408225|PROCEDURE|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
48477193|NCT02191566|DRUG|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
48477194|NCT02191566|DRUG|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
48477195|NCT03263793|BEHAVIORAL|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
48296279|NCT03991377|DRUG|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
48296280|NCT05061888|OTHER|Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables|Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.
48296281|NCT05061888|OTHER|Smart Intervention for Stress Managment|Will receive a Smart Intervention on stress management practices and strategies.
48296282|NCT00616239|DRUG|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
48296283|NCT00616239|DRUG|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
48296284|NCT03511638|DEVICE|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
48296285|NCT03511638|DEVICE|Alcon VISCOAT®|Ophthalmic viscosurgical device
48296286|NCT05456100|BEHAVIORAL|Expressive Helping|Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
48296287|NCT05456100|BEHAVIORAL|Expressive Writing|Expressive writing involves emotional disclosure writing over four weeks.
48296288|NCT05456100|BEHAVIORAL|Factual Writing|Factual writing involves writing facts about cancer treatment and experiences over four weeks.
48296289|NCT02561377|BEHAVIORAL|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
48296290|NCT02561377|BEHAVIORAL|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
48296291|NCT03345862|BEHAVIORAL|non-pharmacological multicomponent|Following the proposal of Nicholson \& Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home \[30-60 minutes\] for 16 weeks (1 fortnightly session) and 5 telephone sessions \[20 min.\] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
48296292|NCT06027086|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
48296293|NCT06027086|DRUG|DRP-104|"Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration."
48296294|NCT06229366|DRUG|[Ac-225]-PSMA-62 (mCRPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles."
48296295|NCT06229366|DRUG|[Ac-225]-PSMA-62 (OmHSPC)|"Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles.~Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles."
48296296|NCT01834326|BIOLOGICAL|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
48296297|NCT01834326|BIOLOGICAL|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
48296298|NCT01652677|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
48296299|NCT01511146|DRUG|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
48296300|NCT01511146|DRUG|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
48296303|NCT04164667|BEHAVIORAL|Mental and physical (MAP) training intervention|"In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise."
48477196|NCT02210052|DEVICE|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
48477197|NCT02008708|BEHAVIORAL|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
48477198|NCT02008708|OTHER|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
48296304|NCT00364039|DRUG|AV650|
48296305|NCT00004184|BIOLOGICAL|monoclonal antibody 4B5 anti-idiotype vaccine|
48296306|NCT00004184|BIOLOGICAL|sargramostim|
48296307|NCT00004184|DRUG|alum adjuvant|
48296308|NCT05823506|COMBINATION_PRODUCT|PDE5 inhibitor (tadalafil) and BTL-6000 fSWT|The mechanism of low-intensity shockwave therapy in patients with ED based on the effect on the endothelium of the cavernous arteries, the release of NO and the enhancement of vascularization due to release of angiogenic factors.
48296309|NCT05823506|DRUG|PDE5 inhibitor (tadalafil)|Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
48296310|NCT04870177|DRUG|AK112|AK112 infusion biweekly
48296311|NCT01236222|BEHAVIORAL|Cycling to school|Regular cycling to school
48296312|NCT03835208|BEHAVIORAL|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
48296313|NCT03245632|OTHER|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
48296314|NCT01837082|DRUG|ferric carboxymaltose|
48296315|NCT01837082|DRUG|Placebo|
48296316|NCT00823329|DEVICE|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
48634990|NCT02421965|BEHAVIORAL|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
48634991|NCT02421965|BEHAVIORAL|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
48296317|NCT03188211|OTHER|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
48296318|NCT03188211|OTHER|Control|Any educational program will be delivered to clinicians assigned to control arm
48296319|NCT04038775|BEHAVIORAL|Volunteering|Subjects recommended volunteer by their provider.
48296320|NCT04524975|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
48296321|NCT04524975|DRUG|Placebo|Placebo capsules
48296322|NCT02892097|DEVICE|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
48296323|NCT02892097|DEVICE|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
48296324|NCT02892097|BEHAVIORAL|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
48296325|NCT03400670|DEVICE|ventilator NCPAP|infants will be randomized into two different NCPAP groups
48296326|NCT06075004|PROCEDURE|Periarticular Local Anesthetic Infiltration|Sixty milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg will be deposited by the orthopedic surgeon at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
48296327|NCT06075004|PROCEDURE|Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block|"From a total of forty-five milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg, 15mL will be deposited by the orthopedic surgeon at the posterior periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure with the remaining 30mL.~After wound closure, an ultrasound-guided pericapsular nerve group block will be performed by an anesthesiologist by injecting 10mL of 0.5% bupivacaine + 5ug/mL epinephrine in the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle."
48477199|NCT06315517|OTHER|Conventional lactose-free cow's milk|"Participants will receive conventional lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
48634992|NCT01642849|DIETARY_SUPPLEMENT|high protein diet|6 months on HP diet
48634993|NCT01642849|DIETARY_SUPPLEMENT|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
48634994|NCT01399086|DRUG|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
48634995|NCT04132180|OTHER|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
48634996|NCT04132180|OTHER|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
48634997|NCT03673722|OTHER|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
48634998|NCT03673722|OTHER|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
48634999|NCT03673722|OTHER|Control|Participants will be given generic healthy eating advice based
48635000|NCT02642276|OTHER|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
48635001|NCT01371565|DRUG|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
48296328|NCT02512016|OTHER|Study Procedures|"* Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~* Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~* Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~* Measures of strength and body habitus:~  8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~  1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~* Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
48296329|NCT02232646|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
48635002|NCT02142829|DRUG|EXPAREL|
48635003|NCT02142829|DRUG|On-Q Pain Ball|bupivacaine HCl 0.25%
48635004|NCT05229354|BIOLOGICAL|TV005|The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.
48635005|NCT05229354|BIOLOGICAL|rDEN2Δ30-7169 attenuated virus strain|based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
48635006|NCT01204281|OTHER|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
48635007|NCT00726427|DRUG|AZD1656|Dose escalation to achieve maximum tolerated dose
48635008|NCT00726427|DRUG|AZD1656|Oral single dose
48635009|NCT05142644|PROCEDURE|ultrasound|An extra ultrasound performed during pregnancy
48635010|NCT04759092|DEVICE|transcranial direct current stimulation (tDCS)|Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
48635011|NCT04999293|DRUG|Ticagrelor|Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
48635012|NCT01936974|DRUG|Gemcitabine|Patient to receive gemzar
48635013|NCT01936974|DRUG|Bevacizumab|Patient to receive avastin
48635014|NCT01936974|DRUG|Carboplatin|Patient to receive carboplatin
48635015|NCT01936974|DRUG|Cisplatin|Patient to receive cisplatin
48635016|NCT01936974|DRUG|Oxaliplatin|Patient to receive Oxaliplatin
48635017|NCT01401205|OTHER|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
48635018|NCT04140903|DRUG|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
48635019|NCT04140903|DRUG|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
47946580|NCT05368090|PROCEDURE|EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
48635020|NCT03325257|OTHER|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
48635021|NCT00420056|DRUG|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
48635022|NCT02627638|OTHER|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
48635023|NCT00666575|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
48635024|NCT00666575|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
48635025|NCT01326897|BEHAVIORAL|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
48635026|NCT01326897|BEHAVIORAL|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
48635027|NCT01065766|DRUG|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
48635028|NCT05014542|PROCEDURE|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
48635029|NCT05014542|DRUG|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
48296330|NCT02229994|OTHER|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.~* From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~* From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
48635030|NCT02105857|OTHER|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
48635031|NCT04783727|DIAGNOSTIC_TEST|Individualised treatment duration based on RNA transcriptomic model|Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.
48635032|NCT03221296|BEHAVIORAL|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
48635033|NCT03168997|DRUG|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
48635034|NCT03632720|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
48635035|NCT03632720|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: suspension for injection; route of administration: deep intramuscular, 0.5 mL
48635036|NCT03632720|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
48635037|NCT03632720|BIOLOGICAL|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
48635038|NCT03632720|BIOLOGICAL|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
48635039|NCT04951063|RADIATION|Hypofractionated radiotherapy|"Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
48635040|NCT04951063|DRUG|Concurrent chemotherapy|weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
48635041|NCT04951063|DRUG|Consolidation immunotherapy|Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
48635042|NCT01326936|BEHAVIORAL|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
48635043|NCT00567801|PROCEDURE|conventional embolectomy/thrombectomy|
48635044|NCT00567801|PROCEDURE|embolectomy/thrombectomy with controlled reperfusion|
48635045|NCT03114644|OTHER|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
48635046|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
48635047|NCT01554852|DRUG|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
48635048|NCT01554852|DRUG|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
48635049|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
48296331|NCT02397720|DRUG|Azacitidine|Given SC or IV
48296332|NCT02397720|DRUG|Ipilimumab|
48296333|NCT02397720|DRUG|Venetoclax|Given Orally
48296334|NCT02397720|DRUG|Nivolumab|Given IV
48635050|NCT01554852|DRUG|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
48635051|NCT01554852|DRUG|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
48635052|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
48635053|NCT01554852|DRUG|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 \& 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
48635054|NCT01554852|DRUG|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
48635055|NCT02380872|PROCEDURE|Connective tissue graft|gingival recession treated with connective tissue graft
48635056|NCT02380872|PROCEDURE|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
48635057|NCT04167436|OTHER|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
48635058|NCT03870971|OTHER|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
48635059|NCT05558670|OTHER|PET-fMRI-EEG|Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap
48635060|NCT03849612|DEVICE|AID System|AID system
48635061|NCT03849612|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
48635062|NCT00001857|DRUG|BG9588|
48635063|NCT02533674|DRUG|Gemcitabine plus PM060184|
48635064|NCT04920825|DIETARY_SUPPLEMENT|Sacha Inchi Oil softgel supplement|A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks
48635065|NCT04920825|DIETARY_SUPPLEMENT|Corn oil softgel|A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
48635066|NCT02820103|BEHAVIORAL|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
48635067|NCT02820103|BEHAVIORAL|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
48635068|NCT02820103|BEHAVIORAL|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
48635069|NCT02434614|DRUG|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
48635070|NCT02434614|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
48635071|NCT02434614|DRUG|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
48635072|NCT00086125|DRUG|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
48635073|NCT02716142|DRUG|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
48635074|NCT02716142|DRUG|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
48635075|NCT02830087|PROCEDURE|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
48635076|NCT05073510|DEVICE|BVE|Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
48635077|NCT05235256|PROCEDURE|bilateral sphenopalatine ganglion block|peripheral n block
47946581|NCT05368090|PROCEDURE|"EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, debulking group"|Patients will fast, receive prophylactic antibiotics and conscious sedation prior to the endoscopic procedure.The procedure is performed with a standard linear echo-endoscope with a 3.7 mm or larger working channel. The left adrenal is identified from the fundus of the stomach. Color-Doppler is used to map adrenal vascularity. Ultrasound contrast is used to demarcate the border of the tumour. EUS-guided fine needle tissue sampling from tumour tissue is performed. The RFA ablation catheter is water-cooled and stable temperature is maintained at 70-75 degrees celsius until formation of heat bubbles can be seen on EUS. If necessary, the procedure is repeated after moving the probe until the whole adenoma volume is ablated. Ultrasound contrast medium is used after the procedure to ensure that the target for the ablation is non vascularized, before termination. The patients will be observed at the postoperative unit a few hours, and further in the ward for 24h
48635078|NCT05235256|PROCEDURE|bilateral greater occipital nerve block|bilateral greater occipital nerve block
48635079|NCT05235256|DRUG|lidocaine plus dexamethasone|lidocaine plus dexamethasone
48635080|NCT03286803|BIOLOGICAL|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
48635081|NCT05706675|PROCEDURE|Non surgical periodontal therapy|Manual root planning+Ultrasonic subgingival debridement
48635082|NCT00449969|DEVICE|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
48635083|NCT00449969|DEVICE|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
48635084|NCT00008268|BIOLOGICAL|filgrastim|
48635085|NCT00008268|DRUG|melphalan|
48635086|NCT04256031|OTHER|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
48635087|NCT04928638|BEHAVIORAL|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
48635088|NCT04928638|BEHAVIORAL|Written educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
48296335|NCT05357040|DRUG|Nitrous oxide gas for inhalation|"60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
48635089|NCT03118271|DEVICE|lumbar traction|
48635090|NCT03118271|PROCEDURE|spinal manipulation|
48635091|NCT03118271|PROCEDURE|surgery|
48635092|NCT01803737|BEHAVIORAL|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
48635093|NCT01803737|BEHAVIORAL|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
48635094|NCT02688231|OTHER|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
48296336|NCT05357040|DRUG|Placebo|"60-minute sessions of inhaled oxygen-air mixture (FiO2 ≈0.3) to be administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide."
48296338|NCT04749108|DRUG|Induction chemotherapy - modified FOLFIRINOX regimen|An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
48296339|NCT04749108|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
48296340|NCT04749108|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of radiotherapy treatment (2 daily intake).
48296341|NCT04749108|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
48296342|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with povidone-iodine solution|Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
48296343|NCT04548661|PROCEDURE|Intraoperative incisional wound irrigation with saline|Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
48296344|NCT05537181|DEVICE|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
48296345|NCT03043365|DRUG|control fish oil|4 capsules, 3 times a day after meals
48635095|NCT02688231|OTHER|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
48635096|NCT04773977|DRUG|IBI362 liquid formulation|Administered by subcutaneous injection
47946582|NCT03250169|DRUG|Alemtuzumab|Licensed dose
47946583|NCT05281952|PROCEDURE|endoscopic ligation|the surgical ligation of one or both sphenopalatine arteries by endoscopic way.
47946584|NCT05281952|PROCEDURE|Supra-selective embolization|occlusion of the terminal branches of the nasal external carotid artery.
48296346|NCT03043365|DRUG|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
48296347|NCT01728259|DRUG|pomalidomide|Given PO
48296348|NCT01728259|DRUG|bortezomib|Given IV
48296349|NCT01728259|DRUG|dexamethasone|Given PO
48296350|NCT01728259|OTHER|Laboratory Biomarker Analysis|Correlative studies
48296351|NCT02482220|BEHAVIORAL|Physical activity intervention|
48296352|NCT05440760|DEVICE|The Oculus Quest 2 Virtual Reality Headset|"The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)"
48296353|NCT01347567|OTHER|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
48296354|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain|CBOT device with beta-caryophyllene
48296355|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactoy stimuli with no BCP
48635097|NCT04773977|DRUG|IBI362 lyophilized powder|Administered by subcutaneous injection
48635098|NCT00782379|DRUG|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
48635099|NCT00782379|DRUG|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
48635100|NCT00782379|DRUG|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
48635101|NCT00782379|DRUG|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
48635102|NCT00782379|DRUG|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
48635103|NCT00782379|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
48296356|NCT02627846|DEVICE|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
48296357|NCT02627846|DEVICE|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
48296358|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
48296359|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
48296360|NCT02627846|DRUG|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
48296361|NCT02627846|DRUG|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
48296362|NCT06672432|OTHER|CareMom (a mobile app-based 8-wekk cognitive behavioral therapy program)|The intervention is divided into daily tasks spread across eight weeks, with each day involving a variety of interactive elements such as videos, text-based content, guided reflections, and mental health check-ins. If the user misses a daily challenge, she can complete that challenge in the later days. Each week has a distinct focus that progressively builds the user's skills and understanding in managing emotional health. Tasks are designed to be short yet impactful, aiming to enhance engagement and adherence.
48296363|NCT06672432|OTHER|Matched Attention Control (a mobile app-based 8-week online relaxation training program)|This program is designed to mirror the structure and engagement level of the intervention group, providing participants with a similar amount of interaction and daily activities. Each day, participants in the control group will complete 1-2 daily tasks focused on relaxation techniques, such as breathing exercises, mindfulness meditation, and guided imagery. Each task is brief, approximately 3 minutes in duration, making it easy for participants to incorporate into their daily routine.
48296364|NCT04364672|DRUG|18F-labeled DPA-714 PET scan|One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
48477200|NCT06315517|OTHER|Nonconventional (A2) cow's milk|"Participants will receive nonconventional (A2) cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
48477201|NCT06315517|OTHER|Nonconventional (A2) lactose-free cow's milk|"Participants will receive nonconventional (A2) lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
48635104|NCT00782379|PROCEDURE|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
48635105|NCT05358782|DEVICE|Dental implant positioning|observational study of the effect of implant malposition
48635106|NCT03536962|OTHER|no intervention|no intervention
48635107|NCT05682469|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
48635108|NCT05682469|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
47946585|NCT03564028|OTHER|energy conservation technique|During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.
48477202|NCT04583696|DIETARY_SUPPLEMENT|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
48296365|NCT01662973|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1\*10E6 UC-MSC/kg body weight for 12 weeks.
48296366|NCT01662973|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
47946586|NCT03564028|OTHER|control session|Patients will realize one session of stair climbing at their own pace
47946587|NCT03695887|DRUG|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
47946588|NCT03695887|DRUG|Placebo|Inactive comparator
47946589|NCT04768725|BEHAVIORAL|Dietary intervention combined with physical-cognitive exergaming|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\] combined with physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
47946590|NCT04768725|BEHAVIORAL|Dietary intervention|Intermittent Fasting (IF) \[self-selected diet with 25-75% of estimated baseline energy requirements for 2 days/week (fast day) along with ad libitum for 5 days/week (feed day)\].
47946591|NCT04768725|BEHAVIORAL|Physical-cognitive intervention|Physical-cognitive exercise \[60-70% of heart rate maximum for aerobic and 60-70% of 1 repetition maximum, 8-12 repetitions/set, 3 sets of each exercise for resistance exercise; memory, attention, and executive function for cognition\], 60 minutes per session, 3 sessions per week for 12 weeks (36 sessions)\].
47946592|NCT00497315|DRUG|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
47946593|NCT00497315|RADIATION|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
47946594|NCT00658008|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
47946595|NCT00658008|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
47946596|NCT00658008|DRUG|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
47946597|NCT00658008|DRUG|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
47946598|NCT00658008|DRUG|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
47946599|NCT01417936|DRUG|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
47946600|NCT03473951|DIAGNOSTIC_TEST|Hyperuricemia|Hyperuricemia vs. normouricemia
48104076|NCT00907218|DRUG|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
47946601|NCT06131320|DIAGNOSTIC_TEST|PVSE Test|Completion of the PVSE test
47946602|NCT06131320|OTHER|Cerebral MRI|Cerebral MRI scan
47946603|NCT03617354|PROCEDURE|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
47946604|NCT02460107|BIOLOGICAL|Botulinum toxin type A|
47946605|NCT02460107|OTHER|Normal saline|Placebo
47946606|NCT01785407|DIETARY_SUPPLEMENT|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
47946607|NCT02979717|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|
48298849|NCT04008862|BEHAVIORAL|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
48477203|NCT05451940|DRUG|Hydroxyurea|Hydroxyurea is an orally available antimetabolite medication that has been shown to reduce the frequency of painful crises and acute chest syndrome in adults and children with sickle cell disease. Hydroxyurea treats sickle cell disease by a number of different mechanisms, including increasing the expression of fetal hemoglobin (HbF), which reduces sickling of red blood cells.
48635109|NCT04376632|DIETARY_SUPPLEMENT|Pecan ADD|Raw pecan halves without dietary substitution instructions
47946608|NCT02979717|OTHER|Low protein, low fiber comparator|
47946609|NCT02193477|DEVICE|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
47946610|NCT02193477|DEVICE|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
48635110|NCT04376632|DIETARY_SUPPLEMENT|Pecan SUB|Raw pecan halves with instructions to substitute pecans with isocaloric foods in the habitual diet
48104077|NCT05216419|DRUG|Cholecalciferol|"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."
48635111|NCT00160615|DRUG|Levetiracetam|"* Pharmaceutical form: Film-coating tablets~* Concentration: 250 mg/ 500 mg~* Route of administration: oral use"
48298850|NCT05527704|DRUG|Salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
48635112|NCT03247712|DRUG|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
48635113|NCT03247712|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
48635114|NCT03247712|RADIATION|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
48477204|NCT05451940|DRUG|Epoetin Alfa|Epoetin alfa is a first-generation erythropoiesis-stimulating agent (ESA), which are recombinant versions of erythropoietin (EPO) produced using recombinant DNA technology. Erythropoietin (EPO) is a glycoprotein hormone, naturally produced mainly in the kidneys in response to hypoxia and stimulates red blood cell production (erythropoiesis) in the bone marrow.
48477205|NCT04735107|PROCEDURE|colorectal anastomosis reinforcement and trans-anal drainage|Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
48635115|NCT03247712|RADIATION|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
48635116|NCT03444688|OTHER|Conventional Gait Training|Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
48104078|NCT05945875|DRUG|Panitumumab-IRDye800|Given by IV
48635117|NCT03444688|DEVICE|Gait rehabilitation with walker|For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
48635118|NCT02455089|OTHER|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
48635119|NCT01234714|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
48635120|NCT01234714|PROCEDURE|Major liver resection|Hepatectomy of \>= 3 liver segments
48635121|NCT00618566|BEHAVIORAL|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
48635122|NCT02238327|PROCEDURE|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
48635123|NCT02238327|PROCEDURE|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
48635124|NCT02238327|PROCEDURE|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
48635125|NCT02238327|PROCEDURE|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to \<88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
48635126|NCT02238327|RADIATION|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
48104079|NCT05945875|OTHER|Indium In 111 Panitumumab|Given by IV
48298851|NCT05527704|DRUG|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
48298852|NCT04638127|BEHAVIORAL|PREEMIE PROGRESS|PREEMIE PROGRESS is a video-based training program for parents of preterm infants hospitalized in the neonatal intensive care unit (NICU).
48635127|NCT02238327|PROCEDURE|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
48635128|NCT02238327|PROCEDURE|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
48298853|NCT04638127|BEHAVIORAL|Attention Control|usual care and welcome videos
48635129|NCT01981993|BIOLOGICAL|Urinary proteomic analysis|
48635130|NCT02948075|DRUG|Quisinostat|
48635131|NCT02948075|DRUG|Paclitaxel|
48635132|NCT02948075|DRUG|Carboplatin|
48635133|NCT03760640|DRUG|LY900014|Administered SC
48635134|NCT03760640|DRUG|Insulin Lispro|Administered SC
48635135|NCT05754775|BEHAVIORAL|Calorie restriction via total food replacement|Restricted foods designed by a clinical nutritionist that delivers to home for diabetic patients.
48635136|NCT01184118|DRUG|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
48635137|NCT00290420|DRUG|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
48635138|NCT03385642|DEVICE|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
48635139|NCT06209125|DEVICE|hybrid aesthetic functional appliance|treatment of class II division one malocclusion
48635140|NCT03760068|DRUG|MYL-1601D Product|(100 U/mL)
48635141|NCT03760068|DRUG|FlexPen NovoLog®|(100 U/mL)
48635142|NCT02856373|PROCEDURE|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
48635143|NCT05340660|RADIATION|[ 18 F]PSS232|\[ 18 F\]PSS232 for imaging metabotropic glutamate receptor subtype 5 and comparing expression of the receptor in healthy persons and ALS patients
48635144|NCT05595395|DRUG|Enteral Dose Form|"In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton."
48635145|NCT05595395|DRUG|Intravenous Infusion|"In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton."
47946611|NCT05588778|BEHAVIORAL|BAILAMOS™ @home/en casa|The BAILAMOS™ dance program and dance manual. BAILAMOS™ originally encompassed four dance styles: Merengue, Cha Cha Cha, Bachata, and Salsa. These four styles of Latin dance are generally considered the most popular in terms of recognition and preference. We have added two styles to appeal to the largely Mexican-origin Latinos in Chicago (i.e., Cumbia and Samba). The dances were jointly choreographed by the PI and Mr. Mendez, a professional dance instructor and owner of The Dance Academy of Salsa and http://www.salsachicago.com/. The PI and dance instructor co-developed the extensive manual is used by program instructors and includes background information on the authors, an introduction describing the goals of the program, and descriptions of the various styles of dance. The manual also has photos and descriptions of each dance broken down into its component parts.
48104080|NCT05945875|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Single Photon Emission Computed Tomography
48104081|NCT05945875|PROCEDURE|Computed Tomography|Undergo Computed Tomography
48635146|NCT05866601|OTHER|Role-playing for learning the clinical interview|"Thirty-one first-year physiotherapy students will carry out the role-playing methodology to learn how to take a clinical history in physiotherapy.~Before and after the realization, they will be measured by means of a validated questionnaire in Spanish, the language in which they study, the variable of empathy and anxiety."
48635147|NCT05440929|BEHAVIORAL|Clinician Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
48635148|NCT02923622|OTHER|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
48104082|NCT05945875|PROCEDURE|Resection|Undergo standard of care surgical resection
48104083|NCT05945875|PROCEDURE|Fluorescence Imaging|Undergo standard of care fluorescence imaging
48104084|NCT02215044|DRUG|BI 2536, intravenous|
48104085|NCT02215044|DRUG|Gemcitabine, intravenous|
48635149|NCT02923622|OTHER|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
48635150|NCT02923622|OTHER|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
48296367|NCT06318923|OTHER|Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment|"The demographic questionnaire collects demographic information: gender, age, level of education, laterality, history of psychiatric or neurological disorders.~The moral judgment task consists in completing 20 vignettes of moral dilemmas. Cognitive disorders will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. If the patient has taken the BICAMS battery recently (less than 6 months), and with no change in pathology since then, the results of these tests will be used in this study.~Affective disorders will be assessed using the following tests:~* The Beck Depression Inventory-Fast Screen (BDI-FS) to assess the level of depression,~* State trait anxiety inventory-Y (STAI-Y) to assess anxiety,~* Toronto Alexithymia Scale-20 (TAS-20)to assess alexithymia,~* The Empathy Quotient-8 (EQ-8) to assess participants' level of empathy,~* The Dot Probe Task to assess participants' emotional information processing style."
48635151|NCT01404065|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
48635152|NCT03056430|BEHAVIORAL|Training|
48296368|NCT06318923|OTHER|MS questionnaire|This questionnaire collects key information on the participant's pathology: clinical form, date of first symptoms, diagnosis, last attack, as well as latest EDSS and functional scores.
48477206|NCT05507034|DIAGNOSTIC_TEST|Biomarkers|Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)
48635153|NCT06480110|DRUG|Docetaxel + Ebastine|Ebastine is administered once daily.
48635154|NCT06480110|DRUG|Docetaxel|docetaxel every three weeks
48635155|NCT03094273|PROCEDURE|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
48635156|NCT06549764|BEHAVIORAL|Youth Aware of Mental Health|Help-seeking and literacy increasing intervention
48635157|NCT04955093|DEVICE|Biofeedback|Technology to provide Heart Rate Variability Biofeedback
48635158|NCT01161121|DRUG|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
48635159|NCT01161121|DRUG|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
48635160|NCT00890097|DRUG|AL-8309B Ophthalmic Solution|
48104086|NCT03568799|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
48477207|NCT06467331|OTHER|Hippotherapy|Hippotherapy, also known as horse-assisted therapy, is a form of animal-assisted therapy. It consists of regularly scheduled sessions designed to enhance functionality in individuals' lives and contribute to their overall health improvement.
48635161|NCT00890097|DRUG|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
48635162|NCT00576407|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Cultured thymus tissue for implantation (CTTI) (previously described as transplantation) is done using allogeneic cultured postnatal tissue from unrelated thymus donors. Thymus tissue, the thymus donor, \& thymus donor's birth mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were implanted into the recipient's quadriceps. Dose was number of grams of cultured thymus tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of CTTI, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-CTTI, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
48635163|NCT05864716|BIOLOGICAL|Colonscopic probiotics spray|20g of multi-strain probiotics powder via colonoscopic spray. The probiotic used in this study is SynPro-15G, which has 15 probiotics, including Bacillus coagulans BC1031, Bifidobacterium bifidum BB14, Bifidobacterium breve BR18, Bifidobacterium animalis subsp. lactis BAL06, Bifidobacterium longum (B. longum) BL986, Lactobacillus acidophilus LA1063, Lactobacillus casei LC122, Lactobacillus delbrueckii subsp. lactis LDL114, Lactobacillus fermentum LF26, Lactobacillus helveticus LH43, Lactobacillus paracasei LPC12, Lactobacillus plantarum LP198, Lactobacillus reuteri LR21, Lactobacillus rhamnosus LRH10, and Streptococcus thermophilus ST37 at a concentration of 2x1010 CFU/g (Synbiotech Corp., Kaohsiung, Taiwan). SynPro-15G is made either as a vial of powder (2x1011 CFU /vial) for colonoscopic spray or as a capsule (2x1010 CFU/capsule) for oral intake.
48635164|NCT03517293|BEHAVIORAL|Aerobic Exercise training|
48635165|NCT04174820|OTHER|Functional Magnetic Resonance Imaging (fMRI)|list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
48635166|NCT01624207|DRUG|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
48635167|NCT01624207|DRUG|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
48635168|NCT01158404|DRUG|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
48635169|NCT01158404|DRUG|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
48635170|NCT04810858|OTHER|Multimodal, multi-parametric MRI|The investigators will use multimodal, multi-parametric sequences to investigate neuroinflammatory and neurodegenerative processes in vivo. Participants will be assessed three times over 2 years.
48635171|NCT04810858|OTHER|Immune and cytokine profiling|Blood samples will be collected for immune and cytokine profiling. Participants will be assessed three times over 2 years.
48635172|NCT04810858|BEHAVIORAL|Neuropsychological testing|Participants will have neuropsychological testing three times over 2 years.
48635173|NCT05721950|DRUG|Brigatinib|Brigatinib Tablets
48635174|NCT02417337|PROCEDURE|Root Canal Treatment|A standardized endodontic procedures performed.
48477208|NCT03755089|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
48635175|NCT02417337|DRUG|Paracetamol|
48477209|NCT03755089|DRUG|Lidocaine 2% Injectable Solution|30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
48635176|NCT02417337|DRUG|Ibuprofen|
48635177|NCT02417337|DRUG|Mefenamic acid|
48635178|NCT02417337|DRUG|Diclofenac|
48635179|NCT00098761|DRUG|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
48635180|NCT02731768|BEHAVIORAL|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
48635181|NCT02731768|BEHAVIORAL|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
48635182|NCT02731768|DEVICE|Fitbit Zip|
48635183|NCT02731768|DEVICE|Digital body weight scale|
48635184|NCT02197104|DRUG|citocoline|Ten subjects will receive 1,000mg once daily of citicoline. Each subject will stay on the study drug for 12 months. The outcome measures will be assessed at baseline and then again at the end of month 3, month 6, and month 12. The subjects will continue taking the same study drug at the same dose throughout the entire trial.
48635185|NCT04561609|OTHER|Transcutaneous CO2 application|"Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes.~Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only)."
48635186|NCT04561609|OTHER|Placebo treatment|Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.
48477210|NCT04927325|OTHER|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
48477211|NCT05889013|DEVICE|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
48635187|NCT06105463|OTHER|Strength training sessions and High-interval intensity training sessions|"During strength training sessions, participants will perform 4 lower limb exercises, including bilateral leg press, unilateral leg extension, unilateral hip extension, and bilateral seated calf raise on conventional weight machines. The intensity of the session will be 70-75% of 1-RM, 4 sets, 10 repetitions (1-2 RIR) and 120 seconds rest between sets.~During High-interval intensity training (HIIT) sessions, participants will perform 10 minutes of warm-up at 50% of peak power + 20 minutes of HIIT consisting of 30 seconds at 90% of peak power followed by 30 seconds of rest + 10 minutes of cool-down at 35-40% of peak power in cycloergometer."
48635188|NCT03600727|DRUG|Propofol|Propofol will be used to offer intraoperative sedation for patients in Propofol group.
48635189|NCT03600727|DRUG|Dexmedetomidine|Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
48635190|NCT05675293|DEVICE|IONTOPHORESIS|The process of increasing the penetration of drugs into the skin by application of an electric current
47946612|NCT05588778|BEHAVIORAL|¡En Forma y Fuerte! @home/en casa|The ¡En Forma y Fuerte! Program. ¡En Forma y Fuerte! is designed to be delivered in Spanish by bilingual, bicultural, qualified exercise instructors. Instructors are required to have an exercise instructor/specialist certification through a national organization such as the American College of Sports Medicine, American Council on Exercise, or Aerobics and Fitness Association of America, or to have an undergraduate degree in an exercise science related field. The 8 hour training uses both didactic and hands-on role modeling for delivering both the exercise and health education components of the program. Instructors in the online version will also participate in a 60 minute training designed for this new version of the program. We have previously developed an asynchronous, online instructor training for the customary program and will translate it to Spanish for this proposal.
47946613|NCT03204461|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
47946614|NCT03204461|OTHER|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
47946615|NCT06464471|OTHER|Self-reported online geriatric assessment (CHAMP)|The CHAMP tool is a self reported online tool that has been developed to increase patients' accessibility to geriatric assessment and improve treatment decision making. The tool includes questions about function, mobility, cognition, nutrition, social support, depression substance use disorders, and miscellaneous items. Based on usability testing in the previous phase of this study, the tool can be completed in approximately 10-15 minutes. The tool generates a summary report with recommendations for patients and clinicians.
47946616|NCT06680739|DRUG|Durvalumab|Durvalumab 1500 mg IV every 4 weeks
48635191|NCT05675293|DRUG|ORAL ANTIBIOTIC|Oral Antibiotic
48104087|NCT05853224|DEVICE|Crosslinked Hyaluronic Acid (CLHA) Hydrogel with and without Lidocaine|The injection should be performed at variable depth of the skin (dermal or subdermal), depending on the area to be treated and on the product variants, in accordance to the IFU of the IPs
48104088|NCT03495284|DIETARY_SUPPLEMENT|Potato-based side dish|Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
48104089|NCT03495284|DIETARY_SUPPLEMENT|Refined grain-based|Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
48104090|NCT01909336|DRUG|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
48635192|NCT04673695|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
48635193|NCT04673695|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
48635194|NCT01300065|DEVICE|Experimental- Soflens|A new pair of lenses will be worn each day while the subject is in the study
48635195|NCT01300065|DEVICE|Marketed - Soflens|A new pair of lenses will be worn each day while the subject is in the study.
48635196|NCT01507727|DRUG|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
48635197|NCT01507727|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
48635198|NCT01091532|DRUG|UK-396,082|"100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
48635199|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
48635200|NCT01091532|DRUG|UK-396,082|"300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
48635201|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
48635202|NCT01091532|DRUG|UK-396,082|"1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
48635203|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
48635204|NCT01091532|DRUG|UK-396,082|"UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
48635205|NCT01091532|DRUG|placebo|given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
48635206|NCT01047397|DRUG|1278863A|25mg, 50mg, 100mg
48635207|NCT01047397|DRUG|Placebo|matching placebo
48635208|NCT05013086|DRUG|1.48 GBq of 177Lu-AB-3PRGD2|accepted intravenous injection of 177Lu-AB-3PRGD2
48635209|NCT02511769|BEHAVIORAL|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
48296369|NCT06318923|OTHER|MONTREAL COGNITIVE ASSESSMENT (MoCA) test|The MoCA is a screening tool for neurocognitive impairment, designed primarily to detect milder impairment. The MoCA is a short-answer questionnaire that includes a number of tasks to be completed by the individual. The items assessed are grouped into six subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space. The tests proposed are often more complex than those found in the mini-mental state examination (MMSE).
48296370|NCT05503134|BIOLOGICAL|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
48296371|NCT06635824|DRUG|Acasunlimab|IV infusion
48296372|NCT06635824|DRUG|Pembrolizumab|IV infusion
48635210|NCT02511769|BEHAVIORAL|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
48635211|NCT03041480|DIAGNOSTIC_TEST|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
48635212|NCT03753503|BEHAVIORAL|exercise|exercised three times a week in the 8-week HIIT program
48635213|NCT03753503|BEHAVIORAL|conventional physical therapy|
48635214|NCT02062684|DRUG|Blisibimod|
48635215|NCT02062684|DRUG|Placebo|
48635216|NCT02883933|OTHER|Data collection|
48635217|NCT02088580|PROCEDURE|Triple Chronotherapy|
48635218|NCT00447369|DRUG|Pregabalin|
48635219|NCT00447369|DRUG|sodium valproate|
47946617|NCT06680739|DRUG|Tremelimumab|Tremelimumab 300 mg IV as a single dose
48104091|NCT01909336|DRUG|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
48296373|NCT06635824|DRUG|Docetaxel|IV infusion
48477212|NCT03449199|DRUG|TMX-049|A certain dose of TMX-049 to be taken orally, once daily
48635220|NCT03847090|DRUG|Reloxaliase|Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
48635221|NCT03847090|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
48635222|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
48635223|NCT00720811|DRUG|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
48635224|NCT00720811|DRUG|paracetamol|paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
48635225|NCT00720811|DEVICE|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
48635226|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
48635227|NCT04168411|PROCEDURE|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
47946618|NCT04048122|BEHAVIORAL|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
48635228|NCT00609973|DRUG|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
48635229|NCT00609973|DRUG|Placebo|Placebo bid for 6 months
48635230|NCT01654250|DRUG|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
48635231|NCT01654250|DRUG|Placebo|Placebo
48635232|NCT04644757|OTHER|Music Listening|The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
48635233|NCT03780712|OTHER|Non applicable|No intervention as it is an observational study
48635234|NCT00930176|BIOLOGICAL|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
48635235|NCT05496699|BEHAVIORAL|Mckenzie Exercises|"1. Cervical Retraction Exercise in Sitting Position The participant sits on the chair, puts the second and third fingers on his chin and pushes his head posteriorly and inferiorly.~2. Cervical Rotation Exercise in Sitting Position~3. Cervical Retraction Exercise in Supine Position~4. Cervical Rotation Exercise in Supine Position The participant turns his head to the right and left, respectively, while taking his head back in the supine position with his head out of the bed.~5. Cervical Lateral Flexion Exercise~6. Cervical Flexion Exercise in Sitting Position"
48635236|NCT05496699|BEHAVIORAL|Mulligan Exercise|"The exercises to be applied are listed below.~1- C1-C2 Self Mobilization Slip is applied for natural apophyseal cervical right rotation. The belt is put on level C1. At the same time, the participant actively pulls the belt and turns his head to the right. To facilitate the rotation of the belt in C1, pressure is applied to the belt in the same direction as C2 and rotation of the head towards the restricted side is requested. It waits like this for 3 seconds. These movements are done in the painless range."
48635237|NCT03954873|OTHER|Glucagon-like peptide 2|Human glucagon-like peptide 2
48104092|NCT01909336|DRUG|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
48104093|NCT04898322|DRUG|SY-005|2.5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
48104094|NCT04898322|DRUG|SY-005|5mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
48635238|NCT03954873|OTHER|Saline|Placebo
48104095|NCT04898322|DRUG|SY-005|10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
48104096|NCT04898322|DRUG|Placebo|Placebo
48635239|NCT03954873|OTHER|Glucose|20% (w/v) glucose infusion for regulating plasma glucose
48635240|NCT03954873|OTHER|Insulin|Actrapid (insulin) for lowering plasma glucose
48635241|NCT03607136|OTHER|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
48635242|NCT03446573|DRUG|DTG + 3TC|DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
48635243|NCT03446573|DRUG|TAF based regimen (TBR)|Participants will continue to receive their TBR.
47946619|NCT04048122|BEHAVIORAL|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper \& pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
47946620|NCT06617026|DRUG|Sucralfate|a topical rectal ointment. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
48635244|NCT03468946|OTHER|salty taste perception|"salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk )."
47946621|NCT06617026|DRUG|Azadirachtin|a topical oil. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
47946622|NCT06617026|PROCEDURE|fissurectomy and lateral sphincterectomy|fissurectomy and lateral sphincterectomy
47946623|NCT02354183|BEHAVIORAL|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
47946624|NCT00570167|PROCEDURE|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
47946625|NCT00570167|PROCEDURE|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
47946626|NCT02585583|RADIATION|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
47946627|NCT05182099|DIAGNOSTIC_TEST|Liver MRI|Gd-EOB-DTPA enhanced MRI consists of T2-weighted image (T2WI), diffusion weighted image (DWI) and precontrast T1-weighted image (T1WI), dynamic T1WI (arterial, portal and transitional phases), and hepatobiliary phase.
47946628|NCT02907580|BEHAVIORAL|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
47946629|NCT02907580|BEHAVIORAL|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
47946630|NCT04515446|DIAGNOSTIC_TEST|Rapid test for diagnosis orientation|Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
47946631|NCT04515446|DIAGNOSTIC_TEST|quantitative PCR|Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
47946632|NCT05962749|OTHER|Assessment|3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
47946633|NCT04916002|DRUG|vidutolimod|Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
47946634|NCT04916002|DRUG|cemiplimab|Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
48104097|NCT04058743|DEVICE|TKA with nickel free components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
48477213|NCT03449199|DRUG|Placebo|Matching placebo to be taken orally, once daily
48635245|NCT03468946|OTHER|bitter taste perception|"bitter taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate bitter taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
48635246|NCT03468946|OTHER|sour taste perception|sour taste perception in high caries risk, medium caries risk, low caries risk. The aim of this study was to evaluate sour taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk ).
48635247|NCT03468946|OTHER|sweet taste perception|"sweet taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate sweet taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
48635248|NCT01545466|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
48635249|NCT01382407|DRUG|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
48635250|NCT06504732|DRUG|IAH0968|Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
48635251|NCT00000483|DRUG|estrogen|
48635252|NCT00000483|DRUG|clofibrate|
48635253|NCT00000483|DRUG|dextrothyroxine sodium|
48477214|NCT02283593|BEHAVIORAL|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
48477215|NCT00001842|DRUG|Granulocyte colony-stimulating factor|
48477216|NCT00001842|DRUG|Dexamethasone|
48635254|NCT00000483|DRUG|niacin|
48635255|NCT05469061|DRUG|Tislelizumab|The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
48635256|NCT05469061|DRUG|5-FU|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m\^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
48635257|NCT05469061|DRUG|cis Platinum|A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
48635258|NCT05474209|OTHER|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes"|"Tai-chi - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes for 12 months"
48635259|NCT04539431|GENETIC|validation of new technologies|Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
48635260|NCT01250314|OTHER|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
48635261|NCT01250314|OTHER|Biological, biochemical and genetic samples|"\*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~\*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~* Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~* Homocysteine~* IGF1~  * Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
48635262|NCT01502072|DRUG|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
48635263|NCT01502072|DRUG|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
48635264|NCT02398474|DRUG|TFP block ropivacaine|
48635265|NCT02398474|DRUG|ropivacaine infiltration of the iliac crest bone|
48635266|NCT04091308|OTHER|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
48635267|NCT04091308|OTHER|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
48477217|NCT02776553|OTHER|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
48477218|NCT02776553|BEHAVIORAL|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
48477219|NCT02776553|BEHAVIORAL|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
47946635|NCT03848104|OTHER|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
47946636|NCT05742958|DRUG|Intrathecal morphine|The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.
48104098|NCT04058743|DEVICE|TKA with standard cobalt chromium components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
48104099|NCT00392418|DRUG|Multiple micronutrient supplement (iron)|
48104100|NCT03396835|DEVICE|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
48104101|NCT03824899|DIAGNOSTIC_TEST|Blood concentration check|Blood concentration check：the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion
48296374|NCT06672783|PROCEDURE|echocardiogrphy|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening) o"
48296375|NCT03851679|DIAGNOSTIC_TEST|B-Type natriuretic peptide (BNP) serum values|"evaluation BNP serum values:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
48296376|NCT03851679|DEVICE|Pulmonary echography|"Pulmonary echography:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
48477220|NCT03886649|DRUG|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
48477221|NCT03886649|DRUG|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
48477222|NCT06615830|DRUG|Standard chemotherapy|Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
48477223|NCT06615830|DRUG|Organoid-guided treatment|Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
48635268|NCT04091308|OTHER|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
48635269|NCT05897502|BEHAVIORAL|multimedia education|"The experimental group use multimedia education, 20 minute nutrition education courses each time, a total of 8 courses.~The control group use routine education."
48635270|NCT03093168|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
47946637|NCT05742958|DRUG|Adductor canal block|After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
47946638|NCT00454701|DRUG|Alefacept exposure|Observational
47946639|NCT00753766|OTHER|Multifactorial Intervention|
47946640|NCT00446420|DRUG|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
47946641|NCT01922674|PROCEDURE|Standard open tension-free inguinal hernia repair with mesh|
47946642|NCT04137432|DRUG|Oxytocin nasal spray|Intranasal administration of 24 international units oxytocin.
48296377|NCT03851679|OTHER|urine collection|6 hour and 24 hour urine collection after Cesarean Section
48635271|NCT03093168|DRUG|Fludarabine|dose: 25mg/m2/d
48635272|NCT03093168|DRUG|Cyclophosphamide|Dose: 40mg/kg
48635273|NCT05645185|DIAGNOSTIC_TEST|Diagnosis test|Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
48635274|NCT02537925|DRUG|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
48635275|NCT02537925|DRUG|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
48635276|NCT02537925|RADIATION|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\~74 Gy for primary tumor (2.0\~2.3 Gy/f/day, 5 day/ week, /6\~7 weeks), and 50\~54 Gy for lymphatic positive area (1.8 \~ 2 Gy/f/day, 5 day/week, /5.0\~5.5 weeks).
48635277|NCT00537082|DRUG|FTY720|Administered orally once daily for 6 months
48635278|NCT00537082|DRUG|Placebo|Administered orally once daily for 6 months
47946643|NCT04137432|DRUG|Placebo|The placebo nasal sprays contains identical ingredients except for the peptide itself.
48635279|NCT05874011|OTHER|understanding of prosody|The inverse correlation test consists of having the same word heard twice, and asking which of the two sounds the most like a question. The exercise will be repeated several times, for a task that will take a total of about thirty minutes
48635280|NCT05792254|DRUG|Huaier granule|Oral Huai Er granules, 20 g once, 3 times a day, continued to progress or intolerance toxicity.
48635281|NCT04364971|PROCEDURE|singleradius and multiradius total knee arthroplasty|singleradius and multiradius total knee arthroplasty
48635282|NCT02914223|DRUG|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
48635283|NCT02798952|BIOLOGICAL|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
48635284|NCT02609451|PROCEDURE|Ileostomy closure|Ileostomy closure at a different time point
48635285|NCT03425370|PROCEDURE|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
47946644|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC GOLD+|Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk
47946645|NCT05695300|DIETARY_SUPPLEMENT|BLM ORGANIC|Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
47946646|NCT05695300|DIETARY_SUPPLEMENT|Breast milk|Participants in this arm need to be fed with breast milk daily for three months, no infant formula
47946647|NCT06525571|DRUG|Cysview|Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.
48477224|NCT02409940|BIOLOGICAL|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
47946648|NCT06525571|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
47946649|NCT04224389|PROCEDURE|transoral resection|The technique of transoral surgery will be left to the choice of the surgeon according to the equipment and the experience of the team and will be gathered. The options are: transoral surgery robot-assisted, endoscopic laser transoral surgery, transoral laser surgery classical instruments. The exact description of the resected area will be collected. of the cross-sections will be made for extemporaneous analysis if necessary in lateral margins and deep until complete excision.
47946650|NCT04224389|RADIATION|IMRT|Intensity modulation radiotherapy (RCMI or IMRT) will be performed using techniques static or rotational (arctherapy, tomotherapy). Restraint is recommended with thermoformed mask
47946651|NCT06652529|DRUG|AROG4-01|AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.
47946652|NCT06652529|DRUG|AROG4-01|"AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2)."
47946653|NCT03670927|OTHER|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
47946654|NCT06150820|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
48477225|NCT06071195|DIAGNOSTIC_TEST|Prostate Cancer Patients|see arm/group description
48477226|NCT04373382|BEHAVIORAL|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
48477227|NCT04373382|BEHAVIORAL|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
48477228|NCT04126343|DRUG|Padsevonil|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
48477229|NCT04126343|DRUG|Moxifloxacin|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period"
48635286|NCT05538468|OTHER|Assessment|Thirty stroke patients were included in the study. After the demographic information was obtained from all patients who accepted to participate in the study by complying with the inclusion criteria; The kinesiophobia scores of the patients were evaluated, depression severity, postural control and pain severity.
47946655|NCT02503709|DRUG|CDK Inhibitor AT7519|Given IV
47946656|NCT02503709|OTHER|Laboratory Biomarker Analysis|Correlative studies
47946657|NCT02503709|DRUG|Onalespib|Given IV
47946658|NCT02503709|OTHER|Pharmacological Study|Correlative studies
47946659|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
47946660|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
48298854|NCT04761380|DIAGNOSTIC_TEST|balloon-based tongue pressure measurement device|The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
48477230|NCT04126343|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
48477231|NCT00585260|DRUG|mannitol|indirect mannitol challenge
48477232|NCT00949728|PROCEDURE|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
48477233|NCT04355299|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
48477234|NCT04355299|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
48477235|NCT04355299|BEHAVIORAL|aerobic exercise|Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
48477236|NCT04355299|BEHAVIORAL|usual care|received usual care
48477237|NCT00311220|DRUG|tuberculin for skin test|
48477238|NCT06083415|OTHER|Environmental health measures|MRI will be used to confirm the presence of breast buds, to measure the size of the ovaries and uterus, as well as the fraction of fat mass (abdominal, subcutaneous, liver and bone marrow). The bood and urine tests will allow to measure different biological and metabolic parameters. The presence of endocrine disruptors will be determined in the hair. The bone age x ray will be estimate the maturity of the child's skeletal system.
48477239|NCT00000555|DRUG|estrogen replacement therapy|
47946661|NCT00876876|DRUG|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
48477240|NCT00000555|DRUG|estrogens, conjugated|
48477241|NCT00000555|DRUG|progesterone|
48477242|NCT00000555|DRUG|hormone replacement therapy|
48477243|NCT00000555|DRUG|supplementation, food|
48635287|NCT01348490|DRUG|Ruxolitinib|Ruxolitinib (INCB018424), 5 mg bid
48635288|NCT05303974|OTHER|Ultrasound guided joint injection|The participants will perform two ultrasound guided joint injections on a mannequin. The performance of both procedures are videorecorded. All videos will be rated by two blinded raters using the modified IUSE assessment tool.
48635289|NCT05813483|OTHER|Skinceuticals skin care product(CE)|fraxel laser therapy combined with Skinceuticals skin care product(CE) and routine moisturizing and sun protection
48635290|NCT05813483|OTHER|fraxel laser therapy|fraxel laser therapy combined with routine moisturizing and sun protection
47946662|NCT03405896|OTHER|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
47946663|NCT06063772|DRUG|Clevidipine|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.
48477244|NCT00000555|DRUG|ascorbic acid|
48477245|NCT00000555|DRUG|vitamin e|
48477246|NCT00606138|DRUG|ranibizumab|One 0.5 mg intravitreal injection
48477247|NCT00606138|PROCEDURE|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
48477248|NCT05924334|OTHER|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
48477249|NCT05924334|OTHER|placebo|placebo
48477250|NCT01682642|DRUG|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
48477251|NCT00006473|DRUG|oxaliplatin|Given IV
48477252|NCT00898820|GENETIC|gene expression analysis|
48477253|NCT00898820|GENETIC|polymorphism analysis|
48477254|NCT00898820|GENETIC|protein expression analysis|
48635291|NCT04336800|DEVICE|LiverMultiscan|The LiverMultiscan is a quick 15 min, contrast free scan that non-invasively provides three metrics of liver health namely liver fat, iron and fibro-inflammation
48635292|NCT03931512|DEVICE|transcranial direct current stimularion|aplication of direct current stimulation on the scalp wiht sponge electrodes
48635293|NCT03473158|DEVICE|Transvaginal ultrasound|using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
48635294|NCT03473158|PROCEDURE|Mechanical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
48635295|NCT03473158|PROCEDURE|Chemical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
48635296|NCT01679665|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
48635297|NCT01679665|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
48635298|NCT00443287|DRUG|ataciguat (HMR1766)|oral administration
47946664|NCT06063772|DRUG|Lactated Ringers, Intravenous|The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
47946665|NCT06039410|DEVICE|ISO-101|ISO-101 is an experimental wearable class 1 medical device which when used is able to raise the blood pressure upon standing via controlled isometric muscular contractions
47946666|NCT00902668|DRUG|lovastatin|
47946667|NCT00902668|OTHER|questionnaire administration|
47946668|NCT00902668|PROCEDURE|adjuvant therapy|
47946669|NCT00902668|RADIATION|accelerated partial breast irradiation|
47946670|NCT00902668|RADIATION|external beam radiation therapy|
48635299|NCT00443287|DRUG|placebo|oral administration
48635300|NCT00443287|DRUG|cilostazol|oral administration
48635301|NCT03683901|DEVICE|TENS|Electrical Stimulation
48635302|NCT03683901|DEVICE|t-NMES|Electrical Stimulation
48635303|NCT03683901|OTHER|No stimulation|No stimulation
48635304|NCT04548050|OTHER|Nurses training|"* Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation."
48635305|NCT00409227|DRUG|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
47946671|NCT02643030|BEHAVIORAL|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
48298855|NCT04848363|PROCEDURE|Quadratus lumborum block|QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
48635306|NCT00409227|DRUG|placebo|placebo once a day for 3 months or stone free
47946672|NCT02643030|BEHAVIORAL|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
47946673|NCT00147758|DRUG|Colesevelam hydrochloride|
47946674|NCT04895436|DRUG|Venetoclax|Oral tablet
47946675|NCT04895436|DRUG|Obinutuzumab|Intravenous (IV) infusion
47946676|NCT05975359|DEVICE|Interi Manifold Drain System|The Interi manifold surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the interi drain will be monitored daily and the Interi drain will remain in the surgical site until criteria for drain removal are met. Removal of the Interi drain will be performed in clinic by surgical staff.
47946677|NCT05975359|DEVICE|Jackson Pratt Drain System|The Jackson Pratt surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the Jackson Pratt drain will be monitored daily and the drain will remain in the surgical site until criteria for drain removal are met. Removal of the Jackson Pratt drain will be performed in clinic by surgical staff.
48635307|NCT04006756|BEHAVIORAL|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
48635308|NCT04006756|BEHAVIORAL|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
48635309|NCT01742052|DRUG|MT-1303-Low|
48635310|NCT01742052|DRUG|MT-1303-Middle|
47946678|NCT02603328|DRUG|Atorvastatin|40-80 mg OD
47946679|NCT02603328|OTHER|Placebo|inactive
48298856|NCT06254469|DRUG|[F-18]Flornaptitril|All participants will receive a single dose of F-18 FNT during an imaging visit.
48298857|NCT03502759|BEHAVIORAL|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
47946680|NCT05781373|PROCEDURE|Peep individualization|Intraoperative Peep individualization in order to achieve the lowest driving pressure
47946681|NCT02187705|DRUG|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
48635311|NCT01742052|DRUG|MT-1303-High|
48635312|NCT01742052|DRUG|Placebo|
48635313|NCT02868710|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
48635314|NCT02327247|DRUG|Felodipine|Extended Release Tablets, 10mg
48635315|NCT02327247|DRUG|PLENDIL®|Extended Release Tablets, 10mg
48635316|NCT02217553|DRUG|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
48635317|NCT04578054|OTHER|Flying transport|Patient care who requires flying transport
48635318|NCT01714388|DRUG|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
48635319|NCT00403065|DRUG|dexamethasone|
48635320|NCT00403065|PROCEDURE|quality-of-life assessment|
48635321|NCT00403065|RADIATION|radiation therapy|
48477255|NCT04045808|OTHER|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
48635322|NCT02809781|BIOLOGICAL|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
48635323|NCT02809781|DRUG|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
48635324|NCT06328621|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48635325|NCT06328621|PROCEDURE|Computed Tomography|Undergo low-dose CT
48635326|NCT06328621|OTHER|Electronic Health Record Review|Review of medical records
48635327|NCT06328621|OTHER|Survey Administration|Complete survey
48477256|NCT03355209|DRUG|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
48635328|NCT05449262|OTHER|functional resistance training GROUP A|"Session of 45-60 min. Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
48635329|NCT05449262|OTHER|functional resistance training GROUP B|"Session of 45-60 min Warm up prior to training Warm up 6-7 min of mild cardiovascular exercise followed by 3-4 min stretching~Cool down post training A cool-down of 1 min of mild cardiovascular exercise followed by 4 min of stretching"
48635330|NCT03588000|OTHER|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
48635331|NCT01783873|OTHER|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
48635332|NCT06469580|OTHER|NPLUS (neonatologist performed lung ultrasound)|"NPLUS is conducted with an ultrasound scanner using a high-frequency (12-15 MHz) linear transducer probe (scanning depth approximately 4-5 cm). The neonate is placed in a supine position. The anterior, lateral and posterior chest areas are scanned using the presets lung or small parts. Landmarks are the anterior and posterior axillary line (longitudinal) on each hemithorax. A sequential scan from right to left, anterior to posterior is performed. (6 lung areas). In the study NPLUS is performed to quantify the lung ultrasound score at time points T0, T1 and T2. Sequences of 3-5 seconds are saved and assessed according to the lung ultrasound score adapted by Rodriguez-Fanjul et al. (0- to 3 point score for each area, resulting in a total score ranging from 0 to 18). To ensure inter-observer reliability the anonymous video sequences are then rated by two independent neonatologists."
48635333|NCT00908388|DEVICE|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
48635334|NCT05528666|OTHER|High Efficacy Therapy (HET)|HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod.
48635335|NCT05528666|OTHER|Non High Efficacy Therapy (Non-HET)|Non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.
48635336|NCT01864096|DRUG|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
48635337|NCT01864096|DRUG|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
48635338|NCT01160744|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
48635339|NCT01160744|DRUG|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
48635340|NCT01160744|DRUG|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
48298858|NCT03611309|OTHER|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
48298859|NCT03611309|OTHER|Surgeon team alone management|The surgeon and surgical team will manage
48477257|NCT03355209|DRUG|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
48477258|NCT00830167|DRUG|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
48635341|NCT01160744|DRUG|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
48635342|NCT01160744|DRUG|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
48635343|NCT01160744|DRUG|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
48635344|NCT05047887|PROCEDURE|Modified socket shield technique with autogenous dentin graft material (in one side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then Tooth particles will be demineralized using 2% HNO3 (El-Gomhouria CO. Egypt) for 20 minutes to expose the dentin organic matrix.
48635345|NCT05047887|PROCEDURE|Modified socket shield technique with alloplast graft material (in contralateral side)|The crown of the hopeless tooth will be decoronated, the root will then be sectioned, the lingual root fragment will be carefully retrieved, the remaining buccal root fragment will be thinned and concaved, The coronal part of this shield will be beveled to make a lingual slope then alloplast graft will be used
48635346|NCT00163852|DRUG|Normal saline IV, salt tablets|
48635347|NCT03049800|DEVICE|Magnetic Resonance Imaging|Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
48635348|NCT04865458|DRUG|HEC89736|HEC89736 tablets QD every 28 days for each cycle
48635349|NCT00160875|DRUG|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
48635350|NCT00160875|DRUG|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
47946682|NCT05426096|OTHER|Best Practice Advisory|The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines through the electronic health record system.
47946683|NCT05790083|OTHER|Body Lotion and Intensive Care|Body Lotion, applied twice daily on whole body, for 3 months. Intensive Care, applied as needed on affected body areas.
47946684|NCT03624244|DRUG|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
48104102|NCT05593042|BIOLOGICAL|CoronaVac®|The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
48104103|NCT05593042|BIOLOGICAL|Omicron Vaccine|"An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant."
48635351|NCT04534725|DRUG|Interferon alfa|intranasal spray
48635352|NCT04534725|DRUG|Selinexor|oral tablet
48635353|NCT04534725|DRUG|Lenzilumab|intravenous infusion
48635354|NCT02137681|DRUG|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
48635355|NCT00723944|DEVICE|Osseotite Certain Prevail|Root form titanium dental implant
48635356|NCT00723944|DEVICE|Osseotite Certain|Dental implant without the lateralized design
48635357|NCT03084679|OTHER|Aerobic exercise in treadmill|30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
48635358|NCT03084679|OTHER|Local strengthening exercises|15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
48635359|NCT03084679|OTHER|Stretching exercises|5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
48635360|NCT03615898|OTHER|Medication errors analysis|TEN YEAR ANALYSIS OF MEDICATION ERRORS IN THE SPANISH INCIDENTS REPORTING SYSTEM IN ANAESTHESIA
48635361|NCT00686218|DRUG|imatinib mesylate|Given orally
48104104|NCT05593042|BIOLOGICAL|Trivalent Vaccine|"An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant)."
48298860|NCT06497647|DRUG|Sulbutiamine|"sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C"
48635362|NCT00686218|DRUG|panobinostat|Given orally
48104105|NCT02580448|DRUG|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
48104106|NCT05019729|DRUG|VRC-MALMAB0114-00-AB|VRC-MALMAB0114-00-AB (L9LS) is a monoclonal antibody that binds an epitope of the Plasmodium falciparum circumsporozoite protein.
48635363|NCT00686218|GENETIC|polymerase chain reaction|Testing
48635364|NCT00686218|GENETIC|protein expression analysis|Testing
48635365|NCT00686218|GENETIC|western blotting|Testing
48635366|NCT00686218|OTHER|flow cytometry|Testing
48635367|NCT00686218|OTHER|laboratory biomarker analysis|Testing
48635368|NCT00686218|OTHER|pharmacological study|Testing
48635369|NCT01239745|DRUG|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
48635370|NCT01004393|DRUG|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
48635371|NCT00949078|DRUG|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
48635372|NCT03522246|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
48635373|NCT03522246|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
48635374|NCT03522246|DRUG|Placebo Oral Tablet|Placebo tablets will be administered twice daily
48635375|NCT03522246|DRUG|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
48635376|NCT04297267|DRUG|Gemcitabine|Gemcitabine 1250mg/m2,d1,d8,every 3 weeks
48635377|NCT04297267|DRUG|Cisplatin|Cisplatin 75mg/m2,d1，every 3 weeks
48635378|NCT06465602|DRUG|Nicotinamide|The subjects will receive 1.5 grams per day of Nicotinamide, orally, for 30 days.
48635379|NCT06465602|DRUG|Placebo|The subjects will receive 1.5 grams per day of placebo, orally, for 30 days.
48635380|NCT00045955|DRUG|Fexofenadine, Comparator = Montelukast|
48635381|NCT06493565|DEVICE|Routine endoscopic anastomosis inspection|"The routine care pathway for early detection of anastomotic leakage includes:~* C-reactive protein guided imaging~* Rectoscopy of the anastomosis three to six days after surgery~* Rectoscopy of the anastomosis two to three weeks after surgery"
48635382|NCT00965094|DRUG|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
48635383|NCT00965094|DRUG|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
48635384|NCT00965094|DRUG|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
48635385|NCT00965094|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
48635386|NCT00965094|DRUG|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg \[prednisone, or equivalent, was used throughout the study period.
48635387|NCT02307500|DRUG|Regorafenib|oral therapy
47946685|NCT01906385|DRUG|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
47946686|NCT00891007|BIOLOGICAL|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
47946687|NCT00891007|BIOLOGICAL|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
47946688|NCT00891007|BIOLOGICAL|Rouvax|Standard measles vaccine, approved in South Africa
48635388|NCT03033212|OTHER|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
48635389|NCT03033212|OTHER|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
48635390|NCT03463239|BIOLOGICAL|Autologous tissue engineered corpora|penile tissue construct
48635391|NCT02609906|DEVICE|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
48635392|NCT02609906|DEVICE|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
48635393|NCT03914014|OTHER|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
48635394|NCT03914014|OTHER|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
47946689|NCT05596942|DIETARY_SUPPLEMENT|Albumin Channa Striata Extract|This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
47946690|NCT01327456|BEHAVIORAL|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
47946691|NCT03388385|DRUG|Sodium Chloride 0.9% Intravenous Solution|Physiologic saline infusion will be infused in day 1.
48635395|NCT05852574|DRUG|CP-101|"CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.~CP101 contains live microbial communities, derived from rigorously screened human donor stool that is tested, stabilized, characterized, and formulated into capsules designed specifically for delivery into the small bowel for release, to avoid potential degradation by gastric acid."
48635396|NCT05852574|DRUG|CP-101 + Placebo|The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
48635397|NCT05759455|DIETARY_SUPPLEMENT|vitamin d|Assessment of Vitamin D level in Children with Autism in assiut university children hospital
48635398|NCT04202211|BIOLOGICAL|FMT oral|lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks
48635399|NCT04202211|BIOLOGICAL|FMT enema|lyophilized FMT given via enema (1) twice weekly for total of 8 weeks
48635400|NCT04202211|OTHER|Placebo oral|placebo given orally (10 capsules) twice weekly for total of 8 weeks
48635401|NCT04202211|OTHER|Placebo enema|placebo given via enema (1) twice weekly for total of 8 weeks
48635402|NCT04197323|DRUG|Alprostadil liposomes for injection|40ug,once a day,continuous administration for 2 weeks
48635403|NCT01052428|DRUG|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
48635404|NCT01052428|DRUG|Placebo|Placebo 100 mg once a day for 2 years
48635405|NCT03112187|DRUG|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
48635406|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in virtual reality|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells. The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in VR:~We will use 360° 3D videos for exposure using an HTC Vive Pro headset. Six different videos will be used for exposure: 1) Taking a seat on a bench in a public park, 2) Being introduced as a new employee, 3) Performing a presentation at a meeting, 4) Entering and shopping in a grocery store, 5) Visiting a café and 6) Using public transportation. The therapist can choose the length of the exposure as well as the difficulty of the exposure. While the participant is in the VR-scenario HR and EDA are measured. These data are collected to continuously estimate the anxiety levels."
48635407|NCT05302518|BEHAVIORAL|Cognitive behavioral therapy with exposure in vivo|"The treatment rationale is based on a model of the maintenance of social phobia by Clark and Wells.The themes of therapy are: a) The general ideas of CBT, b) The maintaining processes of social phobia, c) negative automatic thoughts, d) shifting focus of attention form self-focus to external focus, e) safety behaviors, f) post-processing, g) self-processing, h) schemas and rules for living.~Exposure in vivo:~Exposure is taking place at Centre for Telepsychiatry and the surrounding areas. The therapist is planning the exposure with the participant and is accompanying the participant during the exposure."
48635408|NCT05128344|DRUG|AMZ002 injectable solution, 0.5mg/mL|Injectable solution
48635409|NCT05128344|DRUG|Vigabatrin, oral|Oral administration
48635410|NCT02872688|OTHER|GanedenBC30|
48635411|NCT01941628|DRUG|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
48635412|NCT01941628|DRUG|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
48635413|NCT04739774|DRUG|CHF6001 DPI|Single dose of CHF6001
48635414|NCT04739774|DRUG|Itraconazole|Repeated doses of oral Itraconazole
48635415|NCT01446510|OTHER|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
48635416|NCT03934879|BEHAVIORAL|FitClub|Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
48635417|NCT03934879|OTHER|Regular School Activities|Students will participate in regular school activities.
48635418|NCT00422461|DRUG|placebo|placebo, oral, tablets, once daily, for 28 days
48635419|NCT00422461|DRUG|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
48635420|NCT00422461|DRUG|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
48635421|NCT00422461|DRUG|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
48635422|NCT02605694|DRUG|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
48635423|NCT02605694|DRUG|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
47946692|NCT03388385|DRUG|Ferinject|Ferric carboxymaltose will be infused in day 2.
47946693|NCT03252938|DRUG|IMP321|LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
47946694|NCT03252938|DRUG|Avelumab|Avelumab i.v.
47946695|NCT06153446|DIAGNOSTIC_TEST|Synovasure® Comprehensive Infection Panel|The Synovasure Comprehensive PJI Test Panel (PJI Panel) is a laboratory-developed test (LDT) panel (CD Laboratories, CLIA Registration No.: 21D0216863) intended to aid the diagnosis of PJI.
47946696|NCT00138177|DRUG|oxaliplatin|Given IV
47946697|NCT00138177|DRUG|leucovorin calcium|Given IV
47946698|NCT00138177|DRUG|vorinostat|Given orally
47946699|NCT00138177|DRUG|fluorouracil|Given IV
48296378|NCT06671223|DRUG|Infiltration|The intervention consists of the administration of infiltrations in the affected plantar fascia of participants with a diagnosis of plantar fasciopathy. A drug such as a corticosteroid, PRP or hyaluronic acid will be used, which will be injected under ultrasound guidance to ensure precision at the site of the injury. This intervention aims to reduce inflammation and pain, thus improving the functionality of the foot. Up to three infiltrations will be performed, depending on the patient\&amp;amp;#39;s response to treatment and medical evaluation. The infiltrations will be compared with a control group that will receive conservative treatment without infiltrations, to evaluate the relative effectiveness of this pharmacological intervention in the management of plantar fasciopathy.
48296379|NCT06671223|OTHER|Conservative treatment|The control group is used to compare the effectiveness of infiltrations with a non-invasive approach in the treatment of plantar fasciopathy. This group will not receive any infiltration and will focus on conservative interventions.
48296380|NCT06519877|DIETARY_SUPPLEMENT|Soluble corn fiber|Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.
48296381|NCT00711451|BEHAVIORAL|Manual removal|Manual removal of placenta during cesarean delivery
48296382|NCT00711451|PROCEDURE|Expressed removal|Surgeon will perform an expressed delivery of the placenta
48296383|NCT05215327|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
48296384|NCT05215327|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
48296385|NCT04239560|DRUG|Boron-based Gel (Fibore)|During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.
48296386|NCT04239560|DRUG|Placebos|During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
48296387|NCT01224353|DRUG|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
48296388|NCT01224353|OTHER|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
48296389|NCT06536985|BEHAVIORAL|treatment group|Researchers will collaborate with participants to develop personalized intervention plans, which include physical exercise, oral function training, basic dietary guidance, and detailed oral health knowledge directly related to oral health behaviors. To facilitate better communication and management, a WeChat group will be created to encourage participants to share their daily exercise achievements. In the first week, face-to-face oral function training sessions will be organized for the intervention group at the nursing home activity center. Concurrently, once a week, the intervention group will gather at the nursing home activity center to practice together using illustrated videos. On Wednesdays, educational articles and videos about oral health are sent via text message. On Fridays, a group communication activity is organized to enhance their social connections. Additionally, we will guide elderly participants to master essential internet skills, enabling them to use smartphones to
48296390|NCT06536985|BEHAVIORAL|Contral group|Participants in the control group will receive general lifestyle advice via text message once or twice a week.They will not participate in the intervention\&#39;s fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group\&#39;s complaints or questions will always be answered with basic health information and suggestions. Researchers won\&#39;t ask for individual advice or comments from other professionals.
48296391|NCT00719173|DRUG|aprepitant|Given orally
48296392|NCT00719173|DRUG|cyclophosphamide|Given IV
48635424|NCT02605694|DRUG|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~* Cyclophosphamide (750 mg/m2)~* Doxorubicin hydrochloride (50 mg/m2)~* Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~* Rituximab (375 mg/m2)"
48635425|NCT02605694|DRUG|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
48635426|NCT03586232|DIETARY_SUPPLEMENT|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
47946700|NCT00917111|DRUG|Nasal CO2|Four times a day for 14 days
47946701|NCT00917111|DRUG|Inactive Placebo Gas|Placebo
47946702|NCT00660751|DRUG|Duloxetine|SNRIs
47946703|NCT00143117|DRUG|UK-390,957|
47946704|NCT03935412|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
47946705|NCT04515979|DRUG|Vactosertib 300 mg BID and pembrolizumab 200 mg IV|Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
47946706|NCT02549729|BEHAVIORAL|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
47946707|NCT03768973|PROCEDURE|Elective cardiac surgery|Both groups will undergo elective cardiac surgery as an intervention.
47946708|NCT04308603|DIAGNOSTIC_TEST|NON-IMMUNE HYDROPS FETALIS diagnosis|Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information. Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure. The results of both procedures will be compared.
48635427|NCT03586232|DIETARY_SUPPLEMENT|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
48635428|NCT03586232|OTHER|Placebo|A pharmacologically inert preparation
48635429|NCT05948982|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion, once every 4 weeks for a total of 3 infusions. All subjects received experimental drugs and conventional treatment during the study period.
48635430|NCT05172310|DRUG|68Ga-FAPI-46|"* \[68Ga\] Ga-FAPI-46 Solution for Injection is manufactured at the Karolinska University Hospital Radiopharmacy facilities, for imaging studies with Positron Emission Tomography (PET).~* It is a radiolabelled Fibroblast Activation Protein Inhibitor (FAPI) used for PET of a number of different cancer entities.~* Depending on the labelling yield 50 - 370 megabecquerel (MBq) of \[68Ga\] Ga-FAPI-46 Solution for Injection will be administered intravenously 60 minutes prior to whole-body PET image acquisition."
48635431|NCT05172310|DEVICE|PET/CT|"* Combined PET and computed tomography (CT) imaging with 68Ga-FAPI-46 will be performed using the same protocol on a Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany) and General Electrics (GE) Discovery 710, Milwaukee, Wisconsin, USA at the Department of Nuclear Medicine, Karolinska Huddinge within 2 weeks before surgery.~* PET/CT imaging will be performed in dynamic mode at one bed position centered over the primary tumor for 45 minutes.~* At 60 minutes post injection, a whole-body PET will be acquired."
48635432|NCT04858529|DRUG|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)|investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
48635433|NCT04858529|DRUG|investigator-selected taxane/trastuzumab/pertuzumab (THP)|investigator-selected taxane/trastuzumab/pertuzumab (THP)
48635434|NCT01235416|DRUG|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
48635435|NCT01558375|DRUG|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
48635436|NCT01558375|DRUG|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
48635437|NCT01512173|DRUG|propranolol gel|Topical administration twice daily
48635438|NCT01512173|DRUG|Placebo|Topical administration twice daily
48635439|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
48635440|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
48635441|NCT01439334|BEHAVIORAL|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
48635442|NCT06355921|PROCEDURE|radiofrequency ablation|"Anesthesia: Local (Novocaine, Lidocaine, Bupivacaine) Access: transcutaneous Navigation under CT control Cannulas are used: 22G 100 and 150 mm, the size of the electrode corresponds to the size of the cannula The starting power is 20W followed by steps of 10W every 2 minutes until the maximum power is reached, the maximum power is 60W.~In order to prevent infectious complications, two-day antibiotic prophylaxis of Cefazolin (1g) is carried out 3 times a day In order to prevent skin burns with superficially located DFS, the skin is cooled during the procedure."
47946709|NCT01689168|BEHAVIORAL|Counseling|Tobacco cessation counseling
47946710|NCT01689168|PROCEDURE|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
47946711|NCT01645904|BEHAVIORAL|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
47946712|NCT01645904|BEHAVIORAL|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
47946713|NCT01645904|BEHAVIORAL|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
47946714|NCT01645904|BEHAVIORAL|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
47946715|NCT05131360|BEHAVIORAL|Introduction Only|This is the placebo condition in which participants engage in one day of introductory mindfulness activities.
47946716|NCT05131360|BEHAVIORAL|Purpose Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of purpose-based mindfulness techniques.
47946717|NCT05131360|BEHAVIORAL|Connection Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection-based mindfulness techniques.
48296393|NCT00719173|OTHER|placebo|Given orally
48635443|NCT03544164|OTHER|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
48635444|NCT05156814|DRUG|Femoston® 1, Femoston® 2|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
48635445|NCT05156814|DRUG|Duphaston|Duphaston®, 10 mg
48635446|NCT05156814|DRUG|Klimadynon|Cimicifuga racemosa rhizomatum extract
48635447|NCT05156814|DRUG|Divigel|Divigel, 0.1%
48635448|NCT03531502|PROCEDURE|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
48635449|NCT03531502|OTHER|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
48296394|NCT04982614|BIOLOGICAL|Gardasil ® 9|"GARDASIL 9 is a vaccine indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer, and Genital warts (condyloma acuminata) caused by Human Papillomavirus (HPV).~0.5-mL suspension for intramuscular injection as a single-dose vial and prefilled syringe at the following regimen/schedule: 9 through 14 years - 2-dose at 0, 6 to 12 months OR 3-dose at 0, 2, 6 months 15 through 45 years - 3-dose at 0, 2, 6 months"
48296395|NCT00576498|OTHER|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
48296396|NCT00576498|OTHER|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
48296397|NCT06250153|BEHAVIORAL|m-SBIRT (mobile-Screening, Brief Intervention, and Referral to Treatment)|M-SBIRT is a mobile phone-based program designed to enhance delivery of Screening, Brief Intervention, and Referral to Treatment (SBIRT), an evidence-based approach for mental health and substance use screening and treatment. The program utilizes mobile phone text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to substance use disorder treatment services.
48296398|NCT06513429|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells by intravenous infusion.
48296399|NCT02687113|DEVICE|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
48296400|NCT03777956|DRUG|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
48296401|NCT03777956|DRUG|Placebo|Identical placebo are given as capsules and taken orally twice a day.
48296402|NCT04522427|DEVICE|Use Multifocal and Extended Depth-of-Focus Intraocular Lenses(IOLs)|IOLs include AT LISA tri 839MP, AcrySof IQ PanOptix IOL, TECNIS Symfony EDOF
48296403|NCT04522427|DEVICE|Use Monofocal intraocular lenses(IOLs)|Monofocal IOLs include 409(Zeiss), AcrySof, TECNIS IOLS
48296404|NCT01447173|DRUG|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
48296405|NCT06093880|DEVICE|monofocal intraocular lens|monofocal aspheric hydrophilic-hydrophobic intraocular lens
48296406|NCT05910879|BEHAVIORAL|Self-Affirmation Implementation Intentions (SAII) Intervention|"In an brief exercise, participants are asked to provide a personal story and positive experience during the challenging and sometimes stressful COVID19 pandemic, ...a time when you felt successful and proud of yourself. ...You can also tell us about a time that you did something to help someone in need. The self-affirmation is designed to offset effects of threats to self. In the next section participants are asked to formulate an if-then plan with one preferred self-affirmation-inducing cognition: If I feel sad, threatened, or discriminated against, then I will... a)...think about things I value about myself, b)...remember things that I have succeeded in, c) ...think about what I stand for, or d)...think about things that are important to me. After selecting response, participants read the full If-Then plan out loud and are provided with a paper copy of their exercise to take home."
48477259|NCT00830167|DRUG|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
48477260|NCT03118219|OTHER|Positive adjustment coping intervention|see arm description
48477261|NCT03118219|OTHER|Brainteaser|see arm description
48477262|NCT03553875|DRUG|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
48477263|NCT03553875|DRUG|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
48477264|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive, behavioral, and peer influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g.desire to get drunk), behavioral (e.g.alcohol consumption), and peer influences (e.g.peer pressure and support).
48477265|NCT06617702|BEHAVIORAL|A text message alcohol intervention focused on cognitive and behavioral influences|Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g. desire to get drunk) and behavioral (e.g. alcohol consumption) influences.
48477266|NCT05524311|DRUG|Baricitinib|Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
48477267|NCT05524311|BIOLOGICAL|pharmacokinetics study|additionnal blood sampling at week 4, 8, 12, and 24
48477268|NCT05524311|BIOLOGICAL|dosage of cytokines|additionnal blood sampling at weeks 0, 4 and 24
48635450|NCT03531502|PROCEDURE|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
48477269|NCT05524311|BIOLOGICAL|transcriptomic analysis|additionnal blood sampling at weeks 0, 4 and 24
47946718|NCT05131360|BEHAVIORAL|Connection and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of connection and purpose-based mindfulness techniques.
48635451|NCT03931785|DRUG|MD-7246|Oral tablet
47946719|NCT05131360|BEHAVIORAL|Awareness Only|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness-based mindfulness techniques.
47946720|NCT05131360|BEHAVIORAL|Awareness and Purpose|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and purpose-based mindfulness techniques.
47946721|NCT05131360|BEHAVIORAL|Awareness, Purpose, and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness, connection, and purpose-based mindfulness techniques
48477270|NCT05524311|BEHAVIORAL|Parent version of the Child Health Questionnaire (CHQ)|Evaluate by parents at each visits
48477271|NCT05524311|BEHAVIORAL|Childhood Health Assessment Questionnaire|Evaluate by parents at each visits
48477272|NCT05524311|BIOLOGICAL|Pregnancy test|Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
48477273|NCT04632706|DRUG|Ivermectin|Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
48477274|NCT04632706|DRUG|Placebo|Matching Placebo to the Active IMP.
48477275|NCT04234464|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol single dose
48477276|NCT04234464|COMBINATION_PRODUCT|Placebo metered-dose inhaler|Placebo inhalation aerosol single dose
48477277|NCT04311151|PROCEDURE|own seizures visualization|At the hospital discharge, patients
48477278|NCT05602779|DEVICE|tVns Program|Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
48477279|NCT05602779|OTHER|Phone App Program|Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.
48477280|NCT05602779|COMBINATION_PRODUCT|tVNS and Phone App Program|Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
48477281|NCT05602779|OTHER|Enhanced Treatment as Usual|Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.
48477282|NCT01729026|OTHER|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
48477283|NCT00277407|PROCEDURE|NAET with acupressure and/or chiropractic procedures|
48635452|NCT03931785|DRUG|Placebo|Matching oral tablet
48635453|NCT02245724|BIOLOGICAL|Stem Cell|Autologous bone marrow mononuclear cell transplantation
48635454|NCT00151463|DRUG|sildenafil citrate|
48635455|NCT04233580|DEVICE|Amnio Excel + weekly|Amnio Excel + weekly
47946722|NCT05131360|BEHAVIORAL|Awareness and Connection|Participants engage in one day of introductory mindfulness activities followed up by 5 days of awareness and connection-based mindfulness techniques.
47946723|NCT03965767|DRUG|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
47946724|NCT01924507|DEVICE|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
47946725|NCT01200524|DRUG|AZD2423|20 mg tablet
47946726|NCT01200524|DRUG|AZD2423|50 mg tablet
47946727|NCT01200524|DRUG|Placebo|Placebo
48635456|NCT04233580|DEVICE|Amnio Excel + max every 2 weeks|Amnio Excel + max every 2 weeks
48635457|NCT03254147|DRUG|warfarin|warfarin
47946728|NCT05284877|OTHER|No intervention|The study is an observational study without intervention.
48477284|NCT02868723|OTHER|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
48477285|NCT06083636|OTHER|Single extra blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
48477286|NCT06083636|OTHER|Single blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
48477287|NCT00060294|BIOLOGICAL|rituximab|
48477288|NCT00060294|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48477289|NCT02216799|DRUG|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
48477290|NCT02216799|DRUG|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
48477291|NCT02775539|DRUG|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
48477292|NCT02775539|DRUG|Placebo|
48477293|NCT04102345|OTHER|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
48635458|NCT03254147|DRUG|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
48635459|NCT03254147|DRUG|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
48635460|NCT03254147|DRUG|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
48635461|NCT03254147|DRUG|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
48635462|NCT06016660|OTHER|Physiotherapy|Resistance exercise, Neuromuscular electrical stimulation, and Transcutaneous electrical stimulation
48296407|NCT05910879|BEHAVIORAL|Promotores de Salud (Health Education)|The Promotores de Salud intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
48298861|NCT06497647|DRUG|Imipramine|"imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C"
48635463|NCT06243926|OTHER|Sperm selection for ICSI|Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
48635464|NCT06291961|GENETIC|CS-101 injection|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
48635465|NCT04560309|DRUG|L-alanyl-L-glutamine dipeptide|Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
48635466|NCT04560309|DRUG|Placebo|Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
48635467|NCT03502772|OTHER|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
48635468|NCT03502772|OTHER|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
48635469|NCT04057638|PROCEDURE|Combined Craniomaxillofacial and Upper Extremity Allotransplantation|Combined Craniomaxillofacial and Upper Extremity Allotransplantation
48635470|NCT05753969|DEVICE|MT1 Device|Pre-and post-evaluation in MT1 device following stimulant treatment or placebo control
48635471|NCT02370693|DRUG|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
48635472|NCT02370693|DRUG|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
48635473|NCT02370693|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
48635474|NCT01496859|DEVICE|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
48635475|NCT04807868|PROCEDURE|Standard of care liver biopsy|Patients undergoing a standard of care liver biopsy for any reason who are willing to participate will be consented for collecting additional biopsy tissue for research purposes. 1-2 additional biopsy tissue cores will be collected for research. Liver tissue will be biobanked for future use.
48635476|NCT04807868|OTHER|Fibroscan|A FibroScan will be performed to evaluate longitudinal changes in liver fat and fibrosis.
48635477|NCT04807868|OTHER|Biospecimen Collection|Blood and urine will be collected.
48635478|NCT04394559|BEHAVIORAL|Discharge Order Sets|Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
48635479|NCT04394559|BEHAVIORAL|Pharmacist-Led Discharge Counseling and Communication|Two visits by a trained inpatient pharmacist, including an intake visit to determine previous barriers to safe medication use, and a discharge counseling session with patients and caregivers regarding safe and effective opioid use after discharge; pharmacist communication with providers regarding the post-discharge pain management plan.
48635480|NCT04394559|BEHAVIORAL|Post-discharge Pain Management Follow-up|An outpatient pharmacist pain management follow-up visit (with additional contact as needed) embedded within routine post-operative care for managing pain and opioid use.
48635481|NCT04394559|BEHAVIORAL|Patient Engagement Pain Management App|A mobile patient-reported outcomes application for assessing pain, function, and possible development of opioid use disorder.
48635482|NCT03974490|OTHER|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
47946729|NCT02913612|DRUG|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
48635483|NCT03309605|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
48635484|NCT03309605|DRUG|Placebo|Placebo
48635485|NCT00121953|DRUG|Rosiglitazone|
48635486|NCT05956457|BEHAVIORAL|Digital Health Coaching Program|Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
48635487|NCT05956457|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
48635488|NCT01793909|OTHER|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
48635489|NCT02914678|OTHER|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
48635490|NCT06016790|GENETIC|cfDNA sequencing|Multi-omics sequencing of cfDNA in peripheral venous blood.
48635491|NCT00104715|DRUG|antiandrogen therapy|
48635492|NCT00104715|DRUG|docetaxel|
48635493|NCT00104715|DRUG|goserelin acetate|
47946730|NCT02913612|DRUG|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
48635494|NCT00104715|PROCEDURE|orchiectomy|
48296408|NCT03977402|OTHER|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
48296409|NCT03649776|OTHER|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
48296410|NCT00147108|DEVICE|ExAblate 2000|
48296411|NCT06330493|DEVICE|PCB|Paclitaxel coated PTA balloon catheter
48296412|NCT06330493|DEVICE|PTA|Non-coated FDA cleared standard percutaneous transluminal angioplasty balloon catheter
48635495|NCT05257161|DEVICE|Emboshield NAV6™|Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
47946731|NCT00195572|DRUG|Isovorin|
47946732|NCT00195572|DRUG|TS-1|
48296413|NCT03199092|BEHAVIORAL|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
48477294|NCT04102345|DRUG|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
48477295|NCT05632692|OTHER|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
48477296|NCT05499234|DRUG|Dolantin|If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
48477297|NCT05499234|DRUG|Paracetamol|If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
48477298|NCT00025740|DRUG|clonazepam and paroxetine|
48477299|NCT06590376|OTHER|midwifery care based on swanson care theory|All stages in the Midwifery Care and Counselling Practitioner Guide for Couples Experiencing Pregnancy Loss, which was developed by the researcher and included care, education and midwife counselling consisting of eight interviews, four of which were face-to-face and four by telephone, were applied.
48477300|NCT02839993|DEVICE|tDCS|
48635496|NCT05257161|DEVICE|Mo.Ma™|Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
48635497|NCT04432298|DRUG|Pamrevlumab|Sterile liquid for injection
47946733|NCT04375969|OTHER|whole body cryostimulation treatment|The WBC is apporved by National Ministry of Health. It uses cryochamber with low temperature -110 oC. The patient, minimally dressed (e.g., bathing suit, socks, clogs, headband, and surgical mask), remains 30sec at -60°C (vestibule) for body adaptation and, then, passes to the cryochamber, at -110°C and stay there 3 minutes.
47946734|NCT04375969|OTHER|Connection WBC treatment and HIIT training|WBC combination with Exercise HIIT according to Litlle protocol from 2011. This exercise protocol will be applied together with cryo-sessions
48477301|NCT02839993|BEHAVIORAL|training|
48477302|NCT00316940|DRUG|bortezomib|
48477303|NCT00316940|RADIATION|samarium Sm 153 lexidronam pentasodium|
48477304|NCT05642169|BEHAVIORAL|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
48477305|NCT05642169|BEHAVIORAL|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
48477306|NCT05642169|BEHAVIORAL|CON|This group will not suffer any changes in their lifestyle
48477307|NCT04007471|OTHER|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
48477308|NCT02396082|BEHAVIORAL|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
48477309|NCT02396082|OTHER|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
48477310|NCT03242616|DRUG|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 \& 8)~* Pemetrexed (500 mg/m2, day 1)"
48477311|NCT03242616|DRUG|Vinorelbine|Vinorelbine (25 mg/m2, day 1 \& 8)
48477312|NCT04010734|PROCEDURE|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
48477313|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 1 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
48477314|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 2 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
48477315|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 3 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
48477316|NCT02228109|DEVICE|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
48477317|NCT02228109|DEVICE|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
48635498|NCT04432298|DRUG|Placebo|Sterile liquid for injection
48635499|NCT02557165|PROCEDURE|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
48635500|NCT02898441|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
48635501|NCT02617212|PROCEDURE|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
48635502|NCT02617212|DEVICE|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
48635503|NCT02617212|DEVICE|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
48296414|NCT03199092|BEHAVIORAL|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
48296415|NCT04795713|DRUG|MT-6402|Experimental Treatment
48635504|NCT03896932|OTHER|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
48635505|NCT00033475|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48635506|NCT03479684|OTHER|Gene-directed dosage of warfarin|the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
48635507|NCT03479684|OTHER|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
48635508|NCT04172064|DIAGNOSTIC_TEST|Myocardial perfusion scintigraphy|
48635509|NCT01407978|BIOLOGICAL|Vaccination with Fluval P monovalent influenza vaccine|"* Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
48635510|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB|"* Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
48635511|NCT01407978|BIOLOGICAL|Vaccination with Fluval AB Novo|"* Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~* Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
48635512|NCT03666702|OTHER|Upper limb physiotherapy programme|Web-based physio programme
48635513|NCT03666702|OTHER|Usual care|Usual physiotherapy care
48635514|NCT02297035|BEHAVIORAL|Behavioural testing|
48635515|NCT02297035|OTHER|Brain imaging|MRI, PET
48635516|NCT02297035|GENETIC|Genetic screening|APOE, Progranulin
48635517|NCT03352180|PROCEDURE|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
48635518|NCT03352180|PROCEDURE|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
48635519|NCT01043029|DRUG|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
48635520|NCT01043029|DRUG|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
48635521|NCT00758043|DRUG|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
48296416|NCT00740506|BEHAVIORAL|Frequency of Intercourse|
48296417|NCT04296630|OTHER|Social media message #1|Social media message promoting colorectal cancer screening
48296418|NCT04296630|OTHER|Social media message #2|A different social media message promoting colorectal cancer screening
48635522|NCT00758043|DRUG|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
48635523|NCT00758043|BIOLOGICAL|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
48635524|NCT00565760|DRUG|Q8003|Capsules
48635525|NCT00565760|DRUG|Placebo|Capsules
48635526|NCT03923842|DRUG|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
48635527|NCT03923842|DRUG|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
48635528|NCT05024786|OTHER|continuous quality improvements|We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
48635529|NCT00100477|DRUG|Topotecan|
48104107|NCT05019729|OTHER|Plasmodium falciparum (P. falciparum) sporozoite challenge|Participants were exposed to bites on the forearm from mosquitoes infected with Plasmodium falciparum
48635530|NCT00100477|DRUG|Mitozantrone|
48635531|NCT00100477|DRUG|Etoposide|
48296419|NCT04296630|OTHER|Social media message #3|A different social media message promoting colorectal cancer screening
48635532|NCT02202720|DRUG|Sevoflurane|Short term sedation with sevoflurane in ICU
48635533|NCT05180773|DRUG|Bromocriptine|Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
48635534|NCT05180773|DRUG|Placebo|Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
48635535|NCT05180773|DRUG|Guideline Directed Medical Therapy for Heart Failure (GDMT)|GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
48635536|NCT05180773|DRUG|Rivaroxaban|Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
48635537|NCT05180773|DRUG|Second Placebo|Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
48635538|NCT02681432|DRUG|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
48635539|NCT02681432|PROCEDURE|No HIPEC|Cytoreductive surgery without HIPEC
48635540|NCT05832814|BEHAVIORAL|Integrated training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.
48635541|NCT05832814|BEHAVIORAL|Rhythm-guided exercise training|For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
48635542|NCT02104011|DRUG|Propranolol|
48635543|NCT01053065|DRUG|Atorvastatin - Cholestyramine - Sitosterol|
48635544|NCT05847335|BEHAVIORAL|Survey work|Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
48635545|NCT01749566|DRUG|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
48296420|NCT04296630|OTHER|Social Media Message #4|A different social media message promoting colorectal cancer screening.
48635546|NCT00135161|PROCEDURE|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
48635547|NCT02466581|DRUG|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
48635548|NCT02466581|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
48635549|NCT02466581|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
48635550|NCT02466581|BIOLOGICAL|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
48635551|NCT00268398|DRUG|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
48635552|NCT00268398|DRUG|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
48635553|NCT02366130|DRUG|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
48104108|NCT04648436|OTHER|Early neurosurgical hematoma evacuation|Early neurosurgical hematoma evacuation (preferably within 2 hours)
48104109|NCT04648436|OTHER|Conservative treatment (best medical management)|Conservative treatment (best medical management) on the ICU or ward
48296421|NCT04296630|OTHER|Tailored Social Media Message|Tailored social media messages promoting colorectal cancer screening.
48104110|NCT02709616|BIOLOGICAL|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
48635554|NCT02366130|DRUG|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
48635555|NCT02366130|DRUG|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
48635556|NCT00693303|BEHAVIORAL|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
47946735|NCT04375969|OTHER|Control Group|This group willnot to change their daily habits . The measurements will be taken at baseline and at the end of the study
48296422|NCT03189225|OTHER|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
48296423|NCT05610891|DRUG|CLR 131|CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
48296424|NCT04509700|DRUG|Parsaclisib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
48296425|NCT04509700|DRUG|parsaclisib + itacitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
48477318|NCT02228109|DEVICE|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
48477319|NCT00468793|PROCEDURE|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
48477320|NCT00476593|DRUG|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
48477321|NCT00476593|DRUG|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
48477322|NCT00004424|DRUG|fentanyl|
48477323|NCT00004424|DRUG|Midazolam|
48477324|NCT00004424|DRUG|propofol|
48477325|NCT02593396|DRUG|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
48477326|NCT02593396|DRUG|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
48477327|NCT01886937|DRUG|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
48477328|NCT01886937|DRUG|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
48477329|NCT02900053|DEVICE|tDCS|tDCS for transcranial Direct-Current Stimulation
48477330|NCT02900053|DEVICE|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
48477331|NCT00791986|DEVICE|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
48477332|NCT06616428|OTHER|Bike group fitness class|Comprised a rhythmic indoor cycling session, characterized by fluctuations in intensity corresponding to changes in position, music rhythm, cadence, and revolutions per minute. Participants were instructed to strictly follow verbal cues from the instructor, adjusting cycling cadence and resistance as directed, for 45 minutes.
48477333|NCT06616428|OTHER|Pump Power|Entails a comprehensive total-body weight-training program with a focus on improving strength, muscular endurance, and overall fitness of large muscle groups. The class, choreographed to music, involved participants performing a combination of barbell, body-weight exercises, and free-weight plates, during 45 minutes. Participants selected weights based on the target muscle group for the specific song or track and their individual fitness goals.
48477334|NCT06616428|OTHER|Global Training|Incorporated both aerobic and resistance components, combining athletic movements like running, lunging, and jumping with strength exercises such as barbells, body-weight exercises, and free-weight plates for the large muscle groups, during 45 minutes.
48477335|NCT06533280|DRUG|Part A, C and D: VH3739937 500 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions
48477336|NCT06533280|DRUG|Part A: VH3739937 100 mg|Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
48477337|NCT06533280|DRUG|Part A and C: Placebo|Oral administration of Placebo in moderate fat/moderate calorie conditions
48477338|NCT06533280|DRUG|Part B: Treatment A|VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
48477339|NCT06533280|DRUG|Part B: Treatment B|VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
47946736|NCT04375969|OTHER|HIIT training group|This group will do the training program without cold exposure
47946737|NCT03565913|DRUG|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
47946738|NCT03565913|OTHER|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
48296426|NCT04509700|DRUG|parsaclisib + ruxolitinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
47946739|NCT03810391|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
47946740|NCT03810391|OTHER|physiological saline|intravenous infusion of the same volume of physiological saline
47946741|NCT05579925|BIOLOGICAL|CM310|CM310 600 mg + 300 mg, subcutaneous injection
48296427|NCT04509700|DRUG|parsaclisib + ibrutinib|Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
48296428|NCT00006346|PROCEDURE|psychosocial assessment and care|
48477340|NCT06533280|DRUG|Part B: Treatment C|VH3739937, 500 mg single tablet administered under fasted conditions.
48477341|NCT06533280|DRUG|Part B: Treatment D|VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
48635557|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
48635558|NCT01964560|DRUG|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
48635559|NCT04885010|DIETARY_SUPPLEMENT|probiotics|participants will be given probiotics twice a day for 15 days
48635560|NCT04885010|DIETARY_SUPPLEMENT|placebo|participants will be given a placebo twice a day for 15 days
48635561|NCT00049309|DIETARY_SUPPLEMENT|dietary intervention|
48635562|NCT00049309|DIETARY_SUPPLEMENT|flaxseed|
47946742|NCT04510376|DEVICE|Test Article|Omeza Collagen Matrix
47946743|NCT04510376|OTHER|Positive Control|1.0 mg/mL Histamine Base
47946744|NCT04510376|OTHER|Negative Control|Aqueous Negative Control
47946745|NCT05278208|DRUG|LUTATHERA® (Lutetium Lu 177 dotatate)|Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
47946746|NCT06562751|OTHER|Questionnaire|Online questionnaire designed by the investigatory team.
47946747|NCT06562751|OTHER|Focus group|Online focus group
47946748|NCT06562751|OTHER|Interview|Online semi-structured interview
47946749|NCT06562751|OTHER|Workshop|Online and face to face co-production workshops
47946750|NCT06680440|DRUG|ASC30|Tablet, QD
47946751|NCT06680440|OTHER|Placebo|Tablets, QD
47946752|NCT01670318|DEVICE|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
48296429|NCT00006346|PROCEDURE|quality-of-life assessment|
48296430|NCT06447181|DEVICE|3D visualization technology ; ICG fluorescence technology .|"Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step.~ICG fluorescence technology is a fluorescent laparoscopic technology that can detect extrahepatic biliary duct misalignment, improving surgical precision and safety."
48296431|NCT03722680|DRUG|Riluzole|Riluzole during chemotherapy (oxaliplatin)
48296432|NCT03722680|DRUG|Placebo Oral Tablet|placebo
48296433|NCT02988804|DEVICE|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
48477342|NCT06533280|DRUG|Part B: Treatment E|VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
48477343|NCT06533280|DRUG|Part D: Probe cocktail|Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
48477344|NCT05116059|DRUG|Amphotericin B colloidal dispersion（ABCD）|The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice
48477345|NCT00375791|DRUG|perifosine|100 - 150 mg daily
48477346|NCT00375791|DRUG|dexamethasone|20 mg twice weekly
48477347|NCT03250455|DIAGNOSTIC_TEST|CTA CTP|CT Angiography myocardial CT Perfusion
48477348|NCT03250455|DIAGNOSTIC_TEST|CTA|CT Angiography
48477349|NCT05247073|PROCEDURE|patients of controlled group with routine closure of episiotomy|"Perineal trauma is traditionally repaired in three stages: a continuous locking stitch is inserted to close the vaginal trauma, commencing at the apex of the wound and finishing at the level of the fourchette with a loop knot. The perineal muscles are then re-approximated with three or four interrupted sutures and finally, the perineal skin is closed by inserting continuous subcutaneous or interrupted transcutaneous stitches.~The skin is then closed with inverted interrupted stitches placed in the subcutaneous tissue a few millimeters under the perineal skin edges (not transcutaneously)."
48477350|NCT05247073|PROCEDURE|The Mostafa Maged four-stitch technique fore closure of the episiotomy|"Identification of the apex of the episiotomy, then a simple suture is taken (0.5 cm) behind the apex of the episiotomy. First, the needle is inserted at the vaginal mucosa of the right edge of the episiotomy then extract the needle.~The second stitch is inserted on the deep muscle layer of the same side (Right side) of the episiotomy cutting edge then extracting the needle.~Then, insert the needle again on the left side of the episiotomy incision in the deep muscle layer on the left side of the episiotomy incision directing the tip of the needle upwards parallel to the second stitch taken.~The fourth step is inserting the needle in the vaginal mucosa of the left side parallel to the first stitch. Continue suturing the episiotomy incision continuously in the same way till reaching the remnant of the hymen.~Then suture the superficial perineal muscle in a continuous manner and the skin in a subcuticular manner as well."
48635563|NCT03209583|DEVICE|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
48635564|NCT03457597|DRUG|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
48635565|NCT03457597|DRUG|Metoprolol tartrate|Metoprolol tartrate 100 mg
48635566|NCT03457597|DRUG|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
48635567|NCT03457597|DRUG|Tolbutamide|Tolbutamide 500 mg
48635568|NCT03457597|DRUG|Omeprazole|Omeprazole 20 mg
48635569|NCT03457597|DRUG|Relacorilant|Relacorilant 350mg
48477351|NCT04526093|OTHER|Medical Cannabis|Verified medical cannabis products available within the current real-world study conform to Health Canada testing requirements
48477352|NCT02004184|DRUG|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
48477353|NCT02004184|DRUG|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
48477354|NCT06614309|OTHER|Acute Placebo Visit|The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.
48477355|NCT06614309|OTHER|Acute Progressive Carbon Dioxide|The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.
48477356|NCT06614309|OTHER|Acute Intermittent Hypoxia|The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
48477357|NCT06614309|OTHER|Training: Progressive Carbon Dioxide Ramping|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.
48477358|NCT06614309|OTHER|Training: Intermittent Hypoxic Exposure|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.
48477359|NCT06614309|OTHER|Training: Placebo Control|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.
48477360|NCT02761213|DRUG|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
48477361|NCT02761213|DRUG|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
48477362|NCT04532177|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
48477363|NCT05516888|PROCEDURE|radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
48477364|NCT05516888|PROCEDURE|radiofrequency of the peripheral trigeminal branches|radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
48477365|NCT02844010|OTHER|weighing|
48477366|NCT00986024|BEHAVIORAL|aerobic exercise|carried out 3 times per week for 12 weeks
48635570|NCT03008330|BIOLOGICAL|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
48477367|NCT00986024|BEHAVIORAL|strength training|carried out 3 times per week for 12 weeks
48477368|NCT00919178|BIOLOGICAL|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
48477369|NCT00919178|BIOLOGICAL|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
48477370|NCT02387567|DRUG|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
48477371|NCT02387567|DRUG|Sham Lidocaine|Sham injection, without lidocaine.
48477372|NCT02387567|OTHER|Standard treatment|Standard treatment only, without lidocaine or sham injection.
48477373|NCT00392782|BIOLOGICAL|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
48477374|NCT00392782|DRUG|fludarabine phosphate|Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).
48477375|NCT00392782|DRUG|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
48635571|NCT01192477|OTHER|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
48635572|NCT03566550|DIAGNOSTIC_TEST|MRI scans|Repeated MRI scans imaging digestion of standard meals
48635573|NCT03983655|DEVICE|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
48635574|NCT04242654|PROCEDURE|Handheld fetal doppler ultrasound|Handheld fetal doppler ultrasound will be used to assess heart rate in high-risk neonates.
48635575|NCT00060385|DRUG|CHOP regimen|
48635576|NCT00060385|DRUG|EPOCH regimen|
48635577|NCT00060385|DRUG|cyclophosphamide|
48635578|NCT00060385|DRUG|doxorubicin hydrochloride|
48635579|NCT00060385|DRUG|etoposide|
48635580|NCT00060385|DRUG|prednisone|
48635581|NCT00060385|DRUG|vincristine sulfate|
48635582|NCT00060385|RADIATION|radiation therapy|
48635583|NCT06362200|DEVICE|40 Hz tACS intervention|The central electrode is placed in the CP6 and the other four electrodes are placed around the CP6. 40 Hz tACS group participants will receive alternating current stimulation (40Hz, 2.0mA, 20min/time, three times a day, 40 times in total) for 1 week. Subjects in the placebo comparator group will receive sham tACS for 1 week, which mimics the tACS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs.
48635584|NCT02950974|DRUG|Sterofundin|Fluid loading
48635585|NCT02950974|DRUG|NSS|Fluid loading
48635586|NCT04641039|PROCEDURE|Anterior lumbar disc annulus removal versus replacement|Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales
48635587|NCT00441740|DRUG|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
48635588|NCT00441740|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
48477376|NCT00392782|PROCEDURE|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
48477377|NCT00392782|RADIATION|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
48477378|NCT01358084|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
48477379|NCT01358084|DRUG|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
48477380|NCT01358084|OTHER|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
48477381|NCT00136760|DRUG|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
48477382|NCT00136760|DRUG|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
48635589|NCT00441740|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
48635590|NCT00441740|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
48635591|NCT05592730|GENETIC|AMHR2 polymorphism in blood|1 tube of blood taken at the first application
48635592|NCT05592730|GENETIC|AMHR2 polymorphism in granulosa cell|Extraction of granulosa cell from the follicle fluid obtained during OPU
48635593|NCT03683199|PROCEDURE|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
48635594|NCT00997191|PROCEDURE|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
48635595|NCT00997191|DRUG|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
48635596|NCT00997191|DRUG|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT\>275um
48635597|NCT03380481|OTHER|observational only-no intervention|Observational only and no predesigned interventions in this study.
48296434|NCT02988804|DEVICE|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
48296435|NCT00832715|PROCEDURE|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
48296436|NCT00478660|DRUG|adalimumab (Humira)|
48296437|NCT00081289|RADIATION|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
48296438|NCT00081289|DRUG|Capecitabine 1650 mg/m^2/day|825 mg/m\^2 q12 hours (1650 mg/m\^2/day) orally 5 days per week during radiotherapy.
48477383|NCT00136760|DRUG|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
48635598|NCT05281640|BEHAVIORAL|Affect Dysregulation intervention|See relevant study arm for description
48477384|NCT00136760|DRUG|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
48635599|NCT05281640|BEHAVIORAL|Negative Self Concept intervention|See relevant study arm for description
48635600|NCT05281640|BEHAVIORAL|Disturbed Relationships intervention|See relevant study arm for description
48477385|NCT01048463|DRUG|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
48477386|NCT01048463|DRUG|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
48477387|NCT01048463|DRUG|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
48635601|NCT01791400|DRUG|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
48635602|NCT01791400|DRUG|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
48635603|NCT00098293|DRUG|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
48635604|NCT00098293|DRUG|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
48635605|NCT00098293|DRUG|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
47946753|NCT06312722|DEVICE|Optilume® BPH Catheter System|The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
48477388|NCT01048463|DRUG|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
48477389|NCT01048463|DRUG|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
48635606|NCT06500221|BEHAVIORAL|incentive spirometry|The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
48635607|NCT04972175|DRUG|50-Hour Intervention - Rapid Insulin lispro|Subcutaneous-delivery of insulin lispro using pump therapy.
48477390|NCT05954819|OTHER|Planned patient education|Patients in the experimental group will be given about 30 minutes of patient education. After the training, a Patient Education Booklet containing Myocardial Infarction and Diabetes Education will be presented to the patients. Control group patients will not be given any training other than the hospital routine.
47946754|NCT02469207|OTHER|Removal of tissue post-mortem|
47946755|NCT00560274|DRUG|Pegasys|As prescribed
48477391|NCT05315245|OTHER|AGI|no intervention, only observation
47946756|NCT00560274|DRUG|Ribavirin|As prescribed
47946757|NCT00560274|DRUG|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
48296439|NCT00081289|DRUG|Capecitabine 1200 mg/m^2/day|600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.
48296440|NCT00081289|DRUG|Irinotecan|50mg/m\^2 IV over 1 hour on days 1, 8, 22, and 29
48296441|NCT00081289|DRUG|Oxaliplatin|50mg/m\^2 IV over 2 hours on days 1, 8, 15, 22, and 29
48296442|NCT00081289|PROCEDURE|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
48296443|NCT00081289|DRUG|Folinic Acid|400 mg/m\^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
48296444|NCT00081289|DRUG|Fluorouracil|"5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles."
48296445|NCT00081289|DRUG|Oxaliplatin|85 mg/m\^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
48296446|NCT06673433|DIAGNOSTIC_TEST|obesity|Patients diagnosed with obesity (BMI ≥ 28kg/m2)
47946758|NCT06565208|DRUG|SAT-3247|SAT-3247 is an oral tablet that is a potent, muscle penetrant, small molecule inhibitor of AAK1; inhibition of AAK1 rescues perturbed asymmetric division of satellite stem cells, resulting in increased muscle regeneration in animal models of DMD. In vitro and in vivo animal pharmacology studies have demonstrated the efficacy of SAT-3247 in improving muscle strength and the necessary target coverage to maximize functional muscle improvement.
48296447|NCT06673433|DIAGNOSTIC_TEST|health|the health control group include paticipants with nomal BMI
48296448|NCT06403774|DRUG|Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)|A laxatives (Two bowel X-M Solution 250 ml.) will be applied for bowel preparation before hemorrhoidectomy. The drug was given to the patient at 3 o'clock (p.m.)before the surgery by mixing it with 1500ml of water.
48296449|NCT06403774|DRUG|Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )|An enema (Two bowel E.S. Enema ) will be applied for bowel preparation before hemorrhoidectomy.The drug was administered to the patient at 00 o'clock (a.m.) and 06 o'clock (a.m.) before the surgery.
48296450|NCT04834986|DRUG|Tislelizumab combined with Lenvatinib|"Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year."
48296451|NCT03425110|OTHER|Modified Ketogenic Diet|
48296452|NCT03721081|DRUG|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
48296453|NCT03721081|OTHER|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
48296454|NCT05797350|DEVICE|Glaucoma Drainage Device|Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
48296455|NCT06260397|PROCEDURE|serratus anterior plane block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the plane between the latissimus dorsi and serratus muscles
48296456|NCT06260397|PROCEDURE|costotransverse block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the costotransverse plane of fourth rib
48296457|NCT06260397|PROCEDURE|patient controlled analgesia|PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr. with self-administration bolus of 0.5ml with 15 min lock-out time.
48296458|NCT04359446|PROCEDURE|NC ( Non- Compliant) Balloon dilatation|NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
48477392|NCT02063308|DIETARY_SUPPLEMENT|Oxaloacetate (OAA)|
48477393|NCT05085782|DRUG|Propranolol Hydrochloride|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
47946759|NCT06565208|DRUG|matched placebo|matched placebo
47946760|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with applesauce
47946761|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of bosutinib capsule contents mixed with yogurt
48296459|NCT04359446|PROCEDURE|Laser Excimer + NC Balloon|Laser Excimer + NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
48296460|NCT05782218|DIETARY_SUPPLEMENT|Almonds|Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
48296461|NCT05782218|DIETARY_SUPPLEMENT|Coconut|Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
48296462|NCT04223167|DIETARY_SUPPLEMENT|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
48296463|NCT04223167|DIETARY_SUPPLEMENT|Water|473 ml Water
48296464|NCT03078517|DEVICE|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
48296465|NCT03078517|DEVICE|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
48296466|NCT06313905|DIETARY_SUPPLEMENT|EVADRY|"The EVADRY oral spray and the placebo are produced by Wellnet laboratory.~• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg)."
48635608|NCT04972175|DRUG|50-Hour Intervention - BC LisPram|Subcutaneous-delivery of BC LisPram using pump therapy.
47946762|NCT04916769|DRUG|Bosutinib capsule|500 mg dose of intact bosutinib capsules
47946763|NCT00902733|OTHER|medical chart review|
47946764|NCT00902733|OTHER|questionnaire administration|
48296467|NCT06313905|OTHER|Placebo|"The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.~Both products are administered at a rate of 5 intra-oral sprays per day."
48296468|NCT00734929|DRUG|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
48296469|NCT00734929|DRUG|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
48296470|NCT02749370|DRUG|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
48296471|NCT01415622|DEVICE|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
48477394|NCT05085782|DRUG|Placebo|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
48477395|NCT05085782|BEHAVIORAL|Reactivation procedure|Description/visualization of painful movements/activities
48635609|NCT05663593|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
48635610|NCT05663593|DRUG|Placebo, tablet|Matching placebo
48635611|NCT00069329|DRUG|anakinra|daily injection of subcutaneous injection
48296472|NCT01415622|PROCEDURE|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
48296473|NCT03435029|BEHAVIORAL|Cognitive Remediation Program (REHACOP)|The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
48296474|NCT03435029|OTHER|Occupational Therapy|The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
48296475|NCT02909296|PROCEDURE|Endoscopic drainage|
48296476|NCT04384640|OTHER|Change of posture after Intra Tympanic injection|Seating position after Intra Tympanic injection
48296477|NCT06082947|DEVICE|CliniMACS®|CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
48296478|NCT01374581|DRUG|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to \< 15 kg 1 tablet per dose 15 to \< 25 kg 2 tablets per dose 25 to \< 35 kg 3 tablets per dose"
48296479|NCT01374581|DRUG|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to \< 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to \< 18 kg)1 tablet(25mg/67,5mg)for 3 days"
48296480|NCT01374581|DRUG|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
48635612|NCT01733888|DEVICE|Office Bleaching|Teeth will be cleaned with pumice first, followed by placing cheek retractors and covering of the lip surface with petroleum gel. Thereafter, teeth will be dried and gingival barrier will be applied to both arches - slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds. This is followed by homogeneous mixing of the powder and liquid in a powder pot the application of a thick layer of the resulting gel to all teeth undergoing treatment (35 % Hydrogen Peroxide, Pola Office, SDI, Australia). The gel will be left in place for 8 minutes and subsequently removed using a surgical aspirator tip.
48635613|NCT01733888|DEVICE|Resin Infiltration|Fluorosed teeth will be isolated using a rubber dam and the resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. In short, tooth surface will be dried using cotton rolls and air syringe. This is followed by an etching (Icon Etch) and drying step (Icon-Dry) to open the lesion surface. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds and subsequent cleaning of the surface with pumice and rubber polishing cup as well as rinsing with water for 30 sec.
48635614|NCT01733888|DEVICE|Resin Infiltration twice|"The intervention will be done similar to the Resin infiltration arm, which the exception that the icon infiltration step will be done twice."
48635615|NCT01733888|DEVICE|Bleaching + Resin Infiltration|"In this arm, the fluorosed teeth of the patients will first be bleached using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia) as explained in the intervention arm Office bleaching; followed by wash over period of 20 days. After these 20 days, patients will be recalled and the fluorosed teeth will treated according to the description in the Resin infiltrant intervention arm using the resin infiltrant (Icon, DMG, Hamburg, Germany) as per manufactures' instructions."
48635616|NCT01570192|DRUG|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
48296481|NCT05847972|PROCEDURE|MWM (Mobilization with movement)|This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.
48296482|NCT05847972|DEVICE|Plantar orthoses|"Procedure: MWM All participants will undergo MWM. This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.~Procedure: Plantar orthoses The moulds will be taken immediately after the manipulation. The PO will be made of resin (0.8mm +1.2mm), 2mm hard EVA heel stabiliser, 3mm semi-hard EVA cover. The PO should be worn for 3 months to obtain the results of the study."
48296483|NCT03556722|DEVICE|Repetitive Transcranial Magnetic Stimulation.|High frequency rTMS on left dorsolateral prefrontal cortex.
48296484|NCT03556722|DEVICE|Sham rTMS|Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
48296485|NCT06279585|OTHER|Physical therapy|Health education sessions and combined therapeutic exercise sessions, based on muscular strength training and cardiorespiratory endurance.
48296486|NCT04494711|BEHAVIORAL|Physical Functional Literacy for Adults|A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
48635617|NCT01570192|DRUG|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
48296487|NCT03005782|DRUG|REGN3767|
48296488|NCT03005782|DRUG|cemiplimab|
47946765|NCT00902733|PROCEDURE|fatigue assessment and management|
47946766|NCT00902733|PROCEDURE|psychosocial assessment and care|
47946767|NCT00902733|PROCEDURE|quality-of-life assessment|
47946768|NCT06448078|DEVICE|External chest wall fixator|External chest wall fixator is applied in the form of external bonding to the rib fracture area
47946769|NCT03368703|DEVICE|Anodal transcranial direct-current-stimulation|2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
47946770|NCT03368703|DEVICE|Sham transcranial direct-current-stimulation|"Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions."
47946771|NCT02872168|OTHER|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
47946772|NCT05883423|OTHER|FPCMP-Old Age|"1. Exercise program：The main purpose of the exercise program is to improve cardiorespiratory endurance, upper and lower limb muscle strength and endurance, body flexibility, sense of balance and coordination. The exercise program is carried out with a suspension training system, which can improve core muscle strength, improve physical fitness, activate more core and stabilizing muscle groups, increase joint stability, and strengthen ligaments.~2. Health integrated nursing management courses (nutrition, psychosocial, drug and other health management activities involved)"
47946773|NCT04056351|DIAGNOSTIC_TEST|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
47946774|NCT04056351|OTHER|Questionnaires on patient activity and comorbidities|"* Shoulder activity scale (Marx)~* Parker Mobility Scale~* Barthel index~* Charlson Comorbidity Score"
47946775|NCT04056351|OTHER|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
47946776|NCT04056351|OTHER|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
48296489|NCT00212238|BEHAVIORAL|internet behavioral weight loss program|
47946777|NCT02664610|BEHAVIORAL|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
47946778|NCT01279031|DEVICE|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
48296490|NCT05646641|OTHER|Strength exercise|The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
48296491|NCT04385901|BEHAVIORAL|Therapy Intervention|Patients receive 2-4 visits (based on patient presentation and need) of physical therapy, up to 4 visits of occupational therapy, up to 4 visits of speech therapy based on need. Treatment focuses on physical strengthening, pulmonary strengthening/breathing exercises, and cognitive rehabilitation.
48296492|NCT00426751|DRUG|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
48296493|NCT00426751|DRUG|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
48296494|NCT00416351|DRUG|clofarabine|
47946779|NCT01279031|DEVICE|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
47946780|NCT05019794|DRUG|Infigratinib|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
47946781|NCT05721222|DRUG|PRO1160|Intravenous infusion of PRO1160
47946782|NCT06681766|DRUG|Nomlabofusp|Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
47946783|NCT06681766|DRUG|Placebo|The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
47946784|NCT04904679|DEVICE|Pars plana Vitrectomy with internal limiting membrane peeling|The vitrectomy technique using pars plana 23-gauge will be performed with removal of the ILM (when present adhered to the macula) and placement of an amniotic membrane plug or a internal limiting membrane flap in the macular hole, with a fluid-air exchange and a buffering gas infusion (C3F8 12, 5%). The amniotic membrane plug will be made with a dermatological punch with a diameter of 1.0 to 2mm depending on the size of the macular hole measured by the OCT, and will be positioned inside de macular hole with the chorionic side facing the RPE ( retinal pigmented epithelium) with a 23 gauge forceps. The chorionic side of the membrane is the sticky one. The internal limiting membrane flap will be created at the same time of peeling and will bem positioned in as inverted flap over and inside the macular hole with a 23 gauge ILM forceps. These technics will be helped with de use of a extra lighting sclerotomy.
47946785|NCT06580080|BEHAVIORAL|Are You Ready? (AYR)|"AYR is a group-based entertainment education (EE) intervention designed for sexually active youth who are at risk for or involved in the juvenile justice and/or child welfare systems. AYR is delivered in one, 2.5-hour (150-minute) session with a group of between 2 to 20 youth. The session includes screening a 40-minute video, Happy Birthday, Leonard and group-based discussions led by one to two facilitators. Discussions are guided by a participant workbook with journal prompts and handouts.~The session includes two modules; each module involves screening approximately 20 minutes of Happy Birthday, Leonard followed by a 40-minute group discussion. Module 1 includes topics related to contraception, condom use (with a condom demonstration), healthy communication, and stress management. Module 2 includes topics related to condom negotiation, communication styles, and intergenerational cycles."
48296495|NCT04493619|DRUG|PLX2853|PLX2853 tablets
48296496|NCT04493619|DRUG|Carboplatin|Carboplatin IV injection, 5 mg•min/mL
48296497|NCT04871321|DRUG|nab-paclitaxel plus gemcitabine-cisplatin|- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days
47946786|NCT06580080|BEHAVIORAL|Social Media Awareness Shorts (SMAS)|SMAS is a virtually delivered, individual-based health program focused on social media use awareness. Participants are directed to a learning management platform that contains a pre-recorded, facilitated program. The program involves watching several short films and independently completing several activities related to social media use. The program does not include information related to the primary outcomes for this study.
47946787|NCT05768802|DEVICE|Myoelectric Implantable Recording Array (MIRA)|The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.
47946788|NCT00102544|DEVICE|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
48296498|NCT05174572|PROCEDURE|IMR|Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
48296499|NCT06102460|DIETARY_SUPPLEMENT|Casein protein|40 grams of casein protein powder mixed with 8-10 fl. oz. of water.
48296500|NCT06102460|DIETARY_SUPPLEMENT|a-lactalbumin protein|40 grams of a-lactalbumin protein powder mixed with 8-10 fl. oz. of water.
48296501|NCT06102460|DIETARY_SUPPLEMENT|Carbohydrate|40 grams of a carbohydrate powder mixed with 8-10 fl. oz. of water.
48296502|NCT06102460|DIETARY_SUPPLEMENT|Placebo|Zero calorie, placebo powder mixed with 8-10 fl. oz. of water.
48296503|NCT04431999|DRUG|Whole blood transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
48296504|NCT04431999|DRUG|Fractionated blood products transfusion|Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
48296505|NCT03446170|BEHAVIORAL|Graphic cigarette warning labels, plain packaging|This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
48296506|NCT03397420|OTHER|FAM-CARE|Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
48296507|NCT00306566|BIOLOGICAL|CYT004-MelQbG10|
47946789|NCT05209178|DIAGNOSTIC_TEST|Collection of nasal and oropharyngeal specimen for COVID19 antigen test|Regarding two independent sampling procedures from the anterior part of the nose and the oropharynx, participants are randomized to either perform the sampling by themselves with written instructions or having the procedure performed by trained personnel. The specimen is meant for a rapid antigen test for COVID-19 infection.
48296508|NCT02133378|DEVICE|Hemopatch|Baxter Hemopatch
48296509|NCT02133378|BEHAVIORAL|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
48635618|NCT01570192|DRUG|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
47946790|NCT02993718|DRUG|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
47946791|NCT02993718|DRUG|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
47946792|NCT04121988|DIAGNOSTIC_TEST|MRI|"1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~* Coronal T2 weighted imaging~* Dynamic contrast enhanced T1 weighted imaging~* Coronal contrast enhanced T1 weighted imaging"
48296510|NCT05900414|BEHAVIORAL|Electronic patient decision aid|Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments
48296511|NCT05900414|OTHER|Information|Link to website with information about atrial fibrillation treatments
48296512|NCT06671379|DRUG|SHR-A2009 monotherapy|SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously
48296513|NCT06671379|DRUG|platinum-based dual-agent chemotherapy|Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
48296514|NCT02927171|OTHER|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
48296515|NCT05477680|DEVICE|Navigation-guided surgery|Surgeon removes brain lesions and assesses brain shift with neuronavigation
48296516|NCT02267577|DEVICE|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
48296517|NCT02267577|DEVICE|GE Dinamap ProCare Automatic Blood Pressure Monitor|This commercially available gold standard blood pressure monitor will be used as a control to assess the accuracy of the Sphygmo device.
48296518|NCT04593498|DIAGNOSTIC_TEST|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
48477396|NCT05085782|BEHAVIORAL|Pain neuroscience education|In the form of 10 videos that participants will watch on their own time
48635619|NCT01570192|DRUG|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
48635620|NCT01570192|DEVICE|tobramycin nebulization|tobramycin nebulization 600mg/day
48635621|NCT02802865|DRUG|Clomiphene|
48635622|NCT02802865|DRUG|Letrozole|
48635623|NCT00094666|DRUG|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
48296519|NCT04593498|DIAGNOSTIC_TEST|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
48296520|NCT04593498|DIAGNOSTIC_TEST|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
48296521|NCT04593498|DIAGNOSTIC_TEST|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
48296522|NCT01719081|PROCEDURE|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
48296523|NCT02042131|BEHAVIORAL|Treatment As Usual (TAU)|
48296524|NCT02042131|BEHAVIORAL|Standard Crisis Response Plan (S-CRP)|
48296525|NCT02042131|BEHAVIORAL|Enhanced Crisis Response Plan (E-CRP)|
48296526|NCT00716404|DEVICE|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
48296527|NCT01144689|BEHAVIORAL|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
48296528|NCT01144689|BEHAVIORAL|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
48477397|NCT05482204|OTHER|Low Climate Impact label|Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
48635624|NCT00094666|DRUG|Comparator: placebo / Duration of Treatment - 6 weeks|
47946793|NCT05771792|OTHER|ECCENTRIC EXERCISE|Eccentric Exercise training group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, Eccentric Exercise training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. Eccentric exercise training protocol is as follow: Prone Hamstring Curl, Seated TheraBand Hamstring Curl, Exercise Ball (or glider) Bridge with Curl, Stiff-Legged Deadlift, Single Leg Deadlift, Nordic Hamstring Curl.
47946794|NCT05771792|OTHER|CONVENTIONAL EXERCISES PROGRAM|The participant of the Control Group will perform 8 weeks of protocol with a total 24 sessions for 45 minutes (3 session per week). During each 45 minutes training session, subjects will complete the warmup for 10 minutes, conventional training for 25 minutes and cool down 10minutes. All players will perform each repetition in a slow, controlled manner, 10 repetition and 3 sets in first 4 week and 15 repetition and 3 sets in last 4 weeks of all exercises for 45 minutes. The exercise will be as follow: Side Lunges, Split Squats, Calf Raises.
47946795|NCT04871074|DRUG|UCB-J|PET imaging with UCB-J
47946796|NCT04871074|DEVICE|MRI Scan|MRI exams will be performed using a 3T MRI scanner, scan duration is typically 60 minutes
47946797|NCT04871074|DEVICE|PET Scan|PET imaging may be collected using either a PET scanner or a PET/Computed Tomography (CT) scanner, a PET scan will be initiated with the injection of radiotracer
47946798|NCT00076973|DRUG|montelukast sodium|Duration of Treatment: 6 months
48296529|NCT04850911|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
48296530|NCT04850911|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
48296531|NCT06570213|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is a first-line, gold-standard psychotherapy intervention for the treatment of PTSD.
48296532|NCT06570213|DRUG|Stellate Ganglion Block|Stellate Ganglion Blocks are an injection of local anesthetic into the stellate ganglion, a collection of nerves in the side of the neck.
48296533|NCT06302322|PROCEDURE|Thin Tissues|Patients with thin tissues received implants 10 years ago and are now followed up after 10 years.
48296534|NCT06302322|PROCEDURE|Thick Tissues|Patients with thick tissues received implants 10 years ago and are now followed up after 10 years.
48296535|NCT06302322|PROCEDURE|Surgically augmented thin tissues|Patients with thin tissues received soft tissue augmentation and implants 10 years ago and are now followed up after 10 years.
48296536|NCT02132390|DRUG|Goserelin|
48296537|NCT02132390|DRUG|Toremifene|
48296538|NCT04704765|OTHER|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
48296539|NCT01160367|OTHER|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
48296540|NCT01160367|OTHER|standard of care|Patient-family dyads will receive standard of care in health decision-making
48296541|NCT03348631|PROCEDURE|Computed Tomography|Undergo CT scan
48296542|NCT03348631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48296543|NCT03348631|DRUG|Tazemetostat|Given PO
48477398|NCT05482204|OTHER|High Climate Impact label|Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
48477399|NCT06358274|OTHER|Thru-hiking|planning to embark on the Colorado Trail
48635625|NCT00063999|DRUG|Carboplatin|Given IV
48635626|NCT00063999|DRUG|Cisplatin|Given IV
48635627|NCT00063999|DRUG|Doxorubicin Hydrochloride|Given IV
48635628|NCT00063999|BIOLOGICAL|Filgrastim|Given SC
48635629|NCT00063999|OTHER|Laboratory Biomarker Analysis|Correlative studies
48635630|NCT00063999|DRUG|Paclitaxel|Given IV
48635631|NCT00063999|BIOLOGICAL|Pegfilgrastim|Given SC
48635632|NCT00063999|OTHER|Quality-of-Life Assessment|Ancillary studies
48635633|NCT06354543|DEVICE|Cemented joint arthroplasty|Joint replacement with cemented prosthetic components
48296544|NCT05707065|OTHER|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
48296545|NCT05707065|OTHER|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
48296546|NCT01147965|BIOLOGICAL|AD5 CEA Vaccine|AD5\[E1-, E2b-\]-CEA Vector Vaccine
48296547|NCT02004340|DEVICE|ear vagus nerve stimulator|
48296548|NCT04953455|OTHER|no intervention|no intervention
48296549|NCT06671730|BEHAVIORAL|8-Week Telehealth-based Occupational Therapy Program|The telehealth-based OT program will be grounded in SDT. The program will be designed to help BC survivors transition from recovery after surgery to achieving levels of aerobic PA and MSE that are recommended according to each participants' specific treatment course and desired outcomes. Participants will engage in eight once-weekly OT sessions with a licensed occupational therapist via Zoom-lasting for up to about an hour. Each session will teach psychoeducational and skill-building techniques that support decreasing functional limitations associated with BC and BC treatment as well as improving behavioral skill sets necessary for maintenance of aerobic PA and MSE. Participants will receive study-provided exercise equipment and a fitness tracker (Fitbit Charge 6) for use engaging in greater amounts of aerobic PA and MSE (keeping these materials post-study)
48296550|NCT06286930|DEVICE|anodal trans cranial direct current stimulation (tDCS)|1 20-minute anodal tDCS stimulation
48296551|NCT06286930|DEVICE|cathodal trans cranial direct current stimulation (tDCS)|1 20-minute cathodal tDCS stimulation
48296552|NCT05501444|OTHER|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
48296553|NCT01742962|PROCEDURE|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
48296554|NCT06530849|DRUG|GC012F Injection|GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
48296555|NCT06343350|DEVICE|OPTDR01 software application|Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection
48296556|NCT02677701|DRUG|azithromycin|500mg tablet over-encapsulated to match placebo
48296557|NCT02677701|DRUG|placebo (for azithromycin)|
48296558|NCT02677701|DRUG|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
48296559|NCT03126227|BIOLOGICAL|AR101|AR101 powder provided in capsules
48296560|NCT03126227|BIOLOGICAL|Placebo|Placebo powder provided in capsules
48635634|NCT02544815|DRUG|Digoxin|Digoxin 0.25 mg pills
48635635|NCT02544815|DRUG|Placebo|Placebo pills
48635636|NCT00576394|DRUG|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
48635637|NCT00576394|DRUG|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
48635638|NCT03556878|BEHAVIORAL|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
48296561|NCT01430221|BEHAVIORAL|Mindfulness-based Personalized Health Planning|
48296562|NCT01430221|OTHER|Structured & Guided Education|
48296563|NCT00547937|DEVICE|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
48296564|NCT04928365|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
48296565|NCT01301911|DRUG|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
48296566|NCT00622934|DRUG|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
48296567|NCT00622934|DRUG|placebo|placebo
47946799|NCT00076973|DRUG|Comparator: placebo|Duration of Treatment: 6 months
47946800|NCT00334815|BIOLOGICAL|Bevacizumab|Given IV
48296568|NCT05624944|DRUG|TS-142 5 mg|Single-dose of 5 mg of TS-142
48296571|NCT06094712|DRUG|CORT125134|CORT125134 150-mg capsule
48296572|NCT03078101|DRUG|Empagliflozin 10 MG [Jardiance]|administered orally once daily
48296573|NCT03078101|DRUG|Placebo Oral Tablet|administered orally once daily
48296574|NCT05870007|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg
48296575|NCT05870007|DRUG|Sodium Bicarbonate 600 Mg Oral Tablet|Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
48296576|NCT02260414|DRUG|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
48296577|NCT02260414|OTHER|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
48296578|NCT06358885|OTHER|Facilitation (FAC)|The facilitation approach will use a flexible clinic level implementation strategy that helps clinics to address common barriers, such as counselor skills, competing priorities, and resource deficits.
48296579|NCT06358885|BEHAVIORAL|Experiential Brief Alcohol Intervention (EBAI)|Clinic staff will be offered the experiential BAI prior to implementation. The BAI comprises 2 in-person sessions and 2 booster phone sessions. Clinic staff responsible for delivering the BAI to PWH participants will be offered 3 additional consolidation sessions to integrate their experiences receiving the BAI with their delivery of the BAI.
48296580|NCT00658970|DRUG|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
48296581|NCT06181617|OTHER|Quality of life assessment|Quality of life assessment
48477400|NCT04747795|DRUG|Vitamin C|IV
47946801|NCT00334815|DRUG|Cisplatin|Given IV
47946802|NCT00334815|DRUG|Docetaxel|Given IV
48477401|NCT04747795|DRUG|Normal saline|IV
48477402|NCT06616493|OTHER|kinesio taping|measure the subjects' lower extremity biomechanical characteristics with 3 different conditions respectively (kinesio taping, placebo kinesio taping, no taping)
48477403|NCT01825837|DRUG|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
48477404|NCT01825837|DRUG|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
48477405|NCT01825837|DRUG|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
48477406|NCT01825837|DRUG|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
48477407|NCT05994248|DEVICE|Enform Mesh|Use of absorbable mesh in umbilical hernia repair
48477408|NCT05994248|DEVICE|Marlex|Use of non-absorbable mesh in umbilical hernia repair
48477409|NCT06208423|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
47946803|NCT00334815|DRUG|Etoposide|Given IV
47946804|NCT00334815|BIOLOGICAL|Filgrastim|Given SC
47946805|NCT00334815|BIOLOGICAL|Pegfilgrastim|Given SC
48296582|NCT04199754|DRUG|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
48296583|NCT04199754|RADIATION|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
48296584|NCT04199754|RADIATION|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
48296585|NCT04199754|DRUG|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
48296586|NCT02595060|DRUG|inhaled molgramostim (rhGM-CSF)|
48296587|NCT02595060|DRUG|inhaled placebo|formulated as the active substance without molgramostim
48296588|NCT02742389|OTHER|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
48477410|NCT05436704|PROCEDURE|EUS-FNB|EUS-FNB
47946806|NCT00334815|RADIATION|Radiation Therapy|Undergo thoracic radiotherapy
47946807|NCT05278520|PROCEDURE|Total hip arthroplasty|Hip joint replacement surgery. Elective for RA and OA cases.
47946808|NCT05954559|DRUG|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
47946809|NCT05372614|PROCEDURE|Biopsy|Correlative studies
47946810|NCT05372614|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47946811|NCT05372614|PROCEDURE|Computed Tomography|Undergo CT scan
47946812|NCT05372614|PROCEDURE|Echocardiography|Undergo echocardiography
48477411|NCT05434130|BEHAVIORAL|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (\>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
47946813|NCT05372614|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
47946814|NCT05372614|DRUG|Neratinib Maleate|Given PO
47946815|NCT05372614|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
48477412|NCT02244424|BEHAVIORAL|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
48477413|NCT04366596|DEVICE|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
48477414|NCT04366596|DEVICE|Angioplasty with plain old balloon|Angioplasty with plain old balloon
48477415|NCT04418531|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
48477416|NCT04472858|DRUG|Donafenib|dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.
48296589|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
48296590|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
48296591|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
48296592|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
48296593|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
48296594|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
48296595|NCT00514449|DRUG|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
48296596|NCT00514449|DRUG|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
48296597|NCT00612846|PROCEDURE|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
48296598|NCT00612846|PROCEDURE|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
48296599|NCT00021853|BEHAVIORAL|constraint-induced movement therapy|
48296600|NCT05933278|BIOLOGICAL|SARS-CoV-2 Subunit Recombinant Protein Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma
48296601|NCT00635531|OTHER|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
48296602|NCT00635531|DRUG|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
48296603|NCT06203678|OTHER|Kinesio taping|therapeutic tape application
48296604|NCT06203678|OTHER|Exercise|Cervical stretching and strengthening exercises home program
47946816|NCT06679686|OTHER|Role Playing|The group will analyse the instant cases given by the researchers using the role-play method.
48296605|NCT06203678|OTHER|Sham taping|patch tape application
47946817|NCT06679686|OTHER|Digital Storytelling|The group will analyse the ethical analysis of the cases containing ethical problems written by themselves by using digital storytelling
48477417|NCT04472858|DRUG|CS1001|CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
48296606|NCT06145490|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 250 mg, oral intake
48296607|NCT06145490|DRUG|Placebo|Placebo capsule, oral intake
48296608|NCT03742804|BIOLOGICAL|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
48296609|NCT01232946|DRUG|liraglutide|1.8mg subcutaneous qd for 3 months
48296610|NCT01232946|DRUG|insulin detemir|5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months
48296611|NCT01232946|DRUG|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.
48296612|NCT02136394|OTHER|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
48296613|NCT02163330|DRUG|Acetazolamide|
48296614|NCT02163330|DRUG|sugar pill|
48296615|NCT03176186|COMBINATION_PRODUCT|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
48296616|NCT00592501|RADIATION|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
48296617|NCT00592501|DRUG|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
48296618|NCT00592501|DRUG|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
48296619|NCT04037358|DRUG|Radium-223|Radium-223 plus SABR will be within two weeks.
48296620|NCT04037358|RADIATION|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
48477418|NCT05125562|DRUG|ExoFlo|Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
48477419|NCT02618226|DEVICE|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
48296621|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
48296622|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
48296623|NCT05595382|BEHAVIORAL|Emotional Appeal|Participants will be presented with a short vignette about a child undergoing cancer treatment and needing a bone marrow transplant in order to survive cancer.
48296624|NCT05595382|BEHAVIORAL|Rational Appeal|Participants will be presented with data regarding the importance of considering race/ethnicity when looking for a bone marrow transplant donor and the likelihood of finding a match based on the patient's racial/ethnic background.
48296625|NCT03281226|DRUG|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
48296626|NCT03281226|DRUG|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
48296627|NCT02806765|DIETARY_SUPPLEMENT|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months
48296628|NCT02806765|OTHER|Control|Placebo in Softgel form
48296629|NCT01205490|OTHER|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
48296630|NCT05574816|DEVICE|Phi-Bra prototype measurements|"The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient."
48296631|NCT02650778|PROCEDURE|Breast ultrasound|automated whole breast ultrasound
48296632|NCT01659944|DRUG|Eliglustat|Capsules for oral administration
48296633|NCT01659944|DRUG|Metoprolol|Tablets for oral administration
48635639|NCT03182556|BEHAVIORAL|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
48635640|NCT03182556|BEHAVIORAL|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
48635641|NCT03556280|DEVICE|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
48635642|NCT03556280|DEVICE|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
48635643|NCT03105401|OTHER|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
47946824|NCT06662942|DRUG|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
47946825|NCT06662942|DRUG|Placebo|The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.
47946826|NCT04794088|DRUG|Imatinib Mesylate intravenous solution|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).
47946827|NCT04794088|DRUG|Placebo|A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
48296634|NCT00001056|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
48298862|NCT01946048|BIOLOGICAL|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
48298863|NCT06375330|DEVICE|PoliArt|PoliArt injections
48298864|NCT00176566|DRUG|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
47946828|NCT06666036|BEHAVIORAL|Connect|Community level enhancements
47946829|NCT06678698|DEVICE|Panel Effective Photobiomodulation Therapy|"Photobiomodulation therapy is the use of low-power light in biological tissues through a non-ionizing source of light (600 to 1.100 nm), with variable power between 1 and 500 mW and therapeutic goals.~This group will receive photobiomodulation from a whole-body panel of low intensity LEDs"
48296635|NCT04859803|PROCEDURE|Patients will be received rhomboid intercostal block under ultrasound guidance.|Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously \[8\]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH \& Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.
48296636|NCT04859803|DRUG|conventional intravenous analgesia|Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
48296637|NCT05665985|DRUG|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
48296638|NCT05671120|PROCEDURE|Transcutaneous levator recession|recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
48296639|NCT02868502|DEVICE|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
48296640|NCT02868502|DEVICE|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
48296641|NCT02868502|DEVICE|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
48296642|NCT02868502|DEVICE|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
48296643|NCT04137172|PROCEDURE|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
48296644|NCT04137172|PROCEDURE|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
48298865|NCT03662334|DRUG|Rapid Acting insulin with pre-treatment of rHuPH20|Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
48298866|NCT03662334|DEVICE|Sham injection|A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
48635644|NCT01341548|DRUG|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
48635645|NCT02080728|DRUG|Ropivacaine 500mg/100ml Naropeine|
48635646|NCT02080728|DRUG|0.9% sodium chloride BAXTER|
48635647|NCT02182700|DRUG|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
48635648|NCT00785447|OTHER|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
48635649|NCT04555733|DRUG|Lemborexant|Lemborexant oral tablets.
47946830|NCT06678698|DEVICE|Sham Panel Photobiomodulation Therapy|Use of common red lamp to perform the sham photobiomodulation for the panel group
47946831|NCT06678698|DEVICE|Modified ILIB Sham Photobiomodulation Therapy|ILIB Therapy device turned off for the sham ILIB therapy
47946832|NCT06678698|DEVICE|Modified ILIB Photobiomodulation Therapy|Common laser used in ILIB mode for modified ILIB therapy
47946833|NCT04430192|DRUG|177Lu-PSMA-617|Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
47946834|NCT03029130|DEVICE|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
47946835|NCT06308094|DIAGNOSTIC_TEST|CT|Pre-ablation CT is clinically acquired in patients undergoing catheter ablation. This study entails additional acquisition of the left ventricle to assess extracellular volume (ECV)
47946836|NCT06010914|OTHER|No Intervention|"Following the manner of observational study, no intervention will be provided in the study.~The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information."
47946837|NCT03217266|DRUG|Navtemadlin|120 mg tablet
48296645|NCT04137172|PROCEDURE|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
48296646|NCT03425565|DRUG|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
48296647|NCT01878006|DRUG|Morphine|
48296648|NCT01878006|DRUG|Placebo|
48296649|NCT06070233|RADIATION|stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation|"Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax \<100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system"
48296650|NCT06070233|OTHER|Sham|Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
48296651|NCT06480071|DRUG|Oxymetazoline, 0.05% Nasal Spray|2 sprays each nostril before the excercise test.
48296652|NCT01380405|BEHAVIORAL|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
48296653|NCT01873664|BEHAVIORAL|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
48296654|NCT04751331|BIOLOGICAL|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
48296655|NCT04751331|BIOLOGICAL|Saline|0.9% saline administered as an intravenous bolus
48635650|NCT06262997|OTHER|Pilates|Pilates training will be given to groups of 3 people for 8 weeks, 2 days a week. Exercises will start with 10-12 repetitions and the number of repetitions will be increased to 20 starting from the 4th week. Before the Pilates training, basic principles such as breathing, concentration, focusing on the center, control, precision and fluid movement will be taught in a special session to inform individuals about the training principles and exercises. Each exercise will be demonstrated by the physiotherapist and cues such as tactile, verbal and imagery will be used to control the participants throughout the training. The difficulty level of Pilates training will be progressed by changing body positions, exercise ball and band use according to the performance of the patients and Pilates principles. The exercise program will start with warm-up exercises and end with 40 minutes of basic Pilates exercises followed by cooling exercises.
48296656|NCT05024838|OTHER|Machine learning methods|This is an observational study of the retrospective collection of patient data. Anesthesia-related factors such as anesthesiologist's expertise, injection site, patient position, the dosage of local anesthetics, needle size, the direction of needle bevel, and basic demographic information of the patients were used for data analysis. Patients less than 18 years old were excluded from this study. Twenty percent of the dataset was used as a testing dataset, and the remaining were used for model training. The investigators will utilize four machine learning algorithms as XGBoost (Extreme Gradient Boosting), AdaBoost (Adaptive Boosting), Random Forest (RF), and support vector machine (SVM). Model performances were evaluated visually with a confusion matrix.
48296657|NCT01461577|DRUG|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
48296658|NCT06671769|DIETARY_SUPPLEMENT|Heart Health Supplement|This is a natural heart health supplement in powdered format, chocolate flavor where participants will take a daily dose.
48296659|NCT06340204|DRUG|Irinotecan Hydrochloride Liposome Injection|Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
48296660|NCT05198986|OTHER|Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)|Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
48296661|NCT04804956|PROCEDURE|Stool sample|One stool sample will be taken at baseline for microbiota characterization
48296662|NCT04804956|PROCEDURE|Rectal mucosa sample|Characterization of tissue microbiota before and after surgery.
48296663|NCT04804956|PROCEDURE|Mesorectal adipose tissue sample|Characterization of tissue microbiota and dysfunction
48635651|NCT06262997|OTHER|Pilates and Kinesiotape|Patients in the Pilates and Kinesiotape group will receive exactly the same Pilates training as in the Pilates group. At the end of each exercise session, Kinesio Tex Gold FP elastic tape (5 cm) will be applied with mechanical correction technique for postural correction and the tape will be renewed in each session. Waterproof, porous, adhesive, 0.5 mm thick tape will be applied to the upper trapezius.
48635652|NCT06128343|OTHER|collection of biological samples|Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas
48635653|NCT04153032|DRUG|Diltiazem|DTZ is a calcium channel blocker for the treatment of chronic anal fissure
48635654|NCT04153032|DRUG|Mebo|Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
48635655|NCT03547232|DRUG|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
48635656|NCT03547232|DRUG|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
48635657|NCT04093882|DIAGNOSTIC_TEST|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
48635658|NCT05766371|DRUG|Pembrolizumab|Given IV
48635659|NCT05766371|DRUG|177Lu-PSMA-617|Given IV
48635660|NCT05560529|BEHAVIORAL|DBT|Applying DBT modules in group format over 20 weeks
48635661|NCT05560529|DRUG|TAU|Giving TAU (usual pharmacotherapy in BED) over 20 weeks
48635662|NCT05560529|DIAGNOSTIC_TEST|Plasma Ghrelin|Measuring fasting plasma ghrelin pre and post treatment in both arms
48635663|NCT06042660|OTHER|the prevalence of comorbid conditions|analysis of history of comorbidities at the time of CML diagnosis
48296664|NCT04804956|PROCEDURE|Subcutaneous adipose tissue sample|Characterization of tissue microbiota and dysfunction
48635664|NCT00366613|PROCEDURE|Cataract surgery with Perfect Capsule and Sodium Chloride|
48635665|NCT02884960|PROCEDURE|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
48635666|NCT01570582|DRUG|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
48635667|NCT04521166|DEVICE|Hearing aid|Settings in a wearable hearing aid will be adjusted within a clinically-relevant range for two features. The features include wide dynamic range compression and microphone directionality.
48635668|NCT02083263|DEVICE|Bilevel|3 months
47946838|NCT03217266|RADIATION|Radiation Therapy|Daily fractions
47946839|NCT03217266|PROCEDURE|Surgery|The surgical procedure necessary to resect the tumor with negative margins should be used.
48635669|NCT02083263|DEVICE|PEP mask|3 months
48635670|NCT05800847|DRUG|Gabapentin|Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
48635671|NCT05800847|DRUG|Placebo|Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
48635672|NCT04023474|PROCEDURE|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
48635673|NCT02286791|BEHAVIORAL|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
48635674|NCT02286791|BEHAVIORAL|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
47946840|NCT05601037|PROCEDURE|Axilla dissection + Lymphovenous anastomosis|surgical bypass between lymphatic vessel and vein
47946841|NCT05330455|DRUG|GSK3965193|GSK3965193 will be administered
47946842|NCT05330455|DRUG|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
47946843|NCT05330455|DRUG|Bepirovirsen|Bepirovirsen will be administered
48296665|NCT04804956|PROCEDURE|Visceral adipose tissue sample|Characterization of tissue microbiota and dysfunction
48296666|NCT04804956|BEHAVIORAL|Dietary assessment|Dietary assessment will be taken at baseline
48635675|NCT03784300|DRUG|50 mg PTI-125|PTI-125 50 mg Oral Solution
48635676|NCT03784300|DRUG|100 mg PTI-125|PTI-125 100 mg Oral Solution
48635677|NCT03784300|DRUG|200 mg PTI-125|PTI-125 200 mg Oral Solution
48635678|NCT04743895|DEVICE|Stainless Steel Wire Cerclage|Wire cerclage used to close sternum after cardiothoracic surgery.
48635679|NCT00429455|BEHAVIORAL|Survey|3-Part Questionnaire
48635680|NCT00784927|BIOLOGICAL|rituximab|
48635681|NCT00784927|DRUG|cyclophosphamide|
48635682|NCT00784927|DRUG|dexamethasone|
48296667|NCT05603286|PROCEDURE|Home-monitoring|Questionnaires for home-monitoring will be send to the participants 11 weeks after the baseline visit via e-mail using Castor EDC and can be completed using a computer, tablet or smartphone. Home-monitoring can be done together with a parent or guardian, if needed.
48296668|NCT03528044|PROCEDURE|Bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
48296669|NCT00100373|DRUG|RSV challenge material|
48296670|NCT03906344|DRUG|INCB052793|
48296671|NCT01379443|OTHER|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
48296672|NCT01764646|RADIATION|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
48296673|NCT01764646|RADIATION|Volumetric modulated arc therapy|Highly conformational dose distribution
48296674|NCT01764646|RADIATION|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
48296675|NCT02389413|DRUG|PQ912 oral|
48296676|NCT02389413|OTHER|Placebo|
48296677|NCT06151015|OTHER|Nitrate-rich beetroot juice plus calorie-restricted diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a calorie-restricted diet (1,000kcal deficit).
48296678|NCT06151015|OTHER|Nitrate-rich beetroot juice plus weight-maintenance diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a weight-maintenance diet (energy will be met).
48296679|NCT05571150|BEHAVIORAL|Dyad-focused strategy training intervention|"The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
48296680|NCT05571150|BEHAVIORAL|Attention-control intervention|The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
48296681|NCT05508971|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
48296682|NCT05508971|PROCEDURE|Adenotonsillectomy|Tonsil and adenoid removal
48635683|NCT00784927|DRUG|lenalidomide|
48635684|NCT02794311|OTHER|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
48635685|NCT01411371|PROCEDURE|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
48635686|NCT01411371|DRUG|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
48635687|NCT02501785|BEHAVIORAL|Caregiver Reaction Assessment (CRA)|
48296683|NCT03184701|OTHER|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
48296684|NCT00430781|DRUG|pazopanib (GW786034)|
48296685|NCT00430781|DRUG|lapatinib (GW572016)|
48296686|NCT01750476|DRUG|Mirena|
48296687|NCT01750476|DRUG|Oral contraception|
48296688|NCT01750476|DRUG|Depo-Provera|
48635688|NCT02501785|BEHAVIORAL|The Caregiver Quality of Life - Cancer (CQOLC)|
48635689|NCT03990337|DEVICE|Ultrasound|Ultrasonography of cricoid cartilage.
48635690|NCT01655212|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
48296689|NCT03463265|DRUG|nab-sirolimus|nab-sirolimus, single agent
48296690|NCT03463265|DRUG|nab-sirolimus + temozolomide|temozolomide, combination
48296691|NCT03463265|DRUG|nab-sirolimus + bevacizumab|bevacizumab, combination
48296692|NCT03463265|DRUG|nab-sirolimus + lomustine|lomustine, combination
48296693|NCT03463265|DRUG|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ), combination
48296694|NCT03463265|DRUG|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy, combination
48296695|NCT02298517|PROCEDURE|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
48296696|NCT02298517|PROCEDURE|inspiratory load equipment|Threshold and Power breathe
48296697|NCT03291782|DRUG|D-0120|oral, single dose
48296698|NCT02626052|BEHAVIORAL|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
48296699|NCT02626052|BEHAVIORAL|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
48296700|NCT02626052|BEHAVIORAL|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
48296701|NCT02626052|PROCEDURE|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
48635691|NCT05040464|DRUG|AZA capsules|oral AZA capsules at a daily dose of 2.5 mg per kilogram,
48635692|NCT05040464|DRUG|MTX|MTX 25 mg SC once a week
48296702|NCT02626052|PROCEDURE|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
48296703|NCT02626052|PROCEDURE|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
48296704|NCT00722345|BEHAVIORAL|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
48296705|NCT00722345|BEHAVIORAL|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current \& past activities; 2) reviewing the pros \& cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
48296706|NCT06483633|BEHAVIORAL|MICT + CPT, HIIT + CPT, SIT + CPT|Single acute intervention, each exercise mode had a washout period of at least 7 days.
48296707|NCT04918940|BIOLOGICAL|Determination of COVID-19 vacciantion efficacy|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
48296708|NCT03044665|DRUG|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
48635693|NCT05040464|BIOLOGICAL|blood sample|The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
48635694|NCT05940636|OTHER|Activity-based rehabilitation+electrical stimulation|Balance training will occur three times per week for four weeks, totaling 12 two-hour sessions. In both groups, you will be asked to stand on a force plate while playing visual feedback training (VFT) games as part of the standing balance training. A force plate is similar to a bathroom scale that you can stand on which measures your body sway during movement. Visual feedback training (VFT) is a type of activity that includes weight-shifting movements in the upright stance. VFT will be done in both groups. There will be different games as shown in figure 1 and the order of the games will be randomly chosen in each session. During each game, there will be targets that will be presented on the screen and you will have to navigate toward them . You will be able to rest between games as needed.
48635695|NCT03932383|DEVICE|Custom CPAP mask|Modified CPAP mask based on 3D image capture
48635696|NCT04889911|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy- Young Adult, Combined with Coordinated Specialty Care|NECT is a psychosocial intervention focused on addressing the effects of self-stigma on individuals diagnosed with severe mental illnesses. For the present study, the intervention has been modified to address the needs of youth who have recently experienced a first episode of psychosis.
48635697|NCT04889911|OTHER|Coordinated Specialty Care|Coordinated Specialty Care is an evidence-based, multimodal intervention for persons who have experienced a first episode of psychosis.
48635698|NCT00279513|DRUG|Traumeel S|
48635699|NCT02852746|BEHAVIORAL|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
48635700|NCT01843504|BIOLOGICAL|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
48635701|NCT01843504|OTHER|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
48635702|NCT00370136|DRUG|ultrasound contrast|
48635703|NCT02636283|DRUG|Entresto|Oral pills
48635704|NCT02636283|DRUG|Placebo group|The placebo pills
48635705|NCT01619449|PROCEDURE|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
48635706|NCT04674904|OTHER|Dry Needling|Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min
48635707|NCT04674904|OTHER|Hot pack , TENS , Stretching|"Treatments are~1. Hot Pack for 15 minutes~2. TENS for 10 minutes~3. Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine"
48635708|NCT03363438|OTHER|no intervention survey|there was no intervention this was a survey
48635709|NCT02201628|DEVICE|Nasopharyngeal and oesophageal temperature probes|
48635710|NCT05032105|DEVICE|Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)|Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
48635711|NCT01514435|DEVICE|Electroconvulsive therapy|treatment for major depression
48635712|NCT01514435|DEVICE|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
48635713|NCT02417480|BEHAVIORAL|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
48635714|NCT02417480|BEHAVIORAL|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
48635715|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (One vaccination)|One dose with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
48635716|NCT05633446|OTHER|Water for injection (One vaccination)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
48635717|NCT05633446|BIOLOGICAL|PepGNP-COVID19 (Two vaccinations)|Two vaccinations with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
48635718|NCT05633446|OTHER|Water for injection (Two vaccinations)|Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
48635719|NCT06027463|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
48635720|NCT01304719|BEHAVIORAL|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
48635721|NCT01304719|BEHAVIORAL|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
48635722|NCT02569775|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
48635723|NCT05803343|BEHAVIORAL|Regulating Together-Canine|RT-C is an animal assisted, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. RT-C meets for 1.5 hours, twice weekly for five weeks with concurrent youth and caregiver groups. The children progress through skills including relaxation training, arousal ratings, problem size, mindfulness, problem solving, and cognitive flexibility. The caregivers learn crisis management, reward systems, and coaching strategies for topics taught to the children. Homework is utilized to reinforce use of skills outside the group. The canines are present throughout as both a calming presence and teaching assistant. Children will be able to interact with the dog when practicing relaxation at the beginning of each session and throughout the session. Additionally, the dog will help to emphasize certain curriculum concepts.
48635724|NCT05803343|BEHAVIORAL|Regulating Together-Standard|RT-S an established, intensive outpatient group intervention for children with autism spectrum disorder and emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
48635725|NCT03977610|DRUG|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
48104111|NCT04857346|DRUG|Indocyanine green|Single application of PDT will be performed. A diode laser (HELBO®TheraLite - Bredent Medical, Germany) with 670 nm wavelength, power of 150 mW, fluency of 22 J/cm2 and density of 1.1 W/cm2 will be used in this study. Indocyanine-green photosensitizer (Sigm Aldrich, USA) with 0.005% concentration will be used as a photosensitizer which will be applied inside the periodontal pockets in a depth of 3 mm with the help of a blunt needle for 10 s. Laser irradiation will be performed for 60 s using a flexible tip. Laser irradiation will be performed at 2 points each on buccal and lingual with the tip stabilized perpendicular to the gingival tissues.
48635726|NCT05012969|DEVICE|Hipstop bandage|12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
48635727|NCT03728231|OTHER|Complete blood count|taking blood sample from venous blood
48635728|NCT00000738|DRUG|Nimodipine|
48635729|NCT00000738|DRUG|Zidovudine|
48635730|NCT06548347|DRUG|Linperlisib|Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
48635731|NCT05041582|DEVICE|tDCS|dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment
48635732|NCT05041582|DRUG|Citalopram|total 3 months, since 2-4 weeks after stroke
48635733|NCT05041582|BEHAVIORAL|Rehabilitation|hospitalized rehabilitation, 3 hours daily
48104112|NCT04220359|DEVICE|non-invasive monitoring|Prospective monitoring with retrospective big-data analysis
48635734|NCT03978156|DRUG|Dronabinol 2.5 MG|Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
48635735|NCT03978156|DRUG|Microcrystalline cellulose|Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
48635736|NCT05961384|DRUG|baxdrostat|a blood pressure lowering drug, oral dose
48635737|NCT00700089|BEHAVIORAL|Assertive intervention|8-20 assertive contacts after suicide attempt
48635738|NCT00700089|OTHER|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
48104113|NCT00496379|DRUG|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
48296709|NCT03044665|DRUG|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
48635739|NCT04129970|DEVICE|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
48635740|NCT01144351|DRUG|ELND002|
48296710|NCT01266148|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
48296711|NCT01266148|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
48296712|NCT01266148|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
48296713|NCT01266148|DRUG|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
48296714|NCT01266148|DRUG|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
48296715|NCT05483543|DRUG|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
48296716|NCT01341509|PROCEDURE|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
48635741|NCT01144351|DRUG|Placebo|
48635742|NCT03048019|DRUG|Tirofiban|Patients will receive Tirofiban during the PCI procedure
48635743|NCT03048019|DRUG|Cangrelor|Patients will receive Cangrelor during the PCI procedure
48635744|NCT03536065|BEHAVIORAL|Opioid Reduction Intervention|Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
48635745|NCT03536065|BEHAVIORAL|Current Care|Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
48635746|NCT06011200|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
48635747|NCT06011200|BIOLOGICAL|MSPV4|1 dose of MSPV4 on Day 0
48635748|NCT06009497|DRUG|Romiplostim|Romiplostim 10 µg/kg, subcutaneous injection, once a week.
48296717|NCT01341509|PROCEDURE|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
48296718|NCT01341509|PROCEDURE|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
48296719|NCT03945331|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
48296720|NCT03945331|DEVICE|Epidural spinal cord stimulation system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
48296721|NCT06672211|OTHER|video-supported training|Patients with stomas were provided with video-supported training in addition to standard stoma care training.
48296722|NCT01962259|BEHAVIORAL|Physical activity|
48296723|NCT05646771|BEHAVIORAL|Partner support|Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)
48635749|NCT06009497|DRUG|Ciclosporin|Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.
48635750|NCT00084279|DRUG|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
48635751|NCT01935154|DRUG|Vx-001|
48635752|NCT01935154|DRUG|Placebo|
48635753|NCT05052307|DRUG|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine|Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
48635754|NCT05052307|DRUG|CoronaVac COVID-19 vaccine|CoronaVac COVID-19 vaccine
48635755|NCT05052307|DRUG|ChAdOx1 nCoV-19 Covid-19 Vaccine|ChAdOx1 nCoV-19 Covid-19 Vaccine
48635756|NCT05052307|DRUG|Ad26.COV2.S COVID-19 Vaccine|Ad26.COV2.S COVID-19 Vaccine
48635757|NCT03217188|RADIATION|conventionally fractionated full dose re-irradiation|re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
48635758|NCT03217188|RADIATION|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles)."
48635759|NCT03149861|PROCEDURE|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS \>=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
48635760|NCT03149861|PROCEDURE|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
48635761|NCT02373163|DRUG|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
48635762|NCT02373163|DRUG|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
48635763|NCT02373163|DRUG|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
48635764|NCT03646188|DRUG|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
48104114|NCT06425237|OTHER|music therapy|standard patient care in interventional radiology associated with a well-being atmosphere with the implementation of music therapy (soothing sound environment) in the preparation box and in the examination room.
48635765|NCT03646188|DRUG|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
48635766|NCT03646188|DRUG|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
48635767|NCT03646188|DRUG|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
48635768|NCT03646188|DRUG|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
48635769|NCT03066375|DEVICE|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
48635770|NCT06300905|DRUG|test product|toothpaste containing 0.45% stannous fluoride
48635771|NCT06300905|DRUG|Control product|toothpaste containing 0.76% sodium monofluorophosphate
48635772|NCT04708054|DRUG|Busulfan|Given IV
48635773|NCT04708054|DRUG|Cladribine|Given IV
48635774|NCT04708054|DRUG|Fludarabine Phosphate|Given IV
48635775|NCT04708054|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplantation
48635776|NCT04708054|DRUG|Thiotepa|Given IV
48635777|NCT04708054|DRUG|Venetoclax|Given PO
48635778|NCT06506903|DEVICE|Medtronic Avalus Ultra|Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.
48635779|NCT06334315|DRUG|Desogestrel / Ethinyl Estradiol Pill|Standard pill packs containing 21 active pills and 7 placebo pills
48635780|NCT05295290|DIAGNOSTIC_TEST|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
48635781|NCT05863364|DRUG|Low-dose of Rifaximin|The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
48635782|NCT05863364|DRUG|Conventional dose of Rifaximin|the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
48635783|NCT04381377|DRUG|azoximer bromide|Investigational medicinal product
48104115|NCT06425237|OTHER|aromatherapy|standard patient care in interventional radiology associated with a well being atmosphere with the implementation of aromatherapy (essential oil of Ylang Ylang) in the preparation box and in the examination room.
48104116|NCT00652119|DRUG|Paclitaxel|Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.
48104117|NCT00652119|DRUG|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
48635784|NCT04381377|OTHER|Placebo|Placebo
48635785|NCT06066515|DRUG|survodutide|once weekly subcutaneous injection
48635786|NCT06066515|DRUG|Placebo|once weekly subcutaneous injection
48635787|NCT03983070|OTHER|Seated Rowing Ergometer|Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
48635788|NCT03983070|OTHER|Deadlift|Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
48635789|NCT03983070|OTHER|Blood flow restriction|An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
48635790|NCT01820104|DRUG|lansoprazole, 30 mg per day for 6 days|
48635791|NCT04860583|OTHER|Renal ultrasound|
48635792|NCT05359757|OTHER|Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder|"In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~* Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~* 40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~* This will be followed for 30 sessions"
48635793|NCT05359757|OTHER|PECS Therapy only|"A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions"
48635794|NCT04266314|DEVICE|Maternal-fetal monitoring|Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)
48104118|NCT00652119|DRUG|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
48635795|NCT04266314|OTHER|NICU Network Neurobehavioral Scale|Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.
48635796|NCT00000538|BEHAVIORAL|diet, fat-restricted|
48635797|NCT01081938|DRUG|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
48635798|NCT01081938|DRUG|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
48635799|NCT03270241|DEVICE|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
48635800|NCT00825175|BEHAVIORAL|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
48296724|NCT01852864|DRUG|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
48296725|NCT04578145|DIAGNOSTIC_TEST|HIV self-testing among female sex workers|"Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret."
48296726|NCT06137170|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
48296727|NCT01589120|BEHAVIORAL|Video decision aid|Video decision aid of the goals of care
48104119|NCT05671198|DIAGNOSTIC_TEST|Ultrasound of the diaphragm|"Sonographic parameters of the diaphragm:~* Thickening Fraction (TF); (Diaphragm thickness end-inspiration- Diaphragm thickness end-expiration) / Diaphragm thickness end-expiration. (continuous variable).~* Diaphragm end-expiratory thickness: Diaphragm thickness at end-expiration (continuous variable)~* Diaphragm excursion (DE): diaphragm inspiratory amplitude during deep breathing (continuous variable)."
48104120|NCT06631222|BEHAVIORAL|cognitive behavioral therapy|The therapeutic patient education (TPE) program was based on a biobehavioral approach and was divided into the following three parts: cognitive, operant, and respondent. The purpose of the TPE program was to modify erroneous beliefs about pain and disability, as well as to provide coping strategies and improve patient self-efficacy through a graded activity.
48635801|NCT00825175|DEVICE|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
48296728|NCT04051567|DRUG|Aspirin 100mg|In LDA group, patients were asked for taking 100mg aspirin per night;
48296729|NCT06672861|OTHER|Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)|To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.
48296730|NCT02152423|DRUG|LOVENOX|LMWH
48296731|NCT02152423|DRUG|ENOXAMED|LMWH
48296732|NCT03664817|BEHAVIORAL|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
48296733|NCT03664817|BEHAVIORAL|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
48635802|NCT04119336|DRUG|Nivolumab|Given intravenously once per cycle
48635803|NCT04119336|DRUG|Ixazomib|Given orally on days 1, 8, 15.
48635804|NCT04119336|DRUG|Dexamethasone|Given orally on days 1, 8, 15, 22
48104121|NCT06631222|OTHER|sub-occipital inhibitory pressure|The suboccipital musculature will be palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure was applied, pushing the atlas anteriorly. The occiput will be rested on the hands of the therapist while the atlas is supported by the fingertips. Finger pressure will be maintained for 10 minutes to produce the proposed therapeutic effect of inhibiting the suboccipital soft tissues.
48104122|NCT06631222|OTHER|deep friction massage|Friction massage is performed with the fingertips placed on the trigger points. Pressure was applied and the fingertips move in a circular manner, while the pressure is gradually increased. This massage will be applied until the patient report a reduction in pain at the trigger point
48296734|NCT00670917|OTHER|questionnaire administration|
48296735|NCT00670917|PROCEDURE|acupressure therapy|
48296736|NCT00670917|PROCEDURE|biopsy|
48296737|NCT00670917|PROCEDURE|bone marrow aspiration|
48296738|NCT00670917|PROCEDURE|pain therapy|
48296739|NCT05502848|BEHAVIORAL|Internet Cognitive Behavior Therapy|ICBT helps change patterns of thinking (cognitions) and behaviors of psychological distress, including relaxation, stress management, while using ICBT can increase personal tolerance for negative thoughts and negative emotions, help patients reduce negative perception of the disease due to long-term recurrent itching, and break the vicious cycle
48296740|NCT02508727|OTHER|MRI|
48296741|NCT02508727|OTHER|3D cardiac ultrasound|
48296742|NCT02973646|DRUG|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
48296743|NCT02973646|DRUG|Peginterferon Alfa-2B|
48298867|NCT03647943|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.
48635805|NCT04119336|DRUG|Cyclophosphamide|Given intravenously on days 1, 8, 15.
48296744|NCT00916721|DRUG|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
48296745|NCT00916721|DRUG|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
48296746|NCT05180305|DIAGNOSTIC_TEST|Mitomic Prostate Test|Mitomic Prostate Test
48296747|NCT00003881|BIOLOGICAL|trastuzumab|
48296748|NCT00003881|DRUG|carboplatin|
48296749|NCT00003881|DRUG|paclitaxel|
48296750|NCT01713036|DRUG|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
48296751|NCT04889495|DRUG|Zirabev|Bevacizumab biosimilar
48296752|NCT03870022|DEVICE|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
48296753|NCT03870022|DEVICE|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
48296754|NCT02090582|OTHER|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
48296755|NCT02090582|OTHER|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
48296756|NCT01161524|DRUG|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
48296757|NCT01161524|DRUG|Placebo|Matching Placebo taken once daily.
48296758|NCT03938662|DIETARY_SUPPLEMENT|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
48296759|NCT03938662|DIETARY_SUPPLEMENT|Placebo|Placebo of same appearance, colour and taste,
48296760|NCT02616029|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
48296761|NCT03071406|DRUG|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
48296762|NCT03071406|DRUG|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
48296763|NCT03071406|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
48296764|NCT04498910|DRUG|LY3451838|Administered IV
48296765|NCT04498910|DRUG|Placebo|Administered IV
48296766|NCT05600712|DEVICE|REDAPT Sleeved Stem|The REDAPT Sleeved Stem is designed to provide secondary proximal support to the distal fixation and enhance implant stability.
48296767|NCT02797873|OTHER|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
48296768|NCT02797873|OTHER|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
48296769|NCT02797873|BEHAVIORAL|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
48296770|NCT02797873|OTHER|SCID-II|See Detailed Study Description.
48296771|NCT02797873|OTHER|SDQ|See Detailed Study Description.
48635806|NCT03807167|OTHER|Mattis Dementia Rating Scale|This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
48296772|NCT02797873|OTHER|ASRS|See Detailed Study Description.
48296773|NCT02797873|OTHER|AQ|See Detailed Study Description.
48296774|NCT02797873|OTHER|TAS-20|See Detailed Study Description.
48296775|NCT02797873|OTHER|Raven's SPM|See Detailed Study Description.
48296776|NCT02797873|OTHER|Reading ability|See Detailed Study Description.
48296777|NCT02797873|OTHER|Ishihara's tests for colour deficiency|See Detailed Study Description.
48296778|NCT02797873|OTHER|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
48635807|NCT03807167|OTHER|Unified Parkinson 's Disease Rating Scale-III|This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
48104123|NCT06631222|OTHER|Spinal manipulation|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateral flexion will be used. Application will be bilateral. First, cephalic decompression will be performed lightly, followed by small circumductions. Selective tension will be applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique will be applied with the aim of increasing occiput, atlas, and axis joint mobility.
48296779|NCT02797873|OTHER|Brown-ADD|See Detailed Study Description.
48296780|NCT02797873|OTHER|MFQ|See Detailed Study Description.
48296781|NCT02797873|OTHER|STAI-T|See Detailed Study Description.
48296782|NCT02797873|OTHER|BIS|See Detailed Study Description.
48296783|NCT02797873|OTHER|DAWBA|See Detailed Study Description.
48296784|NCT02797873|OTHER|STAI-S|See Detailed Study Description.
48296785|NCT02797873|OTHER|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
48296786|NCT02797873|OTHER|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
48296787|NCT02797873|BEHAVIORAL|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
48296788|NCT02797873|OTHER|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
48296789|NCT02797873|OTHER|Structural T2 MRI scan|See Detailed Study Description.
48635808|NCT03807167|OTHER|Mini Neuropsychiatric Investigation|This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
48296790|NCT02797873|OTHER|DTI MRI scan|See Detailed Study Description and Outcome Measures.
48296791|NCT02797873|OTHER|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
48635809|NCT03807167|OTHER|Montgomery and Asberg depression Rating Scale|This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
48296792|NCT05980598|DRUG|TransCon TLR7/8 Agonist|TLR7/8 agonist prodrug
48296793|NCT05980598|DRUG|Pembrolizumab|A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
48635810|NCT03807167|OTHER|Clinical Global Impression|heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
48635811|NCT03807167|OTHER|Apathy diagnostic criteria|The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
48635812|NCT03807167|OTHER|walking speed test|The patient is timed to walk 10m. A speed \<1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
48635813|NCT03807167|OTHER|accelerometer presentation|accelerometer presentation and pose
48296794|NCT05980598|DRUG|TransCon IL-2 β/γ|Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
48296795|NCT05409885|OTHER|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
48635814|NCT03807167|OTHER|data acquisition from the accelerometer|withdrawal of the accelerometer and data acquisition from the accelerometer
48296796|NCT05409885|OTHER|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
48296797|NCT01971879|PROCEDURE|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
48296798|NCT01971879|PROCEDURE|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
48296799|NCT05174689|DIAGNOSTIC_TEST|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
48298868|NCT03647943|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
48298869|NCT06151756|BEHAVIORAL|Video Supported Mobile Application|The video-supported mobile application was developed to be interactively utilized on smartphones. T
48296800|NCT05174689|DIAGNOSTIC_TEST|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
48296801|NCT05174689|DIAGNOSTIC_TEST|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
48296802|NCT04076072|DEVICE|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
48296803|NCT04076072|DEVICE|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
48296804|NCT02060708|DEVICE|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
48296805|NCT05814575|BEHAVIORAL|NEXUS intervention|During the fetal ultrasound protocol, the NEXUS intervention is added for the component of 'attachment promotion' as it is a natural extension to share with the pregnant person the behavioral and social strengths of their unborn child. As the participant observes the fetus on the monitor (a second external monitor is set up for easy viewing by the mother), she may also feel fetal movement simultaneously in the womb (after 23 weeks gestation), creating a visual and sensory link between the mother and fetus. A trained nurse or ultrasonographer shares observations of fetal behavior with the mother and others if present. The nurse is also trained in motivational interviewing techniques to use the strengths of the mother and those attributed to her fetus to explore readiness to change and other motivational factors that may be barriers to health promotion.
48296806|NCT05814575|BEHAVIORAL|Standardized Non-Medical fetal ultrasound|A standardized protocol using non-diagnostic fetal ultrasound that includes basic maternal-fetal health assessment by a trained nurse, fetal neurobehavioral assessment, measures of fetal growth, and pictures \& videos given to parents.
48296807|NCT03008590|DRUG|Naltrexone|One 4.5 mg capsule each evening
48296808|NCT03008590|DRUG|Placebo|One capsule each evening
48296809|NCT02698423|DEVICE|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
48296810|NCT02698423|OTHER|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
48296811|NCT03412630|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
48296812|NCT02046564|DRUG|ASC-01|
48296813|NCT02046564|DRUG|Placebo|
48296814|NCT01294254|DRUG|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
48296815|NCT01294254|PROCEDURE|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
48296816|NCT01198418|BEHAVIORAL|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
48296817|NCT02881307|DIETARY_SUPPLEMENT|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
48296818|NCT02881307|BEHAVIORAL|Dietary Counseling|Dietary Counseling
48296819|NCT02881307|BEHAVIORAL|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
48296820|NCT05427682|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule on Day 1
48296821|NCT05035186|DRUG|Amoxicillin|Anti-H. pylori regimens
48296822|NCT01544595|DRUG|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
48296823|NCT01544595|DRUG|Placebo|Placebo
48296824|NCT06672419|OTHER|AI-Guided Exercise and Pain Neuroscience Education|This intervention consists of a 12-week tele-rehabilitation program that uses artificial intelligence (AI) and computer vision technology to guide personalized exercise sessions. Participants will complete three exercise sessions per week, which are monitored in real time by AI to ensure proper form and progression. Additionally, participants will attend weekly educational sessions focused on pain neuroscience to improve their understanding of chronic pain mechanisms and develop better pain management strategies. The intervention is delivered remotely via a digital platform and is overseen by a trained therapist who provides real-time feedback and adjusts the program as needed.
48296825|NCT06672419|OTHER|Usual Care for Fibromyalgia|"Participants in this arm will receive the standard care for fibromyalgia, which includes pharmacological treatments and general management recommendations.~Drug: Pain Relievers~Description: Pain relievers, such as paracetamol and tramadol, are included in the standard care for fibromyalgia to manage pain levels. Drug: Antidepressants~Description: Antidepressants, such as amitriptyline and duloxetine, are prescribed to improve mood and reduce pain sensitivity as part of usual fibromyalgia care. Drug: Anticonvulsants~Description: Anticonvulsants, such as pregabalin and gabapentin, are used in standard care to manage pain and enhance sleep quality. Other: General Physical Activity and Disease Education~Description: Participants receive general recommendations on physical activity and disease management, consistent with clinical guidelines for fibromyalgia treatment."
48298870|NCT00229372|BEHAVIORAL|Prolonged Exposure (PE) therapy|
48298871|NCT06396156|PROCEDURE|Anterior enclavation|Anterior enclavation of iris-claw lens
48296826|NCT02487745|BEHAVIORAL|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
48296827|NCT02487745|BEHAVIORAL|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
47946844|NCT06010706|OTHER|Supervised physical therapy manual exercise program.|"1. Mobilization Techniques :~   The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~2. Stretching Exercise:~   Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~3. Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al \[10\] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric."
48104124|NCT06631222|OTHER|Exercises for forward head posture|"Scapular stabilization exercises:~1. In quadruped position, the patient lift¬ up his arms alternatively with shoulder abduction and 120 ° flexion.~2. In sitting position, with 90° knee flexion on a stool or bed without backrest, patient hold a pair of dumb¬bells (2 kg) in each hand and lift them up laterally while maintaining scapulae's height below 80°. The patient was instructed to hold each stage for 10 seconds and then re-turn to the starting position and three sets of 10 repetitions with 30-second pause in between were completed.~3. As for the progression of scapular stability exercise, T to Y the patient was instructed to lie in prone lying position on Swiss ball with arms abducted to 90° (the letter T); then she asked to flex elbows to 90°, retract scapulae and externally ro¬tate arms while keeping arm in 90° abductions. While maintaining the retraction of scapula, the patient is asked to raise his arms above head and extend the elbow while his arm flexed and abducted to 120°"
48296828|NCT01753752|DRUG|Chitosan- N- Acetylcysteine eye drops|
48296829|NCT01753752|DRUG|Placebo|
48296830|NCT03762252|OTHER|Dry needling|A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
48296831|NCT03762252|OTHER|Manual Therapy|The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
48296832|NCT03778255|PROCEDURE|Sentinel Lymph Node Biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
48296833|NCT04018170|DRUG|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
48104125|NCT02442466|DRUG|Endothelin Receptor B inhibitor BQ788|
48296834|NCT04018170|DRUG|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
48296835|NCT03912467|OTHER|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
48296836|NCT06287424|DIETARY_SUPPLEMENT|Aged Garlic Extract|Subjects will be instructed to continue using their regular home oral hygiene products until the Product Distribution Visit (Visit 2). They will also be instructed not to add or change any of their regular home oral hygiene products during that time.
48296837|NCT06287424|DIETARY_SUPPLEMENT|Placebo|Placebo
48296838|NCT06444581|BEHAVIORAL|Super Skills Schools|Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
48296839|NCT00477373|DRUG|depakine chrono|Depakine Chrono 500 mg
48296840|NCT04222725|DRUG|TRS01 eye drops|Dosed 4 times a day (QID)
48296841|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
48296842|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
48296843|NCT04222725|DRUG|Placebo eye drops|Dosed QID
48296844|NCT04977999|OTHER|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
48298872|NCT06396156|PROCEDURE|Posterior enclavation|Posterior enclavation of iris-claw lens
48635815|NCT03807167|OTHER|Apathy Evaluation Scale,|clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
48635816|NCT03807167|OTHER|fatigue Visual Analog Scale|To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
47946845|NCT06010706|OTHER|Stretching exercise, ROM, Strengthening exercises.|Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
47946846|NCT04901546|OTHER|Patient's own saliva|Infants with esophageal atresia will be given their own saliva
48477420|NCT05621954|PROCEDURE|Telehealth Monitoring|Connected devices and smartphone apps to measure symptoms and observations at home, with centralisation of results to a staffed hub
48477421|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
48477422|NCT03314363|DEVICE|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
48477423|NCT03314363|DEVICE|IC|monitor patients during the whole study period with indirect calorimetry
48477424|NCT03314363|DRUG|NaCl predilution|Replace citrate predilution with NaCl
48477425|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
48477426|NCT03314363|DRUG|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
48477427|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
48477428|NCT03314363|DIETARY_SUPPLEMENT|pause and restart nutritional therapy|pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
47946847|NCT06119035|OTHER|Single dose of 75 grams glucose in 200ml water|Consume single dose of 75 grams glucose in 200ml water
47946848|NCT05960942|DRUG|propofol combined with esketamine|In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
47946849|NCT05960942|DRUG|propofol-sufentanil|In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
47946850|NCT01962831|DRUG|Dinoprostone|
47946851|NCT01962831|DEVICE|Single balloon foley catheter|
47946852|NCT06319352|DEVICE|Active UroShield|Participants will have an active device (i.e., ultrasound energy is being produced by actuator) attached to their urinary catheter tube.
47946853|NCT06319352|DEVICE|Sham UroShield|Participants will have an inactive device (i.e., no ultrasound energy being produced by the actuator) attached to their urinary catheter tube. All other aspects of the sham device (look, weight, feel, sound, and operation) are identical to the active device.
47946854|NCT02556736|DRUG|RST-001|RST-001 is a gene therapeutic delivered by intravitreal injection
47946855|NCT04300647|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
47946856|NCT04300647|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
47946857|NCT06111521|DRUG|LY3537982|Administered orally
47946858|NCT06111521|DRUG|Digoxin|Administered orally
47946859|NCT06111521|DRUG|Rosuvastatin|Administered orally
47946860|NCT06111521|DRUG|Midazolam|Administered orally
47946861|NCT06111521|DRUG|Midazolam|Administered IV
47946862|NCT06084936|DRUG|Obinutuzumab|Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
47946863|NCT06084936|DRUG|Glofitamab|Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
47946864|NCT06084936|DRUG|Rituximab|Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
47946865|NCT06084936|DRUG|Bendamustine|Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
47946866|NCT06084936|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
47946867|NCT06084936|DRUG|Tocilizumab|Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
47946868|NCT01140373|BIOLOGICAL|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
47946869|NCT01140373|DRUG|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10\^7 CAR+ T cells/kg, 3 x 10\^7 CAR+ T cells/kg, and 1 x 10\^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
48296845|NCT04621123|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
48296846|NCT04621123|OTHER|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
48296847|NCT02526615|DRUG|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
48296848|NCT02526615|DRUG|Metformin|Patients received either placebo, metformin or rosiglitazone
48296849|NCT02526615|DRUG|Placebo|Patients received either placebo, metformin or rosiglitazone
48477429|NCT03314363|DIAGNOSTIC_TEST|evolution of vitamin and trace elements|blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
48477430|NCT02023008|PROCEDURE|yoga therapy|Undergo integral yoga intervention with videoconferencing
48477431|NCT02023008|OTHER|internet-based intervention|Undergo integral yoga intervention with videoconferencing
48477432|NCT02023008|OTHER|questionnaire administration|Ancillary studies
48477433|NCT05389670|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
48477434|NCT05389670|DEVICE|Sham Continuous Theta-burst stimulation (cTBS)|Sham cTBS, inhibitory-like patterned form of TMS.
48477435|NCT05725902|DRUG|Etavopivat|The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
48477436|NCT02137382|DRUG|Creon®|active comparator
48477437|NCT02137382|DRUG|Creon N|experimental drug
48477438|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
47946870|NCT06665724|DRUG|5-Aminolevulinic acid Hydrochloride (Gliolan®)|Patients will receive 5-Aminolevulinic acid hydrochloride via oral administration (20 mg/kg) 6-8 hours before CV01 treatment.
48296850|NCT04021784|DEVICE|SDS|The patient is implanted with SDS.
48296851|NCT04021784|DEVICE|NEMOST|The patient is implanted with NEMOST.
48296852|NCT03982459|BEHAVIORAL|decision support tool|computerized online decision support tool
48296853|NCT02047123|DIETARY_SUPPLEMENT|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
48296854|NCT00068952|DRUG|Edotecarin|
48296855|NCT00068952|DRUG|Temozolomide|
47946871|NCT06665724|DEVICE|CV01|Ultrasound will be delivered 6-8 hours after administration of 5-aminolevulinic acid hydrochloride. A total of 12 fields will be treated (10 treatment sites across the hemisphere with 2 additional treatments over areas of increased enhancement).
48104126|NCT02442466|DRUG|PBS|
48104127|NCT02563704|DRUG|Artesunate|
48104128|NCT02563704|DRUG|Quinine|
48104129|NCT03370055|DEVICE|LeucoPatch®|LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
48104130|NCT03370055|OTHER|Control,|Usual wound care in a specialized clinic
48296856|NCT00068952|DRUG|Carmustine (BCNU)|
48296857|NCT00068952|DRUG|Lomustine (CCNU)|
48296858|NCT01595646|DRUG|Saline|Saline, administered intranasally twice per day for a 16 week duration
48296859|NCT01595646|DRUG|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
48298873|NCT05986344|DEVICE|Copper intrauterine contraceptive device|copper T-380 IUD
48477439|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
48477440|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
48477441|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
48296860|NCT01595646|DRUG|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
48296861|NCT01301612|DRUG|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
48296862|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
48296863|NCT01301612|RADIATION|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
48296864|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
48296865|NCT01301612|RADIATION|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
48296866|NCT02088216|DRUG|N-acetylcysteine|600mg po twice a day for 12 months
48296867|NCT02088216|OTHER|On-demand treatment|receive as-needed therapy
48296868|NCT05602467|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
48296869|NCT05602467|OTHER|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
48296870|NCT05690594|OTHER|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~* General questionnaire (to collect socio-demographic data)~* ICIQ score to evaluate urinary continence~* FLQI score to evaluate fecal continence~* FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~* SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
48296871|NCT05762939|BEHAVIORAL|Chatbot|Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
48296872|NCT05762939|BEHAVIORAL|Control (book)|Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
48296873|NCT03344497|OTHER|VC Group|VC (Conventional Consultation/Video) Group
47946872|NCT05430022|BEHAVIORAL|Autism-adapted Group Cognitive Behavioral Therapy|The autism-adapted Group Cognitive Behavioral Therapy (CBT) was designed by the PI and research team in collaboration with autistic stakeholders (i.e., adults, parents, researchers). It is a 12-week group intervention (90 min) delivered on a weekly basis in an outpatient psychiatry clinic by licensed clinical psychologists and psychology trainees. Each group is comprised of 8-9 autistic adolescents (11-17 years old; middle and high school) with depression. The intervention targets adolescents' perception and understanding of self, including autistic identity, through a series of cognitive-behavioral approaches including psychoeducation, emotion regulation, cognitive distortions, cognitive restructuring, behavioral rehearsals, and weekly homework assignments.
48296874|NCT03510143|DEVICE|Neoveil (Polyglycolic Acid Mesh)|Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
48296875|NCT00500149|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
48296876|NCT00500149|DRUG|Placebo|Placebo
48296877|NCT01120327|DRUG|Placebo|Placebo
48296878|NCT01120327|DRUG|Amlodipine|Amlodipine
48296879|NCT03059563|DRUG|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
48296880|NCT03059563|OTHER|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
48296881|NCT00003210|BIOLOGICAL|recombinant interleukin-12|Given subcutaneously
48296882|NCT00003210|OTHER|laboratory biomarker analysis|Correlative studies
48296883|NCT00599430|DIETARY_SUPPLEMENT|Placebo|Inert excipient
48296884|NCT00599430|DIETARY_SUPPLEMENT|Lactobacillus acidophilus NCFM|1e10 CFU/day
48296885|NCT00599430|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
48296886|NCT04083911|DRUG|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~9,intravenous infusion; Aclarubicin:10mg/d, d3\~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
48296887|NCT01123447|PROCEDURE|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
48296888|NCT01123447|PROCEDURE|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
48296889|NCT00882869|DRUG|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
47946873|NCT00913575|OTHER|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
47946874|NCT00913575|BEHAVIORAL|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
48296890|NCT00882869|DRUG|Sorafenib|Sorafenib will be administered at 400 mg BID every day
48296891|NCT01571674|PROCEDURE|Manipulation + Exercise Group|"First 2 sessions~* High-velocity, low-amplitude manipulations to the thoracic spine.~* Low-velocity mid to end-range mobilizations to the cervical spine.~* Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
48296892|NCT01571674|PROCEDURE|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
48296893|NCT05270213|DRUG|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
48104131|NCT02950194|PROCEDURE|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
48296894|NCT01302769|DEVICE|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
48296895|NCT05348005|DEVICE|Ovira Transcutaneous Electrical Nerve Stimulation Unit|TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
48296896|NCT04055935|PROCEDURE|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
48296897|NCT04055935|DEVICE|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
48296898|NCT04925544|DRUG|VK-2019|VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,
48296899|NCT05424692|DRUG|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
48296900|NCT02251223|DRUG|Tipranavir low dose|
48296901|NCT02251223|DRUG|Tipranavir medium dose|
48296902|NCT02251223|DRUG|Tipranavir high dose|
48296903|NCT02251223|DRUG|Ritonavir low dose|
48296904|NCT02251223|DRUG|Ritonavir high dose|
48477442|NCT03898531|PROCEDURE|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
47946875|NCT05887908|DRUG|co-administration of cefepime and nacubactam|2 g cefepime and 1 g nacubactam
47946876|NCT05887908|DRUG|co-administration of aztreonam and nacubactam|2 g aztreonama and 1 g nacubactam
48104132|NCT02135458|OTHER|Telemonitoring|
48104133|NCT02135458|OTHER|Conventional care|
48296905|NCT06570902|DEVICE|WCD|An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion
48298874|NCT05986344|DEVICE|LNG-IUS|Levonorgestrel Intrauterine System
48298875|NCT02664246|DEVICE|percutaneous coronary intervention|
48298876|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject
48477443|NCT03898531|PROCEDURE|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
48298877|NCT00317941|DRUG|Rebif|44ug administered with Rebiject II
48298878|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject light
48104134|NCT01066741|DRUG|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
48104135|NCT01066741|DRUG|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
48296906|NCT05783401|OTHER|Data acquisition: Speech acquisition|Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.
48296907|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: G8 Screening tool|The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.
48296908|NCT05783401|DIAGNOSTIC_TEST|Data acquisition: Distress Thermometer|The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.
48296909|NCT04675346|OTHER|Questionnaire|Questionnaire
48296910|NCT01516450|DRUG|GSK1550188 IV|Single IV dose of belimumab 200 mg
48296911|NCT01516450|DRUG|GSK1550188 SC|Single SC dose of belimumab 200mg
48296912|NCT04188366|BEHAVIORAL|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
48296913|NCT04188366|BEHAVIORAL|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
48296914|NCT00784784|BIOLOGICAL|Fluviral|One dose
48296915|NCT00784784|DRUG|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
48296916|NCT03154450|DEVICE|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
48296917|NCT03154450|DEVICE|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
48296918|NCT05552599|PROCEDURE|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
48296919|NCT01469923|DRUG|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
48296920|NCT01469923|DRUG|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
48296921|NCT02758145|OTHER|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
48296922|NCT00577330|DIETARY_SUPPLEMENT|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
47946877|NCT05887908|DRUG|imipenem/cilastatin|1 g imipenem/1 g cilastatin
48296923|NCT01421849|PROCEDURE|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
48296924|NCT05641623|DRUG|OSU6162|OSU6162
47946878|NCT05549219|DRUG|GLM101|GLM101 IV Infusion
47946879|NCT06680635|DIETARY_SUPPLEMENT|Flavonoid-enriched juice and a low-calorie diet|Orange juice enriched in flavonoids (14%: nobiletin, sinensetin, tangeretin) (200 ml/day) and low calorie diet
48296925|NCT05641623|DRUG|Placebo|Placebo
48296926|NCT03153397|OTHER|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
48296927|NCT03153397|OTHER|Osmolite|non-prebiotic fiber containing formula (Osmolite)
48296928|NCT06408831|BEHAVIORAL|Classroom Teaching University Students Intervention Group|Web-based cyber sexual violence training and counseling will be provided to female classroom teaching students, who are the intervention group, and the effect of the intervention on cyber sexual violence experience, sensitivity and cyber security will be examined.
48296929|NCT06673329|DRUG|Brodalumab|Brodalumab 210 mg subcutaneous injection
48296930|NCT06673329|RADIATION|CT scan|CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment
48296931|NCT04902950|DRUG|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
47946880|NCT06680635|DIETARY_SUPPLEMENT|Food supplement: placebo juice and a low calorie diet|Placebo juice (200 ml/day) and a low calorie diet
47946881|NCT06677242|DIAGNOSTIC_TEST|Blood sample (serum) for circulating tumor DNA and cervical smear for genome-wide methylation sequencing|These are additional tests, added to the observational study to collect information on tumor characteristics and to pursue early detection of this diagnosis.
48296932|NCT04902950|DRUG|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
48296933|NCT05451121|DRUG|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
48296934|NCT05451121|DRUG|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
48296935|NCT05451121|DRUG|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
48104136|NCT01606995|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
48104137|NCT05444179|BEHAVIORAL|Mommies can Eat & Exercise with No Stress (MomEENS)|This intervention involving behaviour modification, incorporates nutrition and physical activity modification. The intervention encourages participants to consume a healthy diet and active lifestyle during postpartum period. For nutrition modification, a general advice on healthy nutrition were given and several nutrients are highlighted which evidenced can reduce postpartum depression. While for physical activity, the mothers are encouraged to do exercise, targeting aerobic, flexibility, and strength type of exercise. The exercise protocol is progressive. During the first month, the participants will be advised to conduct flexibility and strength exercises for 8 repetitions (1 set), at least 3 days per week for both aerobic and flexibility exercise. While during the second month, participants are asked to increase repetitions and frequency of exercises, up to 16 repetitions (2 set) for each flexibility exercise, and conduct exercise at least 5 days per week.
48296936|NCT00810797|DRUG|exemestane|Given orally
48296937|NCT00810797|OTHER|laboratory biomarker analysis|One year after completion of study treatment
48296938|NCT00810797|PROCEDURE|quality-of-life assessment|One year after completion of study treatment
48296939|NCT00810797|OTHER|immunohistochemistry staining method|Correlative studies
48296940|NCT03642795|OTHER|Questionnaire|Patients are asked to complete several questionnaires
48296941|NCT06321484|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.
48296942|NCT06321484|DRUG|Interleukin 2|Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
48296943|NCT03723564|DRUG|Lactated Ringers Solution for Injection|Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
48477444|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
48477445|NCT01571726|DRUG|Fluciclatide|7mCi
48477446|NCT06600750|PROCEDURE|Arteriovenous fistula|Patients who underwent Radiocephalic arteriovenous fistula surgery
48477447|NCT05833152|PROCEDURE|total knee arthroplasty|To observe the postoperative functional outcome of patients with knee extension lag at different angles
48296944|NCT06469658|OTHER|The standard practice dietary supplements intervention|Participants receive supplements prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
48296945|NCT06469658|OTHER|The AI-guided practice dietary supplements group|Participants receive DS prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
48296946|NCT03687034|DRUG|Temozolomide|Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
48296947|NCT03687034|DEVICE|Optune|Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
48298879|NCT03061968|BEHAVIORAL|acupressure|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
48298880|NCT00991172|DRUG|REGN475|Single Subcutaneous injection dose level 1
48477448|NCT04830917|OTHER|Immobilization type for mallet injury|Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
47946882|NCT02054377|OTHER|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
48296948|NCT06671860|OTHER|Exercise|"Individuals were randomly assigned to the REP (Routine Exercise Program) group and the OHP group. The REP group received the traditional exercise protocol and the OHP group received oculomotor exercises and myofascial release techniques in addition to the traditional exercise. The groups were evaluated before the treatment and at the end of the 6-week treatment sessions. Patient education was given to the patients before both programs. Patient education included information about nonspecific chronic neck pain, symptoms, and complications, as well as assessment methods, parameters, tests, and exercises.~The first group, the REP group (n=19), received routine exercises, and the second group, the OHP group (n=19), received oculomotor exercises and myofascial relaxation techniques in addition to the routine exercise program. The treatments were applied for six weeks, three sessions per week, under the supervision and guidance of a physiotherapist in the clinic."
48296949|NCT06662994|DRUG|Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)|Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.
48296950|NCT06571045|DRUG|Ranibizumab|Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
48296951|NCT06571045|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
48296952|NCT01553539|DRUG|therapeutic angiotensin-(1-7)|Given SC
48296953|NCT01553539|OTHER|laboratory biomarker analysis|Correlative study
48104138|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
48296954|NCT03337841|DRUG|Pembrolizumab|Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
48296957|NCT04424498|PROCEDURE|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
48296958|NCT02659345|BEHAVIORAL|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
48296959|NCT02659345|BEHAVIORAL|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
48296960|NCT05011422|DEVICE|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
48296961|NCT01326598|DEVICE|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
48296962|NCT01996319|DRUG|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
48296963|NCT01996319|DRUG|Placebo|Placebo once a day via Breezhaler® device
48104139|NCT02261688|DIETARY_SUPPLEMENT|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
48104140|NCT02261688|DIETARY_SUPPLEMENT|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
48104141|NCT00299702|DRUG|Abilify|10-30 mg once daily for 104 weeks
48104142|NCT00299702|DRUG|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
48104143|NCT04159636|OTHER|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
48104144|NCT05305989|DRUG|Belumosudil 200 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
48104145|NCT05305989|DRUG|Belumosudil 200 mg BID|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
48104146|NCT05305989|DRUG|Belumosudil 400 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
48104147|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
48104148|NCT02317016|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
48104149|NCT02317016|DRUG|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
48104150|NCT02317016|PROCEDURE|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
48296964|NCT00478972|DRUG|Rimonabant|Tablet, oral administration
48296965|NCT00478972|DRUG|placebo (for Rimonabant)|Tablet, oral administration
48296966|NCT00478972|OTHER|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
48296967|NCT02158143|DIETARY_SUPPLEMENT|vitamin D3|
48296968|NCT00044044|DRUG|Lurasidone 20 mg|Lurasidone 20mg/day tablets
48296969|NCT00044044|DRUG|Lurasidone 40mg|Lurasidone 40mg/day tablets
48296970|NCT00044044|DRUG|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
48296971|NCT00044044|DRUG|Haloperidol 10mg|Haloperidol 10mg/day tablets
48296972|NCT00044044|DRUG|Placebo|Matching Placebo to Lurasdione and Haloperidol
48296973|NCT04716439|PROCEDURE|Spine Surgery|spine decompression and fixation
48296974|NCT00691197|DEVICE|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
48296975|NCT00691197|DEVICE|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
48296976|NCT02549677|DRUG|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
48104151|NCT02317016|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
48104152|NCT00751036|DRUG|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
48296977|NCT02549677|DRUG|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
48296978|NCT02549677|DRUG|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
48296979|NCT04594408|DRUG|Epinephrine|1 mL of 1:1000 mixed into irrigation bag.
48104153|NCT00751036|DRUG|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
48104154|NCT05593952|OTHER|Dual task|exercise with dual task + usual treatment
48104155|NCT05593952|OTHER|Single task|exercise without dual task + usual treatment.
48104156|NCT00462410|OTHER|counseling intervention|
48104157|NCT00462410|PROCEDURE|psychosocial assessment and care|
48296980|NCT04594408|DRUG|Tranexamic acid|1 g IV x 1 dose to be administered intraoperatively.
48296981|NCT04594408|DRUG|Epinephrine and Tranexamic Acid|1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
48296982|NCT05111119|BEHAVIORAL|Making PrEP Smart|"The Making PrEP Smart intervention is a mobile-based application with the following components:~* Notification-based PrEP Reminders and Adherence Self-Monitoring~* HIV self-testing facilitation, interpretation of results, and testing support~* HIV partner testing facilitation, interpretation of results, and testing support~* Nearby HIV clinic contact information"
48296983|NCT06131645|DIAGNOSTIC_TEST|IASLC grading system|A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.
48296984|NCT06672731|DIAGNOSTIC_TEST|REMS: Radiofrequency Echographic Multi Spectrometry|it is a non invasive ultrasonographic evaluation of bone and muscle quality
48296985|NCT04846153|OTHER|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
48296986|NCT04846153|DEVICE|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
48296987|NCT01926379|BEHAVIORAL|Combination intervention components|"The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators."
48296988|NCT01926379|DRUG|Isoniazid Prevention Therapy|Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
48296989|NCT02204540|BEHAVIORAL|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
48296990|NCT05699460|OTHER|This is an observational study.|This is an observational study.
48296991|NCT04157660|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
48296992|NCT04157660|PROCEDURE|Sham room air|Room air will be applied via mask
48298881|NCT00991172|DRUG|REGN475|Single subcutaneous injection dose level 2
48104158|NCT01403792|DRUG|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
47946883|NCT04140097|OTHER|Prospective monitoring of a large variety of parameters|Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
47946884|NCT00300105|DRUG|Tesaglitazar|
48104159|NCT06022042|DEVICE|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
48104160|NCT02686554|OTHER|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
48296993|NCT01677611|DRUG|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
48296994|NCT01677611|DRUG|Placebo|
48296995|NCT05749822|DRUG|Fenofibrate 200mg|Fenofibrate 200mg/day
48296996|NCT05749822|DRUG|Placebo|1 tablet/ day
48296997|NCT05749822|DRUG|UDCA|UDCA 13-15mg/kg/day
48296998|NCT00754429|DRUG|losartan|losartan 50mg qd for 30 weeks.
48296999|NCT00754429|DRUG|amlodipine|amlodipine 5 mg q.d for 30 weeks.
48297000|NCT04608097|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
48297001|NCT04608097|BEHAVIORAL|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
48297002|NCT06440304|DRUG|Fosfomycin|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
48297003|NCT06440304|DRUG|Eravacycline|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
48297004|NCT06440304|DRUG|ampicillin/sulbactam|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
47946885|NCT06680102|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
47946886|NCT06680102|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
48104161|NCT03942042|DRUG|Ixekizumab|Administered SC
48104162|NCT02575235|DRUG|Cetylpyridinium Chloride (CPC)|Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.
48104163|NCT02575235|DRUG|placebo|Control group takes the placebo for the same period.
48104164|NCT05302713|DIETARY_SUPPLEMENT|Ionic Calcium|Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.
48104165|NCT05302713|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
48297005|NCT06014905|DRUG|Hyperpolarized carbon C 13 pyruvate|Given Intravenously (IV)
48297006|NCT06014905|PROCEDURE|Magnetic Resonance Image (MRI)|Imaging procedure
48297007|NCT06014905|OTHER|Saline|Given IV
48297008|NCT05885685|DRUG|Nabilone Oral Capsule|Each oral capsule contains a 0.25 mg dose of nabilone. Participants begin by taking 1 capsule at night then 1 capsule in the morning and 1 at night for the next 2 days. On the 4th day, the dose is doubled. On the 6th day, the dose is doubled again.
48297009|NCT00644319|DRUG|ibuprofen|
48297010|NCT00644319|DRUG|morphine sulfate|
48297011|NCT00644319|PROCEDURE|management of therapy complications|
48297012|NCT00644319|PROCEDURE|pleurodesis|
48297013|NCT06344520|BEHAVIORAL|pektoralis minor shortnes|One factor that is effective in acceleration during swimming is the force of the arm pulling the water. While the pectoralis minor muscle pulls the crocoid process forward, it pulls its posterolateral corner down, which helps the latismus dorsi to make an extension movement and the lower trapezius to depress the scapula. When the pectoralis minor muscle is short, it prevents maximum reach in the arm because its full function cannot be revealed. It is thought that depression of the scapula will directly affect acceleration in swimming, as it increases the backward thrust of the arm.
48297014|NCT06344520|BEHAVIORAL|Group in which the Pectoralis Minor stretching exercise was performed in a sham manner|In most cases, exercise practices also affect the person psychologically. In order to ignore the psychological effects of the exercises, they were made to perform exercises that were similar to pectoralis minor stretching exercises but did not activate the muscle
48297015|NCT06344520|BEHAVIORAL|The group in which Pectoralis Minor stretching exercise was not applied|The Control Group was not given any exercise and they continued to do their own training.
48297016|NCT06203145|DRUG|Bortezomib|A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
48297017|NCT03424330|DEVICE|ReX-C intervention|Patients receive medication by the ReX-C device
48297018|NCT03424330|OTHER|Standard of Care|Patients receive medication as usual
48297019|NCT03237260|DRUG|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
48297020|NCT03847337|OTHER|Telehealth-Screening Tool for Autism in Toddlers (STAT)|Structured autism screening tool
48297021|NCT03847337|OTHER|Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)|Semi-structured autism screening tool
48297022|NCT02458612|OTHER|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
48297023|NCT02458612|OTHER|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
48297024|NCT03829189|DIETARY_SUPPLEMENT|inulin|prebiotic supplement
48297025|NCT03829189|DIETARY_SUPPLEMENT|maltodextrin|placebo supplement
47946887|NCT02207465|RADIATION|Radiotherapy|
47946888|NCT02207465|DRUG|Abraxane|Dose varies within subtrial 1 to determine maximum dose. All patients in subtrial 2 receive 125mg Abraxane
47946889|NCT06677567|OTHER|Air-Q Intubating Airway|Patients will be inserted Air-Q Intubating Airway under general anesthesia
48104166|NCT05174286|BEHAVIORAL|SBIRT|"SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
48104167|NCT05174286|BEHAVIORAL|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
48104168|NCT06343584|OTHER|Study will conducted over a six-month period using a quasi-experimental Pre-test/Post-test design using Stamm's (2009) ProQOL Scale.|Group 1 will receive a list of suggested tools used to decrease the amount of smartphone interruptions after business hours (Appendix B) and Group 2 will receive a work-issued smartphone with instructions for use (Appendix C). Both groups will use a pre-post test format designed to compare the outcomes between the two groups. Post-study analysis will compare pre- and post-tests within each group and will compare Group 1 and Group 2 post-intervention outcomes.
47946890|NCT06677567|OTHER|proseal laryngeal mask|Patients will be inserted proseal laryngeal mask under general anesthesia.
47946891|NCT06680583|OTHER|physical indicators such as shock index relatives|shock index relatives indicators used in the prediction of cirrhosis with gastrointestinal bleeding
48104169|NCT02087306|DRUG|Brincidofovir|BCV administered twice weekly, dose depending on weight.
48104170|NCT06169904|DRUG|Cisplatin injection|We observed the UC patients from Zhongshan Hospital receiving or not receiving adjuvant cisplatin-based chemotherapy after radical cystectomy.
48104171|NCT00100984|DRUG|FUZEON [enfuvirtide]|
48104172|NCT05264467|BIOLOGICAL|Platelet rich fibrin on colorectal anastomosis|Platelet rich fibrin on colorectal anastomosis
48104173|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
48104174|NCT00882882|DRUG|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
48104175|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
48104176|NCT00882882|DRUG|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
48297026|NCT03984760|DRUG|Ferric Citrate|Take the capsules with meals or immediately after meals.
48297027|NCT03984760|DRUG|Sevelamer Carbonate|Take the tablets with meals.
48297028|NCT03112837|OTHER|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
48297029|NCT05774691|DRUG|Protamine sulfate|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
48297030|NCT05774691|DRUG|Protamine sulfate|Selective protamine administration, in case of (threatening) bleeding
47946892|NCT05394350|DRUG|MK-1088|Oral Tablet
47946893|NCT05394350|BIOLOGICAL|Pembrolizumab|IV Infusion
47946894|NCT05443360|DIETARY_SUPPLEMENT|DENSITY™ (Amorphous calcium carbonate, ACC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
47946895|NCT05443360|DIETARY_SUPPLEMENT|Crystalized calcium carbonate (CCC)|"1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner."
47946896|NCT06085794|PROCEDURE|Endoscopic combined intrarenal surgery|Combined complex stone clearance with mini-nephroscope and flexible URS
47946897|NCT06085794|PROCEDURE|Percutaneous nephrolithotomy|Clearance of renal stone with nephroscope in prone position
48104177|NCT04090190|DRUG|Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine|Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
48104178|NCT01105884|PROCEDURE|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
48104179|NCT01105884|PROCEDURE|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
48104180|NCT01105884|PROCEDURE|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
48298882|NCT00991172|DRUG|Placebo Injection|Placebo Subcutaneous injection
48298883|NCT06286280|DEVICE|cytokine adsorber (CytoSorb®)|binding of cytokines to the sorbent polystyrene of the adsorber during cardiac surgery with extracorporeal circulation
48297031|NCT06427681|DRUG|BH006 for injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
48297032|NCT06427681|DRUG|Fosaprepitant for injection+Palonosetron hydrochloride injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
48297033|NCT00275379|DRUG|ERB-041|
48297034|NCT06312007|OTHER|Semi seated position|The patient is positioned 45-90 degrees
48297035|NCT06312007|OTHER|side lying position|Side lying position
48297036|NCT01422304|DRUG|Sugammadex|Sugammadex 4 mg/kg intravenously
48297037|NCT01422304|DRUG|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
48297038|NCT01422304|DRUG|Placebo to neostigmine|Normal saline (NaCl 0.9%)
48297039|NCT01422304|DRUG|Placebo to sugammadex|Normal saline (NaCl 0.9%)
48297040|NCT02405039|DRUG|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
48297041|NCT02405039|DRUG|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
48477449|NCT03844997|DRUG|Palcociclib|"Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base"
48297042|NCT06672965|DIETARY_SUPPLEMENT|anti-stress supplement|The anti-stress supplement was developed to provide relief from anxiety and depression levels.Subjects were given 60 capsules of calming supplement (30-day supply) and instructed to take two capsules each day orally with water.
48104181|NCT01105884|PROCEDURE|Hydrogel|All the subjects in this group will be treated with Hydrogel
48104182|NCT01105884|PROCEDURE|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
48297043|NCT06672965|DIETARY_SUPPLEMENT|Placebo|Subjects were given 60 capsules of placebo (30-day supply) and instructed to take two capsules each day orally with water.
48297044|NCT02711748|DEVICE|electrostimulation|Electrostimulation using manual defibrillator
48297045|NCT02711748|DEVICE|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
48297046|NCT05437029|DRUG|Q-Griffithsin 3.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
48297047|NCT05437029|DRUG|Q-Griffithsin 6.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of high dose Q GRFT intranasal spray DP
48297048|NCT00392002|DRUG|Esomeprazole|
48104183|NCT03367494|DIAGNOSTIC_TEST|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
48297049|NCT05034783|DRUG|[68Ga]Ga-HBED-CC-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-HBED-CC-exendin-4. Tracer doses of \[68Ga\]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
48297050|NCT05034783|DRUG|[68Ga]Ga-NOTA-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-NOTA-exendin-4. Tracer doses of \[68Ga\]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
48297051|NCT02891746|OTHER|non invasive sampling|
48297052|NCT06338696|OTHER|No intervention|No intervention
48297053|NCT03251976|BEHAVIORAL|video|informational video
48104184|NCT02892162|PROCEDURE|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
48297054|NCT03251976|BEHAVIORAL|usual care|usual physician counseling on end of life care
48297055|NCT02690467|DEVICE|Insupen G34x3,5mm|
48297056|NCT02690467|DEVICE|Insupen G32x4mm|
48297057|NCT00042185|BEHAVIORAL|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
48298884|NCT04457726|BIOLOGICAL|SARS-CoV-2 Specific T Cells|Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
48298885|NCT03193151|PROCEDURE|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
48298886|NCT00447213|DRUG|Insulin glargine|Patient specific, injected, daily, 24 weeks
48298887|NCT00447213|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
48297058|NCT00042185|BEHAVIORAL|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
48297059|NCT00042185|BEHAVIORAL|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
48297060|NCT00210561|DRUG|tramadol hydrochloride , acetaminophen|
48297061|NCT00890968|DRUG|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
48297062|NCT00890968|DRUG|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
48297063|NCT02504892|DRUG|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
48297064|NCT01732263|DRUG|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
48297065|NCT05995522|DIETARY_SUPPLEMENT|Vitamin K2|100 µg per day for 90 days
48297066|NCT05995522|OTHER|Cornstarch|500 mg per day for 90 days
48297067|NCT02229149|DRUG|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
48297068|NCT02229149|DRUG|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
48297069|NCT02229149|DRUG|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
48297070|NCT01863563|DEVICE|QuickClot|1 application of treatment to each tonsil/adenoid removal area
48297071|NCT05068596|OTHER|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
48297072|NCT05068596|OTHER|CONTROL|Designed physical therapy program
48297073|NCT06497426|OTHER|Study intervention|Participants will be asked to drink water. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance.
48104185|NCT06405555|DRUG|Midodrine Oral Tablet|Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.
48104186|NCT05968352|DEVICE|Sacral Anterior Root Stimulation (SARS)|Comparison of High frequency versus low frequency stimulation
47946898|NCT04940325|DRUG|DS-1062a|First infusion for 90 minutes and then infusion duration can be decreased to 30 minutes if participant didn't experience infusion related reactions (IRR)
48104187|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
48297074|NCT04545112|DEVICE|CABG|Elective, on-pump coronary artery bypass (CABG) surgery. Each study subject will receive an internal mammary artery (IMA) conduit to the left anterior descending (LAD) coronary artery, one saphenous vein graft and one XABG medical device.
48297075|NCT06378658|DRUG|BAY2927088|Oral administration
48297076|NCT06378658|DRUG|Esomeprazole|Oral administration
48297077|NCT06378658|OTHER|Food|light low-fat meal or high fat, high calorie meal
48477450|NCT03844997|DRUG|CPX-351|CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
47946899|NCT06237647|DIETARY_SUPPLEMENT|Hyaluronic acid, HA|improve tissue repair
47946900|NCT05797610|DRUG|RO7434656|RO7434656 will be administered subcutaneously per schedule as specified.
47946901|NCT05797610|DRUG|Placebo|Matching placebo will be administered subcutaneously per schedule as specified.
48297078|NCT04135261|DRUG|HBM4003|Intravenous (IV) administration
48298888|NCT00447213|DRUG|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
48477451|NCT02394691|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
47946902|NCT04052282|DEVICE|Mobile Health App|There is no intervention
47946903|NCT06560645|DRUG|PRT7732|PRT7732 capsules will be self-administered once daily at the dose-level assigned
47946904|NCT00546650|DRUG|Sumatriptan succinate|NP101 iontophoretic transdermal system
47946905|NCT00546650|DRUG|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
47946906|NCT00501579|DRUG|Difluprednate|
48104188|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
48297079|NCT03799315|DRUG|Nicotine Replacement Therapy|All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
48297080|NCT03799315|BEHAVIORAL|Counseling|All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
48297081|NCT02004054|OTHER|measure of pupil diameter|The measure will use infra-red cameras
48297082|NCT05496803|OTHER|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
48297083|NCT05496803|OTHER|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
48297084|NCT04050904|DEVICE|ExpHeart|ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
48297085|NCT02855814|OTHER|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
48297086|NCT06132490|DEVICE|Valveless Insufflator with 12 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.
48297087|NCT06132490|DEVICE|Valveless Insufflator with 8 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
48297088|NCT02077049|DEVICE|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists."
48297089|NCT02077049|OTHER|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
48297090|NCT02484573|DRUG|Propanolol|
48297091|NCT06438276|BEHAVIORAL|Psychiatric outreach nurse service|Mental health service provided by psychiatric outreach nurses for 12-16 year old students in secondary schools
48297092|NCT04373980|DEVICE|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
48297093|NCT02004405|OTHER|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
48297094|NCT02004405|OTHER|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
47946907|NCT00501579|DRUG|Prednisolone Acetate|
47946908|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + guided spontaneous breathing exercises lasting about 20 minutes per session
47946909|NCT05759611|OTHER|Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program|Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
47946910|NCT00986479|DRUG|AZD6765|Single IV infusion of 150 mg AZD6765.
47946911|NCT00986479|DRUG|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
48104189|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
48297095|NCT01949064|DEVICE|Grindcare|
48297096|NCT01949064|DEVICE|Michigan-type occlusal splint|
48297097|NCT04976075|OTHER|no interventions|no interventions
48477452|NCT05816200|DEVICE|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
48104190|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
47946912|NCT00817544|DRUG|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
47946913|NCT02801305|DRUG|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
48104191|NCT01596725|BIOLOGICAL|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
48297098|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
48297099|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
48297100|NCT00469014|DRUG|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
48297101|NCT00469014|DRUG|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7."
48297102|NCT00469014|DRUG|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
48297103|NCT00469014|OTHER|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
48297104|NCT00469014|DRUG|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
48297105|NCT00469014|DRUG|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
47946914|NCT02801305|DRUG|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
47946915|NCT02801305|DRUG|Vaseline|This is used as the topical placebo agent.
47946916|NCT02372240|DRUG|VLX1570 and dexamethasone|
47946917|NCT06061731|DRUG|low-frequency acupoint electrical stimulation|In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
48297106|NCT01588574|BIOLOGICAL|MT10109|Botulinum toxin type A
48297107|NCT01588574|BIOLOGICAL|BOTOX(Registered trade mark)|Botulinum toxin type A
48297108|NCT04942418|OTHER|Multicolor hybrid ceramic laminate veneers.|Multi shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
48297109|NCT04942418|OTHER|Multicolor fieldspathic ceramic laminate veneers.|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
48297110|NCT05030623|DRUG|Tadalafil 5Mg Tab|Tadalafil 5Mg Tab plus Fluoxetine 20 mg capsule
48297111|NCT05030623|DRUG|Placebo|Placebo Tab plus Fluoxetine 20 mg capsule
48297112|NCT02168946|DRUG|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
48297113|NCT02168946|DRUG|Best Available Therapy|Antibiotic(s) chosen by Investigator
48297114|NCT00830427|DRUG|PF-00610355|100 mcg, QD, dry powder inhaler
47946918|NCT01810432|DRUG|Evacetrapib|Administered orally
47946919|NCT01810432|OTHER|High-fat Meal|Administered orally, at breakfast.
47946920|NCT04804540|DRUG|Vedolizumab IV|Vedolizumab IV infusion
47946921|NCT01874743|DRUG|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
48104192|NCT01596725|BIOLOGICAL|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
48104193|NCT00568542|DRUG|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
48104194|NCT00568542|DRUG|placebo|35 I.E. kg body weight placebo to erythropoetin beta
48104195|NCT02207075|DRUG|[C11]PK-1195 PET scan|PET scan with tracer \[C11\]PK-1195
48297115|NCT00830427|DRUG|PF - 00610355|600 mcg, QD, dry powder inhaler
48297116|NCT00830427|OTHER|Placebo|QD, dry powder inhaler
48297117|NCT00830427|DRUG|PF - 00610355|300 mcg, QD, dry powder inhaler
48297118|NCT02213198|BEHAVIORAL|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
48297119|NCT02213198|BEHAVIORAL|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
48297120|NCT04995744|PROCEDURE|Pectoralis Major Pedicle Bone Graft|It is aimed to restore the integrity of the medial cortex with the bone pedicle from the insertion region of the pectoralis major muscle in middle-aged patients with Neer type 4 proximal humerus fractures. Researchers aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method. The investigators aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method.
48477453|NCT05816200|DEVICE|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
48104196|NCT06213051|DEVICE|• COPAN Self-collection FLOQSwabs® (COPAN, Italy)|COPAN swabs evaluated on Roche COBAS and Cepheid Xpert PCRs
48297121|NCT02203838|DRUG|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
48297122|NCT01009385|PROCEDURE|cervical epidural steroid injection|"* After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
48104197|NCT05242926|DRUG|ModraDoc006/r|One time bi-daily dosing (30/20 mg) of ModraDoc006 in combination with ritonavir 100 mg tablets
48104198|NCT02357784|DEVICE|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
48104199|NCT04479540|RADIATION|Angiography scanner|systematic thoracic angiography scanner to diagnose pulmonary embolism and additional blood sample (hemostasis exploration)
48104200|NCT03635112|DRUG|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
48104201|NCT03635112|DRUG|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
48104202|NCT00162071|DRUG|apadenoson|
48477454|NCT04194437|DEVICE|OCS Liver System|The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.
48477455|NCT04514497|PROCEDURE|Biopsy|Undergo tumor biopsy
48477456|NCT04514497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48477457|NCT04514497|PROCEDURE|Computed Tomography|Undergo CT
48477458|NCT04514497|DRUG|Elimusertib|Given PO
48477459|NCT04514497|DRUG|Irinotecan Hydrochloride|Given IV
48477460|NCT04514497|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48477461|NCT04514497|DRUG|Topotecan Hydrochloride|Given IV
48477462|NCT03932331|DRUG|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
48297123|NCT01009385|PROCEDURE|epidural pressure measurement|"* The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system."
48297124|NCT02255786|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
48297125|NCT01891747|DRUG|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)
48297126|NCT01891747|DRUG|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)
48297127|NCT01891747|DIETARY_SUPPLEMENT|Vitamin C|250 mg vitamin C once a day (oral) - Phase I \& Phase II
48297128|NCT06242340|OTHER|Preterm group bathing 24 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
48297129|NCT06242340|OTHER|Preterm group bathing 48 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
48297130|NCT06242340|OTHER|Early term group bathing 24 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
48297131|NCT06242340|OTHER|Early term group bathing 48 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
48297132|NCT02911363|DEVICE|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
48297133|NCT02911363|OTHER|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
48297134|NCT05926089|DIAGNOSTIC_TEST|Blood sampling|blood sampling to measure APR
48297135|NCT06043310|DRUG|Nω-nitro-L-arginine methyl ester (L-NAME)|L-NAME will be infused locally through microdialysis catheters.
48297136|NCT06043310|DRUG|Acetylcholine|ACh will be infused locally through microdialysis catheters.
48297137|NCT06043310|DRUG|Sodium Nitroprusside|SNP will be infused locally through microdialysis catheters.
48297138|NCT02572206|RADIATION|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
48297139|NCT02572206|DEVICE|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
48297140|NCT00856427|RADIATION|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
48297141|NCT00856427|PROCEDURE|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
48297142|NCT04630340|DEVICE|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
48297143|NCT00384280|DRUG|Rifampin|
48297144|NCT03321617|DRUG|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
48635817|NCT03807167|OTHER|executive function|"* Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.~* Trail Making Test (TMT): This test is used to assess mental flexibility.~* Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.~* Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses."
48297145|NCT04844047|OTHER|Exercise|refer to arm descriptors
48297146|NCT04844047|OTHER|Exercise|refer to arm descriptors
48635818|NCT03807167|OTHER|MRI|An MRI lasting 30 minutes is programmed
48635819|NCT03807167|OTHER|Apathy Motivation Index|"This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between behavioral apathy and social apathy.~Emotional."
48297147|NCT03041376|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
48297148|NCT04803708|BIOLOGICAL|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).
48297149|NCT06521008|DRUG|anti muscarinic drugs|a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
48297150|NCT06521008|OTHER|Instructions including bladder training|The program teaches women skills and strategies to prevent incontinence, including bladder irritants like caffeine and discussing bowel habits to prevent constipation. It also teaches them how to respond adaptively to urgency, such as pause, sit down, relax, and contract pelvic muscles to diminish urgency and prevent urine loss. Once urgency subsides, they can proceed to the toilet at a normal pace. The program emphasizes the importance of educating patients about bladder irritants and bowel habits.
48297151|NCT06521008|OTHER|pelvic floor muscle training (PFMT)|The training program teaches bladder control through contracting the striated skeletal pelvic floor muscles (PFM). The women are instructed to empty their bladder, lie in a lithotomy position, and tighten their pelvic floor muscles. The duration of contraction and repetitions is gradually increased, totaling 20-30 minutes. The program is 3 sessions per week under supervision for 12 weeks, and each woman is instructed to perform exercises at home until they can do 300 contractions per day.
48635820|NCT00170755|DRUG|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
48297152|NCT06521008|OTHER|abdominal exercise|Women will engage in transverse abdominis exercises, focusing on drawing the lower abdominal wall towards the spine and pressing the lumbar region downward, repeated for 15 minutes per session, three times per week.
48297153|NCT06521008|OTHER|Diaphragmatic Training|The therapist will instruct each woman to lie on her back with knees bent, place one hand on her upper chest and the other on her belly. They will breathe in slowly, tighten abdominal muscles, and exhale through pursed lips. Expiration should be relaxed and lightly controlled, and not forceful. Expiration should not be prolonged, and the woman should not initiate inspiration with accessory muscles or upper chest. The session will be repeated 3-4 times, lasting 5-10 minutes, and repeated three times per week for 12 weeks.
48297154|NCT04634162|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
48297155|NCT04634162|DRUG|Placebo|Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
48297156|NCT00576693|DEVICE|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).
48297157|NCT00576693|OTHER|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
48297158|NCT06512857|OTHER|Hand puppet method|Children in the experimental group were shown a hand puppet to distract them during the skin test for allergy.
48297159|NCT06512857|OTHER|Kaleidoscope method|Children in the other experimental group were look at kaleidoscope to distract them during the skin test for allergy.
48297160|NCT00001269|DRUG|IL-3|
48297161|NCT03687177|OTHER|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
48297162|NCT03687177|OTHER|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
48297163|NCT04323709|OTHER|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
48297164|NCT04323709|OTHER|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
48635821|NCT06145282|DRUG|Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept|All participants will receive the same dose of the investigational briquilimab antibody and abatacept added to the NIH-established regimen of alemtuzumab-TBI-sirolimus and infusion of filgrastim-mobilized peripheral blood hematopoietic cells from haploidentical related donors.
48635822|NCT01506336|DRUG|masitinib|masitinib 12 mg/kg/day
48104203|NCT04890821|DEVICE|CI Percutaneous Ring Annuloplasty System|Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
48635823|NCT01506336|DRUG|sunitinib|sunitinib 50 mg/day
48104204|NCT03889678|DIAGNOSTIC_TEST|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
48104205|NCT01930019|DRUG|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
48104206|NCT01149681|DRUG|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
48104207|NCT02206386|OTHER|MHTraining-Net|See Arm Description for more details.
47946922|NCT03590873|DRUG|Vasopressin|Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
47946923|NCT06030310|OTHER|The developmental Exercise Programme of INPP|"The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills"
47946924|NCT04965051|DRUG|insulin degludec/insulin aspart (IDegAsp)|To evaluate the efficacy and safety of the IDegAsp in T1DM
47946925|NCT04965051|DRUG|basal insulin plus pre-prandial insulin|To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
48297165|NCT00121810|DRUG|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
48297166|NCT00121810|DRUG|Corticosteroids|As prescribed
48297167|NCT00121810|DRUG|Calcineurin inhibitors|As prescribed
48297168|NCT00121810|DRUG|Sirolimus|As prescribed
48297169|NCT04450355|DRUG|Nefopam 80mg/day|continuous nefopam infusion
48297170|NCT04450355|DRUG|Normal saline|continuous normal saline infusion
48297171|NCT06182527|DEVICE|Free Style Libre Pro IQ|Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.
48297172|NCT01797432|DRUG|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
48297173|NCT01797432|DEVICE|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
48297174|NCT01628991|BEHAVIORAL|behavioural program|interventional behavioural program
48297175|NCT01628991|DEVICE|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
48297176|NCT06342297|DEVICE|Dermatoscopy|Dermatoscopy used in decision of surgical margin before resection of basal cell carcinoma or cutaneous squamous cell carcinoma
48297177|NCT00014573|BIOLOGICAL|aldesleukin|
48297178|NCT00014573|BIOLOGICAL|autologous tumor cell vaccine|
48297179|NCT00014573|BIOLOGICAL|filgrastim|
48297180|NCT00014573|BIOLOGICAL|sargramostim|
48297181|NCT00014573|BIOLOGICAL|therapeutic autologous lymphocytes|
48297182|NCT00014573|DRUG|carmustine|
48635824|NCT02687165|DRUG|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
48297183|NCT00014573|DRUG|cisplatin|
48635825|NCT00754559|DRUG|Tocilizumab|8mg/kg iv every 4 weeks
48635826|NCT00324194|DRUG|MGCD0103|MGCD0103 oral dose given 2 times per week.
48297184|NCT00014573|DRUG|cyclophosphamide|
48297185|NCT00014573|DRUG|paclitaxel|
48297186|NCT00014573|PROCEDURE|autologous bone marrow transplantation|
48297187|NCT00014573|PROCEDURE|conventional surgery|
48297188|NCT00014573|PROCEDURE|peripheral blood stem cell transplantation|
48297189|NCT02110134|DEVICE|Revlite Laser System with hydroquinone skin care regimen|Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
48297190|NCT02110134|OTHER|Hydroquinone skin care regimen|Hydroquinone skin care regimen for the Treatment of Melasma
48297191|NCT04969393|DEVICE|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
48297192|NCT04969393|OTHER|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
48297193|NCT02596347|PROCEDURE|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
48297194|NCT02596347|PROCEDURE|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
48298889|NCT00723840|OTHER|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
48298890|NCT02345434|OTHER|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
48297195|NCT01288040|BEHAVIORAL|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
48297196|NCT01129791|BEHAVIORAL|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
48297197|NCT01129791|BEHAVIORAL|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
48635827|NCT00664677|DRUG|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
47946926|NCT01068652|DRUG|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
47946927|NCT01068652|DRUG|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
47946928|NCT01068652|DRUG|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
47946929|NCT01068652|DRUG|metformin|1000-2000 mg/day in combination with insulin treatment
47946930|NCT01061983|DEVICE|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
47946931|NCT02910362|DEVICE|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
47946932|NCT02910362|DEVICE|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
47946933|NCT02027376|DRUG|LDE225|
47946934|NCT02027376|DRUG|Docetaxel|
47946935|NCT01624337|DRUG|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
48104208|NCT02206386|OTHER|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
47946936|NCT01624337|DRUG|placebo|
47946937|NCT02055807|OTHER|PEEP and recruitment maneuvers|
47946938|NCT02055807|OTHER|ZEEP (no PEEP nor recruitment maneuver)|
47946939|NCT00244517|DRUG|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
47946940|NCT00244517|DRUG|Sevoflurane, Isoflurane, Desflurane|1 MAC
47946941|NCT05782231|BEHAVIORAL|GetActive+|This is a 10-week group mind body program focused on improving self- report, performance based and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increased in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
47946942|NCT04578678|OTHER|Steering|Fine tuning of the STN-DBS settings
47946943|NCT02387710|DRUG|Tiagabine|GABA reuptake inhibitor
47946944|NCT02387710|DRUG|Placebo|Placebo comparator
47946945|NCT01270542|DRUG|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
47946946|NCT01270542|OTHER|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
47946947|NCT06324708|DIAGNOSTIC_TEST|DXA|Patients will undergo a femoral and lumbar DXA
47946948|NCT00175695|DRUG|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
47946949|NCT02073110|DEVICE|Percutaneous Optical Biopsy (OCT and DRS)|
47946950|NCT01223638|OTHER|Audiometry|Audiometry
47946951|NCT06679842|DIAGNOSTIC_TEST|ascitis paracentesis|ascitis paracentesis
47946952|NCT04949464|PROCEDURE|Computed Tomography|Undergo LDCT
47946953|NCT04949464|BEHAVIORAL|Smoking Cessation Intervention|Use Positively Smoke Free - Mobile
47946954|NCT03477604|DEVICE|MicroStent and Standard PTA|Self-expanding stent and standard PTA balloon
48104209|NCT04704102|BEHAVIORAL|Muscle energy technique (MET)|A manual therapy technique that uses the gentle muscle contractions of the patient to relax and lengthen muscles and normalize joint motion.
48104210|NCT04704102|BEHAVIORAL|Strain-counterstrain (SCS)|"It's also called the positional release technique, a manual therapy technique that passively positions the hypertonic (spasmed) muscles and dysfunctional joints in positions of shortened or comfort."
48297198|NCT01129791|BEHAVIORAL|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
48297199|NCT04205591|PROCEDURE|split bone block technique|A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
47946955|NCT03477604|DEVICE|Standard PTA|Standard PTA balloon
47946956|NCT04986579|DEVICE|Paxman Scalp Cooling System|Cap attached to coolant lines connected to a refrigeration unit placed on scalp
47946957|NCT04986579|DRUG|Eribulin|Intravenous Infusion
47946958|NCT04986579|DRUG|Sacituzumab govitecan|Intravenous Infusion
47946959|NCT04986579|DRUG|Trastuzumab deruxtecan|Intravenous Infusion
47946960|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Received liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20 ml)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. Receive liposomal bupivacaine 93 mg and bupivacaine 25 mg diluted to 20ml.
47946961|NCT06392191|PROCEDURE|Rhombic intercostal nerve block(Receive standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg.)|The patient was placed in lateral recumbency and placed medial to the medial border of the scapula in the oblique sagittal plane using a line array ultrasound probe to identify ultrasound landmarks, trapezius, obliques, intercostals, pleura, and lungs, The block needle was then entered in-plane at the T5 level, with the margins retracting on insertion, and the nerve block perforating needle was imaged and then inserted into the fascial gap between the trapezius and the external intercostal muscles. A mixture of standard bupivacaine 105 mg diluted to 20 ml with dexamethasone 5 mg was received.
47946962|NCT00685555|BEHAVIORAL|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
47946963|NCT00685555|BEHAVIORAL|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
48104211|NCT04704102|BEHAVIORAL|sham SCS|SCS intervention that position with opposite site limb and direction, and with modified method as consider the easiness of a practitioner to press the tender points
48104212|NCT02786771|DEVICE|Spire|
47946964|NCT01422252|DEVICE|Vigi'Fall®|Precocious fall detection device
47946965|NCT01481181|DIETARY_SUPPLEMENT|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
47946966|NCT04950166|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
47946967|NCT01818661|DRUG|AV-1451|This is used to assess Tau burden in the brain.
48104213|NCT02786771|DEVICE|Muse headband|
48104214|NCT04178395|DEVICE|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
48297200|NCT05619211|BEHAVIORAL|Sprint-Intensity Interval Training with Telecoaching|Maximal intensity exercises that use the arms.
48297201|NCT02630277|DRUG|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
48297202|NCT01771679|BIOLOGICAL|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
47946968|NCT01691898|DRUG|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
47946969|NCT01691898|DRUG|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
48297203|NCT00935233|GENETIC|DNA analysis|
48297204|NCT00935233|GENETIC|polymorphism analysis|
48297205|NCT00935233|GENETIC|protein analysis|
48297206|NCT00935233|OTHER|laboratory biomarker analysis|
48297207|NCT00935233|OTHER|questionnaire administration|
48297208|NCT00935233|OTHER|survey administration|
47946970|NCT01691898|DRUG|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
47946971|NCT01691898|DRUG|Rituximab|RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
47946972|NCT02511028|DRUG|Ferumoxytol|510mg (17mL) IV
47946973|NCT04889222|DEVICE|INVSENSOR00050|Noninvasive pulse oximeter sensor
47946974|NCT04889222|DEVICE|RD SET SpO2|Noninvasive pulse oximeter sensor
48477463|NCT03895619|OTHER|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
48477464|NCT03690167|OTHER|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
48477465|NCT03690167|OTHER|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
47946975|NCT06101563|PROCEDURE|Early ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 7 days after drainage.
47946976|NCT06101563|PROCEDURE|Delayed Ureteroscopy|Patients will be managed by ureteroscopic lithotripsy 14-21 days after drainage.
47946977|NCT02563951|DRUG|GNS Spray 0.5mg|
47946978|NCT02563951|DRUG|GNS Spray 1.0mg|
47946979|NCT02563951|DRUG|GNS Spray 2.0mg|
47946980|NCT02563951|DRUG|Kytril 1mg (IV injection)|
47946981|NCT02563951|DRUG|Kytril 1mg (Tablet)|
48477466|NCT03690167|OTHER|Control|Nothing applied after extraction
47946982|NCT04348643|BIOLOGICAL|CEA CAR-T cells|CEA-CAR-T cells will be administered intravenously.
47946983|NCT01904565|RADIATION|Hyperthermia and Proton Beam|"1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
48104215|NCT02687646|DRUG|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
48104216|NCT02869620|OTHER|Data collection|
48104217|NCT00048828|DRUG|Olanzapine|Participants will receive olanzapine for 12 weeks.
48104218|NCT00048828|DRUG|Clozapine|Participants will receive 12 weeks of clozapine.
48477467|NCT00678327|BIOLOGICAL|bleomycin sulfate|Given IV
48477468|NCT00678327|BIOLOGICAL|filgrastim|Given subcutaneously
48477469|NCT00678327|BIOLOGICAL|pegfilgrastim|Given subcutaneously
48477470|NCT00678327|DRUG|cyclophosphamide|Given IV
48477471|NCT00678327|DRUG|dacarbazine|Given IV
48477472|NCT00678327|DRUG|doxorubicin hydrochloride|Given IV
48477473|NCT00678327|DRUG|etoposide|Given IV
48477474|NCT00678327|DRUG|prednisolone|Given orally
48477475|NCT00678327|DRUG|procarbazine hydrochloride|Given orally
48477476|NCT00678327|DRUG|vinblastine sulfate|Given IV
47946984|NCT01193660|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells \> 3x10\^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
47946985|NCT01193660|DRUG|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
47946986|NCT01193660|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
47946987|NCT01193660|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
47946988|NCT01193660|OTHER|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
47946994|NCT04181320|DEVICE|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
47946995|NCT06636123|DRUG|Investigational Agent Administration|GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
47946996|NCT00437320|DRUG|Metvix Cream 160 mg/g|Participants were treated with topical administration of Metvix cream.
48104219|NCT02763124|PROCEDURE|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
48477477|NCT00678327|DRUG|vincristine sulfate|Given IV
48477478|NCT05925244|OTHER|Control Condition|Control (no alteration to body mass).
48477479|NCT05925244|OTHER|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
48477480|NCT05925244|OTHER|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
48477481|NCT03990116|PROCEDURE|Lateral|Posture lateral kangaroo care
48477482|NCT03990116|PROCEDURE|Prone|Posture prone kangaroo care
48635828|NCT04993911|OTHER|Experimental Group|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~* Walking forward~* Walking backward~* Side stepping~* Walk heel to toe~* Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
48635829|NCT04993911|OTHER|Control Group|"Participants of this group will receive only conventional therapy which will include; before beginning the program, each session will feature a 5-minute warm-up on a fitness bike or treadmill, followed by a 5-minute cool-down. Participants of this group will receive only conventional therapy which will include.~* CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
47946997|NCT00437320|DRUG|Metvix Vehicle Group|Participants were treated with topical administration of Metvix Vehicle cream.
47946998|NCT04537039|DIAGNOSTIC_TEST|Frailty screening for people over 65 living at home.|The home care services will carry out the SEGA-A test.
47946999|NCT02921360|DRUG|acetylsalicylic acid|
48104220|NCT00003604|BIOLOGICAL|aldesleukin|
48104221|NCT00610753|BEHAVIORAL|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
47947000|NCT01997502|DEVICE|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
47947001|NCT01997502|OTHER|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
47947002|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
48104222|NCT00610753|BEHAVIORAL|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
48104223|NCT00600457|DEVICE|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
48104224|NCT04301687|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
48104225|NCT04301687|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
48104226|NCT03061474|DRUG|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
48104227|NCT03061474|DRUG|Placebo Comparator|Oral Tablet
48104228|NCT00324506|DRUG|Mycophenolate Mofetil (CellCept)|
47947003|NCT04533685|BEHAVIORAL|Portal Reminders for Influenza Vaccination: No direct scheduling link|Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
47947004|NCT04533685|BEHAVIORAL|Pre-Commitment Prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
47947005|NCT04533685|BEHAVIORAL|Pre-Appointment flu vaccine reminders|Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
47947006|NCT05660070|BEHAVIORAL|mobile Social Interaction Therapy by Exposure (mSITE)|mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
48104229|NCT04800224|DRUG|Standardized Brazilian Green Propolis Extract|900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
48104230|NCT04800224|DRUG|Placebo|900mg/day of Placebo for 10 days.
48104231|NCT02486588|OTHER|Messaging|See detailed study description for overview of the different messaging interventions in this study
48104232|NCT02486588|OTHER|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
48104233|NCT00722215|DRUG|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
48104234|NCT00722215|DRUG|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
48297209|NCT02940886|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
48297210|NCT02940886|DRUG|Iron sucrose|"Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended."
48297211|NCT02378428|DRUG|MIBG|
48297212|NCT00474630|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
48297213|NCT00474630|DRUG|Placebo|
48297214|NCT00474630|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
48297215|NCT01883245|DEVICE|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
48297216|NCT01883245|DEVICE|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
48297217|NCT00397228|DRUG|ALTROPANE®|ALTROPANE® SPECT imaging
48297218|NCT05257577|PROCEDURE|Breast conserving surgery|Patients receive standard of care breast surgery and subsequent whole breast irradiation
48297219|NCT04963218|DIAGNOSTIC_TEST|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
48297220|NCT03207828|BEHAVIORAL|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, \& Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
48297221|NCT03207828|OTHER|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
48297222|NCT03388177|BEHAVIORAL|Yoga-based therapy|
48297223|NCT03388177|OTHER|Treatment as usual|
48297224|NCT01133639|DRUG|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
48297225|NCT01133639|DRUG|Placebo|Placebo plus standard of care
48297226|NCT04220047|PROCEDURE|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
48297227|NCT01019590|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
48297228|NCT01019590|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|
47947007|NCT04960800|OTHER|Specific exercises|Specific exercises which aims to contract the recti abdominis combined with functional exercises with the aim to contract all the layers of the anterior abdominal wall. Strengthening dosage will be applied with 3 sets, containing between 8 and 12 repetitions of maximal load.
47947008|NCT06173934|DRUG|insulin injection 15 minutes before meals|Adjust insulin injection time to observe blood glucose spectrum
47947009|NCT06173934|DRUG|Insulin injection 15 minutes after eating|Adjust insulin injection time to observe blood glucose spectrum
48104235|NCT00722215|DRUG|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
48104236|NCT04480593|DRUG|Brazilian Green Propolis Extract (EPP-AF)|Green propolis extract (EPP-AF) administered orally or via nasoenteral tube.
48297229|NCT05895175|OTHER|Questionnaires|Questionnaires
48297230|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10\^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
48297231|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
48477483|NCT04919382|BIOLOGICAL|Atezolizumab|Given IV
48477484|NCT04919382|DRUG|Temozolomide|Given PO
48104237|NCT04480593|OTHER|Standard care|Standard treatment includes, as needed, supplemental oxygen (non-invasive and invasive), antibiotics or antivirals, corticosteroids, vasopressor support, renal replacement therapy and extracorporeal membrane oxygenation (ECMO).
47947010|NCT02484183|DEVICE|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher \& Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer \& Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer \& Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
47947011|NCT05650242|DRUG|BA1106|"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."
47947012|NCT02208531|BEHAVIORAL|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
47947013|NCT06388187|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
47947014|NCT06388187|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
47947015|NCT06388187|DRUG|Placebo|Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
47947016|NCT05416151|OTHER|Freeze-dried biotic|2 sticks of 3g consumed daily for 28 days
47947017|NCT05416151|OTHER|Maltodextrin|2 sticks of 3g consumed daily for 28 days
47947018|NCT02046733|DRUG|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
47947019|NCT02046733|DRUG|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
47947020|NCT05901311|DRUG|LY3537982|Administered orally.
48104238|NCT04611360|OTHER|Anodal Transcranial Direct Current Stimulation Group|"Experimental group were received anodal transcranial direct current stimulation and conventional training exercises for 3 days a weeks for 6 consecutive weeks on alternate days.~Anodal tDCS were given through:~i. Anodal electrode:It has been placed over primary motor cortex(ipsilesional) ii. Cathodal electrode: It has been above contralateral eye. iii. Intensity: 2mA iv Density: 0.07C/cm2 iv. Duration:20 min vi Rectangular electrodes(25cm2 ) inserted in saline soaked sponge used"
48104239|NCT04611360|OTHER|Conventional Training Exercises Group|Conventional physical exercises were given for 3 days a week on alternate days upto 6 weeks. It includes: progressive Conventional Training Exercises : From Bridging,Sitting: weight-bearing, Standing: weight-bearing, Sit to stand, Squat exercises and Tandem walk.
48104240|NCT00415558|DEVICE|Microwave Ablation System|
48104241|NCT06443320|DEVICE|videodrama sessions|Patients will benefit from videodrama sessions, one per week for 9 sessions
48104242|NCT01537133|DRUG|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
47947021|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered orally.
47947022|NCT05901311|DRUG|[¹⁴C]-LY3537982|Administered IV.
47947023|NCT06680297|DIETARY_SUPPLEMENT|Carbohydrates loading|Patient who is randomised in the intervention group will receive Nestle drink 2hours before the operation and a night before operation. They will receive 10mls/kg a night before operation and 5mls/kg 2 hour before operation of the carbohydrate drink.
48104243|NCT01537133|DRUG|Placebo|Dry Powder Inhaler: Placebo
47947024|NCT06680297|DIETARY_SUPPLEMENT|Control group|Patient assigned to this group will receive standard surgical fasting treatment which include 6hrs of fasting and 2 hrs of clear fluid prior operation
47947025|NCT05828134|OTHER|protein-enriched soup|The participants in experimental group have a protein-enriched soup a day and do exercise a week
47947026|NCT04855929|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
47947027|NCT04855929|DRUG|Ipilimumab|Ipilimumab administered by intravenous (IV) infusion
47947028|NCT04041375|BEHAVIORAL|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
47947029|NCT04041375|OTHER|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
47947030|NCT02479269|OTHER|Aerobic exercise|Aerobic exercise for 8 weeks
47947031|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
48104244|NCT00457990|DRUG|Oral administration of ferrous sulphate|
48104245|NCT03264248|DEVICE|E-Scale|Daily bodyweight system used under legs of bed
47947032|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
47947033|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
47947034|NCT00529984|BIOLOGICAL|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
47947035|NCT00529984|BIOLOGICAL|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
48104246|NCT03179787|DRUG|Aripiprazole oral product|oral administration of aripiprazole
48104247|NCT03414710|BEHAVIORAL|Health education booklet plus video plus brief counseling|Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
48297232|NCT05165329|COMBINATION_PRODUCT|PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
48297233|NCT04986293|DEVICE|CPAP|Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
48297234|NCT00914628|GENETIC|HSV-Tk|Infusion of approximately 1±0.2 x 10\^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
48477485|NCT03332251|DEVICE|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
47947036|NCT03764085|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
47947037|NCT03764085|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
48477486|NCT04509999|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily
48477487|NCT04509999|DRUG|Placebo|Placebo as formulated by mouth daily
48104248|NCT03414710|BEHAVIORAL|Health education booklet only|Participants in the intervention group will only receive a health education booklet
48104249|NCT02573818|DEVICE|SEDASYS System|propofol sedation with the SEDASYS System
48104250|NCT03265717|BIOLOGICAL|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
48104251|NCT00248391|BEHAVIORAL|upright feeding|
48104252|NCT02714127|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
48104253|NCT02714127|OTHER|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
48104254|NCT02638415|PROCEDURE|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
48477488|NCT05332834|BIOLOGICAL|SM17|Peripheral intravenous injection
48477489|NCT05332834|OTHER|Placebo|Peripheral intravenous injection
48477490|NCT04862962|DRUG|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
48477491|NCT01911104|BEHAVIORAL|Exercise|10 weeks of aerobic exercise
48104255|NCT02638415|OTHER|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
48104256|NCT02638415|DRUG|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
48104257|NCT02410538|OTHER|"list of FAQ"|
48104258|NCT02191852|DRUG|Seresis®|
47947040|NCT05237232|OTHER|Magnetic Resonance Angiography (MRA) additional acquisition time|Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.
47947041|NCT05237232|OTHER|Modeling cerebral vascularization|"The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling \& Simulation) requires several inputs:~* The MRA images~* The cardiac function curve~* The cerebral blood flow~* Measurement of systolic, diastolic and mean arterial blood pressure"
47947042|NCT04330183|DRUG|Ketamine|0.3mg/kg of ketamine
47947043|NCT04330183|DRUG|Normal Saline|3cc of normal saline
47947044|NCT06002243|DIAGNOSTIC_TEST|SPLASH echocardiography screening|Screening echocardiogram performed by a briefly trained health worker with images reviewed off site by an expert cardiologist or cardiac sonographer to determine screening outcome. Screening outcome may include: screen positive, screen negative or uninterpretable images.
48297235|NCT00914628|OTHER|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10\^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
48104259|NCT02857491|DRUG|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
48104260|NCT02857491|DRUG|sham|sham intravitreal injection before vitrectomy
48104261|NCT02857491|PROCEDURE|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
48104262|NCT02876471|OTHER|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
48104263|NCT02628093|DEVICE|THUNDERBEAT|Tissue dissection and vessels ligation
48104264|NCT02628093|DEVICE|LIGASURE|Tissue dissection and vessels ligation
48104265|NCT00147355|DRUG|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
48104266|NCT00147355|DRUG|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
48104267|NCT00147355|DRUG|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
48104268|NCT00147355|DRUG|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
48104269|NCT03234621|OTHER|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
48297236|NCT00393289|BEHAVIORAL|Calcium controlled diet|
47947045|NCT05703672|DRUG|Varenicline Tartrate|0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.
47947046|NCT05703672|DRUG|Placebo|One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
48104270|NCT05301400|DEVICE|Bti Unit|Comparison with or without the device
48104271|NCT01249300|OTHER|No intervention|No intervention
48297237|NCT03340441|DEVICE|Prizma|sensor unit with mobile application installed on smartphone
48297238|NCT00262262|DRUG|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
48297239|NCT04921722|DRUG|Percutaneous sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
48297240|NCT04921722|DRUG|Oral sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
48297241|NCT01008930|PROCEDURE|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
48297242|NCT00005398|OTHER|There is no intervention|No applicable
47947047|NCT05703672|OTHER|Electronic cigarette|Nicotine salt pod based e-cigarette in 5% nicotine
47947048|NCT01695148|DIETARY_SUPPLEMENT|β-Carotene Biofortified Maize Flour|
47947049|NCT01695148|DIETARY_SUPPLEMENT|White Maize Flour|
47947050|NCT00796185|DRUG|Paliperidone ER|
47947051|NCT05529927|DRUG|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
47947052|NCT05529927|DRUG|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
47947053|NCT03469570|DEVICE|EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature|Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
47947054|NCT06449417|BEHAVIORAL|Experimental Aurora Training|Patients will be asked to record their physical activity in the logbook every week, at the end of the intervention, each patient will have to dedicate a letter to another patient who will receive the same Aurora Kit.
47947055|NCT06487078|DRUG|Lorlatinib|ALK-positive NSCL treatment
47947056|NCT05218239|BEHAVIORAL|Active Comparator: Routine education group|Behavior guidance on pelvic floor muscle function training , including Knack method education , and Kegel exercise and other pelvic floor muscle training methods were taught to postpartum women.
47947057|NCT05218239|BEHAVIORAL|Experimental: Global training group|Global training was added on the basis of control group. The 30min-training plan is divided into 9 sections, of which, groups 1 to 8, each group takes about 3 minutes, the ninth group is cool down section, including stretching for 5 minutes and foam axis stretching for 1 minute.
47947058|NCT01442038|DRUG|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
47947059|NCT01442038|DRUG|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
47947060|NCT06680505|DRUG|YZJ-1139 10mg|YZJ-1139 10mg tablets
47947061|NCT06680505|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets
47947062|NCT06680505|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets
47947063|NCT06680505|DRUG|YZJ-1139 60mg|YZJ-1139 60mg tablets
47947064|NCT06680505|DRUG|Placebo|Match placebo tablets
47947065|NCT03805607|DRUG|Ketorolac Tromethamine 30 MG/ML|Ketorolac 30 mg
47947066|NCT03805607|DRUG|Placebos|Normal Saline
47947067|NCT05034432|PROCEDURE|Intra-Op Prophylactic VT ablation|For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping
47947068|NCT05034432|OTHER|Conventional Management|To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
47947069|NCT01088737|DRUG|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
47947070|NCT03469050|DRUG|Rifaximin delayed released 400mg Tablet|Rifaximin delayed released
47947071|NCT03469050|OTHER|Placebo|Placebo BID + Placebo BID
47947072|NCT03183011|OTHER|MRI|Cardiac MRI
47947073|NCT00673946|OTHER|True saturation values displayed|Physicians will be presented with real saturations.
47947074|NCT00673946|OTHER|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
47947075|NCT04589325|DRUG|Ixekizumab|"Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
47947076|NCT04589325|DRUG|Placebo|"Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
47947077|NCT05584371|DIETARY_SUPPLEMENT|Free Beta-hydroxybutyrate|Participants will be asked to ingest 10 grams of beta-hydroxybutyrate, diluted in water and sweetened with Stevia, every morning between 9:00 and 11:00 for four weeks.
48104272|NCT03008018|DRUG|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
48104273|NCT00324038|DRUG|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
48635830|NCT02953964|OTHER|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
47947078|NCT04170842|OTHER|Music intervention|Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
47947079|NCT06515977|PROCEDURE|TXI (Group A)|Patients in Group A will undergo colonoscopy with TXI.
47947080|NCT06515977|PROCEDURE|TXI followed by WLI (Group B)|Patients in group B will first undergo colonoscopy with TXI and every polyp found should be removed. Then switch to WLI for a second withdrawal to detect lesions that were not observed the first time.
47947081|NCT06515977|PROCEDURE|WLI (Group C)|Patients in Group C will undergo colonoscopy with WLI.
47947082|NCT06515977|PROCEDURE|WLI followed by TXI (Group D)|Patients in group D will first undergo colonoscopy with WLI and every polyp found should be removed. Then switch to TXI for a second withdrawal to detect lesions that were not observed the first time.
47947083|NCT00718302|DEVICE|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
47947084|NCT00718302|DEVICE|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
47947085|NCT03652376|DRUG|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
47947086|NCT02753933|OTHER|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
47947087|NCT02753933|OTHER|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
47947088|NCT01340547|DRUG|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
48104274|NCT00324038|DRUG|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
47947089|NCT01340547|DRUG|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
47947090|NCT04718961|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
47947091|NCT04718961|DRUG|Placebo|Capsules matched to study drug minus active substance.
48297243|NCT05197868|PROCEDURE|Intubation with traditional laryngoscope|Participants will be invited to intubate the mannequin with a traditional laryngoscope
47947092|NCT04488939|DEVICE|Restylane® Skinboosters™ Vital (SBV)|Hyaluronic acid
47947093|NCT05589272|OTHER|Active tDCS|cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
47947094|NCT05589272|OTHER|Sham tDCS|cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
47947095|NCT02604056|BEHAVIORAL|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
47947096|NCT02604056|BEHAVIORAL|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
48104275|NCT04173572|BEHAVIORAL|PACE-Life|PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.
48104276|NCT04173572|BEHAVIORAL|Exercise Intervention|Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
48104277|NCT06258980|DRUG|Proph7|Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females
48297244|NCT05197868|PROCEDURE|Intubation with a straight blade video laryngoscope|Intubation with a straight blade video laryngoscope
48297245|NCT05197868|PROCEDURE|Intubation with a hyper-angulated video laryngoscope|Participants will be asked to intubate the mannequin with a hyper-angulated video laryngoscope
48297246|NCT00906256|DRUG|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
48297247|NCT00906256|DRUG|Placebo|Placebo
48635831|NCT02953964|OTHER|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
48635832|NCT02953964|OTHER|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
47947097|NCT05955053|OTHER|Midwifery care applied in line with Midwife-Pregnant cooperation|Pregnant women who apply to the obstetrics clinic will be informed about the research by the doctor and the pregnant woman whose labor has started will be sent to the delivery room. The researcher will be welcomed by the midwife from the first time the pregnant woman arrives in labor (delivery room), and firstly she will be informed about the purpose of the research and an informative consent form and a pregnant identification form will be filled in that she agrees to participate in the research. During labor and labor, the research midwife (HYY) will be with a pregnant woman until she gives birth and care will be given according to the items in the midwifery care checklist prepared based on the partnership model. After giving birth to a pregnant woman and applying the scales, another pregnant woman will be transferred and care will be given in the same way according to the midwifery care model checklist.
47947098|NCT02103218|BEHAVIORAL|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
47947099|NCT02103218|BEHAVIORAL|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
47947100|NCT00982124|DRUG|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
47947101|NCT05635669|DEVICE|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
47947102|NCT05635669|DEVICE|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
48104278|NCT04760119|PROCEDURE|Vein bypass surgery first strategy|Vein bypass will be performed with standart anaesthetic and surgical techniques using reversed great saphenous vein conduit. Location of proximal and distal anastomosis will be recorded. Post surgery completion angiography imaging will be performed.
48104279|NCT04760119|PROCEDURE|Endovascular treatment first (drug coated balloon angioplasty) strategy|Endovascular treatment using drug-coated balloons will be performed under local anaesthetic via common femoral artery. Final angiography imaging will be demonstrated.
48104280|NCT02960139|DEVICE|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
48104281|NCT04261855|DRUG|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
48104282|NCT04261855|RADIATION|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
47947103|NCT05635669|DEVICE|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
47947104|NCT05610514|OTHER|E-Cigarette|Altering the availability of e-cigarettes
48104283|NCT04261855|RADIATION|Lutetium-177 (177Lu)-DOTATATE|Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart
48104284|NCT02787369|DRUG|ACY-1215|
48104285|NCT02787369|DRUG|Ibrutinib|
48104286|NCT02787369|DRUG|Idelalisib|
48104287|NCT02488252|DRUG|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
48104288|NCT02488252|DRUG|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
48104289|NCT01467700|DRUG|Ramelteon SL|Ramelteon SL tablets
48104290|NCT01467700|DRUG|Placebo|Ramelteon placebo-matching tablets
48104291|NCT06479733|PROCEDURE|buccal pedicle flap|For the first group (buccal pedicle flap group), outlining the full-thickness palatal flap 1 mm greater than the diameter of the underlying cover screw will be done, making a partial incision at the hinge portion of the created mini-pedicle flap to facilitate buccal rolling, de-epithelializing the mini-pedicle flap, then two small vertical incisions will be performed similarly mesial and distal to the screw border as wide as possible preserving the papilla and extending labially to include all the keratinized mucosa, elevating a full-thickness flap, then rolling of the pedicle flap into the created buccal pouch. The flap will be then sutured all around in place using a 5/0 vicryl suture
48104292|NCT06479733|PROCEDURE|connective tissue graft|For the second group (free CTG group), masticatory mucosa on the palate between palatal raphae and maxillary posterior teeth is the most common location for the donor site for free CTG. It will be obtained by harvesting and de-epithelializing FGG asbeing a CTG derived from de-epithelialization of FGG mainly composed of lamina propria. Then the donor site will be covered by gel foam , sutured and protected.
48635833|NCT04289272|BEHAVIORAL|Dove Confident Me|Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
48104293|NCT06479733|PROCEDURE|acellular dermal matrix|"* For the third group (ADM group) , The matrix will be trimmed so that it is gently adapted to the artificial envelope created on the buccal aspect of the ridge.The matrix will be trimmed and beveled to make its adaptation into the artificial envelope easier. Before placement, matrix will be hydrated for 10 minutes in fresh human blood collected after flap elevation in each patient.~* For both second and third groups, graft will be carefully positioned under the buccal pouch, sutured to it, light pressure will be applied over the inserted graft with moist gauze for 10 minutes to minimize blood clot and dead space formation between the graft and the underlying bone."
48104294|NCT06479733|PROCEDURE|control group|only placement of dental implant without soft tissue augmentation
48104295|NCT01070251|BEHAVIORAL|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
48635834|NCT06212739|PROCEDURE|Laser|Diode laser used to effect closure of the anal fistula tract
48635835|NCT06212739|PROCEDURE|LIFT|The intersphincteric portion of the fistula is excised and ligated.
48635836|NCT05151965|PROCEDURE|Bankart Repair and Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
47947105|NCT05610514|BEHAVIORAL|Financial Incentives|Altering the availability of financial incentives for abstaining from combustible cigarettes
47947106|NCT04554173|PROCEDURE|surgical resection neurogenic tumors|Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
47947107|NCT03845543|DEVICE|Luminor-14 Paclitaxel eluting balloon|Patients will be treated with the Luminor-14 paclitaxel eluting balloon
48635837|NCT05151965|PROCEDURE|Latarjet Coracoid Transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
48635838|NCT04169412|DIAGNOSTIC_TEST|Blood Collection|Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
48635839|NCT06404554|OTHER|without any intervention|without any intervention
47947108|NCT00496509|DRUG|ZD6474 (Zactima) 100mg|
47947109|NCT00496509|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
47947110|NCT00496509|PROCEDURE|Biomarker Draws|
48477492|NCT03659084|DRUG|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
47947111|NCT00496509|DRUG|ZD6474 (Zactima) 300mg|
47947112|NCT06391385|PROCEDURE|protective ileostomy|Preparation of the bowel was performed before surgery with the administration of intravenous perioperative antibiotic prophylaxis. The surgical procedure was performed by laparotomy, with resection of the rectum and mesorectum (TME) up to the level of the pelvic diaphragm, sparing the autonomic nerves. End-to-end anastomosis was performed either with a stapler or by hand-sewn.
47947113|NCT05263596|DIAGNOSTIC_TEST|dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound|"Results from the routine geriatric assessment:~* Mini Mental State Exam (MMSE)~* Clock-drawing test (CDT)~* Geriatric depression scale (GDS)~* Functional independence measure (FIM) at admission~* Timed up and go Test (TUG)~* Gait speed~* Hand grip strength (HGS)~* Nutritional risk screening (NRS)~Additional measurements:~* Chair-stand-test~* Clinical frailty scale (CFS)~* Calf circumference and mid-arm circumference~* Body impedance analysis (BIA)~* US~* DXA"
47947114|NCT00752024|DEVICE|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
47947115|NCT00752024|DRUG|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
48104296|NCT01070251|BEHAVIORAL|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
47947116|NCT02143700|OTHER|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
48104297|NCT00088673|DRUG|3APS|
48104298|NCT01377623|DRUG|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
48297248|NCT05563532|BEHAVIORAL|dental anxiety and oral hygiene|Evaluation of the effect of mothers' dental anxiety and oral hygiene on children's dental anxiety and periodontal status.
48297249|NCT00282165|DRUG|naratriptan|four weeks double blind experimental treatment using oral naratriptan
48297250|NCT00282165|DRUG|placebo|four weeks double blind placebo treatment
48297251|NCT05743543|OTHER|Sphenopalatine ganglion block|The block is performed with a nasoscope and the administration of a local anesthetic.
48297252|NCT02239094|DRUG|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
48477493|NCT01253928|DRUG|Pioglitazone|45mg qd for 4 months
48477494|NCT05734209|BEHAVIORAL|Virtual food|Virtual food eaten using immersive virtual reality equipment
48477495|NCT05734209|BEHAVIORAL|Real food|Real food eaten using regular utensils
48477496|NCT06021054|DRUG|Veligrotug (VRDN-001)|Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor
48477497|NCT06021054|DRUG|Placebo|5 IV infusions of placebo
48635840|NCT02241915|PROCEDURE|Open Colorectal Surgery|
48635841|NCT02241915|PROCEDURE|Laparoscopic Surgery|
48297253|NCT05760937|DRUG|BMS-986447|Specified dose on specified days
48297254|NCT05760937|DRUG|Placebo|Specified dose on specified days
48297255|NCT03855917|DRUG|Sofosbuvir 400mg [Sovaldi]|Four weeks.
48297256|NCT03855917|DRUG|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
48297257|NCT04860713|DRUG|aspirin and ketamine|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
48477498|NCT01736787|DIETARY_SUPPLEMENT|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
48477499|NCT01736787|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
48635842|NCT00051142|DRUG|Travoprost|
48635843|NCT00051142|DRUG|Latanoprost|
48635844|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
48635845|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
48297258|NCT04860713|DRUG|Nurtec (Rimegepant)|Drug: 75 mg of ODT
48297259|NCT02807116|DRUG|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
47947117|NCT04796571|BEHAVIORAL|Proactive Symptom Monitoring and Care Coordination|Patients randomized to the intervention arm were assigned an IBD-focused care coordinator who facilitated a symptom-based monitoring algorithm and supported patient navigation to complement usual care. Symptom monitoring was facilitated through regular push notifications to participants to complete a validated PRO instrument through the Epic EMR patient portal or telephone. These notifications were scheduled on a monthly basis. The IBD-focused care coordinator made two attempts to reach each participant using portal messaging, followed by a phone call to reduce non-response. PRO questionnaires were reviewed by the care coordinator and out of range scores triggered algorithm-based recommendations to the IBD specialist including stricter monitoring of disease activity, behavioral and medication adherence counseling, facilitation of expedited follow-up with treating providers, and referrals to social work, mental health, and gastroenterology-specific behavioral health services.
47947118|NCT06039488|BEHAVIORAL|Exercise|"A combination of resistance exercise and cardiovascular exercise (performed 2 days per week for 8-weeks) is tailored to each individual in accordance with their medical/cancer-related history, baseline assessments of physical function, and overall goals.~Resistance exercise includes 6-8 exercises targeting major muscle groups. The first week of the program is used to familiarize participants to the exercises of the program, provide coaching on safe and appropriate technique, and identifying initial load for 2 sets of 12 repetitions (equivalent to \~65% 1 repetition maximum), with a goal of working towards 4 sets of 8 reps. Additionally, participants are asked to perform 20-30 minutes of moderate-to-vigorous aerobic activity (approximately 60-85% age-predicted heart rate maximum) via walking, jogging, or cycling each session."
47947119|NCT04422743|DIETARY_SUPPLEMENT|Citicoline 500 mg plus Homotaurine 50 mg|Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
47947120|NCT00993161|DEVICE|Motriplate|Number of contact couples
47947121|NCT00993161|DEVICE|Motriplate|Number of contact couples
47947122|NCT06025643|OTHER|TENS - Cervical stimulation group|TENS will be applied bilaterally through self-adhesive electrodes in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes.
47947123|NCT06025643|OTHER|TENS - Plus cervical stimulation group|TENS will be applied bilaterally in the cervicothoracic ganglionic region, located between the C7 and T4 vertebral processes, on the earlobe, on the wrists and ankles simultaneously.
47947124|NCT06025643|OTHER|TENS - Renal stimulation group|TENS will be applied through self-adhesive electrodes in the abdomen (anatomical region corresponding to the kidneys) and dorsal region at the level of the 10th thoracic vertebra.
47947125|NCT00892918|DRUG|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
47947126|NCT03445520|BEHAVIORAL|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
47947127|NCT06382831|DRUG|Dexmedetomidine|Opioid free anesthesia
47947128|NCT06382831|DRUG|Fentanyl|Control given Opioid balanced anesthesia
47947129|NCT03267303|DRUG|TS-091 5mg|Orally taken once daily for 3 weeks
47947130|NCT03267303|DRUG|TS-091 10mg|Orally taken once daily for 3 weeks
47947131|NCT03267303|DRUG|Placebo|Orally taken once daily for 3 weeks
47947132|NCT04706910|DRUG|18F-DOPA|All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
48297260|NCT02807116|DRUG|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
48477500|NCT05498493|BEHAVIORAL|Cognitive Rehabilitation|The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
47947133|NCT04706910|DRUG|Furosemide Injection|Some participants will receive an intravenous injection of furosemide (40mg, single dose)
47947134|NCT00036296|DRUG|talampanel|75mg per day divided into 3 doses for 22 days
47947135|NCT01231347|DRUG|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
47947136|NCT01231347|DRUG|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
47947137|NCT01231347|DRUG|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
47947138|NCT01231347|DRUG|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
47947139|NCT00894023|DRUG|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
47947140|NCT00894023|DRUG|IV abciximab|IV abciximab + infusion
47947141|NCT05733390|DRUG|JZP541|Oral suspension
47947142|NCT05733390|OTHER|Placebo|Oral suspension
47947143|NCT00743899|PROCEDURE|The aggressive group|Stents were implanted in lesions with diameter stenosis \>50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis \>50% and RD ≥2.0 mm and \<2.25 mm.
47947144|NCT00743899|PROCEDURE|The conservative group|Stenting was performed only in lesions with diameter stenosis \>70% and reference diameter (RD) ≥2.25 mm
48297261|NCT02807116|DRUG|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
48297262|NCT06554366|DEVICE|GentleWave|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the GentleWave procedure will be performed
47947145|NCT06482749|DEVICE|Repetitive transcranial magnetic stimulation|"Repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
47947146|NCT06482749|DEVICE|Sham stimulation|"Sham repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped sham coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
47947147|NCT05936281|DRUG|Genakumab for injection|150 mg/1ml/bottle
47947148|NCT05936281|DRUG|Etoricorxib|60mg/table
47947149|NCT04433533|DRUG|Rosuvastatin 20|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
47947150|NCT04433533|DRUG|Rosuvamibe 10/10|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
47947153|NCT05136131|PROCEDURE|Electrical cardioversion|"Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion."
47947154|NCT05136131|OTHER|Sham electrical cardioversion|No shock is delivered in the sham procedure arm.
47947155|NCT05464173|DRUG|Chidamide|10-30mg biw
47947156|NCT05464173|DRUG|Abemaciclib|150mg or 100mg bid
47947157|NCT05464173|DRUG|endocrinotherapy（doctor's choice）|According to the drug insert
48104299|NCT01377623|DRUG|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
48104300|NCT00016913|DRUG|carboplatin|AUC=6 week one of each 4 week cycle
48104301|NCT00016913|DRUG|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
48477501|NCT05498493|BEHAVIORAL|Brain Health Education Program|The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
48477502|NCT00841152|DEVICE|Bioactive glass|Surgical implantation
47947158|NCT04763928|DRUG|Venetoclax+Decitabine|"Patients will receive treatment with a combination of decitabine and venetoclax as follows:~* Decitabine 20 mg/sqm intravenously on days 1 to 5 of 28-days courses~* Venetoclax 400 mg per day orally on days 1 to 28 of 28-days courses; a dose escalation period is provided at first cycle (ramp-up) in which VEN is administered as follows: 100 mg on day -2, 200 mg on day -1, and 400 mg on day 1, a dose that is continued subsequently, daily, for 28-day cycles.~In case of achievement of response, the treatment will be continued until disease progression or death by other causes."
47947159|NCT01945112|DEVICE|Paper Tape|Applied to blister prone areas of the foot
47947160|NCT05005078|DRUG|WST-057|WST-057 topical solution
47947161|NCT05005078|DRUG|Placebo|WST-057 Matching placebo
47947162|NCT05040399|OTHER|Locking Compression Plates|Plates and screws for sternal fixation
48104302|NCT00016913|DRUG|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
47947163|NCT05040399|OTHER|Sternal Wires|sternal wires used for fixation of sternum
48104303|NCT00016913|RADIATION|radiation therapy|77.4 Gy in 1.8 Gy fractions
48477503|NCT00841152|DEVICE|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
48477504|NCT00841152|PROCEDURE|Autograft|Surgical transplantation from iliac crest
48477505|NCT00841152|PROCEDURE|Allograft (frozen femoral head)|Surgical transplantation
48477506|NCT06433206|OTHER|no intervention|no intervention
48477507|NCT03253094|DRUG|Fluconazole|Oral Antifungal comparator
47947164|NCT01199328|DRUG|Aspirin|81mg Tablet oral, once daily
48104304|NCT00016913|DRUG|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
48104305|NCT00138606|DRUG|vildagliptin|
48104306|NCT00197236|BIOLOGICAL|Havrix™|2 intramuscular injections, 6 months apart
48104307|NCT00197236|BIOLOGICAL|Infanrix™|1 intramuscular injection
48104308|NCT00197236|BIOLOGICAL|ActHIB™|1 intramuscular injection
48104309|NCT00215306|DEVICE|CHARITÉ Artificial Disc|
48104310|NCT00215306|DEVICE|Anterior Interbody Fusion with BAK Cage|
47947165|NCT01199328|DRUG|Esomeprazole|20 mg Tablet oral, once daily
48297263|NCT06554366|DEVICE|EdgePro laser irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the EdgePro procedure will be performed
47947166|NCT05936125|OTHER|Annuloplasty Using Flexible Band|Tricuspid valve annuloplasty using a flexible band; (Polyethylene terephthalate band): (Dacron band)
48297264|NCT06554366|DEVICE|Irrisafe passive ultrasonic irrigation|Root canals will be shaped using a Vortex Blue and ProTaper gold rotary system. Once the root canals have been shaped, the passive ultrasonic irrigation procedure will be performed
47947167|NCT02643290|DEVICE|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
47947168|NCT01914731|DRUG|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
47947169|NCT00903318|BEHAVIORAL|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
47947170|NCT03509831|DRUG|INT-2150|"1. Period: INT-2150~2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"
47947171|NCT03509831|DRUG|Irsogladine maleate 2 mg+Nizatidine 150 mg|"1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~2. Period: INT-2150"
47947172|NCT05391529|BEHAVIORAL|Interview|Semi structured patient interview via telephone
47947173|NCT05692167|DRUG|Topical dexmedetomidine|Patients will receive mixture of one milliliter of dexmedetomidine-HCl and local anesthetic
47947174|NCT05692167|DRUG|Reginal dexmedetomidine|Patients will receive mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) in peribulbar block
47947175|NCT04214873|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of POH
47947176|NCT00004920|DRUG|cisplatin|
47947177|NCT00004920|DRUG|raltitrexed|
48297265|NCT00909090|DIETARY_SUPPLEMENT|12 mg Lutein + Zeaxanthin|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
48297266|NCT00909090|DIETARY_SUPPLEMENT|Visually identical placebo|Visually identical placebo, taken once daily for one year
48297267|NCT01588301|BEHAVIORAL|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
48297268|NCT01588301|BEHAVIORAL|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
48297269|NCT05161962|COMBINATION_PRODUCT|One group received standard oral care.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
48297270|NCT05161962|COMBINATION_PRODUCT|It was applied to the other group by aspiration.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
48477508|NCT03253094|DRUG|SCY-078|Investigational Antifungal
47947178|NCT05991349|DRUG|IBI129|Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
47947179|NCT02835131|DRUG|Pasireotide|
47947180|NCT01076231|RADIATION|proton beam radiation therapy|
47947181|NCT01076231|DRUG|cisplatin|Given IV
47947182|NCT01076231|DRUG|etoposide|Given IV
47947183|NCT01076231|PROCEDURE|therapeutic conventional surgery|
47947184|NCT03953417|DEVICE|Accelerated intermittent theta-burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left DLPFC using the MagPRo stimulator."
47947185|NCT03956134|DRUG|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
47947186|NCT03956134|DRUG|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
47947187|NCT03956134|DRUG|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
47947188|NCT05355610|DRUG|Gentamicin|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
47947189|NCT05355610|DRUG|Dexamethasone|Intratympanic gentamicin and dexamethasone administered in two doses one week apart
47947190|NCT05400824|DIAGNOSTIC_TEST|Blood, DNA, feces, urine, hair and skin microbiota collection|See above
47947191|NCT00620347|DRUG|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
47947192|NCT06450080|OTHER|MRI and MRS acquisitions|All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
47947193|NCT00544999|DRUG|cytarabine|
48104312|NCT03244787|BEHAVIORAL|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
47947194|NCT00544999|DRUG|daunorubicin hydrochloride|
47947195|NCT00544999|DRUG|everolimus|
47947196|NCT00544999|OTHER|laboratory biomarker analysis|
48104313|NCT03178994|DRUG|2% ketoconazole cream|2% ketoconazole cream applies twice daily
47947197|NCT00544999|OTHER|pharmacological study|
47947198|NCT00658580|DRUG|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
47947199|NCT00658580|DRUG|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
47947200|NCT02634749|OTHER|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
47947201|NCT02634749|OTHER|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
47947202|NCT02634749|OTHER|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
47947203|NCT05420675|OTHER|Single Leg Squat|After initial data collection (Demographic data, Inclusion criteria), surface electromyography EMG assessments will be obtained from 1 muscle ( Vastus Medialis). EMG evaluation will be done in different arm positions during the single leg squat. These records will be taken in 4 different situations: 1) Arms free, 2) Arms flexed to 90 degrees, 3) Hands on hips, 4) Arms across the chest.
48297271|NCT05283538|DIAGNOSTIC_TEST|Coronary Artery Calcification Realization|Coronary Artery Calcification Realization
48297272|NCT04211324|DEVICE|TENS|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
48297273|NCT04211324|DEVICE|electro-acupuncture|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
48297274|NCT00112138|DRUG|gabapentin|
48297275|NCT00002221|DRUG|Peripheral blood stem cells|
48297276|NCT00193362|DRUG|Paclitaxel|
48297277|NCT00193362|DRUG|Carboplatin|
48297278|NCT00193362|DRUG|Gemcitabine|
48297279|NCT00193362|DRUG|Vinorelbine|
48297280|NCT05113823|PROCEDURE|Simulation Training|Simulation Training using High and Low Fidelity Simulator
48635846|NCT01560130|BEHAVIORAL|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
48635847|NCT01029197|BEHAVIORAL|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
48635848|NCT01029197|OTHER|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
48635849|NCT06249477|DEVICE|Wrist activity tracker and scale|Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.
47947204|NCT04578808|OTHER|Unruptured intracranial aneurysms|UIA of bifurcation between 3 and 7 mm for whom a clinical and imaging follow-up without occlusion treatment was scheduled by local multidisciplinary staff will be included. Extensive clinical, biological and imaging data will be recorded during a 3 years follow-up (visits at 1 and 3 years after inclusion).
47947205|NCT03995836|DEVICE|CPAP|Decision of CPAP treatment is according to clinical guidelines
47947206|NCT03995836|PROCEDURE|Bariatric Surgery|All patients.
47947207|NCT00643396|RADIATION|thoracic radiotherapy|
47947208|NCT06265051|DRUG|Tirofiban|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
48297281|NCT05233267|OTHER|Blood sample|Dosage of neopterin
48297282|NCT05477966|OTHER|Medical records review|The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.
47947209|NCT06265051|DRUG|Saline placebo|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
47947210|NCT03075046|DEVICE|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
48104314|NCT03178994|DRUG|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
48104315|NCT00269399|DRUG|Rifaximin (Xifaxan)|
48104316|NCT00269399|DRUG|Vancomycin|
48104317|NCT03533556|DIETARY_SUPPLEMENT|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
48104318|NCT03533556|DIETARY_SUPPLEMENT|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
48297283|NCT05938881|PROCEDURE|self-cut mesh procedure|transvaginal mesh procedure using self-cut mesh
48297284|NCT05938881|PROCEDURE|mesh-kit procedure|transvaginal mesh procedure using mesh-kit
48297285|NCT05930873|BEHAVIORAL|Immersive room|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented on one of the four walls of the immersive room and a set of stimuli, including the target stimulus, which the subject will have to touch within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
48635850|NCT06249477|BEHAVIORAL|Nutritional Coaching group sessions|Nutritional coaching group sessions held via zoom and performed by a certified clinical nutritionist regarding nutrition, and physical activity specific for weight loss.
48104319|NCT03533556|DIETARY_SUPPLEMENT|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
48104320|NCT03533556|OTHER|Placebo|Oral administration of 100 ml of water
48297286|NCT05930873|BEHAVIORAL|stimuli in a paper format|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented in a paper format and a set of stimuli, including the target stimulus, which the subject will have to indicate within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
48297287|NCT02345369|DEVICE|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
48297288|NCT02345369|DEVICE|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
47947211|NCT03075046|OTHER|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
48297289|NCT01051388|DRUG|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
48297290|NCT01051388|DRUG|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
48297291|NCT01051388|DRUG|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
48635851|NCT05224648|DEVICE|TOF scan train of four ratio monitoring|Device : TOF Scan For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
47947212|NCT03959072|DEVICE|Robotic CTO PCI|Randomized to robotic CTO PCI.
47947213|NCT03959072|PROCEDURE|Conventional (Manual) CTO PCI|Randomized to manual CTO PCI.
47947214|NCT05919004|DIAGNOSTIC_TEST|App-based spirometer|App-based spirometer to perform serial spirometry to assess lung function variatione
47947215|NCT01725607|DRUG|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
47947216|NCT01725607|PROCEDURE|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
48104321|NCT02488317|OTHER|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
48297292|NCT06671574|OTHER|Emotional intelligence and Relaxation techniques|In each session, participants will engage in exercises aimed at recognizing, understanding, and regulating their emotions. These interactive activities will foster personal reflection and group discussion, helping individuals identify emotions in various situations and their impact on behavior. This approach will enhance emotional awareness and equip participants with practical tools for managing stress and anxiety. Various relaxation techniques will also be introduced. Deep breathing exercises will teach participants to calm their minds and bodies, reducing tension. Guided meditation will help them focus inward, promoting mental peace and deep relaxation. Additionally, visualization exercises will encourage imagining calming scenarios, alleviating anxiety and improving overall well-being.
48297293|NCT04701255|PROCEDURE|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
48297294|NCT04701255|DEVICE|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
47947217|NCT00532155|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
47947218|NCT00532155|DRUG|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
47947219|NCT00532155|DRUG|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
47947220|NCT00532155|DRUG|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
48104322|NCT03413319|DRUG|ABBV-8E12|Solution for infusion
48104323|NCT05711095|DIETARY_SUPPLEMENT|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
47947221|NCT04357340|OTHER|Pulmonary Physiotherapy Techniques|Participants will receive pulmonary physiotherapy techniques in six session during three days (twice daily). Four distinguished interventions will be provided for the patients: 1) Chest expansion exercises (for prevention and treatment of potential atelectasis); 2) Techniques to Mobilize or loosen the pulmonary secretions (Active cycle breathing, Coughing techniques, Vibration and Postural drainage); 3) Hold breathing exercise (3 sets, 10 repetition) and; 4) Walking training (based on patient's tolerance until 6 minute).
47947222|NCT00598702|DRUG|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
47947223|NCT05428293|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)|Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
48297295|NCT01227915|DRUG|Tobracort|tobramycin 0.3% + dexamethasone 1%
47947224|NCT05428293|DRUG|A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
48297296|NCT01227915|DRUG|Tobradex|tobramycin 0.3% + dexamethasone 1%
48477509|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.
48477510|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
48477511|NCT04768296|DRUG|Topotecan|Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
48477512|NCT04999696|PROCEDURE|radical hysterectomy|To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy
48477513|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
48477514|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
48477515|NCT03645382|DIETARY_SUPPLEMENT|baked barley powder|The baked barley was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The baked barley powder capsule had approximately 900 mg/day, 336 mg of baked barley and 564 mg of nondigestible maltodextrin.
48477516|NCT03645382|DIETARY_SUPPLEMENT|jeju steam onion|The jeju steam onion was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The jeju steam onion capsule had approximately 900 mg/day, 336 mg of jeju steam onion powder and 564 mg of nondigestible maltodextrin.
47947225|NCT05428293|DRUG|A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)|Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
48104324|NCT05711095|DIETARY_SUPPLEMENT|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
48104325|NCT05711095|DIETARY_SUPPLEMENT|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
48104326|NCT03771027|OTHER|The low FODMAP diet.|The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
48297297|NCT04576351|OTHER|Observation|The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
48297298|NCT03225755|DRUG|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
48297299|NCT03078673|OTHER|training intervention, motor skill training|cross country specific motor skill strength training
48297300|NCT03078673|OTHER|training intervention, maximal strength training|general maximal strength training
48297301|NCT03078673|OTHER|control group|regular training
48297302|NCT06119698|BEHAVIORAL|GetActive+|This is a 10-week group mind body program focused on improving self-reported physical activity, performance-based physical activity, and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increase in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
48297303|NCT02813330|OTHER|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
48297304|NCT02813330|OTHER|saline injection|Saline injection in two points of low back pain
48297305|NCT05009472|DEVICE|expander with deferential opening and petit face mask|bonded expander with two screws and vertical hooks for attachment face mask. adjustment face mask with forehead and chin anchorage
48297306|NCT06043323|DRUG|Axicabtagene Ciloleucel|Given by IV (vein)
48297307|NCT06043323|DRUG|Cyclophosphamide|Given by IV (vein)
47947226|NCT05305339|OTHER|Placental and Umbilical cord biopsy|After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
47947227|NCT04549961|OTHER|Nutrition|type and amount of food eaten or type and amount of oral nutritional supplements as well as enteral or parenteral nutrition
47947228|NCT05860933|DRUG|LY3537982|Administered orally.
47947229|NCT05860933|DRUG|Itraconazole|Administered orally.
47947230|NCT05860933|DRUG|Carbamazepine|Administered orally.
47947231|NCT06680726|OTHER|Matching with RWD|A set of clinical and genetic data are matched to generate a RWD cohort for comparison.
47947232|NCT06680726|OTHER|Imaging Mass Cytometry|Protein expression patterns in tumor tissue and tumor microenvironment are analyzed by Imaging Mass Cytometry.
47947233|NCT06680674|OTHER|Routine care for people with diabetes, with or without obesity, in the hospital setting|Routine care for people with diabetes, with or without obesity, in the hospital setting, including routine pharmacological treatment for diabetes and obesity.
47947234|NCT05030324|DRUG|XC221 100 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
47947235|NCT05030324|DRUG|XC221 200 mg|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
47947236|NCT05030324|DRUG|Placebo|Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
47947237|NCT04439266|DRUG|Crizotinib|Given PO
47947238|NCT05084833|BEHAVIORAL|Control|Electronic educational materials
47947239|NCT05084833|BEHAVIORAL|Patient activation|Interactive text messages with links to videos (e.g. colorectal cancer screening options, cost of colorectal cancer screening, perspective from a cancer survivor, why regular appointments are important for cancer survivors) and resources (e.g. helpful websites) are sent to participants
47947240|NCT05084833|BEHAVIORAL|Primary care provider activation|Faxed educational materials (e.g. current colorectal cancer screening recommendations, frequently asked questions, insurance letter template, cover letter with overview of patient's cancer treatment history) sent to primary care providers
47947241|NCT02760576|DRUG|BAY 987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
47947242|NCT05600426|DRUG|cyclosporine|cyclosporine
47947243|NCT05600426|PROCEDURE|Matched Unrelated Donor Hematopoetic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
47947244|NCT05600426|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
47947245|NCT05600426|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
47947246|NCT05600426|DRUG|Methotrexate|methotrexate
47947247|NCT05600426|DRUG|Fludarabine|fludarabine
47947248|NCT05600426|DRUG|Cyclophosphamide|cyclophosphamide
48477517|NCT01456429|PROCEDURE|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
47947249|NCT05600426|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
47947250|NCT05600426|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
47947251|NCT04434066|PROCEDURE|Total Laparoscopic Hysterectomy|Participants will be randomized into either abdominal or vaginal morcellation at time of total laparoscopic hysterectomy
47947252|NCT05047913|DRUG|18F-FTX|Given By IV
47947253|NCT06278207|DRUG|Finerenone (BAY 94-8862)|10 mg or 20 mg daily
48104327|NCT03771027|OTHER|The diet based on NICE guidelines.|The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
48104328|NCT03114020|DRUG|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
48104329|NCT03114020|DRUG|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
48635852|NCT05224648|DEVICE|ITF device tetanus stimulation monitoring|Device ITF For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand. Once 4 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 40 µg/kg neostigmine will be injected. Train of four ratio (delivered every minute) will be recorded. This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 6 times. For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 30 minutes after neostigmine administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover.
48635853|NCT06051292|OTHER|Fast method|Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
47947254|NCT06247423|DEVICE|Active group 10kHz|"For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 10 kHz will be applied for 20 minutes. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the motor threshold. One electrode will be placed over the median and radial nerves, while the other over the radial nerve.~The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol had been used in previous studies conducted by our research group."
47947255|NCT06247423|DEVICE|Sham intervention|"Sham electrical stimulation will be performed with the same equipment, time, and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) will be reached and after that, the intensity will be reduced to 0 milliamperes (mA) with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants."
47947256|NCT05964205|OTHER|Electronic clinical decision support tool|Electronic clinical decision support tool
47947257|NCT05957978|DRUG|LXE408|Film-coated tablets
47947258|NCT05957978|DRUG|sodium stibogluconate|Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.
48635854|NCT06051292|OTHER|Conventional method|Conventional catheter volume titration will be applied and optimal filling volume will be determined according to the measurements
48635855|NCT00370604|DEVICE|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
48635856|NCT00370604|DEVICE|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
48635857|NCT00601016|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
48635858|NCT02326688|OTHER|Kinematic analysis of trunk compensation|
48635859|NCT04280861|OTHER|Multicomponent Intervention|Multicomponent intervention conducted by and expert psychologist that target different aspects of the caregiving experience (affective responses, communication skills, burden experience, social support and loneliness, cognitive performance, the practice of mindfulness and health-related behaviours). The number of sessions will be 8, 1 session of 90 minutes a week, and the number of participants will be 12-14 per group. In some sessions other collaborators will be invited to participate (social workers, physiotherapist).
48635860|NCT03702374|DRUG|Combined antioxidant therapy|It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
48635861|NCT03702374|OTHER|Placebo|It consists in a capsule with 100mg of magnesium oxide.
48635862|NCT05232305|DIETARY_SUPPLEMENT|Pomegranate Peel|Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
47947259|NCT05957978|DRUG|Paromomycin|Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.
47947260|NCT00051389|DRUG|Fosinopril|
47947261|NCT05626582|PROCEDURE|pain delivery - learning only|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin just during the Day 1 learning period.
48635863|NCT00185055|DRUG|Olmesartan medoxomil|
48297308|NCT06043323|DRUG|Fludarabine phosphate|Given by IV (vein)
48297309|NCT06043323|DRUG|Prednisone|Given by IV (vein)
48635864|NCT00185055|DRUG|Irbesartan|
48635865|NCT00185055|DRUG|Valsartan|
48635866|NCT02531711|OTHER|Diet A|Experimental analgesic dietary intervention
48635867|NCT02531711|OTHER|Diet B|Healthy comparator diet
48635868|NCT02874131|BEHAVIORAL|Behavioral Activation|Behavioral activation
48635869|NCT02874131|BEHAVIORAL|Cognitive Processing Therapy|Cognitive processing therapy
48635870|NCT05414942|BEHAVIORAL|Opioid Reduction Program|Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
47947262|NCT05626582|PROCEDURE|pain delivery - learning and retention|Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful. Applied to skin during the Day 1 learning period and again during the Day 2 retention period.
47947263|NCT02080637|DRUG|Ambrisentan|Once daily oral dosing
47947264|NCT02080637|OTHER|Placebo|
47947265|NCT02475031|DEVICE|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
47947266|NCT02475031|DRUG|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
47947267|NCT03835910|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
48635871|NCT03318419|DRUG|Cladribine|5mg/㎡ d1-5
48635872|NCT03318419|DRUG|G-CSF|300ug d0-14
48635873|NCT03318419|DRUG|Cytarabine|10mg/㎡ q12h SC d1-14
48635874|NCT03318419|DRUG|Pegaspargase|2500U/m2 im d1
48635875|NCT00592527|DRUG|insulin detemir|
48297310|NCT06043323|DRUG|Diphenhydramine|Given by IV (vein)
48635876|NCT01216085|DRUG|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
48635877|NCT01124266|PROCEDURE|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
48104330|NCT04635488|PROCEDURE|lateral lymph node dissection|All participted would receive lateral lymph node dissection for rectal cancer.
48104331|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 1|Each subject will use this product during one of the five treatment periods in the crossover study design.
48297311|NCT06043323|DRUG|Acetaminophen|Given by IV (vein)
48297312|NCT06003751|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
48297313|NCT06003751|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
48297314|NCT06003751|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
48297315|NCT00005029|DRUG|topotecan hydrochloride|
48297316|NCT03731416|PROCEDURE|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
48297317|NCT01805700|OTHER|Caffeine enhanced energy drink|Comparison of different energy drinks
48297318|NCT01805700|OTHER|Glucose drink|Glucose drink (containing 84mg glucose alone)
47947268|NCT03835910|PROCEDURE|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
47947269|NCT03835910|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
47947270|NCT03835910|PROCEDURE|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
47947271|NCT04637113|OTHER|This is a non-interventional study|This is a non-interventional study.
47947272|NCT01933711|DRUG|rituximab|
48104332|NCT06140745|DRUG|1100 ppm NaF Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
48104333|NCT06140745|DRUG|1500 ppm NaMFP Fluoride Dentifrice|Each subject will use this product during one of the five treatment periods in the crossover study design.
48297319|NCT06672445|DRUG|ARO-ATXN2 Injection|single dose of ARO-ATXN2 by intrathecal (IT) administration
48297320|NCT06672445|DRUG|Placebo|calculated volume to match active treatment by IT administration
48635878|NCT01124266|PROCEDURE|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
48635879|NCT03785132|PROCEDURE|Cardiac surgery|The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
48635880|NCT05145439|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
48635881|NCT04314180|DEVICE|Taking slit-lamp images|The participant only needs to take several slit-lamp images as usual.
48635882|NCT02405637|DRUG|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
48635883|NCT02405637|DRUG|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
48635884|NCT05697003|DRUG|Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals|2 inhalations in one study period
48635885|NCT05697003|DRUG|ADVAIR DISKUS 100/50|2 inhalations in one study period
47947273|NCT06668103|DRUG|ABSK043 in combination with Firmonertinib|"Two potential dose levels ：400 mg twice daily （BID） and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD).~Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy.~Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.~After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
47947274|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
47947275|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
47947276|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
47947277|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
47947278|NCT03981952|OTHER|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
47947279|NCT06065423|OTHER|Manuel Lymphatic Drainage(MLD), Exercises|"MLD:It is a unique massage technique that uses specific hand movements to provide a gentle pumping effect on the skin.~Massage movements follow the direction of lymph flow and produce rapid results. The aim of this method is to achieve maximum skin tightening effect with minimum pressure.~Exercise, on the other hand, increases physical performance, improves body composition, and provides an increase in quality of life by providing acute and chronic reductions in fatigue. Both aerobic exercises and strengthening exercises have been found effective on physical performance. It shows that a mixed program consisting of components such as aerobics, strengthening, coordination and stretching can positively affect flexibility, pain and energy expenditure in breast cancer patients."
47947280|NCT00309478|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
47947281|NCT00309478|DRUG|Methotrexate|Methotrexate 40mg/m2
47947282|NCT00309478|DRUG|Fluorouracil implant|Fluorouracil 600mg/m2
47947283|NCT00309478|DRUG|Goserelin|Zoladex 3.6mg/28 days for 3 years
47947284|NCT00309478|DRUG|Tamoxifen|Nolvadex 20mg/day for 5 years
47947285|NCT02857985|DEVICE|3D RA|3D RA is realised just after angioplasty.
47947286|NCT02857985|DEVICE|MRI|MRI is realised between 24h and 96h post angioplasty.
47947287|NCT04112888|COMBINATION_PRODUCT|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
47947288|NCT04112888|PROCEDURE|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
47947289|NCT04743349|PROCEDURE|Steam inhalations|Exposure of airway mucosae to humidified steam through steam inhalation for at least 20 min (4 cycles of 5 min) daily, for 10 days.
48635886|NCT02306785|DRUG|TP05 Coating D|One radio-labelled tablet given to subjects
47947290|NCT00057954|PROCEDURE|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
47947291|NCT00057954|DRUG|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
48297321|NCT02602873|OTHER|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
48297322|NCT00455858|DRUG|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
47947292|NCT00057954|RADIATION|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
47947293|NCT00057954|PROCEDURE|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10\^6 CD34/kg
48297323|NCT05121597|DEVICE|HugeMed Videolaryngoscope|Macintosh laryngoscope
48297324|NCT04652492|DRUG|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
48297325|NCT04367337|OTHER|No intervention|Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
48297326|NCT01149278|DRUG|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
48635887|NCT02306785|DRUG|TP05 Coating E|One radio-labelled tablet given to subjects
48635888|NCT02306785|DRUG|TP05 Coating H|One radio-labelled tablet given to subjects
48635889|NCT04874441|DIAGNOSTIC_TEST|Diagnosis strategy based on C. glabrata / krusei PCR|For diagnosis, a blood cultures and blood tubes for PCR will be collected and patients will be treated with echinocandins in the first instance with an early switch to fluconazole if the C. glabrata / krusei PCR is negative
47947294|NCT00057954|DRUG|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
47947295|NCT00057954|DRUG|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
47947296|NCT00057954|DRUG|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
48635890|NCT03903770|DEVICE|Upper extremity rehabilitation|Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
47947297|NCT02192073|PROCEDURE|Suprapectoral Biceps tenodesis|
47947298|NCT02192073|PROCEDURE|Subpectoral biceps tenodesis|
47947299|NCT02642029|DEVICE|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
47947300|NCT02642029|DEVICE|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
47947301|NCT02642029|DEVICE|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
47947302|NCT00571610|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
48477518|NCT01997684|PROCEDURE|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
48477519|NCT01997684|PROCEDURE|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
48477520|NCT04883424|BEHAVIORAL|Diabetes Education Program Based on Health Belief Model|After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
48635891|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
48635892|NCT03924076|DIETARY_SUPPLEMENT|UHT Milk|125 ml UHT milk given to placebo group
47947303|NCT00992927|PROCEDURE|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
48635893|NCT03080714|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
48635894|NCT03080714|DEVICE|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
48635895|NCT05789069|DRUG|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
48635896|NCT05789069|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
47947304|NCT00992927|PROCEDURE|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
47947305|NCT03234673|DRUG|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
47947306|NCT03234673|DRUG|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
47947307|NCT03234673|DRUG|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
47947308|NCT05008614|PROCEDURE|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
47947309|NCT05008614|PROCEDURE|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
47947310|NCT00535366|DRUG|Tiotropium|Oral inhalation by HandiHaler® device
47947311|NCT00535366|DRUG|Salmeterol|Oral inhalation from Diskus®
47947312|NCT00535366|DRUG|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
48477521|NCT01076556|DRUG|Alvocidib Hydrochloride|Given IV
48477522|NCT01076556|DRUG|Cyclophosphamide|Given IV
47947313|NCT00535366|DRUG|Ciclesonide low|Oral inhalation from MDI
47947314|NCT00535366|DRUG|Ciclesonide high|Oral inhalation from MDI
47947315|NCT00535366|DRUG|Placebo|Oral inhalation from MDI
47947316|NCT04543409|BIOLOGICAL|Benralizumab|Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
47947317|NCT04543409|BIOLOGICAL|Matching placebo|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
47947318|NCT04670055|DRUG|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
48297327|NCT01149278|OTHER|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
48297328|NCT06353971|DRUG|Briquilimab|Subcutaneous Injection
48297329|NCT05552586|DIETARY_SUPPLEMENT|Melatonin|patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
48297330|NCT05552586|OTHER|placebo|patients will receive capsules of the same size and color
48297331|NCT05154214|PROCEDURE|Adenotonsillectomy|Removal of tonsils and adenoids
48297332|NCT05154214|PROCEDURE|Drug-induced sleep endoscopy directed surgery|Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
48297333|NCT05782556|DEVICE|Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
48297334|NCT04833933|OTHER|Phone survey about smoking cessation process since intervention in DISCO trial|We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
47947319|NCT01782833|OTHER|This is Non-interventional study|
48297335|NCT05476692|OTHER|AOFAS score and VAS|Clinical outcome by the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score.
48297336|NCT02091622|OTHER|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
48297337|NCT03710785|BEHAVIORAL|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
48297338|NCT06208709|DEVICE|carpal arch space augmentation (CASA)|A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
48297339|NCT06208709|DEVICE|standard of care (SOC)|A BOA brace that can be adjusted to the arm of the participant.
48635897|NCT05648357|BIOLOGICAL|Fluarix Tetra Vaccine|A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
48635898|NCT00425854|DRUG|BIBW 2992|high dose once daily
48635899|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
48635900|NCT00984633|DRUG|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
48297340|NCT05405543|DRUG|MYK-224|Specified dose on specified days
48297341|NCT05405543|OTHER|Placebo|Specified dose on specified days
48297342|NCT06173752|BEHAVIORAL|Exposure therapy|Participants will complete exposure therapy for up to 12 weeks, and coached exposure session will be approximately 50 minutes.
48477523|NCT01076556|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48635901|NCT00984633|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
48635902|NCT00984633|DRUG|Propofol|4-10 mg/kg/hr maintenance anesthesia
47947320|NCT03115073|DRUG|Candiplus|Administration of Candiplus
47947321|NCT03115073|DRUG|Clotrimazole|Administration of Clotrimazole
47947322|NCT06187337|DEVICE|Maxillary expansion device|The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
47947323|NCT03503136|DRUG|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
47947324|NCT03503136|DRUG|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
47947325|NCT03503136|DRUG|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
47947326|NCT03503136|DRUG|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
47947327|NCT03503136|DRUG|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
47947328|NCT03503136|DRUG|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
47947329|NCT06033612|DRUG|RV299|Oral Suspension
47947330|NCT06033612|DRUG|Placebo|matching placebo
48297343|NCT00590681|DRUG|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
47947331|NCT06033612|DRUG|Midazolam|pre-filled oral syringe
48297344|NCT06671041|DRUG|Preservative Free eye drop|Participants were required to use a lubricating eye drop
48297345|NCT01858428|DEVICE|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
48297346|NCT01858428|DEVICE|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
48297347|NCT04297163|OTHER|Telemedicine|Remote CPAP monitoring, mobile app and voice mail
48297348|NCT04297163|OTHER|In Hospital|Face-to-face follow up
48297349|NCT00785746|OTHER|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
48297350|NCT06477016|DEVICE|OsciPulse|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
48297351|NCT06477016|DEVICE|Intermittent Pneumatic Compression|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
48297352|NCT02768909|DEVICE|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
48297353|NCT02768909|OTHER|Survey & Physical Exam|2. Perform a oriented survey for risk factors and a complete physical exam.
48477524|NCT01076556|OTHER|Pharmacological Study|Correlative studies
48635903|NCT06256874|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
47947332|NCT01724411|OTHER|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
47947333|NCT03793556|DEVICE|GERDOFF® + Omeprazole|GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
48635904|NCT06469775|DEVICE|Low intensity shock wave|6 sessions of low intensity shock wave therapy, applied in 15 minute appointments once weekly.
48635905|NCT06469775|COMBINATION_PRODUCT|Control|Standard of care treatment: phosphodiesterase 5 inhibitor therapy, vacuum erectile device, constriction bands, intracorporal injections, and penile implant.
48635906|NCT04354688|DEVICE|T3 Certain Tapered Implant|Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
47947334|NCT03793556|DRUG|Omeprazole|Omeprazole, 2 capsules 20 mg, once a day before breakfast
47947335|NCT03344354|DEVICE|Biogel|Sterile surgical gloves used during surgical procedures.
47947336|NCT03344354|DEVICE|Ansell|Sterile surgical gloves used during surgical procedures.
47947337|NCT03344354|DEVICE|Cardinal|Sterile surgical gloves used during surgical procedures.
47947338|NCT03344354|DEVICE|Medline|Sterile surgical gloves used during surgical procedures.
47947339|NCT04075110|DRUG|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
47947340|NCT04075110|DRUG|Placebo|Placebo tablet once daily
48297354|NCT02768909|OTHER|Chest X-ray|Perform anteroposterior chest X-ray
48297355|NCT02768909|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
48297356|NCT02768909|DEVICE|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
48297357|NCT02768909|DEVICE|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
48297358|NCT02768909|DEVICE|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
48297359|NCT02768909|DEVICE|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
48297360|NCT02575482|DRUG|SUVN-D4010|
48297361|NCT02575482|DRUG|Placebo|
48477525|NCT01076556|BIOLOGICAL|Rituximab|Given IV
48477526|NCT05646979|BEHAVIORAL|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
48477527|NCT00982631|DRUG|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
48635907|NCT04452370|DRUG|oral etoposide + anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
48635908|NCT06031051|DEVICE|Pillcam Crohn's Capsule Endoscopy|Patients with scheduled colonoscopy are invited to a previous exploration with capsule endoscopy
48635909|NCT04472208|DEVICE|Ambulatory monitoring solution|Subjects participating in this study will be monitored with the site's standard of care primary monitor and the evaluable device as the secondary monitor.
47947341|NCT01924624|DRUG|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
47947342|NCT03397173|DRUG|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
47947343|NCT03397173|DRUG|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
47947344|NCT02908867|OTHER|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
47947345|NCT05806983|OTHER|Technology Based Psychosocial Program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
47947346|NCT00185835|DRUG|ZD-1839|
47947347|NCT00185835|DRUG|Cisplatin|
47947348|NCT04638296|OTHER|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
47947349|NCT00415376|DRUG|levetiracetam|
47947350|NCT00415376|PROCEDURE|quality-of-life assessment|
47947351|NCT00629772|DRUG|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
47947352|NCT00629772|DRUG|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
47947353|NCT00003099|DRUG|Fenretinide|Daily for 14-28 days.
47947354|NCT00003099|DRUG|Tamoxifen Citrate|Daily for 14-28 days.
47947355|NCT00003099|OTHER|Placebo|Daily for 14-28 days
48298891|NCT01312350|DRUG|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
47947356|NCT06212310|OTHER|Telephone genetic counseling|genetic counseling service delivered audio-only
47947357|NCT06229418|OTHER|DFR AED Pilot Program|Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
47947358|NCT04516369|GENETIC|voretigene neparvovec|Voretigene neparvovec is an adeno-associated viral type 2 (AAV2) gene therapy vector driving expression of normal human retinal pigment epithelium 65 kDa protein (hRPE65) gene.
47947359|NCT05410015|OTHER|Normal clinical treatment without intervention|Normal clinical treatment without intervention
47947360|NCT00520832|DEVICE|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
47947361|NCT00520832|DEVICE|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
47947362|NCT04247776|COMBINATION_PRODUCT|Prehab|Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
47947363|NCT04247776|OTHER|ERAS|Enhanced Recovery After Surgery guidelines are applied.
48298892|NCT01312350|DRUG|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
48635910|NCT05461092|DRUG|Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
48635911|NCT05461092|DIAGNOSTIC_TEST|Blood Test|Blood Tests measuring inflammatory markers: IL-10, MCP-1, IL-8, IL-6, TNFa
48635912|NCT05461092|OTHER|3D CAM Delirium Severity Scoring|Questionnaire that will rate each symptom of delirium
48635913|NCT05461092|OTHER|Generalized Anxiety Disorder 7-item (GAD-7) scale|Questionnaire for screening and severity measurement of generalized anxiety disorder.
48635914|NCT05461092|OTHER|Numerical Rating Score (NRS)|Questionnaire assessing pain intensity
48635915|NCT05461092|OTHER|PROMIS-Pain Interference|Questionnaire measuring the effect of pain on patient physical, emotional, and social functioning.
48635916|NCT05461092|OTHER|Oswestry Disability Index (ODI)|Questionnaire assessing disability and quality of life impairment in adults with lower back pain.
48635917|NCT05461092|OTHER|Saint Louis University Mental Status Examination (SLUMs)|Questionnaire assessing baseline cognition.
47947364|NCT04247776|BEHAVIORAL|Fitbit|Fitbit is worn to monitor step counts.
47947365|NCT02752204|DRUG|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
47947366|NCT02752204|DRUG|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
47947367|NCT01820156|DEVICE|Home Respiratory Polygraphy|
47947368|NCT01820156|DEVICE|Standard Polysomnography|
47947369|NCT00725504|DRUG|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
48104334|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 2|Each subject will use this product during one of the five treatment periods in the crossover study design.
48104335|NCT06140745|DRUG|0 ppm Fluoride Dentifrice 3|Each subject will use this product during one of the five treatment periods in the crossover study design.
47947370|NCT03057509|DRUG|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
47947371|NCT03057509|DEVICE|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
47947372|NCT03057509|OTHER|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
47947373|NCT03057509|DRUG|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
47947374|NCT00352443|DRUG|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
47947375|NCT00352443|DRUG|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
47947376|NCT02185755|OTHER|Internet-Based Glucose Monitoring System|
48297362|NCT03896867|DEVICE|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
48297363|NCT03896867|DEVICE|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
48297364|NCT00339079|DRUG|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
48477528|NCT00471991|DRUG|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
48477529|NCT00471991|DRUG|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
48477530|NCT03068949|BIOLOGICAL|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
48477531|NCT03068949|BIOLOGICAL|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
48477532|NCT03068949|BIOLOGICAL|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
48477533|NCT03068949|BIOLOGICAL|Fluzone HD|Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
48477534|NCT03056768|BEHAVIORAL|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
48635918|NCT05461092|OTHER|Delirium Rating Scale-Revised-98 (DRS)|16 item clinician rated scale assessing delirium severity.
48635919|NCT05461092|OTHER|Telephone Interview for Cognitive Status - Modified (TICS-M)|Telephone interview questionnaire evaluating patient cognitive status.
48635920|NCT05461092|OTHER|Opioid Equivalents measured by Morphine Milligram Equivalents (MME)|The amount of opioids administered will be collected through patient self-report
48635921|NCT05461092|OTHER|Patient Health Questionnaire depression scale (PHQ-8)|Questionnaire used to diagnose and determine the severity measure for depressive disorders.
47947377|NCT02185755|DRUG|Normal Medication Positive Control|
47947378|NCT00130676|DRUG|Mifepristone|daily for 7 days
47947379|NCT00130676|DRUG|matching placebo|daily for 7 days
47947380|NCT04152031|OTHER|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
48477535|NCT03056768|BEHAVIORAL|Active control|Health promotion activities provided by local health bureau.
48297365|NCT00339079|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
48297366|NCT00339079|OTHER|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
48297367|NCT00339079|DRUG|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
47947381|NCT05995808|PROCEDURE|Bone marow biopsy and aspiration|Bone marrow biopsy and biopsy aspiration
47947382|NCT05995808|DIAGNOSTIC_TEST|biochemical and heamatological tests|complete blood count ,serum urea and creatinine
47947383|NCT01851915|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
48297368|NCT06671418|PROCEDURE|Primary percutaneous stenting (PPS)|PPS bridging malignant hilar biliary obstruction with self-expandable uncovered metal stents without crossing the ampulla and without leaving an external drain. The procedure is performed by an interventional radiologist who has performed at least 5 PPS procedures.
48297369|NCT06671418|PROCEDURE|Endoscopic biliary drainage|EBD according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines of 2021. The procedure is performed by a gastro-enterologist who is experienced in performing EBD in patients with a MHBO.
48297370|NCT05967195|BEHAVIORAL|Financial Incentive and Text-Messages|"Patient-participants will receive modest financial incentive for attending therapy or medication management appointments combined with text messages to encourage attendance at these appointments. Text messages will be informed by principles of behavioral economics. Maximum incentive = $50/month if all appointments attended. Incentives will be pro-rated by percentage of appointments attended. Pro-rating strategies (e.g., uniform amount per appointment, escalating \[aka, 'back-loaded'\], or decreasing \[aka 'frontloaded'\] will be sequentially changed based on acceptability and other intervention-related data gathered from participants during the trial.~Clinician-participants will not receive any intervention, but will receive surveys and interviews to assess their perceptions about the optimization, acceptability, scalability, and other implementation barriers/facilitators for the intervention."
48297371|NCT06518863|BEHAVIORAL|Education|Educational handouts on how to adhere to the corresponding diet.
48297372|NCT00443430|DRUG|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
48477536|NCT02309424|DIETARY_SUPPLEMENT|Vinegar|0,50mmol vinegar (6% acetic acid)
48477537|NCT02309424|OTHER|Placebo|50 ml water
48477538|NCT02067767|DRUG|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
48477539|NCT01553747|DRUG|Eluxadoline|Oral tablets twice daily
48477540|NCT01553747|DRUG|Placebo|Oral tablets twice daily
48477541|NCT02297750|PROCEDURE|double-wire technique in patients undergoing ERCP with biliary cannulation|
48477542|NCT02297750|PROCEDURE|single-wire technique in patients undergoing ERCP with biliary cannulation|
48477543|NCT05494502|PROCEDURE|Erector spinae plane block|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
48477544|NCT05494502|PROCEDURE|Control group|General anesthesia alone.
48477545|NCT05340582|DRUG|Acetaminophen Injection|Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
48477546|NCT05340582|DRUG|Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)|Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
48477547|NCT05340582|OTHER|Sodium chloride 0.9% injection|Placebo- IV q6h for 3 days
48477548|NCT06153160|DEVICE|HemaShock device|The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
48635922|NCT05461092|OTHER|Pain Catastrophizing|Scale used to determine pain catastrophizing and it's severity.
48635923|NCT05461092|OTHER|Fear Avoidance Beliefs Questionnaire (FABQ)|Questionnaire used to help predict patients that have a high pain avoidance behavior.
48635924|NCT05461092|OTHER|Opioid Side Effects and Likeability Questionnaire|Survey determining adverse events related to opioid side effects and complications.
48104336|NCT00622830|DRUG|SB-480848 (Darapladib)|
48635925|NCT05461092|OTHER|Daily Pain Trajectory|Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
48635926|NCT05461092|OTHER|Tampa Scale of Kinesiophobia|Questionnaire assessing Kinesiophobia
48635927|NCT05461092|OTHER|Quality of Recovery 15|Questionnaire assessing postoperative quality of recovery
47947384|NCT01851915|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
47947385|NCT05059587|DRUG|MBA-P01|MBA-P01 will be injected into the Glabellar line.
47947386|NCT05059587|DRUG|BOTOX|Botox will be injected into the Glabellar line.
47947387|NCT06235307|OTHER|motivational interviewing|Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.
47947388|NCT02169284|DRUG|Erlotinib Hydrochloride|Given PO
47947389|NCT02169284|OTHER|Laboratory Biomarker Analysis|Correlative studies
47947390|NCT02169284|OTHER|Pharmacological Study|Correlative studies
48297373|NCT00443430|DRUG|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
48477549|NCT06078540|OTHER|USeeBP|"USeeBP is a low risk mobile medical app that proposes to do no more than:~* Help patients (i.e., users) self-manage their disease or conditions without providing specific treatment or treatment suggestions;~* Provide patients with simple tools to organize and track their health information;~* Provide easy access to information related to patients' health conditions or treatments;~* Help patients document, show, or communicate potential medical conditions to health care providers;"
47947391|NCT02169284|OTHER|Placebo|Given PO
47947392|NCT02169284|OTHER|Quality-of-Life Assessment|Ancillary studies
48477550|NCT02715232|DRUG|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
48477551|NCT02715232|DRUG|Lynestrenol|2-3 tablets/day, if menstruation still occurs
47947393|NCT02169284|PROCEDURE|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
48297374|NCT00394914|DRUG|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
48297375|NCT00394914|DRUG|Placebo to Pleconaril|Placebo nasal suspension
48297376|NCT01531218|DRUG|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
47947394|NCT01317381|PROCEDURE|Observational|Blood draw
47947395|NCT04971707|OTHER|Standardized exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
47947396|NCT04971707|OTHER|HRV-guided exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
47947397|NCT04515173|DIAGNOSTIC_TEST|Artificial intelligence diagnosis and treatment assistance system|An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
47947398|NCT02876744|OTHER|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
47947399|NCT01674283|DRUG|Glucagon|
47947400|NCT01674283|DRUG|placebo|
47947401|NCT04386031|DIAGNOSTIC_TEST|Throat culture for fungal pathogens|Throat culture for fungal pathogens will be taken before surgery, at post-operative day (POD) 3 and 2 weeks after the operation
48297377|NCT01531218|DRUG|Placebo|
48297378|NCT02719418|DRUG|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
48297379|NCT00541359|DRUG|bortezomib|Given IV
48477552|NCT02715232|DRUG|Cyproterone Acetate|25mg daily
48477553|NCT02715232|DRUG|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
48477554|NCT02715232|DRUG|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
48477555|NCT02669160|DEVICE|PC Innowalk|
48477556|NCT02669160|DEVICE|Conventional passive stander|
48477557|NCT04382430|PROCEDURE|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
48477558|NCT04382430|PROCEDURE|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
48477559|NCT05073250|DRUG|IBI376|IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.
48477560|NCT05073250|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m\^2 intravenously in the first 4 weeks, once a week. Subsequently, rituximab will be dosed once every 4 weeks. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of rituximab at a dose of 375 mg/m\^2 intravenously once every 4 weeks.
48477561|NCT00668447|DIETARY_SUPPLEMENT|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
48477562|NCT00668447|DIETARY_SUPPLEMENT|Control protein|20 grams of powder mixed in beverages or food daily for one year
48477563|NCT00668447|DIETARY_SUPPLEMENT|Novasoy isoflavones|3 tablets daily for one year
48477564|NCT00668447|DIETARY_SUPPLEMENT|Placebo tablets|3 tablets daily for one year
47947402|NCT05805930|DRUG|Anakinra|: Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
48104337|NCT05918159|OTHER|Sarcopenia Assessment|The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
48104338|NCT04983745|DRUG|Combination drug|niraparib and dostarlimab combination
48635928|NCT03921437|RADIATION|decision support intervention|CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
48104339|NCT01645917|DEVICE|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
48104340|NCT00002937|DRUG|paclitaxel|
48635929|NCT04535479|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
48635930|NCT04612231|BEHAVIORAL|TEACCH School Transition to Employment and Postsecondary Education (T-STEP)|The T-STEP Program is a 12-week transition intervention targeting specific challenges that young adults with ASD experience in executive function, social communication, and emotion regulation including group intervention, internship, and counseling services
48635931|NCT04612231|BEHAVIORAL|Counseling Services Alone|The Counseling Services Alone Intervention will receive 12 hours of individual counseling focused on job exploration/career counseling, academic counseling, and self-advocacy counseling.
47947403|NCT05805930|DRUG|Prednisone|Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
47947404|NCT01241773|DRUG|raltegravir|One 400 mg tablet twice daily for 7 days
47947405|NCT01241773|DRUG|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
47947406|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 7 days
47947407|NCT01241773|DRUG|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
47947408|NCT01241773|DRUG|TMC435|Two 75 mg capsules once daily for 14 days
47947409|NCT01241773|DRUG|efavirenz|One 600 mg tablet once daily for 14 days
47947410|NCT03644680|DIAGNOSTIC_TEST|Nasal Provocation with Birch Extract|Nasal spray containing birch extract from Allergopharma
47947411|NCT03644680|OTHER|Nasal Provocation with NaCl 0.9%|Nasal spray containing sterile sodium chloride 0.9%
47947412|NCT04251273|OTHER|This is Quitting|Text message-based intervention for quit vaping support.
47947413|NCT04251273|OTHER|Assessment only Control|Assessment only
47947414|NCT06070311|COMBINATION_PRODUCT|Thymoquinone (0.5%) and Olive oil ointment|"Preparation of the Thymoquinone and Olive oil ointment:~Thymoquinone Oleaginous base ointment containing olive oil will be prepared for intranasal administration. The ointment will be prepared using the fusion method as follows:~Anhydrous lanolin and white soft paraffin will be melted at 70°C and then olive oil will be added with continuous stirring, Thymoquinone will be added to the congealing mixture as it is being cooled and stirred finally, the congealing mixture is left to cool at room temperature tell solidification and sterilized using UV radiation. The final product will be characterized for spreadability, drug content, drug release and stability."
48104341|NCT00002937|DRUG|valspodar|
48104342|NCT02030028|DRUG|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
48104343|NCT00185016|BEHAVIORAL|a training to improve recognition of partner abuse.|
48104344|NCT00876044|DRUG|aflibercept (AVE0005)|Intravenous route
48104345|NCT00876044|DRUG|placebo|Intravenous route
48104346|NCT05912751|OTHER|Exercise Then Foam Roll|Participants in AB will perform the experimental (exercise) intervention first and the control (foam rolling) intervention second.
48635932|NCT03954938|BEHAVIORAL|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
48635933|NCT03954938|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
48104347|NCT05912751|OTHER|Foam Roll Then Exercise|Participants in BA will perform the control (foam rolling) intervention first and the experimental (exercise) intervention second.
48104348|NCT01513642|BEHAVIORAL|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
48104349|NCT02606409|DRUG|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
48104350|NCT02606409|DRUG|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
48104351|NCT02008734|DRUG|PD0332991|
48104352|NCT03489317|DRUG|Metformin|Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
48104353|NCT03489317|BEHAVIORAL|lifestyle modification|Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
48104354|NCT03489317|DRUG|Simvastatin 10mg|Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
48104355|NCT03489317|DRUG|Amlodipine 5mg|Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
48104356|NCT02209740|OTHER|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
48297380|NCT00541359|DRUG|topotecan hydrochloride|Given IV
48297381|NCT00541359|OTHER|immunohistochemistry staining method|Correlative studies
48297382|NCT00541359|OTHER|pharmacological study|Correlative studies
48297383|NCT04792138|DIAGNOSTIC_TEST|VERDICT MRI|Advanced Diffusion Model
48297384|NCT04792138|DIAGNOSTIC_TEST|Luminal Index Imaging|Advanced T2 mapping
48297385|NCT02558699|PROCEDURE|physician's personal experience|physician's personal experience
48297386|NCT02558699|PROCEDURE|Virtual rotor mapping|Virtual rotor mapping
48297387|NCT04346823|DRUG|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3minutes. Then, parturients breath 1% of sevoflurane in a mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min.~Thirty seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure.The duration of ECV in addition to the level of difficulty estimated by obstetricians will be recorded. Usually, the duration of ECV does not exceed 10 minutes.~The intervention will be stopped if the woman reported severe pain, if version could not be achieved readily, or if prolonged fetal bradycardia, uterine bleeding or placental abruption occurred.~Parturient will be kept in Post Anesthesia Care Unit (PACU) for 45minutes. CTG will be monitored during PACU stay."
48297388|NCT00089128|DRUG|gemcitabine hydrochloride|
48297389|NCT00089128|DRUG|irinotecan hydrochloride|
48297390|NCT03750110|OTHER|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~* For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~* For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
48297391|NCT03750110|OTHER|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
48297392|NCT01080989|OTHER|diagnosis, treatment and education|"Drug:~anti-intestinal parasitic drugs:~1. mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~2. albendazole(400 mg bid \* 7days) or Ivermectin(200 mcg/kg/day \* 2 days) (For Strongyloidiasis).~Behavior:~1. Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~2. Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
48297393|NCT02702193|BEHAVIORAL|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
48298893|NCT03196050|DEVICE|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire"
48477565|NCT01915641|DEVICE|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
48477566|NCT00251316|DRUG|Lithium Carbonate|30 mCi of 131I
47947415|NCT06681883|BEHAVIORAL|Action group|"A nursing care program based on the Model of Modifiable Factors Specific to Problematic Internet Use in Adolescents (MFPA)~The nursing care program based on the MFPA model is designed for adolescents with problematic internet use. The program is grounded in the concepts of the draft model. It consists of eight sessions, each expected to last 40-50 minutes. One session will be held per week. The first session includes introductions and an overview of the program, the second session aims to strengthen the adolescent's motivation for change, the third session focuses on improving the adolescent's self-control skills, the fourth session aims to enhance family functionality, the fifth session helps develop offline activities to replace internet use, the sixth and seventh sessions work on developing coping skills, and the eighth session includes the evaluation and termination of the program."
47947416|NCT01131156|BEHAVIORAL|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
48298894|NCT01073748|DRUG|paracetamol|single dose of paracetamol 15mg/kg.
48477567|NCT00251316|DRUG|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
48477568|NCT00551616|DRUG|CDB-2914|Single dose
48477569|NCT00551616|DRUG|Levonorgestrel|Single dose
48477570|NCT00030407|DRUG|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
48635934|NCT03954938|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
48477571|NCT00030407|DRUG|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
48477572|NCT00385788|DRUG|Gemcitabine|800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)
48477573|NCT00385788|DRUG|Fludarabine|33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)
48477574|NCT00385788|DRUG|Melphalan|70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
48477575|NCT00385788|DRUG|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
48477576|NCT00385788|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
48635935|NCT05623605|DRUG|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
48297394|NCT06049420|BEHAVIORAL|Lifestyle counseling and coaching|Each participant will be provided with personalized exercise therapy that is best suited for their personal goals and disease states. Participants in this study will be encouraged to establish accountability through setting SMART goals, and through monitoring their activity using wearable fitness technology provided to them. This program will also aim to create a sense of community as group activity classes will be available for those that wish to attend. Individualized exercise/physical activity prescriptions will be provided and discussed.
48297395|NCT06164795|DRUG|Zoledronate|intravenous infusion
48635936|NCT05623605|DRUG|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
48635937|NCT05623605|DRUG|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
48635938|NCT06091605|PROCEDURE|Soft tissue augmentation around dental implants.|Soft tissue augmentation around dental implants using Omega roll envelope flap (OREF) technique.
48297396|NCT06164795|DRUG|Denosumab|subcutaneous injection
48297397|NCT06164795|DRUG|Teriparatide|subcutaneous injection
48297398|NCT06164795|DRUG|Romosozumab|subcutaneous injection
48104357|NCT03393117|DRUG|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
48635939|NCT04038658|BEHAVIORAL|Move-It|
48635940|NCT04874779|OTHER|non|follow up investigations
48477577|NCT00385788|DRUG|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
48635941|NCT05062369|DEVICE|TaskFlow Transcranial Electrical Stimulation device|The TaskFlow Transcranial Electrical Stimulation device (TaskFlow-TES) is a custom brain stimulation device developed in-house at the University of Minnesota. Each tDCS intervention will last 20 minutes of either (i) 10 active (2-mA) or (ii) 5 active and 5 sham transcranial direct current stimulation (tDCS) over the course of 10 treatment sessions.
48635942|NCT05062369|BEHAVIORAL|Executive Function Focused Cognitive Training|Working memory focused training occurs on a computer and consists of a variety of exercises selected to (i) place demands on the executive and storage functions of working memory (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across verbal, visual and spatial modalities. Training tasks are developed in-house. Tasks for each participant are delivered from and responses, audio, and video are stored on the HST server. The aim of using multiple tasks that require executive functions is to engage brain network functional connectivity in a number of different ways to promote generalization. Investigators will monitor each participant's training and customize the intervention to balance challenge and engagement. In addition, pre- and post-intervention, participants will perform 4-minute versions of a word and a spatial 3-back task identical across all weeks (but differing from the assessment versions).
48635943|NCT01173926|DRUG|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
48635944|NCT01173926|DRUG|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
48635945|NCT01173926|DRUG|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
47947417|NCT04575454|OTHER|Multimodal evaluation of brain function : PET-MRI, electrophysiology, eye-tracking|"After 2 days of sedation withdrawal, each data should be collected within 3 days for organisation purposes :~1. After installation and movement management with standardized routine care protocol: 18Fluoro-Desoxy-Glucose's infusion for PET~2. Starting PET continuous acquisition~3. Morphological MRI sequences~4. MRI in Resting state N°1~5. MRI DTI acquisition~6. IRM in 2D-Arterial Spin Labelling~7. IRM in Resting state 2~8. End of PET continuous acquisition The day before or the day after PET-MR: standard 20 min EEG, somaesthetic evoked potentials, auditory evoked potentials, mismatch negativity, P300 oddball paradigm, local-global paradigm, P300 after music stimulation, EEG resting state for 10 min, CRS-R repeated before each examination (and at least 5 times for chronic patients), eye-tracking study of the environmental exploration."
47947418|NCT05735353|BEHAVIORAL|High-Speed Circuit Resistance Training|three times per week; 45 minutes per session; 12-weeks
48297399|NCT00916604|DRUG|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
48297400|NCT00916604|DRUG|Placebo|Placebo oral suspension, 8 days treatment
48297401|NCT01937208|RADIATION|intensity modulated radiation therapy in both arms|
48477578|NCT00385788|DRUG|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
48297402|NCT01937208|DRUG|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
48297403|NCT06351215|DRUG|Methadone group|5mg PO methadone for participants \&lt;50kg or 10mg PO methadone for participants \&gt;50kg
48297404|NCT06351215|DRUG|Placebo|sugar pill that is identical look-alike to study drug
48297405|NCT01841008|DRUG|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
48297406|NCT01841008|DRUG|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
48297407|NCT05163808|DRUG|zatolmilast|Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo
48297408|NCT05163808|DRUG|Placebo|Placebo
48298895|NCT05715086|PROCEDURE|Ureteroscopy|Upfront ureteroscopy
48635946|NCT05999552|OTHER|Eye exercises|The treatment will be applied in three sessions a week for eight weeks and each session will be approximately 20 minutes. Individuals will do each exercise shown at home as a home program on other days (days when the physiotherapist does not perform the exercise by video call).
47947419|NCT05735353|BEHAVIORAL|High-Speed Multidirectional Yoga|two times per week; 60 minutes per session; 12-weeks
47947420|NCT02002390|DRUG|Fingolimod|A sphingosine-1-phosphate receptor regulator
47947421|NCT05708586|BEHAVIORAL|Control|This is the control condition and anxiety is addressed in a standard way of having the care taker calm the child during the intervention.
48635947|NCT03211832|OTHER|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
47947422|NCT05708586|DEVICE|Virtual Reality (VR)|The child who is undergoing a procedure uses VR as a distraction during the intervention
48635948|NCT00067873|BEHAVIORAL|Diet|
47947423|NCT06207838|DEVICE|MiniMed 780G system|The MiniMed™ 780G system automatically adjust insulin delivery to patient needs for an easier way to stabilise glucose levels. It features an advance level of automation for diabetes management, known as SmartGuard™ technology. If patient glucose levels are trending high, it gives patient more insulin. Technology is CE marked.
47947424|NCT02836275|OTHER|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
47947425|NCT05131919|DRUG|Pembrolizumab|Treatment with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle. Treatment will be continued for a maximum duration of 2 years, or until the tumor becomes resectable.
47947426|NCT04332380|DRUG|Plasma|Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
47947427|NCT06294236|BIOLOGICAL|SC291|SC291 is an allogeneic CAR T cell therapy
47947428|NCT06680284|OTHER|Staff Education Program|A staff education and environmental awareness campaign and in-service to highlight strategies to reduce, reuse, and recycle waste, as well as proper waste disposal practice, will be implemented by way of instructional posters, e-learning modules, a grand rounds presentation, journal club discussion, and brainstorming sessions for waste reduction, reuse and recycle and a brief knowledge test at the end.
47947429|NCT06681246|OTHER|Antibiotic treatment|10 days of either antibiotics- Augmentin (amoxicillin+clauvonate), 875mg, 2 /day
47947430|NCT06681246|OTHER|Placebo|consist of a combination of agarose in normal saline/glycerol
48104358|NCT03393117|DRUG|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
48104359|NCT03393117|DRUG|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
48104360|NCT03393117|DRUG|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
48104361|NCT06331754|OTHER|Technology-enabled blood pressure management|The intervention will consist of a technology-enabled remote hypertension management program.
48104362|NCT01450072|DEVICE|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
48104363|NCT01450072|OTHER|Control arm|Venography and sham angioplasty
48104364|NCT03163953|BEHAVIORAL|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
48104365|NCT03163953|BEHAVIORAL|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
48104366|NCT03163953|OTHER|Control|No intervention
48635949|NCT00067873|BEHAVIORAL|Aerobic exercise|
47947431|NCT04540575|BEHAVIORAL|NICU Acquires MOM|Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
47947432|NCT04540575|BEHAVIORAL|Mother Provides MOM|Mother receives standard Rush NICU lactation care
47947433|NCT05405933|DIAGNOSTIC_TEST|Propioceptive Neuromuscular Facilitation|Propioceptive Neuromuscular Facilitation With Conventional Therapy for Balance and Gait
47947434|NCT05405933|DIAGNOSTIC_TEST|Balance Exercise|Balance Exercise Along With Conventional Therapy for Balance and Gait
48104367|NCT01603719|DIETARY_SUPPLEMENT|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
48104368|NCT04072822|DRUG|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
48104369|NCT04072822|DRUG|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
48104370|NCT04072822|DRUG|Placebos|Matching placebo
48104371|NCT03652207|OTHER|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
48635950|NCT00067873|BEHAVIORAL|Resistance exercise|
47947435|NCT04416633|DRUG|Durvalumab|500-mg/120-mg IV
47947436|NCT03283917|BIOLOGICAL|Daratumumab|Given IV
47947437|NCT03283917|DRUG|Dexamethasone|Given IV or PO
48635951|NCT02262273|OTHER|Data Collection|Colleciton of data from medical records only
47947438|NCT03283917|DRUG|Ixazomib|Given PO
47947439|NCT02608203|DRUG|[68Ga]-DOTANOC PET/CT|
47947440|NCT03304418|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
47947441|NCT03304418|RADIATION|Radiation|"All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~* Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~* Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~* Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~* Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
47947442|NCT06184126|DEVICE|Virtual Reality Headset and Hand-Held Controllers|Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.
47947443|NCT06184126|OTHER|Blindfolding and Noise Cancelling|Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.
47947444|NCT06481839|OTHER|Starting dose of NE|Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.
47947447|NCT05266716|BEHAVIORAL|Affect Methamphetamine Treatment Program|"Components of the treatment services include: contingency management (CM; monetary incentives for drug tests negative for stimulants), the digital behavioral therapy curriculum (based on CBT) delivered via the Affect app on smartphones, weekly one-on-one telemedicine (TM) with clinical personnel and group therapy, and referral to psychiatrist for medication support, as needed. The program incrementally builds skills and beliefs to develop personally meaningful strategies to combat cravings, using such techniques as regular app-promoted deep breathing exercises, daily exercise, and help in making and sticking to a relapse prevention plan. Counseling sessions are arranged via text sent by the Team Care advocate and also presented to the participant via the app as a reminder. Individual and group therapy sessions occur over Zoom, which is integrated into the app.~Contingency Management (CM). CM utilizes monetary incentives and rewards to promote behavior change."
47947448|NCT01580358|DRUG|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
47947449|NCT01580358|DRUG|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
47947450|NCT05048082|DRUG|pegsitacianine|An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
47947451|NCT05048082|PROCEDURE|Tumor resection surgery|Standard of care surgical removal of cancerous lung lesion
48104372|NCT03652207|OTHER|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
48297409|NCT06404008|BEHAVIORAL|REST|After randomization, individuals will attend an in-person training session in the REST protocol. This is a 15 minute controlled breath protocol that includes 3 yoga breathing techniques: 3-part dirgha breath, alternate nostril breathing, and 2:1 breathing. Each technique will be completed for 5 minutes, for a total of 15 minutes. After the training session, participants will practice the REST protocol for 15 minutes twice a day with guidance from research staff over zoom (Days 1-7) with daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and exacerbation education. On Day 8, participants will attend the Trial Session where they will complete the REST protocol (15 minutes) while vitals, lung function, and ECG measurements are taken. Surveys will be administered before and after the REST protocol to document patient reported stress and dyspnea.
48477579|NCT00385788|DRUG|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
48635952|NCT02441816|DRUG|Aflibercept|
48104373|NCT00392678|DRUG|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
48104374|NCT00392678|DRUG|Placebo|Placebo to Salsalate
48477580|NCT02488031|BEHAVIORAL|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
48477581|NCT02488031|BEHAVIORAL|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
48104375|NCT05956600|DRUG|Amisulpride 50 MG|Amisulpride 50 mg titrated to dose range of 50 to 1200 mg
48297410|NCT06404008|OTHER|Education|After randomization, individuals will attend an in-person education session led by a research coordinator. For the following 7 days, the research staff will call patients daily and provide daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and COPD exacerbation education. On Day 8, participants will attend the Trial Session where they will do spontaneous breathing (15 minutes) while vitals, lung function, and EKG measurements are taken. Surveys will be administered before and after the spontaneous breathing period to document patient reported stress and dyspnea. After the study, participants will be asked to complete a close out survey and interview over zoom.
48477582|NCT02488031|BEHAVIORAL|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
48477583|NCT02488031|BEHAVIORAL|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
48477584|NCT02488031|BEHAVIORAL|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
48477585|NCT02488031|BEHAVIORAL|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
48477586|NCT02488031|BEHAVIORAL|Brief Test of Attention|A cognitive test assessing focus and attention.
48477587|NCT02488031|BEHAVIORAL|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
48477588|NCT02488031|BEHAVIORAL|Hand Grip Dynamometer|This tests measures hand grip strength.
48477589|NCT02488031|BEHAVIORAL|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
48477590|NCT02488031|BEHAVIORAL|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
48477591|NCT02488031|BEHAVIORAL|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
48477592|NCT02488031|BEHAVIORAL|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
48477593|NCT02488031|BEHAVIORAL|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
48477594|NCT00577148|DRUG|Rimonabant|Tablet, oral administration
48477595|NCT00577148|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
48477596|NCT03669016|BEHAVIORAL|Face-to-face group-based mindfulness|"An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams \& Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized."
48477597|NCT03669016|BEHAVIORAL|Internet-based mindfulness|An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
48477598|NCT00508027|DRUG|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
48477599|NCT04567758|OTHER|Telerehabilitation|"The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
48477600|NCT04567758|OTHER|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
47947452|NCT05558644|OTHER|single arm for all patients|"* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
47947453|NCT06261268|PROCEDURE|Strip graft with Mucograft|"An apically repositioned flap is made in the vestibular region. The flap is then elevated with a split-thickness preparation, and the mucogingival junction will be repositioned apically and fixed with periosteal-anchored sutures. Then, a free epithelialized gingival strip graft will be harvested from the molar area of the palate. The Strip graft is sutured to the apical end of the recipient bed. The remaining uncovered part of the periosteal bed will be covered with a xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) fixed with simple interrupted and crossed sutures. The edges of the palatal wound (donor area) will be approximated with crossed sutures."
47947454|NCT06261268|PROCEDURE|Free gingival graft|The preparation of the apically repositioned flap and the recipient bed with its apico-coronal design and dimension is performed as in the test group. Subsequently, an epithelialized free gingival graft with the size of the entire recipient area with a thickness of 2 mm will be harvested from the molar area of the palate. The graft is sutured to the recipient periosteal bed using simple interrupted and crossed sutures. In the donor area, a collagen sponge is sutured to the wound by means of crossed sutures.
47947455|NCT06067828|DRUG|Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
48297411|NCT06274138|BEHAVIORAL|haptonomy|Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
48297412|NCT06591819|RADIATION|Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost|Brachytherapy boost will be delivered and then whole pelvis proton radiation therapy in 5 fractions.
48635953|NCT02441816|OTHER|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
48635954|NCT02957227|DEVICE|No intervention is part of this study but patients use an EEG device during observational data collection.|
48635955|NCT00416754|OTHER|counseling intervention|subjects will receive genetic counseling
48635956|NCT02030639|DRUG|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
48104376|NCT04479254|DIETARY_SUPPLEMENT|Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)|Enteral nutrition feeding formula is used in powder form and will be reconstituted by attending nurses, Continuous feeding is commonly used which will be prescribed by the attending clinicians, Energy and protein intake from EN will be estimated by multiplying the volume of feed given to energy (kcal) and protein (g) in 1 ml of standard dilution, and for Standard PN product, energy and protein intake will also be calculated based on the volume infused.
48104377|NCT04836624|DEVICE|Co-designing of personalised aids of daily living|"In the initial session the researcher will work with the participants to identify challenges in daily living for the device to overcome.~In between sessions the researcher will design and manufacture different solutions which will then be sent out for the participant to trial. The participant will then meet with the researcher to and feedback on the device provided. Feedback from the user is used to alter and improve the design of the device; new device(s) are then , enabling the design to be adapted to the participants needs. The process of design changes and feedback forms an iterative loop. This is expected to continue for 4-5 appointments over a period of serveral months until a final design is agreed upon.~After the device is issue, both qualitative and quantitative outcome measures are provided to participants to complete, including questionnaires and semi-structured interviews. ."
48635957|NCT00894647|DRUG|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
48104378|NCT03082430|BIOLOGICAL|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
48104379|NCT00500500|DRUG|EGb 761® (Tanakan®)|
48635958|NCT00894647|DRUG|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
48635959|NCT02690740|OTHER|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
48635960|NCT00209638|DRUG|irinotecan|
47947456|NCT06067828|DRUG|Treatment B: Budesonide and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
48104380|NCT00001994|DRUG|Atovaquone|
48104381|NCT05042193|OTHER|SARS-CoV-2|Observational
48297413|NCT03609229|PROCEDURE|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
48297414|NCT03609229|PROCEDURE|Abdominal Sacrocolpopexy|"* By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
48104382|NCT05355415|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
48104383|NCT02939495|DRUG|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
48297415|NCT06651697|RADIATION|Radiation therapy|Radiation therapy with full bladder or empty bladder protocols
48635961|NCT00209638|DRUG|S-1|
48635962|NCT04286503|DRUG|Carrimycin|Carrimycin
48635963|NCT04286503|DRUG|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate
48635964|NCT04286503|DRUG|basic treatment|basic treatment
48635965|NCT03118895|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
48635966|NCT02597361|DRUG|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
47947457|NCT06067828|DRUG|Treatment C : Placebo|Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
47947458|NCT06681675|PROCEDURE|The group that applied the Intrapartum Care Model|"In pregnant women with cervical dilatation of 5 cm, the Personal Information Form was completed at the initial clinic admission.~•The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations.~Data were collected using the Personal Information Form, Labor and Postpartum Follow-up Form, Visual Analog Scale (VAS), Labor Comfort Scale (CSC), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Labor Scale. VAS, CSC, and Fear of Labor Scale were applied to women when cervical dilation was 5 cm and 9 cm. After delivery, the Women's Perception of Supportive Care Given During Labor Scale was applied."
47947459|NCT02770170|DRUG|BI 655064 dose 1|
47947460|NCT02770170|DRUG|BI 655064 dose 2|
47947461|NCT02770170|DRUG|BI 655064 dose 3|
47947462|NCT02770170|DRUG|Placebo|
47947463|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
48104384|NCT04851730|PROCEDURE|Orthopedic Physical Therapy Intervention|"First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits."
48104385|NCT04851730|DEVICE|Dry Needling|"Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima \& Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L."
48104386|NCT04454892|OTHER|Amyotrophic lateral sclerosis|AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
48297416|NCT04355117|DRUG|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
48297417|NCT05020938|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
48635967|NCT02597361|DRUG|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
48635968|NCT00857051|OTHER|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
48635969|NCT00857051|OTHER|Film|A DVD addressing common stressors in the early postpartum.
48297418|NCT00163722|OTHER|Culture and histology|
48297419|NCT00163722|OTHER|Aspergillus galactomannan and PCR|
48477601|NCT00641199|OTHER|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
48477602|NCT00305916|PROCEDURE|Multislice spiral computed tomography coronary angiography|
48477603|NCT00305916|PROCEDURE|conventional coronary angiography|
48477604|NCT05986136|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
48477605|NCT05986136|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
48477606|NCT01529307|DRUG|TAS266|TAS266 IV infusions given weekly
48477607|NCT01039194|DRUG|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
48635970|NCT04667728|DEVICE|Professional continuous glucose monitoring (CGM) sensor (iPro™2)|Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
47947464|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
48477608|NCT01039194|DRUG|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
48635971|NCT02503865|DRUG|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
48635972|NCT02503865|DIETARY_SUPPLEMENT|"Analimentary detoxication"|Vegetable and salt diet
48635973|NCT00580294|DRUG|Oxymorphone|IV PO
48635974|NCT01197105|BIOLOGICAL|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
47947465|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
47947466|NCT04162600|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp.
47947467|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
47947468|NCT04162600|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
48297420|NCT06550674|GENETIC|Constitutional exome analysis|"For each patient included:~* A family tree is drawn up, reporting personal and family histories of cancer. The patient's anatomopathological reports, related to his or her tumor lesions, are retrieved, in order to confirm/clarify individual or family diagnoses.~* A blood sample and a jugal smear are taken to enable constitutional genetic exome analysis for research purposes."
47947469|NCT04893707|BIOLOGICAL|CM310|"adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
47947470|NCT06681181|DRUG|GSK4528287|GSK4528287 will be administered.
48297421|NCT04098601|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
47947471|NCT06681181|DRUG|Placebo|Placebo will be administered.
47947472|NCT05741658|DRUG|Dapagliflozin 10mg Tab|Participants will take one Dapagliflozin 10mg tablet once per day for 4 weeks.
47947473|NCT01180634|DRUG|Aeroquin|Inhalation Solution
47947474|NCT01180634|DRUG|Placebo|Inhalation Solution
48104387|NCT01278433|BIOLOGICAL|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
48104388|NCT01460342|DRUG|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
48297422|NCT02379416|DRUG|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
48297423|NCT02518178|DEVICE|NFC Necklace|
48477609|NCT01039194|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
48104389|NCT01460342|DRUG|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
48477610|NCT04067193|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
48477611|NCT02076776|BEHAVIORAL|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
48477612|NCT02076776|BEHAVIORAL|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
48104391|NCT04137874|DIAGNOSTIC_TEST|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
48104392|NCT04137874|OTHER|Control|Conventional prehospital care
48635975|NCT04000711|OTHER|Outpatient oral treatment.|Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
47947475|NCT00751218|DRUG|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
48104393|NCT01913119|DRUG|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
48104394|NCT03255018|BIOLOGICAL|Pembrolizumab|Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
48104395|NCT01762241|BEHAVIORAL|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
48104396|NCT01662180|DRUG|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
48104397|NCT06112119|DEVICE|MSCT|Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
48104398|NCT04089046|BEHAVIORAL|TEAM-UP for Teens|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
47947476|NCT00751218|DRUG|placebo|placebo, once daily for 28 days
47947477|NCT00751218|DRUG|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
47947478|NCT06676709|BIOLOGICAL|IMMUNEPOTENT-CRP (I-CRP)|IMMUNEPOTENT-CRP (I-CRP), a bovine dialyzable leukocyte extract (DLE) obtained from disrupted spleen cells, is a mixture of low-molecular-weight peptides (\<12 kDa) that exhibit non-specific immunomodulatory properties.
48477613|NCT02076776|BEHAVIORAL|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
48477614|NCT05269992|OTHER|Real food products|As per arm/group descriptions.
48477615|NCT04719611|DIETARY_SUPPLEMENT|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10\^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
48477616|NCT04273555|DRUG|[18F]-FDG|\[18F\]-FDG will be injected prior to PET/MRI imaging up to three times over the course of six months.
47947479|NCT06676709|BIOLOGICAL|Placebo Comparator|The placebo was prepared from a lyophilized corn starch extract and was provided in an identical appearance and presentation to IMMUNEPOTENT-CRP (I-CRP).
47947480|NCT04047576|DRUG|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
47947481|NCT04047576|DRUG|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
47947482|NCT05225649|BEHAVIORAL|Behavior Change Intervention|Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
48477617|NCT04094740|DEVICE|Jet Injector without A Needle|Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
47947483|NCT03835819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
47947484|NCT03835819|DRUG|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
47947485|NCT02097043|DRUG|DA-7218|
48297424|NCT02518178|DEVICE|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
48297425|NCT02518178|DEVICE|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
48297426|NCT01264965|DRUG|long acting oxycodone|10mg twice daily
48297427|NCT01264965|DRUG|extra strength acetaminophen|1,000 mg twice daily
48297428|NCT06169748|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
48477618|NCT01897168|DEVICE|No intervention|
47947486|NCT02097043|DRUG|Placebo|
47947487|NCT05137704|OTHER|No intervention|This is a non-interventional study.
47947488|NCT03203070|DRUG|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
48477619|NCT03856905|OTHER|Physical therapy program|It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
48635976|NCT04000711|OTHER|Inpatient intravenous treatment.|Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC \> 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
47947489|NCT03203070|PROCEDURE|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
47947490|NCT05509751|BEHAVIORAL|GAM, exercise, health education|geriatric assessment, exercise and health education
47947491|NCT05509751|BEHAVIORAL|online chair-based exercise combined with health education|online chair-based exercise and health education for 12 weeks
47947492|NCT05720507|BEHAVIORAL|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
48297429|NCT06169748|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
48297430|NCT06169748|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
48297431|NCT00051688|DRUG|tezacitabine|
48297432|NCT00051688|DRUG|oxaliplatin|
48297433|NCT05479812|DRUG|WTX-124|Investigation Product Monotherapy
48297434|NCT05479812|DRUG|pembrolizumab|Investigation Product in combination with approved therapy
48297435|NCT04798417|DIETARY_SUPPLEMENT|Probiotic supplement|Use of a probiotic sachet
48297436|NCT04798417|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic sachets
48297437|NCT04798417|DIETARY_SUPPLEMENT|Maltodextrin|Placebo comparator
48297438|NCT04487847|DIAGNOSTIC_TEST|18F-PSMA-1007 PET/CT|18F-PSMA-1007 PET/CT
48297439|NCT00193310|DRUG|Paclitaxel|
48297440|NCT00193310|DRUG|Carboplatin|
48297441|NCT05156710|DRUG|BIVV020 (SAR445088)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
48297442|NCT05156710|DRUG|Intravenous immunoglobulin (IVIg)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
48297443|NCT05156710|DRUG|Rituximab or biosimilar|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
48297444|NCT05156710|DRUG|Antithymocyte globulin (ATG)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
48297445|NCT05156710|DRUG|Tacrolimus|Pharmaceutical Form: Tablet Route of Administration: Oral
48297446|NCT05156710|DRUG|Mycophenolate|Pharmaceutical Form: Tablet Route of Administration: Oral
48297447|NCT05156710|DRUG|Corticosteroids|Pharmaceutical Form: Vary Route of Administration: Vary
48297448|NCT04069767|PROCEDURE|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~1. Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~2. Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~3. Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~4. Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~5. Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~6. Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
48297449|NCT04069767|PROCEDURE|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
48297450|NCT00972998|DRUG|Phenyephrine|Phenyephrine coated suppositories
48297451|NCT02572661|RADIATION|radiation in Squamous Head and Neck Cancer|
48297452|NCT00471471|BIOLOGICAL|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
48297453|NCT00471471|BIOLOGICAL|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
48297454|NCT00471471|BIOLOGICAL|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
48297455|NCT06671587|DRUG|iGlarLixi (insulin glargine/lixisenatide)|"iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~- iGlarLixi must not be mixed with other insulins nor diluted."
48297456|NCT06671587|DRUG|Gla-100 (insulin glargine)|Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
48297457|NCT00038194|DRUG|imatinib mesylate|
47947493|NCT05273996|DRUG|Sertraline, bupropion, desvenlafaxine|Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
47947494|NCT03166878|BIOLOGICAL|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
48297458|NCT00038194|DRUG|docetaxel|
48297459|NCT03553238|DRUG|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
48297460|NCT03553238|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
48297461|NCT03553238|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
48297462|NCT03553238|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
48297463|NCT03553238|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
48297464|NCT03553238|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
48297465|NCT03553238|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
48297466|NCT03553238|DRUG|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
48297467|NCT03553238|DRUG|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
48297468|NCT03553238|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
48297469|NCT03553238|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
48297470|NCT03553238|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
48297471|NCT03553238|PROCEDURE|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
48297472|NCT03553238|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
48635977|NCT02209909|DRUG|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
48635978|NCT02209909|DRUG|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
48635979|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|TID
48635980|NCT00560638|DRUG|loteprednol etabonate ophthalmic suspension, 0.5%|QID
47947495|NCT05318482|BEHAVIORAL|Motivational group|In addition to the activities of the usual rehabilitation program, the PT will perform a daily motivational session of 15 minutes in a 1 patient: 1 physiotherapist modality. On that occasion, the patient will report the number of steps performed the previous day; the physiotherapist will check and promote the increase of 10% in the number of steps for the next day. If the patient fails to achieve the goal, the PT will analyze the reasons with the patient, in order to facilitate the achievement of the goal. The PT will advise on the time and place to perform physical activity and the patients will receive a diary to record his/her progress (number of steps and heart rate, Borg Fatigue and Borg Dyspnea before and after an exercise task). The PT will record all these evaluations on an excel database.
47947496|NCT05318482|OTHER|Control group|Besides the activities of the usual rehabilitation program, the patients of this group will be provided by the PT only with the generic recommendations of daily exercise during the in-hospital stay
47947497|NCT06632691|DEVICE|Virtual reality headset|Use of a virtual reality headset during rectosigmoidoscopy
47947498|NCT06002490|DRUG|P1101|"The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms."
47947499|NCT06002490|DRUG|Low-dose aspirin|Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
47947500|NCT06002490|PROCEDURE|Phlebotomy|Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.
48477620|NCT03856905|DEVICE|Extracorporeal shock wave therapy|It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.
48477621|NCT03856905|DEVICE|Functional electrical stimulation|It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
48635981|NCT00560638|DRUG|vehicle of loteprednol etabonate|TID or BID according to the randomization
48635982|NCT04006457|DRUG|PF-06651600|50 mg oral tablets/capsules
48635983|NCT04006457|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
48635984|NCT04006457|BIOLOGICAL|Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine|Single intramuscular injection administered to patients participating in the vaccine sub-study
48297473|NCT03553238|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
48297474|NCT03553238|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
48297475|NCT03553238|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
48477622|NCT01461291|DEVICE|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
48477623|NCT01461291|PROCEDURE|Cataract surgery|Cataract surgery alone
48477624|NCT04657250|BEHAVIORAL|Smoking cessation + quitline linkage text messages|Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.
48477625|NCT04657250|BEHAVIORAL|Passive quitline referral|Single text message with contact information for the Quitline
48477626|NCT00194792|DRUG|exemestane|Given PO
48477627|NCT00194792|DRUG|triptorelin pamoate|Given IM
48635985|NCT02205138|DRUG|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
48635986|NCT04634175|BEHAVIORAL|Mind-body intervention|The mind-body intervention is composed of kundalini yoga techniques.
48635987|NCT04634175|BEHAVIORAL|Sham intervention|The sham intervention is composed of stretching and muscle flexion techniques.
48297476|NCT03553238|DIAGNOSTIC_TEST|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
48297477|NCT03553238|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
48297478|NCT03553238|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
48477628|NCT00194792|DRUG|capecitabine|Given PO
48477629|NCT00194792|DRUG|methotrexate|Given IV
48477630|NCT00194792|DRUG|vinorelbine tartrate|Given IV
47947501|NCT03031158|BEHAVIORAL|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
47947502|NCT03031158|BEHAVIORAL|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
47947503|NCT05103631|GENETIC|CATCH T cells|"Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
47947504|NCT00428662|DEVICE|drug eluting nonpolymeric nanoporous stent|
47947505|NCT00807131|BEHAVIORAL|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
47947506|NCT00807131|BEHAVIORAL|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
47947507|NCT00807131|BEHAVIORAL|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
47947508|NCT00807131|BEHAVIORAL|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
47947509|NCT00514566|DEVICE|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
47947510|NCT00359918|DRUG|fibrinolysis|Primary PCI
47947511|NCT00359918|PROCEDURE|Primary PCI|Primary PCI
48297479|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
48297480|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
48297481|NCT06015737|COMBINATION_PRODUCT|Anifrolumab|Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
48297482|NCT06015737|OTHER|Placebo|Matching placebo solution for injection in aPFS.
48297483|NCT06242925|DEVICE|AbCLO (Abdominal Wall Closure) Device|They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.
48297484|NCT03428191|DRUG|Remifentanyl+Dexmedetomidine|In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
48297485|NCT01448551|BEHAVIORAL|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
48297486|NCT05404854|OTHER|Physical Activity|wearing an accelerometer for 7 days before and after the rehabilitation program
48477631|NCT00194792|DRUG|paclitaxel|Given IV
48477632|NCT00194792|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
48477633|NCT00194792|RADIATION|radiation therapy|Undergo radiation therapy
48635988|NCT00563563|DRUG|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
48477634|NCT00194792|OTHER|laboratory biomarker analysis|Correlative studies
48477635|NCT03504761|DEVICE|ClariCore Optical Biopsy System|Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
48477636|NCT00437190|DEVICE|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
48477637|NCT00437190|DEVICE|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
48635989|NCT00563563|BEHAVIORAL|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
47947512|NCT00985816|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
47947513|NCT00985816|DIETARY_SUPPLEMENT|Placebo|Placebo
48297487|NCT05404854|OTHER|sedentarity|wearing an accelerometer for 7 days before and after the rehabilitation program
48297488|NCT05404854|OTHER|Measurement of explicit motivation|Explicit motivation will be assessed using self-report questionnaires. Explicit attitudes using a 7-point bipolar response scale, participants will be asked to indicate for each of the 4 pairs of positive and negative adjectives used how much they associate them with regular PA and sedentary behaviors, respectively. Perceived behavioral control using a 7-point bipolar response scale, patients will be asked to indicate how well they felt they were able to engage in regular PA, and limit their sedentary behaviors, respectively, based on two items. Intentions using a 7-point bipolar response scale, patients will be asked to indicate how much they intend to adopt regular physical activity, and limit their sedentary behaviors, respectively, according to two items. Fears and beliefs related to physical activity and work will be measured by the FABQ in its French version
48477638|NCT05633238|BEHAVIORAL|Visual Search Information Type (target or distractor information)|Participants will have information about targets, distractors, or neither in different blocks of the intervention.
47947514|NCT04210583|DEVICE|Vulvovaginal Treatment|"Device model(s) - Venus Fiore™ Device settings and programming internal applicator - 42°C - 45°C Temperature output via automatic temperature control (ATC) (optional treatment).~Duration of exposure and frequency of exposure with internal applicator - one treatment for 12-15 minutes at 12 months (optional treatment).~Device settings and programming external mons pubis and labia applicators - 10-35% output (optional treatment).~Duration of exposure and frequency of exposure external applicators - one treament for 15 minutes for the mons pubis, 10 minutes for labia at 12 months (optional treatment)."
47947515|NCT04625790|DEVICE|Repetitive transcranial magnetic stimulation|"Transcranial Magnetic Stimulation(TMS) has been used for diagnostic and therapeutic purposes in the treatment of many neurological and psychiatric diseases such as stroke, multiple sclerosis, myelopathy, amyotrophic lateral sclerosis, movement disorders, epilepsy, and depression. It is a way to stimulate the targeted areas in the cerebral cortex without invasive methods. The application of TMS in the aphasia usually consists of repetitive stimulations, in order to activate or deactivate the target area.~In this study, 10 sessions of 1-Hz low frequency rTMS for 20 minutes will be applied to the inferior frontal gyrus of the right frontal lobe."
47947516|NCT04625790|OTHER|Speech therapy|Speech therapy will be given to each patient by the same therapist, and the treatment will last 10 days, 60 minutes a day. It will consist of exercises to improve the articulation and comprehension.
47947517|NCT02810340|BIOLOGICAL|Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.
47947518|NCT02810340|BIOLOGICAL|Non-Adjuvanted MCV-5|Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).
47947519|NCT02810340|BIOLOGICAL|Menactra®|Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
47947520|NCT02239224|BIOLOGICAL|Placebo|Concentrate for solution for infusion
47947521|NCT02239224|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
47947522|NCT03285672|DRUG|FP-101|Dose 1
47947523|NCT03285672|DRUG|Placebo Comparator|Dose 1
47947524|NCT00729755|DIETARY_SUPPLEMENT|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
47947525|NCT00729755|DIETARY_SUPPLEMENT|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
47947526|NCT02943460|DRUG|Cilofexor|Tablet(s) administered orally once daily with food
47947527|NCT02943460|DRUG|Placebo to match cilofexor|Tablet(s) administered orally once daily with food
47947528|NCT06215612|OTHER|Blood draw, MRI|Blood draw, MRI
47947529|NCT04139473|PROCEDURE|Hepaticojejunostomy / Duct-to-duct anastomosis|
47947530|NCT02670434|DRUG|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
47947531|NCT02670434|DRUG|Placebo|Placebo daily for 12 weeks
47947532|NCT02670434|DRUG|Livalo|Livalo® IR daily from week 12 to week 52
47947533|NCT01934881|DEVICE|voltage adjustment only|Only voltage will be adjusted in all programming sections.
48477639|NCT02536469|DRUG|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
48477640|NCT05248204|DEVICE|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
48477641|NCT05248204|DEVICE|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
47947534|NCT01934881|DEVICE|Multiple parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
47947535|NCT02160782|DRUG|LUM001 (Maralixibat)|LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
47947536|NCT02160782|DRUG|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
48297489|NCT05404854|OTHER|Measurement of implicit attitudes|Implicit attitudes will be assessed by administering an Implicit Association Test on physical and sedentary activities. Sitting in front of a computer, participants will see a series of words appear in the middle of the screen referring to 4 conceptual categories - located at the top of the screen. Two represent the targeted behaviours (here, physical activity versus sedentary lifestyle) while the remaining two represent attributes (here, positive versus negative adjectives). The adjectives used will be the same as those used to measure explicit attitudes. The instructions given to the participant are to classify the words as quickly as possible, according to the semantic category to which they belong
48297490|NCT05182229|OTHER|Home-based (a hybrid model) CDT|Participants will be provided therapist-administered, in person complete decongestive therapy (CDT) two times per week for two weeks (4 sessions), followed by real-time, virtual CDT consultations two times per week for three weeks (7 sessions) and one in person follow-up visit.
48297491|NCT05182229|OTHER|Clinic-based CDT|Participants will be provided therapist administered, in-person CDT two times per week for six weeks (12 sessions).
48297492|NCT05328778|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
48297493|NCT00726323|DRUG|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
48297494|NCT06298097|DEVICE|Connectivity measures|Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.
48297495|NCT04579081|DEVICE|Contour Neurovascular System|Intrasaccular flow disruptor/divertor
48297496|NCT01674543|OTHER|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
48297497|NCT01674543|OTHER|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
48297498|NCT01674543|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
47947537|NCT06293079|OTHER|Exercise Program|Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
47947538|NCT00221260|PROCEDURE|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
47947539|NCT01727843|DRUG|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
47947540|NCT01727843|OTHER|placebo|applied topically to surgical site in OR.
47947541|NCT03903601|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.
47947542|NCT03903601|DIAGNOSTIC_TEST|Blood samples collection|Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.
47947543|NCT03903601|DIAGNOSTIC_TEST|Neuropsychological tests|Cognitive functions assessment
47947544|NCT05734833|DIETARY_SUPPLEMENT|Culturelle Probiotic + Fiber|The experimental group will receive the study product which is Culturelle Probiotic + Fiber
47947545|NCT05734833|OTHER|Placebo|The Placebo comparator arm will receive placebo sachets
47947546|NCT04093414|DEVICE|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
47947547|NCT05803473|DEVICE|Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)|"For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2."
47947548|NCT05803473|DEVICE|FreeStyle Precision Pro Glucometer for glucose POC testing|For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
47947549|NCT00424801|DRUG|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
47947550|NCT00424801|DRUG|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
48297499|NCT03663985|OTHER|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
48635990|NCT01805570|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
47947551|NCT00424801|DRUG|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
47947552|NCT00424801|DRUG|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
47947553|NCT00424801|DRUG|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
47947554|NCT00424801|DRUG|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
47947555|NCT00424801|DRUG|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
47947556|NCT04288180|OTHER|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
47947557|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
47947558|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
48297500|NCT06512038|RADIATION|DEXA Scan|If the participant consents to take part in the trial, they will have an additional DEXA scan.
48297501|NCT01022853|DRUG|BI 6727|intravenous each 21 days
48297502|NCT01022853|DRUG|BIBF 1120|oral continuously
48297503|NCT03633578|BEHAVIORAL|walk test|"The patient will have to walk on a treadmill in four different conditions:~* without distraction at preferential speed~* with distraction at preferential speed~* without distraction at the speed of 130% of the preferential speed~* with distraction at the speed of 130% of the preferential speed"
47947559|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
47947560|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
47947561|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
47947562|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
47947563|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
47947564|NCT01522807|DRUG|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
48297504|NCT05311007|OTHER|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
48297505|NCT02088944|DRUG|Infliximab|
48297506|NCT05754827|DIAGNOSTIC_TEST|RDW to platlet count ratio|RDW to platlet ratio will be measured for all patients and results will be compared between groups
48297507|NCT03401177|DRUG|Naproxen 500 Mg|Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
48297508|NCT03401177|DRUG|Placebo Oral Tablet|Placebo is used, to provide a control to the active group.
48297509|NCT03401177|OTHER|Heavy resistance training|Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
48297510|NCT02062151|OTHER|Acupuncture|Acupuncture
48297511|NCT01210950|BIOLOGICAL|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
47947565|NCT01310504|PROCEDURE|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
47947566|NCT01310504|PROCEDURE|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
47947567|NCT03835104|DEVICE|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
47947568|NCT02765685|DEVICE|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
47947569|NCT02765685|OTHER|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, ...), non-medicinal (physiotherapy, port of an orthosis, ...), even surgical, according to the influencers."
47947570|NCT01704521|DRUG|PegInterferon|
47947571|NCT01704521|DRUG|Ribavirin|
47947572|NCT01704521|DRUG|Telaprevir|
47947573|NCT05233293|PROCEDURE|Spyglass + RFA|SpyGlass direct Vision guided RFA
47947574|NCT05233293|PROCEDURE|Cytobrush + RFA|After Cytobrush ,taking RFA through ERCP
47947575|NCT03310710|DEVICE|Viabahn BX stent|Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
47947576|NCT04112524|DEVICE|App|"* Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~* AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices."
47947577|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
47947578|NCT00591266|DRUG|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
47947579|NCT00591266|DRUG|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
48104399|NCT04089046|BEHAVIORAL|Enhanced Care (EC)|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
48104400|NCT04471467|PROCEDURE|Fixed tracheal tube|Tracheal tube fixation is determined by the surgeon according to the needs of the operation and is an independent process. Our research simply installed a monitoring device between the tube and the nose. The tube fixation takes place whether the observation of pressures is agreed to or not, as per standard protocol.
48477642|NCT06616285|BEHAVIORAL|Self-Guided Multidomain Lifestyle Intervention|Participants will receive guidance on healthy dietary habits, physical activity, mental stimulation, and cardiovascular/metabolic monitoring based on national recommendations and individual consultations with the study physician. Based on this guidance, participants will create their own healthy lifestyle plan. Participants' cardiovascular/metabolic risk factors will be regularly monitored.
47947580|NCT01514331|OTHER|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
47947581|NCT01514331|OTHER|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
47947582|NCT06392607|DEVICE|Euclid orthokeratology (standard coating)|Lens with the current coating
47947583|NCT06392607|DEVICE|Euclid orthokeratology (enhanced coating)|Lens with the enhanced coating
47947584|NCT02503007|DIETARY_SUPPLEMENT|Placebo|
47947585|NCT02503007|DIETARY_SUPPLEMENT|HMB-FA|
48104401|NCT00641381|DRUG|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
48104402|NCT00641381|DRUG|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
48104403|NCT00641381|DRUG|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
47947586|NCT00969254|DRUG|Pílulas de Lussen|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo."
47947587|NCT00969254|DRUG|Pyridium®|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo."
47947588|NCT06195683|DRUG|Serplulimab|Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
47947589|NCT00835159|DRUG|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
47947590|NCT00835159|OTHER|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
47947591|NCT01636531|DRUG|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
47947592|NCT01636531|DRUG|gantenerumab|Lyophilized formulation (LyoF), single dose sc
47947593|NCT01304160|RADIATION|stereotactic body radiotherapy|30Gray in 5 fractions
48297512|NCT05181917|BEHAVIORAL|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
48297513|NCT05885256|DIAGNOSTIC_TEST|Amending current standard trauma order set|Blood draw happens as part of routine clinical care for all trauma activations. As part of the study, we will use existing blood that is drawn as part of routine clinical care, or when necessary, draw additional blood to obtain samples at 0, 3, 6, 12, 18, and 24 hours assessing ionized calcium, serum calcium, and magnesium. We will strive to have draws occur within +/- 1 hour of the goal times. However, given that the blood draws will be performed by way of the clinical team and the unpredictable nature of trauma care, missed draws or draws out of the goal time frame will not be considered protocol violations
48297514|NCT06129994|OTHER|Observational|Participants will complete an in-person baseline study visit with fasting blood draw, medical and health history, anthropometrics and vital signs, and surveys. If participants are not currently using a CGM, one will be placed. The LifeData study mobile app will be installed on the participant's smartphone. Over the two-week home monitoring period, participants will be asked to wear the CGM and respond to EMA questions three times daily. After the end of the home monitoring period, a remote visit will be performed in which the CGM will be removed by the study participant at home; the study team will obtain all data available from the CGM and insulin pump (if available); and surveys will be collected.
47947594|NCT00543491|DRUG|MK0767|
47947595|NCT03297814|BIOLOGICAL|Platelet lysate|Intramuscular injection of platelet lysate
47947596|NCT03297814|BIOLOGICAL|Placebo|intramuscular injection of normal saline
48297515|NCT05986539|OTHER|Observational|This study is only observational in nature and will not include an intervention.
48635991|NCT01805570|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
48635992|NCT00941421|DEVICE|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
48635993|NCT00201773|DRUG|Exemestane|25 mg orally once per day for 16 weeks.
48635994|NCT00201773|DRUG|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
47947597|NCT00420667|DRUG|Enoxaparin|
47947598|NCT04118933|DRUG|JS001|JS001 240mg, Q3W
47947599|NCT03606629|DEVICE|Endoprosthesis implantation|Endoprosthesis implantation by Percutaneous Angioplasty
47947600|NCT03805906|PROCEDURE|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
47947601|NCT05804474|OTHER|Observational study|Observational study
47947602|NCT06348680|OTHER|Video assisted episiotomy repair training|Midwifery Intervention The 'video recording' prepared by researchers specialized in the field of midwifery to increase the episiotomy repair skills of midwifery students will be used as training material. The content of the video recording is as follows: control before episiotomy repair, episiotomy repair, subcutaneous suturing, skin suturing, suturing techniques (Continuous, Simple Intermittent, Mattress). After the video recording is completed, it will be restarted and shown to the students in the experimental group continuously throughout the application period. At the end of the application period, students will be re-evaluated.
47947603|NCT03634644|DRUG|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
47947604|NCT03634644|DRUG|Placebo oral capsule|mainly composed of corn oil
47947605|NCT04964843|DRUG|N-acetylcysteine|N-acetylcysteine is an FDA approved medication that is used to treat acetaminophen overdose.
47947606|NCT04964843|DRUG|Placebo|Placebo
47947607|NCT00997061|DRUG|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
47947608|NCT04676217|PROCEDURE|Postoperative positioning advice|The postoperative positioning advice until 3 am the same day.
47947609|NCT01526122|DRUG|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg \& Aspirin 100mg in 1 capsule), PO
47947610|NCT01526122|DRUG|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules, PO
48635995|NCT00201773|OTHER|Correlative studies|
48635996|NCT04394000|OTHER|thromboprofylaxis protocol|This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
47947611|NCT02224092|DIETARY_SUPPLEMENT|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
47947612|NCT01783054|PROCEDURE|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
47947613|NCT01783054|GENETIC|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
47947614|NCT01783054|DRUG|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
47947615|NCT02715401|DRUG|HCP1303|
47947616|NCT02715401|DRUG|HGP1201|
47947617|NCT02715401|DRUG|HIP1402|
47947618|NCT01033188|PROCEDURE|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
47947619|NCT01033188|PROCEDURE|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith \& Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
47947620|NCT06377306|BEHAVIORAL|Effect of training loads and sport performance level on health and sport performance|Effect of training loads and sport performance level on health and sport performance
47947621|NCT00136331|BIOLOGICAL|Pandemic influenza vaccine|
47947622|NCT01945827|DEVICE|DeltaMaxx Microcoil System|
48635997|NCT04394000|OTHER|standard protocol|This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
48635998|NCT04556825|DRUG|PRP|After the arthroscopic operation was completed, a local PRP with 4ml was injected
47947623|NCT04680156|DRUG|Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies|No treatment to be administered - Observational only
47947624|NCT00167557|DRUG|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
47947625|NCT00167557|DRUG|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
48104404|NCT00641381|OTHER|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
48104405|NCT00641381|PROCEDURE|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
48635999|NCT04556825|DRUG|normal saline|After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
48636000|NCT03574779|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
48636001|NCT03574779|BIOLOGICAL|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to Programmed cell death protein 1 (PD-1) resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
48636002|NCT03574779|BIOLOGICAL|Bevacizumab|Bevacizumab is an Food Drug and Administration (FDA) approved antiangiogenic recombinant humanized monoclonal Immunoglobulin (Ig) G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
48636003|NCT03574779|DRUG|Carboplatin|Carboplatin will be infused intravenously over 60 minutes at the prescribed dose of area under the concentration versus time curve of 5 to 6 mg/milliliters (mL) per minute on Day 1 of every 21-day cycle
47947626|NCT00167557|PROCEDURE|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
47947627|NCT04840732|BEHAVIORAL|VR training program|Use VR software to make a training education program.
48104406|NCT00641381|PROCEDURE|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
48636004|NCT03574779|DRUG|Paclitaxel|Paclitaxel will be administered intravenously over 180 minutes at the prescribed dose of 175 mg/meter square (m\^2) on Day 1 of every 21-day cycle
48636005|NCT04880889|DRUG|BL 3000|capsule 500 mg
48636006|NCT04880889|DRUG|Reference Pantogar|capsule
48636007|NCT04880889|DRUG|BL3000 Placebo|capsule 500 mg
48636008|NCT04880889|DRUG|Pantogar - Placebo|capsule
47947628|NCT04840732|BEHAVIORAL|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
48297516|NCT04284917|DRUG|Carglumic Acid (Carbaglu®)|"A. Study period: 24 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12. (Check Plasma Amino Acid Analysis, Ammonia, acylcarnitine profile, Urinary organic acid analysis.)~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis will be recorded during treatment period."
48297517|NCT03120403|PROCEDURE|intrathecal morphine|
48297518|NCT05664685|DRUG|Optimized bismuth quadruple therapy|Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
48297519|NCT05664685|DRUG|Control|Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
48297520|NCT05186558|DRUG|penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin|"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months."
48297521|NCT00611130|DRUG|vigabatrin|Tablets twice a day for 9 weeks
48297522|NCT00611130|DRUG|placebo|tablets twice daily for 9 weeks
48297523|NCT03068026|DEVICE|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
48297524|NCT03068026|OTHER|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
48297525|NCT04016363|OTHER|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
48636009|NCT06145594|OTHER|EMA Monitoring|Weekly prompts to participants' smart phones for collection of PHQ-9 data
47947629|NCT01499069|DRUG|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
47947630|NCT05096728|DRUG|Nifedipine XL|"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg"
47947631|NCT00979069|BEHAVIORAL|Aerobic group|12 weeks of aerobic exercise 3 times a week
48636010|NCT06145594|OTHER|Scheduling Maintenance TMS sessions|When threshold score is reached, the participants is offered TMS maintenance treatments
48636011|NCT05808127|BEHAVIORAL|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
48636012|NCT04799639|DRUG|Sindilimab +paclitaxel+ cisplantin|standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
48636013|NCT04102982|DRUG|Camrelizumab|Patients will be treated with camrelizumab alone.
47947632|NCT01209728|OTHER|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
47947633|NCT02138435|OTHER|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
47947634|NCT02138435|OTHER|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
47947635|NCT03461263|OTHER|phonophoresis treatment using pumpkin seeds oil|phonophoresis treatment using pumpkin seeds oil
47947636|NCT04036734|DIAGNOSTIC_TEST|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
47947637|NCT04036734|DIAGNOSTIC_TEST|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
47947638|NCT05067907|PROCEDURE|Early physiotherapy|"Respiratory physiotherapy included:~1. early and functional mobilization: passive and active mobilization, muscle strengthening, improving independence in activities of daily living (ADL), sitting out of bed, standing, walking;~2. patient positioning to achieve better ventilation/perfusion ratio and gas exchange;~3. airway clearance;~4. aerosol administration;~5. invasive mechanical ventilation weaning;~6. use of non-invasive mechanical ventilation (NIMV) and continuous positive airway pressure (CPAP);~7. tracheostomy management and weaning;~8. swallowing assessment;~9. management of oxygen delivery;~10. lung expansion;~11. patient assessment and functional scale administration."
47947639|NCT03412708|OTHER|Vestibular Rehabilitation supported with Virtual Reality|Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
48297526|NCT04016363|OTHER|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
48297527|NCT06672224|PROCEDURE|Fluid Therapy|Given IV
48297528|NCT06672224|DRUG|Indocyanine Green|Given subcutaneously
48297529|NCT06672224|OTHER|Questionnaire Administration|Ancillary studies
48297530|NCT06672224|OTHER|Research or Clinical Assessment Tool|Undergo lymphedema assessment
48636014|NCT04102982|OTHER|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
48297531|NCT06672224|PROCEDURE|SPY Elite Fluorescence Imaging|Undergo SPY imaging
47947640|NCT06045104|DIETARY_SUPPLEMENT|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling|Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
47947641|NCT06045104|DIETARY_SUPPLEMENT|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling|15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
47947642|NCT05631665|OTHER|Survey results before and after laser treatment|Determination of sexual activity rates as points with a questionnaire before and after laser treatment for patients with postmenopausal sexual function problems.
47947643|NCT05080907|OTHER|Observational|Subjects for observational study Various conditions \& healthy subjects
47947644|NCT02404467|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
47947645|NCT00234273|PROCEDURE|Rehabilitation programme in Adapted Physical Activity (APA)|
47947646|NCT00234273|BEHAVIORAL|Therapeutic education primarily focused on dietary|
47947647|NCT04793698|OTHER|Compassion meditation|10 week meditation course taught in 90-minute groups
47947648|NCT04793698|BEHAVIORAL|Applied relaxation|10 week applied relaxation course taught in 90-minute groups
48636015|NCT01061710|DRUG|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
47947649|NCT00356733|DRUG|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
48297532|NCT06672224|OTHER|Survey Administration|Ancillary studies
48297533|NCT00886821|BIOLOGICAL|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
48297534|NCT01943279|OTHER|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
48636016|NCT01454063|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
48636017|NCT01454063|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
47947650|NCT05038046|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
47947651|NCT05140850|BIOLOGICAL|neuroimaging examination,neuro-cognitive test,blood pressure,blood sample|neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
47947652|NCT06203236|DRUG|Furosemide 20 MG|"1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation."
47947653|NCT06203236|OTHER|diuretic therapy|diuretic therapy
47947654|NCT02600351|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
47947655|NCT02600351|DRUG|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
47947656|NCT01790776|RADIATION|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
48297535|NCT01943279|OTHER|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
48297536|NCT02255591|DRUG|Lidocaine-adrenaline added gadolinium.|
48297537|NCT04372693|OTHER|impliminting Online Distance Learning|as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
48636018|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with counter-displaced skin-subcutaneous fascial flaps after extralevatory abdominal-perineal extirpation of the rectum|Skin-subcutaneous fascial flap on the leg is cut out from one side of the perineal wound, and deepithelized, forming a diamond-shaped perineal wound. The cut flap is immersed in the aperture of the pelvis and fixed with single sutures to the remains of levators of the opposite side. The flap width should be 3-4 cm, sufficient to fill the pelvic aperture. On the opposite side of the wound, a skin-subcutaneous fascial flap is cut out on a triangular leg equal to the width of the previously formed diamond-shaped wound. The flap is moved to the center of the wound, additionally filling wound cavity with it, combining the vertex of the triangle with the vertex of the rhombus. The perineal wound is drained through the contraperture. The flap is fixed with separate nodal seams.
48636019|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with local tissues|Simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.
48636020|NCT06066931|PROCEDURE|Plastic surgery of the pelvic floor and perineal wound with mesh endoprosthesis|A mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
47947657|NCT01790776|RADIATION|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
47947658|NCT05536479|PROCEDURE|Autogenous stored mineralized dentin graft (ASMDG)|"Autogenous stored mineralized dentin graft (ASMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.~The disinfected particles will then be stored at room temperature for 21 days in a sterile container. After 21 days, a second extraction will be performed followed by mixing the stored graft with a few drops of sterile saline to be packed in a socket after extraction"
48297538|NCT04967755|DRUG|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
47947659|NCT05536479|PROCEDURE|Autogenous fresh mineralized dentin graft (AFMDG)|Autogenous fresh mineralized dentin graft (AFMDG) particles will be prepared by immersing tooth particles in basic ethanol for 10 min for disinfection, then washed twice in saline and dried using sterile gauze.
47947660|NCT03300960|DRUG|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
47947661|NCT03300960|DRUG|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
47947662|NCT06397573|RADIATION|Reirradiation|Ablative reirradiation of 50 Gy in 5 fractions (5 sessions) that will occur once per day, either for 5 days in a row, or every other day.
47947663|NCT00715923|OTHER|Modified consent form|modified consent form used
47947664|NCT00715923|OTHER|Standard consent form|standard consent form used
47947665|NCT04327973|BIOLOGICAL|ATB200|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
47947666|NCT04327973|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
47947667|NCT05991700|DRUG|Freeze-Dried California Table Grape|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
48477643|NCT06616285|BEHAVIORAL|Folk Dance Multidomain Lifestyle Intervention|"Participants will receive structured, intensive lifestyle intervention with the following components: diet, physical exercise, mental stimulation, cardiovascular/metabolic risk monitoring, social interaction.~One-hour long folk dancing sessions, delivered by professional teachers 3 times weekly, will provide opportunities for physical and mental exercise and social interaction. These sessions were specifically developed to foster physical and mental stimulation through the learning of coordinated movement and different choreographies (rhythmic and gradually more complex movements with folk songs) individually, in pairs, and circles. As such, social stimulation is naturally embedded in the sessions.~Participants will receive advice about diet and cardiovascular/metabolic risk factors based on national recommendations via group sessions and individual consultations. Participants' cardiovascular/metabolic risk factors will be regularly monitored."
48477644|NCT00946491|DRUG|Haloperidol 10 mg Tablets (Cord Laboratories)|
48477645|NCT00946491|DRUG|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
47947668|NCT05991700|DRUG|Placebo|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
47947669|NCT06556472|DRUG|Terlipressin|1. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.
47947670|NCT06556472|DRUG|Norephrine|1. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
48104407|NCT02727972|BEHAVIORAL|Cognitive Testing|Verbal assessments as well as computer testing.
47947671|NCT04043728|BEHAVIORAL|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
47947672|NCT05995119|DRUG|Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)|The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
47947673|NCT00795925|DRUG|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
48297539|NCT01332929|DRUG|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
47947674|NCT03210623|DEVICE|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
47947675|NCT03210623|DEVICE|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
47947676|NCT00521612|DRUG|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
47947677|NCT00521612|DRUG|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
47947678|NCT05722457|OTHER|external focus task focus in addition to physiotherapy and rehabilitation exercises|"The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
47947679|NCT05722457|OTHER|internal focus task focus in addition to physiotherapy and rehabilitation exercises|"he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement."
47947680|NCT05124405|OTHER|Fitbit|wearable activity tracker
47947681|NCT05124405|OTHER|Continuous Glucose Monitor|wearable activity tracker
48104408|NCT02727972|OTHER|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.
48297540|NCT06671106|OTHER|toothbrushing|manual toothbrush (meridol)
48297541|NCT06671106|OTHER|flossing|dental floss (meridol)
48477646|NCT06276686|OTHER|Supervised Vigorous intensity aerobic interval exercise|11-weeks course of aerobic and resistance exercise, delivered 2 weeks before long course NACRT, 5-weeks during NACRT and 4 weeks post NACRT. Alongside twice weekly unsupervised resistance exercise training.
48297542|NCT06671106|DEVICE|Toothpaste Product|amine and zinc lactate - containing toothpaste (meridol Gum Protection)
48297543|NCT06671106|DEVICE|Mouthrinse|amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
48297544|NCT02559232|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
48477647|NCT05734131|OTHER|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up\&Go test (TUG).
47947682|NCT03063203|DRUG|Decitabine|"* After 2 cycles, patients with progressive disease or relapse (a clear progression with at least \>20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~* Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~* Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~* Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~* Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
47947683|NCT03063203|PROCEDURE|Bone marrow biopsy/aspirate|"* Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~* Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~* Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"
47947684|NCT03063203|PROCEDURE|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
47947685|NCT03063203|PROCEDURE|Skin biopsy|"* Optional but if refuse skin biopsy then participant can provided buccal swab~* There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~* If WBC at time of enrollment is \>30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"
47947686|NCT03063203|PROCEDURE|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
47947687|NCT00473473|DRUG|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
47947688|NCT00473473|DRUG|Placebo homeopathic remedy|identical to treatment without active component
47947689|NCT06115785|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive Stimulation Therapy CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and in progress10 min. 45 minutes in total, including the ending.
47947690|NCT03078907|DRUG|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
47947691|NCT03078907|DRUG|Placebo|Matching film coated tablets
47947692|NCT04197752|OTHER|Regional anesthesia/analgesia techniques|Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
47947693|NCT06609668|BIOLOGICAL|Additional blood samples|"* 2 dry tubes (5 mL)~* 2 EDTA tubes (6 mL)~Performed at inclusion (before any corticosteroid treatment) and at follow-up visit (3 months after inclusion)"
47947694|NCT02372370|PROCEDURE|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
47947695|NCT02372370|PROCEDURE|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
47947696|NCT02372370|PROCEDURE|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
47947697|NCT02372370|PROCEDURE|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
47947698|NCT02372370|PROCEDURE|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
47947699|NCT02372370|DRUG|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
48477648|NCT05344716|DEVICE|Laser|Intraurethral and vaginal laser treatment
48477649|NCT01472926|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
48477650|NCT01472926|DRUG|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
47947700|NCT02372370|OTHER|Untreated Control|Untreated control. No interventions.
48104409|NCT02727972|RADIATION|PET|High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB or ABP688.
47947701|NCT06363357|DEVICE|Shoulder orthosis|muscle-mimicking, fabric-type shoulder orthosis
48297545|NCT05908383|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
48297546|NCT05908383|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
47947702|NCT04666675|DRUG|Upadacitinib|Oral; Tablet
47947703|NCT04666675|DRUG|Placebo for Upadacitinib|Oral; Tablet
47947704|NCT02322021|DRUG|E2609|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
47947705|NCT02322021|DRUG|Placebo|Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
47947706|NCT02764697|DRUG|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
48104410|NCT05817409|DRUG|Intrathecal Baclofen Pump|intrathecal baclofen treatment
48104411|NCT05621811|DRUG|Naronapride|Naronapride is a 5HT-4 agonist
48104412|NCT05621811|DRUG|Placebo|Placebo
48104413|NCT03841019|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
48104414|NCT03841019|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
48104415|NCT01322919|PROCEDURE|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
48104416|NCT01087684|PROCEDURE|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
47947707|NCT01336192|DRUG|Gemcitabine|Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD
48104417|NCT01087684|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
48297548|NCT03785197|OTHER|Prolonged modified fasting|The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths
48297549|NCT02565823|OTHER|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
48297550|NCT00828867|DRUG|100 mg GSK investigational drug|
48477651|NCT02036801|OTHER|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
47947708|NCT01336192|DRUG|Best supportive care|Best supportive care
47947709|NCT05133076|BIOLOGICAL|Lactobacillus gasseri BGP345A|Active and placebo capsules for oral use
47947710|NCT05133076|BIOLOGICAL|Placebo|Placebo
47947711|NCT04124653|DRUG|PF-06842874|Single dose administration of PF-06842874
47947712|NCT04124653|DRUG|Placebo|Single dose administration of placebo
47947713|NCT04124653|DRUG|Relative Bioavailability|Relative bioavailability assessment of modified-release formulation
47947714|NCT02207023|BEHAVIORAL|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
48104418|NCT03987451|DRUG|Semaglutide|Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
48104419|NCT03987451|DRUG|Placebo (semaglutide)|Semaglutide placebo s.c. given once-weekly for 48 weeks
48104420|NCT06553287|DRUG|LNK01004 ointment 0.3%|LNK01004 ointment 0.3% for topical application
48104421|NCT06553287|DRUG|LNK01004 ointment 1.0%|LNK01004 ointment 1.0% for topical application
48104422|NCT06553287|DRUG|LNK01004 ointment 1.5%|LNK01004 ointment 1.5% for topical application
48104423|NCT06553287|DRUG|Vehicle BID|Inactive vehicle matched to LNK01004 ointment for topical application.
48297551|NCT00828867|DRUG|200 mg GSK investigational drug|
48297552|NCT00828867|DRUG|400 mg GSK investigational drug|
48297553|NCT00828867|DRUG|800 mg GSK investigational drug|
48297554|NCT00828867|DRUG|2000 mg GSK investigational drug|
48297555|NCT00828867|DRUG|1500 mg GSK investigational drug|
48297556|NCT00828867|DRUG|800mg fed GSK investigational drug|
48297557|NCT00828867|DRUG|3000mg GSK investigational drug|
48297558|NCT00828867|DRUG|4000mg GSK investigational drug|
47947715|NCT00706810|DRUG|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
47947716|NCT00706810|DRUG|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
47947717|NCT05203289|DRUG|BI 695501 - higher concentration|BI 695501 - higher concentration
47947718|NCT05203289|DRUG|BI 695501 - lower concentration|BI 695501 - lower concentration
47947719|NCT02001181|DRUG|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
47947720|NCT02001181|DRUG|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
47947721|NCT01658852|DRUG|metronidazole|
47947722|NCT01658852|DRUG|Placebo|
47947723|NCT03132012|BEHAVIORAL|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
47947724|NCT03132012|BEHAVIORAL|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
47947725|NCT00785018|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
47947726|NCT00785018|DRUG|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
48104424|NCT05603767|OTHER|RMT+ VR|(RMT+ VR). The responsive music therapy session combined with virtual reality involves four stages: a) Background settings; b) VR video and music selection; c) Listening experience and VR; and e) Return to alert status. The therapist will help the patient to select the video to be used for the experience. Utilizing the application created by the research team, the patient will be provided with four possible scenarios. As for the music, patients are asked to choose music that relaxes them the most. Chosen music can be instrumental music (guitar, electric piano or violin) or sung music with harmonic accompaniment (piano or guitar). In both cases the music will be played live.
47947727|NCT01164683|BEHAVIORAL|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
47947728|NCT01164683|OTHER|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
48104425|NCT00608933|OTHER|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
48104426|NCT00608933|OTHER|questionnaire administration|Patients complete questionnaires
48104427|NCT01887041|PROCEDURE|Stent|Endoscopically inserted biliary tract drainage
48104428|NCT01887041|PROCEDURE|Biliodigestive anastomosis|Biliodigestive anastomosis
47947729|NCT03126370|DRUG|TDF with a boosted protease inhibitor|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
47947730|NCT03126370|DRUG|TAF with a boosted protease inhibitor|"Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
47947731|NCT03126370|DRUG|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
48297559|NCT02714634|DRUG|Methotrexate + targeted therapy administration|"* Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib"
47947732|NCT04340297|DRUG|Tongjiang series prescription(Tongjiang granules, Jianpi Qinghua granules and Wenpi Qingwei granules)|According to the syndrome differentiation of TCM, Tongjiang granules are taken orally by patients with liver-stomach depression-heat syndrome, Jianpi Qinghua granules are taken orally by patients with spleen deficiency damp-heat syndrome, Wenpi Qingwei granules are taken orally by patients with cold-heat complicated syndrome, 1 bag per time, 3 times a day and 1 hour after a meal.
47947733|NCT04340297|DRUG|Acid inhibitors|In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
47947734|NCT04340297|DRUG|Placebo|Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
48636021|NCT02504385|DEVICE|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
48636022|NCT02504385|OTHER|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
48636023|NCT03636269|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
48636024|NCT03636269|DRUG|Placebo|IV placebo administered three times/week
48636025|NCT01415453|PROCEDURE|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
48636026|NCT05084885|OTHER|Online therapy|Standard counseling provided over the internet.
48636027|NCT04796220|DRUG|Gemcitabine|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.
48636028|NCT04796220|DEVICE|Focused Ultrasound|Focused ultrasound will be applied to up to 2 breast lesions on day 8.
48636029|NCT04796220|OTHER|Gemcitabine and Focused Ultrasound|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
48636030|NCT03940092|OTHER|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (\>18 years), and female patients (\>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
48636031|NCT03940092|OTHER|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
48636032|NCT06305858|PROCEDURE|Prosthetic Surgical Procedure|"The population consists of 48 patients divided into two groups:~24 patients Group A experimental group: partial denture surgical procedure~24 patients Group B control group: total denture surgical procedure with patellar resurfacing"
48636033|NCT04102111|DRUG|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
48636034|NCT04102111|DRUG|Placebo|Participants will receive oral tablets of matching placebo twice daily.
48636035|NCT01990352|DRUG|Pegylated liposomal doxorubicin|Doxil will be administered intravenously at 30mg/m2 on days 1 of a 21 day cycle.
48636036|NCT01141543|DRUG|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
48636037|NCT04431778|DRUG|Ethosuximide|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
48636038|NCT04431778|DRUG|Placebo|"Taking the treatment (1 daily intake during the evening meal) according to increasing dosage:~Step 1: 2.5 ml (125 mg) / day for 7 days Step 2: 5 ml (250 mg) / day for 7 days Step 3: 7.5 ml (375 mg) / day for 7 days Step 4 (final): 10 ml (500 mg) / day for the remainder of the study (12 weeks)."
48636039|NCT00906750|BIOLOGICAL|FluMist|FluMist is a live attenuated intranasal influenza vaccine
48636040|NCT00906750|BIOLOGICAL|Inactivated influenza vaccine|Inactivated influenza vaccine
48636041|NCT03488485|DRUG|Direct Acting Antivirals|DAAs given in patients with viremic chronic hepatitis C
47947735|NCT04669327|OTHER|gait analysis|Vicon nexus with MTI force plate form
48636042|NCT00773110|DRUG|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
48636043|NCT00773110|DRUG|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
48636044|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
48636045|NCT01104337|DRUG|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
47947736|NCT00752037|DRUG|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
48104429|NCT04092985|DEVICE|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
48636046|NCT01104337|DRUG|Placebo|Treatment consisted of two matching placebo tablets three times a day.
48636047|NCT00538265|DRUG|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
47947737|NCT05885854|DRUG|XTR003|"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."
47947738|NCT03004443|DRUG|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
47947739|NCT03004443|DRUG|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
47947740|NCT02121782|BIOLOGICAL|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
47947741|NCT02121782|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
47947742|NCT04208568|PROCEDURE|Laparoscopic cholecystectomy|Four ports laparoscopic cholecystectomy under general anaesthesia
47947743|NCT06161272|DRUG|Fluzoparib|single
47947744|NCT06161272|DRUG|Fluzoparib+Apatinib|combination
47947745|NCT05076071|GENETIC|NGS|Next Generation Sequencing
47947746|NCT02470416|DEVICE|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
47947747|NCT06529965|BEHAVIORAL|covivio|Participants will receive access to the digital health intervention covivio in addition to TAU.
47947748|NCT06340061|OTHER|Observational study|The ocular biomechanical differences between the normal control group and primary glaucoma patients, including those treated with conventional medication, laser therapy, and surgery, were compared. Additionally, an investigation was conducted to explore the relationship between anterior chamber parameters, corneal biomechanics, and the severity of glaucoma
47947749|NCT00006363|DRUG|cytarabine|Given IV
47947750|NCT00006363|DRUG|daunorubicin hydrochloride|Given IV
47947751|NCT00006363|DRUG|etoposide|Given IV
47947752|NCT00006363|DRUG|valspodar|Given IV
47947753|NCT00006363|BIOLOGICAL|filgrastim|Given SC
47947754|NCT00006363|DRUG|busulfan|Given orally
47947755|NCT00006363|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
47947756|NCT00006363|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous PBSCT
48297560|NCT02714634|DRUG|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
48297561|NCT02392208|DRUG|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
48297562|NCT02392208|PROCEDURE|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
48477652|NCT04769752|OTHER|collection of the allocated treatment|collection of the allocated treatment
47947757|NCT00006363|BIOLOGICAL|aldesleukin|Given SC
47947758|NCT00006363|OTHER|clinical observation|Undergo clinical observation
47947759|NCT00006363|OTHER|pharmacological study|Correlative studies
47947760|NCT00772083|BEHAVIORAL|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
47947761|NCT00772083|BEHAVIORAL|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
47947762|NCT00973271|DRUG|290 mg DCCR|290 mg diazoxide choline
47947763|NCT00973271|DRUG|435 mg DCCR|435 mg diazoxide choline
47947764|NCT00973271|DRUG|135 mg fenofibric acid|135 mg fenofibric acid
47947765|NCT00973271|DRUG|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
47947766|NCT00973271|DRUG|atorvastatin|20 mg atorvastatin
47947767|NCT04357366|DRUG|Anakinra|Treatment with 100mg Anakinra subcutaneously (sc) once daily for ten days
47947768|NCT04937855|OTHER|no intervention|no intervention
47947769|NCT00351000|DRUG|Ziprasidone|
47947770|NCT04223583|DRUG|Anlotinib Hydrochloride|The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
47947771|NCT02414451|DRUG|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning \& night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, \& 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning \& 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
47947772|NCT02414451|DRUG|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules"
47947773|NCT04790396|DEVICE|Carotid ultrasound under pulsed-wave doppler mode|Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
47947774|NCT01904539|DRUG|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
47947775|NCT04814862|BEHAVIORAL|3 validated questionnaires (ADHD-RS, SRS, BRIEF) for the diagnosis of neurodevelopmental disorders|Completion of three validated questionnaires for the diagnosis of neurodevelopmental disorders
47947776|NCT06525597|BIOLOGICAL|Stapokibart Injection|IL-4Rα monoclonal antibody
47947777|NCT06525597|DRUG|Placebo|Placebo
48477653|NCT04769752|OTHER|collection of medical complications|collection of medical complications
48477654|NCT01556282|DEVICE|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
48477655|NCT00389220|DEVICE|Coronary stent placement|Coronary stent placement
48477656|NCT05171894|DRUG|Hemopfin+Green Light|All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
48477657|NCT05171894|DEVICE|Vehicle+Green Light|All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
48636048|NCT00538265|DRUG|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
48636049|NCT00538265|DRUG|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
48636050|NCT03394846|BEHAVIORAL|Test of Existing MI Products|Three widely available MI products (GoNoodle, Take10, ABC for Fitness) will be tested by teachers in their classrooms. Teachers will participate in the study for four weeks (one baseline week, one week for each product).
48636051|NCT04122495|DIETARY_SUPPLEMENT|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
48636052|NCT04122495|DIETARY_SUPPLEMENT|Placebo|Oral administration of maltodextrin daily for 4-weeks
48636053|NCT03193307|DRUG|Microgynon® 30|Run in period \& Treatment Period
48636054|NCT03193307|DRUG|BI 409306|Day 18 \& 29 (Treatment Period)
48636055|NCT02440529|BEHAVIORAL|Intervention|Discussion
48636056|NCT02440529|BEHAVIORAL|Verbal Group|Detailed Discussion
48636057|NCT06465901|OTHER|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower|Chlorhexidine Gluconate 2.0% to 4.0% (e.g. Hibiscrub) preoperative shower
48636058|NCT06465901|OTHER|Intraoperative wound wash (e.g. Granudacyn)|Intraoperative wound wash (e.g. Granudacyn)
48636059|NCT06465901|OTHER|DACC surgical wound dressing (e.g. Leukomed Sorbact)|DACC surgical wound dressing (e.g. Leukomed Sorbact)
48636060|NCT03799367|DEVICE|Drug delivery during breastfeeding|This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.
48636061|NCT05539911|DRUG|Fentanyl|50 mic fentanyl added as an adjuvant
48636062|NCT01691092|DRUG|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
48636063|NCT06069271|OTHER|Kettlebell swing|The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
48636064|NCT05647382|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
48636065|NCT06491576|DRUG|BGT-002|taking the study drug orally
48636066|NCT06491576|DRUG|Placebo|taking the placebo orally
48636067|NCT06358989|OTHER|HOMA IR|Homa ir
48636068|NCT03393975|BIOLOGICAL|BAX930|Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
47947778|NCT03647332|PROCEDURE|Cooled RFA treatment|cooled radiofrequency ablation
48636069|NCT03393975|BIOLOGICAL|Standard of care|Participants will receive Investigator-recommended Standard of care (SoC).
48636070|NCT02458495|BEHAVIORAL|Diabetes MAP Intervention|
48297563|NCT06211322|DEVICE|"Urika, a self-management application for patients with gout"|The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
47947779|NCT03647332|DRUG|Steroid Drug|steroid injection
47947780|NCT05982548|OTHER|VR intervention|"VR intervention of no more than 7 minutes~Participants viewed the home as a first person character and experience psychotic phenomena including auditory hallucinations."
47947781|NCT05982548|OTHER|VR control intervention|"VR intervention of no more than 7 minutes~Participants viewed the same home as a first person character without psychotic phenomena"
47947782|NCT06052072|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
48636071|NCT03967665|DRUG|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
48297564|NCT00092547|BIOLOGICAL|V501|0.5 mL intramuscular injection of V501
47947783|NCT06064604|OTHER|Control|The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
47947784|NCT06064604|DEVICE|Hip Exoskeleton|The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.
48104430|NCT00837616|DRUG|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
48636072|NCT04560114|DRUG|Essential oils|"The patient will be invited to inhale the essential oils via the stick:~* 4 times a day before each meal and snack.~* if necessary when nausea appears, as many times as he deems necessary."
47947785|NCT06064604|DEVICE|Ankle Exoskeleton|The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
47947786|NCT02434367|BEHAVIORAL|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
47947787|NCT01135212|DRUG|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
48297565|NCT00092547|BIOLOGICAL|Comparator: Placebo|0.5 mL intramuscular injection of placebo
48636073|NCT05826470|DEVICE|"TRANBERG®|Thermal Therapy System"|Focal laser ablation.
48636074|NCT03240432|DEVICE|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
47947788|NCT01135212|DRUG|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
47947789|NCT01135212|DRUG|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
47947792|NCT04297059|OTHER|Ajyal Salima|It comprises in class-activities, meetings with parents and improvement of school foodservice
47947793|NCT03181815|DRUG|Cladribine|5mg/㎡ d1-5
47947794|NCT03181815|DRUG|G-CSF|300ug d0-9
48297566|NCT05342831|OTHER|Biological Nutrition Technique|Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
48297567|NCT04575662|RADIATION|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
47947795|NCT03181815|DRUG|Aclarubicin|10mg d3-6
47947796|NCT03181815|DRUG|Cytarabine|10mg/㎡ q12h SC d3-9
47947797|NCT01460368|DRUG|LY2409021|Administered orally
47947798|NCT01460368|DRUG|Placebo|Administered orally
47947799|NCT01460368|DRUG|Moxifloxacin|Administered orally
48104431|NCT00837616|DRUG|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
48104432|NCT06505824|DRUG|BL-M14D1|Administration by intravenous infusion for a cycle of 3 weeks.
48104433|NCT01814644|BEHAVIORAL|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
48104434|NCT01814644|BEHAVIORAL|Standard Care|Individual assessment, lifestyle counseling
48104435|NCT01364519|DRUG|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
48104436|NCT01364519|DRUG|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
48636075|NCT01716195|RADIATION|Induction Chemotherapy followed by Response Adapted Chemoradiation|All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.
48104437|NCT05990569|OTHER|Ultrasound guided Pudendal nerve block|Ultrasound guided bilateral pudendal nerve block
48104438|NCT04889664|DRUG|Ketamine|Repeated intravenous Ketamine infusions.
48636076|NCT05257980|DIETARY_SUPPLEMENT|Dietary supplement (ONS)|At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.
48636077|NCT03730701|BEHAVIORAL|Prevention program for stroke|The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
48104439|NCT04889664|BEHAVIORAL|Written Exposure Therapy|WET is a brief, 5-session evidence-based written trauma-focused therapy
48636078|NCT06272929|DEVICE|doppler ultrasound|doppler US
48636079|NCT05522556|DRUG|Ritlecitinib|capsules
48636080|NCT03600155|BIOLOGICAL|Ipilimumab|Given IV
48104440|NCT05663918|BEHAVIORAL|Self- determined Intensity Interval Training|Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes
48636081|NCT03600155|BIOLOGICAL|Nivolumab|Given IV
48636082|NCT01932424|DEVICE|Pelorus 1500|a bedside blood propofol measurement device
48636083|NCT01932424|DRUG|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
47947800|NCT02140242|DRUG|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
48104441|NCT04963621|BEHAVIORAL|Child-Adolescent Emotion and Stress Intervention Program|Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
48104442|NCT00466076|DRUG|Copaxone (Glatiramer acetate)|
48104443|NCT00045916|PROCEDURE|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
48104444|NCT00045916|DRUG|Nortriptyline|Participants will receive nortriptyline.
47947801|NCT02140242|PROCEDURE|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
47947802|NCT02674776|DRUG|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
47947803|NCT02674776|DRUG|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
47947804|NCT01147640|DRUG|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
47947805|NCT01147640|DRUG|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
47947806|NCT01262573|PROCEDURE|Closure of vaginal cuff|Closure of the vaginal cuff
47947807|NCT05595642|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
47947808|NCT05595642|DRUG|Placebo|Participants will receive SC placebo Q2W
48104445|NCT00045916|DRUG|Venlafaxine|Participants will receive venlafaxine.
48104446|NCT00045916|DRUG|Lithium|Participants will receive lithium.
48297568|NCT01571882|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
48297569|NCT01571882|OTHER|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
48297570|NCT01571882|OTHER|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
48297571|NCT01588197|BEHAVIORAL|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
48297572|NCT01588197|BEHAVIORAL|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
48297573|NCT01588197|BEHAVIORAL|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
48297574|NCT02517112|OTHER|Parabolic flight|
48297575|NCT02517112|OTHER|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
48297576|NCT02517112|DEVICE|3D-BCG sensor|
48297577|NCT02979873|DRUG|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).
48297578|NCT01563588|BEHAVIORAL|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
48297579|NCT05574504|DRUG|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|"Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~* Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~* Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion"
48297580|NCT02458651|OTHER|No intervention|No intervention administered in this study
48297581|NCT06119178|DEVICE|EX-PRESS P-50 filtration device|FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
48297582|NCT06119178|DEVICE|EX-PRESS P-200 filtration device|FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
48297583|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
48297584|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
48636084|NCT03542357|DRUG|Calcitonin Gene Related Peptide|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
48636085|NCT03542357|DRUG|Sumatriptan 50 mg|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
47947809|NCT04060849|DRUG|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
47947810|NCT04060849|OTHER|Best Practice|Receive standard of care
47947811|NCT05886218|DEVICE|Quantitative Neuromuscular Function Monitoring|Quantitative electromyographic (EMG) monitoring
48297585|NCT00299884|DRUG|Lipitor 20 mg|A/A for 6 weeks
47947812|NCT05517993|DRUG|Gui-Lu-Er-Xian-Jiao-Wan|Gui-Lu-Er-Xian-Jiao-Wan (GLEXJW) is an ancient CHM formula, mainly originating from processed tortoise shells, antlers, Ginseng, and wolfberry.
47947813|NCT06043817|DRUG|STX-721 (Escalated)|STX-721 dose will be escalated per cBLRM-design.
48297586|NCT00299884|DRUG|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
48297587|NCT03020524|BIOLOGICAL|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
48297588|NCT04349995|DEVICE|Amplatzer PFO Occluder|Percutaneous PFO closure using Amplatzer PFO Occluder
48297589|NCT06671249|PROCEDURE|Laparoscopic breast-conserving surgery|Use laparoscopic surgery to treat breast cancer patients who want and have the opportunity to preserve their breast
48297590|NCT06671249|PROCEDURE|Traditional open breast-conserving surgery|Treat breast cancer patients who want and have the opportunity to preserve their breast with traditional open breast-conserving surgery.
48297591|NCT01157858|DRUG|Everolimus|2.5 mg every day orally
48636086|NCT03542357|DRUG|Placebo Oral Tablet|CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
48636087|NCT03837535|PROCEDURE|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
48297592|NCT01157858|DRUG|Octreotide LAR|40 mg every 28 days IM
48297593|NCT00001693|DRUG|Celecoxib (SC-58635)|
48297594|NCT05453370|DEVICE|CALMA m-health app|CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.
48297595|NCT05453370|OTHER|Treatment As Usual (TAU)|Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
48297596|NCT02983981|DRUG|Topicort Topical Spray|open label Topicort spray
48297597|NCT00004778|DRUG|betamethasone|
48297598|NCT00004778|DRUG|dexamethasone|
48297599|NCT00004778|DRUG|thyrotropin-releasing hormone|
48297600|NCT05458232|DRUG|Tadalafil 5mg|Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
48297601|NCT03894904|DRUG|Papaverine|0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
48297602|NCT03894904|DRUG|Heparin|2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
48297603|NCT03894904|DRUG|Rescue papaverine, as needed|If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
47947814|NCT06043817|DRUG|STX-721 (2 doses)|Participants will receive STX-721 at one of two doses.
47947815|NCT06043817|DRUG|STX-721 (RP2D)|Participants will receive the RP2D of STX-721.
47947816|NCT06400212|OTHER|Cardiopulmonary exercise test|Participants undergo a cardiopulmonary exercise test following a standardised protocol used in national guidelines
47947817|NCT02144129|OTHER|active Whole Body Electromyostimulation|
47947818|NCT02144129|OTHER|Passive WB-EMS|
47947819|NCT02144129|DEVICE|WB-EMS application|
47947820|NCT02612038|DEVICE|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
47947821|NCT02612038|DEVICE|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
47947822|NCT02245178|PROCEDURE|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
47947823|NCT02245178|OTHER|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
48104447|NCT00045916|PROCEDURE|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
47947824|NCT04560543|PROCEDURE|McCall suture|Laparoscopic suture including the uterosacral ligaments and the peritoneum
47947825|NCT04560543|PROCEDURE|Standard cuff closure|Standard laparoscopic barbed suture of the vaginal cuff
47947826|NCT04779996|DIAGNOSTIC_TEST|Laboratory Samples|"1. After full vaccination with a Covid 19 vaccine, the following laboratory samples will be taken one time only, two weeks after full dose vaccination: i. Serologic rapid test (IgG, IgM) ii. Serum quantitative immunoglobulin levels iii. CD4 level iv. CD8 level~2. Laboratory samples will be taken at Hospital Auxilio Mutuo Laboratorio Clínico. Likewise, the Immuno Reference Lab might be used as an alternative.~3. Since monoclonal antibody therapy can induce hypogammaglobulinemia, we will measure gammaglobulin levels to correlate with antibody response to vaccine. Similarly, we will evaluate the CD4 and CD8 counts."
48297604|NCT06340555|OTHER|GUIA ATENCION MULTIDISCIPLINAR SANT BOI|Women with losses attended according to the multidisciplinary intervention proposed at the SJD Hospital de Sant Boi
48297605|NCT06340555|OTHER|USUAL CARE|Women with losses treated at the Hospital Comarcal del l'Alt Penedes.
48297606|NCT05845164|DEVICE|tDCS|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~tDCS: The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. This reduces the risk of burn or irritation and increases conduction. The 2 electrodes are connected to the tKIWI device which delivers a low intensity electrical current (\</=2A), thereby polarizing membrane potential of neurons in the stimulated area. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory. We will be initiating bilateral stimulation of the Dorsolateral pre-frontal cortex (DLPFC), which has been shown in the literature to elicit a significant decrease in ambiguous risk-taking behavior in healthy human subjects and a decrease in impulsivity on a non-ambiguous risk task."
48297607|NCT05845164|DEVICE|tDCS Sham|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~The sham group will receive ramped up current from 0.0mA to no more than 0.5mA for the first minute at the initiation of each of the three ramp ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
48636088|NCT04299425|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
48636089|NCT00001309|OTHER|Vitamin C|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
48636090|NCT03002909|DEVICE|epidural catheter|
48636091|NCT03002909|DEVICE|preperitoneal catheter|
48636092|NCT06087510|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative analgesia.
47947827|NCT05809622|BEHAVIORAL|Elbow focused rehabilitation|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)"
47947828|NCT05809622|BEHAVIORAL|Scapular and rotator cuff muscles strengthening|"* Patient education~* Activity modification~* 2 days/week, 8 weeks in total~* Exercises for the wrist extensor tendon, especially the extensor carpi radialis brevis (EKRB) (stretching + strengthening)~* Scapular stabilizer muscle + rotator cuff (RM) strengthening"
47947829|NCT03920410|OTHER|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
47947830|NCT03920410|OTHER|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
48104448|NCT00339469|DIETARY_SUPPLEMENT|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
48104449|NCT04194502|DIAGNOSTIC_TEST|Transesophageal echocardiogram (TEE)|All patients enrolled in the study will undergo a pre-operative research TEE and an intra-operative clinical TEE.
47947831|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness and self-monitoring|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
48104450|NCT01315886|DRUG|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
48104451|NCT03643029|DEVICE|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
48104452|NCT03923725|DRUG|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
48104453|NCT03923725|DRUG|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets."
48297608|NCT00479440|DRUG|SAM-315|
48477658|NCT01054352|DRUG|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
48636093|NCT04568512|DIAGNOSTIC_TEST|Control|Brushed biliary samples from a known case of benign biliary stricture were sent for DNA Methylation Biomarker test and cell cytology
48636094|NCT04568512|DIAGNOSTIC_TEST|Cholangiocarcinoma|Brushed biliary samples from a known case of cholangiocarcinoma were sent for DNA Methylation Biomarker test and cell cytology
48636095|NCT04294849|OTHER|Magnetic Resonance Imaging|A. Phosphorous 31 MR Spectroscopy to evaluate skeletal muscle metabolism via measurement of depletion and recovery of phosphocreatine (PCr) B. Non-invasive arterial spin labeling MRI to evaluate lymphatic flow velocities and venous flow
48636096|NCT04294849|OTHER|Bicycle Ergometry|To measure peak VO2 as a representation of global aerobic fitness
48636097|NCT04294849|OTHER|Lab Panel|A. Inflammatory lab panel (IL-6, IL-8, TNF alpha, P-selectin, high sensitivity CRP, IL-6 receptor, TNF R1/R2) drawn at diagnosis B. Thrombin Generation Assay to measure hypercoagulability and Thromboelastography prior to initiating anticoagulation
48636098|NCT04294849|BEHAVIORAL|Questionnaires|A. Dalhousie Dyspnea Scale B. Godin Leisure Time Exercise Questionnaire C. Pediatric Venous Quality of Life Questionnaire
48636099|NCT05363085|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
48636100|NCT04002427|DRUG|Intravenous Infusion|30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
48636101|NCT04002427|DRUG|Inhaled dose|A single inhalation on one occasion.
48636102|NCT02955550|DRUG|rhIL-2|Human recombinant Interleukin-2
47947832|NCT05235243|OTHER|Online therapeutic intervention for maladaptive daydreaming based on mindfulness|An 8-weeks internet-based self-guided intervention program, accompanied by e-mail. The content of the intervention and training modules comprised texts, illustrations, explanatory video and audio lectures, as well as interactive worksheets embedded in each week's lesson. Typically, a lesson started with a textual description of its target and duration. Then, participants received a summary of what had been taught thus far, and finally, a novel technique or skill was introduced. Each lesson required about 60 minutes to complete. Users had open access to web pages of previous lessons. Upon completion of each lesson, participants received a list of home assignments to practice during the following week. Our internet-based program featured a notification and download center containing the program's materials and pertinent messages from the researchers.
47947833|NCT02730689|DRUG|DP-R207|
47947834|NCT02730689|DRUG|Rosuvastatin|
47947835|NCT02730689|DRUG|Ezetimibe|
47947836|NCT06670365|OTHER|Heat acclimation by warm-water immersion|Participants will be immersed in a whirlpool tub to the shoulder level in a circulated water bath maintained at \~40°C until their core temperature achieves a steady-state of 38.5°C for 60 minutes. The warm-water immersion protocol will be repeated for 6 more consecutive days.
47947837|NCT04398992|OTHER|observation|Data were collected by a designed form. Statistic software was used to analyze clinical data.
47947838|NCT02279238|PROCEDURE|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest \[Washout time\] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of \[HR, SPO2, PSG RPE scale, Distance walked, BP\] the participants are collected before, during and after the completion of each lap \[according to American Thoracic Society \[ATS\] protocol\]."
47947839|NCT04512170|DRUG|HEC585|single or Mulltiple doses up to 10 days
47947840|NCT04512170|DRUG|placebo|single or Mulltiple doses up to 10 days
48297609|NCT04471740|PROCEDURE|CSF shunt diversion|Clinical response to a CSF shunt insertion
48297610|NCT04901026|OTHER|An in-house manikin|Participants obtain an in-house manikin
48297611|NCT01627756|OTHER|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
48297612|NCT01627756|OTHER|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
48297613|NCT06512311|DIAGNOSTIC_TEST|CBMed Drug Screening Plattform|The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.
48297614|NCT01062399|DRUG|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
48477659|NCT01054352|DRUG|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
48477660|NCT01054352|DRUG|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
48636103|NCT02955550|BIOLOGICAL|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
48636104|NCT00032331|PROCEDURE|PET Imaging|
48636105|NCT00032331|PROCEDURE|CT scan|
48636106|NCT06633419|DRUG|Opevesostat|Administered via oral tablet per dosing regimen.
48636107|NCT06633419|DRUG|Prednisone|Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.
48636108|NCT06633419|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.
48636109|NCT06633419|DRUG|Carbamazepine|Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).
48477661|NCT01054352|DRUG|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
48636110|NCT05061355|PROCEDURE|Heart valve surgery|Heart valve surgery will be performed as soon as possible and preferably within 48 hours
48636111|NCT05901831|DRUG|Finerenone|Dose A, Dose B, oral
48636112|NCT05901831|OTHER|Placebo|Oral
48636113|NCT00158470|DRUG|efavirenz|
48636114|NCT00158470|DRUG|didanosine|
48636115|NCT00158470|DRUG|lamivudine|
48636116|NCT06007248|DIAGNOSTIC_TEST|Protocol-defined Examinations|Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.
48636117|NCT06532071|DRUG|[68Ga]CBP8|Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8
48636118|NCT06532071|DRUG|Gadoterate Meglumine|Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI
48636119|NCT00137280|BEHAVIORAL|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
48636120|NCT03724097|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
48636121|NCT03724097|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
48636122|NCT03724097|DRUG|target drug with the score above 0,1|target drug with the score above 0,1
48636123|NCT03724097|DRUG|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
48636124|NCT03724097|DRUG|non-target drug|non-target drug
48636125|NCT03724097|DRUG|palliative care|palliative care
48636126|NCT02058407|DRUG|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
48636127|NCT02058407|DRUG|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
48636128|NCT02058407|DRUG|Placebo solution|Matching placebo to GSK2793660 solution
48636129|NCT02058407|DRUG|Placebo capsule|Matching placebo to GSK2793660 capsule
48636130|NCT00008333|DRUG|vinorelbine tartrate|
48636131|NCT03177915|DRUG|Hylase|median nerve hydro-dissection using Hyalase + 10 cc saline injection
48636132|NCT03177915|DRUG|Saline|median nerve hydro-dissection using 10 cc saline injection
48636133|NCT00754039|DRUG|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
48636134|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
48636135|NCT00754039|DRUG|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
48636136|NCT06092957|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
48636137|NCT06092957|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
47947841|NCT00857883|DRUG|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
48636138|NCT06092957|RADIATION|Reduced-dose IMRT|GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
48636139|NCT06092957|RADIATION|Standard-dose IMRT|GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
48636140|NCT06092957|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
48477662|NCT06367699|BEHAVIORAL|Usual Care|Parent/guardian and adolescent participants will not receive the ECA-HPV system intervention. A survey will be given via REDCap to the parent/guardian and adolescent participants at baseline, after the first well child clinic visit, and after the second well child clinic visit to assess self-reported vaccination attitudes and behaviors. Adolescent participants will receive usual care.
48477663|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Disabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app. The clinic notification and adolescent functions of the complete ECA-HPV app are disabled. Adolescent participants will receive usual care.
48636141|NCT01893762|BIOLOGICAL|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
48636142|NCT01893762|BIOLOGICAL|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
48636143|NCT02786511|DRUG|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
48636144|NCT03043469|OTHER|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
48636145|NCT03043469|OTHER|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
48636146|NCT03043469|OTHER|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
48636147|NCT03043469|OTHER|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
48636148|NCT03043469|OTHER|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
48636149|NCT03043469|OTHER|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
48636150|NCT03043469|OTHER|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
48297615|NCT01062399|DRUG|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
48297616|NCT01062399|RADIATION|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
48297617|NCT01062399|DRUG|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
48297618|NCT01062399|DRUG|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
48297619|NCT01062399|DRUG|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
48297620|NCT01062399|DRUG|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
48297621|NCT00537940|DRUG|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
48297622|NCT00537940|DRUG|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
48297623|NCT03528252|OTHER|Written advice LDL Cholesterol|One A4 paper with written information on both sides
48297624|NCT03528252|OTHER|Written advice Triglycerides|One A4 paper with written information on both sides
48297625|NCT05215392|BEHAVIORAL|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
48297626|NCT03787004|DRUG|CNTX-6970|Oral dose CNTX-6970
48297627|NCT03787004|OTHER|Placebo|Oral dose placebo
48636151|NCT03043469|OTHER|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
48636152|NCT03043469|OTHER|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
48636153|NCT03043469|OTHER|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
48636154|NCT03043469|DIAGNOSTIC_TEST|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
48636155|NCT03043469|OTHER|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
47947842|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 1 dose of inactivated Japanese encephalitis vaccine.
47947843|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 28 days.
48636156|NCT03043469|OTHER|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
48636157|NCT03043469|OTHER|Breath-hold test|Holding the breath a few times for as long as possible.
48636158|NCT03043469|OTHER|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
48636159|NCT03043469|OTHER|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
48297628|NCT00620204|DRUG|atorvastatin|atorvastatin 40mg qd for 1 year
48297629|NCT06559163|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
48297630|NCT06559163|DRUG|Placebo|Placebo
48297631|NCT05772650|BEHAVIORAL|e-Health Program|Lifestyle modification for health and disease management using digital solutions
48297632|NCT01378754|DRUG|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
48297633|NCT01378754|DRUG|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
48297634|NCT01378754|DRUG|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
48297635|NCT00593112|DRUG|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
48297636|NCT00593112|OTHER|No intervention|No intervention
48297637|NCT05876572|DRUG|intradermal naloxone|One time 8 mg/0.1 mL dose of naloxone to be administered intradermally
48297638|NCT05876572|DEVICE|microneedle injection|Intradermal delivery of naloxone using microneedle
48297639|NCT04907604|DEVICE|A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace|It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.
48636160|NCT04556097|BEHAVIORAL|Care Ecosystem|"The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system."
47947844|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
48297640|NCT01765647|OTHER|AGY|AGY is a natural health product produced in egg yolks
48297641|NCT06255990|OTHER|Standard of care|Standard of care
48297642|NCT02094079|OTHER|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
48297643|NCT04303390|DRUG|Cefuroxime|second generation cephalosporin
48297644|NCT04303390|DRUG|Cefazolin|First generation cephalosporin
48297645|NCT04303390|OTHER|24 hours|Duration of antibiotic therapy
48297646|NCT04303390|OTHER|48 hours|Duration of antibiotic therapy
48297647|NCT02295098|OTHER|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
48297648|NCT02295098|OTHER|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
48297649|NCT04755400|OTHER|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
47947845|NCT04060862|DRUG|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
47947846|NCT04060862|DRUG|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
48297650|NCT04755400|DIETARY_SUPPLEMENT|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
48297651|NCT04755400|DIETARY_SUPPLEMENT|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
48297652|NCT01898546|PROCEDURE|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
47947847|NCT04060862|DRUG|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
47947848|NCT04060862|DRUG|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
47947849|NCT04612582|DRUG|Thalidomide|Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection); thalidomide (d 1-28 50-100mg, oral); dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, the patients will complete six courses of treatment after entering the group, and the total observation time is one year after the end of treatment.
48297653|NCT01898546|PROCEDURE|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
48297654|NCT04046484|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
48297655|NCT04046484|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
48297656|NCT01918215|DEVICE|ICD|
48297657|NCT01918215|DEVICE|ILR|
48297658|NCT01081210|OTHER|Ultrasound examination|Screening with bedside ultrasound examination
48297659|NCT00247390|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
48297660|NCT00247390|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
48297661|NCT00719732|DEVICE|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
48297662|NCT03330691|BIOLOGICAL|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
48297663|NCT05582577|COMBINATION_PRODUCT|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
48297664|NCT05582577|DRUG|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
48297665|NCT05310383|COMBINATION_PRODUCT|Tislelizumab plus radiotherapy|During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
48297666|NCT05023486|DRUG|NP-G2-044 Monotherapy|1600 mg QD, 2000mg QD, and 2100 mg QD
48636161|NCT04656028|GENETIC|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database \<0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
47947850|NCT04612582|DRUG|Cyclophosphamide|Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
47947851|NCT04239092|DRUG|9-ING-41|9-ING-41 will be administered by intravenous infusion twice weekly at an initial dose of 9.3 mg/kg. Cycle duration is 21 days.
47947852|NCT04239092|DRUG|Irinotecan|Irinotecan 50 mg/m2/day administered over 90 minutes IV on days 1-5 every 21 days.
47947853|NCT04239092|DRUG|Temozolomide|Temozolomide will be administered at a dose of 100 mg/m2/dose by mouth on Days 1 through 5 of a 21 day cycle.
47947854|NCT04239092|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2/dose administered intravenously over 30 min on Days 1 through 5 of a 21 day cycle.
47947855|NCT04239092|DRUG|Topotecan|Topotecan 1.2 mg/m2/dose administered intravenously over 30 min once on Days 1 through 5 of a 21 day cycle.
47947857|NCT06157151|BIOLOGICAL|PRGN-2009 plus Pembrolizumab|Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
47947858|NCT06157151|DRUG|Pembrolizumab alone|Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
47947859|NCT06630806|DRUG|SAR446523|Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
47947860|NCT05015530|DEVICE|Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract|Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
48104454|NCT03923725|DRUG|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
48297667|NCT05023486|DRUG|Anti-PD-1 Therapy|previously initiated per standard of care, at a dose and frequency in accordance with the package insert
48297668|NCT05023486|DRUG|NP-G2-044 Combination therapy|1600 mg QD or 2100 mg QD
48297669|NCT03587909|PROCEDURE|Phacoemulsification Cataract SUrgery|Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)
47947861|NCT01869491|DRUG|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
47947862|NCT01869491|DRUG|Matching placebo tablets|2 tablets four times daily
47947863|NCT05662202|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
47947864|NCT05662202|COMBINATION_PRODUCT|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
47947865|NCT06084013|OTHER|Non-Interventional Study|Non-interventional study
47947866|NCT05324137|DRUG|CM326|CM326 injection
47947867|NCT05324137|OTHER|Placebo|Placebo
47947868|NCT05741060|DRUG|S-equol|Experimental drug
48297670|NCT03587909|PROCEDURE|Femtosecond Cataract Surgery|Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm
48297671|NCT06066918|DRUG|Pregabalin 75mg|Pregabalin 75 mg twice a day
48297672|NCT03223038|OTHER|No intervention|No intervention - exposure is mechanical ventilation in PICU
48297673|NCT05330442|BEHAVIORAL|Written Exposure Therapy (WET)|The WET protocol for primary care settings consists of six, 30-minute sessions. The first session consists of psychoeducation of PTSD and treatment rationale. Written narratives are conducted in sessions 2-6, following specific writing instructions and 20 minutes of writing in each session.
48297674|NCT06184919|OTHER|Process Mapping: Observations|Direct observations of the POSH clinic visit.
48297675|NCT06184919|OTHER|Process Mapping: Interviews|Semi-structured interviews of patients and providers involved in the POSH clinic.
47947869|NCT05741060|DRUG|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
48297676|NCT06184919|OTHER|Process Mapping: Focus Group|Focus group of providers and staff who conduct the POSH clinic.
48297677|NCT06184919|OTHER|Participatory Design|"Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups."
48297678|NCT01511289|DRUG|Imatinib|400mg/Tab, QD
47947870|NCT00484809|DRUG|Enbrel (Etanercept)|
47947871|NCT06648850|DRUG|DA-001|Phenyephrine + Alpha 1 Agonist (GRAS) + TAAR Agonist (GRAS) Topical Solution
48477664|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors. Parent/guardian participants will also be asked questions about the ECA-HPV app and the clinic notification feature. The clinic notification is enabled on the parent/guardian ECA-HPV app, however, the adolescent does not have access to the adolescent ECA-HPV app. Adolescent participants will receive usual care.
48477665|NCT06367699|BEHAVIORAL|ECA-HPV App with Adolescent Function Enabled|Parent/guardian participants will interact with the ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction. The adolescent function is enabled, however, the clinic notification function is disabled. Thus, the ECA-HPV system app will have an adolescent-facing feature for adolescent participants to engage with the agent. Adolescent participants will receive usual care and will be able to engage with the adolescent version of the ECA-HPV app throughout the duration of the study.
47947872|NCT06648850|OTHER|Placebo|Placebo Topical Solution
47947873|NCT06648850|DRUG|Phenylephrine|Phenylephrine Topical Solution
47947874|NCT06416722|OTHER|Cognitive-Motor Dual Task Activities|Patients included in this group will be given additional cognitive tasks (e.g. counting months, subtracting 5 from 100) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
48297679|NCT01511289|DRUG|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
48297680|NCT06673186|OTHER|overdenture|Patient satisfaction (primary outcome) was measured by a visual analog scale (VAS). OHRQoL (secondary outcome) was measured by oral health impact profile (OHIP-14). Questions of VAS and OHIP-14 were evaluated after 3 months The patients were divided into two equal groups.
48297681|NCT03808714|BEHAVIORAL|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
48297682|NCT03808714|BEHAVIORAL|Control Group|Alabama Quitline
47947875|NCT06416722|OTHER|Motor-Motor Dual Task Activities|Patients included in this group will be given additional motor tasks (e.g. passing the ball from the right hand to the left hand while standing on a soft surface, clapping) in accordance with the physiotherapist's commands simultaneously with balance and large amplitude functional activities (such as stepping forward-sideways-backwards, sitting and standing).
47947876|NCT06416722|OTHER|Cognitive-Motor & Motor-Motor Dual Task Activities|Simultaneously with balance and large amplitude functional activities (such as stepping forwards-sideways-backwards, sitting and standing), patients included in this group will be given additional cognitive (e.g. counting while standing with feet closed) and motor (e.g. passing the ball from the right hand to the left hand while standing on a soft surface) tasks in accordance with the physiotherapist's commands.
47947877|NCT01545258|OTHER|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
47947878|NCT05853120|DRUG|Doxycycline|Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
47947879|NCT04053634|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
47947880|NCT04053634|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
47947881|NCT03606044|DEVICE|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
47947882|NCT04410536|DRUG|Symptomatic drugs|indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
47947883|NCT04410536|DRUG|Bridge therapy|prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
47947884|NCT04410536|BEHAVIORAL|Mindfulness program|home based withdrawal program
47947885|NCT04719637|DEVICE|PRDS-001 Renal Denervation Ultrasound System|Renal Denervation Ultrasound System
47947886|NCT01502007|OTHER|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
48104455|NCT03923725|DRUG|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets."
48104456|NCT02765373|DRUG|Exemestane|
48104457|NCT02765373|DRUG|Letrozole|
48104458|NCT02765373|DRUG|Anastrozole|
48104459|NCT06217354|DRUG|Carbetocin 100 Microgram/mL Solution for Injection|All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
48104460|NCT01465243|DRUG|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
48104461|NCT06412406|PROCEDURE|External Oblique Intercostal (EOI) block|EOI block technique A linear ultrasound transducer placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, The transducer was then rotated so the cranial end was directed slightly medially and the caudal end laterally to produce a paramedian sagittal oblique view with a short-axis view of the ribs, The following structures were identified, from superficial to deep: subcutaneous tissue, external oblique muscle, intercostal muscles between ribs, pleura, and lung. The skin entry point for the injection was cranial to the sixth rib level just medial to the anterior axillary line, with ultrasound opaque needle advanced in plane from a superomedial-to-inferolateral direction, through the external oblique muscle hydrodissecting the tissue plane between the sixth and seventh ribs, and then the needle was directed caudally toward the eighth rib. and inject 20 ml volume of (0.25 % bupivacaine).
48104462|NCT06412406|PROCEDURE|Transversus abdominis plane (TAP) block|"TAP block technique:~abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest (18) . Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. and ingect 20 ml volume of (0.25 % bupivacaine). If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
48104463|NCT02722356|DRUG|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
48104464|NCT03925194|DRUG|Anakinra|Application of Anakinra once daily for 28 days
47947887|NCT01502007|OTHER|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
47947888|NCT02919098|BEHAVIORAL|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
47947889|NCT02919098|BEHAVIORAL|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
47947890|NCT00978471|DRUG|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
47947891|NCT05264688|DIAGNOSTIC_TEST|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
47947892|NCT02952729|DRUG|XMT-1522|one intravenous dose administered in-clinic every 21 days
48477666|NCT06367699|BEHAVIORAL|ECA-HPV App with Clinic Notification and Adolescent Functions Enabled|Parent/guardian participants will interact with the complete ECA-HPV smartphone-based system over a period of \~16 months. The ECA-HPV is designed to interact with parents/guardians to increase vaccine acceptability prior to the clinic visit. A survey will be given to parent/guardian participants via REDCap at baseline, after the first well child clinic visit, and after the second well child clinic visit to both the parent/ guardian and adolescent to assess self-reported vaccination attitudes and behaviors as well as ECA-HPV app use and satisfaction and questions about the clinic notification feature. The complete ECA-HPV app includes the parent version and adolescent versions of the ECA-HPV app. Both versions have the clinic notification feature enabled. Adolescent participants will receive usual care and can engage with the adolescent version of the ECA-HPV app throughout the study.
48477667|NCT01157715|BIOLOGICAL|intravitreal injection of KH902|
48477668|NCT04377906|BEHAVIORAL|Modification Lifesyle|high protein-fiber and exercise
48477669|NCT05354089|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
48477670|NCT05354089|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
48477671|NCT05354089|DRUG|Placebo|Placebo IM on day 0 and day 21.
48477672|NCT02281331|DIETARY_SUPPLEMENT|Supplement|supplement/placebo plus exercise training
47947893|NCT02494362|OTHER|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
47947894|NCT06319638|BEHAVIORAL|Rehabilitation therapy|During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.
47947895|NCT06319638|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
47947896|NCT06319638|PROCEDURE|Placebo block|1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48104465|NCT01512966|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
48477673|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.
48477674|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.
48477675|NCT03711916|DEVICE|PlasmaBlade 3.0S|PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
48636162|NCT04656028|BEHAVIORAL|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~1. Increasing motivation for a healthy lifestyle;~2. Increasing adherence to treatment;~3. Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
48636163|NCT04656028|DIAGNOSTIC_TEST|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
48636164|NCT04656028|OTHER|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
48477676|NCT06215131|BEHAVIORAL|In-person dietary weight loss counseling|The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.
47947897|NCT06319638|DRUG|Lidocaine Hydrochloride|the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
47947898|NCT03180593|DRUG|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
47947899|NCT05032248|DRUG|Tacrolimus ointment|oral gel
48104466|NCT03460327|DRUG|Candesartan|Patients are tested for their normal prescription candesartan medication
47947900|NCT03226678|DRUG|APL-2|Complement (C3) Inhibitor
47947901|NCT04171765|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
47947902|NCT04171765|DRUG|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
47947903|NCT00237887|DRUG|adalimumab|
48297683|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
48297684|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
47947904|NCT02544074|BEHAVIORAL|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
47947905|NCT02544074|BEHAVIORAL|eSAGE testing|Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
47947906|NCT02613949|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
48297685|NCT05268094|DEVICE|Ductal Arterial Stent|Drug-eluting ductal arterial stents will be placed by transcatheter method.
48297686|NCT05268094|PROCEDURE|Systemic-to-Pulmonary Artery Shunt|A surgical connection will be made between a systemic artery and the pulmonary artery.
47947907|NCT04855370|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds every 15 minutes for 12 to 24 hours. If two finger probes are available, measurements will alternate between fingers.
47947908|NCT04203810|DEVICE|Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
47947909|NCT04203810|DEVICE|EMSER® Hals-und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
47947910|NCT04741230|DEVICE|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
47947911|NCT00884533|DRUG|Rosi XR|Rosi XR
47947912|NCT00884533|OTHER|Placebo|Placebo
47947913|NCT00884533|DRUG|Moxifloxacin|400mg single dose
47947914|NCT03311529|BEHAVIORAL|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
47947915|NCT04894292|OTHER|Non intervention|During the study there is no extra intervention planned for the participants.
48297687|NCT01781026|DRUG|Vemurafenib|Single arm trial
48297688|NCT04174131|DEVICE|Restylane + Lidocaine|Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
48297689|NCT04174131|DEVICE|Restylane® Lyft|Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
47947916|NCT00736957|DRUG|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
47947917|NCT04206007|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06
47947918|NCT03537612|DRUG|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
47947919|NCT03537612|OTHER|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
47947920|NCT02805972|DRUG|Naloxone|4 mg / 0.1 ml
47947921|NCT02805972|DRUG|Placebo|0.1 ml
47947922|NCT06201663|DRUG|Romiplostim|Weekly subcutaneous injections
47947923|NCT01568515|PROCEDURE|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
47947924|NCT03439657|BIOLOGICAL|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
47947925|NCT03439657|BIOLOGICAL|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
47947926|NCT06270329|OTHER|Neuromuscular training program|"Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase"
47947927|NCT06270329|OTHER|conventional physical therapy program|Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
48297690|NCT03392519|OTHER|Chronic stroke|MRI data acquisition and behavioral test
48297691|NCT01053624|PROCEDURE|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
48297692|NCT01652378|DRUG|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
47947928|NCT02942927|OTHER|Medication reduction|Systematic approach to reduction in polypharmacy.
47947929|NCT00044720|DRUG|Rapamune|
47947930|NCT01470859|DRUG|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
47947931|NCT01470859|DRUG|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
47947932|NCT00715000|PROCEDURE|Oral rehydration therapy|oral rehydration solution
48297693|NCT06238999|DEVICE|Restoration of non-carious cervical lesions|Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.
47947933|NCT00715000|PROCEDURE|classical hydration via intravenous infusion|intravenous infusion
47947934|NCT04659239|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
47947935|NCT04659239|BIOLOGICAL|Placebo|The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
47947936|NCT02557659|DEVICE|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
47947937|NCT03023787|DRUG|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
47947938|NCT03023787|DRUG|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
48297694|NCT06488326|DRUG|Mulberry leaf extract 6 mg capsule|Take one capsule of the sample one time.
48297695|NCT06488326|DRUG|Mulberry leaf extract 12 mg capsule|Take one capsule of the sample one time.
48297696|NCT06488326|DRUG|Mulberry leaf extract 18 mg capsule|Take one capsule of the sample one time.
48297697|NCT06488326|DRUG|Placebo capsule|Take one capsule of the sample one time.
47947939|NCT05341934|OTHER|Evaluative Conditionning Task|A word will appear in one of the four quadrants on the computer screen. They will have to answer the word as quickly as possible by pressing the space bar. They will also be told that an image will be displayed briefly (400 ms) in the same quadrant by pressing the answer key. This procedure will be repeated for 120 trials: 30 trials with alcohol-related Conditional Stimulus (CS), 30 trials with CS related to non-alcoholic beverages and 60 trials with the CS of filling. The CS referring to alcohol will be the words Beer, Wine ...; The CS referring to soft drinks will be the words Coca-Cola, Fanta... and Filling CS referring to vegetables and fruits will be: Apple, Banana...In experimental conditions, alcohol-related CS will be followed by negative Unconditional Stimuli (US) (images from the International Affective Picture System (Lang, Bradley, \& Cuthbert, 1997)), CS referring to soft drinks linked to positive images and CS referring to fruits and vegetables will be linked to neutral US.
48297698|NCT00739297|DRUG|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
48297699|NCT00739297|DRUG|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
48297700|NCT02816762|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
48297701|NCT02816762|DRUG|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
48297702|NCT02816762|OTHER|Diet|Conventional anti-diabetic diet recommendations
48297703|NCT02228512|DRUG|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
48297704|NCT02228512|DRUG|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
48297705|NCT02228512|DRUG|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
48297706|NCT02228512|DRUG|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
48297707|NCT02228512|DRUG|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
48297708|NCT02228512|DRUG|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
48104467|NCT04431934|DIETARY_SUPPLEMENT|PROBIOTIC|"Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet."
48104468|NCT04431934|DIETARY_SUPPLEMENT|FMT REGIMEN|The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (\~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
48104469|NCT06113939|DEVICE|airway clearance|mechanical suctioning of airway secretions
48104470|NCT00042588|DRUG|Recombinant Chimeric Monoclonal Antibody|
48297709|NCT02228512|DRUG|Cyclophosphamide|Part B: 750 mg/m2 Day 5
48297710|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
48477677|NCT06215131|BEHAVIORAL|Virtual reality dietary weight loss counseling|The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
48636165|NCT04656028|OTHER|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
48297711|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
48297712|NCT00435539|DRUG|Sham Comparator|Intravitreal sham injection
48477678|NCT02589886|OTHER|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
48477679|NCT01523587|DRUG|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
48636166|NCT04656028|OTHER|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
48104471|NCT00183638|BEHAVIORAL|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
48636167|NCT04656028|OTHER|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
48636168|NCT04656028|OTHER|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
48104472|NCT00183638|BEHAVIORAL|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
48104473|NCT05040750|OTHER|laboratory investigation|observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
47947940|NCT03352765|DRUG|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
47947941|NCT03352765|DRUG|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
47947942|NCT03352765|DRUG|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
47947943|NCT03352765|PROCEDURE|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
47947944|NCT00920933|BIOLOGICAL|AIN457|
47947945|NCT00920933|OTHER|Placebo|
47947946|NCT00920933|DRUG|prednisolone|
47947947|NCT00117195|DEVICE|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
47947948|NCT01303354|PROCEDURE|Lumbar Transforaminal Epidural Steroid Injection|
47947949|NCT03701399|DRUG|troriluzole|200 mg by mouth
47947950|NCT03701399|DRUG|Placebos|200 mg by mouth
47947951|NCT00261300|DRUG|Pantoprazole|Long term Pantoprozole trial
47947952|NCT06277492|DRUG|Single ascending doses SUL-238|PART 1: SUL-238 single ascending doses
47947953|NCT06277492|DRUG|Single dose Placebo|PART 1: Placebo single dose
47947954|NCT06277492|DRUG|Single dose SUL-238|PART 2: SUL-238 single dose for pharmacokinetics
47947955|NCT06277492|DRUG|Multiple ascending doses SUL-238|PART 3: SUL-238 multiple ascending doses
47947956|NCT06277492|DRUG|Multiple doses Placebo|PART 3: Placebo multiple doses
47947957|NCT06277492|DRUG|2000 mg SUL-238 single dose for pharmacokinetics (food effect)|PART 2B: 2000 mg single dose of SUL-238
47947958|NCT06277492|DRUG|Single dose placebo (food effect)|PART 2B: Placebo single dose
47947959|NCT05352373|DIETARY_SUPPLEMENT|calcium|calcium carbonate
47947960|NCT05352373|DIETARY_SUPPLEMENT|placebo|sodium bicarbonate
47947961|NCT03594734|BEHAVIORAL|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
48104474|NCT05112250|DEVICE|Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)
48104475|NCT04480814|DIAGNOSTIC_TEST|PIK3CA kit|Prospective investigation of clinical samples for evaluation of IVD clinical performance
48104476|NCT05421988|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an efficacious method demonstrated in over 100 clinical trials. It combines cognitive and exposure techniques with acupressure, in the form of fingertip percussion on acupuncture meridian points.
48104477|NCT00807430|DEVICE|Grindcare (Active)|Active treatment
48104478|NCT00807430|DEVICE|Grindcare (Placebo - the device is not activated)|Placebo treatment
48104479|NCT01886014|DRUG|Oxytocin|
48104480|NCT01886014|OTHER|placebo|
48104481|NCT03674190|PROCEDURE|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
48104482|NCT03674190|PROCEDURE|Total Disc Replacement|Total Disc Replacement
48297713|NCT06415578|OTHER|ergonomics training|In this training; What is ergonomics, the importance of ergonomics, the purpose of ergonomics, risk factors for musculoskeletal disorders that can be seen in e-sports players, ergonomic arrangements that can be made in the working environment and methods of protection from musculoskeletal injuries, posture disorders and various ergonomic arrangements that can be made for posture disorders and chair selection, screen selection. selection and rest breaks were included. Participants will be trained twice in total, on the first day of the study and at the end of the 4th week. The training will be carried out interactively, supported by videos and visuals. Training will be done individually and will last approximately 2 hours.
48297714|NCT06415578|OTHER|Exercises|The exercise training program will be implemented for 8 weeks, 3 days a week, lasting an average of 45 minutes. All participants will be given information about the exercises before the exercise training. The exercise protocol was designed as 3 parts: warm-up, exercise and cool-down. Stretching exercises, mobility and strength exercises will be applied. A rest period of 30-45 seconds was given between sets and 2-3 minutes between exercises. Participants will be given dynamic and static stretching, nerve stretching, postural strength and functional exercises for the upper extremity. Relevant movements will be modified according to the exercise capacity of the participants. Exercise content will also include median, ulnar and radial nerve stretching, neck and thoracic mobility exercises, and functional strength exercises for the shoulder, arm, hand and wrist. Exercise tracking will be checked regularly through online conversations.
48297715|NCT04094506|DRUG|ASP1948|Intravenous
48297716|NCT02729311|BEHAVIORAL|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
47947962|NCT03594734|OTHER|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
48104483|NCT01161719|BEHAVIORAL|parent training|Behavioral management skill training
47947963|NCT00000612|DRUG|estrogens, conjugated|
47947964|NCT00000612|BEHAVIORAL|diet, soy proteins|
47947965|NCT00000612|BEHAVIORAL|dietary supplements|
48477680|NCT01523587|DRUG|erlotinib|erlotinib taken once daily
48104484|NCT03465007|DRUG|Hydrocortisone|we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
48297717|NCT03718104|OTHER|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
48297718|NCT03718104|OTHER|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
48477681|NCT01640184|PROCEDURE|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
47947966|NCT06680856|COMBINATION_PRODUCT|PRP+HA|treatment of diabetic foot ulcers with allogeneic PRP+HA
47947967|NCT06680856|COMBINATION_PRODUCT|HA|treatment of diabetic foot ulcers with HA
48104485|NCT03465007|DRUG|Normal saline|we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
48477682|NCT01640184|DRUG|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
48636169|NCT04086615|DEVICE|NMES and exercise supplemented with high BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
48636170|NCT04086615|DEVICE|NMES and exercise supplemented with low BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
48477683|NCT01640184|PROCEDURE|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
48636171|NCT04795362|BIOLOGICAL|blood sample|"5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml)."
48636172|NCT00400205|DRUG|Docetaxel|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
48636173|NCT00400205|DRUG|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
48636174|NCT00400205|DRUG|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
48297719|NCT03718104|GENETIC|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
48477684|NCT00109486|DRUG|GW685698X|
48477685|NCT03069677|OTHER|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
48477686|NCT03069677|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
47947968|NCT01617525|OTHER|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
47947969|NCT01210131|DRUG|[18F]HX4|Intravenous injection
47947970|NCT04862663|DRUG|Capivasertib|Phase Ib: Capivasertib 320 mg/ 400 mg administered PO BD 4 days on /3 days off per week for 4 weeks (28 days cycle) Phase III: : Capivasertib, administered PO BD 4 days on / 3 days off per week for 4 weeks (28 days cycle) at the dose confirmed in the phase Ib portion
48297720|NCT03718104|OTHER|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
47947971|NCT04862663|DRUG|Fulvestrant|Phase Ib and Phase III: 500 mg (2 injections of 250 mg) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
47947972|NCT04862663|DRUG|Palbociclib|Phase Ib: 100 mg/ 125 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose of 125 mg.
48477687|NCT05259904|DRUG|L-citrulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
48477688|NCT05259904|DRUG|Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
48477689|NCT03245307|DRUG|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
48477690|NCT03245307|DRUG|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
48477691|NCT03245307|DRUG|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
48477692|NCT06135376|BEHAVIORAL|comprehensive multi-component interventions|It is a combination of educational and behavioral interventions. 4 PHCCs will be randomized to 2 groups: 2 PHCCs will receive single intervention and 2 PHCCs will receive all 4 interventions.
48477693|NCT02959476|DRUG|Ropivacaine|Anesthetic
48297721|NCT04789746|BEHAVIORAL|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
48636175|NCT06440759|DEVICE|oXiris filter|"Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared."
48636176|NCT06440759|DEVICE|M100 filter|Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
48636177|NCT06471517|DEVICE|Somatosensory feedback|Performing different mobility tasks in 10 separate sessions while the device is providing or not somatotopic sensations through non-invasive electrical stimulation. Benefits connected to the stimulation of sensory nerves will be assessed.
47947973|NCT04862663|DRUG|Ribociclib|Phase Ib: 200 mg/ 400 mg/ 600 mg. Once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28-day cycle Phase III: Administered once daily for 21 days of 28-day cycle, at the dose confirmed in the phase 1b portion.
47947974|NCT04862663|DRUG|Abemaciclib|Phase Ib: 50 mg/ 100 mg/ 150 mg. Twice daily for 28 consecutive days to comprise a complete 28-day cycle
47947975|NCT02590926|PROCEDURE|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
47947976|NCT05508997|DEVICE|respiratory parameters on mechanical ventilator (PEEP)|"The 3rd \& 4th phases of operation in the group (A) and (B): Each patient received one single session inside the Operation Room (OR) as one shot of the treatment procedure. Arterial Blood Gases (ABGs) were obtained to measure:~1. Oxygenation by PaO2/FiO2 ratio with constant FiO2 = 100% (oxygen) through the procedure time as a primary outcome.~2. Secondary outcome.~   * Ventilation by PaCO2 value from ABGs.~  * Static compliance (Cstat) was measured as the amount of recruitment of alveoli in the lung.~  * Blood pressure (systolic/diastolic) one of the hemodynamics measurements was measured pre/post the procedure in the two groups."
48477694|NCT02959476|DRUG|Placebos|Inactive comparator
47947977|NCT00190970|DRUG|Ruboxistaurin|
47947978|NCT00299182|DRUG|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
47947979|NCT00299182|DRUG|Rituximab|375 mg/m\^2 by vein over 4-6 hour infusion day 1, each cycle.
47947980|NCT00299182|DRUG|Cyclophosphamide|300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
47947981|NCT00299182|DRUG|Vincristine|1.4 mg/m\^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,\& 5.
48477695|NCT02601768|DEVICE|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
48104486|NCT05060679|OTHER|Supportive therapy at the ICU|Non-septic ICU patients received adequate supportive treatment (fluid resuscitation, respiratory, anticoagulation, antimicrobial and vasopressor therapy along with sedation, ulcer prophylaxis and nutrition. Blood sampling for non-septic patients were the first (T1) and third (T3) postoperative morning at the ICU. Besides, 23 healthy outpatients were documented without sepsis or sepsis-related organ dysfuntion as a control group.
47947982|NCT00299182|DRUG|Doxorubicin|50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
47947983|NCT00299182|DRUG|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,\& 5.
48477696|NCT06083090|PROCEDURE|Yogatherapy|The experimental arm will benefit from support by a physiotherapist trained in yoga, in a group for ten weeks with two weekly sessions of approximately 1 hour each. A new yoga program adapted for the axSPA will be implemented.
48477697|NCT06083090|PROCEDURE|Physiotherapy|The comparator arm will benefit from support by a physiotherapist, in groups for ten weeks at the rate of two weekly sessions of approximately 1 hour each. An already existing program adapted for the axSPA will be implemented.
47947984|NCT00299182|DRUG|Methotrexate|200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
47947985|NCT00299182|DRUG|Cytarabine|3 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4; OR,1 g/m\^2 by vein over 2 hours every 12 hours for 4 doses, days 3 \& 4 for patients \> 60 years and for patients with serum creatinine \> 1.5 mg/dL; Cycles 2,4,\& 6.
47947986|NCT00299182|DRUG|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
47947987|NCT02708901|DIETARY_SUPPLEMENT|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
47947988|NCT02708901|DIETARY_SUPPLEMENT|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
48104487|NCT05060679|OTHER|Sepsis therapy|Patients receiving sepsis therapy followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis and nutrition. Blood samples were collected at the ICU from this patient group at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
48636178|NCT05939609|OTHER|Ballistic Stretching Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
48636179|NCT05939609|OTHER|Extender Exercise|It will be applied 4 times a week for 6 weeks and before starting on-water training.
48636180|NCT05939609|OTHER|Kinesiotaping|It will be applied 4 times a week for 6 weeks and before starting on-water training.
48636181|NCT04707183|DRUG|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
48636182|NCT04707183|DRUG|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
48636183|NCT03854448|DEVICE|holter monitoring|"Transthoracic Echocardiography (TTE) Left atrial ( LA) volume will be measured using standard apical two- and four-chamber views on the frame just prior to mitral valve opening and as specified by current American Society of Echocardiography guidelines (10) LA volume is indexed to body surface area. Mitral inflow velocity is obtained in the apical four-chamber view by placing a pulsed-Doppler sample volume between the tips of the mitral leaflets. Mitral annular velocity is assessed during the early phase of diastole(e=) using pulsed-wave Doppler sampling of septal mitral annular motion from the four chamber view.~24 to 48 hours Holter monitoring after 1 month after PCI"
48636184|NCT03943992|DRUG|YYD601 40mg|Patients should take druges 30 minutes before breakfast.
47947989|NCT06680817|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
48477698|NCT05363995|BEHAVIORAL|i-Sleep & BioClock Intervention|"The 'i-Sleep \& BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~1. psychoeducation on insomnia, sleep hygiene and the biological clock,~2. stimulus control and sleep restriction therapy,~3. worrying and relaxation exercises,~4. cognitive therapy to change dysfunctional thoughts about sleep, and~5. summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep \& light exposure diary daily."
48636185|NCT03943992|DRUG|Nexium 40mg|Patients should take druges 30 minutes before breakfast.
48636186|NCT03943992|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
48636187|NCT02824549|DEVICE|FreeStyle Libre Flash Glucose Monitoring|
48636188|NCT00932503|DEVICE|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
48636189|NCT00000665|DRUG|Foscarnet sodium|
48636190|NCT00000665|DRUG|Ganciclovir|
48636191|NCT03622931|DRUG|Standard chemotherapy|Chemotherapy
48636192|NCT03622931|DRUG|Romiplostim|
48636193|NCT03622931|DRUG|Placebos|
48636194|NCT02111980|DEVICE|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
47947990|NCT03331250|DRUG|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
47947991|NCT06311851|DRUG|Bevacizumab|Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
47947992|NCT06615739|DEVICE|Regenerex Tissue Attachment Augments|Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
48477699|NCT05160636|BIOLOGICAL|COVID-19 Vaccine|Receipt of Pfizer BioNTech COVID-19 vaccine
48477700|NCT00113724|DRUG|TPI 287 Injection|
48477701|NCT06462131|BEHAVIORAL|Cultural Adapted Group cognitive Behaviroal therapy (CaGCBT)|In first session, introduction of the therapist/facilitator and group members will be made. Group rules will be discussed with members. Group members' introduction primarily focuses on participant/clients' expectations, addictive behaviors and its status, and goals. Moreover, it also emphasize on identification of any other significant issue that is contributing in burden of disease.
48477702|NCT04228978|BEHAVIORAL|Weight loss|Walking exercise combined with weight loss
48104488|NCT05060679|OTHER|Sepsis-related organ dysfunction therapy|Patient management of sepsis and sepsis-related organ dysfunction followed the international guidelines of the 2016 Surviving Sepsis Campaign (SSC) regarding respiratory, antimicrobial, anticoagulation, vasopressor and hydrocortisone therapy, along with adequate fluid resuscitation, sedation, ulcer prophylaxis, nutrition and renal replacement therapy (if needed). In this patient group, blood sampling was performed at three time points (T1-3): T1: within 12 hours after admission; T2: second day morning; T3: third day morning of follow-up.
48104489|NCT02920359|DRUG|LEUPRORELIN ACETATE|
48104490|NCT01406262|BIOLOGICAL|Albiglutide|once weekly subcutaneous injection
48477703|NCT04228978|BEHAVIORAL|Exercise|Walking exercise
48477704|NCT01294566|DRUG|GSK1322888|1 mg, 5 mg or 25 mg capsule
48104491|NCT01406262|DRUG|Moxifloxacin|oral tablet
47947993|NCT05130918|DEVICE|Phenolmicin P3 and Bosexil suppository|The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the Boswellia serrata, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria.
47947994|NCT03894046|DRUG|Sulbactam|1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
48477705|NCT01294566|DRUG|Placebo|matching placebo capsules
48477706|NCT00900016|GENETIC|protein expression analysis|
48477707|NCT00900016|GENETIC|western blotting|
48477708|NCT00900016|OTHER|immunohistochemistry staining method|
48477709|NCT00900016|OTHER|immunologic technique|
48477710|NCT00900016|OTHER|laboratory biomarker analysis|
48477711|NCT03081910|GENETIC|Autologous CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
48477712|NCT03081910|GENETIC|Allogeneic CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
48477713|NCT05518032|PROCEDURE|Biopsy|Undergo biopsy
48477714|NCT05518032|BIOLOGICAL|Pembrolizumab|Given IV
48477715|NCT05518032|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given intratumorally
48477716|NCT00521989|DRUG|CRx-102 (2.7/90)|CRx-102 dose 1
48477717|NCT00521989|DRUG|Prednisolone|Prednisolone
48477718|NCT00521989|DRUG|Placebo|Placebo
48477719|NCT00521989|DRUG|CRx-102 (2.7/180)|CRx-102 dose 2
48477720|NCT00521989|DRUG|CRx-102 (2.7/360)|CRx-102 dose 3
48477721|NCT03809637|DRUG|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
48477722|NCT06346106|GENETIC|Male Rett|This study does not have an intervention. Participants of this study must be parents or caregivers to boys with Rett syndrome.
48477723|NCT04065568|DEVICE|DISKO-tool|The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
48477724|NCT01033578|OTHER|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
48477725|NCT02994251|DRUG|gemcitabine|1000 mg/m\^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
47947995|NCT03894046|DRUG|Durlobactam|"1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated."
48477726|NCT02994251|DRUG|Cisplatin|25 mg/m\^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
48477727|NCT02994251|DRUG|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
48477728|NCT04766229|COMBINATION_PRODUCT|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
48477729|NCT06405542|BEHAVIORAL|EX-CIPN|"The 10-week intervention includes:~Individualized Exercise Program: Each participant will receive an individualized progressive exercise program that includes cardiovascular and strength training as well as balance and desensitization exercises and will be adjusted to the needs of the patient.~Remote Monitoring: Fitbit™ devices will be used to monitor patients' physical activity over the duration of the program. Fitness trackers can promote behaviour change and allows for self-monitoring and feedback to the participant.~Remote Person-to-Person Clinical Support: Participants will have scheduled remote check-ins and health coaching sessions with their assigned RKin over Microsoft Teams (MSTeams) on weeks 2, 3, 4, 6, and 8 of the intervention. During these calls, the RKin will review, adapt, and progress the exercise program as needed, discuss and develop goals for the following week, and identify potential barriers and solutions in achieving their goals."
48477730|NCT05202288|BIOLOGICAL|Ervebo|Administration of r-VSV-ZEBOV vaccine
48477731|NCT05202288|DRUG|Inmazeb|Administration of Inmazeb
48477732|NCT06467552|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols.
48297722|NCT05582122|BIOLOGICAL|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
48297723|NCT03531957|DRUG|ASN002|Daily dose of ASN002 for 12 weeks
48297724|NCT03531957|DRUG|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
48297725|NCT00968578|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
48297726|NCT00968578|DRUG|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
48297727|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
47947996|NCT03894046|DRUG|Colistin|Treatment for 7 days up to 14 days if clinically indicated.
47947997|NCT03894046|DRUG|Imipenem/Cilastatin 500 mg/500 mg|1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
48297728|NCT03474718|BIOLOGICAL|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
48297729|NCT06565338|DRUG|Dexmedetomidine|drug
48297730|NCT06565338|DRUG|Vitamin D3|drug
48297731|NCT03453463|OTHER|exercise|3x week predominately resistance exercise for 18 months
48297732|NCT05509894|DRUG|Ngenla|As provided in real world practice
47947998|NCT02232334|OTHER|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
47947999|NCT05586646|DIETARY_SUPPLEMENT|alanyl-glutamine|Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
47948000|NCT03824418|PROCEDURE|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
47948001|NCT04120948|DEVICE|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
47948002|NCT04120948|DEVICE|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
47948003|NCT05522231|DRUG|fruquintinib+sintilimab|fruquintinib, 5 mg, QD, PO, 2 weeks on/1 week off, 3 weeks/cycle; sintilimab, 200 mg, IV infusion, Q3W, 3 weeks/cycle.
47948004|NCT05522231|DRUG|axitinib / everolimus|axitinib, 5 mg, twice daily (BID), PO, 3 weeks/cycle, dose escalation will be at the investigator 's discretion based on clinical; everolimus, 10 mg, QD, PO, 3 weeks/cycle.
47948005|NCT05522231|DRUG|fruquintinib|fruquintinib, 5 mg, QD, PO, 3 weeks on/ 1 week off, 4 weeks/cycle.
47948006|NCT00815607|DRUG|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
48104492|NCT02247063|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
47948007|NCT00815607|BIOLOGICAL|INXN-3001|Intratumoral injection
47948008|NCT05390931|BEHAVIORAL|6-session motivational interviews|A total of 6 motivational interviews will be held once a month. Motivational interviews will be conducted individually.
47948009|NCT05390931|OTHER|Health education structured according to the health belief model|After the participants enrolled in the study, the patients in the study group will be given a health education structured according to the health belief model at the first interview.
47948010|NCT05390931|OTHER|Training booklet prepared by the researchers on healthy lifestyle behavior changes|After the participants enrolled in the study and take health education, a training booklet prepared by the researchers on healthy lifestyle behavior changes will be given to the participants.
47948011|NCT05390931|OTHER|6 month follow-up|Follow-ups will be made 3 times in total, on the basis of pre-test, intermediate follow-up test (3 months), and post-test (6 months).
48104493|NCT05498337|OTHER|calcium hydroxide|Dental pulp medicament material
48104494|NCT05498337|OTHER|MTA|Dental pulp medicament material
48104495|NCT05498337|DEVICE|Diode Laser|Device used in pulp therapy
48104496|NCT04270175|DRUG|Daratumumab SC|Given as 1800mg via injection
48297733|NCT05649124|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
48297734|NCT02563184|BIOLOGICAL|Fluzone|
48297735|NCT05879926|DRUG|Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
48297736|NCT05879926|DRUG|Adjuvant Chemotherapy + Ovarian Function Suppression|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
48297737|NCT01188018|BEHAVIORAL|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
47948012|NCT03220984|BIOLOGICAL|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
48297738|NCT01188018|BEHAVIORAL|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
48297739|NCT01188018|BEHAVIORAL|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
48297740|NCT01716260|DRUG|Chloroquine|
48297741|NCT01716260|DRUG|Primaquine|
48297742|NCT05065944|BEHAVIORAL|Telemedicine|Pre-anesthesia assessment (history and physical examination) via telemedicine. Intervention is a one-time telemedicine clinic visit for approximately 30 minutes to 1 hour. Individual patients will be randomized to telemedicine and that visit will be scheduled via the Zoom video conferencing platform.
48636195|NCT03748563|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows.~Procedure of EGD:~The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
47948013|NCT02439294|OTHER|Without Obstructive Sleep Apnea (syndrome)|
47948014|NCT02439294|OTHER|Mild or moderate Obstructive Sleep Apnea (syndrome)|
47948015|NCT02439294|OTHER|Severe Obstructive Sleep Apnea (syndrome)|
47948016|NCT02439294|DEVICE|CPAP|
47948017|NCT06388382|OTHER|Alert tone demonstration|Patients are demonstrated the alert tone of their ICD
47948018|NCT01334892|DRUG|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
47948019|NCT04040270|BEHAVIORAL|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
47948020|NCT04040270|BEHAVIORAL|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
47948021|NCT00550849|DRUG|RTA 402|5 mg oral capsules
47948022|NCT00550849|DRUG|RTA 402|25 mg oral capsules
47948023|NCT00550849|DRUG|RTA 402|50 mg oral capsules
47948024|NCT04008173|OTHER|Non-interventional patient registry|Non-interventional patient registry
47948025|NCT01542333|GENETIC|gene expression analysis|
47948026|NCT01542333|GENETIC|proteomic profiling|
47948027|NCT01542333|GENETIC|reverse transcriptase-polymerase chain reaction|
47948028|NCT01542333|GENETIC|western blotting|
47948029|NCT01542333|OTHER|immunohistochemistry staining method|
47948030|NCT01542333|OTHER|laboratory biomarker analysis|
47948031|NCT01542333|PROCEDURE|spectroscopy|
47948032|NCT03877731|PROCEDURE|isolated septal myectomy|
48297743|NCT05065944|BEHAVIORAL|In Person Visit|Pre-anesthesia assessment (history and physical examination) in person at Moffitt Cancer Center (usual care)
47948033|NCT03877731|PROCEDURE|septal myectomy + edge-to-edge mitral valve repair|
48104497|NCT04270175|DRUG|Pomalidomide|Given as 4mg oral capsule
48104498|NCT04270175|DRUG|Dexamethasone|Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.
47948034|NCT03877731|PROCEDURE|septal myectomy + posterior leaflet sliding plasty|
47948035|NCT03877731|PROCEDURE|septal myectomy + secondary chordae transection|
47948036|NCT02163980|DRUG|Caudal ropivacaine + normal saline|
47948037|NCT02163980|DRUG|Caudal ropivacaine + dexmedetomidine|
48297744|NCT04663867|DEVICE|AngioSafe Peripheral CTO Crossing System|The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.
48297745|NCT03412422|DIAGNOSTIC_TEST|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
48297746|NCT02729454|OTHER|Mental practice and physical therapy|
48297747|NCT02729454|OTHER|physical therapy|
48297748|NCT01512524|OTHER|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
48297749|NCT03090191|BIOLOGICAL|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
47948038|NCT05199493|DRUG|Angiotensin II|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.
47948039|NCT05199493|DRUG|Control|Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo
47948040|NCT03422042|OTHER|Short duration of antibiotic|Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
47948041|NCT03422042|OTHER|Standard treatment of antibiotic|Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
47948042|NCT02595138|DRUG|Zoledronic acid|
47948043|NCT02706054|OTHER|saline|The patients received an IM injection of saline near the nerve root (periradicular)
47948044|NCT02706054|DRUG|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
47948045|NCT04558593|PROCEDURE|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
47948046|NCT04558593|PROCEDURE|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
47948047|NCT03897023|BIOLOGICAL|Gut Microbiota|Status of microbiota
48297750|NCT03090191|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
48297751|NCT02234115|DRUG|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
48297752|NCT06578650|DEVICE|Synthetic Electrospun Fiber Matrix|Patients who are eligible for enrollment will be treated with Synthetic Electrospun Fiber Matrix immediately after surgical resection to the resulting wound
48297753|NCT05720039|DEVICE|Robotic NSM|Robotic-assisted Nipple sparing mastectomy procedures
48297754|NCT05720039|PROCEDURE|Open NSM|open nipple-sparing mastectomy procedures
48297755|NCT04295304|DEVICE|Retinal surgery with implantation of epi-retinal device|Retinal surgery and implantation of epi-retinal prosthesis
48297756|NCT02865044|OTHER|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
48297757|NCT02865044|OTHER|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
48297758|NCT05189015|DRUG|Olmesartan|- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
48297759|NCT01686204|OTHER|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
48297760|NCT01686204|OTHER|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
48477733|NCT06467552|DIETARY_SUPPLEMENT|Nucare Curact group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
48477734|NCT04598360|PROCEDURE|Heart-Lung-Machine|blood sample before and during a single Heart-Lung-Machine procedure
47948048|NCT03107663|DRUG|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
47948049|NCT00263770|DEVICE|soft palate implant|
47948050|NCT00263770|OTHER|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
47948051|NCT04343820|PROCEDURE|Breast reconstruction|Breast reconstruction by prepectoral positioned implant after lipo-preparation of the wall.
47948052|NCT00563355|DRUG|erythropoietin|
47948053|NCT03270644|DRUG|Lasmiditan|Administered orally
47948054|NCT03270644|DRUG|Propranolol|Administered orally
47948055|NCT01756053|DRUG|ABT-089|Selective neuronal nicotinic receptor agonist.
47948056|NCT01756053|DRUG|Placebo|Matched placebo capsules supplied by study drug supplier.
47948057|NCT05111808|DEVICE|Methylene blue fluorescence|IV administration of methylene blue, detection with deep infrared camera and light source
47948058|NCT05504395|DRUG|CSTI-500|Single 10 mg capsule
47948059|NCT04823182|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
48636196|NCT02441114|DRUG|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
48636197|NCT04566380|DRUG|ONO-4538|IV infusion over 30 minutes
47948060|NCT02286583|DEVICE|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
47948061|NCT05113927|DEVICE|Selene|SELENE imaging of all margins, with record of each margin assessment and an opportunity to excise tissue from the lumpectomy cavity post-imaging. The new margin will be imaged with SELENE and the surgeon will record the assessment and may take additional tissue (up to a maximum of six total shaves, including up to two shaves in each orientation) or record why no further tissue may be taken.
47948062|NCT02725034|DEVICE|Standard endoscopy|
47948063|NCT02725034|DEVICE|High definition endoscopy with Optic Enhancement|
47948064|NCT06679413|DRUG|midazolam|Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study
47948065|NCT06679413|DRUG|metformin|Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study
47948066|NCT06679413|DRUG|bupropion|Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study
47948067|NCT06679413|DRUG|fenfluramine HCl|Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study
47948068|NCT05907122|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.
47948069|NCT05907122|DRUG|FDA-licensed Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
47948070|NCT05907122|DRUG|EU-authorized Nivolumab|FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
47948071|NCT04817735|PROCEDURE|TAVI|TAVI sizing with dedicated algorithm
47948072|NCT06681779|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam
47948073|NCT06681779|OTHER|Standard of Care (SOC)|Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.
47948074|NCT06680531|DRUG|YZJ-1139 tablets|YZJ-1139 tablets are administered orally single dose
47948075|NCT06680531|DRUG|Escitalopram oxalate tablets|•oral tablet, QD
48636198|NCT04566380|DRUG|oxaliplatin|IV infusion over 2 hours
48636199|NCT04566380|DRUG|S-1|Administered orally twice daily
47948076|NCT06680531|DRUG|YZJ-1139 simulated tablets|oral tablet, QD
47948077|NCT02787460|BEHAVIORAL|Behavioral Text Messages|
47948078|NCT02329821|OTHER|hartmann solution|hartmann solution infusion in patients for hepatic resection
48636200|NCT04566380|DRUG|capecitabine|Administered orally twice daily
48636201|NCT04566380|DRUG|bevacizumab|IV infusion over 30 minutes
48636202|NCT04566380|DRUG|temozolomide|Administered orally once daily for 5 days every 28 days
47948079|NCT06047925|PROCEDURE|3D printed crown|Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid material) material.The 3d printed crown is cemented with resin cement.
47948080|NCT06047925|PROCEDURE|stanless steel crown|The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
47948081|NCT03883399|OTHER|Survey|Survey among colorectal surgeons
47948082|NCT04210778|BEHAVIORAL|Cognitive orientation to daily occupational performance (CO-OP)|The CO-OP is a client-centered, goal directed approach aimed at enabling individuals to identify strategies that will improve daily function. A Weekly (1hr) session is delivered remotely via video conferencing.
47948083|NCT04210778|BEHAVIORAL|Computerized Cognitive Training (BrainHQ, posit science)|The BrainHQ training targets multiple cognitive domains. The training will be delivered remotely, using a web-based program. Training progresses in an adaptive, individualized manner, based on individual progression of each participant . Participants are required to practice a minimum of half hour, three times a week (total of 1.5hr)
47948084|NCT05077527|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
47948085|NCT05077527|DRUG|Cyclophosphamide|Given IV
47948086|NCT05077527|DRUG|Fludarabine|Given IV
48297761|NCT06228183|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48297762|NCT06228183|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48297763|NCT06228183|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48297764|NCT03691012|DIAGNOSTIC_TEST|Circulating tumour DNA testing|Circulating tumour DNA testing
48297765|NCT06134375|DRUG|Tetrathiomolybdate|Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer. TM forms stable copper-molybdenum clusters sequestering copper and thereby limiting its availability, for the proper functioning of angiogenic factors, including secreted metalloenzymes. TM inhibits several copper containing enzymes including ceruloplasmin, cytochrome oxidase, tyrosinase and downregulates cytokines such as MMP9 and VEGF as well as transcription factors such as NF-kB. Both pre-clinical and clinical data suggest that TM may effectively reduce both overt and sub-clinical tumor load by both targeting the metastases initiating stem cell component of primary tumors inactivating Complex IV, shifting oxphos to glycolysis and through stromal remodeling.
48297766|NCT06134375|DRUG|Capecitabine|1000mg/m2 twice daily, Days 1-14 Q21days for 6 months
48297767|NCT06134375|DRUG|Pembrolizumab|If pembrolizumab was administered in the neoadjuvant setting and the oncology team chooses to continue in the adjuvant setting, standard doses will be used (200 mg IV Q3weeks or 400 mg IV Q6 weeks for one year total as per package insert)
48297768|NCT01463852|DRUG|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
48297769|NCT06671093|GENETIC|Tune-401|Epigenetic gene silencing therapy
48297770|NCT04759911|OTHER|Quality-of-Life Assessment|Ancillary studies
48297771|NCT04759911|OTHER|Questionnaire Administration|Ancillary studies
48297772|NCT04759911|DRUG|Selpercatinib|Given PO
48297773|NCT04759911|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
48297774|NCT06649903|BEHAVIORAL|Chiropractic|high speed low amplitude neck manipulation
48297775|NCT06649903|BEHAVIORAL|Osteopathy|the stomach and liver technique was applied
48297776|NCT06649955|DEVICE|Multi-site direct current stimulation (DCS)|The MyoRegulator® treatment is a non-invasive intervention that suppresses motor neuron hyperexcitability and activates protein degradation pathways through the use of multi-site direct current stimulation (multi-site DCS).
48297777|NCT04358250|PROCEDURE|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
48297778|NCT04358250|PROCEDURE|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
47948087|NCT01856907|DRUG|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
47948088|NCT01856907|DRUG|Metformin|Biguanide- insulin sensitizer
48297779|NCT00499993|DRUG|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
48297780|NCT02158858|DRUG|Pelabresib (CPI-0610)|
48297781|NCT02158858|DRUG|Ruxolitinib|
48297782|NCT01623778|DRUG|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
47948089|NCT01856907|DRUG|Placebo pill|Will evaluate effect of lifestyle and diet only
47948090|NCT02197273|DRUG|Liposomal bupivacaine|
47948091|NCT02197273|DRUG|Standard of care analgesia|
48297783|NCT01764178|DRUG|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
48297784|NCT01764178|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
48297787|NCT05208983|BIOLOGICAL|mRNA Vaccines or Viral vector-based vaccines for COVID|Participants receiving an approved COVID vaccine
48297788|NCT00970203|BIOLOGICAL|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
48297789|NCT00970203|BIOLOGICAL|DC1 vaccine|3-5 x 10e6 cells total
47948092|NCT03629210|DRUG|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
48297790|NCT06048003|OTHER|No specific intervention|No specific intervention
47948093|NCT03629210|BIOLOGICAL|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
48297791|NCT01426048|OTHER|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
48297792|NCT02179307|BEHAVIORAL|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
48297793|NCT05700344|DRUG|Avelumab|Single Group Assignment
48297794|NCT04346394|DRUG|Yohimbine HCl|Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
48297795|NCT06672549|DRUG|Orforglipron|Administered orally. ISA specific interventions will be listed in the ISA.
48297796|NCT06672549|DRUG|Placebo|Administered orally. ISA specific interventions will be listed in the ISA.
48297797|NCT03869073|DRUG|Evolocumab|Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
47948094|NCT03819426|BEHAVIORAL|Low Intensity Exercise Intervention|Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
47948095|NCT03819426|BEHAVIORAL|High Intensity Intervention|Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
47948096|NCT04197531|OTHER|Irrigation Method|Irrigation Method
47948097|NCT06681506|DEVICE|Metronomic breathing, exercise rehabilitation, external counterpulsation, extracorporeal shock wave.|Phase I rehabilitation(Metronomic breathing，exercise rehabilitation）,Phase II rehabilitation (exercise rehabilitation, external counterpulsation, extracorporeal shock) wave.)
47948098|NCT06681506|DEVICE|bedside rehabilitation and breathing, balance, flexibility, movement rehabilitation|Phase I rehabilitation (bedside rehabilitation, breathing rehabilitation), Phase II rehabilitation (breathing, balance, flexibility, movement)
47948099|NCT04517500|BEHAVIORAL|Home-based pulmonary rehabilitation program|Subjects will wear an activity monitor while doing at home exercises using a computer tablet
47948100|NCT04517500|BEHAVIORAL|Mindful breathing module|Additional module on the computer tablet that involves inhaling and exhaling while following an animated ball on the computer screen.
47948101|NCT04517500|BEHAVIORAL|Health coaching|Weekly coaching calls to discuss rehabilitation and health process using motivational interviewing
47948102|NCT01309165|BEHAVIORAL|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
47948103|NCT01309165|BEHAVIORAL|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
47948104|NCT00449527|DRUG|Budesonide/formoterol pMDI|
47948105|NCT00449527|DRUG|Budesonide HFA pMDI|
47948106|NCT02996734|PROCEDURE|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
47948107|NCT00335478|DRUG|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is \>500 cells/mm\^3.
47948108|NCT01641874|PROCEDURE|Exercise|Directional specific exercise
48297798|NCT03869073|DRUG|Placebo|Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
47948109|NCT01641874|PROCEDURE|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
48297799|NCT00492401|DRUG|decitabine|Given IV
48297800|NCT00492401|OTHER|laboratory biomarker analysis|Correlative studies
48297801|NCT00492401|OTHER|pharmacological study|Correlative studies
48297802|NCT00492401|OTHER|high performance liquid chromatography|Correlative studies
48297803|NCT00492401|GENETIC|microarray analysis|Correlative studies
48297804|NCT00492401|GENETIC|RNA analysis|Correlative studies
48297805|NCT00492401|OTHER|mass spectrometry|Correlative studies
48297806|NCT00492401|GENETIC|DNA methylation analysis|Correlative studies
48297807|NCT00492401|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
48297808|NCT05292222|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
48297809|NCT02270632|DRUG|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
48297810|NCT02270632|DRUG|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
48297811|NCT02270632|DRUG|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
48297812|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
48297813|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
48297814|NCT03898583|DRUG|Microarray patch A|Microarray patch
48297815|NCT03898583|DRUG|Microarray patch B|Microarray patch
48297816|NCT03898583|DRUG|Placebo|Microarray patch vehicle
48297817|NCT03898583|DRUG|Daivobet|Daivobet Gel
48297818|NCT06672744|OTHER|Exercise|Lumbar muscles (especially quadratus lumborum) and thoracolumbar fascia stretching exercises and strengthening exercises for the lumbar and abdominal muscles were described by the physiotherapist. Participants were asked to perform the exercises three times a day, five days a week
48297819|NCT06672744|OTHER|Myofascial release technique|Myofascial release technique was applied by the same researcher (YY) twice a week for four weeks.
48297820|NCT06672744|OTHER|Kinesiotaping|Kinesiotaping was performed by the same researcher (XX) for two sessions per week for four weeks with fascia correction technique
48297821|NCT06274112|DEVICE|TMS|TMS will be administered in either an active format that induces neuromodulatory effects or a sham comparison format that does not induce neuromodulatory effects.
48297822|NCT06524882|DEVICE|Vivid Vision|dichoptic video games played through a virtual reality headset
48297823|NCT06524882|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
48297824|NCT06524882|DEVICE|Optical Correction|Glasses prescribed at investigator discretion
48297825|NCT06343207|DEVICE|Percussive massage gun therapy|Between pre and post-test, there was a one and half minute period during which each participant were in a prone position on a medical examination bed. The experimental PT groups received a 30-second triceps surae massage on each limb, while the control group maintained the same prone position without massage. The massage gun was set to 2100bpm and 1 bar of surface pressure was indicated by the device. The massage gun movement was performed according to the manufactu'er's instructions.
47948110|NCT05934942|DRUG|Yasmin®|Ethinylestradiol (EE) and Drospirenone (DRSP)
48104499|NCT04518566|BEHAVIORAL|Nudges|Behavioral nudges will be delivered to patients' FitBit device through adaptive intervention platform via notification syncing. To ensure the delivered nudges are timely and personalized, predictive nudges will be developed based on patterns in patients' sociodemographic, clinical and baseline activity tracking. These nudges will be sent automatically to patients upon specific triggers. The nudges will also be assessed for its effectiveness in behavior change. For example, a predictive nudge to encourage patients to take a short walk after detecting long periods of sedentary time will be assessed for its effects by step counts data after delivery of nudge. An iterative approach will be used to generate an effective set of nudges and its most appropriate delivery times for specific activity patterns.
48297826|NCT02951130|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
48297827|NCT02951130|DRUG|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
47948111|NCT05934942|DRUG|BI 1358894|BI 1358894
47948112|NCT00251173|BEHAVIORAL|Strengths Based Case Management (SBCM)|
47948113|NCT00251173|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
48104500|NCT04038229|OTHER|Enhanced recovery pathway|The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
48297828|NCT03384849|DIAGNOSTIC_TEST|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
48297829|NCT04877782|DEVICE|Transcutaneous vagus verne stimulation|Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
48297830|NCT00002826|DRUG|paclitaxel|
48297831|NCT00002826|DRUG|valspodar|
48104501|NCT04837313|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
48297832|NCT06249126|PROCEDURE|Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)|Definitive fixation by joint fusion
48297833|NCT06249126|PROCEDURE|Open Reduction Internal Fixation (ORIF) only|Definitive fixation with plates and screws
47948114|NCT00251173|BEHAVIORAL|Brief Informational Feedback (BIF) session|
47948115|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
47948116|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
48477735|NCT06468748|DRUG|Semaglutide|During the first visit, participants will be taught how to self-administer the pen injector by medical staff. Participants will also be provided instructions for self-administering injections and a compliance log to track adherence to the treatment, and additional information about each injection (date, time, injection site)
48477736|NCT05303935|DRUG|Quetiapine 50 MG|A single dose of 50mg of quetiapine taken at bedtime for one night.
48477737|NCT05303935|DRUG|Placebo|A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
48636203|NCT03193385|PROCEDURE|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
47948117|NCT02955797|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
47948118|NCT02955797|BIOLOGICAL|Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine|0.5 mL, Intramuscular
47948119|NCT02699359|DEVICE|HS-1000 recording|
48104502|NCT05356923|RADIATION|68Gallium FAPI PET/MR scan|68Gallium FAPI PET/MR scan
48297834|NCT04988516|DEVICE|Virtual reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
48297835|NCT04988516|OTHER|Standard protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
48477738|NCT06058221|DEVICE|simultaneous videolaryngoscopy|Two specialists perform tracheal intubation, one using a video laryngoscope to expose the vocal cords and the other using a fiberoptic bronchoscope.
48477739|NCT06058221|DEVICE|supraglottic airway|After inserting the supraglottic airway, the specialist performs intubation using a fiberoptic bronchoscope through the supraglottic airway.
48477740|NCT03547726|OTHER|Physical Therapy|These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
48477741|NCT03547726|OTHER|Self-Rehab|These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
48636204|NCT03387774|DRUG|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
48636205|NCT03387774|RADIATION|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
48636206|NCT03387774|DRUG|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
47948120|NCT04776694|DRUG|Dupilumab|
47948121|NCT03225742|DIAGNOSTIC_TEST|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
47948122|NCT01913223|DEVICE|Nestis® jet injector system with a bi-functional catheter|
47948123|NCT04886739|DRUG|CGB-400|Topical gel
47948124|NCT04886739|DRUG|Vehicle Gel|Topical gel
47948125|NCT01225627|OTHER|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
47948126|NCT01225627|OTHER|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
47948127|NCT03342014|DEVICE|Ultrasound|3DPD and UAD acquisitions (10 min)
47948128|NCT03342014|BIOLOGICAL|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
47948129|NCT00836030|OTHER|No treatment given|No treatment given
48104503|NCT00435799|PROCEDURE|corneal cross-linking (CCL)|
48636207|NCT04375215|PROCEDURE|Selective caries removal|After caries removal restoration of tooth will be performed
48636208|NCT04375215|PROCEDURE|Stepwise caries removal|After caries removal restoration of tooth will be performed
48636209|NCT00029900|DRUG|ADI PEG|
48636210|NCT01032278|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
47948130|NCT05734989|DIAGNOSTIC_TEST|BP|Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.
47948131|NCT05734989|DIAGNOSTIC_TEST|HbA1c|HbA1c will screen to identify patients with Type 2 diabetes
48104504|NCT00435799|DRUG|Riboflavin/dextran eyedrops|
48104505|NCT00435799|DEVICE|UV-X system|
48104506|NCT02639429|DRUG|Vaginal Misoprostol|
48104507|NCT02639429|DEVICE|Foley Balloon + Vaginal Misoprostol|
48477742|NCT05025280|OTHER|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
48477745|NCT00005026|DRUG|carboplatin|
48477746|NCT00005026|DRUG|paclitaxel|
48297836|NCT03065803|PROCEDURE|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
48297837|NCT03065803|PROCEDURE|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
48297838|NCT04565561|DEVICE|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3."
48297839|NCT00418886|DRUG|Vandetanib|oral once daily tablet
48297840|NCT00418886|DRUG|Pemetrexed|intravenous infusion
48297841|NCT05790304|DRUG|Camizestrant|Camizestrant 75 mg tablets. Experimental drug.
48297842|NCT03407391|OTHER|None - observational|No intervention - observational only
48297843|NCT04064684|DRUG|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
48297844|NCT04064684|DRUG|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
48297845|NCT04064684|DEVICE|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
47948132|NCT05734989|BEHAVIORAL|PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD|Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
48297851|NCT06255977|DRUG|CN-105|Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
48297852|NCT00003356|BIOLOGICAL|aldesleukin|
48297853|NCT00003356|BIOLOGICAL|rituximab|
48477747|NCT00005026|DRUG|topotecan hydrochloride|
48477748|NCT03791294|DRUG|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
48477749|NCT05454358|DRUG|Letrozole 2.5mg|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
48477750|NCT04948671|OTHER|there will be no intervention, this is an observational study|this is an observational study
47948133|NCT05280171|OTHER|Teach back|"Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum."
47948134|NCT05280171|OTHER|Standard of care|Standard of care
48297854|NCT02734992|BEHAVIORAL|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
48297855|NCT02734992|BEHAVIORAL|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
48297856|NCT04880057|OTHER|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition\[3\]. It took the participants 25 minutes to complete AeT."
48297857|NCT04880057|OTHER|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
48297858|NCT01378390|DRUG|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
48297859|NCT01378390|DRUG|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
48297860|NCT02538146|DIETARY_SUPPLEMENT|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
48297861|NCT05187338|DRUG|ipilimumab +pembrolizumab +durvalumab|"This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
48297862|NCT01731691|BIOLOGICAL|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
48297863|NCT01731691|DRUG|Placebos|Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
48297864|NCT05970055|PROCEDURE|elective surgery|All elective surgical procedures performed under the study period will be included.
48297865|NCT05243550|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
48297866|NCT06560918|DEVICE|hearing aids|OTC devices for a week
48297867|NCT02404831|OTHER|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
47948135|NCT03615573|OTHER|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
48104508|NCT03171896|OTHER|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
48104509|NCT03171896|OTHER|Sham|No clown will be present in the room during labor
48104510|NCT04689321|OTHER|No intervention|This is not an interventional study.
47948136|NCT06132841|DRUG|AZD6234|Participants will receive repeated doses of AZD6234 as a solution via SC
47948137|NCT06132841|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC
47948138|NCT02496065|DRUG|BLZ-100|
48104511|NCT05104905|DRUG|bexmarilimab|A single neoadjuvant dose will be administered prior to surgery.
48104512|NCT06069986|PROCEDURE|coronary artery bypass graft CABG|comparison between onpump and off pump CABG
48104513|NCT06184451|OTHER|Therapeutic exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
47948139|NCT04579029|PROCEDURE|Lymphaticovenous anastomosis surgery combined with near infrared spectroscopy imaging|Lymphoedema is well recognized as a chronic debilitating disease resulting from an abnormal collection of protein-rich fluid within the subcutaneous tissues of the body. Given the need to identify more effective treatments, more recent advances in super microsurgical techniques have seen the introduction of new procedures, perhaps the most successful of which have involved re-routing the lymphatic fluid by using microsurgery to divert small lymphatic channels into venules in the sub-dermal plane (LVA surgery). This procedure is performed under regional or general anaesthetic as a day-case operation, leaving only a few very short scars in the skin of the arm or leg.
48477751|NCT05274633|DRUG|Ravulizumab|Participants will be observed for 52 weeks after the start of ravulizumab.
47948140|NCT01123850|DEVICE|Copios|Bone Void Filler
47948141|NCT03989765|OTHER|Programme to reduce involuntary treatment episodes|See description of trial arms
47948142|NCT01974154|OTHER|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
48477752|NCT02983032|BEHAVIORAL|BBTI|3 group sessions over 4 weeks
48477753|NCT03416556|PROCEDURE|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
48477754|NCT03416556|PROCEDURE|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
48477755|NCT03416556|OTHER|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
48636211|NCT01032278|BEHAVIORAL|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
47948143|NCT01974154|OTHER|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
47948144|NCT05061966|BEHAVIORAL|immi|The intervention has four main content areas: 1) gender identity (the gender guide), 2) sexual orientation (the queerness guide), 3)stress and coping (the stress guide), and 4) internalized stigma (the internalized stigma guide).
47948145|NCT05061966|BEHAVIORAL|Control|The control will have access to resources on the website, but will not receive any engagement reminders, matching the conditions present in real world contexts in which web-based resource lists are available.
47948146|NCT04906460|DRUG|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
47948147|NCT00399620|PROCEDURE|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
48477756|NCT03877341|PROCEDURE|posterolateral fusion|Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
48477757|NCT03877341|PROCEDURE|posterior lumbar interbody fusion|Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
48477758|NCT04707586|OTHER|Cold Application|Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
47948148|NCT04834674|COMBINATION_PRODUCT|DEB-TACE combined with apatinib and PD-1 antibody|combination of local therapy (DEB-TACE), antiangiogenic therapy (apatinib), and immunotherapy (PD-1 antibody)
47948149|NCT03577873|OTHER|gallbladder preserved|Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
47948150|NCT03577873|PROCEDURE|cholecystectomy|Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
47948151|NCT05240599|OTHER|Exercise Training|Exercise training will be applied 3 times a day for 8 weeks.
47948152|NCT05736510|OTHER|Binaural sound|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
48297868|NCT02404831|OTHER|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
48297869|NCT00233220|BEHAVIORAL|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
48297870|NCT00233220|BEHAVIORAL|Usual Care|Patients will receive usual care.
48297871|NCT04013581|DRUG|TZD group|Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
48297872|NCT04013581|DRUG|SGLT-2 group|Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
48297873|NCT03290300|DEVICE|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
48297874|NCT02500030|PROCEDURE|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
48297875|NCT02500030|PROCEDURE|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
48297876|NCT03531268|OTHER|PGx Testing|Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
48297877|NCT00931892|DIETARY_SUPPLEMENT|Gluten|3g
48297878|NCT00931892|DIETARY_SUPPLEMENT|Gluten|10g
48297879|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
48297880|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
48297881|NCT00546819|BIOLOGICAL|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
48297882|NCT00546819|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
48297883|NCT03332004|DRUG|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
47948153|NCT05736510|OTHER|Control|"When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation."
47948154|NCT02140112|BIOLOGICAL|Trichuris suis ova|
48297884|NCT02379910|DRUG|AM1030-CREAM or placebo|
48477759|NCT06616922|DRUG|RD03/2016 eye drops|1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
48477760|NCT06616922|DRUG|Levofloxacin 0.5% eye drops solution (Oftaquix®)|1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
48297885|NCT04513808|DRUG|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia, titrated to clinical need.
48297886|NCT04513808|DRUG|Sevoflurane intravenous anesthesia|Sevoflurane intravenous anesthesia, titrated to clinical need.
48297887|NCT03080922|BIOLOGICAL|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
48297888|NCT06494904|DRUG|Buprenorphine|All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
48297889|NCT00815984|PROCEDURE|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
48477761|NCT02456987|DEVICE|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
48477762|NCT04412486|BIOLOGICAL|COVID Convalescent Plasma|One unit of COVID Convalescent Plasma transfused on Day 0
48477763|NCT05624528|DRUG|Tolcapone|catechol-O-methyl transferase inhibitor
48297890|NCT06335173|DRUG|sabirnetug|Intravenous sabirnetug
47948155|NCT02140112|OTHER|Placebo|
47948156|NCT01179893|BIOLOGICAL|IVIG|Intravenous immunoglobulin
47948157|NCT01179893|PROCEDURE|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
47948158|NCT06019949|DEVICE|Transcutaneous spinal cord stimulator|Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.
48477764|NCT05624528|DRUG|Placebo|Pill that contains no medicine
48297891|NCT06335173|DRUG|Placebo|Intravenous Placebo
47948159|NCT06019949|DEVICE|Respiratory Training|Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
47948160|NCT04209062|DEVICE|Medical device validation|The medical devices will both record electrical signals for comparison
47948161|NCT00364754|DRUG|Tesmilifene (YMB 1002)|
48297892|NCT03426215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
48297893|NCT06671743|PROCEDURE|Root canal treatment|"History of presenting illness will be recorded and vitality testing will be done in addition to pre-operative radiograph.~Patient will read and sign the consent form. Pre-operative pain score will be recorded using visual analogue scale. The patient will take the preoperative medication 1 hour prior to the procedure.~The patient will receive 1 cartridge of LA with inferior alveolar nerve block (2% lidocaine 1:80000) and a rubber dam will be used for isolation.~Access cavity will be prepared and working length will be determined. Cleaning and shaping of the root canal system will be performed followed by obturation using a standardized protocol followed by final coronal restoration.~Postoperative pain score will be recorded at the 6, 12, 24, and 48 hours using visual analogue pain scale."
48297894|NCT03499041|DRUG|LY3314814|Administered orally
48297895|NCT03969433|DEVICE|TMSi Porti|Data collections
48297896|NCT03969433|DEVICE|Bloomlife sensor|Data collections
48477765|NCT05361486|OTHER|Training on revised algorithm|relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
48477766|NCT05361486|OTHER|Enhancing Pharmacovigilance|Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
48477767|NCT05361486|OTHER|Supervision of malaria services in selected facilities.|Supervisors in target regions will be trained as for the HCPs.
48477768|NCT05361486|DIAGNOSTIC_TEST|G6PD testing|G6PD test after Malaria Vivax diagnosis
48477769|NCT05361486|DRUG|Tafenoquine|300 mg (2x150mg tablets) tafenoquine
47948162|NCT04281641|DIAGNOSTIC_TEST|TCHP|"Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery."
47948163|NCT02965716|BIOLOGICAL|Pembrolizumab|Given IV
47948164|NCT02965716|BIOLOGICAL|Talimogene Laherparepvec|Given IL
48477770|NCT05361486|DRUG|Primaquine|0.5mg/kg/7 days
48477771|NCT05361486|OTHER|Follow Up Visit at Day 3 [+2 days] after treatment start|It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
48477772|NCT04473716|DRUG|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
48477773|NCT04473716|DRUG|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
48477774|NCT04473716|DRUG|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
48297897|NCT06214949|DEVICE|Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over 3-4 weeks. Specifically, the active or sham treatments will be conducted \~5 times a week during the treatment phase of the study. The treatment protocol parameters (stimulus location, frequency, duration, and intensity) will be derived from the PrTMS software algorithm which incorporates clinical inputs from neurocognitive surveys and quantitative EEG analysis. The mechanical parameters will adhere to the recommended PrTMS parameters for pain treatment: figure of 8 coil that produces biphasic stimulatory pulses to the central zone cortex, frontal zone cortex, Broca's area, and frontal pre-cortex areas at a stimulation depth of 2 cm. Treatment parameters will be unique to each participant but will remain within known ranges. The frequency will be between 8 and 13 Hz, at an amplitude of 20-30% (approximately 30-40% of RMT), and about 3200-7200 pulses per session. Since parameters are specific to each participant, treatment settings will vary.
48297898|NCT06214949|DEVICE|Sham Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over the course of 3-4 weeks. More specifically, the active or sham treatments will be conducted roughly 5 times a week during the course of the treatment phase of the study. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
48297899|NCT06671171|DEVICE|Apple Watch Series 9|"Participants will wear Apple Watch Series 9 during cardiopulmonary exercise test (in Visit 1), 1-week study period and 6-Minute walk distance test (in Visit 2) to have assessment of maximal oxygen uptake and pre- and post-SaO2.~During 1-week study period, participants will measure their oxygen saturation once daily with a medical-grade pulse oximeter while wearing the smartwatch continuously."
48297900|NCT06172257|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|"The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
48297901|NCT06172257|DRUG|Vehicle|"The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
48297902|NCT03544060|DRUG|Volanesorsen|Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
47948165|NCT04267003|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
47948166|NCT06679881|DRUG|Deucrictibant|Deucrictibant extended-release tablet for once daily oral use
47948167|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
47948168|NCT00494455|DEVICE|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
48297903|NCT02654106|RADIATION|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
48636212|NCT03674450|BEHAVIORAL|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
48636213|NCT03995511|PROCEDURE|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
48636214|NCT05690191|DRUG|Chidamide|Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
48636215|NCT05690191|DRUG|Lenalidomide|Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
48636216|NCT05690191|DRUG|Rituximab|Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
47948169|NCT03714308|DRUG|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
47948170|NCT00235469|DRUG|SPM 927|
47948171|NCT00052273|DRUG|capecitabine|
47948172|NCT00052273|DRUG|enzastaurin hydrochloride|
47948173|NCT04156477|DIETARY_SUPPLEMENT|Ketone ester|Intake of weight adjusted drink of a ketone ester
47948174|NCT04156477|DIETARY_SUPPLEMENT|Glucose|Isocaloric and - volumetric taste adjusted drink
47948175|NCT04156477|DIETARY_SUPPLEMENT|Tap water|Isovolumetric taste adjusted tap water (placebo)
47948176|NCT00994318|DRUG|FCM (Ferric carboxymaltose) high ferritin target|
47948177|NCT00994318|DRUG|FCM (Ferric carboxymaltose) low ferritin target|
47948178|NCT00994318|DRUG|Oral Iron (Ferrous sulphate)|
48297904|NCT02654106|DRUG|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles
48297905|NCT03378401|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
48297906|NCT03378401|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
48477775|NCT04473716|PROCEDURE|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
48477776|NCT04473716|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
48297907|NCT01789073|DIETARY_SUPPLEMENT|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
48297908|NCT04258553|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
48297909|NCT04258553|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
48297910|NCT04258553|DIAGNOSTIC_TEST|Ischemia Modified Albumin(IU/mL)|The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
48297911|NCT00259025|DRUG|lipid emulsion with a high content of n-3 fatty acids|
48297912|NCT06149312|OTHER|Advance Care Planning Intervention|Standardized interview based on The letter Project (Stanford Medicine) and Questions Prompt List
48297913|NCT00077623|DRUG|epoetin alfa or beta|iv 3 times weekly, as prescribed
48297914|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
48297915|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
48477777|NCT05867524|OTHER|Oral Glucose Tolerance Test|75g oral glucose tolerance test, sampled over three hours
48477778|NCT05867524|OTHER|Cycling test|2 hours of moderate activity level cycling
48477779|NCT00913796|DRUG|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
48636217|NCT04948632|OTHER|Complete LeoMed application|Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.
48636218|NCT04948632|OTHER|Basic LeoMed application|Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
48636219|NCT02920567|DRUG|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
48477780|NCT00913796|DRUG|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
48477781|NCT06247501|GENETIC|SNUH-CD19-CAR-T|CD19 CAR-T is a gene therapy that uses genetically modified autologous peripheral blood T-cells to target CD19 on the surface of B-cells. In this approach using CARs, lymphocytes are genetically manipulated, introducing the chimeric antigen receptor gene into the lymphocytes to combine the function of effector T-cells with antibody-like abilities. The chimeric antigen receptor can recognize cell surface antigens without the need for antigen processing. By using a single-chain variable fragment (scFv) antibody, which combines the variable regions of the heavy chain (VH) and light chain (VL) through a peptide linker of approximately 15 amino acids in length, the CAR gains the ability to bind to tumor antigens.
47948179|NCT06137560|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
48297916|NCT04524936|DIAGNOSTIC_TEST|blood sample|
48297917|NCT00359814|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
48297918|NCT00359814|DRUG|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
48297919|NCT05603910|DRUG|Lenvatinib|Lenvatinib capsules taken daily by mouth
48297920|NCT05603910|DRUG|Pembrolizumab|200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
48297921|NCT05603910|RADIATION|Hypofractionated External Beam Radiation Therapy|HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
48297922|NCT03988816|DRUG|Roflumilast|500Mcg Tab, once daily
48297923|NCT03988816|DRUG|Placebo oral tablet|once daily
48297924|NCT04241835|DRUG|Tazemetostat|"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
48297925|NCT01742221|BIOLOGICAL|HemaMax|single subcutaneous 12 microgram dose of HemaMax
48297926|NCT01742221|DRUG|Placebo|single subcutaneous dose
47948180|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 1|Standard single vision spectacle lens + S.T.O.P.® Kit 1
47948181|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Kit 2|Standard single vision spectacle lens + S.T.O.P.® Kit 2
47948182|NCT06137560|DEVICE|Single vision spectacle lens + S.T.O.P.® Film|Standard single vision spectacle lens + S.T.O.P.® Film
47948183|NCT06137560|DEVICE|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2|Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
47948184|NCT01604187|DRUG|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
47948185|NCT01604187|DRUG|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
47948186|NCT01133041|OTHER|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
47948187|NCT01133041|OTHER|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
47948188|NCT02589405|DRUG|Benzoyl Peroxide|
47948189|NCT02589405|OTHER|Dermotivin® Soft Liquid cleanser|
47948190|NCT02589405|OTHER|Cetaphil® Dermacontrol Moisturizer SPF30|
47948191|NCT01051466|DRUG|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
47948192|NCT00580970|DRUG|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
48636220|NCT02920567|DRUG|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
47948193|NCT04493580|BEHAVIORAL|iDBT|Electronic DBT sessions designed to mirror in-person DBT.
47948194|NCT04493580|BEHAVIORAL|In-Person DBT|In-person DBT
47948195|NCT05862597|DIAGNOSTIC_TEST|HRV and Pulse diagnosis|Palpation of the 6 pulse positions (right cun, right guan, right chi, left cun, left guan, left chi) measured by the pulse diagnostic instrument.
47948196|NCT00361582|DRUG|CG5503 IR; tapentadol|
47948197|NCT04820166|OTHER|monitoring portal pressure gradient or hepatic venous pressure gradient|measuring portal pressure gradient or hepatic venous pressure gradient regularly
47948198|NCT06501924|DIETARY_SUPPLEMENT|DA-005|Oral Botanical Supplement HIF-1a inhibitor
47948199|NCT06501924|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
47948200|NCT06501924|DRUG|DA-002|Topical Alpha 1 Agonist (GRAS)
47948201|NCT06501924|DIETARY_SUPPLEMENT|Placebo Oral Tablet|Placebo Oral Tablet
47948202|NCT06501924|OTHER|Placebo Topical Solution|Placebo Topical Solution
47948203|NCT05027464|BEHAVIORAL|Moving to COVID-19 Vaccine Acceptance Intervention|The intervention utilizes a multi-pronged approach to increase Veteran vaccine acceptance. First, the research team will train Health Behavior Coordinators (HBCs) at VAI sites. HBCs will then train PACT teams at their site and Whole Health Coaches, Peer Specialists and other VA Staff in VAI strategies to use with unvaccinated Veterans. Whole Health Coaches, Peer Specialists and other VA Staff will conduct outreach calls, using strategies, with unvaccinated Veterans.
47948204|NCT03906136|BIOLOGICAL|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab-Biosimilar, s.c.
47948205|NCT03906136|OTHER|Standard-of-care|Patients will receive treatment according to local practice standards by their treating physician following the current treatment recommendations.
47948206|NCT05734495|DRUG|Pirtobrutinib|Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
47948207|NCT05734495|DRUG|Venetoclax|Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.
47948208|NCT04113720|DRUG|Levobupivacaine hydrochloride|levobupivacaine 0.25%
47948209|NCT04113720|DRUG|Levobupivacaine Hydrochloride + Dexmedetomidine|Levobupivacaine plus Dexmedetomidine
47948210|NCT05254223|OTHER|Antiinflammatory Diet|The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
47948211|NCT05254223|OTHER|Control Diet|The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
47948212|NCT06681792|BEHAVIORAL|Climate Change Workshops Based on Protection Motivation Theory|"The experimental group will take part in seven weekly workshops. One workshop will last 40 minutes.The workshop to be applied to the experimental group will take place every week and will last 40 minutes. The workshops, which are based on the Protection Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring environmentally friendly behaviour, recycling and the Green School Programme for sustainable environmental education.~The workshops include interactive applications such as students expressing their thoughts on the weekly themes, games, brainstorming, word cloud, planting trees, painting cloth bags, watching videos, making presentations on the themes. Motivation Theory, consist of topics such as the balance of nature, climate change, carbon and ecological footprints, reducing the effects of climate change and adaptation workshop, acquiring enviro"
47948213|NCT06666127|OTHER|LONG and SHORT Resistance Training|One side of the body will be randomly assigned to perform exercises in position 3 (LONG) with the other randomly assigned to position 2 (SHORT) of Prime Fitness horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Each exercise will include 1 warm up set at 50% 1RM followed by 4-5 sets of 8-12 repetitions per limb. 2 minutes of rest between sets on the same side of body will be administered as the participant will alternate between the right and left limb. The left and right side limbs will alternate each session in which one starts each exercise, resulting in 10 training sessions each where the left and right limbs starts first on each exercise. All sets will be performed to momentary failure. A Dynamic Double Progression will be employed to ensure intensity is maintained.
48636221|NCT03061214|DRUG|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
48636222|NCT03061214|DRUG|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
48297927|NCT06378073|DIAGNOSTIC_TEST|Incentive Spirometer|"Specificity and sensitivity: Incentive spirometry is a specific type of spirometry that aims to encourage people to breathe deeply intentionally but does not provide a measurement or inform management of chronic lung diseases. Less than 5 repetitions per day (sensitivity 93%, specificity 77%) and less than 2 balls per repetition (sensitivity 93%, specificity 77%) were predictive of postoperative pulmonary complications. (1) Validity and reliability: Incentive spirometry can be used as a simple mean to follow lung function, especially VC, in the postoperative period in spontaneously breathing patients. Incentive spirometry is noninvasive and can be performed repeatedly at the bedside in the intensive care setting. (2)~Interpretation:~There are only three numeric values that are required to interpret spirometry:~* Forced Vital Capacity (FVC)~* Forced Expiratory Volume (FEV1)~* FEV1/FVC ratio."
48297928|NCT06378073|DIAGNOSTIC_TEST|Numeric Pain Rating Scale|"Sensitivity: The area under the receiver operator characteristic curve for the NRS as a test for pain that interferes with functioning was 0.76, indicating fair accuracy. A pain screening NRS score of 1 was 69% sensitive for pain that interferes with functioning. (4) he diagnostic value of different NRS cut-off values for administering analgesics is determined by an ROC curve. Sensitivity of NRS \> 3 for 'unbearable' pain in older patients was 72% with a specificity of 97·2%. With a cut-off point NRS \> 4, sensitivity increased to 83%, while specificity was 96·7%. (5) Validity and reliability: The numerical rating scale is a reliable and valid tool for pain assessment in patients with musculoskeletal impairments. (3)~Measurement (circle): Categorical /Numerical /Both:~Numerical:~The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine or worst pain imaginable)"
48297929|NCT05227274|OTHER|Items completion with or without a MFM-Play|Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
48297930|NCT00246883|PROCEDURE|Exercise|
48297931|NCT02409420|BEHAVIORAL|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
48297932|NCT04897412|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
48297933|NCT04897412|OTHER|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
48297934|NCT05975567|OTHER|Three-dimensional imaging of the collected cardiac specimens|The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
48297935|NCT05135975|DRUG|Cabozantinib|Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
48297936|NCT06048016|DIAGNOSTIC_TEST|Scaling and Root Planning|Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
48297937|NCT06187961|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
48297938|NCT06187961|DRUG|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
48297939|NCT04083742|DEVICE|ANTERION|3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices
48297940|NCT00097422|DRUG|OPT-80|
48297941|NCT02674607|DIETARY_SUPPLEMENT|Spirulina|
48636223|NCT03061214|DRUG|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
48104514|NCT06184451|DEVICE|Transcutaneous electrical nerve stimulation|"TENS will be applied with a portable device, Neurodyn Portable System from Ibramed, while carrying out the entire therapeutic exercise program. The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. The application time will be proportional to the time of the exercise session, approximately 60 minutes. The researcher will evaluate the need to adjust the current intensity through the pulse amplitude regularly so that the stimulus does not accommodate."
48636224|NCT03061214|DRUG|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
48636225|NCT03061214|DRUG|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
48636226|NCT03061214|DRUG|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
48636227|NCT03548792|RADIATION|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
48104515|NCT06184451|DEVICE|Placebo transcutaneous electrical nerve stimulation|"The equipment has a two-phase and pulsed symmetric quadratic waveform. 5x5cm adhesive electrodes will be applied to the lateral and medial edges and superior and inferior to the patella, in a crossed manner, surrounding the region.~The parameters established for the protocol of this study are based on a survey already carried out, with continuous pulse mode, frequency of 150Hz, duration of 150us, and amplitude varying from 1-60mA or more as long as tolerated by the study participant, without causing pain. To do this, the device will only be turned on during the first minute of therapeutic exercises. The same TENS parameters as the experimental group will be applied for this."
48297942|NCT06287125|DEVICE|Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147|"Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI"
48297943|NCT04546256|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
48297944|NCT04546256|DRUG|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
48297945|NCT04498858|OTHER|Patient interview|"Patient will be interviewed :~* tobacco consumption~* reported question asked by the dentist about his/her tobacco consumption~* presence and nature of reported advices given by the dentist~* presence and nature of actions proposed by dentists for patients reporting tobacco consumption, including prescription of NRT~* presence and nature of the actions carried out or envisaged by these patients, including - smoking cessation~* contact with the general practioner~* Fagerstrom score (2 questions)~* demographic variables, age, sex, level of education~* satisfaction"
48297946|NCT06574269|DRUG|TLC590|Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
48297947|NCT06574269|DRUG|TLC590|TLC590 Dose 1
48297948|NCT06574269|DRUG|TLC590|TLC590 Dose 2
48297949|NCT06574269|DRUG|TLC590|The MTD of TLC590
48297950|NCT06574269|DRUG|TLC590|TLC590 Dose 3 (The SMC-suggested dose)
48297951|NCT06574269|DRUG|Ropivacaine|Ropivacaine
48297952|NCT06574269|DRUG|TLC590|TLC590
48297953|NCT04979572|DRUG|TS-172|"* Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner"
48297954|NCT04979572|DRUG|Placebo|"* Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner"
47948214|NCT06666127|OTHER|Maximal Isotonic Strength Testing (1RM)|Each limb will perform a 1RM strength test with each Prime Fitness machine training horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension respectively. Each machine will be set to position 1 (maximal load in mid-range). Testing will occur in weeks 1 and 12 of the study with the non-dominant arm and leg tested before the dominant arm and leg in each exercise. Participants self-selects first warm up set with a weight that is performed between 6-10 repetitions on both limbs. Rest for 1 minute between limbs and subsequent set. A weight is then selected by research staff to perform 3 repetitions with based on previous set. Load is now increased until 1RM is achieved. Rest periods should remain at least 1 minute alternating between limbs, with 1RM being complete within 3-5 attempts. Participant will rest 2-5 minutes before starting testing on the next exercise. Repeat for all exercises. Use pre testing data to inform 1RM attempts for post testing.
48297955|NCT02832440|OTHER|Exercise programmes|
47948215|NCT06666127|OTHER|Isokinetic Strength Testing|Participants will engage in isokinetic strength testing on the isokinetic dynamometer (Biodex) in weeks 1 and 12 for each of the four movements: Horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Participants will perform each movement unilaterally. Participants will start with the non-dominant arm and leg for each movement. Each movement will be tested through A maximal active range of motion. Participants will complete 10 sub-maximal repetitions to allow familiarization each movement. After a 2-minute rest, participants will complete 3 maximal concentric and eccentric repetitions with 30 seconds rest at 30 degrees per second before the Biodex is reset for the next movement.
48104516|NCT05660395|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
48104517|NCT03515720|PROCEDURE|Prolotherapy|It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
48104518|NCT02799095|DRUG|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
48104519|NCT02799095|DRUG|ALKS 4230 + pembrolizumab|IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
48104520|NCT03357640|DRUG|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
48297958|NCT00693355|OTHER|Sodium butyrate|sodium butyrate
48297959|NCT00693355|OTHER|NaCl|NaCl
48297960|NCT01245894|DRUG|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
48297961|NCT01245894|DRUG|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
48297962|NCT00812071|BIOLOGICAL|RiVax|vaccine
48297963|NCT06096233|OTHER|Bouts of Exercise|The participants will run on the treadmill for 10 minutes (short) or 30 minutes (prolonged).
48297964|NCT00000289|DRUG|Ondansetron|
48297965|NCT00805883|PROCEDURE|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
48297966|NCT05851846|BEHAVIORAL|Amygdala insula retraining|Mind body intrevention
48297967|NCT00702312|BEHAVIORAL|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
48297968|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
48297969|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
48297970|NCT01392989|DRUG|CIK cells|Standard of care
48297971|NCT01392989|DRUG|Cyclosporine|5 mg/kg, po
48297972|NCT01392989|DRUG|Mycophenolate Mofetil|15 mg/kg, oral
48297973|NCT01392989|DRUG|Thymoglobulin|7.5 mg/kg, IV
48297974|NCT01392989|RADIATION|Total Lymphoid Irradiation (TLI)|
48297975|NCT06434740|RADIATION|Stereotactic Body Radiation Therapy，SBRT|The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.
48297976|NCT06434740|DRUG|Puterizumab|Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
48297977|NCT04459910|PROCEDURE|Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair|After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
48297978|NCT01594476|DRUG|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
48297979|NCT02553603|DRUG|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
48297980|NCT02553603|DRUG|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
48297981|NCT02788916|OTHER|No Intervention|
48297982|NCT01360164|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
48297983|NCT04326322|DIETARY_SUPPLEMENT|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
48297984|NCT06190912|DRUG|Bryostatin 1|Eligible participants will be treated with bryostatin over a 26-week period. Doses 1, 2, 8, and 9 of the study drug will be a loading dose 20% higher (i.e., 24 µg) than the assigned fixed dose and will be administered one week apart. Otherwise, the assigned fixed dose is 20 µg. Drug is administered intravenously (IV) by continuous infusion over 45(±5) minutes. Participants are scheduled to receive 14 doses over 26 weeks.
48297985|NCT01780389|DRUG|Open-label flexibly dosed milnacipran|
48297986|NCT02021123|DRUG|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
48297987|NCT03216265|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
48297988|NCT03216265|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
48297989|NCT03216265|OTHER|No treatment|No treatment.
48297990|NCT06116591|BIOLOGICAL|mPnC candidate|monovalent pneumococcal conjugate candidate
48297991|NCT06116591|BIOLOGICAL|mPnC control|monovalent pneumococcal conjugate control
48297992|NCT06186336|OTHER|Deep Learning-based Vulnerable Plaque Detection and Assessment Tool|"Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study."
48297993|NCT03996538|DRUG|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
48297994|NCT03996538|BIOLOGICAL|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
48297995|NCT05468086|DEVICE|VR Solace|Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
48297996|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 1，IVI
47948216|NCT06666127|OTHER|Muscle Oxygenation|During the first and last LONG and SHORT training session (visit 5 and visit 24), A near infrared spectroscopy sensor (NIRS device) (Trainred) will be affixed to the muscle belly of the deltoid during the lateral raise exercise to measure muscle oxygenation.
48297997|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 2，IVI
48297998|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 3，IVI
48636228|NCT03548792|BEHAVIORAL|Clinical comparison|ActivePAL, walking speed
48636229|NCT04727827|OTHER|Pharmacogenomic-guided supportive care|Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations
48297999|NCT04552236|DEVICE|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
48298000|NCT02760407|DRUG|Olokizumab 64mg q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
47948217|NCT06668649|DIAGNOSTIC_TEST|Testing with Questionnaires|Testing with following Questionnaires: pFSS, Polish-language version of Modified Fatigue Impact Scale, Visual Analogue Scale of Fatigue, EQ-5D-5L (EuroQol-5 dimension) questionnaire, Beck Depression Inventory II. In randomly selected 30 patients and 20 controls questionnaires will be administered twice with two weeks interval to assess the test-retest reliability.
47948218|NCT02330484|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
48298001|NCT02760407|DRUG|Olokizumab 64mg q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
48298002|NCT02760407|DRUG|Adalimumab 40mg q2w|0.4 or 0.8 mL prefilled, single-dose syringe
48298003|NCT02760407|DRUG|Placebo q2w|sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
48298004|NCT03177876|PROCEDURE|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
47948219|NCT02330484|BEHAVIORAL|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
48298005|NCT03177876|PROCEDURE|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
48298006|NCT03059303|DRUG|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
47948220|NCT00215683|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
47948221|NCT01242228|DRUG|ipragliflozin|oral
48298007|NCT03059303|DRUG|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
48298008|NCT03059303|DRUG|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
47948222|NCT01242228|DRUG|DPP-4 inhibitor|oral
47948223|NCT02175784|DRUG|ipragliflozin|oral
47948224|NCT02175784|DRUG|placebo|oral
47948225|NCT01455831|DRUG|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
47948226|NCT01455831|DRUG|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
47948227|NCT03070444|DEVICE|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
48298009|NCT03059303|DRUG|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
48477782|NCT04157452|PROCEDURE|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
48477783|NCT03359915|BEHAVIORAL|COPD Self-Management Plan|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
48477784|NCT04157517|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion.
48477785|NCT04157517|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
48477786|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
48477787|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
48477788|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
48477789|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
47948228|NCT03070444|DEVICE|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
47948229|NCT03070444|DEVICE|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
48477790|NCT01841073|DIETARY_SUPPLEMENT|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
47948230|NCT03070444|PROCEDURE|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
47948231|NCT03070444|OTHER|Questionnaire|A questionnaire is completed at the follow-up visits.
47948232|NCT04205253|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to evaluate the tongue areas and compare the tongue areas before the implementation of rigid direct laryngoscope and after the rigid direct laryngoscope.
48477791|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
47948233|NCT05150145|RADIATION|Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.|Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
47948234|NCT00814866|DRUG|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
47948235|NCT06512597|BEHAVIORAL|Primary Intervention for Combination Therapy - IBD Coping Strategies Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
47948236|NCT06512597|BEHAVIORAL|Time and Attention Control - IBD Support Program|psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
47948237|NCT02043314|DRUG|Isoniazida|
47948238|NCT05991388|DRUG|Odronextamab|CD20xCD3 bispecific antibody
47948239|NCT05991388|DRUG|Loncastuximab tesirine|CD-19-directed antibody-drug conjugate
48104521|NCT05836935|RADIATION|Multislice CT scan of the paranasal sinuses.|MSCT scan using GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) , Toshiba Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Or Canon Aquilion Prime SP 160 -multidetector- row CT scanner (Canon Medical Systems, Tochigi, Japan) Thin slice Axial scans will be taken at 0.625-1.0 mm slice thickness, commencing from the hard palate till above the end of frontal sinuses, coronal and sagittal multiplanar reconstruction images will be obtained.
48298010|NCT03059303|DRUG|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
48298011|NCT03059303|DRUG|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
48477792|NCT00850226|BEHAVIORAL|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
47948240|NCT05991388|DRUG|Rituximab|Modified R-ICE chemotherapy
47948241|NCT05991388|DRUG|Ifosfamide|Modified R-ICE chemotherapy
47948242|NCT05991388|DRUG|Carboplatin|Modified R-ICE chemotherapy
47948243|NCT05991388|DRUG|Etoposide|Modified R-ICE chemotherapy
47948244|NCT05991388|DRUG|Etoposide Phosphate|Modified R-ICE (Treatment Arm II)
47948245|NCT05991388|DRUG|Dexamethasone|Modified R-ICE chemotherapy
47948246|NCT05991388|BIOLOGICAL|CAR T-cells (TBC)|Modified R-ICE chemotherapy
47948247|NCT03660345|PROCEDURE|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
47948248|NCT03660345|DRUG|Intravitreal injection|Intravitreal ziv-Aflibercept
47948249|NCT05454306|DEVICE|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
47948250|NCT04603053|BEHAVIORAL|mHealth app|Participants will receive access to CBot-A app for 12 weeks.
47948251|NCT04094051|DRUG|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
48104522|NCT05836935|RADIATION|MRI examination of the paranasal sinuses|MRI imaging using Philips Achieva 1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea 1.5T MRI device (Siemens Healthineers, Germany) for suspected intracranial and orbital complications.
48298012|NCT03059303|DRUG|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
48298013|NCT02109003|DEVICE|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
48298014|NCT02109003|DEVICE|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
48298015|NCT06671197|DEVICE|Pulmonary vein isolation|Pulsed field ablation
48298016|NCT06671197|DEVICE|Pulmonary vein isolation+posterior left atrial wall line|Pulsed field ablation
48298017|NCT06671197|DEVICE|Pulmonary vein isolation+posterior left atrial wall line+superior vena cava isolation|Pulsed field ablation
48298018|NCT05606822|OTHER|Observational|Collection of data from electronic health record
48298019|NCT04056130|DRUG|KBL697|"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"
47948252|NCT03903874|BEHAVIORAL|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
47948253|NCT01006460|DRUG|Rhodiola rosea, L|3 Capsules twice a day
48298020|NCT04056130|DRUG|KBL697|"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"
48298021|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"
48298022|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"
48298023|NCT05441969|OTHER|No intervention/expousure|No interventions/expousure since this is an observational study.
48298024|NCT02856789|OTHER|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
48298025|NCT02856789|OTHER|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
48298026|NCT02856789|OTHER|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
48298027|NCT02856789|OTHER|Specialized hemostasis tests|Coagulation factors
48298028|NCT03540368|DRUG|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
48298029|NCT03540368|OTHER|Placebo|Administering placebo or sodium chloride 0,9% intravenously
48298030|NCT05232591|DIAGNOSTIC_TEST|The teeth diagnosed with chronic apical periodontitis|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
48298031|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
48298032|NCT00911664|DRUG|No supplementation|Control
48298033|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
48298034|NCT04704882|OTHER|omental patchwork|the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
48298035|NCT05636085|DEVICE|Mainz Biomed Colorectal Cancer Screening Test|There is no intervention.
48298036|NCT06284421|DEVICE|Shore durometer|The durometer will be held on the exterior of the lower uterine segment and fundus to measure the hardness reading at each location.
48298037|NCT01597193|DRUG|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
48298038|NCT01597193|DRUG|anastrozole|1 mg/day
48298039|NCT01597193|DRUG|exemestane|The exemestane dose is 25mg daily.
48298040|NCT01597193|DRUG|fulvestrant|500 mg every 28 days
47948254|NCT01006460|DRUG|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
47948255|NCT01006460|DRUG|Panax ginseng|3 capsules twice a day
47948256|NCT01006460|DRUG|Placebo - dark brown sugar|3 capsules twice a day
48298041|NCT01597193|DRUG|enzalutamide|160 mg (4 capsules) taken orally daily.
48298042|NCT01597193|DRUG|exemestane|The exemestane dose is 50 mg daily.
48298043|NCT06673173|OTHER|Implant|A long cone paralleling approach with a specially made film holder will be used to assess each patient's vertical marginal bone loss to ensure standardized radiography analysis and avoid any magnification errors. The linear distance between the proximal crestal bone level and the implant shoulder will be measured at the mesial and distal aspects of the implant measured in millimeters (mm). Measurements will performed using image measurement software patient satisfaction comparison between 2 groups
48298044|NCT06533644|DRUG|SV-102|SV-102 will be administered as an intratumoral infusion.
48298045|NCT02787512|DEVICE|Stent|Endoscopic biliary stent insertion
48298046|NCT02740153|OTHER|No Intervention Given|
48298047|NCT02221076|DEVICE|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
48298048|NCT04439253|DRUG|Crizotinib|Given PO
48298049|NCT02739698|DRUG|Paclitaxel|
48298050|NCT02739698|PROCEDURE|Radical surgery-peritonectomy|
48298051|NCT05279469|OTHER|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
48298052|NCT02666911|PROCEDURE|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
48298053|NCT02666911|PROCEDURE|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
48298054|NCT00098345|DRUG|ZD6474 (vandetanib)|oral once daily tablet
48298055|NCT04579068|BEHAVIORAL|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
48298056|NCT03918642|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
48298057|NCT03918642|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
48298058|NCT01541592|OTHER|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.
47948257|NCT05116007|DRUG|AK112|IV infusion
48298059|NCT00942877|DRUG|AZD2171|Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
48298060|NCT04864977|DRUG|Basal Insulin|Participants administered basal insulin
48298061|NCT00295399|DEVICE|The Jerusalem Telerehabilitation System|
48298062|NCT04944979|BIOLOGICAL|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
48298063|NCT03809572|BEHAVIORAL|Mindfulness Based Cognitive Therapy|See Arm description
48298064|NCT03578354|DRUG|4-aminopyridine|an oral drug to be swallowed
48298065|NCT03578354|DRUG|Atenolol|an oral drug to be swallowed
48298066|NCT03578354|OTHER|Placebo|a masked placebo to be swallowed
48298067|NCT05786261|DEVICE|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
48298068|NCT05786261|DEVICE|EEG task rTMS, fMRI|EEG task rTMS, fMRI
47913925|NCT06087289|DRUG|KAND567|"KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression)."
48298069|NCT06671821|DRUG|HRS-7535|HRS-7535
48298070|NCT02299908|DRUG|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
48298071|NCT02299908|DRUG|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
47948258|NCT05116007|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
47948259|NCT05116007|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)
47948260|NCT06276231|DRUG|Salbutamol|Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).
47948261|NCT06276231|OTHER|0.9% Normal Saline|Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
47948262|NCT06276231|DRUG|Diclofenac Injection|75 mg of Diclofenac intramuscular Injection
48298073|NCT03141307|BEHAVIORAL|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
48298074|NCT03141307|BEHAVIORAL|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
48298075|NCT03141307|BEHAVIORAL|Control|Standard of care, paper-based brochure
48298076|NCT03746574|BEHAVIORAL|Compassion Curriculum|12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
48298077|NCT04523779|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
48298078|NCT05436808|RADIATION|Partial Chest Wall Radiation Therapy|Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day
48298079|NCT00149825|DRUG|Escitalopram|5 to 20 mg for 12 weeks
48298080|NCT00149825|BEHAVIORAL|CBTI|Cognitive Behavioral Treatment for Insomnia
48298081|NCT00149825|BEHAVIORAL|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
48298082|NCT05164276|OTHER|Head position|Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
48298083|NCT00701740|DRUG|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
48298084|NCT00701740|DRUG|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
48298085|NCT02717767|OTHER|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
48298086|NCT01582724|PROCEDURE|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
48298087|NCT03832868|BEHAVIORAL|Pre-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
48298088|NCT03832868|BEHAVIORAL|Post-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
48298089|NCT02383719|DEVICE|Oro-nasal Mask|
48298090|NCT05407298|OTHER|Non applicable|Non Applicable
48298091|NCT05064345|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
48298092|NCT05064345|DRUG|Placebo|Palcebo
47948263|NCT01863420|RADIATION|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
48298093|NCT03291197|DRUG|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
48298094|NCT02575313|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
48298095|NCT01362400|DRUG|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
48298096|NCT01362400|DRUG|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
48298097|NCT04548947|PROCEDURE|Cold snare polypectomy in conjunction with a submucosal injection|The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
48298098|NCT01025778|DRUG|Clofarabine for remission induction|
48298099|NCT01025778|DRUG|Etoposide for remission induction|
48298100|NCT01025778|DRUG|Cyclophosphamide for remission induction|
48298101|NCT01025778|DRUG|Clofarabine in conditioning before transplantation|
48298102|NCT01025778|DRUG|Thiotepa in conditioning before transplantation|
48298103|NCT01025778|DRUG|Melfalan in conditioning before transplantation|
48298104|NCT01025778|PROCEDURE|Haploidentical transplantation of T-cell depleted graft|
48477793|NCT00850226|BEHAVIORAL|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
48298105|NCT01025778|PROCEDURE|Donor lymphocyte infusion|
48298106|NCT04116632|DRUG|BMS-963272|Single dose with varying frequency among groups
48298107|NCT04116632|DRUG|Placebo|Specified dose on specified days
47948264|NCT02979197|DRUG|OE 10 mg amlodipine besylate tablet|
47948265|NCT02979197|DRUG|OE 200 mg celecoxib capsule|
48298108|NCT00273858|OTHER|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
48298109|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
47948266|NCT02979197|DRUG|Matched placebo for OE amlodipine besylate tablet|
47948267|NCT02979197|DRUG|Matched placebo for OE celecoxib capsule|
47948268|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10mg OD (once-daily)
47948269|NCT02556203|DRUG|Acetylsalicylic Acid (ASA)|75-100mg OD
47948270|NCT02556203|DRUG|Clopidogrel|75mg OD
47948271|NCT02556203|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|In case of NOAF, 20/15 mg OD (once-daily)
48298110|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement with reference|blood glucose measurement with reference method using finger tip capillary blood
48298111|NCT04523285|DRUG|TQB3728|TQB3728 tablets is a small molecule oral drug.
48298112|NCT00573326|DRUG|Imatinib|200 mg p.o. once a day for 6 months
48298113|NCT01955174|DRUG|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
48298114|NCT01955174|OTHER|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
48298115|NCT00004429|DRUG|growth hormone|
48298116|NCT05828446|DEVICE|MRI|To compare the diagnostic performance of US+/- Constrast-enhanced US and AMRI for HCC detection in an at-risk population
48477794|NCT05927142|BIOLOGICAL|Durvalumab|Human anti-PD-L1 antibody
48477795|NCT05927142|DRUG|Rintatolimod|TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
48477796|NCT04920526|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|No intervention will be administered
48477797|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
48298117|NCT02463266|BEHAVIORAL|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
48298118|NCT02238405|OTHER|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
48298119|NCT04973228|DRUG|Roflumilast Foam|Roflumilast 0.3% foam for topical application
48298120|NCT04973228|DRUG|Vehicle Foam|Vehicle foam for topical application
48298121|NCT01201369|DEVICE|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
48298122|NCT01201369|DEVICE|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
48298123|NCT01165801|PROCEDURE|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
48298124|NCT06133829|BEHAVIORAL|upREACH Home Visitation Program|upREACH is a brief perinatal home visitation program delivered by community health workers or similarly qualified personnel. The mission statement of the program is: Families are prepared to bring home their newborn to a safe, stable, and nurturing environment, and have access to tools, resources, and knowledge that promote family health and well-being. Through the program, families will receive a minimum of 2 home visits during pregnancy and/or postpartum from a home visitor (community health worker (CHW) or similarly qualified personnel). The home visitor will assess each family's strengths and needs so they may provide tailored support and brief education to promote maternal health and self-care, infant health and safety, and connection to and knowledge of resources (community orientation).
48298125|NCT02976493|OTHER|No Intervention|No Intervention
48298126|NCT01283581|DRUG|Delafloxacin|300mg IV every 12 hours for 5-14 days
48298127|NCT01283581|DRUG|Linezolid|600mg IV every 12 hours for 5-14 days
48298128|NCT01283581|DRUG|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
48298129|NCT04670653|DRUG|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
48298130|NCT04670653|DRUG|MOMETASONE FUROATE|Mometasone furoate nasal spray
48298131|NCT01340287|DIETARY_SUPPLEMENT|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
48298132|NCT01340287|DIETARY_SUPPLEMENT|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
48298133|NCT05224622|DIAGNOSTIC_TEST|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
48477798|NCT03284502|DRUG|HM95573, cetuximab|Regimen: twice daily (BID), continuous dosing for HM95573
48477799|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1
48477800|NCT03284502|DRUG|HM95573, cetuximab|Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
48298134|NCT04283461|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
48298135|NCT02897635|BEHAVIORAL|Individualized Integrative Medicine Intervention|
48298136|NCT00348972|DRUG|Lantus® (insulin glargine)|
48298137|NCT02778048|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter
48298138|NCT02778048|OTHER|US (ultra sound)|Assessment of the sphincter
48298139|NCT02778048|OTHER|FLIP (functional lumen imaging probe)|Assessment of the sphincter
48298140|NCT02778048|OTHER|HRAM (high resolution anal manometry)|Assessment of the sphincter
48298141|NCT02850575|DEVICE|Mpact Double Mobility cup|
48298142|NCT05938088|DRUG|Arm I (mirogabalin group)|Take two capsules of Mirogabalin 5 mg within 30 minutes before going to the operating room. Patients take 5 mg of mirogabalin twice daily at 12-hour intervals until POD 7 days.
48477801|NCT05585931|DRUG|TPN171H 10mg|Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
48477802|NCT05585931|DRUG|TPN171H Placebo|Subjects were given Placebo with 240 mL warm water under fasting condition.
48477803|NCT05775562|DIAGNOSTIC_TEST|Pre and post dive examinations|"Performing pre-dive examinations:~- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement"
48477804|NCT03071913|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
48298143|NCT05938088|DRUG|Arm II (placebo group)|It is performed in the same way as Arm l.
48298144|NCT06173492|PROCEDURE|Dental extraction|After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.
48298145|NCT06173492|DEVICE|Platelet Rich Fibrin|The clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
48298146|NCT02688114|PROCEDURE|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
48298147|NCT02688114|PROCEDURE|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
48477805|NCT03071913|OTHER|Laboratory Biomarker Analysis|Correlative studies
48104523|NCT05689216|BEHAVIORAL|Awake timed prone and repositioning|"Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours."
48477806|NCT03153787|OTHER|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
48477807|NCT03804788|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
48104524|NCT05999864|OTHER|Rehabilitation|Proprioceptive neuromuscular facilitation exercise will be given to the study group as previously described (Gstoettner et al., 2011). These applications will be applied to the patients for 8 weeks, 2 days a week in the clinical environment after the initial evaluation. In addition, both groups will be told that they can contact the researcher when requested.
48104525|NCT03018119|OTHER|Survey|
48477808|NCT03804788|BEHAVIORAL|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
48636230|NCT06493071|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
47948272|NCT02556203|DRUG|Vitamin K antagonist (VKA)|In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
47948273|NCT03366012|DEVICE|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
48104526|NCT00390403|DRUG|R-(-)-gossypol acetic acid|
48104527|NCT00390403|DRUG|temozolomide|
48104528|NCT00390403|GENETIC|gene expression analysis|
48104529|NCT00390403|GENETIC|mutation analysis|
48104530|NCT00390403|GENETIC|protein expression analysis|
48104531|NCT00390403|OTHER|laboratory biomarker analysis|
48104532|NCT00390403|OTHER|pharmacological study|
48104533|NCT00390403|PROCEDURE|adjuvant therapy|
48104534|NCT00390403|RADIATION|radiation therapy|
48104535|NCT01043406|DEVICE|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
48298148|NCT02688114|PROCEDURE|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
48298149|NCT02688114|PROCEDURE|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
48298150|NCT02688114|PROCEDURE|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
48298151|NCT01682369|BIOLOGICAL|TIV (Aggripal)|
48298152|NCT01682369|BIOLOGICAL|ATIV (Fluad)|
48298153|NCT04177654|DRUG|Benzimidazoles|A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
48104536|NCT06116812|OTHER|the laughter yoga group|"They will gather in five-person chemotherapy rooms, and laughter therapy will be applied to the women in the application group while they are receiving chemotherapy. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
48298154|NCT01612793|DEVICE|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
48298155|NCT03029403|DRUG|Pembrolizumab|Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
48298156|NCT03029403|BIOLOGICAL|DPX-Survivac|Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
48298157|NCT03029403|DRUG|Cyclophosphamide|Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
48298158|NCT04174885|PROCEDURE|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
48298159|NCT06513728|OTHER|MPACT Intervention|MPACT has 4 components: accredited training about patient centered, trauma informed methadone treatment, staff education about trauma symptoms with navigation to self screening and treatment or stress management, clinic self assessment tools for trauma informed, patient centered care, and reflective supervision for counselors, case managers and peer staff.
48298160|NCT02089386|DRUG|Tamoxifen|
48298161|NCT02089386|PROCEDURE|Endoscopy|
48298162|NCT02517047|DEVICE|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
48298163|NCT04637321|PROCEDURE|Solid organ transplant|Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
48298164|NCT04708964|DRUG|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
48298165|NCT04708964|DRUG|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
48298166|NCT01696877|DRUG|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
48298167|NCT01696877|DRUG|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
48298168|NCT01696877|DRUG|GVAX|GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
48298169|NCT01782183|DEVICE|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
48298170|NCT02169635|PROCEDURE|macular buckle|macular buckle with a three-armed silicone capsule
48298171|NCT04004507|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
48298172|NCT04004507|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
48298173|NCT00199511|DRUG|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
48298174|NCT02786459|DEVICE|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
48298175|NCT02786459|DEVICE|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
48298176|NCT02786459|DEVICE|SPECT-CT|Used as a comparative to ProxiScan.
48298177|NCT02039271|OTHER|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
48298178|NCT00065975|PROCEDURE|massage therapy|
48298179|NCT00065975|PROCEDURE|chiropractic|
48298180|NCT00065975|PROCEDURE|acupuncture|
48298181|NCT04724486|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
48477809|NCT02040519|BEHAVIORAL|Filling out voiding diaries.|
47948274|NCT00737438|DRUG|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. \> 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
47948275|NCT02413372|DRUG|BMS-986036|
47948276|NCT02413372|DRUG|BMS-986036|
48298182|NCT04724486|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
48477810|NCT04301518|OTHER|Multimodal intervention strategy|"* Once weekly nurse support~* 200 mg/daily micronized progesterone as vaginal suppository~* 81 mg/daily low dose aspirin~* two transvaginal ultrasounds~* cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation"
48477811|NCT01765751|PROCEDURE|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
48298183|NCT04724486|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
48298184|NCT04724486|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
48477812|NCT03026309|OTHER|no intervantion|no intervention is being performed, only observational evaluations.
48477813|NCT04410575|OTHER|Standard Pharmacist Care|Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)
48636231|NCT06493071|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
47948277|NCT02413372|DRUG|Placebo|
47948278|NCT06681025|DIAGNOSTIC_TEST|NeuMoDx EBV Quant 2.0 Assay|The NeuMoDx™ EBV Quant Assay 2.0 is an automated in vitro nucleic acid amplification test for the quantification of Epstein-Barr virus (EBV) DNA in EDTA plasma from immunocompromised transplant patients. Transplant patients are screened for EBV viral load as part of their standard of care. The remaining samples from these in vitro diagnostic nucleic acid amplification tests (NAAT) will be analyzed using the NeuMoDx EBV Quant Assay 2.0 to quantify EBV DNA in EDTA plasma. That result will be compared to a comparator in vitro diagnostic assay to evaluate the performance of the NeuMoDx EBV Quant 2.0 assay.
47948279|NCT02231918|DRUG|MIRAPEX® - low|
47948280|NCT02231918|DRUG|MIRAPEX® - medium|
47948281|NCT02231918|DRUG|MIRAPEX® - high|
47948282|NCT02943031|OTHER|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
47948283|NCT02851940|PROCEDURE|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
47948284|NCT02851940|PROCEDURE|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
47948285|NCT00659360|DRUG|saracatinib|Given orally
48298185|NCT02971644|DEVICE|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
48298186|NCT01361529|DRUG|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
48298187|NCT06400602|BEHAVIORAL|Usual ED Care plus Health Coaching|Patients will participate in eight remotely-delivered sessions of health coaching after ED discharge. Patients will receive usual care during their ED visit.
47948286|NCT05192733|OTHER|Survey|This is a cross-sectional practice survey. There is no intervention.
48298188|NCT06400602|BEHAVIORAL|Usual ED Care plus Education|Patients will participate in eight remotely-delivered sessions of education after ED discharge. Patients will receive usual care during their ED visit.
48298189|NCT00128206|DRUG|Isoniazid|Isoniazid 900 mg twice weekly
48477814|NCT04410575|OTHER|Reviewed Questionnaire tool results with participant|Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment
48477815|NCT04410575|OTHER|Patient Clinical Assessment|Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status
48477816|NCT04410575|OTHER|Psychotherapy Referral|Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist
48477817|NCT04410575|OTHER|Pharmacist initiated interim telephone follow-up with participant|Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up \& a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)
48477818|NCT04410575|OTHER|Communication update with physician after participant contact|Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant
48477819|NCT04410575|OTHER|Medication Counselling and Educational Support|Pharmacist provides medication related counselling and educational support to participant
48477820|NCT04410575|OTHER|Non-medication Counselling|Pharmacist provides non-medication related counselling and educational support to participant
48477821|NCT04410575|OTHER|Identification of drug interaction|Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety
48477822|NCT04410575|OTHER|Identification of drug adverse effect|Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety
48477823|NCT04410575|OTHER|Identification of severe deterioration|Pharmacist identification of participant severe deterioration (i.e. suicide attempt)
48477824|NCT04410575|OTHER|Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
48477825|NCT04410575|OTHER|Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing|Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing
48477826|NCT03358160|BEHAVIORAL|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
48477827|NCT01553201|DRUG|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
48477828|NCT01553201|DRUG|Placebo|Saline, 4cc, one time intramuscular administration
48477829|NCT05369091|DRUG|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
48477830|NCT02423317|DEVICE|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
48477831|NCT02423317|DEVICE|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
48477832|NCT06080659|DIAGNOSTIC_TEST|fMRI|functional MRI
48477833|NCT06080659|DIAGNOSTIC_TEST|CONFMEM|The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
48477834|NCT04490473|OTHER|survey work|Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
48477835|NCT00006263|BIOLOGICAL|filgrastim|
48477836|NCT00006263|DRUG|carboplatin|
48477837|NCT00006263|DRUG|temozolomide|
48636232|NCT05264584|DRUG|Isotonic saline|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
48636233|NCT05264584|DRUG|N-acetyl cysteine|all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .
47948287|NCT00152529|BEHAVIORAL|Screening (Behavior)|
48298190|NCT00128206|DRUG|Rifampin|Rifampin 600mg once per day
48298191|NCT03138850|DEVICE|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
48298192|NCT03138850|DEVICE|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
48636234|NCT05264584|DRUG|Febuxostat 80 MG|All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
48636235|NCT05890001|DRUG|BLI5100|Patients will take BLI5100 once daily, orally, for up to 29 weeks.
48636236|NCT04468009|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
48636237|NCT06274476|OTHER|implant placement|ridge splitting piezo surgery and implant placement
48636238|NCT05714228|PROCEDURE|Surgical Mitral Valve Repair|Mitral valve is repaired using open surgical approach
48636239|NCT05714228|PROCEDURE|Transcatheter Mitral Valve Repair|Mitral valve is repaired using Mitraclip transcatheter device
47948288|NCT02840240|DRUG|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
47948289|NCT02840240|DRUG|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
47948290|NCT04484948|OTHER|scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT|"1. Participants will perform the SHAQ.~2. BHT and 6MWT will be performed in the randomized way for each participant.~3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests.~4. 6MWT will be performed according to the ATS guidelines.~5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed.~6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness.~7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT."
47948291|NCT06403215|OTHER|Chewing gum group|Women in this group chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation.
48298193|NCT03138850|DEVICE|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
48298194|NCT03698240|BEHAVIORAL|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
48477838|NCT06015113|DRUG|Disitamab Vedotin plus pyrotinib or naratinib|"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."
48477839|NCT02374203|DIETARY_SUPPLEMENT|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
48477840|NCT03064243|DRUG|apatinib|apatinib 500mg po. qd.
48477841|NCT04869709|DRUG|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
48477842|NCT05403619|DIAGNOSTIC_TEST|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
48477843|NCT05235425|BEHAVIORAL|Standard NDPP|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's standard National Diabetes Prevention Program. It teaches a lower calorie, lower fat diet.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
48477844|NCT05235425|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's National Diabetes Prevention Program, adapted to teach a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
48477845|NCT03977168|PROCEDURE|Application of circumferential pelvic compression (CPC) device|Application of circumferential pelvic compression (CPC) device used at any time within 24 hours of injury
48477846|NCT03401073|DRUG|Intravenous immunoglobulin|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
48477847|NCT03401073|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
48636240|NCT01528852|DRUG|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
48636241|NCT01528852|DRUG|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
48636242|NCT01528852|OTHER|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
48636243|NCT03657407|DRUG|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
48636244|NCT03657407|DRUG|Glycerin Suppository|Glycerine rectal suppository
48636245|NCT05914259|OTHER|No Intervention|Following the manner of observational study, no intervention will be provided in the study.
48636246|NCT02455856|DRUG|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter \[mL\] oral solution on Day 1 and Day 6.
48636247|NCT02455856|DRUG|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2\*100 mg capsule) from Day 2 to Day 6.
48636248|NCT05925855|OTHER|US with fastum|apply fastum on trigger point with US
48298195|NCT00693212|DRUG|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
48298196|NCT00693212|DRUG|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
48298197|NCT00693212|DRUG|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
48298198|NCT03568006|OTHER|Specific passive mobilization|Specific passive mobilizations for the shoulder
48298199|NCT03568006|OTHER|Standardized treatment (standard protocol)|Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
48298200|NCT03095534|BEHAVIORAL|3-Step Workout for Life|a 10-week moderate exercise program
48298201|NCT01188798|DRUG|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
48636249|NCT05925855|OTHER|US with reparil|apply reparil on trigger point with US
48636250|NCT05925855|OTHER|US with plain gel|apply gel on trigger point with US
48104537|NCT06116812|OTHER|the mindfulness based stress reduction group|"Mindfulnes therapy will be applied to the women in the application group while they are receiving chemotherapy, in five-person chemotherapy rooms. Sessions will last approximately 40-60 minutes.The application will last for a total of 8 weeks, twice a week.~The 9th and 16th sessions will be held face to face and the scales will be filled in face to face meetings in these weeks (at the end of the 4th week and the 8th week). Since patients receive chemotherapy treatment once a month, face-to-face sessions are planned to be administered while the patient is receiving treatment. (Those whose treatment timing frequency is not appropriate will be excluded).~* Other sessions will be held online via smartphone applications. Online sessions will be determined according to the mutual decision of the participants, at a time convenient for the participants.~* In the 12th week, all groups will have the scales filled in again."
48104538|NCT04288492|BEHAVIORAL|Respiratory biofeedback|Repeat the inspiration and exhalation breaths for a fixed period of time using a biofeedback device (ResCalm)
48104539|NCT06555471|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1
48104540|NCT06555471|DRUG|S-1|po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)
48636251|NCT00036465|BEHAVIORAL|Treatment regimen change|
48636252|NCT00331149|DRUG|Ropinirole prolonged release|
48104541|NCT06555471|DRUG|Capecitabine|1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
48104542|NCT06555471|RADIATION|Extraperitoneal radiation therapy|once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy. Radiation therapy starts from the first cycle of Sintilimab Injection combined with chemotherapy
48298202|NCT01188798|DRUG|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
48298203|NCT06487494|PROCEDURE|Circumcision wound closure using 2-octyl cyanoacrylate glue with four interrupted sutures|2-octyl cyanoacrylate glue is a wound closure adhesive which will be used with four interrupted sutures following circumcision for wound closure.
48298204|NCT06487494|PROCEDURE|Circumcision wound closure using continuous sutuing|Continuous suturing is the standard following circumcision for wound closure.
48636253|NCT00331149|DRUG|ropinirole immediate release|
48298205|NCT06286852|BEHAVIORAL|Administration of K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)|Administration of 1) K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)
48298206|NCT06286852|BEHAVIORAL|Administration of ChEDE- Child Version of the EatingDisorder Examination|Administration of ChEDE- Child Version of the EatingDisorder Examination
48298207|NCT00898053|OTHER|laboratory biomarker analysis|Correlative studies
48298208|NCT02874794|DRUG|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
48298209|NCT02874794|DRUG|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
48298210|NCT02874794|DRUG|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
48298211|NCT02874794|DRUG|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
48636254|NCT00781664|OTHER|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
48104543|NCT04631549|DRUG|SHR3680|SHR3680, PO, single dose
48104544|NCT04653350|OTHER|High Intensity Exercises|Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
48298213|NCT04370028|DRUG|Divaza|Oral administration.
48298214|NCT06211283|DRUG|Sodium valproate|fasted
48298215|NCT06211283|DRUG|Sodium valproate|fed
48636255|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
48636256|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
48636257|NCT00781664|OTHER|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
48636258|NCT00781664|DRUG|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
48636259|NCT00781664|DRUG|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
48636260|NCT00781664|DRUG|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
48636261|NCT00781664|DRUG|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
48636262|NCT00781664|OTHER|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
48636263|NCT02187081|PROCEDURE|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
48298216|NCT01447056|BIOLOGICAL|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
48298217|NCT05521685|PROCEDURE|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
48298218|NCT06020859|DEVICE|undergo NaviEC-2000Pro Gastro Scan mode|Patients undergo NaviEC-2000Pro Gastro Scan mode.
48298219|NCT06020859|DEVICE|NaviEC-2000Pro Routine gastric examination|Patients undergo NaviEC-2000Pro Routine gastric examination mode.
48298220|NCT06020859|DEVICE|NaviEC-1000 Routine gastric examination|Patients undergo NaviEC-1000 Routine gastric examination mode.
48298221|NCT04020237|BEHAVIORAL|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~* 1) Start air purifier~* 2) Do not go out and make it to the minimum when absolutely necessary~* 3) It is recommended to wear a mask when going out.~* 4) The investigators recommend a lot of water, fresh fruit and vegetables.~* 5) Prepare an inhaler and use it when symptoms get worse."
48298222|NCT06008171|OTHER|Patient Decision Aid|A designed tool (by us) that help patients and providers talk and decide together about field-directed treatment options for actinic keratosis.
48298223|NCT00546858|OTHER|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
48298224|NCT01499238|DEVICE|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
48298225|NCT01499238|DEVICE|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
48298226|NCT04710589|RADIATION|CTV|According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
48298227|NCT04128592|DEVICE|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
48298228|NCT01903239|PROCEDURE|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
48298229|NCT05207436|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
48298230|NCT05207436|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
48477848|NCT02785653|DRUG|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
47948292|NCT06403215|OTHER|Fennel tea group|Women in this group started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
48477849|NCT02785653|DRUG|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
48477850|NCT04359407|OTHER|Prone positioning|Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone
48477851|NCT01109758|DRUG|Fenofibrate|145 mg
48477852|NCT03224078|OTHER|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
48477853|NCT00968500|BEHAVIORAL|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
48477854|NCT02372591|DRUG|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
48477855|NCT02372591|DRUG|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
48636264|NCT02187081|PROCEDURE|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
47948293|NCT06403215|OTHER|Chewing gum+Fennel tea group|Women in this group both chewed sugar-free and non-xylite gum for 15 minutes every two hours (2nd, 4th, and 6th) following the cesarean operation and started oral intake 6 hours after cesarean delivery and were allowed to drink 2 grams of fennel tea in the 6th, 8th, and 10th hours (a total of 6 grams of fennel tea).
47948294|NCT06403215|OTHER|Control group|No intervention
47948295|NCT02556658|DEVICE|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
48104545|NCT04653350|OTHER|General Exercises|Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training \& balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months
48298231|NCT02540174|PROCEDURE|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
48477856|NCT02372591|DRUG|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
48477857|NCT06531642|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days|Within 2 hours of ED admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40mg, then followed by 40mg q12hrs for 2 additional days.
48636265|NCT04757857|DRUG|Rivaroxaban 10 mg|Rivaroxaban pharmaceutical form will be tablets of 10 mg
48636266|NCT05417386|DRUG|FOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
48636267|NCT05417386|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
48636268|NCT05417386|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
48636269|NCT05417386|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
48636270|NCT05417386|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
48636271|NCT05417386|DRUG|NIS793|Given by intravenous infusion
47948296|NCT02556658|DEVICE|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
48636272|NCT05417386|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
48636273|NCT05417386|DRUG|Capecitabine|Taken Orally as part of Chemoradiation
47948297|NCT03675620|DEVICE|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
47948298|NCT03675620|OTHER|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
47948299|NCT04087174|DRUG|Capivasertib|Patients will receive multiple oral dose of capivasertib.
47948300|NCT04087174|DRUG|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
48636274|NCT05417386|RADIATION|Radiation Therapy|Radiation Therapy as part of Chemoradiation
48636275|NCT05417386|PROCEDURE|Surgery|Surgical removal of tumor
48636276|NCT06397066|PROCEDURE|White light endoscopy group|White light endoscopy observe the characteristics of mucosa under white light
48636277|NCT06397066|PROCEDURE|Magnifying endoscopy group|NBI+ME to observe the non atrophic area of the gastric fundus gland. The results depend on the ratio of gastric fundus gland.
48636278|NCT02608346|PROCEDURE|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~* with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~* with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
48636279|NCT03451305|OTHER|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
48636280|NCT05161156|COMBINATION_PRODUCT|Test Product (tiotropium bromide inhalation powder)|A single dose of test product
48636281|NCT05161156|COMBINATION_PRODUCT|18 mcg of Spiriva (Reference Product)|A single dose of reference product (Spiriva)
48636282|NCT05161156|COMBINATION_PRODUCT|Placebo|A single dose of placebo
48636283|NCT01435980|PROCEDURE|Gastric Bypass|basal treatment and Gastric Bypass
48636284|NCT01435980|DRUG|Exenatide|basal treatment and Exenatide
48636285|NCT04920123|DEVICE|Neuro-World|Neuro-World is a collection of six games that are developed for cognitive training that focuses on memory and attention.
48636286|NCT03355261|PROCEDURE|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
48636287|NCT03355261|PROCEDURE|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
47948301|NCT04087174|DRUG|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
47948302|NCT06090591|OTHER|SGLT-2 inh therapy, CIED implantation, thromboaspiration,|long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
48298232|NCT02540174|PROCEDURE|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~* At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~* At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
48298233|NCT03196297|DRUG|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
48298234|NCT03196297|DRUG|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
48298235|NCT02416687|DEVICE|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
48298236|NCT02890771|PROCEDURE|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
48298237|NCT02890771|PROCEDURE|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
48298238|NCT02890771|PROCEDURE|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
48298239|NCT03335631|BEHAVIORAL|Exercise|Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
48298240|NCT04673409|DIAGNOSTIC_TEST|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
47948303|NCT06407271|DEVICE|CAD/CAM custom ZrO2 healing abutment|Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.
47948304|NCT06407271|DEVICE|Cylindrical ZrO2 healing abutment|Application of cylindrical, zirconium-dioxide healing abutment following immediate implantation.
47948305|NCT03659955|OTHER|Autologous blood applied to dry eye|See previous description for the study arm.
47948306|NCT04676412|BIOLOGICAL|Pembrolizumab|IV infusion
47948307|NCT04676412|DRUG|Lenvatinib|oral capsule
47948308|NCT04676412|DRUG|Placebo for lenvatinib|oral capsule
47948309|NCT00265551|DRUG|SCA-136 (200 mg)|
47948310|NCT00265551|DRUG|SCA-136 (400 mg)|
47948311|NCT00265551|DRUG|olanzapine (15 mg)|
48298241|NCT01147731|BIOLOGICAL|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
48298242|NCT06138847|DIAGNOSTIC_TEST|electroencephalogram|Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
48298243|NCT01370798|DRUG|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
48298244|NCT01370798|DRUG|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
48298245|NCT01370798|PROCEDURE|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
48298246|NCT01370798|RADIATION|Wrist X ray|Wrist X ray to follow the degree of bone maturation
48298247|NCT01370798|PROCEDURE|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
48298248|NCT03856073|BEHAVIORAL|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
48298249|NCT05164952|DRUG|Zoledronic Acid 4 MG|(4 mg via 15-min infusion every 6 months) for 24 months
48298250|NCT00918762|PROCEDURE|assessment of therapy complications|
48298251|NCT00918762|PROCEDURE|diagnostic endoscopic surgery|
48298252|NCT00918762|PROCEDURE|quality-of-life assessment|
48298253|NCT00918762|PROCEDURE|therapeutic conventional surgery|
48636288|NCT03355261|PROCEDURE|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
47948312|NCT00265551|DRUG|placebo|
47948313|NCT05007093|DRUG|Anlotinib hydrochloride|If intolerance occurs, the dose can be downregulated
47948314|NCT04955132|BEHAVIORAL|E-learning|The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
47948315|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 180 mg/day
47948316|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 300 mg/day
47948317|NCT03250871|OTHER|Hypnosis|Hypnosis will be supervised by a nurse trained by the French Institute of Hypnosis.
47948318|NCT03250871|OTHER|Placebo|Placebo consists in non-hypnotic relaxation suggestions and in hearing white noise through headphones
47948319|NCT05568407|DRUG|Avelumab|As used in real world practice
48477858|NCT06531642|DRUG|Protonix (pantoprazole) 40 mg q 24 hrs for 2 days|Administer 1st dose of 40mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40mg daily for 2 additional days.
48298254|NCT00918762|PROCEDURE|therapeutic endoscopic surgery|
48298255|NCT00918762|PROCEDURE|transoral robotic surgery|
48298256|NCT00918762|PROCEDURE|video-assisted surgery|
48298257|NCT00381316|DRUG|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
48636289|NCT03355261|PROCEDURE|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
48477859|NCT01841541|BEHAVIORAL|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
48477860|NCT01303068|DEVICE|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
48477861|NCT00873106|DEVICE|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
47948325|NCT03004196|DRUG|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
47948326|NCT03004196|DRUG|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
47948327|NCT03004196|OTHER|Control Group|No Probiotic toothpaste \& Chlorhexidine Mouthwash
47948328|NCT05059171|DEVICE|OneSahpe single file|The rotary motion of OneShape single file
47948329|NCT05059171|DEVICE|WaveOne Gold single file|reciprocation motions of WaveOne Gold single file
47948330|NCT04751942|DEVICE|Non-compressive Bioactive Garment|patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
47948331|NCT04751942|DEVICE|thrombo-embolic deterrent|patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
47948332|NCT04821856|DRUG|Cannabidiol Oil|Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma
47948333|NCT04821856|DRUG|Placebo|MCT oil and flavoring solution, also manufactured by THC Pharma
47948334|NCT04746196|OTHER|Serum galectin-3 concentration was measured.|Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.
48104546|NCT03460210|DRUG|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
48104547|NCT00966199|DRUG|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
48104548|NCT03140176|DRUG|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
48104549|NCT05778071|COMBINATION_PRODUCT|eneboparatide|Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens
48104550|NCT05778071|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
48104551|NCT05969730|DRUG|Baricitinib 4 MG|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, baricitinib 4-mg daily plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm A). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
48104552|NCT05969730|DRUG|Azathioprine 1.5-2.5 mg/kg|In visit 1 which will be scheduled after the washout period, demographic information and baseline assessment will be conducted and patients will randomize into arms, azathioprine 1.5-2.5 mg/kg plus fluocinolone 0.025% topical ointment and daily emollient of urea 10% topical cream (Arm B). Six weeks after visit 1, Visit 2 will be set to follow up on the patient condition, particularly in terms of adverse effects, and reorder their intervention. Visit 3 will be 12 weeks after visit 1 to perform the final assessment.
47948335|NCT05397873|DEVICE|Biofeedback training|The training of oculomotor functions is done on the biofeedback module of a microperimeter MAIA.
47948336|NCT02869503|OTHER|Data collection|
47948337|NCT06106607|BEHAVIORAL|Intervention group|"A 20-week intervention with a basic part, including~1. A group session with education about IBD,physical activity and exercise in relation to IBD (definitions, evidence and recommendations). Furthermore, access to a video with general information about IBD, physical activity and exercise~2. Four individual motivational counselling sessions (two physical, two by telephone) with a project nurse. These will involve identifying individual motivation and opportunities for increasing physical activity and behavioral goal setting.~An optional intervention part will follow, including choises between (or all of)~1. A one-hour individual session with a physiotherapist, involving guidance in physical activity and exercise tailored to the individual.~2. Being teamed up with 1-2 'exercise buddies' (other participants from the overall intervention group).~3. Access to 4 short 2-3 minutes videos/'reels' of a physiotherapist explaining and demonstrating beneficial physical exercises."
47948338|NCT01017471|PROCEDURE|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
48104553|NCT03045900|OTHER|Shaded bulk-fill resin composite|Dental bulk-fill resin composite with shades A1, A2, A3
48104554|NCT04470193|OTHER|MyChildCMC app|Patients/parents will self-monitor their symptoms daily using the MyChildCMC app completing the daily vitals form. After patient/parents complete the daily form, the app provides in-app alerts and graphs showing symptom data over time.
48104555|NCT00586339|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
48298258|NCT00381316|DRUG|Thallous Chloride T1-201|Myoview SPECT Imaging
48298259|NCT01437631|PROCEDURE|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
48298260|NCT00593086|PROCEDURE|Pain management|Pain mamagement for burn care procedures.
48298261|NCT00593086|OTHER|Standard of care/no virtual reality game|no intervention for standard of care
48298262|NCT00614003|BEHAVIORAL|Decision support skills building Intervention|Decision support skills
48298263|NCT01322607|BEHAVIORAL|High-intensity Treadmill Exercise|High-intensity treadmill walking program
48298264|NCT01322607|BEHAVIORAL|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
48298265|NCT01320579|DRUG|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
48298266|NCT01320579|DRUG|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
48636290|NCT00893581|DRUG|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
48636291|NCT00893581|DRUG|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
48636292|NCT00893581|OTHER|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
47948339|NCT04269590|BEHAVIORAL|Dual Task (DT) training|Participants will practice the Swipe Slide Pattern (SSP) task in combination with a secondary task, i.e. counting red or green lights. On day 1, participants perform 2 runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, 9 trials of 30s are performed, alternated with rest periods of 14s. Instructions are provided before each trial (i.e. view of the pattern in combination with instruction to count red or green lights, 4s), as well as an answer option (i.e. participants have to indicate how many red or green lights they counted by circling a number from zero to nine, 6s). For the following 4 days, participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. During at home practice, the same pattern as during scans is included, in combination with 2 new patterns.
47948340|NCT04269590|BEHAVIORAL|Single Task (ST) training|Participants will practice the Swipe Slide Pattern (SSP) task without the presence of a secondary task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
47948341|NCT04795622|DEVICE|Ultherapy treatment|Focused ultrasound energy delivered below the surface of the skin
47948342|NCT04795622|DEVICE|Untreated-control / delayed-treatment|Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
47948343|NCT04903522|BEHAVIORAL|Baroque music listening|"Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires"
48298267|NCT01320579|DRUG|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
48298268|NCT01320579|DRUG|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
48298269|NCT05827146|DRUG|Hepalatide|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
48298270|NCT05827146|DRUG|Hepalatide Placebo|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
48298271|NCT01359826|DRUG|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
48298272|NCT02461732|BEHAVIORAL|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
47948344|NCT04143087|DRUG|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
47948345|NCT00914485|BEHAVIORAL|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
48298273|NCT02461732|BEHAVIORAL|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
48298274|NCT01128972|DRUG|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
47948346|NCT04498312|OTHER|Extracorporeal shock wave|The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
47948347|NCT02380001|DRUG|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
47948348|NCT02380001|DRUG|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
48104556|NCT00586339|BIOLOGICAL|Placebo Control|Intramuscular injection, 3 doses
48104557|NCT06629649|OTHER|Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.|Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
48104558|NCT01833832|DRUG|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
48104559|NCT01833832|PROCEDURE|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
48104560|NCT01833832|DRUG|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
48104561|NCT03761654|DIAGNOSTIC_TEST|Global Longitudinal Strain measure|Global Longitudinal Strain measure on day 1 of hospitalization
48104562|NCT01539655|DRUG|vandetanib|Oral tablets, 300 mg, single dose
48104563|NCT01539655|DRUG|omeprazole|Oral capsules, 40 mg, multiple doses
48104564|NCT01539655|DRUG|ranitidine|Oral tables, 150 mg, multiple doses
48104565|NCT06200636|DEVICE|Use of the PELSA System for dISF extraction|Dermal interstitial fluid will be extracted using the investigational device, for further analysis.
48104566|NCT05889286|DRUG|[F-18]MHF|Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
48104567|NCT06138951|OTHER|Endurance exercise|On the trial day before commencing the indicator amino acid oxidation metabolic trial, participants will either rest, perform a 10km run on a treadmill, or perform a 20km run on a treadmill.
48104568|NCT04008420|OTHER|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
48104569|NCT00202865|BIOLOGICAL|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
48104570|NCT00202865|BIOLOGICAL|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
48104571|NCT02592837|DEVICE|Flexible 19G EBUS-TBNA needle|
48104572|NCT02592837|DEVICE|21G EBUS-TBNA needle|
48104573|NCT00762619|DRUG|Fluoride|Brush twice daily
48104574|NCT00762619|DRUG|Triclosan, fluoride|Brush twice daily
48104575|NCT05141890|DIETARY_SUPPLEMENT|Lactobacillus Plantarum|Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.
48104576|NCT02586454|PROCEDURE|Transmuscular quadratus lumborum block|
48104577|NCT02586454|DRUG|morphine|
48104578|NCT02586454|DRUG|ropivacaine|
48104579|NCT01992354|DEVICE|PET MR Device|GE PET/MRI system
48104580|NCT05954507|DIAGNOSTIC_TEST|PET/MRI|PET/MRI is a new-generation hybrid camera capable of simultaneously performing FDG positron emission tomography and gadolinium-injected MRI. PET/MRI could be a relevant prognostic marker of progression, and could significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis.
48298275|NCT01128972|DRUG|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
48298276|NCT01128972|DRUG|Sterile water|Sterile water rinse
47948349|NCT06681285|DRUG|Cadonilimab ;Anlotinib|Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
47948350|NCT05835531|DEVICE|Catheters comparation|Assessment of incidence of complications associated with midline catheters
47948351|NCT00244283|DRUG|Sevoflurane|
47948352|NCT00244283|PROCEDURE|High thoracic epidural analgesia|
48104581|NCT00371566|DRUG|Lapatinib oral tablets|
48104582|NCT00371566|DRUG|Placebo|
48104583|NCT00387465|DRUG|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
48298277|NCT04463160|OTHER|"prevention program for prediabetes Say No to Diabetes"|10 therapeutic education sessions
48298278|NCT01673048|PROCEDURE|3-Nail-ESIN in femoral shaft fractures|
48298279|NCT03658330|DRUG|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
48298280|NCT02206711|DRUG|BMS-955176|Single dose of drug on Day 1
48636293|NCT01491932|DRUG|AFQ056|AFQ056 will be supplied as oral capsules.
48298281|NCT03591029|OTHER|blood samples|blood samples will be obtained from the superior vena cava (via centra venous catheter), from the pulmonary artery (via Swan Ganz catheter), and from a radial or femoral artery catheter
48298282|NCT00956241|PROCEDURE|j-pouch coloanal anastomosis|
48298283|NCT00956241|PROCEDURE|side-to-end coloanal anastomosis|
48636294|NCT05463666|OTHER|Rheumatoid arthritis|A diagnosis of rheumatoid arthritis.
48636295|NCT05684614|OTHER|Negative mood induction procedure|"The negative mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce negative mood: 1) Velten's tasks, consisting of interactive phrase formulations with negative thoughts and beliefs about the self (e.g., I don't have any future); 2) visualizing International Affective Pictures; and 3) recalling a negative autobiographical memory related to a significant loss (e.g., a person, a pet)."
48298284|NCT05678790|OTHER|Passive Stretching|Sustained passive stretching of hamstring, tendo-achilles, and adductors 10 (30 s, with three repetitions, five times per week)
48298285|NCT05678790|OTHER|Mobilization|Grade four mobilizations is a stretching motion performed at the talocrural joint with anterior-posterior gliding. Mobilization was performed once a day, 6 times a day, and 5 times a week, only on both deformed feet of the older sibling
48298286|NCT05678790|OTHER|Muscle strengthening|Abdominal muscle strengthening exercises were given to both siblings once a day, 10 times a day, 5 times a week. In the supine position, the patients were asked to lie on their knees with the knees flexed. The hip extensors were trained in the prone position on the bed by resisting hip extension
48298287|NCT05678790|OTHER|Balance and Coordination|"The following exercises were applied 5 times a week, with 1o repetition once a day.~* Standing on one leg in front of the mirror,~* Tandem walking,~* Rhythmic Dynamic Stabilization,~* Swiss ball sitting (eyes open and closed),~* Counting the alphabet or numbers while marching"
48298288|NCT04175197|DEVICE|Drug Coated Balloon|Legflow Drug Coated Balloon
48298289|NCT04250493|BIOLOGICAL|Homeostasis Model Assessment of insulin resistance (HOMA)|Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
48298290|NCT04250493|BEHAVIORAL|MOntreal Cognitive Assessment (MoCA)|Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
48298291|NCT04250493|BEHAVIORAL|Clinical characteristics of AMS patients|Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
48636296|NCT05684614|OTHER|Spontaneous emotion regulation task|Participants are instructed to use whatever strategy they want by doing, saying, and/or thinking whatever they want to feel better for 2 min
48636297|NCT05684614|OTHER|Positive mood induction procedure|"The positive mood induction procedure (MIP) used in this study has previously been shown to effectively induce sadness. This MIP takes place in a virtual environment of an urban park and includes the following methods to induce positive mood: 1) Velten's tasks, consisting of interactive phrase formulations with positive thoughts and beliefs (e.g., Life is wonderful); 2) visualizing International Affective Pictures; and 3) recalling a positive autobiographical memory"
48636298|NCT06110182|DIETARY_SUPPLEMENT|enteral or parenteral nutritional support|Parents will be classified based on whether they received enteral or parenteral nutritional support during treatment.
47948353|NCT05548673|BEHAVIORAL|Psychoeducation|The implementation phase is planned for Ankara Yıldırım Beyazıt University (AYBU) Nursing Faculty students. The stress management training program, which consists of eight sessions, is completed in 8 weeks, once a week.
47948354|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
47948355|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
48636299|NCT02268487|DRUG|Sertraline|Treatment
48636300|NCT01786109|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
48636301|NCT01786109|DRUG|Placebo|Placebo will match study drug; taken as one dose orally with water.
47948356|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
48636302|NCT04179162|DRUG|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
47948357|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
47948358|NCT01303783|DRUG|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
48298292|NCT04250493|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
48298293|NCT04250493|BIOLOGICAL|Blood sampling|Optional blood sampling for the constitution of a biological collection
47948359|NCT01303783|DRUG|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
47948360|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
47948361|NCT01303783|DRUG|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
48104584|NCT00387465|DRUG|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
48104585|NCT00387465|DRUG|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
48298294|NCT04788719|OTHER|Gait analysis|Gait analysis
48298295|NCT05409976|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
48298296|NCT01984593|OTHER|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~1. Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~2. Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
47948362|NCT01556880|BEHAVIORAL|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
47948363|NCT03312998|RADIATION|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
47948364|NCT02519465|OTHER|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 10l/min
47948365|NCT02519465|OTHER|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 30l/min.
47948366|NCT02519465|OTHER|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher \& Paykel healthcare, New Zealand) and nasal cannula (Fisher \& Paykel healthcare, New Zealand) with flow 50l/min.
47948367|NCT03222011|PROCEDURE|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
47948368|NCT03222011|PROCEDURE|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
47948369|NCT01824342|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
47948370|NCT06313827|BEHAVIORAL|Exercise plus Monitoring Group (TG-2)|Participants will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus a dossier on the use of monitoring equipment such as: pulse oximeter, thermometer, digital spirometer, Medical Research Council dyspnoea scale. If the patient detects an exacerbation (due to symptoms or monitoring of the equipment), they can contact a physiotherapist who can adjust the treatment.
47948371|NCT06313827|BEHAVIORAL|Exercise plus monitoring and follow-up group (TGF-3)|"Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene, plus dossiers on the use of monitoring equipment ; plus telematic control of exacerbations (questionnaires and monitoring of the parameters of the aforementioned equipment). Depending on the follow-up, physiotherapy treatment will be adjusted.~The questionnaire includes tracking of the following parameters: cough, secretions (quantity, colour, viscosity), chest tightness, dyspnoea, exercise tolerance, tiredness and appetite).~The follow-up will consist of weekly filling the spreadsheet to which the physiotherapist will have access and who, by reviewing the parameters, will be able to adjust the treatment. The physiotherapist will systematically make videocalls to the participants and if the follow-up values require it, he/she will call every week."
47948372|NCT06313827|BEHAVIORAL|Exercise Group (CG-1)|Participants who will receive their usual physiotherapy treatment and user education on bronchial care and hygiene
47948373|NCT01275456|PROCEDURE|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
48298297|NCT01157871|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
48298298|NCT01157871|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intramuscular"
48298299|NCT00309777|DRUG|Pitavastatin|Pitavastatin once daily
48298300|NCT00309777|DRUG|Simvastatin|Simvastatin once daily
48298301|NCT06192446|DRUG|Survey using a questionnaire.|An observational study conducted in a cross-sectional manner using a questionnaire.
48298302|NCT03492450|OTHER|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
48298303|NCT02815631|DEVICE|Cardiogoniometry (CGM)|
47948374|NCT04253912|DRUG|VBP-245|2% Povidone-Iodine Gel
47948375|NCT04253912|DRUG|Placebo Gel (no Povidone-Iodine)|Placebo Gel (no Povidone-Iodine)
48298304|NCT02815631|DEVICE|Fractional Flow Reserve (FFR)|
48298305|NCT01454089|DRUG|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
48298306|NCT01454089|DRUG|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
48636303|NCT04179162|DRUG|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
48636304|NCT05086172|BEHAVIORAL|Ultrabrief Behavioral Activation|The ultrabrief behavior activation (UBA) intervention is a condensed version of the LETS ACT intervention. The main treatment elements include: (1) explanation of treatment rationale to facilitate behavior change via increased engagement in values-related activities, (2) identification of participant-specific values via detailed assessment of life areas, values and activities, (3) values-based activity planning and scheduling, and (4) post-treatment planning. The overall goal of behavioral activation (BA) is to shift from values-incongruent behavior (including alcohol use) to behaviors that provide positive reinforcement and environmental reward with the overall goal of increasing the number of engaged-in, value-based activities. This intervention will take 90 minutes.
48636305|NCT05848232|DEVICE|coraFlex Catheter|The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
48636306|NCT05848232|DEVICE|coraForce Catheter|The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
48636307|NCT05848232|DEVICE|coraCross Catheter|The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
48636308|NCT01454557|OTHER|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
48636309|NCT00069550|DRUG|dextromethorphan|
48636310|NCT00069550|DRUG|donepezil hydrochloride|
48636311|NCT05243017|GENETIC|intra-striatal rAAV5-miHTT|One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
47948376|NCT01090973|DRUG|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
48298307|NCT01454089|DRUG|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
48298308|NCT01454089|DRUG|Gemcitabine|Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
48298309|NCT01454089|DRUG|Cisplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
48298310|NCT01454089|DRUG|Carboplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
48636312|NCT00819832|PROCEDURE|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
48636313|NCT00819832|PROCEDURE|Vertebroplasty|Medical cement will be injected into broken back bone.
48636314|NCT00819832|DEVICE|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
48636315|NCT02002195|DRUG|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
48636316|NCT02002195|DRUG|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
48636317|NCT04140929|OTHER|Oral Health Tool Box|Please see, description of the intervention group
47948377|NCT02301130|BIOLOGICAL|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
47948378|NCT02301130|BIOLOGICAL|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
47948379|NCT02301130|BIOLOGICAL|tremelimumab|Tremelimumab will be administered intravenously (IV).
48636318|NCT05987137|OTHER|No intervention is being administered.|No intervention is being administered.
48636319|NCT04403126|OTHER|forgiveness education intervention|The forgiveness education intervention primarily teaches the concept of forgiveness through stories. We chose the kind of stories that should appeal to children ages 10 through 12. Each lesson is planned according to the following procedure: story-telling/movie-watching, discussion, and in-class activities.
47948380|NCT02526901|OTHER|No intervention|
47948381|NCT04642612|DEVICE|TCD Measurement|"CBFV measurements will be acquired continuously with the patient supine and the head neutral. Analysis of CBFV measurements will be undertaken at 3 timepoints:~1. Patient awake and supine in the holding area~2. After sedation~3. After interscalene nerve block"
47948382|NCT05353309|PROCEDURE|Standard Angioplasty|Angioplasty Iliac done following standard practice
47948383|NCT05353309|PROCEDURE|Angioplasty with D images|Angioplasty Iliac under additional 3D Images merged as surgery support
47948384|NCT03316339|DRUG|Dexmedetomidine|Opioid-free anesthesia
47948385|NCT03316339|DRUG|Remifentanil|Opioid anesthesia
47948386|NCT01562158|PROCEDURE|standard therapy|Standard treatment of bleeding
47948387|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
47948388|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
47948389|NCT01562158|DRUG|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
47948390|NCT01562158|DRUG|placebo|Placebo
47948391|NCT04953299|BEHAVIORAL|Functional Imagery training|Behavioural intervention focused upon motivation and reaching achievable goals.
47948392|NCT04953299|BEHAVIORAL|NHS 12 week weight loss programme|The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
47948393|NCT00032942|DRUG|Lofexidine|
47948394|NCT02443519|BEHAVIORAL|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
47948395|NCT05816226|DRUG|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
47948396|NCT05816226|DRUG|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
47948397|NCT01237938|BEHAVIORAL|Low Glycemic Diet|Changing to low glycemic diet
47948398|NCT05446636|DEVICE|Huawei bracelet|Huawei bracelet was used to continuously record maternal respiration, heart rate, temperature and sleep data, and then calculate maternal circadian rhythm state
47948399|NCT05047185|DRUG|Deucrictibant low dose|Deucrictibant softgel capsules for oral use (PHVS416)
47948400|NCT05047185|DRUG|Deucrictibant high dose|Deucrictibant softgel capsules for oral use (PHVS416)
47948401|NCT05047185|DRUG|Placebo|Matching placebo capsules for oral use
47948402|NCT06254378|PROCEDURE|Sinus lifting with allograft|Participants will receive sinus lifting and allograft with immediate implant in premolar-molar area.
48298311|NCT02135601|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
47948403|NCT06254378|OTHER|Sinus lifting without graft|Participants will receive sinus lifting with immediate implant in premolar-molar area without graft
47948404|NCT05427162|DRUG|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
47948405|NCT02640573|DRUG|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
47948406|NCT04388384|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
47948407|NCT00769522|BIOLOGICAL|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
47948408|NCT00769522|DRUG|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
47948409|NCT00769522|DRUG|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
47948410|NCT00769522|DRUG|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
47948411|NCT00449410|DRUG|Atorvastatin|
47948412|NCT00449410|DRUG|ezetimibe|
47948413|NCT02575131|OTHER|whole wheat bread yeast basis|
47948414|NCT02575131|OTHER|Oatmeal|
47948415|NCT02575131|OTHER|Cheerios|
47948416|NCT02575131|OTHER|whole wheat sourdough bread|
47948417|NCT02575131|OTHER|standard breakfast|
47948418|NCT04134702|OTHER|Acupuncture|Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
47948419|NCT06117358|OTHER||Descriptive cross section study
47948420|NCT06151431|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
47948421|NCT06151431|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
47948422|NCT02447562|DEVICE|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
47948423|NCT02447562|OTHER|Phone-based care group|
47948424|NCT02447562|OTHER|Usual care group|
47948425|NCT06391840|OTHER|Airway ultrasound|Pre-operative airway ultrasound
47948426|NCT00357357|DRUG|HF0220|comparison of different dosages of drug
47948427|NCT06680115|DRUG|Sintilimab|Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine
47948428|NCT02439983|DIETARY_SUPPLEMENT|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
48298312|NCT00363012|BIOLOGICAL|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
48298313|NCT00363012|OTHER|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
48298314|NCT00363012|OTHER|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
48298315|NCT00363012|PROCEDURE|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
48298316|NCT00363012|OTHER|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
48298317|NCT02349906|DRUG|Treosulfan|
48298318|NCT02349906|DRUG|Busilvex|
48298319|NCT06480474|DEVICE|Deprexis|The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.
48477862|NCT06384729|DEVICE|EXOPULSE Mollii Ⓡ|The EXOPULSE Mollii method (EXONEURAL NETWORK AB, Danderyd, Sweden) is an innovative approach to non-invasive and self-administered electrical stimulation with multiple electrodes incorporated into a full-body suit. It consists of comfortable, breathable, and washable synthetic material pants and a jacket. It has been primarily designed to reduce disabling spasticity and improve motor function. The method refers to the concept of reciprocal inhibition induced by stimulating the antagonist of a spastic muscle, at low frequencies and intensities, which is considered to reduce spasticity.
47948429|NCT02439983|DIETARY_SUPPLEMENT|Placebo|2 capsules taken by mouth with morning and evening meals.
47948430|NCT02607007|OTHER|2% M.F. Milk|
47948431|NCT02607007|OTHER|White Bread|
47948432|NCT02607007|OTHER|Strawberry Jam|
48477863|NCT01225055|DRUG|Teriparatide|20 ug daily over 12 months
48477864|NCT01225055|DEVICE|vibration|10 min/day for 12 months
48477865|NCT01445418|DRUG|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
48477866|NCT04881734|OTHER|Overtime pancreaticoduodenectomy|Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.
47948433|NCT02607007|OTHER|31% M.F. Cheddar Cheese|
47948434|NCT02607007|OTHER|2% M.F. Plain Greek yogurt|
48298320|NCT06480474|DEVICE|Deprexis with online forum|Those in this group will have access to deprexis ( same as the first group) as well as an online forum built for the study. This forum will feature a general discussion page where participants can ask and answer questions, and they will be divided into groups of 10 to share experiences if they wish. Additionally, there will be subforums related to specific modules of the program. Participants can share their experiences and ask questions related to the modules. A moderator will regularly check to ensure no personal or sensitive information is disclosed and will ask questions weekly to encourage contributions to the forum.
48298321|NCT02209233|OTHER|Massage Therapy|
47948435|NCT02607007|OTHER|Soy Beverage|
47948436|NCT02607007|OTHER|Water|
47948437|NCT00334607|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
47948438|NCT06680466|DRUG|YZJ-4729|Dose Group 1
47948439|NCT06680466|DRUG|morphine|morphine,
47948440|NCT06680466|DRUG|placebo|placebo
47948441|NCT06680466|DRUG|YZJ-4729|Dose Group 2
47948442|NCT06680466|DRUG|YZJ-4729|Dose Group 3
47948443|NCT06680466|DRUG|YZJ-4729|Dose Group 4
48104586|NCT05280964|BEHAVIORAL|Better Together Physician Coaching|6 month, online group coaching program
48104587|NCT00768131|DRUG|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
48298322|NCT02590679|DEVICE|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
48298323|NCT03558321|PROCEDURE|Hysteroscopic guided fractional curretage|Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
48298324|NCT03558321|PROCEDURE|total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection|Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
48298325|NCT02601001|DRUG|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
48298326|NCT02601001|DRUG|Placebo|Matching placebo tablets
48477867|NCT01657084|DEVICE|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
48477868|NCT01657084|DEVICE|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
48477869|NCT04091802|PROCEDURE|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
48477870|NCT03214302|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
48477871|NCT02792218|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
48477872|NCT02792218|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
48477873|NCT02792218|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
48477874|NCT02792218|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
47948444|NCT06679803|BEHAVIORAL|Physical Activity Chats after Stroke (PA-ChatS)|"PA-ChatS consists of (1) self-monitoring step count using a Fitbit Inspire, and (2) behavioral activation for stepping activity delivered via the telephone and guided by the PA-ChatS workbook.~Participants will receive education regarding the physical activity after stroke, American Heart/Stroke Association guidelines for post-stroke physical activity levels, and an overview of the intervention activities. They will then use the Fitbit data to monitor average daily step counts, set a new step count goals (increasing by 5 to 10% of the daily average step count from the prior week), and create a specific plan for achieving the new step count goal. The interventionist will collaboratively problem solve with the participant to identify strategies to overcome barriers to stepping activity and maintain safety."
47948445|NCT06681467|OTHER|Respiratory monitoring band|The only intervention in this study is the application of two CE marked study approved chest bands- the Go direct respiratory sensor and a biosignal respiration belt
47948446|NCT01526772|PROCEDURE|Endoscopy|Transoral endoscopy versus transoral endoscopy
47948447|NCT01054326|OTHER|Exercises|
47948448|NCT00152360|DRUG|Orlistat|See Detailed Description.
47948449|NCT01626495|BIOLOGICAL|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
47948450|NCT03585842|OTHER|No intervention|No intervention
47948451|NCT01518023|OTHER|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
48104588|NCT00768131|DRUG|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
48636320|NCT03944005|PROCEDURE|Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA|"ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection."
47948452|NCT04666480|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
47948453|NCT04363177|BEHAVIORAL|Web-based psychosocial peer-to-peer support|"The evidence-based eHealth peer-to-peer psychosocial intervention Thinking Healthy, will be tested in this RCT. In line with the World Health Organization's mhGAP Intervention Guide (mhGAP-IG), Thinking Healthy is used to identify and manage perinatal mental health conditions (distress, symptoms of depression, and anxiety) in non-specialized psychosocial support setting."
47948454|NCT03763864|OTHER|Skin Biopsy|Skin Biopsy
47948455|NCT01940562|DRUG|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
47948456|NCT04651985|OTHER|Eccentric strengthening exercises of the Achilles tendon|This exercise will require the completion of slow active eccentric plantar flexion exercises with the forefoot positioned over the edge of a step. These exercises will be repeated twice daily (three sets of 15 repetitions with the knee in extension and three sets of 15 repetitions with the knee in flexion) during a three-month period. The amount of loading will be calibrated and progressed on a weekly basis by the physiotherapist according the participant's perceived effort and pain intensity.
48104589|NCT00768131|DRUG|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
48104590|NCT04643405|DRUG|APG-1387 for Injection|APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
48104591|NCT04643405|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
48104592|NCT04643405|DRUG|Nab paclitaxel|Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
48477875|NCT06609434|PROCEDURE|Radiofrequency ablation|This study is the first to apply radiofrequency ablation to multiple recurrent intrahepatic lesions of colorectal cancer liver metastases.
48477876|NCT05707455|OTHER|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
47948457|NCT02890667|OTHER|Incident cancer|The number of incident cancer cases
47948458|NCT00082589|DRUG|Eplerenone|
47948459|NCT01404975|OTHER|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
47948460|NCT06478706|DRUG|ETD001|Twice daily doses
47948461|NCT06478706|DRUG|Placebo|Twice daily doses
47948462|NCT05288478|COMBINATION_PRODUCT|Dentoxol mouthrinse dosages|Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.
47948463|NCT00740077|OTHER|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
47948464|NCT00619593|OTHER|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"* Assessment of general health status (weight, BP, NYHA)~* Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~* Echocardiography (LVEF, LVEDD, mitral regurgitation)~* Non-invasive ischemia evaluation~* Coronary angiography (if indicated by ischemia evaluation)~* Upgrade to CRT, if indicated~* Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~* 24 hrs ECG Holter (Heart rate variability)~* Further treatment (if applicable)~* Changes in ICD settings, or medication"
47948465|NCT00619593|OTHER|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
47948466|NCT00952042|OTHER|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
47948467|NCT00952042|OTHER|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
47948468|NCT05272878|DRUG|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
47948469|NCT05272878|DRUG|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
47948470|NCT06253884|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
47948471|NCT06678971|OTHER|FIFA 11+|The FIFA 11+ protocol consists of fifteen exercises organized into three segments, with three levels of difficulty. The first segment includes six running exercises, the second focuses on six exercises to enhance lower body strength, balance, and agility, and the third segment involves three running exercises aimed at activating the cardiovascular system.
47948472|NCT06678971|OTHER|Basket-Up|"The Basket-Up warm-up program is developed by a committee of experts, including the medical staff and the Performance Department of Valencia Basket Club, with detailed information previously published. This protocol is specifically designed to address the physiological, functional, and physical demands of basketball training. Like the FIFA 11+ program, it is structured into three phases with progressively increasing levels of difficulty, lasting a total of 20 minutes.~Phase 1 includes three exercises aimed at improving mobility. Phase 2 features six exercises focused on strength, direction changes, and plyometric activities. Phase 3 consists of six exercises designed to enhance agility and neurocognitive skills."
47948473|NCT00678080|DRUG|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
47948474|NCT00678080|DRUG|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
48104593|NCT04369807|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to 3 visits to a partnering imaging facility - this will include measurement of height and weight (to calculate BMI), blood pressure measurement, 3 sets of blood tests, 3 Questionnaires and 3 MRI tests.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications."
48104594|NCT00315120|PROCEDURE|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
47948475|NCT03773367|DRUG|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
47948476|NCT03773367|DRUG|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
47948477|NCT03773367|DRUG|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
48104595|NCT00315120|PROCEDURE|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
48104596|NCT00315120|PROCEDURE|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
48104597|NCT00315120|PROCEDURE|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
48104598|NCT01285258|PROCEDURE|hysterectomy|excluding the uterus with saving ovaries
48104599|NCT02294643|DRUG|Sarpogrelate|
48104600|NCT02294643|DRUG|Aspirin|
48104601|NCT02294643|DRUG|Clopidogrel|
47948478|NCT00005878|DRUG|celecoxib|
48104602|NCT02294643|DRUG|Placebo (for Sarpogrelate)|
48104603|NCT03425890|BEHAVIORAL|SURE program|SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
47948479|NCT05438784|PROCEDURE|orbital bone reconstruction with patient specific titanium implant|orbital defects reconstruction will be virtually planned by software and a patient specific titanium implant will be manufactured using milling technique depending on CAD-CAM technology
48104604|NCT05720546|OTHER|Baseline Survey|A survey that measures participant satisfaction will be offered to participants during infusion at baseline.
48104605|NCT05720546|OTHER|Semi-structured interviews|Semi-structured interviews will be conducted in the same infusion spaces.
48104606|NCT05720546|OTHER|Follow-up Survey|A survey that measures participant satisfaction will be offered to participants during following infusion.
48104607|NCT03610997|PROCEDURE|Photorefractive keratectomy|
47913926|NCT06087289|DRUG|Carboplatin|Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
47913927|NCT00238342|GENETIC|proteomic profiling|
47913928|NCT00238342|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
47948480|NCT05438784|PROCEDURE|orbital bone reconstruction with preformed titanium plate preoperatively bended on stereolithographic model|orbital defects reconstruction will be virtually planned by software and a reconstructed stereolithographic model will be 3D printed and used for preoperatively bending of preformed titanium implant.
47948481|NCT00569270|DRUG|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
48104608|NCT05154942|DEVICE|DOXO+electroacupuncture|DOXO+electroacupuncture
48104609|NCT01793272|OTHER|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
48104610|NCT02801929|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - SR15-72_V27-010).
48104611|NCT06435338|BEHAVIORAL|Patient decision aid|The patient decision aid for HPV vaccination among mid-adults, named HPV Decide. It is delivered online on a website.
48104612|NCT06435338|BEHAVIORAL|Control|Vaccine information sheet on HPV vaccination. Attention control condition.
48477877|NCT03244475|DEVICE|TES|"The EEG interface device is the J\&J Engineering I-330 C2. IASIS is delivered via the 4 EEG leads with respect to the Common Neck Reference. During each session, 2 electrodes are attached to the participant's left and right mastoids, while the remaining 2 electrodes are moved to various locations on the scalp to record EEG signals. All 4 electrodes are involved in applying weak electric current pulses back to the brain. The feedback signal consists 2 types of narrow pulse trains, both with 150mV in amplitude.~The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 4Hz, 40Hz, and 77.5Hz at 0 to 15mA peak current. Evidence shows this waveform, at these frequencies, results in improved clinical outcomes for anxiety and pain. We hypothesize that repeated TES treatments serve to stimulate long-term neurochemical changes."
48477878|NCT03123757|OTHER|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
48477879|NCT03123757|OTHER|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
48636321|NCT03944005|PROCEDURE|Spinal Anesthesia + LIA + Sham Blocks|"ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 10mg of morphine around the knee capsule."
47948482|NCT02395666|DRUG|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
47948483|NCT03346044|DEVICE|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
47948484|NCT03346044|DEVICE|Medtronic Mosaic bioprostheses|
47948485|NCT05420792|BEHAVIORAL|Peplau Interpersonal Relations based IPSRT will be applied to the intervention group|IPSRT based on peplau Interpersonal Relations theory will be applied to the intervention group. First of all, information about the study will be given. An informed consent form will be filled and a history will be taken from the patient. With the Life Events Chart, past attacks and life events, interpersonal relations will be compared. Interpersonal Circle will be made to better understand the individual and relationships. A Joint Study Plan, which summarizes the disease history, life events, and interpersonal circle, will be created and presented to the patient in summary form. The patient will be given psychoeducation about his illness, drugs and social rhythms. A Social Rhythm Metric (SRM) will be created and monitored throughout therapy to assess their daily routine. Early warning signs of impending attacks will be discussed, managing symptoms, situations that may disrupt social rhythm will be determined (travel, vacation, moving, changing job)
47948486|NCT02387177|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
47948487|NCT02387177|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
48477880|NCT03123757|OTHER|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
48477881|NCT01836614|DRUG|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
48477882|NCT02371421|DRUG|Allopurinol|
48477883|NCT05281926|DRUG|Poly ICLC|IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
48477884|NCT05551702|BEHAVIORAL|CBT-txt|Cognitive Behavioral Therapy delivered via automated text messaging.
48477885|NCT05217589|OTHER|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
47913929|NCT00238342|PROCEDURE|biopsy|
48477886|NCT05217589|OTHER|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
48477887|NCT05217589|OTHER|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
48477888|NCT02958852|DRUG|Letrozole|
48477889|NCT02958852|DRUG|Letrozole and atorvastatin|
48477890|NCT02958852|DRUG|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
48477891|NCT00030524|DRUG|gefitinib|
48477892|NCT02485158|DRUG|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
48477893|NCT02485158|DRUG|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
48477894|NCT02485158|DRUG|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
48477895|NCT02485158|DRUG|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
48477896|NCT02485158|DRUG|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
48477897|NCT04923516|OTHER|Dosage of Delta-aminolevulinic acid and Porphobilinogen|Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded
48477898|NCT00026052|DRUG|riluzole|
47913930|NCT02086513|DRUG|LDE225|Treatment with LDE225
47913931|NCT02122003|DRUG|Sorafenib|Sorafenib 400 mg bid
47913932|NCT00973011|DRUG|FCFD4514S|Intravitreal escalating dose
47913933|NCT01913496|OTHER|ebalance|using the ebalance application for 14 weeks
47913934|NCT02059096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
48477899|NCT00079521|PROCEDURE|Therapeutic Touch|
48636322|NCT05099588|OTHER|Other: observational study|Observational study
47913935|NCT02934503|BIOLOGICAL|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
47913936|NCT02934503|DRUG|Cisplatin|75 mg/m2
47913937|NCT02934503|DRUG|Carboplatin|AUC 6
47948488|NCT00417508|DIETARY_SUPPLEMENT|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
47948489|NCT00417508|DIETARY_SUPPLEMENT|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
47948490|NCT06115746|BEHAVIORAL|iDECIDE|iDECIDE is a 4-session drug education and diversion program that addresses topics such as the neurobiology and addiction, adolescent brain development, industry tactics, motives for using substances, risk and protective factors, identifying triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. The iDECIDE drug curriculum will be delivered weekly for 4 weeks via videoconference or in-person visits. Each session typically takes 60-75 minutes. For this study, facilitators are members of study staff.
48477900|NCT03493321|OTHER|PRF with Theracal|using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
47948491|NCT06573359|OTHER|questionnaire|Turkish translation of the scale will be made by a native English speaker and the back translation will be made into English, and the consistency of the original and Turkish translation will be evaluated by a three-person expert committee. The psychometric properties of the scale will be investigated according to the methods used for the validity of the original scale. The validity of the scale was validated by analyzing the correlations between the rcs-e-tr score obtained at admission (both for each partial item and the total score) and other suitability indicators used in Turkey (FIM Motor and Barthel) using Spearman's rank correlation coefficient r (rho). will be evaluated. Additionally, to check the ability of rcs-e-tr to capture case complexity, it will be correlated with other scores usually recorded in our rehabilitation services on admission, using Spearman's rank correlation coefficient r(rho).
47948492|NCT01509508|DRUG|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
47948493|NCT01509508|OTHER|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
47948494|NCT03309644|OTHER|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
47948495|NCT03309644|OTHER|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
47948496|NCT05089162|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation
48636323|NCT06633406|OTHER|Age-appropriate Wechsler Intelligence Test|"2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~\>17 years: Wechsler Adult Intelligence Scale (WAIS IV)"
48636324|NCT06633406|OTHER|Disruptive Behavior Disorders Rating Scale|Dutch version of the Disruptive Behavior Disorders Rating Scale
47913938|NCT02934503|DRUG|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
47948497|NCT05089162|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional
47948498|NCT05089162|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
47948499|NCT05089162|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation
47948500|NCT05089162|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
47948501|NCT04439149|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
48477901|NCT01139684|BEHAVIORAL|Repeated sprint test|
47948502|NCT04795986|PROCEDURE|HEARO Procedure|robotic access to the middle and inner ear in cochlear implantation
47948503|NCT02232191|BIOLOGICAL|Pneumovax-23|
47948504|NCT06474325|BEHAVIORAL|Intervention via mobile application|Intervention via mobile application include psychoeducational videos, reminders, and virtual rewards and badges for completing the challenges to encourage adherence of medications
47948505|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
47948506|NCT06455449|OTHER|Placebo|Matched placebo delivered subcutaneously, once weekly for 52 weeks
47948507|NCT06455449|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all study participants on anifrolumab or placebo will receive open label anifrolumab once weekly for an additional 52 weeks
48477902|NCT00992563|DRUG|AL-39324 ophthalmic suspension|
48477903|NCT00992563|DRUG|Ranibizumab 10 mg/mL|
48477904|NCT06317389|OTHER|Questionnaires|Patients will benefit of supervision by the ONCORAL team in the usual way and their intervention will be limited to completing questionnaires.
48477905|NCT03028896|PROCEDURE|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
48477906|NCT06188507|DRUG|GSK4347859|GSK4347859 will be administered
48477907|NCT06188507|DRUG|Placebo|Placebo will be administered
48477908|NCT04648150|DEVICE|Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms|Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
48636325|NCT06633406|OTHER|Social Responsiveness Scale|"3-18 years: social responsiveness scale 2 (SRS-2)~\>19 years: Social Responsiveness Scale - Adult version (SRS-A)"
48636326|NCT06074185|DRUG|Ipratropium Bromide|The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.
48636327|NCT05301231|DIAGNOSTIC_TEST|Genomics (DNA Extraction)|"Blood samples for detection of:~Genes for Dyslipidemia BY WES and NGS (4 GWA) (30 cases) Genes polymorphism for NAFLD/NASH BY TaqMan SNP Genotyping Assay on 10 GWAS"
48636328|NCT05301231|DIAGNOSTIC_TEST|Epi-genomics|"* blood samples for detection of Expression profiling of plasma microRNAs~* PCR array to determine the altered miRNAs for 168 plasma miRNAs (12 cases)~* Expression analysis of top 5 altered miRNAs (All)"
48636329|NCT05301231|DIAGNOSTIC_TEST|Proteomics (Glycoproteomics)|blood samples for Identifying glycosylation pattern of five glycoproteins linked with NAFLD/NASH (transferrin, apoC III, haptoglobin, Mac2 binding protein, IgG)
48636330|NCT05301231|DIAGNOSTIC_TEST|Salivary Metabolomics|"Salivary Samples for detecting Salivary Metabolomics~1. Genome analysis (Identification of microbial strains common among Egyptians BY apid RT-PCR (DNA sequencing: 16S rRNA gene amplicons)~2. Microbiome related Metabolites Identification using GC-MS Analysis (the top 5 identified microbial-related metabolites) as metabolomics~3. Meta-genomic assess of three microbiome-related metabolites; lactoferrin, (LPS), (IgA) BY Commercial ELISA kits"
47948508|NCT01461980|BIOLOGICAL|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
47948509|NCT01461980|BIOLOGICAL|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
47913939|NCT02934503|RADIATION|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
48477909|NCT05040126|DRUG|Linezolid|"Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment"
47948510|NCT01461980|BIOLOGICAL|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
47948511|NCT05109234|DRUG|Brivaracetam Film-coated tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses."
47948512|NCT05109234|DRUG|Brivaracetam oral solution|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses."
48104613|NCT02927132|BEHAVIORAL|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
48477910|NCT05040126|DRUG|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
48477911|NCT05040126|DRUG|Pretomanid|Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
47948513|NCT05415683|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
48477912|NCT00941720|DRUG|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
48636331|NCT05301231|BEHAVIORAL|Individualized counselling for behavioural modification|"Individualized counselling for behavioral modification (3 sessions):~Nutritional education, Promotion of physical activities and Cognitive \& Psychological support"
48636332|NCT01377311|PROCEDURE|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
47948514|NCT02605785|DRUG|F-18 AV 1451|Tau PET scan
48636333|NCT00657501|DRUG|testosterone gel|once daily transdermal gel, 300 mcg
48636334|NCT00657501|DRUG|placebo gel|once daily transdermal placebo gel
48636335|NCT06278298|DEVICE|Shockwave|CDT and different dose of shockwave
48636336|NCT06278298|OTHER|CDT|CDT
47913940|NCT00800254|DEVICE|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
47913941|NCT00800254|OTHER|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
47913942|NCT00637780|DRUG|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
47913943|NCT04011215|OTHER|wool clothing|superfine merino wool ensembles for baby/child wear
47948515|NCT04193358|DIETARY_SUPPLEMENT|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
47948516|NCT04193358|OTHER|PLACEBO|Sugar pills
47948517|NCT05298774|DEVICE|G-tech WPS|G-tech WPS patches applied and activated within 4 hours of surgery
48477913|NCT00941720|DRUG|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
48477914|NCT00941720|PROCEDURE|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
48477915|NCT04512326|PROCEDURE|Total or Subtotal colectomy|Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
48477916|NCT05099523|PROCEDURE|taking arterial blood sample through the injector|taking blood samples from patients applied with different oxygen concentrations
48477917|NCT06038396|DRUG|RC118|RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
48477918|NCT06038396|DRUG|Toripalimab|Toripalimab is a recombinant humanized anti-PD1 monoclonal antibody
48477919|NCT02788513|DRUG|BI 425809 dose 1|
48477920|NCT02788513|DRUG|BI 425809 dose 2|
48636337|NCT01745302|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
48636338|NCT01745302|DRUG|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
48636339|NCT04520451|DRUG|rilzabrutinib|oral tablet
48636340|NCT04520451|DRUG|Glucocorticoids|oral tablet or capsule
48636341|NCT01579305|DEVICE|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
48636342|NCT01579305|DEVICE|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
48636343|NCT04305431|BEHAVIORAL|Cooking Intervention|90-minute culinary education sessions.
48636344|NCT03495895|BEHAVIORAL|Minding the Baby|Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
48636345|NCT03495895|BEHAVIORAL|Usual Care|Usual care condition
48636346|NCT03003897|OTHER|Soluble Fiber|Participants receiving soluble fiber.
48636347|NCT03003897|OTHER|Placebo|Participants receiving placebo.
47948518|NCT01710046|DRUG|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
47948519|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
47948520|NCT01710046|DRUG|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
48477921|NCT02788513|DRUG|BI 425809 dose 3|
48477922|NCT02788513|DRUG|BI 425809 dose 4|
47948521|NCT01710046|DRUG|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
47948522|NCT05991323|DRUG|Dupilumab|Injection solution; subcutaneous
47948523|NCT05354505|DEVICE|Placement of the GOLDBAL2 balloon|The Fetal Endoscopic Tracheal Occlusion (FETO) procedure using the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) will be used to treat fetuses diagnosed with severe Congenital Diaphragmatic Hernia (CDH)
48477923|NCT02788513|DRUG|Placebo|
48636348|NCT06532422|PROCEDURE|Partial or total laparoscopic nephrectomy|Nephrectomy is currently the primary indication for localised kidney cancer. All patients consulting a surgeon at the Clinique de la Sauvegarde for localised kidney cancer, for which surgical excision has been validated by the multidisciplinary consultation meeting and who are eligible for outpatient treatment, will be offered the opportunity to take part in this study during the preoperative consultation.
48636349|NCT03788928|DIAGNOSTIC_TEST|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
47948524|NCT06681324|DRUG|AZD7798|AZD7798
48636350|NCT06161441|DRUG|Fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
48636351|NCT06161441|DRUG|Cemiplimab|Administered IV Q3W
48636352|NCT06161441|DRUG|Pemetrexed|Administered IV Q3W
47948525|NCT06681324|OTHER|Placebo|Placebo
47948526|NCT00147251|DRUG|FDA approved drugs to treat blood pressure and cholesterol|
47948527|NCT05922956|OTHER|Facial emotion recognition test|Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
47948528|NCT04738487|BIOLOGICAL|Pembrolizumab/Vibostolimab|Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
47948529|NCT04738487|BIOLOGICAL|Pembrolizumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
47948530|NCT03277157|DIETARY_SUPPLEMENT|B. lactis B94|A probiotic dose of 15 billion per capsule.
48477924|NCT01533649|BEHAVIORAL|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
48477925|NCT01533649|BEHAVIORAL|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
48636353|NCT06161441|DRUG|Paclitaxel|Administered IV Q3W
48636354|NCT06161441|DRUG|Carboplatin|Administered IV Q3W
48636355|NCT06161441|DRUG|Cisplatin|Administered IV Q3W
48636356|NCT06161441|DRUG|Placebo|Administered IV Q3W
48636357|NCT05380570|RADIATION|Occupational radiation exposure|Ionizing radiation in workplaces
48636358|NCT02004275|DRUG|pomalidomide|given PO
48636359|NCT02004275|DRUG|ixazomib|given PO
48636360|NCT02004275|DRUG|dexamethasone|given PO
48636361|NCT05034978|OTHER|no intervention|evaluating the performance of a novel point-of-care test
48636362|NCT05020912|DRUG|ALA|At first visit, ALA applied to one BCC lesion
48636363|NCT05020912|PROCEDURE|PDT|PDT with blue light (for 30 min (\~20 mJ/cm2))
48636364|NCT06277830|DEVICE|Wearable sensor|Participants will wear a pendant sensor for 7 days and then participate in an on-site examination with using a tablet designed to evaluate weakness in MG.
48636365|NCT06185530|DIAGNOSTIC_TEST|Detection of obstructive coronary disease|Detection of obstructive coronary disease
47948531|NCT03277157|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
47948532|NCT04875429|DEVICE|Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2|Endovascular aneurysm repair
47948533|NCT06662383|DRUG|Retatrutide|Administered SC
47948534|NCT06662383|DRUG|Tirzepatide|Administered SC
47948535|NCT04693117|OTHER|Interval Training|All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
47948536|NCT02098252|PROCEDURE|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
47948537|NCT02098252|RADIATION|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
47948538|NCT02098252|PROCEDURE|Embolization|Curative embolization, when the lesion is considered curable by embolization.
47948539|NCT03616132|DEVICE|Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
47948540|NCT00046748|DRUG|Omalizumab|
48104614|NCT02927132|BEHAVIORAL|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
48104615|NCT02175212|DRUG|Short term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months"
48104616|NCT02175212|DRUG|Long term androgen deprivation|"* Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
48104617|NCT02175212|RADIATION|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
48104618|NCT02175212|RADIATION|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
48104619|NCT02648425|DRUG|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
48104620|NCT02648425|DRUG|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
48104621|NCT02648425|DRUG|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
48104622|NCT00557804|DEVICE|MUSE clinical system|non-invasive external monitoring device
48636366|NCT02627443|DRUG|Berzosertib|Given IV
48636367|NCT02627443|DRUG|Carboplatin|Given IV
48636368|NCT02627443|DRUG|Gemcitabine Hydrochloride|Given IV
48636369|NCT02627443|OTHER|Laboratory Biomarker Analysis|Correlative studies
48636370|NCT02627443|OTHER|Pharmacological Study|Correlative studies
47948541|NCT06679790|OTHER|None interventional|Observational study
47948542|NCT04180774|BIOLOGICAL|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
47948543|NCT00003742|DRUG|cisplatin|
47948544|NCT00003742|DRUG|irinotecan hydrochloride|
47948545|NCT00003742|DRUG|paclitaxel|
47948546|NCT01528033|DEVICE|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
47948547|NCT01528033|OTHER|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
47948548|NCT06529406|DRUG|Ozanimod|De-escalation of anti-CD20 treatment using ozanimod.
48477926|NCT05863559|BEHAVIORAL|Super Chef: Family Fun in the Kitchen!|Two-phase intervention: in the online phase, a professional chef will demonstrate cooking strategies to help families modify existing recipes to be consistent with the Mediterranean Dietary pattern. Effective food parenting practices will also be integrated into the intervention. The intervention is guided by theory - Family Systems, Social Cognitive, and Self Determination - and gamification techniques. At the end of the online phase, dyads will set a goal to use the cooking strategy and make a plan to facilitate goal attainment. In the home phase, the dyad will work together to use the plan to meet the goal. Dyads can also participate in bonus activities. Prior to viewing the next session, dyads will report whether the goal was attained and any bonus activities completed. Collectively, this will determine level of Super Chef status the family achieves at the end of the program (Session 4).
48104623|NCT00931593|DEVICE|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~* Subject selection~* Obtaining of written informed consent~Visit V1 (day 0):~* Fasting subject~* Randomization to determine the examination order~* Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~* Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
48477927|NCT03239977|BEHAVIORAL|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
47948549|NCT05907590|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
47948550|NCT05907590|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
47948551|NCT05907590|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
47948552|NCT05907590|OTHER|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
47948553|NCT05907590|OTHER|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
47948554|NCT06558487|OTHER|Cancer Admission Score Prediction Model|A prediction model that calculates the chance for a patient to be admitted after triage and after first blood results
47948561|NCT02837068|DEVICE|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
47948562|NCT02837068|DEVICE|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
48636371|NCT06104306|DRUG|B/F/TAF|Tablets administered without regard to food
48636372|NCT06359626|DRUG|YHP2205|Test drug: YHP2205
48636373|NCT06359626|DRUG|YHR2401|comparator: YHR2401
48636374|NCT04593329|DRUG|TIRADENTES ASSOCIATION|Tiradentes association tablet
48636375|NCT04593329|DRUG|DIPYRONE|Dipyrone 500 mg
47948563|NCT01565642|BEHAVIORAL|Goals of care decision support|Decision aid and care plan meeting
47948564|NCT04351958|BEHAVIORAL|"Experimental: Augmented Reality (No Time Wasted)"|"No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message."
47948565|NCT03421340|DEVICE|DSC|Stone removal without fluoroscopy using the SpyGlass device.
47948566|NCT03421340|DEVICE|ERC|Standard of care stone removal with fluoroscopy.
47948567|NCT01672762|DRUG|ipragliflozin|oral
48636376|NCT04593329|DRUG|TRAMADOL|Tramadol 50 mg
48636377|NCT04593329|OTHER|TIRADENTES ASSOCIATION PLACEBO|Tiradentes association placebo tablet
48636378|NCT04593329|OTHER|DIPYRONE PLACEBO|Dipyrone placebo tablet
48636379|NCT04593329|OTHER|TRAMADOL PLACEBO|Tramadol placebo capsule
48636380|NCT06322862|OTHER|Indocyanine green|Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
48477928|NCT03239977|BEHAVIORAL|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
48477929|NCT06416969|DRUG|Somatostatin|Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
47948568|NCT06341764|DRUG|Durvalumab 1120 mg|Durvalumab 1120 mg day 1 i.v
47948569|NCT06341764|DRUG|Durvalumab 1500 mg|Durvalumab i.v. at 1500 mg once every 4 weeks
47948570|NCT06341764|DRUG|Tremelimumab i.v. at 300 mg|Single dose
47948571|NCT06341764|COMBINATION_PRODUCT|Cisplatin (CDDP) 25 mg/mq i.v|Four cycles
47948572|NCT06341764|COMBINATION_PRODUCT|Gemcitabine (GEM) 1000 mg/mq i.v.|Days 1 and 8 every 21 days
47948573|NCT05393674|DRUG|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
47948574|NCT05393674|DRUG|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
47948575|NCT05879601|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding.
47948576|NCT05879601|OTHER|delayed orthodontic retainer delivery.|post orthodontic treatment patients will be given orthodontic retainer after 24 hours of debonding.
47948577|NCT04710134|BIOLOGICAL|Reslizumab|Reslizumab 3,4, or 5 mg/kg IV q4 weeks
47948578|NCT01823354|OTHER|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
47948579|NCT01823354|OTHER|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
47948580|NCT01823354|OTHER|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
47948581|NCT01823354|OTHER|Medical consultation|open questions
47948582|NCT03757338|DRUG|Fingolimod Reference Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
47948583|NCT03757338|DRUG|Fingolimod Test Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
47948584|NCT05934643|DEVICE|ActivPAL accelerometer|All patient will have an accelerometer (activPAL) applied to characterise the type and quantity of movement during the inpatient postoperative period after undergoing major surgery for colorectal cancer surgery.
47948585|NCT05934643|OTHER|Hospital Anxiety and Depression Scale (HADS) Questionnaire|The use of the HADS questionnaire to ascertain if any correlation between level of activity and and inpatient mood.
47948586|NCT04743856|BEHAVIORAL|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
47948587|NCT04743856|BEHAVIORAL|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
48104624|NCT02387749|GENETIC|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
48104625|NCT06202118|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
48477930|NCT06416969|DRUG|Epinephrine|Intravenous infusion
47948588|NCT05767970|BEHAVIORAL|Integrated Stress Toolbox for Healthcare Providers (ISTH)|The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
47948589|NCT00611533|DRUG|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
48104626|NCT01025869|DEVICE|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
48104627|NCT03206931|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
48104628|NCT04442984|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
48477931|NCT01661634|DRUG|Ularitide|
48477932|NCT01661634|DRUG|Placebo|
48477933|NCT04286919|BEHAVIORAL|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
48477934|NCT01443689|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
47948590|NCT00611533|DRUG|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
47948591|NCT02635776|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
47948592|NCT02635776|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
47948593|NCT05099393|DIETARY_SUPPLEMENT|Non Nutritive Sweeteners|"The 2 arms will participate in 3 periods and each of these periods will correspond to the intake of either sucralose, AceK or a placebo.~The order will be defined randomly. There will be 3 periods and each period will last 4 weeks. 7 to 14 days of break will be respected between each period."
47948594|NCT04049643|DEVICE|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
47948595|NCT04049643|DEVICE|Service-only Fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.
48477935|NCT01443689|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
48477936|NCT01443689|DRUG|Conventional therapy|Participants will be given conventional therapy only.
47948596|NCT04049643|DEVICE|Device-only fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
47948597|NCT00882466|DRUG|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
48104629|NCT04442984|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
48636381|NCT06034652|DEVICE|Integra® Gentrix® Surgical Matrix|Integra® Gentrix® Surgical Matrix is intended for implantation to reinforce soft tissue where weakness exists in patients requiring gastroenterological or plastic \& reconstructive surgery.
48636382|NCT05311982|DEVICE|DLPFC-R (F4) TDCS|direct current brain stimulation- The study was developed through a triple-blind, crossover, randomized, placebo-controlled clinical trial (dummy tDCS). Participants were randomized into three groups receiving unilateral tDCS in DLPFC-L F3 (Block A), combined tDCS in DLPFC-L (F3) and DLPFC-R (F4) simultaneously (Block B) or sham-tDCS (Block C) with equal electrode configuration guaranteed blindness. After the procedures, each participant received the following intervention in the order ABC, BCA or CAB with a period of 1 week between each one. Each block took 3 weeks, organized into: 1) Assessment; 2) Application of stimulation; 3) Reassessment and washout week. Adding 1 more week of final evaluation, the study totaled the period of 10 weeks. During this period, patients were instructed to continue their behavioral/educational treatment and medication routines.
48636383|NCT05311982|DEVICE|DLPFC-L (F3) and DLPFC-R (F4) TDCS|DLPFC-L (F3) and DLPFC-R (F4) (Bock B)
48636384|NCT05311982|DEVICE|sham-tDCS|sham-tDCS (Block C) with equal electrode configuration guaranteed blindness
48636385|NCT03255499|BEHAVIORAL|Exercise|Exercise
47948598|NCT01087242|DRUG|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
48104630|NCT04442984|DRUG|5-FU|d1-2 5-FU 2200 mg/m² every two weeks
48104631|NCT04442984|DRUG|5-FU|d1 5-FU 250 mg/m² every two weeks
48104632|NCT04442984|DRUG|Leucovorin|d1 Leucovorin 400 mg every two weeks
48104633|NCT04442984|DRUG|5-FU|d1 5-FU 400 mg/m² every two weeks
48636386|NCT03255499|BEHAVIORAL|Cognitive|Cognitive
48636387|NCT03255499|BEHAVIORAL|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
48636388|NCT05343650|DEVICE|NOVAPAK nasal packing applied to forearm|Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
48636389|NCT05343650|DEVICE|NOVAPAK nasal packing applied to nasal cavity|A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
47948599|NCT01785420|DRUG|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
47948600|NCT01785420|DRUG|Placebo|A 90 minute intravenous infusion of saline as placebo
48477937|NCT03206567|DIETARY_SUPPLEMENT|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
48104634|NCT04442984|DRUG|5-FU|d1-2 5-FU 2400 mg/m² every two weeks
48477938|NCT03206567|OTHER|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
47948601|NCT00176527|BIOLOGICAL|recombinant interferon alfa-2b|
47948602|NCT00176527|DRUG|docetaxel|
47948603|NCT00176527|DRUG|estramustine phosphate sodium|
47948604|NCT00176527|DRUG|isotretinoin|
48104635|NCT00541697|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
48104636|NCT00541697|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
48477939|NCT02137694|OTHER|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
48104637|NCT05539248|DRUG|CAN106 20 mg/kg|"Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;"
48104638|NCT05539248|DRUG|CAN106 40 mg/kg|"Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；"
48104639|NCT05539248|DRUG|CAN106 80 mg/kg|"Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter."
48636390|NCT05265637|DEVICE|Visian|Visian implantable collamer lens (ICL)
48636391|NCT01091415|PROCEDURE|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
48636392|NCT06579248|DEVICE|Intraoral Device|Device that circulates cooled water through the oral cavity.
48636393|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
48636394|NCT03962816|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
48636395|NCT03962816|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
48636396|NCT06396403|OTHER|Collection of venous blood samples|collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL
47948605|NCT00176527|GENETIC|polyacrylamide gel electrophoresis|
47948606|NCT00176527|GENETIC|protein expression analysis|
47948607|NCT00176527|OTHER|immunohistochemistry staining method|
47948608|NCT03438383|DEVICE|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
47948609|NCT03438383|DEVICE|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
47948610|NCT05050929|RADIATION|Targeting All Brain Metastases|Volumetric Modulated Arc Therapy
47948611|NCT06333093|PROCEDURE|Cold snare|Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
47948612|NCT06359990|BEHAVIORAL|BrotherlyACT|BrotherlyACT is a digital intervention to prevent youth violence and substance use among trauma-exposed young Black males, ages 125-24. This intervention combines life skills coaching, safety planning tools, and an AI-driven chatbot to reduce the risk and effects of violence and early substance use.
48104640|NCT02817217|DRUG|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
47948613|NCT06359990|OTHER|BrotherlyACT Waitlist Control Group (WCG)|During the waiting period, participants in the control group do not receive the BrotherlyACT intervention but may continue with their usual activities or interventions.
48104641|NCT02817217|DRUG|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
48104642|NCT04601467|DRUG|AZD5718|Oral dose of AZD5718 (tablet) once daily for 12 months
48104643|NCT04601467|DRUG|Placebo|Oral dose of matching placebo (tablet) once daily for 12 months
48104644|NCT02373228|OTHER|Audio signal processing (applied offline before playback)|
48104645|NCT02061332|BIOLOGICAL|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
48104646|NCT03581968|DEVICE|Artificial Pancreas|"The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
48104647|NCT04346524|OTHER|sampling of microbiome|women will sample from vagina, feces, and saliva during pregnancy
48104648|NCT02466048|PROCEDURE|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
48104649|NCT02466048|DEVICE|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
48104650|NCT05542953|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
48104651|NCT00768781|BEHAVIORAL|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
48104652|NCT00768781|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
48104653|NCT00768781|BEHAVIORAL|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
48104654|NCT03583021|DRUG|Sugammadex Injectable Product|Sugammadex of 3 mg/kg is injected.
47948614|NCT00977574|BIOLOGICAL|Bevacizumab|Given IV
48104655|NCT03583021|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
48104656|NCT03926819|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
48636397|NCT05213351|OTHER|Graded Motor Imagery|"Graded Motor Imagery program will be performed two times a week for six consecutive weeks and will include the following three steps: laterality training, imagined movements, and mirror therapy.~1. Right-left discrimination training (lateralization training)~2. Imagination of hand movements (motor imagery):~3. Mirror therapy Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc."
48636398|NCT05213351|OTHER|Exercise|Treatments including traditional physiotherapy approaches; joint mobilizations, stretching, scapula focused exercises etc.
47948615|NCT00977574|DRUG|Carboplatin|Given IV
47948616|NCT00977574|DRUG|Ixabepilone|Given IV
47948617|NCT00977574|OTHER|Laboratory Biomarker Analysis|Correlative studies
47948618|NCT00977574|DRUG|Paclitaxel|Given IV
47948619|NCT00977574|DRUG|Temsirolimus|Given IV
47948620|NCT05659992|DRUG|azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte|"1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"
47948621|NCT05913648|OTHER|Tool Translation|The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.
47948622|NCT06019585|DEVICE|Splint inmmobilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks
47948623|NCT06019585|DEVICE|Bandage immovilization|After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
47948624|NCT01061216|DEVICE|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
47948625|NCT01061216|DEVICE|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
47948626|NCT01561729|DEVICE|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
48477940|NCT04741529|BEHAVIORAL|Healthy Minds Program app|"The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP."
47948627|NCT01561729|RADIATION|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
48298327|NCT03752853|BEHAVIORAL|internet-based intervention for mild to moderate depression|The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
48636399|NCT03593408|DRUG|Dexmedetomidine|Administered for sedation management per hospital protocol
47948628|NCT05400863|BEHAVIORAL|avoid sugary and NNS drinks plus start Metformin|Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day
47948629|NCT05400863|BEHAVIORAL|avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin|Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
47948630|NCT06595121|DRUG|budesonide|Budesonide 1 mg/2mL nebuliser suspension
48298328|NCT04232501|DEVICE|Cirvo Compression device|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
47948631|NCT06595121|DRUG|budesonide|Pulmicort(r) 1 mg/2mL nebuliser suspension
47948632|NCT06595121|OTHER|Activated Charcoal|suspension of 10g activated charcoal slurried in 70mL of water
47948633|NCT01031706|DRUG|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
47948634|NCT01031706|DRUG|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
48104657|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|40 mg, QD
48104658|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|80 mg, QD
48104659|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|160 mg, QD
48104660|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|240 mg, QD
48104661|NCT04993391|DRUG|JS111(AP-L1898 Capsules)|320 mg, QD
48298329|NCT01250067|PROCEDURE|Motor-related cortical potential (Procedure)|
48298330|NCT05429684|DRUG|Trastuzumab|Trastuzumab (6mg/Kg, iv.drip, d1, q3w)
48298331|NCT05429684|DRUG|Pertuzumab|Patuzumab (420mg iv.drip, d1,q3w)
48298332|NCT05429684|DRUG|Nab paclitaxel|nab-paclitaxel (200mg iv.drip, d1,d8, q3w)
48298333|NCT05429684|DRUG|Pyrotinib|Pyroltinib (400mg po qd)
48298334|NCT05429684|DRUG|Capecitabine|Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
48298335|NCT05429684|DRUG|T-DM1|T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
48298336|NCT05429684|DRUG|Everolimus|Everolimus (4mg, po, qd)
48298337|NCT05429684|DRUG|CDK4/6 inhibitor|Palbociclib (125mg, po, qd)
47948635|NCT06677866|BEHAVIORAL|Cognitive behavioral therapy|"Cooperative Group Therapy (CGT) is a cognitive-behavioral group therapy based on the theoretical and practical principles of the Cooperative Parent-Mediated Therapy model \[Valeri et al., 2020\].~The goal of CGT is to promote the following core skills: Pragmatics, Executive Functions, and Cooperative Interactions. The CGT program consists of 15 sessions over a total duration of 6 months: 12 group therapy sessions with adolescents and 3 sessions with their parents. Each session focuses on a specific topic and lasts between 90 and 120 minutes.~The CGT therapist is a psychotherapist with a cognitive-behavioral orientation who utilizes evidence.-based strategies to enhance pragmatic, socio-conversational skills, cognitive flexibility, emotional regulation, and cooperative interactions. The CGT intervention is conducted by two cognitive-behavioral psychotherapists specialized respectively in the treatment of FXS and ASD."
47948636|NCT06677866|OTHER|Waiting List|The Waiting List (WL) is a control group in which participants who do not receive the experimental treatment are placed on a waiting list to receive the intervention after the active treatment group has completed it. In the case of the WL, the CGT intervention is carried out after at least 6 months to allow the patients in the first group to complete the treatment cycle. This approach enables a comparison between a group of treated patients and a group of patients who have not yet been treated, while still allowing the latter to access the treatment at a later stage.
47948637|NCT01162928|DRUG|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
47948638|NCT01162928|DRUG|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
47948639|NCT01683019|DEVICE|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
47948640|NCT01683019|DEVICE|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
48104662|NCT06067178|BEHAVIORAL|Health Dialogue Intervention|"1. Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose.~2. Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines."
47948641|NCT03563976|OTHER|Retrospective Study|The medical charts are the subjects. The institutional charts will be identified by the use of definitive radiation therapy correlating with an early stage lung cancer diagnosis during the above time frame. The data from these charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number. These are all patients treated by all hospitals and clinics affiliated with UTSW and Parkland. At the time of study, some of the patients will have expired but some will be alive and in the regional North Texas area. Thus, given the minimal risk nature of this retrospective chart review, we could not reasonably conduct this research with a full waiver of consent. The NLST external dataset is proved by the NCI, with no identifying characteristics.
48477941|NCT06437314|BEHAVIORAL|Aquatic program based on the back school|Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
47948642|NCT06557317|BEHAVIORAL|Black Girls for Wellness In-Person|Weekly for 12 weeks, adolescent/caregiver dyads will attend 1) an in-person Wellness Session (mindfulness, nutrition lesson, dance class, program reflection) (90 min/wk) and 2) a home cooking experience using ingredients provided at the Wellness Session (60 min/wk).
47948643|NCT05378373|BEHAVIORAL|Garmin, Pattern Health App|Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
48477942|NCT04570176|PROCEDURE|adrenalectomy for adrenal adenoma|adrenalectomy， cystectomy and nephrectomy
47948644|NCT06335134|DRUG|XW003 injection|Administered subcutaneously
48477943|NCT06004869|BEHAVIORAL|Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)|an integrated system based on an existing multicomponent cognitive behavioural therapy for insomnia (CBT-I) and EMA app
47948645|NCT06335134|DRUG|Metformin|Administered orally
47948646|NCT06335134|DRUG|Warfarin|Administered orally
47948647|NCT06335134|DRUG|Rosuvastatin|Administered orally
48298338|NCT05429684|DRUG|AI|Letrozole (2.5mg, qd).
48298339|NCT05429684|DRUG|Anti-PD-1 monoclonal antibody|Cindilimab (200mg, iv.drip, d1, q3w)
48477944|NCT06004869|BEHAVIORAL|Self-help cognitive behavioural therapy for insomnia|An mobile app that delivers CBT-I content.
48477945|NCT06430918|OTHER|physical examination, questionnaires and inventories|Questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
48477946|NCT02932917|DEVICE|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
48477947|NCT06616454|BEHAVIORAL|Intervention group - Time restricted feeding|Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
48636400|NCT03593408|DRUG|Fentanyl|Administered for sedation management per hospital protocol
48298340|NCT01977534|DEVICE|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].
47948648|NCT06335134|DRUG|Digoxin|Administered orally
47948649|NCT04467931|DRUG|ACEI/ARB|Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
47948650|NCT04467931|DRUG|Non-ACEI/ARB|Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
47948651|NCT04467931|DRUG|ACEI|Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
47948652|NCT04467931|DRUG|ARB|Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
47948653|NCT06623149|BEHAVIORAL|Non-Surgical Intervention|"After referral from the general practitioner to the orthopedic department, the patient is offered a 3-month non-operative treatment program. The conservative program consists of several elements that are offered on an individual basis. The program consists of 3 main elements:~* Patient education/information~* Specialized exercise supervised by a physiotherapist~* Weight loss counseling with a dietician"
47948654|NCT06623149|PROCEDURE|Current practice|After referral from the general practitioner to the orthopedic department, the patient is assessed by an orthopedic surgeon in the out-patient clinic according to standard practice with a focus on symptoms, history, physical examination, radiography, and an appraisal of the patient's expectations. If an indication for knee arthroplasty is found, the patient is offered knee arthroplasty, and if the patient accepts the offer, he/she is scheduled according to usual practice. If a patient declines the offer, the patient is informed that the hospital cannot offer any additional service, and the patient is referred back to primary care.
48104663|NCT06067178|OTHER|Opportunistic Screening|"1. Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment.~2. Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening."
48104664|NCT05612659|PROCEDURE|Transcranial Electrical stimulation|Noninvasive electrical stimulation of lateral frontal cortex.
48477948|NCT01552369|DRUG|Valganciclovir|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
48477949|NCT05290337|DRUG|zanubrutinib|BTK inhibitor
48477950|NCT06615908|DRUG|Psilocybin|See treatment arm description.
48477951|NCT01426737|DRUG|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
48477952|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
48477953|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
48477954|NCT06214611|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy in the head and neck region
48477955|NCT03569488|DIAGNOSTIC_TEST|FT-LARS questionnaire|FT-LARS questionnaire
48477956|NCT02067702|PROCEDURE|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
48636401|NCT03593408|DRUG|Midazolam|Administered for sedation management per hospital protocol
48636402|NCT03593408|DRUG|Morphine|Administered for sedation management per hospital protocol
48636403|NCT05507229|BIOLOGICAL|Hillchol vaccine|HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
48636404|NCT05507229|BIOLOGICAL|Shanchol Vaccine|Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
48636405|NCT03522259|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
48636406|NCT00617903|DRUG|Azelaic acid|15% foam to be applied topically twice daily
48636407|NCT00617903|DRUG|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
48636408|NCT01263028|DRUG|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
48104665|NCT05612659|PROCEDURE|Transcutaneous direct current stimulation|Noninvasive electrical stimulation of the T10 spinal column.
48104666|NCT00123747|PROCEDURE|Positron Emission Tomography (PET) scan Imaging|
48104667|NCT06632015|PROCEDURE|root canal treatment and intracanal medicament|Root canal treatment and intracanal medicament procedures explained in arm descriptions.
48104668|NCT04856228|DIAGNOSTIC_TEST|diagnostic posterior interosseous nerve lidocaine injection|ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
48477957|NCT05386056|DRUG|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
48636409|NCT05167058|DEVICE|Cardiologs Platform|Smartwatch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
48636410|NCT04124510|DRUG|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
48636411|NCT02841631|GENETIC|HPV status and typing of tissue|HPV status and typing of tissue
48636412|NCT01126398|PROCEDURE|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
48636413|NCT04861805|DEVICE|Vienna Aortic Valve SE System|Vienna Aortic Valve SE system for TAVI.
48636414|NCT04145622|DRUG|Ifinatamab deruxtecan (I-DXd)|A total anti-B7H3 antibody and MAAA-1181a
48636415|NCT03142204|DRUG|[18F]F-AraG|Single dose IV injection of \[18F\]F-AraG for each imaging day.
48636416|NCT06499220|DEVICE|Spinal Cord Stimulator|Spinal Cord Stimulation (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or limbs.
48636417|NCT05051657|DIETARY_SUPPLEMENT|PKU express plus|PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
47913944|NCT04011215|OTHER|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
47913945|NCT03504176|OTHER|Ventilation bundle|ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures \<28-32cmH2O PEEP-FiO2 titration tables
47913946|NCT01852396|PROCEDURE|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
48104669|NCT00944801|DRUG|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
48636418|NCT05229367|OTHER|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
48636419|NCT05229367|OTHER|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
48636420|NCT03996421|DIETARY_SUPPLEMENT|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
48636421|NCT03996421|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
48636422|NCT03133780|DRUG|Ketamine|Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
48636423|NCT03133780|DRUG|Midazolam|Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
47948655|NCT05870774|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Harvesting of free connective tissue graft from the maxilla tuberosity area~4. Fixation of the graft to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
48104670|NCT02988596|OTHER|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
48104671|NCT02988596|OTHER|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
48104672|NCT06411405|OTHER|Maternal medical history|See above; multiple factors to be collected broadly grouped into maternal medical, obstetric, and sociodemographic/lifestyle factors.
48104673|NCT03369587|BEHAVIORAL|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
48298341|NCT03634215|DIAGNOSTIC_TEST|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
48298342|NCT00005628|BIOLOGICAL|vitespen|
48298343|NCT02101606|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
48298344|NCT05255562|PROCEDURE|Combined Serratus Anterior Plane Block|Combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
48298345|NCT05255562|DRUG|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
48636424|NCT03907566|OTHER|The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals|Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
48636425|NCT05306015|COMBINATION_PRODUCT|Mindfulness meditation based on brain-computer interface|"Before surgery, The nurses will teach and explain the methods and significance of meditation training. Let the patient be familiar with the function and background of this method, and explain the use of the headband during the operation, so that the patient believes that meditation training can relieve pain.~In surgery, Wear a brain-computer interface headband for the patient to collect EEG, monitor the patient's psychological changes, and provide real-time feedback.~The patient wears a Bluetooth headset, according to the patient's preferences, different types of music are selected, and voice playback guides the patient to prepare, relax muscles and regulate breathing.~APP judges the patient's meditation state based on EEG signals, and adjusts music, voice guidance.~The nurse will give personalized guidance based on the patient's specific situation and the EEG displayed on the APP to help the patient achieve a state of meditation and relaxation."
47913947|NCT04354649|DRUG|Hydroxychloroquine|Hydroxychloroquine 5mg/kg PO daily
47913948|NCT04354649|OTHER|Placebo|Hydroxychloroquine-matching placebo
47913949|NCT05390619|PROCEDURE|50% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
47913950|NCT05390619|PROCEDURE|70% dose of photodynamic therapy|Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2.
47913951|NCT02080819|DRUG|levodopa/carbidopa 400/100 BID|"Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance."
47913952|NCT02011724|DEVICE|Apligraf|
47913953|NCT04334395|PROCEDURE|primary tumor resection group|resection of cancer at colon
48104674|NCT04914936|DRUG|ACP-196|Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.
48104675|NCT04914936|DRUG|Calcium carbonate|Participants will receive a single oral dose of calcium carbonate 1 g tablet on Day 1 of Period 2 in Part 1.
48104676|NCT04914936|DRUG|Omeprazole|Participants will receive multiple oral doses of omeprazole 40 mg capsules QD for 5 consecutive days in Period 2 of Part 2.
48104677|NCT04914936|DRUG|Rifampin|Participants will receive multiple oral doses of rifampin 600 mg capsule QD for 9 consecutive days in Period 2 of Part 3.
48104678|NCT04218669|PROCEDURE|Roux-en-Y Hepaticojejunostomy|The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.
48477958|NCT05386056|DRUG|Sinoporphyrin Sodium|0.2mg/kg, intravenously on day -2 of cycle 1.
48477959|NCT05386056|PROCEDURE|Photodynamic therapy|PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
48477960|NCT04923126|DRUG|Mirdametinib|By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
47948656|NCT05870774|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
47948657|NCT02362178|PROCEDURE|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time\>40 mm and/or platelets (PLTs 10 units/Kg) for MA\<30 mm
47948658|NCT02362178|PROCEDURE|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR\>1.8 and/or PLTS (10 units/Kg) If PLTs count \< 50000/μl
47948659|NCT05766501|DRUG|DOR/ISL|FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
47948660|NCT04625816|DEVICE|whole body tilt device (Spine Balance 3D)|The symmetry of the deep muscle was evaluated using a whole body tilt device (Spine Balance 3D, Cyber Medic Co., Ltd., Korea). Spine Balance 3D can evaluate the maintenance strength and maximum strength of the core muscles, and perform a personalized core muscle training program based on the evaluated results.
47948661|NCT00253760|DRUG|dietary amino acids; cysteine and methionine|
47948662|NCT01938872|PROCEDURE|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
47948663|NCT02148107|DRUG|BI 691751|BI 691751 Dose 1
47948664|NCT02148107|DRUG|BI 691751|BI 691751 Dose 2
47948665|NCT02148107|DRUG|BI 691751|BI 691751 Dose 3
47948666|NCT02148107|DRUG|BI 691751|BI 691751 Dose 4
48104679|NCT04218669|PROCEDURE|T-tube drainage|The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
48104680|NCT00999492|DEVICE|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
48104681|NCT02376036|DRUG|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
48104682|NCT02376036|DRUG|Placebo|Placebo comparator.
48104683|NCT02376036|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
47948667|NCT02148107|DRUG|BI 691751|BI 691751 Dose 5
47948668|NCT02148107|DRUG|BI 691751|BI 691751 Dose 6
47948669|NCT02148107|DRUG|Placebo|Placebo
47948670|NCT00282074|PROCEDURE|laparoscopic bilateral hernia repair|
47948671|NCT00400231|DRUG|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
47948672|NCT00400231|DRUG|Study Drug: Metformin|2000mg/day
47948673|NCT00400231|DRUG|Study Drug: fenofibrate|145mg/day of fenofibrate
47948674|NCT00400231|DRUG|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
47948675|NCT04979520|DRUG|Brodalumab|Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week
48104684|NCT04615299|DEVICE|Auricular acupuncture|Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
48104685|NCT00396058|DRUG|Methylphenidate|
48104686|NCT03972813|BEHAVIORAL|Broadened information about cancers|Caregivers receive information that HPV causes more than just cervical cancer.
48104687|NCT03972813|BEHAVIORAL|Information about STDs|Caregivers learn that HPV is an STD.
48104688|NCT03972813|BEHAVIORAL|Information about infectious disease|Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
48477961|NCT02558465|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
48477962|NCT03085225|DRUG|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
47948676|NCT01358773|OTHER|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
48104689|NCT03972813|BEHAVIORAL|Recommendation for children 12 years old|Caregivers are prompted to get their child vaccinated when the child is 12 years old.
48104690|NCT03972813|BEHAVIORAL|Recommendation for children 18 years old|Caregivers are prompted to get their child vaccinated when the child is 18 years old.
48104691|NCT03972813|BEHAVIORAL|Standard age information|Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
48104692|NCT03972813|BEHAVIORAL|Cervical cancer|Caregivers are told that HPV causes cervical cancer.
48104693|NCT03972813|BEHAVIORAL|Blank information about communicability|Caregivers are not given any information on how HPV is spread.
48104694|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
48104695|NCT01428349|OTHER|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
48104696|NCT05490654|PROCEDURE|Abdominal Massage|Abdominal Massage delivered by manual method or by Mowoot device
48104697|NCT02215278|DIETARY_SUPPLEMENT|10 x 55 g/ bean per arm|
48104698|NCT02242929|DRUG|Imiquimod 5% cream with prior curettage|
48104699|NCT02242929|PROCEDURE|Standard surgical excision|
48104700|NCT00866554|DRUG|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
48104701|NCT00866554|DRUG|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
48477963|NCT05744700|DIETARY_SUPPLEMENT|Inulinase|Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
48636426|NCT05306015|COMBINATION_PRODUCT|Routine care|Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
48636427|NCT02829957|DRUG|Apixaban|10mg BID for 7 days, then 5mg BID for three months
48636428|NCT02829957|DRUG|Rivaroxaban|15mg BID for 7 days, then 20mg daily for three months
48636429|NCT04570423|DRUG|Eflapegrastim|Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
48104702|NCT00004560|DEVICE|defibrillator|
48298346|NCT06394219|PROCEDURE|traditional transperitoneal laparoscopic pyelolithotomy|Performing anterior Pyelotomy.
48477964|NCT05744700|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
47913954|NCT03181737|BEHAVIORAL|Covivio/Relaxio|Informations already included in arm/group descriptions.
47948677|NCT00343590|DEVICE|Whole Body Vibration machine|
48477965|NCT00478452|BIOLOGICAL|DC-Ova|
48636430|NCT04570423|DRUG|Chemotherapy|Chemotherapy agents may include doxorubicin, ifosfamide, docetaxel, CHOP regimen, etoposide, cyclophosphamide and vincristine which will be administered as per standard of care per the Primary Care physician's treatment plan.
47913955|NCT04140578|DRUG|Ertapenem|inject from iv drip before endoscopic cyanoacrylateinjection obliteration
47913956|NCT01401660|OTHER|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
47913957|NCT02948036|OTHER|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
47913958|NCT02035254|OTHER|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
47913959|NCT04556383|DRUG|GB004|oral tablet
47913960|NCT04556383|DRUG|Placebo|oral tablet
47913961|NCT04088058|DRUG|GXHPC1|autologous ADSCs
47913962|NCT00744042|BIOLOGICAL|asfotase alfa|
48104703|NCT02884583|OTHER|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
47948678|NCT00269594|DRUG|Lamictal (lamotrigine)|
47948679|NCT03253458|DEVICE|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
47948680|NCT03848338|PROCEDURE|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
47948681|NCT05165407|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
47948682|NCT05165407|DRUG|IBI310|IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
47948683|NCT05165407|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously
48104704|NCT06441279|PROCEDURE|intra-articular injection with Platelet lysate (PL).|2 ml of Platelet lysate will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly
48104705|NCT06441279|PROCEDURE|intra-articular injection with Hyaluronic Acid.|2 ml of Hyaluronic Acid will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly.
48104706|NCT05639023|OTHER|Manipulation Techniques|Subjects will received 12 times orthopedic manipulation. Three times of treatment per months, and less than twice a week.
48104707|NCT05639023|OTHER|Physiotherapy Scoliosis-Specific Exercise|Subjects will receive 14 supervise training, 5 times of intensive supervise training for first two weeks and then 1-2 trainings per month for the rest. Subjects are encouraged to perform home exercise everyday on their own throughout the study.
48104708|NCT03675139|DRUG|Medroxyprogesterone Acetate|At a dosage of 10mg/day
47948684|NCT05593471|OTHER|high intensity exercises|resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body
47948685|NCT05593471|OTHER|low intensity aerobic exercises|low-intensity exercises performed using arm or leg ergometer machines
47948686|NCT05768971|OTHER|Mild diet|
48104709|NCT03675139|DRUG|Dydrogesterone 10 MG|At a dosage of 20 mg/day
47948687|NCT05768971|OTHER|Provocative diet|
48104710|NCT05901519|DRUG|Prednisone|Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
47948688|NCT00187031|DRUG|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
48104711|NCT04411836|DRUG|Tafenoquine|patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
48104712|NCT04411836|DRUG|Primaquine|patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
48104713|NCT00223314|BEHAVIORAL|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
47948689|NCT02058173|DRUG|150 mg/daily chloroquine compare to placebo for 12 week|
47948690|NCT02058173|DRUG|Chloroquine|
48104714|NCT02572024|DEVICE|BAT|Baroreflex activation therapy device ON
48104715|NCT02572024|OTHER|Placebo|Baroreflex activation therapy device OFF
47948691|NCT02058173|DRUG|placebo|
47948692|NCT03268837|DEVICE|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
47948693|NCT03268837|DEVICE|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
47948694|NCT00484094|DRUG|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
47948695|NCT05169268|DRUG|ARIPiprazole Injection [Abilify]|subject already receiving the combination of Abilify Maintena and Rexulti
47948696|NCT05169268|DRUG|Brexpiprazole|subject already receiving the combination of Abilify Maintena and Rexulti
47948697|NCT03157960|OTHER|Blueberry drink|Participant receive blueberry drink
47948698|NCT03157960|OTHER|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
47948699|NCT03157960|OTHER|Soft beverage|Participant receive a soft beverage drink
47948700|NCT03157960|OTHER|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
47948701|NCT03157960|OTHER|Fructose|Participant receive a drink containing fructose
47948702|NCT03157960|OTHER|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
47948703|NCT05135247|OTHER|Exercise|3 different types of training or control
48104716|NCT03563391|OTHER|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
48477966|NCT00478452|BIOLOGICAL|DC Ova with Cyclophosphamide|
48636431|NCT01578746|PROCEDURE|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
48636432|NCT01578746|PROCEDURE|Anterior approach|The use of anterior approach in total hip arthroplasty
48477967|NCT03968731|OTHER|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
48636433|NCT00826293|PROCEDURE|Stabilization belt|Patients receive true stabilization.
48477968|NCT01706861|DEVICE|Celotres|Celotres following surgical removal of earlobe keloid.
48477969|NCT03027011|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
48477970|NCT03027011|PROCEDURE|Control|Control group without remote ischemic preconditioning
48477971|NCT02295813|BIOLOGICAL|FBF001|
48477972|NCT02295813|DRUG|Placebo|
48477973|NCT00929981|DRUG|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
48477974|NCT00213057|DRUG|Carraguard (PC-515)|
48477975|NCT00401167|DRUG|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
48636434|NCT00826293|PROCEDURE|Stabilization belt|Patients receive sham stabilization.
48636435|NCT06483555|DRUG|Gemcitabine|1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.
48636436|NCT06483555|DRUG|Nab paclitaxel|125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.
48104718|NCT03254394|DRUG|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
48104719|NCT03254394|DRUG|Placebo|Dextrose 5% in water will be administered as active comparator.
48104720|NCT03254394|DRUG|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
48104721|NCT06530875|BEHAVIORAL|training on hesitations regarding childhood vaccinations|Training will be given to expectant mothers on childhood vaccination hesitations
48104722|NCT03425162|DRUG|Morphine Sulfate|patient-controlled analgesia (PCA) morphine
48104723|NCT03425162|PROCEDURE|Group P|Group P:patient-controlled analgesia (PCA) morphine
48104724|NCT03425162|PROCEDURE|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
48104725|NCT02834182|BEHAVIORAL|IRMf|
48104726|NCT02834182|BEHAVIORAL|Mini International Neuropsychiatric Interview|
48104727|NCT02834182|BEHAVIORAL|Positive And Negative Syndrom Scale|
47948704|NCT05377008|BEHAVIORAL|OPTIMAL-SSI|The purpose of the intervention feedback session will be twofold: 1) to provide the results of the previous assessment, and 2) to provide general psychoeducation on psychological and neurocognitive functioning and tailored cognitive and behavioral interventions based on the results in order to reduce the impact of psychological and neurocognitive deficits.
47948705|NCT03401593|DRUG|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
47948706|NCT03886662|DRUG|LB-100|"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."
47948707|NCT05306431|DRUG|Polyhexamethylene biguanide|Polyhexamethylene biguanide (PHMB), is a disinfectant solution having a broad spectrum of antimicrobial activity and is investigated as an endodontic irrigant
47948708|NCT05306431|DRUG|Sodium Hypochlorite|A number of irrigant solution has thus been proposed to serve the purpose, the most popular being sodium hypochlorite (NaOCl) because of its excellent antimicrobial activity but also the ability to dissolve organic matter
47948709|NCT05419986|GENETIC|Blood collection|Molecular monitoring by measure of DNA methylation levels in blood samples collected by fingerstick blood drops, as opposed to veinous phlebotomy
47948710|NCT00749515|DRUG|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
47948711|NCT00749515|DRUG|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
47948712|NCT00749515|RADIATION|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
47948713|NCT00886912|OTHER|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
47948714|NCT00886912|OTHER|normoxia|training under normoxic conditions
47948715|NCT02396251|DEVICE|HA experimental|
47948716|NCT02396251|DEVICE|HA comparator|
47948717|NCT04909931|DRUG|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
47948718|NCT04909931|DRUG|Placebo|Second arm : add on placebo for 12 weeks
47948719|NCT06533748|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
47948720|NCT06533748|DRUG|Vincristine|Given IV.
47948721|NCT06533748|DRUG|Inotuzumab|Given IV.
47948722|NCT06533748|DRUG|Blinatumomab|Given IV.
47948723|NCT06533748|DRUG|Dasatinib|Given PO.
47948724|NCT06533748|PROCEDURE|IT MHA|Given Intrathecal (IT), Age adjusted.
47948725|NCT06533748|DRUG|Cyclophosphamide|Given IV.
47948726|NCT06533748|DRUG|Cytarabine|Given IV or IT.
47948727|NCT06533748|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
47948728|NCT06533748|DRUG|6-Mercaptopurine|Given PO.
47948729|NCT06533748|DRUG|Calaspargase|Given IV.
47948730|NCT06533748|DRUG|Daunorubicin|Given IV.
47948731|NCT06533748|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
47948732|NCT04128371|BIOLOGICAL|mepolizumab|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials were reconstituted according to the manufacturer, for a total dose of 700mg administered as intravenous infusion.
48104728|NCT02834182|BEHAVIORAL|Young Mania Rating Scale|
48104729|NCT02834182|BEHAVIORAL|Hamilton Depression Scale|
48104730|NCT00755781|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
48104731|NCT05788146|OTHER|Cognitive Behavioural Therapy|A psychological intervention used to target depression
48104732|NCT02170636|DRUG|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
48104733|NCT02170636|DRUG|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
48298347|NCT06394219|PROCEDURE|modified transperitoneal laparoscopic pyelolithotomy|Performing posterior pyelotomy
48104734|NCT02170636|DRUG|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
48104735|NCT02170636|DRUG|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
48104736|NCT02170636|DRUG|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
48104737|NCT02170636|DRUG|Pantoprazole|40 mg Pantoprazole
48477976|NCT05155605|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
48636437|NCT06483555|DRUG|Erlotinib|50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.
48104738|NCT03764943|DIETARY_SUPPLEMENT|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
48104739|NCT02770430|BIOLOGICAL|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
48636438|NCT06483555|DRUG|NALIRIFOX|Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
48104740|NCT02770430|DRUG|conventional treatment|"1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
48104741|NCT03083405|DRUG|Opipramol|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
48104742|NCT02076919|DRUG|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
48636439|NCT06483555|DRUG|Folfirinox|Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
48104743|NCT02076919|DRUG|LHA510 Vehicle|Inactive ingredients used for masking purposes
48104744|NCT03184558|DRUG|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.
48104745|NCT06628401|BEHAVIORAL|Educational information (Control)|Information packs will be developed for participants outlining the importance of a control group in research studies to maximise compliance. Participants will receive a £10 gift voucher weekly that they can spend at selected retailers of their choosing.
48104746|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, excluding fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
48636440|NCT05257213|DRUG|Heparin solution|3 ml saline solution containing 5000 IU heparin.
47948733|NCT01558193|DIETARY_SUPPLEMENT|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
48104747|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake + Juice)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, including fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
48298348|NCT05555030|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
48298349|NCT05555030|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
48298350|NCT04670146|DIAGNOSTIC_TEST|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
48477977|NCT05612087|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
48477978|NCT00869440|DRUG|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
48477979|NCT00869440|DRUG|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
48477980|NCT05183412|DEVICE|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
48636441|NCT05257213|DRUG|Anti-adhesion barrier gel|2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
48636442|NCT00083447|DRUG|TransMID™|
48636443|NCT03820947|DEVICE|VenaSeal™ Closure System|The VenaSeal™ closure system is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
47948734|NCT01558193|DIETARY_SUPPLEMENT|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
47948735|NCT01558193|DIETARY_SUPPLEMENT|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
47948736|NCT01558193|DIETARY_SUPPLEMENT|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
47948737|NCT01892865|OTHER|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
47948738|NCT01892865|OTHER|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
47948739|NCT03081143|DRUG|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
47948740|NCT03081143|DRUG|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
47948741|NCT03081143|DRUG|Paclitaxel|80 mg/m2 on day 1, 8, 15
47948742|NCT02276365|DRUG|BI 10773|
47948743|NCT02276365|DRUG|Pioglitazone|
47948744|NCT05248620|DRUG|Amoxicillin Clavulanic 500/125mg or placebo|Prophylactic antibiotic treatment
47948745|NCT04183062|DRUG|Chemotherapy (gemcitabine & docetaxel) plus BIO-11006|"BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes.~GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8."
48104748|NCT06443060|BEHAVIORAL|Virtual Reality Group|Before starting the Prick procedure, the child in the virtual reality group, which is determined by randomisation, will be given a brief information about how the allergy test will be performed and about virtual reality. Before the Prick test (approximately 2 minutes before the Prick test), the child will start to watch a film deemed appropriate by the experts by wearing virtual reality and headphones. After the child starts watching the film, the child will be asked to extend his/her left arm and solutions will be dripped on the forearm and the puncture will be performed with a lancet. The child will continue to watch the film during the whole procedure.
47948746|NCT00365651|PROCEDURE|Youth Soccer|
48104749|NCT06443060|BEHAVIORAL|Buzzy Application Group|Before starting the prick procedure, the child in the buzzy group, which was determined by randomisation, will be given a brief information about how the allergy test will be performed and the buzzy device. The children in the buzzy experimental group will be connected to the buzzy cold and vibration device at least 8-10 cm above the area to be treated (upper part of the left arm antecubital fossa) 5-10 seconds before starting the procedure and the prick test application will be started.
47913963|NCT03351283|OTHER|Severe sodium restriction|Patients will be assigned to a diet with sodium restriction of two grams.
47948747|NCT03540030|DRUG|Gabapentin|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948748|NCT03540030|DRUG|Celecoxib|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948749|NCT03540030|DRUG|toradol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948750|NCT03540030|DRUG|acetaminophen|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948751|NCT03540030|DRUG|regional block|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948752|NCT03540030|DRUG|propofol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47913964|NCT03351283|OTHER|Moderate sodium restriction|Patients will be assigned to a diet with sodium restriction of three grams.
47948753|NCT03540030|DRUG|IV lidocaine|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948754|NCT03540030|DRUG|rocuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948755|NCT03540030|DRUG|vecuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948756|NCT03540030|DRUG|sevoflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948757|NCT03540030|DRUG|desflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
47948758|NCT05798156|DRUG|Glofitamab|Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
47948759|NCT05798156|DRUG|Rituximab|Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
47948760|NCT05798156|DRUG|Obinutuzumab|Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
47948761|NCT05798156|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
48104750|NCT06443060|OTHER|Control Group|Before starting the prick procedure, the children in the control group determined by randomisation will be given routine explanations according to the outpatient clinic procedure before starting the procedure and the prick test will be applied.
48104751|NCT06327919|DIETARY_SUPPLEMENT|Probiotic supplement|multi-strain probiotics were used in this study. Each probiotic capsule contains Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus reuteri, Lactobacillus rhamnosus, magnesium stearate and maltodextrin. 1.8 × 109 CFU / capsule. 2 capsules per day, for 12 weeks
48104752|NCT06327919|OTHER|Placebo supplement|The placebo capsule contains 300 mg of starch. 2 capsules per day, for 12 weeks
48104753|NCT02422121|DRUG|RNS60|
48104754|NCT02422121|DRUG|Placebo|
48104755|NCT00234377|DRUG|Seroquel SR|
48104756|NCT02160106|DRUG|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
48104757|NCT05292638|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
48104758|NCT05292638|DRUG|Botox®|Intramuscular injection Botox®
48104759|NCT00094809|DRUG|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
47948762|NCT02120612|OTHER|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
47948763|NCT05440188|DIAGNOSTIC_TEST|Breath Detect Platform|Use of the Breath Detect platform for respiratory health monitoring.
47948764|NCT06679920|DEVICE|Optical coherence tomography|Measurement with opctical coherence tomography of tumour and normal bladder tissue during transurethral resection of a bladder tumour (TURBT)
47948765|NCT00006223|BIOLOGICAL|recombinant flt3 ligand|
47948766|NCT02759874|DEVICE|specialized breathalyzer w face recognition technology|
47948767|NCT03949842|DRUG|Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists|A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
47948768|NCT03949842|DRUG|Fluticasone furoate/umeclidinium/vilanterol|The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
47948769|NCT02239354|COMBINATION_PRODUCT|VC-01™ Combination Product|Biologic and Device
47948770|NCT00643773|DIETARY_SUPPLEMENT|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
47948771|NCT00643773|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour
47948772|NCT03992729|DRUG|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
47948773|NCT03992729|DRUG|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
47948774|NCT06680414|OTHER|Supportive Vaccine Communication Using Motivational Interviewing|Supportive Vaccine Communication using Motivational Interviewing will be administered to the pregnant mothers in the experimental group by the researcher. The training will take place in 3-part and 6-sessions, one week apart, and each session will last approximately 40 minutes. The training will be carried out as group training with 3-5 people. Data collection forms will be applied before and after the program.
47948775|NCT03553927|DIETARY_SUPPLEMENT|Low Energy Diet|Caloric restriction to achieve weight loss
47948776|NCT03553927|OTHER|NHS advice on healthy eating|Advice on energy requirements as per the British Dietetic Association
47948777|NCT06345092|DRUG|Vitamin C|addition of vitamin C to IPRF
47948778|NCT06345092|OTHER|Injectable platelet rich fibrin|injection of IPRF alone
47948779|NCT01342276|BEHAVIORAL|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
47948780|NCT06175975|OTHER|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer|The effect of placing the auricle position on the measurement values and comfort in measurements made with a tympanic membrane thermometer
48104760|NCT00094809|DRUG|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
48104761|NCT02009735|DEVICE|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
47948781|NCT06122116|OTHER|Physical Therapy|The PT treatment participants receive in this study will be standard of care; that is, the PT treatment regimen will not be standardized across study participants and/or dictated by study-specific criteria. Participants will be referred to the Physical Therapy Department at the Madigan Army Medical Center (MAMC). Number of PT treatments will be documented on a follow-up Chart Review.
48104762|NCT04008797|DRUG|E7386|E7386 dosing.
48104763|NCT04008797|DRUG|Lenvatinib|Lenvatinib, capsules, orally.
47948782|NCT06122116|BIOLOGICAL|Platelet-Rich Plasma Injection|PRP injection procedures will follow current clinical recommendation and standard operating procedures. Prior to the injection, the area will be sterilely prepared and anesthetized with either ethyl chloride spray or lidocaine (limited to the cutaneous and subcutaneous layer, so as not to alter the synovial contents). Then, the participant will receive LP-PRP injection in the affected knee area under ultrasound guidance. Qualified study providers will inject 2-5cc LP-PRP using an 18-gauge 1/5-inch needle for both aspiration and subsequent injection. Study providers will select the injection portal they are most comfortable with, in order to achieve an accurate intra-articular injection. The PRP injection procedure is expected to take approximately one hour.
47948783|NCT06122116|DEVICE|Photobiomodulation Therapy|PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. PBMT will be delivered at 6 J/cm\^2 and applied in a circular pattern to the knee area.
48104764|NCT04008797|DRUG|Doxorubicin|Doxorubicin dosing.
48104765|NCT04008797|DRUG|Paclitaxel|Paclitaxel dosing.
48104766|NCT00195078|DRUG|ZD1839 (IRESSA)|
48104767|NCT00195078|DRUG|Cisplatin|
48104768|NCT00195078|PROCEDURE|Radiation Therapy|
48104769|NCT04602936|DRUG|Solriamfetol|Solriamfetol is a novel DNRI (novel dopamine and norepinephrine reuptake inhibitor) that has recently received regulatory approval for the treatment of excessive daytime sleepiness in individuals with narcolepsy or obstructive sleep apnea.
48104770|NCT04602936|DRUG|Placebo|"A placebo is a substance or treatment which is designed to have no therapeutic value (an inactive compound, i.e. inert, often called a sugar pill)."
48298351|NCT04822922|GENETIC|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.
48298352|NCT01312428|DEVICE|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
48298353|NCT01312428|DEVICE|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
47948784|NCT04680897|BEHAVIORAL|Early restriction release|Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.
47948785|NCT04680897|BEHAVIORAL|Standard restriction recommendation|Participants will return to intercourse after 6 weeks
48104771|NCT04361253|BIOLOGICAL|High-Titer COVID-19 Convalescent Plasma (HT-CCP)|250mL HT-CCP x2 doses given sequentially.
48104772|NCT04361253|BIOLOGICAL|Standard Plasma (FFP)|250mL FFP or FP24 x2 doses given sequentially.
48104773|NCT05983484|DEVICE|Skiin Underwear|All participants enrolled will wear simultaneously the PocketECG (Standard Holter) and the Skiin Underwear Chestband (wearable textile). Each participant will wear both systems for the duration prescribed by their physician (1 to 14 days).
47948786|NCT04081324|DRUG|Lasmiditan|Administered orally
47948787|NCT04081324|DRUG|Placebo|Administered orally
47948788|NCT06680882|OTHER|Auricular Acupoint Stimulation +prucapride|The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
47948789|NCT06680882|DRUG|prucapride|was administered prucapride as a monotherapy
47948790|NCT01038193|OTHER|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
47948791|NCT03672643|DRUG|Crizotinib|receive crizotinib orally
47948792|NCT06359379|DRUG|Ropidoxuridine|Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.
48477981|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
48477982|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
48477983|NCT03018093|BIOLOGICAL|C-CAR-011|CD19-targeted chimeric antigen receptor T cells
47948798|NCT03699683|OTHER|Combined aerobic and resistance training program|
48104774|NCT06552533|OTHER|Resistance Exercises with Plyometric exercises|"We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.~Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane).After resistance training the athletes will go for plyometric exercises and will follow the following guidelines.Tubing Exercises,Plyometric Ankle Jumps Ankle Circles"
48298354|NCT05670119|OTHER|Structured Training|Structured catheter-related infection control training was prepared by using evidence-based information and receiving 10 expert opinions. This training will be given to the participants with a face-to-face PowerPoint presentation by the infection control nurse (researcher) and will also be presented as written material.
47948799|NCT06680180|DIAGNOSTIC_TEST|Viscoelastometric assessment of fibrinolysis|Viscoelastometric assessment of whole blood fibrinolysis using supplemental tissue plasminogen activator (tPA) and other agents ex vivo to influence fibrinolysis capacity.
47948800|NCT05272462|DRUG|Minoxidil|Minoxidil is an antihypertensive vasodilator medication commonly used for the treatment of high blood pressure and pattern hair loss.
47948801|NCT00895232|DRUG|Cohort I|
47948802|NCT00895232|DRUG|Cohort II|
47948803|NCT00895232|DRUG|Cohort III|
47948804|NCT06681753|OTHER|Experimental|No training will be planned for the Control Group, and their undergraduate education will be included in the study. After the study data is collected and the study is concluded, the control group will be given breastfeeding support training from the intervention group.
47948805|NCT05655052|DEVICE|Virtual Reality (VR) Group|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
47948806|NCT05655052|DEVICE|Group using distraction cards|"At the beginning of the study, the women who applied for the IUD procedure will be interviewed, and then the following procedures will be applied; Informed consent of all women will be obtained about the study.~* An introductory information form will be filled in for women in all three groups.~* While the Intervention Group 1 IUD is being applied, a nature video will be watched with Virtual Glasses.~* Distraction Cards will be shown while the Intervention Group 2 IUD is being administered.~* The Control Group will be given routine IUD application and care."
47948807|NCT01524757|DRUG|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
47948808|NCT05173597|DRUG|Follitropin delta|REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
47948809|NCT01512342|BEHAVIORAL|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
47948810|NCT01512342|BEHAVIORAL|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
48298355|NCT04714463|PROCEDURE|Implant-based breast reconstruction|All types of implant based breast reconstructions
47948811|NCT02715245|PROCEDURE|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
48636444|NCT03820947|DEVICE|Endothermal Ablation (ETA)|"ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.~Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice."
48298356|NCT04714463|PROCEDURE|Autologous breast reconstruction|All types of autologous breast reconstructions
47948812|NCT04079010|PROCEDURE|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
48104775|NCT06552533|OTHER|Resistance Exercises without Plyometric exercises|We will apply protocol for 8 weeks 24 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions. Resistive training will start in the form of manual resistive exercise for dorsiflexion, plantar flexion, eversion and inversion (manual resistance was applied for 3 to 5 seconds for ten repetitions in each cardinal plane). While controlling the time that a maximal contraction will be maintained, the therapist will assure that the targeted musculature will being maximally loaded
48104776|NCT02780947|PROCEDURE|Ventricular tachycardia substrate ablation|"Study protocol~1. Baseline programmed ventricular stimulation performed from the LV~2. High density endocardial LV mapping using CARTO® 3 System~3. Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~4. Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
48104777|NCT06321913|DRUG|IBI343 combined with IBI308|IBI343 Specifications: 100 mg/bottle Approval method: TBD Q3W intravenous infusion (IV) sintilimab Specifications: 100mg (10ml)/bottle Afghan way: 200 mg Q3W IV infusion
48636445|NCT03820947|PROCEDURE|Surgical Stripping|Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
48636446|NCT04418479|DRUG|Aspirin|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken aspirin 100 mg once daily during the study period."
48104778|NCT00001886|PROCEDURE|Real time 3-dimensional stress echocardiography|
48104779|NCT00845611|BIOLOGICAL|peptide vaccine|peptides emulsified with Montanide ISA51
48104780|NCT02054299|DRUG|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
48104781|NCT02054299|DRUG|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
48104782|NCT02054299|DRUG|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
48104783|NCT02054299|DRUG|Drug application Proguanil|Proguanil: 200mg, single oral application
48104784|NCT02054299|DRUG|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
48104785|NCT02054299|DRUG|Drug application Thiamine|Thiamine: 200mg, single oral application
48104786|NCT01535989|DRUG|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
48104787|NCT01535989|DRUG|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
48104788|NCT00434018|BEHAVIORAL|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
48104789|NCT00434018|BEHAVIORAL|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
48298357|NCT04714463|PROCEDURE|Combined methods|All types of breast reconstructions combining autologous and implant based techniques
48636447|NCT04418479|DRUG|Clopidogrel|"Randomization will be performed 1:1 between clopidogrel and aspirin monotherapy in patients who completed standard duration of dual antiplatelet therapy (DAPT) and who were at high risk for recurrent ischemic events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).~This group will be taken clopidogrel 75 mg once daily during the study period."
48636448|NCT04432584|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.
47948813|NCT04079010|DIETARY_SUPPLEMENT|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
48104790|NCT04128423|BIOLOGICAL|AMV564|AMV564 will be administered daily
48104791|NCT06269536|OTHER|HRV biofeedback|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
48104792|NCT00089258|BIOLOGICAL|beta-glucan|
48104793|NCT00089258|BIOLOGICAL|monoclonal antibody 3F8|
48636449|NCT04432584|DRUG|Eculizumab|Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
48636450|NCT04197505|BEHAVIORAL|FLIR E95 camera|Video will be recorded during the thermal reading for later computer analysis. The following variables will be analyzed: (1) the difference between the mean temperature between the injured and healthy extremities, (2) the difference between the maximum temperatures of both the injured and healthy extremities (ΔTmax), and (3) the difference between the area covered by each isotherm in both the injured and uninjured extremities (Δpix). FLIR software tools and MATLAB software will be used for the analysis.
48636451|NCT06121219|DEVICE|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
48636452|NCT03098407|DRUG|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
48636453|NCT03098407|DRUG|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
48636454|NCT06119412|OTHER|blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.|Each participant will have their blood pressure measured with two different techniques.
48636455|NCT02080130|DIETARY_SUPPLEMENT|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
48104794|NCT00089258|BIOLOGICAL|sargramostim|
48104795|NCT00089258|DRUG|isotretinoin|
48104796|NCT04868799|BIOLOGICAL|Mass spectrometry|Characterization of the proteomic and phosphoproteomic landscape using mass spectrometry
48104797|NCT02321306|DRUG|LUM001|LUM001 administered orally once each day.
48104798|NCT03478501|BEHAVIORAL|Decision Aid|This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
48104799|NCT06252727|DRUG|Aminolevulinic Acid|Given PO
48104800|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
48104801|NCT01360840|DRUG|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
48104802|NCT01360840|OTHER|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
48104803|NCT01360840|OTHER|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
48104804|NCT01514903|DRUG|HIP0908|SINGLE DOSE , CROSS OVER
48104805|NCT01514903|DRUG|viagra|single dose, cross over
48104806|NCT00695006|OTHER|Sham Traction|Traction \<5lbs
48104807|NCT00695006|OTHER|Traction|Standard supine intermittent traction
48104808|NCT05950113|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48104809|NCT05950113|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48104810|NCT05950113|PROCEDURE|Computed Tomography|Undergo PET/CT
48104811|NCT05950113|DRUG|Cyclophosphamide|Receive IV
48104812|NCT05950113|PROCEDURE|Echocardiography|Undergo ECHO
48104813|NCT05950113|DRUG|Fludarabine|Receive IV
48636456|NCT02080130|DIETARY_SUPPLEMENT|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
48636457|NCT02080130|OTHER|Placebo|Placebo
47948814|NCT04079010|DIETARY_SUPPLEMENT|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
48104814|NCT05950113|OTHER|Fludeoxyglucose F-18|Receive IV
48477984|NCT02369718|OTHER|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
48477985|NCT02369718|OTHER|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR\*2 coding strategies\*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
48477986|NCT01712815|OTHER|laboratory biomarker analysis|Correlative studies
48477987|NCT01712815|OTHER|pharmacological study|Correlative studies
48477988|NCT01712815|OTHER|questionnaire administration|Ancillary studies
48477989|NCT01712815|RADIATION|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
48477990|NCT01712815|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
48477991|NCT06256835|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48477992|NCT06256835|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
48477993|NCT04437888|DRUG|Ketamine|Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
48477994|NCT02212340|DRUG|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
48477995|NCT02212340|DRUG|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
48477996|NCT01038037|DRUG|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
48477997|NCT01038037|DRUG|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
48477998|NCT01038037|DRUG|panitumumab|i.v. day 1: 9 mg/kg q3w
48477999|NCT04554095|OTHER|Clinical data collection|Respiratory parameters, analytic values, lung ultrasound and echocardiography
48478000|NCT04489186|DEVICE|Wearable device|Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
48478001|NCT02371993|DIETARY_SUPPLEMENT|Choline|
48478002|NCT02371993|OTHER|Placebo|
48478003|NCT05237128|BEHAVIORAL|Very low-carbohydrate diet|"Participants in this arm will be taught to manage their type 2 diabetes using a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
48478004|NCT05237128|BEHAVIORAL|Moderate-carbohydrate plate-method diet|"Participants in this arm will be taught to manage their type 2 diabetes using a plate-method approach. This diet involves eating different categories of foods based on the proportions of a plate, balancing proteins, vegetables, fruits, starches, and fats.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month."
48478005|NCT00203541|DEVICE|TELFA™ A.M.D. Island dressing|
48104815|NCT05950113|OTHER|Immunotherapy|Receive CART-BCMA/CS1 cells IV
48104816|NCT05950113|PROCEDURE|Leukapheresis|Undergo leukapheresis
48636458|NCT06550453|DRUG|Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)|"Pabolizumab is an lgG4 subclass monoclonal antibody humanized against PD-l molecules thatblocks the immune escape mechanism of cancer cells by inhibiting the PD-l receptor oflymphocytes, thereby allowing the immune system to destroy them.~In the single-arm study, all enrolled patients received a combination of chemotherapy and immunotherapy, as outlined below:~Pembrolizumab:~Day 1：Pembrolizumab injection 200mg was administered once and repeated every 21 days, expected to last 2-4 cycles. Two vials (200 mg) of pembrolizumab injection should be diluted into 100-200 mL of saline, and the infusion time should be more than 30 minutes.~Chemotherapy (CapeOX regimen):~Day 2: Bevacizumab (7.5 mg/kg) + Oxaliplatin (135 mg/m2) + Capecitabine (1 g/m2, did, d1-d14). Treatment repeated every 3 weeks (q3w) until disease progression or intolerable toxicity."
48636459|NCT03268161|DIAGNOSTIC_TEST|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
48636460|NCT05226689|DEVICE|POROUS TIBIA BASEPLATE W/ JRNY LOCK|Fixed-bearing POROUS TIBIA BASEPLATE W/ JRNY LOCK and a Legion cruciate-retaining High-Flex or Deep-dish XLPE tibial insert
48636461|NCT05358938|OTHER|Exercise|30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
48636462|NCT05358938|DRUG|Checkpoint Blockade, Immune|Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
48636463|NCT04865978|DRUG|Apixaban|Patients randomized to apixaban will be started on a dose of 5 mg BID.
48636464|NCT04865978|DRUG|Warfarin|Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
48636465|NCT04865978|DEVICE|LVAD implant|Subjects will undergo HeartMate 3 LVAD implant prior to randomization
48636466|NCT04465305|PROCEDURE|entraped treatment|patients with tarlov cysts treated by entraped and plasty nerve root
48636467|NCT04465305|PROCEDURE|plasty treatment|patients with tarlov cysts treated by plasty nerve root
48636468|NCT06572228|DRUG|dupilumab|Administered by subcutaneous (SC) injection
48636469|NCT06572228|DRUG|Matching Placebo|Administered by SC injection
48636470|NCT06572228|DRUG|ICS/LABA|Administered at a blinded doses
48636471|NCT01289535|PROCEDURE|Blood sample|Blood sample of 7 ml
48636472|NCT04010253|DEVICE|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
48636473|NCT04010253|OTHER|Autogenic drainage|Manual aiway clearance by autogenic drainage
48637453|NCT06549127|DEVICE|Soft Wearable Robot|This study aims to enroll 20 participants who will receive assistance in flexion and extension of the knee and hip during overground walking adaptation training. Following the initial assessment, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered hip assistive device over two weeks. After completing these sessions, Post-intervention Assessment 1 will be conducted. Then, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered knee assistive device over two weeks, followed by Post-intervention Assessment 2. Each participant will have a total of nine visits, including three functional assessments and six adaptation training sessions. The first visit will involve scheduling subsequent visits. The familiarization process will occur two to three times per week, adjustable for participants' convenience, with each set of three visits completed within three weeks.
48104817|NCT05950113|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48104818|NCT05950113|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48104819|NCT00319085|PROCEDURE|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
48104820|NCT05794373|PROCEDURE|Standard physiotherapy for low back pain in a municipality setting|Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
48637454|NCT02221297|DIETARY_SUPPLEMENT|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
48104821|NCT03061513|DRUG|Ubiquinol|Ubiquinol caplets 600mg/day
48104822|NCT03061513|DIETARY_SUPPLEMENT|Placebo|placebo
48637455|NCT06168799|DRUG|Ilofotase alfa|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
48637456|NCT06168799|DRUG|Placebo|After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)
48637457|NCT06172049|OTHER|treatment|the actual treatment CRC patients have reveived
48637458|NCT03112369|BEHAVIORAL|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
48104823|NCT04366882|PROCEDURE|CT-scan with minimal invasive autopsy|CT-guided biopsies will be performed directly following the diagnostic CT-scan. Biopsies will be taken from heart, liver, lungs, spleen, kidneys and abdominal fat according to a standard operation procedure. Biopsies will be taken for further histological examination and storage in the biobank. Of the lung, additional samples will be taken for microbiological examination. Additional samples will be taken in case of (focal) abnormalities on CT-imaging. In case of pleural, cardiac or abdominal fluid, this will be aspirated for further cytological, biochemical and microbiological examination. Finally, 15 cc blood will be drawn from the heart.
48104824|NCT06001372|DRUG|Ketamine|"Ketamine, 0.5-1.2mg/kg, administered intramuscularly~* Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~* Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~* Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)"
47948815|NCT02647840|BEHAVIORAL|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
47948816|NCT02488850|PROCEDURE|Surgery|
47948817|NCT02488850|RADIATION|SABR|
47948818|NCT01318642|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
47948819|NCT01318642|DRUG|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
48104825|NCT05190913|OTHER|Instrumental perineal massage|In the active phase of labor, perineal massage will be performed with an instrument twice with an interval of one hour.
47948820|NCT01318642|DRUG|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
48104826|NCT05190913|OTHER|manual perineal massage|In the active phase of labor, manual perineal massage is performed twice an hour apart.
48104827|NCT03069781|DRUG|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
47948821|NCT04423783|BEHAVIORAL|7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)|Confrontation with spiders via gamified app
47948822|NCT04423783|BEHAVIORAL|Therapist-guided one-session online exposure therapy according to (Öst, 1989)|Massed exposure therapy over the course of one single session, applied in a remote-online context
47948823|NCT04931251|BEHAVIORAL|Financial Navigation|providing financial navigation for cancer patients in NC to identify available financial assistance resources to assist patients with the cost of cancer
48104828|NCT03069781|DRUG|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
48104829|NCT00770978|DRUG|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
48104830|NCT00770978|DRUG|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
48636474|NCT02070380|DRUG|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
47948824|NCT06263478|DRUG|INCA034176|IV infusion
47948825|NCT06647069|DRUG|DR-0201|DR-0201 is a bispecific antibody
47948826|NCT02633501|DRUG|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
48478006|NCT00444236|DRUG|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
48478007|NCT00444236|DRUG|Placebo|matching placebo for active drug
48478008|NCT02644798|OTHER|Baseline-recorded data recorded|Baseline-recorded data recorded. Peripheral blood samples were drawn.
48478009|NCT03211039|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
48478010|NCT02255188|PROCEDURE|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
48636475|NCT02070380|DRUG|Dotarem|Dotarem administered at 0.1 mmol/kg
47948827|NCT02633501|DRUG|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
48104831|NCT06351280|OTHER|Standardised Physiotherapy Plan|"Single session of coached deep breathing and coughing exercises. 10 supervised slow flow deep breaths to total lung capacity with a 3-5 second end inspiratory hold completed with 2 end inspiratory sniffs. 2-3 supported coughs or huffs. Repeated for another set. Patients instructed to perform independently hourly. Assisted ambulation according to the following protocol:~* Stage 1 of 2 minutes.~* Stage 2 of 0-1 minute.~* Stage 3 of 1 - 3 minutes.~* Stage 4 of 3 - 6 minutes.~* Stage 5 of 6 - 10 minutes.~* Stage 6 of 10 - 15 minutes.~* Stage 7 \> 15 minutes. Total session time is the accumulative work time."
48104832|NCT02319785|BEHAVIORAL|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
48104833|NCT02319785|BEHAVIORAL|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
48104834|NCT02319785|BEHAVIORAL|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
47948828|NCT02633501|DEVICE|MRI|
48478011|NCT01660022|DRUG|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
47948829|NCT00092768|DRUG|MK0663, etoricoxib|
47948830|NCT00092768|DRUG|Comparator: celecoxib|
47948831|NCT06549556|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
47948832|NCT06549556|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
47948833|NCT01982578|DIETARY_SUPPLEMENT|Genistein|Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
47948834|NCT01982578|OTHER|Placebo|360 days of double blind treatment of placebo.
47948835|NCT06357312|DEVICE|hip trochanteric nail|hip trochanteric nail with and without distal interlocking screw
48636476|NCT02070380|DRUG|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
48636477|NCT03212469|DRUG|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
48478012|NCT01660022|DRUG|Placebo|Placebo
48478013|NCT01660022|DRUG|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
48104835|NCT02319785|BEHAVIORAL|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
48104836|NCT02319785|BEHAVIORAL|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
48104837|NCT02319785|BEHAVIORAL|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
48104838|NCT03255772|DIAGNOSTIC_TEST|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
48478014|NCT01660022|DRUG|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
48104839|NCT02834143|OTHER|No intervention|The is no intervention. This study is a descriptive one
48104840|NCT04658615|PROCEDURE|Non-surgical periodontal therapy|A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
48104841|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
48104842|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
48104843|NCT00939848|DRUG|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
48104844|NCT00939848|DRUG|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
48104845|NCT00939848|DRUG|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
48104846|NCT00939848|DRUG|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
48104847|NCT04431206|DRUG|Oxytocin|Oxytocin administered by IV infusion
48104848|NCT02589210|OTHER|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
48104849|NCT00819884|DRUG|AZD1656|Oral suspension
47948836|NCT03577288|BEHAVIORAL|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
48104850|NCT06368609|DIAGNOSTIC_TEST|IgG RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
48104851|NCT06368609|DIAGNOSTIC_TEST|IgG4 RDT|Sera will be thawed at room temperature; 15 µL of serum will be added to the sample pad of each dipstick, which will then be placed upright into a well containing 3 drops of buffer. The pads at the bottom of the dipstick shall then wick up the buffer to run up the nitrocellulose membrane towards the absorbent pad. The results can be read after 15-20 minutes. The presence of the control line will indicate proper execution of the test, with valid result. In case of absence of this line, the result will be considered invalid. Positive results will be defined as test with presence of both control and positive (including faint) lines; negative results will be defined as tests with presence of control line only.
48104852|NCT00345202|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
48104853|NCT04481386|DEVICE|Vitargus, BFC-1401|A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
48104854|NCT05534100|DEVICE|Biostrap EVO Wristband|Participants in both groups will wear the Biostrap wearable device
48478015|NCT01660022|DRUG|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
48478016|NCT01660022|DRUG|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
48478017|NCT01660022|DRUG|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
48478018|NCT00489749|PROCEDURE|Protected early weightbearing/Achilles tendon surgery|
48104855|NCT02987335|DRUG|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
48478019|NCT06298214|BEHAVIORAL|Her Health Program|Addition of a community health worker navigator to assist subject in navigating their health in the first year postpartum.
48478020|NCT05376137|DEVICE|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
47948837|NCT03577288|BEHAVIORAL|manipulation of the presence and size of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~Children will be exposed to only one of the two possible situations: with an avatar or without an avatar for the entire experience. Adults will be exposed to only one of the four possible situations: with standard size avatar, with giant avatar, with tiny avatar, or without avatar.~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
47948838|NCT03577288|BEHAVIORAL|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
47948839|NCT03577288|BEHAVIORAL|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
47948840|NCT06680024|PROCEDURE|Intercostal tube|Intercostal tube drainage as a first management of second stage empyema
48478021|NCT00660088|OTHER|Ketasyn|10g for 7 days, 20g for 7 or 14 days
47948841|NCT06680024|PROCEDURE|Video assisted thoracoscope|Video assisted thoracoscopic surgery as a first management for second stage empyema
47948842|NCT01634763|DRUG|LDK378|
47948843|NCT03148418|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
47948844|NCT03148418|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
47948845|NCT04931212|PROCEDURE|FETO with Smart-TO balloon|Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
47948846|NCT05196035|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 180±7 days
47948847|NCT05196035|DRUG|Placebo|Placebo to finerenone, treatment duration will be 180±7 days
47948848|NCT01453660|OTHER|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
48104856|NCT01272648|BEHAVIORAL|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
48104857|NCT04517331|PROCEDURE|Thoracic paravertebral block-single injection|The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
48104858|NCT04517331|PROCEDURE|Thoracic paravertebral block-double injection|The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
48104859|NCT03252106|PROCEDURE|Contour augmentation with implant placement|Contour augmentation with implant placement
48104860|NCT03045419|PROCEDURE|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
48104861|NCT06401018|PROCEDURE|No noise cancellation and no music playing|In this group of patients, no apparatus was used to prevent noise in the environment, and they were not exposed to any music in the environment.
48478022|NCT01845116|DRUG|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
48478023|NCT00117741|BEHAVIORAL|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
48478024|NCT00117741|BEHAVIORAL|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
48636478|NCT03212469|DRUG|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
48636479|NCT03212469|RADIATION|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses"
47948849|NCT01453660|OTHER|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, \& urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure \& heart rate, including orthostatics \& Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, \& urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
47948850|NCT06116136|DRUG|S095029|Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).
47948851|NCT06116136|DRUG|pembrolizumab 200 mg (KEYTRUDA ®)|Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
47948852|NCT06680219|DIETARY_SUPPLEMENT|Placebo|Crystal Light Raspberry Lemonade: Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily (8-12 oz of water is approximately 236-354 mL of water).
47948853|NCT06680219|DIETARY_SUPPLEMENT|Active comparator|"ACTIVE - Nu Biome (Formula #: 95001996; Batch #: EV24931): Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily.~(8-12 oz of water is approximately 236-354 mL of water)."
48104862|NCT06401018|PROCEDURE|Noise cancelled but not allowed to listen to music|In this group of patients, only noise cancelling was performed during the operation, but no music was played in the environment.
48636480|NCT00358579|DRUG|Adrenaline|1 mg
48636481|NCT00358579|DRUG|Vasopressin|40 IU
48636482|NCT04235062|DRUG|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
48636483|NCT04235062|DRUG|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
48636484|NCT00920270|DRUG|nebulized colistin|nebulized colistin 75 mg every 12 hours
48636485|NCT00920270|DRUG|antibiotics|conventional parenteral antibiotics
47948854|NCT04741607|DEVICE|Implant placement (BLX implant system, Straumann, Basel, Switzerland)|Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
47948855|NCT04741607|PROCEDURE|Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)|Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
47948856|NCT04741607|PROCEDURE|Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)|The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
48104863|NCT06401018|PROCEDURE|Music is played but noise is not cancelled|In this group of patients, ambient noise cancelling was not applied and music, which has been proven to reduce anxiety in studies, was played during surgery.
48104864|NCT04691973|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
48104865|NCT04691973|OTHER|Usual care|Usual care at ordinary healthcare provider
48104866|NCT01967407|PROCEDURE|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
48298358|NCT05372575|BIOLOGICAL|PCV13 PAC study|To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
48636486|NCT03383133|DRUG|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
48298359|NCT01558089|DRUG|etanercept|according to SmPC and clinical practice
48298360|NCT01558089|DRUG|methotrexate|according to SmPC and clinical practice
48298361|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
48636487|NCT06253728|DIETARY_SUPPLEMENT|High fiber and protein meal|In the intervention participants are assigned to eat high protein and fiber meal that differ in protein source or structure.
48636488|NCT06253728|DIETARY_SUPPLEMENT|Control|The control meal is low fiber and low protein meal.
47913965|NCT02285608|OTHER|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
47913966|NCT00654550|DRUG|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
47913967|NCT03825861|DRUG|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
47948857|NCT04932759|BEHAVIORAL|music listening|music listening during dental treatment
47913968|NCT06384118|BEHAVIORAL|Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study|Based on IMB health education theory Questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; questionnaire collection, face-to-face interview, and manual interpretation on the first day of admission; hypoglycemia knowledge promotion on the second day; Peer experience sharing on the third day; access to WeChat group and knowledge pushing on the fourth day; hypoglycemia-related lectures and practical teaching on the fifth day, face-to-face teaching and development of blood glucose management plan. Hypoglycemia knowledge contest on the day before discharge; One week, two weeks and three weeks after discharge for WeChat push or phone call; WeChat push, phone call and questionnaire.
47913969|NCT06067620|PROCEDURE|Robotic right hemicolectomy|Robotic right hemicolectomy with intracorporeal anastomosis and extraction through a C-section, using the Da Vinci Xi.
47913970|NCT06067620|PROCEDURE|Laparoscopic right hemicolectomy|Laparoscopic right hemicolectomy with extracorporeal anastomosis and extraction through midline.
48636489|NCT00711204|DRUG|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
47948859|NCT01836965|BEHAVIORAL|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
47948860|NCT00901407|DRUG|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
47948861|NCT00901407|DRUG|placebo|placebo: 1-2 tablets bid; 10 weeks
47948862|NCT00901407|DRUG|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
47948863|NCT02635763|PROCEDURE|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
47948864|NCT02635763|PROCEDURE|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
47948865|NCT05983445|DRUG|genakumab|200mg s.c.
47948866|NCT05983445|DRUG|placebo for Diprospan|i.m.
47948867|NCT05983445|DRUG|placebo for genakumab|s.c.
47948868|NCT05983445|DRUG|Diprospan|7mg i.m.
47948869|NCT03793478|DRUG|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
47948870|NCT03793478|DRUG|Fludarabine|30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
47948871|NCT03793478|DRUG|Cytarabine|"2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
47948872|NCT03793478|DRUG|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
47948873|NCT03793478|DRUG|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
47948874|NCT04357782|DRUG|L-ascorbic acid|50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses)
47948875|NCT02443116|BIOLOGICAL|NGM282|
47948876|NCT02443116|OTHER|Placebo|
47948877|NCT06681870|DRUG|ASP1893|Intravenous infusion
47948878|NCT01879514|DRUG|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
47948879|NCT01879514|DRUG|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
47948880|NCT03090841|BIOLOGICAL|Bio-specimen collected|
47948881|NCT03339687|BEHAVIORAL|Experimental Mindset Induction|"This induction of a psychological state was extensively studied in cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
48298362|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
47913971|NCT02422459|BEHAVIORAL|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
47948882|NCT06119399|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)
48478025|NCT03443817|BEHAVIORAL|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
48478026|NCT02152462|OTHER|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
48478027|NCT00088049|DRUG|Olanzapine|
47948883|NCT06119399|OTHER|Pursed Lip Breathing Exercise|Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips
47948884|NCT06119399|OTHER|Doming of the diaphragm|"* The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~* The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~* The patient is instructed to inhale, and the physiotherapist gently resists this motion.~* The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~* The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~* This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation."
47948885|NCT06119399|OTHER|Conventional exercise program for chronic neck pain|"Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks."
47948886|NCT01768767|DRUG|Placebo|
48104867|NCT05963308|BEHAVIORAL|Healthy Minds|"The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care."
48104868|NCT03844854|OTHER|Stabilization occlusal splint and manual therapy|Providing stabilization occlusal splint and manual therapy
48104869|NCT05723991|DRUG|Disitamab Vedotin and Gemcitabine|Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
48636490|NCT03087123|BEHAVIORAL|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
47948887|NCT01768767|DRUG|Ketamine|
47948888|NCT01768767|DRUG|Ketamine/Lithium|
48104870|NCT00079482|DRUG|CEP-701|
48104871|NCT00079482|DRUG|high-dose cytarabine|Chemotherapy
48104872|NCT00079482|DRUG|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
48104873|NCT06252506|DRUG|N,N-dimethyltryptamine (DMT) + harmine|DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.
48478028|NCT00088049|DRUG|Aripiprazole|
48478029|NCT05209906|DRUG|Fentanyl Buccal Soluble Film|Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
48636491|NCT05318560|DRUG|Lidocaine 2% Injectable Solution|for MPS
48104874|NCT06252506|DRUG|Placebo|Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
47948889|NCT00619138|BEHAVIORAL|individual cognitive-behavioural therapy|1 session per week for 12 weeks
48104875|NCT04259632|BEHAVIORAL|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
48104876|NCT04259632|BEHAVIORAL|Caloric Restriction (CR)|15% daily caloric deficient
48104877|NCT06000618|DEVICE|Intrapulmonary Percussive ventilator|The volunteers will undergo three minutes low frequency and high frequency intrapulmonary percussive treatments.
48104878|NCT05043987|DRUG|CPO102|Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
48104879|NCT05998096|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Caffeine-based energy drink containing 200 mg caffeine
48104880|NCT05998096|DIETARY_SUPPLEMENT|Placebo|Placebo void of all active ingredients
48104881|NCT06106087|OTHER|Mixed methods quality improvement intervention|Quality improvement training for frontline PCH staff
48104882|NCT02236559|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 \> 88%."
47948890|NCT00619138|BEHAVIORAL|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
48298363|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
48298364|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
47948891|NCT05028569|DRUG|BOTOX|Intramuscular Injection
48298365|NCT04470752|DRUG|Capsaicin 1% oral solution|Capsaicin 1.0 micrograms/ml
48298366|NCT04470752|DRUG|InOrpha Solution|glycerol based suspension vehicle
48298367|NCT05541692|BEHAVIORAL|Sleep Hygiene Toolkit|The sleep hygiene toolkit includes multiple resources including assistive devices (ie. eye masks and ear plugs), sensory-based tools (ie. aromatherapy, music, meditation, and breathing techniques), cognitive behavioral therapy (CBT) activities (ie. addressing anxiety and worry), and education and training on sleep hygiene.
48298368|NCT01950481|DRUG|LDK378|Oral LDK378 750 mg once
47948892|NCT05028569|DRUG|Placebo|Intramuscular Injection
47948893|NCT06681493|DRUG|YZJ-4729 Tartrate injection|Infusion, QD
47948894|NCT06681493|DRUG|YZJ-4729 simulated injection|Infusion, QD
47948895|NCT00753428|OTHER|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
48298369|NCT01712438|BIOLOGICAL|Human cl rhFVIII|
48298370|NCT01518192|DRUG|doxycycline|100 mg bid; 15 days
48478030|NCT03090490|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
47948896|NCT05333328|DRUG|Ovarian function suppression with endocrine treatments|"* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients."
47948897|NCT06430320|OTHER|NA- no intervention|NA- no intervention
47948898|NCT03306810|OTHER|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
48298371|NCT01518192|DRUG|cefuroxime axetil|500 mg bid; 15 days
48298372|NCT00144105|DRUG|TPV500mg/RTV200mgBID|
48298373|NCT00144105|DRUG|TPV500mg/RTV100mgBID|
48298374|NCT00144105|DRUG|LPV400mg/RTV100mgBID|
48478031|NCT03090490|OTHER|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
48478032|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
47948899|NCT06680700|DEVICE|Perin Health Patch|The Perin Health Patch (PHP) is a non-invasive, chest-worn device designed to monitor blood oxygen saturation (SpO2) and additional vital signs, including heart rate, respiratory rate, ECG, and bioimpedance (BioZ). Unlike traditional fingertip pulse oximeters, the PHP integrates multi-wavelength photoplethysmography (PPG) sensors with ECG and BioZ technology, allowing for continuous SpO2 tracking even during movement and daily activities.
47948900|NCT05310656|BEHAVIORAL|Mindfulness Based Empowerment Programme|Mindfulness Based Strengthening Program consists of 8 sessions, once a week. Each session has specific goals and objectives, and each session also has a separate theme along with its subject. The subject of the program sessions is as follows: 1st session; Getting to know, explaining the operation plan of the program, defining violence against women and its causes, 2nd session; Emotions and Perceptions, session 3; Being in the Body and Developing Self-Esteem; Session 4, Stress and Meeting Stress with Conscious Awareness; Session 5, The Case of Violence and the Meanings We Ascribe; Session 6, Aware Communication and Conflict Resolution; Session 7, Self-Care and Self-Compassion; Session 8 is Ending the Empowerment Program, Farewell, and a New Beginning. Each session is planned to last an average of 90-120 minutes. Mindfulness teachings and practices will be applied in the content of the program.
48104883|NCT02236559|DEVICE|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 \> 88%.
48104884|NCT06111690|PROCEDURE|Blood Flow Restriction Training (BFRT)|Participants will be performing low-resistance exercise with (BFRT). Intervention will start at least seven days after initial evaluation, so it does not influence measures of real-time physical activity. We will use a log to register exercise completion and to record bilateral knee pain before, during and after each intervention session
48104885|NCT02028637|OTHER|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
47948901|NCT06079658|BEHAVIORAL|Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss|This intervention seeks to investigate two different caloric restriction protocol on fat mass.
48104886|NCT00426036|DRUG|Licarbazepine|
48104887|NCT00549536|DIETARY_SUPPLEMENT|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
47948902|NCT04704973|BEHAVIORAL|Transdiagnostic short-term psychotherapy|Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
47948903|NCT06096935|OTHER|bood sample|Exome measurements
47948904|NCT01161732|PROCEDURE|Early surgery|Early surgery is performed within 2 months of randomization.
47948905|NCT02228434|BEHAVIORAL|Monitoring and Tailored prescription|
47948906|NCT02228434|BEHAVIORAL|Happy 10 program|
47948907|NCT02228434|BEHAVIORAL|Specified nutrition education|
47948908|NCT02228434|BEHAVIORAL|General Health Education|
47948909|NCT04609761|DRUG|Privigen Injectable Product (Intravenous Immunoglobulin)|Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
47948910|NCT03009500|DRUG|Bupivacaine|
48104888|NCT03720613|DRUG|Naldemedine|0.2 mg tablet once a day at any time with or without food
48298375|NCT00915967|DRUG|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
47948911|NCT03009500|DRUG|Depo-Medrol Injectable Product|
47948912|NCT03009500|OTHER|Saline (Sodium Chloride) solution|
47948913|NCT03009500|DRUG|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
47948914|NCT05340374|DRUG|Cabazitaxel|Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
47948915|NCT05340374|DRUG|177Lu-PSMA-617|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
47948916|NCT05860335|DRUG|Cisplatin/Nedaplatin, albumin paclitaxel|During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
47948917|NCT05098704|DRUG|clopidogrel treatment|75 mg daily during 24 months
48104889|NCT03720613|DRUG|Lubiprostone|0.024 mg twice a day \[adjust dose based on liver function\]
48478033|NCT04407832|DEVICE|heat probe or hemoclip|for hemostasis
48636492|NCT05318560|DRUG|Ozone|for MPS
47948918|NCT05098704|DRUG|Placebo|75 mg daily during 24 months
47948919|NCT01039844|DRUG|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
48104890|NCT03720613|DRUG|Naloxegol|25 mg tablet once a day in morning, 1 hour before or 2 hours after food
48104891|NCT03107286|DRUG|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
48104892|NCT03107286|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
48104893|NCT01020838|DRUG|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
48104894|NCT01276990|DRUG|BI 224436|Oral drinking solution
48104895|NCT01276990|DRUG|BI 224436|Oral drinking solution
48104896|NCT01276990|DRUG|BI 224436|Oral drinking solution
47948920|NCT04110587|BIOLOGICAL|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
47948921|NCT04110587|PROCEDURE|Temporomandibular Joint Arthroscopy|Lysis and Lavage
47948922|NCT04110587|DRUG|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
47948923|NCT04110587|DRUG|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
47948924|NCT04110587|DRUG|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
47948925|NCT04110587|DRUG|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
47948926|NCT04110587|OTHER|Exercise program|Home exercise program
47948927|NCT03495427|DRUG|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
47948928|NCT03495427|DIAGNOSTIC_TEST|PSMA PET|PSMA PET imaging (for men with high GC \>0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
47948929|NCT06556758|OTHER|stripping massage + conventional therapy|Stripping massage on rhomboid major and minor active trigger point in the direction of muscle fiber from origin to insertion of muscle. Frequency: 3 minutes for 3 times/week for 4 consecutive weeks. Conventional PT including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set) Frequency: 3 times/ week for 4 weeks
47948930|NCT06556758|OTHER|Conventional therapy|conventional therapy including Hot pack for 10 minutes + ischemic compression for 90 secs + CPA glides grade 3 kaltenborn mobilization on thoracic T1 to T4 (5 reps x 1 set ) Frequency : 3 times/ week for 4 weeks
47948931|NCT06676995|DEVICE|Transcranial Pulse Stimulation (TPS)|Transcranial Pulse Stimulation (TPS) is a non invasive brain stimulation technology that applies repetitive single high-pressure ultrashort shockwave pulses within the ultrasound frequency range to stimulate the brain. Subjects will receive 12 TPS sessions conducted three times weekly, for about 40 to 50 minutes/day, over four consecutive weeks.
47948932|NCT03227328|DRUG|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy|"CDK4/6 inhibitor:~* palbociclib~* ribociclib~* abemaciclib~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
48104897|NCT01276990|DRUG|BI 224436|Oral drinking solution
48104898|NCT01276990|DRUG|BI 224436|Oral drinking solution
47948933|NCT03227328|DRUG|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)|"Standard Chemotherapy regimens will be classified as:~* anthracycline + taxane,~* taxane,~* anthracycline,~* capecitabine / fluoropyrimidines,~* others.~Endocrine therapy:~* non-steroidal or steroidal AI~* fulvestrant"
47948934|NCT01085435|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
47948935|NCT00488280|BEHAVIORAL|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
47948936|NCT04439175|DRUG|Taselisib|Given PO
47948937|NCT05763576|DRUG|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
47948938|NCT05763576|OTHER|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
48104899|NCT01276990|DRUG|BI 224436|Oral drinking solution
48104900|NCT01276990|DRUG|BI 224436|Oral drinking solution
48104901|NCT01276990|DRUG|BI 224436|Oral drinking solution
48636493|NCT05318560|OTHER|stretching exercise|for MPS
47948939|NCT05763576|DRUG|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
47948940|NCT05180097|DRUG|Gemcitabine|1000mg/m2 IV, 30 mins D1, D8
47948941|NCT05180097|DRUG|Dexamethasone|40mg daily PO, D1-D4
48104902|NCT01276990|DRUG|BI 224436|Oral drinking solution
48104903|NCT01276990|DRUG|Placebo|Oral drinking solution
48104904|NCT00208767|DRUG|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
48104905|NCT00208767|DRUG|Placebo|A matched placebo pill will be given orally daily.
48104906|NCT02188758|OTHER|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
48104907|NCT05140564|BEHAVIORAL|STEADY intervention|STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
48104908|NCT00092833|DRUG|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
48104909|NCT03906734|PROCEDURE|Septal myectomy|Transaortic septal myectomy
48104910|NCT03906734|PROCEDURE|alfieri stich|Transaortic Mitral valve repair using alfieri technique
48104911|NCT03906734|PROCEDURE|Subvalvular intervention|Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
48104912|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of the energy drink (Red Bull®)|Ingestion of 250 ml of the energy drink (Red Bull®)
47948942|NCT05180097|DRUG|Cisplatin|75mg/m2 IV, 1 hour, D1
47948943|NCT05180097|DRUG|Brentuximab vedotin|1.8 mg/kg IV, 30 mins, Q21 days
47948944|NCT05180097|DRUG|Pembrolizumab|200mg IV, 30 mins, Q 21 days
47948945|NCT06064266|OTHER|plant-based mild ketogenic controlled diet|Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.
48104913|NCT05575895|DIETARY_SUPPLEMENT|Ingestion of mineral water|Ingestion of 250 ml of mineral water (Minalba®)
48104914|NCT02716649|OTHER|No intervention|
47948946|NCT06064266|OTHER|high-fat shake|The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
47948947|NCT01841177|DRUG|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
47948948|NCT01596387|DRUG|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
47948949|NCT06681090|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|The patients were administered topical corticosteroids in the form of a 0.1% triamcinolone acetonide preparation (Kenacort TM 0.1% Abbott). The medication was to be used 3 times every day for 4 weeks or until the lesion has healed, whichever occurs first. After applying the gel, the patients were instructed not to consume any fluids or food for at least 1 hour. In addition, a topical antifungal treatment consisting of Miconazole oral gel at a concentration of 2% should be applied once a day for 4 weeks
47948950|NCT06681090|DEVICE|980 nm diode laser|First group (Group A) underwent PBM therapy using a 980 nm diode laser (elexxion nano dental laser with a flat top handpiece). The therapy included 8 sessions for 4 weeks, with 2 sessions conducted per week, all administered by the same operator. The energy was evenly distributed across all the mucosal lesions and the surrounding tissues within a 0.5 cm range using a spot-technique method with little overlap.
48104915|NCT00307450|DRUG|Levetiracetam|up to 200 mg per day in two dosages per day.
48104916|NCT04245501|OTHER|Cognitive Bias Modification for Interpretations (CBM-I)|Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related. Youth receive feedback aimed to reduce interpretation bias.
48104917|NCT04245501|OTHER|Interpretation Control Condition (ICC)|"Computerized control condition in which youth see word-sentence pairs personalized to their anxiety symptoms. Youth indicate whether these are related, but are not provided with feedback that aims to train a reduction in interpretation bias."
48104918|NCT01230346|OTHER|questionnaire administration|Ancillary studies
48104919|NCT01230346|OTHER|survey administration|Ancillary studies
48104920|NCT01230346|OTHER|counseling intervention|Telephone intervention
48636494|NCT05517785|OTHER|Motor performance tests|Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance
48636495|NCT01568229|DRUG|AMG 747|Three dose levels once-daily oral administration
48636496|NCT01568229|DRUG|Placebo|Once-daily oral administration
48104921|NCT01230346|OTHER|educational intervention|Telephone intervention
48104922|NCT01198340|PROCEDURE|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
48636497|NCT04229381|PROCEDURE|Physical Therapy|Undergo physical therapy
48104923|NCT01198340|PROCEDURE|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
48104924|NCT04374708|DIAGNOSTIC_TEST|fMRI|fMRI: body morph test and neurocognitive testing
48104925|NCT00243399|DRUG|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
48104926|NCT06320119|OTHER|PDO Group|Patients in the intervention gruop with set a personalized outcome within a usual asthma review consultation
48104927|NCT03641950|DRUG|Botulinum toxin type A|Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).
48636498|NCT04229381|OTHER|Quality-of-Life Assessment|Ancillary studies
48636499|NCT04229381|OTHER|Questionnaire Administration|Ancillary studies
48636500|NCT04229381|PROCEDURE|Relaxation Therapy|Undergo progressive muscle relaxation
48636501|NCT04385836|DRUG|alpha one antitrypsin inhalation|- we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
48636502|NCT03173508|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
48636503|NCT03173508|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
48636504|NCT04755478|PROCEDURE|Thoracotomy|Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.
48636505|NCT04755478|PROCEDURE|VATS|Participants will undergo lobectomy via VATS at the discretion of the surgical team.
48636506|NCT06393426|DRUG|Chinese Herb|Chinese herbal medicine
48104928|NCT04957654|OTHER|VST with collagen plug soaked in blood|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood
48104929|NCT04957654|OTHER|VST with Allograft Demineralized bone matrix Grafton|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton
48104930|NCT04957654|OTHER|VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles|-A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
48104931|NCT03904199|DRUG|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
48104932|NCT04208802|OTHER|Use of fluoridated toothpaste|Use of fluoridated toothpaste
48104933|NCT04208802|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
48104934|NCT04208802|OTHER|Wearing of an intraoral device with resin samples|Wearing of an intraoral device with resin samples
48104935|NCT04687553|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
48104936|NCT02590042|BIOLOGICAL|ADSC-SVF-002|"ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)"
48104937|NCT01466881|DRUG|Alisertib|Given PO
48104938|NCT01466881|OTHER|Laboratory Biomarker Analysis|Correlative studies
48104939|NCT01466881|OTHER|Pharmacological Study|Correlative studies
48104940|NCT01396291|DRUG|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
48104941|NCT01396291|DRUG|placebo|asenapine-matched placebo, sublingual tablets, BID
47948951|NCT06676670|OTHER|real acupuncture|Real Acupuncture Group Main acupoints: Hegu (bilateral), Taichong (bilateral), Taiyang (unilateral), shuogu (unilateral), Fengchi (unilateral); Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning Operation method: supine position, skin routine disinfection. The special model of acupuncture and moxibustion (0.30mm × 30mm), fix the gasket on the acupoint skin with seam free tape, and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept for 30 minutes. During this period, the technique of small amplitude uniform lifting, inserting and twisting (3 times) will be performed every 10 minutes. A total of four times of needling will be performed.
48104942|NCT00032799|DRUG|natalizumab|
48104943|NCT02521116|OTHER|Dynamic Vessel Analyzer|
48104944|NCT02521116|OTHER|Oxymap T1|
48104945|NCT04364269|DRUG|VIT-2763 once a day (QD)|Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
48104946|NCT04364269|DRUG|VIT-2763 twice a day (BID)|Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
48104947|NCT04364269|DRUG|Placebo|Participants will receive hard capsules of Placebo, twice a day.
48104948|NCT04880733|PROCEDURE|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
48104949|NCT04880733|OTHER|Usual care for pain management|Patient will receive usual care for pain management.
48104950|NCT00984087|DEVICE|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
48104951|NCT01168011|DRUG|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
48104952|NCT03014050|DEVICE|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
48104953|NCT00219687|OTHER|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
48104954|NCT00219687|OTHER|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
48104955|NCT02808442|BIOLOGICAL|UCART19|
48104956|NCT05817331|OTHER|Carer Treatment Preference Myelodysplasia Questionnaire|Caregiver-reported outcome measure in MDS
48104957|NCT05817331|OTHER|Clinician Treatment Preference Myelodysplasia Questionnaire|Clinician-reported outcome measure in MDS
48104958|NCT05817331|OTHER|Patient Treatment Preference Myelodysplasia Questionnaire|Patient-reported outcome measure (PROM) in MDS
48298376|NCT00915967|DRUG|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
48478034|NCT06292975|OTHER|Supervised Vigorous intensity aerobic interval exercise|7-weeks course of aerobic and resistance exercise, delivered 2 weeks before neoadjuvant radiotherapy (NART), 1 week of NART and 4 weeks post NART.
48104959|NCT03640455|DEVICE|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
48104960|NCT03640455|DEVICE|Anodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
48636507|NCT05299970|OTHER|Fermented porridge|A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
47948952|NCT06676670|OTHER|sham acupuncture|"Sham acupuncture group Acupoint selection: select eight stimulation points at the neck and shoulder. Stimulation point 1: the midpoint of the line between the shoulder well and the giant bone (both sides); Stimulation point 2: 5 inches (both sides) of the inferior paraspinal process of the seventh thoracic vertebra; Stimulus point 3: the inferior paraspinal process of the eighth thoracic vertebra will be opened 5 inches (bilateral); Stimulus point 4: 5 inches (both sides) of the infraspinous process of the ninth thoracic vertebra.~Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning to avoid acupoints.~Operation method: supine position, skin routine disinfection. Streitberger acupuncture (0. 300×30mm). Fix the gasket on the acupoint skin with seam free tape,and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept fo"
47948953|NCT06679699|DEVICE|Trunk control exercises combined with patient education program|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces. In addition, the experimental group provided a patient education program which focuses on the importance of trunk control and benefits of trunk control exercises during the rehabilitation process. Further, caregivers and family members were also explained about the patient education program and adherence with treatment protocol during and after the interventions.
47948954|NCT06679699|DEVICE|Trunk control exercises|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces.
48478035|NCT04954859|DRUG|Bepirovirsen|No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.
48478036|NCT04954859|DRUG|Placebo|No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.
48478037|NCT04624659|DRUG|Etavopivat Tablets Low dose|200 mg once daily
48478038|NCT04624659|DRUG|Etavopivat Tablets High dose|400 mg once daily
48478039|NCT04624659|DRUG|Placebo Tablets|Placebo once daily
48478040|NCT04624659|DRUG|Etavopivat Tablets|Selected dose once daily
48478041|NCT00810862|DRUG|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
48478042|NCT00810862|OTHER|placebo base cream|apply to affected study area twice daily for 21 days
48478043|NCT05086198|BEHAVIORAL|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
48478044|NCT05086198|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
48478045|NCT04871568|PROCEDURE|Temporary central dialysis catheterization|Placement of temporary central dialysis catheter
48478046|NCT06616649|DEVICE|Spinal cord stimulator implant|Participants will receive intervention in the operating room setting
48478047|NCT04377048|DRUG|Nivolumab|"as described in NGS Arm"
48478048|NCT04377048|DRUG|Gemcitabine|"as described in NGS Arm"
48478049|NCT04377048|DRUG|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
48478050|NCT02743728|DEVICE|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
48478051|NCT02743728|DEVICE|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
48478052|NCT02743728|BEHAVIORAL|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
48478053|NCT04964674|BEHAVIORAL|Behavioral Measurement|Take measurements of behavioral performance
48636508|NCT02514746|BIOLOGICAL|Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine|0.5 mL subcutaneous injection
47948955|NCT03865771|BEHAVIORAL|Neuropsychological testing|memory, executive testing, behaviour questionnaire, visual attention,
47948956|NCT03865771|BEHAVIORAL|Neuropsychological procedure|Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
47948957|NCT03865771|OTHER|Video EEG and polysomnography|Video EEG : 10 electrodes + 3 electrodes for PSG 2h wake EEG Whole night EEG
47948958|NCT06680037|DRUG|Azercabtagene zapreleucel (azer-cel)|IV infusion
47948959|NCT03458962|GENETIC|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
47948960|NCT04858256|DRUG|Pacritinib|Pacritinib will be dosed at 200mg twice daily.
47948961|NCT03054753|BEHAVIORAL|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
47948962|NCT06609512|DRUG|Enlicitide|Oral Tablet
47948963|NCT04067752|OTHER|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
47948964|NCT04067752|OTHER|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
47948965|NCT00784641|DEVICE|Novel Bausch & Lomb daily disposable contact lenses|Lenses to be worn and replaced daily for 2 weeks.
47948966|NCT00784641|DEVICE|Bausch & Lomb SofLens daily disposable contact lenses.|Lenses to be worn and replaced daily for 2 weeks.
47948967|NCT00784641|DEVICE|Johnson and Johnson 1-Day Acuvue Moist contact lenses|Lenses to be worn and replaced daily for 2 weeks.
47948968|NCT05757869|DRUG|Milvexian|Milvexian will be administered orally.
47948969|NCT05757869|DRUG|Apixaban|Apixaban will be administered orally.
47948970|NCT05757869|DRUG|Placebo|Milvexian matching milvexian placebo will be administered orally.
47948971|NCT05757869|DRUG|Apixaban Placebo|Apixaban matching apixaban placebo will be administered orally.
47948972|NCT03425513|DIAGNOSTIC_TEST|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).
47948973|NCT03425513|OTHER|Questionnaire|Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
47948974|NCT05436275|BIOLOGICAL|CM310|300 mg every two weeks
47948975|NCT05436275|BIOLOGICAL|Placebo|once every two weeks
47948976|NCT06325371|DEVICE|Visceral aneurysm stenting|Flow diverter stenting
47948977|NCT04673448|BIOLOGICAL|Dostarlimab|Given IV
47948978|NCT04673448|DRUG|Niraparib|Given PO
47948979|NCT04673448|PROCEDURE|Biopsy|Undergo biopsy
47948980|NCT04673448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47948981|NCT04673448|PROCEDURE|Computed Tomography|Undergo CT
47948982|NCT04673448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47948983|NCT06076642|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
47948984|NCT06076642|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
47948985|NCT05755438|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
47948986|NCT05755438|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
47948987|NCT05559866|DEVICE|Apollo ESG with ERBE HAPC|Utilizing two approved devices in combination to assess durability of suturing.
47948988|NCT05559866|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label.
47948989|NCT04238546|DEVICE|sirolimus-coated balloon catheter|angioplasty with sirolimus-coated balloon catheter
47948990|NCT04238546|DEVICE|uncoated balloon catheter|angioplasty with uncoated balloon catheter
47948991|NCT04773119|PROCEDURE|PVI only|Patients in this group receive PVI only
47948992|NCT04773119|PROCEDURE|PVI with substrate ablation|Patients in this group receive PVI as well as substrate ablation
47948993|NCT04627701|DEVICE|Omega|Omega Implantation
47948994|NCT03527030|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
47948995|NCT03527030|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
47948996|NCT05857384|DRUG|IHL42X|IHL-42X consists of acetazolamide and dronabinol.
47948997|NCT05857384|DRUG|Acetazolamide 250 MG|A solid tablet containing 250 mg acetazolamide
47948998|NCT05857384|DRUG|Dronabinol 2.5 MG|A soft gelatin capsules containing 2.5mg dronabinol
48104961|NCT03640455|DEVICE|Cathodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
47948999|NCT05556798|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
48104962|NCT00001318|DRUG|interferon gamma|
48104963|NCT02962674|DEVICE|prostaFix System|
48104964|NCT02246816|DRUG|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
48104965|NCT05679830|DRUG|Cannabidiol|Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
48104966|NCT05838664|DRUG|No OAC|AF Patient who were not exposed to oral anticoagulation
48104967|NCT05838664|DRUG|VKA|AF patients who received VKA
48104968|NCT05838664|DRUG|apixaban|AF patients who received apixaban
48104969|NCT05838664|DRUG|rivaroxaban|AF patients who received rivaroxaban
48104970|NCT05838664|DRUG|dabigatran|AF patients who received dabigatran
48298377|NCT05964725|DEVICE|Receive traditional medical therapy and transcranial direct current stimulation|Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
47949000|NCT05556798|DRUG|Nirogacestat|1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
47949001|NCT05556798|DRUG|Pomalidomide|After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
47949002|NCT01035580|DRUG|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
47949003|NCT01035580|DRUG|curcumin|all patients received the drug
47949004|NCT04934475|DRUG|Isatuximab|Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
47949005|NCT04934475|PROCEDURE|ASCT|ASCT for ams B, C and D during consolidation
47949006|NCT02977130|BEHAVIORAL|Map group|diabetes shared care plus conversation map intervention
47949007|NCT02977130|BEHAVIORAL|Control group|diabetes shared care
48104971|NCT01123928|BEHAVIORAL|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
48104972|NCT02982213|OTHER|Companion Present|A companion will be present during the epidural catheter placement.
48104973|NCT04402320|DRUG|Midazolam|reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
48104974|NCT04402320|DEVICE|ventilator|reconnected to mechanical ventilation before extubation for one hour with sedation
48104976|NCT04639349|BEHAVIORAL|exercise group|the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.
48104977|NCT04639349|OTHER|control group|the control group will not be trained
48104978|NCT03036735|DEVICE|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
47949008|NCT04439344|DRUG|Binimetinib|Given PO
48104979|NCT00752817|OTHER|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
48104980|NCT00752817|OTHER|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
48104981|NCT00565708|OTHER|placebo|Placebo Comparator
48104982|NCT00565708|DRUG|Acetylsalicylic acid|Adjuvant Therapy
48104983|NCT02390557|OTHER|Survey|PDQS survey reports only
48104984|NCT02390557|OTHER|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
48104985|NCT04542369|DRUG|Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)|Inductive/neoadjuvant therapy: Tislelizumab + EP Maintenance/adjuvant therapy: Tislelizumab + EP
48104986|NCT00355914|PROCEDURE|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
47949009|NCT05055128|DRUG|X842|Patients will receive X842 tablets.
48104987|NCT04142788|DRUG|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
48104988|NCT06018194|DEVICE|ElucidVivo|Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
48104989|NCT02509780|OTHER|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
48104990|NCT00284973|BIOLOGICAL|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
48104991|NCT01413594|BEHAVIORAL|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
47949010|NCT05055128|DRUG|X842 Dummy|Patients will receive matching placebo tablets for X842.
47949011|NCT05055128|DRUG|Lansoprazole|Patients will receive Lansoprazole capsule.
47949012|NCT05055128|DRUG|Lansoprazole Dummy|Patients will receive matching placebo capsules for Lansoprazole.
47949013|NCT06680973|OTHER|Hospital-Based Resistance Training|"Participants will undergo resistance training using a weight training station and elastic equipment (elastic bands and tubes).~The intensity of the resistance training with the weight training station will be determined based on 1 Repetition Maximum (1RM). Resistance training with the weight training station will be conducted at 30-70% of the 1RM intensity and will include the following exercises: leg extension, pull down, chest press, and pec deck.~The intensity of resistance training using elastic equipment will be determined according to the individual's perceived exertion. Resistance training with elastic equipment will be performed at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard) for movements involving hip flexion, extension, abduction, and adduction.~The resistance training regimen will consist of 8-12 repetitions, 2-3 sets, with at least 1 minute of rest between sets, twice a week for 12 weeks."
48104992|NCT03461991|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
48104993|NCT03639324|DRUG|Dose combination 1-1|100 mg QD of idelalisib + 100 mg QD of venetoclax
48104994|NCT03639324|DRUG|dose combination 1-2|100 mg QD of idelalisib + 200 mg QD of venetoclax
48104995|NCT03639324|DRUG|Dose combination 1-3|100 mg BID of idelalisib + 200 mg QD of venetoclax
48478054|NCT02974491|OTHER|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
48478055|NCT06010745|DIETARY_SUPPLEMENT|Biotin and silicon|The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
48104996|NCT03639324|DRUG|dose combination 1-4|150 mg BID of idelalisib + 200 mg QD of venetoclax
48104997|NCT03639324|DRUG|Sub-Trial: Dose combination 2-1|100 mg BID of idelalisib + 100 mg QD of venetoclax
48478056|NCT06010745|DIETARY_SUPPLEMENT|Placebo|Inert ingredients only
48478057|NCT00611325|DRUG|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
48104998|NCT03639324|DRUG|Sub-Trial: Dose combination 2-2|150 mg BID of idelalisib + 100 mg QD of venetoclax
48104999|NCT06544382|OTHER|The Long COVID Rehabilitation Intervention|The intervention is a structured rehabilitation intervention with a duration of minimum 3 months comprising 4-12 individual sessions and 1-4 group-based courses delivered by physiotherapists and occupational therapists.
48105000|NCT06544382|OTHER|Usual care|A less structured rehabilitation programme comprising individual session with a few group options with patients with long COVID or mixed diagnoses.
48478058|NCT00611325|DRUG|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.
48478059|NCT01573533|BIOLOGICAL|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
48478060|NCT00435305|DRUG|Meropenem|
48478061|NCT00435305|DRUG|Vancomycin|
48478062|NCT00435305|DRUG|Linezolid|
48105001|NCT02915055|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
48105002|NCT02915055|DRUG|standard oxycodone/acetaminophen|
48105003|NCT05060562|OTHER|COVID 19 positive|Diagnosed as COVID 19 patient using Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab with suggestive symptoms.
48478063|NCT00435305|DRUG|Piperacillin/Tazobactam|
48478064|NCT00435305|DRUG|Cefepim|
48478065|NCT00435305|DRUG|Ceftazidim|
48478066|NCT01353846|OTHER|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
48105004|NCT05060562|OTHER|COVID 19 negative|Suspected COVID 19 patients who were tested negative using either Real-Time Polymerase Chain Reaction (RT-PCR) with the nasopharyngeal swab, or Rapid Antigen test of nasopharyngeal swab.
48636509|NCT06025058|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
48636510|NCT03941262|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
48105005|NCT01738802|DIETARY_SUPPLEMENT|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
48105006|NCT01738802|DRUG|Placebo|This group will take a placebo.
48105007|NCT04652076|DRUG|NP137|Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
48105008|NCT04652076|DRUG|Pembrolizumab|Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
48105009|NCT04652076|DRUG|Paclitaxel|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
48636511|NCT03941262|DRUG|Avelumab|Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
47949014|NCT06680973|OTHER|Home-Based Resistance Training|"Participants will undergo resistance training at home using elastic equipment (elastic bands and tubes). The intensity of the resistance training will be determined based on the individual's perceived exertion. The training will be conducted at an intensity of 12-14 on the Borg Scale (moderate to somewhat hard), with 8-12 repetitions, 2-3 sets, and a rest period of at least 1 minute between sets, twice a week for 12 weeks. Progression in training intensity will be achieved by increasing the weight once the perceived exertion, as measured on the Modified Borg Scale, falls below 3 (moderate) after completing 20 repetitions.~Resistance training will include exercises such as leg extension, pull down, chest press, pec deck, and movements involving hip flexion, extension, abduction, and adduction. To ensure individuals perform exercises correctly, follow-up will be conducted through online meetings every two weeks. These meetings will not be recorded."
47949015|NCT05355051|DRUG|Azacytidine|Given by Vein (IV)
47949016|NCT05355051|DRUG|Pembrolizumab|Given by Vein (IV)
47949017|NCT06680713|BEHAVIORAL|Exercise|Progressive exercise testing on a cyclo ergometer
47949018|NCT05234658|BIOLOGICAL|PHITAH|Tissue Engineered Human Artificial Skin: Fibrin-Hyaluronic Acid
47949019|NCT05234658|BIOLOGICAL|PHIT|Human artificial skin created by tissue engineering: fibrin-agarose
47949020|NCT05234658|BIOLOGICAL|Skin Autograft|Skin Autograft
47949021|NCT02415257|DRUG|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
47949022|NCT00348179|PROCEDURE|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
47949023|NCT02476422|DRUG|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
47949024|NCT02476422|DRUG|Ibuprofen|Single dose of ibuprofen 400 mg tablet
47949025|NCT02476422|DRUG|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
47949026|NCT02476422|DRUG|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
48105010|NCT04652076|DRUG|Carboplatin|Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
48105011|NCT05026034|DEVICE|non-invasive Cardiopulmonary Management (CPM) wearable device|non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
48636512|NCT03941262|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
48636513|NCT05352113|DRUG|SSRIs|SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
48636514|NCT05352113|PROCEDURE|acupuncture|This study will use the intradermal needle as an acupuncture intervention. Acupoints related to MDD will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
48636515|NCT05352113|PROCEDURE|sham acupuncture|Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to MDD-related acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
47949027|NCT05961059|BIOLOGICAL|2.5 μg InvaplexAR-Detox|2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
47949028|NCT05961059|BIOLOGICAL|10 μg InvaplexAR-Detox|10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
48105012|NCT03297749|OTHER|Observational study (no intervention)|No interventions
48105013|NCT05837468|BEHAVIORAL|BETTERapp|The BETTER app offers a 'tailor-made' lifestyle programme including the option of personal coaching for a duration of 6 weeks. The BETTER app is an automated and digitised lifestyle programme based on the previously developed and evaluated BETTER programme.
48105014|NCT02167243|BEHAVIORAL|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
48105015|NCT02167243|OTHER|Standard of care|Subjects receive standard of care
48105016|NCT03059264|OTHER|Natural history|Longitudinal disease progression
48636516|NCT05352113|DRUG|placebo|Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
48636517|NCT04849507|DEVICE|transcutaneous auricular vagus nerve stimulation|Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
48636518|NCT03167398|BIOLOGICAL|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
47949029|NCT05961059|BIOLOGICAL|0.1 μg of dmLT|0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
47949030|NCT05961059|BIOLOGICAL|Placebo|Placebo vaccination with commercially available saline solution.
48636519|NCT06125379|BEHAVIORAL|brief mindfulness|The mindfulness intervention protocol in this study is an adaptation of the Mindfulness Based Stress Reduction (MBSR) protocol with the cultural adaptation suits Indonesia population with addition of Islamic elements (i.e., a series of spiritual approaches) to improve emotional regulation, make sense of their life, be grateful and feel closer to God.
47949031|NCT01902238|PROCEDURE|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
47949032|NCT05750160|OTHER|music therapy|Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
47949033|NCT05348473|DEVICE|Alpha type|Tips of the seton will be tied as alpha-shaped.
47949034|NCT05348473|DEVICE|Beta type|Tips of the seton in this group will be overlapped and tied
47949035|NCT05348473|DEVICE|Comfort type|Knotless seton will be applied
47949036|NCT01663025|BEHAVIORAL|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
47949037|NCT03725215|BEHAVIORAL|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
47949038|NCT01440452|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
47949039|NCT01440452|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
47949040|NCT01440452|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
47949041|NCT01440452|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
47949042|NCT02806570|DEVICE|Mitral valve repair|
47949043|NCT03275792|DRUG|D5-0.9%NS|Admission for intravascular volume expansion
48636520|NCT03644446|BIOLOGICAL|Bisoprolol plasma residual concentration dosage|Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance \< 30mL/min, mild altered between 30-60mL/min, normal \> 60mL/min as estimated by the CKD-EPI formula)
48636521|NCT02526316|BIOLOGICAL|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
47949044|NCT03275792|DRUG|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
47949045|NCT05171387|DRUG|Darolutamide 600 mg twice daily|The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.
47949046|NCT05171387|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
47949047|NCT01649388|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
48105017|NCT06523855|PROCEDURE|bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation|bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
48105018|NCT02650596|DRUG|GLP-1|Liraglutide were taken daily for 3 months
48105019|NCT02650596|DRUG|Placebo|Placebo were taken daily for 3 months
47949048|NCT06218602|DRUG|Fecal Microbiota Transplantation|Given by PO
48105020|NCT00697229|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 or 3 doses
48105021|NCT00697229|BIOLOGICAL|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
48105022|NCT05401916|DRUG|Tramadol|Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
48105023|NCT05401916|DRUG|Paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
48105024|NCT05401916|DRUG|Ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
48105025|NCT05070104|DRUG|CPI-613|250-1000mg/m2 -14 day cycle
48105026|NCT05070104|DRUG|modified FFX|Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
48105027|NCT05070104|DRUG|Bevacizumab|5mg/kg IV
47949049|NCT06218602|PROCEDURE|Chemotherapy|Given by Infusion
48105028|NCT00168467|DRUG|Ramipril|
48105029|NCT04472806|DRUG|Toripalimab|"Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years."
48105030|NCT04472806|DRUG|chemotherapy in combination with Endostar|chemotherapy+ Endostar
48105031|NCT05586204|BEHAVIORAL|Eligibility reminder|Patients will receive a reminder of their eligibility for the bivalent COVID-19 booster
48105032|NCT05586204|BEHAVIORAL|Link to a narrow set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to CVS pharmacy
48105033|NCT05586204|BEHAVIORAL|Link to a broad set of vaccine venues|The reminder will encourage people to claim their dose today by booking an appointment. It will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find a wide set of local pharmacies that carry the bivalent booster).
48105034|NCT05586204|BEHAVIORAL|Doctors' recommendation and value of vaccine|The reminder will contain information about the value of the bivalent booster and doctors' recommendation to get it
48105035|NCT06031350|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optovue, Inc., Fremont, CA, USA
48105036|NCT00778739|DRUG|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
47949050|NCT06218602|PROCEDURE|CAR-T Therapy|Given by Infusion
48105037|NCT00513734|OTHER|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
48105038|NCT00513734|OTHER|Lacrilube ointment|lubricant put into eye (inferior formix)
48105039|NCT03601507|DRUG|Alpelisib|Given PO
47949051|NCT05053711|DEVICE|rTMS+rPMS_iTBS_M|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
48105040|NCT03601507|OTHER|Laboratory Biomarker Analysis|Correlative studies
48105041|NCT03601507|OTHER|Pharmacodynamic Study|Correlative studies
48105042|NCT03601507|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48105043|NCT04188028|DRUG|Dextromethorphan 5 MG|dextromethorphan 5 mg po
48105044|NCT04188028|DRUG|Paroxetine 10Mg Tablet|Paroxetine 10 mg po
48105045|NCT04188028|DRUG|Paroxetine 20Mg Tablet|Paroxetine 20 mg po
48105046|NCT03557658|DRUG|Bexagliflozin|Single oral dose of bexagliflozin tablet, 20 mg
48105047|NCT03881358|DEVICE|ortho-k lenses and thinner spectacles|Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
48105048|NCT03881358|DEVICE|newly designed ortho-k lenses|Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
48105049|NCT05126329|DRUG|amcenestrant|tablet for oral use
48298378|NCT05964725|DEVICE|Receive traditional medical therapy and sham stimulation|By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
48298379|NCT00089180|DRUG|liposomal T4N5 lotion|Given topically
48298380|NCT00089180|OTHER|placebo|Given topically
48298381|NCT00089180|OTHER|laboratory biomarker analysis|Correlative studies
48298382|NCT00480753|DRUG|Nitroglycerin|
48298383|NCT01721369|DIAGNOSTIC_TEST|Transient Loss of Consciousness (T-LOC)|
48105050|NCT00307307|DRUG|Niacin/simvastatin compared to simvastatin alone at 2 doses|
48105051|NCT03537651|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
48105052|NCT03537651|DRUG|IVA|Tablet for oral administration.
48105053|NCT06414382|OTHER|Tape-stripping|22mm tapes x 40 will be attached and removed to skin of all for limbs (tape stripping). On left arm and leg skin will also be subject to micro needling.
48105054|NCT03042520|OTHER|Observation only|
48105055|NCT00803933|DRUG|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
48105056|NCT00803933|DRUG|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
48105057|NCT05609448|PROCEDURE|MRI-guided radioembolization|Catheter placement will be performed using fluoroscopy, after which patients are transferred to the MRI scanner, where holmium microspheres are administered based on MRI dosimetry. Thereby, patients get a personalized dose administration.
48105058|NCT00516503|DRUG|baclofen/amitriptyline/ketamine gel|Applied topically
48105059|NCT00516503|OTHER|placebo|Applied topically
48105060|NCT04816825|DEVICE|Alkit eSence|Home-based rehabilitation program including computer games and supervised by a physiotherapist.
48105061|NCT04816825|OTHER|Standard rehabilitation|Standard rehabilitation program at the COPD-Center
48105062|NCT00132119|DRUG|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
48105063|NCT00132119|OTHER|Placebo|Placebo tablet
48105064|NCT04240730|PROCEDURE|Transvaginal natural orifice endoscopic surgery for endometrial cancer staging|Cases of extreme obese patients with early stage endometrial cancer who underwent v-NOTES
48636522|NCT02526316|BIOLOGICAL|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
48105065|NCT05485129|DEVICE|BIORICS|Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
47949052|NCT05053711|DEVICE|rTMS+rPMS_cTBS_M|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at median nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
48105066|NCT04593797|DIAGNOSTIC_TEST|carotid blood flow measurement with ultrasound|carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
48636523|NCT01594372|PROCEDURE|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
48636524|NCT01594372|PROCEDURE|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
47949053|NCT05053711|DEVICE|rTMS+sham rPMS_M|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at median nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
47949054|NCT05053711|DEVICE|rTMS+rPMS_iTBS_U|Repetitive peripheral magnetic stimulation (rPMS) intermittent theta-burst stimulation pattern (iTBS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times at ulnaris nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
47949055|NCT05053711|DEVICE|rTMS+rPMS_cTBS_U|Repetitive peripheral magnetic stimulation (rPMS) continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times at ulnar nerve on the affected hand(low pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a 2 s train of iTBS every 10s repeated 2 times for a total of 40 times on affected hemisphere(low pulse: 1200 pulses in total).
47949056|NCT05053711|DEVICE|rTMS+sham rPMS_U|Repetitive peripheral magnetic stimulation (rPMS) sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds at ulnar nerve on the affected hand(almost no pulse: 1200 pulses in total). Then following Repetitive transcranial magnetic stimulation (rTMS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds on affected hemisphere(almost no pulse: 1200 pulses in total).
47949057|NCT06469515|OTHER|Elective or urgent cardiac surgery|This is a longitudinal observational study to explore postoperative cognitive recovery among older persons (aged 65 or older) undergoing elective or urgent cardiac surgery via sternotomy.
47949058|NCT03098459|OTHER|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
47949059|NCT00000862|DRUG|Zidovudine|
47949060|NCT01995630|DEVICE|AMO Tecnis ZA9003|
47949061|NCT01995630|DEVICE|AMO Sensar AR40e|
47949062|NCT05986760|BEHAVIORAL|SPARK|Functional Motor training
47949063|NCT02516254|DIETARY_SUPPLEMENT|fortified bread|50 g of fortified bread + placebo daily
47949064|NCT02516254|DIETARY_SUPPLEMENT|supplement|vitamin D supplement+ plain bread
47949065|NCT02516254|DIETARY_SUPPLEMENT|placebo|plain bread+placebo
47949066|NCT03179696|BEHAVIORAL|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
48105067|NCT04673851|DEVICE|Horyzons USA|Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
47949067|NCT05413421|DRUG|ORIC-944|Oral, once daily, continuous
47949068|NCT05413421|DRUG|Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets|Oral, 1000 mg once daily, continuous
47949069|NCT05413421|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|Oral, 240 mg once daily, continuous
47949070|NCT05413421|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|Oral, 600 mg twice daily, continuous
47949071|NCT05413421|DRUG|Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets|Oral, 160 mg once daily, continuous
47949072|NCT06681584|DIAGNOSTIC_TEST|CTCA|CTCA is a non-invasive test for diagnosis of anatomic coronary stenosis. Additionally, the diagnostic performance of FFRB (derived from in house calculation) with CCTA data in patients with intermediate coronary artery disease (CAD), as compared to an invasive FFR reference standard (FFR\<=0.80)
47949073|NCT02972853|BEHAVIORAL|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
47949074|NCT00098072|PROCEDURE|Heart Catheterization|Heart Catheterization and collection of samples
47949075|NCT03318900|BIOLOGICAL|Aldesleukin|Given IV
47949076|NCT03318900|DRUG|CD8-Positive T-Lymphocyte|Given IV
47949077|NCT03318900|DRUG|Cyclophosphamide|Given IV
47949078|NCT03318900|PROCEDURE|Leukapheresis|Undergo leukapheresis
47949079|NCT03318900|BIOLOGICAL|Utomilumab|Given IV
47949080|NCT06461650|BEHAVIORAL|Nicotine cessation program|Participants will complete up to 4 sessions of a nicotine cessation program over either 12-24 weeks if receiving neoadjuvant chemotherapy prior to surgery or over 4-6 weeks if not receiving neoadjuvant chemotherapy prior to surgery. Each session will be 30-60 minutes long. Participants receiving neoadjuvant chemotherapy will also be eligible for nicotine replacement therapy; however, it must be stopped 6 weeks before surgery.
47949081|NCT05343000|BEHAVIORAL|Home-based pulmonary rehabilitation (PR) system|Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
47949082|NCT06496464|BEHAVIORAL|Intervention|"Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices."
47949083|NCT00154557|BEHAVIORAL|elite judo athletes program|
47949084|NCT06235983|DRUG|LY3537982|Administered orally.
47949085|NCT05898659|DEVICE|ABFnoS then ABFS (Cochlear implant)|Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid
47949086|NCT05898659|DEVICE|ABFS then ABFnoS (Cochlear implant)|Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
47949087|NCT01433731|DRUG|placebo for SHAPE (SHP-141)|topical gelled solution
47949088|NCT01433731|DRUG|SHAPE (SHP-141) 0.1% BID|topical gelled solution
47949089|NCT01433731|DRUG|SHAPE (SHP-141) 0.5% BID|topical gelled solution
47949090|NCT01433731|DRUG|SHAPE (SHP-141) 1.0% BID|topical gelled solution
47949091|NCT04766710|OTHER|Community-based ART delivery (CAD)|The frontline workers to implement the CAD model intervention will be people living with HIV recruited from the community who will plays roles as CAWs. The CAWs will receive intensive training, coaching, and mentoring from their respective ART clinics and implementing partners' field staff on ARV dispensing, drug storage, patient's vital sign assessment and recording, HIV education and counseling, medication adherence, referral systems, mental health, stigma and discrimination, and sexual and reproductive health of people living with HIV. To closely monitor the work of the CAWs, a respective ART clinic team, consisting of an ART counselor and a physician, will be tasked to conduct regular supervision along with the program team of the implementing partners to the community groups at least once a month in the first six months. After the six months, supervisory visits will be extended to once every two months.
47949092|NCT04766710|OTHER|ART multi-month dispensing (MMD)|The control arm participants will receive routine services under the MMD model based on standard community-based prevention, care, and support practices in Cambodia. The NCHADS has introduced MDD in all ART sites across the country. However, so far, not all ART sites currently operate the MMD. The MMD is designed to help ART service providers implement MMD for eligible patients-that is, patients whose condition is determined to be stable-which will reduce the need for frequent visits and providers' workload. Stable people living with HIV receive care and support from counselors and ARVs at the clinics every four to six months.
47949093|NCT06261060|DRUG|Sirolimus|Given by PO
48105068|NCT05061524|DRUG|YH35324|Subcutaneous injection of YH35324
48636525|NCT01395602|DRUG|Cabergoline|cabergoline 0.5 mg twice weekly
47949094|NCT05164250|DRUG|REGN5458|
47949095|NCT02095067|DEVICE|Video consultation|
47949096|NCT03326726|DRUG|2% CHG|Chlorhexidine Gluconate
47949097|NCT04070144|DEVICE|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
47949098|NCT04996823|DRUG|Ipilimumab|Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
48105069|NCT05061524|DRUG|Placebo|Subcutaneous injection of None of active ingredient
48105070|NCT05061524|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
48105071|NCT01670110|DRUG|Pasireotide LAR|Injectible, 60mg per month
48105072|NCT01670110|DRUG|Placebo|To be injected once per month
48636526|NCT01395602|OTHER|placebo|1 pill twice weekly
48105073|NCT06262919|DRUG|Tafinlar/Mekinist|There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
48105074|NCT00127647|DRUG|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
48105075|NCT00127647|DRUG|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
48105076|NCT05719818|DRUG|biphosphonates|Initiation of bisphosphonate therapy
48105077|NCT05719818|PROCEDURE|Dental care|Surgical dental care
48636527|NCT04356001|PROCEDURE|Socket preservation|'One-Piece' autologous tuberosity graft combining hard and soft tissue, harvested from the maxillary tuberosity, placed in extraction sockets.
48636528|NCT00158431|PROCEDURE|Arthroscopy plus Medical Management|Arthroscopic Surgery
48636529|NCT00158431|OTHER|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
48636530|NCT04774146|PROCEDURE|pars plana vitrectomy|silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
48636531|NCT02936271|OTHER|Vasculera|"Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment."
48636532|NCT02936271|OTHER|Placebo|
47949099|NCT04996823|DRUG|Axitinib|Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
47949100|NCT03898843|OTHER|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
47949101|NCT03898843|BIOLOGICAL|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
47949102|NCT03898843|BEHAVIORAL|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
47949103|NCT03898843|PROCEDURE|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
48105078|NCT03961152|BEHAVIORAL|PainCoach app|In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
48105079|NCT05922215|OTHER|Dynamic Balance training|The Experimental group will be given the Baseline treatment comprising of Stretching \& Static balance training (i.e. heel and toe raises, alternate rising of the left and right foot above the floor and tandem standing.) alongside Dynamic Balance training which will include (weight shifting forward, backward, sideward, and diagonally with eyes opened and eyes closed, walking toe-to-heel barefoot, side walking, reverse walking and one-foot jumps), and Progressive activity training (such as stepping over/on obstacles, throwing and catching a ball, and kicking a ball.) for 40 minutes per day, twice each week for 8 weeks.
48105080|NCT05922215|OTHER|Static balance training|The Control group will continue their regular school schedule, which will include participation in physical education activities at the same frequency. Along with that Baseline treatment including Static balance training (i.e. alternate rising of the left and right foot above the floor and tandem standing.) only, at the same intervals and for the same length of time as the intervention group, with the exception of additional Dynamic balance training and progressive activity training.
47949104|NCT03898843|OTHER|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
47949105|NCT03898843|BEHAVIORAL|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
48105081|NCT05253339|PROCEDURE|target-controlled infusion (one of the administration methods)|a method of administering cefoxitin while maintaining a constant target concentration.
48105082|NCT05253339|PROCEDURE|Standard administration method|Standard method of administering cefoxitin in the current clinical setting
48636533|NCT06253208|PROCEDURE|postoperative pain|Postoperative analgesia in laparoscopic sleeve gastrectomies: laparoscopic versus ultrasound-guided transversus abdominis plane block
48636534|NCT05540600|DRUG|Digoxin 0.25 mg|Patients will have the dose of one tablet of 0.25mg per day
48636535|NCT05540600|DRUG|Bisoprolol|Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
48636536|NCT05414747|DEVICE|ABV-1701|ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)
48636537|NCT05414747|DEVICE|SF6 Gas|SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)
48637459|NCT03112369|BEHAVIORAL|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
48105083|NCT03931044|PROCEDURE|Image-Guided Robotic Gastrectomy|The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
48105084|NCT01819038|PROCEDURE|continuous renal replacement therapy|
47949106|NCT03898843|BEHAVIORAL|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
48105085|NCT06394791|DRUG|Tislelizumab + IL-2 Combined with Capox|Tislelizumab + IL-2 Combined with Capox
48105086|NCT03086512|DEVICE|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
48105087|NCT03086512|DEVICE|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
48105088|NCT01286415|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
48105089|NCT01286415|BEHAVIORAL|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
48105090|NCT00880906|PROCEDURE|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
48105091|NCT00880906|DRUG|Steroid and Proton Pump Inhibitor Therapy|
48105092|NCT04588285|DRUG|Ambroxol|Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
48105093|NCT04588285|DRUG|Placebo|Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
47949107|NCT03898843|BIOLOGICAL|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
48105094|NCT02885350|DRUG|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
48105095|NCT02885350|DRUG|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
48105096|NCT01848548|PROCEDURE|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
48105097|NCT01076335|DRUG|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
48105098|NCT01076335|DRUG|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
48636538|NCT03307850|OTHER|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
47949108|NCT05211986|DRUG|IMM01-STEM|IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
47949109|NCT00662688|DRUG|daltéparine|
47949110|NCT00662688|DRUG|Chemotherapy at the investigator's discretion|
47949111|NCT03276988|DRUG|Period 1 GX-30, Period 2 THYROGEN®|Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
48105099|NCT03705299|DEVICE|Non-Invasive CVP vs Standard CVP|
48105100|NCT00130637|DRUG|Daclizumab|
48105101|NCT00380627|DRUG|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
48105102|NCT00137605|BIOLOGICAL|Pneumovax|
48105103|NCT00137605|BIOLOGICAL|Prevnar|
48105104|NCT05076656|DIETARY_SUPPLEMENT|Lactobacillus fermentum D3|Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.
48105105|NCT05076656|BIOLOGICAL|Fecal microbiota transplant (FMT)|Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.
48105106|NCT05076656|DRUG|Placebo|Placebo in a white, gelatin capsule (orally), with powder milk
48105107|NCT04030559|DRUG|Niraparib|Given PO
48105108|NCT04030559|DRUG|Niraparib Tosylate Monohydrate|Given PO
48105109|NCT04030559|PROCEDURE|Radical Prostatectomy|Undergo standard of care surgery
48105110|NCT01810250|DEVICE|Endurant Stent Graft|
48105111|NCT05787730|DEVICE|Transobturator tape|
48105112|NCT02773160|OTHER|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
48105113|NCT02773160|OTHER|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
48105114|NCT02773160|OTHER|Control group|Subjects will receive no feedback during the learning phase of a motor control task
48105115|NCT05027087|DIETARY_SUPPLEMENT|Blueberry gummy|Gummy bear containing blueberry powder
48105116|NCT05027087|DIETARY_SUPPLEMENT|Placebo gummy|Gummy bear with no active ingredients
48105117|NCT02528591|DEVICE|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
48105118|NCT04761237|DRUG|Goal-directed fluid therapy (GDET)|Compensatory dilatation was performed firstly and 5ml/kg crystal solution was added within 30min before induction of anesthesia.When SVV≥13%, infusion of colloidal solution 2ml/kg was performed 15-20 minutes.If the increase of SV was≥10% after the liquid impact and the SVV was still≥13%, the colloidal solution was used again for 2mL/kg and the infusion was maintained until the SVV \< 13%.The infusion was stopped when the SVV \< 10%.If the increase of SV was less than 10% or CI \< 2.0L/min/m2 after infusion, dobutamine was given intravenously to observe the change of SV. If the increase of SV was greater than 10%, dobutamine could be maintained and the above fluid regimen continued.If the increase of SV was less than 10% and MAP≥65mmHg, the infusion of liquid was stopped and replaced with 4ml/kg/h infusion for maintenance.If the increase of SV was less than 10% and MAP was less than 65mmHg, the infusion was suspended.
48105119|NCT03985917|OTHER|Singing Group Intervention Program|Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.
48105120|NCT03985917|OTHER|Alternative Social and Leisure Activities|Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
48105121|NCT00837499|BEHAVIORAL|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
48105122|NCT04590924|PROCEDURE|Hip arthroscopy|Patients that had hip arthroscopic surgery 5 years ago will be invited for 5 year follow up. The surgical procedures consisted of femoral osteoplasty, labral refixation and acetabular osteoplasty
48105123|NCT04066738|DIAGNOSTIC_TEST|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
48105124|NCT04066738|DIAGNOSTIC_TEST|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
48105125|NCT04066738|DIAGNOSTIC_TEST|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
48636539|NCT03376009|DIAGNOSTIC_TEST|Blood sample for serum and plasma biomarkers:|Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
48636540|NCT03376009|DIAGNOSTIC_TEST|Urine sample for biomarkers|Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
47949112|NCT03276988|DRUG|Period 1 THYROGEN®, Period 2 GX-30|Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
47949113|NCT02781779|DEVICE|Silverlon®|Silverlon wound dressings
47949114|NCT02781779|DEVICE|AQUACEL® AG|AQUACEL® AG wound dressings
47949115|NCT05623839|DRUG|LY3305677|Administered SC
47949116|NCT05623839|DRUG|Placebo|Administered SC
47949117|NCT00694707|DRUG|Placebo|Placebo was supplied in capsules.
47949118|NCT00694707|DRUG|Cariprazine|Cariprazine was supplied in capsules
47949119|NCT00694707|DRUG|Risperidone|Risperidone was supplied in capsules
48105126|NCT03014596|OTHER|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
48105127|NCT02642419|DRUG|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"* Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~* Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~  * Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~ * Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~ * Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
48105128|NCT02642419|DRUG|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
48105129|NCT03235349|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
48105130|NCT06227286|DEVICE|EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, initiates with 0.030MPa.
48105131|NCT06227286|DEVICE|Sham-EECP|EECP: 30-45 minutes/day, 5 days/week, 7 weeks, constant to 75 mmHg.
48636541|NCT03376009|DIAGNOSTIC_TEST|Cardiac bio-impedance (Cardioscreen Medis)|Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
48105132|NCT05379881|BEHAVIORAL|Common Elements Toolbox (COMET)|COMET is an unguided single-session intervention (SSI) combining elements of cognitive-behavioral therapy (CBT) and positive psychology.
48105133|NCT01326988|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
48105134|NCT04546997|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
47949120|NCT02409810|DRUG|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
48105135|NCT04744779|BEHAVIORAL|Office-based accommodative/vergence therapy and home reinforcement|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
48105136|NCT05356312|BIOLOGICAL|Vaccination|Personalized neoantigen vaccination
48105137|NCT06187480|PROCEDURE|total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2)|The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, systolic and diastolic function, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging.
48105138|NCT06133452|PROCEDURE|skin reducing mastectomy|"The goal of mastectomy skin reducing is to create a breast reconstruction that appears natural and aesthetically harmonious by minimizing excess skin. Excess skin can be removed in two main ways: as a conventional ellipse around the nipple-areola complex or, preferably, as part of an inverted T-shaped incision, commonly used in reduction mammoplasty. This procedure adheres to oncological principles of skin-conserving mastectomy and also incorporates a lower dermal flap, used to create a dermo-muscular pocket that reinforces the coverage of the prosthetic implant.~This technique allows complete detachment of the pectoral muscle at the bottom while ensuring full coverage of the prosthetic implant with a dermo-muscular layer. By increasing the implant pocket and providing an additional tissue layer at the bottom of the breast, this technique can reduce the risk of complications and improve aesthetic outcomes."
48105139|NCT04830722|DEVICE|Sculptra Aesthetic|One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
48298384|NCT03395171|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
47949121|NCT02933112|DEVICE|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
48478067|NCT01353846|DRUG|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
48478068|NCT06586151|BEHAVIORAL|Transcendent Health|Gender-inclusive HIV prevention program: Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one\&#39;s gender.
48105140|NCT04765163|DEVICE|Intelligent Operating Handle|Intelligent Operating Handle
48105141|NCT04087746|DRUG|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
48105142|NCT04087746|DRUG|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
48105143|NCT00604006|DRUG|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
48105144|NCT00604006|DRUG|Placebo|Placebo (lactose in capsules for blinding) once daily
48105145|NCT00789919|PROCEDURE|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
48298385|NCT01319929|DRUG|LY2828360|Administered orally
48298386|NCT01319929|DRUG|Placebo|Administered orally
48298387|NCT01748448|DRUG|Vitamin D|"* prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening"
48298388|NCT01748448|DRUG|arachides oleum raffinatum|
48298389|NCT02385032|DRUG|Ursodiol|
48298390|NCT02385032|DRUG|URSO Forte|
48298391|NCT00467909|BEHAVIORAL|micronutrients|
48478069|NCT06586151|BEHAVIORAL|Text Messaging with Information|Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
48636542|NCT03376009|DIAGNOSTIC_TEST|Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)|"Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes \~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort."
48105146|NCT04548011|OTHER|Acupuncture|The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
48105147|NCT00202748|BEHAVIORAL|Increase in activity to control weight|
48105148|NCT00202748|BEHAVIORAL|Increase in activity to control weight.|
48105149|NCT04519450|DEVICE|Mindray TE7 ultrasound machine|The study was performed using a Mindray TE7 ultrasound machine with the depth of the linear probe at 70 mm and gain of 90 dB; settings remained unchanged during the study. Measurements of the right m. sternocleidomastoideus, the right m. trapezius, and the right upper leg were taken, with the final value being the average of three measurements for each. The probe was set at the musculoskeletal ultrasound setting.
48105150|NCT03231436|DRUG|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
48105151|NCT03231436|DRUG|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
48105152|NCT04768920|BEHAVIORAL|MI-CBT Teletx|"Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 \~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)"
48105153|NCT02168335|OTHER|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
48478070|NCT00000202|DRUG|Buprenorphine|
48478071|NCT05659134|OTHER|Alfredson protocol|Alfredson eccentric therapeutical protocol.
48478072|NCT05659134|OTHER|Silbernagel protocol|Silbernagel concentric-eccentric protocol.
48478073|NCT04782752|RADIATION|Radiation: Varying Doses of RT|3+3 radiation dose escalation model to see the maximum tolerated dose
48478074|NCT04233138|OTHER|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
48478075|NCT05752292|BEHAVIORAL|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
48478076|NCT05752292|BEHAVIORAL|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
48105154|NCT02168335|OTHER|Sea salt|Unmedicated sea salt
48478077|NCT05752292|BEHAVIORAL|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
48478078|NCT05752292|BEHAVIORAL|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
48478079|NCT05752292|BEHAVIORAL|Action planning (AP)|Interactive prompts to problem solve challenges
48478080|NCT02555319|DEVICE|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
48478081|NCT03776734|OTHER|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
48636543|NCT03376009|DIAGNOSTIC_TEST|Optical Coherence Tomography (Spectralis OCT)|"OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes."
48636544|NCT03376009|DIAGNOSTIC_TEST|Arterial Spin Labelling Magnetic Resonance Imaging|"Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~* We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR\<60ml/min/1.73m2)~* ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period."
48105155|NCT00666939|DRUG|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
48105156|NCT00666939|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
48105157|NCT00666939|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime
48105158|NCT00730002|PROCEDURE|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
48636545|NCT02143778|DEVICE|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
48636546|NCT00276380|DRUG|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
48105159|NCT00730002|PROCEDURE|Magnetic resonance imaging|MR spectroscopy
48105160|NCT00730002|PROCEDURE|MRA|MRA of the brain
48636547|NCT00276380|DRUG|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
48636548|NCT00276380|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
48636549|NCT03269786|DIAGNOSTIC_TEST|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
48636550|NCT03269786|DEVICE|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
48636551|NCT06500468|DEVICE|PillSense System|"The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display. The PillSense Capsule is a minimally invasive, single use medical device designed to detect the presence of bleeding in the upper digestive tract, to aid with patient care. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule within 10 minutes. The PillSense Receiver interprets the data and displays a result message Blood detected or No blood detected."
48636552|NCT02123511|DRUG|acetylcysteine|Oral rinse
48636553|NCT02123511|OTHER|placebo|Oral rinse
48105161|NCT00730002|PROCEDURE|MRA|
48105162|NCT00730002|PROCEDURE|diffusion Imaging|MRA of the Brain
48105163|NCT00730002|PROCEDURE|perfusion imaging.|MRA of the brain
48105164|NCT01977612|DEVICE|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
48105165|NCT01977612|DEVICE|Stainless steel staples|Skin closure using stainless steel staples.
48105166|NCT03834753|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
48636554|NCT02123511|OTHER|quality-of-life assessment|Ancillary studies
48105167|NCT03834753|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
48105168|NCT02971930|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
48105169|NCT04408287|OTHER|WebEx Physical Activity Program|The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
48105170|NCT03128658|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
48478082|NCT02445287|RADIATION|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
48478083|NCT06164275|PROCEDURE|Biopsy|Undergo tumor biopsy
48636555|NCT02123511|OTHER|questionnaire administration|Ancillary studies
48636556|NCT04993768|DRUG|TPN-101, 100 mg/day|100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
48636557|NCT04993768|DRUG|TPN-101, 200 mg/day|200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
48636558|NCT04993768|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
48105171|NCT03128658|DIAGNOSTIC_TEST|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
48105172|NCT02596035|DRUG|Nivolumab|
48105173|NCT05125367|PROCEDURE|coronary stent implantation|coronary stent implantation using everolimus-eluting balloon expandable stents
48105174|NCT05125367|PROCEDURE|bypass grafting|coronary artery bypass graft
48105175|NCT00344019|DRUG|Placebo Oral Tablet|placebo pre-PCI for ACS
48105176|NCT00344019|DRUG|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
48105177|NCT00344019|OTHER|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
48105178|NCT04243213|OTHER|Vibration Plate|Vibration at 15° tilt, which means the patients partly use their own body weight (resistive vibration exercise).
48105179|NCT04243213|OTHER|Tilt at 15°|To compare if a possible effect derives from the vibration or the tilting only, a second group was added who will only receive 10 min of 15° tilt without the vibration.
48636559|NCT04993768|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
48636560|NCT05785000|OTHER|Physical exercise programme as an add-on|Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation
48636561|NCT05785000|OTHER|Control patients receiving usual care|No exercise intervention
48636562|NCT04841876|OTHER|rugby matches|standard rugby-7s match
48636563|NCT01190371|DRUG|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
48636564|NCT05381636|PROCEDURE|Esophageal arterial infusion chemotherapy|Percutaneous femoral artery puncture was performed to search for feeding arterial vessels corresponding to the lesion, and chemotherapeutic drugs were directly injected into the tumor vessels via targeted blood vessels.
48636565|NCT05381636|DRUG|Systemic intravenous chemotherapy|Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle
48636566|NCT04642066|OTHER|Cold water immersion|Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
48636567|NCT04642066|OTHER|No cold water immersion|People without cold water immersion
47949124|NCT06651437|OTHER|Experimental dietary educational intervention|At the end of the baseline examination, the Experimental group received a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content. In addition, written information was provided. All participants will be clinically followed every month, with potential titration of the antihypertensive therapy. After 3 months of follow-up, the baseline measurements will be carried out again. During the entire study period, subjects will be asked to maintain their lifestyle and report using additional medications.
47949125|NCT00258284|DRUG|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
47949126|NCT00258284|DRUG|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
47949127|NCT04441671|DRUG|Disodium Pyrophosphate|Absorption trial
47949128|NCT06681662|DRUG|Ephedrine Hydrochloride 30 mg/ml|0.15 mg/kg during induction.
48105180|NCT04243213|OTHER|Standard hospital mobilization|early mobilization of patients 24h post surgery, done routinely, and physiotherapy this is done routinely in all patients
48105181|NCT03650322|BEHAVIORAL|Yoga|12 weeks, total of 150 minutes of exercise per week.
48105182|NCT03650322|BEHAVIORAL|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
48105183|NCT03650322|BEHAVIORAL|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
48478084|NCT06164275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48478085|NCT06164275|PROCEDURE|Computed Tomography|Undergo CT scan
48478086|NCT06164275|DRUG|Dacarbazine|Given IV
48478087|NCT06164275|DRUG|Doxorubicin|Given IV
48478088|NCT06164275|PROCEDURE|Echocardiography|Undergo echocardiography
48478089|NCT06164275|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48478090|NCT06164275|BIOLOGICAL|Pembrolizumab|Given IV
48478091|NCT06164275|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48478092|NCT06164275|DRUG|Vinblastine|Given IV
47949129|NCT06681662|DRUG|Saline (NaCl 0,9 %) (placebo)|1 ml during induction.
47949130|NCT00312182|DRUG|Nelfinavir|
48105184|NCT02678624|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
48105185|NCT01188629|BEHAVIORAL|Safety Training|IT intervention focuses on safety in the home.
48105186|NCT01188629|BEHAVIORAL|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
48636568|NCT02466997|DRUG|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
48636569|NCT02466997|DRUG|Placebo|
48105187|NCT06406101|OTHER|Floor|Uninterrupted 2-minute chest compressions on a manikin that has been moved from the bed to the floor in a simulated scenario of out-of-hospital cardiac arrest
48105188|NCT06406101|OTHER|Bed|Uninterrupted 2-minute chest compressions on a manikin that is laying on bed in a simulated scenario of out-of-hospital cardiac arrest
48636570|NCT04429971|OTHER|PrEP screening program|ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
48105189|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) High Dose|Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
48636571|NCT04429971|OTHER|PrEP starter pack|emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil
48636572|NCT02427672|DEVICE|Transcranial direct current stimulation|
48636573|NCT02427672|DEVICE|Sham transcranial direct current stimulation|
48636574|NCT04553536|DRUG|Esketamine, Sulfentanil or/and Remifentanil|The esketamine or the opioids will be intravenously injected or infused to the patients with propofol and one of the muscle relaxants to induce and maitain general anesthesia.
48636575|NCT02037880|PROCEDURE|Lumbar puncture|
48636576|NCT02037880|DEVICE|Magnetic Resonance Imaging (MRI) of the brain|
48636577|NCT00985192|DRUG|everolimus|
48636578|NCT00985192|OTHER|laboratory biomarker analysis|
48636579|NCT05558254|OTHER|Robert - intervention to enhance muscle strength|"Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting."
48105190|NCT03462199|DIETARY_SUPPLEMENT|Actazin (green kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
48105191|NCT03462199|DIETARY_SUPPLEMENT|Control Formula (Actazin green kiwi powder + PreticX prebiotic)|Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
48636580|NCT04792970|DRUG|Talc|All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
48105192|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) High Dose|Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
48105193|NCT03462199|DIETARY_SUPPLEMENT|Livaux (gold kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
48636581|NCT01111487|DEVICE|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
48636582|NCT03768674|OTHER|Assessment of diagnoses, functioning and health services|Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
48636583|NCT06024161|OTHER|Weight gain|≥5% weight gain
48636584|NCT06024161|OTHER|Weight loss|≥5% weight loss after arthroplasty
47949131|NCT04552925|OTHER|Rehabilitation|Exercises and rehabilitation for massive rotator cuff tears
48105194|NCT03462199|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|Participants will consume 4 capsules containing no active ingredients daily for 28-days
48105195|NCT03203356|DRUG|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
48478093|NCT00996437|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
48478094|NCT00996437|DRUG|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
48636585|NCT06024161|OTHER|Weight unchanged|\<5% weight change after arthroplasty
48636586|NCT06129682|OTHER|Self rehabilitation at home|6 week program of exercise at home of gradual intensity and duration
48636587|NCT02645162|BEHAVIORAL|Community-based Preschool|"* Preschool sessions in community-based preschool~* Run by trained community youth leaders from the same village."
48636588|NCT01534715|DRUG|IMGN529|
48636589|NCT04720833|DIETARY_SUPPLEMENT|dried plum|Dried plum
47949132|NCT05663502|PROCEDURE|Biospecimen Collection|Undergo blood and/or tumor tissue sample collection
48478095|NCT05301686|PROCEDURE|Patients with Cyclop lesion|Arthroscopy with resection of Cyclop formation
48636590|NCT04720833|DIETARY_SUPPLEMENT|Calcium and vitamin D|Calcium and vitamin D supplement
48636591|NCT02065804|DRUG|Bupivacaine|injection, once, 5 min
48636592|NCT02583477|DRUG|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
48636593|NCT02583477|DRUG|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
48105196|NCT02918786|DEVICE|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
48105197|NCT02918786|DEVICE|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
48105198|NCT06374667|PROCEDURE|Y-3 ICO injection|Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.
48105199|NCT06374667|DRUG|Y-3 intravenous injection|Patients included will be given Y-3 intravenous injection for 7 consecutive days.
48105200|NCT06374667|OTHER|Conventional treatment|standard treatment and management according to related guidelines during the entire treatment period
48105201|NCT00597103|OTHER|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
48105202|NCT00597103|OTHER|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
48105203|NCT00597103|OTHER|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
48105204|NCT03250104|OTHER|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
48105205|NCT03250104|OTHER|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
48105206|NCT00908336|DRUG|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
48105207|NCT00908336|DRUG|Erlotinib|150 mg/day po daily
48105208|NCT00943605|DEVICE|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
48105209|NCT00943605|DEVICE|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
48105210|NCT00995150|DRUG|LNG20|levonorgestrel-releasing intrauterine system for contraception
48105211|NCT00995150|DRUG|Mirena|Mirena intrauterine system
48105212|NCT04283825|BEHAVIORAL|Psychological and physical rehabilitation based humanistic care|This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
48105213|NCT06009419|OTHER|Rehabilitation|The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
48105214|NCT05753644|PROCEDURE|stellate ganglion blocks|At the level between C6 and C7, a 25-gauge needle is inserted laterally, and the needle tip is placed posterior to the carotid artery and anterior to the longus colli muscle using an in-plane approach.
48105215|NCT05753644|DRUG|Ropivacaine|5 mL of 0.5% ropivacaine injected in the plane of the right stellate ganglion
48105216|NCT05753644|DRUG|Sham treatment|5 mL of saline injected in the plane of the right stellate ganglion
48105217|NCT00109967|BIOLOGICAL|rituximab|375 mg/m\^2 Given IV
48105218|NCT00109967|DRUG|temsirolimus|25 mg given IV
48105219|NCT00961142|DRUG|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
48105220|NCT00466414|DEVICE|Polycaprolactone Scaffold|
48105221|NCT00957229|DRUG|GDC-0449|capsule, 150 mg, one pill daily, 18 months
48105222|NCT03558204|PROCEDURE|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
48105223|NCT03558204|PROCEDURE|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
48105224|NCT03721432|DRUG|Pregabalin 150mg|pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia
48105225|NCT03721432|DRUG|Placebo oral capsule|Placebo oral capsule given 60 minutes prior to epidural anesthesia
48105226|NCT02881125|DRUG|Nortriptyline Hydrochloride|Given PO
48105227|NCT02881125|DRUG|Paclitaxel|Given IV
48105228|NCT02371135|GENETIC|colonic biopsies|
48105229|NCT02371135|GENETIC|questionnaires|
48105230|NCT00846313|OTHER|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
48478096|NCT02084927|BIOLOGICAL|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
48478097|NCT05432206|DRUG|Cannabis Sativa Oil|Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
48478098|NCT05432206|DRUG|Placebo|Hemp virgin seed oil
48478099|NCT05203445|DRUG|Olaparib|Olaparib 300 mg orally BID
48478100|NCT05203445|DRUG|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
48105231|NCT05735444|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
48105232|NCT02703740|DEVICE|Hyaluronic acid dermal filler with lidocaine 0.3%|injection in labial fold of a dermal filler
48105233|NCT04408274|BEHAVIORAL|Emotional Processing Training|
48105234|NCT04408274|BEHAVIORAL|Placebo Control|
48105235|NCT05315336|DRUG|L-DEP and PD-1 antibody|Doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; PD-1 antibody injection 200mg day 5; L-asparaginases 6000iu/m2 day2, day4. This regimen was repeated after 2 weeks.
48105236|NCT01830166|RADIATION|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
48105237|NCT02496793|BEHAVIORAL|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
48105238|NCT05005819|DRUG|[18F] APN-1607|Subjects will undergo PET imaging using \[18F\]APN-1607.
48105239|NCT01936753|BEHAVIORAL|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
48105240|NCT02861937|PROCEDURE|non surgical periodontal therapy|and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
48105241|NCT00559949|OTHER|Laboratory Biomarker Analysis|Correlative studies
48105242|NCT00559949|DRUG|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
48105243|NCT02533908|DRUG|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
48105244|NCT02533908|DRUG|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
48105245|NCT01122420|OTHER|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
48105246|NCT01122420|OTHER|Health Web Sites|Access to publicly available health-related web sites
48105247|NCT01899872|BEHAVIORAL|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
48105248|NCT01899872|BEHAVIORAL|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
48105249|NCT05246956|OTHER|Intradialytic exercise|Intradialytic exercise group
48105250|NCT02796976|OTHER|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
48105251|NCT01204528|DRUG|Zemplar|Vitamin D receptor activator (VDRA)
48105252|NCT02537522|DEVICE|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
48105253|NCT02537522|DEVICE|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
48105254|NCT01988233|BEHAVIORAL|BAILAMOS© Dance Program|
48105255|NCT01988233|BEHAVIORAL|Health Education Control Group|
48105256|NCT00964366|DRUG|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
48105257|NCT00964366|DRUG|Dapsone gel|Twice-daily applications of dapsone gel
48636594|NCT06567301|COMBINATION_PRODUCT|Ultrasound therapy combined with Chitosan nanoparticles gel|Gymna - Belgian
48105258|NCT00590603|DRUG|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
48105259|NCT03693742|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
47949133|NCT00161473|DRUG|prazosin|"Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks."
47949134|NCT00161473|DRUG|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
47949135|NCT03648827|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
47949136|NCT00294476|DRUG|IVIG|
47949137|NCT00294476|PROCEDURE|Biological Therapy|
47949138|NCT06414408|DRUG|Doxycycline Pill|200mg Dose
47949139|NCT00227929|PROCEDURE|Care Management|
47949140|NCT04315701|BIOLOGICAL|Cemiplimab|Given IV
47949141|NCT04315701|PROCEDURE|Resection|Undergo surgical resection
47949142|NCT06677021|BEHAVIORAL|Exercise|Physical activity promotion and engagement
47949143|NCT02297048|DIETARY_SUPPLEMENT|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
47949144|NCT06655285|OTHER|This was a retrospective study and no patient intervention was performed.|This was a retrospective study and no patient intervention was performed.
47949145|NCT05816031|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
47949146|NCT02927782|PROCEDURE|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
47949147|NCT02927782|PROCEDURE|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
47949148|NCT06051214|BIOLOGICAL|thrombogram|blood sampling every month for 12 months
47949149|NCT06561932|DEVICE|WiSE CRT System|The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
47949150|NCT05883683|OTHER|Molecular Profiling & drug testing in tumor organoids and PDXs|Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
47949151|NCT06328738|DRUG|ELVN-002|capsule
47949152|NCT06328738|DRUG|Trastuzumab|intravenous
47949153|NCT06328738|DRUG|5-Fluorouracil|intravenous
47949154|NCT06328738|DRUG|Oxaliplatin|intravenous
47949155|NCT06328738|DRUG|Capecitabine|capsule
48478101|NCT06285240|DRUG|MK-1167|1 mg and 5 mg oral capsules
48478102|NCT06285240|DRUG|Donepezil|10 mg oral tablets
47949156|NCT06328738|DRUG|Eribulin|intravenous
47949157|NCT06328738|DRUG|paclitaxel|intravenous
47949158|NCT06328738|DRUG|Leucovorin|intravenous
47949159|NCT06077448|DEVICE|MRI|imaging modality
47949160|NCT05788653|PROCEDURE|Thiele Massage|Transvaginal Massage
47949161|NCT05788653|PROCEDURE|Transverse Friction Massage|Transvaginal Massage
47949162|NCT06681831|DEVICE|DaVinci SP|robotic single-port hysterectomy (R-SPH) with DaVinci SP
47949163|NCT06501690|BEHAVIORAL|Late bedtime|Participants will go to bed 1 hour later than their habitual bedtime
47949164|NCT06501690|BEHAVIORAL|Variable bedtime|Participants will go to bed at a prescribed time that varies each day within +/-1 hour of habitual bedtime
47949165|NCT04996797|DRUG|Tulisokibart|Administered by IV infusion
47949166|NCT04996797|DEVICE|Companion Diagnostic (CDx) Testing|PRA023 CDx Genotyping Assay
47949167|NCT04996797|OTHER|Placebo|Placebo administered by IV infusion
47949168|NCT03855956|OTHER|KB174|KB174 is a novel mixture of oligosaccharides.
47949169|NCT03855956|OTHER|Maltodextrin|Maltodextrin is a commercially available easily digestible polysaccharide.
47949170|NCT06680752|BIOLOGICAL|ARD103|ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion
47949171|NCT06680752|DRUG|Cyclophosphamide|iv administration for lymphodepletion
47949172|NCT06680752|DRUG|Fludarabine|iv administration for lymphodepletion
47949173|NCT06678945|PROCEDURE|Bar-Clip attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using clip.
47949174|NCT06678945|PROCEDURE|Bar- OT Equator attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using the OT Equator.
47949175|NCT05587296|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
47949176|NCT05587296|DRUG|Placebo|Matching placebo orally once daily.
47949177|NCT01180647|DRUG|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
47949178|NCT01180647|BEHAVIORAL|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
47949179|NCT06680141|OTHER|Virtual reality glasses|control group
47949180|NCT06680843|PROCEDURE|Whole blood collection|30 mL at Day 0 with optional visits for up to 2 additional whole blood collections at least 30 days apart
47949181|NCT06672146|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47949182|NCT06672146|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
47949183|NCT06672146|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
47949184|NCT06672146|DRUG|Decitabine and Cedazuridine|Given PO
47949185|NCT06672146|DRUG|Enasidenib|Given PO
47949186|NCT06672146|DRUG|Venetoclax|Given PO
48105260|NCT03693742|OTHER|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
48478103|NCT06285240|DRUG|Placebo|MK-1167 matching placebo administered oral capsules
48478104|NCT00003242|DRUG|bryostatin 1|
48478105|NCT00003242|DRUG|cisplatin|
48478106|NCT00003242|DRUG|paclitaxel|
48105261|NCT03693742|OTHER|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
48105262|NCT05593822|PROCEDURE|primary percutaneous intervention|percutaneous catheterization through peripheral arteries to coronary arteries
48105263|NCT04472871|DEVICE|Left atrial appendage closure|The left atrial appendage (LAA) is a small, ear-shaped sac in the muscle wall of the left atrium (top left chamber of the heart). It is unclear what function, if any, the LAA performs. In patients with heart failure and atrial fibrillation, reduced left atrial appendage (LAA) emptying velocities leads to LAA thrombus formation therefor a higher rate of stroke and embolism are observed even on oral anticoagulants. FDA approved devices for left atrial appendage closure will be used under guidance of angiography and trans-esophageal echo with highly efficient and trained personnel.
48105264|NCT01080599|PROCEDURE|obturator nerve block|
48105265|NCT05576051|OTHER|patterns of use of combination therapy and monotherapy|
48105266|NCT02840994|BIOLOGICAL|CV301|
48105267|NCT02840994|BIOLOGICAL|Pembrolizumab|
47949187|NCT05581966|DIAGNOSTIC_TEST|DV-SSP Imaging|DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
47949188|NCT05996848|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide subcutaneously.
47949189|NCT05996848|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide subcutaneously.
48105268|NCT02840994|BIOLOGICAL|Nivolumab|
48105269|NCT01291004|DRUG|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
48105270|NCT01291004|DRUG|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
48105271|NCT01291004|DRUG|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
48105272|NCT04533139|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens"
48105273|NCT04265625|DEVICE|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
48105274|NCT04428320|PROCEDURE|Pelvic floor injection|Injection of 10 cc of bupivacaine
48105275|NCT02703727|BEHAVIORAL|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
48105276|NCT06141980|DRUG|DWP16001 0.3 mg|DWP16001 0.3mg, Tablets, Orally, Once daily
48105277|NCT05591001|DRUG|ketamine and dexmeditomidine combination|Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
48105278|NCT05591001|DRUG|Propofol|propofol (100 ug /kg/min) infusion
48105279|NCT02673788|OTHER|observation without intervention in this follow up study|observation without intervention in this follow up study
48105280|NCT01833507|BEHAVIORAL|Self-Exercise|Behavioral Goal Setting
48105281|NCT01833507|BEHAVIORAL|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
48105282|NCT06345534|DEVICE|Questionnaire|"Patients will be asked to complete questionnaires at different times (before, during and after radiation) to evaluate which schedule gives the fewest side effects and the best quality of life.~The basic questionnaire and questionnaire about early side effects will be completed weekly up to 6 weeks after radiotherapy. The questionnaire about late side effects will be completed: after 6 months, 1 year, 2 years, 3 years, 4 years and 5 years."
48478107|NCT02264535|DRUG|0.1mg/ml Ginkgolides Meglumine Injection|
48478108|NCT02264535|DRUG|1mg/ml Ginkgolides Meglumine Injection|
48478109|NCT02264535|DRUG|5mg/ml Ginkgolides Meglumine Injection|
48478110|NCT04679142|DRUG|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
48478111|NCT00256529|PROCEDURE|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
48478112|NCT02218307|DRUG|Mupirocin|
47949190|NCT05996848|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
48478113|NCT02218307|DRUG|Placebo|
47949191|NCT05996848|DRUG|Placebo Cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
48478114|NCT02415387|BIOLOGICAL|typhoid vaccine|Given IM
48478115|NCT02415387|OTHER|Placebo|Given IM
48478116|NCT01644487|DEVICE|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
48478117|NCT01644487|DEVICE|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
47949192|NCT04532502|DRUG|Anesthetics, Inhalation|Work environmental exposure
47949193|NCT03193190|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
48478118|NCT01357434|BEHAVIORAL|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
48478119|NCT03439631|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
48478120|NCT04703543|DEVICE|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
48478121|NCT03808870|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
48105283|NCT05708014|BEHAVIORAL|Intervention LuvHub|From day 1 to day 487 (i.e., entire 16-month duration, post baseline) of the trial, participants randomized to the intervention arm will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
48105284|NCT05708014|BEHAVIORAL|Waitlist Control LuvHub|From day 243 to day 487 (i.e., starting after 8-month assessment) of the trial, participants randomized to the waitlist control condition will have access to use the five modules as directed. The LuvHub intervention includes modules focused on topics of: HIV/STI prevention, sexual agreements, communication/decision-making skills, strengthening relationships and creating goals, and physical activity.
48636595|NCT04778709|DEVICE|Puros allograft|"Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone."
48636596|NCT00456911|BEHAVIORAL|Fat and carbohydrate controlled diet|
48636597|NCT00006135|DRUG|acyclovir|
48636598|NCT02551809|BIOLOGICAL|UB-311|Intramuscular injection
48636599|NCT02551809|DRUG|Placebo|Intramuscular injection
48636600|NCT00721890|DIETARY_SUPPLEMENT|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
48636601|NCT02842281|OTHER|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
47949194|NCT03193190|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
47949195|NCT03193190|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
47949196|NCT03193190|DRUG|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
47949197|NCT03193190|DRUG|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
47949198|NCT03193190|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
47949199|NCT03193190|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
47949200|NCT03193190|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
47949201|NCT03193190|DRUG|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
47949202|NCT03193190|DRUG|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
47949203|NCT03193190|DRUG|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
47949204|NCT03193190|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
47949205|NCT03193190|DRUG|AB928|AB928 will be administered as per the schedule specified in the respective arm.
47949206|NCT03193190|DRUG|Tiragolumab|Tiragolumab will be administered as per the schedule specified in the respective arm.
47949207|NCT03193190|DRUG|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the respective arm.
47949208|NCT03118713|DRUG|metformin|oral
47949209|NCT03118713|DRUG|ipragliflozin|oral
47949210|NCT03118713|DRUG|glimepiride|oral
47949211|NCT05683756|BEHAVIORAL|Brief Parent Behavioral Intervention|PBI administered in pediatric primary care by an embedded therapist.
47949212|NCT05683756|BEHAVIORAL|Sleep-Focused Parent Behavioral Intervention|SF-PBI administered in pediatric primary care by an embedded therapist.
47949213|NCT06044922|DEVICE|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
47949214|NCT06302543|PROCEDURE|autologous bone marrow cells injection|under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
47949215|NCT06540547|BEHAVIORAL|MomMA Intervention|Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
47949216|NCT01498835|DRUG|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
47949217|NCT05914376|BIOLOGICAL|Recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
48105285|NCT01955694|DRUG|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
48105286|NCT01955694|DRUG|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
48105287|NCT01955694|DRUG|Placebo|matching placebo
48478122|NCT04791488|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy protocol
48478123|NCT04791488|PROCEDURE|Diving simulation|Hyperbaric chamber diving simulation protocol
48478124|NCT06185972|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
48478125|NCT06185972|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
48636602|NCT02842281|OTHER|Maltodextrin|Polysaccharide produced from starch
48636603|NCT00141193|DRUG|Celecoxib|
48636604|NCT03955185|PROCEDURE|minimally invasive surgery|Laparoscopic or robotic assisted radical hysterectomy
48636605|NCT03955185|PROCEDURE|open abdominal surgery|Traditional open abdominal radical hysterectomy
48636606|NCT01775410|DEVICE|Wolverine System to perform atherectomy|
48636607|NCT02618395|DRUG|SPARC001A|
48636608|NCT02618395|DRUG|SPARC001B|
48636609|NCT02618395|DRUG|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
47949218|NCT03737604|DRUG|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
47949219|NCT03737604|DRUG|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
47949220|NCT05693766|DRUG|Capecitabine|2000 mg taken by mouth twice daily for 7 days on, 7 days off
48105288|NCT05633199|OTHER|cytoreductive surgery|Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.
48105289|NCT01189006|DRUG|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
48105290|NCT00161447|DRUG|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
48105291|NCT00161447|DRUG|Testosterone Gel|Testosterone Gel (10 g daily
48105292|NCT00161447|DRUG|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 \& month 3
48105293|NCT03087539|BIOLOGICAL|Abciximab|
48105294|NCT03087539|BIOLOGICAL|Placebo|
48105295|NCT06556134|DRUG|Intravenous Iron Sucrose|Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months
48105296|NCT06556134|DRUG|Oral Iron|One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid
48105297|NCT02355535|DRUG|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
48636610|NCT03095976|PROCEDURE|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
48636611|NCT01155310|DRUG|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
47949221|NCT05693766|OTHER|Endocrine-therapy|Endocrine therapy administered
47949222|NCT05693766|OTHER|MammoPrint ® and BluePrint assays|Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
47949223|NCT05142722|DRUG|Placebo|placebo tablet made to resemble active
48105298|NCT00095004|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
48105299|NCT00095004|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
48105300|NCT01566513|BEHAVIORAL|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
48105301|NCT01566513|BEHAVIORAL|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
48636612|NCT01155310|DRUG|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
48636613|NCT01098357|DRUG|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
47949224|NCT05142722|DRUG|Obicetrapib|10mg obicetrapib tablet
47949225|NCT06242600|DEVICE|Drainage of the bladder by indwelling Foley catheter|Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
47949226|NCT06677918|DRUG|EP395|Capsule for oral use
47949227|NCT06677918|DRUG|Placebo|Capsule for oral use
47949228|NCT04635059|DRUG|Pacritinib|Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
47949229|NCT00689078|DRUG|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
47949230|NCT00689078|DRUG|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
47949231|NCT00689078|DRUG|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
47949232|NCT00689078|DRUG|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
48105302|NCT01566513|BEHAVIORAL|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
48105303|NCT00744393|DRUG|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
48105304|NCT00744393|DRUG|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
48105305|NCT02866214|DRUG|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
48105306|NCT02866214|DRUG|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
48105307|NCT03376399|OTHER|Gastroparesis Cardinal Symptom Index Questionnaire|Patients with an established diagnosis of Diabetic Gastroparesis that are interested in a sleeve gastrectomy for weight loss will be asked to participate in the registry. Once the consent process is complete the patient will be asked to complete the Gastroparesis Cardinal Symptom Index Questionnaire prior to weight loss surgery and 30 days, 3 months, 6 months and 12 months after surgery.
48105308|NCT03419156|OTHER|Text Message Arm Intervention|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
48636614|NCT01098357|DRUG|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
48105309|NCT01000129|OTHER|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
48105310|NCT01000129|OTHER|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
48105311|NCT01094041|OTHER|Gluten free diet|A 4-week gluten free diet provided
48636615|NCT01098357|DRUG|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
48105312|NCT01094041|OTHER|Gluten rich diet|A 4-week gluten rich diet is provided
48105313|NCT06409637|DRUG|FOLFOX4 regimen|FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.
48105314|NCT06409637|DRUG|lenvatinib|Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study.
48105315|NCT01111903|DRUG|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
48478126|NCT05839145|OTHER|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
48105316|NCT01813825|OTHER|Registry|
48105317|NCT02780245|DRUG|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
48105318|NCT02780245|PROCEDURE|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
48105319|NCT06248788|DEVICE|PoC Device|PoC Device for Testing Salivary IgA
48105320|NCT05522699|BEHAVIORAL|Cough suppressive therapy|"The cough suppressive therapy based on the treatment regime Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough (PSALTI) developed by S. Chamberlain et al (Thorax. 2017 Feb;72(2):129-136)."
48105321|NCT05522699|BEHAVIORAL|General healthy lifestyle instructions|The general healthy lifestyle instructions are based on the recommendations from the The Public Health Agency of Sweden.
48478127|NCT05839145|OTHER|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
48478128|NCT05839145|OTHER|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
48478129|NCT05839145|OTHER|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
48478130|NCT05839145|DEVICE|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
48478131|NCT05839145|OTHER|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
48478132|NCT05839145|OTHER|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
48478133|NCT04158635|DRUG|Bosentan|Given PO
48478134|NCT04158635|DRUG|Gemcitabine|Given IV
48478135|NCT04158635|DRUG|Nab-paclitaxel|Given IV
48478136|NCT04158635|OTHER|Quality-of-Life Assessment|Ancillary studies
48478137|NCT04158635|OTHER|Questionnaire Administration|Ancillary studies
48478138|NCT00810173|BEHAVIORAL|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
48478139|NCT01191476|DRUG|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
48478140|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
48105322|NCT04588480|BIOLOGICAL|BNT162b2|BNT162b2 (intramuscular injection)
48105323|NCT04588480|OTHER|Placebo|Placebo (intramuscular injection)
48107166|NCT03936348|DEVICE|Exercise training program with and without FB|"Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale."
48107167|NCT01557998|BEHAVIORAL|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 \<500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
48107168|NCT01557998|DRUG|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
48107169|NCT01557998|BEHAVIORAL|Control - No intervention|
48107170|NCT03394027|DRUG|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
48107171|NCT01975311|OTHER|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
48107172|NCT01975311|OTHER|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
48107173|NCT00722670|BEHAVIORAL|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
48107174|NCT00722670|BEHAVIORAL|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
48107175|NCT01036113|DRUG|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
48107176|NCT02612818|DEVICE|Coelioscopy|
48107177|NCT02882230|DRUG|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
48107178|NCT03279718|PROCEDURE|Periodontal Treatment|Scaling and root planing
48107179|NCT02674451|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
48107180|NCT04852432|DEVICE|high flow nasal cannula|The heated air is administered at a rate of 2L/kg/min using an Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand). Inhalation oxygen concentration starts with 50%.
48107181|NCT04852432|DEVICE|nasal prong|Oxygen is administered via nasal prong
48107182|NCT00325013|DRUG|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
48107183|NCT03993613|BIOLOGICAL|human apotransferrin|Intravenous infusions
48107184|NCT05576181|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B-ALL.
48107185|NCT05576181|DRUG|Fludarabine Oral Tablet|Fludarabine is used for lymphodepletion.
48107186|NCT05576181|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
48107187|NCT05576181|DRUG|VP-16|VP-16 is used for lymphodepletion.
48107188|NCT05576181|PROCEDURE|HSCT|Hematological stem cell transplantation
48107189|NCT04915885|OTHER|Routine care|Routine contraceptive counseling and routine method availability
48107190|NCT04915885|OTHER|Package of contraceptive counseling interventions|The implementation package will be co-designed by providers and clients during the formative and research design phases
48107191|NCT04915885|OTHER|Expanded methods|Expanded range of contraceptive methods as recommended by national policies
48107192|NCT00719017|PROCEDURE|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
48478141|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
48107193|NCT00719017|RADIATION|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
48107194|NCT00719017|PROCEDURE|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
48478142|NCT01254461|DRUG|AZD1981|100 mg per oral, twice daily for 8 days
48107195|NCT03009513|DRUG|Teneligliptin+Glimepiride|
48107196|NCT00215345|DRUG|Taxotere|
48107197|NCT00215345|DRUG|Celecoxib|
48107198|NCT03780816|OTHER|Observation of provider-patient interactions and interviews|Clinical interactions between cancer patients and providers will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with providers, patients, caregivers, and other informants will take place following initial observation.
48478143|NCT01254461|DRUG|AZD1981|4x100 mg per oral, twice daily for 8 days
48107200|NCT04768361|BEHAVIORAL|Behavioral Activation without Mindfulness|"Behavioral Activation without Mindfulness includes functional analysis as key to defining out-of-session and activation strategies as central to mood change."
48478144|NCT01254461|DRUG|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
48107201|NCT04768361|BEHAVIORAL|Behavioral Activation with Mindfulness|"Behavioral Activation with Mindfulness includes functional analysis as key to defining out-of-session and activation strategies and mindfulness as central to mood change."
48107202|NCT02332369|DEVICE|Capsular Tension Ring|
47949233|NCT03036904|DRUG|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
47949234|NCT03036904|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
47949235|NCT03036904|DRUG|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
47949236|NCT03036904|DRUG|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
47949237|NCT03036904|DRUG|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
47949238|NCT03036904|DRUG|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
47949239|NCT03036904|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
47949240|NCT06323174|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
47949241|NCT06323174|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
47949242|NCT06323174|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
47949243|NCT06452732|OTHER|MFC for the determination of leukemia stem cell|MFC for the determination of leukemia stem cell
47949244|NCT04280146|BEHAVIORAL|daily energy intake|Investigate daily energy intake according to eating rate and food processing
47949245|NCT06331026|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
47949246|NCT06331026|DRUG|PEG-rhGH with present preparation (R)|A single subcutaneous injection of PEG-rhGH with present preparation
47949247|NCT06679894|PROCEDURE|Implant site preparation with osteotomes and electrified mallet|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~A pilot osteotome (100-P) was used to easily perforate the cortical plate. Subsequently, osteotomes with gradually increasing diameters were employed until the final diameter of 3.2 mm was reached.~The sequence of osteotomes and their respective diameters were as follows:~1. Osteotome 100-P: At a height of 8.5 mm, the diameter was 2.2 mm;~2. Osteotome 160: At a height of 8.5 mm, the diameter was 2.8 mm;~3. Osteotome 200: At a height of 8.5 mm, the diameter was 3.2 mm. Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
47949248|NCT06679894|PROCEDURE|Implant site preparation with osseodensification drills|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~The implant site preparation was realized using osseodensification burs at a rotation speed of 1200 rpm. The osseodensification burs sequence was as follows:~1. Initial pilot hole (rotated clockwise);~2. WT1828 bur (rotated counterclockwise),~3. WT2838 bur (rotated counterclockwise). Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
47949249|NCT06403852|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) with propofol|Three 16-min sessions in wakeful baseline, light sedation, and recovery will be conducted (Fig. 2). Light sedation will be achieved by IV infusion of propofol to achieve effect-site concentrations of 1.0 μg/ml. Infusion rate will be manually controlled. An initial bolus dose (525 µg/kg) and subsequent infusion rate (82 µg/kg/min) for each participant
47949250|NCT06406790|DEVICE|CraniSeal|CraniSeal is a PEG Dural Sealant
47949251|NCT06406790|DEVICE|DuraSeal|DuraSeal is a PEG Dural Sealant
47949252|NCT00309738|DRUG|pitavastatin|
47949253|NCT00309738|DRUG|simvastatin|
47949254|NCT04968847|DEVICE|FemaSeed Localized Directional Insemination|Subjects undergoing FemaSeed Artificial Insemination
47949255|NCT04644003|DRUG|STP1|STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
47949256|NCT04644003|DRUG|Placebo|Placebo medication (capsule and tablet) identical in appearance to active medication
47949257|NCT02521493|DRUG|Asparaginase|Given IM or IV
47949258|NCT02521493|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
48105324|NCT02499471|OTHER|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
47949259|NCT02521493|DRUG|Cytarabine|Given IT and IV
48105325|NCT00227032|DRUG|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs"
48105326|NCT05679037|OTHER|Placebo|Inactive capsules
48105327|NCT05679037|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Universal antioxidant
47949260|NCT02521493|DRUG|Daunorubicin Hydrochloride|Given IV
48105328|NCT05537766|BIOLOGICAL|Brexucabtagene Autoleucel|Administered intravenously
47949261|NCT02521493|DRUG|Etoposide|Given IV
47949262|NCT02521493|OTHER|Laboratory Biomarker Analysis|Correlative studies
47949263|NCT02521493|DRUG|Mitoxantrone Hydrochloride|Given IV
48636616|NCT01098357|DRUG|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
48636617|NCT05470725|DRUG|CIN-107|A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
48636618|NCT00392509|PROCEDURE|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
48636619|NCT00252889|DRUG|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
48636620|NCT00293982|BEHAVIORAL|Physician knowledge of parental expectations for the visit|
47913972|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing both vibrations and nature sounds distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing both vibrations and nature sounds. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
48478145|NCT02674633|DEVICE|AKL-T01|Videogame-like digital therapy
47949264|NCT02521493|DRUG|Thioguanine|Given PO
47949265|NCT03120559|DEVICE|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
47949266|NCT03120559|DEVICE|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
48478146|NCT02674633|DEVICE|AKL-T09|Videogame-like digital therapy
47949267|NCT06680050|DRUG|Durvalumab (MEDI4736)|Durvalumab will be administered via IV infusion at a dose of 1500 mg on day 8 Q4W until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
47949268|NCT06680050|DRUG|Ceralasertib|Ceralasertib dose will be administered orally, 240mg BID, approximately 12 ± 2 hours apart, days 1 to 7 q28 (Q4W), up to progression or unacceptable toxicity.
48105329|NCT05537766|DRUG|Cyclophosphamide|Administered intravenously
48105330|NCT05537766|DRUG|Fludarabine|Administered intravenously
48478147|NCT02650141|DRUG|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
48478148|NCT02650141|DRUG|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
48478149|NCT03680079|OTHER|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
48636621|NCT05919212|DIAGNOSTIC_TEST|HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment|We study the circulating changes associated with resistance to T-DXd, including changes in HER2 status,studied through a new approach called HER2-2D that simultaneously assesses HER2 amplification and overexpression in blood
48636622|NCT01573728|BEHAVIORAL|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
48636623|NCT01573728|BEHAVIORAL|Public Health Exercise|At least 150 minutes at moderate intensity
48636624|NCT02631031|DRUG|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
48636625|NCT04822909|DRUG|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"
48636626|NCT01743703|OTHER|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
48636627|NCT05804292|OTHER|Questionnaire administration|Questionnaire administration
48636628|NCT00649571|DRUG|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
47949269|NCT06680050|RADIATION|radiotherapy|Loco-regional recurrences of the primary tumor and regional lymph node metastases will be treated with a total dose of 36 to 50 Gy in daily fractions with a dose of 2 to 3 Gy per fraction. Two weeks from the last dose of radiotherapy, a systemic treatment with durvalumab and ceralasertib will be started.
47949270|NCT05838573|DRUG|Metformin treatment|Participants assigned to the metformin group will receive 500mg metformin three times daily (tid) for 24 weeks. The initial dose will be 500 mg orally in the evening for the first two days, followed by an increase to 500mg twice a day for the subsequent two days. By day 5, the dosage will be further increased to 500mg tid. The highest tolerated dosage will be maintained for participants who could not tolerate the maximum dosage.
48636629|NCT00649571|DRUG|Adoxa Tablets 100 mg|100mg, single dose fasting
48636630|NCT02079285|PROCEDURE|EUS-FNA|
48636631|NCT05414812|BEHAVIORAL|Multi-component oncofertility care intervention|"The intervention includes:~1. Young breast cancer patients presenting to oncology visits will complete a clinic-based oncofertility needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future, ii) need for contraception, and iii) sexual health/menopause symptoms.~2. A women's health survivorship care plan (SCP) in Spanish and English encompasses content on screening and management strategies for a) fertility concerns/pregnancy health; b) contraception; c) hot flashes and d) sexual health.~3. Oncofertility navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's oncofertility needs, ii) review the women's health SCP, iii) provide support with the goal of engaging in oncofertility care.~4. Oncofertility consultation as indicated via telehealth or in person will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
47949271|NCT05838573|DRUG|Placebo treatment|Parallel-dose adjustments will be made for the placebo group to maintain consistency in dosing between the two groups.
47949272|NCT05838573|OTHER|Baseline assessments|Schizophrenic participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations.
47949273|NCT05838573|OTHER|Volunteer assessments|Apart from psychiatry scales(Hamilton Depression Scale, Young Mania Rating Scale and Self-reporting Inventory-90), other assessments for the healthy subjects are the same as the baseline for sczhiophrenic participants.
47949274|NCT03825523|OTHER|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
47949275|NCT03825523|OTHER|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
47949276|NCT05625061|BEHAVIORAL|Core Behavioral Weight Loss (BWL) Intervention|"All participants receive a mobile behavioral weight loss intervention delivered through a study smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback, and daily weight-related behavioral goals; a connected physical activity tracker and wireless scale. As micro-randomized trials are sequential, full factorial experiments, this core intervention component is combined with each of the 7 intervention messages (i.e., Behavior Change Technique (BCT) messages) to be tested repeatedly over time.~Participants will be evaluated at each of 3 decision points (morning, midday, evening) on each day of the study, and if eligible then micro-randomized, to receive or not receive, 1 of 7 types of daily intervention messages promoting achievement of proximal weight-related behavioral goals."
47949277|NCT05625061|BEHAVIORAL|Behavior Change Technique 1 Message (Action Planning)|Core BWL Intervention + Message in smartphone app prompts detailed planning of performance of one of the 3 target behaviors (daily weighing, active minutes, red food intake).
47949278|NCT05625061|BEHAVIORAL|Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal)|Core BWL Intervention + Message in smartphone app provides feedback on each of the 3 target behaviors (daily weighing, active minutes, red food intake) in the form of information drawing attention to discrepancies between participants' current behavior and participants' daily goals.
47949279|NCT05625061|BEHAVIORAL|Behavior Change Technique 3 Message (Feedback on Outcome of Behavior)|Core BWL Intervention + Message in smartphone app provides participants with feedback on their weight change, relating it to their performance on one of the 3 target behaviors (daily weighing, active minutes, red food intake).
47949280|NCT05625061|BEHAVIORAL|Behavior Change Technique 4 Message (Social Support)|Core BWL Intervention + Message in smartphone app advises participants on eliciting the provision of social support from their existing network related to one of the 3 target behaviors (daily weighing, active minutes, red food intake).
47949281|NCT05625061|BEHAVIORAL|Behavior Change Technique 5 Message (Social Comparison)|Core BWL Intervention + Message in smartphone app systematically induces comparison of participants' behavioral performance with other participants, including general, upward (i.e., comparison to participants doing better: weighing more, engaging in more activity, staying within red food limits), and downward comparisons (to participants doing worse).
47949282|NCT05625061|BEHAVIORAL|Behavior Change Technique 6 Message (Social Reward)|Core BWL Intervention + Message in smartphone app reinforces participants' effort or progress in performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
47949283|NCT05625061|BEHAVIORAL|Behavior Change Technique 7 Message (Focus on Past Success)|Core BWL Intervention + Message in smartphone app advises participants to think about or list previous successes related to performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
47949284|NCT02974582|BEHAVIORAL|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
47949285|NCT02974582|BEHAVIORAL|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
47949286|NCT02974582|BEHAVIORAL|Exposure to non health related images|Control group
48105331|NCT00573833|OTHER|questionnaire administration|
47949287|NCT04965766|DRUG|U3-1402|U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.
47949288|NCT06680427|DEVICE|Siegel Transcatheter Aortic Valve (TAVR)|Replacement of native aortic valve with the Siegel Transcatheter Aortic Valve (TAVR) by a transfemoral approach.
47949289|NCT06624137|DRUG|Serotonergic Psychedelic|"Any serotonergic or classic psychedelic that exhibits mainly Serotonin 2A receptor (5-HT2AR) agonism and is judged to produce subjectively similar effects."
47949290|NCT06624137|DRUG|Placebo|Matched Placebo
47949291|NCT05013034|DRUG|Basiliximab Injection|Subjects will be given IV dosing with basiliximab up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
48105332|NCT00573833|PROCEDURE|quality-of-life assessment|
48105333|NCT00573833|RADIATION|brachytherapy|
48105334|NCT00206258|DRUG|Pramlintide and glucagon|
48105335|NCT02169154|DRUG|1% Diclofenac Sodium|1% diclofenac sodium
48105336|NCT02169154|DRUG|3% Menthol|3% Menthol
48105337|NCT02169154|DRUG|0.09% Menthol|0.09% Menthol
48105338|NCT02169154|DRUG|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
48105339|NCT02169154|DRUG|0.9% Saline|0.9% Saline
48105340|NCT05127499|OTHER|progressive relaxation exercises|progressive relaxation exercises will do
48105341|NCT01037530|DRUG|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
48478150|NCT00894933|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
48478151|NCT04871516|OTHER|Quality-of-Life Assessment|Ancillary studies
48105342|NCT02428088|DRUG|Dasotraline|Dasotraline 2 mg once daily
48478152|NCT04871516|OTHER|Questionnaire Administration|Ancillary studies
47949292|NCT05013034|DRUG|Placebo|Subjects will be given IV dosing with placebo (1/2 normal saline) up to a maximum of 2 treatments (day 0 and day 4) for all patients on study. Treatment for patients may stop for unacceptable side-effects, the Investigator's, or patient's decision to discontinue treatment or other reasons. Exclusion for second dose is first dose returned patient to SpO2 ≥94% on room air.
48105343|NCT02428088|DRUG|Dasotraline|Dasotraline 4 mg once daily
48105344|NCT02428088|DRUG|Placebo Comparator|Placebo once daily
48105345|NCT00982033|DRUG|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
47949293|NCT06049173|DEVICE|Negative extra-abdominal pressure (NEXAP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, the abdominal pressure cardiopulmonary resuscitation (CPR-LW100) instrument was adopted and adsorbed on the epigastrium of patients. The LRM was performed by pulling up (tension of 20-30 kg) and compressing downward (tension\<10 kg) alternately on the abdomen of the patients with a frequency of 12 times per minute to support and maintain breathing. The whole LRM procedure lasted for 3 minutes in total. After LRM, the ventilator mode was changed to its baseline settings.
48105346|NCT00982033|DRUG|placebo|placebo qd for 24 weeks
48105347|NCT00423254|BIOLOGICAL|PSMA/PRAME|Low dose
48105348|NCT00423254|BIOLOGICAL|PSMA/PRAME|high dose
48105349|NCT04473638|PROCEDURE|Arthroscopic Deltoid Repair|. A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
48105350|NCT03665090|BEHAVIORAL|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
48105351|NCT04861012|DEVICE|Ultrasound|All subjects initially will be subjected to abdominal ultrasound, and if fatty liver is detected fibroscan will be done
48105352|NCT03142646|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
48105353|NCT04034901|DEVICE|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~* Activity~* Step count~* Heart rate~* Respiratory rate~* Skin temperature~* SpO2"
48105354|NCT00329732|DRUG|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
48105355|NCT00329732|DRUG|Saline placebo|matching volume of saline (placebo)
48105356|NCT05904535|OTHER|Cerbrospinal fluid sampling.|Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.
48105357|NCT00395018|DRUG|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
48105358|NCT02425254|DRUG|Intravenous paracetamol|1000mg intravenous solution for infusion
48105359|NCT02425254|DRUG|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
47949294|NCT06049173|OTHER|stepwise positive end-expiratory pressure (PEEP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, PEEP was increased gradually (every 3-5cmH2O per 30s) from baseline (5-8 cmH2O) to 20cmH2O. The PEEP level was maintained at 20cmH2O for 60s, followed by decrements to baseline PEEP (every 3-5cmH2O per 30s). After LRM, the ventilator was changed to the baseline settings.
47949295|NCT06222697|DRUG|Damoctocog-alfa-pegol (Jivi, BAY94-9027)|Follow clinical practice/administration. No drug is provided to participants due to the observational nature of the study.
48105360|NCT02937792|DRUG|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
48105361|NCT04143919|DIAGNOSTIC_TEST|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
48105362|NCT04143919|PROCEDURE|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
48105363|NCT04143919|DIAGNOSTIC_TEST|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
48105364|NCT00117988|DRUG|tanespimycin|
48105365|NCT06457568|DIAGNOSTIC_TEST|Blood pressure measurement|The blood pressure measurement was taken simultaneously by two observers using mercury sphygmomanometer and by a supervisor using the tested device, CONTEC08C.
48105366|NCT02305082|OTHER|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
48105367|NCT00620217|GENETIC|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
48105368|NCT03310996|OTHER|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
48105369|NCT06347952|PROCEDURE|Use of Acoustic and color imaging doppler during surgery for breast cancer|The intervention (post pilot study) is to systematically record the effect of routine use of acoustic as well as color imaging doppler during mammoplasty for breast cancer (for both the therapeutic and symmetrising breast reduction).
48105370|NCT05543837|DRUG|Capsaicin|Patients will receive a fixed dose of capsaicin
48105371|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
48105372|NCT00961636|DRUG|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
48105373|NCT00961636|DRUG|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
48105374|NCT00961636|DRUG|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
48105375|NCT01425983|DIETARY_SUPPLEMENT|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
48636632|NCT04947904|OTHER|Reduction of the patient's fluid intake during the first 7 days|The volume of fluids infused to the patient will be reduced by the doctor in charge of the patient for the first 7 days of the patient's stay in the intensive care unit according to a protocol with instructions to reduce fluid intake as far as possible in terms of maintenance fluids, dilution of medication and artificial nutrition. This protocol will be begun immediately following the patient's inclusion on Day 1 and pursued for 7 days after inclusion (i.e. from Day 1 - to Day 7). The fluid restriction strategy does not involve the administration of any medication (i.e. diuretics). A clinical pharmacist will help the intensive care teams apply the fluid restriction protocol with a daily check. If the restrictive strategy leads to hypovolemia and / or a electrolyte anomaly (sodium, potassium, chloride, etc.), the physician in charge will be authorised to treat these anomalies in conformance with the protocol recommendations.
48105376|NCT01425983|OTHER|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
48105377|NCT06206330|OTHER|Platelet rich plasma|After application of platelet rich plasma after surgery, the patients have examined for infection, hematoma, pain, recurrence and the time of epithelialization of the wound.
48105378|NCT04352582|OTHER|Survey|Survey
48105379|NCT00055432|DRUG|Gemzar and Alimta|
48105380|NCT04008394|GENETIC|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
48105381|NCT03590288|PROCEDURE|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
48105382|NCT02482233|BEHAVIORAL|ENDD (NJOY)|As described above.
48105383|NCT02482233|DRUG|NRT (NicoDerm CQ)|As described above.
48105384|NCT02482233|BEHAVIORAL|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
48478153|NCT04871516|RADIATION|Radiation Boost|Undergo radiation therapy boost
48478154|NCT04871516|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard surgery
48478155|NCT04871516|RADIATION|Whole Breast Irradiation|Undergo standard WBI
48478156|NCT04871516|OTHER|Breast MRI|A baseline breast MRI
47949296|NCT06612424|DRUG|ANTERİOR QUADRATUS LUMBORUM BLOCK|In the Quadratus Lumborum block group, Participants will be placed in the lateral decubitus position. A convex ultrasound probe will be placed in sterile conditions along the midaxillary line, in the subcostal area above the iliac crest, to visualize the quadratus lumborum and psoas major muscles, as well as the L4 vertebral transverse process. Using an in-plane technique, a 22G, 100 mm peripheral block needle will be advanced anterior to the quadratus lumborum muscle and into the subfascial space between the quadratus lumborum and psoas major muscles. After confirming the correct location with hydrodissection, 25 mL of 0.25% bupivacaine will be injected slowly, observing the fascial displacement on ultrasound. The same procedure will be repeated on the contralateral side.
47949297|NCT06612424|DRUG|İNTRATECHAL MORPHİNE GROUP|In the intrathecal morphine group, 100 micrograms of morphine (0.1 mL) will be added to the 12 mg of intrathecally administered bupivacaine.
48105385|NCT02482233|BEHAVIORAL|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
48105386|NCT02482233|BEHAVIORAL|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf"
48478157|NCT00605917|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
48478158|NCT06166758|BEHAVIORAL|Educational Video|Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
48478159|NCT01215799|DRUG|Bafetinib|Bafetinib 240 mg bid
48478160|NCT05510115|DRUG|Empagliflozin|Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-\[4-chloro-3-\[\[4-\[\[(3S)-tetrahydro-3furanyl\]oxy\]phenyl\]methyl\]phenyl\]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
48478161|NCT05510115|DRUG|Placebo|Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
48478162|NCT04924244|OTHER|Music Therapy|We will play music of the subject's choice of genre during the procedure.
48478163|NCT04924244|OTHER|No Music|No music will be played during the subject's interventional procedure
48478164|NCT02266849|DRUG|Loperamide|12 mg Loperamide each day for three days
48478165|NCT02266849|DRUG|Placebo|6 tablets daily for three days
48478166|NCT05220891|OTHER|Paracentesis|Paracentesis from ascitic patient
48636633|NCT03898609|OTHER|Dietary intervention|3 weeks
48636634|NCT01187875|DIETARY_SUPPLEMENT|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
48636635|NCT01187875|DIETARY_SUPPLEMENT|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
48636636|NCT01187875|DIETARY_SUPPLEMENT|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
48636637|NCT01187875|DIETARY_SUPPLEMENT|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
48636638|NCT04146909|DIAGNOSTIC_TEST|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
48636639|NCT01290354|DRUG|Lapatinib|Unlabelled, administered orally
48636640|NCT01290354|DRUG|[11C] lapatinib|Radiolabelled, administered intravenously
48636641|NCT02037984|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
47949298|NCT04644536|DEVICE|Bone graft substitute|Orthopaedic or Spine bony defects
47949299|NCT06476600|DRUG|Dexmedetomidine injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
48636642|NCT02037984|BIOLOGICAL|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
48636643|NCT02037984|BIOLOGICAL|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
47949300|NCT06476600|DRUG|Nalbuphine Injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
48636644|NCT02037984|BIOLOGICAL|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
48636645|NCT02037984|BIOLOGICAL|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
47949301|NCT05570877|DEVICE|ChitoCare medical Wound Healing Gel|ChitoCare medical Wound Healing Gel is a CE-marked medical device.
47949302|NCT03120312|PROCEDURE|total hip replacement|primary hip replacement patients during past 5 years．
47949303|NCT06681038|DRUG|Standard Medical Therapy|"Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses."
47949304|NCT06681038|PROCEDURE|PIPAC|"In addition to standard systemic treatment, patients receive also four PIPAC procedures with pressurized aerosol containing oxaliplatin.~The PIPAC procedure is repeated up to a maximum of 4 times every 6 weeks."
47949305|NCT06008158|RADIATION|Accelerated Partial Breast Irradiation|Undergo APBI
47949306|NCT06150664|DRUG|CTX-8371|Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
47949307|NCT05015439|DRUG|Cannabidiol|The study intervention will be supplied as a softgel capsule containing cannabidiol.
47949308|NCT05015439|DRUG|Placebo|The study intervention will be supplied as a softgel capsule containing inert filler.
48636646|NCT02037984|BIOLOGICAL|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
48636647|NCT04985656|DRUG|Pevonedistat|Pevonedistat IV infusion
48636648|NCT04985656|DRUG|Decitabine|Decitabine tablets
48636649|NCT04985656|DRUG|Cedazuridine|Cedazuridine tablets
48636650|NCT05610150|DEVICE|Myobrace Functional Appliance|An Appliance for treating growing Class II patients with mandibular deficiency
48636651|NCT05610150|DEVICE|Twin Block|An Appliance for treating growing Class II patients with mandibular deficiency
48636652|NCT03905174|DEVICE|custom made device|surgical intervention to place custom made orthopaedic device
47949309|NCT04732416|DRUG|HM15136|Low dose of HM15136/ High dose of HM15136, SC injection, weekly
47949310|NCT00772473|OTHER|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
47949311|NCT04359108|DEVICE|Navigation System for Users of a Visual Prosthesis|We use common psychophysical judgments such as the following: discriminating between two alternatives by saying which is present in the field of view, touching a tablet computer to indicate the apparent location of a target in the frontal plane, and looking for targets by rotating the head and pointing when one is found. We will compare user performance using the Basic system with user performance using the Augmented and Augmented + Modal systems where contextual information associated with the task is conveyed to users via enhanced visual, auditory, and haptic modalities.
47949312|NCT04042181|DIETARY_SUPPLEMENT|Placebo|standard food grade excipients
47949313|NCT04042181|DIETARY_SUPPLEMENT|Bifidobacterium longum|Target dose of 1x10\^10 CFU/day, plus standard food grade excipients
48105387|NCT01831791|DRUG|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
48105388|NCT05387837|DRUG|D-4517.2|D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
48105389|NCT04850482|OTHER|MyJourney|MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
48105390|NCT05924074|BIOLOGICAL|Biological sampling|The procedure will consist of an additional bone marrow sample and blood sample
48105391|NCT04642794|OTHER|observational study|patients admitted for AP with portosplenomesenteric vein thrombosis.
48105392|NCT02012166|DRUG|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
48105393|NCT02012166|DRUG|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
48105394|NCT02012166|DRUG|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
48105395|NCT02012166|DRUG|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
48105396|NCT02012166|DRUG|Placebo|Placebo administered orally in 240 mL of water
48105397|NCT02012166|BIOLOGICAL|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
48105398|NCT02012166|BIOLOGICAL|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
48105399|NCT02012166|BIOLOGICAL|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
48105400|NCT02071979|DEVICE|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
48105401|NCT02071979|DEVICE|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
48105402|NCT02071979|DEVICE|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
48105403|NCT02071979|PROCEDURE|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
48105404|NCT00662636|DRUG|dasatinib|Given orally
48105405|NCT00662636|DRUG|lapatinib ditosylate|Given orally
48105406|NCT00662636|OTHER|pharmacological study|Correlative study (cohort II only)
48105407|NCT00662636|OTHER|laboratory biomarker analysis|Correlative study (cohort II only)
48105408|NCT05066113|DEVICE|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
48105409|NCT03896841|OTHER|Observation|Ocular Findings Observations
48105410|NCT02535624|PROCEDURE|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
48105411|NCT02535624|PROCEDURE|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
48105412|NCT03718793|DIAGNOSTIC_TEST|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
48636653|NCT05135780|OTHER|Osteopathic manual treatment|Between 5 and 8 sessions of osteopathy will be carried out, and the time interval between sessions may vary depending on the need and individual evolution of each child, assessed by the team of osteopaths.
48636654|NCT05135780|OTHER|Social education|"* Intervention in children:~  * During the school year there will be activities of two days per week with a duration of 2.5 hours per session in the afternoon.~ * The activities will focus on school reinforcement, facilitating snacks and having a recreational space.~ * Groups will be made by age ranges (from 4 to 6 and from 7 to 12) of maximum 10 children, due to the current COVID situation. The number could vary in the event of a change in measures at the institutional level.~* Family intervention:~  * Quarterly tutoring spaces between the coordinators and the team of social educators to evaluate needs, specify objectives and assess evolution.~ * Monthly group spaces for mothers managed by the team of educators where they will exchange experiences and create an informal support network.~ * Monthly spaces shared between parents and children accompanied by the educational team, where family ties will be worked through play."
47949314|NCT06681649|BEHAVIORAL|Intervention|"The intervention group will receive follow-up care through the specialized post-ICU follow-up clinic at KHSC at approximately 1- and 3-months following ICU discharge. Caregivers will also be invited to participate in the follow-up clinic along with the ICU survivor participant.~In addition to receiving specialized follow-up clinical care, ICU survivor participants and their caregivers will also receive the following additional items as part of a bundled care intervention program (see Appendix):~* Informational pamphlet on critical illness and expectations following ICU discharge~* Flyer on critical illness and expectations following ICU discharge (brief version, which may be placed on the participant's refrigerator or other location at home as a consistent reminder)~* Diaries in which the healthcare team, family members, and the patient themselves are able to journal their experiences, updates, progress, and barriers in the ICU and following discharge"
48105413|NCT04204720|DEVICE|needle (Chiba)|intravascular injection using chiba needle during caudal epidural block
48105414|NCT04204720|DEVICE|needle (Whitacre)|intravascular injection using whitacre needle during caudal epidural block
48478167|NCT05631535|OTHER|Intensive lifestyle change program with a very-low-energy diet|The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.
48478168|NCT05631535|OTHER|Intensive lifestyle change program with a low-energy diet|The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
48478169|NCT04625062|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.
48478170|NCT04625062|BEHAVIORAL|Motor-based treatment|Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
48478171|NCT05723198|DRUG|Baricitinib|Administered orally
48478172|NCT05723198|DRUG|Placebo|Administered orally
48636655|NCT05624957|DRUG|Lidocaine epinephrine|Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.
48478173|NCT03124290|OTHER|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
48478174|NCT05329285|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
48636656|NCT05624957|DRUG|Epinephrin|0.25 mg epinephrine mixed with one litre of fluid irrigation
48636657|NCT01200134|OTHER|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
48636658|NCT04032327|DRUG|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
48636659|NCT04032327|DRUG|Bupivacaine|20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
48636660|NCT01391494|BIOLOGICAL|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
48636661|NCT01391494|BIOLOGICAL|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
48105415|NCT06420713|PROCEDURE|Horizontal Bone Augmentation of Alveolar Ridge|Elevation of the flap in the anterior region of atrophic maxilla to receive particulate autogenous bone mixed with deproteinized bovine bone graft (Group A) or Leukocyte-and-Platelet-Rich Fibrin (L-PRF) mixed with deproteinized bovine bone graft (Group B). In both groups, bone augmentations were covered with a collagen membrane stabilized with pins.
48478175|NCT01905059|DRUG|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
48478176|NCT01905059|DRUG|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
48478177|NCT04438850|DRUG|Ivermectin|Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
48478178|NCT04438850|OTHER|Placebo|Patients should take placebo orally on an empty stomach with water
48478179|NCT02130778|DRUG|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
48478180|NCT02130778|OTHER|500 ml 0.9% saline|infusion of saline
48478181|NCT00685802|DRUG|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
48478182|NCT00685802|DRUG|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
48478183|NCT05184699|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with psoriatic disease will be randomized to receive food supplement Endocalyx for 4 months.
48478184|NCT05184699|DIETARY_SUPPLEMENT|Placebo|Patients with psoriatic disease will be randomized to receive placebo for 4 months.
48478185|NCT00094367|DRUG|Abacavir/Lamivudine|
48478186|NCT00869687|DEVICE|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
48478187|NCT00945334|DRUG|Neomycin|500 mg po bid for 14 days
48478188|NCT00945334|DRUG|Placebo|placebo for 14 days tid
48478189|NCT00945334|DRUG|Rifaximin|550 mg po tid
48478190|NCT05162729|BEHAVIORAL|Game-like online working memory training|Participants in the WM group will be receiving two types of WM training tasks (two mini-games) in each session. Half of the training time will be spent on playing a game that requires visual-spatial WM, and the other half of the training time will be spent on playing a game that demands verbal WM. In both the games, the participant is asked to remember the pictures or audios (numbers) presented, and then recall them and select them on the screen.
48478191|NCT05162729|BEHAVIORAL|Game-like online social emotional training|"Participants in the SE group will be also receiving two types of SE training tasks in each session, to match with the ones in the WM training. There are two mini-games for training.~To match with the spatial-visual WM training, participants in the SE group will be asked to first look at a picture that depicts a daily social scenario (i.e., a child who fell down and hurt himself), and then to choose an emotion that the child in the picture may feel from four options of facial emotions displayed on the screen. The other mini-game, with the aim to match with the auditory WM training, will first tell a short story of a social scenario (i.e. David accidentally fell down and got hurt), and then will ask the child to choose the emotion that the character in the story may feel from the four options displayed on the screen. Each mini game lasts for about 7 minutes in each training session."
48478192|NCT05318976|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
48478193|NCT05318976|DRUG|Placebo|Placebo will be delivered by subcutaneous injection once a week
48478194|NCT06322615|PROCEDURE|Acupressure Therapy|Undergo acupressure
48478195|NCT06322615|OTHER|Educational Intervention|Receive education session about using acupressure at home
48478196|NCT06322615|OTHER|Electronic Health Record Review|Ancillary studies
48478197|NCT06322615|OTHER|Questionnaire Administration|Ancillary studies
48478198|NCT01216410|DRUG|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
48478199|NCT01216410|DRUG|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
48636662|NCT01391494|BIOLOGICAL|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
48636663|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
48636664|NCT01391494|BIOLOGICAL|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
48636665|NCT01391494|BIOLOGICAL|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
48636666|NCT01391494|BIOLOGICAL|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
48636667|NCT01391494|BIOLOGICAL|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
48636668|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
48636669|NCT01391494|BIOLOGICAL|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
48636670|NCT01391494|BIOLOGICAL|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
48636671|NCT01391494|BIOLOGICAL|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
48636672|NCT01391494|BIOLOGICAL|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
48636673|NCT01391494|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
48636674|NCT01391494|BIOLOGICAL|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
48636675|NCT02631694|DRUG|Propranolol|Intake of propranolol pill (40 milligram)
47949315|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
47949316|NCT04904575|PROCEDURE|Erector spinae plane block|"Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
47949317|NCT06680999|OTHER|Data collection|Preoperative, intraoperative and follow-up data collection: consultation and anesthesia reports, hospitalization reports and imaging data to evaluate the feasibility and efficacy of endovascular treatment of superior vena cava syndromes involving the trifurcation. Data collection will last 1 month and will be performed by a Vascular Surgery resident of the hospital.
47949318|NCT06110572|DRUG|Carboplatin|Given by IV
47949319|NCT06110572|BIOLOGICAL|Atezolizumab|Given by IV
48478200|NCT01216410|DRUG|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
48478201|NCT03002480|OTHER|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
48478202|NCT01247792|BEHAVIORAL|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
48478203|NCT00500006|DRUG|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
48478204|NCT00500006|DRUG|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
48478205|NCT05752188|OTHER|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
48478206|NCT00744172|PROCEDURE|laparoscopy|laparoscopic hysterectomy
48478207|NCT00744172|PROCEDURE|vaginal|vaginal hysterectomy
48478208|NCT00744172|PROCEDURE|abdominal|abdominal hysterectomy
48478209|NCT04126954|OTHER|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
48478210|NCT04429841|PROCEDURE|Radical gastrectomy with D1 lymphadenectomy|
48636676|NCT02631694|DRUG|Placebo|Intake of placebo pill (40 milligram)
48636677|NCT02631694|OTHER|Carbon dioxide|Inhalation of 35% carbon dioxide
48636678|NCT02631694|OTHER|Compressed air|Inhalation of air
48636679|NCT03681093|DRUG|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily administered orally as tablet
48636680|NCT03681093|DRUG|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily administered orally as tablet
48636681|NCT03681093|DRUG|Placebo|Placebo once daily administered orally as tablet
47949320|NCT06110572|DRUG|Etoposide|Given by IV
47949321|NCT06110572|RADIATION|Total Body Irradiation|Undergo Total Body Irradiation
47949322|NCT06110572|RADIATION|Hypofractionated Radiation Therapy|Undergo Hypofractionated Radiation Therapy
47949323|NCT06110572|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging
47949324|NCT01872897|DRUG|Sodium Alginate Double Action Tablets|Four tablets as a single dose
47949325|NCT01872897|DRUG|Placebo|4 tablets as a single dose
47949326|NCT03404427|BEHAVIORAL|Normal sleep night|Usual hours of sleep
48478211|NCT04429841|PROCEDURE|Radical gastrectomy with D2 lymphadenectomy|
48478212|NCT00104247|DRUG|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
48478213|NCT01965626|DRUG|Oseltamivir|Oseltamivir 75 mg twice per day, 10 consecutive days
48478214|NCT01965626|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
48478215|NCT04676815|PROCEDURE|NBI and interventional bronchoscopy|NBI used to enhance the contrast between the mucosal surface and underlying blood vessels
48636682|NCT05610761|BEHAVIORAL|Core stabilization exercises with Kegel exercises|Core stabilization exercise program consists of two phases: teaching the basic movement (contraction of the Transversus abdominis and other muscles with diaphragmatic breathing) and incremental exercises added to the basic movement. The basic movement will be studied before each exercise and then the specified exercises will be added. The physiatrist will teach the exercise program to the patients. The first 6 of the 12 exercises classified according to the degree of difficulty will be performed for 5 weeks, and the next 5 weeks will be moved to the other 6 exercises. The exercises will be performed at least 3 days a week, with 10 repetitions of each movement, and the program will last for 10 weeks. Compliance with the exercise program will be questioned over the phone, and patients will be evaluated with a follow-up form before the study, at the 10th week, and at the 20th week. In addition, the Kegel exercise program specified in the other group will be applied.
48636683|NCT05610761|BEHAVIORAL|Kegel exercises|"Kegel Exercises The exercise will start as 2 sets of 10 repetitions in the morning and evening, and after getting used to it, it will be increased to 3 sets of 10 repetitions per day.~The patient, lying on his back with his knees bent, feet slightly apart from each other, will try to lift the breech, urinary tract opening and vagina on the pelvic floor by counting to 5, and should not tighten your abdominal and leg muscles, and should not hold your breath while doing this exercise.~In this way, he will count up to 5 while contracting, then he will relax by counting to 10 (after getting used to it, the holding time will be increased to 10 seconds)."
48636684|NCT02912520|DRUG|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
48636685|NCT01367756|DRUG|RO4995819|multiple oral doses, Days 10-16
48636686|NCT01367756|DRUG|citalopram|multiple oral doses, Days 1-16
48636687|NCT01367756|DRUG|placebo|multiple oral doses, Days 10-16
48636688|NCT03347539|DEVICE|Nexplaon|This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
48636689|NCT04606966|OTHER|Therapeutic Horseback Riding|Horse therapy
48636690|NCT04606966|OTHER|Barn Activity|Horsemanship group
48636691|NCT04606966|OTHER|Hybrid|Ground and riding activities
47949327|NCT03404427|BEHAVIORAL|Sleepless night|Total sleep deprivation the first night
47949328|NCT05630755|DRUG|DOR/ISL|DOR/ISL 100 mg/0.25 mg oral tablets once daily
47949329|NCT05630755|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
47949330|NCT05630755|DRUG|Placebo to BIC/FTC/TAF|0 mg oral tablets once daily
47949331|NCT05630755|DRUG|Placebo to DOR/ISL|0 mg oral tablets once daily
47949332|NCT06376734|DEVICE|Transcranial magnetic stimulation|Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
47949333|NCT05491538|BEHAVIORAL|Social Cognition and Interaction Training-Work Edition (SCIT-WE)|Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
47949334|NCT05895864|DRUG|utidelone injection|utidelone monotherapy in patients with recurrent or metastatic urothelial carcinoma by utidelone
47949335|NCT06681376|OTHER|Comfort menu and cart|"The comfort menu and cart will be implemented after the pre-intervention data collection phase is completed. The menu will list the items available on the cart and will be presented to eligible patients in printed or digital format (on a tablet). The cart will be placed in an easily accessible area within the ED. Approximated retail prices have been previously reported.~Comfort Cart Contents:~* Hot and cold packs;~* Extra blanket and pillow;~* Face towel;~* Gloves and hat;~* Personal hygiene kit;~* Items for distraction;~* Items to enhance communication.~Comfort Menu Options:~* Physiotherapy assessment;~* Conversation with chaplain, concierge, or social worker;~* List of resources for older adults needing community services;~* Home care assistance."
47949336|NCT05232110|DRUG|Pozelimab|
47949337|NCT05443594|DEVICE|Phase 1: FARAPULSE Ablation System|PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.
47949338|NCT05443594|DEVICE|Phase 2: FARAPULSE Ablation System|PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.
47949339|NCT05181462|DRUG|Carboplatin|Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks
47949340|NCT05181462|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks
47949341|NCT05181462|DRUG|Nadunolimab|Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.
47949342|NCT03630042|DRUG|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
47949343|NCT03630042|DRUG|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
47949344|NCT02900976|BIOLOGICAL|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
47949345|NCT02900976|BIOLOGICAL|Rituximab|Given IV
47949346|NCT04821544|BEHAVIORAL|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
47949347|NCT01331733|DRUG|hMG-HP|
47949348|NCT01331733|DRUG|hMG + GnRH antagonist|
47949349|NCT04229979|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
47949350|NCT04229979|DRUG|Azacitidine|injection
47949351|NCT04229979|DRUG|Venetoclax|tablet
47949352|NCT04229979|DRUG|Decitabine|injection
47949353|NCT04229979|DRUG|Cytarabine|injection
47949354|NCT04229979|OTHER|Observation|palliative management
48636692|NCT05055336|OTHER|Gastric emptying breath test|The gastric emptying breath test is used to diagnose gastroparesis. Participants ingest spirulina in a meal and samples are taken every 45 minutes for 4 hours.
48636693|NCT05055336|OTHER|Stomach ultrasound|Ultrasound of the fundus of the stomach will be done immediately after ingestion of the test meal, at 15 minutes, and at 30 minutes.
48105416|NCT06420713|PROCEDURE|Groups|"The patients underwent Guided Bone Regeneration (GBR) procedures for the reconstruction of atrophic edentulous alveolar ridges and were divided into two groups according to the proposed treatment:~Group A - GBR using a mixture of particulate autogenous bone graft and deproteinized bovine bone graft (Bio-Oss® Small; Geistlich AG, Wolhusen, Switzerland).~Group B - GBR using a mixture of deproteinized bovine bone graft (Bio-Oss® Small) and L-PRF + Liquid Fibrinogen."
48105417|NCT06420713|PROCEDURE|Dental Implants|"After 8 months of GBR healing, dental implants were placed in the grafted regions using guided surgery techniques.~Cone beam computed tomography (CBCT) scans were performed preoperatively, immediately after the surgical procedure, and after 8 months of follow-up to measure the linear and volumetric changes in the alveolar ridge. At the time of dental implant placement, after an 8-month period following the GBR procedures, bone biopsies were obtained from the grafted area for histological and micro-CT analysis.~The stability of the implants was assessed using resonance frequency analysis in the immediate postoperative period and at 6 months postoperatively.~After the 6-month period following dental implant placement, the patients were cleared for implant-supported prosthetic rehabilitation."
48105418|NCT06289348|BEHAVIORAL|socio-psychological questionnaire|ton collecte socio-demographic variable
47949355|NCT04229979|BIOLOGICAL|GM-CSF|subcutaneous injection
47949356|NCT04229979|OTHER|Montanide|adjuvant
47949357|NCT03491215|DRUG|Ruxolitinib|All enrolled pediatric participants received ruxolitinib as a 5 mg tablet (adult and adolescent formulation) or an oral pediatric formulation (administered as oral solution or capsule dispersed in liquid).
47949358|NCT06681701|PROCEDURE|Combined Manual Therapy and Pulmonary Exercises|"Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:"
48636694|NCT03152890|DRUG|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
48636695|NCT04579419|DRUG|Sodium Bicarbonate|Botulinum Toxin diluted in Sodium Bicarbonate
48105419|NCT06289348|BEHAVIORAL|revised event impact scale (IER-S)|22 items assessed on a scale of frequency from 0 (not at all) to 4 (extremely)
48105420|NCT06289348|OTHER|Non directive interview|composed of a very broad opening sentence to encourage the parents' discourse
48105421|NCT06289348|OTHER|Stern interview|54 questions to investigate the impact of the announcement and the parenthood construction
48105422|NCT06289348|OTHER|semi-directive interview|to propose ideas for improving and harmonizing practices
48105423|NCT04167917|DRUG|NTX-301|oral hypomethylating agent
48105424|NCT03591809|OTHER|combined exercise training|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
48636696|NCT04579419|DRUG|Normal Saline|0.9 NaCl
48105425|NCT05398965|DRUG|Eucalyptus Oil|The Eucalyptus Oil pack contains Oleum Eucalyptus citriodora, Oleum Eucalyptus globulus, and Peppermint oil, given 4 times daily for 45 minutes each frequency, applied to the mask.
48105426|NCT05398965|DRUG|Standard COVID medication|This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day, zinc 20 mg a day, tablet of complex vitamin B, and other symptomatic treatments.
48105427|NCT02590913|DIETARY_SUPPLEMENT|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
48105428|NCT02590913|DIETARY_SUPPLEMENT|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
48105429|NCT05623384|PROCEDURE|Stellate ganglion block|A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
48105430|NCT05623384|PROCEDURE|Facial and glossopharyngeal nerve blocks|The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
48105431|NCT05623384|DRUG|Mecobalamin Tablets|oral Mecobalamin Tablets tid-8
48105432|NCT04256876|DEVICE|TTNS|See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
48636697|NCT03103308|OTHER|Walk Training and Transplant|Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
48636698|NCT03103308|OTHER|Activity Monitoring and Transplant|Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
48636699|NCT00252473|DEVICE|MedTec S-frame Immobilization Masks|
48637460|NCT06232031|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
48105433|NCT04256876|DEVICE|TTNS Sham|See section 'arms'
48105434|NCT04874571|OTHER|Muscle Energy Technique group|In addition to the home exercise program of 12 sessions for 4 weeks, 3 days a week, muscle energy technique will be applied to the individuals in the MET(Musculer Energy Technique) group.
48105435|NCT02707913|DRUG|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
48105436|NCT02707913|DRUG|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
48105437|NCT06375824|DRUG|Bufei Recipe|Bufei Recipe: Roasted Astragalus, Codonopsis pilosula, Walnut kernels, Sichuan Fritillaria, Angelica sinensis, Stir fried Purple Su Zi, Honey Baibu, Roasted Purple Aster, etc. Take 1 dose daily, 5 days a week.
48105438|NCT06375824|DRUG|Bufei Recipe placebo|The placebo was prepared using 5% of the drug, with color, odor, taste, appearance, and weight similar to the experimental group drug, and packaging consistent with the experimental group drug.
48105439|NCT02378116|PROCEDURE|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
48105440|NCT04572217|DRUG|Topiramate|Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
48636700|NCT05371223|DRUG|Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine|"Each combined course is constituted by two consecutive 28-day cycles of systemic chemotherapy (three adminstrations per cycle: days 1,8 and 15) and one cycle of PIPAC administered within 10-13 days from the last administration of systemic chemotherapy. Between each combined course a 7-10 days pause is observed.~The recommended dose of Nabpaclitaxel in combination with Gemcitabine is 125 mg/m2 administered endovenous over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. The concurrent recommended dose of Gemcitabine is 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of Nabpaclitaxel administration on Days 1, 8 and 15 of each 28-day cycle.~A pressurized aerosol containing Nabpaclitaxel at the dose of 112,5 mg/m2 diluted in a total volume of 200 ml of NaCl 0.9% is applied through the nebulizer inside the abdominal cavity during laparoscopy."
48105441|NCT04572217|DRUG|Phentermine|Phentermine (starting dose 8 mg, max dose 16 mg)
48105442|NCT03915769|DRUG|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
48105443|NCT03915769|OTHER|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
48105444|NCT01952795|BEHAVIORAL|Diet and exercise|Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
48105445|NCT02768272|DEVICE|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
48105446|NCT02768272|PROCEDURE|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
48105447|NCT00309088|DRUG|tacrolimus|oral
48105448|NCT00309088|DRUG|placebo|oral
48105449|NCT02309580|DRUG|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
48105450|NCT02883088|PROCEDURE|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
48105451|NCT03709693|DEVICE|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
48105452|NCT00596167|DRUG|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
48105453|NCT05351372|RADIATION|Ultra-low dose protocol|
48105454|NCT05351372|RADIATION|Standard dose protocol|
48105455|NCT03719391|OTHER|Virginia Tobacco flavored JUUL 5% ENDS|Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
48105456|NCT03719391|OTHER|Cool Mint flavored JUUL 5% ENDS|Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
48636701|NCT06375876|BEHAVIORAL|Single-session intervention (SSI)|The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.
48636702|NCT05259176|DEVICE|transcranial Direct Current Stimulation (tDCS)|Direct current transcranial stimulation will be applied for 20 minutes over the left posterior parietal cortex with an intensity set to 2 mA.
48636703|NCT05259176|DEVICE|Sham stimulation (sham-tDCS)|The same positioning of electrodes as the stimulation condition will be used, but the current will be applied for 30 seconds and then progressively reduced.
48636704|NCT05259176|DEVICE|Behavioural|Treatment for upper limbs ideomotor apraxia (Smania et al., 2000)
48105457|NCT03719391|OTHER|Mango flavored JUUL 5% ENDS|Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
48636705|NCT03486470|DIAGNOSTIC_TEST|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
48636706|NCT05556187|OTHER|Individualized automated oxygen titration|Automated oxygen titration based on the oxygen saturation during the entire day.
48636707|NCT03005574|BEHAVIORAL|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
48636708|NCT03005574|BEHAVIORAL|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
48636709|NCT03081078|BEHAVIORAL|Volunteer support|Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.
48636710|NCT03081078|OTHER|Mobile app|Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
48636711|NCT02758080|OTHER|Matching on the basis of molecular analysis|
48636712|NCT02758080|OTHER|Matching on the basis of physician's choice|
47949359|NCT06574178|BEHAVIORAL|Dietary Counseling|A Registered Dietitian or Nutritionist will provide nutrition education either in person, over the phone, or via Zoom. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant.
47949360|NCT06619587|DRUG|Phase I Arm A|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
47949361|NCT06619587|DRUG|Phase I Arm B|Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
48105458|NCT03719391|OTHER|Creme Brulee flavored JUUL 5% ENDS|Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
48105459|NCT03719391|OTHER|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
48105460|NCT03719391|OTHER|Nicorette White Ice Mint 4mg nicotine polacrilex gum|Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
48105461|NCT03719391|OTHER|Usual Brand combustible cigarette|Treatment with usual brand cigarette (10 puffs).
48105462|NCT03900637|DRUG|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
48105463|NCT03900637|DRUG|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
48105464|NCT03900637|GENETIC|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
48636713|NCT01358305|OTHER|Protein Blend|Single intake of approximately 20 grams of total protein
48636714|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
48636715|NCT04163770|DEVICE|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
48636716|NCT02245893|PROCEDURE|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
48636717|NCT06501235|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|An adaptation of the Robles and Peralta's (2010) stress management program will be followed. This program includes key techniques from the CBT approach, such as deactivation techniques, cognitive restructuring, and assertiveness training.
48636718|NCT06501235|BEHAVIORAL|Virtue-Based Intervention (VBI)|A Well-being Training based on Contemplative Practices (WTCP) (Cebolla \& Alvear, 2019; Alvear \& Cebolla, 2023) will be followed. WTCP combines mindfulness practices with various activities based on virtues such as gratitude, altruism, or compassion. This program focuses on generative or constructive meditations, and puts special emphasis on virtuous actions, emotion regulation (both positive and negative emotions) and compassion, and includes strategies from positive psychology, such as strengths-based interventions, savoring, kindness, or the three good things.
47949362|NCT02890095|PROCEDURE|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :~* 1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* 1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.~These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
47949363|NCT02890095|PROCEDURE|plastic surgery|"The excision piece will follow the classical pathological circuit.~A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:~* measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
47949364|NCT00559754|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
47949365|NCT00559754|DRUG|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
47949366|NCT00559754|DRUG|Standard chemotherapy|As prescribed
47949367|NCT06680661|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) is one part of the conditioning regimen. 50 mg/kg beginning on day -6.
47949368|NCT06680661|DRUG|Fludarabine|Fludarabine (Flu) is one part of the conditioning regimen. 150 mg/m2 (30 mg/m2 per day on days -6 to -2)
47949369|NCT06680661|DRUG|Thiotepa|Thiotepa (Thio) is one part of the conditioning regimen.10 mg/kg (5 mg/kg per day on days -5 and -4)
47949370|NCT06680661|RADIATION|Total Body Irradiation|400 cGy (200 cGy per day on days -2 and -1).
47949371|NCT06680661|BIOLOGICAL|Double Umbilical Cord Transplant|Cord blood is a regulated biologic. Selection of cord blood units will be based on published guidelines.
47949372|NCT06680661|DRUG|Tacrolimus|Tacrolimus will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. Tacrolimus will continue at least until day 180 and then be tapered off.
47949373|NCT06680661|DRUG|Mycophenolate Mofetil|MMF will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. MMF will continue until day 30.
47949374|NCT06680661|DRUG|Abatacept|Abatacept at a dose of 10mg/kg will be given on days T-1, T+5, T+14 and T+28.
48105465|NCT05384392|OTHER|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
48105466|NCT05384392|OTHER|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
48105467|NCT05384392|BIOLOGICAL|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
48105468|NCT05384392|OTHER|MRI scans of the brain|The MRI scans of the brain will be performed. This exam is performed in routine care in the context of this pathology
48105469|NCT01651949|BIOLOGICAL|9vHPV Vaccine|9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
48636719|NCT02155855|OTHER|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (\<70 mg/dL \> 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
47949375|NCT02366988|DEVICE|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
47949376|NCT02366988|PROCEDURE|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
47949377|NCT06293469|PROCEDURE|Accelerated Flap Coverage Surgery|Timing of the flap surgery is with a goal of 72 hours from injury
47949378|NCT06293469|PROCEDURE|Standard of Care Flap Timing|Timing of the flap surgery is the standard of care flap timing for the participating institution.
47949379|NCT06680479|BIOLOGICAL|CH505 TF chTrimer|Stabilized CH505 TF chTrimer, 300 mcg
48105470|NCT04743128|BEHAVIORAL|Exercise|The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
48105471|NCT02723929|DEVICE|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
48105472|NCT02723929|DEVICE|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
48636720|NCT02155855|OTHER|Control|Routine care
48636721|NCT01602458|PROCEDURE|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
48636722|NCT01602458|PROCEDURE|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
48636723|NCT05664646|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
48636724|NCT05664646|OTHER|Arm Ergometry|Study 1 will use the arm ergometry as a form of exercise.
47949380|NCT06680479|BIOLOGICAL|3M-052-AF|3 mcg
47949381|NCT06680479|BIOLOGICAL|Aluminum Hydroxide Suspension|500 mcg
47949382|NCT06680479|OTHER|Sodium Chloride for Injection|Sodium chloride for injection, 0.9% USP volume-matched placebo injection.
47949383|NCT04275557|OTHER|Blood Sample collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date), 4-6 weeks post-surgery, if applicable, and at the time of follow-up (approximately 1 year and approximately 2 years after baseline).
47949384|NCT04275557|OTHER|Tissue sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue, muscle, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
47949385|NCT04275557|OTHER|Data collection|Participants will be asked to complete questionnaires at baseline and at 1 year and 2 year follow-ups.
47949386|NCT05515198|OTHER|Patient Education|Patients will be provided educational opportunities.
47949387|NCT05515198|OTHER|Nurse Navigation|A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
48105473|NCT00002415|DRUG|Tenofovir disoproxil fumarate|
48636725|NCT05664646|OTHER|Cool Environment|Study 2 will be completed in a cool environment setting.
48636726|NCT04187690|DRUG|Jin-shui Huan-xian granule|Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
48636727|NCT04187690|DRUG|Jin-shui Huan-xian granule placebo|Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.
48636728|NCT00756314|BEHAVIORAL|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
47949388|NCT05515198|OTHER|ChatBot|"A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms."
47949389|NCT03405610|BEHAVIORAL|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
48636729|NCT05791149|DIAGNOSTIC_TEST|saliva tube|1 tube of saliva (\~2 ml) will be collected from all patients enrolled in the study. For operated OSCC patients a second tube will be collected during the routine hospital visit 4 weeks after surgery
47949390|NCT06271538|COMBINATION_PRODUCT|Skal Pro|One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS
47949391|NCT06271538|OTHER|Placebo|One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
47949392|NCT03678883|DRUG|9-ING-41|Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
47949393|NCT03678883|DRUG|Gemcitabine - 21 day cycle|Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
47949394|NCT03678883|DRUG|Doxorubicin.|Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
48636730|NCT03686722|DRUG|Metformin|Metformin is used primarly in treatment of diabetes type II
48636731|NCT03686722|DRUG|Daclatasvir|Daclatsvir is a direct acting antiviral drug
48636732|NCT02835521|PROCEDURE|Reception|
47949395|NCT03678883|DRUG|Lomustine|Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
47949396|NCT03678883|DRUG|Carboplatin.|Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
48478216|NCT06494280|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
47949397|NCT03678883|DRUG|Nab paclitaxel.|Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
48636733|NCT02835521|DRUG|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
48636734|NCT01215162|RADIATION|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
47949398|NCT03678883|DRUG|Paclitaxel.|Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
47949399|NCT03678883|DRUG|Gemcitabine - 28 day cycle|Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
47949400|NCT03678883|DRUG|Irinotecan|Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
47949401|NCT04256096|DEVICE|Thrombectomy|Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
47949402|NCT02687373|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
47949403|NCT02687373|OTHER|Normal Saline|0.9% Sodium chloride
48636735|NCT01152385|DRUG|AZD1656|Oral tablet administered twice daily during 4 months
48636736|NCT01152385|DRUG|Placebo|administered twice daily during 4 months
48636737|NCT02149797|PROCEDURE|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
48637461|NCT05165524|DEVICE|QS Nd:YAG laser|Patients will be treated with Quality-switched (QS) Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (MedLite® C6) operating at a wavelength of 1064 nm, fluence range from 2.1 J/cm2 to 8.1 J/cm2 with a 4-6mm spot size.
47949404|NCT03979131|COMBINATION_PRODUCT|Avelumab addition to perioperative chemotherapy in GC and GEJC|Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
47949405|NCT06005597|COMBINATION_PRODUCT|Combination Therapy|tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
47949406|NCT06005597|DRUG|Monotherapy obicetrapib|tablet; 10mg obicetrapib
47949407|NCT06005597|DRUG|Monotherapy ezetimibe|capsule; 10mg ezetimibe
47949408|NCT06005597|OTHER|Combination Therapy placebo|tablet; no active ingredient
47949409|NCT06005597|OTHER|Obicetrapib Placebo|tablet; no active ingredient
47949410|NCT06005597|OTHER|Ezetimibe Placebo|capsule; no active ingredient
47949411|NCT05804097|DRUG|Hyperbaric oxygen|90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
47949412|NCT04064177|DEVICE|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
47949413|NCT04439279|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
47949414|NCT06293131|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
47949415|NCT02706678|DRUG|Tacrolimus sustained-release capsule|Oral
47949416|NCT01645137|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
47949417|NCT01645137|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
47949418|NCT02589379|PROCEDURE|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
47949419|NCT04709471|DRUG|Nicotine|Participants will reduce their nicotine intake
47949420|NCT04709471|DEVICE|Juul e-cigarette|Participants will switch to Juul pods containing less nicotine
47949421|NCT04709471|BEHAVIORAL|Reduction|Participants will reduce the number of Juul pods that they use
47949422|NCT04979052|DRUG|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
47949423|NCT05275478|DRUG|TNG908|TNG908, a selective PRMT5 inhibitor, will be administered orally
47949424|NCT01905410|DRUG|VVZ-149 Injection|VVZ-149 in water for injection
47949425|NCT01905410|DRUG|placebo|water for injection
47949426|NCT06680596|DRUG|trastuzumab derxutecan|T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment).
47949427|NCT05636826|DRUG|atherolive-drug|The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
47949428|NCT05636826|DRUG|Placebo Atherolive|The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
47949429|NCT04815278|BEHAVIORAL|Immediate Chronic Disease Prevention Program (CDPP)|The CDPP is an adaptation of the Diabetes Prevention Program (DPP). It will take place over a 24 week period and involve online instruction and individualized lifestyle coaching sessions. The online classroom curriculum includes 8 modules: Goal setting, self-monitoring and problem solving (M1), Managing stress and negative thoughts (M2), Healthy eating (M3), Taking more steps (M4), Keeping alcohol in check (M5), Lifestyle change (M6), Taking charge of what (and who) is around you (M7), and Staying motivated (M8). The lifestyle coaches will meet in person and over the phone intermittently over the 24 week period (Weeks 2, 4, 6, 10, 12, 16, 24).
47949430|NCT04815278|BEHAVIORAL|Workplace Equity, Job and Health Supports Employer Intervention|The employer intervention combines implicit bias awareness training for supervisors of hired DSS-E clients, and regular, structured, interactions between supervisors and DSS-E hires.
47949431|NCT04815278|BEHAVIORAL|Delayed, attenuated Chronic Disease Prevention Program (CDPP)|Participants will have access to a delayed, attenuated online-only version of the CDPP at the time they complete the 12 month data collection. This version will provide all modules, self-monitoring options (including through use of a Fitbit contingent on the completion of the 12 month data collection) but will not include face-to-face or phone lifestyle coach sessions.
47949432|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.5 mg/kg
47949433|NCT05144841|BIOLOGICAL|MK-2140 (zilovertamab vedotin)|IV infusion of 2.25 mg/kg
47949434|NCT04812730|OTHER|2D versus 3D analysis of EOS stereo radiographic analysis|The use of EOS stereo radiographic analysis and health related quality of life scores to measure the distance of the center of acoustic meati in the transversal plane with respect to the gravity line
47949435|NCT04812730|OTHER|Static versus dynamic analysis|The use of clinical postural tests and instrumented movement analysis to evaluate the importance of muscle fatigue and compensation mechanisms
48105474|NCT04282304|BEHAVIORAL|Preoperative usual care|"Usual care during the preoperative preparation for bariatric surgery consists of:~* Endocrinologist work-up and follow-up, with at least 2 consultations;~* Dietary advice, provided during the endocrine consultation or dietician consultation~* Psychological counselling with the patient's usual psychiatrist (at least 2 consultations~* Physical activity and nutrition are encouraged, but entrusted to the patient's freedom of choice. Weight loss, or at least, weight stabilization, is recommended before the surgery, without initiating a specific behavioural procedure."
48105475|NCT04282304|BEHAVIORAL|Preoperative intensive behavioral lifestyle intervention|"The intensive behavioral lifestyle intervention program takes place over 4 weeks of 5 days. It includes:~* Rehabilitation to physical exercise every morning~* Therapeutic cooking sessions; during these sessions, the patients prepare the day's meals under the supervision of a nutritionist~* Psychological counselling~* One swimming session per week~* One relaxation session~* Regular physical activity (aerobics, work-up)~* Individual entertainment with the physiotherapist physician and discussion groups~* Weight, BMI and waist circumference control at the end of each week."
48105476|NCT02785718|OTHER|Global Haemostasis assays|
48107203|NCT05571436|BEHAVIORAL|iCan Diabetes Self-management and Prevention Support Group|"Participants will be asked to attend six weekly sessions and complete pre-and post-assessments with an optional focus group.~The intervention will cover the following topics: 1) Yes, iCan! - Affirmations and Empowerment, 2) The Language of Diabetes - Diabetes Synopsis, 3) Diabetes and Me - Management Strategies, 4) Extraordinary Health - Dream Team, 5) Food for Thought - Food Conscious, and 6) Discussion - Stories/Goals.~Each session is composed of a Check-in, Affirmation/Empowerment Activity, Short Presentation, Q\&A and Discussion, Goal setting, and Testing Healthy Snacks."
48107204|NCT00221637|DRUG|Sodium Valproate|
48636738|NCT02149797|PROCEDURE|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
47949436|NCT04812730|OTHER|Pre- versus postoperative analysis|The use of EOS stereo radiographic imaging and motion analysis to understand the compensation mechanisms in trunk, pelvis and lower limbs and the correlation between primary and secondary mechanisms.
47949437|NCT04812730|OTHER|Reliability of the dynamic evaluation|Repeated measurements of the different aspects of the dynamic evaluation protocol (strenght measurements of trunk muscles, balance evaluation and movement analysis) will serve to evaluate the test-retest reliability and intra-rater reliability of the different protocols
47949438|NCT04454164|BIOLOGICAL|PRP|platelet rich plasma
47949439|NCT04454164|DRUG|Saline|serum physiologic
48636739|NCT02149797|PROCEDURE|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
48636740|NCT05362175|DEVICE|Obstetric ultrasound|ultrasound measurement of the cross sectional area of umbilical cord within 1 cm from the cord insertion in to fetal abdomen and the standard Hadlock's formula
48636741|NCT01682603|DRUG|Botulinum toxin A|BoNT-A (BOTOX 300U)
48636742|NCT06359535|DRUG|HSK21542|This study is an economic study and does not interfere with patients' medical treatment.
48636743|NCT06359535|DRUG|Placebo|Placebo
48636744|NCT03614585|BEHAVIORAL|12 weeks of High-intensity Interval Training|Cardiovascular exercise
47949440|NCT04130984|DEVICE|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
47949441|NCT02598726|DRUG|Curcumin|Given PO
48636745|NCT03614585|BEHAVIORAL|12 weeks of Moderate-Intensity Continuous Training|Cardiovascular exercise
47949442|NCT02598726|OTHER|Laboratory Biomarker Analysis|Correlative studies
47949443|NCT02598726|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
47949444|NCT02598726|OTHER|Quality-of-Life Assessment|Ancillary studies
47949445|NCT04350866|BEHAVIORAL|Expert Recommendations for Implementing Change bundle of strategies|"* Develop a formal implementation blueprint/checklist~* Conduct educational meetings~* Develop and distribute educational materials~* Organize implementation meetings~* Facilitation~* Increase demand with marketing to patients~* Promote adaptability"
47949446|NCT04350866|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|"An adapted version of Cognitive Behavioral Therapy for Insomnia (CBT-I) that is focused on behavioral components stimulus control and sleep restriction (the four rules):~1. Reduce time awake in bed.~2. Don't go to bed unless ready for sleep.~3. Don't stay in bed unless asleep.~4. Get up and out of bed at the same time everyday.~Delivered weekly to bi-weekly over 4-6 sessions, with each session typically 30 minutes or less, consistent with other interventions delivered in PCMHI."
47949447|NCT05027074|DRUG|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion
47949448|NCT05027074|DRUG|Placebo|Normal saline administered via IV infusion
48636746|NCT04919551|DRUG|vicagrel|Oral administration after fasting/high-fat meal/low-fat meal
48636747|NCT03235492|DEVICE|SmartAlbu|"Plan:~1. Consent an individual~2. Measure and record temperature, blood pressure, heart rate, height and weight~3. Obtain two samples of saliva for the SmartAlbu portable salivary sensor~4. Take a venous blood sample for HbA1c and~5. Glycated albumin~6. Obtain blood sample from a finger stick for point of care HbA1c device"
48636748|NCT00511290|OTHER|no generic names|
48637462|NCT05165524|DRUG|Triple cream|Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
48637463|NCT06291376|DRUG|Ravulizumab|Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
48637464|NCT06291376|DRUG|Placebo|Participants will receive placebo via weight-based IV infusion.
47949449|NCT00071396|DRUG|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
48636749|NCT03430570|BEHAVIORAL|Tablet TRAC Emotion Regulation Intervention|The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
48636750|NCT02296359|BIOLOGICAL|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
48636751|NCT03568786|PROCEDURE|End-inspiratory pause 10%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 10% of the total inspiratory time
47949450|NCT00071396|DRUG|Rituximab|375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.
47949451|NCT06671457|DEVICE|Active transcranial direct current stimulation|"The intervention uses transcranial direct current stimulation (tDCS). The targeted brain regions are identified by conducting simultaneous fMRI-EEG data collection and sleep staging, comparing fMRI data between wakefulness and sleep states. Brain regions that show differences are calculated as potential targets for electrical stimulation. If no differentiated regions are found in a participant, specific areas are chosen based on individualized modeling results from previous experiments, targeting areas such as the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Two regions are selected within each brain area for parameter scanning (with each stimulation lasting 10 seconds and EEG data recorded 10 seconds before and after stimulation).~In our prior studies, we observed a decrease in EEG microstate complexity during sleep, with electrical stimulation influencing this complexity reduction to some"
47949452|NCT06671457|DEVICE|Sham transcranial direct current stimulation|In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group. After the stimulation begins, the current gradually increases over 15 seconds. However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session. During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA. This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
47949453|NCT06237309|DRUG|REGN5381|Single dose intravenous (IV) infusion
47949454|NCT06237309|DRUG|Placebo|Single dose IV infusion
47949455|NCT01285453|DRUG|vadimezan|
47949456|NCT03207204|PROCEDURE|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
47949457|NCT03207204|PROCEDURE|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
48478217|NCT06494280|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
48478218|NCT00707434|DEVICE|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
48298392|NCT03434132|PROCEDURE|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
48636752|NCT03568786|PROCEDURE|End-inspiratory pause 30%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 30% of the total inspiratory time
47949458|NCT03207204|PROCEDURE|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
47949459|NCT03207204|PROCEDURE|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
47949460|NCT03207204|PROCEDURE|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
47949461|NCT03207204|PROCEDURE|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
47949462|NCT03207204|PROCEDURE|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
48478219|NCT02285348|PROCEDURE|Lumbar puncture|Lumbar puncture is done according to general practice
47949463|NCT03207204|PROCEDURE|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
47949465|NCT06289673|DRUG|Dexamethasone|Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
47949466|NCT06289673|DRUG|Vincristine|Intravenously (IV) for 1 dose on Day 1 or 2
47949467|NCT06289673|DRUG|Daunorubicin|Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
47949468|NCT06289673|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
47949469|NCT06289673|DRUG|Methotrexate|Given IT as part of Intrathecal triple therapy.
47949470|NCT06289673|DRUG|Cytarabine|Given IT as part of Intrathecal triple therapy.
47949471|NCT06681311|OTHER|Exercises|During the research period, all participants will undergo swimming training for 1 hour per day, 3-4 days a week for 6 weeks. The control group will perform a 5-minute land warm-up covering traditional shoulder, torso, and leg areas before their routine swimming training. In addition to the traditional warm-up program and swimming training, the experimental group will also participate in core and shoulder stabilization exercises under the supervision of a physiotherapist.
47949472|NCT05392257|DRUG|Rituximab + zanubrutinib + lenalidomide|Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
47949473|NCT05208697|BEHAVIORAL|Tele-Harm Reduction|THR is telehealth-enhanced, on-demand services including low-barrier access to antiretrovirals, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an SSP, integrated with the provision of evidence-based naloxone and injection equipment.
47949474|NCT05208697|OTHER|off-site linkage|standard of care linkage to a Ryan White clinic
47949475|NCT04877873|BEHAVIORAL|Gait analysis pre- and post- surgery|None (observational)
47949476|NCT06617923|DRUG|Senaparib|Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
47949477|NCT06617923|DRUG|Temozolomide|Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
47949478|NCT05966792|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
47949479|NCT05966792|DRUG|metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
47949480|NCT05789381|PROCEDURE|Magnesium sulfate|This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
47949481|NCT05929053|OTHER|Vaccine Education Program Based on Integrated Change Model|Vaccine Education Program Based on Integrated Change Model The training will take place in four sessions, one week apart, and each session will last approximately 45 minutes. The training will be carried out as group training with 4-5 people.
47949482|NCT04779697|DRUG|GLP-1 analogue - semaglutide|GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
47949483|NCT04779697|OTHER|Placebo|Placebo - administered once weekly for a total of 12 weeks
47949484|NCT03516617|DRUG|Acalabrutinib|Given PO
47949485|NCT03516617|OTHER|Laboratory Biomarker Analysis|Correlative studies
47949486|NCT03516617|BIOLOGICAL|Obinutuzumab|Given IV
47949487|NCT03516617|OTHER|Patient Observation|Undergo observation
47949488|NCT03516617|OTHER|Quality-of-Life Assessment|Ancillary studies
47949489|NCT04855864|OTHER|Follow-up of BCR TKA|Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation
47949490|NCT04855864|OTHER|Follow-up of BCS TKA|Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation
47949491|NCT04855864|OTHER|Follow-up of PS TKA|Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
48636753|NCT01801527|BEHAVIORAL|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
47949492|NCT06664606|BEHAVIORAL|Pain Neuroscience Education Program (PNE)|The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.
48298393|NCT01187797|OTHER|Emotional stimulation|Increase of the physical correlates of an emotion
48298394|NCT04329923|DRUG|Hydroxychloroquine Sulfate 400 mg twice a day|Antimalarial compound
48636754|NCT01509209|DRUG|Pseudoephedrine / Levocetirizine|tablet, BID everyday
48636755|NCT00348374|DRUG|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
48298395|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg twice a day|Antimalarial compound
48636756|NCT00348374|DRUG|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
47949493|NCT05975073|DRUG|AMG 193|Administered PO
47949494|NCT05975073|DRUG|IDE397|Administered PO
47949495|NCT06451848|DRUG|Genakumab Injection (T, Solution for injection)|A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1
47949496|NCT06451848|DRUG|Genakumab for Injection (R, Powder for solution for injection)|A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1
48298396|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg once a day|Antimalarial compound
48298397|NCT04329923|DRUG|Placebo oral tablet|Placebo
48478220|NCT05540873|DRUG|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
48636757|NCT03383081|BIOLOGICAL|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);
47949497|NCT04082143|DEVICE|Allograft mucosal enhancement with dental implant|implant placement with allograft mucosal enhancement
47949498|NCT04082143|DEVICE|No allograft mucosal enhancement at time of dental implant placement|implant placement without allograft mucosal enhancement
47949499|NCT06681519|PROCEDURE|Experimental Group 1 - Acupoint Pressure Experimental Group 2 - Pressure Ball Control Group - Conventional Treatment|"Interventions Group 1 - Acupoint Pressure Group 2 - Hand-Held Pressure Ball Control Group 3 - Conventional Treatment Other Names: Stress ball holding, acupoint pressure, conventional treatment~Description: Before the intervention, subjects completed a pre-test. Afterward, they assumed a relaxed, comfortable lying position. The examiner applied acupoint pressure at four specific points: Hegu (LI4), Shenmen (HT7), Neiguan (PC6), and Zhongchong (PC9).~The technique involves using the thumb pad to apply circular and vertical pressure on each acupoint, with the other four fingers stabilizing against the skin to ensure even pressure. The pressure is gradually increased from light to moderate until the patient experiences sensations of soreness, numbness, or swelling, commonly described as deqi (Ye Meiling et al., 2020).~Each acupoint is pressed vertically for 3 seconds, then rotated clockwise at a rate of 2-3 rotations per second for another 3 second"
48298398|NCT02625142|OTHER|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
48298399|NCT02481518|DRUG|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
48298400|NCT02481518|OTHER|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
48298401|NCT06395142|OTHER|pedal walking|Pedal walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation. A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during pedal walking in stroke participants.
48298402|NCT06395142|OTHER|visual-deprivation walking|visual-deprivation walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation.A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during visual-deprivation walking in stroke participants.
48298403|NCT00778999|DRUG|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
48298404|NCT02466269|PROCEDURE|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
48636758|NCT03383081|BIOLOGICAL|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)
48636759|NCT03383081|PROCEDURE|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
48636760|NCT01467856|PROCEDURE|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP \> 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
48636761|NCT04826757|OTHER|Coordinated care|"Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)"
48636762|NCT05492682|DRUG|PeptiCRAd-1|All patients will receive 6 doses of PeptiCRAd-1.
48636763|NCT05492682|DRUG|Cyclophosphamide|All patients will be pre-treated with one single dose of Cyclophosphamide.
47949500|NCT06416033|PROCEDURE|Serum Irisin|Measurement of plasma irisin level in leprosy patients.
47949501|NCT05054036|DRUG|MoviPrep|Split-dose MoviPrep bowel preparation
47949502|NCT05054036|DRUG|Golytely|Split-dose GoLYTELY bowel preparation
48298405|NCT05836012|BIOLOGICAL|HIL-214|2 injections - given at 4 months and the second at 6 months of age.
48298406|NCT05836012|BIOLOGICAL|Placebo|2 injections - given at 4 months and the second at 6 months of age.
47949503|NCT03516812|OTHER|Laboratory Biomarker Analysis|Correlative studies
48298407|NCT02979067|PROCEDURE|Nasal oxygen flow|Nasal oxygen flow during apnoea
48298408|NCT01636869|DRUG|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
48298409|NCT04115631|DRUG|Acalabrutinib|Given PO
48298410|NCT04115631|DRUG|Bendamustine|Given IV
48298411|NCT04115631|DRUG|Bendamustine Hydrochloride|Given IV
48298412|NCT04115631|DRUG|Cytarabine|Given IV
47949504|NCT03516812|DRUG|Olaparib|Given PO
47949505|NCT03516812|OTHER|Quality-of-Life Assessment|Ancillary studies
47949506|NCT03516812|OTHER|Survey Administration|Ancillary studies
47949507|NCT03516812|DRUG|Testosterone Enanthate|Given IM
47949508|NCT03516812|DRUG|Testosterone Cypionate|Given IM
47949509|NCT05694052|BEHAVIORAL|Multifaceted Intervention of environment control|Dynamic light therapy, auditory masking, and rationalization of ICU nocturnal patient activities.
47949510|NCT00114101|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
47949511|NCT00114101|OTHER|Laboratory Biomarker Analysis|Correlative studies
47949512|NCT00114101|DRUG|Lenalidomide|Given PO
47949513|NCT00114101|DRUG|Melphalan|Given IV
48266472|NCT05286606|BEHAVIORAL|Exercise and Social Groups|"Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support."
48298413|NCT04115631|BIOLOGICAL|Rituximab|Given IV
48298414|NCT03688646|DIETARY_SUPPLEMENT|Intensive Nutrition Intervention|
48298415|NCT02480075|OTHER|Observational|Observational Study only
47949514|NCT00114101|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
47949515|NCT00114101|OTHER|Placebo Administration|Given PO
47949516|NCT04543838|DIAGNOSTIC_TEST|Intervention|Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring
47949517|NCT04543838|OTHER|Standard of Care BP management|If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
47949518|NCT06070441|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
47949519|NCT06070441|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
47949520|NCT06070441|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
47949521|NCT05380310|DEVICE|"Active SMART ANGEL solution"|Nurse intervention according to the alert level + traditional monitoring
47949522|NCT05380310|DEVICE|"Inactive SMART ANGEL solution"|No alert + traditional monitoring + alert in case of imminent life threat
47949523|NCT03487523|BEHAVIORAL|Text Message|As already stated
48298416|NCT02967848|OTHER|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
47949524|NCT05917210|BEHAVIORAL|Standard TB-EC|Standard TB-EC by healthcare workers
47949525|NCT05917210|BEHAVIORAL|Peer navigation strategy for TB-EC|multi-component, peer-navigation strategy for TB-EC
47949526|NCT01815983|OTHER|Videolaryngoscopy review.|Review of video recordings.
47949527|NCT03812653|DEVICE|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
47949528|NCT05626751|DRUG|HZN-825|HZN-825 will be administered BID for 52 weeks
47949529|NCT06387511|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax|"1. The SQ-LNS distribution program will be implemented for 12 consecutive months in the NutriVax arm.~2. Community mobilizers in the NutriVax arm will give information in the community about SQ-LNS and eligibility criteria for SQ-LNS distributions.~3. All SQ-LNS distributions will take place at the primary health care center (PHCC) of each ward.~4. Children aged 6-22m, residing in settlements of the catchment area of the NutriVax arm are eligible for a monthly ration of SQ-LNS (28 sachets per month) following a check and update of his or her vaccine status at PHCC; unless there are serious issues related to access to PHCC, in which cases ration sizes may be revised upwards to three months' worth.~5. All children will exit the SQ-LNS distribution program when they are 23 months of age OR after receiving a maximum of 12 consecutive monthly rations, whichever comes first.~6. The total amount of SQ-LNS a child receives will depend on when they enroll in the SQ-LNS distribution program."
47949530|NCT06387511|BEHAVIORAL|Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices|"1. Parents or guardian of children will be encouraged/sensitised to attend their scheduled preventive visits to receive other essential paediatric services;~2. Sensitization on vaccination and recommended Infant and Young Child Feeding (IYCF) practices including the need to consume a diverse nutritious diet and support for continued breastfeeding will be conducted according to the Ministry of Health's routine plans in the community and at primary health care centres;~3. Community mobilizers will promote the importance of vaccinations according to the Expanded Program on Immunization (EPI) as well as IYCF good practices messages."
47949531|NCT06355934|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
47949532|NCT06681389|DRUG|NP-201 acetate injection (Part A)|Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days
48298417|NCT02967848|OTHER|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
48298418|NCT02967848|OTHER|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
48298419|NCT05588492|DRUG|Rifamycin-containing regimen|Rifamycin-containing regimen
48298420|NCT05588492|DRUG|Rifamycin-free regimen|Rifamycin-free regimen
48298421|NCT00204633|DRUG|Darbepoetin alfa|
47949533|NCT06681389|DRUG|Placebo|Matching placebo administered across Part A and Part B
47949534|NCT05751434|BEHAVIORAL|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
47949535|NCT02661997|BEHAVIORAL|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
47949536|NCT02661997|BEHAVIORAL|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
48298422|NCT05299827|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
47949537|NCT03866460|DIAGNOSTIC_TEST|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
47949538|NCT05514132|DRUG|Ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
47949539|NCT05514132|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
47949540|NCT00904397|DRUG|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
47949541|NCT00904397|DRUG|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
47949542|NCT06560684|DRUG|Oral F/TDF Pills|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated RAI.
47949543|NCT06560684|DRUG|TFV rectal douche|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
47949544|NCT04185376|OTHER|Questionnaire|a self-administered questionnaire for the assessment of pelvic floor disorders, their risk factors and their impact of quality of life during pregnancy and postpartum period which integrates bladder, bowel and sexual function, pelvic organ prolapse, severity, bothersomeness and conditions specific quality of life in women with urinary incontinence (UI) and/or POP. The questionnaire is divided into four main domains (bladder, bowel, pelvic organ prolapse, sexual function) and each question is scored from zero to three. The additive scores are divided by the maximum reachable score and multiplied by ten, giving a value between zero (0 = no symptoms) and ten (10 = maximum symptoms) for each of the domains.
47949545|NCT06427473|BEHAVIORAL|Dietary program|Participants will attend 8-week online dietary course. In addition to weekly classes, participants are required to photograph each meal.
47949546|NCT06427473|BEHAVIORAL|Exercise program|Everyday walking steps more than 4000 steps. To accurately track participants' daily step counts, the research team provided quailfied pedometers.
47949547|NCT06427473|BEHAVIORAL|Mindfulness program|Participants will attend 8-week online mindfulness course. In addition to weekly classes, participants practiced mindfulness individually for 5 minutes each day and maintained a mindfulness diary.
48266473|NCT06549088|DEVICE|Spatial Frequency Domain Imaging|Resected lung tissue will be removed from the surgical field and labeled with sutures per standard of care. The specimen will then be immediately analyzed using two SFDI devices in the operating room using sterile technique. Each specimen will be recorded up to three times to ensure at least one high fidelity recording is captured. The SFDI data will be analyzed and compared to the official pathology report from the electronic medical record.
48478221|NCT04276935|OTHER|Interview|Participate in cognitive interview
48266474|NCT01653119|DRUG|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
48266475|NCT04478825|DRUG|BBT-401-1S|BBT-401-1S, 8 weeks, once a day
48266476|NCT01871090|DEVICE|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
48266477|NCT05137561|PROCEDURE|PSMA PET guided prostate biopsy|PSMA PET-guided prostate biopsy from PSMA avid prostatic lesion will be done.
48266478|NCT05137561|PROCEDURE|MRI directed TRUS guided prostate biopsy|TRUS guided MR directed Cognitive fusion prostate biopsy based on the PIRADS scoring
48266479|NCT05723432|DRUG|KD6001|KD6001 will be administered intravenously.
48266480|NCT05723432|DRUG|Toripalimab|Toripalimab will be administered intravenously.
48478222|NCT04276935|OTHER|Quality-of-Life Assessment|Ancillary studies
48478223|NCT04276935|OTHER|Questionnaire Administration|Ancillary studies
48478224|NCT01754987|DRUG|Ascorbic Acid + Sorafenib|
48478225|NCT01754987|DRUG|Sorafenib|
48636764|NCT05492682|DRUG|Pembrolizumab|All patients will receive 6 doses of Pembrolizumab within the study.
48636765|NCT05181631|OTHER|Biobanking|"Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL. "
48636766|NCT04635982|OTHER|Kinesiotape of the physical performance|It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
47949548|NCT06449521|BEHAVIORAL|BECOME intervention|The intervention, BECOME, includes: a) Evidence-based stress reduction (EBSR): as recommended in the WHO mhGAP guidelines, diaphragmatic breathing and body scan will be used to manage stress and anxiety. b) Behavioral activation (BA): as recommended in the mhGAP guidelines, this evidence-based strategy will increase the time that patients spend engaging in pleasurable activities to both treat depression and increase physical activity, depending on their cognitive and physical capabilities (e.g., going to a neighbor's house for tea or walking to the local market). c) Motivational interviewing (MI): an evidence-based patient-interaction strategy that increases the patient's internal motivation to engage in healthy behaviors (e.g., quit tobacco) both to prompt change (if they are not engaging in healthy behaviors) and maintain them (if they are already engaged in healthy behaviors), as recommended by Package of Essential Noncommunicable disease interventions) PEN protocols.
47949549|NCT05485155|DRUG|Alpha-proteinase inhibitor|Intravenous infusion at 120 mg/kg body weight dose/week for 8 weeks for a total of 8 infusions.
47949550|NCT05304208|BIOLOGICAL|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
47949551|NCT02373878|BEHAVIORAL|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
47949552|NCT02373878|BEHAVIORAL|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
48105477|NCT05646745|PROCEDURE|Autologous Transobturator Fascia Lata Sling|"Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip."
48266481|NCT00453401|DRUG|NB-001|
48636767|NCT05389800|OTHER|Upper Extremity Aerobic Exercise|Using a cycle-ergometer (Monark 881E)
47949553|NCT05852691|DRUG|Tobemstomig|Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
47949554|NCT05852691|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
47949555|NCT05852691|DRUG|Nab-Paclitaxel|Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
47949556|NCT06426433|OTHER|Proprioceptive Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Proprioceptive exercises aim to restore muscle balances, unconscious joint control with reactive muscle activations and feedforward joint control.
48636768|NCT04380025|DIETARY_SUPPLEMENT|Experimental: Oral Mirtogenol|The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
48636769|NCT04380025|DIETARY_SUPPLEMENT|Placebo of oral Dietary supplement|This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
48636770|NCT03055078|BIOLOGICAL|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
48636771|NCT05541471|DRUG|VX-548|Tablets for oral administration.
48636772|NCT05541471|DRUG|Midazolam|Syrup for oral administration.
48636773|NCT05541471|DRUG|Digoxin|Tablets for oral administration.
48636774|NCT01310114|BIOLOGICAL|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
48636775|NCT01310114|DRUG|Placebo|Thawed placebo
48636776|NCT00862277|BIOLOGICAL|Menactra®|0.5 mL, Intramuscular (from a previous study)
48636777|NCT00862277|BIOLOGICAL|Menomune®|0.5 mL, Intramuscular (from a previous study)
48636778|NCT00017186|DRUG|epirubicin hydrochloride|
48636779|NCT00017186|DRUG|gemcitabine hydrochloride|
48637465|NCT06533111|OTHER|Epic Health Record semi-structured handoff cognitive aid|Epic Health Record cognitive aid will be used for intraoperative anesthesia handoff
47949557|NCT06426433|OTHER|Upper Extremity Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.
47949558|NCT02987842|DEVICE|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
47949559|NCT05191563|DRUG|HCP1904-1|Take it once per period.
47949560|NCT05191563|DRUG|RLD2006|Take it once per period.
48266482|NCT05273684|OTHER|High intensity interval training|Participants will undergo 4x4 and 1x10 minutes of interval training on two separate days.
48266483|NCT06334094|DRUG|Ozanimod|A hard capsule that is taken daily for one year.
47949561|NCT05191563|DRUG|RLD2001-2|Take it once per period.
47949562|NCT04199182|BEHAVIORAL|Exercise Training|A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.
47949563|NCT04199182|OTHER|Healthy Aging Attention Control (HA-ATC)|"Participants in the HA-ATC group will receive a health education program modeled on the 10 Keys to Healthy Aging curriculum and the National Council on Aging's Aging Mastery Program. HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months."
47949564|NCT00378339|DEVICE|gold berlocks|
47949565|NCT06278051|DRUG|Rivaroxaban granules for oral suspension|Treatment dose and period decided by its prescription
47949566|NCT06278051|DRUG|Warfarin|Treatment dose and period decided by its prescription
48636780|NCT05180656|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of two 60-minute yoga classes each week, taught by a certified yoga instructor and delivered remotely through videoconferencing. Participants will be asked to participate in the intervention for 8 weeks.
48636781|NCT03075436|BEHAVIORAL|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
48636782|NCT03075436|BEHAVIORAL|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
48478226|NCT01119807|DEVICE|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
48105478|NCT05329454|DRUG|Ibuprofen Tablets|"Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing)."
48105479|NCT05691660|DRUG|TAS3731 Dose1|Oral administration,1 day,QD
48105480|NCT05691660|DRUG|TAS3731 Dose2|Oral administration,7 days,QD
48637466|NCT06533111|OTHER|Usual care|Epic Health Record cognitive aid will not be used for intraoperative anesthesia handoff
48478227|NCT01119807|DEVICE|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
48478228|NCT01119807|DEVICE|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
47949573|NCT06679959|DRUG|ASC30|Injection, for subcutaneous use
47949574|NCT06679959|OTHER|Placebo|Injection, for subcutaneous use
47949575|NCT06084416|DRUG|Sovilnesib|Sovilnesib tablets will be given orally.
48105481|NCT05691660|DRUG|TAS3731 Dose3|Oral administration,7 days,BID
47949576|NCT05847283|PROCEDURE|Dydrogesterone priming ovarian stiumulation protocol|Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.
47949577|NCT05847283|PROCEDURE|GnRH antagonist protocol|In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
47949578|NCT04610866|DRUG|Mitapivat|Investigational drug mitapivat (also known as AG-348, AGI-1480 and AGX-0841) is an orally bioavailable, broad-spectrum allosteric activator of alleles of the RBC-specific form of pyruvate kinase (PKR), as well as liver-type pyruvate kinase (PKL) and muscle pyruvate kinase (PKM1 and PKM2).
47949579|NCT02149875|DRUG|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
47949580|NCT02149875|DRUG|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
47949581|NCT02149875|DRUG|Placebo|100 ml saline intravenous infusion once daily for 10 days.
47949582|NCT01796756|OTHER|Handover program|
47949583|NCT03755388|DEVICE|Episealer|Placing Episealer device
47949584|NCT04452032|PROCEDURE|Dental avulsion|Before radiotherapy, each subject undergoes a dental evaluation and if it is necessary, dental avulsions if their long-term survival is compromised (see in section 6.1.2) and if they are located in an area at risk to receive more than 40 Gy, so to develop osteoradionecrosis of the jaw. The avulsions should be performed as far as possible from the start of radiotherapy (RT) namely at least 2 weeks before irradiation to allow mucosal healing.
48105482|NCT05691660|DRUG|Placebo|Oral administration, 1 day,QD
48105483|NCT05691660|DRUG|Placebo|Oral administration, 7 days,QD
48105484|NCT05691660|DRUG|Placebo|Oral administration, 7 days,BID
48105485|NCT00363116|DRUG|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
47949585|NCT04452032|RADIATION|Radiotherapy|"Radiotherapy:~All Subjects will be treated by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) / volumetric modulated arc therapy (VMAT)."
47949586|NCT02791594|DRUG|Pembrolizumab|Patients were treated with pembrolizumab according to standard of care.
47949587|NCT06681298|DRUG|The experimental group received Nivolumab|Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.
47949588|NCT05162846|OTHER|Publicly available genetic testing resources|Participants may view the publicly available Michigan Department of Health and Human Services (MDHHS) website as they wish.
47949589|NCT05162846|BEHAVIORAL|Virtual genetics navigator|A mobile-optimized website/online genetic tool developed by investigators from the University of Michigan's Center for Health Communications Research (CHCR).
48105486|NCT05081310|DEVICE|superior vena cava isolation|SVC isolation by the means of cryoballoon
48105487|NCT05081310|DEVICE|pulmonary vein isolation|conventional pulmonary vein isolation by the means of cryoballoon
48105488|NCT02675491|DRUG|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
48636783|NCT01520714|DEVICE|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
48105489|NCT00430300|DRUG|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
48105490|NCT00430300|DRUG|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
48105491|NCT05677178|OTHER|observational|This study is an observational study without any intervention.
48105492|NCT02072213|DRUG|GL2702 GLARS-NF1|0.4mg once a day
48105493|NCT02072213|DRUG|Omix Ocas|0.4mg once a day
48105494|NCT05338996|BEHAVIORAL|iENGAGE for PrEP|This intervention originally developed for people living with HIV (PLWH), is designed to promote engagement, retention, and adherence to treatment by addressing the social determinants of health that often act as barrier to remaining in care and achieving viral suppression. Based on our experience with this intervention we believe that it is well suited to similarly promote engagement, retention, and utilization of PrEP care among our proposed target population of WOC by a) removing barriers to care and b) addressing unmet needs by providing c) point-to-point linkage to care services delivered by multi-disciplinary teams of individuals within or outside of the health facility, and d) the use of telehealth visits to facilitate engagement in care and improve health visit attendance. The original iENGAGE is a 4-session, in-clinic behavioral intervention.
48105495|NCT03328949|DEVICE|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
47949590|NCT05162846|BEHAVIORAL|Motivational interviewing (MI)|At least 2 phone calls delivered by trained genetic health coaches using motivational interviewing and providing genetic testing information.
47949591|NCT00561769|DRUG|Norditropin pen|12 IU per day
48105496|NCT02491723|DRUG|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
48105497|NCT00839540|DRUG|micafungin|100 mg qd by slow IV infusion for 24 h
48105498|NCT00839540|DRUG|Micafungin|200 mg qd by slow IV infusion for 24 h
47949592|NCT05184556|BEHAVIORAL|Family-based treatment (FBT)|FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.
48105499|NCT00839540|DRUG|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
48105500|NCT04965467|DIAGNOSTIC_TEST|Screening for Fabry disease|A questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.
48105501|NCT03551067|DRUG|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
48105502|NCT03551067|COMBINATION_PRODUCT|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
48105503|NCT05744206|OTHER|Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time|The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
48105504|NCT02247258|DRUG|Azathioprine|See arm/group descriptions
48105505|NCT02247258|DRUG|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
48105506|NCT02247258|PROCEDURE|Ileocolonoscopy|See arm/group descriptions
48105507|NCT02247258|PROCEDURE|Small bowel follow trough|See arm/group descriptions
48105508|NCT06321809|BEHAVIORAL|intensive lifestyle|INTENSIVE LIFESTYLE INTERVENTIONS
48266484|NCT05730387|OTHER|Observational only|This is a non-interventional study
48636784|NCT03438656|BEHAVIORAL|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
48105509|NCT02117401|DRUG|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
48105510|NCT02117401|DRUG|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
48105511|NCT02117401|DRUG|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
48105512|NCT02117401|DRUG|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
48636785|NCT02539394|DRUG|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
47949593|NCT05184556|BEHAVIORAL|Integrative family therapy|The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.
47949594|NCT01134731|DRUG|paliperidone|1-5 mg daily (QD)
47949595|NCT01134731|DRUG|lithium|300-1500mg QD
47949596|NCT01134731|DRUG|Placebo|1-5 placebo capsules
47949597|NCT06680258|DRUG|TPST-1120|TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)
47949598|NCT06680258|BIOLOGICAL|Atezolizumab|Atezolizumab is an IV administered biologic.
47949599|NCT06680258|BIOLOGICAL|Bevacizumab|Bevacizumab is an IV administered biologic.
47949600|NCT02291874|DRUG|Ipragliflozin|oral
47949601|NCT06681402|DRUG|FLAMOD|FLAMOD (GMP-grade flagellin) inhalation
48105513|NCT02117401|DRUG|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
48105514|NCT06248359|DRUG|L-Arginine hydrochloride|Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI
48105515|NCT02179281|DEVICE|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
47949602|NCT06681402|DRUG|Placebo|Placebo inhalation
47949603|NCT06680778|DEVICE|Proactive Monitoring|Proactive monitoring of vital signs for the duration of the first two cycles of chemotherapy by using a Fitbit
47949604|NCT03624231|DRUG|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
47949605|NCT03624231|DRUG|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
48105516|NCT01260298|DEVICE|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
48105517|NCT04114383|OTHER|D3-Creatine|30mg D3-Creatine to measure muscle mass
48105518|NCT04114383|OTHER|Deuterium Oxide|D2O provided to measure muscle protein synthesis
48105519|NCT04114383|OTHER|D3-3-methylhistidine|D3-3-methylhistidine is provided to measure muscle protein breakdown
48105520|NCT04351113|DIETARY_SUPPLEMENT|MITO-AO|Participants will receive 160 mg with breakfast on day 1 of bed rest and 40 mg with breakfast on days 2-5.
48105521|NCT04351113|DIETARY_SUPPLEMENT|PB-125|Participants will receive 100 mg on days 1-5 of bed rest.
47949606|NCT03624231|RADIATION|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
48105522|NCT04351113|OTHER|Placebo|Participants will receive Placebo on days 1-5 of bed rest.
48105523|NCT04351113|OTHER|Passive Leg Movement (PLM)|Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
48105524|NCT04351113|OTHER|Plantar flexion|Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
48105525|NCT04351113|OTHER|Isometric knee extensor test|Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
48636786|NCT02539394|OTHER|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
48637467|NCT06493383|DEVICE|Lotrafilcon B plano cosmetic contact lenses|Commercially approved colored contact lenses worn for cosmetic purposes to alter or enhance the apparent color of the eye
48637468|NCT05017948|OTHER|Risk score based intervention|Targeted interventions based off of risk score software
48637469|NCT02405208|DEVICE|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
48637470|NCT03044288|OTHER|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
47949607|NCT04871282|DRUG|AL102|AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
47949608|NCT04871282|OTHER|Placebo|Placebo to match AL102
48637471|NCT03044288|OTHER|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
47949609|NCT06302127|OTHER|Team-based care|The RISIMA model is provided by a family healthcare team composed of one village doctor, one general physician at township health centers and one specialist including cardiologists, neurologists or endocrinologists from county hospital. For villages without village doctor, public health professionals from township health centers would join the service team as the supplement. Within the team, three team members carry the different function. Village doctor is responsible for regular home visits, CVD risk measurement and organizing health education course. GP as the core service provider in the team is responsible for CVD risk monitoring, providing health education course for middle-high risk participants, and generating integrated care plans for each participant. Specialist is responsible for providing guidance particularly for high-risk population management to township and village doctors within the team.
47949610|NCT06302127|PROCEDURE|Risk-stratified care pathway|Based on WHO/ISH score, baseline population will be divided into three groups-low risk (10-year CVD risk: \&lt;10%), middle risk (10-year CVD risk: 10%\~20%) and high risk (10-year risk: \&gt;20%). With the support from experts and health care professionals, study had developed a risk-stratified care pathway on the basis of clinical guidance. According to the pathway, participants at different risk tertile are provided with differentiated management plan especially in terms of health education, follow-up frequency and treatment plan.
47949611|NCT06302127|BEHAVIORAL|Strengthened health education|The education comprised 8 monthly sessions developed by GP and village doctors. At the 4th month, individual health counseling by village doctors will be done to encourage the imitation and maintenance of self-management behaviors, and to identify any potential problems in the program. It took half an hour per each participant. At the 8th month, self-management evaluation will be done to assess personal self-management ability. High risk participants are required to take the education course, and middle risk participants are only encouraging to take. All participants would receive the education messages twice a month, which introduce tips about the management of hypertension, diabetes and CVD risk factors.
47949612|NCT06302127|OTHER|Financial incentives for integration of care|Specialists receive reimbursement for case discussion and high risk population management; GP receive reimbursement for providing education program and risk monitoring; Village doctor receive reimbursement for assisting education program, risk measurement and home visits. And overall services quality will be measured, and taken into account for annual performance evaluation.
47949613|NCT06302127|OTHER|Supporting health information system|A dynamic patient risk monitoring information system is established for simplifying the risk data collection and entry for village doctors, meanwhile, GP and specialist can receive the updates of risk scores simultaneously. Apart from the function of risk monitoring, this system also incorporates the e-records of home visits, health education attendance as well as medical records including outpatient visits and hospitalizations. The upgraded information systems not only can support the healthcare professionals with comprehensive and real-time data, but also provide the performance evaluation data for policymakers.
47949614|NCT02507973|OTHER|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
47949615|NCT02507973|OTHER|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
47949616|NCT05764408|DEVICE|traxi® Panniculus Retractor|traxi® Panniculus Retractor is a disposable adhesive medical device designed for surgical patients with a BMI of at least 30kg/m2, to retract a pannus cephalad and expose the lower abdomen. The device is like a large sticker or bandage, posing no more than minimal risk to participants. The adhesive will be applied to the abdomen according to manufacturer instructions, just prior to a participant's scheduled ultrasound. Once the ultrasound exam has ended, the adhesive will be immediately removed and discarded.
47949617|NCT04334759|DRUG|Durvalumab|Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
47949618|NCT04334759|DRUG|Standard Chemotherapy|Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
48637472|NCT06135012|DEVICE|Cavitron ultrasonic surgical aspirator (CUSA)|Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).
48637473|NCT06135012|OTHER|Scalpel|Transection of pancreatic tissue with scalpel.
48637474|NCT06154447|DRUG|VX-828|Suspension for Oral Administration
48637475|NCT06154447|DRUG|Placebo|Suspension for Oral Administration
48637476|NCT06154447|DRUG|Itraconazole|Solution for Oral Administration
48637477|NCT06154447|DRUG|Midazolam|Syrup for Oral Administration
48637478|NCT03640988|DEVICE|dermaPACE|Shockwave application
48637479|NCT02565186|DRUG|Lasmiditan|oral tablet
48637480|NCT06566196|PROCEDURE|Cardiac Cath|Patient will undergo standard of care Cardiac Cath and in addition invasive CPET (Cardiopulmonary exercise testing) will be performed during the procedure.
48478229|NCT02754024|PROCEDURE|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
48478230|NCT02754024|PROCEDURE|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
47949619|NCT04334759|DRUG|Ipilimumab and Nivolumab|Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
47949620|NCT03697057|PROCEDURE|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
47949621|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus liposomal bupivacaine|Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
47949622|NCT03816982|PROCEDURE|Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB|Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
47949623|NCT05012657|DEVICE|Point Partial|The Point Partial partial finger prosthetic system consists of 1-4 ratcheting mechanical partial digits and mounting brackets
47949624|NCT00214643|DRUG|Fosmidomycin|30 mg/kg
47949625|NCT00214643|DRUG|clindamycin|10 mg/kg
47949626|NCT06323954|PROCEDURE|tVNS stimulation|Electrical stimulation to the vagus nerve area.
47949627|NCT06323954|PROCEDURE|Sham stimulation|Electrical stimulation to the non-vagus nerve area.
47949628|NCT05276024|DEVICE|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
47949629|NCT01299987|RADIATION|intraoperative radiotherapy|intraoperative single dose radiotherapy (20 Gy)
47949630|NCT03999853|DRUG|BKR-017|BKR-017
47949631|NCT05733377|DIAGNOSTIC_TEST|Arrow Test|It consists of taking the widest measurement between the rope of a plumb bob on her upper and lower back.
47949632|NCT05733377|DIAGNOSTIC_TEST|Angle measurement by imaging device|First, three anatomical landmarks are located, and a sticker is placed on each of them: the 12th thoracic vertebra at its intersection with the midline descending from the axilla, the greater trochanter, and the anterior superior iliac spine. After this, the woman will be asked to stand in a normal position facing forward with her hands crossed over her shoulders, and a picture will be taken and pixelated with anything that could identify her. The angle formed by the three stickers will be measured with this image and the software.
47949633|NCT00482261|DRUG|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
47949634|NCT00482261|DRUG|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
48636787|NCT06557369|DEVICE|reSEES|"The treatment consists of combining SMPL and PBM light therapies to exploit the full advantage of their action. The combination will result in an additive or synergetic effect.~* Treatment sessions are scheduled for three weeks after enrolment (Loading-Phase).~* Two visits per week are needed.~* At the first visit of every treatment week, two treatment sessions will follow each other; PBM is applied at least 15' after SMPL (treatment pairs).~* Only PBM will be administered during the second visit of every treatment week.~Patients will receive:~* 1x SMPL treatment at days 0, 7, and 14 (3 in total),~* 1x PBM treatment at days 0, 3, 7, 10, 14, and 17 (6 in total)~Nine treatments will be delivered within three weeks. The study will be concluded with three follow-up visits at 18, 24, and 54 weeks."
48636788|NCT06208163|PROCEDURE|Chiropractic|Chiropractic spinal adjustments
47949635|NCT00482261|DRUG|aspirin|100mg/day
47949636|NCT05701033|OTHER|Access to heritage|Unmediated access to heritage sites for wellbeing
48105526|NCT04351113|OTHER|Bed rest|Participants will undergo 5 days bed rest after 5 day baseline assessments
48105527|NCT03038399|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
48478231|NCT02754024|DEVICE|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
48478232|NCT02278718|DRUG|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
48478233|NCT02278718|PROCEDURE|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
48636789|NCT02992431|BEHAVIORAL|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
48636790|NCT02992431|OTHER|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
48636791|NCT06234111|COMBINATION_PRODUCT|Semaglutide 2.4 mg, total diet replacement, behavioural intervention|Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
48636792|NCT05816473|OTHER|LLM|Use of a Large Language Model (LLM) chatbot interface to Interact with the Machine Learning Algorithm and interpretability dashboard.
48636793|NCT01433965|DRUG|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
48636794|NCT01229670|OTHER|exercise|"* 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
48636795|NCT00601900|BIOLOGICAL|Bevacizumab|Given IV
48636796|NCT00601900|OTHER|Laboratory Biomarker Analysis|Correlative studies
47949637|NCT04190667|DIAGNOSTIC_TEST|Genomic testing|A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status.
47949638|NCT04622462|PROCEDURE|Standard of Care Histopathology|Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
48105528|NCT03038399|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
48636797|NCT00601900|DRUG|Letrozole|Given PO
48636798|NCT00601900|OTHER|Questionnaire Administration|Ancillary studies
47949639|NCT04622462|PROCEDURE|STRATICYTE Assessment|Assessment for risk of progression to oral cancer
48636799|NCT00601900|DRUG|Tamoxifen Citrate|Given PO
48636800|NCT03604978|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48636801|NCT03604978|PROCEDURE|Echocardiography|Undergo ECHO
48636802|NCT03604978|BIOLOGICAL|Ipilimumab|Given IV
48636803|NCT03604978|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
48636804|NCT03604978|BIOLOGICAL|Nivolumab|Given IV
48636805|NCT03604978|RADIATION|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
47949640|NCT06046833|DEVICE|FreeStyle Libre 3 continuous glucose monitoring sensor|The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
47949641|NCT06046833|OTHER|Nutritional drink|Balanced nutritional drink (Boost plus 8 ounces/237 mL)
47949642|NCT04680130|DRUG|C-11 PiB|Completing PET scan looking for amyloid protein
47949643|NCT04680130|DRUG|AV1451 Tau|Completing PET scan looking for tau protein
48105529|NCT03038399|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
48105530|NCT03038399|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
48105531|NCT06381492|DEVICE|MRI|MRI using DTI technology
48105532|NCT06381492|DEVICE|Ultrasound (US)|Standard US
48636806|NCT06356597|DRUG|Tislelizumab with Fruquintinib, Metronidazole|"Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle."
48636807|NCT03056755|DRUG|Alpelisib|300 mg of alpelisib film-coated tablets administered orally once daily
48636808|NCT03056755|DRUG|Fulvestrant|500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
48636809|NCT03056755|DRUG|Letrozole|2.5 mg of letrozole film-coated tablets administered orally once daily
48636810|NCT03056755|DRUG|Goserelin|3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
48636811|NCT03056755|DRUG|Leuprolide|7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
48636812|NCT00831896|BIOLOGICAL|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
48636813|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 Low Dose
48636814|NCT00908687|BIOLOGICAL|A/H5N1|A/H5N1 High Dose
48636815|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
48636816|NCT00908687|BIOLOGICAL|LT Adjuvant Patch|LT Adjuvant Patch High Dose
48636817|NCT03912415|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
48636818|NCT03912415|BIOLOGICAL|Bevacizumab|IV infusion
48636819|NCT03912415|DRUG|Paclitaxel|IV infusion
48105533|NCT04461236|DIETARY_SUPPLEMENT|Oral Supplement|Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
48105534|NCT04461236|DIETARY_SUPPLEMENT|Placebo|Placebo
48105535|NCT00547118|DRUG|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
48105536|NCT00547118|DRUG|Placebo|One placebo tablet given 1 time per day for 112 days.
48105537|NCT02787109|BIOLOGICAL|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
48105538|NCT02787109|BIOLOGICAL|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
48636820|NCT03912415|DRUG|Cisplatin (or Carboplatin)|IV infusion
48636821|NCT03912415|OTHER|Placebo|Placebo
48636822|NCT05067244|DRUG|MDMA|MDMA assisted psychotherapy
48636823|NCT06580912|DRUG|Krill oil|4 grams of krill oil per day
48105539|NCT02787109|BIOLOGICAL|Placebo|Saline
48105540|NCT03284411|DEVICE|Spinal Cord Stimulation|Programming
47949644|NCT04680130|DRUG|C-11 ER176|Completing PET scan looking for neuroinflammation
48105541|NCT06261450|DRUG|CBD Oral Solution (eCBD system Target)|Participants receive orally 6 ml of CBD Oral Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD) followed by 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution 3 weeks later.
48105542|NCT06261450|DRUG|Placebo|Participants receive orally 6 ml of a placebo composed of the inactive ingredients of CBD Oral Solution followed by 6 ml of Oral CBD Solution (100 mg / ml; 60 mg / kg; max 600 mg of CBD)
48478234|NCT03543852|BEHAVIORAL|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
48636824|NCT06580912|DIETARY_SUPPLEMENT|Mixed vegetable oil|4 grams of mixed vegetable oil per day
48636825|NCT06349473|DRUG|SR604|SR604 will be administered as SC injection.
48636826|NCT06349473|DRUG|Placebo|Placebo will be administered as single SC injection.
48636827|NCT03779854|RADIATION|Total-Body Irradiation|Undergo TBI
48636828|NCT03779854|DRUG|Thiotepa|Given IV
48636829|NCT03779854|DRUG|Fludarabine|Given IV
48636830|NCT03779854|DRUG|Cyclophosphamide|Given IV
48636831|NCT03779854|DRUG|Busulfan|Given IV
48636832|NCT03779854|PROCEDURE|Allogeneic Bone Marrow Transplantation|Receive unmanipulated T cell replete BM
48636833|NCT03779854|DRUG|Tacrolimus|Given IV
48636834|NCT03779854|DRUG|Methotrexate|Given IV
48636835|NCT03779854|PROCEDURE|Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|Receive naive T-cell depleted PBSCs
48636836|NCT03779854|PROCEDURE|Echocardiography|Undergo ECHO
48636837|NCT03779854|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
48105543|NCT01400750|DRUG|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
48105544|NCT01400750|DRUG|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
48266485|NCT04749069|DIAGNOSTIC_TEST|Comparison of pain intensity rating scale|Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
48636838|NCT03779854|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48636839|NCT03779854|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48636840|NCT06081465|DRUG|VG290131|The study drug and matching placebo will be administered orally.
48636841|NCT03876808|DEVICE|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
48636842|NCT03876808|DEVICE|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
48636843|NCT02285959|DRUG|Bevacizumab|
48636844|NCT04262427|DRUG|Cyclophosphamide 50mg|cytotoxic chemotherapy
48636845|NCT04262427|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
48636846|NCT02520947|DEVICE|BIS|Bispectral index monitoring
48636847|NCT02520947|DRUG|Desflurane|volatile agent for maintenance of anesthesia
48478235|NCT04500548|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
48636848|NCT00077012|DRUG|QLT0074|
48636849|NCT00077012|DRUG|Photodynamic therapy|
48636850|NCT02589912|DEVICE|Nucleus Profile ABI541 Auditory Brainstem Implant|
48636851|NCT05123105|OTHER|1) cupping therapy|The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
48636852|NCT05123105|OTHER|2) control test (no intervention)|The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
48636853|NCT05123105|OTHER|3) ischemic compression|The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
48636854|NCT01595178|BEHAVIORAL|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
48636855|NCT01064284|DRUG|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
48636856|NCT01064284|DRUG|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
47949646|NCT04485910|OTHER|Single step media|Usage of single step media in embryo culture
47949647|NCT04485910|OTHER|Sequential media|Usage of sequential media in embryo culture
48478236|NCT04500548|BIOLOGICAL|Ipilimumab|Given IV
48478237|NCT04500548|BIOLOGICAL|Nivolumab|Given IV
47949650|NCT01293773|DEVICE|Taxus Element stent|paclitaxel-eluting stent
47949651|NCT01293773|DEVICE|Integrity Resolute stent|ABT 578-eluting stent
47949652|NCT01293773|DEVICE|Xience Prime stent|Everolimus-eluting stent
47949653|NCT01454960|BEHAVIORAL|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
47949654|NCT01454960|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
47949655|NCT01454960|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
47949656|NCT05586243|OTHER|No intervention|This is an observational study looking at brain chemicals related to oxidative stress and inflammation using magnetic resonance spectroscopy (MRS).
47949657|NCT04398316|DRUG|Lidocaine Iv|2 mg/kg over 5 minutes
47949658|NCT04398316|DRUG|HYDROmorphone Injection|1 mg over 5 minutes
47949659|NCT04292769|DRUG|Decitabine|Decitabine 10mg / d, intravenous administration d-5 ～ d-1
47949660|NCT04292769|BIOLOGICAL|DC-CIK|Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;
47949661|NCT05843955|OTHER|Questionnaire|Nutritional status, physical activity levels, anthropometric measurements, and biochemical parameters of individuals were examined. A food consumption frequency questionnaire was administered.
47949662|NCT05661357|DRUG|Disitamab Vedotin Combined With Fruquintinib|Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
47949663|NCT04383158|OTHER|PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)|ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
48478238|NCT06329791|DRUG|AZR-MD-001|AZR-MD-001 sterile ophthalmic ointment 0.5%
48478239|NCT06329791|OTHER|Vehicle|AZR-MD-001 Vehicle
48478240|NCT02390310|DEVICE|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
48478241|NCT02390310|DRUG|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
48478242|NCT02390310|DRUG|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
48478243|NCT05556343|DRUG|MYK-224|Specified dose on specified days
48636857|NCT01253356|DEVICE|IABP|Insertion of intra-aortic balloon \< or = 3 hours before noncardiac surgery and maintained \> or = 12-24 hours after surgery
48478244|NCT05500092|DRUG|Nivolumab|Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
48478245|NCT05500092|RADIATION|(8gy x 3)|sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
48636858|NCT06092580|BIOLOGICAL|AWT020|Participants receiving AWT020 once every two weeks at designated dose levels
48636859|NCT01104298|DRUG|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
48636860|NCT01104298|DRUG|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
48636861|NCT02219451|OTHER|exercise training|exercise training
48636862|NCT00127543|BEHAVIORAL|Medication Education for Children|
48636863|NCT06502080|RADIATION|Consolidative radiotherapy|Consolidative radiotherapy: total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
48636864|NCT06502080|DRUG|Standard-of-care systemic therapy: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab|Standard-of-care systemic therapy as decided by the treating medical oncologist: Gemcitabine + cisplatin/oxaliplatin + Durvalumab/Pembrolizumab/Sintilimab/Toripalimab
47949664|NCT05688007|DIAGNOSTIC_TEST|parathyroid hormone level|Serum level of parathyroid hormone
47949665|NCT05688007|DIAGNOSTIC_TEST|serum electrolytes|Serum levels of: magnesium, phosphorus, calcium, and albumin
48478246|NCT05500092|DRUG|Platinum Doublet|Standard of care doublet platinum therapy
47949666|NCT02025166|DRUG|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
48636865|NCT05685407|DRUG|Caffeine|300mg caffeine will be administered orally via capsules to participants with female sexual arousal disorder.
48636866|NCT05685407|OTHER|Placebo|A placebo pill that matches in size, shape, and color will be administered to participants with female sexual arousal disorder.
48636867|NCT01018056|DRUG|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
48636868|NCT01018056|DRUG|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
47949667|NCT02025166|DRUG|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
47949668|NCT02448810|BIOLOGICAL|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
47949669|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection"
47949670|NCT02448810|BIOLOGICAL|BAX69 + 5-FU/LV|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
48478247|NCT03836482|DEVICE|Selective Cytopheretic Device|Treatment will be delivered for 6 hours a day for up to 6 consecutive days.
48478248|NCT01297816|DRUG|placebo|100mg,BD, fo three month
48478249|NCT01297816|DRUG|Minocycline|100mg
48478250|NCT04972331|PROCEDURE|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
48636869|NCT01018056|DRUG|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
48636870|NCT03017755|OTHER|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
48636871|NCT01326637|OTHER|Patient Overview Document|"The Intervention has two components:~1. Pre-visit care coordination:~   * 5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~  * The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~2. Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
48636872|NCT06335303|DRUG|BI 1819479|BI 1819479
48636873|NCT06335303|DRUG|Placebo matching BI 1819479|Placebo matching BI 1819479
48478251|NCT04972331|PROCEDURE|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have \< 1% blood cells and \<1% white cells in the injection.
48105545|NCT03357549|OTHER|Brief Motivational Intervention|The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
48105546|NCT03357549|OTHER|Breastfeeding education|It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
48105547|NCT01976754|DRUG|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
48105548|NCT06051500|BEHAVIORAL|Nostril focus followed by belly focus|Focused breathing on the nostrils followed by focus breathing on the belly.
48105549|NCT06051500|BEHAVIORAL|Belly focus followed by nostril focus|Focused breathing on the bellyfollowed by focus breathing on the nostrils.
48105550|NCT01092806|DRUG|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
48105551|NCT05359224|DRUG|Prasugrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.
48105552|NCT05359224|DRUG|Clopidogrel group|Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
48105553|NCT03710564|BIOLOGICAL|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
48105554|NCT03710564|BIOLOGICAL|Aflibercept|2 mg/0.05mL solution for intravitreal injection
48105555|NCT03976336|DIETARY_SUPPLEMENT|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
48478252|NCT04972331|OTHER|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
48478253|NCT01128582|DRUG|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
48636874|NCT05139862|DEVICE|Repetitive Transcranial Magnetic Stimulation|This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
48266486|NCT00109148|DRUG|MK0364|
47949671|NCT02448810|BIOLOGICAL|BAX69 + panitumumab|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
47949672|NCT02448810|DRUG|Standard of Care|"* Investigator's choice~* Dose according to drug label"
47949673|NCT02448810|BIOLOGICAL|Standard of Care|"* Investigator's choice~* Dose according to drug label~* Choice includes panitumumab in KRAS \&NRAS wt group only"
47949674|NCT00976677|DRUG|erlotinib hydrochloride|Given PO
48478254|NCT01128582|DRUG|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
48478255|NCT00567476|DRUG|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
47949675|NCT00976677|DRUG|paclitaxel|Given IV
47949676|NCT00976677|DRUG|carboplatin|Given IV
47949677|NCT00976677|BIOLOGICAL|bevacizumab|Given IV
47949678|NCT06169293|BEHAVIORAL|I-AM-WELL|"The I-AM-WELL program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher.~Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics.~Overall, the program will be delivered over in one week lasting six hours."
47949679|NCT00935298|DRUG|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5\*1/\*1 type and CYP3A5\*1/\*3 type administer 0.15mg/kg/d，CYP3A5\*3/\*3 type administer 0.08mg/kg/d).
48105556|NCT03976336|OTHER|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
48105557|NCT00608673|DRUG|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
48105558|NCT00608673|DRUG|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
48105559|NCT03617406|DIAGNOSTIC_TEST|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
48105560|NCT02644239|DIETARY_SUPPLEMENT|ketogenic diet|Ketogenic diet with high fat (90%)
48105561|NCT01006746|OTHER|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
48105562|NCT06432569|DIETARY_SUPPLEMENT|ButirBioma + PeaBioma|randomized in a 1:1 ratio to treatment Butir+Pea or treatment with Placebo for six weeks. After the first treatment period, there is a 14-day washout period.
48105563|NCT06432569|DIETARY_SUPPLEMENT|Placebo|Placebo( 3+3 cps/die)
48478256|NCT00567476|DRUG|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
48636875|NCT04218682|BEHAVIORAL|Shadow's Edge Mobile Application Gameplay|6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
47949680|NCT06279520|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
47949681|NCT06279520|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
47949682|NCT06279520|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
47949683|NCT06279520|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
48105564|NCT00548119|BIOLOGICAL|NeoCart|autologous tissue implant
48105565|NCT00548119|PROCEDURE|microfracture|microfracture
48105566|NCT02026219|DRUG|Clopidogrel|Clopidogrel 600mg loading
48105567|NCT02026219|DRUG|Ticagrelor|Ticagrelor 180mg loading
48105568|NCT03728595|DIAGNOSTIC_TEST|Venepuncture|A blood sample will be taken for serum bicarbonate
48105569|NCT03728595|DIAGNOSTIC_TEST|Spirometry|All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
48105570|NCT03728595|DIAGNOSTIC_TEST|Hypoxic altitude simulation test (HAST)|HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
48266487|NCT00939692|DRUG|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
48478257|NCT00567476|DRUG|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
48478258|NCT00567476|DRUG|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
48478259|NCT02367625|DEVICE|CryoPop|The new CryoPop device will be compared to standard cryotherapy
48478260|NCT02367625|DEVICE|MedGyn MGC 200|Standard cryotherapy
48105571|NCT05647044|DEVICE|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
48105572|NCT05647044|DEVICE|placebo intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
48105573|NCT01199237|DRUG|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
47949684|NCT04750603|DRUG|Fluticasone furoate (FF)/Vilanterol (VI)|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints
47949685|NCT04750603|DRUG|Salbutamol|Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
47949686|NCT00394446|DRUG|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
47949687|NCT06287190|OTHER|Dental interns|Assessing self-assessment
47949688|NCT00109200|DRUG|Xolair (omalizumab)|
47949689|NCT03283111|BIOLOGICAL|autologous stem cell transplantation|autologous stem cell transplantation
48105574|NCT01199237|DRUG|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
48105575|NCT01199237|DRUG|Rocuronium|
48478261|NCT04596306|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
47949690|NCT00632840|DRUG|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
47949691|NCT06534034|PROCEDURE|Dental implant placement|Dental implant placement on edentulous jaw.
47949692|NCT04956926|DRUG|JS201|JS201 is administered intravenously Q3W at the corresponding dose.
48105576|NCT01199237|DRUG|Neostigmine|
48105577|NCT01199237|DRUG|Glycopyrrolate|
48105578|NCT03598972|OTHER|intervention|elementary analysis
48105579|NCT00327665|BIOLOGICAL|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
48105580|NCT00327665|BIOLOGICAL|Pneumo 23™|Single-dose intramuscular injection.
48105581|NCT00327665|BIOLOGICAL|Placebo|1 intramuscular injection.
48105582|NCT00327665|BIOLOGICAL|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
48105583|NCT04853017|DRUG|ELI-002 2P|Amph-CpG-7909 admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)
48105584|NCT06405867|PROCEDURE|delayed cord clamping (> 60 sec)|In the DCC group, cord pulse was checked without allowing clamping. Waited until the cord pulse stopped. It was wrapped in a sterile and warm cloth and dried. The cord was clamped when the pulse stopped. The cord clamping time was noted on the case report form. In DCC, the baby was placed on the mother's legs in cesarean section (C/S) births and on the mother's mons pubis region in normal vaginal births. The baby was administered a routine delivery room neonatal resuscitation program (NRP) by the pediatrician. After cord clamping, the baby was handed over to the pediatric team.
48105585|NCT04731051|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
48105586|NCT04731051|DRUG|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
48105587|NCT04727723|DRUG|Lutathera®|Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.
48105588|NCT02211898|DRUG|BNS003|
48478262|NCT06023862|DRUG|Dostarlimab|Intravenous (IV) infusion
48478263|NCT06023862|DRUG|Bevacizumab|Intravenous (IV) infusion
48478264|NCT06023862|DRUG|Doxorubicin|Intravenous (IV) infusion
48478265|NCT06023862|DRUG|Gemcitabine|Intravenous (IV) infusion
48478266|NCT06023862|DRUG|Paclitaxel|Intravenous (IV) infusion
48478267|NCT06023862|DRUG|Pegylated liposomal doxorubicin|Intravenous (IV) infusion
48478268|NCT00267358|DRUG|RC-1291 HCl|
48478269|NCT00267358|DRUG|Placebo|
48478270|NCT01185379|DIETARY_SUPPLEMENT|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
48478271|NCT01185379|DIETARY_SUPPLEMENT|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
47949693|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
47949694|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
47949695|NCT03325270|DIETARY_SUPPLEMENT|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
47949696|NCT04943718|BIOLOGICAL|personalized vaccine|Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20.
48478272|NCT01185379|DIETARY_SUPPLEMENT|Placebo|4 x 500 mg capsules to be taken daily for 6 months
48105589|NCT05882578|OTHER|Oncological physical exercise intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
48105590|NCT05882578|OTHER|Active Physical Activities intervention|"An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life."
48105591|NCT02128789|OTHER|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
48105592|NCT04475224|DRUG|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
48105593|NCT03917706|OTHER|Questionnaire|Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
48105594|NCT01421654|DEVICE|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
48105595|NCT01421654|DEVICE|S9 Elite|S9 Elite Flow Generator
48105596|NCT04572672|OTHER|Non-pharmacologic treatment; Pursed-Lip Breathing Combined with Number Counting|"Pursed-lip breathing and number counting one and two during inspiration, and then number counting, one, two, three, and four during exhalation. The nurse advised the patient to continue pursed-lip breathing with number counting for the first 15 minutes (min) of each hour to prevent the patient from being exhausted, total study time was 3 hours, or until the patient was discharged from the ER, or was withdrawn from the study."
48105597|NCT00814346|DRUG|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
48105598|NCT00814346|DRUG|Placebo|Placebo 1 tablet BID
48105599|NCT01682200|DRUG|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
48105600|NCT01486550|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
48105601|NCT01486550|DRUG|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
48105602|NCT05851768|DRUG|Bupivacaine|Bupivacaine 0.25%
48105603|NCT05851768|DRUG|Bupivacaine + Magnesium|Bupivacaine 0.25% + Magnesium
48105604|NCT05851768|DRUG|Bupivacaine + Dexmedetomidine|Bupivacaine 0.25% + Dexmedetomidine
48105605|NCT03554902|PROCEDURE|Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
48105606|NCT05112354|DRUG|systemic and intratympanic injection of steoid|"-If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator."
48105607|NCT01228448|PROCEDURE|PET scan|In-Room PET scan
47949697|NCT04633356|DEVICE|EUS-portal pressure gradient measurement (PPGM)|EUS-guided PPGM is performed under conscious sedation. An OGD would be performed to evaluate for findings consistent with portal hypertension such as varices and portal hypertensive gastropathy. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein. A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle. Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The process is repeated for the hepatic vein. The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
47949698|NCT02229331|OTHER|Gait analysis|
48266488|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
48266489|NCT01968460|DRUG|Placebo|placebo
47949699|NCT03555734|OTHER|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
48298423|NCT01311206|OTHER|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
47949700|NCT03368612|OTHER|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
47949701|NCT03368612|OTHER|Electronic evaluation system|AirGo recording
47949702|NCT06285461|BEHAVIORAL|Non-palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with low hedonic reward.
47949703|NCT06285461|BEHAVIORAL|Palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with high-hedonic reward.
47949704|NCT00487682|DRUG|ASP2151|oral
48636876|NCT03612895|BEHAVIORAL|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
48636877|NCT03612895|BEHAVIORAL|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
48636878|NCT03612895|BEHAVIORAL|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
48636879|NCT04558138|OTHER|Discharge timing|Patients will be discharged home on the day of surgery as opposed to POD #1
47949705|NCT00487682|DRUG|Valacyclovir hydrochloride|oral
48636880|NCT06101862|PROCEDURE|CCTA|Participants will be examined with CCTA during admission.
48636881|NCT06101862|PROCEDURE|Conventional ICA|Patients will be examined with conventional standard-of-care ICA.
48636882|NCT06101862|OTHER|Team-based interventional triage|The CCTA will be discussed at a coronary CT-team conference to establish the treatment strategy and provide guidance for any necessary interventional procedure.
48636883|NCT04503642|PROCEDURE|Changing the surgical team for wound closure|The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
48636884|NCT06072482|DRUG|Avacopan|Administered orally.
47949706|NCT03454685|OTHER|without intervention type|Without intervention,this study is just an observational study.
47949707|NCT03497078|OTHER|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
47949708|NCT04069169|DRUG|Lidocaine|Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
47949709|NCT04069169|DRUG|Saline Solution|Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
47949710|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
47949711|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
47949712|NCT04090073|PROCEDURE|Electroacupuncture|As above
47949713|NCT04090073|OTHER|Fast-track Perioperative program|As above
47949714|NCT02821637|OTHER|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
47949715|NCT02821637|BEHAVIORAL|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
47949716|NCT02821637|OTHER|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
47949717|NCT01146912|OTHER|Text Message|Text message vaccine reminders
48636885|NCT06072482|DRUG|Placebo|Administered orally.
48636886|NCT06072482|DRUG|Standard of Care|All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
47949718|NCT01146912|OTHER|automated call|Automated call
47949719|NCT01479023|DRUG|64Cu-DOTA-U3-1287|
47949720|NCT01479023|DRUG|U3-1287 (unlabeled)|
47949721|NCT00543543|BIOLOGICAL|Comparator: GARDASIL|GARDASIL (quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
47949722|NCT00543543|BIOLOGICAL|Experimental: V503|V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
47949723|NCT05092854|OTHER|PR Lotion - AMP Human Performance|"Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.~Other Names:~NDC Code: 72358-101-01 NDC Code: 72358-101-02 NDC Code: 72358-101-03"
47949724|NCT05092854|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
47949725|NCT05092854|OTHER|AminoVital - Rapid Recovery|AminoVITAL Rapid Recovery is a commercially available supplement that is not currently regulated by the FDA but does complete both internal quality control and third-party testing for all of their products. AminoVITAL Rapid Recovery has been certified by the Banned Substance Control Group (BSCG; https://www.bscg.org/certified-drug- free-supplements/?AminoVITAL) and has been certified to be free of 496+ drugs including WADA Prohibited Substances as well as prescription, over the counter, and illicit drugs not banned in sport. AminoVITAL Rapid Recovery is safe to consume multiple times within a single day and has been found most effective when taken within 30 minutes of cessation of exercise. No known side effects are associated with the ingestion of aminoVITAL Rapid Recovery; however, side effects of amino acid toxicity include gastrointestinal distress, nausea and headache.
47949726|NCT05092854|OTHER|Placebo Supplement|Supplement will be created by the aminoVITAL company and will include all ingredients similar to the commercially available Rapid Recovery product except for the exclusion of the amino acid blend.
47949727|NCT00484627|PROCEDURE|Use of creatine monohydrate (a dietary supplement)|
47949728|NCT00484627|BEHAVIORAL|Progressive resistance exercise training|
48105608|NCT03586596|BEHAVIORAL|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
48105609|NCT03586596|BEHAVIORAL|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
47949729|NCT06181591|DRUG|Mirabegron 50 MG|Mirabegron (IP: Hibero) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It is used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. Through a 8 weeks clinical trial, it aims to evaluate the efficacy and safety of Hibero (Mirabegron), especially in maximum voided volume.
48105610|NCT01099891|DRUG|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
48105611|NCT01099891|DRUG|Placebo|Placebo, Spray type, Twice a day
48105612|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
48105613|NCT00817817|DEVICE|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
47949730|NCT06181591|DRUG|Oxybutynin Chloride 5 MG|Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.
48105614|NCT03773861|OTHER|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
48105615|NCT04184804|BEHAVIORAL|Behavioral Intervention|"The intervention package will be consisted of:~1. Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~2. Signs in school areas about organic fruits and vegetables~3. Workshops and interactive games for children~4. Seminars for parents"
48105616|NCT04612894|DRUG|Camrelizumab and Apatinib|All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
48105617|NCT04612894|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
48105618|NCT04612894|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
48105619|NCT05943652|DIAGNOSTIC_TEST|Neurological examination|A neurological examination following a protocol to detect positive signs of functional neurological disorders.
48105620|NCT05943652|DIAGNOSTIC_TEST|Anamnesis|"A standardized question about the patient´s history. The response time is measured.~Question: Could you tell me about the problems with the movement disorder you are experiencing?"
48105621|NCT05943652|DIAGNOSTIC_TEST|Neuropsychological testing|"Neuropsychological cognitive testing including:~* Montreal Cognitive Assessment (MOCA)~* Rey-Osterrieth Complex Figure Test (ROCFT)~* Wechsler Memory Scale IV~* Comprehensive Trail Making Test (CTMT)~* semantic and phonematic fluency tests"
48105622|NCT05943652|DIAGNOSTIC_TEST|Questionnaires|"* Short Form 36 (SF 36)~* Somatic Symptom Disorder - B Criteria Scale (SSD 12)~* Patient Health Questionnaire 9 (PHQ 9)~* Patient Health Questionnaire 15 (PHQ 15)~* Generalized Anxiety Disorder 7 (GAD 7)~* Fatigue Severity Scale (FSS)~* Psychosomatic Competence Inventory (PSCI)~* Work Ability Index (WAI)~* Level of Personality Functioning Scale~* Toronto Alexithymia Scale~* Levels of Emotional Awareness Scale (short version)~* Certainty About Mental States Questionnaire~* Somatosensoric Amplification Scale~* Personality Inventory for DSM-5 short version (PID5BF+M)~* Childhood Trauma Questionnaire~* European Quality of Life 5 Dimensions 5 Level Version (EQ5D5L)"
48105623|NCT05943652|DIAGNOSTIC_TEST|Tremor recording|Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)
48105624|NCT04124068|OTHER|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
48105625|NCT04124068|DEVICE|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
48105626|NCT04124068|DEVICE|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
48105627|NCT04124068|DEVICE|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
48105628|NCT04392713|DRUG|Ivermectin 6 MG Oral Tablet (2 tablets)|12 mg single dose of Ivermectin will be given to intervention arm
48105629|NCT00111722|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
48105630|NCT00111722|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
48105631|NCT00798122|PROCEDURE|Intravascular ultrasound|intravascular ultrasound
48105632|NCT00798122|PROCEDURE|MRI|cardiac MRI
48636887|NCT03721107|BIOLOGICAL|Blautix|Blautix is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen was two capsules two times per day for the duration of the treatment period.
48636888|NCT03721107|OTHER|Placebo|Placebo control
48636889|NCT06083467|DIAGNOSTIC_TEST|Brain MRI Scan|MRI scan of the brain
48105633|NCT02108743|DRUG|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
48105634|NCT02108743|DRUG|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
48105635|NCT00855153|OTHER|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
48105636|NCT00855153|DRUG|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
48105637|NCT00612586|DRUG|Enzastaurin|1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
48105638|NCT00612586|DRUG|Placebo|oral, daily (up to 1 yr or until progressive disease)
48105639|NCT00612586|DRUG|Leucovorin (LV)|400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
48105640|NCT00612586|DRUG|5-fluorouracil (5-FU)|400 mg/m\^2 bolus then 2400 mg/m\^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
48105641|NCT00612586|DRUG|Bevacizumab (Bev)|5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
48105642|NCT02018224|PROCEDURE|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
48478273|NCT04778618|DRUG|Antithymocyte Globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
48636890|NCT06083467|BEHAVIORAL|Neurologic exam|Neurologic exam and assessments, including video interview
48636891|NCT04869410|PROCEDURE|Modification Broselow Tape|Intubation using modified Broselow Tape prediction for predicting ETT size
48105643|NCT02018224|PROCEDURE|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
48105644|NCT00155558|DRUG|5-Fluorouracil, Leucovorin|
48105645|NCT00002819|DRUG|carboplatin|
48105646|NCT00002819|DRUG|cyclophosphamide|
48105647|NCT00002819|DRUG|mitoxantrone hydrochloride|
48105648|NCT00002819|DRUG|paclitaxel|
48105649|NCT00002819|PROCEDURE|autologous bone marrow transplantation|
48478274|NCT00386646|DRUG|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
48478275|NCT02574715|DRUG|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
48636892|NCT04869410|PROCEDURE|Cole Formula|Intubation using Cole Formula prediction for predicting ETT size
48636893|NCT01324466|DRUG|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
48636894|NCT01324466|DRUG|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
48636895|NCT05125627|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
48636896|NCT05125627|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Each dose was administered Intravaginally, the capsule introduced deeply into the vagina while lying down, after at least 10 hrs of fasting, under the direct supervision of the Principal and/ or clinical Investigator
48105650|NCT00002819|PROCEDURE|peripheral blood stem cell transplantation|
48105651|NCT02674750|DRUG|CUDC-907|
48105652|NCT03055416|OTHER|Mobile Men App Prototype|Testing of app functionality
48105653|NCT01456078|DRUG|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
48105654|NCT02833272|BEHAVIORAL|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
48266490|NCT01968460|DRUG|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
48266491|NCT04982640|BEHAVIORAL|Iyengar yoga|60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks
47949731|NCT03868306|OTHER|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
47949732|NCT03183531|DIAGNOSTIC_TEST|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
47949733|NCT02428608|BIOLOGICAL|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
47949734|NCT04958772|BIOLOGICAL|Filgrastim Megalabs|Filgrastim Megalabs 5 μg/Kg/day, subcutaneous single dose
48105655|NCT01133132|BEHAVIORAL|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
48105656|NCT01133132|OTHER|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
48105657|NCT03937843|DRUG|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
48105658|NCT03937843|DRUG|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
48105659|NCT03937843|DRUG|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
48105660|NCT04441593|BEHAVIORAL|Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)|Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
48105661|NCT04441593|BEHAVIORAL|Treatment as Usual|Psychoeducation and Information about Treatment Resources
48105662|NCT04670419|OTHER|Viral clade|Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
48105663|NCT02615912|OTHER|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
48105664|NCT02615912|OTHER|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
48105665|NCT02615912|OTHER|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
48105666|NCT02615912|OTHER|Silwet* DA-63 (Momentive) 1.5%|
48105667|NCT02615912|OTHER|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
48105668|NCT02615912|OTHER|Water (control)|
48105669|NCT05092412|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
48105670|NCT05092412|DRUG|Durvalumab|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
48105671|NCT05092412|DRUG|Etoposide, and cisplatin/carboplatin|Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
48105672|NCT03145935|DIAGNOSTIC_TEST|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
48105673|NCT03145935|DIAGNOSTIC_TEST|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
48105674|NCT02531568|DRUG|Warfarin|
47949735|NCT04958772|BIOLOGICAL|Granulokine|Granulokine 5 μg/Kg/day, subcutaneous single dose
47949736|NCT06503055|OTHER|Questionnaire|"A questionnaire targeting a convenience sample of medical field professionals including physicians with different specialties, pharmacists, medical students, nursing staff, and the general population in Gharbia governorate (about 1000 subjects).~The questionnaire will be written and digital in both Arabic and English versions. Moreover, an awareness campaign will be designed to educate the participants on appropriate antibiotic use principles."
47949737|NCT06047808|BEHAVIORAL|Storytelling Through Music|"Storytelling Through Music is a six-week expressive arts intervention."
47949738|NCT04940767|DRUG|Isotretinoin|Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
48105675|NCT02531568|DRUG|MT-3995|
48266492|NCT04982640|BEHAVIORAL|Standard Exercise|60 minutes, twice weekly for 12 weeks, group-based walking program
48266493|NCT04982640|BEHAVIORAL|Nutrition Counseling|One, 30-minute session with registered dietitian
48266494|NCT00808743|DRUG|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
48266495|NCT00808743|DRUG|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
48636897|NCT00859274|DRUG|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
47949739|NCT04940767|DRUG|Amzeeq 4% Topical Foam|AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
47949740|NCT06680245|DRUG|Mitomycin c|Patients needing Ahmed valve implants to control intraocular pressures will be eligible. Eligible patients who consent will be randomized to receive either mitomycin-C or no intervention during implant surgery. Screening visits occur one week before surgery to assess eligibility and take baseline measurements (visual acuity, IOP, anterior chamber reaction). On surgery day, patients register at SJHH King Campus and undergo randomization. IOP is measured using a tonopen in the OR. An experienced glaucoma specialist performs the surgery, injecting 0.2 mg/ml mitomycin-C into the sclera for the experimental group, while the control group receives no intervention. The area is irrigated with 40mL balanced salt solution before implant insertion. Post-operative care includes topical antibiotics and steroids for six weeks, with follow-ups at 1 and 2 weeks, and 1, 3, 6, and 12 months to monitor visual acuity, IOP, anterior chamber reaction, complications, and additional glaucoma medications.
47949741|NCT00860288|DRUG|Vildagliptin|
47949742|NCT00860288|DRUG|Metformin|
47949743|NCT00860288|DRUG|Placebo|
47949744|NCT00860288|DRUG|Sitagliptin|
47949745|NCT00002449|DRUG|Aldesleukin|
47949746|NCT02772055|OTHER|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
47949747|NCT02772055|OTHER|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
47949748|NCT06680349|DRUG|Anti-CD20 antibodies|comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
47949749|NCT02295410|BEHAVIORAL|CPT|
47949750|NCT01761175|PROCEDURE|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
47949751|NCT01761175|PROCEDURE|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
47949752|NCT00388830|PROCEDURE|Ultrasound|
47949753|NCT01826773|DRUG|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
47949754|NCT05191173|PROCEDURE|Cardiac Surgery|No intervention, just observation is performed.
48105676|NCT06186739|BEHAVIORAL|home-based motor rehabilitation training participated by caregivers|The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.
48105677|NCT06186739|BEHAVIORAL|routine self-care|the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
47949755|NCT04151173|PROCEDURE|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
47949756|NCT04151173|PROCEDURE|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
47949757|NCT00114387|DRUG|DL-alpha-tocopherol|
47949758|NCT03595774|DIETARY_SUPPLEMENT|Beet root juice|Beet root juice
47949759|NCT05290207|DIAGNOSTIC_TEST|The hyperinsulinaemic hypoglycaemic clamp|Glucose will be clamped at 5.0 mmol/L for approximately 30 minutes, and then be lowered to 3.0 mmol/L for 30 minutes
47949760|NCT02122432|OTHER|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
48636898|NCT00387309|DRUG|Methylnaltrexone (MOA-728)|
48636899|NCT06386874|DEVICE|BQ 3.0 system|frequency and intensity parameters will be set to zero so that no stimulation is delivered
47949761|NCT01703273|BEHAVIORAL|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
47949762|NCT01703273|BEHAVIORAL|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
47949763|NCT06217380|DEVICE|Masimo SafetyNet Alert (MSNA)|This study will explore the feasibility of implementing the Masimo SafetyNet Alert (MSNA) oxygen saturation monitoring system and the acceptance of MSNA by individuals living in a supportive housing program, who inject opioids.
47949764|NCT00203073|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
47949765|NCT00203073|DRUG|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
47949766|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (T4030)|Eye drop
47949767|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (Ganfort)|Eye drop
47949768|NCT02654847|DRUG|Norepinephrine|
47949769|NCT02654847|DRUG|Normal Saline|0.9% sodium chloride solution, used as a diluent.
47949770|NCT05749211|DRUG|Huaier granule|Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
47949771|NCT01877018|BEHAVIORAL|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
47949772|NCT04524806|OTHER|stabilization splint|Stabilization splint is an appliance which applied to upper or lower jaw and regulating the occlusal forces in the temporomandibular joint that can cause disorders, also preventing excessive contraction of the masticatory muscles
48105678|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
48105679|NCT00362206|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
48105680|NCT00362206|DRUG|Pravastatin|Pravastatin 40 mg
48105681|NCT03150563|OTHER|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
48105682|NCT05662891|OTHER|Blood Flow Restriction|After randomization, a cuff was placed proximal to one lower extremity. Blood flow was restricted from 60% of the arterial occlusion pressure. The other extremity was determined as the control group. 3x5 nordic hamstring exercises were performed. Surface emg was measured for hamstring muscles during exercise.
48105683|NCT05586113|DRUG|10-day Tegoprazan bismuth-containing quadruple therapy|10-day Tegoprazan bismuth-containing quadruple therapy: Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co., LTD) 1000mg bid Tetracycline (Huanan Brand, Guangdong Huanan Pharmaceutical Co. LTD.) 500mg qid Bismuth potassium Citrate (Lizhu Delle, Lizhu Group Pharmaceutical Factory) 2g bid
48105684|NCT06070207|PROCEDURE|TEP group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
48105685|NCT06070207|PROCEDURE|eTEP group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
48105686|NCT06113406|BEHAVIORAL|Classroom Training|Active Comparator
48105687|NCT06113406|BEHAVIORAL|Virtual Reality Training|Experimental
48105688|NCT00921830|DRUG|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
48105689|NCT01230619|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
48105690|NCT01230619|DRUG|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
47949773|NCT00168701|DRUG|BG00012|
47949774|NCT02727413|PROCEDURE|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
47949775|NCT02727413|OTHER|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
47949776|NCT02973490|DEVICE|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
47949777|NCT03368248|OTHER|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
47949778|NCT03292575|DRUG|Anticoagulants|
47949779|NCT02976922|DIETARY_SUPPLEMENT|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
47949780|NCT06241118|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
47949781|NCT06241118|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
47949782|NCT06241118|DRUG|Topical corticosteroids|Pharmaceutical form: Various Topical formulation Route of administration: Topical
47949783|NCT06241118|DRUG|Topical tacrolimus or pimecrolimus|Pharmaceutical form: Various Topical formulation Route of administration: Topical
47949784|NCT04248751|DEVICE|Regeneten|A new scaffold material made of highly purified, type I collagen from bovine tendons has shown great promise as a bioinductive implant that helps induce the formation of new tendon-like tissue over the surface of partial- or full-thickness rotator cuff tears. This new graft material has the benefit of decreasing surgery time, as it takes a few minutes to put in place, while increasing healing and tendon thickness.
47949785|NCT04248751|PROCEDURE|Debridement|The bursa will be debrided thoroughly, and rotator cuff edges will be shaved down to stable tissue. The rotator cuff will be repaired using multiple single row triple loaded suture anchor placed adjacent to the articular margin
47949786|NCT01823146|DRUG|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
47949787|NCT01823146|DRUG|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
47949788|NCT04263831|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
47949789|NCT00004195|DRUG|eniluracil|Will be given to either subject pre-operative and metastatic disease
47949790|NCT00004195|PROCEDURE|conventional colon surgery|Only if the subject is amenable to surgical resections
47949791|NCT00958789|DEVICE|Triathlon TS Knee System|Total knee replacement for revision cases
47949792|NCT01975051|DRUG|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
47949793|NCT02524093|BEHAVIORAL|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
47949794|NCT02524093|OTHER|treatment as usual|
47949795|NCT05906979|OTHER|PAHOLA (digital health assistant)|Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.
47949796|NCT05906979|OTHER|Standard information on alcohol use and health|A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.
47949797|NCT02672228|DEVICE|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
47949798|NCT01022749|DRUG|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
47949799|NCT01022749|BIOLOGICAL|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
48105691|NCT01844141|DRUG|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
48105692|NCT01844141|DRUG|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
48105693|NCT03895788|DRUG|niraparib|Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
47949800|NCT00810472|OTHER|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
47949801|NCT00810472|PROCEDURE|Penetrating keratoplasty|Corneal transplantation.
47949802|NCT00191906|DRUG|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
47949803|NCT00191906|DRUG|placebo|Placebo, every day (QD), by mouth (PO)
47949804|NCT04423510|PROCEDURE|Crystallized phenol treatment|
48105694|NCT03895788|DRUG|Brivanib|Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
48105695|NCT02770196|BEHAVIORAL|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
48105696|NCT03680391|PROCEDURE|Cesarean section|"Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used"
48105697|NCT03665701|PROCEDURE|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
47949805|NCT02505178|OTHER|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
48105698|NCT06156306|BEHAVIORAL|CBT-I|The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.
48105699|NCT06156306|BEHAVIORAL|CBT-I combined ACT|In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
48105700|NCT00383188|DRUG|placebo|Capsule, once daily (QD) for 12 weeks
48105701|NCT00383188|DRUG|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
48105702|NCT00383188|DRUG|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
48105703|NCT00383188|DRUG|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
48105704|NCT00383188|DRUG|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
47949813|NCT04603612|PROCEDURE|Primary TURBT|"As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT."
47949814|NCT00508222|DRUG|Kaletra Tablets|Kaletra 800/200 OD
47949815|NCT04935281|OTHER|percutaneous repair with an intraoperative assisted ultrasound|Under general or regional anesthesia, the patient laid in prone position In group A, an intraoperative ultrasound was done by a radiologist before the repair .
47949816|NCT04935281|OTHER|percutaneous repair without an intraoperative assisted ultrasound|For patients in group B, the course of the sural nerve was determined according to the technique described by Blackmon et al.The medial and lateral borders of both stumps were outlined by palpation with identification of the gap in-between. We used the technique described byMaffulli et al with six stab incisions, one cm each. Four incisions were on medial and lateral edge of the proximal stump and the other two were around distal stump.
47949817|NCT06391125|DRUG|normal Saline|0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
47949818|NCT06391125|DRUG|Lidocaine|0.5ml 1% lidocaine solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
47949819|NCT01136031|DRUG|Paclitaxel and irinotecan|"In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~1. 100 100~2. 100 120~3. 135 120~4. 135 160~every 3 week"
48105705|NCT05347199|DRUG|Amisulpride Pill|Two single low doses amisulpride (100 mg); orally
47949820|NCT04933695|DRUG|Sotorasib|Oral tablet
47949821|NCT06681818|OTHER|carbon monoxide measurement via smokerlyzer|participants in this study will provide breath samples for carbon monoxide measurements pre and post liver resection
47949822|NCT02755298|DRUG|Acetazolamide|
47949823|NCT02755298|DRUG|Placebo|
47949824|NCT04693546|DIAGNOSTIC_TEST|LifeKit Prevent Colorectal Neoplasia Test|Procedure: Colonoscopy
47949825|NCT04693546|DIAGNOSTIC_TEST|FIT Test|Procedure: Colonoscopy
47949826|NCT02919371|DRUG|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
47949827|NCT02919371|DRUG|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
47949828|NCT01349179|DEVICE|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
47949829|NCT05117333|OTHER|Reminder (information letter)|Reminders
48105706|NCT05347199|DRUG|Placebo|two doses, orally
48105707|NCT00640029|PROCEDURE|Arthrodesis|"* posterior,~* anterior,~* circumference approach"
48105708|NCT00640029|DEVICE|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"* SYNTHES : PRODISC-C® , PRODISC-L®~* LDR : Mobi-C®, Mobidisc®~* MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~* SCIENT'X : DISCOCERV®"
48105709|NCT01420718|DRUG|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
48105710|NCT01420718|DRUG|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
48105711|NCT00208078|DEVICE|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
48105712|NCT05991986|OTHER|somatic cell collection|One or more types of somatic cells will be collected from every participant by collecting approximately 100\~500 ml of midstream urine, 20\~30 ml of peripheral blood, skin biopsies (3mm), conjunctiva biopsies (5mm×5mm), etc.
48105713|NCT05826704|DIETARY_SUPPLEMENT|Probiotics|Participants will be taking 2 capsule a day for 6 weeks
48105714|NCT01496209|BIOLOGICAL|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
48105715|NCT01496209|BIOLOGICAL|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
48105716|NCT01792830|DRUG|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c \< 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
48105717|NCT01792830|DRUG|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c \> 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
48105718|NCT01792830|DRUG|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
48105719|NCT05860140|OTHER|Education video|Six minutes long education video focusing on protein and energy meals
48105720|NCT05538988|DRUG|Cemiplimab|Cemiplimab is a recombinant human IgG monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. The PD-1 pathway is an immune system checkpoint that may be exploited by tumour cells to escape active T-cell surveillance. Cemiplimab binds to PD-1 on T cells and blocks the interaction with its ligands, PD-L1 and PD-L2. Inhibition of the receptor/ligand signaling restores the anti-tumour immune response
48105721|NCT01326130|BEHAVIORAL|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
48105722|NCT00060099|BIOLOGICAL|HspE7|
48105723|NCT02131324|DRUG|DFD06 Cream|
48105724|NCT02131324|DRUG|Clobetasol Propionate Cream 0.05%|
48105725|NCT02813486|BIOLOGICAL|Biological: GC3111 vaccine|0.5mL, Intramuscular
48105726|NCT02813486|BIOLOGICAL|Biological: Boostrix® vaccine|0.5mL, Intramuscular
48636900|NCT06386874|DEVICE|BQ 3.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
48636901|NCT04505280|DRUG|Lidocaine 1% Injectable Solution|Greater occipital nerve and cervical region injections once a week for 4 weeks
48636902|NCT01257893|DRUG|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
48266496|NCT00808743|DRUG|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
48636903|NCT01257893|DRUG|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
48636904|NCT03172559|RADIATION|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
48636905|NCT01655069|DRUG|Solifenacin succinate suspension|Oral suspension
48636906|NCT00544687|DRUG|CRx-191|topical (mometasone furoate + nortriptyline HCl)
48636907|NCT00544687|DRUG|mometasone furoate|topical mometasone furoate
48636908|NCT00544687|DRUG|nortriptyline HCl|topical nortriptyline HCl
48105727|NCT05584046|OTHER|CDAM|Novel drugs such as Traditional Chinese Medicine (TCM) formula that can suppress inflammation may augment tissue healing and reduce activity-related pain in patients suffering from plantar fasciitis. Our team has experiences of using TCM for the treatment of plantar fasciitis. Based on our previous experience, our group has developed a new proprietary topical TCM herbal formula, CDAM, containing Carthami Flos , Dipsaci Radix , Aconiti Lateralis Radix Praeparata and Herba Menthae for the treatment of plantar fasciitis.
48105728|NCT02267980|DRUG|Sevoflurane|Inhalation anesthetic agent
48105729|NCT02267980|DRUG|Ketamine|Intravenous anesthetic agent
48105730|NCT02267980|DRUG|Saline|Isotonic solution for placebo group
48105731|NCT02546219|OTHER|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
48105732|NCT02148133|DRUG|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
48105733|NCT02148133|DRUG|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
48105734|NCT01703130|PROCEDURE|Dose of of ropivacaine 0.75% used in block procedure|
48105735|NCT00161018|DRUG|Quetiapine, Risperidone, Fluphenazine|
48105736|NCT02060019|DRUG|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
48105737|NCT02909751|DRUG|Epirubicin 90 mg/m2 iv|Max. 3 months
48105738|NCT02909751|DRUG|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
48105739|NCT02909751|DRUG|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
48478276|NCT06617533|OTHER|PCF model|PCF practices practices receive (1) a per-beneficiary-per-month prospective payment that depends on the average health of their attributed Medicare beneficiaries; (2) a Flat Visit Fee for primary care visits, subject to a geographic adjustment factor, and (3) a Performance-based Adjustment (PBA). The PBAs depend on practices' performance on several quality measures in addition to their performance in reducing beneficiaries' use of inpatient care or total cost of care, relative to national and regional benchmarks. Practices must meet a limited set of care delivery requirements and can use the PCF Model's flexible use of payments to invest in strategies that best suit their practices' unique patient population and resources. In return, practices take on limited financial risk in exchange for performance-based payments that reward participants that meet certain performance and quality benchmarks for selected outcomes.
48636909|NCT00544687|DRUG|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
48636910|NCT00544687|DRUG|Vehicle|topical (placebo)
48636911|NCT01682720|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
48636912|NCT01682720|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48636913|NCT01682720|DRUG|Placebo to match SOF|Placebo to match SOF administered orally once daily
48636914|NCT01682720|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
48105740|NCT02909751|DRUG|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
48105741|NCT02909751|DRUG|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
48105742|NCT02909751|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily|Max. 6 months
48105743|NCT06080373|BEHAVIORAL|PROBECO|"Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.~German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention."
48105744|NCT06080373|BEHAVIORAL|Formulation-based cognitive behavioral therapy|"The CBT program includes these core modules:~A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.~B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.~C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.~D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges."
48105745|NCT03967795|DRUG|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
48636915|NCT04879485|BIOLOGICAL|Blood products|Compare two different transfusion strategies against standard transfusion regimen
48105746|NCT04644185|DRUG|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
48105747|NCT04644185|OTHER|Placebo|all SCTA01 excipients without active component+best supportive care
48105748|NCT01505101|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
48105749|NCT01505101|BEHAVIORAL|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
48105750|NCT04635358|BEHAVIORAL|Hypnosis|Setting up hypnosis sessions
48105751|NCT04635358|BEHAVIORAL|Psychological support|Setting up psychological support
48105752|NCT04635358|BEHAVIORAL|Nutrional support|Setting up nutritional support
48105753|NCT04910932|OTHER|Breathing Exercises|Breathing exercises including diaphragmatic breathing, thoracic expansion and breathing control exercises
48105754|NCT04910932|OTHER|Information on COVID-19|"Information about COVID-19 based on the advices in COVID-19 advice for the public section of World Health Organization website."
48105755|NCT02994654|DEVICE|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
48105756|NCT06238154|DRUG|Flurbiprofen|The efficacy of two different forms and amounts of active ingredient (100mg tablet vs 25% oral spray) on postoperative pain of different flurbiprofen
48478277|NCT02026544|DEVICE|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
48636916|NCT02917538|PROCEDURE|RFA|Both groups will receive radiofrequency ablation treatment
48105757|NCT05068167|DIAGNOSTIC_TEST|Kidney function test|Creatinine twice the baseline and urine output of fewer than 0.5 ml/kg per hour for 12 hours
48636917|NCT05349773|PROCEDURE|Pneumatic tourniquet, endoscopic left radial artery harvesting|"Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes."
48636918|NCT05119907|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
48636919|NCT02402231|DRUG|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
48636920|NCT06642532|DEVICE|TCD group|Transcranial Doppler ultrasound to examine bilateral hemodynamic parameters of middle cerebral artery(MCA), terminal internal carotid artery(TICA), (anterior communicating artery)ACA, and posterior cerebral artery(PCA) (Vs, Vd, Vm, PI index, RI index) from temporal window
48636921|NCT04302168|DIETARY_SUPPLEMENT|Choline supplement|Choline 470mg twice daily for 8 weeks.
47949830|NCT06281678|DRUG|IBI363|IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
48105758|NCT00408928|DRUG|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
48105759|NCT01989910|DRUG|Raltegravir|Raltegravir 400mg oral twice daily
48105760|NCT01989910|DRUG|Efavirenz|Efavirenz 600mg oral at bedtime
48105761|NCT00572000|BIOLOGICAL|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
47949831|NCT03053583|DEVICE|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
47949832|NCT03169686|BEHAVIORAL|Cognitive and Behavioral Intervention|Participants who allocate to the intervention group will receive regular smoking cessation related information by professional team.
47949833|NCT02637154|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing method
47949834|NCT02637154|BEHAVIORAL|Standard Education|Standard Education material will be used
47949835|NCT01381484|DRUG|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
47949836|NCT05485454|DEVICE|Aria Health Aria Free|An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
47949837|NCT05485454|DEVICE|A Traditional PCD|An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
47949838|NCT02653183|DEVICE|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
47949839|NCT02653183|DEVICE|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
47949840|NCT05047068|DEVICE|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
47949841|NCT03570697|DRUG|Evolocumab|Participants will receive evolocumab (AMG 145) subcutaneous monthly.
47949842|NCT03570697|DRUG|Placebo|Participants will receive matching placebo subcutaneous monthly.
47949843|NCT03570697|DRUG|Statin therapy|"high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization."
47949844|NCT03455582|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
48105762|NCT06202599|DRUG|Fruquintinib|For patients with pulmonary metastasis only, we mostly gave them fruquintinib with 7 mg in adults and 3-5 mg in children (\<10 years) orally per day (5 days on and 2 days off). If patients were extrapulmonary metastasis, we usually used combinations with metronomic chemotherapy (2/3 or 3/5 or even 1/2 of the usual dose) or immunotherapy.
48105763|NCT00300040|DRUG|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
48105764|NCT00300040|DRUG|6% Hydroxyethylstarch|250ml for intravenous infusion
48105765|NCT01390402|DRUG|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
48105766|NCT01390402|DRUG|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
48105767|NCT01390402|PROCEDURE|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
48105768|NCT01390402|DRUG|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
48105769|NCT01390402|DRUG|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
48105770|NCT01390402|PROCEDURE|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
48636922|NCT04302168|DIETARY_SUPPLEMENT|Placebo|Placebo pill twice daily for 8 weeks
48636923|NCT01389284|DRUG|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
48636924|NCT01389284|DRUG|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
48636925|NCT01389284|DRUG|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
47949845|NCT03455582|OTHER|Ecological evaluation|Virtual reality task and Actual reality
47949846|NCT03455582|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
47949847|NCT03455582|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
47949848|NCT03455582|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
48105771|NCT01390402|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
48105772|NCT01390402|DRUG|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
47949849|NCT05920694|DEVICE|Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
47949850|NCT05920694|OTHER|Delayed Continuous Positive Airway Pressure Device (CPAP)|Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
47949851|NCT02068027|DRUG|Clonidine Gel 0.1%|
47949852|NCT02068027|DRUG|Placebo|
47949853|NCT05438888|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
47949854|NCT05438888|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
47949855|NCT05826808|DIAGNOSTIC_TEST|Polysomnography|The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.
47949856|NCT01154829|DRUG|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
47949857|NCT01154829|DRUG|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
47949858|NCT05034718|OTHER|PIBIS clinical decision support|The intervention is the presence of the PIBIS physician alert and powerform, which is clinical decision support for the treating provider if a patient meets inclusion criteria for Pittsburgh Infant Brain Injury Score (PIBIS) calculation.
47949859|NCT05034718|OTHER|Standard of care|Standard of care, absent the PIBIS powerform and alert for providers.
47949860|NCT06509139|DRUG|Drug: Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
47949861|NCT06509139|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
47949862|NCT06509139|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
47949863|NCT06509139|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
47949864|NCT04908709|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo sMRI
47949865|NCT04908709|DEVICE|Proton Therapy|Target volume treatment
47949866|NCT05106894|BEHAVIORAL|smartphone application to promote nurturing care|see arm description
47949867|NCT05106894|BEHAVIORAL|printed caregiving materials|see arm description
47949868|NCT06418750|OTHER|dermo-cosmetic product|For patients in the preventive group, treatment with hand serum, gloves/slippers and fortifying solution/dissolving oil will be started on the day of the first administration of Ac bispecific. In the curative group, treatment will begin on inclusion in the study and will be adapted to the lesions present on D0. Treatment will be readjusted on a weekly basis according to the lesions present at the time of the follow-up visit.
47949869|NCT00971880|OTHER|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
47949870|NCT04956952|DEVICE|EECP|1 hour of treatment with EECP
47949871|NCT03467048|DEVICE|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
47949872|NCT03467048|DEVICE|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
47949873|NCT02951338|BEHAVIORAL|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
48105773|NCT01390402|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
48105774|NCT01789489|DEVICE|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
48105775|NCT00301990|BIOLOGICAL|aldesleukin|
48105776|NCT00301990|BIOLOGICAL|bevacizumab|
48266497|NCT03739528|DRUG|Levofloxacin + dexamethasone followed by dexamethasone|Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
48478278|NCT03187028|BEHAVIORAL|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
48636926|NCT01389284|DRUG|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
48105777|NCT02983370|PROCEDURE|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
48105778|NCT06235606|DRUG|Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
48105779|NCT06235606|DRUG|Dexmedetomidine 0.5milligram (50micrograms)|Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.
48105780|NCT03248011|OTHER|Stretching|Lower extremity flexibility exercises will be performed
48105781|NCT03248011|OTHER|Strengthening|Eccentric hamstring strengthening exercises will be performed
48105782|NCT03248011|OTHER|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
48105783|NCT02064660|DEVICE|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
48105784|NCT04726813|BEHAVIORAL|MyADHD|The main goals of the intervention are to help participants with better functioning in daily life; offer strategies that will lead to stress reduction and reduce inattention and improve quality of life.The intervention includes: a short introductory chapter (open to everyone), followed by a start module (goal setting), followed by 6 different themed optional modules. Module content is based on GMT, DBT and CBT techniques and is tailored towards key concerns and difficulties experienced adults with ADHD as informed by previous research (focus-groups, lived experience groups) and experiences from group GMT and DBT.
48105785|NCT04726813|BEHAVIORAL|Psychoeducation|Participants in the control condition will be assigned to psychoeducation modules (see Table 2) and will receive restricted access to the platform. They can contact or be contacted if their symptoms levels increases.
48105786|NCT05626504|DEVICE|Pipeline Embolization Device with Vantage Technology|Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
48105787|NCT00862680|PROCEDURE|4-Dimensional Computed Tomography|Undergo 4D PET/CT
48105788|NCT00862680|PROCEDURE|4D PET Scan|Undergo 4D PET/CT scan
48105789|NCT03911245|OTHER|Retrospective study. Analyze of data in medical records|Retrospective study. Analyze of data in medical records
48105790|NCT05875155|DIAGNOSTIC_TEST|Infectious Disease Labwork|Infectious disease labs will be drawn and resulted.
48105791|NCT05875155|DIAGNOSTIC_TEST|Fertility-Based Labwork|Other labwork to understand fertility may be drawn.
48105792|NCT04117191|DIETARY_SUPPLEMENT|Doctor's Best L-Tryptophan|2g tryptophan loading once
48105793|NCT01817036|DIETARY_SUPPLEMENT|Placebo|placebo
48105794|NCT01817036|DIETARY_SUPPLEMENT|Vitamin D|400 IU vitamin D per pill
48105795|NCT00878462|DRUG|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
48105796|NCT00878462|DRUG|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
48105797|NCT00878462|DRUG|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
48105798|NCT05079269|OTHER|Crystalloid Solutions|As above
48105799|NCT05817318|DEVICE|Renal Denervation|Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
48105800|NCT05183906|DIAGNOSTIC_TEST|Next generation sequencing|Evaluation of microbiological culturing versus next generation sequencing for ribosomal DNA
48105801|NCT01639638|DRUG|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
48105802|NCT04552886|BIOLOGICAL|TH-1 Dendritic Cell Immunotherapy|Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.
48105803|NCT00299741|DRUG|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
48105804|NCT06477302|BEHAVIORAL|Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer (STA-RR-LC)|Patients will be given a measurement instrument to determine the level of therapeutic adherence.
48105805|NCT01843491|BIOLOGICAL|Ad-PfCA|Vaccine
48105806|NCT01023490|DRUG|Vitamin D|34,5000 IU vitamin D per week
48105807|NCT01023490|DRUG|Placebo|Placebo
48105808|NCT05977933|DEVICE|Shape II CPET|Submaximal Cardiopulmonary exercise test equipment
48105809|NCT05463354|BIOLOGICAL|Recombinant COVID-19 Vaccine (Sf9 Cell)|1dose, Intramuscular Injection
48105810|NCT05463354|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|1dose, Intramuscular Injection
48105811|NCT05795946|DIETARY_SUPPLEMENT|Whole food-based B and D vitamins|Looking at whole food-based B and D vitamins to reduce TMAO levels and if this can modulate gut diversity
48105812|NCT00015990|DRUG|thalidomide|Given orally
48105813|NCT00015990|OTHER|laboratory biomarker analysis|Correlative studies
48105814|NCT00242190|DRUG|oxaliplatin|
48105815|NCT00242190|DRUG|gemcitabine|
48105816|NCT00242190|PROCEDURE|radiation therapy|
48105817|NCT03122704|PROCEDURE|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
48105818|NCT00092599|DRUG|MK0653, ezetimibe|
48105819|NCT00092599|DRUG|Comparator: ezetimibe, placebo|
48266498|NCT03739528|DRUG|Tobramycin + Dexamethasone|Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
47949874|NCT02951338|OTHER|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
47949875|NCT06135402|DEVICE|Treatment with Monalisa Glide Laser|3 fractional laser treatment-sessions with Monalisa Glide
47949876|NCT06135402|DRUG|Treatment with Clobetasol|Application of Clobetasol twice per week
47949877|NCT05634031|RADIATION|PET imaging|PET imaging visit, which will take approximately 1-2 hours.
47949878|NCT05634031|RADIATION|Coronary CT angiogram|A coronary CT angiogram if the participant has not had one recently.
47949879|NCT05634031|PROCEDURE|Functional Angiography|"A subset of patients with abnormal results on cardiac PET myocardial perfusion imaging study (estimated number of patients = 12) will be invited to participate in an invasive sub-study wherein they would undergo detailed invasive coronary physiology evaluation.~Functional Angiography (coronary reactivity test- CRT): is an angiography procedure done in the catheterization laboratory. It evaluates the coronary artery microcirculation and how the blood vessels respond to different medications."
47949880|NCT05634031|PROCEDURE|Treadmill exercise stress study|A treadmill exercise stress study
47949881|NCT01291953|PROCEDURE|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
47949882|NCT01291953|PROCEDURE|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
47949883|NCT05744713|OTHER|Observational|Observational
47949884|NCT00485433|DRUG|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
47949885|NCT00485433|DRUG|SKY0402|SKY0402 given during hernia repair
47949886|NCT02899845|OTHER|postural task|
47949887|NCT02899845|OTHER|walk task|
47949888|NCT01115361|BEHAVIORAL|Family planning for postpartum women|"A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants."
48478279|NCT03187028|BEHAVIORAL|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
48478280|NCT04031092|DEVICE|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
47949889|NCT00467857|PROCEDURE|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal\* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
48105820|NCT03819361|DIAGNOSTIC_TEST|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
47949890|NCT00467857|OTHER|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
47949891|NCT05739630|DRUG|mitoxantrone liposome|Mitoxantrone liposomes with 36mg/m2 and Bu 3.2mg/kg -5 to -4, Flu 30mg/m2 -12 to -9, Ara-C 1.5g/m2 -12 to -9，CTX 15mg/kg/d -3 to -2, was used as conditioning regimen, Post Transplant Cyclophosphamide 50 mg/kg IV daily on days +3 and +4.
47949892|NCT05739630|DRUG|ATG|Control group:the conditioning regimen involved Ara-C 2g/m2 q12h -8, BU 3.2 mg/kg -7 to -5,CTX 1.8 g/m2 -4 to -3, to prevent GVHD, MTX 15mg/m2 +1d, 10mg/m2 +3,+6,+11,CsA 3mg/kg/d from -8d,MMF 1g q12h from -8d， ATG 2.5mg/kg/d -5 to -2.
47949893|NCT04138004|DRUG|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
47949894|NCT04138004|DRUG|polyethylene glycol alone|4-litre polyethylene glycol split-dose
47949895|NCT03912064|DRUG|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
47949896|NCT03912064|BIOLOGICAL|CD25hi Treg depleted DLI|Donor lymphocyte product
47949897|NCT03369470|BEHAVIORAL|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
47949898|NCT03369470|BEHAVIORAL|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
48105821|NCT03731936|OTHER|No intervention|No intervention
48105822|NCT04002973|DEVICE|INVSENSOR00037|Noninvasive regional oximeter.
48105823|NCT02669524|DRUG|LY2409021|
48105824|NCT02669524|DRUG|LY2409021 placebo|
48105825|NCT02669524|PROCEDURE|OGTT|
48105826|NCT02669524|PROCEDURE|IIGI|
48105827|NCT02669524|PROCEDURE|Standardised liquid meal|
48105828|NCT00206024|DRUG|Esomeprazole magnesium (Nexium)|
48478281|NCT04031092|DEVICE|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
48478282|NCT04031092|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program.
48105829|NCT03914170|DRUG|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
48105830|NCT01591616|DRUG|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
48636927|NCT04352166|DRUG|extended-release buprenorphine (BXR)|Three monthly injections will be provided during the course of the 12 week trial.
48636928|NCT04352166|DRUG|sublingual buprenorphine (BSL)|On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
48636929|NCT03576820|DRUG|Lidocaine|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
48636930|NCT03576820|DRUG|Placebo|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
48636931|NCT06153251|DRUG|BMS-986453|Specified dose on specified days
48636932|NCT06153251|DRUG|Fludarabine|Specified dose on specified days
48636933|NCT06153251|DRUG|Cyclophosphamide|Specified dose on specified days
47949899|NCT03728530|OTHER|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
47949900|NCT01187433|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
47949901|NCT01187433|BIOLOGICAL|NaCl 0.9%|0.5 mL, Subcutaneous
48105831|NCT03278028|DRUG|A-101 Topical Solution|A-101 Topical Solution
48636934|NCT03014388|OTHER|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
47949902|NCT01187433|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
47949903|NCT01187433|BIOLOGICAL|Meningococcal A+C vaccine|0.5 mL, Intramuscular
48105832|NCT03278028|DRUG|A-101 Vehicle Solution|A-101 Vehicle Solution
48105833|NCT05565391|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
47949904|NCT04044495|OTHER|Multimodal brain imaging (MRI)|Multimodal brain imaging (MRI)
48105834|NCT05565391|DRUG|Standard of care|Standard of care
48636935|NCT03014388|OTHER|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
47949905|NCT04044495|OTHER|Actimetry|7 days actimetry
47949906|NCT04044495|OTHER|Sleep Diary|7 days Record of sleep and wake cycle
47949907|NCT05024201|BEHAVIORAL|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
48105835|NCT01018524|PROCEDURE|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
48105836|NCT06489860|DRUG|HIV|"Directions: For adults and for Children 1-12 years old. Indication: Anti-AIDS Drug. Ingredient: Organic Rice 91% and Honey 9% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date."
48105837|NCT06489860|DRUG|Neoplasms|"Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Rice 90% and Honey 10% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5%. Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time. Use within two years from the manufacturing date."
48105838|NCT06074380|DRUG|MIST surfactant|Surfactant will be given via MIST while neonate is on CPAP
48636936|NCT05534607|BEHAVIORAL|Ola Mau i ka Hula|"The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly."
47949908|NCT04348110|DIETARY_SUPPLEMENT|Placebo tablets|consume 2 tablets per day for 8 weeks
47949909|NCT04348110|DIETARY_SUPPLEMENT|Blueberry Chewable Tablets|consume 2 tablets per day for 8 weeks
47949910|NCT01922557|DEVICE|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
48636937|NCT00337688|DEVICE|isometric joystick|isometric joystick
48636938|NCT01341938|DRUG|Commit® nicotine lozenges (4 mg) & self-help materials|"Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
48636939|NCT01341938|BEHAVIORAL|Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + lozenge nicotine replacement therapy (NRT) + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
47949911|NCT06413927|BEHAVIORAL|Online Vehicle and Driver Safety Training|This online video education program provides education in vehicle and driver safety (e.g. vehicle maintenance, adjusting car seats and seatbelts). This online training will take up to 2 hours to complete and will have a short quiz at the end to determine compliance with this online training.
47949912|NCT06413927|BEHAVIORAL|Online Driver Skills Training|The online driver training is the Accelerated Curriculum to Create Effective Learning (ACCEL) is designed to enhance the ability to anticipate, recognize and respond to hazards and to maintain attention to the road. The training is delivered online via a computer and can be done from home or at a school or other site that has a computer with internet access. It requires up to two hours to complete, and will be hosted on a platform that will track progress and completion through the training (such as accuracy, duration in modules, time to complete) and a short quiz will be provided at the end to assess learning.
47949913|NCT06413927|BEHAVIORAL|Behind-the-Wheel Driver Training|The professional behind-the-wheel training course will be conducted in-person, delivered by local driving school partner Driver Training Services. The curriculum consists of 6 hours of training with assigned practice between lessons, and meets Pennsylvania and national standards. Post-lesson forms completed by the instructors will record adherence and consistency (intervention fidelity).
47949914|NCT01542073|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
47949915|NCT00302107|DRUG|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
47949916|NCT00302107|DRUG|Placebo|Look-a-like placebo tablets under double-blind conditions
47949917|NCT01050491|DRUG|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
47949918|NCT01050491|DRUG|placebo|placebo, one per day, during one year. Bronchial fibroscopy
47949919|NCT05095454|DEVICE|Percutaneous epidural electrical spinal stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System"
47949920|NCT05095454|DEVICE|Transcutaneous electrical spinal stimulation|Digitimer DS8R Bipolar Constant Current Stimulator
47949921|NCT02420158|DEVICE|Trans-cutaneous vagal nerve electrical stimulation|
47949922|NCT02932423|OTHER|Control product E|Plain water
47949923|NCT02932423|OTHER|Test product A|Beverage with no sugar but sweetener
47949924|NCT02932423|OTHER|Test product B|Beverage with 22 g/L sugar and sweetener
47949925|NCT02932423|OTHER|Test product C|Beverage with 33 g/L sugar and sweetener
47949926|NCT02932423|OTHER|Test product D|Beverage with 47 g/L sugar and sweetener
47949927|NCT02932423|OTHER|Comparative product F|Beverage with 98 g/L sugar
47949928|NCT00851344|DRUG|GSK835726 (10mg)|GSK835726 (10mg) tablet
47949929|NCT00851344|DRUG|GSK835726 (50mg)|GSK835726 (50mg) tablet
47949930|NCT00851344|DRUG|GSK835726 (100mg)|GSK835726 (100mg) tablet
47949931|NCT00851344|DRUG|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
47949932|NCT00851344|OTHER|Placebo|Placebo to match active
47949933|NCT06681571|OTHER|TAP Block|TAP block will be performed immediately after the induction of anesthesia, under ultrasond guidence.
47949934|NCT06681571|OTHER|RSB|Rectus Sheath block will be performed immediately after the induction of anesthesia, under Ultrasond guidence.
47949935|NCT01501370|DRUG|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
48478283|NCT04778306|PROCEDURE|Transoral Laser Surgery|Remove of the laryngeal tumour via diode laser
47949936|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
47949937|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
47949938|NCT01501370|DRUG|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
47949939|NCT01501370|DRUG|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
47949940|NCT01527175|OTHER|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
48478284|NCT01343069|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
47949941|NCT02243969|DIETARY_SUPPLEMENT|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
47949942|NCT02243969|DIETARY_SUPPLEMENT|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
47949943|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
47949944|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
47949945|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
47949946|NCT00177996|DRUG|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
47949947|NCT02256072|OTHER|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
48105839|NCT03181958|DEVICE|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
48105840|NCT03181958|DEVICE|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
47949948|NCT02256072|OTHER|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
47949949|NCT06332859|OTHER|Resilience training|The resilience training consists of two sessions of psychological group therapy, each lasting 100 minutes, with a special focus on resilience. Additionally, there are two sessions of relaxation training, known as 'heart yoga', each lasting 25 minutes.
47949950|NCT03260920|DRUG|Syntocinon|Intranasal Oxytocin
47949951|NCT03468985|DRUG|Cabozantinib|Given PO
47949952|NCT03468985|BIOLOGICAL|Ipilimumab|Given IV
47949953|NCT03468985|BIOLOGICAL|Nivolumab|Given IV
47949954|NCT03600298|OTHER|Simulation|Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
47949955|NCT06419608|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 6 weeks
48105841|NCT03181958|DEVICE|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
48636940|NCT01341938|BEHAVIORAL|Phone counseling & self-help materials|"Three phone counseling sessions to assist in cessation from use of all tobacco + The Enough Snuff video and printed guide providing strategies for tobacco cessation."
48636941|NCT03258957|OTHER|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
48636942|NCT01183182|DEVICE|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
48636943|NCT05013229|DRUG|IcoSema|Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
48298424|NCT01311206|OTHER|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
48478285|NCT06616246|BEHAVIORAL|HealthyLifetime|HealthyLifetimeTM \[HL\] seeks to intervene early in the aging process when individuals have the best chance for longer-term benefits of changing their health behavior, staving off functional decline, and minimizing the onset or exacerbation of chronic conditions.
47949956|NCT06419608|DRUG|Placebo|Matching placebo taken once daily for 6 weeks
47949957|NCT00299351|DRUG|Depsipeptide|
48105842|NCT01499134|DRUG|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
48636944|NCT05013229|DRUG|Insulin glargine|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
48636945|NCT05013229|DRUG|insulin aspart|Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.
48636946|NCT03401580|DRUG|Viena II 160/10|once daily
48105843|NCT01499134|DRUG|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
48105844|NCT04565691|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 40% of the cases.
48105845|NCT02837497|OTHER|ICU-RESUS CPR Improvement Bundle|"1. Point-of-care CPR training~2. Post-cardiac arrest educational debriefings"
48105846|NCT00100100|DRUG|Modafinil|
48298425|NCT06314906|DEVICE|Electroacupuncture|Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
48298426|NCT06314906|DRUG|Antiemetic Therapy|Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
48478286|NCT02907099|DRUG|CXCR4 Antagonist BL-8040|Given SC
48636947|NCT03401580|DRUG|Viena II 190/10|once daily
48636948|NCT03401580|DRUG|Viena II 160/12|once daily
47949958|NCT01434407|OTHER|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
48478287|NCT02907099|BIOLOGICAL|Pembrolizumab|Given IV
48478288|NCT02907099|OTHER|Pharmacological Study|Correlative studies
48478289|NCT00251914|DRUG|Esomeprazole|
48478290|NCT04231123|PROCEDURE|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
48478291|NCT04231123|PROCEDURE|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
48478292|NCT04615312|DRUG|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
48636949|NCT03401580|DRUG|Viena II 190/12|once daily
47949959|NCT02063711|BEHAVIORAL|Yoga intervention|
47949960|NCT03785938|DIETARY_SUPPLEMENT|Probiotic|Liquid probiotic supplied by the company Symprove
47949961|NCT03785938|OTHER|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
47949962|NCT02919696|DRUG|Abemaciclib|Administered orally
47949963|NCT01464996|PROCEDURE|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
47949964|NCT01464996|PROCEDURE|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
48105847|NCT01048788|DRUG|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
48636950|NCT06548672|DRUG|BC3195|BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
48478293|NCT05945992|BEHAVIORAL|Emotion regulation|Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises
48478294|NCT05945992|BEHAVIORAL|Self-acceptance|Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
47949965|NCT04953351|PROCEDURE|Cognitive registration targeted biopsy and TRUS-system biopsy|Cognitive registration is a visual guidance technique in which the surgeon samples a visually estimated location on ultrasound that corresponds to the MRI suspicious regions location. TRUS-system biopsy includes 12 biopsy cores.
48478295|NCT05945992|BEHAVIORAL|Mindfulness|Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group
47949966|NCT04953351|PROCEDURE|MRI-ultrasound fusion targeted biopsy and TRUS-system biopsy|MRI-ultrasound fusion targeted biopsy is conducted with an mpMRI-TRUS biopsy system that provides realtime fusion of TRUS images and MRI images to guide the biopsy needles. TRUS-system biopsy includes 12 biopsy cores.
48105848|NCT04608955|DRUG|WX-081|WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
48105849|NCT04608955|DRUG|Bedaquiline|This licensed drug will be used in arm F as positive comparator.
48478296|NCT05945992|BEHAVIORAL|Resource activation|Exercises focusing on developing positive emotions and fostering personal strengths, based on the Positive Psychology movement of Martin Seligman, working on individual values, life goals and sense of life.
48478297|NCT05945992|BEHAVIORAL|Control component 1_social behaviors in groups|Control component for emotion regulation
48478298|NCT05945992|BEHAVIORAL|Control component 2_communication skills|Control component for self-acceptance
48478299|NCT05945992|BEHAVIORAL|Control component 3_stress management|Control component for mindfulness
48478300|NCT05945992|BEHAVIORAL|Control component 4_constructive conflict resolution|Control component for resource activation
48478301|NCT05464719|DRUG|Loncastuximab Tesirine|Given by IV
48636951|NCT06450340|BEHAVIORAL|Moderate-intensity aerobic exercise refers to rhythmic and long-lasting exercise with increased heart rate, slight sweating and slight wheezing.|Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups.
48636952|NCT05521282|DRUG|Treatment group|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
48636953|NCT06395636|DEVICE|Infection-Prediction Algorithm|This machine learning algorithm will be developed(Aim1a) and validated(Aim 1b) using the participant Fitbit data and survey results collected during Aim 1. In Aim 2 the algorithm will be used in real time to predict postoperative infection.
47949967|NCT02421029|DRUG|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
47949968|NCT06679829|DRUG|Siltuximab|11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
47949969|NCT06679829|DRUG|Melphalan|"Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2"
48105850|NCT04608955|DRUG|Standard treatment|Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
48105851|NCT04608955|DRUG|Multi-drug background treatment (MBT)|MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
48105852|NCT04882449|DEVICE|Bodyport Scale|The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
48105853|NCT00680472|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
48105854|NCT00680472|OTHER|Placebo Patch|Treatment with Placebo Patch
48478302|NCT04334928|DRUG|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
48478303|NCT04334928|DRUG|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
48478304|NCT04334928|DRUG|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
48478305|NCT04334928|DRUG|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
48478306|NCT02044432|OTHER|ginger compress|Kidney ginger compress
48478307|NCT02508116|GENETIC|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
48478308|NCT02409186|DRUG|Nimotuzumab|400mg/w，d1, week 1-7
48105855|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|a single dose of 1 mg AEF0117 in fed condition
48105856|NCT05451017|DRUG|3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition|a single dose of 1 mg AEF0117 in fasting condition
48105857|NCT02248480|DRUG|Duloxetine|Administered orally
48105858|NCT02248480|DRUG|Placebo|Administered orally
48105859|NCT03990272|DRUG|AIT drops|once a day
48105860|NCT03990272|DRUG|placebo drops|once a day
48105861|NCT05879588|OTHER|immediate orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer immediately after debonding
48105862|NCT05879588|OTHER|delayed orthodontic retainer delivery|post orthodontic treatment patients will be given orthodontic retainer after 3 days of debonding
47949970|NCT03652740|DRUG|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
47949971|NCT02772887|DIETARY_SUPPLEMENT|L-Citrulline|amino acid supplement
48105863|NCT02049866|DRUG|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
48105864|NCT04652817|DEVICE|MMI-22-04-2019|A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
48105865|NCT06553222|BIOLOGICAL|Putty bone - Tricalcium phosphate with Collagen gel|Minimally invasive debridement periodontal flap and Bone graft placement to augment the lost alveolar bone
48298427|NCT06314906|DEVICE|Sham electroacupuncture|Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
48478309|NCT02409186|RADIATION|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
47949972|NCT02772887|OTHER|Placebo|placebo
47949973|NCT00411112|PROCEDURE|blue and isotopic detection of sentinel lymph nodes|
47949974|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
47949975|NCT00662454|DRUG|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
47949976|NCT05179850|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
47949977|NCT02196207|DRUG|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
47949978|NCT02196207|DRUG|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
47949979|NCT02196207|DRUG|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
47949980|NCT02196207|DRUG|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
47949981|NCT04021420|DEVICE|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~1. an implantable ultrasound transducer,~2. a needle connection device,~3. an external radiofrequency generator, and~4. an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
47949982|NCT04021420|DRUG|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
47949983|NCT02761928|OTHER|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
47949984|NCT00657449|DRUG|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
47949985|NCT00657449|DRUG|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
47949986|NCT04512950|DRUG|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
47949987|NCT04512950|DRUG|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
47949988|NCT02550041|OTHER|T specific response for diagnostic of aspergillus bronchitis|
47949989|NCT03376048|PROCEDURE|Wound infiltration plus TAP|"1. TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~2. Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
47949990|NCT03376048|PROCEDURE|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
47949991|NCT00555685|DRUG|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
47949992|NCT00555685|DRUG|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
48478310|NCT02409186|DRUG|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
47949993|NCT03657446|DRUG|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
47949994|NCT03657446|DRUG|Placebo|Matching placebo infusion
47949995|NCT03657446|DRUG|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
47949996|NCT05927701|OTHER|Group comparaison|Questionnaires
47949997|NCT01999751|DEVICE|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
48636954|NCT04396860|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced brain MRI
47949998|NCT00445978|DRUG|Sapropterin Dihydrochloride|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
48298428|NCT06314906|DRUG|Antiemetic Therapy|They will also receive the same antiemetic medications as the experimental group.
48636955|NCT04396860|BIOLOGICAL|Ipilimumab|Given IV
48636956|NCT04396860|BIOLOGICAL|Nivolumab|Given IV
48636957|NCT04396860|DEVICE|NovoTTF-100A Device|Wear Optune device
47949999|NCT05745012|PROCEDURE|endoscopic mucosal resection|The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.
47950000|NCT05745012|PROCEDURE|sham|The procedure consists of performing endoscopic exploration, no mucosal resection
47950001|NCT02614651|PROCEDURE|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
48478311|NCT02409186|DRUG|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
48478312|NCT02409186|OTHER|placebo|400mg/w，d1, week 1-7
48478313|NCT06617715|BIOLOGICAL|Sinovac PCV13|One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.
48478314|NCT06617715|BIOLOGICAL|Prevnar®|One dose of Prevnar® (0.5 mL) is administered intramuscularly.
48478315|NCT02291367|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
48478316|NCT02291367|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
48478317|NCT01749358|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
48478318|NCT01749358|BEHAVIORAL|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
48478319|NCT04836520|DRUG|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
48478320|NCT02443584|OTHER|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
48478321|NCT00942331|BIOLOGICAL|Bevacizumab|Given IV
48478322|NCT00942331|DRUG|Cisplatin|Given IV
48478323|NCT00942331|DRUG|Gemcitabine Hydrochloride|Given IV
48478324|NCT00942331|OTHER|Laboratory Biomarker Analysis|Correlative studies
48478325|NCT00942331|OTHER|Placebo Administration|Given IV
48478326|NCT01920984|DRUG|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
48636958|NCT04396860|OTHER|Quality-of-Life Assessment|Ancillary studies
47950002|NCT02614651|PROCEDURE|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
48298429|NCT00450606|PROCEDURE|Balneotherapy and hydrotherapy|
48298430|NCT02033551|DRUG|Veliparib|
48298431|NCT02033551|DRUG|Carboplatin|
48298432|NCT02033551|DRUG|Paclitaxel|
48298433|NCT02033551|DRUG|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
48478327|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
48478328|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
48636959|NCT04396860|OTHER|Questionnaire Administration|Ancillary studies
48636960|NCT04396860|RADIATION|Radiation Therapy|Undergo radiation therapy
48636961|NCT04396860|DRUG|Temozolomide|Given PO
48636962|NCT03485209|DRUG|tisotumab vedotin|Given into the vein (IV; intravenously)
48636963|NCT03485209|DRUG|pembrolizumab|200mg or 400mg given by IV
48636964|NCT03485209|DRUG|carboplatin|AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
48636965|NCT03485209|DRUG|cisplatin|100mg/m\^2 given by IV
48636966|NCT04189588|DRUG|Cetirizine HCl 10 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
47950003|NCT02614651|PROCEDURE|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
48105866|NCT03510091|BEHAVIORAL|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
47950004|NCT02614651|PROCEDURE|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
48105867|NCT00896948|GENETIC|Southern blotting|
47950005|NCT02614651|DEVICE|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
47950006|NCT00617851|BIOLOGICAL|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
48105868|NCT00896948|GENETIC|TdT-mediated dUTP nick end labeling assay|
48105869|NCT00896948|GENETIC|gene expression analysis|
48636967|NCT04189588|DRUG|Diphenhydramine 50 mg/mL|Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
48105870|NCT00896948|GENETIC|protein expression analysis|
48105871|NCT00896948|OTHER|flow cytometry|
48636968|NCT04189588|DRUG|anti-CD20 such as Rituximab or Paclitaxel|Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
48636969|NCT06358651|DRUG|Fasedienol Nasal Spray|Nasal spray delivered 20 minutes before the PSC
48636970|NCT06358651|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the PSC
48636971|NCT00063362|DRUG|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
47950007|NCT00617851|BIOLOGICAL|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
47950008|NCT00617851|BIOLOGICAL|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
47950009|NCT00617851|BIOLOGICAL|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
47950010|NCT00617851|BIOLOGICAL|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
47950011|NCT00002451|DRUG|Indinavir sulfate|
47950012|NCT00002451|DRUG|Ritonavir|
47950013|NCT00002451|DRUG|Lamivudine|
48105872|NCT00896948|OTHER|fluorescent antibody technique|
48478329|NCT06110286|OTHER|Photorefractive keratectomy|Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation
48478330|NCT01682629|OTHER|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
48105873|NCT00896948|OTHER|immunoenzyme technique|
48105874|NCT00896948|OTHER|immunohistochemistry staining method|
48105875|NCT00896948|OTHER|immunologic technique|
47950014|NCT00002451|DRUG|Stavudine|
47950015|NCT04186936|DRUG|Combination Caplet with Loperamide HCl and Simethicone|Participants will receive combination caplet with loperamide HCl 2 mg and simethicone 125 mg as Test product A per assigned treatment sequence.
47950016|NCT04186936|DRUG|Loperamide HCl|Participants will receive loperamide HCl 2 mg tablet-lyophilizate orally as part of Reference product B per assigned treatment sequence.
48105876|NCT04886180|DEVICE|Oxiris membrane|Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.
48105877|NCT04886180|DEVICE|Prismaflex membrane|Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.
48105878|NCT04886180|BIOLOGICAL|Blood tests|Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement
48105879|NCT03611530|DEVICE|Coqun® ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution
48105880|NCT03611530|OTHER|Placebo ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
47950017|NCT04186936|DRUG|Simethicone|Participants will receive Simethicone 40 mg capsule orally as part of Reference product B per assigned treatment sequence.
47950018|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise and moderate intensity functional training|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (15-30 min.) and moderate intensity functional training (MIFT) (15 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min. In MIFT, subjects must complete in 15 min. the highest number of repetitions / rounds possible (AMRAP) to a circuit composed of 6 global functional exercises from which they performed 10 repetitions with a rating of perceived exertion (RPE) of 5-7 on a 1 to 10 scale in each exercise.
47950019|NCT05126680|OTHER|Supervised exercise therapy: intermittent treadmill walking exercise|Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (30-45 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min.
47950020|NCT04972929|OTHER|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
47950021|NCT04972929|OTHER|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
47950022|NCT02524405|OTHER|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B \[11C\]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
47950023|NCT06681337|BIOLOGICAL|BCMA CART + CD19 CART|BCMA CART + CD19 CART
48105881|NCT05856708|OTHER|DISEASE|
48105882|NCT05179837|DEVICE|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
48105883|NCT04709796|DRUG|EmbryoGlue®, Vitrolife|The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.
48105884|NCT04709796|DRUG|Conventional Transfer|The control arm is the conventional embryo transfer without Embryo glue medium
47950024|NCT00017017|DRUG|paclitaxel poliglumex|
47950025|NCT03761667|OTHER|Endoscopy using Narrow band imaging|Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
47950026|NCT02703220|OTHER|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
48105885|NCT02212535|DRUG|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
48105886|NCT04838210|BEHAVIORAL|EleVATE Group Care|10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG. In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life. Groups are facilitated by an obstetric clinician.
48105887|NCT04838210|BEHAVIORAL|Individual Prenatal Care|The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician. Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery. Visits focus on routine screening tests and prenatal care.
48105888|NCT06121596|BEHAVIORAL|Breathing Exercise|A breathing exercise is a relaxation technique (or therapy) to increase relaxation (induces a relaxation response) and decrease stress (reduces a stress response).
48105889|NCT03121131|OTHER|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
48105890|NCT03121131|OTHER|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
48105891|NCT03121131|OTHER|No clinical exam findings|No clinical exam findings are given to the radiologists
48105892|NCT04941924|PROCEDURE|Intraductal Radio-Frequency Ablation|"The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used."
48105893|NCT04941924|DEVICE|Biliary Stent Placement|Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
48105894|NCT02050724|DRUG|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
48105895|NCT02050724|DEVICE|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
48105896|NCT02050724|DEVICE|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
48105897|NCT05917249|DEVICE|Capacitive-Resistive Noninvasive Radiofrequency|The two passive plates were under the back of the patient. The active capacitive plates of the machine (CAPENGERY, C200, Spain) will be applied initially for 20 minutes over the sole of both feet, with the machine adjusted on the A-thermal mode (37 oC). During the remaining 20 minutes, active capacitive plates are relocated over femoral vessels at the femoral triangle with the machine adjusted on the frank thermal mode (41 oC).
48105898|NCT03800667|DRUG|Ascorbic Acid 1000 MG|1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
48105899|NCT01499108|DRUG|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
48478331|NCT01682629|OTHER|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
48636972|NCT00063362|DRUG|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
48636973|NCT00063362|DRUG|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
48636974|NCT00063362|DRUG|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
48105900|NCT04307316|OTHER|ACBT group|"ACBT:~Breathing control 3 to 4 Thoracic Expansion Exercise A: 3 seconds hold B: Chest clapping C: Chest vibration Forced Expiratory Technique Breathing control A: 3 seconds hold B: Chest clapping C: Chest vibration 3 to 4 Thoracic Expansion Exercise Breathing control 1-2 Huff combine with breathing control Huff and cough~Chest Physical Therapy Early mobilization"
48105901|NCT04307316|OTHER|Conventional Physical therapy|Chest percussion, deep breathing, Huff and cough. Early mobilization
48105902|NCT05506098|OTHER|no intervention|no intervention
48105903|NCT00564967|BEHAVIORAL|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
48105904|NCT00564967|BEHAVIORAL|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
48105905|NCT01137266|DEVICE|TENS|TENS
47950027|NCT02703220|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
48105906|NCT04881136|DEVICE|Reveal LINQ™|The physical device is the Reveal LINQ™, which is a small implantable loop recorder that is used to monitor cardiac parameters at present. The Investigational Falls Prediction RAMware is software that will be downloaded on to the Reveal LINQ™ that will enable it to collect additional sensor information including accelerometer and posture count data that will be used for gait analysis.
48105907|NCT00402155|BEHAVIORAL|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
48105908|NCT04329663|DEVICE|Indonesian computer-based game prototype|In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
48105909|NCT05538455|DEVICE|PC4L solutions|Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
48105910|NCT01153750|DRUG|Glivec|
48105911|NCT02931123|DRUG|lattulose and rifaximine|
48105912|NCT05323682|OTHER|Individualized physical exercise program|An individualized physical exercise program was programmed, monitored remotely by e-mail or the use of an activity wristband
48105913|NCT05323682|OTHER|NO Individualized physical exercise program|Usual medication
48105914|NCT06555809|DRUG|Artesunate Injection|Additional blood sample will be collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous artesunate treatment.
48105915|NCT05676736|OTHER|No intervention|No intervention to be done for the group
48105916|NCT00877422|DIETARY_SUPPLEMENT|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
47950028|NCT02703220|DRUG|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
48105917|NCT04536441|BEHAVIORAL|Ultra Brief Online Mindfulness-based Intervention|We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley \& Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
48105918|NCT04536441|BEHAVIORAL|Control|The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
48105919|NCT04164563|DEVICE|Even-Up|Orthotic shoe lift worn on contralateral foot to increase leg length
48105920|NCT00336232|DRUG|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
48105921|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2321138A|intramuscular injections
48105922|NCT01196988|BIOLOGICAL|FluarixTM|intramuscular injections
48105923|NCT01196988|BIOLOGICAL|Influenza vaccine GSK2604409A|intramuscular injections
48105924|NCT00001575|BIOLOGICAL|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
48105925|NCT00001575|DRUG|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
48105926|NCT01717794|PROCEDURE|Thunderbeat technology|
48105927|NCT01717794|PROCEDURE|Standard bipolar electrosurgery|
48105928|NCT06493214|BEHAVIORAL|Physical activity|Participants will be asked to complete three eight-minute InPACT at Home exercise videos per day, five days a week, for 12 weeks.
48105929|NCT02770248|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
48105930|NCT02770248|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
48105931|NCT01845896|BEHAVIORAL|Training|
48105932|NCT03748433|DEVICE|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
48105933|NCT03748433|DEVICE|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
47950029|NCT00646919|PROCEDURE|Nose swab|
47950030|NCT01298310|DRUG|Xylocaine|1 mg/mL solution for injection
47950031|NCT01298310|DRUG|Xylocaine|10 mg/mL solution for injection
47950032|NCT01298310|DRUG|Placebo|solution for injection
48105934|NCT02087644|BIOLOGICAL|CYT003|Injections
48105935|NCT02087644|BIOLOGICAL|Placebo|Injections
48298434|NCT03705104|BEHAVIORAL|EPIO|App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
47950033|NCT06307873|DIAGNOSTIC_TEST|pre and post operative POP-Q results|Comparison of pre and postoperative POP-Q values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
48636975|NCT04463979|OTHER|Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia|"Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.~Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire."
48636976|NCT04094610|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
48636977|NCT03477591|OTHER|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
48636978|NCT03477591|OTHER|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
47950034|NCT06307873|BEHAVIORAL|pre and post operative PİSQ-12 results|Comparison of pre and postoperative PİSQ-12 values of the patients undergone Sacrospinous Fixation operation and V-notes Lateral Suspension Operation
47950035|NCT04839146|BIOLOGICAL|ABNCoV2 Vaccine|SARS-CoV-2 vaccine
47950036|NCT02165371|BEHAVIORAL|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
47950037|NCT04634838|DEVICE|MedCu Antibacterial Wound Dressings with Copper Oxide|Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
47950038|NCT05560776|PROCEDURE|Endobronchial ultrasound|Two or three passes per lymph node
47950039|NCT02248415|OTHER|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
47950040|NCT02248415|OTHER|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
47950041|NCT02248415|OTHER|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
47950042|NCT02248415|OTHER|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
47950043|NCT02248415|OTHER|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
47950044|NCT02248415|OTHER|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
47950045|NCT04016233|DRUG|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
47950046|NCT06121180|DRUG|ZIV-Aflibercept|Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer.
47950047|NCT06121180|DRUG|Cemiplimab|"Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells.~Blocking the receptor is expected to help immune cells attack cancer cells."
47950048|NCT03901547|BEHAVIORAL|Communication Skills Training|Education training in the serious illness communication guide (SICG) by Ariadne labs.
47950049|NCT03901547|BEHAVIORAL|Profile feedback|Providing participants their personal documentation rate of SICG in the electronic medical record
47950050|NCT03901547|OTHER|Maslach burnout inventory|Maslach burnout inventory
47950051|NCT03901547|OTHER|Emotion Regulation Skills Question (ERSQ)|This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
48266499|NCT03536351|BEHAVIORAL|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities that target understanding of emotions, intentions, and appropriate social interactions have been planned by a team of drama teachers, occupational therapists, and speech-language pathologists.
48636979|NCT03477591|OTHER|Sham information|Educational information not specific to PSA testing or cancer screening
47950052|NCT03901547|OTHER|Semi-structured interview|Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
48298435|NCT02599766|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
48636980|NCT05359718|OTHER|Questionnaire|Questionnaire
48298436|NCT02599766|OTHER|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
48636981|NCT05612295|BEHAVIORAL|MBPP|"MBPP program consist of three fundamental principles (i.e., attention monitoring, acceptance, sport-specific rationale) and six performance-related core mental attributes including three behavioral and three neurocognitive components.~Each session will start with a brief homework discussion and recap of the preceding session, and instructors will deliver a topic-related brief story or group activity to participants, followed by a theoretical introduction and practice of mindfulness. Finally, at the end of each session, instructors will guide participant to discuss mindfulness applications related to specific sports performances. At the end of the session, participants will be assigned homework to increase the effectiveness of MBPP, and participants will be encouraged to practice daily for at least 10-15 min between the sessions."
47950053|NCT03901547|BEHAVIORAL|Priming|"Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?"
47950054|NCT01254630|BIOLOGICAL|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
47950055|NCT01254630|BIOLOGICAL|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
47950056|NCT03677908|OTHER|ElectroEncephaloGraphy|Density ElectroEncephaloGraphy analysis
47950057|NCT00853034|DIETARY_SUPPLEMENT|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
47950058|NCT00853034|DIETARY_SUPPLEMENT|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
47950059|NCT05797662|DRUG|Propranolol|Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks
47950060|NCT02020577|DRUG|Cetuximab( erbitux®)|once per week
47950061|NCT02020577|DRUG|Afatinib|once per day
47950062|NCT05261282|BEHAVIORAL|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
47950063|NCT00452855|PROCEDURE|Sevoflurane-remifentanil anaesthesia|
47950064|NCT00384254|BEHAVIORAL|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
47950065|NCT00384254|BEHAVIORAL|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
47950066|NCT05467371|BEHAVIORAL|Parenting Action Plan|The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.
47950067|NCT05467371|BEHAVIORAL|Safe Kids Home Safety Checklist|Safe Kids created a home safety checklist to help keep kids safe, room by room.
47950068|NCT00392080|DRUG|CJ-023,423|75 mg BID
47950069|NCT00392080|DRUG|placebo|placebo
47950070|NCT00392080|DRUG|naproxen|naproxen
47950071|NCT03532958|DRUG|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
47950072|NCT03532958|DRUG|Normal saline|Dose volume consistent with weight-based dosing of BNZ-1
47950073|NCT00444652|DRUG|Enoxaparin|injection of enoxaparin a few time
47950074|NCT06557109|OTHER|Popular Music|A funky D mix version of a popular Turkish song
47950075|NCT06681480|DEVICE|figure-of-eight active rTMS coil device|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at low frequency 0,5Hz Device: figure-of-eight active rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil, optic navigation system
47950076|NCT06681480|DEVICE|figure-of-eight sham rTMS coil device|rTMS is administered using the figure-of-eight sham coil, in trains with a total of 15000 pulses during 5 weekdays Device: figure-of-eight sham rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight sham rTMS coil, optic navigation system
47950077|NCT00751166|DRUG|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
47950078|NCT00751166|DRUG|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
47950079|NCT00751166|DRUG|placebo|placebo once daily for 28 days
47950080|NCT00423514|BIOLOGICAL|filgrastim|
47950081|NCT00423514|DRUG|clofarabine|
47950082|NCT00423514|DRUG|melphalan|
47950083|NCT00423514|DRUG|mycophenolate mofetil|
47950084|NCT00423514|DRUG|tacrolimus|
47950085|NCT00423514|DRUG|thiotepa|
48298437|NCT02046915|DRUG|Imnovid (pomalidomide)|
48298438|NCT02046915|DRUG|Dexamethasone|
48105936|NCT01299974|OTHER|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
48636982|NCT05612295|BEHAVIORAL|Self-talk|self-talk sessions include: Session 1 \& 2. The concepts, types, and the importance of self-talk will be introduced; Session 3. Researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific instructional scripts for specific sports performance (e.g., running); Session 4. practice of sport-specific instructional self-talk; Session 5. researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific motivational self-talk scripts for specific sports performances; Session 6. practice of sport-specific motivational self-talk; and Session 7 \& 8. general practice for learned self-talk techniques.
48636983|NCT03000166|BEHAVIORAL|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
48636984|NCT03021005|BEHAVIORAL|HIV Self-testing|
48636985|NCT01637571|DRUG|Dexilant|60mg of Dexilant QD for 12 weeks
48636986|NCT01637571|DRUG|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
48636987|NCT02759263|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
48636988|NCT03012152|PROCEDURE|Standard conservative breast surgery|
48636989|NCT03012152|PROCEDURE|Oncoplastic breast surgery|
48636990|NCT05297019|PROCEDURE|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
48636991|NCT06233461|DRUG|TAK-279|TAK-279 capsules.
48636992|NCT06233461|DRUG|Placebo|TAK-279 placebo-matching capsules.
48636993|NCT01983904|DEVICE|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
48636994|NCT03072342|PROCEDURE|Intensive Periodontal Treatment|
47950086|NCT00423514|PROCEDURE|allogeneic bone marrow transplantation|
48636995|NCT03072342|PROCEDURE|Control Periodontal Treatment|
48636996|NCT05537857|OTHER|High dietary salt|Controlled feeding study that varies in salt content.
48636997|NCT05738291|DRUG|BI 1839100|BI 1839100
48636998|NCT05738291|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
48636999|NCT05738291|DRUG|midazolam|midazolam
48637000|NCT05738291|DRUG|digoxin|digoxin
48637001|NCT05738291|DRUG|rosuvastatin|rosuvastatin
48637002|NCT03379493|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
48637003|NCT06269601|DIAGNOSTIC_TEST|Upper Limb Rotation Test|The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated.
48637004|NCT03101670|DRUG|filgotinib|one filgotinib oral tablet q.d.
48637005|NCT03101670|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
48637006|NCT04129333|OTHER|Hypnosis|"The hypnosis session :~* Creation of the therapist-patient link~* Choice of a theme and the preferred sensory channel by the patient~* Collection of the theme chosen by the patient~* Orientation in the here and now.~* Induction~* Realization of the gesture and hypnosis~* At the end of the procedure, reassociation of the patient in the here and now"
48637007|NCT04129333|OTHER|No hypnosis|No hypnosis
48637008|NCT04032431|BEHAVIORAL|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
48105937|NCT00191035|DRUG|Atomoxetine|
48637009|NCT00485342|DRUG|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
48637010|NCT00485342|DRUG|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
48637011|NCT00007774|DRUG|Haloperidol|
48637012|NCT00007774|DRUG|Olanzapine|
48637013|NCT00047632|DRUG|Interferon gamma-1b|100 mcg, SQ, 3x per week
48637014|NCT05358912|DRUG|Vasopressor Agent|"Patients will receive vasopressor agents according to Surviving Sepsis Campaign Guidelines 2021"
47950087|NCT00423514|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
47950088|NCT00423514|PROCEDURE|peripheral blood stem cell transplantation|
47950089|NCT05707936|DRUG|Normal Saline Flush 20 ml|Normal Saline Flush 20 ml
47950090|NCT05707936|DRUG|Normal Saline Flush 10 ml|Normal Saline Flush 10 ml
47950091|NCT05707936|DRUG|Heparin Flush (1000 USP, 10ml)|Heparin Flush (1000 USP, 10ml)
47950092|NCT04529915|DIAGNOSTIC_TEST|Exosome sampling|"* Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis"
48105938|NCT03140579|OTHER|APRV|Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
48105939|NCT06358066|DRUG|self assembling peptide p11-4 with fluoride|"Self-assembling peptide (P11-4) fluoride plus will be applied according to the manufacturer's instructions by pushing the two cylinders together and will left for 5 min till the tooth surface appears dry to insure its diffusion~The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment"
48105940|NCT06358066|DRUG|5% sodium fluoride varnish|Fluoride varnish will be applied under manufacturer instructions by applying thin layer of varnish with a brush in strokes The remineralizing process of the early enamel carious lesions will be assessed quantitatively using the laser fluorescence DIAGNOdent measuring and assessed qualitatively using ICDAS II scoring system at baseline 1, 3, 6 months post-treatment
48105941|NCT00667745|DRUG|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
48105942|NCT00667745|DRUG|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
48105943|NCT03162887|OTHER|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
48105944|NCT03162887|OTHER|Counseling|Undergo a web-based decision counseling session
48105945|NCT03162887|OTHER|Informational Intervention|"Receive a next steps document"
48105946|NCT01581736|DRUG|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
48105947|NCT01581736|OTHER|Exercise|Single episode of exercise riding a stationary bike.
48105948|NCT04276987|BIOLOGICAL|MSCs-derived exosomes|5 times aerosol inhalation of MSCs-derived exosomes (2.0\*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
48298439|NCT02046915|DRUG|Endoxan (Cyclophosphamide)|
48478332|NCT06611150|DRUG|Nab-paclitaxel|All participants enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²).
48478333|NCT03549455|BEHAVIORAL|Exposure Therapy and Self Distancing|Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 \& 4 will have Exposure therapy with Self-Distancing; Weeks 5 \& 6 will have Exposure therapy only; Weeks 7 \& 8 will have Exposure therapy with Self-Distancing;
48478334|NCT03618329|OTHER|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
48637015|NCT05358912|DRUG|Crystalloid Solutions|"Patients will receive crystalloid solutions according to Surviving Sepsis Campaign Guidelines 2021"
48637016|NCT05358912|PROCEDURE|Invasive Blood Pressure Monitoring|Invasive blood pressure monitoring will be performed through an intra-arterial cannula placed in the radial artery. Philips Intellivue mx 500 monitors will be used for bedside monitoring.
48637017|NCT05358912|PROCEDURE|Intra-Abdominal Pressure Monitoring|"IAP will be measured indirectly by monitoring the pressure in the bladder.~Bladder pressure will be measured through an indwelling Foley catheter every twelve hours. Twenty-five mL of sterile normal saline will be injected in each measurement and readings will be recorded with a pressure transducer."
48637018|NCT05358912|OTHER|Abdominal Perfusion Pressure|APP will be calculated with the following formula: (Mean arterial pressure) - (Intra-abdominal Pressure)
48637019|NCT00005078|DRUG|carboplatin|
47950093|NCT02566668|OTHER|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
48478335|NCT00386815|DRUG|pemetrexed|
48478336|NCT00386815|DRUG|cisplatin|
48637020|NCT00005078|DRUG|paclitaxel|
48478337|NCT04329715|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
48637021|NCT00005078|DRUG|tirapazamine|
48637022|NCT01011231|PROCEDURE|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
48637023|NCT05203237|BIOLOGICAL|VK2735|Administered SC
48637024|NCT05203237|BIOLOGICAL|Placebo|Administered SC
47950094|NCT01072669|DRUG|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily\[if the lower dose is tolerated\] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
47950095|NCT05538871|DIAGNOSTIC_TEST|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
47950096|NCT03071159|DEVICE|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
47950097|NCT00072631|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
47950098|NCT05859256|OTHER|Experimental|The intervention consists of the application of a treatment protocol based on an initial active warm-up consisting of 3 active exercises, walking for 1 minute performing slow and controlled movement of the ankle, raising the heels, 15 repetitions, dorsiflexion of the ankle in the standing position. gentleman, 15 reps. Subsequently, the floss band will be placed, performing again the 3 active warm-up exercises with the band on. After this, the passive manual techniques will be carried out for the remaining time, removing the flossing at the end of the latter, and actively mobilizing again.
47950099|NCT05859256|OTHER|Control|The same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without sliding and without joint mobilization.
47950100|NCT06400251|PROCEDURE|Biopsy|Undergo biopsy
47950101|NCT06400251|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47950102|NCT06400251|PROCEDURE|Computed Tomography|Undergo CT scan
47950103|NCT06400251|DRUG|Ipatasertib|Given PO
47950104|NCT06400251|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47950105|NCT01193842|DRUG|Cyclophosphamide|Given IV
47950106|NCT01193842|DRUG|Doxorubicin Hydrochloride|Given IV
47950107|NCT01193842|DRUG|Etoposide|Given IV
47950108|NCT01193842|OTHER|Laboratory Biomarker Analysis|Correlative studies
47950109|NCT01193842|OTHER|Pharmacological Study|Correlative studies
47950110|NCT01193842|DRUG|Prednisone|Given PO
47950111|NCT01193842|BIOLOGICAL|Rituximab|Given IV
47950112|NCT01193842|DRUG|Vincristine Sulfate|Given IV
47950113|NCT01193842|DRUG|Vorinostat|Given PO
47950114|NCT03041987|OTHER|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
47950115|NCT04212871|OTHER|watch food video 1|A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.
47950116|NCT04212871|OTHER|watch food video 2|A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.
48478338|NCT04329715|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
48478339|NCT02527239|OTHER|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
48478340|NCT05933473|PROCEDURE|Percutaneous coronary intervention|percutaneous intervention to oseal LAD with or without LM stenting
48478341|NCT06615752|DRUG|green tea and quercetin + docetaxel|green tea and quercetin supplements in combination with docetaxel infusion
48478342|NCT06615752|DRUG|Placebo + docetaxel|Placebo will be given along with docetaxel chemotherapy
48478343|NCT03788915|BEHAVIORAL|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
47950117|NCT04212871|OTHER|watch a non-food content video|a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
47950118|NCT02250859|DRUG|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
47950119|NCT02595359|DRUG|Moxifloxacin|Moxifloxacin intracameral
47950120|NCT03844607|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
47950121|NCT03844607|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
47950122|NCT05723601|DRUG|Estradiol vaginal cream|Participants will use vaginal estradiol cream for 3 months
47950123|NCT05723601|DRUG|Estradiol Vaginal Tablet|Participants will use vaginal estradiol tablet for 3 months
48105949|NCT01697319|DRUG|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
48637025|NCT05203237|DRUG|VK2735 Placebo|Administered orally
48637026|NCT05203237|DRUG|VK2735 Drug|Administered orally
48637027|NCT03142334|BIOLOGICAL|Pembrolizumab|IV infusion
47950124|NCT03325088|PROCEDURE|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
47950125|NCT03325088|PROCEDURE|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
47950126|NCT03325088|PROCEDURE|Bronchial alveolar enema|For participants who had signed ancillary research consent
47950127|NCT05657925|DRUG|ondansetron 8 mg|Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
47950128|NCT05657925|DRUG|Matching placebo|Matching placebo will be identical in appearance to the active treatment pill
47950129|NCT01108120|DRUG|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
47950130|NCT01108120|DRUG|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
47950131|NCT02544178|RADIATION|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
47950132|NCT06393868|DRUG|Omeprazole 20 mg Oral Tablet|Omeprazole once daily for 90 days
47950133|NCT06393868|OTHER|Placebo|Placebo once daily for 90 days
47950134|NCT03081975|DEVICE|HD white light or NBI|Use of NBI or HD white light
47950135|NCT02276326|DIETARY_SUPPLEMENT|VSL#3 sachets|4 sachets a day for 4 months
47950136|NCT01008176|BEHAVIORAL|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
48105950|NCT05553613|DRUG|Ticagrelor 90 MG Oral Tablet|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
48105951|NCT05553613|DRUG|Clopidogrel tablet|efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
48105952|NCT00337818|BIOLOGICAL|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
48637028|NCT03142334|DRUG|Placebo|IV infusion
48637029|NCT04958239|DRUG|BI 765179|BI 765179
48637030|NCT04958239|DRUG|Ezabenlimab|Ezabenlimab
47950137|NCT04470271|OTHER|Patients with hepatitis C lost follow up|Patients with chronic HCV who were lost of follow up will be contacted by phone or email. At least 3 phone calls will be made on three different days. In case the patient is not contacted it will be considered lost of follow-up
47950138|NCT05650060|DRUG|Secukinumab|all patients with psoriasis who received secukinumab
47950139|NCT03364569|PROCEDURE|Tranexamic acid|Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
48637031|NCT04958239|DRUG|Pembrolizumab|Pembrolizumab
48637032|NCT05882331|PROCEDURE|Extracorporeal photopheresis|ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
48637033|NCT00292370|DRUG|Open Label (OL) Paroxetine|Open-label Paroxetine
48637034|NCT00292370|DRUG|Placebo|Double-blind placebo taken with OL paroxetine
48637035|NCT00292370|DRUG|Quetiapine|Double-blind quetiapine taken with OL paroxetine
48637036|NCT04747626|DEVICE|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
48637037|NCT04103970|BEHAVIORAL|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
48637038|NCT04089085|BEHAVIORAL|STRONGer Together|STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
47950140|NCT05824091|DRUG|MK-7762 (TBD09)|Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
47950141|NCT05824091|OTHER|Placebo|A subset of participants from each of the 6 dosing cohorts will receive placebo.
47950142|NCT00333177|BEHAVIORAL|Cognitive remediation training (CT)|Cognitive remediation training includes computerized cognitive training plus learning skills group.
48478344|NCT03788915|BEHAVIORAL|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
48478345|NCT05985694|DRUG|AD17002|"The investigational intranasal pharmaceutical product named AD17002 contains a detoxified Escherichia coli heat-labile enterotoxin, LTh(αK).~Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32."
48478346|NCT05985694|DRUG|Placebo|Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.
48637039|NCT02957123|DRUG|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
48637040|NCT03966118|DRUG|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
48637041|NCT03966118|DRUG|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
48637042|NCT03966118|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
48637043|NCT03099863|DRUG|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
48637044|NCT03099863|PROCEDURE|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
47950143|NCT00333177|BEHAVIORAL|Healthy behavior training (HBT)|Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.
47950144|NCT00333177|DRUG|Risperidone, administered orally (Oral Ris)|Oral risperidone at dosage judged optimal by treating psychiatrist
47950145|NCT00333177|DRUG|Risperidone, administered via injection (RLAI)|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
47950146|NCT02511990|BIOLOGICAL|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
47950147|NCT02511990|BIOLOGICAL|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
48478347|NCT04670406|BEHAVIORAL|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
48478348|NCT03529565|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48478349|NCT03529565|OTHER|Laboratory Biomarker Analysis|Correlative studies
48478350|NCT03529565|OTHER|Quality-of-Life Assessment|Ancillary studies
48478351|NCT03529565|OTHER|Questionnaire Administration|Ancillary studies
48478352|NCT01961882|DRUG|OCV-501|
48478353|NCT01961882|DRUG|Placebo|
48478354|NCT04491578|BEHAVIORAL|"ACP programme Have a Say"|Each dyad of participants will receive a 4-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 2 group-based sessions and 2 dyadic discussions. One hour for each session. The group-based sessions are nurse-led, in which dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are led by trained ACP facilitator. Dyads of participants will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
48478355|NCT00478049|DRUG|Gefitinib|250 mg oral tablet
48478356|NCT00478049|DRUG|Docetaxel|intravenous infusion
48478357|NCT01915940|DRUG|Bimatoprost|Bimatoprost ocular insert
48478358|NCT01915940|DRUG|Timolol 0.5%|Timolol 0.5% solution
48478359|NCT01915940|DRUG|Placebo Eye Drops|Placebo topical eye drops
48637045|NCT03099863|DRUG|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
48637046|NCT02226783|DRUG|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
47950148|NCT02511990|BIOLOGICAL|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
48637047|NCT02226783|DRUG|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
48637048|NCT02226783|DRUG|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
48637049|NCT01210599|DRUG|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
48637050|NCT00225758|DRUG|Lapatinib|1500 mg po daily for 26 weeks or longer
48637051|NCT02424786|OTHER|STOPP/START criteria|Evaluation of medication lists
48637052|NCT05196646|DEVICE|Respiratory Acoustic Sensors|Wireless sensor that contains a dual microphone and an inertial measurement unit (IMU) will capture the breathing sound and respiratory effect. Two wireless sensors will be used, with one placed on the suprasternal notch and the other placed on the right upper chest of the infant, in order to determine the sensor placement yielding the best respiratory signal. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller (ISP1807, Insight SIP) and stored on the same device for future analysis.
48637053|NCT05196646|DEVICE|Nasal thermistor|The nasal temperature probe that detects changes in temperature between inhaled and exhaled gases allows for the surrogate measure of airflow. It will be placed in one naris and secured with tape at the upper lip or cheek. The nasal temperature signal will be acquired using the Power Lab analog-digital acquisition system and stored for later analysis.
48637054|NCT05196646|DEVICE|Respiratory Inductive Plethysmography|Two respiratory bands will be placed circumferentially around the infant's chest (at the level of nipple line) and around the abdomen (just above the level of the umbilicus) in order to measure chest and abdominal wall movements, respectively. These movements will be recorded using Respiratory Inductive Plethysmography (Respitrace QDC®, Viasys® Healthcare, USA). The Respitrace® signals will be acquired using the Power Lab data acquisition system and stored for later analysis.
48637055|NCT05196646|DEVICE|Pneumotachometer|The pneumotachometer is a pressure-differential based flow sensor that is used to measure respiratory flow. It will be connected to a standard face mask that is gently applied to cover the infant's mouth and nose. The face mask will be similar to the masks used as part of standard of care in the NICU for infants who require continuous positive pressure, with or without ventilation. The flow measurements will be recorded using the Power Lab data acquisition system and stored for later analysis.
48637056|NCT04409119|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
47950149|NCT00528177|DRUG|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
47950150|NCT03860610|DIAGNOSTIC_TEST|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
47950151|NCT03860610|DIAGNOSTIC_TEST|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
48478360|NCT01915940|DEVICE|Placebo Ocular Insert|Ocular insert without any active drug
48478361|NCT06503549|OTHER|Assessments|Only the current assessments will be made
48478362|NCT03400917|BIOLOGICAL|AV-GBM-1|Investigational treatment with AV-GBM-1
48478363|NCT02512614|OTHER|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
48478364|NCT06214559|DEVICE|Sérum VERRUPRO|To be applied twice a day
48478365|NCT05743634|BIOLOGICAL|YY001|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
48478366|NCT05743634|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
48637057|NCT04409119|DEVICE|LV pacing|LV lead in a CS branch
48637058|NCT04952688|OTHER|OCT- Angiographie|Ophthalmological examinations
48637059|NCT05160285|DRUG|Nivolumab 100 MG in 10 ML Injection|If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
48478367|NCT05743634|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
48478368|NCT02080507|DEVICE|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
48478369|NCT02080507|DEVICE|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
48478370|NCT06295744|RADIATION|Radiation Therapy|WBI with SIB delivered over 5 fractions
48478371|NCT00903552|BIOLOGICAL|Influenza VLP Vaccine|
48478372|NCT00903552|BIOLOGICAL|Placebo|phosphate-buffered saline (PBS)
48637060|NCT01260831|OTHER|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
48637061|NCT01260831|OTHER|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
48637062|NCT05417256|DEVICE|Tappa Endobronchial Blocker|After intubation, the Tappa bronchial blocker will be advanced either through the intubation tube or outside the tube using a fiberoptic broncoscope. Once the position of the blocker is confirmed, the cuff of the blocker will be inflated with 1-3 mL of air. Since Tappa blocker has an autoinflation system, the anaesthetist can both inflate the cuff with one hand and operate the fiberoptic broncoscope at the same time.
48105953|NCT03386929|DRUG|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
47950152|NCT03860610|DIAGNOSTIC_TEST|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
47950153|NCT03860610|DIAGNOSTIC_TEST|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
48105954|NCT03386929|DRUG|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
48105955|NCT03386929|DRUG|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
48105956|NCT01212757|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
48478373|NCT05261789|OTHER|Turkish Get Up exercise|"Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes."
48478374|NCT05261789|OTHER|Core Stability exercise|"After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied"
47950154|NCT03860610|DIAGNOSTIC_TEST|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
47950155|NCT03860610|DIAGNOSTIC_TEST|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
47950156|NCT03860610|DIAGNOSTIC_TEST|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
47950157|NCT00067574|BEHAVIORAL|Structured treatment interruption|
47950158|NCT02084212|OTHER|Microperimetry|
47950159|NCT05929976|OTHER|No intervention|No intervention
47950160|NCT04664959|DRUG|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
48105957|NCT01212757|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
48105958|NCT01212757|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
48105959|NCT01212757|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
48105960|NCT02310295|DEVICE|Laser|focal macular laser therapy
48105961|NCT02310295|DRUG|Bevacizumab|Intravitreal injection of Bevacizumab
48105962|NCT02310295|DRUG|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
48105963|NCT02918071|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
48105964|NCT03707678|DRUG|GSK2245035|GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
48478375|NCT05261789|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
48478376|NCT05951348|PROCEDURE|Delayed cord clamping for 30 seconds|waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
48478377|NCT06043622|OTHER|Optical coherence tomography angiography|Optical coherence tomography angiography
48478378|NCT06043622|OTHER|ophthalmological exam|ophthalmological exam
48105965|NCT03707678|DRUG|Placebo|Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
48478379|NCT06446388|DRUG|QLS31905|Administered as an intravenous infusion.
48478380|NCT06446388|DRUG|Oxaliplatin|130 mg/m2, intravenous infusion, D1, up to 8 cycles.
48478381|NCT06446388|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D14
48478382|NCT06446388|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
48637063|NCT05417256|DEVICE|Arndt Endobronchial Blocker|After intubation, the endobronchial blocker will be passed through a multiport airway adapter that is placed at the proximal end of the tracheal tube.The fiberoptic broncoscope will be passed through the port and then through the guidewire loop at the end of the blocker. The bronchial blocker and the broncoscope will be advanced as a single unit into the target part of a right or left lung. The broncoscope will be withdrawn into the trachea and the blocker cuff will be inflated and the position of the blocker will be confirmed using the fiberoptic broncoscope. The wire loop will be removed after correct placement of the blocker. Once the guide wire is removed, the blocker can't be replaced.
48637064|NCT05678959|DRUG|Ligelizumab 120 mg|1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo
48637065|NCT05678959|DRUG|Ligelizumab 240 mg|2 injections of 1.0 mL ligelizumab
48637066|NCT01867554|GENETIC|gene analysis|gene analysis
48478383|NCT06446388|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
48478384|NCT06446388|DRUG|QL1706|5 mg/kg, intravenous infusion,D1
48637067|NCT06290024|DEVICE|A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function|Using the use of pain visual analog scale (VAS), digital pain grading method (NRS), neuropathic pain assessment scale (DN4), sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), social support assessment scale (SSQ), Montreal cognitive assessment scale (MoCA), Barrett impulse scale (BIS), anxiety and depression score (GAD-7, PHQ-9), emotional tasks, cognitive function (N-back, time perception, delay-discount), electroencephalogram (EEG), near-infrared brain function imaging (fNIRS) and other indicators to study the dynamic changes of various factors in the process of acute pain.
47950161|NCT04664959|DRUG|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
48478385|NCT06446388|DRUG|Chemotherapy drug|Standard chemotherapy recommended by guidelines.
47950162|NCT03285984|OTHER|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
47950163|NCT03285984|OTHER|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
47950164|NCT03285984|OTHER|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
47950165|NCT03285984|OTHER|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
47950166|NCT02538328|DEVICE|Harmonic scapel|different surgical devices used in the obesity surgery
47950167|NCT02538328|DEVICE|Ligasure|Bipolar vessel sealing system used in obesity surgery
47950168|NCT04379544|OTHER|Observation only|There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
47950169|NCT06557525|BEHAVIORAL|Neurofeedback|Subjects will receive neurofeedback training by visual stimulation using a software program on a PC or tablet (monitor) with reference to EEG data acquired with a portable electroencephalograph (EEG) to provide feedback on the state of the DLPFC in the brain. The DLPFC status of the subject's brain is then fed back to the subject to continue stimulating the subject's reward system. Before and after these neurofeedback training sessions, fMRI imaging will be performed to confirm changes in brain activity.
47950170|NCT00316771|DRUG|P38 Inhibitor (4) 150mg|150mg po qd
47950171|NCT00316771|DRUG|P38 Inhibitor (4) 25mg|25mg po bid
48637068|NCT03992430|DRUG|Eteplirsen|Solution for intravenous (IV) infusion.
48637069|NCT01927861|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
48637070|NCT03199365|BEHAVIORAL|Behavioral Dietary Intervention|Undergo TSSC intervention sessions
48637071|NCT03199365|BEHAVIORAL|Behavioral Intervention|Undergo TSSC intervention sessions
47950172|NCT00316771|DRUG|P38 Inhibitor (4) 300mg|300mg po qd
47950173|NCT00316771|DRUG|P38 Inhibitor (4) 50mg|50mg po qd
47950174|NCT00316771|DRUG|P38 Inhibitor (4) 75mg|75mg po bid
47950175|NCT00316771|DRUG|Placebo|po bid
47950176|NCT04965246|BEHAVIORAL|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
47950177|NCT04965246|OTHER|Usual Care|Participants in the usual care group will receive no intervention
48105966|NCT03707678|DRUG|FP-DPI|FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
48478386|NCT05487560|DRUG|Esomezol Cap|Esomezol Cap, Once daily administered per the locally approved product information
48478387|NCT04013698|OTHER|PEEP level 5 cmH2O|PEEP level set for 45 minutes
48478388|NCT04013698|OTHER|PEEP level 15 cmH2O|PEEP level set for 45 minutes
48478389|NCT00891072|DRUG|R-(-)-gossypol acetic acid|Given orally
48478390|NCT00891072|DRUG|paclitaxel|Given IV
48478391|NCT00891072|DRUG|carboplatin|Given IV
48478392|NCT00891072|OTHER|pharmacological study|Correlative studies
48478393|NCT06416917|DEVICE|bubble inclinometer|to measure range of motion
48637072|NCT04729387|DRUG|Alpelisib|Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
48637073|NCT04729387|DRUG|Olaparib|Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
48637074|NCT04729387|DRUG|Paclitaxel|Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
47950178|NCT05533723|PROCEDURE|Endoscopic epidural neuroplasty|"EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding."
47950179|NCT05533723|PROCEDURE|Percutaneous epidural neuroplasty (PEN)|PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
47950180|NCT03242889|DRUG|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
47950181|NCT01642407|DRUG|Sildenafil|Body weight \> 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
47950182|NCT05027672|DRUG|Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
47950183|NCT00001122|DRUG|Nelfinavir mesylate|
47950184|NCT00001122|DRUG|Efavirenz|
47950185|NCT00001122|DRUG|Stavudine|
47950186|NCT00001122|DRUG|Didanosine|
47950187|NCT01416844|BIOLOGICAL|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
47950188|NCT03502096|BEHAVIORAL|To-Go container|Subjects were provided a to-go container in which leftover foods would be packaged
47950189|NCT03502096|OTHER|Control|Subjects were not provided a to-go container with the meal
47950190|NCT06312956|DEVICE|Continuous Positive Airway Pressure Ventilotherapy|Breathing support device during sleeping
47950191|NCT06681636|BIOLOGICAL|Human papillomavirus 9-valent vaccine, Recombinant|HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58
47950192|NCT03042325|DRUG|Alogliptin|Alogliptin tablets
47950193|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized theta-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
47950194|NCT04141046|DEVICE|XCSITE100 Stimulator - Individualized alpha-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
47950195|NCT04141046|DEVICE|XCSITE100 Stimulator - Active Sham|20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
47950196|NCT03621774|BEHAVIORAL|Mobile-assisted CBT-informed Skills Training|mCBTn combines the CBT-informed components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group skills training and mobile smartphone interventions from our prior clinical trials research.
47950197|NCT03621774|BEHAVIORAL|Supportive Contact|The SC intervention will provide the same amount of group and mobile device contact as the mCBTn condition. Participants will be carrying a phone but will not have access to the CBT-informed app. Group contact sessions will be semi-structured and consist of trouble-shooting device use and check-in about symptoms and potential crisis management, followed by a flexible discussion involving psychoeducation, instructions for accessing community crisis lines and related community resources, empathy, and non-directive reinforcement of health, coping, and symptom management behaviors that grow out of group discussions, with only minimal group leader guidance.
47950198|NCT04697056|DRUG|Imsidolimab|Humanized Monoclonal Antibody
47950199|NCT04697056|BIOLOGICAL|placebo|placebo
47950200|NCT06303921|DRUG|11C-M503 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
47950201|NCT06303921|DIAGNOSTIC_TEST|Brain MRI|MRI scan of brain.
48478394|NCT04629599|BEHAVIORAL|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
48637075|NCT04729387|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
48637076|NCT00026403|DRUG|cisplatin|
47950202|NCT06303921|DIAGNOSTIC_TEST|Amyloid PET|PET scan with Florbetaben F18 or 11C-PiB
47950203|NCT06303921|BEHAVIORAL|Neurological assessments|Neurological assessments, including a video interview.
48105967|NCT03707678|DRUG|Albuterol/Salbutamol|Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
47950204|NCT04759144|DEVICE|CamAPS FX using faster insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
48478395|NCT04629599|BEHAVIORAL|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
48478396|NCT05108506|BEHAVIORAL|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
47950205|NCT04759144|DEVICE|CamAPS FX using standard insulin aspart|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
47950206|NCT00202059|DRUG|Zoledronic acid|
47950207|NCT00202059|BEHAVIORAL|Physical activity intervention|
47950208|NCT06556719|BEHAVIORAL|Hoosier Sport Re-Social|Hoosier Sport Re-Social is a 6-week school-based intervention designed to reduce cardiovascular disease risk in rural children. It includes twice-weekly physical activity sessions during PE classes and weekly social media literacy training in health classes, promoting healthier physical and digital behaviors.
47950209|NCT04268589|OTHER|virtual reality game|routine
47950210|NCT05735197|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.
47950211|NCT05735197|DRUG|Placebo|Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
47950212|NCT00828854|DRUG|Entinostat|Entinostat 5 mg PO every week
47950213|NCT00828854|DRUG|Aromatase Inhibitor (AI) Therapy|AI therapy at labeled dose and schedule as prescribed in clinical practice. AI therapies include: Arimidex® (anastrozole) 1 mg/day by mouth (PO), Fermara® (letrozole) 2.5 mg/day PO , Aromasin® (exemestane) 25 mg/day PO.
47950214|NCT06428825|DRUG|BAY3283142|oral administration
47950215|NCT06428825|DRUG|Placebo to BAY3283142|oral administration
47950216|NCT04634799|DRUG|TM5614|TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
47950217|NCT04634799|OTHER|Placebo|Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
47950218|NCT03049722|DEVICE|Pacemaker|
47950219|NCT02258425|BEHAVIORAL|FEM-CARE|
47950220|NCT02258425|BEHAVIORAL|Health Promotion|
47950221|NCT03985111|DEVICE|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
47950222|NCT00804622|DRUG|telbivudine|daily oral administration,600mg,over 12 weeks
47950223|NCT00804622|DRUG|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
47950224|NCT00804622|DRUG|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
47950225|NCT00261079|DRUG|Fexofenadine|
47950226|NCT04102943|DRUG|tacrolimus tablet|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
47950227|NCT04102943|DRUG|tacrolimus capsules|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
47950228|NCT05215886|BEHAVIORAL|Surgery|Study subjects scheduled for or have already completed weight loss surgery and have already completed psychological screening as part of their pre-surgery work up
47950229|NCT02850354|OTHER|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
47950230|NCT02004600|PROCEDURE|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
47950231|NCT03090438|PROCEDURE|Varicocele embolization|Ultrasound guided right internal jugular vein access with placement of a vascular sheath. Fluoroscopically guided selective catheterization of the left and right (if bilateral) spermatic veins to the level of the inguinal ligament. Occlusion of the spermatic vein(s) by embolization coils and a sclerosing agent (sodium tetradecyl sulphate 3%).
47950232|NCT05530785|COMBINATION_PRODUCT|radiotherapy combined with sintilimab and bevacizumab biosimilar|After signing informed consent, patients received sintilimab 200 mg intravenously on the first day of each cycle, Q3W; Bevacizumab biosimilar 7.5mg/kg was administered intravenously on the first day of each cycle, Q3W; Concurrent radiotherapy (single dose 3-8Gy, times 3-10, total dose 20-50Gy; The duration of radiotherapy was completed between the first administration of sintilimab and the second administration of bevacizumab, but it should be noted that the interval between before and after the administration of sintilimab and bevacizumab was at least 3 days.
47950233|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
47950234|NCT04794634|DIAGNOSTIC_TEST|Optical coherence tomograpohy angiography (OCTA)|to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
48478397|NCT05108506|BEHAVIORAL|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
48105968|NCT03707678|OTHER|eDairy|Subjects will record all the alerts indicative of worsening of asthma in eDairy.
48105969|NCT03707678|OTHER|ACQ-6|ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
48105970|NCT01981330|BIOLOGICAL|aMSC|aMSC injected into the vocal fold of the patient
48105971|NCT01981330|BIOLOGICAL|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
48105972|NCT03573258|DIETARY_SUPPLEMENT|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
48105973|NCT01186848|DEVICE|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
48105974|NCT01186848|DEVICE|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
48105975|NCT04811079|OTHER|419 nm Spectacle Filter|TEST
48105976|NCT04811079|OTHER|437 nm Spectacle Filter|TEST
48105977|NCT04811079|OTHER|456 nm Spectacle Filter|TEST
48105978|NCT04811079|OTHER|476 nm Spectacle Filter|TEST
48105979|NCT04811079|OTHER|373 nm Spectacle Filter|CONTROL
48105980|NCT05714735|RADIATION|Cerebral Venography|Cerebral Venography Observation by DSA examinations
48105981|NCT06165172|DEVICE|MyoRegulator®|Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
48105982|NCT04848649|OTHER|Study arm|Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
48105983|NCT02712411|DRUG|HCP1303|
48105984|NCT02712411|DRUG|HGP1201|
48105985|NCT02712411|DRUG|HIP1402|
48478398|NCT01032460|DEVICE|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
48478399|NCT01032460|DEVICE|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
48105986|NCT05813899|DIETARY_SUPPLEMENT|PS23 heat-treated|PS23 heat-treated, 2 caps daily use
48105987|NCT00639366|BIOLOGICAL|trastuzumab|
48105988|NCT00639366|DRUG|chemotherapy|
48105989|NCT00639366|RADIATION|radiation therapy|
48105990|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Sport|Vitamin -supplemented chewing gum
48105991|NCT03230396|DIETARY_SUPPLEMENT|Vitamingum Immunity|Vitamin -supplemented chewing gum
48105992|NCT03230396|DIETARY_SUPPLEMENT|Placebo|Control chewing gum. No vitamin content.
48105993|NCT02704819|OTHER|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~1. Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~2. Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
48105994|NCT02704819|OTHER|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
48478400|NCT01032460|DEVICE|intubate with the Airtraq device|intubate with the Airtraq device
48478401|NCT02244749|OTHER|skin specimen|skin specimen
48478402|NCT05854706|DEVICE|Theta Burst Stimulation|Theta Burst Stimulation
48478403|NCT06326034|DRUG|Dapagliflozin|Dapagliflozin 5 mg orally given once daily for four months.
48637077|NCT00026403|DRUG|gemcitabine hydrochloride|
48105995|NCT02704819|OTHER|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~1. Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~2. Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
48105996|NCT02704819|OTHER|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
48105997|NCT02704819|OTHER|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
48478404|NCT05965791|DIAGNOSTIC_TEST|Phalen's wrist flexion test|The Phalen's test will be performed at different wrist flexion angles from 0 to 90 degrees.
48478405|NCT04992793|COMBINATION_PRODUCT|Congenital heart surgery|Paediatric congenital heart surgery
48637078|NCT00026403|RADIATION|radiation therapy|
48478406|NCT04005963|DIAGNOSTIC_TEST|13N-NH3 PET cardiac blood flow perfusion rest and load imaging|"Immediately after the bedside injection of 13N-NH3 370 MBq, dynamic 2D collection of heart images 10 min, scanning 1 bed; , a total of 6 min), 3min bedside injection 13N?NH3 370-540 MBq immediately after the dynamic 2D collection of heart image 10 min. Both rest and load imaging are corrected for CT attenuation.~Image reconstruction is carried out by the method of maximum expectation of an ordered subset, the dynamic image is divided into the early phase of the first 2 min and the late phase of the last 8 min, the captured image is replayed (VIP replay) of the volume image protocol and the gated data is reconstructed."
48478407|NCT00274885|DRUG|oxaliplatin|
48478408|NCT00274885|PROCEDURE|management of therapy complications|
48478409|NCT01677013|OTHER|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
48478410|NCT05011006|DIAGNOSTIC_TEST|NT3 blood draw|blood draw
48478411|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, low dose|infusion
48478412|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, high dose|infusion
47950235|NCT05373173|BEHAVIORAL|Tele-assessment + In-person assessment|All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
47950236|NCT04355507|DIAGNOSTIC_TEST|Chest computed tomography (CT)|Chest computed tomography (CT) examination
47950237|NCT04355507|DIAGNOSTIC_TEST|Reverse-transcription polymerase chain reaction (RT-PCR)|Identification of viral RNA by reverse-transcription polymerase chain reaction
47950238|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
47950239|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
47950240|NCT03971123|DRUG|Placebo|Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
47950241|NCT03971123|DRUG|Tricaprilin|Tricaprilin formulated as AC-1202 60g of AC-1202 (20g caprlic triglyceride) mixed in 240mL dosing liquid at Hour 0 Day 1
47950242|NCT01033851|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course
47950243|NCT01033851|BEHAVIORAL|Stress Management Education|8 week course
47950244|NCT00447005|DRUG|Axitinib (AG-013736)|AG-013736 5mg twice daily \[BID\]
47950245|NCT06434298|BEHAVIORAL|Choose to Move|As described under study arm description
47950246|NCT00540319|BEHAVIORAL|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
47950247|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique|"Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
47950248|NCT03901651|DIAGNOSTIC_TEST|Colonoscopy with standard colonoscope and forward withdrawal technique|"A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location."
48478413|NCT05445076|OTHER|placebo|infusion
47950249|NCT03845751|DRUG|HIFU hemi-ablation combined with ADT.|Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
47950250|NCT00661973|DRUG|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
47950251|NCT02907268|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
47950252|NCT02907268|DRUG|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
47950253|NCT05239260|DIAGNOSTIC_TEST|CMR|CMR
47950254|NCT06681532|PROCEDURE|Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars|The bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with native collagen membrane.
47950255|NCT06681532|PROCEDURE|Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars|the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with bovine pericardium membrane.
47950256|NCT01090284|DEVICE|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
47950257|NCT01499758|DRUG|Atorvastatin|80 Mg tablets
48105998|NCT00698191|BIOLOGICAL|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
48105999|NCT06630338|OTHER|Non-Interventional Study|Non-interventional study
48106000|NCT06152484|OTHER|Pentacam, Corvis ST and CASIA2|morphological and biomechanical parameters of corneal were obtain by CASIA2, Pentacam and Corvis ST
48478414|NCT02025088|PROCEDURE|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
48478415|NCT02025088|PROCEDURE|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
48478416|NCT00739973|DRUG|Placebo|
48637079|NCT04009135|BEHAVIORAL|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
48637080|NCT04009135|BEHAVIORAL|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
48637081|NCT04009135|OTHER|Attention Control (AC)|1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
48637082|NCT03357445|OTHER|Avantage Reload cup|Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
47950258|NCT06681207|COMBINATION_PRODUCT|anodal transcranial direct current stimulation (a-tDCS)|Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Stroke participants in the first two groups will receive five sessions of the assigned brain stimulation combined with visuomotor stepping training over five consecutive days. Healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.
47950259|NCT06679946|DRUG|Vutrisiran|Vutrisiran administered SC q3M
47950260|NCT05537896|DRUG|Eravacycline|"Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)"
47950261|NCT02717273|DRUG|standard|peri-operative antibiotic regimen only
47950262|NCT02717273|DRUG|extended|extended three-day course of antibiotics
47950263|NCT02717273|OTHER|liver transplant|orthotopic liver transplantation
47950264|NCT03180697|DIAGNOSTIC_TEST|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
47950265|NCT00651391|DRUG|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
47950266|NCT00651391|DRUG|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
47950267|NCT00651391|DRUG|Placebo|oral placebo once daily in the evening for 12 weeks
47950268|NCT00885053|DIETARY_SUPPLEMENT|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
47950269|NCT00885053|DIETARY_SUPPLEMENT|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
47950270|NCT06393543|OTHER|No intervention, only registration|No intervention, only registration
48106001|NCT00909363|DRUG|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
48478417|NCT00739973|DRUG|Aliskiren 150 mg tablet|
48478418|NCT00739973|DRUG|Aliskiren 300 mg tablet|
48478419|NCT00739973|DRUG|Amlodipine 5 mg capsule|
48478420|NCT00739973|DRUG|Amlodipine 10 mg capsule|
48478421|NCT00739973|DRUG|Aliskiren/amlodipine 150/5 mg tablet|
48478422|NCT00739973|DRUG|Aliskiren/amlodipine 150/10 mg tablet|
48478423|NCT00739973|DRUG|Aliskiren/amlodipine 300/5 mg tablet|
48478424|NCT00739973|DRUG|Aliskiren/amlodipine 300/10 mg tablet|
48478425|NCT05016934|BIOLOGICAL|A vaccine composed of a recombinant S1 antigen|Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
47950271|NCT00493532|DRUG|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
47950272|NCT00754988|DRUG|Metformin|As prescribed
47950273|NCT00754988|DRUG|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
47950274|NCT00754988|DRUG|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
47950275|NCT00754988|DRUG|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
47950276|NCT00754988|DRUG|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
47950277|NCT00805701|DRUG|avodart|0.5 avodart once daily for 13 weeks
47950278|NCT00805701|DRUG|Placebo|placebo
47950279|NCT00136123|PROCEDURE|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
47950280|NCT02976792|PROCEDURE|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
48106002|NCT00909363|DIAGNOSTIC_TEST|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
48106003|NCT00909363|DIAGNOSTIC_TEST|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
48106004|NCT03505099|BIOLOGICAL|onasemnogene abeparvovec-xioi|A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
48106005|NCT06555523|OTHER|Ultrasound guided injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The linear probe (PLT-704SBT, 7.5 MHz) of the ultrasound device will be kept parallel to the trapezoidal fibers on the marked trigger point and the dental-tipped needle will be directed to the targeted point in plane with real-time imaging
48106006|NCT06555523|OTHER|Blinded injection|The skin will be cleaned with a suitable antiseptic solution and a sterile, 25 G, 1.5 inch dental-tipped needle will be used. Patients will be injected with 5 ml 2% lidocaine + 5 ml 0.9% NaCl. The needle will be directed to the most sensitive point and advanced until it will be reached the trigger point.
48106007|NCT01192542|DEVICE|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
48106008|NCT01192542|DEVICE|enfilcon A lens|Marketed silicone hydrogel contact lens
48106009|NCT04296513|DIAGNOSTIC_TEST|High-Definition white light endoscopy.|evaluation of the gastric mucosa with high-definition white light endoscopy (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by
48106010|NCT04296513|DIAGNOSTIC_TEST|High-definition magnification with digital chromoendoscopy.|Subject will be evaluated by upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves the use of a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode 1 and mode 2 without optical magnification, to obtain an overview of the gastric body and identify any gross changes in the mucosa, then optical magnification will be implemented.
48106011|NCT01549730|PROCEDURE|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
48106012|NCT04629118|DEVICE|Selution SLR™ 018 Drug Eluting Balloon|Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
48106013|NCT04280913|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19.
48106014|NCT01623349|DRUG|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
48106015|NCT01623349|DRUG|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
48106016|NCT04076202|DEVICE|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
48637083|NCT06566365|OTHER|Subcostal Transversus Abdominis Plane Block|After ensuring airway safety under general anesthesia, a bilateral Transversus Abdominis Plane Block using 20 cc of 0.25% bupivacaine with a subcostal approach under ultrasound guidance will be administered
48106017|NCT02736799|DEVICE|Sham vibrating capsule|Sham device without vibration
48106018|NCT02736799|DEVICE|Vibrant Capsule (1 vibration)|1 vibration/min
48106019|NCT02736799|DEVICE|Vibrant Capsule (3 vibration)|3 vibration/min
48106020|NCT02736799|DEVICE|Vibrant Capsule (5 vibration)|5 vibration/min
48106021|NCT04933136|DEVICE|Terry2 Band|Hemostasis protocol following radial or cubital approach catheterization using the dual artery hemostasis device Terry2Band.
48106022|NCT00530842|DRUG|Tiotropium plus Salmeterol|
48637084|NCT00107289|DRUG|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year."
48637085|NCT06247215|BEHAVIORAL|Culturally tailored resilience-building intervention|A booklist teaching resilience skills for advance care planning discussions
48637086|NCT02618733|DRUG|Ticagrelor|90mg, twice a day
48637087|NCT02618733|DRUG|Clopidogrel|75mg, once a day
48637088|NCT05529173|DRUG|Povidone-Iodine 10%|Nasal swab stick application of Povidone-Iodine 10% prior to surgery
48106023|NCT00530842|DRUG|Fluticasone/Salmeterol|
48106024|NCT04107129|PROCEDURE|Endometrial Biopsy|An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers
48106025|NCT04107129|OTHER|Euploid embryo transfer|Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
48106026|NCT04107129|DIAGNOSTIC_TEST|Blood sample|Estradiol and Progesterone levels in the blood will be checked
48637089|NCT05529173|DRUG|0.9% NaCl Solution|Nasal swab stick application of 0.9% NaCl Solution prior to surgery
48637090|NCT06384703|DIAGNOSTIC_TEST|Taking blood for kit study|Taking blood for kit study (Elisa kit)
48106027|NCT02747732|DRUG|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
48106028|NCT04139538|PROCEDURE|orthodontic treatment|Malocclusion will be treated with orthodontic appliances (fixed or removable)
48106029|NCT02931656|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
48478426|NCT06617637|OTHER|Aerobic Based Virtual Reality Exercise Training|"With Aerobic Based Virtual Reality Exercise Training, participants will perform aerobic exercise training with the Xbox Kinect 360 game Your Shape Fitness Evolved 2012. Your Shape Fitness Evolved 2012 is a game that requires basic coordination and is designed to improve the fitness levels of individuals. The game is used as an entertaining aerobic training tool that includes many aerobic activities such as boxing, yoga, dancing, etc. with adjustable difficulty levels."
47950281|NCT01368978|DEVICE|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
47950282|NCT04143893|DEVICE|Mechanical circulatory support|Patients with cardiogenic shock who underwent MCS
47950283|NCT04143893|DRUG|Optimal medical treatment|Patients with cardiogenic shock who received optimal medical treatment including vasopressor
47950284|NCT05427734|DEVICE|Jaspr2.0|Participants assigned to this condition will receive access to Jaspr2.0 and its companion mobile app, Jaspr-at-Home, for 12 weeks.
47950285|NCT05427734|DEVICE|Active-Control app + electronic wellness resources brochure|Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
47950286|NCT06392802|DEVICE|Rehabilitation treatment using Muvity|The users have the support of the telerehabilitation system Muvity
47950287|NCT05841836|DEVICE|the Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
47950288|NCT05841836|DEVICE|Perclose ProGlide Suture-Mediated Closure System|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
47950289|NCT00590889|DEVICE|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
47950290|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
47950291|NCT03873610|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
47950292|NCT00286507|PROCEDURE|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
47950293|NCT00331422|DRUG|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
47950294|NCT00331422|DRUG|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
47950295|NCT00331422|PROCEDURE|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
47950296|NCT04094623|OTHER|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
47950297|NCT04094623|OTHER|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
47950298|NCT00095992|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
47950299|NCT04406220|OTHER|Small clog size|Participants will be randomized to run in small clogs
47950300|NCT04406220|OTHER|Large clog size|Participants will be randomized to run in large clogs
47950301|NCT05737849|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
47950302|NCT03299270|OTHER|Questionnaires|Quality of Life and Functional recovery questionnaires
47950303|NCT02128906|DRUG|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
47950304|NCT02128906|RADIATION|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
47950305|NCT02128906|DRUG|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
47950306|NCT02128906|DRUG|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
47950307|NCT00721123|DRUG|Tocilizumab|Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
47950308|NCT01543971|DRUG|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
47950309|NCT01543971|DRUG|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
47950310|NCT01100346|DRUG|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
47950311|NCT05667142|DRUG|XEN1101|XEN1101 capsules
47950312|NCT05667142|DRUG|Placebo|Placebo capsules
47950313|NCT05667142|DRUG|XEN1101|XEN1101 capsules
47950314|NCT04540276|DRUG|Inspiratory oxygen fraction|Median inspiratory oxygen fraction during general anesthesia
47950315|NCT05938530|DEVICE|Sirolimus drug-coated balloon|The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.
48106030|NCT01604447|PROCEDURE|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
48106031|NCT01604447|PROCEDURE|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
48106032|NCT04208243|BEHAVIORAL|Creative Arts Therapy|"The intervention will consist of approximately weekly CAT in the infusion center during cancer therapy. The interventionist is a Master's prepared, licensed dance/movement therapist who is experienced in music and art therapies as well. The CAT includes dance/movement such as playing with a parachute, simple yoga breathing and postures, and work with physioballs. The music includes singing, listening to music, and playing instruments. The art consists of drawing, finger painting, working with clay. The CAT may occur in individual sessions in private infusion rooms, or in groups in the middle of the infusion center. The CAT is not only a distraction, but also a therapeutic process addressing the stressors of cancer and its treatment. The dose of CAT will be recorded (number and type of sessions) and will be factored into the analysis."
48106033|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
48106034|NCT01316978|DRUG|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
48106035|NCT01316978|DRUG|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
48106036|NCT02662530|DRUG|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
48106037|NCT06435260|DRUG|Camrelizumab+chemotherapy|"Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles."
48106038|NCT06435260|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy: pGTV:40Gy/5F, PTV≥25Gy/5F.
48106039|NCT02204618|DEVICE|cochlear implantation|
48106040|NCT02204618|OTHER|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
48106041|NCT00762099|DRUG|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
48106042|NCT00762099|DRUG|Placebo|Placebo/sugar tabs will look identical to active drug.
48106043|NCT00174434|DRUG|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
48106044|NCT00174434|DRUG|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
48637091|NCT05266950|BIOLOGICAL|CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)|Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
48106045|NCT01912703|OTHER|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
48106046|NCT04776993|DRUG|Methimazole|Methimazole for 72 weeks
48106047|NCT04776993|PROCEDURE|Radioiodine or thyroidectomy|Treatment with radioiodine or with thyroidectomy
48106048|NCT02116543|DRUG|TD-6450|
48106049|NCT02116543|DRUG|Placebo|
48106050|NCT02621593|DEVICE|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
48106051|NCT05237258|BEHAVIORAL|Specialty Palliative Care|Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
48106052|NCT05237258|BEHAVIORAL|Primary Palliative Care|Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
48106053|NCT01586780|DIETARY_SUPPLEMENT|Protein drink|Test drink providing 9g protein
48106054|NCT01586780|DIETARY_SUPPLEMENT|Reference meal|Control meal
48106055|NCT06553248|DRUG|GZR4|Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
48106056|NCT06553248|DRUG|Insulin Degludec|Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
48106057|NCT00497562|DRUG|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
48106058|NCT00497562|DRUG|amitriptyline, fluoxetine and tramadol alone (control group)|
48106059|NCT05725889|DEVICE|recation time test|visual-finger tapping and auditory reaction time tests
48106060|NCT04788433|DIAGNOSTIC_TEST|glycomic analysis|Analysis of glycans on plasma samples
48106061|NCT04788433|OTHER|Phone interview|patients are followed up by phone up to 1 year
48106062|NCT00413179|DRUG|Metformin|
48106063|NCT00413179|DRUG|Clomiphene citrate|
48106064|NCT00413179|DRUG|Placebo|
48106065|NCT06359054|DIAGNOSTIC_TEST|18F FDG PET/CT|"18F-FDG PET/CT Imaging: Preparation: Participants will be instructed to fast for at least 6 hours before the procedure to ensure low insulin levels and high FDG uptake by cancer cells.~Radiopharmaceutical Administration: Each participant will receive an intravenous injection of 18F-FDG, dosed at approximately 5.2 MBq/kg (0.14 mCi/kg) of body weight.~Imaging Protocol: After the injection, participants will rest in a quiet and dimly lit room for approximately 60 minutes to allow for optimal distribution and uptake of 18F-FDG by the tissues. Subsequently, they will be positioned on the PET/CT scanner bed, and imaging will be performed from the vertex to the proximal thighs. The scan will include a low-dose CT for attenuation correction followed by PET imaging, with the acquisition time adjusted based on the specific protocol (typically 2-3 minutes per bed position)."
48106066|NCT06359054|DIAGNOSTIC_TEST|68Ga DOTATATE PET/CT|"68Ga-DOTATATE PET/CT Imaging: Preparation: No specific fasting is required for 68Ga-DOTATATE PET/CT. However, participants may be advised to hydrate well before the procedure.~Radiopharmaceutical Administration: Participants will receive an intravenous injection of 68Ga-DOTATATE, dosed at approximately 2.2 MBq/kg (0.06 mCi/kg) of body weight.~Imaging Protocol: Similar to the 18F-FDG protocol, after receiving 68Ga-DOTATATE, participants will wait for about 60 minutes to allow for sufficient uptake of the tracer. They will then undergo PET/CT scanning in a supine position, covering the same body regions as the FDG scan. A low-dose CT scan will be conducted first for attenuation correction, followed by the PET scan, with acquisition parameters tailored to the optimal detection of somatostatin receptor expression."
48106067|NCT04851561|DIAGNOSTIC_TEST|Cardiopulmonary stress test (CPET)|Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
48106068|NCT02806518|PROCEDURE|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
48106069|NCT03165149|DRUG|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
48106070|NCT03165149|DRUG|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
48478427|NCT06617637|OTHER|Traditional Aerobic Exercise Training|Using a treadmill, participants will be put through an exercise training consisting of a 10-minute warm-up at 0 degree incline, a 20-30-minute (by increasing the walking time by 5 minutes at the end of the first four weeks and the beginning of the last four weeks) walking at 40-80% of the heart rate reserve (moderate-vigorous intensity) and a 10-minute cool-down period. Treadmill walking levels will be changed if necessary to ensure the targeted exercise intensity.
48106071|NCT03165149|DRUG|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
48106072|NCT02970708|DEVICE|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
48106073|NCT02970708|DEVICE|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
48478428|NCT00346164|DRUG|doxorubicin hydrochloride|Given IV
48478429|NCT00346164|OTHER|clinical observation|Patients undergo observation
48478430|NCT00346164|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
48478431|NCT00346164|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
48106074|NCT00345852|PROCEDURE|Fetoscopic Selective Laser Photocoagulation|
48106075|NCT00921076|BEHAVIORAL|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
48106076|NCT00018525|PROCEDURE|Lung Volume Reduction Surgery|
48106077|NCT05903963|DRUG|Midazolam|midazolam infusion by 0.03-0.3mg/kg in increments of 1-2.5mg followed by Maintenance dose: 0.03-0.2mg/kg/hour for midazolam.
48106078|NCT05903963|DRUG|dexmedetomidine|dexmedetomidine infusion 1 µg/kg dexmedetomidine for 10 minutes followed by a continuous IV infusion at 0.2-0.3 µg/kg/hour .
48106079|NCT02918968|DRUG|Enzalutamide|Oral Capsule
48106080|NCT02918968|DRUG|Flutamide|Oral tablet
48106081|NCT02918968|OTHER|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
48478432|NCT00346164|DRUG|ifosfamide|Given IV
48478433|NCT03714555|DIAGNOSTIC_TEST|Safety Laboratories|Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
48478434|NCT03714555|OTHER|AE Assessment|Assessment of Adverse Events (AE)
48478435|NCT03714555|OTHER|Physical Exam|Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
48478436|NCT03714555|OTHER|Concomitant Medication Review|Prior and Concomitant Medication Review
48478437|NCT03714555|DIAGNOSTIC_TEST|Tumor Imaging|Tumor CT or MRI
48478438|NCT03714555|DRUG|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
48478439|NCT03714555|DRUG|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
48106082|NCT04461418|DRUG|Glucocorticoid therapy|The study intervention is defined as treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms; patients with symptomatic brain metastases with a requirement for glucocorticoid therapy will be treated with an available, standard-of-care immune checkpoint inhibitor regimen.
48106083|NCT00432458|DRUG|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
48106084|NCT00432458|DRUG|zoledronic acid|4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
48106085|NCT02278848|OTHER|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
48106086|NCT01291563|DRUG|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
47950316|NCT05938530|DEVICE|Stent graft|Stent graft has been shown to be superior than plain balloon angioplasty in the treatment of AVG dysfunction.
47950317|NCT06680609|DRUG|Nefopam 20 MG/ML|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg was infused over 20 min
47950318|NCT06680609|DRUG|Placebo|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
47950319|NCT03860597|DRUG|Memantine|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
47950320|NCT03860597|DRUG|Placebos|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
47950321|NCT02833350|DRUG|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
47950322|NCT02833350|DRUG|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
47950323|NCT02833350|DRUG|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
47950324|NCT02833350|DRUG|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
47950325|NCT02833350|DRUG|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
47950326|NCT05454501|OTHER|Exercise Training|For eight weeks, they will receive real-time online exercise training for 30 minutes, three days a week, with a peer group of 5-6 people. Before starting the exercise, physical activity will be monitored for seven days.
48106087|NCT01291563|DRUG|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
48106088|NCT01291563|DRUG|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
48106089|NCT01291563|DRUG|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
48106090|NCT04574024|DRUG|NBT-NM108 (60 g/day)|Patients will receive NBT-NM108 at 60 g/day.
48106091|NCT04574024|OTHER|NBT-NM108 (0 g/day)|Patients will receive NBT-NM108 at 0 g/day.
48106092|NCT06053242|DRUG|CELZ-201-DDT|Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
48106093|NCT06053242|OTHER|Placebo|Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
48478440|NCT03714555|DRUG|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
47950327|NCT05454501|OTHER|Patient Education|After the first face-to-face evaluation session, these patients and their families will receive a 1-hour patient education program specific to the disease and exercise. Information brochures containing physical activity and exercise recommendations will be given. They will be followed up with weekly phone calls throughout the study period. At the end of 8 weeks, the second evaluation interview will be held. Afterward, the patients in the control group will be able to participate in the online exercise training program if they request it.
47950328|NCT04324931|OTHER|Biomechanical corrections|Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
47950329|NCT04324931|OTHER|Conventional Physiotherapy|Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
48106094|NCT03887546|DEVICE|Inspiratory muscle trainer|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
48106095|NCT03887546|PROCEDURE|Respiratory exercise|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
48106096|NCT00166192|PROCEDURE|Jessner's solution chemical peel|
48106097|NCT00166192|PROCEDURE|Trichloroacetic acid chemical peel|
48106098|NCT00364286|DRUG|Dasatinib (BMS-354825)|50mg Orally twice daily
48478441|NCT05765799|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
48637092|NCT05456841|BEHAVIORAL|Empathic Communication Skills (ECS) training|"The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others"
47950330|NCT05543889|OTHER|Educational package|Online learning package that will discuss the van Herick technique, grading, accuracy and information and discusses the current guidelines for primary angle closure suspect referral.
47950331|NCT01356979|PROCEDURE|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
47950332|NCT02030418|DEVICE|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
47950333|NCT00833820|PROCEDURE|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
47950334|NCT00833820|PROCEDURE|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
47950335|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
47950336|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
48478442|NCT03286608|OTHER|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
48478443|NCT02586363|DRUG|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
48478444|NCT02586363|DRUG|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
48478445|NCT02586363|DRUG|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
48478446|NCT02588079|BEHAVIORAL|Internet-based cognitive behavioral therapy|
48478447|NCT04904055|OTHER|Value-based Formulary|Prescription drug formulary tiers informed by estimated value
48478448|NCT02731963|DRUG|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
48478449|NCT01118117|DEVICE|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
48478450|NCT00273416|DRUG|PF-00592379|
48478451|NCT00273416|DRUG|Sildenafil 100mg|
48478452|NCT03783988|COMBINATION_PRODUCT|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
48478453|NCT01343875|PROCEDURE|tear of the distal tendon in the biceps muscle|
48478454|NCT06525857|OTHER|LTOT|Patients with newly prescribed LTOT will be monitored for physiological changes
48478455|NCT04057248|DEVICE|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
48478456|NCT04057248|BEHAVIORAL|CDE|Certified Diabetes Educator Sessions
48478457|NCT03523845|OTHER|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
48478458|NCT02538835|BEHAVIORAL|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
48478459|NCT02538835|BEHAVIORAL|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel \& Segal.
48478460|NCT02538835|BEHAVIORAL|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
48478461|NCT06277050|DRUG|Maintenance Therapy with Toripalimab and Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
48478462|NCT06277050|DRUG|Maintenance Therapy with Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
48478463|NCT02354807|DRUG|Mirabegron|One-time dose of 100mg of Mirabegron
48478464|NCT02354807|OTHER|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
48478465|NCT06239714|DRUG|SGB-3403|SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
48478466|NCT06239714|OTHER|Atorvastatin|The dosage of atorvastatin was determined by the investigator
47950337|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
47950338|NCT04495933|OTHER|Placebo|sterile saline
47950339|NCT02728622|DRUG|Tamoxifen|endocrine treatment
47950340|NCT02728622|DRUG|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
47950341|NCT04336358|OTHER|Telemedicine|Telemedicine consultation online
47950342|NCT05350306|DEVICE|Chincup|Patients will receive an individual fabricated bonded bite block and occipital chincup. A 400-500g/side retroactive force will be applied in the direction of the condyles. Patients or panthers will be instructed to wear the appliance /14-16/ hours a day.
48478467|NCT06239714|OTHER|Placebo|Normal saline 0.9%
48106099|NCT05429424|OTHER|Verum acupuncture group|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
48106100|NCT05429424|OTHER|Sham control group I|The needle does not penetrate the skin and retract in the handle while the acupuncturist needling into the skin. The participants easily believe their intervention owing to the sensation of needling into the skin that the device mimics. The needles were fixed with a plastic ring and micropore on the body of the participants without manipulation.
48106101|NCT05429424|OTHER|Sham control group II|"The acupuncturist disinfected the skin of the selected acupoints with alcohol, then vertically penetrated the skin with disposable stainless-steel needles (size, brand, Taiwan) to the depth predetermined for each point (between 8-25 mm, depending on the location of the acupoint) and achieved a deqi response, often described as a pressure, fullness, or achiness feeling around the acupoints."
48106102|NCT00065052|BEHAVIORAL|Behavior modification|
48106103|NCT01801930|DRUG|OCV-103 and OCV-104|0.3 mg of each
48106104|NCT01801930|DRUG|OCV-103 and OCV-104|1 mg of each
48106105|NCT01801930|DRUG|OCV-103 and OCV-104|3 mg of each
48106106|NCT01801930|DRUG|OCV-103 and OCV-104|6 mg of each
48106107|NCT04891887|BEHAVIORAL|Health education program|"Seven face to face sessions and group discussion health education sessions. Two prepared booklets were distributed to all attendants titled Diabetes mellitus and how to control its complications and Mild cognitive impairment and how to prevent it.~Lab results were discussed individually with each participant to discuss his adherence to the lifestyle modification program.~Clinical follow-up and management with endocrinology and neurology specialists. Individualized Medical Nutrition. Participants were then counselled on healthy eating habits.~Individualized biweekly follow-up scheme through mobile phone. A WhatsApp group was created for all participants to contact the research team whenever they have any inquiry concerning life style modifications. Through this group, 12 HE audio electronic messages were shared with participants.~Final reassessment of clinical status and laboratory profile was carried out with participants who continued till the end of the study."
48106108|NCT01242150|DEVICE|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow \>40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
48106109|NCT01242150|DEVICE|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
48106110|NCT01935869|DRUG|LEO 90100|
48106111|NCT01935869|DRUG|Vehicle|
48106112|NCT01935869|DRUG|Petrolatum ointment|
48106113|NCT01194258|DRUG|Insulin lispro|
48106114|NCT01194258|DRUG|Insulin aspart|
48637093|NCT05456841|OTHER|Standard of Care participant interaction|Standard of Care participant interaction
48106115|NCT01194258|DRUG|Recombinant human hyaluronidase PH20|
48637094|NCT02562235|DRUG|Riociguat (Adempas, BAY63-2521)|For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
48637095|NCT05358821|DRUG|SAGE-718|SAGE-718 oral softgel lipid capsules
48637096|NCT05358821|DRUG|Placebo|SAGE-718-matching oral capsules
48637097|NCT06478940|DRUG|3 mixtatin pulpotomy|pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
48637098|NCT06478940|DRUG|MTA pulpotomy|pulp treatment with applying MTA
48637099|NCT02500342|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
48637100|NCT02500342|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
48106116|NCT01194258|DRUG|Insulin glulisine|
48106117|NCT01194258|DRUG|Insulin glargine|
48106118|NCT05739929|DRUG|Colchicine 0.5 MG Oral Tablet|0.5 mg colchicine tablets twice daily.
48106119|NCT05739929|DRUG|Placebo|Placebo tablets twice daily
48106120|NCT00957658|DEVICE|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
48106121|NCT05079061|DRUG|Misoprostol|sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
48637101|NCT02145611|DRUG|Glibenclamide|Glibenclamide
48637102|NCT02145611|DRUG|Vildagliptin|Vildagliptin
48637103|NCT03852693|OTHER|Histopathological review|Histopathological review
47950343|NCT05350306|OTHER|Control group|The changes in condyle-mandibular volumes and superficial areas and relative positions of the condyles and glenoid fossa will be calculated after 16 months of observation.
47950344|NCT02477839|DRUG|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
47950345|NCT02477839|OTHER|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
47950346|NCT00496223|DRUG|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
47950347|NCT00496223|DRUG|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
47950348|NCT05967000|OTHER|Preventive heart health and menopause programme|"This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass:~* Individualised risk assessment, screening, diagnosis, and treatment of CVD.~* Lifestyle education, adjustment, stress management, and counselling.~* Smoking cessation programs.~* Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy.~* Virtual consults and health coaching."
47950349|NCT06631755|DEVICE|Xience Skypoint stent over calcified coronary lesions|Patients with Xience Skypoint stent implanted after OCT assesment of calcification
48478468|NCT03536494|BEHAVIORAL|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~* General practitioners: information and training with written material and patient-centred prescribing.~* Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~* Management support with the definition of a structured strategy.~* Monthly monitoring of the intervention."
48478469|NCT00872326|PROCEDURE|Autologous Bone Marrow Mononuclear Cells|Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
48478470|NCT02710591|DRUG|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline"
48478471|NCT00465231|DRUG|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
48478472|NCT00465231|DRUG|preservative free saline|10mL saline solution
48478473|NCT02012452|BEHAVIORAL|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
48478474|NCT02012452|BEHAVIORAL|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
48478475|NCT01906424|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
48478476|NCT01249014|OTHER|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
48478477|NCT01249014|OTHER|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
48478478|NCT01249014|DEVICE|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
48478479|NCT01249014|DEVICE|Bair hugger warming blanket|Bair hugger warming blanket laid on body
48478480|NCT01877460|OTHER|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
48478481|NCT05623852|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
48478482|NCT03143387|OTHER|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
48478483|NCT03143387|OTHER|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
48478484|NCT04974619|BEHAVIORAL|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
48478485|NCT04974619|BEHAVIORAL|Focus groups or Individual Interviews|Focus groups and/or individual interviews will be conducted in-person and/or remotely to receive feedback on the HPV vaccine education materials. Focus groups and/or individual interviews will be conducted with 24 young adult Latino men who have sex with men (YLMSM) in either English or Spanish (approximately 12 in Puerto Rico and approximately 12 in Florida). The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference, and aesthetics of the theoretically informed HPV education materials culturally targeted for Spanish- and/or English-speaking YLMSM.
48266500|NCT00746967|DRUG|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
48478486|NCT04974619|BEHAVIORAL|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
48478487|NCT00920114|BIOLOGICAL|blood sample|
48478488|NCT05967416|BIOLOGICAL|SIRPant-M|Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection
48478489|NCT05967416|RADIATION|External-beam radiotherapy (XRT)|Radiotherapy given by external beam
48478490|NCT05402306|OTHER|Treatment group|Group metacognitive therapy, mainly with attention training technique over two weeks.
48637104|NCT04484662|OTHER|Potted Mint Plants|We will measure 2 indoor environments (living room and bedroom) for placing potted plants.
47950350|NCT06266312|BEHAVIORAL|A multimodal prehabilitation programme|"1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~   * 5 min. warm-up~  * 35 min. cycling at 40-60% of (HR reserve + resting HR)~  * 5-10 min. cool-down~2. + strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~* 3 min warm-up (20W)~* 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week."
48298440|NCT06149884|PROCEDURE|Sentinel lymph node biopsy, axillary lymph node dissection|"SLNB was performed using single or dual tracers. For the single tracer technique, Technetium 99, a radioactive substance, was administered periareolarly prior to surgery, and SLNs were identified intraoperatively via a gamma detection system (Neoprobe®). The dual tracer method employed both an isosulfan blue dye and Technetium 99 concurrently. The choice of SLNB technique was contingent upon the surgeon's discretion. SLNs were categorized as one or multiple, and any LN identified by either or both methods was defined as SLN. LNs resected during SLNB without tracer signal were not classified as SLNs.~ALND was characterized by the removal of all LNs in axillary levels I and II. Patients documented to have undergone ALND in surgical records were primarily selected from our registry. Among them, those with fewer than 10 LNs were excluded, based on the assumption that a competent ALND necessitated the removal of 10 or more LNs as defined in previous studies"
48298441|NCT02421120|DRUG|Ceftolozane/Tazobactam|1 hour intravenous infusion
48298442|NCT02151500|BEHAVIORAL|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
48298443|NCT01494961|BEHAVIORAL|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
48298444|NCT01827540|DRUG|Cenicriviroc|
48298445|NCT01827540|DRUG|Dolutegravir|
48298446|NCT01827540|DRUG|Midazolam|
48298447|NCT00153634|DRUG|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
48298448|NCT00153634|DRUG|PO azithromycin|250 mg once daily
48298449|NCT00153634|DRUG|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
48298450|NCT00153634|DRUG|PO ciprofloxacin|500 mg every 12 hours if weight \<50 kg 750 mg every 12 hours if weight ≥50 kg
48298451|NCT00153634|DRUG|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
48298452|NCT00153634|DRUG|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
48478491|NCT02247518|DRUG|Cialis Tab. 5mg|
48637105|NCT06174532|PROCEDURE|Traditional Medthod|Before surgery, the patient's lower jawbone tumor is replicated using a 3D-printed original model without adjustments. Then, the model undergoes manual modification by drilling and adjusting the jawbone model at the tumor site using drills and manual instruments. Subsequently, the reconstructed model is formed preoperatively based on this modified model. During surgery, the patient isn't guided by surgical guides, and the incision lines are relatively dependent on the surgeon. Additionally, while fixing the remaining bone after the sectioning, the surgeon uses pre-bent fixation plates made earlier to assist in stabilizing the bone.
48637106|NCT06174532|PROCEDURE|Virtual surgical planning|Before surgery, the patient's lower jawbone is 3D-printed, designed to remove the tumor mass, and create a suitable margin for reconstructive plate bending. Subsequently, the reconstruction plate is pre-bent preoperatively based on this model. During surgery, the patient is guided by specific surgical guiding tools: cutting guides. Additionally, while fixing the remaining bone after sectioning, the surgeon is assisted by bone fixation instruments to stabilize the alignment of the two bone fragments according to anatomical structure and then proceeds to use pre-bent reconstruction plates to secure the bone.
48637107|NCT03573765|PROCEDURE|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
48478492|NCT02247518|DRUG|Harnal-D Cap. 0.2mg|
48478493|NCT00308360|DRUG|Risperidone, divalproex|
48637108|NCT03573765|PROCEDURE|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
48478494|NCT00384293|DRUG|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
48478495|NCT00384293|DRUG|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
48478496|NCT04214665|DRUG|Alpha Lipoic acid 600 mg HR film coated tablets|
48478497|NCT02563769|DRUG|Clavulanic acid|Clavulanic acid will be administered orally in 250mg capsules
48478498|NCT02563769|DRUG|Intravenous cocaine|20/40mg Cocaine will be administered by IV
48478499|NCT02563769|DRUG|Placebo|Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
48478500|NCT05500768|PROCEDURE|hypothermic compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
48478501|NCT05500768|PROCEDURE|Conventional compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
48637109|NCT03573765|PROCEDURE|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
48637110|NCT03573765|PROCEDURE|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
48298453|NCT00153634|DRUG|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
48298454|NCT00153634|DRUG|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
48298455|NCT01264133|DRUG|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
48298456|NCT02793908|DRUG|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
48478502|NCT01560884|DRUG|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
48478503|NCT01560884|DRUG|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
48637111|NCT03573765|PROCEDURE|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
48478504|NCT01560884|DRUG|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
48478505|NCT01560884|DRUG|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
48637112|NCT03573765|PROCEDURE|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
48478506|NCT02339415|DRUG|Edoxaban 30mg daily|
48637113|NCT03573765|PROCEDURE|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
48637114|NCT03573765|PROCEDURE|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
48298457|NCT02793908|DRUG|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
48298458|NCT00087204|DRUG|becatecarin|Given IV
48298459|NCT00087204|OTHER|laboratory biomarker analysis|Correlative studies
48298460|NCT02717546|DEVICE|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
48298461|NCT00374907|DRUG|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
48298462|NCT00374907|DRUG|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
48298463|NCT00374907|DRUG|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
48298464|NCT00374907|DRUG|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
48298465|NCT04791397|PROCEDURE|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
48298466|NCT04791397|PROCEDURE|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
48298467|NCT01096550|BEHAVIORAL|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
48298468|NCT01096550|BEHAVIORAL|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
48298469|NCT01809990|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
48298470|NCT06385964|DRUG|SHR-4597|SHR-4597 by dry powder inhalation
48298471|NCT06385964|DRUG|Placebo|Placebo by dry powder inhalation
48298472|NCT01185535|PROCEDURE|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
48478507|NCT02339415|DRUG|Matching placebo|
47950351|NCT01497275|DRUG|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
48478508|NCT04000243|DIAGNOSTIC_TEST|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
47950352|NCT02641132|DRUG|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
47950353|NCT02641132|PROCEDURE|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
47950354|NCT02100579|DRUG|Bupivacaine|10 ml of 0.25% bupivacaine
47950355|NCT02100579|DRUG|Preservative free normal saline|10 ml of preservative free normal saline
47950356|NCT01212107|DRUG|FGF Receptor|LY2874455 administered orally.
47950357|NCT01212107|DRUG|Phosphate Binders|
47950358|NCT05464550|BEHAVIORAL|Eye tracker|Eye movements on a screen are captured with an eye tracker during a repeated measures before/after a directed autobiographical recall.
48478509|NCT06369506|DIAGNOSTIC_TEST|GTmeasurement|GT was measured from the point corresponding to the base of the gingival sulcus and 1 mm and 2 mm apical to this point. If the GT was ≤1 mm, it was considered a thin phenotype, and if it was \>1 mm, it was considered a thick phenotype.
47950359|NCT00928395|DEVICE|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
47950360|NCT00178750|DEVICE|18G Tuohy epidural needle|
47950361|NCT00178750|DEVICE|CompuFlo® computerized syringe pump|
47950362|NCT00418249|DRUG|AS101|
47950363|NCT00183820|DRUG|paclitaxel, gemcitabine, and oxaliplatin|"1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days"
48478510|NCT04529772|DRUG|acalabrutinib|Investigational Product
48478511|NCT04529772|DRUG|placebo|Placebo comparator
48478512|NCT04529772|DRUG|Prednisone|Investigational Product
48478513|NCT04529772|DRUG|Rituximab|Investigational Product
48478514|NCT04529772|DRUG|Cyclophosphamide|Investigational Product
48478515|NCT04529772|DRUG|Vincristine|Investigational Product
48478516|NCT04529772|DRUG|Doxorubicin|Investigational Product
48478517|NCT01960868|OTHER|standard physiotherapy|
48478518|NCT01960868|OTHER|experimental physical therapy|
47950364|NCT01611610|OTHER|Functional tests|"The ambulant patients will perform~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Timed tests (time to rise from the floor,...)~* 6 minute walk test~* PedsQL - neuromuscular module"
47950365|NCT01611610|OTHER|Functional tests|"The non-ambulant patients will perform:~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Upper Limb Functional Items~* Egen Klassifikation 2 questionnaire - EK2~* PedsQL questionnaire - neuromuscular module"
48478519|NCT01525576|BEHAVIORAL|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
48478520|NCT00909571|DRUG|FK506E (modified release tacrolimus)|oral
48478521|NCT00909571|DRUG|Prograf (tacrolimus)|injection
48478522|NCT06617624|OTHER|MRI|Healthy volunteer will have a non-injected cardiovascular MRI
48478523|NCT06617624|OTHER|MRI Contrast|Patients will have the gadolinium injected cardiovascular MRI
48478524|NCT05053724|OTHER|Star to move Protocol|"Progressive physical therapy according to the Gosslink protocol called Start to move."
48478525|NCT03671187|OTHER|Exercise|8 week exercise program
48478526|NCT03474809|DEVICE|Blood sampling|Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
48478527|NCT06300827|OTHER|Structured digital-based training|The eight week intervention will be delivered in 15 different sessions, each session lasting 40 minutes. It is expected that the seventh week session will last approximately 150 minutes. The control group is expected to continue with their daily lives.
48478528|NCT00258778|DRUG|Human Glucocerebrosidase (prGCD)|
48478529|NCT00798681|DIETARY_SUPPLEMENT|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
48478530|NCT00798681|OTHER|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
48478531|NCT00798681|OTHER|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
48478532|NCT03016741|BIOLOGICAL|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
48478533|NCT03016741|DRUG|Prednisone|Given by mouth
47950366|NCT02817074|BEHAVIORAL|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
47950367|NCT02817074|BEHAVIORAL|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
47950368|NCT04216121|RADIATION|Local ablative therapy|Stereotactic body radiotherapy
47950369|NCT04216121|PROCEDURE|Local ablative therapy|Surgery
47950370|NCT05602142|DRUG|[11C]CPPC PET ligand|Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
47950371|NCT06193525|DRUG|Talazoparib|Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
47950372|NCT01498978|BIOLOGICAL|ipilimumab|Given IV
47950373|NCT01498978|OTHER|laboratory biomarker analysis|Correlative studies
47950374|NCT03800173|DRUG|galidesivir|galidesivir IV infusion
47950375|NCT03800173|DRUG|placebo|placebo IV infusion
47950376|NCT04716088|DIAGNOSTIC_TEST|Rapid antigen test for SARS CoV2|Defining diagnostic performance of repeated testing regimen in hospital setting
47950377|NCT04977557|DIETARY_SUPPLEMENT|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
48478534|NCT03016741|DRUG|Abiraterone Acetate|Given by mouth
48478535|NCT03016741|DRUG|Enzalutamide|Given by mouth
48478536|NCT01567241|OTHER|clinical hypnosis or relaxation music|25 minute tape recording
48478537|NCT02593487|DRUG|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
48478538|NCT02593487|DRUG|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
48478539|NCT02904499|DRUG|Dabigatran|
48478540|NCT06617403|OTHER|non|non
48478541|NCT03887416|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
48478542|NCT03887416|DRUG|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
48478543|NCT03399578|BIOLOGICAL|ChAdOx1 MERS|The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
48478544|NCT05158140|BIOLOGICAL|V110|Single intramuscular (IM) dose of 0.5 mL V110, a pneumococcal polysaccharide vaccine (PCV), containing the 23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
48478545|NCT05158140|BIOLOGICAL|V114|Single IM dose of 0.5 mL V114 a 15-valent PCV containing the 15 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F
48478546|NCT05158140|BIOLOGICAL|mRNA-1273|Single IM dose of 50 μg/0.25 mL mRNA-1273
48478547|NCT05158140|BIOLOGICAL|Placebo for V110|Single IM dose of 0.5 mL placebo for V110
48478548|NCT05158140|BIOLOGICAL|Placebo for V114|Single IM dose of 0.5 mL placebo for V114
48478549|NCT06365684|DRUG|Sodium zirconium cyclosilicate|In the case of hyperkalemia patients will be treated with Sodium zirconium cyclosilicate to allow the continuation of potassium enriched diet. In case hyperkalemia arises in the control group, patients will be treated with Sodium zirconium cyclosilicate as well.
48478550|NCT02487082|DRUG|Melatonin and Donepezil|10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
48478551|NCT02487082|OTHER|Placebo|For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.
48637115|NCT03573765|PROCEDURE|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
48637116|NCT03573765|PROCEDURE|Intra-articular injection|Any intra-articular injection
48637117|NCT04716309|PROCEDURE|Open reduction and volar locking plate and closed reduction and K-wires.|DVR Anatomic Plate, K-wires
48637118|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
48637119|NCT01063803|DRUG|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
48637120|NCT04605588|DRUG|Nitazoxanide|Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
47950378|NCT03775031|DEVICE|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
47950379|NCT02436681|DEVICE|MIROMESH|
48478552|NCT04975893|BIOLOGICAL|mRNA-1647|No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.
48478553|NCT04975893|OTHER|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
48478554|NCT03992313|OTHER|Community-based HCV rapid test|HCV rapid tests will be done in the village
48478555|NCT03992313|OTHER|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
48478556|NCT03992313|OTHER|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
48478557|NCT03992313|OTHER|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
48478558|NCT06345963|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
48478559|NCT00095862|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|
48478560|NCT00095862|BIOLOGICAL|recombinant interferon alfa|
48478561|NCT00095862|DRUG|cyclophosphamide|
48478562|NCT00332124|DRUG|Choline|900 mg every day until birth of infant
48478563|NCT00332124|DIETARY_SUPPLEMENT|Placebo|Corn oil every day in place of choline
48478564|NCT02498249|DEVICE|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
48478565|NCT02498249|DEVICE|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
48478566|NCT05309720|PROCEDURE|Glyaderm|All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.
48478567|NCT05338476|DRUG|Midazolam|Administered orally.
48478568|NCT05338476|DRUG|Selpercatinib|Administered orally.
48478569|NCT04508699|OTHER|semantic learning|Experimental semantic learning from linguistic context task
48478570|NCT05684224|BEHAVIORAL|Dynamic accommodation|Dynamic accommodation will be tracked using the Tobii Glasses
48637121|NCT04605588|DRUG|Placebo Nitazoxanide|Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
47950380|NCT02400177|BEHAVIORAL|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
48298473|NCT03809065|DRUG|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
48298474|NCT03809065|DRUG|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
48637122|NCT04605588|DRUG|Ribavirin|Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
47950381|NCT03207893|BEHAVIORAL|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
48637123|NCT04605588|DRUG|Placebo Ribavirin|Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
48637124|NCT04605588|DRUG|Hydroxychloroquine|Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
48637125|NCT04605588|DRUG|Placebo Hydroxychloroquine|Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
48637126|NCT06032975|OTHER|Questionnaires|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
48106122|NCT03119363|DEVICE|AYO light glasses (Experimental)|The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
48106123|NCT03119363|DEVICE|AYO light glasses (Comparator)|The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
48298475|NCT01581112|BIOLOGICAL|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
48298476|NCT00890630|PROCEDURE|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
47950382|NCT03207893|OTHER|Routine Care|Subject's current t2d treatment
47950383|NCT03719820|DRUG|aggressive medical management|Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
47950384|NCT06679933|OTHER|Hand grip strength measurament|That intervention includes making the patient sit down and rest for 5 minutes on a comfortable chair. Then make them handle a hand dynamometer with their dominant hand and ask them to squeeze it with all of their effort. Repeat that squeeze three times with 2-minute intervals. The highest number recorded on the dynamometer is the hand grip strength of the patient.
47950385|NCT04410029|OTHER|Healthwise Decision Aid|Healthwise, a non-profit company that develops health content and patient information for hospitals, has created a decision aid for EPL management that is available through the EPIC Systems, an electronic medical record. Participants will be given this decision aid after EPL diagnosis and prior to options consultation with a provider.
47950386|NCT04410029|OTHER|Control informational handout|Participants randomized to the control arm will be given an informational handout of treatment options after EPL diagnosis and prior to options consultation with a provider.
47950387|NCT03059433|OTHER|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
47950388|NCT04993560|BIOLOGICAL|BBIBP-CorV|Inactivated virus COVID-19 vaccine
48298477|NCT00890630|DRUG|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
48298478|NCT01864577|OTHER|Negative Pleural Suction at -20 cm H2O|
48298479|NCT01864577|OTHER|Water seal|
48298480|NCT04132752|OTHER|Motivation|Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
48298481|NCT05632133|DRUG|Lacosamide 50 MG Oral Tablet|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
48478571|NCT02639728|OTHER|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
48637127|NCT01812941|OTHER|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
47950389|NCT04993560|BIOLOGICAL|BNT162b2|mRNA-based COVID-19 vaccine
47950390|NCT00169754|OTHER|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
47950391|NCT03008226|DEVICE|Implementation of 9 mm intrabronchial valves|
47950392|NCT02059902|DRUG|Lidocaine|Lidocaine infusion runs for a total of 24 hours
47950393|NCT02059902|OTHER|Placebo|Normal saline runs for a total of 24 hours
47950394|NCT01336296|DRUG|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
48106124|NCT06438406|DEVICE|Orthotic devices and therapeutic exercise (Group A)|Group A consisting of patients who were prescribed orthoses, to use gradually, and a 20-session rehabilitation programme, based on the Back School method
47950395|NCT04274387|BEHAVIORAL|Mindfulness-based Stress Reduction(MBSR)|A structural program focusing on the practice about attending to the current moment with non-judgmental attitude
48637128|NCT01812941|OTHER|healthy volunteers: blood collection|blood collected at designated time intervals
47950396|NCT01498328|DRUG|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
47950397|NCT01498328|DRUG|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
48106125|NCT06438406|DEVICE|Orthotic devices (Group B)|Group B consisting of patients who were only prescribed orthoses for the lower limbs
48106126|NCT05453955|DRUG|Propofol|Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
47950398|NCT01498328|DRUG|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
47950399|NCT00920634|DRUG|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
47950400|NCT06383065|OTHER|IMT Group|Inspiratory muscle training involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in.
47950401|NCT03452228|DRUG|evinacumab|Administered by Intravenous (IV)
47950402|NCT03452228|DRUG|Placebo|Administered by Intravenous (IV)
47950403|NCT02662634|BIOLOGICAL|AGS-003-LNG|autologous dendritic cell immunotherapy
47950404|NCT02662634|DRUG|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
48106127|NCT05453955|DRUG|Remimazolam Besylate|Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
48106128|NCT00480012|DEVICE|rTMS|repetitive transcranial meagnetic stimulation of the brain
48106129|NCT04729244|DRUG|CBD|Hemp Oil
48298482|NCT05632133|DRUG|Ibuprofen 400 mg|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
48478572|NCT02639728|OTHER|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
47950405|NCT02662634|DRUG|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
48478573|NCT02639728|OTHER|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
47950406|NCT02662634|DRUG|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
47950407|NCT02662634|DRUG|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
47950408|NCT02662634|DRUG|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
47950409|NCT02662634|RADIATION|Radiation Therapy|Causes DNA strand breaks.
47950410|NCT03009409|DRUG|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
48106130|NCT00105820|PROCEDURE|System level depression care quality improvement|
48298483|NCT06555094|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
48298484|NCT06555094|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
48478574|NCT05402787|OTHER|Virtual visit|A virtual visit will be made to mothers whose babies are hospitalized in the neonatal intensive care unit
48478575|NCT00298740|DEVICE|Aventis U-400 Insulin|
48478576|NCT05308680|BIOLOGICAL|BNT162b2|Administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19
48620067|NCT05073471|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"We will apply five small electrodes to participant's head. Once the electrodes are in place, a small electrical current will be passed between the electrodes. Participants will also get sham tDCS, which means they will not receive any real stimulation from the electrodes. Most individuals do not find the procedure uncomfortable, and there are no known long-term risks of tDCS. When the current goes through the electrodes, you may feel an itching or tingling sensation under the electrodes or see brief flashes of light, or you may not feel anything at all. If the sensation is unpleasant, participant can report to co-investigator immediately. If participant finds the procedures too uncomfortable, they may stop it at any time. A trained staff member will be present throughout the procedure."
48106131|NCT04107805|DRUG|BI 1323495|Tablet
48106132|NCT04107805|DRUG|Placebo|Tablet
48106133|NCT04107805|DRUG|Midazolam|Oral administration
48106134|NCT04767035|DRUG|midazolam / ketamine sublingual tablet|sublingual tablet
48106135|NCT02576340|DRUG|otilonium bromide|otilonium bromide was administered before the procedure
48106136|NCT02072226|DRUG|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
48106137|NCT02072226|DRUG|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
48620068|NCT03834168|OTHER|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
48106138|NCT02072226|DRUG|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
48106139|NCT02072226|DRUG|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
48106140|NCT02721225|DIETARY_SUPPLEMENT|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
48106141|NCT02721225|DIETARY_SUPPLEMENT|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
48106142|NCT00145041|DRUG|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
48106143|NCT05923008|DRUG|IBI130|Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
48637129|NCT01812941|OTHER|Burn: blood collection|blood collected at designated time intervals
48637130|NCT01151631|DEVICE|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
48637131|NCT02059642|DRUG|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
48106144|NCT04371536|DRUG|Ferrous Sulfate|Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
47950411|NCT03009409|OTHER|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
48106145|NCT04371536|BEHAVIORAL|IRONCHILD|"Delivery of the intervention at each visit should take 15 minutes or less.~* Baseline visit (Session 1) content will be viewed~* At 1-month follow-up visit, additional (Session 2) content will be viewed~* At 3-month final visit, patients will view final (Session 3) content"
48106146|NCT00290849|DRUG|Bivalirudin|
48106147|NCT05279092|DRUG|Bupivacaine-Liposomal Bupivacaine|Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
48620069|NCT05507177|OTHER|communication training programme for healthcare providers|the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
48620070|NCT05295589|PROCEDURE|Computed Tomography|Undergo CT scan
48620071|NCT05295589|DRUG|Copanlisib Hydrochloride|Given IV
48620072|NCT05295589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48637132|NCT02059642|DRUG|placebo|Placebo 1400 mg administered orally once daily
48637133|NCT04202783|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
48637134|NCT00322426|DEVICE|Sensory Cueing Device|
48298485|NCT06555094|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
48298486|NCT03312140|DRUG|Choline Chloride|
48106148|NCT05279092|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
48106149|NCT00276250|DRUG|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
48106150|NCT00276250|DRUG|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
48106151|NCT00276250|DRUG|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
48106152|NCT03970590|BEHAVIORAL|CTC Intervention|"An integrated peer narrative-based intervention (VIEW \> SELECT \> GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
48106153|NCT03970590|BEHAVIORAL|Control|6-month HTN management assessment text messages without narrative component
48106154|NCT02864095|DRUG|Tranexamic acid (TXA)|IV and topical administration
48106155|NCT02864095|DRUG|Epinephrine|
48298487|NCT04256746|OTHER|Boiled Rice|
48106156|NCT03993392|DRUG|TM buprenorphine|4mg TM buprenorphine, investigator choice as to brand
48106157|NCT03993392|DRUG|SUBLOCADE|300mg subcutaneous injection
48106158|NCT02200341|BEHAVIORAL|MBCT|
48298488|NCT04256746|OTHER|Boiled Rice+0.37 gr mulberry fruit powdered extract|
48298489|NCT04256746|OTHER|Boiled Rice+0.75 gr mulberry fruit powdered extract|
48298490|NCT04256746|OTHER|Boiled Rice+1.12 gr mulberry fruit powdered extract|
48298491|NCT04256746|OTHER|Boiled Rice+1.50 gr mulberry fruit powdered extract|
47950412|NCT05782712|BIOLOGICAL|adenosine dosage|Whole blood is collected using finger puncture followed by deposit a drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
47950413|NCT05868759|RADIATION|Roentgen Stereophotogrammetric Analysis (RSA)|"Roentgenstereophotogrammetric analysis (RSA) is a radiographic technique, highly accurate both to evaluate the primary stability of the implant, then the micromovements between bone and implant prosthetic, both for the evaluation of the kinematics of the prosthetic components. The RSA technique in dynamics is able to obtain, with patient in motion, a series of radiographic frames in sequence in two projections, which are captured simultaneously. Each pair of orthogonal projections corresponds to a specific moment of the movement carried out by the patient and will be used to obtain, through dedicated software, a reconstruction three-dimensional instant defined RSA scenes."
48106159|NCT02200341|BEHAVIORAL|PRT-PsyEd|
48106160|NCT00762463|DRUG|Celecoxib|capsule, 200 mg QD, 6-12 weeks
48106161|NCT00762463|DRUG|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
48106162|NCT05171998|PROCEDURE|venous blood sample|Phlebotomy procedure for a venous blood draw.
48106163|NCT02139449|PROCEDURE|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
48106164|NCT04148937|DRUG|LY3475070|Administered orally
48106165|NCT04148937|DRUG|Pembrolizumab|Administered IV
48106166|NCT01909778|DRUG|BI 201335|single oral doses
48106167|NCT01406028|BEHAVIORAL|Phone calls|Phone calls to offer emotional support
48106168|NCT05356819|DEVICE|Smart Capnography™, Microstream®|patients monitored by capnograph
48106169|NCT00553189|DRUG|ABT-888|
48106170|NCT00553189|DRUG|Topotecan|
48106171|NCT02182414|DRUG|BI 207127 NA (TF-I)|200 mg tablet
48106172|NCT02182414|DRUG|BI 207127 NA (TF-II)|400 mg tablet
48106173|NCT02182414|DRUG|BI 207127 NA delayed release|400 mg tablet
48106174|NCT02182414|DRUG|BI 207127 NA extended release (10% HPMC)|400 mg tablet
48298492|NCT04256746|OTHER|Rice Porridge|
48298493|NCT04256746|OTHER|Rice porridge+1.50 gr mulberry fruit powdered extract|
48298494|NCT05641376|DRUG|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
48298495|NCT05641376|DRUG|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
48298496|NCT04476537|DEVICE|OncoTreat|OncoTreat is a computational pipeline that begins with a tumor expression profile and ends with a list of several candidate regimens.
48298497|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, clarithromycin|non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
48298498|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, metronidazole|clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
47950414|NCT05868759|DEVICE|Delos Postural Proprioceptive System (computerized oscillating platform)|The Delos Postural Proprioceptive System uses electronic tilting tables (on a single axis or three axes) with high frequency that allows very short stop and reversal times that allow both to study the proprioception and the patient's response to the modification of movement of the inclined plane
47950415|NCT05868759|DIAGNOSTIC_TEST|Modified Star Excursional Balance Tests|The Star Excursional Balance Test (SEBT) is a clinical test designed for the evaluation of dynamic physical performance of the tibiotarsica. The first literary references date back to 1998 and the test, remaining in balance with the ankle in the studio, the achievement of the maximum possible distance with the contralateral foot along well-defined axes.
47950416|NCT05868759|DEVICE|Inertial sensors Xsens MVN|"The inertial motion acquisition system Xsens MVN is easy to use and economic to detect the movement of different anatomical districts. MVN is based on inertial sensors in miniature through communication solutions combined with advanced fusion algorithms sensors, using hypotheses of biomechanical models.~This MVN system is a system of inertial kinematic measurement of the whole body, which incorporates synchronized data. Instant graphic output is provided, including angles of motion articular."
47950417|NCT05868759|OTHER|American Orthopaedic Foot and Ankle Score (AOFAs)|American Orthopaedic Foot and Ankle Score (AOFAs) is a clinical trial commonly used in scientific literature which serves to assess, in terms of value from 0 to 100, the autonomy, pain, stability, ankle alignment and back foot of the patient.
47950418|NCT05868759|OTHER|Visual Analogue Scale (VAS)|The Visual Analogue Scale (VAS) is a visual representation of the extent of pain that the patient subjectively warns. The VAS is represented by a 10 cm long line in the original version validated, with or without notches at each centimeter. One end indicates the absence of pain and corresponds to 0, the other end indicates the worst pain imaginable and corresponds to 10.
47950419|NCT05868759|OTHER|12-Item Short Form Survey (SF-12)|The 12-Item Short Form Survey (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
47950420|NCT04507100|BEHAVIORAL|World Health Organization Health Promoting Schools|"Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school."
47950421|NCT01055522|DRUG|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
47950422|NCT01055522|DRUG|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
48106175|NCT02182414|DRUG|BI 207127 NA extended release (15% PEO)|400 mg tablet
48106176|NCT02182414|DRUG|BI 207127 NA extended release (20% HPMC)|400 mg tablet
48106177|NCT02611414|DEVICE|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
48106178|NCT02611414|DEVICE|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
48298499|NCT00292292|DEVICE|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
48637135|NCT05072041|DEVICE|Nexsphere™|Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
48298500|NCT00292292|DEVICE|Charite Artificial Disc|Insertion of the Charite
48298501|NCT03454048|DRUG|Piperaquine (low dose)|subcurative regimen (480 mg)
48298502|NCT03454048|DRUG|Piperaquine (high dose)|Curative regimen (960mg)
48298503|NCT03454048|DRUG|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
48298504|NCT03454048|DRUG|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
48298505|NCT03454048|OTHER|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
48298506|NCT03454048|OTHER|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
48298507|NCT03388983|OTHER|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
48298508|NCT05090150|OTHER|Home delivery of ART|Home ART refill and monitoring, adherence support
48298509|NCT05090150|OTHER|Smart Lockers (Pele boxes)|Decentralized ART refills and monitoring, adherence support
48298510|NCT05090150|OTHER|Best clinic practices + conditional lottery incentives|Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
48298511|NCT05090150|OTHER|Best clinic practices|Continue with best clinic practices
48298512|NCT05055661|OTHER|Pharmaceutical Teleconsultation|The pharmacist will apply the teleconsultation according to the elaborated workflows and will follow in seven steps: scheduling the teleconsultation; pre-consultation, in which the pharmacist will make a checklist of the adequacy of the teleconsultation environment; presentation of the professional and the objectives of the teleconsultation to the patient; search for information about the patient and their pharmacotherapy; identification of problems related to pharmacotherapy; elaboration of a care plan and appointment for the re-consultation.
48298513|NCT01601392|PROCEDURE|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
48298514|NCT01601392|PROCEDURE|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
48298515|NCT01601392|PROCEDURE|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
48298516|NCT05694819|DRUG|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
48298517|NCT05694819|DRUG|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
48298518|NCT00985881|DEVICE|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
48298519|NCT00985881|DEVICE|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
48298520|NCT06504550|OTHER|Schroth Exercises|The patients in the Schroth exercise group will start their exercise program under physiotherapist supervision.Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.These exercises include spinal elongation, de-rotation, de-flexion, stretching, strengthening exercises to maintain vertebral alignment.The participants will be asked to combine these exercises with their daily living activities (ADLs).During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support.Exercises are progressed from lying, sitting, or standing positions and from most to least passive support per a review of the quality of the performance.Decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises will depend on the patient's improvement in exercise performance
48298521|NCT06504550|OTHER|Klapp Exercises|The patients in the Klapp exercise group will be treated with supervised klapp exercises. Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.In each session, a sequence of 8 postures of Klapp Exercises will be carried out. Each posture will be maintained for 4-5 minutes with rest breaks when needed.Positions that will be held are: 1) Lateral crawl, 2) Horizontal sliding, 3) Crawl posture near the ground, 4) Bunny hopping, 5) Arm turn, 6) Big arch, 7) Lateral crawl near the ground, 8) Big curve
48298522|NCT01371838|DRUG|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
48298523|NCT01371838|DRUG|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
48298524|NCT04292119|DRUG|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
48298525|NCT04292119|DRUG|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
47913973|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of eye massage device producing vibratory stimulations distraction in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
48298526|NCT04292119|DRUG|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
48298527|NCT04292119|DRUG|TNO155|TNO155 will be taken orally once daily for 14 days.
48298528|NCT02110108|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
48620073|NCT05295589|DRUG|Olaparib|Given PO
48620074|NCT05295589|DRUG|Paclitaxel|Given IV
48620075|NCT05295589|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48298529|NCT01095952|DEVICE|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
48637136|NCT06369051|OTHER|Self-employment support intervention|A new intervention developed to assist stroke survivors in becoming self-employed by developing entrepreneurial skills. It consists of one home visit, three online individual sessions, and four online group sessions held once a week for eight weeks.
48637137|NCT03727061|BIOLOGICAL|Nivolumab|Immunotherapy - Standard of care
48106179|NCT03426683|OTHER|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
48298530|NCT02124720|BEHAVIORAL|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
48298531|NCT06339996|DIETARY_SUPPLEMENT|Male supplement|Participants will be administered supplements for a three-month treatment period
48637138|NCT03727061|DRUG|Porfimer Sodium|Given IV
48637139|NCT03727061|PROCEDURE|Interstitial Illumination Photodynamic Therapy|Undergo I-PDT
48637140|NCT03727061|OTHER|Quality of Life Assessment|Ancillary Studies
47950423|NCT01055522|DRUG|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
47950424|NCT05095038|DIETARY_SUPPLEMENT|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
47950425|NCT05095038|DIETARY_SUPPLEMENT|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
47950426|NCT05269433|BEHAVIORAL|OCAT-sham|Placebo version of the online contingent attention training preceded by a psycho-education movieclip.
48298532|NCT01950936|OTHER|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
48298533|NCT06554496|DEVICE|CPAP Treatment|Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
48298534|NCT02037919|OTHER|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
48637141|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
48637142|NCT00564070|BEHAVIORAL|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
48637143|NCT01081574|DRUG|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
47950427|NCT05269433|BEHAVIORAL|OCAT|Online contingent attention training preceded by a psycho-education movieclip.
47950428|NCT05269433|OTHER|Psycho-education video|All groups watch a psycho-education video before the start of the 10-day attention training.
47950429|NCT05269433|OTHER|Motivational video|Participants in the OCAT+ condition watch a short motivational video before each training session.
47950430|NCT01588639|DRUG|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
47950431|NCT01588639|DRUG|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
47950432|NCT01588639|DRUG|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
47950433|NCT03920748|OTHER|Group D|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D
47950434|NCT03920748|OTHER|Group E|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
48298535|NCT02037919|OTHER|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
48620076|NCT05295589|DRUG|Topotecan Hydrochloride|Given IV
47950435|NCT03272516|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
48298536|NCT03053089|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
48298537|NCT01142323|DRUG|fenofibrate|160 mg po daily
47950436|NCT03272516|OTHER|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
47950437|NCT02502175|DRUG|opium|Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
47950438|NCT02502175|DRUG|methadone|Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
47950439|NCT01419626|DEVICE|Interdental cleaning device with water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
47950440|NCT01419626|DEVICE|Interdental cleaning device with essential-oil mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
48298538|NCT00708994|DRUG|THC|"* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
47950441|NCT01960673|DEVICE|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
47950442|NCT01960673|DEVICE|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
47950443|NCT01960673|DEVICE|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
47950444|NCT01960673|DEVICE|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
47950445|NCT01466179|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
47950446|NCT00100061|DRUG|Cranberry juice|liquid juice taken daily
47950447|NCT00100061|DIETARY_SUPPLEMENT|Cranberry Juice|Taken orally
47950448|NCT00100061|DIETARY_SUPPLEMENT|Placebo cranberry juice|Placebo comparitor
47950449|NCT05128318|PROCEDURE|Nissen Fundoplication, cholecystectomy|Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
47950450|NCT05271071|DIAGNOSTIC_TEST|Ultrasound guided piriformis muscle and gluteus maximus muscle lidocaine injection|Ultrasound guided piriformis muscle (piriformis syndrome) and gluteus maximus muscle 5 ml %1 lidocaine injection
47950451|NCT05863273|DRUG|Apremilast|Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
47950452|NCT03841448|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
48106180|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
48106181|NCT01233154|DIETARY_SUPPLEMENT|probiotic|
48298539|NCT00708994|DRUG|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
48620077|NCT02587416|DRUG|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
48620078|NCT02587416|DRUG|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
48620079|NCT02587416|DRUG|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
47950453|NCT03841448|DRUG|Cemdisiran|Cemdisiran was administered by SC injection.
47950454|NCT05180617|BEHAVIORAL|Music Therapy|Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments to choose from. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
47950455|NCT06679998|DRUG|Single dose, AAPB by injection, intravenous drip.|Subjects received a single intravenous infusion of AAPB for injection. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, and each time was continuously injected for 60 min±5min.
48106182|NCT02675920|DRUG|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
48106183|NCT06125106|DRUG|Blinatumomab|Haploidentical hematopoietic stem cell transplantation was performed using a Conditioning regimen containing Blinatumomab. 28ug of Blinatumomab was administered intravenously once a day for a total of 7 days, followed by a routine conditioning regimen and haploid hematopoietic stem cell transplantation.
48106184|NCT01919697|DRUG|Plecanatide|
48106185|NCT05102266|DRUG|BR1016C|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
48298540|NCT06134167|DEVICE|Transdermal Compress Device|Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
48298541|NCT01327339|DRUG|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
48298542|NCT01795469|DEVICE|Zoex compression garment|5-strap compression of abdomen, thighs and legs
48298543|NCT03094936|PROCEDURE|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
48298544|NCT03094936|DEVICE|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
48298545|NCT03774017|PROCEDURE|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
48298546|NCT03774017|PROCEDURE|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
48298547|NCT00001259|DRUG|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
47950456|NCT06679998|OTHER|Single dose, placebo, intravenous drip.|Subjects received a single intravenous infusion of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time.
47950457|NCT06679998|DRUG|Multiple dosing, AAPB for injection, intravenous drip|Subjects received AAPB for injection with multiple intravenous drips. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, 60 min±5min each time, for 7 consecutive days.
48298548|NCT00001259|DRUG|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
48298549|NCT00001259|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
48298550|NCT00001259|DRUG|Placebo patch|Placebo by skin patch
48298551|NCT00001259|DRUG|Placebo injection|Placebo given intramuscularly monthly
47950458|NCT06679998|OTHER|Multiple dosing, placebo, IV drip|Subjects received multiple intravenous doses of placebo. Each dose of placebo was dissolved by 0.9% sodium chloride injection with an infusion volume of 100mL once a day for 60 min±5min each time for 7 consecutive days.
47950459|NCT05014217|BEHAVIORAL|Mentalization-based Treatment|An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.
47950460|NCT05014217|BEHAVIORAL|Dialectical Behavior Therapy-inspired Treatment|A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. \& Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
47950461|NCT02796742|OTHER|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
47950462|NCT03157167|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
48106186|NCT05102266|DRUG|BR1016D|All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
48106187|NCT04854993|DRUG|Sugammadex 6 mg/kg|i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
48106188|NCT04854993|DRUG|Sugammadex 4 mg/kg|i.v. injection of a standard dose of sugammadex to reverse dNMB
48106189|NCT05607953|DRUG|SD-101|SD-101 doses are administered via PRVI using the PEDD method of administration
48106190|NCT05607953|BIOLOGICAL|anti-PD-1|In the Phase 1b, anti-PD-1 will be administered together with SD-101
48106191|NCT02167646|PROCEDURE|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
48106192|NCT00338858|OTHER|walking and balance performance evaluation|
48106193|NCT00338858|PROCEDURE|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
48106194|NCT04991974|BEHAVIORAL|Patient Navigation|A Patient Navigator will work with participants to facilitate their entry into OUD treatment in the community (e.g., by selecting a program, scheduling intake appointments, and addressing barriers to facilitate successful treatment linkage).
47950463|NCT02563977|DEVICE|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
47950464|NCT02548533|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
47950465|NCT02548533|DRUG|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
47950466|NCT02548533|DRUG|EMLA cream|Topical application 2 hours prior to the treatment.
47950467|NCT03645928|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by IL-2 administration. Lifileucel will be administered to patients once (on Day 0) during the study.
48106195|NCT04991974|DRUG|Buprenorphine|"Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community."
48106196|NCT01598948|DRUG|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
48106197|NCT05672446|OTHER|simulation with standardized child patient|49 students in the experimental group experienced the ability to prepare a school-age child for the procedure with a simulation using standardized pediatric patients. In the simulation, a school-aged child was used as the standard patient.
48106198|NCT02044523|DEVICE|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
48298552|NCT00001259|DRUG|Placebo suppository|Placebo vaginal suppository
48106199|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Test Drug tablet|Investigational Medicinal Product
48106200|NCT05250141|DRUG|Levodopa 250mg and Carbidopa 25mg Referent Product tablet|Sinemet (Savio Industrial S.R.L, Brazil)
48620080|NCT04989933|PROCEDURE|Ultrasound-guided erector spinae plane block|Ultrasound-Guided erector spinae plane block with 0.25% bupivacaine
47950468|NCT03645928|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
47950469|NCT03645928|DRUG|Pembrolizumab|"Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years."
47950470|NCT03645928|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
48106201|NCT03589651|DRUG|Retifanlimab|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
48106202|NCT03589651|DRUG|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
48298553|NCT04376346|BEHAVIORAL|Native WYSE CHOICES|Native WYSE (Women, Young, Strong, and Empowered) CHOICES (Changing High-risk alcohOl use and Increasing Contraception Effectiveness Study) is an alcohol-exposed pregnancy prevention program that translates CHOICES, an evidence-based targeted intervention, into an mHealth universal intervention for young urban American Indian/Alaska Native (AI/AN) women ages 16-20.
48298554|NCT01810146|OTHER|Digestive functions investigations|
47950471|NCT03645928|DRUG|Ipilimumab|"Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection."
47950472|NCT03645928|DRUG|Nivolumab|"Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years."
47950473|NCT01297920|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
47950474|NCT01297920|DRUG|Brinzolamide ophthalmic suspension, 1%|
47950475|NCT01297920|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
48106203|NCT03589651|DRUG|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
48637144|NCT05034354|DEVICE|Remote physiological monitoring|Participants will be provided with a Bluetooth capable weight scale (A\&D Medical UC-352BLE or Beurer BY90), oxygen saturation monitor (Contec Medical Systems CMS50D-BT) and automatic blood pressure monitor (A\&D Medical UA- 651BLE) to use daily for at least 10 days of a 14-day trial period. Data will be sent via the Sphygmo App to the pediatric cardiology for monitoring. Parents and healthcare providers will be asked to participate in a qualitative interview and the end of the 14-day period to provide feedback on the devices and Sphygmo™ platform.
48637145|NCT03123562|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
47950476|NCT03666624|BEHAVIORAL|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
47950477|NCT06333301|OTHER|Surveys|Group will complete several surveys
47950478|NCT04638400|DRUG|Simvastatin 40mg|Simvastatin administered daily for 6 weeks
47950479|NCT04638400|DRUG|Ezetimibe 10mg|Ezetimibe administered daily for 6 weeks
47950480|NCT00698984|DIETARY_SUPPLEMENT|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
47950481|NCT00698984|DIETARY_SUPPLEMENT|Placebo|2 capsules per day over a period of 6 months
47950482|NCT05226273|OTHER|no intervention|no intervention
47950483|NCT06681233|DEVICE|Comparison of HyperSight CBCT imaging to conventional CBCT imaging.|Participants will receive their daily radiation treatment on a radiation therapy system equipped with HyperSight CBCT imaging. For at least 1 and up to 3 treatment fractions, participants will receive their daily radiation treatment on a system equipped with conventional CBCT imaging.
47950484|NCT04222231|OTHER|Blood-flow restriction resistance training|Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
47950485|NCT04222231|OTHER|Classical resistance training|Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
48106204|NCT02129933|DRUG|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~\* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
47950486|NCT00140946|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
47950487|NCT00140946|DRUG|Comparator: placebo / Duration of Treatment: 16 weeks|
47950488|NCT05629546|BIOLOGICAL|Cytokine-induced memory-like natural killer cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
47950489|NCT05629546|BIOLOGICAL|Relatilmab|Standard of care
47950490|NCT05629546|BIOLOGICAL|Nivolumab|Standard of care
47950491|NCT06680388|DRUG|Drug：CD19 CAR-T|A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
47950492|NCT03533101|DRUG|Tocilizumab|IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
48298555|NCT01518699|DRUG|Ha44|Abametapir Lotion 0.74%
47950493|NCT02854150|GENETIC|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
47950494|NCT02831244|DEVICE|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
47950495|NCT00173888|DRUG|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
47950496|NCT00173888|DRUG|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
47950497|NCT05530798|DEVICE|Definity Perflutren Lipid Microsphere Ultrasound Contrast|"1. Before the spinal decompression surgery has started, the study team will inject the ultrasound contrast to visualize the spinal cord prior to decompression of the spinal cord.~2. After the spinal cord has been decompressed, the study team will inject the ultrasound contrast to visualize the spinal cord directly after decompression of the spinal cord.~3. Prior to completion and closure of the incision, the study team will once more inject the ultrasound contrast to visualize the spinal cord.~4. A member of the research team will follow up with study participants within a week of the procedure by phone. The research staff will also review the participants' medical record for up to 360 days after your procedure to collect information on clinical outcomes and any additional treatments, tests or procedures the study participants may have had."
47950498|NCT04896879|BEHAVIORAL|interviews|semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
47950499|NCT05338359|BIOLOGICAL|Blood sample|Blood sample of 34 mL
47950500|NCT05338359|OTHER|Phone-call|Phone-call to the participant 15 days after recruitment to fix the final diagnosis
47950501|NCT00080275|DRUG|Niacin Extended-Release and simvastatin Tablets|
47950502|NCT01658631|DEVICE|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
47950503|NCT06681168|DEVICE|transcutaneous auricular vagal nerve stimulation|"Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days.~Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20)."
47950504|NCT06681168|DEVICE|Sham (No Treatment)|The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
48106205|NCT02129933|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
48637146|NCT05625971|OTHER|MRD Assessment|MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).
48637147|NCT05047250|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
48106206|NCT03404154|DIAGNOSTIC_TEST|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
48106207|NCT03404154|PROCEDURE|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
48106208|NCT02816632|OTHER|mRI|Neural bases of feedbacks' influence on decision making processes
48298556|NCT01518699|DRUG|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
48298557|NCT01518699|DRUG|Moxifloxacin Placebo|Moxifloxacin Placebo
48298558|NCT01518699|DRUG|Moxifloxacin|Moxifloxacin 400mg
48637148|NCT05633667|DRUG|Zimberelimab (ZIM)|Administered intravenously
48637149|NCT05633667|DRUG|Domvanalimab (DOM)|Administered intravenously
48637150|NCT05633667|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
48637151|NCT05633667|DRUG|Etrumadenant (ETRUMA)|Administered orally
48637152|NCT05633667|DRUG|Carboplatin|Administered intravenously
48637153|NCT05633667|DRUG|Cisplatin|Administered intravenously
48637154|NCT05633667|DRUG|Pemetrexed|Administered intravenously
48637155|NCT05633667|DRUG|Paclitaxel|Administered intravenously
48637156|NCT05633667|DRUG|Nab-paclitaxel|Administered intravenously
48637157|NCT05633667|DRUG|Docetaxel|Administered intravenously
48637158|NCT05633667|DRUG|Nivolumab|Administered intravenously
48637159|NCT03574714|OTHER|Extracellular pH|Extracellular pH gradient
48637160|NCT02743754|OTHER|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
48637161|NCT02743754|OTHER|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
48637162|NCT04891861|DRUG|Apixaban|Direct Oral Anticoagulation all at label dose and frequency
48637163|NCT04541693|DEVICE|Full revision|Both cup and stem require revision
48637164|NCT04541693|DEVICE|Cup revision|Only the cup requires revision
48478577|NCT04333017|DEVICE|Percutaneous radiofrequency ablation of parietal endometriosis|Treatment is carried out under local anaesthesia after surgical asepsis, in interventional radiology room. Radiofrequency needles are inserted percutaneously under ultrasound guidance. Number of needles depends on the size of lesion (1 or 2 or 3 needles). In case of proximity between lesion and peritoneum, artificial ascites can be performed. Treatment is carried out in accordance with device's instructions for use (thyroid nodules treatment algorithm), with a gradual increase in power every 5 minutes, without exceeding the maximum authorised power (depending on number and length of needles). State of coagulation is monitored under visual ultrasound control of ablation area (diffusion of Co bubbles), until a decrease in effective power is obtained. Several ablation zones are performed on the same nodule with overlapping of the different impacts. An ice pack is applied to the treated area. An analgesic PO treatment of step 1 and/or 2 is prescribed for 5 days.
48637165|NCT04541693|DEVICE|Stem revision|Only the stem requires revision
48478578|NCT05934513|DRUG|GFH009|patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
48478579|NCT02928536|OTHER|no intervention|This is an observational study. No intervention is considered
48478580|NCT00977431|DRUG|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
48478581|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
48478582|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
48478583|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
48637166|NCT05414253|DEVICE|Parallel Assignment|Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
48637167|NCT05542901|DIAGNOSTIC_TEST|Joint Position Sense Analysis|The Xsens DOT Motion Capture System will be used to analyze joint position sense.
48637168|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (hyaluronic acid) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
48637169|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
48637170|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (methylprednisolone acetate) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
47950505|NCT06274307|PROCEDURE|Transversus abdominis plane block|A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.
47950506|NCT05093140|DRUG|Camrelizumab|"Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles"
47950507|NCT03021304|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
47950508|NCT02043275|OTHER|Leg training|Lower body resistance training twice per week for one hour each time.
47950509|NCT02043275|OTHER|Arm training|Upper body resistance training twice per week for one hour each time.
47950510|NCT00002651|DRUG|bicalutamide|Given orally
47950511|NCT00002651|DRUG|goserelin acetate|Given subcutaneously
47950512|NCT00002651|OTHER|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
47950513|NCT02397031|BEHAVIORAL|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
47950514|NCT02397031|BEHAVIORAL|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
47950515|NCT03801083|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
47950516|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
48298559|NCT02533960|OTHER|not applicable (observational study)|Observational study without study related intervention.
48298560|NCT01066416|PROCEDURE|Endoscopic Sinus Surgery|
48298561|NCT01066416|OTHER|medical therapy|Subjects will undergo surgery 6 months after randomization
48478584|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
48478585|NCT04691440|DRUG|Hyperbaric oxygen|The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
47950517|NCT00810693|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
47950518|NCT00810693|DRUG|Placebo|Matching Placebo tid orally for 12 weeks
47950519|NCT04396665|BEHAVIORAL|Precam|6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
47950520|NCT06556641|DRUG|GZR33 Injection|Administered as once daily subcutaneous dose
47950521|NCT06556641|DRUG|GZR101 Injection|Administered as once daily subcutaneous dose
47950522|NCT06556641|DRUG|Placebo|Administered as once daily subcutaneous dose
47950523|NCT06556641|DRUG|Insulin Degludec|Administered as once daily subcutaneous dose
48106209|NCT02816632|OTHER|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
47950524|NCT00000304|DRUG|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
47950525|NCT00000304|DRUG|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
48106210|NCT05112718|BIOLOGICAL|Platelet Rich Plasma Injections|"PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections."
48478586|NCT06072157|DRUG|AK006-IV|Intravenous infusion
48478587|NCT06072157|DRUG|Placebo-IV|Intravenous infusion
48478588|NCT06072157|DRUG|AK006-SC|Subcutaneous
48478589|NCT06072157|DRUG|Placebo-SC|Subcutaneous
48478590|NCT05610449|DIAGNOSTIC_TEST|Testing Done Simple SARS CoV-2 Antigen Test|Collections of specimens from subjects presenting with Covid-19 like symptoms or known/suspected exposure to SARS CoV-2 via nasal swabs administered by trained medical personnel.
48637171|NCT04681937|COMBINATION_PRODUCT|Subacromial Injection (Serum Saline) + Physical Therapy.|arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
48637172|NCT03426852|OTHER|No intervention|No intervention
48637173|NCT01277731|DRUG|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
47950526|NCT00000304|DRUG|Placebo|Placebo
47950527|NCT01892267|DEVICE|PEG-J placement|PEG-J placement
47950528|NCT06557824|OTHER|speleotherapeutic intervention|In the study, medical records of 415 Czech children diagnosed with bronchial asthma who took part in speleotherapeutic intervention between January 2022 and October 2023 were analysed.
47950529|NCT05077878|BIOLOGICAL|DSPP level in GCF|quantification of DSPP
47950530|NCT03954132|DRUG|Spiolto® Respimat®|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
47950531|NCT03954132|DRUG|Triple-Therapy (LAMA/LABA/ICS)|Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
47950532|NCT02003365|DRUG|FX006 10 mg|Extended-release formulation
47950533|NCT02003365|DRUG|FX006 40 mg|Extended-release formulation
47950534|NCT02003365|DRUG|TCA IR 40 mg|Immediate-release formulation
47950535|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
47950536|NCT01436396|BIOLOGICAL|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
47950537|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
47950538|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
47950539|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
47950540|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
48106211|NCT05112718|OTHER|Normal Saline Injections|"Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).~The participants will receive 2 injections at 4-6-week intervals."
47950541|NCT01436396|BIOLOGICAL|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
47950542|NCT01436396|BIOLOGICAL|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
47950543|NCT01436396|BIOLOGICAL|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
48106212|NCT03302741|DRUG|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
48106213|NCT03302741|OTHER|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
48106214|NCT03302741|DEVICE|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
48106215|NCT03302741|DEVICE|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
48106216|NCT00851240|DRUG|BTT-1023|intravenous
48106217|NCT00851240|DRUG|Placebo|Intravenous
48106218|NCT04990219|DRUG|Lu AG06466|Lu AG06466 - capsule
48106219|NCT04990219|DRUG|Placebo|Placebo - capsule
48106220|NCT03109886|DRUG|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
48106221|NCT01034943|PROCEDURE|External fixation|Operation with external fixation and optional addition of k-wire
48106222|NCT01034943|PROCEDURE|Volar plate|Operation with a Synthes volar two column plate (TCP)
48106223|NCT01393912|DRUG|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
48106224|NCT01672840|DIETARY_SUPPLEMENT|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
48106225|NCT01672840|DIETARY_SUPPLEMENT|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
48106226|NCT02713048|OTHER|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
48106227|NCT05739513|DIAGNOSTIC_TEST|miRNA analysis in plasma|blood sample
48106228|NCT03782558|PROCEDURE|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
48637174|NCT06035549|BEHAVIORAL|Culturally Tailored Digital Resilience-Building|The Culturally Tailored Digital Resilience-Building intervention consists of 6 modules, including an introduction of advance care planning and resilience skills that specifically address cultural beliefs and barriers.
48637175|NCT02562040|PROCEDURE|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
48106229|NCT02438124|BEHAVIORAL|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
48106230|NCT00680537|PROCEDURE|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
48637176|NCT02562040|BEHAVIORAL|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
48637177|NCT04609046|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
47950544|NCT01436396|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
47950545|NCT01436396|BIOLOGICAL|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
47950546|NCT01436396|BIOLOGICAL|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
47950547|NCT01436396|BIOLOGICAL|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
47950548|NCT04888078|PROCEDURE|Bassini hernia repair|Non-mesh tissue inguinal hernia repairs
47950549|NCT00003023|BIOLOGICAL|BCG vaccine|
48106231|NCT02205086|OTHER|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
48106232|NCT01967654|OTHER|Technical Assistance, training and clinical reminders|
48106233|NCT01967654|OTHER|Referral to Community Health Worker|
47950550|NCT00003023|BIOLOGICAL|monoclonal antibody A1G4 anti-idiotype vaccine|
48106234|NCT00950404|DRUG|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
48106235|NCT00950404|DRUG|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
47950551|NCT05501223|OTHER|Medication review|30-60 minutes extra consultation regarding the patients drugs
47950552|NCT05501223|OTHER|Standard care|Standard care i.e. visit at the Dept. of Endocrinology.
47950553|NCT02154737|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
47950554|NCT02154737|DRUG|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
47950555|NCT01706796|DRUG|PF-06273340|Oral solution, single dose, fasted
47950556|NCT01706796|DRUG|PF-06273340|Immediate Release Tablet, single dose, fasted
48478591|NCT04411823|DEVICE|EndoFLIP measurement|EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern under FDA cleared indication. It is performed during endoscopy.
48106236|NCT00950404|DRUG|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
48637178|NCT04609046|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
47950557|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
47950558|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
47950559|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
47950560|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
47950561|NCT02623920|DRUG|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
47950562|NCT02623920|DRUG|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
47950563|NCT02623920|DRUG|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
47950564|NCT04318327|BIOLOGICAL|PHE885|Infusion
48106237|NCT00950404|DRUG|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
48106238|NCT05784688|DRUG|TU2218 + Pembrolizumab|TU2218: Orally administered Pembrolizumab: Intravenously administered
48106239|NCT05337657|DRUG|GB491+Letrozole|Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
48106240|NCT02313441|OTHER|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
48478592|NCT02375217|DRUG|Sugammadex|half dose
48478593|NCT02375217|DRUG|Sugammadex|full dose
48478594|NCT02375217|DRUG|Neostigmine|IV = 50mcg/kg
48478595|NCT02375217|DRUG|glycopyrrolate|
48478596|NCT00955552|DRUG|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
48478597|NCT00955552|DRUG|Cosamin DS® (Nutramax)|oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
47950565|NCT03102112|OTHER|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
47950566|NCT01464892|BEHAVIORAL|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
47950567|NCT01464892|BEHAVIORAL|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
48478598|NCT03840499|DRUG|Optimal medical therapy|Optimal medical therapy
48478599|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
48478600|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
48478601|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
48637179|NCT04609046|PROCEDURE|Echocardiography|Undergo ECHO
48637180|NCT04609046|DRUG|Lenalidomide|Given PO
48637181|NCT04609046|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48637182|NCT04609046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48637183|NCT04609046|DRUG|Methotrexate|Given IV or PO
48637184|NCT04609046|BIOLOGICAL|Nivolumab|Given IV
48637185|NCT04609046|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48637186|NCT04609046|BIOLOGICAL|Rituximab|Given IV
48637187|NCT04609046|PROCEDURE|Ultrasound Imaging|Undergo testicular ultrasound
48106241|NCT00980135|DEVICE|Sinecort cream|Application over 29 days
48106242|NCT00980135|DRUG|Hydrocortison cream|Application over 29 days
48106243|NCT00980135|OTHER|Untreated skin|
48106244|NCT06341491|BEHAVIORAL|Pé-de-Meia Program|"The Pé-de-Meia Program was established by the Brazilian Federal Government with the aim of encouraging the retention of low-income students in high school by providing maintenance scholarships and savings opportunities. To be eligible for the program, a young person must: Be properly enrolled in a regular public high school course, be between 14 to 24 years old, come from a low-income family, and be registered in the Bolsa Família Program. The Program offers four types of incentives:~An enrollment grant registered at the beginning of the academic year, paid once a year in the amount of 200 BRL.~A minimum school attendance of 80% of the total class hours, paid in nine installments throughout the year at 200 BRL each.~Proven participation in the National High School Exam (ENEM), paid once to the student enrolled in the third year of high school, in the amount of 200 BRL.~Completion of the high school academic years, paid in a single installment of 1,000 BRL."
48106245|NCT00243256|DRUG|Cholecalciferol|
48298562|NCT02844205|OTHER|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
48298563|NCT00958568|DRUG|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
47950568|NCT04604314|DEVICE|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
48298564|NCT00958568|DRUG|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
48298565|NCT05694078|OTHER|Hand Therapy Splinting Protocol|Relative motion splinting protocol
48298566|NCT06313281|PROCEDURE|Preoperative Antiseptic preparation prior to transnasal skull base surgery|The patient received one of three antiseptic preparation before transnasal skull base surgery
48298567|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
48298568|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
48298569|NCT02658162|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
48298570|NCT02658162|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
48298571|NCT03679481|DRUG|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
48106246|NCT02664194|DEVICE|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
48298572|NCT03679481|DRUG|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
48298573|NCT00231985|BEHAVIORAL|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
48298574|NCT00231985|BEHAVIORAL|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
48298575|NCT03360981|DRUG|Incretins|after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
48298576|NCT04784299|DEVICE|YVOIRE volume plus|Hyaluronic acid dermal filler
48298577|NCT04784299|DEVICE|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
48298578|NCT01450930|DRUG|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
47950569|NCT05353361|DRUG|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
48106247|NCT02664194|PROCEDURE|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
48106248|NCT04279171|DIAGNOSTIC_TEST|Greyson NDE scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 7/32
48106249|NCT04279171|DIAGNOSTIC_TEST|DES dissociation scale|Screening for dissociative symptoms
48106250|NCT04279171|DIAGNOSTIC_TEST|WHOQOL-SRPB|WHOQOL-SRPB is an instrument developed to evaluate how spirituality, religiosity and personal beliefs (SRPB) are related to quality of life in health and health care.
48298579|NCT01450930|DRUG|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
48298580|NCT03267095|BEHAVIORAL|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
48478602|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
48478603|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
48478604|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
47950570|NCT05353361|DRUG|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
47950571|NCT05353361|DRUG|SHR-A1811；Adebrelimab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
47950572|NCT05353361|DRUG|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
47950573|NCT05657431|OTHER|essential oils (Ylang ylang oil)|inhaler aromatherapy
48298581|NCT04217902|OTHER|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
48106251|NCT04279171|DIAGNOSTIC_TEST|cerebral magnetic resonance imaging|Types of images to be acquired: T1, T2, Diffusion Weighted Imaging-DWI, Fluid Attenuated Inversion Recovery and spectroscopy
48106252|NCT00959920|PROCEDURE|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
48106253|NCT00959920|PROCEDURE|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
48106254|NCT01784146|OTHER|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
48298582|NCT04217902|OTHER|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
48298583|NCT04688567|BEHAVIORAL|Patient-driven iCBT|1) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
48298584|NCT04688567|BEHAVIORAL|Standardized iCBT (TAU)|2) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
48298585|NCT05894018|DRUG|Fluzoparib|150mg, orally, bid
48298586|NCT05894018|PROCEDURE|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
48298587|NCT03070457|OTHER|Early discharge|Patients randomised to early discharge or not
48298588|NCT03070457|OTHER|Conventional protocol|Discharge as usually done 48-72 hours after surgery
48298589|NCT03807999|DRUG|Nab-paclitaxel|
48298590|NCT03807999|DRUG|Gemcitabine|
48298591|NCT00020852|PROCEDURE|conventional surgery|
48298592|NCT00020852|PROCEDURE|cryosurgery|
48298593|NCT06328075|OTHER|non interventional study|non interventional study
48298594|NCT06438913|DRUG|Tezepelumab|Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation.
47950574|NCT05657431|OTHER|placebo (saline solutions)|placebo saline solutions
47950575|NCT05657431|OTHER|essential oils (lemon oil)|inhaler aromatherapy
47950576|NCT03439787|DRUG|Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution|10 ml
48298595|NCT01830452|PROCEDURE|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
48298596|NCT05914311|DEVICE|Suture|secures SCS trial leads with a suture
48298597|NCT05914311|DEVICE|Dermabond|secures SCS trial leads with dermabond
48298598|NCT01759784|BIOLOGICAL|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
48478605|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
47950577|NCT03439787|OTHER|Sodium Chloride 0.9 %|10 ml
47950578|NCT03025009|DRUG|LY3192767|Administered SC.
47950579|NCT03025009|DRUG|Basal Insulin Peglispro|Administered SC.
47950580|NCT03025009|DRUG|Insulin Glargine|Administered SC.
47950581|NCT03025009|DRUG|Placebo|Administered SC.
48106255|NCT01784146|OTHER|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
48106256|NCT01784146|OTHER|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
48298599|NCT05355363|DIAGNOSTIC_TEST|Standard Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
48298600|NCT03634605|PROCEDURE|Chemical pleurodesis|
47950582|NCT04997915|OTHER|Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU|Critical COVID-19 patients admitted to the ICU
47950583|NCT02969551|DEVICE|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
48298601|NCT03634605|DRUG|Tetracycline Topical Ointment|
48298602|NCT03634605|DRUG|Normal saline|
48298603|NCT03634605|DRUG|Lidocaine 2% Injectable Solution|
48298604|NCT03509753|DIETARY_SUPPLEMENT|High Fiber|See intervention description.
48298605|NCT03509753|DIETARY_SUPPLEMENT|Low Fiber|See intervention description.
48298606|NCT03375658|OTHER|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
48298607|NCT01254604|DRUG|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
47950584|NCT01122433|DEVICE|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
47950585|NCT05270122|DEVICE|Mechanical thrombectomy with ThrombX Retriever|Revascularization
47950586|NCT05938062|PROCEDURE|the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)|the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
47950587|NCT02808793|DRUG|AK002|
47950588|NCT02797015|DRUG|RPC1063|Oral capsule daily
47950589|NCT02350569|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
47950590|NCT05931640|DEVICE|Virtual Reality|Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
47950591|NCT05931640|DEVICE|Plyometric Training|Plyometric therapy that includes 10 minutes of ball throwing, push-ups, jumping and hopping/skipping. At start intensity and speed is low, but will be increased gradually. Every score will be noted with the help of additional tools.
48298608|NCT01254604|DRUG|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
48478606|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
48478607|NCT04756596|DIAGNOSTIC_TEST|DDVIT testing|One randomly selected eye will be included for each study participant. Participants respond to the DDVIT test in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
48478608|NCT04756596|DIAGNOSTIC_TEST|ETDRS testing|The same eye is included for each study participant. Participants respond to the standard ETDRS chart of our Ophthalmology Department in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
48478609|NCT06121258|OTHER|Educational video series|The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.
48478610|NCT06490887|OTHER|Use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.
47950592|NCT01180101|BEHAVIORAL|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
47950593|NCT01180101|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery
47950594|NCT02214407|DRUG|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
47950595|NCT02214407|DRUG|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
48298609|NCT01981122|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
48298610|NCT01981122|DRUG|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
48298611|NCT04347811|BEHAVIORAL|Death Cafe|Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
48298612|NCT00682825|BEHAVIORAL|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
48298613|NCT00682825|BEHAVIORAL|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
48478611|NCT01563237|DEVICE|MIDI Arrow|Implantation of MIDI Arrow
48478612|NCT01996423|DIETARY_SUPPLEMENT|Vitamin D3|
48478613|NCT01996423|DIETARY_SUPPLEMENT|Placebo|
48478614|NCT04147962|DEVICE|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
48478615|NCT02407067|DEVICE|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
47950596|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
47950597|NCT05158608|DRUG|Post-transplantation Cyclophosphamide at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
47950598|NCT01039870|PROCEDURE|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
47950599|NCT01039870|PROCEDURE|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
47950600|NCT00424450|PROCEDURE|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
48106257|NCT05678491|OTHER|Endoscopic mucosal band ligation|The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
48106258|NCT04840862|DRUG|Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]|Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.
48637188|NCT04617938|BEHAVIORAL|TACUNA plus Wellness Circle|TACUNA provides three virtual workshops (one hour each) that use motivational interviewing and a virtual Wellness Circle (WC). The workshops combine a 30-minute discussion of opioid, alcohol and marijuana use, and social networks with another 30 minutes focused on three different traditional practices (one per workshop). TACUNA was adapted from our three-session workshop, MICUNAY (Motivational Interviewing and Culture for Urban Native American Youth) protocol, which was developed and tested for urban AI/AN adolescents and from focus groups conducted in Year 1. For the Wellness Circle, youth will have members of their social network virtually attend these once-a-month gatherings. The WC will bring people together to celebrate health and wellness and tradition. The WC will focus on the importance of social networks in making healthy choices, and provide discussion on the role that AOD use and engagement in traditional practices among members of their social networks affect their choices.
48478616|NCT02407067|DEVICE|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
48478617|NCT05545111|DRUG|NBI-1117568|Active treatment with orally administered NBI-1117568
48106259|NCT04840862|DRUG|Rifabutin 300mg|After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.
48106260|NCT01352507|DRUG|Tadalafil|Administered Orally
48478618|NCT05545111|DRUG|Placebo|Placebo matching NBI-1117568
48637189|NCT04617938|BEHAVIORAL|Opioid Education Workshop|The virtual opioid education workshop draws from prevention and education materials supplied and recommended by the National AI/AN Technology and Transfer Center, which is funded by SAMHSA. Materials are culturally relevant educational packages addressing opioid use through recorded webinars, toolkits, and other resources.
48478619|NCT00051831|DRUG|Emtricitabine|Will be administered as one 200-mg capsule orally daily
48637190|NCT06072430|DRUG|VBI-S|VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
48637191|NCT05097287|DRUG|Dupilumab|solution for injection subcutaneous
47950601|NCT00424450|PROCEDURE|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
47950602|NCT00176787|DRUG|Capecitabine|
47950603|NCT00176787|PROCEDURE|Radiation|
47950604|NCT00176787|PROCEDURE|Surgery|
47950605|NCT03829774|DEVICE|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
47950606|NCT03829774|DRUG|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
47950607|NCT00562471|OTHER|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
48106261|NCT01352507|DRUG|Sildenafil|Administered Orally
48106262|NCT04174495|DIAGNOSTIC_TEST|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
48106263|NCT00237107|PROCEDURE|Curretage|
48106264|NCT01603810|OTHER|OCT|Optical coherence tomography of periocular basal cell carcinoma
48106265|NCT00829751|DEVICE|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
48106266|NCT00829751|DEVICE|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
48106267|NCT02710149|BIOLOGICAL|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
48106268|NCT02145182|DRUG|Eculizumab|Eculizumab is a complement component 5 inhibitor.
48106269|NCT02145182|DRUG|Placebo|0.9% sodium chloride
48106270|NCT04367376|OTHER|mobilization|central postroanterion mobilization on the most painful vertebral level at the lumbar spine
48106271|NCT04367376|OTHER|manual therapy|manual therapy
48106272|NCT04367376|OTHER|instrumental manual therapy|instrumental manual therapy
48106273|NCT00964184|DRUG|Metformin|
48106274|NCT00964184|BEHAVIORAL|Lifestyle modification|
48637192|NCT05097287|DRUG|Placebo|solution for injection subcutaneous
48637193|NCT06415344|DRUG|GTX-102|Antisense Oligonucleotide
48106275|NCT02355158|DRUG|clonidine hydrochloride topical gel, 0.1%|
48106276|NCT04650048|DEVICE|Active HD-tDCS|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
48106277|NCT04650048|DEVICE|Sham HD-tDCS|"Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.~This sham-configuration is intended to mimic the sensory experience of active HD-tDCS."
48106278|NCT04680741|BEHAVIORAL|Addiction Pilot App behavior tracking|a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
48478620|NCT00051831|DRUG|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
48478621|NCT00051831|DRUG|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
48106279|NCT01253226|DRUG|LY2127399 (Tabalumab)|Administered subcutaneously
48106280|NCT01253226|DRUG|Placebo|Administered subcutaneously
48106281|NCT04701294|DEVICE|Giomer Beautifil flow plusF03 Shofu-Japan|A pair of permanent first molars will be used for each participant homologs The operator will apply in the upper / lower first molars the sealant material in the order assigned according to the previous randomization. For the intervention group, they will be sealed based on a fluid resin with s-prg glass ionomer filling (Giomer F03 Beautiful -Shofu) in association with a bottle of adhesive (Single Bond) . The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
48106282|NCT04701294|DEVICE|Tetric N flow ivoclar vivadent-Germany|And on the contralateral side (control) the first upper / lower molars will be sealed will be sealed with a fluid resin compound (Tetric N-Flow ivoclar vivadent) in association with a bottle of adhesive (Single Bond). Both materials have a similar color. The operator and the child will not be informed about the brand of the material used. The assistant will collect the data in the file. The evaluation and monitoring process; another operator will record the retention of the sealant in a period of 6, 9 and 12 months.
48478622|NCT00051831|DRUG|Saquinavir|Will be administered as five hard gel capsules orally twice daily
48637194|NCT04980794|BEHAVIORAL|Parent-child intervention|Families (two adult caregivers, child between 4 and 17) receive four interactive, asynchronous psychoeducation modules to review on their own paired with weekly contact with a communication coach and two live sessions with a communication coach to discuss psychoeducation, receive feedback on their interactions, and practice a communication technique.
48637195|NCT04980794|BEHAVIORAL|Self-study Intervention|Families (two adult caregivers) receive information in a newsletter format to review on their own, paired with weekly contact from a communication coach to answer questions and direct their attention toward specific topics in the newsletter.
48637196|NCT06462404|DRUG|E2086|E2086 oral tablets.
48106283|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
48106284|NCT05392179|DRUG|ADX-2191|Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
48106285|NCT00201695|DRUG|Doxil®|40 mg/m2 IV day 1
47950608|NCT00562471|OTHER|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
47950609|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
47950610|NCT01457820|DRUG|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
47950611|NCT01457820|DRUG|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
47950612|NCT04989803|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
47950613|NCT04989803|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
47950614|NCT04989803|BIOLOGICAL|KITE-363|A single infusion of CAR-transduced autologous T cells administered intravenously
47950615|NCT04989803|BIOLOGICAL|KITE-753|A single infusion of CAR-transduced autologous T cells administered intravenously
47950616|NCT02777333|BEHAVIORAL|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
47950617|NCT00068328|PROCEDURE|psychosocial assessment and care|
48106286|NCT00201695|DRUG|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
48106287|NCT00201695|DRUG|Dexamethasone|40 mg PO days 1-4
48106288|NCT00201695|DRUG|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
48106289|NCT02083991|DRUG|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
48478623|NCT00051831|DRUG|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
48478624|NCT03902002|DRUG|Omaveloxolone 50 mg capsules|Capsules containing 50 mg of omaveloxolone
47950618|NCT00068328|PROCEDURE|quality-of-life assessment|
47950619|NCT05000723|OTHER|Standard of care|"Standard of care consisting of~* clearance of infection~* treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~* Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip"
48106290|NCT04835987|DIAGNOSTIC_TEST|Holter ECG|Measurement of the modification of the sympathomimetic balance
48478625|NCT05172102|OTHER|breathing exercise, Aerobic exercises|6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
48637197|NCT06462404|DRUG|E2086 Placebo|E2086 matching placebo tablet.
48637198|NCT06462404|DRUG|Active Comparator|Active comparator oral tablets.
48637199|NCT06462404|DRUG|Active Comparator Placebo|Active comparator matching placebo tablet.
48637200|NCT06312813|DRUG|Imipramine|4% imipramine
48637201|NCT06312813|DRUG|Amitriptyline|4% amitriptyline
48637202|NCT06312813|DRUG|Vehicle|0.1ml propylene glycol
48637203|NCT04329806|DRUG|Moxonidine 0.2 MG|Moxonidine 0.2 MG twice daily
48637204|NCT04329806|DRUG|Amlodipine 5 MG|Amlodipine 5 MG twice daily
48478626|NCT06286761|OTHER|endothelial cell collection|Participants may opt to have testing performed including blood sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
47950620|NCT01395667|OTHER|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
47950621|NCT06328777|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
47950622|NCT00003052|DRUG|doxorubicin hydrochloride|
47950623|NCT00003052|DRUG|etoposide|
47950624|NCT00003052|DRUG|ifosfamide|
47950625|NCT00003052|PROCEDURE|conventional surgery|
47950626|NCT00003052|PROCEDURE|hyperthermia treatment|
47950627|NCT00003052|RADIATION|radiation therapy|
47950628|NCT00283231|BEHAVIORAL|Paced Respiration|
47950629|NCT02416219|PROCEDURE|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
47950630|NCT02416219|DEVICE|Ultrasound|
47950631|NCT00239395|DRUG|Meloxicam ampoule|
47950632|NCT00239395|DRUG|Meloxicam tablet|
47950633|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
47950634|NCT00867685|DRUG|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
47950635|NCT00000702|DRUG|Zidovudine|
47950636|NCT00322101|RADIATION|total-body irradiation|Radiation
47950637|NCT00322101|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
48478627|NCT04285827|BIOLOGICAL|CSL889|Administered as an IV infusion
47950638|NCT00322101|DRUG|cyclophosphamide|Given IV
48106291|NCT04835987|BEHAVIORAL|Questionary|Lifestyle questionary (time spent in front of television, physical activity)
48478628|NCT05021887|DRUG|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
47950639|NCT00322101|DRUG|mycophenolate mofetil|Given orally
47950640|NCT00322101|DRUG|busulfan|Given IV or orally
47950641|NCT00322101|DRUG|cyclosporine|Given IV or orally
47950642|NCT00322101|DRUG|fludarabine phosphate|Given IV
47950643|NCT00322101|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
47950644|NCT00322101|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
48478629|NCT05021887|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
47950645|NCT00322101|OTHER|laboratory biomarker analysis|Correlative studies
47950646|NCT00322101|GENETIC|cytogenetic analysis|Correlative studies
48106292|NCT04835987|DIAGNOSTIC_TEST|Pupillometry|Monitoring of nociception and autonomic nervous system by pupillometry in intraoperative.
48637205|NCT01362530|DRUG|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
48637206|NCT01362530|DRUG|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
48637207|NCT01362530|DRUG|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
47950647|NCT00322101|OTHER|flow cytometry|Correlative studies
47950648|NCT00322101|GENETIC|fluorescence in situ hybridization|Correlative studies
47950649|NCT00322101|OTHER|pharmacological study|Correlative studies
47950650|NCT00322101|GENETIC|polymorphism analysis|Correlative studies
47950651|NCT00322101|DRUG|tacrolimus|Given IV or orally
47950652|NCT00322101|DRUG|methotrexate|Given IV
47950653|NCT05582031|COMBINATION_PRODUCT|Regorafenib in combination with Tislelizumab|Regorafenib 30 mg/tablet + Tislelizumab 100 mg/10 ml vial
47950654|NCT02422173|DEVICE|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
47950655|NCT02422173|DEVICE|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
47950656|NCT02422173|DEVICE|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
47950657|NCT02422173|DEVICE|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
47950658|NCT04789239|DRUG|Sodium zirconium cyclosilicate|SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease
47950659|NCT04789239|OTHER|Placebo|Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
47950660|NCT01806558|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
47950661|NCT00200642|DEVICE|Stretta® System|
47950662|NCT04979104|PROCEDURE|Hip arthroplasty with SL Cementless|Total or partial hip arthroplasty with implant of SL cementless femoral stem.
47950663|NCT04352946|DRUG|Hydroxychloroquine Pre-Exposure Prophylaxis|HCQ PreP 400mg daily
47950664|NCT04352946|DRUG|Placebo oral tablet|Placebo tablets 400mg daily
47950665|NCT06680960|OTHER|Trunk stabilisation exercises|This exercise program includes aerobic exercise, resistance exercise and trunk stabilisation training for eight weeks.
47950666|NCT06680960|OTHER|Respiratory exercises|This exercise program includes aerobic exercise, resistance exercise and respiratory exercise training for eight weeks.
47950667|NCT06623344|OTHER|Magnetic Resonance Imaging with or without Contrast|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
47950668|NCT00002240|DRUG|Atazanavir|
47950669|NCT00002240|DRUG|Nelfinavir mesylate|
47950670|NCT00002240|DRUG|Stavudine|
47950671|NCT00002240|DRUG|Didanosine|
47950672|NCT06281938|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
47950673|NCT06281938|OTHER|Standard care weight estimation|Standard care (unspecified) will be used to determine weight-based dosing and other management.
47950674|NCT03610360|DRUG|MesoPher|Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
47950675|NCT02819869|DRUG|Statin and Metformin use|
47950676|NCT06052306|DRUG|BAY3546828|Intravenous (IV) infusion on Day 1 of each cycle.
48637208|NCT01362530|DRUG|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
48637209|NCT01362530|DRUG|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
47950677|NCT06052306|DRUG|BAY2616505|Each participant in the substudy will receive the BAY2616505 administered at baseline (Day 1) by intravenous (i.v.), after completion of the screening period and before the first dose of BAY3546828 in Cycle 1.
47950678|NCT06052306|DRUG|BAY2315493|If the planned dose of total antibody is more than 1 mg, BAY2315493 will be administered by intravenous (i.v.), starting one hour prior to the i.v. injection of BAY2616505.
47950679|NCT05526391|DRUG|TAK-341|TAK-341 IV infusion
47950680|NCT05526391|DRUG|Placebo|TAK-341 placebo-matching IV infusion
47950681|NCT05730699|BIOLOGICAL|divozilimab|anti-CD20 monoclonal antibody
47950682|NCT03929510|DRUG|14C-PF-06651600|Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
47950683|NCT03929510|DRUG|14C-PF-06651600 IV|IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
47950684|NCT03929510|DRUG|PF-06651600|Oral solution 200mg
47950685|NCT04336410|DRUG|INO-4800|INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit.
47950686|NCT04336410|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit.
47950687|NCT06681155|DIAGNOSTIC_TEST|Assessment of plaque morphology, structure, and stability in non-culprit lesions|Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.
47950688|NCT04200560|OTHER|Rhythmic Handgrip Exercise|60 minute rhythmic handgrip exercise
47950689|NCT04200560|OTHER|Chronic Exercise Training|Handgrip exercise training consisting of three 60-minute training sessions per week for eight weeks.
47950690|NCT00591994|DRUG|piribedil|50 mg once a day, after lunch 3 month therapy
47950691|NCT00240695|DRUG|galantamine hydrobromide|
47950692|NCT00763048|DRUG|Fluoride|Brush twice daily for 6 weeks
47950693|NCT00763048|DRUG|Fluoride, triclosan|Brush twice daily
47950694|NCT05100901|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.
47950695|NCT04736342|OTHER|PALI questionaire|Survey comprised of a series of multiple choice questions
48637210|NCT01362530|DRUG|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
48637211|NCT01362530|DRUG|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to \<12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to \<12 years of age
47950696|NCT01491971|DRUG|Degarelix|
47950697|NCT03228420|DEVICE|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
47950698|NCT03228420|OTHER|CMM|Conventional Medical Management
47950699|NCT00808561|OTHER|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
47950700|NCT00808561|OTHER|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
47950701|NCT01807039|PROCEDURE|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
47950702|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
48637212|NCT01362530|DRUG|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
48637213|NCT05219344|PROCEDURE|Tissue flossing|After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
48637214|NCT03434301|DEVICE|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
48637215|NCT03434301|DEVICE|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
48106293|NCT02498158|DEVICE|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~1. anatomical scan according to standard protocol~2. functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
48637216|NCT02883049|DRUG|Clofarabine|Given IV
48637217|NCT02883049|DRUG|Cyclophosphamide|Given IV
48637218|NCT02883049|DRUG|Cytarabine|Given IT, IV, or SC
48637219|NCT02883049|DRUG|Dasatinib|Given PO
48637220|NCT02883049|DRUG|Daunorubicin Hydrochloride|Given IV
47913974|NCT05592587|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during inferior alveolar nerve.|"The child will be provided inferior alveolar nerve during eye massage device producing vibratory stimulations. Children will be assessed by using a combination of measures: Wong-Baker faces and the Children's Fear Scale (self-report), heart pulse rate and blood pressure (physiological), and behavior (using Anxiety levels using Face - Legs - Activity - Cry - Consolability FLACC scale external evaluator). Acceptance will be measured using a two-point Likert scale"
47950703|NCT03956381|DEVICE|Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
47950704|NCT00482027|BIOLOGICAL|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
47950705|NCT04863235|BEHAVIORAL|Control Group|Eight week behavioural change program aimed to increase physical activity plus information on general health topics among individuals with prediabetes.
47950706|NCT04863235|BEHAVIORAL|Intervention Group|Eight week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes.
47950707|NCT00268866|BEHAVIORAL|Education|
47950708|NCT00921128|DRUG|Muscimol|
47950709|NCT01979965|DRUG|Ranolazine (Active drug)|Ranolazine therapy for three months
47950710|NCT01979965|DRUG|Placebo|Placebo therapy for three months
47950711|NCT04757246|OTHER|MouthLab Device|Use of MouthLab system
47950712|NCT03239600|DRUG|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
47950713|NCT03239600|DRUG|Placebo|Placebo solution will be administered by IV infusion.
47950714|NCT03239600|DRUG|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
47950715|NCT05785351|PROCEDURE|Laparoscopic Bariatric Surgery|Laparoscopic Bariatric Surgery: Gastric Sleeve and Roux-en-Y Gastric Bypass
47950716|NCT01303861|DRUG|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
47950717|NCT01303861|DRUG|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
48106294|NCT01729819|DRUG|Tolterodine tartrate extended release capsules|
48106295|NCT01729819|DRUG|Desmopressin orally disintegrating tablets|
48637221|NCT02883049|DRUG|Dexamethasone|PO or IV
48637222|NCT02883049|DRUG|Doxorubicin Hydrochloride|Given IV
48637223|NCT02883049|DRUG|Etoposide|Given IV
48637224|NCT02883049|DRUG|Hydrocortisone Sodium Succinate|Given IT
48637225|NCT02883049|OTHER|Laboratory Biomarker Analysis|Correlative studies
48637226|NCT02883049|DRUG|Leucovorin Calcium|Given PO or IV
48637227|NCT02883049|DRUG|Mercaptopurine|Given PO
48637228|NCT02883049|DRUG|Methotrexate|Given IT and IV
48637229|NCT02883049|DRUG|Pegaspargase|Given IV
47913975|NCT00713167|DRUG|Grape Seed Extract (Vitagrape)|"Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months"
47950718|NCT01303861|DRUG|Nicotine patches|"Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week"
47950719|NCT01303861|DRUG|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
48637230|NCT02883049|DRUG|Prednisone|Given PO or IV
48637231|NCT02883049|RADIATION|Radiation Therapy|Undergo radiation therapy
48106296|NCT01729819|DRUG|Placebo orally disintegrating tablets|
48106297|NCT02390258|DRUG|10mg XEN-D0103|
48106298|NCT02390258|DRUG|Placebo|
48106299|NCT02390258|DRUG|30mg XEN-D0103|
48106300|NCT02390258|DRUG|60mg XEN-D0103|
48106301|NCT02390258|DRUG|120mg XEN-D0103|
48106302|NCT02390258|DRUG|200mg XEN-D0103|
48106303|NCT02390258|DRUG|150mg XEN-D0103|
48106304|NCT03870191|OTHER|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
48106305|NCT01986686|PROCEDURE|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
48106306|NCT04842604|DRUG|Glasdegib|25 mg or 100 mg tablet
48106307|NCT04842604|DRUG|Azacitidine|100 mg/vial powder for 25 mg/mL suspension for injection
48106308|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
48106309|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft. The injectable PRF will be added to the particulate demineralized dentin graft forming sticky demineralized tooth graft then inserted in the extraction socket and covered then suturing
48478630|NCT00992212|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
48106310|NCT06374784|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
48106311|NCT01552304|OTHER|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
48106312|NCT01552304|OTHER|Control group|
48106313|NCT02787694|OTHER|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
48106314|NCT02787694|DEVICE|treadmill|
48478631|NCT03297619|BEHAVIORAL|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
48637232|NCT02883049|DRUG|Thioguanine|Given PO
47950720|NCT01513096|DRUG|itopride|itopride, 10mg, twice per day, for 1 day
48637233|NCT02883049|DRUG|Vincristine Sulfate|Given IV
47950721|NCT02353520|OTHER|motricity index strength assessment|
47950722|NCT05185323|OTHER|Breastfeeding usual known aids and osteopathic treatment|Breastfeeding usual known aids and osteopathic treatment
47950723|NCT05185323|OTHER|Breastfeeding usual known aids|Breastfeeding usual known aids
47950724|NCT02645097|PROCEDURE|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
47950725|NCT04976062|DIAGNOSTIC_TEST|Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)|The NIRS-IVUS technique is an intravascular imaging technique, combining morphological information derived from intravascular ultrasound (IVUS) and molecular information on plaque composition, namely its respective lipid-core burden, using spectral differences between cholesterol and collagen, detected by near-infrared spectroscopy (NIRS). A combined NIRS-IVUS pullback results in a color-coded map indicating the probability of lipid-rich plaque presence in yellow, co-registered to the corresponding IVUS cross-sections.
47950726|NCT06679816|DRUG|Hormone replacement therapy|Perioperative Hydrocortisone Reduction Therapy
47950727|NCT06679816|DRUG|Placebo|Perioperative placebo Reduction Therapy
48106315|NCT04666818|DEVICE|Use of Flash Glucose Monitoring|Participants in the intervention group were advised to monitor glucose levels by means of flash glucose system.
48106316|NCT06140680|BEHAVIORAL|LifelongU|"The LifelongU intervention is an abbreviation name from LifelongU: Cultivating Physical Literacy for University \& Beyond. LifelongU is a unique and coined term that symbolizes the program's commitment to promoting physical literacy as a lifelong journey. It combines the words Lifelong and University to represent an intervention that focuses on physical literacy development not only during the university years but also throughout a person's entire life. The name is designed to convey the idea that physical literacy is an asset that will benefit individuals in all aspects of life, even after they leave the university."
48106317|NCT06140680|BEHAVIORAL|Physical education|The control group received 12-week traditional physical education lesson as usual.
48106318|NCT05381571|OTHER|Motivating reminiscence physical therapy|The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
48106319|NCT00005786|DRUG|arsenic trioxide|Given IV
48106320|NCT00005786|OTHER|laboratory biomarker analysis|Correlative studies
48478632|NCT03297619|BEHAVIORAL|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
48478633|NCT00329628|DRUG|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
48478634|NCT00329628|DRUG|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
47950728|NCT00702689|DRUG|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)"
48637234|NCT03967574|DEVICE|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
47950729|NCT02682771|DEVICE|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
47950730|NCT02682771|DEVICE|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
47950731|NCT02682771|PROCEDURE|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
47950732|NCT05376449|BEHAVIORAL|HealthPartners NeuroWell Exercise Program|A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
48637235|NCT02096965|DRUG|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
47950733|NCT04568421|DRUG|Immunosuppressive Agents|Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
47950734|NCT00002665|DRUG|asparaginase|10,000 units/d IV or IM 15 - 24
47950735|NCT00002665|DRUG|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
47950736|NCT00002665|DRUG|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
47950737|NCT00002665|DRUG|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
47950738|NCT00002665|DRUG|dexamethasone|main: 10 mg/m2/day PO 1 - 28
47950739|NCT00002665|DRUG|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
47950740|NCT00002665|DRUG|etoposide|60 mg/kg based on ideal body weight day -3
48478635|NCT03469817|DIAGNOSTIC_TEST|MRI|"Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit."
48478636|NCT06472544|BEHAVIORAL|Culturally Grounded Intervention|Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
48478637|NCT05849688|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied.
48637236|NCT02096965|DRUG|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
48637237|NCT00527748|DEVICE|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
47950741|NCT00002665|DRUG|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC \< 3,000 /μl
48637238|NCT01730976|DIETARY_SUPPLEMENT|Vitamin D 2,000 I.U.|
47950742|NCT00002665|DRUG|mercaptopurine|con: 60 mg/m2 PO 1 - 28
47950743|NCT00002665|DRUG|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
48637239|NCT04938674|DEVICE|ultrasonic guidance|Standard process for blood collection using Ultrasonic Guided puncture
47950744|NCT00002665|DRUG|prednisone|"ind: 60 mg/m2/d PO 1 - 21\*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
47950745|NCT00002665|DRUG|thioguanine|main: 60 mg/m2/day PO 1 - 14
48637240|NCT03760666|DRUG|Brequinar/Brequinar + Ribavirin|The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
48637241|NCT04920292|DRUG|Oxfendazole|Oxfendazole is a benzimidazole anthelminthic drug.
47950746|NCT00002665|DRUG|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
47950747|NCT00002665|PROCEDURE|allogeneic bone marrow transplantation|day 0
47950748|NCT00002665|RADIATION|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
47950749|NCT01677546|DEVICE|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
48637242|NCT04920292|DRUG|Placebo|The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.
48637243|NCT05301699|OTHER|data analysis; validating the nomogram|Not Applicable. Our study did not involve intervention
47950750|NCT01677546|DEVICE|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
47950751|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
47950752|NCT04342273|DRUG|KW-6356|KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
48106321|NCT01346930|DRUG|Macitentan|10 mg, tablet, once daily
48106322|NCT00780663|DRUG|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
47950753|NCT04342273|DRUG|Placebo|Placebo will be administered once daily at Day 1 through Day 7
48106323|NCT06163586|OTHER|Neonatal Touch and Massage Therapy|Structured touch and massage therapy performed by certified providers.
48106324|NCT03187782|DIAGNOSTIC_TEST|ANSWatch|
48106325|NCT03031262|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
48106326|NCT03031262|DRUG|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
48106327|NCT02947568|OTHER|non-interventional study|
47950754|NCT04342273|DRUG|Moxifloxacin|Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
47950755|NCT02758171|DRUG|Empagliflozin|
48106328|NCT00000919|DRUG|Indinavir sulfate|
48106329|NCT00000919|DRUG|Lamivudine/Zidovudine|
48106330|NCT00000919|DRUG|Ritonavir|
48106331|NCT00000919|DRUG|Hydroxyurea|
48478638|NCT05849688|OTHER|Bicycle Ergometry Training|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied + bicycle ergometry training
48478639|NCT03201978|DRUG|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
47950756|NCT02758171|DRUG|Linagliptin|
47950757|NCT02602392|BEHAVIORAL|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
47950758|NCT02602392|BEHAVIORAL|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
47950759|NCT05384860|DEVICE|Auricular Trauma Protocol (ATP) Acupuncture|Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.
47950760|NCT05384860|OTHER|No Acupuncture Group|This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
47950761|NCT02617888|RADIATION|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
48106332|NCT00000919|DRUG|Abacavir sulfate|
48106333|NCT00000919|DRUG|Amprenavir|
48106334|NCT00000919|DRUG|Nelfinavir mesylate|
48106335|NCT00000919|DRUG|Efavirenz|
48106336|NCT00000919|DRUG|Lamivudine|
48106337|NCT00000919|DRUG|Stavudine|
48106338|NCT00000919|DRUG|Zidovudine|
47950762|NCT05249699|DRUG|Isoniazid|prevent the development of tuberculosis
48478640|NCT03201978|DRUG|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
48478641|NCT02971722|DRUG|JY09|2mg/1ml/bottle
47950763|NCT05249699|OTHER|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
48106339|NCT00000919|DRUG|Didanosine|
48106340|NCT00028093|DRUG|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
48106341|NCT00028093|DRUG|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
48106342|NCT03531853|DEVICE|hand-held swept source optical coherence tomography|images the eye
48106343|NCT03168204|BEHAVIORAL|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
48106344|NCT04025606|DRUG|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
48106345|NCT04025606|DRUG|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
48106346|NCT06260696|OTHER|No treatment is given|No treatment is given
48106347|NCT02467296|OTHER|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
48106348|NCT06450977|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
48106349|NCT06450977|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
48106350|NCT03621761|BEHAVIORAL|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
48478642|NCT02971722|DRUG|Placebo|1ml/bottle
48106351|NCT03621761|DRUG|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
48106352|NCT04580199|PROCEDURE|thyroidectomy|to excise the thyroid gland
48106353|NCT05165849|DRUG|GFS101A|GFS101A will be administrated intravenously Q3W.
48478643|NCT02842463|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|
48637244|NCT05885997|BEHAVIORAL|Supported HBPM program plus multifaceted implementation strategy|"Supported HBPM Program:~* Patients are loaned a wireless home BP device or use their own device~* Navigator or app support for onboarding and engaging patients in HBPM~* Nursing or app support for monitoring and triaging home BP data for extreme readings~* EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~* Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~* Prompts and reminders to increase clinician referrals~* Instructional materials for patients and clinicians~* Problem-solving meetings to tailor implementation for individual practices"
47913976|NCT00713167|DRUG|Placebo of Grape Seed Extract|"Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months"
47913977|NCT00336648|DRUG|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
47913978|NCT00336648|DRUG|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
48478644|NCT04846647|BEHAVIORAL|unexplained hypophoshatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
48478645|NCT05687682|BIOLOGICAL|AM-928|AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
48637245|NCT05885997|OTHER|Usual care|Usual care
48637246|NCT04293965|DRUG|Single ascending dose of X842|A total of 7 dose groups will be set for the ascending dose: 5.6 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg. In the 5.6 mg dose group, 4 subjects will receive X842; in the 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 225 mg dose groups, 8 subjects in each group will receive X842. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
48637247|NCT04293965|DRUG|Multiple ascending dose of X842|Two dose groups will be set, including the groups receiving the recommended phase II dose and a higher dose; Eight subjects will be enrolled in each group, with half male and half female, who will receive X842 once daily for 5 consecutive days. Each subject can only receive a certain dose level and cannot enter in multiple dose groups repeatedly.
48637248|NCT04293965|OTHER|Food Effect|Twelve subjects (appropriate ratio of male to female) screened for eligibility will be randomized into Group A and B. The 6 subjects in Group A will take the study drug (X842) in fasted condition and subject in Group B will take the study drug in fed condition in the 1st cycle. In the 2nd Cycle, subjects in Group A will take the study drug in fed condition, and subjects in Group B will take the study drug in fasted condition. The interval between the two cycles is at least 7 days.
47913979|NCT00336648|PROCEDURE|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
47913980|NCT01814241|DRUG|Open label peanut OIT|Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
48478646|NCT02729779|OTHER|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
48620081|NCT04492670|PROCEDURE|Tui-na|For administering of Tui-na manipulation practice, responsible Tui-na CMP must have at least 2 years of clinical experience. The pre-trial workshops led by a senior practitioner will be organized to ensure standardization of Tui-na treatment manipulation and procedures.
48620082|NCT04492670|DRUG|Du-Huo-Ji-Sheng-Tang (DHJST)|This study medication is derived from Du-Huo-Ji-Sheng-Tang (DHJST) and concentrated Chinese Medicine granules will be used.
47950764|NCT03867279|OTHER|Flossing|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.
47950765|NCT03867279|OTHER|Reeducation exercises|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
47950766|NCT06196346|BEHAVIORAL|Psychotherapy|see group description
48637249|NCT01356056|DEVICE|Kinesia HomeView|Quantifies motor symptom severity in the home
48637250|NCT04105660|OTHER|Training for EEG monitoring|Training for reading EEG curves during anaesthesia
48637251|NCT04105660|OTHER|Standard monitoring|Standard monitoring including clinical parameters and BIS index
47950767|NCT02829073|DEVICE|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
48637252|NCT04180423|DEVICE|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
48637253|NCT04180423|DEVICE|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
47950768|NCT02829073|DEVICE|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
47950769|NCT05626816|DEVICE|Genital Nerve Stimulation|Electrical stimulation applied to the genital nerve with surface electrodes using an off the shelf TENS unit (Ultima Plus). First, an amplitude threshold for the pudendo-anal reflex responses will be determined. Then, sham (1-2 Hz) and effective stimulation (20 Hz) will be briefly applied to record responses. Then, stimulation will be applied in random presentation order to record any changes in anorectal manometry outcomes due to both sham and effective stimulation.
47950770|NCT05626816|DIAGNOSTIC_TEST|Clinical exam|Examination by physician determines the presence of pelvic reflexes (pudendo-anal and bulbocavernosus) which are essential for GNS to have an effect.
48637254|NCT04165096|BIOLOGICAL|Pembrolizumab|IV infusion
47950771|NCT05626816|DIAGNOSTIC_TEST|Collection of SCI common data elements|Data regarding participant demographics, history of injury, and medical history will be collected.
48106354|NCT05165849|DRUG|Toripalimab|Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
48106355|NCT00954707|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
48106356|NCT00954707|DRUG|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
48106357|NCT04297982|OTHER|Mandala Activity|Mandala is a method of expressing one's feelings and thoughts. The person draws and paints the paper in a round shape.
48106358|NCT04297982|OTHER|Routine nursing care|Interventions routinely implemented by nurses in the clinic
48106359|NCT05458141|BEHAVIORAL|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
48106360|NCT06552676|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy is a widely used technique in intensive care. It involves creating a passage between the tracheal lumen and the outside, through which a cannula is placed.
48106361|NCT00272935|DRUG|Cenestin 0.3 mg Tablets|1 tablet daily
48106362|NCT00272935|OTHER|Placebo|1 tablet daily
48106363|NCT05154955|DRUG|10XB-101 Solution for Injection|One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
48620083|NCT06516224|OTHER|Liftactiv® B3 Serum|In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
48637255|NCT04165096|BIOLOGICAL|Boserolimab|IV infusion
48637256|NCT04165096|BIOLOGICAL|MK-4830|IV infusion
48637257|NCT04165096|DRUG|diphenhydramine|PO
48637258|NCT04165096|DRUG|acetaminophen|PO
47913981|NCT03444636|DRUG|Ropivacaine/Fentanyl|Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
47913982|NCT03444636|DRUG|Bupivacaine/Fentanyl|Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
47913983|NCT05603234|BEHAVIORAL|Symptom Monitoring|Reporting symptoms each day via a symptom questionnaire
47913984|NCT02780011|DRUG|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
47913985|NCT02780011|DRUG|Alsertib|Aurora A kinase inhibitor
47913986|NCT04229537|BIOLOGICAL|SCT-I10A|200 mg intravenous (IV) on Day 1 of Q3W.
47913987|NCT04229537|BIOLOGICAL|SCT200|6mg/kg intravenous (IV) on Day 1 of QW, then 8mg/kg intravenous (IV) on Day 1 of Q2W
47913988|NCT04229537|OTHER|Chemotherapy|Capecitabine and Oxaliplatin.
47913989|NCT04343105|PROCEDURE|pecto-intercostal plane block|under ultrasound guidance, pecto-intercostal plane block will be performed between 3rd and 4th rib 2 cm lateral to sternal border in supine position at the interfascial plane between pectoralis major muscle and intercostal muscles
47913990|NCT00554710|DRUG|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
47913991|NCT00554710|DRUG|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
47913992|NCT01237015|DEVICE|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
47913993|NCT00916929|DEVICE|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
47913994|NCT01859520|PROCEDURE|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
47913995|NCT01236976|DEVICE|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It is registered with the FDA (Regulation Number 890.5380).
47913996|NCT01236976|DEVICE|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD).
47913997|NCT01236976|OTHER|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality.
47913998|NCT01236976|OTHER|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
47913999|NCT02014337|DRUG|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
47914000|NCT04596059|OTHER|Frisolac Gold Intensive HA|Regular medical care
48637259|NCT04165096|BIOLOGICAL|MK-0482|IV infusion
48637260|NCT01642667|DRUG|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
48637261|NCT01642667|DRUG|Placebo|
48637262|NCT03638271|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
48637263|NCT06466772|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
48637264|NCT06466772|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
48637265|NCT06466772|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
48637266|NCT03094221|DEVICE|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
48637267|NCT05098236|OTHER|Training in the Blind Field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
48637268|NCT05098236|OTHER|Training in the Sighted Field|This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
47950772|NCT05626816|DIAGNOSTIC_TEST|Bowel function survey completion|Two surveys will be conducted to assess the bowel function of the participant. The International SCI Bowel Function Basic Data Set (ISCI BF BDS v2.1) and the SCI Qulaity of Life Bowel Management Difficulties (SCI-QoL BMD) survey scales collect data on overall bowel function and how any difficulties impact the participants quality of life.
47950773|NCT05626816|DIAGNOSTIC_TEST|International Standard for Neurological Classification of SCI (ISNCSCI)|The physician will conduct the ISNCSCI to determine the level and severity of injury to the spinal cord. This is done by determining the ability to detect light touch and pinprick stimulation. Outcomes will be a Spinal Injury Association Impairment Scale (AIS) grade of A-D.
47950774|NCT05626816|DIAGNOSTIC_TEST|Response to genital nerve stimulation (GNS)|GNS will be applied to determine if there is a response in the participant. If the participant has no response to the stimulation they will be excluded from the second visit as it is dependent on the ability to respond to GNS.
47950775|NCT05626816|DIAGNOSTIC_TEST|Anorectal Manometry testing (ARM)|"The participant will be instrumented for ARM testing. This requires a special balloon catheter to be inserted into the anus and secured, surface electrode pads being applied to the anal sphincter, and electrode pads being applied to the genital nerve stimulation sites.~Once instrumented, the participant will be tested with the London Classification procedure. This procedure asks the participant to perform several actions (squeeze to withhold a bowel movement, push to have a bowel movement, and cough) as well as inflating the balloon on the catheter to determine reflex thresholds (RAIR, retroanal inhibitory reflex which relaxes the anal sphincter in response to rectal distension) and sensory thresholds (first senstation,"
47950776|NCT04123652|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
47950777|NCT05352178|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
47950778|NCT05352178|DRUG|Androgen deprivation therapy|Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
47950779|NCT05352178|DRUG|Androgen receptor targeted therapy|Enzalutamide
47950780|NCT02626767|OTHER|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
48106364|NCT05154955|DRUG|10XB-101 Vehicle Solution for Injection|This is the placebo control
48298614|NCT05196997|OTHER|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
48637269|NCT01368731|PROCEDURE|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
48637270|NCT00969085|DRUG|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams"
48298615|NCT06175312|OTHER|Stimulus properties: salience-defining feature|The feature used to define a salient location will be varied across trials (checkerboard contrast; motion direction; color hue)
48637271|NCT00969085|BEHAVIORAL|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
48637272|NCT00969085|OTHER|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
48637273|NCT05163535|DRUG|VM-1500A-LAI|VM-1500A (parent drug of elsulfavirine) IM injection dosage form
48106365|NCT05527236|OTHER|Breathing Exercise|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercises again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.
48298616|NCT06175312|OTHER|Stimulus properties: magnitude of salience|The magnitude of the salient location will be varied across trials independently from salience-defining feature (based on feature contrast)
48298617|NCT04340830|PROCEDURE|Free gingival graft|Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
48637274|NCT05163535|OTHER|ELPIDA®|Elsulfavirine capsules
47950781|NCT04872153|BEHAVIORAL|Dividat Senso Exergames|"The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min)."
48298618|NCT05082571|DRUG|vadadustat|Vadadustat tablet orally once a day for 52 weeks
48298619|NCT00417365|DEVICE|WaterWorks Douching Device|
48298620|NCT02847936|PROCEDURE|vicryl plus suture|episiotomy with triclosan-coated sutures
48298621|NCT02847936|PROCEDURE|vicryl suture|episiotomy with non antibacterial coated suture
48298622|NCT00434850|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
48298623|NCT00434850|DRUG|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
48637275|NCT03721965|DRUG|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
48637276|NCT03721965|DRUG|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
48637277|NCT06514248|DEVICE|V5med Lung AI|"During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the left window and the same original without any AI mark with be display on the right window. Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension."
48637278|NCT03238157|DRUG|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
48637279|NCT00002480|RADIATION|radiation therapy|
48637280|NCT05861453|DRUG|Epeleuton|Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
48637281|NCT06126744|BIOLOGICAL|MVR-C5252|MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
48637282|NCT05889000|OTHER|questionnaire responses|questionnaire responses - Pelvic Varicose Veins Questionnaire (PVVQ) and Pelvic Venous Clinical Severity Score (PVCSS)
48637283|NCT01959971|DRUG|alirocumab|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
48298624|NCT00434850|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
48298625|NCT00434850|BIOLOGICAL|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
48298626|NCT00434850|DRUG|Sirolimus|Maintenance immunosuppressive therapy
48298627|NCT00434850|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
48298628|NCT00434850|BIOLOGICAL|Etanercept|Blocks TNF-alpha which is toxic to islet cells
48298629|NCT00724035|DRUG|Midazolam|"Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus"
48298630|NCT00724035|DRUG|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
48298631|NCT00724035|DRUG|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
48298632|NCT00724035|PROCEDURE|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
48637284|NCT01959971|DRUG|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
47950782|NCT04296110|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
47950783|NCT04296110|OTHER|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
47950784|NCT01388595|DRUG|FLUTICASONE PROPRIONATE|1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
48298633|NCT00724035|PROCEDURE|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
47950785|NCT01388595|DRUG|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
47950786|NCT01388595|DRUG|PLACEBO|4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
47950787|NCT00560768|DEVICE|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~* A right ventricular defibrillation lead~* In case of use of a dual chamber ICD a right atrial pacing lead~* A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
47950788|NCT00524654|PROCEDURE|HVLA chiropractic manipulation|
47950789|NCT05593133|OTHER|Pnf exercises|"PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks."
47950790|NCT05593133|OTHER|Gait training exercises|gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
47950791|NCT04314934|DRUG|ANAVEX2-73|Oral capsules
47950792|NCT00834678|DRUG|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
47950793|NCT00834678|DRUG|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
47950794|NCT00834678|DRUG|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
47950795|NCT02703233|DRUG|Nitrous Oxide|
47950796|NCT02703233|OTHER|Oxygen|
47950797|NCT00599950|DRUG|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
47950798|NCT04206059|RADIATION|MRI|A non-contrast brain MRI will be acquired for localizing EEG slow waves
47950799|NCT04206059|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
48298634|NCT00724035|PROCEDURE|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
48298635|NCT05592470|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).|Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
48637285|NCT04933058|DRUG|IV acetaminophen|Pain management
48637286|NCT04933058|DRUG|IV fentanyl|Pain management
48637287|NCT03167424|DEVICE|Treatment of restenosis|Treatment of in-stent restenosis
47950800|NCT04206059|DIAGNOSTIC_TEST|Home sleep study|Unattended home sleep studies will be conducted on the night preceding sedation and on the night following sedation to assess changes in slow wave homeostasis.
47950801|NCT04206059|OTHER|Acoustic stimulation (65db) up-slope of EEG with QST|Acoustic stimulation (65 db) synchronized in-phase with the up-slope of EEG slow waves
47950802|NCT04206059|OTHER|Acoustic stimulation (65db) down-slope of EEG with QST|65 dB acoustic stimulation synchronized with the down-slope of the EEG slow waves (anti-phase)
47950803|NCT04206059|OTHER|0 db with QST|sham stimulation (0 dB volume)
47950804|NCT04206059|DRUG|Dexmedetomidine|All participants will receive dexmedetomidine with sedation titrated step-wise to 2, 3 or 4 ng/ml
47950805|NCT04206059|OTHER|Breathe-Squeeze Task|All participants will be asked to perform the breathe-squeeze task throughout the experiment. This will allow us to determine loss and return of responsiveness.
47950806|NCT04824976|DIETARY_SUPPLEMENT|Blueberry|freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal
47950807|NCT04824976|DIETARY_SUPPLEMENT|Placebo|matched powder maltodextrin twice daily = 60kcal
47950808|NCT03134833|BEHAVIORAL|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
47950809|NCT03134833|BEHAVIORAL|Peer Support|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
47950810|NCT03134833|BEHAVIORAL|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
47950811|NCT05342610|OTHER|Distant reiki|Reiki; It is the transfer of energy to other people by the hands of the person who receives the theoretical training and attunement (initiation) from the reiki master, close or distant. When the hands are brought closer to the body in suitable positions or when the reiki practitioner visualizes the person in his/her thoughts, the energy flow starts spontaneously and the transferred energy is shaped according to the needs of the reiki recipient. The biggest advantage of Reiki; It is an easy and cost-effective method to ensure that the individual restores the balance between body, mind and spirit, has no side effects, has no negative effects on behavior and attitudes.
47950812|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
47950813|NCT02091908|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
47950814|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
47950815|NCT02091908|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
47950816|NCT04686604|OTHER|Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)|Providers will receive a best practice alert for each of their eligible patients upon opening of the order entry screen in the patient's medical record. The alert will inform the provider to the presence of HFrEF and of the patient's current left ventricular ejection fraction, most recent blood pressure and heart rate, most recent potassium and estimated glomerular filtration rate, and current evidence-based medications for HFrEF. It will also provide access to an order set with recommended evidence-based HFrEF therapies as well as a link to the best available guideline-recommended information regarding the treatment of heart failure.
47950817|NCT03970642|OTHER|Video directly observed therapy|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
47950818|NCT06400875|DEVICE|InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM)|weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and compression therapy
47950819|NCT01923987|RADIATION|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
47950820|NCT01923987|DRUG|Chemotherapy|"* Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~* Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~* Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~* 5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~* Bevacizumab 5 mg/kg IV over 90 mins on Day 1~* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~* FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~* Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
47950821|NCT01923987|PROCEDURE|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
47950822|NCT04406974|PROCEDURE|Surgery or treatment for local recurrence|Surgery or treatment for local recurrence
48106366|NCT05527236|OTHER|Virtual Reality|The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm) the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
48106367|NCT01544140|DRUG|Midazolam|Oral syrup 7.5 mg, single dose
48298636|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
48637288|NCT06582771|DRUG|Sotorasib|Sotorasib 960 mg (8 pills) daily
48298637|NCT00569920|DRUG|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
48106368|NCT01544140|DRUG|vandetanib|Oral tablets, 800 mg, single dose
48298638|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
48298639|NCT01853124|DRUG|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
48298640|NCT01853124|DRUG|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
48298641|NCT01806870|DIETARY_SUPPLEMENT|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
48298642|NCT03554499|PROCEDURE|Bichectomy with hydrodissection|Intraoral removal of buccal fat pads using hydrodissection technique
48298643|NCT03554499|PROCEDURE|Bichectomy|Intraoral removal of buccal fat pads using conventional technique
48298644|NCT01193725|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
48298645|NCT01193725|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
48298646|NCT01193725|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
48106369|NCT04577625|DIETARY_SUPPLEMENT|Lactobacillus reuteri (L. reuteri)|L.reuteri high or low dose with vitamin D3 compared to vitamin D3 only
48106370|NCT05407480|OTHER|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
48298647|NCT05967234|BEHAVIORAL|Telehealth solution|Telehealth solution offered for breastfeeding education.
48637289|NCT03438032|DIAGNOSTIC_TEST|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
47950823|NCT04406974|PROCEDURE|Surgery for advanced colorectal cancer|Surgery for advanced colorectal cancer
48298648|NCT03621969|OTHER|Physical exam and medical history|This will be completed by a medical doctor on the research team
48298649|NCT03621969|DIAGNOSTIC_TEST|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
48298650|NCT03621969|DEVICE|Patient Instruction and use of Device (RePlay)|"1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
47950824|NCT06218212|DIETARY_SUPPLEMENT|Renastart formula|"* Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~* Readjusting dosage ratio according to serum electrolytes levels especially potassium."
47950825|NCT06218212|DRUG|calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.|calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
48298651|NCT04770168|BEHAVIORAL|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
48298652|NCT05941884|DIAGNOSTIC_TEST|Immunohistochemistry staining,|"Tissue samples:~* Histopathological examination: Hematoxylin and Eosin slides will be prepared and examined.~  * The only dependable criterion for the diagnosis of bilharzial infestation is the microscopic detection of Bilharzia ova in pathological sections.~ * Pathology (cystitis- cancer and its grade staging will be reported in accordance with the 2022 World Health Organization Classification of Tumors of the Urinary System (17).~* To quantify levels of Nuclear factor kappa B and protein kinase c α:~  * Immunohistochemistry according to the manufacturer's instructions."
48637290|NCT04621786|DEVICE|Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface|The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
48637291|NCT04138082|OTHER|Exposition to high-dB soundtrack|Already stated
48637292|NCT04191733|DEVICE|KINCISE(TM) Surgical Automated System|Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System
48637293|NCT04597333|DRUG|Dinoprostone|Dinoprostone vaginal insert.
47950826|NCT03893175|DRUG|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
47950827|NCT03893175|DRUG|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
47950828|NCT03893175|DRUG|Placebo|By mouth
48298653|NCT05941884|DIAGNOSTIC_TEST|microscopic examination of urine|"Urine samples:~* Mic roscopic examination (detection of S. haematobium egg - egg counting)~* Detection of HSP 70 Measurements: indirect ELISA will be used to quantify HSP concentrations in urine."
47950829|NCT03893175|DRUG|Oxycodone|5 mg by mouth every 6 hours as needed for pain
47950830|NCT01135823|PROCEDURE|Patient survey|
47950831|NCT04127942|PROCEDURE|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
47950832|NCT04348279|DEVICE|propylene mesh|propylene mesh as a palatal stent for palatal wound
47950833|NCT00376376|DRUG|levofloxacin at 250, 500, 750, and 1000 mg doses|
48106371|NCT02706067|DRUG|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent \[%\] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
48106372|NCT05213715|OTHER|assessment|assessment of upper extremity functions, somatosensorial functions and proprioseption of upper extremity
48298654|NCT05553379|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement at each visit
47950834|NCT00415350|DRUG|Azithromycin|Azithromycin Tablet 250 mg daily
48298655|NCT02341014|DRUG|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
48106373|NCT04688268|DRUG|deep neuromuscular blockade|Train of Four=0/4, Post tetanic count 1-2
48106374|NCT01726530|DRUG|transdermal fentanyl patch (50 mcg/hour)|
48106375|NCT01726530|DRUG|Placebo|
48106376|NCT05907720|BEHAVIORAL|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
48106377|NCT06010888|DRUG|Fruquintinib+mFOLFOX6/FOLFIRI|Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
47950835|NCT00415350|OTHER|Placebo|Placebo tablet 1 daily
47950836|NCT04306029|OTHER|Postpartum Family Planning Package|"Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application."
48106378|NCT05773612|OTHER|Rock Steady Boxing Class|Rock Steady Boxing is a non-contact fitness program designed specifically for people with Parkinson's Disease.
48298656|NCT02341014|DRUG|Romidepsin|
47914001|NCT02129088|DRUG|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
47914002|NCT02129088|DRUG|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
47914003|NCT02314637|DRUG|Teneligliptin|Teneligliptin for 52 weeks
47914004|NCT02314637|DRUG|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
47914005|NCT02753452|BEHAVIORAL|Residential Immersive Life Skills programming|
47914006|NCT02753452|BEHAVIORAL|Non-residential life skills programming|
47914007|NCT02361632|DIETARY_SUPPLEMENT|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
47914008|NCT02565667|DEVICE|KOL|KOL staple was used for rectal anastomosis
47914009|NCT02565667|DEVICE|traditional staple|traditional staple was used for rectal anastomosis
47914010|NCT04254770|DEVICE|ADA approved Manual Toothbrush|ADA approved Manual Toothbrush
47914011|NCT04254770|DEVICE|Marketed Power Toothbrush|Marketed Power Toothbrush
47950837|NCT00358423|DRUG|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
48106379|NCT01461213|DRUG|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
48106380|NCT03161392|DIAGNOSTIC_TEST|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
48298657|NCT02341014|DRUG|Lenalidomide|
48298658|NCT01941368|DIETARY_SUPPLEMENT|Placebo|
48298659|NCT01941368|DIETARY_SUPPLEMENT|HMB-FA|
48637294|NCT04597333|DEVICE|Cervical ripening balloon.|Double lumen cervical ripening balloon.
47950838|NCT00358423|DRUG|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
47950839|NCT00589901|DRUG|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
47950840|NCT01931930|DIETARY_SUPPLEMENT|Perilla extract|
47950841|NCT01931930|DIETARY_SUPPLEMENT|Maltodextrin|
47950842|NCT03007407|DRUG|durvalumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
47950843|NCT03007407|DRUG|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
47950844|NCT03001882|BIOLOGICAL|Nivolumab|Specified dose on specified days
47950845|NCT03001882|BIOLOGICAL|Ipilimumab|Specified dose on specified days
47950846|NCT03584061|PROCEDURE|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
47950847|NCT04677790|BEHAVIORAL|assigned period of specific dietary restrictions|Step by step gradual introduction of egg containing food products
47950848|NCT05847361|DIAGNOSTIC_TEST|BH4 blood level|from admission to END OF PREGNANCY, a blood sample is taken.
47950849|NCT06681116|DIETARY_SUPPLEMENT|structured nano-water|Hydrochlorothiazide is a drug used to prevent recurrent renal stone formation in patients with idiopathic hypercalciuria
47950850|NCT06681116|DRUG|Hydrochlorothiazide (HCTZ)|hydrochlorothiazide is a drug used to prevent recurrent stone formation i patients with idiopathic hypercalciuria
47950851|NCT06681116|OTHER|ordinary bottled drinking water|Patients with idiopathic hypercalciuria receiving regular bottled drinking water as a placebo to see its effect.
47950852|NCT06324760|DIETARY_SUPPLEMENT|Alpha-lipoic acid combined with B vitamins|The investigational product utilized in this research, Tiobec® 400 is a dietary supplement enriched with ALA, B vitamins, and vitamins E and C. T400 is designed to mitigate oxidative stress and support the optimal functioning of the nervous system
47950853|NCT04968795|OTHER|Heartfulness Meditation|A four-week Heartfulness Wellness seminar, where people are exposed to Heartfulness Meditation and its meditation tools. Participants experience: Heartfulness Guided Relaxation, Heartfulness Meditation and Heartfulness Unwinding/Rejuvenation Technique.
47950854|NCT01578330|DRUG|Fingolimod|Fingolimod 0.5mg orally once a day without food.
47950855|NCT03138304|BEHAVIORAL|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
47950856|NCT03138304|BEHAVIORAL|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
47950857|NCT02403856|DRUG|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
47950858|NCT02403856|DRUG|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
47950859|NCT02403856|PROCEDURE|Ultrasound-guided Needling and Lavage|
47950860|NCT04752683|OTHER|MyBuddy Employee Wellbeing App|"The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data)."
47950861|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Cognitive Behavioral Therapy|10-session LGBTQ-affirmative psychotherapy using CBT techniques
47950862|NCT05509166|BEHAVIORAL|LGBTQ-affirmative Treatment-As-Usual|10-session LGBTQ-affirmative psychotherapy
47950863|NCT05688449|DRUG|Bupivacaine-fentanyl|A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
47950864|NCT05688449|DRUG|Saline|A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
47950865|NCT02891694|OTHER|in vitro immuno-histo-chemical analysis of corneal epithelium|
48637295|NCT01123525|DRUG|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
47950866|NCT05738629|DRUG|Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops|Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
48298660|NCT01941368|PROCEDURE|High Intensity Interval Training|
48637296|NCT01856829|DIETARY_SUPPLEMENT|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
48106381|NCT03161392|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
48106382|NCT06343896|OTHER|monitorization reliability|evaluation of the use of the integral pulmonary index in the child patient group
48106383|NCT02515682|DIETARY_SUPPLEMENT|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
48106384|NCT02515682|DIETARY_SUPPLEMENT|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
48106385|NCT02515682|DIETARY_SUPPLEMENT|Placebo|Participants will be give placebo for 24 weeks.
48106386|NCT03255642|DRUG|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
48106387|NCT03255642|DRUG|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
48106388|NCT04744519|OTHER|Collect data|- Controlled ovarian stimulation with GnRH antagonists effected to the patients in order to get their eggs through follicular puncture, which will be trigger by GnRH analogue. The eggs will be isolated and processed according to the standard protocol.
48106389|NCT05113355|DRUG|Chidamide|30mg; administered orally; twice a week (d1, d4, d8, d11, d15, d18). Repeat every 3 weeks for up to 24 months.
48106390|NCT05113355|DRUG|Sintilimab|200mg; intravenous infusion; d1. Repeat every 3 weeks for up to 24 months.
48106391|NCT04118699|DRUG|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
48106392|NCT04118699|DRUG|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
48106393|NCT01671241|DEVICE|Polyethylene wrap|
48298661|NCT05186181|BEHAVIORAL|In situ fenestration|Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
48298662|NCT04397068|PROCEDURE|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
48298663|NCT04072237|BIOLOGICAL|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
48298664|NCT03442426|OTHER|Integrated model of primary care|Intervention includes: 1) consistent risk screening and assessment; 2) care coordination and system navigation; 3) patient/caregiver engagement and shared decision-making; and 4) enabling technology supports.
48298665|NCT01052012|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
48298666|NCT01052012|DRUG|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
48298667|NCT01052012|DRUG|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
48298668|NCT02384369|DRUG|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
48298669|NCT02868125|RADIATION|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
48106394|NCT01671241|DEVICE|Polyethylene wrap|
48106395|NCT00812136|BEHAVIORAL|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
48106396|NCT03552913|PROCEDURE|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
48106397|NCT03552913|PROCEDURE|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
48106398|NCT03552913|PROCEDURE|No specific program toward improving practices|No specific program toward improving practices
48106399|NCT00479141|BEHAVIORAL|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
48106400|NCT00479141|BEHAVIORAL|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
48106401|NCT03356665|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT)|The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
48106402|NCT03356665|DIAGNOSTIC_TEST|Serological and molecular tests on DBS|Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
48106403|NCT04154241|DIAGNOSTIC_TEST|PET/MR scan|"The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity \[11\] \[12\]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results."
48106404|NCT01368406|BEHAVIORAL|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
48298670|NCT00434460|BEHAVIORAL|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
48620084|NCT06516224|OTHER|Liftactiv® B3 retinol night cream|In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
48637297|NCT01856829|OTHER|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
47950867|NCT06319131|PROCEDURE|TIPS|Using the transjugular approach, TIPS was created under local anesthesia. The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography. After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate. A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.
47950868|NCT06319131|DRUG|Nadroparin|Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
47950869|NCT06308419|DRUG|Gemcitabine|Given by IV
47950870|NCT06308419|DRUG|Nab-Sirolimus|Given by IV
47950871|NCT02796703|DIETARY_SUPPLEMENT|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
47950872|NCT02796703|DIETARY_SUPPLEMENT|Placebo|2 cc of milk will be given to control group
47950873|NCT03540212|DRUG|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
47950874|NCT03477123|DEVICE|Walking therapy with Exo-H2 exoskeleton|
47950875|NCT02107404|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
47950876|NCT05877573|DRUG|Toripalimab|Toripalimab 240mg,d1,q3w
48106405|NCT03963128|DIETARY_SUPPLEMENT|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
47950877|NCT05877573|RADIATION|short-term radiotherapy|25Gy/5Fx
47950878|NCT05877573|DRUG|Oxaliplatin|135mg/m2 d1 q3w
47950879|NCT05877573|DRUG|Capecitabine|1200mg/m2 d1-14 q3w
47950880|NCT06210464|OTHER||Trial have no Intervention measures.
47950881|NCT02309593|DEVICE|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
48106406|NCT03963128|DIETARY_SUPPLEMENT|Placebo|Placebo administred every two months
48106407|NCT01057758|DRUG|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
47950882|NCT04633733|DRUG|HL237 tablet|HL237 400mg will be administered orally twice a day.
47950883|NCT04633733|DRUG|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
47950884|NCT04509869|PROCEDURE|varicocelectomy|operation for varix ligation
47950885|NCT03012971|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
48106408|NCT01057758|DRUG|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
48106409|NCT01517542|OTHER|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
48106410|NCT04687085|OTHER|10 minute mindful meditation recording|10 minute mindful meditation recording
48106411|NCT02313090|OTHER|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
48620085|NCT06516224|OTHER|Sunscreen UVAage® Inter SPF 50+|twice daily (morning and beginning of the afternoon)
48620086|NCT06516224|OTHER|Mineral 89 cream|2 drops in the morning before sunscreen application for 6 months
48637298|NCT04433026|DIAGNOSTIC_TEST|N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I|Biomarkers detected in the serum of patients
48620087|NCT04943783|DRUG|Atorvastatin 20mg|One with the intervention (Atorvastatin, 20mg OD), 20 patients for this arm.
47950886|NCT03012971|DRUG|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
47950887|NCT03253575|DIAGNOSTIC_TEST|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
47950888|NCT00547573|DRUG|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
47950889|NCT00547573|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
47950890|NCT00547573|DRUG|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
48298671|NCT04940598|OTHER|high intensity interval exercise|HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
48298672|NCT04940598|OTHER|No-exercise control group|No-exercise control group
48298673|NCT01010841|DIETARY_SUPPLEMENT|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
48298674|NCT01010841|OTHER|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
48298675|NCT00163553|DRUG|Pethidine|
48298676|NCT00163553|DRUG|Placebo|
48637299|NCT03240055|DRUG|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
48637300|NCT03240055|OTHER|etomidate|receive etomidate only
47950891|NCT00844584|PROCEDURE|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
47950892|NCT00468468|BEHAVIORAL|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
48637301|NCT00983957|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
47950893|NCT02974478|DIETARY_SUPPLEMENT|Orange juice with meals|orange juice (20% of energy requirement/day)
47950894|NCT02974478|DIETARY_SUPPLEMENT|Orange juice between meals|orange juice (20% of energy requirement/day)
47950895|NCT02974478|DIETARY_SUPPLEMENT|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
47950896|NCT03039192|DRUG|Esketamine|Intranasal esketamine solution 84 milligram (mg)
47950897|NCT03039192|OTHER|Placebo|Intranasal Placebo solution
47950898|NCT03039192|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
48298677|NCT03493503|DRUG|Salbutamol|Intravenous Salbutamol loading dose
48298678|NCT03493503|DRUG|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
48298679|NCT01729364|DRUG|crystalloid|
48298680|NCT01729364|DRUG|colloid|
48637302|NCT00983957|DRUG|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
48298681|NCT05335070|DRUG|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
48298682|NCT02805088|OTHER|Electroencephalographic recordings|
48298683|NCT02805088|OTHER|neuropsychological evaluation|
48298684|NCT02805088|OTHER|clinical evaluation of symptoms|
48298685|NCT04936672|BEHAVIORAL|Brisk walking and Tai Chi Chuan|This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
48298686|NCT03622164|RADIATION|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
48478647|NCT02729779|OTHER|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
48478648|NCT02560779|DRUG|Carotuximab (TRC105)|Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
48478649|NCT02560779|DRUG|Sorafenib|400 mg of sorafenib will be given twice daily.
48478650|NCT06307041|DEVICE|Dental floss+Gengigel|0.2% Hyaluronic Acid Gel-Impregnated Dental Flosses
48106412|NCT00732368|DRUG|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
48106413|NCT03833102|OTHER|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
48106414|NCT02404233|DRUG|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
48298687|NCT03622164|RADIATION|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
48106415|NCT02404233|DRUG|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
48298688|NCT04444700|DRUG|Therapeutic anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
48298689|NCT01417780|DRUG|AB103|AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
48298690|NCT01417780|DRUG|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
48298691|NCT02495077|BIOLOGICAL|Infliximab|A single dose, of 3mg/kg infusion
48298692|NCT02495077|DRUG|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
48298693|NCT02495077|DRUG|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
48298694|NCT02495077|DRUG|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
48298695|NCT02495077|BIOLOGICAL|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
48298696|NCT02495077|DRUG|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~* Tylenol, 600 to 1000mg by mouth or~* Suppository form"
48298697|NCT02495077|DRUG|Loratadine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
48298698|NCT02495077|BIOLOGICAL|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
48478651|NCT06307041|DEVICE|Dental Floss|Dental Flosses
48637303|NCT04576221|DEVICE|stacked breathing exercise|"• Breath stacking was done using a bag which is a simple device used to give artificial breaths..~* It is best done in a sitting position but can be done reclining or lying flat whichever position is used, try to avoid slouching. If sitting: rest against the back of a chair and keep the shoulders, arms and hands relaxed.~* If using the mouthpiece, place the lips tightly around the mouthpiece to create a tight seal."
48637304|NCT04576221|DEVICE|NIV by CPAP mask|provides pressurized air through a mask to help push air into your lungs and help you breathe
48637305|NCT00180700|BEHAVIORAL|Hypnosis|
48637306|NCT05978414|OTHER|Visceral therapy|Visceral therapy will be performed manually by a physiotherapist, a detailed description of the techniques is above. Therapy will be in 2 subgroups with prolapse of the usual genitals and endometriosis.
48106416|NCT00367055|DRUG|rosiglitazone-metformin|
48106417|NCT00367055|DRUG|Metformin|
48106418|NCT00367055|DRUG|metformin+ gliclazide|
48106419|NCT03109704|PROCEDURE|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
48298699|NCT02495077|DRUG|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
47950899|NCT05155150|BEHAVIORAL|Providing patient-reported outcome|Patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
47950900|NCT03459482|OTHER|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
47950901|NCT02359344|DRUG|CNV1014802|
47950902|NCT02359344|DRUG|Placebo|
47950903|NCT02838446|PROCEDURE|Cognitive Therapy|"Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
47950904|NCT03686761|PROCEDURE|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
47950905|NCT06000397|OTHER|Enhanced reminders|"The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically:~* Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine,~* Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and~* Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit"
47950906|NCT06000397|OTHER|Standard CANImmunize notifications|"Push notifications at two time points:~* two weeks prior to the immunization due date~* one week after the immunization due date"
48478652|NCT04436926|BEHAVIORAL|opioid approach bias modification|The investigators will use a training version of the Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different opioid and 20 different non-medication alternative pain managing activities. Training effect is achieved by presenting opioid pictures in push format only and non-opioid pictures in pull format only. Two hundred training trials are presented per session.
47950907|NCT04599829|DEVICE|AnkleSTRONG100/500/900|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
47950908|NCT00752102|DRUG|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
47950909|NCT00752102|DRUG|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
47950910|NCT04442139|OTHER|Mini-Gastric Bypass|Mini-Gastric Bypass bariatric surgery
47950911|NCT05346497|PROCEDURE|Bentall|Bentall procedure: include replacement of both aortic valve and root
47950912|NCT05346497|PROCEDURE|David|David procedure: include replacement of aortic root and aortic valvuloplasty
47950913|NCT05346497|PROCEDURE|ARR|Aortic root reconstruction: reconstruction instead of replacement of aortic root, without surgery of the valve. include sandwich procedure, adventitia invertion procedure, etc.
48106420|NCT03109704|PROCEDURE|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
48298700|NCT02495077|DRUG|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
48298701|NCT01477216|OTHER|ELSA 1-9|Measuring GI and II values for Finnish foods
48298702|NCT03121352|DRUG|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
48478653|NCT04436926|BEHAVIORAL|sham training|Sham training is identical to opioid approach bias training, except pictures are presented randomly in both formats.
48478654|NCT06363630|DRUG|Itraconazole|Specified dose on specified days.
48478655|NCT06363630|DRUG|Rifampin|Specified dose on specified days
48478656|NCT06363630|DRUG|Golcadomide|Specified dose on specified days
48298703|NCT03121352|DRUG|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
48298704|NCT03121352|DRUG|Pembrolizumab|200 mg IV every 21 days
48478657|NCT02910414|DRUG|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
48637307|NCT05978414|OTHER|Placebo|Placebo will be in 2 subgroups that will not have visceral therapy. The placebo will consist of the physiotherapist holding hands on the patient's pelvis.
47950914|NCT00194909|DRUG|sildenafil (Viagra)|
47950915|NCT02666885|RADIATION|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
47950916|NCT02949531|DRUG|oxygen|
47950917|NCT01941693|BEHAVIORAL|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
47950918|NCT01941693|BEHAVIORAL|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
47950919|NCT02081131|PROCEDURE|Open surgery|pancreatic head resection by open method
47950920|NCT02081131|PROCEDURE|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
47950921|NCT00907712|OTHER|cardiac echo examination|cardiac echo examination - before and after the surgery
48106421|NCT03109704|PROCEDURE|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
48106422|NCT03308461|DRUG|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
48106423|NCT02824367|BEHAVIORAL|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
48106424|NCT01455051|DRUG|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
48106425|NCT00541606|OTHER|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
48106426|NCT00541606|OTHER|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
48106427|NCT02699801|DRUG|propofol|propofol for post-sternal closure sedation
48106428|NCT02699801|DRUG|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
48106429|NCT05257785|BEHAVIORAL|Lymfit exercise intervention|Participants randomized to this arm will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed. Participants will be followed-up at 6 months and 12 months.
48106430|NCT05257785|BEHAVIORAL|Waitlist control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
48106431|NCT03211637|COMBINATION_PRODUCT|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
48106432|NCT00607503|DRUG|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
48106433|NCT00471029|DRUG|esomeprazole|
48106434|NCT00796068|DRUG|Cyclosporine|Given IV or PO
48106435|NCT00796068|DRUG|Fludarabine Phosphate|Given IV
48106436|NCT00796068|OTHER|Laboratory Biomarker Analysis|Correlative studies
48106437|NCT00796068|DRUG|Mycophenolate Mofetil|Given IV
48106438|NCT00796068|RADIATION|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
48106439|NCT00796068|DRUG|Treosulfan|Given IV
48106440|NCT00796068|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
48106441|NCT04265703|PROCEDURE|Internal jugular vein catheterization|Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position. Standard aseptic technique.
48106442|NCT04265703|PROCEDURE|Subclavian vein catheterization|Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction. Standard aseptic technique.
48106443|NCT04265703|PROCEDURE|Innominate vein catheterization|Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction. Standard aseptic technique.
48106444|NCT04302519|BIOLOGICAL|Dental pulp mesenchymal stem cells|On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
48106445|NCT01405924|DRUG|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
48106446|NCT01405924|DRUG|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
48106447|NCT01405924|DRUG|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
48106448|NCT01405924|DRUG|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
47950922|NCT01699490|DRUG|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
47950923|NCT01699490|DRUG|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
48478658|NCT02910414|DEVICE|Peregrine System Kit (Sham Procedure)|Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
48478659|NCT03500367|DRUG|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
47950925|NCT04595331|DEVICE|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
47950926|NCT03376100|PROCEDURE|Ultrasound guided nerve blocks|Ultrasound guided nerve blocks of the radial and median nerves
47950927|NCT03376100|PROCEDURE|Hematoma Block|Conventional local anesthetic method using hematoma block
47950928|NCT02956070|DRUG|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
48106449|NCT04151550|DEVICE|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
48106450|NCT03206554|DRUG|Ropivacaine|Large volume local anaesthetic intraarticularly
48106451|NCT03206554|OTHER|Saline|sham injection
48106452|NCT02299635|DRUG|PF-03084014|Tablet, 10 mg, twice a day.
48106453|NCT02299635|DRUG|PF-03084014|Tablet, 50 mg, twice a day
48106454|NCT02299635|DRUG|PF-03084014|Tablet, 100 mg, twice a day
48106455|NCT06416202|DEVICE|Advanced hybrid closed loop insulin pump|All groups will receive comprehensive diabetes education and extensive carbohydrate counting training. Continuous glucose monitoring (CGM) will be conducted using the Guardian 4 sensor or Dexcom G6 for the intervention group depending on the type of pump used. fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
48106456|NCT06416202|OTHER|Open Loop Insulin Delivery system|the control group will continue using their current CGM device. Data on glycemic control, hypoglycemic events, and patient satisfaction will be collected before and throughout Ramadan. Additionally, fructosamine levels for all patients will be checked both before and after Ramadan to provide a more immediate assessment of glycemic control.
48106457|NCT04201327|BEHAVIORAL|Project Jumpstart|PrEP focused intervention to improve PrEP related health outcomes
47914012|NCT03652285|DEVICE|Esophageal stent implantation|"An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement."
47914013|NCT03652285|DEVICE|Stent removal|Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
47914014|NCT02791763|DRUG|1 to 4 mg tablets of GSK1278863|7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
47914015|NCT02791763|DRUG|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
47950929|NCT02956070|DRUG|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch \[50%\], lactose monohydrate \[35%\], dibasic calcium phosphate \[14%\], and magnesium stearate \[1%\]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
47950930|NCT01737502|DRUG|Auranofin|Given PO
48106458|NCT02397317|RADIATION|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
48106459|NCT03946813|OTHER|Autologous PRP preparation|For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
48106460|NCT00059241|BEHAVIORAL|Parent-child communication education|
48106461|NCT00059241|BEHAVIORAL|Service learning|
48106462|NCT00059241|BEHAVIORAL|Classroom health curriculum|
48106463|NCT02733250|BIOLOGICAL|Pembrolizumab|200mg IV Day 1 of each 21 cycles
48106464|NCT02733250|DRUG|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
48106465|NCT02925000|DRUG|TLC178|TLC178
48298705|NCT02055027|OTHER|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
48478660|NCT00440609|DRUG|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
48478661|NCT04945018|BIOLOGICAL|HS-001 CS|Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
48637308|NCT03307070|BEHAVIORAL|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
48637309|NCT03307070|OTHER|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
48637310|NCT00198744|BEHAVIORAL|Medifast FIT! for Kids|
48637311|NCT00198744|BEHAVIORAL|standard recommendations for dietary intake in children|
48637312|NCT00198744|BEHAVIORAL|both diet plans with and without a parent dieting|
47914016|NCT02791763|DRUG|Epoetin beta pegol|An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
47914017|NCT04162691|DIAGNOSTIC_TEST|Tissue|Four 4-5 mm tissues of the thymoma
48106466|NCT01876654|DEVICE|TruMatch® patient specific cutting guide|
48106467|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made
48106468|NCT00684034|OTHER|Sampling of blood|A sampling of bood will be made before the dialysis
48106469|NCT00684034|OTHER|Sampling of blood|A sampling of blood will be made.
48106470|NCT05937919|DRUG|Intravenous injection of 68Ga-PMD22|68Ga-PMD22 were intravenous injected into the patients before PET/CT scans
48106471|NCT01152190|DRUG|Tadalafil|Administered orally, once daily for 8 weeks
48106472|NCT01152190|DRUG|Placebo|Administered orally, once daily for 8 weeks
48106473|NCT00241930|BEHAVIORAL|Integrating drug treatment into HIV services|
48106474|NCT01689519|DRUG|Placebo|Placebo supplied as tablets
48106475|NCT01689519|DRUG|Vemurafenib|Vemurafenib supplied as tablets
48106476|NCT01689519|DRUG|Cobimetinib|Cobimetinib supplied as tablets
48106477|NCT00424762|DRUG|rosiglitazone|6 months of treatment of blinded study drug
48478662|NCT04945018|DEVICE|HS-001-D needle, HS-001-D Adaptor|Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
48637313|NCT01825252|BEHAVIORAL|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
48637314|NCT01825252|BEHAVIORAL|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
47914018|NCT05788016|BEHAVIORAL|opioid taper|The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period
47914019|NCT04662515|PROCEDURE|Type of surgery|surgical or non-surgical extraction one or more teeth
47914020|NCT04662515|DRUG|Dabigatran|
47914021|NCT04662515|DRUG|Rivaroxaban|
47914022|NCT04662515|DRUG|Apixaban|
47914023|NCT04662515|DRUG|Edoxaban|
47914024|NCT04662515|DRUG|Warfarin|
47914025|NCT00787618|DRUG|50 mg Proellex|Single dose
47914026|NCT02802267|DRUG|Inecalcitol|vitamin D receptor agonist
47914027|NCT02802267|DRUG|Placebo Oral Tablet|placebo
47914028|NCT00746512|DRUG|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
47914029|NCT00746512|DRUG|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
47914030|NCT00746512|DRUG|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
48106478|NCT00424762|DRUG|placebo|blinded treatment with matching placebo
48298706|NCT01171547|DRUG|Daptomycin|once daily over 5 days
48106479|NCT01838824|BEHAVIORAL|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
48106480|NCT06495424|DRUG|Capsaicin 8% Patch Kit,1|Repeat applications every 12 weeks in patients with PDPN of the feet.
48106481|NCT04448418|OTHER|web based survey|Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
48106482|NCT02819336|DEVICE|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.~1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~3. The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~4. After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
48106483|NCT02819336|DEVICE|Sham electroacupuncture|"1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally \& SP11 and SP6 bilaterally.~3. The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~4. The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
48106484|NCT03958500|PROCEDURE|Indocyanine green fluorescent angiography intraluminally and intraperitoneally|The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
48106485|NCT00913913|BIOLOGICAL|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
48106486|NCT00913913|DRUG|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
48106487|NCT00913913|BIOLOGICAL|IL-2|IL-2 18 MiU/m2 CI 5 days
48106488|NCT00913913|BIOLOGICAL|IFN|IFN 6 MiU subc TIW
48106489|NCT00820079|DRUG|ADX10059|oral administration
48106490|NCT00820079|DRUG|ADX10059 Matching Placebo|oral administration
48106491|NCT03684265|DRUG|Meloxicam Capsule (Test)|single dose
48106492|NCT03684265|DRUG|Meloxicam Tablet (Reference)|single dose
48298707|NCT03142997|DIAGNOSTIC_TEST|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
48298708|NCT01641315|BIOLOGICAL|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
48478663|NCT00708708|DRUG|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
48637315|NCT01210911|DRUG|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
48637316|NCT01210911|DRUG|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
48106493|NCT01021865|DRUG|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
48106494|NCT02864628|BIOLOGICAL|MVA-BN-RSV|MVA-mBN294B
48106495|NCT02864628|OTHER|Placebo|Tris Buffered Saline
48106496|NCT02026076|OTHER|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
48298709|NCT04269512|PROCEDURE|lymph node dissection|At least 10 lymph nodes must be removed.
48298710|NCT00568789|DRUG|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
48298711|NCT01481571|DEVICE|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
48298712|NCT05934799|DRUG|Clopidogrel film-coated tablet 75 mg|Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
48298713|NCT05934799|DRUG|Plavix® film-coated tablet 75 mg|Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
47950931|NCT01737502|DRUG|Sirolimus|Given PO
48298714|NCT05805085|DEVICE|Lens A (Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
48637317|NCT01210911|DRUG|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
48637318|NCT01210911|DRUG|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
48637319|NCT01561612|BEHAVIORAL|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
48637320|NCT05977946|DEVICE|Volta System|The Volta System is a wearable, battery-operated, neurostimulation system designed to deliver tAN or taVNS. The device will be used to deliver two 30-minute sessions of active or sham therapy according to the participant's randomization group (taVNS or tAN).
48637321|NCT06549725|DEVICE|software Lipidica|"The investigational medical device software (MDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device."
48637322|NCT06549725|PROCEDURE|endoscopic ultrasonography|Endoscopic ultrasonography - maximum frequency: 3 times during the participation
48106497|NCT04154137|OTHER|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
48106498|NCT01765686|DEVICE|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
48106499|NCT01765686|DEVICE|Ligasure Small Jaw (Covidien, USA)|
48106500|NCT03439124|DRUG|ceftobiprole medocaril|"Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole).~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment."
48106501|NCT03439124|DRUG|IV standard-of-care cephalosporin|"Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days.~After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.~At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
48106502|NCT03835390|BEHAVIORAL|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
48106503|NCT00487578|DRUG|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
48106504|NCT02709343|DRUG|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
48106505|NCT02709343|DRUG|Placebo|Placebo product visually very similar to mesenchymal stromal cells
48106506|NCT01115049|DRUG|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
48106507|NCT01115049|DRUG|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
48106508|NCT00548964|DRUG|Lithium|600-900mg of Li carbonate
48106509|NCT00548964|DRUG|Ketamine|0.5mg/kg of ketamine
48106510|NCT00606580|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
48106511|NCT00606580|DRUG|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
48637323|NCT06549725|PROCEDURE|magnetic resonance|Magnetic resonance - maximum frequency: 3 times during the participation
48637324|NCT06549725|DIAGNOSTIC_TEST|laboratory examination|Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
48637325|NCT06549725|PROCEDURE|computed tomography|computed tomography - maximum frequency: 3 times during the participation
48106512|NCT00606580|DRUG|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
48106513|NCT01520350|DRUG|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
48106514|NCT01520350|DRUG|placebo|Placebo
48106515|NCT00578656|DIETARY_SUPPLEMENT|Baked Milk|Extensively heated milk
48106516|NCT03199235|DEVICE|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
48106517|NCT03199235|OTHER|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
48106518|NCT00253058|DRUG|Cetirizine Dry Syrup|
48106519|NCT00002932|DRUG|cisplatin|
48106520|NCT00002932|RADIATION|radiation therapy|
48106521|NCT02909049|DRUG|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
48106522|NCT02909049|DRUG|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
48106523|NCT02909049|DRUG|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
48106524|NCT02909049|DRUG|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
48106525|NCT01050569|DRUG|Nicotine Patch|21 mg
48106526|NCT01050569|OTHER|VLNC Cigarette|Cigarette where the tobacco contains \<0.1 mg of nicotine yield.
48106527|NCT01050569|OTHER|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
48478664|NCT05878379|BEHAVIORAL|Dietary Iron Program|"Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)"
48478665|NCT01803269|DRUG|topotecan hydrochloride|Given IV
48106528|NCT05716373|BEHAVIORAL|pain|reiki
48106529|NCT01910636|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
48106530|NCT01910636|DRUG|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
48106531|NCT04267250|DRUG|PF-06700841|60 mg by mouth (PO) once daily (QD).
48106532|NCT04267250|DRUG|Ethinyl estradiol (EE) and levonorgestrel (LN)|Oral tablet containing 30 mcg EE and 150 mcg LN.
48106533|NCT03747354|DIAGNOSTIC_TEST|blood samples|blood samples
48106534|NCT03769233|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
48106535|NCT06461637|BEHAVIORAL|Stepped Care Mental Health for Foreign Domestic Helpers (SCMH-FDH)|The SCMH-FDH intervention consists of 4 steps. Step 1 involves a self-help intervention (through 12 mental health booklets) delivered in 6 sessions and an online peer support group. Those who did not respond to Step 1 will be referred to Step 2 (group-based resilience workshop). The intervention will be also be delivered in 6 weekly sessions lasting 1-1.5-hours. Those who did not respond to Step 2 will be referred to Step 3 (guided self-help cognitive behavioral therapy, CBT) with guidance from a trained therapist. Self-help materials will be provided. The sessions are spread out over six weeks, with each sessions lasting 30-45 minutes. Those who did not respond to Step 3 will be referred to Step 4 (high intensity interventions provided by mental health professionals). Stepping up is determined by the IAPT-minimum data set. If assessment scores after previous treatment exceeds the defined threshold (PHQ-9 ≥ 10 or GAD-7 ≥ 8), then participants need to step up to the next intervention.
48106536|NCT03103971|BIOLOGICAL|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
48106537|NCT03103971|DRUG|Cyclophosphamide|Given IV
48106538|NCT03103971|DRUG|Fludarabine|Given IV
48106539|NCT03103971|OTHER|Laboratory Biomarker Analysis|Correlative studies
48106540|NCT03103971|PROCEDURE|Leukapheresis|Undergo leukapheresis
48106541|NCT03103971|OTHER|Pharmacological Study|Correlative studies
48637326|NCT04318886|BEHAVIORAL|ENABLE Cornerstone|The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
48637327|NCT03987880|PROCEDURE|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
48637328|NCT03987880|PROCEDURE|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
48637329|NCT05230758|DRUG|Metformin hydrochloride (HCl) 500mg tablet|"Metformin HCl 500mg tablets contain 500mg of active pharmaceutical ingredient (API) and are white, round, biconvex, film-coated tablets, with a score line on one face and debossed with HMR on the other. Each tablet contains the non-medicinal ingredients magnesium stearate and povidone. Tablet coating is comprised of hydroxypropyl methylcellulose, polyethylene glycol and titanium dioxide."
48478666|NCT01803269|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
48478667|NCT00407745|DRUG|placebo|Placebo
48637330|NCT05230758|DRUG|Placebo|Matching white round tablet containing excipients only. The placebo tablets will match the active drug as closely as possible in terms of appearance.
47950932|NCT01737502|OTHER|Laboratory Biomarker Analysis|Correlative studies
47950933|NCT01737502|OTHER|Pharmacological Study|Correlative studies
47950934|NCT05839587|PROCEDURE|Robotic TAPP|Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
47950935|NCT05839587|PROCEDURE|Laparoscopic TAPP|Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
47950936|NCT01413412|PROCEDURE|Ventral hernia repair using full thickness skin graft|25 patients
47950937|NCT01413412|PROCEDURE|Ventral hernia repair using mesh|25 patients
47950938|NCT05516589|DRUG|Nab-paclitaxel|260mg/m\^2 IV Q3W
47950939|NCT05516589|DRUG|Cisplatin|75mg/m\^2 IV Q3W
47950940|NCT05516589|BIOLOGICAL|Tislelizumab|200mg IV Q3W
47950941|NCT05516589|DRUG|Afatinib|30mg PO QD
47950942|NCT00783965|DRUG|tazarotene|Applied to the skin
47950943|NCT00783965|OTHER|placebo|Applied to the skin
47950944|NCT03925064|OTHER|myocardial performance index|fetal right ventricular myocardial performance index measured with tissue doppler
47950945|NCT01067066|DRUG|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
48478668|NCT00407745|DRUG|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
48478669|NCT03601624|DRUG|Pomalidomide|"1. Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~2. Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~3. Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
48478670|NCT05419349|PROCEDURE|esophagogastric junction cancer surgery|esophagogastric junction cancer surgery
48478671|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
48478672|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
48478673|NCT06616597|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg/ day
48637331|NCT01204372|DRUG|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~* Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~* Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~* Erlotinib: oral route 100 mg/day from C1D1."
48637332|NCT00148538|BEHAVIORAL|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
48637333|NCT04739345|DRUG|Pentoxifylline|400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
48637334|NCT02244528|DRUG|Sildenafil|
48106542|NCT04090762|BEHAVIORAL|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
48478674|NCT06616597|DRUG|Dexamethasone|Dexamethasone 0.5mg/day
48106543|NCT04090762|BEHAVIORAL|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
48106544|NCT02138331|BIOLOGICAL|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
48106545|NCT03677999|DIAGNOSTIC_TEST|MEGA-PRESS sequence Magnetic Resonance Spectroscopy|MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
48106546|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
48106547|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
48106548|NCT01209039|DRUG|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
48106549|NCT02685033|DRUG|Dalbavancin|
48106550|NCT02685033|DRUG|Comparator|
48298715|NCT05805085|DEVICE|Lens B (Silicone Hydrogel Daily Disposable Toric Contact Lens)|15 minutes
48106551|NCT05482854|OTHER|Analytical Treatment Interruption (ATI)|"Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria"
48106552|NCT05645432|DRUG|Brexanolone|Brexanolone IV infusion
48106553|NCT00939991|DRUG|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
48106554|NCT03745118|DEVICE|EpiTel EpiLog|Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
48106555|NCT03745118|DEVICE|Byte Flies Sensor Dots|Plastic pads that will be adhered to your chest area
48106556|NCT03745118|DEVICE|Empatica E4|wearable seizure detection wristband
48106557|NCT03745118|DEVICE|Biovotion Everion|wearable seizure detection device armband that is attached to upper arm
48478675|NCT06616597|DRUG|Metronidazole|Metronidazole 1500mg/ per day
48478676|NCT00707421|DRUG|ketorolac acetate|
48478677|NCT00707421|DRUG|fluorometholone|
48478678|NCT00707421|DRUG|artificial lacrimal tears|
48478679|NCT03020784|DRUG|Placebo|Placebo
48478680|NCT03020784|DRUG|PF-06818883|Treatment
48478681|NCT03330314|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
48106558|NCT03745118|DEVICE|GeneActiv|wearable seizure detection watch
48106559|NCT03448757|OTHER|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
48106560|NCT05990517|BIOLOGICAL|YD01-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
48106561|NCT02400151|DRUG|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
48106562|NCT02400151|DRUG|Placebo|Patients randomized to this group will receive placebo for 90 days.
48298716|NCT04339946|DIAGNOSTIC_TEST|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
48298717|NCT04339946|DIAGNOSTIC_TEST|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
48298718|NCT04655677|BIOLOGICAL|CD19/CD20-directed CAR-T cells|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
48298719|NCT03026504|DRUG|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
48298720|NCT05892185|DEVICE|GELA|GELA glaucoma implant
48298721|NCT05892185|DEVICE|XEN|XEN gel stent implant
48106563|NCT02400151|OTHER|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
48106564|NCT02400151|OTHER|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
48106565|NCT04825652|DRUG|177Lu-PSMA-617|Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles.
48106566|NCT04825652|DRUG|PSMA-11|Patients will receive a dose of gallium (68Ga) gozetotide that is 1.8-2.2 MBq/kg of body weight (0.049-0.059 mCi/kg), with a minimum dose of 111 MBq (3mCi) up to a maximum dose of 259 MBq (7 mCi).
48106567|NCT06350045|COMBINATION_PRODUCT|PCNL|percutaneous nephrolithotomy
48106568|NCT06553989|OTHER|osteopatic visceral mobilization|a combination of breathing and visceral mobilizations
48106569|NCT05457478|OTHER|Medical Device Qardio® smart scale Usage and Evaluation|Weight monitored using a Qardio® smart scale
48106570|NCT05457478|OTHER|Questionnaire Administration|Ancillary studies
48106571|NCT05230641|OTHER|No intervention|This is a prospective observational study
48106572|NCT02979899|BIOLOGICAL|TRC105|TRC105 antibody
48106573|NCT02979899|DRUG|Votrient|pazopanib
48106574|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|5mg/day
48106575|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|10mg/day
48106576|NCT00288691|DRUG|Asoprisnil (BAY86-5294)|25mg/day
48106577|NCT00288691|DRUG|Placebo|Placebo
48106578|NCT05862363|DIETARY_SUPPLEMENT|Microbiota-directed balanced energy protein (MD-BEP)|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
48106579|NCT05862363|DIETARY_SUPPLEMENT|Ready-to-use supplementary food-balanced energy protein (RUSF-BEP)|RUSF-BEP is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MD-BEP is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth. RUSF-BEP will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
48106580|NCT05862363|PROCEDURE|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (\<18.5kg/m2; 18-35 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
48106581|NCT05862363|BEHAVIORAL|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care.
48106582|NCT06070324|PROCEDURE|Breast surgery|Any surgery involving incisions made along the nipple areolar complex. These would include transgender mastectomy, cisgender female breast reduction/augmentation/reconstruction, and cisgender male gynecomastia correction.
48478682|NCT02201459|DRUG|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
48106583|NCT06070324|DEVICE|Suturing of surgical incision|The closing of a surgical incision by using sutures so appose and maintain apposition of two skin edges. Suturing may or may not require knot-tying depending on the material of suture used.
48106584|NCT01847651|PROCEDURE|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106585|NCT01847651|DRUG|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
48106586|NCT01847651|OTHER|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106587|NCT01847651|OTHER|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106588|NCT01847651|OTHER|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106589|NCT01847651|OTHER|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106590|NCT01847651|OTHER|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106591|NCT01847651|OTHER|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106592|NCT01847651|OTHER|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
48106593|NCT06555276|DEVICE|Disposable endoscope linear cutting stapler and components|to use the study device for excision, transection and anastomosis of lung, bronchial tissue, stomach and intestine in open or endoscopic surgery.
48106594|NCT04900142|PROCEDURE|Micropulsed laser trabeculoplasty|Trabeculoplasty
48106595|NCT02925195|DIETARY_SUPPLEMENT|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
48106596|NCT02925195|DRUG|Placebo|
48478683|NCT02201459|DRUG|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"* Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~* Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
48478684|NCT01275560|DRUG|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
47914031|NCT00746512|DRUG|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
48106597|NCT05391724|DRUG|CMX001|single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg
48298722|NCT03081325|PROCEDURE|low-dose lymphocyte immunotherapy|Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
47950946|NCT01067066|DRUG|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.
48106598|NCT01558921|OTHER|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
48106599|NCT01558921|OTHER|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
48106600|NCT01144182|BEHAVIORAL|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
48106601|NCT00697814|DRUG|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
48106602|NCT02823106|DRUG|Verapamil and Citicoline|Single dosing strategy will be used.
48106603|NCT02823106|OTHER|Placebo|Single matching dosing strategy will be used.
48478685|NCT01275560|DRUG|CArbosylane|
48478686|NCT02394639|OTHER|video-EEG monitoring|
48478687|NCT02418455|DRUG|UX003|solution for intravenous infusion
47950947|NCT02386631|DEVICE|Custom Made Orthotic|Provides longitudinal arch support
47950948|NCT02124486|PROCEDURE|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
47950949|NCT02124486|BEHAVIORAL|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
47950950|NCT00904319|OTHER|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
47950951|NCT04951804|PROCEDURE|EUS-CPN without bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to inject a neurolytic agent such as absolute alcohol around the base of the celiac artery.
47950952|NCT04951804|PROCEDURE|EUS-CPN with bupivacaine|Under conscious sedation, an echoendoscope is advanced into the stomach, just distal to the gastro-esophageal junction. The region of the celiac plexus is identified around the takeoff of the celiac artery from the aorta. Then, under real-time ultrasound guidance, a 19g needle is used to firstly inject bupivacaine and secondly a neurolytic agent such as absolute alcohol around the base of the celiac artery.
47950953|NCT06681545|OTHER|one to one interviews and or focus groups|one to one interviews and or focus groups
47950954|NCT06680271|OTHER|Remote exercise|The intervention group will consist of 25 subjects receiving a multicomponent physical exercise intervention (aerobic, strength, flexibility, and neuromotor) delivered by a physical therapist via the Microsoft Teams platform
47950955|NCT06680271|OTHER|Home exercise|The control group will consist of 25 subjects receiving traditional physical therapy at home from a physical therapist.
47950956|NCT00398294|DRUG|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
47950957|NCT03325049|BEHAVIORAL|The health-promoting conversations|The health-promoting conversations
47950958|NCT03325049|OTHER|Usual Care|Usual Care
47950959|NCT06229639|DEVICE|Passy Muir Valve|
48478688|NCT05813379|COMBINATION_PRODUCT|exosime injection|Treatment- exosome injection
48478689|NCT01142531|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
48478690|NCT00165386|PROCEDURE|Magnetic Resonance Imaging|
48478691|NCT00165386|PROCEDURE|Bone Marrow Biopsy|
48478692|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
48478693|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
47950960|NCT06229639|DEVICE|Tracheostomy Plug|
47950961|NCT04351854|OTHER|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
47950962|NCT05952934|BIOLOGICAL|0.5 mL Candin®/injection|Candin or placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
47950963|NCT05952934|OTHER|Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)|Placebo injection every 3 weeks until 4 injections then every 3 months until a total of 7 injections.
47950964|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation|
47950965|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
47950966|NCT00547547|DIETARY_SUPPLEMENT|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
47950967|NCT00547547|DRUG|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
47950968|NCT00547547|DRUG|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
47950969|NCT01092507|BIOLOGICAL|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
47950970|NCT01092507|BIOLOGICAL|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
47950971|NCT03626168|DIETARY_SUPPLEMENT|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
48106604|NCT00819819|DIETARY_SUPPLEMENT|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
48106605|NCT00819819|DIETARY_SUPPLEMENT|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
48106606|NCT06165185|OTHER|Water|Please see the associated arm description
48106607|NCT06165185|OTHER|Coffee|Please see the associated arm description
48106608|NCT06165185|OTHER|Control|Please see the associated arm description
48106609|NCT03885596|DRUG|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
48637335|NCT02166762|PROCEDURE|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
48106610|NCT03885596|DRUG|Ketorolac|30 mg IV at the onset of anesthesia
48106611|NCT03885596|DRUG|Acetaminophen IV|1 g at the onset of anesthesia
48106612|NCT03885596|DRUG|Fentanyl|100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
48106613|NCT03885596|DRUG|Bupivacaine Hydrochloride|0.25% 30 mL (75 mg) prior to surgery
48106614|NCT03885596|DRUG|Lidocaine HCl|1.5% 12 mL at the end of surgery
48106615|NCT03885596|DRUG|Celecoxib|200 mg PO bid each day postoperative
48106616|NCT03885596|DRUG|Acetaminophen Oral|1 g postoperative
48298723|NCT06258629|DIAGNOSTIC_TEST|Flowcytometry on bone marrow aspiration|Flowcytometry on bone marrow aspiration
48298724|NCT02241850|OTHER|High intensity training|9 weeks of supervised high intensity training
48298725|NCT06499090|DRUG|Mirtazapine 30 MG|patients will receive orally the night before surgery the study medication and daily up to two weeks after Mirtazapine 30 mg tablet
48298726|NCT06499090|DRUG|Placebo|patients will receive orally the night before surgery the study medication and daily up to two weeks after placebo tablet
47914032|NCT04988503|DEVICE|Coil embolization|coil embolization for ruptured intracranial aneurysm with bare platinum coils or second-generation hydrogel coils
47950972|NCT03626168|OTHER|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
48106617|NCT03885596|DRUG|Lidocaine Hydrochloride|2% 15 mL at the end of surgery
48106618|NCT03885596|DRUG|Exparel|Bupivacaine liposome injection suspension
48106619|NCT02555631|BEHAVIORAL|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
48478694|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
47914033|NCT05933239|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
47914034|NCT05054387|DRUG|Agalsidase beta|Powder for concentration into a solution Intravenous (IV) infusion
48106620|NCT06476002|OTHER|Questionnaire|Completion of translated VPAQscreen, VPAQdesc, VPAQcope and VPAQpartner questionnaires by patients, followed by assessment of comprehension of the various items.
48106621|NCT06452446|DRUG|Selinexor|Selinexor is an oral therapy that is FDA approved for multiple myeloma and diffuse large B-cell lymphoma that have returned after prior therapy. Side effects like nausea, vomiting, and fatigue can affect how long a patient is able to continue taking Selinexor, which could mean that treatment might stop sooner.
48106622|NCT01295918|DIETARY_SUPPLEMENT|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
48478695|NCT03699241|BIOLOGICAL|Placebo|Tris-NaCl Diluent
48637336|NCT06272682|PROCEDURE|Systemic bethametasone injection|betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
48637337|NCT06272682|PROCEDURE|Local bethametasone injection|Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
47914035|NCT02929407|DRUG|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
47914036|NCT02929407|DRUG|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
47914037|NCT00740857|DRUG|placebo|2 placebo gels capsules delivered as a single dose.
47914038|NCT00740857|DRUG|ibuprofen Formulation 1|2 marketed ibuprofen gels
47914039|NCT00740857|DRUG|ibuprofen Formulation 2|2 marketed ibuprofen gels
47914040|NCT00588497|PROCEDURE|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
47914041|NCT00588497|RADIATION|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
47914042|NCT00588497|PROCEDURE|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
48298727|NCT04360330|RADIATION|Stereotactic Ablative Breast Radiotherapy|"Preoperative SABER: Participants will be treated with an assigned dose level of preoperative SABER, delivered in once a day, 5 fractions given on non-consecutive days, over a period of 2 weeks. In this phase I study, starting with dose level II, a dose level of preoperative SABER will be assigned per study dose-escalation design, treating 2 to 6 patients per dose level. The tested doses are the following:~* Dose Level I: 35 Gy (5 fractions of 7 Gy)~* Dose Level II (Starting Dose): 40 Gy (5 fractions of 8 Gy)~* Dose Level III: 45 Gy (5 fractions of 9 Gy)~* Dose Level IV: 50 Gy (5 fractions of 10 Gy)"
48106623|NCT04589130|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day).~Participants randomized to the control arm for the first 6 months will crossover and be administered 4 Contrave tablets a day during the second 6 months (2 tablets taken twice a day). All participants will be in the treatment group (Contrave) during the second 6 month phase of the study."
48298728|NCT01225263|DRUG|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
48298729|NCT01225263|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
48298730|NCT01225263|OTHER|Placebo|Two placebo pills, taken twice daily for 6 months
48298731|NCT01383044|PROCEDURE|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
48298732|NCT01383044|DRUG|carvedilol|carvedilol 6.25mg-12.5 mg per day
48637338|NCT04761588|DIETARY_SUPPLEMENT|Tyr sphere|"Tyr sphere is a powdered, low phenylalanine and tyrosine protein substitute, containing a balanced mix of casein glycomacropeptide (cGMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and the long chain polyunsaturated fatty acid (LCP) and docosahexaenoic acid (DHA). It contains sugars and sweetener.~The product is designed to be prescribed based on its protein content, not its energy content."
48637339|NCT06353932|OTHER|keeping the endotracheal tube cuff pressure within a certain range|The endotracheal tube cuff pressures of the study group patients were kept within the range of 20-25 cm H2O.
48637340|NCT03291236|OTHER|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
48637341|NCT00709345|BEHAVIORAL|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
48637342|NCT00709345|BEHAVIORAL|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
48637343|NCT04986969|BEHAVIORAL|Online cognitive behavioral therapy|online cognitive behavioral therapy delivered using one of two active methods
48637344|NCT05373836|DIAGNOSTIC_TEST|prognostic nutritional index calculated from laboratory parameters|Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
48478696|NCT02471937|BIOLOGICAL|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
48298733|NCT02844582|DRUG|Cabazitaxel|Given IV
48298734|NCT02844582|DRUG|Prednisone|Given PO
48106624|NCT04589130|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day (2 tablets, taken twice a day) during the first 6 months of the study. These participants will crossover to treatment with Contrave for the second 6 months of the study.
48106625|NCT02824159|OTHER|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
48106626|NCT02824159|OTHER|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
48298735|NCT05762185|DEVICE|nursing consultation|nursing consultation
47950973|NCT01904227|BEHAVIORAL|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
48106627|NCT02824159|OTHER|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
48106628|NCT02824159|OTHER|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
48106629|NCT02824159|GENETIC|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
48106630|NCT02824159|GENETIC|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
48298736|NCT05682807|DRUG|Caffeine|5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.
48298737|NCT05682807|DRUG|Probiotic Formula|probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.
48298738|NCT04829318|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
48478697|NCT06326502|DRUG|ETN101|Oral administration
48478698|NCT05435586|OTHER|Web Based Breastfeeding Education and Counseling with Digital Game Support|The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
47914043|NCT00588497|RADIATION|Hysterosalpingogram|Performed 3 months after micro-inserts placement
48106631|NCT02824159|OTHER|Biological statement|"The following parameters will be assessed :~* Complete blood count~* Hemoglobin~* Hepatic enzymes~* Creatinine clearance~* Lactate dehydrogenase rate~* Total bilirubin rate~* Cluster of differentiation 4 T lymphocytes rate~* Total gamma-globulins rate"
48106632|NCT02824159|OTHER|Clinical examination|"The clinical examination are composed by :~* Weigh, Height and body mass index measurement~* Clinical state of patient during examination~* Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~* Presence of B symptomatology~* Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
47950974|NCT01904227|BEHAVIORAL|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
47950975|NCT01033721|DRUG|Palomid 529|comparison of different dosages of drug
47950976|NCT06680622|DRUG|bemarituzumab, paclitaxel, ramucirumab|Cohort 2 will receive bemarituzumab plus SOC treatment with paclitaxel and ramucirumab
47950977|NCT06680622|DRUG|bemarituzumab, irinotecan|Cohort 1 will receive bemarituzumab plus SOC treatment with irinotecan
47950978|NCT06680622|DRUG|bemarituzumab, trifluridine/tipiracil|Cohort 3 will receive bemarituzumab plus SOC treatment with trifluridine/tipiracil
47950979|NCT04264689|PROCEDURE|serratus anterior block|ultrasound guided block
48478699|NCT03669068|PROCEDURE|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy."
48478700|NCT06504147|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
48637345|NCT01509456|DIETARY_SUPPLEMENT|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
48637346|NCT06367153|DRUG|BI 1569912|BI 1569912
47950980|NCT04264689|PROCEDURE|thoracic epidural|thoracic epidural
47950981|NCT04264689|PROCEDURE|erector spinae block|ultrasound guided block
47950982|NCT01200862|DRUG|Investigational new drug company code: BGS649|
47950983|NCT01200862|DRUG|Placebo|
47950984|NCT01517685|DIETARY_SUPPLEMENT|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
47950985|NCT01517685|DIETARY_SUPPLEMENT|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
47950986|NCT05816720|DRUG|Lutetium-177 DOTATATE|Intravenous administration
47950987|NCT01578421|DEVICE|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
47950988|NCT01865188|DRUG|LCZ696|Experimental monotherapy doses
47950989|NCT01865188|DRUG|Amlodipine|Active comparator monotherapy doses
47950990|NCT01865188|DRUG|LCZ696 and amlodipine combination|Experimental combination doses
47950991|NCT01865188|DRUG|Placebo|Placebo comparator dose
47950992|NCT03237078|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
47950993|NCT04148820|DRUG|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
47950994|NCT04833673|BEHAVIORAL|PMR: Progressive Muscle Relaxation|tensing and relaxing the body muscles accompanied with deep breathing
47950995|NCT04833673|BEHAVIORAL|BRT:Benson Relaxation Technique|relaxation using mental imagery and mediation
47950996|NCT06680804|OTHER|chance for vaginal delivery.|chance for vaginal delivery in patients who had delivered by Caesarean section in first pregnancy
47950997|NCT01438073|DRUG|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
47950998|NCT01438073|DRUG|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
47950999|NCT02841436|DEVICE|Irreversible Electroporation (IRE) System|
47951000|NCT05021081|DEVICE|TRP-200|JJVC Investigational Contact Lens
47951001|NCT05021081|DEVICE|ACUVUE Oasys 1-Day|JJVC Marketed Contact Lens
47951002|NCT03625934|BIOLOGICAL|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
47951003|NCT03625934|BIOLOGICAL|Placebo|5 s.c. injections of matching Placebo four weeks apart
48106633|NCT03334019|OTHER|blood test|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
48106634|NCT02814305|BEHAVIORAL|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
48106635|NCT02814305|BEHAVIORAL|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
48106636|NCT00132717|DRUG|MK0653A (ezetimibe [+] simvastatin)|
48106637|NCT00132717|DRUG|Comparator: atorvastatin|
48106638|NCT00132717|DRUG|Comparator: fluvastatin|
48106639|NCT00132717|DRUG|Comparator: lovastatin|
48106640|NCT00132717|DRUG|Comparator: pravastatin|
48106641|NCT00132717|DRUG|Comparator: rosuvastatin|
48106642|NCT00132717|DRUG|Comparator: simvastatin|
48106643|NCT02196051|OTHER|one bout of 45 minutes exercise|45 minutes of exercise on an elliptical exercise machine
48106644|NCT00354640|DRUG|anastrozole|1 milligram tablet PO QD for 14 days
48298739|NCT04829318|DRUG|SSRI/SNRI|Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
48298740|NCT04644575|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:Solution for Injection Route of administration: Intravenous
48298741|NCT01219244|BEHAVIORAL|caloric restriction|6 months of caloric restriction (15 %)
48298742|NCT01219244|BEHAVIORAL|omega-3 supplementation|6 months of omega-3 supplementation
48637347|NCT06367153|DRUG|repaglinide|repaglinide
48637348|NCT06367153|DRUG|midazolam|midazolam
48637349|NCT06367153|DRUG|bupropion|bupropion
48637350|NCT03932409|DRUG|Pembrolizumab|"prior to VCB: 200mg IV given one week (7 days) before radiation~after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy"
48637351|NCT03932409|RADIATION|Vaginal cuff brachytherapy (VCB)|Treatment should commence within 12 weeks of the surgery/hysterectomy
48106645|NCT00354640|DRUG|simvastatin|40 milligram tablet PO QD for 14 days
48106646|NCT00354640|OTHER|pharmacological study|laboratory analysis
48106647|NCT00354640|PROCEDURE|adjuvant therapy|laboratory analysis
48106648|NCT05163418|DEVICE|Foot orthosis for flat feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
48106649|NCT05163418|DEVICE|Foot orthoses for high arches feet|Plantar orthotics based on a unique process of footprinting, software design and orthotic printing to create custom 3D printed orthotics.
48106650|NCT06357169|DEVICE|Venus Glow|two treatments over a one week period. At the first visit they will complete an initial questionnaire regarding current scalp care practices, skin type, and hair type. An initial baseline scalp swab and HairMetrix photography in the two swab sites will be taken at the beginning of this visit. Treatment with the Venus Glow™ device will also occur. To treat, the scalp will be divided into four quadrants. Swab samples will be collected at the first baseline and concurrent treatment session, second treatment session and 3-6 days after the last treatment when participants have returned to their usual cleansing routine.
48106651|NCT00238316|DRUG|letrozole|2.5 mg PO daily for 1 year
48478701|NCT03276676|DRUG|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine|Multi-tracer PET exams of \[18F\]FLT and \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
48637352|NCT03932409|DRUG|Paclitaxel|after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
48637353|NCT03932409|DRUG|Carboplatin|after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
48106652|NCT00238316|OTHER|Placebo|2.5 mg PO daily for one 1 year
48106653|NCT01830842|DRUG|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
48106654|NCT01830842|DRUG|Placebo|nonsmokers will be measured following placebo administration
48106655|NCT01830842|OTHER|satiety|smokers will be measured in a smoking satiated condition
48106656|NCT01830842|OTHER|abstinence|smokers will be measured following 24-hours of smoking abstinence
48106657|NCT03870854|PROCEDURE|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
48106658|NCT02435199|DRUG|EMA401 600mg|
48106659|NCT02435199|DRUG|Placebo|
48106660|NCT03999554|BIOLOGICAL|LD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
48106661|NCT03999554|BIOLOGICAL|MD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
48106662|NCT03999554|BIOLOGICAL|HD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
48298743|NCT01219244|BEHAVIORAL|resveratrol supplementation|6 months of resveratrol supplementation
48298744|NCT01219244|BEHAVIORAL|Placebo|6 months of placebo intake
48298745|NCT01219244|BEHAVIORAL|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
48298746|NCT01219244|BEHAVIORAL|2nd step: intervention + control|most effective dietary intervention plus control
48298747|NCT03749993|OTHER|Screening|Use of bpMRI for opportunistic prostate cancer screening.
48478702|NCT06400485|DRUG|AMT-676|Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
48637354|NCT03918031|BEHAVIORAL|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
48637355|NCT03918031|BEHAVIORAL|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
48637356|NCT04744129|DRUG|NN414|To investigate the role of NN414 on cerebral hemodynamic in migraine patients
48637357|NCT04744129|DRUG|Saline|To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.
47951004|NCT03633136|BEHAVIORAL|electronic video education|Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
47951005|NCT00767949|BIOLOGICAL|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
47951006|NCT06557538|DEVICE|Automatic Ankle Brachial Pressure Index device assessment|The automatic device assesses 3 limbs, providing automatic simultaneous ABPI measurement of systolic, diastolic and mean arterial blood pressure on to calculate the patient\&#39;s ABPI (Medi UK 2022).
47951007|NCT06557538|DEVICE|Manual Ankle Brachial Pressure Index assessment|The manual device assesses 4 limbs, providing brachial, ankle and pedal systolic pressures. A simple calculation is then made by the clinician to determine the ratio of ankle and brachial systolic pressure (ABPI) (Day 2015).
48637358|NCT04170075|BEHAVIORAL|Whole Body Vibration|Undergo WBV
48478703|NCT04660955|OTHER|No Intervention - Observational study with MRI|90 minute MRI of the knees
48478704|NCT05143203|OTHER|Self-hypnosis training|Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
48478705|NCT04935788|DIETARY_SUPPLEMENT|milk protein|milk protein supplement
48637359|NCT00227955|DRUG|Imipramine|
47951008|NCT06623682|BEHAVIORAL|Transdiagnostic cognitive behavioural therapy|Transdiagnostic cognitive behavioural therapy for both depression and anxiety that including modules from (1) Mindfulness-based intervention, (2) Rumination-focused cognitive behavioural therapy, and also including modules for insomnia and from Mindwork (Internet-based cognitive behavioural therapy).
47951009|NCT03202888|BEHAVIORAL|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
47951010|NCT05423054|OTHER|Abdominal massage|"* Patients will be positioned on their back while their knees will be flexed.~* Each patient will receive a 15-minute abdominal massage intervention half an hour before enteral feeding twice per day and the interval between two massages is 2 hours for consecutive 3 days.~* The PR will be standed on the right side of the patient during the massage practice.~* The abdominal massage technique will be delivered to each patient in four consecutive strokes including stroking, effleurage, kneading and vibration."
47951011|NCT00528827|DRUG|Cardene® I.V.|"* 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V."
47951012|NCT04903665|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
48298748|NCT00978445|OTHER|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
48298749|NCT02438436|DIETARY_SUPPLEMENT|simo decoction|
48298750|NCT02438436|OTHER|gum chewing|
48298751|NCT02815397|DRUG|Metformin|given in addition to standard of care treatment
48298752|NCT00370149|DEVICE|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
48478706|NCT04935788|DIETARY_SUPPLEMENT|micellar casein|micellar casein supplement
48478707|NCT04935788|DIETARY_SUPPLEMENT|pea protein|pea protein supplement
48478708|NCT04935788|DIETARY_SUPPLEMENT|milk/pea protein blend|milk/pea protein supplement
48478709|NCT03623620|BEHAVIORAL|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
48637360|NCT00227955|BEHAVIORAL|Interpersonal Psychotherapy|
48637361|NCT04704921|GENETIC|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
48637362|NCT04704921|GENETIC|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
48637363|NCT04704921|BIOLOGICAL|Ranibizumab (LUCENTIS®)|0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
48637364|NCT04076579|DRUG|Olaparib|Olaparib taken by mouth twice daily
48637365|NCT04076579|DRUG|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
47951013|NCT03814473|OTHER|Diet|"Participants provided with a brochure providing a thorough description of the diet, \~8 example recipes for each meal (i.e. breakfast, lunch, dinner, and snacks) included as a sample menu, and guidance to assist in shopping and self-preparation of food for the prescribed diet and to improve adherence. Diet consisted of following the popular paleolithic diet"
48298753|NCT00370149|DEVICE|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
48298754|NCT06511869|DRUG|AZD4205|AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
48298755|NCT03336398|DRUG|Ketamine Hydrochloride in saline|0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
48298756|NCT03336398|DRUG|Saline|Saline will be administered with the other MRS scan
48298757|NCT01271478|DRUG|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
47951014|NCT06680765|BEHAVIORAL|Intervention group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
47951015|NCT06680765|BEHAVIORAL|Comparison group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
47951016|NCT04122534|BEHAVIORAL|Somatic Mindfulness Training|Educational and experiential training to reduce occupational-based secondary trauma.
47951017|NCT01891110|PROCEDURE|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
47951018|NCT01891110|PROCEDURE|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
47951019|NCT01891110|PROCEDURE|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
47951020|NCT02398656|DRUG|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
47951021|NCT02398656|DRUG|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
47951022|NCT00147212|DRUG|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
47951023|NCT02325648|DRUG|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
47951024|NCT02810522|DEVICE|OneTouch Select® Plus Glucose Test Strips|
47951025|NCT02651350|DRUG|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
48298758|NCT01271478|DRUG|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
48298759|NCT01271478|DRUG|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
48298760|NCT01271478|DRUG|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
48298761|NCT04715724|OTHER|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
47951026|NCT02651350|DRUG|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
47951027|NCT02402101|DEVICE|Procedure: active tDCS|Intensity 2 mA during 20 minutes
48298762|NCT01678807|BIOLOGICAL|MK-8237 6 DU|
48298763|NCT01678807|BIOLOGICAL|MK-8237 12 DU|
48298764|NCT01678807|BIOLOGICAL|Placebo|
47951028|NCT02402101|DEVICE|Procedure: sham tDCS|sham condition as delivered by the stimulator
47951029|NCT04120441|BEHAVIORAL|Group Mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions.
47951030|NCT04708379|BEHAVIORAL|Lifestyle intervention|Nutrition and physical activity education.
47951031|NCT03949439|PROCEDURE|Elective Cardiac Surgery|Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).
47951032|NCT02770833|OTHER|Fish and carbohydrats with low or high GI|
47951033|NCT02770833|OTHER|Veal and carbohydrats with low or high GI|
48298765|NCT05650450|DEVICE|DES+DCB|Hybrid approach is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES for a de novo long (\>38 mm) lesion (located in the larger, more proximal part of the vessel -reference vessel diameter -RVD \>2.75 mm-) and DCB inflation for a concomitant and contiguous de novo small vessel disease (distally located with RVD ≤2.75 mm ≥ 2.0 mm)
48298766|NCT00935857|DEVICE|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
48298767|NCT00935857|DEVICE|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
48637366|NCT06434506|OTHER|no intervention|No intervention
47951034|NCT03836703|DRUG|Feroglobin single daily use|Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
48478710|NCT05450484|DRUG|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
48298768|NCT03645837|OTHER|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
48298769|NCT04919486|BEHAVIORAL|visual feedback with non-weight bearing exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
48637367|NCT05708599|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
48478711|NCT05227131|DRUG|Margetuximab|Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
48637368|NCT02539407|OTHER|Pharmacokinetics|
48637369|NCT01640535|DRUG|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
48637370|NCT01640535|DRUG|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
48637371|NCT01640535|DRUG|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
48637372|NCT05971888|BEHAVIORAL|Food system and demand generation|GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
48298770|NCT04919486|BEHAVIORAL|elastic band exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
48298771|NCT02328573|BEHAVIORAL|Communal singing|
48478712|NCT05227131|DRUG|Tucatinib|Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
48478713|NCT05227131|DRUG|Capecitabine|Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
48637373|NCT06193629|DRUG|Lang Qingata|Lang Qingata: (Artificial bezoar: 0.1g, Safflower: 15g, five spirit fat: 15g, Tangerine: 30g, Swertia: 15g, nutmeg: 10g, Astragalus: 25g, wood fragrance: 10g, Parasol tiger grass: 15g, Coriander fruit: 10g, Agarwood: 3g, pomegranate seed: 20g, Rhododendron: 8g, Dongquai fruit: 15g, licorice: 10g). Water decoction (hospital decoction), Decoction in water for oral use，2 times/day, 4 weeks for a course of treatment.
48637374|NCT06193629|DRUG|placebo|Placebo is a Chinese medicine granule with 5% active ingredient and has the same taste as Lang Qingata，Decoction in water for oral use
48637375|NCT00240773|DRUG|acetaminophen|4 grams daily for six months
48637376|NCT00240773|DRUG|naproxen|750 mg daily for 12 months
48637377|NCT00240773|DRUG|acetaminophen|4 grams daily for 12 months
48637378|NCT00240773|DRUG|naproxen|750 mg daily for six months
48637379|NCT05829317|DRUG|Magnesium sulfate|Intravenous Magnesium sulfate
48637380|NCT05829317|DRUG|Placebo|0.9% NaCl
47951035|NCT03836703|DRUG|Feroglobin twice daily dose|Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
47951036|NCT00422097|DRUG|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
47951037|NCT00422097|DRUG|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
47951038|NCT00422097|DRUG|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
47951039|NCT00422097|DRUG|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
47951040|NCT00422097|DRUG|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
48637381|NCT04007874|DRUG|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
48637382|NCT04007874|DRUG|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
48637383|NCT03606213|BIOLOGICAL|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
48637384|NCT03606213|BIOLOGICAL|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
48637385|NCT03606213|BIOLOGICAL|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
48637386|NCT03606213|DEVICE|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
48637387|NCT06209086|DEVICE|skeletal anchored twin block|"This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally."
48637388|NCT00463775|DRUG|Topiramate|SSRI plus topiramate SSRI plus placebo
48637389|NCT06428474|OTHER|Health education|Oral health education program designed for orphans children
48637390|NCT04998149|DEVICE|Peanut Ball positioning device|Peanut Ball manufactured by Clinton industries at graylinemedical.com https://www.graylinemedical.com/products/clinton-industries-peanut-ball-peanut-ball-40-cm-yellow-8540?_pos=3\&_sid=d6e52e63c\&_ss=r
47951041|NCT00422097|DRUG|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
47951042|NCT00422097|DRUG|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
48478714|NCT05899920|DIAGNOSTIC_TEST|Blood samples will be taken for pharmacokinetics and pharmacogenetics|To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
48478715|NCT00006399|DRUG|Donepezil|
48637391|NCT05280158|DRUG|mRNA-1273 (Moderna COVID-19 vaccine)|Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
48637392|NCT05704829|DRUG|Trastuzumab deruxtecan|T-DXd i.v.
48637393|NCT05704829|DRUG|Standard-of-Care|Chemotherapy+T+P
48637394|NCT02429167|DEVICE|Cranial nerve non-invasive neuromodulation via PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
47951043|NCT00422097|DRUG|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
48478716|NCT00006399|DRUG|Estrogen|
48478717|NCT00006399|DRUG|Progesterone|
48478718|NCT01010815|PROCEDURE|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
48478719|NCT01010815|OTHER|stool collection|Stool will be collected from participants at study entry
48478720|NCT01010815|PROCEDURE|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
48478721|NCT01010815|OTHER|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
47951044|NCT06059573|PROCEDURE|dental implant robot|Implant placement will be navigated by a dental implant robot based on a digital plan.
47951045|NCT06059573|PROCEDURE|Freehand surgery|Implant will be placed under freehand surgery.
48478722|NCT03576287|DRUG|Apremilast Oral Product|Apremilast
48478723|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed.
47951046|NCT02173873|DRUG|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
48298772|NCT05019183|OTHER|Physical training|The subjects will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) with a target heart rate zone of 60%.
48298773|NCT05019183|OTHER|Virtual reality|The subjects will be able to move freely in virtual environments while training on the indoor rower.
48298774|NCT05019183|DEVICE|Single-photon emission computed tomography (SPECT)|SPECT allows the measurement of cerebral perfusion, reflecting the global synaptic activity, via a 3D acquisition of 20 minutes, 15 minutes after injection of 740 MBq of radiotracers (ECD - Neurolite or HMPAo - Cerestab), with iterative reconstruction. The data will be processed at the voxel scale by the SPM12 software, with analysis of brain connectivity.
48298775|NCT05019183|BIOLOGICAL|Metabolomics|This qualitative approach will aim to identify pathways that are not known (or have not been explored) to optimize the chances of detecting metabolites present depending on the group (physical activity coupled or not with VR). This method is favorable for biomarker discovery.
48298776|NCT04255186|DEVICE|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
48298777|NCT04255186|DEVICE|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
48298778|NCT04255186|DEVICE|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
48298779|NCT00688493|DRUG|Dapagliflozin|3 x 50 mg tablets, single oral dose
48298780|NCT00688493|DRUG|Dapagliflozin|2 x 10 mg capsules, single oral dose
48298781|NCT00688493|DRUG|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
48298782|NCT00688493|DRUG|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
48298783|NCT05603624|PROCEDURE|Cervical examination to assess labor|Patients were randomized to receive cervical examinations to assess progression in labor with either sterile or clean gloves.
48298784|NCT05106972|DRUG|UC-MSC infusion|UC-MSC infusion by introvenus
47951047|NCT00878670|DRUG|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
47951048|NCT00776724|DRUG|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
48106663|NCT03999554|BIOLOGICAL|LD Bris10 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
48106664|NCT03999554|OTHER|Placebo|This group will receive saline placebo administered intranasally.
48298785|NCT03849469|BIOLOGICAL|XmAb®22841|Monoclonal bispecific antibody
48298786|NCT03849469|BIOLOGICAL|Pembrolizumab (Keytruda®)|FDA-approved humanized monoclonal antibody
48106665|NCT03814395|OTHER|No intervention|This is an observational study without any intervention
48106666|NCT02657629|OTHER|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
48106667|NCT02657629|OTHER|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
48106668|NCT02534441|OTHER|Skin patch test|
48106669|NCT00481234|DEVICE|Heart Rate Variability analysis|
48106670|NCT05262803|GENETIC|CYP2C19*2/*3|"* Non-carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with clopidogrel and ASA~* Carriers of CYP2C19\*2/\*3 loss-of-function alleles: DAPT with prasugrel (or ticagrelor) and ASA"
48298787|NCT04014504|DIAGNOSTIC_TEST|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
48298788|NCT00909285|DEVICE|TMS stimulation|TMS stimulation and cognitive training
48298789|NCT00909285|DEVICE|Sham comparator|Sham comparator
48298790|NCT00909285|BEHAVIORAL|Cognitive training|TMS stimulation and cognitive training
48298791|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
48298792|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
48298793|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
48106671|NCT05262803|OTHER|Shorter DAPT duration|Duration of DAPT is shortened to 3 months
48106672|NCT03684096|DIETARY_SUPPLEMENT|non-estrogenic pollen extract PCC-100|non-estrogenic pollen extract PCC-100
48106673|NCT03684096|OTHER|placebo|placebo -non-estrogenic pollen extract PCC-100
48106674|NCT01709266|DIETARY_SUPPLEMENT|Probiotics|
48106675|NCT01709266|DIETARY_SUPPLEMENT|Placebo|
48637395|NCT02429167|DEVICE|Sham PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
48478724|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
48637396|NCT05702619|DRUG|Optional non-IMP pimonidazole|patients will be asked to ingest an oral formulation of pimonidazole hydrochloride (HCl) (Oral HypoxyprobeTM-1). Pimonidazole HCl is a marker for hypoxia in tumour tissue when ingested as an encapsulated solid. Following oral administration, pimonidazole distributes throughout the body where it covalently binds to normal and tumour tissues that have regions of low oxygen concentrations (pO2 of ≤ 10 mmHg at 37oC). The tissue binding can be visualised by immunohistochemistry / light microscopy. The capsules are to be taken within 8-16 hours (optimal timepoint 12 hours) before the planned first biopsy within Arm 1 and before radical prostatectomy for patients in Arm 2. If the patient refuses the pimonidazole, forgets to take it, or if it is not available, the patient can still participate in the study and their samples will be stained for hypoxia post-biopsy.
47951049|NCT00776724|DRUG|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
47951050|NCT04523948|BEHAVIORAL|Behavioral and pharmacological support to reduce combustible tobacco use.|Behavioral and pharmacological support to reduce combustible tobacco use.
48637397|NCT05702619|DIAGNOSTIC_TEST|CT-guided Bone Biopsy|A CT-guided biopsy of a bone metastasis that is deemed to be easy to biopsy and in an area without major risk for pathological fracture or bleeding will be taken during the biopsy visit. Patients will receive routine local anaesthetic of the region to be biopsied followed by thorough disinfection of the biopsy site with antiseptic wipes. Patients will be asked to fast on the day of the procedure and to have an intravenous cannula inserted to allow the use of medication causing minimal sedation (for example midazolam and/or fentanyl) during the procedure if required to alleviate discomfort or pain.
48478725|NCT02332408|RADIATION|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
48637398|NCT05702619|DIAGNOSTIC_TEST|TRUS-guided Targeted Transperineal Prostate Biopsy|Transperineal Prostate Biopsy will be performed following standard clinical practice of local department. This will include pre-operative oral analgesia and prophylactic antibiotic treatment according to local hospital policy for transperineal prostate biopsies.
48637399|NCT05702619|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy will be performed according to standard of care robotic approach and as relayed to the patient by the attending urologic surgeon. The side effects of the surgery are the ones reported in the literature and the latest participant information leaflet provided prior patient consent (e.g. risk of erection disfunction, incontinence, etc.).
48478726|NCT02332408|RADIATION|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
48478727|NCT06193031|DRUG|C16TR|Administered as inhalation using a Philips Micro device inhaler.
47951052|NCT06282393|DEVICE|FibriCheck recordings|PPG and single-lead ECG measurements
47951053|NCT06243484|DIETARY_SUPPLEMENT|TOTUM-070|12 weeks of TOTUM-070 supplementation with Placebo (blinded arms)
47951054|NCT06243484|DIETARY_SUPPLEMENT|PLACEBO|8 capsules per day to consume orally in two intakes
47951055|NCT02876094|DRUG|celecoxib|dose-response
47951056|NCT04781504|BEHAVIORAL|Exercise|intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
47951057|NCT03815539|DEVICE|0.1% sodium hyaluronate|In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
47951058|NCT02863276|PROCEDURE|Intensified insulin therapy|
47951059|NCT01601132|DRUG|theophylline|300mg (80mg/15ml elixir)
48478728|NCT06193031|DRUG|Placebo|Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
48478729|NCT06193031|DRUG|Tyvaso®|Administered as inhalation.
48478730|NCT02270749|DRUG|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
48478731|NCT02270749|DRUG|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
48106676|NCT04935749|DEVICE|Ultra wide-field retinal imaging|Diabetic patients will be imaged with an ultra wide-field retinal imaging device (Optos, California). Patients will be imaged either with or without mydriasis.
47951060|NCT01601132|DRUG|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
47951061|NCT06142903|OTHER|7 versus 21 medically tailored meals per week|Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
47951062|NCT00033605|DRUG|octreotide acetate|
47951063|NCT00033605|OTHER|placebo|
47951064|NCT00033605|RADIATION|radiation|
47951065|NCT02186431|DEVICE|senofilcon A|
47951066|NCT01225770|DIETARY_SUPPLEMENT|green tea|Gargling three times daily for 90 days
47951067|NCT05376943|DRUG|Direct Acting Antivirals|Our observational study will assess the exposure to direct acting antivirals - the specific drugs, dose, duration of the therapy and the effect of the treatment.
47951068|NCT06680570|DIAGNOSTIC_TEST|Pulmonary Function Testing, Carbon Monoxide (CO) Breath Testing|"Pulmonary Function Testing FEV1 and FVC spirometry tests used to measure lung capacity among both smoker and non-smoker students.~Carbon Monoxide (CO) Breath Testing Measurements taken using a CO breath analyzer to assess CO levels in the smoker group.~Physical Activity Assessment (IPAQ-SF) The International Physical Activity Questionnaire Short Form (IPAQ-SF) used to evaluate physical activity levels and sedentary behavior among students.~Headache Impact Test (HIT-6) HIT-6 questionnaire used to assess the impact of headaches on daily life."
47951069|NCT03081468|DEVICE|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
47951070|NCT03081468|DEVICE|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
47951071|NCT06680921|DRUG|SIM0270|Experimental
47951072|NCT06680921|DRUG|Everolimus (Afinitor®)|Experimental and Active comparator
47951073|NCT06680921|DRUG|Exemestane tablets|Active Comparator
47951074|NCT06680921|DRUG|Fulvestrant injection|Active Comparator
47951075|NCT06289985|DEVICE|Endovascular thrombectomy with any FDA-approved category POL or NRY device|Endovascular thrombectomy with any FDA-approved category POL or NRY device - Neurovascular Mechanical Thrombectomy Device For Acute Ischemic Stroke Treatment (POL), and/or Catheter, Thrombus Retriever (NRY)
47951076|NCT06289985|OTHER|Medical Management|Medical Management (MM) may involve any combination of the following: intravenous thrombolysis, antiplatelets, anti-hypertensives, cholesterol-lowering medications, and rehabilitative care.
47951077|NCT05186285|DRUG|CM338|CM338 : a humanized monoclonal antibody.
47951078|NCT05186285|DRUG|Placebo|Placebo.
47951079|NCT01346969|DRUG|EXC 001|Single-dose administered by injection four different times
47951080|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
47951081|NCT01346969|DRUG|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
47951082|NCT01346969|DRUG|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
47951083|NCT04300439|DEVICE|knee total arthroplasty with two types of ancillaries|"-For the Arm A, the surgical procedure of knee total arthroplasty will be done with metallic reusable ancillary.~For the Arm B, the surgical procedure of knee total arthroplasty will be done with Efficiency single use ancillary."
47951084|NCT06218368|BEHAVIORAL|Educational toolkit on MMR and polio vaccination|The educational video about vaccines was adapted from a health educational toolkit that aims to promote community confidence in vaccines in the ultra-poor Philippine households. This toolkit contains persuasive messaging on vaccination guidelines, vaccines safety and efficacy, and myths and misconceptions of MMR and polio vaccines. Participants in the intervention arm will receive our educational video about MMR and polio vaccines. Additionally, health educators from ICM will teach the participants to understand their vaccination cards and orally remind them to have their children vaccinated at each week's Transform Program session from week 12 until week 15. After the end of the Transform Program, about 40-50% of the participants in the intervention arm will attend another community-based program run by ICM called the Savings Groups, where the participants will receive weekly reminding messages about MMR and polio vaccination in their group meetings for three months.
47951085|NCT01192373|OTHER|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
47951086|NCT01192373|OTHER|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
47951087|NCT05264727|DRUG|Dextrose|Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
47951088|NCT05264727|DRUG|Clinisol 15%|Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
47951089|NCT05168449|OTHER|Mobile Application|mobile phone applications directed to chronic kidney disease patients to improve their medication.
47951090|NCT04110678|DRUG|NeuroEPO|NeuroEPO \[CIMAB S.A, Havana, Cuba\]
47951091|NCT06550687|OTHER|Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis|Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools
47951092|NCT06449898|OTHER|hemodialysis group|Data were collected from patients undergoing treatment at a hemodialysis center in Kırşehir. Participants were informed about the study objectives and provided written consent. Data collection took approximately 20-30 minutes per participant and included a face-to-face interview where socio-demographic and clinical information was recorded.
48106677|NCT06346769|OTHER|Polyethylene Fiber|In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.
48298794|NCT05163561|BIOLOGICAL|Sii Licensed IPV|Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
48106678|NCT01792648|OTHER|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
48106679|NCT01792648|OTHER|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
48106680|NCT01792648|OTHER|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
48106681|NCT04749433|DRUG|[11C]CPPC Injection|A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
48298795|NCT00907140|PROCEDURE|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
48637400|NCT05702619|DIAGNOSTIC_TEST|Whole-body MRI|Whole-body MR imaging (wbMRI) will be performed once, before or after the biopsy study visit, depending on available examination slots in the Department of Radiology. WbMRI images will allow comparison of the numbers of bone metastases detected by routine bone scan and wbMRI for sensitivity assessment of both techniques for oligometastatic disease.
47951093|NCT05616273|OTHER|Mixed Meal Tolerance Test (MMTT)|At either Visit 1 or Visit 2, participants will be given Ensure HP or Fortisip (a drink containing the same amounts of carbohydrates, protein and fats as there would be in a meal; 6ml/kg to a max of 360mls), and have blood samples collected, to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 30, 60, 90, 120 minutes post meal. This test is used to measure how a participant's beta cells are working to produce insulin after a meal and to check for reactive hypoglycaemia.
47951094|NCT05616273|OTHER|Arginine Stimulation Test (AST)|At either Visit 1 or Visit 2, and Visit 3, participants will be given a dose of Arginine Hydrochloride (5 g Arginine during 1 min) by intravenous injection, and have blood samples collected to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 2, 5, 10, 15 and 30 minutes following the Arginine bolus injection. This test is designed primarily to test the maximum insulin secretion capacity of a participant's beta cells.
47951095|NCT05616273|OTHER|Home Finger Prick Sample|Participants will be provided with a kit to collect an optional home finger prick sample the day after each visit, and return the sample using the prepaid addressed padded envelope provided.
47951096|NCT05504473|DEVICE|NEURO-BLINK Device|The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
47951097|NCT06680128|BIOLOGICAL|GBP560-A|"injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
47951098|NCT06680128|BIOLOGICAL|GBP560-B|"injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"
47951099|NCT06680128|BIOLOGICAL|IXIARO|injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2
48106682|NCT01457560|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
48106683|NCT01457560|BIOLOGICAL|OPV|One dose administered orally
48106684|NCT00415272|BEHAVIORAL|Pulmonary Rehabilitation|
48106685|NCT05422716|DEVICE|Epidural implant stimulation device|Individuals randomized to the Baclofen pump device group will continue with their clinical surgical and maintenance plan while also participating in all of the outcomes (assessments). The epidural implant group will undergo the research protocol for epidural stimulator surgical implant followed by mapping studies to identify targeted stimulation configurations for spasticity.
48298796|NCT03136211|BEHAVIORAL|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
47951100|NCT06680128|BIOLOGICAL|IMOJEV|injection volume of 0.5mL on V5 (29day) in stage1 and stage2
47951101|NCT06680128|BIOLOGICAL|Normal Saline (Placebo)|injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)
47951102|NCT00775073|DRUG|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
47951103|NCT02787265|DEVICE|spinal cord stimulation|
47951104|NCT04017000|DIAGNOSTIC_TEST|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
47951105|NCT04017000|OTHER|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
47951106|NCT00052780|DRUG|O6-benzylguanine|Given IV
47951107|NCT00052780|DRUG|temozolomide|Given PO
47951108|NCT00052780|BIOLOGICAL|filgrastim|Given SC or IV
47951109|NCT00052780|OTHER|pharmacological study|Correlative studies
48106686|NCT05774119|OTHER|breakfast with coffee|breakfast with coffee with 6 mg/caffeine/kg body weight
48106687|NCT05774119|OTHER|breakfast with water|breakfast with 250 mL of water
48106688|NCT02967237|DRUG|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
48106689|NCT02633358|DEVICE|Therapeutic hypothermia group|Therapeutic hypothermia
48106690|NCT04741971|DIETARY_SUPPLEMENT|Probiotics group|Will give Probiotics with Vitamin D3 one drop per day for 90 days
48106691|NCT04741971|DIETARY_SUPPLEMENT|Non-probiotics group|Will give Vitamin D3 five drops per day for 90 days
48106692|NCT02520570|DRUG|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
47951110|NCT00052780|OTHER|laboratory biomarker analysis|Correlative studies
47951111|NCT06681610|DEVICE|Transcranial Pulse Stimulation|low intensity shock-waves stimulation of the motor cortex, bilateral
47951112|NCT03464877|OTHER|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
47951113|NCT04672720|DRUG|L-carnitine 1000 Mg|Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
47951114|NCT04040244|OTHER|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
47951115|NCT04040244|OTHER|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
47951116|NCT01757262|DRUG|90 mg Ticagrelor|Morning and Evening dose for 5 days
48106693|NCT05010304|DRUG|Amoxicillin|Two-dose amoxicillin challenge
48106694|NCT00454792|OTHER|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
48106695|NCT00454792|OTHER|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
48106696|NCT05114044|OTHER|Core stability training|The core stability training were performed 5 days a week for 15 min over a period of 3 weeks. The conventional therapy were performed 5 days a week for 30 min (remaining time of each session) over a period of 3 weeks. Duration of each session was 45 min.
48106697|NCT05114044|OTHER|Conventional therapy|The conventional therapy were performed 5 days a week for 45 min over a period of 3 weeks. Duration of each session was 45 min
48106698|NCT06301035|DEVICE|Asymmetric High flow nasal cannula|"* Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group.~* The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%.~* After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary."
48298797|NCT03852888|BIOLOGICAL|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
48298798|NCT05923905|DRUG|FB1006|30mg/day
48298799|NCT05923905|DRUG|Placebo|30mg/day
47951117|NCT01757262|DRUG|75mg Clopidogrel|Morning dose for 5 days
47951118|NCT04721951|PROCEDURE|Endovascular Aortic Repair using Carbon Dioxide Angiography|Endovascular Aortic Repair using Carbon Dioxide Angiography
47951119|NCT03378765|BEHAVIORAL|Diet and physical activity monitoring|Lifestyle monitoring
47951120|NCT05893498|DEVICE|FFRangio|A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.
47951121|NCT05893498|DEVICE|FFR or NHPR|Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
47951122|NCT05227378|BIOLOGICAL|neoantigen tumor vaccine with or without PD-1/L1|personalized neoantigen tumor vaccine with or without PD-1/L1
47951123|NCT06680167|DRUG|Spinal anesthesia (heavy bupivacaine 0.5%)|12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section
47951124|NCT06680167|DRUG|spinal anesthesia (hyperbaric Prilocaine 2%)|60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
47951125|NCT04537195|BEHAVIORAL|ADSMP-C|A transdiagnostic, lay-led, group-based self-management program consisting of seven 2 ½ hour weekly sessions focusing on increasing patient self-efficacy in symptom management of anxiety and depression in cancer (ADSMP-C)
47951126|NCT06680869|DRUG|Amiodarone Hydrochloride Injection|"The use of a modified treatment protocol by emergency medical services where the initial dose of amiodarone is given after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
47951127|NCT06680869|OTHER|Usual Care Protocol|"The use of a usual care treatment protocol by emergency medical services where the initial dose of amiodarone is given after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
47951128|NCT00141388|DRUG|Pregabalin|
48298800|NCT06201195|PROCEDURE|Adductor canal blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
48298801|NCT06201195|PROCEDURE|Distal adductor canala blockade and anterior cutaneus nerve blockade|VAS, VAS move, incision place pain for up and down to patella, drain place pain, motor strenght for femoral nerve and siyatic nerve muscles, side effects, first analgesic requirement time, opioid requirement, other analgesics
48298802|NCT02145767|DRUG|Progesterone|
48298803|NCT02145767|DRUG|Placebo|
48107205|NCT04158154|OTHER|Evidence-based fixed-dose combination protocol based treatment|The intervention has been adapted based on a local needs' assessment including exploration of health care workers and patient's knowledge, attitudes, and behaviors related to HTN, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable barriers to HTN treatment and control across capability, intentional, and system domains using CFIR. Sites will randomly be assigned to receive either: Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 2 separate pills); Step 3 amlodipine 10 mg + losartan 100 mg (as 4 separate pills); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo) or Step 1 amlodipine 5mg; Step 2 amlodipine 5 mg + losartan 50 mg (as 1 single pill combo); Step 3 amlodipine 10 mg + losartan 100 mg (as 2 single pill combo); Step 4 amlodipine 10/losartan 100/HCTZ 25 (as 2 single pill combo).
48107206|NCT05377346|OTHER|Placement of the i-gel|The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
48107207|NCT03615248|DEVICE|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~1. the dose was given,~2. the metered dose inhaler was properly shaken,~3. the metered dose inhaler is properly aligned,~4. the flow of medication is appropriate and~5. there is no accidental exhalation into the inhaler."
48107208|NCT06368804|DRUG|Antibiotic monotherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
48107209|NCT06368804|DRUG|Antibiotic bitherapy treatment and follow-up|"1. a 3-months treatment period, including:~   * an initial phase of 14 days, combining an IV beta-lactam antibitic (ceftazidime 4 or 6g/d) and an oral fluoroquinolone (ciprofloxacin 750mg tw/d) with nebulized sodium colistimethate (1 Million Units tw/d)~  * a maintenance phase of 2.5 months: nebulized sodium colistimethate (1 MU tw/d) ;~2. a subsequent follow-up period of 9 months (i.e. until 12 months after the start of antibiotic therapy against Pseudomonas aeruginosa)."
48107210|NCT03219645|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
48107211|NCT03219645|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
48339808|NCT03549819|DRUG|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
47951394|NCT04234802|OTHER|Heat Education and Awareness Tools|HEAT training will be delivered to agricultural workers by research staff in this study in the spring. HEAT training uses interactive approaches to engage participants and posters with visuals. Training covers types of heat-related illness and treatments, risk factors, appropriate clothing and hydration, and keeping cool in the home and community. The HEAT awareness application was developed in collaboration with Washington State University's AgWeatherNet Program to notify supervisors signed up for the service about hot weather conditions that might increase the risk for adverse health effects for workers. The HEAT awareness application is designed to allow subscribers to select weather stations of interest and view current heat indices as well as maximum daily heat indices forecasted over the following week. This information is coupled with information about health effects and prevention of adverse heat health effects. Materials are provided in English and Spanish.
47951395|NCT01771042|OTHER|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
47951396|NCT01411618|OTHER|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
47951397|NCT00333801|BEHAVIORAL|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
47951398|NCT00333801|BEHAVIORAL|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
47951399|NCT01887223|PROCEDURE|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
48107212|NCT00676533|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
48298896|NCT06321744|OTHER|adapted physical activity program (APA Program)|"Content of the APA program:~* Strengthening of the lower limbs: Exercises alternating different regimes of muscular contractions (eccentric, concentric and isometric), with the use of elastics, balls or even body weight. These exercises will mainly work the quadriceps and hamstrings.~* Upper limb strengthening: Exercises focused on eccentric and concentric contraction regimes, in a global movement approach (as opposed to a segmental approach), with the use of elastics, dumbbells, weighted balls, etc. These exercises will work the muscles of the biceps, triceps, pectorals, deltoids and lats.~* Walking: In the room and/or in the corridor, with technical assistance (cane/walker, etc.) or human work~* Balance and proprioception: Balance work in a bi- and uni-pedal situation, statically and dynamically (eyes open and closed) will be offered with the use of proprioception boards and/or mats combining if possible work in dual task."
48298897|NCT00004640|DRUG|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
48298898|NCT06512363|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
48637481|NCT05339061|DEVICE|Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).|"Modification~* Deploy the graft on the sterile, surgical table~* Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~* Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~* If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~* If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~* Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch"
48107213|NCT06134804|BIOLOGICAL|ExPEC9V|ExPEC9V will be administered as an IM injection.
48107214|NCT06134804|BIOLOGICAL|Placebo|Placebo will be administered as an IM injection.
48107215|NCT06134804|BIOLOGICAL|HD quadrivalent influenza vaccine|HD quadrivalent influenza vaccine will be administered as IM injection.
48107216|NCT03008915|DRUG|Aspirin|81mg aspirin taken once per day in the morning
48298899|NCT06512363|DRUG|Ramelteon placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
48298900|NCT00279903|DRUG|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
48298901|NCT00279903|DRUG|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
48298902|NCT03691623|DRUG|EDP-938 Dose 1|Oral suspension for 5 days
48298903|NCT03691623|DRUG|EDP-938 Dose 2|Oral suspension for 5 days
48298904|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
48298905|NCT03691623|DRUG|EDP-938 Dose 3|Oral suspension for 5 days
48298906|NCT03691623|DRUG|EDP-938 Dose 4|Oral suspension for 5 days
48298907|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
48298908|NCT02389946|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
48298909|NCT02389946|DEVICE|Xience DES|
48637482|NCT06027892|RADIATION|Two-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a dose biologically comparable to 40 Gy in 5 treatments, but in only 2 treatments
48637483|NCT06027892|RADIATION|Five-fraction stereotactic radiotherapy|Definitive prostate radiotherapy will be delivered to a standard stereotactic dose of 40 Gy in 5 treatments
48107217|NCT03008915|DRUG|Placebo|placebo taken once per day in the morning
48107218|NCT03008915|OTHER|Withdrawal from alpha1 antitrypsin replacement therapy|After the completion of the randomization to aspirin and placebo, participants who are on alpha1 replacement therapy are asked to withhold their usual alpha1 antitrypsin replacement therapy for 5 weeks. This is not randomized.
48655889|NCT06645015|DEVICE|AI augmented risk-stratification|A state-of-the-art artificial intelligence (AI) model called AIDPRO manual CRC is used as a decision support tool to estimate the 1-year mortality risk for each patient
48655890|NCT04932577|BIOLOGICAL|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
48107219|NCT06107738|DRUG|Iberdomide|Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
48107220|NCT06107738|DRUG|Daratumumab/rHuPH20 Co-formulation|"Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)"
48107221|NCT00303836|DRUG|cyclophosphamide|Given IV
48107222|NCT00303836|DRUG|fludarabine phosphate|Given IV
48107223|NCT00303836|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
48107224|NCT00303836|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
48107225|NCT00303836|BIOLOGICAL|gp100 antigen|Given SC
48107226|NCT00303836|BIOLOGICAL|MART-1 antigen|Given SC
48107227|NCT00303836|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
48107228|NCT00303836|BIOLOGICAL|filgrastim|Given SC
48107229|NCT00303836|BIOLOGICAL|aldesleukin|Given IV
48107230|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Inulin-fructan 15mg/day for 28days
48107231|NCT01277445|DIETARY_SUPPLEMENT|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
48655891|NCT04932577|BIOLOGICAL|Placebo|Placebo
48655892|NCT06057623|OTHER|Evaluation of central and peripheral neuromuscular fatigue|To define peripheral and central component of fatigue, the investigators will test, before, during and after the fatigue task, the force produced during a Maximal Voluntary Contraction (MVC) and the force produced by the electrically evoked Resting Twitch (RT) produced, at rest, 5 seconds after the MVC.
48298910|NCT02633072|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
48298911|NCT01072864|OTHER|Walnuts|Consumption of 5 g of walnuts.
48298912|NCT01072864|OTHER|Walnuts|Consumption of 20 g of walnuts.
48637484|NCT05023889|DRUG|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
48298913|NCT01072864|OTHER|Walnuts|Consumption of 30 g of walnuts.
48298914|NCT01072864|OTHER|Walnuts|Consumption of 40 g of walnuts.
48298915|NCT04311476|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
48298916|NCT04311476|DRUG|0.9% Sodiun Chloride|0.9% Sodiun Chloride in control group
48298917|NCT03415464|OTHER|Exercise|neuromuscular training
48298918|NCT03197675|OTHER|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
48298919|NCT04911101|DEVICE|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
48298920|NCT04911101|DEVICE|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
48298921|NCT02241512|DRUG|Ibuprofen|
48298922|NCT02241512|DRUG|placebo|
48298923|NCT02551367|DRUG|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
48298924|NCT02551367|DRUG|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
48298925|NCT02551367|DRUG|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
48298926|NCT06111326|DRUG|BC3402 injection|Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
48298927|NCT06111326|DRUG|Durvalumab injection|Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
48298928|NCT03510663|DRUG|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
48298929|NCT03510663|DRUG|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
48298930|NCT03510663|DRUG|Moxifloxacin|400mg tablet will be administrated once a week.
48637485|NCT03137407|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
48298931|NCT03510663|DRUG|Placebos|Placebo will be intravenously administered once a week.
48298932|NCT01892527|DRUG|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
48298933|NCT05070949|BEHAVIORAL|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
48298934|NCT03666143|DRUG|Sitravatinib|Administered orally as a capsule
48298935|NCT03666143|DRUG|Tislelizumab|Administered intravenously
48298936|NCT05091060|DEVICE|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
48298937|NCT03298854|DEVICE|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
48298938|NCT03893903|DRUG|IDH1R132H peptide vaccine|"The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks."
48298939|NCT03893903|DRUG|Avelumab|"Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression."
48298940|NCT03823937|OTHER|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
48637486|NCT03137407|BIOLOGICAL|Placebo|Intramuscular injection
48298941|NCT01765764|DRUG|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
47951400|NCT01887223|DRUG|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
48298942|NCT01765764|DRUG|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
48298943|NCT01983345|PROCEDURE|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
48637487|NCT03607786|PROCEDURE|Retrograde Inferior Vena Caval Perfusion|Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.
48298944|NCT03321929|COMBINATION_PRODUCT|LUM Imaging System|Drug: LUM015 Device: LUM 2.6 Imaging Device
48637488|NCT03607786|PROCEDURE|Select antegrade cerebral perfusion|Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
47951401|NCT03368534|DEVICE|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
47951402|NCT06220279|DRUG|Diclofenac|Each were monitored for pain within 24 hours
47951403|NCT05296733|DRUG|BI 456906|BI 456906
47951404|NCT00406718|BEHAVIORAL|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
48298945|NCT03888300|OTHER|Physiotherapy|Chest Physiotherapy, physical exercises
48298946|NCT02444637|DRUG|Rivastigmine|
47951405|NCT00406718|BEHAVIORAL|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
47951406|NCT00406718|BEHAVIORAL|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
47951407|NCT06556524|BEHAVIORAL|observation|Behavioral observation and trauma measurement in live mannequin application
47951408|NCT00675259|DRUG|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days \[1 cycle\] for 5 cycles
47951409|NCT00675259|DRUG|carboplatin|AUC 2 IV on days 1, 8, and 15
47951410|NCT00675259|DRUG|nab-paclitaxel|100 mg/M2 IV
47951411|NCT00675259|PROCEDURE|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
47951412|NCT00675259|DRUG|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
47951413|NCT06205966|DIETARY_SUPPLEMENT|BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)|BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
47951414|NCT06205966|OTHER|Placebo|Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
47951415|NCT00806338|DRUG|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
47951416|NCT00806338|DRUG|Placebo|
47951417|NCT02973828|PROCEDURE|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
47951418|NCT03375008|DIAGNOSTIC_TEST|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
47951419|NCT03071146|DEVICE|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
48298947|NCT01289392|DEVICE|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
48298948|NCT01289392|DEVICE|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
48298949|NCT01289392|BEHAVIORAL|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
48298950|NCT01168804|DRUG|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
48298951|NCT04577859|DEVICE|ensoETM. Esophageal cooling during AF ablation|Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
48298952|NCT04577859|DEVICE|Esophageal temperature monitoring probe|An esophageal temperature monitoring probe is a typical monitoring device used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches \>38 degrees then it is widely recognized that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
48339809|NCT00791804|DRUG|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
47951420|NCT01230723|DEVICE|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
47951421|NCT01230723|DEVICE|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
48637489|NCT00253955|DRUG|Levofloxacin|
47951422|NCT06203379|OTHER|Neuromuscular Exercise Training|Neuromuscular Exercise Training
48107232|NCT02853474|BEHAVIORAL|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm."
47951423|NCT06203379|OTHER|control exercise|Exercise Training
48298953|NCT04365816|OTHER|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
48298954|NCT04005443|OTHER|radiopharmaceutical|his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
48298955|NCT04829643|DIAGNOSTIC_TEST|PET/MRI|A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
48298956|NCT00650429|DRUG|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
48298957|NCT00903461|BIOLOGICAL|EGFR Antisense DNA|"* Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~* EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
48298958|NCT05228652|OTHER|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
48298959|NCT01654562|DRUG|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
48298960|NCT00053846|DRUG|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
48298961|NCT00053846|DRUG|Placebo|Placebo
48637490|NCT00253955|DRUG|Piperacillin/Tazobactam|
48637491|NCT04220190|BIOLOGICAL|RAPA-501 Autologous T cells|TREG/Th2 cells
47951424|NCT06324383|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
48107233|NCT02853474|OTHER|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
48107234|NCT02853474|OTHER|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
48107235|NCT05426863|BEHAVIORAL|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
48107236|NCT00686517|BIOLOGICAL|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
48107237|NCT00686517|DRUG|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
48107238|NCT02171663|DRUG|BIBW 2992|
48107239|NCT02106442|DRUG|Sodium risedronate|Sodium risedronate tablets
47951425|NCT04234997|DRUG|Suvorexant 20 mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
48107240|NCT00217672|BIOLOGICAL|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
48107241|NCT00217672|DRUG|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
48637492|NCT04880590|OTHER|Sex intercourse|A heterosexual sexual relationship
48637493|NCT04518670|DEVICE|Comaneci Embolization Assist Device|assist in the coil embolization of wide-necked intracranial aneurysms with a neck width ≤ 10 mm.
47951426|NCT04234997|DRUG|Suvorexant 0mg|Participants will be advised to take the medication at 10PM for 7 days.Participants will be instructed to stop smoking by 10 pm the day before, in order to ensure they meet the breath CO criterion (CO ≤ 4 ppm) indicating overnight abstinence.
47951427|NCT06284096|BEHAVIORAL|Psychoeducation|The study is planned to consist of 7 sessions, occurring once a week, with approximately 70-80 minutes allocated for each session. Considering the attention span of the participants, the sessions will be divided into two parts, with a session lasting 30-40 minutes followed by a 15-minute break.
47951428|NCT05640804|DRUG|CTTQ Dasatinib tablet|Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.
47951429|NCT05640804|DRUG|Sprycel Dasatinib tablet|Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
48107242|NCT01863004|DRUG|Bortezomib|
48107243|NCT00504114|PROCEDURE|ACL Reconstruction Surgery|
48298962|NCT03532555|DIETARY_SUPPLEMENT|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
47951430|NCT04226560|DEVICE|41% Silicone Hydrogel Soft Contact Lenses(SHSCL)|Silicone Hydrogel
48298963|NCT03532555|OTHER|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
48298964|NCT03808272|DEVICE|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
48298965|NCT02971696|DRUG|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
48298966|NCT02971696|DRUG|Best Supportive care|Liver Support, pain management
48298967|NCT01825044|DRUG|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
48107244|NCT00504114|PROCEDURE|Cartilage Resurfacing Surgery|
48298968|NCT01825044|DRUG|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
48298969|NCT01263535|DEVICE|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
48298970|NCT03661541|DRUG|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
48637494|NCT05935215|DRUG|Iptacopan|Open Label
48637495|NCT05199935|BEHAVIORAL|Video|Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
48637496|NCT05199935|OTHER|Control|Control video on healthy pregnancy
48298971|NCT06322823|PROCEDURE|direct thawing|Vitrified blastocysts will be thawed directly into 1ml G-TL medium
48637497|NCT04460794|BEHAVIORAL|Ballet-inspired workouts|8 weeks, delivered by volunteers with a self-directed resource package
48637498|NCT04460794|OTHER|Usual care|Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
48637499|NCT01744418|DEVICE|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
48637500|NCT04919590|BEHAVIORAL|This is Quitting|Text message-based intervention for quit vaping support.
48637501|NCT04919590|OTHER|Assessment only control|Assessment only
48637502|NCT04919590|OTHER|Waitlist control|No contact until follow-up survey, waitlisted to receive intervention post study
48637503|NCT06565156|OTHER|BR-AM|BR-AM is a single-layer amniotic membrane allograft. BR-AM is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
48637504|NCT06565156|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
47951431|NCT04226560|DEVICE|ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens|Senofilcon C (USFDA Device License #K160212)
48107245|NCT00504114|PROCEDURE|Total Knee Replacement|
48107246|NCT06112717|OTHER|Supportive-Educative Nursing Care|Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
48298972|NCT06322823|PROCEDURE|Vitrification|Vitrified blastocysts will be thawed using commercially available one-step media.
48298973|NCT03022656|DEVICE|Active Brace system|
48298974|NCT01050179|OTHER|carbon dioxide|sinusoidal carbon dioxide delivery
48298975|NCT01048229|DRUG|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
48298976|NCT01048229|DRUG|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
48298977|NCT03130101|OTHER|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
48298978|NCT04706507|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
48339810|NCT02444936|DRUG|ZOSTAVAX|Shingles vaccine
48339811|NCT03101527|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
48339812|NCT02679781|DRUG|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
48655893|NCT06637137|DRUG|Iron|Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
48107247|NCT00786448|DRUG|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
48107248|NCT01491698|PROCEDURE|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
48298979|NCT01600131|BEHAVIORAL|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
48107249|NCT01491698|PROCEDURE|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
48298980|NCT01600131|OTHER|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
48298981|NCT03013751|DRUG|Udenafil|Active drug
48107250|NCT05923762|BEHAVIORAL|OHRQoL|"Oral health-related quality of life will be measured by the Oral Impact on Daily Performance (OIDP)"
48107251|NCT04158999|DEVICE|milk analyzer|Human Milk Sample
48298982|NCT02096939|PROCEDURE|Adrenal extirpation|
48298983|NCT02096939|DRUG|Antihypertensive medication|
48637505|NCT05945732|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC."
48637506|NCT04509011|DEVICE|Fluobeam® LX|Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
47951432|NCT04226560|OTHER|Contact Lens Care Product|Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
48107252|NCT04158999|BEHAVIORAL|Mother's nutrition values|evaluation of nutritional elements of maternal onset with Bebis Program
48107253|NCT03439904|OTHER|Pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
48107254|NCT02919176|DRUG|Mirabegron|Mirabegron 50 mg/day
48298984|NCT03760380|DEVICE|Sole 1 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
48298985|NCT03760380|DEVICE|Sole 1 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
48298986|NCT03760380|DEVICE|Sole 2 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
48497838|NCT05691686|OTHER|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
48637507|NCT03586609|DRUG|Azacitidine|Given SC or IV
48637508|NCT03586609|DRUG|Cladribine|Given IV
48637509|NCT03586609|DRUG|Cytarabine|Given SC
47951433|NCT04226560|OTHER|Contact Lens Case|"Alcon Soft (hydrophilic) Contact Lens Case (Non-Sterile)"
47951434|NCT01593410|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
47951435|NCT01593410|DRUG|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
47951436|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
47951437|NCT01229371|BIOLOGICAL|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
47951438|NCT02319512|OTHER|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
47951439|NCT02319512|OTHER|Glucose|12ml glucose solution (13,6g) per day
48637510|NCT03586609|DRUG|Venetoclax|Given PO
47951440|NCT06375512|BIOLOGICAL|HZ Vaccine (IN001)|Formulation for injection
48107255|NCT02919176|DRUG|Pioglitazone|Pioglitazone 30 mg/day
48637511|NCT04139499|PROCEDURE|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
47951441|NCT06375512|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) for injection
48107256|NCT02919176|DRUG|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
48107257|NCT02523391|DRUG|TA-8995|Capsule
48107258|NCT02523391|DRUG|TA-8995|Tablet
48637512|NCT04139499|PROCEDURE|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
48637513|NCT06132503|DRUG|LP-284|LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
47951442|NCT06375512|BIOLOGICAL|Shingrix|Sterile suspension for injection
47951443|NCT01408797|PROCEDURE|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
47951444|NCT01408797|DRUG|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
47951445|NCT01408797|PROCEDURE|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
47951446|NCT03211871|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
47951447|NCT03211871|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
47951448|NCT03920787|DIETARY_SUPPLEMENT|Inofolic Combi|Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.
47951449|NCT03920787|OTHER|Placebo|2 capsules every day for 1 month
47951450|NCT04466176|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
47951451|NCT04466176|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
47951452|NCT01612104|BEHAVIORAL|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
47951453|NCT00723398|DIETARY_SUPPLEMENT|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
47951454|NCT00723398|DRUG|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
47951455|NCT00723398|DRUG|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
47951456|NCT00723398|DRUG|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
47951457|NCT04853030|DRUG|Fiasp|Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)
47951458|NCT04853030|DRUG|Novorapid|Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid
48637514|NCT04117087|DRUG|KRAS peptide vaccine|"1. KRAS peptide vaccine will be administered on cycle 1 (days 1, 8, 15) and R-Cycle 2 Day 1 (R-C2D1). Boost vaccinations with will be administered every 28 days at Reinduction cycle 5, 7, 9, 13. Extended vaccinations will be administered on Reinduction cycles 15 to 18, 19 and beyond (180 days ± 30 days for a total of 5 years on study.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
48637515|NCT04117087|DRUG|Nivolumab|"1. Nivolumab will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle. Boost Phase will be administered every 28 days on cycles 5 thru 14.~2. Drug: 3mg/kg IV, 480 mg IV"
47951459|NCT01833988|DEVICE|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
47951460|NCT01833988|OTHER|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
47951461|NCT04260711|DRUG|DMT|Discontinuation of patients' own disease modifying therapy (any of the interferons, glatiramer acetate, dimethylfumarate, teriflunomide)
47951462|NCT01964131|DRUG|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
47951463|NCT01964131|DRUG|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
47951464|NCT05241431|DRUG|SGLT2 inhibitor|10 mg orally once daily in addition to standard medical treatment.
47951465|NCT05241431|DRUG|Placebo|Placebo tablets similar to active treatment.
47951466|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
47951467|NCT04948788|DRUG|SHR1459 ；YY-20394|SHR1459 plus YY-20394
47951468|NCT04948788|DRUG|Gemcitabine-Oxaliplatin|Gemcitabine-Oxaliplatin
47951469|NCT05340465|DRUG|Darbepoetin Alfa|Infants in groups 2-5 will be started on Darbe 10 mcg/kg/week between 72 and 84 hours after birth.
47951470|NCT05340465|DRUG|Low Molecular Weight Iron Dextran|Infants in groups 2 and 3 will be given LMW-ID IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
47951471|NCT05340465|DRUG|Ferumoxytol injection|Infants in groups 4 and 5 will be given FMX IV, 10 or 20 mg/kg/dose. They will be re-dosed if ferritin falls below 76. Iron parameters will be checked biweekly.
48298987|NCT03760380|DEVICE|Sole 2 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
48298988|NCT01079793|DRUG|ixabepilone|
48298989|NCT01079793|PROCEDURE|adjuvant therapy|
48298990|NCT01079793|RADIATION|intensity-modulated radiation therapy|
48298991|NCT06554613|DRUG|Olanzapine|Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
48298992|NCT06554613|DRUG|Nivolumab|Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
48298993|NCT01775046|DEVICE|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
48298994|NCT04196842|DEVICE|Telemonitoring devices|Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
48298995|NCT06498063|OTHER|Glucagon|Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
48298996|NCT06498063|OTHER|Placebo|Placebo (0.9% NaCl).
48298997|NCT06498063|OTHER|Glucagon and exendin 9-39|Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
48298998|NCT06024330|DIAGNOSTIC_TEST|VAN assessment|An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.
48637516|NCT04117087|DRUG|Ipilimumab|"1. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1 and 3 of the study.~2. Drug: 1mg/kg IV"
47951472|NCT05340465|DRUG|Oral iron supplements|Infants in group 1 will receive standard care in the UW NICU with iron started on day 7 if tolerating 100 mL/kg/day enteral feeding. Iron supplements are adjusted every 2 weeks based on ferritin, zinc protoporphyrin to heme ratio and complete blood count (CBC).
47951473|NCT00014118|DRUG|carboplatin|
47951474|NCT00014118|DRUG|paclitaxel|
47951475|NCT00014118|PROCEDURE|conventional surgery|
47951476|NCT00014118|RADIATION|radiation therapy|
47951477|NCT04875962|DRUG|UCB0599|Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
48298999|NCT06024330|DIAGNOSTIC_TEST|VES assessment|An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.
48299000|NCT06024330|DIAGNOSTIC_TEST|LARIO assessment|An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
48299001|NCT03505697|OTHER|inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
48299002|NCT03505697|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
48299003|NCT05006807|DEVICE|Mechanomyograph Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
48299004|NCT05006807|DEVICE|Stimpod Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
48299005|NCT05006807|DEVICE|TetraGraph Twitch Monitor|Measurement of train-of-four count and ratio and post titanic count
47951478|NCT04875962|DRUG|Placebo|Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
48299006|NCT05006807|DEVICE|TwitchView Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
48299007|NCT05006807|DEVICE|Nihon Kohden Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
48299008|NCT05006807|OTHER|Palpation of twitch count|The train-of-four count is determined by manual palpation of the evoked twitch response
48299009|NCT04356105|DRUG|Minimal stimulation protocol|Letrozole, Recombinant FSH, GnRH antagonist
48299010|NCT04356105|DRUG|Microflare protocol|OCP, GnRH agonist, Recombinant FSH
48299011|NCT04356105|PROCEDURE|IVF/ICSI cycle|Involving ovum pickup and embryo transfer
48299012|NCT04827056|DRUG|Placebo|Placebo will be administered orally, as individual films in the SL space.
48299013|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the SL space.
48299014|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space.
48339813|NCT02679781|DRUG|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
48637517|NCT00420407|DRUG|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
48637518|NCT00420407|DRUG|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
48637519|NCT05537740|DRUG|BAY3375968|Intravenous (IV) infusion
48637520|NCT05537740|DRUG|Pembrolizumab|IV infusion
48637521|NCT04419389|DRUG|APR-246 (eprenetapopt) + Acalabrutinib in CLL|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
48107259|NCT05926180|DRUG|DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)|Patients will receive single oral doses of probe drugs alone and after at least 27 days of treatment with DZD9008, 300 mg, once daily, until a treatment discontinuation criterion is met. Each patient will receive a single oral dose of DZD9008 on Day 7, and DZD9008 once daily for 27 days from Day 9 to Day 35. Patients will also receive a single oral dose of 2 mg midazolam on Day 1 and Day 32, and oral dose of 10 mg rosuvastatin and 0.25 mg digoxin cocktail on Day 2, Day 7 and Day 33.
48637522|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL|APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)
48637523|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT|APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule
48637524|NCT04419389|DRUG|APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT|APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule
48637525|NCT05837247|OTHER|Game-based telerehabilitation exercises|online Game-based home exercises are physiotherapy programs that include exercises transformed into game activities to increase the child's participation in the rehabilitation process. The exercises were planned such as; the dwarf camel game as squat exercises; the flamingo balance game as single leg balance exercises and weight-bearing activities etc. The exercise program will be conducted for 6 weeks and 3 sessions in a week.
48637526|NCT05837247|OTHER|Home exercises|The physiotherapist will evaluate the control group patients and monitor them using only a home exercise program.
48107260|NCT06356116|OTHER|Usual care|"During hospitalization, physical therapist visits the patient once or twice on day one or two post-operative (treatments including bedside standing, ambulation, stepping, active-assisted range of motion exercises).~Educational material will be given at discharge from hospital."
48107261|NCT06356116|OTHER|Accelerated rehabilitation|"Physical therapist visits 5 times during hospitalization, including~1. Pre-operatively: instruction regarding range of motion exercises, use of assistive device.~2. Post-operative day zero: bedside standing, ambulation, stepping, active-assisted range of motion exercises.~3. Post-operative day one: visit #1 continuing the day-zero exercises;~4. Post-operative day one: visit #2 mini-squat against wall; stair negotiation training (1/2 flight).~5. Post-operative day two: continuing the day-zero exercises; stair negotiation (1 flight); discharge from hospital in the afternoon.~After discharge from hospital: post-operative day three \~ week 4: telerehabilitation"
48107262|NCT05348226|DIAGNOSTIC_TEST|Additional Cardiac Magnetic Resonance Scan|Standard of care medical treatment with sacubitril/valsartan (Entresto). Additional Cardiac Magnetic Resonance Imaging (CMR) Scan after 4-6 months of treatment.
48107263|NCT04588337|DRUG|rhTNK-tPA|Thrombolysis
48107264|NCT02940561|DRUG|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
48107265|NCT02940561|DRUG|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
48107266|NCT00920244|PROCEDURE|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
48107267|NCT00920244|DRUG|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
48107268|NCT00920244|DRUG|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency \< 60 beat/min.
48107269|NCT00920244|DRUG|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
48107270|NCT00920244|DEVICE|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
48107271|NCT03930823|OTHER|Interview|One to one interview
48107272|NCT00002810|BIOLOGICAL|filgrastim|
48107273|NCT00002810|DRUG|melphalan|
48107274|NCT00002810|PROCEDURE|bone marrow ablation with stem cell support|
48107275|NCT00002810|PROCEDURE|peripheral blood stem cell transplantation|
48637527|NCT01406054|OTHER|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
48637528|NCT03860961|OTHER|Questionnaire Administration|Ancillary studies
48637529|NCT03860961|OTHER|Survivorship Care Plan (SCP)|Given survivorship care plan
48107276|NCT03320096|DEVICE|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3\*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
48107277|NCT00680342|DRUG|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
48107278|NCT00680342|DRUG|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
48107279|NCT00680342|OTHER|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
48107280|NCT00999843|DRUG|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
48107281|NCT00868595|BIOLOGICAL|BPX-101|Vaccine
48107282|NCT00868595|DRUG|AP1903|Activating agent, infusion
48637530|NCT03860961|OTHER|Treatment Plan|Given treatment plan
48107283|NCT01114945|DEVICE|McGrath|Intubation with the McGrath device
48107284|NCT01114945|DEVICE|GlideScope|Intubation with the GlideScope device
48107285|NCT01114945|DEVICE|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
48107286|NCT01114945|DEVICE|Video-Mac|Intubation with the Video-Mac device
48107287|NCT04832542|OTHER|outpatient follow-up|The patients were evaluated every six months in order to assess the incidence of traumatic syncope recurrence during follow-up after implantable loop recorder implantation.
48107288|NCT06070688|DIAGNOSTIC_TEST|MeMed BV® biomarker test|one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
47951479|NCT05647057|COMBINATION_PRODUCT|A: gelofusine + ringers|750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
48107289|NCT06070688|DIAGNOSTIC_TEST|Usual care|Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
48107290|NCT01335165|DRUG|ALXN1102|Single Ascending Dose IV
47951480|NCT05647057|COMBINATION_PRODUCT|B: albumine + ringers|200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
48107291|NCT01335165|DRUG|ALXN1103|Single Ascending Dose IV or SC
48107292|NCT01966055|DRUG|Solithromycin|
48107293|NCT00978237|DRUG|EFV|one pill QD VO.
48107294|NCT00978237|DRUG|LPV/r|2 pills QD VO
48107295|NCT00003880|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
48107296|NCT00003880|DRUG|carboplatin|
48107297|NCT00003880|DRUG|paclitaxel|
48107298|NCT00002436|DRUG|Lamivudine|
48107299|NCT00002436|DRUG|Zidovudine|
48107300|NCT00002436|DRUG|Zalcitabine|
48107301|NCT02660645|DRUG|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
48107302|NCT02660645|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
48107303|NCT04321642|DRUG|Entonox|Entonox gas with mouth piece
48107304|NCT04321642|DRUG|Not receive Entonox|Not receive any gas
48107305|NCT04364789|DRUG|TT-00920|Tablets
48107306|NCT04364789|DRUG|Placebos|Tablets
48107307|NCT02491749|PROCEDURE|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
48107308|NCT02892968|PROCEDURE|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
48107309|NCT02892968|PROCEDURE|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
48107310|NCT05593146|BEHAVIORAL|modified anteversion angle placement(( α-15°)±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
47980429|NCT03898141|OTHER|Dog only (DO)|In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
47980430|NCT03898141|OTHER|Animal-assisted placebo (AAPL)|Participants receive the placebo intervention in the presence of a dog.
48107311|NCT05593146|BEHAVIORAL|conventional anteversion angle placement ( α±10°)|"Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does."
48107312|NCT04126330|DIETARY_SUPPLEMENT|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
48107313|NCT04126330|DIETARY_SUPPLEMENT|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
48107314|NCT03285191|OTHER|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
48107315|NCT03285191|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
48107316|NCT00563537|RADIATION|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
48107317|NCT01897233|DRUG|Lumacaftor|
48107318|NCT01897233|DRUG|Ivacaftor|
48107319|NCT05785494|OTHER|Narstaende.se|Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
48107320|NCT02614560|DRUG|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
48299015|NCT04827056|PROCEDURE|Ethanol Infusion|Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
48299016|NCT04827056|BEHAVIORAL|PTSD Reactivity Condition|Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
48107321|NCT02614560|DRUG|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
48107322|NCT02614560|DRUG|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
48107323|NCT02614560|DRUG|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
48107324|NCT06025019|BEHAVIORAL|parent-based Electronic Health intervention|"The eHealth intervention comprises 12 modules on three interaction modules related to physical activity, dietary behavior, and sleep. The intervention groups will be invited to a WeChat group. A 3-minute video (made on the TikTok APP) will be sent to each WeChat group. Based upon the social media studies recommendation, five to nine members in a group will produce the desirable group interactive effect. Therefore, the present study allocates eight parents to one WeChat group. In total, there will be 26 groups (206 parents) according to the sample size calculation. Consistent with Social Cognitive THeory, the content of each module will follow the four steps: 1. Attention (Read educational material and watch TikTok/Douyin video (less than 3 minutes). 2.Retention (parental interaction). 3.Reproduction (Set goals and conduct behaviors). 4.Motivation (feedback and making changes)."
48107325|NCT06281704|BIOLOGICAL|AK101 IV|AK101 will be administered intravenously.
48107326|NCT06281704|BIOLOGICAL|AK101 SC|AK101 will be administered subcutaneously.
48107327|NCT06281704|BIOLOGICAL|Placebo|Placebo will be administered subcutaneously or intravenously.
48107328|NCT06281704|BIOLOGICAL|AK101 IV/AK101 SC|AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
48107329|NCT02065050|OTHER|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
48107330|NCT02984124|BEHAVIORAL|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~1. Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~2. Description of CPR and dying process provided~3. Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~4. Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
48107331|NCT02984124|BEHAVIORAL|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
48107332|NCT00367692|DRUG|PSI-697|
48107333|NCT01256034|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
48107334|NCT04191434|DRUG|Flamboyant 125/12|Flamboyant 125/12 capsule
48107335|NCT04191434|DRUG|Budesonide/formoterol 200/6|Budesonid/formoterol 200/6 capsule
48107336|NCT04191434|OTHER|Flamboyant 125/12 Placebo|Flamboyant 125/12 Placebo capsule
48107337|NCT04191434|OTHER|Budesonide/formoterol 200/6 placebo|Budesonid/formoterol 200/6 Placebo capsule
48107338|NCT00764920|DEVICE|non-invasive imaging modalities for assessment of skin|skin imaging
48299017|NCT04827056|BEHAVIORAL|Alcohol Cue Reactivity|Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
48299018|NCT02131467|DRUG|Perampanel|oral drug
48339814|NCT05031104|OTHER|Physical Exercise|The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.
48107339|NCT00130013|DRUG|Oral Amoxicillin|
48107340|NCT05566080|PROCEDURE|Carotid endarterectomy|Patients who have a significant carotid stenosis and who undergo surgical carotid endarterectomy
48107341|NCT05470894|BIOLOGICAL|Approved COVID-19 vaccine|Vaccination for COVI9-19
48107342|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets|
48107343|NCT02184325|DRUG|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
48107344|NCT02184325|DRUG|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
48107345|NCT04531488|PROCEDURE|Powered Mobility Training Simulator|Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.
48299019|NCT00590083|BIOLOGICAL|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
47951481|NCT05647057|COMBINATION_PRODUCT|C: ringers + retrograde autologous priming|"1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming.~Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain \>90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area \<1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol."
47951482|NCT03419611|BEHAVIORAL|Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
47951483|NCT03419611|OTHER|Treatment as Usual|Teacher provided with word list and teacher intervening as usual.
47951484|NCT03419611|BEHAVIORAL|High Intensity Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
47951485|NCT06558097|DRUG|XXB750|Single SC dose of XXB750 (administered by single or multiple injections)
47951486|NCT06558097|OTHER|Placebo|Single SC dose of matching placebo (administered by single or multiple injections)
48107346|NCT04531488|OTHER|Training with Powered Wheel Chair|Training with Powered Wheel Chair
48107347|NCT00798096|DRUG|Fostamatinib Disodium|200 mg PO BID
48107348|NCT02540551|PROCEDURE|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
48299020|NCT02876224|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
48299021|NCT02876224|DRUG|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
48497839|NCT05691686|OTHER|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
48497840|NCT05691686|OTHER|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
48637531|NCT06295146|OTHER|Intervention A: 1-on-1 wheelchair skills training by a peer coach|"Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback."
47951487|NCT06104176|BEHAVIORAL|CBT in group|"All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
47951488|NCT06104176|OTHER|Virtual reality exposure|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
48107349|NCT04327882|DIAGNOSTIC_TEST|Point-of-care ultrasound|performance of a POCUS: lung and cardiac ultrasound mainly
48107350|NCT03496649|DRUG|Dysport 500 Unit Powder for Injection|Dysport administered by intramuscular injection
48107351|NCT02232178|DRUG|2 100mg Xaracoll implants|
48107352|NCT02232178|DRUG|3 100mg Xaracoll implants|
48107353|NCT02232178|DRUG|150mg Bupivacaine HCl injection|
48637532|NCT06295146|OTHER|Intervention B: Training via educational videos|Intervention B will be a series of educational videos that participants review and then are encouraged to the practice the skills. Participants will have access to the materials for 8 weeks. Group 3 will have access to approximately 3 hours of wheelchair skills video training content. Actual viewing time will depend upon the individual's training goal. While they will receive a weekly reminder about practicing, there is no prescribed frequency for how often they should be practicing the skills in the videos.
48299022|NCT02876224|DRUG|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
47951489|NCT06104176|BEHAVIORAL|individual CBT|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
48299023|NCT00716937|PROCEDURE|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
48299024|NCT00716937|PROCEDURE|laying open|laying open the site of excision of sinus or cyst without any flap
48299025|NCT01306058|DRUG|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
48299026|NCT01306058|DRUG|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
48299027|NCT04985773|DEVICE|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
48299028|NCT06451237|DRUG|Isotretinoin capsules|A one year follow up for patients on three maintenance regimens after acne clearance, including weekend isotretinoin and adapalene gel.
48299029|NCT03616769|DRUG|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
48299030|NCT03445039|DEVICE|traditional TSFE|The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
48299031|NCT03445039|PROCEDURE|bone grafting materials|The bone substitute is placed into the siuns under the membrane before the implant placement
48299032|NCT03445039|DEVICE|TSFE by DASK drills|The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
48299033|NCT03445039|PROCEDURE|without bone grafting materials|The bone substitute will not be placed into the sinus before the implant placement.
48299034|NCT00244205|PROCEDURE|Identifying genes methylated in urine|
48299035|NCT02183467|DRUG|BI 1356, low dose|
48299036|NCT02183467|DRUG|BI 1356, high dose|
48299037|NCT02183467|DRUG|Placebo|
48299038|NCT02183467|DRUG|Moxifloxacin|
48299039|NCT03753568|DEVICE|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
48299040|NCT05955859|PROCEDURE|Samplings from patient's affected paranasal sinus|Samplings from patient's affected paranasal sinus during endoscopic surgery.
47951490|NCT02437513|DEVICE|NewBreez|Intralaryngeal prosthesis to protect the airways
47951491|NCT01995643|DIETARY_SUPPLEMENT|Active Capsule|GSE Capsule
47951492|NCT01995643|DIETARY_SUPPLEMENT|Placebo Capsule|Placebo Capsule
47951493|NCT04308304|DRUG|MK-1942|MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.
48478881|NCT00519922|OTHER|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion \& agility, dynamic proprioception,functional strength \& endurance.~Kinesthesia \& Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability \& confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia \& balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
48655894|NCT05195840|BEHAVIORAL|Personalized Treatment for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
47951494|NCT04308304|DRUG|Donepezil|Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.
48299041|NCT04756089|DEVICE|Electronic breast pump|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
48299042|NCT04756089|OTHER|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
48299043|NCT04487860|DRUG|AS012|oral administration
48299044|NCT04487860|DRUG|Placebo|oral administration
47951495|NCT04308304|DRUG|Placebo|Placebo capsule matched to MK-1942 taken BID by mouth.
48299045|NCT04644419|OTHER|none (observational study)|This is an observational study and does not include intervention delivery.
48299046|NCT05217979|DEVICE|Transcutaneous pulsed radiofrequency|single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
48299047|NCT05217979|DEVICE|Sham|Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
48299048|NCT04181203|DRUG|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
48299049|NCT04181203|RADIATION|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
47951496|NCT06083857|DRUG|Amivantamab|Given by IV (vein)
48299050|NCT04181203|DRUG|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
47951497|NCT06083857|DRUG|Tepotinib|Given by PO
48299051|NCT05655546|OTHER|Access to Cue Health COVID-19 Remote testing and treatment for COVID-19|Participants will receive at home COVID-19 test for themselves and others in their household.
47951498|NCT04569253|DEVICE|TempSure|Non-invasive radiofrequency treatments
47951499|NCT02175628|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
47951500|NCT03265301|PROCEDURE|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
47951501|NCT03265301|PROCEDURE|Office hysteroscopy|will be done in out patient clinic without anesthesia
47951502|NCT03265301|PROCEDURE|Conventional hysteroscopy|will be done in operative room under general anesthesia
47951503|NCT03561363|BEHAVIORAL|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
47951504|NCT03906461|DEVICE|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
47951505|NCT04242173|DRUG|Cemiplimab-Rwlc|Cemiplimab-rwlc will be administered as a flat dose of 350 mg IV over approximately 30 minutes every 21 days (+/- 3 days)
47951506|NCT01209507|OTHER|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
47951507|NCT05303077|DIETARY_SUPPLEMENT|Nutribén Innova® 1|Infants are fed solely with infant formula supplemented with an inactive probiotic and omega 3 fatty acids over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's
47951508|NCT05303077|DIETARY_SUPPLEMENT|Nutribén®|Infants are fed solely with infant formula over the first 6 months of their life, from then on the infants are fed with the study formula and the usual supplementary food, recommended to the baby's age.
48107354|NCT06410963|BEHAVIORAL|Reactivate|The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
48107355|NCT00601848|DRUG|chemotherapy|
48299052|NCT01286844|DRUG|GSK2190915A 5mg|Oral powder for dispersion in water
48299053|NCT01286844|DRUG|GSK2190915A 10mg|Oral powder for dispersion in water
48299054|NCT01286844|DRUG|GSK2190915A 25mg|Oral powder for dispersion in water
47951509|NCT05303077|DIETARY_SUPPLEMENT|Breastfeed|Infants are breastfeeding solely over the first 6 months of their life, from then on the infants are fed as recommended by their caregiver, as if they are not participating in a research study.
48107356|NCT00601848|DRUG|porfimer sodium|
48107357|NCT00601848|OTHER|immunohistochemistry staining method|
48299055|NCT01286844|DRUG|GSK2190915A 50mg|Oral powder for dispersion in water
48299056|NCT01286844|DRUG|GSK2190915A 100mg|Oral powder for dispersion in water
48299057|NCT04099446|OTHER|Non-interventional|There is no intervention for this study
48299058|NCT00178321|DEVICE|earplugs|
48299059|NCT04080115|BEHAVIORAL|Attention Training Technique|ATT will be administered through a customized Expiwell smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.
47951510|NCT06417125|DRUG|Dexmedetomidine Hydrochloride|Patients were premedicated with intranasal dexmedetomidine 2 μg/kg in the holding area.
47951511|NCT06417125|DRUG|Midazolam|Patients were premedicated with oral midazolam 0.5 mg/kg in the holding area.
47951512|NCT06417125|DRUG|normal Saline|Patients were premedicated with normal saline 0.02 mL/kg in the holding area.
48107358|NCT00601848|OTHER|laboratory biomarker analysis|
48107359|NCT00601848|PROCEDURE|spectroscopy|
48107360|NCT00601848|PROCEDURE|therapeutic conventional surgery|
48107361|NCT04514419|DRUG|HS627|Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
47951513|NCT06417125|DRUG|Glucose solution|Patients were premedicated with oral sweet solution 0.25 mL/kg in the holding area.
47951514|NCT03355781|DEVICE|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
47951515|NCT03355781|PROCEDURE|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
47951516|NCT03355781|OTHER|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
47951517|NCT02830061|OTHER|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
47951518|NCT01898208|DEVICE|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
47951519|NCT01898208|BEHAVIORAL|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
47951520|NCT01898208|OTHER|Bacterial culture|This test identifies the pathogen responsible for an infection.
47951521|NCT01898208|OTHER|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
47951522|NCT05744011|OTHER|Tango intervention|"The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks."
48107362|NCT04514419|DRUG|Pertuzumab|Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
48107363|NCT04316234|OTHER|Passive vape|On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
48107364|NCT02183246|DRUG|Porfiromycin|
48107365|NCT02183246|DRUG|Placebo|
48107366|NCT02183246|RADIATION|Radiotherapy|
48107367|NCT04352452|PROCEDURE|laparoscopic surgery|differences in musculoskeletal and cognitive stress
48107368|NCT03709628|DRUG|EB8018 (First-in-class FimH blocker)|"Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13."
48107369|NCT02039713|DEVICE|DeSyne drug eluting stent group|
48107370|NCT04930393|PROCEDURE|Nerve Block - either PECS II or axillary ring|In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
48107371|NCT03624140|DEVICE|blood measurement|Hemoglobin measurement
48107372|NCT03624140|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
48107373|NCT03624140|DEVICE|hemoCue|non invasive method of hemoglobin measurement
48299060|NCT04080115|BEHAVIORAL|Sham intervention control condition|The sham control condition consists of the same 12 minutes of simultaneous sounds as the ATT technique, but will not include any verbal instruction, thus isolating the effects of intentional orientation of attention.
48107374|NCT00595218|BEHAVIORAL|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
48107375|NCT00595218|OTHER|Patient Preference Results|Knowledge of Patient Preference Results
48107376|NCT00320502|DRUG|BXT-51072|
48299061|NCT02983903|PROCEDURE|transbronchial biopsy|
48107377|NCT02655367|OTHER|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
48299062|NCT00428727|DRUG|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
48299063|NCT00428727|DRUG|placebo patch|daily application during 90 days
48299064|NCT04011436|OTHER|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
48299065|NCT04904146|DIAGNOSTIC_TEST|Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.|The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
47951523|NCT05744011|OTHER|Adapted Physical Activity|"The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks."
47951524|NCT00369122|BIOLOGICAL|Bevacizumab|Given IV
47951525|NCT00369122|DRUG|Cisplatin|Given IV
47951526|NCT00369122|RADIATION|External Beam Radiation Therapy|Undergo EBRT
47951527|NCT00369122|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
47951528|NCT04161027|DRUG|Pregabalin 75mg|Pregabalin 75 mg capsule
47951529|NCT04161027|DRUG|Placebos|Placebo capsule
47951530|NCT01869881|DRUG|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
48107378|NCT02655367|OTHER|Milled oats|Test meal consisting of 264g porridge made with milled oats
48107379|NCT04246619|DRUG|Pregabalin|"Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.~Duration: 12 weeks"
48107380|NCT04246619|DRUG|Duloxetine|"Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.~Duration: 12 weeks"
48107381|NCT04327063|DRUG|Saline|Injection of the solution of Saline not exceeding 30 mL of maximal volume.
48107382|NCT04327063|DRUG|Ropivacaine|Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume
48107383|NCT00015236|BEHAVIORAL|Amantadine|
48107384|NCT02444013|DRUG|Folic acid|
48107385|NCT02444013|DRUG|Placebo|
48107386|NCT05685173|DRUG|Odronextamab|Odronextamab will be administered by IV infusion
48107387|NCT05685173|DRUG|REGN5837|REGN5837 will be administered by IV infusion
48107388|NCT02526641|PROCEDURE|Functional Hepatic Nitrogen Clearance (FHNC)|
48107389|NCT02526641|PROCEDURE|Galactose Elimination Capacity (GEC)|
48107390|NCT02526641|PROCEDURE|Liver vein catheterization|
48107391|NCT04181307|BEHAVIORAL|BE-EHR module|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
48107392|NCT06555198|BEHAVIORAL|Foot(at)Work intervention|Foot(at)Work intervention is targeted for nurses working in clinical settings to promote their competence in lower extremity health self-care.
47951531|NCT01869881|DRUG|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
47951532|NCT05466929|BEHAVIORAL|TeACH System Resources|Patients who screen positive for anxiety will receive psychoeducation and mental health recommendations (e.g., evidence-based apps) selected for use with the TeACH System through a collaborative, stakeholder-engaged approach completed in phases 1 and 2 of this project.
47980431|NCT05430737|RADIATION|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
47980432|NCT00263133|DRUG|Sertraline|
47980433|NCT05575986|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
48107393|NCT01713530|DRUG|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
48107394|NCT01713530|DRUG|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
48107395|NCT01713530|DRUG|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
48107396|NCT05697718|BIOLOGICAL|MSC|a single injection dose i.v.
48107397|NCT00005840|DRUG|Paclitaxel|Given IV
48107398|NCT00005840|DRUG|Cisplatin|Given IV
48107399|NCT00005840|RADIATION|Radiation Therapy|Undergo whole abdominal radiation therapy
48299066|NCT01808703|DEVICE|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
48299067|NCT01808703|PROCEDURE|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
48107400|NCT05318573|DRUG|Pembrolizumab|Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
48107401|NCT05318573|DRUG|FF-10832|Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
48107402|NCT02887768|DEVICE|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
48107403|NCT02887768|PROCEDURE|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
48107404|NCT00273949|DRUG|lactulose|
48107405|NCT01510041|OTHER|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
48107406|NCT01510041|OTHER|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
48107407|NCT01955668|DRUG|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
48107408|NCT04727424|DIETARY_SUPPLEMENT|Spirulin Platensis|Two tablets every 12 hours since randomization through day 09 following randomization
48299068|NCT03827148|OTHER|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
48299069|NCT05914272|DRUG|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
48299070|NCT05958303|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Total dosing of 1000 mg vitamin C, 600 IU vitamin E, and 600 mg of alpha lipoic acid.
48299071|NCT05958303|OTHER|Placebo|Placebo
48655895|NCT05195840|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
47951533|NCT05285657|DIAGNOSTIC_TEST|Two-step malaria RDT detecting PfHRP2/pLDH (SD Ag Bioline Malaria Ag P.f/Pan: Standard Diagnostics, Hagal-Dong, Korea)|"The interpretation of the two-step malaria RDT will be done as follow:~* PfHRP2(+)/pLDH(+): falciparum malaria or co-infection with non-falciparum malaria;~* PfHRP2(-)/pLDH(+): non-falciparum malaria or falciparum malaria with deletion of hrp2;~* PfHRP2(-)/pLDH(-): negative results~* PfHRP2(+)/pLDH(-): inconclusive results and information on previous antimalarial treatment is needed to differentiate:~Within the past 28 days:~* If previous antimalarial treatment is reported, the malaria diagnosis is reported as negative result. Nonetheless, the antimalarial treatment decision will be based on malaria microscopy;~* If previous antimalarial treatment is not reported, the malaria diagnosis is reported as positive result.~Other PoC tests for bacterial infections The two-step malaria RDT will be supported by PoC test listed above to diagnose bacterial or viral infection in all patients."
47951534|NCT04324619|OTHER|Online interactive learning activities|"1. 3-hour video-storyline-based interactive learning program~2. Micro-learning activities that can be completed on mobile devices (eg, smartphones)"
47951535|NCT00537875|DIETARY_SUPPLEMENT|Ginger|Capsule, 1000 mg, BID, 3 days
47951536|NCT00537875|DIETARY_SUPPLEMENT|Placebo|Capsule, 1000 mg, BID, 3 days
47951537|NCT03352973|OTHER|active tDCS on the dlPFC|During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
47951538|NCT03352973|OTHER|sham tDCS on the dlPFC|During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
47951539|NCT05160090|DRUG|Bupropion HCl MR tablets 300mg|In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
47951540|NCT01052376|DEVICE|Confocal endomicroscopy|
47951541|NCT02530463|DRUG|Azacitidine|Given IV
47951542|NCT02530463|BIOLOGICAL|Ipilimumab|Given IV
47951543|NCT02530463|OTHER|Laboratory Biomarker Analysis|Correlative studies
47951544|NCT02530463|BIOLOGICAL|Nivolumab|Given IV
47951545|NCT03917459|DRUG|LCZ696|sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
47951546|NCT03917459|DRUG|Enalapril matching placebo|Placebo to Enalapril 10 mg film-coated tablets
47951547|NCT03917459|DRUG|Enalapril|Enalapril 10 mg film-coated tablets
47951548|NCT03917459|DRUG|LCZ696 matching placebo|Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
47951549|NCT01739361|DRUG|Acetaminophen|
48299072|NCT00950352|DRUG|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
47951550|NCT01739361|DRUG|placebo|
47951551|NCT06076954|BEHAVIORAL|CoolMinds|CoolMinds consists of 11 adolescent sessions and 9 parent sessions to be completed simultaneously during a 14-week treatment period. The main components comprise psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The parent program also comprises information on how to handle school absenteeism for parents and teachers or pedagogues. The intervention is mainly transdiagnostic within the anxiety disorders but also includes diagnosis specific modules and content allowing for more personalized treatment. The treatment is delivered via a telephone app but can also be accessed via computer.
48107409|NCT04727424|DRUG|Budesonide Powder|"One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09."
47951552|NCT01286727|DRUG|BB3|intravenous drug
47951553|NCT01372228|BIOLOGICAL|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
47951554|NCT06435728|DIAGNOSTIC_TEST|AccuIMR and AccuFFR|AccuFFR and AccuIMR were obtained by reviewing coronary angiography at the time of primary PCI
47951555|NCT02297191|PROCEDURE|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~1. Ultrasound images will be saved using the nomenclature TLIP Anatomy~2. Photos will only include surface anatomy of the low-to-mid back.~3. Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
47951556|NCT02297191|DRUG|Ropivicaine|
47951557|NCT03510754|PROCEDURE|Eus guided biliary drainage|"After reaching the cardia or the lesser curvature of the stomach, for the transgastric approach, or the duodenal bulb, for the transduodenal one, intrahepatic left and extrahepatic bile ducts were punctured with a 19-gouge needle and the access was confirmed the injection of contrast under fluoroscopy to obtain an anterograde cholangiogram.~A 0.035-inch guide was advanced into the selected bile duct and under EUS and fluoroscopic view a stent was placed through the hepatogastrostomy between a left bile duct and the gastric lumen or through the choledochoduodenostomy between the common bile duct and the duodenal lumen."
48299073|NCT00950352|DRUG|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
48299074|NCT06104345|BIOLOGICAL|Oral typhoid fever vaccine|Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.
48637533|NCT06468046|BEHAVIORAL|Mama Empoderada [Mom Power]|'Mamá Empoderada' \[Mom Power\] is a theory-based, trauma-informed group intervention to promote mental health and positive parenting among mothers with young children (0-5 years). It has been adapted for migrant mothers, and will conduct a pilot randomized controlled trial (RCT) of the intervention with migrant mothers with young children (MMC). The intervention group (IG) will receive 10 group and 3 individual sessions addressing attachment theory, hands-on parenting skills, linkage to resources (e.g., food, shelter), social support, and self-care and resilience.
48299075|NCT06104345|BIOLOGICAL|Oral cholera vaccine|Oral cholera vaccine (Dukoral®) on Days 0 and 7.
48299076|NCT04550546|DRUG|Nystatin|600,000 U/mL of nystatin in a rinse suspension
47951558|NCT02586064|BEHAVIORAL|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
48299077|NCT02243527|OTHER|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
48637534|NCT04325386|OTHER|Education Sessions|Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
48107410|NCT04727424|DRUG|Fluoxetine 20 MG|"Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07."
48132597|NCT05930106|OTHER|Intraoperative fluid ratio|This ratio is calculated by dividing the sum of procedure subcutaneous infiltration and intravenous fluid by the total aspirate volume during surgery
48299078|NCT02243527|OTHER|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
48299079|NCT01095250|DRUG|AIN457|
48299080|NCT01095250|DRUG|AIN457|
48299081|NCT01095250|DRUG|AIN457|
48299082|NCT01095250|DRUG|Placebo|
48299083|NCT06107062|DRUG|Cannabidiol - fsCBD|Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.
48299084|NCT06107062|DRUG|Placebo|Placebo arm
48299085|NCT06107062|DRUG|Cannabidiol - bsCBD|Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
47980434|NCT00877383|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
48299086|NCT00179920|DRUG|Carboplatin|
48299087|NCT00179920|DRUG|VP-16|
48299088|NCT00179920|PROCEDURE|Local Surgery|
48299089|NCT00179920|PROCEDURE|Cryotherapy|
48299090|NCT00179920|PROCEDURE|Laser hyperthermia|
48299091|NCT05091801|BEHAVIORAL|Intervention|Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
48299092|NCT05031325|DEVICE|Endoscopic submucosal dissection with Purastat|Purastat (peptidic gel) application
48299093|NCT02225223|DEVICE|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
48299094|NCT02225223|DEVICE|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
48299095|NCT05305638|OTHER|Exercise|Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
48299096|NCT04191278|DRUG|Varenicline|All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
48299097|NCT04191278|DEVICE|Mobile phone application|Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.
48299098|NCT04191278|BEHAVIORAL|Contingency management|Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.
48299099|NCT03893929|DIAGNOSTIC_TEST|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
48299100|NCT02527876|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training
48299101|NCT02527876|BEHAVIORAL|Moderate Intensity|Moderate Intensity Training
48299102|NCT02527876|BEHAVIORAL|Delayed Control|Delayed Control
48299103|NCT02527876|DEVICE|FitBit Flex|Use to measure increase in Physical Activity
48299104|NCT05713305|PROCEDURE|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
48299105|NCT05713305|PROCEDURE|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
48299106|NCT03684161|DIAGNOSTIC_TEST|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
48299107|NCT06475222|OTHER|Study 1: Facial serum with alpha albutin|Applying with facial serum with 2% alpha albutin as active comparator daily for 12 weeks.
48299108|NCT06475222|OTHER|Study 1: Facial serum with Tubtim Chumpae rice extract|Applying with facial serum with Tubtim Chumpae rice extract as experimental intervention daily for 12 weeks.
48299109|NCT06475222|OTHER|Study 2: Facial mask with Hom Pathum rice extract|Applying with facial mask with Hom Pathum rice extract as experimental intervention for 30 min/day, 2 days/week for 12 weeks.
48637535|NCT04325386|OTHER|No Education Session|No Education Session
48637536|NCT04889924|RADIATION|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
48637537|NCT04889924|PROCEDURE|Lymphadenectomy|Axillary Lymph node dissection
48299110|NCT06475222|OTHER|Study 3: Control jelly|Consumption with control jelly as active comparator at 3.5 g/kg body weight.
48299111|NCT06475222|OTHER|Study 3: Jelly with Tubtim Chumpae rice|Consumption with jelly with Tubtim Chumpae rice as experimental intervention at 3.5 g/kg body weight.
48299112|NCT06475222|OTHER|Study 3: Jelly with Hom Pathum rice|Consumption with jelly with Hom Pathum rice as experimental intervention at 3.5 g/kg body weight.
48299113|NCT00592150|DRUG|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
48299114|NCT00592150|DRUG|Placebo|Placebo infusion for 3 hours
48299115|NCT01413178|DRUG|Busulfan|Test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
48299116|NCT01413178|DRUG|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
48637538|NCT02718482|DRUG|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
48637539|NCT02718482|DRUG|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
48637540|NCT05239741|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
48637541|NCT05239741|DRUG|Oxaliplatin|85 mg/m\^2 given as an intravenous infusion (IV) on Day 1 in each 14-day cycle (Q2W) as part of the mFOLFOX6 regimen
48637542|NCT05239741|DRUG|Leucovorin|400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
48637543|NCT05239741|DRUG|5-fluorouracil|400 mg/m\^2 given as an IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for a total dose of 2400 mg/m\^2 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
48637544|NCT05239741|DRUG|Irinotecan|180 mg/m\^2 IV on Day 1 Q2W as part of the FOLFIRI regimen
48637545|NCT05239741|BIOLOGICAL|Bevacizumab|IV infusion
48637546|NCT05239741|BIOLOGICAL|Cetuximab|IV infusion
48637547|NCT04576949|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
48637548|NCT04576949|DRUG|Placebo|film-coated oral tablets containing matched placebo
48637549|NCT04576949|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
48299117|NCT01413178|OTHER|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
48299118|NCT01413178|DRUG|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
47951559|NCT02586064|BEHAVIORAL|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
47951560|NCT05486754|BEHAVIORAL|Cognitive behavioral stress management|Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.
47951561|NCT05486754|BEHAVIORAL|Psychoeducational Control|Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
47980435|NCT00877383|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
48107411|NCT04727424|DRUG|Placebo|"Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)"
48107412|NCT05273242|DRUG|Artesunate Injection|"* Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies."
48107413|NCT06250270|DIETARY_SUPPLEMENT|protein or placebo|casein protein (30g) or placebo (maltodextrin, 30g)
48107414|NCT04756050|DRUG|Bupivacaine HCl 0.5% Injectable Solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
48107415|NCT04756050|DRUG|Prilocaine HCl % 2 injectable solution|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
48107416|NCT04756050|DRUG|adrenaline amp 0.5mg|20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
48107417|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance. Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.
48107418|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block Corner pocket + intracluster approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance .10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).
48107419|NCT04756050|PROCEDURE|Ultrasound Guided Supraclavicular Block multi approach|The blocks will be performed by an experienced anesthesiologist with a USG guidance Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image.
48107420|NCT04756050|PROCEDURE|diagraphma muscle evaluation with ultrasound|"All patients will be evaluated with USG in a head-up position facing the side to be operated before and 30 minutes after the block is performed.~The probe will be placed perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines, 0.5 to 2 cm below the costophrenic sinus."
48107421|NCT05566418|OTHER|mulligan mobilization|Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide.
48299119|NCT01413178|DRUG|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
48299120|NCT01413178|PROCEDURE|Stem cell transplant|Stem cell infusion on Day 0.
48299121|NCT03465852|BEHAVIORAL|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
48299122|NCT03474003|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
48299123|NCT02275026|PROCEDURE|Functional magnetic resonance imaging|Diffusion tensor imaging
48299124|NCT02313480|OTHER|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
48299125|NCT05347914|BEHAVIORAL|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
47951562|NCT01175460|DRUG|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
48107422|NCT05566418|OTHER|myofascial release|Myofascial release will be performed on the patient, commencing at the common extensor origin and progressing all the way to the extensor retinaculum in the wrist. The periosteum will be engaged with the fingertips, with contact progressing inferiorly to the common extensor tendon and then to the wrist's extensor retinaculum
48107423|NCT00261053|DRUG|i.v. recombinant human C1 inhibitor|
48107424|NCT04964479|DRUG|TQB2450 injection|1200mg injection once every 3 week
48299126|NCT02100657|DRUG|Plitidepsin|
48107425|NCT04964479|DRUG|Anlotinib Hydrochloride Capsules|12mg capsule once daily
48107426|NCT04964479|DRUG|Pembrolizumab injection|200mg injection once every 3 week
48107427|NCT04964479|DRUG|Placebo|Placebo capsule once daily
48107428|NCT01668212|PROCEDURE|Doppler ultrasound|Doppler Ultrasound
48107429|NCT03546608|DRUG|Tepotinib|Participants received a single oral dose of tepotinib in Part 1.
48107430|NCT04618458|BEHAVIORAL|Power to Prevent|Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
48107431|NCT00207532|DRUG|folic acid|
48107432|NCT04742842|BIOLOGICAL|COVIGEN C19 0.8 mg ID or Placebo ID|2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.
48107433|NCT04742842|BIOLOGICAL|COVIGEN C19 2.0 mg IM or Placebo IM|2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
48107434|NCT04742842|BIOLOGICAL|COVIGEN C19 4.0 mg IM or Placebo IM|2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.
48107435|NCT04742842|BIOLOGICAL|COVIGEN C20 1.0mg vaccine ID|COVIGEN C20 1.0mg ID vaccine will be given at Day 1
48107436|NCT06460948|DRUG|Norethindrone Acetate-Ethinyl Estradiol|Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
48107437|NCT05907551|OTHER|Questionnaires|25-items questionnaire
48107438|NCT02418806|BEHAVIORAL|Psychotherapy groups|
48107439|NCT02418806|BEHAVIORAL|Self-help groups|
48107440|NCT00189202|DRUG|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
48299127|NCT02100657|DRUG|Bortezomib|
48299128|NCT02100657|DRUG|Dexamethasone|
48299129|NCT02064218|DRUG|Anti-hypertensive drugs|
48299130|NCT02205385|PROCEDURE|Targeted Muscle Reinnervation|
48299131|NCT02205385|PROCEDURE|Traction Neurectomy|
48299132|NCT02664285|OTHER|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
47951563|NCT04872400|DRUG|Vancomycin|1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
47951564|NCT04872400|DRUG|Tobramycin|1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
47951565|NCT06556550|RADIATION|stereotactic ablative radiation therapy|stereotactic ablative radiation therapy in effective doses to each metastatic site
47951566|NCT06556550|RADIATION|palliative radiation therapy|palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)
47951567|NCT06556550|DRUG|Chemotherapy|prescribed drug line
47951568|NCT03839498|DRUG|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
47951569|NCT02671409|OTHER|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
47951570|NCT06061341|DIAGNOSTIC_TEST|TruGraf®|TruGraf® is a non-invasive blood-based test to assist the clinician in lowering immunosuppression in liver transplant patients. It is the first and only blood-based test that offers biomarker guidance to aid physicians in minimizing immunosuppression in transplant recipients.
47951571|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, single, 1 day
47951572|NCT01691274|DRUG|PF-04895162|Tablets, 300 mg, twice a day, 14 days
47951573|NCT01691274|DRUG|PF-04895162|Tablets, to be decided, twice a day, 14 days
47951574|NCT01691274|DRUG|Placebo|Tablets, twice a day, 14 days
47951575|NCT04356742|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg, orally, once daily, up to 24weeks
47951576|NCT04356742|DRUG|Placebo|Dapagliflozin Placebo, orally, once daily, up to 24weeks
47951577|NCT04356742|DRUG|Evogliptin 5mg|Evogliptin 5mg, orally, once daily for background therapy
47951578|NCT04356742|DRUG|Metformin≥1000mg|Metformin≥1000mg, orally, daily for background therapy
47951579|NCT03428607|DRUG|AZD6738|AZD6738 160mg QD
47951580|NCT03428607|DRUG|Olaparib|Olaparib 300mg BID
47951581|NCT05776472|DRUG|Pegcetacoplan|Pegcetacoplan will be prescribed according to the label in patients with PNH.
47951582|NCT04668807|DEVICE|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
47951583|NCT04668807|DEVICE|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
48299133|NCT02664285|OTHER|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
48299134|NCT01564290|DIETARY_SUPPLEMENT|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
48299135|NCT01564290|DRUG|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
48299136|NCT05663086|BIOLOGICAL|One dose group|The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
48299137|NCT05663086|BIOLOGICAL|Two doses group|The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
48107441|NCT03657017|DIAGNOSTIC_TEST|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
48299138|NCT05663086|BIOLOGICAL|Aged 18-59 years|The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
48299139|NCT05663086|BIOLOGICAL|Aged 60 years old and above|The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
48299140|NCT02025972|PROCEDURE|Allogeneic umbilical cord blood therapy|
48299141|NCT00758303|DRUG|Low Dose TRIA-662|One Capsule 3 times a day
48299142|NCT00758303|DRUG|High Dose TRIA-662|3 Capsules 3 times daily
48299143|NCT00758303|DRUG|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
48299144|NCT05466149|DRUG|Furmonertinib|240mg QD on a continuous dosing schedule.
48299145|NCT04018014|OTHER|CT angiography|CT angiography in detection of pulmonary embolism
48299146|NCT01775488|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
48299147|NCT04210336|DEVICE|PAPILOCARE|"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."
48299148|NCT04210336|DEVICE|PLACEBO|The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
48107442|NCT03192046|DEVICE|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
48299149|NCT05078567|DEVICE|5% Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
48107443|NCT03192046|OTHER|Standardized walking/exercise program|standardized walking/exercise program without any brace or AFO
48107444|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
48107445|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
48107446|NCT00981630|BIOLOGICAL|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
48299150|NCT04869579|DRUG|Selenium (as Selenious Acid)|Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
48299151|NCT04869579|OTHER|Placebo|Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
48299152|NCT00390780|DRUG|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
48299153|NCT00390780|DRUG|Clotrimazole|10mg troches administered Five Times a Day for 14 days
48299154|NCT04592276|DIETARY_SUPPLEMENT|PS128|Participants took two capsules with PS128 after dinner for 30 days.
48299155|NCT04592276|DIETARY_SUPPLEMENT|placebo|Participants took two capsules without PS128 after dinner for 30 days.
48299156|NCT04429425|PROCEDURE|epidural anesthesia|epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
48107447|NCT00981630|BIOLOGICAL|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
48107448|NCT04671641|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat varicose veins patients
48107449|NCT00395434|DRUG|Combretastatin A4 Phosphate (CA4P)|
48299157|NCT05776186|DRUG|Spinal anesthesia with heavy bupivacaine|Spinal anesthesia
48299158|NCT00829166|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
48299159|NCT00829166|DRUG|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
48299160|NCT00829166|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
48299161|NCT05162612|DIAGNOSTIC_TEST|abtominal CT|standard basic Abdominal Ct scan
48299162|NCT00824486|BEHAVIORAL|Injury prevention education (TIPP)|using TIPP materials
48299163|NCT00824486|BEHAVIORAL|Injury prevention education (safe home)|using safe home model
48299164|NCT05673135|DRUG|Anti-Hypertensive|For control of the blood pressure
48299165|NCT05673135|RADIATION|Ultrasound|For assessment of gestational age and fetal weight
48299166|NCT05673135|RADIATION|Doppler ultrasound|Umbilical artery Doppler assessment
48299167|NCT05673135|DIAGNOSTIC_TEST|complete blood count|For assessment of platelet count
48299168|NCT05673135|DIAGNOSTIC_TEST|Body mass index|for assessment of maternal weight during pregnancy
48299169|NCT04525222|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via text notifications
48299170|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Actify app)|Use Actify app
48299171|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Current Standard Care app)|Use (USCPG) Current Standard Care app
48299172|NCT04525222|OTHER|Survey Administration|Ancillary studies
48299173|NCT06504082|DRUG|Letrozole|Patients in the MTX + letrozole group received letrozole tablets (Femara 2.5 mg) once daily for ten days starting from the day of MTX administration.
48299174|NCT06504082|DRUG|Methotrexate|After confirming the diagnosis of tubal ectopic pregnancy, each patient will receive a single dose of intramuscular MTX (50 mg/m² MTX) on the same day
48299175|NCT03262493|DEVICE|Interventional Group|Use of the feeding tube attachment device (FTAD).
48299176|NCT05579561|OTHER|Diet|Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.
48299177|NCT03591705|DRUG|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
48299178|NCT03591705|DRUG|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
48299179|NCT02134704|OTHER|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
47951584|NCT02103907|OTHER|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
47951585|NCT01834118|PROCEDURE|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
47951586|NCT05590494|PROCEDURE|Ultrasonic tenotomy|Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
47951587|NCT06146205|PROCEDURE|Direct lateral approach|The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
47951588|NCT06146205|PROCEDURE|SPAIRE|The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
47951589|NCT02848404|DEVICE|Categorical Language Fluency Smartphone Application|4 weeks' training
47951590|NCT05317624|COMBINATION_PRODUCT|Platelet rich plasma|platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
48299180|NCT06535399|DRUG|BMS-986369|Specified dose on specified days
48299181|NCT04579588|BIOLOGICAL|Flu shot|All participants will receive a single shot of the flu vaccine
48299182|NCT03690622|DRUG|Dexmedetomidine|Instillation of eyedrops
48299183|NCT03690622|DRUG|Balanced salt solution|instillation of eyedrop
48299184|NCT00592358|DRUG|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
48299185|NCT00192517|DRUG|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
48299186|NCT00192517|OTHER|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
48299187|NCT01310595|PROCEDURE|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
48299188|NCT01310595|PROCEDURE|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
48299189|NCT02018614|OTHER|algoplus|
48299190|NCT03201328|OTHER|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
48299191|NCT03201328|OTHER|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
48299192|NCT03201328|OTHER|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
48299193|NCT02110121|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
47951591|NCT05317624|COMBINATION_PRODUCT|Methylprednisolone|1ml methyl prednisolone 40mg\\ml mixed with normal saline and bupivacaine
47951592|NCT04928443|OTHER|Scar dressing group|Patients treated with scar dressing for surgical scar care are invited to participate this study and allocated in scar dressing group despite the length of caring period.
47951593|NCT04928443|OTHER|Regular care group|Patients receiving regular scar care are retrospectively identified with matching factors, such as gender, age, length of surgical wound and surgical procedure.
47951594|NCT02280070|OTHER|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
47951595|NCT02280070|OTHER|Medical history and physical examination|medical history and physical examination
48107450|NCT00395434|DRUG|Bevacizumab (Avastin)|
48107451|NCT06060002|PROCEDURE|Group A - Stent exchange if cholecystectomy dated beyond 3 months|Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months
48299194|NCT02110121|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
48339815|NCT05031104|OTHER|Physical Exercise plus Low-energy Laser Therapy|The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
48339816|NCT01082588|DRUG|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
48299195|NCT02890082|DRUG|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~* Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~* Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~* Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
48299196|NCT02890082|DRUG|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~* Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~* Ovulation induction by OVITRELLE® 250μg.~* Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
47951596|NCT02280070|OTHER|BW and height|Body weight (kg) and height (cm)
47951597|NCT02280070|OTHER|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
48107452|NCT06060002|DIAGNOSTIC_TEST|Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months|Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
48107453|NCT05622188|OTHER|Elevated ambient heat|Temporary exposure to increased ambient temperature +10°C (the effect of the intervention is fully and spontaneously reversible)
48107454|NCT05622188|OTHER|Elevated relative humidity|Temporary exposure to increased ambient relative humidity +40% (max. 90%) (the effect of the intervention is fully and spontaneously reversible)
48107455|NCT05622188|OTHER|Exertion|Temporary exertion on an ergometer (1W/kg body weight) (the effect of the intervention is fully and spontaneously reversible)
48107456|NCT03988036|DRUG|Pembrolizumab|Intravenous infusion; 200 mg; every 3 weeks
48107457|NCT03988036|DRUG|Trastuzumab Biosimilar ABP 980|Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
48107458|NCT03988036|DRUG|Pertuzumab|Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
48299197|NCT02890082|DRUG|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~* 1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
48339817|NCT01082588|DRUG|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
48339818|NCT04628611|DEVICE|Video laryngoscopy|Endotracheal intubation using video laryngoscopy
48339819|NCT04628611|DEVICE|Flexible intubating laryngoscopy|Endotracheal intubation using flexible intubating laryngoscope
48339820|NCT01690988|DRUG|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
47951598|NCT02280070|OTHER|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft \& Gault method using serum creatinine (mg/dL), age and body weight (kg).
47951599|NCT02280070|OTHER|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
47951600|NCT02280070|RADIATION|Contrasting CT|Computed tomography
47951601|NCT02280070|OTHER|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
47951602|NCT02280070|OTHER|HBs antigen and HCV antibody|check for exclusion criteria
47951603|NCT02280070|OTHER|Endoscopy|Endoscopy for lower digestive tract
47951604|NCT02280070|OTHER|HBs antibody and HBc antibody|Check according to hepatitis B guideline
47951605|NCT02280070|DRUG|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
47951606|NCT02280070|DRUG|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
47951607|NCT02280070|DRUG|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
47951608|NCT02280070|DRUG|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
47951609|NCT02280070|DRUG|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
47951610|NCT01148888|DRUG|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
47951611|NCT04483973|DRUG|Ebselen|Glutathione peroxidase mimetic
47951612|NCT04483973|DRUG|Placebo|Matching placebo containing excipients
47951613|NCT05804396|DEVICE|Relivion®|Active stimulation device
47951614|NCT00993876|DRUG|citalopram|20 to 30 mg per day for 4 weeks
47951615|NCT00993876|DRUG|reboxetine|4 to 8 mg per day for 4 weeks
47951616|NCT00993876|BEHAVIORAL|interpersonal psychotherapy|
47980436|NCT00877383|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
48299198|NCT02288728|PROCEDURE|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
48299199|NCT02288728|PROCEDURE|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
48299200|NCT03230175|BIOLOGICAL|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
48299201|NCT03230175|PROCEDURE|Surgical resection and debridement|"Perform surgical sharp debridement in the OR, to remove:~* infectious agents and biofilms (purulence),~* all debris, eschar, callus and macerated non-viable tissue from the wound base, and~* dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate."
48299202|NCT03230175|DRUG|Systemic antibiotics|Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
48299203|NCT03230175|DEVICE|Off-loading|Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
48299204|NCT06512467|DRUG|Donafenib|200 mg BID,oral administration will start before the first HAIC treatment .
48299205|NCT06512467|DRUG|Sintilimab|200 mg Q3W,Intravenous infusion will perform before HAIC treatment.
48299206|NCT06512467|OTHER|HAIC|HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).
48299207|NCT02942550|DRUG|Methylnaltrexone bromide (Relistor®).|
48299208|NCT02942550|DRUG|Sodium Chloride 9mg/mL|
48299209|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
48299210|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
48299211|NCT02959710|DRUG|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
48299212|NCT02959710|DRUG|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
48299213|NCT02959710|DRUG|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
47951617|NCT03002363|BEHAVIORAL|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
47951618|NCT03002363|BEHAVIORAL|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
48299214|NCT00862381|DRUG|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
48299215|NCT00862381|DRUG|Placebo|NaCl 0.9%
48299216|NCT02199522|PROCEDURE|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
48299217|NCT02951546|DIETARY_SUPPLEMENT|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.
48299218|NCT02951546|DIETARY_SUPPLEMENT|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
48299219|NCT02951546|OTHER|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
48299220|NCT02229864|DEVICE|Coronary artery stenting: Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm"
48299221|NCT05615701|DIAGNOSTIC_TEST|EOSedge imaging|Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
48299222|NCT02114632|DIETARY_SUPPLEMENT|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
48299223|NCT00004048|BIOLOGICAL|filgrastim|
48299224|NCT00004048|DRUG|doxorubicin hydrochloride|
48299225|NCT00004048|PROCEDURE|autologous bone marrow transplantation|
48299226|NCT00004048|PROCEDURE|peripheral blood stem cell transplantation|
48299227|NCT00004048|RADIATION|indium In 111 monoclonal antibody MN-14|
48299228|NCT00004048|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
48339821|NCT01690988|DRUG|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
47951619|NCT02298023|BIOLOGICAL|allogenic adipose stem cell injection|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
47951620|NCT02298023|BIOLOGICAL|fibrin glue/normal saline injection|Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise
47951621|NCT02298023|BIOLOGICAL|normal saline injection|Total 1cc of normal saline injection and range of motion exercise
48637550|NCT06382805|OTHER|Physiotherapy program|The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.
48637551|NCT06382805|OTHER|Kinesio Tape|The longitudinal muscle technique will be applied from the origin to the insertion of the forearm extensor muscles by a researcher with a Kinesio tape application certificate. In addition, transverse kinesio tape will be applied on the elbow using the fascia correction technique. The treatment program will last for a total of two weeks, 5 days a week.
47951622|NCT03216642|DIAGNOSTIC_TEST|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
47951623|NCT02660931|OTHER|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
47951624|NCT04786392|DIETARY_SUPPLEMENT|Lutein supplement|5 mg lutein supplement.
47951625|NCT04786392|OTHER|Food, blended|5 mg lutein from baby spinach, blended.
47951626|NCT04786392|OTHER|Food, unprocessed|5 mg lutein from baby spinach, in whole food form.
47951627|NCT04562792|DRUG|Daunorubicin|Eligible patients with relapsed and/or refractory acute leukemia will receive daunorubicin 6.75mg/m2 daily for 5 consecutive days.
47951628|NCT05098899|GENETIC|MyGeneMyDiet® Recommendations for Weight Management|This group will receive Nutrition and Lifestyle recommendation based on SNPs known to have an impact to body weight and body composition, and responses to physical activity and dietary fat intake
47951629|NCT05098899|OTHER|Usual Standard of Care for Weight Management|This group will receive the conventional and standard nutrition lifestyle recommendation for weight management
47951630|NCT03326739|PROCEDURE|Arterial Line Placement|arterial line placement
47951631|NCT01173757|DRUG|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
47951632|NCT01033461|DIETARY_SUPPLEMENT|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
47951633|NCT01033461|DIETARY_SUPPLEMENT|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
47951634|NCT01033461|OTHER|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
47951635|NCT01254292|DRUG|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
47951636|NCT01254292|DRUG|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
48637552|NCT06382805|OTHER|High Intensity Laser therapy|High intensity laser applications will be performed using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area for 75 seconds at a dose of 4W 6 J/cm2 (analgesic effect) by making circular movements from the center to the outside. The remaining 5 sessions will be applied to the painful area with linear movements for 12 minutes and 30 seconds at a dose of 6W 100-150 J/cm2 (biostimulation effect). The treatment program will last for a total of two weeks, 5 days a week.
48637553|NCT05238103|COMBINATION_PRODUCT|Corrie Hybrid Cardiac Rehabilitation Program|The Corrie Hybrid Cardiac Rehabilitation Program is a multi-component intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
48637554|NCT04874207|DRUG|Regorafenib|Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
48655896|NCT00855335|DRUG|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
48655897|NCT00855335|DRUG|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
47951637|NCT01768052|DEVICE|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
47951638|NCT02478372|DRUG|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
47951639|NCT02478372|DRUG|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
47951640|NCT03617510|DRUG|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
47951641|NCT03617510|DRUG|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
47951642|NCT00997880|DRUG|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
48637555|NCT02476916|DRUG|AG-348|Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
48637556|NCT05206331|DEVICE|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
48637557|NCT05206331|DRUG|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
48637558|NCT06128226|GENETIC|Blood Sampling|For Tripeptidyl Peptidase 1 enzyme level measurement, blood will be taken from the patient into a 5 mL EDTA tube at Gazi University Faculty of Medicine, Metabolism Laboratory, and for patients with low enzyme activity, the genetic evaluation test will be performed with whole blood at the Gene2Info Laboratory.
48637559|NCT05991466|DRUG|Dexmedetomidine|"All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT\&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block."
48637560|NCT00052715|DRUG|poly ICLC|
48637561|NCT03226418|DRUG|Cytarabine|Given IV
48637562|NCT03226418|DRUG|Decitabine|Given IV
48637563|NCT03226418|DRUG|Idarubicin|Given IV
48637564|NCT03226418|OTHER|Laboratory Biomarker Analysis|Correlative studies
48637565|NCT03226418|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48637566|NCT03226418|OTHER|Quality-of-Life Assessment|Ancillary studies
48637567|NCT03226418|OTHER|Questionnaire Administration|Ancillary studies
48637568|NCT03226418|DRUG|Azacitidine|Given by infusion
47951643|NCT00997880|DRUG|Rosuvastatin calcium10mg|Rosuvastatin 10mg
48637569|NCT03226418|DRUG|Venetoclax|oral tablet
48637570|NCT03226418|DRUG|glasdegib|oral tablet
48299229|NCT03664986|DRUG|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
48637571|NCT00002835|BIOLOGICAL|Bleomycin Sulfate (BLM)|
48637572|NCT00002835|BIOLOGICAL|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
47951644|NCT03746171|DIAGNOSTIC_TEST|Colonic polyp characterization by BLI|"All rectosigmoid \<5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
48299230|NCT04138524|OTHER|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
48299231|NCT04485169|PROCEDURE|Therapeutic Plasma Exchange|a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
48637573|NCT00002835|BIOLOGICAL|Recombinant Interferon Alfa|
48637574|NCT00002835|DRUG|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
48637575|NCT00002835|DRUG|Cisplatin (CDDP)|
48637576|NCT00002835|DRUG|Cyclophosphamide|
48637577|NCT00002835|DRUG|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
48637578|NCT00002835|DRUG|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
48637579|NCT00002835|DRUG|Idarubicin|
48637580|NCT00002835|DRUG|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
48637581|NCT00002835|DRUG|Leucovorin Calcium|
48637582|NCT00002835|DRUG|Melphalan|
48637583|NCT00002835|DRUG|Methotrexate|
48637584|NCT00002835|DRUG|Methylprednisolone|
48637585|NCT00002835|DRUG|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
48637586|NCT00002835|DRUG|Vincristine Sulfate|
48637587|NCT00002835|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
48637588|NCT00002835|RADIATION|Radiation Therapy|
48637589|NCT05214027|OTHER|Treadmill-Based Exercise (60% VO2 Max for 60 minutes)|"Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max."
48299232|NCT05366933|DRUG|Vitamin B-Complex Supplement|Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
48637590|NCT05214027|OTHER|Rest (60 minutes)|Each participant will undergo a 60-minute rest period in a randomised order.
48637591|NCT03815019|DRUG|Megestrol Acetate|The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
48637592|NCT03815019|BEHAVIORAL|iKanEat Behavioral Intervention|"The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding."
48637593|NCT04319276|DRUG|Gallium maltolate (500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
48339822|NCT01690988|DRUG|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
48637594|NCT04319276|DRUG|Gallium maltolate (1,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
48637595|NCT04319276|DRUG|Gallium maltolate (1,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
48637596|NCT04319276|DRUG|Gallium maltolate (2,000 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
48655898|NCT00855335|DRUG|Etravirine|200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
47951645|NCT03130608|OTHER|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
47951646|NCT02739165|DRUG|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
47951647|NCT02739165|DRUG|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
47951648|NCT03419520|BEHAVIORAL|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
47951649|NCT06306989|DRUG|Letermovir|Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.
48655899|NCT00855335|DRUG|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
47951650|NCT02818361|DRUG|Topical tripterygium gel|
47951651|NCT02818361|DRUG|Placebo gel|
47951652|NCT01415895|DRUG|Naltrexone and Clonidine Combination|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
47951653|NCT01415895|DRUG|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
47951654|NCT03997604|DEVICE|Full Dentures created by additive manufacturing|Full dentures created by Additive manufacturing (Carbon Printers)
47951655|NCT02437383|DRUG|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
47951656|NCT02437383|DRUG|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
48107459|NCT05230875|BEHAVIORAL|self-administered questionnaire|"All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program."
48107460|NCT00319566|DRUG|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
48107461|NCT05737095|PROCEDURE|Pulmonary ultrasound|Within 6 hours of admission to Neonatal Pediatrics and Intensive Care
47951657|NCT04300231|DRUG|epidural bupivacaine 0.05%|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
47951658|NCT04300231|DRUG|Liposomal bupivacaine|20 ml
47951659|NCT04300231|DRUG|bupivacaine 0.125%|40 mL
47951660|NCT04300231|DRUG|bupivacaine 0.5%|60 mL
47951661|NCT04300231|DRUG|/hydromorphone 0.05mg/ml|Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
47951662|NCT04300231|DRUG|injectable saline|40 mL
47951663|NCT01484041|DRUG|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
47951664|NCT01484041|DRUG|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
48107462|NCT01981850|BIOLOGICAL|RO7490677|IV infusion
48107463|NCT01981850|DRUG|Ruxolitinib|IV infusion
48339823|NCT04559412|DEVICE|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
48339824|NCT04559412|DRUG|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
48299233|NCT03570229|OTHER|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
48299234|NCT04811677|OTHER|radiology|image analysis
48299235|NCT03533478|DIETARY_SUPPLEMENT|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
48299236|NCT03533478|DIETARY_SUPPLEMENT|Placebo|Placebo treatment
48299237|NCT02116972|DRUG|FX006 32 mg|Single 5 mL IA injection
48299238|NCT02116972|DRUG|Placebo|Single 5 mL IA injection
48299239|NCT02116972|DRUG|FX006 16 mg|Single 5 mL IA injection
48299240|NCT00677963|DRUG|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
48299241|NCT01772225|OTHER|Data collection|Medical record abstraction form and patient survey questionnaire.
48299242|NCT01874782|DEVICE|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
48299243|NCT00400491|DRUG|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
48299244|NCT00400491|DRUG|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
48299245|NCT02636764|OTHER|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
48299246|NCT02636764|DEVICE|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (\<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
48299247|NCT02636764|DEVICE|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
48299248|NCT02636764|DEVICE|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
48299249|NCT02636764|DEVICE|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
48299250|NCT06023199|DRUG|Voxelotor|Voxelotor is administered orally at a dose of 1500mg daily.
48299251|NCT02429427|DRUG|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
48299252|NCT02429427|OTHER|Placebo|Two capsules once daily with food
48637597|NCT04319276|DRUG|Gallium maltolate (2,500 mg)|This is a 3+3 design. The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
48637598|NCT04319276|DRUG|Gallium maltolate (recommended phase 2 dose)|The maximum-tolerated dose (recommended phase 2 dose).
48637599|NCT02709226|RADIATION|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
48299253|NCT01512368|OTHER|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
48299254|NCT05242588|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
48299255|NCT05242588|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
48299256|NCT01438710|DRUG|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
48299257|NCT01438710|DRUG|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
48299259|NCT06497725|DEVICE|Teleguidance-facilitated Airway Management|tele-guidence will be provided by an experienced airway expert
48339825|NCT03340311|DEVICE|iHealth Wireless Smart Gluco- Monitoring System (BG5)|Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
48299260|NCT01524211|DEVICE|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
48339826|NCT05761860|DRUG|OxyCODONE 5 mg Oral Tablet|Oxycodone 5mg oral administration
48107464|NCT05737238|BEHAVIORAL|Intervention during phase B: Compensatory brain game supporting Goal Management Training intervention|The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently at their own home. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
48107465|NCT02511197|DRUG|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
48107466|NCT02511197|DEVICE|PET/CT|
48107467|NCT05876130|RADIATION|POHIM_EM|hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
48107468|NCT04333329|DEVICE|NEUROLITH|transcranial pulse stimulation (TPS)
48107469|NCT02414204|DRUG|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
48107470|NCT02414204|OTHER|Placebo|Placebo will be over encapsulated to identical to drug comparison
48107471|NCT05989412|OTHER|Patient health questionnaire-9 via the Your Research application|Both intervention arms will have 4-weekly screening with either lenient follow-up or screening with stricter follow-up for a time period of one year. Data will be collected via an app designed by Your Research which runs on Microsoft Azure server, as the primary of participants' response collection. A dedicated backup system will serve as a secondary data collection.
48107472|NCT03080038|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
48107473|NCT00661648|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
48107474|NCT02466672|OTHER|none - observational only|
48107475|NCT00573339|OTHER|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
48107476|NCT00811057|DRUG|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
48107477|NCT00811057|DRUG|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
48107478|NCT00811057|DRUG|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
48107479|NCT04866823|BEHAVIORAL|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
48339827|NCT05761860|DRUG|OxyCODONE 2.5 mg Oral Tablet|Oxycodone 2.5mg oral administration
48339828|NCT05761860|OTHER|Placebo oxyCODONE Oral Tablet|Oxycodone 0mg (placebo) oral administration
48339829|NCT05761860|DRUG|Oxytocin Nasal Spray (48 IU)|Intranasal oxytocin administration (48 IU)
48339830|NCT05761860|OTHER|Placebo Oxytocin Nasal Spray|Intranasal oxytocin placebo administration
48107480|NCT06556186|PROCEDURE|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy|Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
48107481|NCT06556186|DRUG|Bromocriptin 2.5mg, 2-3 times a day|Bromocriptin 2.5mg, 2-3 times a day
48107482|NCT00831415|DRUG|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
48107483|NCT01953757|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
48107484|NCT01953757|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
48107485|NCT00932022|DRUG|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
48107486|NCT00932022|OTHER|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
47951665|NCT03124446|BEHAVIORAL|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
47951666|NCT03124446|BEHAVIORAL|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
48299261|NCT01524211|DEVICE|Terumo Arch Branch|The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.
48299262|NCT03469245|OTHER|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
48299263|NCT05492383|DEVICE|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
48299264|NCT03714386|DEVICE|A synthetic high-flux dialyzer will be used for OL-HDF.|A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
48299265|NCT03714386|DEVICE|A medium cut-off dialyzer will be used for HDx.|A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
48299266|NCT03912571|DIAGNOSTIC_TEST|Structural 3T MRI|measures of global and hippocampal atrophy)
48299267|NCT03912571|DIAGNOSTIC_TEST|MRI Based Perfusion Imaging|brain blood flow
48299268|NCT03912571|DIAGNOSTIC_TEST|VR-CO2 MRI Scans|reduced vaso reactivity to carbon dioxide
48299269|NCT05725369|BEHAVIORAL|Combined Lifestyle Intervention (CLI)|In the Netherlands, the combined lifestyle intervention (CLI, in Dutch: gecombineerde leefstijlinterventie (GLI)) is available for all Dutch citizens with a BMI ≥ 30 mg/kg2 or a BMI between 25 and 30 mg/kg2 and an increased risk of diabetes or cardiovascular disease. The CLI aims to realize health benefits for people with a moderate weight-related health risk and consists of a two-year program with advice and counseling to improve health-related behavior such as physical activity and diet.
48299270|NCT03207256|DRUG|TGR-1202|Oral Daily TGR-1202
48107487|NCT05033509|OTHER|supervision the Kidney fonction on ECMO|patients who benefited from ECMO, and presented an acute kidney injury afterwards
48299271|NCT03207256|DRUG|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
48299272|NCT02306772|DRUG|TP05 Coating A|One radio-labelled tablet given to subjects
48637600|NCT05809154|DIAGNOSTIC_TEST|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
48637601|NCT06517316|DEVICE|Nelfilcon A plano cosmetic contact lenses|Commercially approved colored contact lenses worn to alter or enhance the apparent color of the eye. Plano contact lenses do not contain visual correction and are worn for cosmetic purposes only.
47951667|NCT02059252|DEVICE|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
48107488|NCT00234442|DRUG|Iressa (Gefitinib)|
48107489|NCT00138138|DRUG|Ritalin|
48107490|NCT00952718|OTHER|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
48107491|NCT05572801|DIAGNOSTIC_TEST|AMR B: HPV positive ctDNA guided imaging in follow-up|Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
48107492|NCT02794350|DEVICE|Cochlear implant|
48107493|NCT01392872|OTHER|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
48107494|NCT02867566|DRUG|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
48299273|NCT02306772|DRUG|TP05 Coating B|One radio-labelled tablet given to subjects
48299274|NCT04221451|DRUG|venglustat GZ402671|"Pharmaceutical form: tablet~Route of administration: oral"
48299275|NCT04221451|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
48299276|NCT01070784|DRUG|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
48299277|NCT01070784|DRUG|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
48299278|NCT02083445|OTHER|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
48299279|NCT02083445|OTHER|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
48299280|NCT02083445|DEVICE|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
48299281|NCT02083445|OTHER|Intermittent hypobaric hypoxia|
48299282|NCT00458250|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|
48299283|NCT00458250|DRUG|Busulfan|
48299284|NCT00458250|DRUG|Cyclophosphamide|
48299285|NCT00458250|DRUG|CAMPATH-1H|
48299286|NCT00458250|DRUG|Cyclosporin A|
48107495|NCT02867566|DRUG|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
48107496|NCT04436055|OTHER|No Intervention will be used|Since this is an observational study, there are no interventions.
48107497|NCT02487316|DRUG|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
48107498|NCT05837390|DEVICE|Cervical stiffness assessment|The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.
48107499|NCT05837390|OTHER|Cervical length measurement|Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.
48107500|NCT05837390|OTHER|Fetal fibronectin|Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
48107501|NCT02032719|BEHAVIORAL|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
48107502|NCT02032719|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
48655900|NCT00855335|DRUG|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
47951668|NCT05769998|BEHAVIORAL|Acceptance and Commitment-based treatment|The ACT-based group intervention includes four 1-hour group sessions over two weeks. The treatment manual was developed by the authors of this study following the ACT framework and adapting materials and resources from ACT-based treatments developed for other settings. The focus of the intervention is to provide patients with pain education specific for patients who underwent TKA and to promote psychological flexibility. Each session employs experiential exercises, including mindfulness meditation, and metaphors addressing the core components of ACT.
47951669|NCT05769998|OTHER|Treatment as usual|Standard pharmacotherapy and physical exercise plan provided to all the patients in the rehabilitation unit.
47951670|NCT01722396|DIETARY_SUPPLEMENT|Vitamin D|
48107503|NCT03794180|DRUG|TJ003234|Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
48107504|NCT03794180|DRUG|Placebo|Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
48107505|NCT02219919|OTHER|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
48299287|NCT00458250|DRUG|Methotrexate|
48299288|NCT00020930|BIOLOGICAL|cetuximab|
48299289|NCT05953740|DRUG|MK-5720|MK-5720 IM injection
48299290|NCT05953740|DRUG|Placebo to MK-5720|Placebo matched to MK-5720 IM injection
48299291|NCT05953740|DRUG|MK-8189|MK-8189 tablet taken by mouth
48299292|NCT05953740|DRUG|Placebo to MK-8189|Placebo tablet matched to MK-8189
48299293|NCT02975869|OTHER|Standard Leukemia Care|
48299294|NCT02975869|OTHER|Palliative Care|
48299295|NCT02313935|OTHER|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
48299296|NCT02313935|OTHER|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
48299297|NCT02313935|OTHER|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
48299298|NCT02313935|OTHER|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
48299299|NCT06329362|PROCEDURE|Minimally invasive implantation|Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.
48299300|NCT06329362|PROCEDURE|Open flap procedure for ridge expansion.|Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
47951671|NCT03343067|DRUG|elagolix|Tablets
47951672|NCT03343067|DRUG|estradiol/norethindrone acetate (E2/NETA)|Capsules
47951673|NCT01863953|DRUG|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
48107506|NCT02219919|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
48107507|NCT06553833|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
48107508|NCT06553833|OTHER|Patient Blood Management|PBM is a strategy to manage the participants own blood. Its focus is on anemia, bleeding and coagulation management (using predominantly pharmaceutical and technological means).
48107509|NCT02975934|DRUG|Rucaparib|Rucaparib will be administered daily.
48107510|NCT02975934|DRUG|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
48107511|NCT04616053|BEHAVIORAL|IMPACT intervention|A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist ...). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology ...) and/or collective care (for example : patient education, physical activity, relaxation ...). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
48107512|NCT00346593|DEVICE|Silicone hydrogel contact lens|
48107513|NCT00244855|OTHER|pharmacological study|Correlative studies
48107514|NCT00244855|BIOLOGICAL|rituximab|Given IV
47951674|NCT01863953|DRUG|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
47951675|NCT01863953|DRUG|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
47951676|NCT01863953|DRUG|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
47951677|NCT01254071|DRUG|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
47951678|NCT01488500|OTHER|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
47951679|NCT02380144|OTHER|Fresh orange fruit and pasteurized fruit juice|
48107515|NCT00244855|DRUG|dexamethasone|Given IV
48107516|NCT00244855|OTHER|laboratory biomarker analysis|Correlative studies
48107517|NCT00647530|BIOLOGICAL|panitumumab|
48107518|NCT00647530|DRUG|capecitabine|
48107519|NCT00647530|DRUG|fluorouracil|
48107520|NCT00647530|DRUG|oxaliplatin|
48107521|NCT03827512|OTHER|Doppler arterial waveforms analysis|terminology used when describing arterial Doppler waveforms
48107522|NCT03162978|OTHER|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
48107523|NCT03162978|OTHER|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
48107524|NCT00316836|PROCEDURE|mammography|
48107525|NCT06226636|OTHER|salt|After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
48107526|NCT00480766|DRUG|MK0217/Duration of Treatment : 12 Months|
48107527|NCT05620303|OTHER|Exercise|Parents/guardians will receive three different contents weekly (i.e., infographics, video recipes, information pills, or videos) each week related to 24-h movement behaviors (i.e., PA, sedentary behavior, sleep duration) or Mediterranean Diet for 36 weeks.
48107528|NCT00202969|DRUG|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
48107529|NCT00202969|DRUG|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
48107530|NCT00202969|DRUG|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
48107531|NCT00538213|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
48107532|NCT00538213|BIOLOGICAL|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
47951680|NCT02624674|DEVICE|Multi-spectral Imaging Device (MSID)|
47951681|NCT04736082|OTHER|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).
47951682|NCT04736082|OTHER|Control Group: Infant Formula with intact protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).
47951683|NCT03141593|DRUG|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
47951684|NCT03141593|DRUG|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
47951685|NCT03141593|DRUG|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
47951686|NCT03141593|DRUG|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
47951687|NCT00451451|DRUG|BG00012|
47951688|NCT00451451|DRUG|Placebo|
47951689|NCT00451451|DRUG|Glatiramer Acetate|
47951690|NCT03881670|DEVICE|Lotrafilcon B|commercially available contact lens
47951691|NCT03881670|DEVICE|lotrafilcon B with Hydraluxe|commercially available contact lens
47951692|NCT06525012|OTHER|Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin|During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.
47951693|NCT06273436|OTHER|H.E.A.R. for Mamas|H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
47951694|NCT04558684|DRUG|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
47951695|NCT04558684|DRUG|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
47951696|NCT04558684|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions)
47951697|NCT04378127|OTHER|Educational program|The educational program consisted of six thematic meetings of 3 hours each, which a 15-minute interval every hour. Each meeting had a key topic and was divided in a teaching session and in a practical session with individual training of both, subject and caregiver. Every lecture was held by a movement disorders specialist with particular expertise in each field of discussion and the content of each lessons (slides, flyers, questionnaires) was adapted to fit the audience.
47951698|NCT04314154|OTHER|Monitoring PROM @ PREM data on participating patients|"125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect)."
47951699|NCT04265053|DRUG|Indomethacin 25 MG/50 MG|Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. We will use Indomethacin to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.
47951700|NCT04265053|DRUG|Placebo - Lactose|Subjects will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.
48107533|NCT05401227|DRUG|Ketamine|Ketamine during an MRI
48107534|NCT05401227|DRUG|Ts-134|4 days of TS-134 20 mg
48107535|NCT05401227|DRUG|Placebo|4 days of placebo TS-134
47951701|NCT04265053|DRUG|Ganirelix Acetate|"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
47951702|NCT04265053|DRUG|Testosterone Transdermal Product|In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
48107536|NCT04344613|DEVICE|ABODpoct device|The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
48107537|NCT03600935|OTHER|Vancouver Clinical Pathway|Vancouver Clinical Pathway
48107538|NCT02747602|DRUG|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
48107539|NCT02747602|DRUG|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
48107540|NCT02747602|DRUG|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
48107541|NCT05607108|DRUG|ZEN003694|ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
47951703|NCT04265053|DRUG|Estradiol Topical|In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
47951704|NCT04265053|DRUG|Antacid|Subjects will also be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Subjects will also be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.
47951705|NCT03387683|DRUG|dapagliflozin|dapagliflozin 10mg
47951706|NCT03387683|DRUG|placebo|placebo to match dapagliflozin
48107542|NCT06236516|RADIATION|One fraction stereotactic body radiotherapy|Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.
48107543|NCT06236516|DEVICE|HyperSight|HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.
48107544|NCT06236516|DEVICE|Ethos|Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
48107545|NCT00382135|DRUG|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
48107546|NCT00382135|DRUG|placebo|Placebo tablet taken by mouth once a day for 40 weeks
48339831|NCT05211609|DIAGNOSTIC_TEST|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
48637602|NCT05986058|BEHAVIORAL|Golden Circle|The original Golden Circle project was deployed in response to the COVID-19 pandemic and the need to implement remote social services in South Korea. Golden Circle had the aim of building a case management model using a healthcare-oriented automation system based on wearable devices (smartwatches and mobile applications). Through innovative system expansions, the goals were to promote healthful CVH and physical function and cultivate self-care management skills in older Korean adults.
48637603|NCT03324958|DEVICE|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
48637604|NCT03324958|OTHER|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
48637605|NCT05227430|OTHER|Educational video tutorials|Educational video tutorials (Hysterectomy, Bilateral salpingo-oophorectomy, Bilateral salpingectomy)
48637606|NCT06350513|OTHER|Animation movie, story book|"Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused."
48299301|NCT04632329|DEVICE|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
48299302|NCT00791128|DEVICE|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
48299303|NCT06048575|PROCEDURE|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
48299304|NCT02407574|DEVICE|External Pacing Box|Atrial pacing using an external pacing box
48637607|NCT02991859|DRUG|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
48655901|NCT06259812|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
48107547|NCT06249204|BEHAVIORAL|Coaching Group|Over a six-month coaching program period, staff members from care communities work with a coach to assess their current level of adoption of Dementia Care Practice Recommendations (DCPR) (published recommendations by Alzheimer's Association) and prioritize areas of need /focus. Teams meet with the coach virtually or in person for 1 hour each month during the six months. Through an action planning and implementation process, care communities are guided to make organization-wide, measurable changes in the areas of (1) policies and procedures, (2) education and training, and/or (3) care practices to increase and maintain person-centered care practices as outlined in the DCPR. Coaches provide ongoing support to the care community through telephone and email support between meetings.
48107548|NCT05047341|DRUG|SHR0302、[14C]SHR0302|8 mg SHR0302/ 80 µCi \[14C\]SHR0302, once, D1
48107549|NCT05767099|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
48107550|NCT01990937|DRUG|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
48107551|NCT03131206|DRUG|Alectinib|"* Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
48107552|NCT05861388|PROCEDURE|implant placement|2 implants were placed at position of lower 2nd premolar and 2nd molar
48107553|NCT00842257|DRUG|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
48107554|NCT04931446|PROCEDURE|Biopsy/surgical tissue and peripheral blood|Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
48107555|NCT01231113|DRUG|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
48107556|NCT01231113|DRUG|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
48299305|NCT03925428|DRUG|Entinostat|Given PO
48299306|NCT03925428|DRUG|Molibresib|Given PO
48299307|NCT02796404|DEVICE|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
48299308|NCT02796404|OTHER|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
48299309|NCT02747043|BIOLOGICAL|ABP 798|ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
48299310|NCT02747043|BIOLOGICAL|Rituximab|Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
48299311|NCT04740593|OTHER|Orthoptic care with the prescription of glasses from age 12-18 months onwards|Children assigned to the intervention group (group 1) will receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, and glasses, based on accurate determinations of refractive error by retinoscopy in cycloplegia by the study orthoptists at age 12-18 months. The spectacles for the children in this study will be provided by the study via their optician without costs.
48299312|NCT04740593|OTHER|Orthoptic care without the prescription of glasses from age 12-18 months onwards|Children with high refractive error in the control group (group 2) will also receive orthoptic care, including exams 1-3 (depending on the refractive error) times a year, but they will not receive glasses.
48299313|NCT04740593|OTHER|First measurement only|Children who have no or mild refractive error (group 3), the majority of all children, will be examined by the study orthoptists only once at the age of 12-18 months, after which youth health care (YHC) physicians and nurses will continue standard vision screening at CHCs, as part of screening for general health disorders and vaccinations. Visual acuity is measured routinely at 42-48 months as part of standard vision screening.
48299314|NCT03014661|OTHER|Quality of life under or after therapy with Pollinex quattro|To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
48299315|NCT01943539|DEVICE|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
48299316|NCT01043523|DRUG|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
48299317|NCT04393181|PROCEDURE|Heart transplantation 1|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
48299318|NCT04393181|PROCEDURE|Heart transplantation 2|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
48299319|NCT04713358|DRUG|Nalmefene|Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
48299320|NCT04713358|DRUG|normal Saline|Immediately Intravenous injection of normal saline 1ml after surgery
48299321|NCT01225393|DRUG|MLTA3698A|Subcutaneous repeating dose
48299322|NCT01225393|DRUG|adalimumab|Subcutaneous repeating dose
48299323|NCT01225393|DRUG|leflunomide|Stable dose if not on methotrexate
48299324|NCT01225393|DRUG|methotrexate|Stable dose if not on leflunomide
48299325|NCT01225393|DRUG|placebo|Subcutaneous repeating dose
48299326|NCT05979129|OTHER|zero PEEP|zero end-expiratory pressure during face mask ventilation
48299327|NCT05979129|OTHER|low PEEP|4 cmH2O PEEP during mask ventilation
48107557|NCT05061342|OTHER|No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.|Any anticancer or palliative care
48299328|NCT05979129|OTHER|high PEEP|8 cmH2O PEEP during mask ventilation
48299329|NCT03151525|DRUG|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
48299330|NCT03151525|DRUG|Infliximab|IFX treatment for maintenance of remission
48299331|NCT06247540|PROCEDURE|Biopsy|Undergo tissue biopsy
48299332|NCT06247540|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48299333|NCT06247540|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48107558|NCT02289625|OTHER|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
48299334|NCT06247540|PROCEDURE|Computed Tomography|Undergo PET/CT, CT
48299335|NCT06247540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48299336|NCT06247540|BIOLOGICAL|Nivolumab|Receive IV
48299337|NCT06247540|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48299338|NCT06247540|BIOLOGICAL|Rituximab|Receive IV
48637608|NCT02991859|DRUG|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
48637609|NCT02991859|DRUG|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
48299339|NCT06247540|DRUG|Venetoclax|Receive PO
48299340|NCT02943551|OTHER|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
48299341|NCT02943551|OTHER|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
48299342|NCT02943551|OTHER|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
48299343|NCT02943551|OTHER|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~* The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~* The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
48299344|NCT02943551|OTHER|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
48299345|NCT05280015|DIETARY_SUPPLEMENT|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
48299346|NCT05280015|OTHER|placebo|placebo add-on venlafaxine
48299347|NCT02502877|DRUG|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
48299348|NCT02502877|DRUG|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
48299349|NCT02502877|DRUG|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
48299350|NCT02502877|DEVICE|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
48299351|NCT00950612|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
48299352|NCT00950612|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
48299353|NCT04803786|DRUG|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
48299354|NCT01654497|DRUG|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
48299355|NCT05667428|DRUG|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
48299356|NCT05667428|DRUG|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
48637610|NCT02991859|DRUG|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
48637611|NCT00510471|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
48299357|NCT00906022|DEVICE|Astron Pulsar Stent|Stenting with Astron Pulsar
48299358|NCT00906022|DEVICE|PTA alone|Balloon angioplasty alone
48299359|NCT05415202|DRUG|Remimazolam 20 MG [Byfavo]|Remimazolam will be administered for sedation and efficacy and safety will be recorded
48299360|NCT01902797|OTHER|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
48339832|NCT05190107|DIAGNOSTIC_TEST|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
48339833|NCT02116361|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
48339834|NCT02116361|DRUG|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
48339835|NCT00956462|DRUG|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
48339836|NCT00034151|DRUG|S-8184 Paclitaxel Injectable Emulsion|
48478882|NCT00519922|OTHER|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal \& external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
48637612|NCT05450718|DRUG|buprenorphine-naloxone|Low-dose initiation of buprenorphine-naloxone protocol
48637613|NCT05450718|DRUG|buprenorphine-naloxone|Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
48637614|NCT04717908|DRUG|Bedaquiline|400 mg once daily for 2 weeks then 200mg 3 times per week;
48637615|NCT04717908|DRUG|Pyrazinamide|1500 mg daily
48637616|NCT04717908|DRUG|Linezolid|600 mg daily
48637617|NCT04717908|DRUG|Cycloserine|≤50kg 500 mg daily, \>50kg 750mg daily;
48637618|NCT04717908|DRUG|Clofazimine|100 mg daily;
48637619|NCT00251966|DRUG|Esomeprazole|
48637620|NCT00629642|DRUG|Solifenacin Succinate|Oral, 10mg
48637621|NCT00629642|DRUG|Solifenacin Succinate|Oral, 5mg
48637622|NCT00629642|DRUG|Oxybutynin Hydrochloride|Oral, 15mg
48478883|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
48637623|NCT00629642|DRUG|Placebo|Oral
47951707|NCT06343233|OTHER|usual care|The aim is to set up a collection of clinical and instrumental data of usual care from patients hospitalized for acute heart failure aged ≥ 65; at the time of admission and after 6-12 and 18 months from the event (admission).
47951708|NCT03020030|DRUG|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
47951709|NCT03020030|DRUG|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
47951710|NCT03020030|DRUG|Cyclophosphamide|Standard of Care
47951711|NCT03020030|DRUG|CYTARABINE|Standard of Care
47951712|NCT03020030|DRUG|DASATINIB|Standard of Care
47951713|NCT03020030|DRUG|DEXAMETHASONE|Standard of Care
47951714|NCT03020030|DRUG|Dexrazoxane|Standard of Care
48637624|NCT02311933|DRUG|Endoxifen Hydrochloride|Given PO
47951715|NCT03020030|DRUG|Doxorubicin|Standard of Care
47951716|NCT03020030|DRUG|ETOPOSIDE|Standard of Care
47951717|NCT03020030|DRUG|HYDROCORTISONE|Standard of Care
47951718|NCT03020030|DRUG|LEUCOVORIN CALCIUM|Standard of Care
47951719|NCT03020030|DRUG|MERCAPTOPURINE|Standard of Care
47951720|NCT03020030|DRUG|METHOTREXATE|Standard of Care
47951721|NCT03020030|DRUG|NELARABINE|Standard of Care
48107559|NCT01335932|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
47951722|NCT03020030|DRUG|Vincristine|Standard of Care
47951723|NCT00294801|DRUG|flex-a-new (food supplement)|
47951724|NCT03269604|PROCEDURE|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
47951725|NCT03269604|PROCEDURE|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
47951726|NCT03269604|PROCEDURE|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
47951727|NCT01680887|DRUG|Varenicline|
47951728|NCT01680887|DRUG|Placebo|
47951729|NCT05693883|OTHER|Pilates training|Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint \& release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation \& depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
47951730|NCT05347277|DIAGNOSTIC_TEST|Kappa Free Light Chain (K-FLC)|A biochemical test measured on CSF sample via nephelometry on Beckman Immage-800 analyzer using kits from Freelite, The Binding Site, according to the manufacturer's instructions.
47951731|NCT05748470|OTHER|SkinCeuticals A.G.E|Ultrasound therapy combined with SkinCeuticals A.G.E + conventional moisturizing and sunscreen.
48107560|NCT01335932|DRUG|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications."
48478884|NCT05646706|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
48478885|NCT05646706|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
48478886|NCT01239472|DRUG|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
47951732|NCT05748470|OTHER|standard cream|Ultrasound therapy combined with standard cream + conventional moisturizing and sunscreen
47951733|NCT03281707|PROCEDURE|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
47951734|NCT03281707|OTHER|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
47951735|NCT05129670|DEVICE|Calcite chewing gum|The calcite chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
47951736|NCT05129670|DEVICE|Unmatched Placebo chewing gum|The placebo chewing gum is administered as two pieces of gum in a single dose, 30 minutes following the consumption of a refluxogenic meal.
47951737|NCT01561378|DRUG|Aspart insulin|40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
48107561|NCT02187900|DRUG|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
48478887|NCT00682552|PROCEDURE|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
48478888|NCT02809820|DRUG|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
48299361|NCT05347589|OTHER|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
48299362|NCT05347589|OTHER|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
48299363|NCT01401829|BEHAVIORAL|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
47951738|NCT01561378|DRUG|Normal saline|200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
47951739|NCT01561378|DEVICE|Intranasal mucosal atomizer device|Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
47951740|NCT01319357|DRUG|Saxagliptin|orally 5 mg/d for 6 weeks
47951741|NCT01319357|DRUG|Placebo|orally for 6 weeks
47951742|NCT04080440|PROCEDURE|Extubation readiness clinical score|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is \>9, extubation has to be completed"
47951743|NCT04080440|PROCEDURE|Standard of care|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to the standard of care"
47951744|NCT00293527|DRUG|Interferon Alpha-2b|
48339837|NCT03454945|DRUG|Vibramycin|Antibiotic
48478889|NCT02809820|DRUG|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
48478890|NCT05730712|PROCEDURE|Biopsy|Undergo biopsy
48107562|NCT02187900|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
48478891|NCT05730712|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48478892|NCT05730712|PROCEDURE|Computed Tomography|Undergo CT
48637625|NCT02311933|OTHER|Laboratory Biomarker Analysis|Correlative studies
48637626|NCT02311933|OTHER|Pharmacological Study|Correlative studies
47951745|NCT03555435|OTHER|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
47951746|NCT03555435|BEHAVIORAL|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
48478893|NCT05730712|PROCEDURE|Echocardiography|Undergo ECHO
48637627|NCT02311933|DRUG|Tamoxifen Citrate|Given PO
48637628|NCT04414202|PROCEDURE|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
48637629|NCT04414202|RADIATION|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
48637630|NCT06150014|DRUG|Placebo|TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
48637631|NCT06150014|DRUG|TQA3605 tablets|TQA3605 inhibits viral replication.
48637632|NCT06150014|DRUG|Entecavir dispersible tablets|Entecavir inhibits viral replication and indicated for chronic hepatitis B treatment.
48637633|NCT06150014|DRUG|Tenofovir disoproxil fumarate tablet|Tenofovir disoproxil fumarate is a Nucleotide reverse transcriptase inhibitor.
47951747|NCT03555435|BEHAVIORAL|Wait|Participants in this group will wait 6 weeks.
47951748|NCT00326066|DEVICE|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
47951749|NCT00326066|PROCEDURE|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
47951750|NCT01669928|DRUG|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
48637634|NCT06150014|DRUG|Tenofovir alafenamide fumarate tablet|Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
48107563|NCT02513238|DRUG|Mesenchymal stem cell|Stemcells injected into submandibularis
48107564|NCT02513238|DRUG|Isotonic NaCl|
48478894|NCT05730712|DRUG|Enzalutamide|Given PO
48299364|NCT01401829|BEHAVIORAL|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
48299365|NCT01401829|BEHAVIORAL|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
48299366|NCT01752517|DRUG|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
48299367|NCT05413473|DEVICE|MR guided radiotherapy|MR guided radiotherapy using the Alberta linac-MR P3 system
48299368|NCT02242149|DRUG|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
48299369|NCT02242149|DRUG|Placebo|Sugar pill manufactured to mimic Diacerein
48299370|NCT03516799|OTHER|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
48299371|NCT06442917|BEHAVIORAL|Breathing Exercise|"32 the Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth was completed before the pregnancy intervention and the VAS was measured. Breathing exercise training and application were carried out during the latent phase process. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made.~During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed every 30 minutes from the beginning of contraction until the end of contraction. During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 15 minutes from the beginning of contraction to the end of contraction."
48299372|NCT06442917|BEHAVIORAL|Affirmation Method|"32 pregnant women who were admitted to the hospital for childbirth and were in the latent phase (0-3 cm) filled out the pre-intervention Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth, and the VAS was measured. During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained. During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and the affirmation phrases were repeated and used by the researcher every 30 minutes from the beginning of the contraction until the end of the contraction.~During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and affirmation sentences and support sentences were said every 15 minutes from the beginning of the contraction to the end of the contraction."
48299373|NCT06442917|BEHAVIORAL|Breathing Exercise and Affirmation Method|During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained and the application was made with breathing exercise training. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made. During the active phase process (4-7 cm), the Congenital Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 30 minutes from the beginning of contraction to the end of contraction, and the affirmation phrases were repeated and used by the researcher
48299374|NCT02273323|OTHER|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
48299375|NCT02273323|OTHER|Placebo|Placebo: tea flavour, colouring and sugar
48299376|NCT02629497|DIETARY_SUPPLEMENT|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
48299377|NCT02629497|DIETARY_SUPPLEMENT|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
48299378|NCT06336824|DRUG|Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
48299379|NCT06336824|DRUG|IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
48299380|NCT00739778|OTHER|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
48299381|NCT00739778|OTHER|food vehicle blank|water blank
48299382|NCT00739778|OTHER|food - sweetener, positive control|4.7% sucrose in water
48339838|NCT03454945|DEVICE|Phototherapy|UVA+Psoralen
48339839|NCT00937326|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
48339840|NCT00937326|DRUG|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
48478895|NCT05730712|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
48478896|NCT05730712|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48478897|NCT05730712|OTHER|Questionnaire Administration|Ancillary studies
48478898|NCT05943041|DRUG|GB104(Level 1)|One capsule QD oral administration for 28 days
48478899|NCT05943041|DRUG|GB104(Level 2)|Three capsules QD oral administration for 28 days
48107565|NCT00828672|DRUG|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
48107566|NCT00828672|DRUG|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
48299383|NCT00739778|OTHER|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
48299384|NCT01209208|DRUG|Budesonide|9 mg per day
48299385|NCT01209208|DRUG|Mesalamine|3 g per day
48299386|NCT01209208|OTHER|Placebo|0 g per day
48299387|NCT01671488|BIOLOGICAL|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
48299388|NCT01671488|DRUG|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
48299389|NCT01671488|DRUG|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
48299390|NCT01671488|RADIATION|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
48299391|NCT05296421|PROCEDURE|Biopsy|Undergo biopsy
48299392|NCT05296421|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48299393|NCT05296421|OTHER|Uniformly-labeled [13C]glucose|Given IV
48299394|NCT05604612|PROCEDURE|Corticision|Incisions in the cortical plate of maxillary bone
48299395|NCT01959308|OTHER||
48299396|NCT05416229|DRUG|Psilocybin|Psilocybin-assisted therapy
48299397|NCT05416229|DRUG|Maltodextrin|Placebo-assisted therapy
48299398|NCT05159232|PROCEDURE|hospital stay|hospital stay in in inguinal hernia repair
48299399|NCT04156646|DRUG|Balovaptan|Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
48299400|NCT04156646|DRUG|Esomeprazole|Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
48299401|NCT05644210|DRUG|Telitacicept|160mg once a week for 24 weeks
48299402|NCT05644210|DRUG|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
48299403|NCT05644210|DRUG|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
48299404|NCT05644210|DRUG|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
48299405|NCT05644210|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
48299406|NCT05644210|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
48107567|NCT00828672|DRUG|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
48107568|NCT00828672|RADIATION|radiotherapy|Total dose 45Gy
48299407|NCT06111573|DIETARY_SUPPLEMENT|Vitamin D|"Study group using Vitamin D for myofascial pain treatment. Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Study group usind Vitamin D for myofascial pain treatment. Medical treatment with Vitamin D (10,000 IU/day) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
48299408|NCT06111573|DRUG|Diclofenac Sodium|"Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
48299409|NCT06274333|DRUG|Dexmedetomidine 0.5 mic/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
48299410|NCT06274333|DRUG|Tramadol 1mg/kg|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
48299411|NCT06274333|DRUG|Paracetamol 10mg/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
48299412|NCT05801926|DEVICE|Heel2Toe[TM] sensor|Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
48299413|NCT00174161|BEHAVIORAL|self-care, health behavior|
48299414|NCT05820295|BEHAVIORAL|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
48299415|NCT05820295|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
48299416|NCT04555655|DIETARY_SUPPLEMENT|Chicken extract supplement|70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
48299417|NCT04555655|DIETARY_SUPPLEMENT|Peptide Supplement|70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
48299418|NCT04555655|OTHER|Placebo|70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
48478900|NCT05943041|DRUG|GB104(Level 3)|Five capsules QD oral administration for 28 days
48299419|NCT02093975|DEVICE|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation"
48299420|NCT01072279|OTHER|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
48299421|NCT01072279|OTHER|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
48299422|NCT02457897|DRUG|Liothyronine|Oral supplement given every 8 hours
48299423|NCT04674852|DEVICE|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
48299424|NCT03215888|PROCEDURE|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
48478901|NCT00088387|DRUG|Divalproex|
48299425|NCT05699616|PROCEDURE|Repair of perforated peptic ulcer|Repair of perforated peptic ulcer either open or laparoscopic.
48299426|NCT01240993|BEHAVIORAL|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
48299427|NCT01240993|BEHAVIORAL|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
48299428|NCT05837312|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|Reconnecting to Internal Sensations and Experiences (RISE) is a novel, self-guided interoceptive intervention designed to be accessible and convenient. RISE is hosted on Qualtrics and accessed on any internet-enabled device. RISE consists of four interactive 30-minute modules: (1) Progressive Muscle Relaxation and Body Functionality, (2) Understanding, Noticing and Managing Emotions, (3) Self-care and Communication, and (4) Body Sensations. The training consists of a mix of audio clips, psychoeducation, self-guided reading, and interactive writing prompts. Intervention materials are separated by multiple free-response prompts so that participants can relate the materials to their own lives, practice the introduced skills, and problem-solve difficulties implementing the skills.
48299429|NCT00013039|BEHAVIORAL|Computer reminders|
48299430|NCT01509586|DRUG|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
48299431|NCT02457351|DRUG|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
48299432|NCT02457351|DRUG|Itraconazole (Sporanox)|Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
48299433|NCT00308295|DRUG|Fish oil capsules|
48299434|NCT00308295|DRUG|matched placebo capsules|
48299435|NCT03085810|DRUG|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
48299436|NCT01369719|DRUG|osveral|receive 20 mg/kg daily orally
48299437|NCT01369719|DRUG|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
48637635|NCT02388256|DEVICE|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
48299438|NCT00126451|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
48299439|NCT00126451|DRUG|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
48299440|NCT05724667|OTHER|Flippin' Pain Seminar Series|A chronic pain education campaign
48299441|NCT00224107|DRUG|Silodosin|8 mg daily for 12 weeks
48299442|NCT00224107|OTHER|Placebo|1 capsule daily for 12 weeks
48637636|NCT02388256|OTHER|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
47951751|NCT03848065|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
47951752|NCT03848065|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
47951753|NCT03848065|BIOLOGICAL|Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)|Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
48299443|NCT02125929|PROCEDURE|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
48299444|NCT02125929|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
48299445|NCT02125929|PROCEDURE|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
48299446|NCT05366907|OTHER|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
48299447|NCT00898144|OTHER|Papanicolaou test|
48299448|NCT00898144|OTHER|laboratory biomarker analysis|
48299449|NCT03949582|OTHER|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
48299450|NCT04855721|DRUG|AUR101|Oral ROR-gamma inverse agonist
48299451|NCT04855721|DRUG|Placebo|Placebo
48299452|NCT00349791|DRUG|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
48299453|NCT00349791|DRUG|Placebo patch|placebo patch replaced twice a week for two years
47951754|NCT01951222|DRUG|V0162|
48478902|NCT00088387|DRUG|Lithium|
48637637|NCT06285695|DEVICE|Clareon Toric IOL|Aspheric hydrophobic acrylic IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery for the visual correction of aphakia and preexisting corneal astigmatism
47951755|NCT01951222|OTHER|Placebo|
47951756|NCT00002746|BIOLOGICAL|aldesleukin|
48107569|NCT05796440|DRUG|LUM-201|Administered orally once daily
48637638|NCT06285695|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon Toric IOL
48637639|NCT06230393|DEVICE|STREAMLINE® SURGICAL SYSTEM|STREAMLINE® SURGICAL SYSTEM
48107570|NCT04875130|DIAGNOSTIC_TEST|blood samples|Taking blood samples (plasma, serum) and measure the level of Adrenomedullin
48107571|NCT01927952|PROCEDURE|Kirschner wire|Surgical fixation utiliziing Kirschner wire
48107572|NCT01927952|PROCEDURE|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
48107573|NCT01927952|PROCEDURE|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
48107574|NCT03425630|DIETARY_SUPPLEMENT|Argicolina|8 weeks
48107575|NCT03425630|DIETARY_SUPPLEMENT|Normolip|8 weeks
48107576|NCT03665298|BEHAVIORAL|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
48637640|NCT00043784|DRUG|enoxaparin|
48637641|NCT02321150|PROCEDURE|Cautery|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Relaxing incisions placed at the corners of the recipient site.~* Graft is slid into place~* Graft / host interface is gently dried with a Qtip~* Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~  * Power setting: 25.~ * Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~* Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~* Cautery is applied at the 4 apices of the graft then in between these points."
47951757|NCT06025305|DIAGNOSTIC_TEST|Intravascular imaging test|Coronary artery disease patients first underwent CCTA and then intravascular imaging test within 3 months
47951758|NCT01649050|DRUG|BGG492|
47951759|NCT01649050|DRUG|Placebo|
47951760|NCT05132634|OTHER|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
47951761|NCT03861650|OTHER|Bone Marrow Aspirate Concentrate|A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
47951762|NCT03861650|OTHER|Saline|Physiological saline is added in control group to act as placebo
47951763|NCT04394611|OTHER|Obstetric ultrasound- doppler examination|Obstetric ultrasound- doppler examination and fetal- maternal assessment Tin (Sn), manganese (Mn), Vanadium (V), Magnesium (Mg), cobalt (Co), nickel (Ni), arsenic (As), chromium (Cr), cadmium (Cd), lead (Pb), mercury (Hg), antimony (Sb), aluminum (Al), zinc (Zn), copper (Cu), selenyum (Se), iron (Fe), vitamin D, vitamin A, vitamin B12 and folate concentrations measurements
47951764|NCT01967433|DRUG|Diphenhydramine|
47951765|NCT01967433|DRUG|Placebo|
48478903|NCT02858726|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
47951766|NCT00328549|DRUG|Pegylated Interferon and Ribavirin|
47951767|NCT01462643|DRUG|LAS41004|once daily, topical ointment, 100 microgram per day
47951768|NCT05736471|DIAGNOSTIC_TEST|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
47951769|NCT03439059|BEHAVIORAL|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (\>1.5 METS) 3x/day for 6 weeks
47951770|NCT00968890|BIOLOGICAL|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
47951771|NCT00968890|BIOLOGICAL|Fluarix™|Intramuscular injection, 1 dose
47951772|NCT00968890|BIOLOGICAL|Placebo|Intramuscular injection, 1 dose
47951773|NCT01512212|PROCEDURE|biopsy|fnab
47951774|NCT03468829|BIOLOGICAL|ALX-0171 Dose 1|Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
47951775|NCT03468829|BIOLOGICAL|ALX-0171 Dose 2|Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
47951776|NCT03468829|BIOLOGICAL|Placebo|Oral inhalation of Placebo once daily for a maximum of 14 days
48107577|NCT00768664|DRUG|PF-00299804|45 mg by continuous oral dosing
48107578|NCT04462107|OTHER|Surveys|All participants will complete surveys that range in time from baseline to 3 months post partum.
48107579|NCT02485379|PROCEDURE|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
48107580|NCT05819541|DRUG|Montelukast Oral Granules|Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
48107581|NCT05819541|DRUG|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
48107582|NCT05819541|DRUG|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
48299454|NCT04093323|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
48299455|NCT04093323|DRUG|Celecoxib|Given PO
48478904|NCT02858726|DRUG|CR845 1 mcg/kg|IV medication delivered three times/week
48478905|NCT02858726|DRUG|CR845 1.5mcg/kg|IV medication delivered three times/week
48299456|NCT04093323|DRUG|PD-1 Ligand Inhibitor|Given IV
47951777|NCT01924988|DEVICE|Prostatic Embolization with Embosphere Micropsheres|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
47951778|NCT02212470|DEVICE|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
48107583|NCT02997280|DRUG|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight \> 40 kg, 0.08 mg/kg bid for children with body weight \< 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
48299457|NCT04093323|DRUG|PD1 Inhibitor|Given IV
48299458|NCT04093323|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
47951779|NCT02212470|DEVICE|Nitinol stenting|Nitinol stent deployment
48299459|NCT04093323|DRUG|Rintatolimod|Given IV
47951780|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of uphill exercise|40 minutes of uphill exercise
47951781|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of uphill exercise completed 1 h before the meal
48107584|NCT01018212|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
48107585|NCT01219218|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
48107586|NCT05481333|DRUG|REGN7999|Ascending IV or SC dose administered per protocol
48107587|NCT05481333|DRUG|Placebo|Ascending IV or SC dose administered per protocol
48299460|NCT01485679|OTHER|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
48299461|NCT05022992|OTHER|Resistance Training|Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
48299462|NCT05482269|OTHER|no intervention|no intervention
48299463|NCT04590937|DRUG|BI 730357|Film-coated tablet
48299464|NCT04590937|DRUG|CRESTOR®|Film-coated tablet
48478906|NCT02858726|DRUG|Placebo|IV medication delivered three times/week
48299465|NCT04590937|DRUG|Lenoxin®|Tablet
48637642|NCT02321150|PROCEDURE|Sutures|"* Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
48637643|NCT02884180|DRUG|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
48637644|NCT02884180|DRUG|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
48637645|NCT06575192|DEVICE|ARTIA Reconstructive Tissue Matrix|Surgical Implant
48637646|NCT06575192|OTHER|No Intervention|No ADM
48637647|NCT04702139|DEVICE|shoulder arthroplastis|- Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
48637648|NCT04702139|DEVICE|shoulder arthroplastis|- Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
48637649|NCT06075264|DRUG|Artesunate ointment|topical ointment, as a non-surgical treatment
47951782|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of uphill exercise|40 minutes of uphill exercise
47951783|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of uphill exercise started 1 hour after gthe meal
48299466|NCT04590937|DRUG|MetfoLiquid GeriaSan®|Oral solution
48299467|NCT04590937|DRUG|Lasix®|Oral solution
48299468|NCT02004756|OTHER|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
48299469|NCT04954469|BIOLOGICAL|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
48299470|NCT05537324|OTHER|Brazil nut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts
48299471|NCT05537324|OTHER|Coconut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
48299472|NCT00841295|DRUG|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
48478907|NCT01684878|DRUG|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
47951784|NCT03930758|COMBINATION_PRODUCT|Behavior intervention of downhill exercise|40 minutes of downhill exercise
48299473|NCT00841295|DRUG|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
48478908|NCT01684878|DRUG|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
48637650|NCT06075264|DRUG|Placebo ointment|topical placebo ointment
48299474|NCT05675280|OTHER|Gluten free diet|All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study
48637651|NCT05371028|OTHER|Non-interventional Study|This is non-interventional study.
48637652|NCT03769116|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
48299475|NCT00480454|BIOLOGICAL|MVA 85A|intradermal vaccine
48299476|NCT03806595|DRUG|Lidocaine 2% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
48637653|NCT03769116|GENETIC|placebo|Single IV infusion of matching placebo
48299477|NCT03806595|DRUG|Normal Saline Flush, 0.9% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
48299478|NCT02013193|DEVICE|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
48299479|NCT02013193|DEVICE|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
48299480|NCT02402192|DRUG|Corifollitropin alfa|
48299481|NCT02680301|DRUG|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
48299482|NCT02680301|DRUG|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
48299483|NCT00698126|DRUG|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
48299484|NCT00698126|DRUG|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
48637654|NCT05062772|DIAGNOSTIC_TEST|Ultrasound|Intraoperative ultrasound imaging
48637655|NCT06064851|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During Second Menstruation, participants will self-administer 2, 1-hour sessions of active tAN daily with the Volta System Device beginning Day 1 of second menstruation through the final day of second menstruation.
48637656|NCT06496971|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
48299485|NCT06152263|OTHER|Compare color information and mucosal microvascular density|To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
48299486|NCT01214616|DRUG|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
47951785|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise before the meal|40 minutes of downhill exercise completed 1 hour before the meal
47951786|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of downhill exercise|40 minutes of downhill exercise
47951787|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of exercise after the meal|40 minutes of downhill exercise started 1 hour after the meal
47951788|NCT03930758|COMBINATION_PRODUCT|Behavioral intervention of sedentary no-exercise trial|Sedentary no-exercise trial
47951789|NCT03930758|COMBINATION_PRODUCT|Dietary intervention of eating two meals|Meals eaten at 10 and 17 h during a sedentary trial
48637657|NCT06496971|DRUG|Microbubble|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
48637658|NCT06496971|DEVICE|Low-Intensity Focused Ultrasound|Open the Blood-Brain Barrier (BBB) using focused ultrasound and microbubble
48478909|NCT01684878|DRUG|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
47951790|NCT03200184|DRUG|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
47951791|NCT01858376|DIETARY_SUPPLEMENT|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
47951792|NCT02188771|DEVICE|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
47951793|NCT00120523|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
47951794|NCT00120523|DRUG|Topical corticosteroids|TCS
47951795|NCT05280639|DEVICE|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
47951796|NCT05280639|OTHER|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
47951797|NCT04526938|DEVICE|Physician-Modified Cook Zenith Alpha Thoracic Endovascular Graft|Cook Zenith® Alpha Thoracic Endovascular Graft will be modified to allow for the maintenance of blood flow into the visceral and renal branch vessels.
47951798|NCT06324331|PROCEDURE|Decidual sparing|Endometrial free uterine closure technique
47951799|NCT06324331|PROCEDURE|Non decidual sparing|Routine uterine closure technique including endometrium
47951800|NCT06419335|DRUG|CoQ10|The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
47951801|NCT00747461|DEVICE|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
47951802|NCT00640861|BIOLOGICAL|CpG oligodeoxynucleotide|
47951803|NCT00640861|BIOLOGICAL|HER-2/neu peptide vaccine|
47951804|NCT00640861|BIOLOGICAL|MUC-1 peptide vaccine|
47951805|NCT00640861|BIOLOGICAL|incomplete Freund's adjuvant|
48299487|NCT01214616|DRUG|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
48299488|NCT01214616|DRUG|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
48637659|NCT05522972|BEHAVIORAL|Video Game Vision Training|A new approach for improving amblyopic vision using video games
48637660|NCT05522972|BEHAVIORAL|Perceptual Learning|A new approach for improving amblyopic vision with perceptual learning
48637661|NCT05522972|BEHAVIORAL|Occlusion Therapy|Conventional treatment for amblyopia
48637662|NCT03075943|DIETARY_SUPPLEMENT|InSea2|Daily supplement: 2 capsules of InSea2
48637663|NCT03075943|DIETARY_SUPPLEMENT|Placebo|Daily supplement: 2 capsules of Placebo
48637664|NCT03335267|DRUG|CPX-351|Cytarabine:Daunorubicin Liposome Injection
48637665|NCT06148285|DEVICE|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
47951806|NCT00640861|BIOLOGICAL|sargramostim|
47951807|NCT00640861|OTHER|immunoenzyme technique|
47951808|NCT00640861|OTHER|immunologic technique|
48107588|NCT04148417|DEVICE|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
48107589|NCT06145854|DRUG|Cabotegravir Injection [Apretude]|Apretude for PrEP
48107590|NCT04010448|BIOLOGICAL|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
48637666|NCT03765918|BIOLOGICAL|Pembrolizumab 200 mg|200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48107591|NCT04010448|BIOLOGICAL|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
48107592|NCT01081340|BEHAVIORAL|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
48107593|NCT01081340|BEHAVIORAL|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
48637667|NCT03765918|RADIATION|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
48107594|NCT05864586|BEHAVIORAL|Vaping study EC A|Vaping two puffs using the study EC device
48107595|NCT05864586|BEHAVIORAL|Vaping study EC B|Vaping two puffs using the study EC device
48107596|NCT05864586|BEHAVIORAL|Vaping study EC C|Vaping two puffs using the study EC device
48299489|NCT02090114|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
48299490|NCT02090114|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
48107597|NCT05864586|BEHAVIORAL|Vaping study EC D|Vaping two puffs using the study EC device
48107598|NCT05864586|BEHAVIORAL|Vaping study EC E|Vaping two puffs using the study EC device
48107599|NCT05864586|BEHAVIORAL|Vaping study EC F|Vaping two puffs using the study EC device
48107600|NCT05864586|BEHAVIORAL|Vaping study EC G|Vaping two puffs using the study EC device
48299491|NCT02090114|DRUG|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
48637668|NCT03765918|RADIATION|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
48637669|NCT03765918|RADIATION|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
47951809|NCT01248208|BIOLOGICAL|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
47951810|NCT01248208|BIOLOGICAL|"Intramuscular influenza injection (flu shot)"|"Subjects \< 2 years or \> 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age \>36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
47951811|NCT04389216|DEVICE|Cool-tip electrode for Radiofrequency Ablation|Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
47951812|NCT05882188|PROCEDURE|Oil-based contrast|oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
47951813|NCT05882188|PROCEDURE|ExEm Foam|ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
47951814|NCT00002561|BIOLOGICAL|bleomycin sulfate|10 units/m2
47951815|NCT00002561|DRUG|dacarbazine|375mg/m2
47951816|NCT00002561|DRUG|doxorubicin hydrochloride|25mg/m2
47951817|NCT00002561|DRUG|vinblastine|6mg/m2
47951818|NCT00002561|RADIATION|radiation therapy|35Gy in 20 fractions (daily)
48107601|NCT05864586|BEHAVIORAL|Vaping study EC H|Vaping two puffs using the study EC device
48107602|NCT05864586|BEHAVIORAL|Vaping study EC I|Vaping two puffs using the study EC device
48107603|NCT05864586|BEHAVIORAL|Vaping study EC J|Vaping two puffs using the study EC device
48107604|NCT06409988|OTHER|Safe discharge|There was no specific intervention, we only aimed to see if those admitted patients could have been safely dicharged from the emergency department.
48637670|NCT03765918|DRUG|Cisplatin 100 mg/m^2|100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
48637671|NCT03375307|PROCEDURE|Biopsy|Undergo tumor biopsy
48637672|NCT03375307|PROCEDURE|Biospecimen Collection|Undergo blood collection
48637673|NCT03375307|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48637674|NCT03375307|PROCEDURE|Bone Scan|Undergo bone scan
48637675|NCT03375307|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
47951819|NCT05663229|DEVICE|Ankle foot orthosis|We evaluate the difference of with or without ankle foot orthosis
48299492|NCT02090114|DRUG|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
48299493|NCT03911674|OTHER|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
47951820|NCT01612858|DRUG|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
48299494|NCT02335450|BEHAVIORAL|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
48299495|NCT02335450|DEVICE|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
48299496|NCT01165203|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
48299497|NCT01165203|BIOLOGICAL|Placebo|intramuscular injection
48299498|NCT05758441|BEHAVIORAL|Mentoring to be Active plus Family|Ten, structured peer mentoring sessions (once a week) covering new content each week and guided skill-building and practice. The MPBA sessions target increasing daily physical activity and replacing sugary drinks with water for hydration. Mentoring sessions are conducted virtually. A 6-month family reinforcement program follows with a reinforcement packet sent to child participants' homes once a month.
48299499|NCT05758441|BEHAVIORAL|Tracking Health and Fitness|10 self-guided, self-paced modules mailed to child participants home.
48299500|NCT03067766|PROCEDURE|Art Therapy|Participate in a comic art creation workshop
48299501|NCT03067766|OTHER|Interview|Undergo qualitative interviews
48299502|NCT03067766|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
48299503|NCT03067766|OTHER|Questionnaire Administration|Ancillary studies
48299504|NCT00000960|DRUG|Zidovudine|
48299505|NCT00787332|DRUG|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
48299506|NCT01193790|PROCEDURE|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
48299507|NCT01988012|BIOLOGICAL|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
48299508|NCT05513612|BIOLOGICAL|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
48299509|NCT05513612|DRUG|Fludarabine|Administered according to package insert
48299510|NCT05513612|DRUG|Cyclophosphamide|Administered according to package insert
48299511|NCT03839433|DRUG|Ciclesonide|
47951821|NCT01612858|DRUG|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
48299512|NCT01198444|DRUG|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
48299513|NCT05799144|BIOLOGICAL|DNA Vaccine|Given pBI-11 IM
47951822|NCT02219438|DRUG|Bolus|An adductor canal catheter was inserted and ropivacaine 0.2% administered as hourly bolus doses of 8 mL each: one at time point zero and then on the hour for 7 additional doses.
47951823|NCT02219438|DRUG|Basal|An adductor canal catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for a total of 8 hours.
47951824|NCT05088395|OTHER|Blood sample|Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples taken per patient for up to 24 months.
47951825|NCT05088395|OTHER|Biopsy|If a specific tumor sample is required, it will be collected only once during the study
48299514|NCT05799144|BIOLOGICAL|Human Papillomavirus Tumor Antigen Vaccine|Given into a muscle
48299515|NCT05799144|BIOLOGICAL|Pembrolizumab|Given into vein
48299516|NCT05799144|PROCEDURE|Computed Tomography (CT)|Undergo a CT
48299517|NCT05799144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo an MRI
48299518|NCT05799144|PROCEDURE|Magnetic Resonance Imaging|Undergo blood sample collection
48299519|NCT05799144|PROCEDURE|Biopsy|Undergo tumor biopsy
48299520|NCT04809727|PROCEDURE|Cervical biopsy|4 quadrant biopsy
48299521|NCT01769404|BIOLOGICAL|LY2605541|
48478910|NCT01684878|DRUG|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
48299522|NCT01769404|BIOLOGICAL|Insulin Glargine|
48299523|NCT03605134|DIAGNOSTIC_TEST|level of cardiac troponin|blood test
48299524|NCT03605134|DIAGNOSTIC_TEST|diastolic function assessment|transthoracic echocardiography
48299525|NCT03115801|DRUG|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
48299526|NCT03115801|DRUG|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
48299527|NCT03115801|RADIATION|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
48299528|NCT03115801|DRUG|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
48299529|NCT05796167|DRUG|Pimavanserin|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
48299530|NCT06070623|DEVICE|US|We use elastography and color Doppler from US machine and compare results with CT
47951826|NCT00630370|DRUG|Placebo|2 Placebo tablets, TID, orally, 58 days
47951827|NCT00630370|DRUG|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
48107605|NCT02881749|RADIATION|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
48299531|NCT04462848|BIOLOGICAL|anti-SARS-CoV-2 human convalescent plasma|Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
48107606|NCT02881749|DRUG|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
48299532|NCT01675921|OTHER|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
48107607|NCT03091712|DEVICE|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
48107608|NCT04056923|PROCEDURE|3D-printing guided|3D printed navigational template guided
48299533|NCT04766424|BEHAVIORAL|Sleep extension intervention|Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.
48299534|NCT04766424|BEHAVIORAL|Health education|Participants will receive 8 weekly health education newsletters delivered via email.
47951828|NCT00630370|DRUG|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
47951829|NCT00630370|DRUG|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
47951830|NCT01050855|DRUG|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
47951831|NCT01050855|DRUG|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
48107609|NCT04056923|PROCEDURE|CT-guided|CT-guided
48107610|NCT04056923|DRUG|Indocyanine Green|The results are shown by comparison of different colors.
48107611|NCT04056923|DRUG|Methylene blue|The results are shown by comparison of different colors.
48107612|NCT04056923|PROCEDURE|Preoperative|Preoperative localization.
48107613|NCT04056923|PROCEDURE|Intraoperative|Intraoperative localization.
48107614|NCT06553391|DRUG|The tetralogy of medication regimen|"During the rewarming process, the study group received an injection of 0.15g amiodarone via the extracorporeal circulation oxygenator. After heart re-beating：~1. If the heart rate is ≥70 beats per minute without specific therapy and in sinus rhythm or atrioventricular junctional rhythm, no special treatment is required. If the heart rate \<70 beats/min, intravenous injection of isoproterenol 2 ug may be administered.~2. In cases where there is sinus rhythm or atrioventricular junctional rhythm with a heart rate \<70 beats/min and perfusion pressure \<60mmHg, intravenous injection of ephedrine 10 mg + aminophylline 0.15 g should be given.~3. For patients with atrioventricular junctional rhythm or sinus rhythm and a heart rate \<70 beats/min but perfusion pressure ≥60mmHg, intravenous injections of aminophylline (0.15g) and ephedrine (10 mg) .~4. In cases where there is atrial fibrillation (AF), and the heart rate is ≥70 beats/min without special treatment."
48107615|NCT00487305|BIOLOGICAL|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
48107616|NCT04306354|DRUG|Oxytocin nasal spray|Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
48107617|NCT04306354|DRUG|placebo nasal spray|Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
48107618|NCT04178109|DRUG|Dexketoprofen/tramadol (27mg/75mg)|Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
48107619|NCT04178109|DRUG|Tramadol hydrochloride|Patients in group B received IV tramadol 75mg every 8h
48107620|NCT04178109|DRUG|Paracetamol|Patients in group B received IV paracetamol 1g every 8h
48107621|NCT04178109|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
48107622|NCT04178109|DRUG|Levobupivacaine Hydrochloride|10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
48299535|NCT02615106|DRUG|Endostar|7.5 mg/m2/day, day 1-14
48299536|NCT02615106|RADIATION|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
48299537|NCT06337851|OTHER|Simultaneous burr hole craniostomy|Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
48478911|NCT01684878|DRUG|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
48478912|NCT00702208|DEVICE|Delphi Screener|Self-sampling device for cervical vaginal lavage
48478913|NCT04579315|OTHER|Intervention group; NNRD group|The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
48637676|NCT03375307|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47951832|NCT01050855|DRUG|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
47951833|NCT02773290|BIOLOGICAL|Romiplostim|Weekly SC administration
48637677|NCT03375307|DRUG|Olaparib|Given PO
48637678|NCT03375307|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48637679|NCT03293563|PROCEDURE|Radical nephrectomy versus partial nephrectomy (according surgeon judgement)|
48637680|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin|Drugs was given a few days after multimodal thermal therapy
48637681|NCT06636591|COMBINATION_PRODUCT|Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin|Drugs was given a few days after multimodal thermal therapy
47951834|NCT04799574|OTHER|music therapy activities|"Music therapy activity course design (Protocol):~The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses and obtained a senior music activity leadership certificate and qualification, such as books and internship certificates. The course design uses the percussion music theory and Dalcroze and Orpff music pedagogy to plan activities, as follows:~Each class in the music therapy activity course design has a fixed process. The 90-minute course includes 10-15 minutes of warm-up activities, 50-60 minutes of main activities, 10-15 minutes of recovery activities, and 10 minutes of rest for the elders in the middle. The content of the weekly main activities uses different music, musical instruments, props, or rhythms to lead the rhythm music activities."
47951835|NCT00994929|BIOLOGICAL|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
47951836|NCT00160589|DRUG|Levocetirizine|
47951837|NCT04875663|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
47951838|NCT00787761|BIOLOGICAL|anti-thymocyte globulin|"Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains \> 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.~Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.~Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration."
48107623|NCT05344300|OTHER|Temperature-measurement in lungs under sauna bath|Through a bronchoscopy procedure under an 88-92℃ environment, the air temperature is measured in the 1st, 2nd and 3rd bronchial segment, at 4th and 5th bronchial segment and at 6th-10th bronchial segment in resp. the right and left lung. The temperature is measured at time: 0 seconds (s), 15 s, 30 s, 45 s, 60 s, 75 s, 90 s, 105 s, 120 s, 135 s and 150 s.
48107624|NCT05308004|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
48107625|NCT05696977|DRUG|Cyclosporine Capsule|Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile
48637682|NCT05630053|DEVICE|Cementless Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
48637683|NCT05630053|DEVICE|Cemented Persona Knee System|The Persona Keel Knee system is a total knee system used in the replacement of the knee joint.
48637684|NCT04269187|DRUG|Theophylline|Theophylline oral 200 mg daily for 12 days
48637685|NCT03963622|OTHER|Respiratory Mechanics|"Different maneuvers based on respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume or pressure-time curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used.~Once spontaneous breathing has started, the occlusion pressure (P0.1) will be maintained within targets."
48107626|NCT03192319|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection
48107627|NCT02667535|DRUG|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
48107628|NCT00974025|DIETARY_SUPPLEMENT|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
48107629|NCT00974025|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered twice daily for four weeks
48655902|NCT06636760|OTHER|Placebo|The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.
48107630|NCT00877513|BEHAVIORAL|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
48107631|NCT02002819|DRUG|levetiracetam|
47951839|NCT00787761|DRUG|busulfan|"Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses."
48299538|NCT06337851|OTHER|Consecutive burr hole craniostomy|In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated. The contralateral hematoma was evacuated.
48299539|NCT04237207|DEVICE|Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software|Control cochlear implant sound processor
48299540|NCT04237207|DEVICE|301-M062 sound processor & software|New cochlear implant sound processor
48299541|NCT01959555|OTHER|No treatment given|Patients will not be treated with any specific product. Data collection only.
48299542|NCT03851393|OTHER|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
48299543|NCT03851393|PROCEDURE|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
48299544|NCT03851393|DIAGNOSTIC_TEST|Peptest™|The Peptest™ lateral flow device
48299545|NCT00250471|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
48299546|NCT03137394|OTHER|Observation|Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
48299547|NCT00410280|BIOLOGICAL|IMA-638 is a biologic|
48299548|NCT01707212|BEHAVIORAL|Pain management education|Education about pain management during infant immunization
48299549|NCT01707212|BEHAVIORAL|No pain management education|Control - no education about pain management during infant immunization
47951840|NCT00787761|DRUG|cyclophosphamide|"Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume)."
48107632|NCT01696578|BEHAVIORAL|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
48107633|NCT01533519|DRUG|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
48299550|NCT05218447|DEVICE|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
48478914|NCT06474299|DRUG|Varenicline|0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily
48478915|NCT06474299|DRUG|Nicotine patch|Following package inserts starting on the TQD, participants who smoke \>10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.
48478916|NCT06474299|BEHAVIORAL|Dual Focused Cessation Counseling|Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).
48478917|NCT06474299|BEHAVIORAL|Smoking Focused Cessation Counseling|Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).
48478918|NCT06474299|OTHER|Counseling Intensity: 1 Session|Participants assigned to one session will complete a single, 15-20 minute, in-person session at Visit 2 (1 week pre-TQD).
48478919|NCT06474299|OTHER|Counseling Intensity: 4 Sessions|Participants assigned to intensive counseling will have four, 15-20-minute sessions, one in-person at Visit 2 and then 3 phone sessions: 1 day post-TQD and Weeks 1 and 2.
48478920|NCT03527004|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
48478921|NCT03527004|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in IQOS users residing in Italy.
48478922|NCT05801302|DEVICE|Foam rolling (shorter volume)|A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
48299551|NCT05218447|OTHER|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
48299552|NCT04277572|PROCEDURE|Aortic valve replacement|Aortic valve surgery
48299553|NCT05346224|DRUG|HLX11|Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
48299554|NCT05346224|DRUG|EU-Perjeta®|Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
48299555|NCT00204893|DRUG|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
48299556|NCT00963521|BIOLOGICAL|therapeutic autologous dendritic cells|
48299557|NCT02270398|BEHAVIORAL|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
48299558|NCT02270398|BEHAVIORAL|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
48299559|NCT02270398|BEHAVIORAL|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
48299560|NCT02284906|DRUG|Pioglitazone|Pioglitazone tablets
48299561|NCT02284906|DRUG|Placebo|Pioglitazone placebo-matching tablets
48299562|NCT04650321|DRUG|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
48299563|NCT04051593|OTHER|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
48299564|NCT05515549|OTHER|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
48299565|NCT01728272|DRUG|blood concentration of metoprolol|measure blood concentration of metoprolol
48299566|NCT01888354|DRUG|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
48299567|NCT02807909|DRUG|BMS-986177|
48132598|NCT05930106|DEVICE|Carotid Artery Doppler Peak Velocity Variation|Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA.
48299568|NCT02807909|DRUG|Itraconazole|
48299569|NCT02807909|DRUG|Diltiazem ER|
48299570|NCT04748783|OTHER|Water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.
48299571|NCT04748783|OTHER|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
48299572|NCT04748783|DRUG|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
48299573|NCT04748783|OTHER|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
48478923|NCT05801302|DEVICE|Foam rolling (longer volume)|A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
48478924|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
48132599|NCT03295994|PROCEDURE|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
48132600|NCT03295994|PROCEDURE|Non-Operative|Physical therapy (without surgery).
48132601|NCT06082037|DRUG|Belumosudil|Tablet, Oral
48132602|NCT06082037|DRUG|Azithromycin|Depends on pharmaceutical presentation, Oral
48299574|NCT04929873|BEHAVIORAL|Closed transdyser|When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure \< 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
48299575|NCT04929873|BEHAVIORAL|Routine monitor|Obtain oxygen saturation, skin color, temperature, etc
48299576|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Acacia Gum-MMST Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
48299577|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Malto-OSA Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
48478925|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
48478926|NCT00164034|DEVICE|Real time computer prompted trauma algorithms|
47951841|NCT00787761|DRUG|fludarabine phosphate|"Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes."
47951842|NCT00787761|DRUG|methotrexate|"Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push."
47951843|NCT00787761|DRUG|tacrolimus|"Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F)."
48107634|NCT00873899|DEVICE|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
48299578|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Collagen Booster|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
48299579|NCT05116982|DIETARY_SUPPLEMENT|Placebo|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
48299580|NCT00923910|DRUG|WT1 Peptide-Pulsed Dendritic Cells|
48478927|NCT02915237|DIETARY_SUPPLEMENT|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
48478928|NCT02915237|DIETARY_SUPPLEMENT|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
47951844|NCT00787761|PROCEDURE|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem \& Seattle, RICT has been used to treat hematologic \& solid malignancies with related \& unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute \& chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
47951845|NCT00922233|DRUG|levonorgestrel|oral contraceptive pills
47951846|NCT02100800|OTHER|MR and CT measurements of emphysema quantification|
48299581|NCT00923910|DRUG|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
48637686|NCT03963622|OTHER|Standard Ventilation Strategy|Patients randomized to the control arm will receive standard care. The PEEP is adjusted for oxygenation based on a PEEP-FiO2 table, either the low PEEP-FiO2 or the high PEEP-FiO2 table. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 \<60%, and is titrated VT 6-8 mL·kg-1.
47951847|NCT05122871|OTHER|Scape Room|Practical training through scape-room with simulator
47951848|NCT05122871|OTHER|Simulation|Practical training through simulator
47951849|NCT04962048|DEVICE|pulse-synchronized negative pressure (PSNP) device|The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.
47951850|NCT04962048|OTHER|Control - no intervention|The other leg serves as non-treated control
47951851|NCT04317404|DRUG|40 mg Triamcinolone acetonide|Unilateral knee steroid injection
47951852|NCT04971421|DIAGNOSTIC_TEST|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
47951853|NCT04971421|DIAGNOSTIC_TEST|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
47951854|NCT05352711|DEVICE|active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con|VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.
48107635|NCT03986424|DRUG|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
48299582|NCT00923910|DRUG|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
48107636|NCT03986424|DRUG|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
48637687|NCT01517776|DRUG|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
48637688|NCT01517776|DRUG|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
48107637|NCT04602052|PROCEDURE|Dilation and evacuation|Abortion is termination of pregannacy by evaccuating the uterus using either medical or surgical technique
48107638|NCT02777099|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
48299583|NCT00923910|DRUG|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
48299584|NCT00923910|DRUG|WT1 Peptides|dendritic cell vaccine
48299585|NCT00923910|DRUG|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
48299586|NCT00923910|DRUG|Diphenhydramine|Pre-medication
48299587|NCT00923910|DRUG|Acetaminophen|Pre-medication
48299588|NCT04110249|PROCEDURE|Photoacoustic Imaging|Undergo PAI
48299589|NCT04110249|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
48299590|NCT00401973|DRUG|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
48299591|NCT00401973|DRUG|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
48478929|NCT05370261|DIETARY_SUPPLEMENT|Berberine LipoMicel|Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
48478930|NCT05370261|DIETARY_SUPPLEMENT|Regular Berberine hard-gels|Total dose of 500 mg of berberine
48478931|NCT06534541|BEHAVIORAL|Attentional bias to food cues|Measurement of the amount of attention given to food cues
48478932|NCT05108116|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
48478933|NCT04563520|DRUG|aPCC-emicizumab|Personalized dose of aPCC-emicizumab will be administered to participants. The max dose allowed for aPCC will be 25 U/kg/dose every 8 hours, for no more than 72 hours without further discussion with the PI.
48478934|NCT04563520|DRUG|FEIBA|"FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, routine prophylaxis to prevent or reduce the frequency of bleeding episodes. If there is less than a good' response in bleed event at 48 hours or less than moderate for surgical event control, the local PI can consider the use of thrombin generation guided rFVIIa with a max dose of no more than 90 µg/kg/dose every 8 hours for 72 hours, with wean to occur for no more than 7 total days."
48478935|NCT04563520|DRUG|rFVIIa|rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
48478936|NCT01396421|DRUG|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
48637689|NCT05978362|PROCEDURE|Latarjet technique|Realization of a stop according to Latarjet
48107639|NCT02777099|PROCEDURE|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
48107640|NCT00576888|OTHER|no intervention|no intervention - observational only
48478937|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
48478938|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
48478939|NCT01396421|DRUG|Placebo|Placebo, once daily, for six weeks
48107641|NCT05100199|DRUG|OnabotulinumtoxinA X|Injection
48478940|NCT06364254|DIETARY_SUPPLEMENT|Cannabidiol Capsules|300 mg of cannabidiol administered 2 hours before 2 mile run
48478941|NCT06616883|DRUG|DA-5221_01|single dose administration (DA-5221_01 one tablet once a day)
48478942|NCT06616883|DRUG|DA-5221_01-R1 + DA-5221_01-R2|single dose administration (DA-5221_01-R1 one tablet once a day + DA-5221_01-R2 one tablet once a day)
48478943|NCT01813071|BIOLOGICAL|WRSS1|
48478944|NCT04344197|OTHER|global survey|surgery questionnaire
48478945|NCT01397955|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
48478946|NCT02666391|BIOLOGICAL|umbilical cord mesenchymal stem cells|
48478947|NCT01431443|OTHER|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
48478948|NCT01431443|OTHER|Placebo Chocolate|Placebo intervention
48478949|NCT04723147|DRUG|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
48107642|NCT05100199|DRUG|Placebo|Injection
48107643|NCT00107835|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
48107644|NCT03991481|BIOLOGICAL|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
48107645|NCT03991481|BIOLOGICAL|Liquid-stored platelets|Liquid-stored platelets as per standard practice
48107646|NCT06097429|DIAGNOSTIC_TEST|blood sample for platelet aggregation|evaluate platelet aggregation using light-transmission aggregometry and adenosine diphosphate (ADP)
48478950|NCT04723147|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
48478951|NCT02117388|BEHAVIORAL|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
48637690|NCT05635409|BIOLOGICAL|STEM-PD|STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
48637691|NCT06065540|DRUG|Cagrilintide|Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of cagrilintide is reached.
48637692|NCT06065540|DRUG|Semaglutide|Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose of 2.4 mg and 1.0 mg of semaglutide is reached.
48637693|NCT06065540|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
48637694|NCT06065540|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
48637695|NCT03180138|BEHAVIORAL|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
48637696|NCT03180138|BEHAVIORAL|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
48637697|NCT02267525|DRUG|Velusetrag|
48637698|NCT02267525|DRUG|Placebo|
48107647|NCT06343103|OTHER|Workers exposed|Workers exposed to cytotoxic agents
48107648|NCT06343103|OTHER|Workers not exposed|Workers not exposed to cytotoxic agents
48132603|NCT06082037|DRUG|Placebo|Tablet, Oral
48132604|NCT03363984|DRUG|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
48132605|NCT03363984|DRUG|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
48478952|NCT02117388|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
48478953|NCT02117388|BEHAVIORAL|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
48132608|NCT05062291|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
48132609|NCT02189252|DRUG|Epanova|
48132610|NCT02189252|DRUG|Lovaza|
48637699|NCT04181463|DRUG|Isopropyl Alcohol|Given via nasal inhalation
48497841|NCT01123837|OTHER|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
48637700|NCT04181463|OTHER|Placebo|Given via nasal inhalation
48637701|NCT04181463|OTHER|Questionnaire Administration|Ancillary studies
48637702|NCT05099211|PROCEDURE|Muscle biopsies|"Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department."
48637703|NCT05099211|OTHER|Muscle Strengthening|3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
48637704|NCT05099211|BIOLOGICAL|Blood and urine samples|fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
48637705|NCT05099211|OTHER|Aerobic Training|"3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities."
48637706|NCT05099211|OTHER|Evaluation 1 pre-surgery|"Carried out at least 15 days before surgery~1. st visit:~   * Nutritional assessment~  * Body composition~  * Psychometric tests of quality of life + IPAQ Test~  * VO2pic~2. nd visit:~   * Neuromuscular tests~  * Functional tests"
48637707|NCT05099211|OTHER|Evaluation 2 post-surgery|"1. st visit:~   * Body composition~  * Nutritional assessment~  * Psychometric tests of quality of life~2. nd visit:~   * neuromuscular tests~  * Functional tests~  * Familiarization with training equipment if patient participates in re-training"
48637708|NCT05099211|OTHER|Intermediate Evaluation 3|performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
47951855|NCT05352711|OTHER|active assisted range of motion exercise|Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
48107649|NCT01927835|BIOLOGICAL|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
48107650|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM
47951856|NCT02337270|BIOLOGICAL|Ad5Ag85A|Aerosol administration of Ad5Ag85A
48107651|NCT01927835|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM
47951857|NCT05890742|DRUG|Sintilimab|In ARM Phase Ib Control group, Sintilimab will be used twice, q3w.
48107652|NCT01927835|BIOLOGICAL|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
48107653|NCT01927835|BIOLOGICAL|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
48107654|NCT03121586|DRUG|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
48107655|NCT06552494|OTHER|L-mHealth program|The intervention group receiving the L-mHealth program plus care as usual. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention.
48107656|NCT03897348|DRUG|Placebo|Oral medication
48107657|NCT03897348|DRUG|Lacosamide 100 mg|Oral medication
48107658|NCT03897348|DRUG|Lacosamide 200 mg|Oral medication
48107659|NCT04870060|DRUG|Curcumin Lozenges|Curcumin lozenges - 4 lozenges to be chewed BD. Each lozenge contained 100 mg of curcumin and the formulation was Solid Lipid Curcumin Particle (SLCP)
48107660|NCT02806869|DRUG|Single dose of ibuprofen (800 mg tablet)|
47951858|NCT05890742|DRUG|IBI310&Sintilimab|In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.
47951859|NCT05890742|PROCEDURE|Radical surgery|In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
47951860|NCT03505554|DRUG|Lorlatinib|100 mg QD
47951861|NCT00040339|PROCEDURE|hypothermia (body temperature lowered to 33°C or 91.4°F)|
48107661|NCT02806869|DIETARY_SUPPLEMENT|Pulmocare, two 8.0 oz (236.6 mL) cans|
48107662|NCT06232629|DEVICE|TUS Active|Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa
48107663|NCT06232629|DEVICE|TUS Sham|"Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa"
48107664|NCT04962074|DEVICE|Microfluidic sperm sorting chip|Fertile Ultimate® (Koek Biotechnology, Turkey) microfluidic sperm sorting chips
48107665|NCT04962074|DEVICE|Density gradient|Density gradient centrifugation
48107666|NCT00924534|DRUG|Placebo|Placebo
48107667|NCT00924534|DRUG|SLV337|SLV337 400 mg/day
48107668|NCT00924534|DRUG|SLV337|SLV337 800 mg/day
47951862|NCT03095833|OTHER|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
48478954|NCT00003098|OTHER|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
48637709|NCT05099211|OTHER|Final post-training evaluation 4|Tests identical to evaluation 1 + TM6
48637710|NCT01755156|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
48637711|NCT01755156|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
48637712|NCT01755156|DRUG|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
47951863|NCT03095833|OTHER|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
47951864|NCT03095833|OTHER|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
48107669|NCT00924534|DRUG|SLV337|SLV337 1400 mg/day
48107670|NCT03175913|DEVICE|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
48107671|NCT03175913|DRUG|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
48637713|NCT01755156|DRUG|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
48299592|NCT00401973|DRUG|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
48637714|NCT01755156|DRUG|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
48637715|NCT01755156|DRUG|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (\>= 1500 mg daily) throughout the study.
48637716|NCT06445179|PROCEDURE|Total Laparoscopic Hysterectomy|"The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection:~* Type A: minimum resection of paracervix.~* Type B: transection of the paracervix and the ureter.~* Type C: Transection of paracervix at the junction with the internal iliac vascular system~* Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy."
48637717|NCT06445179|DEVICE|Ureterolysis|unilateral or bilateral ureterolysis with or without bilateral adnexectomy
48637718|NCT00186992|RADIATION|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
48637719|NCT02298504|DRUG|Mineral Trioxide Aggregate|Vital pulp therapy
48637720|NCT02298504|DRUG|Biodentin|Vital pulp therapy
48637721|NCT02298504|DEVICE|Vitrebond|Vital pulp therapy
48637722|NCT06406478|BEHAVIORAL|Schedule Change|This 4-day workweek is defined by any 4 ten hour shifts between Sunday and Saturday. It will be up to the discretion of participants in the intervention group to coordinate which 4 days they work. The 4 days will most likely be weekdays, but some participants may work weekends. If participants do any work from home, they will clock in remotely to account for the time.
48637723|NCT06406478|BEHAVIORAL|No Schedule Change|The control group will continue to work five days per week, receiving standard practice for the schedule policies at the participating study sites.
48637724|NCT06057428|PROCEDURE|Decompressive surgery|Decompressive surgery for lumbar spinal stenosis
48637725|NCT03834259|PROCEDURE|sitting position|keeping the patient in a sitting position after spinal anaesthesia
48299593|NCT00401973|DRUG|zonisamide|Zonisamide, 100-400mg, oral, daily.
48299594|NCT00401973|BEHAVIORAL|Wellness education|weight management
47951865|NCT03095833|OTHER|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
47951866|NCT03095833|OTHER|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
48107672|NCT06245629|DRUG|Bortezomib-bendamustine-melphalan|The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
48299595|NCT06362408|DRUG|Dexmedetomidine|Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
48299596|NCT04790006|DRUG|TG103|Administered SC
48637726|NCT03834259|PROCEDURE|supine position|keeping the patient in supine position after spinal anaesthesia
48637727|NCT03382860|DIAGNOSTIC_TEST|Fundus videos|Recordings of fundus videos
48637728|NCT06019819|OTHER|strengthening exercise|Perform general physical training activities conducted in schools including upper limb forward elevation, lateral elevation, touching toes in standing and cervical range of motion, strengthening exercise will be performed for 3days a week for 4 weeks.
48655903|NCT06636760|DIETARY_SUPPLEMENT|herbal compound|The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.
48107673|NCT04928053|GENETIC|ocytocine dosage and genetic analyse|All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment
47951867|NCT03095833|OTHER|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
48107674|NCT04994054|DIETARY_SUPPLEMENT|silkworms (Bombyx mori L.) pupae extracts group|silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks
48107675|NCT04994054|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,400 mg/day for 12 weeks
48107676|NCT00873691|DEVICE|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
48107677|NCT05922124|DRUG|Cefiderocol|Test drug regimen
48107678|NCT05922124|DRUG|Ampicillin-sulbactam|Synergistic combination
48107679|NCT05922124|DRUG|Colistin|Historical comparator
48299597|NCT04790006|DRUG|Placebo|Administered SC
48107680|NCT05922124|DRUG|Meropenem|Historical comparator synergistic combination
48299598|NCT05137522|DRUG|Chidamide combines with VP-16 and methylprednisolone|Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
48299599|NCT02392546|DRUG|elobixibat|
47951868|NCT03095833|OTHER|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
47951869|NCT03095833|OTHER|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
47951870|NCT03095833|OTHER|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
48107681|NCT05574530|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|6-week intervention of one dietary supplement a day, containing vitamin B2 (10mg), vitamin B3 (4mg), vitamin B6 (1.4mg), vitamin B9 (400μg), vitamin C (200mg) and vitamin D3 (15ug).
48107682|NCT05574530|DIETARY_SUPPLEMENT|Placebo supplement|6-week intervention of one dietary supplement a day, containing 200 mg of microcrystalline cellulose.
48107683|NCT06553014|OTHER|Endovascular Plug Embolization|Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
48107684|NCT02747563|OTHER|Blood test (PSA)|Measurement of blood PSA levels
48107685|NCT06554080|PROCEDURE|Platform-switched implant placement|NobelParallel or NobelActive implants placed
48107686|NCT06554080|PROCEDURE|Platform-matched implant placement|Nobel Brånemark, NobelSpeedy Groovy implants placed
48107687|NCT00605033|DRUG|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
48107688|NCT00605033|DRUG|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
48107689|NCT02079324|BIOLOGICAL|GX-051|intratumoral injection
48107690|NCT01209546|OTHER|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
47951871|NCT03095833|OTHER|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
48107691|NCT01209546|OTHER|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
48299600|NCT02392546|DRUG|placebo|
48299601|NCT01856946|DIETARY_SUPPLEMENT|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
48299602|NCT04737122|DRUG|LM-061|Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
47951872|NCT03095833|OTHER|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
47951873|NCT01025154|DRUG|Clofarabine|Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)
48107692|NCT01209546|OTHER|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
48107693|NCT01209546|OTHER|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
48107694|NCT05969236|DRUG|MDI-1228_mesylate Ophthalmic Solution|"MDI-1228_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)"
48299603|NCT04737122|DRUG|Toripalimab|For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
48299604|NCT02426242|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
48299605|NCT04195074|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
48478955|NCT00003098|OTHER|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
48655904|NCT00099905|DRUG|vildagliptin|
48637729|NCT06019819|OTHER|Postural correction exercises|Chin Tuck, Strengthening shoulder retractors, Stretching sternocleidomastoiD, Pectorals stretch For strengthening exercises 3 sets of 10 repetitions were performed with 6 seconds rest period between each set and a hold of 6 seconds. Stretching exercises will be performed in 3 sets of 10 repetitions ,30 seconds hold and 30 seconds rest period between each exercise. The exercises were performed 3days a week for 4 weeks.
48107695|NCT05969236|DRUG|Placebo|The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228_mesylate is absent.
48107696|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
47951874|NCT01025154|DRUG|Idarubicin|Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
47951875|NCT01025154|DRUG|Cytarabine|Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
48107697|NCT03202849|DIETARY_SUPPLEMENT|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
48107698|NCT04658849|DRUG|Pioglitazone 30 Mg Oral Tablet|"Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily."
48107699|NCT04658849|DRUG|Pioglitazone placebo tablet|Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
48478956|NCT03347357|DRUG|Tacrolimus|Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
48478957|NCT06470360|OTHER|Surgycal procedure|surgical technique
48478958|NCT06111079|DRUG|aspirin discontinuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
48478959|NCT06111079|DRUG|aspirin continuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
48478960|NCT00316394|DEVICE|Preventive Care Checklist Form|
48478961|NCT04387071|BIOLOGICAL|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Given IT
48478962|NCT04387071|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC and IT
48637730|NCT05099172|DRUG|BAY2927088_formulation A|Oral administration
47951876|NCT00431678|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
47951877|NCT00431678|DRUG|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
47951878|NCT02552784|BEHAVIORAL|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
47951879|NCT05542199|OTHER|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
47951880|NCT05542199|BEHAVIORAL|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
48107700|NCT02485236|DEVICE|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of \> 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
48107701|NCT02485236|DEVICE|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
48478963|NCT00810888|DRUG|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
48478964|NCT00810888|DRUG|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
48478965|NCT02365948|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection"
48299606|NCT04195074|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
48478966|NCT02365948|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
48478967|NCT01397981|BEHAVIORAL|Gait retraining|Changing the kinematics of walking
48637731|NCT05099172|DRUG|BAY2927088_formulation B_1|Oral administration
48637732|NCT05099172|DRUG|BAY2927088_formulation B_2|Oral administration
48637733|NCT05416632|DIAGNOSTIC_TEST|Athrometer|Arthrometer
48637734|NCT03077308|PROCEDURE|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
48299607|NCT04195074|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
48299608|NCT00056212|BEHAVIORAL|Yoga|
47951881|NCT06248567|DRUG|ZSP1273|Oral
48299609|NCT00056212|BEHAVIORAL|Exercise|
48299610|NCT05111834|BEHAVIORAL|Supervised resistance training plus nutritional endorsement|resistance training 2x per week, nutritional endorsement/therapy based on individual needs
48299611|NCT05111834|BEHAVIORAL|Nutritional endorsement|nutritional endorsement/therapy based on individual needs
48299612|NCT01284179|BEHAVIORAL|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
48299613|NCT01284179|BEHAVIORAL|Educational|Educational recordings regarding FCP and FGIDs.
48299614|NCT03802422|DRUG|Vitamin B12|Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
48299615|NCT03802422|DRUG|Normal saline|Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
48299616|NCT05263882|DRUG|Gemcitabine combined with eribulin|"* Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
48299617|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
48299618|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
48299619|NCT01495546|OTHER|Early loading|Patients stepping down immediately after THA
48299620|NCT01495546|OTHER|Late loading|Patients stepping down after three weeks of HTA
48299621|NCT03645252|PROCEDURE|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
48299622|NCT03645252|PROCEDURE|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
48478968|NCT05373381|DIETARY_SUPPLEMENT|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition \[Healthtrac\].
48107702|NCT04879082|OTHER|Professional course, occupational exposures|"The data collected are the following variables: age, sex, diploma, professional course coded in CITP (International Standard Classification of Professions) and NAF (French Nomenclature of Activities), occupational exposures, smoking, risk factors non-professionals, clinical elements of ILD and elements relating to an occupational disease certificate. This database is anonymized.~The precise diagnosis of ILD is retained during the multidisiciplinary meeting.~Occupational exposures are assessed in specialized consultation :~* a first professional interview phase: The professional history is traced, listing the training courses followed and the trades carried out. The questioning is precise and focuses on the different tasks performed, and the products used.~* a second step, where a questionnaire is completed by the doctor: A list of specific substances is offered to the patient, who responds whether or not he thinks he has been exposed to them in his professional past."
48478969|NCT00982891|DRUG|Opioid (morphine sulphate) in low dose|individualized titration
48478970|NCT05022368|DEVICE|LabraGuard|Protection of the lips and the oral commissure during transoral procedures
48478971|NCT05918757|OTHER|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
48478972|NCT05918757|OTHER|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
48478973|NCT03944681|DRUG|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
48299623|NCT04736511|OTHER|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
48299624|NCT04736511|OTHER|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
48299625|NCT04736511|OTHER|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
48107703|NCT01254019|DRUG|GSK2402968 6mg/kg/week|subcutaneous
48299626|NCT04736511|OTHER|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
48299627|NCT02296840|DRUG|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
48299628|NCT02296840|DRUG|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
48299629|NCT04615390|BEHAVIORAL|Early rehabilitation|The intervention is primarily focused on the recovery of mobility and functional autonomy. The treatment sessions are dependent on the patient's exercise tolerance.
48299630|NCT04615390|BEHAVIORAL|Subacute rehabilitation|Comprehensive intensive rehabilitation in the hospital
48299631|NCT04615390|BEHAVIORAL|Mindfulness training|The home mindfulness training consists of 2 parts: 1) explanation and reflection of the Mindfulness practice 2) formal and informal practice.
48107704|NCT00597519|DRUG|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
47951882|NCT06452589|DEVICE|FieldForce Ablation System|The FieldForce Ablation System is indicated for cardiac electrophysiologic mapping, delivery of diagnostic pacing stimuli, and pulse field ablation of cardiac tissue. When used with the FieldForce Ablation Catheter, the FieldForce System is intended to be used in the right/left atria and/or left/right ventricle to deliver PFA ablation lesions in the selected areas of the chamber.
48299632|NCT04615390|BEHAVIORAL|Personalized ambulatory training|Low-intensity walking exercises at home
48299633|NCT06272253|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|Dose : 1 dose 0.5 ml containing 5 μg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
48299634|NCT06074822|OTHER|Residual neuromuscular biopsy|recovery of residual neuromuscular biopsy (nerve ans muscle)
48299635|NCT02101411|DIAGNOSTIC_TEST|PRU(Platelet reactivity unit)|measure by VeryfyNow.
48478974|NCT05922631|PROCEDURE|Airway pressure release ventilation|ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
48478975|NCT05922631|PROCEDURE|low tidal volume|The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
48107705|NCT00597519|PROCEDURE|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
48478976|NCT04923711|BEHAVIORAL|Moderate intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold."
48478977|NCT04923711|BEHAVIORAL|High intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold."
48107706|NCT06156319|OTHER|No intervention|No intervention
48478978|NCT04737850|DRUG|Hetrombopag|Thrombopoietin receptor agonist
48478979|NCT04737850|DRUG|Placebo|Placebo with no active pharmaceutical ingredient
48478980|NCT02265406|DRUG|Anti-Infective Agents|
48478981|NCT02265406|DRUG|Placebo|
47951883|NCT01743183|DEVICE|Threshold|The load adjustment was done weekly by a single examiner.
47951884|NCT05522452|OTHER|Telerehabilitation|Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
47951885|NCT05522452|OTHER|Face to face rehabilitation|Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
47951886|NCT06557018|DRUG|liposomal bupivacaine|liposomal bupivacaine group
47951887|NCT06557018|DRUG|traditional peri-articular injection|traditional peri-articular injection group
47951888|NCT02410551|DRUG|Pacritinib|200 mg by mouth twice a day for 60 days.
47951889|NCT02410551|DRUG|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
47951890|NCT02410551|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
47951891|NCT02410551|BEHAVIORAL|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
47951892|NCT02410551|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
47951893|NCT02410551|DRUG|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
48299636|NCT04330235|OTHER|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
48299637|NCT04997837|DRUG|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
48299638|NCT04997837|DRUG|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
48299639|NCT04997837|DRUG|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
48637735|NCT00231465|DRUG|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
48637736|NCT00231465|DRUG|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
48637737|NCT05694208|BEHAVIORAL|Education Group|In the first pre-operative interview at the gynecological oncology outpatient clinic of the relevant hospital, the purpose of the research will be explained to the patients and an informed consent form will be filled. The patients in the experimental group will use the mobile-based care support application developed within the scope of the research.
48637738|NCT01169337|OTHER|Clinical Observation|Undergo observation
48637739|NCT01169337|DRUG|Lenalidomide|Given PO
48107707|NCT01940003|OTHER|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
48299640|NCT04997837|DRUG|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
48299641|NCT04997837|DRUG|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
48299642|NCT04997837|RADIATION|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
48299643|NCT04997837|DRUG|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
48637740|NCT01169337|OTHER|Quality-of-Life Assessment|Ancillary studies
47951894|NCT02519218|DEVICE|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
47951895|NCT06412224|DRUG|RRG001|Administered by subretinal injection. Dosage form: injection.
47951896|NCT01031602|BEHAVIORAL|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
48107708|NCT02516644|BEHAVIORAL|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
48478982|NCT03653026|DRUG|Placebo|Tablet for oral administration
48478983|NCT03653026|DRUG|Upadacitinib|Tablet for oral administration
48478984|NCT00279539|GENETIC|Vascular Endothelial Growth Factor (VEGF1)|
48637741|NCT05858151|BEHAVIORAL|Food system and demand generation|The Global Alliance for Improved Nutrition (GAIN) will implement the Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable program, which will use a market-based approach to improving diets through food systems. The set of interventions proposed is based on characteristics and challenges of the food environments of bottom of pyramid consumers in Mozambique. GAIN will focus on elements of the food environment related to accessibility, affordability, and desirability of animal source foods (ASFs) in Mozambique.
48637742|NCT06286046|DRUG|Mitapivat|Tablets
48637743|NCT02261532|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
48637744|NCT03397719|BEHAVIORAL|Treatment Condition|This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
47951897|NCT05594654|OTHER|Smart Phone Application|"Breathe is an app that can be used by people with asthma to promote collaborative self-management. It is a platform that empowers patients to self-manage their condition. Breathe helps patients detect when they might be exacerbating or adequately controlled based on symptoms entered by the user into the application. The application then feeds these symptoms through a rules-based algorithm that identifies the early onset of an exacerbation, based on the user's zone of control or action plan. It also stores the patient's self-management action plan and gives them relevant instructions when it sees that their symptoms are getting better or worse. These instructions are delivered through a chatbot that provides information, support, and education to the patient through a friendly, human-like text message conversation."
48107709|NCT02516644|BEHAVIORAL|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
48107710|NCT04911842|DEVICE|HydroMID|Hydrophilic biomaterial
48107711|NCT04911842|DEVICE|TPU|Thermoplastic polyurethane
48107712|NCT03038503|DRUG|Methylene Blue|after defined refractory shock (need NE\>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr\*4 hr (intervention add on to standard care)
48107713|NCT03038503|DRUG|Terlipressin|after defined refractory shock (need NE\>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
48107714|NCT02201173|BEHAVIORAL|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
48107715|NCT06129370|DEVICE|Standard practice|Lexicomp and manual calculator
48107716|NCT06129370|DEVICE|Medication dosing software|Medication dosing software
48107717|NCT01456819|BIOLOGICAL|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
48107718|NCT01456819|BIOLOGICAL|Mononuclear cells|Intramuscular administration into the ischemic limb
48107719|NCT01125306|DEVICE|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
48637745|NCT03397719|BEHAVIORAL|Control Group|This group will receive in-vivo parent coaching three hours per week.
48637746|NCT06096038|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/meter square IV
48637747|NCT06096038|DRUG|Fludarabine|fludarabine 30 mg/meter square IV × 3 days
48637748|NCT06096038|BIOLOGICAL|Cell Therapy|the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion
48107720|NCT06553794|OTHER|Gastroscopy with duodenal mucosal tissue biopsies|"Subjects will undergo a standardized heavy water dosing protocol for 2 days (1 loading day, 1 maintenance day) and consume a standardized diet for 2 days. On the experimental test day, a gastroscopy with collection of duodenal mucosa tissue samples will be performed."
48107721|NCT04561037|DEVICE|Pulsed Electromagnetic Field therapy (PEMFT)|PEMFT was connected to electrical mains supplying 220v. Pair of applicators sized 16x10x3 cm was adjust to be over TMJ, on both sides of the face; the appliance was adjusted to the frequency of 50 HZ and intensity of 90 Gauss. Twelve PEMF treatment sessions of 30 min duration were provided 3 times per week TMJ mobilization techniques and isometric exercises against resistance for muscles of mastication
48107722|NCT04561037|OTHER|TMJ physical therapy program|TMJ manual physical therapy program (mobilization and gentle isometric exercises) for 30, 3 times a week, for 4 weeks.
48478985|NCT06214754|PROCEDURE|PCI|The subjects underwent immediate coronary angiography after Percutaneous transluminal coronary angioplasty to evaluate the success rate of instruments, and immediate coronary angiography after PCI to evaluate the success rate of clinical treatment
48478986|NCT00925756|DRUG|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
48478987|NCT03471208|DEVICE|Dynamic Navigation Assisted Implant Surgery|Implant surgery using dynamic navigation assistance
48478988|NCT03471208|PROCEDURE|Freehand Implant Surgery|Dental implant surgery via conventional freehand
48478989|NCT06616103|DIAGNOSTIC_TEST|computerized tomography|noncontrast abdominal CT
48478990|NCT04814784|RADIATION|Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum|Study the effect of neoadjuvent radiotherapy in treatment of locally advanced cancer rectum e higher possiblity of preservation of anal sphincter and decreased rate of locoregional recurrence compared to surgery alone
48637749|NCT06584409|DEVICE|Laser Pen|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
48132616|NCT00455650|DRUG|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
48299644|NCT00575822|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
48299645|NCT00575822|DEVICE|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
48299646|NCT04743414|DRUG|CTP-543|Itraconazole in solution dosage form
48299647|NCT06361277|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
48299648|NCT01266707|BIOLOGICAL|antiangiogenic paptide vaccine|for drugs include administration time frame
48478991|NCT00574067|DRUG|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
48478992|NCT00574067|DRUG|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
48478993|NCT00574067|DRUG|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
48637750|NCT06584409|OTHER|Observation|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
48637751|NCT00663611|DRUG|Norditropin|Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
48637752|NCT00663611|DRUG|Placebo|0.9% normal saline
47914294|NCT00538668|DRUG|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
47951898|NCT00965809|DRUG|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
48299649|NCT04493710|DIAGNOSTIC_TEST|Sarcopenia estimation|Analysis of pre-existing CT imaging
48299650|NCT01220752|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
48478994|NCT00574067|DRUG|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
48478995|NCT00928226|RADIATION|Fractionated Stereotactic Radiosurgery (SRS)|Standard of care
48478996|NCT00928226|PROCEDURE|Surgical resection|Standard of care
48637753|NCT06212323|OTHER|Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.|"Patients with high-risk smoldering myeloma will be prospectively followed and chart review will be performed to determine if progression events happen, and how they happen.~All patients on the study are recommended to undergo the following standard of care surveillance protocol:~* Complete Blood Count (CBC), Complete Metabolic Panel (CMP), myeloma blood tests (serum kappa/lambda light chains, monoclonal protein evaluation, immunoglobulin levels), to be done monthly for first year, and then every two months for the second year.~* WB DW-MRIs every 6 months during the study period.~* 24-hour urine Immunofixation/electrophoresis is expected to be completed approximately every 6 months.~* Bone marrow biopsy will be performed annually during the study time-period."
47914295|NCT02584556|DRUG|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
47951899|NCT00965809|OTHER|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
47951900|NCT02856698|DRUG|Midazolam|Dose use according to the product technical sheet
47951901|NCT02856698|DRUG|Morphine|Dose use according to the product technical sheet
47951902|NCT00320931|DEVICE|Hybrid PET/CT|Rest and vasodilation stress rubidium PET and coronary angiography with CT were performed using standard doses for clinically indicated studies.
47951903|NCT01268150|DRUG|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
47951904|NCT05931874|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the study self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the study. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the study app and provide Fitbit data to the study team in real-time.~The core study app will support BCS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
48107723|NCT06076382|PROCEDURE|endoscopic ultrasound guided colorectal ESD surgery|The experimental group first underwent endoscopic ultrasound examination, with a small ultrasound probe inserted into the intestinal cavity through the biopsy port. After water injection, the lesion was scanned and (1) the direction of gravity was determined. (2) fibrosis/infiltration under the mucosa, and the fibrosis was divided into F0 (no fibrosis), F1 (cold fibrosis), or F2 (severe fibrosis). (3) The lesion was divided into nine compartments. Mark submucosal fibrosis/infiltration sites, according to nine compartments. (4) Based on the results of endoscopic ultrasound scanning of the lesion, the surgeon draw up surgical approach and perform injection and dissection.
48107724|NCT06076382|PROCEDURE|the traditional colorectal ESD surgery|The control group underwent injection and dissection directly.
48107725|NCT04459988|DRUG|Ocrelizumab|Description Needed
48107726|NCT00480519|PROCEDURE|Meatotomy|
48107727|NCT03967717|OTHER|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
48107728|NCT03140735|OTHER|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
48107729|NCT03140735|OTHER|Control group without heart disease|Control group without heart disease
48107730|NCT00333060|DRUG|OT-551 ophthalmic solution|
48107731|NCT04983537|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
48107732|NCT00001182|PROCEDURE|current standard of care treatments|
48107733|NCT04069182|BEHAVIORAL|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
48107734|NCT02845856|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
48107735|NCT02845856|BIOLOGICAL|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
48107736|NCT04848441|OTHER|The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1|The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.
48107737|NCT04126239|OTHER|Online survey - questionnaire|Online survey - questionnaire
48107738|NCT01463046|DRUG|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
47951905|NCT05931874|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
47951906|NCT05931874|BEHAVIORAL|Buddy|"Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the study app modules the participant has access to for their assigned condition.~The study app include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcast (one every 3 weeks) during the first 24 weeks of the intervention. Each webinar will provide social support training and peer discussion of challenges and successes in providing BCS with MVPA support."
47951907|NCT05931874|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the study app.
47951908|NCT05931874|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the study app.
47951909|NCT03333304|DIAGNOSTIC_TEST|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
47951910|NCT01736462|DRUG|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
48107739|NCT01463046|DRUG|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
48107740|NCT01463046|DRUG|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
48107741|NCT02824094|DRUG|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
48299651|NCT04788303|OTHER|School meal, garden, education, and community workshops|"School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
48478997|NCT02270216|PROCEDURE|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
48637754|NCT04476680|DIETARY_SUPPLEMENT|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
48637755|NCT02469961|DRUG|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
47951911|NCT01070758|DRUG|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
48107742|NCT05714358|BEHAVIORAL|Education|"* The patients were given face-to-face training on nutrition, physical activity and drug use in chronic renal failure .~* After the training, the biochemical parameters of the patients were followed for 6 months.~* In this process, the questions asked by the patients in order not to hinder their right to receive information were answered."
48497842|NCT01123837|OTHER|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
48637756|NCT02469961|DRUG|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
48637757|NCT02469961|OTHER|Interscalene block|Interscalene block is used for the main anesthetic for the case
48637758|NCT04284436|BEHAVIORAL|Treadmill walking|Treadmill walking 4 days per week for 30 minutes in the target heart rate
48637759|NCT03244384|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48637760|NCT03244384|OTHER|Clinical Observation|Undergo observation
48637761|NCT03244384|PROCEDURE|Computed Tomography|Undergo a CT scan
48637762|NCT03244384|PROCEDURE|CT Urography|Undergo a CT urography
48637763|NCT03244384|PROCEDURE|Cystoscopy|Undergo a cystoscopy
48637764|NCT03244384|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
48637765|NCT03244384|BIOLOGICAL|Pembrolizumab|Given IV
48637766|NCT03244384|OTHER|Pharmacological Study|Correlative studies
48637767|NCT03244384|OTHER|Quality-of-Life Assessment|Ancillary studies
48107743|NCT03630224|DRUG|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
48637768|NCT03244384|OTHER|Questionnaire Administration|Ancillary studies
48637769|NCT00310479|DEVICE|Magnetic Resonance Spectroscopy (3Tesla)|
48637770|NCT05719389|DRUG|CT-P13|CT-P13 is a biosimilar of infliximab approved by EMA since 2015, and it is administered intravenously (i.v.) at a standard dose of 5 mg/kg at week 0, 2, 6 and then every 8 weeks, although the scheduled maintenance regimen can be optimized by administering the drug every 4-6 weeks or increasing the dose up to 10 mg/kg2.The safety profile of CT-P13 SC was comparable to that of CT-P13 i.v.; There were also fewer patients with positive anti-drug antibodies with CT-P13 SC than with CT-P13 i.v.3 At the moment, no data are available on the effectiveness, safety and immunogenicity in a real-world population of patients who have been switched from i.v. to s.c. infliximab.
48637771|NCT04635163|OTHER|None intervention|None intervention
48637772|NCT05980455|DEVICE|Enterra® Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
48637773|NCT06434779|DEVICE|JETi 6F and 8F Thrombectomy system|To demonstrate the efficacy and safety of the mechanical thrombectomy device (JETi 6F and 8F) for treatment of patients with symptomatic peripheral artery disease (PAD) due to acute or acute on chronic occlusions of the femoral and/or popliteal arteries and the first 10 cm of the below-the -knee arteries.
48637774|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention Training|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release."
48637775|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Structured Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Structured Training includes four structured in-home coaching sessions."
47951912|NCT05405465|DRUG|Exposure to golimumab|Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
48637776|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Responsive Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Responsive Training includes at least 2 structured in-home coaching sessions plus additional sessions indefinitely as needed."
48637777|NCT01853085|DRUG|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
47951913|NCT01817244|OTHER|care management|6-month care management
47951914|NCT06345131|OTHER|Non invasive blood pressure monitoring|Non invasive blood pressure monitoring
47951915|NCT04683562|OTHER|Pregnant women at 28-32 weeks|Pregnant women at gestational age 28-32 weeks
47951916|NCT04683562|OTHER|at delivery|women delivered at term
47951917|NCT04200573|DRUG|Ampreloxetine|The study drug will be administered orally as a single Dose A tablet
48637778|NCT04745988|DRUG|Lenvatinib 20mg|Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
47951918|NCT02826278|OTHER|External genitalia measurements in female newborns|
47951919|NCT01066403|DRUG|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
48299652|NCT04788303|OTHER|Garden, education, and community workshops|"School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
48299653|NCT00016861|DRUG|irinotecan hydrochloride|
48299654|NCT03531372|DEVICE|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
48299655|NCT03531372|DEVICE|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
47951920|NCT06102915|DRUG|Rocuronium Bromide 10 MG/ML|Comparative
48299656|NCT00088010|DRUG|Arzoxifene|20mg, oral, tablet, once a day for 36 months
48299657|NCT00088010|DRUG|Placebo|oral, tablet, once a day for 36 months
48299658|NCT06175507|DRUG|Naltrexon|Naltrexone 50mg orally once daily will give for 12 weeks
48299659|NCT06175507|DRUG|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
48299660|NCT05547373|BEHAVIORAL|Infection prevention and control (IPC)|The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
48299661|NCT04036058|OTHER|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
48299662|NCT02188121|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
48299663|NCT02188121|DRUG|Losartan|Angiotensin II receptor antagonist
48299664|NCT05841498|DEVICE|Immunoadsorption|Immunoadsorption (IA) is a well-established extracorporeal therapy for several autoimmune diseases such as systemic lupus. Its therapeutic effect is based on the removal of antibodies (ABs) from the plasma including auto-ABs and it is used if an immediate response to therapy is necessary. Side effects (SE) of the IA are rare, but angiotensin-converting enzyme (ACE)-inhibitors are prohibited concomitant medication. Notable SE may include increased susceptibility to infection, transient disorders of blood coagulation, or allergic reactions to materials of the adsorber or tubing system. To ensure an effective therapy, a blood flow of at least 45 ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins but in most patients is the placement of a central venous catheter necessary. Central venous catheter placement carries potential risks such as injury to the lung or mispuncture of the carotid artery.
48497843|NCT05702671|DIAGNOSTIC_TEST|Total Immunoglobulin E, Obtained From Fingerstick Sample|The Kenota 1 System is intended to be a specialized tool in a professional allergist setting. It will help streamline the patient testing process by bringing quantitative, minimally invasive fingerstick IgE blood testing to the allergy clinic.
48497844|NCT03188666|DRUG|REGN2477|Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
47951921|NCT06102915|DRUG|Nimbex 10 MG in 5 ML Injection|Comparative
48497845|NCT03188666|DRUG|Matching placebo|Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
48497846|NCT04175535|PROCEDURE|Percutaneous Posterior Endoscopic Cervical Discectomy|The most common alternative in the case of soft cervical disc herniations.
48497847|NCT04175535|PROCEDURE|Anterior cervical decompression and fusion|The standard procedure for operation of cervical disc herniations.
48497848|NCT04847349|DIETARY_SUPPLEMENT|OL-1, standard dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
48497849|NCT04847349|DIETARY_SUPPLEMENT|OL-1, high dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
47951922|NCT06556511|DRUG|Zinc Sulfate|Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.
48497850|NCT04847349|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
48497851|NCT05331157|DEVICE|ultrasound|the efficacy of prepuncture ultrasonography to facilitate epidural block in pediatric patients undergoing elective urological operations compared with the conventional anatomical landmark technique
48497852|NCT00601809|OTHER|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
48497853|NCT00601809|DRUG|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
48497854|NCT06236451|DRUG|Aripiprazole|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
48299665|NCT05841498|DEVICE|Sham-apheresis|Sham-apheresis is a procedure without any known therapeutic effects. As there are no known therapeutic effects there are also no known side effects excepted the risk of an allergic reaction to materials of the tubing system or to citrate, which is necessary to prevent clotting inside the extracorporeal system. To ensure a smooth operation a blood-flow of at least 45ml/min is necessary. In some patients, adequate blood flow can be achieved by cannulation of peripheral veins. However, in most patients, placement of a Shaldon catheter into the internal jugular vein is necessary. Shaldon catheter placement carries other potential risks such as injury to the lung resulting in pneumothorax or mispuncture of the carotid artery. However, since the catheter placement is sonography-guided, the risks for such adverse events are minimized.
48299666|NCT02231216|PROCEDURE|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
48299667|NCT02231216|PROCEDURE|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
47951923|NCT06556511|DRUG|Placebo|Placebo is administered with standard therapy in the placebo group for a period of 10 days.
48107744|NCT03630224|DRUG|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
48107745|NCT02203630|DRUG|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
48107746|NCT02203630|DRUG|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
48107747|NCT02854319|DEVICE|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
48107748|NCT04948151|DRUG|Sildenafil|Patients will apply 2-gram applications up to 9 times per month.
48107749|NCT04948151|DRUG|Placebo|Patients will apply 2-gram applications up to 9 times per month
48107750|NCT03244696|BEHAVIORAL|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
48107751|NCT03244696|BEHAVIORAL|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
48107752|NCT04683263|OTHER|Placebo|topical cream with same composition as Intervention but without active ingredients
48299668|NCT02231216|PROCEDURE|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
48299669|NCT05393583|PROCEDURE|Outpatient hysterectomy|Discharge on the day of the hysterectomy
48299670|NCT05393583|PROCEDURE|Inpatient hysterectomy|1 night hospital stay after hysterectomy
47951924|NCT00032097|DRUG|motexafin gadolinium|
47951925|NCT00032097|RADIATION|radiation therapy|
47951926|NCT02902068|DEVICE|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
48299671|NCT02492750|BIOLOGICAL|Anakinra|Given SC
47951927|NCT02213042|DRUG|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
47951928|NCT02213042|BIOLOGICAL|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
47951929|NCT02213042|DRUG|Aromatase Inhibitors (AIs)|Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
48107753|NCT04683263|OTHER|Fisiocrem|a natural topical composition containing Arnica montana, Hypericum perforatum, Calendula officinalis, Melaleuca sp. and menthol
48107754|NCT02162420|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
48107755|NCT02162420|DRUG|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
48107756|NCT02162420|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
48107757|NCT02162420|RADIATION|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
48107758|NCT02162420|BIOLOGICAL|Stem Cell Transplant|Stem cell transplant on day 0.
48107759|NCT02162420|DRUG|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
48107760|NCT04476095|DEVICE|Active PBMT|Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.
48299672|NCT02492750|DRUG|Dexamethasone|Given PO
48299673|NCT02492750|OTHER|Laboratory Biomarker Analysis|Correlative studies
48299674|NCT02492750|DRUG|Lenalidomide|Given PO
48299675|NCT02492750|OTHER|Placebo|Given SC
48299676|NCT05148208|DEVICE|Creatine supplementation to dialysate|Creatine supplementation to dialysate
48299677|NCT01618981|PROCEDURE|pace make active/inactive cross over|
48299678|NCT00000455|DRUG|naltrexone|
48299679|NCT05846386|BEHAVIORAL|Resistance training|moderate-intensity resistance training: three sessions per week for one month. Participants had been instructed to perform exercises at a 4:2:4 tempo; that is, four sets of concentric contraction, two sets of isometric hold, and four sets of eccentric contraction. Participants had been instructed to complete a single set until volitional fatigue or been instructed to stop by the physiotherapist when the technique falters
48299680|NCT05846386|BEHAVIORAL|Aerobic training|"The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks."
48299681|NCT04885244|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
48299682|NCT00198159|DRUG|ZD1839 Iressa|
48299683|NCT04813679|DIAGNOSTIC_TEST|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
48299684|NCT06340737|DRUG|CD22CART Infusion|Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.
48299685|NCT00607646|DRUG|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
48299686|NCT00607646|DRUG|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
48299687|NCT02995681|OTHER|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
48299688|NCT02995681|OTHER|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
48299689|NCT04761497|OTHER|Actice music therapy|active music therapy sessions for three months
48299690|NCT04761497|OTHER|Watching nature videos|nature videos sessions for three months
48299691|NCT04761497|OTHER|Passive music therapy|passive music therapy for three months
48299692|NCT03952312|BEHAVIORAL|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
48299693|NCT03952312|BEHAVIORAL|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
48299694|NCT04955743|DRUG|Pembrolizumab|200 mg intravenous (IV) is administered every 3 weeks
47951930|NCT00747812|DEVICE|Precision|Implantable Neurostimulator
47951931|NCT05825781|DRUG|Pertuzumab|i.v.
47951932|NCT05825781|DRUG|Perjeta®|i.v.
47951933|NCT05147584|DEVICE|Dual fetal oxygen sensors|Placement of both internal and external fetal oxygen sensors
48497855|NCT06236451|DRUG|Risperidone|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
47951934|NCT02423837|DRUG|Rituximab, bendamustine|
48299695|NCT04955743|DRUG|Lenvatinib|20 mg orally (PO) is administered daily
48299696|NCT03070977|OTHER|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
48299697|NCT06284928|OTHER|Gut Microbiota Analysis|This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.
48299698|NCT00619931|DRUG|APD791|APD791 or matching placebo in escalating doses
48299699|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
48299700|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
48299701|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
48299702|NCT01132573|DRUG|entinostat|Given PO
48299703|NCT01132573|DRUG|clofarabine|Given IV
48299704|NCT01132573|OTHER|pharmacological study|Correlative studies
48299705|NCT01132573|OTHER|laboratory biomarker analysis|Correlative studies
48497856|NCT05738759|DRUG|Epidural Anesthetic Cocktail|The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
48637779|NCT04745988|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
48637780|NCT04745988|DRUG|Lenvatinib 8mg|Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
48637781|NCT04745988|DRUG|Docetaxel|Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.
48637782|NCT04745988|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.
48637783|NCT04745988|DRUG|Levofolinate|Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.
48637784|NCT04745988|DRUG|Fluorouracil|Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
48637785|NCT02379897|OTHER|Diet|
48637786|NCT03486106|OTHER|Music|Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
48637787|NCT03486106|OTHER|Headphones|All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
47951935|NCT04864301|PROCEDURE|Tumescent Stretching Measurement Technique|"The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus."
47951936|NCT03225599|OTHER|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
47951937|NCT05088720|DRUG|misoprostol 800 µg|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
47951938|NCT05088720|DRUG|misoprostol 400 µg|received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
47951939|NCT04087304|BEHAVIORAL|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
47951940|NCT03082261|DEVICE|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
48299706|NCT04436510|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"
48299707|NCT04436510|DRUG|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
48497857|NCT05738759|DRUG|Placebo|The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
48497858|NCT04121754|DEVICE|MR-001|Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.
48497859|NCT04121754|OTHER|Active Walking|Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
48637788|NCT03486106|DRUG|Propofol|All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
48637789|NCT04765072|BEHAVIORAL|Survivorship Patient Navigation Intervention|Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources
48637790|NCT04765072|BEHAVIORAL|Telehealth Survivorship Visit Intervention|Individualized survivorship care plan
48637791|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~30 seconds|Care team will wait to clamp the umbilical between 1-\<60 seconds after birth. 30 seconds is the ideal time of clamping.
48637792|NCT06153459|PROCEDURE|Umbilical Cord Clamping at ~120 seconds|Care team will wait to clamp the umbilical cord between 60-180 seconds after birth.120 seconds is the ideal time of clamping
47951941|NCT02360995|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
47951942|NCT02360995|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
47951943|NCT02360995|DRUG|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
48637793|NCT06153459|PROCEDURE|Umbilical Cord Milking|"For infants who need their cord clamped before the target in the DCC-120 group. Care team may milk the umbilical cord towards the infant four times. Cord milking should NOT be performed if the delay meets or exceeds 60 seconds.~Umbilical cord milking will not be provided among participant-infant dyads in the DCC-30 group."
48637794|NCT05107128|DRUG|SAGE-718|Oral capsules.
48637795|NCT05107128|DRUG|Placebo|SAGE-718-matching oral capsules.
48637796|NCT06126380|DRUG|AT-1501|AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
47951944|NCT02360995|DRUG|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
47951945|NCT02360995|DRUG|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
47951946|NCT00004307|BEHAVIORAL|Protein and calorie controlled diet|
47951947|NCT00004307|GENETIC|Ornithine transcarbamylase vector|
48637797|NCT06126380|DRUG|Tacrolimus|Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
48107761|NCT04476095|DEVICE|Placebo PBMT|The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
48107762|NCT04340284|BIOLOGICAL|autologous adipose tissue derived stromal vascular fraction (SVF)|"liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.~This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,~, the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%)."
48107763|NCT00234091|DRUG|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
48637798|NCT06535776|OTHER|Matrix Rhythm Therapy|Individuals in this group will be taught home exercises face-to-face in a single session as in the home-based exercise group and will be asked to perform the exercises themselves at home for 3 non-consecutive days a week for 6 weeks. In addition to home-based exercises, a total of 12 sessions of face-to-face matrix rhythm therapy will be performed, 2 non-consecutive days a week for 6 weeks. Matrix rhythm therapy applications will be applied by a specialist physiotherapist who has received training with the matrix rhythm therapy vibromassage device.
48637799|NCT06535776|OTHER|Home-based Exercise|Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
48637800|NCT03216291|BEHAVIORAL|biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
48637801|NCT03216291|DEVICE|Home Biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
48637802|NCT02166463|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
47951948|NCT04365920|COMBINATION_PRODUCT|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
48107764|NCT00234091|DRUG|Efavirenz|200 to 600 mg taken orally once daily
48107765|NCT00234091|DRUG|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
48107766|NCT00234091|DRUG|Lopinavir/Ritonavir|230 mg/57.5 mg/m\^2 body surface area taken orally twice daily with food
48107767|NCT00234091|DRUG|Nelfinavir|45-55 mg/kg taken orally twice daily with food
48107768|NCT00234091|DRUG|Nevirapine|120 mg/m\^2 once daily for first 14 days, tehn 200 mg/m\^2 (up to 400 mg/day) twice daily
48107769|NCT00234091|DRUG|Zidovudine|180-240 mg/m\^2 every 12 hours (up to 300 mg/dose)
48107770|NCT04538755|DRUG|Placebo oral capsule|Placebo before sleep
48637803|NCT02166463|DRUG|Brentuximab Vedotin|Given IV
48637804|NCT02166463|DRUG|Cyclophosphamide|Given IV
48637805|NCT02166463|DRUG|Doxorubicin Hydrochloride|Given IV
48637806|NCT02166463|DRUG|Etoposide|Given IV
48637807|NCT02166463|OTHER|Laboratory Biomarker Analysis|Correlative studies
48637808|NCT02166463|DRUG|Methylprednisolone|Given IV
48637809|NCT02166463|OTHER|Pharmacological Study|Correlative studies
48637810|NCT02166463|DRUG|Prednisone|Given PO
47951949|NCT04365920|COMBINATION_PRODUCT|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
47951950|NCT01769989|PROCEDURE|Electrodermabrasion|
47951951|NCT01769989|PROCEDURE|Dermabrasion|
47951952|NCT06167564|DIAGNOSTIC_TEST|Routine allergy tests|Prick test, specific IgE detection
48637811|NCT02166463|OTHER|Quality-of-Life Assessment|Ancillary studies
48637812|NCT02166463|OTHER|Questionnaire Administration|Ancillary studies
47951953|NCT06167564|DIAGNOSTIC_TEST|Newly developed microarray-based diagnostic test system|Newly developed microarray-based diagnostic test system for the detection of the specific IgE
47951954|NCT01934244|DEVICE|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
47951955|NCT04295551|DRUG|Lopinavir / ritonavir tablets combined with Xiyanping injection|Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,
47951956|NCT04295551|DRUG|Lopinavir/ritonavir treatment|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization
47951957|NCT00808483|OTHER|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
47951958|NCT03384888|DEVICE|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
47951959|NCT03384888|DEVICE|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
48637813|NCT02166463|DRUG|Vincristine Sulfate|Given IV
48637814|NCT04098744|DRUG|Artesunate vaginal insert|Artesunate formulated as vaginal inserts, 200mg
48637815|NCT04098744|DRUG|Placebo vaginal insert|Placebo for artesunate vaginal inserts
47951960|NCT01967173|DRUG|Flovent Diskus® 100 mcg|Flovent is an ICS
47951961|NCT01967173|DRUG|Flovent Diskus® 250 mcg|Flovent is an ICS
48107771|NCT04538755|DRUG|DAW2020 oral capsule|DAW2020 34 mg 4 h before sleep, single night administration
47951962|NCT01967173|DRUG|Flovent Diskus® 500 mcg|Flovent is an ICS
47951963|NCT01967173|DRUG|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
47951964|NCT01967173|DRUG|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
47951965|NCT06397833|DEVICE|Acorai ICPM system|Patient will have the handheld Acorai ICPM system placed on their chest, for a period of 5 minutes for sensor recording time
48478998|NCT02270216|PROCEDURE|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
48478999|NCT05827484|BIOLOGICAL|Autologous platelets rich plasma|30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
47951966|NCT01377571|BIOLOGICAL|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
47951967|NCT05073640|DRUG|Oxopurin|Subjects will receive two capsules per day.
47951968|NCT00973674|DRUG|Premarin IV|One time dose of Premarin IV
48107772|NCT03012230|OTHER|Laboratory Biomarker Analysis|Correlative studies
48107773|NCT03012230|BIOLOGICAL|Pembrolizumab|Given IV
48107774|NCT03012230|DRUG|Ruxolitinib Phosphate|Given PO
48107775|NCT00271167|DRUG|INO-1001|
48479000|NCT05827484|COMBINATION_PRODUCT|Autologous platelets rich plasma + oral LOSARTAN administration|in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
48479001|NCT01258088|DRUG|AN2728 Ointment|5mg/cm2, BID
48479002|NCT01258088|DRUG|AN2728 Vehicle|5mg/cm2 BID
48479003|NCT00037531|DRUG|Sirolimus (RAPAMUNE)|
47951969|NCT00973674|DRUG|Placebo|One time dose of Placebo
47951970|NCT00776282|DRUG|loratadine 10 mg orally disintegrating|
48107776|NCT02163954|DRUG|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
48637816|NCT05397405|DRUG|PCSK9 inhibitor|The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
48637817|NCT05938010|DEVICE|Dailies Total1® contact lenses for astigmatism (T30fA)|Dailies Total1® contact lenses for astigmatism (T30fA)
48637818|NCT05618028|DRUG|ABBV-525|Oral; Tablet
48637819|NCT04370847|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using a 25-gauge spinal needle
47951971|NCT01519154|DRUG|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
47951972|NCT01519154|DRUG|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
47951973|NCT02570360|BEHAVIORAL|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
48107777|NCT02163954|DRUG|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
48107778|NCT02120313|OTHER|inpatient rehabilitation|
48107779|NCT02120313|OTHER|outpatient rehabilitation|
48107780|NCT02888002|BEHAVIORAL|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
48107781|NCT04128436|OTHER|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
47951974|NCT02570360|BEHAVIORAL|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
47951975|NCT05981430|BIOLOGICAL|Fecal microbiota transplant|Active comparator will receive infusion of 125mL fecal suspension via enema
47951976|NCT05981430|BIOLOGICAL|Sham fecal microbiota transplant|Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
47951977|NCT05693116|PROCEDURE|Rhinectomy|Surgery will be performed according to extension of the tumour, i.e. local resection limited to the vestibule, partial rhinectomy, total rhinectomy, extended total rhinectomy
47951978|NCT06041997|BEHAVIORAL|Smartphone restriction|The patients will then be advised to cut down the usage by one-third in terms of usage hours. The compliance will be checked at the time of outcome assessment.
47951979|NCT00079768|DRUG|Alemtuzumab (Campath)|
47951980|NCT01042678|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye
47951981|NCT05574998|DRUG|Recombinant human endostatin (Endostar)|"The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed."
47951982|NCT03599388|BEHAVIORAL|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains \>90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
48107782|NCT02698891|DRUG|Paclitaxel|
48107783|NCT02698891|DRUG|Neulasta|
48107784|NCT01891968|DRUG|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
48107785|NCT00738075|DEVICE|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
48107786|NCT04915599|DEVICE|Cooral® mouth cooling device (MCD)|Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
48107787|NCT01946035|DRUG|Doxazosin XL|
48107788|NCT01946035|OTHER|Placebo|
48107789|NCT01130818|DRUG|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
48107790|NCT01130818|DRUG|placebo|single dose, oral solution
48107791|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting
48637820|NCT04370847|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
48637821|NCT04370847|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
48637822|NCT04370847|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
48637823|NCT04370847|RADIATION|lung ultrasound scans|lung ultrasound scans will be performed while the patient is in the supine position with left lateral tilt by 30 degrees using a 2-5 MHz curved array transducer. The echo comet score (ECS) which corresponds to the amount of EVLW will be obtained by the 28-rib interspaces technique. An increased amount of (EVLW) is diagnosed by multiple B-lines or 'comet tails' which are defined as discrete laser-like vertical hyperechoic reverberation artifacts that arise from the pleural line and extend to the bottom of the screen without fading and move synchronously with lung sliding. The sum of the B-lines found on each of the 28 chest-wall areas yields the ECS.
48637824|NCT04370847|OTHER|Ultrasound Assessment of the Inferior Vena Cava|The IVC largest and smallest diameters will be measured proximal to the opening of the M-mode using s2-4 MHz transducer placed longitudinally in the subcostal region.
48637825|NCT04370847|OTHER|Optic nerve sheath diameter|Optic nerve sheath diameter measurement will be conducted in two axes of transverse and oblique sagittal using a 12-4MHz linear array transducer. Depth of the optic nerve will be localized and marked at 3 mm behind the retinal and optic nerve junction transverse diameter of optic nerve sheath will be calculated. The reported ONSD corresponds to the mean of the four values obtained for each patient transverse and sagittal plane for both eyes.
48637826|NCT04370847|DRUG|ringer acetate|1000 ml ringer acetate will be administered over 2 hours.
48637827|NCT04370847|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
48637828|NCT04370847|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
48637829|NCT05524532|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
48637830|NCT05524532|DIETARY_SUPPLEMENT|Placebo|Placebo is an inert form of cellulose acetate.
48107792|NCT01130818|DRUG|GLPG0492|single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
48107793|NCT05582187|DRUG|Fosmanogepix|a single dose of fosmanogepix administered by mouth under fasted conditions
48107794|NCT00001063|DRUG|Stavudine|
48107795|NCT00001063|DRUG|Zidovudine|
47951983|NCT05520099|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
48107796|NCT00001063|DRUG|Didanosine|
48637831|NCT06470828|DRUG|TAK-861|Oral tablet.
48637832|NCT06470828|DRUG|Placebo|TAK-861-matching placebo tablet.
47951984|NCT01315912|DRUG|Letrozole|2.5 mg /day for 5 days
48107797|NCT01959412|DRUG|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
48107798|NCT01959412|DRUG|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
48107799|NCT01959412|DRUG|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
48107800|NCT01959412|DRUG|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
48107801|NCT01959412|DRUG|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
48637833|NCT05035693|DEVICE|MOVE®-C|Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
48637834|NCT04147234|DRUG|BI 1387446|intratumoral injection
48107802|NCT01959412|DRUG|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
48107803|NCT04304859|DIAGNOSTIC_TEST|BASIC|Validation
48107804|NCT04033432|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
48107805|NCT05647980|OTHER|TACTIC|Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk
48107806|NCT00223119|DEVICE|Absorbable Sutures|
48299708|NCT03542240|DIETARY_SUPPLEMENT|Curcumin|500 milligram daily supplement
48637835|NCT04147234|DRUG|BI 754091|intravenous infusion
47951985|NCT01297075|BEHAVIORAL|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
47951986|NCT02116231|DRUG|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
47951987|NCT02116231|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
47951988|NCT02389062|OTHER|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
47951989|NCT05584332|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|0.5 ml injection in 3 dosing regimen
47951990|NCT05584332|BIOLOGICAL|Placebo|0.5 ml injection in 3 dosing regimen
47951991|NCT06315023|DEVICE|DETOUR System|Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System
47951992|NCT00223171|DRUG|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
47951993|NCT03594526|BEHAVIORAL|Maternal support to become mother|"AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~1. Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~2. Four Educational sessions and support sessions for maternal empowerment in each home visit.~3. Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
47951994|NCT03594526|BEHAVIORAL|Control Group: usual care|"This intervention is usual care, which consists of:~1. care of the mother and her newborn during the puerperium~2. Teaching about breastfeeding."
47951995|NCT00722332|BIOLOGICAL|HepaGam B|Hepatitis B Immunoglobulin
48299709|NCT02401256|DRUG|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
48299710|NCT02401256|DRUG|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
47951996|NCT02937428|BEHAVIORAL|Look away from the needle|Participant looks away from the needle during vaccination
47951997|NCT02937428|BEHAVIORAL|Look at the needle|Participant looks at the needle during vaccination
47951998|NCT04607980|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
47951999|NCT04607980|DRUG|Ustekinumab|Participants will receive SC injection of ustekinumab.
47952000|NCT03731845|GENETIC|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
47952001|NCT03731845|BIOLOGICAL|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
47952002|NCT03731845|OTHER|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
47952003|NCT01110304|OTHER|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
48107807|NCT02020824|BEHAVIORAL|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
48107808|NCT02020824|OTHER|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
48479004|NCT06615947|DEVICE|Robotic gait training|"RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern."
48107809|NCT02020824|OTHER|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
48107810|NCT02020824|OTHER|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
48107811|NCT02020824|OTHER|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
48107812|NCT00156117|DRUG|asenapine|5 mg BID or 10mg BID
48107813|NCT00156117|DRUG|Placebo|Placebo
48107814|NCT00156117|DRUG|olanzapine|olanzapine 15 mg QD
48107815|NCT01460290|DRUG|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
48107816|NCT04676568|PROCEDURE|Extravesical VVF repair|Both standard transvesical and extravesical approach for VVF repair will be utilised
48107817|NCT06281431|PROCEDURE|Echogenic nerve block needle|A 22G 8-cm echogenic nerve block needle (LEAPMED, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The spread of the medication will be assessed through short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the incidence of punctures, and any associated complications are all meticulously appraised.
48107818|NCT06281431|PROCEDURE|Non-echogenic nerve block needle|A 22G 8-cm thin wall low bottom nerve block needle (KDL, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The distribution of the medication will be assessed using short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the number of punctures, and any associated complications are all meticulously appraised.
48107819|NCT00389246|BEHAVIORAL|Consultation without genetic information|
48107820|NCT00389246|BEHAVIORAL|Consultation with genetic information|
48107821|NCT04671719|BIOLOGICAL|blood sample|blood sample for circulating autotaxin measurement (5ml).
48107822|NCT05596630|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
48107823|NCT00296907|BEHAVIORAL|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
48107824|NCT06278025|DIAGNOSTIC_TEST|assessment|"DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle."
48107825|NCT05303155|DIAGNOSTIC_TEST|16S rRNA sequencing|Fecal microbiome analysis using 16S rRNA sequencing
48107826|NCT01490580|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
48107827|NCT01490580|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
48107828|NCT03758950|DRUG|Placebo|Once daily inhaled placebo for 48 weeks
48107829|NCT03758950|DRUG|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
48107830|NCT03398837|DRUG|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
48107831|NCT03398837|DRUG|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
48107832|NCT03398837|OTHER|Placebo oral capsule|Subjects will receive placebo twice daily.
48107833|NCT04866069|BIOLOGICAL|SARS-CoV-2 vaccine|Adjuvanted inactivated vaccine
48107834|NCT04866069|BIOLOGICAL|Placebo|0.9% NaCl
48107835|NCT00135135|DRUG|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
48107836|NCT00135135|PROCEDURE|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
48107837|NCT06111937|OTHER|after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours|Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
48107838|NCT04710017|DRUG|Tranexamic acid|will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
48107839|NCT04710017|DRUG|Medroxyprogesterone Acetate 150 MG/ML|will be given MPA at 150 mg once intramuscular injection
48107840|NCT02558218|DRUG|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
48107841|NCT02558218|DRUG|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
48107842|NCT03987763|DRUG|IDP-122 Lotion|Topical
48107843|NCT06081829|DRUG|Ivosidenib|Subjects will take 2 tablets (500 mg total) orally once daily.
48107844|NCT00305695|OTHER|Laboratory Biomarker Analysis|Correlative studies
48107845|NCT00305695|DRUG|Zoledronic Acid|Given IV
48107846|NCT00415389|BEHAVIORAL|interactive educational program|2-session interactive stroke educational program
48107847|NCT00415389|BEHAVIORAL|usual medical care|standard educational materials and usual care
48107848|NCT02874430|DRUG|Metformin Hydrochloride|Given orally
48107849|NCT02874430|DRUG|Doxycycline|Given orally
48637836|NCT05922033|DRUG|Patient-led Insulin (intervention group)|Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.
48107850|NCT05285514|DIAGNOSTIC_TEST|Comparison of macro- and microcirculatory parameters|"Microcirculation examination using sublingual videomicroscopy, tissue O2 saturation (StO2) by NIRS and transcutaneous CO2 pressure (tcpCO2) monitoring, in conjunction with macrocirculatory parameters measures including cardiac output, arterial pressure and pulsed O2 saturation, in order to establish the relationship between the macrocirculatory changes in blood pressure and cardiac output and the microcirculatory flow and capillary density during vasoactive agent use. . Participants receive interventions as part of routine medical care to restore Cerebral Perfusion pressure (CPP) to appropriate levels (60-70 mmHg)"
48107851|NCT03743246|DRUG|JCAR017|JCAR017
48107852|NCT03743246|DRUG|Lymphodepleting|Lymphodepleting
48107853|NCT03743246|DRUG|Fludarabine|Fludarabine
48107854|NCT03743246|DRUG|Cyclophosphamide|Cyclophosphamide
48107855|NCT02885311|BEHAVIORAL|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
48107856|NCT02885311|BEHAVIORAL|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
48107857|NCT02885311|DRUG|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
48107858|NCT02885311|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
48107859|NCT02885311|OTHER|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
48107860|NCT01337869|PROCEDURE|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
48107861|NCT01337869|PROCEDURE|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
48132617|NCT00455650|DRUG|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
48637837|NCT05922033|DRUG|Provider-led Insulin (standard care)|Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
48637838|NCT02388100|PROCEDURE|Capillary HbA1c collection|
48637839|NCT00714363|PROCEDURE|LASIK|Refractive surgery
48637840|NCT00714363|PROCEDURE|SBK|Refractive surgery
48637841|NCT05138822|DRUG|GSK3882347|GSK3882347 will be administered on each dosing day.
48637842|NCT05138822|DRUG|Nitrofurantoin|Nitrofurantoin will be administered on each dosing day.
48637843|NCT05138822|DRUG|Placebo|Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
47952004|NCT01110304|DEVICE|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
47952005|NCT01943773|PROCEDURE|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
47952006|NCT01943773|PROCEDURE|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
47952007|NCT00579592|DRUG|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
47952008|NCT02645201|DIETARY_SUPPLEMENT|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
47952009|NCT02645201|OTHER|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
47952010|NCT00586651|DRUG|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
47952011|NCT00082342|DEVICE|Phoressor II (IOMED)|sham stimulation
47952012|NCT00082342|DEVICE|Phoressor II (IOMED)|real tDCS stimulation
47952013|NCT02932683|DEVICE|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
47952014|NCT00601198|DRUG|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
47952015|NCT01120535|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
47952016|NCT02661685|BIOLOGICAL|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
47952017|NCT05649566|DEVICE|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
47952018|NCT00020774|DRUG|gemcitabine hydrochloride|
47952019|NCT00020774|DRUG|lonafarnib|
47952020|NCT00020774|PROCEDURE|conventional surgery|
48107862|NCT00633854|PROCEDURE|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
48479005|NCT06615947|OTHER|tRHB|"Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions."
48479006|NCT03463018|DIETARY_SUPPLEMENT|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
48637844|NCT05151380|DEVICE|CO2 laser MonaLisa Touch ®|"3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.~The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice"
47952021|NCT04876144|DEVICE|Kogito|"Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks"
48107863|NCT00542087|DRUG|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
48107864|NCT00542087|DRUG|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
48107865|NCT00227682|DIETARY_SUPPLEMENT|ascorbic acid|
48107866|NCT00227682|DRUG|arsenic trioxide|
48107867|NCT00227682|DRUG|dexamethasone|
48107868|NCT00227682|DRUG|thalidomide|
48107869|NCT04048018|DIAGNOSTIC_TEST|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
47952022|NCT06041490|DRUG|multi-kinase inhibitors in combination with bevacizumab|The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
47952023|NCT02725931|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
48107870|NCT05831007|GENETIC|LX102-C01 Injection|Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial.
48107871|NCT01345604|PROCEDURE|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
48479007|NCT03463018|DIETARY_SUPPLEMENT|Placebo|Placebo tablet containing matching excipients to the active intervention
48479008|NCT06615869|DRUG|Molnupiravir|Oral Administration.
48637845|NCT05487495|BIOLOGICAL|CD5 CAR T (CT125B)|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
48637846|NCT05215847|DRUG|ARD-101|Twice daily, oral administration
48637847|NCT04125719|BIOLOGICAL|PVSRIPO|Intralesional injection of PVSRIPO
48637848|NCT04125719|DRUG|Nivolumab|Nivolumab infusion
48637849|NCT02443077|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
48637850|NCT02443077|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
48107872|NCT01345604|PROCEDURE|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
48637851|NCT02443077|DRUG|Carmustine|Given IV
48637852|NCT02443077|DRUG|Cyclophosphamide|Given IV
48637853|NCT02443077|DRUG|Cytarabine|Given IV
48637854|NCT02443077|DRUG|Etoposide|Given IV
48637855|NCT02443077|DRUG|Ibrutinib|Given PO
48637856|NCT02443077|OTHER|Laboratory Biomarker Analysis|Correlative studies
47952024|NCT04045548|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
47952025|NCT04045548|DRUG|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
47952026|NCT02789631|OTHER|assessment|
47952027|NCT04390061|DRUG|Tofacitinib|Jak-1/3 inhibitor
48107873|NCT00099619|DRUG|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
48107874|NCT00099619|DRUG|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
48107875|NCT00199342|DRUG|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
48479009|NCT00489164|DEVICE|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
48637857|NCT02443077|DRUG|Melphalan|Given IV
48637858|NCT02443077|OTHER|Pharmacogenomic Study|Correlative studies
48637859|NCT02443077|OTHER|Placebo Administration|Given PO
48637860|NCT05621980|BEHAVIORAL|Actuated Virtual Keyboard (AVK) system|"The participant controls an avatar hand by the movement of their own digits. Each avatar digit corresponds to a given virtual key. Sufficient digit flexion results in playing of that key, with visual and auditory feedback of key strike. Participants will wear a soft exoskeleton, the PneuGlove, with embedded bend sensors to provide real-time measurement of digit flexion. Pneumatic resistance to flexion can be applied to each digit independently, along with extension assistance, through air chambers running through the glove. The FES is intended to assist finger flexion by activating extrinsic finger flexor muscles. A high-density 2×8 stimulation electrode grid will be placed over the median and ulnar nerves at the medial side of the upper arm. The stimulator can deliver electrical stimulation to any pair of electrodes. At the beginning of each session, the investigators will identify the electrode pairs which best produce flexion of each digit with minimal discomfort."
48637861|NCT05621980|BEHAVIORAL|Occupational Therapy (OT)|Traditional occupational therapy training sessions.
48637862|NCT05977530|BEHAVIORAL|self-rescue training|children will receive training for self-rescue if they are alone in water
48637863|NCT01633112|DRUG|fingolimod|capsule
48637864|NCT01633112|DRUG|glatiramer acetate|subcutaneous injection
48637865|NCT05059860|DEVICE|Tandem Control IQ Hybrid Closed Loop Insulin Delivery System|The Tandem Control IQ hybrid closed loop insulin delivery system is made up of an externally worn Tandem insulin pump which communicates wirelessly to the Dexcom G6 CGM worn as a patch on the skin. The CGM measures glucose levels transmitting them into the computer within the pump. The computer then calculates how much insulin is required then dose delivery completes the cycle. The Control-IQ™ advanced technology adjusts insulin delivery to avoid glycaemic excursions, while still allowing the user to manually bolus at mealtimes.
48637866|NCT04863807|PROCEDURE|Regional Anaesthesia|Thoracic epidural/Erector Spinae block/Serratus Anterior block
47952028|NCT04390061|DRUG|Hydroxychloroquine|Standard Therapy
47952029|NCT00272428|BEHAVIORAL|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
48107876|NCT03649165|DRUG|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
48637867|NCT04886609|DEVICE|ORISE gel|To establish if ORISE Gel an effective and feasible submucosal injecting solution during endoscopic resection of large colorectal polyps
48637868|NCT05672836|DRUG|Enavogliflozin|0.3 mg 1 tablet once daily
48637869|NCT05672836|DRUG|Standard-of-Care|Standard-of-Care medical therapy plus Enavogliflozin matching placebo
48637870|NCT05669599|BIOLOGICAL|Maridebart Cafraglutide|Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
48637871|NCT05669599|DRUG|Placebo|Participants will receive placebo by SC injection.
48637872|NCT06353386|DRUG|Opevesostat|Oral Tablet
48637873|NCT06353386|DRUG|Olaparib|Oral Tablet
47952030|NCT01928069|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
47952031|NCT03320226|DIETARY_SUPPLEMENT|Probiotic 10 (Nature's Bounty)|The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
47952032|NCT02121522|DRUG|BI 144807|twice daily
47952033|NCT02547675|DRUG|Rociletinib|Rociletinib will be administered to patients orally
48107877|NCT03649165|DRUG|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
48107878|NCT03649165|DRUG|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
48107879|NCT03649165|DRUG|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
48107880|NCT03649165|DRUG|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
48107881|NCT02217644|DRUG|BI 653048 H3PO4 solution|
48107882|NCT02217644|DRUG|BI 653048 H3PO4 low dose capsule|
48107883|NCT02217644|DRUG|BI 653048 H3PO4 high dose capsule|
48107884|NCT02217644|DRUG|Placebo|
48107885|NCT03050788|DEVICE|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
48637874|NCT06353386|DRUG|Docetaxel|IV Infusion
48637875|NCT06353386|DRUG|Cabazitaxel|IV Infusion
48107886|NCT04083833|DRUG|Tetrodotoxin|A single TTX dose in a dose ascending study
48107887|NCT04083833|DRUG|Placebos|matching placebo comparator
48107888|NCT00285688|PROCEDURE|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
48637876|NCT06353386|DRUG|Fludrocortisone acetate|Oral Tablet
48637877|NCT06353386|DRUG|Dexamethasone|Oral Tablet
48637878|NCT06353386|DRUG|Prednisone|Oral Tablet
48637879|NCT04410133|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
48637880|NCT01522976|DRUG|Azacitidine|Given SC or IV
48637881|NCT01522976|OTHER|Laboratory Biomarker Analysis|Correlative studies
47952034|NCT05722093|DRUG|Manzi Guben granules|Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
47952035|NCT02320617|PROCEDURE|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
47952036|NCT00193531|DRUG|Paclitaxel|
47952037|NCT00193531|DRUG|Carboplatin|
47952038|NCT00193531|DRUG|Etoposide|
48637882|NCT01522976|DRUG|Lenalidomide|Given PO
48637883|NCT01522976|DRUG|Vorinostat|Given PO
48637884|NCT05001555|DRUG|Dexketoprofen/Vitamin B|1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
48637885|NCT05001555|DRUG|Dexketoprofen|1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
48637886|NCT03914326|DRUG|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
48637887|NCT03914326|DRUG|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
48637888|NCT01574495|OTHER|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
48637889|NCT05919056|OTHER|Frequent and automatic cardiovascular risk assessment|The 10-year cardiovascular risk scores using the 2019 World Health Organization (WHO) laboratory-based risk charts will be automatically calculated using the latest health information on an EHR-based system per month.
47952039|NCT01161784|DIETARY_SUPPLEMENT|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
47952040|NCT01161784|DIETARY_SUPPLEMENT|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
47952041|NCT01365247|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
47952042|NCT01365247|BEHAVIORAL|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
47952043|NCT01365247|BEHAVIORAL|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
47952044|NCT01001013|DRUG|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
47952045|NCT00185562|DRUG|Adalimumab|
47952046|NCT02940080|OTHER|Dietary|
48637890|NCT05919056|OTHER|Dynamic risk monitoring|High-risk individuals will be reassessed by the Dynamic Risk-based Early wArning and Monitoring (DREAM) system to obtain the short-term risk. The DREAM system will send a text message about advice to the high-risk individual every month. The text message includes information on the health status (e.g., current cardiovascular risk, level of blood pressure and lipid) and real-time warning messages (e.g., high short-term risk).
48637891|NCT05919056|OTHER|Regular GP visits|"The general practitioners will communicate with the participants based on the information automatically generated from the DREAM system every three months: each participant's cardiovascular risk score, health status (e.g., diabetes mellitus and/or hypertension), and Chinese guidelines-based recommendations (e.g., for the management of dyslipidemia, to provide clear treatment targets for high-risk participants)."
47952047|NCT01628172|DEVICE|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
47952048|NCT04142593|OTHER||
47952049|NCT04069962|BEHAVIORAL|CGA coordination by geriatric team including intensive patient coaching and follow-up|In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
47952050|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
48637892|NCT06070051|BIOLOGICAL|VRON-0200-AdC6|VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
47952051|NCT02537028|DRUG|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
47952052|NCT02537028|DRUG|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
48107889|NCT03324152|OTHER|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
48479010|NCT00885677|DEVICE|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
48637893|NCT06070051|BIOLOGICAL|VRON-0200-AdC7|VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
48637894|NCT06070051|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
47952053|NCT02824237|DEVICE|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
47952054|NCT06321562|DRUG|TimoD implant|Consists of 1 TimoD implant administration in the study eye
48479011|NCT04039048|DEVICE|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
48479012|NCT04039048|DEVICE|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
48479013|NCT04039048|OTHER|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
48479014|NCT03057002|DIAGNOSTIC_TEST|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.
48479015|NCT00455416|DRUG|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
48479016|NCT00455416|DRUG|Selenium (L-Selenomethionine),|100mcgx2 daily
48479017|NCT00455416|DRUG|Garlic extract (Allicin)|6 garlic pearls daily
48479018|NCT00455416|DRUG|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
47952055|NCT06321562|DEVICE|Injector system|"This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use."
47952056|NCT01114152|DRUG|AZD9742|IV Formulation
47952057|NCT01114152|DRUG|Placebo|IV Formulation
47952058|NCT04525352|BIOLOGICAL|RP-L401|CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
47952059|NCT02145585|DEVICE|Test of pharmacologic anesthesia robot (labVIEW® software)|
48107890|NCT03324152|OTHER|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
47980437|NCT01545986|BEHAVIORAL|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
48107891|NCT03324152|OTHER|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
48637895|NCT06070051|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
48107892|NCT05272046|PROCEDURE|Per-oral Endoscopic Myotomy|Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
48107893|NCT05272046|DEVICE|Speedboat (Bipolar electrocautery knife)|Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
48107894|NCT02404337|DRUG|Betaine|
48107895|NCT05903833|DRUG|Pembrolizumab|400 mg Q6W
48107896|NCT05903833|DRUG|Lenvatinib|20 mg QD
48107897|NCT02696707|PROCEDURE|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
48107898|NCT02696707|PROCEDURE|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
48107899|NCT02524288|DRUG|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
48107900|NCT02939469|OTHER|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
48107901|NCT02457702|OTHER|Orally administered labeled glycerol|Oral administration of labeled glycerol
48107902|NCT03253913|DRUG|Sirolimus|Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
48107903|NCT03253913|DRUG|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
48107904|NCT01835899|DRUG|Placebo|Placebo to BI 1015550
48107905|NCT01835899|DRUG|BI 1015550|medium dose 1 powder for oral solution
48107906|NCT01835899|DRUG|BI 1015550|medium dose 2 powder for oral solution
48107907|NCT01835899|DRUG|BI1015550|low dose 2 powder for oral solution
48107908|NCT01835899|DRUG|BI 1015550|low dose 1 powder for oral solution
48107909|NCT02652936|DRUG|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
48107910|NCT02652936|DRUG|Placebo comparator|AF-130 matching placebo capsule
48107911|NCT05726292|DRUG|Relacorilant|Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.
48107912|NCT05726292|DRUG|Enzalutamide|Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
48479019|NCT00455416|DRUG|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
48479020|NCT00455416|DRUG|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
48637896|NCT05725525|BEHAVIORAL|Remote PCIT augmented with wearable devices|Participants will be enrolled in remote PCIT and be asked to wear a Garmin watch throughout the course of the study in order to measure biometric fluctuations
48637897|NCT05569174|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
48637898|NCT05569174|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
48637899|NCT02584244|DRUG|LUM015|
48637900|NCT02584244|DEVICE|LUM 2.6 Imaging Device|
48637901|NCT02403037|DEVICE|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
48637902|NCT02403037|DEVICE|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
47952060|NCT06558474|BEHAVIORAL|Liberal post-dilatation strategy during PCI|"A liberal post-dilatation strategy for stent optimization during PCI will be implemented in multiple centers in the Netherlands.~This include an increase of post-dilatation use of at least 20% per operator, or a percentage of post-dilatation of at least 85%.~Operators will be asked to enforce a very low threshold for post-dilatation in general, with a mandatory HPNC post-dilatation for the following indications:~* In case of any calcification~* Delta of ≥ 0.5mm between the distal and proximal reference diameter of the treated coronary segment~* Stent length \>24 mm~* Signs of incomplete stentframe-deployment on angiography or StentBoost~* In case of CTO~* In case of bifurcation PCI (Left main and non-left main)~  * Proximal Optimisation Technique (POT) with NC balloon~ * Final Kissing Balloon dilatation (FKB) with preferentially first sequential high-pressure inflations and final low pressure kiss both with NC balloons"
47952061|NCT05255211|DRUG|Remimazolam tosilate|IV before procedure
47952062|NCT05255211|DRUG|Propofol|IV before procedure
47952063|NCT05255211|OTHER|saline solution|IV before procedure
48107913|NCT05726292|OTHER|Placebo (Sugar Pill)|This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
48107914|NCT05726292|OTHER|Androgen Deprivation Therapy|"All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy."
48107915|NCT05726292|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
48107916|NCT06084117|OTHER|HFNO|Respiratory support with HFNO (as opposed to NIV, as per standard of care)
48107917|NCT06084117|OTHER|NIV|Respiratory support with Non-invasive ventilation, standard of care
48107918|NCT04988048|BIOLOGICAL|COVID-19 vaccines|"Gam-COVID-Vac Gamaleya National Center for Epidemiology and Microbiology - Russia. Non-replicative viral vector. Multi-dose vial (5 doses in 3 mL) Single-dose vial (1 dose in 0.5 mL). Intramuscular T° less than -18 ° C~BBIBP-CorV Beijing Institute of Biological Products - People's Republic of China. Inactivated viruses. Single-dose vials (1 dose in 0.5 mL) or multi-dose vial (2 doses per vial). Intramuscular T° 2 to 8 ° C~ChAdOx1 nCoV-19 vaccine AZD1222 AstraZeneca-Oxford - United Kingdom. Non-replicative viral vector. Multi-dose vial (10 doses in 5 mL). Intramuscular T°: 2 to 8 ° C~mRNA-1273 or Spikevax Moderna Switzerland GmbH and the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. mRNA. Multi-dose vial (maximum 15 doses per 0.5ml vial). Intramuscular. T°-15 ° to -50 °"
48107919|NCT04620018|DRUG|Amoxicillin|Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
48107920|NCT02561923|DRUG|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
48107921|NCT02561923|DRUG|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
48107922|NCT02561923|DRUG|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.
48107923|NCT02561923|DRUG|Saline|Saline \[Kcentra saline control or TXA saline control\] on Day 4.
48107924|NCT02446223|DRUG|Inggenol Mebutate 0.015%|
48107925|NCT02336776|OTHER|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
48107926|NCT05027178|OTHER|Chiropractic Care|Chiropractic care on stroke participants
48107927|NCT00506181|DRUG|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
48107928|NCT00506181|DRUG|Placebo|
48107929|NCT03906942|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content in the form of 152 BET I CAN challenges \[1\]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
47952064|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
47952065|NCT00871325|DRUG|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
47952066|NCT00871325|DRUG|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
47952067|NCT00537992|PROCEDURE|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
47952068|NCT04165473|BEHAVIORAL|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
47952069|NCT05021263|DRUG|IV Medications|IV magnesium sulfate, used to replete magnesium stores
47952070|NCT05021263|OTHER|placebo|placebo
47952071|NCT01152983|DEVICE|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
47952072|NCT03020173|OTHER|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
47952073|NCT06166680|OTHER|Sleep quality assessment|"The following item will be assessed in all subjects (n=420):~1. Sleep, through the Pediatric Sleep Questionnaire."
47952074|NCT06166680|OTHER|Anthropometry|"The following items will be assessed in all subjects (n=420):~2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)"
47952075|NCT06166680|OTHER|Tongue strength assessment|"The following items will be assessed in all subjects (n=420):~3. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5. Tongue peak pressure during 3 sec. of tongue protrusion."
47952076|NCT06166680|OTHER|Tongue endurance assessment|"The following items will be assessed in all subjects (n=420):~6. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7. The tongue endurance during tongue protrusion."
47952077|NCT06166680|OTHER|Orofacial praxis assessment|- The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
47952078|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
47952079|NCT02705872|DRUG|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
47952080|NCT05046184|DRUG|Ketamine Hydrochloride|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of ketamine (0.5 mg/kg). Ketamine will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
48637903|NCT02403037|DRUG|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
48107930|NCT00174317|DRUG|Celecoxib|
48107931|NCT00174317|DRUG|Diclofenac|
48637904|NCT06236009|DRUG|TAK-004|TAK-004 subcutaneous injections.
47952081|NCT05046184|DRUG|Midazolam injection|Subjects with MDD will receive 2 weeks of twice-weekly 40-minutes long IV infusion of midazolam (0.02 mg/kg). Midazolam will be dissolved in 0.9% saline in a total volume of 100 mL and administered with an infusion pump at a constant rate.
47952082|NCT05886816|DRUG|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
47952083|NCT05886816|OTHER|Placebo|Placebo pills
48107932|NCT04806256|BEHAVIORAL|Clinical Decision Support System|This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.
48107933|NCT04806256|OTHER|Routine intervention|The routine intervention without CDSS is also the clinically common intervention at present.
48132618|NCT00455650|DRUG|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
48479021|NCT06168318|DRUG|VH4004280 Formulation A|Oral administration of VH4004280 Formulation A in fasted or fed conditions.
48479022|NCT06168318|DRUG|VH4004280 Formulation B|Oral administration of VH4004280 Formulation B in fasted or fed conditions.
48479023|NCT06168318|DRUG|VH4004280 Formulation C|Oral administration of VH4004280 Formulation C in fasted or fed conditions.
48637905|NCT06236009|DRUG|Placebo|Matching- placebo subcutaneous injections.
48637906|NCT05290818|DEVICE|MAKO™ Partial Knee Arthroplasty|The robotic-arm will be used to position a partial knee arthroplasty.
47952084|NCT04192370|DRUG|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol for 3 days in an open-label fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL, and the drug will be procured by the Brigham and Women's Hospital (BWH) Investigational Drug Services (IDS) pharmacy. The first dose will be administered at the BWH Center for Clinical Investigation, while doses 2 and 3 will be self-administrated at home. The CBD will be repacked in pre-drawn syringes for the subjects to self-administer at home.
47952085|NCT06134492|DRUG|Acyclovir|"Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information.~Mode of administration: intravenous (i.v.)"
48479024|NCT06168318|DRUG|VH4004280 Formulation D|Oral administration of VH4004280 Formulation D in fasted or fed conditions.
48637907|NCT05290818|DEVICE|Triathlon (Stryker) Total Knee Arthroplasty|Triathlon (Stryker) TKA with a cruciate retaining polyethylene insert.
48299711|NCT02401256|DRUG|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
48299712|NCT02401256|DRUG|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
48299713|NCT01801046|DRUG|mitoxantrone hydrochloride|Given IV
48299714|NCT01801046|DRUG|cytarabine|Given IV
48299715|NCT01801046|PROCEDURE|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
48299716|NCT01801046|OTHER|laboratory biomarker analysis|Correlative studies
48299717|NCT04611464|DRUG|Misoprostol|Misoprostol is a PGE1 analog
47952086|NCT04961294|DEVICE|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
47952087|NCT00489060|PROCEDURE|Cryoablation and External Beam Radiation|
48299720|NCT06169865|OTHER|cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.
48299721|NCT05547555|DIAGNOSTIC_TEST|embryo selection|The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
48479025|NCT06168318|DRUG|VH4004280 Formulation E|Oral administration of VH4004280 Formulation E in fasted or fed conditions.
48299722|NCT02950662|OTHER|Overdenture|Active comparator will be metal housing and peek housing
48299723|NCT01856634|DRUG|100 mg Delamanid|100 mg Delamanid BID for 10 days
48299724|NCT01856634|DRUG|50 mg Delamanid|50 mg Delamanid BID for 10 days
48299725|NCT01856634|DRUG|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
48299726|NCT01856634|DRUG|10 mg Delamanid Pediatric Formulation|Patients \> 10 kg will receive DPF 10 mg BID for 10 days
48299727|NCT01856634|DRUG|5 mg Delamanid Pediatric Formulation|"Patients \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
48299728|NCT01856634|DRUG|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
48299729|NCT02897193|DEVICE|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
48299730|NCT02897193|DEVICE|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
48299731|NCT02897193|DEVICE|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
48299732|NCT02897193|DEVICE|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
48299733|NCT06439719|PROCEDURE|Blood sample collection|Collection of blood sample
48637908|NCT01087619|PROCEDURE|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
47952088|NCT04087213|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
48299734|NCT03070418|PROCEDURE|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
48299735|NCT03070730|DRUG|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
48299736|NCT03070730|DRUG|Atenolol|Atenolol: 50 mg Q.D.
48299737|NCT03070730|DRUG|Placebos|Placebo: t.i.d
48299738|NCT04302883|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
48479026|NCT01784198|DIETARY_SUPPLEMENT|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
48479027|NCT03176368|OTHER|Coconut Oil|Coconut Oil
47952089|NCT04668573|OTHER|Trunk exercise|Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
47952090|NCT01743417|BEHAVIORAL|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
47952091|NCT01042574|DRUG|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
47952092|NCT05158634|OTHER|Evaluations|"Within the scope of the study, the participants will be evaluated for 30 minutes in a single session. The participants' trunk stabilization and endurance, balance, functional mobility, upper extremity endurance, functional health and quality of life will be questioned by questionnaires, scales and tests. Evaluation will begin with a literature-supported demographic data form prepared for the participants.~Assessments to be made are listed below. Trunk Control Measurement Scale (TCMS) Pediatric Balance Scale (PBS) Time Up and Go test (TUG) Trunk Flexor Test (TFT) The Pediatric Outcomes Data Collection Instrument (PODCI)"
47952093|NCT04228874|DEVICE|coronary artery stents|"Coronary angiography was done for all the patients according to the Judkins technique. All images were evaluated by an experienced operator, significant coronary artery disease was defined as \> 70 % luminar diameter stenos. The following data was obtained:~* Site of stent implantation within LAD. The first Diagonal branch serves as the boundary between the proximal and mid portion of the LAD. Thus, the portion of the artery prior to the origin of the 1st diagonal is known as the proximal LAD, while the segment just below the1st diagonal branch is the mid LAD. The distal segment of the LAD is the terminal third of the artery (Cao et al., 2017).~* Length, diameter and number of stents.~* TIMI flow after stent deployment."
47952094|NCT02827227|BIOLOGICAL|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (\< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
47952095|NCT01229826|RADIATION|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
48107934|NCT03502317|BEHAVIORAL|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
48299739|NCT04302883|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
48299740|NCT04142476|OTHER|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
48299741|NCT01177150|DRUG|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
48299742|NCT01177150|DRUG|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
47980438|NCT05436392|BEHAVIORAL|Peer Comparison Feedback|USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
48107935|NCT03502317|BEHAVIORAL|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
48479028|NCT05530473|DEVICE|capsular tension ring|To insert a capsular tension ring during the cataract surgery
48479029|NCT00063882|RADIATION|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
48479030|NCT00063882|RADIATION|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
47914296|NCT02584556|DRUG|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
47914297|NCT05504642|DRUG|Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)|Two weeks before start of Chemo-radio-immunotherapy one administration of Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV over 30 minutes, with a 30 minute break between Nivolumab and Ipilimumab.
48299743|NCT02698761|OTHER|Comprehensive Care Plan|"Care Plan~1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~2. Other Medications. All medications will be given during daytime hours, if possible.~3. Pain Psychology.~4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
48299744|NCT01430429|DRUG|NI-0801|
48299745|NCT00049413|BIOLOGICAL|rituximab|
48107936|NCT03193619|DEVICE|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
48107937|NCT01490112|DRUG|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
48107938|NCT03869918|OTHER|Exercise Program|Exercise at home or through a class as chosen by the subject.
48299746|NCT00049413|DRUG|cyclophosphamide|
48299747|NCT00049413|DRUG|pentostatin|
48107939|NCT00024531|DRUG|Atorvastatin calcium|
48107940|NCT04314830|DEVICE|Gait training with perturbations|Changes in speed of one of the belt of the split belt treadmill during swing phase
48107941|NCT04314830|DEVICE|Gait training without perturbation|Walking on a treadmill with steady belt speed
48107942|NCT04770935|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:solution for injection Route of administration: intravenous injection
48107943|NCT02241668|PROCEDURE|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
48107944|NCT02241668|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
48107945|NCT04619914|DRUG|Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt|CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
48107946|NCT04619914|DRUG|letrozole (Femara; Novartis pharma AG, Basle, Switzerland)|Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
48299748|NCT03074448|DEVICE|Aquanet|Aquanet bowel cleansing devices
48299749|NCT03074448|DRUG|Sodium Picosulfate|Sodium Picosulfate solution (Picoprep)
48299750|NCT00897559|GENETIC|gene expression analysis|
48479031|NCT00063882|RADIATION|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
48107947|NCT02196818|DEVICE|Mpact Acetabular Shell|Total Hip Replacement
48107948|NCT04156724|DEVICE|Helmet vetilation|We will apply non-invasive positive pressure ventilation via a helmet as interface
48107949|NCT06127888|OTHER|Interviews|Semi-structured interviews
48107950|NCT06127888|OTHER|Surveys|Estructured survey
48107951|NCT01615432|DEVICE|V-PAP III ventilator|
48107952|NCT01615432|DEVICE|Stellar 150 ventilator|
48107953|NCT01615432|DEVICE|BiPAP vision ventilator|
48107954|NCT01615432|DEVICE|V60 ventilator|
48107955|NCT05826951|DRUG|Alcohol|Alcohol (0.8g/kg)
48107956|NCT05826951|DRUG|Placebo|Placebo
48107957|NCT02399696|BEHAVIORAL|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
48299751|NCT00897559|GENETIC|mutation analysis|
48299752|NCT00897559|GENETIC|polymorphism analysis|
48299753|NCT00897559|GENETIC|protein analysis|
48107958|NCT02399696|BEHAVIORAL|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
48107959|NCT00579189|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
48107960|NCT00579189|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
48107961|NCT00579189|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
48107962|NCT00168662|BIOLOGICAL|Measles and inactivated polio vaccine|
48107963|NCT01768676|DRUG|avanafil|100 mg
48107964|NCT01768676|DRUG|Placebo|
48107965|NCT03561610|DIETARY_SUPPLEMENT|sip feed|normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
48107966|NCT03561610|DIETARY_SUPPLEMENT|gumdrops|normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
48107967|NCT05639699|OTHER|motivational interview|Quitting smoking with motivational interviewing
48107968|NCT01595906|PROCEDURE|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
48299754|NCT00897559|OTHER|flow cytometry|
48299755|NCT00897559|OTHER|laboratory biomarker analysis|
47952096|NCT06366100|BEHAVIORAL|Dialectical Behavior Therapy for Substance Use Disorder (DBT-SUD)|"In phase 1, DBT online training will consist of the following contents:~Block 1~1.1. Introduction to the key concepts 1.2. DBT-SUD program 1.3. Why DBT for alcohol addiction? 1.4. Proposed content for the group intervention.~Block 2~2.1. DBT skills training modules~In phase 2, DBT-SUD intervention will consist of about the following sessions:~GOALS OF SKILLS TRAINING AND MINDFULNESS:~S1: Goals of skills training; Observing, Describing and Participating~S2: Non-judgmentally, One-mindfulness, Effectively~DISTRESS TOLERANCE:~S3: Crisis Survival skills~S4: Crisis Survival and Radical Acceptance~ADDICTION SKILLS:~S5: Dialectical Abstinence.~S6: Clear Mind~S7: Burning Bridges-Building New Bridges~S8: Community Reinforcement~EMOTIONAL REGULATION:~S9: Identifying emotions and model of emotion~S10: Check the facts. Opposing Action~S11: Problem Solving. Reducing vulnerability~S12: Self-management and rehabilitation"
48637909|NCT03270163|DIAGNOSTIC_TEST|Transcutaneous electrical stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple electrical stimulations,~* three electrical doublets at the frequency of 100Hz~For each type of electrical stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
47952097|NCT06366100|BEHAVIORAL|Unified Protocol (UP)|"In phase 1, the UP training will have following contents:~Block 1~1.1. Introduction to key concepts 1.2. Why UP for alcohol addiction? 1.3. Dimensional assessment and case formulation. 1.4. Main characteristics of UP~Block 2~2.1. Modules of UP~In phase 2, UP intervention will consist of:~MOTIVATION:~S1: Motivation enhancement for treatment~UNDERSTANDING EMOTIONS:~S2: Understanding and model of emotions S3: Tracking emotional responses~MINDFULNESS:~S4: Emotion awareness~COGNITIVE FLEXIBILITY:~S5: Cognitive reappraisal to increase thinking flexibility~EMOTION DRIVEN BEHAVIORS:~S6: Emotional avoidance S7: Emotion-driven behaviors and alternative action~AWARENESS AND TOLERANCE:~S8: Tolerance of physical sensations~EMOTIONAL EXPOSURE:~S9: Interoceptive and situational emotion exposure S10: Exposure practice~RELAPSE PREVENTION:~S11: Relapse prevention S12: Review of progress"
48107969|NCT02592954|DRUG|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
48107970|NCT02592954|DRUG|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
48107971|NCT01436838|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
48107972|NCT01320280|DRUG|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
48107973|NCT05762419|DRUG|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m\^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
48107974|NCT05762419|DEVICE|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
48299756|NCT00976768|DRUG|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
48107975|NCT03265210|BEHAVIORAL|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
48107976|NCT05227066|OTHER|adding lower extremity weights|All children in the two groups received physical therapy protocol for 30 minutes in addition to half kg of sandbags weights attached for each leg
48107977|NCT05227066|OTHER|traditional physical therapy group|traditional physical therapy group
48107978|NCT00562679|OTHER|There is no intervention|
48107979|NCT04645394|DIETARY_SUPPLEMENT|Aronia melanocarpa|Administered once (acute study)
48107980|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa high dose|Administered once (acute study)
48299757|NCT04742946|OTHER|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
48299758|NCT00900133|OTHER|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
48107981|NCT04645394|DIETARY_SUPPLEMENT|Fermented Aronia Melanocarpa low dose|Administered once (acute study)
48107982|NCT04645394|DIETARY_SUPPLEMENT|Placebo|Administered once (acute study)
48107983|NCT00696618|DRUG|Fleet Enema|hyper-osmolar preparation
48107984|NCT00696618|DRUG|tap water enema|hypo-osmolar preparation
48107985|NCT00696618|DRUG|Normosol-R enema|iso-osmolar preparation
48107986|NCT02834871|DEVICE|Electromyogram|
48107987|NCT06401174|BEHAVIORAL|Delivery of patient navigation|Clinics will receive educational materials and access a referral order for patient navigation. Iterative strategies will be used to increase CRC screening
48107988|NCT05847842|PROCEDURE|Anterior quadratus lumborum block|20 mL of 0.25% bupivacaine will be given
48107989|NCT05847842|PROCEDURE|Transversus abdominis plane block|20 mL of 0.25% bupivacaine will be given
48107990|NCT05847842|PROCEDURE|Local infiltration|20 mL of 0.25% bupivacaine will be given
48107991|NCT02618317|DRUG|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
48299759|NCT00900133|OTHER|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
48299760|NCT03387124|OTHER|Breastfed infants|Breastmilk
48299761|NCT04239274|DEVICE|transcranial direct current stimulation|Subjects in this arm will receive one session of tDCS for 20 minutes at 2.0 milliamps.
48299762|NCT04239274|DEVICE|transcranial pulsed current stimulation|Subjects in this arm will receive one session of tPCS for 20 minutes at 2.0 milliamps.
47952098|NCT05244993|DRUG|AK105|AK105: 100mg per bottle, 200mg IV Day 1, cycled every 21 days
47952099|NCT05244993|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride: 12mg per capsule, 12 mg PO once daily on Days 1-14, cycled every 21 days
47952100|NCT05244993|DRUG|Albumin Paclitaxel|Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days
47952101|NCT05181033|DRUG|Lenvatinib + Letrozole|"Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole."
47952102|NCT05181033|DRUG|Fulvestrant|Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
47952103|NCT01315184|BEHAVIORAL|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
47952104|NCT05616975|OTHER|test-retest reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.
47952105|NCT05616975|OTHER|construct validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.
47952106|NCT05616975|OTHER|normative data|Collection of normative SWAY Balance, Functional, and Cognitive data.
47952107|NCT02026960|DEVICE|RNA extraction and amplification from biopsy specimens|
48479032|NCT03063216|PROCEDURE|intraocular lens implantation|1）Pediatric cataract patients with intraocular lens implantation and those without intraocular lens implantation；2）Traumatic cataract patients with intraocular lens implantation and those without intraocular lens implantation
47952108|NCT03682887|PROCEDURE|Cryoballoon PV isolation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
48479033|NCT02457611|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
48107992|NCT02618317|DRUG|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
48107993|NCT02618317|DRUG|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
48107994|NCT02525510|OTHER|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
48107995|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
48299763|NCT04239274|DEVICE|Sham-no stimulation|Subjects in this arm will receive one session of sham for 20 minutes.
48299764|NCT03435653|OTHER|OFD with DFDBA|Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
48479034|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
48479035|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
48479036|NCT05738655|DIETARY_SUPPLEMENT|Placebo|Placeo (300 mg/day)
48479037|NCT03452618|DIAGNOSTIC_TEST|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
48479038|NCT05058560|DRUG|Tislelizumab|tislelizumab, 200 mg IV Q3W, up to one year.
48479039|NCT02868541|OTHER|Naso pharyngeal swab|Naso pharyngeal swab
48479040|NCT05698706|DEVICE|TOOsonix System ONE-M|Selected BCC sites will be treated using high intensity focused ultrasound
48479041|NCT02224066|DRUG|Ticagrelor 90 mg twice per day during three months following TAVI|
48479042|NCT02224066|DRUG|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
48479043|NCT02316158|OTHER|Web-based support|Comparison between the efficacy between webb-based support and informational support
48479044|NCT00873119|DRUG|belinostat, carboplatin, paclitaxel|
48479045|NCT00873119|DRUG|carboplatin, paclitaxel|
47952109|NCT03682887|PROCEDURE|Cryoballoon PV isolation with Additional RA linear ablation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
47952110|NCT03838146|BEHAVIORAL|Types of Exercise|moderate intensity exercise
48107996|NCT02525510|OTHER|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
48299765|NCT03435653|OTHER|OFD with decortication and DFDBA|Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
48107997|NCT02525510|OTHER|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
48299766|NCT00300872|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
48299767|NCT00300872|DEVICE|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
48299768|NCT00814840|DEVICE|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
48107998|NCT02525510|OTHER|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
48107999|NCT02388139|PROCEDURE|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
48108000|NCT02388139|PROCEDURE|coronarography|
48108001|NCT02388139|PROCEDURE|coronary angioplasty|
48299769|NCT00814840|DEVICE|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
48299770|NCT02773758|OTHER|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
48299771|NCT02773758|OTHER|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
48299772|NCT05452161|OTHER|Control group|All patients follow only the standard care of the department, which includes a preoperative group session of 1h30, with 15 to 30 participants, 6 to 8 weeks before the operation The objectives of these sessions are to inform the patients in a general way about the operation, its preparation and the postoperative process in order to standardize the information received. The content includes general information from the surgeon, explanations related to the course and management of patients by the various professionals (nurse, surgeon, anesthesist, physiotherapist, ergotherapist and liaison-nurse).
48497860|NCT05940753|OTHER|Survey about travel willingness regarding cancer treatment and follow-up|No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.
48497861|NCT02216513|DRUG|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
47952111|NCT00302263|DRUG|Metobes-compound|
47952112|NCT02103712|OTHER|Qualitative|
48108002|NCT02388139|PROCEDURE|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
48108003|NCT02388139|PROCEDURE|body composition monitoring|using Fresenius device
48108004|NCT04544761|OTHER|Structured Interview|Structured interview with research staff about your experience living with spinal cord injury
48108005|NCT01196429|DRUG|Carboplatin|Given IV
48108006|NCT01196429|DRUG|Docetaxel|Given IV
48108007|NCT01196429|OTHER|Laboratory Biomarker Analysis|Correlative studies
48108008|NCT01196429|DRUG|Paclitaxel|Given IV
48108009|NCT01196429|DRUG|Temsirolimus|Given IV
48108010|NCT02248025|OTHER|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
48108011|NCT01586299|DRUG|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
48108012|NCT01586299|DRUG|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
48108013|NCT03316794|DRUG|SC-005|intravenous
48132620|NCT04337944|PROCEDURE|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
48637910|NCT03270163|DIAGNOSTIC_TEST|Magnetic stimulation|"The following tests and measurements will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening:~* three simple magnetic stimulations,~* three magnetic doublets at the frequency of 100Hz~For each type of magnetic stimulation, the stimulations will be carried out 3 times and reproduced at 1 hour intervals."
47952113|NCT02677064|OTHER|assessments|All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
47952114|NCT02577497|DRUG|beclomethasone|
47952115|NCT02577497|DRUG|fluticasone|
47952116|NCT05320185|DEVICE|RuiXin-CoronaryAI software|RuiXin-CoronaryAI, based on Computed Tomography Angiography (CTA) and was independently designed by RaysightMed Inc., which has been already authorized by National Medical Products Administration (NMPA).
48479046|NCT00097786|DRUG|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
48479047|NCT00097786|DRUG|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
48479048|NCT00097786|DRUG|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
48497862|NCT02216513|DRUG|placebo|normal saline IV for 4 hours for 5 consecutive days
48497863|NCT05477498|DRUG|Ferric carboxymaltose|Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
48497864|NCT05477498|DRUG|Placebo|Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
47952117|NCT05096052|DRUG|Galactomannan|Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
47952118|NCT05096052|DRUG|PLACEBO|A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
47952119|NCT04080960|BEHAVIORAL|Lifestyle modification education|Lifestyle modification education and goal setting
47952120|NCT03427671|DEVICE|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
47952121|NCT00005017|DRUG|Ritonavir|
47952122|NCT00005017|DRUG|Abacavir sulfate|
47952123|NCT00005017|DRUG|Amprenavir|
47952124|NCT00005017|DRUG|Efavirenz|
47952125|NCT00005017|DRUG|Lamivudine|
47952126|NCT00005017|DRUG|Stavudine|
47952127|NCT00413244|DRUG|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
47952128|NCT00413244|DRUG|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
47952129|NCT02960152|OTHER|diagnostic|full-mouth periodontal examination
47952130|NCT00085904|DRUG|SB-485232|
47952131|NCT03643575|DRUG|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
47952132|NCT03643575|DRUG|Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
47952133|NCT03643575|DRUG|Organ-I- NR tablet|Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
47952134|NCT04977921|OTHER|lab session|assign students to clinical modules for study the clinical lab scope of practice
47952135|NCT02108782|DRUG|dovitinib lactate|Given PO
47952136|NCT02108782|OTHER|pharmacological study|Correlative studies
47952137|NCT02108782|OTHER|laboratory biomarker analysis|Correlative studies
47952138|NCT03521427|OTHER|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
47952139|NCT03521427|OTHER|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
48299773|NCT05452161|OTHER|Intervention group A|The day of the preparatory surgical consultation (CPC), the patient has a 30 minute patient-centered education session by a physiotherapist and a 30 minute patient-centered education session by a nurse. The physiotherapist's session addresses the technical skills to be mastered postoperatively (crutching, stairs, exercises), the course of postoperative rehabilitation, the patient's role in the rehabilitation process, the questions still remaining on this subject and the patient's perspective concerning the rehabilitation (degree and sources of anxiety, expectations of follow-up and results, degree of self-efficacy). The nursing intervention addresses the postoperative pain management, the patient's role in pain management, the care pathway, the organization of the return home and the postoperative follow-up.
48299774|NCT05452161|OTHER|Intervention group B|"In addition to intervention A, patients receive a interdisciplinary intervention of three 10-15 minute phone or video conferences between the patient, a physiotherapist and a nurse.~The aim of these interviews is to identify the patient's difficulties in the living environment, to detect possible postoperative complications and to provide advice on practical aspects (e.g. ability to perform activities), therapeutic aspects (e.g. exercises to be performed, medication), pain management, interpretation of symptoms and subjective needs (e.g. need for support). Advice on rehabilitation and care is individualized according to the results of the questionnaires administered on the day of the pre-surgical consultation and those administered at discharge, as well as the needs of the moment discussed with the patient. Any suspected complication is reported to the operating physician for appropriate management."
48299775|NCT01467739|DEVICE|Ambu ® aScope®|
48299776|NCT01467739|DEVICE|a conventional reusable fiberscope|
48299777|NCT00123526|BEHAVIORAL|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
48299778|NCT00123526|BEHAVIORAL|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
48299779|NCT05653726|OTHER|Telemonitoring follow-up using medical devices and telematic consultations|Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months
48299780|NCT03114241|BEHAVIORAL|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
48299781|NCT05356910|BEHAVIORAL|OPPEN|OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.
48299782|NCT05356910|BEHAVIORAL|Control Condition|Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
48299783|NCT04367701|DIAGNOSTIC_TEST|Hemolysis|Authors measured free plasma hemoglobin concentration in gram
47914298|NCT05504642|DRUG|Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)|In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy. Simultaneous application of Nivolumab 3mg/kg week 1, 3, 5, 7 (on Thursday) and Ipilimumab 1mg/kg in week 5 (on Thursday).
47952140|NCT04425356|BEHAVIORAL|LifeXT Program|The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
48479049|NCT00097786|DRUG|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
48637911|NCT03270163|DIAGNOSTIC_TEST|ultrasound measurement|The ultrasound measurement of the thickness of the quadriceps muscle will be carried out on the patient within 3 days of inclusion and again between the 4th and 6th day after inclusion and upon awakening.
48637912|NCT06054464|DRUG|PC14586|Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
48637913|NCT06054464|DRUG|Rabeprazole|Part 1: Daily oral dose of rabeprazole on days 11-14.
47952141|NCT00091416|BIOLOGICAL|VRC-HIVADV014-00-VP|
47952142|NCT00734123|DRUG|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
48479050|NCT02400476|DRUG|Neratinib|
48479051|NCT02400476|DRUG|Loperamide|
48479052|NCT02400476|DRUG|Colestipol|2 g twice daily with or without food for one 28 day cycle
48637914|NCT06054464|DRUG|Famotidine|Part 2: Twice daily oral dose of famotidine on days 11-13. Single, oral dose of famotidine on day 14.
48637915|NCT04367454|OTHER|Use of Personal Protective Equipment|As described in the arm descriptions
48637916|NCT04584554|BEHAVIORAL|BETTER Transitional Care Intervention|Patient and family will receive pre- and post-discharge support and education from interventionist.
47914299|NCT05504642|PROCEDURE|Maintenance Treatment (Nivolumab/Ipilimumab)|For six months after Chemo-radio-immunotherapy, Nivolumab 3mg/kg every two weeks x12 (week +2, +4, +6, +8, +10, +12, +14, +16, +18, +20, +22, +24 (twelve applications), each application over 30 minutes and Ipilimumab every six weeks x4 (week +6,+12, +18, +24).
48637917|NCT01497093|DRUG|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
48637918|NCT01497093|DRUG|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
47952143|NCT00734123|DRUG|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
47952144|NCT00734123|DRUG|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
47952145|NCT00734123|DRUG|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
47952146|NCT05361421|DRUG|Intensive targeting group|Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
47952147|NCT05361421|DRUG|Conventional therapy group|Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
47952148|NCT04118842|DRUG|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
47952149|NCT04118842|DRUG|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
47952150|NCT01172262|PROCEDURE|MRI|This is an observational study, no intervention will occur.
47952151|NCT05273333|DEVICE|Ultra-gyn®|Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
47952152|NCT04764487|DEVICE|KidneyPRO|Web-application for symptoms assessment
47952153|NCT04764487|OTHER|standard follow-up|usual follow-up
47952154|NCT00000663|DRUG|CD4-IgG|
47952155|NCT04189575|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
47952156|NCT06170892|OTHER|Kangaroo method|The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.
47952157|NCT03945266|BEHAVIORAL|Intervention group|During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.
47952158|NCT03945266|BEHAVIORAL|Control group|Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
47952159|NCT03523234|DRUG|neoadjuvant chemotherapy|etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
47952160|NCT03523234|PROCEDURE|radical surgery for stage II and IIIA small cell lung cancer (SCLC)|Lobectomy/total lung resection plus mediastinal lymph node dissection.
47952161|NCT03523234|PROCEDURE|prophylactic cranial irradiation|prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
47952162|NCT03523234|DRUG|Chemotherapy|etoposide with cisplatin/carboplatin
47952163|NCT00946478|DRUG|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
47952164|NCT00946478|OTHER|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
47952165|NCT03645590|BEHAVIORAL|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
48479053|NCT02400476|DRUG|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
48479054|NCT01834898|DRUG|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
47952166|NCT02299882|DRUG|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
47952167|NCT02846545|BIOLOGICAL|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
47952168|NCT02846545|BIOLOGICAL|Placebo|Matching Placebo to golimumab.
47952169|NCT01074372|DRUG|REGN727|4 cohorts (dose 1, 2, 3, 4)
47952170|NCT01074372|DRUG|Placebo|4 cohorts (dose 1, 2, 3, 4)
47952171|NCT06295536|DEVICE|Comparator device, Closed-field autorefractometer|"* Objective refraction without cycloplegia~* Distance visual acuity with objective refraction without cycloplegia~* Objective refraction with cycloplegia~* Distance visual acuity with objective refraction with cycloplegia"
48479055|NCT02946216|GENETIC|ctDNA analysis|
48479056|NCT02440516|OTHER|Early treatment group|Physical- and occupational Therapy
48479057|NCT02440516|OTHER|Late treatment group|Waiting list - then Physical- and occupational Therapy
48497865|NCT00446537|PROCEDURE|Methylphenidate|
48479058|NCT04052698|DRUG|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
48108014|NCT05416450|DEVICE|intravaginal electrical stimulation added to bladder training|BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
48108015|NCT04209049|DRUG|NNC0174-0833|A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
48479059|NCT04196452|DRUG|Ipilimumab|Specified dose on specified days
48479060|NCT06360757|DIAGNOSTIC_TEST|NeuMoDx SARS-CoV-2 Assay|The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome.
48479061|NCT03701711|DRUG|Lenalidomide|"Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study."
48108016|NCT00057850|DRUG|cisplatin|
48108017|NCT00057850|DRUG|ixabepilone|
48108018|NCT02375581|DRUG|Icotinib|125mg, Po, TID during RT
48108019|NCT02375581|RADIATION|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
48108020|NCT03245060|BEHAVIORAL|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
48108021|NCT02886741|OTHER|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
48108022|NCT05268042|OTHER|Moderately carbohydrate-restricted diet|For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
48108023|NCT05268042|OTHER|Fat-restricted diet|The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
48479062|NCT01104090|DEVICE|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
48479063|NCT01104090|DEVICE|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
48497866|NCT02716935|DIETARY_SUPPLEMENT|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
48637919|NCT01497093|DRUG|Dexamethasone|Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
48637920|NCT04031768|OTHER|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
48637921|NCT05587998|DRUG|Morphine|Participants will receive IV dose of Morphine as stated in arm description.
48108024|NCT03588845|OTHER|Treatment Protocol|Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.
48108025|NCT03588845|OTHER|Standard of Care|Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
48299784|NCT03524365|PROCEDURE|RYGB|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
48299785|NCT03524365|PROCEDURE|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
48299786|NCT03524365|OTHER|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF."
48299787|NCT00783705|OTHER|placebo|Given orally
48299788|NCT00783705|DRUG|inositol|Given orally
48299789|NCT04734756|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
48299790|NCT02703116|BEHAVIORAL|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
48299791|NCT02703116|BEHAVIORAL|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
48299792|NCT02257814|BEHAVIORAL|Incredible Years Teacher Training|
48479064|NCT06152705|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
48479065|NCT04314544|DRUG|TILD|one 1 mL injection of study medication
48637922|NCT05587998|DRUG|AZD4041|Participants will receive oral doses of AZD4041 as stated in arm description.
48637923|NCT05587998|OTHER|Placebo|Participants will receive oral doses of placebo as stated in arm description.
48637924|NCT06162221|DRUG|RMC-6291|Oral tablet
48637925|NCT06162221|DRUG|RMC-6236|Oral tablet
48637926|NCT06162221|DRUG|Pembrolizumab|IV Infusion
48299793|NCT02257814|BEHAVIORAL|Preschool PATHS|
48299794|NCT02257814|BEHAVIORAL|Tools of the Mind|
48299795|NCT05971290|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure administered by face mask
48299796|NCT05971290|DEVICE|Ambient air|Air (fraction of inspired oxygen) at 14000 feet in elevation
48299797|NCT03119038|DRUG|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
48299798|NCT03119038|DRUG|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
48299799|NCT03119038|DRUG|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
48637927|NCT06162221|DRUG|Cisplatin|IV Infusion
48637928|NCT06162221|DRUG|Carboplatin|IV Infusion
48637929|NCT06162221|DRUG|Pemetrexed|IV infusion
48637930|NCT05514899|DRUG|THC|THC capsule
48637931|NCT05514899|DRUG|CBD|oral solution
48637932|NCT06157398|OTHER|Increased EPA, DHA, fruit, and vegetable intake|Participants will receive food deliveries for approximately 4-weeks via online ordering, meal delivery, and dietician counseling.
48299800|NCT03119038|DRUG|Ketorolac|Intraoperative periarticular injection of 30 mg
48299801|NCT03119038|DRUG|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
48299802|NCT00477529|DRUG|ABI-008|nab-docetaxel
48299803|NCT00202410|BIOLOGICAL|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
48299804|NCT00202410|OTHER|placebo|subcutaneous administration of physiologic solution
48299805|NCT02948192|OTHER|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
48299806|NCT03640143|OTHER|venous blood lead|data about ve,nous blood lead
48299807|NCT02003742|DRUG|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
48299808|NCT02003742|DRUG|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
48299809|NCT03827577|PROCEDURE|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
48299810|NCT03827577|RADIATION|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
48299811|NCT03827577|DRUG|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
48299812|NCT03567499|DRUG|GSK3039294|GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
48299813|NCT03567499|DRUG|Placebo|Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
48299814|NCT01025245|DRUG|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ \& Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
48299815|NCT01382589|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
48479066|NCT04314544|DRUG|matching placebo injections|one 1 mL injection of placebo
48479067|NCT06092190|DEVICE|EMG|Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction
48479068|NCT03635268|OTHER|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
48479069|NCT02406794|DRUG|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
48479070|NCT05493761|DRUG|Denosumab|60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
48479071|NCT05493761|DRUG|Alendronate Sodium|70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
48479072|NCT06601621|COMBINATION_PRODUCT|electroacupuncture+ self-acupressure|"Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi; for three minutes."
48479073|NCT06601621|COMBINATION_PRODUCT|sham electroacupuncture + sham self-acupressure|"Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
48479074|NCT00168116|PROCEDURE|radiation treatment and surgery|
48479075|NCT00168116|PROCEDURE|radiation alone|
48479076|NCT01913795|OTHER|integrated pest management|integrated pest management and environmental strategy
48479077|NCT01913795|OTHER|air purifier|air purifiers
48132628|NCT04910776|DRUG|avalglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
48132629|NCT06450301|PROCEDURE|Endometrial Biopsy|"An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial biopsies are commonly done to check for the window of implantation, to determine ovulation or for enhancing implantation (procedure called endometrial scratching). For this purpose, we will use a Pipelle catheter. This procedure is very common in gynecologic practice and~generally considered safe. In most of the cases this procedure is indicated for evaluation of irregular vaginal bleeding, vaginal bleeding in post-menopausal women and for infertility related problems (recurrent implantation failures for example)."
48108026|NCT06427252|DRUG|HIPEC|In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min) was performed on the first day after the first exploratory laparotomy and on the third day after the radical surgery for a total of 2-3 times (total amount of paclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic therapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.
48108027|NCT06427252|DRUG|Systemic therapy|"1. Tirilizumab: 200 mg, i.v., D1, Q3W;~2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;~3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg followed by 6 mg/kg Q3W.~4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;"
48108028|NCT00665379|OTHER|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
48108029|NCT00665379|OTHER|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
48108030|NCT04009226|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
48299816|NCT01382589|DEVICE|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
48299817|NCT03843658|OTHER|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
47952172|NCT06136195|DRUG|Mavoglurant|The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
48108031|NCT02306343|DEVICE|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
48108032|NCT02545751|RADIATION|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
48108033|NCT02545751|DRUG|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
47952173|NCT03931824|OTHER|PRP|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape."
48108034|NCT05304663|DRUG|Onfekafusp alfa|Patients will be treated with 10 µg/kg L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26
48108035|NCT05304663|DRUG|Lomustine|"Arm 1: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (60 mg/m2 and 75 mg/m2) on Day 1 and Day 22 (taken in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.~Arm 2: Patients will be treated in escalating cohorts of 6 patients with lomustine at different doses (90 mg/m2 and 110 mg/m2) on Day 5 (in the evening after infusion of L19TNF) of a 42-day cycle for up to a maximum of 6 cycles."
48108036|NCT03052361|DRUG|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
48108037|NCT03052361|DRUG|Placebos|similar looking and tasting liquid placebo
48108038|NCT03068468|DRUG|BIIB092|BIIB092 intravenous infusion on specified days
48108039|NCT03068468|DRUG|Placebo|Placebo intravenous infusion on specified days
47952174|NCT03931824|OTHER|Exercise|All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
48108040|NCT03245593|OTHER|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
48108041|NCT03245593|OTHER|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
48108042|NCT02732678|DRUG|PROPRANOLOL|
48108043|NCT00520208|DRUG|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
48299818|NCT00120796|DRUG|Lamivudine|
48299819|NCT00120796|BIOLOGICAL|Recombinant hepatitis B surface antigen|
48299820|NCT02665442|DEVICE|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
48299821|NCT06361745|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
48299822|NCT04013737|DEVICE|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
48637933|NCT06567691|PROCEDURE|EUS Gastrojejunostomy|Endoscopic Ultrasound (EUS) Gastrojejunostomy. Under live real-time EUS visualization, a solution of normal saline or water and dilute methylene blue will be infused through the nasobiliary drainage catheter to mechanically distend the small intestine and create a suitable, expanded fluid-filled target for transgastric access. Once a suitable target has been identified, a lumen apposing metal stent (LAMS) will then be deployed securely across the newly created gastroenterostomy tract. Appropriate stent placement will be confirmed.
47952175|NCT02081183|DRUG|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
47952176|NCT02081183|DRUG|Cyclophosphamide, Maintenance Phase|0.5-1 g/m\^2 IV pulse once every 3 months
47952177|NCT02081183|DRUG|Cyclophosphamide, Induction Phase|0.5 - 1 g/m\^2 IV pulse once per month
47952178|NCT02081183|DRUG|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
48108044|NCT06549933|OTHER|Criostymulation|"Method: Cryosauna. Temperature: -160°C. Duration: 5 days. Session Timing: 9:00 a.m.~Session Length: 3 minutes per day"
48108045|NCT04849416|DRUG|LOXO-305|Administered orally.
48108046|NCT02178540|DRUG|Placebo|one dose (4 capsules) of placebo
48108047|NCT02178540|DEVICE|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
48108048|NCT03813706|PROCEDURE|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
48108049|NCT01595321|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 200 mg/m\^2 administered one day prior to GVAX (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
48108050|NCT01595321|BIOLOGICAL|GVAX Pancreas Vaccine|GVAX administered one day after Cy (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional CY/GVAX boosts may be given every 6 months thereafter until disease recurrence.
48299823|NCT03747172|DIETARY_SUPPLEMENT|complementary and alternative therapy|complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.
48299824|NCT00151411|DRUG|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
48299825|NCT00151411|DRUG|Placebo|Placebo
48299826|NCT00151411|BEHAVIORAL|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
48655905|NCT06637241|BEHAVIORAL|Risk stratification care|In this group, Taiwanese adolescent baseball players are categorized into high-risk, medium-risk, and low-risk groups based on injury risk from a previous study. High-risk players receive sports protection education and physician referrals for shoulder and elbow assessments, with further imaging if necessary. Common issues like Little League shoulder and elbow are managed with conservative treatments. The sports protection education includes the Modified Yokohama Baseball-9 (mYKB-9), a program that significantly reduces injuries with exercises targeting shoulder and elbow health. Medium-risk players receive mYKB-9 education only, while low-risk players are observed without changes to their training methods.
48108051|NCT01595321|RADIATION|Stereotactic Body Radiation|"Cohort 1 and 2: SBRT (6.6 Gy per day, 33 Gy total dose) will be administered over 5 days within 6-10 weeks of pancreas surgery (Whipple).~Cohort 3: SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first dose of CY/GVAX."
48479078|NCT01913795|OTHER|Sham air purifier|sham air purifiers
47952179|NCT00702104|OTHER|survey administration|
47952180|NCT05920278|DEVICE|Pulse oximeter|Devices (2) were placed on the finger and the fingertip. Blood samples were taken at each stable level of oxygenation.
47952181|NCT02969330|DEVICE|Stimulator|
47952182|NCT02969330|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose
47952183|NCT00854542|BEHAVIORAL|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
47952184|NCT00001966|DRUG|Mind-body therapy|
47952185|NCT06142630|OTHER|Alteration of patients' position after erector spinae plane block|After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic
48299827|NCT06024005|DRUG|Oral Solifenacin 5mg|Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
48299828|NCT06024005|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)|Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
48299829|NCT04222127|OTHER|EUS guided injection of gastric varices by CYA|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle
47952186|NCT02414659|PROCEDURE|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
47952187|NCT02806245|OTHER|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~1. Atrial sensing- right ventricular pacing 10 min.~2. 5 min no pacing (washout).~3. Atrial sensing - biventricular pacing 10 min.~4. 5 min no pacing (washout).~5. Intrinsic rhythm~6. 5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
47952188|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS at sham point
47952189|NCT01492569|OTHER|questionnaire administration|Ancillary studies
47952190|NCT01492569|PROCEDURE|electroacupuncture therapy|Undergo TAPS
48108052|NCT01595321|DRUG|FOLFIRINOX|"FOLFIRINOX is given over six 28-day cycles, starting at least 1 weeks after SBRT.~FOLFIRINOX consists of the following drugs given IV on days 1 and 15 of each cycle:~Oxaliplatin (85 mg/m\^2), Irinotecan (180 mg/m\^2), Leucovorin (400 mg/m\^2), Fluorouracil (400 mg/m\^2 bolus followed by 2,400 mg/m\^2 continuous infusion over 46-48 hours);~modified FOLFIRINOX consists of the same regimen described above but without the 400 mg/m\^2 Fluorouracil bolus."
48108053|NCT00758602|DRUG|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
48108054|NCT00758602|DRUG|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
48108055|NCT00758602|DRUG|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
48108056|NCT00758602|DRUG|corticosteroids|According to center's practice
48108057|NCT00972504|DRUG|GSK835726 10mg|GSK835726 10mg tablet
48108058|NCT00972504|DRUG|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
48108059|NCT00972504|DRUG|Cetirizine 10mg|Cetirizine 10mg active comparator
48108060|NCT00972504|DRUG|placebo|placebo to match actives
48108061|NCT00708032|DEVICE|spectacles|habitual spectacles
48108062|NCT00708032|DEVICE|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
48108063|NCT01377519|PROCEDURE|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
48299830|NCT04222127|OTHER|Direct endoscopic injection of gastric varices by CYA|Direct endoscopic injection of gastric varix by CYA
48108064|NCT01377519|PROCEDURE|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
48108065|NCT01694628|BEHAVIORAL|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
48108066|NCT03125382|DEVICE|Carelink System|Patients start to perform device data transmission through Carelink system
48108067|NCT03125382|DEVICE|In office standard visit|Patients start or maintain in office standard visits
48108068|NCT02281318|BIOLOGICAL|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
48299831|NCT04490668|BIOLOGICAL|Human albumin|Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
48299832|NCT05573594|OTHER|Muscle Energy Technique|"The Janda method (Post isometric relaxation PIR Technique), one of the Muscle Energy Techniques, was used on m.piriformis, m.quadratus lumborum, m.hamstring, m.psoas major muscles in the study group. First, the dysfunctional muscle was stretched passively by the physiotherapist up to the movement barrier, and 5-7 seconds of isometric muscle contraction in the opposite direction was requested from the patient at the barrier. This practice was continued until muscle tension or joint dysfunction disappeared.~All participants performed standard home exercises consisting of stretching and strengthening. These exercises were taught to the participants by the physiotherapist in the first treatment session, and when they came to each treatment session, it was questioned whether they did it or not, and a control chart was created for exercise follow-up."
48497867|NCT02716935|DIETARY_SUPPLEMENT|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
48299833|NCT05573594|OTHER|conventional physical therapy and rehabilitation|In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.
48299834|NCT04705597|DRUG|BGE-175|Drug
48299835|NCT04705597|OTHER|Placebo|Placebo
48299836|NCT04736524|OTHER|Rapid antibody test|Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.
48299837|NCT05419154|PROCEDURE|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
47952191|NCT00735254|DEVICE|pulsed dye laser|patient will have scar treated with pulsed dye laser
48299838|NCT05598996|BEHAVIORAL|COT-Based Intervention|The COT-based approach uses a controller that runs case-by-case dynamical systems simulations modeling based on answers to daily questions rooted in social cognitive theory to produce ambitious but achievable daily adaptive step goal recommendations. The process for the COT-based approach is as follows: Phase 1) 2-week measurement only; Phase 2) open-loop system identification experiment (meant to create individualized dynamical models for each participant); Phase 3) closed-loop experiment to optimize for PA initiation, and Phase 4) closed-loop experiment to optimize for PA maintenance.
48299839|NCT01582282|DIETARY_SUPPLEMENT|placebo|fiber-free placebo
48299840|NCT01582282|DIETARY_SUPPLEMENT|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
48299841|NCT01582282|DIETARY_SUPPLEMENT|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
48299842|NCT05348850|DEVICE|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
48299843|NCT03020810|DRUG|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
48299844|NCT04422756|DIAGNOSTIC_TEST|Seated intravenous saline infusion test|"The test will be conducted by infusing two litres of normal saline intravenously over 4 hours with the patient seated.Blood collection (for aldosterone, cortisol, renin, and electrolytes) will be performed at baseline and after completion of the infusion. Following infusion, plasma aldosterone levels \<140 pmol/L will be considered as negative, levels \>280 pmol/L as positive, and levels in between classified as indeterminate."
47952192|NCT00735254|DEVICE|Affirm Laser|patient will have scar treated with Affirm laser
48108069|NCT02281318|DRUG|Placebo|Sterile 0.9% sodium chloride solution
48108070|NCT02281318|DRUG|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
48108071|NCT04860258|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection in the deltoid area, preferably in the non-dominant arm.
48299845|NCT04422756|DIAGNOSTIC_TEST|Ultra low-dose ACTH stimulation test|"The test will be performed by injecting 0.03 mcg of ACTH intravenously. Blood collection (for aldosterone, cortisol, and renin) will be performed at baseline and after 15 minutes. We expect a positive response to correspond with a plasma aldosterone \>2200 pmol/L and ARR \>220 pmol/L/mIU/L following stimulation."
48108072|NCT04619303|DRUG|Dexamethasone intravitreal implant|Intravitreal injection of 0.7mg dexamethasone implant
48108073|NCT04619303|DRUG|Bevacizumab Injectable Product|Invtravitreal injection of 1.25mg/0.05mL bevacizumab
48108074|NCT03774914|DRUG|Alemtuzumab (GZ402673)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
48655906|NCT06562946|DRUG|Pimicotinib|Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
48108075|NCT06392009|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
48108076|NCT04672590|OTHER|Primary exposure is hypoxia (no intervention)|The primary exposure, hypoxia, will be defined as severe, non-severe or none for each participant, based on pre-defined criteria.
48299846|NCT05106660|PROCEDURE|Ambulatory Laparoscopic Sleeve Gastrectomy|Same-day discharge
48299847|NCT05106660|PROCEDURE|Conventional Laparoscopic Sleeve Gastrectomy|Next-day discharge
48299848|NCT02948777|DRUG|Evolocumab|
48299849|NCT03767205|DEVICE|Ankle Assist Robot|"1. overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~2. treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy)."
48299850|NCT03135028|DRUG|Entospletinib|400 mg (2 × 200 mg tablets) orally twice daily
48299851|NCT03135028|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
48479079|NCT05804435|DEVICE|iNod™ System|The iNod™ Ultrasound Imaging System enables visualization of endobronchial lesions, peripheral lung nodules, or lung masses (referred to as lesions) using R-EBUS and performance of lung biopsy under direct R-EBUS visualization.
48655907|NCT04987775|DRUG|N-Acetyl Cysteine|900mg 2x daily
48655908|NCT04987775|DRUG|Placebo|Matching placebo bid
48655909|NCT06116526|DRUG|Dupilumab - Discontinuation|Drug injections are discontinued.
48655910|NCT06116526|DRUG|Dupilumab - Dose Reduction|The drug is given as a subcutaneous injection.
48655911|NCT06116526|DRUG|Dupilumab - Standard Dose|The drug is given as a subcutaneous injection.
47952193|NCT00735254|DEVICE|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
47952194|NCT00735254|OTHER|Placebo|patient will receive no treatment
47952195|NCT04377243|BIOLOGICAL|V8|one pill per day either V8 or placebo
47952196|NCT04108702|DEVICE|Virtual reality heart|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
47952197|NCT04108702|DEVICE|Virtual reality control|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
47952198|NCT04108702|OTHER|Standard therapy|Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
47952199|NCT04601402|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)
47952200|NCT04601402|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
47952201|NCT03307642|OTHER|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
47952202|NCT00879099|DRUG|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
47952203|NCT00879099|DRUG|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
47952204|NCT00879099|DRUG|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
47952205|NCT00879099|DRUG|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
47952206|NCT02758132|BIOLOGICAL|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
48299852|NCT03135028|DRUG|Cytarabine|"100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (\> 60 years of age) of each 28-day post-remission cycle"
48299853|NCT05090410|DRUG|filgotinib 200mg/day|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
48299854|NCT05090410|DRUG|subcutaneous tocilizumab 162mg/biweekly|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
48299855|NCT01285921|OTHER|vestibular test before and after hippocampal surgery|"* Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~* HIT (testing semicircular canal function at high frequency).Results: Gain in %~* VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~* ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~* Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
48108077|NCT02560519|DRUG|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision."
48108078|NCT02560519|DRUG|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision."
48299856|NCT04220866|DRUG|Ulevostinag|IT injection
48299857|NCT04220866|BIOLOGICAL|Pembrolizumab|IV infusion
48299858|NCT02909166|DRUG|aliskiren|
48299859|NCT04302389|BEHAVIORAL|myWW App, Virtual Workshops, and Private Facebook Group|The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
47952207|NCT02758132|DRUG|Enzalutamide|160 mg enzalutamide by mouth daily
47952208|NCT02758132|DRUG|Abiraterone|1000 mg abiraterone by mouth daily
47952209|NCT02758132|DRUG|Prednisone|5 mg prednisone by mouth twice daily
47952210|NCT04769661|DIAGNOSTIC_TEST|Cytokines|Doing cord blood cytokines level in preterm infants
47952211|NCT02387931|DIETARY_SUPPLEMENT|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
47952212|NCT02387931|DIETARY_SUPPLEMENT|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
47952213|NCT02387931|OTHER|Placebo|Placebo capsule, 2 taken daily
47952214|NCT01593189|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
47952215|NCT01044706|DRUG|Bicalutamide|50 mg Oral Tablet
48108079|NCT05192863|OTHER|No Intervention|This is a non-interventional study.
48108080|NCT04593719|OTHER|Experiment|The main components of the Lactation Management Model; breastfeeding training in the prenatal period (from the 30th week of pregnancy), early postpartum period (first 48 hours) skin to skin contact, early breastfeeding, relaxation using a dreaming technique, warm application to the breast, breast massage and for the first 48 hours after postpartum 6 months of continuous support (face to face, by phone, via social media).
48108081|NCT01552018|DRUG|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
48108082|NCT01552018|DRUG|Placebo|Placebo, 1 tablet per day for 3 months.
48108083|NCT02783755|BEHAVIORAL|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
48108084|NCT02623868|DRUG|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
48108085|NCT02623868|DRUG|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
48108086|NCT02623868|DRUG|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
48108087|NCT01315899|DRUG|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
48108088|NCT01315899|DRUG|ORM-12471|Given as a single dose once during the study as per Williams crossover design
48108089|NCT01315899|DRUG|placebo|Given once as a single dose during the study as per Williams crossover design
48108090|NCT04487236|DRUG|ZN-A-1041 50mg BID|Orally 21days for one cycle
48108091|NCT04487236|DRUG|ZN-A-1041 100mg BID|Orally 21days for one cycle
48108092|NCT04487236|DRUG|ZN-A-1041 200mg BID|Orally 21days for one cycle
48108093|NCT04487236|DRUG|ZN-A-1041 400mg BID|Orally 21days for one cycle
48108094|NCT04487236|DRUG|ZN-A-1041 600mg BID|Orally 21days for one cycle
48108095|NCT04487236|DRUG|ZN-A-1041 800mg BID|Orally 21days for one cycle
48108096|NCT04487236|DRUG|ZN-A-1041 1000mg BID|Orally 21days for one cycle
48108097|NCT04487236|DRUG|ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
48108098|NCT04487236|DRUG|ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
48479080|NCT05244018|DRUG|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
48479081|NCT05244018|DRUG|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
47914300|NCT02165267|BIOLOGICAL|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
47914301|NCT02165267|BIOLOGICAL|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
47914302|NCT02165267|BIOLOGICAL|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
47914303|NCT01229696|PROCEDURE|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
47914304|NCT01229696|PROCEDURE|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
47914305|NCT00002751|BIOLOGICAL|monoclonal antibody Me1-14 F(ab')2|
47914306|NCT04240132|OTHER|Adherence to Hand Hygiene|determine the colonization of microorganisms due to microbial reproduction on the external surface of the distal end of the enteral feeding tube (EFT), hub of the EFT and other feeding system components and assess the relation between the colonization and adherence to hand hygiene practices by nurses and other healthcare workers
47914307|NCT00788177|DRUG|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
47914308|NCT01192685|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
47914309|NCT01192685|DEVICE|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
47914310|NCT03540836|DRUG|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
47914311|NCT03540836|DRUG|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
47914312|NCT03540836|DRUG|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
47914313|NCT03925779|DRUG|Dexmedetomidine|dexmedetomidine sedation
47914314|NCT03925779|DRUG|Propofol|propofol sedation
47914315|NCT03925779|DRUG|Remifentanil|Remifentanil sedation
47914316|NCT05231096|OTHER|Aloe-vera gel|Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific \& Industrial Research (PCSIR) laboratory.
48479082|NCT06306092|BEHAVIORAL|Sleep on Schedule|Sleep education at school
48299860|NCT04215081|DEVICE|Gait training using ExoAtlet exoskeleton|Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
48299861|NCT05504330|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
48299862|NCT00164424|DRUG|Acyclovir|
48299863|NCT00114114|DRUG|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
48299864|NCT00114114|DRUG|Goserelin acetate|3.6 gms sc every 4 weeks
48299865|NCT02422043|OTHER|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
48299866|NCT04196036|PROCEDURE|Day of vitrification|Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
48299867|NCT04272905|OTHER|Non-interventional study|The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.
48299868|NCT04079556|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
48299869|NCT00667758|DRUG|Cetrorelix|3-5 mg s.c. on days 1-5
48299870|NCT00667758|DRUG|Placebo|3-5 ml NaCl s.c. on days 1-5
48299871|NCT05777434|PROCEDURE|Conventional Physical Therapy for Chronic Neck Pain|Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.
48299872|NCT05777434|PROCEDURE|Scapulothoracic Stabilization Exercises|• Scapulothoracic stabilization exercises in addition to conventional physical therapy will include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance. After 2 weeks, functional training will be added. Sets aand repetitions will be increased progressively.
48299873|NCT03303339|DRUG|Onvansertib|Onvansertib orally
48299874|NCT03303339|DRUG|Cytarabine|subcutaneously
48299875|NCT03303339|DRUG|Decitabine|intravenously
48299876|NCT03212547|BEHAVIORAL|Verbal Intervention|"Promotion of verbal interventions:~1. Detecting whether the infant has social withdrawal.~2. The physician will verbally intervene.~3. Positive response (+) from the infant, the evaluator will point out this to the parents.~4. Negative response (-) from the infant, the evaluator will include the parents in the interaction.~5. If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~6. If the infant does not establish positive contact (-)with the parents, repeat step 2.~7. If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~8. At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
48299877|NCT00800033|BEHAVIORAL|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
48299878|NCT00800033|DIETARY_SUPPLEMENT|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
48299879|NCT04239235|BEHAVIORAL|CRAFT|CRAFT is an evidence-based and non-confrontational approach for teaching friends/family members strategies to help their loved one reduce/refrain from using substances. It focuses on improving the lives of both the friends/family members and the individual struggling with substance use.
48299880|NCT05638386|PROCEDURE|Bone plug|The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
48479083|NCT06306092|BEHAVIORAL|Technology restriction|Reduction of electronic media use before bedtime
48108099|NCT04487236|DRUG|ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle|ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
48108100|NCT04487236|DRUG|ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle|Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
48108101|NCT05127551|DEVICE|iStent Infinite|Implantation of the iStent Infinite
48108102|NCT05127551|DEVICE|Competitor Device|Implantation of competitor device
48108103|NCT01926002|DRUG|Low-Dose MK-8351|Single administration of low-dose MK-8351.
48108104|NCT01926002|DRUG|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
48108105|NCT01926002|DRUG|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
48108106|NCT03720990|DRUG|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
48108107|NCT05451199|DRUG|ICP-488|ICP-488 will be administered as tablet
48108108|NCT05451199|DRUG|Placebo|Matching placebo will be administered as tablet
48299881|NCT02102061|OTHER|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
48299882|NCT03132246|DIAGNOSTIC_TEST|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
48299883|NCT06247696|OTHER|Herbal Pillows|Pillows containing herbs
48299884|NCT02832726|DIETARY_SUPPLEMENT|Vitamin B12|
48299885|NCT00279500|DEVICE|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
48299886|NCT03564665|DIETARY_SUPPLEMENT|400mg Magnesium Glycinate BID|400mg Magnesium Glycinate BID for 8 weeks.
48299887|NCT03564665|OTHER|Placebo|Placebo BID for 8 weeks.
48479084|NCT05918822|DRUG|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
48637934|NCT06567691|PROCEDURE|Surgical Gastrojejunostomy|Gastrojejunostomy will be performed via an open technique using an upper midline or left sub-costal incision (at the discretion of the surgeon). An antecolic, pro-peristaltic, gastrojejunostomy will be performed using one of two standard techniques: 1) hand-sewn: 2-layer anastomosis using absorbable suture or 2) stapled: single-layer anastomosis using a surgical stapler with closed staple height ranging from 1.0 - 1.5 mm and suture closure of the common enterotomy. Feeding tube placement will be at the discretion of the operating surgeon and if performed, will be performed via a Stamm technique. Abdominal fascial closure will be performed with absorbable, monofilament, suture and skin will be closed using staples or suture at the discretion of the surgeon.
47914317|NCT05231096|OTHER|sidr honey|Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.
47914318|NCT05231096|PROCEDURE|Scaling ans root Debridement|non-surgical periodontal therapy was given to all the participants of all the three groups
47952216|NCT03864770|DEVICE|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
47952217|NCT03864770|PROCEDURE|General physical therapy|The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
48108109|NCT01597752|BIOLOGICAL|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
48108110|NCT05053009|DRUG|Brufen Retard|800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
47952218|NCT02030938|DEVICE|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
47952219|NCT02173938|OTHER|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
48108111|NCT00018226|BEHAVIORAL|Case Management|
47952220|NCT02364622|DEVICE|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
47952221|NCT02364622|DEVICE|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
48479085|NCT05918822|DRUG|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
48479086|NCT05918822|DRUG|Rabeprazole|Rabeprazole tablet.
48299888|NCT04197297|DIAGNOSTIC_TEST|CT and MRI Scans|CT and MRI scans will occur before and after radiation therapy.
48299889|NCT02286011|BIOLOGICAL|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
48299890|NCT02286011|OTHER|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
48299891|NCT00092144|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
48299892|NCT00092144|DRUG|Comparator: placebo / Duration of Treatment: 4 weeks|
48479087|NCT02591563|OTHER|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
48479088|NCT00092950|BEHAVIORAL|Physical activity|
48479089|NCT05176379|DRUG|Fluconazole 150 mg|A single acute 150 mg dose
48637935|NCT06567691|OTHER|Gastric Outlet Obstruction Scoring System (GOOSS)|A previously validated instrument for assessing tolerance of oral intake.
47914319|NCT04336501|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later
47914320|NCT06240416|PROCEDURE|Low speed drilling without irrigation|Low-speed drilling (50 rpm) irrigation to perform the osteotomy
47914321|NCT06240416|PROCEDURE|High speed drilling with irrigation|High-speed drilling (800 rpm) irrigation to perform the osteotomy
47914322|NCT04211909|DRUG|SOF/VEL|400/100 mg FDC tablet orally once daily.
47914323|NCT04211909|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet orally once daily.
47914324|NCT06069895|DRUG|NNC0113-6856|NNC0113-6856 will be administered as oral tablets.
47914325|NCT06069895|DRUG|Placebo|NNC0113-6856 matching placebo will be administered as oral tablets.
48637936|NCT03508570|BIOLOGICAL|Ipilimumab|Given i.p.
48637937|NCT03508570|OTHER|Laboratory Biomarker Analysis|Correlative studies
47952222|NCT02364622|DEVICE|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
48108112|NCT02049697|DRUG|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
48108113|NCT02624219|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
47952223|NCT01638364|DRUG|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
47952224|NCT01638364|DRUG|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
47952225|NCT03416907|BEHAVIORAL|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
48108114|NCT02624219|DRUG|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
48108115|NCT02624219|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
48108116|NCT00540202|DRUG|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
48108117|NCT00540202|DRUG|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
48108118|NCT01523249|DEVICE|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
48108119|NCT01918163|DIETARY_SUPPLEMENT|Pomegranate pills|
48108120|NCT01607619|DIETARY_SUPPLEMENT|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
48108121|NCT06184854|OTHER|3D-Enhanced Training Models|3D-enhanced Jenga polo model for task 1 and 3D-enhanced suturing model for task 2
48108122|NCT06184854|OTHER|Standard 3D LapPass Training Models|Standard 3D LapPass polo model for task 1 and standard 3D LapPass model for task 2
48108123|NCT01976910|DRUG|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
47952226|NCT03416907|BEHAVIORAL|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
47952227|NCT03416907|BEHAVIORAL|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
48479090|NCT05886231|OTHER|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
47952228|NCT03416907|BEHAVIORAL|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
47952229|NCT03416907|BEHAVIORAL|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
48108124|NCT01998555|OTHER|CBT|
48108125|NCT04340154|BIOLOGICAL|chimeric antigen receptor T cell|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
48108126|NCT01221142|DEVICE|"Cincinnati Sub-Zero, Blanketrol III"|
48108127|NCT05804604|PROCEDURE|Surgical treatment of proximal femur fracture and blood sample test|Open reduction of femoral neck or pertrochanteric fracture with hemi/total hip arthroplasty or gamma nail. Analysis of serum concentration of: SHBG, CTX - I, CK-MB
48637938|NCT03508570|BIOLOGICAL|Nivolumab|Given i.p.
48637939|NCT03508570|OTHER|Pharmacokinetic Study|Correlative studies
48637940|NCT05627986|OTHER|No intervention|No intervention
48637941|NCT03822819|DIETARY_SUPPLEMENT|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
48108128|NCT05804604|PROCEDURE|Blood sample test|Analysis of serum concentration of: SHBG, CTX - I, CK-MB
48108129|NCT00162331|DRUG|Technetium Tc99m Sestamibi|
48108130|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
48637942|NCT03822819|DIETARY_SUPPLEMENT|placebo capsules|Daily uptake of placebo capsule for three weeks
48637943|NCT04315142|DEVICE|Experimental TTNS|30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
48637944|NCT04315142|DEVICE|Sham TTNS|30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
48637945|NCT05462873|BIOLOGICAL|QEQ278|Intravenous dosing of QEQ278
48637946|NCT06009926|PROCEDURE|Biospecimen Collection|Undergo urine sample collection
48637947|NCT06009926|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
48637948|NCT06009926|DRUG|Placebo Administration|Given PO
48637949|NCT06009926|OTHER|Questionnaire Administration|Ancillary studies
48299893|NCT04942483|DIAGNOSTIC_TEST|Blood eosinophil count|Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
48299894|NCT04942483|DIAGNOSTIC_TEST|Atopic sensitization|Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
48299895|NCT04942483|DIAGNOSTIC_TEST|FeNO (offline method)|The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
48299896|NCT06231940|OTHER|Complex Decongestive Therapy (CDT) in venous insufficiency,|Complex Decongestive Therapy (CDT) is a comprehensive treatment approach primarily used for lymphedema and related conditions, but it's also beneficial for chronic venous insufficiency and other edematous conditions. CDT aims to reduce swelling and maintain the reduction, improve skin condition, and alleviate symptoms. It typically involves two phases: an intensive phase to reduce swelling as much as possible and a maintenance phase to sustain the achieved results. The main components of CDT include: Manual Lymph Drainage (MLD),Compression Therapy, Exercise, Skin Care, Education and Self-Care:
48299897|NCT04151381|DRUG|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
48299898|NCT01818167|DRUG|10% Benzoyl Peroxide Topical Body Wash|
48299899|NCT01818167|DRUG|Provodine Topical Cream|
48299900|NCT05283915|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: oral
48299901|NCT05413967|OTHER|Mills manipulation in addition to myofasical release therapy|Group A will receive Mills manipulation in addition to myofasical release therapy as baselin
48299902|NCT05413967|OTHER|Nirschl exercises in addition to myofascial release therapy|Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
48299903|NCT03067662|OTHER|Aerobic exercise|
48299904|NCT01706445|OTHER|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
48299905|NCT05952219|DRUG|CKD-379|2 tablet administration under fed condition
48299906|NCT05952219|DRUG|D759+D745+D029+D150|4 tablet co-administration under fed condition
48299907|NCT05801523|PROCEDURE|laparoscopic ethanol sclerotherapy|ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline
48299908|NCT05801523|PROCEDURE|laparoscopic cystectomy of endometrioma|cystectomy of endometrioma - removal of endometrioma from ovary surgically
48299909|NCT01569204|DRUG|Etoposide|
48299910|NCT01569204|DRUG|Cyclophosphamide|
48299911|NCT01569204|DRUG|Doxorubicin|
47952230|NCT02601599|BEHAVIORAL|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
48108131|NCT00740155|BIOLOGICAL|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
48299912|NCT01569204|DRUG|Prednisone|
48299913|NCT01569204|DRUG|Procarbazine|
48299914|NCT01569204|DRUG|Dexamethasone|
48479091|NCT04415684|DEVICE|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
48479092|NCT04415684|DEVICE|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
48479093|NCT01891305|DRUG|VT-1161|
48479094|NCT01891305|DRUG|placebo|
48108132|NCT00740155|BIOLOGICAL|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
48108133|NCT00740155|BIOLOGICAL|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
48479095|NCT05196100|DEVICE|Amparo confidence socket|Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
48479096|NCT01286558|DRUG|40 mg telmisartan|once daily
48479097|NCT01286558|DRUG|5 mg amlodipine|once daily
48479098|NCT01286558|DRUG|5 mg amlodipine|once daily
48479099|NCT01286558|DRUG|80 mg telmisartan|once daily
48479100|NCT05386394|DEVICE|Active tDCS + Language Therapy|Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.
48479101|NCT05386394|DEVICE|Sham tDCS + Language Therapy|During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.
48299915|NCT01569204|DRUG|Dacarbazine|
48299916|NCT01569204|DRUG|Brentuximab Vedotin|
48299917|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
48299918|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
48299919|NCT04556331|BEHAVIORAL|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
48299920|NCT06338059|OTHER|Vitamin B12 Level|Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
48299921|NCT05379023|BEHAVIORAL|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
48299922|NCT05379023|BEHAVIORAL|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
48299923|NCT04066556|OTHER|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~* Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~* Cut-off values in areas of irreversible changes according to non-contrast CT images~* Cut-off values in occlusion sites and collateral scores according to CT angiographies~* Cut-off values of consolidated CT imaging index including clot, core, and collateral score~* Cut-off values of comorbidity index~* Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
48299924|NCT04772365|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
48299925|NCT04772365|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels;
48299926|NCT00036205|DRUG|sumanirole|
48637950|NCT06009926|OTHER|Training|Undergo flashover training
48299927|NCT04357093|OTHER|Grape seed extract mouthwash|Mouthwash 15% grape seed extract
48299928|NCT04357093|OTHER|Sodium fluoride mouthwash|Sodium fluoride mouthwash
48299929|NCT02886026|DEVICE|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
48637951|NCT01544075|BEHAVIORAL|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
48637952|NCT01544075|BEHAVIORAL|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
48108134|NCT00740155|BIOLOGICAL|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
48108135|NCT04178954|DIAGNOSTIC_TEST|semen fluid analysis|semen fluid analysis
48108136|NCT01065636|BEHAVIORAL|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
48108137|NCT01065636|BEHAVIORAL|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
48108138|NCT01065636|BEHAVIORAL|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
48299930|NCT02886026|DEVICE|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
48299931|NCT01583192|PROCEDURE|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
48299932|NCT05933291|DRUG|steroid|Moderate- or high-dose steroids
48299933|NCT02385695|PROCEDURE|Posterior Dynamic Stabilization|
48299934|NCT02385695|PROCEDURE|Internal Fixation and Fusion|
48299935|NCT03028025|DEVICE|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
48299936|NCT03028025|DEVICE|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
48637953|NCT06081348|DRUG|Sertraline|Oral capsule (25mg, 50mg, 100mg, 200mg)
47952231|NCT03550664|DEVICE|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
47952232|NCT04680052|DRUG|tafasitamab|tafasitamab will be administered IV for 12 cycles
47952233|NCT04680052|DRUG|rituximab|Rituximab will be administered IV on cycles 1 - 5
48108139|NCT02734056|OTHER|Music|Listening to music that the patient likes
47952234|NCT04680052|DRUG|lenalidomide|Lenalidomide will be administered PO for 12 cycles
47952235|NCT04680052|DRUG|placebo|placebo will be administered IV for 12 cycles
48108140|NCT02734056|OTHER|Control|Control
48108141|NCT04420195|DRUG|Extended-Release Tacrolimus|Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.
48108142|NCT04420195|DRUG|Immediate-Release Tacrolimus|Historical cohort of 20 subjects who will be maintained on IR tacrolimus following transplant. Dosing will be converted on an individual basis (Capsules: 0.5 mg, 1 mg and 5 mg or Injection: 5 mg) . All patients will be initiated on IR tacrolimus either under the tongue (sublingual) or as a solution given through a tube placed through the nose into the stomach, which is standard of care for all lung transplant recipients.
48108143|NCT00192400|BIOLOGICAL|CAIV-T|
48108144|NCT01838200|BIOLOGICAL|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
48108145|NCT01838200|DRUG|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
48108146|NCT01838200|DRUG|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
48108147|NCT04411446|DRUG|Vitamin D|5 capsules of 100.000 UI Vitamin D orally given all at once. One dose.
48108148|NCT04411446|DRUG|Placebo|5 capsules of containing placebo orally given all at once. One dose.
48108149|NCT01482013|DRUG|HPP854|Oral, once a day for 28 days.
48299937|NCT01264991|PROCEDURE|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
48479102|NCT01637831|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
48479103|NCT05349747|BIOLOGICAL|Biologic drugs|Assess the results of treatment with biologic drugs
47952236|NCT05780073|DRUG|Dasatinib 70 mg|Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
47952237|NCT05780073|OTHER|Placebo|Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
47952238|NCT02572388|BIOLOGICAL|R21|
47952239|NCT02572388|BIOLOGICAL|Matrix-M1|
47952240|NCT03274232|DEVICE|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
47952241|NCT04365868|DRUG|belapectin|intravenous
47952242|NCT04365868|DRUG|Placebo|intravenous
47952243|NCT03396705|PROCEDURE|Liver Biopsy|liver tissue will be collected via core biopsy during liver resection surgery and post-operatively by fine needle aspiration biosy
47952244|NCT03608371|DRUG|BTRX-246040|oral capsule 40 mg
47952245|NCT03608371|DRUG|Placebo|oral capsule matching BTRX-246040 40 mg capsule
47952246|NCT04204122|DRUG|Vigamox|-FDA approved medication
47952247|NCT04204122|DRUG|Placebo|-The placebo is artificial tear drops
47952248|NCT03659539|DRUG|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
47952249|NCT03659539|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
48108150|NCT01482013|DRUG|Placebo|Oral, once a day for 28 days.
48108151|NCT01740817|DRUG|Intralipid 20%|30 ml/h for 48 h
48108152|NCT01740817|DRUG|Saline|30 ml/h for 48 h
48108153|NCT02008253|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
48108154|NCT04243304|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
47952250|NCT03352310|BIOLOGICAL|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
48299938|NCT01264991|PROCEDURE|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
48299939|NCT01432314|OTHER|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
48299940|NCT01432314|OTHER|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
48299941|NCT00802165|DEVICE|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
48299942|NCT00802165|DEVICE|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
48299943|NCT02532868|DRUG|MK-0457|
48299944|NCT02022423|BEHAVIORAL|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
48299945|NCT02022423|BEHAVIORAL|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals
48299946|NCT00016523|DRUG|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
48299947|NCT00016523|DRUG|Placebo|Started at 5 ppm and could be increased to 10 ppm
48299948|NCT05117710|DRUG|Ebselen|Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
48299949|NCT05117710|DRUG|Placebo|Matched placebo capsules
48299950|NCT03290638|PROCEDURE|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
48299951|NCT04805567|DEVICE|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
48299952|NCT06326229|OTHER|ICF entities assessment|A visual analog scale will be used by the participants to evaluate the relevance of the ICF entities in relation to their musculoskeletal condition. The scale will range from 0 (no problem) to 100 (complete problem).
48299953|NCT00256828|DRUG|didanosine + lamivudine + efavirenz|
48479104|NCT04744454|DRUG|Isauvuconazole group|Patients who are treated with Isavuconazole according to its protocol label.
48479105|NCT04669548|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
48479106|NCT04291508|DRUG|Intravenous Acetaminophen (room temperature)|Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
48479107|NCT04291508|DRUG|Intravenous Vitamin C (refrigerated)|Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
48479108|NCT04291508|DRUG|5% Dextrose (room temperature)|Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
48108155|NCT04243304|OTHER|18F-PE2I PET-MR|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
48479109|NCT04291508|DRUG|5% Dextrose refrigerated|Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
48479110|NCT04886557|PROCEDURE|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (\< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
48479111|NCT03800225|PROCEDURE|Repair|Anterior ligament repair with internal brace.
48479112|NCT00005075|PROCEDURE|high-intensity focused ultrasound ablation|
48479113|NCT04183179|BEHAVIORAL|Happy Family, Healthy Kids Program|"The 14-week healthy eating program activities including four components:~1. A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~2. Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~3. 14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~4. Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
48479114|NCT05554289|DEVICE|Depression Auxiliary Intervention Treatment Software|Depression Auxiliary Intervention Treatment Software
48479115|NCT03404401|DRUG|BLI4700|Oral bowel preparation
47952251|NCT03352310|PROCEDURE|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
47952252|NCT02231697|OTHER|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
48299954|NCT04497246|OTHER|Questionnaire|Data collection by means of various questionnaires
48299955|NCT00234104|DRUG|OPC-41061(Tolvaptan)|
48299956|NCT01270893|DRUG|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
48299957|NCT02279589|BIOLOGICAL|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
48299958|NCT02279589|BIOLOGICAL|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
48299959|NCT02279589|BIOLOGICAL|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
48299960|NCT05756621|DRUG|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution."
48299961|NCT05756621|DRUG|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
48299962|NCT04446143|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
48299963|NCT06098885|OTHER|extraction orthodontic treatment|bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
48299964|NCT04604730|PROCEDURE|Primary anastomosis without protective stoma|Primary anastomosis without protective stoma
47952253|NCT06556355|OTHER|neoadjuvant chemoradiation and McKeown esophagectomy|"Treatment protocol:~1. All patients were irradiated a total prescribed dose of 40-50.4 Gy in 20-28 fractions by a 6-8 MV photons linear accelerator with the intensity-modulated radiotherapy or volumetric modulated arc therapy technique.~2. Concurrent chemotherapy was cisplatin-based.~3. McKeown esophagectomy (three incision) consisted of thoracic esophageal mobilization with lymphadenectomy, abdominal exploration and stomach mobilization with lymphadenectomy, and subsequently left cervical incision for anastomosis. The lymphadenectomy was total two-field (thoracic + abdomen)."
47952254|NCT05189379|OTHER|Non-Alcoholic Odour|A chemical used in fragrances and flavouring with a smell close to a nutty, buttery structure. Used as a 1:100 deionised water dilution.
48108156|NCT03624413|BEHAVIORAL|Social Media Intervention|The social media intervention is a behavioral intervention developed by the study investigators and is delivered via mobile phones. The intervention uses the Social-ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) model, highlighting modifiable targets of intervention that can be addressed through a social media platform. The SMART model incorporates modifiable factors such as knowledge, skills/self-efficacy, relationships and social support that can be targets of interventions to improve transition care. The SMART model emphasizes eight modifiable factors, three key stakeholders (adolescents, caregivers, and clinicians) and their interconnected relationship in influencing successful transition to adult care. The intervention is designed to overcome barriers and enhance facilitators to transitioning care among adolescents living with HIV who are transitioning to adult care in South Africa.
48108157|NCT03624413|OTHER|Standard of Care|Standard of care transition from pediatric to adult care for HIV.
48108158|NCT00154648|PROCEDURE|CE-MRA|
48108159|NCT01778712|BEHAVIORAL|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
48299965|NCT04604730|PROCEDURE|Anastomosis with protective stoma|Anastomosis with protective stoma
48299966|NCT03625219|DRUG|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
48299967|NCT03625219|DRUG|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
48299968|NCT03468023|PROCEDURE|Short arm cast|Application of a below-elbow cast
48299969|NCT03468023|PROCEDURE|Long arm cast|Application of an above-elbow cast
48299970|NCT04964921|OTHER|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
48299971|NCT00147628|DRUG|sildenafil citrate|
48299972|NCT00147628|DRUG|placebo for sildenafil citrate|
48299973|NCT04195451|OTHER|Live-Video-Supervised Exercise Intervention|The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
48479116|NCT03404401|DRUG|Polyethylene glycol bowel preparation|Oral bowel preparation
48479117|NCT06199713|DIAGNOSTIC_TEST|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography|research scan 3-4 weeks after start of immunotherapy
48479118|NCT00380549|DIAGNOSTIC_TEST|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
48479119|NCT01111214|OTHER|no intervention|There is no intervention. This is a non interventional study.
48479120|NCT06616506|DEVICE|newly-invented AI model|Apply newly-invented AI models to assist in determining surgical plans and outcome prediction.
48479121|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
48479122|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
48479123|NCT05307406|BIOLOGICAL|Experimental|Participants will receive a single IV infusion in a double blind manner
48299974|NCT04195451|OTHER|Usual Care then Live-Video Supervised Exercise Intervention|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
48299975|NCT02033980|DEVICE|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
48299976|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
48299977|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
48299978|NCT00004033|DRUG|liposomal NDDP|
48299979|NCT00004033|PROCEDURE|therapeutic thoracoscopy|
48299980|NCT00509873|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
48299981|NCT00509873|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
48299982|NCT01182129|DRUG|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
48299983|NCT01182129|DRUG|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
48637954|NCT06081348|OTHER|Placebo|Oral placebo capsule
48108160|NCT05576844|BEHAVIORAL|8-week interpersonal and social rhythm intervention|The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.
48299984|NCT01256619|DRUG|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
48299985|NCT03561285|DIAGNOSTIC_TEST|antiphospholipid Abs|Laboratory test
48299986|NCT05159583|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
48299987|NCT05159583|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
48299988|NCT03903029|DRUG|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
48299989|NCT00657761|DRUG|Enfuvirtide|90 mg/12h sc for 7 days
48299990|NCT00657761|DRUG|Placebo|0.9% saline solution/12h sc for 7 days
48299991|NCT04333433|DEVICE|PRESERFLO® MicroShunt|Device surgically implanted
48299992|NCT04333433|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
48108161|NCT05576844|OTHER|Usual care|Control group participants received usual care, including daily disease management and routine drug guidance.
48299993|NCT05868642|PROCEDURE|subarachnoid block|subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
48299994|NCT02060396|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
48299995|NCT00598533|DEVICE|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
48299996|NCT00598533|DEVICE|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
48299997|NCT03206034|BEHAVIORAL|Stylistic Memory Enhancement|
48299998|NCT04578717|PROCEDURE|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
48479124|NCT03633552|DRUG|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
48479125|NCT04601233|DRUG|XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector|Self injection testosterone treatment
48637955|NCT05661916|DRUG|ALN-TTRSC04|ALN-TTRSC04 will be administered by subcutaneous (SC) injection.
48637956|NCT05661916|DRUG|Placebo|Placebo will be administered by SC injection.
48637957|NCT02192697|DRUG|ASP8273|Oral administration
48655912|NCT06565000|OTHER|AHA Not Instrumented then AHA Instrumented|First, the participant will undergo a performance assessment using the Assisting Hand Assessment test, following the standard protocol in the occupational therapy room. Subsequently, they will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Finally, a second round of assessment using the Assisting Hand Assessment will be conducted.
48299999|NCT04578717|PROCEDURE|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
48300000|NCT04578717|BIOLOGICAL|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
48300001|NCT03268304|OTHER|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
47952255|NCT05189379|OTHER|Alcoholic Odour|Alcoholic beverage beer / Alcoholic beverage red wine / Alcoholic beverage brandy / The type of the Alcoholic Odour intervention will be presented in a participant-preference basis.
47952256|NCT05189379|OTHER|Non-Alcoholic Images|Images of non-alcoholic items, namely; broom, duster, clothing iron, lightbulb, mat, mulch, penlight, rack, rock, kitchen scissors, trough, vent are presented in parallel with the non-alcoholic odour
47952257|NCT05189379|OTHER|Alcoholic Images|Images of alcoholic items, namely, beer, wine, schnapps are presented in parallel with the alcoholic odour
47952258|NCT04040946|DIAGNOSTIC_TEST|MIBI scintigraphy|Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
47952259|NCT04040946|DIAGNOSTIC_TEST|F18-choline PET|Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
48108162|NCT02508896|BIOLOGICAL|AFFITOPE® AT04A+adjuvant|subcutaneous injection
48300002|NCT02420964|OTHER|video instruction|Patient Directed Video Instruction
47952260|NCT04198116|DRUG|Varenicline|Varenicline 2mg/day
47952261|NCT04198116|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
47952262|NCT01910948|DRUG|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
48479126|NCT01491308|OTHER|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
48479127|NCT03005067|DRUG|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
48479128|NCT03005067|OTHER|Placebo|Reference product containing vehicle without carbomer 980 gel
48479129|NCT02605213|DRUG|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
48300003|NCT02420964|OTHER|Nurse instruction|Nurse directed instruction
48300004|NCT01804361|DRUG|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
47952263|NCT03996759|DIAGNOSTIC_TEST|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
48300005|NCT01804361|DRUG|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
48479130|NCT02605213|DRUG|Placebo|Placebo for control Group of primary sclerosing vhlangitis
47952264|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 500mg tablet, orally once on Day 1
47952265|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 750mg tablet, orally once on Day 1
48300006|NCT00038259|DRUG|Aldesleukin|
47952266|NCT06473948|DRUG|JMKX001899|Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
47952267|NCT06473948|DRUG|Placebo|Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1
47952268|NCT00014482|PROCEDURE|pain therapy|
47952269|NCT00014482|PROCEDURE|psychosocial assessment and care|
47952270|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
48108163|NCT02508896|BIOLOGICAL|AFFITOPE® AT06A+adjuvant|subcutaneous injection
48300007|NCT05496426|DRUG|KL130008/Placebo|Drug: KL130008 Drug: Placebo
48300008|NCT05044169|DRUG|Broncho-Vaxom|administration for 6 months after remmission
47952271|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
47952272|NCT01634061|DRUG|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
48108164|NCT02508896|BIOLOGICAL|Adjuvant without active component|subcutaneous injection
48108165|NCT02807558|DRUG|Tamibarotene|Administered as oral tablets
47952273|NCT01634061|DRUG|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
47952274|NCT03319173|BEHAVIORAL|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
47952275|NCT03250221|DEVICE|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
47952276|NCT03250221|DEVICE|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
47952277|NCT05384678|DRUG|N,N-Dimethyltryptamine (54 mg)|A dose rate of 0.6 mg/min will be administered
47952278|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg)|A dose rate of 1.2 mg/min will be administered
47952279|NCT05384678|DRUG|N,N-Dimethyltryptamine (162 mg)|A dose rate of 1.8 mg/min will be administered
48108166|NCT02807558|DRUG|Azacitidine|Administered via intravenous (IV) or subcutaneous (SC) infusion
47952280|NCT05384678|DRUG|N,N-Dimethyltryptamine (216 mg)|A dose rate of 2.4 mg/min will be administered
47952281|NCT05384678|DRUG|Placebo|A Placebo (saline infusion) will be administered.
47952282|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg) + dose titration|A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
47952283|NCT06231732|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA
47952284|NCT06231732|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
47952285|NCT04172896|PROCEDURE|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
47952286|NCT04172896|PROCEDURE|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
47952287|NCT02007616|OTHER|Non-action video game training|Based on cognitive training Lumosity
47952288|NCT03600701|DRUG|Atezolizumab|Given IV
47952289|NCT03600701|PROCEDURE|Biopsy|Undergo biopsy
47952290|NCT03600701|PROCEDURE|Biospecimen Collection|Undergo collection of blood
47952291|NCT03600701|DRUG|Cobimetinib|Given PO
47952292|NCT03600701|PROCEDURE|Computed Tomography|Undergo CT scan
47952293|NCT03600701|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47952294|NCT03025841|DRUG|Ceftaroline|
47952295|NCT05592951|DIETARY_SUPPLEMENT|Crystal Light (once serving)|Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
48108167|NCT02807558|DRUG|Daratumumab|Administered via IV infusion
48108168|NCT01301196|BEHAVIORAL|Educational workshop|3h attendance at educational workshop plus self-monitoring
48300009|NCT01099826|BEHAVIORAL|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
48300010|NCT01099826|BEHAVIORAL|Motivational Interview|motivational interview by trained MI counselors by phone
47952296|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (one serving)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
47952297|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (two servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
47952298|NCT05592951|DIETARY_SUPPLEMENT|Liquid IV with amino acids (three servings)|Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
47952299|NCT02218255|DEVICE|Eeva™ results|
47952300|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with VR-IOMSs|Learning Orientation and Mobility skills from virtual-reality-based, automated, intelligent computer training programs - VR-IOMSs
47952301|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with COMS|Learning Orientation and Mobility skills from human Certified Orientation and Mobility Specialists (COMS)
48300011|NCT05463679|DRUG|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
48300012|NCT05463679|DRUG|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
47952302|NCT04639531|BEHAVIORAL|No Orientation and Mobility Training|No Orientation and Mobility training. Watch low vision education videos and discuss low vision issues not related to O\&M with COMS
47952303|NCT04138069|OTHER|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
47952304|NCT04138069|OTHER|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
47952305|NCT02239588|OTHER|Oral consumption|"Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~1. Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~2. Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~3. Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~4. Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~5. Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~6. Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
47952306|NCT01988220|OTHER|sensory retraining|
48108169|NCT06044545|DIAGNOSTIC_TEST|Web Based Pregnancy Preparation Education Structured According to the Health Promotion Model Knowledge Attitude and Health Behaviors|"With this research, according to the health promotion model for the care that should be taken during the preconceptional period (pre-pregnancy) of women who are not yet pregnant, who will marry soon and who are considering pregnancy.~It is thought that they will gain knowledge, increase their awareness and develop positive health behaviors with the web-based pregnancy preparation training. In data collection; Introductory Characteristics Form, Preconceptional Knowledge and Attitudes Scale, Preconception Health Behaviours Scale will be used."
48108170|NCT01159249|DRUG|Vildagliptin|
48108171|NCT00982618|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
48108172|NCT00982618|PROCEDURE|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
48108173|NCT00982618|DRUG|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
48108174|NCT04012853|DEVICE|transcranial direct current stimulation|Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
48108175|NCT04178941|BEHAVIORAL|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
48108176|NCT04178941|BEHAVIORAL|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
48108177|NCT02618239|DIETARY_SUPPLEMENT|Bimuno Galacto-oligo-saccharide|
48108178|NCT03861741|GENETIC|WES|A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
47952307|NCT01988220|OTHER|repeated sensory input|sensory stimulation without attentive learning focus
47952308|NCT05490407|DRUG|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
47952309|NCT04864418|DRUG|AST-021p|3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
47952310|NCT02186873|DRUG|Placebo|Participants will receive matching placebo.
47952311|NCT02186873|DRUG|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
47952312|NCT03815474|DRUG|anlotinib|Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
47952313|NCT04135365|BEHAVIORAL|neurocognitive assessment|Observational study therefore there are no interventions
47952314|NCT04135365|BEHAVIORAL|neuroimaging assessment|Observational study therefore there are no interventions
47952315|NCT03849807|OTHER|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
47952316|NCT03849807|OTHER|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
47952317|NCT03658057|DRUG|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
47952318|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
48108179|NCT03861741|DIAGNOSTIC_TEST|MRI|A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
48108180|NCT03861741|DIAGNOSTIC_TEST|TTE|TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.
48300013|NCT00003369|DRUG|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
47952319|NCT01132274|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
48108181|NCT03861741|OTHER|Questionnaire|Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
48300014|NCT00003369|DRUG|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
48300015|NCT04956692|BIOLOGICAL|Pembrolizumab SC|SC injection
48300016|NCT04956692|BIOLOGICAL|Pembrolizumab IV|IV injection
47952320|NCT03592654|BEHAVIORAL|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
48300017|NCT04956692|DRUG|Paclitaxel|IV injection
48300018|NCT04956692|DRUG|Nab-Paclitaxel|IV infusion
48108182|NCT05272124|OTHER|Hip Abductor Strengthening|"Elastic resisted training of Hip Abductors (5-10 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
48300019|NCT04956692|DRUG|Carboplatin|IV infusion
48300020|NCT04956692|DRUG|Cisplatin|IV infusion
48300021|NCT04956692|DRUG|Pemetrexed|IV infusion
48300022|NCT00733512|DEVICE|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
48108183|NCT05272124|OTHER|Traditional Physical Therapy|"Elastic resisted training of Quadriceps (5-7 seconds hold) 10 repetitions x 3 sets, 3 alternate days per week.~Static Stretching of 5 seconds hold (Calf, Hamstrings, Gluteal muscles and Iliotibial band) 10 repetitions x 3 sets, 3 alternate days per week.~Patellar Mobilization in all four directions 10 repetitions x 3 sets, 3 alternate days per week.~Total 18 sessions were given in 06 weeks."
48108184|NCT05802264|COMBINATION_PRODUCT|ABCI|Subjects will receive ABCI via oral inhalation
48108185|NCT05802264|COMBINATION_PRODUCT|Placebo|Subjects will receive ABCI via oral inhalation
47952321|NCT05751044|DRUG|Dasatinib|Oral
47952322|NCT05751044|DRUG|Venetoclax|oral
47952323|NCT05751044|DRUG|Dexamethasone|oral/intervenous
47952324|NCT05751044|DRUG|Cyclophosphamide|intravenous
47952325|NCT05751044|DRUG|Cytarabine|intravenous
48108186|NCT00664911|OTHER|chemotherapy|
48108187|NCT00511160|PROCEDURE|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
48108188|NCT00511160|PROCEDURE|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
48108189|NCT03390569|BEHAVIORAL|Exercise|The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
48108190|NCT02177318|DRUG|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
48108191|NCT03485859|DEVICE|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
48108192|NCT03485859|DEVICE|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
48108193|NCT04606069|DRUG|Regadenoson|Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
48108194|NCT04606069|OTHER|Placebo Control|The same volume of saline will be given intravenously for 6 and half hours.
48108195|NCT01145248|DEVICE|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
48108196|NCT01145248|DEVICE|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
48108197|NCT04680871|DEVICE|In-Ear Sensor|The device will passively monitor participants' biometrics
48108198|NCT01795144|DRUG|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
48108199|NCT01795144|DRUG|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
48108200|NCT05489406|DRUG|DTG DT (6 x 5 mg)|DTG 5mg dispersible tablet
48108201|NCT05489406|DRUG|F/TAF TOS (3 x 60/7.5 mg)|60/7.5 mg TOS emtricitabine/TAF
48108202|NCT03775551|BEHAVIORAL|Improvement cycle|at least 6 workshops (sessions) will be held with the members of the care system, in order to identify opportunities for improvement oriented to the design and application of an innovative intervention based on best practices.
48108203|NCT01273844|DRUG|Bortezomib|Bortezomib
48108204|NCT00479206|DRUG|Artesunate|
48108205|NCT06027372|DEVICE|"LARGAN ECG Holter"|"wear LARGAN ECG Holter during sleep once after completion of pulmonary function test"
47952326|NCT05751044|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
47952327|NCT01759511|DRUG|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
47952328|NCT00416546|DRUG|AEB071|
47952329|NCT01997853|DRUG|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
48300023|NCT05762744|DRUG|Exenatide Injection|Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
48108206|NCT01505946|OTHER|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
48300024|NCT05762744|DRUG|Saline injection|Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
48300025|NCT03340493|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
48300026|NCT00221845|DRUG|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
48300027|NCT00221845|DRUG|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
48300028|NCT00221845|DRUG|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
48300029|NCT06237842|DIAGNOSTIC_TEST|Diagnostic Test: EEG headband+Ring oximeter (RO)+Actigraphy (ACT)|Combination of ACT+RO+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
48300030|NCT06007430|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
48300031|NCT06007430|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
48300032|NCT04534062|OTHER|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
48300033|NCT02860468|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
48300034|NCT02860468|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
48300035|NCT06309810|RADIATION|Radiotherapy|"The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral~1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs)."
48300036|NCT06021652|DEVICE|MindCotine Virtual reality|Virtual reality platform
48300037|NCT02413398|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
48300038|NCT02413398|DRUG|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
48300039|NCT03444363|DEVICE|Laser group|Laser application in addition to SRP
48300040|NCT03444363|DEVICE|Control group|Placebo laser application in addition to SRP
48300041|NCT05628233|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
47952330|NCT01997853|DRUG|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
47952331|NCT04962620|DRUG|Bovhyaluronidase azoximer|Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.
47952332|NCT04932460|PROCEDURE|CEUS|CEUS is performed before neoadjuvant treatment and surgery to evaluate the status of axillary lymph node and locate the sentinel lymph node.
47952333|NCT04932460|PROCEDURE|blue dye|Before operation, blue dye is injected for sentinel lymph node mapping.
47952334|NCT01772160|OTHER|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
47952335|NCT06319261|PROCEDURE|guided biofilm therapy|Removing plaque and calculus by initially detecting it with a disclosing agent followed by the use of air abrasive powder for the removal of supra and subgingival plaque.
47952336|NCT06319261|PROCEDURE|root surface debridement|Removing plaque and calculus by conventional root surface debridement
47952337|NCT05534685|OTHER|intratracheal administration of surfactant/budesonide|328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
48108207|NCT05214287|DRUG|Hypoxic Gas Mixture|Using a commercially available hypoxicator, varying gas mixtures as described will be administered via a tight-fitting oxygen mask. In the circuitry, a three-way valve is placed that allows for the intermittent administration of hypoxia: the valve either passes the hypoxic mixture from the hypoxicator or room air.
47952338|NCT05534685|OTHER|incidence of bronchopulmonary dysplasia|. Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
47952339|NCT05592262|DRUG|SHR2554|On an empty stomach - after meals
48108208|NCT03009006|DRUG|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
47952340|NCT05592262|DRUG|SHR2554|After meals - on an empty stomach
47952341|NCT04805762|OTHER|Your COACH Next Door|Children in the study are attending the lifestyle intervention Your COACH Next Door. A coach is supporting the child and it's family to reach their goals regarding lifestyle.
47952342|NCT02639546|DRUG|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
47952343|NCT01341197|OTHER|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
47952344|NCT03677427|RADIATION|Radiation|Radiation in breast cancer
48108209|NCT03009006|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
48108210|NCT03709719|DRUG|Blinatumomab Injection|Blinatumomab 28 μg/day : D1 to D28
48108211|NCT03861767|DRUG|Metformin ER|tablet
48108212|NCT03861767|DRUG|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
48108213|NCT03479736|DRUG|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
48108214|NCT03479736|DRUG|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
48108215|NCT03479736|OTHER|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
48108216|NCT03768856|RADIATION|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
48108217|NCT06537544|OTHER|Comprehensive Rehabilitation Program|Pelvic Floor Muscle Strengthening Exercises Core Strengthening Exercises Breathing Exercises Patient education about bladder diary Postural education
48300042|NCT03743558|BEHAVIORAL|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
48479131|NCT06583850|OTHER|The Neck Disability Index|The Neck Disability Index (NDI) is the most widely used self-report tool to assess neck pain status, and provides information not only about pain experiences but also about a person\&#39;s functional status. The NDI consists of 10 questions related to pain, functional activities, self-care, and quality of life that are measured on a 6-point scale (0, no disability; 5, full disability). The numeric score for each item is summed for a score ranging from 0 to 50; 0-4 points are defined as no disability, 5-14 points as mild disability, 15-24 points as moderate disability, 25-34 points as severe disability and above 35 points as complete disability.
47952345|NCT01028885|PROCEDURE|radiation therapy treatment planning/simulation|
47952346|NCT01028885|PROCEDURE|intensity-modulated radiation therapy|
47952347|NCT01028885|PROCEDURE|image-guided radiation therapy|
47952348|NCT01028885|PROCEDURE|magnetic resonance imaging|
47952349|NCT01028885|PROCEDURE|computed tomography|
47952350|NCT02322073|PROCEDURE|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
47952351|NCT03358797|BEHAVIORAL|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
48108218|NCT06537544|OTHER|Conventional Pelvic Floor Training|Kegels exercises in different body positions
48108219|NCT00019669|BIOLOGICAL|aldesleukin|
48300043|NCT01819220|DRUG|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
47952352|NCT03358797|BEHAVIORAL|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
47952353|NCT03358797|BEHAVIORAL|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
47952354|NCT03358797|BEHAVIORAL|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
47952355|NCT01423578|BEHAVIORAL|Hatha Yoga (HY)|3 Sessions of yoga instruction
48479132|NCT06583850|OTHER|Visual analog scale (VAS)|A 10 cm VAS numbered from 0 to 10 was used for the assessment. 0 indicates no pain and 10 indicates unbearable pain. Participants were asked to mark a point between 0-10 according to their pain status
47952356|NCT01423578|BEHAVIORAL|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
47952357|NCT01423578|BEHAVIORAL|Smoking Cessation Counseling|4 smoking cessation counseling visits.
47952358|NCT00304239|COMBINATION_PRODUCT|Metvix-PDT|Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
47952359|NCT00304239|COMBINATION_PRODUCT|Vehicle-PDT|Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
47952360|NCT06015464|DRUG|Orelabrutinib|Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
47952361|NCT02235519|DRUG|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
47952362|NCT02235519|DRUG|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
47952363|NCT03702517|DEVICE|lateral stair walking exercise|15 minutes of lateral stair walking exercise
47952364|NCT03702517|DEVICE|traditional physiotherapy|strengthening exercise, balance training and gait training
48479133|NCT06583850|OTHER|Pittsburgh Sleep Quality Index|Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report questionnaire
47952365|NCT00004868|DRUG|semaxanib|
47952366|NCT03504254|DIAGNOSTIC_TEST|MRI examination|Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
48108220|NCT00019669|BIOLOGICAL|fowlpox virus vaccine vector|
48300044|NCT01819220|DRUG|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
47952367|NCT00237172|DRUG|Imatinib Mesylate|once daily
47952368|NCT04195282|OTHER|Plasma exchange|Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.
47952369|NCT04195282|OTHER|RL-1 Novel Human-derived Bio-artificial Liver Treatment|Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
47952370|NCT02436252|DRUG|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
48108221|NCT00019669|BIOLOGICAL|gp100 antigen|
48300045|NCT01420640|BEHAVIORAL|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
48300046|NCT01420640|BEHAVIORAL|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
48300047|NCT01420640|BEHAVIORAL|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
48300048|NCT01420640|BEHAVIORAL|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
48300049|NCT01420640|BEHAVIORAL|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
48300050|NCT05680129|DRUG|Ecnoglutide high dosage|Administered subcutaneously
48300051|NCT05680129|DRUG|Ecnoglutide low dosage|Administered subcutaneously
48300052|NCT05680129|DRUG|Dulaglutide|Administered subcutaneously
48300053|NCT05680129|DRUG|Metformin|Administered orally
48300054|NCT06466720|BEHAVIORAL|Neurocognitive testing|The MoCA is a brief tool developed to screen mild cognitive impairment and has been validated in patients aged 55-85 years old. It has been tested and validated in patients with brain metastases, and its acceptability has been tested in the general brain tumour population. The paper version of the MoCA is available in nearly 100 languages. The online version is available currently in 5 languages.
48300055|NCT06466720|BEHAVIORAL|Quality of Life questionnaire|The EORTC-QLQ-C30 is a quality-of-life questionnaire that was developed by the European Organisation for Research and Treatment of Cancer (EORTC) for use in clinical trials. It is a 30-item questionnaire that incorporates the following five scales: physical, role, cognitive, emotional and social. It has also been validated and is available in more than 100 languages. The EORTC-QLQ-BN20 is a questionnaire that was developed for use specifically with patients that have brain cancer. The BN20 is a 20-item questionnaire and addresses four different scales (multi-item): future uncertainty, visual disorder, motor dysfunction and communication deficit. There are seven items that assess physical symptoms: headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs and bladder control. The questionnaire has been validated in over 15 languages. The two questionnaires are meant to complement each other when used in patients with brain cancer.
48300056|NCT06466720|RADIATION|Stereotactic radiosurgery|This is a Standard of Care treatment for all the patients that will be recruited in both cohorts. Stereotactic radiosurgery will be delivered to one or more sites and in the prospective cohort can be delivered more than once.
48300057|NCT05782101|DIAGNOSTIC_TEST|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
48300058|NCT05378789|PROCEDURE|Nap|"ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
48300059|NCT01978912|DRUG|KTP-001|KTP-001 is one time dose intradiscally.
48300060|NCT03120390|OTHER|Best Practice|Undergo usual care
48300061|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo AE
48108222|NCT06372912|PROCEDURE|Sleeve gastrectomy, Roux-en-Y gastric bypass, mini-gastric bypass, SADIS, intragastric balloon insertion, and gastric band placement are bariatric surgeries.|Sleeve gastrectomy: reduces stomach size. Roux-en-Y gastric bypass: limits calorie absorption. Mini gastric bypass: achieves weight loss with fewer incisions. SADIS: combines sleeve gastrectomy with small bowel bypass. Intragastric balloon: reduces stomach volume. Gastric banding: restricts food intake.
48108223|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 500|Experimental arm
48108224|NCT03574844|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae, dose 1000|Experimental arm
48108225|NCT03574844|DIETARY_SUPPLEMENT|Placebo|Placebo comparator arm
48108226|NCT01118338|DEVICE|Redesigned Purevision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
48108227|NCT01118338|DEVICE|PureVision Contact Lens|Lenses will be dispensed at screening visit, subjects will wear lenses on a daily wear basis for one month.
48108228|NCT01326715|DRUG|Mangafodipir (Teslascan)|gadolinium enhancement on contrast enhanced brain MRI.
48300062|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo RE
48300063|NCT03120390|OTHER|Laboratory Biomarker Analysis|Correlative studies
48300064|NCT03120390|DEVICE|Monitoring Device|Receive Polar heart rate monitor
48300065|NCT03120390|OTHER|Quality-of-Life Assessment|Ancillary studies
48300066|NCT03120390|OTHER|Questionnaire Administration|Ancillary studies
48300067|NCT00763204|DRUG|AN2728 Cream, 2%|
48300068|NCT00763204|DRUG|AN2728 Cream, 1%|
48300069|NCT00763204|DRUG|AN2728 Cream, 0.3%|
48300070|NCT00763204|DRUG|AN2728 Cream Vehicle|
48300071|NCT00763204|DRUG|Betnesol®-V Creme, 0.1%|
48300072|NCT00854932|OTHER|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
48479134|NCT06583850|OTHER|Cervical Range of Motion Assessment|Active Cervical Range Of Motion was measured with a universal goniometer in all three planes of motion in the cervical region: lateral flexion (frontal plane), axial rotation to both right and left sides (horizontal plane), and flexion-extension (sagittal plane).
48479135|NCT00172419|DRUG|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
48132649|NCT06457971|DEVICE|Robotic Ventral Hernia Repair|The AnovoTM Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS with graspers and electrosurgery devices for endoscopic manipulation of tissue including grasping, blunt dissection, approximation, and electrosurgery, during single site, laparoscopic surgical procedures. The AnovoTM System's articulated robotic arms allow the surgeon to access and reach different structures in the pelvic and abdominal cavity. Closing the fascial defect robotically is easier from a technical standpoint than attempting it with classical laparoscopic instruments
48132652|NCT05058651|BIOLOGICAL|Atezolizumab|Given IV
48132653|NCT05058651|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48132654|NCT05058651|DRUG|Carboplatin|Given IV
48132655|NCT05058651|DRUG|Cisplatin|Given IV
48132656|NCT05058651|PROCEDURE|Computed Tomography|Undergo CT scan
48132657|NCT05058651|DRUG|Etoposide|Given IV
48132658|NCT05058651|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48132659|NCT05058651|OTHER|Patient Observation|Undergo observation
48108229|NCT03804086|PROCEDURE|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~* The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~* After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
48300073|NCT04473443|OTHER|FEops HEARTguideTM|A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.
48300074|NCT02546856|OTHER|Heart Failure (HF) nurse up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support."
48108230|NCT03804086|PROCEDURE|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
48108231|NCT01156935|OTHER|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
48108232|NCT03949335|DEVICE|IOL Model ZFR00V|Bilateral implantation with Investigational IOL Model ZFR00V
48108233|NCT03949335|DEVICE|IOL Model ZCB00|Bilateral Implantation with control IOL Model ZCB00
48108234|NCT00223548|DRUG|sodium 2-mercaptoethane sulfonate|
48300075|NCT02546856|OTHER|Heart Failure (HF) cardiologist up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist."
48479136|NCT00865098|DRUG|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m\^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m\^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
48479137|NCT06605625|BIOLOGICAL|Influenza vaccination|one annual dose of inactivated influenza vaccine
48479138|NCT06605625|BIOLOGICAL|SARS-CoV-2 vaccine|dose of SARS CoV2 vaccine
48479139|NCT06605625|BIOLOGICAL|Zoster Vaccine Recombinant|first and/or second vaccination for shingles (Herpes zoster)
48479140|NCT02598245|DEVICE|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
48479141|NCT02598245|DEVICE|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
48497868|NCT02767895|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
48497869|NCT04175444|DIAGNOSTIC_TEST|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
47952371|NCT05403658|BEHAVIORAL|Family Navigation|FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
48300076|NCT05691244|DRUG|Drug: Normal Saline|Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
48300077|NCT05691244|DRUG|Sovateltide|Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
48300078|NCT05228912|DRUG|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
48300079|NCT01639859|OTHER|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
48300080|NCT00126542|BIOLOGICAL|bevacizumab|Given IV
48300081|NCT00126542|DRUG|erlotinib hydrochloride|Given orally
48300082|NCT00126542|OTHER|laboratory biomarker analysis|Correlative studies
48300083|NCT00606697|DRUG|GR205171|10 milligrams (mg)
48479142|NCT01680874|DIETARY_SUPPLEMENT|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
48637958|NCT04286139|BEHAVIORAL|SHAPE|The SHAPE intervention provides information for carers, and maintains the dignity and autonomy of the person with dementia, supporting them in planning for the future with their family. The person with dementia attends an online 10 week facilitator lead group based course. It is designed to develop self-management skills in areas including decision-making, symptom management and social interaction. It also provides information on the disease process and the development of healthy behaviors in a supportive learning environment to prevent problems that are common in the later stages of the disease. The adjunctive e-learning platform for carers provides the same information that the person with dementia receives plus additional material and signposting to support them in their role. This will empower the whole family to support and enable more effective self-management by the person with dementia, and enhance their ability to plan ahead together and make key decisions jointly.
48637959|NCT06220201|DRUG|CC-97540|Specified dose on specified days
48637960|NCT06220201|DRUG|Fludarabine|Specified dose on specified days
48108235|NCT04330950|OTHER|Neurocognitive tests|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
48300084|NCT00606697|DRUG|GW597599|15 mg
48300085|NCT00472342|BEHAVIORAL|exercise prescription|
48300086|NCT00973830|OTHER|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
48300087|NCT00075751|DRUG|gemcitabine hydrochloride|Given IV
48300088|NCT00075751|DRUG|carboplatin|Given IV
48300089|NCT00075751|DRUG|bortezomib|Given IV
48300090|NCT01842893|DRUG|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
48300091|NCT03408873|DRUG|Abilify Maintena|Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
48479143|NCT01680874|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
48479144|NCT04344626|DEVICE|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
48479145|NCT00752284|PROCEDURE|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
48479146|NCT00752284|PROCEDURE|Total Excision|Total excision of lower third molar
48479147|NCT03955939|DRUG|LY3295668 Erbumine|Administered orally.
48479148|NCT03955939|DRUG|Endocrine therapy|Administered according to label instructions.
48479149|NCT03955939|DRUG|Midazolam|Administered orally.
48479150|NCT00455026|DRUG|remifentanil|target effect site concentration during induction
48479151|NCT04499378|DIAGNOSTIC_TEST|Lung CT|Computed tomography of the thorax
48479152|NCT03489226|DIETARY_SUPPLEMENT|Capsimax|Capsimax
48479153|NCT03489226|DIETARY_SUPPLEMENT|Placebo|Placebo
48479154|NCT03489226|OTHER|Meal|Meal
48479155|NCT05636995|DIAGNOSTIC_TEST|Aldosterone/Renin Ratio|Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
48637961|NCT06220201|DRUG|Cyclophosphamide|Specified dose on specified days
48479156|NCT03115606|DEVICE|C-Mac D Blade|Videolaryngoscope
48479157|NCT03115606|DEVICE|Fastrach LMA|Laryngeal mask airway
48637962|NCT02573441|BEHAVIORAL|Jump Math|Jump Math is a workbook based program aimed at improving math skills
48637963|NCT02573441|BEHAVIORAL|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
48637964|NCT02573441|BEHAVIORAL|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
48637965|NCT06169397|DRUG|XTMAB-16|XTMAB-16 infusion
48637966|NCT05298969|PROCEDURE|Temporalis Myofascial flap|Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
48637967|NCT01311011|PROCEDURE|SCT|SCT
48479158|NCT02765672|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
48479159|NCT02765672|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
48479160|NCT02765672|BEHAVIORAL|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
48637968|NCT04491383|DRUG|Tocovid Suprabio (HOV-12020)|Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol
48637969|NCT04491383|OTHER|Placebo|Dietary supplement: Placebo. Placebo.
48479161|NCT02765672|BEHAVIORAL|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
48132660|NCT06638463|BEHAVIORAL|My Health Coach app|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
48132661|NCT01979276|DRUG|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
48132662|NCT01979276|DRUG|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
48479162|NCT02765672|BEHAVIORAL|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
48479163|NCT02765672|BEHAVIORAL|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
48479164|NCT02765672|PROCEDURE|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
48479165|NCT02765672|PROCEDURE|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
48479166|NCT02765672|PROCEDURE|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
48479167|NCT02765672|PROCEDURE|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
48479168|NCT02765672|PROCEDURE|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
48479169|NCT02950142|OTHER|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
48479170|NCT02950142|OTHER|CPOE without order sets for lab testing|CPOE only
48637970|NCT05814627|DRUG|Upadacitinib|Oral Tablets
48637971|NCT05814627|DRUG|Adalimumab|Subcutaneous Injection
48637972|NCT05814627|DRUG|Upadacitinib Matching Placebo|Oral Tablets
48637973|NCT05814627|DRUG|Adalimumab Matching Placebo|Subcutaneous Injection
48637974|NCT06106295|DRUG|Metyrapone|250 to 1000 milligram (mg) orally in one or two doses in the evening (administered 4 and 2 hours prior to bed)
48637975|NCT03040973|DRUG|Capmatinib|Tablet for oral use; 150 mg, 200 mg; twice a day
48637976|NCT03040973|DRUG|Nazartinib|Capsule for oral use; 25 mg, 50 mg; once a day
48637977|NCT03040973|DRUG|Gefitinib|tablets for oral use; 250mg; once a day
48637978|NCT03040973|DRUG|Osimertinib|Tablets for oral use; 40 mg, 80 mg; once a day.
48637979|NCT05199272|DRUG|23ME-00610|23ME-00610 given by IV infusion
48637980|NCT02302326|DRUG|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
48637981|NCT02302326|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
48637982|NCT02225795|OTHER|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~* 6 r-ATG 2 mg/kg~* 5 r-ATG3 2 mg/kg~* 4 r-ATG3 2 mg/kg~* 3 Cyclophosphamide with Mesna~* 2 Cyclophosphamide with Mesna~* 1 REST 0 PBSC infusion~  * 3 Cyclophosphamide with Mesna~ * 4 Cyclophosphamide with Mesna~ * 6 Start GCSF"
47952372|NCT05403658|BEHAVIORAL|Usual Care|Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
48637983|NCT06366958|PROCEDURE|excision of dorsal wrist ganglion|open and arthroscopic excision of dorsal wrist ganglion
48637984|NCT05477576|DRUG|RYZ101|RP3D as determined in Phase 1b
47952373|NCT01844557|OTHER|Swallowing Exercises|Participants perform 3 swallowing exercises.
47952374|NCT01844557|BEHAVIORAL|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
48637985|NCT05477576|DRUG|Everolimus|Everolimus
47952375|NCT01844557|BEHAVIORAL|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
47952376|NCT00325702|BEHAVIORAL|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
48637986|NCT05477576|DRUG|Sunitinib|Sunitinib
48479171|NCT03988452|DRUG|Darunavir|Antiretroviral therapy
48479172|NCT03988452|DRUG|Ritonavir|Antiretroviral therapy
48479173|NCT03988452|DRUG|Dolutegravir|Antiretroviral therapy
48637987|NCT05477576|DRUG|Octreotide|High-dose octreotide
48637988|NCT05477576|DRUG|Lanreotide|Lanreotide
47952377|NCT01549600|DIETARY_SUPPLEMENT|psyllium|1 level tablespoon (\~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
48479174|NCT03988452|DRUG|Zidovudine|Antiretroviral therapy
48637989|NCT04512183|OTHER|High-Fidelity Simulation|Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.
48479175|NCT03988452|DRUG|Tenofovir|Antiretroviral therapy
48479176|NCT03988452|DRUG|Lamivudine|Antiretroviral therapy
48637990|NCT04512183|OTHER|Low-Fidelity Simulation|Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
48479177|NCT02457819|DRUG|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
48479178|NCT00855075|DEVICE|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
48479179|NCT05589350|OTHER|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
48637991|NCT05524909|GENETIC|Genetic Risk Estimate|The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).
48637992|NCT05524909|DEVICE|Genetic Risk Estimate + Fitbit Functions|"The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for T2D as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk).~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate."
48479180|NCT02641002|DRUG|CC-90002|Monoclonal Ab to CD47
48637993|NCT04818177|DRUG|Institutional standard intravenous immune globulin treatment|No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
48637994|NCT00050427|DRUG|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
48637995|NCT00050427|DRUG|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
47952378|NCT01549600|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|1 level tablespoon (\~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
47952379|NCT04673968|OTHER|prehabilitation|inhospital exercise training 5 times/week, 5\~6 weeks during nCRT; home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
47952380|NCT04594811|DRUG|NT-I7|Administered by intramuscular (IM) injection.
47952381|NCT04594811|DRUG|Nivolumab|Administered by intravenous (IV) injection.
47952382|NCT03436004|DEVICE|Colonoscopy|Patients undergoing screening colonoscopy
47952383|NCT03436004|DEVICE|Colonoscopy with specific device (Endocuff Vision)|Patients undergoing screening colonoscopy using the Endocuff Vision device
47952384|NCT04489459|DRUG|Colistin|Intravenous colistin 9 MIU IV infusion over 2 hours loading dose followed by maintenance dose 4.5 MIU IV infusion over 2 hours q12 h
47952385|NCT04489459|DRUG|Meropenem|Intravenous meropenem 2 g IV infusion over 30 minutes q8 h
48479181|NCT04520776|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
48479182|NCT04520776|DEVICE|Mobi-C® Cervical Disc|surgery
48108236|NCT05544578|BEHAVIORAL|Nurses Taking On Readiness Measures (N- TORM)|The intervention group will be educated about household emergency preparedness via a presentation and the Korean version of a New York City community-specific booklet called Ready New York: My Emergency Plan (NYC Emergency Management, 2022). The intervention will begin with instructing the participant to start the booklet during class 1 and completing it for homework. The class content will complement the booklet and the K-HEPI. The booklet includes preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. During class 2, study personnel will check for completion of the booklets, answer any questions that the participants may have about the evacuation and communication plans and disaster kits, and facilitate group discussion to foster social support from other community members.
48108237|NCT03185819|DRUG|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
48108238|NCT03185819|DRUG|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
48108239|NCT03185819|DRUG|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
48108240|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
48108241|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
48108242|NCT03185819|DRUG|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
48108243|NCT02328352|PROCEDURE|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
48108244|NCT02328352|PROCEDURE|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
48108245|NCT02328352|PROCEDURE|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
47952386|NCT04489459|DRUG|Tigecycline|Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
47952387|NCT00462631|DEVICE|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
47952388|NCT00462631|DEVICE|paclitaxel eluting stent|paclitaxel eluting stent
47952389|NCT00462631|DEVICE|bare metal stent|bare metal stent
47952390|NCT05034562|PROCEDURE|Computed Tomography|Undergo PET/CT
47952391|NCT05034562|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
47952392|NCT05034562|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
47952393|NCT05034562|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
48108246|NCT02328352|PROCEDURE|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
48108247|NCT04333589|DRUG|Favipiravir|On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 14 days.
48479183|NCT03994367|OTHER|High animal protein isolate|Increased dietary protein content from animal protein isolates
48479184|NCT03994367|OTHER|High animal protein whole food|Increased dietary protein content from animal protein whole food
48479185|NCT03994367|OTHER|High plant protein isolate|Increased dietary protein content from plant protein isolates
48479186|NCT03994367|OTHER|High plant protein whole food|Increased dietary protein content from animal protein whole food
48479187|NCT03187496|DRUG|Midazolam|Each subject will receive midazolam on Days 1 and 12.
48479188|NCT03187496|DRUG|Caffeine|Each subject will receive caffeine on Days 1 and 12.
48479189|NCT03187496|DRUG|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
48479190|NCT03187496|DRUG|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
48479191|NCT03220113|COMBINATION_PRODUCT|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
48479192|NCT04208269|OTHER|postcard campaign|Post card sent to parent only
48479193|NCT04208269|OTHER|Health Information Technology system|Accessed by adolescent and provider only
48479194|NCT02285205|DRUG|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
48479195|NCT04940702|OTHER|Focal Vibration|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~The exercise is the same than traditional training group."
48479196|NCT04940702|OTHER|Blood Flow Restriction|Training with Blood Flow Restriction, the restriction is in the proximal part of the lower limb. The exercise is the same than traditional training group.
48479197|NCT04940702|OTHER|Traditional Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
48479198|NCT02220725|BIOLOGICAL|Andexanet|
48479199|NCT02220725|OTHER|Placebo|
48497870|NCT04175444|DIAGNOSTIC_TEST|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
48479200|NCT05021237|RADIATION|Ultra-fractionated radiation therapy|Patients enrolled in this study are planned to receive systemic therapy. Imaging based Ultra-fractionated radiation therapy using a PULSAR technique, which is 5 pulses to gross tumor in pelvis.
47952394|NCT05493332|PROCEDURE|HAIC(FOLFOX)|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.
47952395|NCT05493332|DRUG|Oxaliplatin|85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
47952396|NCT05493332|DRUG|Leucovorin|400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
47952397|NCT05493332|DRUG|Fluorouracil|400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
47952398|NCT05493332|DRUG|Toripalimab|240mg IVdrip，D3, Q3W
47952399|NCT05493332|DRUG|Donafenib|0.1g. P.O, BID, continuously
47952400|NCT06221670|DRUG|Toripalimab|This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
47952401|NCT03018600|BEHAVIORAL|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
47952402|NCT05830773|OTHER|Resonance Breathing Exercises|This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices. The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate. PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation. The app also has a timer (to allow the participant to see how long they use the app in each session). The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale). Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
47952403|NCT05997550|OTHER|Pursed Lip Breathing Exercise|Pursed Lip Breathing Exercise for The COPD
48479201|NCT00272506|DRUG|inhaled corticosteroid|
47952404|NCT05997550|OTHER|Laughter Therapy|Laughter Therapy for the COPD
47952405|NCT05997550|OTHER|the control group.|Attention-match training is given to the patients in the control group.
47952406|NCT04446572|BIOLOGICAL|Lactobacillus salivarius CECT5713|Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
47952407|NCT03539146|OTHER|Dietary fiber|Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
47952408|NCT03539146|OTHER|Control yogurt|Control yogurt
47952409|NCT05551208|DRUG|fluzopanib and bevacizumab|fluzopanib and bevacizumab were used for maintenance treatment
47952410|NCT03798847|DEVICE|Journey II XR TKA|Journey II XR Total Knee System
47952411|NCT04414748|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
47952412|NCT04414748|DRUG|oral Duphaston|oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
47952413|NCT00627549|PROCEDURE|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
47952414|NCT00627549|PROCEDURE|Conventional surgery (anterior repair)|Anterior repair surgery
47952415|NCT04273373|BIOLOGICAL|Low Dose Albumin|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
47952416|NCT04273373|BIOLOGICAL|Standard dose Albumin|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
47952417|NCT03898960|DEVICE|NIMBUS Device|NIMBUS Geometric Clot Extractor
48108248|NCT05975788|DRUG|Staphylococcus and Neisseria Tablets|Staphylococcus and Neisseria tablets is used as an adjuvant treatment drug for respiratory disease in acute attack period, such as chronic tracheitis, bronchitis and various types of colds. It has been proved to effectively shorten the course of disease. In this study, Staphylococcus and Neisseria tablets will be administered with 4 tablets each time and 3 times a day, and treatment period ranges from 3 to 6 months according to clinicians.
48479202|NCT00272506|DRUG|long-acting beta2-agonist|
48479203|NCT04462484|BEHAVIORAL|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
48479204|NCT00356824|DRUG|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
47952418|NCT06295107|DIAGNOSTIC_TEST|Ankle Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
47952419|NCT06295107|DIAGNOSTIC_TEST|Knee Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
47952420|NCT05329532|BIOLOGICAL|Modi-1/Modi-1v|Modi-1/Modi-1v administered intradermally (i.d.) using the MicronJet600™ microneedle device (NanoPass).
47952421|NCT05329532|BIOLOGICAL|Pembrolizumab|Pembrolizumab (exploratory cohorts) will be administered by intravenous infusion on Day 8, prior to tumour resection surgery at 6 weeks.
48479205|NCT00356824|DRUG|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
48300092|NCT03408873|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
48300093|NCT05323552|PROCEDURE|Laparoscopic TEP hernia repair without curare and without orotracheal intubation.|"All the techniques and protocols used for this monocentric study are standardized:~* The anesthesia is general, the anesthetic products administered are identical,~* ventilation is ensured by the use of a laryngeal mask airway, without curare administered~* the surgery is an extraperitoneal laparoscopy with an optical trocar under the umbilical and two operators with the placement of a preformed type 3G polypropylene prosthesis~* the analgesic protocol is free of opioids (Opioid Free Anesthesia - OFA)"
48479206|NCT00038831|DRUG|Mylotarg|Starting dose 2 mg/m\^2 over 2-hour intravenous infusion on day -12.
48108249|NCT04575285|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.
48108250|NCT01606553|DEVICE|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
48108251|NCT01606553|DEVICE|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
48108252|NCT01192633|DRUG|GVP|"Drug: gemcitabine, vincristine,cisplatin~cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
48108253|NCT06423742|DEVICE|Transcranial direct current stimulation|The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
48108254|NCT00238446|DRUG|EC-MPS|
48108255|NCT01727128|DRUG|BKM120|
48108256|NCT01169363|GENETIC|proteomic profiling|
48108257|NCT01169363|OTHER|flow cytometry|
48108258|NCT01169363|OTHER|laboratory biomarker analysis|
48108259|NCT04789798|DEVICE|TeleDiab (Telemedicine)|"TeleDiab program components consist of:~1. Electronic transmission of capillary blood glucose measurement results~2. Electronic transmission of blood pressure measurements~3. Synchronized video-conferencing, secure messaging~4. Access to clinical data from patient files when necessary~5. Reminding of routine follow-up tests and examinations~6. Providing web-based educational materials to patients."
48108260|NCT04789798|OTHER|Usual care|Usual diabetes care, as provided by primary care providers
48108261|NCT00878722|DRUG|PXD101|
48108262|NCT00878722|DRUG|idarubicin|
48108263|NCT04168619|DRUG|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
48108264|NCT04168619|OTHER|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
48108265|NCT05376930|DRUG|DWP16001 Amg|DWP16001 Amg, Tablets, Orally, Once daily
48108266|NCT01572337|PROCEDURE|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
48108267|NCT01572337|OTHER|Standard care|
48300094|NCT00479804|DEVICE|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
48300095|NCT00479804|DEVICE|spirometry|spirometry for testing the ventilatory function
48300096|NCT00479804|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
48300097|NCT00002191|DRUG|Albendazole|
48479207|NCT00038831|DRUG|Fludarabine|30 mg/m\^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
48479208|NCT00038831|DRUG|Melphalan|140 mg/m\^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
48479209|NCT00038831|DRUG|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
48479210|NCT00038831|PROCEDURE|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
48479211|NCT01297322|OTHER|Manual compression|Standard of Care
48479212|NCT01297322|DEVICE|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
48479213|NCT02221596|DIETARY_SUPPLEMENT|vitamin D|50,000IU/wk of vitamin D3
48479214|NCT02221596|OTHER|aerobic training|7 days of treadmill training during the 13th week of study
48479215|NCT03885219|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
48497871|NCT02277678|DRUG|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
48637996|NCT06522529|OTHER|Multifaceted implementation strategy|The multifaceted implementation strategy consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local context analysis, identifying barriers to improvements in clinical practice, and developing and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
48637997|NCT03732898|DEVICE|Novel Programming (nDBS)|The commercial CP installed with the investigational DBS programming software will be used to set up Novel Programming (nDBS) therapy on the IPG.
48300098|NCT05005559|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
48300099|NCT05005559|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
48637998|NCT03732898|DEVICE|Conventional Programming (cDBS)|The commercial CP installed with commercial software will be used to set up standard cDBS therapy on the IPG.
48637999|NCT00948935|DRUG|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
48638000|NCT06009354|OTHER|Rehabilitation|The control group will receive post-operative usual practices. The study group will receive multi-component education in addition to the usual practices.
48638001|NCT02598999|DRUG|ALX-009|Solution for inhalation administered through nebulization
48638002|NCT02598999|DRUG|OSCN-|Solution for inhalation administered through nebulization
48638003|NCT02598999|DRUG|bLF|Solution for inhalation administered through nebulization
48638004|NCT02598999|DRUG|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
48638005|NCT04165902|DRUG|compare the effects of steroid plus hyaluronic acid and destrose plus hyaluronic acid on knee osteroarthritis|compare the immediate effect (one week after 3 times of injections), short-term effects (one month and three months after 3 times of injections), and midterm effect (6 months after 3 times of injections).
48638006|NCT02088411|DRUG|Diclofenac|
47952422|NCT05329532|DEVICE|MicronJet600™ microneedle device (NanoPass)|Intradermal injection device
48300100|NCT02974257|DRUG|Thiamine|Thiamine 500mg IV twice daily for 2 days
48300101|NCT02974257|OTHER|placebo|100mL normal saline IV every 12 hours for 2 days
48300102|NCT04883385|OTHER|medical data collection|collection of medical data from patients' medical records
48300103|NCT02288975|DEVICE|CytoSorb 300ml device (3804606CE01)|
48300104|NCT03195634|DRUG|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate \>55 beats per minute, or up to 12.5 mg/day
48300105|NCT00604448|OTHER|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
48300106|NCT00604448|OTHER|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
48300107|NCT03789773|DEVICE|Millimeter-Wave Holographic Imaging|Undergo mm-wave holographic imaging
47952423|NCT00122109|BEHAVIORAL|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
47952424|NCT00881257|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
48300108|NCT03336138|OTHER|AMA (Assistance for ambulatory patients)|telephone follow-up modality
48300109|NCT04579055|OTHER|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
48300110|NCT04579055|OTHER|1-min STS test: standardized|Standardized chair seat height of 46 cm
48300111|NCT01624129|DRUG|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
48638007|NCT02088411|DIETARY_SUPPLEMENT|Wobenzym|
48638008|NCT02088411|OTHER|Placebo|
48638009|NCT03261258|OTHER|Questionnaire|
48638010|NCT06360341|BEHAVIORAL|Emergency Department Digital Pain Self-Management Intervention (EDPSI)|The EDPSI is a developed supplemental digital video for patients presenting to the emergency department with acute low back pain (aLBP). The content consists of self-management approaches for diverse adult patient preferences including biopsychosocial contributors to pain and clinical practice guidelines to self-management options. Highlights of the discharge instructions summary include follow-up with provider, red flag warnings, and medication safety. Actor demonstration of ergonomics and range of motion movements provide application of Physical Therapy (PT)-based preventative strategies. Combination therapies including PT counseling, complementary alternative medicine (acupuncture, massage, yoga, or Pilates), and use of and safety with ice or heat thermal therapies. Active participation, stress management, and involvement of support systems are addressed.
48638011|NCT06360341|OTHER|Routine Discharge Care|Routine Discharge Care
48638012|NCT05843578|DRUG|AGMB-129|Oral capsule
48638013|NCT05843578|DRUG|Placebo|Matching oral capsule
48300112|NCT04499508|DEVICE|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
48300113|NCT04927988|OTHER|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
48300114|NCT01445743|BIOLOGICAL|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
48300115|NCT01094964|BIOLOGICAL|BCG solution|
48300116|NCT01094964|BIOLOGICAL|recombinant interferon alfa|
48300117|NCT01094964|DRUG|epirubicin hydrochloride|
48300118|NCT01094964|DRUG|mitomycin C|
48300119|NCT01094964|OTHER|laboratory biomarker analysis|
48300120|NCT01094964|PROCEDURE|hyperthermia treatment|
48300121|NCT01094964|PROCEDURE|quality-of-life assessment|
48300122|NCT04676139|DRUG|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
48300123|NCT04676139|DRUG|Placebo|placebo for 12 months
48300124|NCT05209568|DIETARY_SUPPLEMENT|Gluten Powder|Single oral dose of gluten powder
48300125|NCT01576861|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
48300126|NCT04985708|OTHER|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
48300127|NCT04547244|OTHER|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
48638014|NCT03279068|OTHER|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
48108268|NCT06121830|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 4 weeks
48300128|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
48300129|NCT00923091|DRUG|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
48300130|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
48300131|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
48300132|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
48300133|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
47952425|NCT02746172|DEVICE|Cochlear implant with in-situ audiometry|
48108269|NCT06121830|DRUG|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily for up to 4 weeks
48300134|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
48300135|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
48300136|NCT00872716|DRUG|Quetiapine XR|100 mg single-dose Quetiapine XR
48300137|NCT00872716|OTHER|Placebo|Placebo
48300138|NCT05815121|OTHER|Acupressing|Acupuncture with placement of 4 vaccaria seeds covered with stickers on the ears and 2 on the wrists.
48300139|NCT05815121|OTHER|Control|with stickers only on the points, and the points should not be massaged.
48300140|NCT03999567|OTHER|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
48300141|NCT03999567|OTHER|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
48300142|NCT03628469|BEHAVIORAL|Proactive Health Support|Active listening, coaching and counselling
48300143|NCT01032785|DEVICE|no interventions|no interventions
47952426|NCT02334631|DRUG|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
48300144|NCT03804346|DIAGNOSTIC_TEST|Acceleromyography|At the End of Surgery, shortly before Extubation, the TOF-Ratio is measured by an independent investigator using Acceleromyography.
48300145|NCT01670851|DEVICE|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
48300146|NCT03887637|DRUG|DAAs|Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
48300147|NCT01332435|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
48300148|NCT00205504|DRUG|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
48300149|NCT01214434|DEVICE|Promiseb Topical Cream|topical non steroidal cream, twice daily
48300150|NCT01214434|OTHER|Bland emollient|Eucerin cream twice daily
48300151|NCT05032443|OTHER|Awareness survey|The 33-item questionnaire will sent to pediatric endoscopy nurses in our country. Questionnaires will be delivered to nurses through hospital visits or electronic media.
48300152|NCT06333470|OTHER|Primary angle closure diseases|Primary angle-closure suspect (PACS), which is characterized by appositional angle closure, is the earliest stage of primary angle closure diseases and can finally progress to primary angle-closure glaucoma (PACG).
48300153|NCT03333785|BEHAVIORAL|eOncoNote|"* Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~* Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~* Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year."
48300154|NCT03501355|DEVICE|Inspiratory muscle strength training|"Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
48300155|NCT03501355|DEVICE|Inspiratory muscle endurance training|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
48300156|NCT05241171|DEVICE|Fitbit|The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
48300157|NCT03819946|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
48479216|NCT06293911|OTHER|Biorepair Plus Parodontgel Intensive|The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
48479217|NCT06293911|OTHER|Placebo gel|The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
48638015|NCT03641677|DEVICE|Centralized Lung Evaluation System|Assessment of allograft lung for transplant suitability
48638016|NCT03641677|PROCEDURE|Lung Transplant|Orthotopic single or double lung transplantation.
47952427|NCT02334631|DRUG|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
47952428|NCT03400995|DRUG|AK0529|A solution containing 300 mg radiolabelled AK0529.
47952429|NCT06246760|OTHER|Exercise|Incremental exercise test until volitional exhaustion
47952430|NCT06404645|DEVICE|Near-infrared spectroscopy detection|Cranial CT confirm intracranial haematoma. Then the near-infrared spectroscopy device to collect date by red sensor probe in the corresponding position on the scalp and blue sensor probe on the opposite side of the hematoma. Collect data for 10 minutes.
47952431|NCT04096742|DRUG|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
47952432|NCT04096742|OTHER|Vehicle|Lotion not containing active ingredient (tretinoin)
48300158|NCT03819946|OTHER|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
48479218|NCT01143649|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
48638017|NCT03309111|BIOLOGICAL|ISB 1342|ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
48638018|NCT05765344|DRUG|Bulevirtide|Administered via subcutaneous injections.
48638019|NCT04731662|BEHAVIORAL|Short sleep|6-hours time-in-bed during weeknights
48638020|NCT04731662|BEHAVIORAL|Variable short sleep|Variable hours of time-in bed during weeknights
48638021|NCT06118281|DRUG|Ziltivekimab|Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
47952433|NCT05290792|BIOLOGICAL|Administration of FluMist (Live Attenuated Influenza Vaccine)|Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
47952434|NCT03455127|OTHER|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
48479219|NCT01143649|PROCEDURE|constraint induced movement therapy (CIMT)|
48479220|NCT01143649|DEVICE|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
47952435|NCT00936611|DRUG|LBH589|
48108270|NCT06121830|DRUG|Placebo|Placebo, tablet, orally, once daily for up to 4 weeks
48108271|NCT04681768|DRUG|Abemaciclib|Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
48108272|NCT01215695|DEVICE|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
47952436|NCT05312073|OTHER|Biological samples|Blood samples Superficial skin Biopsy Collection of fallen squames Tapes - stripping
47952437|NCT05312073|OTHER|Skin biopsy|healthy skin from surgery interventions
48108273|NCT01215695|DEVICE|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
48108274|NCT01370707|DRUG|Metformin|1000\~1500mg/day, 24weeks
48108275|NCT01370707|DRUG|CJ-30001/CJ-30002|0.6/1500mg\~0.9/1500mg/day, 24weeks
48108276|NCT03197337|PROCEDURE|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
48108277|NCT03432780|DRUG|Docetaxel|
47952438|NCT06228274|DEVICE|ARTHRUM 2.5%|ARTHRUM 2.5%
48108278|NCT03432780|BIOLOGICAL|Hormone and radiation therapy|
48108279|NCT03432780|RADIATION|Radiation therapy|
48108280|NCT05093712|OTHER|Educational Intervention|Watch educational video
48108281|NCT05093712|OTHER|Survey Administration|Complete surveys
48108282|NCT01252316|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
48108283|NCT01252316|OTHER|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
48108284|NCT00075972|BEHAVIORAL|Mood Tolearance|
48108285|NCT00075972|BEHAVIORAL|Mood Management|
48108286|NCT00075972|DRUG|Nicotine Replacement therapy|
47952439|NCT02627625|DRUG|Tiotropium|4 inhalations
47952440|NCT00065988|DEVICE|Dispersed phase amalgam restoration /composite restoration|
47952441|NCT00027716|DRUG|bortezomib|
48108287|NCT04203264|DIAGNOSTIC_TEST|Real-time artificial intelligence identification system|The patients swallowed the MCE with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. The magnetic steering time for passing through the pylorus was not allowed more than 15 min. The real-time auxiliary system implemented real-time processing for the output image of MCE system. Professional operators guarantee the integrity of the examination and the diagnostic results of professional endoscopist was used as the gold standard. The system diagnosis results was recorded at the same time. The sensitivity, delay time, specificity of lesions and anatomical landmarks will be analyzed.
48108288|NCT01941277|BEHAVIORAL|Current Recommendations Exercise Group|
48108289|NCT01941277|BEHAVIORAL|Intensive Exercise Group|
48108290|NCT00817830|DRUG|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
48108291|NCT00681252|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
48108292|NCT04162119|BIOLOGICAL|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
48108293|NCT02066441|DIETARY_SUPPLEMENT|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
48479221|NCT04204031|BEHAVIORAL|Presentation of the adherence record|Adherence record will be presented to participants with an actual time of use less than prescribed. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
48479222|NCT06327217|RADIATION|Bilateral hip x-ray|Patients will be asked to visit the clinic for a bilateral hip x-ray, in order to evaluate the degree os osteoarthritis.
48497872|NCT02277678|DRUG|Opioid administration morphine|
47952442|NCT06180291|OTHER|PRECOP program|"PRECOP program is the first program combining early detection of cerebral palsy with implementation of early interventions following the latest international recommendations (multidisciplinary program at home, with the possibility of intensive courses, coaching parental, in the first 2 years of life).~This comprehensive monitoring is implemented as soon as the infant arrives at home, by a multidisciplinary team and continues during the child's first 2 years. It includes:~* Follow-up organized primarily at home~* Monitoring of psychomotor development~* Screening for possible cerebral palsy~* Comprehensive support for the child's development: weight, diet, sleep...~* Reeducation, implementation of SMART type objectives (Specific, Measurable, Achievable, Achievable, Timely defined) determined with parents~* Creation of equipment if necessary: early seating installation in particular~* Parental support and guidance for optimizing early care~* Parental psychological support."
47952443|NCT05815173|DRUG|Sotorasib|Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.
47952444|NCT05815173|DRUG|Ladarixin|"Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles."
47952445|NCT00989157|DRUG|Duloxetine|Single dose of 60 mg of duloxetine
47952446|NCT00486473|DRUG|Multihance|0.5 Molar at a single dose injection
47952447|NCT00486473|DRUG|Magnevist|0.5M at a single dose injection
47952448|NCT03014557|DEVICE|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
47952449|NCT00166465|DRUG|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
47952450|NCT02890927|OTHER|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~1. Low risk patients are expected to do well and will not receive co-management.~2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
47952451|NCT03155282|PROCEDURE|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
48108294|NCT02066441|OTHER|Placebo|
48108295|NCT03353116|PROCEDURE|the mandible first|the mandible osteotomy is going to be done and fixed first
48108296|NCT03353116|PROCEDURE|the maxilla first|the maxilla osteotomy is going to be done and fixed first
48108297|NCT04135378|DRUG|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
48108298|NCT04135378|OTHER|placebo|:- included 30 students given placebo for one week before presentation.
48108299|NCT01052454|BEHAVIORAL|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
48108300|NCT02130128|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
48108301|NCT05345561|OTHER|Clinical data collection|Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
48108302|NCT05573854|DIETARY_SUPPLEMENT|Gastric emptying after an oral supplement containing carbohydrates and whey protein|Ingestion of an oral supplement containing carbohydrates and whey protein
48108303|NCT05573854|DIETARY_SUPPLEMENT|Overnight Fast|Residual Gastric Volume assessed by MRI after overnight fast (8h)
48108304|NCT02582437|OTHER|History for opioid use|
48108305|NCT06391619|OTHER|No intervention|Study is observational
48132663|NCT01979276|DRUG|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
47952452|NCT05444101|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
47952453|NCT05444101|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
47952454|NCT05444101|BEHAVIORAL|Values and committed action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
47952455|NCT02540226|DRUG|Intravenous tranexamic acid|
48108306|NCT05074615|OTHER|Cranio-Cervical Flexion Training|"Participants of this group will receive conventional training along with Cranio-cervical flexion training:~* The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks."
48108307|NCT05074615|OTHER|Conventional Therapy|"Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks"
48108308|NCT00476060|PROCEDURE|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
48479223|NCT06327217|OTHER|Questionnaires|Patients will be asked to complete questionnaires on function, quality of life and pain (the modified Harris Hip Score (mHHS), Hip Outcome Score (HOS), the World Health Organisation Quality of Life Questionnaire (WHOWOL) and Visual Analogue Scale (VAS) for pain). One question will be asked: 'How satisfied are you with the results of the surgery?' on a 10-point scale.
48638022|NCT06118281|DRUG|Placebo|Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
47952456|NCT02540226|DRUG|Topical tranexamic acid|
47952457|NCT02540226|DRUG|Intravenous saline|
48300159|NCT05322460|OTHER|CUMACA-M Program|The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
48300160|NCT02561416|BEHAVIORAL|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
48300161|NCT02561416|BEHAVIORAL|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
47952458|NCT02540226|DRUG|Topical saline|
47952459|NCT03091933|BIOLOGICAL|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
47952460|NCT05193552|DRUG|Hizentra|subjects level of immunoglobulin replacement therapy will be adjusted for bioavailability as per manufacturer's instructions
47952461|NCT06125548|OTHER|Lactation Management Model|The mother provides skin-to-skin contact to her baby 12 times a day, 8 times on the 2nd day, 4 times on the 3rd day, hot application to the breast (5 minutes), relaxation technique (3 minutes) and breast massage (5 minutes by hand milking, 2 minutes by breast massage). Head stimulation, stroking for 3 minutes) were asked.
47952462|NCT01826721|OTHER|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
47952463|NCT01015599|BEHAVIORAL|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
47952464|NCT02330965|PROCEDURE|Blood Draw|Blood draws (65 mLs \[\~4 tablespoons\] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
47952465|NCT02330965|PROCEDURE|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (\<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
48132667|NCT06117774|DRUG|Tarlatamab|Intravenous (IV) infusion
48132668|NCT06117774|DRUG|Placebo|IV infusion
48300162|NCT02561416|DRUG|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
47952466|NCT03414281|PROCEDURE|TMQLB group 1|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
48300163|NCT04337138|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
48300164|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 25 mg tablet
47952467|NCT03414281|PROCEDURE|TMQLB group 2|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
47952468|NCT03414281|PROCEDURE|TPVB|"The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
47952469|NCT03010670|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
47952470|NCT03010670|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
47952471|NCT03373071|BIOLOGICAL|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
48108309|NCT05638620|DRUG|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
48108310|NCT04021381|DIETARY_SUPPLEMENT|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
48108311|NCT04021381|DIETARY_SUPPLEMENT|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
48108312|NCT01405872|OTHER|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
48108313|NCT00819442|PROCEDURE|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
48108314|NCT03584646|DEVICE|Nokia GO Wearable StepTracker|All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
48108315|NCT03584646|OTHER|Medication Reminder|Medication reminders are sent to participants in Arm 2 on a daily basis.
48108316|NCT03584646|OTHER|Weekly Check-in appointment with study team or provider|Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
48108317|NCT03502278|BEHAVIORAL|Islamic Trauma Healing|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
48108318|NCT00562913|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
48108319|NCT01138215|BIOLOGICAL|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
48108320|NCT01291290|PROCEDURE|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
48300165|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 50 mg tablet
48300166|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 100 mg tablet
48300167|NCT03395340|DRUG|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
48300168|NCT03395340|DRUG|vehicle cream|Matching vehicle cream applied as a thin film
48300169|NCT02772497|DRUG|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
48300170|NCT03477630|BIOLOGICAL|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
48300171|NCT03477630|DRUG|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
48638023|NCT05828823|DEVICE|Hemodialysis twice weekly|Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
47952472|NCT04810481|DEVICE|BIS Complete Monitoring System|The BIS™ complete monitoring system is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS™ complete system processes raw EEG signals to produce a single number, called the BIS™ index, which correlates with the patient's level of hypnosis. A sensor placed on the patient's head transmits EEG signals to the BISx™ unit. The BIS™ unit filters and digitizes the signal, analyzes it for the artifact, and processes it using digital signal processing techniques to derive processed EEG parameters to a single Bispectral Index (BIS™), and finally sends the processed data to the monitor for display. The purpose of processing the EEG waveform data is to extract characteristic features from the complex signal that the BIS™ algorithm can utilize to derive BIS Index.
47952473|NCT01747226|OTHER|Fluoride rinse|rinse with 15 ml for 1 minute
47952474|NCT01747226|OTHER|Halita|rinsing with 15 ml for 1 minute
47952475|NCT01747226|OTHER|Meridol Halitosis|rinsing with 15 ml for 1 minute
47952476|NCT01747226|OTHER|Water|rinsing with 15ml for 1 minute
48108321|NCT03259932|OTHER|no physical activity|no physical activity
48108322|NCT03259932|OTHER|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
48108323|NCT02251613|DRUG|Olopatadine HCl ophthalmic solution, 0.1%|
48108324|NCT02251613|DRUG|Epinastine HCl ophthalmic solution, 0.05%|
48108325|NCT02999048|DRUG|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
48108326|NCT05456386|BEHAVIORAL|The Circadian Rhythm Approach to Weight Loss (CRAWL)|The Circadian Rhythm Approach to Weight Loss (CRAWL) is a behavioral intervention that is designed to provide support for behavioral change to improve sleep and feeding parameters that will lead to sustainable weight loss.
48108327|NCT01069341|DRUG|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
48108328|NCT03073499|PROCEDURE|Oncological Home Hospitalization|
48108329|NCT04519671|DRUG|Mesenchymal Stem Cells|Direct injection of adult allogeneic bone marrow derived mesenchymal stem cell product, at a dose of 75 million cells into perianal fistula(s)
48108330|NCT04519671|OTHER|Placebo|Normal saline
48108331|NCT03614611|DEVICE|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
48108332|NCT05442463|DRUG|Captopril Tablets|Captorpril challenge to each participant
48108333|NCT03181464|DRUG|Lidocaine 4%|lidocaine solution
48108334|NCT03181464|DRUG|Placebo|saline .9% injection
48108335|NCT04558437|OTHER|Questionnaire|"Questionnaire at M0 M3 M6:~PCL-5 (Post-Traumatic Stress Disorder Checklist Scale, version DSM-5) HAD (Hospital Anxiety and Depression Scale) SDS (Sheehan Disability Scales)"
48479224|NCT03965624|DRUG|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
48638024|NCT05828823|OTHER|Hemodialysis thrice weekly|Conventional hemodialysis regimen
47952477|NCT01322659|DEVICE|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
47952478|NCT01322659|DEVICE|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
48108336|NCT03806751|DRUG|[O-15]Water|All study participants with undergo brain imaging with \[O-15\]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
48108337|NCT03806751|DRUG|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
48108338|NCT03636919|OTHER|e-BOOK|Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
48108339|NCT01521013|BEHAVIORAL|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
48108340|NCT01521013|BEHAVIORAL|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
48108341|NCT03168646|PROCEDURE|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
48300172|NCT04319289|OTHER|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~* Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
47952479|NCT05578079|OTHER|Music|"Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach."
47952480|NCT05578079|OTHER|Music|Intervention-2 group will listen to lullaby.
47952481|NCT02155881|DRUG|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
47952482|NCT02155881|DRUG|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
47952483|NCT02727842|DEVICE|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
47952484|NCT02727842|DEVICE|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
47952485|NCT00611208|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
48300173|NCT04319289|DRUG|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
48108342|NCT03168646|PROCEDURE|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
48108343|NCT04674332|DRUG|Long acting insulin|long acting insulin analogue once daily at bed time
48300174|NCT04319289|OTHER|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~* Frequency: 3 days/week. The whole training lasting for 12 weeks"
48479225|NCT03389256|DRUG|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
47952486|NCT01908920|OTHER|Osteopathic manipulative treatment|
47952487|NCT01908920|OTHER|SHAM|
47952488|NCT01908920|OTHER|CONTROL|
47952491|NCT01501396|DRUG|Megestrol Acetate|
48108344|NCT04674332|DRUG|multiple dose regimen|intermediate and short acting insulin
48108345|NCT04132440|OTHER|Interview|Complete interview
48108346|NCT04132440|OTHER|Questionnaire Administration|Complete questionnaire
48108347|NCT03801551|DIAGNOSTIC_TEST|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
47952492|NCT01501396|DRUG|Mirtazapine|
47952493|NCT00747331|DRUG|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
47952494|NCT00747331|DRUG|Placebo|"Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug"
47952495|NCT02242188|DRUG|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
47952496|NCT02242188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (packed in identical sachets as active products)
47952497|NCT01118871|DRUG|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
48300175|NCT03280732|DEVICE|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
48108348|NCT06183918|DRUG|Tranexamic acid|"1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration."
48108349|NCT06183918|OTHER|Saline|3. Group: Gauze soaked with 10 cc of saline-topical. The prepared anterior nasal packing and medication administration were performed. Pressure was applied to both sides of the nose wings during the application for 10 minutes. It was checked whether the bleeding continued at the 5th and 10th minutes after anterior nasal packing and medication administration.
48300176|NCT01140542|DRUG|Roflumilast|500µg, once daily
48479226|NCT03389256|DRUG|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
48479227|NCT01123096|PROCEDURE|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
48108350|NCT05826678|DEVICE|Continuous Glucose Monitor|The Clinical Diabetes Educator (CDE) will follow up with the participants at Month 1 after the baseline study visit, at the study midpoint (Month 3), and at the end of the study (Month 6) to check CGM usage, including timely calibration and change adherence. At the end of the study, participants will be invited to complete a survey and participate in virtual interviews to assess changes in their health behaviors and the acceptability of CGM devices.
47952498|NCT01118871|DRUG|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
47952499|NCT02437812|DRUG|Metformin|Metformin with standard chemotherapy
48108351|NCT05826678|BEHAVIORAL|Finger stick glucose monitoring|Participants will adhere to the standard care protocol and continue self-monitoring of blood glucose through fingersticks as per usual practice\[46\]. The Clinical Diabetes Educator (CDE) will monitor and provide follow-up to the control group participants as per the same schedule followed for the intervention group.
48108352|NCT03099824|DRUG|GC4711 Oral Capsule G-101|82 mg (1 capsule)
48108353|NCT03099824|DRUG|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
48108354|NCT03099824|DRUG|GC4711 Oral Capsule G-101|164 mg (2 capsules)
48108355|NCT03099824|DRUG|GC4711 Oral Capsule G-101|246 mg (3 capsules)
48108356|NCT03099824|DRUG|GC4711 Oral Capsule G-111|175 mg (1 capsule)
48108357|NCT03099824|DRUG|GC4711 Oral Capsule G-112|145 mg (1 capsule)
48300177|NCT01346137|DRUG|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
48300178|NCT01823796|OTHER|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
48300179|NCT01823796|OTHER|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
48300180|NCT04764123|DIAGNOSTIC_TEST|AVNRT mapping|AV annuli mapping during AVNRT
47952500|NCT02437812|DRUG|Paclitaxel|Standard chemotherapy
47952501|NCT02437812|DRUG|Carboplatin|Standard chemotherapy
47952502|NCT05634915|DRUG|Individual ATG|Individual dose of ATG: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on population pharmacokinetic modeling). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
48108358|NCT03099824|DRUG|GC4711 Oral Capsule G-119|233 mg (1 capsule)
48108359|NCT03099824|DRUG|GC4711 Oral Capsule G-125|233 mg (1 capsule)
48108360|NCT03099824|DRUG|IV GC4711|GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
48108361|NCT04116515|BEHAVIORAL|Xbox / active video games|The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
48108362|NCT04116515|BEHAVIORAL|Animated cartoon narratives|The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
48108363|NCT04116515|BEHAVIORAL|Standard clinical care|Each clinic will provide standard clinical care to the participants.
48108364|NCT00397358|DRUG|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
48108365|NCT01134562|DRUG|Placebo|Single IV injection.
48108366|NCT01134562|DRUG|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
48108367|NCT00385801|DRUG|Risperidone|
48108368|NCT00385801|DRUG|Placebo|
48108369|NCT04551781|DRUG|20 Mg Prednisone for 14 days|20 Mg Prednisone for 14 days
48108370|NCT04551781|DRUG|control|symptomatic ttt
48108371|NCT03996746|DIAGNOSTIC_TEST|No intervention|No intervention
48479228|NCT01123096|OTHER|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
48638025|NCT01157429|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
48300181|NCT01070550|DRUG|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
48300182|NCT01554878|PROCEDURE|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
48638026|NCT01157429|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
48108372|NCT06039852|OTHER|Novel Postural Management Night-time Intervention|"Essential elements and components of PMN-TI:~* Safe and comfortable position to enable sleep~* Positioning to enable UAD overnight~* Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~* Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~* Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk."
48638027|NCT01157429|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
48638028|NCT04738669|OTHER|mHealth|The mHealth intervention includes telephonic call and SMS.
48300183|NCT03123939|BIOLOGICAL|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)
48300184|NCT04554030|BEHAVIORAL|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
48300185|NCT02082067|PROCEDURE|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
48638029|NCT04738669|BEHAVIORAL|Teach-back|While the teach-back includes counselling session related to discharge instruction including medication adherence.
48638030|NCT06425731|OTHER|Fasting|Participants (Dance for PD, in-person only) will engage in one of their routine weekly dance sessions while a portable indirect calorimeter is used for energy expenditure analysis. Before this session, participants will be asked to fast for at least 4-hours. In this way, participants in this study arm will engage in a self-controlled study design wherein they complete a 4-hour fast before engaging in an oxygen uptake assessment during their routine dance classes. During the 4-hour fasting period, participants will be asked to refrain from eating any food and drinking any beverages except for water.
48638031|NCT06425731|OTHER|No Intervention|No Intervention
48638032|NCT01189227|PROCEDURE|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
48638033|NCT01189227|PROCEDURE|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
48638034|NCT00693732|DRUG|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
48638035|NCT00693732|BEHAVIORAL|Quantitative sensory testing|Rectal Distention Stimulation
48638036|NCT03302611|BEHAVIORAL|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
47952503|NCT05634915|DRUG|ATG|ATG 10mg/kg: The total ATG dose was 10mg/kg. ATG was intravenously infused every day from day -5 to day -2. Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A, mycophenolate mofetil, and low-dose methotrexate.
48108373|NCT02054455|DIETARY_SUPPLEMENT|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
48108374|NCT02054455|DIETARY_SUPPLEMENT|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
48108375|NCT00114699|DRUG|CCR5mAb004|
48300186|NCT02082067|PROCEDURE|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
48300187|NCT02082067|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
48300188|NCT02082067|PROCEDURE|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
48300189|NCT02082067|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
48300190|NCT02082067|DRUG|Ropivacaine 0,75%|
48300191|NCT02082067|DRUG|Levobupivacaine 0,5%|
48300192|NCT02082067|DRUG|Levobupivacaine 0,125%|
48300193|NCT02082067|DRUG|Ketorolac 30mg|
48300194|NCT02082067|DRUG|Morphine|
48300195|NCT02082067|DEVICE|stimulong sono, Pajunk, Germany|
48479229|NCT05194449|OTHER|Comfort Talk® App|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
48132672|NCT06419777|DRUG|Insulin|Insulin will be used in gestational diabetics to control blood glucose levels
48300196|NCT00734422|BEHAVIORAL|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
48300197|NCT05716607|DRUG|OD dual-release Hydrocortisone|Treatment with once-daily dual-release hydrocortisone
48300198|NCT05716607|DRUG|TID Hydrocortisone|Treatment with thrice-daily conventional immediate-release hydrocortisone
48300199|NCT01844700|DRUG|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
48638037|NCT02719860|DIETARY_SUPPLEMENT|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
48638038|NCT02719860|DIETARY_SUPPLEMENT|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
48638039|NCT02719860|DIETARY_SUPPLEMENT|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
48638040|NCT05241834|DRUG|LOXO-260|Oral
47952504|NCT05977712|OTHER|Questionnaire|The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
47952505|NCT05977712|OTHER|Clinical examination|This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
47952506|NCT05977712|OTHER|Accelerometer port|Participants will be wearing an accelerometer for 9 days.
48108376|NCT04988841|DRUG|MaaT013|study is an experimental drug , produced by MaaT Pharma, and composed of pooled-donor, full-ecosystem intestinal microbiome (455 species approximately against 274 on average)
48108377|NCT04988841|DRUG|Ipilimumab|Anti cytotoxicT-lymphocyte-associated protein 4 ( immunothérapy)
48108378|NCT04988841|DRUG|Nivolumab|AntiPD1 ( immunothérapy)
48108379|NCT04988841|DRUG|MoviPrep|Osmotic laxative solution : patients take a single dose of two liters of Moviprep® or equivalent the night before the first administration of experimental treatment (Fecal microbiota transfer or placebo)
48108380|NCT04988841|DRUG|Normacol|hypertonic enema solution
48108381|NCT04988841|DRUG|Placebo of Maat013|expérimental drug placebo of MaaT013
48108382|NCT04456348|OTHER|there is no intervention|There is no intervention
48479230|NCT05194449|OTHER|Placebo App|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
48108383|NCT04960176|PROCEDURE|Acupuncture|Acupuncture will be applied by using 0,25x25mm needles.
48108384|NCT04960176|PROCEDURE|Non-invasive Sham Acupuncture|Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
48108385|NCT04633980|DRUG|Mixture 3,6% H2 in N2 (96.4%)|Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
48108386|NCT05823350|OTHER|Abdominal massage|Abdominal massage after colonoscopy
48108387|NCT03003988|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
48108388|NCT03003988|DIETARY_SUPPLEMENT|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
48108389|NCT03003988|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
48108390|NCT01414842|DEVICE|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
47952507|NCT05977712|OTHER|Eye examination|Eye fundus photo, OCT and OCT-A exams
47952508|NCT05933824|DRUG|LP-98 injection|Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
47952509|NCT04612439|DEVICE|VABB Elite 10G|If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle
47952510|NCT04612439|DEVICE|BARD 14G CNB|If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
47952511|NCT05375708|RADIATION|Stereotactic body radiation therapy (SBRT)|Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.
48108391|NCT01414842|DEVICE|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
48108392|NCT02299336|DRUG|Aflibercept|pro re nata (PRN)
48108393|NCT02299336|PROCEDURE|Focal Laser|Focal laser administered based on pre-specified criteria
48108394|NCT03608618|BIOLOGICAL|MCY-M11|Intraperitoneal administration
48108395|NCT03608618|DRUG|Cyclophosphamide|Intravenous administration for preconditioning
48108396|NCT04136496|DEVICE|Black-Eye Ink|There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
48108397|NCT05039606|DRUG|Nedaplatin|Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
48108398|NCT05039606|DRUG|Cisplatin|Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
48108399|NCT05161507|PROCEDURE|Magseed|Patients with the non-palpable histologically confirmed breast cancer lesion - the tumor lesion will be labeled with Magseed and patient will undergo breast-conserving surgery and sentinel lymph node detection with Tc99.
48479231|NCT00451152|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
48479232|NCT00451152|OTHER|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
47952512|NCT05375708|DRUG|Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)|"CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks."
48638041|NCT06298864|BEHAVIORAL|Internet-CBT|"* Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet.~* Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure to avoided situations, activities and increase in physical activity.~* Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
48479233|NCT01839370|DEVICE|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
48479234|NCT06334419|DRUG|Gaboxadol|Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)
48479235|NCT06334419|DRUG|Placebo|Two placebo capsules
47952513|NCT06540027|PROCEDURE|rectal cacer surgery|minimally invasive surgery
47952514|NCT05059795|DRUG|Albumin|Type of resuscitation fluid, dose and use of inotrope
47952515|NCT06022601|DEVICE|DNA Nudge|DNA Nudge wearable, DNA-based dietary advice
48479236|NCT05850052|OTHER|Conventional direct laryngoscopy using a Macintosh blade|Examine a patient's airway to aid placement of tracheal tube with ease.
48479237|NCT05850052|DEVICE|McGrath videolaryngoscope for rapid sequence endotracheal intubation|Visualize a patient's airway to aid placement of tracheal tube with ease.
48479238|NCT05311761|OTHER|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q\&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
48479239|NCT01333202|OTHER|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
48479240|NCT05367765|DRUG|Flumatinib|Flumatinib 600mg orally daily
48479241|NCT05367765|DRUG|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
48479242|NCT05175924|OTHER|Nanpharmacological method|Virtual Reality
48479243|NCT02997657|BEHAVIORAL|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
48479244|NCT02997657|BEHAVIORAL|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
48479245|NCT01559935|DRUG|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
48479246|NCT01559935|DRUG|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
48638042|NCT06298864|BEHAVIORAL|Internet-CL|"* Education on ACS, risk factors, its treatments and medication.~* Education and advice promoting healthy habits regarding diet, alcohol and tobacco.~* Education and advice regarding physical activity and the beneficial effects on health.~* Education regarding common emotional reactions following ACS.~* Prevention of relapse and plan forward to maintain a healthy lifestyle."
48638043|NCT04836910|OTHER|Dietary recommendations|"Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day."
48479247|NCT01559935|DRUG|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
48479248|NCT01559935|DRUG|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
48479249|NCT01559935|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
48479250|NCT01559935|DRUG|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
48638044|NCT04836910|DRUG|Oral contraceptive pills|Hormonal treatment
48638045|NCT04836910|DRUG|Metformin|Insulin resistance treatment
48638046|NCT05580562|DRUG|Dordaviprone (ONC201)|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
48638047|NCT05580562|DRUG|Dordaviprone (ONC201) + Placebo|Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
48108400|NCT05161507|PROCEDURE|Magtrace|Patients with the palpable histologically confirmed breast cancer lesion - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag. Patient will undergo sentinel lymph node detection with Tc99 and Sentimag localization system with breast surgery.
48108401|NCT05161507|PROCEDURE|Axillary lymph node metastasis - needle biopsy|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy, and later during target axillary dissection will be performed the biopsy of labeled lymph node during breast surgery.
48108402|NCT01832506|DRUG|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
48108403|NCT02905968|DEVICE|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
48108404|NCT02980718|BEHAVIORAL|intensive olfactory training|
48108405|NCT02980718|BEHAVIORAL|ordinary olfactory training|
48108406|NCT02873754|BEHAVIORAL|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
48108407|NCT02873754|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
48108408|NCT02873754|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
48300200|NCT01844700|DRUG|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
48300201|NCT04532463|DRUG|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week|To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
48479251|NCT06615895|BEHAVIORAL|Telehealth home activity|Several course activities with diverse sensory modalities are provided a week. Caregivers or caretakers need to help children participate in the course content and implement relevant suggestions at least 3-5 times a week for six weeks. The research will be conducted on an online platform. Course announcements, reminders and confirmation of work execution, through caregivers\&#39; feedback records, urge caregivers to engage in parent-child games related to sensory integration and integrated into life at home. Such high-frequency, short-term sensory activities will be adapted to the equipment available at home. It will mainly focus on movement planning, bilateral integration/crossing the midline, vestibular system , visual perception, visual-motor integration, eye movements, core strength activities and Activities focused on balance ability.
47952516|NCT06002126|DIAGNOSTIC_TEST|Xpert HPV|The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV16, HPV18/45, HPV 31/33/35/52/58, HPV51/59, HPV39/68/56/66 all with a corresponding cycle threshold.
47952517|NCT06002126|DIAGNOSTIC_TEST|S5 DNA methylation classifier|The S5 classifier is a combination of DNA methylation levels of the late regions of the L1 and L2 proteins from HPV16, HPV18, HPV31, and HPV33, as well as DNA methylation of the promotor region of the human tumor suppressor gene, Erythrocyte Membrane Protein Band 4.1 Like 3 (EPB41L3).
47952518|NCT05888454|OTHER|Integrative Group Program|The integrative group program consists of 6 in-person sessions directed by a health coach and occurring every other week, and 6 asynchronous educative sessions during a period of 12 weeks.
48108409|NCT02873754|DRUG|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
48108410|NCT02873754|DRUG|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
48108411|NCT02873754|DRUG|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
48300202|NCT02362711|DRUG|NPC-16 Standard Dosing Regimen Group|
48300203|NCT02362711|DRUG|NPC-16 Continuous Dosing Regimen Group|
48300204|NCT02362711|DRUG|Placebo Group|
48300205|NCT04291417|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
48300206|NCT02084134|DRUG|hydrocortisone|100mg at the time of surgery
48300207|NCT02084134|DRUG|dexamethasone|0.5mg every 6 hours for a total of four doses
48638048|NCT05580562|OTHER|Placebo|Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
48638049|NCT03737994|DRUG|Alectinib|Given PO
48638050|NCT03737994|DRUG|Brigatinib|Given PO
48638051|NCT03737994|DRUG|Carboplatin|Given IV
48638052|NCT03737994|DRUG|Ceritinib|Given PO
48300208|NCT04006743|BEHAVIORAL|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
48300209|NCT04006743|BEHAVIORAL|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
48638053|NCT03737994|DRUG|Cisplatin|Given IV
48638054|NCT03737994|DRUG|Crizotinib|Given PO
48638055|NCT03737994|DRUG|Ensartinib|Given PO
48638056|NCT03737994|DRUG|Lorlatinib|Given PO
48638057|NCT03737994|DRUG|Pemetrexed|Given IV
48638058|NCT02181621|DEVICE|Iodosorb|Cadexomer iodine gel
48638059|NCT02181621|DEVICE|Solosite gel|Hydrogel
48638060|NCT06631092|BIOLOGICAL|Oral DNA Vaccine|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
48300210|NCT04006743|BEHAVIORAL|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
48638061|NCT06235905|DRUG|NV-5138|NV-5138 is a novel , orally bioavailable, activator of mTORC1
48638062|NCT04508413|OTHER|KB295|KB295 is a novel glycan
48638063|NCT01300520|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
48638064|NCT01812018|DRUG|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
48638065|NCT01812018|DRUG|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
48638066|NCT01812018|DRUG|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
48108412|NCT03900819|OTHER|dexterity measurement|4 non-invasive tests will be performed
48638067|NCT05400941|BEHAVIORAL|Practice Led Intervention|This is a quality improvement intervention that includes learning collaboratives, practice facilitation, expert consultation and audit and feedback.
48638068|NCT06254495|DRUG|SGN-35C|Given into the vein (IV; intravenously)
48638069|NCT02635672|DRUG|VIP152 (BAY 1251152)|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
48638070|NCT02635672|DRUG|VIP152 (BAY 1251152) 30 mg|30 mg IV (30 minute infusion) fixed dose once weekly of a 21 day cycle.
48108413|NCT01293604|OTHER|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
48638071|NCT02635672|DRUG|Keytruda|200 mg IV fixed dose once every 3 weeks of a 21 day cycle
48638072|NCT02635672|DRUG|VIP152 (BAY 1251152) 15 mg|The starting dose of Cohort 3 will be 15 mg IV (30 minute infusion) fixed dose once weekly (15 mg/week) for 21 day cycles.
48638073|NCT05956392|BEHAVIORAL|Screen-use reduction + Sleep extension|60 minutes of a participants' daily screen-use time on school days will be repurposed for more sleep time.
48638074|NCT03442465|BEHAVIORAL|Toronto Extremity Salvage Score|Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
48638075|NCT03442465|BEHAVIORAL|Musculoskeletal Tumor Society Score|Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
48638076|NCT03442465|BEHAVIORAL|Timed Get Up and Go Test|Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
48108414|NCT03020108|OTHER|Blood sample|2 cc blood samples will be drawn from antecubital vein
47952519|NCT05888454|OTHER|Conventional treatment for T2DM|Conventional medical treatment for T2DM
47952520|NCT00694915|BIOLOGICAL|Mycobacterium w|Immunomodulator
47952521|NCT00694915|BIOLOGICAL|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
47952522|NCT02282358|DRUG|Mocetinostat|
47952523|NCT05058716|DIAGNOSTIC_TEST|blood sample|weekly blood sample - coenzym q10 levels
47952524|NCT01047670|DRUG|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
47952525|NCT02029001|DRUG|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
47952526|NCT02029001|DRUG|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
47952527|NCT02029001|DRUG|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
48108415|NCT02812459|OTHER|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
48108416|NCT02812459|OTHER|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
48108417|NCT02914522|DRUG|Filgotinib|Tablet(s) administered orally once daily
48108418|NCT02914522|DRUG|PTM filgotinib|Tablet(s) administered orally once daily
48638077|NCT03442465|DIAGNOSTIC_TEST|Orthogonal Radiographs|The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
48638078|NCT03442465|DIAGNOSTIC_TEST|Weight Bearing for lower extremities only|As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
47952528|NCT02029001|DRUG|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
47952529|NCT02029001|DRUG|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT\* or amplification /translocation of the genes and/or of the ligands.
47952530|NCT02029001|DRUG|Olaparib (300 mg BID)|"ATM, BAP1 et BRIP1 Mutation only if double hit documented; BRCA2, BRCA1, RAD51C, PALB2, RAD51D Mutation; BRCA1, BRCA2, ATM and BAP1 Loss; BRCA1, BRCA2, ATM and BAP 1 : mutation and heterozygote deletion. except for patients eligible to olaparib's available labels and reimbursements in France.~NOTE : only prostate cancer with RECIST 1.1 evaluable disease are eligible until the French price and reimbursement"
47952531|NCT02029001|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
47952532|NCT04198597|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
47952533|NCT04198597|BEHAVIORAL|Process-based Cognitive Behavioral Therapy|Please see arm/group descriptions
47952534|NCT04255030|BEHAVIORAL|Coping Together Booklets and Workbook|Dyads in this group will complete Coping-Together, a 6-week, booklet-based, self-directed coping and self-management skills training intervention. This intervention addresses key psychosocial challenges by offering evidence-based practical skills to: (a) manage symptoms, (b) cope with anxiety, (c) collaborate with the health care team, (d) engage in shared decision-making, (e) communicate with partner and family, and/or (f) obtain the community resources needed. A relaxation CD is also included, in addition to a workbook that accompanies the Coping-Together booklet-based intervention. The workbook aims at helping dyads choose a booklet relevant to their cancer-related challenges faced, find coping skills that best meet these challenges, and make a plan to use one of the coping skills successfully.
48108419|NCT01783977|BIOLOGICAL|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
48108420|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
48108421|NCT01783977|BIOLOGICAL|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
48108422|NCT01783977|BIOLOGICAL|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
48108423|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
48108424|NCT01783977|BIOLOGICAL|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
47952535|NCT04255030|BEHAVIORAL|Lay telephone coaching|Dyads will receive Coping-Together support via weekly telephone calls from a lay coach. Sessions will range between 10-15 minutes. The goal of coaching will be to provide information on how to use the workbook and booklets. Although no formal therapy will be provided, the coach will maintain a positive and encouraging attitude when interacting with participants regardless of their adherence to the intervention recommendations. The sessions will start with the coach setting a predetermined agenda based on the section of the workbook to review that week that week. Then, coaches will ask about the use of the booklets over the previous week, and ask participants about any required support or clarification in using the booklets. Sessions conclude with setting a goal related to the workbook, booklets and/or coping technique to focus on over the coming week.
47952536|NCT04255030|BEHAVIORAL|Motivational Interviewing|Six, 45-60 minute weekly telephone-based sessions with a trained Motivational Interviewing Specialist to progress toward goals. Here, dyads are given one-on-one guidance from a HCP Motivational Interviewing Specialist to practice the skills they need. Calls will focus on problem-solving principles and core components of self-management (70), including: (a) identifying dyads' concerns, (b) reviewing management efforts, (c) identifying goals, (d) identifying skills needed to achieve goals, and (e) addressing barriers to applying skills to current situations, including level of self-efficacy. At each meeting, progress, subsequent goals, and corresponding plans will be discussed.
47952537|NCT04610385|PROCEDURE|radical cystectomy with urinary diversion|surgical removal of the urinary bladder and other organs and perform a urinary shunt
47952538|NCT00839852|DRUG|Cariprazine|Cariprazine was supplied in capsules.
47952539|NCT06438939|OTHER|Biopsy for diagnostical purposes|Incisional biopsy is the current golden standard for OPMD/OSCC diagnosis. Yet, the site it shall be performed is choosen by clinician at naked eyes. We will compare and study the results of performing the common golden standard biopsy site when guided by NBI.
47952540|NCT04108871|PROCEDURE|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
47952541|NCT05254808|DRUG|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
47952542|NCT05254808|DRUG|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
47952543|NCT05653037|DRUG|RBD4059|Subcutaneously Administered RBD4059 in Healthy Subjects.
47952544|NCT05653037|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
48638079|NCT03442465|DIAGNOSTIC_TEST|Range of Motion|As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
47952545|NCT05829031|BEHAVIORAL|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
47952546|NCT03388931|RADIATION|Radiation Therapy|Increased radiation therapy dose
47952547|NCT03388931|COMBINATION_PRODUCT|Chemotherapy|Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
47952548|NCT03687112|OTHER|non ontervention / observational study|non intervention
47952549|NCT04925726|OTHER|Land based exercise|The patients who had land based exercise
48638080|NCT02250573|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
48638081|NCT05225012|OTHER|Acceptance and Commitment Therapy|Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
47952550|NCT04925726|OTHER|Water based exercise|The patients who had water based exercise
47952551|NCT00709657|DRUG|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
47952552|NCT00446615|BEHAVIORAL|computer decision support tool|
47952553|NCT00446615|BEHAVIORAL|audit and feedback|
47952554|NCT00446615|BEHAVIORAL|group learning session|
47952555|NCT00004006|BIOLOGICAL|filgrastim|
47952556|NCT00004006|DRUG|carboplatin|
47952557|NCT00004006|DRUG|cyclophosphamide|
47952558|NCT00004006|DRUG|doxorubicin hydrochloride|
47952559|NCT00004006|DRUG|etoposide|
48108425|NCT06345417|OTHER|Patient Blood Management (PBM)|PBM is a strategy to manage the participant's own blood. Its focus is on anemia, bleeding and coagulation management.
47952560|NCT00004006|DRUG|topotecan hydrochloride|
47952561|NCT00004006|PROCEDURE|autologous bone marrow transplantation|
48300211|NCT04006743|BEHAVIORAL|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
48300212|NCT04006743|BEHAVIORAL|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
48300213|NCT01734993|DRUG|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
48300214|NCT02834403|DRUG|L-NMMA|Nitric oxide synthase inhibitor
48300215|NCT02834403|DRUG|Docetaxel|Mitotic inhibitor, cytotoxic
48300216|NCT02834403|DRUG|Amlodipine|Long-acting calcium channel blocker
48300217|NCT02834403|DRUG|Pegfilgrastim|Colony-stimulating factor
48300218|NCT02834403|DRUG|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
48300219|NCT02112162|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/MRI
48300220|NCT02112162|DEVICE|positron emission tomography|Undergo FDG PET/MRI
48300221|NCT02112162|DEVICE|magnetic resonance imaging|Undergo FDG PET/MRI
48638082|NCT03852615|DIAGNOSTIC_TEST|Pre operation Blood sample for AMH|Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
48108426|NCT06345417|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
48638083|NCT03852615|DIAGNOSTIC_TEST|3 month post operation blood sample for AMH|Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
48300222|NCT02112162|OTHER|laboratory biomarker analysis|Correlative studies
48300223|NCT03511261|DRUG|10% Curcumin mucoadhesive gel|Group 1 10%of mucoadhesive gel for topical application two times per day.
48300224|NCT03511261|DRUG|Curcumin capsules 500mg|Group 2 curcumin 500 mg capsules for oral intake two times per day
48300225|NCT03511261|DRUG|5% curcumin mucoadhesive gel + Curcumin capsules 250 mg|Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day
48300226|NCT03511261|DRUG|Placebo capsule|Group 4 placebo capsules for oral intake two times per day
48300227|NCT02706093|OTHER|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at \~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
48638084|NCT00602641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48638085|NCT00602641|DRUG|Lenalidomide|Given PO
48638086|NCT00602641|DRUG|Melphalan|Given PO
48638087|NCT00602641|DRUG|Prednisone|Given PO
48638088|NCT00602641|OTHER|Quality-of-Life Assessment|Ancillary studies
47952562|NCT00004006|RADIATION|radiation therapy|
47952563|NCT04032548|DRUG|Placebo mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
47952564|NCT04032548|DRUG|Propolis mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
48300228|NCT02706093|OTHER|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
48300229|NCT02706093|OTHER|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax \[25min; \~150kcals; 4d/wk\]
48300230|NCT02706093|OTHER|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax \[15min; \~90kcals; 4d/wk\]
48300231|NCT01605071|DRUG|Estradiol|"1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo"
48300232|NCT00319618|DRUG|Gefitinib|
48300233|NCT00319618|DRUG|Docetaxel|
48300234|NCT02816710|DRUG|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
47952565|NCT04032548|DRUG|Chlorhexidine mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
47952566|NCT05745623|DRUG|ICP-723|ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
47952567|NCT06283524|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
47952568|NCT03417219|BEHAVIORAL|Education and Skill Building Rehabilitation-mobile (ESBR-m)|Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
48300235|NCT01396408|DRUG|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
48300236|NCT01396408|DRUG|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
48300237|NCT01004146|PROCEDURE|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
48638089|NCT00602641|DRUG|Thalidomide|Given PO
48638090|NCT05156125|DRUG|VTX002|Dose A tablet administered orally once daily
48638091|NCT05156125|DRUG|VTX002|Dose B Tablet administered orally once daily
48638092|NCT05156125|DRUG|Placebo|Placebo Tablet for VTX002 administered orally once daily
48638093|NCT02362412|DRUG|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
48638094|NCT03391323|DEVICE|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
48638095|NCT03391323|DEVICE|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
48108427|NCT05042076|DRUG|BK-specific T cells from Donor Lymphocytes|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."
48108428|NCT00623506|DRUG|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
48638096|NCT06410807|OTHER|Focus groups|The present study consists of 5 focus groups over 3 waves to inform the development and refinement of internet-based mindfulness (iMBSR) and lifestyle education (iLifeEd) protocols for use in future clinical trials. 50% females and 50% minoritized participants will be recruited to ensure representation across sex and race. For all focus groups, adults (over the age of 50 years) who report SCD will be recruited. Specifically, the Everyday Cognition Questionnaire (E-Cog) will be administered to quantify informant-reported deficits in cognitive functioning.
48638097|NCT04065256|OTHER|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
48638098|NCT04065256|OTHER|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
48638099|NCT04738162|DRUG|5-Aminolevulinic Acid Hydrochloride, Oral|Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
48108429|NCT00623506|DRUG|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
48479252|NCT06369649|DEVICE|Coolsense and Buzzy|Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.
48108430|NCT01526642|DEVICE|Non Invasive Ventilation|NIV during night
48108431|NCT04628650|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
48108432|NCT01148719|OTHER|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
48479253|NCT04025684|OTHER|Oral B Indicator 123|Manual toothbrush (medium bristle stiffness; compact head, UK market).
48108433|NCT02734628|DRUG|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
48108434|NCT02734628|DRUG|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
48108435|NCT03814668|DIETARY_SUPPLEMENT|Probiotic|Intake of probiotic
48108436|NCT03814668|DIETARY_SUPPLEMENT|Lactase|Intake of lactase
48108437|NCT03814668|OTHER|Placebo|Intake of placebo
48108438|NCT02830750|PROCEDURE|Ablation|
48108439|NCT01114919|BEHAVIORAL|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
48108440|NCT01114919|BEHAVIORAL|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
48108441|NCT05469802|BIOLOGICAL|Purified Inactivated Zika Virus Vaccine (PIZV)|PIZV vaccine with aluminium hydroxide adjuvant IM injection.
48108442|NCT05469802|OTHER|Placebo|Placebo (normal saline (0.9% NaCl) IM injection.
48479254|NCT04025684|OTHER|Dr Best Original|Manual toothbrush (medium bristle stiffness; regular head, German market)
48479255|NCT04025684|OTHER|Dr Best Multi Expert|Manual toothbrush (medium bristle stiffness; compact head, German market)
48479256|NCT04025684|OTHER|parodontax Interdental|Manual toothbrush (soft bristle stiffness; compact head, German market)
48479257|NCT06617390|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
48479258|NCT05724446|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
48479259|NCT05724446|DRUG|Prednisolone acetate ophthalmic suspension, 1%|Microfine sterile ophthalmic suspension of dense and whitish appearance.
48108443|NCT01456936|DRUG|Placebo|Triple dummy placebo for each treatment arm
48638100|NCT05835557|OTHER|BFR-ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Blood flow restriction will be applied for 2 mins during the passive rest at 80% of limb occlusion pressure.
48108444|NCT01456936|DRUG|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
48108445|NCT01456936|DRUG|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
48638101|NCT05835557|OTHER|ST|Undergo 9 sessions of high intensity short interval training involving 3 sets of 8-10 repetitions of 30 secs interval cycling and 30 secs recovery at 100-110% of maximal aerobic power. In between sets there will be 3 mins of passive rest. Cycling will be conducted in an environmental chamber and participants informed that the altitude is set to 2500m - actual altitude will be sea level.
48638102|NCT06569264|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. Followed by inspection of extraction socket integrity, using a William's graduated periodontal probe. Extracted teeth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries or restorations using a high-speed fine finishing stone and saline irrigation. The pulp chamber will be cleaned with sterile endodontic files. Teeth will be ground, using hand bone mill.The (ADDG) particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralized then washed twice in saline and dried with sterile gauze. For i-PRF blood will be withdrawn in plastic tubes. The tube will be centrifuged at around 700 RPM for 3 minutes, and extraction socket will be filled with the graft material.
48479260|NCT02717078|OTHER|Diet Therapy|The intervention for both study groups will be a change in diet.
48300238|NCT02914743|BEHAVIORAL|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
48300239|NCT02914743|PROCEDURE|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
48300240|NCT02186327|BEHAVIORAL|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
47952569|NCT03417219|BEHAVIORAL|Usual Care (UC)|"Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
47952570|NCT00932126|DRUG|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
47952571|NCT04020588|DRUG|Celecoxib 200mg|Will be administered for 6 weeks
47952572|NCT04020588|DRUG|Placebo oral capsule|Will be administered for 6 weeks
48300241|NCT03883048|OTHER|Observation of bronchiectasis with pulmonary hypertension|
48300242|NCT04027465|DIETARY_SUPPLEMENT|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
48300243|NCT02461485|OTHER|Fermented milk product containing Probiotics|2 pots/day during 28 days
48300244|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
47952573|NCT04020588|DRUG|Minocycline 100mg|Will be administered for 6 weeks
47952574|NCT04326829|DRUG|QL1604|QL1604, IV infusion
47952575|NCT01103336|DRUG|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"* Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
47952576|NCT02056639|DEVICE|Bioteque cup pessary|
47952577|NCT01669499|DRUG|Dexamethasone acetate|
47952578|NCT01669499|DRUG|Placebo|
48300245|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
48479261|NCT00099268|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
48479262|NCT00099268|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
48479263|NCT03381937|OTHER|speech trial|speech trial during different ventilation conditions
48479264|NCT03829007|DIAGNOSTIC_TEST|PD-L1 imaging|89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection
48479265|NCT03829007|DRUG|Durvalumab|Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
48479266|NCT04741152|PROCEDURE|Pancreatic resection|Different pancreatic resections
48479267|NCT04528576|DEVICE|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
47952579|NCT02740439|OTHER|Avocado|The intervention meals will contain 1 large avocado.
47952580|NCT02740439|OTHER|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
47952581|NCT00579098|DRUG|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
47952582|NCT00579098|DRUG|Placebo|Placebo tablet taken by mouth once daily for 90 days
47952583|NCT00978770|DRUG|systemic chemotherapy|
47952584|NCT00978770|PROCEDURE|diffusion-weighted magnetic resonance imaging|
47952585|NCT00978770|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
47952586|NCT00978770|PROCEDURE|magnetic resonance spectroscopic imaging|
47952587|NCT00978770|PROCEDURE|neoadjuvant therapy|
47952588|NCT03980977|OTHER|skin biopsy|"skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G)."
47952589|NCT03980977|OTHER|tumor biopsy|an additional tumor sample will be taken during programmed diagnostic procedure.
47952590|NCT03980977|OTHER|blood sample|blood sample will be taken for biological collection
47952591|NCT02016573|DEVICE|Renal Denervation|Renal Denervation Catheter
48108446|NCT01456936|DRUG|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
48108447|NCT03498170|DRUG|BCT197|Single dose of BCT197
48108448|NCT03498170|DRUG|Itraconazole 200 mg|Single dose of itraconazole
48108449|NCT01802632|DRUG|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
48108450|NCT01270633|DEVICE|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
48108451|NCT01270633|OTHER|Standard of Care|Following sharp debridement, moist wound therapy
48108452|NCT03910517|OTHER|No intervention|No intervention
48108453|NCT04956224|BIOLOGICAL|VLA2001|"whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide (Wuhan strain)~2 vaccinations 28 days apart~Booster Vaccination on Visit B1"
48108454|NCT01320436|DIETARY_SUPPLEMENT|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
48108455|NCT01320436|DRUG|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
48108456|NCT01563991|PROCEDURE|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
48108457|NCT01563991|PROCEDURE|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
48108458|NCT02061930|PROCEDURE|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
48108459|NCT05602909|DEVICE|Guided biaxial alveolar distraction device|A crestal incision will be done, a surgical guide will be placed to assist the correct position of osteotomy, an Extraosseous alveolar distractor will be placed on the ridge to mark screw sites and then will be removed, A distractor will be stabilized to the basal segment with a monocortical screw.
48108460|NCT01943799|BIOLOGICAL|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
47952592|NCT04354103|DRUG|Atomoxetine|Atomoxetine
48638103|NCT06569264|PROCEDURE|Alveolar ridge preservation using vitamin C with dentin graft and i-PRF|Flapless atraumatic extraction. After thorough mechanical cleaning, the sockets will be rinsed with 5 ml of an aqueous 0.125% chlorhexidine digluconate solution, followed by a 5 ml sterile saline rinse to remove tissue debris from the socket. 25mM of pure vitamin C in Fresh blood, and the tube will be centrifuged at around 700 RPM for 3 minutes. Extraction socket will be filled with the corresponding graft material and the dentin graft.
47952593|NCT02169479|DRUG|BIA 9-1067|OPC, Opicapone
47952594|NCT02169479|DRUG|Placebo|PLC, Placebo
48108461|NCT01943799|DRUG|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
48108462|NCT00232635|DRUG|A-60444|
48108463|NCT02375048|RADIATION|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
48132680|NCT04541303|DRUG|Tranexamic acid|tranexamic acid diluted to concentration of 25ml/mg
47952595|NCT02169479|DRUG|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
47952596|NCT01934972|OTHER|CR + DCS (D-cycloserine)|CR + DCS
47952597|NCT01934972|OTHER|CR + placebo|CR + placebo
47952598|NCT02954627|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
47952599|NCT02869074|GENETIC|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
47952600|NCT05626062|DEVICE|Toilet alarm|A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
47952601|NCT02713373|BIOLOGICAL|Cetuximab|Given IV
47952602|NCT02713373|OTHER|Laboratory Biomarker Analysis|Correlative studies
47952603|NCT02713373|BIOLOGICAL|Pembrolizumab|Given IV
47952604|NCT03395392|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
47952605|NCT03395392|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
47952606|NCT01272973|DRUG|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
47952607|NCT01272973|DRUG|placebo|Placebo (oral) administered once daily for 10 weeks.
47952608|NCT01272973|DRUG|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
47952609|NCT01931618|BEHAVIORAL|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
48108464|NCT02375048|RADIATION|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
48108465|NCT05039723|DRUG|Radiesse, Xeomin, Belotero|Rejuvenation with Radiesse, Xeomin, Belotero
48108466|NCT03890263|BEHAVIORAL|Chronic Pain Self-Management Support|"Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program."
48108467|NCT03773120|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
48108468|NCT01424332|DRUG|Darexaban|oral
48108469|NCT01424332|DRUG|Acetyl Salicylic Acid (ASA)|oral
48108470|NCT05830604|PROCEDURE|Occlusal Splint Treatment- Non Invasive treatment|Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
48479268|NCT04394338|OTHER|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
48479269|NCT05032326|DRUG|Follow-up study of the treated cohort|follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
48108473|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions at sea|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) at sea Standard pharmacological treatment usually provided to patients with fibromyalgia."
48108474|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions in nature|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) 4 face-to-face sessions (1 per mounth) in nature Standard pharmacological treatment usually provided to patients with fibromyalgia."
48479270|NCT05032326|OTHER|Follow-up study of the untreated cohort|follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
48479271|NCT04119219|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
48638104|NCT02763748|PROCEDURE|Laparoscopic endoscopy combined surgery|
48638105|NCT02763748|PROCEDURE|laparoscopic and endoscopic cooperative surgery|
48638106|NCT02763748|PROCEDURE|Single-arch laparoscopic and endoscopic cooperative surgery|
47952610|NCT01931618|BEHAVIORAL|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
47952611|NCT01931618|BEHAVIORAL|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
47952612|NCT06453902|DRUG|TGRX-678|All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
47952613|NCT03813043|DRUG|Midazolam injection|Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
47952614|NCT05342935|DEVICE|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
47952615|NCT06135480|OTHER|subcision ,PRP or saline and microneedling|minimally invasive procedures
47952616|NCT02499276|DEVICE|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
47952617|NCT02423109|DEVICE|fanfilcon A|contact lens
48479272|NCT03900117|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
48638107|NCT04882215|BEHAVIORAL|GMT combined with WMU Training|"GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial."
48108475|NCT05395832|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~Pain neuroscience education (15 min.) Cognitive restructuring (15 min.) Mindfulness techniques (15 min.) Physical exercise(15 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
48479273|NCT03900117|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
48638108|NCT05512377|DRUG|brigimadlin|brigimadlin
48638109|NCT01284088|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
48638110|NCT01284088|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
48638111|NCT01336972|DRUG|Tolvaptan|Tolvaptan was supplied as 15 and 30 mg tablets.
47952618|NCT02423109|DEVICE|enfilcon A|contact lens
47952619|NCT02520830|DIETARY_SUPPLEMENT|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
47952620|NCT02520830|DIETARY_SUPPLEMENT|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
47952621|NCT06034847|DEVICE|Mechanical thrombectomy in proximal large vessels|mechanical thrombectomy with retrievable stents to remove clots in proximal large vessels, combined or not with distal aspiration, combined or not with IV thrombolytics
48108476|NCT05654012|DEVICE|MRI|Grey Matter Volume (T1) Resting state BOLD
47952622|NCT06034847|DEVICE|Rescue mechanical thrombectomy in distal vessels|In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
47952623|NCT05698056|OTHER|No intervention.|No intervention.
47952624|NCT03429660|OTHER|Medical information|"The information collected are about :~* Introduction or non-introduction of treatment~* Cumulative dose of treatment~* Drug dispensation and withdrawal~* Hospitalization reason~* Safety information~* Demographic data (date of death)"
47952625|NCT02617043|RADIATION|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
47952626|NCT06393036|DEVICE|Continuous Positive Airway Pressure|The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
47952627|NCT01787422|OTHER|Traditional versus Telemedicine office visit|
47952628|NCT05105230|DIAGNOSTIC_TEST|soluble programmed death 1biomarker|soluble programmed death 1biomarker
47952629|NCT01315964|DIETARY_SUPPLEMENT|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
48132681|NCT04541303|DRUG|normal saline|0.9% sodium chloride
48479274|NCT01741467|BEHAVIORAL|RT-CGM|Dexcom Seven+
48479275|NCT02156921|OTHER|App-based training|
48479276|NCT06614699|OTHER|abdominal fat and muscle area|Abdominal fat and muscle area were calculated based on abdominal CT.
48300246|NCT02461485|OTHER|Non fermented Milk Product|2 pots/day during 28 days
48479277|NCT06132048|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
48479278|NCT01796964|DRUG|ESBA1008 solution|For intravitreal (IVT) injection
48479279|NCT01796964|DRUG|Aflibercept|For intravitreal (IVT) injection
47952630|NCT03582878|DRUG|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
47952631|NCT03582878|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
48638112|NCT00281853|PROCEDURE|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
48638113|NCT03526432|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
48638114|NCT03526432|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
47952632|NCT00248131|DRUG|Octreotide acetate in microspheres|
47952633|NCT01032174|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
47952634|NCT01032174|DRUG|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
47952635|NCT05143450|OTHER|Manual Pressure|In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
47952636|NCT00011973|DRUG|fenretinide|
48479280|NCT01606059|DRUG|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
47952637|NCT00671333|PROCEDURE|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
47952638|NCT00671333|PROCEDURE|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
47952639|NCT01488305|DIETARY_SUPPLEMENT|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
47952640|NCT01488305|OTHER|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
47952641|NCT04567823|DIETARY_SUPPLEMENT|Smoothie with microalgae|Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
47952642|NCT01497431|DIETARY_SUPPLEMENT|Selenium|Given PO
48479281|NCT01606059|DRUG|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
48479282|NCT05305768|DRUG|IncobotulinumtoxinA|Injection of glabellar rhytids
48479283|NCT03764735|DRUG|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
47952643|NCT01497431|OTHER|Placebo|Given PO
47952644|NCT01497431|OTHER|Laboratory Biomarker Analysis|Correlative studies
48479284|NCT03764735|DRUG|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
48479285|NCT03764735|DRUG|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
48479286|NCT05606952|DEVICE|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
48479287|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|250 mg
48479288|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|500 mg
48479289|NCT05927779|DRUG|TFX06 tablet|TFX06 tablet taken orally
48479290|NCT04143295|DRUG|Diiodothyropropionic acid|Drug Administration
48479291|NCT06483737|DRUG|Human albumin infusion at a modified dosage|Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.
48479292|NCT06483737|DRUG|Human albumin infusion at a routine dosage|Participants receive intravenous infusion of human albumin according to the current clinical practice.
48479293|NCT06483737|DRUG|Lactulose|All participants will receive standard treatment of overt HE according to the current practice guideline.
48479294|NCT06483737|DRUG|Rifaximin|All participants will receive standard treatment of overt HE according to the current practice guideline.
48479295|NCT06483737|DRUG|Ornithine Aspartate|All participants will receive standard treatment of overt HE according to the current practice guideline.
48479296|NCT06483737|DRUG|Branched-Chain Amino Acids|All participants will receive standard treatment of overt HE according to the current practice guideline.
48479297|NCT06483737|DRUG|Arginine|All participants will receive standard treatment of overt HE according to the current practice guideline.
48479298|NCT06483737|DEVICE|plasma exchange|All participants will receive standard treatment of overt HE according to the current practice guideline.
48479299|NCT02930629|DEVICE|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~* Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~* The TOF force transducer will be placed on the volar aspect of the thumb.~* The TOF Watch leads will be attached to the ECG electrodes.~* A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~* Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
47952645|NCT01497431|OTHER|Pharmacological Study|Correlative studies
48479300|NCT06466798|DRUG|Nivolumab|Nivolumab infusions will be given intraventricularly once every other week for 12 weeks. Dosing will be based upon patient body weight.
48479301|NCT06466798|DRUG|Methotrexate|2 mg methotrexate infusions will be given intraventricularly daily for 4 consecutive days per week every other week for 12 weeks.
48479302|NCT06466798|DRUG|5-Azacytidine|10 mg 5-Azacytidine infusions will be given intraventricularly once weekly for twelve consecutive weeks.
48108477|NCT05654012|DEVICE|Thermal Stimuli|The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
48108478|NCT05654012|DEVICE|Pressure stimuli|Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
48300247|NCT04479501|OTHER|Asthma exacerbation related hospitalization|Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
48108479|NCT05654012|BEHAVIORAL|Pain ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
48108480|NCT05654012|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
48108481|NCT05654012|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
48479303|NCT01362426|DRUG|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
48479304|NCT06452329|DRUG|Nivolumab|As prescribed by treating physician
48638115|NCT04776252|DRUG|MK-8591A|FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
48638116|NCT01857115|DRUG|Carfilzomib|
48638117|NCT01857115|DRUG|Cyclophosphamide|
48638118|NCT01857115|DRUG|Dexamethasone|
48638119|NCT05629338|COMBINATION_PRODUCT|Autologous Spray Dried Plasma|Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers
48638120|NCT04934865|DEVICE|Patients treated for their lung cancer.|"In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.~In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator."
48108482|NCT05654012|DIAGNOSTIC_TEST|Hormonal assessment|Blood samples will be collected for analyses of sex hormone levels
48108483|NCT05654012|BEHAVIORAL|Migraine-related measures|Adolescents with migraine will complete questions regarding their headache frequency and migraine symptoms.
48479305|NCT02105155|DRUG|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
48479306|NCT02105155|DRUG|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
48638121|NCT04720170|PROCEDURE|Revascularization|Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
48638122|NCT03322891|OTHER|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
48108484|NCT05654012|BEHAVIORAL|Neural assessments|MRI and fMRI scans
48108485|NCT05654012|DIAGNOSTIC_TEST|Pubertal status|Pubertal status will be assessed using the self-reported Physical Developmental Scale-
48300248|NCT00950690|DRUG|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
48300249|NCT06150105|OTHER|Exercise training|Intense endurance training
48300250|NCT03591796|DEVICE|HFOV|Ventilated infants were randomized to HFOV
48300251|NCT03591796|DEVICE|CMV|Ventilated infants were randomized to CMV.
48300252|NCT02222987|DRUG|Terbogrel|
48300253|NCT02222987|DRUG|Clopidogrel|
48300254|NCT01809262|DRUG|single dose of 5 mcg|solution for inhalation
48300255|NCT01809262|DRUG|single dose of placebo|solution for inhalation
48300256|NCT01809262|DRUG|single dose of 40 mcg|solution for inhalation
48638123|NCT03322891|OTHER|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
48638124|NCT00028288|DRUG|Daclizumab|
48300257|NCT01809262|DRUG|single dose of 20 mcg|solution for inhalation
48479307|NCT05690815|DRUG|Descovy|Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
48638125|NCT02258919|PROCEDURE|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
48638126|NCT02258919|PROCEDURE|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
48638127|NCT04171310|DRUG|SAR442168|Pharmaceutical form:oral solution Route of administration: Oral
48638128|NCT02920554|PROCEDURE|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
48300258|NCT01809262|DRUG|single dose of 2 mcg|solution for inhalation
48300259|NCT01809262|DRUG|single dose of 10 mcg|solution for inhalation
47952646|NCT01497431|DRUG|Methylselenocysteine|Given PO
48479308|NCT06615232|BEHAVIORAL|Vaginal washing cessation|Participants will attend weekly small group (\~10 women per group) sessions that are structured using the transtheoretical model of behavioral change to promote vaginal washing cessation.
48300260|NCT00000800|DRUG|Methadone hydrochloride|
47952647|NCT00479323|BIOLOGICAL|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
47952648|NCT00251212|BEHAVIORAL|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
47952649|NCT04332133|PROCEDURE|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
47952650|NCT00026962|PROCEDURE|measuring estradiol and progesterone levels in saliva|
47952651|NCT02000934|DRUG|TAK-659|TAK-659 tablet
47952652|NCT02296281|DRUG|Pirfenidone|
48300261|NCT00000800|DRUG|Zidovudine|
48479309|NCT04372719|DRUG|H3N2|
48479310|NCT04060511|DRUG|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
48479311|NCT03920683|OTHER|Data collection|Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
48479312|NCT04403516|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
48300262|NCT02538666|BIOLOGICAL|Nivolumab|
48300263|NCT02538666|BIOLOGICAL|Ipilimumab|
48479313|NCT04403516|DRUG|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
48479314|NCT00759434|PROCEDURE|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
48479315|NCT00759434|PROCEDURE|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
48479316|NCT05952453|DRUG|Carboplatin|neoadjuvant treatment , followed by surgery, then maintenance chemotherapy
48479317|NCT05952453|DRUG|olaparibp, embro|maintenance chemotherapy : olaparib, pembro
48479318|NCT01850719|PROCEDURE|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
48479319|NCT01850719|OTHER|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
47952653|NCT05731323|DRUG|D-cycloserine|Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).
47952654|NCT05731323|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
47952655|NCT00092157|DRUG|MK0733, simvastatin|
47952656|NCT00092157|DRUG|Comparator: simvastatin|
47952657|NCT03061097|BIOLOGICAL|Autologous fecal microbiota transplant (Auto-FMP Enema)|FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.
47952658|NCT03061097|OTHER|Placebo Enema Preparation|The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
47952659|NCT04032392|BIOLOGICAL|autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
47952660|NCT05909683|DIAGNOSTIC_TEST|Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.|After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.
47952661|NCT05909683|OTHER|Standard of Care|Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.
48300264|NCT02538666|OTHER|Placebo|
48300265|NCT00849693|DRUG|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
48300266|NCT00849693|DRUG|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
48300267|NCT00849693|DRUG|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
48300268|NCT00849693|DRUG|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
48300269|NCT02137434|OTHER|Dietary calcium|Dietary calcium from skimmed milk
48638129|NCT02920554|PROCEDURE|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
47952662|NCT00549380|DEVICE|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
47952663|NCT03685695|OTHER|Laboratory Biomarker Analysis|Correlative studies
47952664|NCT03685695|DEVICE|Monitoring Device|Wear Fitbit Charge 2
47952665|NCT03685695|OTHER|Physical Activity|Complete aimed walking steps
47952666|NCT03685695|OTHER|Quality-of-Life Assessment|Ancillary studies
47952667|NCT03685695|OTHER|Questionnaire Administration|Ancillary studies
47952668|NCT01330784|DRUG|hMG-HP|
48638130|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1 mg/kg CDP6038 IV"
48638131|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~0.1mg/kg CDP6038 IV"
47952669|NCT04779918|DEVICE|OviTex Reinforced Tissue Matrix|All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.
48108486|NCT03419325|GENETIC|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
48108487|NCT03419325|DIAGNOSTIC_TEST|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
48108488|NCT03646006|DRUG|Bupivacaine|10 mL (5mg/mL)
48108489|NCT03646006|DRUG|Placebo|10 mL normal saline
48479320|NCT03171441|DIAGNOSTIC_TEST|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
48479321|NCT03171441|DIAGNOSTIC_TEST|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
48479322|NCT02804282|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
48479323|NCT00442546|DRUG|pregabalin|150 milligram (mg)/ day (double blind)
48479324|NCT00442546|DRUG|pregabalin|300 mg/day (double blind)
48479325|NCT00442546|DRUG|Placebo|Placebo
48479326|NCT05990504|DEVICE|ultrasound real-time guidance combined with Dural Puncture Epidural Labor Anagesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
48638132|NCT01009242|BIOLOGICAL|CDP6038|"Single dose:~1.0mg/kg CDP6038 SC"
48638133|NCT01009242|OTHER|Placebo IV|"Single dose:~Placebo IV"
47952670|NCT01825070|DIETARY_SUPPLEMENT|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
47952671|NCT00257465|BIOLOGICAL|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
47952672|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
47952673|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|2.5 million cells
47952674|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0.5 million cells
47952675|NCT00257465|BIOLOGICAL|Autologous, DNP-Modified Vaccine|0 cells
47952676|NCT02037958|DEVICE|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
47952677|NCT02037958|DEVICE|Endotracheal Tube|Patients who receive endotracheal intubation
47952678|NCT03605212|DRUG|Febuxostat|Intervention is orally administered to patients in this arm.
47952679|NCT04619927|GENETIC|Direct CYP2C19 genotyping|CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.
47952680|NCT04619927|GENETIC|CYP2C19 genotyping at the end of the study|Blood-based CYP2C19 genotyping will be performed at the end of the study
47952681|NCT04619927|DRUG|Poor metabolisers|Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
47952682|NCT04619927|DRUG|Intermediate metabolisers|Clopidogrel 75mg twice daily
47952683|NCT04619927|DRUG|Normal metabolisers and unknown metaboliser state|Clopidogrel 75mg once daily
47952684|NCT04638660|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
47952685|NCT04638660|DRUG|Phentolamine Ophthalmic Solution Vehicle (Placebo)|Topical sterile ophthalmic solution
47952686|NCT06255184|BEHAVIORAL|Sernity intervention|Serenity Therapy is a holistic intervention that boosts psychological well-being and emotional balance through relaxation techniques, mindfulness, and guided imagery
47952687|NCT02910115|OTHER|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
47952688|NCT02910115|DRUG|Pitocin|Pitocin is administered intravenously according to the usual protocol.
48108490|NCT02777632|PROCEDURE|Living donor liver transplantation|
48108491|NCT02274493|DEVICE|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
48108492|NCT02274493|PROCEDURE|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
48108493|NCT02274493|PROCEDURE|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
48108494|NCT02274493|BEHAVIORAL|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
48638134|NCT01009242|OTHER|Placebo SC|"Single dose:~Placebo SC"
48638135|NCT01009242|DRUG|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
48638136|NCT01009242|DRUG|Methotrexate|Individual stable doses of methotrexate.
48638137|NCT05649553|BEHAVIORAL|digital game and video animation based diabetes education|While creating the digital game and video animation, an agreement was made with a software company and this company was responsible for the software and repair of the game. Digital games and video animations cover the basic educational topics of Type 1 diabetes. Expert opinions were received from experts in the field of Child Health and Disease Nursing to ensure the suitability of the content of the educational material. The name of the game site and how to use it were explained to the children in the intervention group by the researcher. In addition, children in the intervention group were given usernames and passwords to log in to the site. Game Sections; What is Diabetes? Medical Nutrition Treatment in Diabetes, Insulin Treatment and Application, Exercise and Physical Activity in Diabetes, Complications of Type 1 Diabetes Mellitus, Diabetes Management at School.
48300270|NCT02137434|DIETARY_SUPPLEMENT|Supplementary calcium|Supplementary calcium from calcium carbonate
48300271|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 200mg PO is given
47952689|NCT01501331|DEVICE|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
47952690|NCT01408264|DEVICE|Conventional 0.035 guidewire|0.035 guidewire
47952691|NCT01408264|DEVICE|Olympus Visiglide 0.025 guidewire|0.025 guidewire
48300272|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 400mg PO is given
48300273|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 600mg PO is given
48300274|NCT02644525|DRUG|Placebo|A single dose of placebo pill is given
47952692|NCT00703196|DIETARY_SUPPLEMENT|folic acid|Given orally once daily
47952693|NCT00703196|OTHER|placebo|Given orally once daily
47952694|NCT04275934|BEHAVIORAL|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
47952695|NCT05295056|DEVICE|AFGen1 Device Wear Test|Participant wears the device for 7 days
47952696|NCT05295056|DEVICE|AFGen 1 Device Single Use|Participant wears the device in conjunction with a standard ECG
47952697|NCT05613400|DRUG|Simvastatin 10mg|One simvastatin 10mg-tablet
47952698|NCT05613400|DRUG|Ezetimibe 10mg|One ezetimibe 10mg-tablet
47952699|NCT02664545|DEVICE|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
48108495|NCT06357819|DEVICE|INSTI HCV Self Test|Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.
48300275|NCT01901471|DRUG|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
48479327|NCT05990504|DEVICE|ultrasound real-time guidance combined with Epidural Labor Anagesia|Epidural is a traditional labor analgesia technique.
48479328|NCT03027921|OTHER|elastography|
47952700|NCT02664545|PROCEDURE|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
47952701|NCT05887232|PROCEDURE|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
47952702|NCT05887232|PROCEDURE|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
47952703|NCT02291354|DRUG|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
47952704|NCT02291354|OTHER|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
47952705|NCT02291354|PROCEDURE|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
47952706|NCT03076619|OTHER|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
47952707|NCT04736693|DRUG|Raloxifene|Raloxifene dispensing claim is used as the reference group.
47952708|NCT04736693|DRUG|Zoledronic Acid|Zoledronic Acid dispensing claim is used as the exposure group.
47952709|NCT00290277|BIOLOGICAL|HPV-16/18 L1/AS04|
47952710|NCT06322069|OTHER|Self-compassion intervention group|Participants would be provided a 14-days online course, and they need to finish the courses within 21 days.
47952711|NCT02985437|DRUG|Surfactants|
47952712|NCT02985437|DRUG|Saline Solution|
47952713|NCT03661710|OTHER|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
47952714|NCT02765269|DEVICE|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
47952715|NCT02547324|RADIATION|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
47952716|NCT02547324|RADIATION|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
47952717|NCT01274650|PROCEDURE|Indirect Calorimetry|Indirect Calorimetry
48479329|NCT03562949|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
48479330|NCT03562949|DRUG|Reference Product|QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
48638138|NCT01596244|BEHAVIORAL|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
48638139|NCT06453876|DEVICE|Ultrasound assisted Thrombolysis|Please see Arms
47952718|NCT00140933|DRUG|MK0966; rofecoxib|
47952719|NCT00140933|DRUG|Comparator: diclofenac, placebo|
47952720|NCT00400738|DRUG|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
47952721|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
47952722|NCT01423019|DIETARY_SUPPLEMENT|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
47952723|NCT01423019|OTHER|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
47952724|NCT06069531|DIETARY_SUPPLEMENT|Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract|Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
47952725|NCT03094988|BEHAVIORAL|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
47952726|NCT03094988|OTHER|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
47952727|NCT05531331|BEHAVIORAL|At home education via video conferencing|Educational booklets are given according to the type of stoma. The individual with the stoma was told that the researcher was always reachable by phone and could communicate if he had any problems. The individuals with stoma in the experimental group received the training of the company representative that sells stoma materials, which is routinely given in the hospital. After discharge, training was given by the researcher via video conference in a total of four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month. A post-test was conducted at the end of the 4th training interview, which was administered via video conferencing.
47952728|NCT02247531|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
48479331|NCT03562949|DRUG|Placebo|Placebo Product
48479332|NCT01949116|DRUG|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
48479333|NCT01949116|DRUG|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
48479334|NCT01949116|DIETARY_SUPPLEMENT|Folic acid|1-mg tablet of folic acid by mouth once a day
48479335|NCT02592772|OTHER|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
48479336|NCT02592772|OTHER|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
47952729|NCT02247531|OTHER|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
47952730|NCT00381550|DRUG|fludarabine phosphate|Given IV
47952731|NCT00381550|DRUG|triapine|Given IV
47952732|NCT00381550|PROCEDURE|laboratory biomarker analysis|Correlative study
47952733|NCT02846324|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
47952734|NCT02846324|DRUG|Placebo|Placebo capsules
47952735|NCT01191411|OTHER|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
47952736|NCT01191411|OTHER|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
48479337|NCT02592772|OTHER|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
48479338|NCT06616727|DRUG|SNC109|SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
48479339|NCT01433887|DRUG|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
48479340|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
47952737|NCT01191411|OTHER|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
47952738|NCT02806531|BIOLOGICAL|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
48479341|NCT01433887|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
48479342|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
48638140|NCT06453876|DEVICE|Percutaneous Embolectomy|Please see arms
48638141|NCT06453876|DRUG|Heparin|Active comparator
48638142|NCT04484441|OTHER|Blood and placenta specimen collection.|Collection of maternal and paternal blood. Collection of infant cord blood and placenta.
48638143|NCT01134614|BIOLOGICAL|Ipilimumab|Given IV
48638144|NCT01134614|BIOLOGICAL|Sargramostim|Given SC
48638145|NCT02819544|DRUG|Sodium chloride administration|Sodium chloride administration
48638146|NCT02819544|DRUG|Ropivacaine administration|Ropivacaine administration
48638147|NCT04879732|DEVICE|ACTIS|ACTIS Hip stem
47952739|NCT06436261|PROCEDURE|Hybrid Fractional Laser|A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.
48300276|NCT01901471|DRUG|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
48300277|NCT00358189|DEVICE|Deep Brain Stimulation|
48300278|NCT05173272|DRUG|Neoadjuvant Therapy|Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
48479343|NCT04221126|DEVICE|TMFI|Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
48479344|NCT04221126|DRUG|ALA cream|ALA compounded in a cream
47952740|NCT06436261|OTHER|Facial Cleanser|Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.
47952741|NCT06436261|OTHER|Facial Moisturizer|"Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon)."
47952742|NCT06436261|OTHER|Sunscreen|During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
48108496|NCT01550666|BEHAVIORAL|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
48108497|NCT02511639|DRUG|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
48108498|NCT02511639|DRUG|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
48300279|NCT05173272|RADIATION|CCRT|weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.
48479345|NCT04221126|DRUG|ALA gel|ALA compounded in a gel
48479346|NCT01301924|DRUG|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
48638148|NCT02243826|DRUG|50:50 mixture of nitrous oxide/oxygen|
48638149|NCT06063083|BEHAVIORAL|"Tell Me More (Dime Mas)"|Participants will receive an initial approximately 1 hour outreach session followed by up to 3 approximately monthly check-in outreach attempts (approximately 15 minutes each). All study visits can be done in person or remotely. Each contact will involve helping participants get connected to PrEP, HIV testing, and behavioral health treatment.
48479347|NCT05982249|DEVICE|Hypnosis|Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten BM examinations at the hematology institute. The length of the recording is about 7 minutes.
48479348|NCT05982249|DEVICE|Virtual reality (VR)|Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
47952743|NCT03897504|PROCEDURE|feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap|the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
47952744|NCT04050072|OTHER|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
47952745|NCT04050072|OTHER|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
47952746|NCT04050072|OTHER|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
47952747|NCT05514301|DIAGNOSTIC_TEST|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~1. High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~2. Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
47952748|NCT03636165|DRUG|Methylprednisolone|The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
47952749|NCT03636165|DRUG|Ropivacaine|The local infiltration solution containing 2mg Ropivacaine per milliliter.
47952750|NCT01238354|BEHAVIORAL|With friend|
47952751|NCT01238354|BEHAVIORAL|Without friend|
47952752|NCT03115047|DRUG|Dexmedetomidine Injection|0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
47952753|NCT03115047|DRUG|Meperidine Injection|0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
48108499|NCT05733936|OTHER|rehabilitation protocol|rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
48108500|NCT03312439|BEHAVIORAL|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
48479349|NCT00931996|DRUG|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
48479350|NCT05471609|DRUG|levodopa/carbidopa oral formulation A|Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
48479351|NCT05471609|DRUG|levodopa/carbidopa oral formulation B|Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
47952754|NCT01828879|DRUG|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
48108501|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
48108502|NCT00494442|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
48108503|NCT02498769|DRUG|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
48108504|NCT02498769|DRUG|Placebo|
48108505|NCT05416671|BEHAVIORAL|guided narrative technique-writing|The experimental group underwent the psychological intervention of guided narrative technique-writing with the theme of teacher criticism for 20 to 30 minutes once a day for three consecutive days.
48108506|NCT04301986|DEVICE|Cytosponge|In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C \[34° to 54°F\]).
48108507|NCT04301986|DEVICE|Transnasal Endoscopy (TNE)|In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.
48108508|NCT04301986|DEVICE|Esophagogastroduodenoscopy|Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
48108509|NCT01184235|DRUG|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
48479352|NCT05471609|DRUG|levodopa/carbidopa oral formulation C|Outer sachet 50mg CD/200mg LD and inner sachet 50mg CD /200mg LD
48479353|NCT01981317|BEHAVIORAL|Stepped Care Cognitive Behavioral Therapy|
48479354|NCT01981317|BEHAVIORAL|Cognitive Behavioral Therapy|
48479355|NCT03670134|DEVICE|The Nvision VLE Imaging System|Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
48479356|NCT03778723|DRUG|Total intravenous anesthesia (TIVA)|Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
47952755|NCT02288598|DEVICE|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
47952756|NCT02288598|BEHAVIORAL|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
48479357|NCT03778723|DRUG|Inhalation Anesthesia|Sevoflurane at a concentration of 2-2.5%
48479358|NCT03778723|DRUG|Rescue fentanyl|Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
48479359|NCT04213209|DRUG|Brentuximab Vedotin (Genetical Recombination)|Brentuximab Vedotin Intravenous Infusion
48479360|NCT06330350|OTHER|Qualitative interview|Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.
48300280|NCT05173272|RADIATION|Brachytherapy|The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
48300281|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
48300282|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
48300283|NCT00690937|DRUG|Colesevelam Cholestagel|Drug comparator
48108510|NCT06331871|PROCEDURE|Ultrasound Guied Percutaneus Electrical Nerve Stimulation (US-PENS) and Manual physiotherapy protocol based on available evidence.|Intervention performed by needling in the vicinity of the peripheral nerves of the shoulder under ultrasound-guided control.
48108511|NCT06331871|PROCEDURE|Manual physiotherapy protocol based on available evidence.|Physiotherapy treatment based on the best scientific evidence available, based on manual therapy and passive and active kinesitherapy
48108512|NCT01667354|BEHAVIORAL|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
48108513|NCT02401633|PROCEDURE|CO-CPR|CPR provided by bystander with chest-compressions only
48108514|NCT02401633|PROCEDURE|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
48108515|NCT00362726|DRUG|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
48108516|NCT00362726|DRUG|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
48108517|NCT00362726|DRUG|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
48108518|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
48108519|NCT00362726|DRUG|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
48108520|NCT02447263|PROCEDURE|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
48108521|NCT01752465|BEHAVIORAL|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
48108522|NCT01752465|BEHAVIORAL|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
48108523|NCT00092664|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
48108524|NCT01289119|DRUG|Alogliptin|Alogliptin tablets
48108525|NCT01289119|DRUG|Placebo to alogliptin|Alogliptin placebo-matching tablets.
48108526|NCT01289119|DRUG|Metformin|Stable metformin dose
48108527|NCT01289119|DRUG|Pioglitazone|Stable pioglitazone dose
48108528|NCT01071993|DRUG|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
48108529|NCT01071993|DRUG|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
48108530|NCT04827654|DIETARY_SUPPLEMENT|Weekly produce box and gift card|Weekly box of produce (5-10 lbs) and $10.00 gift card to a local grocery store to purchase preferred produce. If progress on self-goals completed, an additional $10.00 card provided, weekly, for 3 weeks.
48108531|NCT03411239|DEVICE|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
48108532|NCT00298649|BEHAVIORAL|Lay Health Advisor|
48108533|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
48108534|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
48108535|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
48108536|NCT00457691|DRUG|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
48108537|NCT00457691|DRUG|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
48108538|NCT00457691|DRUG|irinotecan|180mg/m2 iv day 1 every 14 days
48108539|NCT00457691|DRUG|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
48108540|NCT00457691|DRUG|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
48108541|NCT00203580|DRUG|Tinzaparin sodium|
48108542|NCT05305235|DEVICE|RISE Guide|Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
48108543|NCT05305235|DEVICE|Relaxation Control|Guides users through relaxation techniques.
48108544|NCT04991233|PROCEDURE|Endoscopic surgery|The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
48108545|NCT04991233|PROCEDURE|Suboccipital craniotomy surgery|The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
48108546|NCT02067026|DIETARY_SUPPLEMENT|Aleurone|
48300284|NCT00690937|DRUG|Placebo|Placebo
48300285|NCT00690937|DRUG|Placebo|Placebo
48300286|NCT03819283|DIAGNOSTIC_TEST|Hepatic evaluation|Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
48479361|NCT06132620|DRUG|Femoston|"Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment."
48479362|NCT06132620|DRUG|Qingxin Zishen Decoction|Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
48479363|NCT00436917|DRUG|zoledronic acid|zoledronic acid
48108547|NCT02067026|DIETARY_SUPPLEMENT|Placebo|
48339841|NCT02069704|DRUG|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
48479364|NCT00436917|PROCEDURE|Letrozole as adjuvant therapy|standard care
47952757|NCT03308786|DRUG|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for four consecutive days(cycle) every 8 weeks for 8 cycles
48108548|NCT01777893|BEHAVIORAL|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
48108549|NCT01777893|BEHAVIORAL|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
48108550|NCT01777893|BEHAVIORAL|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
48108551|NCT01777893|BEHAVIORAL|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
48108552|NCT02379546|DRUG|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
47952758|NCT01385761|DEVICE|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
48108553|NCT02379546|DEVICE|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
48108554|NCT06554886|DEVICE|Cryoneurolysis|Cryoneurolysis
48108555|NCT00714558|DRUG|Fentanyl citrate; Naltrexone; Naloxone|
48108556|NCT05245825|OTHER|Flaxseed|A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
48108557|NCT05245825|OTHER|Dietary plan|Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
48108558|NCT03954015|DIAGNOSTIC_TEST|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
48479365|NCT06055673|GENETIC|DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD|Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
47952759|NCT01385761|DEVICE|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
47952760|NCT00704678|DRUG|SBR759|1g tid
47952761|NCT00704678|DRUG|Sevelamer HCl|1.6 g tid
47952762|NCT00704678|DRUG|Sevelamer HCl|1.5 g tid
47952763|NCT00704678|DRUG|Sevelamer HCl|0.8 g tid
47952764|NCT01870284|DRUG|Ixekizumab|Administered SC
47952765|NCT01870284|DRUG|Placebo|Administered SC
47952766|NCT01870284|DRUG|Adalimumab|Administered SC
47952767|NCT02486354|DRUG|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
48108559|NCT03954015|DRUG|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
48108560|NCT02582710|DIETARY_SUPPLEMENT|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
48108561|NCT02582710|DIETARY_SUPPLEMENT|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
48108562|NCT02871999|DEVICE|Acupuncture therapy|
48108563|NCT02871999|PROCEDURE|Laparoscopic Surgery|
48108564|NCT04467788|OTHER|Computer-aided sessions|Changing participants' KAP of ergonomics in dentistry
48108565|NCT04467788|OTHER|Clinical simulation sessions|Changing participants' KAP of ergonomics in dentistry
48108566|NCT02779608|DRUG|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
48108567|NCT02779608|DRUG|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
48132686|NCT06011954|DRUG|Enfortumab Vedotin|Intravenous
48479366|NCT04395248|PROCEDURE|Exploring potential risk factors of difficult intubation using ultrasound|Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
48638150|NCT06063083|BEHAVIORAL|"Peer Ambassador Stories [Listen Miami (Oye Miami)]"|Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.
48638151|NCT06063083|BEHAVIORAL|Standard Community Outreach|Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
48638152|NCT06144086|DRUG|Foscenvivint|Administered by intravenous (IV) infusion over 3-4 hours
48638153|NCT06568536|OTHER|Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG|The presence of consciousness will be classified considering the highest level of consciousness revealed by repeated behavioral examinations, functional electroencephalography (task-based EEG), and functional brain imagery (task-based fMRI). Based on the results of this composite standard reference, we will evaluate the diagnostic and prognostic accuracy of TMS-EEG measurements of brain complexity
48638154|NCT00432991|DRUG|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
48638155|NCT00432991|DRUG|Saline Placebo|0.5 mL, IM (in the muscle), one time
48638156|NCT05519085|DRUG|mezigdomide|Specified dose on specified days
48638157|NCT05519085|DRUG|Pomalidomide|Specified dose on specified days
48638158|NCT05519085|DRUG|Bortezomib|Specified dose on specified days
48638159|NCT05519085|DRUG|Dexamethasone|Specified dose on specified days
48638160|NCT06223009|DRUG|cNP8|cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
48479367|NCT04395248|PROCEDURE|Radial artery catheterization using ultrasound guidance or blind palpation|For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.
48638161|NCT06223009|OTHER|Placebo|Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
48638162|NCT02605538|BIOLOGICAL|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
47952768|NCT00826046|DRUG|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
47952769|NCT03545100|OTHER|motor control therapy|scapular muscle progressive resistive exercise(PRE)
47952770|NCT03545100|OTHER|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
48638163|NCT03517020|DRUG|Torrent's Nebivolol Tablets|
47952771|NCT03472651|DRUG|test treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
47952772|NCT03472651|DRUG|reference treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
47952773|NCT00005865|DRUG|vinorelbine tartrate|
47952774|NCT04112420|DIAGNOSTIC_TEST|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
47952775|NCT05069610|BIOLOGICAL|AD17002|A recombinant protein
47952776|NCT05069610|BIOLOGICAL|Placebo (Formulation buffer)|Formulation buffer
47952777|NCT06022393|BEHAVIORAL|Cognitive Reappraisal|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.
47952778|NCT06022393|BEHAVIORAL|Reflection|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
47952779|NCT06199778|BEHAVIORAL|Rehabilitation therapy|"1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers."
47952780|NCT06199778|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
47952781|NCT06199778|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
47952782|NCT06199778|DRUG|Reserpine|Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.
47952783|NCT06199778|DRUG|Levofloxacin|The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
47952784|NCT00132210|DRUG|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
47952785|NCT02572362|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
47952786|NCT01975714|DRUG|Preservative-free latanoprost|
47952787|NCT01975714|DRUG|Preservative-free bimatoprost|
47952788|NCT05517551|PROCEDURE|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
47952789|NCT04027829|DRUG|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
47952790|NCT00610623|DRUG|azithromycin|300 mg/day, IV from day 1 to 20
47952791|NCT00610623|DRUG|placebo|once per day, IV from day 1 to 20
47952792|NCT03652168|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
48479368|NCT04395248|DEVICE|Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher \& Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
48638164|NCT03517020|DRUG|Forest Pharmaceuticals Inc's Bystolic Tablets|
48638165|NCT02642042|DRUG|Docetaxel|Given IV
47980439|NCT05436392|BEHAVIORAL|Patient Informational Letter|Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
48638166|NCT02642042|OTHER|Laboratory Biomarker Analysis|Correlative studies
48638167|NCT02642042|DRUG|Trametinib|Given PO
48638168|NCT01652105|DIETARY_SUPPLEMENT|Standard diet versus standard VLCD (Prodimed)|
48638169|NCT04422132|RADIATION|5 days Radiation Therapy (32.5 Gy in 5 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
48300287|NCT04061798|DRUG|ACT guided heparinization|"If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is \>200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is \>200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If \>250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
48479369|NCT04395248|DRUG|Type of volatile anesthetics and M-Entropy guidance of anesthesia depth|"At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge."
47952793|NCT02424448|PROCEDURE|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
47952794|NCT00839722|PROCEDURE|embolization|fertility after embolization
47952795|NCT06354062|BEHAVIORAL|Talent management intervention program|Talent management intervention program
47952796|NCT00631696|DRUG|Pregabalin|pregabalin 600 mg given twice a day
48479370|NCT00970255|PROCEDURE|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
48479371|NCT00970255|PROCEDURE|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
47952797|NCT00631696|DRUG|Placebo|Placebo
47952798|NCT06467942|DRUG|Chinese medicine and Lactobacillus|combined drug group
47952799|NCT06467942|DRUG|Chinese medicine|Single Chinese medicine group
47952800|NCT06467942|DRUG|Lactobacillus|Single Lactobacillus group
47952801|NCT00169546|DRUG|Salmeterol/fluticasone propionate|
47952802|NCT00169546|DRUG|Fluticasone propionate|
48479372|NCT01625481|DEVICE|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
48479373|NCT00319046|DRUG|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
48479374|NCT04626544|DEVICE|Body-worn inertial sensors|The device typically includes accelerometers that capture body accelerations in three directions (anteroposteriorly, mediolaterally and vertically) and gyrometers that capture rotations (yaw, pitch and roll). The method of measuring gait using body-worn inertial sensors has been found reliable \[15\] and valid \[20\]. This project will use Opal sensors and the Mobility Lab software from the manufacturer APDM (https://www.apdm.com/wearable-sensors/).
48479375|NCT02754284|BIOLOGICAL|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
47952803|NCT01384942|BEHAVIORAL|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
47952804|NCT01384942|BEHAVIORAL|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
47952805|NCT05916820|OTHER|Tanzberger Exercises|It consists of patients who will receive Tanzberger exercise 3 sessions per week for 4 weeks. e.g. Rolling on the ball forward, Back to back sitting.
47952806|NCT05916820|OTHER|Pelvic floor muscle training|It consists of patients who will pelvic floor muscles exercise 3 sessions per week for 4 weeks. e.g. Assisted heel drop, Bridge, Dead Bug, Bird DOG
47952807|NCT05679518|BEHAVIORAL|ConquerFear intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
48300288|NCT04061798|DRUG|5 000 IU of heparin|"A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again."
48300289|NCT01486316|DEVICE|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
48300290|NCT01486316|OTHER|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
48300291|NCT03568539|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks.
48300292|NCT02474017|DRUG|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
48300293|NCT02474017|DEVICE|CRC749 inhaler|
48300294|NCT02433210|DEVICE|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
48300295|NCT02433210|DEVICE|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
48300296|NCT02433210|DEVICE|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
48300297|NCT02818153|OTHER|Self questionnaire for allergic rhinitis control|
48300298|NCT01270646|DEVICE|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
48300299|NCT01323673|DRUG|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
48300300|NCT01323673|DRUG|Vehicle / Placebo|2 times a day, 14 total days of study treatment
48300301|NCT01197378|DRUG|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
48300302|NCT01563627|OTHER|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
48300303|NCT01563627|DEVICE|Magnetic Resonance Imaging|
48300304|NCT04328064|DRUG|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
48300305|NCT04328064|DRUG|Placebo oral tablet|40 mg placebo for 12 months
48300306|NCT03285009|OTHER|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
48300307|NCT01232972|PROCEDURE|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
48479376|NCT02754284|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
47952808|NCT05679518|BEHAVIORAL|CALM intervention|CALM is a semi-structured, manualized, individual psychotherapy intervention designed for patients with advanced cancer. It includes 3-6 individual therapy sessions, with each approximately lasts 45-60 minutes, delivered over 3-6 months. The sessions cover 4 domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. All modules will be addressed with each patient, but the sequencing and time devoted to each domain can be varied, based on the concerns that are most relevant to each patient.
47952809|NCT05679518|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
47952810|NCT01882348|BEHAVIORAL|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)-including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
48300308|NCT06300619|BEHAVIORAL|Pilates+4|12 weeks of seated Pilates twice weekly. In weeks 1-3, participants receive training on hip and shoulder cuff activation. This occurs through active isometric pressure on the stabilizing limb (not the moving limb during a Pilates movement) for 3 seconds at 30% strength using the participants' own hand (e.g., pressure on the outside of the knee with knee pressing against hand) prior to engaging in each exercise. Following the first 3 weeks, participants in the Pilates+4 group engage in the same Pilates protocol as the comparator group, however, they receive 4-quadrant cues for hip and shoulder cuff activation as they learned in weeks 1-3.
48300309|NCT06300619|BEHAVIORAL|Pilates|12 weeks of seated Pilates twice weekly. 18 exercises standard in Pilates instruction will be provided with standard Pilates cues (i.e., core activation, cuing the moving limb, breathing synchronization).
48479377|NCT05296876|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
48638170|NCT04422132|RADIATION|20 days Radiation therapy (55 Gy in 20 fractions)|Patients will receive treatment to the prostate fossa +/- nodes in either 32.5 Gy in 5 fractions or 55 Gy in 20 fractions.
48638171|NCT02153957|BEHAVIORAL|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
48638172|NCT06519175|OTHER|Conservative treatment|Patients are provided with physiotherapy support and the provision of prostheses with the goal of ensuring as much walking functionality as possible.
48638173|NCT06519175|PROCEDURE|Single or multi-stage surgery|Correction of the deformity is pursued by one or more surgical procedures with the timing and the techniques (growth modulation, acute correction, gradual correction, soft tissues procedures, combined techniques) chosen according to the surgeon's preference to achieve the maximum possible walking functionality without orthopedic aids.
48638174|NCT06519175|PROCEDURE|Amputation|Limb surgery, whether or not associated with realignment or soft-tissue surgery, is performed, aimed at providing the maximum possible walking function through a prosthesis.
47952811|NCT01149837|DEVICE|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
47952812|NCT01976676|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate|
48300310|NCT02096393|DEVICE|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
48300311|NCT02096393|DEVICE|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
48300312|NCT04963712|DRUG|Zadaxin|1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
48300313|NCT03662152|DEVICE|Foam roller|Foam roller massage after DOMS
48300314|NCT03662152|DEVICE|Vibration foam roller|Foam roller massage with vibration after DOMS
48479378|NCT00518882|DRUG|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
48479379|NCT00518882|DRUG|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
48479380|NCT04959383|OTHER|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
48638175|NCT04332185|PROCEDURE|vestibular socket therapy|(VST) included the following steps. a-traumatic tooth extraction, the socket curetted and rinsed with normal saline thoroughly . One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone apical to the base of the socket .
48638176|NCT02409901|BEHAVIORAL|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
47952813|NCT01976676|DIETARY_SUPPLEMENT|folic Acid|
47952814|NCT01386008|DEVICE|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
47952815|NCT01386008|DEVICE|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
47952816|NCT04429048|DEVICE|Acupressure elastic band (Sea-Band)|The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy
47952817|NCT04429048|DEVICE|General elastic band (no bud)|general elastic band was put over bilateral PC6 acupoints
47980440|NCT02825992|DEVICE|AcQMap System|3D imaging and mapping system for cardiac chambers
47952818|NCT05823532|DRUG|Infliximab|"Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist."
47952819|NCT05823532|DRUG|Placebo|Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
47952820|NCT05631600|BIOLOGICAL|Manuka honey|The honey was applied with special designed cannula. The dosage is not exactly define so we inject the amount of honey until until the excess of the material was observed in the sulcus.
48638177|NCT04483219|DRUG|TKI ± anti-PD-1 antibody|"After one cycle of TKI, evaluations would be performed according to RECIST v 1.1. (1) obvious response (A): CR, PR or shrunken SD, or cavitation in metastatic lung lesions, or decrease in the density of liver metastatic targets ≥15%; (2) general response (B): enlarged SD; (3) poor response (C): PD. TKI ＋ anti-PD-1 antibody will be administered in group A. The subjects in group C will exit the study. The subjects in group B will continue TKI for another one cycle, the obvious response subjects will entered group A, the general response subjects will keep in arm B and continue the TKI monotherapy, and the poor response subjects will exit the study.~1. Fruquintinib 5mg or regorafenib 120mg, qd po, 3 weeks, Q4w. (The investigators decide to choose fruquintinib or regorafenib)~2. Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years."
47952821|NCT00805454|DRUG|OPC-34712|Single oral dose, 0.5 to 25 mg
47952822|NCT03029442|DRUG|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
47952823|NCT03029442|OTHER|Placebo (normal saline)|Identical Denosumab volume of normal saline
47952824|NCT01146275|RADIATION|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
47952825|NCT00277446|DRUG|Soy isoflavones|
47952826|NCT04153604|DRUG|doxycycline|a tetracycline antibiotic that fights bacteria in the body.
47952827|NCT00646789|DRUG|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
47952828|NCT04203329|DEVICE|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
47952829|NCT06044389|DEVICE|Fructosin|"Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase."
47952830|NCT01570166|PROCEDURE|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
47952831|NCT01570166|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
47952832|NCT02863744|PROCEDURE|coronally advanced flap with subepithelial connective tissue graft|"* Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~* The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
48479381|NCT04959383|OTHER|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
48479382|NCT04959383|OTHER|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
48479383|NCT04959383|OTHER|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
48479384|NCT04703842|BIOLOGICAL|SRD-001|AAV1/SERCA2a
48479385|NCT04703842|DRUG|Placebo|SRD-001 matching placebo
48479386|NCT06227624|DRUG|Oral zinc sulfate and standard phototherapy|study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
47952833|NCT02128932|DRUG|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
47952834|NCT02128932|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
47952835|NCT03993470|BEHAVIORAL|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
47952836|NCT05224414|BEHAVIORAL|Cognitive bias modification for interpretation bias|Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
47952837|NCT05224414|BEHAVIORAL|Psychoeducation|Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
47952838|NCT00547235|BIOLOGICAL|therapeutic allogeneic lymphocytes|
47952839|NCT00547235|PROCEDURE|allogeneic bone marrow transplantation|
47952840|NCT00547235|RADIATION|total-body irradiation|
47952841|NCT04783038|OTHER|Distance Reiki|Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.
47952842|NCT04783038|OTHER|Sham distance Reiki|Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
47952843|NCT05661110|OTHER|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
47952844|NCT01792271|OTHER|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
47952845|NCT05972473|DRUG|Aflibercept Ophthalmic|2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).
47952846|NCT05972473|BIOLOGICAL|IBI302|8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
47952847|NCT01837407|PROCEDURE|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
47952848|NCT03783975|GENETIC|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
47952849|NCT03633617|DRUG|Dupilumab|Solution for injection administered subcutaneously
48479387|NCT01264640|DRUG|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
48479388|NCT02656082|DRUG|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
47952850|NCT03633617|DRUG|Placebo|Matching placebo
47952851|NCT02268955|DRUG|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
47952852|NCT02268955|DRUG|Saline|Saline will be administered to the placebo group
47952853|NCT03252119|DEVICE|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
47952854|NCT00912860|DRUG|Interferon beta-1a|serum free Avonex given IM once a week
47952855|NCT05744908|OTHER|Pentosan Polysulphate|300mg 3 times a day
47952856|NCT02994134|BEHAVIORAL|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
47952857|NCT02994134|BEHAVIORAL|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
47952858|NCT01030068|BEHAVIORAL|Yoga|Yoga twice weekly
47952859|NCT01030068|BEHAVIORAL|Wellness|Health and wellness classes twice weekly
47952860|NCT01030068|OTHER|Smoking cessation therapy|Smoking cessation therapy
47952861|NCT05363410|DIETARY_SUPPLEMENT|MagnéVie B6®|micronutrient supplement
47952862|NCT05363410|OTHER|Placebo|placebo supplement
47952863|NCT03292484|BIOLOGICAL|AR101|AR101
47952864|NCT02585154|PROCEDURE|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
47952865|NCT02585154|PROCEDURE|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
47952866|NCT02585154|PROCEDURE|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
47952867|NCT02585154|DEVICE|local field potentials and electroencephalography recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
47952868|NCT02402829|PROCEDURE|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
47980441|NCT05885789|PROCEDURE|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
47980442|NCT02194205|DRUG|COMBIVENT HFA|
47952869|NCT04464057|DIETARY_SUPPLEMENT|early oral feeding or early enteral nurtrion|The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
47952870|NCT00437892|DRUG|atorvastatin|tablets, 40 mg day, 3 months
48108568|NCT06535958|BEHAVIORAL|OHI|All patients (test and control) will be instructed to brush the implants twice daily to remove supragingival biofilms with a low-abrasive dentifrice and to use specific cylindrical or conical brushes in the interproximal area. Patients will be indicated to brush under, around, and in the peri-implant crevice circumferentially. In those cases with no access for proper OHI, prosthesis will be modified.The interproximal brush device used will be chosen for the patient individually, according to the interproximal space available, the thicker brush that can be used comfortably will be the selected one. It will be previously tested on the patient and its use will be taught, patients should demonstrate proficiency
48108569|NCT06535958|PROCEDURE|OHI+PMPR|Supra- and sub-gingival debridement of the implant surface, the implant neck, and the abutment will be carried out by means of a combination of ultrasonics with a plastic tip and plastic curettes . Finally, the prosthetic components will be polished with a rubber cup
48108570|NCT00901069|DRUG|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2\^ Azacitidine 50 mg/m2\^ Azacitidine 75 mg/m2\^ Azacitidine 100 mg/m2\^
48479389|NCT04641247|DRUG|Niraparib|Niraparib tablets or capsules will be given once a day via the oral route.
48638178|NCT05862441|DRUG|AV2-SA2|AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
48638179|NCT05862441|DRUG|SA|Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis.
48638180|NCT05938270|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) given orally once daily
48638181|NCT05938270|DRUG|Darolutamide|Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
48638182|NCT05938270|OTHER|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
48638183|NCT03516708|DRUG|Epacadostat|Drug provided.
48638184|NCT03516708|RADIATION|Short-course radiation therapy|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
48638185|NCT03516708|DRUG|CAPOX chemotherapy|Standard of care
48638186|NCT03516708|DRUG|FOLFOX chemotherapy|Standard of care
48638187|NCT03390400|DEVICE|Femtosecondlaser-assisted|Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
48638188|NCT03390400|PROCEDURE|Anterior Capsulotomy|Cataract Surgery
48638189|NCT03390400|PROCEDURE|Lens Fragmentation|Cataract Surgery
48638190|NCT05718518|DRUG|ASC11 tablets|"Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)"
47952871|NCT00437892|DRUG|atorvastatin|tablets, 40 mg once daily
47952872|NCT00437892|BEHAVIORAL|diet|daily
47952873|NCT00437892|BEHAVIORAL|diet|daily diet
47952874|NCT01171040|OTHER|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
47952875|NCT05780684|OTHER|FOX dose-escalation algorithm|Chemotherapy dose-escalation algorithm based on the FOLFOX and FOLFOXIRI regimens
47952876|NCT05959733|PROCEDURE|Bridging Reconstruction using BioBrace|Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
48638191|NCT05718518|DRUG|Placebo|Part 1 and 2: Subjects will be randomized to receive placebo.
47980443|NCT02194205|DRUG|Placebo HFA|
47980444|NCT02194205|DRUG|COMBIVENT CFC|
47980445|NCT02194205|DRUG|Placebo CFC|
47980446|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
48638192|NCT05718518|DRUG|RTV tablets|"Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)"
48638193|NCT02942407|DRUG|apixaban|oral anticoagulant
48638194|NCT02942407|DRUG|warfarin|oral anticoagulant
48479390|NCT01011075|DRUG|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
48479391|NCT01011075|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
48638195|NCT05527314|DRUG|Remimazolam|Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
48638196|NCT05527314|DRUG|Sevoflurane|Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
48638197|NCT05527314|DRUG|Fentanyl|Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
48638198|NCT05527314|DRUG|Cisatracurium Besylate|Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
48638199|NCT05527314|DRUG|Remifentanil|After the LoC, remifentanil 0.1\~0.3 ug/kg/min inject intravenously until the end of surgery.
48638200|NCT04630626|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
47952877|NCT05959733|PROCEDURE|Repair|Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.
47952878|NCT06432231|OTHER|Low glycemic index diet treatment|This study was a non-randomized, single centre, pre/post-intervention study. A low glycemic index diet was prescribed by a dietician for 3 months. LGID treatment consisted of 10% (40-60 g) low glycaemic index (glycaemic index \<50) carbohydrate, 20-30% protein and 60-70% lipid
48479392|NCT03485482|DRUG|Bisoprolol|bisoprolo 5 mg tablets
48479393|NCT03485482|DRUG|Ivabradine|Ivabradine 10 mg tablet
48479394|NCT03485482|DRUG|combination of Ivabradine and bisoprolol|combination of 10 mg ivabradine and 5 mg bisoprolol
48638201|NCT04630626|OTHER|ACDF|Historical ACDF control data
47952879|NCT05460260|DEVICE|Cascade CGM|21-days of CGM wear
47952880|NCT00562250|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
47952881|NCT00562250|DRUG|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
48479395|NCT00111566|DRUG|eptifibatide|
48479396|NCT04638270|BIOLOGICAL|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
48479397|NCT04082936|DRUG|imvotamab|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
48638202|NCT06632457|DRUG|Survodutide|Subcutaneous injection
48638203|NCT06632457|DRUG|Placebo matching survodutide|Subcutaneous injection
47952882|NCT00562250|DRUG|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
47952883|NCT00744276|DRUG|danazol|danazol applied topically once per day for 4 treatment cycles
47952884|NCT00744276|DRUG|Placebo|placebo topically applied once daily for 4 treatment cycles
47952885|NCT00607815|BEHAVIORAL|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
47952886|NCT00607815|BEHAVIORAL|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
47980447|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
48479398|NCT03336879|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
48638204|NCT06408649|DEVICE|Lehfilcon A spherical contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia)
48638205|NCT06408649|DEVICE|Lehfilcon A toric contact lenses|Silicone hydrogel contact lenses for the correction of ametropia (myopia or hyperopia) with astigmatism
48638206|NCT04032262|DIAGNOSTIC_TEST|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
48638207|NCT05439863|DEVICE|transcatheter heart valve|patients with severe aortic valve disease underwent transcatheter heart valve
48638208|NCT03497286|BEHAVIORAL|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
48638209|NCT03497286|BEHAVIORAL|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
47952887|NCT02127710|DRUG|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
48638210|NCT05470296|BEHAVIORAL|Move & Eat 2 Live|American Indians suffer disproportionately from several chronic diseases that may be prevented with healthier modifiable factors. Nutrition, physical activity and a healthy weight are key factors that may prevent and reduce risk of disease incidence. The major goals of this project are to develop a culturally adapted intervention that addresses barriers and uses positive cultural values as guiding principles for behavior changes to enhance program retention and improve behaviors. This project will pilot a 12-week standard lifestyle intervention in American Indians.
47952888|NCT04223973|DEVICE|Medtrum A7+ insulin Pump|Use of the Medtrum pump during 3 months in combination with a CGM (Continuous Glucose Measurement)
47952889|NCT04223973|BIOLOGICAL|Lab A1C|Measure of Lab A1C at baseline and end of study
47952890|NCT02932215|DRUG|lorcaserin|Open label
47952891|NCT02932215|OTHER|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
47952892|NCT01161108|DRUG|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
47952893|NCT01161108|DRUG|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
47952894|NCT01161108|DRUG|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
48108571|NCT02220491|RADIATION|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
48108572|NCT02220491|RADIATION|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
48108573|NCT01956669|DRUG|Pazopanib|Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
48108574|NCT03023280|PROCEDURE|Radiofrequency ablation|
48108575|NCT04805073|DRUG|Promethazine|1cc 25mg/ml Promethazine (study medication)
47952895|NCT01161108|DRUG|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
48108576|NCT04805073|DRUG|Placebo|1cc 0.9% Sodium Chloride (placebo)
47952896|NCT04048187|DEVICE|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
48638211|NCT03055013|PROCEDURE|Nephrectomy|Undergo nephrectomy
48638212|NCT03055013|BIOLOGICAL|Nivolumab|Given IV
47952897|NCT05051995|DRUG|Open-label placebo|Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
48108577|NCT05209880|BEHAVIORAL|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
48108578|NCT00537563|DRUG|Telithromycin|
48108579|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 12 μg|CVGBM will be administered as an IM injection.
48108580|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 25 μg|CVGBM will be administered as an IM injection.
48108581|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 50 μg|CVGBM will be administered as an IM injection.
48108582|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 100 μg|CVGBM will be administered as an IM injection.
48108583|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine RDE 100 μg|CVGBM will be administered as an IM injection.
45482167|NCT06676150|PROCEDURE|Human Papillomavirus|Human papillomavirus (HPV) testing is usually done at the doctor's office. The doctor or nurse puts a metal or plastic speculum into your vagina to see your cervix. Then they gently use a sampler (a small brush or spatula) to take small number of cells from your cervix to test for HPV.
48108584|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 6 μg|CVGBM will be administered as an IM injection.
48108585|NCT01181375|OTHER|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
48108586|NCT00328523|DRUG|MK-0653, ezetimibe|
48108587|NCT00328523|DRUG|Duration of Treatment: 3 months|
47952898|NCT05051995|OTHER|No-treatment|During the no-treatment phase, participants receive no treatment for 2 weeks.
48108588|NCT00546871|DRUG|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
48108589|NCT00816049|DRUG|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
48108590|NCT00816049|DRUG|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
48108591|NCT04063826|DEVICE|PET MRI|All participants will have a liver scan
48108592|NCT05232630|DRUG|Fenfluramine|"Administration of fenfluramine. Fenfluramine treatment dose: Between 0.2 and 0.7 mg/kg/day if no concomitant Stiripentol (STP), maximum dose: 40 mg/day \[or 0.5 mg/kg/day, maximum 30 mg/day, for subjects taking concomitant STP\]. Dosing will be started with 0.1mg/day per one week, then 0.2mg/kg/day per one week, then as investigator clinical decision-making, up to 0.4, 0.6 or 0.7mg/kg/day, with a maximum of 0.2mg/kg/day escalation every week.~Visits: There will be four visits; (visit 1) screening; (visit 2) treatment initiation, +2 weeks; (visit 3, telematic) +8 weeks; (visit 4) +14 weeks."
48638213|NCT03055013|OTHER|Patient Observation|Undergo observation
48638214|NCT03055013|OTHER|Quality-of-Life Assessment|Ancillary studies
48638215|NCT03055013|OTHER|Questionnaire Administration|Ancillary studies
48638216|NCT03488693|RADIATION|Radiation|Radiotherapy given
47952899|NCT04500730|DRUG|Shaoyao Gancao Decoction Jiawei|"Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56."
47952900|NCT02503410|BEHAVIORAL|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
47952901|NCT02503410|BEHAVIORAL|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
47952902|NCT06398808|DRUG|Arm1|ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
47952903|NCT06398808|DRUG|Arm 2|ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
47980448|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
47980449|NCT05982626|RADIATION|68Ga/131I-SGMIB-ZT-199|68Ga-SGMIB-ZT-199: PET imaging; 131I-SGMIB-ZT-199: SPECT imaging.
48638217|NCT03488693|OTHER|No Radiation|No radiotherapy given
48638218|NCT03907631|OTHER|Standard of care|care decisions driven by local physicians; this is an observational cohort
48638219|NCT06488001|DRUG|pantoprazole|Pantoprazole 40mg given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
48638220|NCT06488001|DRUG|Placebo|Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
48638221|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 1|The study foresees the intake of 1 capsule per day during 56 days
48638222|NCT06571409|DIETARY_SUPPLEMENT|Coriander Seed Oil - Dose 2|The study foresees the intake of 1 capsule per day during 56 days
48638223|NCT06571409|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
48638224|NCT00320320|DRUG|Irinotecan|
48638225|NCT03048279|BEHAVIORAL|Questionnaires|"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."
48638226|NCT05666960|DRUG|R-3750|Probiotic
48638227|NCT04874961|DIETARY_SUPPLEMENT|Tensiofytol®|standardized olive extract
47952904|NCT02409212|BEHAVIORAL|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
48638228|NCT04874961|OTHER|Placebo|contains excipients only
48300315|NCT05392192|DRUG|ADX-629|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
48300316|NCT05392192|DRUG|Placebo|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
48300317|NCT02979795|PROCEDURE|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)
48300318|NCT04514367|DRUG|ANX005|Intravenous Infusion
48300319|NCT06260176|BEHAVIORAL|exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
48300320|NCT06260176|BEHAVIORAL|exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
48300321|NCT06260176|BEHAVIORAL|exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
48300322|NCT06260176|BEHAVIORAL|exposure to sweetened beverage tax messaging|Message reminding consumers to make healthier choices
48300323|NCT03637868|DRUG|Eribulin|Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
48300324|NCT05910736|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
48300325|NCT04412603|OTHER|Conventional Mirror Therapy|The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
48300326|NCT02434315|DEVICE|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
48300327|NCT02434315|DEVICE|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
48300328|NCT02434315|DEVICE|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
48300329|NCT00844428|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
48638229|NCT02091830|DRUG|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
48638230|NCT02091830|OTHER|Physiotherapy|
48638231|NCT02091830|DRUG|Cortisone Injection|
48638232|NCT02091830|OTHER|Others|
48638233|NCT06268717|OTHER|Ground pork containing alpha-gal|150 grams of cooked, ground pork meat containing alpha-gal sugar eaten once
48638234|NCT06268717|OTHER|Pork meat not containing alpha-gal|150 grams of cooked, ground pork meat not containing alpha-gal sugar
47952905|NCT02409212|BEHAVIORAL|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
47952906|NCT03678025|DRUG|Abiraterone|Given PO
47952907|NCT03678025|DRUG|Bicalutamide|Given PO
47952908|NCT03678025|DRUG|Degarelix|Given via injection
47952909|NCT03678025|DRUG|Docetaxel|intravenous
47952910|NCT03678025|DRUG|Flutamide|Given PO
47952911|NCT03678025|DRUG|Goserelin Acetate|Given SC
48300330|NCT06113354|DEVICE|Transcatheter mitral valve repair (MRace Implant and Delivery System)|"The MRace Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture~Other Names:~TMVr"
48300331|NCT01835990|DEVICE|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
48300332|NCT01835990|DEVICE|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
48300333|NCT00370786|DRUG|bevacizumab|
48300334|NCT01945931|OTHER|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
48300335|NCT03543891|OTHER||
48300336|NCT03218852|DRUG|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
48300337|NCT03218852|DRUG|prednisone alone|Prednisone is administered to participants in this group.
48638235|NCT03287349|OTHER|Blood draw|Two 12.5 mL blood draws
48638236|NCT03287349|OTHER|Photograph|Photograph of severe reaction, will be anonymized
48638237|NCT03287349|DIAGNOSTIC_TEST|Autoimmune testing|Autoimmune testing in patients without prior testing
48479399|NCT02315547|DRUG|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
47952912|NCT03678025|DRUG|Histrelin Acetate|Receive SC
48300338|NCT01208896|DRUG|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
48479400|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot A|
47952913|NCT03678025|DRUG|Leuprolide Acetate|Receive SC or IM
47952914|NCT03678025|DRUG|Nilutamide|Given PO
47952915|NCT03678025|PROCEDURE|Orchiectomy|Undergo bilateral orchiectomy
47952916|NCT03678025|DRUG|Prednisone|Given PO
47952917|NCT03678025|OTHER|Quality-of-Life Assessment|Ancillary studies
48108593|NCT02830152|DEVICE|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
48108594|NCT02830152|DRUG|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
48108595|NCT00033163|DRUG|Adefovir dipivoxil|
48479401|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot B|
47952918|NCT03678025|RADIATION|Radiation Therapy|Standard radiation
47952919|NCT03678025|PROCEDURE|Radical Prostatectomy|Standard surgery
47952920|NCT03678025|DRUG|Triptorelin|injection
47952921|NCT03528707|DIETARY_SUPPLEMENT|Symbiter-Omega|"Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101"
47952922|NCT03528707|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
47952923|NCT04098848|OTHER|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
47952924|NCT01896336|DRUG|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
48108596|NCT00033163|DRUG|Tenofovir disoproxil fumarate|
48108597|NCT00000313|DRUG|Fenfluramine|
48108598|NCT01850017|DRUG|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
48108599|NCT03514251|PROCEDURE|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
48300339|NCT05890638|DRUG|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
48300340|NCT05890638|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
48479402|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot C|
48479403|NCT00489099|BIOLOGICAL|V232 Current Process Hepatitis B Vaccine|
48479404|NCT06587464|OTHER|No Intervention|This is a non-interventional study.
48479405|NCT06143956|DRUG|LY3305677|Administered SC. ISA specific interventions will be listed in the ISA.
48479406|NCT06143956|DRUG|LY3841136|Administered SC. ISA specific interventions will be listed in the ISA.
48479407|NCT06143956|DRUG|Tirzepatide|Administered SC. ISA specific interventions will be listed in the ISA.
48638238|NCT06505642|DEVICE|needle-based confocal laser endomicroscopy|needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
47952925|NCT03465358|OTHER|Items completion|"Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet.~The order of completion between conventional material or digital tablet will be allocate randomly."
47952926|NCT05369676|DRUG|SSD8432 dose 1/Ritonavir|Cohort 1:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
47952927|NCT05369676|DRUG|SSD8432 dose 2/Ritonavir|Cohort 2:SSD8432/ritonavir or placebo, on day 1 \~day5，BID；
47952928|NCT02292342|DIETARY_SUPPLEMENT|Water|Control
47952929|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
47952930|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 0.5 mg/kg|EC 0.5
47952931|NCT02292342|DIETARY_SUPPLEMENT|Epicatechin 1.0 mg/kg|EC 1.0
47952932|NCT02970916|DRUG|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
47952933|NCT01469624|DRUG|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
47952934|NCT00805948|DEVICE|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
47952935|NCT03113916|BEHAVIORAL|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
47980450|NCT06382584|PROCEDURE|Femoral fracture surgery|Hip fracture surgery
47980451|NCT00137046|DRUG|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
47980452|NCT00137046|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
48638239|NCT01401075|DRUG|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
48638240|NCT01401075|DRUG|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
48638241|NCT05577065|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
47980453|NCT01133483|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
48108600|NCT04141917|COMBINATION_PRODUCT|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
48108601|NCT03420209|BEHAVIORAL|Group applying PNF technique|
48108602|NCT03815396|DRUG|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
48638242|NCT05577065|DIETARY_SUPPLEMENT|Placebo|Matching placebo in the form of a sachet once daily for 26 weeks
48638243|NCT04302259|DEVICE|Intelligent Spine Interface|"ISI-C is a bi-directional, two anatomical location Epidural Electrical Stimulation (EES) system to bridge the lesion core in patients with chronic complete and incomplete spinal cord injury (SCI). This Intelligent Spine Interface, or ISI will interpret recorded neural information from above a spinal cord lesion and transfer that information, via deep neural network-based interpreters (i.e. models), to stimulation sites (electrodes) below the lesion with the aim of restoring volitional control of the lower limb."
48638244|NCT03531567|BEHAVIORAL|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
48300341|NCT03121742|BEHAVIORAL|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
48300342|NCT03121742|BEHAVIORAL|Treatment as Usual|Standard care as part of inpatient hospitalization.
48638245|NCT03531567|BEHAVIORAL|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
48300343|NCT00207376|DEVICE|Solysafe Septal Occluder|
48638246|NCT06065748|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
48638247|NCT06065748|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
48479408|NCT06143956|DRUG|Placebo|Administered SC. ISA specific interventions will be listed in the ISA.
48638248|NCT06065748|DRUG|Abemaciclib|If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
48638249|NCT06065748|DRUG|Palbociclib|If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
48638250|NCT06065748|DRUG|Ribociclib|If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
48638251|NCT06065748|DRUG|LHRH Agonist|Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
47980454|NCT05263323|OTHER|Patient education|Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
48638252|NCT06065748|DIAGNOSTIC_TEST|FoundationOne Liquid CDx Assay (F1LCDx)|F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
48638253|NCT02650349|OTHER|fMRI|
48638254|NCT05384626|DRUG|NVL-655|Oral Tablet of NVL-655
47980455|NCT05263323|OTHER|Data Collecting, No Education|Data were collected at the beginning and end of the study without training the control group.
48638255|NCT03723525|COMBINATION_PRODUCT|Package of HIV care|"A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~1. PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~2. PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care."
47952936|NCT05031273|BEHAVIORAL|Residents moving into a congregate-living development with more features that support healthy living|Our team is making evidence-based recommendations to the developer and design team of an upcoming congregate-living development to support the physical activity, healthy eating, and social connections of residents moving into the new building(s). We hope for the developer to integrate into the new building(s) as many as possible of our team's built environment design and amenity recommendations into their site and/or building plans. Additionally, discussions with the municipality are also occuring on built environment design and amenity recommendations to improve the neighbourhood surrounding the site. Although our team has provided these recommendations, it is ulimatily up to the discretion of the developer and the municipality as to whether and what design and amenity changes are made.
47952937|NCT04313842|DEVICE|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
47952938|NCT06302478|BEHAVIORAL|5E program|"Participants in the 5E program group will receive 7-day nursing interventions including~* Education: health education regarding venous thromboembolism prevention~* Elevation: leg elevation of 10-20 degrees~* Exercise: ankle exercises~* Enough fluid: adequate fluid uptake~* Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission"
47952939|NCT05322733|DRUG|Orelabrutinib|150 mg capsules administered orally once daily (28-day cycles). Until 12 or 24 cycles and following BM undetectable MRD, or disease progression, or intolerant toxicity.
47952940|NCT05322733|DRUG|Obinutuzumab|1000 mg administered intravenously once on Day 1, 8, 15 of first cycle and on Day 1 of following cycles for maximal 12 cycles (28-day cycles).
47952941|NCT05322733|DRUG|Fludarabine|25mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
48108603|NCT03058991|BEHAVIORAL|Distress Tolerance Intervention|See arm/group description.
48108604|NCT03058991|BEHAVIORAL|Working Memory Intervention|See arm/group description.
48108605|NCT03058991|BEHAVIORAL|Control Informational Intervention|See arm/group description.
48300344|NCT03781193|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
48479409|NCT05811221|DRUG|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
48479410|NCT05811221|DRUG|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
48479411|NCT06595147|BEHAVIORAL|Structured Exercise Training|Participants will complete 12-weeks of supervised, structured moderate-to-high intensity aerobic and resistance training three times per week.
48479412|NCT06595147|BEHAVIORAL|Group-based Yoga and Stretching|Participants will complete 12-weeks of supervised group-based yoga and stretching once per week.
48479413|NCT02250924|DIETARY_SUPPLEMENT|Caffeine|caffeinated gum
48479414|NCT02250924|OTHER|Gum|Chewing gum
48638256|NCT03723525|COMBINATION_PRODUCT|Standard HIV care|Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4\<350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).
48479415|NCT02250924|BEHAVIORAL|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
48638257|NCT02035228|DEVICE|Abdominal Stimulation - low / early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation"
48638258|NCT02035228|DEVICE|Abdominal stimulation - low/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation"
48108606|NCT00349583|DRUG|Topical Cyclosporine, Tears|
48108607|NCT05386680|GENETIC|OAV101|Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
48108608|NCT03522519|BEHAVIORAL|Real world performance of physical activity and arm use|Patients will be assessed by using movement sensors and standard clinical assessments
48108609|NCT02929485|DRUG|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
48108610|NCT02929485|DRUG|Placebo|Placebo (200mg) administered at study visit
48479416|NCT01876238|OTHER|T-PAT|
48638259|NCT02035228|DEVICE|Abdominal Stimulation - low/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation"
48108611|NCT02929485|DRUG|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
48300345|NCT03781193|OTHER|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
48300346|NCT03781193|OTHER|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
48300347|NCT03781193|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
48479417|NCT01876238|OTHER|Surveys|Pre-test and posttest surveys and questionnaires
48479418|NCT04373629|BEHAVIORAL|attentional modulation|Attentional instructions when viewing faces will be given
48479419|NCT04373629|OTHER|perceptual modulation|Faces will be presented of varying durations
48479420|NCT04373629|OTHER|naturalistic viewing|Faces will be viewed without specific instructions
48479421|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
47952942|NCT05322733|DRUG|Cyclophosphamide|250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
48479422|NCT03658473|DRUG|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
48479423|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
48479424|NCT03658473|DRUG|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
48479425|NCT02013752|DEVICE|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
48638260|NCT02035228|DEVICE|Abdominal stimulation - med/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation"
48638261|NCT02035228|DEVICE|Abdominal stimulation - med/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation"
48638262|NCT02035228|DEVICE|Abdominal Stimulation - med/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation"
47952943|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction with Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the power arm will be used for canine retraction.
47952944|NCT06352996|OTHER|Three-Dimensional Assessment of Maxillary Canine Retraction without Power Arm|A nickel titanium closed coil spring will be stretched from the mini-implant to the canine bracket will be used for canine retraction.
47952945|NCT05043675|DRUG|[18F]APN-1607|Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
48108612|NCT02955069|DRUG|PDR001|PDR001 was administered at a dose of 400 mg via intravenous infusion once every 4 weeks (Q4W). PDR001 was administered on Day 1 of every cycle. Each cycle was 28 days.
47952946|NCT02983565|DEVICE|Intelligent oxygen therapy system (iO2Ts)|
47952947|NCT00439023|PROCEDURE|dialysis with glucose in dialysis water|
47952948|NCT01469234|DRUG|loratadine|loratadine, one 10 mg tablet, orally
47952949|NCT01469234|DRUG|fexofenadine|fexofenadine, one 180 mg tablet, orally
48108613|NCT03321344|DEVICE|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
48108614|NCT02874326|DRUG|Octreotide LAR|
48108615|NCT02061228|DEVICE|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
48108616|NCT04195516|OTHER|web based training,individual counseling, using reminders|"Health Promotion Model based Health Promotion Program will be applied to the experimental group. Health promotion program; The Web-based Health Promotion Program includes individual counseling and reminder practices.~Within the context of the Web Based Health Promotion Program, 8 weeks of training to improve healthy eating and physical activity behaviors, individual counseling will be given.~Colorful picture reminders will be sent to the experimental group through Whatsapp groups.~At the end of the intervention, cognitive and physical measurements of the students will be done at 1st, 3rd and 6th months."
48108617|NCT01036412|DRUG|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
48108618|NCT01036412|BEHAVIORAL|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
48108619|NCT02276820|BIOLOGICAL|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
48479426|NCT00860678|OTHER|Physical activity|
48479427|NCT00860678|OTHER|no Intervention|
48479428|NCT02533284|DRUG|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
48479429|NCT02533284|DRUG|bupevecaine|US guided TAP using Bupevecaine 0.25 %
48479430|NCT02533284|DRUG|saline|US guided TAP using placebo (saline)
48479431|NCT02629588|BEHAVIORAL|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
48300348|NCT03781193|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
48300349|NCT03781193|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
48300350|NCT03781193|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
48300351|NCT03781193|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
48300352|NCT03781193|OTHER|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
48300353|NCT01893840|DEVICE|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
48300354|NCT01818622|DEVICE|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
48300355|NCT01818622|DEVICE|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
48300356|NCT01452074|OTHER|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, \~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
48300357|NCT01452074|OTHER|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
48300358|NCT03604692|DRUG|SNDX-6352|SNDX-6352 is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
48300359|NCT02728635|OTHER|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
48300360|NCT02728635|PROCEDURE|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
48300361|NCT02728635|OTHER|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
47952950|NCT01469234|DRUG|placebo to loratadine|one tablet, orally
47952951|NCT01469234|DRUG|placebo to fexofenadine|one tablet, orally
47952952|NCT02486666|DRUG|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES AND CHILDREN WITH THROMBOSIS (FiXET)
47952953|NCT03403374|DRUG|evolocumab|Administered by SC injection via autoinjector (AI)/pen
47952954|NCT01973569|DRUG|denosumab|denosumab administered subcutaneously
48300362|NCT04961801|DRUG|Acalabrutinib, tacrolimus, methotrexate|For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
48479432|NCT00799942|DRUG|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
48479433|NCT03550534|DRUG|Calcium Carbonate|Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
47952955|NCT01973569|DRUG|placebo|placebo administered subcutaneously to match denosumab
47952956|NCT01595672|DEVICE|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
47952957|NCT01595672|OTHER|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
47952958|NCT01222624|DRUG|PankoMab-GEX™|
47952959|NCT01578070|BIOLOGICAL|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
47952960|NCT01578070|BIOLOGICAL|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
47952961|NCT01578070|BIOLOGICAL|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
47952962|NCT01578070|BIOLOGICAL|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
47952963|NCT01578070|BIOLOGICAL|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
47952964|NCT00292214|DRUG|Paracetamol (acetaminophen)|
47980456|NCT02150798|OTHER|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
48300363|NCT04626219|OTHER|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
48300364|NCT04626219|BEHAVIORAL|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
48479434|NCT03550534|DRUG|Placebo oral capsule|Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
48479435|NCT00458107|DRUG|SCA-136|
48479436|NCT03358095|DEVICE|Tannenbaum Fr 10 stent or WallFlex stent|A plastic or metallic endoprosthesis is placed to the biliary ducts.
47952965|NCT02405780|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
47952966|NCT02405780|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
47952967|NCT00914173|DEVICE|Scanlaf Circulator and water bath|Cold Pressor Test
47952968|NCT00914173|DEVICE|Medoc TSA 2000|Thermal stimuli pain
47952969|NCT03332290|BEHAVIORAL|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
47952970|NCT03005418|BIOLOGICAL|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
47952971|NCT04043273|BEHAVIORAL|Noninterventional characterization of patients expectations and preferences regarding their treatment|Patients will be clustered before and after a principal components analysis (PCA) on Patients Needs Questionnaire (PNQ). Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
47952972|NCT04022434|DIETARY_SUPPLEMENT|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
47952973|NCT04022434|DIETARY_SUPPLEMENT|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
47952974|NCT02735408|OTHER|Kinesiotape (KT)|
47952975|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
47952976|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device|Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.
47952977|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
48300365|NCT04626219|BEHAVIORAL|regulated meals|standardized diet from noon until 9 a.m. the next day
48108620|NCT06006091|DRUG|Letrozole|Different endothelial preparations according to groups, see arm descriptions for details
48638263|NCT02035228|DEVICE|Abdominal Stimulation - high/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation"
48638264|NCT02035228|DEVICE|Abdominal Stimulation - high/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation"
47952978|NCT05108714|PROCEDURE|Intravenous cannulation after without prior interventions|insertion of 18G catheter in a cubital vein without prior interventions.
47952979|NCT00112008|DRUG|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
47980457|NCT02150798|OTHER|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
48108621|NCT04407325|DEVICE|electronic nose device|electronic nose device will be tested as a triage instrument for tuberculosis in a high risk population
48108622|NCT04407325|DEVICE|dig chest Xray with automated readings|software for tuberculosis detection on digital Chest Xray providing a probability score from 0-100
48108623|NCT04213599|DIAGNOSTIC_TEST|Coronary intervention|Patients with STEMI undergo coronary intervention
48108624|NCT05211544|OTHER|physical therapy modalities and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive physical therapy modalities during two weeks for ten times. physical therapy modalities include hotpack, tens, ultrasound.
47952980|NCT06367361|DRUG|Oxfendazole|Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.
47952981|NCT06367361|DRUG|Triclabendazole|The standard of care for the treatment of fascioliasis according to the same guidelines is two 10 mg/kg doses of TCBZ 24 hours apart administered with a fat containing meal. The subjects in one of the arms of the study will receive this treatment as the standard of care. Subjects from any of the arms that fail to achieve parasitological cure will receive rescue treatment off the study with two doses of TCBZ as recommended by the Peruvian guidelines.
47952982|NCT03023462|DRUG|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
47952983|NCT03023462|DRUG|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
47952984|NCT03023462|DRUG|Ropivacaine|Local anesthetic for the block
47952985|NCT02340507|OTHER|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
48108625|NCT05211544|OTHER|kinesio taping and exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks. Also they will receive kinesio tape for their knee three times a week for two week
48108626|NCT05211544|OTHER|exercise|30 patient with osteoartritis will do knee strengthening exercise for half an hour a day,3 days a week. This exercise program will continue for 4 weeks.
48108627|NCT03400969|DEVICE|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
48108628|NCT03400969|DEVICE|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
48108629|NCT03400969|DEVICE|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
48108630|NCT05758727|OTHER|Exercise intervention|The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
48479437|NCT04113824|PROCEDURE|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
48479438|NCT04113824|PROCEDURE|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
48479439|NCT06289829|DRUG|remifentanil of the assigned dose|Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
48108631|NCT00414999|DRUG|TG100801|
48479440|NCT06289829|DEVICE|Ambu Auragain for airway management|Ambu Auragain, a type of laryngeal mask airway, will be inserted into every patient after general anesthesia has been induced.
48479441|NCT00729131|DRUG|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
48479442|NCT03398148|DRUG|risankizumab IV|risankizumab intravenous (IV) infusion
48479443|NCT03398148|DRUG|placebo for risankizumab|placebo for risankizumab
48479444|NCT03398148|DRUG|risankizumab SC|risankizumab subcutaneous (SC) injection
48479445|NCT03605823|DEVICE|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
48479446|NCT00641784|DRUG|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
48479447|NCT00641784|DRUG|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
48479448|NCT05253222|DIAGNOSTIC_TEST|retrograde image by colonic TET|"Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated."
48479449|NCT05259085|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
47952986|NCT02340507|OTHER|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
47952987|NCT03148314|DRUG|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
47952988|NCT03148314|DRUG|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
47952989|NCT02656914|DRUG|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
47952990|NCT02656914|DRUG|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
47952991|NCT02777619|DRUG|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
47952992|NCT02777619|DRUG|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
47952993|NCT02777619|DRUG|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
47952994|NCT02777619|DRUG|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
47952995|NCT02777619|DRUG|Propofol|
47952996|NCT00100178|DRUG|Mycophenolate mofeteil (MMF)|
47952997|NCT00100178|DRUG|Daclizumab (DZB)|
47952998|NCT00100178|DRUG|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
48108632|NCT03445130|OTHER|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
48108633|NCT03445130|OTHER|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
48108634|NCT03445130|OTHER|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
48108635|NCT03445130|OTHER|Water|two drops on the inside of an oxygen face mask for 15 minutes.
48638265|NCT02035228|DEVICE|Abdominal Stimulation - high/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation"
48108636|NCT04911049|DIAGNOSTIC_TEST|Blood Pressure measurement|Blood Pressure measurement
48108637|NCT05162144|PROCEDURE|Proximal Medial Gastrocnemius Recession|Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
48108638|NCT00233519|DRUG|SomatoKine/IPLEX|"Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection."
48108639|NCT02842424|DRUG|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
48108640|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
48108641|NCT01221779|BEHAVIORAL|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
48108642|NCT05499351|BIOLOGICAL|Adult group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
48108643|NCT05499351|BIOLOGICAL|Elderly group in immunogenicity and safety study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
48300366|NCT01605305|DRUG|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
48300367|NCT01275261|BEHAVIORAL|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
48300368|NCT02440178|DRUG|Micafungin|
48300369|NCT02980835|DRUG|Normal Saline|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
48638266|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the iTrack Advance device|360 degree microcatheterization and viscodilation of Schlemm's canal
48638267|NCT05786196|DEVICE|Ab-interno canaloplasty utilizing the OMNI Surgical System|360 degree microcatheterization and viscodilation of Schlemm's canal
48638268|NCT05304962|DRUG|RGT-419B|oral capsules
47952999|NCT00100178|DRUG|Placebo control for Daclizumab (DZB)|saline intravenous infusions
47953000|NCT04187677|PROCEDURE|Sensory Training|The sensory training group includes sensory-oriented interventions and exercises unlike the other classical hand therapy group.
47953001|NCT04187677|OTHER|classical hand therapy|classical hand therapy
47953002|NCT04393285|DRUG|Abemaciclib|Abemaciclib 150mg orally twice a day
47953003|NCT04393285|DRUG|Letrozole|Letrozole 2.5mg orally once a day
47953004|NCT00318058|BIOLOGICAL|influenza vaccine Fluarix, Adjuvanted Fluarix|
47953005|NCT03565601|OTHER|Follow-up|Clinical data, radiological data and laboratory tests follow-up
47953006|NCT03248336|PROCEDURE|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
47953007|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 1)|10 g / day at breakfast during 7 days (Day 8 - Day 14)
47953008|NCT06204978|DIETARY_SUPPLEMENT|short-chain fructo-oligosaccharides (dose 2)|20 g / day at breakfast during 7 days (Day 8 - Day 14)
47953009|NCT06204978|OTHER|Baseline|0 g / day of short-chain fructo-oligosaccharides during 7 days (Day 1 - Day 7)
47953010|NCT01332084|OTHER|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
48479450|NCT03612739|BIOLOGICAL|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
48638269|NCT05304962|DRUG|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
48300370|NCT02980835|DRUG|Ropivacaine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
47953011|NCT02029170|PROCEDURE|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
47953012|NCT02029170|PROCEDURE|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
48479451|NCT01103479|BEHAVIORAL|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
48638270|NCT05761483|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography, placement of stents using a duodenoscope and making an access through the papilla of Vater
48638271|NCT05552495|DRUG|CKD-386(4) F1|1 Tablet
48479452|NCT01103479|BEHAVIORAL|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
48638272|NCT05552495|DRUG|CKD-386(4) F2|1 Tablet
48638273|NCT05552495|DRUG|D013, D326, D337|D013 1 Tablet, D326 1Tablet, D337 1 Tablet
47953013|NCT02216760|DEVICE|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
48479453|NCT01730560|OTHER|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
48479454|NCT01730560|OTHER|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month)."
48479455|NCT00613860|DEVICE|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
48479456|NCT05341804|BEHAVIORAL|cognitive and balance dual task training|a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
48638274|NCT06319287|BIOLOGICAL|PEP (Purified Exosome Product) / TISSEEL|"PEP Drug Product is a lyophilized powder contained within a 10R glass vial. PEP Drug Product is a lyophilized powder derived from apheresed platelets in plasma. The powder cake weighs approximately 75 mg per vial. This protocol will evaluate 2 vials of PEP Drug Product delivered in 10 mL TISSEEL fibrin sealant (15mg/mL PEP-TISSEEL) for 12 weeks.~TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies"
47953014|NCT02216760|DEVICE|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
47953015|NCT00417118|DRUG|Saredutant|oral administration (capsules)
48479457|NCT05341804|BEHAVIORAL|balance training|Includes static balance, dynamic balance and strength training
48479458|NCT04808349|OTHER|no intervention|no intervention
47953016|NCT00417118|DRUG|Escitalopram|oral administration (capsules)
47953017|NCT00417118|DRUG|Placebo|oral administration (capsules)
47953018|NCT00876525|DEVICE|Surgical Replacement of the diseased native aortic heart valve with the Freedom SOLO Valve prosthesis|The Freedom SOLO prosthesis is designed for implantation in a supra-annular, sub-coronary position, with a single suture line.
47953019|NCT04188470|BEHAVIORAL|person-centered care model|A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
47953020|NCT02736994|DRUG|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
47953021|NCT02736994|DRUG|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
47953022|NCT02736994|OTHER|Water|Water
47953023|NCT06558461|DRUG|3% Sodium Chloride|4ml nebulized three times daily
47953024|NCT06558461|OTHER|Standard care|Standard care
48300371|NCT02980835|DRUG|Epinephrine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
48300372|NCT02980835|DRUG|Dexamethasone|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
48108644|NCT05499351|BIOLOGICAL|Adult group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
48300373|NCT05221450|PROCEDURE|primary endodontic treatment|
47953025|NCT04382391|DEVICE|gammaCore® Sapphire (non-invasive vagus nerve stimulator)|"Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment."
47953026|NCT04382391|OTHER|Standard of care therapies|Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
47953027|NCT06389500|DRUG|Adebrelimab|Adebrelimab, IV
47953028|NCT06389500|DRUG|Lenvatinib|Lenvatinib, PO
47953029|NCT06389500|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|GC regimen±5-FU
47953030|NCT05332730|DRUG|BAT2506 injection|50 mg, subcutaneous administration
48479459|NCT01764867|DRUG|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
48479460|NCT01764867|DRUG|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
48300374|NCT00700752|DEVICE|senofilcon A|silicone hydrogel contact lens
48300375|NCT00700752|DEVICE|balafilcon A|silicone hydrogel contact lens
48479461|NCT01764867|OTHER|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
48479462|NCT01764867|OTHER|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
48300376|NCT06295510|OTHER|No interventions.|It's only observational study.
48300377|NCT02083250|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
47953031|NCT05332730|DRUG|Simponi® (EU commercially available product)|50 mg, subcutaneous administration
47953032|NCT05332730|DRUG|Simponi® (US commercially available product)|50 mg, subcutaneous administration
47953033|NCT00731068|BIOLOGICAL|PRGF|injection of 6cc into injured area of tendon
47953034|NCT00731068|BIOLOGICAL|placebo|injection of 6 cc of saline into injured area
47953035|NCT04835480|DRUG|OrsHSA|OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
47953036|NCT04835480|DRUG|HSA|Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
47953037|NCT02182739|DRUG|Meloxicam|tablets or injectable solution
47953038|NCT00387803|DEVICE|Cardiac Resynchronization Therapy with Defibrillation|
47953039|NCT01358851|PROCEDURE|Cryotherapy|1-2 times during the treatment time
47953040|NCT01358851|DRUG|LAS41005|once daily
47953041|NCT05969808|OTHER|baseline therapy and conventional therapy|These activities included were warm-up activities, general playtime, basic gross motor activities, and free play with toys three times a week for 45 minutes for a period of 12 weeks.
47953042|NCT05969808|OTHER|baseline treatment and adaptive physical activity|The experimental group's intervention plan had the following 12 elements . Each of which was completed for 10 minutes with two-minute breaks. Warm-up activities, puzzles and manipulatives, e.g., interlocking blocks or shape sorting toys, Balloon Badminton, Obstacle course (crawl in Tunnel ), Peg board play, Tactile sensory bin exploration filled with sand, Ball roll and catch, Tracing shapes, Play dough and clay activities, Cutting and pasting.
48300378|NCT02083250|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
47953043|NCT01903031|DEVICE|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
47953044|NCT01903031|DRUG|EFV|Participants received EFV 600 mg daily with two or more NRTIs
47953045|NCT01903031|DRUG|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
47953046|NCT01903031|DRUG|TDF|Participants received 300 mg of tenofovir in Arm C
47953047|NCT01903031|DRUG|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
48300379|NCT02083250|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
48300380|NCT02083250|DRUG|Busulfan|Given IV
48300381|NCT02083250|DRUG|Clofarabine|Given IV
48300382|NCT02083250|DRUG|Fludarabine Phosphate|Given IV
48300383|NCT02083250|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
48300384|NCT02083250|OTHER|Pharmacological Study|Correlative studies
47953048|NCT03330288|DRUG|Theraflex, BAY 874017|The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
48300385|NCT02083250|DRUG|Vorinostat|Given PO
48479463|NCT01764867|DRUG|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
47953049|NCT04746222|BIOLOGICAL|Oral capsule faecal microbiota transplantation|Single dose of 30 oral capsules containing healthy donor stool from a stool bank
48300386|NCT03943667|DRUG|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
48300387|NCT03943667|DRUG|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
48300388|NCT05394272|OTHER|Energy Therapy - Pranic Healing|Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
48479464|NCT01764867|DRUG|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479465|NCT01764867|DRUG|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479466|NCT01764867|DRUG|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479467|NCT01764867|DRUG|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479468|NCT01764867|DRUG|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479469|NCT01764867|DRUG|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479470|NCT01764867|DRUG|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479471|NCT01764867|DRUG|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
47953050|NCT04746222|OTHER|Placebo|Single dose of 30 oral placebo capsules
47953051|NCT04443699|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
47953052|NCT01801826|DEVICE|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
48479472|NCT01764867|DRUG|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479473|NCT01764867|DRUG|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
48479474|NCT00538655|DRUG|modafinil|400mg vs. 200mg (PO) daily
48479475|NCT03998319|DRUG|Tenecteplase (1/3 systemic weight based dose)|50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
47953053|NCT01081288|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
47953054|NCT01250431|BEHAVIORAL|EFT (Emotional Freedom Techniques)|10 EFT sessions
47953055|NCT01127035|BIOLOGICAL|sublingual immunotherapy|
47953056|NCT01127035|BIOLOGICAL|placebo|
48300389|NCT03717324|OTHER|Procedure created in co-creation group|Interventions will be those obtained from the co-creation workshop with patients
48300390|NCT06109623|OTHER|observation|To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.
48300391|NCT06109623|OTHER|sex hormone|Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)
48300392|NCT01555463|DRUG|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
48300393|NCT01555463|DRUG|Vehicle foam|twice daily topical application
48479476|NCT03998319|OTHER|Sterile water for injection (WFI)|Placebo comparative arm.
48300394|NCT00164905|DEVICE|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
48300395|NCT04739124|OTHER|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
47953057|NCT01461083|DRUG|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
47953058|NCT02298231|OTHER|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
47953059|NCT02298231|OTHER|Mystic Isle Balance Intervention|Balance therapy using virtual reality
47953060|NCT02298231|OTHER|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
47953061|NCT03277690|DRUG|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
47953062|NCT03277690|DRUG|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
47953063|NCT03716193|OTHER|Oxygen|Patients will be given oxygen via a facemask during the measurement session
47953064|NCT06557928|OTHER|measurement|Measurement of multiple physiological indicators and psychological status and multi-omics study
48108645|NCT05499351|BIOLOGICAL|Elderly group in safety observation study of combined immunization|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd,and the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The quadrivalent influenza vaccine:15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection;PPV23:capsular polysaccharides of 23 serotypes of pneumococcus in 0.5 mL of Sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.
48108646|NCT04340362|DRUG|VX-147|Tablets for oral administration.
48108647|NCT02529696|DEVICE|Accelerometer|Measures patient movement
48108648|NCT04423328|BEHAVIORAL|acupressure|self-acupressure
48108649|NCT01576133|BEHAVIORAL|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
48108650|NCT01576133|BEHAVIORAL|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
48108651|NCT04704037|OTHER|Guideline implementation tool|Family physicians will receive a tailored letter with their patient's mental health screening test results and associated mental health treatment recommendations from the Ontario Neurotrauma Foundation guidelines, as well as a list of mental health treatment resources. In addition, the patient will receive a written information package about mental health problems after mTBI and treatment options to discuss with their family physician.
48300396|NCT04739124|OTHER|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
48108652|NCT04704037|OTHER|Generic information about concussion management|Family physicians will receive a generic letter drawing their attention to Canadian clinical practice guidelines for mild Traumatic Brain Injury (developed by the Ontario Neurotrauma Foundation). Patients will receive instructions about how to access generic education materials about mTBI (from concussion.vch.ca/), which they should have received anyway as part of usual care.
48108653|NCT00794118|OTHER|As per clinical practice|As per clinical practice
48108654|NCT00130741|DRUG|CHT - herbal therapy|
48108655|NCT06223113|DEVICE|EyenableTM PA60AS1 IOL|Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
48300397|NCT00403117|DRUG|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
48300398|NCT00403117|DRUG|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
48300399|NCT00403117|DRUG|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
48300400|NCT00403117|DRUG|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
47953065|NCT02858011|OTHER|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
47953066|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
47953067|NCT02858011|DIETARY_SUPPLEMENT|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
48108656|NCT04152616|OTHER|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
47953068|NCT02858011|OTHER|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
47953069|NCT02858011|BEHAVIORAL|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
47953070|NCT04842734|OTHER|Physical exercise|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
47953071|NCT04842734|OTHER|Physical exercise and computerized cognitive training|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour. The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
47953072|NCT03434574|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
48108657|NCT00038714|DRUG|SGN-00101|
48108658|NCT04123132|OTHER|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
48108659|NCT06028984|DEVICE|Intervention app|An app-based intervention for depression
48108660|NCT06028984|OTHER|Control app|An app with non-therapeutic content
48108661|NCT00653341|DRUG|insulin glargine|
48108662|NCT00653341|DRUG|NPH human insulin|
48108663|NCT03163186|PROCEDURE|Transarterial embolization|Transarterial hepatic embolization of liver cancer
47953073|NCT03434574|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
48108664|NCT00740415|BIOLOGICAL|rituximab|Rituximab, 375 mg/m2 Intraveinous
48108665|NCT00740415|DRUG|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
48108666|NCT00740415|DRUG|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
48479477|NCT05037773|BEHAVIORAL|Intervention targeting parental reminiscing style|8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
47953074|NCT05012033|OTHER|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
48479478|NCT04441645|OTHER|Acupressure|acupressure once per day, five times per week, a total of 12 weeks
48479479|NCT05255952|PROCEDURE|Electrical stimulation|Electrical stimulation of the cardiac plexus
47953075|NCT01252381|OTHER|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
48479480|NCT06468696|PROCEDURE|Suturing the cervical linea alba during endoscopic thyroid surgery.|Suturing the cervical linea alba during endoscopic thyroid surgery.
48479481|NCT06468696|GENETIC|Performing transcriptome sequencing|Performing transcriptome sequencing
48479482|NCT03034161|DEVICE|Thermal imaging|Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
48108667|NCT00740415|DRUG|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
48479483|NCT00201916|PROCEDURE|5250 cGy/20 fractions over 28 days|see above
47953076|NCT04796545|DEVICE|SING IMT(TM) System, model NG SI IMT 3X|The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
47980458|NCT06347614|PROCEDURE|Two-step Radical Prostatectomy|The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
48108668|NCT03329066|BEHAVIORAL|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
48108669|NCT03329066|BEHAVIORAL|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
48108670|NCT03329066|BEHAVIORAL|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
48108671|NCT05982353|DEVICE|PTFE application|Polytetrafluoroethylene membrane used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
48479484|NCT00201916|PROCEDURE|6600 cGy/33 fractions over 45 days|see above
47980459|NCT04465331|OTHER|Questionnaires|completion of Exercise Adherence Rating Scale (EARS)
48108672|NCT05982353|DEVICE|Gelatin sponge|gelatin sponge used over immediate implants intraoperatively. Healing and osseointegration with the exposed membrane is assessed at the end of followup
48108673|NCT01465724|PROCEDURE|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
48108674|NCT00197886|DRUG|Changing dose of norepinephrine and blood pressure|
47953077|NCT03398200|BIOLOGICAL|Hyperbaric Oxygen Therapy|The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
47953078|NCT03398200|OTHER|No Hyperbaric Oxygen Therapy|The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
48108675|NCT01027299|DEVICE|Biventricular pacing|Optimised temporary biventricular pacing.
48108676|NCT05185830|OTHER|Interactive robots|Children will mobilize with the interactive robot when control group will mobilize with nurse.
48108677|NCT01985906|PROCEDURE|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
48108678|NCT01985906|DEVICE|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
48108679|NCT05093218|DIETARY_SUPPLEMENT|branch chain amino acid|• Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: \<5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm
48108680|NCT05093218|OTHER|placebo|Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
48108681|NCT02674646|RADIATION|Radiotherapy|Radiation as indicated by the cancer diagnosis
48108682|NCT02674646|DEVICE|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
48108683|NCT01169311|DEVICE|Hemorrhoidopexy|
47953079|NCT04088643|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
47953080|NCT04088643|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
47953081|NCT02935231|DRUG|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
48300401|NCT00403117|DRUG|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
47953082|NCT02935231|BEHAVIORAL|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
48108684|NCT04408898|GENETIC|ADP-A2M4 in combination with pembrolizumab.|Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
48108685|NCT05761834|OTHER|Sample blood and 2D-echocardiography with Doppler|Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
48300402|NCT00403117|DRUG|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
48300403|NCT00403117|DRUG|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
48300404|NCT00403117|DRUG|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
48300405|NCT00403117|DRUG|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
48300406|NCT00403117|DRUG|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
48300407|NCT01651130|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
48300408|NCT06272383|DRUG|0.15 mg/kg dexamethasone|25% less than the standard practice of dexamethasone at 0.6mg/kg
48300409|NCT00957346|DRUG|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
48108686|NCT03566186|OTHER|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
48108687|NCT03566186|OTHER|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
48108688|NCT03566186|OTHER|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
48108689|NCT04018508|OTHER|Massage|Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
48108690|NCT00112983|BIOLOGICAL|eculizumab|
48300410|NCT00957346|DRUG|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
48300411|NCT01792986|BEHAVIORAL|water-only 24-hour fasting once per week for 6 weeks|
47953083|NCT02935231|OTHER|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
47953084|NCT03950011|PROCEDURE|Enhanced recovery after surgery program|Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
47953085|NCT06180746|BEHAVIORAL|Knowledge mobilization to facilitate the structuring of health mediation|"The ECEMSo intervention involves knowledge mobilization to facilitate the structuring of health mediation throughout French territory, and the development of a co-designed effective action plan to facilitate cancer screening uptake by people living in informal housing.~The action plan will, consider territorial specificities at the regional level. The ECEMSo project team will organize a seminar and three workshops. The aim of the seminar and workshops is to mobilize knowledge to facilitate i) the structuring of health mediation in the regions, and ii) the development of an action plan with health mediators and other stakeholders to foster organized cancer screenings uptake by underserved people. This action plan must match with the needs of people living in informal housing, and must be coordinated, suitable and feasible to implement, in terms of knowledge about people living in informal housing specificities and specific local collaborations"
47953086|NCT02954250|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
47953087|NCT01938573|DRUG|Cisplatin|Given IV
47953088|NCT01938573|DRUG|Gemcitabine Hydrochloride|Given IV
47953089|NCT01938573|DRUG|Sirolimus|Given PO
47953090|NCT01938573|PROCEDURE|Cystectomy|Undergo cystectomy when appropriate
48108691|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - GUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones). Participants in this arm will receive weekly feedback from counselors through the web software used.
47953091|NCT02759484|BEHAVIORAL|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
47953092|NCT02759484|BEHAVIORAL|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
47953093|NCT02495831|DRUG|Diclofenac sodium|Diclofenac sodium 50 mg single dose
47953094|NCT02495831|DRUG|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
47980460|NCT03653650|COMBINATION_PRODUCT|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
48479485|NCT05288166|DRUG|Abemaciclib|Administered orally.
48479486|NCT05288166|DRUG|Abiraterone|Administered orally.
48479487|NCT05288166|DRUG|Prednisone or Prednisolone|Administered orally.
48479488|NCT05288166|DRUG|Placebo for Abemaciclib|Administered orally.
48479489|NCT00618033|PROCEDURE|Hemodialysis|varying concentration of glucose in dialysate
48479490|NCT04021355|OTHER|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
48479491|NCT02408445|DRUG|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
48479492|NCT01914523|DEVICE|Macintosh|Laryngeal exposure and tracheal intubation using that device
48479493|NCT01914523|DEVICE|King Vision|Laryngeal exposure and tracheal intubation using that device
48479494|NCT01914523|DEVICE|Glidescope|Laryngeal exposure and tracheal intubation using that device
48479495|NCT01914523|DEVICE|AirTraq|Laryngeal exposure and tracheal intubation using that device
48479496|NCT04461210|DIAGNOSTIC_TEST|Thermographic Imaging and Mechanical Pain Assessment|Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
48479497|NCT04366180|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10\^9 cfu/day) during 2 months
48479498|NCT04366180|DIETARY_SUPPLEMENT|Control|The control group will received one placebo capsule per day during 2 months
48479499|NCT01897623|OTHER|ultrasound of aorta|
48479500|NCT01658202|DRUG|V0116 transdermal patch (Test treatment )|
48479501|NCT01658202|DRUG|Nicotine transdermal patch (Reference Treatment )|
48479502|NCT02083419|DEVICE|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
48479503|NCT01503463|PROCEDURE|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
47953095|NCT03529812|BEHAVIORAL|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
48108692|NCT06245200|OTHER|UNIPDES - Internet Based Intervention - UNGUIDED|The experimental group participants will receive the internet-based intervention consisting of six weeks. This intervention has cognitive, emotional and behavioral components. Users will be able to use content created with video, audio, animation and interactive forms on their electronic devices (PC; tabs or smartphones).
47953096|NCT05182866|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
47953097|NCT05473208|DEVICE|Exoskeleton|Lumbar assistive exoskeleton evaluation
47953098|NCT04403360|PROCEDURE|ESPB|Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
47953099|NCT04403360|PROCEDURE|Local infiltration by the surgeon|Local infiltration of anesthetics at surgical site after skin incision
47953100|NCT04208997|DRUG|Antiarrhythmic drug|Continuation of amiodarone or sotalol.
48108693|NCT03726268|DRUG|Methadone|"Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients (10 mg if ≤55kg), and 10 mg in same-day surgery patients."
48108694|NCT03726268|DRUG|Fentanyl|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
48300412|NCT01733069|DEVICE|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
48300413|NCT02385461|DRUG|Low Molecular Weight Heparins (LMWHs)|
48300414|NCT01704781|DRUG|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
48300415|NCT01704781|DRUG|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
48638275|NCT05061095|OTHER|Assessment Surveys|Patients will complete surveys in three periods. An initial baseline survey, longitudinal assessments completed every 2 weeks over the course of the first three months on study (6 times maximum), and extended assessments that will happen every 3 months after the initial longitudinal period up to 2 years on the study (7 times maximum). Baseline questionnaire will collect demographic and background medical record information. Longitudinal assessments will consist of a BWS questionnaire (patients rate importance of 7 treatment goals), decisional conflict scales, EQ-5D-5L, distress thermometer, and items from PRO-CTCAE. Extended assessments will use same questionnaires as longitudinal assessments.
47953101|NCT04687995|PROCEDURE|Endoscopic myringoplasty|Endoscopic myringoplasty by using two different grafts one each time
47953102|NCT05231304|PROCEDURE|Total Talus Replacement (TTR)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
47953103|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement (TATTR)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
47953104|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
47953105|NCT05231304|PROCEDURE|Total Talus Replacement + Subtalar Fusion (TTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
47953106|NCT00174330|DRUG|atorvastatin|
47953107|NCT00174330|DRUG|amlodipine|
47953108|NCT06215807|PROCEDURE|Femtosecond laser arcuate keratotomy|The patient will receive femtosecond laser arcuate keratotomy and femtosecond laser-assisted cataract surgery with implantation of a monofocal intraocular lens in one eye.
47953109|NCT06215807|PROCEDURE|Toric intraocular lens implantation|The patient will receive femtosecond laser-assisted cataract surgery with implantation of a Toric monofocal intraocular lens in the contralateral eye.
47953110|NCT02884882|OTHER|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
47953111|NCT02296073|DRUG|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
47953112|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
47953113|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
47953114|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
47953115|NCT02296073|DRUG|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
47953116|NCT02296073|OTHER|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
47953117|NCT01524731|DRUG|Saline|Normal Saline
47953118|NCT01524731|DRUG|Dexamethasone|4 mg
47953119|NCT01524731|DRUG|Dexamethasone|8 mg
47953120|NCT05406648|OTHER|Morus nigra concentrate|The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
48108695|NCT03726268|DRUG|Hydromorphone|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
48108696|NCT03726268|DRUG|Morphine|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
48300416|NCT01704781|DRUG|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
48300417|NCT01704781|DRUG|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
48300418|NCT06403384|DEVICE|Vibration|Local vibration was applied
48479504|NCT04572139|DIAGNOSTIC_TEST|Pituitary stimulation test|Pituitary stimulation with 0.1 mg LHRH, 0.2 mg TRH and 0.25 mg ACTH
47953121|NCT01845142|DRUG|single administration of 100.000 I.U. vitamin D|
47953122|NCT01845142|DRUG|Placebo|
47953123|NCT00760500|OTHER|Nasopharyngeal Swab|Nasopharyngeal Swab
47953124|NCT03334110|PROCEDURE|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
47953125|NCT03334110|PROCEDURE|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
47953126|NCT00933829|PROCEDURE|Absorbable Suture Arm|use of irradiated polyglactin 910
47953127|NCT00933829|DEVICE|Non-absorbable suture (Prolene)|suture
47953128|NCT00933829|PROCEDURE|suture|non-absorable sutures and absorable sutures
47953129|NCT04708106|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS Tobacco Flavor product
47953130|NCT04708106|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS Menthol product
47953131|NCT04708106|OTHER|RELX ENDS Tobacco and Menthol Flavors|Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products
48108697|NCT03726268|DRUG|Sufentanil|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
48479505|NCT00265044|BEHAVIORAL|Provider Education|
47953132|NCT00794703|DRUG|micafungin (Mycamine)|Intravenous
47953133|NCT00794703|DRUG|itraconazole|oral
47953134|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|"After course 1 MRD will be evaluated:~- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance."
48108698|NCT01441453|PROCEDURE|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
48108699|NCT00460785|DRUG|Opioid|
48108700|NCT03488056|OTHER|ICCMS|"The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
48108701|NCT03488056|OTHER|SESC standard care|Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
48108702|NCT03301454|DRUG|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
48108703|NCT00967512|DRUG|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
48479506|NCT00265044|BEHAVIORAL|Hypertension Alert|
48479507|NCT00265044|BEHAVIORAL|Patient Education|
47953135|NCT03610438|DRUG|Inotuzumab Ozogamicin (IO)|After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
47953136|NCT04726670|OTHER|Evaluation of postoperative pain|"A participant voluntary consent form was obtained from each patient. Ninety patients were numerically coded in computer environment by someone who was not included in the study for randomization (www.random.org).~A single clinician performed retreatment on each of the 90 teeth during a single visit."
47953137|NCT06429111|PROCEDURE|Epidural analgesia|Consists of a central nerve block by injecting a local anesthetic near the nerves that transmit pain, in the lumbar region, for pain relief during labor.
47953138|NCT06429111|PROCEDURE|Immersion water|Consists of the use of hot water immersion in a birthing tub during labor and/or delivery.
47953139|NCT01999153|DRUG|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
47953140|NCT01999153|DRUG|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
47953141|NCT05007210|OTHER|Prenatal massage therapy|Pregnant women in the intervention group had a whole body prenatal massage therapy every week between 30th and 34th gestational weeks (once a week, 5-weeks in total and 60-minutes each).Session content for the prenatal massage therapy group was created by the researcher who was 640-hours trained massaging midwife.It included 12 different massage techniques (Osborne 2015, Osborne 2021).Also, the session, which included deep tissue and Sweden massage methods, had been applied.Each session began with the pregnant woman in a side-lying position with standart special pillows (30-minutes for left, 30-minutes for right).EFM, BPP, vital signs, FHR evaluation were carried out for all participants per visiting the hospital for the study.BPP before and after prenatal massage therapy was evaluated by an obstetrician.A phone number was set for the study, and this phone number was used by the massaging midwife.The service has been provided for pregnant women to reach her whenever they want.
47953142|NCT04521374|BEHAVIORAL|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
47953143|NCT00896935|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
47953144|NCT01034189|DRUG|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
48300419|NCT03271008|DEVICE|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
48300420|NCT03271008|DEVICE|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
48300421|NCT03271008|DEVICE|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
48300422|NCT05174052|DRUG|Dapagliflozin 10Mg Tab|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
48300423|NCT05174052|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
48300424|NCT05666011|DEVICE|M22 IPL|IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
48300425|NCT06030895|DRUG|Sorafenib Tablets|Sorafenib Tablets (200 -400 mg) twice daily
48300426|NCT02804802|OTHER|questionnaire|dietary habits and physical activity questionnaire
48300427|NCT02615717|BEHAVIORAL|Attention Bias Modification|comparison of treatment versus control
48300428|NCT04353622|DEVICE|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~* 10 minutes elbow flexion/extension~* 10 minutes forearm supination/pronation~* 10 minutes wrist flexion/extension~* 10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
48108704|NCT00967512|DRUG|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
48300429|NCT04353622|OTHER|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
48300430|NCT05940987|BEHAVIORAL|Phone-based smoking cessation intervention|Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
48479508|NCT01665651|DRUG|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
48108705|NCT00967512|DRUG|idarubicin, cytarabine|idarubicin, cytarabine
48108706|NCT04433429|DIETARY_SUPPLEMENT|Liposcudil Plus|
48108707|NCT05675956|DEVICE|Experimental group with 100% intensity setting on Apollo Neuro device|The group will have the device set to 100% intensity at one of their two experimental visits.
48108708|NCT05675956|DEVICE|Active Comparator group with 10% intensity setting on the Apollo Neuro device|The group will have the device set to 10% intensity at one of their two experimental visits.
48300431|NCT02143518|BIOLOGICAL|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
48300432|NCT02143518|BIOLOGICAL|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
48300433|NCT03321786|OTHER|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
48479509|NCT01665651|DRUG|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
48479510|NCT01665651|DRUG|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
48479511|NCT01665651|DRUG|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
48479512|NCT05755087|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48108709|NCT01002768|DRUG|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
48108710|NCT01002768|DRUG|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
48108711|NCT01979354|DRUG|Spinal morphine|0.15 mg spinal morphine
48108712|NCT01393353|OTHER|Cognitive Training|
48108713|NCT01393353|OTHER|computer game|
48300434|NCT03340077|OTHER|Medicines Optimisation Review toolkit|The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
48300435|NCT03340077|OTHER|Standard of Care|Pharmacist review of ART medications
48300436|NCT04863287|BIOLOGICAL|2217LS|Fully Human Monoclonal Antibody
48300437|NCT04863287|OTHER|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
48300438|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
48300439|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
48300440|NCT02992470|DIETARY_SUPPLEMENT|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
48300441|NCT02992470|DIETARY_SUPPLEMENT|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
48300442|NCT02703805|OTHER|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
47953145|NCT01034189|DRUG|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
47953146|NCT01034189|DRUG|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
47953147|NCT01034189|RADIATION|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
47953148|NCT02649088|DEVICE|Microscan|It allows to look at sublingual microcirculation
47953149|NCT02649088|DEVICE|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
48108714|NCT05434650|DEVICE|electrophysiology study and ablation with an Abbott Ablation Catheter|During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
48300443|NCT02703805|OTHER|Standard YMCA membership|A 12 week standard YMCA membership.
48300444|NCT00653835|DRUG|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
48300445|NCT00653835|DRUG|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
48300446|NCT05385718|OTHER|Magnetic Resonance Imaging|Participants are required to undergo a non-invasive magnetic resonance imaging (MRI) scan approximately 30 minutes in length.
48300447|NCT01868373|BIOLOGICAL|Microbiota Transplantation (FMT)|Active therapy
48300448|NCT00275405|DRUG|Garlic Oil Macerate|
48300449|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
48300450|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
48300451|NCT06252610|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
48300452|NCT06252610|DRUG|Contrast Media, Magnetic Resonance|"The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected."
48479513|NCT05755087|PROCEDURE|Computed Tomography|Undergo CT
48479514|NCT05755087|PROCEDURE|Positron Emission Tomography|Undergo PET scan
47980461|NCT03653650|COMBINATION_PRODUCT|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
47980462|NCT03653650|COMBINATION_PRODUCT|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
48479515|NCT05755087|DRUG|Tegavivint|Given IV
48479516|NCT01755117|OTHER|Sciatic, femoral, obturator nerve blocks|
48479517|NCT01755117|OTHER|Sciatic nerve block, posterior lumbar plexus block|
47980463|NCT00089765|DRUG|Ranibizumab|
47980464|NCT02638727|DRUG|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
48108715|NCT04132024|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
48108716|NCT02740686|OTHER|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
48108717|NCT01630772|OTHER|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
48108718|NCT01630772|OTHER|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
48638276|NCT05061095|OTHER|Qualitative Interviews|Patients will participate in 2 interviews (1 initial interview, 1 follow up). These will be cognitive interviews focusing on establishing content validity for BWS questionnaire. Will establish patient understanding of questions asked in BWS, understanding of how preferences affect treatment decisions, expected outcomes, and feedback from patients on other potentially important attributes not included in BWS.
47953150|NCT05218720|DIAGNOSTIC_TEST|EuroSCORE II|"* Euro score II: Predicts risk of in-hospital mortality after major cardiac surgery. Risk category will be defined as very low risk \<1, low risk 1-2.99, moderate risk 3-4.99, high risk \>5.~* CAM- ICU: The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a tool used to assess delirium among patients in the intensive care unit. It is an adaptation of the CAM which was originally developed to allow non-psychiatrists to assess delirium at the bedside. It ranges from 0 to 7, score greater to or equal to 3 will be considered positive for delirium, further categorized as 0-2 no delirium, 3-5 mild delirium 6-7 severe delirium with 7 being most severe."
47953151|NCT04768075|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
47953152|NCT04768075|DRUG|Placebo|IV infusion Simulator of Camrelizumab
47953153|NCT04768075|DRUG|Cisplatin|IV infusion
47953154|NCT04768075|DRUG|Carboplatin|IV infusion
48108719|NCT05664100|DRUG|FX-345|Single intratympanic injection of FX-345
48108720|NCT05664100|DRUG|Placebo|Single intratympanic injection of placebo
48108721|NCT02371746|DRUG|ENV515-3 Travoprost XR|
48108722|NCT02371746|DRUG|ENV515-1 Travoprost XR|
48108723|NCT02371746|DRUG|ENV515-3-2 Travoprost XR|
48108724|NCT00390728|DRUG|Insulin Glargine|
48638277|NCT04287647|DEVICE|Transpyloric stent|See arm/group descriptions
48108725|NCT02391207|PROCEDURE|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
48638278|NCT04287647|OTHER|Sham|Sham
48638279|NCT05441449|DEVICE|Cooling Vest|"A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user."
48638280|NCT05051358|PROCEDURE|Therapeutic Endoscopic Ultrasound|Therapeutic Endoscopic Ultrasound or Interventional Endoscopy for Gastrointestinal Indications
48638281|NCT05265364|RADIATION|IMRT with SIB|moderate hypofractioation using 2.5gy/fr in prostate cancer patients usig IMRT SIB technique
48638282|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
48638283|NCT01504542|BIOLOGICAL|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
48638284|NCT01504542|BIOLOGICAL|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
48638285|NCT01125644|DRUG|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
48638286|NCT03989908|OTHER|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
48638287|NCT03989908|OTHER|Control noodle|In this intervention arm, subjects will be served with normal noodle.
48655913|NCT06565000|OTHER|AHA Instrumented then AHA Not Instrumented|"First, the participant will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Then, will undergo a performance assessment using the Assisting Hand Assessment test.~Finally, they will go to the occupational therapy room where a second round of assessment using the Assisting Hand Assessment without markers will be conducted."
47953155|NCT04768075|DRUG|Pemetrexed|IV infusion
47953156|NCT04768075|DRUG|Paclitaxel|IV infusion
47953157|NCT04768075|DRUG|Albumin paclitaxel|IV infusion
47953158|NCT01482273|PROCEDURE|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
47953159|NCT01482273|PROCEDURE|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
47953160|NCT05668975|DEVICE|Inspiratory Muscle Training|A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
47953161|NCT02600065|OTHER|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
47953162|NCT06203093|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
48108726|NCT06182462|DEVICE|Virtual Reality Distraction|"The experimental group will receive a VR video game called DREAM DENTAL designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. The VR video game aims at reducing anxiety in children aged 6 to 17 years old by means of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant or resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded."
48108727|NCT06182462|DEVICE|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes viewing cartoons on a muted mounted television set and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia, according to the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
48300453|NCT06252610|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
48300454|NCT03702205|DIETARY_SUPPLEMENT|Betaine supplementation|Group taking oral betaine supplementation
48300455|NCT03702205|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
48339842|NCT02069704|DRUG|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
48339843|NCT04657354|PROCEDURE|Assessment|Early surgical assessment
48479518|NCT06147531|BIOLOGICAL|Delayed Cold-Stored Buffy Coat Platelets|To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
48655914|NCT06492928|OTHER|Psychomotor Vigilance Task|T0 - at the start of the shift: completion of the 1st PVT / socio-demographic and workstation questionnaire T1 - at the end of the shift: completion of the second PVT and questionnaire on the course of the shift that has just taken place T2 - 1 week after the end of the shift: additional questionnaire sent with scales to assess work-related fatigue (MBI), anxiety (PSS), sleep quality (PSQI) and chronotype (MEQ).
47953163|NCT03070886|DRUG|Bicalutamide|Given orally (PO)
47953164|NCT03070886|DRUG|Degarelix|Given IM
47953165|NCT03070886|DRUG|Docetaxel|Given IV
47953166|NCT03070886|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
48108728|NCT03229707|DEVICE|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~* Images are then opened into Photoshop.~* The INFO panel must be open.~* Click on the small eyedropper in the Info panel window and click on ''Lab Color.~* Place the mouse over the center of the tooth to be measured for L value.~* Click on the HSB Color option, which stands for hue, saturation, and brightness."
48108729|NCT03229707|DEVICE|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
48108730|NCT03824080|DRUG|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
48108731|NCT01056835|DRUG|prostaglandin I2 analogue|
48108732|NCT01168154|DIETARY_SUPPLEMENT|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
48108733|NCT01168154|DIETARY_SUPPLEMENT|placebo|placebo
48108734|NCT01736098|OTHER|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
48108735|NCT05244486|DEVICE|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
47953167|NCT03070886|DRUG|Flutamide|Given PO
47953168|NCT03070886|DRUG|Goserelin|Given IM
47953169|NCT03070886|DRUG|Goserelin Acetate|Given IM
47953170|NCT03070886|OTHER|Laboratory Biomarker Analysis|Correlative studies
47953171|NCT03070886|DRUG|Leuprolide|Given intramuscularly (IM)
48638288|NCT06149013|DEVICE|MindAhead Active|MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.
48638289|NCT06149013|OTHER|Treatment-as-usual|Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
48638290|NCT05249855|BEHAVIORAL|Psychological measurement|Psychological assessment
48300456|NCT04376268|DRUG|Chlorhexidine mouthwash|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48638291|NCT01433081|DRUG|Placebo infusion of .9 normal saline|administration of .9 normal saline
48300457|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48300458|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48479519|NCT06147531|BIOLOGICAL|Room Temperature Buffy Coat Platelets|Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
48638292|NCT01433081|DRUG|administration of magnesium sulfate|administration of magnesium sulfate
48638293|NCT03091491|DRUG|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
48638294|NCT03091491|DRUG|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
47953172|NCT03070886|DRUG|Leuprolide Acetate|Given IM
47953173|NCT03070886|DRUG|Nilutamide|Given PO
47953174|NCT06295757|OTHER|Cigarettes|Participants will smoke their own usual brand cigarettes. Cigarette butts will be collected.
47953175|NCT00887653|DRUG|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
47953176|NCT00232648|DRUG|Pulmicort (budesonide) Respules|
47953177|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
47953178|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
48638295|NCT01748552|DRUG|Placebo|Administered orally as capsules
48638296|NCT01748552|DRUG|LY2922083|Administered orally as capsules
47953179|NCT04875169|DRUG|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
47953180|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
47953181|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
47953182|NCT01181908|DRUG|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
47953183|NCT00806975|DEVICE|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
47953184|NCT00315146|DRUG|Pioglitazone|
48638297|NCT05835687|DRUG|B7-H3-CAR T cells|Autologous T cells transduced with a lentiviral vector expressing a B7-H3-CAR with a CD28z signaling domain and 41BB ligand (B7-H3-CAR T cells). Four (4) infusions of B7-H3-CAR T cells will be locoregionally administered via CNS reservoir catheter.
48638298|NCT06012695|DRUG|NBM-BMX Capsule|Each capsule contains 100 mg of the active ingredient.
48300459|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48638299|NCT06012695|DRUG|Temozolomide|TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
48638300|NCT06012695|RADIATION|Standard radiotherapy|A total dose of 60 Gy will be administered in 6 weeks.
47953185|NCT00315146|BEHAVIORAL|Resistance exercise training to maximize muscle power|
47953186|NCT00315146|BEHAVIORAL|Hypocaloric diet|
48300460|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48339844|NCT05488418|OTHER|Clinical, cognitive and biological tests|"Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests.~A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood.~For eligible subjects a brain MRI will be proposed at the first visit."
48339845|NCT00880607|DRUG|Intrathecal morphine|Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
48479520|NCT05518916|OTHER|Nonfarmacology method|Yakson Method and Swaddling
48479521|NCT04733209|OTHER|TENS, US, exercise|Physiotherapy
48479522|NCT06334861|BIOLOGICAL|Herpes Zoster adjuvanted recombinant vaccine|patients will receive two doses of vaccine with an interval between the first and second dose of 2 months
48638301|NCT05348915|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
47953187|NCT00315146|DRUG|Placebo|
47953188|NCT01228864|PROCEDURE|quality of life|survey
47953189|NCT01228864|PROCEDURE|Quality of life|
47953190|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 3% NaOCl in partial pulpotomy
48108736|NCT05244486|DEVICE|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
48638302|NCT05356611|BEHAVIORAL|Engage|Engage is a 9-week, behavioral-based, psychotherapy treatment protocol for late-life depression.
48638303|NCT02532946|BEHAVIORAL|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
48638304|NCT01766843|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
48638305|NCT01766843|DRUG|Seretide Diskus|2 inhalations as a single dose
48638306|NCT01766843|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
48638307|NCT01766843|DRUG|SF Easyhaler|2 inhalations as a single dose
47953191|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 2% Chlorhexidine in partial pulpotomy
47953192|NCT03980431|DIAGNOSTIC_TEST|FBY PET Examination|A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
47953193|NCT03498066|DRUG|Beta-blockers withdrawal|withdrawal of all type of betablockers
47953194|NCT03498066|DRUG|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
47980465|NCT02638727|DRUG|placebo|This group treat with placebo dayley
47953195|NCT04575623|DIAGNOSTIC_TEST|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~* Duration Pattern test (DPT) designed to test temporal ordering abilities.~* Dichotic Digits Test (DDT) it assesses binaural integration skills.~* Auditory fusion test-revised (ART-R) to measure temporal resolution.~* speech in test to assess central auditory function."
48300461|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48300462|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48300463|NCT04376268|PROCEDURE|Boric acid mouthwash (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48300464|NCT05331664|PROCEDURE|Pars plana vitrectomy|Standard of care surgery
48300465|NCT05331664|DRUG|Triamcinolone Acetonide 40mg/mL|Sub-tenon injection of triamcinolone acetonide (40mg/mL) at the time of surgery
48300466|NCT05331664|DRUG|Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin|Antibiotic eye drop 4 times per day for 1 week after surgery
48300467|NCT05331664|DRUG|Prednisolone 1%|Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
48300468|NCT05331664|DRUG|Atropine 1%|Eye drop daily for 1 week after surgery
48300469|NCT01139723|DRUG|MINT1526A|Intravenous escalating dose
48300470|NCT01139723|DRUG|bevacizumab|Intravenous repeating dose
48108737|NCT06400446|OTHER|Standard care|The babies in this group will receive the standard care of the unit. The vital signs and pain scores of the babies will be recorded before the mother's visit for seven days. The vital signs and pain scores of the infants who received the standard care of the unit during one hour, which is the time of the mother's visit, will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
48300471|NCT04559906|OTHER|Spray and Stretch technique (Ethyl chloride)|"Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times."
48479523|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
48479524|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
48479525|NCT01634412|DRUG|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
48479526|NCT01634412|DRUG|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
47980466|NCT02422511|GENETIC|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
48638308|NCT05029362|BEHAVIORAL|SmokefreeSGM|Participants will have access to a text-based smoking cessation program tailored to sexual minority individuals (SmokefreeSGM). The text-based program will be beta-tested by these participants for a period of 2 weeks before and 10 weeks after their quit date. Messages originated from the text-based smoking cessation program will be sent by a fictitious quit coach who will offer evidence-based advice on quitting smoking based on real-life experiences of sexual minority individuals.
48300472|NCT04559906|OTHER|Sustain pressure release|"Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers."
48300473|NCT03103269|BEHAVIORAL|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
48300474|NCT03103269|OTHER|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
48300475|NCT03566537|PROCEDURE|Thyroidectomy|Thyroidectomy
48300476|NCT02610088|DRUG|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
48300477|NCT02610088|DRUG|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
48300478|NCT04389606|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
48300479|NCT04389606|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
48108738|NCT06400446|OTHER|Kangaroo care|Kangaroo care will be applied to the experimental group for seven days. Kangaroo care will be started for the babies in the intervention group when the baby is extubated, when the baby starts oral feeding and when the chest incision is closed. Consistent with previous research, mothers will provide skin-to-skin contact for at least 1 hour per day for seven days, starting immediately after feeding. The vital signs and pain scores of the babies will be recorded during the kangaroo care of the mother for seven days. During the kangaroo care, vital signs and pain scores of the infants will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
48300480|NCT03593304|DRUG|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
48300481|NCT03593304|DRUG|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
48300482|NCT03593304|DRUG|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
48300483|NCT03593304|DRUG|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
48638309|NCT04829214|DRUG|OTO-313|Single intratympanic injection
48638310|NCT04829214|DRUG|Placebo|Single intratympanic injection
48108739|NCT04424836|DEVICE|high flow nasal cannula device|device is supplying oxygen with heated and humidified air in a high flow rate
48300484|NCT01893593|OTHER|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
48300485|NCT01893593|OTHER|Control|Guideline summary and data feedback from a baseline medical record review
48300486|NCT05564598|BIOLOGICAL|CMV Cytotoxic T-Lymphocytes|Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.
48300487|NCT05564598|DRUG|Anti-viral Therapy|"All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months"
48300488|NCT03287297|DIAGNOSTIC_TEST|OGTT & HBA1c|oral glucose tolerance test \& HBA1c: by measuring glycated hemoglobin
48300489|NCT02682888|BEHAVIORAL|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
48300490|NCT02682888|DRUG|Oxytocin|intranasal administration of oxytocin
48300491|NCT02682888|DRUG|Placebo|intranasal administration of placebo
48300492|NCT06298773|OTHER|Spatial analysis of paraffin samples from solid tumors|The intervention involves the collection of tumour samples included in paraffin present in the pathological anatomy archive or requested to external archives for samples older than 2003 and the subsequent multiparametric spatial analysis of the main populations of the microenvironment tumor.
48638311|NCT06240143|DRUG|Ipilimumab|intradermal
47980467|NCT02422511|OTHER|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
48638312|NCT06240143|DRUG|Nivolumab|intradermal
48638313|NCT06240143|DRUG|Nivolumab|intravenous
48638314|NCT05100017|DRUG|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
48300493|NCT03919890|DRUG|ONO-7684|Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
48300494|NCT03919890|DRUG|ONO-7684 Placebo|Placebo comparator
48300495|NCT00293072|DRUG|Rituximab|
48300496|NCT05354284|OTHER|online questionnaire|Questionnaire at three timepoints
48300497|NCT01809561|PROCEDURE|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
48300498|NCT01972477|DRUG|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
48300499|NCT01972477|OTHER|Placebo|Placebo will be given every day for 8 weeks.
48300500|NCT00390364|DRUG|everolimus|
47953196|NCT04575623|DEVICE|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~* Dual band pure tone audiometer (Orbiter 992).~* Impedance audiometer (AT 235h).~* Sound treated booth (industrial acoustic company IAC model 1602-A-t)~* Panasonic stereo CD player SA-AK 240."
48300501|NCT00390364|PROCEDURE|antiangiogenesis therapy|
48300502|NCT00390364|PROCEDURE|biopsy|
48300503|NCT00390364|PROCEDURE|diagnostic procedure|
47953197|NCT04753528|DEVICE|AuriMod CT01_A|AuriMod CT01 is a wearable medical device for personalised pain treatment through auricular vagus nerve stimulation. AuriMod CT01 is a battery-operated electrical stimulation device, to be placed behind the ear on the neck. AuriMod CT01 connects to three needle electrodes, which are placed in vagally innervated regions of the auricle. It emits electrical signals with a personalized set of stimulation parameters and adjustable amplitude.
47953198|NCT04753528|DEVICE|AuriMod CT01_B|AuriMod CT01 with a fixed set of stimulation parameters and adjustable stimulation amplitude.
47953199|NCT04753528|DEVICE|AuriMod CT01_C|AuriMod CT01 with a fixed set of stimulation parameters and amplitude.
47953200|NCT03959631|BEHAVIORAL|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
48300504|NCT00390364|PROCEDURE|gene expression analysis|
48300505|NCT00390364|PROCEDURE|immunohistochemistry staining method|
47953201|NCT06362070|DEVICE|DaVinci® Surgical System|Assisted-robotic radical Gastrectomy
48300506|NCT00390364|PROCEDURE|laboratory biomarker analysis|
48300507|NCT00390364|PROCEDURE|mutation analysis|
48300508|NCT00390364|PROCEDURE|protein tyrosine kinase inhibitor therapy|
48300509|NCT00390364|PROCEDURE|reverse transcriptase-polymerase chain reaction|
47953202|NCT06362070|DEVICE|Hugo™ RAS System|Assisted-robotic radical Gastrectomy
48300510|NCT02316093|OTHER|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
48300511|NCT05506332|DRUG|Venetoclax|Venetoclax and 6-mercaptopurine
48300512|NCT05506332|DRUG|6-mercaptopurine|Venetoclax and 6-mercaptopurine
48300513|NCT03247907|DEVICE|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
47953203|NCT06362070|DEVICE|Versius® Robotic Surgery System|Assisted-robotic radical Gastrectomy
47953204|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
47953205|NCT00853346|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
47953206|NCT00137683|BEHAVIORAL|one-on-one education, group education, small media|
47980468|NCT02845544|OTHER|Pilates-based exercises|
47980469|NCT03007160|DRUG|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
47980470|NCT01428089|DRUG|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
48300514|NCT03247907|DEVICE|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
47980471|NCT01428089|DRUG|Placebo|Placebo
48300515|NCT03247907|DEVICE|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
48300516|NCT03247907|DEVICE|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
48300517|NCT03247907|DEVICE|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
48300518|NCT03247907|DEVICE|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
48300519|NCT03247907|DEVICE|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
48300520|NCT03247907|DEVICE|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
48300521|NCT03321292|DRUG|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
48300522|NCT03321292|DRUG|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
48300523|NCT02543398|PROCEDURE|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
48300524|NCT03556683|DEVICE|3% Hypertonic Saline|4 mL of 3% hypertonic saline
48300525|NCT03556683|DEVICE|7% Hypertonic Saline|4 mL of 7% hypertonic saline
48300526|NCT01818791|BEHAVIORAL|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
48300527|NCT01818791|BEHAVIORAL|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
48300528|NCT01052597|DRUG|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
48300529|NCT06488573|BEHAVIORAL|Nutritional intervention|7 individual sessions + 8 small group sessions
48300530|NCT04076124|DEVICE|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
48300531|NCT04076124|DEVICE|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
48300532|NCT04076124|DEVICE|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
48300533|NCT03474523|OTHER|Experimental group|"Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
48300534|NCT03474523|OTHER|Control group|"Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
48300535|NCT01300780|DRUG|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
48300536|NCT01300780|OTHER|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
48300537|NCT06106022|DRUG|Vonoprazan|Administered orally
48300538|NCT05423158|BEHAVIORAL|d-Coaching|"MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device \& mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features."
48300539|NCT02021500|DRUG|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
48108740|NCT06556251|DEVICE|PIPPEP App|"Digital platform with psichoeducative content in infographics, animated and testimonial videos about:~* psychotic and comorbid symptoms, substance use, available treatments, healthy lifestyle habits, social and health emergency resources and outpatient clinics for young people.~* Regular self-completed questionnaires to measure alarm symptoms, side effects of pharmacological treatment, emotional state, and treatment adherence. There will be a feedback for patients in the form of graphs of the evolution of the different types of questionnaires.~* A bidirectional messaging service with the professional reference team, allowing better accessibility in non-urgent cases.~* A gamification system to encourage use of the application, which includes points, rewards, a leaderboard and mini-games.~* A folder where patients can keep documents they find useful (personal reports, relapse prevention plan, crisis plan)."
48108741|NCT03749590|DRUG|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
48108742|NCT03749590|DRUG|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
48300540|NCT00085540|DRUG|depsipeptide|Given IV
48300541|NCT04613583|OTHER|SAFeR fetuses|NO active intervention performed.
48300542|NCT00692705|DRUG|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
48300543|NCT00692705|DRUG|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
48108743|NCT02616835|DEVICE|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
48300544|NCT01344811|PROCEDURE|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
47953207|NCT05328063|OTHER|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
48300545|NCT01344811|OTHER|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
48300546|NCT01280123|DRUG|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
48300547|NCT01280123|DRUG|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
48300548|NCT00672542|BIOLOGICAL|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
48300549|NCT03170336|DRUG|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
48300550|NCT03170336|DRUG|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
48300551|NCT00355004|OTHER|counseling intervention|
48300552|NCT00355004|PROCEDURE|fecal occult blood test|
48300553|NCT00355004|PROCEDURE|screening colonoscopy|
48300554|NCT04002440|COMBINATION_PRODUCT|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
48300555|NCT04002440|DEVICE|HomeChoice PRO|Usual care
48300556|NCT03632512|DIETARY_SUPPLEMENT|Hericium honey bolus|The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
48300557|NCT03632512|DIETARY_SUPPLEMENT|Placebo honey bolus|The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
48300558|NCT03159754|PROCEDURE|Early Appendectomy|Removal of the appendix within 24 hours of admission
48300559|NCT03159754|PROCEDURE|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
48300560|NCT03159754|DRUG|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
48300561|NCT02657252|DRUG|Glucose|Sclerotherapy of telangiectasis in one lower limb.
48300562|NCT02657252|DRUG|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
48300563|NCT06273241|OTHER|food intake|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics..
48300564|NCT00003667|DRUG|cyclophosphamide|
47980472|NCT00462774|PROCEDURE|Intramyocardial injection of autologous CD133+ marrow cells|
47980473|NCT03599024|PROCEDURE|PCEA|The patients were able to control the administration of analgesics by themselves.
48300565|NCT00003667|DRUG|dexrazoxane hydrochloride|
48300566|NCT00003667|DRUG|disaccharide tripeptide glycerol dipalmitoyl|
48300567|NCT00003667|DRUG|doxorubicin hydrochloride|
48300568|NCT00003667|DRUG|vincristine sulfate|
48300569|NCT00003667|PROCEDURE|surgical procedure|
48300570|NCT00003667|RADIATION|radiation therapy|
48300571|NCT06307080|DEVICE|Multi-mode thermal ablation device|The tumor tissue was rapidly frozen until the ice ball exceeded 5mm of the lesion tissue, kept for 5 minutes, then thawed and warmed. Then, complete ablation was performed according to the radiofrequency temperature control mode of multimodal tumor therapy to ensure that the ablation area included a safe range of 5\~10mm around the tumor.
48300572|NCT06307080|DRUG|Intravenous anti-PD-1 and chemotherapy|intravenous anti-PD-1 and chemotherapy
48300573|NCT01401088|DEVICE|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
48300574|NCT02456116|DEVICE|acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
48300575|NCT02456116|DEVICE|sham acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
48300576|NCT02456116|OTHER|PCA/NSAID|standard boli of morphine by pressing a button of PCA
48300577|NCT04747574|DRUG|EXO-CD24|The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
48300578|NCT05438485|OTHER|Registry|Observational (Registry)
48300579|NCT03198169|DEVICE|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
48300580|NCT03198169|DEVICE|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
48300581|NCT03551145|OTHER|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
48300582|NCT03551145|OTHER|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
48300583|NCT00984464|BIOLOGICAL|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
48300584|NCT00984464|DRUG|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
48300585|NCT00984464|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
48300586|NCT01997567|DRUG|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
48300587|NCT01997567|DRUG|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
48300588|NCT02573805|DEVICE|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
48300589|NCT04341844|DRUG|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
48479527|NCT06598293|BEHAVIORAL|PRO-CTCAE, Pain NRS|The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
48638315|NCT05100017|DRUG|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
48638316|NCT00144508|DRUG|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
47980474|NCT03599024|PROCEDURE|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
48300590|NCT04341844|DRUG|Placebo|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
48300591|NCT05104151|DIETARY_SUPPLEMENT|Nutritional bar|Protein-based nutritional bar, providing 155 calories per bar
48300592|NCT05104151|BEHAVIORAL|Healthy Habits Intervention|The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
48300593|NCT02791789|OTHER|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
48300594|NCT02028689|DRUG|Lesinurad 400 mg|
48300595|NCT02028689|DRUG|Metformin 850 mg|
48300596|NCT02028689|DRUG|Furosemide 40 mg|
48300597|NCT05262595|DRUG|NNC0471-0119 A|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
48300598|NCT05262595|DRUG|NNC0471-0119 B|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
48479528|NCT03889834|PROCEDURE|Autologous Blood Transfusion|Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
48479529|NCT03889834|OTHER|No transfusion|no transfusion
48479530|NCT01082887|OTHER|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
48479531|NCT00031928|DRUG|mafosfamide|
48479532|NCT02147587|DRUG|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
48479533|NCT02147587|DRUG|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
47980475|NCT03599024|PROCEDURE|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
48638317|NCT00144508|OTHER|current treatment|continue current treatment
48638318|NCT03076164|DRUG|Trametinib|Trametinib 1.5mg once daily by mouth
48638319|NCT03076164|DRUG|Erlotinib|Erlotinib 75mg once daily by mouth
48638320|NCT03976141|DIAGNOSTIC_TEST|mri|knee mri
48638321|NCT06134895|DRUG|Tramadol with Ketamine|Tramadol with Ketamine is being provided randomly using prospective, double-blind
48300599|NCT05262595|DRUG|NNC0471-0119 D|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
48300600|NCT05262595|DRUG|Faster aspart|"Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
48300601|NCT02887105|OTHER|Standard neuropsychological assessment|
48300602|NCT02887105|OTHER|Brain MRI|
48479534|NCT01253317|DRUG|rhIGF-1|1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
48108744|NCT02616835|DEVICE|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
48108745|NCT02020616|DRUG|LY3053102|Administered SC
48479535|NCT01638858|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
48479536|NCT05015374|DIETARY_SUPPLEMENT|Astaxanthin|350 mg/capsule (2mg Astaxanthin)
48479537|NCT05015374|DIETARY_SUPPLEMENT|Placebo|Placebo
48479538|NCT03925935|BIOLOGICAL|AB-205|Engineered human umbilical vein endothelial cells
47980476|NCT02625272|PROCEDURE|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
47980477|NCT00934973|DRUG|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
47980478|NCT00934973|DRUG|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
48479539|NCT01909128|DIETARY_SUPPLEMENT|fermented milk|fermented milk with Lactobacillus CBA-L74
48479540|NCT01909128|DIETARY_SUPPLEMENT|fermented rice|fermented rice wit Lactobacillus CBA-L74
47980479|NCT00934973|DRUG|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
48108746|NCT02020616|DRUG|Exenatide ER|Administered SC
48479541|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration) in a HRT cycle, according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET."
48638322|NCT06134895|DRUG|Tramadol|Tramadol alone is being provided randomly using prospective, double-blind
48638323|NCT04721691|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is a schedule 5 controlled substance that is a colorless to yellow oral liquid solution that is prepackaged into 100mL vials with 5mL syringes for use. It is typically used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome in patients 2 years of age and older.
48108747|NCT02020616|DRUG|Placebo|Administered SC
48108748|NCT02020616|DRUG|Metformin|Administered orally (PO)
48108749|NCT02786602|GENETIC|pyrosequencing|
48108750|NCT01141322|DRUG|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
48108751|NCT01141322|DRUG|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
48300603|NCT03855306|DRUG|Glibesyn|1 tablet contains 5 mg Glibenclamide
48300604|NCT03855306|DRUG|Daonil|1 tablet contains 5 mg Glibenclamide
48300605|NCT03406949|BIOLOGICAL|obrindatamab|B7-H3 x CD3 DART protein
48300606|NCT03406949|BIOLOGICAL|retifanlimab|anti-PD-1 antibody
48300607|NCT05399758|DEVICE|NOL monitor|NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.
48300608|NCT02260193|DRUG|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
48300609|NCT02260193|DRUG|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
48300610|NCT02260193|DRUG|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
48300611|NCT01930734|DRUG|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
48300612|NCT01930734|DRUG|Normal Saline|Normal Saline solution 0.9% Placebo Arm
48300613|NCT01000064|DRUG|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
48300614|NCT01000064|PROCEDURE|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
48300615|NCT01000064|DRUG|Placebo|Placebo capsules taken every morning for 6 weeks.
48300616|NCT04656964|DRUG|remimazolam tosilate group|Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
48300617|NCT04656964|DRUG|Midazolam group|Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
48300618|NCT03502707|BIOLOGICAL|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
48300619|NCT03502707|BIOLOGICAL|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
48300620|NCT03502707|BIOLOGICAL|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
48300621|NCT03502707|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1\*10\^11 vp.
48300622|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
48300623|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
48300624|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
47953208|NCT05328063|OTHER|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
48300625|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
47953209|NCT02912078|OTHER|Pocket-warming|Pocket-warming of epidural medication
48300626|NCT03502707|BIOLOGICAL|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
47953210|NCT02912078|OTHER|Standard of Care Labor Epidural|Labor epidural medication administered per standard of care; no pocket warming.
48638324|NCT04721691|OTHER|Placebo|Placebo is composed of dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose.
48300627|NCT04205903|DRUG|Nilotinib|Given PO
48300628|NCT04205903|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.
47953211|NCT02812173|DEVICE|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
47953212|NCT02812173|DEVICE|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
47953213|NCT02812173|DEVICE|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
48300629|NCT04205903|DRUG|Paclitaxel|Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2
48300630|NCT04205903|OTHER|Placebo|Given PO
48300631|NCT04205903|OTHER|Questionnaire Administration|Ancillary studies
48300632|NCT02718794|PROCEDURE|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
48300633|NCT02718794|PROCEDURE|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
48300634|NCT00377065|DRUG|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
48300635|NCT06471140|OTHER|magnetic resonance imaging (MRI)|MRI performed three times during pregnancy and 6 months postpartum
48638325|NCT02761057|PROCEDURE|Biospecimen Collection|Undergo collection of plasma and serum samples
47953214|NCT03239184|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
47953215|NCT03239184|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
47953216|NCT01773252|DEVICE|Flow Detection System|
47953217|NCT03918473|OTHER|Mobilization with Movement|The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.
47980480|NCT00934973|BEHAVIORAL|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
47980481|NCT00934973|BEHAVIORAL|No website|No CBT website
47980482|NCT00934973|BEHAVIORAL|CBT website with minimal support|
48300636|NCT03216551|DIAGNOSTIC_TEST|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
48300637|NCT00058578|DRUG|Cyclophosphamide|
48300638|NCT00058578|DRUG|Mesna|
48300639|NCT00058578|DRUG|G-CSF|
48300640|NCT00058578|PROCEDURE|Leukopheresis|
48300641|NCT00058578|PROCEDURE|Total Body Irradiation|
48300642|NCT01544114|DRUG|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
48300643|NCT01544114|DRUG|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
48300644|NCT01544114|DRUG|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
48300645|NCT05433298|BIOLOGICAL|Mesenchymal stem cell|Administration of advanced cell product
48300646|NCT05433298|OTHER|Placebo|Ringer's lactate, albumin and heparin solution
48638326|NCT02761057|PROCEDURE|Bone Scan|Undergo bone scan
48638327|NCT02761057|DRUG|Cabozantinib S-malate|Given PO
47953218|NCT03918473|OTHER|Thrust Mobilization|The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
48300647|NCT03952897|OTHER|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
48300648|NCT00161304|DRUG|Testosterone Enanthate|Testosterone Enanthate
47953219|NCT00555451|DRUG|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~1. HE3286 5 mg or placebo QD for 28 days;~2. HE3286 10 mg (5 mg BID) or placebo BID for 28 days~3. HE3286 20 mg (10 mg BID) or placebo BID for 28 days~4. HE3286 40 mg (20 mg BID) or placebo BID for 28 days~5. HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~6. HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
47953220|NCT00740571|DRUG|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
48479542|NCT06097559|DIAGNOSTIC_TEST|Endometrial fluid and biopsy collection|"The ERA and EMMA test require an endometrial biopsy to be taken at P+5 (after 120±6 hours of exogenous progesterone administration), according to the common clinical practice. On the same day, a sample of endometrial fluid will be aspirated immediately prior to the biopsy.~Regardless of the endometrial receptivity profile, a subsequent regular FET will be performed within the standard WOI (after 120±6 hours of progesterone exposure) in an HRT cycle following the clinical standard practice.~Those patients willing to participate in the rescue phase will follow the recommendation of the ERA test for the subsequent pET. In case of a non-receptive endometrium result, a second EB sample must be collected when indicated by the ERA report. Fluid sample collection will not be repeated in these cases."
47953221|NCT00740571|DRUG|pregabalin|Strategy in which patient starts with pregabalin
48300649|NCT00161304|OTHER|Placebo|placebo
48300650|NCT02354170|DRUG|Mifepristone|
48300651|NCT02354170|DRUG|Placebo|
48300652|NCT00002706|PROCEDURE|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
47953222|NCT03064230|OTHER|QoL questionnaire SF-12 and and a screening questionnaire|patient were asked to fill questionnaires
47953223|NCT04789499|DRUG|Theophylline Powder|Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
48300653|NCT00002706|OTHER|Quality-of-Life Assessment|Ancillary studies
48300654|NCT00002706|PROCEDURE|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
48479543|NCT05089929|DEVICE|Endoflip 2.0|FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
48479544|NCT05089929|PROCEDURE|High Resolution Manometry|All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
48479545|NCT04649450|OTHER|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
48638328|NCT02761057|PROCEDURE|Computed Tomography|Undergo CT
48638329|NCT02761057|DRUG|Crizotinib|Given PO
48638330|NCT02761057|DRUG|Savolitinib|Given PO
48638331|NCT02761057|DRUG|Sunitinib Malate|Given PO
47953224|NCT04789499|DRUG|Placebo Comparator|Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
48300655|NCT03340792|DEVICE|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
48300656|NCT05611684|DRUG|Polyethylene Glycol Losenatide|Treatment 0.2mg QW for 12 weeks
48300657|NCT05839990|PROCEDURE|Surgery|Replacement of the ascending aorta in case of anerysm and dilatation
48300658|NCT01074411|DRUG|Bortezomib|Given IP
47980483|NCT04113304|BEHAVIORAL|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
48300659|NCT01074411|DRUG|Carboplatin|Given IP
48300660|NCT01074411|OTHER|Laboratory Biomarker Analysis|Correlative studies
48300661|NCT01074411|OTHER|Pharmacological Study|Correlative studies
48300662|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
48300663|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
48300664|NCT04729452|OTHER|blood test|blood test to test immune response to SARS-CoV-2
48300665|NCT05312905|OTHER|Mirror Therapy|Mirror Therapy applied alone
48300666|NCT05312905|OTHER|Mirror Therapy + Cognitive Therapy|Mirror Therapy supported with Cognitive Exercises
48300667|NCT01912872|DRUG|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
47953225|NCT05444621|RADIATION|Ultrasound and doppler|All patients are then assessed by transthoracic echocardiography to measure Left ventricle and Right ventricle function and to assess LVOT-VTI and SV. Doppler Ultrasound assessment of carotid arteries to assess corrected flow time (FTc), velocity time integral (VTI) and respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak). The patient will be assessed pre- and post- passive leg raising (PLR) and after fluid challenge of 30 mL/Kg of IV crystalloid
48300668|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
48300669|NCT01912872|DRUG|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
48300670|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
48300671|NCT01912872|DRUG|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
48300672|NCT05602597|DRUG|Itraconazole 200 mg|Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.
48300673|NCT05602597|DRUG|Fluconazole 400 mg|Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.
48300674|NCT05602597|DRUG|Rifampin 600 mg|Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.
48300675|NCT05602597|DRUG|Rabeprazole 40 mg|Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
48300676|NCT02292199|DEVICE|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
48300677|NCT02292199|DEVICE|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
48300678|NCT02292199|DEVICE|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
48300679|NCT05873413|BEHAVIORAL|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
48479546|NCT03786419|DRUG|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
48479547|NCT01729988|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
48479548|NCT01095523|PROCEDURE|Laparotomy+ HIPEC +/- CRS|
47953226|NCT06452238|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block .
48108752|NCT03400462|DRUG|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
48300680|NCT05873413|BEHAVIORAL|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
48479549|NCT02695940|DRUG|LEO 124249 ointment 30 mg/g|
47953227|NCT06452238|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound-guided transversus abdominis plane block.
48108753|NCT03400462|DEVICE|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
48300681|NCT05873413|BEHAVIORAL|Attention-only Control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
48300682|NCT02074215|OTHER|Aerobic exercises|Aerobic exercises + dual task
48300683|NCT02074215|OTHER|Stretch exercise|Stretch exercise
48300684|NCT01937130|DRUG|IDN-6556|
48300685|NCT01937130|OTHER|Placebo|
48300686|NCT05329467|OTHER|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
48479550|NCT02695940|OTHER|LEO 124249 ointment vehicle|
48479551|NCT01345526|DEVICE|Reconval K1 Cream|
48479552|NCT01345526|DEVICE|Reconval Cream|
48479553|NCT04855448|DEVICE|Micro Hand S robot and da Vinci robot|The surgeries are performed with the Micro Hand S robot and da Vinci robot
48479554|NCT04855448|DEVICE|da Vinci robot|The surgeries are performed with the da Vinci robot
48479555|NCT00604084|DRUG|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
48638332|NCT04097912|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|75-100mg
48479556|NCT00604084|DRUG|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
48479557|NCT00987831|OTHER|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
48479558|NCT00987831|OTHER|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
48479559|NCT00987831|DRUG|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
48638333|NCT04545866|DRUG|budesonide (Pulmicort nebulizing suspension).|The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
48638334|NCT04545866|DRUG|surfactant (poractant alfa;Curosurf)|The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
48638335|NCT06499948|DRUG|Treatment with Spironolactone followed by Dapagliflozin followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Dapagliflozin will be started. Patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone 25 mg and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
48638336|NCT06499948|DRUG|Treatment with Dapagliflozin followed by Spironolactone followed by their combination|After titrating the renin-angiotensin-system inhibitor dose, patients will receive 10 mg of Dapagliflozin once daily for 4 weeks. Dapagliflozin will be stopped after 4 weeks. The first treatment period will be followed by 4 weeks of wash-out. After the first wash-out period, treatment with Spironolactone will be started. Patients will receive 25 mg of Spironolactone once daily for 4 weeks. Spironolactone will be stopped after 4 weeks. The second treatment period will be followed by 4 weeks of wash-out. After the second wash-out period, treatment with both Spironolactone and Dapagliflozin will be started. Patients will receive 25 mg of Spironolactone once daily in combination with 10 mg of Dapagliflozin daily for a duration of 4 weeks. Spironolactone and Dapagliflozin will be stopped after 4 weeks. The third treatment period will be followed by 4 weeks of wash-out, after which the study will be finalized.
48638337|NCT04951453|OTHER|None (observational)|None (observational)
48108754|NCT03400462|OTHER|dry needling|Equipment: acupuncture needle 0,6\*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
48479560|NCT05483387|DEVICE|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
48638338|NCT01237093|OTHER|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda
47953228|NCT05420597|DRUG|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
47953229|NCT02694809|DRUG|Conjugated Estrogens/Bazedoxifene|Given PO
47953230|NCT02694809|OTHER|Laboratory Biomarker Analysis|Correlative studies
47953231|NCT02694809|OTHER|Pharmacological Study|Correlative studies
47953232|NCT02694809|OTHER|Placebo|Given PO
47953233|NCT02694809|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
47953234|NCT02694809|OTHER|Questionnaire Administration|Ancillary studies
47953235|NCT03862560|OTHER|Strength training program|Strength training program in female soccer players
48108755|NCT01490086|DRUG|RP5063|daily
48108756|NCT01490086|DRUG|placebo|daily
48108757|NCT01490086|DRUG|RP5063|daily
48108758|NCT01490086|DRUG|RP5063|daily
48300687|NCT04695730|OTHER|Active physical therapy (including both pain education and home exercises)|"One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks."
48300688|NCT04695730|OTHER|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
48479561|NCT01358149|OTHER|cocoa-based food|single intake of cocoa-based food
48479562|NCT01358149|OTHER|cocoa-based food|Single intake of cocoa-based food
48108759|NCT01490086|DRUG|aripiprazole|daily
48638339|NCT01237093|OTHER|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish
48638340|NCT01237093|OTHER|3. Meat and fish, no soda|weight maintaining diet with meat and fish but no soda
48638341|NCT01237093|OTHER|4. Meat and fish and soda|weight maintaining diet with meat, fish and soda
48638342|NCT01237093|OTHER|5. Fish, no meat or soda|weight maintaining diet with fish but no meat or soda
48300689|NCT03520023|OTHER|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
48300690|NCT01062646|BEHAVIORAL|Multimodal music therapy|
48300691|NCT01062646|BEHAVIORAL|Community treatment as usual|
48300692|NCT02605733|DEVICE|EEG|amplitude integrated electroencephalography
48300693|NCT02605733|DEVICE|NIRS|regional tissue oximetry
48300694|NCT03939130|DIETARY_SUPPLEMENT|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
48300695|NCT03939130|DIETARY_SUPPLEMENT|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
48638343|NCT01237093|OTHER|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat
48638344|NCT01237093|OTHER|7. No meat, fish or soda|weight maintaining diet with no meat, no fish, and no soda (vegetarian)
48300696|NCT03939130|OTHER|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
48300697|NCT01058577|DEVICE|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
48479563|NCT03959995|OTHER|High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)|Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
48479564|NCT03959995|OTHER|Wellness|control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.
48479565|NCT03440424|DRUG|Lemborexant|oral tablet
48479566|NCT02507245|DRUG|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
48479567|NCT05800145|BEHAVIORAL|Resource information Supplemental Nutrition Assistance Program (SNAP)|Participants randomized to the resource referral arm will receive a tailored list of information about community resources. The list will include information about local emergency food resources (e.g. local food pantries) and government programs to address FI (e.g. SNAP).
48479568|NCT05800145|BEHAVIORAL|community health worker (CHW)|Participants randomized to the CHW intervention will have an initial baseline visit scheduled at a mutually convenient location.
48638345|NCT01237093|OTHER|8. Soda, no meat or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda)
48638346|NCT03990844|DIETARY_SUPPLEMENT|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
48638347|NCT05456191|DRUG|Asciminib|Asciminib 80 mg QD administered under fasting conditions.
48638348|NCT05456191|DRUG|Nilotinib|Nilotinib 300 mg BID administered under fasting conditions.
48638349|NCT04241718|DEVICE|Aquadex FlexFlow System and BVA-100|Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
48638350|NCT02596984|DRUG|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
47953236|NCT03134404|OTHER|No Intervention|No Intervention is required for this study
47953237|NCT06557434|DEVICE|MIRIA|The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.
48108760|NCT05936671|PROCEDURE|EEG-and-ANI-guided anesthesia|During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
48108761|NCT05936671|PROCEDURE|standard anesthesia|During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
48108762|NCT05936671|DRUG|Sevoflurane and remifentanil|For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
48108763|NCT05936671|DEVICE|EEG and ANI|EEG monitoring using SEDline (Masimo, Irvine, California, USA) and Analgesia Nociception Index (ANI; MetroDoloris Medical Systems, Lille, France) monitoring will be performed.
48108764|NCT05676190|COMBINATION_PRODUCT|CIK combined with chemotherapy group|Combination of chemotherapy and autologous cytokine induced killer cells
48108765|NCT05676190|COMBINATION_PRODUCT|CIK combined immunotherapy group|Combination of immunotherapy and autologous cytokine induced killer cells
48300698|NCT01058577|PROCEDURE|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
48638351|NCT00344669|DRUG|Albendazole 400 mg, given 6 monthly|
48638352|NCT06427642|BIOLOGICAL|Mononuclear cells|UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
48638353|NCT06427642|DEVICE|Mild hypothermia therapy|Mild hypothermia therapy via hypothermia therapy apparatus
47953238|NCT00287365|DRUG|ozone|2 hour exposure to 0.4 ppm ozone
47953239|NCT03943160|DEVICE|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
47953240|NCT05553314|DRUG|Carvedilol|patients randomized to carvedilol group will receive carvedilol-SR.
47953241|NCT05553314|DRUG|Placebo|patients randomized to placebo group will receive placebo.
47953242|NCT05488171|DRUG|Methylone|Single oral dose of 200 mg of methylone.
48108766|NCT05676190|COMBINATION_PRODUCT|CIK combined targeted therapy group|Combination of targeted therapy and autologous cytokine induced killer cells
48300699|NCT02823262|OTHER|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
48300700|NCT02823262|OTHER|Usual Care|
48300701|NCT05321797|OTHER|Aerobic Training|This group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 12-week period
48300702|NCT05321797|OTHER|Conventional Physiotherapy|This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
48300703|NCT00449748|DRUG|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
48300704|NCT05566756|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
48479569|NCT05800145|BEHAVIORAL|medically tailored meals|Participants will receive 10 medically tailored meals delivery to their home weekly for 3 months
48479570|NCT00004490|DRUG|sodium dichloroacetate|
48638354|NCT06427642|DEVICE|Breathing support technique|Breathing support via ventilator
48638355|NCT06427642|PROCEDURE|Total parenteral nutrition|Liquid nutrition injected directly into the bloodstream
48638356|NCT06377930|DRUG|RAP-219|RAP-219 oral tablet
48638357|NCT05994534|DRUG|Cysteamine Bitartrate|Single dose, tablets at current therapeutic dose
48638358|NCT05994534|DRUG|N-Acetylcysteine Amide|Single dose, oral solution
48638359|NCT05460000|DRUG|3 cycles chemotherapy instead of 6 cycles chemotherapy|We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
48638360|NCT05460000|DRUG|6 cycles chemotherapy|Standard chemotherapy as comparator
47953243|NCT05488171|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
47953244|NCT05488171|DRUG|Placebo|Single oral dose of placebo.
47953245|NCT02122458|DEVICE|mild-gain hearing aids with high-frequency emphasis over 6-months|open-fit hearing aids with mild amplification in the high frequencies.
47953246|NCT03414229|DRUG|Epacadostat|100mg bid days 1-21
47953247|NCT03414229|DRUG|Pembrolizumab|200mg/dose Day 1, Q 3 weeks
47953248|NCT03691935|DRUG|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
47953249|NCT03691935|DRUG|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
47953250|NCT03212690|DRUG|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
47953251|NCT03212690|PROCEDURE|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
47953252|NCT06078410|PROCEDURE|Cardiac surgery|The TA-BSM group will undergo transapical beating-heart septal myectomy and the group of cardiac surgery involving left heart operation will udergo patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect.
48638361|NCT06580925|DEVICE|sham tape|sham
47953255|NCT06058026|OTHER|World Dental Federation criteria (FDI)|Restorations were evaluated with FDI criteria.
47953256|NCT06054893|DRUG|Omaveloxolone|Administered as specified in the treatment arm
47953257|NCT00333840|DRUG|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
47953258|NCT00333840|DRUG|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
47953259|NCT00333840|DRUG|cytarabine (ARA-C)|cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
47953260|NCT06012487|DRUG|Low BPV Regimen|Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
47953261|NCT00506337|DRUG|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
47953262|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
47953263|NCT01298531|DRUG|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
47953264|NCT01298531|DRUG|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
48300705|NCT01685294|BEHAVIORAL|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
48638362|NCT06580925|DEVICE|kinesio tape|Kinesio taping will be applied to correct shoulder posture and facilitate shoulder external rotators
48108767|NCT05676190|COMBINATION_PRODUCT|CIK in combination with other therapies|CIK combined with any two or three of them (i.e. chemotherapy, immunotherapy and targeted therapy)
48108768|NCT05154799|BEHAVIORAL|Proprioception and tactile localization with manual or ocular response and/or free hand grasp|"In the first part of the study, the subject must designate a target in 2 ways: manual pointing or ocular saccadic response.~In the second part of the study the subject will have to reach and grasp a rectangular block of wood placed on the table at a distance of 35 cm. He will have to catch the wooden block, lift it a few centimeters and put it back on the table. Tool use and control phases: the subject grasps the wooden block with a tool or without the tool but with a weighted bracelet loading his wrist by the same amount as the tool."
48300706|NCT02092415|DEVICE|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
48300707|NCT04296136|OTHER|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
48300708|NCT02369978|DRUG|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
48108769|NCT05679154|BEHAVIORAL|Team-focused Implementation|CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.
48300709|NCT02369978|DRUG|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
48300710|NCT02369978|DRUG|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
48300711|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.5 mL|Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
48300712|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.5 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
48300713|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.25 mL|Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
48300714|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.25 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
48300715|NCT06135597|OTHER|This is a blood test without regarding to intervention nor diagnostic tests|This is a blood test without regarding to intervention nor diagnostic tests
48300716|NCT04770233|PROCEDURE|Early ACL reconstruction|ACL reconstruction followed by rehabilitation
48300717|NCT04770233|PROCEDURE|Active rehabilitation|Non-operative treatment with active rehabilitation led by a physiotherapist with optional delayed surgery if indicated.
48300718|NCT02099799|BEHAVIORAL|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
48479571|NCT02346851|PROCEDURE|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
48479572|NCT02432118|PROCEDURE|Lumpectomy|Undergo lumpectomy
48638363|NCT06580925|DEVICE|dynamic tape|Dynamic tape will be applied to correct shoulder alignment and assist concentric contraction and eccentric control of external rotators
48638364|NCT04401631|DEVICE|Blood Collection|"Between-Run Reproducibility K3-EDTA venous whole blood 3 mL 1 venous draw~Operator-to-operator imprecision (abioSCOPE) K3-EDTA capillary whole blood 0.05 mL/draw; 0.15 mL total 3 finger sticks (3 different fingers)~Sample type comparison (abioSCOPE) K3-EDTA capillary whole blood, venous serum, venous K3-EDTA plasma 0.35 mL (finger stick), 9 mL of whole blood to get a minimum of 3 mL of serum and 9 mL of whole blood K3-EDTA to get a minimum of 3 mL of plasma 1 finger stick; 1 venous draw into serum tube (9 mL) and 1 venous draw into K3-EDTA plasma tube (9 mL), in total 18 mL~Method comparison (abioSCOPE and ImmunoCAP/Phadia) K3-EDTA capillary whole blood, venous K3-EDTA plasma 0.05 mL (finger stick), 9 mL of whole blood to get a minimum of 3 ml of plasma 1 finger stick; 1 venous draw into K3-EDTA plasma tube (9 mL tube)"
48108770|NCT05679154|BEHAVIORAL|Standard Implementation|CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
48108771|NCT02001623|DRUG|Tisotumab Vedotin (HuMax-TF-ADC)|
48108772|NCT02813252|GENETIC|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
48108773|NCT01802866|DRUG|ACU-4429|Take orally once daily for 24 months
48300719|NCT05688267|OTHER|Continuous Mobility Training|The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.
48479573|NCT02432118|OTHER|Questionnaire Administration|Ancillary studies
48638365|NCT03643991|OTHER|Weighted Blanket|Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
48638366|NCT03306290|DRUG|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~1. Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (\~30 min), 1 tube (5 ml) of blood will be withdrawn~2. Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~3. Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
48638367|NCT05508165|DEVICE|Stream Dx|home uroflowmetry device
48638368|NCT05508165|DEVICE|DFree|at home wearable bladder scanner
47953265|NCT04354142|DEVICE|iSpy|iSpy is a novel healthcare application that hopes to address an important clinical need by facilitating carbohydrate counting using pictures or voice recognition. Proprietary algorithms adjust for portion size and identify hidden carbohydrates (such as in ketchup or other condiments) and quantify the amount of carbohydrates in a meal.
47953266|NCT02837146|BIOLOGICAL|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
48108774|NCT01802866|DRUG|Placebo|Take orally once daily for 24 months
48108775|NCT00044148|DRUG|LY333531|
48108776|NCT02462369|DRUG|Saxagliptin|
48108777|NCT02462369|DRUG|glimepiride|
48108778|NCT02318381|PROCEDURE|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
48108779|NCT03506373|DRUG|Ibrutinib|Given PO
48108780|NCT03506373|DRUG|Ixazomib Citrate|Given PO
48108781|NCT03506373|OTHER|Laboratory Biomarker Analysis|Correlative studies
48108782|NCT03506373|OTHER|Pharmacodynamic Study|Correlative studies
48108783|NCT03506373|OTHER|Pharmacokinetic Study|Correlative studies
48108784|NCT00956306|DRUG|Udenafil|100mg Single Oral Dose of Udenafil
48108785|NCT02668263|PROCEDURE|Surgery alone|Surgery
48108786|NCT02668263|PROCEDURE|Surgery and Drain(s)|Drains inserted as per standard practice
48108787|NCT02668263|PROCEDURE|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
48108788|NCT04021615|OTHER|Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training|A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
48108789|NCT04021615|OTHER|Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training|The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
47953267|NCT02837146|DRUG|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
47953268|NCT01014000|DEVICE|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
47953269|NCT01014000|DEVICE|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
48108790|NCT04932707|OTHER|sub-occipital muscle inhibition technique|this technique will be conducted from a supine lying position. The therapist stretches the suboccipital, placing the hands beneath the patient's head applying pressure up and backward, pressure was maintained till tissue relaxation occurred flexes the head of the patient to get the chin to the manibiurim sternm.
48108791|NCT04932707|OTHER|Neurodynamic mobilization|Patient in a comfortable short sitting position at the edge of the bed with the trunk in an military straight position then ask the patient to slump; flex her neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot.
48108792|NCT04932707|OTHER|control (passive stretch exercises)|The patient in a comfortable supine lying position, the patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side
48108793|NCT02678091|DEVICE|Ultrasound exam with Doppler|Ultrasound exam of the orbit
48108794|NCT05110391|DRUG|Hormonal Therapy Agent|Consecutive patients with NOA and hypogonadism (defined by baseline total testosterone levels equal or below 350 ng/dL) subjected to microdissection testicular sperm extraction who received or not pre-sperm retrieval gonadotropin therapy.
48108795|NCT00130819|BEHAVIORAL|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
48300720|NCT05688267|OTHER|Usual Care|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
48479574|NCT02432118|PROCEDURE|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
48479575|NCT01917435|DEVICE|video-stylet|
48479576|NCT01917435|DEVICE|fiberoptic bronchoscope|
48479577|NCT02056067|BEHAVIORAL|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
48300721|NCT02222727|DRUG|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
48300722|NCT00337298|DRUG|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
48638369|NCT05508165|DEVICE|TestCard|mobile urinalysis reader
48638370|NCT05984667|BEHAVIORAL|C-SMART|The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.
48638371|NCT01694186|DRUG|FAI insert|
48638372|NCT01694186|DRUG|Sham injection|
48479578|NCT02056067|BEHAVIORAL|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
48638373|NCT05826158|DIAGNOSTIC_TEST|18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)|18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
48638374|NCT04798924|DEVICE|Subacute Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
48638375|NCT04798924|DEVICE|Subacute Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
48638376|NCT04798924|DEVICE|Chronic Training in the blind field|After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
48638377|NCT06512155|DRUG|Pregabalin|Start taking 75mg bid of pregabalin two days before surgery, and take 150mg bid of pregabalin from one day before surgery to three days after surgery
48300723|NCT00337298|DRUG|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
48300724|NCT06111846|DRUG|human Bone Marrow Mesenchymal Stem Cell (hBMMSC)|Group 1: 1.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 2: 2.0×10\^6 cells/kg (participant's body weight) single dose (n=3) Group 3: 2.0×10\^6 cells/kg (participant's body weight) administered twice (n=4)
48300725|NCT00945750|DRUG|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
48300726|NCT00945750|DRUG|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
48300727|NCT00524745|BIOLOGICAL|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
48638378|NCT06512155|DRUG|Zolpidem|Take zolpidem 10mg qn from two days before surgery to three days after surgery
48108796|NCT00130819|BEHAVIORAL|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
48108797|NCT02662855|OTHER|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
48300728|NCT00084422|DRUG|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
48300729|NCT05037903|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
48300730|NCT04648878|OTHER|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
48300731|NCT04648878|OTHER|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
48300732|NCT04648878|OTHER|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
48300733|NCT03611400|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10\^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10\^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
48300734|NCT03611400|DIETARY_SUPPLEMENT|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
48300735|NCT05524272|OTHER|This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.|Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
48300736|NCT05420467|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
48300737|NCT05420467|DRUG|Carboplatin|AUC 6, d1, q3w,6 cycles
48300738|NCT05420467|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
48638379|NCT06454487|OTHER|Isometric Hand Grip Training|IHG training will be performed with an inflatable ball three days per week for 12 weeks (with at least a day of rest between each session) with intensity set based on RPE (Borg CR-10 scale).
48300739|NCT05420467|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
48638380|NCT06454487|OTHER|CR|Standard of Care
48638381|NCT06422052|OTHER|Epidemiological questionnaire and Functional Dyspepsia Symptom Diary（FDSD）|H. pylori infection was confirmed by 13C/ 14C-breath test and/or rapid urease test under endoscopy and histopathological examination. Epidemiological questionnaire and Functional Dyspepsia Symptom Diary (FDSD) were used to investigate basic information and assess dyspeptic symptoms. Patients with dyspepsia who successfully eradicated Helicobacter pylori infection will be followed up for dyspeptic symptoms after 2 months and 6 months to evaluate the relief of dyspeptic symptoms.
48300740|NCT05420467|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
48300741|NCT05420467|DRUG|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
48300742|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
48300743|NCT05420467|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
48479579|NCT04340999|DIAGNOSTIC_TEST|Nerve conduction studies and Quantitative EMG ( MUNE and IPA)|"Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy"
48479580|NCT06614608|DRUG|5% ASKC200|5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
48479581|NCT06614608|DRUG|1% ASKC200|1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.
48479582|NCT02113371|BEHAVIORAL|Intervention|
48479583|NCT00132054|DRUG|amrubicin hydrochloride|
48638382|NCT04487730|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
48638383|NCT04487730|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
48638384|NCT06023368|DRUG|Num Vapocoolant Spray|Spray applied around port prior to access
48638385|NCT06023368|DRUG|EMLA Cream|cream applied around the port prior to access
48638386|NCT04544189|DRUG|Alpelisib|300mg (oral) once daily, in a 28-day cycle
48638387|NCT04544189|DRUG|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
48638388|NCT04544189|DRUG|Placebo|300 mg by mouth once daily, in a 28-day cycle
48108798|NCT02662855|DRUG|Favipiravir|oral administration of Favipiravir tablets
48300744|NCT05420467|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
48300745|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
48300746|NCT05420467|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
48300747|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
48300748|NCT05379322|DRUG|Anti-TNF|Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
48300749|NCT05379322|DRUG|JAK inhibitor|Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
48300750|NCT02025738|DEVICE|MAGNET APPLICATION|
48300751|NCT02025738|DEVICE|REPROGRAMING|
48300752|NCT02025738|DEVICE|NO ACTION|
48638389|NCT05467228|DEVICE|vibro-tactile stimulation (VTS)|To apply vibro-tactile stimulation, participants will use a wearable device. It contains two vibratory motors (Precision MicrodrivesTM, Model 307 - 100) that are low-voltage (\~1V), non-invasive and will be located approximately above the lateral portions of the thyroid cartilage. For this protocol, they vibrate at frequencies between 40 - 100 Hz (i.e., 100 times per second
48638390|NCT03566667|DRUG|Metoprolol|Betablocker
48300753|NCT03242928|DRUG|AFQ056|50 mg and 100 mg tablets taken orally
48300754|NCT03242928|DRUG|Placebo|Matching placebo tablets taken orally BID
48300755|NCT01784562|DRUG|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
48479584|NCT00132054|DRUG|irinotecan hydrochloride|
48479585|NCT01789957|DRUG|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
48479586|NCT00035321|DRUG|Olanzapine|
48479587|NCT00035321|DRUG|Fluoxetine|
48479588|NCT00368316|BIOLOGICAL|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
48479589|NCT06469619|BEHAVIORAL|Music listening|Listening to music of one's choice one hour daily.
48479590|NCT00319787|DRUG|Iressa|
48479591|NCT04829760|DIETARY_SUPPLEMENT|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
48479592|NCT04829760|DIETARY_SUPPLEMENT|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
48300756|NCT03048240|DEVICE|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
47953270|NCT05188196|PROCEDURE|alveolar ridge preservation|Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
47953271|NCT00214760|DEVICE|PGET|resolbable liner
48300757|NCT03048240|DRUG|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
48300758|NCT00203645|BEHAVIORAL|Self-help treatment|"Workbook Becoming a Winner,"
48300759|NCT04012268|DEVICE|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
48300760|NCT04012268|DRUG|Aspirin|patients will accept medication guided by neurologists
48479593|NCT04829760|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (\~2 tablespoons) in two doses each day for 8 weeks
48638391|NCT03566667|DRUG|Standard care|Standard care
48638392|NCT04995003|GENETIC|T cells or CAR T cells|"There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."
48638393|NCT04995003|DRUG|Pembrolizumab Injectable Product|2 mg/kg/dose (max 200 mg/dose) every 3 weeks
47953272|NCT00214760|DEVICE|PMMA|cement liner
47953273|NCT00332878|BEHAVIORAL|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
47953274|NCT00332878|BEHAVIORAL|stepping Stones short|3 hour intervention on HIV and safer sex
47953275|NCT01884532|DEVICE|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
47953276|NCT01672008|DRUG|NOX-100|
47953277|NCT04242550|BEHAVIORAL|Executive Function- Enhanced CBT for BED (EF-BED+CBT)|EF-BED+CBT will combine CBT (see description below) with executive function training. EF-BED will focus on teaching compensatory strategies to enhance adherence to the strategies recommended in CBT.
47953278|NCT04242550|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"CBT will be based on the Overcoming Binge Eating book. All participants will be provided a copy of the book. CBT addresses disturbed eating patterns and problematic thoughts/beliefs related to eating, shape and weight that contribute to binge eating. CBT is the current gold standard treatment for BED."
47953279|NCT01473043|DRUG|Axitinib|5mg twice daily \[BD\] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
47953280|NCT00384410|DRUG|Nabilone|
47953281|NCT06292104|DIAGNOSTIC_TEST|multimodal diagnostic testing|Serological testing, cardiac MRI, skin biopsy, cardiovascular testing, blood volume measurements
48108799|NCT05968833|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric kidney transplant recipients who are trained to offer vital peer support and mentorship.
48108800|NCT06367517|DRUG|Tocilizumab|Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks
48108801|NCT04106141|OTHER|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
48108802|NCT04106141|OTHER|4 weeks changing of archwire|changing the archwire every 4 weeks
48108803|NCT06444386|DEVICE|MPP + SyncAV|Cardiac resynchronization therapy (CRT) features of MultiPoint Pacing (MPP) and SyncAV (dynamic atrioventricular delay programming) enabled.
48108804|NCT01733238|DRUG|PNT2258|
48300761|NCT01609959|DRUG|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
48300762|NCT01609959|DRUG|Valsartan|Valsartan 160 mg per day
48300763|NCT04497220|BEHAVIORAL|Negative Connotation Langauge|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
48300764|NCT04497220|BEHAVIORAL|Positive Connotation Language|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
48638394|NCT04995003|DRUG|Nivolumab Injectable Product|3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
48638395|NCT01888198|BEHAVIORAL|(EORTC QLQ-C30) questionnaire|
48638396|NCT01888198|BEHAVIORAL|EuroQol EQ-5D 7-item questionnaire|
48108805|NCT00746330|DRUG|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
48108806|NCT00746330|DRUG|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
48108807|NCT00746330|DRUG|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
48108808|NCT00746330|DRUG|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
48108809|NCT00746330|DRUG|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
48300765|NCT04707144|DEVICE|MRI 1.5 tesla|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence.~* 3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)"
48300766|NCT05413499|OTHER|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
48300767|NCT01985685|DRUG|Thiamine|200 mg IV thiamine
48300768|NCT00798967|DRUG|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
48300769|NCT00798967|DRUG|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
48300770|NCT01791868|DRUG|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
48300771|NCT01791868|DRUG|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
48300772|NCT00763685|DRUG|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
48300773|NCT04466683|RADIATION|Low dose radiation 35 cGy|A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint
48300774|NCT04466683|RADIATION|High dose radiation 100 cGy|A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
48300775|NCT01595750|DRUG|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
48300776|NCT01595750|DRUG|Placebo|Placebo 500 mcg , 12 weeks of treatment
48300777|NCT06503302|DIAGNOSTIC_TEST|ultrasound Doppler function detection|Doppler function detection is an ultrasound technique that measures and visualizes blood flow within an object, such as vessels and soft tissue. It can be used to check for the inflammation status of calcifications by detecting blood flow around the calcified areas before performing an ultrasound-guided injection.
48300778|NCT01746667|BEHAVIORAL|Exposure in vivo|
48300779|NCT01746667|BEHAVIORAL|Virtual Reality Exposure Therapy|
47953282|NCT00331864|DRUG|Ranibizumab|
47953283|NCT00646074|BEHAVIORAL|Self-Care Talk|6 conversational sessions
47953284|NCT04325646|OTHER|Human Biological samples|Blood samples for serological tests
48479594|NCT01884402|DRUG|Peginterferon alfa-2a|Treatment as usual clinical practice
48479595|NCT01884402|DRUG|Ribavirin|Treatment as usual clinical practice
47953285|NCT04325646|OTHER|Human Biological samples|Blood samples, saliva, nasopharyngeal swab for serological tests
47953286|NCT01422460|BIOLOGICAL|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
48300780|NCT01837147|BEHAVIORAL|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
48300781|NCT01837147|BEHAVIORAL|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
48300782|NCT05921916|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
48300783|NCT05921916|DRUG|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
48300784|NCT04955145|DRUG|RUTA C 60|Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
48300785|NCT02290639|BEHAVIORAL|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
48300786|NCT02290639|BEHAVIORAL|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
48300787|NCT01127425|PROCEDURE|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
48479596|NCT00792623|BIOLOGICAL|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
47953287|NCT03872323|PROCEDURE|Endovascular treatment|The arteries injuries are repaired by endovascular treatment.
47953288|NCT03872323|PROCEDURE|Open surgery|The arteries injuries are repaired by open surgical operation.
47953289|NCT00697359|DEVICE|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
47953290|NCT01419522|OTHER|Gait Training Method|Treadmill training at constant velocity
47953291|NCT01613365|DRUG|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
47953292|NCT01613365|DRUG|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
47953293|NCT03189420|PROCEDURE|Tumor resection|The tumors will be resected in routine therapeutic surgeries
48300788|NCT01127425|PROCEDURE|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
48479597|NCT05468463|BEHAVIORAL|Living Donor Navigator Program|The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
48479598|NCT04953416|DEVICE|1565nm non ablative fractional laser|The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
47953294|NCT02651467|OTHER|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
47953295|NCT02651467|OTHER|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
48479599|NCT02781935|PROCEDURE|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
48638397|NCT04471844|DEVICE|Optune®|"Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression."
48638398|NCT05338450|DRUG|Clemastine Fumarate|4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)
48339846|NCT00880607|DRUG|Extended Release Epidural Morphine|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
48479600|NCT01521078|BEHAVIORAL|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
47953296|NCT02651467|OTHER|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
47953297|NCT01328431|OTHER|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
47953298|NCT05820373|BEHAVIORAL|Yoga therapy|Women being allocated to the intervention group will attend a 12-week, bi-weekly, specially designed yoga therapy course. In each yoga class, participants will be taught to perform a standardized yoga sequence including postures and breathing exercise. Each class lasts 60 minutes. A DVD demonstrating the yoga sequence will be given to each participant to prompt daily home practice.
47953299|NCT05820373|BEHAVIORAL|Active control group|Women being allocated to the active control group will attend a 12-week, weekly, relaxation course. In each relaxation class, participants will be taught to learn mediation and guided relaxation, called Shavasana. Participants will be asked to lie on their back, with legs apart and their eyes closed. During the practice, participants learn how to relax the body and breath normally. Each session lasts 60 minutes.
47953300|NCT05820373|BEHAVIORAL|Passive control group|The passtive control intervention will be the standard post-operative exercises which are currently introduced to women following surgery, for all women allocated to the control group. A DVD demonstrating the post-operative exercise will be given to participants to practice at home daily.
47953301|NCT04136366|DRUG|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
48638399|NCT05338450|DRUG|Placebo|Placebo equivalent to experimental arm
48638400|NCT06236438|DRUG|Livmoniplimab|Intravenously (IV) Infusion
48638401|NCT06236438|DRUG|Budigalimab|IV Infusion
48638402|NCT06236438|DRUG|Pembrolizumab|IV Infusion
48638403|NCT06236438|DRUG|Pemetrexed|IV Infusion
47953302|NCT04136366|OTHER|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
47953303|NCT05903495|DEVICE|Deep Brain Stimulation|randomized, sham-controlled, partial crossover study investigating DBS, targeting the nucleus accumbens (NAc) and ventral internal capsule (VC), for participants with severe, treatment refractory OUD.
48638404|NCT06236438|DRUG|Cisplatin|IV Infusion
48638405|NCT06236438|DRUG|Carboplatin|IV Injection
48638406|NCT06236438|DRUG|Carboplatin|IV Infusion
48638407|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
48638408|NCT02615496|BEHAVIORAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
48638409|NCT06426888|OTHER|Experimental interventional group 1(scapular stabilization exercise therapy)|"Ball stabilization exercise: While standing close to the wall, the participant will be asked to position her affected hand on the ball and keep the ball from moving as disturbance will be applied in different directions.~Wall push up: While facing wall patient will be asked to place both hands on wall, shoulder width apart. He will be instruct to breath in, bend his elbows, lean into wall and hold this position for one second then breath out slowly push back until arms are straight again Wall slides~• Patient will be asked to lean his head, upper thorax and butts against the wall, place his hands and arms against the wall in high five position."
48638410|NCT06426888|OTHER|Experimental :interventional group II (scapular mobilizations)|"Patient lies on unaffected side close to the edge of the treatment bench with hips and knees bent for stability.~Therapist will start by supporting the patient arm on his/her forearm so that shoulder is in maximally loose pack position.~Then he/she will grab on the scapula with both hands. One hand supports the scapula from cranial around the acromion and scapular spine and other hand from the caudal at the inferior angle of scapula.~Then both hands move the scapula cranially over the thorax into elevation and caudally into the depression, upward/downward rotation as well as retraction and protraction."
48638411|NCT00861705|BIOLOGICAL|Bevacizumab|Given IV
48638412|NCT00861705|DRUG|Carboplatin|Given IV
48638413|NCT00861705|DRUG|Cyclophosphamide|Given IV
48638414|NCT00861705|DRUG|Doxorubicin Hydrochloride|Given IV
48638415|NCT00861705|OTHER|Laboratory Biomarker Analysis|Correlative studies
48638416|NCT00861705|DRUG|Paclitaxel|Given IV
48638417|NCT06547359|DRUG|Obicetrapib 10mg|tablets
48638418|NCT06547359|DRUG|Ezetimibe 10mg|tablets
48638419|NCT06165653|BEHAVIORAL|5-Minute, Audio-Recorded Guided Mediation Practice|"Five different meditation practices will be provided, all of which have been validated in prior research.~* The Body Scan practice consists of instruction in how to direct non-judgmental attention to different regions of the body~* The Mindful Breathing practice consists of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations~* The Mindfulness of Discomfort practice consists of instruction in how to zoom in to deconstruct discomfort and map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences~* The Savoring practice consists of instruction in identifying and amplifying pleasant memories~* The Loving-Kindness practice consists of instruction in cultivating feeling of warmth and compassion toward the self and others"
48638420|NCT05656976|OTHER|Provision of self sampling device by the GP|In a group of 45 GP practices, over a course of 9 months, all long-term unscreened women with a GMD will be addressed by their GP when they consult for any reason. The GP will discuss the pros and cons of screening for cervical cancer, the various options for screening for cervical cancer including the possibility of using a SSD. For this, the GP can use on accessible brochure and video materials. After the woman agrees, she is given a self-taking kit that she can use when and where it suits her and send it to the lab with the prepaid envelope. The woman is informed of the result of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g. via letter, by phone or during the next consultation).
48638421|NCT05656976|OTHER|Provision of self sampling device by letter|In the second arm, a second group of 45 GP practices in Flanders will be recruited. With the intervention of the Centre for Cancer Prevention (Flanders), 25 at randomly selected long-term unscreened women with a Global Medical Form (in dutch: 'Globaal Medisch Dossier, GMD) in one of these practices will receive an envelope containing a letter of invitation from their GP for cervical cancer screening, a brochure with the advantages and disadvantages of cervical cancer screening and more specifically the use of a self-taking kit, and a self-taking kit. If the woman wishes, she can use the kit when and where it suits her and send it to the lab with the pre-paid envelope. As in arm A, the woman will be informed of the Human Papilloma Virus test result by her GP according to the usual way in the practice (e.g., by letter, by phone or during the next consultation). All women will receive a study-related reminder letter after 4 months.
48638422|NCT03367351|BEHAVIORAL|Web-Based Education|Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
47953304|NCT02633813|DRUG|Naftifine hydrochloride 2%|Topical application for two weeks
47953305|NCT02633813|DRUG|Placebo|Topical application for two weeks
48479601|NCT03181048|PROCEDURE|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
48479602|NCT03181048|PROCEDURE|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
48479603|NCT05380921|DEVICE|standard EEG|all subjects will receive both a standard EEG and a dry electrode EEG
48479604|NCT05380921|DEVICE|dry electrode EEG|all subjects will receive both a standard EEG and a dry electrode EEG
48479605|NCT06617676|DEVICE|Transcutaneous tibial nerve stimulation|Two electrodes will be place over the tibial nerve over the medial ankle. The electrical stimulation will be turned up to patient tolerance at a sensory level only.
48479606|NCT06616207|DRUG|Placebo|Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
48638423|NCT03367351|BEHAVIORAL|Social Support|Engagement in peer-led CGM specific discussion boards
48638424|NCT03367351|BEHAVIORAL|Standard of Care|Standard of Care - serves as the control group for the treatment arm
48339847|NCT01755741|COMBINATION_PRODUCT|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
48339848|NCT01755741|DEVICE|Condom|Male condom
47953306|NCT02633813|DRUG|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
47953307|NCT00117455|DRUG|pegfilgrastim|
47953308|NCT00117455|DRUG|filgrastim|
47953309|NCT02761733|BEHAVIORAL|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
47953310|NCT02655978|OTHER|Magnetic Resonance Imaging|
47953311|NCT01554436|BEHAVIORAL|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
47953312|NCT04696523|DRUG|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
47953313|NCT04696523|DRUG|air/oxygen|Control group will be treated with air/oxygen
47953314|NCT05570383|DRUG|Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).|The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
47953315|NCT03985306|PROCEDURE|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
47953316|NCT02759497|OTHER|serum amyloid A level|serum amyloid A level (SAA)
47953317|NCT04099407|DRUG|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
47953318|NCT04099407|OTHER|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
48108810|NCT05831917|RADIATION|Radiotherapy|"Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles."
48479607|NCT06616207|DRUG|Povidone-iodine solution|Povidone-iodine solution will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
48479608|NCT04627831|DRUG|CE-Iohexol|Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
48479609|NCT04627831|DRUG|Iohexol|Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
48479610|NCT05724368|DIAGNOSTIC_TEST|Fecal Calprotectin ELISA kit|"* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions."
48479611|NCT05992987|DIAGNOSTIC_TEST|Adenosine deaminase serum level|Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).
48479612|NCT05992987|DIAGNOSTIC_TEST|IgE antibodies serum level|Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).
48479613|NCT01631682|DRUG|Propranolol|40mg single pill
48479614|NCT01631682|BEHAVIORAL|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
48638425|NCT01431573|BEHAVIORAL|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
48638426|NCT01431573|DEVICE|light box|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
47953319|NCT04151433|PROCEDURE|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
48108811|NCT01656096|DEVICE|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
48108812|NCT01656096|OTHER|Sham procedure|
48479615|NCT01631682|DRUG|Mifepristone|1800mg, 9 tablets
48479616|NCT01631682|DRUG|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
48479617|NCT00474604|PROCEDURE|diffusion-weighted magnetic resonance imaging|A scan will be performed.
48479618|NCT00474604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
48479619|NCT00474604|PROCEDURE|magnetic resonance spectroscopic imaging|A scan will be performed.
48479620|NCT01139294|DRUG|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
48300789|NCT03643432|BEHAVIORAL|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
48300790|NCT03643432|BEHAVIORAL|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
48300791|NCT03472482|DIAGNOSTIC_TEST|non-invasive retinal imaging|
48300792|NCT02339298|OTHER|music application|music is applied during anaesthesia using headphones
48300793|NCT02339298|OTHER|only headphones|music is not applied, only headphones are placed
48300794|NCT02339298|DRUG|a caudal block|
48300795|NCT01489787|PROCEDURE|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~* One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~* One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
48300796|NCT01489787|PROCEDURE|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
48300797|NCT01489787|PROCEDURE|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
48300798|NCT00227279|BIOLOGICAL|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
48300799|NCT05118139|OTHER|P1211216|Flavor variant P1211216 of a 1.5% nicotine ENDS product
48300800|NCT05118139|OTHER|P1213416|Flavor variant P1213416 of a 1.5% nicotine ENDS product
48300801|NCT05118139|OTHER|P1213716|Flavor variant P1213716 of a 1.5% nicotine ENDS product
48300802|NCT05118139|OTHER|P1213616|Flavor variant P1213616 of a 1.5% nicotine ENDS product
48300803|NCT05118139|OTHER|P1213816|Flavor variant P1213816 of a 1.5% nicotine ENDS product
48300804|NCT05118139|OTHER|P1211916|Flavor variant P1211916 of a 1.5% nicotine ENDS product
48300805|NCT05118139|OTHER|P1210016|Flavor variant P1210016 of a 1.5% nicotine ENDS product
48300806|NCT05118139|OTHER|P1211217|Flavor variant P1211217 of a 2.4% nicotine ENDS product
48300807|NCT05118139|OTHER|P1213417|Flavor variant P1213417 of a 2.4% nicotine ENDS product
48300808|NCT05118139|OTHER|P1211222|Flavor variant P1211222 of a 5% nicotine ENDS product
48300809|NCT05118139|OTHER|P1213422|Flavor variant P1213422 of a 5% nicotine ENDS product
48300810|NCT05118139|OTHER|P1213722|Flavor variant P1213722 of a 5% nicotine ENDS product
48300811|NCT05118139|OTHER|P1213622|Flavor variant P1213622 of a 5% nicotine ENDS product
48479621|NCT03060850|DRUG|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
48479622|NCT03887988|PROCEDURE|"Primary early reconstruction"|Primary surgical reconstruction of the fracture within 3 weeks after injury
47953320|NCT03993132|DRUG|Empagliflozin|new users (initiators) of Empagliflozin
48108813|NCT01911169|DRUG|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
48479623|NCT03887988|OTHER|Nonsurgical|Nonsurgical treatment of fracture
48479624|NCT03887988|PROCEDURE|"Primary delayed reconstruction"|Primary surgical reconstruction of the fracture more than 3 weeks after injury
48479625|NCT03887988|PROCEDURE|Secondary reconstruction|Second surgical reconstruction of the fracture after a primary reconstruction.
48479626|NCT00891423|DRUG|Meropenem short infusion|
48479627|NCT00891423|DRUG|Meropenem extended infusion|
48479628|NCT04819854|DRUG|EP395|capsule for oral treatment
47953321|NCT03993132|DRUG|Liraglutide|initiators of Liraglutide
47953322|NCT00292396|DRUG|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
47953323|NCT00292396|DRUG|placebo|12 doses
48108814|NCT02520856|OTHER|blood sample|
48300812|NCT05118139|OTHER|P1213822|Flavor variant P1213822 of a 5% nicotine ENDS product
48300813|NCT05118139|OTHER|P1211922|Flavor variant P1211922 of a 5% nicotine ENDS product
48300814|NCT05118139|OTHER|P1210022|Flavor variant P1210022 of a 5% nicotine ENDS product
48300815|NCT05318625|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
48300816|NCT00002089|DRUG|Azithromycin|
48300817|NCT03532971|OTHER|Symptom index questionnaire|A survey administered to identify the symptoms of the patient
48479629|NCT04819854|DRUG|Placebo|capsule for oral treatment
48479630|NCT00406588|DRUG|Levodopa (Pardoprunox)|12-42mg
48479631|NCT00406588|DRUG|Placebo Comparator|Placebo
48479632|NCT02181296|DRUG|ropivacaine|
48300818|NCT03532971|DIAGNOSTIC_TEST|BK polyomavirus PCR|quantitative PCR testing
48300819|NCT03532971|OTHER|quality of life questionnaires|Standard questionnaires validated for HCT recipients
48300820|NCT02305251|OTHER|Survey|Standard Gamble Survey
48300821|NCT05279794|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
48300822|NCT05279794|OTHER|Myofascial Induction Group|Myofascial Induction technique on the lumbar fascia
48300823|NCT05279794|OTHER|Placebo Group|No pain positioning of participants
48300824|NCT06058494|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
48300825|NCT04742153|DRUG|MRG002|Administrated intravenously
48300826|NCT00369434|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|
48300827|NCT05927246|DIAGNOSTIC_TEST|ECG|12 lead ecg for each participant
48300828|NCT04146584|DEVICE|Sofwave Treatments|The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
48300829|NCT02222129|DRUG|Bupivacaine|
48300830|NCT02222129|DRUG|liposomal bupivacaine|
48300831|NCT04637659|PROCEDURE|Root Canal Treatment|Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
47953324|NCT00239590|DRUG|Testosterone undecanoate|Licensed for androgen deficiency
48300832|NCT01605396|DRUG|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.
48300833|NCT01605396|DRUG|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
48300834|NCT01605396|DRUG|Exemestane|Exemestane 25 mg tablet administered PO QD.
48300835|NCT00282958|DRUG|Botulinum Toxin type a (Botox)|
48300836|NCT02237495|DRUG|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
48479633|NCT04594005|DRUG|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
48479634|NCT00468871|DRUG|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
47953325|NCT02663908|DRUG|Degarelix|
47953326|NCT02663908|DRUG|Leuprolide|
47953327|NCT01216670|BEHAVIORAL|remote patient's management|scheduled remote CareLink data transmission
48300837|NCT02237495|DRUG|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
48300838|NCT05606354|OTHER|Intervention group|Experimental
48300839|NCT05670847|DRUG|Exogenous ketone ester|500 mg/kg orally three times daily (with at least 4 hours between each dose) for 28 days
48479635|NCT00468871|DRUG|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
48479636|NCT02644161|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
47953328|NCT04330274|OTHER|Bipedal with open eyes|Standing bipedal with open eyes on force platform
47953329|NCT04330274|OTHER|Bipedal with closed eyes|Standing bipedal with closed eyes on force platform
47953330|NCT04330274|OTHER|Bipedal with open eyes and with platform|Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
47953331|NCT04330274|OTHER|Bipedal with closed eyes and with platform|Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
47953332|NCT03656107|BEHAVIORAL|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
47953333|NCT01919671|DRUG|Tongxinluo capsule|for 90 days
47953334|NCT01919671|DRUG|placebo capsule|for 90 days
47953335|NCT02998983|DRUG|Racotumomab|
48479637|NCT02644161|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
48479638|NCT02644161|DRUG|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
48479639|NCT02644161|OTHER|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
48479640|NCT02644161|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
48638427|NCT01431573|DRUG|Lithium|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
47953336|NCT02002832|DRUG|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
47953337|NCT02002832|DRUG|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
47953338|NCT00472719|BIOLOGICAL|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
47953339|NCT00472719|BIOLOGICAL|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
47953340|NCT00472719|BIOLOGICAL|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
47953341|NCT01470937|DRUG|Acarbose|acarbose 100 mg PO once daily
47953342|NCT01470937|DRUG|Placebo|acarbose placebo
47953343|NCT04652440|DRUG|PD-1 monoclonal antibody|The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and 21(±7) days, 42(+7) and 63(+7) after ablation.
47953344|NCT04652440|PROCEDURE|Radiofequencey or microwave ablation|The enrolled patients received primary radiofrequency or microwave ablation on the day after the first dose of PD-1 antibody treatment.
47953345|NCT00745940|BEHAVIORAL|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
47953346|NCT03177057|BEHAVIORAL|Compliance Monitoring|Record behavior
47953347|NCT03177057|OTHER|Health Telemonitoring|Receive health monitoring text messages
47953348|NCT03177057|OTHER|Questionnaire Administration|Ancillary studies
47953349|NCT05089279|DRUG|D113|QD, PO
47953350|NCT05089279|DRUG|CKD-349|QD, PO
47953351|NCT02754154|DRUG|Warfarin|
47953352|NCT02754154|DRUG|Apixaban|
47953353|NCT02754154|DRUG|Dabigatran|
47953354|NCT02754154|DRUG|Rivaroxaban|
48108815|NCT00078533|BIOLOGICAL|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10\^7cells/m2 and the highest will be 1x10\^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
48108816|NCT00586586|BEHAVIORAL|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
47953355|NCT01570088|DIETARY_SUPPLEMENT|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
47953356|NCT01570088|DIETARY_SUPPLEMENT|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
47953357|NCT01570088|OTHER|Placebo|Placebo contains no folic acids
47953358|NCT04634383|DEVICE|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
47953359|NCT05653193|DRUG|Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
47953360|NCT05653193|DRUG|Antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
47953361|NCT04948489|DRUG|norethindrone acetate (NETA)|5mg of the NETA capsule by mouth daily for 12 months
47953362|NCT04948489|DRUG|Placebo|Placebo capsule everyday for 12 months
47953363|NCT02406183|RADIATION|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
47953364|NCT02406183|DRUG|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
48108817|NCT05022251|PROCEDURE|Lumbar discectomy|surgically removing a hernia
48108818|NCT01039142|DRUG|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
48108819|NCT01596751|DRUG|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
48300840|NCT03940950|BIOLOGICAL|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
48300841|NCT03940950|DRUG|Placebo|Saline control that contains no active ingredient
48300842|NCT00149331|BEHAVIORAL|Structured education program|
48300843|NCT02393599|DRUG|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
48300844|NCT02393599|DRUG|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
48300845|NCT02393599|DRUG|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
48300846|NCT06270797|PROCEDURE|intubation for general anesthesia|routine intubation for general anesthesia
48300847|NCT02475707|BIOLOGICAL|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
48300848|NCT01904877|BEHAVIORAL|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
48300849|NCT00921505|DRUG|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
48300850|NCT00921505|DRUG|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
48300851|NCT00921505|DRUG|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
48300852|NCT00921505|DRUG|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
48300853|NCT00984802|DRUG|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
48300854|NCT00984802|DRUG|Placebo control|Vehicle solution for IV administration single dose.
48300855|NCT02952066|PROCEDURE|Bronchial biopsy|Bronchial tissue taken during biopsy
48300856|NCT02826044|DRUG|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
48300857|NCT00973908|DRUG|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
48300858|NCT00973908|DRUG|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
48300859|NCT05952167|OTHER|Intensive cervical traction protocol|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
48300860|NCT05952167|OTHER|Intensive cervical traction protocol - placebo|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
48300861|NCT02944799|DRUG|Placebo|Discontinuation of alendronate treatment
48300862|NCT02944799|DRUG|Alendronate|
48108820|NCT01596751|DRUG|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
48108821|NCT00091624|DRUG|CC-5013|
48108822|NCT02230358|PROCEDURE|Regional anesthesia|Regional anesthesia
48108823|NCT02230358|PROCEDURE|General anesthesia|General anesthesia
48300863|NCT02944799|DRUG|Calcium|Daily dietary supplement of 800mg calcium
48300864|NCT02944799|DRUG|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
48300865|NCT02020343|BEHAVIORAL|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
48300866|NCT03025191|BEHAVIORAL|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
48300867|NCT03025191|BEHAVIORAL|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
48300868|NCT03025191|BEHAVIORAL|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
48300869|NCT03025191|BEHAVIORAL|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
48300870|NCT00634543|DRUG|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
48479641|NCT05342311|DIAGNOSTIC_TEST|preoperative ultrasonographic evaluation of right common femoral vein diameter|preoperative ultrasonographic evaluation of right common femoral vein diameter to predict spinal anesthesia-induced hypotension in elderly patients
48300871|NCT00634543|DRUG|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
48300872|NCT03872583|OTHER|Understanding MRI in MS (website)|Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
48300873|NCT03872583|OTHER|Control website|Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
48300874|NCT03938376|DIAGNOSTIC_TEST|Micro-Ultrasound guided biopsy|High-resolution imaging device
48300875|NCT01454401|DEVICE|LeucoPatch treatment|weekly
48300876|NCT02416908|DRUG|Selinexor|
48300877|NCT02416908|DRUG|Cladribine|
48300878|NCT02416908|DRUG|G-CSF|
48300879|NCT02416908|DRUG|Cytarabine|
48300880|NCT02416908|PROCEDURE|Bone marrow biopsy|
48300881|NCT01646008|OTHER|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
48300882|NCT01646008|OTHER|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
48300883|NCT04547296|DRUG|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
48300884|NCT00436215|DRUG|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
48300885|NCT00436215|DRUG|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
48300886|NCT00674336|PROCEDURE|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
48300887|NCT05840289|OTHER|fractionated first dose rituximab|Patients at high-risk to develop tumor lysis syndrome received a initial fractionated dose of rituximab over 2 or 3 days
48300888|NCT05447130|PROCEDURE|phacoemulsification|phacoemulsification with corneal endothelial evaluation by specular microscopy
48300889|NCT03345836|DRUG|Matching Placebo for Upadacitinib|Matching placebo tablets
48300890|NCT03345836|DRUG|Upadacitinib|Upadacitinib tablets
48300891|NCT04016883|OTHER|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
48300892|NCT04016883|OTHER|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
47953365|NCT04553185|OTHER|Study procedure|All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
47953366|NCT02407795|RADIATION|conventional radiotherapy|1x8Gy
48108824|NCT02230358|DEVICE|Transcranial Doppler ultrasonography|6x for 4 hours
48300893|NCT00893594|DRUG|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
48300894|NCT00893594|DRUG|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
48479642|NCT03321526|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
48479643|NCT03321526|DRUG|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
48479644|NCT03321526|DRUG|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
48479645|NCT03321526|DRUG|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
48108825|NCT02230358|PROCEDURE|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
48108826|NCT02230358|PROCEDURE|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
48108827|NCT02230358|PROCEDURE|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
48108828|NCT02230358|BEHAVIORAL|Neurological Control|perioperative, 2-3 days, as done in clinical routine
48479646|NCT03321526|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
48300895|NCT02494349|DRUG|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
48479647|NCT03321526|DRUG|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
48638428|NCT05623085|OTHER|Aerobic exercise|Individuals in this group will be given 8-week individualized exercise according to the Karvonen protocol (heart rate reserve percentage-% HR). Exercise training will be 30 minutes at 50% of HR between weeks 0-2, 45 minutes at 50% of HR between weeks 2-4, 45 minutes at 60% of HR between weeks 4-6 and 6-8 weeks It will be done on the treadmill 3 days a week, for 60 minutes at 60% of HR between weeks. The treadmill speed will be adjusted during exercise to maintain the set target heart rate level.
47953367|NCT02407795|RADIATION|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
47953368|NCT02969564|OTHER|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
47953369|NCT02969564|OTHER|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
47953370|NCT00003962|BIOLOGICAL|aldesleukin|
47953371|NCT05539131|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) suppresses excitability and regulates excitability of neurons by injecting a small amount of current through electrodes attached to the scalp.
47953372|NCT01424709|DRUG|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
47953373|NCT01424709|DRUG|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
48300896|NCT02494349|DRUG|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
48300897|NCT05844527|DRUG|MRG-001|MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
48300898|NCT05844527|DRUG|Saline|Sterile saline will serve as placebo treatment.
48300899|NCT06115577|DIAGNOSTIC_TEST|endometrial tissue and peripheral blood mononuclear cells receptivity|Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
48300900|NCT05480137|PROCEDURE|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
48479648|NCT03401554|PROCEDURE|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
48479649|NCT03401554|PROCEDURE|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
48479650|NCT02997137|DIETARY_SUPPLEMENT|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
48638429|NCT05623085|OTHER|Yoga exercise|Individuals in this group will be given 8-week individualized yoga exercise including stretching, relaxing, strength training. Exercise training will be done 3 days a week. The duration of the exercise will be adjusted to be the same as the aerobic exercise group.
48638430|NCT06053164|DRUG|Exertional Oxygen|Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes
47953374|NCT03808129|DRUG|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
47953375|NCT05660226|OTHER|Home blood pressure monitoring (telemonitoring)|Using a digital mobile phone based telemonitoring platform to A: monitor patients and adjust their treatment accordingly based on the remote monitoring outcomes and B: provide E-Coaching/self learning modules (lifestyle)
47953376|NCT05660226|OTHER|Standard care|Standard outpatient blood pressure management
47953377|NCT05379777|DRUG|Remimazolam|Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
47953378|NCT04925908|DIAGNOSTIC_TEST|RT-PCR for SARS-Cov-2|Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
47953379|NCT02001103|DRUG|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
47953380|NCT02001103|DRUG|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
47953381|NCT04436731|OTHER|Hypoxia Exposure|Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
48300901|NCT03701165|DEVICE|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
48300902|NCT01807507|DEVICE|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
48300903|NCT06397872|DRUG|100 mg Resmetirom Tablet|Once daily oral dose for 6 days
48300904|NCT04743882|OTHER||
48300905|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
48300906|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
48339849|NCT05432024|DEVICE|Catheter ablation|An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.
48479651|NCT02997137|OTHER|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
47953382|NCT04436731|DRUG|Phenylephrine|Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
48479652|NCT03399994|DEVICE|device implantation during coronary angioplasty|device implantation during coronary angioplasty
48479653|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa
48479654|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
48638431|NCT06053164|BEHAVIORAL|Education and Support|Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.
48638432|NCT02246036|DEVICE|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
47953383|NCT04436731|DRUG|Dexmedetomidine|Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
47953384|NCT04436731|DRUG|Phentolamine|Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.
47953385|NCT04436731|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
47953386|NCT04055961|DEVICE|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
47953387|NCT03985059|OTHER|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
48479655|NCT04329416|OTHER|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
48638433|NCT03345810|DRUG|Durvalumab|Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W
48638434|NCT03345810|DRUG|Vinorelbine|(30 mg/m2 D1 + D8 as infusion) cycle Q3W
48638435|NCT03345810|DRUG|Gemcitabine|(1000 mg/m2 D1 + D8 as infusion) cycle Q3W
47953388|NCT00065208|BEHAVIORAL|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
47953389|NCT00065208|BEHAVIORAL|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
48479656|NCT04329416|OTHER|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
48479657|NCT04329416|OTHER|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
48479658|NCT03752398|BIOLOGICAL|XmAb®23104|Monoclonal bispecific antibody
48479659|NCT03752398|BIOLOGICAL|Yervoy® (ipilimumab)|Monoclonal antibody
48479660|NCT02971982|DRUG|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
48638436|NCT03345810|DRUG|nab-Paclitaxel|(100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
48638437|NCT03345810|DRUG|Carboplatin|(AUC = 5 mg•min/mL on Day 1) cycle Q3W
47953390|NCT00065208|BEHAVIORAL|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
47953391|NCT06323187|DIAGNOSTIC_TEST|Cervical Sampling|Each participant will provide a sample of fluid or mucus collected from the uterine endocervix.
47953392|NCT00004756|PROCEDURE|Tailored educational program|
47953393|NCT00004756|PROCEDURE|Educational materials|
48108829|NCT02230358|BEHAVIORAL|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
48300907|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
48300908|NCT01776099|DIETARY_SUPPLEMENT|Dietary supplement (4 arms, 2 active, 2 placebo)|
48300909|NCT03466346|DRUG|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
48300910|NCT03466346|BEHAVIORAL|Interpersonal Psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
48300911|NCT06421415|DRUG|Allergen Immunotherapy Extract|Patients will be treated as usual. The study is an observation of the long term effect of the treatment
48300913|NCT03952546|DEVICE|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
48300914|NCT03952546|DEVICE|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
48300915|NCT04331158|OTHER|Dry cupping therapy|Dry cupping therapy application on the patient's skin
48300916|NCT02232516|DRUG|romidepsin|Given IV
48479661|NCT02971982|DRUG|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
48479662|NCT03658187|DIETARY_SUPPLEMENT|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
48479663|NCT03658187|DIETARY_SUPPLEMENT|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
48479664|NCT04227938|DRUG|ALPN-101|A single dose of ALPN-101 will be administered via intravenous infusion.
48479665|NCT04474093|OTHER|Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)|
48479666|NCT02762617|DRUG|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
48479667|NCT02762617|DRUG|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
48479668|NCT05414864|DRUG|Ramelteon (RozeremR)|8mg daily
48479669|NCT05414864|BEHAVIORAL|sleep hygiene|sleep behavioral guidelines
48479670|NCT02000531|DRUG|Erlotinib|150 mg oral dose of erlotinib given once daily
48638438|NCT02276833|OTHER|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
48300917|NCT02232516|DRUG|lenalidomide|Given PO
48300918|NCT02232516|OTHER|laboratory biomarker analysis|Correlative studies
48300919|NCT06069557|OTHER|Respiratory exercise|This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
48300920|NCT05313919|DIAGNOSTIC_TEST|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines"
47953394|NCT05291325|DRUG|3L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
47953395|NCT05291325|DRUG|3L PEG|Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
47953396|NCT05291325|DRUG|2L PEG + Linaclotide|Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
47953397|NCT01297556|BEHAVIORAL|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
47953398|NCT03459261|DIAGNOSTIC_TEST|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
48300921|NCT03558932|DIAGNOSTIC_TEST|pleural biopsy|diagnostic sampling
48300922|NCT01279135|RADIATION|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
48300923|NCT01279135|RADIATION|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
48300924|NCT00863928|DRUG|belladonna 16.2 mg and opium 60 mg suppository|belladonna 16.2 mg and opium 60 mg suppository
48300925|NCT02467452|DRUG|BDP/FF/GB|
48300926|NCT02467452|DRUG|FlF/VI + Tiotropium|
48300927|NCT01287234|OTHER|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
48108830|NCT02230358|DEVICE|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
48108831|NCT06479668|BEHAVIORAL|Trier Social Stress Task|Specify details not covered in associated Arm Description.
48479671|NCT02000531|DRUG|Chemotherapy|Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
48479672|NCT03223454|BIOLOGICAL|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
48479673|NCT03223454|BIOLOGICAL|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
47953399|NCT02285647|DRUG|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
47953400|NCT02285647|DRUG|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
47953401|NCT05667987|DRUG|Intravenous lidocaine administration|General anesthesia with intravenous lidocaine administration
48108832|NCT03272113|BEHAVIORAL|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
48108833|NCT02846480|OTHER|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
48108834|NCT02846480|OTHER|surgical treatment|Surgical correction of POP.
48108835|NCT02846480|OTHER|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
48479674|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Knowledge Intervention|Counseling scripts assessing and addressing vaccination-related knowledge gaps
48108836|NCT03458546|DRUG|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
48638439|NCT03718403|DRUG|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
48638440|NCT06500845|OTHER|Bevel marginal design endocrown for endodontically treated teeth|Bevel marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
48638441|NCT06500845|OTHER|Butt marginal design endocrown for endodontically treated teeth|Butt marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
48638442|NCT06173843|OTHER|PFAS / heavy metal testing, exposures|PFAS / heavy metal concentrations, exposure survey
48638443|NCT03997591|OTHER|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
47953402|NCT00967629|DRUG|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
47953403|NCT00967629|DRUG|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
47953404|NCT00097318|DRUG|Interferon beta-1a|
47953405|NCT05396846|BEHAVIORAL|Eating Plan 1|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
47953406|NCT05396846|BEHAVIORAL|Eating Plan 2|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
48479675|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Reminders|Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
48479676|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Incentives|Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
48479677|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Service notifications|Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
48479678|NCT04142619|BIOLOGICAL|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
48638444|NCT04250415|PROCEDURE|Surgery|
47953407|NCT05396846|BEHAVIORAL|Eating Plan 3|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
47953408|NCT05136287|DRUG|GLP-1 receptor agonist|Patients are included after GLP1 agonists prescription , at the first dispensation
47953409|NCT06292234|DEVICE|PSI|Fabrication of PSI implants using virtual surgical planning
47953410|NCT06292234|DEVICE|Conventional miniplates|Ready made miniplates
47953411|NCT05890144|OTHER|Big Canoe|The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).
48108837|NCT02261467|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
48108838|NCT02261467|DRUG|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
48479679|NCT02608840|OTHER|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
48479680|NCT02608840|OTHER|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
48479681|NCT00523328|DRUG|BG9924|dosage administered as per Biogen-idec protocol
48479682|NCT01652976|DRUG|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
48638445|NCT01728961|DRUG|Artemether/Lumefantrine (AL)|
48300928|NCT04838444|BIOLOGICAL|VLA1553|Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
48300929|NCT04316572|BEHAVIORAL|mental health specialist video consultation|"The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner"
48300930|NCT02612077|OTHER|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
48300931|NCT02612077|DRUG|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
48300932|NCT04993027|DRUG|Vancomycin Powder|Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
48300933|NCT00328263|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
48300934|NCT00328263|DIETARY_SUPPLEMENT|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
48300935|NCT03792269|DRUG|Irinotecan|intraperitoneal
48300936|NCT03792269|DRUG|Oxaliplatin|intravenous
48300937|NCT03792269|DRUG|Capecitabine|
48300938|NCT06520072|BEHAVIORAL|Children Eating Well (CHEW) mobile app|"The target users of the CHEW app are parents/guardians of preschool aged children. The purpose of the CHEW app is to provide parents/guardians with easy, practical ways to improve nutrition and wellness among their preschool-aged children. The app provides guided goal setting and tracking tools. Parents/guardians set goals related to their preschool-aged children focused on nutrition, physical activity, sleep behaviors and parenting styles. The parents/guardians can also to set goals for themselves for behaviors related to nutrition, physical activity, sleep, and stress. The app does not have features that target children as users.~The CHEW app was developed by the study team and can be downloaded for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). After downloading the CHEW app, enrolled participants must enter the Access Code provided by the study team in order to unlock the app and use it."
48300939|NCT06520072|BEHAVIORAL|Beanstalk mobile app|"Beanstack is free commercially-available mobile app that provides goal setting and tracking tools similar to the CHEW app, but focused on a different topic, specifically encouraging parents/guardians to read to their preschool children more frequently. In the case that a parent/guardian is not able to successfully download Beanstack to their mobile device, as a backup alternative they will be asked to use a similar free commercially-available mobile application called Bookroo.~Beanstack is available to the public for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). Bookroo is a web-based application that users access via the mobile device's web browser and looks and functions like a regular mobile application. It should work on any mobile device with a browser and data/wifi access,"
48300940|NCT03102775|OTHER|Comprehensive follow-up program for low-income families|The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.
48300941|NCT03102775|OTHER|local family projects|The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
48300942|NCT04539301|DIAGNOSTIC_TEST|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
48300943|NCT03744169|DIAGNOSTIC_TEST|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
48300944|NCT03744169|DIAGNOSTIC_TEST|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
48300945|NCT03744169|DIAGNOSTIC_TEST|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
48300946|NCT02457338|DIETARY_SUPPLEMENT|Bifidobacterium|
48339850|NCT05674604|PROCEDURE|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
48339851|NCT03537092|DEVICE|Vaginal Film|"2 x 2 vaginal film with no active drug"
48300947|NCT06097936|DIAGNOSTIC_TEST|HPV-ASSOCIATED OROPHARYNGEAL CANCER|The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.
48300948|NCT01790438|DRUG|LY2605541|
48300949|NCT01790438|DRUG|Human Insulin NPH|
48479683|NCT01652976|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
48479684|NCT04497272|OTHER|COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
48479685|NCT05592249|OTHER|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 6 weeks in clinic.
48479686|NCT05592249|OTHER|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 6 weeks in clinic.
48479687|NCT04845646|DRUG|ASC41|5mg/tablet
48479688|NCT04845646|DRUG|Itraconazole|200mg/capsule
48479689|NCT04845646|DRUG|Phenytoin|300mg/capsule
48479690|NCT05593731|BIOLOGICAL|dental implants with melatonin gel|platelet rich fibrin membrane around dental implants
48479691|NCT02752802|DEVICE|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
48638446|NCT04469530|DRUG|Sirolimus|Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
48108839|NCT00843193|DRUG|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
48108840|NCT00843193|DRUG|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
48108841|NCT00843193|DRUG|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
48108842|NCT01971788|DEVICE|Optical Coherence Tomography of the infarct related artery|
48108843|NCT01491399|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
48108844|NCT01491399|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
48108845|NCT02950896|OTHER|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
48108846|NCT02361437|DIETARY_SUPPLEMENT|Vasculera|Vasculera 630 mg b.i.d.
48108847|NCT02533635|DIETARY_SUPPLEMENT|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
48108848|NCT00947596|DRUG|atropine sulfate|dry powder for inhalation
48108849|NCT00947596|DRUG|atropine sulfate|intramuscular injection
48108850|NCT05211063|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 42 days.
48108851|NCT05211063|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 42 days.
48108852|NCT05112861|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
48108853|NCT04405063|DEVICE|Paclitaxel Coated PTCA Balloon Catheter|Drug coated balloon
48108854|NCT00709644|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid.|
48108855|NCT05380869|DIAGNOSTIC_TEST|Point-of-care Test|to test Point-of-care procalcitonin in suspected pneumonia
48108856|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
48108857|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
48300950|NCT01790438|DRUG|Oral Antihyperglycemic Medications (OAM)|
48300951|NCT01302041|DRUG|Enzalutamide|Oral
48300952|NCT05518344|DEVICE|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."
48300953|NCT03260335|BEHAVIORAL|Anxiety management strategy|Anxiety management strategy as per standard care plan
48479692|NCT03329534|OTHER|Gluten free diet|A month long gluten free diet
48479693|NCT00918463|DRUG|dasatinib|100 mg daily dosing
48479694|NCT03728023|DRUG|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
48479695|NCT03728023|DRUG|Placebo|Single dose in SAD and once daily for 14 days
48300954|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus (ST) tendon only|ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw
48300955|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith \& Nephew, London, UK).
48300956|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
48300957|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
48300958|NCT02286115|BEHAVIORAL|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
48300959|NCT00312780|DRUG|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
48300960|NCT02928393|DRUG|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
48300961|NCT02928393|DRUG|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
48300962|NCT03729869|DRUG|Progesterone|200 mg of exogenous progesterone twice a day
48300963|NCT03729869|DRUG|Placebo|One dose of matched placebo twice a day.
48300964|NCT01573208|DEVICE|Custom guides|Symbios custom guides for TKA
48108858|NCT03959241|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
48108859|NCT03959241|PROCEDURE|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
48300965|NCT02058355|BEHAVIORAL|Consequences List Feedback|
48300966|NCT02058355|BEHAVIORAL|Personalized Normative Feedback|
48300967|NCT00611793|DRUG|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
48300968|NCT02052960|DRUG|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
48300969|NCT02052960|DRUG|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
48300970|NCT02052960|DRUG|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
48300971|NCT00004297|DRUG|diazepam|
48300972|NCT00004297|DRUG|lorazepam|
48300973|NCT02805907|DRUG|Calcifediol|
48638447|NCT04469530|DRUG|Cyclophosphamide|"A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube."
48638448|NCT04469530|DRUG|Etoposide|A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
48638449|NCT04469530|DRUG|Celecoxib|The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
48300974|NCT02805907|DRUG|Placebo|
48300975|NCT00003068|DRUG|amifostine trihydrate|
48300976|NCT00003068|DRUG|cyclophosphamide|
48300977|NCT00003068|DRUG|mitoxantrone hydrochloride|
48300978|NCT00003068|DRUG|thiotepa|
48300979|NCT00003068|PROCEDURE|peripheral blood stem cell transplantation|
48300980|NCT02926573|DRUG|Gabapentin|
48300981|NCT02926573|DRUG|Placebo|
48300982|NCT04569305|PROCEDURE|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
48300983|NCT04569305|PROCEDURE|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
48300984|NCT05402501|BEHAVIORAL|"Lifestyle intervention program Leef! met MS"|The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
48300985|NCT05443958|OTHER||
48638450|NCT04204642|OTHER|CAA patients data collection|Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.
48638451|NCT03699995|OTHER|Confocal Microscopy|Undergo confocal microscopy
48638452|NCT03699995|OTHER|Dermoscopy|Undergo digital dermoscopy
48638453|NCT03699995|PROCEDURE|Imaging Technique|Undergo MoleMapper/Sklip app/native smartphone camera app imaging with smartphone
48638454|NCT03699995|DRUG|Lidocaine|Given SC
48638455|NCT03699995|PROCEDURE|Punch Biopsy|Undergo punch biopsy
48638456|NCT03699995|PROCEDURE|Shave Biopsy|Undergo shave biopsy
48638457|NCT05730660|DIETARY_SUPPLEMENT|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
48638458|NCT05730660|DIETARY_SUPPLEMENT|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
48638459|NCT02169401|DEVICE|Implantation with the commercially available Axium Neurostimulator|
48638460|NCT00000778|DRUG|Isoniazid|
48638461|NCT00000778|DRUG|Pyridoxine hydrochloride|
48638462|NCT00000778|DRUG|Levofloxacin|
48638463|NCT01340118|DRUG|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
47953412|NCT05890144|OTHER|Little Canoe|The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
48638464|NCT02218151|OTHER|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
48638465|NCT02218151|OTHER|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
47953413|NCT05890144|OTHER|Control|The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
48638466|NCT04029038|BIOLOGICAL|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Given IV
48638467|NCT04029038|DRUG|Cyclophosphamide|Given IV
48638468|NCT04029038|DRUG|Fludarabine|Given IV
48638469|NCT06169423|OTHER|Educative intervention|"an activity for simulation-based learning First, a theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation."
48638470|NCT06630676|BEHAVIORAL|Control|Brief 4-slide presentation without a separate session for questions and answers
48638471|NCT06630676|BEHAVIORAL|Education|Patients will review 27 slides that discuss the different etiologies (causes) of back pain, how common they are, what causes them (e.g., wear and tear, trauma), factors that exacerbate and alleviate the pain, how they are diagnosed and treated, and have an opportunity to ask questions.
48638472|NCT04895280|DRUG|Ketorolac|Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
48300986|NCT03117049|DRUG|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
48300987|NCT03117049|DRUG|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
48339852|NCT06192667|DEVICE|GC Geanial Injectable (Tokyo,Japan)|Highly filled composite resin
48638473|NCT04895280|DRUG|Marcaine|Marcaine (control): will receive an injection of 4 cc 0.25% Marcaine without epinephrine
48638474|NCT04895280|DRUG|Kenalog|Kenalog: 4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1.
48638475|NCT00675233|DRUG|HPPH|Given IV
48638476|NCT00675233|PROCEDURE|laser therapy|Escalating light doses with 665 nm light
48638477|NCT06628622|DRUG|BI 1356225|BI 1356225
48638478|NCT06628622|DRUG|Placebo|Placebo
48638479|NCT06109441|BIOLOGICAL|ALTB-268|ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
48300988|NCT03117049|DRUG|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
48300989|NCT03117049|DRUG|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
48300990|NCT03117049|DRUG|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
48300991|NCT03837756|DRUG|Saline|Placebo
48300992|NCT03837756|DRUG|Lefitolimod|A TLR9 agonist administered s.c. once weekly for 8 weeks.
48638480|NCT01391299|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
48638481|NCT01391299|DRUG|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
48638482|NCT00756444|DRUG|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
48638483|NCT00756444|DRUG|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
48638484|NCT00756444|DRUG|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
48300993|NCT03837756|DRUG|3BNC117 and 10-1074|Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
48300994|NCT01748396|DRUG|Calcitriol|
48300995|NCT01748396|DRUG|Calcium Carbonate|
48300996|NCT04452812|BIOLOGICAL|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
48300997|NCT05791799|DRUG|Etonogestrel|Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
48300998|NCT05170139|DIETARY_SUPPLEMENT|Caffeine|Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates
48300999|NCT05170139|DIETARY_SUPPLEMENT|Placebo drink|Participants will ingest the exact same drink without caffeine
48301000|NCT00764972|DRUG|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
48479696|NCT03811132|OTHER|Observation|There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
48479697|NCT00850681|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
48479698|NCT00000745|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
48479699|NCT00000745|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
48479700|NCT06151067|DIAGNOSTIC_TEST|High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testing|High-Resolution Manometry Upper-GI endoscopy pH-Impedance testing
48479701|NCT01066117|OTHER|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
48479702|NCT05265221|PROCEDURE|Endoscopic submucosal dissection|ESD was performed under conscious sedation. For sedation, midazolam and/or propofol were administered intravenously, with cardiorespiratory monitoring. Initially, indigo carmine dye was sprayed onto the tumor to clarify the margin. Then, markings were made 10 mm outside the tumor margin using argon plasma coagulation. After marking, a mixture of sodium hyaluronate with indigo carmine and epinephrine was injected into the submucosa outside the marking dots. Circumferential mucosal incision and submucosal dissection were performed using a Dual and/or IT knife. During the procedure, immediate bleeding was treated by Coagrasper. After ESD, chest and abdominal plain radiography were performed routinely for detection of gastric perforation.
48479703|NCT02401841|DRUG|Two different types of drug for resolution of neuro-muscular blockade|
48479704|NCT04938986|DIAGNOSTIC_TEST|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
48638485|NCT00265642|DRUG|Irbesartan|one tablet of 150 mg/d during 2 years
48638486|NCT00265642|DRUG|placebo|one tablet per day during 2 years
48301001|NCT01783522|DRUG|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
48301002|NCT01783522|OTHER|quality-of-life assessment|Ancillary studies
48301003|NCT01783522|OTHER|placebo|Given PO
48479705|NCT05966987|COMBINATION_PRODUCT|Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin|laser and platelet rich fibrin
48479706|NCT05487768|OTHER|EEG measurement|"EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)"
48638487|NCT05525715|DRUG|2mg QY201 tablets or 2mg QY201 placebo,BID|2mg QY201 tablets or 2mg QY201 placebo,BID
48638488|NCT05525715|DRUG|5mg QY201 tablets or 5mg QY201 placebo,BID|5mg QY201 tablets or 5mg QY201 placebo,BID
48638489|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,QD|10mg QY201 tablets or 10mg QY201 placebo,QD
48301004|NCT03814317|DRUG|Inhaled Treprostinil|"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
48301005|NCT03920852|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
48301006|NCT02669927|OTHER|Observational|
48301007|NCT01562015|DRUG|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
48301008|NCT00380484|DRUG|Budesonide|200µg daily
48301009|NCT00380484|DRUG|Montelukast|5 mg daily
48301010|NCT05857202|DRUG|Analgesics, Opioid|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
48301011|NCT05857202|DRUG|Analgesics, Non-Narcotic|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
48301012|NCT03339648|BEHAVIORAL|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
48301013|NCT04289103|BIOLOGICAL|Inolimomab (Leukotac)|"* Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
48301014|NCT02553720|OTHER|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
48301015|NCT02553720|OTHER|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
48301016|NCT01970579|DEVICE|Paclitaxel coated balloon|"* Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
48301017|NCT01970579|DEVICE|uncoated PTA catheter|"* Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
48301018|NCT03652415|DEVICE|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
48301019|NCT06332053|DRUG|SY-5007|SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
48301020|NCT06332053|DRUG|Itraconazole|Itraconazole 200 mg, Capsules, Day 8-Day 18
48301021|NCT06332053|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
48301022|NCT06332053|DRUG|Rifampin|Rifampin 600 mg, Capsules, Day 8-Day 21
48301023|NCT01259297|DRUG|Aliskiren|Aliskiren 150/300 mg once daily
48301024|NCT01259297|DRUG|Amlodipine|Amlodipine 5 mg
48301025|NCT01259297|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
48301026|NCT01259297|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
48301027|NCT01259297|DRUG|Placebo for Amlodipine|Placebo for Amlodipine
48301028|NCT01259297|DRUG|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
48301029|NCT04760314|DRUG|Lebrikizumab|Administered SC
48301030|NCT04760314|DRUG|Placebo|Administered SC
48301031|NCT04760314|DRUG|Topical Corticosteroid|Self-applied
48479707|NCT03010618|OTHER|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
48479708|NCT03235609|DRUG|Fentanyl|fentanyl used with propofol for sedation
48301032|NCT00003264|DRUG|cisplatin|
48301033|NCT00003264|DRUG|gemcitabine hydrochloride|
48301034|NCT03518229|DEVICE|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
48301035|NCT03518229|DEVICE|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
48301036|NCT03854591|OTHER|No intervention|No intervention
48301037|NCT02145910|DRUG|Vemurafenib|Given PO
48301038|NCT02145910|RADIATION|Whole-brain radiation therapy (WBRT)|Undergo WBRT
48301039|NCT02145910|RADIATION|Radiosurgery (SRS)|Undergo SRS
48301040|NCT00755352|DRUG|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
48301041|NCT00755352|DRUG|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
48301042|NCT04877548|OTHER|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
48301043|NCT04877548|OTHER|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
48301044|NCT04877548|OTHER|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
48301045|NCT00615706|OTHER|No intervention|no intervention
48301046|NCT04983940|DRUG|Jatenzo|237 mg soft gel capsule taken twice a day by mouth with food.
48479709|NCT03235609|DRUG|Ketamine|ketamine used with propofol for sedation
47953414|NCT05058235|OTHER|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
47953415|NCT05058235|OTHER|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
47953416|NCT05797259|DRUG|Danosumab|60 mg subcutaneous Danosumab
47953417|NCT05797259|OTHER|Normal Saline|Placebo comparator arm
47953418|NCT01966601|DRUG|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
47953419|NCT01966601|DRUG|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
47953420|NCT01966601|DRUG|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
48301047|NCT00110383|BEHAVIORAL|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
48301048|NCT00177268|OTHER|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
48479710|NCT03594409|DIAGNOSTIC_TEST|Biochemistry of gall stones|Analysis of gallstones is done to determine the biochemical types of gallstone like cholesterol stone, pigmented stones or mix stones
48479711|NCT06304714|OTHER|Patients suffering from envenomation by Bothrops|"For research purposes, the investigator will collect six additional tubes of blood during a venipuncture. This additional volume of blood will be used for research analysis.~The total volume drawn will be within the maximum volume of blood that can be drawn based on body weight.~Venous sampling is planned as part of routine care and the additional blood volumes collected are not significant. This is a low risk procedure due to the small amount of extra blood taken (25,5 ml)."
48479712|NCT05421104|OTHER|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
47953421|NCT01966601|DRUG|Placebo|Placebo continuous intravenous infusion
47953422|NCT02829060|DRUG|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
47953423|NCT02829060|DRUG|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
47953424|NCT02829060|DRUG|Ampicillin 2g|Peri-operative dose: 2 grams, IV
47953425|NCT02829060|DRUG|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
47953426|NCT02829060|DRUG|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
47953427|NCT02829060|DRUG|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
47953428|NCT04057508|OTHER|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
47953429|NCT03750461|DEVICE|Mesh Implantation|Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
47953430|NCT05143281|DRUG|Dexamethasone 0.4 MG [Dextenza]|Ophthalmic Intracanalicular Insert
47953431|NCT03401736|DEVICE|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
47953432|NCT03401736|DRUG|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
47953433|NCT03401736|DRUG|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
47953434|NCT02152800|DRUG|valacyclovir hydrocholoride|
47953435|NCT03414320|OTHER|Gathering data|Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
47953436|NCT00254761|DRUG|Cannabis|
47953437|NCT06530225|OTHER|Education and Mentoring for Prescribing Pharmacists|Pharmacists enrolled in the PrEP prescribing cohort will receive implicit bias, health disparity and health equity training for HIV prevention. In addition, the pharmacists will receive mentorship and receive an implementation toolkit on best practices for PrEP prescribing.
47953438|NCT05538533|RADIATION|46 Gy Radiation Therapy|Dose per fraction of 4.6.
47953439|NCT05538533|RADIATION|40 Gy Radiation Therapy|Dose per fraction 5.7.
47953440|NCT05538533|RADIATION|35 Gy Radiation Therapy|Dose per fraction 7.0.
47953441|NCT03820180|DRUG|Test Product|2 inhalations of Test and Reference product in each study period
47953442|NCT03820180|DRUG|Reference Product|2 inhalations of Test and Reference product in each study period
47953443|NCT02842307|PROCEDURE|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
47953444|NCT02842307|PROCEDURE|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
47953445|NCT02842307|PROCEDURE|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
47953446|NCT02736838|DEVICE|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
47953447|NCT02736838|DEVICE|Laser Doppler|
48339853|NCT06192667|DEVICE|3M Filtek Z250 Universal Restorative (Germany)|Conventional composite resin
48638490|NCT05525715|DRUG|10mg QY201 tablets or 10mg QY201 placebo,BID|10mg QY201 tablets or 10mg QY201 placebo,BID
48638491|NCT05525715|DRUG|15mg QY201 tablets or 15mg QY201 placebo,BID|15mg QY201 tablets or 15mg QY201 placebo,BID
48638492|NCT05525715|DRUG|20mg QY201 tablets or 20mg QY201 placebo,BID|20mg QY201 tablets or 20mg QY201 placebo,BID
48638493|NCT05525715|DRUG|5mg QY201 tablets，BID|5mg QY201 tablets，BID
48638494|NCT05525715|DRUG|10mg QY201 tablets，BID|10mg QY201 tablets，BID
47953448|NCT02938312|BEHAVIORAL|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
47953449|NCT02938312|BEHAVIORAL|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
47953450|NCT05668429|DRUG|Ibrexafungerp|carbon-14 (\[14\^C\])-Ibrexafungerp
47953451|NCT00137215|DEVICE|Silverlon|dressing for donor site mamagement
47953452|NCT03951714|BEHAVIORAL|Marketed experience application on adherence|To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
47953453|NCT05888077|OTHER|ESWL_LL|Extracorporeal shock wave lithotripsy using latest lithotripter and laser lithotripsy for difficult Bile duct stones
47953454|NCT00276146|DRUG|oral dipyridamole, oral magnesium, or a combination of both|
47953455|NCT04845477|DEVICE|Magnetic tape|magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
47953456|NCT04845477|DEVICE|Kinesiology tape|kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
47953457|NCT01706978|PROCEDURE|Bone Trephination|
47953458|NCT01706978|PROCEDURE|Soft Tissue Trephination|
47953459|NCT03947996|OTHER|Stretching exercise|Stretching (30 minutes, 5 days per week, 8 weeks)
48479713|NCT06085339|BEHAVIORAL|Social Media|The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
48108860|NCT03959241|DRUG|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
48638495|NCT05525715|DRUG|20mg QY201 tablets，BID|20mg QY201 tablets，BID
47953460|NCT03947996|OTHER|Walking exercise|Walking (30 minutes, 5 days per week, 8 weeks)
47953461|NCT00241358|DRUG|AMD3100|
47953462|NCT00241358|PROCEDURE|Stem Cell Transplant|
47953463|NCT04730687|DEVICE|Traditional non surgical mechanical therapy|Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).
47953464|NCT04730687|DEVICE|Diode laser assisted non-surgical mechancal therapy|One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).
47953465|NCT04730687|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
48638496|NCT05525715|DRUG|QY201 placebo，BID|QY201placebo，BID
48638497|NCT05209737|PROCEDURE|Trendelenburg position|A 10-degree head-down position will be used in this group
48638498|NCT05209737|PROCEDURE|Semirecumbent position|A 30-degree head-up position will be used in this group
48638499|NCT05890573|DRUG|Bailing capsule|6 Bailing capsules,po,tid,12 weeks
48638500|NCT03575000|DRUG|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
47953466|NCT02051231|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
47953467|NCT02502318|PROCEDURE|Video-thoracoscopy|
47953468|NCT02502318|PROCEDURE|thoracotomy|
47953469|NCT01757327|DRUG|Erismodegib|
47953470|NCT01757327|DRUG|Placebo|
47953471|NCT03830385|DRUG|PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin|All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
47953472|NCT06319378|DRUG|psilocybin 25 mg sod|psilocybin 25 mg sod
47953473|NCT06319378|DRUG|psilocybin 1 mg sod|active placebo
47953474|NCT03704987|DIAGNOSTIC_TEST|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
47953475|NCT05183815|OTHER|slow stroke massage and murrotal quran|murrotal quran and slow stroke massage
47953476|NCT05942300|DRUG|CPI-0209|A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
47953477|NCT05942300|DRUG|carboplatin|Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
48638501|NCT04701983|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
48479714|NCT04435002|OTHER|Acupressure|Acupressure technics applied to (Liv- 4 , Ht-7 Bilateral, Liv-3 Bilateral, Anmian Bilateral, Yin-Tang unilateral ve Sp-6 Bilateral)
47953478|NCT01825525|DEVICE|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
48638502|NCT04701983|DRUG|Placebo|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
48638503|NCT06021522|DRUG|Ecopipam|Selective dopamine D1 and D5 receptor antagonist
48638504|NCT05812599|OTHER|Educational Module|The COVID Test Learning Module will present four multi-part character scenarios that someone might experience when considering testing for COVID-19. Participants will answer questions about the character's behavior. Accurate guidelines will be provided in response to each scenario to educate participants about what to do in nuanced COVID testing decision-making situations.
48638505|NCT05799950|DEVICE|AcrySof single-piece IOL|Acrylic single-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
48638506|NCT05799950|DEVICE|AcrySof multi-piece IOL|Acrylic multi-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
48638507|NCT03656562|DRUG|VAY736|150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
47953479|NCT00376883|DRUG|pamidronate|
48479715|NCT01507090|DEVICE|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
48479716|NCT05965102|DRUG|Tirelizumab；Chemotherapy monotherapy|Tirelizumab combined with chemotherapy in first-line treatment of relapsed/metastatic non-small cell lung cancer with ECOG PS score of 2
48479717|NCT03113578|DEVICE|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
48479718|NCT04622124|DRUG|Placebo|
48479719|NCT04622124|DIETARY_SUPPLEMENT|fasted vs. high-fat meal|
48479720|NCT04622124|DRUG|Placebo|
48479721|NCT01745952|DEVICE|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
48479722|NCT01745952|DEVICE|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
48479723|NCT01745952|DEVICE|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
48638508|NCT03656562|DRUG|VAY736 Placebo|solution for injection; 0 mg/mL administered as 2 mL s.c. injection
48638509|NCT03656562|DRUG|CFZ533|150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
48638510|NCT03656562|DRUG|CFZ533 Placebo|Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
48638511|NCT01286272|DRUG|Bendamustine Hydrochloride|Given IV
48638512|NCT01286272|DRUG|Bortezomib|Given IV or SC
48638513|NCT01286272|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET
48638514|NCT01286272|OTHER|Laboratory Biomarker Analysis|Correlative studies
48638515|NCT01286272|BIOLOGICAL|Ofatumumab|Given IV
48638516|NCT01286272|PROCEDURE|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
47953480|NCT04402060|DRUG|APL-9|Complement (C3) Inhibitor
47953481|NCT04402060|OTHER|Vehicle Control|Normal saline of equal volume to active arm
47953482|NCT02448186|BEHAVIORAL|ESTEEM|10-session cognitive behavioral treatment
47953483|NCT05258643|OTHER|Blood analysis|Venipuncture and collection of serum and whole blood
47953484|NCT03082482|BEHAVIORAL|Self-help materials|Self-help smoking cessation materials
47953485|NCT03082482|DRUG|nicotine patch|Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
47953486|NCT03082482|BEHAVIORAL|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
47953487|NCT03082482|OTHER|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
47953488|NCT03526575|DRUG|Zolpidem|
47953489|NCT02264639|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
47953490|NCT01346579|OTHER|laboratory biomarker analysis|Correlative sciences
48479724|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Formulation 1 (FM1) powder for oral suspension.
48479725|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Formulation 2 (FM2) powder for oral suspension.
48479726|NCT03275584|DRUG|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
48479727|NCT02310789|DRUG|Ivacaftor|150mg administered orally twice daily.
48479728|NCT02310789|DRUG|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
48479729|NCT02310789|DRUG|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
48479730|NCT02310789|DEVICE|Macroduct sweat stimulator|
48479731|NCT04083352|DIETARY_SUPPLEMENT|Pruvit Ketomax Ketone Salt|6-week supplementation with ketone salts
48479732|NCT04083352|DIETARY_SUPPLEMENT|Placebo|Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
48479733|NCT04661449|OTHER|Comprehensive lifestyle intervention|Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
48638517|NCT03543020|RADIATION|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
48638518|NCT06570798|DRUG|Inebilizumab|Intravenous (IV) Infusion
48638519|NCT06570798|DRUG|Blinatumomab|SC Injection
48638520|NCT01553500|DIETARY_SUPPLEMENT|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
48638521|NCT01553500|BEHAVIORAL|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
48301049|NCT00400933|BEHAVIORAL|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
48301050|NCT02771808|OTHER|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
48301051|NCT03718494|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
48301052|NCT03718494|DIAGNOSTIC_TEST|F-18 Florbetapir Positron Emission Tomography (PET) Imaging|After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
48301053|NCT03718494|DIAGNOSTIC_TEST|F-18 AV-1451 Positron Emission Tomography (PET) Imaging|Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
48301054|NCT03718494|OTHER|Neuropsychological Testing|A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
48301055|NCT02019381|DIETARY_SUPPLEMENT|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
48301056|NCT02019381|DIETARY_SUPPLEMENT|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
48301057|NCT02019381|DIETARY_SUPPLEMENT|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
48301058|NCT04473261|DRUG|Iodine Complex|Iodine Complex capsule (200mg) will be given three times a day
48301059|NCT04473261|DRUG|Iodine Complex|Iodine Complex syrup form (40ml) will be given three times a day
48479734|NCT03567525|PROCEDURE|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
48638522|NCT02168439|DRUG|Dexmedetomidine|
48638523|NCT02168439|DRUG|Midazolam|
48301060|NCT04473261|DRUG|Placebo|Empty capsule will be given as placebo
48301061|NCT04473261|DRUG|Idoine Complex|Iodine Complex spray form 2 puffs will be given three times a day
47953491|NCT04761510|BEHAVIORAL|Mindfulness-SOS for Refugees|Mindfulness-SOS for Refugees is a brief internet-based mobile-supported intervention program which is a mobile-health adaptation of MBTR-R - a mindfulness- and compassion-based, trauma-sensitive, and socio-culturally adapted group intervention program designed for FDPs. Mindfulness-SOS for Refugees entails 8 brief sessions and 9 mindfulness meditation practice exercises - delivered via audio recordings using participants' smartphones. The intervention program is specifically designed to mitigate acute stress and related mental health symptoms among FDPs. During participation in the Mindfulness-SOS for Refugees intervention program, participants will be encouraged to complete 2 sessions per week and practice each day for 4 weeks but can choose to extend this up to 8 weeks. Delivery of Mindfulness-SOS for Refugees entails administrative guidance as well as adherence-focused guidance.
47953492|NCT02927886|PROCEDURE|Per-oral endoscopy pyloromyotomy|
48301062|NCT00992446|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
48301063|NCT00992446|DRUG|Bortezomib|Given IV
48301064|NCT00992446|DRUG|Carmustine|Given IV
48301065|NCT00992446|DRUG|Cytarabine|Given IV
48638524|NCT00770809|OTHER|Laboratory Biomarker Analysis|Correlative studies
48638525|NCT00770809|DRUG|Lapatinib Ditosylate|Given PO
48638526|NCT00770809|DRUG|Paclitaxel|Given IV
47953493|NCT02927886|PROCEDURE|Intrapyloric injection of Botulinum toxin|
47953494|NCT00412997|DRUG|LBH589|
48301066|NCT00992446|DRUG|Etoposide|Given IV
48301067|NCT00992446|DRUG|Melphalan|Given IV
48301068|NCT00992446|DRUG|Rituximab|Given IV
48301069|NCT00992446|DRUG|Vorinostat|Given PO
48301070|NCT03292627|DEVICE|Portable Noninvasive Hemodynamic Monitor|A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
48301071|NCT03630640|DRUG|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
48301072|NCT00382889|DRUG|beclomethasone/salbutamol combination|
48301073|NCT00382889|DRUG|beclomethasone|
48301074|NCT00382889|DRUG|salbutamol|
48301075|NCT05949814|DIAGNOSTIC_TEST|acceptability of a PrEP program among HIV-negative MSM and TG|STI screening by rapid tests and self-sampling after contact on a geolocated community application or a community physical place of sociability
48301076|NCT03206944|DRUG|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
48301077|NCT03206944|DRUG|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
48301078|NCT00409630|DRUG|fluticasone|
48479735|NCT03567525|PROCEDURE|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
48479736|NCT01215071|PROCEDURE|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
48638527|NCT00770809|BIOLOGICAL|Trastuzumab|Given IV
48638528|NCT06338670|DEVICE|Cochlear Osia 3 Sound Processor|Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
48638529|NCT06338670|DEVICE|Cochlear™ Osia® 2 Sound Processor|Osia® 2 Sound Processor
48638530|NCT05116189|BIOLOGICAL|Pembrolizumab|IV infusion
48638531|NCT05116189|DRUG|Paclitaxel|IV infusion
48638532|NCT05116189|DRUG|Bevacizumab|IV infusion
48638533|NCT05116189|OTHER|Placebo for pembrolizumab|IV infusion
47953495|NCT03664180|DRUG|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
47953496|NCT03664180|DRUG|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
47953497|NCT03664180|DRUG|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
47953498|NCT03664180|DRUG|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
47953499|NCT03664180|DRUG|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
47953500|NCT03664180|DRUG|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
47953501|NCT04574973|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
47953502|NCT04574973|BEHAVIORAL|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
47953503|NCT05646095|BEHAVIORAL|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
47953504|NCT03272230|BEHAVIORAL|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
48108861|NCT03959241|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
48301079|NCT01847638|DRUG|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
48301080|NCT01847638|DRUG|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
48301081|NCT00320385|DRUG|Lapatinib|oral lapatinib once daily
48301082|NCT00320385|BIOLOGICAL|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
48638534|NCT05116189|DRUG|Docetaxel|IV infusion
48638535|NCT05705804|DRUG|Pitavastatin|Pitavastatin 4 mg will be given.
48638536|NCT05705804|DRUG|Pitavastatin plus Ezetemibe|Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
48638537|NCT05705804|DRUG|Atorvastatin|Atorvastatin 40 mg will be given.
48638538|NCT01179620|DRUG|Certoparin|Certoparin
48638539|NCT05899816|DRUG|Rocatinlimab|Subcutaneous (SC) injection
48638540|NCT05899816|DRUG|Placebo|SC injection
48638541|NCT06335979|DRUG|PIT565|In each cohort, there will be 3 sentinel participants. Additional participants might be added depending on safety and observed biological activity.
47953505|NCT03272230|BEHAVIORAL|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
47953506|NCT03272230|DIAGNOSTIC_TEST|Neuropsychological assessment|MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS
47953507|NCT03272230|BEHAVIORAL|ICM_APATHY_TASKS|Apathy experimental task
47953508|NCT03272230|OTHER|MRI|T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI
47953509|NCT03272230|BIOLOGICAL|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
47953510|NCT03272230|DIAGNOSTIC_TEST|Supplementary Neuropsychological Assessment - Parkinson's Disease|ACDD / QUIP / BIS-11 / ECMP / QUIP-RS
47953511|NCT00354614|DEVICE|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
47953512|NCT05769309|PROCEDURE|Erector spinae block|After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine
47953513|NCT05769309|DRUG|Fentanyl|fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
47953514|NCT05207254|DIAGNOSTIC_TEST|Ultrasonic test|Ultrasonic test to the patient's head, neck and jaw area.
48108862|NCT03959241|DRUG|Cyclophosphamide|Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if actual body weight (ABW) \< IBW, use ABW\] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
48301083|NCT02857023|BEHAVIORAL|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
48339854|NCT00458367|DRUG|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
48638542|NCT05826587|BEHAVIORAL|Home-based, m-Health Delivered Physical Function Training|An individualized home exercise physical function training will be prescribed. This would include 5 balance training exercises and 1-2 upper and lower-body muscular conditioning exercises (i.e., wall push-up and chair stand) prescribed 3 days/week over the course of a 6-week period. Subjects will be assigned exercises from 1 of 3 different levels of exercise progression based on performance during the baseline muscular fitness assessment (functional chair stand and static chest throw).
48638543|NCT05826587|BEHAVIORAL|Cardiac Rehabilitation & Exercise Prescription|Standard, clinically indicated cardiac rehabilitation and exercise program. Approximately 30 to 40 minutes of aerobic exercise within a prescribed rating of perceived exertion (RPE 11-14) and/or target heart rate and approximately 15 to 20 minutes of both upper and lower body resistance exercise up to three times per week for up to at least 12 weeks. In addition, subjects are provided with home exercise instructions, and will be expected to exercise for 30 to 60 minutes at home.
47953515|NCT04597229|DIETARY_SUPPLEMENT|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
47953516|NCT01495975|OTHER|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
47953517|NCT00370071|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
47953518|NCT05544812|DRUG|Sintilimab ，bevcizumab/cetuximab，XELOX|"Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W"
47953519|NCT03731039|OTHER|Observational study|Pain assessment, Anxiety assessment, Depression assessment
47953520|NCT03127046|DRUG|Aceclofenac|Oral single dose administration of aceclofenac 200mg
47953521|NCT03127046|DRUG|Esomeprazole|Oral single dose administration of aceclofenac 200mg
47953522|NCT03127046|DRUG|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
47953523|NCT04970641|BEHAVIORAL|Three Good Things (3GT) Positive Psychology journaling activity|Evening journaling activity each day to reflect on three good things that the subject has noticed about their day's events.
47953524|NCT03643159|COMBINATION_PRODUCT|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
47953525|NCT03643159|DRUG|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
47953526|NCT00611507|DRUG|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
47953527|NCT02061618|BEHAVIORAL|Bollywood Dance Exercise|
47953528|NCT02138773|DRUG|Tamsulosin formulation-A|oral
47953529|NCT02138773|DRUG|Tamsulosin formulation-B|oral
47953530|NCT02749331|DRUG|AdVince|Virus solution for infusion in intrahepatic artery
48339855|NCT04233710|COMBINATION_PRODUCT|Robot Rehabilitation + tDCS|Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.
48479737|NCT01215071|PROCEDURE|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
47953531|NCT02215096|DRUG|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
47953532|NCT02215096|DRUG|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
47953533|NCT02031796|OTHER|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
47953534|NCT00685542|DRUG|diacerein|Diacerein 50mg bid
47953535|NCT00685542|DRUG|placebo|placebo
47953536|NCT02788760|DEVICE|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
48638544|NCT05826587|OTHER|Connected mHealth mobile application|Mobile application that allows subjects to track their independent home exercise with the option of heart rate monitoring by connecting to an external heart rate monitoring device.
48638545|NCT05337137|DRUG|Relatlimab|Specified dose on specified days
47953537|NCT02798146|OTHER|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
47953538|NCT05310448|DEVICE|Optune device|Wear Optune device
48339856|NCT04233710|BEHAVIORAL|Robotic Rehabilitation + sham tDCS|Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
48479738|NCT01359579|DRUG|varespladib methyl|Single oral 500 mg dose
48479739|NCT04414137|OTHER|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
48638546|NCT05337137|DRUG|Nivolumab|Specified dose on specified days
47953539|NCT03808831|DEVICE|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
47953540|NCT03808831|DEVICE|Sham fall detection and prevention system|The sham system with record but no alert function
47953541|NCT01680965|DRUG|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
48301084|NCT02937103|BIOLOGICAL|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
47953542|NCT06541847|DRUG|HLX-1502|Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)
48638547|NCT05337137|DRUG|Bevacizumab|Specified dose on specified days
47953543|NCT04230395|BEHAVIORAL|CAP|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
48108863|NCT01450124|DRUG|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
48479740|NCT06616259|DRUG|mCapOX plus Cetuximab|"mCapOX plus Cetuximab Induction therapy：Capecitabine 1000mg/m2 po, bid, D1-7 + Oxaliplatin ivgtt 85mg/m2, D1 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
48638548|NCT05337137|OTHER|Placebo|Specified dose on specified days
48638549|NCT06458166|OTHER|Assessment of low frequency fatigue using low frequency eletrical stimulation|Pre-programmed muscle electrical stimuli will be applied via Myocene® software using 3 electrodes: 1 cathode (5 x 10 cm) placed transversely over the proximal quadriceps femoris, and 2 anodes (5 x 5 cm) over the distal vastus medialis and vastus lateralis. Sixteen sets of stimuli will be administered with 5 seconds between sets. Each set consists of a single pulse, a train of 5 stimuli at 20 Hz, and a train of 18 stimuli at 120 Hz, with 1-second intervals between. The stimulation intensity starts at 25 mA and increases by 1 mA per set, reaching 40 mA in the final set. The Myocene® software calculates the ratio of low- to high-frequency evoked forces within each set. The outcome (Powerdex) is the median value of these 16 ratios for each leg. This evaluation will be conducted on both legs, taking 2 minutes per leg.
48638550|NCT06238921|RADIATION|Stereotactic Radiation|Stereotactic Radiation to intact brain metastases or post-operative cavity.
47953544|NCT04230395|OTHER|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
48339857|NCT03292341|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
47953545|NCT00946361|OTHER|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
48339858|NCT03292341|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
47953546|NCT01518348|BIOLOGICAL|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
47953547|NCT04834232|DEVICE|compression therapy|compression bandaging or graduated compression hosiery consists of applying a type of elastic device, mainly on the limbs, to exert a controlled pressure on the lower limbs. The controlled pressure exerted by medical compression stockings reduces the diameter of major veins, thereby increasing the velocity and volume of blood flow, along with conditions beneficial for the healing of chronic inflammatory disorders (e.g. cellulitis, erysipelas, venous leg ulcers, etc.), through reduced pro-inflammatory cytokine levels and higher levels of the anti-inflammatory cytokines.
47953548|NCT04834232|PROCEDURE|iliac vein stenting|using x-ray guidance (fluoroscopy) to place a an expandable metal mesh tube against the vein walls, acting as a scaffold to keep the veins open and improve blood flow
48108864|NCT00781196|DRUG|folic acid|capsule 0.5 mg once a day
48108865|NCT00781196|DRUG|placebo|capsule, once a day
48108866|NCT03698396|BIOLOGICAL|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
48108867|NCT03795558|DRUG|Etelcalcetide|Up-Titration
48108868|NCT03391635|DEVICE|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
48108869|NCT03391635|DEVICE|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
48108870|NCT00587925|OTHER|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
48108871|NCT03994055|OTHER|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
48339859|NCT03292341|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
48638551|NCT06238921|DRUG|Zimberelimab|One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.
48301085|NCT01099410|PROCEDURE|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
48638552|NCT06238921|DRUG|Sacituzumab govitecan|SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
48638553|NCT03623490|OTHER|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
48638554|NCT03899805|DRUG|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
48638555|NCT03899805|DRUG|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
48638556|NCT01795339|DRUG|AZD3293|Oral solution
48301086|NCT01099410|PROCEDURE|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
48108872|NCT03994055|OTHER|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
48301087|NCT01099410|PROCEDURE|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
48301088|NCT02848846|DEVICE|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
48638557|NCT01795339|DRUG|Placebo|Oral solution
48638558|NCT04209803|DRUG|Minoxidil 5% topically and oral NAC 600 mg|Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally
48108873|NCT03994055|OTHER|Soluble fiber|Diet will include foods rich in soluble fiber.
48108874|NCT03994055|OTHER|Probiotics|Diet will include foods rich in probiotics.
48108875|NCT03994055|OTHER|Lactose restriction|Diet will be restricted to 5g lactose/day
48108876|NCT03994055|OTHER|Fiber restriction|Diet will be restricted to 20g fiber/day
48108877|NCT03994055|OTHER|Fat restriction|Diet will be restricted to 20% total energy intake
48108878|NCT05200247|DRUG|spesolimab|solution for infusion
48108879|NCT00078572|DRUG|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
48108880|NCT00078572|DRUG|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
48108881|NCT01086917|BIOLOGICAL|PfSPZ Challenge|each volunteer to receive a single dose
48108882|NCT03257813|DRUG|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
48108883|NCT03257813|DRUG|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
48108884|NCT01606163|BIOLOGICAL|GC1102|"1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
48108885|NCT01606163|OTHER|JW normal saline|"1. Description: Normal saline IV bolus injection through 10\~ 30 seconds.~   * Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~2. Subject number: 9~3. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
48108886|NCT01269736|BEHAVIORAL|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
48108887|NCT03884244|OTHER|chewing gum|The group who take chewing gum after operation
48301089|NCT02353078|DRUG|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
48301090|NCT02353078|PROCEDURE|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
48638559|NCT04725903|RADIATION|High-Dose Rate Brachytherapy|Receive high-dose rate brachytherapy boost
48638560|NCT04725903|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam therapy
48638561|NCT04725903|OTHER|Quality-of-Life Assessment|Ancillary studies
48638562|NCT04725903|OTHER|Survey Administration|Ancillary studies
48638563|NCT05526248|DRUG|Darolutamide(BAY1841788, Nubeqa)|tablet, oral
48638564|NCT05526248|DRUG|Enzalutamide|tablet, oral
48638565|NCT04867369|DRUG|Bupivacaine 20mL 0.5%|Interscalene nerve block with 20 mL 0.5% bupivacaine.
48638566|NCT04867369|DRUG|Bupivacaine 20mL 0.25%|Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
48638567|NCT04867369|DRUG|Bupivacaine up to 15mL 0.25%|Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
47953549|NCT06462638|OTHER|Neurobehavioral states and physiological parameters evaluation|"Each individual infant included in the study will be assessed 3 times a week for at least two weeks: specifically, two detections of neurobehavioral states in response to interaction with the mother, two detections with the father, and two detections with the nurse(s) will be made.~For each infant involved in the study, an audio/video recording of cradle movements and vocalizations will be made at 3 different consecutive times (5 minutes each): baseline; recording during interaction with either parent or nurse; post-interaction assessment.~The parent or nurse is asked to interact freely with the baby, choosing whether to use voice and touch or only one of the sensory stimulation channels. During the interactions, parents and nurse will in turn be assessed relative to some basic physiological parameters through the use of a band applied to the chest; the infant's physiological parameters during the 3 times will also be recorded."
48108888|NCT04569318|DEVICE|Treatment Beam|One of the subject's eyes will be treated with the 415 nm treatment beam (20mW) up to 8 times for 15 minutes.
48108889|NCT06175572|DEVICE|coronary physiological indices|coronary physiological indices
48108890|NCT00860353|DRUG|AZD2551|Single dose of oral solution.
48108891|NCT00860353|DRUG|Placebo|Single dose of oral solution
48108892|NCT04017169|OTHER|No intervention as observational study|
48108893|NCT00887835|DEVICE|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
48301091|NCT02353078|DEVICE|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
48301092|NCT05814770|DRUG|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
48108894|NCT03522558|BEHAVIORAL|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
48108895|NCT03522558|BEHAVIORAL|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
48108896|NCT06554197|DIAGNOSTIC_TEST|CMV/EBV-CMI|The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.
48108897|NCT03259919|DRUG|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
48301093|NCT05814770|DRUG|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
48301094|NCT00538382|DRUG|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
48301095|NCT00504166|DRUG|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
48301096|NCT00504166|OTHER|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
48301097|NCT02690480|DRUG|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
48301098|NCT02690480|DRUG|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
48301099|NCT02690480|DRUG|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
48301100|NCT04166045|DEVICE|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
48301101|NCT04166045|DEVICE|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
48301102|NCT03907722|OTHER|Long pentraxin 3|Primary PCI
48301103|NCT00266110|BIOLOGICAL|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
48301104|NCT00266110|BIOLOGICAL|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
48339860|NCT03292341|OTHER|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
48301105|NCT00266110|BIOLOGICAL|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
48108898|NCT03259919|DRUG|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
48108899|NCT00510601|DEVICE|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
48638568|NCT05671679|OTHER|SNAQ app|SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
48638569|NCT05671679|OTHER|Traditional carbohydrate counting|Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
48638570|NCT04481438|OTHER|Acupunch Exercises|The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
48108900|NCT02023125|DRUG|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
48638571|NCT01649583|DEVICE|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
48638572|NCT04149457|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
47953550|NCT06462638|OTHER|Maternal vocal pitch evaluation to assess depressive/anxious state|"Regarding the assessment of any depressive/anxious states of the mother, as an additional support to the self-report questionnaires the maternal vocal pitch will be specifically assessed through the Talking about software (AI algorithm applied to maternal postpartum depression research)."
48108901|NCT02023125|DRUG|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
48479741|NCT06616259|DRUG|mFOLFOX6 plus Cetuximab|"mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
48108902|NCT02023125|OTHER|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
48108903|NCT02023125|OTHER|Standard Meal|Standard meal served prior to alectinib administration
48108904|NCT02698241|DEVICE|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
48479742|NCT00759278|PROCEDURE|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
48479743|NCT02994394|DRUG|OPC-41061|
48479744|NCT00024388|DRUG|DHA-paclitaxel|
48479745|NCT00483548|DRUG|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
48638573|NCT04149457|OTHER|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
48108905|NCT02378714|DRUG|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
48108906|NCT02378714|BEHAVIORAL|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
48301106|NCT00266110|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
48638574|NCT00070499|DRUG|Dasatinib|Given PO
48638575|NCT00070499|DRUG|Imatinib Mesylate|Given PO
48638576|NCT00070499|OTHER|Laboratory Biomarker Analysis|Correlative studies
48638577|NCT05531344|DEVICE|Composite Steep-pulse Treatment Device|Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
48638578|NCT05531344|DRUG|Tamsulosin Hydrochloride Capsules|Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
48638579|NCT04477512|DRUG|Cabozantinib|Supplied by Exelixis
48638580|NCT04477512|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
48479746|NCT00483548|DRUG|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
48638581|NCT04477512|DRUG|Abiraterone acetate|Commercially available
48479747|NCT02014441|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
48301107|NCT06416839|BEHAVIORAL|VR exercise|Participation in high intensity interval training delivered on a virtual reality headset over six-week period. Participants may exercise with others in the multiplayer mode and use any feature of the application.
48479748|NCT02378051|BEHAVIORAL|Staying Strong with Schools Intervention|"1. On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~2. Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
48638582|NCT04477512|DRUG|Prednisone|Commercially available
48479749|NCT02378051|OTHER|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
47953551|NCT05147935|BEHAVIORAL|Palliative Care Consultation|In person or telehealth clinic visit with palliative care physician or nurse practitioner
48301108|NCT06326840|DRUG|Metformin|All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
48301109|NCT00006270|DRUG|cosyntropin|
48301110|NCT00006270|DRUG|metyrapone|
48479750|NCT04177641|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
48479751|NCT04177641|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
48479752|NCT06616116|DEVICE|Biosignal feedback|"1. Real-time neurofeedback guided mindfulness~   : Unlike standard mindfulness therapies, this intervention integrates real-time monitoring of brainwave activity (EEG). Participants in the experimental group receive immediate auditory feedback during their mindfulness sessions, which helps guide their practice and enhance engagement.~2. Tailored progress report In addition to real-time feedback, participants in the Mindfulness with biosignal feedback group receive detailed reports of their biosignal data (EEG and HRV) before, during, and after each session. These reports allow for deeper self-reflection and personalized adjustments to their mindfulness practice, which is not commonly provided in other mindfulness programs."
48479753|NCT06616116|DEVICE|Sham Comparator|Biosignal Monitoring (EEG and HRV) during Mindfulness without real-time feedback
48479754|NCT00094094|DRUG|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
48638583|NCT04477512|PROCEDURE|Peripheral blood collection|Prior to start of treatment, after 8 weeks of combination therapy, with every subsequent imaging (every 12 weeks), end of treatment
48638584|NCT00705965|BEHAVIORAL|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
48638585|NCT00705965|BEHAVIORAL|Information session|One information session about living with heart disease.
48638586|NCT00705965|OTHER|Usual cardiological care|Usual cardiological care
48638587|NCT05032599|BIOLOGICAL|CD5 CART|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
47953552|NCT00502944|BEHAVIORAL|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
47953553|NCT00502944|BEHAVIORAL|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
47953554|NCT02359422|BEHAVIORAL|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
47953555|NCT04531839|BEHAVIORAL|Evidence-based collaborative quality improvement|Evidence-based collaborative quality improvement interventions including benchmarking, potential better practice list, PDSA implementation and collaborative learning
47953556|NCT01967342|BEHAVIORAL|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
48301111|NCT00222729|DRUG|Pemetrexed|500 mg/m2 day 1 q 21 days
48301112|NCT00222729|DRUG|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
48301113|NCT05553548|PROCEDURE|biologically oriented alveolar ridge preservation|xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal
48301114|NCT05553548|PROCEDURE|xenogenic bone graft in entire (apico-coronal) extension|xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
47953557|NCT01967342|BEHAVIORAL|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
48638588|NCT03268499|PROCEDURE|Lipiodol-based transarterial chemoembolization|Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.
48638589|NCT05051410|PROCEDURE|intracanal cryotherapy using needle irrigation and EndoVac system|a cold saline will be used as final irrigant in two groups but with different irrigation systems.
47953558|NCT01967342|OTHER|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
47953559|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
48638590|NCT05174702|RADIATION|Irradiation collected at the end of the operation on the active dosimeter|Mesure of the irradiation collected at the end of the operation on the active dosimeter for the surgeon, the patient and the operating team
48638591|NCT03154112|DEVICE|Measurement of oxygen consumption and caloric expenditure|This study will involve an \~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
48638592|NCT03041337|DIAGNOSTIC_TEST|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
48638593|NCT05451004|OTHER|Lymphatic Mapping with SPECT-CT|Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
48479755|NCT04172025|DIAGNOSTIC_TEST|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
48479756|NCT06617117|OTHER|High-intensity combined exercise|The main part consisted of interval cycling exercise, comprising 5x2 min at the second ventilatory threshold interspersed with 4x2 min at the first ventilatory threshold, followed by 2-min unloading pedalling. Subsequently, participants completed resistance exercises (2 sets of 12 repetitions), targeting the same muscle groups of the moderate-intensity exercise, at an intensity of 80% of their 1 repetition maximum.
48638594|NCT05451004|RADIATION|Ipsilateral and Contralateral Neck|Radiotherapy
48638595|NCT03468426|DRUG|BI 836880|intra-venous infusion
47953560|NCT01361568|DRUG|Placebo|Single i.v. dose administered preoperatively
48479757|NCT06617117|OTHER|Moderate-intensity combined exercise|The main part of the exercise session consisted of an 18-min cycling continuous aerobic exercise at the first ventilatory threshold, followed by 2-min of unloading cycling. Subsequently, participants engaged in resistance exercises - 2 sets of 12 repetitions at 60% of their one repetition maximum. These resistance exercises were part of a machine-assisted circuit training program, encompassing Chest Press, Leg Curl, Low Row, Leg Press, Lat Pull-down, and Leg Extension.
48479758|NCT00392457|DRUG|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
48479759|NCT00392457|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
48638596|NCT03468426|DRUG|ezabenlimab|intra-venous infusion
47953561|NCT01361568|DRUG|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
47953562|NCT01361568|DRUG|Placebo|Single i.v. dose administered postoperatively for pain
47953563|NCT04111809|BIOLOGICAL|Blood and urine collection|collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
47953564|NCT01788488|OTHER|Use of procalcitonin as biomarker to guide therapy|
47953565|NCT03676998|DEVICE|Measurement of diaphragm function|A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
47953566|NCT00643331|BEHAVIORAL|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
47953567|NCT05200559|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
47953568|NCT05200559|DRUG|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
48479760|NCT01704937|DRUG|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
48479761|NCT04978844|BEHAVIORAL|IWOTCH|Arm 1
48479762|NCT04978844|BEHAVIORAL|Dyadic therapy|Arm 2
47953569|NCT02528604|PROCEDURE|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
48638597|NCT03932201|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
48638598|NCT00109070|DRUG|Avastin (bevacizumab)|
48638599|NCT04294160|DRUG|Dabrafenib|Capsule for oral use
48638600|NCT04294160|DRUG|LTT462|Capsule for oral use
48638601|NCT04294160|DRUG|Trametinib|Tablet for oral use
48638602|NCT04294160|DRUG|LXH254|Tablet for oral use
47953570|NCT02528604|PROCEDURE|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
47953571|NCT02528604|PROCEDURE|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
47953572|NCT02528604|DEVICE|Implantable loop recorder|
47953573|NCT01571310|OTHER|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
47953574|NCT01571310|OTHER|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
47953575|NCT03282370|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
48479763|NCT06616181|DEVICE|Anodal tDCS over M1|The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
48479764|NCT06616181|DEVICE|Anodal tDCS over DLPFC|The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
48479765|NCT06616181|BEHAVIORAL|Exercise telerehabilitation|Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance training will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.
48479766|NCT01913379|DRUG|MDV3100|Oral
48479767|NCT01913379|DRUG|Gemfibrozil|Oral
48479768|NCT01913379|DRUG|Itraconazole|Oral
48479769|NCT06148545|DRUG|Elemental iron|Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
48479770|NCT06148545|DRUG|Elemental iron and Vit D|Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
48479771|NCT00006245|DRUG|alvocidib|
48479772|NCT00006245|DRUG|paclitaxel|
48479773|NCT06429982|DRUG|Dexamethasone|Steroid five day treatment
48479774|NCT06429982|DRUG|Placebo|Placebo control group
48479775|NCT02997878|BIOLOGICAL|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human umbilical cord
48638603|NCT04294160|DRUG|TNO155|Capsule for oral use
48638604|NCT04294160|BIOLOGICAL|Spartalizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
48638605|NCT04294160|BIOLOGICAL|Tislelizumab|Liquid in vial (Concentrate for solution for infusion) for intravenous use
47953576|NCT03282370|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
47953577|NCT03530358|DEVICE|Technology-aided rehabilitation|"VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target."
47953578|NCT03530358|BEHAVIORAL|Conventional rehabilitation|The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
48301115|NCT00581711|OTHER|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
48479776|NCT00426530|DRUG|everolimus (RAD001)|
48479777|NCT05589038|OTHER|Baby Wash/Shampoo|Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.
48479778|NCT05589038|OTHER|Baby Lotion|Parent participant will use the baby lotion on baby participants at least once daily.
48479779|NCT04785131|OTHER|Prune|daily consumption of 50 grams prune.
48638606|NCT04629157|DEVICE|Innova Lateral Flow Device|The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
48638607|NCT04255199|BEHAVIORAL|Control|Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
48301116|NCT00581711|OTHER|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
48301117|NCT00581711|OTHER|1-part intervention|Provision of feedback on otitis media quality indicators
48301118|NCT01761955|OTHER|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
48301119|NCT00772512|DRUG|PF-04802540|5 mg capsule, single dose
48301120|NCT00772512|DRUG|PF-04802540|15 mg capsule, single dose
48301121|NCT00772512|DRUG|Placebo|Placebo capsule, single dose
48301122|NCT03239808|PROCEDURE|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
48301123|NCT03239808|PROCEDURE|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
48301124|NCT04530812|OTHER|Best Practice|Maintain usual diet
48301125|NCT04530812|DIETARY_SUPPLEMENT|Kefir|Consume commercial kefir beverage
48301126|NCT04530812|OTHER|Quality-of-Life Assessment|Ancillary studies
48301127|NCT04530812|OTHER|Questionnaire Administration|Ancillary studies
48301128|NCT02146989|OTHER|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
48301129|NCT06513182|OTHER|No Alexis orthopaedic protector|No Alexis orthopaedic protector will be used during the course of the surgery.
48301130|NCT06513182|DEVICE|Alexis orthopaedic protector|Alexis orthopaedic protector will be inserted after making an initial superficial approach to the shoulder.
48301131|NCT00303342|BEHAVIORAL|mind body treatment|regulation of attention, respiration and posture
48301132|NCT00303342|BEHAVIORAL|desensitization|mentation on insomnia behaviors and cognitive activity
48301133|NCT00352781|DRUG|nicotine replacement therapy|nicotine transdermal patches as per product monograph
48301134|NCT00352781|BEHAVIORAL|behavioural intervention|Smoking cessation counselling and relapse prevention
48301135|NCT00005999|DRUG|arsenic trioxide|
48301136|NCT00729118|DRUG|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
48301137|NCT00729118|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
48479780|NCT03917511|BEHAVIORAL|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
48479781|NCT03917511|BEHAVIORAL|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
48479782|NCT05068960|DRUG|Liposomal bupivacaine|Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty
48479783|NCT05068960|DRUG|Bupivacaine|Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
47953579|NCT02925832|PROCEDURE|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
48301138|NCT04786028|OTHER|Isatuximab|Brand name for interventional drug is Sarclisa
48301139|NCT05360615|DRUG|Empagliflozin 10 MG|SGLT2 inhibitors
48301140|NCT05360615|DRUG|Placebo|Placebo
48301141|NCT01335568|PROCEDURE|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
48301142|NCT01883583|DEVICE|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
48479784|NCT02283671|BIOLOGICAL|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
48479785|NCT01246362|DRUG|Control|Given placebo
48301143|NCT00764842|DEVICE|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
48301144|NCT00122746|RADIATION|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
48301145|NCT00122746|RADIATION|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
48301146|NCT02755740|OTHER|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
48301147|NCT00003859|DRUG|carboplatin|
48301148|NCT00003859|DRUG|cyclophosphamide|
48301149|NCT00003859|DRUG|etoposide|
48301150|NCT00003859|DRUG|vincristine sulfate|
48301151|NCT00003859|PROCEDURE|surgical procedure|
48479786|NCT01246362|DRUG|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
48638608|NCT04255199|BEHAVIORAL|Intervention|Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over \~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
47953580|NCT02925832|DRUG|Ropivacaine|0.75% ropivacaine soaked sponges
47953581|NCT02925832|DRUG|Bupivacaine|0.5% bupivacaine soaked sponges
48638609|NCT06287463|DRUG|DCC-3084|Administered orally
48638610|NCT03565588|BEHAVIORAL|Education session with fixed incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
48638611|NCT03565588|BEHAVIORAL|Education session with lottery incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
48638612|NCT03929055|DEVICE|Physiological assesment|"1. Arterial blood gas analysis.~2. esophageal pressure variation during inspiration and expiration~3. Arterial blood pressure, central venous pressure (CVP), heart rate.~4. diaphragmatic contraction detected by ultrasound"
48638613|NCT06403267|DRUG|NoNO-42|a single dose sterile 20 ml vial containing lyophilized powder for reconstitution containing 300 mg of NoNO-42 active ingredient.
48479787|NCT02918331|DRUG|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
48479788|NCT02918331|DRUG|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
48479789|NCT02918331|DRUG|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
48479790|NCT04890080|OTHER|Pulmonary Rehabilitation|Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
48479791|NCT00698087|BIOLOGICAL|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
48479792|NCT00698087|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 or 3 doses
48479793|NCT04881162|DEVICE|NOVIS Transcarotid Neuroprotection System (NPS)|The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
48479794|NCT02269956|BEHAVIORAL|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
48479795|NCT04174716|DRUG|IDX-1197|Until progression or unacceptable toxicity develops
48479796|NCT00134329|PROCEDURE|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
48479797|NCT05571033|BEHAVIORAL|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
48479798|NCT02836301|BEHAVIORAL|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
47953582|NCT02925832|DRUG|Proparacaine|For anaesthetising conjunctiva
47953583|NCT05927584|PROCEDURE|Transanal local excision|Transanal full thickness local excision
47953584|NCT02758314|OTHER|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
47953585|NCT00238888|PROCEDURE|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
47953586|NCT00238888|PROCEDURE|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
47953587|NCT04903678|DRUG|Melphalan|Melphalan is performed for intrathecal chemotherapy
47953588|NCT00111501|BEHAVIORAL|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
47953589|NCT00111501|BEHAVIORAL|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
47953590|NCT05877768|DIAGNOSTIC_TEST|Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Photon Counting Detector Coronary Computed Tomography Angiography for the suspicion of coronary artery disease or the progression thereof.
47953591|NCT00493623|DRUG|Placebo|Placebo i.v. single dose
47953592|NCT00493623|DRUG|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
48638614|NCT06403267|DRUG|Placebo|100 ml 0.9% normal Saline
48638615|NCT05253833|DRUG|AR882 Dose 1|Solid Oral Capsule
48638616|NCT05253833|DRUG|AR882 Dose 2|Solid Oral Capsule
48638617|NCT05253833|DRUG|Allopurinol Tablet|Solid tablet
48638618|NCT01693237|OTHER|Group psychotherapy|20 sessions of systemic and narrative group therapy
48638619|NCT01693237|OTHER|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
48638620|NCT01704573|DRUG|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA."
48638621|NCT03318159|DRUG|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
48638622|NCT06567561|BEHAVIORAL|Whole Foods Plant-Based Diet|Whole foods, predominantly plant-based diet, with the addition of fish, eggs, and fermented dairy.
48638623|NCT06567561|BEHAVIORAL|Usual Firehouse Diet|Usual firehouse meals.
48638624|NCT05459935|DEVICE|PBM Tonsil Arm|exposure of hypertrophic tonsils to photobiomodulation
47953593|NCT05369767|DRUG|SAD, SHR-2004|Ascending dose
48479799|NCT02836301|BEHAVIORAL|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots...a missed opportunity.
48479800|NCT02836301|BEHAVIORAL|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
48479801|NCT01584895|BEHAVIORAL|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
48479802|NCT00990847|DRUG|Procaterol, Salbultamol|
48638625|NCT05459935|DEVICE|Sham PBM Tonsil Arm|non-powered exposure of hypertrophic tonsils to photobiomodulation
48638626|NCT06531473|PROCEDURE|HoLEP|Patients will be randomized to one of the laser energy groups day of surgery.
48638627|NCT05577715|DRUG|MORAb-202|Specified dose on specified days
48638628|NCT00933166|DEVICE|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
48638629|NCT04849741|DRUG|zilganersen|zilganersen will be administered by ITB injection.
48638630|NCT04849741|DRUG|Placebo|zilganersen-matching placebo will be administered by ITB injection.
48638631|NCT04208178|DRUG|Alpelisib|Alpelisib orally taken - continuous once daily, in a 21-day cycle.
48638632|NCT04208178|DRUG|Alpelisib matching Placebo|Alpelisib matching placebo orally taken - continuous once daily, in a 21-day cycle
48638633|NCT04208178|DRUG|Trastuzumab|Trastuzumab 6mg/kg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
48638634|NCT04208178|DRUG|Pertuzumab|Pertuzumab 420 mg given intravenously - Day 1 of Cycle 1, and on Day 1 of every cycle thereafter (Cycle=21 days)
48638635|NCT06572930|DRUG|Gonal-f (gonadotropin)|Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.
47953594|NCT05369767|DRUG|SAD, SHR-2004 placebo|Ascending dose
47953595|NCT00826761|DIETARY_SUPPLEMENT|probiotic|One capsule per meal test (high dose or low dose)
47953596|NCT00826761|DIETARY_SUPPLEMENT|placebo|1 capsuel every morning
47953597|NCT00005118|DRUG|Indinavir sulfate|
47953598|NCT00005118|DRUG|Ritonavir|
47953599|NCT02526446|BEHAVIORAL|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
47953600|NCT02526446|OTHER|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
48301152|NCT00003859|RADIATION|radiation therapy|
48479803|NCT05085769|PROCEDURE|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
48638636|NCT03765359|DRUG|metforminhydrochloride|metformin 500 mg tablets and insulin
48638637|NCT03765359|DRUG|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
47953601|NCT03760055|DEVICE|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
48479804|NCT01034852|PROCEDURE|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
48638638|NCT05463055|RADIATION|Proton Therapy System (ProBeam)|All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
48638639|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
48638640|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
48479805|NCT04714281|DEVICE|Dialyser|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
48479806|NCT03318887|DRUG|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
48638641|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
48638642|NCT00960856|DRUG|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
47953602|NCT04462770|DRUG|EPX-100 (clemizole HCl)|Daily dose of EPX-100
48479807|NCT04814459|OTHER|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
48479808|NCT05468372|DRUG|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
47953603|NCT04462770|DRUG|Placebo|Daily dose of placebo
47953604|NCT06544122|DEVICE|Transcranial direct current stimulation|Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.
47953605|NCT05197621|BIOLOGICAL|mRNA COVID-19 vaccine (Pfizer or Moderna)|mRNA vaccine received at any time during pregnancy course
47953606|NCT03320317|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
47953607|NCT03320317|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
48479809|NCT05468372|DRUG|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
48638643|NCT06538038|DRUG|Osimertinib|Single agent Osimertinib by mouth once daily. Dosing and administration of osimertinib will be administered as per routine standard of care per the package insert or per institutional guidelines.
48638644|NCT06538038|DRUG|Osimertinib + Chemotherapy|Osimertinib by mouth once daily + Chemotherapy. Chemotherapy choice will be per treating physician. Dosing and administration of osimertinib +/- chemotherapy agents will be administered as per routine standard of care per the package insert or per institutional guidelines.
48638645|NCT03932786|PROCEDURE|Biospecimen collection|Collection of tissue and saliva samples
47953608|NCT03320317|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
47953609|NCT03320317|OTHER|Learning session 4|Feedback report, Best practice symposium
47953610|NCT05212922|DRUG|YH001 + Toripalimab|YH001 + Toripalimab
47953611|NCT04171154|BEHAVIORAL|Expectation|writing task
47953612|NCT04171154|BEHAVIORAL|Acceptance|listening
48638646|NCT03932786|OTHER|Vision assessment|Undergo vision assessment
48638647|NCT03932786|OTHER|Questionnaire administration|Complete questionnaires
48638648|NCT03932786|OTHER|Quality of life assessment|Complete questionnaires
47953613|NCT01784757|DRUG|ODM-201 Tablet A|Tablet A formulation of ODM-201
47953614|NCT01784757|DRUG|ODM-201 Tablet B|Tablet B formulation of ODM-201
48638649|NCT03932786|OTHER|Laboratory Biomarker Analysis|Correlative studies
47953615|NCT01784757|DRUG|ODM-201 capsule formulation|Capsule formulation of ODM-201
47953616|NCT04737928|DRUG|Latanoprost|latanoprost 0.05%(one drop, once daily)
47953617|NCT04737928|DRUG|tafluprost|tafluprost 0.015% (one drop, once daily)
47953618|NCT01847742|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|
47953619|NCT05602350|BEHAVIORAL|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
47953620|NCT05602350|BEHAVIORAL|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
47953621|NCT04997278|DEVICE|Coordinated Reset spinal cord stimulation|"Abnormal neuronal synchrony in terms of enhanced 4-9 Hz theta oscillations in EEG/MEG recordings appears to be an important pathophysiological finding in patients with neurogenic pain. To specifically counteract abnormal neuronal synchrony, we here set out to perform Coordinated Reset (CR)-Spinal Cord Stimulation (SCS). CR stimulation (Tass, 2003) aims at an anti-kindling, i.e. an unlearning or resetting of abnormal neuronal synchrony and abnormal synaptic connectivity, and, hence, long-lasting, sustained therapeutic effects that persist following cessation of stimulation (Tass \& Majtanik, 2006)."
47953622|NCT03695744|DRUG|Daratumumab|Daratumumab
47953623|NCT03695744|DRUG|Bortezomib|Bortezomib
47953624|NCT03695744|DRUG|Dexamethasone|Dexamethasone
47953625|NCT06556290|OTHER|Gluten free and casein free diet|Parents will be advised for three months to ensure that children with autism spectrum disorder follow a casein-free and gluten-free diet during this period.
47953626|NCT02281773|DRUG|BI 409306 100 mg QD|
47953627|NCT02281773|DRUG|BI 498306 50 mg QD|
48638650|NCT06229145|BIOLOGICAL|Pegloticase|IV infusion
48638651|NCT06229145|DRUG|Methotrexate|Oral
48638652|NCT03600103|BEHAVIORAL|Tech2Check|The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
48638653|NCT00043680|DRUG|Celecoxib|
48638654|NCT06130540|DRUG|Secukinumab|Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8
48638655|NCT03897010|DEVICE|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
48638656|NCT06226415|BEHAVIORAL|Rehabilitation therapy|"The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
48301153|NCT00633828|BEHAVIORAL|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
48301154|NCT04973111|DRUG|CT-868 as SC Injection|CT-868
48301155|NCT04973111|DRUG|Placebo as SC Injection|Placebo
48301156|NCT04973111|DRUG|Active Comparator as SC Injection|Active Comparator
48301157|NCT04187222|OTHER|Mechanical debridements|Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
48301158|NCT04187222|BIOLOGICAL|Bifidobacterium animalis subsp. lactis|Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
48301159|NCT04708145|DRUG|Aflibercept Injection|Intravitreal 2mg aflibercept injection
48638657|NCT06226415|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48638658|NCT06226415|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
47953628|NCT02281773|DRUG|Placebo|
47953629|NCT02281773|DRUG|BI 498306 25 mg QD|
47953630|NCT02281773|DRUG|BI 409306 10 mg QD|
47953631|NCT01870050|DRUG|Dapsone gel - verum|
47953632|NCT03715101|DRUG|Rosuvastatin|Open-label, one-sequence, multiple administration
47953633|NCT05515315|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
47953634|NCT05515315|DRUG|Albumin paclitaxel|Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks
47953635|NCT05515315|DRUG|Nedaplatin|Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks
47953636|NCT05515315|RADIATION|radiotherapy|50-60Gy/25-30f
47953637|NCT04202471|DEVICE|Chlorhexidine Cloth|2% chlorhexidine gluconate cloth
48301160|NCT06419036|DEVICE|Pneumowave DC|Pneumowave biosensor(s) will be used to collect data from chest +/- movement.
48301161|NCT04338022|DRUG|Evobrutinib|Evobrutinib twice daily (BID) in DBTP.
48301162|NCT04338022|DRUG|Placebo (match to Teriflunomide)|Placebo match to Teriflunomide once daily in DBTP.
47953638|NCT02345226|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
47953639|NCT02345226|DRUG|EFV/FTC/TDF Placebo|Tablets administered orally once daily
48301163|NCT04338022|DRUG|Teriflunomide|Teriflunomide once daily in DBTP.
48301164|NCT04338022|DRUG|Placebo (match to Evobrutinib)|Placebo match to Evobrutinib BID in DBTP.
48301165|NCT04209868|DRUG|Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection|As per arm description
48301166|NCT04209868|DRUG|0.9% Sodium Chloride 20mL Injection|As per arm description
48301167|NCT01429012|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
47953640|NCT02345226|DRUG|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
47953641|NCT02345226|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
48301168|NCT01429012|OTHER|Culture medium without MSC.|2 ml of culture medium.
48301169|NCT02214199|OTHER|Manipulative Therapy Techniques|
48301170|NCT02214199|OTHER|Home Exercises|
48301171|NCT00031577|DRUG|paclitaxel|
48301172|NCT00031577|RADIATION|radiation therapy|
48301173|NCT01207739|DRUG|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
48301174|NCT01207739|DRUG|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
48301175|NCT01207739|DRUG|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
48301176|NCT04207853|OTHER|whole body vibration em DM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
48301177|NCT04207853|OTHER|"Vibration sham em DM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
48339861|NCT00845845|DRUG|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
48339862|NCT00845845|DRUG|Placebo|Daily placebo with dietary counseling for 24 weeks.
48638659|NCT04901052|DIETARY_SUPPLEMENT|n-3 supplementation group|n-3 supplementation group (1.5g of omega 3)
48638660|NCT04901052|DIETARY_SUPPLEMENT|Placebo group|Placebo group (sunflower oil)
48638661|NCT05958875|DRUG|Clozapine|Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
48301178|NCT04207853|OTHER|whole body vibration em NDM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
47953642|NCT03812120|PROCEDURE|Dural closure with L-PRF|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
47953643|NCT03812120|PROCEDURE|Dural closure with classical fibrin sealants|Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
47953644|NCT05401968|BEHAVIORAL|Osteoporosis patient education|During osteoporosis patient education the participants get knowledge about e.g. osteoporosis, medication, and diet, and they participate in physical exercises. Though, differences between municipalities exist. The participants meet in groups and face-to-face.
47953645|NCT01373489|BEHAVIORAL|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
47953646|NCT00522015|DRUG|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
47953647|NCT02248831|DEVICE|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
47953648|NCT00239304|DRUG|Gefitinib|
47953649|NCT00239304|DRUG|Cisplatin|
47953650|NCT00239304|PROCEDURE|Radiotherapy|
47953651|NCT05576675|DRUG|sufentanil + nalbuphine|sufentanil 100 μ g + nalbuphine 40 mg
47953652|NCT05576675|DRUG|Sufentanil|sufentanil 200 μ g
48108907|NCT02378714|BEHAVIORAL|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
48108908|NCT00431431|DRUG|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
48479810|NCT02084368|PROCEDURE|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
48479811|NCT02084368|PROCEDURE|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8\~10mg at L2-3 or L3-4.
48479812|NCT02084368|DRUG|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
48479813|NCT02084368|DRUG|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8\~10mg.
48479814|NCT02284347|DEVICE|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
48479815|NCT06074263|DRUG|Dexamethasone 8mg|Dexamethasone 8mg will be taken orally just prior to surgery.
48479816|NCT06074263|OTHER|Placebo|Placebo capsule which looks identical to dexamethasone capsule
47953653|NCT05576675|DRUG|hydromorphone + nalbuphine|hydromorphone 10 mg+ nalbuphine 40 mg
47953654|NCT02235805|DIETARY_SUPPLEMENT|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
47953655|NCT02235805|DIETARY_SUPPLEMENT|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
47953656|NCT04185948|BEHAVIORAL|Mediterranean diet guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
47953657|NCT04185948|BEHAVIORAL|UK Eatwell guidelines plus intermittent fasting|For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
48108909|NCT00431431|DRUG|raloxifen|2 years treatment with raloxifene (60 mg)
48108910|NCT02993510|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
48339863|NCT02953067|PROCEDURE|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
48339864|NCT02953067|PROCEDURE|Primary arthrodesis|Primary arthrodesis versus ORIF
48479817|NCT05183087|DIAGNOSTIC_TEST|3T Connectome MRI|MRI scan of structural connectivity
48479818|NCT05183087|DIAGNOSTIC_TEST|7 Tesla MRI|MRI scan of functional connectivity
48479819|NCT05183087|DIAGNOSTIC_TEST|TSPO PET|PET scan of neuroinflammation
48479820|NCT05183087|DIAGNOSTIC_TEST|Tau PET|PET scan of tau deposition
48479821|NCT05183087|DIAGNOSTIC_TEST|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
48638662|NCT05958875|DRUG|Second-line Antipsychotics (treatment as usual)|Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
47953658|NCT04828239|DEVICE|laser acupuncture|400 mW, near-infrared, continuous wavelength, 810 nm. about 24J/cm2
47953659|NCT04828239|OTHER|acupuncture|Needle type: C\&G, gauge and size: 0.25x40mm
47953660|NCT04828239|DEVICE|Sham laser acupuncture|This laser pen is the same device with a red light was pasted on the acu-points in the same way, using the same protocol as for the active laser stimulation, but the laser apparatus was not switched on.
48638663|NCT01638299|DEVICE|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
47953661|NCT00003678|DRUG|tamoxifen citrate|
47953662|NCT00003678|PROCEDURE|adjuvant therapy|
47953663|NCT00810355|BEHAVIORAL|Support Group|General support and problem solving for work activity
47953664|NCT00810355|BEHAVIORAL|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
47953665|NCT00810355|BEHAVIORAL|Cognitive Remediation|Computerized training to enhance cognitive functioning.
47953666|NCT06284902|DRUG|Fexofenadine HCl Coated tablet|Film-coated tablet.
47953667|NCT06284902|DRUG|Fexofenadine HCl New Formulation Tablet|New formulation tablet.
48638664|NCT02832505|OTHER|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
48479822|NCT05183087|DIAGNOSTIC_TEST|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
48479823|NCT06136416|OTHER|Questionnaire for Non-dystrophic myotonias|Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
48479824|NCT01780480|DRUG|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
48638665|NCT00134498|DRUG|torcetrapib/atorvastatin|
48638666|NCT00134498|DRUG|atorvastatin|
48638667|NCT04903288|GENETIC|Eladocagene Exuparvovec|Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
48638668|NCT02960022|DRUG|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
48638669|NCT02960022|DRUG|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
48638670|NCT02960022|DRUG|prednisone|Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
48638671|NCT00825448|PROCEDURE|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
48638672|NCT01433978|DRUG|Eltrombopag|
48638673|NCT01433978|DRUG|Avatrombopag|
48638674|NCT01433978|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
47953668|NCT00285818|DRUG|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
47953669|NCT00285818|DRUG|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
47953670|NCT04600570|OTHER|ultrasound|ultrasound measurement for optic nerve outer diameter
47953671|NCT00519454|OTHER|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
47953672|NCT05677022|OTHER|Adapted motor activity|15-month adapted motor activity program based on a postural and functional analysis
47953673|NCT04067882|OTHER|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
47953674|NCT04046198|OTHER|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
47953675|NCT05819281|DIETARY_SUPPLEMENT|Probiotic blend|(Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).
47953676|NCT05819281|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin
47953677|NCT01874600|DEVICE|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
47953678|NCT03350165|DRUG|K-877|0.2mg tablet
47953679|NCT03350165|DRUG|Placebo|K-877 matching placebo tablet
47953680|NCT02308189|BEHAVIORAL|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
48301179|NCT04207853|OTHER|"Vibration sham em NDM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
48301180|NCT03268746|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
48301181|NCT01877330|PROCEDURE|Interscalene block for shoulder arthroscopy|
48301182|NCT00619684|DRUG|lenalidomide|Given PO
48301183|NCT05732155|DRUG|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
48301184|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
48301185|NCT01505491|DRUG|BI695501|BI 695501 single s.c injection
48301186|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
48301187|NCT01914445|DRUG|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
48301188|NCT04990544|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
48301189|NCT04990544|BIOLOGICAL|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
48301190|NCT04990544|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
48301191|NCT04990544|BIOLOGICAL|Placebo|Normal saline solution
48301192|NCT00898261|GENETIC|microarray analysis|
48301193|NCT00898261|GENETIC|reverse transcriptase-polymerase chain reaction|
48301194|NCT00898261|OTHER|flow cytometry|
47953681|NCT02308189|BEHAVIORAL|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
47953682|NCT01800396|DIETARY_SUPPLEMENT|Milk protein|
47953683|NCT01800396|DIETARY_SUPPLEMENT|Milk protein rich in phospholipids|
47953684|NCT02761070|DRUG|Temozolomide|
48301195|NCT01884285|DRUG|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
48301196|NCT01884285|DRUG|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
48301197|NCT01884285|DRUG|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
48301198|NCT01884285|DRUG|Part D1: AZD2014 combination with AZD8186|Dose \& schedule finding of AZD8186 in combination with AZD2014
48301199|NCT01884285|DRUG|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
48301200|NCT01884285|DRUG|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
48301201|NCT01568905|OTHER|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
48301202|NCT01568905|OTHER|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
48301203|NCT01568905|OTHER|High level nicotine cigarette|smoke the study cigarette exclusively for one week
48479825|NCT01780480|DRUG|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
47953685|NCT02761070|DRUG|Bevacizumab|
47953686|NCT01442454|OTHER|chronic pancreatitis|No intervention, subjects followed through surgery
47953687|NCT02543580|OTHER|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
47953688|NCT02543580|OTHER|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
47953689|NCT04335032|DRUG|Eicosapentaenoic acid gastro-resistant capsules|same as in arm/group description
47953690|NCT04335032|DRUG|Placebo|same as in arm/group description
47953691|NCT04667481|OTHER|Aerobic Exercise Intervention|Participate in aerobic exercise intervention
48301204|NCT00230581|DRUG|DDP225|
48301205|NCT02723162|DRUG|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
48301206|NCT02723162|DRUG|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
48301207|NCT02723162|DRUG|Placebo|Matched placebo
48301208|NCT01394029|DRUG|deferasirox|
48301209|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
48301210|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
48301211|NCT01869894|PROCEDURE|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
48339865|NCT02953067|PROCEDURE|Conservative treatment|Conservative treatment versus open reduction and internal fixation
48339866|NCT05587608|PROCEDURE|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
48339867|NCT02833818|DIETARY_SUPPLEMENT|CAKE-intervention|Increased protein and energy supplementation and conversations
47953692|NCT04667481|OTHER|Resistance Exercise Intervention|Participate in resistance exercise intervention
48638675|NCT04810078|BIOLOGICAL|Nivolumab and rHuPH20|Specified dose on specified days
48638676|NCT04810078|BIOLOGICAL|Nivolumab|Specified dose on specified days
48638677|NCT05441696|DEVICE|ezCVP measurement|"* Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~* Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~* Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan)."
48638678|NCT03109925|DEVICE|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
47953693|NCT04667481|OTHER|Exercise Intervention: Digital copies and outline of sessions|Receive digital copy of AE and RE sessions and an outline of sessions
47953694|NCT04667481|OTHER|Questionnaire Administration|Ancillary studies
48108911|NCT02993510|DEVICE|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
48108912|NCT02993510|DEVICE|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
48108913|NCT03092713|BEHAVIORAL|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
48108914|NCT03092713|BEHAVIORAL|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
48108915|NCT00481390|PROCEDURE|Cheek cells sample|Cheek cells sample
48108916|NCT00481390|PROCEDURE|Blood sample|Blood sample
48108917|NCT00707135|DRUG|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
48108918|NCT03920371|OTHER|gamma camera imaging|Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
48108919|NCT05136443|DRUG|loteprednol etabonate 0.25% ophthalmic suspension|tapering dose
48108920|NCT04143555|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
48108921|NCT02331043|DIETARY_SUPPLEMENT|Plant stanol ester|
48108922|NCT02331043|DIETARY_SUPPLEMENT|Placebo|
48479826|NCT01780480|PROCEDURE|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
48638679|NCT04918914|DRUG|Dapsone 100 MG|Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID
48638680|NCT02129881|BIOLOGICAL|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
48638681|NCT03106402|DRUG|topical bromfenac sodium hydrate|
48638682|NCT06501261|BEHAVIORAL|CALM psychotherapy|psychotherapy sessions
48638683|NCT02756091|OTHER|No study-specific intervention|
48638684|NCT03749174|PROCEDURE|Long acting Supraclivicular block vs Short acting Supraclavicular block|"Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block"
48638685|NCT05715346|DRUG|LEV102 1.0%|Oxymetazoline ophthalmic gel
48638686|NCT05715346|DRUG|LEV102 2.0%|Oxymetazoline ophthalmic gel
47953695|NCT04667481|OTHER|Quality-of-Life Assessment|Ancillary studies
47953696|NCT02922855|BEHAVIORAL|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
47953697|NCT02922855|BEHAVIORAL|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
47953698|NCT02922855|BEHAVIORAL|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
47953699|NCT01422018|DRUG|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
48108923|NCT01442935|DRUG|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
48108924|NCT01442935|DRUG|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
48108925|NCT01442935|DRUG|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
48108926|NCT01442935|DRUG|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
48108927|NCT01442935|DRUG|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
48108928|NCT01442935|DRUG|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
48638687|NCT05715346|DRUG|Vehicle|Vehicle ophthalmic gel
48638688|NCT06184503|DRUG|Velmanase Alfa|Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
48479827|NCT05659524|OTHER|Nasal saline irrigation|"The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~* Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~* Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative."
48479828|NCT05391659|DEVICE|deep learning|a form of artificial intelligence (AI), has been introduced for automated analysis of images
48479829|NCT05391659|DIAGNOSTIC_TEST|remote grading of fundus images|referrable cases identified by DR AI tool will be remotely graded by a human
48479830|NCT05391659|DIAGNOSTIC_TEST|gold standard|examination by ophthalmologist
48479831|NCT06502587|OTHER|blood flow restriction training|"we will apply blood flow restriction training with low intensity exercises like knee flexion ,knee extension and straight leg raise 10 repetitions 2 sets a day and 3 times/week a rest interval of 2 minutes between exercises, for 30 minutes of this whole procedure.~total 12 sessions given in 4 weeks each session of maximum 30 minutes"
48479832|NCT06502587|OTHER|ultrasound therapy|All subjects will be given Ultrasound therapy as per patient requirement with 1.5 Watts/cm\^2 in continuous mode around knee joint. Conservative exercises(quads isometric exercise, pillow squeeze, heel raise, straight leg raise and side leg raise) will be applied for 3 times per week (daily one set of 10 repetitions) They will be given this treatment for 3 times per week
48479833|NCT05082324|OTHER|Adapted physical activity|Patient participates in an adapted physical activity program for 3 months, with 2 one-hour sports sessions per week
48479834|NCT00583518|DRUG|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
48479835|NCT04417751|BEHAVIORAL|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation \[CS\] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
48479836|NCT01039454|DRUG|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
48479837|NCT01039454|DRUG|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
48479838|NCT01236417|BEHAVIORAL|Exercising block|Exercising for 8 weeks using an elastic band
48479839|NCT00024349|DRUG|fluorouracil|
48479840|NCT00024349|DRUG|mitomycin C|
48479841|NCT00024349|RADIATION|radiation therapy|
48479842|NCT02370459|OTHER|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
48479843|NCT02370459|OTHER|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
47953700|NCT00821483|DRUG|Frovatriptan|2.5mg, qd
48479844|NCT06118502|BEHAVIORAL|Switching to a different medication|Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.
48479845|NCT06118502|BEHAVIORAL|Continued use of the same medication|Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.
48479846|NCT06118502|BEHAVIORAL|Switching to a harm reduction tobacco product|Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
48638689|NCT04123795|DRUG|Certolizumab pegol|"Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~Other Names:~* Cimzia~* CDP870~* CZP"
47953701|NCT01715935|DRUG|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
47953702|NCT02888301|PROCEDURE|Computed Tomography|Undergo 18F-clofarabine PET/CT
47953703|NCT02888301|RADIATION|Fluorine F 18 Clofarabine|Given IV
47953704|NCT02888301|PROCEDURE|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
48339868|NCT02833818|DIETARY_SUPPLEMENT|CAKE-control|nutrition according to established procedures
47953705|NCT04416659|DEVICE|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
47953706|NCT00507091|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
47953707|NCT00507091|DRUG|Irinotecan|intravenous infusion
47953708|NCT00507091|DRUG|5-Fluorouracil|intravenous infusion
48108929|NCT01442935|DRUG|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
48479847|NCT06229119|DEVICE|Implantable Collamer Lens|The EVO ICL lens is intended to be placed entirely within the posterior chamber directly behind the iris and in front of the anterior capsule of the human crystalline lens. When correctly positioned, the EVO ICL lens functions as a refractive element to optically reduce moderate to high myopia with or without astigmatism.
48479848|NCT03844828|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
48479849|NCT04977037|DEVICE|Active tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
48479850|NCT04977037|DEVICE|Sham tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
48479851|NCT05260723|BEHAVIORAL|Behavioral: Sit Less|The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
47953709|NCT00507091|DRUG|Leucovorin|intravenous infusion
48108930|NCT05389462|DRUG|ADCT-601|Intravenous (IV) infusion
48108931|NCT05389462|DRUG|Gemcitabine|Intravenous (IV) infusion
48108932|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
48108933|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
48108934|NCT00641654|DRUG|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
48108935|NCT03419208|OTHER|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
47953710|NCT00507091|DRUG|ZD6474 (vandetanib) 300mg|once daily oral tablet
47953711|NCT00152620|DRUG|Dexamethasone|
47953712|NCT00152620|DRUG|Methylprednisolone|
47953713|NCT00697788|DRUG|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
47953714|NCT03257696|DIAGNOSTIC_TEST|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
47953715|NCT05884788|OTHER|free interview, and questionnaires in a second time|"After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible.~Each interview will be conducted by the same person to allow for better interpersonal reproducibility.~After the interview, the patients will be seen again to complete two questionnaires:~* An attachment questionnaire: Relationship Scales Questionnaire~* A questionnaire on symptoms: Distress thermometer"
47953716|NCT00763529|DRUG|Mometasone|Mometasone furoate cream 0.1% applied once daily
47953717|NCT00763529|DRUG|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
47953718|NCT02024555|DRUG|Levofloxacin|
47953719|NCT02024555|DRUG|Ethambutol|
47953720|NCT02024555|DRUG|Azithromycin|
47953721|NCT02024555|DRUG|Rifampin|
47953722|NCT02024555|DRUG|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
47953723|NCT01669135|OTHER|Spinal Anesthesia with cerebral oxygen saturation monitoring|
47953724|NCT02515448|DRUG|gentamicin|
47953725|NCT04798456|BEHAVIORAL|Coma scales|CRS-R and GOSE
47953726|NCT04798456|DIAGNOSTIC_TEST|Imaging, electrophysiology, body signals, and brain stimulation|MRI, fMRI, EEG, TMS-EEG, Olfaction, Respiration, EKG
47953727|NCT04798456|BEHAVIORAL|Questionnaires|several questionnaires and an interview with the caregiver
47953728|NCT02221024|PROCEDURE|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
47953729|NCT02221024|DRUG|Normal saline|
47953730|NCT02221024|DEVICE|MicroClave ICU Medica|
47953731|NCT05894226|PROCEDURE|laparoscopic ventral mesh rectopexy|patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
47953732|NCT01391754|BEHAVIORAL|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
47953733|NCT01391754|OTHER|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
47953734|NCT01391754|BEHAVIORAL|Services As Usual|Home based services not using the SafeCare model
47953735|NCT01391754|OTHER|Uncoached|No in vivo coached quality control or fidelity monitoring
48638690|NCT04123795|DRUG|Placebo|"Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~Other Names:~-PBO"
48479852|NCT00966381|OTHER|Exercise and weight loss intervention|randomized control trial, stratified by parity
48479853|NCT04008524|BIOLOGICAL|CAR-T cells|Chimeric Antigen Receptor-T cells
48479854|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity Only|The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
48638691|NCT05687110|PROCEDURE|Biopsy|Undergo tumor biopsy
48638692|NCT05687110|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48638693|NCT05687110|PROCEDURE|Diagnostic Imaging|Undergo medical imaging scans
48638694|NCT05687110|BIOLOGICAL|Novobiocin Sodium|Given PO
48638695|NCT00501943|DRUG|Avonex (Interferon beta 1a)|
48638696|NCT00501943|DRUG|Riluzole|
48638697|NCT00501943|DRUG|Placebo|
48638698|NCT02544087|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
48638699|NCT02544087|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
48638700|NCT02544087|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
48638701|NCT03550391|DRUG|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
48638702|NCT03550391|RADIATION|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
48638703|NCT03550391|PROCEDURE|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
48638704|NCT01095965|BEHAVIORAL|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
48479855|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity + cooking Workshop|The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
48479856|NCT01935479|DRUG|AK159|transdermal administration of teriparatide acetate
48638705|NCT03759379|DRUG|Patisiran|Patisiran will be administered by IV infusion.
48638706|NCT03759379|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
48638707|NCT06450444|DEVICE|PRIMUS|The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
48638708|NCT06129734|DRUG|Venetoclax|Venetoclax is a BCL2 inhibitor. It is administered at low doses and used in combination with other hypomethylating agents such as decitabine to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants will initiate therapy with decitabine that will be followed by venetoclax 400 mg oral 6-8 hours later. Participants will continue this dose each week. The venetoclax dose will be reduced to 100 mg once per week if the participant is being treated with posaconazole or voriconazole (strong CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). The venetoclax dose will be reduced 200 mg once per week if the participant is being treated with fluconazole or isavuconazole (moderate CYP3A4 inhibitors) (considered dose equivalent to venetoclax 400 mg 1X/week). This clinical trial is administering venetoclax well below the current FDA approved dosing.
48479857|NCT01935479|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
47953736|NCT00621959|DRUG|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
47953737|NCT00621959|DRUG|placebo|0mg (matching oral tablet)for 14 days
47953738|NCT04256226|PROCEDURE|Tumor excision|Excision of GIST
47953739|NCT00494299|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
47953740|NCT00494299|DRUG|Placebo|Placebo: matching placebo
48479858|NCT01935479|DRUG|Placebo|Placebo AK159
47953741|NCT03613480|OTHER|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
47953742|NCT06045780|OTHER|nothing|disease
48479859|NCT06173596|DRUG|ALXN2080|Participants will receive ALXN2080 orally.
48479860|NCT06173596|DRUG|Itraconazole|Participants will receive Itraconazole orally.
48638709|NCT06129734|DRUG|Decitabine|Decitabine is a hypomethylating agent. It is administered at low doses and used in combination with venetoclax to manage participants with acute myeloid lymphoma who have undergone stem cell transplant. Participants initiate therapy with 5 mg/m2 decitabine subcutaneous every week followed by venetoclax.
48638710|NCT06361810|DRUG|Pembrolizumab|"Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase."
47953743|NCT02148159|DEVICE|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
47953744|NCT02148159|DEVICE|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
47953745|NCT00291889|BIOLOGICAL|Mtb72F/AS02.|
47953746|NCT03761693|OTHER|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~* blood glucose concentration drops \< 3.6 mmol/L;~* the child shows symptoms/signs of a low blood glucose concentration;~* patients parent(s) or guardian(s) request end of fast."
47953747|NCT06358131|DEVICE|Endoscopy|upper and lower endoscopy
47953748|NCT03273543|DEVICE|Restylane® Defyne|hyaluronic acid filler injection
47953749|NCT01323959|BIOLOGICAL|BoostrixTM Polio|Single dose, intramuscular administration.
47953750|NCT04894695|DIAGNOSTIC_TEST|biomarkers detection in different groups|Biomarkers of urine exosomes in different groups were identified by sequencing technology，then biomarkers were validated using urine samples of different groups
47953751|NCT02583282|OTHER|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
47953752|NCT02583282|OTHER|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
47953753|NCT02371304|RADIATION|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
47953754|NCT02371304|PROCEDURE|Additional TME surgery|
47953755|NCT02371304|DRUG|capecitabine|
47953756|NCT06134908|BEHAVIORAL|Multifaceted Intervention|The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
47953757|NCT01403311|DRUG|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
47953758|NCT04642807|PROCEDURE|Long arm soft cast|Participants in group 2 will have a long arm soft cast applied without clinical or radiological follow up.
47953759|NCT04642807|PROCEDURE|Long arm full cast|Participants in group 1 will have a long arm full cast applied.
47953760|NCT06112548|PROCEDURE|primary unilateral TKA|Primary unilateral total knee arthroplasty with cruciate scarifying cemented DePuy Synthes PFC Sigma prosthesis.
47953761|NCT06112548|DRUG|Bupivacain|low body weight (0.50%, 20cc) intraoperative periarticular injection
47953762|NCT06112548|DRUG|ketorolac|1ml of 30mg/ml ketorolac intraoperative periarticular injection
47953763|NCT06112548|DRUG|epinephrine|0.5ml Adrenaline 1mg/ml intraoperative periarticular injection
47953764|NCT06112548|DRUG|Paracetamol|IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery
47953765|NCT06112548|DRUG|Ketorolac|IV Ketorolac {Toradol} introduced every 12 hours after surgery.
47953766|NCT06112548|DRUG|Tramadol|IV Tramadol \[Ultram\] introduced when needed after surgery
47953767|NCT02112344|RADIATION|IMRT|
47953768|NCT02349542|DRUG|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
47953769|NCT04987268|GENETIC|clonal hematopoiesis of indeterminate potential|Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
47953770|NCT00003591|DRUG|paclitaxel|
47953771|NCT00003591|RADIATION|radiation therapy|
47953772|NCT04112459|OTHER|prolonged mechanical ventilation|No intervention will be applied in this study
47953773|NCT02201849|DRUG|Study Drug|
47953774|NCT02201849|DRUG|Active Control|
47953775|NCT02201849|DRUG|Placebo|
47953776|NCT00436774|PROCEDURE|assessment of therapy complications|
47953777|NCT00436774|PROCEDURE|quality-of-life assessment|
47953778|NCT05648578|OTHER|Reiki attempt|Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
47953779|NCT05239442|OTHER|Taste Commission|"Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe."
47953780|NCT05239442|OTHER|Evaluation of the taste commissions|"At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)"
47953781|NCT05239442|OTHER|Entretien SWOT|Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
47953782|NCT04053322|DRUG|Durvalumab|Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
47953783|NCT04053322|DRUG|Olaparib|2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
47953784|NCT04053322|DRUG|Fulvestrant|Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
47953785|NCT05146310|DEVICE|I.SPACE®|"I.SPACE® is a viscoelastic sodium hyaluronate gel use as a surgical aid in ophthalmic anterior segment surgery by maintaining the intraocular space and protecting the corneal endothelium.~The baseline injection is performed at V1. The volume of product to use will be at the Investigator discretion, and will be completely removed after surgery."
47953786|NCT02505295|DIETARY_SUPPLEMENT|Selenium|4 vials selenase stat and 2 vials daily for 5 days
47953787|NCT02505295|DRUG|normal saline|Normal saline infusion like intervention group
47953788|NCT01219673|OTHER|Placebo|1 by mouth twice a day.
47953789|NCT01219673|DRUG|Armodafinil|150 mg by mouth once a day.
47953790|NCT01219673|DRUG|Minocycline|100 mg by mouth twice a day.
47953791|NCT01219673|DRUG|Bupropion|100 mg by mouth twice a day.
47953792|NCT00929123|PROCEDURE|neural mobilization|manual therapy technique known to directly stress the median nerve
47953793|NCT00929123|PROCEDURE|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
47953794|NCT00929123|OTHER|healthy controls|People without carpal tunnel syndrome for comparison
47953795|NCT03774758|DIAGNOSTIC_TEST|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
47953796|NCT00028782|DRUG|etanidazole|Given IV
47953797|NCT00028782|PROCEDURE|therapeutic conventional surgery|Undergo surgery
47953798|NCT00028782|OTHER|laboratory biomarker analysis|Correlative studies
48479861|NCT06173596|DRUG|Fluconazole (AxMP)|Participants will receive Fluconazole orally.
47953799|NCT01021306|DEVICE|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
47953800|NCT01021306|DEVICE|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
47953801|NCT01021306|OTHER|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
47953802|NCT01021306|OTHER|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
47953803|NCT03945214|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
47953804|NCT03945214|BEHAVIORAL|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
47953805|NCT03945214|BEHAVIORAL|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
48479862|NCT06173596|DRUG|Carbamazepine (AxMP)|Participants will receive Carbamazepine orally.
47953806|NCT05384938|BIOLOGICAL|Benralizumab|Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
47953807|NCT02272478|DRUG|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
47953808|NCT02272478|DRUG|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
47953809|NCT02272478|DRUG|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
47953810|NCT02272478|DRUG|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
47953811|NCT02272478|DRUG|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
47953812|NCT02272478|DRUG|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
48479863|NCT05777824|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
48479864|NCT05777824|RADIATION|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
48479865|NCT01607177|BEHAVIORAL|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
48479866|NCT00755378|DRUG|AZD8529|Oral
47953813|NCT04763785|DEVICE|Corneal tomography with Eyestar 900|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
47953814|NCT04763785|DEVICE|Corneal tomography with Pentacam|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
47953815|NCT04763785|DEVICE|Biometry with IOL-Master|Non-invasive biometry for presurgical intraocular lens calculation
47953816|NCT04763785|OTHER|retrospective analysis, no intervention|retrospective analysis of 4500 existing, fully anonymised picture data
47953817|NCT06556901|OTHER|retrospective study about reasons for consultations|retrospective study about reasons for consultations
48479867|NCT00755378|DRUG|Placebo|Oral
47953818|NCT04640857|DEVICE|Silk'n Toothwave|patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
47953819|NCT04308096|DRUG|KRN23|The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
47953820|NCT01497717|DRUG|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~1. Open label treatment period of 24 weeks.~2. Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~3. Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
47953821|NCT02515643|OTHER|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:~1. Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~2. Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~3. Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~4. Estimation of glomerular filtration rate by Iohexol method"
47953822|NCT02281565|BEHAVIORAL|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
47953823|NCT05758571|DRUG|EGCG|EGCG (high pressure liquid chromatographic purity ≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day.
47953824|NCT01480648|DRUG|BI 144807 Placebo|Placebo that represents BI drug
47953825|NCT01480648|DRUG|BI 144807|single dose (low to high dose)
47953826|NCT03002220|DRUG|radium-223|Radium-223 at a dose of 55 kBq
47953827|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
48301212|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
48339869|NCT04331925|BEHAVIORAL|Anxiety and depression screening|At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.
48339870|NCT04331925|BEHAVIORAL|Journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
48638711|NCT06361810|DRUG|177Lu-PNT2002|"177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.~177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles."
48638712|NCT06361810|DRUG|(F-18)-DCFPyL|Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
47953828|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
48638713|NCT06081530|DRUG|BI 3802876|BI 3802876
47953829|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
47953830|NCT02124161|OTHER|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
47953831|NCT02124161|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
47953832|NCT02124161|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
47953833|NCT02605304|DRUG|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
48638714|NCT06081530|DRUG|Placebo matching BI 3802876|Placebo matching BI 3802876
48638715|NCT04869124|DRUG|Dapagliflozin|Dapagliflozin propanediol (FORXIGA) tablet: 10 mg once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
48638716|NCT04869124|DRUG|Placebo|Placebo tablet, matching Dapagliflozin, once daily p.o. on top of recommended standard therapy, duration of administration: 12 weeks.
48638717|NCT05909202|DEVICE|Sham VR|Nature-based non-immersive VR program
47953834|NCT02605304|DRUG|Ribavirin|"Based on weight at entry:~For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
47953835|NCT02259101|BEHAVIORAL|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
47953836|NCT02259101|BEHAVIORAL|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
48108936|NCT02156050|DEVICE|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
48479868|NCT06052787|DRUG|Cerebrolysin|Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.
48108937|NCT00660439|BEHAVIORAL|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
48108938|NCT05307614|DRUG|Moksi® 400mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
48108939|NCT05307614|DRUG|Drug: Avelox® 400Mg Tablet|Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
48108940|NCT02297880|OTHER|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
48108941|NCT02297880|OTHER|Still water|Still water (no flavour)
48108942|NCT04664049|DIETARY_SUPPLEMENT|NRICM101|"Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
48108943|NCT05402735|DIAGNOSTIC_TEST|Serum uric acid level|Serum uric acid level
48108944|NCT06454734|DEVICE|Extracorporeal shock wave therapy by radial device|Patients will receive treatment by extracorporeal shock waves therapy (ESWT).
48108945|NCT06454734|DEVICE|Placebo extracorporeal shock wave therapy by radial device|Patients will receive treatment sham extracorporeal shock waves.
48108946|NCT06454734|OTHER|DLT|Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
48108947|NCT04645069|BIOLOGICAL|ADG126 Mono|ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
48638718|NCT05909202|DEVICE|Active VR|Nature-based immersive VR program
48638719|NCT06411691|DRUG|KRAS Vaccine with Poly-ICLC adjuvant|"SLP mKRASvax with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22 in Cycle 1 (Prime Phase) and on day 1 in cycle 4 and every other cycle and beyond (Boost Phase). Up to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
48108948|NCT04645069|BIOLOGICAL|ADG126-anti PD1|ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
48108949|NCT04645069|BIOLOGICAL|ADG126-ADG106|ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
48108950|NCT01212991|DRUG|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
48108951|NCT01212991|DRUG|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
48108952|NCT03215251|OTHER|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
48638720|NCT06411691|DRUG|Balstilimab|"75 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on day 1 and day 15 during Cycle 1 in Prime Phase and on day 1 and day 15 of every cycle in the Boost Phase beginning on Cycle 2 (for a maximum of 2 years from initial vaccination).~Drug: 75 mg IV"
48108953|NCT00793286|PROCEDURE|Mesh fixation by staples|Mesh fixation by staples
48638721|NCT06411691|DRUG|Botensilimab|"240 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on Cycle 1 day 1 in Prime Phase and on Cycle 2 day 1 in the Boost Phase.~Drug: 240 mg IV"
48638722|NCT01153542|DRUG|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
47953837|NCT00087165|BIOLOGICAL|GTI-2040|
47953838|NCT00087165|DRUG|docetaxel|
47953839|NCT00087165|DRUG|prednisone|
47953840|NCT00770939|DEVICE|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
47953841|NCT01633073|DEVICE|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
48108954|NCT00793286|PROCEDURE|Mesh fixation by glue|Mesh fixation by glue
47953842|NCT01633073|DEVICE|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
47953843|NCT02905149|PROCEDURE|Serrato|Serratus plane block.
48638723|NCT01153542|DRUG|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
47953844|NCT02905149|PROCEDURE|Control|Standard anesthesia
47953845|NCT04304274|PROCEDURE|Paravertebral block-ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
47953846|NCT04304274|PROCEDURE|Paravertebral block-saline|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
47953847|NCT04304274|DRUG|patient controlled analgesia with morphine|Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
47953848|NCT06450262|DRUG|Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
47953849|NCT06450262|DRUG|Synjardy® 12.5mg/1000mg film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
47953850|NCT04238585|BEHAVIORAL|Mobile messaging|Mobile health messages
47953851|NCT01854996|DRUG|PF-05089771|450mg
48638724|NCT04189757|DRUG|Acalabrutinib|Given PO
47953852|NCT01854996|DRUG|PF-05089771|450mg
47953853|NCT01854996|DRUG|PF-05089771|450mg
47953854|NCT01444131|DRUG|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
47953855|NCT01444131|DRUG|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
47953856|NCT06558175|RADIATION|stereotactic body radiation therapy (SBRT)|Patients will be assigned to treatment doses using the TITE-CRM model.
47953857|NCT00111488|DEVICE|Flex 4 and Generator|
48638725|NCT05292183|OTHER|Electrical Stimulation|We will use a computer randomized stimulation of specific areas in the amygdala while showing a computer randomized set of pictures.
48638726|NCT05803499|BEHAVIORAL|Targeted Cognitive Behavior Therapy for Insomnia|This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.
48108955|NCT02770599|OTHER|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
48108956|NCT00786942|PROCEDURE|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
48108957|NCT00786942|PROCEDURE|higi tibial osteotomy|the gap of the tibia is unfilled
47953858|NCT03499925|BEHAVIORAL|cognitive behaviors|Telephone consultation effectiveness and cognitive behaviors
47953859|NCT03499925|BEHAVIORAL|Telephone consultation|Telephone consultation effectiveness and cognitive behaviors
47953860|NCT06327009|BEHAVIORAL|fasting month of ramadan|100 patients with glomerulonephritis who decided to fast month of ramadan
47953861|NCT05183763|BEHAVIORAL|STAR-MAP health coaching|Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
47953862|NCT05183763|BEHAVIORAL|Medication reminder tools|Medication-taking reminder app and pillbox
47953863|NCT00037622|DRUG|ACH-126, 443 (beta-L-Fd4C)|
47953864|NCT03031132|BEHAVIORAL|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
47953865|NCT03031132|BEHAVIORAL|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
47953866|NCT03031132|BEHAVIORAL|Breakfast Skipping|Participants will skip breakfast each morning.
47953867|NCT02162316|DRUG|Motilitone®|
47953868|NCT02162316|DRUG|A-Cilin®, Clari® and Pantoline®|
47953869|NCT05297201|DRUG|CPL500036 - low dose|CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
47953870|NCT05297201|DRUG|CPL500036 - high dose|CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
47953871|NCT05297201|DRUG|Placebo|Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
48108958|NCT03597841|DRUG|Combination therapy|Patients who are given combination therapy will be allocated to this group.
48108959|NCT06158048|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48108960|NCT06158048|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
48108961|NCT02724085|DRUG|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
48108962|NCT02937831|BIOLOGICAL|RIXUBIS|
47953872|NCT04767620|DRUG|Rugdenzengsheng No. 1 prescription|The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
47953873|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
48638727|NCT05803499|OTHER|Information-Only Control|The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
47953874|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
47953875|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
47953876|NCT01620554|DRUG|BF2.649|1 capsule per week during 2 weeks
47953877|NCT01620554|DRUG|Placebo|1 capsule per week during 2 weeks
47953878|NCT03730675|PROCEDURE|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
47953879|NCT03730675|PROCEDURE|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
47953880|NCT03730675|DRUG|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
47953881|NCT05559398|DRUG|Glenzocimab|"Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion."
47953882|NCT05559398|DRUG|Placebo|Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
47953883|NCT06239025|OTHER|ultrasound-guided Transversus Thoracis Muscle Plane Block|block with ropivacaine 0.5 %, 30 mL
47953884|NCT03918161|DEVICE|MRE exam|Magnetic Resonance Elastography
47953885|NCT01554085|DRUG|ALS-002158|ALS-002158
47953886|NCT01554085|DRUG|Placebo|placebo
47953887|NCT02211222|DRUG|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
47953888|NCT01554020|DIETARY_SUPPLEMENT|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
47953889|NCT01554020|DIETARY_SUPPLEMENT|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
47953890|NCT03516825|OTHER|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
47953891|NCT05780190|DEVICE|New artificial liver CABA system (BS330+CA280) +PE|The new artificial liver CABA system (BS330+CA280) combioned plasma exchange in the treatment of end-stage liver disease with inflammatory status
47953892|NCT03530800|DRUG|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
47953893|NCT03530800|DRUG|Placebo|Placebo for 10 weeks
47953894|NCT03243942|DRUG|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
47953895|NCT00041288|BIOLOGICAL|therapeutic allogeneic lymphocytes|
47953896|NCT00041288|DRUG|cyclophosphamide|
48638728|NCT06237907|OTHER|Patients underwent lymphedema surgery|Patients who have developed lymphedema and undergone lymphedema surgery.
47953897|NCT00041288|DRUG|cyclosporine|
47953898|NCT00041288|DRUG|fludarabine phosphate|
48638729|NCT06237907|OTHER|Patients underwent surgery without LVA|For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
48638730|NCT05800015|DRUG|fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
48638731|NCT05800015|DRUG|cemiplimab|Administered IV Q3W
48638732|NCT05800015|DRUG|Pemetrexed|IV Infusion, Q3W
47953899|NCT00041288|DRUG|methotrexate|
47953900|NCT00041288|DRUG|mycophenolate mofetil|
47953901|NCT00041288|DRUG|tacrolimus|
47953902|NCT00041288|PROCEDURE|peripheral blood stem cell transplantation|
47953903|NCT00041288|RADIATION|radiation therapy|
48638733|NCT05800015|DRUG|Paclitaxel|IV Infusion, Q3W
48638734|NCT05800015|DRUG|Carboplatin|IV Infusion, Q3W
48638735|NCT05800015|DRUG|Cisplatin|IV infusion, Q3W
47953904|NCT02390908|BEHAVIORAL|Immediate PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
48638736|NCT05800015|DRUG|Placebo|IV infusion, Q3W
47953905|NCT02390908|BEHAVIORAL|Wait-list PLUS intervention|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
47953906|NCT04576429|PROCEDURE|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months)."
48638737|NCT03382561|DRUG|Carboplatin|Given IV
48638738|NCT03382561|DRUG|Cisplatin|Given IV
48638739|NCT03382561|DRUG|Etoposide|Given IV
48638740|NCT03382561|BIOLOGICAL|Nivolumab|Given IV
48638741|NCT01218256|OTHER|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
47953907|NCT04576429|PROCEDURE|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
47953908|NCT02017418|DIETARY_SUPPLEMENT|zeaxanthin|softgel
47953909|NCT02017418|DIETARY_SUPPLEMENT|combinatory supplement|softgel
47953910|NCT03140228|DEVICE|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
47953911|NCT03140228|DEVICE|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
48108963|NCT01367548|DRUG|IV Methylnaltrexone (MNTX)|
48638742|NCT00779883|BIOLOGICAL|ISF35|Subjects participating in this study will receive a single dose of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells.
48638743|NCT06463899|PROCEDURE|multi-perforated catheter|After skin closure, cardiac surgeons place multi-perforated catheters aseptically.
48638744|NCT06463899|PROCEDURE|Classic procedure|opioid analgesia (PCA morphine in bolus mode alone or morphine titration if PCA not available), nefopam, non-steroidal anti-inflammatory drugs, ketamine, pregabalin and paracetamol
48638745|NCT06300307|DRUG|ATX-01|Solution for infusion
48638746|NCT06300307|DRUG|Placebo|Solution for infusion
48638747|NCT05645692|DRUG|Atezolizumab|Participants will receive 1200 mg IV atezolizumab Q3W.
48108964|NCT01367548|DRUG|Placebo|
48108965|NCT03258619|BIOLOGICAL|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
48108966|NCT03258619|BIOLOGICAL|Natriuresis|natriuresis levels
48638748|NCT05645692|DRUG|Tobemstomig|Participants will receive 600 mg IV tobemstomig Q3W.
48638749|NCT05645692|DRUG|Tiragolumab|Participants will receive 600 mg IV tiragolumab Q3W.
48638750|NCT05379985|DRUG|RMC-6236|Oral Tablets
48638751|NCT02660346|DRUG|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
48638752|NCT02660346|DRUG|Vancomycin|Control Arm Treatment
48638753|NCT02660346|DRUG|Ceftaroline|Study Arm Treatment
48638754|NCT04632381|DRUG|Zotatifin|Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
48638755|NCT04632381|DRUG|Placebo|5% dextrose injection, USP
47953912|NCT06083077|OTHER|Chest wall strapping|An elastic band (6 cm wide) is placed around the lower part of the chest wall (at the junction of the chest and abdomen) to tighten the chest wall for 10 min at PEEP 7 cmH2O and 10 min without PEEP
48479869|NCT06052787|DRUG|amantadine sulfate|The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
48479870|NCT04407299|BEHAVIORAL|self-administered structured questionnaire|It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.
48479871|NCT00833508|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
48638756|NCT05853939|DEVICE|repetitive transcranial magnetic stimulation|Repetitive TMS targeted by neuronavigation to left lower visual field of primary visual cortex. Randomized to 10 Hz or 1 Hz on different treatment days. Stimulation at 110% of phosphene threshold, or 110% resting motor threshold if phosphenes not detectable. 1 Hz: 1000 pulses total over 1000 seconds. 10 Hz: 1000 pulses over 10 10 second pulse trains, with 50 second intertrain intervals
48638757|NCT02738398|RADIATION|FDG PET/CT|
48638758|NCT06419634|DRUG|BMS-986497|Specified dose on specified days
48638759|NCT04994717|DRUG|Blinatumomab|Continuous intravenous (cIV) infusion
48638760|NCT04994717|DRUG|Low-intensity chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
48638761|NCT04994717|DRUG|SOC chemotherapy regimen|Intravenous (IV), oral (PO), subcutaneous (SC), or intrathecal (IT) administration.
48638762|NCT06344286|DIETARY_SUPPLEMENT|Minimal enteral nutrition|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
48638763|NCT06344286|DIETARY_SUPPLEMENT|Distilled water|The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements.
48638764|NCT06255938|DIAGNOSTIC_TEST|smears|PCR smears for HPV testing will be performed
48638765|NCT06062108|OTHER|Pain evaluation|All included patients will have an evaluation of their pain, if they have no pain, the assessment stop with one date (pain or no pain), if they have pain, an assessment is done (localization of the pain, pain intensity), if they have a pain duration over 3 months, a DN4 questionnaire, HAD scale, ISI scale and SF-1 questionnaire is evaluated.
47953913|NCT05613881|OTHER|Education and Telephone Follow-up|The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
47953914|NCT00629720|DRUG|alfuzosin (SL770499)|
47953915|NCT04622293|DRUG|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
47953916|NCT04622293|DRUG|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
47953917|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (high dose)|Mothers will receive 20 grams of moringa leaf powder in porridge consumed daily for three months.
47953918|NCT04587271|DIETARY_SUPPLEMENT|Moringa oleifera (low dose)|Children will receive 5-10 grams of moringa leaf powder in porridge consumed daily for three months.
47953919|NCT04587271|DIETARY_SUPPLEMENT|Placebo|Mothers and children will receive porridge with placebo.
47953920|NCT03064750|BEHAVIORAL|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
48108967|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
48638766|NCT04288531|DIETARY_SUPPLEMENT|Iodine supplementation|Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
48638767|NCT04883645|DRUG|Imiquimod 5% Cream|Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.
47953921|NCT03064750|OTHER|Waiting list|patients wait as usual until surgery without special treatment.
48108968|NCT03285685|DEVICE|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
48638768|NCT01758471|DRUG|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
48638769|NCT01758471|DRUG|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
48638770|NCT06305624|DEVICE|Connections App|mobile application, a place where participants can find community and support to help them manage their ALD, learn liver health self-care, coping skills, and alcohol abstinence strategies.
47953922|NCT06556784|BEHAVIORAL|12-week at-home immersive virtual reality exergame|12-week training of at least 150 minutes per week at-home immersive virtual reality exergame playing with a set device of Meta Quest 2 and maintaining regular eating and working habits without making significant changes.
48108969|NCT03285685|DEVICE|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
48479872|NCT00021216|DRUG|bortezomib|Given IV
48479873|NCT00021216|OTHER|laboratory biomarker analysis|Correlative studies
48479874|NCT00021216|OTHER|pharmacological study|Correlative studies
48479875|NCT02286973|DRUG|Tranexamic Acid|
48479876|NCT01269450|DRUG|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
48638771|NCT04619082|DRUG|Tenofovir alafenamide|Tenofovir alafenamide 25 mg once per day for one year
48638772|NCT04695782|RADIATION|Pencil beam proton radiotherapy|Doseescalated pencil beam proton Therapy
48638773|NCT05382325|BIOLOGICAL|MK-1484|Subcutaneous (SC) injection
48638774|NCT05382325|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
47953923|NCT03301701|PROCEDURE|Radical prostatectomy|Radical prostatectomy
47953924|NCT03301701|RADIATION|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
47953925|NCT04205708|DIAGNOSTIC_TEST|Tuberculosis test|Tuberculosis (TB) test: A blood sample is collected for lab testing to determine if you have tuberculosis (QuantiFeron test). Alternatively, the test is done by injecting a small amount of fluid (called tuberculin) into the skin on the lower part of the arm. A person given the tuberculin skin test must return within 48 to 72 hours to have a trained health care worker look for a reaction on the arm.
47953926|NCT04205708|DIAGNOSTIC_TEST|Chest X-ray|Chest X ray: non-invasive medical test that helps physicians diagnose and treat medical conditions of the lungs and chest. The Chest X-ray will be done to check for abnormalities on the lungs. The test is non-invasive.
47953927|NCT04205708|DIAGNOSTIC_TEST|Pulmonary Function Test|A pulmonary function test (PFT, spirometry) is a breathing test that measures how much air your lungs can hold as well as how hard and fast you can blow air out of your lungs. The test is not invasive and involves blowing into a machine.
47953928|NCT05148065|DEVICE|BIS|Bispectral index monitoring
48638775|NCT02057666|DRUG|Tasquinimod|A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
48638776|NCT02057666|DRUG|Placebo|Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
48638777|NCT06380530|PROCEDURE|Deformity correction|Surgeries to correct bone defomity, supported by the use of preoperative planning and/or patient-specific instruments
48638778|NCT05775575|DRUG|TQB3909 tablets|TQB3909 is an inhibitor targeting BCL-2 protein
47953929|NCT05148065|DEVICE|PSi|Patient state index monitoring
47953930|NCT00914680|PROCEDURE|magnetic seizure therapy|antidepressant treatment with MST
47953931|NCT03845777|DIAGNOSTIC_TEST|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
47953932|NCT04857957|DRUG|Oral dose CNTX-6016 or oral dose Placebo|CNTX-6016 or Placebo
48108970|NCT02421081|PROCEDURE|vessel microsurgery|That is a surgery ro repair artery laceration.
48108971|NCT02421081|PROCEDURE|tendon repair|That is a surgery ro repair tendon cut.
48108972|NCT02421081|PROCEDURE|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
48479877|NCT01269450|DRUG|placebo|placebo 200mg vaginal tablets
48479878|NCT05543252|DRUG|Minzasolmin (UCB0599)|Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
48479879|NCT06613061|OTHER|Breathing exercise|"The researcher has a breathing exercise certificate. In our study, the breathing exercise application consists of three stages: box breathing, sigh breathing and diaphragm breathing.~Patients will be asked to continue the breathing exercise application for 2 weeks and will be reminded to do the breathing exercises. Box and sigh breathing will be done 3 times a day (morning, noon and evening) every day for 2 weeks. Diaphragm breathing exercise will be applied for 2 minutes in the first week and 4 minutes in the second week."
48479880|NCT01216098|BEHAVIORAL|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
48479881|NCT02262559|DRUG|BIBR 277 tablet|
48479882|NCT02262559|DRUG|BIBR 277 capsule|
48638779|NCT03297060|OTHER|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
48479883|NCT06502652|OTHER|hippotherapy|A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally
48479884|NCT06502652|OTHER|balance training|The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
48479885|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
48479886|NCT03009487|DRUG|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
48479887|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
48638780|NCT04967274|PROCEDURE|Startling acoustic stimulus|StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
48638781|NCT02430610|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
48638782|NCT02430610|DEVICE|NanoKnife|
48638783|NCT01688401|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
48638784|NCT04475939|DRUG|Niraparib|Niraparib will be administered
48638785|NCT04475939|DRUG|Pembrolizumab|Pembrolizumab will be administered
48638786|NCT04475939|DRUG|Placebo|Matching placebo will be administered
48638787|NCT06500000|DIAGNOSTIC_TEST|liquid chromatography-mass spectrometry (LC/MS)|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.
48638788|NCT03258554|BIOLOGICAL|Cetuximab|Given IV
48638789|NCT03258554|BIOLOGICAL|Durvalumab|Given IV
48638790|NCT03258554|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48638791|NCT03258554|OTHER|Laboratory Biomarker Analysis|Correlative studies
48638792|NCT03258554|OTHER|Quality-of-Life Assessment|Ancillary studies
48638793|NCT03258554|OTHER|Questionnaire Administration|Ancillary studies
48638794|NCT02344355|DRUG|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
48638795|NCT02344355|RADIATION|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
48638796|NCT02344355|DRUG|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
48638797|NCT00130559|PROCEDURE|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
48638798|NCT04245865|DRUG|Fluorouracil|2800 mg/m2 iv
48638799|NCT04245865|DRUG|Calcium folinate|400 mg/m2 iv
48638800|NCT04245865|DRUG|Oxaliplatin|85 mg/m2 iv
48479888|NCT02400515|OTHER|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
48479889|NCT06457620|BEHAVIORAL|Conventional Physiotherapy|Each participant received conventional physiotherapy at the clinic as a part of their management plan. Group A exercise was five times a week for thirty minutes, beginning on the third day after total knee arthroplasty (TKA). The program aimed to improve leg strength, core stability, balance, and overall performance through exercise instructions. The baseline evaluation was completed one day before the TKA, and the posttest was completed four weeks after the TKA.
48638801|NCT04245865|DRUG|Bevacizumab|5 mg/kg OR 7.5 mg/kg iv
48638802|NCT04245865|DRUG|Capecitabine|2000 mg/m2 orally daily for two weeks
48638803|NCT04245865|DIETARY_SUPPLEMENT|Tocotrienol|300 mg orally x 3 daily
48638804|NCT04245865|OTHER|Placebo|Placebo orally x 3 daily
48638805|NCT01467284|BEHAVIORAL|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
48638806|NCT01467284|BEHAVIORAL|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
48638807|NCT06119581|DRUG|LY3537982|Administered orally.
48638808|NCT06119581|DRUG|Pembrolizumab|Administered IV.
48638809|NCT06119581|DRUG|Placebo|Administered orally.
48638810|NCT06119581|DRUG|Cisplatin|Administered IV.
48638811|NCT06119581|DRUG|Carboplatin|Administered IV.
48638812|NCT06119581|DRUG|Pemetrexed|Administered IV.
47953933|NCT03145363|BEHAVIORAL|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
47953934|NCT03145363|BEHAVIORAL|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
48108973|NCT00565110|BEHAVIORAL|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
48108974|NCT03794193|PROCEDURE|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
47953935|NCT01781754|PROCEDURE|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
48479890|NCT06457620|OTHER|Traditional Physical Preatment|Each participant got traditional physical treatment during a video conference as part of telerehabilitation. The physiotherapy assistant contacted Group B to arrange a virtual follow-up clinic appointment via Zoom or WhatsApp, along with a 4-week program. We inquired about the patient's level of satisfaction with their TKR procedure. The patient was informed that clinical photos were taken, and the video call was to be recorded. Before the virtual clinic, each patient's verbal agreement was acquired. With workout instructions, the program pursued to enhance leg strength, core stability, balance, and overall performance. The posttest was conducted four weeks after the TKA, and the baseline assessment was finished one day before the procedure.
48479891|NCT06375369|PROCEDURE|Digital health pathway for children with medical complexity requiring tracheostomy (DECIDE-T)|The intervention involves developing a standardized clinical pathway for these children requiring tracheostomy. The pathway comprises of a hospital to home directive, incorporating digital health solutions to support family, caregivers, and healthcare professionals. These digital supports include but are not limited to a Connect Care pathway, resources to aid families to make informed choices during the clinical decision-making process, education modules and high-fidelity simulations to enhance family/caregiver education, an online parental resource center and access to peer support (spanning from hospital to community) and a telehealth post discharge program.
48479892|NCT00139724|DRUG|tolterodine extended release capsule|
48479893|NCT01684215|DRUG|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
48638813|NCT03346746|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
48638814|NCT03346746|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
48638815|NCT04499053|DRUG|Durvalumab|durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
48638816|NCT04499053|DRUG|Tremelimumab|tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
48638817|NCT03588429|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
48638818|NCT03588429|DRUG|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
48638819|NCT02203760|DRUG|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
47953936|NCT01690585|DRUG|Ferinject 1000 mg|
47953937|NCT01690585|DRUG|Sodium chlorure 0,9 %|
47953938|NCT03907228|DIETARY_SUPPLEMENT|RHT-3201|PROBIOTIC
47953939|NCT05073211|PROCEDURE|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
48108975|NCT01870479|OTHER|Live music|
48108976|NCT01870479|OTHER|Taped music|
48108977|NCT05307991|DRUG|PrEP|HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
48638820|NCT02203760|DRUG|Pazopanib|Pazopanib 800 mg orally once daily
48638821|NCT05810116|DRUG|Levagen+|Daily dose of 1-2 capsules (1 capsule containing 350mg Levagen+ equivalent to 300mg PEA)
48638822|NCT05810116|DRUG|Microcrystalline cellulose|Daily dose of 1-2 capsules (1 capsule containing 350mg)
48638823|NCT02206438|DEVICE|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
48638824|NCT02206438|DEVICE|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
48638825|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day
48301213|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
48638826|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
48301214|NCT01745627|DEVICE|755nm Alex laser|
47953940|NCT02328417|OTHER|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
48301215|NCT03864172|DIETARY_SUPPLEMENT|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
48301216|NCT03864172|DIETARY_SUPPLEMENT|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
47953941|NCT04361825|DRUG|Durvalumab|Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each cycle days 1 and 7. One cycle is consisted of 28 days.
48301217|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
48301218|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
48301219|NCT05337267|DRUG|sintilimab (after the change)|0.3mg/kg，I.V.，single dose
48301220|NCT05337267|DRUG|sintilimab (before the change)|0.3mg/kg，I.V.，single dose
48301221|NCT02157831|BIOLOGICAL|CP-870,893|
48301222|NCT00006386|DRUG|carmustine|
48301223|NCT00006386|RADIATION|radiation therapy|
48301224|NCT00006386|RADIATION|stereotactic radiosurgery|
48301225|NCT03723265|DEVICE|Cardiac Resynchronization Therapy|
48301226|NCT01854567|BIOLOGICAL|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
48479894|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
48479895|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
48479896|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
48479897|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
48479898|NCT03297294|DRUG|EMA401|capsules, oral
47953942|NCT05531383|DRUG|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
48479899|NCT03297294|DRUG|Placebo|Placebo to EMA401 capsules, oral
47953943|NCT01254331|DRUG|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
48479900|NCT01730040|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
48479901|NCT01730040|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
48479902|NCT01730040|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
48479903|NCT01730040|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
48479904|NCT01730040|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
48479905|NCT02900482|OTHER|Sampling saliva|
48479906|NCT01044394|DRUG|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
48479907|NCT06273787|OTHER|diaphragmatic release|diaphragmatic myofascial release for 1 months 3 sessions per week
48638827|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.
48638828|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
47953944|NCT01354457|DRUG|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
48301227|NCT01854567|BIOLOGICAL|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
48479908|NCT01923194|DRUG|Highly Purified Urofollitropin|for Injection
48301228|NCT02225067|DRUG|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
48301229|NCT03880227|DEVICE|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
48301230|NCT03880227|DEVICE|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
48301231|NCT00024297|DRUG|warfarin|
48301232|NCT02013934|DIETARY_SUPPLEMENT|Probiotic|
48301233|NCT02013934|DIETARY_SUPPLEMENT|Placebo|
48301234|NCT04982549|DRUG|Durvalumab|Durvalumab (intravenous infusion)
48301235|NCT04982549|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
48301236|NCT04982549|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
48301237|NCT04982549|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
48301238|NCT04982549|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
48301239|NCT00064662|PROCEDURE|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
48301240|NCT00064662|PROCEDURE|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
48301241|NCT05351086|DRUG|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
48301242|NCT05351086|DRUG|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
48301243|NCT05351086|OTHER|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
48301244|NCT05351086|OTHER|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
48301245|NCT00627640|DRUG|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
48301246|NCT00627640|DRUG|Matching Placebo|Matching Placebo
48301247|NCT00061308|DRUG|Topotecan|
48301248|NCT00061308|DRUG|Gemcitabine|
48301249|NCT03690258|DEVICE|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
48301250|NCT05221294|DRUG|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
48301251|NCT04149327|DRUG|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
48301252|NCT04149327|PROCEDURE|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
48301253|NCT00008164|PROCEDURE|umbilical cord blood transplantation|
48301254|NCT05932628|OTHER|This study will observe participants who receive a supported self management approach for thumb base osteoarthritis but it is not an interventional study.|Participants will receive an occupational or physiotherapist led supported self-management programme, which equates to normal NHS care, having been adopted by the sites involved. This involves education, progressive exercises and hand splints if required. The educational materials used, and a minimum number of appointments will be consistent across the study sites. Additional treatments for coexisting conditions will be provided, additional stepped care for thumb base osteoarthritis will also be recorded.
48301255|NCT02806778|OTHER|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
48301256|NCT02806778|OTHER|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
48479909|NCT01923194|DRUG|Recombinant Human Follitropin Alfa|for Injection
48479910|NCT03246906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
48479911|NCT03246906|DRUG|Cyclophosphamide|Given IV
48479912|NCT03246906|DRUG|Cyclosporine|Given PO
48479913|NCT03246906|DRUG|Mycophenolate Mofetil|Given PO
48479914|NCT03246906|DRUG|Sirolimus|Given PO
48479915|NCT03142659|OTHER|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
48479916|NCT03483311|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
48479917|NCT05601778|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
48479918|NCT05601778|DRUG|placebo|the placebo comparator of study
48479919|NCT00388934|DEVICE|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
48479920|NCT00002006|DRUG|Zidovudine|
48479921|NCT00002006|DRUG|Sargramostim|
48479922|NCT06099990|DRUG|dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets|dalpiciclib+ abiraterone+ prednisone
48108978|NCT05307991|DEVICE|STI testing|Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ \[FDA approved\]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA \[CE mark\]) if RPR is positive.
48108979|NCT05307991|BEHAVIORAL|Assisted partner notification|"Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant.~Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient."
48108980|NCT05307991|DIAGNOSTIC_TEST|Acute HIV testing|Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).
48108981|NCT00970307|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
48108982|NCT00970307|BIOLOGICAL|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
48108983|NCT00970307|BIOLOGICAL|Infanrix hexa™|Intramuscular, three doses
48108984|NCT00970307|BIOLOGICAL|Menjugate®|Intramuscular, two doses
48479923|NCT06099990|DRUG|placebo; abiraterone acetate tablets; prednisone tablets|placebo+abirarerone+prenisone
48479924|NCT02564848|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
48479925|NCT01726127|OTHER|Broccoli and Brussels Sprouts|
48479926|NCT01726127|DIETARY_SUPPLEMENT|Cruciferous Complete|
48638829|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day
48638830|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
48638831|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
48638832|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
48638833|NCT02043847|RADIATION|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
48638834|NCT02043847|DRUG|Melphalan|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant
48638835|NCT02043847|DRUG|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days
48108985|NCT00158028|DRUG|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
48108986|NCT00158028|DRUG|Placebo|placebo match in identical tablets
48479927|NCT01726127|OTHER|Placebo|
48638836|NCT02043847|PROCEDURE|Autologous transplant|Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue
48638837|NCT05448027|DEVICE|Low intensity laser therapy|It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
48638838|NCT05448027|DEVICE|High intensity laser therapy|It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
48108987|NCT01377129|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
48638839|NCT04055207|OTHER|VVC|Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
48638840|NCT06248086|DRUG|ASP2802|Intravenous (IV) infusion
48638841|NCT06248086|DRUG|MA-20|IV infusion
48638842|NCT02684292|BIOLOGICAL|pembrolizumab|IV infusion
48108988|NCT01377129|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
48479928|NCT04629274|PROCEDURE|Blood sampling|The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
48479929|NCT01766791|OTHER|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM
48479930|NCT01766791|OTHER|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - \< 75 1RM
48479931|NCT01766791|OTHER|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM and Protein Supplementation
48638843|NCT02684292|BIOLOGICAL|brentuximab vedotin|IV infusion
48638844|NCT06202989|DRUG|Multiprofen-CC™ plus standard treatment|Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
48638845|NCT06202989|OTHER|Placebo plus standard treatment|The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
48301257|NCT05782413|OTHER|mechanical vestibular stimulation|Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
48301258|NCT05782413|OTHER|The design exercise program|"A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand"
48301259|NCT03765567|DRUG|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
48301260|NCT05061225|BEHAVIORAL|Physical activity counselling|Educational content on several topics regarding physical activity and its implementation in daily living
48301261|NCT02782455|DRUG|Flavonoids|Daflon is administered
48301262|NCT02782455|DRUG|CDobi|Calcium dobesylate is administered
48301263|NCT02412644|DRUG|apremilast|
48301264|NCT00002677|DRUG|chemotherapy|
48301265|NCT00002677|DRUG|tributyrin|
48301266|NCT05780853|DIAGNOSTIC_TEST|Tablet Game-based Assessment - YARN assessment service|Tablet game-based assessment to assess neurodevelopmental profile.
48108989|NCT03818178|DIETARY_SUPPLEMENT|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
48301267|NCT05780853|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
48301268|NCT05780853|OTHER|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
48301269|NCT02272621|PROCEDURE|Minimally invasive aortic valve replacement|
48301270|NCT02272621|PROCEDURE|Full sternotomy aortic valve replacement|
48301271|NCT02829346|DRUG|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
48301272|NCT02829346|DRUG|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
48301273|NCT00920465|DRUG|mifegyne and cytotec|One day dosage versus two days dosage
48301274|NCT05847270|PROCEDURE|Anterior and posterior treatment strategy|Before surgery, a large weight traction of 1/6 body weight was used to determine the reversibility of atlantoaxial dislocation. After determining that it is difficult to restore the dislocation, a technique of anterior oral release and posterior fixation fusion was used for reduction, with sequential release of the longus colli and longus capitis, the anterior longitudinal ligament, the blitateral lateral mass joints, the contracted soft-tissue mass between the odotiod and the anterior C1 tubercle, and the peri-odontoid ligaments (i.e., the alar ligaments and the apical ligament), followed by posterior internal fixation and bone grafting was used between C1 and C2 lamina.
48301275|NCT05847270|PROCEDURE|Simple posterior approach treatment strategy|Preceding the surgical procedure, an assessment was conducted utilizing 1/6 weight traction to ascertain the reducibility of atlantoaxial dislocation. Upon confirmation of IAAD, the chosen approach involved the utilization of a specially designed spreader, tailored to the patient's atlanto-axial joint morphology. Upon entering the joint space, the spreaders were skillfully maneuvered to gently open the joint through rotational and prying actions. Subsequently, two cages, pre-filled with autogenous bone grafts, and designed with the appropriate angle and height, were meticulously placed between the Atlanto-axial joints via a posterior approach. This procedure facilitated direct distraction and reduction of the dislocated joint. In the final step of the surgical process, stabilization was achieved by securing the atlas and axis with screws and rods. This surgical approach was selected to address the unique challenges posed by IAAD, with the aim of achieving optimal patient outcomes.
48108990|NCT03818178|DIETARY_SUPPLEMENT|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
48108991|NCT03818178|OTHER|Saline|All participants will serve as their own controls with a saline infusion study day.
48108992|NCT03463135|DRUG|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
48108993|NCT03463135|DRUG|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
48108994|NCT03463135|DRUG|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
48301276|NCT01094340|DRUG|Thalidomide|fixed dose over 8 clinic visits
48301277|NCT00306436|PROCEDURE|comprehensive management|
48301278|NCT03836118|PROCEDURE|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E\&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
48301279|NCT05431582|DRUG|ZN-c3|Given by PO 1 time a day with a glass (about 8 ounces) of water
48301280|NCT05431582|DRUG|Bevacizumab|Given by vein over about 30-60 minutes on Day 1 of each cycle
48301281|NCT05431582|DRUG|Pembrolizumab|Given by vein over 30-60 minutes on Day 1 of each cycle.
48301282|NCT05866822|OTHER|APA|24 APA sessions
48301283|NCT05866822|OTHER|PAE|8 individuals sessions of PAE
48301284|NCT01208662|DRUG|Lenalidomide|oral administration
48108995|NCT03463135|DRUG|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
48301285|NCT01208662|DRUG|Bortezomib|intravenous or, following protocol amendment, subcutaneous administration
48301286|NCT01208662|DRUG|Dexamethasone|"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
48301287|NCT01208662|PROCEDURE|Autologous Stem Cell Transplant|Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
48301288|NCT01784510|PROCEDURE|distance of dissection of gastrocolic ligament from pylorus|
48301289|NCT03805295|OTHER|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
48301290|NCT03397797|DRUG|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
48301291|NCT06029816|DRUG|Neratinib tablets|Neratinib tablets
48301292|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwN) plus active varenicline tablets|"The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph."
48301293|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline|"The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph."
48301294|NCT03630614|DRUG|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline|The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
48301295|NCT00812916|PROCEDURE|RF ablation, using specialized CFAE software|RF ablation
48301296|NCT01347918|DEVICE|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
48301297|NCT01347918|DIETARY_SUPPLEMENT|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
48301298|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
48301299|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
48301300|NCT01257217|DEVICE|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
48301301|NCT01257217|DEVICE|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
48301302|NCT04338945|BEHAVIORAL|COVID-surgRES questionaire|The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
48301303|NCT01315015|OTHER|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
48479932|NCT01766791|OTHER|Control|control group, no intervention, maintenance of physical activity
48479933|NCT05735002|DIAGNOSTIC_TEST|13C-butyrate breath test|breath test
48479934|NCT05424133|OTHER|High frequency chest wall oscillation|High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
48108996|NCT06009120|OTHER|Education|The education program emphasized the characteristics of the oral stage, positive traits that can be acquired when the baby's needs are met during this stage, negative traits that may develop in the baby when their needs are not met, and the relationship between the oral stage and breastfeeding.
48479935|NCT05424133|OTHER|Active cycle of breathing|Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
48479936|NCT05494216|OTHER|PICSI|Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
48479937|NCT05494216|OTHER|MACS|Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
48638846|NCT06501170|OTHER|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes|Retrospective Data Analysis of Emergency Abdominal Surgery Outcomes
48301304|NCT02547077|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
48479938|NCT01941888|DRUG|Propofol|
48479939|NCT01941888|DRUG|Midazolam|
48479940|NCT01941888|DEVICE|Target Controlled Infusion|
48479941|NCT03839277|DEVICE|Endocuff Vision|Endocuff Vision is attached to the tip of colonoscope before intubation.
48479942|NCT04549922|DRUG|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
48479943|NCT04549922|DRUG|Normal Saline|1.2 mL subcutaneous
48479944|NCT03393481|DRUG|MAA868|MAA868 dose 1 and dose 2, single administration, subcutaneous,
48479945|NCT03393481|DRUG|Enoxaparin|Enoxaparin 40 mg, o.d X 10 days
48479946|NCT03221452|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
48479947|NCT03743090|DIAGNOSTIC_TEST|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
48638847|NCT04704661|PROCEDURE|Biopsy|Undergo tissue biopsy
48638848|NCT04704661|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48638849|NCT04704661|DRUG|Ceralasertib|Given PO
48301305|NCT02547077|PROCEDURE|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
48301306|NCT05272059|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
48301307|NCT05272059|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
48301308|NCT00271440|PROCEDURE|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
48301309|NCT02749487|OTHER|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
48301310|NCT05314595|PROCEDURE|bilateral uterine artery ligation|"* Spinal anaethesia with intrathecal morphia~* Transverse skin incision~* Adequate dissection of the bladder.~* Incision of the uterus above placental edge.~* Delivery of the fetus.~* Delayed cord clamping (60 seconds) if the baby appears well.~* Exteriorization of the uterus.~* Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~* At this point, a gentile trial to deliver the placenta is performed~* A catheter is placed in the cervix from above to secure the cervical opening~* Compression is applied to the site of bleeding from placenta site~* Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~* Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss."
48301311|NCT06004531|BEHAVIORAL|Prompting open-ended question promoting sustainability|This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.
48301312|NCT06004531|BEHAVIORAL|Sustainability Passage|This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.
47953945|NCT04034836|DRUG|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
48301313|NCT02146807|DEVICE|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
48301314|NCT01020292|DRUG|Nelfinavir|
48301315|NCT06058780|PROCEDURE|Implantable Collamer Lens (ICL)|Phakic intraocular lenses (pIOL) have proven to be a great alternative to corneal refractive surgery in certain situations. They offer several advantages over corneal techniques, such as being suitable for high myopes and causing relatively fewer higher-order aberrations
48301316|NCT06058780|PROCEDURE|Implantable Intraocular Lens (IPCL)|The IPCL offers a distinct economic advantage as the cost of the IPCL implant is only 2. times that of the ICL implant. Moreover, the IPCL can correct higher degrees of myopia, up to -30. D, compared to the maximum correction of -18. D provided by the ICL.
48301317|NCT00034112|PROCEDURE|osteopathic manipulative treatment|
48301318|NCT02157272|DRUG|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
48301319|NCT05057949|DRUG|Larotinib|Larotinib Capsules
48301320|NCT05057949|DRUG|Rifampin|Rifampin Capsules
48301321|NCT05057949|DRUG|Itraconazole|Itraconazole Capsules
48301322|NCT02372903|DRUG|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
48479948|NCT04034355|DRUG|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
48638850|NCT04704661|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48638851|NCT04704661|PROCEDURE|Echocardiography|Undergo ECHO
48638852|NCT04704661|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
47953946|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
47980484|NCT01596608|DEVICE|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
48638853|NCT04704661|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48638854|NCT04704661|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
47953947|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
48638855|NCT06558214|DRUG|Pembrolizumab|Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
48638856|NCT06558214|DEVICE|Optune GIO®|".~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2."
48638857|NCT06558214|DEVICE|NeuroBlate®|Treatment with NeuroBlate will occur one time at the beginning of the study.
48638858|NCT04286386|OTHER|Hyperpolarized Carbon C 13 Pyruvate|Given IV
48638859|NCT04286386|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
48638860|NCT04286386|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
48638861|NCT04895722|BIOLOGICAL|Pembrolizumab|400 mg or 200 mg pembrolizumab administered via IV infusion.
47953948|NCT04596800|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
47953949|NCT04596800|OTHER|Enhanced Recovery After Surgery|ERAS
47953950|NCT01716390|DIETARY_SUPPLEMENT|Drink that contains plant stanols|
47953951|NCT01716390|DIETARY_SUPPLEMENT|Placebo drink|
47953952|NCT02358681|DRUG|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
48108997|NCT03816124|PROCEDURE|radiofrequency ablation|radiofrequency ablation of the genicular nerves
48108998|NCT03699293|DRUG|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
48108999|NCT03699293|DRUG|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
48109000|NCT03699293|DRUG|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
48109001|NCT01353963|DRUG|desvenlafaxine succinate|50 mg tablet once daily
48109002|NCT00779545|DRUG|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
48109003|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
48479949|NCT04034355|OTHER|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
48109004|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
48479950|NCT06614959|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) Therapy|The smart OPEP device is a standard OPEP device equipped with an additional detachable sensor that collects diagnostic information on the total elapsed time of OPEP use, the pressure generated during use, frequency and amplitude of pressure oscillations, respiratory information (inhalations/exhalation number/time), and sum of all oscillations with a pressure over 1 centimeter of water (cmH2O), all of which will inform the duration and quality of home use.
48479951|NCT04821752|BEHAVIORAL|Avoidance Education|Reduction of environmental toxins exposure from the diet will be achieved by switching to organic foods. Reduction of residential and occupational exposure to toxins from household cleaning products, cosmetics, personal care products, and other sources will be achieved by switching to safer products or avoidance of the toxic exposure.
48638862|NCT04895722|BIOLOGICAL|Pembrolizumab/Quavonlimab|Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
48638863|NCT04895722|BIOLOGICAL|Pembrolizumab/Favezelimab|Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
48638864|NCT04895722|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
48638865|NCT04895722|BIOLOGICAL|MK-4830|800 mg MK-4830 administered via IV infusion
48638866|NCT03456297|OTHER|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
48638867|NCT03083730|OTHER|Narrow band UVB treatment (NB-UVB)|NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
48638868|NCT05165966|BIOLOGICAL|High-dosage of COVID-19 vaccine (Vero cell), Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
48638869|NCT05165966|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
48638870|NCT03902483|DEVICE|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
48638871|NCT03570892|DRUG|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
48301323|NCT04534426|DRUG|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
48301324|NCT04534426|DRUG|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
48301325|NCT04534426|OTHER|Control group|In Control group, only standard therapy was performed after surgery
48301326|NCT01442129|BIOLOGICAL|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
48301327|NCT01442129|BIOLOGICAL|Control Solution|Injection of control solution during the LVAD implantation.
48301328|NCT02632058|OTHER|Cognitive Behavioral Therapy|
48301329|NCT01780558|OTHER|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
48301330|NCT01780558|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
48301331|NCT01221233|OTHER|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
48301332|NCT01221233|OTHER|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
48301333|NCT02228278|BEHAVIORAL|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
48301334|NCT02228278|OTHER|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
48109005|NCT00779545|DRUG|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
48301335|NCT05715541|OTHER|"mobile applications with the name Set My INR"|"The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital"
48301336|NCT06247592|PROCEDURE|Greater occipital nerve block|Pulse Radiofrequency application to the greater occipital nerve will be applicated after radiofrequency cannula placed near the greater occipital nerve location at 42 degree, for 240 seconds.
48301337|NCT06247592|PROCEDURE|Greater occipital nerve pulse radiofrequency|The greater occipital nerve will be blocked with 5 cc 2% prilocaine.
48301338|NCT04825093|DIETARY_SUPPLEMENT|Vitamin D supplementation in pregnant women|Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
48109006|NCT00779545|DRUG|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
48301339|NCT03421990|PROCEDURE|General anesthesia|general anesthesia and regional anesthesia techniques are used
48479952|NCT00847743|DIETARY_SUPPLEMENT|Tart Cherry Juice|8 fl.oz. twice per day
48479953|NCT03028064|OTHER|blood taking|in this cohort study, we will take blood to examine the platelet function
48479954|NCT03743259|DRUG|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
48479955|NCT03743259|DRUG|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
47953953|NCT02358681|DRUG|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
47953954|NCT02358681|DRUG|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
48109007|NCT00779545|DRUG|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
48109008|NCT01335542|PROCEDURE|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
48479956|NCT03743259|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
48109009|NCT01335542|PROCEDURE|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
48109010|NCT04250285|OTHER|descriptive method|After obtaining relevant permissions from the university and organization of education and selecting participants, the study was explained for students and their satisfaction obtained. Then questionnaires were given to participants. To observe ethical considerations, questionnaires were anonymous and has been confided that the participants' responses was maintained in the study and is not given anyone
48109011|NCT06122896|OTHER|Screening Blood Tests|Carbohydrate antigen (CA) 19-9, Hemoglobin A1C (HbA1c), and Fasting blood glucose (FBG) per standard-of-care.
48109012|NCT06122896|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
48109013|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Imaging|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
48109014|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Cholangiopancreatography|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
48109015|NCT05790928|DEVICE|Lotrafilcon A spherical contact lenses|CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
48109016|NCT00517933|DRUG|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
48109017|NCT00517933|OTHER|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
48109018|NCT05781555|DEVICE|Experimental: DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed. The study objectives are to collect data on the general safety and efficacy of DaRT among patients who do not fit the entry criteria of existing investigational trials.
48109019|NCT01026233|DRUG|brentuximab vedotin|1.8 mg/kg IV every 21 days
48109020|NCT04989725|OTHER|Standard arm|Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
48109021|NCT04989725|RADIATION|Experimental arm|SABR to all oligoprogressive lesions + continuation of current systemic therapy
48109022|NCT04948593|PROCEDURE|Native kidney biopsy|
48109023|NCT04710225|PROCEDURE|Upper limb fracture surgery and arterial occlusion pressure (AOP) estimation based tourniquet pressure (TP) setting|"Upper limb fracture surgery will be performed with the aid of a pneumatic tourniquet.~The cuff (11 cm) of the tourniquet will be placed around the arm with the distal edge 5 cm above the olecranon. AOP estimation formula according to initial systolic blood pressure (SBP) and Tissue Padding Coefficient (KTP) values (AOP= \[SBP+10\]/KTP) from a list (Table 1) will be used to calculate AOP (17). After calculation of AOP, a safety margin of 20 mmHg will be added to AOP to determine the TP (TP=AOP+20 mm Hg). Exsanguination of the limb will be provided with an Esmarch bandage and the cuff will be inflated to the predetermined TP. TP will be manually raised in response to each 10 mmHg increase in SBP during the surgical procedure."
48109024|NCT00003717|DRUG|estramustine phosphate sodium|
48109025|NCT00003717|DRUG|paclitaxel|
48109026|NCT03180450|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
48109027|NCT03180450|DRUG|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
48109028|NCT03505619|BEHAVIORAL|ASSIST 1.0|10 weeks intervention applying a person-centred approach by using goal setting and smart products.
48109029|NCT03465345|DRUG|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
48109030|NCT03465345|DRUG|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
48479957|NCT06533657|DRUG|Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)|Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
48479958|NCT06617208|DEVICE|Neuropixel probe recording|Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.
48479959|NCT06258161|PROCEDURE|Spinal Fusion|Realignment and fusion of adult spinal deformity
48479960|NCT06258161|OTHER|No intervention|No intervention for control group.
48479961|NCT03662256|OTHER|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
48638872|NCT03570892|DRUG|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~\*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
47953955|NCT02358681|DRUG|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
47953956|NCT01232231|DRUG|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
48301340|NCT03613090|DRUG|Collagen-hydroxyapatite scaffold (Syn-Oss)|The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
48301341|NCT03613090|DRUG|Collagen Scaffold (Colla-Plug)|Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
48301342|NCT06300970|DRUG|Amodiaquine-artesunate (ASAQ)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
48301343|NCT06300970|DRUG|Artemether+Lumefantrine (AL)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
48301344|NCT01221467|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
48301345|NCT00431860|PROCEDURE|Coronary computed tomographic angiography|
48301346|NCT05573165|OTHER|3 hours of preoperative fasting for breast milk|3 hours of preoperative fasting for breast milk
48301347|NCT05573165|OTHER|4 hours of preoperative fasting for breast milk|4 hours of preoperative fasting for breast milk
48301348|NCT05094154|DRUG|anti-pseudomonal cephalosporin|Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
48301349|NCT05094154|DRUG|anti-pseudomonal penicillin|Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
48301350|NCT02498080|PROCEDURE|DEB PTA|paclitaxel drug eluting balloon PTA
48301351|NCT02498080|PROCEDURE|Standard PTA|Standard PTA
48301352|NCT06181396|DRUG|Oxytocin|Native oxytocin analog
48301353|NCT00445055|DRUG|Droperidol|Intravenous injection
48301354|NCT00003207|DRUG|pegylated liposomal doxorubicin hydrochloride|
48479962|NCT03662256|OTHER|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
48479963|NCT06469112|DEVICE|Vibration|The device was used to provide vibration with the participants in this group. This device, designed as a combination of cold application and local vibration to reduce pain experienced during invasive procedures, is frequently chosen for all age groups.
48479964|NCT06469112|OTHER|Placebo|The device was used with participants in this group. The device, at room temperature, was placed by the researcher 5cm proximal to the injection site before the injection was performed. With participants in this group, the device was placed on the procedure site, but no vibration was made. The device was held on the participants for one minute before the injection and throughout the procedure, with the vibration switched off.
48638873|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
48638874|NCT04057794|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by centralized genetic counseling group at Indiana University.
47953957|NCT01232231|BEHAVIORAL|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
47953958|NCT05414877|DRUG|Ephedrine|vasopressor
47953959|NCT05414877|DRUG|Phenylephrine|vasopressor
47953960|NCT05414877|DRUG|Norepinephrine|vasopressor
48301355|NCT00003207|DRUG|PSC 833|
48301356|NCT03299517|DRUG|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
48301357|NCT03299517|DRUG|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
48301358|NCT01356602|DRUG|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
48301359|NCT01356602|DRUG|Canakinumab lyophilized powder|Canakinumab lyophilized powder
48301360|NCT01356602|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide
48301361|NCT01356602|DRUG|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
48301362|NCT06080113|RADIATION|Focal Brachytherapy|Targeted focal brachytherapy is an image-guided technique, where the radioactive source is placed only, and directly into the cancerous area of the prostate. The aim is to preserve the normal surrounding prostate gland tissue to limit treatment-related side effects to the adjacent anatomical structures. A multiparametric prostate MRI is used to identify, localize, and delineate the intraprostatic PCa tumour lesion and plan treatment. A specialized MRI-ultrasound image-fusion software combines the MRI-images with dynamic ultrasound performed in the operating room and is used to focally guide the placement of the radioactive source in the prostate cancer (PCa) tumour focus based on focal dosimetry calculations. A safety margin around the tumour is applied where it is possible to account for MRI tumour volume underestimation, microscopic spread, and treatment uncertainties.
48301363|NCT04039828|DRUG|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
48301364|NCT03695523|BEHAVIORAL|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
48301365|NCT01519427|DRUG|Akt inhibitor MK2206|Given PO
48301366|NCT01519427|DRUG|selumetinib|Given PO
48301367|NCT01519427|OTHER|laboratory biomarker analysis|Correlative studies
48301368|NCT02014532|DRUG|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
48479965|NCT03829579|DRUG|Esketamine|Participants will self-administer esketamine nasal spray, under the supervision of the healthcare professional at the site of care. A starting dose of 56 milligram (mg) will be administered intranasally into each nostril on Day 1 with subsequent doses of 56 mg or 84 mg administered during Weeks 1-4 (2 treatment sessions per week). For participants who respond, treatment is continued as follows: 56 mg or 84 mg of esketamine nasal spray during Weeks 5-8 (once weekly), and Week 9 onwards (every 2 weeks or once weekly), with period re-evaluation to determine the need for continued treatment. Doses will be adjusted based on efficacy and tolerability to the previous dosing.
48301369|NCT02014532|DRUG|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
48301370|NCT00004697|DRUG|choline chloride|
48301371|NCT01680224|BEHAVIORAL|Healthy Weight|
48301372|NCT01680224|BEHAVIORAL|Project Health|
48301373|NCT01680224|BEHAVIORAL|Placebo Control|Participants will view a video on overweight and obesity
47953961|NCT01479127|DRUG|ABT-SLV187|
48301374|NCT06474741|BEHAVIORAL|in-app notification|Parents will receive bi-weekly prompts in a baby monitor app to change infant's orientation within crib, allow for tummy time several times per day, alternate the side from which infants are fed, alternate the side the infant faces during carrying, and in general note any side preferences of the infant so that positioning can assist in symmetry.
48301375|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
48301376|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.
48301377|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
48301378|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
48301379|NCT03747016|DIETARY_SUPPLEMENT|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
48638875|NCT05908786|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
48638876|NCT05908786|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.
48301380|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
48301381|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G1|The women in delivery room are given glucose injection 300ml.
48638877|NCT05908786|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.
47953962|NCT01479127|DRUG|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
47953963|NCT01479127|DEVICE|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
48301382|NCT03747016|DIETARY_SUPPLEMENT|normal saline N1|The women in delivery room are given normal saline 300ml.
48301383|NCT03851744|OTHER|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
48301384|NCT03851744|OTHER|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
48638878|NCT05908786|DRUG|Tobemstomig|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
47953964|NCT01479127|DEVICE|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
48109031|NCT05787964|PROCEDURE|Biological sample collection|Whole blood (blood draw/phlebotomy) will be obtained to proceed with immunologic analysis of samples. Collection of biologic samples will occur up to 12 months.
48109032|NCT01799148|OTHER|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
48301385|NCT03545152|BEHAVIORAL|Exercise|"Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)"
48301386|NCT03545152|BEHAVIORAL|Cognitive training|Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
48301387|NCT03545152|BEHAVIORAL|New life-style|Combination of exercise and cognitive interventions
48301388|NCT02629081|OTHER|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
48301389|NCT05219721|DRUG|CAR-T (CAR-GPRC5D)|CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain. The amplification and persistence of CAR T are enhanced by 4-1BB costimulation signal.
48301390|NCT01660841|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
48301391|NCT02676349|DRUG|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
48301392|NCT02676349|RADIATION|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
48301393|NCT02676349|PROCEDURE|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
48301394|NCT02676349|DRUG|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
48301395|NCT00011193|BEHAVIORAL|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
48301396|NCT03692910|DRUG|SAGE-217|SAGE-217 capsule
48301397|NCT03692910|DRUG|Placebo|SAGE-217 matching placebo capsule
48301398|NCT03819244|DEVICE|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
48301399|NCT03819244|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
48301400|NCT05203133|DIETARY_SUPPLEMENT|Energy Balance|Energy balance phase to elicit weight-maintenance
48301401|NCT05203133|DIETARY_SUPPLEMENT|Energy Deficit|Energy deficit phase to elicit weight-loss
48301402|NCT05203133|DIETARY_SUPPLEMENT|Baseline Assessment|Free-living assessment of energy status
48301403|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
48301404|NCT04795804|DIETARY_SUPPLEMENT|Maltodextrin|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
48301405|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide and resistant starch|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
48301406|NCT03844633|DRUG|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
48479966|NCT05746819|OTHER|Aggressive antipyretics therapy of fever vs usual care in the Malaria RCT study|After clinical trial of the Malaria RCT study, this study will compare children allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities after recovery from CNS malaria.
48301407|NCT03844633|DRUG|Placebos|Placebos -- Shot administered within 48 hours of childbirth
48301408|NCT01641016|DRUG|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
48301409|NCT06171880|DRUG|JLP-1901|administration of JLP-1901
47953965|NCT01479127|DEVICE|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
48109033|NCT05686434|DRUG|Osimertinib|This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
48109034|NCT02457507|DIETARY_SUPPLEMENT|Vitamin B12|2 tablets
48109035|NCT02457507|DIETARY_SUPPLEMENT|Placebo|2 tablets
48109036|NCT01649180|DRUG|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
48109037|NCT01035658|DRUG|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
48109038|NCT01035658|DRUG|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
48301410|NCT06171880|DRUG|JC-001(active comparator)|administration of JC-001(tenofovir)
48301411|NCT05605327|DEVICE|EUS-guided gastroenterostomy|EUS-guided gastroenterostomy using the Hot-Axios and the WEST approach.
48301412|NCT05605327|OTHER|Laparoscopic gastroenterostomy|Laparoscopic gastroenterostomy
48301413|NCT03711552|OTHER|ObsQoR-11|Quality of recovery questionnaire
48301414|NCT03711552|OTHER|QoR-15|Quality of recovery questionnaire
48301415|NCT03023644|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
48301416|NCT05212194|OTHER|examination|Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
48479967|NCT04575714|OTHER|Data record|Data record
48479968|NCT06616129|DIAGNOSTIC_TEST|Geriatric assessment|At the clinic further information on the somatic, social, psychological and functional domain will be gathered by the nurse and two validated tests to map the vulnerability and resilience of the patient will be used; the Cognitive Impairment Test and the timed Up and Go Test.
48638879|NCT05286385|DEVICE|CP1150 Sound Processor|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
48638880|NCT05286385|DEVICE|CP1150 NF|Speech perception tests whilst the subject is fitted with the CP1150 modified firmware (the addition of notch filters at 978Hz, 1956Hz, 2934Hz, 3912Hz).
48301417|NCT03089177|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year."
48301418|NCT02890199|DRUG|Bupivacaine liposomal|
47953966|NCT04203498|DRUG|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
47953967|NCT04203498|DRUG|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
47953968|NCT04659720|DEVICE|Hydrolic lifter device|evaluation of implant stability after closed sinus lifting by hydraulic lift technique using hydraulic lifter device
47953969|NCT04659720|BEHAVIORAL|Patient satisfaction evalution using hydraulic lifter device|patients satisfaction will be evaluated numerically after using hydraulic lift technique by hydraulic lifter device for closed sinus lifting in posterior edentulous maxilla
47953970|NCT06068023|DRUG|Folfirinox|"Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice."
47953971|NCT06068023|DRUG|Capox|or 8 CAPOX cycles (Arm 1) every 3 weeks.
48109039|NCT05983107|DRUG|Everolimus|Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
48301419|NCT02890199|DRUG|Lidocaine|
48301420|NCT05057273|DRUG|BT-11|Oral once daily tablet
47953972|NCT05169190|PROCEDURE|Stellate Ganglion Block|After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.
47953973|NCT05169190|PROCEDURE|Sham Stellate Ganglion Block|"The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject."
47953974|NCT05824572|OTHER|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
47953975|NCT05824572|OTHER|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
47953976|NCT01254097|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsule, 2 capsules twice daily
47953977|NCT04806503|DRUG|UNR844|Ophthalmic solution for topical ocular administration
47953978|NCT04806503|DRUG|Placebo|Placebo
47953979|NCT05413070|BEHAVIORAL|Multimodal approach to QI for Low-Value Care|Up to 4 brief educational components in existing quality meetings Informational email/newsletter Individualized performance feedback reports Educational resources for patients
47953980|NCT02867150|DEVICE|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
47953981|NCT02160990|DRUG|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
48301421|NCT05057273|DRUG|Active comparator|Biologic
48301422|NCT01936649|DRUG|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
48301423|NCT01938820|DRUG|entecavir|anti-viral therapy
48301424|NCT01938820|DRUG|Thymosin-α|antiviral and antifibrosis therapy
48301425|NCT00000451|DRUG|sertraline|16 week outpatient study
48301426|NCT00000451|DRUG|naltrexone|16 week outpatient study
48301427|NCT02952547|DRUG|Co-administration of DWC20155 and DWC20156|
48301428|NCT02952547|DRUG|DWJ1366 Tab.|
48301429|NCT00938327|BIOLOGICAL|Rotarix™|Two doses of oral vaccine.
48301430|NCT03742960|BEHAVIORAL|Behavioral Sleep Restriction|Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
48301431|NCT03527615|OTHER|Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.
48301432|NCT01441687|OTHER|laboratory biomarker analysis|Correlative studies
48479969|NCT06616129|OTHER|Shared decision-making conversation|"The nurse and nurse practitioner together will talk with the patient and their partner about possible treatment options as well as patients' expectations, preferences and their life in general.~During the conversation the OPT (Outcome Prioritization Tool) will be used to clarify the most important goals of treatment for the patient. The OPT exists of four universal treatment goals rated on a visual analogue scale from 0 to 100. The goals represented are: life extension, maintaining independence, reducing pain and reducing other symptoms. The goals will be explained and the patient will be asked to rate each outcome according to the trade-off principle meaning that two outcomes cannot be rated equally."
48479970|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
48479971|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
48109040|NCT05983107|DRUG|Chidamide|Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
48479972|NCT00515034|DRUG|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
48479973|NCT00515034|DRUG|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
48479974|NCT01758419|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
48479975|NCT05947526|PROCEDURE|Oocyte pick-up|With the needle, transvaginally USG-guided oocyte pick-up procedure is going to be performed
48479976|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
48479977|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
48109041|NCT05983107|DRUG|Endocrine therapy|Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
48301433|NCT01441687|PROCEDURE|transrectal prostate biopsy|Undergo prostate biopsy
48301434|NCT03466320|BIOLOGICAL|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
48301435|NCT02645305|BIOLOGICAL|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
48301436|NCT01414088|OTHER|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
48301437|NCT01414088|OTHER|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
48109042|NCT05983107|DRUG|Ovarian function suppression(OFS)|Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
48109043|NCT03484585|DRUG|Rogaratinib (BAY1163877)|Single dose, intake orally, 200 mg
48301438|NCT01414088|OTHER|glucose 5%|infusion, 23 ml/kg, during 50 minutes
48638881|NCT05286385|DEVICE|CP1150 + FF|Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
48638882|NCT05286385|DEVICE|CP1110|Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
48638883|NCT05690386|BIOLOGICAL|Lonapegsomatropin|Once-weekly subcutaneous injection of Lonapegsomatropin
48301439|NCT04449068|OTHER|Neurological and neuropsychological Follow-up after deep brain stimulation|Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
48301440|NCT02002078|DRUG|methylprednisolon|
47953982|NCT02160990|DRUG|Placebo|placebo subcutaneously twice daily for 30 days
48109044|NCT02967588|BEHAVIORAL|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
48301441|NCT01863264|OTHER|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
48301442|NCT02508701|BEHAVIORAL|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
48301443|NCT05889130|OTHER|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
48301444|NCT03249896|BEHAVIORAL|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
48479978|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
47953983|NCT04154930|DEVICE|Restylane-L®|Intradermal injection.
47953984|NCT02357979|DEVICE|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
48479979|NCT03836924|DRUG|Perampanel|Perampanel tablets.
48479980|NCT02946606|DRUG|GX-H9|Human growth hormone
48479981|NCT02946606|DRUG|Genotropin|Human growth hormone
48479982|NCT00920894|DIETARY_SUPPLEMENT|plant stanol ester|the effect of plant stanol esters on plasma lipids
48479983|NCT00190580|DRUG|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
48479984|NCT00190580|DRUG|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
48638884|NCT05690386|DRUG|Somatropin|Once-daily subcutaneous injection of Somatropin
48638885|NCT00573820|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
48638886|NCT04713046|BIOLOGICAL|CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16|Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.
48638887|NCT04713046|BIOLOGICAL|Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16|Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
48638888|NCT05181475|DRUG|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
48301445|NCT06286787|OTHER|Intervention|The training programme will consist of a 3-hour lecture. The contents of the lecture will include knowledge of mountaineering in Hong Kong, country codes and care for the environment, environmental awareness when undertaking outdoor activities, hiking skills, knowledge and choice of hiking equipment and clothing, trip planning, mountain safety, map reading, the use of a compass, mountain safety, basic first aid, methods of calling for help in an emergency and sources of weather data. After completing the lecture, participants will be required to join a 6-day hiking training programme on weekends within a 3-month period (each training will be at least 5 kilometres and the duration will be at least 4 hours).
48301446|NCT06286787|OTHER|Placebo|Control participants will be asked to join six day-time leisure activities on weekends within a 3-month period. Leisure activities will be organised by the Asbury Methodist Social Service and will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and eating a healthy diet, and day visits to a museum and theme park. Children in the placebo control group will receive free access to leisure activities, including visits to museums and theme parks as an incentive for his/her participation.
48301447|NCT03671759|BEHAVIORAL|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
48301448|NCT03671759|BEHAVIORAL|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
48301449|NCT06162676|BEHAVIORAL|HPV game|A brief health game for parent-child dyads to promote child's HPV vaccination
48301450|NCT00193674|DRUG|Dydrogesterone|20 mg/day, oral
48301451|NCT00193674|DRUG|Placebo|Placebo
48301452|NCT01829789|BEHAVIORAL|Group Community Reinforcement Training for Parents|
48301453|NCT01829789|BEHAVIORAL|Individual Community Reinforcement Training for Parents|
48301454|NCT00000579|PROCEDURE|Low Tidal Volume Ventilation|
48301455|NCT00000579|PROCEDURE|Positive End-Expiratory Pressure|
48301456|NCT00000579|DRUG|Lysofylline|
48479985|NCT01338714|OTHER|Compound Herbal Formula (RHD-1)|100 ml/per day
48479986|NCT01338714|OTHER|dilute RHD-1|100 ml/per day
48479987|NCT06051604|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
48479988|NCT02459717|OTHER|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
48479989|NCT02459717|OTHER|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
48109045|NCT06549517|BEHAVIORAL|Cognitive training|MTT24.5 consists in the learning of 40 new datas or knowledges, along 24.5 hours distributted on classes or sessions, during which an average of 3.5 new pieces of knowledge are taught and reinforced through training. Participants are trained using 4 techniques assigned to each new piece of information from a total of 100 available techniques. These techniques include the use of non-dominant skills, literacy in Braille for sighted individuals, and performing 5 actions simultaneously. Each technique is designed to aid in the memorization and learning of new knowledge
48109046|NCT01629186|OTHER|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) \<5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) \<80 beats/min or oxygen saturation (SpO2) \<85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
48109047|NCT02008019|DRUG|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
48301457|NCT00000579|DRUG|Methylprednisolone|
48301458|NCT00000579|DRUG|Ketoconazole|
48301459|NCT00000579|PROCEDURE|Fluid Management|
48638889|NCT01625078|DEVICE|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
48301460|NCT00000579|PROCEDURE|Pulmonary Artery Catheter|
48301461|NCT04802356|DRUG|Belantamab mafodotin|"Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first"
48301462|NCT04802356|DRUG|Bortezomib|Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles
48301463|NCT04802356|DRUG|Lenalidomide|Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first
48301464|NCT04802356|DRUG|Dexamethasone|Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles
48301465|NCT04802356|PROCEDURE|Autologous stem cell transplant (ASCT)|High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice
48301466|NCT01220310|BEHAVIORAL|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
48301467|NCT03067896|DRUG|Bupivacaine|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
48479990|NCT02078921|DRUG|Sodium Nitrate|
48479991|NCT02078921|DRUG|Placebo|
48638890|NCT03600441|DRUG|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
48301468|NCT03067896|DRUG|Dexmedetomidine|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
48301469|NCT03067896|DRUG|Magnesium Sulfate|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
48479992|NCT02061176|PROCEDURE|Transanal Haemorrhoidal Dearterialization|
48479993|NCT02061176|PROCEDURE|Open Haemorrhoidectomy|
48479994|NCT04619199|DIAGNOSTIC_TEST|Blood sample|Blood sample performed at the inclusion and during the follow-up.
48479995|NCT00848042|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
48479996|NCT00808509|BIOLOGICAL|adalimumab|40 mg every other week via subcutaneous injection
48479997|NCT00808509|DRUG|methotrexate|At least 10 mg/week administered orally or subcutaneously
48479998|NCT03956589|DRUG|Orkambi|Open label of Orkambi treatment during 3 months
48479999|NCT06617299|BEHAVIORAL|Intervention Identifies and Responds|"The treatment of Experimental Group is described, which is made up of eight individual sessions taught over three months. Session one will be in face-to-face format, the content, resources and activities are described in tables 2 and 3. The remaining seven sessions will be follow-up sessions (four sessions by message (WhatsApp®) where motivational messages and reinforcement information will be sent; and 3 sessions by phone call for feedback, see details of time, content, activities and resources in tables 2 and 3.~The design of the intervention is aimed at increasing the practice of Responsive Feeding in mothers with children under 6 months of age, is based on the methodology of Sidani and Braden (2021); on CHW (Bandura, 1986); and behavior change techniques to help people have healthy eating habits (Michie et al., 2011)."
48480000|NCT05633082|DEVICE|Lens 1 (omafilcon B)|Toric daily wear contact lens for 15 minutes
47953985|NCT02357979|OTHER|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
47953986|NCT04799327|DRUG|SHR20004|SHR20004：low dose
48109048|NCT02008019|DRUG|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
48109049|NCT00561743|DRUG|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
48480001|NCT05633082|DEVICE|Lens 2 (fanfilcon A)|Toric daily wear contact lens for 15 minutes
48480002|NCT00988208|DRUG|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
47953987|NCT04799327|DRUG|SHR20004|SHR20004: medium dose
47953988|NCT04799327|DRUG|SHR20004|SHR20004: high dose
47953989|NCT04799327|DRUG|placebo|Placebo
48109050|NCT04120051|DIETARY_SUPPLEMENT|Fermented canola-seaweed|A daily sachet with 5 gram FCS-granulate for 6 weeks
48109051|NCT04120051|OTHER|Placebo|A daily sachet with 5 gram rye cereal for 6 weeks
48109052|NCT00269880|DRUG|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
48109053|NCT00269880|DRUG|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
48109054|NCT00269880|DRUG|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
48109055|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
48109056|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
48109057|NCT01595854|DRUG|Ticagrelor|high dose ticagrelor
48109058|NCT01595854|DRUG|dabigatran etexilate|low dose dabigatran
48109059|NCT01595854|DRUG|dabigatran etexilate|medium dose dabigatran
48109060|NCT00190216|DEVICE|Magnetic stimulator|
48109061|NCT01510912|DRUG|Diclofenac|35 mg bid or tid Capsules
48109062|NCT00027820|DRUG|Fludarabine Phosphate|Given IV
48109063|NCT00027820|RADIATION|Total-Body Irradiation|Undergo TBI
48109064|NCT00027820|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
48109065|NCT00027820|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
48109066|NCT00027820|DRUG|Cyclosporine|Given PO
48109067|NCT00027820|DRUG|Mycophenolate Mofetil|Given PO
48109068|NCT06037187|DIAGNOSTIC_TEST|Blood Draw|Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
48109069|NCT05977634|BEHAVIORAL|Bladder training|Bladder training has 4 components, educating the patient about anatomy, fluid intake control, pelvic floor muscle contractions and increasing the interval between visits to the bathroom
48301470|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
48301471|NCT02075255|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
48301472|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
48480003|NCT00988208|DRUG|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
48480004|NCT00988208|DRUG|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
48480005|NCT00988208|DRUG|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
48480006|NCT06206603|DIAGNOSTIC_TEST|Intestinal biopsies|Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
48480007|NCT06206603|DIAGNOSTIC_TEST|Blood sample|A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
48480008|NCT01049347|DRUG|amitriptyline|150 mg oral, daily, single evening dose, 35 days
48480009|NCT01049347|DRUG|paroxetine|40 mg oral, single dose, morning, 35 days
48301473|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation)|"Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours."
48301474|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation) ECOMODYN|"TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode."
48301475|NCT05360186|DEVICE|MateRegen® gel (BioRegen)|Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
48301476|NCT06047431|DRUG|QL1706H|QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
48301477|NCT03824977|DIAGNOSTIC_TEST|Six minutes stepper test (6MST)|"The 6MST is done using a stepper (Stepper essential, Decathlon(TM), France), with a walking height of 20 cm, placed in front of a wall or parallel bars, so patients can hold on if necessary.~Patients are instructed to make the maximum number of steps possible in 6 minutes, and are given a time check at one minute intervals."
48301478|NCT03824977|DIAGNOSTIC_TEST|Sit to stand test (STST)|The STST is done using a chair measuring 47 cm in height. The patient are instructed to sit in the chair and then to do the maximum number of lifts possible from the chair, in 1 minute, with arms folded and without leaning against the chair.
48301479|NCT03245671|DRUG|Kenalog Injectable Product|80 mg of Kenalog will be used.
48301480|NCT03245671|DRUG|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
48301481|NCT03245671|PROCEDURE|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
48301482|NCT00523822|OTHER|Spinal Manipulative Therapy|
48301483|NCT00962065|DRUG|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
48301484|NCT00962065|DRUG|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
48301485|NCT00962065|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days
48301486|NCT01974674|PROCEDURE|Allogeneic transplantation of intrahepatic islet|
48301487|NCT03586843|DRUG|JNJ-64565111|JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
48301488|NCT00779727|PROCEDURE|Placement of drainages|
48301489|NCT00353847|DEVICE|Acupuncture|
48301490|NCT01943864|DRUG|Trametinib (single tablet)|The drug substance is blended with inert
48301491|NCT01943864|DRUG|Trametinib (Multiple tablet)|The drug substance is blended with inert
48301492|NCT00288470|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
48301493|NCT06039254|DRUG|HRS-1780|Single dose in each arm
48301494|NCT03306069|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
48301495|NCT03306069|OTHER|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~* 2 sessions per week~* 5x1 min at 80-95% HRmax~* time-effort per week: \~30 min"
48301496|NCT03306069|OTHER|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~* 2 sessions per week~* 5x1 min at 65-79% HRmax~* time-effort per week: \~30 min"
48480010|NCT02427984|OTHER|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
48480011|NCT02427984|OTHER|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise"
48480012|NCT02427984|OTHER|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
48480013|NCT03648619|DIAGNOSTIC_TEST|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
48480014|NCT05286840|DIAGNOSTIC_TEST|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
48480015|NCT01118845|DRUG|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
48480016|NCT01118845|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
48480017|NCT03901391|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing
48480018|NCT05802199|DIAGNOSTIC_TEST|Hepatic fat fraction and hepatic fibrosis|"All patients underwent measurement of UDFF for hepatic fat fraction and auto-pSWE for hepatic fibrosis.~All patients underwent measurement of MRI-PDFF for hepatic fat fraction and MRE for hepatic fibrosis as reference standard."
48480019|NCT01647711|DRUG|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
48480020|NCT03519282|DEVICE|comfilcon A multifocal toric lens|contact lens
48480021|NCT03519282|DEVICE|omafilcon A Multifocal Toric Lens|contact lens
48480022|NCT00108082|DRUG|carvedilol MR|Study drug
48480023|NCT00108082|DRUG|atenolol|Comparator
48480024|NCT00108082|DRUG|lisinopril|Comparator
48109070|NCT05977634|DEVICE|Transcutaneous tibial nerve stimulation|A combined electrotherapy device capable of applying transcutaneous electrical nerve stimulation will be used. Each session will take 30 minutes. Patient will visit the hospital twice a week for 6 weeks. An electrical current of 0-50 amperes with a frequency of 20 herz, and a duration of 200 micro seconds will be applied using 50x50 mm surface electordes. The aim is to create a tingling sensation without causing any pain on the tibial nerve, at the ankle level.
48301497|NCT03306069|OTHER|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~* 2 sessions per week~* session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~* time-effort per week: \~30 min"
48301498|NCT03174860|DRUG|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
48109071|NCT00384436|DRUG|escitalopram|
47953990|NCT03632200|OTHER|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions"
47953991|NCT04299542|PROCEDURE|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
48301499|NCT03174860|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
48301500|NCT01257126|DRUG|diclofenac potassium|
48301501|NCT01257126|DRUG|nimesulide|
48301502|NCT05027646|DRUG|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
48301503|NCT05027646|DRUG|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
48301504|NCT05915819|OTHER|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump \& turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
47953992|NCT04299542|PROCEDURE|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
47953993|NCT04562467|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|2 x 1g capsules BID as per REDUCE-IT
47953994|NCT00910273|DRUG|etanercept|etanercept 50 mg/week
48301505|NCT05915819|OTHER|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
48301506|NCT00189007|DRUG|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
48301507|NCT00189007|DRUG|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
48301508|NCT02491658|BIOLOGICAL|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
48301509|NCT04221074|PROCEDURE|PECS II versus ESP|compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
48301510|NCT02031380|DEVICE|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
48301511|NCT05144295|DRUG|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
48301512|NCT05144295|DRUG|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
48301513|NCT05144295|DRUG|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years
48301514|NCT05144295|DRUG|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
48301515|NCT05875935|PROCEDURE|ECoG : electrocorticography|"The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA)."
48480025|NCT06287268|OTHER|eltrombopag|This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
48480026|NCT06537232|DIETARY_SUPPLEMENT|Greens-based Supplement|Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
47953995|NCT03805425|RADIATION|PiXL|The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
47953996|NCT02047383|OTHER|Respiratory infection|An assessment of the patients included in the study will be conducted
47953997|NCT05952817|DEVICE|virtual reality|Virtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022)
47953998|NCT05952817|PROCEDURE|Physical Exercise|Rehabilitation program of exercise
47953999|NCT06557031|DIAGNOSTIC_TEST|ABTest Card®REF and ABTest Card®NEW|Pre transfusional control with the ABTest Card®REF device (predicate device) and the ABTest Card®NEW device (investigational device).
47954000|NCT03352479|OTHER|Opioid Return|Calculate the percentage of prescribed to returned opioids
47954001|NCT03437512|DEVICE|Anodal tDCS|20 minutes of 2mA anodal stimulation.
47954002|NCT03437512|BEHAVIORAL|Fluency training|Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
47954003|NCT03437512|DEVICE|Sham tDCS|For sham stimulation, current is ramped up and back down over 30 seconds.
47954004|NCT04185038|BIOLOGICAL|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
48301516|NCT06472505|DEVICE|polyglycolic acid(Neoveil)|This study plans to enroll patients with pituitary tumors who need to undergo surgical treatment according to current routine medical standards. After the tumor tissue is removed, the integrity of the spider web or skull base will be thoroughly checked by endoscopy during the operation to confirm whether there is any cerebrospinal fluid leakage. At the end of the operation, use a 100\*50\*0.15mm, green sheet-like Navi tissue repair patch, cut it aseptically to fit the size of the defect for repair (the common case is 2\*3.5cm defect), and place it on the spider web or skull base Tissue repair at the surgical site to prevent cerebrospinal fluid leakage.
48301517|NCT00376402|BIOLOGICAL|H5N1 Pandemic Influenza Vaccine|
48301518|NCT01044277|DRUG|Glutathione supplementation|500 mg, two times daily
48301519|NCT01044277|DRUG|Gluthathione peroxidases|125 mg, two times daily
48480027|NCT06185595|OTHER|Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.|9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
48480028|NCT02334241|DEVICE|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
48480029|NCT02334241|DEVICE|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
48480030|NCT04352270|OTHER|AD printed educational materials|Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.
47954005|NCT02552589|OTHER|Amine fluoride|toothpaste
47954006|NCT02552589|OTHER|Placebo|toothpaste
47954007|NCT04224038|OTHER|The Inspire Bio-resource Research Platform for Healthy Aging|Several follow-up visits will be undertaken during the 10-year time frame of this project. Some of these visits are not regularly scheduled and will be conditioned by the remote monitoring of intrinsic capacity (IC) and the onset of other major clinical conditions. Other visits correspond to the regularly scheduled (yearly or every two years (biannual visits), depending on the outcome measures) waves of data collection.
47954008|NCT03714620|DRUG|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
48480031|NCT04352270|OTHER|AD educational videos|Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
48480032|NCT06238661|DIAGNOSTIC_TEST|Urology visit with Risk Calculator and MRI|Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
47954009|NCT03867344|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
47954010|NCT03867344|OTHER|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
47954011|NCT00406354|DRUG|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
47954012|NCT00406354|DRUG|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
47954013|NCT02269748|PROCEDURE|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
48301520|NCT01044277|OTHER|Placebo|2 times daily
48480033|NCT00442754|BIOLOGICAL|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
48480034|NCT03010852|BEHAVIORAL|Focused incentive spirometer education and monitoring|
48480035|NCT00670241|DRUG|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
48480036|NCT00670241|DRUG|LEO 80185 vehicle|Once daily application
48480037|NCT00670241|DRUG|Tacalcitol ointment|Once daily application
48480038|NCT03851588|OTHER|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
48480039|NCT03851588|DRUG|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
48480040|NCT00638833|DRUG|Memantine|Memantine 30 mg/day (20-10-0)
48480041|NCT00638833|DRUG|Placebo|Placebo pills
48301521|NCT00216021|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
48301522|NCT00216021|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
47954014|NCT02269748|PROCEDURE|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
48301523|NCT03378011|OTHER|phototherapy|phototherapy either UVA1 or topical PUVA on acral vitiligo
48301524|NCT00114205|DRUG|docetaxel|
48301525|NCT00114205|PROCEDURE|therapeutic thoracoscopy|
48301526|NCT02133235|PROCEDURE|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
48301527|NCT02133235|PROCEDURE|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
48301528|NCT03330743|BEHAVIORAL|Parent Mentor with Standard Education|Parent mentors will provide coaching based on the current guidelines around diet and physical activity
48301529|NCT03330743|BEHAVIORAL|Parent Mentor with Positive Deviance|Parent mentors will provide coaching based on findings from the positive deviance study
48301530|NCT04413240|DEVICE|Telerehabilitation|"* VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~* K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~* Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved."
48301531|NCT04413240|OTHER|Conventional rehabilitation|It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
48301532|NCT01519570|OTHER|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
48301533|NCT05216211|DRUG|Bupivacaine Hydrochloride|1 ml / kg, % 0.25 bupivacaine
48301534|NCT00003771|BIOLOGICAL|therapeutic estradiol|
48301535|NCT00003771|DRUG|norethindrone acetate|
48301536|NCT00371033|DRUG|Pregabalin|dosage
48301537|NCT00371033|DRUG|Placebo|dosage
48301538|NCT05920850|OTHER|Educational Video about LDCT lung cancer screening|A culturally tailored video that provides education about the process LDCT lung cancer screening
48301539|NCT05920850|OTHER|A culturally tailored shared decision-making tool|A culturally tailored shared decision-making tool that educates participants about the shared decision-making process
47954015|NCT02269748|DRUG|Analgesic Therapy|Ibuprofen 600 mg TID
47954016|NCT00885287|DRUG|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
47954017|NCT03055182|OTHER|Physical rehabilitation program|Patients participate during 4 weeks to a physical rehabilitation program.
48301540|NCT05920850|OTHER|Flip chart|The use of a flip chart that reinforces the information provided in the video and shared decision-making tool
48301541|NCT05920850|OTHER|Navigation support|Navigation support for participants who express interest in LDCT and quitting smoking.
48301542|NCT02050048|OTHER|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes"
48638891|NCT01842386|DRUG|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months (+/-5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
48638892|NCT05511844|DRUG|ORM-5029|Intravenous infusion
47954018|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm1|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
47954019|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm1|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
47954020|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm1|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
47954021|NCT04798638|DRUG|Osimertinib Mesylate Tablets under Fasted Condition - Arm2|Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
47954022|NCT04798638|DRUG|TY-9591 Tablets under Fasted Condition - Arm2|Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
48301543|NCT00138125|DRUG|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
48301544|NCT00138125|BIOLOGICAL|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
47954023|NCT04798638|DRUG|TY-9591 Tablets after a High-fat Meal - Arm2|Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
47954024|NCT03947892|DIAGNOSTIC_TEST|PET-CT|A PET-CT scan will be performed systematically for all patients included with the SUVmax, SUV peak, MTV of the lesion, and up to 3 suspicious ganglia during the visual analysis.
47954025|NCT03967301|DIETARY_SUPPLEMENT|Probiotic|Intervention: defined as probiotic consumption
47954026|NCT03967301|DIETARY_SUPPLEMENT|Placebo|Placebo consumption. The placebo will be provided by the company that produces the probiotic.
47954027|NCT06557694|OTHER|Data collection|Data collected included maternal demographics, medication during pregnancy, the gestational week when COVID-19 was diagnosed, antenatal diseases occurring after COVID-19 detection during pregnancy, intrauterine growth retardation (IUGR), small for gestational age (SGA), fetal distress, intrauterine fetal demise (IUFD), intrapartum complications, gestational age (GA) at delivery, mode of delivery, postpartum hemorrhage (PPH), admission to the maternal ICU, birth weight, admission to the NICU, and the indication for NICU hospitalization Pregnancy outcomes included mode of delivery, gestational age at delivery, pre-eclampsia, and postpartum hemorrhage (defined as an estimated blood loss of 1,000 mL or greater).
47954028|NCT02551861|DRUG|Daclatasvir|
47954029|NCT02551861|DRUG|Sofosbuvir|
47954030|NCT02551861|DRUG|Ribavirin|
47954031|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group without motivational intervention (UNSUP)|UNSUP will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
47954032|NCT05619250|BEHAVIORAL|Unsupervised home-based exercise group with motivational intervention (UNSUP+)|UNSUP+ will receive a non-supervised physical exercise intervention using a mobile app at home. The UNSUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the supervised groups, but is adapted to be performed at home with the use of elastic bands and the participant's own body weight. The exercise program will be divided into 3 different levels. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises, 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
47954033|NCT05619250|BEHAVIORAL|Supervised center-based exercise group without motivational intervention (SUP)|SUP will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks.
47954034|NCT05619250|BEHAVIORAL|Supervised center-based exercise group with motivational intervention (SUP+)|SUP+ will attend the university facilities and will perform training in small groups, being supervised by an exercise professional. The SUP+ training program comprises the same exercise structure and is based on the same muscle groups and movements as the unsupervised groups, but is performed in a center using the equipment available at the facility (weight machines, free weight, stationary bikes, etc.). The exercise program will be divided into 3 different levels, progressing the difficulty every 8 weeks. Each level will contain 3 different sessions including 10 warm-up and joint mobility exercises, 1 balance exercise, 7 strength exercises (for upper and lower limbs), 2 aerobic exercises, and 6 flexibility exercises. This multicomponent training will be performed 3 times per week (60 min/session) for 24 weeks. Further, motivational strategies will be applied based on self-determination theory.
47954035|NCT04195906|DRUG|Experimental: SNF472|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
47954036|NCT04195906|DRUG|Placebo Comparator: Placebo|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
47954037|NCT04195906|DRUG|Experimatenl SNF472 (Open-label)|Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
48301545|NCT05927389|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
48339871|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"* 30 quality of life questions for the participant to answer~* The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~* The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
48480042|NCT04733248|OTHER|Kinesiotaping group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHING EXERCISES(10 reps 3sets) hold for 2 sec~* Apply KINESO- TAPE on upper trapezius (from I-O for Inhibition purpose)~HOME PLAN OF EXPERIMENTAL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec (In neck flexion, In neck extension, In side bending) In experimental group kinesiotape was applied on upper trapezius from insertion to origin for inhibition purpose. As it had increased the functional status of the patient. Post -intervention assessment was taken on 1 st, 2nd and 3rd visit."
48638893|NCT03272893|BEHAVIORAL|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
48638894|NCT06635889|DRUG|Bupivacaine|The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
48638895|NCT06635889|OTHER|Normal saline|Placebo of 50 ml of Normal Saline
48638896|NCT05748171|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
48638897|NCT05748171|DRUG|ALLR3|The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase \[or erwinia-asparaginase in the event of an allergic reaction to PEG-asparaginase\]) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
48638898|NCT06064526|OTHER|No intervention|Non-interventional study based on secondary use of hospital medical records
47954038|NCT02387138|DRUG|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
48480043|NCT04733248|OTHER|stretching group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHINGS EXERCISES (10 reps 3sets) hold for 2 sec 5.9HOME PLAN OF CONTROL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec In neck flexion In neck extension In side bending Post-intervention assessment was taken on 1 st, 2nd and 3 rd visit"
48480044|NCT03329976|OTHER|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
48480045|NCT03669575|DIETARY_SUPPLEMENT|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
48480046|NCT03669575|DIETARY_SUPPLEMENT|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
48480047|NCT01767610|DRUG|micronized fenofibrate 160mg|
48480048|NCT01767610|DRUG|pitavastatin Ca 2mg|
48480049|NCT01767610|DRUG|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
48480050|NCT05910528|DRUG|RO7790121|RO7790121 will be administered during the Induction, Maintenance and OLE period.
48480051|NCT00303667|BIOLOGICAL|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
48480052|NCT00303667|BIOLOGICAL|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.
48480053|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
48480054|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14
48480055|NCT00303667|PROCEDURE|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
48480056|NCT00303667|RADIATION|total body irradiation|Administered on Day -13, 200 cGy two times.
47954039|NCT02387138|DRUG|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
47954040|NCT02387138|DRUG|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
47954041|NCT02387138|OTHER|G-csf|G-csf : d8 to d13 systematically
48480057|NCT00303667|BIOLOGICAL|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
48480058|NCT00303667|DRUG|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
48480059|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
48480060|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
48638899|NCT06067230|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
48638900|NCT05215561|OTHER|Cosentyx|There is no treatment allocation. Patients administered Cosentyx by prescription that have started before inclusion of the patient into the study will be enrolled.
47954042|NCT05583565|OTHER|sensory integration approach|Sensory integration refers to how the nervous system receives messages from multimodal sensory information systems to maintain balance, posture, and balance by monitoring head movement and stabilizing the eyes about the environment
48480061|NCT02682186|DRUG|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted."
48480062|NCT02198924|DRUG|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
48480063|NCT02198924|DRUG|placebo|control patients are supplied with the corresponding placebo with the same instructions.
47954043|NCT05583565|OTHER|traditional physical therapy program|"conventional physiotherapy training programs such as the following: 1)Hand function training by locating the Grading of the hand and training this level until it is well developed to transfer to the next level according to 8 parameters (partner's height-shape-weight-texture -reaction time-speed-accuracy-number of trials).~2) equilibrium training by promoting posture reaction. 3)ADL activity training (nutrition training-dressing training-toilet training). 4) Functional skill training through walking (walking on sand, weight on legs, and Climbing stairs )."
48638901|NCT02754037|RADIATION|Fluorodeoxyglucose (FDG) positron emission tomography (PET)|This imaging method uses radiotracers for functional analysis of liver inflammation. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
47954044|NCT04812171|PROCEDURE|non-surgical endodontic treatment|standard non-surgical endodontic treatment performed by endodontic specialist
48638902|NCT02754037|OTHER|Magnetic resonance imaging (MRI)|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
47954045|NCT05276596|DRUG|Ephedrine|The control group will be taken care of according to the protocols in force. The first anesthetic post-induction hypotension will be managed by intravenous injection of ephedrine (dilution: 3 mg / ml) at a dose of 6 mg (i.e. 2 ml). Any subsequent hypotension will be treated with ephedrine until injection of a total dose of 30 mg. Thereafter, if a new arterial hypotension occurs, we will pass to the administration of noradrenaline in intravenous injection using an electric syringe pump, at the dilution of 0.016 mg / ml, posology adapted to the objectives. blood pressure.
47954046|NCT05276596|DRUG|Norepinephrine|Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
47954047|NCT00645723|DRUG|Colistin|intravenous colistin and nebulized colistin
47954048|NCT00645723|DRUG|Colistin and saline solution|intravenous colistin and nebulized saline solution
47954049|NCT05704231|BEHAVIORAL|Behavioral: Motivational Interviewing with WhatsApp video call|The intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interviews will be applied every two weeks, 6 times in total.
47954050|NCT01890746|DRUG|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.
48109072|NCT02900326|OTHER|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
48339872|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"* 13 quality of life questions for the participant to answer~* The answers range from 1 (Not at All) to 4 (Very Much)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
47954051|NCT01890746|DRUG|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
47954052|NCT01890746|DRUG|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were \<100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were \<100 Gi/L.
47954053|NCT01890746|DRUG|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were \<100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were \<100 Gi/L.
47954054|NCT01975961|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
47954055|NCT03198078|DRUG|Brexpiprazole (OPC-34712)|Once-daily, tablets
47954056|NCT03198078|DRUG|Aripiprazole|Once-daily, tablets
47954057|NCT03198078|DRUG|Placebo|Once-daily, tablets
48109073|NCT02900326|OTHER|Mindfulness-based-stress-reduction|
48109074|NCT02900326|OTHER|Both interventions together|
48109075|NCT02900326|OTHER|Vo2max measurements|
48109076|NCT02900326|GENETIC|Telomerase activity on a blood sample|
48109077|NCT02900326|OTHER|Quality of life (questionnaires)|
48109078|NCT02900326|OTHER|Cerebral IRMf|
48109079|NCT03103295|BIOLOGICAL|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
48339873|NCT02562027|BEHAVIORAL|Modified Medical Research Council|"* Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
48301546|NCT01123239|BEHAVIORAL|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care."
48301547|NCT01123239|BEHAVIORAL|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
48301548|NCT04922125|COMBINATION_PRODUCT|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
48301549|NCT04922125|COMBINATION_PRODUCT|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
48301550|NCT05258058|BEHAVIORAL|Memory and Adaptation Training-Geriatrics|MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
48301551|NCT05823909|DEVICE|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
48480064|NCT03400280|OTHER|Best practice algorithm for postoperative care|See arm/group description
48480065|NCT05802446|OTHER|Real-time fMRI Neurofeedback|Neurofeedback with real-time fMRI is a recent technique that allows to record the BOLD signal from a particular brain region and to display it back in real-time to the participant. With this feedback on brain activity, subjects can learn to control the activity of selected brain areas. Trial after trial, participants develop their individual strategies to voluntarily regulate the signal. The main objective of the neurofeedback training is that the participant develops an enhanced ability to exert control over activity in the target area(s) even without feedback. By manipulating targeted brain circuits, this training can induce modifications in particular behaviors and promote selective plasticity within the corresponding brain networks.
48480066|NCT05382156|DRUG|Osilodrostat|oral administration of Osilodrostat tablets at different doses according to patient's need
48109080|NCT06556199|DRUG|Selinexor|Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
47954058|NCT00005673|DRUG|Capravirine|
47954059|NCT04035109|DRUG|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
47954060|NCT04035109|DRUG|Preservative-free 0.9% sodium chloride (Placebo)|A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
47954061|NCT04035109|BIOLOGICAL|House dust mite allergen|Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
48480067|NCT05186779|DRUG|Progestagen|Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
48480068|NCT00987142|DRUG|CX501|Cultured chimeric skin
47954062|NCT04035109|BIOLOGICAL|Cat hair allergen|Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
47954063|NCT02518204|OTHER|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
48480069|NCT00987142|DEVICE|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
47954064|NCT02518204|OTHER|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV"
47954065|NCT06043882|PROCEDURE|flexible bronchoscopy|fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
47954066|NCT06134960|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
48480070|NCT01467479|DRUG|Telaprevir|Tablet
48480071|NCT01467479|DRUG|Ribavirin|Tablet
47954067|NCT02800343|PROCEDURE|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
47954068|NCT03830632|OTHER|Plyometric Training|
47954069|NCT03830632|OTHER|Traditional Training|
47954070|NCT04450888|OTHER|The strategic use of messages in risk communication|The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
48109081|NCT06556199|DRUG|Temozolomide|Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
48109082|NCT06556199|DRUG|Anti-PD-1 monoclonal antibody|The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
47954071|NCT05427006|DEVICE|Z5-BL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
47954072|NCT05427006|DEVICE|Z5-TL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
47954073|NCT00072657|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
47954074|NCT00072657|BEHAVIORAL|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
47954075|NCT00072657|BEHAVIORAL|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
47954076|NCT05351021|DRUG|Metformin|cidophage 850 gm twice daily
47954077|NCT05351021|DRUG|Placebo|placebo twice daily for treatment period
47954078|NCT03926871|OTHER|Ergonomic Training|The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
47954079|NCT04820517|OTHER|Roy Adaptation Model Based Strengthening Program|"Applications included in the strengthening program sessions:~* Awareness study on social media addiction and its effects~* Awareness work on the correct and effective use of leisure time~* As a result of social media addiction, within the scope of Roy Adaptation Model, scenario sharing and problem solving process related to the problems arising in the fields of physical, group identity - self, role and interdependence~* Awareness work on recognizing and managing emotions~* Relaxation and Breathing Exercise in Emotion Management"
47954080|NCT05276531|DRUG|subcutaneous progesterone|clinical pregnancy rates
47954081|NCT05276531|DRUG|vaginal progesterone|clinical pregnancy rates
48301552|NCT05823909|DEVICE|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
47954082|NCT05979506|PROCEDURE|Cutaneous wraps|"The topical treatment that will be used in this study are:~* For the body, an emollient cream with a high lipid content: Cold cream~* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~* Occlusion by wrapping the patient in a plastic film, then covering with a blanket~* After 1 hour, the unabsorbed excess cream is removed with a towel"
47954083|NCT03882190|DRUG|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
48480072|NCT01467479|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
47954084|NCT02650427|DRUG|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
47954085|NCT03947203|BEHAVIORAL|Social media|Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
47954086|NCT04537429|DRUG|Eptinezumab|up to four iv infusions of eptinezumab
47954087|NCT02835742|DRUG|Sargramostim|
47954088|NCT02835742|DRUG|Placebo|
47954089|NCT05246397|DRUG|Sugammadex administration|Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
48301553|NCT01798706|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
48480073|NCT01467479|DRUG|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
47954090|NCT00966771|DRUG|Copper T380 IUD|copper T 380 IUD
47954091|NCT00966771|DRUG|Oral levonorgestrel|1.5 mg
48301554|NCT01798706|DRUG|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
48480074|NCT00918918|DIETARY_SUPPLEMENT|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
48109083|NCT05640791|DRUG|Cisplatin|25mg/m2；d1, 8, 21 d cycle
48109084|NCT05640791|DRUG|Gemcitabine|1000mg/m2；d1, 8, 21 d cycle
48109085|NCT05640791|DRUG|Nab-paclitaxel|100mg/m2；d1, 8, 21 d cycle
48109086|NCT05640791|DRUG|Durvalumab|1000mg；d1, 21 d cycle
48109087|NCT05023512|BEHAVIORAL|Communication about the COVID-19 vaccination from the Massachusetts Department of Public Health|Participants will be randomized to receive one of two different versions of messages from the Massachusetts Department of Public Health. The message that participants in each experimental group receive will vary slightly and systematically. Specific content and wording of these messages were developed to address and mitigate concerns about the Covid-19 vaccination.
48109088|NCT04610008|OTHER|No intervention. Purely observation|Retrospective image analysis of the shape of the optic nerve head in both groups
48480075|NCT00918918|DIETARY_SUPPLEMENT|Orange juice|200 mL orange juice
48480076|NCT01522079|PROCEDURE|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
48480077|NCT06042127|PROCEDURE|POEM-F|POEM-F would be performed as described in the arms section
48480078|NCT06042127|PROCEDURE|Conventional POEM|Anterior POEM performed as described in the arms section
48480079|NCT02168140|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
48480080|NCT02168140|DRUG|bendamustine hydrochloride|Given IV
48480081|NCT06200584|DRUG|Risperidone|Antipsychotic Agent
48480082|NCT06200584|DRUG|Olanzapine|Antipsychotic Agent
48480083|NCT06200584|DRUG|Quetiapine|Antipsychotic Agent
48480084|NCT06200584|DRUG|Risperidone and Vitamin D and Vitamin E|vitamin
48480085|NCT06200584|DRUG|Olanzapine and Vitamin D and Vitamin E|vitamin and Antipsychotic agent
47954092|NCT03813667|BEHAVIORAL|Intervention FamPALcare|"The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear."
47954093|NCT05844410|DRUG|Corticosteroid|Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
47954094|NCT02716805|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
48480086|NCT06200584|DRUG|Quetiapine and Vitamin D and Vitamin E|Vitamin and Antipsychotic agents
48480087|NCT03304782|OTHER|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
47954095|NCT02716805|DRUG|Durvalumab|"Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing \> 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion."
47954096|NCT02716805|BIOLOGICAL|Prevnar-13|Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
47954097|NCT02716805|DRUG|Melphalan|Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
47954098|NCT05968456|OTHER|Data collection|Observational study in patients undergoing thoracic, cardiac and vascular surgery.
47954099|NCT06318234|DIAGNOSTIC_TEST|18F-FAPI，18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy
47954100|NCT03913468|DRUG|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
47954101|NCT04032652|PROCEDURE|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
47954102|NCT04032652|DRUG|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
47954103|NCT00413400|DRUG|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
47954104|NCT00413400|DRUG|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
48109089|NCT02891278|DRUG|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
48109090|NCT02891278|DRUG|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
48109091|NCT02891278|PROCEDURE|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
48480088|NCT03255863|OTHER|Questionnaire|Patient Self reported questionnaire filled in.
48480089|NCT06043791|RADIATION|1.5 Tesla magnet MR arthrography|MR arthrogram is an invasive procedure where the patient's joint is injected with a mixture of dilute gadolinium, iodinated contrast medium, local anesthetic, and saline solution followed by imaging with 1.5 Tesla MRI.
48480090|NCT06043791|RADIATION|3 Tesla magnet non-contrast MRI|3T MRI uses very powerful magnets that produce a 3-tesla magnetic field. A 3-tesla magnetic field is twice as powerful as the fields used in conventional high-field MRI scanners, and as much as 15 times stronger than low-field or open MRI scanners. This results in a clearer and more complete image. Studies have shown that it is highly sensitive and specific in detecting labral and cartilage pathology
48480091|NCT03694808|DRUG|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
47954105|NCT06205823|DRUG|Immunotherapy|Immunotherapy
47954106|NCT06378138|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
47954107|NCT06378138|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
47954108|NCT03080454|DEVICE|sham Doublestim|PathMaker MyoRegulator device
47954109|NCT03080454|DEVICE|anodal Doublestim|PathMaker MyoRegulator device
48480092|NCT03694808|DRUG|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
48480093|NCT02985398|BIOLOGICAL|ALD403 (Eptinezumab)|
48480094|NCT01772355|DEVICE|semi automated core needle biopsy of orbital tumors|
47954110|NCT04311775|DEVICE|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
47954111|NCT04311775|OTHER|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
47954112|NCT00905827|BEHAVIORAL|CAMS|Collaborative assessment management in suicidality
47954113|NCT05353179|DRUG|Meperizumab injection|Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
47954114|NCT05353179|DRUG|NUCALA®|NUCALA® is a humanized monoclonal antibody of IgG1 injection
47954115|NCT00215748|DRUG|Dexamethasone|
47954116|NCT05202028|OTHER|Reflexology|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
47954117|NCT05202028|OTHER|Connective Tissue Massage|After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
47954118|NCT05202028|OTHER|Classic abdominal massage|After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
47954119|NCT02044445|PROCEDURE|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
47954120|NCT00003821|DRUG|aminopterin|
47954121|NCT01723657|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
47954122|NCT01723657|OTHER|Autologous peripheral blood stem cell transplantation.|"* In patients with favorable cytogenetics with a Leukocyte index above 20.~* Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
47954123|NCT01723657|OTHER|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
48109092|NCT04353830|DRUG|IBI939|Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
48480095|NCT01677208|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
48480096|NCT01677208|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
48480097|NCT01677208|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
48480098|NCT01453153|DRUG|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
48480099|NCT01453153|DRUG|PEGPH20|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
48480100|NCT01453153|DRUG|Placebo|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
48480101|NCT04468906|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
48480102|NCT04468906|PROCEDURE|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
48480103|NCT04824859|BEHAVIORAL|Behavioral|eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
48480104|NCT04043819|DRUG|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
48480105|NCT01303237|DRUG|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
48480106|NCT01610063|OTHER|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
48480107|NCT03166124|DRUG|LY900014|Administered SC
48109093|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: Several dose levels will be evaluated for IBI939 in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
47954124|NCT01723657|DRUG|G-CSF|"* Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
47954125|NCT01723657|OTHER|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
47954126|NCT01723657|OTHER|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
47954127|NCT02718066|DRUG|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
47954128|NCT04915027|OTHER|a usual follow-up with Rehabkompassen®|Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.
47954129|NCT04915027|OTHER|a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®|Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.
47954130|NCT05263375|DEVICE|Innovalve TMVR system|Innovalve TMVR system
47954131|NCT00513656|DRUG|Oxycodone|
47954132|NCT00513656|DRUG|Oxycodone/Naloxone|
47954133|NCT06462885|BEHAVIORAL|home support, hiving alone|Home support: living alone
47954134|NCT06462885|BEHAVIORAL|home support, living with others|Home support: living with others
47954135|NCT00171743|DRUG|Cyclosporine microemulsion|
47954136|NCT05133908|BEHAVIORAL|Sleep Hygiene and Self-Monitoring Control|An app with self-monitoring function and videos and written materials about sleep hygiene will be provided.
47954137|NCT05133908|BEHAVIORAL|dCBTi-ADHD|The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
47954138|NCT01727401|DRUG|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
48480108|NCT03166124|DRUG|Insulin Lispro|Administered SC
47954139|NCT00224705|DEVICE|Molecular Adsorbent Recirculating System (MARS®)|
47954140|NCT03499548|OTHER|INSPiRe Programme|Intensive CBT for suicide
47954141|NCT04676698|BEHAVIORAL|Three Good Things|"The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction."
47954142|NCT04676698|BEHAVIORAL|Wait list control arm and then Three Good Things|Surveys will be completed for 3 months prior to treatment and then after treatment.
47954143|NCT05567315|DRUG|local anaesthetic injection|Infiltration of 40 to 80 ml of a non-adrenalized 0.5% lidocaine solution into the vaginal wall at the level of the vaginal pouches, under ultrasound guidance. (within the limit of the toxic doses, i.e. 5mg/kg)
47954144|NCT05567315|DEVICE|hypnosis with Virtual reality mask|A 20-minute virtual reality hypnosis session is performed from the time the patient is placed on the surgical table until the end of the oocyte poncture
47954145|NCT04172623|BEHAVIORAL|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
47954146|NCT04172623|BEHAVIORAL|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
47954147|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Colonic-Delivery capsule)|250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
47954148|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Regular Administration capsule)|250mg post-biotic once daily in a regular uncoated vegan gelatine capsule
47954149|NCT06097182|OTHER|Placebo|250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
47954150|NCT01954160|DEVICE|Symplicity Renal Denervation|Renal denervation
47954151|NCT00122096|DRUG|valdecoxib|
47954152|NCT05748080|OTHER|Eating apples|the eating of 2 apples a day for a period of 6 weeks
47954153|NCT02225197|RADIATION|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
47954154|NCT01701921|DRUG|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
47954155|NCT01701921|DRUG|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
47954156|NCT01701921|DRUG|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
47954157|NCT03868761|BEHAVIORAL|Sonoma Rises|All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
48480109|NCT04341272|DEVICE|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
47954158|NCT02344862|DRUG|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
48301555|NCT01798706|DRUG|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
48301556|NCT02644083|DRUG|Dimethyl fumarate|
48301557|NCT04962321|BEHAVIORAL|Wellness Education|Psychoeducation on relationships between mood, anxiety, eating, and exercise behaviors. One one-hour session each week for 8 weeks.
48301558|NCT00325442|DRUG|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
48301559|NCT00325442|DRUG|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
48301560|NCT04160156|DEVICE|Long term sensor|Observational study including subjects using long term sensor according to local guidelines and patients preferences
48480110|NCT01828645|DIETARY_SUPPLEMENT|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
48480111|NCT05931120|DEVICE|Dry needling|"dry needling using 50mm or 60mm sized needles based on individual muscle bulk. Targeted dry needling will be performed on the muscles presenting with tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
48480112|NCT05931120|DEVICE|IASTM|"Instrument assisted soft tissue mobilization tools targeting tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
48480113|NCT03518216|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
47954159|NCT02344862|DRUG|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
48301561|NCT04738045|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
48301562|NCT04738045|DRUG|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
48480114|NCT01230892|DRUG|Nebivolol|10 mg PO qday
48480115|NCT01230892|DRUG|Atenolol|100 mg PO qday
47954160|NCT02344862|DRUG|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
47954161|NCT02344862|DRUG|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
47954162|NCT01976195|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
47954163|NCT01976195|DRUG|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
47954164|NCT01287078|DRUG|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
47954165|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
47954166|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
47954167|NCT03071471|DEVICE|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~* Only two screws are used~* Incision size is much smaller~* Simpler operation with shorter operative time~* Less complication thanks to the three points above.~* Minimal spinal mobility loss"
47954168|NCT03650556|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™|Ablation procedure for Persistent AF
47954169|NCT02326662|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
47954170|NCT05928793|BEHAVIORAL|mindfulness practices|"Mindfulness, according to Kabat-Zinn, is to pay attention to the present moment in a purposeful way, without judgment. Being conscious involves both attention and awareness. Conscious awareness is an observer in the background of the state of consciousness, constantly observing the inner and outer environment. It is to direct our awareness and attention to our experiences in the present moment in an accepting way with our whole body and thoughts."
47954171|NCT06267248|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
47954172|NCT04685967|DEVICE|Glass ionomer|Equia Forte HT, GC, Tokyo, Japan
48301563|NCT02183545|DRUG|BI 1060469|single rising doses given as tablet
48301564|NCT02183545|DRUG|Placebo|given as tablet (matching placebo of BI 1060469)
48301565|NCT04833075|OTHER|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
48301566|NCT01166659|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
47954173|NCT04685967|DEVICE|Bulk-fill composite|SonicFill2, Orange, CA, USA
47954174|NCT02751866|DIETARY_SUPPLEMENT|Berry fruit powder OR nutritional ketosis|Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
47954175|NCT02751866|DIETARY_SUPPLEMENT|Placebo powder OR higher carbohydrate|Daily supplementation with placebo powder OR higher carbohydrate intake
47954176|NCT06145373|DRUG|Fitusiran (SAR439774)|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
47954177|NCT06145373|BIOLOGICAL|Clotting factor concentrates (CFC) or bypassing agents (BPA)|Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection
47954178|NCT06145373|BIOLOGICAL|Antithrombin concentrate (ATIIIC)|Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection
47954179|NCT06145373|BIOLOGICAL|Emicizumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
47954180|NCT03566862|DIAGNOSTIC_TEST|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
47954181|NCT05221710|BEHAVIORAL|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
47954182|NCT02583126|BEHAVIORAL|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
47954183|NCT00801320|PROCEDURE|Tumor collection|Tumor collected at the time of planned surgery
47954184|NCT03192956|OTHER|No active intervention|No active intervention is performed
47954185|NCT05873062|DRUG|AUT00201|Single oral dose
47954186|NCT05873062|DRUG|Placebo|Single oral dose
47954187|NCT03015857|DRUG|phenylephrine|- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
47954188|NCT03015857|DRUG|Norepinephrine|- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
47954189|NCT03015857|DRUG|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
47954190|NCT03015857|DRUG|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
47954191|NCT03015857|DRUG|Placebo (normal saline)|
47954192|NCT00107783|DRUG|Nitisinone (NTBC)|Treatment
47954193|NCT05316285|OTHER|Yoga exercise|Yoga lesson practices will be designed and implemented by instructors physiotherapists who have completed 200 hours of yoga instructor training (RYT-200). The yoga program, which will consist of one-hour sessions once a week, is planned to last 14 weeks. 4 weeks of classes will be theoretical lessons related to yoga philosophy, 10 weeks of yoga sessions will be applied every week on different concepts such as upper extremity and / or lower extremity focused strengthening and / or flexibility and breathing exercises. In addition to this training, students will be advised to repeat the practices once a week. Sessions will begin with breathing practices called pranayama, followed by yoga postures called asanas, and the sequence will be finished with savasana pose. In this pose, guided meditations will be performed on subjects such as body awareness and self-compassion.
47954194|NCT03515252|BIOLOGICAL|Immune Killer Cells (IKC)|
47954195|NCT00142610|DIETARY_SUPPLEMENT|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
48109094|NCT04353830|DRUG|IBI939+ Sintilimab|"IBI939: IBI939 in combination with Sintilimab will be given with RP2D. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI939. Combination treatment may continue until disease progression or loss of clinical benefit."
48109095|NCT04942249|OTHER|No intervention|No intervention
48109096|NCT00255281|DRUG|AZD7009, no generic name available|
47954196|NCT05243355|DRUG|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|"Envafolimab: 300 mg，D1，Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total.~Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total."
47954197|NCT03468101|OTHER|Pulmonary Function Testing|Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
47954198|NCT02908451|BIOLOGICAL|AbGn-107|Antibody Drug Conjugate
47954199|NCT00121381|DRUG|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
47954200|NCT00121381|DRUG|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
47954201|NCT05824988|OTHER|Drug exposure|Drug concentrations will be measured after one-month antimycobacterial treatment. Area under drug concentration-time curve (AUC) and maximum concentration (Cmax) will be calculated.
47954202|NCT03216187|DRUG|Pregabalin|pregabalin 150 mg capsules
47954203|NCT03216187|DRUG|Placebos|capsules identical to pregabalin but without active drug
47954204|NCT03631875|DRUG|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
47954205|NCT00566111|DRUG|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
47954206|NCT00566111|DRUG|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
47954207|NCT03026361|GENETIC|global proteomic profiling|Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
47954208|NCT06188533|OTHER|Urinary activin A in AKI|Urinary activin A in AKI patient
48638903|NCT02754037|RADIATION|PET Explorer|Similar to the regular PET-Scan, this imaging method uses radiotracers to scan multiple organs of the body. It does involve placement of an intravenous catheter and a radiotracer. One blood sample (10cc) will be drawn after PET scan using a butterfly method with the time recorded. The blood sample will be centrifuged in the Main Hospital to get the plasma and a well counter will be used to calculate the radioactivity in the plasma as per established protocol. Potential risks from an intravenous catheter insertion and blood draw include pain, minimal blood loss and local erythema. Radiotracer exposure from FDG-PET is minimal and has been well-characterized. Radiation Use Committee approval has been obtained for FDG-PET use.
47954209|NCT05194657|DEVICE|enhanced depth of focus IOL|Acrysof IQ Vivity, enhanced depth of focus IOL
47954210|NCT05194657|DEVICE|monofocal IOL|Acrysof IQ, monofocal IOL
47954211|NCT03622814|BEHAVIORAL|Partners at Meals|The focus of the intervention is to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals.
48301567|NCT02972723|DRUG|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
48480116|NCT02617641|BEHAVIORAL|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
48480117|NCT02617641|BEHAVIORAL|Publicly available websites|"* Le Programme de marche (Institut de Cardiologie de Montréal)~* L'activité physique (Institut de Cardiologie de Montréal)~* L'activité physique (Fondation des maladies du cœur et de l'AVC)~* Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~* Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
48480118|NCT01485484|DEVICE|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
48480119|NCT04235972|OTHER|Follow-up consultation|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
48480120|NCT00114231|DRUG|capecitabine|
48480121|NCT00114231|DRUG|oxaliplatin|Given IV
48480122|NCT00114231|PROCEDURE|neoadjuvant therapy|Undergo surgery
48480123|NCT00114231|RADIATION|radiation therapy|Undergo radiotherapy
48480124|NCT03361124|DRUG|Oxytocin|Administration of additional 20 mU Oxytocin
48480125|NCT01273857|PROCEDURE|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
48480126|NCT01273857|PROCEDURE|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
48638904|NCT02152982|OTHER|Laboratory Biomarker Analysis|Correlative studies
47954212|NCT03622814|BEHAVIORAL|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites will receive training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month. The Project Manager will attend the monthly support group for family members about communication. The administrator of the EUC RCC will be interviewed every 6 months the project is in place.
47954213|NCT03924635|COMBINATION_PRODUCT|SYMBICORT and salbutamol|Salbutamol is a short-acting β-agonist and SYMBICORT (fixed dose combination of inhaled corticosteroid plus long-acting β2-agonist) is an anti-inflammatory reliever for asthma. SYMBICORT will be given in a TURBOHALER. Salbutamol will be given in a pressurised metered dose inhaler.
47954214|NCT01333579|OTHER|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
48301568|NCT03158649|OTHER|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
48480127|NCT06497075|DRUG|Albendazole 400mg|Single oral dose of Albendazole 400mg tablet
48480128|NCT06497075|DRUG|Ivermectin 3 MG|Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)
48638905|NCT02152982|OTHER|Placebo Administration|Given PO
48638906|NCT02152982|OTHER|Quality-of-Life Assessment|Ancillary studies
48638907|NCT02152982|DRUG|Temozolomide|Given PO
48638908|NCT02152982|DRUG|Veliparib|Given PO
48638909|NCT05623059|DRUG|Slow Release DHEA|DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
48638910|NCT03748212|DRUG|D935 Cap. 1T|single oral administration under fed condition
48638911|NCT03748212|DRUG|CKD-385 Tab. 1T|single oral administration under fed condition
48638912|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
47954215|NCT06556459|PROCEDURE|Bariatric Surgery|"The patient performs:~* psychological clinical interview~* psychodiagnostic examination~* internal medical examination~* blood tests~* electrocardiogram~* bariatric surgery~* surgical visit"
47954216|NCT03395665|OTHER|Estradiol level|Estradiol level measured at previous day of embryo transfer procedure
48480129|NCT04253015|OTHER|Data-collection|Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
47954217|NCT03395665|OTHER|Progesterone level|Progesterone level measured at previous day of embryo transfer procedure
47954218|NCT03395665|OTHER|Endometrial thickness|Endometrial thickness measured at previous day of embryo transfer procedure
47954219|NCT04582370|BEHAVIORAL|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
48480130|NCT04845620|DRUG|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
47954220|NCT02967432|DRUG|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
47954221|NCT02967432|DRUG|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
47954222|NCT00812851|DRUG|Dronabinol|
47954223|NCT01298635|PROCEDURE|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
47954224|NCT01298635|PROCEDURE|trabeculectomy|
48480131|NCT04845620|DRUG|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
48480132|NCT04941131|DRUG|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
48480133|NCT05942976|OTHER|ULTRASOUND|10 enthesis areas will be evaluated in 20 minutes with ultrasound.
48480134|NCT06250751|BEHAVIORAL|Behavioral Exercise Training (BET) intervention|Introduce and refine concept of exercise and cardiovascular health by initiating walking or cycling and provide behavioral counseling sessions to foster support for adoption and maintenance of exercise, and to troubleshoot barriers. During the first two weeks, the study team will meet with participants twice per week (virtually) to introduce the intervention, familiarize men with the exercise program, exercise logs, resistance bands for strength training. Contact will drop to once per week during weeks 3-8 (total=10 contacts in weeks 1-8). Behavioral counseling will be delivered by the PI or the study coordinator for 30-40 minutes prior to 20-30 mins of an individual or group-based strength training class.
48480135|NCT04022031|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
48480136|NCT03993327|BIOLOGICAL|Iodine I 124 Monoclonal Antibody M5A|Given IV
48480137|NCT03993327|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48480138|NCT05302479|OTHER|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
48480139|NCT03842852|PROCEDURE|Inguinal hernia repair|The grupo one underwent open repair and laparoscopic repair
48480140|NCT05209997|OTHER|Source document data collection|Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
48638913|NCT03539198|RADIATION|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
48638914|NCT03539198|DRUG|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
47954225|NCT01245920|BIOLOGICAL|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
47954226|NCT01245920|OTHER|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
47954227|NCT03878238|DIETARY_SUPPLEMENT|Probiotic Bths-003|Probiotic with maltodextrin as a carrier.
47954228|NCT03878238|OTHER|Placebo|Placebo with maltodextrin base.
47954229|NCT04213482|RADIATION|Panoramic Radiography|Diagnostic Panoramic Dental Radiographs were taken.
47954230|NCT01782547|BEHAVIORAL|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
47954231|NCT01782547|OTHER|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
47954232|NCT00053573|BIOLOGICAL|Myozyme|20 mg/kg to 40 mg/kg qow
47954233|NCT03363997|DRUG|Estriol 0.125 mg/day|Application of one vaginal ring
47954234|NCT03363997|DRUG|Estriol 0.250 mg/day|Application of one vaginal ring
47954235|NCT03363997|DRUG|Estriol 0.500 mg/day|Application of one vaginal ring
47954236|NCT01816529|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
47954237|NCT01816529|DRUG|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
47954238|NCT01816529|DRUG|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
47954239|NCT01816529|DRUG|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
47954240|NCT01888757|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
47954241|NCT01422174|PROCEDURE|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
47954242|NCT05571670|DRUG|Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor|Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
47954243|NCT01067937|PROCEDURE|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
48109097|NCT03118804|DIAGNOSTIC_TEST|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
48109098|NCT04925492|RADIATION|Positron Emission Tomography|An imaging method that uses radiotracers to view changes in the metabolic process.
47954244|NCT00000503|DRUG|nitroglycerin|
47954245|NCT00000503|DRUG|streptokinase|
48109099|NCT04925492|DRUG|Cu-64]-LLP2A|A radioactive tracer used in PET imaging.
48109100|NCT00042224|PROCEDURE|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
48109101|NCT00042224|DRUG|Clozapine|Patients with psychotic symptoms will receive clozapine
48480141|NCT04776746|DRUG|trofinetide|Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
48480142|NCT02390648|DRUG|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
48480143|NCT02390648|DRUG|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
48480144|NCT05688397|DIETARY_SUPPLEMENT|Experimental 1|L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
48480145|NCT05688397|DIETARY_SUPPLEMENT|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
48480146|NCT05688397|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
48480147|NCT00399737|DRUG|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
47954246|NCT00000503|PROCEDURE|heart catheterization|
47954247|NCT00113087|DRUG|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
47954248|NCT00113087|DRUG|Placebo|Participants will receive placebo
47954249|NCT00163111|DRUG|VFENDÂ® I.V., Oral|
47954250|NCT00163111|DRUG|Conventional amphotericin B|
47954251|NCT00163111|DRUG|Diflucan IV, oral|
47954252|NCT01355120|DRUG|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
47954253|NCT00820352|DRUG|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
47954254|NCT00820352|DRUG|placebo|placebo twice a day for 12 weeks
47954255|NCT04877483|PROCEDURE|Acupuncture|Acupuncture is a form of treatment that inserting very thin needles through a person's skin at specific points on the body. Group GB20 and Group GB20 plus BL2 will received the acupuncture treatment.
47954256|NCT04877483|DIAGNOSTIC_TEST|Oral microbiota|Group GB20, Group GB20 plus BL2 and Healthy control will take the oral microbiota analysis.
47954257|NCT04877483|DIAGNOSTIC_TEST|Schirmer's test|Group GB20 and Group GB20 plus BL2 will take the Schirmer's test.
47954258|NCT04877483|DIAGNOSTIC_TEST|Tear breakup time|Group GB20 and Group GB20 plus BL2 will take the tear breakup time test.
47954259|NCT04877483|DIAGNOSTIC_TEST|OSDI(Ocular Surface Disease Index)|Group GB20 and Group GB20 plus BL2 will take the OSDI test.
47954260|NCT04877483|DIAGNOSTIC_TEST|TCM pattern|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine pattern diagnosis.
47954261|NCT04877483|DIAGNOSTIC_TEST|Traditional Chinese Medicine (TCM) tongue diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) tongue diagnosis.
47954262|NCT04877483|DIAGNOSTIC_TEST|TCM pulse diagnosis|Group GB20, Group GB20 plus BL2 and Healthy control will take the Traditional Chinese Medicine(TCM) pulse diagnosis.
47954263|NCT04877483|DIAGNOSTIC_TEST|TCM heart rate variability|Group GB20, Group GB20 plus BL2 and Healthy control will take the TCM Heart rate variability.
48109102|NCT01483248|BIOLOGICAL|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks."
48301569|NCT01951482|DRUG|Pemetrexed/cisplatin|receive Pemetrexed/cisplatin every 21 days
48480148|NCT01337765|DRUG|BEZ235 + MEK162|
48480149|NCT06094998|DIAGNOSTIC_TEST|hemogram examination|It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
48480150|NCT00497250|DRUG|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
48480151|NCT00497250|DEVICE|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
48480152|NCT03172052|DRUG|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
48480153|NCT03172052|DRUG|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
47954264|NCT04877483|DIAGNOSTIC_TEST|ESSPRI(EULAR Sjögren's Syndrome Patient Reported Index)|Group GB20 and Group GB20 plus BL2 will take the ESSPRI.
47954265|NCT04877483|DIAGNOSTIC_TEST|Whole-genome genotyping(TWBv2.0)|Group GB20, Group GB20 plus BL2 and Healthy control will take the Whole-genome genotyping(TWBv2.0).
47954266|NCT04877483|DIAGNOSTIC_TEST|Cytokine markers|Group GB20, Group GB20 plus BL2 and Healthy control will take the cytokine markers(IL-17、MMP-9、BAFF、BCMA) analysis.
47954267|NCT04877483|DIAGNOSTIC_TEST|Blood biochemical analysis|Group GB20 and Group GB20 plus BL2 will take the Blood biochemical analysis(BUN,Cre,AST,ALT,ESR and CRP).
47954268|NCT04877483|DIAGNOSTIC_TEST|complete blood count (CBC)|Group GB20 and Group GB20 plus BL2 will take the CBC(WBC、RBC、Hb、Platelet) analysis.
47954269|NCT04877483|DIAGNOSTIC_TEST|SF-36(36-Item Short Form Survey )|Group GB20 and Group GB20 plus BL2 will take the SF-36 test.
47954270|NCT03828994|BEHAVIORAL|Tech-PN|"* text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~* enhanced community health nurse visits on day 3-5, 14 and 30~* field based treatment visits~* clinical assistance with notification, testing and treatment"
47954271|NCT03024879|DRUG|Erythromycin|
47954272|NCT03024879|DRUG|Saline|
48109103|NCT01483248|DRUG|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
48480154|NCT03172052|DEVICE|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
48480155|NCT03172052|DEVICE|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
48480156|NCT00697970|BIOLOGICAL|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
48480157|NCT00697970|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
48480158|NCT05530070|OTHER|Dietary intervention|Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
48480159|NCT05530070|OTHER|Standard of care|Patients will receive standard of care and baseline dietary education.
48480160|NCT05530070|DIAGNOSTIC_TEST|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
48480161|NCT02111122|DRUG|Sodium Oxybate|
47954273|NCT06149026|OTHER|Physical and nutritional therapy|The patients will be evaluated and followed by a nutritionist and a physical therapist for 12 weeks. In that time, the patients will receive workouts according to their evaluations and a specific nutritional guide according to the nutritionist's evaluations.
47954274|NCT00737243|DRUG|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
47954275|NCT00737243|DRUG|Carboplatin|AUC 6.0 IV Day 1
48109104|NCT00880048|DRUG|orvepitant|neurokinin-1 antagonist
48109105|NCT00880048|OTHER|Placebo|Placebo to match orvepitant 30 mg and 60 mg
48480162|NCT02111122|DRUG|Placebo|
48480163|NCT06616090|BEHAVIORAL|Nurse Implemented Infant-Mother Attachment Security Program|The intervention will draw on video-feedback of mother-infant interactions during the well-child visit. Nurses will videotape the dyad during routine visit in the Family Health Center and show short clips to mothers during the session in order to provide mother positive feedback on their sensitive caregiving. Additionaly, intervention mothers will be exposed to the reminders (e.g., pictures, posters, short film screenings) reflecting maternal sensitivity and secure attachment in the waiting rooms of the intervention Family Health Centers.
48480164|NCT00548379|DRUG|vitamin D|vitamin D 100,000 units once in 3 months
48480165|NCT00548379|DRUG|placebo|olive oil 1ml
48480166|NCT03052972|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
48480167|NCT03052972|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
48480168|NCT02575339|DRUG|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
48480169|NCT02575339|DRUG|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
47954276|NCT00737243|DRUG|Bevacizumab|15 mg/kg IV infusion Day 1
47954277|NCT00737243|DRUG|Erlotinib|150 mg PO
47954278|NCT00737243|OTHER|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
48109106|NCT04273412|BEHAVIORAL|moderate-intensity lifestyle intervention|standardized 12- week program and would be delivered in 4 sessions (2 individual, 2 telephonic). This lifestyle modification program is a combination of diet therapy (optimum calorie), increased daily physical activity and behavioral modification (self-monitoring, stimulus control, motivational interviewing)
47954279|NCT04177121|OTHER|qualitative analysis|Qualitative analysis of physiotherapy prescriptions
47954280|NCT03484637|OTHER|Lifestyle-medicine intervention|
47954281|NCT05328674|PROCEDURE|Arthroscopic reconstruction of cartilage defects in the knee joint with the use of autogenous cartilage transplant with PRP GF (platelet plasma with growth factor)|Arthroscopic reconstruction of cartilage defects in the knee joint using an autogenous PRP GF cartilage transplant.
47954282|NCT05328674|PROCEDURE|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method|Arthroscopic reconstruction of the cartilage defects of the knee joint using the microfracture method.
47954283|NCT05192967|BEHAVIORAL|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
48109107|NCT04689425|DRUG|Umbilical cord blood mononuclear cell gel（MNC）|Local wound treatment by combination of PRP and MNC, once;
47954284|NCT05192967|BEHAVIORAL|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
47954285|NCT06072196|DRUG|Novel hormonal therapy|As provided in real-world setting
47954286|NCT05111704|OTHER|Balance Body Tape|The intervention group received a three-week treatment with Balance Body Tape (BBT) (product by Babota AB), the control group received no treatment. A questionnaire regarding pain, including a Numeric Rating Scale (NRS) measuring pain intensity, and a Photographic posture analysis measurement (PPAM) of habitual sitting posture were accomplished before and after the intervention for both groups.
47954287|NCT03144531|BEHAVIORAL|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
47954288|NCT04232774|DEVICE|The Neurotronic arterial ablation catheter|a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
47954289|NCT03110926|DRUG|mFOLFOX6|Induction Chemotherapy
47954290|NCT03110926|COMBINATION_PRODUCT|Chemoradiation|Chemoradiation
47954291|NCT03470961|DRUG|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
47954292|NCT03470961|DRUG|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
47954293|NCT05689710|DIETARY_SUPPLEMENT|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
47954294|NCT06263595|DEVICE|gastric antral sonography|Participant will undergo gastric antrum ultrasound and be scanned in the supine position followed by the right lateral decubitus position. Qualitative and quantitative assessments will be completed.
47954295|NCT02104752|DRUG|Curcumin|360 mg/day (divided into twice daily oral doses)
47954296|NCT02104752|DRUG|Placebo|"Inactive, matched placebo (Sugar Pill)"
47954297|NCT03789396|OTHER|Targeted Normoxia (oxygen saturation 90-96%)|The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
47954298|NCT03789396|OTHER|Usual Care Oxygenation|The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
47954299|NCT02266498|DRUG|BIBB 515 BS|
47954300|NCT02266498|OTHER|Standard breakfast (40 g fat)|
47954301|NCT04231890|OTHER|IPI monitoring|Patients in this arm will have IPI monitoring
47954302|NCT00837356|DRUG|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
47954303|NCT00837356|DRUG|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
47954304|NCT06558331|OTHER|Preoperative Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, preoperative
47954305|NCT06558331|OTHER|Postoperative 24th hour Quality of Recovery-15 (QoR-15T)|The quality of recovery score (QoR)-15 questionnaire, postoperative 24th hour
48480170|NCT02575339|DRUG|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
48480171|NCT04664816|DRUG|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
48480172|NCT04664816|DRUG|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
48480173|NCT05364437|DIETARY_SUPPLEMENT|Dietary Fibres Mix|The Fibre Mix, which comprises of a mix of dietary fibres (inulin, pectin and oat beta-glucan) will need to be taken by participants twice daily for 2 weeks with their usual food.
47954306|NCT01971242|DRUG|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
48109108|NCT04689425|DRUG|The platelet rich plasma（PRP）|Local wound treatment by PRP alone, once.
48480174|NCT05364437|DIETARY_SUPPLEMENT|Placebo|The placebo, which comprises of cellulose will need to be taken by participants twice daily for 2 weeks with their usual food.
48480175|NCT03226119|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
48480176|NCT00206102|DRUG|quetiapine fumarate|flexible dose oral
48480177|NCT00206102|DRUG|risperidone|flexible dose oral
48480178|NCT06490120|OTHER|sampling method|feasibility outcomes will be compared between the 3 groups
48480179|NCT04257214|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
48480180|NCT04330911|PROCEDURE|Aerobic Exercise|Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
48480181|NCT02428582|DEVICE|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
48480182|NCT02428582|DEVICE|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
47954307|NCT01971242|OTHER|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
47954308|NCT00252824|DRUG|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
47954309|NCT00408629|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
47954310|NCT00408629|BIOLOGICAL|placebo|Matching Placebo for prefilled syringe, 40 mg,
47954311|NCT04729621|COMBINATION_PRODUCT|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
47954312|NCT04729621|COMBINATION_PRODUCT|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
48109109|NCT05206630|OTHER|ED Physical Therapy|All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
48109110|NCT02666742|DRUG|DOAC|DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
48480183|NCT00345215|BEHAVIORAL|High Sodium Diet|250-350 mmol
47954313|NCT05169996|OTHER|Real Food|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
47954314|NCT05169996|OTHER|Real Nonfood|The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
47954315|NCT05169996|OTHER|Virtual reality Food|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
48480184|NCT00345215|BEHAVIORAL|Low Sodium Diet|25-35 mmol
47954316|NCT05169996|OTHER|Virtual reality Nonfood|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
47954317|NCT05169996|OTHER|Virtual reality Food Branded|The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
47954318|NCT03671980|OTHER|My Medical record website|Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
47954319|NCT01758523|DRUG|Dutasteride|
47954320|NCT01758523|DRUG|sugar pill|
47954321|NCT03439917|DIETARY_SUPPLEMENT|L-Carnitine tartrate|2g L-Carnitine tartrate as a powder consumed twice a day
48109111|NCT02666742|DRUG|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
48109112|NCT03556137|DRUG|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
48480185|NCT00766831|DRUG|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram \[mg\] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
48480186|NCT06475625|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
48480187|NCT06475625|DEVICE|Orsiro™ or Orsiro_Mission™ stent|Percutaneous coronary intervention with Orsiro™ or Orsiro_Mission™ stents
48480188|NCT04859387|OTHER|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
48480189|NCT04859387|OTHER|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
48480190|NCT03243929|BEHAVIORAL|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
48480191|NCT03243929|BEHAVIORAL|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
48480192|NCT01158352|DIETARY_SUPPLEMENT|Nutritional supplementation formula|Nutritional supplementation formula
47954322|NCT03439917|DIETARY_SUPPLEMENT|Meal Replacement Drink|325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
47954323|NCT03439917|DIETARY_SUPPLEMENT|Maltodextrin|2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
47954324|NCT00135564|BIOLOGICAL|MenC-TT|
47954325|NCT00135564|BIOLOGICAL|Hib-MenC-TT|
47954326|NCT04157543|OTHER|electroacupuncture|acupuncture with electricity
47954327|NCT03564431|DEVICE|Magnetic resonance|magnetic resonance spectrum of brain
48109113|NCT03002246|OTHER|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
48109114|NCT06406972|OTHER|Brief Admission by self-referral (BA)|Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.
48301570|NCT01951482|DRUG|Bevacizumab and Pemetrexed/cisplatin|receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
48301571|NCT05152160|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell Therapy|Umbilical Cord Mesenchymal Stem Cell Therapy
47954328|NCT03096483|DEVICE|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
47954329|NCT01932359|OTHER|rapidly absorbable suture (Vicryl Rapide)|
47954330|NCT01932359|OTHER|non-absorbable suture (Ethilon)|
47954331|NCT04010032|DEVICE|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
47954332|NCT04010032|DEVICE|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
47954333|NCT05005910|DRUG|Vonoprazan|Vonoprazan 20 mg oral every 12 hours (total 72 hours)
47954334|NCT05005910|DRUG|PPIs IV infusion|Pantoprazole 80 mg IV loading then 8 mg/hr
47954335|NCT06291246|BEHAVIORAL|Virtual Family Navigation|4 sessions of 1:1 virtual family navigation delivered via phone or video call.
47954336|NCT06291246|BEHAVIORAL|Educational Materials|Participants will receive individualized recommendations for early intervention for their child at the time of the diagnosis of autism spectrum disorder.
47954337|NCT02439190|DRUG|BMS-986120|
47954338|NCT02439190|DRUG|Aspirin|
47954339|NCT02439190|DRUG|Clopidogrel|
47954340|NCT04948515|DIAGNOSTIC_TEST|laboratory test|genotyping of IL 17 and IL23
47954341|NCT04948515|DIAGNOSTIC_TEST|laboratory test|estimation of serum level of IL 17
47954342|NCT02681601|DIETARY_SUPPLEMENT|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
47954343|NCT02681601|OTHER|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
48301572|NCT03822403|DEVICE|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
47954344|NCT02681601|DIETARY_SUPPLEMENT|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
47954345|NCT00016159|BIOLOGICAL|filgrastim|
47954346|NCT00016159|BIOLOGICAL|lintuzumab|
48480193|NCT01158352|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
47954347|NCT00016159|DRUG|arsenic trioxide|
48301573|NCT03822403|DEVICE|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
48480194|NCT04936919|DEVICE|BroadBand Light|Treatment arm will receive Broadband light treatment
48301574|NCT02974946|DEVICE|RenalGuard|
47954348|NCT00016159|DRUG|idarubicin|
47954349|NCT00016159|DRUG|tretinoin|
47954350|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
47954351|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
48480195|NCT03186599|BEHAVIORAL|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
48480196|NCT04247984|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered on day 1 of a 2-week cycle.
47954352|NCT00809848|DRUG|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
47954353|NCT00809848|DRUG|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
47954354|NCT00809848|DRUG|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
47954355|NCT02180165|DRUG|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
47954356|NCT02180165|DRUG|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
47954357|NCT05303363|DEVICE|VV-ECMO|VV-ECMO is indicated in case of severe respiratory failure refractory to other therapies. Indications for VV-ECMO include severe pneumonia, acute respiratory distress syndrome (ARDS) (a.o. due to COVID-19) or near-drowning. ECMO is considered a 'last resort' therapy, in which other maneuvers - such as prone positioning and neuromuscular blockage - have shown to be insufficient. Patients are generally receiving invasive mechanical ventilation and are almost always unconscious, since due to the severe respiratory failure, high doses of sedatives and neuromuscular blockage are often applied to prevent further ventilator-induced damage. After the decision for VV-ECMO is made, the patient is directly cannulated in the ICU or OR following standard protocols.
48480197|NCT04247984|DRUG|Capecitabine|2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
48480198|NCT04247984|DRUG|Irinotecan|180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
47954358|NCT02277730|DEVICE|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
47954359|NCT02277730|DRUG|phenylephrine|
47954360|NCT02277730|DRUG|ephedrine|
47954361|NCT02277730|DEVICE|manual vasopressor delivery|
47954362|NCT00569465|DRUG|Arginine|1200 mg, once a day
48301575|NCT01390701|DEVICE|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
48301576|NCT01390701|DRUG|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
48480199|NCT04247984|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.
48480200|NCT04247984|DRUG|CF|300 mg/m2 intravenously administered on day 1 of a 2-week cycle.
48480201|NCT04247984|DRUG|Irinotecan|150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
48480202|NCT00878696|PROCEDURE|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
48638915|NCT03539198|RADIATION|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
48638916|NCT05591768|PROCEDURE|Monopolar radiofrequency|In monopolar group : . Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be \< 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
48638917|NCT05591768|PROCEDURE|Bipolar radiofrequency|a similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures.
47954363|NCT00569465|DRUG|Acetylcysteine|600 mg twice a day
47954364|NCT00569465|DRUG|Placebo|3 vials a day
48301577|NCT00733356|DRUG|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
48301578|NCT02178618|DEVICE|Deployment of Partially covered biliary self expandable metal stent|
48301579|NCT02178618|DEVICE|Deployment of uncovered biliary self expandable metal stent|
48480203|NCT03418792|OTHER|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head \& neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
48480204|NCT02994628|OTHER|Water|Water only without carbohydrate
48480205|NCT02994628|OTHER|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
48480206|NCT02994628|OTHER|Cavendish banana|Ingest Cavendish banana (common banana)
48480207|NCT02994628|OTHER|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
48480208|NCT04191824|DIAGNOSTIC_TEST|APOL1 status|Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.
47954365|NCT02151695|PROCEDURE|panretinal photocoagulation|
47954366|NCT02151695|DRUG|Aflibercept intravitreal injections|
47954367|NCT04448938|OTHER|MRI|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO."
47954368|NCT04448938|OTHER|visual acuity|Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
47954369|NCT02891109|BIOLOGICAL|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
47954370|NCT05661409|DRUG|Sugammadex|"Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated."
48480209|NCT06364878|DIAGNOSTIC_TEST|In vivo confocal microscopy|The patients cornea will be examined non-invasively by IVCM
48480210|NCT06364878|DIAGNOSTIC_TEST|Tear film sampling|Patients tear film will be collected and stored at -80 degrees for analysis
48480211|NCT00384488|BEHAVIORAL|Interactive Voice Response System (IVR)|
48480212|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
48480213|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
48638918|NCT06570603|BEHAVIORAL|Self-Efficacy|Brief skills based psychotherapy session to increase perceived self-efficacy for withstanding distress, giving participants increased beliefs that they \*can\* do it.
48638919|NCT06570603|BEHAVIORAL|Willingness|Brief skills based psychotherapy session to increase perceived willingness to engage with distress for withstanding distress, giving participants increased motivation to try.
48638920|NCT06570603|BEHAVIORAL|Psychoeducation|Psychoeducation about the components and functions of emotion.
47954371|NCT05661409|DRUG|Placebo|Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
47954372|NCT05458934|OTHER|No intervention|no intervention
48480214|NCT01258101|DRUG|ribavirin|800 mg orally daily
47954373|NCT05342792|DRUG|PD-1 antibody|Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
47954374|NCT05342792|DRUG|Capecitabine|Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
47954375|NCT01138839|DRUG|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
47954376|NCT01138839|DRUG|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
47954377|NCT00257608|DRUG|bevacizumab|Intravenous repeating dose
47954378|NCT00257608|DRUG|placebo|Oral repeating dose
47954379|NCT00257608|DRUG|erlotinib HCl|Oral repeating dose
47954380|NCT01050283|PROCEDURE|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
47954381|NCT05933148|DEVICE|Siemens 7T MRI|The active neurofeedback session will be done within the 7T MRI.
47954382|NCT05933148|DEVICE|Sham Neurofeedback|The sham Neurofeedback resembles the active condition but participants will not see their own brain activity and will instead view a past participant's active feedback from their same population group.
48109115|NCT04097418|BEHAVIORAL|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
48109116|NCT02572219|DIETARY_SUPPLEMENT|Nutraceutical compound|
48301580|NCT01733316|DRUG|RP103|
48480215|NCT01258101|DRUG|ribavirin|400 mg orally daily
48480216|NCT02629250|PROCEDURE|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR \<100 bpm, Hb \>8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV \>10% or blood loss \>250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
47954383|NCT04167969|DRUG|(64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
48109117|NCT02572219|DIETARY_SUPPLEMENT|Placebo|
48109118|NCT01717677|PROCEDURE|radical prostatectomy|
48109119|NCT01717677|RADIATION|percutaneous radiation therapy|
48109120|NCT01717677|RADIATION|permanent seed implantation|
48109121|NCT01717677|PROCEDURE|Active Surveillance|
48109122|NCT00293865|PROCEDURE|sentinel node|detection of the sentinel node in breast cancer
48109123|NCT00293865|PROCEDURE|GAS|
48638921|NCT00926705|DRUG|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
48638922|NCT00926705|DRUG|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
47954384|NCT04167969|DIAGNOSTIC_TEST|PET/MRI|Imaging will be performed using the GE Signa PET/MRI.
47954385|NCT04167969|OTHER|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
48109124|NCT03884855|OTHER|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
48109125|NCT03884855|OTHER|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
48301581|NCT01733316|DRUG|Cystagon®|
48301582|NCT05764798|DRUG|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
48301583|NCT05764798|DRUG|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
48301584|NCT02190435|DEVICE|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
48301585|NCT02190435|DEVICE|Conventional technique|Conventional Technique
48301586|NCT01005472|DRUG|sunitinib malate|
48301587|NCT01005472|DRUG|temozolomide|
48301588|NCT03601338|DRUG|Bemiparin|second generation low molecular weight Heparin
47954386|NCT04167969|PROCEDURE|laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
47954387|NCT02904993|OTHER|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
47954388|NCT02904993|OTHER|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
47954389|NCT00222560|BEHAVIORAL|Intensive physical activity counselling by an integrated physical activity counsellor|
47954390|NCT05788900|BIOLOGICAL|Heparin|intravenous Heparin
47954391|NCT01557049|OTHER|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
47954392|NCT01557049|OTHER|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
47954393|NCT00003831|PROCEDURE|conventional surgery|
47954394|NCT04245072|PROCEDURE|Intravitreal injection|Intravitreal injection of Aflibercept 2 mg (0.05 ml) or Ranibizumab 0.5 mg (0.05 ml) to the regimen pro re nata.
47954395|NCT04245072|DIAGNOSTIC_TEST|Fluorescent angiography|Ophthalmic examination
47954396|NCT04245072|DIAGNOSTIC_TEST|Visometry|Ophthalmic examination
47954397|NCT04245072|DIAGNOSTIC_TEST|Refractometry|Ophthalmic examination
47954398|NCT04245072|DIAGNOSTIC_TEST|Slit lamp examination|Ophthalmic examination
47954399|NCT04245072|DIAGNOSTIC_TEST|Ophthalmoscopy|Ophthalmic examination
47954400|NCT04245072|DIAGNOSTIC_TEST|OKT|Ophthalmic examination
47954401|NCT02474381|BIOLOGICAL|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
47954402|NCT02474381|DEVICE|Single PTA|Angioplasty of arteries below tibial plateau level only
47954403|NCT04168697|BEHAVIORAL|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
47954404|NCT04140838|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
47954405|NCT04140838|BEHAVIORAL|Behavioral Activation Therapy for Depression (BATD)|"Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about."
48109126|NCT03014830|DRUG|Alirocumab|150 mg SQ every 2 weeks
48109127|NCT03014830|DRUG|Placebos|Placebo injections SQ every 2 weeks
48109128|NCT01834703|PROCEDURE|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
48301589|NCT03601338|OTHER|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
48301590|NCT05200949|PROCEDURE|Kidney transplant|Transplant surgery of Kidney
47954406|NCT04140838|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
47954407|NCT05089955|BEHAVIORAL|Ambient Experience|MRI examination with Ambient Experience
47954408|NCT02389517|DRUG|Ixazomib Citrate|Given PO
47954409|NCT02389517|DRUG|Lenalidomide|Given PO
47954410|NCT02389517|DRUG|Dexamethasone|Given PO
47954411|NCT01739114|PROCEDURE|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
47954412|NCT01739114|PROCEDURE|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
47954413|NCT00066729|BIOLOGICAL|NY-ESO-1 peptide vaccine|NY-ESO-1b peptide 100 μg mixed with 0.5 mL of Montanide® ISA-51
47954414|NCT04404062|DIAGNOSTIC_TEST|Membrane-based immunoassay kit|The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
47954415|NCT04404062|DIAGNOSTIC_TEST|Quantitative antibody Tests|Antibody titres will be measured from whole blood samples taken from volunteers.
47954416|NCT04404062|DIAGNOSTIC_TEST|PCR Test|PCR tests will be conducted on throat swabs taken from volunteers.
47980485|NCT02940145|OTHER|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
47980486|NCT06207994|DEVICE|Narrow TR|The width of the PRICO SpO2 TR is set to 3% SpO2.
47980487|NCT06207994|DEVICE|Shifted TR|The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
48301591|NCT04937894|DRUG|Tigecycline|Efficacy and safety of Tigecycline
48301592|NCT01741194|DRUG|AC-1204|AC-1204 taken once daily, by mouth
48301593|NCT01741194|DRUG|Placebo|Placebo taken once daily, by mouth
48301594|NCT01313026|PROCEDURE|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
48301595|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
48301596|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
48301597|NCT04122768|BEHAVIORAL|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
48301598|NCT04122768|BEHAVIORAL|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
48301599|NCT02712684|PROCEDURE|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
48638923|NCT04080232|DEVICE|lung MRI|lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
47954417|NCT02785484|OTHER|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
48109129|NCT01834703|PROCEDURE|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
48109130|NCT02884544|DRUG|HLD100|Treatment
48109131|NCT00102063|DRUG|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
48109132|NCT00102063|DRUG|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
48109133|NCT00102063|DRUG|Placebo tablet|Placebo tablet po qd x 42 days
48109134|NCT00618540|BIOLOGICAL|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
48109135|NCT00618540|DRUG|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age \<12 months)
48109136|NCT00618540|DRUG|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age \<12 months)
48109137|NCT00618540|PROCEDURE|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
48109138|NCT05390099|DRUG|Moringa oleifera leaf|Moringa toothpaste
48109139|NCT02001714|BEHAVIORAL|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
48109140|NCT04757103|PROCEDURE|Resection of the retrorectal tumor|Surgical resection of the retrorectal mass
48109141|NCT05460936|OTHER|Lower Extremity Functional Training|motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps
48109142|NCT05460936|OTHER|conventional physical therapy|Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
48109143|NCT03799380|DIETARY_SUPPLEMENT|Gatorade G2|Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)
48109144|NCT03799380|DIETARY_SUPPLEMENT|Standard of care nutritional support|Standard of care nutritional support
48301600|NCT03005847|DIETARY_SUPPLEMENT|fermented papaya preparation|dietary supplementation with fermented papaya preparation
48301601|NCT06532019|OTHER|Targeted intervention based on risk factors|Correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower NT-proBNP, CRP, NYHA Classification, to add diuretics for patients with higher RADs, multidiscipline intervention for patients complicating COPD, and actively reperfusion for ischemic HFpEF patients.
48301602|NCT00367497|DRUG|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
48301603|NCT04082767|DRUG|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
48301604|NCT04082767|DRUG|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
48301605|NCT00565695|DEVICE|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
48109145|NCT02618278|OTHER|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
48301606|NCT01423240|DRUG|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
48301607|NCT01423240|DRUG|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
48301608|NCT01423240|DRUG|Placebo|Placebo once daily orally in the evening
48301609|NCT02467907|DRUG|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
48301610|NCT02467907|DRUG|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles
48301611|NCT02467907|DRUG|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles
48480217|NCT02629250|PROCEDURE|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
48480218|NCT04008537|DEVICE|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
48480219|NCT00539708|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
48480220|NCT04805619|DEVICE|Biomime Morph, a tapered drug eluting stent (DES) with hybrid design|Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
48480221|NCT04553991|PROCEDURE|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
48480222|NCT04553991|PROCEDURE|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
48480223|NCT01352182|DRUG|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
48480224|NCT04825002|DIAGNOSTIC_TEST|Urinary multimarker sensor|We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.
48480225|NCT05031247|OTHER|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
48301612|NCT03408080|DRUG|BHV-4157|BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
48480226|NCT01245036|DRUG|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
47954418|NCT02785484|OTHER|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
47954419|NCT01790425|PROCEDURE|to infuse water into colon to open the lumen for water infusion colonoscopy|
47954420|NCT01790425|PROCEDURE|Air colonoscopy|
47954421|NCT00917501|DRUG|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
48480227|NCT00772616|DRUG|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
48480228|NCT00772616|DRUG|Sufentanil|dosage according to usual criteria
47954422|NCT00917501|DRUG|Placebo|Placebo given twice a day which will be compared to Omega 3
47954423|NCT05510531|BEHAVIORAL|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
47954424|NCT03890315|DIAGNOSTIC_TEST|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
47954425|NCT03088371|DRUG|Bupivacaine 0.25%|For psoas sciatic block.
47954426|NCT03088371|OTHER|Pajunk Needle|For local anaesthesia application in psoas sciatic block
48638924|NCT02470871|BIOLOGICAL|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
48638925|NCT02470871|BIOLOGICAL|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
48480229|NCT01745354|DRUG|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
48480230|NCT01745354|RADIATION|Local Radiation|
48638926|NCT03606590|DEVICE|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
48638927|NCT03606590|DRUG|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
48638928|NCT00937937|DRUG|Dinaciclib|Given IV
48638929|NCT05206435|DRUG|Electronic Cigarette|Electronic Cigarettes are provided to replace tobacco cigarettes
48638930|NCT05206435|DRUG|Nicotine Lozenge|Nicotine Lozenges are provided to replace tobacco cigarettes
48638931|NCT03319654|DIAGNOSTIC_TEST|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
47954427|NCT03088371|OTHER|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
48480231|NCT03221231|DRUG|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
48638932|NCT04160221|OTHER|12 hours interval|Time interval between treatments
47954428|NCT03088371|DRUG|Lidocaine 1%|For psoas sciatic block.
47954429|NCT03088371|DRUG|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
47954430|NCT03088371|DRUG|Lidocaine 2 %|For psoas sciatic block in the post-operative period
47954431|NCT03088371|DRUG|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
47954432|NCT06557135|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.
47954433|NCT05763095|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
47954434|NCT04470778|DRUG|BMS-986256|Specified dose on specified days
48480232|NCT03221231|DRUG|Placebo Oral Tablet|twice daily, placebo
48480233|NCT03221231|OTHER|Magnetic Resonance Imaging|
48480234|NCT03221231|OTHER|Neurocognitive measures|
48480235|NCT03221231|OTHER|Neuro-inflammatory measures|
48638933|NCT04160221|OTHER|24 hours interval|Time interval between treatments
48638934|NCT06362642|DRUG|PC14586|First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
48638935|NCT06362642|DRUG|Itraconazole|Antifungal treatment that is a potent inhibitor of CYP3A4.
48638936|NCT06284278|OTHER|Diaphragmatic breathing retraining|8 weeks diaphragmatic breathing training
48638937|NCT06284278|OTHER|Pelvic stabilization exercise|8 weeks pelvic stabilization exercise training
48638938|NCT06284278|OTHER|pelvic anatomy education|pelvic anatomy education
48638939|NCT04250259|DRUG|Placebo|2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
48638940|NCT04250259|DRUG|SAMe 400 mg tablet|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
48301613|NCT05809011|DRUG|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
48301614|NCT05809011|DRUG|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
48301615|NCT04003506|DRUG|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
48301616|NCT04003506|DRUG|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
48638941|NCT04514549|DEVICE|Emerald|The Emerald is a wireless sensor that can track the motion, breathing, and sleep of subjects without touching or requiring any interaction with the subjects, allowing them to go about their normal lives. The physical device is roughly a 30 x 35 x 5 cm box that contains directional antennas and a motherboard to process these signals. In typical operation, the device is mounted onto a wall within a clinic or home setting using peel-away (reversible) mount strips.
48638942|NCT05029882|DRUG|ABBV-400|Intravenous (IV) Infusion
48638943|NCT05029882|DRUG|Trifluridine/Tipiracil|Oral Tablet
47954435|NCT04470778|DRUG|Famotidine|Specified dose on specified days
48301617|NCT03501706|BEHAVIORAL|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
48301618|NCT03501706|BEHAVIORAL|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
48301619|NCT03501706|BEHAVIORAL|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
48301620|NCT03501706|BEHAVIORAL|Verbal Memory--Visual|word recognition AT memory component
48301621|NCT05085548|DRUG|ProAgio Dose Levels (DL) 1,2,3|ProAgio is administered to study participants by intravenous injections once every 14 days.
48301622|NCT05085548|DRUG|ProAgio Dose Levels (DL) 4,5,6|ProAgio is administered to study participants by intravenous injections once every 7 days.
48301623|NCT05085548|DRUG|ProAgio Dose Levels 4a,5a,6a|ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.
48638944|NCT05029882|DRUG|Bevacizumab|IV Infusion
48638945|NCT03318874|DEVICE|Blephasteam|Steam delivery goggles, once daily
48301624|NCT03102736|DRUG|Placebos|Placebo saline
48301625|NCT03102736|DRUG|Ketamine|0.5 mg/kg ketamine
48638946|NCT03318874|DEVICE|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
47954436|NCT01034150|DEVICE|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
48301626|NCT03102736|DRUG|Nitroprusside|0.5 mcg/kg nitroprusside
48301627|NCT03990766|DRUG|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
48301628|NCT03990766|DRUG|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
47954437|NCT01034150|DEVICE|Placebo stimulation|Placebo stimulation
47954438|NCT03102333|DEVICE|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
48301629|NCT02058199|DRUG|rivaroxaban|Single dose pharmacodynamic study
48339874|NCT02562027|BEHAVIORAL|EQ-5D|"* 5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~* The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
48339875|NCT02562027|BEHAVIORAL|Center for Epidemiological Studies Depression Scale|"* 20 quality of life questions for the participant to answer~* Answers range from Rarely or none of the time to Most or all of the time~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
48638947|NCT03318874|DRUG|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
48638948|NCT04082689|BEHAVIORAL|Assisted Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty."
48638949|NCT04480853|DRUG|Fingolimod|Fingolimod 0.5 mg QD, oral
48638950|NCT04213274|BIOLOGICAL|80 mg RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
48480236|NCT06316713|BEHAVIORAL|One MORE (Spanish Adaptation)|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into two, 1-hour segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Participants will also be guided through a mindful pain management practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The second segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, as well as learning to focus on increasing the positive emotions that can attenuate pain with mindful savoring.
48638951|NCT04213274|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
48638952|NCT05390320|PROCEDURE|PAOO|Periodontally accelerated osteogenic orthodontics will be applied to treat patients with moderate crowding.
48638953|NCT05390320|OTHER|Fixed appliance|Fixed appliances will be applied to treat patients with moderate crowding without any acceleration methods.
48480237|NCT04744155|BEHAVIORAL|Multi-Level Intervention|Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
48638954|NCT06412198|DRUG|Cetuximab|Given by IV
48638955|NCT06412198|DRUG|Cemiplimab|Given by IV
47954439|NCT03102333|DEVICE|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
48480238|NCT04744155|BEHAVIORAL|Enhanced Standard of Care|Behavioral intervention that assesses uptake of contraception from follow-up care.
48480239|NCT00277160|DRUG|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
48480240|NCT03322020|RADIATION|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
48480241|NCT03322020|RADIATION|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
48480242|NCT01281787|DRUG|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
48480243|NCT01281787|DRUG|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
48638956|NCT06412198|DRUG|Adagrasib|Given by PO
48480244|NCT04692025|DRUG|ASC41 tablet|Oral tablet
47954440|NCT06556771|OTHER|Gongs mobilization + conventional physical therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks
48480245|NCT03856515|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
48480246|NCT03856515|OTHER|Questionnaire Administration|Ancillary studies
48480247|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette - with Nicotine
48480248|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette -without Nicotine
48638957|NCT00259701|DEVICE|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
48638958|NCT04188509|DRUG|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).
48638959|NCT04189783|DRUG|Liposomal Bupivacaine|Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
48638960|NCT04189783|DRUG|Quadratus Lumborum Block|"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
48638961|NCT04189783|OTHER|Questionnaire Administration|Ancillary studies
48638962|NCT05607459|OTHER|Dry Needling|"Dry needling consists of a skilled intervention which uses a thin filiform needle (as those used in acupuncture) to penetrate the skin and stimulate underlying myofascial trigger points (defined as a hyperirritable spot in skeletal muscle that is associated with a hypersensitive palpable nodule in a taut band which is painful on manual compression and can give rise to characteristic referred pain, referred tenderness, motor dysfunction and autonomic phenomena.)~This intervention will be performed targeting the upper trapezius and cervical multifidus muscles"
48638963|NCT05607459|BEHAVIORAL|Therapeutic Exercise|Patients will include a supervised therapeutic exercise program in their daily life, based on strengthening exercises for neck muscles.
47954441|NCT06556771|OTHER|Kaltenborn mobilization along with traction + conventional therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks.
47954442|NCT00764296|OTHER|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
47954443|NCT00764296|OTHER|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
47954444|NCT02651818|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
47954445|NCT03724786|DIAGNOSTIC_TEST|Six-hour urine protein collection|This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
48480249|NCT00003531|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48480250|NCT01010750|DRUG|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
48480251|NCT01010750|DRUG|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
48480252|NCT01010750|DRUG|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
48480253|NCT00556491|DRUG|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
48480254|NCT00556491|DRUG|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
48480255|NCT06020482|OTHER|Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity|The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
48480256|NCT04329299|DIAGNOSTIC_TEST|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
48480257|NCT02170831|DRUG|BIBR 1048 MS low|
48480258|NCT02170831|DRUG|BIBR 1048 MS medium 1|
48480259|NCT02170831|DRUG|BIBR 1048 MS medium 2|
48480260|NCT02170831|DRUG|BIBR 1048 MS high|
48480261|NCT02170831|DRUG|BIBR 1048 MS placebo|
48480262|NCT04072549|BEHAVIORAL|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
48480263|NCT02327793|DRUG|Nitroglycerin|
48480264|NCT02327793|DRUG|Labetalol|
48480265|NCT04526652|DRUG|Dexmedetomidine|Evaluating anxiety score in both arms
48480266|NCT04526652|DRUG|Placebo|Evaluating anxiety score in both arms
48480267|NCT01761669|DRUG|Vitamin D|
48480268|NCT04130178|DRUG|Nerve block|block of the digital nerves in rheumatoid arthritis patient
47954446|NCT00310648|BIOLOGICAL|Influenza vaccine|
47954447|NCT00142935|BEHAVIORAL|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
47954448|NCT00142935|BEHAVIORAL|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
47954449|NCT00142935|BEHAVIORAL|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
48266633|NCT04550130|DEVICE|TLA Gut™|The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
48480269|NCT04130178|DRUG|Saline injection|subcutaneous saline injection
48480270|NCT05289934|BEHAVIORAL|Music Stimuli|Nine-minute-long Mozart K.448 (1st movement) and instrumental age-appropriate songs will be played via single-use earbuds with 10 minutes wash-out in between music stimuli.
48480271|NCT04022824|OTHER|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
48480272|NCT04022824|OTHER|Non-OSA|Patients without OSA (apnea hypopnea index \<15) based on sleep study
48109146|NCT06466902|OTHER|Quality assessment of D2 lymphadenectomy using the PhotoNode Score|"During the surgical procedure, a set of 5 high quality laparoscopic intraoperative images of the surgical field will be put on record. Photographs will be taken at the end of the lymphadenectomy phase, before the reconstructive phase begins.~Three surgeons will review the images. Quality of D2 lymphadenectomy will be assessed independently rating eight node stations (1, 5, 6, 7, 8a, 9, 11p and 12a), based upon the evaluation of the 5 images. Each node station will be given a score from 0 to 3, corresponding to a judgment of Unevaluable (0), Poor (1), Doubtful (2) or Excellent (3) lymphadenectomy respectively, in that specific node station.~A total score for each patient will be independently obtained from each reviewer ranging from a minimum of 7 (poor lymphadenectomy) to a maximum of 24 (excellent lymphadenectomy). The PNS for each patient will originate from the average score among the three reviewers."
48301630|NCT00778752|DRUG|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
48301631|NCT04207567|BEHAVIORAL|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
48301632|NCT00510588|OTHER|training|regular physical exercise training for 6 months
48301633|NCT00510588|OTHER|training + metformin|regular physical exercise training in combination with metformin for 6 months
48301634|NCT00510588|OTHER|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
48301635|NCT01345786|DRUG|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
48301636|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
48301637|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
48301638|NCT02429596|DRUG|Experimental|Switch from brand to generic
48301639|NCT00641043|DRUG|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
48301640|NCT00641043|DRUG|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
48301641|NCT06442709|DRUG|Tocilizumab Asprin|"Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients."
48301642|NCT06442709|OTHER|Placebo|Placebo replaces tocilizumab and asprin in advanced NPC patients.
48301643|NCT02467595|DRUG|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
48480273|NCT03727737|DEVICE|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
48480274|NCT01161394|DRUG|Pioglitazone 15mg|
48480275|NCT01161394|DRUG|pioglitazone 30mg|
48480276|NCT01161394|DRUG|placebo|
48480277|NCT05279508|BEHAVIORAL|Make My Day - stroke prevention program|A stroke prevention program within primary healthcare
48301644|NCT02467595|DRUG|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
48301645|NCT02467595|DRUG|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
48301646|NCT02467595|DRUG|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
48301647|NCT02467595|DRUG|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
48301648|NCT00858702|DRUG|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
48301649|NCT00858702|DRUG|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
48301650|NCT00003386|BIOLOGICAL|BCG vaccine|
48301651|NCT00003386|BIOLOGICAL|autologous tumor cell vaccine|
48301652|NCT00003386|DRUG|carboplatin|
48301653|NCT00003386|DRUG|cisplatin|
48301654|NCT00003386|DRUG|cyclophosphamide|
48301655|NCT00003386|DRUG|paclitaxel|
48301656|NCT00003386|OTHER|dinitrophenyl|
48301657|NCT00003386|PROCEDURE|surgical procedure|
48301658|NCT06514469|DRUG|Sufentanil intravenous administration followed consultation of remote physician|Intravenous administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
48301659|NCT06514469|DRUG|Sufentanil intravenous administration based on paramedic competency|Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
48301660|NCT00876980|DEVICE|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
48301661|NCT01477697|DIETARY_SUPPLEMENT|Omega-3|50 mg/kg per day of omega-3 fatty acids
48301662|NCT01477697|DIETARY_SUPPLEMENT|Placebo|50 mg/kg per day of placebo equivalent
48301663|NCT01266798|BEHAVIORAL|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~1. A checklist for critical assessment of health information~2. Access to research databases for health information and an introduction to research methods and principles of science~3. A checklist to the consultation"
48301664|NCT03519308|DRUG|Nivolumab|Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
48301665|NCT03519308|DRUG|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
48301666|NCT03519308|DRUG|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
48301667|NCT03519308|DRUG|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
48109147|NCT05695833|DEVICE|Radiofrequency|Device emitting electric waves generating heat
48109148|NCT04246762|DRUG|Olokizumab|Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
48109149|NCT04246762|DRUG|Omeprazole|Tablets, 20 mg, oral
48109150|NCT04246762|DRUG|Caffeine|Tablets, 100 mg, oral
48301668|NCT05775692|DRUG|fluconazole|According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
48301669|NCT00854529|DRUG|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
48301670|NCT03735693|DIAGNOSTIC_TEST|Ulstrasound|measurement of right femoral cross-section
48301671|NCT01037374|OTHER|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
48301672|NCT00004154|DRUG|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
48301673|NCT00004154|OTHER|Placebo|Two placebo capsules for 25 days of 28 day cycle.
48301674|NCT05876650|OTHER|Pilates exercises|Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
48301675|NCT05876650|OTHER|Yoga|Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
48301676|NCT05819632|OTHER|curcumin gel 2%|curcumin gel 2%
48301677|NCT02111824|DEVICE|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
48301678|NCT02111824|DRUG|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
48301679|NCT00206115|DRUG|Seroquel Sustained Release (SR)|
48301680|NCT00206115|DRUG|Seroquel Immediate Release (IR)|
48301681|NCT00206115|DRUG|Placebo|
48301682|NCT00260741|DRUG|Smoked Cannabis|
48301683|NCT03792750|DRUG|BMS-986205|Specified Dose on Specified Day
48109151|NCT04246762|DRUG|Warfarin+ Vitamin K|Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
48109152|NCT04246762|DRUG|Midazolam|Syrup, 2 mg/mL, oral
48109153|NCT01585558|DRUG|Ospemifene (Dose 1)|
48301684|NCT03792750|BIOLOGICAL|Nivolumab|Specified Dose on Specified Day
48301685|NCT02237807|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
48301686|NCT02237807|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
48301687|NCT03713723|DEVICE|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
48301688|NCT00096096|DRUG|mycophenolate mofetil|
48301689|NCT00096096|DRUG|tacrolimus|
47954450|NCT05119673|OTHER|bi-plane sonographic view to difficult peripheral vascular access using Butterfly iQ+®|Bi-plane Butterfly iQ+® sonographic visualization will be used to help Emergency Department operators to get a venous peripheral access in a population of patients considered difficult for this task based on their history or the present clinical situation.
47954451|NCT03260101|OTHER|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
47954452|NCT04280835|BEHAVIORAL|Group Psychoeducation that Focused on Social Skill Development|Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
47954453|NCT01407822|DRUG|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
47954454|NCT01407822|DRUG|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
47954455|NCT01805128|OTHER|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
48109154|NCT01585558|DRUG|Ospemifene (Dose 2)|
48109155|NCT01585558|DRUG|Placebo|
48109156|NCT00109785|PROCEDURE|positron emission tomography|
48109157|NCT00109785|RADIATION|fludeoxyglucose F 18|
48109158|NCT00109785|RADIATION|iodine I 124 iododeoxyuridine|
48109159|NCT04014933|DIAGNOSTIC_TEST|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
48638964|NCT05607459|OTHER|Manual Therapy|Patients will receive a manual compression (30 seconds) over myofascial trigger points located at the upper trapezius muscle, scalene muscles and cervical multifidus muscle.
48301690|NCT01893723|PROCEDURE|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
48301691|NCT01893723|PROCEDURE|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
48301692|NCT01746992|DRUG|Cyclophosphamide 750mg/m2|day 1 in both arms
47954456|NCT01805128|OTHER|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
47954457|NCT01805128|OTHER|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
47954458|NCT05247593|DRUG|Dayingpian|The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
48301693|NCT01746992|DRUG|Vincristine 1.4mg/m2|day 1
48301694|NCT01746992|DRUG|Doxorubicin 50mg/m2|day 1
48109160|NCT05607186|RADIATION|neoadjuvant long course chemoradiotherapy|neoadjuvant long course chemoradiotherapy consist of radiosensitizing 5FU or capecitabine and 50.4 Gy in 28 fractions over 5 weeks
48109161|NCT03922412|PROCEDURE|PLANTAR BLOCK|"1. Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of mepivacain 1% (200mg)~2. Plantar block 10 minutes later : patient in supine position. Medial midfoot injection of 5 ml of the mixture labelled  BLOC PLANTAIRE  containing 5 ml of Ropivacaine 0,5% (25mg) with 0,5 ml dexaméthasone (2mg)~3. Distal deep fibular block : patient in supine position, injection around the dorsal foot artery of 2 ml of the mixture labelled  BLOC FIBULAIRE  containing 2 ml of Ropivacaine 0,5% (10mg)."
48109162|NCT03922412|PROCEDURE|Sciatic popliteal block|"1-Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of ropivacaine 0,5% (100mg) with 2mg (0,5 ml) of dexamethasone"
48109163|NCT03636867|OTHER|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
48301695|NCT01746992|DRUG|prednisone 60mg/m2|day1-day5
48301696|NCT01746992|DRUG|ifosfamide 2000mg/m2|day 22-day 24
48301697|NCT01746992|DRUG|pirarubicin 50mg/m2|day 1
48301698|NCT01746992|DRUG|pirarubicin 25mg/m2|day 22
48301699|NCT01746992|DRUG|Etoposide phosphate 100mg/m2|day 22-day 24
48301700|NCT01746992|DRUG|methotrexate 1500mg/m2|day 43
48638965|NCT05607459|OTHER|Sham Dry Needling|"For the sham DN intervention, a similar approach will be used, but the skin will be not pierced since the material used will be a telescopic Park's sham device.~The guide tube will be pressed against the skin mark and the sham needle will be allowed to drop. The handle will be tapped briskly, but the (blunted) needle tip will not not break the skin."
47954459|NCT05247593|DRUG|conventional mood stabilizers|Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
47954460|NCT04771312|BEHAVIORAL|Mobile app information-only intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
48109164|NCT02542852|DRUG|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
48301701|NCT02005601|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
48301702|NCT02005601|DRUG|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
48638966|NCT04298658|DIAGNOSTIC_TEST|Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised|Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
48109165|NCT04628572|DRUG|Ceftazidime-avibactam|Non-Interventional Study
48109166|NCT02891525|DIETARY_SUPPLEMENT|50g glucose|
48301703|NCT05872425|DRUG|DingKunDan(GuangYuYuan)|"The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment."
48638967|NCT04298658|DIAGNOSTIC_TEST|Resmed ApneaLink Air device (Resmed, San Diego, CA).|Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
47954461|NCT04771312|BEHAVIORAL|Mobile app social support network intervention|Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
47954462|NCT00156520|DRUG|aprotonin; epsilon aminocaproic acid|
47954463|NCT04401826|PROCEDURE|Tunneling micro-surgical crown lengthening approach using piezo-surgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
48109167|NCT02891525|DIETARY_SUPPLEMENT|25g fructose|
47954464|NCT04401826|PROCEDURE|Micro-surgical crown lengthening approach using Piezosurgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
47954465|NCT00002008|DRUG|Sargramostim|
47954466|NCT00991120|DEVICE|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
48109168|NCT02891525|DIETARY_SUPPLEMENT|220mg acesulfame-K|
48109169|NCT02891525|DIETARY_SUPPLEMENT|250mL tap water|
48109170|NCT04323358|DIAGNOSTIC_TEST|Biometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
48109171|NCT04323358|DIAGNOSTIC_TEST|Keratometry|Patients will be asked to place the chin in position and open their eyes wide. In between measurements, the patient will be arranged so his eyes are in one horizontal line and each time before measurement the patient will be asked to blink several times.
48109172|NCT05097924|OTHER|NAN Supreme HypoAllergenic Starter Infant Formula in ready-to-feed format|Post-market observational study with formula feeding administered via standard of care
48109173|NCT00509639|DRUG|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
48266634|NCT05710263|PROCEDURE|bariatric embolization|bariatric or left gastric artery embolization
48266635|NCT03729778|BIOLOGICAL|Prevnar-13|One time administration of prevnar-13 vaccine
48339876|NCT02562027|BEHAVIORAL|Medical Outcomes Study Social Support Survey|"* 19 quality of life questions for the participant to answer~* Answers from from 1 (None of the time) to 5 (All of the time)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
47954467|NCT05734573|BEHAVIORAL|Family-based treatment|FBT is carried out by a family therapist who has received FBT training. The duration of FBT is commonly 6-12 months, in most cases comprising 10-20 sessions. At the beginning of treatment, there are weekly sessions; later in treatment, the sessions are less frequent. The patient and their family meet their psychiatrist every four to six weeks, and the family therapist also takes part in these meetings. The treatment is implemented in accordance with the FBT treatment manual.
47954468|NCT02601027|PROCEDURE|Transversus Abdominis Plane (TAP) block|
47954469|NCT02601027|DEVICE|Nimbus Infusion Pump IV Administration|
47954470|NCT02601027|DRUG|Bupivacaine infusion|
47954471|NCT02601027|DRUG|Acetominophen|
48109174|NCT01183871|PROCEDURE|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
48301704|NCT05872425|DRUG|Drospirenone and Ethinylestradiol Tablets (Ⅱ)|The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
48301705|NCT04893330|DIETARY_SUPPLEMENT|pepticate syneo|follow up of pepticate syneo for one month
48301706|NCT05813210|DIAGNOSTIC_TEST|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
48301707|NCT03465735|COMBINATION_PRODUCT|Vascular Boot|The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
47954472|NCT02601027|DRUG|Hydromorphone|
47954473|NCT02601027|DRUG|Oxycodone|
47954474|NCT02601027|DRUG|Ondansetron|
47954475|NCT00961649|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
47954476|NCT00961649|DRUG|Brinzolamide ophthalmic suspension, 1%|
47954477|NCT00961649|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
47954478|NCT00961649|OTHER|Vehicle|Inactive ingredients used as placebo
47954479|NCT04937361|OTHER|rectal swab|collection of rectal swabs
47954480|NCT03646825|DIETARY_SUPPLEMENT|Natural Antioxidant supplement|1 capsule orally three times a day for 12 weeks
47954481|NCT05412875|OTHER|Best Practice|Given usual care
47954482|NCT05412875|DRUG|Nicotine Replacement|Given JUUL
47954483|NCT05412875|OTHER|Quality-of-Life Assessment|Ancillary studies
47954484|NCT05412875|OTHER|Questionnaire Administration|Ancillary studies
47954485|NCT03867188|DRUG|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
47954486|NCT02234570|DRUG|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
47954487|NCT02234570|OTHER|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
47954488|NCT01331122|DRUG|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
48109175|NCT00979537|DRUG|Nisoldipine Extended-release Tablets, 40 mg|
48301708|NCT03465735|DRUG|Standard of Care|Anticoagulant therapy will be decided by physician and patient.
48339877|NCT02843178|BEHAVIORAL|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
48339878|NCT04585672|OTHER|Ammonia infusion|Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)
48339879|NCT01525667|BIOLOGICAL|150M PLX-PAD|Single course, multiple IM injections
47954489|NCT03748108|DRUG|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
47954490|NCT03748108|DRUG|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
47954491|NCT03749473|BEHAVIORAL|Choice + Immediate|Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
47954492|NCT03749473|BEHAVIORAL|Choice + Gradual|Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
47954493|NCT03749473|BEHAVIORAL|Assigned + Immediate|Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
47954494|NCT03749473|BEHAVIORAL|Assigned + Gradual|Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
47954495|NCT03749473|BEHAVIORAL|Daily performance feedback|Participants will receive daily performance feedback on their daily step count.
47954496|NCT03749473|BEHAVIORAL|Gamification|All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
47954497|NCT06460922|PROCEDURE|Radial osteotomy|3D printing models and personalized guides in surgical planning in distal radius osteotomies for Kienböck´s disease. Osteosynthesis with a plate in distal radius.
47954498|NCT00000546|BEHAVIORAL|meditation|
47954499|NCT05934578|OTHER|Exercise training|Aerobic and light muscle resistance exercise by online cardiovascular rehabilitation
47954500|NCT02624960|DEVICE|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
47954501|NCT05175027|DRUG|hypochlorous acid|Randomize
47954502|NCT03420625|DEVICE|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
47954503|NCT03420625|DEVICE|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
47954504|NCT03420625|DEVICE|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
47954505|NCT03420625|DEVICE|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
47954506|NCT03879395|PROCEDURE|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
47954507|NCT01937754|DIETARY_SUPPLEMENT|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
47954508|NCT01937754|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
47954509|NCT05955625|OTHER|TIMELY|The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
48638968|NCT04298658|OTHER|Quantitative Sensory testing (QST)|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
48638969|NCT04298658|DIAGNOSTIC_TEST|OraQuick Advance Rapid HIV 1/2 Swab test|Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
48638970|NCT04298658|DIAGNOSTIC_TEST|Cluster of Differentiation 4 (CD4) and Viral load|Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
48638971|NCT04641975|DRUG|Mirabegron|Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
47954510|NCT04674202|OTHER|Phone interview|The participant will have 2 phone interview in which they will be asked about their knowledge of direct oral anticoagulants.
47954511|NCT01914757|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
47954512|NCT01914757|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
48339880|NCT01525667|BIOLOGICAL|300M PLX-PAD|Single course, multiple IM injections
47954513|NCT06557096|DRUG|Osimertinib 80 MG|Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.
47954514|NCT06557096|DRUG|Bevacizumab|Sequential combination therapy with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight on the first day of each cycle, with medication given once every 3 weeks, for a continuous treatment duration of 21 days.
47954515|NCT03078400|DRUG|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
47954516|NCT02670720|DRUG|avoralstat|
47954517|NCT05741307|BEHAVIORAL|Self-hypnosis application|"The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children.~The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment."
47954518|NCT05741307|OTHER|Questionnaires|"Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS).~* T0: inclusion~* T1: 6 weeks after T0 (inclusion)~* T2: 2 weeks after T1~* T3: 6 weeks after T2"
47954519|NCT01601860|OTHER|Use of non-pharmacological|"Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Walking (with cervical dilation between 4 and 5 cm)~* Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~* Shower (with dilation\> 7 cm);"
47954520|NCT01601860|OTHER|Other: Routine care|Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
47954521|NCT05994365|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
48109176|NCT00979537|DRUG|Sular Tablets, 40 mg|
48109177|NCT00129948|DRUG|Troxatyl™ (troxacitabine)|
48109178|NCT02158481|DIETARY_SUPPLEMENT|A capsule containing both polyphenols and carotenoids|
48109179|NCT02158481|DIETARY_SUPPLEMENT|Placebo intervention|Placebo intervention
48109180|NCT05875350|PROCEDURE|Intraligamental local anesthetic injection|The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
48109181|NCT00436644|DRUG|Lapatinib|1250 mg orally days 1 -28.
48339881|NCT01525667|BIOLOGICAL|Placebo|Single course, multiple IM injections
47954522|NCT02840721|DRUG|PF-06480605|PF-06480605 500 mg IV Q2W x 7 Doses
48109182|NCT00436644|DRUG|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
48109183|NCT03572023|OTHER|Integrative characterization of MINOCA patients|"Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
48109184|NCT03572023|OTHER|Characterization of MI patients with coronary obstruction|"Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
48109185|NCT03326648|OTHER|Strength training|Heavy load strength training performed twice a week for 10 weeks.
48339882|NCT03289052|DEVICE|Restylane Volyme|Subcutis injection
48480278|NCT00412737|DRUG|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
48109186|NCT03326648|DIETARY_SUPPLEMENT|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
48480279|NCT00412737|DRUG|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
48480280|NCT05220553|DEVICE|PROLIMB Prosthesis|Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
48480281|NCT02227459|DRUG|ND-L02-s0201 Injection|
48480282|NCT00980889|DEVICE|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
48480283|NCT00980889|DEVICE|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
48480284|NCT06279806|OTHER|Mobile health application use|"Women will be asked to use the app for at least 8 weeks. In order to monitor the usage, the researcher will monitor whether the women log in to the Information and Counseling section from the admin panel. Women who do not log in to the Information and Counseling section will be removed from the study at this stage. A weekly reminder will be sent to women via the mobile application. The questions asked by the participants through the question-and-answer section of the mobile health application will be examined every day and answered by the researcher between 10:00-11:00 every morning and 22:00-23:00 every evening. Likewise, the content shared by women in the forum section of the mobile application will be checked daily by the researcher and content that is harmful to women will be removed."
48480285|NCT06279806|OTHER|Information of the breast cancer survivor period booklet|Women in the control group will be given information of the breast cancer survivor period booklet.
48480286|NCT04188548|DRUG|LY3484356|Administered orally
48480287|NCT04188548|DRUG|Abemaciclib|Administered orally
48638972|NCT04641975|DRUG|Placebo|Oral/ Oral Suspension
47954523|NCT01780571|PROCEDURE|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
47954524|NCT00645749|BIOLOGICAL|Helminth ova|2500 ova per dose (liquid form)
47954525|NCT01076920|GENETIC|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
47954526|NCT00408460|DRUG|imatinib mesylate|Given PO
47954527|NCT00408460|DRUG|paclitaxel|Given IV
48339883|NCT01495364|BIOLOGICAL|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
48339884|NCT01495364|OTHER|placebo|matching placebo
48339885|NCT05450744|DRUG|131I-IPA|131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
47954528|NCT06556628|DEVICE|Increased Body Temperatures|Collecting data on patients whose body temperatures increase due to fighting an illness.
48339886|NCT00005905|DRUG|hu Leptin (A-100)|
48339887|NCT00159718|DRUG|amlodipine|
47954529|NCT03105804|OTHER|FT21039|An electronic cigarette
48339888|NCT00159718|DRUG|atorvastatin|
48339889|NCT00033111|DRUG|Cabergoline|
47954530|NCT03105804|OTHER|FT21041|An electronic cigarette
47954531|NCT03105804|OTHER|FT21044|An electronic cigarette
47954532|NCT03105804|OTHER|FT21042|An electronic cigarette
47954533|NCT00669396|DRUG|Copper T380 IUD|Copper T380 IUD
47954534|NCT00669396|DRUG|levonorgestrel|1.5 mg
48480288|NCT04188548|DRUG|Everolimus|Administered orally
48480289|NCT04188548|DRUG|Alpelisib|Administered orally
48480290|NCT04188548|DRUG|Trastuzumab|Administered intravenously
48480291|NCT04188548|DRUG|Aromatase Inhibitor (AI)|Anastrozole or Exemestane or Letrozole administered orally (physician choice)
48480292|NCT04188548|DRUG|Pertuzumab|Administered intravenously
48480293|NCT02918682|OTHER|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
48638973|NCT05144256|DRUG|Mitapivat|Tablets or granules
48638974|NCT05144256|DRUG|Mitapivat-matching placebo|Tablets or granules
48638975|NCT02594956|DEVICE|no nasogastric tube|
48638976|NCT02594956|DEVICE|nasogastric tube|
48109187|NCT05455424|DRUG|Niraparib Oral Product|Niraparib (\[3S\]-3-\[4-\[7-(aminocarbonyl)-2H-indazol-2-yl\] phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
48109188|NCT05455424|OTHER|Active Symptom Control|ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
48109189|NCT02053363|DRUG|Tranexamic Acid (Cyklokapron)|
48109190|NCT05129124|DEVICE|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses at different fittings
48109191|NCT05129124|DEVICE|Commercially available Ultra for Astigmatism Contact Lenses|Commercially available Ultra for Astigmatism Contact Lenses at different fittings
48109192|NCT02202499|DRUG|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
48339890|NCT00033111|DRUG|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
48339891|NCT05185219|DRUG|Valerian|A natural plant
48480294|NCT02918682|OTHER|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
48480295|NCT02918682|OTHER|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
48638977|NCT04488419|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
48638978|NCT04488419|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
48638979|NCT00382928|DEVICE|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
48638980|NCT06077747|PROCEDURE|Coil Embolization of the Lumbar Vein|Catheter based venography will first confirm Nutcracker physiology with retrograde lumbar vein flow and epidural venous plexus congestion. The lumbar vein will then be coil embolized.
48638981|NCT05623020|DRUG|Elranatamab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
48638982|NCT05623020|DRUG|Daratumumab|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
48339892|NCT00040469|DRUG|Campath -1H|
48638983|NCT05623020|DRUG|Lenalidomide|Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
48109193|NCT02202499|OTHER|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
48109194|NCT02202499|OTHER|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
48109195|NCT05250895|OTHER|18F-Fluoromisonidazole|Given IV
48109196|NCT05250895|PROCEDURE|Biopsy|Undergo biopsy
48109197|NCT05250895|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
48109198|NCT05250895|PROCEDURE|Positron Emission Tomography|Undergo PET
48109199|NCT02278393|OTHER|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
48109200|NCT02278393|OTHER|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
48109201|NCT02854761|DRUG|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
48109202|NCT02057692|DRUG|LUM001|LUM001 administered orally
48339893|NCT00040469|DRUG|Dilantin|
48339894|NCT00040469|DRUG|Busulfan|
48339895|NCT00040469|DRUG|Cyclophosphamide|
48339896|NCT06039969|OTHER||This is an obvertional study and there is no intervention
48638984|NCT05623020|DRUG|Dexamethasone|Randomized
48638985|NCT03975647|DRUG|tucatinib|300mg given twice per day by mouth (orally)
48109203|NCT02057692|DRUG|Placebo|Placebo administered orally
48301709|NCT06207500|PROCEDURE|Pharmacist-led Medication Reconciliation|The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
48301710|NCT01695980|PROCEDURE|ETT with non modified retractor|adenotonsillectomy
48301711|NCT01695980|OTHER|LMA with modified retractor|LMA with modified retractor
48301712|NCT02375698|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
48301713|NCT02375698|BIOLOGICAL|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
48301714|NCT02725073|PROCEDURE|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter \[MAJ-1419; Olympus America, Center Valley, Pa., USA\]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research \& Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
48480296|NCT02918682|OTHER|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
48638986|NCT03975647|DRUG|placebo|Given twice per day orally
47954535|NCT01307982|PROCEDURE|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
47954536|NCT01307982|PROCEDURE|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
47954537|NCT02623140|DEVICE|Biofreedom|PCI with Biofreedom stent
48109204|NCT05498363|BIOLOGICAL|Bacteriophage therapy|Difficult-to-treat bacterial infections were treated with bacteriophages (selected from a collection of 25 individual bacteriophages and 6 bacteriophage cocktails), which were shown to target the patient's infecting bacterial strain (in vitro)
48109205|NCT01566708|BEHAVIORAL|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
48109206|NCT01566708|BEHAVIORAL|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
48109207|NCT01566708|BEHAVIORAL|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
48109208|NCT05300919|OTHER|Measurement based care|Measurement-based care based on arm.
48109209|NCT02214693|DRUG|DA-1229|
48109210|NCT00031512|OTHER|Placebo|Placebo.
48109211|NCT00031512|DRUG|Pleconaril|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
48109212|NCT04973735|DRUG|LY-CovMab|single IV infusion
48301715|NCT01243606|BEHAVIORAL|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
48301716|NCT01243606|BEHAVIORAL|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
48301717|NCT01651182|DRUG|No tranexamic acid|Control
48301718|NCT01651182|DRUG|Tranexamic Acid|
48301719|NCT00002141|DRUG|Abacavir sulfate|
48301720|NCT04330508|OTHER|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
47954538|NCT02623140|DEVICE|Orsiro|PCI with Orsiro stent
47954539|NCT04544085|BEHAVIORAL|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
47954540|NCT03397615|BEHAVIORAL|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
47954541|NCT06557486|BEHAVIORAL|Mindfulness-Based Stress reduction|Participants assigned to the 8-week mindfulness program attended weekly 120-150 minute in-person group sessions for the entire duration. In these sessions, the instructor progressively will introduce and guide formal mindfulness practices while facilitating the sharing of experiences.
47954542|NCT02112006|PROCEDURE|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
47954543|NCT02112006|PROCEDURE|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
47954544|NCT00573937|DRUG|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
47954545|NCT00573937|DRUG|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
47954546|NCT03974360|DRUG|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
48301721|NCT06553313|DEVICE|Micro-Western Array|The subjects first took the energy measurement of the pulse sphygmograph and Ryodoraku, rested for 20 minutes, and then repeated the measurements again. In order to comply with the acupuncture treatment course was 5 weeks in the previous study, we have two blood draw point. Each subject's blood was drawn for the first time, and then for the second time in 5 weeks later. Each subject drew 10ml of blood each time. The blood samples are analyzed by Micro-Western Array (MWA) and Enzyme-linked immunosorbent assay (ELISA) to obtain the serum protein content value of healthy individuals.
48339897|NCT01582958|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
48480297|NCT02309853|OTHER|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~1. Visual or tactile scanning in the personal space~2. Visual or tactile scanning and trunk rotation in the peripersonal space~3. Visual scanning and trunk rotation in the extrapersonal space"
48638987|NCT03975647|DRUG|T-DM1|3.6 mg/kg given into the vein (IV; intravenously) every 21 days
48480298|NCT02309853|OTHER|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
47954547|NCT03883360|DRUG|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
47954548|NCT03883360|DRUG|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
48638988|NCT04090359|DEVICE|Dual Mobility Implant|Patients in this intervention will receive a dual mobility implant
48638989|NCT04090359|DEVICE|Conventional, single-bearing implant|Patients in this intervention will receive a conventional, single-bearing implant
47954549|NCT05929131|OTHER|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
47954550|NCT05929131|OTHER|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
47954551|NCT05929131|OTHER|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
48638990|NCT03378934|DRUG|Berberine|Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
48638991|NCT03378934|DRUG|Standard treatment|Standard treatment for 12±1 weeks.
48638992|NCT03378934|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
48638993|NCT03378934|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
48638994|NCT01965483|RADIATION|once-weekly breast irradiation|
48638995|NCT01121458|DRUG|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP\< 80 mmHg), hypertension (SBP\>150 mmHg), tachycardia (120 beats per minute), bradycardia (\<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
47954552|NCT06557915|PROCEDURE|screening|screening and detection of nasal problems in Neonates and Infants Subjected to CPAP
47954553|NCT01088750|DRUG|cyclophosphamide|
47954554|NCT01088750|DRUG|prednisolone|
48109213|NCT06552962|DEVICE|Whole body vibration|The aim of this study is to reveal the effect of exercises performed with WBV on the myofascial tissue of the lumbar region and the tone of superficial back muscles, as well as to investigate the effects on pain, function, muscle strength, balance, proprioception and endurance parameters, compared to the exercise-only group.
48109214|NCT06552962|BEHAVIORAL|lumbar stabilization exercises|The control group will undergo lumbar stabilization exercises twice a week for 6 weeks.
47954555|NCT01088750|DRUG|vinblastine sulfate|
47954556|NCT01088750|OTHER|watchful waiting|
48109215|NCT03738111|DRUG|TG02 Citrate|TG02 citrate capsules
48109216|NCT04558112|DRUG|L-DOPA|two gel capsules with 100mg L-DOPA (with 25 mg carbidopa to inhibit peripheral decarboxylase)
48109217|NCT04558112|DRUG|Placebo|two gel capsules of placebo
48109218|NCT00075491|DRUG|fenretinide|Given orally
48109219|NCT00075491|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48109220|NCT00075491|OTHER|pharmacological study|Correlative studies
48109221|NCT00075491|OTHER|laboratory biomarker analysis|Correlative studies
48109222|NCT03781206|DEVICE|PICO™ 7|PICO™ system (Smith\&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
48109223|NCT06354738|PROCEDURE|total hysterectomy with bilateral salpingo-oophorectomy, lymph node staging and comprehensive peritoneal staging|"Surgical treatment will consist of total hysterectomy with bilateral salpingo-oophorectomy according to international guidelines.~In low- and intermediate-risk EC patients, staging will include a sentinel lymph node (SLN) procedure. In high intermediate-risk and high-risk EC patients, lymph node staging will involve SLN procedure and/or pelvic and para-aortic lymph node dissection (LND), depending on the local protocol.~The Study-related procedures include infracolic omentectomy or two separate omental representative biopsies, biopsies of all suspicious lesions as well as six peritoneal sites (bladder, pouch of Douglas, bilateral paracolic gutter and bilateral diaphragm).~Stage IV patients will be treated according to European guidelines. When feasible, full surgical intervention (i.e. debulking) is recommended. If this cannot be achieved, a radiologic and/or histologic confirmation of tumor spread beyond the uterus will be accepted."
48109224|NCT01687452|BIOLOGICAL|Blood samples|
48109225|NCT05859971|DRUG|SLN mapping using technetium-99m +/- isosulfan blue dye|The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
48109226|NCT05859971|DEVICE|SLN mapping with ICG fluorescence using the Asimov Platform|2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
48109227|NCT02771171|RADIATION|CT Scan|CT imaging
48109228|NCT04292093|BEHAVIORAL|Home rehabilitation training|The rehabilitation training will be provided via Lumosity platform. Participants will be asked to play computer video-games aimed at strengthening specific sub-functions pertaining to the macro area of executive functions for 30 minutes a day, 5 days a week, for a total of 8 weeks. Specifically, 20 games out of a total of 64 available games provided by the platform have been selected. The selected games are aimed at training 4 cognitive skills: memory, attention, cognitive flexibility and problem solving. In particular, 5 different games were chosen for each cognitive ability.
48109229|NCT04292093|BEHAVIORAL|Home control activity|The control group will watch a series of animated / TV shows suitable for the sample age, again for 30 minutes a day, 5 days a week, for 8 weeks. The videos will be provided by the experimenter and participants will watch them on their personal computer. At the end of each videos, participants will answer a series of multiple-choice questions aimed at evaluating the attention deployed to the content of the videos.
48301722|NCT00824499|OTHER|Complex regional intervention|"Components of the complex intervention:~* Introduction of a program coordinator~* Introduction of a self-management education program~* Bottom up development of a interdisciplinary care protocol~* Support program for the intiation of insulin therapy in primary care~* Regional audit"
48301723|NCT00278265|DRUG|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
48301724|NCT00403702|DRUG|Oxane HD [oil-RMN3-mixture]|
48301725|NCT00403702|DRUG|Densiron [(F6H8)|
47954557|NCT01088750|PROCEDURE|therapeutic conventional surgery|
47954558|NCT03991858|OTHER|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
47954559|NCT03991858|OTHER|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
47954560|NCT05702918|DEVICE|BTL-6000 FSWT|The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).
47954561|NCT05702918|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
47954562|NCT02651831|OTHER|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
47954563|NCT02651831|OTHER|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
47954564|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
47954565|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)
47954566|NCT04045275|BEHAVIORAL|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
47954567|NCT01660204|OTHER|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
47954568|NCT00595465|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
47954569|NCT04743466|OTHER|Electronic Health Record Review|Biobank records are reviewed
47954570|NCT01310153|PROCEDURE|prone positioning|newborn babies in prone positioning
47954571|NCT01310153|PROCEDURE|Supine|newborn babies in supine positioning
47954572|NCT01197664|DRUG|paricalcitol|Given PO
47954573|NCT01197664|RADIATION|radiation therapy|Undergo radiotherapy
47954574|NCT01197664|OTHER|laboratory biomarker analysis|Correlative studies
47954575|NCT01197664|DRUG|fluorouracil|Given PO
47954576|NCT02698878|DIETARY_SUPPLEMENT|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
47954577|NCT02698878|OTHER|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
47954578|NCT02698878|DEVICE|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
47954579|NCT03144973|DIAGNOSTIC_TEST|periosafe|mouth rinsing quick-test
47954580|NCT01117948|DRUG|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
47954581|NCT01117948|DRUG|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
48109230|NCT05158361|OTHER|Acupuncture|Participants will receive acupuncture, three times per week for eight weeks. The selected acupoints include bilateral BL33, BL35, SP6, and ST36. All acupoints areas have been sterilized before acupuncture. For BL33, a needle (Ф0.40×100mm) will be inserted with an angle of 60° in an inferomedial direction at a depth of 90-100mm. For BL35, the same needle will be inserted with a direction to the ischial rectal fossa at a depth of 60-70 mm deep. For SP6 and ST36, needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. After the needles are inserted, a portable electro-acupuncture machine will be connected to the handles of needles located in BL33 and BL35 to provide the electrical stimulation for 30 minutes with a disperse-dense wave (4/20Hz). All current intensities will be as high as can be tolerated.
48301726|NCT03490669|BIOLOGICAL|MSC-1|humanized monoclonal antibody for intravenous administration
47954582|NCT01820065|PROCEDURE|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
47954583|NCT02650635|DRUG|Cyclophosphamide|Given IV
47954584|NCT02650635|OTHER|Laboratory Biomarker Analysis|Correlative studies
47954585|NCT02650635|BIOLOGICAL|Pegfilgrastim|Given SC
47954586|NCT02650635|OTHER|Pharmacological Study|Correlative studies
47954587|NCT02650635|DRUG|TLR8 Agonist VTX-2337|Given SC
48109231|NCT05158361|OTHER|Sham acupuncture|The sham acupoints will be located at 20 mm outward to BL33, BL35, SP6, and ST36, and the needless will be inserted with a depth of 2 mm. The BL33 and BL35 will not receive any electrical stimulation, though the handles of needles will be connected to the same machine as the acupuncture group, and the parameter setting and course are also the same.
48301727|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
48339898|NCT01582958|OTHER|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
48339899|NCT02887365|DRUG|tegafur-uracil|
48109232|NCT04260750|BEHAVIORAL|Internet-administered Cognitive behavioral therapy (ICBT)|"The intervention consists of fifteen modules, each having a specific focus on a problem (e.g. comorbid worry alongside the depression) or containing a specific strategy or element (e.g. behavioral activation).~The fifteen modules are:~Introduction/Psychoeducation about depression, Behavioral activation 1, Behavioral activation 2, Cognitive restructuring, Acceptance, Psychoeducation about emotions, Anxiety and exposure, Comorbid social anxiety, Comorbid worrying and generalized anxiety, Comorbid panic disorder, Sleep problems, Perfectionism, Stress management, Relaxation, and Relapse prevention.~The first and last module are assigned to all participants. The rest is picked either by the participants themselves or by the therapist conducting the intake interview."
48301728|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
48301729|NCT02205567|DIETARY_SUPPLEMENT|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
48301730|NCT03037320|PROCEDURE|comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth|
48638996|NCT04474158|BEHAVIORAL|Creating Peace|Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
48638997|NCT04474158|BEHAVIORAL|Job Readiness|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
48638998|NCT06630286|DRUG|ISL/LEN|Tablet administered orally
48638999|NCT06630286|DRUG|B/F/TAF|Tablet administered orally
48639000|NCT06630286|DRUG|PTM B/F/TAF|Tablet administered orally
48639001|NCT06630286|DRUG|PTM ISL/LEN|Tablet administered orally
48639002|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
48639003|NCT00562107|DEVICE|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
48639004|NCT05836987|DEVICE|AFSW Guided DOAC|The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
48639005|NCT05836987|DRUG|Continuous DOAC therapy|DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
48639006|NCT05979272|BEHAVIORAL|Treatment as usual|Treatment as Usual at the local family court, which includes a brief, computerized motivation enhancement intervention. All CINI youth will receive TAU, regardless of condition.
48639007|NCT05979272|BEHAVIORAL|Teen Empowerment through Computerized Health (TECH) app|An adjunct smartphone app (i.e., TECH) developed to support TAU. All participants randomly assigned to TAU+TECH will receive the TECH app.
48639008|NCT06383052|DRUG|177Lu-NYM032 injection|Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose.
48639009|NCT05698563|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scan with contrast of the foot or feet
48639010|NCT05698563|DIAGNOSTIC_TEST|Ultrasound|Ultrasound scan of the feet
48109233|NCT00534937|PROCEDURE|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
48639011|NCT05698563|DRUG|Corticosteroid injection|Administered ultrasound guided to patients with intermetatarsal bursitis
48109234|NCT00534937|PROCEDURE|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
48639012|NCT05698563|OTHER|Clinical foot evaluation|An examination of the feet
48639013|NCT05698563|OTHER|Picture of the feet|To evaluate the presence of V-sign/spreading toes
48639014|NCT06000904|OTHER|Exergame-based balance training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute balance exercise, and 15-minute ground walking as a cool-down.
48639015|NCT06000904|OTHER|Upper limb and trunk training|For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute upper-limb and trunk exercise, and 15-minute ground walking as a cool-down.
48109235|NCT04637152|DRUG|Sacubitril-Valsartan|Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
47954588|NCT06266689|BEHAVIORAL|Personalized Diet Information|These participants will receive a report detailing their genomic food data based on the investigators' DNA metabarcoding technique in addition to standard dietary guidance to see if receiving the report modifies what they choose to feed their infant.
48109236|NCT04658212|PROCEDURE|3D LCBDE|three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
48109237|NCT04658212|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
48109238|NCT02221219|DRUG|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
48639016|NCT04128215|BEHAVIORAL|Control Period|Participants completed an 8-week control period of normal lifestyle.
47954589|NCT05856188|DIETARY_SUPPLEMENT|Glutamine|Biologic
47954590|NCT00395733|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
47954591|NCT00395733|DRUG|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
47954592|NCT05024604|DRUG|Progesterone Only Product in Oral Dose Form|mini pills as a contraceptive method
47954593|NCT05024604|OTHER|office hysterscopy|office hysteroscoy
47954594|NCT05746494|DEVICE|tDCS|active anodal tDCS and sham tDCS
48639017|NCT04128215|BEHAVIORAL|Exercise Period|Participants completed an 8-week exercise intervention period of remotely supervised home-based non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT consisted of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax were included.
48639018|NCT01972919|RADIATION|Radiation Therapy|Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.
47954595|NCT01068834|GENETIC|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
48639019|NCT01972919|DRUG|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
47954596|NCT00227006|BEHAVIORAL|Behavioral lifestyle/weight-loss intervention|
47954597|NCT01234831|DEVICE|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
47954598|NCT01234831|OTHER|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
47954599|NCT05712434|OTHER|Long Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 2 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 6-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
48109239|NCT02221219|PROCEDURE|delay in umbilical cord clamp at birth|provision of a \~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
47954600|NCT05712434|OTHER|Mid-length Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 4 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 4-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
48109240|NCT02221219|DRUG|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
48109241|NCT02221219|PROCEDURE|immediate cord clamp at birth|no delay in umbilical cord clamp; \<10sec (recorded in delivery note)
48109242|NCT03008499|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
48109243|NCT03988504|DIAGNOSTIC_TEST|Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing
48109244|NCT02785380|PROCEDURE|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
48109245|NCT02785380|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
48109246|NCT05664880|DRUG|Paricalcitol|2 MCG Oral Capsule
48109247|NCT05664880|DRUG|Placebo|Matching capsule to 2 MCG Paricalcitol Oral Capsule
48109248|NCT00074633|BEHAVIORAL|Health at Every Size (HAES)|
48109249|NCT00074633|BEHAVIORAL|Diet (Traditional, moderate energy restriction)|
48109250|NCT04421391|DIETARY_SUPPLEMENT|QuadraMune(TM)|QuadraMune(TM) is a commercially available nutritional supplement
48109251|NCT02897622|OTHER|Case management|Case management by Eira unit
48301731|NCT06056739|DEVICE|Alio platform|Remote monitoring platform
48301732|NCT05807022|PROCEDURE|Percutaneous or transbronchial argon-helium cryoablation|The participants would undergo Percutaneous or transbronchial argon-helium cryoablation.
48639020|NCT03227627|DEVICE|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
48639021|NCT03227627|OTHER|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
48639022|NCT00004163|DRUG|Trastuzumab|
48639023|NCT05914649|OTHER|IV normal saline (999 mL infusion)|999 mL of IV normal saline will be infused intravenously
48639024|NCT05914649|OTHER|IV normal saline (50 mL infusion)|50 mL of IV normal saline will be infused intravenously as a placebo control.
48639025|NCT03047213|DRUG|Sapanisertib|Given PO
47954601|NCT05712434|OTHER|Short Intervention|Each unit will start with iodine protocol, which uses 10% povidone-iodine for disinfection during Foley insertion, for 6 months. After the designated duration of protocol (determined by the results of randomization), each unit will than switched to CHG protocol for 4 months, in which 2% aqueous chlorhexidine solution are used instead of iodine solution. Subsequently, in the final 2-month phase of study, each unit will than switched to CHG plus protocol, in which 0.05% CHG impregnated gel will be used alongside 2% CHG solution during Foley insertion.
47954602|NCT02606084|DRUG|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
47954603|NCT02697487|OTHER|No treatment|This is an observational study with no intervention.
47954604|NCT00864721|DRUG|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
48639026|NCT04065854|BEHAVIORAL|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
48639027|NCT05793125|DEVICE|Ultrasonography|"A full obstetrics ultrasound scan will be performed within 24 hours before delivery to document fetal biometry, estimated fetal weight and correlate it to fetal growth charts to exclude IUGR, amniotic fluid index and umbilical artery Doppler studies.~Fetal echocardiography will be done.Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time (At/Et) ratio will be measured in the main pulmonary artery."
48639028|NCT05877365|DIETARY_SUPPLEMENT|Standard Process 21-Day Purification Program|Purification, also known as detoxification, may help remove natural toxins from the body, while maintaining a healthy weight. The toxin load humans are exposed to daily may take a toll on physical and emotional well-being. Internally, human bodies produce waste byproducts because of normal metabolic function. Although the body is designed to rid itself of these toxins naturally, it can become overburdened. Purification may offer the body additional support to expel these toxins and manage weight, which is important to maintaining health and vitality.
47954605|NCT04635228|DEVICE|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
47954606|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-A）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
47954607|NCT05806086|DRUG|Panfoshu+Conventional Treatment（program-B）|On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
47954608|NCT05806086|OTHER|Conventional Treatment|Patients in this group were treated with only the conventional treatment.
47954609|NCT02053870|OTHER|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
48301733|NCT04241237|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
48639029|NCT06045689|DRUG|Luspatercept|Specified dose on specified days.
48639030|NCT06343883|DEVICE|low-intensity focused ultrasound - low pressure|low-intensity focused ultrasound applied to the S1.
47954610|NCT02053870|DRUG|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
47954611|NCT06309186|OTHER|Evaluation of midwifes' burnout|Burnout evaluated by questionnaires
47954612|NCT05556330|PROCEDURE|computer guided autogenous cortical shell technique|computer guided autogenous cortical shell technique
48301734|NCT05254522|OTHER|not aplicable since it is a Registry|not aplicable since it is a registry
48639031|NCT06343883|DEVICE|low-intensity focused ultrasound - medium pressure|low-intensity focused ultrasound applied to the S1.
47954613|NCT00532324|OTHER|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
47954614|NCT00092573|DRUG|MK0653, ezetimibe|
47954615|NCT00092573|DRUG|Comparator: fenofibrate monotherapy|
47954616|NCT00144131|DRUG|Aranesp®|
47954617|NCT04239053|DRUG|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
47954618|NCT01389271|DRUG|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
47954619|NCT06301217|OTHER|There is no intervention|There is no intervention
48301735|NCT01225783|OTHER|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
48301736|NCT04303585|PROCEDURE|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
48301737|NCT04303585|PROCEDURE|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
48301738|NCT01947374|PROCEDURE|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
48301739|NCT01947374|PROCEDURE|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
48301740|NCT06182033|BEHAVIORAL|Peer-mediated pivotal response training|Teachers support children in the implementation of three strategies directed toward a target child identified as having language impairment and as isolated from the classroom social network.
48301741|NCT01084499|DRUG|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
48301742|NCT01084499|DRUG|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
48301743|NCT01084499|DRUG|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
48301744|NCT01084499|DRUG|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
48301745|NCT04990245|DIAGNOSTIC_TEST|endoscopic biopsies|patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
48301746|NCT00247910|DRUG|Hydrochlorothiazide|Not recorded in detailed description.
48301747|NCT04048967|BEHAVIORAL|Professional development|professional development of preschool staff
48639032|NCT06343883|DEVICE|low-intensity focused ultrasound - high pressure|low-intensity focused ultrasound applied to the S1.
48639033|NCT01708954|DRUG|Cabozantinib S-malate|Given PO
48639034|NCT01708954|DRUG|Erlotinib Hydrochloride|Given PO
48639035|NCT01708954|OTHER|Laboratory Biomarker Analysis|Correlative studies
48639036|NCT06084052|DEVICE|Path Active|Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). All participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.
47954620|NCT00062946|DRUG|(18F)fallypride|
47954621|NCT00418639|DRUG|Nitazoxanide|
47954622|NCT05312372|DRUG|Combination (S095033 + paclitaxel)|"Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)"
47954623|NCT00934479|DRUG|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
47954624|NCT05859685|OTHER|Experimental|"Manual therapy techniques:~* Talar dorsal sliding technique. Dorsal mobilization of the talus, with the patient in the supine position and ankle dorsiflexion, without pain or discomfort. The physiotherapist will exercise an anteroposterior mobilization of the talus, with a dorsal glide~* Mulligan movement mobilization technique: The patient will be in a standing position, with the ankle to be treated forward. You will be given an aid or support in the upper extremity to maintain stability."
47954625|NCT05859685|OTHER|Control|The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and times of administration will be the same
48109252|NCT04876573|DRUG|Cyproheptadine Hydrochloride 4 MG|"Phase 1: Cyproheptadine 4 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~Phase 2: Cyproheptadine 8 mg three time a day for 10 days, per oral administration associated to Standard care of COVID 19 patient currently recommend by WHO~The dose will be adjusted according to the renal function."
48109253|NCT06351787|BEHAVIORAL|Resting and movement-based focused awareness meditations|Resting and movement-based focused awareness meditations
47954626|NCT01681940|DRUG|Lamazym|ERT, i.v. infusions weekly
48109254|NCT06419933|OTHER|The SuperKids Program|The SuperKids program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment
48109255|NCT02422095|PROCEDURE|Endoscopy-based (EUS-guided) interventions for pancreatic fluid collections|Data included are patient demographics, symptoms, disease severity, procedural indications, details of the pancreatic fluid collection on cross-sectional imaging/EUS, review of laboratory results/imaging, details of interventions, clinical response to intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, response to treatment including any recurrent hospital admissions, recurrence of pancreatic fluid collections, need for repeat interventions, details of pancreatic duct integrity (e.g. presence of disconnected pancreatic duct syndrome), and clinical status at follow-up.
48109256|NCT02422095|PROCEDURE|EUS of pancreatic cysts|Data included are patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, cyst features on EUS, technical details of EUS-guided sampling, results of cyst fluid analysis, final diagnosis, any follow up and repeat examinations and details of any treatment performed.
48301748|NCT02645448|OTHER|Resistance Exercise|"Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect"
48301749|NCT02126644|DRUG|70% glycolic acid|
48301750|NCT01105403|DRUG|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
48301751|NCT06510296|BEHAVIORAL|Digital Mind Body Intervention mobile application|A DMBI mobile application with psychoeducation and skill-building in illness perception, coping, mindfulness, and disease acceptance informed by needs/barriers of Black and Hispanic patients with IBD who have elevated psychological distress and GI professionals caring for IBD patients.
48301752|NCT03177135|DEVICE|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
47954627|NCT05175508|DRUG|Azacitidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
48639037|NCT06084052|OTHER|Control Group|Control Group will receive care as usual.
48639038|NCT01272622|RADIATION|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
48639039|NCT01272622|OTHER|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
48639040|NCT06283667|DRUG|Semaglutide|Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
48639041|NCT05918302|DRUG|177Lu-edotreotide|6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
48639042|NCT05918302|DRUG|Everolimus|10 mg orally once daily (QD)
47954628|NCT05175508|DRUG|all trans retinoic acid|ATRA 20mg tid by po on days 1-21 of every cycle 28 days
47954629|NCT05371730|DRUG|NCR300|Intravenous infusion of NK cells（NCR300）
47954630|NCT02947555|OTHER|Non interventional|
48109257|NCT05393336|OTHER|V-sitting posture stabilization|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the V-sitting exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
48301753|NCT04318743|DRUG|Glepaglutide|GLP-2
48301754|NCT03907735|OTHER|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
48639043|NCT05737693|DRUG|Ketamine|Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
48639044|NCT05737693|DRUG|Midazolam|Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
48639045|NCT05503732|OTHER|Energy Drink|Two 16-oz energy drinks consumed orally to be finished approximately 4 hours prior to bed
48639046|NCT05503732|OTHER|Placebo Drink|Two 16-oz identical looking placebo drink without caffeine consumed orally to be finished approximately 4 hours prior to bed
48639047|NCT04560296|BEHAVIORAL|Community-based E-Health Program|Community-based E-Health Program will be developed to engage and empower older adults to manage the chronic conditions effectively.
48639048|NCT04560296|BEHAVIORAL|usual self-management and follow up with doctors/nurse|usual self-management and follow up with doctors/nurse as planned in the community nurse post.
48639049|NCT06399471|DEVICE|Microprocessor prosthetic knee|Microprocessor prosthetic knees for use in a transfemoral prosthesis
48639050|NCT03997734|DRUG|AB001|single and repeated dosing
48639051|NCT03997734|DRUG|oral capsule|single dose
48639052|NCT03997734|DRUG|positive comparative patch|single and repeated dosing
47954631|NCT00076206|DRUG|CCI-779|
47954632|NCT00076206|DRUG|Placebo|
47954633|NCT04558580|DRUG|Rufinamide|Rufinamide
48109258|NCT05393336|OTHER|Modified clamshell exercises|15 patients will be given a hot pack with TENS for 15 minutes. Followed by static stretching of the gluteus, hamstrings, and Iliopsoas muscles for 10 to 30 seconds hold and 2 to 4 repetitions. Then the patient will perform the modified clamshell exercise for 10 seconds starting with 5 repetitions and progressing to 15 overtime. Each patient will receive treatment for 6 days per week and 6 weeks.
48301755|NCT04459299|DEVICE|Robotic-PCI (CorPath GRX System)|Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
48639053|NCT03997734|DRUG|Placebos|single and repeated dosing
48639054|NCT03824054|PROCEDURE|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
48639055|NCT05660980|DRUG|Once daily CAB tablet + RPV tablet|Tablet
48639056|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
48639057|NCT05660980|DRUG|Long acting CAB injectable + long acting RPV injectable|Injectable
48639058|NCT05638139|BIOLOGICAL|SygeLIX-F + SygeLIX-G|SygeLIX-F (plug) is inserted through the internal orifice while cryptoglandular space is filled by SygeLIX-G (gel).
48639059|NCT05561140|DRUG|Voxelotor Oral Tablet|Synthetic small molecule supplied as 500 mg tablets, administered Orally
48639060|NCT05561140|OTHER|Placebo|Placebo
47954634|NCT01868503|DRUG|lapatinib ditosylate|Given PO
47954635|NCT01868503|RADIATION|radiation therapy|Undergo radiation therapy
47954636|NCT01868503|OTHER|laboratory biomarker analysis|Correlative studies
47954637|NCT06022250|DRUG|JS207|Patients will receive specific dose of JS207 via intravenous infusion.
47954638|NCT00408538|DRUG|UC-781 microbicide gel (0.1% and 0.25%)|
47954639|NCT00408538|DRUG|placebo|
47954640|NCT05687175|OTHER|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
47954641|NCT01724931|DRUG|LD-aminopterin|
47954642|NCT01724931|DRUG|placebo|
47954643|NCT03855228|DRUG|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
47954644|NCT03855228|DRUG|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
47954645|NCT03855228|DRUG|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
47954646|NCT03855228|DRUG|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
47954647|NCT04435587|DRUG|Ivermectin Pill|3 days of once daily oral ivermectin 600mcg/kg/d
47954648|NCT04435587|DRUG|Combined ART/hydroxychloroquine|"1. Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~2. Darunavir/ritonavir (400/100mg) q 12 hours for 5 days"
47954649|NCT01206166|DRUG|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
47954650|NCT04359667|DRUG|Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]|1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
48639061|NCT05679401|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
48639062|NCT05679401|PROCEDURE|Plasma exchange (PLEX)|PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
48639063|NCT05679401|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
48639064|NCT05679401|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
48639065|NCT06101329|DRUG|Lenacapavir Tablet|Tablets administered orally without regard of food
48639066|NCT06101329|DRUG|Lenacapavir Injection|Injection administered subcutaneously
48639067|NCT06101329|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)|200/300mg fixed dose combination (FDC) tablets administered orally
47954651|NCT01872221|PROCEDURE|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
47954652|NCT02938429|OTHER|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
48639068|NCT05571163|DRUG|AMG 510|Tablets
48639069|NCT03752073|DEVICE|Trans-cervical cervical balloon|Insertion of Foley Catheter
47954653|NCT04945512|PROCEDURE|Epidural Analgesia|In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
47954654|NCT06208865|PROCEDURE|lumbar erector spinae plane block|All procedures were performed under ultrasound (US) guidance. The patient was monitored in the operating room and placed in the prone position under a sterile drape. A 2-6 MHz convex US probe was used during the procedure. The transverse processes of the lumbar vertebrae were visualized and then a 22 gauge spinal needle was advanced to the transverse process of the L3 vertebra. After contacting the transverse process, a total of 15 mL of drug consisting of 2 mL of methylprednisolone and 6 mL of 0.025% bupivacaine was injected into this area, and the spread of the drug in the craniocaudal area was visualized. The patients were followed up for possible complications after the procedure.
47954655|NCT01469312|OTHER|modified pasta|50 grams carbohydrate as a single breakfast meal
47954656|NCT05834569|DRUG|Acetaminophen and Ibuprofen|Patients in the Maxigesic group will be administered a total of 5 doses of the drug (20mg/kg, maximum dose per serving: 1g) every 6 h from immediately after anesthetic induction.
48109259|NCT06041893|DRUG|ATG-LDPTCy|antithymocyte globulin with low dose post-transplant cyclophosphamide
48109260|NCT02886793|DRUG|fludeoxyglucose|
48109261|NCT06131047|OTHER|High intensity Traditional Resistance Traning without Blood Flow Restriction|Group A will undergo Traditional Resistance training without blood flow Restriction. A 30-minute progressive, weight training program will be initiated 8 weeks after the ACL-reconstruction and will be conducted subsequent to the individual based program. The resistance (training loads) will be increased when the individual could do more repetitions than the number specified in the weight training protocol. The exercises will be performed at a slow speed to ensure full control of the movement
48109262|NCT06131047|OTHER|High intensity Traditional Resistance Traning with Blood Flow Restriction|Group B will recieve low-load blood flow restriction (LL-BFR) training using external loads of 20-40% 1RM has been suggested as an alternative to traditional strength rehabilitation. Minimum of 2 -3 sets and maximum total 5 sets,20-30 repetitions of each exercise with 30 to 60 seconds rest period and 2-3 times per weekly for 4-6 weeks to During LL-BFR training, a pressurized cuff is applied to the proximal thigh that oc¬cludes venous outflow while maintaining arterial in¬flow. The combination of venous occlusion and resis¬tance training is believed to induce muscle hypertrophy secondary to elevated systematic hormone production, cell swelling, production of reactive oxygen species, intramus¬cular anabolic signaling and fast-twitch fiber recruit¬ment
48109263|NCT02709863|DRUG|Sevoflurane|1-1.5 MAC, inhalation route, during operation
48109264|NCT02709863|DRUG|Desflurane|1-1.5 MAC, inhalation route, during operation
48109265|NCT02709863|DRUG|Propofol|6-10 mg/kg/h, iv infusion, during operation
48109266|NCT06015581|BEHAVIORAL|Workforce Development: Tailored Motivational Interviewing and Technical Assistance|TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.
48109267|NCT06015581|BEHAVIORAL|Quality Management, Mystery Shopper Feedback|Mystery shoppers visit each agency two times per quarter to systematically examine testing clinics' environmental characteristics and their experiences with clinic staff (e.g., quality of testing session, safer sex discussions, perceived provider competency, PrEP discussions and referral). The investigator team meets with each agency once per quarter to review the data and provide technical assistance.
47954657|NCT05834569|DRUG|Normal saline|Patients in the control group will be administered equal amounts of normal saline at the same time points.
47954658|NCT01126970|DRUG|Velneperit 400 mg|Velneperit 400 mg q.d.
47954659|NCT01126970|DRUG|Orlistat 120 mg|Orlistat 120 mg t.i.d
47954660|NCT01126970|DRUG|Orlistat Placebo|Orlistat Placebo t.i.d.
47954661|NCT01126970|DRUG|Velneperit Placebo|Velneperit Placebo q.d
48109268|NCT05998525|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria and after catheterization will be randomized to receive Dapagliflozin 10 mg every 24 hours and upon dischargetreatment will continue for 12 months
48109269|NCT05998525|DRUG|Placebo|patients who meet the inclusion criteria and after catheterization will be randomized to receive a placebo pill 24 hours and upon discharge treatment will continue for 12 months
48109270|NCT03015974|DRUG|Corticosteroid|
48109271|NCT03015974|DRUG|Cyclophosphamide|
48109272|NCT03015974|DRUG|Mycophenolate mofetil|
48109273|NCT03015974|DRUG|Dipyridamole|
48109274|NCT03015974|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|
48639070|NCT03752073|DEVICE|Hygroscopic cervical dilator|Insertion of Dilapan-s
48639071|NCT05868954|BEHAVIORAL|MedDiet Program|Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.
47954662|NCT01126970|OTHER|Reduced Calorie Diet|Reduced calorie diet
47954663|NCT00216476|DRUG|Aripiprazole|10-30 mg oral once daily for 104 weeks
47954664|NCT00216476|DRUG|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
47954665|NCT00216476|DRUG|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
47954666|NCT04784039|DIAGNOSTIC_TEST|Transesophageal echocardiography|Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE
47954667|NCT04784039|DIAGNOSTIC_TEST|D-Dimer analysis|Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
47954668|NCT04184544|OTHER|Improving of quality of care at health facility and outreach level|Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
47954669|NCT05356078|DRUG|Antidepressant|"Delirium event reported in the World Health Organization global database in subjects aged over 65 years taking antidepressants, comparative analysis by antidepressant class"
47954670|NCT04765982|DIAGNOSTIC_TEST|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
47954671|NCT02882412|OTHER|observational|
47954672|NCT00819299|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
47954673|NCT01565720|DRUG|Isavuconazole|oral
47954674|NCT01565720|DRUG|Placebo|oral
47954675|NCT01565720|DRUG|Moxifloxacin|oral
47954676|NCT05432375|DRUG|Tinostamustine|infusion given over 60 minutes
47954677|NCT05842733|DRUG|Naldebain|Oral Placebo A 650 mg + Naldebain 37.5 mg (0.5 mL oil solution) + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
47954678|NCT05842733|DRUG|SafeTynadol|Oral SafeTynadol 650 mg + Placebo B (0.5 mL oil solution) +Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
47954679|NCT05842733|DRUG|Naldebain + SafeTynadol|Oral Naldebain 37.5 mg (0.5 mL oil solution) + SafeTynadol 650 mg + Tween 20 and PEG 400 (1 capsule), multiple doses for 3 days. Dosing at 0（2 ± 2 hour after surgery）, 6 ± 2, 14 ± 2, 22 ± 2, 34 ± 2, 46 ± 2, 58 ± 2 and 70 ± 2 hours after the first dose.
47954680|NCT01770496|BEHAVIORAL|Childhood vaccination reminder / recall notification|
47954681|NCT01484275|DRUG|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
47954682|NCT01484275|DRUG|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
47954683|NCT03519971|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
47954684|NCT03519971|OTHER|Placebo|Placebo IV (intravenous infusion)
47954685|NCT03519971|DRUG|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
47954686|NCT03519971|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
47954687|NCT03519971|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
47954688|NCT03519971|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
47954689|NCT03519971|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
47954690|NCT03117920|DRUG|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
47954691|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
47954692|NCT01604915|PROCEDURE|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
48109275|NCT01437358|OTHER|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
48109276|NCT04176367|DRUG|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
48109277|NCT04176367|DRUG|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
48301756|NCT00235729|DRUG|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
48301757|NCT00235729|DRUG|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
47954693|NCT03722069|OTHER|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
47954694|NCT03722069|OTHER|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
47954695|NCT05882357|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
47954696|NCT05882357|DRUG|IVA|Granules for oral administration
47954697|NCT01031381|DRUG|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
47954698|NCT01031381|DRUG|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
48301758|NCT06532461|DEVICE|Mio Advanced infusions set|Insulin infusionsset fitting Medtronic 780 G insulin pump
47954699|NCT05198583|OTHER|E-Fit|The intervention lasts a total of 8 weeks and is structured in 3 modules. The first module consists of a weekly strategy training in which problems resulting from executive dysfunction are addressed. Online games form the second module. These are games implemented online to promote EF through play. The third module is also based on games: The families receive several board games to play together at home. This third module is voluntary.
47954700|NCT00446056|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
47954701|NCT00446056|DRUG|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
47954702|NCT05943028|DRUG|Subanesthetic dose of esketamine|Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
47954703|NCT05890950|DRUG|K-757 and K-833|Both administered orally
47954704|NCT05890950|DRUG|Matching placebo to K-757 and K-833|Both administered orally
47954705|NCT05228860|BEHAVIORAL|Vida Sana (a Group Lifestyle Intervention)|"Vida Sana is a Group Lifestyle intervention that has been shown to be effective among patients with type 2 diabetes (T2DM). Vida Sana includes 23 group sessions with a trained health coach:~* Months 1-4: 1 family-wide orientation + 12 weekly sessions~* Months 5-6: 4 bimonthly group sessions~* Months 7-12: 6 monthly group sessions~All regular primary care and diabetes care will remain as usual."
47954706|NCT05228860|BEHAVIORAL|Supplemental Healthy Food Deliveries|"Participants will receive 12 weeks of weekly food deliveries from Dig Deep Farms.~Each delivery will include a selection of seasonal fresh vegetables and a rotation of either a whole grain or a whole-grain food (3+ grams of fiber/serving). Whole grains will include brown rice, oatmeal, barley, quinoa; whole grain foods will include cereal, pasta, tortillas, bread, crackers. Delivery sizes will be scaled to the three corresponding household sizes: 2-3 people; 4-5 people; or 6 or more people.~Food will be delivered by Dig Deep Farms, which already has an established food subscription delivery system.~(Control group participants will receive the same delivery schedule, but delayed to begin 6 months after their study enrollment.)"
47954707|NCT04395404|DIAGNOSTIC_TEST|MRI|Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
47954708|NCT04954287|BIOLOGICAL|CVXGA1 low dose|see arm/group description
47954709|NCT04954287|BIOLOGICAL|CVXGA1 high dose|see arm/group description
47954710|NCT05773443|DEVICE|Digital biomarkers|Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
47954711|NCT05224089|DRUG|Liposomal Bupivicaine/Bupivacaine Admixture|60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL
47954712|NCT05224089|DRUG|Bupivacaine HCL|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
47954713|NCT02431338|PROCEDURE|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
47954714|NCT03611491|DEVICE|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
47954715|NCT04064957|BIOLOGICAL|HB-adMSCs|
47980574|NCT01735513|DEVICE|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
48301759|NCT06532461|DRUG|Novorapid|Randomized to either Novorapid or Humalog
48301760|NCT06532461|DEVICE|Extended wear insulin infusion (EWIS)|Insulin infusionsset fitting Medtronic 780 G insulin pump
48301761|NCT06532461|DRUG|Humalog|Randomized to either Novorapid or Humalog
48301762|NCT00493116|DRUG|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
48301763|NCT00493116|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
48301764|NCT02963077|DRUG|A4250|
48301765|NCT02963077|DRUG|CRC (A3384)|
48301766|NCT02963077|DRUG|Questran|
48301767|NCT02963077|DRUG|Placebo|
48301768|NCT02592304|DEVICE|Dual energy computed tomography|one extra scanning with a dual energy ct.
48301769|NCT01444521|DRUG|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
48339900|NCT00004467|DRUG|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
48339901|NCT00004467|DRUG|Placebo|Infusion of 5% dextrose
48339902|NCT02667028|PROCEDURE|PCI|percutaneous coronary intervention
48339903|NCT00113412|DRUG|SP01A|
48339904|NCT04326881|DRUG|SHR-1314|single dosing
47954716|NCT04852770|BEHAVIORAL|Trial-Based Cognitive Therapy|TBCT is an approach that includes psychoeducation and cognitive restructuring techniques concerning automatic thoughts, underlying assumptions and core beliefs related to the traumatic events. It is conducted in a therapeutic setting that makes use of experiential techniques, allowing the patient to refer to him/herself in the third person and thus taking distance from him or herself. One of TBCT techniques for dealing with guilt and shame, emotions that provoke great limitation to patients with PTSD, is the participation grid (PG). Another important technique is the consensual role-play (CRP), designed to help patients resolve ambivalence and make decisions. In addition, the most important TBCT technique, the Trial, was developed to help patients change dysfunctional negative core beliefs. Therapists who will conduct this approach have a specialization level in CBT. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
47954717|NCT04852770|BEHAVIORAL|Mindfulness-Based Health Promotion|"The MBHP protocol is a structured program developed over 8 sessions, in group, where participants (8-15 people) meet every week for 2 hours (standard duration of one session), to experience the concepts and techniques of mindfulness. Participants are also given suggestions of daily activities to be implemented at home or in the workplace, that last in average 15-20 minutes, but may last up to 45 minutes in the case of more motivated and compliant participants. They are also encouraged to incorporate the idea of Mindfulness in their daily lives (the so-called informal practice), so that all daily activities somehow become opportunities to practice Mindfulness. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line."
47954718|NCT04852770|BEHAVIORAL|Positive psychotherapy|PPT is the clinical and therapeutic work derived from PP. PPT consists of 15 specific practices that have been empirically validated, either separately, or in conjunction with two or three practices. After empirical validation, these practices were organized in a cohesive protocol of 15 sessions called PPT. Many of these practices have been studied through online interventions. In the present study, the protocol will be reduced to 14 sessions, with sessions called positive relationships, positive communication, and practical wisdom removed. It was understood that the other 12 would be more easily adapted to the moment of the study. (DUCKWORTH; STEEN; SELIGMAN, 2005; MONGRAIN; ANSELMO-MATTHEWS, 2012; RASHID; SELIGMAN, 2019). In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
47954719|NCT01252147|OTHER|No treatment|No treatment (intervention) will be provided in this study
47954720|NCT06050369|DEVICE|EEG|Recording, from the scalp, the electrophysiological activity of the brain.
47954721|NCT06050369|DEVICE|MRI|Get the anatomical shape of the brain.
47954722|NCT02106975|DRUG|Ascorbic Acid|Intervention
47954723|NCT02106975|DRUG|Placebo: 5% Dextrose in water|Placebo
47954724|NCT03921073|DRUG|T-VEC|Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
47954725|NCT01570556|OTHER|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
47954726|NCT02325986|DRUG|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
47954727|NCT02325986|DRUG|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
47954728|NCT02325986|RADIATION|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
47954729|NCT03638622|COMBINATION_PRODUCT|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
47954730|NCT06051422|DEVICE|three dimensional formetric system|A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner.
47954731|NCT03656770|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
47954732|NCT00590135|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
48301770|NCT06191276|BEHAVIORAL|STEP@Home Intervention|STEP@Home is a multi-component exercise program designed for prefrail older adults that incorporates active strategies to promote long-term engagement. The optimal level of training is 45-60 minutes of exercise three times per week for at least 20 weeks. For prefrailty management, emphasis is placed on balancing and resistance training (around 15-20 min each) to improve muscle strength and gross mobility and prevent falls. Aerobic and flexibility exercises (10 min each) are also included to improve fitness and walking pace. Sixteen training tasks, including but not limited to those recommended by Vivifrail, for each exercise component (namely, resistance, balance, flexibility and aerobic training) will be adopted. A training manual with step-by-step illustrations of each task in pictures and text will be provided to the subjects, together with a set of simple, easy-to-access equipment (water bottle, elastic band and weight-bearing belt) to support task fulfilment.
48301771|NCT06191276|BEHAVIORAL|Usual care|Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
47954733|NCT01585870|DRUG|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
47954734|NCT01585870|DRUG|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
47954735|NCT01781364|BEHAVIORAL|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
47954736|NCT00092807|DRUG|MK0653, ezetimibe|
47954737|NCT00092807|DRUG|Comparator: placebo|
47954738|NCT05767125|DEVICE|APRV|Patients with moderate-to-severe ARDS were supported with APRV.
47954739|NCT05767125|DEVICE|LTV|Patients with moderate-to-severe ARDS were supported with LTV.
47954740|NCT02760797|DRUG|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
47954741|NCT02760797|DRUG|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
47954742|NCT05487352|OTHER|hyperglycemia exposure in the first trimester|The exposure means the hyperglycemia identified by the 75g oral glucose tolerance test before the 14 weeks of gestation
47954743|NCT02883959|OTHER|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
47954744|NCT06057077|DRUG|Semaglutide weekly injection|semaglutide is Glp1 AGONIST WHICH IS NEW CHALLENGE IN DIABETES DISEASE TREATMENT EITHER TYPE 2 AND IS APPROVED BY FDA FOE children aged above 12 years at obesity
47954745|NCT00366977|BEHAVIORAL|Multi-session telephone counseling|
48109278|NCT06264648|OTHER|Pressure sensitivity education|Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurement, the value shown on the scale was recorded without being shown to the participant.After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain this pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
48109279|NCT02462551|DEVICE|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
48109280|NCT00845832|DRUG|Placebo|iv on days 1 and 15 (Parts 1 and 2)
48109281|NCT00845832|DRUG|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
48109282|NCT00845832|DRUG|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
48109283|NCT04219137|GENETIC|Molecular Profiling|This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
48109284|NCT02253719|PROCEDURE|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
48109285|NCT02928757|OTHER|Complex care clinic as part of the CCKO initiative|"The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families."
48109286|NCT05505279|DEVICE|THRIVE (High Flow Nasal Cannula)|2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
47954746|NCT00366977|DRUG|NRT patches|
48109287|NCT04599582|DEVICE|Hip Arthroplasty|Patients are operated with hip replacement.
48109288|NCT05266599|OTHER|MTA Fillapex root canal sealer|Root canal treatments were performed with MTA Fillapex
48109289|NCT05266599|OTHER|AH Plus root canal sealer|Root canal treatments were performed with AH plus
48301772|NCT02967120|OTHER|no intervention|
48301773|NCT03974646|BEHAVIORAL|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
48339905|NCT06090929|DEVICE|STN-DBS|STN-DBS was implanted according normal process
47954747|NCT03901885|OTHER|Female Sexual Function Index questionnaire|Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
47954748|NCT04930822|OTHER|Table Top Visual Intervention|Table top visual interventions and exercises.
47954749|NCT04930822|DEVICE|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
47954750|NCT05489757|DEVICE|SPY Portable Handheld Imaging (SPY-PHI) System with SPY-QP Software|Perfusion assessment with SPY Q-ICG system
47954751|NCT01595035|BEHAVIORAL|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
47954752|NCT06340516|DIAGNOSTIC_TEST|Plasma NT-proBNP|Replacement of measurement of plasma NT-proBNP instead of ECHO/MUGA at 6 months and 12 months of trastuzumab treatment to assess cardiotoxicity
47954753|NCT05490303|OTHER|recording of the probe position|For each patient, a cardiac ultrasound acquisition will be performed with an optical tracking system (infrared) recording the probe's position in real time.
47954754|NCT03529331|DRUG|Morphine Sulfate Immediate Release|15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
47954755|NCT03529331|DRUG|Oxycodone/Acetaminophen|5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
47954756|NCT03529331|DRUG|Hydrocodone/Acetaminophen|5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
47954757|NCT01522248|BIOLOGICAL|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
47954758|NCT02597231|DIETARY_SUPPLEMENT|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
47954759|NCT02597231|OTHER|Placebo|Patients in this group will receive a matching placebo pill.
47954760|NCT01786655|DRUG|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
47954761|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
47954762|NCT01786655|DRUG|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
47954763|NCT01786655|OTHER|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
47954764|NCT05768074|OTHER|Qualitative Interview|Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
47954765|NCT02058693|DRUG|mixed salts amphetamine|adjunctive to ADT
47954766|NCT00562835|DRUG|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14\*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21\*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25\*‡ 0.25 mg/kg/day; Days 26 to 28\*‡ 0.125 mg/kg/day~\*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
48639072|NCT05868954|BEHAVIORAL|ACOG-based Dietary Program|Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
48639073|NCT01835431|DRUG|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
48639074|NCT01835431|DRUG|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
48639075|NCT01835431|DRUG|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
48639076|NCT01835431|DRUG|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
48109290|NCT03349736|OTHER|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
48639077|NCT06429124|BEHAVIORAL|Dietary Intervention|Participants will be instructed to follow a 16/8 regimen characterized by 16 hours of fasting and an 8-hour eating window daily, on approximately 5 days/week, for 3 months. Previous research has shown that 16 hours of fasting is feasible, safe and well-tolerated among older adults, and that most persons report easy adjustment (Anton, Lee et al. 2019, Lee, Sypniewski et al. 2020). The intervention will be implemented through individual and group sessions with participants and will involve extensive education, coaching, guidance, and support throughout the 3-month intervention. Educational materials on lifestyle factors including physical activity will be provided to each participant. We will be also be collecting data on physical activity and sedentary behavior. These data will be co-variates when we conduct the statistical analysis.
48639078|NCT00122863|DRUG|Duloxetine Hydrochloride|
47954767|NCT00562835|OTHER|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc \[prednisolone + diluting fluid\], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
48109291|NCT03035045|DRUG|Paracetamol|
48109292|NCT03035045|DRUG|Placebo Oral Tablet|
47954768|NCT00066352|DRUG|bortezomib|
48109293|NCT01376336|DEVICE|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
48301774|NCT04864535|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
48301775|NCT01729598|DRUG|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
48639079|NCT00122863|DRUG|placebo|
48639080|NCT02289014|OTHER|online stress Management program|Active treatment group
47954769|NCT03948243|DIETARY_SUPPLEMENT|Licorice|Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
47954770|NCT03948243|DRUG|Alprazolam 2 MG|probe substrate
47954771|NCT03948243|DRUG|Caffeine 100 MG|probe substrate
47954772|NCT03948243|DRUG|Tolbutamide 250 mg|probe substrate
47954773|NCT03948243|DRUG|Dextromethorphan 30mg|probe substrate
47954774|NCT04978597|DRUG|Opicapone 50 mg|Capsule, 50 mg, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
47954775|NCT04978597|DRUG|Placebo|Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
47954776|NCT00179543|BEHAVIORAL|Relaxation response|
48301776|NCT01729598|DRUG|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
48480299|NCT06260020|BEHAVIORAL|Comprehensive module for management of sleep disorders[Behavioral and pharmacological therapy]|"Development of module by Delphi method:components of Module include Behavioural intervention Modifying stimulus by change in location,using bedtime stories. Giving schedules to activities which interfere with sleep before bedtime. Using a bedtime pass to allow child to make a prefixed number of requests for parental attention while in bed.~Giving sleep items like cuddle toys to replace parental presence. Gradually delaying the bedtime so the child feels urge to sleep. Sleep hygiene by providing suitable environment to sleep, proper bedtime routine, sleep wake schedules Providing rewards for following good bedtime routine as positive reinforcement. Pharmacological intervention Sleep disorders due to underlying ENT, pulmonary conditions, to be treated as per standard protocol Usage of melatonin if required for sleep onset difficulty An 80%agreement over an intervention will be included in the module"
47954777|NCT00000488|DRUG|cholestyramine|
47954778|NCT00000488|BEHAVIORAL|diet, fat-restricted|
47954779|NCT01595711|DEVICE|Pain Monitor|Measurement of cutaneous conductance
47954780|NCT01426438|DRUG|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
47954781|NCT01426438|DRUG|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
47954782|NCT01426438|DRUG|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
47954783|NCT01744873|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
47954784|NCT01744873|DRUG|Bisoprolol|10 mg tablet once a day
47954785|NCT02764333|BIOLOGICAL|TPIV200|
47954786|NCT02764333|BIOLOGICAL|Durvalumab|
48301777|NCT02991820|DEVICE|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
47954787|NCT01685866|DEVICE|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
48480300|NCT06366945|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 1, 3, and 6
48480301|NCT06366945|DRUG|Tislelizumab|Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
48480302|NCT06366945|DRUG|Polymeric Micellar Paclitaxel|Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
48480303|NCT06366945|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
47954788|NCT04213417|OTHER|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
47954789|NCT04213417|OTHER|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
47954790|NCT04624854|DRUG|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
47954791|NCT04624854|DRUG|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
47954792|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~* BRCA positive patients: standard adjuvant chemotherapy + olaparib~* BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
48301778|NCT02991820|DEVICE|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
47954793|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~* Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~* Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
47954794|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~* Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
47954795|NCT05345860|OTHER|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
47954796|NCT05345860|OTHER|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~* Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
48480304|NCT06366945|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic assesment following induction systemic therapy and surgery is ypT(pCR 或 MPR) and ypN(pCR) or ypT（ pCR 或 MPR）and ypN（ MPR）without the presence of Serious Adverse Event, adjuvant radiation will not be administered. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
48480305|NCT03345264|BEHAVIORAL|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
48480306|NCT00881413|DRUG|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
48480307|NCT00881413|DRUG|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
48480308|NCT00285519|DRUG|Doxazosin (drug)|
48480309|NCT03658863|PROCEDURE|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
48480310|NCT03658863|PROCEDURE|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
48480311|NCT03658863|PROCEDURE|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
48480312|NCT03658863|DEVICE|Ultrasound endoscope|Endoscope with built-in ultrasound function
48480313|NCT02241135|BIOLOGICAL|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
48480314|NCT01449045|DRUG|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
48480315|NCT01449045|DRUG|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
48480316|NCT02279784|DEVICE|Freeway PTA|angioplasty with Freeway drug-eluting balloon
48480317|NCT02279784|DEVICE|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
48480318|NCT01332786|DRUG|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest"
48480319|NCT03313648|PROCEDURE|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
48480320|NCT03313648|PROCEDURE|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
48480321|NCT00911755|PROCEDURE|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
48480322|NCT00911755|PROCEDURE|Endotracheal Intubation|
48480323|NCT02439632|DRUG|prulifloxacin|
48480324|NCT02439632|DRUG|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
48480325|NCT02439632|DRUG|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
47980575|NCT01050426|OTHER|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
48480326|NCT02439632|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
48639081|NCT02555358|DRUG|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
47980576|NCT01050426|OTHER|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
48639082|NCT02555358|DRUG|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
48639083|NCT06545955|DRUG|Nadofaragene Firadenovec|vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
48639084|NCT06545955|DRUG|Gemcitabine|Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
48639085|NCT06545955|DRUG|Docetaxel|Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
48639086|NCT06545955|DRUG|Pembrolizumab|Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
48639087|NCT05821088|PROCEDURE|Biopsy|Undergo tissue biopsy
47954797|NCT05345860|OTHER|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~* Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
47954798|NCT02317588|DIETARY_SUPPLEMENT|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
47954799|NCT02317588|DIETARY_SUPPLEMENT|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
47954800|NCT02210650|PROCEDURE|Symptomatic stone removal|Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy
47954801|NCT02210650|PROCEDURE|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy
47954802|NCT05636644|DRUG|Taxol|All patients received TAC regimen: both groups received AC (epirubicin 75 mg/m ² and cyclophosphamide 500mg/m ²)， Group A was treated with docetaxel for 6 cycles every 3 weeks (75 mg/m on the first day ²)； Group B received six cycles of nab paclitaxel (125 mg/m ²)， every 3 weeks is a course of treatment.
47954803|NCT05807230|BEHAVIORAL|Three-level network rehabilitation services within the medical alliance|Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
47954804|NCT00802087|DRUG|hydrocodone|Extended Release tablet
47954805|NCT00802087|DRUG|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
47954806|NCT00111982|BIOLOGICAL|Liatermin|Liatermin
47954807|NCT02394483|DRUG|F901318 safety|Safety assessments
47954808|NCT02394483|DRUG|F901318 tolerability|Tolerability assessments
47954809|NCT02394483|DRUG|F901318 pharmacokinetics|Pharmacokinetic assessments
47954810|NCT02394483|OTHER|Placebo safety|Safety assessments
47954811|NCT02394483|OTHER|Placebo tolerability|Placebo tolerability
47954812|NCT02394483|OTHER|Placebo pharmacokinetics|Plaacebo pharmacokinetics
47954813|NCT00369824|BIOLOGICAL|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
47954814|NCT00369824|BIOLOGICAL|Menactra TM|One dose of vaccine administered intramuscularly
47954815|NCT00369824|BIOLOGICAL|Boostrix TM|One dose of vaccine administered intramuscularly
47954816|NCT04001933|OTHER|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
47954817|NCT01573260|OTHER|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
47954818|NCT01573260|OTHER|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
47954819|NCT01610531|OTHER|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
47954820|NCT03106350|OTHER|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
47954821|NCT03798197|DRUG|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
47954822|NCT01265251|DEVICE|Computerized neuropsychological test|Computerized neuropsychological test battery.
47954823|NCT01265251|OTHER|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
47954824|NCT00993902|PROCEDURE|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
47954825|NCT00993902|PROCEDURE|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
47954826|NCT03363269|DRUG|ID1201|
47954827|NCT02619669|DRUG|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
48301779|NCT02991820|DEVICE|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
48301780|NCT02991820|DEVICE|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
48301781|NCT03579875|DRUG|Total Body Irradiation (TBI) (Plan 1)|300 cGy with thymic shielding on day -6
48301782|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 1)|10 mg/kg IV daily on days -5, -4, -3, and -2
48301783|NCT03579875|DRUG|Fludarabine (FLU)|35 mg/m2 IV daily on days -5, -4, -3, and -2
48301784|NCT03579875|DRUG|Methylprednisolone (MP)|1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
48301785|NCT03579875|DEVICE|Donor mobilized PBSC infusion|T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
47954828|NCT02619669|DRUG|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
47954829|NCT02515396|DRUG|MMI-0100|
47954830|NCT02515396|DRUG|Placebo|
48301786|NCT03579875|DRUG|G-CSF|Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days)
48301787|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 2)|5 mg/kg IV daily on days -5, -4, -3, and -2
48301788|NCT03579875|DRUG|Rituximab|200 mg/m2 IV once on day -1
48301789|NCT03579875|DRUG|Busulfan|Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.
48301790|NCT03579875|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)
48301791|NCT03579875|DRUG|Melphalan|If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.
48301792|NCT01011881|OTHER|pleural level of procalcitonin|no intervention
48480327|NCT05275959|OTHER|A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China|"Myopia and obesity in children and adolescents have become serious public health problems that endanger public health, especially in China. Unhealthy lifestyle behaviors are environmental drivers of both myopia and obesity. This protocol describes a study to evaluate the effectiveness of 22510SS, that is 2 h of daytime outdoor activities ('2'); Limit screen time to no more than 2 h per day ('2'); Consume at least 5 servings of fruits and vegetables daily ('5'); Attain 1 h of physical activity daily ('1'); Consume 0 sugar-sweetened beverages ('0'); Reasonable sleep duration ('S'); Regular supervision ('S'). A school-based, multifaceted intervention strategy for myopia and obesity prevention, and to assess and explore the implementation of 22510SS with regards to acceptability, feasibility, adoption, usage and maintenance."
48480328|NCT04187209|DEVICE|Use of the Atalante exoskeleton|A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
47954831|NCT06285331|DEVICE|Automatic Bed|The automatic bed is controlled by a screen and allows clinicians to perform passive leg raising on patients without touching them physically.
47954832|NCT06285331|DEVICE|Manual|The clinicians will perform passive leg raising on patients by touching their legs physically.
47954833|NCT06378151|OTHER|TLT training|"Emergency clinicians assigned to the intervention group will receive the following training and resources.~1. The TLT Conversation Guide: The structured conversation guide entails discussing patients' values and goals, prognosis, and shared decision-making to use a trial of intensive care. Originally used in ICU settings, we systematically refined the guide to be used in the ED incorporating inputs from patient advisors' and emergency clinicians' inputs.~2. Clinician Training: The clinician training will include a one-hour didactic on research methodologies and serious illness communication skills, followed by a four-hour communication training with trained actors.~3. EHR Documentation: An EHR template for documenting the TLT conversation findings has been developed.~4. Intensivist Communication: A standard template to communicate the TLT conversation findings to the intensivists has been developed."
48301793|NCT05555446|DIETARY_SUPPLEMENT|Bovine colostrum|Subject will receive bovine colostrum with gluten.
48301794|NCT05555446|DIETARY_SUPPLEMENT|Placebo|Subject will receive a placebo with gluten.
48480329|NCT05264961|BEHAVIORAL|voice therapy|sessions of voice therapy
48480330|NCT00949195|OTHER|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
48480331|NCT00949195|OTHER|Pulmonary pressure response during exercise|Semi-supine echocardiography test
48480332|NCT02972021|DEVICE|High-flow nasal cannula|
48480333|NCT05440331|OTHER|Training with AnesList©|Training with AnesList© as tool
48480334|NCT00332267|PROCEDURE|Endotoxin infusion, Normobaric hypoxia|
47954834|NCT02256592|DRUG|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
47954835|NCT02643173|OTHER|Volatile anesthetics|
47954836|NCT02643173|OTHER|Intravenous anesthetics|
47954837|NCT05727930|BEHAVIORAL|High-intensity, task-specific (i.e., walking) interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities
47954838|NCT05727930|BEHAVIORAL|High-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities
47954839|NCT05727930|BEHAVIORAL|Low-intensity, task-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities
47954840|NCT05727930|BEHAVIORAL|Low-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
48301795|NCT04631471|DRUG|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
48301796|NCT04631471|PROCEDURE|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
48301797|NCT04631471|DRUG|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
48301798|NCT00301067|DIETARY_SUPPLEMENT|Calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
48639088|NCT05821088|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48639089|NCT05821088|DRUG|Carboplatin|Given IV
48639090|NCT05821088|PROCEDURE|Computed Tomography|Undergo CT
48639091|NCT05821088|DRUG|Etoposide|Given IV
48639092|NCT05821088|DRUG|Ifosfamide|Given IV
48639093|NCT05821088|DRUG|Lenalidomide|Given PO
48639094|NCT05821088|PROCEDURE|Positron Emission Tomography|Undergo PET
48639095|NCT05821088|BIOLOGICAL|Tafasitamab|Given IV
48639096|NCT01871727|DRUG|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
48639097|NCT01565694|DRUG|Solifenacin succinate|Oral suspension administered once a day via syringe.
48639098|NCT02907957|DEVICE|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
48639099|NCT02907957|PROCEDURE|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
48639100|NCT06230055|DEVICE|Ommaya reservoir|Intrathecal chemotherapy through Ommaya reservoir
47954841|NCT03051750|OTHER|Complex Physical Therapy plus Pressotherapy|
48301799|NCT00301067|DRUG|Temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
48480335|NCT04126486|OTHER|Zio®XT Monitor|A Zio® XT monitor will be affixed to the participant's chest
48480336|NCT01196117|DEVICE|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
48480337|NCT01196117|DEVICE|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
48639101|NCT06230055|DRUG|Systematic chemotherapy|Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), or iribrin(1.4mg/m2, d1,8, q3w, iv).
47954842|NCT03051750|OTHER|Kinesio Taping|
47954843|NCT00195546|DRUG|DVS-233|
48639102|NCT05759364|DRUG|IV Papaverine 80 mg|Opium alkaloid antispasmodic drug
48639103|NCT05759364|DRUG|Placebo|Placebo
48639104|NCT03241420|DEVICE|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
48639105|NCT01120444|DEVICE|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
47954844|NCT02701699|BIOLOGICAL|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
47954845|NCT02758704|OTHER|High stress|Generation of a stressful environment during a neonatal intubation procedure.
47954846|NCT02758704|OTHER|Low stress|Absence of stressful stimuli during neonatal intubation procedure
48301800|NCT00211770|BEHAVIORAL|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
48639106|NCT01120444|DEVICE|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
48639107|NCT06190613|BEHAVIORAL|Combination Peer navigation and mHealth intervention|Peer navigation and SMS text message medication reminders (adapted to YMSM and YTW in community outreach-based delivery approach)
48639108|NCT04111549|OTHER|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
48639109|NCT04111549|OTHER|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
47954847|NCT02758704|OTHER|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
47954848|NCT01191918|DRUG|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
47954849|NCT01191918|DRUG|Placebo plus Lithium|
47980577|NCT03957707|PROCEDURE|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
48301801|NCT02242071|BIOLOGICAL|Stem Cell|intrathecal autologous bone marrow mononuclear cell transplantation
48301802|NCT00299533|DRUG|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
48339906|NCT04547998|DEVICE|Control Intervention (UVB)|Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
48480338|NCT05353036|OTHER|Survey|Survey assessing incidence, frequency, and type of illicit substance use
48480339|NCT04017559|BEHAVIORAL|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
48480340|NCT04817215|DRUG|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
48480341|NCT04788537|BEHAVIORAL|Training to Understand and Navigate Emotions and Interactions (TUNE In)|A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
48480342|NCT03316326|DRUG|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
48480343|NCT03316326|DRUG|Oxaliplatin|85 mg/m2, D1
47954850|NCT04534972|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \> 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
48480344|NCT03316326|DRUG|Irinotecan|150 mg/m2, D8
47954851|NCT02935842|OTHER|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
47954852|NCT02935842|OTHER|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
47954853|NCT06253975|BIOLOGICAL|adipose tissue derived extracellular vesicles (AT-EVs)|Extracellular vesicles from patient's adipose tissue together with HA
47954854|NCT06253975|DRUG|Hyaluronic acid|Use HA only as a placebo
47954855|NCT02829255|OTHER|altitude exposure|altitude exposure
47954856|NCT02514525|DEVICE|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
47954857|NCT06277596|OTHER|Exercise|Clinical Pilates exercises (basic and advanced stabilization exercises)
47954858|NCT03307785|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
47954859|NCT03307785|DRUG|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
47954860|NCT03307785|DRUG|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer \[NSCLC\], ovarian cancer, endometrial cancer, and head and neck cancer.
47954861|NCT03307785|DRUG|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
48109294|NCT05147389|DIAGNOSTIC_TEST|AI model classification|AIWorks is an artificial intelligence model for real-time cholangioscopic detection of neoplastic and non-neoplastic bile duct lesions. It allows you to choose using a video file or a USB camera input as the detection source. Once the input source has been selected, the software performs real-time detection by surrounding the area of interest (i.e., the area with malignancy features) inside a bounding box. All detections made are displayed on the right side of the screen and can also be reviewed afterwards.
48301803|NCT01889810|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
48301804|NCT00915811|DRUG|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
48480345|NCT02784678|PROCEDURE|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
48480346|NCT02784678|DEVICE|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
48480347|NCT06233357|DRUG|treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)|IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
48480348|NCT00002262|DRUG|Tumor Necrosis Factor|
48480349|NCT03365999|DRUG|Oral Tranexamic Acid|Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
48655915|NCT06644677|DIAGNOSTIC_TEST|HPV integration|Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.
48655916|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol + geranylgeraniol|Combination of ubiquinol and geranylgeraniol
47954862|NCT03307785|DRUG|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
48480350|NCT03365999|DRUG|Oral Aminocaproic Acid|Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
48480351|NCT02166034|BEHAVIORAL|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
47954863|NCT03307785|DRUG|Carboplatin-Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
47954864|NCT03307785|DRUG|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
48109295|NCT05147389|DIAGNOSTIC_TEST|DSOC endoscopist experts' classification|"Six endoscopists with high DSOC expertise will observe and classify a set of videos among neoplastic or non-neoplastic bile duct lesions following a Bernoulli distribution; blinded to clinical records and should have never attended said patients.~Gastroenterologists from each center, with non-DSOC responsibility, will select DSOC videos and corresponding baseline data. DSOC videos and data will be gathered in one set. Each video represents a full DSOC for a single patient. The patient will be the unit of this study.~The neoplastic bile duct criteria are in accordance with the Robles-Medranda et al and the Mendoza classifications (ie. Irregular mucosa surface, Tortuous and dilated vascularity, Irregular nodulations, Polyps, Ulceration, Honeycomb pattern, etc.). The experts will assess neoplastic bile duct by presence or absence of disaggregated criteria. Likewise, by Boolean logical operators, the statistical software will compute disaggregated answers."
48109296|NCT01319435|PROCEDURE|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
48109297|NCT05134025|OTHER|Pump settings|Alteration in the pump setting prior to exercise commencement
48109298|NCT05619107|DEVICE|Active Transauricular nerve stimulation|The first allocated intervention will be undertaken for 30 minutes. The electrode placement and stimulation parameters are described in the arm/group section. After the 30-minute intervention, day 1 of the protocol will be complete. The investigator will remain present in the room with the participant to ensure compliance and adherence to the protocol. The allocated intervention will then be repeated by the participant at a similar time of day for 7 consecutive days. The investigator will arrange video-calls with the participant whilst off-site to ensure ongoing compliance and adherence to the protocol. On the seventh day, participants return to the clinical research facility to take the final first allocated intervention. A 14-day rest period will follow. Then the participants will perform the same 7-day protocol for the opposite intervention to their first treatment allocation.
48301805|NCT00915811|DRUG|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
48480352|NCT06318832|OTHER|ICBT|ICBT: Participants will receive the 10-week tailored ICBT Wellbeing program consists of 1) education about how taking on the role of care-partner can impact emotional and cognitive wellbeing through introduction to the CBT model; 2) structured problem solving; 3) cognitive therapy and thought challenging to manage one's wellbeing and impact of caregiving; 4) building communication and intimacy; 5) physical symptoms of depression (i.e., hypo-arousal), anxiety/anger (i.e., hyper-arousal); practicing behavioural activation and controlled relaxation; 6) overdoing-underdoing cycle of activity levels and issues around the fear avoidance of social, physical, and cognitive activities; practicing activity pacing and gradually tackling avoidance; 7) occurrence of setbacks in thought, physical, behavioural, and cognitive symptoms; signs of setbacks and creating setback plans.
48480353|NCT04403763|DRUG|AGN-241622|Topical eye drop
47954865|NCT03784703|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
48109299|NCT05619107|DEVICE|Sham transauricular nerve stimulation|Protocol as for active but sham ear leads are applied, unable to deliver current.
48109300|NCT03298919|BEHAVIORAL|Exercise Video Games|12 weeks laboratory based exercise videogames
48109301|NCT03298919|BEHAVIORAL|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
48109302|NCT03298919|BEHAVIORAL|Home exercise videogames|videogame console and active videogames
48109303|NCT03298919|BEHAVIORAL|Home Standard Exercise|Personalized physical activity promotion materials
48109304|NCT05975983|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
48109305|NCT05975983|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
48109306|NCT02243813|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
48109307|NCT02135172|BEHAVIORAL|Sitting|
48109308|NCT02135172|BEHAVIORAL|Standing|
48301806|NCT00915811|DRUG|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
48301807|NCT00915811|PROCEDURE|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
48301808|NCT03013491|DRUG|CX-072|
48480354|NCT04403763|DRUG|Vehicle|Topical eye drop
48480355|NCT05647707|DIETARY_SUPPLEMENT|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
48480356|NCT02923414|DEVICE|Standard escalating shocks|125 J, 150 J, 200 J
48655917|NCT06640465|DIETARY_SUPPLEMENT|Geranylgeraniol|Geranylgeraniol alone
47954866|NCT03784703|DRUG|Rosuvastatin 10 Mg Oral Tablet|10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
48109309|NCT02135172|BEHAVIORAL|Walking|
48301809|NCT03013491|DRUG|ipilimumab|
48301810|NCT03013491|DRUG|vemurafenib|
48301811|NCT04686734|OTHER|No active intervention (observational only)|No active intervention (observational only)
48655918|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinol|Ubiquinol alone
48655919|NCT06640465|DIETARY_SUPPLEMENT|Ubiquinone|Ubiquinone alone
48655920|NCT06640465|OTHER|Placebo|Placebo capsule
48301812|NCT06499753|OTHER|high molecular weight HA-based artificial tears|use of high molecular weight HA-based artificial tears three times per day
47954867|NCT06463405|OTHER|Splinted|The investigators will compare splinted versus non-splinted crowns in a randomized design. Whether the crowns will be splinted or not are decided by distant randomization separate from clinicians conducting the trial. Twenty sealed envelopes will be opened where its stands whether the crowns has to be splinted crowns or non-splinted crowns. The implants in the splinted side will have an intermediate titanium abutment and impression will be taken at abutment level, whereas impressions in the non-splinted side will be taken directly at the fixture level. The splinted as well as the non-splinted crowns will be screw-retained and produced in monolithic zirconia. An open-tray technique / (scanning) will be used for both reconstructions.
47954868|NCT05837585|DEVICE|Air quality sensors|The air quality sensors detect air quality, including temperature, humidity, carbon dioxide, respirable suspended particulates (PM10 or PM2.5), total volatile organic compounds (TVOC) and formaldehyde (HCHO), which may influence health of residences. The managers of the service unit will decide the changes of activities to improve air quality and long-term measures based on the detected air quality indexes. The care staff will follow these decisions.
48301813|NCT02892851|DEVICE|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~* Parameter setting~* Cross-over double-bind (ON/OFF)~* Open Phase (ON)"
47954869|NCT00659750|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
47954870|NCT00659750|DRUG|Placebo|placebo
47954871|NCT00227448|DRUG|intravenous saline|
47954872|NCT00227448|DRUG|intravenous phenylephrine|
47954873|NCT00227448|DRUG|intravenous levophed|
47954874|NCT00227448|DRUG|oral midodrine|
47954875|NCT02256371|BEHAVIORAL|Hypnosis sessions|1 session per week during 8 weeks
47954876|NCT02256371|BEHAVIORAL|Relaxation group|1 relaxation session per week during 8 weeks
47954877|NCT05377879|DEVICE|OPT-IVF dosage|Dosage predicted for each patient by the decision support tool OPTIVF
48109310|NCT06465680|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
48109311|NCT01393119|DRUG|GTx-758|3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist
48480357|NCT02923414|DEVICE|High energy shock protocol|360 J, 360 J, 360 J.
48655921|NCT06435221|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
48655922|NCT06300684|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|This intervention involves structured sessions aimed at addressing maladaptive sleep behaviors and promoting healthy sleep habits. Participants in this group will engage in cognitive restructuring, relaxation techniques, and sleep hygiene education to improve sleep quality and duration. The goal of CBTi is to modify behaviors and thoughts that contribute to insomnia, leading to more restful and consolidated sleep patterns.
47954878|NCT02508831|PROCEDURE|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
47954879|NCT04264338|DIAGNOSTIC_TEST|Thyromental height test|Assessment of difficult airway
47954880|NCT01224964|DRUG|Montelukast|Montelukast, 10 mg
47954881|NCT01224964|DRUG|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
47954882|NCT00079248|BIOLOGICAL|therapeutic progesterone|
47954883|NCT00079248|DRUG|conjugated estrogens|
48301814|NCT02743403|DEVICE|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
48301815|NCT02743403|DEVICE|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
48301816|NCT02743403|DEVICE|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
48301817|NCT02009137|DEVICE|EVERA|EVERA apply for 12 weeks
48301818|NCT02009137|DEVICE|ESTES|ESTES apply for 12 weeks
48480358|NCT01579760|DRUG|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
48480359|NCT01579760|DRUG|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
47954884|NCT02722369|DRUG|Gemcitabine|Chemotherapy
47954885|NCT02722369|DRUG|Carboplatin|Chemotherapy
47954886|NCT02722369|DRUG|Etoposide|Chemotherapy
47954887|NCT02722369|DRUG|Hydroxychloroquine|Maintenance Agent
47954888|NCT02037022|BEHAVIORAL|Pivotal Response Treatment Package (PRT-P)|
47954889|NCT00427947|DRUG|ropivacaine/placebo|Continuous sciatic nerve bloc
47954890|NCT02486302|DRUG|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
47954891|NCT03231657|DIAGNOSTIC_TEST|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
47954892|NCT01321060|PROCEDURE|Aspiration|
47954893|NCT01321060|PROCEDURE|Catheter drainage|
47954894|NCT01321060|DRUG|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
47954895|NCT05491720|DRUG|RisperiDONE 1 MG/ML|Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
47954896|NCT05491720|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
47954897|NCT05491720|DRUG|Placebo|Patients will receive placebo tablet (Galenus pharmaceutical company)
48109312|NCT04178291|DEVICE|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
48480360|NCT03050697|DEVICE|HARMONI® Modular Toric Intraocular Lens|Two-component system consisting of a base and a separate toric optic
48480361|NCT03050697|PROCEDURE|Cataract extraction with intraocular lens (IOL) implantation|Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
48301819|NCT04877015|DEVICE|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
48301820|NCT04877015|DEVICE|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
48639110|NCT06064695|DEVICE|Whole-body Electrical Muscle Stimulation Exercise|This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.
48639111|NCT05402085|DIETARY_SUPPLEMENT|High Protein Diet|Subjects will be provided with high protein diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
48639112|NCT05402085|DIETARY_SUPPLEMENT|High Fat Diet|Subjects will be provided with high fat diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
48639113|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-Low Glycemic Index Diet|Subjects will be provided with high carbohydrate-low glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
48639114|NCT05402085|DIETARY_SUPPLEMENT|High Carbohydrate-High Glycemic Index Diet|Subjects will be provided with high carbohydrate-high glycemic index diet meals for breakfast, lunch, and dinner. A continuous glucose monitoring device will be used to measure post-prandial glycemic responses.
48639115|NCT00433511|BIOLOGICAL|Bevacizumab|Given IV
47954898|NCT05491720|DEVICE|sham transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
47954899|NCT01551901|DEVICE|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
48301821|NCT00175006|OTHER|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
48301822|NCT01924897|BEHAVIORAL|Exercise training|
48301823|NCT01299597|DRUG|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
48301824|NCT01299597|DRUG|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
48301825|NCT01299597|DRUG|SB649868|20mg daily given for 14 days.
48480362|NCT02563418|DEVICE|Eye-tracking|
48480363|NCT06200428|OTHER|sleep support pillow|A sleep support pillow will be used in this study.
48639116|NCT00433511|DRUG|Cyclophosphamide|Given IV
48639117|NCT00433511|DRUG|Doxorubicin Hydrochloride|Given IV
48639118|NCT00433511|OTHER|Laboratory Biomarker Analysis|Correlative studies
48639119|NCT00433511|DRUG|Paclitaxel|Given IV
48639120|NCT00433511|OTHER|Placebo Administration|Given IV
48301826|NCT02065869|BIOLOGICAL|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
48301827|NCT02065869|DRUG|Rimiducid|0.4mg/kg administered IV to treat GVHD
48301828|NCT03642015|BEHAVIORAL|Music listening|listening the music 15 min
48301829|NCT04841499|DRUG|BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)|take 2 capsules orally each day for 7 days
47954900|NCT01881074|DRUG|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
48109313|NCT04178291|DEVICE|Air polishing with erythritol powder|Air flow PLUS
48301830|NCT02582749|DRUG|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
48301831|NCT02582749|DRUG|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
48480364|NCT03537157|DRUG|Rifaximin delayed release tablets|Active intervention
48109314|NCT03578640|DRUG|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
48109315|NCT00567515|DEVICE|AtriCure LAA Exclusion System|Placement of clip of LAA.
48480365|NCT03537157|OTHER|Placebo|Comparator placebo
48480366|NCT05927181|PROCEDURE|TAOM|In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
48480367|NCT00468429|DRUG|Subconjunctival Bevacizumab|
48480368|NCT02280720|PROCEDURE|Stenting using Optimax™|
48480369|NCT02280720|PROCEDURE|Stenting using PROMUS Element™ Plus|
48480370|NCT04815252|BEHAVIORAL|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
47954901|NCT01881074|DRUG|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
47954902|NCT02194855|DRUG|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
47954903|NCT02194855|DRUG|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
48639121|NCT00433511|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
47954904|NCT01539083|DRUG|Thalidomide|Thalidomide 100 mg tablet, orally.
47954905|NCT01539083|DRUG|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).
47954906|NCT01539083|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 orally.
47954907|NCT01539083|DRUG|Dexamethasone|Dexamethasone 20 mg orally.
47954908|NCT01539083|DRUG|Prednisolone|Prednisolone 50 mg orally.
47954909|NCT02432742|DEVICE|Restylane Perlane|Intradermal injection
47954910|NCT02432742|DEVICE|Restylane|Intradermal injection
47954911|NCT00734474|DRUG|LY2189265|
47954912|NCT00734474|DRUG|Sitagliptin|
47954913|NCT00734474|DRUG|Placebo solution|
47954914|NCT00734474|DRUG|Placebo tablet|
47954915|NCT00734474|DRUG|Metformin|
47954916|NCT04686695|DEVICE|taVNS|taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
47954917|NCT04980781|BEHAVIORAL|Physical exercise and dietary therapy (PED-t)|Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
48480371|NCT06240689|DRUG|Sintilimab|Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
48480372|NCT06240689|DRUG|Placebo|Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
48480373|NCT00072072|DRUG|celecoxib|
47954918|NCT04980781|PROCEDURE|Implementation program for PED-t in ERC|Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
48301832|NCT02582749|RADIATION|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
47954919|NCT05072782|DRUG|Infliximab CT-P13|"Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors"
47954920|NCT05072782|DRUG|Immunosuppressors (Thiopurines or Methotrexate)|"Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose"
47954921|NCT02785315|BEHAVIORAL|rehabilitation & remediation approach|The rehabilitation \& remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
47954922|NCT02785315|BEHAVIORAL|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
47954923|NCT02494674|BEHAVIORAL|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
47954924|NCT00478946|DRUG|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
48109316|NCT06316206|DRUG|Ethinylestradiol/Dienogest 0.03mg/2mg|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
48480374|NCT00072072|DRUG|erlotinib hydrochloride|
48480375|NCT00094458|BIOLOGICAL|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
47954925|NCT00478946|DRUG|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
47954926|NCT00478946|DRUG|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
48480376|NCT00094458|OTHER|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
48480377|NCT00094458|DRUG|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
48639122|NCT06025227|DRUG|Etrasimod|tablets
48639123|NCT01033370|DRUG|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes \& titrated to the desired BP lowering effect to SBP goal of \< 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
48639124|NCT03928704|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
48301833|NCT00069095|DRUG|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
48301834|NCT00069095|DRUG|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
48301835|NCT00069095|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
48301836|NCT00069095|DRUG|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
48639125|NCT03928704|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
47954927|NCT05331651|DRUG|Glycopyrronium in Combination With Tropisetron|Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
47954928|NCT05331651|DRUG|Normal Saline in Combination With Tropisetron|Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
48301837|NCT00069095|DRUG|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.
48301838|NCT00069095|DRUG|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
48301839|NCT00069095|DRUG|Fluorouracil 400 mg/m^2|
48301840|NCT00069095|DRUG|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
48301841|NCT00069095|DRUG|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
48639126|NCT03568071|DRUG|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
47954929|NCT03766074|DIETARY_SUPPLEMENT|vitamin D supplement|The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
47954930|NCT03766074|DIETARY_SUPPLEMENT|Placebo|placebo
47954931|NCT03349931|DIAGNOSTIC_TEST|DNA extraction and detection of Aspergillus fumigatus in serum samples|Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
48301842|NCT06467760|DEVICE|InDx CMC Implant|The InDx CMC Implant is a hemiarthroplasty device for the CMC joint which consists of a unified assembly of three components: metacarpal stem, polyethylene liner, and articulating head. Because the device functions as a hemiarthroplasty, it does not link or constrain the CMC joint
48301843|NCT06276972|OTHER|no intervention|there's no intervention. it's a cross sectional study correlation study
48301844|NCT00000650|DRUG|Ditiocarb sodium|
48301845|NCT03640091|PROCEDURE|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
48301846|NCT04529551|OTHER|1601A|A filtered, king size cigarette with a menthol capsule in the filter.
48301847|NCT04529551|OTHER|1601B|A filtered, king size cigarette with a menthol capsule in the filter.
48301848|NCT01670630|PROCEDURE|Sheathed speculum examination|
48301849|NCT01670630|PROCEDURE|Standard speculum examination|
48301850|NCT03517046|DRUG|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
48301851|NCT06075758|OTHER|ribociclib|"There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription."
48301852|NCT03865407|DRUG|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
48301853|NCT04742465|OTHER|Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
48301854|NCT00744146|BIOLOGICAL|Protexia|Single 50 mg IM dose
48639127|NCT03568071|DRUG|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
48639128|NCT02890355|DRUG|Fluorouracil|Given IV
47954932|NCT04783818|RADIATION|Adjuvant Radiotherapy|PMRT
47954933|NCT00446862|DRUG|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
48109317|NCT04581824|DRUG|Dostarlimab|Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
48109318|NCT04581824|DRUG|Pembrolizumab|Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
48301855|NCT00744146|BIOLOGICAL|Protexia|Single 100 mg dose
48301856|NCT00744146|BIOLOGICAL|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
48301857|NCT00744146|BIOLOGICAL|Protexia|Single 500 mg dose, IM
48301858|NCT00744146|BIOLOGICAL|Protexia|Single 750 mg dose, IM
47954934|NCT03475680|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
47954935|NCT03475680|DRUG|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
48301859|NCT02678988|DEVICE|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
48301860|NCT02678988|DEVICE|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
48639129|NCT02890355|DRUG|Fluorouracil|Given IV bolus
47954936|NCT03475680|DRUG|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
47954937|NCT03475680|DRUG|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
47954938|NCT03475680|DRUG|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
47954939|NCT03159221|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
47954940|NCT04846842|DRUG|Gimatecan|Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks.
47954941|NCT01655797|BEHAVIORAL|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
47954942|NCT01453725|BIOLOGICAL|Golimumab|Golimumab 50 mg SC injection every 4 weeks
47954943|NCT01453725|BIOLOGICAL|Placebo|Placebo SC injection every 4 weeks
47954944|NCT05914012|OTHER|Telerehabilitation based on Otago Exercise Program|It took a total of 21 sessions, 7 days a week for 3 weeks. The sessions lasted 30 minutes. It is recommended to do exercises with comfortable shoes at least 1 hour after a meal. Each of his exercises will be videotaped and numbered and delivered to the intervention group via social networks and the Internet or by memory. In each exercise session, the physiotherapist followed the exercise sessions through social networks and answered questions from the older adults.
47954945|NCT04288752|DEVICE|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
47954946|NCT04288752|DEVICE|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
47954947|NCT03166059|DEVICE|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
47954948|NCT04045964|DRUG|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
47954949|NCT04045964|BEHAVIORAL|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
47954950|NCT04045964|BEHAVIORAL|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
47954951|NCT04711434|DRUG|PD-1 Antibody|Toripalimab: 240mg IV every 3 months for a year
47954952|NCT01589978|DEVICE|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
47954953|NCT01589978|DRUG|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
47954954|NCT01589978|DRUG|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
47954955|NCT00578383|DEVICE|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
48301861|NCT02678988|DRUG|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
48639130|NCT02890355|DRUG|Irinotecan Hydrochloride|Given IV
47954956|NCT06557148|DIAGNOSTIC_TEST|18F-Fluoroestradiol PET/CT|Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT
47954957|NCT02041767|DRUG|Ertapenem|One single injection of 1g of ertapenem before surgery
47954958|NCT05143541|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
47954959|NCT02906332|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
47954960|NCT02906332|DRUG|Lenalidomide|Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.
47954961|NCT02906332|DRUG|Dexamethasone|Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
48301862|NCT05041192|DIETARY_SUPPLEMENT|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
48301863|NCT05041192|DIETARY_SUPPLEMENT|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
47954962|NCT01691131|OTHER|Exercise training|Comparison of high intensity exercise training on land versus water.
47954963|NCT04206800|DIAGNOSTIC_TEST|Ejaculatory abstinence less than 24 hours|Males will have ejaculatory abstinence less than 24 hours before providing a semen sample the day of egg retrieval
47954964|NCT01554683|DRUG|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
48639131|NCT02890355|OTHER|Laboratory Biomarker Analysis|Correlative studies
48639132|NCT02890355|DRUG|Leucovorin Calcium|Given IV
47954965|NCT00705926|DRUG|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
47954966|NCT00705926|OTHER|No treatment|Participants in this group will not receive treatment at this stage of their infection.
47954967|NCT03314142|OTHER|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
47954968|NCT03314142|OTHER|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48301864|NCT03567291|DRUG|TEV-50717|6, 9, and 12 mg oral tablets
48301865|NCT03567291|DRUG|Placebo|Placebo comparator
48639133|NCT02890355|DRUG|Veliparib|Given PO
48639134|NCT05014230|DIETARY_SUPPLEMENT|Open Placebo|Zeebo
48639135|NCT05014230|OTHER|Opioid medication as part of standard care|Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
48639136|NCT03701308|PROCEDURE|Biospecimen Collection|Undergo blood collection
48639137|NCT03701308|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
48109319|NCT04581824|DRUG|Chemotherapy|"Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
48109320|NCT04379713|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
48109321|NCT04379713|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
48109322|NCT03998280|DEVICE|Assessment|Neck proprioception and postural stability
48109323|NCT03457246|OTHER|D-Pigment rich texture|
48109324|NCT03457246|OTHER|Hydrance optimale riche|
48301866|NCT01943123|DIETARY_SUPPLEMENT|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
48301867|NCT01943123|DIETARY_SUPPLEMENT|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
48301868|NCT05415956|BEHAVIORAL|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
48639138|NCT03701308|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48639139|NCT03701308|DRUG|Cytarabine|Given IV
48639140|NCT03701308|DRUG|Daunorubicin|Given IV
48639141|NCT03701308|PROCEDURE|Echocardiography|Undergo ECHO
48639142|NCT03701308|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48639143|NCT03701308|DRUG|Uproleselan|Given IV
48639144|NCT06232421|DRUG|Foscelantan|"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus"
48639145|NCT06232421|DRUG|Povidon-iodine|Povidone-iodine solution 100 mg/ml produced by BelAseptika CJSC, Republic of Belarus
48639146|NCT03896503|DRUG|Berzosertib|Given intravenously (IV).
48639147|NCT03896503|PROCEDURE|Biopsy|Undergo a tumor biopsy
48639148|NCT03896503|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48639149|NCT03896503|PROCEDURE|Computed Tomography|Undergo a computed tomography (CT) scan
47954969|NCT03314142|OTHER|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
47954970|NCT03314142|OTHER|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
47954971|NCT03314142|OTHER|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
47954972|NCT05314738|COMBINATION_PRODUCT|NXL Energy 1|Riboflavin drops + NXL System to Total Energy Level 1
47954973|NCT05314738|COMBINATION_PRODUCT|NXL Energy 2|Riboflavin drops + NXL System to Total Energy Level 2
47954974|NCT05314738|COMBINATION_PRODUCT|NXL Energy 3|Riboflavin drops + NXL System to Total Energy Level 3
48109325|NCT05924438|DRUG|Delstrigo|Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily.
48301869|NCT03369301|DRUG|Gammanorm|Gammanorm given per standard of care
48639150|NCT03896503|DRUG|Topotecan Hydrochloride|Given intravenously (IV).
48639151|NCT06056024|DRUG|BI 3706674|BI 3706674
48655923|NCT05726370|DRUG|Pembrolizumab|Immunoglobulin G4 monoclonal antibody, via IV infusion
48655924|NCT05726370|DRUG|CISPLATIN|Platinum agent, via IV infusion
48655925|NCT05726370|DRUG|Carboplatin|Platinum agent, via IV infusion
48655926|NCT05726370|DRUG|Docetaxel|Antineoplastic agent, via IV infusion.
48655927|NCT06636110|DEVICE|Jun mHealth app|The intervention will be a mHealth app, JUN, across 3 months during pregnancy.
48655928|NCT04598087|BEHAVIORAL|Prehabilitation|The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically \~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
47954975|NCT05314738|COMBINATION_PRODUCT|Sham Treatment|Sham Drops and No exposure to NXL system
47954976|NCT06101550|PROCEDURE|partial pulpotomy|Partial removal of pulp tissue in young permanent teeth
47954977|NCT06101550|PROCEDURE|Complete pulpotomy|Complete removal of pulp tissue in young permanent teeth
47954978|NCT02549534|PROCEDURE|Axon Reflexes|"\*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
47954979|NCT02549534|PROCEDURE|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
48301870|NCT03369301|DRUG|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
48301871|NCT03179098|OTHER|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
48301872|NCT03179098|OTHER|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
48301873|NCT03179098|OTHER|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
48301874|NCT03670082|DRUG|Lu AF35700|20 mg Lu AF35700 single oral dose
48301875|NCT03670082|DRUG|Lu AF35700 iv|100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
47954980|NCT02549534|PROCEDURE|Self-Reported Signs & Symptoms of CIPN|Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
48301876|NCT03465800|BEHAVIORAL|self-monitoring|self-monitoring of physical activity
48301877|NCT03465800|BEHAVIORAL|daily incentives|daily incentive payments for physical activity
48301878|NCT03465800|BEHAVIORAL|delayed lump sum incentives|delayed lump sum payments for physical activity
48301879|NCT06121947|PROCEDURE|The DBS electrodes are implanted into MLR.|MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
47954981|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
47954982|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
48301880|NCT06121947|PROCEDURE|The electrodes are implanted into the patient's vagus nerve|A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
48301881|NCT02552355|DRUG|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
48301882|NCT02552355|DRUG|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
48301883|NCT02552355|DIETARY_SUPPLEMENT|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
48301884|NCT02552355|DIETARY_SUPPLEMENT|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
48301885|NCT02309736|DEVICE|ReSure Sealant|
48301886|NCT05029076|DRUG|Liraglutide injection|Human glucagon-like peptides-1 analogue
48301887|NCT05029076|DRUG|Victoza|Human glucagon-like peptides-1 analogue
48301888|NCT01506414|DRUG|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
48301889|NCT01386099|DRUG|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
48301890|NCT01386099|DRUG|Placebo|Placebo twice a day for 12 weeks.
48301891|NCT05895825|DRUG|EOC237|EOC237 for orally
48301892|NCT01819922|DRUG|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
48301893|NCT01819922|DRUG|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
48301894|NCT04005092|DEVICE|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
48655929|NCT05611775|DEVICE|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
48655930|NCT03395093|DRUG|Fentanyl|Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
48301895|NCT02445378|PROCEDURE|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
47954983|NCT00354887|DRUG|Capecitabine|Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
47954984|NCT00354887|DRUG|Oxaliplatin|130 mg/m\^2 by vein Day 1 over 2 hours in 21 Day Cycle
47954985|NCT03084731|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
47954986|NCT05434078|DEVICE|Orthofeet Shoes|Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
48301896|NCT02445378|OTHER|Placebo|Undergo placebo intervention using rose water
48301897|NCT02445378|OTHER|Questionnaire Administration|Ancillary studies
47954987|NCT02643602|OTHER|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
47954988|NCT02643602|OTHER|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
47954989|NCT04166500|PROCEDURE|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
47954990|NCT05204251|BEHAVIORAL|Questionnaire|Quality of Life assessed with the SF-36 questionnaire
48301898|NCT03732768|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
48301899|NCT02558881|PROCEDURE|Virtual colonoscopy|
48301900|NCT02558881|PROCEDURE|Colon capsule|
47954991|NCT04786938|DRUG|Saccharomyces Boulardii-Containing Product in Oral Dose Form|S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
48301901|NCT01744847|DEVICE|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
48301902|NCT02316470|BIOLOGICAL|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
48480378|NCT05178108|OTHER|Real-time MRI of swallowing|"The examination recording a total of 9 sequences of less than 30 seconds will be performed, in transverse section (passing through the epiglottis), frontal section, in the plane of the posterior pharyngeal wall, and in median sagittal section.~Each bolus of 20 ml will be administered in full, in one go, using a syringe. It is kept in the mouth for a few seconds and swallowed on demand.~The semi-liquid bolus of 20 ml comes from the mixture of 198 ml of pineapple juice to 10 gr of Nutilis Powder (NUTRICIA), food thickener containing neither gluten, nor lactose.~Ingredients: Dextrin-maltose, thickeners (modified starch (corn), tara gum, xanthan gum, guar gum).~* 3 sequences with no food~* 3 sequences with ingestion of a liquid bolus of 20 ml (pineapple juice) mouth closed~* 3 sequences with ingestion of a semi-liquid bolus of 20 ml (pineapple juice + Nutilis Powder) mouth closed"
48480379|NCT06616909|BEHAVIORAL|ACP GAME|,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents
48480380|NCT06616909|BEHAVIORAL|acp manual|acp manual
48655931|NCT03395093|DRUG|Midazolam|Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.
48301903|NCT02316470|BIOLOGICAL|Placebo|phosphate buffered saline (PBS) solution
48301904|NCT05360277|DRUG|Tislelizumab + Capecitabine|"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
48301905|NCT05360277|OTHER|Best supportive care|Best supportive care
48301906|NCT03172546|GENETIC|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
47954992|NCT06374212|DRUG|Anifrolumab|900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20
48301907|NCT00161824|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
48301908|NCT00775359|DRUG|Fenofibrate 160 mg tablets|
47954993|NCT03442101|DRUG|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
47954994|NCT02168127|DRUG|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
47954995|NCT02168127|DRUG|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
47954996|NCT05747287|DEVICE|microcatheter|supports the insertion of the guide wire，exchange of the guide wire and the delivery of contrast media
47954997|NCT03463174|PROCEDURE|Mandibular overdenture|Placement of an implant in the mandibular midline.
47954998|NCT03463174|OTHER|Mandibular complete denture|No intervention.
47954999|NCT03726944|BEHAVIORAL|Calm App Meditation|The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
47955000|NCT03726944|BEHAVIORAL|Unnamed Consumer-Based App Meditation|The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
48480381|NCT03704857|OTHER|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
47955001|NCT03726944|OTHER|Educational Control|The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
47955002|NCT01560403|DRUG|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
47955003|NCT06308367|DRUG|Betaine|50mg/kg for 12 weeks
48109326|NCT05924438|DRUG|KOCITAF|Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily.
47955004|NCT06308367|DRUG|Placebo|Placebo
47955005|NCT03417323|OTHER|Compression|Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
47955006|NCT02284516|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
47955007|NCT02284516|DRUG|Placebo|Placebo to match active treatment, BID for 84 days
47955008|NCT03888586|DEVICE|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
47955009|NCT03888586|OTHER|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
47955010|NCT06534684|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
48109327|NCT02798718|DIETARY_SUPPLEMENT|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
48109328|NCT06440824|DRUG|Romiplostim N01|2.0 µg/kg, subcutaneous injection, once a week, up to a maximum of 8 weeks. Stop medication when platelet count increases by 50 × 109/L or more compared to before medication
48109329|NCT06440824|DRUG|Recombinant Human Thrombopoietin|30000 U/d, subcutaneously injected once a day, for a maximum of 8 weeks. Medication should be stopped when platelets increase by 50 × 109/L or more compared to before medication
48109330|NCT06005220|OTHER|SBD121|Medical Food
48109331|NCT06005220|OTHER|Placebo|Placebo
48109332|NCT04347954|DRUG|Povidone-Iodine 2%|Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
48109333|NCT04347954|DRUG|Povidone-Iodine 0.5%|Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
48109334|NCT04347954|DRUG|Isotonic saline 0.9%|Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
48109335|NCT02717299|DEVICE|Verasense|Verasense will collect balancing data on all patients in this trial.
48301909|NCT03985072|DRUG|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
48639152|NCT05608668|DEVICE|Pro2 - 60% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
48639153|NCT05608668|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
48655932|NCT03395093|DRUG|Propofol|Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.
47955011|NCT05720260|DRUG|Goserelin|Hormone therapy
47955012|NCT05720260|DRUG|Fulvestrant|Hormone therapy
47955013|NCT05720260|DRUG|Capivasertib|AKT inhibitor
47955014|NCT05720260|DRUG|Durvalumab|immunotherapy
47955015|NCT01157923|DEVICE|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
47955016|NCT06271213|OTHER|observational only - no interventions as part of study|Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
47955017|NCT04629807|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)
47955018|NCT01582204|DRUG|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
47955019|NCT03882112|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
48480382|NCT03704857|OTHER|Photobiomodulation|aPDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
48480383|NCT03704857|OTHER|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
47955020|NCT02921542|DEVICE|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
47955021|NCT01903174|DEVICE|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
47955022|NCT02465645|DRUG|Carvedilol|
47955023|NCT02465645|DRUG|Carvedilol + Simvastatin|
47955024|NCT02692222|OTHER|Calculation of PPV and CO with two methods|
47955025|NCT04945577|DIAGNOSTIC_TEST|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
48109336|NCT00588419|BEHAVIORAL|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
48655933|NCT03395093|DEVICE|Bispectral Index monitoring|Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
47955026|NCT04945577|OTHER|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
47955027|NCT06033144|DIAGNOSTIC_TEST|Diagnosis of Tapia's Syndrome|"The diagnostic includes :~* Lingual clinical examination~* Nasofibroscopy~* Ultrasonography"
47955028|NCT02489578|OTHER|other|retrospective cohort study
47955029|NCT06440902|DRUG|Cetuximab|Cetuximab is given In patients with NeoRAS WT
47955030|NCT00644189|DRUG|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
47955031|NCT01811680|DEVICE|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
47955032|NCT04121923|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Total sleep time (Ring-TST) and respiratory event index (Ring-REI) are estimated
48655934|NCT05703165|BEHAVIORAL|animal-assisted intervention|horse-assisted intervention
48639154|NCT06260618|DEVICE|Gelfoam|GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.
48301910|NCT04628559|DRUG|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
48301911|NCT04628559|DRUG|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
48301912|NCT04628559|DRUG|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
48301913|NCT02684240|DRUG|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
48480384|NCT03704857|OTHER|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
48655935|NCT05703165|BEHAVIORAL|watching the countryside|just watching the countryside
47955033|NCT05776368|OTHER|Syntactic comprehension battery (BCS)|"The BCS is a battery for assessing syntactic skills. In this study, only one part of the BCS will be performed, namely task C2.~It consists in assessing the ability to assign thematic roles. To do this, the participant selects the image corresponding to the sentence he/she hears on a board of 2 images.~Task C2 consists of 50 tests of 2 images. A total score is given out of 50 points. The higher the score, the more successful the test."
47955034|NCT05776368|OTHER|Montreal Cognitive Assessment (MOCA)|"The MOCA is a short 30-question test that assesses several cognitive domains and allows for early detection of cognitive disorders. The MOCA test takes about 10-15 minutes to administer and consists of several sections, the first of which is an assessment of orientation in time and space. Then there are tasks that assess memory, concentration and reasoning ability, as well as language and visuospatial ability tasks.~The MOCA score can range from 0 to 30 points, with a score of 26 points or more considered normal."
47955035|NCT05776368|OTHER|Purdue Pegboard Test|"The Purdue Pegboard Test is a test of fine motor skills and hand-eye coordination. The test consists of a perforated board with holes into which participants must insert pegs or counters.~The assessment consists of four subtests, each repeated 3 times:~* Right hand (30 seconds): The total number of pins placed in the right column with the right hand in 30 seconds.~* Left hand (30 seconds): The total number of rods placed in the left column with the left hand in 30 seconds.~* Two hands (30 seconds): The total number of pairs of rods placed in both columns using both hands simultaneously, in 30 seconds.~* Assembly (60 seconds): The total number of rods, washers and clamps assembled in the allotted time, using both hands."
47955036|NCT05776368|OTHER|The Box and Block Test (BBT)|"The Box and Block Test (BBT) is a standardised test of manual dexterity used to assess motor function and hand-eye coordination in people of all ages.~The subject must move, one by one, a maximum number of cubes from one compartment of the box to another of equal size for 60 seconds. He starts with the healthy upper limb or, if not, with the dominant side. A 15 second trial period is allowed at the beginning of each side."
47955037|NCT05776368|OTHER|Motor training with a tool|"The patient will do around 30 minutes of motor training with a tool (pliers). They have to put most pieces as possible in the board with the pliers. Patients hold the pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder).~For E1 Arm1 and E1 Arm 4: the participant will do the motor training with a tool one time in this study.~For E3 Arm 1: the participant will do the motor training with a tool During 4 weeks (3 to 5 training sessions of 30 minutes)"
47955038|NCT05776368|OTHER|Motor training with a hand|The patient will do around 30 minutes of motor training with the hand. They have to put most pieces as possible in the board with the right hand (dominant hand) or with the left one if not possible (motor disorder).
47955039|NCT05776368|OTHER|on/off effect of tool motor training|"During 4 weeks, patients switch between tool training weeks (on) and control weeks (off) during which they don't practice motor training.~During on weeks they do 3 to 5 tool motor training sessions of 30 minutes. They use pliers with the right hand (dominant hand) or with the left one if not possible (motor disorder) and have to put most pieces as possible in the board.~During off weeks they do 3 to 5 control sessions where they only do the two linguistic tasks separated between a 30-minutes break."
48301914|NCT02684240|OTHER|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
48301915|NCT01111981|DRUG|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
48301916|NCT02324530|DEVICE|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
48339907|NCT04547998|DEVICE|Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)|Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
48480385|NCT03704857|OTHER|Assessment of pain and edema|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
48480386|NCT03704857|OTHER|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
48639155|NCT06260618|DEVICE|Chitodex|"The Chitogel Endoscopic Sinus Surgery Kit contains components and equipment for the preparation of a nasal gel to be applied to the sinus cavities via a supplied and specifically designed malleable cannula.~The Gel preparation will take approximately 30 minutes, so preparation must start sufficiently in advance of when the Gel is expected to be used in surgery.~Once the Gel has been prepared it should be applied to the sinus cavities on both sides within six hours using the malleable cannula supplied with the Kit.~The Gel must be prepared on a sterile surface following these instructions. There are two main components to the Gel.~1. Dextran Aldehyde (B), which is a dry powder, and is reconstituted into a liquid form through mixing the powder with a liquid Sodium Phosphate Buffer (A). Both of these components are supplied sterile.~2. The second component Chitosan Succinamide (C), is a liquid and is also supplied sterile."
48639156|NCT02773537|DRUG|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
48301917|NCT03391440|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
48639157|NCT02773537|DRUG|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
48639158|NCT02773537|DRUG|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
48639159|NCT03646617|RADIATION|Hypofractionated Radiation Therapy (HFRT)|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
48655936|NCT04476147|OTHER|Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.|This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
47955040|NCT05776368|OTHER|linguistic tasks|"The linguistic tasks consists in the presentation of correct sentences at the center of a computer screen. The sentence can be a coordinated one ( The policeman stopped the woman and asked the question ), or a subject relative (i.e.,  The policeman who stopped the woman asked the question ), or an object relative ( The policeman who the woman stopped asked the question ). After the sentence an affirmation test is proposed of the kind  the policeman stopped the woman , and the participant has to respond ads quick as possible whether it is true or false."
47955041|NCT06025825|DRUG|Articaine Hydrochloride + Epinephrine|"Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction."
47955042|NCT06025825|DRUG|Lidocaine Hydrochloride + Epinephrine|Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
47955043|NCT01439633|DEVICE|MGH OFDI marking|Imaging of esophagus with OFDI system
47955044|NCT04687384|PROCEDURE|Robotic-assisted colectomy|Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
47955045|NCT04687384|PROCEDURE|Conventional laparoscopic colectomy|Conventional laparoscopic colectomy
47955046|NCT03154593|OTHER|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
47955047|NCT04511104|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
47955048|NCT04511104|OTHER|Standard of Care|Standard of care rehabilitation
47955049|NCT00169793|OTHER|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
47955050|NCT00169793|OTHER|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
47955051|NCT04608487|DRUG|Fludarabine|Intravenous infusion
47955052|NCT04608487|DRUG|Cyclophosphamide|Intravenous infusion
47955053|NCT04608487|BIOLOGICAL|Axicabtagene Ciloleucel|Intravenous infusion
47955054|NCT03354078|PROCEDURE|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
47955055|NCT03354078|PROCEDURE|continous sutures|The way of closure of subcutanous tissue is by continous sutures
47955056|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
47955057|NCT00715455|DRUG|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
47955058|NCT00715455|DRUG|Unfractionated Heparin|Heparin will be administered per standard of care at sites
47955059|NCT02304718|BEHAVIORAL|Stationary bike|
47955060|NCT04213729|BEHAVIORAL|Diet Counseling|Standard of care diet counseling provided at clinic visit 1.
48301918|NCT03828838|DRUG|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
48339908|NCT05920200|PROCEDURE|open non-mesh hernia repair|A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
48480387|NCT03704857|OTHER|Longevity of rehabilitations|The teeth will be rehabilitated with resin and glass fiber post. The longevity of rehabilitations will be performed clinically and radiographically for 24 months.
48639160|NCT03646617|DRUG|Nivolumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.
48639161|NCT03646617|DRUG|Ipilimumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
48639162|NCT05993325|BIOLOGICAL|AdCLD-CoV19-1 OMI|3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle
48639163|NCT05993325|BIOLOGICAL|Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)|1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle
48639164|NCT06582641|BEHAVIORAL|Peer Group Connection - Middle School (PGC-MS)|Peer Group Connection - Middle School (PGC-MS) is the treatment condition. PGC-MS is a school-based positive youth development program for students entering the transition year into middle school (6th or 7th grade). PGC-MS aims to improve school engagement and social-emotional learning skills that support adolescent health and educational outcomes for program participants. Participants receive 45-minute outreach sessions held 3 to 4 times per month for the full school year. Schools are expected to implement a minimum of 18 outreach sessions over the school year. PGC-MS outreach sessions are delivered by older peer leaders (8th, 9th, or 10th graders) who are carefully selected by faculty advisors and trained on how to deliver program content.
48639165|NCT05883449|DRUG|AFM13|anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
48639166|NCT05883449|DRUG|AB-101|NK cell therapy, intravenous infusion
48639167|NCT05883449|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy, intravenous infusion
48639168|NCT05883449|DRUG|Fludarabine|Lymphodepleting chemotherapy, intravenous infusion
48639169|NCT05883449|DRUG|Interleukin-2|Immune cytokine, subcutaneously
48639170|NCT06539650|OTHER|Fractal Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
48639171|NCT06539650|OTHER|Isochronus Paced|The intervention consists in a single session of metronome paced strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
48480388|NCT03704857|OTHER|Cryotherapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
48480389|NCT03704857|OTHER|Ozone therapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
48109337|NCT03382080|OTHER|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
48339909|NCT05920200|PROCEDURE|open mesh hernia repair|"A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures."
48480390|NCT01358799|DEVICE|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
48480391|NCT06443359|RADIATION|hypofractionated radiation|All patients will receive a dose of 42.56 Gy in 16 daily fractions to the whole breast or chest wall and regional lymph nodes. A boost dose of 10 or 12.5 Gy in 4 or 5 daily fractions of 2.5 Gy, respectively, will be administered to either the lumpectomy cavity or mastectomy scar, as appropriate.
48480392|NCT04847596|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
48639172|NCT06539650|OTHER|Self Paced|The intervention consists in a single session of strength training composed by 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at at participants' own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
48639173|NCT01266057|DRUG|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
48639174|NCT01266057|DRUG|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
48301919|NCT01704248|DEVICE|Eye Drop Guide technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~5. Then place the upper lip down to cover the whole orbital rim area.~6. Tilt the head back if seated or standing.~7. Insert the bottle in the device all the way. Hold the bottle gently.~8. Look upward.~9. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~10. Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
48301920|NCT01704248|BEHAVIORAL|Routine self-instillation technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Lie down or tilt the head back if seated or standing.~5. Using the other hand, pull the lower lid down.~6. Hold the bottle over the eye and look up.~7. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~8. Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
48301921|NCT02713581|BIOLOGICAL|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
48301922|NCT02407951|BEHAVIORAL|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
47955061|NCT04213729|OTHER|CD LFD|Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
48109338|NCT03382080|OTHER|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
48109339|NCT05815342|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
48301923|NCT02407951|BEHAVIORAL|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
48301924|NCT03841149|OTHER|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
48301925|NCT05892783|OTHER|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
48301926|NCT00404781|DRUG|cilostazol in addition to aspirin and clopidogrel|
48301927|NCT02870452|BEHAVIORAL|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
48639175|NCT01266057|DRUG|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
48301928|NCT02870452|BEHAVIORAL|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
48639176|NCT06581692|OTHER|This is a routine procedure, no intervention will be provided.|This is a routine procedure, no intervention will be provided.
48639177|NCT00005684|DRUG|warfarin|
48639178|NCT00005684|DRUG|heparin|
47955062|NCT04213729|BEHAVIORAL|Dyadic Psychological Support (DPS)|The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
48109340|NCT04574635|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47955063|NCT03866954|COMBINATION_PRODUCT|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
48639179|NCT03862053|DRUG|Manuka honey|manuka eyedrops applied to the ocular surface
48639180|NCT04165486|DRUG|ION464|ION464 will be administered by IT injection.
47955064|NCT06126926|BEHAVIORAL|group therapy|32 weeks of group therapy
48109341|NCT01070888|DRUG|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
48109342|NCT01070888|DRUG|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
48109343|NCT02423135|BIOLOGICAL|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
48109344|NCT02469337|DRUG|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
48109345|NCT02469337|DIETARY_SUPPLEMENT|Carbohydrate drinks|preoperative carbohydrate drinks
48639181|NCT04165486|DRUG|Placebo|ION464-matching placebo will be administered by IT injection.
48639182|NCT04140344|OTHER|Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
48639183|NCT05667493|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
48639184|NCT06167083|DIAGNOSTIC_TEST|Machine Learning to Estimate Mortality|Using deep learning we try to develop an algorithm and anticipate mortality
48639185|NCT03177070|DRUG|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
48301929|NCT05547438|DRUG|NTS-104 TRIS|Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
48109346|NCT02469337|BEHAVIORAL|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
48301930|NCT05547438|DRUG|Placebo|Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
48301931|NCT00541892|OTHER|Medium with no human serum albumine added|See above
48301932|NCT00541892|OTHER|Conventional medium|See above
48301933|NCT00228488|DRUG|Gefitinib|
48639186|NCT06082817|DRUG|Oral Testosterone Undecanoate|50mg oral testosterone undecanoate daily
47955065|NCT06126926|OTHER|Treatment as usual|Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
47955066|NCT02388919|DRUG|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
47955067|NCT02388919|DRUG|Placebo|Basic dosage, take once when limosis in the morning.
47955068|NCT00593008|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
47955069|NCT00593008|DRUG|Gemcitabine|Given intravenously every other week of each 28-day cycle.
47955070|NCT04225962|OTHER|Intimate quality of life questionnaire|Preparation of an intimate quality of life questionnaire
47955071|NCT05708274|DRUG|CPH + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
47955072|NCT05708274|DRUG|CD-LD + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
47955073|NCT05708274|DRUG|ATX + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
47955074|NCT05708274|DRUG|Placebo + hand training|Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements.
48301934|NCT03791983|OTHER|Scalp Acupuncture|Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
48301935|NCT03791983|OTHER|Body Acupenture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
48301936|NCT04362579|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing or in the home setting
48301937|NCT05493956|RADIATION|chemoradiation|Radiation dose of 54 Gy will be given alongwith concurrent capecitabine
48301938|NCT03629626|PROCEDURE|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
48301939|NCT04618692|OTHER|Surgical Loupes|Biliary reconstruction will be performed using surgical loupe
48301940|NCT04618692|OTHER|Microscope|Biliary reconstruction will be performed using microscope
48301941|NCT03175003|OTHER|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
48301942|NCT00210015|DRUG|INS37217 Nasal Spray|
48301943|NCT02601885|DRUG|ABT-555|Intravenous Infusion
48109347|NCT03521037|DRUG|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
48109348|NCT03305003|OTHER|Spiral notebook|
48109349|NCT03305003|OTHER|Mobile application|
48301944|NCT02601885|OTHER|Placebo|Intravenous Infusion
48480393|NCT04847596|OTHER|Covid-19 vaccine|Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
48480394|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
48480395|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
48480396|NCT06473506|DIAGNOSTIC_TEST|Saliva collection|Self-collected saliva sample with molecular testing performed. Results are compared to rapid antigen testing, bacterial throat culture and bacterial throat molecular testing
48480397|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) orally
48109350|NCT01290224|OTHER|scrambler therapy|Undergo MC5-A therapy
48109351|NCT01290224|PROCEDURE|sham intervention|Undergo sham procedure
48109352|NCT01290224|OTHER|questionnaire administration|Ancillary studies
48109353|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
48109354|NCT04877834|DRUG|Dexlansoprazole|Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
48301945|NCT02253667|DEVICE|HFONC|
48301946|NCT02253667|DEVICE|Conventional oxygen therapy|
48301947|NCT03342612|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|
48301948|NCT02152865|DRUG|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
48301949|NCT02152865|DRUG|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
48301950|NCT05663723|DEVICE|Intervention group with the IV and V LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
48339910|NCT05920200|PROCEDURE|MIS hernia repair|"A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation ."
48339911|NCT01010269|DEVICE|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
48339912|NCT01010269|DEVICE|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
48480398|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
48480399|NCT04815395|DRUG|Placebo|Administration of placebo orally
48480400|NCT02096484|BEHAVIORAL|Group Metacognitive Therapy|
48109355|NCT00470938|DEVICE|SpineForce Reactive Neuromuscular Trainer|
48109356|NCT05875285|OTHER|Iontophoresis with methotrexate|"The methotrexate iontophoresis group the patient's hands are placed in direct contact with the conductive electrodes.~The patient will receive full explanation to the purpose of the treatment, the therapeutic and physiological benefits of this method of treatment. Before starting the treatment, all the previous measurements of each patient in this group is taken for a comparison.~Every patient will receive 12 sessions 3times/week every session consist of 30 minutes application of methotrexate iontophoresis using continuous direct current, the patient should feel mild tingling sensation (not painful), the polarity should be reversed halftime of treatment session, as the anodal current is more effective."
48339913|NCT00356668|DEVICE|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
48480401|NCT02096484|BEHAVIORAL|Mindfulness Meditation Therapy|
48480402|NCT05258851|DRUG|Ceftazidime-avibactam|Experimental
48480403|NCT05258851|DRUG|Colistin|Control
48480404|NCT00549952|OTHER|no intervention study|
48480405|NCT00780260|BEHAVIORAL|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
48480406|NCT04686994|DRUG|ASC 41|Oral tablets
48480407|NCT04686994|DRUG|ASC 41 Placebo|Oral tablets
48301951|NCT05663723|DEVICE|Intervention group with the IV, V and Violet LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
48301952|NCT05663723|DEVICE|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
48301953|NCT03186404|DRUG|Atorvastatin|Atorvastatin 40mg OD
48301954|NCT03186404|DRUG|Placebo oral tablet|Placebo
48301955|NCT00450372|BIOLOGICAL|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
48301956|NCT00450372|OTHER|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
48301957|NCT02310958|PROCEDURE|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
48301958|NCT00540176|DRUG|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
48301959|NCT01100307|DRUG|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
48301960|NCT01100307|OTHER|sham injection|sham injection every 6 weeks
48301961|NCT06261138|DRUG|Transarterial chemoembolization|A 5-French RH catheter was then introduced to the celiac artery, superior mesenteric and artery common hepatic artery for angiography to determine tumor location, quantity, size, and vascularity. After confirmation by C-arm cone-beam computed tomography (CBCT), chemoembolization was administered by superselective catheterization of the branches of the tumor-feeding arteries using a 2.8-French coaxial microcatheter. For cTACE, oxaliplatin, raltitrexed and an emulsion containing idarubicin and ethiodized oil were infused for over 20 minutes, followed by combined embolization with blank embolic microspheres. For DEB-TACE, DC/LC Beads® (Biocompatibles, Farnham, Surrey, UK), as drug carriers and embolic materials, were loaded with doxorubicin hydrochloride and mixed with nonionic contrast medium. Real-time assessment of embolization was performed with the assistance of CBCT.
48301962|NCT06261138|OTHER|Systemic treatment|"sorafenib (Bayer HealthCare, Berlin, Germany), lenvatinib (Eisai, Tokyo, Japan), apatinib (Hengrui Pharmaceuticals, Lianyungang, China) and donafenib (Zelgen Biopharmaceuticals, Suzhou, China), while a minority of patients received bevacizumab (Innovent Biologics, Suzhou, China).~sintilimab (Innovent Biologics, Suzhou, China), toripalimab (Junshi Biosciences, Suzhou, China), camrelizumab (Hengrui Pharmaceuticals, Lianyungang, China), tislelizumab (BeiGene, Shanghai, China), pembrolizumab (Merck Sharp \& Dohme, NewJersey, USA), nivolumab (Bristol Myers Squibb, New York, USA), atezolizumab (Roche, Basel, Switzerland) and envafolimab (Alphamab Biopharmaceuticals, Suzhou, China)."
48301963|NCT06000722|OTHER|eDelphi method|This is a Delphi technique-based study using a purposive sample of convenience. Consensus development methods will be used to generate clinical guidelines, endorsed by key clinical groups, on the use of SGLT2i's in patients with diabetic foot ulcer disease, including acknowledgement of specific scenarios or patient characteristics that may influence these guidelines.
48301964|NCT04260022|DRUG|Ascentage Pharma HQP1351 bioavailable inhibitor|HQP1351 taken by mouth every other day
48301965|NCT04260022|DRUG|Blinatumomab|Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
48301966|NCT03363828|DRUG|Estrofem|Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
48480408|NCT03039348|OTHER|semi-structured interview using a questionnaire|semi-structured interview using a questionnaire
48480409|NCT03472742|DRUG|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
48480410|NCT02262195|OTHER|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
48639187|NCT05757700|BIOLOGICAL|19(T2)28z1xx TRAC T cell|"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6"
48639188|NCT00000810|DRUG|Delavirdine mesylate|
48639189|NCT00000810|DRUG|Zidovudine|
48639190|NCT00000810|DRUG|Didanosine|
48639191|NCT04783168|OTHER|Best Practice|Receive usual care
48639192|NCT04783168|OTHER|Health Promotion and Education|Install and use Fitbit app
48639193|NCT04783168|OTHER|Medical Device Usage and Evaluation|Use Fitbit to monitor step count
48639194|NCT04783168|OTHER|Quality-of-Life Assessment|Ancillary studies
48639195|NCT04783168|OTHER|Questionnaire Administration|Ancillary studies
48301967|NCT02896426|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
47955075|NCT01858571|DRUG|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Etoposide (50 mg/m2/d)~Cycle B~* Daily oral Thalidomide (at 3mg/kg)~* Daily oral Celecoxib (100 mg BID for patients \< 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients \> 50 kg)~* Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
47955076|NCT04249531|DRUG|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
47955077|NCT04249531|DRUG|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
47955078|NCT03254290|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
47955079|NCT03254290|BIOLOGICAL|Formocresol|Control group
48480411|NCT05522218|DEVICE|Eluvia drug eluting stent|Eluvia drug eluting stent for peripheral arterial disease
47955080|NCT01611155|DRUG|venlafaxine|Given PO
48480412|NCT00466895|DRUG|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
48301968|NCT02896426|BEHAVIORAL|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
48301969|NCT03636503|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen
48301970|NCT03636503|DRUG|Utomilumab|Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
48301971|NCT03636503|DRUG|Avelumab|Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
48301972|NCT03636503|DRUG|PF04518600|In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
48301973|NCT03604471|DRUG|Atorvastatin|Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
48480413|NCT01409590|BEHAVIORAL|Exercise program|Homogenous exercise program in local fitness centers
48480414|NCT01409590|BEHAVIORAL|Diet|Weigh loss diet program prescribed by a professional nutritionist
48480415|NCT04831320|DRUG|nab-paclitaxel|Supplied by Celgene Corporation
48639196|NCT03159442|DRUG|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
47955081|NCT01611155|DRUG|placebo|Given PO
47955082|NCT01611155|OTHER|questionnaire administration|Ancillary studies
47955083|NCT01611155|OTHER|quality-of-life assessment|Ancillary studies
47955084|NCT05038670|DEVICE|Total Knee Replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either PERSONA PS or JOURNEY II BCS
47955085|NCT02848170|DRUG|CS-3150|CS-3150 2.5mg, oral
47955086|NCT02848170|DRUG|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
47955087|NCT03624985|DRUG|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
47955088|NCT03624985|DRUG|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
48109357|NCT05875285|OTHER|Iontophoresis with coal tar ointement|For coal tar ointement group the ointement is putted direct on the skin after describing the instruction and method of application and time of application and do alarm instead not to forget.
48109358|NCT05582057|BEHAVIORAL|Strengths to Grow: Preteen|An online, strength based parenting program for parents of preteens (aged 9-14).
48480416|NCT04831320|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
48480417|NCT02087176|DRUG|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
48480418|NCT02087176|DRUG|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
48480419|NCT02087176|DRUG|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
48480420|NCT02087176|DRUG|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
48301974|NCT01820689|OTHER|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
48301975|NCT06499506|PROCEDURE|Below knee amputation|trans tibial amputation one hand breadth below tibial tuberosity
48301976|NCT00069082|DRUG|Civamide (Zucapsaicin)|Nasal Solution 0.01%
48480421|NCT03899649|DRUG|SOC|Standard of Care treatment
48480422|NCT03899649|DEVICE|NanoKnife System|Irreversible Electroporation
48480423|NCT00258375|DRUG|custirsen sodium|
47955089|NCT02678273|OTHER|Intervention group|"The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~."
47955090|NCT01848730|DRUG|CNV2197944|
47955091|NCT01848730|DRUG|Placebo|
47955092|NCT06274320|OTHER|Group A: holistic approach|2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)
48301977|NCT00069082|DRUG|Sodium Chloride|Nasal Solution 10%
48480424|NCT00258375|DRUG|docetaxel|
48480425|NCT05081245|DRUG|ML-004 (IR)/(ER) tablet|Participants will receive ML-004 once daily.
48480426|NCT05081245|DRUG|ML-004 Placebo|Participants will receive matching placebo once daily.
47955093|NCT06274320|OTHER|Group B: Tolak® Standard of use|4-week Tolak® alone treatment (once daily in the evening)
47955094|NCT03922126|OTHER|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
47955095|NCT03922126|DIAGNOSTIC_TEST|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
47980578|NCT04450966|BEHAVIORAL|Computer-facilitated Screening and Brief Intervention|cSBI includes: 1) computer self-administered screening that adolescents complete prior to seeing their clinician, immediately followed by 2) computer-delivered brief psychoeducation on the health risks of substance use to prime patients for the clinician encounter, and 3) a Clinician Report Form with screen results and prompts that clinicians use to provide motivational interviewing-based individualized counseling during the visit.
48301978|NCT02568826|DRUG|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
48301979|NCT02605863|DRUG|Enzalutamide|160 mg by mouth daily for 12 months
48301980|NCT01796353|OTHER|sexual rehabilitation|exercise plus psycho-education
48301981|NCT01796353|OTHER|Usual care|usual care
48301982|NCT00830453|PROCEDURE|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
48480427|NCT01118819|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
48480428|NCT04951414|DIAGNOSTIC_TEST|ICF core set|KOA rehabilitation regimen based on the complete core combination of ICF was accepted
48480429|NCT00237419|DRUG|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
48480430|NCT00467987|DRUG|androgel|androgel 1%
48480431|NCT00467987|DRUG|placebo|placebo
48480432|NCT01478828|DRUG|Lovastatin|oral qd varying dose escalations/de-escalations
48480433|NCT02052791|DRUG|nusinersen|Administered by intrathecal (IT) injection
48639197|NCT03159442|DRUG|Placebo|Powder for inhalation administered via single dose DPI
48639198|NCT01396785|DRUG|33525|Daily for 14 days
48639199|NCT01396785|DRUG|Placebo|Daily for 14 days
48639200|NCT04741256|BEHAVIORAL|Education booklet & standardized discharge training|Tracheostomy education booklet and tracheostomy teaching performed by nurses during hospitalization as dictated by the booklet.
48639201|NCT01749293|PROCEDURE|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
48639202|NCT01749293|DRUG|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
48109359|NCT05773326|DRUG|Temsirolimus|TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
48480434|NCT04885192|OTHER|Stepped-Care Model|"Step 0: Screening via Manage My Pain (MMP) App. Patients using MMP will be prompted to complete questionnaires on pain catastrophizing, depressive symptoms, anxiety, suicide risk and opioid risk. Those scoring above clinical risk cut-offs will be referred to Step 1.~Step 1: Acceptance and Commitment Therapy (ACT) Workshop. Patients will be offered a virtual ACT workshop focusing on practical coping skills for dealing with pain, emotional dysregulation, and disability, while maximizing functioning and quality of life with chronic pain. Thirty days later, patients will be prompted to complete all questionnaires through MMP again; those who score above clinical risk cut-offs will be referred to Step 2.~Step 2: Dialectic Behavior Therapy (DBT) group. A 6-week DBT-based skills group will cover topics such as self-compassion, radical acceptance, distress tolerance, and mindfulness, among others. Thirty days later, patients will be prompted to complete questionnaires through MMP."
48480435|NCT03122717|DRUG|Gefitinib|gefitinib is a EGFR inhibitor
48109360|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
48109361|NCT00128193|OTHER|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
48109362|NCT00128193|OTHER|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
48109363|NCT00128193|BIOLOGICAL|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
48109364|NCT00128193|OTHER|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
48109365|NCT04580303|DRUG|collagenase clostridium histolyticum|Delivered via uniform grid injection techniques.
48109366|NCT04700930|OTHER|CBD-Cigarettes|CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes
48109367|NCT05826275|DRUG|TGN-S11|Small Molecule
48480436|NCT03122717|DRUG|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
48480437|NCT00733369|DEVICE|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
48480438|NCT00733369|DEVICE|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
48480439|NCT01189500|DRUG|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
48480440|NCT01189500|DRUG|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
48480441|NCT01838382|DEVICE|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
48480442|NCT06603181|OTHER|conventional treatment|exercise and splint
48480443|NCT06603181|OTHER|phonophoresis|exercise, splint and phonophoresis
48480444|NCT06603181|OTHER|extracorporeal shock wave therapy|exercise, splint and ESWT
48480445|NCT05767736|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
48480446|NCT05767736|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
48480447|NCT05767736|DRUG|Disease-Modifying Therapies (DMTs)|Administered as specified in the treatment arm.
48480448|NCT06239961|BEHAVIORAL|Social Connection|6 weekly Behavioral Activation Intervention calls with a 1 hour duration for each call.
47955096|NCT03172819|BIOLOGICAL|OBP-301|"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."
47955097|NCT03172819|DRUG|Pembrolizumab|200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
47955098|NCT05681663|OTHER|Electroshock Wave therapy|Randomized- Controlled trial
48109368|NCT05826275|DRUG|Pembrolizumab|PD-1 checkpoint blockade
48109369|NCT00209443|DRUG|Gadodiamide Injection|
48109370|NCT01091298|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
48109371|NCT01091298|OTHER|Placebo|Single dose (0.5 mL) of the placebo administered orally
48109372|NCT04946045|OTHER|Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)|"Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol."
48109373|NCT04267744|OTHER|Myia Health® remote patient monitoring unblinded treatment arm|"After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)"
48109374|NCT01026636|DRUG|Ceftobiprole|
48109375|NCT00571818|PROCEDURE|Oral glucose tolerance test|test done over 2 hours
48109376|NCT00571818|PROCEDURE|IV Glucose Tolerance Test|Done over 4 hours
48109377|NCT05951218|OTHER|inhibition technique|Inhibition treatment consists of applying progressive pressure with the finger until resistance is felt. The patient should feel discomfort but not pain. They should stop when they consider that the trigger point has been sufficiently relaxed. All the techniques should last less than 5 minutes. Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator
48109378|NCT05951218|OTHER|placebo|"The osteopath will perform a light touch on 4 areas for 30 seconds each time. The trigger point area must be lightly touched, followed by the upper part of the pectoralis major, the elbow and finally the anterior part of the opposite glenohumeral region.~Osteopaths will be trained to have a close strength during techniques. The number of Newton that will be apply will be decided during training with the investigator with a palpatory pressure measurement tool. A proposition of 1N will be proposed to have a very light touch, without activating the C-tactile sensors."
48639203|NCT01749293|DRUG|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol\*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
48639204|NCT01749293|RADIATION|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
47955099|NCT03610282|DRUG|IV Methylphenidate|Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
47955100|NCT03610282|DRUG|Propofol|Subjects will received propofol for up to 100 minutes.
47955101|NCT02678975|DRUG|Disulfiram|Disulfiram 400 mg daily
47955102|NCT02678975|DIETARY_SUPPLEMENT|Copper|nutritional supplement with copper, 2 mg daily
48109379|NCT01105143|BEHAVIORAL|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
48109380|NCT01105143|BEHAVIORAL|placebo|no intervention, only follow up
48109381|NCT05216653|DRUG|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
48109382|NCT05216653|DRUG|Oxaliplatin|130mg/m2，ivgtt，d1
47955103|NCT02678975|DRUG|Alkylating Agents|Alkylating antineoplastic agent
47955104|NCT06287008|PROCEDURE|robot-assisted kidney transplantation|The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
47955105|NCT00944671|DRUG|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
48109383|NCT05216653|DRUG|Capecitabine|1000mg/m2，po，bid，d1-14
48109384|NCT05216653|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
48109385|NCT05216653|PROCEDURE|TME surgery, total mesorectal excision|The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.
48109386|NCT00541125|BIOLOGICAL|bevacizumab|
48109387|NCT00541125|BIOLOGICAL|filgrastim|
48109388|NCT00541125|DRUG|fluorouracil|
48480449|NCT06239961|BEHAVIORAL|Nutritional Coaching|4 weekly nutritional coaching calls with a Registered Dietician with a 1 hour duration for each call.
48480450|NCT06239961|BEHAVIORAL|Physical Activity Coaching|4 weekly physical activity coaching sessions with a 1 hour duration for each call.
48480451|NCT05972018|DRUG|Liposomal bupivacaine|Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)
48480452|NCT05972018|DRUG|Ropivacaine|Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)
48480453|NCT05972018|DRUG|Bupivacain|Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
48109389|NCT00541125|DRUG|irinotecan hydrochloride|
48109390|NCT00541125|DRUG|leucovorin calcium|
48109391|NCT03812354|OTHER|THRIVE 4L/kg/min|High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
48109392|NCT03812354|OTHER|THRIVE 2L/kg/min|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
48339914|NCT04814511|DRUG|InfectoScab 5 % Creme|InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
48480454|NCT00042549|DEVICE|Extracorporeal Shock Wave Lithotripsy|
48480455|NCT00042549|DRUG|ursodiol|
48480456|NCT05857462|PROCEDURE|Post-admission FICB|Post-admission supra-inguinal FICB in hip fracture patient with 0.33% bupivacaine 30 ml
48480457|NCT04134026|DRUG|HIF-PHI|Drug will be dosed orally three times a week.
48480458|NCT04134026|DRUG|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
48639205|NCT01749293|DRUG|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
48639206|NCT06211270|BEHAVIORAL|FRESH|FRESH-T2D Intervention consisting of bimonthly food, recipes, and diabetes self-management resources + 4 meetings with Registered Dietitian Nutritionists x 6 months duration
48639207|NCT06553820|BEHAVIORAL|Intervention group I, Yoga 20 minutes x2 pr week|App-based MediYoga exercises, 20 minutes per session, twice a week for a total of 10 weeks.
48639208|NCT06553820|BEHAVIORAL|Intervention Group II, Yoga 40 minutes x2 pr week|App-based MediYoga exercises, 40 minutes per session, twice a week for a total of 10 weeks.
48639209|NCT06553820|OTHER|Control Group, No intervention|standard of care only
48639210|NCT04598919|DRUG|Saracatinab|125 mg once daily by mouth for 24 weeks
48639211|NCT04598919|DRUG|Placebo|once daily by mouth for 24 weeks
48639212|NCT04638647|BIOLOGICAL|Secukinumab s.c. injection|Secukinumab pre-filled syringes (PFS) for s.c. injection
48639213|NCT05107934|BIOLOGICAL|RPH-104|solution for subcutaneous injection, 40 mg/mL
48639214|NCT05107934|DRUG|Placebo|0.9% Sodium Chloride solution for Injection
48639215|NCT03363464|DRUG|Empagliflozin|Empagliflozin
48639216|NCT03363464|DRUG|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
48639217|NCT03363464|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist
48109393|NCT04696341|PROCEDURE|Matrix Rhythm Therapy|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.Five sessions of MRT (2., 5., 6., 8., 10. sessions of combined physiotherapy programme) was added at combined physiotherapy to Matrix Rhythm Group. Matrix Rhythm Therapy was applied to cervical and thoracic regions using 10 Hz frequency for 30 min (15 min for right and left sides each) according to the instructions of the technique developer.
48109394|NCT04696341|PROCEDURE|Control|Hot pack to cervical and upper thoracic regions (20 min), conventional TENS (100 Hz for 40 μsec), therapeutic ultrasound (1 MHz for 5 min) and conventional massage (using stroking, kneading and friction techniques for 5 minutes) were applied as passive physiotherapy modalities. Normal range of motion exercises, posture exercises, stretching exercises and isometric exercises were instructed as part of active physiotherapy.
48301983|NCT05387720|PROCEDURE|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
48301984|NCT05387720|PROCEDURE|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
48301985|NCT05387720|PROCEDURE|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
48301986|NCT03259542|DRUG|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
48301987|NCT03259542|DRUG|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
48301988|NCT05060510|DIAGNOSTIC_TEST|Take home saliva kit|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
48301989|NCT06127225|DRUG|Proliverenol|1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
48301990|NCT06127225|DRUG|Placebo caplets of Proliverenol|2 caplets of Proliverenol Placebo daily
48301991|NCT02260167|OTHER|A mix of natural treatments and medications|
48301992|NCT04359823|DRUG|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
48301993|NCT04359823|DRUG|Lovastatin 2% Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
48301994|NCT05108324|PROCEDURE|zygomatic implant|2 zygomatic implants and 2 anterior conventional implant
48301995|NCT05108324|PROCEDURE|conventional implant|patients will receive 4 conventional dental implant
48480459|NCT04865913|OTHER|Observational|A brief 15 min phone call 1 week, 30 and 90 days post discharge.
48480460|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
48301996|NCT05165810|BEHAVIORAL|Same-day ART initiation [experimental]|Participants assigned to same-day ART initiation will be offered standard, first-line ART on the day of trial enrollment. Participants, will be provided with focused counseling and instructions on where to follow-up for ongoing HIV care (either community-based HIV care or government-based HIV care, depending on randomization).
48480461|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
48480462|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
48639218|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
47955106|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
47955107|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
47955108|NCT05929794|DRUG|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
47955109|NCT05929794|DRUG|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
47955110|NCT05929794|DIAGNOSTIC_TEST|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
48480463|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
48480464|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
47980579|NCT04563793|DEVICE|Superion™ IDS|All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.
48109395|NCT05037344|BEHAVIORAL|Cognitive-behavioral psychotherapy|The goal is to develop an internet and smart phone delivered CBT (iCBT) for the treatment of pediatric OCD on the bases of our feasibility study. This group will start directly with therapy of 16 weeks. The waiting group gets the same intervention after 16 weeks of waiting.
48109396|NCT03137966|DRUG|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
48109397|NCT03137966|DRUG|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
48301997|NCT05165810|BEHAVIORAL|Standard ART initiation [usual care]|Participants randomized to standard ART initiation will not initiate ART on the day of trial enrollment, but only after linking to their assigned source of HIV care (either community-based HIV care or government-based HIV care, depending on randomization). In standard ART initiation, patients typically, complete an intake visit at the HIV clinic, with baseline laboratory testing, and return to the clinic approximately 2 weeks later to begin ART.
48109398|NCT01043263|DRUG|EN3324 (axomadol)|twice daily dosing
48109399|NCT01043263|DRUG|Placebo|twice daily dosing
48480465|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
48480466|NCT04834739|OTHER|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
48639219|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 1.1|Participants will use their Radicle Relaxation Active Study Product 1.1 as directed for a period of 6 weeks.
48639220|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
48639221|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 2.1|Participants will use their Radicle Relaxation Active Study Product 2.1 as directed for a period of 6 weeks.
48639222|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
48301998|NCT05165810|OTHER|Community-based HIV care [experimental]|Participants randomized to community-based HIV care will be referred to PWID-focused integrated care centers (ICCs) for ongoing HIV clinical management - a prototype of decentralized HIV care in India. ICCs will provide free HIV care that will adhere closely to Indian HIV treatment guidelines and, when relevant, to local HIV treatment standards.
48639223|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 3.1|Participants will use their Radicle Relaxation Active Study Product 3.1 as directed for a period of 6 weeks.
48301999|NCT05165810|OTHER|Government-based HIV care [usual care]|Participants randomized to government-based HIV care will be referred to government-based HIV clinics for ongoing HIV clinical management. Government-based clinics provide free HIV care that adheres closely to Indian HIV treatment guidelines
48302000|NCT05165810|BEHAVIORAL|Enhanced adherence support [experimental]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to enhanced adherence support will receive an intensive, tailored adherence intervention lasting a maximum of 6 months, with two components: 1) tracking and outreach, and 2) psychosocial support and navigation. These will aim to equip PWID with skills to independently manage their ART using motivational interviewing and strengths-based case management.
48302001|NCT05165810|BEHAVIORAL|Routine adherence support [usual care]|Participants who i) experience virologic failure after 6 months in the study and ii) are randomized to routine adherence support will receive a guideline-based, HIV clinic-based adherence counselling intervention lasting a maximum of 6 months
48302002|NCT02752867|DRUG|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
48302003|NCT02752867|OTHER|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
48302004|NCT04857398|DRUG|insulin icodec|"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."
48302005|NCT00620620|DRUG|Inhaled placebo|Inhaled Staccato Placebo
48639224|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
48639225|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.1|Participants will use their Radicle Relaxation Active Study Product 4.1 as directed for a period of 6 weeks.
48639226|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.2|Participants will use their Radicle Relaxation Active Study Product 4.2 as directed for a period of 6 weeks.
48639227|NCT01478087|DEVICE|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
47955111|NCT05929794|DIAGNOSTIC_TEST|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
47955112|NCT05929794|DIAGNOSTIC_TEST|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
48109403|NCT04157530|DEVICE|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
48109404|NCT04157530|DEVICE|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
48109405|NCT04157530|DEVICE|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
48302006|NCT00620620|DRUG|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
48302007|NCT00620620|DRUG|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
48302008|NCT00620620|DRUG|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
48302009|NCT00620620|DRUG|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
48302010|NCT05916196|DRUG|18F-Fluoroestradiol|18F-FES PET/CT
48302011|NCT01421290|PROCEDURE|Surgery|Knee surgery
48109406|NCT06241235|DRUG|ZG005 Powder for Injection|ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
48302012|NCT01421290|OTHER|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
48639228|NCT04651374|DEVICE|geko T3|The device stimulates the peroneal nerve.It will be applied for the entire duration of ICU stay and replaced once every 24 hours.
48639229|NCT05882903|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
48639230|NCT05882903|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
48109407|NCT06241235|DRUG|Paclitaxel|IV infusion
47980580|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
48109408|NCT06241235|BIOLOGICAL|Bevacizumab|IV infusion
48109409|NCT06241235|DRUG|Cisplatin|IV infusion
48109410|NCT06241235|DRUG|Carboplatin|IV infusion
48109411|NCT04292054|DRUG|active intervention|The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
48109412|NCT04292054|OTHER|placebo intervention|The control group will received, as placebo NaCl 0.9% solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
48109413|NCT00105794|PROCEDURE|Psychiatric Advance Directives intervention|
48109414|NCT05400707|DIAGNOSTIC_TEST|Assessment of vital signs|heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
48109415|NCT05400707|DIAGNOSTIC_TEST|Assessment of patient mobility at presentation|Patients are asked how they assess their own mobility: - Stable walking without aids or limited mobility with aids (walking aid, wheelchair, lying down).
48109416|NCT05400707|DIAGNOSTIC_TEST|Assessment of level of consciousness by AVPUC scale|Assessment of level of consciousness by AVPUC scale (alert, new confusion, verbal, pain, unresponsive, new confusion)
48109417|NCT05400707|DIAGNOSTIC_TEST|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 37 symptoms
48109418|NCT05400707|DIAGNOSTIC_TEST|Assessment of what matters most in patients of 65 years and older|"Patients over the age of 65 are asked the following: generally asked: what matters most to you at the moment? and why is that important for you?."
48109419|NCT05400707|DIAGNOSTIC_TEST|Assessment of Decision-making in senior physicians|Questionnaire consisting of 10 questions about the decision-making processes in the emergency department and the factors that form the basis of their decisions regarding the diagnosis, treatment, and disposition of the patient.
48109420|NCT05400707|DIAGNOSTIC_TEST|Pain Numeric Rating Scale (NRS)|"The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain ('0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine))"
48109421|NCT05400707|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|The CFS is a commonly used score to assess frailty. It was developed within the Canadian Study of Health and Aging and consists of a 9-level ordinal scale ranging from very fit (score 1) to living with very severe frailty (score 8), and score 9 reserved for those who are terminally ill.
48109422|NCT02508844|DIETARY_SUPPLEMENT|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
48109423|NCT02508844|DIETARY_SUPPLEMENT|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
48109424|NCT01443416|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
48109425|NCT01443416|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
48109426|NCT02296619|PROCEDURE|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
48109427|NCT02296619|PROCEDURE|Control|A sham band-aid will be applied to the abdomen of subjects
48109428|NCT01842724|PROCEDURE|Motec total wrist arthroplasty|
48109429|NCT01842724|PROCEDURE|Remotion total wrist arthroplasty|
48109430|NCT01852019|DRUG|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
48109431|NCT01852019|DRUG|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
48109432|NCT06304636|DRUG|Descartes-15|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
48109433|NCT05647967|DIAGNOSTIC_TEST|Ultrasound|Each patient underwent ultrasound after admission of ICU.
48109434|NCT04128839|DIETARY_SUPPLEMENT|Aronia berry juice|A juice blend of three different cultivars was used: Viking, MacKenzie and Autumn Magic. Raw juice was heat pasteurized before provided to participants. Participants consumed 100 mL of juice per day.
48109435|NCT04128839|OTHER|Sham comparator|The placebo was flavor, color, and carbohydrate-matched to aronia juice. The placebo consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL of juice per day.
48302013|NCT00887692|BEHAVIORAL|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
48302014|NCT05378659|BEHAVIORAL|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
48302015|NCT05378659|BEHAVIORAL|Stroop Test|Evaluates Processing Speed and Executive Control
48302016|NCT05378659|DIAGNOSTIC_TEST|4AT Delirium|Screening tool to test for delirium post surgery
48302017|NCT05378659|BEHAVIORAL|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
48639231|NCT06451926|OTHER|Escape room game|Educational escape rooms are live action games where teams use content knowledge to complete tasks and puzzles to reach a final goal, such as escaping from a room or completing a final puzzle
48302018|NCT05378659|BEHAVIORAL|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
48302019|NCT05378659|DIAGNOSTIC_TEST|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
48302020|NCT05378659|DIAGNOSTIC_TEST|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
48302021|NCT05378659|DIAGNOSTIC_TEST|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
48480467|NCT04834739|OTHER|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
48480468|NCT04834739|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
48639232|NCT06109181|GENETIC|LX2020|LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
48639233|NCT01923974|DRUG|Melatonin 10 mg|
48639234|NCT01923974|DRUG|Melatonin 100 mg|
48639235|NCT01923974|DRUG|Placebo|
48639236|NCT05894798|OTHER|Acupuncture|Acupuncture at point LI 4 in the thumb grip on the upper side of the hand, bilaterally, with a sterile disposable needle of dimension 0.20 x 13 mm. The stitch is approximately three mm deep. The needle is allowed to remain in place for about 30 seconds
48639237|NCT04154488|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
48639238|NCT05514444|BIOLOGICAL|MK-4464|MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.
48639239|NCT05514444|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered as an IV infusion every three weeks.
48109436|NCT04247204|BIOLOGICAL|Platelet-rich plasma intrauterine infusion|For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
48480469|NCT04834739|OTHER|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
48639240|NCT05514444|DRUG|89Zr-MK-4464|89ZR-MK-4464 administered as an IV infusion on C1D1.
48639241|NCT05492578|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
48302022|NCT04154267|PROCEDURE|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
48302023|NCT05387395|OTHER|NO intervention|no intervention
48302024|NCT00373971|BEHAVIORAL|Involving the patients in their own nutritional care|
48480470|NCT04834739|OTHER|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
48639242|NCT05492578|DRUG|Topical corticosteroids|Pharmaceutical form: Topical Route of administration: Topical
48639243|NCT05492578|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical Route of administration: Topical
48639244|NCT05492578|DRUG|Oral corticosteroids|Pharmaceutical form: Oral Route of administration: Oral
48639245|NCT06457139|DIAGNOSTIC_TEST|Glucose tolerance test (2 hour)|Early testing with the 2 hour glucose tolerance test will occur during their inpatient postpartum hospitalization.
48639246|NCT06457139|OTHER|Active Comparator|Subjects randomized to the comparison condition will receive the usual standard of care. The standard of care will consist of administration of educational materials adapted from the American Diabetes Association that discusses healthy lifestyle behaviors and the increased risks of developing T2DM after a pregnancy complicated by GDM.
47955113|NCT05929794|OTHER|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
47955114|NCT06009692|OTHER|Upper limb Neuro-dynamics (Slider/ Tensioner Technique)|The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.
47955115|NCT06009692|OTHER|Conventional Therapy for Upper limb|Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
47955116|NCT00575991|DIETARY_SUPPLEMENT|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
48109437|NCT02952768|BEHAVIORAL|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
48639247|NCT02924402|BIOLOGICAL|XmAb13676|Biological
48109438|NCT00612391|PROCEDURE|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
48109439|NCT00612391|PROCEDURE|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
48109440|NCT02052648|DRUG|Indoximod|
48109441|NCT02052648|DRUG|Temozolomide|
48109442|NCT02052648|DRUG|Bevacizumab|
48109443|NCT02052648|RADIATION|Stereotactic Radiation|
48109444|NCT01219699|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
48109445|NCT01219699|DRUG|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
48109446|NCT03119636|BIOLOGICAL|NPC transplantation|The cells are stereotactically implanted in the striatum.
48109447|NCT03119636|DRUG|Levodopa|Levodopa is used depending on the patient's condition
48109448|NCT05987969|OTHER|"Alena mobile application"|This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
48109449|NCT02845050|DRUG|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
48109450|NCT02845050|DRUG|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
48109451|NCT02845050|PROCEDURE|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
48302025|NCT03047577|BEHAVIORAL|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
48302026|NCT04842721|DRUG|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
48639248|NCT01701635|BEHAVIORAL|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
48639249|NCT01701635|BEHAVIORAL|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
48639250|NCT04704128|OTHER|Salivic sample|Collection of total saliva not stimulated
48302027|NCT04842721|OTHER|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
48302028|NCT03009656|OTHER|No study specific interventions|
48302029|NCT06376604|OTHER|Fasting Mimicking Diet|Subject will consume 6 cycles of 5-day fasting mimicking diet: 3 days prior to, the day of, and 1 day following chemotherapy treatments.
48302030|NCT06376604|DRUG|Chemotherapy|6 cycles of standard chemotherapy for the gynecologic malignancy.
48302031|NCT03974828|DEVICE|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
48302032|NCT03585374|COMBINATION_PRODUCT|Methoxyflurane and Penthrox inhaler|3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.
48302033|NCT03585374|DRUG|Morphine|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
48302034|NCT03585374|DRUG|Paracetamol|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
47955117|NCT04471246|DRUG|Cephalexin|1000 mg PO QID for 7 days
47955118|NCT04471246|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
48302035|NCT03585374|DRUG|Ketoprofen|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
48302036|NCT04772183|DEVICE|SpO2 and SaO2 comparison|"Several pulse oximeter will be place on patient find few minutes before arterial blood gases.~During an arterial blood sample, all SpO2 will be recorded"
48302037|NCT00041236|DRUG|exatecan mesylate|
48639251|NCT04524000|DRUG|Alpelisib|"\[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1."
48639252|NCT04524000|DRUG|Fulvestrant|Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
47955119|NCT05099081|PROCEDURE|diode laser application|Local anesthesia will be applied Lesion will be excised with diode laser (Medency, Italy) continuous wave mode 980 nm wave length with an output power 3 W in contact mode
48302038|NCT05336968|DRUG|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
48302039|NCT03715569|DIAGNOSTIC_TEST|Vestibular function|Vhit, Caloric test
48302040|NCT03715569|DIAGNOSTIC_TEST|OAE/WBT|Oto acoustic emissions Wide Band Tympanometry
48302041|NCT03715569|DIAGNOSTIC_TEST|Biomarker|Biomarker examination
48302042|NCT03715569|DIAGNOSTIC_TEST|MOCA, eGOS|Cognitive tests
47955120|NCT05099081|PROCEDURE|intra-lesional injection of ethanolamine oleate|"Local anesthesia will be applied Injection of ethanolamine oleate (sclerosing gent) with concentration 5% diluted in distilled water to form 2.5% ethanolamine oleate According to lesion size range from 1.5 to 3 ml of solution will be injected slowly into lesion using gauge needle until leaked from lesion.~Lesion will be compressed for 5 minutes. Lesion will be observed once a week after injection until it becomes necrotic and falls off spontaneously.~Repeated injection may be needed."
47955121|NCT00810108|DRUG|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
47955122|NCT03601078|BIOLOGICAL|bb2121|bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
48302043|NCT03715569|DIAGNOSTIC_TEST|Audiometry|Hearing test
48302044|NCT01147315|PROCEDURE|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
48302045|NCT00995735|PROCEDURE|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
48302046|NCT00995735|PROCEDURE|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
48302047|NCT02691247|BIOLOGICAL|CLBS03 Low Dose|
48302048|NCT02691247|BIOLOGICAL|CLBS03 High Dose|
47955123|NCT03601078|DRUG|Lenalomide|Specified dose on specified days
47955124|NCT03601078|DRUG|Talquetamab|Specified dose on specified days
47955125|NCT01193270|DRUG|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
47955126|NCT01193270|DRUG|Placebo|Sterile water in volume equal to that of the comparator drug
48480471|NCT04834739|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
48480472|NCT04834739|OTHER|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
48302049|NCT02691247|BIOLOGICAL|Placebo|
48302050|NCT00000615|BEHAVIORAL|diet, reducing|
48302051|NCT02894047|BIOLOGICAL|blood|measurement of CaSR expression levels on synovial fluid monocytes
48302052|NCT05567068|DRUG|Atorvastatin 80mg|Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties
48302053|NCT05567068|DRUG|Mesalamine|Mesalamine
47955127|NCT05235451|OTHER|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
47955128|NCT03584100|DEVICE|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
47955129|NCT00689780|DRUG|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
48302054|NCT05684978|DRUG|Perampanel|The purpose of this study is to determine the efficacy of Perampanel, an approved antiseizure medication, in the treatment of refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
48302055|NCT04866420|BEHAVIORAL|The MenFAS Study|A cross over repeated exposure randomized design observational study
47955130|NCT00689780|DRUG|Midazolam|Oral solution given orally once daily on day -1 and day 14
48302056|NCT01031758|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
47955132|NCT05153772|DRUG|AlphaMedix|212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
47955133|NCT03570944|PROCEDURE|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
48302057|NCT00049959|DRUG|verteporfin PDT|
48302058|NCT00038545|DRUG|Filgrastim SD/01|
48302059|NCT00038545|DRUG|Paclitaxel|
48302060|NCT00038545|DRUG|Topotecan|
48302061|NCT00469196|PROCEDURE|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
48302062|NCT05552378|DEVICE|Multi-Gyn FloraFem|Vaginal gel packed in 5 single use plastic tubes.
48302063|NCT00718861|DRUG|Placebo|
48302064|NCT00718861|DRUG|Zoledronic acid|
48302065|NCT06444737|DRUG|Intravenous ondansetron|Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia
48109452|NCT05688761|DRUG|Proton pump inhibitor|Long-term use of medications, particularly proton pump inhibitors
48302066|NCT06444737|DRUG|Intravenous normal saline|Intravenous normal saline 5 ml (control group) 5 min before spinal anesthesia
48302067|NCT05774912|OTHER|Ultrasound evaluation|Fetal ultrasound evaluation will be collected longitudinally during the prenatal period from the weeks 14 every 4-5 weeks, for a total of maximum 6 ultrasound scans
48302068|NCT02695485|PROCEDURE|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
48302069|NCT01108809|DRUG|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
48302070|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
48302071|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
48302072|NCT05157672|DIETARY_SUPPLEMENT|Cinnamon (2 g)|oral capsules, 2 g
48302073|NCT05157672|DRUG|Nicotine gum (2.5 mg)|gum, 2.5 mg
48109453|NCT05928819|PROCEDURE|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.|Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
48109454|NCT02950558|DRUG|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
48302074|NCT05157672|DRUG|Letrozole (2.5 mg)|tablet, 2.5 mg
48302075|NCT03403491|OTHER|patientMpower application|electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
48302076|NCT03403491|OTHER|sham application|dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
48302077|NCT05424900|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
48302078|NCT01530399|DRUG|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
48302079|NCT01530399|DRUG|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
48302080|NCT01530399|DRUG|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
48639253|NCT05705128|DRUG|Dexmedetomidine|Dexmedetomidine will be given with bupivaciane for postoperative pain control
48302081|NCT01530399|DRUG|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
48639254|NCT04970576|DRUG|Rivaroxaban|Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
47955134|NCT04721730|BEHAVIORAL|PLH-YC|There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
47955135|NCT04721730|BEHAVIORAL|Lecture|Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
47955136|NCT00165659|DRUG|DONEPEZIL HYDROCHLORIDE|
47955137|NCT03944031|DRUG|LY3372689|Administered orally.
47955138|NCT03944031|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered IV.
48109455|NCT02950558|PROCEDURE|Nerve block|insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
48109456|NCT05218837|OTHER|Vaginal birth|Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
48109457|NCT01788930|DEVICE|CPAP|
48302082|NCT01530399|DRUG|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
48480473|NCT04834739|OTHER|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
48639255|NCT04970576|DRUG|Warfarin|Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
48639256|NCT05480046|DRUG|Risperidone ISM|Risperidone ISM is administered every 4 weeks
48639257|NCT06219707|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
47955139|NCT06421116|PROCEDURE|Synovial ultrasound-guided biopsy Intestinal biopsy|Patients will undergo biopsies if needed for standard-of-care follow-up and after clinical indication.
47955140|NCT03386474|DRUG|Brolucizumab 6 mg|Administered as opthalmic solution for an intravitreal injection to the study eye
47955141|NCT03386474|DRUG|Aflibercept 2 mg|Administered as an opthalmic solution for intravitreal injection to the study eye
47955142|NCT05381844|OTHER|Blood sampling|30 ml blood sampling for virological research
47955143|NCT04382300|DRUG|pyrotinib combined with thalidomide|Single Group Assignment
47955144|NCT02834728|BEHAVIORAL|telephone interview|
47955145|NCT00354861|BIOLOGICAL|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
47955146|NCT00354861|BIOLOGICAL|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
47955147|NCT00354861|BIOLOGICAL|Engerix B|20 µg hepatitis B antigen absorbed on alum
47955148|NCT02318537|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
47955149|NCT02318537|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol.
47955150|NCT03788629|OTHER|Talocrural joint MWM mobilization|There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.
47955151|NCT03788629|OTHER|Subtalar joint MWM mobilization|There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
47955152|NCT00393354|DRUG|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
48109458|NCT00979056|DRUG|Rifaximin|400 mg per day, oral use, maximum duration 28 days
48109459|NCT00979056|DRUG|Lactose|Coated Tablet, Oral Use
48109460|NCT06028451|OTHER|Record the information data|Record the information data
48109461|NCT06226714|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
48109462|NCT06226714|BIOLOGICAL|MPSV4|1 dose of MSPV4 on Day 0
48109463|NCT05270551|PROCEDURE|ACL Reconstruction|All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
48109464|NCT05399394|DRUG|Chemotherapy|The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.
48639258|NCT02858661|OTHER|Nasopharyngeal swab|
48639259|NCT05941442|DRUG|Darigabat|Oral tablets
48639260|NCT05941442|DRUG|Placebo|Oral tablets
48639261|NCT06492720|DEVICE|Focused ultrasound (FUS) treatment|The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.
48639262|NCT04969107|PROCEDURE|taTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.
48639263|NCT04969107|PROCEDURE|abdTME|Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.
48639264|NCT05587543|BEHAVIORAL|PK Blood Collection|All subjects were subjected to PK blood sampling as prescribed by the protocol.
48639265|NCT05587543|DRUG|CAR|Target A positive subjects will receive CAR-T cell therapy.
47955153|NCT00393354|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
47955154|NCT04135742|DEVICE|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
48480474|NCT04834739|OTHER|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
48480475|NCT05327855|DRUG|OPL-0301 Dose 1|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
48480476|NCT05327855|DRUG|OPL-0301 Dose 2|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
48480477|NCT05327855|DRUG|Placebo|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
48480478|NCT05944458|DRUG|N acetyl cysteine|Fluimucil 600 mg iv to be taken twice daily as infusion
48480479|NCT05356182|OTHER|Diet|Control diet consisting of 20% protein, intervention diet consisting of 10% protein
48480480|NCT05814991|DRUG|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
48480481|NCT05814991|DEVICE|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
48480482|NCT06424717|DRUG|Avelumab|Participants will be administered Avelumab intravenously (IV).
48480483|NCT06424717|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
48480484|NCT05453786|DRUG|SID1903|Single oral administration of SID1903 after an overnight fast
48639266|NCT05587543|DRUG|TCR|Target A negative, Target B positive and Target C positive subjects will receive TCR-T cell therapy.
48639267|NCT00025935|DRUG|Lithium|
48639268|NCT05274035|DRUG|Perampanel|"For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children \<4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
48639269|NCT04545489|BEHAVIORAL|Intervention group|This is a intervention for 12 months which focuses on behavioral and medication management, led by a health coach (nurse or pharmacist)
47955155|NCT04135742|BEHAVIORAL|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
47955156|NCT00585962|RADIATION|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
48302083|NCT01530399|DRUG|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
48480485|NCT05453786|DRUG|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
48480486|NCT02503475|OTHER|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
48480487|NCT02503475|BEHAVIORAL|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
48480488|NCT02503475|DEVICE|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
48639270|NCT04545489|BEHAVIORAL|Education control group|This group will receive education materials related to CVD risk reduction at each 4 month visit over the course of 12 months.
48639271|NCT01029873|DRUG|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
48639272|NCT01029873|BIOLOGICAL|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
48639273|NCT05950126|OTHER|pain catastrophizing scala|"The PCS, a 13-item self-report inventory used to determine the extent to which individuals catastrophize in response to pain, was developed. Total possible scores range from 0 to 52, with higher scores indicating negative results.~The Turkish version was tested for reliability and validity and the Cronbach alpha coefficient was measured at 0.90. PCS scores of 16 or lower are regarded as normal, and scores of 17 or above as high."
48639274|NCT03464448|DRUG|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
48639275|NCT04893109|DRUG|trastuzumab-emtansine|intravenous infusion
48639276|NCT04893109|DRUG|Trastuzumab SC|Muscular injection
48639277|NCT04893109|DRUG|Paclitaxel|intravenous infusion
48639278|NCT02506153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48302084|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy + app|In the group ACT+app, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer and interleaved non-contact activities, which will serve as support for each of the modules. The non-contact activities will consist of assigning tasks, practices (mindfulness, breathing), reminder systems, recording, reinforcement and monitoring. Resources such as short texts, videos, audio files and recording systems will be used
48302085|NCT05126823|BEHAVIORAL|Acceptance and commitment therapy|In the group ACT, experiential exercises are carried out, metaphors, discussions and assignments are used to promote awareness and flexibility about the thoughts and emotions associated with cancer
48302086|NCT05815329|OTHER|cognitive training|After the multidimensional evaluation at T0, the participants will be randomly allocated into an experimental group and a wait list control group. Specifically, cognitive training will be offered to half of the outpatients included in this research by means of technological devices (Neurotablet). A neuropsychologist will supervise the cognitive training offline (about 30 minutes per 5 days, 8 weeks) and through a face-to-face 1 hour-session each week per each outpatient.
48302087|NCT00698516|DRUG|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
48302088|NCT02986958|OTHER|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
48302089|NCT02986958|OTHER|Usual care|routine primary care
48302090|NCT05951764|DIAGNOSTIC_TEST|Non-invasive measurement of arterial stiffness by Pulse Wave Velocity (PWV)|For all patients PWV in (cm/s) will be collected from D-30 to D-1 before the procedure and at D3 postoperatively.
48302091|NCT00055419|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
48302092|NCT01729910|BEHAVIORAL|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
48480489|NCT03302572|OTHER|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
48480490|NCT01463150|DRUG|Clopidogrel|Clopidogrel 150mg per day for 15 days
48639279|NCT02506153|PROCEDURE|Computed Tomography|Undergo CT scan
48639280|NCT02506153|BIOLOGICAL|Ipilimumab|Given IV
48639281|NCT02506153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48639282|NCT02506153|BIOLOGICAL|Pembrolizumab|Given IV
47955157|NCT04234607|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48480491|NCT01463150|DRUG|Prasugrel|Prasugrel 5mg per day for 15 days
48480492|NCT00343434|BEHAVIORAL|behavioral dietary intervention|
48480493|NCT00343434|BEHAVIORAL|exercise intervention|
48480494|NCT00343434|DIETARY_SUPPLEMENT|soy isoflavones|
48480495|NCT00343434|DIETARY_SUPPLEMENT|soy protein isolate|
48639283|NCT02506153|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48639284|NCT02506153|OTHER|Quality-of-Life Assessment|Ancillary studies
48639285|NCT02506153|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
48639286|NCT04096885|DIAGNOSTIC_TEST|Blood and urine samples, skin and stool swabs|Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
48639287|NCT05061134|DRUG|Ceralasertib|Ceralasertib (240 mg) will be administered orally twice daily.
48639288|NCT05061134|BIOLOGICAL|Durvalumab|Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
48639289|NCT04572841|DRUG|SAR441344|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
48639290|NCT04572841|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
48639291|NCT06394739|DEVICE|Thrombectomy|RevCore Thrombectomy to treat in-stent thrombosis
48639292|NCT04540900|BIOLOGICAL|KB301|non-integrating HSV-1 vector expressing human type III collagen
48639293|NCT04540900|OTHER|Placebo|sterile isotonic saline
48639294|NCT04895358|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
48639295|NCT04895358|DRUG|paclitaxel|IV infusion
47955158|NCT04234607|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
47955159|NCT04234607|DRUG|Etoposide|Etoposide is a cell cycle-specific antitumor drug
47955160|NCT04234607|DRUG|Carboplatin|Carboplatin is cell cycle nonspecific antitumor drug
48302093|NCT01729910|BEHAVIORAL|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
48302094|NCT06421428|OTHER|LEI Interview|"In accordance with the IPA (Interpretative phenomenological analysis) methodology, a semi-structured interview outline will be defined, aimed at understanding the lived experiences of women (lived experience) during their coexistence with urinary incontinence and during the treatment process.~The screwdriver questions were formulated starting from the reference literature and will be discussed in a focus group composed of a uro-gynecologist, two midwives, a nurse, an expert in qualitative methodology. The final screwdriver questions resulting from the focus group will be tested on a small group of women."
48302095|NCT06421428|OTHER|LEI Survey|Some sociodemographic data identified from the reference literature will be collected in paper form immediately at the end of each interview, for the description of the sample. The data will concern: age, nationality, marital status, level of education, number of children, menopause, social relationships, level of information, period of onset of symptoms, type of symptomatology, frequency of episodes of urinary incontinence, quantity of urinary leakage, uro-gynecological pathological history.
48302096|NCT04531319|DIAGNOSTIC_TEST|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
48302097|NCT03774693|OTHER|General anesthesia with fentanyl boluses|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
47955161|NCT04234607|DRUG|TQB2450（blank）|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
48302098|NCT03774693|PROCEDURE|Regional block|Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
48302099|NCT00502905|DRUG|Busulfan|130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
47955162|NCT04234607|DRUG|Anlotinib（blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
48302100|NCT00502905|DRUG|Fludarabine|40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.
48302101|NCT02606045|DRUG|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
48302102|NCT02606045|DRUG|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
48302103|NCT05301322|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine
48302104|NCT05301322|OTHER|Placebo|Placebo
48302105|NCT05301322|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV
48302106|NCT03048721|PROCEDURE|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
48302107|NCT03048721|PROCEDURE|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
48302108|NCT06116435|BEHAVIORAL|Prevent T2|The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
48302109|NCT06116435|BEHAVIORAL|Move group-based classes|The Move physical activity support program group-based classes are based on Self-Determination Theory and encourage improvements in autonomous motivation for physical activity. These group-based classes are integrated within the Prevent T2 program curricula.
48302110|NCT06116435|BEHAVIORAL|Fitness Membership|Participants will receive 6 months of the Peloton fitness membership. This includes access to livestream and on-demand fitness classes including walking, strength training, yoga, meditation, stretching, etc.
48302111|NCT06116435|BEHAVIORAL|Mental Imagery|Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
48480496|NCT00343434|OTHER|counseling intervention|
48480497|NCT00343434|OTHER|educational intervention|
47955163|NCT00281307|DRUG|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
47955164|NCT03047707|DIAGNOSTIC_TEST|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
47955165|NCT03609879|DEVICE|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
47955166|NCT03609879|DEVICE|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
47955167|NCT03609879|DEVICE|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
47955168|NCT03609879|DEVICE|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
47955169|NCT03609879|DEVICE|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
47955170|NCT05253846|DRUG|Irinotecan|chemotherapy treatment
48109465|NCT05399394|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.
48302112|NCT06116435|BEHAVIORAL|Move 1:1 Support|Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
48302113|NCT02199977|OTHER|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
48302114|NCT02199977|OTHER|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
48302115|NCT02199977|OTHER|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
48302116|NCT04200170|DEVICE|Rose|Rose is a patient-centric, mobile mental health platform designed for in-between clinical mental health monitoring in form of mood tracking, clinical surveys and daily journaling. Rose is used as a participant-facing mobile app and clinician-facing dashboard. Each day, they complete mood and anxiety scales and update their journals. Biweekly, they are also asked to complete the PHQ-9 and GAD-7 assessments as well. The Rose mobile app sends timely self-help articles and notifications for users. The curated insights are selected based on participant responses to the daily mood and anxiety surveys, as well as a built-in sentiment analysis of the journaling. The clinical dashboard is a secure, web-based portal that has a unique login for each provider. Providers have access to only their patients through the system and are able to see all the health metrics collected with the Rose mobile app and the summarized metrics produced by our models.
48302117|NCT00002206|DRUG|Adefovir dipivoxil|
48302118|NCT00496873|DRUG|Cytoxan|600 mg/m\^2 on Day 1 of 21-day cycle.
48302119|NCT00496873|DRUG|Nipent|4 mg/m\^2 on Day 1 of 21 Day Cycle.
48302120|NCT00496873|DRUG|Rituxan|375 mg/m\^2 on Day 1 of 21 Day Cycle.
48302121|NCT03769740|DEVICE|Cerebral Oximetry|Non invasive, near infrared spectroscopy cerebral oximetry
48302122|NCT01167595|OTHER|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
48480498|NCT00343434|PROCEDURE|psychosocial assessment and care|
48480499|NCT00343434|PROCEDURE|quality-of-life assessment|
48639296|NCT04895358|DRUG|nab-paclitaxel|IV infusion
47955171|NCT05253846|DRUG|Oxaliplatin|chemotherapy treatment
48480500|NCT05865392|BEHAVIORAL|Move physical activity support program|The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
48480501|NCT05732272|DRUG|Bupropion|150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
48480502|NCT02029781|PROCEDURE|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
48639297|NCT04895358|DRUG|liposomal doxorubicin|IV infusion
47955172|NCT05253846|DRUG|Lederfolin|treatment
47955173|NCT05253846|DRUG|5-Fluorouracil|chemotherapy treatment
47955174|NCT05253846|RADIATION|Short-course radiotherapy|RT
48109466|NCT00574743|DRUG|Enteric-coated Mycophenolate Sodium|
48109467|NCT04241224|DEVICE|Atherectomy|Endovascular treatment of peripheral arterial disease
48109468|NCT04191265|DIAGNOSTIC_TEST|serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock
48639298|NCT04895358|DRUG|capecitabine|oral administration
48639299|NCT04895358|DRUG|normal saline|IV infusion
48639300|NCT04895358|DRUG|dextrose|IV infusion
47955175|NCT05253846|PROCEDURE|TME|surgery
47955176|NCT04793867|DIAGNOSTIC_TEST|Xenon|"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."
47955177|NCT05568823|OTHER|Blood sampling|Measurement of markers of disease evolution
47955178|NCT00000315|DRUG|Cocaine|
47955179|NCT02488161|OTHER|No intervention|
47955180|NCT02778087|BEHAVIORAL|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
48302123|NCT01613469|DRUG|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
48302124|NCT02660424|DRUG|VX-150|
48302125|NCT02660424|DRUG|Placebo|
48302126|NCT05000580|PROCEDURE|Surgical|Conservative vs surgical management
48302127|NCT04263662|OTHER|Analgesia-Sedation algorithm|The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
48302128|NCT05269134|DRUG|Bacteriophage|Phage Therapy
47955181|NCT02778087|BEHAVIORAL|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
48109469|NCT04704739|DRUG|GLPG1205 film-coated tablets|Single oral dose of GLPG1205
48109470|NCT04704739|DRUG|[14C]-GLPG1205 solution for infusion|A 15-minute IV infusion of \[14C\]-GLPG1205
47955182|NCT05792787|DIAGNOSTIC_TEST|Echo-color-doppler|"To perform the initial screening patients will undergo panoramic radiography and clinical examination followed by periapical radiographs of the teeth suspected of AP using the long cone paralleling technique with a film holder. The following parameters will be recorded:~1. The number of decayed, missing and filled teeth (DMFT index)~2. The number of teeth with AP~3. Periapical Index Score All individuals will undergo a cardiovascular examination in the Unit of Vascular Surgery, University of Siena (Siena, Italy). The cardiovascular assessment included physical examination, blood pressure measurement, past medical history and echo-color-doppler for the assessment of carotid intima-media thickness (cIMT), presence of abdominal aortic aneurysm and presence of peripheral pulses."
47955183|NCT04592978|BEHAVIORAL|Pain-Alcohol Personalized Feeback Intervention|The intervention will be designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations as well as increase motivation and intention to reduce hazardous drinking and positive attitudes and intentions regarding concurrent use of alcohol and prescription opioid medications.
47955184|NCT04592978|BEHAVIORAL|Control Personalized Feedback Intervention|The control intervention will incorporate personalized feedback relevant to exercise and nutrition but not address drinking reduction or pain-alcohol-opioid interrelations.
47955185|NCT02885207|BIOLOGICAL|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~* Crisis with clinical symptoms indicating focal seizure~* \& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~* No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~* No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~* No argument for metabolic or neurodegenerative genetic epilepsy.~* Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
48109471|NCT04704739|DRUG|GLPG1205 capsules|Single oral dose of GLPG1205 as solid formulation
48109472|NCT00810680|DRUG|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
48109473|NCT00745446|PROCEDURE|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
48109474|NCT04672772|DRUG|Cetuximab|Weekly cetuximab at starting dose, that could be switched to biweekly
48109475|NCT04672772|DRUG|Paclitaxel|Paclitaxel at starting dose of 80 mg/m2
48302129|NCT05269134|DRUG|Placebo|Placebo
48302130|NCT00000348|DRUG|Dihydrexidine|
48109476|NCT04266080|OTHER|Fitbit Inspire HR|assessing step counts
48109477|NCT04266080|OTHER|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
48302131|NCT00912158|OTHER|standard therapy (ST)|standard medical therapy
48302132|NCT00912158|DEVICE|CPAP|Non-invasive mechanical ventilation (CPAP)
48302133|NCT00912158|DEVICE|BIPAP|Non-invasive mechanical ventilation (BIPAP)
48302134|NCT03471676|OTHER|Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording
48302135|NCT02078622|OTHER|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
48302136|NCT02829086|OTHER|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
48302137|NCT02829086|OTHER|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
48302138|NCT02829086|OTHER|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
48339915|NCT04814511|DRUG|Permethrin 10 % Creme|Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
48480503|NCT00176631|DIETARY_SUPPLEMENT|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
48302139|NCT06041672|BEHAVIORAL|Warm Water Hand Baths|"1. Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~2. The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~3. The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position."
48302140|NCT03549273|DIETARY_SUPPLEMENT|Glizigen® + Ocoxin-Viusid®|"* Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~* Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption."
47955186|NCT02213354|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
48302141|NCT03874598|PROCEDURE|Ear acupuncture|Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
48302142|NCT03874598|BEHAVIORAL|Psychoeducation|Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
48302143|NCT00668343|DRUG|simvastatin|40 mg/ day
48302144|NCT00668343|DRUG|placebo|80 mg /day
48302145|NCT03015350|DRUG|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
48302146|NCT03015350|DRUG|Desflurane|Measurement of blood desflurane level during one lung ventilation
48302147|NCT00073593|DRUG|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) \>300 seconds (s).
48302148|NCT00073593|DRUG|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
48302149|NCT00073593|DRUG|Protamine|Per institutional practice. Batches from hospital stock.
48302150|NCT03993691|DEVICE|Tomo-E scan|High-resolution limited-angle tomography positioning and examination will vary depending on injury.
47955187|NCT02213354|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
48302151|NCT03993691|DEVICE|Radiograph|Standard of Care radiographic imaging of wrist.
48302152|NCT05896982|OTHER|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
48302153|NCT05896982|OTHER|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
48302154|NCT05896982|OTHER|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
48302155|NCT00633139|BIOLOGICAL|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
48302156|NCT02583789|DRUG|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
47955188|NCT02401022|DRUG|AZD8529|comparison of different dosages of drug
47955189|NCT02429843|DRUG|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
47955190|NCT01160211|DRUG|lapatinib|1000 mg by mouth once a day
48302157|NCT02583789|DRUG|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
47955191|NCT01160211|DRUG|trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
47955192|NCT01160211|DRUG|Aromatase inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
48302158|NCT02028338|COMBINATION_PRODUCT|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
48302159|NCT02028338|COMBINATION_PRODUCT|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
48480504|NCT00176631|DRUG|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
47955193|NCT01160211|DRUG|lapatinib|1500 mg by mouth once daily
47955194|NCT05772208|DRUG|Camrelizumab|camrelizumab 200mg q3w
47955195|NCT05772208|DRUG|Nimotuzumab|nimotuzumab 200mg qw
47955196|NCT05772208|DRUG|neoadjuvant chemotherapy and CCRT|the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
47955197|NCT00531401|DRUG|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
48302160|NCT00406315|DRUG|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
48302161|NCT00916799|DEVICE|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
48302162|NCT04328740|DRUG|TP-1454 monotherapy|Flat dose once or twice daily, alone
48302163|NCT00027040|DRUG|Selegiline hydrochloride|
48302164|NCT06114953|DRUG|Mizoribine|Mizoribine+glucocorticoid+tacrolimus after kidney transplantation
48302165|NCT06114953|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
48302166|NCT01905397|DEVICE|Conventional wound therapy|Sterile bandages and wound coverings
48480505|NCT00143299|DRUG|varenicline (CP-526,555)|
48302167|NCT01905397|DEVICE|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
48302168|NCT05040178|DRUG|Carglumic Acid|Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
48302169|NCT04592380|DRUG|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
48302170|NCT04592380|DRUG|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
48302171|NCT04592380|DRUG|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
48302172|NCT04592380|DRUG|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
48302173|NCT01244334|DRUG|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
48302174|NCT01244334|DRUG|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
48302175|NCT01465178|DIETARY_SUPPLEMENT|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
48302176|NCT01465178|DIETARY_SUPPLEMENT|Placebo|matching placebo
48302177|NCT04250298|DIETARY_SUPPLEMENT|sucrosomal iron|oral intake of iron as sachets or capsules
48639301|NCT03387579|DRUG|Smoflipid 20% Lipid Emulsion for Injection|Intravenous lipid containing soy, MCT, olive, and fish oils at goal doses of 3 g/kg/day
47955198|NCT00789490|DIETARY_SUPPLEMENT|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
47955199|NCT00789490|DIETARY_SUPPLEMENT|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
48639302|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 1 g/kg/day
48639303|NCT03387579|DRUG|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil at goal doses of 2-3 g/kg/day
48639304|NCT04356027|PROCEDURE|ICA (Invasive Coronary Angiography)|Patients will undergo a Pre-PCI Angiography
48639305|NCT04356027|PROCEDURE|OCT|OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure
48302178|NCT02354391|DRUG|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
48302179|NCT02354391|DRUG|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
47955200|NCT03547960|DIETARY_SUPPLEMENT|Guar gum|Fibre supplement to be taken with each meal
47955201|NCT03547960|DIETARY_SUPPLEMENT|Cellulose|Placebo. Fibre supplement to be taken with each meal
47955202|NCT05923749|DEVICE|Biatain Ag|Biatain with silver
47955203|NCT05923749|DEVICE|Cutimed Siltec Sorbact|comparator device
47955204|NCT00199485|DRUG|Angelica Sinensis|Angelica Sinensis / placebo
47955205|NCT02964975|PROCEDURE|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
47955206|NCT02964975|DRUG|Optimal medical therapy|Medical threatment according to guidelines
48302180|NCT02354391|PROCEDURE|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
48302181|NCT02060617|BEHAVIORAL|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
48639306|NCT04356027|PROCEDURE|FFR|FFR will be measured
48639307|NCT04356027|OTHER|VFR Analysis|VFR will be calculated offline using the OCT pullback images
48639308|NCT00327431|GENETIC|Cheek swab samples for DNA|
48639309|NCT03365908|PROCEDURE|Adductor Canal Nerve Block|An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.
48639310|NCT03365908|DRUG|Ropivacaine injection|15 mL of 0.5% ropivacaine will be administered for the adductor canal block
48655937|NCT06645132|BEHAVIORAL|exercise intervention|Exercise intervention leveraging wearable devices and a custom smartphone application to cue exercise as a reminder during idle time during an inpatient hospital stay, post allogenic bone marrow transplant.
47955207|NCT04185311|BIOLOGICAL|Ipilimumab|Given IV
47955208|NCT04185311|BIOLOGICAL|Nivolumab|Given IV
47955209|NCT04185311|BIOLOGICAL|Talimogene Laherparepvec|Given intratumorally
47955210|NCT04339686|DIAGNOSTIC_TEST|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
47955211|NCT02855073|BIOLOGICAL|ReJoinTM|adipose derived mesenchymal progeinitor cells
48639311|NCT06010108|BEHAVIORAL|Heroes for Her|Market outreach intervention- daily awareness creation through public market announcements, and distribution of educational fliers in local dialects. Community women will also be involved in the spread awareness through door to door approach. Thee will be repeated radio jingles to promote awareness. Interested women and girls will be provided with screening and vaccination services at a designated community health facility. All samples will be returned to the facility by the women and sent to a designated laboratory for testing. Participants contact information will be collected for follow up
48639312|NCT06010108|BEHAVIORAL|The Reach Initiative|School based intervention-The Reach Initiative involves the organisation of the Mother-Daughter Day (MDD) by Mother-Daughter Planning Committee (MDPC) who are volunteer young school girls and their mothers and provision of a Key-Card which is a cervical cancer awareness card attached to a key chain for awareness creation. HPV vaccination and HPV -self sampling will be carried out in private rooms within the venue of the intervention and all samples will be sent to designated laboratory for testing. Participants contact information will be collected for follow up and communication of results
48639313|NCT06010108|BEHAVIORAL|W.H.I.T.E project|Community based intervention- This will involve the engagement of women's trade unions and organisations in the community to create awareness and women and girls interested in the uptake of HPV prevention services will be directed to receive these services at a designated community facility accessible to women and girls in the community. Participants contact details will be collected for follow uo and communication of results
48302182|NCT02060617|PROCEDURE|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
48302183|NCT02060617|PROCEDURE|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
48302184|NCT02060617|PROCEDURE|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
48302185|NCT01959867|DEVICE|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
48302186|NCT01959867|OTHER|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
48302187|NCT05427851|PROCEDURE|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
48302188|NCT05427851|DEVICE|Diode laser - fonalaser|diode laser beam application
48302189|NCT00216606|DRUG|topiramate|
48302190|NCT01397669|PROCEDURE|Colon biopsy, lymph node biopsy, lumbar puncture|Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
48302191|NCT01653366|BEHAVIORAL|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
48480506|NCT05592093|DRUG|Korean red ginseng capsule (marketed product in Korea)|Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.
48302192|NCT05416931|DRUG|ACD440 Gel 14mg/g|Topical application to painful area
48302193|NCT05416931|DRUG|Placebo Gel|Topical application to painful area
48302194|NCT03736083|DEVICE|Freestyle Libre Blood Glucose Monitor|The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
48302195|NCT06097195|DEVICE|BioEP|When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
48655938|NCT06641050|DIAGNOSTIC_TEST|Triage+ Score|The TriAGE+ score is used to evaluate the risk of cerebrovascular disease in patients presenting with dizziness. The score assists in determining the necessity of advanced diagnostic evaluation for stroke, potentially improving diagnostic accuracy and patient outcomes.
48109478|NCT03825133|PROCEDURE|Bone Marrow Aspirate Concentrate|Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
48302196|NCT00931788|DRUG|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
48302197|NCT00931788|OTHER|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
48302198|NCT02285764|OTHER|Nutritional Supplement|Modified carbohydrate
48302199|NCT02285764|OTHER|Standard of Care|As determined by the study site
48302200|NCT04070378|DRUG|Daratumumab Injection|Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
48302201|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens with comfort additive|
48302202|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens|
48302203|NCT02946710|BIOLOGICAL|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
48302204|NCT02811133|DRUG|Inositol|Subjects will receive inositol
48302205|NCT03819803|BIOLOGICAL|Fecal microbiota transplantation|200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
48480507|NCT05592093|DRUG|Korean red ginseng capsule(placebo)|"KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group.~The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time."
48480508|NCT04385095|DRUG|SNG001|SNG001 via inhalation
48109479|NCT03825133|PROCEDURE|Leukocyte Rich Platelet Rich Plasma|Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
47955212|NCT02855073|DRUG|Sodium Hyaluronate|Sodium Hyaluronate Injection
48109480|NCT03825133|DRUG|Hyaluronic Acid|Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
48109481|NCT02031471|DRUG|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
48109482|NCT03319706|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
48109483|NCT03319706|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
48302206|NCT01832311|DRUG|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
48302207|NCT01792622|OTHER|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
48302208|NCT01792622|OTHER|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
48302209|NCT04614545|DRUG|Phentermine 37.5 Mg|Patients will receive 37.5 mg of phentermine daily for a 12 week duration
48302210|NCT04614545|BEHAVIORAL|Dietary program|Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
48302211|NCT04614545|BEHAVIORAL|Exercise program|Patients will be provided with a personalized exercise program
48302212|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
48302213|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
48302214|NCT02811484|DRUG|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%
48302215|NCT02811484|BEHAVIORAL|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
48302216|NCT01414816|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
48302217|NCT04841629|OTHER|PreBioGyn Gel|Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.
48302218|NCT04841629|OTHER|Trimosan Gel|Carbomer-based gel
48302219|NCT04841629|OTHER|RepHresh Gel|Carbomer-based gel
48302220|NCT00282490|DEVICE|Nerve stimulator|
48302221|NCT05791825|BEHAVIORAL|Cultivating Healthy Intentional Mindful Educators|The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
48302222|NCT03313505|BIOLOGICAL|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
48302223|NCT03313505|OTHER|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
48480509|NCT04385095|DRUG|Placebo|Placebo via inhalation
48655939|NCT06028412|PROCEDURE|Sublobar|"The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group."
48655940|NCT06028412|PROCEDURE|Lobectomy|lobectomy+system lymph node dissection
48639314|NCT06010108|BEHAVIORAL|Project Shield|Utilization of community based structures (pharmacy and health center)- The intervention will involve the creation of a branded self-sampling kit for HPV screening and a free vaccination voucher to encourage mother-daughter uptake of cervical cancer prevention measures. Awareness will be raised through banners at the points of access of the vaccines and kits, use of jingles, and the involvement of the Community Development Association (CDA) to help mobilize girls, women and the men. Women and girls will be referred to community health centers to receive the HPV vaccination and carry out the screening
48639315|NCT06010108|BEHAVIORAL|Project SHADE|"Community-based approach- health education of girls and women. The use of a uniquely designed bag Eno Iban to package and distribute the self-collection tool, vaccination of the adolescent girls. Screening and HPV will be provided at designated areas within the community for women and girls. A simple app (d-SHADE) will be used to collect data of the girls and women by the health professionals and volunteers, as well as send the reminders for next screening dates and test results"
48655941|NCT00581919|DRUG|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
47955213|NCT04555421|DEVICE|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
47955214|NCT00124228|DRUG|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
47955215|NCT05658913|DRUG|AV-1451|This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.
47955216|NCT04394975|COMBINATION_PRODUCT|Biological : Toripalimab Drug: Axitinib|Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet
47955217|NCT04394975|DRUG|sunitinib|Drug: Sunitinib, oral capsule
47955218|NCT02033187|OTHER|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
47955219|NCT02033187|OTHER|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
47955220|NCT03012009|DEVICE|full ablative CO2 laser|ablation to the level of de dermal papilla
47955221|NCT03012009|DEVICE|fractional ablative CO2 laser|180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
47955222|NCT03012009|DRUG|MAL|
47955223|NCT03012009|DEVICE|LED lamp|peak wavelength 630 nm, 37J/cm2
47955224|NCT03012009|DRUG|lidocaine hydrochloride 2% with epinephrine|
47955225|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet (PROMED) Intervention|Researchers will provide individually tailored dietary advice and written materials to encourage 'a little and often' meal plan to support adoption of the PROMED intervention. The daily energy and protein requirements of each participant will be calculated based on National Institute of Health \& Care Excellence guidance for Nutrition Support in Adults at Risk of Malnutrition. Several resources have been developed to facilitate behaviour change: a) A PROMED Diet Information Booklet to include an overview of the PROMED Diet, tips for incorporating more PROMED foods into the diet and information on the health benefits of a PROMED diet, b) A PROMED Recipe Book offering ideas for breakfast, lunch and dinner as well as suitable snack ideas and c) key PROMED foods ordered through a local supermarket's online delivery service and delivered to participants' homes on a weekly or fortnightly basis for the 3-month active intervention phase.
48109484|NCT04354610|PROCEDURE|Biological samples specific to research|Blood samples, saliva collection, and urine collection to carry out biomarker assays and for the constitution of a biological collection.
48109485|NCT04354610|PROCEDURE|Clinical examination|Clinical examination
48109486|NCT04354610|PROCEDURE|Telephone follow-up|Telephone follow-up at 3 months after discharge from hospital
48109487|NCT05692947|DEVICE|Core body temperature device|This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
48655942|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.0 mg (Arm A)|2.0 mg/kg intravenous (IV) every 4 weeks
48655943|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine 2.7 mg (Arm B)|2.7 mg.kg IV every 4 weeks
48109488|NCT01705249|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
48109489|NCT05967819|BEHAVIORAL|Exercise Stress|Increased exercise volume
48109490|NCT05967819|BEHAVIORAL|Psychosocial Stress|cognitive tasks
48109491|NCT05145517|DEVICE|Open repair|Open repair of the aorta and peripheral arteries
48480510|NCT05904249|OTHER|Internet Based Synchronized Telerehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
48655944|NCT05551117|BIOLOGICAL|vobramitamab duocarmazine|2.7 mg.kg IV every 4 weeks
48655945|NCT05551117|DRUG|Abiraterone|1000 mg once daily
48109492|NCT02331004|OTHER|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
48109493|NCT02331004|OTHER|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
48109494|NCT02411942|DRUG|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
48109495|NCT02411942|DRUG|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
48109496|NCT02411942|DRUG|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
48109497|NCT04800016|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.
48109498|NCT04800016|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
48109499|NCT02311907|DRUG|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
48109500|NCT02311907|DRUG|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
48109501|NCT02311907|OTHER|Laboratory Biomarker Analysis|Correlative studies
48109502|NCT02311907|DRUG|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
48109503|NCT02311907|OTHER|Placebo|Given IV
48109504|NCT02311907|OTHER|Quality-of-Life Assessment|Ancillary studies
48109505|NCT02953080|OTHER|Call for life mHealth adherence support|Daily/ weekly pill reminder support Health Info-tips Appointment visit reminders Self-reported symptom support
48109506|NCT03853655|RADIATION|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
48655946|NCT05551117|DRUG|Enzalutamide|160 mg daily
48109511|NCT00604019|DRUG|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
48109512|NCT00604019|DRUG|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
48109513|NCT00255437|DRUG|ferumoxytol or oral iron|
48109514|NCT06554912|PROCEDURE|Lymphatic Decompression|"Patients will be prepared according to standard procedures Clinical examinations, para-clinical assessment and biological tests Patient will be set in angiography room and local anesthesia at the puncture area (femoral vein or brachial vein).~Obtain access to the femoral vein per standard procedures (option for brachial access depending on anatomy based on pre-operative CT, per physician discretion) After setting introducer sheath, catheterism of cardiac cavity will be performed for assess the following standard hemodynamic measures Catheterism of thoracic duct through the subclavian vein will be performed under fluoro guidance and phlebography using contrast Measure TD and central venous pressures Deploy stent under fluoro guidance Standard vascular stent deployed in subclavian vein and into lymphovenous junction Evaluate the procedure with standard phlebography and hemodynamic measures Remove catheters, and temporary compression as standard venous procedures"
48109515|NCT03571191|DRUG|Denosumab|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
48109516|NCT00003900|DRUG|docetaxel|
48109517|NCT00003900|DRUG|irinotecan hydrochloride|
48109518|NCT06456762|BEHAVIORAL|iPEACE: Intervention for Parent Education about Care after the ED|Automated texting intervention for parents to increase engagement in their child's outpatient mental health treatment over an 8-week period.
48109519|NCT06456762|BEHAVIORAL|Text Messaging Reminders Only|Weekly automated text reminders to instruct parents to make an appointment with their child's outpatient mental health provider over an 8-week period.
48109520|NCT06554158|RADIATION|Radiation Therapy|De-escalation of Adjuvant Radiotherapy
48109521|NCT02212522|OTHER|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
48109522|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
48109523|NCT02212522|OTHER|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
48109524|NCT02212522|OTHER|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
48302224|NCT02707705|DEVICE|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
48302225|NCT02707705|DEVICE|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~* T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~* T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~* T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~* T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
48302226|NCT02707705|PROCEDURE|Disinfection|The ear is disinfected by applying Chlorhexidine®.
48302227|NCT03318640|BEHAVIORAL|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
48302228|NCT05718791|DIAGNOSTIC_TEST|blood sample|blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
48302229|NCT00430625|BIOLOGICAL|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
48302230|NCT00543751|DRUG|MK0767|
48302231|NCT03983876|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
48302232|NCT00004865|BIOLOGICAL|cetuximab|
48302233|NCT00004865|DRUG|cisplatin|
48302234|NCT00004865|DRUG|fluorouracil|
48302235|NCT00004865|DRUG|paclitaxel|
48302236|NCT00542685|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
48302237|NCT00542685|DRUG|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
48639316|NCT06010108|BEHAVIORAL|Operation Reach Her (ORH) program|"Faith based approach- Awareness programs would be conducted in the chosen religious centres to educate women and girls about their health, cervical cancer, its prevention, and the benefits of screening and HPV vaccination. This would be achieved by organizing a  Health Day  for free health check-ups for all members of the congregation. The self-sampling kit would be distributed to women aged 30-65 in mobile tents stationed in churches in Akoka and HPV vaccinations would be administered to girls aged 9-14 in mobile tents stationed at churches and mosques in Akoka, Lagos"
48639317|NCT06010108|BEHAVIORAL|Project Care|Community pharmacy intervention-Trained community volunteers will be involved in creating awareness of HPV prevention services and cervical cancer. There will be distribution of cervical cancer self-sampling kits to community pharmacies which will serve as service points for screening (self-collection point) and vaccination point for girls in the community,
48655947|NCT06131112|DIAGNOSTIC_TEST|64Cu-DOTATATE PET/CT scan|Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
48655948|NCT06405529|OTHER|Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge|"During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto."
48655949|NCT04774445|BEHAVIORAL|MyCancerGene|Interactive Health Communication Application
48302238|NCT00542685|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
48302239|NCT00542685|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
48302240|NCT01247818|DRUG|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
48302241|NCT01247818|DRUG|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
48302242|NCT01247818|DRUG|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
48302243|NCT01247818|DRUG|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
48302244|NCT02124187|DEVICE|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
47955226|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention|Participants will receive a dietary intervention identical to PROMED participants, plus an exercise intervention. The home-based exercises are based on a modified version of the 'ExWell@home' programme developed by health professionals with significant expertise in community-based exercise rehabilitation for chronic disease. Cardiorespiratory fitness will be determined using a 3-minute step test and pulse rate. Participants will receive access to pre-recorded exercise classes and a written resource designed for older adults (ExWell@home) and adapted for the current study. Participants will be encouraged to complete two sessions per week (30-60 minutes per session). To cater for differing abilities, four levels of classes will be available for participants: Chair based, basic, standard and advanced.
48480511|NCT05904249|OTHER|Face-to-Face Rehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
47955227|NCT01085474|OTHER|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
47955228|NCT01085474|OTHER|2|The best intervention used in the pilot study will be chosen and included in the main study.
47955229|NCT03877549|DRUG|Dexamethasone|Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
47955230|NCT04861909|DEVICE|AT LISA tri 839MP|Non interventional study
47955231|NCT06556264|DRUG|Dupilumab|Dupilumab 300mg every 2 weeks for 24 weeks
47955232|NCT06556264|OTHER|Placebo|Placebo 300mg every 2 weeks for 24 weeks
47955233|NCT03137342|BEHAVIORAL|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
47955234|NCT02176343|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
47955235|NCT04569903|DEVICE|Computer algorithm for ATTR|Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm
47955236|NCT05615779|OTHER|Placebo Comparator: Randomized pectin diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
47955237|NCT05615779|OTHER|Randomized B-fructan diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
48302245|NCT02124187|DEVICE|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
48302246|NCT02124187|DEVICE|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
48302247|NCT03940651|DRUG|Spinal Anesthesia|Patients will be randomized to type of anesthesia
47955238|NCT05615779|OTHER|Personalized pectin diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
47955239|NCT05615779|OTHER|Personalized B-fructan diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
47955240|NCT04150055|BEHAVIORAL|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
47955241|NCT04058873|DRUG|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
47955242|NCT00354744|BIOLOGICAL|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), \< 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
47955243|NCT00354744|DRUG|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
47955244|NCT00354744|DRUG|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
47955245|NCT00354744|DRUG|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
47955246|NCT00354744|DRUG|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
47955247|NCT00354744|DRUG|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
48109525|NCT02212522|GENETIC|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
48109526|NCT02452242|DRUG|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
48302248|NCT03940651|DRUG|General Anesthetics|Patients will be randomized to type of anesthesia
48302249|NCT06553781|DRUG|Temozolomide、Fruquintinib、Cadonilimab|"Combination treatment period:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; Temozolomide: 150\~200mg/m2, poqd, d1-5, q4W; The combined treatment lasted 6 cycles.~Maintenance treatment:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; The maximum duration of maintenance treatment is not more than 2 years."
48302250|NCT04542798|DEVICE|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
48302251|NCT06302205|OTHER|Physical activity|The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
47955248|NCT00354744|DRUG|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
47955249|NCT00354744|PROCEDURE|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
48302252|NCT06302205|OTHER|Sham intervention|2 times a week, flexibility and balance training
48302253|NCT01752569|DRUG|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
48302254|NCT01373567|DRUG|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
48302255|NCT04343885|DRUG|177Lu-PSMA-617|Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
48302256|NCT04343885|DRUG|Docetaxel|Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
48302257|NCT01461863|DIETARY_SUPPLEMENT|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
48302258|NCT01461863|DIETARY_SUPPLEMENT|multivitamin|Standard multivitamin
48480512|NCT01546142|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
48480513|NCT01546142|DRUG|Placebo|Phosphate buffered saline placebo for injection
47955250|NCT00354744|RADIATION|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
47955251|NCT00354744|BIOLOGICAL|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
47955252|NCT05664074|DRUG|Rectal indomethacin|"Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg"
47955253|NCT05664074|DRUG|IV ketorolac|Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
48109527|NCT02452242|OTHER|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
48109528|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
48109529|NCT00758433|DRUG|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
48480514|NCT01597219|PROCEDURE|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4
48480515|NCT01597219|PROCEDURE|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0
47955254|NCT02187744|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
47955255|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
48109530|NCT00758433|DRUG|Placebo patch|Placebo patch q.d. 24 hours for 7 days
48109531|NCT01130558|OTHER|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
48109532|NCT00739102|DEVICE|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
48302259|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
48302260|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
48302261|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
48302262|NCT03074162|DRUG|Diclofenac Sodium|twice daily
48302263|NCT03074162|DRUG|Diclofenac & Capsaicin|twice daily
48302264|NCT03074162|DRUG|Diclofenac Sodium Topical Gel|twice daily
48302265|NCT00813553|DIETARY_SUPPLEMENT|placebo|daily
47955256|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
48109533|NCT05026086|OTHER|pressure biofeedback|10 patients will be treated with isometric exercises and pressure biofeedback.
48109534|NCT05026086|OTHER|isometric exercises|10 patients will be treated with isometric exercises
48302266|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
47955257|NCT02187744|BIOLOGICAL|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
47955258|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
47955259|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
47955260|NCT02999074|OTHER|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
47955261|NCT02999074|OTHER|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
47955262|NCT02999074|OTHER|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
47955263|NCT00968864|DEVICE|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
47955264|NCT06557902|DRUG|Lumateperone 10.5 mg capsule|Lumateperone 10.5 mg capsule, oral administration
47955265|NCT06557902|DRUG|Lumateperone 21 mg capsule|Lumateperone 21 mg capsule, oral administration
47955266|NCT06557902|DRUG|Lumateperone 5 mg ODT|Lumateperone 5 mg ODT, oral administration
47955267|NCT06557902|DRUG|Lumateperone 10.5 mg ODT|Lumateperone 10.5 mg ODT, oral administration
47955268|NCT06557902|DRUG|Lumateperone 15.5 mg ODT|Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
47955269|NCT06557902|DRUG|Lumateperone 21 mg ODT|Lumateperone 21 mg ODT, oral administration
48302267|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
47955270|NCT06049082|DRUG|KB408 (Nebulization)|Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
47955271|NCT06157255|DRUG|AZD4604 Inhalation Powder, 1 mg|3 mg dose, inhaled, fasted
47955272|NCT06157255|DRUG|[14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)|30 μg, intravenous, fasted
48109535|NCT05300399|DEVICE|mHealth app|The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
48109536|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
48302268|NCT05588362|OTHER|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
48302269|NCT00897520|BIOLOGICAL|recombinant interferon alfa|
48109537|NCT01241292|BIOLOGICAL|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
48109538|NCT03958513|DRUG|Bupivacaine|1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
48109539|NCT03958513|DRUG|0.9% normal saline|1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
48109540|NCT01007344|DIETARY_SUPPLEMENT|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
48109541|NCT01007344|DIETARY_SUPPLEMENT|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
48302270|NCT00897520|GENETIC|proteomic profiling|
47955273|NCT06157255|DRUG|[14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)|4 mg, oral, fasted
47955274|NCT00385710|DRUG|valproic acid|Depakine
47955275|NCT00385710|DRUG|Placebo|Placebo
47955276|NCT02229383|DRUG|Exenatide|2 mg weekly suspension injection
47955277|NCT02229383|DRUG|Exenatide matching placebo|Once weekly Placebo injection
48109542|NCT03575819|DRUG|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
48302271|NCT00897520|OTHER|immunoenzyme technique|
48302272|NCT00897520|OTHER|laboratory biomarker analysis|
48302273|NCT02060201|DRUG|Saxagliptin|
48302274|NCT02060201|DRUG|Dapagliflozin|
48302275|NCT02060201|DRUG|Saxagliptin/Dapagliflozin FDC|
48302276|NCT03344731|BEHAVIORAL|Cognitive evaluation|Cognitive task
47955278|NCT04752384|DRUG|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
47955279|NCT04752384|DRUG|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
47955280|NCT04752384|DEVICE|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
47955281|NCT05925465|PROCEDURE|Maxillary and mandibular nerve block|receive bilateral combined maxillary and mandibular nerve block
47955282|NCT05925465|OTHER|Control|not receive any nerve block
48302277|NCT03344731|DEVICE|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
48302278|NCT03037957|DEVICE|ARIES Group A Strep Assay|
47955283|NCT02706184|DRUG|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
47955284|NCT02706184|DRUG|Placebo|Placebo
47955285|NCT05869760|OTHER|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
47955286|NCT05869760|OTHER|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
47955287|NCT01428271|OTHER|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
48302279|NCT01958034|DIETARY_SUPPLEMENT|Bilberry extract|
48302280|NCT05071781|DRUG|Corticotropin-release hormone|intravenous CRH (100 µg)
48302281|NCT05071781|DRUG|Corticotropin-release hormone|a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
48302282|NCT00745264|DRUG|Diractin|100 mg Ketoprofen to 2 joints
47955288|NCT00866788|DRUG|omalizumab|Administered by subcutaneous injection
47955289|NCT00866788|DRUG|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
48109543|NCT03311568|DEVICE|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
48109544|NCT04028635|BEHAVIORAL|Cognitive-behavioral therapy plus VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
48109545|NCT04028635|BEHAVIORAL|Cognitive behavioral therapy|Usual CBT
48109546|NCT03101436|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil and Red Wine|"Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)"
48302283|NCT00745264|DRUG|Diractin|400 mg ketoprofen to 4 joints
48302284|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
48302285|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
48302286|NCT00989430|BEHAVIORAL|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
48302287|NCT05633576|DRUG|steroid eye drops|Self-administration of steroid eye drops three times a day for four consecutive weeks.
48302288|NCT05633576|DRUG|Placebo|Self-administration of placebo eye drops three times a day for four consecutive weeks.
48302289|NCT02205970|DEVICE|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
48302290|NCT02205970|DEVICE|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
48302291|NCT01158534|DRUG|celecoxib|Given orally
48302292|NCT01158534|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously
48302293|NCT01158534|OTHER|polymerase chain reaction|Correlative studies
48302294|NCT01158534|OTHER|laboratory biomarker analysis|Correlative studies
47955290|NCT00866788|DRUG|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
47955291|NCT00866788|DRUG|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
47955292|NCT04125888|DRUG|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
48109547|NCT00009646|DRUG|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
48109548|NCT00009646|DRUG|Indomethacin|0.1 mg per kilogram of body weight
48302295|NCT01158534|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
48302296|NCT01158534|OTHER|immunologic technique|Correlative studies
48302297|NCT01158534|OTHER|immunohistochemistry staining method|Correlative studies
48302298|NCT01158534|OTHER|flow cytometry|Correlative studies
48302299|NCT00401622|BEHAVIORAL|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
48302300|NCT00401622|BEHAVIORAL|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
48302301|NCT01465737|OTHER|Histologic types|evaluate survival among different histologic types
48109549|NCT00009646|DRUG|Placebo|0.1 mg per kilogram of body weight
48109550|NCT02968472|GENETIC|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
48109551|NCT06249295|OTHER|oral cryotherapy|The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth)
48109552|NCT00809120|DEVICE|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
48109553|NCT06513559|DEVICE|Anatomic total shoulder replacement|Humeral head with a metal ball and the glenoid socket with a polyethylene glenoid component.
48302302|NCT01194557|DEVICE|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
48302303|NCT01194557|DRUG|Lumartem|Presumptive treatment of malaria/fever
48302304|NCT02545296|OTHER|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
48302305|NCT00515008|BEHAVIORAL|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
48109554|NCT06513559|DEVICE|Reverse total shoulder replacement|Polyethylene socket on the humeral side and the glenosphere going on the glenoid side.
48302306|NCT00515008|BEHAVIORAL|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
48302307|NCT02126111|BIOLOGICAL|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
48302308|NCT02126111|BIOLOGICAL|DEPIGOID Placebo|Placebo for subcutaneous administration
48302309|NCT02637791|DEVICE|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
48302310|NCT01229488|DEVICE|Intervention|Project was withdrawn before starting. There were no interventions
48302311|NCT02551133|DRUG|dexamethasone|1 hour before surgery
48109555|NCT01948999|PROCEDURE|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
48109556|NCT01948999|PROCEDURE|SHAM ECT|Anesthesia and concomitant muscular paralysis
48302312|NCT04209504|DIAGNOSTIC_TEST|Ultrasound|Ultrasound guided evaluation of diaphragm ipsilateral to the block side.
48302313|NCT04209504|DRUG|Ropivacaine|Local anesthetic (numbing drug)
47955293|NCT01044251|DRUG|Frovatriptan|2.5 mg po bid for 10 days
47955294|NCT01044251|DRUG|Placebo|1 tab po bid for 10 days
47955295|NCT04652427|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
48109557|NCT01948999|DRUG|Anesthesia|Temporary induced state of analgesia
48109558|NCT02303444|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
48109559|NCT02303444|DRUG|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
48109560|NCT03224299|DRUG|OCT - clear|Investigational Product #1: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
47955296|NCT04652427|DRUG|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
47955297|NCT03659734|BEHAVIORAL|Motivational Interviewing and Guided Opioid Tapering Support|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
48302314|NCT04209504|DRUG|Bupivacaine|Local anesthetic (numbing drug)
47955298|NCT03659734|BEHAVIORAL|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
48302315|NCT04209504|DEVICE|MediPines AGM100 Advanced Respiratory Monitoring System|Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
48302316|NCT01013948|OTHER|Non-Interventional|Non-Investigational Product (Survey Study)
48302317|NCT03606083|DEVICE|Endovascular repair|Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)
48302318|NCT00589472|DRUG|Bicalutamide|Given PO
48302319|NCT00589472|DRUG|Goserelin Acetate|Given SC
48302320|NCT00589472|OTHER|Laboratory Biomarker Analysis|Correlative studies
47955299|NCT02083081|BEHAVIORAL|Community level intervention|Community intervention plus individual counseling
48302321|NCT00589472|DRUG|Leuprolide Acetate|Given IM
48302322|NCT00589472|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical prostatectomy
48302323|NCT00589472|DRUG|Vorinostat|Given PO
48302324|NCT05937854|DRUG|Tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
48302325|NCT05937854|DRUG|Placebo|one or two encapsulated tablets of placebo po QD
48302326|NCT05590234|DRUG|Dexmedetomidine injection|1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
47955300|NCT04608929|BEHAVIORAL|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
48109561|NCT03224299|DRUG|OCT- tinted|Investigational product #2: octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
48109562|NCT03224299|OTHER|ChloraPrep|Active Control: ChloraPrep® - Hi-Lite Orange® applicator
48109563|NCT03224299|OTHER|Saline|Negative Control: sterile 0.9% saline applied with single use applicator
48109564|NCT03617653|DIAGNOSTIC_TEST|Group A|Refer to detailed study Description
48302327|NCT05590234|DRUG|Bupivacaine 0.25% Injectable Solution|20 ml of bupivacaine 0.25%,
48302328|NCT05590234|DRUG|normal saline|20 ml of normal saline 0.9%.
48302329|NCT02778867|OTHER|1 Food Elimination Diet Therapy|
48302330|NCT02778867|OTHER|6 Food Elimination Diet Therapy|
48302331|NCT02778867|OTHER|6 Food Elimination Diet (after 1FED failure)|
48302332|NCT02778867|DRUG|Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)|
48480516|NCT04144426|BEHAVIORAL|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
48480517|NCT04144426|BEHAVIORAL|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
48302333|NCT05288985|DEVICE|Erector spinae plane catheter group in addition to Systemic Analgesia|Erector spinae plane catheter is placed in the post-interventional surveillance room in the operating theatre by an anaesthetist-intensive care physician or in the MIR department by the intensive care physician in charge of the patient within 2 hours after randomisation. The local anaesthetic injected into the catheter is Ropivacaine, prescribed according to a protocol of continuous flow, bolus and refractory period. The catheter is repositioned if a secondary displacement occurs.
48302334|NCT05288985|DRUG|Systemic Analgesia Only Group|Systemic analgesia alone consists only of the 3 levels of analgesic treatment
48302335|NCT03108755|DRUG|ASP7713|oral
48302336|NCT03108755|DRUG|Placebo|oral
48302337|NCT06203496|DIAGNOSTIC_TEST|Blood sample|Blood sample
48302338|NCT05069051|DRUG|Belimumab 200 MG/ML [Benlysta]|Patients obtain belimumab treatment in combination with rituximab and venetoclax
48302339|NCT05069051|DRUG|standard of care|Patients obtain the standard of care: combination rituximab and venetoclax
48302340|NCT02495649|OTHER|[18F]-DOPA|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
48302341|NCT02495649|DEVICE|PET-CT|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
48302342|NCT01915849|DRUG|LIK066|LIK066 15 mg, 50 mg and 150 mg
48302343|NCT01915849|DRUG|Placebo|
48302344|NCT02805218|DRUG|PEG-rhG-CSF|
47955301|NCT04608929|OTHER|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
47955302|NCT05788120|OTHER|Follow up by phone call|Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
47955303|NCT04693455|DRUG|ZD03|ZD03 capsule
47955304|NCT04693455|OTHER|Placebo|placebo capsule
47955305|NCT04578483|OTHER|PCA group|Patients receiving PCA are allocated in PCA group despite the route of administration. Intravenous PCA is commonly used with morphine or fentanyl while epidural PCA is used with ropivacaine and/or fentanyl frequently.
47955306|NCT04578483|OTHER|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
47955307|NCT03829839|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
47955308|NCT03829839|DRUG|Lorazepam 1 mg|Oral administration of 1mg lorazepam
47955309|NCT03829839|DRUG|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
47955310|NCT03829839|DRUG|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
47955311|NCT05335629|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
47955312|NCT01632917|DRUG|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
47955313|NCT01632917|DRUG|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
47955314|NCT01846104|BIOLOGICAL|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
47955315|NCT02738034|OTHER|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
47955316|NCT03823456|OTHER|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
48302345|NCT03525587|OTHER|"Use of MAGHD App/MAGHD Framework"|Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
48302346|NCT06554457|DRUG|Multimodal analgesia with oral strong opioids|Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics
48109565|NCT06465563|DRUG|SHR-8068|SHR-8068
48109566|NCT06465563|DRUG|Adebrelimab|Adebrelimab
48109567|NCT06465563|DRUG|Cisplatin|Cisplatin
48109568|NCT06465563|DRUG|Gemcitabine|Gemcitabine
48109569|NCT02960542|BEHAVIORAL|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
48302347|NCT00188500|BEHAVIORAL|atkins diet|
48480518|NCT04998422|DRUG|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
48109570|NCT01025999|OTHER|No intervention|
48480519|NCT03115528|BEHAVIORAL|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
48302348|NCT00188500|BEHAVIORAL|ability to follow low carbohydrate diet|
48480520|NCT05289986|DRUG|DELSTRIGO 100Mg-300Mg-300Mg Tablet|"Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine~- TDF/3TC/DOR)"
48480521|NCT04691375|DRUG|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
48480522|NCT04691375|DRUG|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
48480523|NCT03470584|OTHER|Diet Exposure|Vegetarian diet vs nonvegetarian diet
48480524|NCT05150418|DRUG|Oxygen gas|Oxygen 15 l/min
48480525|NCT05150418|DRUG|Air|Room air 15 l/min
48480526|NCT01226251|DEVICE|In vitro chair side test|Colour evaluation of a strip
48302349|NCT01911182|OTHER|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
48109571|NCT04952129|DRUG|Selenomethionine|Seleno-amino acid
47955317|NCT03823456|OTHER|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
47955318|NCT03328767|BEHAVIORAL|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
47955319|NCT02439060|OTHER|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
47955320|NCT01067690|DRUG|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
47955321|NCT04326673|OTHER|Testosterone Measurements in healthy volunteers after fasting|salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
47955322|NCT04326673|OTHER|Testosterone Measurements after glucose loading|salivary tstosterone and blood testosterone measurements
47955323|NCT01597531|DRUG|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
47955324|NCT01597531|DRUG|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
47955325|NCT01597531|DRUG|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
47955326|NCT00810914|DRUG|bupivicaine epidural|bupivicaine continuous epidural infusion
47955327|NCT00810914|DRUG|bupivicaine epidural infusion patient epidural|bupivicaine
47955328|NCT00810914|DRUG|bupivicaine|patient controlled anesthesia only
48109572|NCT04952129|DRUG|Methylselenocysteine|Seleno-amino acid
48109573|NCT03920215|DRUG|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray
48109574|NCT03920215|DRUG|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray
48302350|NCT01570985|DRUG|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
48302351|NCT01570985|DRUG|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
48302352|NCT01720511|DIETARY_SUPPLEMENT|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
48302353|NCT01720511|DIETARY_SUPPLEMENT|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
48302354|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
48302355|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
47955329|NCT00261456|DIAGNOSTIC_TEST|PSA test|Patients tested for their level of Prostate Specific Antigen.
48109575|NCT03920215|DRUG|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray
48109576|NCT03920215|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
48109577|NCT01137799|DRUG|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
48109578|NCT01137799|DRUG|placebo|Once daily (single dose)
48109579|NCT01137799|DRUG|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
48109580|NCT01137799|DRUG|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
48109581|NCT01137799|DRUG|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
48109582|NCT01137799|DRUG|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
48109583|NCT04042519|DIAGNOSTIC_TEST|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
48109584|NCT04042519|DIAGNOSTIC_TEST|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
48302356|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
48302357|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
47955330|NCT00261456|PROCEDURE|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
47955331|NCT04207320|DEVICE|αβ+ T-cell depletion with Miltenyi CliniMACS system|Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.
47955332|NCT03938467|DRUG|Antiseptic Cleanser|Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
47955333|NCT06142032|BEHAVIORAL|Metaverse support group|"Delivery method: Online, virtual platforms. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
48302358|NCT05794997|DRUG|Propranolol or Carvedilol|Propranolol or Carvedilol claim is used as the exposure group.
47955334|NCT06142032|BEHAVIORAL|In-Person support group|"Delivery method: In-Person, traditional. Number of sessions: 5. Duration of each session: 1.5 hours. Sessions will adhere to evidence-based protocols for conducting support groups with a trauma-informed approach. Each session will cover a specific topic of interest related to the challenges faced by Ukrainian refugees (e.g., stress management, cultural adjustment, self-care, etc.).~Support group session structure:~* Introduction, check-in, ground rules;~* Introducing the topic (topics will be chosen based on the feedback received from a previous session; the first session will cover a topic chosen by the facilitator);~* Encouragement of participants to share thoughts, ideas and experiences;~* Psychoeducation on the topics;~* Summary, takeaway, feedback."
47955335|NCT06364475|BEHAVIORAL|16:8 Time-Restricted Intermittent Fasting Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have a feeding window 8 hours and eating plan of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). Participants in the time-restricted eating group were allowed to drink calorie-free. They were expected to follow their diet for two months during the study.
48109585|NCT04042519|DIAGNOSTIC_TEST|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
48109586|NCT02275325|OTHER|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
48109587|NCT05803850|DRUG|HNC1058 Capsules|HNC1058 Capsules/Placebos, single dose, PO, starting dose of 10 mg escalating up to 80 mg；HNC1058 Capsules/Placebos, 50 mg, single dose, FED.
48302359|NCT05794997|DRUG|Atenolol, Bisoprolol or Sotalol|Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
48302360|NCT03242096|COMBINATION_PRODUCT|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
47955336|NCT06364475|BEHAVIORAL|Energy-Restricted Six-Meal Group|Participants total daily energy expenditures were calculated using the Harris-Benedict formula. This group have an eating plan three meals and three snacks of 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein). They were expected to follow their diet for two months during the study.
48302361|NCT03242096|COMBINATION_PRODUCT|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
48302362|NCT04445467|DRUG|Favipiravir|Favipiravir
48302363|NCT04498429|OTHER|Integrated Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
47955337|NCT01595607|OTHER|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
48109588|NCT04365400|DRUG|DS102|DS102 Epeleuton capsules
48109589|NCT04365400|DRUG|Placebo|Placebo capsules
48109590|NCT01785004|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
48109591|NCT01785004|DRUG|omega-3 fatty acids (fish oil)|
48109592|NCT06409949|DIAGNOSTIC_TEST|Walking assessment|"Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)"
48339916|NCT04814511|DRUG|Driponin 3 mg Tabletten|Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
48109593|NCT06409949|OTHER|QOL Survey|Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
48109594|NCT06409949|DIAGNOSTIC_TEST|Ankle pressure at rest and after stress|Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index
48109595|NCT06409949|DIAGNOSTIC_TEST|Muscle Oxygen|Evaluation of calf muscle heme oxygen saturation
48109596|NCT06409949|DIAGNOSTIC_TEST|Serum MitoQ Level|Evaluation of serum concentrations of MitoQ
48339917|NCT00832481|DRUG|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
48302364|NCT04498429|OTHER|Verbal Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
48302365|NCT01222338|BIOLOGICAL|V-5 immunitor|once per day dosing for 2 months
48302366|NCT02166840|PROCEDURE|Plastic stent (7-10Fr)|
48302367|NCT02166840|PROCEDURE|Self Expanding Metal Stent|
47955338|NCT03663946|OTHER|Non-Interventional|Non-Interventional
48302368|NCT02226510|DRUG|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
48302369|NCT02226510|DRUG|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
48302370|NCT01009996|PROCEDURE|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
48302371|NCT03275883|PROCEDURE|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
48302372|NCT05943977|DRUG|MB-102 DMID|130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
47955339|NCT00507923|DEVICE|Actigraph|Wear actigraph
47955340|NCT00507923|OTHER|Best Practice|Receive usual care
47955341|NCT00507923|OTHER|Quality-of-Life Assessment|Ancillary studies
47955342|NCT00507923|OTHER|Questionnaire Administration|Ancillary studies
48109597|NCT06409949|PROCEDURE|Needle Biopsy|Needle biopsy of the calf muscle
48109598|NCT04405713|PROCEDURE|from the onset of symptoms within the first 3 days|ELC within 3 days of onset of ACC
48109599|NCT04405713|PROCEDURE|: from the onset of symptoms within the 4-7 days|ELC 4-7days of onset of ACC
48109600|NCT04405713|PROCEDURE|from the onset of symptoms beyond 7 days|ELC after 7days of onset of ACC
48109601|NCT01306513|BIOLOGICAL|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
48302373|NCT05943977|DRUG|MB-102 OMID|130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
48302374|NCT05943977|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
48302375|NCT04278118|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
48302376|NCT04278118|RADIATION|Photon Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
48302377|NCT04278118|RADIATION|Proton Beam Radiation Therapy|Undergo hypofractionated proton or photon radiation therapy
48302378|NCT04278118|OTHER|Quality-of-Life Assessment|Ancillary studies
48480527|NCT05287503|DRUG|Ambroxol Hydrochloride|Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
48480528|NCT05287503|DRUG|Placebo|Excipients
48480529|NCT03740620|PROCEDURE|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
48480530|NCT03740620|PROCEDURE|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
47955343|NCT00507923|OTHER|Sleep Diary|Complete sleep diary
47955344|NCT00507923|OTHER|Stretching|Participate in stretching sessions
47955345|NCT00507923|PROCEDURE|Yoga|Participate in Tibetan yoga
47955346|NCT01893203|DRUG|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
47955347|NCT01893203|DRUG|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
48109602|NCT01194154|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
48109603|NCT01194154|DRUG|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
48109604|NCT00165451|DRUG|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
48109605|NCT00165451|DRUG|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
48109606|NCT00165451|DRUG|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
48109607|NCT00165451|DRUG|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
48109608|NCT04911439|OTHER|Low Arousal|This group will see affective images of the International Affective Picture System with low arousal level
47955348|NCT04710602|PROCEDURE|Minimally invasive surgical fixation of unstable rib cage|Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).
48109609|NCT04911439|OTHER|Medium arousal|This group will see affective images of the International Affective Picture System with medium arousal level
48109610|NCT04911439|OTHER|High arousal|This group will see affective images of the International Affective Picture System with high arousal level
48302379|NCT04278118|OTHER|Questionnaire Administration|Ancillary studies
48302380|NCT00909987|DRUG|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
48302381|NCT00909987|DRUG|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
48302382|NCT00909987|DRUG|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
48302383|NCT00909987|RADIATION|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
48302384|NCT00909987|DRUG|Capecitabine during all Radiotherapy period|825 mg/m2 bid
48302385|NCT00909987|PROCEDURE|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
48339918|NCT00832481|DRUG|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
48480531|NCT02624167|DRUG|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
48480532|NCT02624167|DRUG|Placebo|Patients will be given oral dose of matching Placebo
48480533|NCT02956616|DRUG|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
48480534|NCT02956616|OTHER|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
48480535|NCT02956616|PROCEDURE|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
48480536|NCT01328912|OTHER|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
48480537|NCT01328912|OTHER|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
48480538|NCT05619159|DEVICE|microscopic pathological evaluation|description of moesin expression between endometrial hyperplasia and endometrial carcinoma
47955349|NCT04710602|PROCEDURE|Large incision surgical fixation of unstable rib cage.|Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
47955351|NCT04628741|BEHAVIORAL|Dynamic Coaching Model|This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.
47955352|NCT04628741|BEHAVIORAL|Apprenticeship Approach|This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
47955353|NCT00432419|PROCEDURE|autologous peripheral blood cell transplantation|
47955354|NCT00524381|DRUG|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
47955355|NCT00524381|DRUG|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
47955356|NCT04862455|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
47955357|NCT04862455|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
47955358|NCT04862455|BIOLOGICAL|Pembrolizumab|Given IV
47955359|NCT04862455|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
47955360|NCT03266731|DRUG|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
47955361|NCT04901676|DRUG|Leronlimab|Leronlimab 700 mg (first dose) followed by weekly 350 mg
47955362|NCT04901676|DRUG|Placebo|Placebo
47955363|NCT01020383|DRUG|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
47955364|NCT01020383|DRUG|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
47955365|NCT02744703|DRUG|total-etch adhesive|comparator use of total-etch adhesive
47955366|NCT02744703|DRUG|CAPE-T|experimental group
47955367|NCT02744703|DRUG|self-etch adhesive|comparator use of total-etch adhesive
47955368|NCT02744703|DRUG|CAPE-S|experimental group
47955369|NCT03642119|DEVICE|iButton®|Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
47955370|NCT05545007|RADIATION|Hypofractionated Radiosurgery (HSRS)|HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
47955371|NCT05545007|PROCEDURE|Brain metastases surgical resection|Complete surgical resection of brain lesions with adeguate margins.
47955372|NCT00282100|DRUG|Gefetinib (Iressa)|
48480539|NCT00724620|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
47955373|NCT00246753|DRUG|lapatinib ditosylate|1500 mg, daily until disease progression
48109611|NCT05119023|BEHAVIORAL|Observational Learning|All participants will complete a computer-based serial response time task intended to measure observational (implicit) learning ability. In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
47955374|NCT03727269|OTHER|Wii Fit Training Experimental Group|Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
47955375|NCT03727269|OTHER|Conventional Training|"Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~1. Knack Maneuver (Ashton -Miller 1998, 2008)~2. Pelvic floor strengthening: kegel Exercise.~3. -Lumbo-Pelvic Stabilization Exercise.~4. Functional Training/ PFM Contraction during ADL~5. Correction of biomechanical/structural deformities"
47955376|NCT05890339|PROCEDURE|Laparoscopic Proximal Gastrectomy With Double-flap Technique|Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
48109612|NCT05119023|BEHAVIORAL|Rule-based Learning|All participants will complete a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability. In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
48109613|NCT04391283|DRUG|Osimertinib|The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.
48480540|NCT00724620|DRUG|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
48480541|NCT02396277|PROCEDURE|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
48480542|NCT05291052|DRUG|Tislelizumab|Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
48480543|NCT05291052|DRUG|Lenvatinib|Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
47955377|NCT05890339|PROCEDURE|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
47955378|NCT04969874|OTHER|Remote follow-up|"The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H\&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6."
47955379|NCT03683160|OTHER|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
48109614|NCT04747392|BIOLOGICAL|SAL001|administrated once by subcutaneous injection
48109615|NCT04747392|BIOLOGICAL|FORSTEO|administrated once by subcutaneous injection
48109616|NCT02890368|DRUG|TTI-621 Monotherapy|"TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
48109617|NCT02890368|DRUG|TTI-621 + PD-1/PD-L1 Inhibitor|TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
48480544|NCT05291052|DRUG|Oxaliplatin|"Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
48302386|NCT01328288|DRUG|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
48480545|NCT05291052|DRUG|Capecitabine|"Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
48639318|NCT05849376|BEHAVIORAL|Emergent Multi-Class Imitation Training|Sessions will be conducted in a room with minimal distractions containing a table, two chairs, a timer, and 3-4 highly preferred (HP) items identified by preference assessments.A minimum of 10 sessions per week will be distributed across at least 3 days per week. Each session will take 20-25 min to conduct. Each session will consist of the instructor presenting imitation training trials and probe trials. During baseline sessions, participants will not receive rewards for correct imitation. During training, participants will receive rewards for correct imitation and evidence-based teaching strategies that are commonly employed in applied behavior analysis therapy will be used to help participants learn how to imitate new responses. Novel probe trials will be embedded throughout all sessions to continuously evaluate the emergence of generalized imitation. When participants can consistently imitate novel probe responses, the intervention will conclude.
47955380|NCT04703387|DIAGNOSTIC_TEST|transthoracic echocardiography|Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
47955381|NCT01182610|DRUG|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
47955382|NCT01182610|DRUG|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
47955383|NCT01182610|DRUG|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
47955384|NCT01182610|DRUG|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
47955385|NCT00647361|DEVICE|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
47955386|NCT02850107|DEVICE|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
47955387|NCT02850107|DEVICE|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
47955388|NCT02850107|DEVICE|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
47955389|NCT02850107|DEVICE|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
47955390|NCT02850107|DEVICE|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
47955391|NCT01497457|PROCEDURE|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
47955392|NCT04040205|DRUG|Abemaciclib|Abemaciclib 200 mg will be taken by mouth twice daily.
48480546|NCT00333723|DRUG|Rosiglitazone|
48480547|NCT05146349|OTHER|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
47955393|NCT05271461|RADIATION|Low level laser Therapy|Pin pointed application of low level laser on 15 acupuncture points each point 1 min time of application 15 min.
47955394|NCT05271461|OTHER|Circulatory exercises|"Active assisted or against mild resistance. Supine with leg up position 18degrees measured by the bed water balance in side rails.~If patient is not comfortable according to the modified Borg scale or contra indicated for the position then assume the supine position.~The subject will have A 3 min rest period to acclimatize themselves to each position.~The ankle pumping exercises consisted of simple repetitions of dorsiflexion 1 sec and planter- flexion for 1 sec with three different exercise intervals:~* repeated dorsiflexion and planter-flexion with no rest (no rest exercise).~* repeated dorsiflexion and planter-flexion with a 2 sec rest period (2 sec rest exercise).~* repeated dorsiflexion and planter-flexion with 4sec rest period (4sec rest exercise).~Subjects will have practiced ankle pumps before the exercise to get familiar and be educated about the procedure."
47955395|NCT02451111|DRUG|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
48302387|NCT03174743|PROCEDURE|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
48302388|NCT03174743|PROCEDURE|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
48302389|NCT03174743|PROCEDURE|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
48480548|NCT00725478|DRUG|Piribedil|
48480549|NCT02843659|DRUG|BMS-931699|Specified dose on specified days
48480550|NCT02843659|DRUG|BMS-986142|Specified dose on specified days
48480551|NCT02843659|DRUG|Placebo|Specified dose on specified days
48480552|NCT06324058|PROCEDURE|Transurethral cryoablation|Using an intracavitary cryoablation balloon, cryoablation is performed on the wound surface after tumor resection. The wound surface is frozen for 2 rounds, with each round lasting 3 minutes, to fully cover the wound surface.
48302390|NCT03174743|PROCEDURE|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
47955396|NCT02451111|DRUG|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
47955397|NCT03623555|BEHAVIORAL|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
47955398|NCT03623555|BIOLOGICAL|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
48480553|NCT06324058|PROCEDURE|Transurethral resection of bladder tumor|Resection of bladder tumor using resectoscopy, which is a standard procedure to treat non-muscle invasive bladder cancer
47955399|NCT04262570|DEVICE|Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)|Non-invasive transcutaneous imaging of molecular muscle components
48480554|NCT06324058|DRUG|Bcg Intravesical|Bacillus Calmette-Guerin instillation of bladder after surgery according to the NCCN bladder cancer guidelines. At least 6 weeks induction instillation is required for high-risk NMIBC patients. At least 1 year maintenance instillation is recommended.
47955400|NCT06372301|DIAGNOSTIC_TEST|Dobutamine stress echocardiography|Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
47955401|NCT04074031|DEVICE|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
47955402|NCT03525366|OTHER|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
47955403|NCT00002854|BIOLOGICAL|filgrastim|
47955404|NCT00002854|DRUG|carboplatin|
47955405|NCT00002854|DRUG|cisplatin|
47955406|NCT00002854|DRUG|cyclophosphamide|
47955407|NCT00002854|DRUG|etoposide|
47955408|NCT00002854|DRUG|ifosfamide|
47955409|NCT00002854|DRUG|mesna|
47955410|NCT00002854|DRUG|paclitaxel|
47955411|NCT00002854|PROCEDURE|peripheral blood stem cell transplantation|
47955412|NCT04961307|DRUG|Trastuzumab|30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
47955413|NCT01349231|DRUG|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
48109618|NCT02890368|DRUG|TTI-621 + pegylated interferon-α2a|TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
48302391|NCT06332625|DIAGNOSTIC_TEST|Brain quantitative magnetic resonance imaging|Identification and predictability of early structural and metabolic markers from 3T and 7T quantitative magnetic resonance imaging (qMRI)
48302392|NCT05242276|DEVICE|USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY|The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
48480555|NCT04922450|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/3weeks)
47955414|NCT03101787|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is \< 60 minutes."
47955415|NCT00474760|DRUG|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
47955416|NCT01963273|PROCEDURE|Video Assisted Ablation of Pilonidal Sinus|
48109619|NCT02890368|OTHER|TTI-621 + T-Vec|TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
48302393|NCT02183025|DRUG|Meloxicam 7.5 mg|
48302394|NCT02183025|DRUG|Meloxicam 15 mg|
48302395|NCT02183025|DRUG|Mefenamic acid 500 mg|
48480556|NCT04922450|DRUG|Albumin Paclitaxel|Albumin Paclitaxel(260mg/m²),every 3 weeks
48480557|NCT04922450|DRUG|Cisplatin|Cisplatin（80mg/m²）, every 3 weeks
48480558|NCT02057445|DRUG|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
47955417|NCT01558739|DRUG|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
47955418|NCT03645564|OTHER|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
47955419|NCT00365222|DRUG|Temozolomide|temozolomide 75 mg/m2 /d
47955420|NCT02628938|OTHER|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
48480559|NCT02057445|OTHER|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
48302396|NCT02183025|DRUG|Placebo matching 7.5 mg meloxicam|
48480560|NCT06616233|DEVICE|Remote Ischaemic Conditioning with exercise|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm). During the cuff deflation phase, participants will undergo handgrip exercise at 20-30% of their maximal voluntary contraction for 3 minutes. There will be a total of 4 cycles of exercise.
47955421|NCT02628938|OTHER|Miswak stick|Miswak stick twice a day for 7 days
48109620|NCT02890368|OTHER|TTI-621 + radiation|TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
48109621|NCT02947217|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
48109622|NCT02947217|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
48109623|NCT02835768|OTHER|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
47955422|NCT02628938|OTHER|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
47955423|NCT03488355|OTHER|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
48109624|NCT06465498|PROCEDURE|LUS decongestive strategy|LUS results are documented in the electronic case report form (eCRF) and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
48480561|NCT06616233|DEVICE|Other: Remote Ischaemic Conditioning|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm).. There will be a total of 4 cycles.
47955424|NCT01313312|BIOLOGICAL|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
47955425|NCT02328183|DRUG|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
48109625|NCT06465498|PROCEDURE|PE decongestive strategy|PE results are documented in the eCRF and converted into a common score ranging from absence of congestion to severe congestion. This generic congestion score will be communicated to the treating physician by the research personnel, along with a proposal to step-up, maintain, or step-down the decongestive therapy.
48109626|NCT00841633|DRUG|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
47955426|NCT04635189|DRUG|Daratumumab|Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
47955427|NCT04635189|DRUG|Lenalidomide|Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
47955428|NCT04635189|DRUG|Dexamethasone|Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
47955429|NCT01475409|BIOLOGICAL|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
47955430|NCT01751893|DRUG|Henna|natural henna in the form of paste
47955431|NCT01751893|DRUG|Placebo|placebo
48109627|NCT01511471|DRUG|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
48302397|NCT02183025|DRUG|Placebo matching 15 mg meloxicam|
48302398|NCT02183025|DRUG|Placebo matching 500 mg mefenamic acid|
48480562|NCT03482167|DRUG|Niagen®|250 mg capsules (4 capsules daily)
48480563|NCT03482167|OTHER|Placebo|placebo
48480564|NCT02731014|OTHER|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
48639319|NCT06059248|OTHER|"the head in the sniffing position "|"Intubation was performed with the head in the  elevation  position"
47955432|NCT00216710|BEHAVIORAL|Home Visiting|
48302399|NCT00246038|DEVICE|Boston Scientific ENOVUS AAA Endograft|
48302400|NCT06435195|PROCEDURE|Surgical Removal|Resection of pituitary pathologies.
48302401|NCT06435195|PROCEDURE|Biopsy|Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
48302402|NCT03988777|DEVICE|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
48302403|NCT04871633|DRUG|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
48302404|NCT04871633|DRUG|Conventional|IV Steroids Antibiotics
48302405|NCT00782925|OTHER|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
48302406|NCT00782925|OTHER|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
47955433|NCT02875912|BEHAVIORAL|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
47955434|NCT06259123|DRUG|[177Lu]Lu-PSMA I&T|2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
47955435|NCT04442113|PROCEDURE|Pulmonary vein isolation plus ablation guided by novel STAR mapping™|Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
47955436|NCT04442113|PROCEDURE|Pulmonary vein isolation|Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
47955437|NCT01713608|DRUG|OZ439|OZ439 x mg once daily for 3 days with milk
47955438|NCT06033053|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
47955439|NCT01049568|BEHAVIORAL|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
47955440|NCT00341055|DRUG|Epoetin alfa|
47955441|NCT04871971|DIETARY_SUPPLEMENT|10 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
47955442|NCT04871971|DIETARY_SUPPLEMENT|20 g NUTRALYS®S85 Plus pea protein|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
48302407|NCT00782925|OTHER|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
48302408|NCT00647777|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fed
48480565|NCT02731014|OTHER|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
48480566|NCT02731014|OTHER|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
47955443|NCT04871971|DIETARY_SUPPLEMENT|10 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
47955444|NCT04871971|DIETARY_SUPPLEMENT|20 g Whey protein concentrate|To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
47955445|NCT04871971|DIETARY_SUPPLEMENT|50 g Glucose|To determine the glycaemic response and insulinaemic response to 50g Glucose
48109628|NCT01112644|DRUG|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
48302409|NCT00647777|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fed
48302410|NCT00057616|DRUG|CC-5013|
48302411|NCT02505555|DEVICE|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
48302412|NCT01873742|OTHER|STIC feedback system|This condition includes the use of the STIC feedback system.
48302413|NCT04229446|BEHAVIORAL|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
48302414|NCT04868461|DIETARY_SUPPLEMENT|Unheated Whey Protein (UWP) beverage|The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
48302415|NCT04868461|DIETARY_SUPPLEMENT|Heated Whey Protein (HWP) beverage|The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
48302416|NCT04868461|DIETARY_SUPPLEMENT|Casein (Cas) beverage|The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
48639320|NCT06176365|DRUG|Survodutide|once weekly subcutaneous injection
47955446|NCT04041297|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
48109629|NCT01112644|OTHER|Placebo (PLA)|Different daily doses; intake every 12 hours
48109630|NCT05322824|DRUG|standard medical treatment|standard medical treatment
48109631|NCT05322824|PROCEDURE|Interventional stenting|Interventional stenting
48109632|NCT05257798|DRUG|IFN-β inhibitor treatment|PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
48109633|NCT05257798|OTHER|Placebo|Placebo for PF-06823859, 0 mg/mL solution for injection
48109634|NCT02698007|DEVICE|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
48109635|NCT00295074|PROCEDURE|neuropsychologic testing|
48109636|NCT01819493|BEHAVIORAL|Lifestyle Intervention|Family-based group lifestyle intervention
48109637|NCT01819493|BEHAVIORAL|Standard Family-Based intervention|Comparison intervention
48109638|NCT00346151|DRUG|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
48109639|NCT00346151|DRUG|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
48109640|NCT00346151|DRUG|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
48109641|NCT00346151|DRUG|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
48109642|NCT01378065|DEVICE|Restorelle Direct Fix A&P|Restorelle Direct Fix A\&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
48109643|NCT01001078|DEVICE|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
48109644|NCT01001078|DEVICE|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
48109645|NCT01001078|DEVICE|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
48109646|NCT04803630|OTHER|Quality-of-Life Assessment|Ancillary studies
48109647|NCT04803630|OTHER|Questionnaire Administration|Ancillary studies
48109648|NCT04803630|PROCEDURE|Thermotherapy|Undergo thermal therapy
48109649|NCT01243619|DRUG|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
48109650|NCT02732314|DRUG|Investigational OTC Cream|
48109651|NCT02732314|OTHER|Cosmetic Eczema Cream|
48109652|NCT02732314|DRUG|0.05% Desonide Cream|
48109653|NCT02732314|OTHER|Placebo Cream|
48109654|NCT01183780|BIOLOGICAL|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
48109655|NCT01183780|BIOLOGICAL|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
48109656|NCT01183780|DRUG|Irinotecan|180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
48109657|NCT01183780|DRUG|Folinic Acid|400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
48109658|NCT01183780|DRUG|5-Fluorouracil|400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
48109659|NCT06259669|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
48109660|NCT00711919|DRUG|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
48109661|NCT00711919|DRUG|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
48109662|NCT02050308|OTHER|Internet-All Nations Breath of Life (I-ANBL)|"* Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~* Weekly procedures will follow the same format as for the first session"
48302417|NCT04868461|DIETARY_SUPPLEMENT|Water|The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
48480567|NCT02731014|OTHER|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
48302418|NCT02379923|DEVICE|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
48302419|NCT02793167|DEVICE|AKI alert|
48302420|NCT06387719|DIAGNOSTIC_TEST|Magnetic resonance imaging|"* Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles."
48302421|NCT01284322|DRUG|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
48302422|NCT01492114|DIETARY_SUPPLEMENT|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
48302423|NCT01492114|DIETARY_SUPPLEMENT|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
48302424|NCT02041351|DRUG|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
48302425|NCT04919993|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|Group presentation
48302426|NCT03732872|DIAGNOSTIC_TEST|Biopsy tissue analysis|biopsy samples for IHC staining and PCR
48302427|NCT03732872|DIAGNOSTIC_TEST|Saliva analysis|Saliva samples for miRNA 21 expression analysis
48302428|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of bupivacaine|270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
48302429|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of saline|270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
48302430|NCT02995343|PROCEDURE|Hypogastric and/or uterine artery ligation|
48302431|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
48302432|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
48302433|NCT00187707|DRUG|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
48302434|NCT03663608|PROCEDURE|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
48302435|NCT00198341|PROCEDURE|Radiological Arm|Clinical Visit + X-Ray Chest
48302436|NCT00198341|PROCEDURE|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
48302437|NCT02731040|DRUG|Bisphosphonate|
48302438|NCT02485366|DRUG|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
48302439|NCT02485366|PROCEDURE|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
48302440|NCT01671436|BEHAVIORAL|Central Meditation and Imagery Therapy|
48302441|NCT04180436|DRUG|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
48302442|NCT01479790|DEVICE|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
48302443|NCT01496573|OTHER|laboratory biomarker analysis|Correlative studies
48302444|NCT00524095|DRUG|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
48302445|NCT00524095|DRUG|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
48302446|NCT01842061|BEHAVIORAL|Active Living Program|
48302447|NCT01842061|BEHAVIORAL|Education|
48302448|NCT00907478|BIOLOGICAL|romiplostim|Romiplostim administered by subcutaneous injection
48302449|NCT03797950|BEHAVIORAL|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
48302450|NCT03797950|BEHAVIORAL|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
48302451|NCT01353833|DRUG|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
48339919|NCT01413828|DRUG|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
48339920|NCT01413828|DRUG|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
48639321|NCT06176365|DRUG|Placebo matching survodutide|once weekly subcutaneous injection
47955447|NCT05734300|PROCEDURE|Combined Endoscopic Laparoscopic Surgery (CELS)|"The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis.~Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response."
48109663|NCT02050308|OTHER|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
48109664|NCT02050308|DRUG|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
48109665|NCT00328055|BEHAVIORAL|AD-Easy (Advance Directive-Easy)|
47955448|NCT05734300|PROCEDURE|Standard resection|In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.
48109666|NCT00328055|BEHAVIORAL|AD-Standard (Advance Directive-Standard)|
48109667|NCT01426750|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
48109668|NCT02695290|DRUG|Afatinib|
48109669|NCT00437346|PROCEDURE|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
48109670|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
48109671|NCT00437346|DRUG|Lanzo Melt|30mg, od, 1/2 h before meal
48109672|NCT01564199|DRUG|salmeterol / fluticasone propionate|100/1000 μg oral capsule
48109673|NCT04956146|DRUG|Fruquintinib，Sintilimab，Pemetrexed，Carboplatin|Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4\~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4\~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
48339921|NCT02715804|OTHER|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
48639322|NCT05978232|BEHAVIORAL|NAVAH|Patient navigator program that aims to inform African-American prostate and breast cancer patients about their treatment options, specifically radiotherapy
48480568|NCT00956787|DRUG|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
48639323|NCT03816345|PROCEDURE|Biospecimen Collection|Undergo collection of blood, CSF, tissue, stool and urine samples
48639324|NCT03816345|BIOLOGICAL|Nivolumab|Given IV
48639325|NCT03763266|OTHER|1 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
47955449|NCT03109730|DRUG|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
48302452|NCT02735317|DRUG|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
48302453|NCT02735317|DRUG|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
48302454|NCT04840654|PROCEDURE|Caudal Block|"A caudal block is a procedure that will help lessen a child's pain after an operation.~100 subjects will be randomized to this block procedure."
48302455|NCT04840654|PROCEDURE|Pudendal Block|"form of local anesthesia commonly used in the practice of obstetrics to relieve pain during the delivery of baby by forceps.~100 Subjects will be randomized to this block procedure."
48302456|NCT02120651|PROCEDURE|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
48302457|NCT02120651|PROCEDURE|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
48302458|NCT03010423|DRUG|Nicorandil|Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
48480569|NCT02449473|BIOLOGICAL|Tralokinumab|Subcutaneous Injection
48480570|NCT02449473|OTHER|Placebo|Subcutaneous Injection
48480571|NCT04108247|DRUG|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
48480572|NCT03512002|DEVICE|HIRREM|Technology
48480573|NCT03512002|OTHER|Continued Current Care|Continue their current clinical care.
48480574|NCT01854086|OTHER|Questionnaires about compliance and persistence with bisphosphonates treatment|
48639326|NCT03763266|OTHER|3 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
48639327|NCT05432960|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
48639328|NCT05432960|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution)
48639329|NCT01512251|DRUG|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
47955450|NCT03109730|DRUG|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
48302459|NCT00486226|DEVICE|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
48339922|NCT02715804|DRUG|Placebo|Matching placebo for PEGPH20
48480575|NCT05914545|DRUG|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
48480576|NCT03024931|OTHER|observational study|No intervention
48480577|NCT04600024|DIAGNOSTIC_TEST|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
48480578|NCT04783116|DIETARY_SUPPLEMENT|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
48480579|NCT04783116|DIETARY_SUPPLEMENT|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
48480580|NCT04661826|DRUG|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
48480581|NCT03717519|DIAGNOSTIC_TEST|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
48480582|NCT04932941|DRUG|MP1032|Hard gelatin capsules for oral administration.
48480583|NCT04932941|DRUG|Placebo|Placebo capsules matched to MP1032 for oral administration.
48480584|NCT03512912|DEVICE|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
48480585|NCT05717244|DEVICE|2WIN-S|Determining pupil diameter by 2WIN-S
48480586|NCT05717244|DEVICE|OPD|Determining pupil diameter by OPD
48639330|NCT04916665|DRUG|Teduglutide|bridging intestinal failure with teduglutide until reconstruction
48639331|NCT03495440|BEHAVIORAL|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
48639332|NCT03495440|BEHAVIORAL|At-home|Self-study resources paired with regular contact with study personnel.
48639333|NCT05509192|DRUG|MTPI|Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.
48639334|NCT05509192|DRUG|Classic Induction|Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
48302460|NCT06401655|BEHAVIORAL|Financial Coaching for People living with Acquired Brain Injury (FC-ABI)|This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant).
48302461|NCT02518620|BIOLOGICAL|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
48302462|NCT03415724|PROCEDURE|Inferior alveolar nerve block|Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
48480587|NCT02607020|OTHER|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
48480588|NCT02607020|OTHER|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
48480589|NCT02737592|DEVICE|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
48639335|NCT00002135|DRUG|Ganciclovir|
48639336|NCT04667559|DEVICE|Conformis iTotal Identity Knee Replacement System|The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.
48639337|NCT05045963|OTHER|Electronic Health Record Review|Medical record reviewed
47955451|NCT03109730|DRUG|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
47955452|NCT03109730|DRUG|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
47955453|NCT03109730|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
48302463|NCT05528042|OTHER|Heart rate and respiratory rate measurement|"Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting"
48109674|NCT04362215|DIAGNOSTIC_TEST|Subjective accomodation amplitude measurement|ECG:Electrocardıography Echocardiography, Holter implementation(for Lf/Hf ratio))
48302464|NCT05327478|PROCEDURE|NRP|Normothermic Regional Perfusion
48302465|NCT05327478|PROCEDURE|DHOPE|Dual Hypothermic Oxygenated Perfusion
48302466|NCT05327478|PROCEDURE|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
48302467|NCT00521339|DRUG|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
48639338|NCT03149380|BEHAVIORAL|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
48302468|NCT01097616|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
48302469|NCT01097616|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
48302470|NCT01097616|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
48302471|NCT02783274|DEVICE|Actis Total Hip System|Total Hip Replacement and Hemi-hip Replacement
48302472|NCT00769704|BIOLOGICAL|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
48302473|NCT00769704|BIOLOGICAL|GM-CSF|125 µg/m² subcutaneous injection
48302474|NCT01635556|BEHAVIORAL|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
48302475|NCT02470013|DIETARY_SUPPLEMENT|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
48302476|NCT04582500|DRUG|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
48302477|NCT00935220|DRUG|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
48302478|NCT03950102|RADIATION|SBRT|Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
48302479|NCT06051253|DRUG|TDM-based infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
48339923|NCT02715804|DRUG|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
48339924|NCT02715804|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
48639339|NCT06565078|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|CUVITRU 20% Solution
48639340|NCT05881330|DEVICE|ArtiAid Intra-articular Injection|Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
48639341|NCT02668315|BIOLOGICAL|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
48639342|NCT01530997|RADIATION|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
48109675|NCT03516604|DRUG|PF-04995274|PF-04995274 tablets
48639343|NCT01530997|DRUG|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
48109676|NCT03516604|DRUG|Citalopram|Citalopram capsule
48109677|NCT03516604|DRUG|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
48109678|NCT03516604|DRUG|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
48302480|NCT06051253|DRUG|Standard infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
48302481|NCT00428506|DRUG|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
48302482|NCT00428506|DRUG|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
48302483|NCT02832804|DEVICE|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
48302484|NCT01990599|OTHER|Nasopharyngeal Tube|
48302485|NCT02284334|OTHER|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
48639344|NCT01530997|PROCEDURE|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
48639345|NCT03323476|OTHER|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
48639346|NCT03323476|DRUG|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
48639347|NCT02864914|DRUG|Empagliflozin|drug
48639348|NCT02864914|DRUG|DPP-4 inhibitors|drug
48639349|NCT01163565|DEVICE|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
48639350|NCT05282927|OTHER|Implementation Strategy: Foundational REP|The goal is to test implementation intensification approaches for group PT sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Group PT for context and provides tools for ongoing evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully implement group PT as a clinical service.
48639351|NCT05282927|OTHER|Implementation Strategy: Enhanced REP (enREP)|The goal is to test implementation intensification approaches for sites that have not met implementation adoption benchmarks, specifically Foundational REP vs. EnREP. The investigators posit that monitoring sites' progress and adding, for sites with low adoption, higher intensity strategies (defined as EnREP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
48639352|NCT05038735|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
48302486|NCT03648996|OTHER|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
48302487|NCT03648996|DRUG|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
48302488|NCT03648996|DRUG|Placebo|6 months of placebo treatment
48302489|NCT03648996|OTHER|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
48302490|NCT03321240|PROCEDURE|visual and quantitative SEEG signal analysis|signal SEEG analysis
48302491|NCT03321240|PROCEDURE|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
48302492|NCT03273075|DRUG|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
48302493|NCT03273075|DRUG|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
48302494|NCT03273075|DRUG|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
48302495|NCT03273075|DRUG|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
48302496|NCT01830153|DRUG|RAD001|
48639353|NCT05038735|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
48639354|NCT05038735|DRUG|Alpelisib-matching placebo|Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
48639355|NCT05874297|OTHER|Best Practice|Receive standard of care
48639356|NCT05874297|BEHAVIORAL|Internet-Based Intervention|Access to enhanced Cook for your life website
48639357|NCT05874297|OTHER|Questionnaire Administration|Ancillary studies
48639358|NCT05922098|OTHER|Texture Modified Foods Manual for chewing dysfunctions in older adult|Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
48639359|NCT05606614|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
48639360|NCT05206227|BEHAVIORAL|Aerobic Exercise|Subjects will complete a single bout of aerobic exercise.
48639361|NCT05206227|DRUG|alpha-FMH|Subjects will undergo either local heating with diathermy or whole body heating with far-infrared sauna.
48639362|NCT05206227|BEHAVIORAL|Resistance and Aerobic Exercise|Subjects will complete bouts of resistance and aerobic exercise.
48639363|NCT05206227|DRUG|Antihistamine|Subjects will complete a single bout of aerobic exercise under placebo vs antihistamine conditions.
48339925|NCT03919006|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
48339926|NCT03919006|OTHER|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
48339927|NCT00201760|DRUG|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
48639364|NCT00790660|DRUG|ASP1941|Oral
48639365|NCT00790660|DRUG|Placebo|Oral
48639366|NCT03865706|DRUG|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
48639367|NCT03865706|DRUG|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
48639368|NCT03865706|DRUG|Broad-spectrum antibiotics|Standard of care treatment for infections
48302497|NCT06092372|BEHAVIORAL|Diet intervention program|"Participants will get 5 meals/day based on their calorie needs minus 500 kcal/day less than their daily calorie expenditure. All meals will be tracked via a mobile application, including any meals outside the recommended food plan. The calories will be calculated based on the information provided.~To calculate the calories burned from any activities, all participants in the diet intervention arm will get an activity tracking device. The first calorie level is calculated based on the information in the registration form: age, height, weight, gender, and personal view of the daily activity. After that, and once the activity tracker is synced to the program, the calorie level is calculated based on the 7-day average calories burned.~The external diet intervention provider will be blinded to whether the study participants belong to the top or bottom 5% of the polygenic score for BMI."
48302498|NCT02711670|DRUG|chlorthalidone|
48302499|NCT02711670|DRUG|Hydrochlorothiazide|
48639369|NCT06494371|BIOLOGICAL|LCAR-HL30 cells|Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
48639370|NCT01899378|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|10\^8 CFU
48639371|NCT01899378|DIETARY_SUPPLEMENT|Bifidobacterium longum infantis|10\^9 CFU
48639372|NCT03254641|DRUG|human chorionic gonadotropin|5000 IE times one
48639373|NCT04576481|BEHAVIORAL|Texting|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
48639374|NCT04576481|BEHAVIORAL|Regret|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
48639375|NCT04576481|BEHAVIORAL|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
48639376|NCT06488222|DRUG|Docetaxel|Subjects will receive 40 mg docetaxel intravesically.
48639377|NCT06488222|DRUG|Gemcitabine|Subjects will receive 1 mg gemcitabine intravesically.
48639378|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Open Label Pilot|"As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype."
48639379|NCT06326905|BEHAVIORAL|CAPABLE Transplant- Randomized Control Trial|As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
48302500|NCT00893113|DRUG|Placebo|Alfuzosin-matched One tablet once daily
48302501|NCT00893113|DRUG|Alfuzosin|10 mg once daily
48302502|NCT03704597|OTHER|cryotherapy|Cooling of oral mucosa
48302503|NCT01710228|DRUG|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
48302504|NCT06282757|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
48302505|NCT06282757|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo stimulating verbal language.
48302506|NCT01152450|DRUG|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
48302507|NCT01152450|DRUG|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
48302508|NCT01152450|DRUG|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
48302509|NCT02244359|BEHAVIORAL|Training|
48302510|NCT02244359|BEHAVIORAL|Usual care|
48302511|NCT01671085|DRUG|LY3015014|Administered SQ
48302512|NCT01671085|DRUG|Placebo|Administered SQ
48302513|NCT00625066|OTHER|biologic sample preservation procedure|
48302514|NCT00625066|OTHER|cytology specimen collection procedure|
48302515|NCT00625066|OTHER|medical chart review|
48302516|NCT00625066|OTHER|questionnaire administration|
48302517|NCT00625066|OTHER|survey administration|
48302518|NCT00625066|PROCEDURE|biopsy|
48302519|NCT00625066|PROCEDURE|evaluation of cancer risk factors|
48109679|NCT06513546|DRUG|PLL001 or placebo daily subcutaneous injections|PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)
48302520|NCT00625066|PROCEDURE|screening colonoscopy|
48480590|NCT05379556|DIAGNOSTIC_TEST|Assessment of andrological profile of LO-COCO-ANDRO male patients|"Assessment of serum prolactin (PRL), luteininzing hormone (LH), follicle stimulating hormone (FSH), 17β-estradiol, testosterone. Physical examination with measurement of body weight, height, body mass index, waist and hip circumference. Andrological physical examination with evaluation of testis volume with Prader orchidometer, testicular consistency and lesions, varicocele. Scrotal ultrasound performed in longitudinal, transverse and oblique scans using a high frequency linear probe with grayscale and color-doppler; transrectal prostate ultrasound performed with transverse, longitudinal and oblique scans using an end fire probe; basal penile ultrasound will be performed in longitudinal and transverse scans using a high frequency linear probe with grayscale and color-doppler; dynamic penile ultrasound performed as described for basal penile ultrasound after intra-cavernous infiltration of 10 mcg of prostaglandin-E1 (PGE1)."
48302521|NCT00392444|DRUG|sunitinib malate|Given orally
48302522|NCT03949049|DRUG|Citicoline|Citacoline as neuroprotector
48302523|NCT03949049|OTHER|Placebo|placebo group
48302524|NCT02337504|OTHER|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
48302525|NCT02203253|DRUG|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
48302526|NCT02203253|DRUG|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
48302527|NCT02203253|DRUG|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
48302528|NCT05406297|PROCEDURE|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
48302529|NCT00840645|DRUG|YM178|Oral
48302530|NCT02140918|DRUG|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
48302531|NCT02140918|DRUG|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
48302532|NCT02140918|DRUG|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
48302533|NCT02140918|DRUG|Placebo|
48302534|NCT06098261|DRUG|Test (T) Bilastine|Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.
48302535|NCT06098261|DRUG|Reference (R) Bilastine|Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.
48302536|NCT03574896|OTHER|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
48302537|NCT04933279|DIETARY_SUPPLEMENT|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
48339928|NCT00201760|DRUG|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
48339929|NCT00201760|DRUG|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
47955454|NCT06038214|OTHER|core exercises|"1.5 minutes walking 2. Stretching exercise~* hallowing in supine and side lying position~* Bracing in supine and side lying position~* Bracing on the prone and forearms~* Bracing in the crawling position~* Bracing in laptop, half-lap and standing position~* Heel slide exercise~* Bridge building exercise~* Unilateral limb flexion exercise in crawling position~* Reciprocal heel slide exercise in supine position~* Bilateral lower extremity lifting exercise~* Unilateral lower extremity flexion in bridging position~* Side bridging exercise with knees extended~* Unilateral lower extremity extension in crawling position~* Contralateral lower and upper extremity lift in the crawling position~* Straight and oblique trunk flexion~* Straight and oblique trunk flexion with hip and knee flexed to 90°~* bracing on the ball~* squat~* bracing while walking"
47955455|NCT06038214|OTHER|home exercises|"Right and left rotation of the head~* lateral flexion of the head~* Flexion and extension of the head~* Stretching the neck extensors~* pectoral stretch~* Stretching the hip extensors~* Hamstrig stretching~* Stretching the lumbar extensors~* Abdominal strengthening~* bridging~* Hip abduction strengthening~* hip extension strengthening~* Upper extremity resistant flexion~* Upper extremity resistant abduction~* Upper extremity relaxation exercise~* Capsule stretching~* Stretching the hip flexors~* Stretching the lower extremity adductors~* relaxation exercise"
48109680|NCT04155177|PROCEDURE|training for french ambulatory caesarean section|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined."
48480591|NCT05379556|DIAGNOSTIC_TEST|Assessment of reproductive function of LO-COCO-ANDRO male patients|Semen samples will be collected on site by masturbation directly into a sterile plastic container after 3-5 days of sexual abstinence. The sample will be analyzed according to World Health Organization (WHO) 2010 guidelines. Semen samples will be stored for biochemical and molecular evaluations.
48480592|NCT05379556|DIAGNOSTIC_TEST|Assessment of sexual function of LO-COCO-ANDRO male patients|Validated questionnaires to assess the prevalence of male sexual disorders, namely erectile dysfunction with International Index of Erectile function 15 (IIEF-15), premature ejaculation with premature ejaculation diagnostic tool (PEDT), hypoactive sexual desire disorder with andrological structured interview on erectile dysfunction (ANDRO-SIEDY). Patients will be also interviewed to evaluate lifestyle habits.
48109681|NCT05452681|OTHER|Educational Intervention|Receive Y-AMBIENT
48109682|NCT05452681|OTHER|Quality-of-Life Assessment|Ancillary studies
48339930|NCT04049812|DEVICE|PEMF|
48480593|NCT05379556|DIAGNOSTIC_TEST|Assessment of olfactory function of LO-COCO-ANDRO male and female patients|"Brief interview to collect patient's anamnesis relative to olfactory function, with particular reference to hypo / anosmia and hypo/ageusia onset timeline, duration and regression.~Interview for the self-assessment of chemosensory skills and for the evaluation of quality of life in relation to olfactory dysfunction.~Sniffin 'Sticks test for the evaluation of odor threshold (T), odor discrimination (D) and odor identification (I) (TDI score)."
48480594|NCT00031811|DRUG|raloxifene|
48480595|NCT00031811|PROCEDURE|quality-of-life assessment|
48480596|NCT03212794|BEHAVIORAL|Recovery coach|The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
48480597|NCT00510315|OTHER|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
48480598|NCT01678651|PROCEDURE|Stimulation with human FSH|Human FSH
48480599|NCT01678651|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
48480600|NCT03663790|OTHER|Foot Progression|The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
48480601|NCT03663790|OTHER|Trunk Lean|The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
48480602|NCT05287152|DEVICE|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
48480603|NCT01096979|DRUG|LIPO-102|subcutaneous injection
48480604|NCT01096979|DRUG|Placebo|Placebo
48480605|NCT02744599|DEVICE|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
48480606|NCT05546242|DRUG|Cabotegravir/Rilpivirine|injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
48339931|NCT04049812|DEVICE|Hot pack|
48339932|NCT04049812|DEVICE|TENS|
48480607|NCT05546242|DRUG|Antiretroviral|Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
48480608|NCT02697539|OTHER|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
48639380|NCT06081114|DIETARY_SUPPLEMENT|Micronutrient Supplement|A packaged food supplement providing calories and protein and fortified with micronutrients provided at an approximate RDA.
48639381|NCT02975700|DRUG|PLX3397|1000 mg/day (400 mg in the morning and 600 mg in the evening)
48639382|NCT06695364|OTHER|survey study|Not all classes were included in the study
48639383|NCT04713007|BEHAVIORAL|Quality of Life Ted Talks|There will be 9 training modules released weekly on the tablet. A survey will be required at baseline, each of the 9 weeks and at 3 months.
48639384|NCT04713007|BEHAVIORAL|Quality of Life Supportive Resources|The tablet will be preloaded with cancer information and supportive care resources from the National Cancer Institute. A survey will be required at baseline, each of the 9 weeks and at 3 months.
48639385|NCT04624204|BIOLOGICAL|Pembrolizumab 200 mg|Pembrolizumab 200 mg Q3W
48639386|NCT04624204|BIOLOGICAL|Pembrolizumab 400 mg|Pembrolizumab 400 mg Q6W
48639387|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q3W
47955456|NCT03502460|OTHER|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
48339933|NCT04049812|DEVICE|Sham PEMF|
48480609|NCT02697539|OTHER|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
48480610|NCT06269809|PROCEDURE|Temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.
48480611|NCT06269809|PROCEDURE|No temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
48480612|NCT05230602|DIETARY_SUPPLEMENT|opuntia (tzabar fruit)|consuming of the tzabar fruit twice a day
48480613|NCT01546922|DRUG|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
48480614|NCT00734942|OTHER|support service|"* professional partners for communication~* befriending with other families concerned~* information and education (about illness, symptoms, first aid, caring)~* free-time activities and time out~* homework assistance~* administrative advise~* support for everyday life"
48480615|NCT04274582|DIETARY_SUPPLEMENT|chokeberry extract|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
48639388|NCT04624204|DRUG|Pembrolizumab placebo (saline)|Pembrolizumab placebo (saline) Q6W
48639389|NCT04624204|DRUG|Olaparib 300 mg BID|Olaparib 300 mg twice daily (BID)
47955457|NCT01355926|OTHER|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
48109683|NCT05452681|OTHER|Questionnaire Administration|Ancillary studies
48480616|NCT01519102|DEVICE|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
48480617|NCT04955366|DRUG|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
48639390|NCT04624204|DRUG|Olaparib matching placebo|Olaparib matching placebo BID
48639391|NCT04624204|DRUG|Etoposide 100 mg/m^2|Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
48639392|NCT04624204|DRUG|Platinum, investigator's choice|Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
48639393|NCT04624204|RADIATION|Standard Thoracic Radiotherapy|Standard Thoracic Radiotherapy
48639394|NCT04624204|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
48639395|NCT03399773|BIOLOGICAL|Dilanubicel|Given IV
48639396|NCT03399773|DRUG|Cyclophosphamide|Given IV
48639397|NCT03399773|DRUG|Fludarabine|Given IV
48639398|NCT03399773|DRUG|Thiotepa|Given IV
48639399|NCT03399773|RADIATION|Total-Body Irradiation|Undergo TBI
48639400|NCT03399773|PROCEDURE|Umbilical Cord Blood Transplantation|Given IV
48639401|NCT03399773|OTHER|Laboratory Biomarker Analysis|Correlative studies
48639402|NCT03399773|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48639403|NCT03399773|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate and biopsy
48639404|NCT03399773|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate and biopsy
48639405|NCT03399773|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48639406|NCT03399773|PROCEDURE|Electrocardiography|Undergo ECHO
48302538|NCT04933279|DIETARY_SUPPLEMENT|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
48302539|NCT04792151|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
48302540|NCT03493308|OTHER|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
48302541|NCT03493308|OTHER|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
48302542|NCT01591018|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
48302543|NCT01591018|PROCEDURE|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
47955458|NCT01355926|OTHER|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
48302544|NCT04143542|PROCEDURE|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
48302545|NCT06148233|RADIATION|[18F]CSF-23|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose.
48302546|NCT04832841|DIAGNOSTIC_TEST|anti-spike SARS-CoV-2 IgG|Immunochemiluminescent assay by DiaSorin S.p.A. Italy
48302547|NCT02401555|DEVICE|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
48302548|NCT03404414|DRUG|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
48302549|NCT03366740|OTHER|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
48302550|NCT03366740|OTHER|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
48302551|NCT03366740|OTHER|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
48339934|NCT03892707|DRUG|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
48339935|NCT05267145|COMBINATION_PRODUCT|blood preservation solution III|Blood bag added blood preservation solution III
48480618|NCT04955366|DRUG|Abatacept|Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
48480619|NCT04104984|DEVICE|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
48480620|NCT04104984|DRUG|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
48639407|NCT03399773|PROCEDURE|Computed Tomography|Undergo CT
48639408|NCT05063383|OTHER|This study does not involve any interventions|This study does not involve any interventions
48639409|NCT04408209|PROCEDURE|Convalescent Plasma|"Convalescent Plasma - early treatment of patients with severe COVID-19. Clinical and laboratory data of patients will be collected before initiation of the procedure, 30 minutes after the first dose, 30 minutes after the second dose and 30 minutes after the third plasma dose and then on days 1-7, 14, 21, 28, 35 from the start of treatment. In case of adverse reactions during transfusion such as acute shortness of breath, haemodynamic instability or high pre-existing and non-disease-related fever, the transfusion will be interrupted and detailed recording of the event as well as updating the Adverse Events Management Committee will be performed.~In addition to the standard assessments, the titer of neutralizing anti-SARS-CoV-2 antibodies will be measured in a sample drawn prior to plasmapheresis.~All donors will be tested for:~1. the titer of IgG anti-SARS-CoV-2 antibodies (Pasteur Institute)~2. the titer of neutralizing anti-SARS-CoV-2 antibodies (Pasteur Institute)"
48639410|NCT05064670|BEHAVIORAL|Exercise|A twice weekly, 3-month supervised exercise program of whole body resistance training using body weight and a resistance band, and moderate to high intensity aerobic activities, consisting of a consecutive series of timed exercises performed one after the other (14-18 on the Borg scale). Classes are conducted live in groups through Microsoft Teams. Participants will not receive any contact or exercise support in the 3-month follow-up period following the initial 3-month intervention
48639411|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
48639412|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app + EHR|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
48302552|NCT01176396|OTHER|Caries prevention active intervention|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
48302553|NCT01176396|OTHER|control treatment|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
48302554|NCT05299203|DRUG|Sapropterin dihydrochloride tablets|dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
48302555|NCT03638089|BEHAVIORAL|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
48302556|NCT00023985|BIOLOGICAL|autologous tumor cell vaccine|
48302557|NCT00023985|BIOLOGICAL|therapeutic autologous dendritic cells|
48302558|NCT00023985|PROCEDURE|conventional surgery|
48302559|NCT00999128|DRUG|GDC-0941|Oral repeating dose
48302560|NCT00999128|DRUG|rabeprazole|Oral repeating dose
48302561|NCT05418062|BEHAVIORAL|Acceptance and commitment therapy (ACT)|8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
48302562|NCT05165576|BEHAVIORAL|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
48302563|NCT05002192|DRUG|Eucalyptol, Limonene and Pinene Enteric Soft Capsule|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
48302564|NCT05002192|DRUG|Ambroxol injection|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB_ONLY cohort
48639413|NCT04463914|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
48639414|NCT04879563|OTHER|ASCAPE-based follow-up strategy|"Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled.~The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues."
48639415|NCT06694597|DRUG|Astragalus Membranaceus Root|Astragalus tablets 15g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
48302565|NCT05002192|DRUG|Other oral mucolytic drugs|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP_ONLY and EXP_ONLY cohort
48302566|NCT00854763|DRUG|olmesartan|olmesartan
48302567|NCT02341170|RADIATION|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
48302568|NCT02379741|BIOLOGICAL|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
48302569|NCT02287792|PROCEDURE|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
48302570|NCT04185324|BEHAVIORAL|Standard zippering vest|Standard zippering vest used to teach zippering
48302571|NCT04185324|BEHAVIORAL|Modified zippering vest|Modified zippering vest used to teach zippering, along with related story
48302572|NCT00781781|DRUG|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
48302573|NCT05646303|DRUG|Psilocybin|Psilocybin and psychotherapy
48302574|NCT05646303|DRUG|Placebo|Placebo and psychotherapy
48302575|NCT00830830|DRUG|Hyalgan (sodium hyaluronate)|
48302576|NCT00387387|DRUG|Pazopanib|Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
48302577|NCT00387387|DRUG|FOLFOX 6|FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.
48302578|NCT00387387|DRUG|CapeOx|CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
48302579|NCT03755531|DRUG|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
48302580|NCT03755531|DRUG|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
48302581|NCT04604249|DIAGNOSTIC_TEST|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
48302582|NCT01104818|BEHAVIORAL|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
48302583|NCT01283191|BEHAVIORAL|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
48302584|NCT01283191|BEHAVIORAL|Education Control|Education class
48302585|NCT04272619|BEHAVIORAL|LIVE-R Life Education|A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
48302586|NCT03869138|BEHAVIORAL|Virtual-reality based dance training|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
48302587|NCT03555539|DRUG|Danicopan|Oral tablet.
48480621|NCT04104984|PROCEDURE|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
48639416|NCT06695520|PROCEDURE|Caudal epidural block|Ultrasound Guidance: Using ultrasound improves the accuracy of the block by allowing real-time visualization of the anatomy and needle placement . injection: .5-1mg/kg of 25% bupivacaine according to the needed block level.
48639417|NCT06641908|DRUG|M3554|M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).
48639418|NCT06676319|DRUG|Lunsekimig|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
48639419|NCT06676319|DRUG|Short-Acting Beta Agonists (SABA)|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
48302588|NCT00365976|DRUG|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
48302589|NCT00365976|DRUG|Placebo|Placebo nightly over duration of double blind study phase
48302590|NCT04788199|OTHER|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
48302591|NCT05153733|DEVICE|RIFRAM implant|Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
48302592|NCT02533648|DRUG|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
48302593|NCT02533648|DRUG|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
48480622|NCT04104984|OTHER|digital vaginal exam|vaginal examination to detect short cervix
48480623|NCT04104984|DEVICE|abdominal ultrasound|use abdominal ultrasound to measure cervical length
48480624|NCT04104984|DRUG|Tocolytic Agents|a medication is given to prevent uterine contraction
48639420|NCT06676319|DRUG|Placebo|Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
48302594|NCT05022004|DRUG|Brinzolamide ophthalmic suspension|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
48302595|NCT05022004|DRUG|Azopt®|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
48302596|NCT06203548|BEHAVIORAL|Lifestyle modification programme|All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
48302597|NCT03338387|DRUG|Acipimox|Acipimox
48302598|NCT03338387|DRUG|Placebo|Placebo Other Names: Placebo (for Olbetam)
48302599|NCT05649514|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
48302600|NCT05649514|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
48302601|NCT05649514|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
48302602|NCT05649514|PROCEDURE|Actimetrics|Measurement of actimetrics for 14 days at inclusion and at 24 months
48302603|NCT05649514|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
48302604|NCT01261728|DRUG|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
48639421|NCT06676319|DRUG|Fluticasone/salmeterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
48639422|NCT06676319|DRUG|Budesonide/formoterol|Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
48639423|NCT01658878|BIOLOGICAL|Nivolumab|
48639424|NCT01658878|DRUG|Sorafenib|
48639425|NCT01658878|DRUG|Ipilimumab|
48639426|NCT01658878|DRUG|Cabozantinib|
48639427|NCT06695130|BIOLOGICAL|RIV (recombinant influenza vaccine)|Influenza, inactivated, split virus or surface antigen
48639428|NCT06695130|BIOLOGICAL|rC19 (dose 1)|Protein subunit
48639429|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 1)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
48639430|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 2)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
48639431|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 3)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
48639432|NCT06695130|BIOLOGICAL|RIV + rC19 (dose 4)|RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
48639433|NCT06695130|OTHER|Placebo (0.9% NaCl)|Normal saline
48639434|NCT06695637|RADIATION|active cTBS|"Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique which employs magnetic fields to stimulate neural activity in the brain. cTBS is a specific TMS protocol, wherein bursts of high-frequency magnetic pulses are repeatedly applied in a rhythmic pattern, mimicking the theta rhythm of neural oscillations. Studies suggest that cTBS has the potential to modulate cortical excitability and synaptic plasticity, leading to alterations in targeted brain function.~Baseline measures will be collected to develop individualized targets for stimulation and also understand how brain structure and activity may change in response to cTBS."
48639435|NCT06695637|RADIATION|sham cTBS|The intervention group receives cTBS and the control group receives sham stimulation using the sham option in the coil that makes the same noise and feeling without delivering significant amount of magnetic energy into the brain. Both groups are exposed to drug and neutral pictures before and after receiving stimulation. People in the active group will receive cTBS with corrected individualized stimulation intensity to have 1 V/m in targeted brain regions while in the sham group people will only receive sham condition with a similar look, sound, and feel of active stimulation.
48639436|NCT06539897|BEHAVIORAL|Sexual education|These sessions of the sexual education program aim to increase women's knowledge and awareness about their own bodies. Women are informed about their own bodies, their identities, and the stages of sexual response, aiming to make the process clearer and more understandable. They will be encouraged to discover what sexuality means to them, their knowledge about sexuality will be questioned, and sexual myths, if any, will be revealed, and correct information about sexual myths will be provided to normalize sexuality. In addition, discussions will be held on the meanings of being a woman and an older woman, and women's perspectives on themselves and their self-esteem will be emphasized. In the third session, participants will be taught effective communication techniques to improve their communication skills with their partners.
48655950|NCT04732468|BIOLOGICAL|hAd5-S-Fusion+N-ETSD (Suspension for injection)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
48302605|NCT02989636|OTHER|Laboratory Biomarker Analysis|Correlative studies
48302606|NCT02989636|BIOLOGICAL|Nivolumab|Given IV
48302607|NCT02989636|RADIATION|Stereotactic Radiosurgery|Undergo SRS
47955459|NCT05061706|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
47955460|NCT05061706|DRUG|Placebo|Matching capsules administered orally, once daily.
47955461|NCT00921401|BEHAVIORAL|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
48302608|NCT02028364|DRUG|Everolimus|10mg orally daily
48639437|NCT06140147|OTHER|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
48639438|NCT06140147|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
48302609|NCT02028364|DRUG|Exemestane|25mg orally daily
48302610|NCT00962923|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
48302611|NCT00114972|DEVICE|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
48302612|NCT00114972|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
48639439|NCT06011889|DRUG|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
48302613|NCT02237053|DRUG|Glucagon|
48302614|NCT02237053|DRUG|Octreotide|
48639440|NCT06011889|DRUG|Placebo|treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
48639441|NCT06695403|PROCEDURE|Pilates Exercise|"1. Pilates Exercise: The Pilates method is a low-intensity form of movement based on body control, which works the body in a complete way, promoting physical and mental health. PET is different when compared to traditional exercises, which, in turn, tend to isolate the working muscles and have specific training approaches using repetitive motions.~2. Telerehabilitation: Telehealth is emerging as a key method for delivering essential healthcare. Primary care research suggests that telehealth is acceptable and has potential to overcome geographical barriers for individuals needing many times rehabilitation by eliminating the need for extensive and costly travel~3. Diet approach: A customized low-carbohydrate high-fat (LCHF) restricted caloric diet in women with lipedema will be used for 12 weeks. The LCHF diet may be a valuable nutritional strategy for lipedema and overweight/obese women, reducing inflammatory status with a beneficial effect on weight, glucose profile the concentration of"
47955462|NCT01058655|DRUG|Everolimus|
48302615|NCT02237053|BEHAVIORAL|Placebo|
48302616|NCT02237053|DRUG|Insulin|
47955463|NCT01058655|DRUG|Tivozanib|
48302617|NCT06529289|OTHER|Training|"We conducted one day of training for FCHVs and four different groups of FCHVs from two municipalities. We conducted training on hypertension knowledge and blood pressure measurement skills for FCHVs. Studies from Nepal show that with appropriate training, FCHV has the potential to promote hypertension education and conduct hypertension screening. Access to essential equipment such as digital blood pressure monitors, would improve FCHV performance on measuring blood pressure. Therefore, our training was to provide hypertension knowledge and to train FCHVs to measure blood pressure.~The training had two objectives referring to enhancing knowledge and building skills."
48302618|NCT00596518|DRUG|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
48302619|NCT02994589|OTHER|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
48302620|NCT02994589|DEVICE|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
47955464|NCT00011557|DEVICE|Assistance in Voiding|
47955465|NCT00144690|DRUG|E2007 (perampanel)|
47955466|NCT00144690|DRUG|Placebo|
47955467|NCT02536651|PROCEDURE|Ankle surgery|Plastic or orthopedic surgery of the ankle
48302621|NCT02994589|OTHER|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
48302622|NCT02371733|OTHER|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
48339936|NCT03568695|DIAGNOSTIC_TEST|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
48302623|NCT02371733|OTHER|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
48302624|NCT01772342|OTHER|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
48302625|NCT01772342|OTHER|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
48302626|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 14 days
48639442|NCT03640208|BEHAVIORAL|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
48639443|NCT06644417|DRUG|TQA3605 tablets plus NAs|TQA3605 tablets is core protein regulator
48302627|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 56 days
48302628|NCT03881917|DIAGNOSTIC_TEST|Cystatin c and beta 2 microglobulin kits|Kits for measurement concentration
48302629|NCT03127202|DEVICE|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
48302630|NCT02769572|OTHER|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
48302631|NCT02769572|DRUG|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
48639444|NCT06644417|DRUG|TQA3605 Placebo plus NAs|Placebo without drug substance
48639445|NCT06360094|DRUG|BI 1839100|BI 1839100
48302632|NCT02769572|DRUG|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
48302633|NCT02769572|OTHER|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
48302634|NCT05325138|OTHER|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
48302635|NCT04743635|DEVICE|Avéli device|Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
48302636|NCT05326399|BEHAVIORAL|renal biospy|Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
48302637|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
48639446|NCT06360094|DRUG|Placebo|Placebo
48639447|NCT06695052|DEVICE|multi modal Us|Greyscale US: grey scale ultrasound Color Doppler US: Color Doppler ultrasound Elastography US: Elastography ultrasound
48302638|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve not preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
48639448|NCT06695702|OTHER|the effect of work-based learning on the level of knowledge|The benefit of workbased learning on nursing students' knowledge of oncology symptom management
48639449|NCT05031780|DRUG|Mitapivat|Mitapivat tablets
48639450|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 50 mg or 100 mg tablets
48639451|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 100 mg tablets
48639452|NCT06673043|DRUG|Anifrolumab|Anifrolumab 300 mg concentrate for solution for infusion
48302639|NCT05817773|DEVICE|breastfeeding cradle|Mothers with postop mobile cesarean section should be breastfed with a nursing cradle for 30 minutes every 2-3 hours, even if the baby does not cry, until after mobilization (for 6 hours after coming to the service) every time the baby cries.
48302640|NCT04220528|DRUG|Capecitabine/Tiggio|"Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2)."
48302641|NCT01800227|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
48302642|NCT01142986|BEHAVIORAL|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
48639453|NCT05415397|DRUG|Celecoxib 400mg|Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
48639454|NCT05415397|DRUG|Placebo|Placebo add-on to treatment as usual (standard antidepressant treatment)
48639455|NCT04250402|PROCEDURE|Resection|Radical resection.
48639456|NCT06097988|DEVICE|ABIO3419|Intra-articular injection
48655951|NCT04732468|DRUG|hAd5-SFusion+ N-ETSD (Oral capsule)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
48639457|NCT03808467|BEHAVIORAL|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
48639458|NCT03808467|OTHER|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants' received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
48302643|NCT01142986|BEHAVIORAL|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
48639459|NCT05411198|DEVICE|XEN45 (Glaucoma Gel Stent)|Ab externo implant
48639460|NCT06670521|DRUG|Methylprednisolone|50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema
48639461|NCT06670521|DRUG|Normal Saline|Normal Saline placebo IV every 6 hours for 4 doses
48302644|NCT01411293|OTHER|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
48302645|NCT01411293|OTHER|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
48639462|NCT05861752|BEHAVIORAL|Treatment as usual|both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
48302646|NCT01669369|DRUG|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
48639463|NCT03420963|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
48639464|NCT03420963|DRUG|Cyclophosphamide|Given IV
48639465|NCT03420963|DRUG|Etoposide|Given IV
48639466|NCT05422222|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination for oral administration.
48639467|NCT06074523|BEHAVIORAL|Behavioral Measurement and self-report|Measurements of behavioral performance and self-report
47955468|NCT05406362|DRUG|VAD044|capsules to be taken once daily for 12 weeks
47955469|NCT00167648|DRUG|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
48302647|NCT01669369|DRUG|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
48302648|NCT01362712|RADIATION|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
48302649|NCT03020901|DRUG|Teicoplanin for Injection|Use Teicoplanin for Injection
48339937|NCT01728727|OTHER|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1\*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
48639468|NCT06447688|DRUG|Verapamil|Prevent
48639469|NCT05810311|DRUG|Roxadustat|"The group will receive Roxadustat (Evrenzo) three times weekly at an initial dose of 70mg (for body weight \<100.0 kg) or 100 mg (for body weight weight ≥100.0 kg). The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
48639470|NCT05810311|DRUG|Darbepoietin Alfa|"The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week. The dosage for both arms will be adjusted to keep Hb at the recommended levels between 11-12g/dl.~The aim is to investigate the effects of systemic administration of Evrenzo (Roxadustat \[RD\]) or Aranesp (darbepoetin alpha \[DA\]) on the levels of renal oxygenation in patients with diabetic nephropathy and associated anemia."
47955470|NCT00167648|DRUG|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
47955471|NCT00239538|DRUG|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
47955472|NCT00239538|DRUG|valsartan combined with hydrochlorothiazide (160/12.5mg)|
47955473|NCT05447897|OTHER|Qualitative Group Interviews|One time interview, 60-90 minutes
47955474|NCT05447897|OTHER|Stakeholder advisory group|The team will meet with the stakeholder advisory group four times for 1-2 hours each
47955475|NCT02245984|OTHER|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
47955476|NCT02245984|OTHER|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
47955477|NCT02550262|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
47955478|NCT02550262|DRUG|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
47955479|NCT02550262|DEVICE|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
47955480|NCT05600803|PROCEDURE|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
47955481|NCT00970073|BIOLOGICAL|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
47955482|NCT00970073|BIOLOGICAL|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
47955483|NCT00970073|DRUG|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
47955484|NCT00970073|DRUG|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
47955485|NCT00970073|DRUG|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
47955486|NCT00316992|DRUG|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
47955487|NCT05983588|DRUG|RAVICTI 1.1 g/ml|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
47955488|NCT05983588|DRUG|Placebo|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
47955489|NCT01630057|DRUG|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
47955490|NCT01630057|DRUG|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
47955491|NCT06454435|DRUG|Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: Fruquintinib Fruquinitinib 4mg/d, QD, PO, D1-D14, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
47955492|NCT06454435|DRUG|Sintilimab + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
47955493|NCT02506465|DEVICE|iTIND|Temporary Implantable Nitinol Device (iTIND)
48109684|NCT05452681|OTHER|Control Intervention|Receive cookbook and socialization calls
47955494|NCT02506465|PROCEDURE|Sham Arm|Foley catheter will be placed and immediately removed.
48109685|NCT02052219|DRUG|Blisibimod|Blisibimod administered subcutaneously
48109686|NCT02052219|DRUG|Placebo|Placebo administered subcutaneously
48339938|NCT01728727|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
47955495|NCT05836181|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
47955496|NCT04211402|OTHER|No Intervention|There is no intervention for this study
47955497|NCT02555774|BEHAVIORAL|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
47955498|NCT02555774|BEHAVIORAL|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
47955499|NCT00526942|BEHAVIORAL|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
47955500|NCT00992277|PROCEDURE|Ablation and skin resurfacing|
48109687|NCT00190619|DRUG|Duloxetine|
48109688|NCT00190619|DRUG|Placebo|
48109689|NCT01080872|DEVICE|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
48109690|NCT05581745|PROCEDURE|Blood group A2 donor to blood group O recipient lung transplant surgery|Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
48109691|NCT00148369|DRUG|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
47955501|NCT01628705|OTHER|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat \<7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
47955502|NCT01628705|DIETARY_SUPPLEMENT|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
47955503|NCT01193699|DRUG|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
47955504|NCT06201442|OTHER|Imaging - magnetic resonance imaging (MRI)|MRI knee - not standard of care
47955505|NCT06201442|OTHER|Blood sampling|blood sample taken and analysis - not standard of care
47955506|NCT06201442|OTHER|Assessment of functionality and strength|Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care
47955507|NCT06201442|OTHER|Activity monitoring|Actigraph measurement- not standard of care
47955508|NCT06201442|OTHER|Imaging - x-ray scan (RX)|RX Knee and EOS radiography full leg - not standard of care
48109692|NCT01807663|DEVICE|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
48109693|NCT01807663|DEVICE|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
48109694|NCT05633368|OTHER|Questionnaires|"Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology"
48109695|NCT05103748|BEHAVIORAL|Traditional vestibular rehabilitation|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target.
48109696|NCT05103748|BEHAVIORAL|Cognitive and vestibular dual task training|The patient shook his head horizontally and looked in the direction of head rotation. Repeated 10 times, and then shook his head with eyes closed and repeated 10 times. The patient holds a small visual target to practice. The small visual target is placed about 30cm in front of the patient. The subject moves his head back and forth while keeping his sight on the target. Besides, patients wear headphones to listen to the numbers at the same time. The numbers contain 1 and 2, and they are played randomly. They shake their heads when they hear 1, and nod when they hear 2. The training takes 30 minutes, once a day in the morning and evening.
48109697|NCT02562911|PROCEDURE|Data collection|"* Clinical examination~* Complete pelvic ultrasound abdominal ultrasound~* Bone age: X-ray~* biological examination~* Lung function assessed by the Maximum Volume Expired~* Brasfield radiological score (if available)"
48109698|NCT00157014|DRUG|Tacrolimus|Oral
48109699|NCT00157014|DRUG|Cyclosporine|Oral
48109700|NCT00157014|DRUG|Mycophenolate mofetil|Intravenous and Oral
48109701|NCT00157014|DRUG|Methylprednisolone|Intravenous
48109702|NCT00157014|DRUG|Prednisone|Oral
48109703|NCT05221736|PROCEDURE|Ultrasound-Guided Ethanol Sclerotherapy (UGES)|Comparison between Ultrasound-Guided Ethanol Sclerotherapy (UGES) \& surgical excision in management of warthin tumor of parotid gland.
48109704|NCT04480827|DRUG|Aramchol free acid tablet 600mg, single dose|Aramchol free acid tablet 600mg, single dose
48109705|NCT04480827|DRUG|Aramchol free acid tablet 300mg, bid|Aramchol acid tablet 300mg, bid for 12 days
48109706|NCT01609517|DRUG|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
48109707|NCT03200587|DRUG|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
48109708|NCT03200587|DRUG|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
48109709|NCT03812003|DRUG|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
47955509|NCT06201442|BEHAVIORAL|Questionnaires|Patient reported outcomes (PROMS)
47955510|NCT02476201|DEVICE|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
47955511|NCT04112407|DEVICE|Blue Light Phototherapy|Phototherapy in the blue light spectrum
47955512|NCT04112407|DRUG|Benzyl Peroxide|Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
48109710|NCT01883908|DEVICE|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
48109711|NCT01883908|OTHER|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
48109712|NCT00294905|BEHAVIORAL|Implementation of a combined smoking cessation strategy|
48109713|NCT03949348|PROCEDURE|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
48109714|NCT03949348|PROCEDURE|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
48109715|NCT04660214|DEVICE|septotomy|endoscopic diverticulotomy
48109716|NCT04714450|BEHAVIORAL|Experimental: MMST+|The format of the MMST will remain the same; however, the white noise, images and math task will be modified to mitigate habituation effects.
48109717|NCT02773017|DRUG|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
48109718|NCT02773017|DRUG|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
48639471|NCT06676982|BIOLOGICAL|anti-CD19 CAR-T|All subjects were intravenous administrated with CNCT19 CAR-T.
48639472|NCT04821830|DRUG|carbidopa/levodopa, as prescribed by treating physician|"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."
48302650|NCT03891069|DEVICE|AHA Exergame System|The AHA Exergame System consists of a mobile computing platform running a set of parameterizable exergames purposely designed for elderly fitness training. The platform is equipped with a 1000 lumens video projector capable of creating a 2.05m by 1.16m floor projection display and a Kinect V2 sensor to serve as game controller. The AHA exercise-based computer games have been designed for and tested with elderly people and were adapted for the functional limitations of PD patients. The system includes five different games that aim to train patients motor ability, cardiorespiratory and muscular strength.
48302651|NCT02284399|OTHER|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
48480625|NCT01922219|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
48480626|NCT01672359|DIETARY_SUPPLEMENT|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
47955513|NCT04112407|OTHER|Control|Standard surgical site preparation with no P. acnes pretreatment
47955514|NCT04805177|PROCEDURE|hematoma evacuation|early minimally invasive image guided hematoma evacuation in patients suffering from ICH
47955515|NCT05682365|BEHAVIORAL|prevANS intervention|prevANS intervention will be self-guided and can be implemented from the prevANS web or from the participants' Smartphone (through an APP). The prevANS intervention will have different intensities depending on the risk level of the population, evaluated from the already validated risk algorithm for anxiety: predictA. Participants will be classified as moderate-high or low risk of anxiety. Both groups of risk will receive information on their level and profile (risk factors) of anxiety and psychoeducational information periodically; also, they will work towards manage stressors and enhance protective factors. However, participants with moderate-high risk of anxiety will also receive a cognitive-behavioral training (problem solving, decision-making, handling thoughts / concerns and emotions and communicational skills).
48302652|NCT00720239|OTHER|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
48480627|NCT01672359|DIETARY_SUPPLEMENT|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
48480628|NCT01672359|DIETARY_SUPPLEMENT|Placebo|
48480629|NCT06084169|DEVICE|Intra Ocular Lens (IOL) Implant|Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
48480630|NCT04705116|BIOLOGICAL|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
48480631|NCT03331614|DEVICE|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
48480632|NCT05017779|BEHAVIORAL|Unstuck & On Target: High School|Unstuck \& On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
48480633|NCT05017779|OTHER|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
48480634|NCT05643716|BEHAVIORAL|Aerobic Exercise|The aerobic exercise intervention is described in the Aerobic Exercise Arm description.
48480635|NCT02244294|DRUG|FLOMAX® capsules|
48480636|NCT02244294|DRUG|Placebo capsules|
48480637|NCT00603863|BIOLOGICAL|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
48480638|NCT06617000|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
48480639|NCT06011382|DEVICE|Advanced Molar Distalization Appliance (amda®)|AMDA is a prefabricated device anchored to the palate by miniscrews and it is a noncompliance appliance for maxillary molar distalization
48480640|NCT06011382|DEVICE|Buccal mini-implants|Buccal mini-implants for maxillary molar distalization
48639473|NCT06521853|OTHER|PEEK With Autogenous Bone Graft|placement of PEEK With Autogenous Bone Graft
48639474|NCT06521853|OTHER|PEEK With Xenograft|placement of PEEK With xenograft
47955516|NCT01126086|DRUG|otamixaban XRP0673|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
47955517|NCT00955318|DRUG|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
47955518|NCT01398553|DEVICE|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
48480641|NCT06022367|DIAGNOSTIC_TEST|Head Turn Activation Technique|Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
48639475|NCT06470048|DRUG|Placebo|Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
48639476|NCT06470048|DRUG|Ianalumab|subcutaneous (s.c.) injection as defined in the protocol
47955519|NCT01398553|OTHER|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
47955520|NCT01135602|DRUG|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
47955521|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment, DCOOP Product, Hydroxytyrosol extract|Intervention group will receive a nutritional formula from DCOOP (Spain).
47955522|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment,Indukern product, Curcumin and selenium extract|Intervention group will receive a nutritional formula from Indukern (Spain).
47955523|NCT05472753|OTHER|Control Treatment|Control group will receive a placebo (product loading substance)
47955524|NCT03128034|DRUG|Cyclosporine|Given PO or IV
47955525|NCT03128034|DRUG|Fludarabine Phosphate|Given IV
47955526|NCT03128034|OTHER|Laboratory Biomarker Analysis|Correlative studies
47955527|NCT03128034|DRUG|Mycophenolate Mofetil|Given PO or IV
47955528|NCT03128034|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
47955529|NCT03128034|OTHER|Pharmacological Study|Correlative studies
47955530|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 211\^At-BC8-B10 IV
47955531|NCT03128034|RADIATION|Total-Body Irradiation|Undergo TBI
47955532|NCT00061477|DRUG|Pemetrexed|
47955533|NCT00061477|DRUG|Gemcitabine|
47955534|NCT05475561|PROCEDURE|Ultrasound guided Pecto-intercostal- fascial plane block|The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
47955535|NCT05475561|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
47955536|NCT05475561|DRUG|Bupivacain|local anesthetic
48480642|NCT06022367|DIAGNOSTIC_TEST|Head Raise Activation Technique|Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
48480643|NCT06461117|OTHER|Beetroot Juice|Beetroot juice (8 mmol NO3-) consumption before training at 6 days
47955537|NCT06429488|OTHER|no intervention, questionnaires were used|"The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD)."
47955538|NCT06402630|DRUG|STS01|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
47955539|NCT06402630|DRUG|Placebo|Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
47955540|NCT06535165|DIETARY_SUPPLEMENT|Red Beetroot Juice|200ml/d for 14 days
47955541|NCT06535165|OTHER|Placebo|200ml/d for 14 days
47955542|NCT01332331|DRUG|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
47955543|NCT01332331|DRUG|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
47955544|NCT05037461|RADIATION|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
48109719|NCT02773017|DRUG|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
48109720|NCT00711958|DRUG|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
48109721|NCT00711958|DRUG|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
47955545|NCT03872154|OTHER|Checklist-guided shared decision-making|"Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility."
48109722|NCT02249988|DRUG|ABX203 therapeutic Hepatitis B vaccine treatment arm|
48480644|NCT06461117|OTHER|Plesabo Drink|Plesabo drink (0,6 mmol NO3-) consumption before training at 6 days
48480645|NCT00894842|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
48655952|NCT02843425|OTHER|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
47955546|NCT03159117|DRUG|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
47955547|NCT03030807|DIAGNOSTIC_TEST|Right heart catheterization (in case of suspected PH)|
47955548|NCT05534529|DRUG|Rezafungin Acetate|This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
47955549|NCT01978418|DRUG|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
47955550|NCT01978418|DRUG|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
47955551|NCT02545257|OTHER|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
47955552|NCT05645354|BEHAVIORAL|SmokefreeSGM|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of LGBTQ+ smokers.
47955553|NCT05645354|BEHAVIORAL|SmokefreeTXT|Participants will be enrolled in a text-based smoking cessation program specifically designed to respond to the needs of the general population
47955554|NCT00654121|DRUG|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
47955555|NCT01400165|DRUG|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
47955556|NCT01400165|DRUG|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
47955557|NCT01400165|DRUG|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
47955558|NCT01400165|PROCEDURE|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
47955559|NCT04765215|BIOLOGICAL|CoronoVAC|SARS-CoV-2 IgM and IgG will be measured from blood samples between 3-6 weeks after the 2nd dose of vaccination
47955560|NCT06261918|PROCEDURE|Influence of metabolic syndrome on the achievement of pathological complete response|The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
47955561|NCT03221699|OTHER|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
47955562|NCT03221699|OTHER|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
47955563|NCT02469740|DRUG|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
47955564|NCT02469740|DRUG|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
47955565|NCT05591807|OTHER|Electroacupuncture|insert the acupuncture needle to SJ3(left side) and connect the electroacupuncture device for 15min, 2mA and 2Hz
47955566|NCT01952145|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
47955567|NCT01952145|DRUG|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
47955568|NCT01173354|DIETARY_SUPPLEMENT|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
48480646|NCT00894842|DRUG|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
47955569|NCT01173354|DIETARY_SUPPLEMENT|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
47955570|NCT02015585|PROCEDURE|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
47955571|NCT02015585|PROCEDURE|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
47955572|NCT02015585|PROCEDURE|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
47955573|NCT05189080|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.
47955574|NCT05189080|OTHER|Interviews|Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.
48109723|NCT06273891|DRUG|Erythromycin|"Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
47955575|NCT05189080|OTHER|Survey|Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
47955576|NCT01468675|OTHER|Intervention|risk assessment survey; decision support for providers for prevention based on risk
48480647|NCT03191708|DIAGNOSTIC_TEST|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
47955577|NCT02279446|OTHER|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
47955578|NCT00017199|DRUG|bortezomib|
47955579|NCT03451578|DEVICE|Alpha MSH assay|Assay to detect levels of alpha MSH in intraocular fluid.
47955580|NCT02454725|BEHAVIORAL|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
47955581|NCT02454725|BEHAVIORAL|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
47955582|NCT04148690|OTHER|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
47955583|NCT04148690|OTHER|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
47955584|NCT04609371|BEHAVIORAL|self-care tools|self-care tools only
48302653|NCT05566197|DIETARY_SUPPLEMENT|Diet Nusantara|Diet Nusantara consists of 1700 kilocalories (or 500 kilocalories lower than basal energy expenditure) on first month and subsequent reduction for the following months (200 kilocalories). The participants should also limit the sodium intake not more than 2300 mg daily
47955585|NCT04609371|BEHAVIORAL|lay telephone coaching|coaching
48109724|NCT06273891|DRUG|Azithromycin|"Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days"
48109725|NCT05121506|COMBINATION_PRODUCT|CBD and THC with GT4 technology|A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.
48302654|NCT05566197|BEHAVIORAL|Nutrition Counseling|Nutrition counseling consists of the definition of balancing food, metabolic syndrome, exercise, and related health parameters.
48302655|NCT04024683|PROCEDURE|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
48302656|NCT05160545|DRUG|GNC-035|Administration by intravenous infusion
48302657|NCT00471367|DRUG|AZD4877|intravenous infusion administered twice a week for 2 weeks
48480648|NCT00638794|DEVICE|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
48480649|NCT00738361|DRUG|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
48480650|NCT00783887|OTHER|Blood sample|Blood sample of 5 ml
47955586|NCT02183142|DRUG|Mobic, China, 7.5 mg|
47955587|NCT02183142|DRUG|Mobic, Germany, 7.5 mg|
47955588|NCT03534362|DEVICE|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
47955589|NCT03534362|DEVICE|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
47955590|NCT05249101|DRUG|Ivaltinostat|Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
47955591|NCT05249101|DRUG|Capecitabine|Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
47955592|NCT00004857|BIOLOGICAL|alemtuzumab|30 mg subQ injection tiw for 6 weeks
48109726|NCT01018836|DRUG|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
48109727|NCT01018836|RADIATION|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
48302658|NCT02098317|DRUG|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
48302659|NCT02098317|DRUG|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
48302660|NCT06011005|OTHER|Ethyl Chloride spray (group A)|Cold test spray
48302661|NCT06011005|OTHER|Benzocaine gel 20% (group B)|Topical analgesia
47955593|NCT00004857|DRUG|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
47955594|NCT04810871|PROCEDURE|Brain Surgery|Undergo surgery
47955595|NCT06260813|DIAGNOSTIC_TEST|Radiography|X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.
47955596|NCT06260813|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the posterior tibial tendon to see if there is an irritation, elongation or rupture.
47955597|NCT06260813|DIAGNOSTIC_TEST|MRI|MRI when ultrasound is not conclusive to identify an irritation, elongation or rupture of the posterior tibial tendon.
47955598|NCT06260813|DIAGNOSTIC_TEST|CT-scan|CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.
47955599|NCT06260813|DIAGNOSTIC_TEST|Gait analysis|This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.
47955600|NCT03561116|DIETARY_SUPPLEMENT|XAN|Daily intake of a sachet containing 12 mg of XAN
47955601|NCT03561116|DIETARY_SUPPLEMENT|Placebo|Daily intake of a sachet containing excipient
47955602|NCT01457573|DRUG|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
47955603|NCT01457573|DRUG|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
47955604|NCT02498132|OTHER|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, \& Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
47955605|NCT02498132|OTHER|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
47955606|NCT02498132|OTHER|Treatment as Usual|Individuals will be provided with one on one therapy sessions
47955607|NCT04930874|OTHER|NIRS (Near-Infrared Spectroscopy)|NIRS assessment of cerebral autoregulation and cerebral blood flow
47955608|NCT00843531|DRUG|RAD001|5 mg/day PO (oral)
48302662|NCT02883465|PROCEDURE|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~* a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~* a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
48302663|NCT06224543|DEVICE|SubtleGAD|SubtleGAD is an image processing software developed to enhance MR images acquired with low dose gadobutrol.
48302664|NCT06224543|DRUG|Gadobutrol|Gadavist is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
48480651|NCT05041114|DEVICE|Motor Neuroprosthesis|Type of implantable brain computer interface
48480652|NCT02194023|DRUG|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
47955609|NCT00843531|DRUG|erlotinib|100 mg/day (oral)
47955610|NCT03673579|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
47955611|NCT00448838|BIOLOGICAL|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
47955612|NCT00448838|DRUG|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
47955613|NCT00448838|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
47955614|NCT05283278|DRUG|Lactoferrin Bovine|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day starting from birth to the 30th day of life for neonates in group A
47955615|NCT05283278|COMBINATION_PRODUCT|Lactoferrin Bovine and probiotics|Lactoferrin granules (Pravotin®) in a dose of 100 mg /kg/day in combination with the probiotic Lactobacillus Delbrueckii and Lactobacillus Fermentum (Lacteol fort®) given in a dose of 5 billions starting from birth to the 30th day of life for neonates in group B
47955616|NCT05283278|OTHER|Placebo|Placebo will be given starting from birth to the 30th day of life for neonates in group C.
47955617|NCT01006369|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
48302665|NCT02352246|PROCEDURE|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
48302666|NCT02352246|PROCEDURE|Physical activity programs high intensity intermittent exercise (HIIE)|
48302667|NCT06189677|OTHER|Observation of biological characteristics of fertile men|Sampling in outpatient settings, after biopsy or after surgery and collection of biological samples in fertile subjects
48302668|NCT00495664|DEVICE|Titan stent and Taxus-Liberte stent|
48302669|NCT03464058|DRUG|BOS172767 tablets|Oral tablets
48302670|NCT03464058|DRUG|BOS172767 liquid capsules|Oral capsules
47955618|NCT04442412|DRUG|Vitamin D3 (Cholecalciferol)|patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment (CGA) result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.
47955619|NCT04442412|DRUG|RCHOP o R-miniCHOP at standard doses|"Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses"
47955620|NCT04221178|OTHER|Cessation of continuous matinenace therapy|Cessation of maintenance therapy for participants in sustained MRD-negative remission while under careful observation
47955621|NCT04370223|BIOLOGICAL|Ozone auto-hemotherapy|ozone auto-hemotherapy
47955622|NCT00001624|DRUG|Insulin|
47955623|NCT03604484|PROCEDURE|Tricuspid annuloplasty|Tricuspid annuloplasty
47955624|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - PIOS MC|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
47955625|NCT05437900|PROCEDURE|Pressure Wire guided strategy - PIOS - PW|Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
47955626|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - Standard of care|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.
47955627|NCT05437900|PROCEDURE|Pressure Wire guided strategy - Standard of care|Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
47955628|NCT04672343|OTHER|Data collection|from D0 to hospital discharge
47955629|NCT04672343|OTHER|Querying the INSEE database|Vital status at 3 months and 12 months
47955630|NCT04734951|OTHER|Power/resistance exercise program|participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.
47955631|NCT04734951|DIETARY_SUPPLEMENT|HMB supplementation|Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
47955632|NCT05498012|COMBINATION_PRODUCT|placebo dental gel, placebo toothpaste|"* Placebo dental gel applied by dentist after oral hygiene; without cannabidiol.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
47955633|NCT05498012|COMBINATION_PRODUCT|Cannabidiol dental gel, Cannabidiol toothpaste|"* Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol.~* Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient."
47955634|NCT05498012|COMBINATION_PRODUCT|Placebo toothpaste, Corsodyl dental gel|"* Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
47955635|NCT00134030|DRUG|Cisplatin|Given IV
47955636|NCT00134030|DRUG|Doxorubicin Hydrochloride|Given IV
47955637|NCT00134030|DRUG|Etoposide|Given IV
48109728|NCT04397198|DIAGNOSTIC_TEST|Speckle Tracking echocardiography|"Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers"
48109729|NCT01140113|PROCEDURE|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
48109730|NCT06345560|DRUG|Drospirenone|4 mg tablet once daily
48109731|NCT04375449|DIETARY_SUPPLEMENT|Pep2dia|what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)
48480653|NCT02194023|DRUG|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
47955638|NCT00134030|DRUG|Ifosfamide|Given IV
47955639|NCT00134030|DRUG|Methotrexate|Given IV
47955640|NCT00134030|BIOLOGICAL|Peginterferon Alfa-2b|Given subcutaneously
47955641|NCT00134030|OTHER|Quality-of-Life Assessment|Ancillary studies
47955642|NCT00134030|OTHER|Questionnaire Administration|Ancillary studies
47955643|NCT00134030|PROCEDURE|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
47955644|NCT04047329|OTHER|general anesthesia or neuraxial anesthesia|
47955645|NCT04423276|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
47955646|NCT04423276|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
48109732|NCT04375449|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
47955647|NCT05511194|OTHER|Enhanced Recovery After Surgery therapeutic protocol|Feeding and early ambulation, double short IV antibiotic regimen.
47955648|NCT05511194|OTHER|Conventional management|Delayed feeding and ambulation, triple short IV antibiotic regimen.
47955649|NCT01074905|DRUG|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
47955650|NCT01074905|DRUG|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
47955651|NCT01074905|DRUG|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
47955652|NCT03179527|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
47955653|NCT03179527|DRUG|Lipid Regulating Drugs|Mainly including statins
47955654|NCT03179527|DRUG|Coronary Vasodilator|Mainly including nitrates
47955655|NCT03179527|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
47955656|NCT05820607|BIOLOGICAL|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
47955657|NCT01435902|DRUG|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
47955658|NCT01435902|DRUG|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
47955659|NCT02081287|DRUG|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
47955660|NCT02081287|DRUG|Lamotrigine|Dose up to 200 mg per day over 10 weeks
47955661|NCT00098956|DRUG|topotecan hydrochloride|Given IV
47955662|NCT00098956|DRUG|7-hydroxystaurosporine|Given IV
47955663|NCT06238271|DEVICE|Acriva BB UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
47955664|NCT03515083|DEVICE|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
47955665|NCT05933447|DRUG|Rodatristat Ethyl|Oral, Tablet, 300 mg QD, 300 mg BID, 600 mg BID, 900 mg BID, 900 mg QD
47955666|NCT05933447|DRUG|Moxifloxacin|Oral, Tablet, 400 mg QD
47955667|NCT05933447|DRUG|Placebo for Rodatristat|Oral, Tablet, O mg QD, 0 mg BID
47955668|NCT05933447|DRUG|Placebo for Moxifloxacin|Oral, Tablet, 0 mg QD
47955669|NCT02173808|BIOLOGICAL|levonorgestrel butanoate|
47955670|NCT00414271|DRUG|Docetaxel|Docetaxel 60 mg/m2 IV on day 1
48109733|NCT03266302|DEVICE|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
48109734|NCT00168922|DRUG|Bendamustin/Ribomustin|
48109735|NCT00401323|DRUG|docetaxel (XRP6976)|
48109736|NCT00401323|DRUG|cisplatin|
48109737|NCT00401323|DRUG|5-fluorouracil (5-FU)|
48109738|NCT05380791|OTHER|Follow-up visits|Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
48480654|NCT02194023|DRUG|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
47955671|NCT00414271|DRUG|Capecitabine|Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
47955672|NCT04622306|DEVICE|Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B|Condom functionality study to determine failure rates
48109739|NCT04586686|PROCEDURE|Ovarian biopsy via laparoscopy|A laparoscopy will be performed to achieve an ovarian cortical biopsy of one of both ovaries. Approximately twenty % of the ovarian volume as initially measured on the baseline ultrasound at the first visit will be removed to be processed in the lab for cortex freezing. The laparoscopic procedure in order to take the ovarian cortex biopsy will be standardised as much as possible. The technique developed by ProFam will be followed and adapted if needed by the surgeon's discretion. A three to four port laparoscopy will be used. The ovarian cortex biopsy will be taken using a curved scissor. Bipolar or unipolar cauterisation will be avoided as much as possible. If necessary for approximation or for hemostatic reasons, the ovarian edges can be stitched or Surgicel ® Absorbable Hemostat can be used.
47955673|NCT06404671|PROCEDURE|Delayed interval cytoreductive surgery (DICS)|"patients will receive six courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by delayed interval cytoreductive surgery (DICS) within 6 weeks of the last cycle of chemotherapy. After DICS, patients will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
48109740|NCT04586686|PROCEDURE|Transvaginal oocyte retrieval|After ovarian stimulation, a transvaginal oocyte retrieval will be performed either under local or general anaesthetics (patient's choice). The oocyte yield between the biopsied and non-biopsied ovary will be evaluated.
48109741|NCT03823911|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
48109742|NCT03823911|PROCEDURE|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
48480655|NCT02194023|DRUG|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
47955674|NCT06404671|PROCEDURE|Early interval cytoreductive surgery (EICS)|"patients will receive three courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by early interval cytoreductive surgery (EICS) within 6 weeks of the last cycle of chemotherapy. After EICS, patients will receive adjuvant three courses of intravenous carboplatin and paclitaxel every 3 weeks, then will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
47955675|NCT01364077|DRUG|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
47955676|NCT01364077|DRUG|Placebo|Matched placebo
47955677|NCT03509883|DRUG|Drug: Apixaban sprinkle capsules|Single dose (25 x 0.1 mg capsules), oral administration
47955678|NCT03509883|DRUG|Experimental: Apixaban tablets followed by apixaban sprinkle capsules|Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
47955679|NCT02212795|DRUG|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
47955680|NCT02212795|DRUG|Levofloxacin 250mg|Levofloxacin 250mg single dose
47955681|NCT02212795|DRUG|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
47955682|NCT06232226|OTHER|Patients suffering from the co-occurrence of ADHD and addiction(s)|All eligible patients over 15 years and 3 months (age limit between child psychiatry and adult psychiatry), presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
47955683|NCT02260440|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
47955684|NCT02260440|DRUG|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
48302671|NCT03464058|DRUG|BOS172767 micronized capsules|Oral capsules
48302672|NCT03464058|DRUG|BOS172767 immediate release capsules|Oral capsules
47955685|NCT05421871|BEHAVIORAL|Spinal Stabilization Exercises|Spinal Stabilization Exercises technique
48302673|NCT03464058|DRUG|BOS172767 matching placebo capsules|Oral capsules
48639477|NCT04900935|BEHAVIORAL|POISE|POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.
48639478|NCT06312124|BEHAVIORAL|Educational Module|Part 1 consists of an education module with premodule and postmodule assessment questionnaires.
47955686|NCT05421871|BEHAVIORAL|Maitland Mobilization Along With Laser Therapy|Maitland Mobilization Along With Laser Therapy technique
47955687|NCT00004635|DRUG|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
47955688|NCT00004635|DRUG|leuprolide acetate|Injections of leuprolide once a month for six months.
48109743|NCT03570827|DRUG|Androgen Suppression|Given androgen suppression therapy
48109744|NCT03570827|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48109745|NCT03570827|OTHER|Quality-of-Life Assessment|Ancillary studies
48109746|NCT03570827|OTHER|Questionnaire Administration|Ancillary studies
48302674|NCT03464058|DRUG|BOS172767 matching placebo tablets|Oral tablets
48302675|NCT03464058|DRUG|Rabeprazole|Oral tablets
48302676|NCT01703819|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
48639479|NCT06312124|PROCEDURE|Salpingectomy|Part 2 consists of incorporating opportunistic salpingectomy /OS into non-gynecologic surgery
48109747|NCT04922658|DRUG|Surufatinib|Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
48639480|NCT05327946|DRUG|BI 770371|BI 770371
48639481|NCT05327946|DRUG|ezabenlimab|ezabenlimab
48109748|NCT04922658|DRUG|Surufatinib Plus Vinorelbine|Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
48109749|NCT00552097|DRUG|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
48109750|NCT00552097|DRUG|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
48109751|NCT01970748|DRUG|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
48109752|NCT01970748|PROCEDURE|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
48302677|NCT01703819|OTHER|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
48639482|NCT03944876|DRUG|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
48639483|NCT03944876|DRUG|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
48639484|NCT06694740|DRUG|Interferon Gamma 1-b|interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
48639485|NCT06694740|DRUG|Placebo|Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
48639486|NCT03388788|RADIATION|PET Imaging|Positron Emission Tomography (PET) imaging for research.
48639487|NCT03388788|BEHAVIORAL|Circadian Study Protocol|5-day circadian study schedule
47955689|NCT00004635|DRUG|goserelin|Injections of Goserelin once a month for six months.
47955690|NCT00004635|OTHER|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
47955691|NCT04108234|DRUG|HR071603|HR071603 monotherapy ,nasal spray
47955692|NCT04108234|DRUG|placebo|placebo,nasal spray
47955693|NCT00436384|PROCEDURE|Monitoring-blood samples drawn for CMV testing|
48302678|NCT03475888|DEVICE|Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Implantation of Medtronic Reveal LINQ™ ICM
48302679|NCT00731445|DRUG|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
48302680|NCT03402867|PROCEDURE|Deep dry needling|Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
48302681|NCT04850040|DRUG|Apatinib Mesylate|250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.
48302682|NCT04850040|DRUG|Camrelizumab|200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.
48302683|NCT04850040|DRUG|Oxaliplatin|85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
48302684|NCT06019780|OTHER|blood flow restriction trainin|"Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient \[Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62\].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated."
48302685|NCT06019780|OTHER|exercise|"Following exercises will be performed without application of pneumatic cuff~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)"
47955694|NCT04584970|DEVICE|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
48639488|NCT03388788|DRUG|11C-Meta-Hydroxyephedrine (mHED)|11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
47955695|NCT04584970|DEVICE|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
47955696|NCT04849923|OTHER|Strength training session|Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
47955697|NCT02135770|DRUG|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
47955698|NCT05968131|OTHER|Conventional Physical Therapy|"The control group will receive only strength training intervention included the following components:~Range Of Motion Exercises: movements to the extent possible of the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion-eversion) and toe (flexion-extension).~5 repetitions of each ROM exercise will be done for 2 minutes. Muscle Strengthening Exercises: active movements against resistance (using a Thera band) at the knee (flexion-extension), ankle (dorsi-plantar flexion), forefoot (inversion- eversion) and toe (flexion-extension).~Each Strengthening exercise will be performed for 5 minutes with 10 repetitions."
47980581|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
48109753|NCT00688519|DRUG|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
48109754|NCT00688519|DRUG|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
48109755|NCT02311972|DEVICE|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
48109756|NCT02311972|DEVICE|Standard of care feeding tube|
48109757|NCT05307666|OTHER|Medication minimization|During the medication minimization visit, and any necessary follow-up visits, patients and providers work together to gradually minimize medication dosages (e.g. reducing 1/4 or 1/2 dose at a time) using the following approach: 1) Medications Treating Symptoms: Find the minimum dose that controls the symptom, 2) Drugs that Lower Blood Pressure: Reduce dosages until systolic BP is in the upper 10mmHg of the target range (e.g. target 130 - 140 mmHg), 3) Drugs That Lower Blood Sugar: Reduce dosages until HbA1c is in the upper 5% of the target range (e.g. target 7.5 - 8.0%).
48639489|NCT03388788|DRUG|11C-CGP12177|Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
48639490|NCT03388788|DRUG|O15-water|Blood flow will be measured via PET imaging with infusion of O15-water.
47980582|NCT02403154|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
48109758|NCT04347499|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
48109759|NCT01336439|DRUG|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
48109760|NCT02314117|DRUG|Ramucirumab|Administered IV
48109761|NCT02314117|DRUG|Capecitabine|Administered orally
48109762|NCT02314117|DRUG|Cisplatin|Administered IV
48109763|NCT02314117|DRUG|Placebo|Administered IV
48109764|NCT02314117|DRUG|Fluorouracil|Administered IV
48639491|NCT04867954|OTHER|Ensure Plus®|In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
48655953|NCT02843425|OTHER|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
48109765|NCT05657041|DRUG|Clopidogrel|Body weight adjusted clopidogrel dosing
48109766|NCT00670020|PROCEDURE|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
48109767|NCT04812951|DRUG|CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion|one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
48109768|NCT04812951|DEVICE|cationorm eye drops|one cationorm eye drop twice a day for 30 preoperative days
48109769|NCT02955524|DRUG|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
48109770|NCT02955524|DRUG|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
48639492|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
48655954|NCT06585384|COMBINATION_PRODUCT|etanercept and repeated contrast ultrasound|Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)
47955699|NCT05968131|OTHER|Conventional Physical Therapy with Proprioceptive Training Exercises|"Interventional group will receive strengthening intervention as well as proprioceptive training for 32 sessions. ROM and Strengthening exercise will be performed same as in control group.~Exercises For Proprioceptive Training: Intervention group will practice an additional 24 minutes of proprioceptive training (two minutes rest prior to performing this training). A circuit with different floor texture composed of 6 stations of exercises to stimulate the sole of foot where participant had to improve gait by stepping with alternate feet marker placed on ground and progression will be done by modify the speed and direction. Material used to build the circuit are in following order: 10 cm thick foam, a wood box with beans, a 2 cm thick mat with density lower than foam, a wooden box filled with sand, balance board to train the lateral balance reactions, a wooden box filled with cotton. Duration of this training is 24 minutes; patient will spend 4 minutes on each station."
48302686|NCT01270672|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
48655955|NCT06587659|DEVICE|Transcranial Magnetic Stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
47955700|NCT04715425|PROCEDURE|Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation|Bilateral pulmonary vein isolation using radiofrequency energy
47955701|NCT04715425|PROCEDURE|Catheter pulmonary vein isolation without additional lesions|Bilateral pulmonary vein isolation using radiofrequency energy
47955702|NCT00630643|BIOLOGICAL|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
48302687|NCT01270672|DRUG|carvedilol|50 mg per os, single dose
48302688|NCT01270672|DRUG|placebo|capsules identical to MDMA or carvedilol
48480656|NCT04423159|BIOLOGICAL|OCV Vaccine|2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
47955703|NCT00630643|DRUG|Placebo|Placebo
47955704|NCT04214184|BEHAVIORAL|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
47955705|NCT03074955|DEVICE|leg wrapping with tension|"1. Apply elastic bandages with tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages."
48480657|NCT04838028|PROCEDURE|TEP|Laparoscopic totally extraperitoneal mesh repair of groin hernia
47955706|NCT03074955|PROCEDURE|Trendelenburg position|"1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position"
47955707|NCT03074955|DEVICE|leg wrapping without tension|"1. Apply elastic bandages without tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages"
47955708|NCT03074955|PROCEDURE|supine position|1.maintain supine position
47955709|NCT00394160|DRUG|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
47955710|NCT00788073|DRUG|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
48302689|NCT01757704|PROCEDURE|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
48339939|NCT01136213|RADIATION|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
48480658|NCT04838028|PROCEDURE|TAPP|Laparoscopic transabdominal mesh repair of groin hernia
47955711|NCT00788073|DRUG|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
48480659|NCT01911806|DEVICE|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
48480660|NCT01911806|PROCEDURE|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
48480661|NCT01216657|DRUG|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
47955712|NCT03531931|DRUG|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
47955713|NCT06558058|DRUG|Rivaroxaban 10 mg film-coated tablet|One tablet of the test drug was given orally after an overnight fast.
48480662|NCT05154552|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
48639493|NCT04867954|OTHER|Clinical validation MRI|"Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~* All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 1/2 or 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~* The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~* All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 or 1/2 dose of GBCA will be administered, if required."
48639494|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI + fasting|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
48639495|NCT06695455|BEHAVIORAL|Swallowing rehabilitation by rhythmic auditory cue|"Three assessments, each spread over two days, will be administered at three different time points during the study: before the experiment (T0), after 7 weeks of the experiment (T1), and 3 months after the intervention (T2). The evaluation will include a pharyngography as well as a clinical assessment of swallowing and rhythmic abilities.~Each subject will be invited to participate in 3 individual rehabilitation sessions per week for 7 weeks, conducted by a speech therapist at La Musse Hospital. Each session will be structured similarly: the subject will be asked to swallow their saliva, followed by a nectar-like texture (IDDSI 2) and a pudding-like texture (IDDSI 4), timed to the rhythm of a metronome. The rhythm will vary throughout the sessions. The goal will be to get as close as possible to the rhythm of a healthy swallow."
48302690|NCT01757704|PROCEDURE|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
48302691|NCT03626753|DRUG|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
48639496|NCT06053450|OTHER|Oil Inhalation Patch|Each participant will wear a patch for a work week (3 worked shifts) and then no patch is worn for a week. This alternates for a total of a month.
48480663|NCT05154552|OTHER|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises"
48480664|NCT01640873|DRUG|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
47955714|NCT06558058|DRUG|Xarelto 10 mg film-coated tablet|One tablet of the reference drug was given orally after an overnight fast.
48639497|NCT06695182|BEHAVIORAL|physical activity|
48639498|NCT06694584|BEHAVIORAL|Tea(m)Time|Tea(m)Time is divided into two phases, starting with the qualification of team leaders. This starts with knowledge transfer about healthy leadership, resilience, occupational health and safety, posture work, psychological empowerment, agile management and the role of the manager. The team leaders also learn various moderation/coaching techniques. The qualification is followed by the implementation of Tea(m)Time. The teams start each hour with self-reflection. This is followed by a stress assessment and prioritization. The teams then work on the problems identified and look for solutions together.
48655956|NCT06587659|DEVICE|Robotic Arm|This robotic system is based on a commercially available collaborative robot. The robot is mounted on a cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
48655957|NCT03941561|DRUG|S-1 for 9 months|S-1 for 9 months after D2 resection
48655958|NCT03941561|DRUG|S-1 for 1 year|S-1 for 1 year after D2 resection
48302692|NCT03626753|DRUG|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
48302693|NCT03626753|DRUG|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
48302694|NCT03626753|DRUG|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
48302695|NCT03626753|DRUG|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
48302696|NCT03626753|DRUG|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
48339940|NCT01136213|OTHER|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
47955715|NCT05446441|PROCEDURE|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
47955716|NCT01413061|PROCEDURE|Subtalar Arthrodesis|
47955717|NCT03086993|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
47955718|NCT03086993|DRUG|Cisplatin and Gemcitabine|continuous treatment with Cis/Gem until disease progression
47955719|NCT01228474|OTHER|Select the Number of embryos to transfer|Select the Number of embryos to transfer
47955720|NCT06029738|BEHAVIORAL|Metacognitive Training for Obsessive-Compulsive Disorder (MCT-OCD)|MCT-OCD is a group education for OCD patients.
48302697|NCT01565629|BEHAVIORAL|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
48302698|NCT04180059|COMBINATION_PRODUCT|CTL 19|Patients candidate for allogeneic transplantation who are both HLA-DPB1\*04:01 and with a HLA-DPB1\*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1\*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
48302699|NCT02515591|OTHER|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
48302700|NCT03105154|OTHER|Prevena Dressing|Prevena dressing is applied on one groin
48302701|NCT03105154|OTHER|Conventional Dressing|Conventional dressing is applied on the contralateral groin
48302702|NCT05163990|OTHER|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
48302703|NCT04390698|PROCEDURE|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
48302704|NCT04390698|DRUG|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
48302705|NCT04390698|PROCEDURE|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
48302706|NCT04390698|PROCEDURE|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
48302707|NCT04845776|DIETARY_SUPPLEMENT|ANRC Essentials Plus|a vitamin/mineral supplement designed for children and adults with autism
48302708|NCT06482645|PROCEDURE|Perilesional/regional systematic biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
48302709|NCT06482645|PROCEDURE|Combination of systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
48339941|NCT01136213|DRUG|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
48480665|NCT01640873|DRUG|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
48480666|NCT04681196|OTHER|patients shifted to nasal mask after persistent OSA with oronasal mask|In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
48480667|NCT05247931|DIAGNOSTIC_TEST|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
48655959|NCT06644781|DRUG|Ifinatamab deruxtecan|Intravenous administration
48655960|NCT06644781|DRUG|Docetaxel|Intravenous administration
48655961|NCT06644781|DRUG|Paclitaxel|Intravenous administration
48655962|NCT06644781|DRUG|Irinotecan|Intravenous administration
47955721|NCT06297317|DIAGNOSTIC_TEST|Ultrasound measurement of triceps surae muscle-tendon architecture|The resting plantar-flexors MTU architecture assessment was performed using a conventional B-mode and extended-field-of-view (EFOV) ultrasound imaging. Achille tendon cross-sectionnal area, Medial gastrocnemius thickness, pennation angle, fascicle length and muscle length were collected on the dominant lower limb.
48302710|NCT00931957|DRUG|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
48302711|NCT06440590|PROCEDURE|suprapectineal quadrilateral buttress plating|15 cases will undergo anatomical supra-pectineal quadrilateral plate
48302712|NCT06440590|PROCEDURE|Infra-pectineal plating|15 cases will undergo conventional manually contoured infra-pectineal plate
48302713|NCT04379804|PROCEDURE|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
48302714|NCT04379804|PROCEDURE|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
48302715|NCT00113802|DRUG|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
48302716|NCT03693287|DRUG|Standardized-parenteral nutrition (S-PN)|NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
48302717|NCT03693287|DRUG|Personalized-parenteral nutrition (P-PN)|"Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist."
48302718|NCT02481960|PROCEDURE|CM-BC2 Irinotecan drug-eluting bead|
48302719|NCT03666000|BIOLOGICAL|Azer-cel|Infusion of Allogeneic Anti-CD19 CAR T cells
48302720|NCT03666000|DRUG|Fludarabine|Specified dose on specified days
48302721|NCT03666000|DRUG|Cyclophosphamide|Specified dose on specified days
48302722|NCT03666000|DRUG|IL-2|Specified dose on specified days
48302723|NCT03666000|DRUG|Bendamustine|Specified dose on specified days
48639499|NCT04046952|DEVICE|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
48302724|NCT06377644|DIAGNOSTIC_TEST|Kinesio taping|Kinesio taping is a physiotherapy method employed to provide support and stability to muscles and joints while allowing freedom of movement (ROM). The elastic nature of kinesio tape closely resembles that of human skin. After application, kinesio tape rebounds, generating a pulling force that acts as the primary stabilizer for the specific area. Physiotherapy treatments often involve a combination of stretching and strengthening exercises, along with electrotherapy modalities. Additionally, Joint mobilization is a form of passive movement in a broad spectrum of exercise used to treat painful and stiff synovial joints.
48302725|NCT06377644|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a minimally invasive technique involving the use of a single filament or acupuncture needle to penetrate painful soft tissue areas. From a neurophysiological standpoint, Dry Needling might stimulate A-delta nerve fibers (group III), which could activate inhibitory dorsal horn interneurons containing enkephalin, leading to pain suppression and relief through opioid mechanisms. (DN) may affect microcirculation. Numerous studies have shown that inserting needles into muscles can increase blood flow in both the skin and the muscle in the treated area. It can lead to an immediate reduction in local and referred pains, as well as enhance range of motion (ROM) and correct muscle activity patterns.
48302726|NCT03471091|DEVICE|NIV with the integrated tele-monitoring management program|Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
48302727|NCT03679208|DEVICE|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
48655963|NCT04957472|DEVICE|fabian HFO, fabian +nCPAP evolution and fabian Therapy evolution with PRICO function|24 hours of automated control of FiO2
47980583|NCT02403154|PROCEDURE|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
48302728|NCT03679208|DEVICE|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
48302729|NCT06430749|DEVICE|Microtaze|Targeted Microwave Tissue Coagulation
48302730|NCT03819179|OTHER|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
48639500|NCT04046952|DEVICE|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
48302731|NCT03819179|OTHER|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
48302732|NCT03819179|OTHER|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
48302733|NCT03819179|OTHER|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
48302734|NCT03819179|OTHER|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
48480668|NCT05715476|PROCEDURE|cesarian surgery|The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
48480669|NCT01522950|DRUG|Nebivolol|5 mg daily or 10 mg daily
48480670|NCT01522950|DRUG|atenolol|25 mg daily or 50 mg daily
48480671|NCT01522950|DRUG|placebo|one tablet daily
48480672|NCT03030326|BEHAVIORAL|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
48480673|NCT01019707|DRUG|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
48480674|NCT01019707|DRUG|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
48480675|NCT02541084|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
48480676|NCT05976347|DRUG|Fluoxetine 20 MG|Fluoxetine 20 mg once daily
48480677|NCT05976347|DRUG|Duloxetine 30 MG|Duloxetine 30 mg once daily
48480678|NCT05976347|OTHER|Observation|Referral to behavioral health and resources for addressing depressive symptoms
48480679|NCT02716350|DIETARY_SUPPLEMENT|B-GOS|comparison versus placebo
47955722|NCT03530527|PROCEDURE|ERCP with biliary stenting|ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
48480680|NCT02716350|DIETARY_SUPPLEMENT|Maltodextrin|placebo
48655964|NCT04957472|OTHER|Manual Control|24 hours of manual control of FiO2
47980584|NCT05322304|DIETARY_SUPPLEMENT|Almond|Intervention (almond supplementation) and Isocaloric diets (control)
48302735|NCT06035432|OTHER|Bluesky software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
48480681|NCT06232239|DRUG|Empagliflozin-Test product|Empagliflozin 10 mg tablets Test product Manufactured by: Thai Meiji Pharmaceuticals Co., Ltd., Thailand
48480682|NCT06232239|DRUG|Empagliflozin-Reference product|Empagliflozin 10 mg tablets Reference product Manufactured by: Boehringer Ingelheim Pharma Gmbh \& Co. Kg, Germany
48480683|NCT05414084|DIETARY_SUPPLEMENT|Oral (poly)phenol challenge test (OPCT)|Nutritional challenge with standardized (poly)phenol-rich tablets
48480684|NCT06177002|DIAGNOSTIC_TEST|Collection of biological data|Biological sample will be collected from the COVID19 patients and from healthy donors
48480685|NCT02736630|OTHER|body temperature|intermittant tympanic temperature measurement during surgery
48480686|NCT04963608|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
48480687|NCT06353191|OTHER|Non-Interventional Study|Non-interventional study
48639501|NCT01273168|DRUG|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit.
48109771|NCT05156450|DRUG|TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone|Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
48109772|NCT04821336|OTHER|Metabolites dosage|"On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones."
48109773|NCT02961179|BEHAVIORAL|Increased dairy product|
48109774|NCT02961179|BEHAVIORAL|Dietary counselling|
48109775|NCT02519452|DRUG|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
48109776|NCT02519452|DRUG|Recombinant Human Hyaluronidase [rHuPH20]) SC Administration|Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
48109777|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 12.5 mg (titration only)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
48109778|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
48109779|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg
48109780|NCT05286762|DRUG|CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)|Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg
48109781|NCT05286762|DRUG|Placebo|Subjects will be randomized at Visit 2 to Placebo
48109782|NCT00440973|DRUG|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
48109783|NCT00440973|DRUG|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation
48109784|NCT02787161|DEVICE|Hemodiafiltration|High volume online HDF
48109785|NCT02787161|DEVICE|Hemodialysis|High-flux HD
48109786|NCT05719038|DIAGNOSTIC_TEST|observational study|observational study
48639502|NCT05378529|OTHER|Lp(a) Screening|Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
48109787|NCT00193518|DRUG|Arsenic Trioxide|
48109788|NCT00987961|BEHAVIORAL|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
48109789|NCT06002360|BEHAVIORAL|Reach Out and Read|Families will be provided with a book and ROR programming from trained study team members (either the principal investigator or a research assistant, both of whom are ROR trained). ROR programming will include discussion of current reading practices, anticipatory guidance on the importance and benefits of reading, modeling of active reading, discussion of how to incorporate reading into a daily routine and answering any questions parents/caregivers may have.
48109790|NCT00958386|DRUG|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
48109791|NCT03043638|PROCEDURE|CAF+ADM+PRP|CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
48109792|NCT03043638|PROCEDURE|CAF+ADM|CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
48109793|NCT01930045|DRUG|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
48109794|NCT01930045|DRUG|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
48109795|NCT04189900|DRUG|Triptorelin|Subjects receive a single subcutaneous dose of 0,1 mg of Triptorelin acetate.
48480688|NCT00003020|BIOLOGICAL|LMB-7 immunotoxin|
48639503|NCT03769168|DRUG|AIN457|Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
48109796|NCT04060537|OTHER|Laboratory analysis of samples|RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues
48109797|NCT04060537|OTHER|Application of machine learning|Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
48109798|NCT01671124|OTHER|Soline capsule|
48109799|NCT04795050|BEHAVIORAL|Project POWER|Diabetes health promotion/cardiovascular disease risk reduction educational curriculum
48109800|NCT01126307|DRUG|Verapamil|80 mg tid
48480689|NCT05424718|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
48480690|NCT05338372|BEHAVIORAL|Two days forest therapy|Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
48480691|NCT05338372|BEHAVIORAL|Three days forest therapy|Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
48302736|NCT06035432|OTHER|3D slicer software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
48302737|NCT06035432|OTHER|OnDemand software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
48302738|NCT06035432|OTHER|Mimics software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
48302739|NCT03351322|DRUG|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
48302740|NCT03351322|DRUG|Regaine|Regaine are applied for treatment of hair loss.
48302741|NCT04738513|PROCEDURE|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
48302742|NCT04738513|PROCEDURE|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
48302743|NCT04328623|PROCEDURE|Hypnosis|"conversational hypnosis technique call the magic glove"
48302744|NCT04328623|PROCEDURE|Infiltration|Ultrasound-guided hand infiltration
48302745|NCT03027817|PROCEDURE|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
48302746|NCT03960710|OTHER|Anonymized CT examinations|The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
48480692|NCT05669807|DRUG|Camrelizumab|200mg d1, the first day, every 14 days as a cycle
48480693|NCT05669807|DRUG|Albumin-Bound Paclitaxel|100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle
48480694|NCT05669807|DRUG|Irinotecan|180 mg/m2, the first day, every 14 days as a cycle
48639504|NCT02960555|BIOLOGICAL|Isatuximab|Given IV
48639505|NCT02960555|OTHER|Laboratory Biomarker Analysis|Correlative studies
48639506|NCT03586453|DRUG|Osimertinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~* Osimertinib: Oral, Daily 28 day cycle.~* Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~* Tumor biopsy between C4 and C8 and at disease progression"
48639507|NCT05782244|DRUG|Sildenafil Citrate low dose|Sildenafil citrate 20 mg, oral, TID
48639508|NCT05782244|DRUG|Placebo|Placebo, oral, TID
48639509|NCT05782244|DRUG|Sildenafil medium dose|Sildenafil 40 mg, oral, TID
48639510|NCT05782244|DRUG|Sildenafil high dose|Sildenafil 80 mg, oral, TID
48109801|NCT01126307|DRUG|placebo|placebo tid
48302747|NCT03960710|OTHER|Training (1)|"An initial training phase of the artificial intelligence network will be carried out :~- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals"
48302748|NCT03960710|OTHER|Training (2)|"An initial training phase of the artificial intelligence network will be carried out :~- Use of computer data to drive the artificial intelligence network."
48302749|NCT03960710|OTHER|Validation (1)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by an intern at the Lyon hospitals"
48302750|NCT03960710|OTHER|Validation (2)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by the neural network"
48302751|NCT00661752|DEVICE|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
48302752|NCT00661752|DEVICE|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
48302753|NCT03334578|DRUG|Gastrografin|Gastrografin group
48480695|NCT04508920|OTHER|Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)|Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
48480696|NCT03492658|DRUG|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
48480697|NCT03492658|DRUG|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
48302754|NCT04895059|DRUG|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
48302755|NCT04895059|DRUG|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
48302756|NCT04895059|DRUG|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
48302757|NCT02508168|DRUG|Alogliptin|Alogliptin 12.5 mg tablets
48302758|NCT02508168|DRUG|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
48302759|NCT02508168|DRUG|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
48302760|NCT01025180|OTHER|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~* \< 0.25 ng/ml: antibiotic should be stopped~* 0.25 \< PCT \<0.5: antibiotic prescription is not recommended~* \> 0.5 ng/ml: antibiotic should be used"
48302761|NCT03953586|DIAGNOSTIC_TEST|Bubble suction test and tubal peristalsis|Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
48302762|NCT02361749|DRUG|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
48302763|NCT02361749|PROCEDURE|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
48302764|NCT00653796|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
48302765|NCT00653796|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
48302766|NCT00227383|DEVICE|Electroacupuncture (device)|
48302767|NCT04567316|DRUG|[14C]-radiolabelled BI 1358894|Part 1
48480698|NCT00003396|BIOLOGICAL|anti-thymocyte globulin|
48480699|NCT00003396|BIOLOGICAL|graft-versus-tumor induction therapy|
48480700|NCT00003396|DRUG|cyclophosphamide|
48480701|NCT00003396|DRUG|melphalan|
48109802|NCT01555684|PROCEDURE|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
48480702|NCT00003396|PROCEDURE|peripheral blood stem cell transplantation|
48480703|NCT00003396|RADIATION|radiation therapy|
48480704|NCT00093184|DRUG|Angiomax (bivalirudin) anticoagulant|
48480705|NCT02453633|OTHER|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
48480706|NCT02453633|OTHER|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
48480707|NCT04682509|DRUG|Glecaprevir/pibrentasvir|Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
48480708|NCT00978913|BIOLOGICAL|DC vaccine|DC vaccination, one vaccine biweekly
48480709|NCT00655278|DRUG|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
48480710|NCT04372849|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
48480711|NCT04372849|OTHER|Placebo|Single dose of placebo solution as nasal spray
48480712|NCT03302377|BEHAVIORAL|physical activity counseling & Fitbit|Participants will receive individual counseling \& guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
48480713|NCT03130348|DRUG|Bortezomib|Given SC
48302768|NCT04567316|DRUG|BI 1358894|Part 2
48302769|NCT04618393|BIOLOGICAL|EMB-02|EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
48302770|NCT03234868|DEVICE|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
48302771|NCT03234868|DEVICE|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
48302772|NCT00807547|BIOLOGICAL|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
48302773|NCT04747808|DRUG|LL-BMT1|Drug-printed contact lens in both eyes
48302774|NCT02584634|DRUG|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
48302775|NCT02584634|DRUG|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
48302776|NCT02584634|DRUG|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
48302777|NCT00500045|DRUG|nicotinic acid|niacin 1500 mg po qd
48480714|NCT03130348|DRUG|Dexamethasone|Given PO
48480715|NCT03130348|DRUG|Ibrutinib|Given PO
48480716|NCT03130348|OTHER|Laboratory Biomarker Analysis|Correlative studies
48480717|NCT06616168|DIAGNOSTIC_TEST|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features
48302778|NCT03380117|BEHAVIORAL|eBridge Online Counseling|In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
48302779|NCT03627455|OTHER|Percutaneous coronary intervention|Percutaneous coronary intervention
48109803|NCT04089488|OTHER|Medical Chart Review|Correlative studies
48302780|NCT03189576|DIAGNOSTIC_TEST|blood draw|
48302781|NCT02175563|DEVICE|Audiovisual feedback from smartphone based app|
48302782|NCT01666444|DRUG|pegylated liposomal doxorubicin (PLD)|
48302783|NCT01666444|DRUG|VTX-2337|TLR8 Agonist
48302784|NCT01666444|DRUG|Placebo|
48302785|NCT05436938|COMBINATION_PRODUCT|Jing Si herbal tea liquid packets use|with or without Jing Si herbal tea liquid packets use
48480718|NCT06616168|DRUG|Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)|Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
48480719|NCT06616168|COMBINATION_PRODUCT|Suppositoria for vaginal microflora recovery (Giynoflor)|Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.
48655965|NCT06460662|OTHER|Routine Physical Therapy|"Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques"
47955723|NCT03530527|PROCEDURE|EUS guided biliary drainage|EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
47955724|NCT01330680|DIETARY_SUPPLEMENT|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
47955725|NCT01330680|DIETARY_SUPPLEMENT|Decaffeinated coffee|40 mL dose of decaffeinated coffee
47955726|NCT06476327|BEHAVIORAL|experimental 1 group|"A camera is installed on the walker used in the training, and the recorded video is mirrored in real-time to a tablet computer. Participants can view this video through smart glasses connected to the tablet computer. A glasses strap will be used to secure the glasses, ensuring there is no interference with walking.~Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
48109804|NCT04089488|OTHER|Survey Administration|Respond to surveys
48109805|NCT03280836|BEHAVIORAL|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
48109806|NCT00630188|OTHER|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
48109807|NCT00630188|OTHER|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
48109808|NCT00860717|PROCEDURE|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
48302786|NCT02936505|DRUG|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; \>12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily."
48302787|NCT02936505|DRUG|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
48302788|NCT02936505|DRUG|Rabbit Anti thymocyte globulin|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
48302789|NCT02936505|DRUG|Corticosteroids|"Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months."
48480720|NCT06616168|DRUG|Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)|Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most
48302790|NCT02936505|DRUG|Tacrolimus|"* Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~* Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, \>12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
48302791|NCT03660371|PROCEDURE|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
48302792|NCT03660371|PROCEDURE|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
48302793|NCT06017232|OTHER|Hybrid telerehabilitation program|"The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics."
48302794|NCT04315649|OTHER|3D movie viewing|3D movie viewing
48302795|NCT03153111|DRUG|Macitentan|macitentan 10 mg; film-coated tablet; oral use
48302796|NCT03153111|DRUG|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
48302797|NCT03252639|PROCEDURE|EVT for RAS & PBV acquisition protocol for target kidneys|
48302798|NCT00722592|DRUG|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
48302799|NCT00722592|DRUG|pegylated liposomal doxorubicin (PLD)|50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
48302800|NCT00722592|OTHER|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
48639511|NCT02315326|DRUG|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
48639512|NCT02315326|DRUG|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
48655966|NCT02473042|PROCEDURE|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
48655967|NCT02473042|DRUG|Zofran|4 mg by vein for 1 dose.
48109809|NCT00860717|RADIATION|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
48302801|NCT01543451|DRUG|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
48302802|NCT01543451|DRUG|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
48302803|NCT00628511|DEVICE|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
48302804|NCT02350894|BEHAVIORAL|Graded and behavevial theraphy|Graded and behavevial theraphy
48302805|NCT05057585|BEHAVIORAL|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
48302806|NCT02662686|OTHER|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
48302807|NCT02662686|OTHER|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
48302808|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
48480721|NCT06064825|OTHER|2 year follow-up of neurodevelopment using a parental questionnaire|A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
48480722|NCT02235584|DRUG|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
48480723|NCT06193447|OTHER|None intervention|None intervention
48302809|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
48302810|NCT04713917|DEVICE|Hyaluronique Acid Gel|Vaginal gel based on HA with liposomal structure applicated 2 times a week
48302811|NCT04713917|DEVICE|Laser CO2|The laser energy delivered along the vaginal wall heats the tissue without damaging it.
48302812|NCT04713917|DEVICE|Hyaluronique Acid Injection|HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
48302813|NCT06044753|DEVICE|Virtual Reality Headset|"Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap."
48302814|NCT01848821|DEVICE|OASIS Ultra|Porcine derived intestinal submucosa
48302815|NCT01848821|DEVICE|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
48302816|NCT04364074|DIETARY_SUPPLEMENT|Goodbelly|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
48302817|NCT04364074|DIETARY_SUPPLEMENT|Placebo|To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
48302818|NCT00540969|PROCEDURE|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
48302819|NCT00540969|RADIATION|radiation therapy|Patients undergo radiotherapy for 1 week
48302820|NCT02927808|BEHAVIORAL|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
48302821|NCT03813563|DRUG|RL|lactated Ringer's
48302822|NCT03813563|DRUG|PLA|PlasmaLyte
48302823|NCT02645747|DRUG|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
48302824|NCT03238092|DRUG|Testosterone|testosterone gel daily during the late luteal phase.
48480724|NCT02159937|OTHER|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
48480725|NCT01748955|DRUG|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
48302825|NCT03238092|DRUG|Estradiol|oral estradiol during the late luteal phase.
48302826|NCT01097330|PROCEDURE|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
48302827|NCT01097330|DRUG|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
48302828|NCT02776280|OTHER|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
48302829|NCT01935908|DRUG|levetiracetam|
48302830|NCT05507944|DIAGNOSTIC_TEST|FeNO measurement|Diurnal measurements before work and at 3 hours after work start.
48302831|NCT00536731|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
48302832|NCT00536731|DRUG|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
48302833|NCT00536731|DRUG|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
48302834|NCT04015297|DIAGNOSTIC_TEST|raman analysis|negative or pozitive
48302835|NCT05622500|PROCEDURE|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
48480726|NCT01748955|DRUG|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
48480727|NCT04372290|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
48302836|NCT05622500|COMBINATION_PRODUCT|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
48639513|NCT02315326|DRUG|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
48480728|NCT04372290|OTHER|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
48480729|NCT04372290|OTHER|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
48480730|NCT04372290|OTHER|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
48639514|NCT02315326|DRUG|procarbazine|Arm D: THIS IS THE ONLY ARM RECRUITING: : Oral procarbazine (100mg/m2/day) will be given on Day 1 through 7 during each cycle. Patients will be maintained on a tyramine-free diet during procarbazine administration.
48639515|NCT06631339|OTHER|Light Intervention|LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.
48109810|NCT05672797|OTHER|Wellth app|The Wellth app will be provided to treatment groups 1 and 2 for free and it is available for download through all common mobile app stores for both iOS and Android phones. The Wellth App is a private company that serves over five million clients that range from patients of healthcare providers and beneficiaries of various health insurance companies to employees of large corporations, where the Wellth App is offered as a behavioral tool for increasing meditation adherence among individuals who are managing chronic conditions through daily meditations, e.g. chronic obstructive pulmonary disease, asthma, high blood pressure, coronary artery disease, and HIV. The Wellth App has already been offered to some members of Arizona Complete Health, so both Wellth and Arizona Complete Health are familiar with implementing this program among this target population.
48109811|NCT05672797|BEHAVIORAL|Habit training|"Participants in treatment groups 1 and 2 will be asked to identify an existing routine behavior that will act as a cue for their daily pill-taking behavior to. However, only participants in treatment group 2 will have to submit visual evidence of their cue to the Wellth app in addition to photos of their medication in order to receive credit for the medication check-in (i.e., financial incentives conditional on using their cue)."
48109812|NCT05769517|DIAGNOSTIC_TEST|Germinal BRCA|We will conduct a multicenter prospective observational study aimed at automatically implementing the predictive model and collecting US images of healthy ovaries from patients tested for germline BRCA pathogenetic variants according to current indications.
48109813|NCT05247034|DIETARY_SUPPLEMENT|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
48109814|NCT05247034|OTHER|Placebo|Each capsule contains 500 mg of methylcellulose
48302837|NCT03521167|DRUG|Ketamine|"Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg."
48302838|NCT03521167|DRUG|Lidocaine|Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
48109815|NCT04288219|DEVICE|Non-Invasive Positive Pressure Ventilation|Continuous positive airway pressure delivered by face mask at 10cmH2O
48109816|NCT04288219|DRUG|Nifedipine|Nifedipine 30mg, Pharmacotherapy
48109817|NCT04288219|OTHER|supplemental oxygen|supplemental oxygen
48109818|NCT02000817|BIOLOGICAL|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
48109819|NCT02000817|BIOLOGICAL|Placebo|Placebo is available 0.9% w/v sodium chloride
48480731|NCT04372290|OTHER|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
48480732|NCT01174524|DRUG|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
48480733|NCT01174524|DRUG|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
48480734|NCT02127073|DRUG|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
48480735|NCT00122447|DRUG|Aspirin|325 mg PO QD
48302839|NCT03521167|DRUG|Dexmedetomidine|Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
48302840|NCT03521167|DRUG|Gabapentin|Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness
48302841|NCT03521167|DRUG|Tylenol|Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg
48302842|NCT03521167|DRUG|Gabapentin Pill|Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea
48302843|NCT03521167|DRUG|Tylenol Pill|Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
48302844|NCT02528669|DEVICE|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
48302845|NCT03319992|DEVICE|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
48480736|NCT00122447|DRUG|Alpha lipoic acid|600 mg PO BID
48302846|NCT00518453|BIOLOGICAL|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
48302847|NCT04695847|DRUG|M1231|M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
48302848|NCT04695847|DRUG|M1231|M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
48302849|NCT05563077|OTHER|Moderate-intensity interval training (MIIT)|MIIT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period (∼6-7 reps of 4 min at ∼4.2 METs, with 3 min of active recovery at ∼2.2 METs between each interval), and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs). We will select the same aerobic dose of training (i.e., kcal/kg of body weight per week) to match total energy expenditure in both exercise groups.
48109820|NCT03750942|DEVICE|Adhesix® monofilament polypropylene mesh (Bard Davol)|The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
48109821|NCT03355495|PROCEDURE|Colonoscopy - Position Change|Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
48109822|NCT02792374|OTHER|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
48109823|NCT03967886|DRUG|YYD601 20mg|Patients should take drugs an hour before breakfast.
48109824|NCT03967886|DRUG|Nexium 20mg|Patients should take drugs an hour before breakfast.
48302850|NCT05563077|OTHER|Moderate-intensity continuous training (MICT)|MICT group: participants will perform 3 sessions per week for 4 months. Each session will involve a ∼3 min warm-up (joint mobility exercises and walking at ∼2.2 METs), a ∼40-50 min main period at ∼3.2 METs, and a ∼3-min cool-down (joint mobility exercises and walking at ∼2.2 METs).
48302851|NCT03803761|DRUG|Copanlisib|Given IV
48302852|NCT03803761|DRUG|Fulvestrant|Given IM
48302853|NCT03716063|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
48302854|NCT02022683|DEVICE|ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves|
48302855|NCT00002466|DRUG|cyclophosphamide|
48302856|NCT00002466|DRUG|doxorubicin hydrochloride|
48302857|NCT00002466|DRUG|etoposide|
48302858|NCT00002466|DRUG|ifosfamide|
48109825|NCT03967886|DRUG|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
48109826|NCT00199108|DRUG|Depocyt|
48302859|NCT00002466|DRUG|vincristine sulfate|
48302860|NCT00002466|PROCEDURE|conventional surgery|
48302861|NCT00002466|RADIATION|radiation therapy|
48302862|NCT03978494|DRUG|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
48302863|NCT03978494|DRUG|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
48302864|NCT01520324|DEVICE|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
48302865|NCT02273154|DRUG|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
48302866|NCT02273154|DRUG|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
48302867|NCT01531491|PROCEDURE|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
48480737|NCT00122447|DRUG|Olmesartan|40 mg PO QD
48480738|NCT00122447|DRUG|Placebo|"Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"
48480739|NCT00003130|DRUG|paclitaxel|
48655968|NCT02473042|DRUG|Dexamethasone|10 mg by vein for 1 dose.
48655969|NCT02473042|DRUG|Phenergan|6.25 mg by vein for 1 dose.
48655970|NCT02473042|DRUG|Pepcid|10 mg by vein for 1 dose.
48109827|NCT00199108|DRUG|Dexamethasone|
48302868|NCT01531491|PROCEDURE|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
48302869|NCT00178360|BEHAVIORAL|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~* Group singing~* Group drumming~* Music assisted relaxation~* Group song writing~* Lyric analysis~* Improvisation~* Music with art"
48302870|NCT06258811|DRUG|albumin paclitaxel, cispatin, tislelizumab|Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
48302871|NCT02229968|DRUG|Amicar (ε-aminocaproic acid)|
48302872|NCT02229968|DRUG|normal saline|
48302873|NCT02538237|DRUG|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
48302874|NCT02538237|DRUG|Ibuprofen 2% mouthwash|
48302875|NCT01517789|DEVICE|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
48302876|NCT06126705|DRUG|Radiation: 18F-AlF-FAPi-04|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
48302877|NCT06126705|DRUG|Radiation: 18F-FDG|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
48302878|NCT06212895|OTHER|Survey|"A survey is handled out at the patient registration. Patients can fill it out during waiting for their appointment. The physician, who treats the patients is not aware aout the filling status or content. The Survy will not influence the treatment.~The Survey consists of 3 parts: patients attidude and expectations, and questionnaire about their usual physical activity and the validated Expectation Treatment Score."
48302879|NCT03421288|DRUG|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
48109828|NCT05911750|DIAGNOSTIC_TEST|Anal pap smear and oral swab for cytology and HPV testing|Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
48109829|NCT02774538|OTHER|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit."
48302880|NCT03421288|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
48302881|NCT03421288|DRUG|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
48302882|NCT03421288|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
48302883|NCT03421288|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
48302884|NCT02650284|DEVICE|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
48302885|NCT02650284|DEVICE|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
48302886|NCT05601999|BIOLOGICAL|GNR-060|GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
48302887|NCT05601999|BIOLOGICAL|Metalyse|Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
48302888|NCT05265845|BEHAVIORAL|Intervention|The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
48302889|NCT05265845|BEHAVIORAL|Text4Baby|Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
48302890|NCT01140516|DRUG|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
48302891|NCT01140516|OTHER|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
48302892|NCT03896399|PROCEDURE|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
48302893|NCT01115946|DRUG|ASP1585|oral
48302894|NCT01115946|DRUG|enalapril|oral
48302895|NCT03229746|DRUG|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
48302896|NCT03229746|DRUG|vincristine|1mg intravenous weekly for 4 weeks
48302897|NCT03229746|DRUG|azathioprine|dose 100mg daily for at least 3 weeks
48302898|NCT03765346|DRUG|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
48302899|NCT03765346|DRUG|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
48302900|NCT03765346|DRUG|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
48302901|NCT03765346|DRUG|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
48302902|NCT00339014|DRUG|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
48302903|NCT00339014|OTHER|Placebo|Identical placebo
48302904|NCT06212557|DEVICE|KIOS App|KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)
48302905|NCT06212557|BEHAVIORAL|KIOS App education|Educational tools provided to participants with opioid use disorder
48302906|NCT06212557|BEHAVIORAL|Treatment as usual|Behavioral counseling in clinic
48302907|NCT02027688|OTHER|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
48302908|NCT02027688|OTHER|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
48302909|NCT03515603|PROCEDURE|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
48302910|NCT03515603|PROCEDURE|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
48302911|NCT04389476|OTHER|Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)|"Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors."
48302912|NCT02460588|DRUG|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
48302913|NCT02460588|DRUG|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
48302914|NCT02460588|DRUG|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
48302915|NCT00878072|DRUG|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
48302916|NCT02241746|OTHER|no intervention|
48302917|NCT00384540|PROCEDURE|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
48302918|NCT00651118|DRUG|Placebo|placebo
47955727|NCT06476327|BEHAVIORAL|experimental 2 group|"Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation."
48302919|NCT00651118|DRUG|azelastine Hcl|azelastine Hcl 548 mcg
48302920|NCT00651118|DRUG|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
48302921|NCT00651118|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
48302922|NCT06523530|DRUG|Goserelin Acetate 3.6 mg inj, implant|3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)
48302923|NCT03677089|BEHAVIORAL|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
48302924|NCT06191354|GENETIC|SKG0201 Injection|SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
48480740|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
48302925|NCT05634590|DRUG|Fruquintinib|4mg, orally, once daily, 3 weeks on/ 1 week off
48302926|NCT05634590|DRUG|FOLFIRI|Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
48302927|NCT05634590|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
48302928|NCT04611126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered 2-6 weeks before surgical removement of the tumor. The medicine is administered i.v. over 30 minutes.
48302929|NCT04611126|DRUG|Cyclophosphamid|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
48302930|NCT04611126|DRUG|Fludarabine Phosphate|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
48480741|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
47955728|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
48302931|NCT04611126|BIOLOGICAL|Tumor Infiltrating Lymphocytes infusion|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion. The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
48302932|NCT04611126|DRUG|Nivolumab|Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.
48302933|NCT04611126|DRUG|Relatlimab|Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
48302934|NCT00602316|DRUG|gadolinium-chelate|
48302935|NCT00602316|PROCEDURE|conventional surgery|
48302936|NCT00602316|PROCEDURE|magnetic resonance imaging|
48302937|NCT00602316|PROCEDURE|magnetic resonance spectroscopic imaging|
48302938|NCT02123017|DRUG|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
48302939|NCT02123017|DRUG|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
48302940|NCT02123017|DRUG|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
48302941|NCT02444897|DRUG|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
48302942|NCT02444897|DRUG|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
48302943|NCT05272163|BEHAVIORAL|Stimulus Type|Targets can be specific or categorical
48302944|NCT05272163|BEHAVIORAL|Target Presence|There is or is not a target present on each trial
48302945|NCT05272163|BEHAVIORAL|Checklist|In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
48639516|NCT06631339|BEHAVIORAL|Digital Intervention|Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).
48302946|NCT05951153|COMBINATION_PRODUCT|Tributyrin|Tributyrin is a nutritional supplement prepared by esterification of glycerin with butyric acid that promotes delivery of free butyrate to distal portions of the gut.
48302947|NCT00004747|DRUG|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
48480742|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
48639517|NCT06631339|OTHER|Control Group|Standard Classroom Lighting + Sham LightUP phone application
47955729|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
47955730|NCT00185068|DRUG|Olmesartan medoxomil|
48302948|NCT05883267|DEVICE|Virtual reality glasses|"PICO model neo 2 VR glasses"
48302949|NCT05883267|DEVICE|Vocal-guided affective imagery|Audio via telephone
48302950|NCT04083040|PROCEDURE|transcatheter aortic valve implantation|"1. Tilt angle.~2. Depth of implantation of the valve.~3. Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve"
48302951|NCT04536415|DRUG|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
48302952|NCT04536415|DRUG|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
48302953|NCT04743037|BEHAVIORAL|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
48480743|NCT06239688|BEHAVIORAL|essentiALZ|essentiALZ is a web-based training that contains three hours of self-paced content separated into five modules, plus a final review. Modules include: 1) Alzheimer's disease and dementia; 2) person-centered care; 3) assessment and care planning; 4) activities of daily living; and 5) behaviors and communication. Staff will be encouraged to take the training over the course of four weeks.
48480744|NCT06239688|BEHAVIORAL|Project ECHO|ECHO is a virtual tele-mentoring model grounded in case-based learning. It includes six weekly one-hour sessions of didactic and discussive learning. The first five sessions will reflect the content of the five essentiALZ modules, and the final session will address maintenance. ECHO sessions are group sessions that will be conducted via Zoom.
47955731|NCT00185068|DRUG|Olmesartan medoxomil/hydrochlorothiazide|
48302954|NCT05898503|BEHAVIORAL|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
48302955|NCT05898503|BEHAVIORAL|Resistance training|Resistance training for 12 weeks
48302956|NCT05898503|BEHAVIORAL|Walking exercise|Walking exercise for 12 weeks
48302957|NCT05898503|BEHAVIORAL|Health promotion|Health promotion for 12 weeks
48302958|NCT02965534|DEVICE|Spectacle/Glasses|
48302959|NCT05017285|PROCEDURE|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
48302960|NCT05017285|PROCEDURE|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
48302961|NCT00136747|DRUG|Memantine|Two capsules of Memantine twice daily for 12 days.
48302962|NCT00136747|DRUG|bupropion|
48302963|NCT00136747|DRUG|placebo|
48302964|NCT05746351|DRUG|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
48302965|NCT05746351|DRUG|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
48302966|NCT05746351|DRUG|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
47955732|NCT00185068|DRUG|Hydrochlorothiazide|
48302967|NCT06259955|OTHER|Mindfulness|In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat \& Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat \& Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
48302968|NCT04632784|DEVICE|Artiflex Presbyopic implantation|Implantation of iris-fixated multifocal Artiflex Presbyopic IOL
48302969|NCT05025072|DRUG|Hydroxycarbamide dispersible tablets|Hydroxycarbamide dispersible tablets (20 x 50 mg)
48302970|NCT05025072|DRUG|Hydroxycarbamide film-coated tablet|Hydroxycarbamide film-coated tablet (1000 mg)
48302971|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension|topical suspension
48302972|NCT00804193|DRUG|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
48302973|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
48302974|NCT05278416|DEVICE|Lumoral treatment -device and Lumorinse tablets|Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
48302975|NCT05192057|DEVICE|Hypertonic Saline inhalation|Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
48302976|NCT06693232|PROCEDURE|Mobile micro-learning|Mobile micro-learning intervention contains a 10-minute video about cardiopulmonary resuscitation to continuously improve their self-confidence, motivation and reduce their stress
48302977|NCT05734547|BEHAVIORAL|Stepping Together for Children after Trauma (ST-CT)|ST-CT is Step One of Stepped Care CBT for Children after Trauma (previously called Stepped Care Trauma-focused Cognitive Behavioral Therapy; Salloum et al., 2014). It consists of five components: psychoeducation, stabilization, trauma narrative, in-vivo exposures and consolidation. The parent and child have 11 at-home-meetings and complete tasks in a workbook, Stepping Together (from the Preschool PTSD Treatment by Michael Scheeringa et al), over 6-9 weeks. In addition, there are weekly calls and five sessions with the therapist. Children who meet responder-criteria (i.e., no more than four symptoms of PTSS) continue to a 6-week maintenance phase, after which treatment is complete if the child still meets responder criteria. For those who do not meet responder-criteria, or are not able to complete the workbook, the responsibility for the treatment is transferred from the municipal service level to the corresponding child and adolescent mental health service (BUP).
48302978|NCT05734547|BEHAVIORAL|Usual care|Therapists in the control group will provide the treatment they usually provide, and develop a treatment plan in collaboration with the parents. This may consist of individual sessions with the child, parent sessions, group treatment, meetings with the school and other collaborating services, or referral to the second line mental health centres (BUP).
48302979|NCT05942885|OTHER|anxiety questionnaire|Patient undergoing hypnosis session will have their anxiety measured just before the third session of hypnosis and after during a telephonic consultation. The result will be compared to the anxiety level before the first hypnosis session
48109830|NCT04589000|OTHER|acupressure|"Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table."
48109831|NCT02091336|DRUG|Metformin|patients treatment
48302980|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)
48480745|NCT05839327|DIAGNOSTIC_TEST|Montreal cognitive assessment scale (MOCA)|Tests to evaluate cognitive disorders (MOCA), anxiety and depression (HADS) Pos-traumatic stress disorder (PCL-C) and quality of life (SF-36)
48480746|NCT00001108|DRUG|Ritonavir|
48480747|NCT00001108|DRUG|Nelfinavir mesylate|
48480748|NCT00001108|DRUG|Saquinavir|
48480749|NCT00001108|DRUG|Nevirapine|
48480750|NCT00001108|DRUG|Lamivudine|
48480751|NCT00001108|DRUG|Stavudine|
48109832|NCT02091336|DRUG|Glyburide|patients treatment
48480752|NCT00001108|DRUG|Didanosine|
48480753|NCT04892316|DIAGNOSTIC_TEST|Diagnostic test|The training dataset was used to train the model, which was validated and tested by the other two datasets.
48480754|NCT03858023|OTHER|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
48480755|NCT05022134|BEHAVIORAL|CHOICE-AYA|Adapted contraceptive counseling specific to AYA experiencing homelessness
48480756|NCT03084809|DRUG|Cytokine-induced killer cells+ FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
47955733|NCT03097913|DEVICE|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
47955734|NCT05267288|DRUG|afatinib|afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.
48109833|NCT00332644|DRUG|nicotine patch|used according to FDA package label
48109834|NCT00332644|DRUG|nicotine lozenge|used according to FDA-approved package directions
48109835|NCT00332644|DRUG|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
48109836|NCT00332644|DRUG|bupropion|dosage according to FDA-approved instructions
48109837|NCT00332644|DRUG|bupropion + lozenge|dosage according to FDA approved standard instructions
48302981|NCT06693375|DEVICE|Rectal Magnetomotoric ultrasound (MMUS)|MMUS examination of lymphnodes in rectum
48302982|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)
48302983|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)
48639518|NCT05406570|PROCEDURE|Standardized ventilation|Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
48302984|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
48302985|NCT04502563|OTHER|Remote monitoring and predictive analytics|Subjects will undergo remote monitoring, remote monitoring data will be analyzed on a predictive platform, alerts indicating HF worsening shared with treating team, and algorithmic response to alerts implements.
48302986|NCT04502563|OTHER|Sham comparator|Subjects will wear a sensor, but data from the sensor will not generate alerts and will not be shared with the treating team.
48302987|NCT04925414|DRUG|oxygenotherapy|High concentration mask delivering 15L/min of oxygen
48302988|NCT04925414|DRUG|placebo air aerosol|High concentration mask delivering 15L/min of air
48302989|NCT05979090|BEHAVIORAL|Mastery learning in communication skills|Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
48480757|NCT03084809|DRUG|FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
48480758|NCT05698927|PROCEDURE|Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)|Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
48109838|NCT00332644|DRUG|placebo|dosage same as active drug conditions
48109839|NCT00515450|BIOLOGICAL|GB-0998 (Intravenous immunoglobulin)|
48109840|NCT00515450|PROCEDURE|Plasmapheresis|
48109841|NCT06073158|PROCEDURE|Esophageal biopsy collection during anastomosis|During the anastomosis, the surgeon will collect an esophageal mucosa biopsy
48302990|NCT05533775|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
48302991|NCT05533775|DRUG|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
48302992|NCT05533775|DRUG|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
48302993|NCT05533775|DRUG|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
48302994|NCT05533775|DRUG|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
48302995|NCT05533775|DRUG|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
48302996|NCT05533775|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
48302997|NCT05017012|BIOLOGICAL|MK-3475A|MK-3475A is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and MK-5180 for SC administration.
48302998|NCT05017012|BIOLOGICAL|Pembrolizumab|Participants will receive pembrolizumab 400 mg IV.
48302999|NCT05017012|DRUG|Pemetrexed|Participants may receive 500 mg/m\^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
48639519|NCT05406570|PROCEDURE|Personalized ventilation|Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
48639520|NCT06201234|DRUG|Olaparib + Elacestrant|Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
48639521|NCT06201234|DRUG|Olaparib|Olaparib 600 mg orally daily
48639522|NCT05553938|DRUG|Empagliflozin 10 mg|Empagliflozin 10mg
48639523|NCT05553938|DRUG|Placebo|Empagliflozin matched placebo tablet
48639524|NCT00044304|DRUG|Imatinib|The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC \<1500/mm3, platelet counts \< 75,000mm3 or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.
48639525|NCT00044304|DRUG|Ruxolitinib|The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts \<100,000/mm3, moderate renal impairment (CrCl \<60 mL/min) or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
48303000|NCT05017012|DRUG|Carboplatin|Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
48303001|NCT05017012|DRUG|Paclitaxel|Participants may receive 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
48303002|NCT05017012|DRUG|Nab-paclitaxel|Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
48303003|NCT05017012|DRUG|Axitinib|Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
48303004|NCT05017012|DRUG|Cisplatin|Participants may receive 75 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
48303005|NCT06601998|OTHER|Blood samples and Oropharyngeal swab|Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)
48303006|NCT06601998|OTHER|Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms|"* Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max"
48303007|NCT06693388|OTHER|Exercise|2 minutes each exercise with 30 sec break - 4 exercises prior to serial casting
48303008|NCT06693388|OTHER|Whole-Body Vibration|WBV prior to serial casting
48303009|NCT06693388|OTHER|Serial Casting|Serial Casting as provided by standard of care
48303010|NCT06692270|DRUG|Tislelizumab|Tislelizumab 200mg Q3W, D1 ; 2 cycles
48639526|NCT03000803|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
48303011|NCT05520619|DRUG|Paclitaxel, Cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
48303012|NCT05520619|DRUG|tislelizumab|Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
48303013|NCT05520619|RADIATION|Radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
48303014|NCT00005051|DRUG|carboplatin|
48303015|NCT00005051|DRUG|cisplatin|
48303016|NCT00005051|DRUG|paclitaxel|
48303017|NCT00005051|DRUG|topotecan hydrochloride|
48303018|NCT02834312|DRUG|Estetrol|All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
48303019|NCT02834312|DRUG|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
48639527|NCT03000803|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
48303020|NCT06004882|OTHER|PNS therapy|PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days
47955735|NCT01435070|PROCEDURE|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
47955736|NCT01435070|PROCEDURE|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
48303021|NCT06004882|DRUG|Triamcinolone|Given by Injection
48303022|NCT06004882|DRUG|Bupivacaine|Given by Injection
48303023|NCT06004882|OTHER|Placebo|Given by Injection
48303024|NCT05853458|DRUG|Hydroxyurea|Hydroxyurea is commercially available in Germany and will be prescribed based on clinical judgment
48303025|NCT06693297|DEVICE|Immediate loading of early placed implants|Implants with active thread design will be used. The implants placed will be randomly allocated into either immediate loading or conventional loading group.
48303026|NCT06693297|DEVICE|Conventional loading of early placed implants|Definitive loading of early placed implants upon successful osteointegration (after 8 weks)
48303027|NCT06693778|OTHER|electronic Clinical Decision Support tool for risk stratification of pediatric patients with mTBI|eCDS tool for risk stratification of pediatric mTBI patients
48303028|NCT06692959|DRUG|PD-1 vaccine IMU-201 (PD1-Vaxx)|Investigational Medicinal Product (IMP) PD1-Vaxx is supplied as lyophilized drug substance APi2568, which is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (G-P-S-L). IMU-201 is combined with water for Injection (WFI) and is emulsified with Montanide ISA 51 VG adjuvant to produce PD1-Vaxx.
48639528|NCT05521399|DIAGNOSTIC_TEST|MRI Sequencing|MRI test-retest (select healthy volunteers) for development of MRI sequence.
48639529|NCT05521399|DIAGNOSTIC_TEST|MRI Testing (pediatric)|Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.
48639530|NCT05521399|DIAGNOSTIC_TEST|MRI Testing|Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction
48639531|NCT04740918|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
48639532|NCT04740918|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
48639533|NCT04740918|OTHER|Placebo|Placebo matched to atezolizumab
48639534|NCT06139796|DRUG|DRV/r FDC (120/20mg)|Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)
48303029|NCT05961592|DRUG|R-2487|Probiotic
48303030|NCT00983450|OTHER|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
48303031|NCT00983450|OTHER|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity \[Celnik et al., 2008\]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
48303032|NCT04742517|DRUG|ASP1128|Intravenous
48639535|NCT05366712|DEVICE|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
47955737|NCT04937946|DRUG|Fentanyl|Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
47955738|NCT06391320|OTHER|other|Observational studies do not involve intervention
47955739|NCT01572350|OTHER|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
47955740|NCT01572350|DRUG|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
47955741|NCT01572350|DRUG|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
47955742|NCT04811378|OTHER|HaemoCer|Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
47955743|NCT04307784|DIETARY_SUPPLEMENT|VD3|VD3 (50.000 IU/week) for 8 weeks
47955744|NCT04307784|DIETARY_SUPPLEMENT|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
47955745|NCT04307784|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
48303033|NCT04742517|DRUG|Placebo|Intravenous
47955746|NCT04307784|OTHER|Control|No intervention is given
47955747|NCT00635375|DEVICE|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
47955748|NCT00635375|DEVICE|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
47955749|NCT00635375|DEVICE|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
48639536|NCT04792216|OTHER|Wild Salmon|Wild salmon fillets
48639537|NCT04792216|OTHER|Farmed Salmon|Farm salmon fillets
47955750|NCT00635375|DEVICE|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
47955751|NCT04123275|OTHER|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
47955752|NCT03827265|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
47955753|NCT02949700|DRUG|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
47955754|NCT00865670|DRUG|Azithromycin Monohydrate 600 mg Tablets|
48303034|NCT06523426|DIAGNOSTIC_TEST|Patient treated by spinal endoscopy|Questionnaire administered by surgeon; assessment of level of autonomy for activities of daily living
48303035|NCT06693479|DEVICE|Shoulder watch load (SWL) feedback|During week 2 and 3 after randomisation, the experimental group will undergo the intervention using the SWL, designed to monitor workers' physical work demands. During this time, the SWL will provide real-time feedback based on parameters set via Ergowatchapp. Two workplace visits by a physiotherapist will be conducted to establish and adjust the feedback thresholds: once in week 2 and again in week 3. The goal is to demonstrate that the feedback promotes changes in strategies used by workers to manage their shoulder pain. Only the experimental group will receive feedback from the SWL during the study period.
48480759|NCT05171764|DEVICE|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
48639538|NCT04077437|BEHAVIORAL|Therapy|Standardized non-directive therapy performed by therapist team.
48639539|NCT04077437|DRUG|Midomafetamine|Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.
47955755|NCT00865670|DRUG|Zithromax (azithromycin dihydrate) 600 mg Tablets|
47955756|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin,Toripalimab|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed."
48639540|NCT04077437|DRUG|Placebo|Administration of placebo with therapy during three experimental sessions
48639541|NCT04636437|DRUG|Doravirine 100 Mg|Participants will receive 100 mg tablet by mouth daily with or without food.
48639542|NCT04636437|DRUG|Tenofovir alafenamide/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
48639543|NCT04636437|DRUG|tenofovir alafenamide/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
48639544|NCT04636437|DRUG|Integrase strand transfer inhibitors|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
47955757|NCT04996771|DRUG|Surufatinib,Etoposide,Cisplatin|"In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed."
47955758|NCT03714802|PROCEDURE|Szabo T-Stenting Technique|2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
47955759|NCT03714802|PROCEDURE|T-Stenting Technique|2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
47955760|NCT05247801|BEHAVIORAL|Psychoeducational intervention for safe medication use at home + Medication dosing device|"The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other."
47955761|NCT05247801|DEVICE|Medication dosing device|Use of medication dosing device.
48303036|NCT06693479|OTHER|Education|Participants will receive an education intervention delivered by a physiotherapist. This intervention will take place at the participants' workplace at the end of the 2nd week post-randomization. The session will last 30 to 45 minutes, and involve personalized, patient-centered education on their condition. The physiotherapist will use open-ended questions to encourage participants to express their goals and address specific concerns related to their shoulder condition. Given the expected diversity in physical constraints (manual vs. non-manual workers) and individual challenges, the session will be tailored to each worker needs. At the end of the session, workers will receive a booklet summarizing key points, including: understanding shoulder anatomy, function and pain, managing shoulder pain, enhancing movement variability, adjusting work environment, and considering factors such as sleep, stress, coping mechanisms, and psychological factors on pain.
48303037|NCT05873452|DEVICE|Kaitoh Atherectomy System|The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
47955762|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
48480760|NCT03261362|DIETARY_SUPPLEMENT|Branched-chain amino acids reduced intake|
48480761|NCT05077956|DIAGNOSTIC_TEST|Cerebrospinal and Blood Serum Semaphorin 4A Levels|Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
48480762|NCT05178914|PROCEDURE|Treatment adaptation|Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance
48480763|NCT05514236|OTHER|Virtual Reality Therapy|"Participants will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
48480764|NCT05514236|OTHER|Music Therapy|"Participants will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the music according to her comfort."
48480765|NCT06217796|COMBINATION_PRODUCT|MydCombi|A single metered spray administered with the MydCombi dispenser
48480766|NCT02123420|DEVICE|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, St-Stevens-Woluwe, Belgium)."
48480767|NCT05375890|OTHER|no intervention|Narcolepsy patients in Russia gathered according to criteria.
48480768|NCT05202041|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
48639545|NCT04636437|DRUG|tenofovir disproxil fumarate/emtricitabine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
48639546|NCT04636437|DRUG|tenofovir disproxil fumarate/lamivudine|NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
48639547|NCT06696027|DIAGNOSTIC_TEST|Single nucleotide polymorphisms (SNP)|Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
48639548|NCT06696027|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
48639549|NCT06696027|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array|Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
48639550|NCT06696027|DIAGNOSTIC_TEST|Flow Cytometry|Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
48303040|NCT06692751|BIOLOGICAL|Blood sampling|2 tubes of 5 mL
48639551|NCT06696027|DIAGNOSTIC_TEST|Laboratory assessment|Serum Chemistry
48639552|NCT06696027|DIAGNOSTIC_TEST|Assessment of Pulmonary Involvement|Results of routine clinical assessment of pulmonary involvement (such as lung ultrasound, computed tomography, chest x-ray, whole-body plethysmography) will be compared to mLOY, ELISA/ Legendplex/ flow cytometry/ transcriptome analysis results.
48480769|NCT05202041|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
47955763|NCT02540109|DEVICE|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
47955764|NCT01212458|DRUG|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
47955765|NCT06487416|DRUG|Tiotropium Bromide Inhalation Powder|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
47955766|NCT06487416|DRUG|Spiriva®Handihaler®|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
48303041|NCT06692751|PROCEDURE|Ophthalmological examination|"angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.~An optional 20-30 minute WLR may be offered following OCT-A."
48303042|NCT06692751|OTHER|angina severity questionnaire|at inclusion, 3 months and 1 year Estimated filling time: 2 minutes
48303043|NCT06551324|DRUG|PF-06821497|875 mg BID (2 times a day)
48303044|NCT06551324|DRUG|Docetaxel|75 mg/m2 IV (every 21 days)
48480770|NCT00743509|DRUG|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
48303045|NCT06551324|DRUG|Enzalutamide|160 mg QD
48480771|NCT04431414|OTHER|Sample collection|"* blood, nasal swab, nasal wash, and saliva~* optional stool swab"
48303046|NCT01098955|BEHAVIORAL|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
48303047|NCT01098955|BEHAVIORAL|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
48480772|NCT03352752|DEVICE|HTC Vive|Wearing VR helmet before operation
48480773|NCT03352752|OTHER|Without HTC Vive|Wearing a blindfold before operation
48480774|NCT00813826|DRUG|SLC022|SLC022 150 mg capsule, 900mg daily dose
48639553|NCT05572697|BEHAVIORAL|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
48639554|NCT05572697|BEHAVIORAL|Usual care|Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
48639555|NCT05250726|BIOLOGICAL|MENISC-T|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of meniscus used as interposition at the STT joint
48639556|NCT06458192|BEHAVIORAL|Adaptive Messaging Intervention|The intervention delivers 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. The intervention will apply reinforcement learning to select daily messaging styles to maximize user engagement.
48639557|NCT06458192|BEHAVIORAL|Non-Adaptive Messaging Intervention|The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. Daily messaging styles will be randomly selected.
47955767|NCT05456009|OTHER|No intervention|No intervention
47955768|NCT00371072|PROCEDURE|trabeculectomy with mitomycin-C|
47955769|NCT03844100|DRUG|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
47955770|NCT06061354|DRUG|Teriparatide|mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® or 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
48303048|NCT01098955|DRUG|Varenicline|2 mg daily for 12 weeks
48303049|NCT05139368|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48303050|NCT06200467|DRUG|BI 456906|Solution for injection
48303051|NCT06200467|DRUG|Placebo to BI 456906|Solution for injection
48303052|NCT06200467|DRUG|Moxifloxacin|Film-coated tablet
48303053|NCT06200467|DRUG|Placebo to moxifloxacin|Film-coated tablet
48303056|NCT06692010|DRUG|Bupivacaine with Dexamethasone Solution|10 to 15 ml %0.25 bupivacaine \& 4 mg Dexamethazone
48303057|NCT05598931|DEVICE|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
48480775|NCT00813826|DRUG|Placebo|Placebo capsule, TID
48480776|NCT00622115|DRUG|Enoxaparin|
48303058|NCT03232424|DEVICE|NovoTTF-200A|"* Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~* Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter."
48303059|NCT03232424|DRUG|Temozolomide|"Concomitant phase:~* 75 mg/m2 per day for 42 days concomitant with radiotherapy.~* Begins 1 day prior to XRT start.~Maintenance phase:~* Begins 4 weeks after concomitant phase completion (+/- 1 week).~* Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~* Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~* Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
48480777|NCT05393063|DRUG|AK127|Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
48480778|NCT05246696|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
48639558|NCT06458192|BEHAVIORAL|Psychoeducation-Only Control|An active control which will deliver psychoeducational content via clickable URLs over 8 weeks.
47955771|NCT06061354|PROCEDURE|Maxillary Sinus Augmentation|Local anesthesia will be performed, mucoperiosteal flap will be raised to access the anterior wall of the maxillary sinus. Access to the maxillary sinus will be done through osteotomy, using a piezosurgery under irrigation with saline solution. Subsequently, the Schneider's membrane will be carefully lifted and, according to the randomization process, the graft material (Bio-Oss® mixed with saline solution or Bio-Oss® mixed with Forteo®) will be delivered for placement on the sinus floor maxilla below Schneider's membrane.Next, the access window to the maxillary sinus and Schneider's membrane will be protected. The mucoperiosteal flap will be repositioned and closed.
48480779|NCT04162353|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
48480780|NCT00191464|DRUG|premeal insulin lispro mixtures|
48480781|NCT00191464|DRUG|insulin glargine|
48480782|NCT00191464|DRUG|metformin|
48480783|NCT01139749|DRUG|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
48480784|NCT01139749|DRUG|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
48480785|NCT03392740|DRUG|Lisinopril|Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
48480786|NCT03392740|DRUG|Placebo Oral Tablet|Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
48480787|NCT06617273|DEVICE|Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation|Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation
48480788|NCT00146406|BEHAVIORAL|Project Connect|
48480789|NCT00528684|BIOLOGICAL|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
48639559|NCT04317105|PROCEDURE|Biopsy|Undergo a tumor biopsy
48639560|NCT04317105|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47955772|NCT06061354|PROCEDURE|Dental Implant Installation|Local anesthesia will be performed a mucoperiosteal flap will be raised in the area for implant placement and a bone core 10 mm high and 2 mm in diameter will be removed with a 2 mm trephine bur. The bone biopsied through this nucleus is part of the region where the implant will be installed, and the height of the sample depends on the surgical planning carried out previously (3-month radiographic control). The sequence of drills to place the implant will continue, installation of the implant itself and, finally, verification of the insertion torque and measurement of the resonance frequency in the already installed implant. The mucoperiosteal flap must be repositioned and sutured.
48303060|NCT03232424|RADIATION|3D conformal or intensity modulated radiation therapy (IMRT)|Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
48303061|NCT05019703|BIOLOGICAL|Atezolizumab|Given IV
48480790|NCT03015064|OTHER|Myocardial Infarction|Observational study of myocardial Infarction patients
48480791|NCT01270490|DRUG|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
48480792|NCT06368752|BIOLOGICAL|GIP[3-30]NH2|GIP\[3-30\]NH2 is the naturally occurring shorter (truncated) variant of GIP\[1-42\]. GIP\[3-30\]NH2 also stimulates the GIP receptor and therefore acts like a GIP receptorantagonist
48480793|NCT06368752|OTHER|Saline|Sodium chlorid with 0,5% human serum albumin.
48480794|NCT01567826|DRUG|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]"
48639561|NCT04317105|PROCEDURE|Computed Tomography|Undergo a CT scan
48639562|NCT04317105|DRUG|Copanlisib Hydrochloride|Given IV
48639563|NCT04317105|PROCEDURE|Echocardiography|Undergo ECHO
48639564|NCT04317105|BIOLOGICAL|Ipilimumab|Given IV
48639565|NCT04317105|BIOLOGICAL|Nivolumab|Given IV
48639566|NCT04317105|PROCEDURE|X-Ray Imaging|Undergo an x-ray
48639567|NCT05187624|DRUG|RO7428731|Participants will receive RO7428731 as described.
48639568|NCT06694363|BIOLOGICAL|Blood samples|A maximum of 27 ml of blood collected at each visit for metabolic markers analysis
48639569|NCT06694363|BIOLOGICAL|Urine samples|One urine sample collected at each visit for enteric virus infection research
48639570|NCT06694363|BIOLOGICAL|Stool samples|One stool sample collected at each visit for enteric virus infection research
48303062|NCT05019703|DRUG|Cabozantinib|Given PO
48303063|NCT06555822|DRUG|AZD5004|Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.
48303064|NCT06555822|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
48303065|NCT06088290|DRUG|Lurbinectedin|Intravenous Infusion
48303066|NCT06088290|DRUG|Doxorubicin|Short intravenous push or bolus (according to label)
48303067|NCT06693310|OTHER|de-escalation or discontinuation of therapy|De-escalation of therapy, defined as a step-down from maintenance with advanced therapy (biologic or synthetic small molecule) to oral aminosalicylate-based therapy or complete discontinuation of therapy if they are allergic or intolerant to aminosalicylate-based therapy. If patients are receiving immunomodulator or oral aminosalicylate maintenance therapy, they will be de-escalated to complete discontinuation of therapy.
48303068|NCT06693310|OTHER|continuation of current therapy|continuation of current maintenance medical therapy for ulcerative colitis
48303069|NCT05588895|OTHER|Notification|"For patients randomized to notification, the affiliated non-EP cardiologist, if present, or if patient does not have one, the PCP will be notified and will receive an electronic health record (EHR) message notifying them of the presence of CAC (with images) and the ACC/AHA guideline recommendation to consider starting statin therapy. Simultaneously, the patient will be notified via a MyHealth message describing the presence of CAC with personalized scan images, its significance, and the recommendation that statin therapy should be considered.~For the notification arm, we will check for either statin prescription or a documented discussion in the EHR at 2 months. For those not prescribed a statin and without a documented discussion in Epic at 2 months follow-up, we will send a repeat notification to their home address and to their affiliated clinician."
48303070|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks
48303071|NCT06384807|DRUG|Cemiplimab|cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks
48303072|NCT06384807|DRUG|BHV-1510|BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks
48303073|NCT06692062|RADIATION|Hypofractionated Radiation Therapy|R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f
48303074|NCT05077917|DRUG|Cromolyn Sodium|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
48303075|NCT05077917|OTHER|Placebo|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
48303076|NCT04716946|DRUG|Durvalumab|Patients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
48303077|NCT04716946|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
48303078|NCT06693362|DRUG|Placebo|The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
48303079|NCT06693362|DRUG|Drug therapy|The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
48303080|NCT06693362|OTHER|Standard Treatment|"Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary."
48303081|NCT06692517|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
48303082|NCT05239728|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
48303083|NCT05239728|BIOLOGICAL|Pembrolizumab|400 mg via IV infusion
48303084|NCT05239728|DRUG|Placebo|Oral tablet
48303085|NCT06490965|OTHER|Repetitive Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) involves generating a magnetic field with specific spatial and temporal properties, allowing the induction of electric current in conductive material near this field. The electro-physiological principle of TMS is based on placing a coil over the skull that will induce a magnetic field generating action potentials in neuronal tissue in response to each TMS pulse. The repetitive application of TMS pulses (rTMS) allows for the modulation of neuronal excitability for a period after rTMS, ranging from inhibition, in the case of low frequencies (\~1 Hz), or facilitation if high frequencies (equal to or greater than 5 Hz) are used.
48480795|NCT01567826|DRUG|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
48639571|NCT03445845|DRUG|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
48303086|NCT06490965|OTHER|Neuronavigation|Neuronavigation is a non-invasive method that allows the creation of computerized three-dimensional models of brain structures based on neuroimaging exams of each individual (e.g., cranial magnetic resonance imaging). As such, this method has been used for various purposes, such as assisting in neurosurgery or mapping functional regions of the brain, but also in the context of TMS (Transcranial Magnetic Stimulation). In this latter area, its use as support for TMS has been employed for therapeutic, diagnostic, and research purposes. The neuronavigation system consists of several components, namely a locating camera, locators for the TMS coil, an adjustable headband with locators, a calibration system for these elements, and the neuronavigation software, which is installed on a supporting computer.
47955773|NCT06061354|COMBINATION_PRODUCT|Bone graft|One arm:mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® In other arm: 1g of Bio-Oss® will be mixed with 0.72ml of saline solution.
48303087|NCT06490965|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that generates detailed images of the internal structures of the body using a strong magnetic field and radio waves. It provides high-resolution images of soft tissues, such as organs, muscles, and the brain, helping doctors diagnose and monitor various conditions, including injuries, tumors, and neurological disorders. MRI is particularly useful because it does not involve ionizing radiation, making it safer for patients than other imaging methods like X-rays or CT scans.
47955774|NCT01811225|DRUG|Low-dose Progesterone|"The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
47955775|NCT01811225|DRUG|High-dose Progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
47955776|NCT04516330|GENETIC|miRNA|miRNA's expressed in breast cancer
47955777|NCT06239831|DEVICE|ExSpiron and ActivPAL Monitors|ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
47955778|NCT03531359|DEVICE|TIBD|Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
47955779|NCT03531359|DRUG|Midazolam|Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
47955780|NCT04835519|BIOLOGICAL|chimeric antigen receptor T cell|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
47955781|NCT02083614|PROCEDURE|to clamp or release the catheter for 2 days before removal|
47955782|NCT03925311|PROCEDURE|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
47955783|NCT00772304|DRUG|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
47955784|NCT02284542|PROCEDURE|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
47955785|NCT02284542|PROCEDURE|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011)."
47955786|NCT00913380|RADIATION|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
47955787|NCT00913380|RADIATION|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
48109842|NCT06360016|BEHAVIORAL|Recreation Activity Program|Students in the study group were subjected to a 24-session RAP, including entertaining games. This program was conducted by the first-name researcher, who had completed their undergraduate education in preschool education and was supported by the second and third-named researchers as assistant instructors. The 24-session program, which included rhythm, balance, and patience acquisition games, was planned according to a game theory model that primarily aimed to entertain children. The program, aimed at developing children's self-regulation skills based on fundamental reflections of the model, would consist of simple rule-based entertaining games. Before the program's application, researchers provided information about the research and program to the experimental group, and verbal consent was obtained.
47955788|NCT03576495|OTHER|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
48639572|NCT03445845|DRUG|TNF blocker|"TNF blocker (originator or biosimilar) :~* infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~* etanercept: 50mg per week in subcutaneous injection,~* adalimumab: 40mg every other week in subcutaneous injection,~* certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~* golimumab: 50mg every month in subcutaneous injection, in case of overweight (\>100kg) an inadequate response, 100mg every month is allow."
47955789|NCT03576495|OTHER|Standard Residency Curriculum|The standard residency curriculum consists of previously scheduled resident didactic sessions at all academic medical centers that may or may not include topics on cultural competency or cross-cultural care.
47955790|NCT04004546|BEHAVIORAL|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
47955791|NCT02737280|DEVICE|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher \& Paykel Healthcare) device
47955792|NCT02737280|DEVICE|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
47955793|NCT00546559|DRUG|statins (simvastatin, pravastatin)|
47955794|NCT02864602|DRUG|IV dexamethasone|An infusion of IV dexamethasone
47955795|NCT00194883|DRUG|Recombinant Human Growth Hormone|
47955796|NCT01664065|DRUG|200 mg Ceftaroline fosamil|1 h infusion
47955797|NCT01664065|DRUG|600 mg Ceftaroline fosamil|1 h infusion
47955798|NCT03608254|OTHER|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
47955799|NCT04627246|BIOLOGICAL|Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)|"SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab: intravenous, starting after the last chemotherapy cycle. Administered as a flat dose of 240mg every 2 weeks during the vaccination period until the last vaccine dose or at least for 8 weeks after the end of last chemotherapy cycle if vaccination stops earlier. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity for a maximum of 2 years."
47955800|NCT01276600|DRUG|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
47955801|NCT01719783|BIOLOGICAL|LAIV H5N2|2 doses provided intranasally
47955802|NCT01719783|OTHER|Placebo|2 doses of placebo provided intranasally
48639573|NCT03445845|BIOLOGICAL|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
47955803|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
48109843|NCT00857142|DRUG|oxymorphone hydrochloride|
48109844|NCT00857142|DRUG|Opana|
48109845|NCT01750463|OTHER|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
48639574|NCT05126277|DRUG|ianalumab s.c. q4w|ianalumab s.c. q4w in addition to SoC
48639575|NCT05126277|DRUG|ianalumab s.c. q12w|ianalumab s.c. q12w in addition to SoC
48639576|NCT05126277|DRUG|placebo s.c.|placebo s.c. q4w in addition to SoC
48639577|NCT05574764|BEHAVIORAL|Cultivating Awareness and Resilience in Education (CARE)|CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
48480796|NCT01461941|DRUG|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
48639578|NCT04743141|DRUG|Rimegepant (PF-07899801)|Rimegepant 75 mg, 50 mg or 35 mg ODT
47955804|NCT00768183|DRUG|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
47955805|NCT00768183|DRUG|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
47955806|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
47955807|NCT01570296|DRUG|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
47955808|NCT04436159|PROCEDURE|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
48639579|NCT06312670|DRUG|EPI-7386|600 mg orally administered twice daily
48639580|NCT06312670|DRUG|Enzalutamide|160 mg administered orally once daily, with or without food
48639581|NCT06312670|DRUG|Androgen Deprivation Therapy (ADT)|LHRH agonist/antagonist or orchiectomy
48639582|NCT04072432|DRUG|RBT-3|intravenous administration
48639583|NCT06494150|DRUG|nab-Sirolimus|nab-Sirolimus will be administered by intravenous infusion at 100mg/m2 on days 1 and 8 of each 21-day cycle
48480797|NCT01461941|DRUG|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
48480798|NCT06615804|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It's primarily used to treat depression, especially in patients who haven't responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
48639584|NCT06494150|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular injection at 500mg on days 1 and 15 of cycle 1 and then every 21 days
48639585|NCT06184724|OTHER|Implementation Package for CGA|The Implementation Package will include a set of implementation strategies to improve the use of CGA before surgery. These strategies will be applied at the clinic-level to help increase the reach and adoption of the CGA.
48639586|NCT06184724|OTHER|Routine Clinical Care|Routine care may or may not include the use of the CGA before surgery. The use of CGA in clinical care is up to the medical and surgical healthcare providers.
48639587|NCT04880031|DRUG|BOS-580|BOS-580 will be administered by subcutaneous injection
48639588|NCT04880031|DRUG|Placebo|Placebo will be administered by subcutaneous injection
48109846|NCT01750463|OTHER|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
48109847|NCT01810263|DIETARY_SUPPLEMENT|high protein supplement|Dietary Supplement: high protein supplement
48109848|NCT05632432|PROCEDURE|Epicardial AAMs-patch transplantation|Perioperative assembly of an AAMs-patch with epicardial transplantation onto the epicardium of the scarred myocardium at the end of CABG surgery
48109849|NCT05632432|DIAGNOSTIC_TEST|RNA-stabilized whole blood sampling|Collection (preoperative and at 6-month-follow-up) of TEMPUS(TM) stabilizing whole blood for epitranscriptomics-oriented measurements
48109850|NCT05632432|DIAGNOSTIC_TEST|Plasma sampling|Collection (preoperative and at 6-month follow-up) of blood-derived both RNA-stabilized and non-stabilized plasma aliquots for epitranscriptomic-oriented and other CVD biomarker oriented measurements, respectively
48109851|NCT05632432|DIAGNOSTIC_TEST|Transthoracic echocardiography|To assess cardiac structure and function both pre- and postoperatively (at both hospital discharge and 3-month follow-up)
48480799|NCT04079049|PROCEDURE|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
48480800|NCT04079049|DRUG|Control|Oncological treatment in control group
48480801|NCT04625192|PROCEDURE|Trephine osteotomy|"* Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~* The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
48480802|NCT03965728|DRUG|BAY1830839|Tablet, oral.
48480803|NCT03965728|DRUG|Placebo|Tablet, oral.
48480804|NCT03965728|DRUG|Midazolam|For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
48639589|NCT05263245|OTHER|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
48639590|NCT06057454|DRUG|R-5280|Modified Superior Starch
48639591|NCT06057454|OTHER|Placebo|Food Grade Starch
48639592|NCT05670197|OTHER|No intervention. Participants will take part in a qualitative interview|No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
48639593|NCT06669533|DRUG|Placebo|Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
48639594|NCT06669533|DRUG|Misoprostol|Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
48639595|NCT02124421|PROCEDURE|Cytoreductive Surgery (CRS)|Cytoreductive surgery
48639596|NCT02124421|DRUG|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
48639597|NCT02124421|OTHER|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
48109852|NCT05632432|DIAGNOSTIC_TEST|Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)|To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
48109853|NCT05632432|OTHER|Symptom-scaling|Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
48109854|NCT05632432|OTHER|6-minute walking test (6MWT)|Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
48109855|NCT05632432|DIAGNOSTIC_TEST|Blood sampling (NT-proBNP)|Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
48639598|NCT02124421|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
48639599|NCT02124421|DRUG|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
47955809|NCT04436159|PROCEDURE|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
48303097|NCT04626479|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg Q6W
48303098|NCT04626479|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
48303099|NCT04626479|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
48303100|NCT04626479|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
48303101|NCT04626479|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
48303102|NCT04626479|DRUG|Vibostolimab/Pembrolizumab|Administered via IV infusion at a dose of 200 mg/200 mg Q6W
48303103|NCT06693258|PROCEDURE|thyroidectomy by robotic surgery via axillary approach|thyroidectomy
48303104|NCT06693258|PROCEDURE|thyroidectomy by standard conventional surgery|thyroidectomy by standard conventional surgery
48639600|NCT02124421|DRUG|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
48639601|NCT02124421|DRUG|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
48639602|NCT02124421|DRUG|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
48639603|NCT05377424|DRUG|Consume 20mg of istradefylline|Consume a single 20 mg istradefylline tablet
48639604|NCT05377424|OTHER|Low Oxygen therapy|Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.
48303105|NCT06693401|OTHER|Intervention group: PD rehabilitation complemented with Occupational Therapy programme|"In intervention group both Physiotherapy and Occupational Therapy programmes were implemented.~Occupational Therapy programme consisted in trainning the amplitude of the movements involved in the realization of each letter of the alphabet separately and through fine motor exercises. Specifically the tasks consisted of performing:~1. 2 types of handwriting exercises, namely for tracing the upper and lower-case letters of the alphabet guided by dotted lines and writing a sentence with and without spatial boundaries, in Portuguese language (to be performed for about 45 minutes, three times a week) and;~2. 4 groups of fine motor tasks exercises, namely for hand manipulation (2 exercises), finger isolation (3 exercises), finger flexion and extension (2 exercises) and coordination (1 exercise). All exercises were performed 10 times, in triplicate, for each hand on a regular basis of 2-3 times per week."
48303106|NCT06693401|OTHER|Control Group: conventional physiotherapy programme|In this group only the conventional physiotherapy programme was implemented. This programme has the purpose of improving balance and reducing the risk of falls, enhancing mobility and motor function, managing muscle stiffness and rigidity, addressing gait abnormalities, and providing education and support. In this regard, participants were guided and supervised in each physiotherapy session by a Parkinson's disease healthcare specialist.
48303107|NCT06693843|DRUG|GSBR-1290 or Placebo|Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
48639605|NCT05377424|DRUG|Placebo counterpart to the istradefylline drug|Consume a single microcrystalline cellulose
48639606|NCT05377424|OTHER|SHAM counterpart to low oxygen therapy.|Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.
48639607|NCT05365451|DRUG|MetFORMIN Oral Solution|liquid
47955810|NCT05840731|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
48303108|NCT06693843|DRUG|GSBR-1290 or Placebo|Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
48639608|NCT05365451|DRUG|Cimetidine 400 MG|tablet
48639609|NCT05365451|DRUG|Furosemide Oral Liquid Product|oral solution
48639610|NCT05365451|DRUG|Probenecid 500 MG|tablet
48639611|NCT06694532|DRUG|Hyaluronic acid|Comparative study between Hyalgan and Hyorth injectable products in TMJ Disorders by arthrocentesis of 2 syringes device
48639612|NCT06694532|DEVICE|Syringes|Whilst you are asleep, two small needles will be inserted into the TMJ / Jaw Joint. One of these needles allows sterile saline to be pumped into the joint under pressure whilst the other needle allows the saline to drain out of the joint then injection of the HA injectiable products .
47955811|NCT05840731|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
47955812|NCT02364921|DEVICE|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
48639613|NCT04044248|DEVICE|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
48639614|NCT04745806|DEVICE|ActiGraft|Whole blood clot (WBC) gel
48639615|NCT06044623|DRUG|CDK 4/6 inhibitors|Either Palbociclib, Ribociclib or Abemaciclib
48639616|NCT06044623|DRUG|Endocrine therapy|Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
48639617|NCT05453201|BEHAVIORAL|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
48639618|NCT06600802|BIOLOGICAL|Blood samples|A total of 3 blood samples (2 tubes of 9mL each) are added. The first sample will be taken at the inclusion visit, the 2nd at the end of the 2nd treatment cycle and the last at the end of Lu-PSMA treatment.
48639619|NCT04087655|BEHAVIORAL|Exercise|Eight weeks of interval exercise training
48639620|NCT05781750|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib
48639621|NCT05781750|DRUG|placebo|Subcutaneous injection of placebo
48639622|NCT01631617|DRUG|Trimethoprim/sulfamethoxazole (TMP/SMZ)|800/160 orally every 12 hours for 14 days
47955813|NCT02364921|DEVICE|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
47955814|NCT05059639|OTHER|Almond|Consume 2 ounces of almond daily for 8 weeks
47955815|NCT05059639|OTHER|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
48480805|NCT03965728|DRUG|Methotrexate|Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
48480806|NCT01885182|DRUG|Oxycodone/Naloxone|
48480807|NCT01885182|DRUG|Oxycodone|
48639623|NCT01631617|DRUG|Cephalexin|500 mg orally every 8 hours for 14 days
48639624|NCT01631617|DRUG|Doxycycline|20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
48480808|NCT06403072|DIAGNOSTIC_TEST|The Gynecologic Imaging-Reporting and Data System (GI-RADS)|The Gynecologic Imaging-Reporting and Data System (GI-RADS) using ultrasound
48639625|NCT01631617|OTHER|Sodium hypochlorite|6 % dilute bleach
48639626|NCT01631617|OTHER|Placebo capsules|Capsule orally every 8 hours daily for 14 days
48109856|NCT05632432|DIAGNOSTIC_TEST|Transesophageal echocardiography|Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
48480809|NCT06045520|BEHAVIORAL|Information-Motivation-Behavioral Skills Model|1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
48480810|NCT05560555|DRUG|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
48639627|NCT01631617|OTHER|Placebo Sodium hypochlorite|Three times a week for 14 days
48639628|NCT06469372|DEVICE|Cardiac amyloidosis deep learning model|This is a deep learning algorithm which intakes a patient's age, sex, clinical factors known to be related to amyloidosis and their ECG and echocardiogram results and determines their estimated risk for having cardiac amyloidosis.
48639629|NCT06144697|DRUG|BMS-986465|Specified dose on specified days
48639630|NCT06144697|OTHER|Placebo|Specified dose on specified days
48639631|NCT06144697|DRUG|Pegasys|Specified dose on specified days
47955816|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
48639632|NCT06144697|DRUG|Famotidine|Specified dose on specified days
48639633|NCT06401772|BEHAVIORAL|Intracranial Hypotension Targeted(IHT) Body Posture|IHT therapy requires CSDH patients to raise their lower limbs 30° higher over the horizontal level of their head.For patients with unilateral CSDH, the head should be tilted towards the hematoma affected side and opposite side lying should be avoided as much as possible. For patients with bilateral CSDH, there is no need for the head lateralization.To avoid food reflux and aspiration pneumonia, IHT therapy was strictly prohibited within 2 hours after each meal
48639634|NCT04813926|DRUG|Riociguat (Adempas, BAY63-2521)|Follow clinical practice.
48639635|NCT06042478|DRUG|Remibrutinib|Active treatment
47955817|NCT00891462|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
47955818|NCT00891462|DRUG|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
47955819|NCT03870100|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
48639636|NCT06042478|DRUG|Placebo to remibrutinib|Placebo followed by active treatment
48639637|NCT06042478|DRUG|Placebo to omalizumab|Placebo followed by active comparator
48639638|NCT06042478|DRUG|Omalizumab|Active comparator
48639639|NCT06643247|DRUG|Drug|1) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
48480811|NCT03020719|DRUG|Oral Glutathione|Oral Glutathione oral powder
48480812|NCT03020719|DRUG|Placebo|Placebo oral powder
48639640|NCT06643247|PROCEDURE|Electroacupuncture|Electroacupuncture Treatment: Needling acupoints include the Jiaji points corresponding to the spinal nerve segment of the affected area, Ashi acupoints along the affected zone, and bilateral Hegu and Waiguan points. Electroacupuncture will be performed once daily for 30 minutes per session, with a total of 7 consecutive sessions. The Jiaji and Ashi acupoints will be connected to an electroacupuncture device, set to disperse-dense wave stimulation at a frequency of 2/100 Hz, with current intensity adjusted to the patient's tolerance level.
48639641|NCT04615988|OTHER|blood draw and questionnaire completion|questionaires provided to subjects during visits while on study and baseline one tube of blood drawn
48639642|NCT04615988|OTHER|questionnaire completion, blood collection|questionnaire provided to subject during study visits. One tube blood collected for research purposes at baseline
48639643|NCT02596490|BEHAVIORAL|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
48639644|NCT02596490|BEHAVIORAL|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
48639645|NCT02596490|BEHAVIORAL|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
48639646|NCT04702672|DIETARY_SUPPLEMENT|100% wheat (control)|Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
48639647|NCT04702672|DIETARY_SUPPLEMENT|100% Lean-baking barley®|"Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou"
48639648|NCT04702672|DIETARY_SUPPLEMENT|100% regular barley|"Intake of 250 ml of tap water and 100 g of bread baked with 100% regular barley flour and 25% wheat flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flour."
48639649|NCT06299163|BIOLOGICAL|NM32-2668|Anti-ROR1/Anti-Cluster of Differentiation 3 (CD3)/Anti-Human Serum Albumin (HSA) Tri-Specific Antibody
47955820|NCT03870100|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
48480813|NCT05892484|DEVICE|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
47955821|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 1|The product under investigation is a unique probiotic.
48109857|NCT05632432|PROCEDURE|Epicardial collagen-based patch transplantation|Epicardial transplantation of the collaged-based patch material without the AAMs onto the epicardium of the scarred myocardium at the end of CABG surgery.
48480814|NCT05892484|DIAGNOSTIC_TEST|X-RAY|Routine X-RAY
48109858|NCT02156687|DEVICE|Y mesh|Y mesh
48109859|NCT02156687|DEVICE|Dual flat mesh|Dual flat mesh
48109860|NCT00043082|DRUG|carboplatin|intravenous q 4 weeks
48480815|NCT04239118|COMBINATION_PRODUCT|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
47955822|NCT03482765|DIETARY_SUPPLEMENT|Probiotic 2|The product under investigation is a unique probiotic.
47955823|NCT03482765|OTHER|Placebo|Microcrystalline Cellulose
47955824|NCT01199172|BEHAVIORAL|voice hygiene|subjects will receive voice hygiene training
47955825|NCT01199172|BEHAVIORAL|VH + VP|subjects will be trained in voice hygiene and voice production training
47955826|NCT02925117|DRUG|Upadacitinib|Tablet for oral use
47955827|NCT02925117|DRUG|Placebo|Tablet
47955828|NCT03172169|OTHER|no Intervention|no Intervention
47955829|NCT03758443|DRUG|TD-1473 Dose A|See Arm description
47955830|NCT03758443|DRUG|TD-1473 Dose B|See Arm description
47955831|NCT03758443|DRUG|TD-1473 Dose C|See Arm description
48480816|NCT04239118|PROCEDURE|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
48480817|NCT02646917|PROCEDURE|Aesthetic Microneedling Treatment|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
48639650|NCT05747027|PROCEDURE|Laparoscopic abdominal ventral rectopexy|Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS. It involves a series of small cuts in the abdomen and the use of mesh to hold the rectum in the correct position.
48639651|NCT05747027|PROCEDURE|Transvaginal sacrospinous rectopexy|Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment. This is a mesh-free and vaginal route procedure.
48639652|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|10mg/kg/day of TMP component
48480818|NCT01052324|DRUG|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5\~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
48109861|NCT00043082|DRUG|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
48109862|NCT01063686|DEVICE|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
48303109|NCT06693843|DRUG|GSBR-1290 or Placebo|Drug: GSBR-1290 Administered orally Drug: Placebo Administered orally
48303110|NCT00331786|DRUG|nitric oxide-releasing acetylsalicylic acid derivative|
48639653|NCT04851015|DRUG|trimethoprim-sulfamethoxazole|15mg/kg/day of TMP component
48639654|NCT04650841|DRUG|Placebo Cream with Naloxone|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
48639655|NCT04650841|DRUG|Control Cream with Naloxone|Participants will be informed that the spray is saline.
48639656|NCT04650841|DRUG|Placebo Cream with Saline|Participants will be informed that the spray is an effective pain and negative emotion reducing agent.
48109863|NCT03915613|DRUG|Humulin R|"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
48109864|NCT03915613|DRUG|Diluent|"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
48109865|NCT04379349|BEHAVIORAL|SMS text messaging - interactive check-in|Interactive SMS text message check-ins delivered once weekly to participants.
48109866|NCT04379349|BEHAVIORAL|SMS text messaging - inactive control|Minimally interactive SMS text message delivered once weekly to participants.
48109867|NCT03418324|DRUG|TRC105|Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
48303111|NCT00331786|OTHER|laboratory biomarker analysis|
48303112|NCT00331786|PROCEDURE|biopsy|
48303113|NCT00675974|DEVICE|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
48303114|NCT00675974|DEVICE|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
48303115|NCT06692322|DRUG|Zongertinib (BI 1810631)|Film-coated tablet
48303116|NCT05185882|OTHER|Single leg squat|Single leg squat exercise in different circumstances
48303117|NCT06693349|DRUG|the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to give superior effects than other procedure used in this study
48303118|NCT06693349|DRUG|the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to be replaced by other procedure be used in this study
48303119|NCT02929992|OTHER|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
48303120|NCT02929992|OTHER|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
48303121|NCT02929992|OTHER|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
48639657|NCT04650841|DRUG|Control Cream with Saline|Participants will be informed that the spray is saline.
47955832|NCT03758443|DRUG|Placebo|See Arm description
48639658|NCT06695260|DIAGNOSTIC_TEST|CT scan|CT will be performed when the wrist is under loading compared to normal conditions. scapholunate kinematics will be examines
48639659|NCT04360018|OTHER|Alcohol beverage|High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.
48639660|NCT04360018|OTHER|Placebo beverage|The final drink will have the same volume of liquid as the alcohol beverage.
48639661|NCT06562283|OTHER|Thumb test|Thumb adduction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
48639662|NCT06562283|OTHER|Grip test|Muscle contraction gripping test, consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
48639663|NCT06562283|OTHER|Quadriceps Intermittent Fatigue test (QIF test))|Quadriceps muscle contraction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
48639664|NCT06694064|PROCEDURE|Pulpotomy|Pulpotomy will be done for mta group
48303122|NCT02929992|OTHER|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
48480819|NCT05440019|DEVICE|IMAGE CAPTURE SESSION|"The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis."
48480820|NCT05983666|DIAGNOSTIC_TEST|Ultrasound Oesophageal Intubation|Ultrasound Oesophageal intubation detection
48639665|NCT06694064|PROCEDURE|extraction for histologic examination|after pulp therapy the teeth exrtracted for histologic examination
48639666|NCT04305041|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
48109868|NCT03418324|DRUG|Abiraterone|Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
48109869|NCT03418324|DRUG|Enzalutamide|Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
48480821|NCT04222114|DRUG|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
48639667|NCT04305041|BIOLOGICAL|Quavonlimab|Administered via IV infusion at a specified dose on specified days
48109870|NCT01507948|BEHAVIORAL|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
48109871|NCT05608343|DRUG|Difamilast|Off-white ointment containing active ingredient, petrolatum and other ingredients
48109872|NCT05608343|DRUG|Placebo|Matching Difamilast (Study drug) ointment without active ingradient
48109873|NCT03775369|OTHER|endurance training|physical activity and exercising (PAE)
48639668|NCT04305041|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
48639669|NCT04305041|DRUG|Lenvatinib|Administered via oral capsules at a specified dose on specified days
48639670|NCT04305041|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
48639671|NCT04365569|BEHAVIORAL|Nutrition and physical activity counseling program|"6-month interventional, counseling program based on nutrition and physical activity consisting of:~1. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program"
48655971|NCT02473042|BEHAVIORAL|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
48109874|NCT03775369|OTHER|social support and counseling|social support and counseling
48109875|NCT03775369|OTHER|resistance training|physical activity and exercising (PAE)
48303123|NCT04841135|OTHER|Multiomics quantification|One time blood, stool and urine samples will be taken.
48303124|NCT04841135|OTHER|Polysomnography|Facultative polysomnography
48303125|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
48303126|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
48303127|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
47955833|NCT03898258|OTHER|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
48303128|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
48303129|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
48303130|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
48303131|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
47955834|NCT03898258|OTHER|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
48303132|NCT05262400|DRUG|PF-07104091 + PF-07220060 + letrozole dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
48303133|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
48303134|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
48303135|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
48303136|NCT05550727|OTHER|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
48303137|NCT05419375|OTHER|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
48480822|NCT04222114|DRUG|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
48480823|NCT00021489|DRUG|Abacavir sulfate|
48480824|NCT00021489|DRUG|Mycophenolate mofetil|
48480825|NCT04528888|DRUG|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
48480826|NCT04528888|DRUG|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
48480827|NCT04528888|DRUG|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
48480828|NCT01087021|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
48480829|NCT06522269|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
48480830|NCT06522269|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
48480831|NCT04702763|OTHER|Eye-Tracker®T2 + e-VOG|"* 1st step: eyes movements assessed with standard video-oculography device~* 2° step: eyes movements assessed with e-VOG digital application~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
48480832|NCT04702763|OTHER|e-VOG + Eye-Tracker®T2|"* 1st step: eyes movements assessed with e-VOG digital application~* 2° step: eyes movements assessed with standard video-oculography device~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
48480833|NCT04588688|DRUG|Mifepristone|Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
48480834|NCT01385826|DRUG|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
48480835|NCT01385826|DRUG|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
47955835|NCT00963222|DRUG|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
48480836|NCT04764630|DRUG|Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
48480837|NCT04764630|DRUG|Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
48480838|NCT04764630|DRUG|Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
48480839|NCT04671537|DRUG|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
48639672|NCT04824066|DEVICE|Device: Wearable Device|A Wearable Device will be placed on the wrist of the patient \~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for \~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
47955836|NCT00963222|DRUG|placebo|1 cap placebo/day for 3 month
47955837|NCT04118504|DEVICE|Mobile application|Lifestyle intervention on through mobile application
48303138|NCT02244450|BIOLOGICAL|SCID screening|
48303139|NCT04497558|DIAGNOSTIC_TEST|Endometrium biopsy|In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
48303140|NCT05015400|OTHER|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
48303141|NCT03481764|GENETIC|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
48639673|NCT06695767|BEHAVIORAL|Neurobehavioral therapy|Participants will receive an introduction session and 12 1-hour long online sessions once per week for a total of 12 weeks that are guided by the investigator who is trained in NBT.Participants will engage in tools to aid in assuming control over their seizures; contextualize their environment; identify moods, situations, and thoughts; train healthy communication and support seeking; understand central nervous system medications and seizures; conduct a functional behavioral analysis; learn relaxation techniques; examine external stressors and internal triggers; and prepare for life after the intervention. Participants will be asked to complete weekly homework, thought records, seizure logs that are found in their workbooks and to engage in journal entries.
48639674|NCT06694025|BIOLOGICAL|Efluelda Tetra Pre-filled syringe|Suspension for injection in a pre-filled syringe
48639675|NCT05415527|OTHER|Presence of sarcopenia evaluated prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management(dietician and APA).|"Sarcopenia will be evaluated by CT-scan. This method will be combined with a bone mineral density test which is also a way of entering into a more specific approach to sarcopenia screening.~The patients will receive optimised treatment by nutritional monitoring and adapted physical activity (APA) in addition to follow-up for sarcopenia."
48639676|NCT06671366|DEVICE|external and internal shoulder rotation using a Cybex dynamometer|"Measurement of the reproducibility, in this precise evaluation position, of the results obtained between the different tests carried out 30 minutes apart, and thus the reliability of each measurement in this test.~measures :~* Concentric internal rotation 60degrees/sec~* Concentric external rotation 60 degrees/sec~* Concentric internal rotation 180 degrees/sec~* Concentric external rotation 180 degrees/sec~* Eccentric internal rotation 60degrees/sec~* Eccentric external rotation 60degrees/sec"
48639677|NCT03394066|DEVICE|TMS (MagVenture MagPro 100 with MagOption)|TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
48639678|NCT05263791|DEVICE|Airmod|Both of the respiratory rate monitor (including experimental and reference device) are installed on the enrolled patients. The practitioners can clearly read the result of both devices.
48639679|NCT06695195|DRUG|Cannabidiol (CBD)|25 mg capsule twice daily
48639680|NCT06695195|DRUG|Placebo|25 mg capsule twice daily
48639681|NCT06696079|DRUG|Early Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma. This early resumption strategy is compared to the standard practice of resuming anticoagulation therapy on the 30th postoperative day.
47955838|NCT03764007|DRUG|18F-Fluorocholine|Given intravenously
47955839|NCT03764007|PROCEDURE|Positron Emission Tomography (PET)|Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
48303142|NCT03537768|DRUG|Ulipristal Acetate|UPA Tablet
48303143|NCT03537768|DRUG|Levonorgestrel|LNG Tablet
48303144|NCT03537768|DRUG|Levonorgestrel|LNG Tablet (x2)
48303145|NCT05998993|RADIATION|Stereotactic Body Radiation Therapy SBRT|This is a non-randomized Phase II study in which all patients receive the experimental treatment with Stereotactic Ablative Radiotherapy (SABR) to residual tumor lesions (up to 5 residual metastatic lesions in a maximum of 2 organs) following 12 weeks of systemic treatment with Osimertinib. The study aims to enroll 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
48303146|NCT01175070|DRUG|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
48303147|NCT05049863|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
48480840|NCT00285584|DRUG|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
48639682|NCT06696079|DRUG|Late Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma. This standard resumption strategy is compared to the early approach of resuming anticoagulation therapy on the 5th postoperative day.
47955840|NCT01369160|BEHAVIORAL|Quality of Life measures|measuring QOL with different therapies
48480841|NCT00285584|DRUG|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
48480842|NCT01705431|BEHAVIORAL|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
48639683|NCT05947955|DRUG|Rhu-pGSN|Intravenous administration based on actual body weight
48639684|NCT05947955|DRUG|normal saline|intravenous administration in the same volume as the active therapy
48655972|NCT01254929|DEVICE|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
47955841|NCT01880619|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
48303148|NCT05049863|DRUG|Allopurinol|Allopurinol is commercially available.
48303149|NCT05049863|DRUG|Irinotecan|Irinotecan is commercially available.
48655973|NCT01254929|DEVICE|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
47955842|NCT01880619|DRUG|Solifenacin|Patients in the arm will receive Solifenacin
47955843|NCT01880619|DRUG|Control|Patients in this are will receive placebo
47955844|NCT03691181|DEVICE|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
47955845|NCT00723580|DRUG|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
47955846|NCT01987635|DEVICE|MEMO 3D ring|The experimental MEMO 3D ring is placed.
47955847|NCT01987635|DEVICE|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
47955848|NCT01987635|PROCEDURE|3D Echocardiography|
47955849|NCT02869607|OTHER|Data collection|
47955850|NCT05818098|DEVICE|Intravascular Lithotripsy System of Shanghai MicroPort Rhythm|The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
47955851|NCT01910961|PROCEDURE|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
47955852|NCT06352983|PROCEDURE|Fixed dental prosthesis|Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
47955853|NCT01944033|DRUG|Bricanyl/Iprovent|5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
47955854|NCT01944033|DRUG|Bricanyl|5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
47955855|NCT02959983|DRUG|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
47955856|NCT02959983|DRUG|Placebo|Placebo matching eluxadoline oral tablets BID with food.
47955857|NCT04605042|PROCEDURE|wet suction|Before pucturing the lesion, the stylet was removed and the needle was pre-flushed with 1-2 mL of saline using a 10-mL syringe, the endoscopist then punctured the lesion and replaced the 10-mL syringe with a 10-mL pre-vacuum syringe
47955858|NCT04605042|PROCEDURE|standard negative pressure suction|after puncturing the lesion, the endoscopist removed the stylet and attached a 10-mL pre-vacuum syringe for aspiration.
47955859|NCT03493620|PROCEDURE|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
47955860|NCT03493620|PROCEDURE|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
47955861|NCT00994071|DRUG|Temozolomide|
47955862|NCT00994071|DRUG|ABT-888|
47955863|NCT03822182|DRUG|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
47955864|NCT03822182|DRUG|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
47955865|NCT04641858|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
47955866|NCT04641858|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
47955867|NCT00993681|BIOLOGICAL|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
47955868|NCT00993681|BIOLOGICAL|TD Vaccine System|placebo
47955869|NCT03123367|DEVICE|Group 1: Nella VuSleeve|Sleeve
47955870|NCT03123367|DEVICE|Group 2: Nella NuSpec|Speculum
47955871|NCT03123367|DEVICE|Group 3: NellaSpec|Speculum
47955872|NCT03123367|DEVICE|Group 4: Nella Insert|Sleeve
48303150|NCT05738096|OTHER|TSEP + rhizotomy surgery|TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery. TSEPs will be measured at baseline prior to surgery. During the rhizotomy procedure, an electrode or balloon is placed through a metal sheath to then damage the nerve. A stylet is introduced to clear tissue from the sheath in preparation for the electrode or balloon. Prior to the final insertion of the RF electrode where the gasserian ganglion will be damaged, we will place a standard stereotactic EEG electrode (SEEG). Following damaging the nerve (clinical procedure), we will record again to measure differences in the TSEPs following cell body damage. The Neuralynx system will be used to record the potentials at 40 KHz.
48303151|NCT05738096|OTHER|TSEPs recording only|TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
48303152|NCT01372878|DEVICE|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
48639685|NCT06461273|BEHAVIORAL|Lifestyle Medicine Program|"Participants will engage in culinary and nutrition education for 6 weeks curated by a professional chef working in conjunction with the project team from community partner Ethos Farm to Health. Lessons will be adapted from the American College of Lifestyle Medicine (ACLM) Culinary Medicine Curriculum~Participants will engage in exercise sessions on weeks without culinary and nutrition instruction for a total of 6 weeks. Exercise sessions will include a variety of activities to include calisthenics, weight training, walking, running, dance, and games delivered by the Rutgers physical therapy team.~Urban Agriculture lessons will occur longitudinally throughout the 12-week course. Participants will learn to cultivate a variety of crops in limited spaces, emphasizing sustainable practices and the importance of local food systems in urban communities.~Additionally, this arm will receive a supplemental food box weekly consistent with the dietary pattern set forth by ACLM."
48639686|NCT06461273|BEHAVIORAL|Medically Tailored Groceries|"Participants in the Food is Medicine arm will receive a supplemental food box weekly curated by a registered dietician and dietetics students. Each food box will contain seasonally available fruit and vegetables and other items including protein, dairy/cheese, and legumes that may be available at the time of the food box delivery. Each box will contain approximately 8 pounds of food and all participants in this group will receive the same food items. Classes and educational materials provided will be tailored to the specific foods contained in the weekly food box and will include simple preparation methods, recipes, nutrition information and grocery shopping tips."
48303153|NCT01372878|PROCEDURE|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.~Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
48303154|NCT05534555|DIAGNOSTIC_TEST|FebriDx|Testing of finger-prick blood sample using FebriDx
48303155|NCT05844566|DEVICE|Decision Support System (DSS)|"This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion."
48639687|NCT04700072|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
48303156|NCT03017586|DEVICE|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
48303157|NCT02039336|DRUG|Dacomitinib|
48303158|NCT02039336|DRUG|PD-0325901|
48639688|NCT04700072|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
48639689|NCT04700072|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
48303159|NCT02039336|DRUG|Docetaxel|
48303160|NCT03711071|OTHER|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
48639690|NCT06695273|DIAGNOSTIC_TEST|AI-derived probability of coronary heart disease.|Physician readers will be assisted with AI-derived probability of coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.
48639691|NCT06695273|DIAGNOSTIC_TEST|PCEs derived ASCVD risk|Physicians use a PCEs to calculate the probability of 10 year ASCVD risk. This approach aligns with current clinical guidelines to assist in decision-making.
48303161|NCT06374498|DEVICE|OCT-NIRAF|Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram. In addition, the subject will also receive two Coronary Computed Tomography Angiography (CCTA) 12 months apart, and images will be analyzed.
48303162|NCT00886132|DRUG|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
48303163|NCT01150877|DRUG|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
48303164|NCT00585299|OTHER|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
48303165|NCT00585299|OTHER|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
48303166|NCT02424955|DRUG|perflutren lipid microspheres|
48303167|NCT02424955|DIAGNOSTIC_TEST|3D ultrasound|
48655974|NCT01561469|DRUG|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
48303168|NCT06038097|PROCEDURE|Radiofrequency Pallidotomy|Radiofrequency bilateral simultaneous pallidotomy
48303169|NCT00059436|BEHAVIORAL|Mental effort in muscle strengthening|
48303170|NCT03872401|DRUG|Evolocumab|Administered subcutaneously using an autoinjector pen.
48303171|NCT03872401|DRUG|Placebo|Administered subcutaneously using an autoinjector pen.
48303172|NCT06693856|DRUG|High-Dose Methylprednisolone|Methylprednisolone 500mg, administered intravenously once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
48303173|NCT06693856|DRUG|Low-Dose Methylprednisolone|Methylprednisolone is administered at a dose of 1mg/kg, given as an intravenous injection once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
48303174|NCT01492647|DRUG|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
48480843|NCT05281978|BEHAVIORAL|Decrease Sedentary Time + Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time
48480844|NCT05281978|BEHAVIORAL|Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
48480845|NCT06260826|DEVICE|Auto CPAP via nasal mask (JPAP machine)|Auto Continuous Positive Airway Pressure via nasal mask using the JPAP system (Metran, Saitama, Japan) which can provide CPAP with a range of 2-10 cmH2O, the initial CPAP 2 cmH2O, then reach 7.5 cmH2O after a ramping time. CPAP values may vary with each breath until the obstruction is resolved
48639692|NCT05416281|OTHER|Robotic Vacuum|Participants will be provided with a Roomba iRobot vacuum and will be asked to use the vacuum in their home for 8 weeks. Exposure to environmental exposures will be evaluated before and after the intervention using silicone wristbands.
48303175|NCT01492647|DRUG|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
48480846|NCT06260826|DEVICE|Constant CPAP via facial mask (O2-Max Trio system)|Patients connected to the O2-Max Trio CPAP system (Pulmodyne, Indianapolis, USA) with a facial mask that was adjusted to maintain a CPAP at 7.5 cm H2O and FiO2 30% continuously for the following 1 hour
48480847|NCT00961454|DEVICE|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
48480848|NCT06617091|DRUG|GRAdHIVNE1 Vaccine|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
48480849|NCT06617091|OTHER|Placebo|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
48480850|NCT02463799|DRUG|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
48480851|NCT02463799|BIOLOGICAL|Sipuleucel-T|3 infusions of sipuleucel-T alone
48639693|NCT05893537|DRUG|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
48639694|NCT05893537|DRUG|Placebo Comparator|123 participants will receive a single daily dose of placebo
48303176|NCT01492647|DRUG|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
48639695|NCT03273023|DEVICE|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
48639696|NCT06580769|OTHER|Physical activity|Implementation of a physical activity program, executed through immersive virtual reality
48639697|NCT06693973|DRUG|AcNK-Sup003 cell injection solution|The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
48639698|NCT02615691|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
48639699|NCT02615691|BIOLOGICAL|ITI|Immune tolerance induction therapy
48480852|NCT01577693|DRUG|dutasteride|novel dutasteride
48480853|NCT01577693|DRUG|dutasteride|dutasteride soft gel capsule
48480854|NCT02979457|BEHAVIORAL|Awareness of degree of worry|degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
48480855|NCT05743049|OTHER|Obtaining blood for analysis of various circulating biomarkers|4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
48480856|NCT03302494|DEVICE|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
48480857|NCT03302494|DEVICE|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
48480858|NCT04161183|DEVICE|Extracoporeal shock wave therapy|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
48480859|NCT04161183|DEVICE|Placebo|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
48480860|NCT06610461|DEVICE|HFNO-Treatment|The investigated intervention is the application of HFNO throughout a high-risk upper GI-endoscopy. Concentration of oxygen is 100%. Prior to induction, flow rate is set to 20 l/min and increased to 30 l/min if tolerated by the patient. After induction of anesthesia, flow rate is increased to 60 l/min and maintained throughout the anesthesia.
48480861|NCT00854373|DRUG|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
48480862|NCT00854373|OTHER|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
48480863|NCT00972907|DRUG|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
48480864|NCT03331159|DEVICE|NanoBone|Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
48639700|NCT06059001|DRUG|OMO-103|Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
48303177|NCT03921281|OTHER|scalp acupuncture treatment|"The parameters for scalp acupuncture are set as follows:~1. Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~2. Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~3. Treatment course: three times a week, 12 weeks in total."
48639701|NCT06059001|DRUG|Nab-Paclitaxel|IV infusion - Standard of Care
48480865|NCT03331159|DEVICE|Homologous Bone|Cage was filled with homologous bone
48639702|NCT06059001|DRUG|Gemcitabine|IV infusion - Standard of Care
48639703|NCT05273437|BEHAVIORAL|System identification experiment for physical activity|The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
48639704|NCT04834388|DRUG|Anakinra|Anakinra treatment is started within 8 hours of symptom onset
48639705|NCT06557577|OTHER|No intervention group.|There is no intervention group.
48639706|NCT05394116|DRUG|Garetosmab|Garetosmab is supplied as a liquid drug product and will be administered IV.
48639707|NCT05394116|DRUG|Placebo|Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
48639708|NCT06158477|DRUG|JYP0035 Experimental Drug Treatment|Single dose intervention
48639709|NCT05317455|DRUG|Dichloroacetate|Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
48639710|NCT06085209|DEVICE|The truFreeze Spray Cryotherapy|A novel FDA cleared technique that allows for liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.
48639711|NCT06085209|DEVICE|Ballon dilation|An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3-9 atm) using a syringe and pressure manometer.
48639712|NCT06085209|DEVICE|Radial Incision|Carbon dioxide (CO2) laser or Monopolar electrocautery knife
48639713|NCT05336721|DRUG|Chiauranib|25mg/35mg/50mg orally once daily
48303178|NCT03921281|OTHER|Rehabilitation Treatment|The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
48303179|NCT02758886|BEHAVIORAL|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
48480866|NCT02430415|DEVICE|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
48480867|NCT02430415|DEVICE|traditional lightwand intubation|traditional lightwand intubation
48480868|NCT02591212|BEHAVIORAL|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
48639714|NCT05336721|DRUG|capecitabine|1000mg/m2 on Days 1-14 in a repeating 21-day cycle
48639715|NCT06275412|BEHAVIORAL|The 3Ms 2.0 Intervention|The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
48639716|NCT06275412|BEHAVIORAL|Educational Attention Control (EAC)|The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
48639717|NCT06159673|DRUG|ACP-204|ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
48639718|NCT06159673|DRUG|Placebo|ACP-204 matching placebo
48655975|NCT01561469|DRUG|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
48303180|NCT02758886|BEHAVIORAL|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
48303181|NCT02758886|BEHAVIORAL|Observing human-animal interaction|Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
48303182|NCT00158652|PROCEDURE|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
48303183|NCT00158652|PROCEDURE|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
48303184|NCT00158652|PROCEDURE|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
48303185|NCT00158652|DRUG|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
48303186|NCT05146232|OTHER|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
48303187|NCT05146232|OTHER|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
48303188|NCT05146232|OTHER|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
48303189|NCT05146232|OTHER|First postoperative analgesia|IV acetaminophen will be administered every 6 h
48639719|NCT06694285|DIAGNOSTIC_TEST|Ultrasound evaluation|The subjects will constitute a cohort whose medical history, clinical, ultrasound and treatment data reported in the appropriate data collection form will be prospectively collected. Enrolled patients will undergo clinical and ultrasonographic evaluation in a manner not unlike routine clinical practice.
48303190|NCT05146232|OTHER|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
48303191|NCT01556945|BIOLOGICAL|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
48303192|NCT01556945|BIOLOGICAL|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
48303193|NCT01556945|OTHER|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
48303194|NCT01556945|OTHER|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
48303195|NCT05441150|DRUG|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
48303196|NCT05441150|DRUG|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
48303197|NCT05251935|OTHER|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
48303198|NCT05251935|COMBINATION_PRODUCT|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
48303199|NCT06274411|PROCEDURE|Standby cannulated ECMO|Femoral cannulas are inserted and connected to the primed circuit. Clamps are kept on circuit, and ECMO is on standby during PCI. ECMO is initiated if needed.
48303200|NCT06274411|PROCEDURE|Prophylactic ECMO|Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI.
48303201|NCT05791318|DRUG|VYD222|Monoclonal antibody
48303202|NCT05791318|OTHER|Placebo|Matching Placebo
48639720|NCT06260748|DRUG|Chenodeoxycholic acid|250mg capsules
48639721|NCT06260748|DRUG|Chenodeoxycholic acid Placebo|Placebo to match
48639722|NCT01063881|DRUG|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
48639723|NCT03390673|DRUG|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
48639724|NCT03390673|DRUG|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
48639725|NCT06694909|DEVICE|tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
48639726|NCT06694909|DEVICE|sham tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
48303203|NCT02381756|DEVICE|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
48303204|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
48303205|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
48303206|NCT02717689|OTHER|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
48303207|NCT00440128|DRUG|Docetaxel|Docetaxel
48303208|NCT00440128|DRUG|Casopitant/Docetaxel|Casopitant/Docetaxel
48303209|NCT06555965|OTHER|Non-interventional study|There is no planned intervention in this study
48303210|NCT05110898|DRUG|fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg|Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
48639727|NCT06694909|DEVICE|tDCS + PNS without action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
48639728|NCT06694909|DEVICE|sham tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
48639729|NCT06694909|DEVICE|tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
47955873|NCT05586893|DEVICE|Acupuncture therapy and Electroacupuncture|"We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
47955874|NCT06556836|DEVICE|Doppler color and M-Mode ultrasound|A diagnostic test intervention using color Doppler and M-Mode ultrasound will be conducted to localize the catheter within the epidural space and compared with epidurography.
47955875|NCT06556836|DEVICE|Epidurography|An epidurography is an imaging procedure used to visualize the epidural space of the spine. The process involves inserting an epidural catheter, through which a contrast dye is injected. Fluoroscopy or X-rays are then used to capture real-time images of the contrast flow, helping to ensure the catheter's correct placement and to detect any localization anomalies. In this study, the epidurography will be performed in the radiology department by a radiologist and a pain management interventionist.
47955876|NCT02423993|BEHAVIORAL|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
47955877|NCT02423993|DEVICE|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
47955878|NCT02423993|DEVICE|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
47955879|NCT02423993|PROCEDURE|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
47955880|NCT02423993|PROCEDURE|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
48109876|NCT05667480|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
48109877|NCT05667480|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and pre-recorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
48109878|NCT01340079|BEHAVIORAL|virtual world|health education using virtual world Second Life
48109879|NCT01340079|BEHAVIORAL|face to face|health education delivered in face to face groups
48109880|NCT00242853|PROCEDURE|Power doppler ultrasonography|
48109881|NCT00242853|PROCEDURE|High frequency ultrasonography|
48480869|NCT02591212|BEHAVIORAL|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
48480870|NCT01027767|DEVICE|Molecular Breast Imaging|Molecular Breast Imaging
48480871|NCT01800435|DRUG|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
48480872|NCT01800435|DRUG|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
48639730|NCT06694805|DRUG|CAB LA + RPV LA|Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.
48639731|NCT06694805|DRUG|Oral ART|Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.
48639732|NCT04267926|DRUG|20 mg MitoQ|a third of subject will receive 20mg of oral MitoQ
48639733|NCT04267926|DRUG|Placebo|Subject will receive Placebo
48639734|NCT04267926|DRUG|40mg of MitoQ|a third of subjects will receive 40mg of MitoQ
47955881|NCT02423993|PROCEDURE|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
47955882|NCT02423993|PROCEDURE|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
47955883|NCT04295772|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
47955884|NCT04716907|GENETIC|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
47955885|NCT04716907|BIOLOGICAL|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
47955886|NCT04716907|DIAGNOSTIC_TEST|CT Scan|Thymus and lung imaging
47955887|NCT04716907|BIOLOGICAL|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
47955888|NCT06206642|DIAGNOSTIC_TEST|PET/CT|Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.
47955889|NCT02718560|BEHAVIORAL|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
47955890|NCT00002532|BIOLOGICAL|filgrastim|
47955891|NCT00002532|DRUG|asparaginase|
47955892|NCT00002532|DRUG|cytarabine|
47955893|NCT00002532|DRUG|daunorubicin hydrochloride|
47955894|NCT00002532|DRUG|dexamethasone|
47955895|NCT00002532|DRUG|etoposide|
47955896|NCT00002532|DRUG|idarubicin|
47955897|NCT00002532|DRUG|ifosfamide|
48480873|NCT06340906|OTHER|Electroacupuncture|EA at 10 standardized acu-points that were chosen for their therapeutic effects: Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6), Shenmen (HT7), Hegu (LI4) bilateral, Zusanli (ST36), Sanyinjiao (SP6), Zhaohai (KI6), Taichong (LR3) bilateral, Tian Shu (ST25) bilateral.
47955898|NCT00002532|DRUG|leucovorin calcium|
48109882|NCT00242853|PROCEDURE|Exhaled nitric oxide assessment|
48639735|NCT05954962|DRUG|Progesterone 200 MG|"The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation."
48639736|NCT05954962|DRUG|Ganirelix Acetate|The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
47955899|NCT00002532|DRUG|methotrexate|
47955900|NCT00002532|DRUG|prednisolone|
48109883|NCT02866435|DRUG|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
48109884|NCT02866435|DRUG|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
47955901|NCT00002532|DRUG|vindesine|
47955902|NCT03468803|DIAGNOSTIC_TEST|Beta D Glucan test|Measurement of BDG before, during and after surgery
47955903|NCT06189690|DEVICE|rTMS|Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
47955904|NCT04899102|BEHAVIORAL|Time-Restricted, Intermittent Fasting|A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
47955905|NCT05862831|BIOLOGICAL|PM1003 Injection|Subjects will receive PM1003 by intravenous administration.
47955906|NCT03757156|OTHER|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
47955907|NCT04748146|OTHER|Brain stimulation|Theta-burst stimulation will be applied to selected regions of distributed networks to test whether distal stimulation can modulate hippocampus-mediated episodic recollection.
47955908|NCT01594671|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
47955909|NCT01594671|DRUG|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
47955910|NCT01594671|OTHER|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
47955911|NCT00000471|BEHAVIORAL|diet, vegetarianism|
47955912|NCT00000471|BEHAVIORAL|diet, fat-restricted|
47955913|NCT00000471|BEHAVIORAL|exercise|
47955914|NCT00000471|BEHAVIORAL|smoking cessation|
47955915|NCT01374841|DRUG|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
47955916|NCT01374841|OTHER|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
47955917|NCT00121095|DRUG|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
47955918|NCT00938236|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
47955919|NCT02903641|BEHAVIORAL|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
48303211|NCT05110898|DRUG|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
48303212|NCT05521997|DRUG|Telaglenastat|-800 mg twice per day by mouth
48303213|NCT05521997|RADIATION|Radiation treatment|"* Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy."
48303214|NCT05521997|DRUG|Cisplatin|"* Standard of care~* Weekly administration of cisplain"
48303215|NCT01753115|BIOLOGICAL|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
48303216|NCT01753115|DRUG|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
48303217|NCT00230386|DEVICE|MRI|
48303218|NCT01861340|DRUG|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
48303219|NCT04930640|DIETARY_SUPPLEMENT|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week
48303220|NCT04930640|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
48109885|NCT02866435|DRUG|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
48303221|NCT05870501|DRUG|Ketamine|0.5mg/kg IV infusion
48303222|NCT05870501|DRUG|Midazolam|0.045mg/kg IV infusion
48303223|NCT04294264|DRUG|Oxaliplatin|Given IV
48303224|NCT04294264|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
48303225|NCT06692582|OTHER|Electrolysed saline rinse|EOS ph = 7, 200 ppm free available Chlorine
48303226|NCT04996849|OTHER|Data Capture|Data collected
48303227|NCT04996849|OTHER|Questionnaire Administration|Ancillary studies
48303228|NCT06352437|DRUG|BI 3034701|BI 3034701
48303229|NCT06352437|DRUG|Placebo matching BI 3034701|Placebo matching BI 3034701
47955920|NCT02903641|BEHAVIORAL|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
47955921|NCT03846804|DIAGNOSTIC_TEST|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
47955922|NCT00897208|OTHER|high performance liquid chromatography|
47955923|NCT00897208|OTHER|laboratory biomarker analysis|
47955924|NCT00897208|OTHER|mass spectrometry|
48109886|NCT03123172|DIAGNOSTIC_TEST|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
48109887|NCT00243854|DRUG|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
48303230|NCT02963467|PROCEDURE|cigarette|smoking 4 conventional cigarettes
48303231|NCT02963467|PROCEDURE|"dummy cigarette"|"smoking a dummy cigarette"
48639737|NCT06694727|DIETARY_SUPPLEMENT|Coenzyme Q10 100 Milligrams Oral Capsule|100 mg capsules given twice daily, per oral use.
47955925|NCT00897208|OTHER|medical chart review|
47955926|NCT00897208|PROCEDURE|evaluation of cancer risk factors|
47955927|NCT05341687|OTHER|No applicable|No applicable
48109888|NCT01830010|DRUG|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
48303232|NCT05816616|DIAGNOSTIC_TEST|Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI|Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
48303233|NCT00002442|DRUG|Indinavir sulfate|
48303234|NCT00002442|DRUG|Nelfinavir mesylate|
48303235|NCT00002442|DRUG|Lamivudine|
48303236|NCT00002442|DRUG|Stavudine|
48303237|NCT03911544|DEVICE|BIS monitor|Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
48303238|NCT02974062|OTHER|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
48303239|NCT02160977|PROCEDURE|total knee arthroplasty|
48303240|NCT02207530|DRUG|MEDI4736|MEDI4736 monotherapy
48303241|NCT05099757|BIOLOGICAL|20 µg dose hepatitis B vaccine|one-dose, two-dose or three-dose, 20 µg per dose
48303242|NCT04854265|OTHER|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
48303243|NCT01723501|DRUG|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
48303244|NCT01723501|DRUG|sterile water|Sterile water wipes (placebo)
48303245|NCT03619148|DEVICE|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen
48303246|NCT05317663|BEHAVIORAL|Test Health Warning Label (HWL)|Effect of Health Warning Label (HWL)
48303247|NCT05317663|BEHAVIORAL|Test without Health Warning Label (no-HWL)|Effect of no Health Warning Label (no-HWL)
48639738|NCT06694727|DIETARY_SUPPLEMENT|Selenium 100 Micrograms Oral Tablets|100 μg tablets given twice daily, per oral use.
48303248|NCT05674747|DEVICE|Swift Microwave treatment - weekly x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
48303249|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
48303250|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 24wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
48303251|NCT04805021|OTHER|no intervention|no intervention
48303252|NCT02154269|DRUG|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
48303253|NCT02154269|DRUG|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
48303254|NCT01585129|DRUG|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
48303255|NCT01585129|DRUG|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
48303256|NCT00382096|DRUG|Vildagliptin|
48303257|NCT00382096|DRUG|Metformin|
48303258|NCT00382096|DRUG|Vildagliptin + Metformin|
48303259|NCT02807454|DRUG|Daratumumab|
48303260|NCT02807454|DRUG|Durvalumab|
48303261|NCT02807454|DRUG|Pomalidomide|
48303262|NCT02807454|DRUG|Dexamethasone|
48303263|NCT00461266|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
48303264|NCT00461266|DRUG|Antiretroviral therapy|As prescribed
48303265|NCT01439529|OTHER|Device programming: nominal|CRT device is programmed to nominal values
48303266|NCT01439529|OTHER|Programming optimization by QRS|CRT device is programmed by QRS optimization
48303267|NCT05183581|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
48303268|NCT01058174|DRUG|micafungin|intravenous infusion
48303269|NCT01058174|DRUG|fluconazole|intravenous infusion
48303270|NCT01058174|DRUG|liposomal amphotericin B|intravenous infusion
48303271|NCT01058174|DRUG|caspofungin|intravenous infusion
47955928|NCT01592682|BEHAVIORAL|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
47955929|NCT00263731|OTHER|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
47955930|NCT06276673|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity wall squats. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
47955931|NCT06382948|DRUG|Everolimus|Patients will receive 7.5 mg of everolimus orally once daily.
47955932|NCT06382948|DRUG|Elacestrant|Patients will receive elacestrant 345 mg orally once daily
47955933|NCT06382948|DRUG|Placebo|Patients will receive placebo orally once daily
48303272|NCT05309590|DRUG|Dose|The outcomes of reducing to half of the topical steroid (i.e. fluticasone \[Flovent\] and Swallowed viscous budesonide \[Pulmicort\]) will be observed with regards to whether the patients continue to be in histologic remission. These patients will have already achieved remission on a full dose of the steroid.
48303273|NCT06513364|DRUG|WH002|"Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."
48303274|NCT06513364|DRUG|paclitaxel injection|"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."
48303275|NCT05975580|DRUG|Topiramate|Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
48303276|NCT05975580|DRUG|Phentermine|Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
48303277|NCT05975580|DRUG|Placebo|Placebo is an inactive substance.
48303278|NCT05182502|DEVICE|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
48303279|NCT06503653|DIAGNOSTIC_TEST|syncope channel|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.~No additional procedures, invasive or non-invasive explorations or blood sampling not provided for as part of routine care will be offered or carried out as part of the study.~The only change in practice for patients included in the syncope pathway The only change in practice concerns the grouping of patients included in the syncope pathway into a single day at a day hospital within 10 days of their emergency consultation."
48303280|NCT06503653|DIAGNOSTIC_TEST|routine care|"The procedures and investigations proposed for the etiological diagnosis of low-risk or neither high nor low syncope and included in the study are those recommended by the European Society of Cardiology.in routine care, medical examinations are carried out by specialists such as cardiologists who do not practice in hospitals"
48303281|NCT02016157|DRUG|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
48303282|NCT03285880|BEHAVIORAL|Napping|Children nap during the nap opportunity
47955934|NCT06382948|DRUG|Auxiliary Medicinal Product - Dexamethasone|10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
47955935|NCT06382948|DRUG|Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues|According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.
47955936|NCT00454623|BEHAVIORAL|drawing serum adiponectin level|
47955937|NCT05783375|OTHER|ADUNU program for delivery of RHD care services|The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
47955938|NCT06427824|OTHER|Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)|An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.
48303283|NCT05938439|DEVICE|MAGUS placement|"An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:~* Placement through the endoscope of a soft guidewire through the upper GI tract;~* Insertion of the MAGUS system on the guidewire;~* Advancement of the MAGUS system until proximal magnet reach the top of the septum;~* Release and placement of the proximal magnet at the bottom of the septum, pouch side;~* Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;~* Release of the distal magnet and activate the retractable wire;~* Insure that wire is not blocked and unblocked it if applicable.~Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets."
47955939|NCT06427824|OTHER|Geriatric Service/ Discharge Planning|A geriatric team will meet with participants after surgery to help them reinforce the strategies they learned in the education video sessions. As part of a geriatric service, this team will also help participants plan/coordinate their discharge from the hospital after surgery.
47955940|NCT06427824|OTHER|Questionnaires|These questionnaires will ask about the participants' mobility, frailty, quality of life and additional health/risk factors before and after surgery.
47955941|NCT05038943|DEVICE|Paragonix SherpaPak Cardiac Transport System|Transportation of cardiac allografts in a device maintaining constant optimal temperature to minimize freezing tissue injury
47955942|NCT00812682|DRUG|Symbicort|
47955943|NCT03146377|DRUG|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
47955944|NCT03146377|DRUG|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
48303284|NCT05152147|DRUG|Zanidatamab|Administered IV
47955945|NCT03146377|DRUG|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
47955946|NCT05092646|BIOLOGICAL|Axolotl Ambient|Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
47955947|NCT05092646|DRUG|"Drug/Placebo: 0.9% Normal Saline"|"Drug/Placebo: 0.9% Normal Saline"
47955948|NCT05357638|BEHAVIORAL|High Intensity Interval Training (HIIT)|8 weeks of HIIT, 2x/week for about 30 minutes/session on a cycle ergometer
47955949|NCT05357638|BEHAVIORAL|Continuous Aerobic Training (CAT)|8 weeks of CAT, 2x/week for about 50 minutes/session on a cycle ergometer
47955950|NCT05357638|BEHAVIORAL|Movement Advice|Weekly step goal, monitored using an activity tracker, +3000 steps/day for 5 days/week, step goal is based on average step count in the 4 weeks of baseline prior to the intervention
47955951|NCT01529242|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
48109889|NCT01830010|DRUG|Study Part 2: KRP203 lower dose|
48109890|NCT01830010|DRUG|Study Part 2: KRP203 higher dose|
48303285|NCT05152147|DRUG|Tislelizumab|Administered IV
48303286|NCT05152147|DRUG|Trastuzumab|Administered intravenously (IV)
48303287|NCT05152147|DRUG|Capecitabine|Administered orally (PO bid)
48303288|NCT05152147|DRUG|Oxaliplatin|Administered IV
47955952|NCT01529242|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
47955953|NCT00889408|BIOLOGICAL|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
47955954|NCT00579878|DRUG|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
48109891|NCT03145246|PROCEDURE|regeneration treated teeth loss|number of regeneration treated teeth loss
48480874|NCT06332313|PROCEDURE|erector spina plane block|ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.
48109892|NCT03145246|PROCEDURE|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
48109893|NCT05383313|DRUG|Psilocybin|Effect of psilocybin on treatment-resistant depression
48303289|NCT05152147|DRUG|Cisplatin|Administered IV
48480875|NCT00144833|DRUG|fosamprenavir/ritonavir (700mg/100mg BID)|
48480876|NCT00144833|DRUG|fosamprenavir/ritonavir (1400mg/100mg BID)|
48639739|NCT06695676|DIAGNOSTIC_TEST|Global Longitudinal Strain|Global longitudinal strain measurement is a more objective method to determine left ventricular systolic function than traditional eyeballing method. It helps to detect and quantify subtle changes even so it is an emerging method to evaluate the cardiotoxicity of chemotherapeutic drugs. It is planned to compare each selected patient's GLS measurement before starting to use lurasidone and after six months of using it. Hereby our aim is to find if lurasidone has any effect on left ventricular systolic function.
48639740|NCT05925972|PROCEDURE|Plane block|Plane block application in laparoscopic hysterectomies
48639741|NCT06567873|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
48639742|NCT06694389|BIOLOGICAL|mRNA-1083|Suspension for injection
48480877|NCT00144833|DRUG|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
48480878|NCT06429514|DIETARY_SUPPLEMENT|Ganoderma lucidum spore powder|One bag at a time, 2 times a day, 2g / bag
48480879|NCT06429514|OTHER|placebo|One bag at a time, 2 times a day, 2g / bag
48480880|NCT02252523|DRUG|Dexmedetomidine|
48480881|NCT01132664|DRUG|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
48480882|NCT01132664|DRUG|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
48480883|NCT01132664|DRUG|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
48480884|NCT01633294|DRUG|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
48109894|NCT05383313|DRUG|Ketamine Hydrochloride|Effect of ketamine on treatment-resistant depression
48109895|NCT05383313|DRUG|Midazolam Ph. Eur 9.0|Effect of midazolam on treatment-resistant depression
48109896|NCT04998903|PROCEDURE|Fiberoptic Bronchoscopy|Fiberoptic bronchoscopy done under conscious sedation
48109897|NCT02040935|DRUG|Trastuzumab|600 mg SC Q3W by SID
48303290|NCT05152147|DRUG|5-Fluorouracil|Administered IV
48303291|NCT06519435|DEVICE|Mayo Dopplex ABIlity|Device used to measure lower extremity venous hemodynamic pressure
48480885|NCT01247779|PROCEDURE|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
48480886|NCT01247779|PROCEDURE|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
48480887|NCT05924867|OTHER|plasma activated saline|The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
48639743|NCT06694389|OTHER|Placebo|0.9% sodium chloride suspension for injection
48639744|NCT06694389|BIOLOGICAL|Licensed Influenza Vaccine|Aqueous injectable (SC) or suspension for injection (IM)
48639745|NCT06694389|BIOLOGICAL|SARS-CoV-2 Vaccine|Suspension for injection
48639746|NCT06695286|OTHER|Multimodal rehabilitation training at high intensity|"In High Intensive Training patients received 1800 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week.~Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise.~No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
48639747|NCT06695286|OTHER|Multimodal rehabilitation training at low intensity|"In Low Intensive Training patients received less than 900 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week. Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise. No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL."
48639748|NCT05494359|DIAGNOSTIC_TEST|The nitrogen isotope|The nitrogen isotope of various mass in oral gas were detected.
48639749|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program Only (Control)|Participants in the control group will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks.
48639750|NCT06695104|BEHAVIORAL|YMCA Produce Rx (YPRx) Program + the Diabetes Prevention Program (DPP)|Participants will receive weekly, home-delivered produce bags of fresh vegetables and fruits and sized for each participants' household. Produce deliveries will be administered for 52 weeks. Additionally, participants will be registered for a free, year-long YMCA membership and enrolled in the DPP. Through the DPP, participants will receive health education, coaching, and peer support via 26 virtual group sessions over a year.
48639751|NCT05035927|DRUG|TRYP-0082|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
48639752|NCT05035927|BEHAVIORAL|Psychotherapy|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
48639753|NCT06694376|OTHER|No intervention|No intervention.
48639754|NCT04928339|DRUG|Bupivacaine Injection|10mL of 0.25% bupivacaine
48639755|NCT04928339|DRUG|Liposomal bupivacaine|15mL of 133mg liposomal bupivacaine
48639756|NCT04928339|OTHER|Saline|25mL saline control
48639757|NCT01399099|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
48639758|NCT05999292|DRUG|68Ga-R8760 injection at pre-defined dose levels|PET/CT imaging at predefined timepoints
48639759|NCT05999292|DRUG|68Ga-R8760 injection|PET/CT imaging at a single timepoint
48303292|NCT06519435|DEVICE|Intermittent Pneumatic Compression (IPC)|Device used to measure lower extremity venous hemodynamic pressure
48303293|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
48303294|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
48303295|NCT01629667|OTHER|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
48303296|NCT03491163|DIAGNOSTIC_TEST|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
48480888|NCT05924867|OTHER|Routine nursing|For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.
48639760|NCT06561204|DEVICE|FMET|A full-mouth electronic toothbrush
48639761|NCT06694714|DRUG|0.5 ml lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
48639762|NCT06694714|DRUG|1.0 ml lidocaine + epinephrine 1:100,000|1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
48639763|NCT06694142|BEHAVIORAL|Rosy app|Participants will be provided a six-month membership subscription to the mobile application ROSY. ROSY will recommend pathways for addressing issues through 1) coaching by board certified coaches or 2) joining a completely anonymous community with other people where they can share experiences and get help as new members of the community to overcome sexual health challenges .Users will work towards their health goals each day using tools from medical and mental health experts . Tools used include 1) virtual workshops and 2) coaching sessions which will provide the opportunity to a) Have an authentic and relatable conversation with an expert b) Explore new pathways to better health experience c) Improve their relationship with themselves, partner, and healthcare providers d) Learn fun ways to improve their everyday wellness e) Access live events from anywhere.
48639764|NCT04568902|DRUG|H3B-6545|H3B-6545 oral tablets.
48639765|NCT04568902|DRUG|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
48639766|NCT06694623|PROCEDURE|Apically positioned flap|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures.
48303297|NCT05904405|OTHER|quationaire|"Data will be collected through a semi-structured interview administered questionnaire which includes:~1. Socio-demographic characteristics of women~2. Family planning practice: This will include number of living children, current use of FP method and its type, and suggested causes of discontinuation of FP, previous contraceptive use, and reason for the visit 3-Facility factors such as gender of providers, qualification of providers, type of the health facility.~4-Quality of contraceptive counseling (QCC) scale: it is a 22-item scale which measures the quality of care received by women during family planning visits. It includes : 1) information exchange, 2) interpersonal relations, and 3) disrespect and abuse in contraceptive counseling. The information exchange subscale consists of ten items, the interpersonal relationship subscale consists of seven items, and the disrespect and abuse subscale consists of five items."
48303298|NCT04080154|DRUG|Anlotinib|12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
48303299|NCT01539837|DRUG|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
48639767|NCT06694623|PROCEDURE|Apically positioned flap with FGG strip|The split thickness flap was apically positioned as much as possible and sutured to the periosteum utilizing T-mattress sutures. FGG strip was sutured to the apical end of recipient bed.
48303300|NCT01539837|DRUG|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
48303301|NCT01539837|DRUG|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
48303302|NCT00637273|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
48303303|NCT00637273|DRUG|sitagliptin|oral tablet, 100mg, once a day
48303304|NCT00637273|DRUG|pioglitazone|oral tablet, 45mg, once a day
48639768|NCT06694038|PROCEDURE|Needle Knife Fistulotomy|Biliary access using needle knife fistulotomy technique
48639769|NCT06694038|PROCEDURE|standard biliary cannulation|standard biliary cannulation
48639770|NCT06695481|PROCEDURE|Conventional RF|The conventional RF group consists of patients who received medial branch RF with a duration of 2 minutes, at 80̊ C temperature, and 7 Volts.
48303305|NCT00637273|DRUG|placebo tablet|oral tablet, once a day
48303306|NCT00637273|DRUG|placebo once weekly|subcutaneous injection, once a week
48303307|NCT00615940|DRUG|WX-671|capsules taken per os once daily until progression or toxicity
48303308|NCT00615940|DRUG|placebo|capsule taken per os once daily until progression or toxicity
48639771|NCT06695481|PROCEDURE|Combined RF|In the combined RF group, treatment was initiated first with a conventional RF duration of 2 minutes at a temperature of 80̊ C at 7 Volts. Then, pulsed RF duration was applied for 6 minutes at a temperature of 42 C at 45 Volts, with a pulse frequency of 2 Hz and a width of 20 ms.
48639772|NCT01517100|OTHER|Nabilone|CB agonist
48639773|NCT01517100|DRUG|CP-945,598|Cannabinoid Receptor 1 antagonist
48639774|NCT01517100|OTHER|hyperglycemic clamp|assesses beta cell response
48639775|NCT01517100|OTHER|euglycemic-hyperinsulinemic clamp|measures insulin sensitivity
48639776|NCT01517100|OTHER|Nabilone|cannabinoid receptor agonist
48303309|NCT02639117|DRUG|Vismodegib|Vismodegib 150 mgs po qd for 3 months
48303310|NCT05544825|DIETARY_SUPPLEMENT|Ice plant group|Ice plant extract 2,000 mg/day for 12 weeks
48303311|NCT05544825|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
48639777|NCT04217057|DRUG|64Cu-DOTA-ECL1i|Will be produced by the Cyclotron Facility at Washington University School of Medicine
48639778|NCT05958017|BEHAVIORAL|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
48303312|NCT05942898|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
48303313|NCT01883882|BEHAVIORAL|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
48639779|NCT05958017|OTHER|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
48639780|NCT06395714|OTHER|Personnalized physiotherapy|"Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist responsible for the rehabilitation."
48639781|NCT06395714|OTHER|Usual physiotherapy|"Following completion of the ankle go test, patients in active comparator group will receive usual physiotherapy"
48639782|NCT03036488|BIOLOGICAL|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
48639783|NCT03036488|DRUG|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
48639784|NCT03036488|DRUG|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
48303314|NCT01106534|DRUG|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
48480889|NCT04079491|OTHER|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
48639785|NCT03036488|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
48639786|NCT03036488|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
48639787|NCT03036488|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
48303315|NCT01106534|DRUG|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
48303316|NCT01106534|DEVICE|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
47955955|NCT00579878|DRUG|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
47955956|NCT00579878|DRUG|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
47955957|NCT00145782|BEHAVIORAL|Life style|
47955958|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
47955959|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
47955960|NCT00900107|PROCEDURE|Exercise|
47955961|NCT04131725|DEVICE|Cardiac Performance System (NSR)|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
47955962|NCT01582568|DRUG|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
48303317|NCT01963117|RADIATION|Combined hyperthermia and radiation therapy|
48639788|NCT03036488|DRUG|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
48639789|NCT03036488|BIOLOGICAL|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
47955963|NCT03120234|DRUG|Dexmedetomidine|
47955964|NCT03120234|DRUG|Ketamine|
48303318|NCT04323397|DEVICE|Non-invasive ventilation|Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher \& Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow \> 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
48480890|NCT01404052|DEVICE|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
48480891|NCT01010789|DRUG|Armodafinil|flexible dose 150-250mg/day
48480892|NCT01010789|DRUG|Armodafinil|150-250mg/day; flexible dose
48480893|NCT01010789|DRUG|Matching placebo|Placebo comparator
48480894|NCT03001999|BEHAVIORAL|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
47955965|NCT03120234|DRUG|Fentanyl|
47955966|NCT03120234|DRUG|Placebos|o.9% normal saline will be used instead of ketamine
48639790|NCT05788328|DRUG|Dabigatran etexilate (DE)|Dabigatran etexilate (DE) as oral capsule
47955967|NCT00657358|DRUG|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
47955968|NCT03383458|BIOLOGICAL|Nivolumab|Specified dose on specified days
47955969|NCT03383458|OTHER|Placebo|specified dose on specified days
47955970|NCT00163878|PROCEDURE|Sensory Stimulation|
48639791|NCT05788328|DRUG|Rosuvastatin|Rosuvastatin as oral tablet
48639792|NCT05788328|DRUG|PF-07081532|PF-07081532 as oral tablets
47955971|NCT00163878|DEVICE|Sesnory Modality Assessment and Rehabilitation Technique|
47955972|NCT01784848|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
47955973|NCT01784848|OTHER|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
47955974|NCT00398788|DRUG|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
48303319|NCT03574467|BEHAVIORAL|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
48639793|NCT06695884|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized. Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
48639794|NCT06694350|DRUG|Pembrolizumab+Flutamide|Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
48639795|NCT06246721|BEHAVIORAL|Self-management of vaginal pessary|Self-management of vaginal pessary
48639796|NCT05467150|DIETARY_SUPPLEMENT|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
48639797|NCT06249386|BEHAVIORAL|Behavioral Activation (BA)|BA reduces alcohol use and posttraumatic stress symptoms and increases psychosocial functioning via psychoeducation, activity monitoring, values clarification, and activity scheduling.
48639798|NCT06249386|BEHAVIORAL|Relapse Prevention (RP)|RP reduces alcohol use via increasing awareness and avoidance of high-risk situations, enhancing drink refusal skills, improving assertiveness, and other strategies.
48639799|NCT06177912|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
47955975|NCT03909646|DRUG|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
47955976|NCT03909646|DRUG|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
47955977|NCT03909646|OTHER|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
47955978|NCT06556498|PROCEDURE|Proflor group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Proflor mesh.
47955979|NCT06556498|PROCEDURE|Progrip group|evaluate the surgical outcomes of patients underwent to laparoscopic inguinal hernia repair with Progrip mesh.
47955980|NCT05948787|BEHAVIORAL|Psychosocial intervention|A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.
48303320|NCT04657289|DRUG|Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
48303321|NCT04657289|DEVICE|Port Delivery System with Ranibizumab|"Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals~Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals"
48639800|NCT06177912|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
48639801|NCT02003209|DRUG|Aromatase Inhibition Therapy|Given at the investigator's discretion
48639802|NCT02003209|DRUG|Carboplatin|Given IV
47955981|NCT06400303|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
47955982|NCT06400303|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
47955983|NCT05449548|DRUG|Lenalidomide 10 mg|All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
48639803|NCT02003209|OTHER|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
48639804|NCT02003209|DRUG|Docetaxel|Given IV
48639805|NCT02003209|DRUG|Goserelin Acetate|Given SC
48639806|NCT02003209|OTHER|Laboratory Biomarker Analysis|Correlative studies
48639807|NCT02003209|BIOLOGICAL|Pertuzumab|Given IV
48639808|NCT02003209|OTHER|Quality-of-Life Assessment|Ancillary studies
48639809|NCT02003209|PROCEDURE|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
48639810|NCT02003209|BIOLOGICAL|Trastuzumab|Given IV
48639811|NCT02003209|RADIATION|Whole Breast Irradiation|Undergo whole breast irradiation
47955984|NCT03542123|DEVICE|NeuroTronik CANS Therapy® System|The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
47980585|NCT06248892|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48109898|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intravenously|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intravenously. The nominal doses were similar, volunteers were randomly assigned to receive a single dose of MEP by IV bolus of 1.5 mL. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
48303322|NCT06650761|DRUG|CDX-622|Up to 3 infusions of one of seven dosages of CDX-622
48303323|NCT06650761|DRUG|Normal Saline|Up to 3 infusions of Normal Saline
48480895|NCT02663882|BEHAVIORAL|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
48639812|NCT05424315|DRUG|Dapagliflozin 10mg|10mg Tab once daily
48639813|NCT05424315|DRUG|Glucose Tab|Placebo Oral Tablet
48639814|NCT03742102|DRUG|Durvalumab|Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
48639815|NCT03742102|DRUG|Capivasertib|Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
48639816|NCT03742102|DRUG|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
48639817|NCT03742102|DRUG|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
48109899|NCT05649878|DRUG|Evaluation of bioavailability of methylprednisolone succinate administered intranasally|Bioavailability of methylprednisolone in healthy subjects of both genders, when administered intranasally. Volunteers were randomly assigned to receive a single dose of MEP intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
48109900|NCT02263508|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec administered by intratumoral injection
48109901|NCT02263508|DRUG|Pembrolizumab|Administered at a dose of 200 mg as an intravenous infusion over approximately 30 minutes.
48109902|NCT02263508|DRUG|Placebo|Administered by intratumoral injection
48303324|NCT02094586|BIOLOGICAL|PXVX0200 Lot A|Lot P700-1CA03
48303325|NCT02094586|BIOLOGICAL|PXVX0200 Lot B|Lot P700-3CA03
48303326|NCT02094586|BIOLOGICAL|PXVX0200 Lot C|Lot P700-6BA03
48303327|NCT02094586|BIOLOGICAL|Placebo|Placebo
48303328|NCT04742257|DEVICE|MyoRegulator® device|Trans-spinal DCS paired with peripheral DCS
48303329|NCT03083158|DRUG|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
48303330|NCT02107391|BIOLOGICAL|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
48303331|NCT02107391|DRUG|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
48303332|NCT02107391|DRUG|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
48639818|NCT03742102|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
48639819|NCT03742102|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
48639820|NCT04423367|DRUG|bortezomib/dexamethasone|Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.
48639821|NCT04573075|PROCEDURE|Ghost ileostomy|a loop of the small bowel is marked with a silicone strap and externalized through the abdominal wall to avoid a loop ileostomy
48639822|NCT04573075|PROCEDURE|loop ileostomy|a protective loop ileostomy is applied after after colorectal resection and forming of a primary anastomosis
48639823|NCT04573075|PROCEDURE|no outlet|no further intervention is used after colorectal resection and forming of a primary anastomosis
48639824|NCT06671054|DRUG|AP1189, 40 mg|AP1189 tablets for oral use
48639825|NCT06671054|DRUG|AP1189, 70 mg|AP1189 tablets for oral use
48639826|NCT06671054|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
48109903|NCT03582618|DRUG|Sorafenib|Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
48109904|NCT03582618|DRUG|CVM-1118|CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
48109905|NCT04801329|DRUG|Vyndamax (tafamidis 61mg)|As prescribed in real world practice
48303333|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|
48303334|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
48303335|NCT04756635|OTHER|Experimental Group|This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values \<135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
48303336|NCT02333240|OTHER|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
48303337|NCT03244891|OTHER|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~1. baseline~2. after fluid shift induced by passive head down position at 15 degrees~3. after fluid challenge with Ringer acetate 15ml\*kg in head down position~A total of six steps will be considered for the analysis"
48639827|NCT06671054|DRUG|AP1189 matching placebo|AP1189 tablets for oral use
48303338|NCT03244891|OTHER|Ventilation mode|"Each previous step will be done in two respiratory conditions:~1. spontaneous breathing~2. noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
48303339|NCT03483688|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
48303340|NCT01143597|OTHER|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
48303341|NCT06115421|DRUG|Roxadustat|hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
48109906|NCT04483063|DRUG|2% chlorhexidine gluconate skin cleanser|2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
48109907|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
48109908|NCT00802490|DEVICE|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
48109909|NCT00134511|DRUG|Torcetrapib/atorvastatin|
48109910|NCT01370694|DRUG|MK-8808|
48109911|NCT01370694|DRUG|cyclophosphamide|
48303342|NCT00004106|DRUG|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
48303343|NCT04510922|DRUG|Droxidopa 100 MG [Northera]|droxidopa taken three times a day titrated up to a maximum of 600 mg.
48303344|NCT03452150|DRUG|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
48639828|NCT06613360|DRUG|CLN-978|Specified dose on specified days
48639829|NCT05496231|BIOLOGICAL|HPV9 High formulation|3 doses of a high formulation investigational adjuvanted HPV9 vaccine intramuscularly (IM) on Day 1, Month 2, and Month 6.
48639830|NCT05496231|BIOLOGICAL|HPV9 Medium formulation|3 doses of a medium formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
48109912|NCT01370694|DRUG|vincristine|
48109913|NCT01370694|DRUG|prednisolone|
48639831|NCT05496231|BIOLOGICAL|HPV9 Low formulation|3 doses of a low formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
48639832|NCT05496231|BIOLOGICAL|Gardasil 9|3 doses of the marketed HPV vaccine (Gradasil 9) administered IM on Day 1, Month 2, and Month 6.
48639833|NCT04013568|OTHER|Exercise|"First Intervention 12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students~Second Intervention- 12-week exercise program, 2 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Group Fitness Classes"
48639834|NCT06675981|OTHER|Real Acupuncture|Patients received 6 sessions of acupuncture (three sessions per week or every other day) for two consecutive weeks
48109914|NCT01233050|DRUG|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
48109915|NCT01233050|DRUG|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
48109916|NCT02107378|BIOLOGICAL|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
48109917|NCT02107378|DRUG|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
48109918|NCT03890016|DIAGNOSTIC_TEST|20'Whole Blood ClottingTest (WBCT)|"1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot."
48639835|NCT06675981|OTHER|Non-acupuncture at real-acupoint|The acupuncture simulation device will be used to perform acupuncture at the same acupoints as those of the real acupuncture group.
48109919|NCT03890016|DIAGNOSTIC_TEST|Modified Lee and White (MLW) Method Clotting Time|"The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot."
48639836|NCT06675981|OTHER|Shallow acupuncture at real-acupoint|At the same acupoint in the acupuncture group, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
48109920|NCT02613364|BEHAVIORAL|Behavioral Intervention|Undergo yoga intervention
48639837|NCT06675981|OTHER|Shallow acupuncture at non-meridian and non-acupoint|At non-meridian and non-acupoint, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
48639838|NCT05515341|DEVICE|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
48639839|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
48639840|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
48639841|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
48109921|NCT02613364|OTHER|Cognitive Intervention|Undergo CBT-I intervention
48109922|NCT02613364|OTHER|Educational Intervention|Receive health education
48109923|NCT02613364|OTHER|Laboratory Biomarker Analysis|Correlative studies
48109924|NCT02613364|DEVICE|Monitoring Device|Correlative studies
48109925|NCT02613364|OTHER|Quality-of-Life Assessment|Ancillary studies
48109926|NCT04074577|DIAGNOSTIC_TEST|Standard technique First|colonoscopy without automated polyp detection software
48109927|NCT04074577|DIAGNOSTIC_TEST|combination technique First|automated polyp detection software
48109928|NCT05679713|DIAGNOSTIC_TEST|Comprehensive risk assessment algorithm|Risk assessment algorithm including clinical and patient-centered information and a novel RNA-based biomarkers using next-generation sequencing technology.
48109929|NCT00383513|BIOLOGICAL|Epratuzumab|360 mg/m\^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
48109930|NCT00637234|DRUG|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
48109931|NCT00637234|DRUG|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
48109932|NCT01949740|OTHER|questionnaire administration|Ancillary studies
48109933|NCT01949740|PROCEDURE|quality-of-life assessment|Ancillary studies
48109934|NCT01948804|DRUG|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
48109935|NCT01948804|DRUG|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
48639842|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
48639843|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
48109936|NCT01948804|DRUG|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
48109937|NCT01948804|DRUG|GnRH antagonist protocol (Cetrotide, Serono)|
48109938|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
48109939|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
48109940|NCT04846491|DRUG|TDF|Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.
48639844|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
48639845|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
48639846|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 4.1 Usage|Participants will use their Radicle GI Health Active Study Product 4.1 as directed for a period of 6 weeks.
48639847|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
47955985|NCT03318666|BEHAVIORAL|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:~* a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~* adolescents will have access to the website specifically for adolescents: sova.pitt.edu~* parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team.~The SOVA websites include articles composed by SOVA Peer Ambassadors who are adolescents and young adults who have experienced symptoms of depression or anxiety and contribute monthly articles and regular comments."
48639848|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 5.1 Usage|Participants will use their Radicle GI Health Active Study Product 5.1 as directed for a period of 6 weeks.
47955986|NCT03318666|OTHER|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
47955987|NCT05945628|BEHAVIORAL|Different cognitive and memory demands during the memory experiment|Study conditions will involve attempting to memorize visual scenes, attempting to memorize arrays of visual objects, viewing in a self-directed manner, viewing in a passive other-directed manner, and making memory judgments about whether stimuli are studied versus novel.
47955988|NCT05945628|OTHER|Different electrical stimulation parameters during cognitive and memory demands|Study conditions will involve different parameters for electrical stimulation delivered through iEEG electrodes, including the presence of stimulation (no stimulation versus stimulation) and the location of stimulation (hippocampus versus amygdala).
47955989|NCT01515878|DEVICE|Hemocontrol|Blood Volume Tracking system using biofeedback
47955990|NCT05171543|PROCEDURE|Periapical surgery with placement of an allograft and a membrane|Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
48109941|NCT04846491|DRUG|Peginterferon alfa-2b injection|Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
48639849|NCT06674187|PROCEDURE|Regular|"The stoma surgery will be performed using conventional non-molding suturing techniques. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Perform routine suturing around the stoma without additional mesentery shaping.~3. Form the stoma, ensuring a tight fit of the surrounding tissues."
48639850|NCT06674187|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery will be shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Separate the mesentery around the stoma and shape it into a sturdy support structure.~3. Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~4. Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
48639851|NCT04852601|OTHER|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
48639852|NCT06481969|PROCEDURE|Conventional IVF|Conventional In Vitro Fertilization (IVF) procedure and standard assisted reproductive treatments.
48639853|NCT06481969|PROCEDURE|Lower abdominal liposuction and preparation of SVF|After lower abdominal liposuction (the liposuction volume is about 100 ml), the preparation and quality inspection of SVF will be completed by a laboratory with good manufacturing practice-approved facilities immediately. The adipose tissue will be cut into pieces of about 1mm3, and the equal volume of 0.1% collagenase I will be added to digest the adipose tissue. The digestion will be terminated after 40 minutes, followed by isolation, filtration, centrifugation, resuspension and dilution to obtain the SVF suspension. The test items, including bacteria, fungi, viruses and endotoxin, will be tested, and the expression of SVF surface markers, including CD45, CD34, CD31, CD11b, CD44, CD73, CD105 and CD90, will be detected by flow cytometry to ensure the quality of the SVF suspension. After about 4 hours of quality control and detection, the SVF suspension will be transported to the operating room on ice in a sealed incubator.
48109942|NCT01418391|PROCEDURE|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12\~18 hours upon to the regional anesthetics choose"
48109943|NCT05661162|DEVICE|CR 500™ SINGLE-DOSE GEL|CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
48109944|NCT05802602|DEVICE|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
48109945|NCT05802602|DEVICE|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
48109946|NCT05045703|DIETARY_SUPPLEMENT|Vitamin A palmitate|Vitamin A palmitate, 15,000 IU daily for 4 months
48109947|NCT06462963|RADIATION|single-fraction SBRT|Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
48639854|NCT06481969|PROCEDURE|Ovarian injection|Under ultrasound guidance, the SVF suspension will be injected into patients' bilateral ovaries. SVF with a total amount of (1\~2)×107 cells from autologous fat tissue will be transplanted into each side of ovary. There are 3 injection points on each side of ovary, and 330±10μl SVF suspension will be administered at each point. The administration volume of each ovary will be 1ml in total. After injection, the patients will be required to lie flat for 2 hours to observe whether there would be adverse events.
48639855|NCT06531824|DRUG|BI 690517|BI 690517
48639856|NCT06531824|DRUG|Placebo matching BI 690517|Placebo matching BI 690517
48639857|NCT06531824|DRUG|Empagliflozin|Empagliflozin
48639858|NCT06132568|DEVICE|VITALYST System|The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
48639859|NCT06694103|OTHER|Reverse Kangaroo Care Position|"* Babies will be taken to the examination table and their clothes other than diapers will be removed.~* Mothers will take off their upper clothes and lie on the examination table and position their babies in the reverse kangaroo care position, with the baby's back against the mother's bare chest.~* Babies will be monitored with disposable probes from their right feet.~* Video recording will be started. -While the position applied to the babies is maintained, the speculum will be placed in the eye by the ophthalmologist and the examination will be recorded on video from the beginning to end.~* After the completion of both eye examinations, the position of the babies whose monitoring continues will be maintained while the video recording will be taken for another 1 minute. The SPO2, HR, PIPP-R score at the end of the 15th second before the examination, the first minute during the examination and the 30th second after the examination will be evaluated."
48639860|NCT06694103|OTHER|ROP Position|"* Babies will be taken to the examination table and monitored with disposable probes from their right feet.~* The nurse will place the infant's own palms on the temporal region and hold them with her hands to support their head, while the mother will also support the infant by holding their legs.~* The video recording will be started.~* SPO2, HR, PIPP-R values will be recorded on video for one minute.~* While the ROP position applied to the babies is maintained, the speculum is placed in the eye by the ophthalmologist and the examination begins.~* SPO2, HR, PIPP-R evaluation at the 1st minute of the examination.~* After the completion of both eye examinations, the babies whose monitoring continues will be kept in their positions and a video recording will be taken for another 1 minute.~* The SPO2, HR values and PIPP-R pain score at the end of the 30 seconds after the examination will be evaluated."
48639861|NCT06237764|OTHER|No intervention|No intervention.
48639862|NCT06327711|OTHER|Control: CHO Blend|2 servings as a snack or between meals morning and evening
48639863|NCT06327711|OTHER|Experimental: CHO Blend plus AN100|2 servings as a snack or between meals morning and evening
48639864|NCT04570280|OTHER|Aerobic Exercises|Aerobic exercises with treadmill will be applied 3 times a week for 12 weeks.
48639865|NCT04570280|OTHER|Resistive Exercises|Resistive exercises with sandbag will be applied 3 times a week for 12 weeks.
48639866|NCT04570280|OTHER|Range of Motion Exercises|Range of Motion Exercises will be applied 3 times a week for 12 weeks.
48639867|NCT03535987|DEVICE|myocardial PET imaging|using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
48639868|NCT05452174|DRUG|Mirtazapine|Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
48639869|NCT01779206|DRUG|Epirubicin|
48639870|NCT01779206|DRUG|Cyclophosphamide|
48639871|NCT01779206|DRUG|Docetaxel|
48639872|NCT01779206|DRUG|Paclitaxel|
48639873|NCT06327256|DRUG|BI 3000202|BI 3000202
48639874|NCT06327256|DRUG|Placebo|Placebo-matching BI 3000202
48639875|NCT06327256|DRUG|Midazolam|Midazolam
48639876|NCT03073304|DRUG|Crystalloid based prime solution|Crystalloid based prime solution
48639877|NCT03073304|DRUG|Erythrocyte based prime solution|Erythrocyte based prime solution
48480896|NCT02663882|BEHAVIORAL|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
48480897|NCT04301622|DEVICE|Primary Knee implants|Primary knee arthroplasty
48639878|NCT06466434|OTHER|Prebiotic Food-Enriched Diet|Given by PO
47955991|NCT01804023|OTHER|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
47955992|NCT03490708|DRUG|Tranilast|Subjects will be treated with tranilast
47955993|NCT06129877|DEVICE|CHAMP App|CHAMP App software platform will have been used in other research studies to be included in the Feeding difficulties repository
48639879|NCT02375256|BIOLOGICAL|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
48639880|NCT02375256|BIOLOGICAL|Placebo|Identical buffer solution in which AERAS-402 is formulated.
48639881|NCT02375256|BIOLOGICAL|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
48639882|NCT05557292|DRUG|RMC-5552|Given IV
48639883|NCT04825587|PROCEDURE|Patients will be randomized into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone.|By randomizing patients into one of two study arms: (1) concomitant ACL and ALL reconstruction or (2) ACL reconstruction alone, following statistical analysis, we hope to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will longitudinally result in a lower rate of graft failure than ACL reconstruction alone.
48639884|NCT05193149|BEHAVIORAL|Inspiratory muscle training|Training of respiratory muscles
47955994|NCT02037360|BEHAVIORAL|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
48109948|NCT06462963|RADIATION|multiple-fraction SBRT|Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.
48639885|NCT05193149|BEHAVIORAL|Exercise training|Supervised aerobic exercise intervention
48109949|NCT05473871|BEHAVIORAL|Faith in Action|"Interpersonal level: Group exercise classes offered 6 days/week (walking, cardio dance, strength training), Kickoff event~Individual level: Motivational Interviewing calls every 6 months, Health handouts on 14 topics distributed at PA classes"
48109950|NCT05473871|BEHAVIORAL|Faith in Action+|Standard Faith in Action Intervention plus: 1) Health Behavior Change Workshop for FBO leaders; 2) Targeted Messaging; and 3) Empowerment Training for Promotoras
48639886|NCT05999851|DEVICE|Arterial applanation tonometry|Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.
48639887|NCT05999851|DEVICE|In vivo endothelial glycocalyx measurement|The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).
48639888|NCT05999851|DIAGNOSTIC_TEST|Serum markers of angiogenesis and endothelial dysfunction|ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).
48639889|NCT05999851|DIAGNOSTIC_TEST|Blood chemistry test|Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
48639890|NCT05999851|DIAGNOSTIC_TEST|Serum xanthine oxidase activity|Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
48639891|NCT04867837|DRUG|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
48639892|NCT06615375|BIOLOGICAL|Shigella4V2|Shigella4V2 is a tetravalent bioconjugate vaccine which consists of the O-antigen polysaccharide of Shigella flexneri 2a, 3a, 6 and of S. sonnei, conjugated to the detoxified Pseudomonas aeruginosa exotoxin A protein as carrier protein.
48639893|NCT06615375|BIOLOGICAL|Placebo|Phosphate-buffered saline
48639894|NCT03424005|DRUG|Capecitabine|Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
48639895|NCT03424005|DRUG|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
48639896|NCT03424005|DRUG|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
48639897|NCT03424005|DRUG|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
48639898|NCT03424005|DRUG|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
47955995|NCT02037360|BEHAVIORAL|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
47955996|NCT00785928|BIOLOGICAL|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
48109951|NCT05473871|BEHAVIORAL|Faith in Action++|Enhanced Condition plus: 1) Foster community collaborations and 2) Provide maintenance support
48639899|NCT03424005|DRUG|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m\^2 on days 1 and 8 of each 21 day cycle."
48639900|NCT03424005|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
48639901|NCT03424005|DRUG|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
48639902|NCT03424005|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
48639903|NCT03424005|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
48639904|NCT03424005|DRUG|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
47955997|NCT00785928|DRUG|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
48639905|NCT03424005|DRUG|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
48639906|NCT03424005|DRUG|Ribociclib (dose #1)|Ribociclib tablets will be administered by mouth once daily.
48639907|NCT03424005|DRUG|Inavolisib (dose #2)|Inavolisib tablets will be administered by mouth once daily.
48639908|NCT03424005|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
47955998|NCT01748266|OTHER|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
47955999|NCT03208127|DRUG|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
47956000|NCT02927327|DEVICE|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
47956001|NCT02927327|DEVICE|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
48639909|NCT03424005|DRUG|Ribociclib (dose #2)|Ribociclib tablets will be administered by mouth once daily.
48639910|NCT03424005|DRUG|Letrozole|Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
48639911|NCT03424005|DRUG|Inavolisib (dose #1)|Inavolisib tablets will be administered by mouth once daily.
48639912|NCT03424005|DRUG|Inavolisib|Inavolisib tablets will be administered by mouth once daily.
48639913|NCT06500455|PROCEDURE|Computed Tomography|Undergo CT
48109952|NCT06427486|OTHER|Parents Telecoaching Intervention|- Synchronous (Zoom platform) and Asynchronous coaching sessions for parents of children with autism.
48480898|NCT03534193|OTHER|Molly Center Diabetes Care Guide (Paper-based)|Diabetes education with Registered Nurse in addition to Paper based education modules
48639914|NCT06500455|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRS
48639915|NCT06500455|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48639916|NCT06500455|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48639917|NCT05954988|DRUG|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
48639918|NCT05954988|DRUG|Placebo|Matching placebo
48639919|NCT05376800|DRUG|BI 907828 (Brigimadlin)|BI 907828 (Brigimadlin)
48639920|NCT04739436|DEVICE|Hearing amplification|Bilateral vs. unilateral hearing aids for hearing loss
48639921|NCT05156398|DRUG|Rimegepant|Rimegepant 75mg or 50mg (2 X 25mg) ODT
48639922|NCT05156398|DRUG|Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
48639923|NCT04837846|OTHER|Differing Tube Voltage Administration|Subjects will undergo CCTA utilizing a scan and contrast media injection protocol that will be tailored to individual body habitus.
47956002|NCT02436304|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
47956003|NCT02436304|PROCEDURE|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
47956004|NCT06556654|DEVICE|TRBR Device|The GORE® Tissue Reinforcement for Breast Reconstruction device is intended to reinforce the soft tissue surrounding the tissue expander in preparation for the breast implant in post-mastectomy breast reconstruction
47956005|NCT04882280|BEHAVIORAL|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
47956006|NCT03022435|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
47956007|NCT03022435|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
48639924|NCT06579391|DIETARY_SUPPLEMENT|Essential amino acids|Twice daily consumption for two weeks before and one week after surgery.
48639925|NCT06579391|DIETARY_SUPPLEMENT|Alanine|Twice daily consumption for two weeks before and one week after surgery.
48639926|NCT05477953|DRUG|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
48639927|NCT02616302|DRUG|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
48639928|NCT05683275|OTHER|IASTM|IASTM will be applied to the affected extremity twice a week for 4 weeks, in total 8 sessions. Participants will be asked to sit comfortably in a chair with back support. IASTM will be applied to the wrist extensor muscles of the participants for 90 seconds in the position where the muscle is tense, with a frequency of 60 beats per minute.
48639929|NCT05683275|OTHER|ESWT|ESWT will be applied to the affected elbow two days a week for 4 weeks, a total of 8 sessions, each session 2000 shock 10 Hz frequency, 2.5 bar intensity point and circumferential application.
48639930|NCT05683275|OTHER|Home Exercise|Special static stretching and eccentric strengthening exercises for the forearm muscles will be taught and they will be asked to perform 2 sets (morning-lunch-evening) 10 repetitions per day, 5 days a week, for 4 weeks.
48109953|NCT01596504|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).~Route of administration: subcutaneous"
48109954|NCT01596504|DRUG|Liraglutide|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
48480899|NCT03534193|OTHER|Tablet based interactive diabetes education modules|Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
48480900|NCT04768894|PROCEDURE|Second transurehral resection of bladder tumour|Remove of the bladder tumour as endoscopically
48639931|NCT03965299|DEVICE|VERUM TTNS|"* Daily 30-minute TTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
48639932|NCT03965299|DEVICE|SHAM TTNS|"* Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~* During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
48639933|NCT06647407|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
48639934|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
48639935|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)
48639936|NCT06647407|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
48639937|NCT06647407|DRUG|Paracetamol|Pharmaceutical form:Suspension-Route of administration:oral
48639938|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
48639939|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
48639940|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Oral solution in tube Route of administration: oral
48639941|NCT06647407|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
48639942|NCT06647407|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
48639943|NCT06694610|PROCEDURE|non-pulmonary vein ablation group|In the non-pulmonary vein ablation group, pulmonary vein isolation was not allowed, but the left atrial low-voltage area was treated first, and then the ablation route that terminated the reentry ring was treated.
48639944|NCT06694610|PROCEDURE|only pulmonary vein ablation group|In the group treated with only pulmonary vein ablation route, only potential isolation of pulmonary vein was performed, and bidirectional block was the end point.
48639945|NCT02103946|PROCEDURE|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
48639946|NCT02103946|PROCEDURE|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
48639947|NCT06548581|DEVICE|SpeedPlate™ Rapid Compression Implants|MTP and/or TMT joint fixation with SpeedPlate™ Rapid Compression Implants
48480901|NCT05807139|OTHER|Placebo|Placebo
48639948|NCT06671184|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
47956008|NCT03022435|BIOLOGICAL|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
48480902|NCT05807139|DRUG|Spironolactone|"Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information."
48639949|NCT05746884|PROCEDURE|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
48639950|NCT05746884|PROCEDURE|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
47956009|NCT05904912|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
47956010|NCT05904912|DRUG|PENG-Bupivacaine|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
47956011|NCT05904912|DRUG|Local infiltration-Bupivacaine|Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
47956012|NCT01881373|OTHER|CHL program|Multiple component environmentally focused program designed with community engagement.
47956013|NCT01881373|OTHER|Delayed Optimized CHL program|CHL programs with fewer component and shorter duration.
47956014|NCT03628794|DEVICE|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
47956015|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
47956016|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
47956017|NCT01015144|DRUG|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
47956018|NCT00011661|BEHAVIORAL|Education on behaviors to reduce lead exposure|
48639951|NCT03517969|DRUG|Berzosertib|Given IV
48639952|NCT03517969|DRUG|Carboplatin|Given IV
48639953|NCT03517969|DRUG|Docetaxel|Given IV
48639954|NCT03517969|OTHER|Laboratory Biomarker Analysis|Correlative studies
48639955|NCT06159127|BEHAVIORAL|SMART@Home|Daily medication and diary completion reminders are provided to participants. Additional educational content regarding self-management skills will be provided.
48639956|NCT06059339|OTHER|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
48639957|NCT02233868|OTHER|connectivity|Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
48639958|NCT02233868|DRUG|neuroinflammation|The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
48639959|NCT02233868|OTHER|neurofunction|To assess regional brain glucose metabolism.
48639960|NCT06380400|BEHAVIORAL|Foot bath|Pregnant women were given footbaths for 20 minutes during the active phase of the first stage of labour (after cervical dilatation of 4 cm) and 20 minutes during the transitional phase of the second stage of labour (cervical dilatation of 9 cm). Pregnant women who completed two footbath sessions were assessed for pain using the visual comparison scale. In addition, the data collection process will be completed by applying the Birth Comfort Scale after the two stages of labour.
47956019|NCT05265416|PROCEDURE|Piezosurgery|Three vertical incisions will be made (3-mm depth and 8-10 mm length) after anesthesia. The cuts will be performed mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar.
47956020|NCT05265416|OTHER|Low-level laser therapy|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal.
48639961|NCT05887661|PROCEDURE|hypovolemic phlebotomy|hypovolemic phlebotomy was performed after induction of anesthesia and before the star of parenchymal division, with a goal-directed low central venous pressure drop to 5mmHg.
48639962|NCT06390371|OTHER|Spotlight AQ Survey platform|A psychosocial assessment pinpointing the needs of patients divided into four domains: Therapy, Psychological, Social, Knowledge which is delivered to health care providers to guide their in clinic visits
48639963|NCT06043765|DEVICE|real repetitive transcranial magnetic stimulation (rTMS)|real rTMS -- 3 sessions a week/7 weeks (21 sessions)
48639964|NCT06043765|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|sham rTMS - 3 sessions a week/7 weeks (21 sessions)
48639965|NCT06043765|BEHAVIORAL|cognitive strategy training|7 weekly sessions with a trained neuropsychologist.
48639966|NCT05869773|DRUG|JZP258|0.5 g/ml calcium, magnesium, potassium, and sodium oxybates oral solution
48639967|NCT05783323|DRUG|Larotrectinib monotherapy|Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
48303345|NCT05433103|OTHER|Low-Load Exercise with Blood Flow Restriction|Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
48303346|NCT05433103|OTHER|Low-Load Exercise Control Group|Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
48480903|NCT05772884|OTHER|Supervised Exercise Intervention|Exercise duration will be gradually increased as tolerated to 50 min/session, with intensity ramping up to 65-75% HRmax by week 3. On-site exercise sessions will occur along a pre-marked walking path, and a trained staff member will walk alongside the participant to monitor their heart rate. Speed will be manipulated to achieve desired intensity and to sustain heart rate in the target zone. Heart rate will be monitored and recorded via telemetry during the on-site exercise sessions. Step cadence (i.e., steps/minute) will also be monitored and recorded during the on-site sessions and discussed with participants as a way to understand and track their speed when completing off-site walking sessions on their own.
48480904|NCT03365544|OTHER|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
48480905|NCT05132725|BEHAVIORAL|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
48480906|NCT03297567|BEHAVIORAL|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
48480907|NCT06023849|DEVICE|IUD insertion|Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
48480908|NCT01817192|DRUG|Adjuvant Chemotherapy|Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
48480909|NCT01817192|OTHER|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
48480910|NCT01817192|OTHER|14-Gene Prognostic Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
48480911|NCT01117467|OTHER|Simulation scenario|Students performing their scenario will be paired, not solo
48480912|NCT01117467|OTHER|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
48639968|NCT05783323|RADIATION|131I therapy|Patients will receive 131I therapy after 6 months of larotrectinib.
48109955|NCT01596504|DRUG|Insulin Glargine|Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
48480913|NCT03509714|DIETARY_SUPPLEMENT|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
48480914|NCT03509714|DIETARY_SUPPLEMENT|rice flour (Placebo)|250 mg rice flour (Placebo)
48639969|NCT05645536|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months
48639970|NCT05645536|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet of solution
48639971|NCT05645536|DRUG|Letrozole tablets|One 2.5 mg tablet taken orally once daily
48639972|NCT05645536|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
48639973|NCT05645536|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
48639974|NCT00775515|PROCEDURE|laparoscopic prostatectomy|laparoscopic prostatectomy
48639975|NCT05811637|OTHER|Pilates Exercise|The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
47956021|NCT05265416|DEVICE|Traditional treatment|The canine retraction in this group will be performed in conventional method. Closed nickel-titanium coil springs applying 150 g of force per side will be used for retraction of the upper canine.
47956022|NCT03114774|DEVICE|The bispectral index (BIS) monitoring|
48109956|NCT01596504|DRUG|Metformin|If previously taken metformin to be continued at stable dose throughout the study
48109957|NCT00717626|DRUG|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
48109958|NCT04502511|DIAGNOSTIC_TEST|Standard diagnosis test|Care as usual
48109959|NCT06017167|DRUG|Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .|compare antiemetic effects between dexmedetomidine and ondansetron in the first group versus dexamethasone and ondansetron in the second group
48109960|NCT06017167|DRUG|Ondansetron 4mg + dexamethasone 8mg + normal saline.|Group II: Ondansetron 4mg + dexamethasone 8mg + normal saline.
48109961|NCT04356612|OTHER|Chart Review|This is a retrospective chart review to determine the etiologies contributing to prolonged PACU discharge at a major Orthopedic Ambulatory Surgical Center.
48109962|NCT00258037|BEHAVIORAL|Pelvic Floor Muscle training|
48303347|NCT06512805|BEHAVIORAL|Routine transport|"1. Before the transfer of the patient:~   ① The doctor determines the destination of the patient based on the patient's condition and issues transfer orders.~  * The responsible nurse assesses the patient's consciousness, circulation, respiration, etc., and fills out the Transfer Patient Handover Record in the transferring department section.~     * The responsible nurse prepares the equipment, medications, and patient's belongings required for the transfer.~2. During the transfer:~   Monitor the patient's vital signs.~3. Upon arrival at the receiving department:~   * Place the patient with the receiving department nurse. ② Verbally hand over the patient's condition to the receiving department nurse and hand over the patient's belongings and medications.~     * The responsible nurse of the receiving department completes the remaining part of the Transfer Patient Handover Record."
48339942|NCT03455062|OTHER|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
48480915|NCT04683237|DRUG|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
48480916|NCT04683237|DRUG|Megestrol Acetate 160 MG|160mg po qd
48639976|NCT05811637|OTHER|Supervised Rehabilitation|The program will be applied with the progression of the supervised rehabilitation in the 4th week
48480917|NCT00858013|DRUG|Nateglinide|Nateglinide 90\~120mg three times a day
47956023|NCT03114774|BEHAVIORAL|Ramsay Sedation Scale (RSS) Score monitoring|
47956024|NCT02019277|DRUG|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
47956025|NCT02019277|DRUG|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
48109963|NCT06077019|DRUG|Vilanterol and Fluticasone Furoate|Participants inhale 25 µg vilanterol + fluticasone furoate daily
48109964|NCT06077019|DRUG|Indacaterol and Mometasone Furoate|Participants inhale 125 µg indacaterol + mometasone furoate daily
48109965|NCT06077019|DRUG|Placebo|Participants inhale placebo daily
48109966|NCT00140972|DRUG|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
48109967|NCT00140972|DRUG|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
48109968|NCT05059730|OTHER|Zero Degrees Cold Environment|Participants will be exposed to zero degrees celsius environment.
48109969|NCT05059730|OTHER|Eight Degrees Cold Environment|Participants will be exposed to eight degrees celsius environment.
48109970|NCT05059730|OTHER|Ten Degrees Cold Environment|Participants will be exposed to Ten degrees celsius environment.
48109971|NCT05059730|OTHER|40 degrees Hot Environment|Participants will be exposed to 40 degrees celsius hot environment.
48109972|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
48109973|NCT00552552|BEHAVIORAL|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
48109974|NCT00480662|DRUG|alendronate|Duration of Treatment : 6 Months
48109975|NCT05685095|BEHAVIORAL|Physical training|Supervised gait training program 3 times a week, 12 weeks
48109976|NCT05001750|DRUG|long term prophylactic antibiotics (Nafcillin or Doxycycline)|VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
48109977|NCT03255096|DRUG|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
48109978|NCT03255096|DRUG|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
48109979|NCT03255096|DRUG|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
48109980|NCT03951207|DRUG|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
48109981|NCT03951207|DRUG|Rosuampin 20/5mg|Rosuampin 20/5mg qd for 8 weeks
48109982|NCT03951207|DRUG|Amlodipine/Atorvastatin 5/20mg|Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
48109983|NCT00940992|DRUG|DER 45 EV|Topical application to face for 12 weeks
48109984|NCT00940992|DRUG|Vehicle|Topical application to face for 12 weeks
47956026|NCT02019277|DRUG|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
48303348|NCT06512805|BEHAVIORAL|Post-guideline transfer|"In the intervention group, nurses receive implementation strategies developed during the preparation phase. These strategies aim to modify the behavior of healthcare personnel through implementation, thereby conducting evidence-based (based on the guidelines) in-hospital transfer interventions for pediatric patients.The interventions received by pediatric patients are derived from the recommended practices evaluated for evidence availability in the guidelines. These include specific transfer procedures, the Transfer Risk Level Classification Criteria, Personnel Qualifications, Equipment, and Medications Allocation Based on Transfer Risk Level, Transfer Preparation Checklist, and Transfer Handover Checklist 2.0."
48303349|NCT03165357|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|
48303350|NCT03165357|DIETARY_SUPPLEMENT|Placebo treatment|
48303351|NCT03422991|OTHER|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
48480918|NCT00858013|DRUG|Glimepiride|Glimepiride 1\~2mg once a day
48480919|NCT04239482|DIETARY_SUPPLEMENT|L-arginine + Nitrate / Nitrite|Longer-term supplementation (8 weeks)
48480920|NCT04239482|DIETARY_SUPPLEMENT|Placebo|Longer-term supplementation (8 weeks)
48303352|NCT04994821|DEVICE|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
48480921|NCT05628558|DRUG|Desmopressin|"The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care."
48480922|NCT01163084|DRUG|Goserelin Acetate|Given SC
48480923|NCT01163084|OTHER|Laboratory Biomarker Analysis|Correlative studies
48480924|NCT01163084|DRUG|Leuprolide Acetate|Given IM
48480925|NCT01163084|DRUG|Vismodegib|Given PO
48480926|NCT05187858|DRUG|LNP3794|LNP3794 capsules administered orally once daily
48480927|NCT04111588|OTHER|Diagnostic Amino acid PET/MRI examination|Diagnostic Amino acid PET/MRI examination
48480928|NCT02466802|DRUG|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
48480929|NCT02466802|DRUG|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
48303353|NCT04994821|BEHAVIORAL|Cognitive Reappraisal|Emotion regulation therapy
48303354|NCT04618497|DRUG|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
48303355|NCT04618497|DRUG|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
48303356|NCT03961919|DRUG|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
48303357|NCT03961919|DRUG|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
48303358|NCT03961919|DRUG|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
48303359|NCT03961919|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
48303360|NCT00216359|DRUG|Fuzeon (Enfuvirtide)|
48303361|NCT00216359|PROCEDURE|Laboratory diagnostic (CD4-cells)|
48303362|NCT00216359|PROCEDURE|Laboratory diagnostics (HIV-1 viral load)|
48303363|NCT00216359|DRUG|antiretroviral co-medication beside Fuzeon|
48480930|NCT03442959|OTHER|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
48480931|NCT01098110|DRUG|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
48480932|NCT01098110|DRUG|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
48480933|NCT01098110|DRUG|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
48480934|NCT02521818|OTHER|Modified Atkins Diet|
48303364|NCT04475185|DEVICE|MakAir|MakAir artificial ventilator
48339943|NCT05037916|OTHER|laser speckle contrast imaging device|laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device
48480935|NCT02521818|OTHER|NIA Diet for Seniors|
47956027|NCT02019277|DRUG|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
48109985|NCT02093533|DRUG|Eculizumab|
48303365|NCT01224912|BEHAVIORAL|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
48303366|NCT03774745|DRUG|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
48303367|NCT03774745|DRUG|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
48303368|NCT03774745|DRUG|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
48303369|NCT03018782|OTHER|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
48303370|NCT01221675|DRUG|Antibody TF2|preciblage with an antibody
48303371|NCT01221675|RADIATION|IMP-288-Lutetium|Internal Radiation
48303372|NCT01221675|RADIATION|IMP-288-Indium|Imaging
47956028|NCT02019277|DRUG|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
48303373|NCT02184416|OTHER|observational|The study is non interventional. All drugs will be prescribed
48303374|NCT02452970|DRUG|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
48303375|NCT02452970|DRUG|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
48303376|NCT03223220|DRUG|Ketamine|IV infusion
48303377|NCT03223220|OTHER|Normal Saline|IV infusion
48480936|NCT02992626|OTHER|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
48303378|NCT03223220|DRUG|Midazolam injection|Injection
48480937|NCT02992626|OTHER|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
48480938|NCT02136303|DIETARY_SUPPLEMENT|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
48480939|NCT02136303|OTHER|S2: Kale extract versus kale purée|
48480940|NCT02136303|OTHER|S3: Kale extract: AMD-patients|
48303379|NCT01571037|DRUG|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
48303380|NCT01571037|DRUG|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
48303381|NCT00592397|OTHER|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
48303382|NCT01011920|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
47956029|NCT05476458|RADIATION|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
47956030|NCT05476458|RADIATION|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
48480941|NCT01826916|DRUG|DX-88 (ecallantide)|solution for injection 10 mg/mL
48480942|NCT01906359|OTHER|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
48480943|NCT01906359|OTHER|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
48480944|NCT01906359|OTHER|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
48639977|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility|PCPs will receive an email from a peer offering encouragement and support in prescribing SGLT-2is and GLP-1RAs that includes specific components designed to reduce diffusion of responsibility. Specifically, these elements will be adapted from interventions that mitigate diffusion of responsibility in other contexts, including: (1) assigning responsibility to individuals or smaller groups, (2) increased perceived harm of the situation to be addressed (3) highlighting competence to act, and (4) modeling the desired behavior. The email will also contain a link to clinical and administrative information to support prescribing and an offer for direct support from the peer.
48303383|NCT01011920|DRUG|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
48303384|NCT01011920|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles
48303385|NCT01011920|DRUG|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4
48303386|NCT01011920|RADIATION|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
48303387|NCT01011920|DRUG|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
48303388|NCT01011920|OTHER|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
48303389|NCT00402974|DRUG|menaquinone 7|
48303390|NCT05907967|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
48109986|NCT05372380|DRUG|BR1017-1|Administration to the F/F+AE group: BR1017-1 will be administered 1 tablet QD, five-day repeat dose
48303391|NCT06486922|BEHAVIORAL|StEP OUT|The details of program structure and content will evolve as the study progresses based on feedback from participants, interventionists, and the community advisory board. Initially, we will plan to have 5 formal sessions structured as groups with multiple participants receiving the session simultaneously, primarily via remote videoconference, though sessions may occur individually, based on participant schedule and preference. All sessions are designed to be supportive, educational, and interactive, with opportunities to practice skills and discuss feeding and parenting concerns.
48303392|NCT04458038|OTHER|driving simulator|For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
48303393|NCT01452776|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
48639978|NCT05463705|BEHAVIORAL|Intervention to address diffusion of responsibility + simplification of prescribing|"PCPs will receive the same contact addressing diffusion of responsibility as in the Intervention to address diffusion of responsibility arm, but will additionally have access to an experienced administrative team for diabetes medication insurance authorization support, by routing their clinic note through the EHR. PCPs will be informed, suing the same email outreach, how to access the administrative team, which consists of medical and administrative assistants and currently supports prescribing within the endocrinology division. The team will follow up with the pharmacy to determine coverage, complete prior authorizations, determine alternate covered options, and track progress."
48639979|NCT06384781|BEHAVIORAL|Peer Support Checklist|Peer support specialists are Certified Peer Support Specialists (CPSS) who have lived experience with Opioid Use Disorder (OUD) and OUD recovery. Peer support specialists offer consistent personalized recovery support and generalized social support. Peer support specialists will maintain contact and provide support for the participant for six-months post-baseline. CPSS will utilize the newly developed checklist from earlier phases of the project to provide patient support.
48109987|NCT05372380|DRUG|BR1017-2|Administration to the AE group: BR1017-2 will be administered 1 tablet QD, 9-day repeat dose Administration to the F+AE group: BR1017-2 will be administered 1 tablet once QD, 5-day repeat dose.
48109988|NCT02178917|OTHER|Neurofeedback therapy|
48303394|NCT01452776|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
48303395|NCT04667195|OTHER|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~* Demographics,~* comorbidity,~* symptoms,~* objective findings,~* triage at admission,~* blood test results,~* urine test results"
47956031|NCT02095418|DRUG|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
47956032|NCT02095418|DRUG|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
47956033|NCT01649804|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
47956034|NCT00676338|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
48303396|NCT00156546|DRUG|antibiotic to reduce the recurrence of infection|
47956035|NCT00676338|DRUG|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
47956036|NCT00676338|DRUG|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
47956037|NCT00676338|DRUG|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
47956038|NCT00978978|DRUG|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"1. Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~2. Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
48639980|NCT06130033|DEVICE|Neuromonitoring|"Multimodal Neuromonitoring:~Transcranial Doppler - middle cerebral artery blood flow velocity Jugular venous bulb oximetry - hemoglobin oxygen saturation at the jugular venous bulb Arterial blood pressure monitoring - mean arterial, systolic and diastolic pressure monitoring at the radial artery via an in situ radial arterial line catheter Pulmonary artery catheter - to measure continuous cardiac output and mixed venous oxygen saturation Near infrared spectroscopy - to measure regional cerebral saturation of oxygen"
48639981|NCT04016402|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Clinical transcranial magnetic stimulation administered as part of usual care for the study population
48639982|NCT04691648|DRUG|Gilteritinib Exposure|Oral
47956039|NCT00347360|DRUG|lisinopril|
47956040|NCT00347360|DRUG|carvedilol controlled release formulation|
47956041|NCT03128827|DEVICE|RAM sensor|Acoustic Respiration Monitor
47956042|NCT03727607|DRUG|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
47956043|NCT01599195|DEVICE|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
47956044|NCT06450158|DEVICE|Robot (Amadeo)-assisted Training|"Amadeo® is an FDA Class I Exempt hand/finger robot that has the capacity to precisely measure hand/finger functions.~To use Amadeo, a participant will be seated in a chair. The height of the robot arm support will be adjusted to achieve a comfortable position for the participant. One of the participant's arms will be will be placed on the robot arm support. Magnetic finger tips will then be attached to fingers and thumb. After this, fingers and thumb will be connected to the robot finger sliders. To use Amadeo, the movement range and maximal force of each finger will be configured according to the finger's capability. The following four types of function assessments will be performed with Amadeo: Force, range of motion, tone, and spasticity. Each session will last approximately one hour."
47956045|NCT00353665|DRUG|Memantine (Ebixa)|10 mg bid
48303397|NCT00174746|DRUG|AVE2635A|
48303398|NCT03143582|OTHER|Running|A 13-week running program where youth run for 30 minutes twice weekly.
47956046|NCT00353665|DRUG|riluzole|riluzole 50 mg bid
47956047|NCT00353665|DRUG|Placebo|
47956048|NCT03270371|DEVICE|Medium cut off dialysis|Hemodialysis
47956049|NCT03270371|DEVICE|Standard High Flux Dialyzer|Hemodialysis
47956050|NCT03404232|DEVICE|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
47956051|NCT01842100|DRUG|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
47956052|NCT01842100|OTHER|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
47956053|NCT06132516|OTHER|HIIT|High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test
47956054|NCT06132516|OTHER|LIGT|Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
47956055|NCT03546062|OTHER|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
48109989|NCT02178917|OTHER|No neurofeedback therapy|
48303399|NCT04488692|OTHER|Early intervention (Mobility functional training)|functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
48303400|NCT04488692|OTHER|Sham intervention|friendly visit and education
48303401|NCT02154854|DRUG|Tacrolimus targeted half-dose|
48303402|NCT02154854|DRUG|Tacrolimus targeted plain dose|
48303403|NCT06370702|OTHER|Handgrip Exercises|Participants will firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
47956056|NCT02095223|DEVICE|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
47956057|NCT02095223|BEHAVIORAL|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
47956058|NCT04188587|DRUG|177 Lu-PSMA-I&T|All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
47956059|NCT00860444|BEHAVIORAL|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
48109990|NCT00774436|PROCEDURE|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
48109991|NCT06109831|DRUG|SHR-1918|SHR-1918
48109992|NCT06109831|DRUG|SHR-1918 placebo|SHR-1918 placebo
48480945|NCT03307057|BEHAVIORAL|Social Communication Growth Charts (SCGC)|The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
48480946|NCT03307057|BEHAVIORAL|Parent-Implemented (P-I) Condition|"The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.~Weekly home sessions with a family navigator include:~1. developing the visit agenda~2. intervention implementation including: guided/caregiver practice, feedback and problem solving~3. planning for parent implementation between sessions~Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat."
48480947|NCT03307057|BEHAVIORAL|Clinician-Implemented (C-I) Condition|The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
48480948|NCT01529658|PROCEDURE|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
48480949|NCT02480231|DEVICE|Retropubic Midurethral Sling|
48480950|NCT03998436|DRUG|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
48480951|NCT03998436|OTHER|Only Standard of Care|Only Standard of Care treatment
48480952|NCT03998436|OTHER|Vehicle Gel|Vehicle gel application along with Standard of Care
48480953|NCT01207440|DRUG|Ponatinib|Ponatinib tablets.
48480954|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group I: 10 patients will be treated with Lysis and lavage
48109993|NCT02551055|DRUG|MLN1117|MLN1117 Tablets
48109994|NCT02551055|DRUG|TAK-659|TAK-659 Tablets
48109995|NCT02551055|DRUG|Alisertib|Alisertib Tablets
48109996|NCT02551055|DRUG|Paclitaxel|Paclitaxel intravenous infusion
48303404|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
48303405|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
48303406|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
48303407|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
48303408|NCT06373081|BIOLOGICAL|Anti-CD19-CD3E-CAR-T cells|The injection of anti-CD19-CD3E chimeric antigen receptor T (CAR-T) cells, referred to as anti-CD19-CD3E-CAR-T cells. The anti-CD19-CD3E-CAR protein is composed of a murine-derived CD19 single-chain variable fragment (scFv) FMC63, CD28 hinge and transmembrane regions, the intracellular domain of CD3E, the intracellular domain of CD28, and the intracellular domain of CD3ζ, all linked in sequence.
48303409|NCT02940054|OTHER|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
48303410|NCT02300077|DRUG|methadone|Escalating dose of methadone up to .3mg/kg.
48480955|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group II: 10 patients will be treated with operative arthroscopy
48480956|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group III: 10 patients will be treated with operative arthroscopy + discopexy
48480957|NCT01051180|PROCEDURE|HALO|Ligation of haemorrhoidal arteries
48480958|NCT05433259|DEVICE|Overnight orthokeratology|Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
48480959|NCT05069155|BEHAVIORAL|Gamification|Each participant signs a pre-commitment contract agreeing to try their best to achieve their daily step goal. Each week over the 12 week intervention period, participants are endowed 70 points (10/day). Participants are informed they will lose 10 points for each day the step goal is not met. Points are replenished at the start of the week. At the end of the week, if the participant has 40 points or more, he/she will advance one level, or drop one level if they have less than 40 points. The levels include: blue (lowest), bronze, silver, gold, platinum (highest). Each participant begins in the middle (silver). Each participant will also select a spouse, family member, or friend that they see often to serve as a supportive sponsor that receives a weekly email participants progress including points, game level, and average step countThis supportive sponsor will help to enhance social incentives to motivate the individual towards his or her goal.
48480960|NCT05039437|DIETARY_SUPPLEMENT|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
48109997|NCT02551055|DRUG|Docetaxel|Docetaxel intravenous infusion
48480961|NCT05039437|DIETARY_SUPPLEMENT|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
48480962|NCT03056079|DRUG|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
48480963|NCT01863056|OTHER|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
47956060|NCT00860444|BEHAVIORAL|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
47956061|NCT05637879|DRUG|Glecaprevir/pibrentasvir|Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
47956062|NCT05637879|OTHER|Placebo|Compounded, inactive pill equal in appearance to active study drug
47956063|NCT00627185|BEHAVIORAL|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
47956064|NCT00627185|OTHER|No intervention arm|
47956065|NCT00270335|DRUG|Propofol|
47956066|NCT04424810|OTHER|High-quality, physician created video|The intervention group will watch a short (2-5 minute) video prior to surgery that will provide them with information about their condition and the procedure they are about to undergo (either carpal tunnel release or trigger finger release).
47956067|NCT04424810|OTHER|Standard of care|Patients in the control group will not be asked to do anything differently prior to their surgery
47956068|NCT05449119|BIOLOGICAL|Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data|at T0, T3 months, T6 months, T9 months and T12 months
47956069|NCT05449119|OTHER|Body Mass Index (BMI)|Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months
47956070|NCT05449119|OTHER|24-hour food and beverage record|at T0, T3 months, T6 months, T9 months and T12 months
48639983|NCT05111964|DEVICE|High Intensity Focused Ultrasound Ablation|"The focused ultrasound exposure will be performed using the Haifu® Model-JC200 Focused Ultrasound Tumour Therapeutic System at the Churchill Hospital site, CE-approved for tumour therapy (or subsequent CE-approved device upgrades by Haifu®). The participant will be positioned over the therapeutic device and water bath used to transmit the focused ultrasound to the target tumour. No anaesthesia or any combination of local anaesthesia, nerve block, epidural, conscious sedation or general anaesthetic may be used, depending on anatomical location, size of tumour, preference of HIFU team, patient and anaesthetist and other patient factors.~In therapy mode, the tumour volume is treated with focused ultrasound to ablate the tumour tissues to high temperatures (in excess of 60ºC) using focused ultrasound targeted from outside the body.~Patients are typically discharged with 24 hours."
48109998|NCT04541706|DRUG|Lorlatinib|Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
48109999|NCT04643236|BEHAVIORAL|Periodontal health education session|This session comprised of a condensed version of motivational interviewing and a periodontal education view/point. First, patients were analysed in terms of expectations from periodontal treatment/oral hygiene practice, knowledge about periodontal diseases and its consequences, daily oral hygiene routine, awareness of the current periodontal status and the main reasons for not doing proper brushing and interproximal cleaning. The same researcher who did not included in the clinic process informed the patients about how periodontal diseases develops, its aetiology, symptoms, consequences and the relationship with the important systemic disorders verbally and via brochure as well. The importance of the patients' own efforts about daily cleaning of the mouth were emphasized. Finally oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
47956071|NCT05449119|OTHER|Mini Nutritional assessment (MNA)|at T0, T3 months, T6 months, T9 months and T12 months
47956072|NCT05449119|OTHER|Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)|at T0, T3 months, T6 months, T9 months and T12 months
47956073|NCT05449119|OTHER|Measurement of sensorimotor functions|at T0, T3 months, T6 months, T9 months and T12 months
48639984|NCT05111964|DIAGNOSTIC_TEST|Tumour Biopsy and Venous Blood Tests|"Where appropriate, participants are also encouraged to undergo a pre-HIFU (and in the case of unresectable STS, post-HIFU) ultrasound biopsy of the target tumour and additional blood tests to inform the immunological aspects of the study. Having the biopsy does not mandate enrolment on the trial, and patients will be free to leave the trial at any stage. The pre-HIFU (and post-HIFU) biopsies are altruistically encouraged but not absolutely essential to enrolment on the trial.~Biopsies will be performed under ultrasound guidance by an experienced radiologist using local anaesthetic."
47956074|NCT05449119|OTHER|Measurement of cognitive functions|at T0, T3 months, T6 months, T9 months and T12 months
47956075|NCT02957929|DRUG|APX001 single IV dose|
47956076|NCT02957929|DRUG|APX001 single oral dose 1|
47956077|NCT02957929|DRUG|APX001 single oral dose 2|
47956078|NCT02957929|DRUG|APX001 single oral dose 3|
47956079|NCT02957929|DRUG|APX001 single oral dose fasted|
47956080|NCT02957929|DRUG|APX001 single oral dose fed|
48303411|NCT02300077|DRUG|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
47956081|NCT02957929|DRUG|APX001 multiple oral doses 1|
47956082|NCT02957929|DRUG|APX001 multiple oral doses 2|
47956083|NCT02957929|DRUG|APX001 multiple oral doses 3|
47956084|NCT02957929|DRUG|Cytochrome P450 substrates|
47956085|NCT02957929|DRUG|Matching placebo control|
47956086|NCT05968339|OTHER|Survey|"The survey will be distributed via scientific anesthesiology societies and will be open for a total of 12 consecutive months.~Participation in the survey will be voluntary and anonymous - individual consent will be implied by willingness to complete the survey.~The survey will be conducted via SurveyMonkey. SurveyMonkey allows Health Insurance Portability and Accountability Act (HIPAA)(12) compliant surveys to be created. These follow strict rules around the protection of health information. Of note, SurveyMonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored. Access to the database will be password protected and only the authors will have access for the purpose of data analysis at the end of the survey period. Analysis using chi squared tests and logistic regressions will be performed by trained statisticians."
47956087|NCT01462487|DRUG|Treatment with zanamivir|Subjects treated with zanamivir
47956088|NCT01739309|DRUG|Abemaciclib|Administered orally
47956089|NCT01728350|BEHAVIORAL|HOPE - Helping Others through Purpose and Engagement|
47956090|NCT04920344|PROCEDURE|Transoral Surgery|Patients will undergo transoral surgery
47956091|NCT04920344|RADIATION|External Beam Radiation Therapy|Patients in Group II and Group III will undergo External Beam Radiation Therapy (EBRT) RT following transoral surgery.
47956092|NCT04920344|DRUG|Cisplatin|Patients in Group III will receive cisplatin, 30 mg/m2, administered intravenously weekly per for 6 weeks.
47956093|NCT04920344|PROCEDURE|Incisional Tumor Biopsy|Incisional biopsy of the primary tumor site will be required to confirm p16/HPV status of the tumor
47956094|NCT04920344|OTHER|Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment|Assess ctDNA levels at baseline, 2 weeks, 4 weeks, 10 weeks, 24 weeks and 1 year after the surgery.
48110000|NCT04643236|BEHAVIORAL|Oral hygiene motivation session|Standard oral hygiene instructions, including brushing and flossing, were demonstrated to each patient after nonsurgical periodontal treatment.
48110001|NCT02523651|GENETIC|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
48110002|NCT02523651|OTHER|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
48110003|NCT05022147|DEVICE|High-Frequency-Only Stimulation|Control condition, constant high-frequency DBS stimulation (130Hz)
48110004|NCT05022147|DEVICE|Low-Frequency-Only Stimulation|Experimental condition, constant low-frequency DBS stimulation (60 Hz)
48110005|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.
48110006|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.
48110007|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.
48303412|NCT05640232|DRUG|CDE100 association|Experimental drug.
48303413|NCT05640232|DRUG|Buscopan® Composto association|Active comparator.
48639985|NCT04978506|DRUG|BI 1569912|BI 1569912
48639986|NCT04978506|DRUG|Placebo|Placebo
47956095|NCT04920344|OTHER|MD Anderson Dysphagia Index|MDADI is a 20 item quality of life questionnaire specifically focusing on swallowing aspects. It was originally designed for head and neck cancer patients. The total score ranges from 20 to 100 with the higher score indicating higher level of function.
47956096|NCT04920344|OTHER|University of Washington Quality of Life Questionnaire|University of Washington Questionnaire is a 15 item quality of life instrument specifically designed for head and neck cancer patients.
47956097|NCT04920344|OTHER|Euro-QOL 5 dimension scale questionnaire|A generic quality of life and cost utility instrument widely used and validated for multiple disease settings, including head and neck cancer.
47956098|NCT04920344|DIAGNOSTIC_TEST|Modified barium swallow (MBS) evaluation with aspiration-penetration scale|"The videofluoroscopic modified barium swallow (MBS) study is the gold standard for for the evaluation of dysphagia, and specifically, airway protective mechanisms.~The penetration/aspiration (PEN/ASP) scale is a routinely used eight-point scale designed to describe the depth of bolus penetration into the airway and the patient response to the penetration or aspiration."
47956099|NCT00551447|DRUG|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
47956100|NCT00551447|DRUG|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
47956101|NCT00551447|DRUG|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
47956102|NCT00736814|DRUG|carboplatin|Given intravenously
47956103|NCT00736814|DRUG|docetaxel|Given intravenously
47956104|NCT00736814|DRUG|gemcitabine hydrochloride|Given intravenously
47956105|NCT00736814|DRUG|vinorelbine tartrate|Given intravenously
47956106|NCT06129162|DEVICE|Conventional Syringe|Dental local anesthesia injection is given by conventional syringe by two injection methods inferior alveolar nerve block and buccal infiltration.
47956107|NCT06129162|DEVICE|STA Single Tooth Anesthesia® System.|Dental local anesthesia injection is given by STA device by two injection methods inferior alveolar nerve block and buccal infiltration.
48110008|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.
48110009|NCT05022147|DRUG|OFF Dopaminergic Medication|All six device interventions will be performed in medication OFF state
48303414|NCT00001933|DRUG|Nefiracetam|
48303415|NCT06283095|PROCEDURE|expansion palatoplasty|surgical procedure
48303416|NCT00491114|DRUG|Gemcitabine|
48339944|NCT04728451|BEHAVIORAL|Spectacle wear support|Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.
48639987|NCT04595370|DRUG|AZD9977|Participants will receive AZD9977 as per the arms they are randomized.
48639988|NCT04595370|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized.
48639989|NCT04581629|DRUG|Encaleret|Tablets administered orally
48639990|NCT06450470|DEVICE|Therapeutic lens alone|Therapeutic lens will be apposed on the patient's eye after crosslinking. Therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
47956108|NCT06129162|DEVICE|Star Pen anesthesia device.|Dental local anesthesia injection is given by Star Pen anesthesia device by two injection methods inferior alveolar nerve block and buccal infiltration.
47956109|NCT06281574|PROCEDURE|Questionnaires|"To assess the shoulder function, the following questionnaires will be used:~The validated Dutch translation of the Oxford Shoulder Score (OSS) The validated Dutch translation of the Simple Shoulder Test (SST) The Subjective Shoulder Value (SVV) To assess the work ability patients will use the validated Dutch work-related questionnaire for upper extremity disorders (WORQ-UP)"
47956110|NCT01788046|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
47956111|NCT01788046|DRUG|Placebo|Administered intravenously (IV) three times per week.
47956112|NCT03953820|DRUG|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
47956113|NCT03953820|DRUG|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
47956114|NCT03028103|DRUG|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
47956115|NCT03028103|DRUG|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
47956116|NCT03028103|DRUG|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
48110010|NCT05022147|DRUG|ON Dopaminergic Medication|All six device interventions will be performed in medication ON state
48110011|NCT00382161|DRUG|Fluvastatin-sodium|
48339945|NCT04728451|DEVICE|Spectacles|Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
48480964|NCT02667821|OTHER|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
48639991|NCT06450470|COMBINATION_PRODUCT|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on the patient's eye after crosslinking. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
48639992|NCT01167712|BIOLOGICAL|Bevacizumab|Given IV
48639993|NCT01167712|DRUG|Carboplatin|Given IV
48639994|NCT01167712|PROCEDURE|Computed Tomography|Correlative studies
48639995|NCT01167712|DRUG|Paclitaxel|Given IV
48639996|NCT01167712|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48639997|NCT06013800|OTHER|Measurement of sodium levels|Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (\>135mEq/L).
48639998|NCT01834300|BEHAVIORAL|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
48639999|NCT01834300|BEHAVIORAL|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
48640000|NCT05894564|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
47956117|NCT03028103|DRUG|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
47956118|NCT06221462|DRUG|Sintilimab|200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year
47956119|NCT06221462|DRUG|Anlotinib|8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
48110012|NCT02823548|DRUG|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
48110013|NCT02823548|DRUG|Placebo|Placebo
48110014|NCT06530264|OTHER|DCR|6. An H shaped incision at the postero-inferior lacrimal sac is made, with a long anterior flap and shorter posterior flap. Similarly an H shaped incision at the nasal mucosa is made. The posterior flap of lacrimal sac is sutured with posterior flap of nasal mucosa in interrupted fashion using 6-0 vicryl sutures in Group A, while in Group B the posterior flap is trimmed without suturing.
48110015|NCT01391130|DRUG|LY2510924|Administered subcutaneously
48110016|NCT01391130|DRUG|Sunitinib|Administered orally
48110017|NCT05824442|BIOLOGICAL|Blood sample for multiplex QPCR technique|Blood sampling specifically for qPCR Echino at inclusion and one year after
48110018|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
48640001|NCT05894564|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
48640002|NCT03927846|BEHAVIORAL|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
47956120|NCT03979612|GENETIC|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
48110019|NCT01807858|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
48110020|NCT01807858|OTHER|Maltodextrin|Maltodextrin
48303417|NCT05222347|DIETARY_SUPPLEMENT|Olive Leaf Tea|Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
48640003|NCT05492994|DIAGNOSTIC_TEST|Spirometry|Pulmonary function test
48110021|NCT01807858|DIETARY_SUPPLEMENT|İnulin|900 mg inulin per day will be given
48110022|NCT02939378|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
48110023|NCT02939378|DIETARY_SUPPLEMENT|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
48110024|NCT05116839|DEVICE|the first 15 minutes with pressure support ventilation|PSV pressure support ventilation:triggered by minute volume \< 3 Liter ,with no frequency
48110025|NCT05116839|DEVICE|the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode|continous positive air way pressure CPAP mode at 10 cm H2o .
48110026|NCT05116839|DEVICE|i gel air way|supraglottic air way device
48110027|NCT01685528|BEHAVIORAL|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
48110028|NCT00754936|DRUG|Escitalopram|20 mg by mouth daily
48110029|NCT01101152|DRUG|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
48110030|NCT03808883|BEHAVIORAL|TGNC Directed Advocacy Meetings|Series of 18 meetings with TGNC cohort, including 3 facilitated dialogues with the healthcare participants, to articulate barriers to access and to enter into dialogue with medical providers and staff.
48110031|NCT03808883|BEHAVIORAL|Facilitated Dialogues between TGNC Cohort and Healthcare Participants|Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.
48110032|NCT00004878|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48110033|NCT00004878|DRUG|cytarabine|
48110034|NCT00004878|DRUG|fludarabine phosphate|
48110035|NCT00004878|DRUG|idarubicin|
48303418|NCT01856491|DEVICE|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
48110036|NCT00004878|DRUG|methotrexate|
48110037|NCT00004878|DRUG|tacrolimus|
48640004|NCT05492994|DIAGNOSTIC_TEST|Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)|Pulmonary function test
48640005|NCT05492994|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging
48640006|NCT05492994|DIAGNOSTIC_TEST|Chest Computer Tomography|Chest Computer Tomography
48110038|NCT00004878|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48110039|NCT00004878|PROCEDURE|peripheral blood stem cell transplantation|
48110040|NCT04628286|OTHER|Sham Laser|Sham Laser in plantar fascia
48110041|NCT04628286|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
48640007|NCT05492994|DIAGNOSTIC_TEST|Blood biomarker analysis|Blood biomarker analysis
48640008|NCT01667952|GENETIC|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
48640009|NCT01667952|GENETIC|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
48110042|NCT01296425|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
48110043|NCT02644174|PROCEDURE|Bariatric Surgery|
48110044|NCT01336283|OTHER|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
48110045|NCT01336283|OTHER|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
48110046|NCT01336283|OTHER|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
47956121|NCT01162070|OTHER|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
47956122|NCT01162070|OTHER|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
47956123|NCT04049864|BIOLOGICAL|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
47956124|NCT04049864|BIOLOGICAL|Salmonella oral vaccine|suspension 10\^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
47956125|NCT04049864|DRUG|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
48303419|NCT03348657|OTHER|Music Session|Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
47956126|NCT01892215|PROCEDURE|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
47956127|NCT01892215|PROCEDURE|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
47956128|NCT03285854|DIAGNOSTIC_TEST|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
48303420|NCT06108323|BEHAVIORAL|Theapeutic exercise plus action observation training|Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
48303421|NCT06108323|BEHAVIORAL|Therapeutic exercise plus sham observation training|Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
48303422|NCT00404404|BIOLOGICAL|bevacizumab|
48303423|NCT00404404|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
48303424|NCT00679159|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
48303425|NCT00679159|BIOLOGICAL|Prevenar|Streptococcus pneumoniae vaccine
48303426|NCT01148056|RADIATION|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
48303427|NCT03962998|DRUG|Lactulose/Rhamnose solution|Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
48303428|NCT03962998|DRUG|MB-102|MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
48640010|NCT01667952|OTHER|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
48640011|NCT06218914|BIOLOGICAL|NT-112: Autologous, engineered T Cells targeting KRAS G12D|"* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion of T cell receptor (TCR) T cells~* Post-infusion recombinant interleukin-2 (rIL-2)"
48640012|NCT04953169|OTHER|Biobank Video|The video describes the process of biobanking with visuals
48640013|NCT04953169|OTHER|Non-Video|The non-video group will receive a written informed consent
47956129|NCT02819739|DRUG|medical oxygen|
47956130|NCT01761864|BEHAVIORAL|academic detailing intervention|
47956131|NCT01354587|DRUG|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
47956132|NCT00423722|DRUG|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
47956133|NCT00423722|DRUG|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
47956134|NCT02987556|DEVICE|Continuous Glucose Monitoring|Collection of glucose data
47956135|NCT02987556|DEVICE|External Insulin Pump|insulin delivery
47956136|NCT02987556|OTHER|telemdecine|Remote follow up by care health providers team
48303429|NCT02209597|DRUG|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
47956137|NCT02987556|DEVICE|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
47956138|NCT05321108|OTHER|Group A (GA)(Aerobic exercise group)|Aerobic Exercise has been demonstrated to be a safe strategy to improve several health outcomes in Systemic lupus erythematosus (SLE)SLE, including depressive symptoms or, even more importantly, fatigue and quality of life.
48303430|NCT01005394|DEVICE|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
48303431|NCT03344328|DRUG|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
48303432|NCT01795040|DIETARY_SUPPLEMENT|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
48339946|NCT01985386|DIETARY_SUPPLEMENT|GDS capsule with meal|GDS capsule with meal
48640014|NCT06189872|DEVICE|Attune Cementless|"* Attune AFFIXIUM Cementless Tibial Baseplate, Fixed Bearing~* Attune POROCOAT Cementless Femoral Component, Cruciate Retaining~* Attune AOX Antioxidant Polyethylene Tibial Insert, Cruciate Retaining~* Attune AOX Patellar Button, Domed or Medialized Dome, Cemented or Cementless (surgeon preference for resurfacing)"
47956139|NCT05321108|OTHER|Group B (GB) (Whole-body vibration (WBV) group)|(WBV) has been growing over the years. WBVE occurs when the subject is in contact with the vibrating platform in operation and is exposed to the generated mechanical vibrations. WBV has a positive action on muscle strength, bone formation, balance, flexibility, functional capacity and fatigue.
47956140|NCT01020149|OTHER|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
47956141|NCT04741711|PROCEDURE|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
47956142|NCT04741711|PROCEDURE|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
47956143|NCT02254941|DRUG|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
48303433|NCT05585411|PROCEDURE|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~1. RBBB configuration observed during unipolar tip pacing~2. One of the following should be met:~   1. Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 \[LV activation time\]) of \>10ms during increasing output~  2. Short and constant stim-LVAT and the shortest stim-LVAT \<75ms in non-LBBB and \<85ms in LBBB~  3. Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~  4. LBB potential (LBB-V interval of 15 to 35ms)~  5. Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
48303434|NCT05585411|PROCEDURE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
48303435|NCT00747890|PROCEDURE|Modified tonsillectomy|"* Tonsillectomy~* Uvulectomy~* Soft palatal resection~* Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
48303436|NCT00747890|OTHER|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
48303437|NCT04933006|DIAGNOSTIC_TEST|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
48303438|NCT04471103|OTHER|Participation in a Delphi survey|Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
48303439|NCT05616065|OTHER|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
48303440|NCT05616065|OTHER|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
48303441|NCT05635084|DRUG|YN001|Dose ranges from 2-90mg
48303442|NCT05635084|DRUG|Placebo for YN001|5% dextrose injection to mimic the YN001
47956144|NCT02254941|BIOLOGICAL|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
48303443|NCT04254237|PROCEDURE|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
48303444|NCT04254237|PROCEDURE|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
48303445|NCT00779090|PROCEDURE|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
48303446|NCT01568190|BIOLOGICAL|AVANZ MITE|Immunotherapy Dermatophagoides mix
48303447|NCT04481425|OTHER|SMS intervention|SMS intervention
48303448|NCT00728507|DRUG|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects \<= 45kg and 450mg for those \>45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
47956145|NCT05073978|OTHER|No intervention|This is an observational study without any intervention
47956146|NCT06015646|BEHAVIORAL|Personalized lifestyle coaching and educational handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
47956147|NCT06015646|BEHAVIORAL|Handout|Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
47956148|NCT04298515|DIAGNOSTIC_TEST|Nesfatin-1|Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
48303449|NCT00728507|DRUG|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
48303450|NCT05300867|OTHER|Neurorehabilitation|Neurorehabilitation with soft exsoskeleton robotic 3-week-long
48303451|NCT05300867|OTHER|Physiotherapy|Physiotherapy 3-week-long
48303452|NCT04072354|DRUG|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
48303453|NCT04072354|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
48303454|NCT04072354|DRUG|Placebo|Placebo tablet dosed once daily
48339947|NCT01985386|DIETARY_SUPPLEMENT|Ferrous sulfate with meal|Ferrous sulfate with meal
48303455|NCT03254017|PROCEDURE|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
48303456|NCT03254017|OTHER|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
48303457|NCT03830801|DEVICE|IVLCM tethered capsule|Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule
48110047|NCT05417893|DEVICE|MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)|The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
47956149|NCT00376064|DRUG|Octreotide acetate and cabergoline/Octrotide and Somavert|
48110048|NCT04065932|DRUG|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
48110049|NCT04065932|DRUG|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
48110050|NCT04065932|DRUG|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
48110051|NCT01348191|PROCEDURE|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
48110052|NCT00226148|PROCEDURE|Use of a membrane to cover bonedefects around implant|
48303458|NCT00450203|BIOLOGICAL|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
48303459|NCT00450203|DRUG|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
47956150|NCT03781843|DRUG|Genicular nerve block with lidocaine|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
47956151|NCT03781843|DRUG|Genicular nerve block with saline|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
47956152|NCT03781843|DRUG|Genicular nerve block with dextrose|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
48110053|NCT00226148|DEVICE|Use of bonechips to fill up defects around implant|
48110054|NCT00226148|PROCEDURE|Use of membrane and bonechips to manage defects|
48110055|NCT00968448|BEHAVIORAL|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
48110056|NCT00968448|BEHAVIORAL|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
48110057|NCT00649935|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fed
48110058|NCT00649935|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fed
48110059|NCT04021667|OTHER|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
48110060|NCT00486330|DRUG|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
48303460|NCT00450203|DRUG|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
48303461|NCT00450203|DRUG|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
48303462|NCT00450203|PROCEDURE|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
48303463|NCT00450203|PROCEDURE|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
48303464|NCT00450203|PROCEDURE|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
48303465|NCT00450203|DRUG|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
48303466|NCT03042013|DRUG|ASP8273|Oral
48303467|NCT00879268|DEVICE|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
48480965|NCT05993598|OTHER|hippotherapy|Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
48480966|NCT01353807|DIETARY_SUPPLEMENT|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
47956153|NCT05289427|PROCEDURE|ultrasound guided triple injection peri-sartorius block|Patients will receive ultrasound guided triple injection peri-sartorius block preoperatively before surgical incision
47956154|NCT05289427|PROCEDURE|Femoral Nerve Block|Patients will receive femoral nerve block (FNB) before surgical incision
48303468|NCT02560701|OTHER|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
48303469|NCT03042611|DRUG|Rivoceranib|Oral tablet
48640015|NCT01581580|DEVICE|Medtronic Activa Tremor Control System|Medtronic DBS Therapy delivers electrical stimulation to an area in the brain to help treat Parkinson's Disease, dystonia, and essential tremor.
48640016|NCT01581580|PROCEDURE|Deep Brain Stimulation|standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
48640017|NCT04702750|BEHAVIORAL|Targeted memory reactivation (odors)|I will unobtrusively and repeatedly present learning-related odors during sleep using an olfactometer. This method was shown to improve memory in various tasks. The odors will be presented in blocks with short breaks in-between. Odors will be pleasant as to not wake the participant up. The odors will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The odors presented will be non-congruently associated with instructions in a previous learning task. This manipulation is within-subject - all participants will be exposed to all the odors during sleep, but odors will be associated with different instructions for each participant (counterbalanced).
48640018|NCT04702750|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will be exposed to sounds, but different specific sounds will be presented for each individual participant.
48640019|NCT04444297|OTHER|3D Telemedicine|A consultation performed with a 3D form of telemedicine
48640020|NCT04444297|OTHER|2D Telemedicine|A consultation performed with 2D (standard) telemedicine
48480967|NCT01353807|DIETARY_SUPPLEMENT|Olive oil|4 1-g gelatine capsules with virgin olive oil
48640021|NCT06694844|PROCEDURE|Socket preservation with M1|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M1 membrane (peramem membrane).
48303470|NCT03042611|DRUG|Placebo|Oral tablet
48303471|NCT02268565|DRUG|Aspirin|81mg aspirin daily at bedtime over a 2 week period
48303472|NCT02268565|DRUG|Placebo|pill that looks like aspirin without the effects of aspirin
47956155|NCT03591185|OTHER|FallSensing Clinical Tool|"FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise."
47956156|NCT00748735|PROCEDURE|Implantation of a cardiac resynchronization therapy device|
48303473|NCT04550442|DRUG|Azacitidine|Given IV or SC
48303474|NCT04550442|DRUG|Venetoclax|Given PO
47956157|NCT00748735|PROCEDURE|Echocardiography (myocardial deformation imaging)|
47956158|NCT05324722|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
48339948|NCT01569997|OTHER|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
48640022|NCT06694844|PROCEDURE|Socket preservation with M2|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M2 membrane (Cytoplast membrane).
48640023|NCT05257083|DRUG|Daratumumab|Daratumumab will be administered SC.
48640024|NCT05257083|DRUG|Bortezomib|Bortezomib will be administered SC.
48640025|NCT05257083|DRUG|Lenalidomide|Lenalidomide will be administered orally.
48640026|NCT05257083|DRUG|Dexamethasone|Dexamethasone will be administered orally.
48640027|NCT05257083|DRUG|Cilta-cel|Cilta-cel will be administered intravenously
48640028|NCT05257083|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
47956159|NCT05324722|OTHER|cross body stretch|crossbody stretch performed by an individual
47956160|NCT02170194|BEHAVIORAL|Resilience Enhancement Training via Smart Phone|
47956161|NCT02170194|BEHAVIORAL|Daily Text Messages|
47956162|NCT05541042|OTHER|Observational only|This is an observational study
48303475|NCT05419921|DIAGNOSTIC_TEST|Hysterosalpingo-lidocaine-foam-sonography combined with power doppler (HyLiFoSy-PD)|"Women in the reproductive age group between 18- and 40-years old presenting with primary or secondary infertility who underwent HSG in the previous 5 years as a part of their infertility work-up with availability of good-quality HSG images, \& did not get pregnant in this period, and gave no history of incidences that might affect their tubes, such as : abdominal surgery or laparoscopy, pelvic inflammatory disease, smoking, and intrauterine device insertion.~Women fitting these inclusion criteria and scheduled for LDT as part of their infertility work up will be considered. HyLiFoSy-PD will be carried out few days before the already scheduled LDT."
47956163|NCT06141018|DEVICE|Cross-linked intra-articular hyaluronic acid|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
48303476|NCT03061123|OTHER|Questionnaire|
48339949|NCT02402621|DRUG|fentanyl|fentanyl with antiemetic drug
48339950|NCT03732521|OTHER|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
48480968|NCT04241133|BEHAVIORAL|The UnProcessed Pantry Project (UP3)|UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
48480969|NCT04028154|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
48480970|NCT04028154|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
48480971|NCT05862272|DRUG|Relugolix Combination Tablet|A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
48480972|NCT06216171|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy
48480973|NCT06216171|RADIATION|image guided radiotherapy without online adaptation|image guided radiotherapy without online adaptation
47956164|NCT06141018|OTHER|Placebo|Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
48480974|NCT03433131|DRUG|Pitolisant|Tablets
48480975|NCT05412524|BEHAVIORAL|reading|Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
48640029|NCT05257083|DRUG|Fludarabine|Fludarabine will be administered intravenously.
48640030|NCT05396170|PROCEDURE|phlebotomy|500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia
48640031|NCT05128032|DEVICE|Standard microcatheter|Small device used for mapping as part of radioembolization procedure
48640032|NCT05128032|DEVICE|PEDD device|Pressure enabled small device used for mapping as part of radioembolization procedure
48640033|NCT06084286|BIOLOGICAL|Dual-targeting CLDN18.2 and PD-L1 CAR-T cells|The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
48640034|NCT06331312|BIOLOGICAL|Secukinumab|2 x 150mg/1mL PFS secukinumab
48640035|NCT06546202|OTHER|No Drug|This is an non-interventional, observational study. No drug was administered during this study.
48640036|NCT03787212|DEVICE|MiBo ThermoFlo|Test Device
48640037|NCT03787212|DEVICE|Bruder Mask|Control Device
48640038|NCT04558853|DRUG|autologous NK cells|Autologous ex vivo expanded and activated NK cells
48640039|NCT06695598|DRUG|CKD-383|QD, PO
48640040|NCT06695845|DRUG|Zanidatamab|Administered by intravenous (IV) infusion
48640041|NCT03687359|OTHER|Standard of care|Treatment as per standard practice
48640042|NCT03725059|BIOLOGICAL|Pembrolizumab (K)|IV infusion Q3W
48640043|NCT03725059|DRUG|Placebo (P)|Normal saline or dextrose IV infusion Q3W
48640044|NCT03725059|DRUG|Paclitaxel (X)|IV infusion QW
48640045|NCT03725059|DRUG|Doxorubicin (A)|IV infusion either in Q2W or Q3W
48640046|NCT03725059|DRUG|Epirubicin (E)|IV infusion either in Q2W or Q3W
48640047|NCT03725059|DRUG|Cyclophosphamide (C)|IV infusion either in Q2W or Q3W
48640048|NCT03725059|DRUG|Endocrine therapy|Variable endocrine therapy for up 10 years
48640049|NCT03725059|RADIATION|Radiation therapy|Variable radiation therapy per local standard of care
48303477|NCT04874909|OTHER|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
48303478|NCT04874909|OTHER|Urine sample|Urine sample (500 ml) once time
48303479|NCT02619253|DRUG|Pembrolizumab|
48303480|NCT02619253|DRUG|Vorinostat|
48303481|NCT06313190|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.
48303482|NCT06313190|DRUG|Sintilimab|Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.
48303483|NCT00013598|DRUG|Pioglitazone|
48303484|NCT01883128|DEVICE|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
48303485|NCT01883128|PROCEDURE|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
48303486|NCT01883128|PROCEDURE|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
48303487|NCT04624893|DRUG|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
48303488|NCT00863785|DRUG|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
48303489|NCT01391312|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
48303490|NCT01391312|DRUG|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
48303491|NCT05777993|DRUG|Mitapivat|Tablets
48303492|NCT06692686|DEVICE|Ankle-foot orthoses (AFOs)|Participants will wear each of the three AFO treatment options (custom-fit, custom fabricated-solid ankle, and custom fabricated-articulating) over three separate four-week periods. During each four-week period, individuals will also receive up to four AFO training sessions to ensure optimized functionality. Through the course of the entire real-world use period, orthotists will provide any care and adjustments needed consistent with routine clinical practice. Within one week of completing the four-week period, the participants will return to their clinic or gait lab for study assessments.
48480976|NCT02281682|DRUG|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
48480977|NCT02281682|DRUG|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
48303493|NCT03697395|DIAGNOSTIC_TEST|Lung transplant recipient without MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.
48303494|NCT03697395|DRUG|Lung transplant recipient with MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)
48303495|NCT03619980|OTHER|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
48480978|NCT02281682|DRUG|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
48480979|NCT02281682|PROCEDURE|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
48640050|NCT03725059|PROCEDURE|Surgery|Surgery for breast cancer
48640051|NCT06456463|DRUG|Tagraxofusp|Tagraxofusp will be administered by intravenous infusion on days 4, 5, and 6 of each 28-day cycle.
48640052|NCT06456463|DRUG|Venetoclax|Venetoclax will be administered as an oral tablet (400 milligrams) daily of each 28-day cycle.
48640053|NCT06456463|DRUG|Azacitidine|Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
48640054|NCT06628362|DRUG|Placebo|Placebo will be volume-matched and administered subcutaneously (SC) once weekly.
48640055|NCT06628362|DRUG|CT-388|CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
48640056|NCT03024671|OTHER|Patch test application|test patch with cosmetic product will be applied to the back
48303496|NCT05904886|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
48303497|NCT05904886|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
48110061|NCT03312309|PROCEDURE|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
48110062|NCT02104765|DRUG|LY2951742|Administered subcutaneously.
48110063|NCT02104765|DRUG|Placebo|Administered subcutaneously.
48110064|NCT01444235|DRUG|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
48110065|NCT01444235|DRUG|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
48110066|NCT04878081|BEHAVIORAL|hot flush|"Hot Flash Diaries to record the change of daily hot flush symptoms for 30 days. The Hot Flash Related Daily Interference Scale to record how much did hot flush effect daily life.~The Kupperman menopausal index to evaluate the severity of menopausal symptoms. The Pittsburgh Sleep Quality Index to evaluate sleep disorder. Wireless temperature monitor to record hot flush and body temperature during sleeping.~Classify patients' traditional Chinese constitution by using Physical classification and judgment self-test table."
48110067|NCT05969665|DEVICE|Fitbit Inspire 2|A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.
48110068|NCT05969665|DEVICE|Abbott Freestyle Libre 3|A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.
48110069|NCT02194933|DRUG|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
48110070|NCT00624312|DRUG|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
48110071|NCT00624312|DRUG|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
48110072|NCT03829917|DRUG|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
48110073|NCT03829917|DRUG|miltefosine|28 days of miltefosine
48110074|NCT03829917|DRUG|paromomycin|28 days of paromomycin creaam
48110075|NCT05964231|DIETARY_SUPPLEMENT|Heat-treated PS23|Lactobacillus paracasei PS23 heat-treated, 2caps daily use
48110076|NCT05964231|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, 2caps daily use
48110077|NCT06554548|DRUG|HS-10518|Treatment A: Single oral dose of HS-10518 160 mg tablet under fasted conditions Treatment B: Single oral dose of HS-10518 160 mg tablet after a high-fat meal
48303498|NCT05904886|DRUG|Tiragolumab|Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
48303499|NCT05904886|OTHER|Placebo|Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.
48303500|NCT04935879|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
47956165|NCT02048969|DRUG|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
47956166|NCT02048969|DRUG|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
47956167|NCT03344133|BEHAVIORAL|Exercise|4-week moderate intensity exercise programme
48110078|NCT00631579|DRUG|Rasburicase (SR29142)|
48110079|NCT01132794|DRUG|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
48110080|NCT01132794|DRUG|Placebo|Intranasal nasal saline
48110081|NCT04439799|DRUG|Testosterone Cypionate 200 Mg/ML|Participants in this group will receive intramuscular testosterone cypionate injections of 1 cc (200mg) once every 14 days for four months.
48110082|NCT04439799|DRUG|Intranasal Testosterone|Participant in this group will receive Intranasal testosterone administered using a multi-dose dispenser, as two or three daily doses (5.5 mg per nostril, 11.0 mg single dose) for 4 consecutive months,
48303501|NCT04935879|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
48303502|NCT06211504|DEVICE|ProStop, sinus tarsi implant (STI)|Insertion of a sinus tarsi implant (ProStop from Arthrex) in sinus tarsi
48303503|NCT06211504|PROCEDURE|Conventional surgery|MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
48480980|NCT06123026|DRUG|Cabergoline|1mg oral cabergoline given to participants once
48110083|NCT04318717|DRUG|Pembrolizumab|Pembrolizumab is commercially available
48110084|NCT04318717|RADIATION|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
48640057|NCT02522260|OTHER|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
47956168|NCT02866708|DEVICE|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
47956169|NCT06086275|DRUG|Buprenorphine|At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
47956170|NCT00003870|DRUG|cyclophosphamide|
47956171|NCT00003870|DRUG|methotrexate|
47956172|NCT00003870|PROCEDURE|allogeneic bone marrow transplantation|
47956173|NCT00003870|RADIATION|iodine I 131 monoclonal antibody BC8|
47956174|NCT00003870|RADIATION|radiation therapy|
47956175|NCT03098121|DRUG|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
47956176|NCT03299465|BEHAVIORAL|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
47956177|NCT04597775|DRUG|hydroxychloroquine|hydroxychloroquine
47956178|NCT05652881|PROCEDURE|Joint Lavage|An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
47956179|NCT04234074|DEVICE|Volusense paediatric monitoring device|Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
48303504|NCT04465370|DEVICE|Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight|A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior to the start of the catheterization procedure. Intermittent cardiac output and other hemodynamic parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.
48303505|NCT02853331|BIOLOGICAL|Pembrolizumab|Intravenous infusion
47956180|NCT04496700|PROCEDURE|Whole blood donation and transfusion|"The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only."
47956181|NCT00187200|DEVICE|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
47956182|NCT00187200|DEVICE|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
48303506|NCT02853331|DRUG|Axitinib|Oral tablet
48303507|NCT02853331|DRUG|Sunitinib|Oral capsule
48480981|NCT06123026|DRUG|Placebo|1 encapsulated placebo tablet given to participants after procedure
48480982|NCT06176625|BEHAVIORAL|Communication Signage|Signage regarding effective communication strategies posted on door to patient's room.
48480983|NCT06176625|BEHAVIORAL|Amplifier Use|Patient is provided amplification device and signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
48303508|NCT04794699|DRUG|IDE397|IDE397 dosed orally
48303509|NCT04794699|DRUG|Docetaxel|Intravenous infusion
48480984|NCT02521077|DRUG|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
48480985|NCT02521077|OTHER|Normal Saline|Saline 0.9%
48480986|NCT04888949|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
48480987|NCT04888949|BIOLOGICAL|Placebo|Commercially available saline.
48480988|NCT06481098|DRUG|HM15275|HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
48480989|NCT06481098|DRUG|Placebo of HM15275|A sterile, matching solution supplied in pre-filled syringes.
48480990|NCT04894071|DRUG|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
48480991|NCT04894071|DRUG|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
48480992|NCT00777933|DRUG|tacrolimus|
48480993|NCT00777933|DRUG|cyclosporine|
48480994|NCT00794417|DRUG|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
48480995|NCT00794417|DRUG|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
48480996|NCT00794417|DRUG|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
48480997|NCT02359201|DRUG|V0018|Oromucosal - Single dose
48480998|NCT02359201|DRUG|Placebo|Oromucosal - Single dose
48640058|NCT02522260|OTHER|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
48640059|NCT02522260|OTHER|Standard supportive care|Standard supportive care
47956183|NCT03939754|BEHAVIORAL|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
48303510|NCT04794699|DRUG|Paclitaxel|Intravenous infusion
48303511|NCT04794699|DRUG|Sacituzumab govitecan|Intravenous infusion
48480999|NCT05312086|OTHER|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
48481000|NCT00965016|PROCEDURE|hypothermia|Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour
48481001|NCT05783661|OTHER|Conventional antibiotic strategies|Treatment according to the local guidelines of the Hospital Clinic de Barcelona.
48481002|NCT05783661|OTHER|Regimens guided by epidemiological surveillance|Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
48481003|NCT00003330|BIOLOGICAL|recombinant interleukin-12|
47956184|NCT00876421|DRUG|Placebo|Placebo / 12 weeks
47956185|NCT00876421|DRUG|Tolterodine|4mg / 12 weeks
47956186|NCT00876421|DRUG|ONO-8539|low dose / 12 weeks
47956187|NCT00876421|DRUG|ONO-8539|medium dose / 12 weeks
47956188|NCT00876421|DRUG|ONO-8539|higher dose / 12 weeks
47956189|NCT05403788|DEVICE|Intervention with virtual reality|"VR intervention with OCULUS QUEST2 (OCULUS VR, USA) consiste on a VR helmet positioned over subject head. The software consisted of a 3D environment with exercises of upper limbs and visual feedback for the treatment of cognitive and motor dysfunction. The therapist have real-time access to the activities in the 3D environment vby real-time video transmission of the helmet activity.~The program include a single session. Each session is monitored on safety aspects of the subjects with emphasis on possible side effects of virtual reality."
47956190|NCT00406965|DRUG|HAE1 (PRO98498)|
47956191|NCT05393011|DRUG|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
47956192|NCT00004397|DRUG|heme arginate|
47956193|NCT00004397|DRUG|tin mesoporphyrin|
48481004|NCT01941108|BEHAVIORAL|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
48481005|NCT05732259|OTHER|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
48481006|NCT05732259|OTHER|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
47956194|NCT02418429|OTHER|waxy maize starch|pancake test meal with waxy maize starch only
47956195|NCT02418429|OTHER|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
48110085|NCT03337568|PROCEDURE|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
48481007|NCT04735731|DIAGNOSTIC_TEST|Echography|Echography of diaphragma and other respiratory muscles
48640060|NCT03958604|PROCEDURE|Neurostimulation|Spinal cord stimulation with burst modality for discogenic low back pain
48640061|NCT06446362|BEHAVIORAL|IMCHB-Based Breastfeeding Support Program|"This intervention includes a structured breastfeeding support program based on the Interaction Model of Client Health Behavior (IMCHB). It consists of:~Educational Sessions: Conducted during the last trimester of pregnancy to provide information and prepare mothers for breastfeeding.~Motivational Interviews: Conducted face-to-face at 1-3 days, 15 days, 30 days, 45 days, and 60 days postpartum to address individual challenges and provide personalized support.~Follow-Up Support: Two follow-up sessions via WhatsApp video calls at 4 and 5 months postpartum to reinforce the intervention and provide ongoing assistance."
48640062|NCT06446362|BEHAVIORAL|Standard Breastfeeding Education|Participants receive the standard care provided at Family Health Centers, which includes routine breastfeeding education and support typically offered to new mothers. This standard care does not include the additional structured support interventions provided in the IMCHB-Based Breastfeeding Support Program.
48481008|NCT02849236|DRUG|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
48640063|NCT06319274|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
48640064|NCT06319274|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
48640065|NCT04818086|DRUG|Lemborexant|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
48481009|NCT02849236|DRUG|Placebo|20 mL saline 0.9%
48481010|NCT03514186|BEHAVIORAL|Speech and Language Therapy|"Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication"
48481011|NCT02924376|DRUG|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
48481012|NCT01754818|DRUG|Bendavia 10mg|
48481013|NCT01754818|DRUG|Bendavia 50mg|
48481014|NCT01754818|DRUG|Bendavia 100mg|
48481015|NCT01754818|DRUG|Placebo|
48110086|NCT01312337|DRUG|salvage iressa|Iressa 250mg per day until progression
48110087|NCT01377259|OTHER|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
48110088|NCT05499637|DRUG|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET/CT
48110089|NCT02692742|DRUG|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
48481016|NCT02382926|OTHER|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
48481017|NCT04121117|OTHER|Chronic obstructive pulmonary disease screening|"To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire."
48481018|NCT06286059|DRUG|Phentolamine|In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.
48481019|NCT01716676|OTHER|Telemedicine CPAP monitoring (webpage and televisit)|
48481020|NCT01716676|OTHER|Standard CPAP monitoring|
48481021|NCT04114942|BEHAVIORAL|Never Coach|20 weeks of didactic training and 10 weeks of internship, but no coaching.
48481022|NCT04114942|BEHAVIORAL|Internship Only Coach|20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
48481023|NCT04114942|BEHAVIORAL|Constant Coach|20 weeks of didactic training and 10 weeks of internship, with coaching throughout.
48481024|NCT05723419|PROCEDURE|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
48481025|NCT01514825|DRUG|YM150|oral
48481026|NCT01514825|DRUG|Placebo|oral
48481027|NCT06412302|OTHER|Whey Protein+Resistance Training|WP group received 25g protein on one scoop of Whey Protein Isolate (Iso100 Dymatize) with 8 weeks of resistance training 3 days a week.
48481028|NCT06412302|OTHER|High protein yogurt+Resistance Training|PY group received 24.6g protein on two High Protein yogurts (Lonco Leche) with 8 weeks of resistance training 3 days a week.
47956196|NCT02418429|OTHER|Resistant Starch|pancake test meal with resistant starch only
47956197|NCT02418429|OTHER|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
47956198|NCT01514071|BEHAVIORAL|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
48640066|NCT04818086|DRUG|Placebo|Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.
48640067|NCT04818086|DRUG|Buprenorphine-naloxone|Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
48640068|NCT04669093|BEHAVIORAL|"Placebo cream- promotion suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings)."
48640069|NCT04669093|BEHAVIORAL|"Placebo cream- prevention suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain)."
48640070|NCT04669093|BEHAVIORAL|Control cream|In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
48640071|NCT04699279|DRUG|Rosuvastatin 10mg|Rosuvastatin 10mg is taken by oral or nasal feeding every day at ang time.
48640072|NCT05399134|DIETARY_SUPPLEMENT|Modified Functional Foods|"Subjects will be provided with ABREP-fortified bread, microfluidic co-flow noodles, and 5ibrePlus™-fortified white rice served in a mixed meal.~ABREP-fortified bread: Anthocyanins are known to exert anti-diabetic effects through modulating digestion, glucose uptake, insulin secretion and sensitivity. Moreover, inhibitory effects of anthocyanins on various carbohydrases, including a-glucosidase and a-amylase have been widely reported.~Microfluidic co-flow noodles: Microfluidic technology is employed to design noodle-food structures consisting of a mix of soy protein isolate and alginate as gelling agents to offer a type of novel noodles with proteins and negligible carbohydrate content.~5ibrePlus™-fortified white rice: 5ibrePlus™ is a patented novel fibre grain product by Alchemy Foodtech Pte. Ltd (WO 2017/142477) with reduced GI. Its main constituents are insoluble resistant starch and soluble fibre."
48640073|NCT05399134|DIETARY_SUPPLEMENT|Control Functional Foods|Subjects will be provided with control function foods including white bread, beehoon noodles, and jasmine white rice served in a mixed meal.
47956199|NCT06036823|DRUG|Insulin regular|Intravenous insulin
47956200|NCT06036823|DRUG|Dextrose 50|to be given to both arms
48110090|NCT02692742|DRUG|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
47956201|NCT06036823|DRUG|salbutamol|to be given to all patients
48110091|NCT04584450|OTHER|Questionnaire|data collection using questionnaire
48110092|NCT04476745|DIETARY_SUPPLEMENT|Vitamin D3|Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
48110093|NCT02312336|OTHER|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
48110094|NCT02312336|OTHER|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
48110095|NCT05857319|BEHAVIORAL|Nutritional Psycho-Behavioral Reeducation Program|"The RNPC Program is based on a clinical protocol in three successive phases:~1. A weight loss phase during which food intake is restricted to 800-1000 kcal per day, with a nutrient distribution of 60% protein, 25% carbohydrates and 15% lipids. Patients eat two meals a day consisting of meat/fish/eggs/shellfish and vegetables, supplemented by products enriched in proteins, vitamins and minerals, and depleted in carbohydrates and lipids.~2. A stabilization phase specifically established for each patient according to their weight loss and their daily caloric needs, allowing them to gradually return to a balanced diet, with a nutrient distribution of 25% protein, 45% carbohydrates and 30% lipids. During this phase, the consumption of meal supplements gradually decreases.~3. A phase of return to dietary balance, unlimited in time, based on the precepts of the Mediterranean diet.~Each patient is followed every 14 days by a dietitian during the entire program."
48640074|NCT05857878|DRUG|BI 1815368|BI 1815368
48640075|NCT05857878|DRUG|Matching placebo|Matching placebo
48640076|NCT04948333|DRUG|ABL001 40mg BID|One tablet of 40 mg will be taken orally twice a day (BID)
48640077|NCT04948333|DRUG|ABL001 80mg QD|Two tablets of 40 mg will be taken orally once a day (QD)
47956202|NCT02051842|DRUG|Metadoxine|
48110096|NCT06296056|BIOLOGICAL|Combi|Biological immune cell therapy
48110097|NCT02959658|DRUG|Dimethyl fumarate|
48110098|NCT02959658|DRUG|Placebo|Manufactured to mimic Dimethyl Fumarate capsules
48110099|NCT01641172|PROCEDURE|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
48110100|NCT01641172|PROCEDURE|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
48481029|NCT01183117|DEVICE|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
48481030|NCT01183117|DEVICE|PTA|balloon angioplasty
47956203|NCT03158896|BIOLOGICAL|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
47956204|NCT00108173|DRUG|Zyban|
47956205|NCT01644539|DIETARY_SUPPLEMENT|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
48640078|NCT04948333|DRUG|ABL001 200mg QD|Five tablets of 40 mg will be taken orally once a day (QD)
47956206|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
47956207|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
48481031|NCT04919759|BEHAVIORAL|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
48481032|NCT04919759|BEHAVIORAL|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
48481033|NCT00209287|BEHAVIORAL|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
48481034|NCT00747292|PROCEDURE|epidural|Patients in this limb receive epidural analgesia
48640079|NCT03535519|DRUG|Methotrexate|standard of care treatment with methotrexate
48110101|NCT01641172|PROCEDURE|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
48110102|NCT01641172|PROCEDURE|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
48110103|NCT01641172|DIETARY_SUPPLEMENT|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
48481035|NCT00747292|PROCEDURE|PCA|Patients in this limb receive a PCA for their pain control
48481036|NCT00747292|PROCEDURE|Spinal|Patients in limb will receive spinal analgesia
48640080|NCT06432452|DRUG|Endothelin Receptor Antagonist|Oral capsules twice daily
48640081|NCT06432452|OTHER|Placebo control|Oral capsules twice daily
48640082|NCT06373159|OTHER|No study intervention|Retrospective observational study using Real World Data (RWD) in Japan without study intervention
48640083|NCT05877287|OTHER|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
48640084|NCT01862029|DRUG|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
48640085|NCT03449381|DRUG|BI 907828|Film-coated tablet
48640086|NCT04873856|DIETARY_SUPPLEMENT|Intervention|"The four dimensions of MINDNUT are described below:~Nutritional plan: is conducted in collaboration with the participant based on nutritional registration and information about routines and habits to reach a daily protein target of 1.5 g/kg/day. The nutritional plan is adjusted at the regular contact, and nutritional supplementation will be handed out to the participant.~Friendly reminder/informal caregiver: is a friendly reminder that encourage the participant to follow the nutritional plan and to ask for support (a note to hang on the refrigerator). The informal caregiver is a person with close contact to the participant.~Regular contacts: The participant will be contacted on regular basis (with an interval of 7-14 days) via phone and besides nutritional plan, this conversation will be used to talk about well-being, compliance and potential side-effects.~Weight diary: participants is instructed in keeping a weight diary which include registration of a daily weight."
48640087|NCT04011189|PROCEDURE|Videotaping|Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract key points, which will be the primary input for modelling algorithms and will further ensure anonymity of the patients in the video sequences.
47956208|NCT04710173|PROCEDURE|ECMO|VV-ECMO
47956209|NCT00181155|DRUG|Allopurinol|intravenous infusion of allopurinol (300mg)
47956210|NCT00181155|DRUG|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
47956211|NCT02932202|OTHER|Longitudinal Nutritional Counseling|
47956212|NCT02932202|OTHER|Standard Care|
47956213|NCT05975879|DIETARY_SUPPLEMENT|undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)|"Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
47956214|NCT05975879|DIETARY_SUPPLEMENT|Placebo|Release form: capsules with an average weight of 585 mg. No active ingredients.
47956215|NCT05933616|DEVICE|Device: Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
47956216|NCT01089673|OTHER|data collection|retrospective data collection
48640088|NCT04011189|OTHER|Questionnaires|"Patients will be asked to fill in 1-2 questionnaires before surgery/procedure/consultation (Hospital Anxiety and Depression Scale (HADS) and/or EQ-5D-3L). After surgery/procedure/consultation, patients will be again asked to fill in HADS questionnaire (optional).~For pediatrics patient, only Child Pain Anxiety Symptoms Scale (CPASS) will be administered before the surgery."
48640089|NCT04011189|DEVICE|Empatica E4 wristband|A medical grade wearable device, Empatica E4 wristband, will be used in phase 3 for pediatrics patients to monitor real-time physiological data on heart rate and body temperature.
48640090|NCT02845180|PROCEDURE|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
48640091|NCT01872260|DRUG|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
48303512|NCT06579040|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device)|Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
48303513|NCT04841304|DEVICE|Loop recorder (Reveal LINQ, Medtronic)|Implantation of a loop-recorder
48640092|NCT01872260|DRUG|Letrozole|Letrozole 2.5 mg/day
47956217|NCT02657538|OTHER|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
48110104|NCT01641172|BEHAVIORAL|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
48303514|NCT04841304|DEVICE|Continuous Glucose Measurement (G6, Dexcom)|Monitoring with a continuous glucose monitor
48303515|NCT05913908|DEVICE|DUO Transcatheter Tricuspid Coaptation Valve System|Reduction of tricuspid regurgitation through a transcatheter approach
48481037|NCT05820386|PROCEDURE|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
48640093|NCT01872260|DRUG|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
48640094|NCT05275244|DEVICE|KD Intra-Articular® gel|Depending on the joint, 3 injections will be administrated to the patient: KD Intra-Articular® gel 2.2% - 44 mg in 2 ml - (Pronolis® HD one 2.2%) in the case of shoulder and hip, or KD Intra-Articular® gel 1.6% - 16 mg in 1 ml - (Pronolis® HD mini 1.6%) in the case of the ankle and base of the thumb. The administration of the infiltrations will be with an interval of one week.
48640095|NCT05615220|DRUG|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
48640096|NCT03981198|DEVICE|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
47956218|NCT02657538|OTHER|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
47956219|NCT02657538|DEVICE|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
48110105|NCT01641172|BEHAVIORAL|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
48110106|NCT00726999|DRUG|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
48303516|NCT06153693|DRUG|Placebo|Placebo once daily (QD) for 12 weeks
48110107|NCT00726999|DRUG|Placebo|
48303517|NCT06153693|DRUG|lorundrostat Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
48303518|NCT06153693|DRUG|lorundrostat Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
48303519|NCT06095973|DRUG|GB-6002|Depending on the cohort, volume will be varied to administer.
48303520|NCT06095973|DRUG|Placebo|Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
48640097|NCT05647122|DRUG|AZD9592|Varying doses of AZD9592
48640098|NCT05647122|DRUG|Osimertinib|tablets administered orally
48640099|NCT05647122|DRUG|5-Fluorouracil (5-FU)|IV infusion
48640100|NCT05647122|DRUG|Leucovorin|IV infusion
48640101|NCT05647122|DRUG|Bevacizumab|IV infusion
47956220|NCT02657538|OTHER|Visual examination and bitewing (BW) radiography|established diagnostic methods
47956221|NCT02433561|PROCEDURE|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
47956222|NCT02433561|PROCEDURE|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
48110108|NCT00726999|DRUG|Morphine|Administered as needed
48110109|NCT06326437|OTHER|6-week dyadic intervention|Comprising 1 session with 60-90min, followed by 5 weekly internet-based sessions.
48110110|NCT00644709|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
48303521|NCT06095973|DRUG|Naropin injection|Single dose of Naropin s.c. injection.
48481038|NCT05820386|PROCEDURE|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
48481039|NCT02571803|BEHAVIORAL|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
48481040|NCT02571803|OTHER|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
48481041|NCT04862884|DRUG|HRS4800 tablets|"1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration"
48481042|NCT04862884|DRUG|placebo|"1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration"
48481043|NCT02605252|DRUG|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
48481044|NCT06050876|PROCEDURE|Laparoscopic cholecystectomy for gallbladder volvulus|Laparoscopic cholecystectomy for volvulus of gallbladder
48481045|NCT05093881|BIOLOGICAL|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
48481046|NCT05876533|DEVICE|Cordio HearO|"Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients"
48481047|NCT03185182|DRUG|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
48481048|NCT03908528|DIETARY_SUPPLEMENT|Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..
48640102|NCT05868577|DRUG|Corticosteroid injection (CSI) with local anesthetic (LA)|The PI will then administer the injection using an infracalcaneal needle peppering
48640103|NCT05868577|DRUG|Local anesthetic (LA) with Saline injection|The PI will then administer the injection using an infracalcaneal needle peppering
48640104|NCT04626596|COMBINATION_PRODUCT|Radiopaque Etonogestrel (ENG) Implant|68 mg subdermal implant
48640105|NCT06576570|BEHAVIORAL|Education presentation of surgical ergonomics|During an individual meeting with participant, a brief presentation will be supplied for review.
48640106|NCT06576570|BEHAVIORAL|Summary of Ergonomic Measurement System|Participant will view a video of their movements with a visual guideline highlighting high-risk angles and movements.
48640107|NCT04946253|BEHAVIORAL|DOCC: Evidence-based treatment for disruptive behavior and ADHD|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
48303522|NCT06371872|PROCEDURE|total transfixing injury to the rotator cuff|develop an appropriate prescription strategy with a view to improving patients' quality of life in the short, medium and long term in this condition
48303523|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Atezolizumab + Bevacizumab|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
48303524|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Placebo (IV)|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
48303525|NCT06402604|BEHAVIORAL|Aerobic exercise training|See above in arm group descriptions.
48303526|NCT06402604|BEHAVIORAL|Mindfulness Based Stress Reduction training|See above in arm group descriptions.
48303527|NCT06025292|OTHER|Lean Pork vs Plant-Based Protein|Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.
48303528|NCT04633824|OTHER|Retrospective Electronic Medical Record Review|Patients will be assessed retrospectively for evidence of successful or failed epidural extension in the setting of need for cesarean section
48303529|NCT06589713|DRUG|Enpatoran|Participants will receive a single oral dose of enpataron tablets once daily.
48303530|NCT04853251|DEVICE|SUSVIMO PDS Implant|The ranibizumab 100 mg/mL will be delivered via PDS
47956223|NCT05138107|OTHER|Synochi Scar Spray Cosmetic|Application of the cosmetic on each skin graft in a blinded fashion in different sections for a 9 month duration.
47956224|NCT05138107|OTHER|Synochi Scar Spray Placebo|Application of the placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.
47956225|NCT03463512|DRUG|Racecadotril plus ORS|Racecadotril plus ORS
48303531|NCT04853251|DRUG|LUCENTIS (ranibizumab injection)|Ranibizumab (intravitreal 0.5-mg intravitreal injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving intravitreal ranibizumab injections in the study eye, per investigator's discretion.
48303532|NCT05554380|PROCEDURE|Biopsy|Undergo tumor biopsy
47956226|NCT03463512|DRUG|ORS|ORS
47956227|NCT05857943|DEVICE|AEYE-DS Software|Eligible participants will undergo the following procedures: Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis. -Additional photographic and OCT images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis. -All study subjects will have their pupils dilated using dilation drops.
47956228|NCT03334591|DRUG|Apatinib|Apatinib 500mg with Docetaxel 60mg/m2
47956229|NCT03382275|DRUG|Iron Supplement|any oral or intravenous prescription iron supplement
48303533|NCT05554380|PROCEDURE|Biospecimen Collection|Undergo blood collection
48303534|NCT05554380|PROCEDURE|Computed Tomography|Undergo CT scan
48303535|NCT05554380|DRUG|Ipatasertib|Given PO
48303536|NCT05554380|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48303537|NCT05554380|DRUG|Paclitaxel|Given IV
48303538|NCT05302063|DEVICE|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
48303539|NCT05570916|DEVICE|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
48303540|NCT05570916|DEVICE|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
48303541|NCT05998408|DRUG|Ruxolitinib|Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
48303542|NCT04225624|BEHAVIORAL|Emotion Regulation Therapy - Attention Regulation (AR-ERT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based AR-ERT. This intervention aims to build attention regulation skills (i.e., the ability to flexibly shift and sustain attention) by teaching participants exercises for Orienting their attention and Allowing the presence of negative emotions. Participants are taught to apply these skills to counteract reactive perseverative thinking when negative emotions arise as well as proactively engage with emotion-laden situations that trigger repetitive negative thinking.
48303543|NCT04225624|BEHAVIORAL|Supportive Psychotherapy (SPT)|Participants will receive a total of eight 60 minute sessions (over 8 weeks) of individual, manual-based SPT. This intervention addresses factors that may affect participants' repetitive negative thinking symptoms (for example, relationships, work, stress), and teaches skills for managing challenges by improving self-esteem and positive coping skills.
48303544|NCT06634901|OTHER|Health Literacy Educational Session- Comparator|During the pre-to-post-test interval for the Knowledge, Attitudes, and Practices (KAP) measure, participants in this arm will take a break and have lunch.
48481049|NCT03908528|OTHER|Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
47956230|NCT04066647|DRUG|Dexamethasone 4mg|1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
47956231|NCT00515177|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
47956232|NCT00515177|DRUG|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
47956233|NCT02620722|DEVICE|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
47956234|NCT02620722|DEVICE|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
48303545|NCT06634901|BEHAVIORAL|Health Literacy Educational Session|The Intervention is a 90 minute small group (n=6-10) session with an expert epilepsy provider reviewing fundamental information about epilepsy being a treatable neurologic condition, with topics including epidemiology, causation facts and myths, treatment and the importance of consistent medication, stigma, barriers to care and well-being. These topics will be covered in the first 45 minutes, leaving the second 45 minutes for Q\&A with the expert. This session provides the basic health information relevant to people with epilepsy, communication of which is often sacrificed in overcrowded clinics found in low resource settings.
48303546|NCT06499259|OTHER|Mandala coloring|Mandala Pack and Application: The mandala pack is a pack consisting of 7 different patterns suitable for adults and 12 pencils. Mandala patterns will be photocopied by the researcher. Packages will be given to the mothers about mandala coloring and their questions will be answered. The choice of the color of the paint to be used in mandala coloring will be entirely up to the mother. No guidance will be given in this regard.
48303547|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303548|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303549|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303550|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303551|NCT04500171|BEHAVIORAL|Colocare Instruction Video: Modified SAM + CAM -Superior rating|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303552|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303553|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
47956235|NCT06026709|BEHAVIORAL|EmoEase|"The online interventionEmoEase integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program."
47956236|NCT04576325|DRUG|Voriconazole Inhalation Powder|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
47956237|NCT04576325|DRUG|Placebo|For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
47956238|NCT04487106|DRUG|Azacitidine|Given IV or SC
48110111|NCT05502458|DRUG|Desﬂurane|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made
48110112|NCT05502458|DRUG|Propofol|Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
48110113|NCT03618849|DEVICE|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
48110114|NCT03206671|DRUG|Rituximab window|Rituximab window (375 mg/m²)
48110115|NCT03206671|DRUG|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
48110116|NCT03206671|DRUG|Cyclophosphamide|see detailed protocol description
48110117|NCT03206671|DRUG|Cytarabine|see detailed protocol description
48110118|NCT03206671|DRUG|Dexamethasone|see detailed protocol description
48110119|NCT03206671|DRUG|Doxorubicin hydrochloride|see detailed protocol description
48640108|NCT04946253|BEHAVIORAL|TEAM: Implementation support strategies at the care team level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Coaching and consultation will be provided to the provider care team to support the use of collaborative care for behavior problems and ADHD. The TEAM intervention includes regular virtual meetings or calls with the providers (about once/month, on average) that cover core chronic care model functions, including registry use, case-finding, collaborative care team roles, and workflows outlining how DOCC is delivered in the practice.
48640109|NCT04946253|BEHAVIORAL|Implementation support strategies at the leadership level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Practice facilitation will be provided to practice leaders to help them support the care team's use of collaborative care for behavior problems and ADHD. The LEAD intervention includes regular virtual meetings or calls with practice leaders (about once/month, on average) that cover the assessment of practice capacity/barriers, ways to overcome organizational barriers and support staff use of DOCC, promoting innovation, and leveraging practice resources to support DOCC delivery and maintenance in the practice.
48110120|NCT03206671|DRUG|Vindesine Sulfate|see detailed protocol description
48481050|NCT03232255|OTHER|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
48481051|NCT01456741|PROCEDURE|EBNA with ROSE|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
48481052|NCT01456741|PROCEDURE|standard EBNA|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
48481053|NCT05009368|DRUG|Drug: Treatment A|CTL0901, single dose, daily, repeated oral administration for 4 days
48481054|NCT05009368|DRUG|Drug: Treatment B|CTL0902, single dose, daily, repeated oral administration for 7 days
48481055|NCT05009368|DRUG|Drug: Treatment C|CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
48481056|NCT05131477|DRUG|KY1005|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
48481057|NCT05131477|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
48481058|NCT02555293|DRUG|XIFAXAN® (Rifaximin)|
48481059|NCT04080609|DRUG|Dorzagliatin|GKA currently under clinical development
48481060|NCT02380313|DRUG|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
48481061|NCT02380313|DRUG|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
48481062|NCT02380313|DRUG|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
48481063|NCT02380313|DRUG|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
48481064|NCT06516913|DEVICE|Syringe Pump|Used to administer buffer solution with hyaluronic acid SC
48481065|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily for one month.
48481066|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
48481067|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
47956239|NCT04487106|DRUG|Trametinib|Given PO
47956240|NCT04487106|DRUG|Venetoclax|Given PO
48110121|NCT03206671|DRUG|Etoposide|see detailed protocol description
48481068|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
47956241|NCT03821909|PROCEDURE|Endoscopic ultrasound-guided protal venous blood sampling|We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
48110122|NCT03206671|DRUG|Ifosfamide|see detailed protocol description
48110123|NCT03206671|DRUG|Methotrexate|see detailed protocol description
48640110|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
48640111|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
48640112|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
48640113|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 2.1 Usage|Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.
48640114|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
48640115|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
48110124|NCT03206671|DRUG|Prednisolone|see detailed protocol description
48110125|NCT03206671|DRUG|Vincristine|see detailed protocol description
48110126|NCT00025987|DEVICE|Head and Neck Cooling System|
48110127|NCT00025987|DEVICE|Thermometer Pill|
48303554|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303555|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
48303556|NCT05471297|OTHER|There is no intervention|There is no any intervention
48303557|NCT05805371|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
48481069|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
48481070|NCT00282750|DEVICE|Bar coded sponge and scanner|
48481071|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
48481072|NCT01037582|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
48481073|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
48481074|NCT01037582|DRUG|placebo|Subjects will be randomized to receive a single dose of placebo.
48481075|NCT01037582|DRUG|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
48481076|NCT01037582|DRUG|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
48481077|NCT01675284|BIOLOGICAL|AT-301|Inactivated H5N1 Influenza Virion Vaccine
48481078|NCT00517543|DRUG|GW856553|
48481079|NCT01402154|BIOLOGICAL|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
48481080|NCT01402154|BIOLOGICAL|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
48481081|NCT00719979|BEHAVIORAL|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
48481082|NCT00719979|BEHAVIORAL|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
48481083|NCT00719979|BEHAVIORAL|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
48110128|NCT02433795|DRUG|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
48110129|NCT03302546|PROCEDURE|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
48640116|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.1 Usage|Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.
48640117|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.2 Usage|Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.
48640118|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.3 Usage|Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
48640119|NCT04630886|DRUG|Tranexamic acid injection|subcutaneous injection of 50mg/ml TXA
48640120|NCT04630886|DRUG|Lidocaine Epinephrine|subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
48640121|NCT05549453|DEVICE|Nexstim SNBT use|Active device use
48640122|NCT06067971|DEVICE|Laparoscopic surgery with augmented reality device|Gynecological laparoscopic surgery with augmented reality device.
48640123|NCT05206604|DRUG|PF-07295324|Ointment
48640124|NCT05206604|DRUG|PF-07259955|Cream
48640125|NCT04652882|DRUG|Tasimelteon|oral capsule
48640126|NCT04652882|DRUG|Placebo|oral capsule
47956242|NCT04276337|DIAGNOSTIC_TEST|LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)|LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
48303558|NCT05805371|PROCEDURE|Biopsy|Undergo tumor biopsy
48303559|NCT05805371|PROCEDURE|Biospecimen Collection|Undergo blood, stool, and urine sample collection
48303560|NCT05805371|PROCEDURE|Bone Scan|Undergo bone scan
48481084|NCT06093087|PROCEDURE|SAIF|The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height
47956243|NCT02961673|BIOLOGICAL|HU-014 Inj|Clostridium botulinum type A
48303561|NCT05805371|PROCEDURE|Computed Tomography|Undergo CT scan
48303562|NCT05805371|RADIATION|External Beam Radiation Therapy|Undergo radiation
48303563|NCT05805371|PROCEDURE|Leukapheresis|Undergo leukapheresis
48481085|NCT06093087|PROCEDURE|BKP|The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.
48481086|NCT03989531|BIOLOGICAL|Adrecizumab|Drip infusion over 60 minutes
48481087|NCT03989531|DRUG|Placebo|Drip infusion over 60 minutes
48481088|NCT06357923|DIAGNOSTIC_TEST|dosage|Presence of mutation on the gene panel and Frequency of allele variation
48481089|NCT06227377|DRUG|QTX3034|QTX3034 will be administered at protocol defined dose
48481090|NCT06227377|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
48481091|NCT01699919|DRUG|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
48481092|NCT05022563|DRUG|Parenteral anticoagulant|Parenteral anticoagulant only
48481093|NCT05022563|DRUG|Warfarin|Warfarin-based
48481094|NCT05022563|DRUG|Apixaban|Apixaban
48481095|NCT05022563|DRUG|Rivaroxaban|Rivaroxaban
48481096|NCT05022563|DRUG|Dabigatran|Dabigatran
48481097|NCT05022563|DRUG|Edoxaban|Edoxaban
48481098|NCT05754229|DEVICE|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
48481099|NCT01443377|BIOLOGICAL|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
48481100|NCT03358043|DEVICE|mechanical ventilation|Consecutive intubated pateints receiving mechanical ventilation with a PaO2/FiO2≤300 mmHg on positive end-expiratory pressure (PEEP) of 5 cmH2O or more and FiO2 of 0.3 or more.
48481101|NCT04785157|BIOLOGICAL|serology testing profiles description|SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
48481102|NCT04785157|BIOLOGICAL|immune response characterization|systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
48481103|NCT04785157|OTHER|in vivo brain PET-TSPO acquisitions|in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
48481104|NCT04785157|OTHER|brain MRI assessment|structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
48640127|NCT06360289|OTHER|Standard of Care|This is an observational study. No study drug will be administered as a part of the study, participants will be treated according to the decision of the treating physician.
48303564|NCT05805371|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
48303565|NCT03993353|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
48303566|NCT03993353|DRUG|Tadalafil|10 mg by mouth daily
47956244|NCT02961673|BIOLOGICAL|Botox Inj|Clostridium botulinum type A
47956245|NCT02362581|OTHER|prophylaxis treatment, on demand treatment|
47956246|NCT05714059|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
48303577|NCT04729959|BIOLOGICAL|Atezolizumab|Given IV
48303578|NCT04729959|PROCEDURE|Biospecimen Collection|Undergo blood sample and tumor tissue collection
48303579|NCT04729959|PROCEDURE|Conventional Surgery|Undergo surgery
48303580|NCT04729959|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRT
48303581|NCT04729959|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47956247|NCT04488796|BEHAVIORAL|Assigned Strategies: Opt-in|Participants will be assigned two behavioural strategies with the opt-in choice structure
47956248|NCT04488796|BEHAVIORAL|Assigned Strategies: Active Choice|Participants will be assigned two behavioural strategies with the Active choice structure
48640128|NCT03938324|BEHAVIORAL|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
47956249|NCT04488796|BEHAVIORAL|Assigned Strategies: Enhanced Active Choice|Participants will be assigned two behavioural strategies with the Enhanced Active choice structure
47956250|NCT04488796|BEHAVIORAL|Choice of Assignment: Opt-in|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure
48640129|NCT03938324|BEHAVIORAL|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
47956251|NCT04488796|BEHAVIORAL|Choice of Assignment: Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure
47956252|NCT04488796|BEHAVIORAL|Choice of Assignment: Enhanced Active Choice|Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
47956253|NCT01334346|OTHER|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
48303582|NCT04729959|BIOLOGICAL|Tocilizumab|Given IV
48481105|NCT04785157|BEHAVIORAL|neurocognitive assessment|multi-domains neurocognitive assessment
48640130|NCT01217411|PROCEDURE|Cognitive Assessment|Ancillary studies
48640131|NCT01217411|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
48640132|NCT01217411|OTHER|Laboratory Biomarker Analysis|Correlative studies
48640133|NCT01217411|RADIATION|Stereotactic Radiosurgery|Undergo SRS
47956254|NCT01334346|OTHER|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
47956255|NCT01334346|OTHER|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
48110130|NCT03302546|PROCEDURE|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
48110131|NCT00369733|DRUG|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
48110132|NCT02570191|DRUG|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
48110133|NCT03487042|DRUG|Bimatoprost 0.03% ophthalmic solution|"Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks."
48303583|NCT05361018|OTHER|Whole Body Vibration exercise - WBV|participants will be randomised to two different training interventions
48481106|NCT03736187|DRUG|Cephalexin|Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
48640134|NCT01217411|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
48640135|NCT04530552|DRUG|Apalutamide|Given PO
48640136|NCT04530552|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48640137|NCT04530552|OTHER|Quality-of-Life Assessment|Ancillary studies
48640138|NCT05970406|OTHER|high intensity dysphagia therapy|Intensive swallowing interventions with Speech Language Pathologists to begin within 24 hours of video swallow study results. Daily treatment will include two 30-minute sessions, 5-6 days a week which will include the evidence-based dysphagia exercises focusing on tongue resistance, head lift/chin tuck against resistance and expiratory muscle strength training tasks
47956256|NCT00342940|BIOLOGICAL|influenza surface antigen inactivated vaccine|
47956257|NCT03820271|OTHER|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
47956258|NCT01164800|DRUG|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
47956259|NCT01164800|DRUG|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
48303584|NCT06347822|BEHAVIORAL|Therapy Session|Single-session intervention (SSI) based on acceptance and commitment therapy (ACT) and solution-focused brief therapy (SFBT) principles
48303585|NCT03762850|DRUG|sparsentan|Target dose of 400 mg daily
48303586|NCT03762850|DRUG|irbesartan|Target dose of 300 mg daily
48303587|NCT03762850|DRUG|Dapagliflozin|Target dose of 10 mg daily
48303588|NCT05497778|DRUG|Gemcitabine|Given by IV (vein)
48303589|NCT05497778|DRUG|Nab paclitaxel|Given by IV (vein)
48303590|NCT05497778|DRUG|IM156|Given by PO
48303591|NCT06400472|DRUG|LY4170156|Intravenous
48303592|NCT05845047|BEHAVIORAL|PICTURE-IT|"The speech-language pathologist (SLP) will provide one of the following stimuli hierarchically:~1. Single words depicted in the picture, then with written and spoken labels~2. 2-word phrases depicted in the picture and then with written and spoken word~3. Subject-Verb-Object sentence depicted in the picture and then with written and spoken sentences~4. Two-sentence event, depicted with photos and subsequently with two written and spoken sentences~5. Short story depicted with a video clip and subsequently with printed and spoken narrative.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
48303593|NCT05845047|BEHAVIORAL|CoDeLT|"The speech-language pathologist (SLP) will facilitate the computer-delivered naming treatment, consisting of a picture/seen and heard spoken word verification task.~A picture will be presented for two seconds on a laptop computer screen and will be immediately followed by an audio-visual display of a speaker's mouth saying a noun. The spoken word either will or will not match the preceding picture, and the participant must indicate whether the picture and video match or do not match. The computer will provide immediate visual feedback following a response.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
48303594|NCT05890963|DRUG|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
48303595|NCT05890963|DRUG|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
48303596|NCT05890963|DRUG|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
48303597|NCT06350604|BEHAVIORAL|Project WHADE: A Partner-Based Physical Activity Program for Women|Combination of behavioral, cognitive, social, and acceptance-based skills training to increase physical activity
48303598|NCT05945927|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered as per local clinical practice and local labeling.
48303603|NCT05795465|DRUG|GEn-1124|Intravenous infusion
48640139|NCT05233917|DIETARY_SUPPLEMENT|Olive oil use|Olive oil, 25-30g/d by day for 6 month
48640140|NCT05233917|DIETARY_SUPPLEMENT|MLCT oil use|MLCT oil, 25-30g/d by day for 6 month
48640141|NCT05568095|DRUG|Domvanalimab|Intravenous (IV) Aqueous Solution
48640142|NCT05568095|DRUG|Zimberelimab|IV Aqueous Solution
48640143|NCT05568095|DRUG|Capecitabine|Oral Tablets
48640144|NCT05568095|DRUG|Fluorouracil|IV Aqueous Solution
48640145|NCT05568095|DRUG|Leucovorin|IV Aqueous Solution
48640146|NCT05568095|DRUG|Oxaliplatin|IV Aqueous Solution
48640147|NCT05568095|DRUG|Nivolumab|IV Aqueous Solution
48640148|NCT05306574|BIOLOGICAL|Telitacicept|Subcutaneous injection weekly for 52 weeks
48640149|NCT05306574|BIOLOGICAL|Placebo|Subcutaneous injection weekly for 52 weeks
48640150|NCT05783349|BIOLOGICAL|Unique blod sample|sampling of 4mL of blood on lithium heparin tube, the day of frozen embryo implantation
48640151|NCT06265610|PROCEDURE|TIVA/TCI|: The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
48303604|NCT05795465|DRUG|Placebo|Intravenous infusion
48303605|NCT04246671|BIOLOGICAL|TAEK-VAC-HerBy|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).
48303606|NCT04115033|DEVICE|Alpha-stim|The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
48303607|NCT05995717|DIETARY_SUPPLEMENT|PKU UP|"PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years.~PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA)."
48640152|NCT04103606|DEVICE|GGBI: Positive Body Image (Mobile App)|Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
48640153|NCT05753683|BEHAVIORAL|mHealth-Women's CoOp|The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a gender-specific human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and gender-based violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
48640154|NCT05753683|BEHAVIORAL|Virtual Group|The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm. The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support. The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
48640155|NCT06171178|DRUG|ASP1012|Intravenous (IV) infusion
48640156|NCT06171178|DRUG|Pembrolizumab|IV infusion
47956260|NCT05962437|DEVICE|Self-guided digital Acceptance and Commitment Therapy|Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.
48303608|NCT04752189|BEHAVIORAL|Enhanced Replicating Effective Programs (Enhanced REP)|Enhanced REP includes 1. a tailored MMH curriculum, 2. tailored training, and 3. ongoing provider consultation or facilitation to support implementation.
48303609|NCT04752189|BEHAVIORAL|Standard implementation|The standard implementation of the Michigan Model for Health is consistent with Standard REP and includes the curriculum materials, standard training, and as-needed technical assistance.
48481107|NCT05208879|BIOLOGICAL|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
48481108|NCT05208879|OTHER|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
48481109|NCT03844789|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Eligible participants will be use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology \& Dexcom G6 CGM
48481110|NCT03844789|DEVICE|Control Group|Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
48481111|NCT03123887|OTHER|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
48481112|NCT03746002|DRUG|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
48640157|NCT05467098|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
48640158|NCT06454812|DEVICE|Mechanical vibration|The vibration device will be placed on the procedure site (on the vastus lateralis muscle) on the left extremity and fixed through a long gauze. The vibration device will be operated for 30 seconds with reference to previous studies, then the nurse will administer routine intramuscular Hepatitis B vaccine. A gap of approximately 1-2 cm will be left between the device and the injection site. After the vaccination procedure is completed, the vibration will be terminated. The baby will be swaddled and placed in the mother's lap.
47956261|NCT05962437|DEVICE|FM symptom tracking app (FM-ST)|Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.
48303610|NCT05556239|BEHAVIORAL|Resistance Exercise Training|Supervised resistance training program planned as 3 sessions per week of approximately 60 minutes. The resistance training program comprises 6 exercises for the major muscle groups, starting at 2 sets of 15 repetitions maximum progressing to 4 sets of 8 repetitions maximum. Each session will be supervised by physiotherapist to ensure proper technique, and progression in training load. The participants will choose an exercise ambassador from their network, who during the period will be encouraged to, on a weekly basis, to be in contact with the participant.
48303611|NCT04557449|DRUG|PF-07220060|CDK4 inhibitor
48303612|NCT04557449|COMBINATION_PRODUCT|Letrozole|Endocrine Therapy
48303613|NCT04557449|COMBINATION_PRODUCT|Fulvestrant|Endocrine Therapy
48303614|NCT04557449|DRUG|Midazolam|Benzodiazepine used for DDI
48303615|NCT04557449|COMBINATION_PRODUCT|Enzalutamide|Androgen Receptor inhibitor
48110134|NCT05647070|PROCEDURE|Autologous rectus Fascia TOT|"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"
48303616|NCT06549686|BIOLOGICAL|CLS2901C (human [allogeneic] chondrocyte sheets)|CLS2901C (human \[allogeneic\] chondrocyte sheets)
48110135|NCT06518798|BEHAVIORAL|Fasting Mimicking Diet|Participants will be instructed to follow their usual diet except for 5 days when they eat the foods in the FMD kit. The FMD consists of a blend of 100% plant based nutrients generally regarded as safe. One FMD kit provides for the replacement of the normal diet with plant products for five consecutive days. The formulation of these products was based on studies carried out at the Longevity Institute of the University of Southern California, led by Dr. Valter Longo and his collaborators over several decades of research.
48303617|NCT01061515|DRUG|Intraperitoneal Oxaliplatin|
48303618|NCT01061515|DRUG|Bevacizumab|
48303619|NCT01061515|DRUG|Capecitabine|
48303620|NCT05784909|DEVICE|rezum|"Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days."
48303621|NCT04116502|DRUG|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
48303622|NCT04116502|DRUG|Hydroxycarbamide|Via standard hospital mechanisms
48303623|NCT04116502|DRUG|Interferon-Alpha|Any formulation, via standard hospital mechanisms
48303624|NCT04514107|OTHER|Brazilian National Dengue Control Program|This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.
48481113|NCT03746002|DRUG|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
48481114|NCT05290779|PROCEDURE|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
48481115|NCT01774825|DIETARY_SUPPLEMENT|IQP-CL-101|2 softgels twice a day
48303625|NCT04514107|OTHER|Wolbachia-infected Aedes aegypti|Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
48303626|NCT02665195|OTHER|saliva specimen|
48303627|NCT02665195|BEHAVIORAL|questionnaire|
48303628|NCT06465108|DRUG|MBX 2109|Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL
48303629|NCT06465108|OTHER|Placebo|Supplied in 1.4 mL water for injection
48481116|NCT01774825|OTHER|Placebo|2 softgels twice a day
48481117|NCT02622659|DRUG|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
48481118|NCT02622659|DRUG|Xiaoer Jiebiao Oral Liquid|"1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day"
48640159|NCT06454812|BEHAVIORAL|Helfer skin tap technique (HSTT)|In this group, HSTT consisting of 4-stage strokes will be applied to the vaccination site. The nurse will make approximately 10 strokes for 5 seconds with the palmar side of the fingers of the dominant hand to the injection site to relax the muscles (Stage 1). The nurse will give a V-shaped position to the thumb and index finger of the non-dominant hand and give 3 strokes to the injection site with the palmar side of the fingers (Stage 2). The skin entry site of the needle will remain inside the V-shape. Simultaneously with the 3rd stroke, the nurse will insert the needle into the muscle at a 90 degree angle. The nurse will inject the vaccine into the muscle while continuing to tap the skin with the palmar side of the fingers of the non-dominant hand (Stage 3). The nurse will make 3 strokes on the skin with the palmar side of the fingers of the non-dominant hand at the injection site, simultaneously with the 3rd stroke, the needle will be removed from the baby's skin (Stage 4)
48640160|NCT00572481|PROCEDURE|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
48640161|NCT06334120|DRUG|Darolutamide (Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
48640162|NCT05315583|OTHER|Collection of biological samples|All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
48640163|NCT06050512|DRUG|Mezigdomide|Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
48640164|NCT06050512|DRUG|Ixazomib|Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.
48640165|NCT06050512|DRUG|Dexamethasone|Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
47956262|NCT05962437|BEHAVIORAL|Treatment as Usual (TAU)|Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
47956263|NCT06285708|BEHAVIORAL|Prolonged exposure|PE therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure (repeated recounting of the most disturbing traumatic memory) followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure (approaching trauma-related situations); psychoeducation about PTSD; and controlled breathing training. Between sessions, participants listen to audio recordings of the imaginal recounting daily and complete in-vivo exercises. Typically, PE is delivered weekly for 10-12, 90-minutes sessions. For this study, participants will complete daily 60-minute sessions for 10 consecutive weekdays during a 2-week period.
48481119|NCT06616142|DRUG|[18F]CETO tracer|PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.
48481120|NCT06616142|DRUG|Dexamethasone oral|Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
47956264|NCT05081765|DRUG|Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)|correlation between C through and taken drug
47956265|NCT05081765|DEVICE|Lynparza|correlation between C through and taken drug
48481121|NCT06616142|PROCEDURE|Adrenal vein sampling|Adrenl vein sampling
48481122|NCT06390124|DRUG|Platelet Derived Growth Factor (PDGF)|Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
48481123|NCT05015335|DRUG|Adalimumab|ADA 40mg q2w
48481124|NCT05015335|DRUG|Methotrexate|MTX 10mg qw
48481125|NCT02165514|PROCEDURE|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
48481126|NCT00466804|PROCEDURE|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
48481127|NCT03460158|DRUG|Restylane-L®|Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
48481128|NCT03460158|DRUG|Restylane-L® Lyft|Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
48481129|NCT03460158|DRUG|Restylane Silk®|Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
48481130|NCT04253353|DRUG|tafamidis|61 mg capsule
48481131|NCT04253353|DRUG|rosuvastatin|10 mg tablet
47956266|NCT04279405|DRUG|YY-20394|YY-20394 80mg tablet administered orally once daily
47956267|NCT01871142|DRUG|Placebo|100 mL
48481132|NCT03224247|PROCEDURE|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
48303630|NCT05299710|PROCEDURE|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
48303631|NCT03332667|RADIATION|131I-MIBG|Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
48303632|NCT03332667|DRUG|Dinutuximab|Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
48303633|NCT03332667|DRUG|Vorinostat|Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
48303634|NCT03332667|DRUG|Sargramostim|Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2
48303635|NCT03332667|DRUG|Potassium Iodide|Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
48481133|NCT03224247|PROCEDURE|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
47956268|NCT01871142|DRUG|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
48110136|NCT04410055|BEHAVIORAL|Sitting|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
48303636|NCT03130569|BEHAVIORAL|Web-based Module Group|
48303637|NCT04240067|DIAGNOSTIC_TEST|READ-MA Multimarker Approach|The presence or absence of ALSHF (gold standard used in the READ study) : diagnosis by 2 experts (cardiologist and emergency physician) based on data collected in the ED and during hospitalization (clinical examination, history, usual treatment, haemodynamic parameters, ECG, chest X-ray, emergency treatment, clinical and paraclinical results during hospitalization), biological assays (except NT-proBNP) and echocardiography (Left Ventricular Ejection Fraction, segmental kinetic, potential valvulopathy, transmitral flow, tissue doppler E' velocity) performed by a cardiologist within 24 hours of admission.
48303638|NCT03851380|BEHAVIORAL|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
48303639|NCT03851380|OTHER|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
48481134|NCT03093935|DEVICE|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
48303640|NCT03851380|DEVICE|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
48303641|NCT03851380|DEVICE|Transcranial Electrical Stimulation (tES)|Home-based Transcranial Direct Current Stimulation
48303642|NCT05755191|DRUG|NEU-411|Oral Doses
48481135|NCT04963387|OTHER|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
48481136|NCT04963387|OTHER|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
47956269|NCT01871142|DRUG|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
48110137|NCT04410055|BEHAVIORAL|Static standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
48303643|NCT05755191|DRUG|Placebo|Oral Doses
48640166|NCT06450171|OTHER|GRAIL Galleri Test|A multi-cancer early detection (MCED) blood test.
48640167|NCT06239480|DRUG|QTORIN 3.9% Rapamycin Anhydrous Gel|QTORIN 3.9% Rapamycin Anhydrous Gel
48640168|NCT06321601|DRUG|Avacopan|Oral administration
47956270|NCT05195190|OTHER|Clinical test|The 2 minutes walking test, the time up and go test and the 30 second sit and stand test will be applied to the patients in order. Each test will be repeated 2 times after the familiarization test and the average of the tests will be taken. There will be a 10-minute rest period between tests. For the re-test, the tests will be repeated after the patients are given a rest period of 2 hour. Testing will be conducted by a single therapist with at least 5 years of experience blinded to the study.
47956271|NCT05376462|DIAGNOSTIC_TEST|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
47956272|NCT05376462|DIAGNOSTIC_TEST|Standard Laboratory Tests|Laboratory tests that provide information about a patient's coagulation status.
47956273|NCT01153074|DEVICE|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
47956274|NCT05248490|OTHER|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
47956275|NCT03602430|DRUG|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
47956276|NCT03602430|DRUG|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
48481137|NCT03661606|OTHER|Simulated Altitude Chamber|"Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study."
48481138|NCT03684031|BEHAVIORAL|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
48481139|NCT03684031|BEHAVIORAL|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
48640169|NCT06476821|DRUG|BMS-986435|Specified dose on specified days
47956277|NCT05361161|DRUG|Transarterial Chemoembolization|Arterial infusion chemotherapy (THP + oxaliplatin + raltitrexed) and THP combined with lipiodol embolization for 2 times, with an interval of 1 month.
48110138|NCT04410055|BEHAVIORAL|Dynamic standing|We proposed a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions were applied: 3 hours of sitting, static standing and dynamic standing. Both standing conditions were done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
48110139|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours
48110140|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours
48303644|NCT02588846|DEVICE|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
47956278|NCT05430152|DRUG|Low-Dose Naltrexone|"Study drug dosing schedule (LDN):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
48110141|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours every 8 hours
48303645|NCT06239064|DIAGNOSTIC_TEST|Genetic testing via blood collection|blood collection
48303646|NCT05819138|DRUG|Semaglutide Pen Injector|Semaglutide injection
48303647|NCT05819138|DRUG|Placebo|Semaglutide placebo injection
48303648|NCT06665477|DEVICE|Restylane Volyme|Subjects in Restylane Volyme treatment group will receive treatment on Day 1 and optiponal treatment 1 month later.
48303649|NCT06392100|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness-based stress reduction interventions include: breathing awareness, loving-kindness meditation, body scan, walking meditation, sitting body awareness, eating meditation, and deep breathing exercises.
48640170|NCT06469697|BEHAVIORAL|School music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at both school and community levels.
48303650|NCT05619744|DRUG|RO7616789|RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.
48303651|NCT05619744|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
48110142|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours every 8 hours
48110143|NCT05905913|DRUG|ANT3310-placebo|ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.
48110144|NCT05905913|DRUG|ANT3310|ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
48303652|NCT05891249|BIOLOGICAL|Luspatercept|Specified dose on specified days
48481140|NCT00798382|OTHER|soy protein formula|ad lib for 0-35 days of age
48481141|NCT00798382|OTHER|Commercially available soy formula|ad lib for 0-35 days of age
48481142|NCT00798382|OTHER|Soy formula experimental #2|ad lib for 0-35 days of age
48640171|NCT06469697|BEHAVIORAL|Community music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at community levels.
47956279|NCT05430152|OTHER|Placebo|"Study drug dosing schedule (Placebo; capsules made to match LDN doses):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
48110145|NCT05905913|DRUG|Meropenem|Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
48110146|NCT05905913|DRUG|Meropenem-placebo|Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.
48110147|NCT05274217|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
48110148|NCT01597154|BEHAVIORAL|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
48110149|NCT00915330|PROCEDURE|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
48481143|NCT05550376|OTHER|Registry|Non-interventional registry
48481144|NCT05999279|BEHAVIORAL|Survey|Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
48640172|NCT06663293|OTHER|Conventional Nasal Cannula|The initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min.
48110150|NCT00915330|PROCEDURE|TBNA|transbronchial needle aspiration
48481145|NCT04647617|BEHAVIORAL|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
48481146|NCT02534233|DEVICE|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
48481147|NCT00512837|BEHAVIORAL|Mobile phone technology|
47956280|NCT04941859|BEHAVIORAL|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
48110151|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
48110152|NCT02559518|DEVICE|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
48110153|NCT02559518|DEVICE|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
48481148|NCT05966311|DEVICE|Percutaneous Ultrasound Gastrostomy|Ultrasound guided placement of gastrostomy tube using the PUMA-G Pediatric System
48640173|NCT06663293|OTHER|High-flow nasal cannula|The high-flow nasal oxygenation device was set to a temperature of 36°C and an FiO2 of 0.4. The initial oxygen flow rate for the high flow group was determined according to the age and weight of the patients, based on our pediatric intensive care team's guidelines and the reference from the Slain study. When SpO2 fell below 94%, it was considered hypoxia, and the flow rate was increased by 2 to 4 L/min.
48110154|NCT02559518|DEVICE|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
48110155|NCT02559518|DEVICE|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
48110156|NCT02559518|DEVICE|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
48110157|NCT02559518|DEVICE|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
48110158|NCT02863380|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
48110159|NCT02863380|DEVICE|Individualized rTMS (transcranial magnetic stimulation)|
48110160|NCT02863380|DEVICE|Classical rTMS (transcranial magnetic stimulation)|
48110161|NCT02863380|DEVICE|Classical tDCS (transcranial direct current stimulation)|
48110162|NCT04275817|OTHER|Data collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
48110163|NCT01511172|DRUG|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
48110164|NCT01511172|DRUG|metformin|1000 mg daily, administered orally
48110165|NCT01511172|DRUG|placebo|Metformin placebo administered orally. 1000 mg daily
48110166|NCT01511172|DRUG|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
48110167|NCT01511172|DRUG|glimepiride|Individually adjusted dose, administered orally
48110168|NCT01240941|DRUG|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
48110169|NCT01240941|DRUG|Exemestane|25 mg orally daily
48481149|NCT00615524|DRUG|exemestane and pazopanib|
48481150|NCT06453460|DRUG|Letermovir|Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.
48481151|NCT06453460|DEVICE|CMV T Cell Immunity Panel (CMV-TCIP)|Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.
48110170|NCT01240941|DRUG|Goserelin|3.6 mg orally monthly
48110171|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), incremental exercise protocol|The incremental work rate exercise test will be performed using a cycle-ergometer. The exercise protocol is initiated by a five-minute warm-up at 50 Watts (W). Subsequently, they will complete a stepwise protocol, which will begin at 100 W and increase by 2 W every 6th second, until exhaustion or until the patient is unable to continue exercise, for any reason.
48640174|NCT06663293|DRUG|midazolam, ketamine, propofol|Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
48640175|NCT06663293|DRUG|Propofol|Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
47956281|NCT06248060|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
47956282|NCT06248060|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
47956283|NCT02424760|DEVICE|Shoulder hemi-arthroplasty|
48481152|NCT06453460|DIAGNOSTIC_TEST|CMV DNA PCR|Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
48481153|NCT05754424|DRUG|AT278|Concentrated rapid acting insulin aspart
48481154|NCT05754424|DRUG|NovoRapid|Rapid-acting insulin aspart
48640176|NCT00453505|DEVICE|TMS|\<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).
48640177|NCT00453505|DEVICE|tDCS|tDCS up to 2 mA for up to 60mins.
48640178|NCT00453505|DEVICE|tACS|tACS up to 1 mA for up to 10 minutes.
48640179|NCT00453505|DEVICE|CPNS|CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
48640180|NCT01665794|DRUG|Pomalidomide|Pomalidomide taken orally at assigned dose.
48640181|NCT01665794|DRUG|Carfilzomib|Carfilzomib given by intravenous (IV) infusion at assigned dose.
48640182|NCT01665794|DRUG|dexamethasone|Dexamethasone taken orally of given by IV infusion.
48640183|NCT01665794|DRUG|Daratumumab|Daratumumab given by intravenous (IV) infusion at assigned dose.
48640184|NCT04480580|DIAGNOSTIC_TEST|SARS-CoV-2 Ab|Patient test for specific antibodies for SARS-CoV-2
48481155|NCT05754424|DRUG|Humulin R 500 UNT/ML Injectable Solution|Regular human insulin
48640185|NCT04135352|DRUG|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
48640186|NCT04135352|BIOLOGICAL|V938|Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
48640187|NCT05398627|DEVICE|Amygdala Neurofeedback|real-time feedback on the hemodynamic response of the amygdala during positive autobiographical memory recall
48640188|NCT05376553|DRUG|Cemiplimab|350mg intravenous infusion over 30 minutes
48640189|NCT05376553|DRUG|Cisplatin|"100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)"
48640190|NCT05376553|DRUG|Docetaxel|"75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)"
48640191|NCT05538897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48640192|NCT05538897|PROCEDURE|Computed Tomography|Undergo CT scan
48481156|NCT03475628|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
48481157|NCT04858659|DRUG|PK101|1 tablet at each time, 2 times a day
48481158|NCT04858659|DRUG|PK101-002|1 tablet at each time, 2 times a day
48481159|NCT04858659|DRUG|PK101 placebo|1 tablet at each time, 2 times a day
48481160|NCT04858659|DRUG|PK101-002 placebo|1 tablet at each time, 2 times a day
48481161|NCT03442010|OTHER|Detection of adverse drug events|Detection of adverse drug events
48481162|NCT04752488|OTHER|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
48481163|NCT04752488|OTHER|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
48640193|NCT05538897|DRUG|Ipatasertib|Given PO
48640194|NCT05538897|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48640195|NCT05538897|DRUG|Megestrol Acetate|Given PO
48640196|NCT04380636|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
48640197|NCT04380636|DRUG|Olaparib|oral tablets
48640198|NCT04380636|DRUG|Placebo for olaparib|oral tablets
48640199|NCT04380636|DRUG|Etoposide|IV infusion
48640200|NCT04380636|DRUG|Carboplatin|IV infusion
48640201|NCT04380636|DRUG|Cisplatin|IV infusion
48640202|NCT04380636|DRUG|Paclitaxel|IV infusion
48640203|NCT04380636|DRUG|Pemetrexed|IV infusion
48640204|NCT04380636|RADIATION|Thoracic Radiotherapy|external beam radiation
48640205|NCT04380636|DRUG|Durvalumab|IV infusion
48640206|NCT05144997|DRUG|Lorlatinib|ALK-positive NSCL treatment
48640207|NCT06609148|DIETARY_SUPPLEMENT|De Simone formulation probiotic|Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days
48640208|NCT06609148|DIETARY_SUPPLEMENT|Placebo|Subjects will be given a placebo for 21-24 days
48640209|NCT05879432|DRUG|LSALT Peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
48640210|NCT05879432|DRUG|Placebo|0.9% saline solution
48640211|NCT06695468|DRUG|Levobupivacaine|40-ml mixture of 20 ml of 0.5% levobupivacaine diluted with 20 ml of 0.9% N.S. (20 ml to be injected on each side
48640212|NCT06695468|DRUG|Levobupivacaine + Dexmedetomidine|60 ml mixture of 1.5 mic/kg dexmedetomidine added to 30 ml of 0.5% levobupivacaine diluted with 30 ml of 0.9% N.S. (30 ml to be administered on each side, divided into 15 ml for the upper segment and 15 ml for the lower segment).
48640213|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).|Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
48303657|NCT05690828|BEHAVIORAL|Cognitive remediation|The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
48303658|NCT06586021|DEVICE|Aortoseal Endostapling System|Aortoseal Endostapling System
48640214|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test to determine the effectiveness of SABR.|Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
48303659|NCT06687876|DRUG|Metformin|Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.
48303660|NCT06424067|DRUG|Fingolimod 0.5 milligram (mg) [Gilenya]|Oral fingolimod will be administered at a dose of 0.5 mg once a day.
48303661|NCT06675799|BEHAVIORAL|Sleep Extension|Weekly educational material about sleep health and weekly brief phone coaching calls for a total of 6 weeks.
48640215|NCT05933876|DIAGNOSTIC_TEST|To propose a diagnostic test for Oligometastatic Cancer (OC).|Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
48640216|NCT06286033|DRUG|AG-181|AG-181 tablets
48303662|NCT06675799|BEHAVIORAL|Healthy Living Psychoeducation|Weekly educational materials about healthy habits and weekly brief phone calls to clarify terms or concepts.
48303663|NCT06265532|DRUG|EGCG 300 mg|"Participants will be administered EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
48303664|NCT06265532|DRUG|Placebo for EGCG 300 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
48303665|NCT06265532|DRUG|EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
48303666|NCT06265532|DRUG|Placebo for EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
48303667|NCT05339308|OTHER|Magnesium oil (BetterYou) dermal application|10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once
48303668|NCT05339308|OTHER|Placebo Control|Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once
48303669|NCT05476926|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
48640217|NCT06286033|DRUG|Placebo|AG-181 matched-placebo tablets
48303670|NCT05476926|COMBINATION_PRODUCT|Port Delivery System with Ranibizumab|The port delivery system with ranibizumab will be administered as per local clinical practice and local labeling.
48303671|NCT06295081|OTHER|Exercise exposure|"Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km"
48303672|NCT05933577|BIOLOGICAL|V940|IM injection
48303673|NCT05933577|BIOLOGICAL|Pembrolizumab|IV infusion
48303674|NCT05933577|OTHER|Placebo|IM injection
48303675|NCT04674969|DEVICE|Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.|Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
48481164|NCT00505648|DRUG|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
48640218|NCT05549882|OTHER|no intervention|no intervention
48640219|NCT06584513|OTHER|Specific tapering plan for sleep medication, educational and cognitive behavioural therapy elements|The intervention consists of a patient-centred intervention to help patients in deprescribing BSHs and better managing their sleep problems. The material used consists of training modules, brochures, and self-monitoring tools. There are materials for physicians and for patients.
48640220|NCT04166409|PROCEDURE|Biospecimen Collection|Correlative studies
48640221|NCT04166409|DRUG|Carboplatin|Given IV
48640222|NCT04166409|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48640223|NCT04166409|OTHER|Quality-of-Life Assessment|Ancillary studies
48640224|NCT04166409|OTHER|Questionnaire Administration|Ancillary studies
48640225|NCT04166409|DRUG|Selumetinib Sulfate|Given PO
48640226|NCT04166409|DRUG|Vincristine Sulfate|Given IV
48303676|NCT06577870|PROCEDURE|Hospitalization in intensive care or continuing care unit|Hospitalization in intensive care or continuing care unit for medical reasons or surgery, conscious or unconscious under mechanical ventilation. Resuscitation patients are then cared for in a continuing care unit.
48303677|NCT02911064|BEHAVIORAL|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
48303678|NCT06137521|PROCEDURE|Coronary angiography|
48303679|NCT04940936|BEHAVIORAL|A Patient Decision Aid|The Patient Decision Aid informs about the pros and cons of each option
48303680|NCT05911009|DRUG|BC 007 or matching placebo|Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
48303681|NCT05872438|DIAGNOSTIC_TEST|Vaginal, Oral and anal sampling|The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
48640227|NCT04848571|COMBINATION_PRODUCT|Fetal Protection Pill|A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.
48640228|NCT06695221|DIETARY_SUPPLEMENT|Traditional Kefir|350 mL/day of traditional fermented/prepared kefir
48110172|NCT05558020|DIAGNOSTIC_TEST|Continuous laryngoscopy during exercise (CLE), continuous work rate protocol|"Within two weeks the participants will perform an additional CLE-test at various intensities. The new exercise protocol is designed to induce EILO at different exercise intensities. Using the participants' individually calculated exercise capacity, three different workloads (70 %, 80 % and 90 %) will be calculated.~The exercise protocol will be initiated with a five-minute warm-up at 50 W, then the workload will increase to the watt equivalent to 70 % of the participant's maximal exercise capacity. This workload will be fixed for ten minutes and only terminated if the participant feels the need to stop due to exhaustion or breathing difficulties. Next, the participant will have a five-minute resting phase with a set workload of 50 W. This protocol will be repeated at a workload equivalent to 80 % and 90 %"
48110173|NCT03451435|DRUG|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
48110174|NCT05509842|DEVICE|rTMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
48110175|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
48110176|NCT00775242|DRUG|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
48110177|NCT04039984|DEVICE|Prime Cup|Patients in this group will have the Prime cementless acetabular cup used during surgery.
48110178|NCT05393180|DEVICE|Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF|"Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. ."
48640229|NCT06695221|DIETARY_SUPPLEMENT|Milk (placebo)|350 mL/day of commercial 2% fat milk
48640230|NCT04316546|DRUG|MK-7075 (miransertib)|MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
48640231|NCT05675410|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48640232|NCT05675410|BIOLOGICAL|Bleomycin Sulfate|Given IV
48640233|NCT05675410|DRUG|Brentuximab Vedotin|Given IV
48640234|NCT05675410|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
48640235|NCT05675410|DRUG|Cyclophosphamide|Given IV
48640236|NCT05675410|DRUG|Dacarbazine|Given IV
48640237|NCT05675410|DRUG|Doxorubicin Hydrochloride|Given IV
48303684|NCT05985291|COMBINATION_PRODUCT|SCS in combination with CMM|Subjects receiving BurstDR spinal cord dorsal column stimulation in combination with conservative medical management for the treatment of painful diabetic neuropathy as part of regular medical care.
48303685|NCT06321302|DRUG|BI 764524|BI 764524
48303686|NCT06321302|DRUG|Sham comparator to BI 764524|Sham comparator to BI 764524
48303687|NCT06321302|DRUG|Aflibercept (Eylea®) - US only|Aflibercept (Eylea®) - US only
48303688|NCT06245577|DEVICE|interdisciplinary mesh sacro colpopexy with resection rectopexy|surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure
48303689|NCT06381414|BEHAVIORAL|Observation|"Identify the prevalence of early wear in primary dentition, using Childhood Early Oral Aging Syndrome (CEOAS) index.~The CEOAS index involves scores of 0 to 3 for the assessment of tooth wear and dental management, whereas scores of I, II and III are used concomitantly in cases of the presence of enamel defects."
48303690|NCT04736706|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
48640238|NCT05675410|DRUG|Etoposide|Given IV
48640239|NCT05675410|DRUG|Etoposide Phosphate|Given IV
48640240|NCT05675410|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
48640241|NCT05675410|RADIATION|Involved-site Radiation Therapy|Undergo ISRT
48640242|NCT05675410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI and/or PET-MRI
48110179|NCT03478956|DRUG|Etrolizumab|Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
48303691|NCT04736706|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
48303692|NCT04736706|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
48303693|NCT04736706|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
48303694|NCT05840770|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48303695|NCT05840770|BIOLOGICAL|Cemiplimab|Given IV
48303696|NCT05840770|PROCEDURE|Computed Tomography|Undergo CT scan
48303697|NCT05840770|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
48303698|NCT05840770|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48303699|NCT05766891|BEHAVIORAL|Group 1|Participants will receive hypnosedation will be restarted after arriving in the operating room and will continue for the whole time of surgery
48303700|NCT05766891|BEHAVIORAL|Group 2|Participants will receive standard general anesthesia and medications to control your pain after arriving in the operating room
48303701|NCT05766891|BEHAVIORAL|Group 3|Participants will receive standard general anesthesia and medications during surgery to control your pain.
48303702|NCT05952869|DRUG|Enlicitide Decanoate|Oral tablet
48303703|NCT05952869|DRUG|Placebo|Placebo
48303704|NCT05458284|PROCEDURE|Real Acupuncture|Real Acupuncture weekly till taxane completion
48303705|NCT05458284|OTHER|Sham Acupuncture|Sham Acupuncture weekly till taxane completion
48303706|NCT05083156|OTHER|Diet Change|Observation Cohort will be observed for treatment response to elimination of cow's milk
48303707|NCT02875314|DRUG|Induction|vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
48303708|NCT02875314|DRUG|Single Cycle Intensive Chemotherapy|Carboplatin, thiotepa, etoposide
48303709|NCT02875314|DRUG|Tandem 3 Cycle Intensive Chemotherapy|Carboplatin, thiotepa
48303710|NCT06027242|DIETARY_SUPPLEMENT|oral glutamine|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
48303711|NCT06027242|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
48303714|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
48303715|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
48640243|NCT05675410|BIOLOGICAL|Nivolumab|Given IV
48640244|NCT05675410|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
48640245|NCT05675410|DRUG|Prednisolone|Given PO
48640246|NCT05675410|DRUG|Prednisone|Given PO
48640247|NCT05675410|DRUG|Procarbazine Hydrochloride|Given PO
48640248|NCT05675410|OTHER|Questionnaire Administration|Ancillary studies
48640249|NCT05675410|DRUG|Vinblastine Sulfate|Given IV
48640250|NCT05675410|DRUG|Vincristine Sulfate|Given IV
48640251|NCT04618965|DRUG|control group|Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
48640252|NCT04618965|DRUG|Intrathecal dexmedetomidine|Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
48640253|NCT04618965|DRUG|Intravenous dexmedetomidine|Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.
48640254|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
48640255|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^10 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
48640256|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
48640257|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^11 vg/gland (both glands)|intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
48640258|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
48303716|NCT01473251|DRUG|Lucentis|0.5 mg monthly for 4 months
48303717|NCT04125914|BEHAVIORAL|Behavioral Dietary Intervention|Record food intake
48303718|NCT04125914|OTHER|E-mail|Receive e-mails
48303719|NCT04125914|BEHAVIORAL|Exercise Intervention|Undergo exercise
48303720|NCT04125914|OTHER|Health Promotion and Education|Receive text messages
48303721|NCT04125914|OTHER|Internet-Based Intervention|Join Facebook page
48303722|NCT04125914|OTHER|Questionnaire Administration|Ancillary studies
48303723|NCT04125914|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
48303724|NCT05638295|PROCEDURE|Biopsy|Undergo tumor biopsy
48640259|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^11 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
48110180|NCT04027426|BEHAVIORAL|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
48303725|NCT05638295|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48303726|NCT05638295|PROCEDURE|Computed Tomography|Undergo CT scan
48303727|NCT05638295|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48303728|NCT05638295|BIOLOGICAL|Panitumumab|Given IV
48640260|NCT04043104|DRUG|AAV2hAQP1: 3 x 10^12 vg/gland (single gland)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
48640261|NCT04043104|DRUG|AAV2hAQP1: 1 x 10^12 vg/gland (both glands)|Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
48640262|NCT06695208|DRUG|Biodentine|biodentine used in socket preservation
48640263|NCT06523153|BIOLOGICAL|VYD2311|Monoclonal antibody
48110181|NCT04027426|BEHAVIORAL|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
48110182|NCT02493933|DRUG|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
48640264|NCT06523153|OTHER|Placebo|Matching Placebo
48110183|NCT00855465|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
48640265|NCT05253534|DEVICE|GlaucoT Glaucoma Treatment Device|"In this study, flicker light therapy, the effectiveness of which was investigated in the treatment of glaucoma based on some methods used in different diseases, is described for the first time in glaucoma.~Studies investigating the neurodegenerative properties of glaucoma have found similarities in the pathophysiology of Alzheimer's disease and glaucoma.~40 Hz flicker of light Alzheimer 's the positive effects on the knitted cortex have also been shown in studies. 40 Hz flicker light is aimed to reduce glaucoma and retinal ganglion cell loss due to glaucoma, by reducing neurodegeneration by decreasing amyloid and metabolite accumulation by increasing both microglial phagocytic activation effect and retinal blood flow."
48110184|NCT00855465|DRUG|Placebo|Matching Placebo tid orally for 16 weeks
48110185|NCT04505813|BIOLOGICAL|NEXI-002 T Cells|The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
48110186|NCT04986683|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate the presence, type, and severity of brain abnormalities in enrolled subjects.
48303729|NCT05638295|DRUG|Sotorasib|Given PO
48303730|NCT04509492|DIAGNOSTIC_TEST|Endoscopic ultrasound ( EUS )|"- EUS will be done to all patients. During EUS examination the liver will be examined thoroughly to detect hepatic focal lesions with possible EUS-FNA of any detected lesions.~All EUS examination will being done by EUS linear array Echoendoscope, Pentax EG-3870UTK attached to Hitachi Avius US machine under Propofol deep sedation"
48640266|NCT03760081|DRUG|ASP1650|Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
48303731|NCT00484250|DRUG|metronidazole,doxycycline|
48303732|NCT02846376|DRUG|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
48303733|NCT02846376|DRUG|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
48303734|NCT06498453|DEVICE|Trak-Physio knee condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
48303735|NCT06498453|DEVICE|Trak-Physio in shoulder condition|The exercise protocol designed for knee conditions is carried out through Trak, the digital rehabilitation tool.
48303736|NCT06498453|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
48303737|NCT06498453|OTHER|Shoulder conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
48303738|NCT05711394|DRUG|Atogepant|Oral Tablet
48303739|NCT05711394|DRUG|Placebo-Matching Atogepant|Oral Tablet
48640267|NCT06221813|BIOLOGICAL|PHV02|Nipah virus vaccine
48640268|NCT06221813|BIOLOGICAL|Lactated Ringer's|Placebo
48640269|NCT04892173|DRUG|NBTXR3|Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
48640270|NCT04892173|DRUG|Cetuximab|Solution for infusion
48640271|NCT04892173|RADIATION|Radiation Therapy|Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
48640272|NCT05816317|BEHAVIORAL|Single-Session Mechanism-Focused Intervention (SSMFI)|A brief intervention for patients hospitalized for suicide risk that directly targets hopelessness and perceptions of social relatedness.
47956284|NCT02067130|PROCEDURE|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
47956285|NCT02652065|OTHER|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
47956286|NCT02652065|OTHER|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
47956287|NCT02652065|OTHER|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
47956288|NCT02652065|OTHER|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
47956289|NCT04458207|PROCEDURE|Oral prosthetic rehabilitation|Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
47956290|NCT04336293|DEVICE|sTMS|"sTMS will be delivered following NeoSync guidelines using the device user~manual"
48110187|NCT04986683|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language, and other neurocognitive functions potentially affected by drug-resistant epilepsy.
48640273|NCT05816317|BEHAVIORAL|Distress Tolerance Skills Review|Treatment as usual at the inpatient setting for this study.
47956291|NCT04336293|DEVICE|sham sTMS|sham sTMS will be delivered following NeoSync guidelines using the device user manual
47956292|NCT05133752|DRUG|Nemonoxacin|500 mg, oral administration, once daily for 7-10 days.
47956293|NCT05075460|DRUG|Tucidinostat, Azacitidine combined with CHOP|"Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment"
48110188|NCT02497092|OTHER|Technique of injection|
48110189|NCT02954016|DEVICE|ePass|Subject is implanted with the device for up to 3 years.
48110190|NCT00761930|DRUG|Fluoride|Brush twice daily
48110191|NCT00761930|DRUG|Triclosan and fluoride|Brush twice daily
48110192|NCT00761930|DRUG|Herbal Ingredient and fluoride|Brush twice daily
48110193|NCT03483662|BEHAVIORAL|Multicomponent Intervention|The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
48303740|NCT05271409|DRUG|Satralizumab|Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
48303741|NCT05271409|OTHER|Placebo|Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
48640274|NCT03943511|OTHER|Oral Antibiotics-Close Monitoring|To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
48640275|NCT03943511|OTHER|Standard of Care|No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
48640276|NCT06017128|OTHER|sexual counseling based on the PLISSIT model|In the initial follow-up, the experimental group will receive information about total hip replacement surgery and its impact on sexual life based on the PLISSIT model. An educational booklet containing information about total hip replacement surgery, the rehabilitation process, and post-operative sexual life will also be prepared and distributed. In the second follow-up (5-7 days after surgery), the experimental group will be provided with information about home care before discharge and returning to sexual life.
48640277|NCT05883137|DEVICE|Optiflow Switch|High flow nasal oxygen with the Optiflow Switch device
48303742|NCT03115489|DRUG|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
48303743|NCT03115489|DRUG|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
48303744|NCT02773914|OTHER|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
48303745|NCT06653023|BIOLOGICAL|Universal CAR-T cells injection for treating HCC and NSCLC|A novel universal CAR-T platform to treat cancer patients
48303746|NCT03969706|DRUG|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
48303747|NCT00611455|DRUG|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
48303748|NCT00611455|DRUG|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
48303749|NCT04292717|BEHAVIORAL|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
48110194|NCT03483662|BEHAVIORAL|Enhanced Usual Care|The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
48303750|NCT02583672|DRUG|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
48110195|NCT05146817|OTHER|Oral care|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine . Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
48110196|NCT01597258|DRUG|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
48110197|NCT04325048|DEVICE|Cordio App|Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app
48303751|NCT06094010|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as oral suspension either as 2 milligrams per kilograms (mg/kg) (if weight less than 20 kg), or 40 mg (if weight more than or equal to 20 kg to less than 80 kg) or 80 mg (if weight more than or equal to 80 kg).
48303752|NCT06569082|DEVICE|CD34+ Selected Donor Cell Boost|The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.
48303753|NCT06569082|PROCEDURE|Blood Stem Cell Infusion|The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.
48303754|NCT05638776|DRUG|REGEND001 Autologous Therapy Product|Transplantation of Autologous Therapy Product by
48303755|NCT05638776|DRUG|Placebo|Transplantation of Placebo
48303756|NCT06419920|OTHER|Flat terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on a level treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
48303757|NCT06419920|OTHER|Uneven terrain locomotor training|The training will be comprised of up to 12 sets of 2-min continuous walking on an uneven terrain treadmill or mat, interspersed with rest breaks of at least one minute. Training will be completed three times per week for four weeks.
48303758|NCT04929236|DRUG|Panzyga|PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
48303759|NCT03422133|OTHER|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
48303760|NCT06475989|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48303761|NCT06475989|DRUG|Cabozantinib|Given PO
48303762|NCT06475989|PROCEDURE|Computed Tomography|Undergo CT scan
48303763|NCT06475989|DRUG|Dabrafenib|Given PO
48640278|NCT00694850|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
47956294|NCT01278836|PROCEDURE|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
48110198|NCT04689568|BEHAVIORAL|Moodkit|"MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips."
48110199|NCT04689568|BEHAVIORAL|Moodgym|The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.
48110200|NCT04689568|BEHAVIORAL|University of Michigan Depression Center Toolkit|The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
48640279|NCT06148948|DRUG|BI 1584862|BI 1584862
48640280|NCT06148948|DRUG|Placebo|Placebo matching BI 1584862
48640281|NCT05313256|DRUG|Lidocaine epinephrine buffered with sodium bicarbonate|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine buffered with sodium bicarbonate.
48640282|NCT05313256|DRUG|Lidocaine epinephrine|When an extremely urgent fetal extraction by caesarean section is decided, the patient will be randomized. An epidural top-up will then be performed with Lidocaine epinephrine.
48110201|NCT05319288|DEVICE|Acupuncture|In DPOG, motion style acupuncture would be used; in LPMG, Traditional Chinese Medicine acupuncture is used.
48110202|NCT04438668|DEVICE|Centaflow and Standard Care|The intervention is screening methods
48110203|NCT04438668|DIAGNOSTIC_TEST|Standard Care|The intervention is screening methods
48110204|NCT03899675|DIETARY_SUPPLEMENT|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
48110205|NCT03899675|OTHER|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
48110206|NCT00143936|BEHAVIORAL|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
48110207|NCT00143936|BEHAVIORAL|Low Calorie Diet|Maintain a low calorie diet
48110208|NCT04678830|DRUG|Placebos|Placebos
48640283|NCT03564730|PROCEDURE|Simultaneous Knee Arthroplasty (UKA)|Patient will have both knees completed under one anesthetic.
48640284|NCT03564730|PROCEDURE|Staged Knee Arthroplasty (UKA)|Patient will have knees completed under 2 anesthetics.
48640285|NCT04941729|DEVICE|OR3O™ - Dual Mobility System|OR3O™ Dual Mobility System is comprised of a diffusion-hardened, oxidized zirconium acetabular liner (OR3O™ Liner), and an insert of highly cross-linked polyethylene (OR3O™ XLPE Insert).
48640286|NCT04941729|DEVICE|Conventional|A conventional, single-bearing design Total Hip System comprised of R3™ Acetabular Shell with XLPE liner and a Smith \& Nephew Oxinium (Ox) femoral head.
48640287|NCT06160206|BIOLOGICAL|Bevacizumab|Given IV
48640288|NCT06160206|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47956295|NCT02807519|GENETIC|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
48110209|NCT04678830|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
48110210|NCT01664871|DEVICE|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
48110211|NCT00355940|DEVICE|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
48110212|NCT00355940|DEVICE|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
48110213|NCT01010919|DIETARY_SUPPLEMENT|Chicory root extract|
48303764|NCT06475989|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48303765|NCT06475989|OTHER|Questionnaire Administration|Ancillary study
48303766|NCT06475989|DRUG|Trametinib|Given PO
48640289|NCT06160206|PROCEDURE|Computed Tomography|Undergo CT
48640290|NCT06160206|OTHER|Electronic Health Record Review|Ancillary studies
48640291|NCT06160206|RADIATION|Hypofractionated Radiation Therapy|Undergo radiation therapy
48640292|NCT06160206|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48640293|NCT06160206|BIOLOGICAL|Retifanlimab|Given IV
48640294|NCT05286684|PROCEDURE|Consultation|History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
48640295|NCT05286684|PROCEDURE|Cerebral and medullary MRI, lumbar puncture, CSF sampling|diagnosis of leptomeningeal involvement
48640296|NCT05286684|BIOLOGICAL|biological test|5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
48640297|NCT05714501|DEVICE|Millipede System|Mechanical thrombectomy
47956296|NCT03047655|BEHAVIORAL|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
47956297|NCT03047655|DIETARY_SUPPLEMENT|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
47956298|NCT05954702|PROCEDURE|Supercharged TRAM esophagectomy|Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
47956299|NCT05954702|PROCEDURE|Conventional Esophagectomy|Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
47956300|NCT00332280|DRUG|AMT2003|
47956301|NCT03745807|BIOLOGICAL|NKTR-214|Specified dose on specified days
47956302|NCT03745807|BIOLOGICAL|Nivolumab|Specified dose on specified days
47956303|NCT05118243|OTHER|Control cracker|The gut symptoms caused by control crackers are studied in IBS persons
47956304|NCT05118243|OTHER|Enzyme-treated cracker|The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
47956305|NCT02581787|BIOLOGICAL|Fresolimumab|Given IV
47956306|NCT02581787|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
47956307|NCT02680535|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
48110214|NCT05723510|DRUG|Tegoprazan 50mg|Oral administration of one tablet of tegoprazan 50 mg once daily
48110215|NCT05723510|DRUG|Edoxaban 60mg|Oral administration of one tablet of edoxaban 60 mg once daily
48481165|NCT05981495|DEVICE|NanoDetect-TB|This study of the NanoDetect-TB investigational device will test plasma and serum samples from TB suspects. There is no intervention for the subjects and there will be a single visit blood draw.
48481166|NCT02342249|DRUG|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
48640298|NCT03225989|DRUG|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
48640299|NCT06095128|DRUG|Vedolizumab|Vedolizumab IV infusions
48640300|NCT06095128|DRUG|Tofacitinib|Tofacitinib Tablets
48640301|NCT06342960|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
48640302|NCT06342960|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
48640303|NCT05522829|BIOLOGICAL|SCTV01E-1 on D0|Day 0; intramuscular injection
48640304|NCT05522829|BIOLOGICAL|SCTV01E-1 on D28|Day 28; intramuscular injection
48640305|NCT05522829|BIOLOGICAL|SCTV01E-1 on D150|Day 150; intramuscular injection
48640306|NCT05522829|BIOLOGICAL|SCTV01E on D0|Day 0; intramuscular injection
48640307|NCT05522829|BIOLOGICAL|SCTV01E on D28|Day 28; intramuscular injection
47956308|NCT06192368|DEVICE|INSPIRE|Virtual reality application for relaxing.
47956309|NCT06192368|DEVICE|Tablet|Gaming tablet
47956310|NCT00193258|DRUG|Bevacizumab|10mg/kg IV infusion every 2 weeks
47956311|NCT00193258|DRUG|Erlotinib|150 mg po daily
47956312|NCT00193258|DRUG|Imatinib|400-600mg daily
47956313|NCT01259765|DRUG|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
47956314|NCT01259765|DRUG|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
47956315|NCT05123170|DRUG|Dexmedetomidine Injectable Solution [Dexdomitor]|two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
47956316|NCT05123170|DRUG|Lidocaine IV|Intravenous regional anaesthesia
47956317|NCT01522508|PROCEDURE|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
47956318|NCT02647242|BEHAVIORAL|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
48110216|NCT05723510|DRUG|Apixaban 5mg|Oral administration of one tablet of apixaban 5 mg twice daily
48110217|NCT05723510|DRUG|Rivaroxaban 20mg|Oral administration of one tablet of rivaroxaban 20 mg once daily
48110218|NCT03213249|OTHER|Normal saline|Intraoperative pocket irrigation with normal saline
48110219|NCT03213249|DRUG|Cefazolin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
48481167|NCT02342249|DRUG|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
48481168|NCT02342249|DRUG|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
48481169|NCT02342249|DRUG|Placebo|Subjects will receive matching placebo of Oseltamivir
48640308|NCT05522829|BIOLOGICAL|SCTV01E on D150|Day 150; intramuscular injection
48640309|NCT05522829|BIOLOGICAL|SCTV01E-1 on D120|Day 120; intramuscular injection
48303769|NCT03997422|PROCEDURE|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
48481170|NCT05520606|PROCEDURE|pancreatoduodenectomy|Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
48481171|NCT01944384|DRUG|aldactone|aldactone 25 mg for 6 months
48640310|NCT05522829|BIOLOGICAL|SCTV01E on D120|Day 120; intramuscular injection
48640311|NCT05879302|BEHAVIORAL|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
48640312|NCT05937152|DRUG|Eptinezumab|Intravenous (IV) infusion of 300 mg
48640313|NCT05937152|DRUG|Placebo|Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
48640314|NCT05306145|PROCEDURE|High freqnence Irreversible electroporation|High freqnence Irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with benign prostatic hyperplasia
48640315|NCT05306145|PROCEDURE|Trans Urethral Resection Prostate|Trans urethral resection prostate will be performed under general anaesthesia to the patient with benign prostatic
48303770|NCT06041529|DRUG|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
48303771|NCT06041529|DRUG|Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
48303772|NCT05053139|DRUG|NNC0365-3769 (Mim8)|Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
48481172|NCT03629613|DIETARY_SUPPLEMENT|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
48481173|NCT03629613|OTHER|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
48640316|NCT05671887|PROCEDURE|Double Lung Transplantation|To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.
48110220|NCT03213249|PROCEDURE|Skin biopsy|Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
48110221|NCT03213249|PROCEDURE|Bilateral skin- or nipple-sparing mastectomies|Standard of care
48303773|NCT04003636|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
48303774|NCT04003636|DRUG|Gemcitabine|Gemcitabine by IV infusion
48303775|NCT04003636|DRUG|Cisplatin|Cisplatin by IV infusion
48303776|NCT04003636|DRUG|Placebo|Placebo to pembrolizumab
48303777|NCT05609968|BIOLOGICAL|Sacituzumab Govitecan|IV infusion
48303778|NCT05609968|BIOLOGICAL|Pembrolizumab|IV infusion
48640317|NCT04195477|BEHAVIORAL|vDPP|virtual Diabetes Prevention Program
48640318|NCT06695026|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
48640319|NCT06695026|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
48640320|NCT06695026|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
48640321|NCT06652828|OTHER|Conventional Treadmill Walking (CTT)|The CTT serves as a comparison to PBT. It involves standard treadmill walking without perturbations on the same treadmill. This intervention is conducted over the same defined period as PBT (3-6 weeks), with a matched frequency and exercise time compared to the PBT group for consistency. Participants are secured with safety harnesses while walking.
48640322|NCT06652828|OTHER|Perturbation-Based Balance Training (PBT)|Overall, 9 training sessions with different objectives and progression regarding perturbation directions, predictability, and intensity will be conducted within 3-6 weeks. During the initial sessions, familiarizing participants with the treadmill and establishing their individual walking pace will be focused. Pace can be individually adjusted in each training session. Participants are secured with safety harnesses while walking.
48640323|NCT01142388|BIOLOGICAL|Cixutumumab|Given IV
48640324|NCT01142388|OTHER|Laboratory Biomarker Analysis|Correlative studies
48640325|NCT01142388|DRUG|Paclitaxel|Given IV
48640326|NCT01142388|OTHER|Pharmacological Study|Correlative studies
48303779|NCT06195280|RADIATION|Magnetic resonance imaging, 3DT1 sequence|The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
48303780|NCT06195280|PROCEDURE|Laparoscopy|After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
48110222|NCT03213249|DEVICE|Tissue expander|Standard of care
48303781|NCT06157697|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Based on previous social transfer programs in Brazil, we will offer gift packages for mothers at 6 months. The options include: diapers, hygiene products, child developmental toys, transport vouchers, or a combination of these.
48303782|NCT05987293|DEVICE|Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.|A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
48303783|NCT04770337|DEVICE|STARSTIM device|Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
48303784|NCT04770337|DEVICE|Sham Device|Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
48303787|NCT05785624|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
48303788|NCT05785624|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arms.
48303789|NCT05232097|BEHAVIORAL|Behavioral therapy|Diaphragmatic breathing exercises
48303790|NCT05232097|BEHAVIORAL|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
48303791|NCT06578585|DRUG|Ubrogepant|Tablet
48303792|NCT06578585|DRUG|Lu AG09222|Solution for injection/infusion
48303793|NCT06578585|DRUG|Placebo|Solution for injection/infusion
48303794|NCT04961996|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
48303795|NCT04961996|DRUG|Endocrine Therapy of Physician's Choice|The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.
48303796|NCT04961996|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
48303797|NCT04961996|DRUG|Abemaciclib|Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
48303798|NCT04489771|DRUG|Belzutifan|Oral administration
48303799|NCT06653010|BIOLOGICAL|Universal CAR-T cells injection for treating mCRC|A novel universal CAR-T platform to treat cancer patients
48303800|NCT04581681|BEHAVIORAL|Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)|"The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer \& Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform."
48303801|NCT04581681|OTHER|No treatment (waitlist control)|Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
48303802|NCT05489133|BEHAVIORAL|Modified prolonged exposure|Imaginary and in vivo expo, in addition to psychoeducation
48303803|NCT03832998|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
48303804|NCT03832998|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
48303805|NCT03832998|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
48303806|NCT03832998|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
48110223|NCT03213249|DEVICE|Breast implant|"* Standard of care~* Either breast implant or autologous flap"
48110224|NCT03213249|PROCEDURE|Autologous flap|"* Standard of care~* Either breast implant or autologous flap"
48110225|NCT03213249|OTHER|Acellular dermal matrix sling|Standard of care
48110226|NCT03213249|DRUG|Gentamicin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
48303807|NCT02763904|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
48303808|NCT02763904|OTHER|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
48640327|NCT04869917|BEHAVIORAL|Decision Aid intervention|"* Displays information about the benefits and risks of ILI and metformin~* Asks open-ended questions: What am I willing to do to prevent T2D? and What do I need to prevent T2D?~* Prompts patients to commit to immediate next steps~* Health educator schedules interested patients for first ILI session or sends message to provider about patients' interest in starting metformin, if chosen"
47956319|NCT04903275|PROCEDURE|Topical fluoride application and Laser irradiation|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
47956320|NCT04903275|PROCEDURE|Topical fluoride application|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
48110227|NCT03213249|DRUG|Bacitracin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
48110228|NCT00258635|BIOLOGICAL|RagweedMATAMPL|
48110229|NCT04258358|OTHER|CASCADE ways of working|Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
48110230|NCT00148434|BEHAVIORAL|Patient-held guideline for hypertension|
48110231|NCT06552364|DRUG|LABA+LAMA|1 dose per day (AM)
48110232|NCT06552364|DRUG|LABA+LAMA+ICS|1 dose per day (AM)
48110233|NCT06552364|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control
48110234|NCT06552364|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
48110235|NCT06112704|DRUG|HS-20093|Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
48110236|NCT04842682|BIOLOGICAL|Solo 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
48110237|NCT04842682|BIOLOGICAL|Solo 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
48110238|NCT04842682|BIOLOGICAL|Solo 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
48110239|NCT04842682|BIOLOGICAL|Combi 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
48110240|NCT04842682|BIOLOGICAL|Combi 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
48110241|NCT04842682|BIOLOGICAL|Combi 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
48110242|NCT04473586|DEVICE|Spartan Cube CYP2C19 System|Using buccal material, determine the genotype of the \*2, \*3 and \*17 SNPs of the CYP2C19 gene on the Spartan Cube CYP2C19 System.
48110243|NCT04233931|BEHAVIORAL|PrEP medication adherence mobile app|Participants use a PrEP medication adherence mobile app for six weeks.
47956321|NCT06428422|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis Bl-04|4 x 10\^9 cfu/g/day Bifidobacterium animalis subsp. lactis Bl-04 for 12 weeks
47956322|NCT06428422|OTHER|Plasebo|1 g/day maltodextrin for 12 weeks
48110244|NCT03646279|DEVICE|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
48110245|NCT04308473|OTHER|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
47956323|NCT00699764|BIOLOGICAL|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
47956324|NCT00699764|BIOLOGICAL|Placebo injection|Intramuscular injection, 3 doses
47956325|NCT05384964|OTHER|Questionnaire|Questionnaire completed by ICU nurses
47956326|NCT00137631|BEHAVIORAL|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
47956327|NCT00940160|DRUG|QAX576|
47956328|NCT00940160|DRUG|QAX576|
47956329|NCT00940160|DRUG|QAX576|
47956330|NCT00940160|DRUG|Placebo|
47956331|NCT06424574|BEHAVIORAL|motivational interview|"The sample of the second phase of the study consisted of 74 parents with Type 1 diabetes children, 37 of which were in the study group and 37 in the control group. İn the collection of data process, Descriptive Information Form, University of Virginia Parent Low Blood Sugar Scale, BAKAS Care-Giving Impact Scale, Fatigue Severity Scale, Parental Version Of The Diabetes-Specific Self-Compassion Scale SCS-(Dp) was used. The scales were applied at the beginning of the study and 10 weeks after the first data. After the first test data were obtained from each parent in our research group, four face-to-face motivational interviews were conducted at two-week intervals. In the xvii interviews, attempts were made to change and improve the behaviors and skills that parents felt inadequate within the scope of fear of hypoglycemia, caregiving, fatigue and self-compassion."
47956332|NCT04218695|DRUG|Ceftriaxone|Antibiotic
47956333|NCT04218695|DRUG|Normal saline|50cc intravenous once daily
47956334|NCT06311825|OTHER|Horticultural Therapy|"One week before horticultural therapy (HT) interventions, face-to-face interviews will be held with the individuals in the experimental group and the forms will be filled in as a pretest.~HT will be applied to the experimental group. The application period was determined as a total of 6 weeks with 50-minute sessions twice a week.~Before starting the HT sessions, area preparations will be made and a safe therapeutic garden will be established.~Medicinal and aromatic plants will be selected that can grow in Turkey, are not harmful to human health, are fragrant and colorful in order to stimulate the senses, and according to air temperature and physical conditions.~HT sessions will consist of gardening activities (group meeting, introduction of plants and cultivation).~After HT interventions, the forms will be filled as a post test. The forms will be filled again 4 weeks after the end of the interventions for follow-up."
47956335|NCT06069323|DEVICE|repetitive Transcranial Magnetic Stimulation|Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
48110246|NCT04308473|OTHER|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
48110247|NCT05944822|OTHER|pro-inflammatory cytokines|compare the levels of pro-inflammatory cytokines in patients with Essure® contraceptive implants and in control patients with endometriosis or adenomyosis.
48110248|NCT06554262|OTHER|No intervention|No intervention was involved in this study
48110249|NCT01957319|DRUG|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
47956336|NCT04539353|OTHER|Heart Rate Variability|Heart Rate Variability will be measured with a Polar device.
47956337|NCT04539353|OTHER|Pain intensity|Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale
47956338|NCT04970784|OTHER|Activities of Daily Living (ADL) questionnaire (The Katz index )|"For patients cared for by the geriatric sector, questionnaire will be filled in at admission D0 and by phone at D30, for the classic emergency patients questionnaire will be submitted by phone the day following the consultation D1, and D30."
47956339|NCT00225550|DRUG|ADH -1 (Exherin™)|
47956340|NCT03062007|DRUG|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
47956341|NCT03278756|BEHAVIORAL|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
47956342|NCT03278756|BEHAVIORAL|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
48303809|NCT02998892|BEHAVIORAL|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 6 weeks. This intervention corresponds to the current recommendations.
48303810|NCT02998892|BEHAVIORAL|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 9 hours, 5 days/week, by brisk walking for 6 weeks.
47956343|NCT04750512|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.2% according to randomization): bilateral injection of 30ml (60ml total) under US guidance between the deep fascia of erector spinae muscle and the the two transverse process at the level of the 10th thoracic vertebrae
48110250|NCT01957319|DRUG|sugar pill|
48481174|NCT05967871|BIOLOGICAL|Fecal Microbiota Transplant|Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
48481175|NCT05147636|PROCEDURE|Extubation with PEEP|No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP
48481176|NCT05147636|PROCEDURE|Endotracheal Aspiration|Aspiration during cuff deflation
48303811|NCT03241056|BEHAVIORAL|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
48640328|NCT04869917|BEHAVIORAL|Text Messaging intervention|"* Defines prediabetes and includes individualized A1c values~* Present benefits and risks of intensive lifestyle intervention and metformin~* States that other prediabetic Erie patients are adopting intensive lifestyle intervention and metformin~* Encourages initiating intensive lifestyle intervention or discussing metformin with provider~* Include selected behavioral content from diabetes prevention program~* Initial message with automatic opt-in, allows opt-out for messages~* Subsequent messages include: information about T2D risk and treatments; prompts to directly schedule intensive lifestyle intervention or office visit to discuss metformin; selected behavioral content from diabetes prevention programming"
48640329|NCT04869917|BEHAVIORAL|Usual Care|Patients receiving care at non-intervention clinic sites will not be exposed to treatment intervention.
48640330|NCT06343298|DRUG|MANP|MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.
47956344|NCT04750512|PROCEDURE|TAP block|"US guided TAP block (saline solution vs Ropivacaine 0.2% according to randomization):~bilateral injection of 30ml (total 60ml) under US guidance in the plane between the internal oblique and transversus abdominis muscles at the level of the midaxillary line in the Petit triangle."
48640331|NCT06343298|OTHER|Placebo Matched control|This is a placebo matched vehicle - Vehicle minus the active ingredient
48640332|NCT06525454|BEHAVIORAL|Personalized coaching messages for blood glucose and emotions|For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires.
48640333|NCT04690348|PROCEDURE|Craniotomy|Craniotomy
48640334|NCT04690348|RADIATION|Cesium-131 brachytherapy|Intracavitary Cesium-131 brachytherapy
48640335|NCT05977179|OTHER|Dietary intervention to mitigate Post-Acute COVID-19 Syndrome|As it was described in the arm/group descriptions.
48640336|NCT05977179|OTHER|Attention Control|As it was described in the arm/group descriptions.
48640337|NCT05168566|DRUG|Sutetinib Maleate Capsule|Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
48640338|NCT06287853|DEVICE|Tapestry Biointegrative Implant|The Tapestry RC Biointegrative Implant System is an arthroscopic delivery and fixation system intended for tendon augmentation with Tapestry Biointegrative Implant during arthroscopic rotator cuff (RC) repair. The system combines the biointegrative collagen-based implant (Tapestry Biointegrative Implant) with bioabsorbable fixation ( Bioabsorbable Anchors). Tapestry Biointegrative Implant is a collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues.
48640339|NCT03731585|BEHAVIORAL|Behavioral Intervention|Participate in psychological sessions
47956345|NCT02649270|BIOLOGICAL|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
48303812|NCT03241056|OTHER|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
48303813|NCT03493685|DRUG|sparsentan|Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
47956346|NCT05791955|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
47956347|NCT05791955|BEHAVIORAL|Acknowledgement of personal responsibility|"The message will contain a request for the participant to take personal responsibility for their health by either clicking on the link to make an appointment or replying noted to the text message."
47956348|NCT05791955|BEHAVIORAL|Planning prompt|The message will prompt people to either click on the link to make an appointment now or text back when they plan to close their health gap
48303814|NCT03493685|DRUG|Irbesartan|target dose of 300 mg daily
48481177|NCT03589131|PROCEDURE|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
48481178|NCT03589131|PROCEDURE|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
48640340|NCT03731585|OTHER|Educational Intervention|Participate in educational sessions
48640341|NCT03731585|OTHER|Questionnaire Administration|Ancillary studies
48640342|NCT03731585|PROCEDURE|Support Group Therapy|Participate in group sessions
48640343|NCT05691439|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
48110251|NCT06553560|OTHER|Parasternal Block and Recto-İntercostal Fascial Plane Block|Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2 cm lateral to the sternal border to visualize the T2-T4 intercostal space and to identify the pectoralis major muscle, intercostal muscle, and pleura. 10 ml of 0.25% bupivacaine local anesthetic is administered between the pectoralis major and intercostal muscle using an in-plane approach with a 100 mm needle. In addition, a Recto-Intercostal Fascial Plane Block is performed with a high-frequency linear USG probe. The probe is placed 2-3 cm lateral to the xiphoid so that the rectus abdominis muscle and 6-7th cartilages are visualized. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique and 1-2 ml of saline is injected. After observing the spread to the target plane, 20 ml of 0.25% bupivacaine is applied. The same process is repeated bilaterally.
48110252|NCT00947986|OTHER|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
48110253|NCT06212167|BEHAVIORAL|Nursing Interventions for Stroke Patient Care|In the first phase of the research, the relatives of the patients who are in the hospital every day for a week during the routine and discharge process will be included in a training program. These trainings will be explained didactically to the caregiver at the bedside by the research supervisor and the intensive care nurse, the practices will be demonstrated with demonstrations, and the caregiver will be asked to apply them themselves. Then, the researchers will call the caregivers and make an appointment for an online meeting twice a week (7 weeks - 14 times). During these meetings, the training the caregivers need will be explained again and any questions they have will be answered. The researcher will also conduct motivational interviews with the caregivers.
48110254|NCT01738308|PROCEDURE|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
48110255|NCT01738308|PROCEDURE|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
48303815|NCT04978376|BEHAVIORAL|Time restricted eating|We will compare the effects of time restricted eating alone and combined with resistance exercise of endurance exercise versus a no intervention control group.
48640344|NCT05691439|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
48303816|NCT06163794|OTHER|Nutritional postprandial test|Metabolic responses to several test meals
48303817|NCT04903548|PROCEDURE|SIRT with Y-90 resin microspheres|Selective internal radiation therapy (SIRT) with Y-90 resin microspheres (Y-90 resin SIRT) is an intra-arterial, catheter-based locoregional therapy that has been used to treat patients with unresectable HCC
48303818|NCT06295731|DRUG|INBRX-106|INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
48303819|NCT06295731|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
48481179|NCT03589131|PROCEDURE|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
48640345|NCT03865498|BEHAVIORAL|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
48640346|NCT03865498|BEHAVIORAL|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
48640347|NCT02639273|DRUG|Nalmefene|Active Drug
48303820|NCT05327010|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
48303821|NCT05327010|PROCEDURE|Biopsy|Undergo tumor biopsy
48303822|NCT05327010|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48640348|NCT02639273|OTHER|Placebo|Single Dose Placebo
47956349|NCT03710005|PROCEDURE|Ascent|Dehydrated Cell and Protein Concentrate injection
48303823|NCT05327010|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
48303824|NCT05327010|DRUG|Talazoparib|Given PO
48303825|NCT03165981|BIOLOGICAL|PCV13|ACIP Recommended vaccine
48640349|NCT06418984|DEVICE|auxiliary|the interventions are related to the adjuncts associated with clear aligners to improve the predictability and accuracy of tooth movement
48640350|NCT06305559|DRUG|obicetrapib 10 mg + ezetimibe 10 mg FDC daily|Active treatment
48640351|NCT06305559|OTHER|Placebo|Baseline lipid modifying therapy
48640352|NCT03430973|BEHAVIORAL|Videos|Videos depicting various aggressive driving and road rage behaviors.
48640353|NCT03430973|BEHAVIORAL|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
48640354|NCT03430973|BEHAVIORAL|Alcohol-related cues|Case of beer or water on passenger seat.
48640355|NCT03430973|BEHAVIORAL|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
48640356|NCT03430973|BEHAVIORAL|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
47956350|NCT03710005|PROCEDURE|Standard|Standard corticosteroid injection
48303826|NCT03165981|BIOLOGICAL|DTaP|ACIP Recommended vaccine
48640357|NCT03430973|BEHAVIORAL|Video game|Participants will play a racing or neutral video game before driving in the simulator.
48640358|NCT04063137|DIETARY_SUPPLEMENT|Anthocyanin fortified bread with beef patty (35% fat)|Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
48640359|NCT06053411|DRUG|Diclofenac|25 mg capsule
47956351|NCT06395129|DEVICE|Low dead-space syringes/needles|LDSS/N are a type of syringe/needle which retains less residual blood following an injecting event when compared to HDSS/N.
47956352|NCT06395129|DEVICE|Hepatitis C Antibody Rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
47956353|NCT06395129|DEVICE|HIV rapid Diagnostic Test|Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months
47956354|NCT01095926|DRUG|doxorubicin|blood sampling before, during and after doxorubicin administration
47956355|NCT05772429|DRUG|Epidiolex|Administered as an oral solution
47956356|NCT05708170|DRUG|Ferinject|"Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject)."
47956357|NCT05708170|DRUG|Ferrous Sulfate 200 MG|Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
47956358|NCT01627483|OTHER|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
47956359|NCT00039078|RADIATION|yttrium Y 90 glass microspheres|
47956360|NCT02272426|BEHAVIORAL|CARET|Combined Aerobic and Resistance Exercise Training
47956361|NCT02272426|BEHAVIORAL|CTI|Cognitive Training Intervention
47956362|NCT02272426|BEHAVIORAL|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
47956363|NCT02272426|BEHAVIORAL|Sham CTI|Sham Cognitive Training Intervention
47956364|NCT00219739|DRUG|Imatinib mesylate 400 mg|
47956365|NCT00219739|DRUG|Imatinib mesylate 600 mg|
47956366|NCT00219739|DRUG|Imatinib 400 mg + Peg-Interferon|
47956367|NCT00219739|DRUG|Imatinib mesylate 400 mg + Cytarabine|
47956368|NCT00227838|BEHAVIORAL|Behavior Therapy|
47956369|NCT05843045|DEVICE|Indoor Air Quality Mitigation|Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
47956370|NCT05427708|BEHAVIORAL|Interoceptive Exposure|See: Arm/group descriptions
48110256|NCT00398606|DRUG|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
48110257|NCT00398606|DRUG|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
48110258|NCT01181180|DIETARY_SUPPLEMENT|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
48303827|NCT03165981|BIOLOGICAL|IIV|ACIP Recommended vaccine
48640360|NCT06053411|DIETARY_SUPPLEMENT|curcumin|2,000 mg tablet
47956371|NCT05427708|DEVICE|Capnometry-Guided Respiratory Intervention|See: Arm/group descriptions
47956372|NCT05427708|BEHAVIORAL|Psycho-Education|See: Arm/group descriptions
47956373|NCT00936156|DRUG|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
48303828|NCT06527378|DIAGNOSTIC_TEST|AI in implant planning|Assessment of Current Technology for Supporting Implant Planning
48303829|NCT06681077|PROCEDURE|Community Health Education|Receive I CAN intervention
48303830|NCT06681077|OTHER|Survey Administration|Ancillary studies
48303831|NCT06691308|COMBINATION_PRODUCT|WL276 CAR-T cells|This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses
48303832|NCT05711667|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48640361|NCT03528642|OTHER|Questionnaire Administration|Ancillary studies
48640362|NCT03528642|RADIATION|Radiation Therapy|Undergo RT
48640363|NCT03528642|DRUG|Telaglenastat Hydrochloride|Given PO
48640364|NCT03528642|DRUG|Temozolomide|Given PO
48640365|NCT04646460|BEHAVIORAL|Observed Success|"The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain."
48640366|NCT04646460|BEHAVIORAL|Observed Failure|The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
48640367|NCT04646460|BEHAVIORAL|Experienced Success|The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.
48640368|NCT04646460|BEHAVIORAL|Experienced Failure|The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
48640369|NCT06695143|DRUG|Fusidic Acid|Fusidic acid 2% cream
48640370|NCT06695143|OTHER|Vehicle cream|Cetomacrogol cream
47956374|NCT05840380|DEVICE|instrumental soft tissue mobilization|Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual. cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied
47956375|NCT03473483|OTHER|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~* Sealed and disposable~* Minimum 350 puffs per tank~* Volume of e-liquid per tank \~ 3ml~E-Liquid Characteristics:~* Tobacco flavored~* Nicotine concentration: 15 mg/ml~* Propylene Glycol:\~ 50% (wt / wt)~* Glycerin: \~ 50% (wt / wt)~* Cotinine: \<1 μg/g~* Nornicotine: 5 μg/g~* Myosmine : 3 μg/g~* Anabasine: \<1 μg/g~* Anatabine: \<1 μg/g~* Beta:nicotyrine: \<1 μg/g~* Diacetyl: \<2 μg/g~* 2,3:Pentanedione: \<1 μg/g~* Arsenic: \<0.1 μg/g~* Cadmium: \<0.1 μg/g~* Chromium: \<0.1 μg/g~* Lead: \<0.1 μg/g~* Nickel: \<0.1 μg/g~* Mercury: \<0.05 μg/g"
47956376|NCT00149734|DRUG|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
47956377|NCT00149734|DRUG|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
47956378|NCT02972671|DEVICE|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
47956379|NCT02972671|DEVICE|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
47956380|NCT04965727|PROCEDURE|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
47956381|NCT03775330|RADIATION|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy \> 2 cm and ≤ 3 cm: 15-18 Gy \> 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions \> 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions \> 15 Gy) when patient is randomized to SRS + WBRT arm"
47956382|NCT03775330|RADIATION|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
47956383|NCT00638482|DRUG|Hydrochlorothiazide|Hydrochlorothiazide
47956384|NCT04742075|DRUG|Olaparib + durvalumab + UV1|The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
47956385|NCT02171065|DEVICE|sham|
47956386|NCT02171065|DEVICE|ABSORB BVS|
48303833|NCT05711667|DRUG|Letermovir|Given PO or IV
48303834|NCT06149403|GENETIC|Experimental: OTL-203|Experimental: OTL-203: Autologous CD34+ enriched cell fraction that contains hematopoietic stem and progenitor cells transduced ex vivo using lentiviral vector encoding the human IDUA gene
48640371|NCT05393908|PROCEDURE|TAP Block Group|Participants will receive a surgeon administered TAP block.
48640372|NCT06328114|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
48640373|NCT04503122|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation : cryoablation or radiofrequency
48640374|NCT05816187|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program.
48640375|NCT05816187|BEHAVIORAL|Habitual|The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking
47956387|NCT05915221|PROCEDURE|SMS|Receive SMS
47956388|NCT00194948|DRUG|escitalopram|
47956389|NCT00194948|BEHAVIORAL|interpersonal psychotherapy|
47956390|NCT04903444|DEVICE|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
47956391|NCT02677961|OTHER|Observation|
48110259|NCT01299753|DRUG|placebo|identically packed placebo
48110260|NCT01299753|DRUG|propranolol|20-40 mg q6-8h
48303835|NCT06149403|GENETIC|Active Comparator: Allo-HSCT|Active Comparator: Allogeneic hematopoietic stem cell transplantation
48303836|NCT02465060|DRUG|Adavosertib|Given PO
48303837|NCT02465060|DRUG|Afatinib|Given PO
48303838|NCT02465060|DRUG|Afatinib Dimaleate|Given PO
48303839|NCT02465060|DRUG|Binimetinib|Given PO
48303840|NCT02465060|PROCEDURE|Biopsy|Undergo tumor biopsy
48303841|NCT02465060|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48303842|NCT02465060|DRUG|Capivasertib|Given PO
48303843|NCT02465060|PROCEDURE|Computed Tomography|Undergo computed tomography (CT)
48303844|NCT02465060|DRUG|Copanlisib|Given IV
48303845|NCT02465060|DRUG|Copanlisib Hydrochloride|Given IV
48303846|NCT02465060|DRUG|Crizotinib|Given PO
48303847|NCT02465060|OTHER|Cytology Specimen Collection Procedure|Optional correlative studies
48303848|NCT02465060|DRUG|Dabrafenib|Given PO
48303849|NCT02465060|DRUG|Dabrafenib Mesylate|Given PO
48640376|NCT05519475|DRUG|ALN-HSD|Administered by subcutaneous injection (SC)
48640377|NCT05519475|DRUG|Placebo|Administered by SC injection
48640378|NCT06475742|DRUG|Cenerimod|Film-coated tablets at a dose of 4 mg.
48303850|NCT02465060|DRUG|Dasatinib|Given PO
48303851|NCT02465060|DRUG|Defactinib|Given PO
48303852|NCT02465060|DRUG|Defactinib Hydrochloride|Given PO
48303853|NCT02465060|PROCEDURE|Echocardiography|Undergo echocardiography (ECHO)
48303854|NCT02465060|DRUG|Erdafitinib|Given PO
48303855|NCT02465060|DRUG|Fexagratinib|Given PO
48303856|NCT02465060|DRUG|Ipatasertib|Given PO
48303857|NCT02465060|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
48303858|NCT02465060|DRUG|Larotrectinib|Given PO
48303859|NCT02465060|DRUG|Larotrectinib Sulfate|Given PO
48303860|NCT02465060|PROCEDURE|Magnetic Resonance Imaging|Undergo magnetic resonance imaging (MRI)
48303861|NCT02465060|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48303862|NCT02465060|BIOLOGICAL|Nivolumab|Given IV
48303863|NCT02465060|DRUG|Osimertinib|Given PO
48303864|NCT02465060|DRUG|Palbociclib|Given PO
48303865|NCT02465060|BIOLOGICAL|Pertuzumab|Given IV
48303866|NCT02465060|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
48303867|NCT02465060|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
48303868|NCT02465060|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
48303869|NCT02465060|BIOLOGICAL|Relatlimab|Given IV
48303870|NCT02465060|DRUG|Sapanisertib|Given PO
48303871|NCT02465060|DRUG|Sunitinib Malate|Given PO
48303872|NCT02465060|DRUG|Taselisib|Given PO
48303873|NCT02465060|DRUG|Trametinib|Given PO
48303874|NCT02465060|BIOLOGICAL|Trastuzumab|Given IV
47956392|NCT06240871|OTHER|Pulmonary artery pressure measurements|The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
48303875|NCT02465060|BIOLOGICAL|Trastuzumab Emtansine|Given IV
48303876|NCT02465060|DRUG|Ulixertinib|Give PO
48303877|NCT02465060|DRUG|Vismodegib|Given PO
48303878|NCT03794726|PROCEDURE|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
48303879|NCT03794726|PROCEDURE|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
48303880|NCT03699982|OTHER|Daily calorie target based on resting energy expenditure|"Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake."
48303881|NCT06631833|BEHAVIORAL|Intervention measures based on the YPAP model.|The intervention group received an 8-week intervention program aimed at gradually increasing their physical activity levels. The intervention program included the following components: 1) 1-2 sessions of moderate-intensity physical activity per week, each lasting 45 minutes, with activities provided by physical activity experts; 2) one health education lecture every two weeks, each lasting 60 minutes; and 3) one family physical activity session per week, each lasting 30 minutes at a lower intensity. At the end of the intervention period, relevant questionnaires were used for measurement.
48303882|NCT06333028|DEVICE|enVista Aspire EA IOLs|Subjects bilaterally implanted with enVista Aspire EA IOLs
48303883|NCT06608849|OTHER|Blood samples|Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea
48303884|NCT06608849|OTHER|Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms|Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
48303885|NCT06003985|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
48640379|NCT02852005|BIOLOGICAL|MVA/HIV62B vaccine|1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
48303886|NCT03107780|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48303887|NCT03107780|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48303888|NCT03107780|DRUG|Navtemadlin|Given PO
48303889|NCT03107780|RADIATION|Radiation Therapy|Undergo radiation therapy
48303890|NCT04117685|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
48303891|NCT06302309|OTHER|Psychological intervention|The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.
48303892|NCT06593912|PROCEDURE|Early Functional Training|Early functional training after 3 weeks using Air Stirrup compared to cast (standard protocol) after peroneal tendon surgery.
48303893|NCT06593912|PROCEDURE|Standard protocol|Cast 6 weeks after peroneal tendon surgery (standard protocol)
48303894|NCT03654248|BEHAVIORAL|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
48303895|NCT03654248|DEVICE|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
48303896|NCT03884101|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
48303897|NCT03884101|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
48303898|NCT03884101|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
48303899|NCT03884101|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
48303900|NCT05574010|DRUG|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
48303901|NCT05574010|DRUG|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
48303902|NCT05574010|OTHER|Placebo: Group 1 in Part B and Part C|Placebo Intravenous (IV) infusion
48303903|NCT05574010|DRUG|Group 2 in Part B and Part C|Dose 3 KAN-101 Intravenous (IV) infusion
48303904|NCT05574010|DRUG|Group 3 in Part B and Part C|Dose 4 KAN-101 Intravenous (IV) infusion
48303905|NCT05574010|DRUG|Group 4 in Part B and Part C|Dose 5 KAN-101 Intravenous (IV) infusion
48303906|NCT06152029|DEVICE|Temporary PNS system|This system remains in place up to 60 days, then removed.
48303907|NCT04246372|DRUG|Tofacitinib|Treatment with oral Tofacitinib for immune mediated skin conditions in adults with Down syndrome
48303908|NCT03249350|BEHAVIORAL|Standard Contingency Management (CM)|"CM utilizes behavior modification \& cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
48303909|NCT03249350|BEHAVIORAL|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
47956393|NCT04672395|BIOLOGICAL|CpG 1018/Alum-adjuvanted SCB-2019 vaccine|Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
47956394|NCT04672395|BIOLOGICAL|Placebo; 0.9% saline|Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
47956395|NCT04672395|BIOLOGICAL|SCB-2019 vaccine|Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
47956396|NCT04672395|BIOLOGICAL|SCB-2019 vaccine for Placebo|Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
47956397|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
47956398|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
47956399|NCT02028143|PROCEDURE|Pulmonary vein isolation|
47956400|NCT02028143|PROCEDURE|ICE catheter placed through one of two existing 8F sheaths|
47956401|NCT03828175|PROCEDURE|spinal anesthesia monitoring|"After attaching all standard monitors (ECG, NIBP, pulse oximeter) and the COP bio-impedance monitor recording basal data (COP, CI, SV, CPI, Do2, DO2I, SVR, SVV.~During sitting position intrathecal anesthesia was conducted in the sitting position under complete aseptic condition using heavy bupivacaine 15mg (3ml) plus 10 mic dexamedatomedine 25G needle after 2 ml Lidocaine skin infiltration. lithotomy position till anesthesia level documented T4 and fixed and lower urinary tract endoscopy then shifting the patient to prone position and after adjustment of the prone position precautions 2 bellows one under the chest and one under the pelvis with pliable free moving abdomen jell ring under the patient head knees and in front of heels, then the basal data recording and after that data recording every 10 minutes till end of the operative procedure. Blood sampling at basal, postoperative"
48303910|NCT06081621|BIOLOGICAL|REGEND001|REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.
47956402|NCT00503295|BIOLOGICAL|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
47956403|NCT00874107|BIOLOGICAL|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
47956404|NCT00874107|BIOLOGICAL|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
47956405|NCT00874107|DRUG|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
47956406|NCT00874107|DRUG|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
47956407|NCT01024075|DRUG|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
47956408|NCT01024075|DRUG|Saline|8cc of Saline mixed with Sinufoam
48303911|NCT06081621|BIOLOGICAL|Placebo|Placebo: Sodium chloride injection administrated by bronchoscopy.
48303912|NCT06692777|DIETARY_SUPPLEMENT|Bergavit|Subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.
48640380|NCT02852005|BIOLOGICAL|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
48303913|NCT06692777|DIETARY_SUPPLEMENT|Placebo|Subjects will take capsule equivalent amount of maltodextrin for 4 months.
48303914|NCT02726750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48303915|NCT02726750|OTHER|Laboratory Biomarker Analysis|Correlative studies
48303916|NCT06649383|DEVICE|Virtual reality|Participant will try virtual reality glasses with tailormade software films to see if it's possible to use them as distraction during awake surgery. We will measure doses of propofol given, level of anxiety, experience of the patient and surgeons satisfaction.
48481180|NCT03589131|PROCEDURE|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
47956409|NCT04859673|DEVICE|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
48303917|NCT02298959|PROCEDURE|Biopsy|Undergo tumor biopsy
48303918|NCT02298959|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48303919|NCT02298959|PROCEDURE|Computed Tomography|Undergo CT scan
48303920|NCT02298959|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
48303921|NCT02298959|BIOLOGICAL|Pembrolizumab|Given IV
48303922|NCT02298959|BIOLOGICAL|Ziv-Aflibercept|Given IV
48303923|NCT04215991|DRUG|Cefiderocol|Administered intravenously over 3 hours
48303924|NCT04215991|DRUG|Standard of Care|Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
48481181|NCT03589131|PROCEDURE|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
48481182|NCT03589131|PROCEDURE|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission \& 30-days mortality. All were analyzed and compared
48481183|NCT02647528|DEVICE|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
48481184|NCT02647528|DEVICE|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
48640381|NCT02852005|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
48640382|NCT06222333|BEHAVIORAL|Respiratory physiotherapy|In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour.
48640383|NCT06222333|DRUG|Conservative Treatment|Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
48303925|NCT05967351|GENETIC|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
48303926|NCT06586515|DRUG|LY3962673|Administered orally.
48640384|NCT05395494|DRUG|D-Cycloserine|"Daily oral D-cycloserine 100mg during TMS treatments (20 days).~Other Names:~Seromycin"
48640385|NCT05395494|DRUG|Placebo oral tablet|Daily oral placebo during the TMS treatments (20 days).
48640386|NCT05395494|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
48303927|NCT06586515|DRUG|Cetuximab|Administered intravenously.
48303928|NCT06586515|DRUG|Gemcitabine|Administered intravenously.
48303929|NCT06586515|DRUG|nab-paclitaxel|Administered intravenously.
48303930|NCT06586515|DRUG|Oxaliplatin|Administered intravenously.
48303931|NCT06586515|DRUG|leucovorin|Administered intravenously.
48303932|NCT06586515|DRUG|Irinotecan|Administered intravenously.
48303933|NCT06586515|DRUG|5-fluorouracil|Administered intravenously.
48303934|NCT06291220|DRUG|Obinutuzumab|Intravenous Infusion
48303935|NCT06291220|DRUG|ABBV-453|Oral; Tablet
48303936|NCT06386744|DRUG|Dusquetide|1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
48303937|NCT04317482|BEHAVIORAL|Standard social stress task|Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
48303938|NCT04317482|BEHAVIORAL|Stressful experience in the ED|Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
48303939|NCT05741593|OTHER|Analysis of the verbatim from the transcription of the recorded interviews.|recorded semi-structured interviews between the patients and the pharmacist
48303940|NCT04061980|DRUG|Binimetinib|Given PO
48303941|NCT04061980|DRUG|Encorafenib|Given PO
48303942|NCT04061980|BIOLOGICAL|Nivolumab|Given IV
48303943|NCT03002389|DRUG|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
48303944|NCT03002389|DRUG|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
48303945|NCT04683848|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
48303946|NCT04683848|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
48303947|NCT04910568|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
48640387|NCT06584357|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.
48640388|NCT06584357|RADIATION|MK6240|Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
47956410|NCT01193530|OTHER|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
48640389|NCT06038032|BEHAVIORAL|Digital wellness platform|A digital wellness platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
48640390|NCT06038032|BEHAVIORAL|Online healthcare professional support|Individual sessions with a registered dietitian, an exercise professional, and a mental health therapist for 16 weeks.
48640391|NCT05378100|DRUG|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
47956411|NCT01193530|OTHER|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
48303948|NCT04910568|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
48303949|NCT04910568|DRUG|Pomalidomide|Pomalidomide will be administered orally (PO) on a 28-day cycle.
48303950|NCT04910568|DRUG|Daratumumab|Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
48303951|NCT04910568|DRUG|Dexamethasone|"Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product."
48303952|NCT04908449|DRUG|Rectus sheath block with bupivacaine|Rectus sheath block with local anesthetic versus sham block with saline
48303953|NCT06590454|DRUG|Pyrvinium|Pyrvinium (2 mg/kg) per day for 14 days
48640392|NCT05378100|DRUG|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
48640393|NCT03741842|BEHAVIORAL|COMBO-KEY|The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
48640394|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + No Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
48640395|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + No Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
47956412|NCT01193530|BEHAVIORAL|Questionnaires|Weekly
47956413|NCT01193530|BEHAVIORAL|Study Diaries|Daily logs
48303954|NCT06590454|DRUG|Placebo|Placebo for 14 days
48303955|NCT06219928|PROCEDURE|Control Group|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline
48303956|NCT06219928|PROCEDURE|Ketamine Group|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
48303957|NCT06219928|PROCEDURE|Dexmedetomidine|After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
48303958|NCT06594523|DRUG|Denifanstat|Tablet
48303959|NCT06594523|DRUG|Placebo|Matching Tablet
48303967|NCT06132685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48303968|NCT06132685|PROCEDURE|Computed Tomography|Undergo CT scan
48303969|NCT06132685|DRUG|Dexamethasone|Given dexamethasone or IV
48303970|NCT06132685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48303971|NCT06132685|OTHER|Questionnaire Administration|Ancillary studies
47956414|NCT01193530|DEVICE|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
48303972|NCT06455787|DEVICE|J-Valve Transfemoral (TF) System|Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR).
48303973|NCT05772715|OTHER|orthosis + exercise therapy|The orthosis + exercise group receives the same orthosis and instructions as the orthosis group (see next section), supplemented by exercise therapy. This includes weekly 25-30-minute physical therapy sessions with a total of 12 sessions. Sessions include patient education on thumb positioning, functional training and home exercise instructions to improve CMC-1 stability during pinch in extension/abduction, as instability and degeneration occurs in flexion/adduction(17,19,28-31). The first phase (week 0 - week 6) comprises coordination exercises for the thumb intrinsics (except adductor pollicis), extensor pollicis brevis and first dorsal interosseous to support CMC-1 extension/abduction. The second phase (week 6 - month 3) comprises reduced orthosis usage and thenar muscle strengthening exercises(except adductor pollicis).
48303974|NCT05772715|OTHER|Orthosis|The orthosis group receives a custom-made thermoplastic orthosis immobilizing the first carpometacarpal joint (CMC-1) in extension/abduction and the metacarpophalangeal joint in flexion. Orthosis usage is 24/7 in the first two weeks, thereafter only during activities with high load until three months. Two appointments take place: one for orthosis fabrication and one for a one-week checkup.
48303975|NCT03309332|DEVICE|AMPLATZER™ PFO Occluder|Implantation of the AMPLATZER™ PFO Occluder in the PFO
48303976|NCT06636071|BIOLOGICAL|setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
48303977|NCT06692387|BEHAVIORAL|Step count increase with the use of a motivational application|The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.
47956415|NCT01193530|DEVICE|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
48303978|NCT06692257|BEHAVIORAL|Observation|To perform a comparative analysis of orofacial functions with an emphasis on breathing and chewing patterns in individuals with and without MIH.
48303979|NCT03992469|DRUG|EBFAHF-2|EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.
48303980|NCT03992469|DRUG|Placebo|Placebo capsules made of cornstarch
47956416|NCT01923831|DRUG|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
48303981|NCT03505320|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
48303982|NCT03505320|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
48303983|NCT03505320|DRUG|leucovorin|Leucovorin will be administered as a 2-hour IV infusion.
48640396|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). 3 monthly booster sessions.
48640397|NCT06181643|BEHAVIORAL|Survivorship Sleep Program with Group Delivery + 3 Booster Sessions|4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). 3 monthly booster sessions.
48640398|NCT05394051|BEHAVIORAL|Positive Affect Regulation sKills (PARK)|"The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up."
47956417|NCT01923831|DRUG|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
47956418|NCT02086292|PROCEDURE|2 ml 1% Lidocaine|
47956419|NCT02086292|PROCEDURE|1 ml 2% Lidocaine|
48303984|NCT03505320|DRUG|fluorouracil|Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
48303985|NCT03505320|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes.
48303986|NCT03505320|DRUG|folinic acid|Folnic acid will be administered as a 2-hour IV infusion.
47956420|NCT05188170|DRUG|Niclosamide|Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy
48303987|NCT03505320|DRUG|nivolumab|Nivolumab will be administered intravenously according to institutional standards.
48303988|NCT03505320|DRUG|Docetaxel|Docetaxel will be administered as a 1-hour IV infusion.
48303989|NCT05993767|DRUG|dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen|Switch or start dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen with a novel dose ratio for HIV treatment
47956421|NCT00567372|DRUG|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
47956422|NCT00236587|DRUG|risperidone|
48303991|NCT03224949|OTHER|Blood draw|Patients will have a one time blood draw
47956423|NCT03349697|DIETARY_SUPPLEMENT|Phyllantus amarus|
47956424|NCT03349697|OTHER|Placebo|
47956425|NCT02028819|DRUG|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
47956426|NCT02028819|DRUG|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
47956427|NCT06315374|OTHER|Use soft mist inhaler|Only use soft mist inhaler
47956428|NCT06315374|DEVICE|Use soft mist inhaler with a 3D assistive device|Use soft mist inhaler with a 3D-printed assist device
47956429|NCT02213640|DEVICE|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
47956430|NCT02213640|DEVICE|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
47956431|NCT06390033|DEVICE|Prosthetic foot|A low-cost prosthetic foot designed to enhance gait mechanics and physical performance in individuals who have undergone traumatic unilateral transtibial amputation, as compared to the traditional K2 - K3 prosthetic feet currently available on the market, during both indoor and outdoor activities, whilst satisfying the users' satisfaction levels after traumatic unilateral transtibial amputation.
47956432|NCT01902823|BEHAVIORAL|Services from a Nurse Navigator|Services from a Nurse Navigator
47956433|NCT05412095|OTHER|Ultrasound of the abdominal wall muscles|the measurements will be performed during inspiration and expiration to take into account variability during the respiratory cycle. The examination is performed bilaterally and comparatively and lasts between 3 and 5 minutes.
48303992|NCT05624255|OTHER|Ophthalmologic consultation|Complete ophthalmologic examination including angio-OCT
47956434|NCT05412095|OTHER|Ultrasound quadricipital|The examination is performed bilaterally and comparatively and takes between 3 and 5 minutes.
48303993|NCT05303519|DRUG|safusidenib|safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
48266636|NCT05783700|DIAGNOSTIC_TEST|BIOIMPEDANCEMETRY|The impedance of cellular tissue can be modeled as a resistor (representing the extracellular path) in parallel with a resistor and capacitor in series (representing the intracellular path, the resistance that of intracellular fluid and the capacitor the cell membrane). This results in a change in impedance versus the frequency used in the measurement. Whole body impedance measurement is generally measured from the wrist to the ipsilateral ankle and uses either two (rarely) or four (overwhelmingly) electrodes. In the 2-elctrode (bipolar) configuration a small current on the order of 1-10 μA is passed between two electrodes, and the voltage is measured between the same whereas in the tetrapolar arrangement resistance is measured between as separate pair of proximally located electrodes. The tetrapolar arrangement is preferred since measurement is not confounded by the impedance of the skin-electrode interface
48303994|NCT03233776|DRUG|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
48481185|NCT05447806|DEVICE|Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support|This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
48481186|NCT00504803|PROCEDURE|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
48481187|NCT02635581|DEVICE|Delta TT acetabular cup|
48481188|NCT06471543|DRUG|RN0361|solution
48303995|NCT05563220|DRUG|Elacestrant|Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
48303996|NCT05563220|DRUG|Alpelisib|Alpelisib 250 mg or 300 mg once daily in cycles of 28 days
48481189|NCT01221090|BEHAVIORAL|PDA|Technological assistance
48303997|NCT05563220|DRUG|Everolimus|Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
48481190|NCT01221090|BEHAVIORAL|CDSMP|6-week classes
48481191|NCT01221090|BEHAVIORAL|PDA/CDSMP|Combined technology and education
47956435|NCT05412095|OTHER|Ultrasound of the diaphragm|The examination is performed bilaterally and comparatively and takes between 5 and 10 minutes.
47956436|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|measurements performed bilaterally on a patient in a half-sitting position at 45° and in spontaneous ventilation
47956437|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|In spontaneous ventilation, lying down, arms by the side of the body, palms up, head down
47956438|NCT06150625|OTHER|Orthopedic Manaual Therapy|Can include either spinal mobilizations or spinal manipulation therapy targeting the stiff or symptomatic level of the lumbar spine. Various types of mobilization or manipulation may be used based on the therapists clinical reasoning. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data. Common mobilizations techniques involve gently and repeatedly applying pressure over different parts of the patient's spine that is associated with their symptoms. For a manipulation, the patient will be positioned in side-lying position. The therapist will then position the patient further to target the symptomatic level. The patient is asked to take a deep breathe in and out. The therapist will slowly add pressure through the trunk and apply a fast but small thrust motion toward the table.
47956439|NCT06150625|OTHER|Dry Needling|dry needling both sides of the symptomatic level(s) of the lumbar spine as well as needling other areas in the lower extremity and pelvis based on the results of their clinical evaluation and/or the subjects presenting symptoms. Dry needling involves the insertion of a monofilament needle (nothing is injected) into symptomatic soft tissue. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data.
47956440|NCT06150625|OTHER|Home exercise program|5 exercises will be selected from 10 options intended to reinforce the improvements made from treatment.
47956441|NCT06150625|OTHER|Patient education|Patient education on the low back condition, advice to stay active, and home exercise performance.
47956442|NCT05292378|OTHER|2500 ppm Carbon Dioxide|2.5 hour exposure to 2500 ppm carbon dioxide
48110261|NCT00130780|DRUG|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
48110262|NCT00130780|DRUG|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
48110263|NCT05239299|OTHER|No intervention, observational study|Focus Group
48481192|NCT05736224|DRUG|Sunscreen|The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.
48110264|NCT05058469|DEVICE|Tracheotomy|Tracheotomy in patients +/- antiplatelet therapy
48110265|NCT02796092|DEVICE|Fibered platinum coils|
48110266|NCT02796092|DEVICE|Vascular plugs|
48481193|NCT05736224|OTHER|UV Light|UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
48640399|NCT01689649|DRUG|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
47956443|NCT05292378|OTHER|600 ppm Carbon Dioxide|2.5 hour exposure to 600 ppm carbon dioxide
47956444|NCT01957774|DRUG|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
48110267|NCT03071848|OTHER|No Intervention|This was an observational study.
48110268|NCT00442117|DRUG|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
48110269|NCT00442117|DRUG|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
48481194|NCT03443518|PROCEDURE|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
48481195|NCT03443518|PROCEDURE|Local Anesthesia infiltration|Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
48481196|NCT03443518|DRUG|Normal saline 0.9% IV infusion|Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
48481197|NCT03443518|DRUG|Remifentanil infusion|Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
47956445|NCT01957774|DRUG|Placebo|
48110270|NCT04781595|DIETARY_SUPPLEMENT|Watermelon|A single dose of watermelon powder containing 3g of L-citrulline
48110271|NCT04781595|DIETARY_SUPPLEMENT|Beetroot|A single dose of beetroot powder containing 8 mmol of nitrate
48110272|NCT04781595|DIETARY_SUPPLEMENT|Watermelon + beetroot|A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate
48303998|NCT05563220|DRUG|Ribociclib|Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
48481198|NCT00002194|DRUG|Erythromycin|
48481199|NCT00002194|DRUG|Nevirapine|
48481200|NCT00002194|DRUG|Clarithromycin|
48481201|NCT01008514|PROCEDURE|adjuvant therapy|
48481202|NCT01008514|RADIATION|accelerated partial breast irradiation|
48481203|NCT01008514|RADIATION|intracavitary balloon brachytherapy|
48640400|NCT02506439|DIETARY_SUPPLEMENT|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
48481204|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
48481205|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
48640401|NCT02506439|DIETARY_SUPPLEMENT|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
48640402|NCT02506439|DIETARY_SUPPLEMENT|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
48640403|NCT05624749|DRUG|ianalumab|ianalumab s.c. monthly
48640404|NCT05624749|DRUG|placebo|placebo s.c. monthly
47956446|NCT04275570|BEHAVIORAL|Motivational interview|The motivational interview is integrated in a structural theoretical mark. This method is a person-centered counseling style that increases the intrinsic motivation of the patient to behavioral changes through spirit, acceptance, compassion and evocation.
47956447|NCT02518074|OTHER|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
48481206|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
47956448|NCT04367233|OTHER|General anesthesia|General anesthesia with fentanyl, propofol and remifentanil.
47956449|NCT04367233|OTHER|Transverse abdominal block|Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil
47956450|NCT04367233|OTHER|Quadratus lumborum block|At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
47956451|NCT02563171|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
47956452|NCT02563171|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
47956453|NCT00957554|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
47956454|NCT00957554|DRUG|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
47956455|NCT01823302|DIETARY_SUPPLEMENT|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
47956456|NCT01823302|OTHER|nutritional counseling|nutritional counseling
47956457|NCT01517620|DRUG|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
47956458|NCT04727073|DRUG|Experimental: Spironolactone|Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.
48110273|NCT04781595|DIETARY_SUPPLEMENT|Placebo|A single dose of maltodextrin
48110274|NCT02886754|BEHAVIORAL|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
48110275|NCT02886754|BEHAVIORAL|National e-learning programme only|National e-learning programme (COMPASS)
48110276|NCT02886754|BEHAVIORAL|Standard simulation|Paper based simulation cases
48481207|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
48481208|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\]
48481209|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
47956459|NCT04727073|DRUG|Placebo Comparator|Placebo of Spironolactone in tablet form taken daily with dosage escalation rules in accordance with dosage of the study drug Spironolactone.
48481210|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
47956460|NCT03622073|OTHER|Misoprostol treatment by Midwife|Medical management of incomplete abortion
47956461|NCT03622073|OTHER|Misoprostol treatment by Doctor|Medical management of incomplete abortion
48110277|NCT04503356|PROCEDURE|OMNI as a standalone procedure|It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
48110278|NCT04503356|PROCEDURE|OMNI combined with cataract surgery|Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
48110279|NCT02916836|OTHER|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
48481211|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
48481212|NCT05893316|DIAGNOSTIC_TEST|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
47956462|NCT04521816|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
47956463|NCT03137420|DIAGNOSTIC_TEST|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
47956464|NCT05084014|OTHER|Deep Stripping|The deep longitudinal stripping can be applied on adhesions and knots in muscles. The lengthening stokes are parallel to muscle fiber and applied in an oblique direction with the help of the thumbs of hands/ elbow/ knuckles
48110280|NCT02916836|OTHER|No Use of therapeutic drug conciliation sheet (TDC)|
48110281|NCT00297674|DRUG|Intravenous Clarithromycin|
48110282|NCT05061953|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
48110283|NCT01045655|BEHAVIORAL|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
48110284|NCT01312441|DRUG|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
48110285|NCT01312441|DRUG|Placebo|Placebo by mouth once weekly for 6 months
48110286|NCT02101190|DRUG|BIA 9-1067|Opicapone, OPC
48110287|NCT05717114|PROCEDURE|Pecs block|(Pecs block):the block will be performed with the patients in the supine position.The infraclavicular and axillary regions will be cleaned with antiseptic solution. the inplane technique will be used from proximal and medial to distal and lateral in an oblique manner at dermatome level T2and T3.The puncture site was infiltrated with 2%lidocaine and once the structures is identified with ultrasound.
48110288|NCT06555146|DRUG|Semaglutide, 0.5 mg/mL|1 subcutaneous injection on baseline day
48110289|NCT06555146|DRUG|Placebo, Saline|1 subcutaneous injection on baseline day
48481213|NCT03199313|DRUG|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
48481214|NCT03199313|DRUG|Placebo|Matching Sutezolid placebo
48481215|NCT00377078|DRUG|recombinant human lactoferrin|
48481216|NCT03995017|DRUG|Rucaparib|Rucaparib tablet
48640405|NCT06465368|DRUG|PF-07220060|PF-07220060 given as tablet by mouth twice a day for 14 days.
48110290|NCT02825225|OTHER|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
48110291|NCT02825225|PROCEDURE|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
48110292|NCT04835870|DRUG|Zanubrutinib|Zanubrutinib-160mg bid PO d0-d20(1-21d)
48110293|NCT04835870|DRUG|Rituximab|Rituximab-375 mg/m2 i.v d0 (/21d)
48110294|NCT04835870|DRUG|Cyclophosphamide|Cyclophosphamide-750 mg/m2 i.v d1 (/21d)
48110295|NCT04835870|DRUG|Doxorubicin|Doxorubicin-50 mg/m2 i.v d1 (/21d)
48110296|NCT04835870|DRUG|Vincristine|Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
48110297|NCT04835870|DRUG|Prednisone|Prednisone-100 mg p.o d1-d5 (/21d)
48110298|NCT00920881|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
48481217|NCT03995017|DRUG|Ramucirumab|Ramucirumab intravenous solution
48481218|NCT03995017|DRUG|Nivolumab|Nivolumab intravenous solution
48481219|NCT00854802|DRUG|Debio 025|Debio 025 supplied in soft gel capsules
48481220|NCT00854802|DRUG|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
48481221|NCT00854802|DRUG|Ribavirin|Ribavirin supplied in tablets
48640406|NCT06465368|DRUG|letrozole|Letrozole given as tablet by mouth once a day for 14 days
48640407|NCT06551701|OTHER|Pharmacist call|Pharmacists will call patients and their providers to discuss benefits of statin use
48640408|NCT04804007|DRUG|Etoposide|etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
48481222|NCT00854802|DRUG|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
48481223|NCT01758146|DRUG|Tamoxifen|20 mg once daily for 5 years
47956465|NCT05084014|OTHER|Kneading|kneading lifts the muscle in circular movements with the help of the hands. It lifted, rolled, and squeezed muscle
47956466|NCT03385512|BEHAVIORAL|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
48110299|NCT04154514|DEVICE|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
48110300|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
48110301|NCT00765973|DRUG|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
48110302|NCT04109534|DIAGNOSTIC_TEST|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc... until the FEV1 decreases 20% below the initial FEV1-value
47956467|NCT03385512|BEHAVIORAL|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
47956468|NCT03385512|BEHAVIORAL|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
48110303|NCT04109534|DIAGNOSTIC_TEST|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
48110304|NCT04109534|DIAGNOSTIC_TEST|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
48110305|NCT04109534|DIAGNOSTIC_TEST|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
48110306|NCT00039455|BIOLOGICAL|trastuzumab|Given IV
48303999|NCT05563220|DRUG|Palbociclib|Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
48304000|NCT05563220|DRUG|Capivasertib|Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
48481224|NCT01758146|DRUG|Letrozole|Letroz, Femara, Letronat
48481225|NCT00036647|DRUG|Tarceva (erlotinib HCl, OSI-774 )|
48110307|NCT00039455|DRUG|alvocidib|Given IV
48110308|NCT00039455|OTHER|laboratory biomarker analysis|Correlative studies
48110309|NCT00039455|OTHER|pharmacological study|Correlative studies
48110310|NCT04847219|DEVICE|Professional flash glucose mornitoring|Subjects will use Professional flash glucose mornitoring once a month for 3 months.
47956469|NCT04099095|BEHAVIORAL|Immediate Appointment|The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
48110311|NCT04847219|DEVICE|Personal flash glucose mornitoring|Subjects will use Personal flash glucose mornitoring once a month for 3 months.
48110312|NCT02607384|BEHAVIORAL|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
48110313|NCT02607384|BEHAVIORAL|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
48110314|NCT02607384|OTHER|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
48110315|NCT03922867|BEHAVIORAL|CBT|A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
48110316|NCT04097210|DIAGNOSTIC_TEST|POC|
48110317|NCT03731312|OTHER|No intervention|This is an observational study and no interventions will be administered.
48110318|NCT04655131|DIETARY_SUPPLEMENT|Whey protein isolate|Commercially available, FDA approved whey protein isolate for dietary supplementation
48110319|NCT01131624|DRUG|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
48266637|NCT00556426|DEVICE|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
48304001|NCT05563220|DRUG|Abemaciclib|Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
48481226|NCT01980160|DEVICE|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
48481227|NCT01980160|DEVICE|Unactivated Nometex Device|
48481228|NCT00908219|DRUG|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
47956470|NCT04099095|BEHAVIORAL|Delayed Appointment|After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
47956471|NCT02105883|OTHER|Use of identification badge during scenarios|
47956472|NCT04002739|DIAGNOSTIC_TEST|Polygraphy|Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
47956473|NCT04715633|DRUG|PD-1 inhibitor plus VEGF inhibitors|Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14
47956474|NCT06534710|DEVICE|electronic moxibustion apparatus|The experimental group used the electronic moxibustion instrument every day on the basis of the control group
47956475|NCT04967378|BEHAVIORAL|HEPPI|10 weekly individual sessions, 90 minutes each, at the participants' homes. The content of sessions includes psychoeducation, cognitive training, psychotherapeutic intervention, and compensatory strategy training.
47956476|NCT00066365|BIOLOGICAL|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
47956477|NCT00066365|PROCEDURE|conventional surgery|thoracotomy
47956478|NCT05492214|PROCEDURE|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
47956479|NCT05492214|PROCEDURE|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
47956480|NCT05492214|PROCEDURE|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
47956481|NCT00892047|DRUG|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
47956482|NCT00892047|DRUG|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
47956483|NCT05644769|OTHER|Determine the presence of Human sequence Ang-(1-12) on no medication|Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.
47956484|NCT05644769|DRUG|Human sequence Ang-(1-12) on Lisinopril 40mg every day|Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.
47956485|NCT04571320|BEHAVIORAL|Summer STRIPES|See arm description.
47956486|NCT04571320|OTHER|Enhanced School Services as Usual|see arm description.
47956487|NCT01457222|BEHAVIORAL|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
47956488|NCT01457222|BEHAVIORAL|Music relaxation|Music relaxation 10 minutes daily
47956489|NCT06144892|DEVICE|Proactive Therapy|Uses AI to make predictions and preventions of future apneic events.
47956490|NCT02544646|OTHER|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
47956491|NCT05154396|DRUG|Neratinib|Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
47956492|NCT03441269|DRUG|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
47956493|NCT05020678|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
47956494|NCT04977674|DRUG|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
47956495|NCT04977674|DRUG|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
47956496|NCT04977674|DRUG|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
47956497|NCT04450173|DRUG|Ibrutinib|Given PO
47956498|NCT04450173|BIOLOGICAL|Obinutuzumab|Given IV
48266638|NCT03544580|PROCEDURE|immediate implant with dentine chips|Using dentin chips
47956499|NCT04450173|DRUG|Venetoclax|Given PO
47956500|NCT00827528|PROCEDURE|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
47956501|NCT00827528|PROCEDURE|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
47956502|NCT04610970|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
47956503|NCT02123342|BEHAVIORAL|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
47956504|NCT05444517|PROCEDURE|Interscalene Block|"Ultrasound-guided brachial plexus block injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml in the Interscalene groove.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
47956505|NCT05444517|PROCEDURE|Infraclavicular - Anterior Supraescapular Nerve Blocks|"Ultrasound-guided combined infraclavicular-anterior suprascapular block of the brachial plexus, injecting 20 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an ultrasound-guided injection of 3 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml under the omohyoid muscle. If the anterior suprascapular nerve could not be identified after five minutes of insonation time, an upper trunk block will be carried out with the same amount of local anesthetic.~Patients will receive dexamethasone 4 mg intravenously and an ultrasound-guided intermediate cervical plexus block (5 ml of bupivacaine 0.5% plus epinephrine 5 micrograms per ml)."
48266639|NCT03544580|PROCEDURE|conventional immediate implant|using xenograft
47956506|NCT01613534|DRUG|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
47956507|NCT01613534|DRUG|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
48640409|NCT05893030|PROCEDURE|anesthesia guided by sedation and analgesia monitoring|"Anesthesia guided by sedation and analgesia monitoring The level of sedation will be monitored by~* Monitoring System BIS™ : Bispectral index (BIS) between 45 and 60 AND Suppression Ratio (SR) at 0;~* or SedLine® Sedation Monitor : Patient State Index (PSi) between 25 and 50;~* or Entropy Sensor™: State entropy (SE) between 45 and 60 AND Burst Suppression Ratio (BSR) at 0;~and the level of nociception by :~* Nociception monitor PMD-200® : Nociception Level (NoL) between 10 and 25."
48640410|NCT05893030|PROCEDURE|anesthesia performed according only to the clinical judgment of the anesthetist as usual practice|Administration of anesthesia will be performed according to the clinical judgment of the anesthetist as usual practice without sedation and analgesia monitoring
48640411|NCT03178890|DEVICE|OHMG|Device will be implanted in all enrolled patients.
48640412|NCT03761914|BIOLOGICAL|galinpepimut-S|"* Induction phase: the first two GPS + Montanide injections are administered Q3W on Week 0 and Week 3. Thereafter, GPS + Montanide is co-administered with pembrolizumab Q3W (Weeks 6, 9, 12, 15, 18).~* Early immune booster phase: A single administration of pembrolizumab (Week 21), and then GPS + Montanide resumes Q3W for six additional doses (Weeks 24, 27, 30, 33, 36, 39).~* Following the early immune booster, there is a 12-week interval of pembrolizumab administration (Weeks 42, 45, 48, 51), and then GPS is resumed every 12 weeks for an additional four doses.~* After 84 weeks, participants who had not progressed will continue in the study and be treated with pembrolizumab alone."
48640413|NCT03761914|BIOLOGICAL|pembrolizumab|Pembrolizumab is administered at a dose of 200 mg intravenously every 3 weeks on Day 1 of each cycle (3-week cycles) starting on Study Week 6 and continuing for up to 2 years thereafter (Study Week 108). Pembrolizumab is to be administered no earlier than 30 minutes after the administration of GPS on Day 1 of each cycle.
48640414|NCT03761914|OTHER|Montanide|Adjuvant
48640415|NCT03761914|BIOLOGICAL|GM-CSF|Participants receive 70 μg GM-CSF SC on Day -2 and on Day 1 before each GPS injection. The GM-CSF injections occur at the same anatomical site of the next planned study treatment injection.
47956508|NCT04763356|OTHER|Symptom Care at Home with NP follow up|In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
47956509|NCT00550121|DRUG|vitamin C|
47956510|NCT00550121|DRUG|placebo|
47956511|NCT03878953|DRUG|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
48110320|NCT01131624|DRUG|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
48110321|NCT03969472|DRUG|probiotics|apply probiotic after operation
48110322|NCT03969472|DEVICE|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
48640416|NCT06404086|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
48640417|NCT06404086|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
47956512|NCT06016920|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
48110323|NCT05727202|DIAGNOSTIC_TEST|The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel|A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
48481229|NCT01695096|OTHER|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
48640418|NCT06404086|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
48640419|NCT06404086|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
47956513|NCT06016920|DRUG|Pembrolizumab|"Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes."
47956514|NCT02676115|OTHER|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
47956515|NCT02676115|OTHER|Medipore Tape|"* One layer of Medipore tape will be placed across the incision.~* Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
47956516|NCT03653338|BIOLOGICAL|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
47956517|NCT03653338|BIOLOGICAL|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
47956518|NCT03653338|DRUG|Hydroxyurea|Sickle Cell Disease Conditioning
47956519|NCT03653338|DRUG|Rituximab|Sickle Cell Disease Conditioning
47956520|NCT03653338|DRUG|Alemtuzumab|Sickle Cell Disease Conditioning
47956521|NCT03653338|DRUG|Fludarabine|Sickle Cell Disease Conditioning
47956522|NCT03653338|DRUG|Thiotepa|Sickle Cell Disease Conditioning
47956523|NCT06419621|DRUG|PM8002|PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
47956524|NCT06419621|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
47956525|NCT06419621|DRUG|Placebo|Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
47956526|NCT03473171|DEVICE|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
47956527|NCT03585231|BEHAVIORAL|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
47956528|NCT03585231|BEHAVIORAL|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
47956529|NCT03585231|BEHAVIORAL|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
47956530|NCT02008630|OTHER|Animal-assisted activity|
47956531|NCT02008630|OTHER|Animal-assisted therapy|
47956532|NCT03113071|DRUG|Decitabine|Decitabine will be administered in combination with Digoxin
47956533|NCT03113071|DRUG|Digoxin|Decitabine will be administered in combination with Digoxin
47956534|NCT02587793|OTHER|not interventional study|
48640420|NCT06404086|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
47956535|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
47956536|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
47956537|NCT05306392|DEVICE|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
48640421|NCT06404086|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
47956538|NCT05306392|DEVICE|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
47956539|NCT06223074|OTHER|IV Methylprednisolone administration|Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
47956540|NCT06223074|DRUG|Nasal Methylprednisolone (MT)|Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
47956541|NCT03524742|OTHER|Avocado-Mediterranean Diet|Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
47956542|NCT03524742|OTHER|Control-Group Diet|A low fat-high complex carbohydrate diet, during 3 months.
47956543|NCT06361160|DEVICE|Active Transcranial Magnetic Stimulation (TMS)|Active rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) at the onset of the Auditory Verbal Hallucinations (AVH).
48110324|NCT04658030|DEVICE|VR 360 video surgery preparation|Preparing children on the surgery by a virtual reality 360 degrees video tour from the pediatric ward to the surgery room. In this video all information is given necessary for the surgery. This takes a maximum of 30 minutes and will be performed 1 time.
48110325|NCT04658030|OTHER|Care as usual|Preparing the children for surgery with the care as usual. A booklet that can be viewed by the children and parents at home.
48110326|NCT05587309|DRUG|BLI5100|Orally via tablet
48110327|NCT05587309|DRUG|PPI Control|Orally via tablet
48110328|NCT05839938|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
48640422|NCT06404086|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
48640423|NCT06404086|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
48640424|NCT06413134|DEVICE|TheraPAP|TheraPAP is a novel CPAP-based therapy in which pressure is dropped as much as 5 cmH2O starting at the beginning of inspiration and extending through the end of expiration where it rises back up to the true therapy pressure for a short period. It improves comfort by providing pressure only when it is needed and maintaining it at a low level the rest of the time. Normal CPAP/APAP therapy keeps pressure at the therapy level during the entire breath cycle, except with some alternate approaches where pressure is decreased but only during the expiratory phase.
48110329|NCT05839938|OTHER|Placebo|Placebo
48110330|NCT00590369|DEVICE|KCI -VAC|Negative pressure wound therapy device
48110331|NCT00590369|DEVICE|Versatile One (EZCare)|Negative pressure wound therapy device
48110332|NCT03897413|DRUG|S-888711|Administered orally as three 0.25 mg tablets
48110333|NCT03897413|DIETARY_SUPPLEMENT|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
48110334|NCT03058965|DRUG|[18F]MNI-958|Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
47956544|NCT06361160|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|"Sham rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) during the onset of the Auditory Verbal Hallucinations (AVH).~An electrical stimulator is synchronised with the magnetic stimulation to recreate the tactile sensation and the coils emits the same noise during sham stimulation as in the active configuration, making it impossible to distinguish between active and placebo magnetic stimulation."
47956545|NCT06434012|OTHER|registry|This is registry for Infective Endocarditis
48110335|NCT03058965|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.
48110336|NCT03058965|DRUG|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
48110337|NCT02749318|GENETIC|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
48110338|NCT05173324|BIOLOGICAL|HPV vaccine|Licensed HPV vaccines (bivalent, quadrivalent, or nonvalent) available in the country of the study site
48110339|NCT05173324|DIAGNOSTIC_TEST|HPV testing|HPV testing with partial genotyping of HPV16/18 (and/or 45) to be used as a primary cervical screening test for all participants regardless of the study arm
48110340|NCT05173324|BIOLOGICAL|HAV vaccine|Hepatitis A virus (HAV) vaccine to be offered as a placebo
48110341|NCT05193188|DRUG|Anlotinib hydrochloride|Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity
48110342|NCT05193188|DRUG|PD-1 inhibitor|Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
48640425|NCT06413134|DEVICE|APAP|Standard CPAP therapy where therapy pressure is automatically adjusted to prevent respiratory events from occurring. The TheraPAP prototype device will be used to operate in the APAP mode in addition to the TheraPAP intervention mode.
47956546|NCT04259320|DEVICE|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
47956547|NCT04259320|BIOLOGICAL|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
47956548|NCT05932966|DEVICE|Insulin closed-loop delivery system|Insulin closed-loop delivery system
47956549|NCT00594048|DEVICE|Resperate|Use of the device 15 minutes a day for 9 weeks
47956550|NCT00594048|DEVICE|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
47956551|NCT00659048|DRUG|Ciclesonide|Ciclesonide 200µg versus Placebo
47956552|NCT00659048|DRUG|Placebo|placebo
47956553|NCT00397215|BIOLOGICAL|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
47956554|NCT00397215|BIOLOGICAL|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
47956555|NCT04639700|BEHAVIORAL|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information \& Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional \& Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
47956556|NCT02659293|DRUG|Lenalidomide|"* Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21"
47956557|NCT02659293|DRUG|Carfilzomib|"* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16"
47956558|NCT02659293|DRUG|Dexamethasone|"* Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22"
47956559|NCT02659293|DRUG|Lenalidomide (Control)|"* Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28"
47956560|NCT06272201|DEVICE|POSE2.0 procedure with g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|POSE2.0 (g-Cath EZ snowshoe suture anchors placed in the mid + distal body without placement in the fundus), with a moderate intensity diet and exercise program
47956561|NCT03348137|OTHER|Questionnaire Administration|Ancillary studies
47956562|NCT03315546|RADIATION|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
47956563|NCT02284269|DRUG|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
47956564|NCT01069016|PROCEDURE|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
47956565|NCT01069016|PROCEDURE|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
48110343|NCT00164333|BEHAVIORAL|TAP: Treatment Advocacy Program|
48304002|NCT06691867|BEHAVIORAL|I-STRONG|"I-STRONG is an evidence-based protocol from the FIT Teens program. This intervention combines mind-body and cognitive-behavioral approaches with neuromuscular movement training informed by pediatric sports medicine and injury prevention research. It aims to teach mind-body skills applicable during movement training to enhance psychological coping and reduce fear of pain and activity avoidance.~I-STRONG consists of 16 group-based telehealth sessions held twice weekly over 8 weeks. Each group can accommodate up to 6 patients with SCD. Adolescents are expected to attend all sessions, while parents will attend 6 of the 16. Parents will receive education about I-STRONG, guidance on supporting their teen's behavior change, and opportunities for networking with other parents of youth with SCD. Sessions will include brief daily homework (e.g., using phone apps to practice skills) to facilitate proficiency. Participants will self-report their practice of assigned skills."
48304003|NCT06691867|OTHER|Enhanced Usual Care (EUC)|The EUC arm is designed to account for potential effects on time and standard medical care outcomes. Patients randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months (i.e., time from enrollment through 6-month post-treatment assessment) before starting the intervention program to coincide with the study duration of the ES arm. After completing the 6-month follow-up assessment, patients will have the opportunity to start the I-STRONG for SCD intervention.
48640426|NCT05792722|PROCEDURE|Prostate capsule-sparing radical cystectomy|Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
47956566|NCT00085709|DRUG|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses \>/= 28 days apart
47956567|NCT00085709|OTHER|observation|No treatment given
48110344|NCT04043364|BEHAVIORAL|LIVE|Learning, Innovation, Volunteers and Empowerment
48110345|NCT04537065|OTHER|cycloplegic refraction|"Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)."
48110346|NCT00101010|BIOLOGICAL|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
48110347|NCT00101010|BIOLOGICAL|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
48110348|NCT00101010|BIOLOGICAL|Rituximab|375 mg/m\^2 intravenous piggy back (IVPB) on day 1, administered 1st
48110349|NCT00101010|DRUG|Cyclophosphamide|750 mg/m\^2 IVPB on day 1
48110350|NCT00101010|DRUG|Pegylated liposomal doxorubicin hydrochloride|40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
48110351|NCT00101010|DRUG|Prednisone|40 mg/m\^2 oral days 1 - 5.
48110352|NCT00101010|DRUG|Vincristine Sulfate|2 mg IV, day 1
48110353|NCT02616237|BEHAVIORAL|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
48640427|NCT05792722|PROCEDURE|Nerve sparing radical cystectomy|Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
48640428|NCT06641505|BEHAVIORAL|Guiding rehydration|Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
47956568|NCT00085709|DRUG|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
47956569|NCT00085709|DRUG|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
48110354|NCT00617812|BIOLOGICAL|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
48110355|NCT04978935|OTHER|Care protocol|"Before starting the application, the investigator (DS) will fill out the Introductory Characteristics Form of all patients, the Pre-thoracotomy Pulmonary Function Test (PFT) section of the Patient Results Form. The PFT section will be re-evaluated on the 1st, 5th day and on the day of discharge after thoracotomy.~Nursing interventions will be applied to the study group (n=40), starting from the 0th day (the first day spent in the intensive care unit) after the thoracotomy in line with the prepared care protocol application steps until discharge. Care protocol consists of patient's position, mobilization, use of spirometer and shoulder exercises."
48110356|NCT03856099|DRUG|TTAC-0001|"* Investigational product (IP): TTAC-0001~* Treatment groups: 3 dose groups~  * Dose group A : TTAC-0001 16 mg/kg on D1 and D15~ * Dose group B : TTAC-0001 20 mg/kg on D1 and D15~ * Dose group C : TTAC-0001 24 mg/kg on D1 and D15~* Cycle: 4 weeks (28 days per cycle)"
48110357|NCT04771234|BEHAVIORAL|Digital self-guided CBT-i|A brief version of CBT-i consisting of brief psychoeducation, and the core components sleep restricion and stimulus control, where sleep restriction is based on a simplified sleep diary.
48110358|NCT03587168|OTHER|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
48110359|NCT03587168|OTHER|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
48110360|NCT03587168|OTHER|Four Square Step Test|The Four Square Step Test measures dynamic balance.
47956570|NCT00981201|DRUG|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
48110361|NCT03587168|OTHER|Functional Reach Test|The Functional Reach Test assesses limits of stability.
48110362|NCT03587168|OTHER|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
48304006|NCT01003028|DRUG|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
48304007|NCT01003028|DRUG|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
48304008|NCT06079476|DRUG|Romosozumab|Single-use prefilled syringe for SC injection.
47956571|NCT00981201|DRUG|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
47956572|NCT00981201|DRUG|Placebo|"Months 1-3:~By mouth twice daily."
47956573|NCT00981201|DRUG|Placebo|"Months 4-6:~By mouth twice daily."
47956574|NCT00841919|DRUG|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
47956575|NCT00841919|DRUG|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
47956576|NCT00841919|DRUG|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
47956577|NCT02275858|DEVICE|Stiffening wire|Stiffening wire
48304013|NCT06269211|DRUG|Toripalimab|240mg IV, Q3W
48304014|NCT05652374|DEVICE|Ialuril 50ml Prefill|50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months
47956578|NCT02275858|DEVICE|Placebo wire|Placebo wire
47956579|NCT00183989|DRUG|Fludarabine, Mitoxantrone and Rituximab|
48304015|NCT05652374|DRUG|Nitrofurantoin|nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
47956580|NCT00760422|DEVICE|NIR|Thermometer
47956581|NCT03267836|DRUG|Avelumab|-10mg/kg IV
47956582|NCT03267836|RADIATION|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
47956583|NCT03267836|PROCEDURE|Surgery|-Standard of care
47956584|NCT00887406|DRUG|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
48110363|NCT03587168|OTHER|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
48110364|NCT03587168|OTHER|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
48304016|NCT06569147|DRUG|Elranatamab|Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
48304017|NCT02956174|DEVICE|Co-Cr single crown|
48304018|NCT02956174|OTHER|Periodontal parameters|
48304019|NCT06693674|DRUG|Entresto Pill|Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
48304020|NCT06693674|OTHER|Placebo|Patients taking placebo tablets will take 1 tablet orally, twice daily
48304021|NCT06438562|DIETARY_SUPPLEMENT|Unfortified bouillon plus vitamin A in oil|Participants consume unfortified bouillon with vitamin A oil
48304022|NCT06438562|DIETARY_SUPPLEMENT|Bouillon fortified with vitamin A #1 plus unfortified oil|Participants consume vitamin A #1 fortified bouillon plus unfortified oil
48304023|NCT06438562|DIETARY_SUPPLEMENT|Bouillon fortified with vitamin A #2 plus unfortified oil|Participants consume vitamin A #2 fortified bouillon plus unfortified oil
48304024|NCT06176040|DRUG|TAVO101|TAVO101 IV Infusion.
48304025|NCT04559581|DRUG|Nintedanib|Capsules
48640429|NCT06585709|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS will be delivered with a MagVenture MagPro X100 rTMS device with a Cool-B65-AP coil. rTMS will be applied to a personalized treatment target within the Left-Dorsolateral Prefrontal Cortex using a Localite Neuronavigation device.
47956585|NCT00887406|DRUG|GSK961081 3mcg SD|single dose delivered via nebulsier
47956586|NCT00887406|DRUG|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
47956587|NCT00887406|DRUG|Placebo SD|single dose via nebuliser
47956588|NCT00887406|DRUG|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
47956589|NCT00887406|DRUG|GSK961081 200mcg SD|single dose via nebuliser
47956590|NCT00887406|DRUG|GSK961081 300mcg SD|single dose via nebuliser
48110365|NCT03587168|OTHER|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
48481230|NCT01695096|OTHER|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
47956591|NCT00887406|DRUG|GSK961081 100mcg RD|repeat dose via nebuliser
47956592|NCT00887406|DRUG|GSK961081 300mcg RD|repeat dose vai nebuliser
47956593|NCT00887406|DRUG|Placebo RD|repeat dose via nebuliser
48640430|NCT06585709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS in an identical fashion to the active-rTMS condition will be delivered via the built-in e-sham system in the MagVenture device.
48640431|NCT06105892|DEVICE|Virtual Eye Rotation Vision Exercise (VERVE)|VERVE utilizes a virtual reality (VR) headset with integrated eye-tracking where the patient makes specific vergence eye movements by playing a VR game controlled by eye movements. Participants will be making convergence and divergence eye movements as steps and ramps.
47956594|NCT01145625|DRUG|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
47956595|NCT01145625|DRUG|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
47956596|NCT03914482|DEVICE|MRI|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
48110366|NCT05041491|BEHAVIORAL|BREAK|The BREAK intervention is a physical activity regimen.
48640432|NCT06105892|DEVICE|Sham VR Therapy|VERVE game without changes in eye movement demands. Maximizing gameplay with no intervention.
48640433|NCT01409200|DRUG|Antiandrogen Therapy|Given per standard of care
48110367|NCT05041491|BEHAVIORAL|ONE|The ONE intervention is a physical activity regimen.
48640434|NCT01409200|DRUG|Axitinib|Given PO
48640435|NCT01409200|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
48640436|NCT01409200|PROCEDURE|Regional Lymph Node Dissection|Undergo pelvic lymph node dissection
48110368|NCT01015404|DRUG|Trafermin|Administered to the bone defect during flap operation
47956597|NCT03985254|OTHER|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]), and in subsequent weeks the goal will be the development of muscle strength (load\> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
47956598|NCT03985254|OTHER|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]). However, in subsequent weeks the goal will be to develop strength (load\> 70% 1RM) and muscle power (load between 40-60% 1RM).
48110369|NCT00001384|DRUG|Adriamycin|
48110370|NCT00001384|DRUG|cyclophosphamide|
48110371|NCT00001384|DRUG|G-CSF|
48110372|NCT00001384|DRUG|paclitaxel|
48110373|NCT02027558|BEHAVIORAL|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
48110374|NCT02027558|BEHAVIORAL|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
48110375|NCT04455516|PROCEDURE|Meniscus repair; partial meniscectomy|69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. The 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect.
48110376|NCT03885817|BEHAVIORAL|Exercise training and nutritional guide|30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
48481231|NCT06342024|OTHER|Pistachio group|Participants will be giving 1.5 ounces of pistachios to consume during the 6-month trial.
48481232|NCT03907514|BEHAVIORAL|"FALE Application"|"FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care."
48481233|NCT02914769|DRUG|Ayahuasca|patients will receive a single dose of ayahuasca.
48481234|NCT02914769|DRUG|placebo|patients will receive a single dose of a passive placebo.
48640437|NCT02257853|OTHER|Stress reduction intervention|Gentle chair yoga and breath work
48640438|NCT02642679|DEVICE|Opticell Ag|Opticell Ag+ applied to STSG donor site
48640439|NCT04260607|DRUG|Ketamine Hydrochloride|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~3. Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
48481235|NCT01711749|DRUG|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
48481236|NCT01711749|DRUG|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
48481237|NCT05466279|DRUG|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
47956599|NCT01500889|PROCEDURE|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
47956600|NCT01500889|PROCEDURE|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
47956601|NCT01500889|PROCEDURE|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
47956602|NCT05146193|OTHER|Nude back photo|Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
47956603|NCT03890406|DRUG|Rocuronium: PTC(Post-tetanic count) 1~2|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
47956604|NCT03890406|DRUG|Rocuronium: TOF(Train-of-four) 1~2|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
47956605|NCT03343379|OTHER|Core stability tests|A test battery comprised of field tests to evaluate core stability
47956606|NCT01890473|DRUG|Abatacept|
47956607|NCT00900237|DRUG|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
47956608|NCT00900237|DRUG|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
48640440|NCT04260607|DRUG|Normal saline|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
47956609|NCT00713856|PROCEDURE|Custom PRK with iris registration|PRK
48304026|NCT05468957|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
48481238|NCT05466279|DRUG|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
48640441|NCT05626777|DRUG|Pre-filled syringe, mepolizumab 100 mg/month|Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient
48640442|NCT05626777|DRUG|Auto-injector pen, mepolizumab 100 mg/month|Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
48640443|NCT05882006|OTHER|gallstones|fellow up if the patients have gallstones
47956610|NCT00713856|PROCEDURE|Conventional PRK|PRK
47956611|NCT04512417|DRUG|Camrelizumab+Radiotherapy|The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.
47956612|NCT04512417|DRUG|Camrelizumab|Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
47956613|NCT05992181|OTHER|NEORTHO|early orofacial stimulation
47956614|NCT03431870|OTHER|Trans-esophageal echocardiography|Perform a trans-esophageal echocardiography before and after anesthesia.
47956615|NCT01443208|DRUG|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
47956616|NCT01443208|DRUG|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
47956617|NCT01443208|DRUG|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
47956618|NCT01072383|DRUG|BT061|administration of BT061 either intravenous or subcutaneous
47956619|NCT01072383|DRUG|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
47956620|NCT06441669|DRUG|Letermovir|Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
47956621|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
47956622|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
47956623|NCT03259217|DRUG|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
47956624|NCT03804008|DRUG|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
47956625|NCT03804008|OTHER|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
48110377|NCT03885817|OTHER|Standard follow-up care|standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
48110378|NCT03318406|DEVICE|Bronchoscopic Thermal Vapor Ablation|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
48110379|NCT06555757|OTHER|Height, weight, and BMI|Height, weight measurement and BMI calculation
48110380|NCT06555757|OTHER|Medical history|Brief medical history including medications/allergies and heart failure related healthcare utilisation over previous 12 months
48110381|NCT06555757|OTHER|Physical examination|Brief physical examination
48110382|NCT06555757|DIAGNOSTIC_TEST|Venous blood samples|Venous blood samples, to include WCC, HB, CRP and NTproBNP
48481239|NCT05466279|DRUG|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
48481240|NCT01563926|DRUG|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
48481241|NCT04375709|OTHER|Physical exercise|The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.
48481242|NCT04375709|BEHAVIORAL|Education sessions|Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.
48481243|NCT02303314|DRUG|Trigonella Foenum-graecum Seed Extract|
48481244|NCT02303314|DRUG|Drug: Placebo|
48481245|NCT04360395|BEHAVIORAL|Gait Therapy|The therapeutic gait training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints.
48481246|NCT02948790|DEVICE|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
48110383|NCT06555757|OTHER|Resting vital signs|HR, BP, RR, oxygen saturations on air)
48110384|NCT06555757|DIAGNOSTIC_TEST|Transthoracic echocardiogram|LVEF, IVC collapsibility, LV filling pressure, PA pressure
48481247|NCT02948790|DEVICE|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
48481248|NCT02801435|DRUG|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
48481249|NCT02801435|DRUG|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
48481250|NCT02801435|DRUG|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
48481251|NCT02801435|DRUG|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
48481252|NCT02801435|DRUG|Placebo|Topical administration for twice daily
48481253|NCT06227702|OTHER|Fluid management according to Venous Excess Ultrasound (VExUS) Score|Management of furosemide intravenous infusion according to VeXus results
47956626|NCT03804008|OTHER|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
47956627|NCT00762216|DEVICE|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
47956628|NCT01268020|DRUG|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
47956629|NCT01952925|PROCEDURE|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
47956630|NCT05235087|DEVICE|Bovine atelocollagen intradermal injection|Intradermal skin test injection
47956631|NCT02167425|OTHER|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
47956632|NCT05143021|OTHER|Multidisciplinary Sickle Cell Disease- Obstetric Team|Modified multidisciplinary teams for pregnant women with sickle cell disease including members from an obstetrics team and sickle cell disease team.
47956633|NCT03854110|DRUG|GP-2250|GP-2250 monotherapy for pharmacokinetics and safety; GP-2250 plus gemcitabine for safety, tolerability, pharmacokinetics, and biomarker assessments
47956634|NCT04525846|OTHER|PFMT|"* program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~* follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~* at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)"
47956635|NCT04525846|OTHER|non PFMT|Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
48481254|NCT04722328|DIAGNOSTIC_TEST|CSF metagenomic next generation sequencing (mNGS)|TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
47956636|NCT01264783|DRUG|RNS60|RNS60 for intravenous administration
47956637|NCT01264783|DRUG|Placebo|0.9% normal saline for injection
47956638|NCT06101511|PROCEDURE|Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs|The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
47956639|NCT02315989|RADIATION|proton therapy|proton therapy
47956640|NCT02472873|PROCEDURE|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
47956641|NCT02472873|PROCEDURE|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
47956642|NCT02472873|DRUG|Ethanol|
47956643|NCT06201364|PROCEDURE|The external oblique intercostal block|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine, 10 ml saline) will be injected under ultrasound guidance and this will be done bilaterally.
47956644|NCT06201364|PROCEDURE|Paravertebral block|involve injection of local anaesthetic in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is being used increasingly for not only intra-operative and post-operative analgesia but also as a sole anaesthetic technique for carrying out various procedures.
48110385|NCT06555757|OTHER|Sound recordings|Sound recordings (voice/cough/chest) recorded with the in-built microphone in a smartphone
48110386|NCT06555757|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound
48110387|NCT06555757|OTHER|KCCQ questionnaire|Kansas City Cardiomyopathy Questionnaire
47956645|NCT06557993|OTHER|Serratus Posterior Superior Intercostal Plane Block|The serratus posterior superior muscle is located deep to the rhomboid major and minor. Ligamentum nuchae starts from the processus spinosus of C7-T3 vertebrae and extends to the 2nd-5th. In the ribs, the angulus ends at the upper edge of the rib. Serratus posterior superior -intercostal plane block (SPSİPB) is a newly defined block, and C7-T7 spread has been shown in cadaver studies
47956646|NCT01483300|DRUG|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
47956647|NCT01483300|DRUG|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
47956648|NCT03532061|BEHAVIORAL|FamCare Program|6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
47956649|NCT03532061|OTHER|Caregiver Support Group|6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
47956650|NCT02432495|OTHER|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
48110388|NCT06555757|OTHER|ASCEND-HF score|An in-hospital congestion score which risk stratifies patients admitted with worsening heart failure, developed for the Acute study of clinical effectiveness of Nesiritide in decompensated heart failure trial
48110389|NCT06555757|OTHER|Composite Everest congestion score|A shortened version of the original 18-point score from the EVEREST trial
47956651|NCT02432495|OTHER|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
47956652|NCT05085730|DEVICE|InMode Morpheus8 System|The InMode Morpheus8 System is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis and neoelastogenesis.
47956653|NCT01509365|DRUG|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
47956654|NCT01509365|DRUG|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
47956655|NCT05775354|DIAGNOSTIC_TEST|Early diagnosis strategy|RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
47956656|NCT00000209|DRUG|Buprenorphine|
47956657|NCT03531983|PROCEDURE|fixation of tochentric fractures by gamma nail|• Thirty patients with recent traumatic extracapsular proximal femoral fractures were treated using a short gamma nail of third-generation assembly
47956658|NCT02758769|BIOLOGICAL|ORENCIA Subcutaneous Injection|
47956659|NCT02040571|DEVICE|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
47956660|NCT02040571|DEVICE|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
47956661|NCT02272075|DEVICE|Mobile OCT M3 scope|
47956662|NCT00003661|BIOLOGICAL|anti-thymocyte globulin|
47956663|NCT00003661|DRUG|busulfan|
47956664|NCT00003661|DRUG|cyclosporine|
48110390|NCT06555757|DIAGNOSTIC_TEST|Bio impedance and total body water measurement|Bio impedance and total body water measurement using TANITA device
48481255|NCT03496883|BIOLOGICAL|Recombinant Activated Factor VII (rFVIIa)|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
48481256|NCT03496883|BIOLOGICAL|Placebo|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
48481257|NCT04924374|DIETARY_SUPPLEMENT|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (\>30g/day).~anti PD1 therapy every 2-3 weeks"
48481258|NCT04924374|DRUG|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
48481259|NCT00498342|DRUG|N-acetylcysteine|
47956665|NCT00003661|DRUG|melphalan|
47956666|NCT00003661|DRUG|methylprednisolone|
47956667|NCT00003661|PROCEDURE|umbilical cord blood transplantation|
47956668|NCT00003661|RADIATION|radiation therapy|
47956669|NCT03155971|DEVICE|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
47956670|NCT02966769|OTHER|Overall survival|Compare overall survival between both groups.
47956671|NCT03553771|DEVICE|LVIS and LVIS JR|Braided coil assist stents used for aneurysm embolization
47956672|NCT01696071|DRUG|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
47956673|NCT01696071|DRUG|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
47956674|NCT00391729|DRUG|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
47956675|NCT00391729|DRUG|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
47956676|NCT00691301|DRUG|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
47956677|NCT00691301|DRUG|pemetrexed disodium|
47956678|NCT06181578|PROCEDURE|ganglionated plexus ablation|This intervention involves the targeted ablation of ganglionated plexus sites, specifically focusing on the left superior ganglionated plexus (LSGP), left inferior ganglionated plexus (LIGP), right anterior ganglionated plexus (RAGP), and right inferior ganglionated plexus (RIGP).
47956679|NCT01056029|DRUG|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
47956680|NCT00044083|OTHER|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
47956681|NCT00044083|DRUG|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
48110391|NCT06126783|DRUG|IBI311|The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
48266640|NCT04989608|OTHER|Neuroimaging|realization of a neuroimaging 1 and 3 years after the transient ischemic accident
48266641|NCT00055952|DRUG|exatecan mesylate|
47956682|NCT02802943|BIOLOGICAL|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
47956683|NCT02802943|DRUG|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
47956684|NCT05436470|DEVICE|PK Papyrus|The PK Papyrus is a balloon mounted stent that will be administered during standard of care treatment of pseudoaneurysms.
47956685|NCT05736614|BEHAVIORAL|Stage 1 Strength Based Case Management (SBCM) Condition|Intervention participants will receive a trained SBCM to motivate, support, and assist in linkage to PrEP prescribers to help facilitate obtaining PrEP medication to initiate treatment.
47956686|NCT05736614|BEHAVIORAL|Stage 2 PrEPare for Work Intervention Condition|Intervention participants will receive 1-on-1 adherence counseling and personalized daily text messaging reminders to increase PrEP adherence. Intervention participants will undergo three adherence intervention sessions (once per week for 3 weeks) with interventionist.
47956687|NCT05023707|BIOLOGICAL|anti-FLT3 CAR-T|Single intravenous infusion of anti-FLT3 CAR-T cells
47956688|NCT01685034|BIOLOGICAL|"Allergy immunotherapy (allergy shots)"|
48110392|NCT06108271|DEVICE|Triglotix®|The Triglotix® has a biocompatible self-expanding viscoelastic cuff that is located in the supraglottic, glottic and subglottic space. This cuff separates the endotracheal tube from the laryngeal vestibule in the supraglottic space and the vocal cords avoiding direct tissue damage from the plastic components of the tube. The viscoelastic cuff self-expands after the endotracheal tube is in adequate position in the airway. Then it adapts progressively and gradually to the shape of structures it comes in contact with, applying minimal pressure to the surrounding tissue. The ETT-T also has two wire reinforced segments: the first is located outside the mouth to prevent deformation related with kinking, while the second segment is positioned distally along the larynx. The primary purpose of this design is to mitigate torsional, rotational and lateralization forces that the tube may encounter while the patient is intubated.
48110393|NCT06108271|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube that is currently used worldwide
48481260|NCT03964519|OTHER|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
48481261|NCT03964519|OTHER|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
48481262|NCT03964519|OTHER|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
48481263|NCT01698593|DRUG|Bupivacaine 0.5%|
48481264|NCT01698593|DRUG|Bupivacaine 0.5% + Epinephrine (1:200,000)|
48481265|NCT04579276|PROCEDURE|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
48481266|NCT04579276|PROCEDURE|thoracic epidural analgesia|locoregional analgesia under ultrasound control
48481267|NCT05693818|OTHER|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
47956689|NCT05136352|PROCEDURE|adductor canal block|loco-regional anesthesia using adductor canal block
47956690|NCT05136352|PROCEDURE|iPACK block|loco-regional anesthesia using infiltration between the popliteal artery and the capsule of the posterior knee
47956691|NCT05123196|DRUG|MT-8554|Oral Capsule
47956692|NCT05123196|DRUG|Placebo|Oral Capsule
47956693|NCT01163331|OTHER|Singing Therapy|Singing therapy as a way to improve voice quality
47956694|NCT04051281|BEHAVIORAL|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
47956695|NCT01080742|DRUG|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
48481268|NCT02104817|DRUG|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
48481269|NCT02104817|DRUG|corn oil control|corn oil control arm
47956696|NCT05866406|BEHAVIORAL|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
47956697|NCT05866406|BEHAVIORAL|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
47956698|NCT05866406|BEHAVIORAL|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
47956699|NCT03905408|DRUG|50 mL of 50% Glucose|1st dose
47956700|NCT03905408|DRUG|100 mL of 50% Glucose|2nd dose
47956701|NCT03905408|DRUG|150 mL of 50% Glucose|3rd dose
47956702|NCT03905408|DRUG|200 mL of 50% Glucose|4th dose
47956703|NCT06166485|OTHER|take a bath|The effects of two different bathtub bath methods on physiological parameters will be compared in babies divided into 2 different groups.
47956704|NCT03364933|BEHAVIORAL|Primary intensivist and nurses|"Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~* Weekly check-in with and availability to patient/family~* Attendance at family meetings~* Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~* Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~* The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings."
47956705|NCT06410599|DRUG|Ketamine|Two ketamine hydrochloride (Ketamin Inresa 2 ml) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Ketamine hydrochloride (Ketamin Inresa 2 ml) is applied continuously over a time span of 40 minutes with a subanesthetic dosage of 0.5 mg per kg body weight.
47956706|NCT06410599|DRUG|Placebo|Two times placebo (Isotone E NaCL 0.9 %) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Placebo is applied continuously over a time span of 40 minutes.
47956707|NCT06410599|BEHAVIORAL|CBASP|In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific.
47956708|NCT06410599|BEHAVIORAL|TAU|Standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements.
47956709|NCT04746248|OTHER|Outpatient labor induction|The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
47956710|NCT04746248|OTHER|Inpatient labor induction|The participants are induced following standard inpatient care
47956711|NCT00752180|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
47956712|NCT00752180|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
47956713|NCT06556862|DRUG|Dalpiciclib|100 mg/d, po., qd, administered on an empty stomach (fasting should be ensured at least 1 hour before and 1 hour after administration). The drug will be administered in a 28-day cycle, with continuously administration in the first 3 weeks (D1-21), and discontinuation in the fourth week (D22-28).
47956714|NCT06556862|DRUG|Tucidinostat|25 mg/BIW, po., q2w. The interval between doses should not be less than 3 days (e.g. Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), administered 30 minutes after meals
47956715|NCT00499239|DRUG|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
47956716|NCT01821196|PROCEDURE|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
48481270|NCT04474782|DIAGNOSTIC_TEST|There is not an intervention|There is not an intervention
48481271|NCT00373425|DRUG|Erlotinib|150 mg tablet
48481272|NCT00373425|DRUG|Placebo|Placebo tablet
47956717|NCT03676192|DRUG|CT-16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
47956718|NCT03676192|DRUG|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
47956719|NCT04325178|OTHER|Protein, calorie and macronutrient controlled diet, derived from either omnivorous or non-animal sources, alongside unilateral resistance exercise, over a three-day period.|Participants received a control diet either derived from omnivorous or non-animal food sources, providing 1.8g.kg.day of protein, for a three-day period. Calories were calculated and set to place participants in a state of energy balance. Participants completed three bouts of unilateral resistance exercise, 5 sets of 30 maximal concentric knee extension contractions, on each morning that they received the control diet. During this three-day period participants also consumed a deuterium oxide tracer allowing for the measurement of muscle protein synthesis, in rested and exercised tissue, with incremental biopsies.
48110394|NCT01321411|OTHER|Near Infrared Spectroscopy|"Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
48481273|NCT02878408|GENETIC|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
48481274|NCT03077529|DIETARY_SUPPLEMENT|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
48481275|NCT03077529|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
48481276|NCT00321594|DRUG|belinostat|Given IV
48481277|NCT05790148|DEVICE|3Shape|original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
48481278|NCT02976259|DRUG|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
48481279|NCT06139055|DRUG|GSBR-1290 (Capsule/Tablet)|Participants will receive GSBR-1290 oral capsules or tablets.
48481280|NCT06139055|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral tablets.
48481281|NCT06139055|DRUG|Placebo|Participants will receive matching-placebo oral tablets.
48481282|NCT06139055|DRUG|Placebo (Capsule/Tablet)|Participants will receive matching-placebo oral capsules or tablets.
47956720|NCT02183896|BIOLOGICAL|Platelet-rich plasma (PRP)|
47956721|NCT02183896|DRUG|Saline|
47956722|NCT00781274|DRUG|MP-424|750 mg every 8 hours for 12 weeks
47956723|NCT00781274|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
47956724|NCT00781274|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
47956725|NCT01765907|DEVICE|HIFU|
47956726|NCT04910945|DEVICE|VENUS AIME (RoboCor)|VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.
47956727|NCT04712383|COMBINATION_PRODUCT|Fitbit Care intervention arm|Entire suite of Fitbit Care.
47956728|NCT02202187|DRUG|GSK2140944|Investigational Study Drug
47956729|NCT02202187|OTHER|Placebo|Placebo
47956730|NCT06558396|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (20 minutes), nutrition education lesson/cooking lab (65 minutes, odd weeks) OR professional development session (65 minutes, even weeks). On any day during the 2-week cooking period, the students will make a dish using groceries they received with their parent/guardian (1 hour).
47956731|NCT00834223|DEVICE|Aquashunt|A shunt which is implanted into the suprachoroidal space.
47956732|NCT06334458|DIAGNOSTIC_TEST|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups|Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile
47956733|NCT03344796|BEHAVIORAL|Goal attainment|After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
47956734|NCT05285800|DRUG|0.5% Hyperbaric Bupivacaine|In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
47956735|NCT04764773|OTHER|No intervention|No intervention
47956736|NCT01601730|DRUG|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
47956737|NCT01601730|DRUG|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
47956738|NCT01601730|DRUG|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
48110395|NCT01321411|OTHER|Near Infrared Spectroscopy|"Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
48110396|NCT01815450|DRUG|BLI1100|BLI1100 topical cream
48110397|NCT01815450|DRUG|BLI1100 - modified formulation|BLI1100 topical cream
48110398|NCT01815450|DRUG|Placebo|Placebo topical cream
48110399|NCT00814047|DRUG|Yohimbine hydrochloride|
48110400|NCT00969371|DEVICE|posterior chamber IOL implantation|
48110401|NCT00969371|DEVICE|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
48339951|NCT04337723|BEHAVIORAL|ABI/WIFI scoring|The initial ABI training workshop will be coordinated by the non-physician clinic staff champion, and all non-provider clinic staff will be asked to participate. The PI and a research assistant will conduct a 1.5-hour telemedicine training session instructing clinical staff in ABI measurement and WIfI and scoring, using the clinical scoring sheet. Following didactic teaching, participants will perform ABI tests under the guidance of the PI/research assistant and with the support of other participants. During each part of the workshop, specific attention will be directed to pitfalls and technical errors of the test. A pre-post assessment will be used to ensure comprehension of key concepts and performance of the ABI and WIfI tools.
48640444|NCT06306157|DRUG|Low dose naltrexone|While naltrexone is FDA-approved for treatment of alcohol or opioid addition, this study will be looking at how naltrexone, when dosed very low, may reduce the painful symptoms associated with CRPS. Naltrexone is not FDA-approved for pain management treatment of CRPS at this time, and therefore the study intervention is using the drug in an off-label manner.
47956739|NCT01601730|DRUG|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
47956740|NCT03493074|DIAGNOSTIC_TEST|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
47956741|NCT05023629|OTHER|Intracoronary balloon inflation|Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
47956742|NCT05552755|DRUG|REC-4881|REC-4881 4mg capsules
47956743|NCT05552755|DRUG|Placebo|Placebo capsules
47956744|NCT05578911|OTHER|"medical students group"|medical student in general practice or in specialty medicine
47956745|NCT04545385|DRUG|TEV-48574|subcutaneous infusion
47956746|NCT04545385|DRUG|Placebo|Matching Placebo
47956747|NCT01907243|PROCEDURE|spreader flap|producing of upper lateral cartilage flap as a spreader flap
47956748|NCT01540266|PROCEDURE|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
47956749|NCT01540266|PROCEDURE|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
47956750|NCT02422472|DEVICE|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
47956751|NCT05070195|DRUG|SKLB1028|SKLB1028, capsule, oral
47956752|NCT05070195|DRUG|Midazolam|Midazolam Maleate, tablet, oral
47956753|NCT02125968|OTHER|interactive video game|short- and medium-term therapeutic effects
47956754|NCT02125968|OTHER|therapeutic exercise|short- and medium-term therapeutic effects
47956755|NCT04565470|OTHER|online questionnaire|Web-based questionnaire about use of self-management strategies
47956756|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
47956757|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
47956758|NCT04725422|DRUG|Methotrexate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956759|NCT04725422|DRUG|Sulfasalazine|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956760|NCT04725422|DRUG|Leflunomide|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956761|NCT04725422|DRUG|Pamidronate|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956762|NCT04725422|DRUG|Zoledronic acid|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956763|NCT04725422|DRUG|Etanercept|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956764|NCT04725422|DRUG|Adalimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956765|NCT04725422|DRUG|Certolizumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956766|NCT04725422|DRUG|Infliximab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
47956767|NCT04725422|DRUG|Golimumab|second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
48110402|NCT06015542|DRUG|Elranatamab|Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).
48110403|NCT05677438|DRUG|CKD-498 dose#1|oral, once daily, 24 weeks
47956768|NCT04725422|DRUG|NSAID|first-line treatment
47956769|NCT03169543|BEHAVIORAL|Sleep deprivation|36-hours total sleep deprivation
47956770|NCT00090168|DRUG|MK0653A , ezetimibe (+) simvastatin|
47956771|NCT00090168|DRUG|Comparator: atorvastatin|
47956772|NCT00090168|DRUG|Duration of Treatment: 6 weeks|
47956773|NCT01390649|BIOLOGICAL|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
48110404|NCT05677438|DRUG|CKD-498 dose#2|oral, once daily, 24 weeks
47956774|NCT05143385|OTHER|Virtual reality|"* Those patients who are randomly assigned as the intervention group will be given an explanatory session on the use of the video game console, controllers and game accessories.~* The intervention will begin 15 calendar days after admission.~* The intervention will be carried out once a week with a duration of 20 minutes with one of the games chosen by the patient together with the physiotherapist.~* The end of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions completed in order to participate in the study.~* The intervention will be carried out with an average of six sessions in each patient, including in the study those who perform a minimum of four sessions. However, the interventions will continue until hospital discharge.~* After completion of the clinical trial, a registry table will be drawn up quantifying the number of sessions for each patient and the type of session:"
47956775|NCT03000283|DRUG|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
47956776|NCT03823508|DEVICE|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
47956777|NCT03823508|DEVICE|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
47956778|NCT04314726|DRUG|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
47956779|NCT04314726|DRUG|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
47956780|NCT00516074|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
47956781|NCT00516074|DRUG|placebo|subcutaneous injection, volume equivalent to active, twice a day
47956782|NCT05157438|BEHAVIORAL|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
48110405|NCT05677438|DRUG|CKD-498 dose#3|oral, once daily, 24 weeks
48110406|NCT05677438|DRUG|Placebo of CKD-498 dose#1|oral, once daily, 24 weeks
48110407|NCT05677438|DRUG|Placebo of CKD-498 dose#2|oral, once daily, 24 weeks
48110408|NCT05677438|DRUG|Placebo of CKD-498 dose#3|oral, once daily, 24 weeks
47956783|NCT05157438|BEHAVIORAL|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
47956784|NCT01865097|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
47956785|NCT01865097|BEHAVIORAL|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
47956786|NCT01846390|DRUG|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
47956787|NCT01846390|DRUG|Dexamethasone|40 mg D1 - D4
47956788|NCT01846390|DRUG|Cisplatin|75 mg/m2 D1
47956789|NCT01846390|DRUG|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
47956790|NCT03403088|DEVICE|Experimental: • Group LA|to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
47956791|NCT03403088|DEVICE|Placebo Comparator: • Group LA-P|to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
47956792|NCT03403088|OTHER|Experimental: • Group DE|to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
47956793|NCT03403088|OTHER|Placebo Comparator: • Group DE-P|to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
47956794|NCT03403088|OTHER|Experimental: • Group RGI|to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
47956795|NCT03403088|OTHER|Experimental: Group RX|to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
47956796|NCT02210546|OTHER|Magnetic Resonance Imaging (MRI)|
47956797|NCT02210546|OTHER|Mammography (Mx) + ultrasonography (US)|
47956798|NCT00529334|RADIATION|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
47956799|NCT00875264|DRUG|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
48110409|NCT04533659|BEHAVIORAL|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
48304027|NCT05468957|DRUG|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
47956800|NCT02281201|BIOLOGICAL|BE1116 (Prothrombin Complex Concentrate)|
47956801|NCT04851457|DRUG|Intravenous tirofiban combination therapy|Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
47956802|NCT00074984|BIOLOGICAL|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
47956803|NCT00074984|BIOLOGICAL|Placebo|1 mg/kg placebo intravenously every 2 weeks
47956804|NCT02038881|BIOLOGICAL|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
47956805|NCT05097612|DEVICE|Placebo LiftSuit Exoskeleton|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). In this condition the EES are removed from the device to create a placebo device.
47956806|NCT05097612|DEVICE|LiftSuit Exoskeleton (low support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
47956807|NCT05097612|DEVICE|LiftSuit Exoskeleton (medium support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
47956808|NCT05097612|DEVICE|LiftSuit Exoskeleton (high support level)|The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
47956809|NCT03896165|OTHER|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
47956810|NCT04792320|DIETARY_SUPPLEMENT|Active bamboo charcoal|4g particle
47956811|NCT04792320|DIETARY_SUPPLEMENT|probiotics|0.8g powder
47956812|NCT06030050|BEHAVIORAL|Animal-assisted intervention|The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
47956813|NCT02043080|OTHER|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
47956814|NCT06227260|OTHER|Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice|Interventions among the 3 studies were categorized as other.
47956815|NCT02420340|BEHAVIORAL|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
47956816|NCT03558087|DRUG|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
47956817|NCT03558087|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four 21-day cycles.
47956818|NCT03558087|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four 21-day cycles.
47956819|NCT02009306|DRUG|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
47956820|NCT02009306|DRUG|Standard subcutaneous medication|"Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide"
47956821|NCT02009306|DRUG|Epistatus Alone|"Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
47956822|NCT06088875|DRUG|Nebulization|Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
47956823|NCT06088875|DRUG|Spray-as-you-go|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
47956824|NCT01086722|DRUG|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
47956825|NCT02096679|DRUG|AZD9291|Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
47956826|NCT03614364|DRUG|nanoxel|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
47956827|NCT03614364|DRUG|herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
47956828|NCT05047770|BIOLOGICAL|HZ/su|2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.
47956829|NCT05047770|COMBINATION_PRODUCT|Flu D-QIV|1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.
47956830|NCT05047770|BIOLOGICAL|mRNA-1273|1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).
47956831|NCT03532841|DRUG|an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
47956832|NCT03532841|DRUG|Placebo Oral Tablet|placebo tablet of the same shape,color and taste will be given in the placebo arm
47956833|NCT03153527|DRUG|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
47956834|NCT03153527|OTHER|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
47956835|NCT05473507|DIAGNOSTIC_TEST|Digital Dermoscopy|Digital Dermoscopy will be performed every 3 months.
47956836|NCT05473507|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM)|Reflectance confocal microscopy (RCM) will be performed every 3 months.
48304028|NCT05646797|DRUG|ASP2074|intravenous (IV) infusion
48304029|NCT06594848|DIETARY_SUPPLEMENT|Black rice extract|Black rice extract is rich in a specific type of anthocyanins, cyanidin. It has been shown by our group that cyanidin-rich food can have beneficial health effects
48304030|NCT06594848|OTHER|Placebo|The placebo for this study is composed by maltodextrin and food colorant
48339952|NCT02732249|DRUG|Esomeprazole|Given 30 min before morning and evening meals
48640445|NCT06306157|DRUG|Placebo sugar capsules|The external appearance of the capsules prepared by the pharmacy will be identical to the LDN capsules. The inactive capsule ingredients will be microcrystalline cellulose (MCC) and Magnesium stearate
47956837|NCT05473507|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) will be performed every 3 months.
47956838|NCT05473507|DIAGNOSTIC_TEST|Dermtech tape-stripping|Dermtech tape-stripping for genetic analysiswill be performed every 6 months.
47956839|NCT05473507|DIAGNOSTIC_TEST|Total Skin Examinations|Total Skin Examinations will be performed every 12 months.
47956840|NCT03108274|DRUG|Danicopan|Oral tablet.
47956841|NCT03108274|DRUG|Midazolam|Oral syrup.
47956842|NCT03108274|DRUG|Fexofenadine|Oral tablet.
47956843|NCT03108274|DRUG|Mycophenolate Mofetil|Oral tablet.
47956844|NCT03948581|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
47956845|NCT02704260|GENETIC|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
47956846|NCT02236442|OTHER|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~1. Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~2. Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~3. Provide a sound-proof helmet to the patient.~4. Provide a light-blocking google to the patient.~5. If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~6. If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
47956847|NCT01551992|PROCEDURE|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
47956848|NCT00241943|PROCEDURE|Hepatitis C educational video|
47956849|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
47956850|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
47956851|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
47956852|NCT01474083|DRUG|Placebo|Dose-matched placebo. Oral administration.
47956853|NCT02077478|DEVICE|Remifentanil and propofol administration using TCI|
47956854|NCT02077478|DEVICE|Remifentanil and propofol administration using MCI|
47956855|NCT01138774|DIETARY_SUPPLEMENT|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
47956856|NCT05469035|OTHER|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
47956857|NCT05469035|OTHER|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
47956858|NCT00910026|PROCEDURE|low tidal volume ventilation|6 ml/kg tidal volume ventilation
47956859|NCT00910026|PROCEDURE|high tidal volume ventilation|12 ml/kg tidal volume ventilation
47956860|NCT01790932|DRUG|BKM120|
48304031|NCT05822583|DRUG|abatacept infusion|The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
48304032|NCT05822583|DRUG|Placebo group|Placebo group (IV infusion of normal saline) + baseline IM
47956861|NCT02505763|PROCEDURE|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
47956862|NCT05192473|DEVICE|Pulse Intravascular Lithotripsy System|Treatment with Pulse Intravascular Lithotripsy System
47956863|NCT04553679|BEHAVIORAL|Mindfulness online intervention|A 3-week mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
47956864|NCT00456157|DRUG|Intra-articular Injection of OP-1 to affected knee|
47956865|NCT02527993|DRUG|Glucobay (acarbose)|Se arm description
47956866|NCT02527993|DRUG|Januvia (sitagliptin)|Se arm description
47956867|NCT02527993|DRUG|Verapamil HEXAL (verapamil)|Se arm description
47956868|NCT02527993|DRUG|Victoza (liraglutide)|Se arm description
47956869|NCT02527993|DRUG|Signifor (pasireotide)|Se arm description
48304033|NCT06632444|DRUG|Survodutide|Subcutaneous injection
48304034|NCT06632444|DRUG|Placebo|Subcutaneous injection
47956870|NCT02527993|DEVICE|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
47956871|NCT02527993|DIETARY_SUPPLEMENT|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
47956872|NCT05209269|OTHER|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
47956873|NCT04078178|DIETARY_SUPPLEMENT|Niagen|Vitamin B3
47956874|NCT02842359|DRUG|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
47956875|NCT02842359|DRUG|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
48481283|NCT03973099|DIETARY_SUPPLEMENT|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
47956876|NCT02842359|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
47956877|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
47956878|NCT00875979|DRUG|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
47956879|NCT00875979|DRUG|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
47956880|NCT06180720|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
47956881|NCT06180720|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
47956882|NCT00618683|PROCEDURE|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
47956883|NCT05138211|DEVICE|Exoskeleton assisted gait on a treadmill|"The experimental protocol is divided in three sessions. During all of them, the patient will walk on a treadmill for 6 minutes while wearing a safety harness and the robotic exoskeleton in the paretic leg.~1. - Training session: The patient will wear the robotic exoskeleton to familiarize with the action of the device.~2. - Ramp Velocity Session: the session will be divided into five trials: (a) Pre, the patient will not wear the device; (b) Free, the patient will wear the robot but it is mechanically decoupled so it will enable the free knee movement; (c) Active, the robot will assist the gait until 75% maximum gait velocity ; (d) MaxActive, the robot will assist the gait until maximum gait velocity ; and (e) Post, the patient will repeat the Pre condition. Velocity will increase from comfortable velocity to the maximum and then come back to the comfortable one.~3. - Random Velocity session: the session will be divided into the same trials than the Ramp Velocity Session."
47956884|NCT04053231|OTHER|liver resection|all type of liver surgical procedures
47956885|NCT04732143|OTHER|Inspiratory muscle training|At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
47956886|NCT02351999|DEVICE|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
47956887|NCT06356909|OTHER|Survey of sedo-analgesia practices before laryngoscopy|The survey will evaluate adequation to the French best practice guidelines to improve their dissemination and to identify current practices of premedication before laryngoscopy in neonates in French units (agents, dosing, efficacy, safety)
47956888|NCT01227317|OTHER|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
47956889|NCT06349018|OTHER|Dietary Supplement: High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
47956890|NCT06349018|OTHER|Dietary Supplement: No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
47956891|NCT00268788|DRUG|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
47956892|NCT00268788|DRUG|Intravenous immunoglobulin|Individual dose and frequency
47956893|NCT04238416|DRUG|Branched chain amino acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
47956894|NCT04238416|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
47956895|NCT04716465|OTHER|Dysautonomia|Indicators of dysautonomia
47956896|NCT00816920|OTHER|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
47956897|NCT00844675|DRUG|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
47956898|NCT00844675|DRUG|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
47956899|NCT04459624|PROCEDURE|Erector Spina Plane Block|Group E (ESP block) will be applied 20 ml of % 0.25 bupivacaine between the erector spina muscle and transverse process at the 8th thoracic level. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
47956900|NCT04459624|PROCEDURE|Quadratus Lumborum Block 2|Group Q (QLB2 block) lumbar interfacial triangle (LIFT) will be applied 20 ml of % 0.25 bupivacaine. The blocks will be administered under general anesthesia in lateral position by the same anesthesiologist.
47956901|NCT00851630|DRUG|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
48640446|NCT06550076|DRUG|TAK-279|TAK-279 oral tablet
47956902|NCT04745884|DEVICE|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
47956903|NCT05727436|DIETARY_SUPPLEMENT|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
47956904|NCT05727436|DIETARY_SUPPLEMENT|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
47956905|NCT04418674|DRUG|Ketamine|in this group, patient will receive ketamine at 0.3mg/kg intravenously.
47956906|NCT04418674|DRUG|Fentanyl|In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
47956907|NCT03412526|DRUG|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
48304037|NCT06560632|DRUG|RP-3467 at assigned dose and schedule|Eligible participants will be treated with escalating doses of RP-3467 monotherapy
48304038|NCT06560632|DRUG|Olaparib 200-300 mg BID, daily|Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
48304039|NCT05910801|PROCEDURE|Biopsy|Undergo biopsy
48304040|NCT05910801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48304041|NCT05910801|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48304042|NCT05910801|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48304043|NCT05910801|PROCEDURE|Computed Tomography|Undergo CT scan
48304044|NCT05910801|DRUG|Lenalidomide|Given PO
48304045|NCT05910801|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48481284|NCT05550220|DIAGNOSTIC_TEST|Cuff Leak Test|Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
48304046|NCT05910801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48640447|NCT05557812|DRUG|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
47956908|NCT03412526|RADIATION|Radiation|Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
47956909|NCT03412526|BIOLOGICAL|TIL administration|TIL Administration
47956910|NCT03412526|DRUG|IL-2|bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
47956911|NCT03777488|DRUG|Tranexamic Acid 1 gram intravenously|Intravenous tranexamic acid crossover to oral and intramuscular arms
48304047|NCT05910801|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48304048|NCT05910801|BIOLOGICAL|Tafasitamab|Given IV
48304049|NCT05910801|DRUG|Venetoclax|Given PO
48304050|NCT04499950|DRUG|Contrave|Initiate Contrave at 1 tab in morning (AM) for Week 9; then 1 tab in AM and 1 tab in evening (PM) for Week 10; then 2 tab in AM and 1 tab in PM for Week 11; then 2 tab in AM and 2 tab in PM for week 12; then constant dose for months 4-6.
48304051|NCT04499950|BEHAVIORAL|Behavioral Weight Loss|6 months of behavioral weight loss. First 3 months are weekly calls with coach and then transition to monthly calls for months 4-6.
48304052|NCT03598231|DEVICE|Sacral neuromodulation|"After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period."
48304053|NCT01201538|DRUG|Nilotinib|
48339953|NCT02732249|DRUG|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
48640448|NCT05557812|DRUG|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
48640449|NCT01886872|DRUG|Bendamustine Hydrochloride|Given IV
48640450|NCT01886872|DRUG|Ibrutinib|Given PO
48339954|NCT02732249|DRUG|Clarithromycin|Given 30 min after morning and evening meals
47956912|NCT03777488|DRUG|Tranexamic acid 2 grams oral solution|Oral tranexamic acid crossover to intravenous and intramuscular arms
47956913|NCT03777488|DRUG|Tranexamic acid 1 gram intramuscular|Intramuscular tranexamic acid crossover to oral and intravenous arms
47956914|NCT03451266|DRUG|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
47956915|NCT03451266|DRUG|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
47956916|NCT02211625|DRUG|Open-label TRV734 125 mg|125 mg
47956917|NCT02211625|DRUG|TRV734 blinded|blinded, multiple ascending dose
47956918|NCT02211625|DRUG|Oxycodone IR 10 mg|
47956919|NCT02211625|DRUG|Placebo|TRV734-matched and oxycodone placebo
47956920|NCT01950169|DRUG|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
47956921|NCT01950169|OTHER|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
47956922|NCT01950169|DIETARY_SUPPLEMENT|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
48481285|NCT05934773|DEVICE|KineAssist robotic treadmill|"A formal standardization procedure will be used. Prior to testing, the participant's weight, height, age, blood pressure, and resting heart rate will be recorded. Each session will take place over a 1 hour period. All of our participants will have 1 evaluation sessions prior to the training sessions (overground) and 1 evaluation sessions at the end of the training sessions (overground).~Each participant will have the training sessions up to 3 times each week. The total number of training sessions would be 12-16 sessions (based on duration of stay) of robotic treadmill training for, distributed equally over each specific training modality (Endurance x 4, Strength x 4, Speed x 4, and Dynamic Balance x 4)."
48640451|NCT01886872|OTHER|Laboratory Biomarker Analysis|Correlative studies
48640452|NCT01886872|OTHER|Quality-of-Life Assessment|Ancillary studies
48640453|NCT01886872|BIOLOGICAL|Rituximab|Given IV
48640454|NCT06200207|DRUG|Ziltivekimab|Zilitivekimab will be administered subcutaneously once-monthly.
48640455|NCT06200207|DRUG|Placebo|Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
48640456|NCT00646022|DRUG|[18F]-DOPA|
48640457|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 single dose as oral suspension.
48640458|NCT06368440|DRUG|AZD6793|Participants will receive AZD6793 multiple doses daily as oral suspension.
48640459|NCT06368440|DRUG|Placebo|Participants will receive matching doses of placebo as oral suspension.
48640460|NCT05443334|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
48640461|NCT06355778|OTHER|Magnetic Resonance Imaging (MRI)|Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.
48481286|NCT05181826|DIAGNOSTIC_TEST|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
48640462|NCT06355778|BEHAVIORAL|Computer Tasks|Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
48640463|NCT03381651|RADIATION|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
48640464|NCT03381651|RADIATION|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
48640465|NCT00097474|DRUG|Hydrocortisone|Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
47956923|NCT01182142|DRUG|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
47956924|NCT05875701|BIOLOGICAL|NVX-CoV2373|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
47956925|NCT05875701|BIOLOGICAL|SARS-CoV-2 rS antigen/Matrix-M Adjuvant|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
48640466|NCT00097474|DRUG|Melatonin|Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
48640467|NCT00097474|DRUG|Placebo|Placebo
48640468|NCT06695741|DRUG|Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
48640469|NCT04653064|BEHAVIORAL|Placebo Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as being analgesic.
48640470|NCT04653064|BEHAVIORAL|Control Cream|Approximately 1 teaspoon of exfoliating skin scrub delivered approximately 5 minutes prior to pain tasks will coincide with verbal descriptors of the cream as one of no effect.
48640471|NCT05435014|DRUG|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
48640472|NCT05435014|DRUG|Lipiodol|TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
48640473|NCT06694662|DIETARY_SUPPLEMENT|PKU EASY Microtabs Plus|"PKU EASY Microtabs Plus is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in patients from 3 years of age upwards.~PKU EASY Microtabs Plus is a microtablet form, slow-release, phenylalanine-free protein substitute containing a blend of essential and non-essential amino acids, vitamins, minerals and trace elements."
48640474|NCT04473937|RADIATION|Radiotherapy|Radiotherapy at pre-determined dose and schedule
48640475|NCT04491955|BIOLOGICAL|CV301|CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.
47956926|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
47956927|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
47956928|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
47956929|NCT02213523|DIETARY_SUPPLEMENT|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
48481287|NCT04067388|OTHER|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
48481288|NCT05466344|DEVICE|Herbst Group|"1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~4. Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~5. When reactivation of the telescopic piston is needed, extension rings are used."
48304054|NCT06346340|DRUG|Miebo|Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
48304055|NCT00493948|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
48304056|NCT06077864|DRUG|survodutide|once weekly subcutaneous injection
48304057|NCT06077864|DRUG|Placebo|once weekly subcutaneous injection
48304058|NCT05438680|DIETARY_SUPPLEMENT|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
48304059|NCT05438680|DIETARY_SUPPLEMENT|Placebo|distilled water with no bovine colostrum
48481289|NCT05466344|DEVICE|TFBC Group|"1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~5. Finally follow finishing steps for each patient."
48481290|NCT04873180|DIAGNOSTIC_TEST|sectioning and staining of renal neoplasms after nephrectomy operation|nephrectomy operations will be done to patients diagnosed as having renel tumors
48481291|NCT00773682|OTHER|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
48481292|NCT00330460|DRUG|Alendronate|ALN; 70 mg; oral; once weekly
48481293|NCT00330460|DRUG|Denosumab|60 mg; SC; every 6 months
47956930|NCT03144765|PROCEDURE|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
47956931|NCT02995031|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
48304066|NCT04174105|GENETIC|zocaglusagene nuzaparvovec|AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
48304067|NCT03421002|DRUG|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
48481294|NCT06484985|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
48481295|NCT06617338|DIAGNOSTIC_TEST|CT scan unilateral knee|Intervention given to the Active Comparator arm
48481296|NCT06617338|DIAGNOSTIC_TEST|CT scan bilateral knee|Intervention given to the Experimental Arm
48481297|NCT04987255|OTHER|Free visit|The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
48481298|NCT04987255|OTHER|Guided visit|The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
47956932|NCT02995031|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
48110410|NCT04533659|BEHAVIORAL|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
48110411|NCT00292383|PROCEDURE|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
48304068|NCT06233799|DRUG|extended-release naltrexone (XR-NTX)|Once per three weeks injections of extended-release naltrexone
48304069|NCT06233799|DRUG|extended release bupropion (BUP-XL) tablets (BUP-XL)|Daily oral extended release bupropion tablets
48481299|NCT04987255|OTHER|Guided visit (stroke)|The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
48481300|NCT01758822|OTHER|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
48481301|NCT01158326|DRUG|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
48481302|NCT01158326|OTHER|Placebo|10 ml of oral placebo every 6 hours for 48 hours
48481303|NCT05871606|DRUG|iNO|Inhaled Nitrous Oxide
47956933|NCT01984983|BIOLOGICAL|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
47956934|NCT01984983|OTHER|0.9% saline placebo|
47956935|NCT02404220|DRUG|Entospletinib|
47956936|NCT02404220|DRUG|Vincristine|
47956937|NCT02404220|DRUG|Dexamethasone|
47956938|NCT02404220|DRUG|CNS Prophylaxis|
47956939|NCT06557382|BEHAVIORAL|Cognitive tests and reading-related evaluations|Tests assessing cognitive status and reading were administered. (Frankfurter; MVPT-3, TILLs; etc.)
47956940|NCT04915898|OTHER|Oral Hygiene - teeth brushing|Oral hygiene using a special kit with recommended materials and instructions: Use of an ADA approved toothbrush, toothpaste with dentifrice, antiseptic mouthwash and non-drying lip moisturizer encouraged after meals and at bedtime
47956941|NCT02368197|DRUG|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
47956942|NCT02368197|DEVICE|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
47956943|NCT04743076|PROCEDURE|Endovascular treatment|Endovascular treatment
47956944|NCT04743076|OTHER|Standard medical treatment|Standard medical treatment
47956945|NCT04767763|DIAGNOSTIC_TEST|Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF|blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
47956946|NCT00003970|DRUG|irinotecan hydrochloride|Given IV
47956947|NCT00981240|DRUG|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
47956948|NCT00768950|PROCEDURE|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
47956949|NCT00768950|PROCEDURE|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
47956950|NCT04797078|PROCEDURE|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
48481304|NCT05246033|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
48481305|NCT05246033|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
47956951|NCT04797078|PROCEDURE|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
47956952|NCT01986946|OTHER|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
47956953|NCT01986946|DRUG|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
47956954|NCT00821106|PROCEDURE|Right radial|diagnostic or interventional procedures performed through right transradial approach
47956955|NCT00821106|PROCEDURE|left radial|diagnostic or interventional procedures performed through left transradial approach
47956956|NCT06199336|BIOLOGICAL|JHM03|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.
48304070|NCT06233799|DRUG|iPLB|Once per three weeks injections of placebo
48304071|NCT06233799|DRUG|oPLB|Daily oral placebo tablets
48339955|NCT02732249|DRUG|Metronidazole|Given 30 min after meals or at bedtime
47956957|NCT06199336|BIOLOGICAL|BOTOX®|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
47956958|NCT06199336|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
47956959|NCT05514418|PROCEDURE|Intensive Adherence Counselling (IAC)|Intensive adherence counselling is offered to people living with HIV (PLHIV) having a non-suppressed viral load (VL) result ( a VL of 1,000 copies/ml or more) and this is given once every month for three months. In our study, we are going to give IAC to PLHIV with low-level viraemia (having a VL of 50 copies/ml but less than 1,000 copies/ml) and determine its effectiveness in causing a non-detectable VL (less than 50 copies/ml), which is desirable for PLHIV on ART.
47956960|NCT03477136|DIAGNOSTIC_TEST|ELISA to evaluate serum and seminal vitamin D level|Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
47956961|NCT04447794|BEHAVIORAL|Step Away Chatbot|"The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
48339956|NCT01781663|DEVICE|KAM2904 Face Cream|
47956962|NCT04447794|BEHAVIORAL|Step Away App|"The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
47956963|NCT05919589|OTHER|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
48339957|NCT01781663|DEVICE|KAM3008 Body Lotion|
48339958|NCT01781663|OTHER|petrolatum-based moisturizer|
48339959|NCT04917250|DRUG|Gemcitabine|1000mg/㎡，d1,4 ivdrip
47956964|NCT03824288|DIAGNOSTIC_TEST|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
47956965|NCT03824288|PROCEDURE|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
47956966|NCT06465095|GENETIC|Baseline|Measurements and sampling
47956967|NCT04312581|DEVICE|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
47956968|NCT04312581|OTHER|Conventional rehabilitation|physical \& occupational therapy
47956969|NCT03258931|DRUG|Crenolanib|Crenolanib will be administered orally
47956970|NCT03258931|DRUG|Midostaurin|Midostaurin will be administered orally
47956971|NCT03258931|DRUG|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
47956972|NCT03258931|DRUG|Duanorubicin|90 mg/m2 IV
47956973|NCT05962671|DRUG|Opioid-sparing based anesthesia|Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
47956974|NCT05962671|DRUG|Sevoflurane-based anesthesia|Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
47956975|NCT05431660|OTHER|education and exercise protocol about diabetic foot|In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
47956976|NCT05431660|OTHER|control group|diabetic foot school information booklet and weekly video conference meeting
47956977|NCT02249442|DRUG|Tipranavir (TPV)|
47956978|NCT02249442|DRUG|Ritonavir (r)|
47956979|NCT02564796|DRUG|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
47956980|NCT02564796|DRUG|Iron|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
47956981|NCT04478981|OTHER|No intervention|This concerns a natural history study; no interventions will be used
47956982|NCT03904732|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
47956983|NCT04905966|BEHAVIORAL|Nutrition education and Physical activity intervention|Schools randomized to the experimental group received nutrition education sessions and physical activity classes.
47956984|NCT04862429|OTHER|Contrast enhanced mammography guided biopsy (diagnostic procedure)|With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).
47956985|NCT04862429|OTHER|Mammography guided biopsy (diagnostic procedure)|"For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.~At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice)."
47956986|NCT00108433|DRUG|Cefazolin IV|
47956987|NCT00108433|DRUG|Linezolid IV|
48304072|NCT05924100|DRUG|Luspatercept Injection [Reblozyl]|"Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit."
47956988|NCT00108433|DRUG|Vancomycin (IV)|
48304073|NCT02821793|OTHER|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
47956989|NCT04419675|OTHER|Observational Cohort, usual care = physical therapy|usual care = physical therapy
47956990|NCT03476278|OTHER|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
47956991|NCT01548287|DRUG|AZD5213|AZD5213 doseA daily
47956992|NCT01548287|DRUG|AZD5213|AZD5213 doseB daily
47956993|NCT01548287|DRUG|AZD5213|AZD5213 doseC daily
47956994|NCT01548287|OTHER|Placebo|Placebo tablet daily
47956995|NCT00334685|DRUG|[S,S]-Reboxetine + Pregabalin|\[S,S\]-Reboxetine oral, tablet 2, 4 or 6 mg per day for 10 weeks Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
47956996|NCT00334685|DRUG|Pregabalin|Pregabalin oral, capsule, 75, 150, 300 or 600 mg per day for 14 weeks
48304074|NCT02821793|OTHER|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
48304075|NCT06453447|DRUG|Prednisone|40 mg PO once daily for 14 days starting day of surgery
48304076|NCT06453447|DRUG|Placebo|Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
48304077|NCT03773523|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
47956997|NCT04250922|DRUG|LAM561|"Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment."
48304078|NCT04246086|DRUG|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
48304079|NCT04246086|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
48304080|NCT04246086|DRUG|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
48304081|NCT04246086|DRUG|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
48304082|NCT06158490|DRUG|JYP0061 15 mg|Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.
48304083|NCT06158490|DRUG|JYP0061 30 mg|articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.
48640476|NCT04491955|DRUG|MSB0011359C|"Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter."
48304084|NCT06158490|DRUG|Placebo|Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
48304085|NCT06561958|DRUG|REKOVELLE|Individualised dosing regiment of REKOVELLE in routine clinical practice.
48640477|NCT04491955|DRUG|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.
47956998|NCT04250922|DRUG|TMZ|"TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles."
47956999|NCT04250922|RADIATION|RT|During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
47957000|NCT01044875|PROCEDURE|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
48304086|NCT05869851|OTHER|Pavlik Harness|The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
48304087|NCT05614739|DRUG|LOXO-435|Oral
48304088|NCT05614739|DRUG|Pembrolizumab|IV
48304089|NCT05714085|DRUG|Vericiguat tablet|2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
48304090|NCT05714085|DRUG|Vericiguat suspension|0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
48304091|NCT05714085|DRUG|Placebo tablet|Placebo for vericiguat administered orally once daily in tablet form
48304092|NCT05714085|DRUG|Placebo suspension|Placebo for vericiguat administered orally once daily in suspension form
48304093|NCT05280704|PROCEDURE|Volar digital block with lidocaine|Volar digital block with lidocaine
48304094|NCT05280704|PROCEDURE|Volar digital block with saline|Volar digital block with saline
48304095|NCT05280704|PROCEDURE|Dorsal digital block with lidocaine|Dorsal digital block with lidocaine
48304096|NCT05280704|PROCEDURE|Dorsal digital block with saline|Dorsal digital block with saline
48481306|NCT02989298|OTHER|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
47957001|NCT01521546|DRUG|eplerenone|25mg tablet, once daily by mouth for 12 months
47957002|NCT01521546|DRUG|placebo|one tablet by mouth daily for 12 months
48304097|NCT05612035|DRUG|MK-5475|MK-5475 380 µg administered as dry powder inhalation once daily.
48304098|NCT05612035|DRUG|Placebo|Placebo administered as dry powder inhalation once daily.
48304099|NCT04145297|DRUG|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
48304100|NCT04145297|DRUG|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
48304101|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken twice a day for 4 weeks
48304102|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken once
48481307|NCT03998709|DRUG|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
47957003|NCT04433663|OTHER|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
47957004|NCT03873025|COMBINATION_PRODUCT|Pembrolizumab and CXD101|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
47957005|NCT06142708|DRUG|Dual trigger (human chorionic gonadotropin plus GnRH-agonist)|Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only
47957006|NCT06142708|DRUG|GnRH-agonist only trigger|GnRH-agonist only will be used for final maturation
47957007|NCT03849248|OTHER|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
47957008|NCT00535457|OTHER|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
47957009|NCT04686214|PROCEDURE|heating|patients were aggressively warmed using multiple heating methods such as pressurized air heater and intravenous fluid heater
47957010|NCT04902131|DRUG|A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|Single dose cross-over bioequivalence trial
47957011|NCT04902131|DRUG|A MENOPUR powder including solvent for solution for injection, 75 IU|Single dose cross-over bioequivalence trial
47957012|NCT03875404|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
48110412|NCT04704778|COMBINATION_PRODUCT|Transcutaneus electrostimulation therapies|"Sterile steel acupuncture needles of 0.25x13mm, disposable AcuBEST brand, and portable electro-stimulator equipment KWD- will be used. The superficial area of the skin of the masseter muscle will be cleaned with alcohol.~Two needles will be placed in each masseter muscle, the area to be punctured is the origin of the masseter muscle or superficial area of the mandibular condyle anterior to the atrial tragus approximately 1cm away, insertion of the masseter muscle at the angle of the mandible. The two double alligator cables will be connected to the head of the needles. The positive pole will be connected at the origin of the masseter muscle and the negative pole at the insertion.~The parameters to be used will be are two frequency bands (210Hz-10140Hz.); amplitude 3050 volts, pulse duration: 40100 msec; and the output intensity: 0.70 (for 100Hz). The treatment time will be 20 minutes."
47957013|NCT00032955|DRUG|Buprenorphine/naloxone|
47957014|NCT03531125|PROCEDURE|Endoscopic Ultrasound|Endoscopic ultrasound for tumour biopsy collection
47957015|NCT03531125|PROCEDURE|Pancreaticoduodenectomy|Surgery to remove pancreatic tumour
47957016|NCT03227185|DEVICE|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
48110413|NCT04704778|COMBINATION_PRODUCT|Percutaneus electrostimulation therapies|"Kendall® MediTrace 100 conductive adhesive ECG electrodes (pediatric) 2.4 cm in diameter, and portable KWD-808 electrostimulator equipment will be used.~The superficial area of the skin will be cleaned, two electrodes will be placed on each muscle (superficial area of the mandibular condyle and at the angle of the jaw). The current leads will then be connected to the KWD-808 electroacupuncturist to the patient.~Current will be transmitted with a square waveform, 210Hz-10140Hz of frequency, 3050 volts of amplitude and 40100 msec pulse time. The treatment time will be 20 minutes."
48481308|NCT03998709|OTHER|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
48339960|NCT04917250|DRUG|Pegaspargase|2500IU/㎡, maximum dose less than 3750IU
48481309|NCT03998709|DRUG|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
48481310|NCT03998709|OTHER|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
48481311|NCT05387148|DRUG|Cannabidiol (CBD)|Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
48481312|NCT05387148|DRUG|Placebo|The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
48481313|NCT05789758|OTHER|No Intervention|Administered as specified in the treatment arm.
47957017|NCT03227185|DEVICE|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
47957018|NCT05760560|DRUG|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
47957019|NCT03835871|DRUG|Placebo|Intervention: Drug: placebo
47957020|NCT03835871|DRUG|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
47957021|NCT03835871|DRUG|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
47957022|NCT03835871|DRUG|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
47957023|NCT04207021|DIETARY_SUPPLEMENT|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
47957024|NCT04207021|DIETARY_SUPPLEMENT|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
47957025|NCT00808626|DRUG|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
48640478|NCT04491955|DRUG|NHS-IL12|NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
47957026|NCT05212519|OTHER||For observational research
47957027|NCT04746339|DRUG|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
47957028|NCT04746339|DRUG|Placebo|placebo twice daily for 30 days
47957029|NCT03549169|BEHAVIORAL|TOMAS|Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
48640479|NCT03596983|BEHAVIORAL|Sleep Intervention|"* Sleep Diaries (Daily)~* Fitbit 24/7~* Phone/ video conference calls (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-evening (weekly)"
47957030|NCT03549169|BEHAVIORAL|Regular attention|Regular attention focused on education for therapeutic adherence
47957031|NCT05244304|DRUG|Tinlarebant|Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
47957032|NCT05244304|DRUG|Placebo|Not active drug
47957033|NCT00046878|DRUG|O6-benzylguanine|
47957034|NCT00046878|DRUG|carmustine|
47957035|NCT05465460|DRUG|Banana Blossom|Banana Blossom 225 mg tablet orally four times per day for 14 days
47957036|NCT05465460|DRUG|Placebo|Placebo tablet orally four times per day for 14 days
47957037|NCT00270439|PROCEDURE|removal of omentum|patients with type 2 diabetes had their omentum removed
47957038|NCT03094403|DRUG|Azelaic Acid 15% topical gel|Gel
47957039|NCT03094403|DRUG|Finacea® (azelaic acid) Gel, 15%|Gel
47957040|NCT03094403|DRUG|Placebo|Gel
48110414|NCT04704778|DIAGNOSTIC_TEST|Oclusal splint|"The occlusal splint is worn 24 hours a day, removed for eating and brushing teeth. It is washed with neutral liquid hand soap.~For the preparation, an impression of the maxillary dental arches will be taken with alginate; It is made with acetate .060 and .080.~Relining is done with self-curing acrylic on the occlusal surface of the splint"
48110415|NCT05859542|DEVICE|Videolaryngoscope first|started the session with 3 intubations using the videolaryngoscope
48110416|NCT05859542|DEVICE|Direct laryngoscope first|started the session with 3 intubations using the Direct laryngoscope
48110417|NCT03324035|DRUG|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
48110418|NCT03324035|DRUG|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
48110419|NCT03324035|DRUG|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
48110420|NCT00566904|DRUG|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
48110421|NCT00566904|DRUG|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
48110422|NCT00566904|OTHER|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
48110423|NCT03127358|DEVICE|AiCure|Smartphone App
48110424|NCT03127358|DEVICE|AiCure with gamification|Smartphone App with gaming.
48110425|NCT04920617|DRUG|DPX-Survivac|SC injection on D7 and D28, then every 8 weeks
48110426|NCT04920617|DRUG|Pembrolizumab|IV infusion every 3 weeks
48110427|NCT04920617|DRUG|CPA|50 mg twice daily, week on then week off
47957041|NCT04594343|DRUG|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
47957042|NCT04594343|DRUG|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
47957043|NCT03378661|DRUG|Benznidazole|Benznidazole tablet
47957044|NCT03378661|DRUG|E1224|E1224 capsules
47957045|NCT03378661|DRUG|E1224 Placebo|E1224 matched placebo capsules
47957046|NCT03378661|DRUG|Benznidazole Placebo|Benznidazole matched placebo tablets
47957047|NCT06260215|OTHER|ST|Participants will perform a soccer training (ST) session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
47957048|NCT05757687|DEVICE|Omega device|"The ProArc Medical Omega system is a prostatic reshaping device. The Omega System is comprised of two main components: Omega Delivery Device and Omega Implant.~The delivery system uses a diathermy electrode to perform a circular and superficial incision through the urethral wall into the prostate tissue, into which the arc-shaped permanent implant is placed. The implant is made up of commonly used surgical implantable nitinol material, coated with Parylene coating. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra."
48110428|NCT05925686|DRUG|Tramadol.|Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
48110429|NCT03336450|DRUG|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
48110430|NCT03336450|DRUG|MHOS/SHP615|MHOS/SHP615
48110431|NCT05745376|BEHAVIORAL|Farm to ECE programming|Students and parents at this center will receive program elements described in arm descriptions.
48110432|NCT04425408|DEVICE|Consecutive trial of two different devices for the treatment of positional sleep apnoea, for 3 nights with each device (positional pillow and vibrating belt).|Patients will be randomly allocated to use either a positional pillow or a vibrating belt for three consecutive nights at home followed by three nights with the other device.
48110433|NCT03571711|DRUG|Meropenem Injection|Meropenem is administered as prescribed by treating physician
48481314|NCT03244124|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
48481315|NCT03244124|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
48481316|NCT03244124|OTHER|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
48481317|NCT03244124|OTHER|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
47957049|NCT06105931|BIOLOGICAL|Hyperinsulinemic-euglycemic clamp|Hyperinsulinemic-euglycemic clamp will be used to assess insulin resistance. After IVs are placed, participants will be transitioned to intravenous insulin administration for the baseline portion of the study. Stable Isotope Tracer Infusions will assess rates of glucose, lipid metabolism, and beta-hydroxybutyrate turnover during the last 30 minutes of the baseline equilibration period and again during the last 30 minutes of the stepped IV insulin infusion periods.
47957050|NCT06105931|OTHER|High Fat Mixed Meal Tolerance Test|After a 12 hour overnight fast, baseline levels of the lipoproteins will be drawn. The YCCI Bionutrition Service kitchen will prepare the standardized high-fat meal. Participants will administer their bolus insulin per their home regimen for the carbohydrates in the high-fat meal, and then they will consume the meal within a 15-minute timeframe.
47957051|NCT02008175|RADIATION|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
48110434|NCT03264235|DEVICE|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
48110435|NCT03264235|OTHER|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
48481318|NCT02975037|DRUG|Sildenafil|sildenafil 25 mg PO
48481319|NCT02975037|DRUG|Clarithromycin|clarithromycin 250 mg PO
48481320|NCT02975037|DRUG|Itraconazole|itraconazole 100 mg PO
48481321|NCT02862249|BIOLOGICAL|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
48481322|NCT02862249|BIOLOGICAL|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
48481323|NCT04206228|DRUG|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
48481324|NCT04206228|DRUG|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
48110436|NCT00092014|DRUG|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
48110437|NCT00092014|DRUG|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
48481325|NCT05477719|DEVICE|Wearing of specific compression stockings|The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
47957052|NCT05464693|DIAGNOSTIC_TEST|ERCP biliary culture|"The sample of biliary aspirate will be assessed as follows.~1. Its macroscopic appearance will be analyzed: yellow, black, or purulent.~2. Biliary culture will be performed; if bacterial growth is observed, its identification will be carried out by means of MALDI-TOF MS mass spectrometry and antibiotic susceptibility tests will be carried out, using the automated VITEK system."
47957053|NCT03643354|DIAGNOSTIC_TEST|Epley maneuver/Barbeque maneuver|Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
47957054|NCT03380715|DEVICE|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
47957055|NCT03380715|DEVICE|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
48481326|NCT04272203|DRUG|ABBV-184|Intravenous (IV) infusion
48110438|NCT00092014|DIETARY_SUPPLEMENT|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
48110439|NCT00092014|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
48110440|NCT00092014|DRUG|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
48110441|NCT00092014|DRUG|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
48481327|NCT03980210|PROCEDURE|Hyperbaric oxygen therapy|"1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA"
48481328|NCT01566279|DRUG|Everolimus|All patients will receive everolimus 10mg q.d.
48110442|NCT00057837|BIOLOGICAL|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery \> 10,000 dL.
48110443|NCT00057837|DRUG|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
48110444|NCT00057837|DRUG|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
48110445|NCT00057837|DRUG|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
48110446|NCT00057837|DRUG|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
48110447|NCT03404583|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
48110448|NCT04120597|DRUG|Zishen Qingre Lishi Huayu Granules|The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
48110449|NCT04120597|DRUG|Placebo|"The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months."
48110450|NCT03855891|DIAGNOSTIC_TEST|blood test|Blood test for spectrum and level of cardiospecific micro-RNA
48110451|NCT01692730|BEHAVIORAL|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
48110452|NCT01692730|BEHAVIORAL|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
48110453|NCT01700400|DRUG|Everolimus|
48110454|NCT01700400|DRUG|Pemetrexed|
48110455|NCT01700400|DRUG|Carboplatin|
48481329|NCT00805402|OTHER|flow cytometry|flow cytometry
48481330|NCT00922324|DRUG|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
48481331|NCT01197768|BEHAVIORAL|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
48481332|NCT02959008|DEVICE|measure TOI and BP|Both groups measure TOI and BP.
48481333|NCT00111956|DRUG|Etanercept|
48481334|NCT00111956|DRUG|Placebo|
48481335|NCT01358539|BEHAVIORAL|Pain education|Patients receiving pain education
48481336|NCT03614494|DRUG|Piroxicam 40 mg|Additional co-treatment
48640480|NCT03596983|BEHAVIORAL|Week 2 Intervention|"* Sleep Diaries (Daily)~* Phone Calls (weekly with study team)~* Wrist Accelerometry and fitbit 24/7 for 14 days~* SAFTEE Questionnaire~* ASA24~* Behavioral risk factor surveillance system (smoking and alcohol use questions)~* Psychological well-being (SF36)~* Index of Self Regulation~* PROMIS fatigue scale-morning (weekly)~* PROMIS fatigue scale-evening (weekly)~* Epworth Sleepiness Scale (weekly)"
48640481|NCT03506633|DIETARY_SUPPLEMENT|MitoQ|"A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each subject in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured."
48481337|NCT03614494|DRUG|Levonorgestrel 1.5mg|Standard treatment
48481338|NCT02154724|DEVICE|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
48640482|NCT05298046|DRUG|Experimental: TAVO101|TAVO101 single ascending dose IV infusion.
48640483|NCT05298046|OTHER|Other: Placebo|Placebo single ascending dose IV infusion.
48640484|NCT05405166|DRUG|Isatuximab IV|Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
48640485|NCT05405166|DRUG|Isatuximab SC|Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
48640486|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: Tablet; Route of administration: Oral
48640487|NCT05405166|DRUG|Pomalidomide|Pharmaceutical form: hard capsules; Route of administration: Oral
48110456|NCT01700400|DRUG|Bevacizumab|
48110457|NCT03823196|DIETARY_SUPPLEMENT|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
48110458|NCT03823196|DIETARY_SUPPLEMENT|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
48481339|NCT02154724|DEVICE|DBS|The aDBS s applied for two hous in DBS modality.
48640488|NCT05405166|DRUG|Dexamethasone|Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
48481340|NCT04969042|DEVICE|Pins Medical G122 RS|G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
48481341|NCT05117047|PROCEDURE|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
48640489|NCT05405166|DRUG|Montelukast|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
48640490|NCT05405166|DRUG|Paracetamol / Acetaminophen|Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
48640491|NCT05405166|DRUG|Diphenhydramine|Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
47957056|NCT03406767|OTHER|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
47957057|NCT03406767|OTHER|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
47957058|NCT02681783|DRUG|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
47957059|NCT02915796|BIOLOGICAL|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
47957060|NCT02915796|BIOLOGICAL|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
47957061|NCT02915796|PROCEDURE|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
47957062|NCT02915796|BIOLOGICAL|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
47957063|NCT06555497|DRUG|topical 1% methotrexate gel|topical 1% methotrexate gel
47957064|NCT06555497|DRUG|clobetasol propionate 0.05% ointment|clobetasol propionate 0.05% ointment
47957065|NCT01913678|OTHER|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
48110459|NCT02590952|DRUG|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
48110460|NCT01477879|OTHER|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
48110461|NCT01477879|OTHER|placebo (versabase gel only)|versabase gel only
48110462|NCT03753594|DEVICE|tissue oxygenation saturation|tissue oxygenation saturation
48110463|NCT02726490|DRUG|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
48110464|NCT02726490|DRUG|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
48110465|NCT02219178|DRUG|lenalidomide|25mg days 1 - 14 of 21 day schedule
48110466|NCT02219178|DRUG|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
48110467|NCT02219178|DRUG|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
48110468|NCT04777968|DRUG|Silver diamine fluoride|a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
48304103|NCT05313633|OTHER|Occupational therapy|Both groups received a designed occupational therapy program for 30 minutes
48110469|NCT06282744|OTHER|Outpatient physical therapy improvement in movement assessment log|The Outpatient Physical Therapy Improvement in Movement Assessment Log (OPTIMAL) is an instrument that measures difficulty and self-confidence in performing 22 movements that a patient needs to accomplish in order to do various functional activities.
48110470|NCT03644329|OTHER|Control group|The volunteers will not performed the interventions.
48110471|NCT03644329|OTHER|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
48110472|NCT03644329|OTHER|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
48110473|NCT03644329|OTHER|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
48304104|NCT05313633|OTHER|Plyometric training|The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association.
48304105|NCT05313633|OTHER|Wii training|The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device.
48304106|NCT04670965|BIOLOGICAL|E-PRF/rhBMP-2 (similar ratios)|During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
48339961|NCT04917250|DRUG|Etoposide|100mg/㎡，d1-3 ivdrip
48339962|NCT04917250|DRUG|Dexamethasone|20mg/d d1-4 ivdrip
48481342|NCT02996019|DRUG|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
48481343|NCT02996019|DEVICE|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
48481344|NCT02996019|DEVICE|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
48640492|NCT05405166|DRUG|Methylprednisolone|Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
47957066|NCT01913678|OTHER|Complete diet|The participants will be given all dietary items in their diet with no additional products.
47957067|NCT01913678|OTHER|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
47957068|NCT01956383|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
47957069|NCT00561457|DEVICE|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
47957070|NCT02538081|DRUG|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
47957071|NCT02538081|DRUG|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
47957072|NCT01460017|PROCEDURE|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
47957073|NCT01460017|PROCEDURE|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
47957074|NCT05761041|DRUG|Sodium Fluoride Varnish (5%)|Applied at baseline
47957075|NCT05761041|BEHAVIORAL|Motivational Interviewing|Two MI sessions: face-to-face at baseline and phone call at 3 months
47957076|NCT05761041|DRUG|SDF|Applied bianually
47957077|NCT01210469|OTHER|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
47957078|NCT01210469|OTHER|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
47957079|NCT05991167|DEVICE|EndeavorRx|EndeavorRx® is an FDA cleared digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. EndeavorRx is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
48110474|NCT02337569|DRUG|NPC-02|
48110475|NCT02337569|DRUG|Placebos|
48110476|NCT03060642|DEVICE|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
48110477|NCT03060642|DEVICE|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
48339963|NCT01067651|DEVICE|Plaster of Paris (POP) casting using the Ponseti Method|
48481345|NCT06052020|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
48481346|NCT06052020|DRUG|Atorvastatin|Atorvastatin 20-40mg
48110478|NCT01551433|DEVICE|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
48640493|NCT01455844|DRUG|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
48110479|NCT00118066|DIETARY_SUPPLEMENT|calcitriol|Given orally
48110480|NCT00118066|PROCEDURE|observation|No initial intervention
48640494|NCT01455844|OTHER|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
48640495|NCT01455844|DRUG|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
48640496|NCT06440746|DRUG|Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)|Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
47957080|NCT05732246|OTHER|First rib mobilization with balloon breathing exercises|Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
47957081|NCT02002273|PROCEDURE|Switching level of suction|
47957082|NCT05248737|DIETARY_SUPPLEMENT|DHA/EPA bioenhanced chicken|Chicken fed on a high DHA/EPA diet
48110481|NCT02032849|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
48481347|NCT00963079|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
48481348|NCT00963079|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
48481349|NCT06397222|DRUG|Sin-Bev-SIRT|Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
48481350|NCT04344132|PROCEDURE|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
48640497|NCT06440746|DRUG|SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL|Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
48640498|NCT04465487|DRUG|REGN6569|Administered by intravenous (IV) infusion
48640499|NCT04465487|DRUG|Cemiplimab|Administered by IV infusion
48640500|NCT05216146|OTHER|Strength and Conditioning|A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
47957083|NCT05248737|DIETARY_SUPPLEMENT|25(OH)D bioenhanced chicken|Chicken fed on a high 25(OH)D diet
47957084|NCT03830242|DIAGNOSTIC_TEST|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
48110482|NCT02032849|DEVICE|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
48110483|NCT01277796|DEVICE|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
48339964|NCT01067651|DEVICE|Semi-Rigid Fiberglass softcast using the Ponseti Method|
48339965|NCT06274268|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
48481351|NCT00190879|DRUG|Atomoxetine hydrochloride|
48481352|NCT00190879|DRUG|placebo|
48481353|NCT04652544|DRUG|Cholecalciferol (Vitamin D3)|Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
48481354|NCT04652544|OTHER|Placebo|A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
48481355|NCT05727449|PROCEDURE|General Anesthesia|General Anesthesia was intruduced for Cesarean Delivery
48304107|NCT04670965|BIOLOGICAL|E-PRF/ACS/rhBMP-2|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
48640501|NCT04323566|DRUG|Rituximab|"Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)"
48640502|NCT04590404|BEHAVIORAL|Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.|Automated calls to assess smoking status, medication use, and additional support for quit attempt.
48640503|NCT04590404|DRUG|Nicotine Replacement Therapy|FDA-approved forms of nicotine replacement therapy for smoking cessation.
47957085|NCT03830242|DIAGNOSTIC_TEST|B-ultrasonography|The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
47957086|NCT00628485|DEVICE|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
47957087|NCT00628485|DEVICE|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
47957088|NCT00628485|DEVICE|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
47957089|NCT04650022|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
47957090|NCT00456248|DRUG|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
47957091|NCT02026284|OTHER|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
47957092|NCT03489148|BEHAVIORAL|Tamarkoz®|Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
47957093|NCT03489148|BEHAVIORAL|Stress management resources|Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
47957094|NCT00860483|OTHER|observational|PET Scan
47957095|NCT03376269|BIOLOGICAL|HBOT|•HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
48481356|NCT05727449|PROCEDURE|Spinal Anesthesia|Spinal Anesthesia was intraduced for Cesarean Delivery
48481357|NCT03653624|OTHER|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
47957096|NCT03376269|BEHAVIORAL|Psychotherapy|creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
48304108|NCT04670965|BIOLOGICAL|rhBMP-2/E-PRF|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
48304109|NCT04670965|BIOLOGICAL|E-PRF only|E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
48304110|NCT06457919|DRUG|Tinengotinib|Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.
48304111|NCT06457919|DRUG|abiraterone acetate|Abiraterone acetate 1000 mg PO QD
48304112|NCT06457919|DRUG|Prednisone or Enzalutamide|Prednisone 5 mg PO once or twice daily (QD or BID) or enzalutamide 160 mg PO QD
48304113|NCT06457919|DRUG|Tinengotinib|The recommended phase 2 dose (RP2D).
48304114|NCT01279538|DRUG|bleselumab|Intravenous (IV) infusion
48640504|NCT04590404|DRUG|Varenicline|FDA-approved smoking cessation medication.
48640505|NCT04590404|OTHER|Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)|Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
48640506|NCT03671148|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous (SC) injection
48640507|NCT03671148|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
48640508|NCT05498038|BEHAVIORAL|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
48640509|NCT03588299|DRUG|BAY2599023 (DTX201)|Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
48640510|NCT06042855|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
48304115|NCT01279538|DRUG|Placebo|Intravenous (IV) infusion
48304116|NCT06448026|DRUG|Cemiplimab|Given by IV
48304117|NCT06448026|DRUG|Cetuximab|Given by IV
48640511|NCT06042855|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
47957097|NCT05426772|OTHER|exercise and kinesiotaping|"Exercise: Aerobic exercise will be performed on the treadmill for 20 minutes with a maximum heart rate of 55%-65% and a perceived exertion of less than 3. The Moxy muscle oxygen monitor will take measurements over the quadriceps femoris muscle at this time.~Kinesiotaping: After 3 days, the same participants will be called for kinesiotaping application. The application will be applied to the quadriceps femoris muscle with the facilitation technique by a physiotherapist who has a kinesio taping training certificate."
47957098|NCT00480285|PROCEDURE|Laparoscopic Nissen Fundoplication|
47957099|NCT00480285|PROCEDURE|Laparoscopic anterior partial fundoplication|
47957100|NCT03302650|DRUG|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
47957101|NCT03302650|DRUG|Normal saline|Patients will receive normal saline.
47957102|NCT03302650|DRUG|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
47957103|NCT03580993|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
47957104|NCT05194865|DEVICE|cardiac MRI|assessment of the viability using CMR
47957105|NCT05194865|PROCEDURE|Percutaneous coronary intervention|direct revascularization using PCI
47957106|NCT05600660|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
47957107|NCT05600660|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
48304118|NCT06689566|DIETARY_SUPPLEMENT|genistein|After enrollment, there will be dose-escalation every 1 month with 3 doses of genistein (250 mg, 500 mg, and 750 mg BID orally) for complete 3 months. Afterwards, there will be 3 months washout period.
47957108|NCT05600660|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
48304119|NCT06684847|BIOLOGICAL|Efgartigimod PH20 SC|subcutaneous efgartigimod PH20 SC given by prefilled syringe
47957109|NCT00795847|DRUG|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
47957110|NCT04544423|OTHER|Block group|Patients received lumbar erector spinae plane Block before operation
47957111|NCT02883686|BEHAVIORAL|Alma|Alma peer-mentoring
47957112|NCT05730283|DRUG|ORC-13661|High-dose intervention (30mg daily)
47957113|NCT05730283|DRUG|ORC-13661|Low-dose intervention (12mg daily)
47957114|NCT05730283|DRUG|Placebo|Placebo intervention
47957115|NCT02008318|DRUG|Galunisertib|Administered orally
47957116|NCT02008318|DRUG|Placebo|Administered orally
47957117|NCT03254979|BEHAVIORAL|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
47957118|NCT03729466|OTHER|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
47957119|NCT00660673|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
47957120|NCT00660673|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
47957121|NCT00660673|DEVICE|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
48304120|NCT06684847|OTHER|Placebo PH20 SC|subcutaneous placebo PH20 SC given by prefilled syringe
48304121|NCT06111053|OTHER|ENDS|Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
48304122|NCT06111053|OTHER|CI|Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
48640512|NCT05435482|BEHAVIORAL|Education|Participants will receive two small group meetings and two follow-up calls
48640513|NCT05435482|OTHER|COVID-19 testing kits|Participants will receive two COVID-19 at-home antigen test kits.
48640514|NCT05435482|OTHER|Instruction|Participants will receive a written guide and a video clip guide to the test kit.
48640515|NCT04146207|DRUG|SHR0302|SHR0302 po QD
48640516|NCT04146207|DRUG|Prednisone|Prednisone 1mg/kg/d po
48640517|NCT04740879|BEHAVIORAL|Be Mindful|The online 4-week Be Mindful intervention was designed to follow the same outline as typical in-person 8-week MBCT courses. Week 1 and Week 2 introduce the topic of mindfulness and encourage its daily use, whereas Week 3 and Week 4 teach the individual to decenter from thoughts and utilize mindfulness when coping with stressors. Each week focuses on a separate mindfulness topic, which is initially presented to the individual in a short (under 5 minute) video containing didactic information and an overview of the experiential activities that will be introduced in subsequent videos. The intervention is provided entirely through audio, video, and text provided on the Be Mindful website (BeMindfulOnline.com).
48640518|NCT06645704|DRUG|EP262|Single dose of \[14C\]-EP262 administered orally.
47957122|NCT05899088|OTHER|Mindful Movement|Mindful Movement Program with Researcher Follow-up
47957123|NCT02747290|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
47957124|NCT05602870|DIAGNOSTIC_TEST|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
47957125|NCT05642767|DIAGNOSTIC_TEST|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
48110484|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program|The internet-based parenting support program is based on social learning theory. A foundation is the Family Check-up program (FCU), which includes approaches from motivational interviewing (MI). The parenting support is also based on similar CBT-parenting strategies as in other evaluated face-to-face CBT-parenting support programs (e.g., Comet) as well as internet-based programs (e.g., iComet; ParentWeb).
48110485|NCT06386562|BEHAVIORAL|Family Check-up and Cognitive behavior therapy online: a Swedish internet-based parenting program with additional parental support|The internet-based parenting program includes the same contents and chat-function as in the other condition. The focus for the digital/phone meetings is to explore potential questions, problem-solve around potential challenges, and motivate parents to practice strategies and complete modules.
48481358|NCT03879096|OTHER|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
48640519|NCT06248177|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
48640520|NCT06248177|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
48640521|NCT04292496|PROCEDURE|Introperative leak testing|After anastomosis was completed. We test the integrity of anastomosis intraoperatively.
48640522|NCT06694935|DRUG|QX1206|QX1206 will be administered orally before bedtime
48640523|NCT06105632|DRUG|PF-07220060 CDK4 inhibitor|Experimental
48640524|NCT06105632|DRUG|Fulvestrant|Experimental and Active comparator
48640525|NCT06105632|DRUG|Everolimus|Active Comparator
48640526|NCT06105632|DRUG|Exemestane|Active Comparator
48640527|NCT02124980|BEHAVIORAL|Recovery Line|
48640528|NCT05763862|GENETIC|Genetic testing|Same information as details in the experimental arm.
48640529|NCT05920616|OTHER|Magnetic Resonance Imaging|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
47957126|NCT05642767|DIAGNOSTIC_TEST|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
47957127|NCT05642767|DIAGNOSTIC_TEST|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
47957128|NCT05642767|DIAGNOSTIC_TEST|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
47957129|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 48-hour course of antibiotics.
48640530|NCT05920616|OTHER|Ultra-High Resolution Computed Tomography (CT) Scan|Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
47957130|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 7 day course of antibiotics.
47957131|NCT03431766|DEVICE|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
47957132|NCT03431766|DEVICE|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
48304123|NCT06111053|OTHER|No ENDS|Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
48304124|NCT06111053|OTHER|NI|Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
48481359|NCT05129254|DEVICE|Fractionated Thulium laser|For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
48481360|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Injection|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
48481361|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Topical Application|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
48481362|NCT01643226|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
48481363|NCT01643226|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
48481364|NCT01643226|DEVICE|KXL System|30 mW/cm2
48481365|NCT03508869|DRUG|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
48481366|NCT03508869|DRUG|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
48481367|NCT03508869|DRUG|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
48481368|NCT04500132|DRUG|EC-18|EC-18 QD
48481369|NCT04500132|DRUG|Placebo EC-18|Placebo EC-18 QD
48481370|NCT04571892|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
48481371|NCT00007761|BEHAVIORAL|Bipolar Disorder Program|
48640531|NCT05309577|BEHAVIORAL|Behavioral Self-Monitoring + Motivational Interviewing|Participants (n=20) will wear a iWatch to continuously measure their objective sleep-wake activity. The iWatch data sync to the new myRhythmWatch app, where participants will monitor their behavioral rhythm. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
47957133|NCT00436241|DRUG|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
47957134|NCT00436241|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
48481372|NCT00007761|BEHAVIORAL|Usual (psychiatric) Care|
48640532|NCT06695494|DIAGNOSTIC_TEST|Gene panel array|Blood sample collection for gene panel testing
48640533|NCT06695494|OTHER|Blood Sample Collection|Blood sample collection for research purposes
47957135|NCT01951937|DIETARY_SUPPLEMENT|Fish Meals|Meals containing salmon
47957136|NCT01951937|DIETARY_SUPPLEMENT|Placebo|No fish meals
47957137|NCT03954691|OTHER|brain tumor-immune cells communication|tumoral and immune cell isolation from biopsis
47957138|NCT03598543|OTHER|no intervention|no intervention, this is an obervational study.
47957139|NCT03567577|DRUG|Solnatide 25 mg powder for reconstitution for solution for inhalation|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
47957140|NCT03567577|DRUG|0.9% Saline Solution|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
48304125|NCT04228991|RADIATION|Locoregional radiation treatment - Conventional fractionation|40 Gray in 15 daily fractions over 3 weeks
48304126|NCT04228991|RADIATION|Locoregional radiation treatment - Hypofractionation|26 Gray in 5 daily fractions over 1 week
48481373|NCT03336242|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
48481374|NCT02978352|OTHER|learning|
48640534|NCT06694480|DRUG|FID-022|Advanced solid tumors
47957141|NCT00398411|DRUG|moxifloxacin|400 mg p.o. per day
47957142|NCT00398411|DRUG|placebo|one tablet per day p.o.
48110487|NCT05311137|PROCEDURE|Radiofrequency ablation|Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.
48339966|NCT01594346|DRUG|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
48339967|NCT01594346|DRUG|Sugar Pill|
48339968|NCT01762527|RADIATION|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
48304127|NCT04897945|BEHAVIORAL|Shared decision-making for diabetes prevention|Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
48304128|NCT06688084|OTHER|Molecular epidemiology of the collection|Next-generation genomic sequencing (MICRO\&BIO platform, MiSeq, Illumina) and bioinformatics analyses. After validating data quality, genomes will be re-assembled using Spades software (version 3.15.4) and CLC® (Qiagen), then compared with the National Center for Biotechnology Information GenBank database. They will also be analysed on the online Type-Strain Genomes Server platform to accurately identify the bacteria. Genome annotation will be done using the DDBJ Fast Annotation and Submission Tool. Single nucleotide polymorphisms (SNP) analysis based on the alignment of whole genomes and core-genomes will be carried out using version 7 of MAFFT (multiple alignment using fast Fourier transform) software, then quantified using snp-dists (version 0.6.3). This approach will enable the molecular epidemiology of the collection of strains in France and other European countries to be clarified, and the main circulating clades to be assessed, particularly depending on the origin of samples.
48304129|NCT06688084|OTHER|Study of the resistome of the S. pettenkoferi population|The resistome will be assessed by identifying known and described resistance genes in staphylococci using bioinformatics analyses of sequenced complete bacterial genomes. A search for plasmids will also be made using various specific software packages (ResFinder, CARD, PointFinder, Plasmidfinder, in-house pipeline).
48304130|NCT06688084|OTHER|Study of the virulome of the S. pettenkoferi population|The virulome of the strains will be studied based on the genomic sequencing data obtained and with reference to the literature on Staphylococci. Various specific software packages (Pathogenfinder, Virulencefinder, in-house pipeline) will be used for this purpose.
48304131|NCT06688084|OTHER|Study of the resistance profiles of all S. pettenkoferi isolates|Antibiotic resistance will be assessed using a Sensititer® plate (Thermo ScientificTM, Illkirch) to evaluate the minimum inhibitory concentration of isolates against a series of antibiotics commonly used for S. pettenkoferi infections, including new molecules currently on the market or in development, such as Ceftaroline, Ceftobiprole, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Minimum inhibitory concentration values will be interpreted in accordance with the recommendations of the Antibiogram Committee of the Société Française de Microbiologie (https://www.sfm-microbiologie.org/2021/04/23/casfm-avril-2021-v1-0/).
48304132|NCT06688084|OTHER|Selection of strains for in-depth phenotypic study|"Different strains of S. pettenkoferi isolated from foot osteitis in diabetic patients and non-diabetic osteitis will be selected according to the clades identified and phenotypically characterised by further analysis:~* Observation of culture characteristics (culture requirements, growth time, colony size and haemolytic capacity), (n=20)~* Determination of growth curves by measuring absorbance at 600 nm using the Infinite M Mano automatic absorbance reader (TECAN, Lyon), (n=20)~* Study of the ability to form biofilm in the presence (antibiofilmogram) (n=85) or absence (BioFilm Ring® test, Biofilm Control, St Beauzire) (n=85) of various antibiotics commonly used for the treatment of S. pettenkoferi infection during osteitis."
48304133|NCT06688084|OTHER|Selection of strains (n=3) for the virulence study|"Three strains of S. pettenkoferi isolated from foot osteitis in diabetic patients will be selected on the basis of the clades identified and the study of the virulome in order to be analysed on :~* In vitro cell culture models of macrophages (RAW 264.7) and osteoblasts (MC3T3-E1) to assess the invasion potential of these isolates by measuring internalisation rates (TECAN, Lyon) and LDH release (CyQUANT LDH Cytotoxicity kit), a sign of cellular toxicity of the isolate.~* An in vivo wound model on diabetic zebrafish (Dario rerio) with evaluation of their survival at 48h in the presence of the isolates by immersion.~These models were developed at the MICRO\&BIO Platform and the INSERM 1047 VBIC unit."
48339969|NCT01482455|OTHER|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
48481375|NCT04977609|BEHAVIORAL|VR+MUSIC|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
48481376|NCT04977609|BEHAVIORAL|VR|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
48481377|NCT04977609|BEHAVIORAL|TAU|Traditional post-stroke upper limb motor rehabilitation under the supervision of a physical therapist, for 0 daily sessions of 30 minutes, over 2 weeks.
48481378|NCT00137657|DRUG|Cotrimoxazole (trimethoprim sulfamethoxazole)|
48481379|NCT03153826|OTHER|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
48481380|NCT06616623|BIOLOGICAL|Atezolizumab|Given IV
48481381|NCT06616623|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
48481382|NCT06616623|PROCEDURE|Computed Tomography|Undergo CT
48481383|NCT06616623|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47957143|NCT04088942|OTHER|High-intensity smoking cessation intervention|"1. Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~2. Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~1. A hotline is established which the high-intensity group can call.~2. Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~   d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
47957144|NCT04088942|DRUG|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
48304134|NCT06099509|OTHER|Self-administered oral glucose tolerance test|Participants will be asked to self-administer the postpartum 75-gram oral glucose tolerance test. They will be provided the glucose solution and instructions. A 4 week virtual visit will be arranged where the test results will be reported to the provider and appropriate follow up arranged based on the results of their screen.
48304135|NCT06246058|BEHAVIORAL|Partner support|The intervention group's survey vignette will include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
48304136|NCT06246058|BEHAVIORAL|Formal recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~FORMAL dress code of the recruiter is the intervention in this case, defined as clinical attire alluding to some clinical authority."
47957145|NCT01102270|DRUG|Eszopiclone|3mg tablet once prior to sleep
48304137|NCT06246058|BEHAVIORAL|Without Partner support|The intervention group's survey vignette will NOT include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
48304138|NCT06246058|BEHAVIORAL|Casual recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~CASUAL dress code of the recruiter is the intervention in this case."
48304139|NCT06094179|DRUG|Monoclonal antibody BAT6026|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
48304140|NCT06094179|DRUG|sodium chloride injection|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
48304141|NCT05513703|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
48304142|NCT05151653|DRUG|BI 765250|BI 765250
48304143|NCT05151653|DRUG|Placebo|Placebo
48339970|NCT01482455|OTHER|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
48339971|NCT04173390|DRUG|Pregabalin 150mg|Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
48339972|NCT04173390|DRUG|Placebo oral tablet|Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
48339973|NCT05150795|DRUG|Pregabalin 150mg|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
48481384|NCT06616623|DRUG|Vismodegib|Given PO
48640535|NCT05159011|BEHAVIORAL|AGILITY (Access to Genetic Information Leveraging Innovative TechnologY)|information about genetic testing through technology
47957146|NCT01102270|DRUG|Placebo|1 placebo capsule prior to sleep
47957147|NCT01536743|DRUG|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
47957148|NCT03449875|DEVICE|TREOVANCE® Stent-Graft with Navitel® Delivery System|Endovascular repair of abdominal aortic aneurysms.
47957149|NCT05565131|DEVICE|Guided placement with PYTHEAS® ODYSSEE|Pre-surgery, the surgeon generates a 3D model of the spine from a preoperative CT scan During the perforation and insertion of the implant, the system indicates the orientation of the pedicle path and the current orientation of the instruments (perforation tool) with the orientation sensor (inertial sensor). The system also displays the position of the entry point of the planned pedicle path on the views.
47957150|NCT00004488|DRUG|alendronate sodium|
47957151|NCT00004488|DRUG|calcium carbonate|
47957152|NCT00004488|DRUG|cholecalciferol|
47957153|NCT02599896|BIOLOGICAL|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
47957154|NCT02599896|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
47957155|NCT03950479|DIAGNOSTIC_TEST|3D and 4D Transperineal Ultrasound|The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
47957156|NCT01404273|BEHAVIORAL|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
48640536|NCT04857034|DRUG|Deucravacitinib|Specified dose on specified days
48640537|NCT04857034|DRUG|Placebo|Specified dose on specified days
47957157|NCT00886561|BEHAVIORAL|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
47957158|NCT03623841|OTHER|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
47957159|NCT03623841|OTHER|Treadmill training|Participants in control group will do treadmill training only
47957160|NCT05840783|DEVICE|Open ended needle irrigation|irrigation during root canal shaping and cleaning using an open-ended needle
47957161|NCT05840783|DEVICE|side vented needle irrigation|irrigation during root canal shaping and cleaning using a 30-guage side-vented needle
47957162|NCT05840783|DEVICE|Sonic activation|Agitation of root canal irrigation solution with a sonic activation device (Endoactivator).
47957163|NCT03491267|DRUG|Retinoic acid|The study team will treat skin with topical retinoic acid
47957164|NCT03491267|DEVICE|Laser|The study team treat skin with a surface laser.
47957165|NCT03491267|DRUG|Sham treatment|No drug will be given
47957166|NCT03491267|DEVICE|Sham treatment|No laser treatment will be given
47957167|NCT05627297|OTHER|CEUS and CEMRI|contrast-enhanced ultrasound and contrast-enhanced MRI examination
48339974|NCT05150795|DRUG|Fentanyl 100 micrograms ampoule|Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
48481385|NCT01651611|BEHAVIORAL|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
48481386|NCT01651611|BEHAVIORAL|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
48640538|NCT06214481|DRUG|Rocatinlimab|Administered SC.
47957168|NCT02754557|OTHER|Breath-Focused Meditation|"Participants will attend two breath-focused meditation sessions per week for three weeks. During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
47957169|NCT02754557|DEVICE|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
47957170|NCT05101785|DRUG|Lidocain hydrochloride 2 % with epinephrine|Local anesthesia infilteration in children
47957171|NCT05101785|DRUG|Articaine chloride 4% with epinephrine|Articaine chloride 4% with epinephrine
47957172|NCT03488732|DEVICE|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
47957173|NCT05978778|DEVICE|wii sports game|wii sports is a collection five sports game stimulation,which have been designed to demonstrate the motion sensing capabilities of wii remote
47957174|NCT05978778|OTHER|pre-hand writing skills|pre-hand writing skills
47957175|NCT03720353|DRUG|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
47957176|NCT03720353|DRUG|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
47957177|NCT03720353|DRUG|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
47957178|NCT05852184|OTHER|Hb Scope APP|"The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use."
47957179|NCT00265629|DEVICE|RF catheter ablation|RF ablation using mesh device
47957180|NCT00778544|DRUG|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
47957181|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
47957182|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
47957183|NCT00425347|DRUG|HuLuc63|Not applicable for HuLuc63.
47957184|NCT01869517|OTHER|intrastromal corneal ring segments (Keraring) implantation|
47957185|NCT01869517|OTHER|Intrastromal corneal continuous ring (Myoring) implantation|
48110488|NCT02076958|BEHAVIORAL|Community Health Advisor education|
48110489|NCT01901276|DRUG|Omeprazole 40 mg bid|As above.
48110490|NCT04418323|PROCEDURE|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula|Video-assisted anal fistula treatment (VAAFT) versus Fistula-tract Laser Closure (filac) versus Conventional seton in the Management of anal fistula
48304144|NCT04960566|OTHER|Cognitive Behavioral Therapy|The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.
48304145|NCT04960566|OTHER|Sham-SOC Lifestyle Coaching|Sham-SOC Lifestyle Coaching
48304146|NCT04374305|DRUG|Brigatinib|Oral daily per predetermined dosage per protocol.
48304147|NCT04374305|DRUG|Neratinib|Oral daily per predetermined dosage per protocol.
48481387|NCT01651611|BEHAVIORAL|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
48481388|NCT01651611|BEHAVIORAL|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
48481389|NCT02419235|OTHER|20% ethanol|Unmedicated 20% ethanol.
48481390|NCT02419235|OTHER|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
47957186|NCT04016064|PROCEDURE|Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery|"1. Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~2. Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~3. Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~4. Conventional surgical method was applied with hand instruments and gingivectomy knives."
47957187|NCT04289623|BEHAVIORAL|Email|Email
48481391|NCT06026631|PROCEDURE|Lipidomic analysis for breast cancer patients|Lipidomic analysis for breast cancer patients
47957188|NCT04289623|BEHAVIORAL|Loss frame|Email
47957189|NCT04289623|BEHAVIORAL|Testimonial (medical expert)|Email
47957190|NCT04289623|BEHAVIORAL|Testimonial (rank-and-file)|Email
47957191|NCT04289623|BEHAVIORAL|Social norms (percentage)|Email
47957192|NCT04289623|BEHAVIORAL|Social norms (number)|Email
47957193|NCT04053075|OTHER|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
47957194|NCT04053075|OTHER|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
47957195|NCT01235689|BIOLOGICAL|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
47957196|NCT01235689|DRUG|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
47957197|NCT01235689|DRUG|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
47957198|NCT02318875|DIETARY_SUPPLEMENT|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
47957199|NCT02318875|OTHER|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
47957200|NCT01848496|PROCEDURE|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
47957201|NCT02206074|DIETARY_SUPPLEMENT|Beetroot|
47957202|NCT00487708|DRUG|canakinumab|
47957203|NCT01897714|DRUG|Melflufen|
47957204|NCT01897714|DRUG|Dexamethasone|
47957205|NCT05285072|RADIATION|PET-CT scan|PET-CT scan using 68Ga-DFO
48110491|NCT00596648|DRUG|XL184|Capsules administered orally daily
48110492|NCT00596648|DRUG|erlotinib|Tablets administered orally daily.
48110493|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
48304150|NCT06691958|OTHER|Tortilla corn chips 4-5 pieces, eat one piece at time|Snack
48640539|NCT06187662|BEHAVIORAL|Checklist|This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs. Meaning, if a clinician in Arm A is faced with a scenario in which it is customary or usual care to consider a blood culture, the clinician will be asked to first review this checklist. The checklist is not a binding or absolute process - the clinician should use both the checklist and typical clinical judgment to decide if the blood culture test is needed or not. The checklist is based on prototypes used in the completed parent study, BrighT STAR and the earlier preliminary studies at Johns Hopkins.
48640540|NCT06187662|BEHAVIORAL|Targeted Messaging|This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date.
48640541|NCT06541249|DRUG|Methotrexate (MTX)|MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
48110494|NCT00542113|BEHAVIORAL|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
48110495|NCT00542113|BEHAVIORAL|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
48110496|NCT04302844|BEHAVIORAL|Imago Relationship Therapy|Imago relationship therapy (IRT) involves learning the Imago dialogue process, which helps couples understand more clearly why they and their partners react as they do. Couples practice communicating in a manner that helps them move from reactivity and blame to understanding and empathy. The dialogue is used to transform conflicts into opportunities for healing and growth, and to connect more deeply and effectively with one another. Specific topics of therapy are determined by the couple's needs and goals. In general, the therapist helps them use the Imago dialogue to promote understanding, heal painful emotions, and make requests of one another to change behaviors. In effort to minimize risk of exposure to the virus that causes COVID-19, since the spring of 2020, therapy sessions will be conducted via telehealth, with a HIPAA-compliant audio/visual platform, and with couples at home or in another private place during the therapy sessions and the therapist in his or her office.
48110497|NCT04302844|BEHAVIORAL|Waitlist with Bibliotherapy followed by Workshop|"Participants assigned to this group will be asked to wait for 12 weeks before receiving any intervention, and will be given a relationship-focused self-help book to read, with exercises to practice, during that time. After 12 weeks and the 12-week assessment has been completed, couples will attend an educational workshop that provides the principles and communication skills of Imago Relationship Therapy, typically in a weekend format that is usually about 18-20 hours. The workshops, called Getting the Love You Want (GTLYW), are led by certified and experienced Imago workshop presenters, and are attended by a group of couples. The workshop includes presentations, discussions, and practice of communication exercises. Participation in the workshops will also be virtual or via telehealth, as described above."
48110498|NCT00012506|DRUG|TNFR:Fc|
48110499|NCT01288326|DRUG|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
48110500|NCT01576484|DRUG|Alirocumab|Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
48110501|NCT01576484|DRUG|Placebo Matched to Alirocumab|Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
48110502|NCT01113333|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
48110503|NCT01113333|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
48110504|NCT05184946|DRUG|Camrelizumab Combined with SOX|Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
48110505|NCT04332666|DRUG|Angiotensin 1-7|endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%
48110506|NCT04332666|DRUG|Placebos|infusion of NaCl 0.9% without diluted peptide in it
48110507|NCT01094405|BIOLOGICAL|Recombinant Epstein-Barr Virus (EBV) Vaccine|
48110508|NCT04504916|DRUG|Zilovertamab vedotin|Intravenous infusion
48110509|NCT03730922|PROCEDURE|Delayed-immediate reconstruction|Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.
48110510|NCT03730922|PROCEDURE|Delayed reconstruction|Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
48110511|NCT06512649|BEHAVIORAL|Early intervention|90-minute parent-coaching session once a week for 6 months with an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention. The intervention is individualized and tailored to each child's needs and identifies with caregivers the ways to embody objectives in daily life.
48110512|NCT06512649|BEHAVIORAL|Active monitoring|90-minute session once a month for 6 months. Sessions will be performed by an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention.
48110513|NCT03385967|DRUG|Dexmedetomidine|Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
48110514|NCT03385967|DRUG|ropivacaine|Standard of care 0.5%ropivacaine
48640542|NCT05156112|DEVICE|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
48640543|NCT05846230|DRUG|BI 1291583|Tablet
48640544|NCT05846230|DRUG|Placebo matching BI 1291583|Tablet
48640545|NCT04799119|BEHAVIORAL|Do As I Do (DAID) dog training|Children and their family dog will participate in this dog training program.
48640546|NCT02277366|PROCEDURE|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
48304151|NCT06691958|OTHER|Tortilla corn chips 90 grams|Snack
48304152|NCT06691958|OTHER|Extruded corn chips 90 grams|Snack
48304153|NCT06691958|OTHER|Extruded corn chips 4-5 pieces, eat one piece at time|Snack
48304154|NCT06625398|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
48304155|NCT06625398|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
48640547|NCT06147245|BEHAVIORAL|Person-centred culturally sensitive course of treatment|12-month person-centred and culturally sensitive intervention: Participants will attend 6 visits at SDCC including visits with a diabetes nurse, physician and dietitian. The course of treatment is focusing on extended time in consultations, use of technology for diabetes monitoring, meeting the same healthcare professionals, awareness of language barriers and use of accurate communication and dialogue tools in participants native language.
48304156|NCT06018831|OTHER|Urine and Ultrasound Screening|When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
48304157|NCT01259492|DRUG|Placebo|Placebo Comparator: Placebo
48304158|NCT01259492|DRUG|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
48304159|NCT01259492|DRUG|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
48304160|NCT06684769|DEVICE|Emdogain® FL|Enamel Matrix Derivatives
48304161|NCT06684769|DEVICE|Labrida BioClean®|Oscillating Chitosan Brush
48481392|NCT06236256|DEVICE|MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system|The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.
48110515|NCT01116180|DRUG|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
48110516|NCT01116180|DRUG|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
48304162|NCT06692829|PROCEDURE|robotic rehabilitation|In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.
48304163|NCT06692829|PROCEDURE|conventional rehabilitation|It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.
48304164|NCT05398003|DEVICE|Implantation of the WAVEWRITER ALPHA ™ device|"The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~* tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~* high frequency stimulation (1000 Hz) High Frequency.~* stimulation in bursts (or Burst)"
48304165|NCT04286867|OTHER|Alcohol Moderation Mobile Application|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
48640548|NCT06389695|DRUG|68Ga-NYM032 injection|The radiation dose is about 3-6 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM032 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
48640549|NCT01698905|DRUG|nilotinib|"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
48640550|NCT01725308|DRUG|FK949E|Taken by mouth (orally).
48640551|NCT01725308|DRUG|Placebo|Taken by mouth (orally).
48640552|NCT06695091|PROCEDURE|Monolithic zirconia crown|All-ceramic crown
48640553|NCT06695091|PROCEDURE|Monolithic lithium disilicate crown|All-ceramic crown
48640554|NCT05882214|DIETARY_SUPPLEMENT|β-nicotinamide Mononucleotide|After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.
48640555|NCT05882214|DIETARY_SUPPLEMENT|Maltodextrin|After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.
48640556|NCT06284798|DRUG|NNC0650-0013 A|NNC0650-0013 will be administered subcutaneously or intravenously.
48640557|NCT06284798|DRUG|Placebo|Subcutaneous administration.
48640558|NCT03368742|GENETIC|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
48304166|NCT04286867|BEHAVIORAL|Alcohol Moderation Drink Tracker|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
48304167|NCT05361980|DEVICE|Pediatric orthopaedic implant|Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
48304168|NCT06616298|OTHER|Assessing and Listening to Individual Goals and Needs (ALIGN)|Assessing and Listening to Individual Goals and Needs (ALIGN). ALIGN utilizes the skills of palliative care social workers (PCSWs) trained in family and systems-level theory to address changing preferences for care, family distress, and to facilitate communication across care transitions to improve care aligned with preferences.3 The intervention is implemented virtually in community SNFs and follows patients for 45 days after SNF discharge to reflect real-world patient flow.
48304169|NCT06476275|BIOLOGICAL|Influenza A/Texas/71/2017 (H3N2)|Virus will be administered intranasally
48304170|NCT06476275|BIOLOGICAL|Sham placebo|Placebo will be administered intranasally
48304171|NCT02512692|DEVICE|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
48304172|NCT02512692|DRUG|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
48304173|NCT02512692|DRUG|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
48481393|NCT06236256|OTHER|MDI/CSII|Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.
48481394|NCT05650424|OTHER|Abdominal massage training|please refer to group description
48481395|NCT06227351|PROCEDURE|completely limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed."
48481396|NCT06227351|PROCEDURE|Partially limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed."
48481397|NCT01865929|DEVICE|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
48481398|NCT01865929|PROCEDURE|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
48481399|NCT00003894|DRUG|thalidomide|
48481400|NCT04341259|DRUG|Ipatasertib|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
48481401|NCT00362817|DRUG|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
48481402|NCT00362817|DRUG|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
48481403|NCT03192852|OTHER|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
48110517|NCT03818204|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
48110518|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
48110519|NCT02079155|PROCEDURE|robot-assisted laparoscopic surgery|Undergo R-LESS RP
48481404|NCT03192852|PROCEDURE|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
48481405|NCT01344382|BEHAVIORAL|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
48481406|NCT01344382|BEHAVIORAL|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
48481407|NCT00537199|OTHER|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
48640559|NCT06694181|OTHER|AI-PERSONALIZED CLINICAL DECISION SUPPORT|AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
48640560|NCT06580743|OTHER|No intervention|This is an observational study
48110520|NCT02079155|OTHER|laboratory biomarker analysis|Correlative studies
48110521|NCT02079155|OTHER|quality-of-life assessment|Ancillary studies
48110522|NCT02079155|OTHER|questionnaire administration|Ancillary studies
48110523|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
48110524|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
48110525|NCT00600548|DRUG|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
48110526|NCT00600548|DRUG|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
48110527|NCT05949255|DIETARY_SUPPLEMENT|Probiotic|10 subject will receive a probiotic daily for 12 weeks.
48110528|NCT05949255|DIETARY_SUPPLEMENT|Placebo|10 subjects will receive a placebo daily for 12 weeks.
48110529|NCT00092937|DRUG|Busulfan|
48110530|NCT05112146|DIETARY_SUPPLEMENT|Whey protein isolate|Oral administration
48110531|NCT05112146|DIETARY_SUPPLEMENT|Whey protein microgel|Oral administration
48481408|NCT00537199|DRUG|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
48640561|NCT00965991|DRUG|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
48110532|NCT05112146|DIETARY_SUPPLEMENT|Water|Oral administration
48481409|NCT02620059|BEHAVIORAL|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
48481410|NCT03891329|DEVICE|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
48110533|NCT05153551|OTHER|Play-based assessment (RITA-T)|"The RITA-T is a play-based assessment that involves nine different activities that can be done safely with a child seated in the exam room. After scoring the RITA-T, the PEARS PCP will immediately provide feedback to the parent regarding results and next steps.~In addition, parents will complete certain assessments/surveys during the study to evaluate the program."
48110534|NCT00486759|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
48110535|NCT00486759|DRUG|Rituximab|Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
48640562|NCT00965991|DRUG|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
48640563|NCT04732221|DRUG|MK-5475|MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
48640564|NCT04732221|DRUG|Placebo to MK-5475|Placebo administered as dry powder inhalation
48640565|NCT05431127|DEVICE|IMT therapy using the Pr02 mobile device|Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
48640566|NCT05212935|BIOLOGICAL|Rotavirus Vaccine|administration of the 3 doses of Rotavirus human bovine pentavalent reassortant vaccine
48640567|NCT03375164|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
47957206|NCT05491109|DEVICE|Venous Assistance and Contracture Management System (VACOM)|Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
47980586|NCT06248892|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48304174|NCT06693804|OTHER|Digital Otoscope and Ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination and magnification during physical examinations.
48304175|NCT06693804|OTHER|Conventional otoscope and ophthalmoscope|The otoscope and ophthalmoscope will be used by residents to examine the eyes and ears under illumination during physical examinations.
48304176|NCT05307289|OTHER|Biposy|Biopsy at inclusion visit and at disease progression if applicable
48304177|NCT03890887|DRUG|BI 1291583|Tablet
48304178|NCT03890887|DRUG|Itraconazole|Oral solution
48304179|NCT04409795|DRUG|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
48481411|NCT03891329|DEVICE|Plexa S DX|Implantation, measurements and follow-up schedule
48481412|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate|1.2 g/kg/h
48481413|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
48481414|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
48481415|NCT05563818|OTHER|WinterLight Mobile Phone Speech Analysis|N/A- observational study
48481416|NCT00616044|PROCEDURE|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
48481417|NCT00616044|PROCEDURE|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
48640568|NCT04052555|DRUG|Berzosertib|Given IV
48304180|NCT04409795|DRUG|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
48304181|NCT06678516|DIETARY_SUPPLEMENT|Intermittent fasting|Participants are asked to abstain from any form of fasting or calorie restriction in one month of the study (which is also a pre-fasting washout for those volunteers that might be performing forms of fasting before the study) and then start with one month of intermittent fasting, with daily fasting duration from 7:30 to 18:30. Food is abstained from during fasting, only water and zero-calorie drinks like black coffee and unsweetened tea are allowed.
48339975|NCT04013165|BEHAVIORAL|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
48481418|NCT00616044|PROCEDURE|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
48481419|NCT04159181|OTHER|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
48481420|NCT04159181|OTHER|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
48481421|NCT04159181|OTHER|Placebo (water)|oral administration of Water (200mL).
48481422|NCT03040752|DRUG|Nifedipine 20 Mg|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
48640569|NCT04052555|PROCEDURE|Biospecimen Collection|Correlative studies
48640570|NCT04052555|OTHER|Quality-of-Life Assessment|Ancillary studies
48640571|NCT04052555|OTHER|Questionnaire Administration|Ancillary studies
48640572|NCT04052555|RADIATION|Radiation Therapy|Undergo RT
48640573|NCT05725655|OTHER|Thermotherapy|Hot baths directly after an exercise session
48640574|NCT06137482|DRUG|REGN13335|Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose
48640575|NCT06137482|DRUG|Matching Placebo|Administered IV or SC, sequential ascending single dose
48640576|NCT06145048|DRUG|VGT-309|Intravenous drug to be given over 15-20 minutes by syringe pump.
48640577|NCT03891953|DRUG|DKY709|Novel immunomodulatory agent
48640578|NCT03891953|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
48640579|NCT06254482|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
47957207|NCT04785092|PROCEDURE|All Autologous Cartilage Regeneration|All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
47957208|NCT00113503|DRUG|Azathioprine weight-based dose|
48304182|NCT06548022|BEHAVIORAL|Rare Group Problem Management Plus|The World Health Organization's Group Problem Management Plus (Group PM+) intervention has been demonstrated to effectively provide psychological help for adults impaired by distress in communities exposed to adversity. Investigators will test an adapted model for use on-line and with family caregivers of children with rare diseases. Managing Stress. Teaching participants a brief stress management strategy will help them better manage problems related to anxiety and stress. Managing Problems. This is a strategy to apply in situations where a participant is experiencing practical problems (e.g. conflict in the family). Get Going, Keep Doing. This strategy targets depression and inactivity. Strengthening Social Support. Individuals with emotional problems can be isolated from supportive people and organizations. Strengthening social support promotes well-being. Staying Well and Looking Forward. This is a review, ends with a closing ceremony.
48304183|NCT06684431|BIOLOGICAL|N-pVAX1|Crimean Congo Hemorrhagic Fever Vaccine
48640580|NCT04254250|DIAGNOSTIC_TEST|Preoperative risk estimation of disc herniation recurrence|Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
47957209|NCT00113503|DRUG|Azathioprine individualised dose|
47957210|NCT00645385|OTHER|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
47957211|NCT00115648|DRUG|Nevirapine|Oral NVP daily dosage
47957212|NCT00115648|DRUG|AZT|Oral AZT daily
47957213|NCT00115648|DRUG|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
48304184|NCT05838755|DRUG|GSK3858279|GSK3858279 will be administered
48304185|NCT05838755|DRUG|Placebo|Placebo will be administered
48304186|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS active|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Each treatment stimulates at a frequency of 20 Hz for 2 seconds, with a sequence interval of 20 seconds. Each treatment consists of 50 sequences, for a total of 2000 pulses.
48304187|NCT06692114|DEVICE|Deep Transcranial Magnetic Stimulation, DTMS sham|The treatment plan is to perform 2 treatments per day for 20 minutes each time, for a total of 28 treatments. Compared with active treatment, the sham stimulation coil only produced sound and scalp vibration.
48640581|NCT06496243|DRUG|obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks|10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks
48640582|NCT05253326|OTHER|Progressive Muscle Relaxation Exercises|It is among the relaxation techniques that require the active participation of the individual.
48640583|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed of POCT results for CT and NG|Molecular, PCR based near-POCT performed by the research assistant on self -collected urine. The outcome is positive or negative
47957214|NCT00115648|DRUG|NVP|Oral NVP daily to age 14 weeks
47957215|NCT00115648|DRUG|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
47957216|NCT00289016|DRUG|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
47957217|NCT01733784|OTHER|Induced central apneas|
47957218|NCT00335413|DRUG|Spironolactone|
47957219|NCT03005145|OTHER|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
48304188|NCT05661578|DRUG|Tiragolumab and Atezolizumab IV FDC|Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).
48481423|NCT03040752|DRUG|Ritodrine Oral Tablet|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
47957220|NCT03005145|OTHER|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
47957221|NCT05543967|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
47957222|NCT05543967|OTHER|Olfactory function measurements|Olfactory Threshold, Odor Identification Score, Odor Memory Score.
47957223|NCT05543967|OTHER|Functional magnetic resonance imaging|resting-state fMRI, odor-induced fMRI.
48640584|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed about POCT result for TV and BV|The pH of vaginal secretion is measured from a self-collected swab by the research assistant, and if above 4.5 a dropp of KOH is added. If it smells fishy, the whiff test is positive.
48640585|NCT05977491|OTHER|addressing psycholsocial problems|"1. Participants screening positive for anxiety, depression or domestic violence will be offered psychological counseling or referral to a crisis management center in the POCT-PLUS arm~2. All participants of the POCT-PLUS arm receive audio- visual and written education on vaginal discharge and antibiotics"
48640586|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)|0.25 mL per dose.
48110536|NCT00486759|DRUG|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
48640587|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)|0.5 mL per dose
48110537|NCT00486759|DRUG|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
48640588|NCT06642558|BIOLOGICAL|Placebo (Saline solution)|0.5 mL per dose
48640589|NCT05794906|DRUG|Darolutamide (BAY1841788, Nubeqa)|Coated tablet, 300 mg / tablet, oral.
48640590|NCT05794906|OTHER|Placebo matching darolutamide|Coated tablet, oral
48640591|NCT05794906|OTHER|ADT|Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists
48640592|NCT04253678|DRUG|Vortioxetine|Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
48481424|NCT00616174|PROCEDURE|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
48640593|NCT02226653|DRUG|Evacetrapib|Administered orally
48640594|NCT05030441|DRUG|Ivosidenib|. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
47957224|NCT06198283|OTHER|Low Level LASER Therapy with Pressure Garment|This group will be treated by low level laser therapy with pressure garment (8-10hrs a day) by Laplace' s Law method because it is more accurate since the range of pressures that can be delivered to a particular range of body circumferences varies depending on the fabric used and its particular tension- extension profile, the method is difficult to utilize manually and till present there is no available design tool to aid in its application. Pressure garments generate an increase in subdermal pressures in the range 9- 90 mmHg depending on the anatomical site. Garments over soft tissues generate pressures ranging from 9 to 33 mmHg. Over bony prominences the pressures range from 47 to 90 mmHg. 25mmHg pressure will be provided by garments and garments will be replaced in every 2 months
47957225|NCT06198283|OTHER|Low Level LASER Therapy without Pressure Garment|This group will receive low level LASER therapy (422-800nm) without pressure garment only for the duration of 6 weeks (3 days in a week with 20-30 minutes per session).
47957226|NCT06201520|PROCEDURE|manual acupuncture|manual acupuncture
47957227|NCT06201520|DEVICE|laser acupuncture|laser acupuncture therapy
48481425|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 1|Laparoscopic Hypo gastric Neural Plexus Block
48640595|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
48640596|NCT01260324|OTHER|No intervention given in this observational study|No intervention given in this observational study
48640597|NCT06649149|OTHER|Genially|In the study, an educational intervention will be prepared with the https://genially.com/ program, which is one of the interactive learning methods.
47957228|NCT06201520|DEVICE|sham laser acupuncture|sham laser acupuncture
47957229|NCT06201520|DEVICE|wrist splint|wear wrist splint at night
48481426|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 2|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
48481427|NCT00141661|DRUG|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
48481428|NCT00141661|DRUG|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
48481429|NCT00141661|DRUG|Placebo Comparator|Matching placebo.
48481430|NCT05026931|OTHER|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
47957230|NCT01635335|BEHAVIORAL|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
47957231|NCT00808990|DIETARY_SUPPLEMENT|BioFemale|BioFemale 6 months.
47957232|NCT03918148|DRUG|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
47957233|NCT03918148|DRUG|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
47957234|NCT05259358|OTHER|exercise|exercises that increase muscular endurance
48481431|NCT05026931|OTHER|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
48110538|NCT03417492|DRUG|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
48110539|NCT00002995|BIOLOGICAL|dactinomycin|
48110540|NCT00002995|BIOLOGICAL|filgrastim|
48110541|NCT00002995|BIOLOGICAL|sargramostim|
48481432|NCT01557582|DEVICE|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
48110542|NCT00002995|DRUG|cyclophosphamide|
48481433|NCT03614533|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
48481434|NCT03614533|BIOLOGICAL|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
48481435|NCT01290237|DRUG|vancomycin hydrocloride|see description of study arms
48481436|NCT02339610|DEVICE|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
48640598|NCT06649149|OTHER|Education|In the study, a case study prepared for the management of an aggressive individual will be discussed in a classroom environment.
47957235|NCT00305214|PROCEDURE|T Wave Alternans Test|
47957236|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
47957237|NCT02202837|DRUG|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
47957238|NCT03197454|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
47957239|NCT03197454|OTHER|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
48110543|NCT00002995|DRUG|vincristine sulfate|
48110544|NCT00002995|RADIATION|radiation therapy|
48110545|NCT04368858|DIAGNOSTIC_TEST|Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.|In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
48640599|NCT01707446|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
47957240|NCT00075218|DRUG|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
47957241|NCT00075218|DRUG|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
47957242|NCT01965821|DEVICE|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
48110546|NCT02104648|OTHER|Placebo RO4602522|Daily oral doses
48110547|NCT02104648|DRUG|RO4602522|Daily oral doses
47957243|NCT01965821|DEVICE|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
48110548|NCT02104648|DRUG|RO4602522|Single, oral dose
48110549|NCT02104648|DRUG|moxifloxacin|400 mg oral dose given on Day 1 or 11
48110550|NCT02104648|OTHER|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
48110551|NCT06228846|DRUG|YY001|Oral
48481437|NCT04762459|DRUG|Almonertinib|Almonertinib 110mg PO once daily
48481438|NCT04762459|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
48481439|NCT04762459|DRUG|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
48481440|NCT06198530|BEHAVIORAL|cognitive training in NLCs|In the nurse-led clinics(NLCs) training group, CCT was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time.
48481441|NCT06198530|BEHAVIORAL|cognitive training in home|In the home-based training group, CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system.
47957244|NCT03951155|BEHAVIORAL|Muscle Relaxation|"* Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~* Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~* Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~* Finally, ask him/her to notice how his/her muscles feel after the exercise."
47957245|NCT03400566|BEHAVIORAL|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
47957246|NCT03400566|BEHAVIORAL|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
47957247|NCT05964387|DEVICE|SDF|38% SDF will be applied to the hypoplastic area of the enrolled first permanent molar.
47957248|NCT05964387|DEVICE|Placebo|An inert liquid will be applied to the hypoplastic area of the enrolled first permanent molar.
47957249|NCT03063242|DRUG|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
47957250|NCT03063242|BIOLOGICAL|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
47957251|NCT01566734|OTHER|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
47957252|NCT01566734|OTHER|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
48110552|NCT04481373|BEHAVIORAL|THRIVE|"The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation).~Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes."
48110553|NCT04481373|OTHER|Treatment as Usual|Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
48110554|NCT02083029|PROCEDURE|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
48110555|NCT03856541|DRUG|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
48110556|NCT00035841|DRUG|TLK286|
48110557|NCT03300037|DEVICE|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
48304189|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy and Identity Exploration (HIP+EYME)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME.
47957253|NCT00539656|BIOLOGICAL|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
47957254|NCT02846714|BEHAVIORAL|FLARE|
47957255|NCT02609828|DRUG|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
48110558|NCT03697616|DEVICE|Ridge augmentation with sticky bone and GBR|"* Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~* Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~* Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~* For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~* Periosteal releasing incision will be done to provide flap advancement for tension free closure~* Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
48110559|NCT01097343|DRUG|clopidogrel 75 mg|75 mg once daily
48110560|NCT01097343|DRUG|Clopidogrel 150 mg|clopidogrel 150 mg
48481442|NCT06198530|BEHAVIORAL|cognitive training in tradition|In the traditional training group, the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed.
48640600|NCT01707446|OTHER|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of \< 75% from baseline is reached for \> 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
48640601|NCT02048813|DRUG|Cyclophosphamide|Given IV
48640602|NCT02048813|DRUG|Fludarabine Phosphate|Given IV
48640603|NCT02048813|DRUG|Ibrutinib|Given PO
48640604|NCT02048813|OTHER|Laboratory Biomarker Analysis|Correlative studies
47957256|NCT00963131|DRUG|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
47957257|NCT00386386|OTHER|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
47957258|NCT04689269|OTHER|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
48640605|NCT02048813|OTHER|Pharmacogenomic Study|Correlative studies
48640606|NCT02048813|OTHER|Quality-of-Life Assessment|Ancillary studies
48640607|NCT02048813|BIOLOGICAL|Rituximab|Given IV
48640608|NCT06438263|DRUG|Rocatinlimab|Vial supplied as a single-use preservative free solution for SC injection.
48640609|NCT06438263|DRUG|Rocatinlimab|Autoinjector for SC injection.
48640610|NCT04929028|PROCEDURE|Anoscopy|Undergo anoscopy
48640611|NCT04929028|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48640612|NCT04929028|DRUG|Capecitabine|Given PO
48640613|NCT04929028|PROCEDURE|Colonoscopy|Undergo colonoscopy
48640614|NCT04929028|PROCEDURE|Computed Tomography|Undergo CT or FDG PET/CT
48640615|NCT04929028|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
48640616|NCT04929028|PROCEDURE|Echocardiography|Undergo ECHO
48640617|NCT04929028|OTHER|Fludeoxyglucose F-18|Receive FDG
48640618|NCT04929028|DRUG|Fluorouracil|Given IV
48640619|NCT04929028|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48640620|NCT04929028|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
48640621|NCT04929028|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
48640622|NCT04929028|DRUG|Mitomycin|Given IV
48640623|NCT04929028|BIOLOGICAL|Nivolumab|Given IV
48640624|NCT04929028|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT or PET/MRI
48640625|NCT04929028|PROCEDURE|Proctoscopy|Undergo proctoscopy
48640626|NCT04929028|OTHER|Questionnaire Administration|Ancillary studies
48640627|NCT04929028|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
48640628|NCT05835973|OTHER|Sleep activity|"Actinography : Patient will wear actinometers on the wrist for 1 year continuously. In the study, MotionWatch 8 actimeters will be used, a class 1 medical device with CE mark (EN ISO 13485:2016 standard).~Ancillary study :~DREEM 3 headband : a subgroup of patients will wear the headband during 2 nights every 3 months."
48640629|NCT05835973|OTHER|Questionnaires|"The PSQI, EPWORTH, FACIT-F, ISI, and ICSD-3 questionnaires will be completed by patients every 3 months during their follow-up consultation according to the usual management.~The questionnaire by Horne and Ostberg will be completed by the patients only during the inclusion visit."
48640630|NCT06292299|DEVICE|Pneumowave|Pneumowave biosensor(s) will be be used to collect data from chest +/- abdominal movement and compared to standard clinical monitoring (e.g. CR-PSG)
48640631|NCT05554224|DIAGNOSTIC_TEST|To propose diagnostic tests for liver diseases before surgical decisions.|Observational although patients are candidates for metabolic surgery.
48640632|NCT04765384|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
48640633|NCT04404283|DRUG|Brentuximab vedotin|1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
48640634|NCT04404283|DRUG|Rituximab|375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
48640635|NCT04404283|DRUG|Lenalidomide|20 mg given by mouth (orally) daily
48640636|NCT04404283|OTHER|Placebo|Administered via intravenous infusion every 3 weeks
48640637|NCT05264675|PROCEDURE|primary suture|Primary suture of the EPL-tendon
48640638|NCT05264675|PROCEDURE|EIP-transfer|transfer of the EIP-tendon to the EPL-tendon
48640639|NCT06334211|DRUG|FP-020|MMP-12 inhibitor
48640640|NCT06334211|OTHER|placebo|placebo
48640641|NCT03162536|DRUG|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
48640642|NCT05348733|DRUG|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
48640643|NCT06321393|OTHER|7-week Core stabilization exercise with abdominal drawing-in maneuver technique|A 7-week core stabilization exercise with abdominal drawing-in maneuver technique consists of 2 stages, including the first stage (week 1-2) and the second stage (week 3-7) consisting of exercise program for 20-minute sessions with 3 sessions per week for 7 weeks. These exercise program will be provided to the participants via a weekly video call with the main researcher as a telerehabilitation program.
48640644|NCT06045754|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
48640645|NCT06045754|DRUG|Adalimumab|Adalimumab subcutaneous injection.
48640646|NCT06045754|DRUG|Ustekinumab|Ustekinumab intravenous infusion.
48640647|NCT06045754|DRUG|Ustekinumab|Ustekinumab subcutaneous injection.
48640648|NCT06567704|BEHAVIORAL|Interviews|Interviews
48640649|NCT06448143|DRUG|Indigotindisulfonate sodium 0.8% injection|Experimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
48640650|NCT05916313|DRUG|BI 764532|BI 764532
48640651|NCT02255383|DEVICE|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
48640652|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
48640653|NCT06258304|DRUG|GIGA-564|Administered by intravenous infusion
48640654|NCT03841617|DRUG|Thyrogen|intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
48640655|NCT03841617|RADIATION|I-131|therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated
48640656|NCT03841617|RADIATION|I-124|one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
48640657|NCT03841617|OTHER|Thyroid hormone withdrawal|withdrawal of thyroid hormone during weeks 4 through 8
48640658|NCT06296537|PROCEDURE|Dynamic Neuromuscular Stabilization Training (DNS)|Dynamic neuromuscular stabilization training has been developed, which optimizes the movement system based on the scientific principles of developmental kinesiology. DNS training aims to stimulate the natural movement control system in the brain to activate the body's stabilization system. Supine, prone, oblique sitting, tripod, high kneeling, hanging stance-midstance faze, hanging stance- propulsion, bear, squat exercises will be applied.
48304190|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy, Identity, and Geniotype Exploration (HIP+EYME+GENIOTYPE)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME. Also, participants will answer the Geniotype questionnaire and the results will be worked with the adolescents.
48304191|NCT06252311|BEHAVIORAL|Mindfulness-Based Breastfeeding Programme|Mindfulness-Based Breastfeeding Programme will consist of structure and anatomy of the breast and milk production, breast milk content, benefits of breast milk, breast care, frequency and duration of breastfeeding, correct and comfortable position for breastfeeding, effects of stress on lactation hormones and milk production, World Health Organization guidelines on duration and continuity of breastfeeding, time to start complementary feeding general information on recommendations, General information about breastfeeding with awareness, mentioning its purpose and programme flow, and it includes formal and informal practices such as breathing awareness exercises, noticing the autopilot, lying/sitting meditation, body scanning exercises and mindful breastfeeding practice.
48304192|NCT05218499|DRUG|Brigimadlin (BI 907828)|Brigimadlin (BI 907828)
48304193|NCT05218499|DRUG|Doxorubicin|doxorubicin
48304194|NCT03277170|DRUG|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
48304195|NCT04267562|DEVICE|Minitouch System|The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
48304196|NCT06688331|BIOLOGICAL|ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)|regulatory T cells with the phenotype CD3(+)CD4(+)CD25(high)CD127(-)doublet(-)lin(-)
48304197|NCT06688331|BIOLOGICAL|Anti-CD20 (rituximab)|rituximab
48304198|NCT06688331|OTHER|Placebo|intrevenous 0,9% NaCl
48304199|NCT06688331|OTHER|Treg sham|intrevenous 0,9% NaCl
48304200|NCT06625320|DRUG|RMC-6236|Oral Tablets
48481443|NCT06617377|OTHER|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).
48481444|NCT02788799|OTHER|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
48481445|NCT02788799|OTHER|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
48481446|NCT02870036|DRUG|Simmitecan|
48481447|NCT02870036|DRUG|5-fluorouracil and Leucovorin Calcium|
48481448|NCT02870036|DRUG|Thalidomide|
48481449|NCT00275275|DRUG|Requip PR|Requip 24-Hour once a day for one month
48481450|NCT00275275|DRUG|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
48481451|NCT06076369|PROCEDURE|The tubular adenoma group|Biopsy or removal of polyps for pathological examination. Collect baseline data such as gender, age, BMI, etc. If the pathology confirms a pure tubular adenoma, the observed object will be included in the group for final comparative analysis.
48481452|NCT02915926|BEHAVIORAL|occupational performance coaching|
48481453|NCT02915926|BEHAVIORAL|standard OT|
48640659|NCT06296537|PROCEDURE|Balance Training|Multi-plane single limb challenges, jumping and landing exercises, proprioceptive exercises, and perturbation exercises
48640660|NCT06296537|PROCEDURE|Conventional Training|Education, electrotherapy, soft tissue fascia massage, stretching, range of motion, strengthening and postural control exercises
48304201|NCT06625320|DRUG|Gemcitabine|intravenous (IV) infusion
48304202|NCT06625320|DRUG|nab-paclitaxel|IV infusion
48304203|NCT06625320|DRUG|Irinotecan|IV infusion
48304204|NCT06625320|DRUG|Liposomal irinotecan|IV infusion
48304205|NCT06625320|DRUG|5-fluorouracil|IV infusion
48304206|NCT06625320|DRUG|leucovorin|IV infusion
48304207|NCT06625320|DRUG|Oxaliplatin|IV infusion
48481454|NCT06463717|DRUG|Transplant, Autologous|High-dose melphalan followed by autologous stem cell transplantation
48481455|NCT06463717|DRUG|Chemotherapy drug|Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone
48481456|NCT00118378|DRUG|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
48481457|NCT00118378|DRUG|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
48481458|NCT02675959|DRUG|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
48481459|NCT02369120|OTHER|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
48481460|NCT02369120|OTHER|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
48481461|NCT02614963|DRUG|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
48481462|NCT02614963|DRUG|placebo|Irritable bowel syndrome patients treated with placebo
48110561|NCT06064357|OTHER|Transverese friction massage and tissue floss technique|"Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs. TFM on each group of muscle for 30 seconds, 3 sets with 10 seconds rest interval.4 session / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular group of muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be performed the rest interval is 2 mint. 4 sessions / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks."
48110562|NCT04091425|DRUG|TAK-925|TAK-925 IV infusion
48304208|NCT06226883|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
48304209|NCT06226883|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
48304210|NCT05005156|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)|All participants will receive two doses vaccine and will be followed to monitor vaccine candidate safety, immunogenicity, and efficacy for a duration of 52 weeks. Fifty four days after the first vaccination, all participants will receive a second injection.
48304211|NCT05465174|DRUG|Nivolumab|Given IV
48304212|NCT05465174|DRUG|Tovorafenib|Given orally
48304213|NCT06691984|DRUG|Xaluritamig|Short-term IV infusion
48304214|NCT06691984|DRUG|Abiraterone|Oral tablets
48304215|NCT06691984|DRUG|Enzalutamide|Oral tablets
48304216|NCT06691984|DRUG|Cabazitaxel|IV infusion
48304217|NCT06692023|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
48304218|NCT06692023|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
48304219|NCT06692335|PROCEDURE|High-Intensity Focused Ultrasound (HIFU)|The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W.
48304220|NCT06692335|PROCEDURE|myomectomy|Laparoscopic or open or hysteroscopic myomectomy will be performed.
48304221|NCT06692491|DRUG|Albumin-Bound Paclitaxel|Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.
48304222|NCT06692491|DRUG|Epirubicin|Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.
48304223|NCT06692491|DRUG|Gemcitabine|Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.
48304224|NCT06692491|DRUG|Vinorelbine|Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.
48304225|NCT06692491|DRUG|Cisplatin|Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.
48110563|NCT04091425|DRUG|Placebo|TAK-925 placebo-matching IV infusion
48481463|NCT01868282|PROCEDURE|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
48110564|NCT00867191|DRUG|Placebo|Placebo, 1 tablet daily, per os., 15 days
48110565|NCT00867191|DRUG|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
48110566|NCT04024631|OTHER|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
48110567|NCT04024631|OTHER|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
48304226|NCT06692491|DRUG|Irinotecan|Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.
48304227|NCT06692491|DRUG|Fluorouracil|Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
48110568|NCT02491554|DEVICE|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
47957259|NCT04689269|OTHER|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
48304228|NCT06692491|DRUG|Nivolumab|Nivolumab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with nivolumab under the guidance of MTB.
48304229|NCT06692491|DRUG|Pembrolizumab|Pembrolizumab 200mg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with pembrolizumab under the guidance of MTB.
47957260|NCT04689269|DEVICE|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
48110569|NCT02491554|DEVICE|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
48304230|NCT06692491|DRUG|Durvalumab|Durvalumab 10mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with durvalumab under the guidance of MTB.
48304231|NCT06692491|DRUG|Atezolizumab|Atezolizumab 1200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with atezolizumab under the guidance of MTB.
48304232|NCT06692491|DRUG|Sintilimab|Sintilimab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with sintilimab under the guidance of MTB.
48481464|NCT01868282|PROCEDURE|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
47957261|NCT04689269|DEVICE|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
47957262|NCT03766568|DEVICE|JGG endoscope(R)|The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
48110570|NCT02627183|PROCEDURE|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
48110571|NCT02627183|BEHAVIORAL|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
48110572|NCT03107403|BEHAVIORAL|web form|The scale assessing the bereavement process is the one reported in Teissier 2010
48110573|NCT04720014|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. an understanding of stress physiology and the physiology of the relaxation response;~2. a regular practice of eliciting the relaxation response; and~3. cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
48110574|NCT02458911|DEVICE|Paclitaxel-eluting balloon|
48110575|NCT06315049|OTHER|Music therapy|Music therapy sessions to reduce anxiety
48304233|NCT06692491|DRUG|Tislelizumab|Tislelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with tislelizumab under the guidance of MTB.
48304234|NCT06692491|DRUG|Camrelizumab|Camrelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with camrelizumab under the guidance of MTB.
48304235|NCT06692491|DRUG|Toripalimab|Toripalimab 240kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with toripalimab under the guidance of MTB.
48304236|NCT06692491|DRUG|Serplulimab|Serplulimab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with serplulimab under the guidance of MTB.
48110576|NCT04617652|DRUG|Magnesium sulfate|Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
48110577|NCT04617652|DRUG|Normal saline|Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
48110578|NCT04783246|BEHAVIORAL|Group Fitness|The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
48110579|NCT04783246|OTHER|Nutrition education|The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
48110580|NCT02042898|OTHER|Restrictive Transfusion Strategy|
48110581|NCT02042898|OTHER|Liberal transfusion strategy|
47957263|NCT06049953|DRUG|Antipsychotics|Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
48304237|NCT06692491|DRUG|Adebrelimab|Adebrelimab 20mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with adebrelimab under the guidance of MTB.
48304238|NCT06692491|DRUG|Envafolimab|Envafolimab 150mg,qw Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with envafolimab under the guidance of MTB.
48304239|NCT06692491|DRUG|Osimertinib|Osimertinib 80mg,qd Patients with advanced rare tumours who failed to standard treatment carrying EGFR mutations will be administrated with osimertinib under the guidance of MTB.
48304240|NCT06692491|DRUG|Alectinib|Alectinib 600mg,bid Patients with advanced rare tumours who failed to standard treatment carrying ALK fusion will be administrated with alectinib under the guidance of MTB.
48304241|NCT06692491|DRUG|Vemurafenib|Vemurafenib 960mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRAF V600E mutation will be administrated with vemurafenib under the guidance of MTB.
48304242|NCT06692491|DRUG|Pamiparib|Pamiparib 60mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRCA1/2 mutation will be administrated with pamiparib under the guidance of MTB.
48304243|NCT06692491|DRUG|Pyrotinib|Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.
48304244|NCT06692491|DRUG|Imatinib|Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.
48304245|NCT06692491|DRUG|Palbociclib|Palbociclib 125mg, 21/7 dosing schedule Patients with advanced rare tumours who failed to standard treatment following HR(+)/HER-2(-) will be administrated with palbociclib under the guidance of MTB.
48304246|NCT06692491|DRUG|Savolitinib|Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.
48304247|NCT06692491|DRUG|Entrectinib|Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.
48304248|NCT06692491|DRUG|Other|"Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments."
48304249|NCT06358430|DRUG|Fludarabine Phosphate|Given by IV
48304250|NCT06358430|DRUG|Cyclophosphamide|Given by IV
48304251|NCT06358430|DRUG|Cetuximab|Given by IV
48481465|NCT01868282|PROCEDURE|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
47957264|NCT06049953|DRUG|Non-antipsychotic medication|Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
47957265|NCT06049953|OTHER|No Medication|Non-psychotropic medications
47957266|NCT05490784|OTHER|Lee Silverman Voice Treatment BIG|Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.
47957267|NCT05490784|OTHER|conventional treatment|patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
47957268|NCT00239109|DRUG|Ziprasidone|
47957269|NCT00239109|DRUG|Olanzapine|
47957270|NCT00239109|PROCEDURE|Scales|
47957271|NCT00239109|PROCEDURE|measures of the body (Weight...)|
47957272|NCT00239109|PROCEDURE|Serum analysis|
47957273|NCT05487846|BEHAVIORAL|Patient Navigation|Receive peer navigation services
47957274|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
47957275|NCT05487846|OTHER|Survey Administration|Ancillary studies
47957276|NCT05487846|OTHER|Best Practice|Receive standard care
47957277|NCT05487846|OTHER|Genetic Counseling|Receive genetic counseling
47957278|NCT05487846|OTHER|Survey Administration|Ancillary studies
48304252|NCT06358430|DRUG|TROP2-CAR-NK Cells|Given by IV
48304253|NCT06358430|DRUG|Rimiducid (AP1903)|Given by IV
48304254|NCT06358430|PROCEDURE|Lymphodepleting Chemotherapy|Given by Chemotherapy
48304255|NCT06619509|DRUG|Brigimadlin|Brigimadlin
48304256|NCT06669676|OTHER|acupuncture|patients will be given acupuncture in addition to standard medical treatment to prevent ponv
48304257|NCT06669676|OTHER|No acupuncture|patients will be given standard medical treatment to prevent ponv
48304258|NCT01215734|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
48304259|NCT01215734|BIOLOGICAL|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
48481466|NCT00004988|DRUG|VNP20009|
48481467|NCT02153892|DEVICE|GDS Accucinch System|Percutaneous Coronary Intervention
48481468|NCT03443791|DIAGNOSTIC_TEST|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
48304260|NCT06674096|DRUG|RLC-CRCHOP|"Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11"
48304261|NCT04886804|DRUG|zongertinib|zongertinib
48304262|NCT02097706|DRUG|NMDA receptor antagonist (active drug)|
48481469|NCT03443791|DIAGNOSTIC_TEST|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
48481470|NCT03803033|OTHER|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
48481471|NCT01832402|DRUG|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
47957279|NCT04639167|BEHAVIORAL|Paths to everyday life (PEER)|The intervention consists of a 10-week group course and the opportunity of individual companionship to e.g. local activities in civil society, municipal social services, education, health and employment. The 10-week group sessions are delivered by two volunteer peers with their own experiential knowledge of mental vulnerability and mental health difficulties. The aim is to form a constructive community through group sessions where exchanges of lived experiences, mutuality and opportunities for social network development can develop.
47957280|NCT04912960|DEVICE|Mechanical ventilation|Optimum PEEP
47957281|NCT02479607|DEVICE|Smartphone or tablet|
47957282|NCT06436274|BIOLOGICAL|GARDASIL®9|GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
47957283|NCT06436274|BIOLOGICAL|Menveo®/Menactra®|Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
47957284|NCT03500575|DEVICE|photopheresis|• Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
47957285|NCT02270008|OTHER|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
47957286|NCT05661123|OTHER|Complete decongestive therapy|"1. Education.~2. Skin care .~3. Pneumatic compression device .~4. Manual lymph draining .~5. Multilayer short stretch compression bandages.~6. Exercises."
47957287|NCT04015492|BIOLOGICAL|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
47957288|NCT04015492|BIOLOGICAL|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
47957289|NCT01141452|DRUG|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
47957290|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
47957291|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
47957292|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
47957293|NCT01141452|DRUG|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
47957294|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
47957295|NCT02202980|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
47957296|NCT02202980|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
47957297|NCT02202980|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
48304263|NCT02097706|OTHER|Lactose packed capsule (inert/inactive arm)|
48304264|NCT06689956|OTHER|Non-Interventional Study|Non-Interventional Study
48304265|NCT05339464|OTHER|Family Wellness program|Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.
47957298|NCT02202980|DRUG|VOX|100 mg tablet administered orally once daily with food
47957299|NCT00214110|DRUG|Tamoxifen|
47957300|NCT02178085|OTHER|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
47957301|NCT05629078|DEVICE|Toric intraocular lens Zeiss AT TORBI|Intraocular lenses are medical devices that are implanted in patients during cataract surgery. At Plymouth University NHS trust the standard lens is a monofocal non-Toric lens unless the patient has astigmatism greater than 4.00D. This study involves implantation of a toric lens in the intervention group where astigmatism is greater than 1.00D. The lens is called the toric IOLS- Zeiss AT TORBI, will be implanted bilaterally instead of standard monofocal IOLs- Zeiss CT ASPHINA, used in routine cataract surgery within NHS.
47957302|NCT03892187|BEHAVIORAL|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
48304266|NCT06692790|OTHER|Venous Sinus Stenting Procedure|"Performed under general or local anesthesia. Targeted stenosis sites included the right transverse sinus, left transverse sinus, bilateral transverse sinuses, and right transverse and sigmoid sinuses.~Stents used included Venous Sinus Stent (CWS), CASPER, PRTCS, and multiple stents where necessary.~Post-procedure care included antiplatelet therapy and routine follow-up assessments"
48304267|NCT04971044|BEHAVIORAL|COACH|Multi-Level Behavioral Intervention
48304268|NCT04971044|BEHAVIORAL|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
48304269|NCT04099901|DRUG|Anakinra|Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
48304270|NCT04099901|DRUG|Placebos|Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
48481472|NCT01832402|DRUG|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
48481473|NCT01832402|OTHER|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
47957303|NCT00667407|DRUG|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
47957304|NCT00667407|DRUG|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"
48304271|NCT06530628|BEHAVIORAL|Adult patients resident in Pavillon C of the Pierre Garraud Hospital|"Adult patients resident in Pavillon C of the Pierre Garraud Hospital, aged over 70, polypathological, with or without undernutrition.~The intervention involves the diffusion of culinary odors using diffusers in the unit's hallways, 20 minutes before lunch, from Monday to Friday, for a period of three weeks.~This experiment will be repeated over 18 weeks (6 cycles), alternating meals without olfactory stimulation (cycles 1, 3 and 5) and meals with stimulation (cycles 2, 4 and 6).~The 3-week rhythm corresponds to the menu cycle proposed by the Unité Centrale de Production Alimentaire (UCPA). Thus, the menu will be the same whether or not it is associated with the diffusion of culinary scents."
48304272|NCT01429246|DIETARY_SUPPLEMENT|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
47957305|NCT04817631|OTHER|tuboovarian abscess|Evaluating the surgical and medical management of tuboovarian abscess
48304273|NCT01429246|DIETARY_SUPPLEMENT|Salt Substitute|Estimated 30 grams per day per household member
48304274|NCT04304495|OTHER|Fall Prevention|The intervention arm participants will receive a physical therapy and pharmacy consults as well as Apple Watch training and an Apple Watch device to test memory and mobility during the ED visit and during our home visits.
48481474|NCT01832402|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
48481475|NCT01832402|BEHAVIORAL|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
47957306|NCT01172522|DRUG|Fexofenadine|Fexofenadine 1%
47957307|NCT01172522|DRUG|Placebo|Placebo
47957308|NCT01705730|DRUG|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
47957309|NCT05686031|OTHER|No interventions were done between groups|No interventions were done between groups
47957310|NCT05363631|DRUG|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
47957311|NCT05363631|DRUG|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
47957312|NCT05363631|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy
47957313|NCT06049043|OTHER|Intervention to Help Orient Men to Excel (IN-HOME)|A multi module online training
47957314|NCT06049043|OTHER|"AARP's English Care at Home resource webpage"|Caregiver information from the American Association of Retired Persons
47957315|NCT06012474|OTHER|Power breath plus|Power breath plus use a variable load calibrated spring. It can be adjusted from the lowest load setting (17cmH2O) when training began and increased as the patient breathing muscles adapt and become stronger (maximum load setting 274cmH2O). Use a comfortable chair, preferably straight-back so that the spine is straight at all times during the exercise. patients will be instructed to exhale calmly, followed by a maximal forced inspiration to total lung capacity using a mouthpiece and a nasal clip as an aid to prevent air leaks and will ask to make 10 breaths for 3 sets once daily for 7 days with 2min rest between sets
47957316|NCT06012474|OTHER|Incrementing the training load|The resistance will be increased incrementally, based on the rate of perceived exertion (RPE) scored by the patient on the modified Borg Scale. If the RPE is less than 5, the resistance of the inspiratory trainer will be increased incrementally by 2cmH2O. The resistance will not change if the level of perceived exertion is rated from 6 to 8, and the resistance will be decreased by 1 to 2 cmH2O if the level of perceived exertion is rated 9 or 10.
47957317|NCT06012474|OTHER|Diaphragmatic breathing exercises|"Training by using incentive spirometer:~* Loosen any tight clothing, especially around neck.~* Each patient will be instructed to sit upright with placing incentive spirometer at the same level of his mouth to promote optimal lung expansion while using the spirometer.~* The patient will be instructed to exhale letting all the breath out.~* patient will asked to close the lips around the mouthpiece of the spirometer.~* patient will be instructed to inhale slowly, breathing in until unable to do any more, this would raise the balls to the top of the column.~* patient will be asked to hold the breath as long as possible (at least five seconds) then exhale slowly.~* Session will be in the form of 30 times in sets, each set consist of 5-6 repetitions with rest 1 minute between sets.~* Intensity of exercise will be increased by increasing time of session, time of holding the breath and numbers of repetitions according to patient's status."
47957318|NCT05501275|BEHAVIORAL|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
48304275|NCT06385262|DRUG|Alirocumab|300 mg subcutaneously every 4 weeks prior to surgery
48304276|NCT06385262|DRUG|Cemiplimab|350mg IV every 3 weeks prior to surgery
48304277|NCT06385262|DRUG|Chemotherapy|Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
48304278|NCT06669104|DEVICE|Medtronic Hugo™ surgical robotic system|undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system
48304279|NCT06600321|DRUG|ALN-BCAT|Administered by intravenous (IV) infusion
48304280|NCT06600321|DRUG|Pembrolizumab|Administered by intravenous (IV) infusion
48304281|NCT06351345|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of participant lung capacity (TLC).
48304283|NCT06689839|DEVICE|F2 Filter and Delivery System|Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure
48304284|NCT06689839|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device
47957319|NCT04521660|DEVICE|Virtual reality glasses|Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
47957320|NCT03499977|BEHAVIORAL|Sitting|10 min bouts
47957321|NCT03499977|BEHAVIORAL|Light-Intensity Cycling|10min bout
47957322|NCT03499977|BEHAVIORAL|Moderate-Intensity Cycling|10 min bout
47957323|NCT03499977|BEHAVIORAL|High-Intensity Cycling|10 min bout
47957324|NCT01132365|DEVICE|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
47957325|NCT00115635|DRUG|docetaxel|
47957326|NCT00115635|DRUG|gemcitabine|
47957327|NCT04282642|BEHAVIORAL|Cognitive Training|Participants (n=20) provided game console with cognitive training games and activities.
47957328|NCT04282642|BEHAVIORAL|WLC (Waitlist Control)|Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
48304285|NCT06692608|OTHER|strength training|Comparison between isometric and dynamic strength training in soccer players
48304286|NCT03183245|BIOLOGICAL|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
48481476|NCT06616350|DEVICE|esTOCma: an app to fight stigma associated with OCD|The intervention consists of playing a serious game, called esTOCma, on a mobile phone. In the game, players must use their knowledge to battle the stigma monster of OCD, complete 10 missions, and release 10 individuals who have been afflicted by the esTOCma monster, a creature that feeds on false beliefs and misinformation in society.
48481477|NCT06364332|BEHAVIORAL|Social Media campaign|Participants receive content three times a week; in total 24 pieces of content in 8 weeks. The content can consist of one or more photos or images with a caption (explanation in text).
48481478|NCT00588328|DEVICE|PET/CT scan|PET/CT scans
47957329|NCT01024335|DRUG|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
47957330|NCT01024335|DRUG|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
47957331|NCT05850065|OTHER|Hu-Friedy 212 clamp|Hu-Friedy 212 clamp is normally used for the retraction with rubber-dam
47957332|NCT05850065|OTHER|dental floss using the simple knot tie method|Dental floss using the simple knot tie method is normally used for the retraction with rubber-dam
48304287|NCT03183245|PROCEDURE|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
48304288|NCT03183245|OTHER|Hemodialysis|Procedure that filters a person's blood when their kidneys are no longer functioning properly
48304289|NCT05615597|PROCEDURE|Para-discal injection of corticoid|In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
48304290|NCT06693765|DRUG|AZD4144|AZD4144 will be administered orally.
48304291|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Additive-Manufactured Personalized Titanium Mesh|Preoperative CBCT datas of participants are obtained to design and manufacture personalized titanium meshes.Use additive-manufactured personalized titanium meshes for guided bone regeneration.In the bone grafting surgery, the additive-manufactured personalized titanium mesh is used to secure the bone substitutes, with fixation screws used to secure the titanium mesh.
47957333|NCT05850065|OTHER|Coltene B4 clamp|Coltene B4 clamp is normally used for the retraction with rubber-dam
48304292|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Prefabricated Titanium Mesh|In bone grafting surgery, prefabricated titanium mesh is used to fix the bone substitutes, and fixation screws are used to secure the titanium mesh.
48304293|NCT06692712|GENETIC|MELPIDA|Gene Therapy agent
48304294|NCT05093933|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
48304295|NCT05093933|DRUG|Placebo|0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
48304296|NCT06613841|DRUG|Fluciclovine F18|To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.
48304297|NCT06395948|DRUG|APG777|APG777 subcutaneous injection
48304298|NCT06395948|DRUG|Placebo|Matching placebo subcutaneous injection
47957334|NCT02587884|PROCEDURE|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
48304299|NCT06678347|BEHAVIORAL|Leadership for recovery|The intervention will be delivered as a group-based programme (6 sessions) to the managers of the included employees. The programme includes educative and reflective parts as well as various strategies promoting both managers' own recovery and the recovery of employees.
48304300|NCT06691672|DIAGNOSTIC_TEST|Robotic Tomographic ultrasound imaging of the arm vasculature.|Semi-autonomous robotic tomographic ultrasound imaging of the arm vasculature for vascular access creation mapping in CKD patients.
48304301|NCT06099717|DEVICE|Dual-cantilevered implant bridge|A 3-unit supported by one implant in the middle
48304302|NCT06099717|DEVICE|3-unit iFDP|3-unit fixed dental prosthesis supported by two implants
48304303|NCT06353945|DEVICE|vaginal moisturizer|vaginal moisturizer
48304304|NCT06618729|OTHER|Pea protein|Ingestion of a meal containing 40 g of protein from pea protein extrudate
48304305|NCT06618729|OTHER|Wheat protein|Ingestion of a meal containing 40 g of protein from wheat protein extrudate
48304306|NCT06618729|OTHER|Soy protein|Ingestion of a meal containing 40 g of protein from soy protein extrudate
48304307|NCT06618729|OTHER|Chicken|Ingestion of a meal containing 40 g of protein from chicken
48304308|NCT01723280|DRUG|Oxygen|During and 2 hrs after surgery
47957335|NCT03151343|DRUG|Empagliflozin|Empagliflozin tablet
48304309|NCT06693440|DRUG|PD-1 Inhibitors|Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
48304310|NCT05965739|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
48304311|NCT05965739|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
48304312|NCT05965739|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
48304313|NCT05965739|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
48304314|NCT05965739|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
47957336|NCT03151343|DRUG|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
48304315|NCT03566108|PROCEDURE|VISTA|Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
48304316|NCT03566108|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
48481479|NCT04574115|DEVICE|Omega Refractive Capsule with an FDA approved Intraocular Lens|Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
48481480|NCT04574115|DEVICE|FDA approved Intraocular Lens|FDA approved Intraocular Lens
47957337|NCT05265715|OTHER|Low AGE diet|"The recommended daily AGE intake will be either:~* 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or~* a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
47957338|NCT05265715|PROCEDURE|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
47957339|NCT03460275|DRUG|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
47957340|NCT02509481|DRUG|Ivermectin|
47957341|NCT02509481|DRUG|Albendazole|
47957342|NCT05766852|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
47957343|NCT01810861|OTHER|There is no intervention in this study|This is a non-interventional study.
47957344|NCT04930991|DRUG|Omeprazole|Treatment will consist of Omeprazole 2 weeks prior to surgical therapy of pancreatectomy.
48481481|NCT02990806|DRUG|NI-071|IV infusion.
48481482|NCT02990806|DRUG|Remicade|IV infusion.
48481483|NCT01198834|DRUG|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
48481484|NCT01198834|DRUG|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
48481485|NCT01198834|DRUG|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
48640661|NCT04305652|OTHER|The Progressively Lowered Stress Threshold Model|PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
48640662|NCT04579380|DRUG|tucatinib|300 mg orally twice daily
48640663|NCT04579380|DRUG|trastuzumab|Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
48640664|NCT04579380|DRUG|fulvestrant|Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
48640665|NCT03947827|DRUG|Minocycline|Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
48640666|NCT03266640|DRUG|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
48640667|NCT02363127|DRUG|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
48640668|NCT02363127|DRUG|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
48640669|NCT04614441|DRUG|OFEV®|nintedanib
48640670|NCT00976300|DRUG|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
48640671|NCT00976300|DRUG|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
48640672|NCT01742299|DRUG|imatinib mesylate|Imatinib will be provided as 100 mg and 400 mg tablets taken orally once daily unless other wise instructed by investigator
48640673|NCT05872945|DIAGNOSTIC_TEST|Electrocardiogram|Study by Artificial Intelligence the biosignal or biodata from profesional football players
48640674|NCT04566731|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.
48640675|NCT04566731|DEVICE|Sham tDCS|tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
48640676|NCT04566731|BEHAVIORAL|Modified Contraint-Induced Language Therapy (mCILT)|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
48640677|NCT03892915|COMBINATION_PRODUCT|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9\>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
48640678|NCT05217446|DRUG|Encorafenib|capsule
48640679|NCT05217446|BIOLOGICAL|Cetuximab|IV
48640680|NCT05217446|BIOLOGICAL|Pembrolizumab|IV
48640681|NCT00449800|DRUG|ceftriaxone|
48640682|NCT05007782|DRUG|GS-1811|Administered Intravenously
48640683|NCT05007782|DRUG|Zimberelimab|Administered Intravenously
48640684|NCT04796818|PROCEDURE|Diffusion Weighted Imaging|Undergo IVIM DWI
47957345|NCT01824875|DRUG|temozolomide|Given PO
48640685|NCT01725282|DRUG|quetiapine extended release (XR)|Extended release tablets
48640686|NCT01725282|DRUG|Placebo|matching tablets
48640687|NCT05916950|DEVICE|Thor laser atherectomy|Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
47957346|NCT01824875|DRUG|capecitabine|Given PO
47957347|NCT03643107|DRUG|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
47957348|NCT03643107|COMBINATION_PRODUCT|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
47957349|NCT00006111|DRUG|cisplatin|
47957350|NCT00006111|DRUG|fluorouracil|
47957351|NCT00006111|PROCEDURE|conventional surgery|
48110582|NCT05979324|DEVICE|ABAStroke Digital Therapeutics|The total time of the study is 30 weeks in total, i.e. 15 weeks of patient recruitment and then a maximum of another 15 weeks until the end of the observation of the last patient. Within 2 weeks from the last patient, the last Monitor's visit will be performed to close the study. The patient will use the ABAStroke application for a maximum of 91 days (the minimum time is 28 days) and standard therapy, including rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke).
48110583|NCT02068430|DRUG|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
48110584|NCT02068430|OTHER|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
48304317|NCT06693596|DIAGNOSTIC_TEST|Group 2: Conservative management (follow-up)|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the adnexal mass is seen and if the decision is to manage the adnexal mass conservatively, the patient will be re-scanned at 6 weeks (maximal range 6-8 weeks), 3 months (+/- 2 weeks) and 12 months (maximal range 10-14 months)"
48304318|NCT06693596|PROCEDURE|Group 1: Surgical management|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the patient requires surgery, no further ultrasound scans will be required."
48304319|NCT06692699|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
48304320|NCT06692699|DEVICE|A.R.R.E.S.T. spectacle film|A.R.R.E.S.T. spectacle film
48304321|NCT06693713|OTHER|Mental Health Youth Series|The Mental Health Youth Series is an eight-week program for youth ages 11-15 that uses games, short films, discussion questions, and exercises to engage with mental health and faith topics. The intervention package includes a facilitation guide and a guide for parents and caregivers. The program is intended to be conducted by an experienced facilitator, although there is no specific training provided for facilitators outside of the facilitation guide.
48304322|NCT06687278|BEHAVIORAL|Interpersonal Relationship Psychotherapy-Based Intervention Program|The Interpersonal Relationship Psychotherapy-Based Intervention Program is based on IPR and developed with reference to relevant literature and a previously published study (Cort et all., 2014). Following the development of the program, expert opinions were obtained from seven experts. The Interpersonal Relationship Psychotherapy-Based Intervention Program is a 2.5-3 month program comprising two individual and eight group sessions. Sessions will be held weekly, with each session lasting approximately 90 minutes.
48110585|NCT02737878|BEHAVIORAL|Aerobic Training|"Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
48640688|NCT06495554|DIAGNOSTIC_TEST|Measurement of circulating tumor-DNA|Liquid biopsies will be collected at baseline and prospectively during follow-up to measure circulating tumor-DNA.
48640689|NCT06495554|OTHER|Collection of patient-reported outcomes|Patient-reported outcomes will be collected at baseline and prospectively during follow-up.
48110586|NCT02737878|BEHAVIORAL|Resistance Training|"Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
47957352|NCT00006111|RADIATION|radiation therapy|
47957353|NCT00004431|DRUG|L-baclofen|
47957354|NCT02389985|DRUG|CRLX101|
47957355|NCT02389985|DRUG|Paclitaxel|
47957356|NCT04211181|OTHER|The multifaceted interventions|"1. An evidence-based clinical guideline and pathway in hospital.~2. A series Written care protocols for the implementation of performance measures.~3. A computer-based clinical decision support system(CDSSs) and a computerized reminder, which was referred to as a key element to enhance VTE assessment and prophylaxis. A well-designed computer program will be integrated into the Electronic Medical Record(EMR) of intervention group and By processing, analyzing, summarizing and representing crucial information, physicians can be altered.~4. A full-time quality coordinator~5. A trained physician or nurse in each intervention cluster will be acted as a quality coordinator. The responsibility of the quality coordinator includes:"
48304323|NCT04585945|DIAGNOSTIC_TEST|Positive for SARS-CoV-2 infection|Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
48304324|NCT06621472|OTHER|Retrolaminar block technique|patients will be placed in a sitting position. The transducer will be positioned vertically 3 cm lateral to the midline at the level of the 7th thoracic transverse process. The muscles of the back, the transverse process, and the pleura between two transverse processes will be visualized. The needle will be introduced in a cranial-caudal direction toward the lamina using the in-plane method until the tip lay in the lamina 1 mL of normal saline will be injected to confirm the correct needle tip position by visualizing the spread. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine. The procedure will be repeated on the opposite side.
48481486|NCT01198834|DRUG|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
48640690|NCT06495554|OTHER|Algorithmically determined telephone interview with a nurse|Dependent on the patient's responses on the patient-reported outcome measures.
48481487|NCT02220595|PROCEDURE|Carotid endarterectomy vs. carotid stenting|
47957357|NCT04211181|OTHER|Routine VTE prophylaxis|Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
48481488|NCT03692091|PROCEDURE|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
48481489|NCT00750048|DRUG|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
47957358|NCT04926142|DEVICE|Implantation of Holter device|Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
48481490|NCT02464488|OTHER|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
48481491|NCT02674386|DRUG|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
48481492|NCT01872845|DRUG|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
47957359|NCT04926142|PROCEDURE|Percutaneous PFO closure|Patients will undergo percutaneous closure of patent foramen ovale
47957360|NCT05577780|PROCEDURE|internal fixation|Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
47957361|NCT01130675|OTHER|caffeinated coffee|8 oz. of caffeinated cofee/breakfast\&noon meal. No intervention for 2nd arm.
47957362|NCT05520112|BIOLOGICAL|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
47957363|NCT05520112|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
47957364|NCT04075760|PROCEDURE|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
47957365|NCT04075760|DRUG|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
47957366|NCT03738033|OTHER|educational platform|The platform would be opened before they entered the study.
47957367|NCT05719376|DRUG|Monofer (experimental)|Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day
47957368|NCT05719376|DRUG|control group|Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
47957369|NCT06127615|DEVICE|ClearFit|Implantation of ClearFit Longeviti Craniectomy Cover
47957370|NCT04477889|OTHER|Treatment for COVID-19|Patients treated for COVID-19
48110587|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
48481493|NCT01872845|DRUG|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
48481494|NCT03678935|OTHER|Low FODMAP diet|The intervention group follows the low FODMAP diet for 4 weeks.
48481495|NCT04783194|DRUG|Dexamethasone+ Bupivacaine|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
48481496|NCT04783194|DRUG|Bupivacaine|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
48640691|NCT04544111|DRUG|Trametinib|"2mg by mouth daily~\*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube"
48640692|NCT04544111|DRUG|Dabrafenib|150 mg twice daily (OR at dose the patient previously tolerated)
48640693|NCT04544111|DRUG|PDR001|400mg IV every 4 weeks
48640694|NCT01585701|BIOLOGICAL|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
48304325|NCT06621472|OTHER|subcostal TAP technique|The transducer will be placed obliquely along the subcostal margin near the xiphisternum in the midline of the abdomen. The rectus abdominis muscle and underlying transversus abdominis muscle will be identified. The position of the transversus abdominis muscle will be confirmed by sliding the transducer laterally until the aponeuroses of the external and internal oblique muscle will be visualized. The transversus abdominis muscle will be then identified, being posterior to the internal oblique muscle and will be followed back medially to confirm its position beneath the rectus muscle. the needle will be introduced through the rectus muscle in a superomedial-to-inferolateral direction towards the transversus abdominis muscle using the in-plane method, and 20 mL of 0.25% isobaric bupivacaine will be injected
48304326|NCT06621472|OTHER|thoracic Epidural|Before induction of general anesthesia the epidural catheter was inserted under sterile condition with a loss of resistance technique by an 18G needle at a mid-thoracic level (Th 7-10) to cover the dermatomes innervating the incision in the upper abdomen. The epidural infusion consisting of bupivacaine 1 mg/mL, and fentanyl 2 μg/mL was activated on the attending anesthesiologist's decision. Following the hospital protocols, the infusion rate was initiated at 5-10 mL/h, increased to maximum 15 mL/h if necessary, bolus dose of 5 mL was allowed every 30 minutes.
48481497|NCT05307133|OTHER|Sleeve Gastreextomy|The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
48640695|NCT05793151|BEHAVIORAL|ENDURE|ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.
48640696|NCT06190249|BIOLOGICAL|LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-144), followed by IL-2.
48304329|NCT03930680|DRUG|Dexrazoxane|One dose of dexrazoxane
48481498|NCT04223778|DRUG|DOR/ISL|A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
48481499|NCT04223778|DRUG|ART|Baseline background ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
48481500|NCT05896969|DRUG|SNK-396 - SAD cohort|A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
48481501|NCT05896969|DRUG|SNK-396 - MAD Cohort|Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
48640697|NCT06190249|DRUG|Cyclophosphamide|Given by IV.
48640698|NCT06190249|DRUG|Mesna|Given by IV.
48640699|NCT06190249|DRUG|Fludarabine|Given by IV.
48640700|NCT06190249|BIOLOGICAL|Interleukin-2 (IL-2)|Given by IV.
48640701|NCT06190249|DRUG|Pembrolizumab|Given by IV.
48640702|NCT05236465|BEHAVIORAL|A 3-day course|The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
48640703|NCT05236465|BEHAVIORAL|Waiting list|Treatment as usual (TAU) in the first 10 weeks. After 10 weeks: Behavioural: A 3-day course. The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology.
48304330|NCT06692036|OTHER|Adaptive Blood Purification (ABP)|Patients in the intervention group, based on standard treatment, received two 6-hour adaptive blood purification (ABP) treatments within 24 hours after enrollment, that is, patients did not indicate renal replacement therapy (RRT), only coupled plasma filtration and adsorption (CPFA) therapy is used to adsorb inflammatory factors; for patients with acute kidney injury (AKI) and meeting RRT indications, CPFA+RRT (plasma filtration adsorption dialysis, PFAD) treatment is used.
47957371|NCT03668275|PROCEDURE|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
47957372|NCT04781023|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
47957373|NCT01955564|DRUG|NW-3509a|single dose
48304331|NCT04976634|DRUG|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
48304332|NCT04976634|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
48304333|NCT04976634|DRUG|Lenvatinib|Lenvantinib dose for HCC is 8 mg QD for body weight \<60 kg and 12 mg QD for body weight ≥ 60 kg administered via oral capsule. For all other tumors, the lenvatinib dose is 20 mg QD administered via oral capsule
48481502|NCT05044728|DRUG|Anti-PD-1 antibody combined with Paclitaxel and carboplatin.|"Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.~Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy."
47957374|NCT04139668|DRUG|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
48304334|NCT03077178|PROCEDURE|Geriatric assessment|Geriatric assessment, questionnaire assessment
48304335|NCT06127173|OTHER|Positive End Expiratory Pressure PEEP|children will receive different levels of PEEP during induction of anesthesia
48304336|NCT06692920|OTHER|DBS stimulation|"* Standard of care DBS surgery~* stimulation through the DBS lead during their DBS lead surgery, the study team will use 2 sets of stimulation settings on each participant:~  1. Stimulation through the DBS contact whose electrical activity is the MOST similar to the area of the brain that controls movement~ 2. Stimulation through the DBS contact whose electrical activity is the LEAST similar to the area of the brain that controls movement"
48304337|NCT06432465|DEVICE|tDCS|The anode will be placed over the right DLPFC (F4 on the EEG 10-20 system) and the cathode over the left DLPFC65 (F3) using 25cm2 sponges at an intensity of 2mA. Stimulation will be delivered via two saline-soaked surface sponge electrodes and a battery-driven, constant current stimulator (NeuroConn DC Stimulator Plus). This device includes a study mode, in which subject-specific codes are entered to deliver active or sham stimulation, keeping the administrator blinded. Sham stimulation will use a method in which stimulation will be ramped up and back down over a 30-second period at the beginning and end of sham tDCS.
48304338|NCT06320665|OTHER|Radiographic measurement|Measurements taken on 3D radiographs, to assess third molar inclusion and skeletal typology (vertical and sagittal)
48304339|NCT06687174|DRUG|MY008211A tablets|MY008211A BID
48304340|NCT06687174|DRUG|MY008211A tablets matched placebo|Matching placebo to MY008211A taken twice a day.
48304341|NCT02639182|DRUG|AGS-16C3F|Intravenous (IV) infusion
48481503|NCT05044728|PROCEDURE|Surgical treatment stage|After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
48481504|NCT04260321|DEVICE|AI|Artificial intelligence colonoscopy
48481505|NCT05251506|DEVICE|laser lancing device or lancet for blood glucose level measurement|Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
48640704|NCT06501365|OTHER|Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS)|"PIC-TRFS is a complex dyadic intervention consisting of 4 essential elements:~1. rehabilitation;~2. health and symptom management;~3. social support;~4. healthcare coordination~It is delivered by an interventionist team via telehealth from the time of randomization at discharge until 6 months after discharge. This Team partners with survivors, families, and the usual care team to deliver the active ingredients of PIC-TRFS."
48304342|NCT02639182|DRUG|Axitinib|Oral
48640705|NCT06501365|OTHER|Enhanced Usual Care Control|Dyads randomized to the Control group will receive: (1) the Run-In; (2) an informational brochure on the post-Intensive Care Syndrome; (3) ongoing assessments on the same schedule as the PIC-TRFS intervention; (4) referral for urgent emergent issues identified during the study
48640706|NCT03033576|BIOLOGICAL|Ipilimumab|Given IV
48640707|NCT03033576|BIOLOGICAL|Nivolumab|Given IV
48640708|NCT06238700|DIETARY_SUPPLEMENT|pregnenolone|Pregnenolone is an endogenous steroid available in the US and elsewhere as an orally administered over-the-counter supplement.
48640709|NCT06238700|OTHER|placebo|Placebo pills are identical-appearing capsules containing cellulose
48304343|NCT05769608|DRUG|Placebo|Placebo once daily for 12 weeks
48304344|NCT05769608|DRUG|lorundrostat Dose 1|lorundrostat Dose 1 once daily for 12 weeks
48304345|NCT05769608|DRUG|lorundrostat Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
48304346|NCT05965440|DRUG|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|Analysis of microbiota
48304347|NCT04165083|BIOLOGICAL|Pembrolizumab|IV infusion
48304348|NCT04165083|BIOLOGICAL|MK-4830|IV infusion
48304349|NCT04165083|BIOLOGICAL|MK-0482|IV infusion
48304350|NCT06675513|BIOLOGICAL|An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:|"Autologous WD-01 CAR-T therapy with Wondercel's Warrior armor strategy will be explored for its advantage over other armor platforms."
48304351|NCT06692569|OTHER|Conventional Physical Therapy|The conventional Physical Therapy, the treatment will be based on the client's capabilities. It included functional reeducation, muscle strengthening and stretching, muscle tone regulation methods, and training for activities of daily living
48304352|NCT06692569|OTHER|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy (mCIMT) which involves trunk constraint along with conventional Physical Therapy treatment. Under the attentive guidance of a physiotherapist, the patient engages in specific hand activities aligned with personalized goals. These activities encompass tasks such as picking up marbles, flipping cards, stacking blocks, combing hair, writing, and other actions relevant to daily life. The difficulty level is dynamically adjusted according to the patient's abilities and progress during the training sessions.Tasks may vary from one patient to another, and each session introduces fresh, goal-oriented challenges to further enhance rehabilitation outcomes, along with the conventional physical therapy treatment. The patients were wearing a trunk west which had a Velcro strap on the non-effected side part of the west, and it was attached to the Velcro straps on the non-affected part on the back support of the treatment chair.
48304353|NCT06692894|OTHER|Observational|Blood will be collected from one cohort to identify potential blood biomarkers.
48304354|NCT06315088|OTHER|Einkorn Diet|Analysis of the oral microbiota before (T0) and after (T2) introduction of einkorn into the diet by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
48304355|NCT06315088|OTHER|Intermediate oral microbiota|Comparison of the number of total bacteria and pathogens of the interdental microbiota before (T0) and in interim analysis (T1) for evaluation of the minimum period of effectiveness, by interdental sampling, on 4 sites, pooled then analyzed by bacterial PCR.
48304356|NCT06315088|OTHER|Periodontal health status|Analysis of the periodontal and oral clinical parameters (plaque index, gingival index, interdental inflammation, pocket depth and loss of clinical attachment, salivary pH) before (T0) and after (T2) introduction of einkorn into the diet, by sampling and periodontal analysis of all of the participants' teeth
48304357|NCT06315088|OTHER|General health status|Analysis of general health indicators (body mass index, measurement of abdominal circumference, blood pressure, MOS SF-36 quality of life questionnaire and eating habits) before (T0) and after (T2) introduction of einkorn in the diet
48304358|NCT03306615|DRUG|Hyaluronidase|HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
48304359|NCT03306615|DRUG|Placebo|0.9% Sodium Chloride Injection
48304360|NCT04258111|BIOLOGICAL|IBI310 (anti-CTLA-4 antibody)|Specified dose on specified days
48304361|NCT04258111|BIOLOGICAL|Sintilimab(anti-PD-1 antibody)|Specified dose on specified days
48304362|NCT06646692|BEHAVIORAL|Mindful Self Compassion|(MSC) is a mind-body integrative health intervention that utilizes meditations, other contemplative practices, home practices, and experiential exercises (including group discussions) to increase SC. MSC can be done in groups of 10-25. To increase feasibility of MSC for use in residential drug treatment facilities, we will aim to adapt MSC to 7 sessions (6 weekly sessions in alignment with the MSC short course plus the half day retreat included in the full course to facilitate skill consolidation). Sessions will be conducted in a group-based format: prior research found group-based formats equivalent to individual-level interventions for PTSD/SUD.
47957375|NCT04139668|BEHAVIORAL|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
47957376|NCT04014946|DEVICE|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
48481506|NCT06529939|DRUG|Psilocybin|"Individuals will be given 15 milligrams (mg) of psilocybin orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) brain scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
48304363|NCT06646692|BEHAVIORAL|Treatment as Usual (TAU)|"Selecting appropriate attention control groups for behavioral intervention research, particularly for mindfulness-based interventions, can be problematic. Comparator groups often also improve as they tend to target related mechanisms (e.g., social support, health behaviors, improved attention). After weighing the pros and cons, a treatment as usual (TAU) approach was selected, whereby the MSC will be compared to TAU. However, to control for the confound of weekly compensation, TAU participants will meet with study staff seven times over the 6-week period and fill out short psychosocial surveys on non-distressing topics (e.g., personality tests, attitudes surveys) in exchange for compensation commensurate with the MSC group. We believe this will also help with retention of the TAU group over time and strike an appropriate balance between controlling for the effects of study participation while minimizing confounds that often occur with active control groups in behavioral trials."
48304364|NCT06692764|DRUG|Placebo|0 mg (Placebo). Participants will receive bottles, with placebo tablets. Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose.
48304365|NCT06692764|DRUG|AZD0780|"Dose 1 Participants will receive three bottles, each containing 35 tablets:~* 1 bottle of dose a AZD0780 tablets~* 1 bottle of dose b AZD0780 tablets~* 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose."
48640710|NCT06695000|DEVICE|digital CBT-I|The intervention is a digital Cognitive Behavioral Therapy for Insomnia (CBT-I) program, delivered via a mobile application. The program includes structured, self-guided modules focusing on sleep hygiene education, cognitive restructuring, stimulus control, bed time restriction, and relaxation techniques. Each module offers interactive exercises and weekly assignments designed to support behavior change and improve sleep. Participants will receive app-based reminders to encourage regular engagement, with features for tracking progress and adherence throughout the 6 week program.
48304366|NCT06692478|BEHAVIORAL|Exercise regimen|"Age 4-6 years: Target lower extremity, core and upper extremity strengthening and activity tolerance. With supervision by the PT, the patient will walk in their room, and complete the following through play: squat, single leg stance, climb onto couch, half kneel to stand, quadruped and tall kneeling.~Age 7-21 years: First component will be strengthening exercises completed in bed or on a mat while sitting or standing. Multiple levels of exercises will be available, so that the program can be tailored to each patient and to their ability to perform activities. The exercises included will focus on core, hip musculature, and upper extremity strengthening; including exercises in quadruped and prone positioning, as well as supine, sitting and standing. Thera-Band will be used to increase resistance as needed. The second component will be endurance. Since the patients will be confined to their room this will include ambulation within the room, recumbent or pedal exerciser and step ups."
48304367|NCT03763643|DRUG|Rituximab|Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant
48304368|NCT03763643|PROCEDURE|Plasmapheresis|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
48304369|NCT06128564|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
48304370|NCT02858193|DRUG|SCMC-lys powder 1.35 g|"Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments."
48304371|NCT02858193|DRUG|Fluifort® syrup|"Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments."
48304372|NCT04246177|DRUG|Lenvatinib|Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.
48304373|NCT04246177|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).
48304374|NCT04246177|DRUG|Oral Placebo|Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.
48304375|NCT04246177|DRUG|IV Placebo|Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).
48640711|NCT05567172|DEVICE|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
48304376|NCT04246177|PROCEDURE|TACE|Conducted as a background procedure of chemotherapeutic and embolic agent(s).
48304377|NCT06625411|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
48304378|NCT06625411|DRUG|Placebo|All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
48304381|NCT06476184|DRUG|Carboplatin|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
47957377|NCT01706146|DRUG|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
48304382|NCT06476184|DRUG|Paclitaxel|"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy"
48304383|NCT04337450|DRUG|Dolutegravir (DTG) and lamivudine (3TC)|Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
48640712|NCT06694467|BEHAVIORAL|Education program|An official diabetes education program designed to provide people with diabetes and their families the information and abilities they need to manage their condition effectively. Diabetes kinds, blood sugar control, self-monitoring methods, nutrition, meal planning, physical activity recommendations, medication management, and problem-solving approaches are all included in these programs. Additionally, they offer psychological assistance to help people manage the emotional challenges of having diabetes.
47957378|NCT05334914|BEHAVIORAL|Acceptance Commitment Therapy|"ACT: Consists of 15 sessions, twice per week. Each session is approximately 2.5 hours including breaks. Clients cover 3 modules (OPEN, ACTIVE, AWARE). Any participant who requires access to a device for any part of the study will be provided with one for the duration of the study.~CM: Participants will be given progressive compensation for session attendance via gift cards or e-gift cards amounting to $520.~Motivation Building Session: The study clinician will meet with each of the participants to explain the process of the therapy, reinforce expectations, and address any concerns or hesitations, and build motivation and commitment to fully engage in the program.~ChillTime App Participants rate their emotional state and choose a coping strategy (either physical, emotional, cognitive or spiritual). The app's algorithm learns the individual's strategy preferences over time, allowing for more personalized suggestions. Participants are also able to access coping strategies ad hoc."
47957379|NCT05106387|OTHER|Noninterventional|No investigational treatment will be given in this noninterventional extension study
47957380|NCT02440971|DEVICE|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
48304384|NCT04337450|DRUG|SOC|2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
48304385|NCT06693167|PROCEDURE|chirurgie canal carpien|study compares a group of patients who received a preoperative auriculotherapy session followed by standard analgesic treatment to a group who received only standard analgesic treatment, and this, during the three days following surgery (D1, D2, and D3).
48304386|NCT03238235|DRUG|Givinostat|suspension of Givinostat (10 mg/mL)
48304387|NCT03238235|DRUG|Placebo|suspension manufactured to mimic Givinostat
48304388|NCT06693063|OTHER|Data collection|Some data will be collected for all patients included: medical and family history, chest pain data and medical care data
48304389|NCT06564844|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
48304390|NCT06564844|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
48304391|NCT06564844|DRUG|Carboplatin|Carboplatin IV (intravenous), Active Comparator
48304392|NCT06564844|DRUG|Cisplatin|Cisplatin IV (intravenous), Active Comparator
48304393|NCT06564844|DRUG|Etoposide|Etoposide IV (intravenous), Active Comparator
48304394|NCT06564844|DRUG|Pemetrexed|Pemetrexed IV (intravenous), Active Comparator
48304395|NCT06564844|DRUG|Vinorelbine|Vinorelbine IV (intravenous), Active Comparator
48304396|NCT06564844|DRUG|UFT|UFT Oral route of administration, Active Comparator
48304397|NCT05239897|DEVICE|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
48304398|NCT06693427|PROCEDURE|Peripheral Nerve Block|Femoral and Sciatic Nerve Blocks
48304399|NCT06692231|BEHAVIORAL|Pharmacist intervention|Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
48640713|NCT05857540|PROCEDURE|Plyometric and strengthening exercises|Each session includes 2 upper-extremity plyometric exercises in bodyweight or with weight ball for 15-20 minutes and 4-5 strengthening exercises with band, dumbbell or barbell for 30-35 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
48640714|NCT05857540|PROCEDURE|Strengthening exercise|Each session includes 5 upper-extremity strengthening exercises with band, dumbbell or barbell for 50 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
47957381|NCT05554588|PROCEDURE|Intrathrombus Thrombolysis During Primary PCI|Intrathrombus Thrombolysis During Primary PCI
47957382|NCT05554588|PROCEDURE|Aspiration Thrombectomy During Primary PCI|Aspiration Thrombectomy During Primary PCI
48304400|NCT04820452|BIOLOGICAL|Low dose IBI302|Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
48304401|NCT04820452|BIOLOGICAL|High dose IBI302|High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
48304402|NCT04820452|DRUG|Aflibercept|Intraocular injection
48304403|NCT06692634|OTHER|mechanical ventilation setting|VT reduction, EIP setting, RR reduction, and a new EIP programing.
48304404|NCT06693544|DIETARY_SUPPLEMENT|Peanut protein|Commercially available plant-based protein powders
48304405|NCT05419856|DRUG|4P-004|single intraarticular administration in the knee joint
48640715|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume whole-foods, fiber-rich diet
48304406|NCT05419856|DRUG|Placebo|single intraarticular administration in the knee joint
48640716|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
48640717|NCT03950635|OTHER|Questionnaire Administration|Ancillary studies
48304408|NCT04212494|PROCEDURE|Thrombus aspiration|Percutaneous Coronary Intervention with manual aspiration thrombectomy
48304409|NCT04212494|PROCEDURE|PCI Alone|Percutaneous Coronary Intervention without manual aspiration thrombectomy
48304410|NCT05994157|DRUG|CD38-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
48304411|NCT02994069|DRUG|Cisplatin|Cisplatin
48304412|NCT02994069|RADIATION|XRT|Radiation Therapy
48304413|NCT06625723|PROCEDURE|Standard postoperative care|This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.
48304414|NCT06625723|DEVICE|Surgical Recovery Systems Sleep Aid|Sleep assistive device
48304415|NCT04898829|DIETARY_SUPPLEMENT|PKU explore|"For 28 consecutive days, participants will take their usual restricted therapeutic diet, either:~- Replacing their usual second stage concentrated protein substitute with PKU explore~OR~- Commencing PKU explore and gradually reducing their Phe-free formula for infants."
48304416|NCT06691906|DRUG|Enlicitide decanoate|Oral tablet
48304417|NCT05130034|BEHAVIORAL|Home-based pulmonary rehabilitation|Home-based tablet-assisted pulmonary rehabilitation with monitoring technology and telephonic health coach calls using motivational interviewing techniques
48304418|NCT06693414|OTHER|Tailored health promotion education|14 weeks tailored education
48304419|NCT06693414|OTHER|Routine nursing education|14 weeks nursing education
48304420|NCT06692153|DEVICE|An AID System.|The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM
48304421|NCT06692153|OTHER|Standard of Care (SC)|Participants will continue to use their current therapy for T2D.
48304422|NCT05030467|BEHAVIORAL|REDUCE-BP Intervention|"Pre-visit:~Providers in the intervention arm will receive dashboards which will highlight racial/ethnic differences in rates of achieving blood pressure control within their patient panel. The dashboard will also provide individual-level information for patients with poorly controlled blood pressure.~During visit:~Providers will receive clinical decision support within relevant patients' charts that highlight the patient's under-treated blood pressure and potential impacts of social needs.~Providers will have the opportunity to provide enhanced patient education materials, which can be automatically ordered within the clinical decision support.~Post-visit:~Patient-subjects' access to the online patient portal will be streamlined by the inclusion of information about the patient portal in the patients' after-visit summary. Providers will also be able to referral patients automatically to nurse BP visits."
48481507|NCT06529939|OTHER|Placebo|"Individuals will be given a placebo orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
48304423|NCT06693206|OTHER|Evaluation of aerobic capacity|A stepwise protocol will be used in which the load increases gradually with the bicycle ergometer. In these protocols, the load increases continuously in small amounts throughout the exercise.
48304424|NCT06018129|BIOLOGICAL|GEN3017|Subcutaneous injection
48304425|NCT06580067|BEHAVIORAL|Pray Until Something Happens (PUSH)|Self-monitoring of outcomes + alerts/reminders + use of PUSH
48481508|NCT00384475|DRUG|Ciclesonide Nasal Spray|
48481509|NCT03810573|DEVICE|NB1|rhNELL-1/DBX
48481510|NCT03323060|DEVICE|Transanal endoscopic surgical procedure|Resection of tumors or lesions
48481511|NCT01978652|BIOLOGICAL|Peginterferon Beta-1a|As specified in the treatment arm
48481512|NCT00402025|BIOLOGICAL|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
48640718|NCT04949451|DIETARY_SUPPLEMENT|Whey protein supplement|Participants consume whey protein at the beginning of the eating period.
48640719|NCT04949451|DIETARY_SUPPLEMENT|Ketogenic aid|Participants consume ketogenic aid upon waking.
47957383|NCT02866916|DRUG|SXL01|Treatment will be administered continuously over 24h through the subcutaneous route.
47957384|NCT01363648|DRUG|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
48304426|NCT06580067|BEHAVIORAL|Self-monitoring|Self-monitoring of outcomes + alerts/reminder
48304427|NCT00483249|DEVICE|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
48304428|NCT06692842|DEVICE|CONEMO App|The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.
48304429|NCT06106828|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
48304430|NCT06106828|DRUG|Placebo|Placebo will be administered by SC injection
48304431|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
48304432|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
48304433|NCT05317416|DRUG|Lenalidomide|Immunomodulatory drug
48304434|NCT05317416|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
48304435|NCT06693102|BEHAVIORAL|Digital intervention targeting cancer-related cognitive impairments|The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.
48304436|NCT06693102|BEHAVIORAL|Crossword and sudoku taks|Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.
48304437|NCT06692738|DRUG|Rilvegostomig|Administered intravenously (IV) on Day 1 of each 21-day cycle
48304438|NCT06692738|DRUG|Pembrolizumab|Administered intravenously (IV) on Day 1 of each 21-day cycle
48304439|NCT06692738|DRUG|Carboplatin|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
48640720|NCT04949451|OTHER|Control group - time restricted feeding only|Time restricted feeding.
48640721|NCT02775851|PROCEDURE|Biopsy|Undergo tumor biopsy
48640722|NCT02775851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48640723|NCT02775851|PROCEDURE|Computed Tomography|Undergo CT scan
48640724|NCT02775851|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
48640725|NCT02775851|BIOLOGICAL|Pembrolizumab|Given IV
47957385|NCT01363648|DRUG|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
47957386|NCT03725137|OTHER|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding the development of cognitive function after stroke
47957387|NCT05879679|BEHAVIORAL|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
48304440|NCT06692738|DRUG|Paclitaxel|Administered intravenously (IV) on Day 1 of each 21-day cycle up to 4 cycles
48304441|NCT06692738|DRUG|Nab-paclitaxel|Administered intravenously (IV) on Days 1, 8, and 15 of each 21-day cycle up to 4 cycles
48640726|NCT02775851|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48640727|NCT02775851|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48640728|NCT03515304|DRUG|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
48640729|NCT03515304|DRUG|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
48640730|NCT04407117|BEHAVIORAL|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
48640731|NCT05966194|DRUG|RRx-001|RRx-001 for injection (4 mg or 8 mg)
48640732|NCT05966194|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy of up to 72 Gy
48640733|NCT05966194|DRUG|Cisplatin for injection 100 mg/m2|Cisplatin for injection 100 mg/m2
48640734|NCT04082442|DRUG|Evolocumab|420 mg evolocumab.
48640735|NCT04082442|DRUG|Placebos|Matching placebo.
47957388|NCT00246623|DRUG|Exubera (inhaled insulin)|
47957389|NCT00246623|PROCEDURE|8-point glucose diary (to assess pre- and post prandial glucoses)|
47957390|NCT00246623|PROCEDURE|Meal Tolerance Test|
48304442|NCT06692140|DEVICE|Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)|Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
48304443|NCT06692140|DEVICE|PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))|Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
48304444|NCT06693791|DRUG|Romiplostim N01|Romiplostim N01 was administered subcutaneously once weekly from +1 day to +28 days after UCBT at a recommended starting dose of 5µg/Kg (maximum single dose not to exceed 250µg) for a total of 4 administrations, with the option of continuation of dosing/switching/discontinuing after +28 days, depending on the patient's platelet profile.
48304445|NCT06682962|DEVICE|Transcorneal electrical stimulation (TES) with the OkuStim 2 System|Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.
48304446|NCT06693752|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
48304447|NCT05140525|DRUG|Macitentan Tablets|10 mg oral once daily
48304448|NCT05140525|DRUG|Riociguat|1 mg to 2.5mg oral three times daily
48640736|NCT01872754|DRUG|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
48640737|NCT01872754|DRUG|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
48640738|NCT05813834|PROCEDURE|Genicular Nerves Block|US guided genicular nerves block
48304449|NCT05140525|DEVICE|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
48304450|NCT06692179|DRUG|Orally administered preparation of fecal microbiota (MTP-101P)|As per standard of care, patients will receive MBP and OA the day prior to surgery as well as IV antibiotics at the time of surgery. MTP-101P will be given 48 hours after the administration of the dose of IV antibiotics to avoid the undesired bactericidal effects of antibiotics on the bacterial load from MTP-101P.
48304451|NCT03011372|DRUG|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
48304452|NCT03587038|DRUG|OKN 007|400 mg OKN-007/mL in a phosphate buffer
48304453|NCT03587038|DRUG|Temozolomide|75 mg/m2
48304454|NCT03587038|RADIATION|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
48304455|NCT06333015|DEVICE|enVista EY Beyond IOL|enVista Beyond Extended Depth of Focus (EDF) Intraocular Lens (IOL) Model EY
48304456|NCT06333015|DEVICE|enVista MX60E monofocal IOL|enVista MX60E monofocal IOL
48304457|NCT06473623|DEVICE|vagus nerve stimulation|Non-invasive Auricular Fiber Vagus Nerve Stimulation (afVNS)
48304458|NCT00608335|DRUG|Micafungin|IV
48304459|NCT06693635|DIAGNOSTIC_TEST|Implant planning|The implant planning will be carried out using various software programs. The AI assistance provided by each software will be evaluated.
48304460|NCT05728489|DRUG|BI 765250|BI 765250
48304461|NCT05728489|DRUG|Placebo|placebo
48304462|NCT05878938|DRUG|NNC0365-3769 (Mim8) PPX|Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
48304463|NCT03178149|DRUG|ASP7317|subretinal injection
48304464|NCT03178149|DRUG|tacrolimus|oral
48304465|NCT03178149|DRUG|trimethoprim-sulfamethoxazole|oral
48304466|NCT03178149|DRUG|Acyclovir|oral
48304467|NCT03178149|DRUG|Nystatin|oral
48304468|NCT06693700|OTHER|Indoor Air Quality Monitor AirGradient ONE|Participants will be asked to set up an Indoor Air Quality Monitor AirGradient ONE (Model: I-9PSL) which is an award winning commercially available indoor air quality monitor designed to enable anyone to monitor their air quality in their home for about 60 days (8 weeks). Indoor air pollution levels within participating households will be measured using these AQMs.
48304469|NCT05090124|DRUG|Adalimumab|Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
48304470|NCT05090124|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
48304471|NCT06693193|DEVICE|Immersive Virtual Reality|Individuals will participate in three VR sessions using Oculus headsets, experiencing virtual environments featuring realistic natural stimuli or custom settings tailored to their preferences and valued activities. Each environment allows for the adjustment of auditory elements (such as animal sounds, rustling wind, or specific music), visual elements (such as people, objects, or animals), and the time of day and weather conditions. The operator will use a user-friendly smartphone app to customize the environment, making real-time adjustments to settings and content. Throughout the VR experience, the operator can monitor the participant's visual focus in real-time.
48304472|NCT06219005|BEHAVIORAL|ultrasound education and simulation workshop|workshop testing emergency physician knowledge and technical skills in performing ultrasound-guided nerve blocks in a simulation model
48304473|NCT06693284|DRUG|mirdametinib and vorinostat|short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for the patient's specific tumor (typically localized radiation followed by surgical resection).
48304474|NCT06692595|DIAGNOSTIC_TEST|digital PCR|digital PCR quantification of subgingival plaque samples
48304475|NCT06683209|DIAGNOSTIC_TEST|Schocket scleral depressor|Use of this instrument to examine one eye
48304476|NCT06683209|DIAGNOSTIC_TEST|Josephberg-Besser|Use of this instrument to examine one eye
48304477|NCT06683209|DIAGNOSTIC_TEST|Cotton tip applicator|Use of this instrument to examine one eye
48304480|NCT06376916|DRUG|Magnesium Sulfate 2 G|Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
48304481|NCT06376916|DRUG|Magnesium Sulfate 4 G|Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
48304482|NCT06376916|DRUG|Saline|The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
47957391|NCT00246623|PROCEDURE|24-hour continuous glucose monitoring (at select sites)|
47957392|NCT00246623|PROCEDURE|Pulmonary Function Testing|
47957393|NCT00246623|PROCEDURE|Hypoglycemic Event Monitoring|
47957394|NCT00246623|PROCEDURE|Laboratory Assessments|
47957395|NCT00246623|BEHAVIORAL|Nutritional Counseling and Diabetes Education|
48304483|NCT05161351|DRUG|Baclofen|Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
48304484|NCT05161351|DRUG|Vitamin D3|Placebo tablets will be vitamin D3, (colecalciferol).
48304485|NCT05566678|OTHER|Cigarette|Subjects who self-selected to continue smoking their own preferred brand of commercially available cigarettes.
48304486|NCT05566678|OTHER|THS|Subjects who self-selected to quit smoking during the study duration will switch from cigarettes to using THS.
48304487|NCT05566678|OTHER|Smoking Abstinence|Subjects who self-selected to quit smoking may be prescribed Nicotine Replacement Therapy (NRT) to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
48304488|NCT06278987|DRUG|PENG block and cryoablation|will receive an ultrasound guided PENG block with 20 mL of 0.5% bupivacaine followed by cryoablation of the PENG nerves.
47957396|NCT01674114|PROCEDURE|TAP block|
47957397|NCT01674114|PROCEDURE|control|
47957398|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
47957399|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
48304489|NCT06278987|DRUG|fascia iliaca compartment block|will receive an ultrasound guided fascia iliaca compartment catheter with initial bolus of 20 mL of 0.5% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour
48304490|NCT05233631|PROCEDURE|Therapeutic Endoscopic ultrasound|A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
48481513|NCT03536182|RADIATION|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
48304491|NCT05454176|DEVICE|Libre 2|"The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level \<=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use."
47957400|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
47957401|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
47957402|NCT00761904|BEHAVIORAL|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
47957403|NCT06150482|OTHER|No intervention|No intervention
47957404|NCT00799383|DRUG|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
47957405|NCT00799383|OTHER|Placebo|
47957406|NCT03474861|BIOLOGICAL|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
47957407|NCT01414608|RADIATION|Brachytherapy|Undergo brachytherapy
47957408|NCT01414608|DRUG|Carboplatin|Given IV
47957409|NCT01414608|DRUG|Cisplatin|Given IV
47957410|NCT01414608|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
47957411|NCT01414608|DRUG|Paclitaxel|Given IV
47957412|NCT01414608|OTHER|Quality-of-Life Assessment|Ancillary studies
47957413|NCT02877134|DRUG|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
47957414|NCT02877134|DRUG|Placebo|Participants will receive placebo Subcutaneously.
47957415|NCT02877134|DRUG|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
47957416|NCT04966832|DRUG|XW10508|XW10508 capsules or tablets
47957417|NCT04966832|OTHER|Placebo|Placebo capsules or tablets
47957418|NCT04205981|OTHER|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
47957419|NCT03412760|DIAGNOSTIC_TEST|Exome sequencing|Expansive genetic test performed for affected fetus or neonate.
48304492|NCT05454176|DEVICE|Device for SMBG and Libre Pro|"A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group."
48304493|NCT06692621|DRUG|Oxytocin|Medicines were administered in appropriate doses
48304494|NCT06692621|DRUG|Carbetocin|Medicines were administered in appropriate doses
48304495|NCT06692348|DRUG|Orforglipron|Administered orally
48304496|NCT04702893|DRUG|Nintedanib|Nintedanib
48304497|NCT06693622|BEHAVIORAL|Patient survey|To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients.
48304498|NCT05529706|OTHER|Brain Health Program|The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
48304499|NCT05861258|DRUG|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
48304500|NCT05684159|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
48304501|NCT06281028|DEVICE|SOLACEA-H/HYDROLINK-NVU|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.
48304502|NCT06281028|DEVICE|HYDROLINK-NVU/SOLACEA-H|Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.
48640739|NCT04253171|DEVICE|Lithoplasty|"The lithoplasty balloon should be utilized as early as possible. If it is necessary for passage of the lithoplasty balloon, the lesion may first be predilated with an undersized conventional balloon, non-compliant or semi-compliant. If passage of the lithoplasty balloon is still not possible, it is recommended to perform rotational atherectomy with a small burr size.~The lithoplasty balloon is sized 1:1 to reference diameter. Lithoplasty is performed with the balloon dilated at 4 atmospheres, and 10 shocks are delivered, after which the balloon is expanded to 6 atmospheres for 30 seconds, and then deflated. Up to 8 series of balloon expansion/deflation can be delivered in this manner if necessary, and several balloons may be used for long lesions."
48640740|NCT04253171|DEVICE|Conventional|Lesion preparation is performed starting with conventional balloons, non-compliant or semi-compliant. Unless fully satisfactory dilatation is achieved with conventional balloons, it is recommended to also use modified balloons (scoring balloons, cutting balloons). If balloons cannot be passed or if dilatation is inadequate, the lesion may first be predilated with an undersized conventional, non-compliant, or semi-compliant balloon. If necessary, rotational atherectomy with a small burr size can be used to facilitate adequate balloon preparation.
48640741|NCT03256656|OTHER|electrical stimulation (non painful) of the lower urinary tract to determine the current perception threshold and record sensory evoked potentials|
48640742|NCT05524948|OTHER|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
48640743|NCT05524948|OTHER|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
48640744|NCT04860336|OTHER|Observational|Observational
48640745|NCT05909709|DRUG|Alocyte low dose|"Low dose containing 0.2 - 1.0 x 10\^11 particles and 3-10x10\^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used."
48640746|NCT05909709|DRUG|Alocyte medium dose|"Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used."
48640747|NCT05909709|DRUG|Alocyte high dose|"High dose containing 1.0 - 5.0 x 10\^11 particles and 15-50x10\^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used."
48640748|NCT05657652|DRUG|cladribine, cytarabine,venetoclax|Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
48304503|NCT05066997|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|"The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Stage 1: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
48304504|NCT05066997|DRUG|Vehicle|"The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Stage 1: Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
48304505|NCT05647811|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
48304506|NCT03037398|DEVICE|Vercise Deep Brain Stimulation System|
48304507|NCT05483816|COMBINATION_PRODUCT|VR+TENS|The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality
48640749|NCT03984461|BIOLOGICAL|Autologous cell therapy|Biologic material is harvested from the participant and re-injected into an osteoarthritic joint
48640750|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
48640751|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
47957420|NCT05656508|BIOLOGICAL|ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)|2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
47957421|NCT06558045|DRUG|Rivaroxaban 20 mg film-coated tablet|One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
48304508|NCT06692309|PROCEDURE|cardiovascular surgery|Heart bypass surgery; Heart valve replacement surgery
48304509|NCT04043507|OTHER|Sample Collection|Blood and urine samples will be collected for research purposes along with the routinely collected blood and urine samples that are collected as part of the standard of care.
47957422|NCT06558045|DRUG|Xarelto 20 mg film-coated tablet|One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
47957423|NCT01552993|DRUG|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
47957424|NCT01552993|DRUG|sucrose|pacifier and sucrose
48304510|NCT04286191|COMBINATION_PRODUCT|Operant Conditioning|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
48304511|NCT04286191|COMBINATION_PRODUCT|Control Group|This is the control intervention, or the non-conditioning group. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
48304512|NCT06564441|DRUG|Survodutide|Survodutide
48481514|NCT03536182|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
48481515|NCT02340221|DRUG|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
48481516|NCT02340221|DRUG|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
48304513|NCT06564441|DRUG|Bupropion|Bupropion
48481517|NCT02340221|DRUG|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
48640752|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
48640753|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
48640754|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
48640755|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.
48640756|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
48640757|NCT06169579|DRUG|ND-003 tablets|ND-003 tablets will be administered orally over continuous 28-days cycles.
48640758|NCT05471856|DRUG|BI 1703880|BI 1703880
48640759|NCT05471856|DRUG|Ezabenlimab|Ezabenlimab
48640760|NCT06107686|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
48640761|NCT05702047|BEHAVIORAL|Nose-only breathing|Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.
48640762|NCT05702047|BEHAVIORAL|Mouth-only breathing|Participants will breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
48640763|NCT04305054|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
48110588|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
48110589|NCT04466904|DRUG|IBI362|Administrated by subcutaneous injection
48640764|NCT04305054|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
48640765|NCT04305054|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
48640766|NCT04305054|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
48640767|NCT04305054|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a specified dose on specified days
48640768|NCT04305054|DRUG|ATRA|Administered via oral capsule at a specified dose on specified days
47957425|NCT03904173|DIAGNOSTIC_TEST|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
47957426|NCT06419738|BEHAVIORAL|Cognitive behavioral treatment (CBT)|Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.
48640769|NCT04876950|COMBINATION_PRODUCT|Virtual care with remote automated monitoring|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
48640770|NCT05556967|DRUG|Immulina|Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
48640771|NCT02662582|DRUG|Reldesemtiv|Oral tablet
48640772|NCT02662582|DRUG|Placebo|Oral tablet
48640773|NCT05136521|DRUG|Trazodone HCl - new polymer|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
48640774|NCT05136521|DRUG|Trazodone HCl - Contramid®|A single 300 mg dose of the test (T) and of the reference (R) products will be administered to the study subjects in two consecutive periods, according to a randomised 2-sequence cross-over design. A wash-out interval of at least 10 days will elapse between the two administrations. The two investigational products will be administered with 240 mL of still mineral water on day 1 of the two study periods, at 08:00±1 h after an overnight fasting.
48110590|NCT04466904|DRUG|Placebo|Administrated by subcutaneous injection
48110591|NCT04466904|DRUG|Dulaglutide|Administrated by subcutaneous injection
48110592|NCT02787941|BEHAVIORAL|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
48110593|NCT00868569|PROCEDURE|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
48304514|NCT06564441|DRUG|Caffeine|Caffeine
48640775|NCT05855551|OTHER|Base cash transfer|Program beneficiaries will receive a monthly transfer of 800 BDT. A government-to-person (G2P) payment system will be used, which will transfer cash on a monthly basis. Under this new system, beneficiaries will select one of the following payment channels based on convenience: mobile financial services or through a bank transfer (which women in remote areas could access through agent banking). Each month, women will receive a text message from the government informing her that the money has been credited to her account.
48640776|NCT05855551|BEHAVIORAL|Behavior change communication (BCC)|"The BCC strategy has two different components:~* Monthly courtyard meetings: Courtyard sessions (12 to 15 women) will be organized at a place no more than 15 to 20 minutes walking distance from the beneficiary's home. Family members (husband, mother-in-law, ...) are invited to join the meeting. Sessions are part of a continuous 4-session cycle. Each session will lasts 1.5 hours and will use different didactic methods. Topics include pregnancy nutrition and care, breastfeeding, importance of different micronutrients, and nutrition and care during lactation. The importance of a healthy diet during pregnancy is repeated in each session. Pregnant women receive a take-home poster that summarizes how to eat a healthy diet during pregnancy.~* Home visits: Visits will cover the content of any sessions missed by pregnant women and will reinforce the messages regarding maternal diet on the take-home poster."
47957427|NCT06419738|RADIATION|Low level laser therapy combined with CBT (LLLT+CBT)|LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.
47957428|NCT06419738|DEVICE|Occlusal Splint combined with CBT (OS+CBT)|Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks.In addition, patients are still instructed CBT as group 1.
48110594|NCT00868569|PROCEDURE|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
48110595|NCT05996588|DRUG|Propofol 1 % Injectable Suspension|Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously
48110596|NCT05996588|DRUG|Sevoflurane|Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25
48640777|NCT05855551|OTHER|Food basket|"The monthly food basket will provide 10 kg micronutrient fortified rice , 3.5 kg of lentils, and 1000 ml of oil, valued at 800 BDT . Assuming a the ration is split equally among the 5 members of an average-sized household in rural Bangladesh and using food composition data for Bangladesh, the food basket is estimated to provide 354 kcal and 11 g of protein per person per day. The food basket will be provided once every month.~The individually packaged foods will be distributed at the Union parishad office, community clinic, or another government facility in the first week of each month. The UDW will inform the beneficiaries of the place and time of the food distribution. Recipients will only receive the food when they present their food card. The card will also be used to record receipt of each ration. If beneficiaries cannot attend the food distribution themselves, a designated nominee can pick up the ration on their behalf."
48640778|NCT05855551|OTHER|Top-up cash|"The monthly top-up cash of 1,000 BDT will be added to the base amount that is part of the standard program. For the top-up cash transfer, a person-to-person payment system is used. WFP will contract with one popular mobile banking service (either bKash or Rockets) for the monthly top-up cash transfers. About two weeks after receiving the base cash transfer, women will receive the top-up cash through a mobile account (which can also be used to receive the base cash transfer). A text message will be sent to the beneficiary to inform her that the top-up transfer has been made into her account."
48640779|NCT01274338|BIOLOGICAL|Ipilimumab|Given IV
48110597|NCT01834248|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
48304515|NCT06564441|DRUG|Midazolam|Midazolam
48304516|NCT06692647|DRUG|MK-4318|Oral administration
48304517|NCT06692647|DRUG|Diltiazem|Oral administration
48640780|NCT01274338|OTHER|Quality-of-Life Assessment|Ancillary studies
48110598|NCT01834248|DRUG|Decitabine|Given IV
48110599|NCT01834248|OTHER|Laboratory Biomarker Analysis|Correlative studies
48110600|NCT01834248|DRUG|Poly ICLC|Given SC
48110601|NCT02434107|PROCEDURE|Completion Lymphadenectomy|
48110602|NCT02434107|PROCEDURE|Clinical Monitoring (Palpation and node ultrasound)|
48110603|NCT03302819|DIAGNOSTIC_TEST|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
48110604|NCT06030713|DRUG|Cefazolin|Cord clamping before or after antibiotic (cefazolin) prophylaxis
48304518|NCT06410209|OTHER|Goal Setting|Set physical activity goals
48304519|NCT06410209|OTHER|Interview|Participate in a one-on-one interview
48640781|NCT01274338|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
48640782|NCT05659251|COMBINATION_PRODUCT|Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy|Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.
48110605|NCT05368025|DEVICE|Mobili-T/Noona|Use of two mobile health systems over a period of 6 months
48304520|NCT06410209|OTHER|Interview|Ancillary studies
48304521|NCT06410209|OTHER|Media Intervention|View private social media peer support group content
48304522|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit physical activity tracker
48304523|NCT06410209|OTHER|Medical Device Usage and Evaluation|Wear a research grade activity measuring device
48304524|NCT06410209|OTHER|Questionnaire Administration|Ancillary studies
48304525|NCT06410209|OTHER|Reward|Receive badges
48304526|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive text messages
48304527|NCT06410209|OTHER|Text Message-Based Navigation Intervention|Receive reminders
48304528|NCT06693505|COMBINATION_PRODUCT|caffeinated chewing gum|two pieces of caffeinated chewing gum at an absolute dose of 200 mg (Military Energy Gum®, Ford Gum and Machine Go, Akron, NY, USA)
48304529|NCT06693505|COMBINATION_PRODUCT|placebo|two pieces of similar looking and tasting placebo gum that did not contain caffeine (xylitol, lime mint, green; Lotte, Saitama, Japan) (PLA trial)
48304530|NCT06692400|PROCEDURE|endotracheal tube suctioning|Endotracheal tube suctioning occurs as part of normal care for intubated patients. This procedure will serve as the painful procedure to assess CPOT and biomarkers of hypoxia and oxidative stress.
47957429|NCT02646514|DEVICE|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
47957430|NCT02646514|DEVICE|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
48304531|NCT05943327|DRUG|Lu AG06474|Oral Solution
48304532|NCT05943327|DRUG|Placebo|Oral Solution
47957431|NCT04755153|OTHER|Practice Facilitation|Tailored interventions provided by a trained Practice Facilitator
47957432|NCT04755153|OTHER|Non-Practice Facilitation|Implementation support without using Practice Facilitation
47957433|NCT03506789|DRUG|Dexamethasone|Dexamethasone 24 mg
47957434|NCT03506789|DRUG|Placebos|Isotonic saline
47957435|NCT01253473|DRUG|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
47957436|NCT01253473|DRUG|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
47957437|NCT01253473|DRUG|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
47957438|NCT00344708|PROCEDURE|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
47957439|NCT05815641|DIETARY_SUPPLEMENT|food (breakfast)|The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds
47957440|NCT05325060|DEVICE|Electromagnetically navigated total knee arthroplasty|The navigated group had surgery using the iNav portable EM navigation system (Zimmer GmbH, Winterthur, Switzerland and Medtronic, Minneapolis, MN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
47957441|NCT05325060|DEVICE|Conventional total knee arthroplasty|The conventional group received surgery using conventional instrumentation and jigs from the implant manufacturer (Zimmer Inc, Warsaw, IN, USA) and the definitive implant used was NexGen LPS implant (Zimmer Inc, Warsaw, IN, USA), a fixed-bearing bicruciate-sacrificing total condylar implant using traditional instrumentation with no patellar resurfacing
47957442|NCT04137029|DRUG|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
47957443|NCT04137029|DRUG|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
47957444|NCT04137029|DIAGNOSTIC_TEST|metacholine test|The participants will receive inhalation of metacholine once
47957445|NCT02847975|DIETARY_SUPPLEMENT|Sodium nitrate|Sodium nitrate will be ingested orally
47957446|NCT03027102|BIOLOGICAL|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
47957447|NCT03166007|BEHAVIORAL|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
48304533|NCT05943327|DRUG|Lu AG06474|Capsule
48304534|NCT06451380|PROCEDURE|orthopaedic surgery|orthopaedic surgery of the upper limb under anaesthesia
47957448|NCT03166007|BEHAVIORAL|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
48304535|NCT06451380|DRUG|propofol anesthesia|The initial dose of propofol and the refractory period will be determined according to a standardized protocol used in current practice.
48304536|NCT05155059|DEVICE|MagStim|Bursts of three at 50Hz with an inter burst interval of 200 ms will be given for 190 seconds and this session will be repeated 3 times with 20 minutes between each session in one day. The set of 3 sessions will be repeated 5 times in 5 consecutive days.
48304537|NCT05155059|OTHER|Sham Comparator|Sham TMS stimulation using a sham coil
47957449|NCT02566447|DEVICE|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
48304538|NCT05346393|PROCEDURE|TIPS|A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
47957450|NCT02815410|DRUG|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
47957451|NCT02084693|DEVICE|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
47957452|NCT02206542|DEVICE|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
47957453|NCT02206542|OTHER|Physical therapy|
47957454|NCT02206542|DEVICE|Electroacupuncture|
47957455|NCT01128556|DRUG|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
47957456|NCT01128556|DRUG|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
47957457|NCT05704062|PROCEDURE|Diffusion Weighted Imaging|Undergo DW-MRI
47957458|NCT05704062|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
47957459|NCT02236403|DRUG|Ivermectin 0.1% Metronidazole 1%|
47957460|NCT02236403|OTHER|None intervention|Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
47957461|NCT04520412|DRUG|GV-971|Administered PO
47957462|NCT04520412|DRUG|Placebo|Administered PO
47957463|NCT06557980|OTHER|toothpaste|group of patients with hypersensitive areas will use the calcium silicate toothpaste twice per day (morning and bedtime) the toothpaste will be applied uniformly using medium toothbrush to the hypersensitive surfaces for 30seconds. After that, the patient will rinse their mouth with plain water. the other group of patients will use the sodium fluoride toothpaste twice per day (morning and bedtime). The toothpaste will be applied uniformly using a medium toothbrush to the hypersensitive areas for 30 seconds after that the patients will rinse their mouth with plain water
47957464|NCT06232694|DRUG|Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;|Induction Phase Regimen
48304539|NCT05346393|DRUG|Standard of Care|Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
47957465|NCT06232694|DRUG|Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;|Consolidation therapy after remission
47957466|NCT06232694|OTHER|utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).|Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
47957467|NCT03974243|DRUG|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
48304540|NCT06692075|PROCEDURE|extracorporeal life support|ECMO supported life support for cardiopulmonary resuscitation in refractory OHCA
48304541|NCT06692075|PROCEDURE|standard ACLS|Standard ACLS in cardioplumonary resuscitation of refractory OHCA
48304542|NCT06250283|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol (500 mg)
48304543|NCT06250283|DIETARY_SUPPLEMENT|Placebo|Placebo (500 mg)
48304544|NCT06692933|DRUG|Cannabidiol in the form of hemp|Cannabidiol (30 mg) in the form of an orally administered hemp oil softgel
48304545|NCT06692933|DRUG|Clopidogrel|75 mg oral clopidogrel
48304546|NCT06062368|BEHAVIORAL|Rate of Entry|The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
47957468|NCT03974243|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
47957469|NCT05433012|DEVICE|Ultrahigh Field MRI at 7T|Assessment of the micro-anatomy of the menisci and cartilage in patients with presumed Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T
47957470|NCT02168361|DRUG|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
47957471|NCT02168361|DRUG|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
47957472|NCT02168361|DRUG|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
47957473|NCT02168361|DRUG|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
47957474|NCT02836392|BEHAVIORAL|Questionnaire|
47957475|NCT01741090|BIOLOGICAL|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
47957476|NCT06556381|PROCEDURE|TAP block|Women will receive TAP block.
48304547|NCT05467891|DRUG|Ribociclib|400 mg orally once daily Days 1-21 (28 day Cycle)
48304548|NCT05467891|DRUG|Fulvestrant|500 mg intramuscularly on Day 1 and 15 of Cycle 1 then Day 1 of Cycle 2+
48304549|NCT05467891|DRUG|Anastrozole|1 mg orally once daily
48304550|NCT05467891|DRUG|Letrozole|2.5 mg orally once daily
48304551|NCT05467891|DRUG|Exemestane|25 mg orally once daily
48304552|NCT04033445|DRUG|Placebo|Participants will receive matching placebo IV or SC.
48304553|NCT04033445|DRUG|Guselkumab|Participants will receive guselkumab IV or SC.
48304554|NCT01737619|PROCEDURE|Computed Tomography|Undergo PET/CT
48304555|NCT01737619|DRUG|Indocyanine Green Solution|Given via superficial and deep cervical injection
48110606|NCT05271188|PROCEDURE|Infiltration of local anaesthetic between popliteal artery and posterior knee capsule|Adductor canal block (ACB) is a popular peripheral nerve block that has been shown to decrease pain significantly and thereby opioid consumption with minimal effect on quadriceps function \[8\]. Though ACB provides analgesia to the peripatellar and intra-articular aspect of knee joint, it does not relieve posterior knee pain which is moderate to severe in intensity \[9, 10\]. The recent technique of an ultrasound (US)-guided local anesthetic infiltration of the interspace between popliteal artery and the capsule of posterior knee (IPACK) has shown to provide significant posterior knee analgesia without affecting the common peroneal nerve (CPN) \[11\]. We postulated that IPACK will provide better pain relief and improve knee function in the immediate postoperative period compared to ACB
48304556|NCT01737619|OTHER|Laboratory Biomarker Analysis|Correlative studies
48304557|NCT01737619|PROCEDURE|Lymph Node Mapping|Undergo lymph node mapping
48304558|NCT01737619|PROCEDURE|Lymphadenectomy|Undergo full lymphadenectomy
48304559|NCT01737619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48304561|NCT06639347|DRUG|SHR-A2102|SHR-A2102
48304562|NCT06639347|DRUG|Adebrelimab injection|Adebrelimab injection
48304563|NCT06639347|DRUG|SHR-8068 injection|SHR-8068 injection
48640783|NCT05659251|PROCEDURE|Esophagectomy|"Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.~The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon."
48640784|NCT05659251|OTHER|sample|"Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.~5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.~Tumour sample will be collected before neoadjuvant therapy and after surgery."
48304564|NCT06693115|DEVICE|CGM with alerts|"CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels (indicated by double down arrow on Dexcom 7)~2. CGM alerts to interstitial glucose level of 150 mg/dL or less."
48304565|NCT05972551|DRUG|Romosozumab|Subcutaneous (SC) injection
48304566|NCT05972551|DRUG|Bisphosphonate|Administration determined by investigator according to the local standard of care
48304567|NCT06693531|DRUG|dupilumab|No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
48304568|NCT06693089|OTHER|MIT-ED|The aim is to develop healthier strategies for managing negative thoughts and feelings linked to Eating Disorder (ED) and engage patients in social interactions that fulfill their relational needs. Participants will learn that perfectionism and the need for control in ED are coping strategies shaped by interpersonal patterns with significant others, where low self-esteem and emotional dysregulation play key roles. Metacognitive Intepersonal Therapy (MIT) aims to improve individuals' ability to understand their own emotions and thoughts, recognizing maladaptive, rigid, and biased schemas about self and others. This awareness helps them form a richer understanding of others' minds and use this knowledge to respond more adaptively to social challenges. MIT also helps individuals reflect on how these schemas trigger ED behaviors and develop better coping strategies for interpersonal stressors.
48304569|NCT06692816|OTHER|Rehabilitation|As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
48304570|NCT06693453|OTHER|Electroacupuncture and Dry cupping|This group will perform electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
48110607|NCT00367991|DRUG|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
48304571|NCT06693453|OTHER|Electroacupuncture and Sham Dry cupping|This group will perform Electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and Sham Dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
48304572|NCT05226598|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
48304573|NCT05226598|DRUG|Carboplatin|Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
48640785|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg QD hard capsules
48640786|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg BID hard capsules
48640787|NCT03874858|DRUG|Asciminib|Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
48110608|NCT00367991|DRUG|Placebo|Normal saline to match active drug (rHuEpo)
48110609|NCT06513234|DRUG|Orelabrutinib and obinutuzumab|Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg
48110610|NCT04707430|OTHER|blood progesterone test|progesterone levels on blood sample
48110611|NCT04275778|DRUG|Plaquenil 200Mg Tablet|Hydroxychloroquine will be taken at a dosage of 400 mg / day until delivery
48110612|NCT04275778|DRUG|Placebo oral tablet|placebo will be taken at a dosage of 400 mg / day until delivery
48110613|NCT00771446|BIOLOGICAL|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
48110614|NCT00771446|OTHER|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
48110615|NCT00317226|DRUG|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
48110616|NCT01829386|OTHER|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
48110617|NCT04645550|DRUG|Apixaban|From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
48481518|NCT05488717|OTHER|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
48481519|NCT01838187|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
48481520|NCT01838187|DRUG|Vorinostat|180 mg/m2 orally once daily on days 0 to +13
48110618|NCT04645550|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
48110619|NCT04645550|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
48110620|NCT04645550|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
48110621|NCT04645550|DRUG|Low molecular weight heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
48110622|NCT03201224|DEVICE|"After Group"|
48110623|NCT04838886|OTHER|Telerehabilitation-based Pilates Exercise|The group that will receive telerehabilitation-based pilates training via telerehabilitation
48110624|NCT06552325|BEHAVIORAL|Single Session Narrative Therapy|The proposed single session narrative therapy intervention has been widely implemented in walk-in therapy clinics in Ontario Province, Canada. In these clinics, 60-minute psychotherapy sessions, informed by narrative therapy, are available on a walk-in basis. The therapist collaborates with a patient to co-develop a useful and meaningful focus for the session and then engages the patient in conversation that is respectful but shifts their way of thinking about the presenting problem. The therapist highlights and documents the patient's values and skills and works with the patient to create an action plan. If the therapist identifies additional treatment needs, the patient is offered an external referral to specialty mental health services.
48110625|NCT06240663|BEHAVIORAL|Exercise|Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
48110626|NCT00753012|DRUG|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
48110627|NCT00977223|DRUG|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
48110628|NCT02013830|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
48110629|NCT02013830|DRUG|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
48110630|NCT05966779|OTHER|modified CDT physical therapy protocol, based on Godoy's Method|modified CDT physical therapy protocol
48304574|NCT05226598|DRUG|Cisplatin|Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
48304575|NCT05226598|DRUG|Paclitaxel|Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
47957477|NCT03039452|BEHAVIORAL|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
47957478|NCT06422767|DRUG|Bepirovirsen|Bepirovirsen will be administered.
47957479|NCT06422767|DRUG|Placebo|Placebo will be administered.
47957480|NCT05232045|DRUG|Automated urinary output collection system group (tight monitoring of urine output)|Automated urinary output collection system group (tight monitoring of urine output)
47957481|NCT04137627|DRUG|Melatonin 20 MG Oral Capsule|The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
47957482|NCT04137627|DRUG|Placebo oral capsule|The administration of placebo capsule in addition to neoadjuvant chemotherapy
47957483|NCT02273232|OTHER|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
47957484|NCT02273232|OTHER|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
48304576|NCT05226598|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
48304577|NCT05226598|DRUG|Pemetrexed|Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
47957485|NCT02273232|OTHER|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
48304578|NCT05226598|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
48304579|NCT06691217|DRUG|CANAKINUMAB (ILARIS®)|Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
48304580|NCT06691217|DRUG|Saline (NaCl 0,9 %) (placebo)|Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.
47957486|NCT00255125|DRUG|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
48110631|NCT02940704|PROCEDURE|Reciproc|"* Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~* There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~* Reciproc file selection: R40 (40/0.06) is to be used."
47957487|NCT00255125|DRUG|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
47957488|NCT05367427|DIETARY_SUPPLEMENT|Heat treated postbiotic Bifidobacterium Longum consumption|Regular consumption in breakfast of heat treated postbiotic B. longum
48304581|NCT06684626|DRUG|Sodium Hyaluronate|Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.
48304582|NCT06684626|DRUG|Levofloxacin 500mg|Treatment typically involves fluoroquinolones alone, such as levofloxacin.
48481521|NCT00271739|DEVICE|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
48481522|NCT00271739|OTHER|usual care|usual diabetes care, as provided by primary care providers
48481523|NCT05443906|BEHAVIORAL|Home exercise|Exercise to address limitations impacting walking
48481524|NCT03451006|DRUG|Metformin|Oral metformin (up to 2gm) will be given in divided doses
47957489|NCT05367427|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
47957490|NCT03523130|DIAGNOSTIC_TEST|Imaging|Macrophage-specific inflammation
47957491|NCT00001438|DRUG|all-trans-retinoic acid with IFN-alpha2a|
47957492|NCT04384783|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
47957493|NCT04284358|OTHER|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
47957494|NCT03317340|OTHER|Background Sounds|Background music or sound of running water
47957495|NCT06278519|BIOLOGICAL|Blood, urinary and feces collection|Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.
47957496|NCT06278519|DEVICE|Cardiac MRI|Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up
47957497|NCT06278519|OTHER|Quality of life and cognitive status questionnaire|Quality of life and cognitive status questionnaire at the acute phase of STEMI and at 1-year follow-up
47957498|NCT00001688|DRUG|Ritonavir|
47957499|NCT00001688|DRUG|Nevirapine|
47957500|NCT00001688|DRUG|Stavudine|
47957501|NCT05692128|OTHER|Hematological and chemistry tests|Laboratory tests
47957502|NCT01689636|DRUG|Tc 99m EC20|
47957503|NCT00515489|DRUG|Risperidone|as prescribed
47957504|NCT00503529|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
47957505|NCT02182102|DRUG|BIBF 1120|
47957506|NCT02182102|DRUG|Pemetrexed|
47957507|NCT02566486|DEVICE|Reciprocating system|Different root canal instrumentation systems
48655976|NCT06111027|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
47957508|NCT02566486|DEVICE|Rotational system|Different root canal instrumentation systems
47957509|NCT01816074|DRUG|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
47957510|NCT01816074|BEHAVIORAL|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
47957511|NCT06409715|OTHER|Enhanced Care with PMRT and Acupressure|Progressive Muscle Relaxation Training (PMRT) is a structured strategy created to reduce psychological and physiological stress by alternating muscle contraction and relaxation.Rooted in traditional Chinese medicine's meridian theory, acupressure employs manipulative techniques on distinct acupoints to induce therapeutic effects 18. Targeting enhanced circulation, pain relief, muscle relaxation, and systemic regulation, acupressure's efficacy as both a preventive and therapeutic modality in complementary and alternative medicine is well-established
47957512|NCT06409715|OTHER|standard care|vital sign monitoring, positional support, dietary management, pain control, psychological support, functional training, and educational initiatives on health matters.
47957513|NCT01830231|DRUG|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
47957514|NCT01830231|DRUG|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years."
47957515|NCT00411528|DRUG|Patupilone|
48304583|NCT05091190|OTHER|Blood draws|"Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration."
48481525|NCT03451006|DRUG|Placebo|Oral Placebo will be given in divided doses
48481526|NCT04779229|BEHAVIORAL|Parent Activation|Parent Activation (PA) is comprised of concrete social learning theory steps (i.e., direct instruction, modeling, practice opportunities, and reinforcement) that aim to enhance a parent's confidence, knowledge, and ability to manage his/her child's health. PA is applicable across a range of conditions, including behavioral and psychiatric problems, and it can be delivered by varied providers, including paraprofessionals.
48481527|NCT04779229|BEHAVIORAL|Usual Services|This intervention refers to the typical techniques that JPOs employ to monitor the juveniles on their caseloads (e.g., regular meetings with youth and parents to ensure the youth is following conditions of probation and issuing swift sanctions \[community service; detention\] if conditions are not being followed).
47957516|NCT00411528|DRUG|prednisone|
47957517|NCT00411528|DRUG|docetaxel|
47957518|NCT05684705|DRUG|BV100|Intravenous infusion
47957519|NCT00667160|DRUG|tacrolimus ointment|topical
47957520|NCT00667160|DRUG|pimecrolimus cream|topical
47957521|NCT01393223|DRUG|LP-08 80mg|Intravesical instillation of 80mg LP08
47957522|NCT01393223|DRUG|Normal saline|Intravesical instillation of normal saline
47957523|NCT01393223|DRUG|LP-08 20mg|Intravesical instillation of 20mg LP08
47957524|NCT02264561|OTHER|Food|Active group
47957525|NCT02264561|OTHER|Food|Control group
47957526|NCT06468852|PROCEDURE|Goal-Directed Fluid Therapy|Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of Goal-Directed fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV\>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.
47957527|NCT03181035|RADIATION|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
47957528|NCT03181035|DRUG|Pimonidazole|oral pimonidazole hypoxia labeling
48304588|NCT06691100|BEHAVIORAL|Aerobic Exercise|30-minute exercise bout in a cycle ergometer at 60 to 70% of the Heart Rate Reserve (HRR) and corresponding power (watts).
47957529|NCT00000337|DRUG|Selegiline|
48110632|NCT02940704|PROCEDURE|One Shape|"* Coronal preflaring will be performed using Gates Glidden drill.~* Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~* For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
48640788|NCT02323581|DEVICE|Endovascular treatment of Thoracoabdominal Aortic Aneurysm|"A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.~This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm."
48640789|NCT02323581|DEVICE|Endovascular treatment of Aortic Arch Aneurysms|"An aortic arch aneurysm is an abnormal enlargement (ballooning out) of the main artery (the aorta). The ascending aorta and aortic arch is the first part of the vessel as it exits the heart and makes a turn around the area of the collar bone. This part of the aorta gives branches that supply the head, brain and arms.~The arch branch endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively."
48640790|NCT03948789|PROCEDURE|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
47957530|NCT04882384|PROCEDURE|Pericapsular Nerve Group Block|This will be a peripheral nerve block.
47957531|NCT02153333|PROCEDURE|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
47957532|NCT03998566|DEVICE|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
48110633|NCT02470949|BEHAVIORAL|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
48110634|NCT02470949|BEHAVIORAL|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
48110635|NCT00309595|DEVICE|stent|Cordis SMART™ Nitinol Stent System
48110636|NCT00309595|DEVICE|balloon|balloon angioplasty
48304589|NCT06624085|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)
48304590|NCT06624085|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
48640791|NCT03948789|PROCEDURE|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
48640792|NCT06558344|DRUG|BI 1569912|BI 1569912
47957533|NCT03495037|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
48110637|NCT06037824|OTHER|cryotherapy|"cryotherapy was added to rehabilitation\*. One group received compressive cryotherapy and the other conventional cold pack cryotherapy.~\* rehabilitation includes (=classic rehabilitation) passive and active of mobilization of knee and patella, treat arthrogenic muscular inhibition, learn to lock the quadriceps, progressive muscular strengthening of the periarticular muscles of the knee, stretching of the quadriceps and the posterior muscular chain, proprioceptive exercises with bi- and unipodal balance, transfer of support and resumption of the walking pattern."
48110638|NCT00001354|DRUG|Interleukin-2/Zidovudine (AZT)|
48304591|NCT06624085|DRUG|Obinutuzumab|Participants will receive IV obinutuzumab pretreatment
48640793|NCT06558344|DRUG|Placebo matching BI 1569912|Placebo matching BI 1569912
48640794|NCT06526195|DEVICE|CardioMEMS HF System|The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
48304592|NCT06624085|DRUG|Gemcitabine|Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)
48481528|NCT01311401|OTHER|NONE intervention|NONE intervention
48640795|NCT06526195|DEVICE|HeartMate 3 Left Ventricular Assist System|The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
48640796|NCT06526195|OTHER|Guideline Medical Directed Therapy|Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
47957534|NCT03495037|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
48110639|NCT04651244|DIAGNOSTIC_TEST|MRI|Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
48481529|NCT05694182|OTHER|Other: Oral superfruits supplement|The supplement contain superfruits that are beneficial for human health
48481530|NCT06188130|OTHER|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.
48640797|NCT06263738|PROCEDURE|Whole Body Hyperthermia|Participants in the heat exposure alone group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes
48640798|NCT06263738|PROCEDURE|Cold Water Plunge|Participants in the heat exposure and cold plunge group will receive a single heat session using the Clearlight Sauna Dome lasting up to 140 minutes followed by a cold plunge session in 55 degree (Fahrenheit) water, lasting up to 10 minutes.
48110640|NCT04651244|DIAGNOSTIC_TEST|Ultrasound performed by a radiologist|US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
48110641|NCT04651244|DIAGNOSTIC_TEST|Point of care ultrasound|Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
48304593|NCT06624085|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)
48304594|NCT06681623|DRUG|Ublituximab|Drug: ublituximab
48304595|NCT06110793|DRUG|Lenvatinib|20mg orally PO daily
48304596|NCT06110793|DRUG|Pembrolizuma|400mg IV Q6W
48304597|NCT06110793|DRUG|Fulvestrant|500mg IM Q4W
48481531|NCT06188130|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
48640799|NCT02100644|DRUG|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
48640800|NCT06034314|DRUG|Dronabinol Capsules|Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.
48640801|NCT01294020|DRUG|Tacrolimus|Oral capsule
48640802|NCT01294020|DRUG|Tacrolimus prolonged release|Oral capsule
48640803|NCT03325803|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
48304598|NCT06099600|PROCEDURE|Reconstructive surgery of the anterior cruciate ligament|surgical reconstruction after rupture of the anterior cruciate ligament is widely proposed as first-line treatment, with the aim of restoring knee joint stability and facilitating functional recovery
48304599|NCT05741385|DRUG|Caffeine|Caffeine
48640804|NCT03325803|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
48110642|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"Establishing optimal temperature and pressure for limb cryocompression therapy. Healthy subjects will undergo 3 hours of limb cryocompression.~The cryocompression device used in this study consists of a control unit, and limb wraps. The control unit contains the coolant reservoir and pump to circulate the coolant and air for compression. It is able to thermoregulate (control the temperature of the circulating coolant) and offer cyclic air pressure in the wraps. The wraps cover the limbs from the elbow/knee to the fingers/toes."
48110643|NCT05095051|DEVICE|Paxman Cryocompression System (PCCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Limb cryocompression sessions comprised of a pre-cooling period (up to one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, limb cryocompression will be administered for no longer than four hours."
48304600|NCT05741385|DRUG|Warfarin sodium|Warfarin sodium
48304601|NCT05741385|DRUG|Omeprazole|Omeprazole
48304602|NCT05741385|DRUG|Metoprolol|Metoprolol
48304603|NCT05741385|DRUG|Midazolam|Midazolam
48304604|NCT03328078|DRUG|Emavusertib|Emavusertib (formulated for oral administration for BID dosing)
48304605|NCT03328078|DRUG|ibrutinib|560 mg QD of oral ibrutinib
48304606|NCT06693583|DEVICE|Virtual Reality Headsets|Virtual reality (VR) headsets are used as a form of distraction technique widely throughout healthcare. Women will be assisted to apply the VR prior to their colposcopy examination beginning. They will be shown an immersive video of walking through a forest that reminds them to breath deeply. The aim is that this will relax them during the colposcopy examination.
48304607|NCT03970226|DRUG|Tocilizumab|"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year)."
48304608|NCT05952856|DRUG|Enlicitide Decanoate|Oral tablet
48304609|NCT05952856|DRUG|Placebo|Oral tablet
48304610|NCT06130280|RADIATION|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
48304611|NCT04430972|PROCEDURE|Aortic valve replacement|Open surgical replacement of aortic valve
48304612|NCT04099056|DEVICE|Neurostimulation|"Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates."
48304613|NCT06674499|OTHER|Self-help rehabilitation model|The intervention measures followed the principles and processes of cognitive-behavioral therapy. Three intervention sessions were conducted over a period of eight weeks. The first session lasted 90 minutes, while the subsequent sessions (in weeks 4 and 8) lasted 45 minutes each and were conducted face-to-face by the therapist.
48304614|NCT06674499|OTHER|Conventional rehabilitation model|The control group, which follows the conventional rehabilitation model, operates under the current standard of cancer treatment and follow-up. In this model, oncology healthcare professionals provide recommendations based on the specific circumstances of the patients. However, the choice of the rehabilitation model is primarily decided by the patients themselves, aligning with current clinical practice.
48304615|NCT06158854|DRUG|ABBV-383|Intravenous Infusion
48304616|NCT06623630|DRUG|Cyclophosphamide|Standard of care
48304617|NCT06623630|DRUG|Ciltacabtagene Autoleucel|Standard of care
48110644|NCT00328393|DRUG|Pioglitazone|45 mg 8 weeks
48110645|NCT00328393|DRUG|Placebo|Placebo
48304618|NCT06623630|RADIATION|Total body irradiation|Radiation doses delivered to the entire body
48304619|NCT06693271|DIETARY_SUPPLEMENT|intervention of protein, blueberries|intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day.
48304620|NCT06693271|BEHAVIORAL|Exercise training|Three 60-minute multimodal exercise sessions per week. Exercise interventions will be individualized to each participant based on their fitness level as per recommended guidelines for older adults. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.
48304621|NCT04165798|DIAGNOSTIC_TEST|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
48304622|NCT04165798|PROCEDURE|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
48640805|NCT03325803|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
48655977|NCT03449576|OTHER|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
47957535|NCT00722800|DRUG|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
47957536|NCT00722800|DRUG|Placebo|1 tablet daily for 24 weeks
47957537|NCT00669656|DRUG|Prostate Health Cocktail|3 capsules daily PO up 12 months
47957538|NCT00915122|RADIATION|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
48110646|NCT02932709|BEHAVIORAL|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
48110647|NCT01771588|DIETARY_SUPPLEMENT|Human milk fortifier|
48110648|NCT01883492|DEVICE|Femoral Stem|JMDN classification/Class III device
48110649|NCT01883492|DEVICE|Acetabular Cup|JMDN classification: Class III device
48110650|NCT01883492|DEVICE|Acetabular Liner|JMDN classification: Class III device
48304623|NCT04165798|PROCEDURE|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~* genetics~* ribonucleic acid (RNA)~* serum biomarker~* plasma biomarker~* circulating tumor DNA (ctDNA)"
48110651|NCT01124188|DRUG|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
48110652|NCT01124188|BEHAVIORAL|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
48110653|NCT01124188|BEHAVIORAL|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
48304624|NCT06693076|PROCEDURE|Laparoscopic cholecystectomy|The intervention in this study is urgent, not elective. The conditions for the surgery are therefore different: any time of day, the surgeon on shift, the state of the patients.
48304625|NCT06692413|OTHER|Questionnaire|Users who consent to the study will receive a questionnaire every 3 months
48304626|NCT06692452|DRUG|Tazemetostat|EZH2 inhibitor, 200 mg tablet, taken orally per protocol.
47957539|NCT03301805|DRUG|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle."
47957540|NCT01810731|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (QIV)|
47957541|NCT01810731|BIOLOGICAL|Inactivated Polio Vaccine|
47957542|NCT01810731|BIOLOGICAL|Double Dose QIV|
47957543|NCT05065814|OTHER|Systemic lupus erythematosus group|Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
47957544|NCT05065814|OTHER|Systemic sclerosis group|Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
47957545|NCT05065814|OTHER|Healthy control group|Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
47957546|NCT05901454|DRUG|Yellow Fever Vaccine|vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
48304627|NCT06692452|DRUG|Doxorubicin|Anthracycline antibiotic, 10, 20, 50, 100, and 200 mg vials, via intravenous (into the vein) infusion per institutional standard of care.
48304628|NCT06692452|DRUG|Vincristine|Vinca Alkaloid, 1, 2, and 5mL vials, via intravenous (into the vein) infusion per institutional standard of care.
48304629|NCT06692452|DRUG|Prednisone|Corticosteroid, 1, 2.5, 5, 10, 20, 25, and 50 mg tablets, taken orally per institutional standard of care.
48304630|NCT06692452|DRUG|Cytoxan|Alkylating agent, 100mg, 200 mg, and 500mg vials, and 1 and 2 gram vials, via intravenous (into the vein) infusion per institutional standard of care.
48304631|NCT06692452|DRUG|Carmustine|Alkylating agent, 100 mg single dose vials, via intravenous (into the vein) infusion per institutional standard of care.
47957547|NCT03100097|DEVICE|Aspen Horizon 627 LSO|
47957548|NCT02371148|DRUG|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22\* Rituximab: 375 mg/sqm i.v. day 1\*\* Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles \*In case of toxicity is omitted~\*\*In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
47957549|NCT03068455|BIOLOGICAL|nivolumab|Specified Dose on Specified Days
47957550|NCT03068455|BIOLOGICAL|ipilimumab|Specified Dose on Specified Days
48304632|NCT06692452|DRUG|Etoposide|Topoisomerase II inhibitor, 100mg single dose vial, via intravenous (into the vein) infusion per institutional standard of care.
48304633|NCT06692452|DRUG|Cytarabine|Antineoplastic, 20mg single dose vial, via intravenous, intrathecal, or subcutaneous injection per institutional standard of care
48304634|NCT06692452|DRUG|Melphalan|Alkylating agent, 90 mg multi-dose vial, via parenteral infusion per institutional standard of care.
48481532|NCT06188130|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.
48640806|NCT03325803|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
48640807|NCT03325803|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
48304635|NCT04626518|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
48304636|NCT04626518|BIOLOGICAL|MK-4830|Administered via IV infusion at a dose of 800 mg Q3W
48640808|NCT06585462|DRUG|AMG 513|AMG 513 will be administered by SC or IV injection.
48640809|NCT06585462|DRUG|Placebo|Placebo will be administered by SC or IV injection.
48640810|NCT01862965|DRUG|PredEver|Firstline treatment with prednisone and Everolimus
48640811|NCT06097481|BEHAVIORAL|Narrative Intervention for Chronic Illness-Heart Failure|The Narrative Intervention for Chronic Illness-Heart Failure includes narrative-based, strengths-based, solution-focused brief therapy, and Unitary Caring Science to improve depression (primary outcome) and anxiety (secondary outcome) for people living with heart failure.
48481533|NCT06188130|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
47957551|NCT04185064|DEVICE|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
47957552|NCT04185064|OTHER|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
47957553|NCT02173223|DRUG|Rho-Kinase Inhibitor|
47957554|NCT05617950|OTHER|salicylic acid|Salicylic acid is applied once daily by the patients (or parents) for a maximum of 12 weeks.
47957555|NCT05617950|OTHER|cryotherapy|Cryotherapy is delivered by a technician up to a maximum of four treatments 3 weeks apart.
48481534|NCT06615700|DRUG|NA-931|NA-931 is a quadruple receptor agonist for weight loss
48481535|NCT06615700|DRUG|Placebo|Placebo of NA-931
48481536|NCT00256776|DRUG|Velcade (Bortezomib)|
48481537|NCT00256776|DRUG|Thalidomide|
48481538|NCT00256776|DRUG|Dexamethasone|
48481539|NCT04802408|COMBINATION_PRODUCT|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
48481540|NCT04802408|COMBINATION_PRODUCT|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
48481541|NCT04802408|COMBINATION_PRODUCT|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
48481542|NCT04802408|COMBINATION_PRODUCT|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
48481543|NCT02688296|DEVICE|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
47957556|NCT03816488|DRUG|Metformin|Metformin (usual dose) administered 2 h before surgery
47957557|NCT03816488|DRUG|Salsalate|Salsalate 1.5 g administered 2 h before surgery
48304637|NCT04626518|DRUG|Belzutifan|Administered via oral tablet at a dose of 120 mg QD
48304638|NCT04626518|DRUG|Lenvatinib|Administered via oral capsule at a dose of 20 mg QD
48481544|NCT04455971|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
48304639|NCT04626518|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a dose of 400 mg/25 mg Q6W
48304640|NCT04626518|BIOLOGICAL|Favezelimab/Pembrolizumab|Administered via IV infusion at a dose of 800 mg/200 mg Q3W
48304641|NCT05236673|DRUG|JARDIANCE®|JARDIANCE® film-coated tablets 10mg
48304642|NCT04188665|DRUG|MASL|Patients treated with MASL lozenge
48304643|NCT04188665|OTHER|Placebo|Patients treated with placebo lozenge
48304644|NCT06693518|DRUG|Treatment B|Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
48304645|NCT06693518|DRUG|Treatment A|Dabigatran Etexilate 150 mg
48304646|NCT06358417|BEHAVIORAL|Nutrition-enhanced CHW|CHW provides nutrition education and skills training in addition to the usual care (Basic CHW) hypertension management.
48640812|NCT06097481|OTHER|Attention Control|Automated emails at similar time points to the intervention will be sent to participants in this arm. Emails will ask participants to reflect on their illness experience and offer general information about heart failure using standardized handouts from the American Heart Association and Up-To-Date.
48640813|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 3T|Non-significant risk device used for brain imaging.
48640814|NCT02543983|DEVICE|NeurOptics PLRTM-3000 Pupillometer|The NeurOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
48640815|NCT02543983|DEVICE|Experimental Anxiety Devices|Acoustic startle and shock devices are used to evaluate anxious responses to stimuli. Both are considered non-significant risk under this study.
48640816|NCT02543983|DEVICE|Magnetic Resonance Imaging scanner, 7T|Non-significant risk device used for brain imaging.
47957558|NCT06557967|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
48110654|NCT00829348|OTHER|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
48304647|NCT06358417|BEHAVIORAL|Basic CHW|CHW provide usual care for hypertension management.
48304648|NCT05824845|PROCEDURE|Hip/Knee Replacement|Hip/Knee Replacement
48304649|NCT06165341|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
48304650|NCT06165341|DRUG|Placebo|Fazirsiran matching placebo.
48304651|NCT03803904|OTHER|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
48304652|NCT06693830|DEVICE|Phased Variant Enrichment and Detection Sequencing (PhasED-seq)|PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.
48304653|NCT06693830|OTHER|Standard of Care Treatment|Standard of Care Treatment for cycles 1-6
48304654|NCT06693830|OTHER|De-escalated Treatment|Standard of Care Treatment for cycles 1-4 and de-escalated treatment for cycles 5 and 6
48304655|NCT06693687|BEHAVIORAL|Metastatic Cancer|Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.
48304656|NCT04790344|DEVICE|Investigational LUX-Dx ICM Implant|All subject will receive an investigational version of the LUX-Dx ICM device.
48304657|NCT06693661|OTHER|Kidney Health Coaching|"The intervention entails support from a KHC that includes:~* An initial rapport-building call~* Ongoing telephone support at least twice a month for six months~* Meeting the patient at all in-person clinic appointments~* Documenting interactions in the EMR using a customized platform~Telephone support begins with a social determinants of health (SDoH) screening tool to identify barriers and facilitators to CKD self-management and appointment adherence. This tool provides access to local resources based on the patient's ZIP code. Subsequent calls will follow up on resource usage, review CKD educational materials and treatment options, complete the Decision Aid for Renal Therapy tool, and facilitate communication through the patient portal. Each call will start with specific goals (e.g., review National Kidney Foundation CKD materials) and conclude with goals for the next session."
48640817|NCT02543983|DRUG|Ketamine Hydrochloride|A non-competitive N-methyl-D-aspartate receptor antagonist. This drug is exempt from FDA IND review under the study.
48640818|NCT03735498|OTHER|Psychological Intervention|Promote effective coping and reduce caregiving burden
48110655|NCT00829348|BEHAVIORAL|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
48110656|NCT05818904|OTHER|Physical Therapy|All arthrosis participants will be treated as the traditional methods using physical therapy.
48110657|NCT06555991|OTHER|SIRSI and TSK-SI|The SIRSI and TSK-SI as well as the WOSI and RTS-, Clinical- and Demographic Information are gathered. The SIRSI and TSK-SI are re-administered one week later
48110658|NCT04456543|PROCEDURE|pressure monitoring|garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
48110659|NCT00419094|DRUG|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
48640819|NCT04525183|BEHAVIORAL|Enhanced Usual Care (EOC)|Educational materials
48640820|NCT04525183|BEHAVIORAL|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
48640821|NCT06343532|DRUG|SXC-2023|200 mg capsules
48640822|NCT06343532|DRUG|SXC-2023 Placebo|200 mg capsules
48640823|NCT02009449|DRUG|Pegilodecakin|Daily subcutaneous injections of pegilodecakin up to 12 months
48640824|NCT02009449|DRUG|Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Day 1 of every 21 day cycle
48640825|NCT02009449|DRUG|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Intravenous administration on Day 1 and 2 of every 14 day cycle
48640826|NCT02009449|DRUG|gemcitabine/nab-paclitaxel|Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
48304658|NCT06693661|OTHER|Usual Care|"ER Discharge (d/c): Patients may receive consultations and support from Care Management in the ER such as transportation or medication assistance. Follow-up by a social worker varies post-discharge.~Hospital d/c: All hospitalized patients are assessed by the care management team to identify psychosocial needs and begin discharge planning, which may include follow-up appointments and resources. High-risk patients receive additional follow-up from a care transitions coordinator for 30 days post-discharge.~Primary Care: Patients in primary care clinics have access to various support services. Those recently hospitalized or identified as high-risk receive care coordination from social workers. Internal referrals are managed by referral coordinators, while external referrals come from clinic staff. Discharge information is provided after visits.~Nephrology: There are no coordinated support services for chronic kidney disease (CKD) patients receiving nephrology care."
48304659|NCT06413173|COMBINATION_PRODUCT|Active tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with active tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
48304660|NCT06413173|COMBINATION_PRODUCT|Sham tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
48304661|NCT06689059|OTHER|Multimodal Data Integration and Multi-Task Learning|This study utilizes a multimodal data integration and multi-task learning approach to predict perioperative events after hip replacement surgery. By combining various data types, including demographics, surgical details, medical history, and lab results, the model enhances prediction accuracy for outcomes like AKI, blood transfusion needs, and ICU transfers. The use of ensemble learning algorithms such as CatBoost optimizes the platform's performance, offering a unique method for clinical decision support.
48304662|NCT03539458|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
48304663|NCT04913259|OTHER|Remote monitoring|Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
48304664|NCT05703854|DRUG|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
48304665|NCT05703854|DRUG|Fludarabine phosphate|Given by IV (vein)
48304666|NCT05703854|DRUG|Cyclophosphamide|Given by IV (vein)
48304667|NCT06637826|BEHAVIORAL|Quaternary Ammonium Compound Disinfectants|"Participants are instructed to use quaternary ammonium compound disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
48304668|NCT06637826|BEHAVIORAL|Alcohol-based Disinfectants|"Participants are instructed to use alcohol-based disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
48304669|NCT06402838|DRUG|RO7269162|Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
48304670|NCT06402838|DRUG|Placebo|Participants will receive daily doses of placebo for up to 72 weeks.
48640827|NCT02009449|DRUG|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
48640828|NCT02009449|DRUG|Pazopanib|Pazopanib will be administered orally daily continuously
48640829|NCT02009449|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
48640830|NCT02009449|DRUG|Paclitaxel|"Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
48640831|NCT02009449|DRUG|nivolumab|Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
48640832|NCT02009449|DRUG|Gemcitabine/carboplatin|gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
48640833|NCT05847543|OTHER|Stool diaper data and sample collection|Stool diaper data and sample collection
48640834|NCT00588770|BIOLOGICAL|Bevacizumab|Given IV
48640835|NCT00588770|DRUG|Carboplatin|Given IV
48640836|NCT00588770|DRUG|Cisplatin|Given IV
48640837|NCT00588770|DRUG|Docetaxel|Given IV
48640838|NCT00588770|DRUG|Fluorouracil|Given IV
48640839|NCT00588770|OTHER|Laboratory Biomarker Analysis|Correlative studies
47957559|NCT05383521|DRUG|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
47957560|NCT05383521|DRUG|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
48304675|NCT06561685|DRUG|LY4050784|Oral
48304676|NCT06692946|BEHAVIORAL|Cooperative Parent-Mediated therapy|Parent-mediated therapy is an intervention where parents are trained to use therapeutic techniques to support their child's development and manage symptoms, often used for conditions like autism spectrum disorder (ASD).
48304677|NCT06692946|BEHAVIORAL|Treatement as Usual|"Cognitive Behavioral Therapy (CBT) is a structured, short-term psychological treatment that focuses on identifying and changing negative thought patterns and behaviors. It aims to help individuals develop healthier ways of thinking and coping with challenges by addressing both cognitive (thought) and behavioral components.~Parent training is an educational intervention where parents learn strategies and techniques to effectively manage their child's behavior and support their development, often used to address challenges associated with conditions like autism or ADHD."
48304678|NCT06691880|BEHAVIORAL|MindPod Dolphin VGT|"The MindPod Dolphin, is an interactive video game that allows users to engage in non-task-based tasks to motivate the users to play and relearn motor skills. The MindPod gaming platform uses markerless tracking to sense the patient's affected arm. The paretic limb controls Bandit the dolphin underwater in an effort to eat fish. The patient learns to map his/her movements to Bandit in a 3-Dimensional work space to reach the targets. During gaming, the therapist titrates game difficulty. Bilateral gaming components are used (the participant uses a controller with the participant's less-affected limb to control the timing of Bandit's movement) and in-game difficulty can be adjusted to create an immersive, challenging, and engaging experience. In order to be successful, the patient must coordinate both arms to control the temporal and spatial aspects of the game."
48304679|NCT06691880|BEHAVIORAL|Bimanual Arm Trainer VGT|"The bimanual arm trainer (BAT) is a device that involves hardware that interfaces with a computer game. The BAT promotes shoulder external rotation and elbow extension in the paretic arm by coupling movements of the paretic arm with the less affected limb as the participant matches his/her arm movements to those of a virtual avatar. The less-affected side and paretic limb are placed in the BAT apparatus and the less affected limb drives the impaired limb through passive, symmetrical movements that simulate rowing down a virtual river. The protocol created by the investigators group, leads the patient through an active-passive training progression similar to paradigms used in neural priming studies. Through these series of movements, the goal is to restore balance between the muscles of the upper back and chest to maximize range of motion in preparation for improved quality of movement."
48304680|NCT04825275|DRUG|Posaconazole Pill|300 mg (three 100 mg tablets) orally
48304681|NCT02699515|DRUG|MSB0011359C|Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
48304682|NCT06692361|BIOLOGICAL|FMT capsule|The experimental group will maintain escitalopram treatment and take 1.0 g of FMT capsules orally with breakfast every day for 4 weeks.
48304683|NCT06692361|DRUG|Escitalopram (Lexapro)|Both the experimental group and the placebo group were treated with the maximum tolerated dose of escitalopram.
48481545|NCT03983798|OTHER|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
48640840|NCT06556394|DRUG|RAG-17|RAG-17 is a therapeutic small interfering RNA (siRNA).
48640841|NCT06556394|DRUG|Placebo|Placebo will be administered via intrathecal injection
47957561|NCT02293161|DRUG|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
47957562|NCT02293161|DRUG|Placebo|It is Sodium Chloride Intravenous Infusion
47957563|NCT02413970|DEVICE|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
47957564|NCT00076843|DRUG|Hu MiK-Beta-1|
47957565|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
47957566|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
47957567|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
48110660|NCT00419094|DRUG|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
48304684|NCT06692361|BIOLOGICAL|Corn Starch capsules|The placebo group will maintain escitalopram treatment and take corn starch capsules 1.0 g orally with breakfast every day for 4 weeks.
48304685|NCT06682481|OTHER|Measurement of biomarker|Measurement of blood levels of 1,5-anhydroglucitol
48304686|NCT03157635|DRUG|Crovalimab|Crovalimab will be administered as per schedule described in individual arm.
48304687|NCT03157635|DRUG|Placebo|Placebo will be administered as per schedule described in Part 1 placebo arm.
47957568|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
47957569|NCT02552992|BEHAVIORAL|Yoga|
47957570|NCT02552992|BEHAVIORAL|Self-Directed Mind-Body Program|
47957571|NCT02598960|DRUG|BMS-986156|
47957572|NCT02598960|DRUG|Nivolumab|
47957573|NCT03321266|DEVICE|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
47957574|NCT02740556|OTHER|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
47957575|NCT02740556|DEVICE|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
47957576|NCT02740556|OTHER|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
47957577|NCT01146990|DRUG|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
47957578|NCT02418650|DRUG|ODM-201 300 mg tablet|
47957579|NCT02418650|DRUG|intravenous14C-ODM-201|
47957580|NCT02418650|DRUG|300 mg 14C-ODM-201 oral solution|
47957581|NCT04392752|OTHER|Dieting intervention|This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
47957582|NCT04432259|DRUG|Dexamethasone|4 mg bid for 4 days
48304688|NCT06032403|BEHAVIORAL|flexible patient centred consultations|In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
48304689|NCT06693180|OTHER|HBOT|Hyperbaric Oxygen Therapy
48304690|NCT04195750|DRUG|Belzutifan|Oral tablets
48304691|NCT04195750|DRUG|Everolimus|Oral tablets
48640842|NCT06668883|PROCEDURE|Sputum collection for molecular analysis|Sputum collection to be used with syndromic multiplex PCR testing
47957583|NCT04432259|DRUG|Placebo|oral placebo
48110661|NCT06449300|OTHER|Resistance exercise-LVT|(low volume training - 3 sessions of 12 exercises per week)
48110662|NCT06449300|OTHER|Resistance exercise-MVT|(moderate volume training - 4 sessions of 12 exercises per week)
48110663|NCT06449300|OTHER|Resistance exercise-HVT|(high volume training - 5 sessions of 12 exercises per week)
48304692|NCT06693245|PROCEDURE|VAS scores of the puncture|All patients were evaluated by our team with CEAP grading and ultrasound measurements to record the diameter of the saphenous vein before surgery。We performed endovenous microwave ablation of the great saphenous vein along with foam sclerotherapy and point stripping treatment. We documented the operating room temperature, puncture site, VAS scores during puncture and catheter placement, the amount of injected tumescent fluid, radiofrequency generator used, and data at the conclusion of the surgery. A descriptive analysis of intraoperative pain scores was conducted to evaluate the level of pain experienced during the surgery. A nonparametric test was utilized to analyze the relationship between preoperative and intraoperative factors and the level of pain experienced during the surgery.
48640843|NCT06668883|DEVICE|Breath and cough collection for molecular analysis|Breath and cough collection with two proprietary devices to be used with syndromic multiplex PCR testing
48640844|NCT06695572|DRUG|CKD-383|QD, PO
48640845|NCT05479643|DEVICE|Surface Electromyography|Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.
48640846|NCT05783765|BEHAVIORAL|Heightened Drive to Eat|Participants' eating rate and eating in the absence of hunger will be assessed during a videotaped experimental meal. The relative reinforcing value of food will be assessed using a computerized behavioral choice task.
48640847|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
48640848|NCT06002074|BEHAVIORAL|Stress Management and Resilience Training Program|One-on-one stress management and resilience consultation by a certified SMART trainer followed by self-guided on-line training consisting of 4 modules.
47957584|NCT05429060|PROCEDURE|Hemorrhoidal surgery|All surgical interventions under general or local anesthesia, either in the office or operation room, including any type of injection, excision, ligation, ablation, mucopexy and suturation.
47957585|NCT05779969|OTHER|Chest CT scan|Comparison of structural damage to the manubriosternal joint (MST) between a population of patients with radiographic axSpA and a control population free of chronic inflammatory rheumatism on chest CT.
48640849|NCT03935048|DIETARY_SUPPLEMENT|Higher protein, low glycemic load diet|"All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided."
48640850|NCT06695689|DRUG|LM303|Treatment with LM303 injection
47957586|NCT06256965|DIAGNOSTIC_TEST|Detection of peri-operative atrial fibrillation|atrial tissue and plasma from patients with atrial fibrillation detection were analyzed for determine lipid and protein oxidation, and detect markers of myocardial injury.
47957587|NCT00066638|DRUG|Romidepsin|Given IV
47957588|NCT00066638|OTHER|Laboratory Biomarker Analysis|Correlative studies
48640851|NCT05418920|PROCEDURE|left-opening single-flap technique|left-opening single-flap technique
48110664|NCT03763721|DEVICE|intraoperative optical coherence tomography (iOCT)|"The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery."
48304693|NCT05975775|PROCEDURE|Laparoscopic radical prostatectomy|Prostate cancer may require laparoscopic radical prostatectomy, a surgical procedure performed under general anaesthetic.
48640852|NCT05418920|PROCEDURE|double-flap group technique|double-flap group technique
48640853|NCT06254326|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment
48640854|NCT06254326|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Participants will receive a single infusion of autologous CD34+ HSCs
48640855|NCT06254326|BIOLOGICAL|TTRNA-xALT|Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells
48640856|NCT06254326|DRUG|Td vaccine|All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.
48640857|NCT04948268|BEHAVIORAL|Adaptive messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
48640858|NCT04948268|BEHAVIORAL|Non-personalized messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
48640859|NCT04948268|BEHAVIORAL|Coaching|Human coaching to support intervention use and engagement via telephone calls, text or email
48640860|NCT04948268|BEHAVIORAL|Psychoeducational links|SMS messages with URLs containing brief psychoeducational information.
48640861|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
48640862|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
48640863|NCT06021223|OTHER|Placebo|140ml of placebo to be consumed daily for 2 weeks
48640864|NCT04128748|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48640865|NCT04128748|DRUG|Quizartinib|Given PO
47957589|NCT03342963|DRUG|ASC-01|Aripiprazole 3 mg/sertraline 100 mg combination drug
47957590|NCT03342963|DRUG|Aripiprazole and sertraline|Aripiprazole 3 mg and sertraline 100 mg
47957591|NCT03606512|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.
47957592|NCT03606512|BIOLOGICAL|Placebo|Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
47957593|NCT03606512|BIOLOGICAL|Nimenrix|Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
47957594|NCT04480008|BEHAVIORAL|Resilient Living Program|Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
47957595|NCT05049616|DRUG|ACE Inhibitors and Diuretics|Hctz/Lisinopril (brand name: Zestoretic)
47957596|NCT05049616|DRUG|NIFEdipine ER|Extended release nifedipine
47957597|NCT02399371|BIOLOGICAL|Pembrolizumab|Given IV
47957598|NCT02399371|OTHER|Laboratory Biomarker Analysis|Correlative studies
47957599|NCT02399371|OTHER|Pharmacogenomic Study|Correlative studies
48640866|NCT06358703|DRUG|Caplacizumab|Early Caplacizumab use
48304694|NCT06691945|COMBINATION_PRODUCT|Saline delivered using an intrauterine pressure catheter (IUPC)|An intrauterine pressure catheter (IUPC) will be placed in participants after membrane rupture, or at 4 cm if membranes previously ruptured. A 300cc bolus of normal saline will be administered. A continuous rate of 100 cc/hr of normal saline will continue until delivery to prevent Postpartum Hemorrhage. If the IUPC is dislodged, it will be replaced by a trained clinician.
48304695|NCT06693323|DRUG|AHCC®capsules|Given PO
48304696|NCT03951467|OTHER|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
48304697|NCT04899661|DRUG|Molidustat (Musredo, BAY85-3934)|Tablets, administered orally at the discretion of investigators
48304698|NCT06238479|DRUG|LY4101174|Intravenous
48640867|NCT06359561|DEVICE|cervical lead placement|implant of cervical lead neurostimulation, using saluda medical devices
48640868|NCT03415048|OTHER|No Intervention|
48640869|NCT05065671|DRUG|Tolcapone 100 MG|Tolcapone 100 mg by mouth once
47957600|NCT00061347|PROCEDURE|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
47957601|NCT01223131|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
48640870|NCT05065671|DRUG|Duloxetine 20 MG|Duloxetine 20 mg by mouth once
48640871|NCT05739162|DEVICE|Apollo Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
48304699|NCT06693908|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified.
48304700|NCT06077487|DRUG|Ketamine|Given orally (PO)
48640872|NCT05739162|BEHAVIORAL|Lifestyle Intervention|Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
48640873|NCT06056102|DRUG|Cyclophosphamide|"* Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3"
48640874|NCT06056102|BIOLOGICAL|CART-BCMA|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
48640875|NCT06056102|BIOLOGICAL|huCART19|"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
48110665|NCT05510544|DRUG|Plerixafor,G-CSF|"G-CSF: 10 μg/kg/day, subcutaneously injected, every morning from day 1 to day 8.~Plerixafor injection: 0.24 mg/kg/day, subcutaneous injection, starting on the 4th day, once a day, up to 4 times in a row. Plerixafor injection and G-CSF administration site should be separated. The interval between plerixafor injection and stem cell collection was 10-11 hours."
48640876|NCT06056102|DRUG|Fludarabine|• Cohort 3: 24mg/m\^2 daily x 3
48640877|NCT04934683|PROCEDURE|Routine blood pressure control|Routine blood pressure control.
48640878|NCT04934683|PROCEDURE|Tight blood pressure control|Tight blood pressure control.
48640879|NCT04934683|DRUG|Etomidate|Anesthetic induction with etomidate.
48304701|NCT06077487|DRUG|Ketamine Injectable Product|Given intramuscularly (IM)
48640880|NCT04934683|DRUG|Propofol|Anesthetic induction with propofol.
47957602|NCT01223131|DRUG|NPH insulin|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
48304702|NCT06077487|BEHAVIORAL|Meaning and Purpose therapy|In-person sessions
48640881|NCT04276701|BIOLOGICAL|blood sample|35 ml whole blood for Peripheral blood mononuclear cell (PBMC), serum and plasma
48640882|NCT04276701|OTHER|Ultrasonography assessment|assessment of atherosclerotic plaques and measurement of carotid intima-media thickness (cIMT)
48640883|NCT04276701|BEHAVIORAL|questionnaires|Food and exercise questionnaires validated by the American heart Association
48640884|NCT04355689|DRUG|NPI-001|oral tablet
48640885|NCT04355689|OTHER|Placebo|Placebo tablets
47957603|NCT02430623|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
47957604|NCT02430623|DEVICE|NanoKnife|
47957605|NCT01786148|BEHAVIORAL|mobile phone application|
47957606|NCT02699593|DEVICE|Test Contact Lens|
47957607|NCT02699593|DEVICE|Control Contact Lens|
47957608|NCT00023946|DRUG|ixabepilone|Given IV
48110666|NCT01454661|DIETARY_SUPPLEMENT|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
48304703|NCT06077487|OTHER|Placebo|Given PO or IM
48304704|NCT06077487|OTHER|Questionnaires|Questionnaires will be given over the course of the study
48304705|NCT06194201|DRUG|HRS9432|Dosing frequency: intravenously once week
48304706|NCT06194201|DRUG|Caspofungin Acetate for Injection|Dosing frequency: D1 70mg，followed by 50mg intravenously once daily
48640886|NCT01327781|DRUG|Endoxifen Hydrochloride|Given PO
48640887|NCT01327781|OTHER|Laboratory Biomarker Analysis|Correlative studies
47957609|NCT00023946|OTHER|laboratory biomarker analysis|Correlative studies
48110667|NCT01454661|DIETARY_SUPPLEMENT|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
48110668|NCT01454661|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is used as placebo.
48110669|NCT03484611|DRUG|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
48110670|NCT03484611|DRUG|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
48110671|NCT03484611|DRUG|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
48110672|NCT03484611|PROCEDURE|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
48110673|NCT03484611|DRUG|Progesterone|vaginal prontogest 400 mg twice daily
48110674|NCT06176716|DRUG|ET-26|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
48110675|NCT04753099|BEHAVIORAL|occupation-based coaching|"Occupation based coaching is an intervention proven to be an effective intervention in family-centered practice. OBC is a strength-based approach that emphases collaboration with clients in goals setting and attainment to increase overall health and quality of life. Clients are the central focus of the intervention and generate their own strategies to address goals as part of the coaching process. In their role as coach, the therapists employ techniques such as reflective questioning and comments to support clients in identifying existing routines and rituals that impact goal attainment and to increase knowledge and access to resources that can promote improved caregiver quality of life after a child's diagnoses with T1D. Occupation based coaching can be divided into the following steps: (1) setting goals, (2) exploring options, (3) planning action, (4) carrying out the plan, (5) checking performance, and (6) generalizing(Little et al., 2018, p.2)."
48110676|NCT02712658|DRUG|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
48110677|NCT02712658|DRUG|Placebo|
48110678|NCT02393716|DEVICE|Endurant Evo AAA Stent Graft System|
48110679|NCT02393716|PROCEDURE|Endovascular aneurysm repair (EVAR)|
48110680|NCT02608528|RADIATION|[18F]fluoroglucose(FDG)|
48110681|NCT03630939|DRUG|ESR-114|ESR-114 Topical Gel
48110682|NCT03630939|OTHER|Placebo|Placebo Topical Gel
48110683|NCT00319397|BEHAVIORAL|Exercise-Training Program|
48110684|NCT03656094|DRUG|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
48110685|NCT03656094|DRUG|Placebo plus chemotherapy|Placebo plus chemotherapy
48110686|NCT04136639|OTHER|Miswak|sticks
48304707|NCT06692049|PROCEDURE|Gonadectomy|Gonadal tissue being removed for risk of malignancy may be cryopreserved for fertility preservation
48304708|NCT05946395|DEVICE|Hearing aid|Fitting a hearing aid
48640888|NCT01327781|OTHER|Pharmacological Study|Correlative studies
47957610|NCT02339285|DEVICE|tACS (alpha)|
47957611|NCT02339285|DEVICE|tACS (gamma)|
47957612|NCT01717911|DRUG|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
47957613|NCT01717911|DRUG|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
48110687|NCT04136639|OTHER|Grape Seed Extract Mouthwash|Mouthwash
48110688|NCT04136639|OTHER|fluoride|mouthwash
48110689|NCT03728036|BEHAVIORAL|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
48110690|NCT02888457|OTHER|Nasopharyngeal sampling with a swab|
48110691|NCT05488366|DRUG|Pembrolizumab|Given IV
48110692|NCT05488366|RADIATION|Radiation therapy|Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.
48110693|NCT05475106|BIOLOGICAL|Neoantigen Peptides|Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
48110694|NCT00136058|PROCEDURE|bone densitometry (DEXA)|
48110695|NCT00136058|DRUG|alendronate or risedronate|
48110696|NCT06355388|DEVICE|Active tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus, and a 10-minute stimulation will be initiated with a pulse width of 200 μs, a frequency of 30 Hz, and an intensity of one mA lower than the patient's sensitivity threshold.~As fort he mid-term phase, a device will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
48110697|NCT06355388|DEVICE|Sham tVNS|"As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus for 10-minute but no current will be delivered.~As fort he mid-term phase, a device (configured to withhold power delivery) will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session."
48110698|NCT00590668|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
48110699|NCT04668391|PROCEDURE|Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament|Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.
47957614|NCT01717911|DRUG|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was \<70mg /dl, discontinued the study if blood glucose was still \<70mg/dl under sitagliptin 50mg per day.
47957615|NCT06051370|PROCEDURE|Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
48110700|NCT04668391|PROCEDURE|Thoracic epidural analgesia|A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
48110701|NCT05001945|DRUG|MLS-101 (Part I)|MLS-101 tablet(s) by mouth once or twice daily.
48110702|NCT05001945|OTHER|Placebo (Part I)|Placebo tablet(s) by mouth once or twice daily.
48110703|NCT05001945|OTHER|Placebo (Part II)|Placebo tablet(s) by mouth once daily.
48110704|NCT05001945|DRUG|MLS-101 (Part II)|MLS-101 tablet(s) by mouth once daily.
48110705|NCT03720210|DEVICE|RFA|Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
48110706|NCT01941563|DRUG|Condoliase|1.25U, intradiscal injection, one time
48304709|NCT05946395|OTHER|Speech therapy session|As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
48481546|NCT05644756|BEHAVIORAL|IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)|IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
48481547|NCT04654234|DEVICE|Total body PET/CT (uExplorer)|A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
48110707|NCT01941563|DRUG|placebo|
48110708|NCT04969172|DRUG|Exosomes overexpressing CD24|The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
48110709|NCT01251354|DRUG|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
48110710|NCT00184925|PROCEDURE|Tracheostomy|trachesotomy with subglottic drainage
48110711|NCT00184925|DEVICE|cannula with subglottic drainage|
48110712|NCT00002555|DRUG|cisplatin|
48110713|NCT00002555|RADIATION|low-LET cobalt-60 gamma ray therapy|
48110714|NCT00002555|RADIATION|low-LET electron therapy|
48110715|NCT00002555|RADIATION|low-LET photon therapy|
48110716|NCT02412774|BEHAVIORAL|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
48110717|NCT02412774|BEHAVIORAL|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
48304710|NCT06428383|DRUG|Vericiguat tablet|Vericiguat tablet at doses 2.5 mg, 5 mg, or 10 mg taken orally once daily
48481548|NCT06127017|PROCEDURE|splinting dental implants with titanium bar|splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.
47957616|NCT06051370|PROCEDURE|Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
47957617|NCT02083965|BIOLOGICAL|rFVIIIFc|Administered as specified in the treatment arm.
47957618|NCT00354822|DRUG|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts\>150x10\^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10\^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
48110718|NCT02519699|DRUG|norepinephrine|Increase in mean arterial pressure using norepinephrine
48110719|NCT05981534|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
48110720|NCT05981534|DRUG|Placebo|Placebo will be used for 6 months
48304711|NCT06428383|DRUG|Vericiguat suspension|"Vericiguat suspension at doses 0.2 mg/mL,~1 mg/mL taken orally once daily"
48304712|NCT04821622|DRUG|talazoparib plus enzalutamide|experimental arm
48481549|NCT06127017|PROCEDURE|splinting dental implants with PEEK bar|in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
48640889|NCT01327781|OTHER|Questionnaire Administration|Ancillary studies
48640890|NCT06445062|DRUG|RMC-6236|Oral tablet
48640891|NCT06445062|DRUG|mFOLFOX6 regimen|IV infusion
48110721|NCT05705700|DRUG|Dutasteride|High dose Dutasteride (3.5 mg daily) as add-on therapy at time of PSA progression
48110722|NCT05705700|DRUG|Abiraterone|1000 mg PO daily
48304713|NCT04821622|DRUG|Placebo plus enzalutamide|Active comparator arm
48304714|NCT04537390|DIAGNOSTIC_TEST|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
47957619|NCT05235048|PROCEDURE|Tooth extraction|Atraumatic tooth extraction without flap elevation
48304717|NCT06063434|BEHAVIORAL|Night Shift|"The player must not only manage the patients who present to the emergency department of the hospital, gaining experience with the consequences of trauma triage, but also solve the mystery of the grandfather, gaining an emotional connection with the character and making the feedback that Andy receives more relevant. Embedded within Night Shift 2024 is a mini-game (Graveyard Shift) that contains a series of puzzles that reinforce the lessons of the overarching game: transfer severely injured patients expeditiously."
48640892|NCT06445062|DRUG|bevacizumab|IV infusion
48304718|NCT06063434|BEHAVIORAL|Usual education|Standard continuing medical education, including Advanced Trauma Life Support, and the American Board of Emergency Medicine educational modules (e.g., trauma resuscitation).
48304719|NCT05741164|PROCEDURE|Biopsy|Undergo tumor biopsy
48304720|NCT05741164|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48304721|NCT05741164|PROCEDURE|Computed Tomography|Undergo CT scan
48304722|NCT05741164|BIOLOGICAL|Pembrolizumab|Given IV
48304723|NCT05741164|DRUG|Propranolol|Given PO
47957620|NCT05235048|PROCEDURE|Tooth extraction and socket seal with connective tissue graft|Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
47957621|NCT05235048|PROCEDURE|Tooth extraction and socket seal with BRG and connective tissue graft and|Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
48304724|NCT05741164|OTHER|Questionnaire Administration|Ancillary studies
48304725|NCT05929027|BEHAVIORAL|NoNo|"Participants in the G2 group will use the Twirlstone (knob-like) device to play a videogame called Nono's World. The Twirlstone is an electromechanical device that resembles a knob and a standard joystick (identical to the discontinued Atari CX-20 Controller). The knob can rotate or move in a push-pull fashion. To control the game's character (an axolotl called Nono), a signal about the knob motion is relayed to the computer wirelessly. This device has been certified by Johns Hopkins University's Clinical Engineering Services, where it was deemed less than minimum risk. The game has been custom built to allow participants to take control of the character using subtle manipulative finger movements to accomplish game-like tasks.~The investigators will use portable communication devices to carry out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
48304726|NCT05929027|BEHAVIORAL|occupational therapy - self directed|"Participants 5 daily sessions over 3 weeks consisting of self-administered, unsupervised occupational therpay. Additionally, participants will have 2, \<15 minutes telemedicine check-in appointments (not standard of care) provided by a licensed occupational therapist for the purposes of assessing safety and providing guidance for the unsupervised sessions. The intervention will focus on stretches, warm-up and strengthening exercises aimed at improving hand function.~The investigators will use portable communication devices for the purposes of carrying out telemedicine sessions. All devices and are low-power battery-operated tools for encouraging hand movement and the components are approved for use in the commercial market."
48304727|NCT06446739|DEVICE|Continuous Renal Replacement Therapy (CRRT)|Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).
48304728|NCT06026254|DRUG|IMSA101|Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
48640893|NCT06445062|DRUG|mFOLFIRINOX regimen|IV infusion
48640894|NCT06445062|DRUG|cetuximab|IV infusion
48304729|NCT06026254|DRUG|Immune Checkpoint Inhibitor|Administered according to product label
48304730|NCT05926804|DRUG|Lansoprazole|14 days of Lansoprazole (30 mg BID) (days 1-14)
48304731|NCT05926804|DRUG|Amoxicillin|7 days of Amoxicillin (1000 mg BID) (days 1-7)
47957622|NCT05235048|PROCEDURE|Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft|Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
47957623|NCT00705289|BIOLOGICAL|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
48304732|NCT05926804|DRUG|Clarithromycin|7 days of Clarithromycin (500 mg BID) (days 8-14)
48304733|NCT05926804|DRUG|Metronidazole|7 days of Metronidazole (500 mg BID) (days 8-14)
48304734|NCT05620836|DRUG|Povorcitinib|Oral, Tablet
48304735|NCT05620836|DRUG|Placebo|Oral, Tablet
48640895|NCT06445062|DRUG|gemcitabine|IV infusion
48640896|NCT06445062|DRUG|nab-paclitaxel|IV infusion
48640897|NCT05599581|BEHAVIORAL|Tu'Washindi|"Tu'Washindi consists of 3 primary components:~1. PrEP Adherence Support Clubs: Eight 2-hour sessions that occur over the intervention period: twice per month for the first 2 months \& once per month for the remaining 4 months. Sessions will use structured \& unstructured activities designed to improve outcomes expectations, increase self-efficacy to use PrEP safely \& consistently, increase peer support for PrEP use, provide access to community IPV resources \& provide skills for healthy communication \& PrEP disclosure with male partners.~2. Community Male Sensitization conducted weekly over the first 3 months of the intervention period aimed to increase PrEP knowledge, reduce stigma, \& promote healthy relationship communication.~3. Buddy Days, which take place 3 months into the intervention period, designed to bring participants \& their male partners together to learn about PrEP, discuss community attitudes \& concerns regarding PrEP use, \& promote HIV prevention \& family well-being."
47957624|NCT02223312|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
47957625|NCT02923596|PROCEDURE|History of prior Surgery|History of prior Surgery will be reviewed
47957626|NCT02923596|RADIATION|History of Radiation Therapy|History of prior radiation therapy will be reviewed
47957627|NCT04789083|OTHER|Propholis extrate|Plassebo
47957628|NCT01225692|BEHAVIORAL|Head Injury Guideline|
47957629|NCT03047876|PROCEDURE|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
47957630|NCT02261454|OTHER|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
48110723|NCT02427269|OTHER|Specimen Collection|"* 1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~* Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~* Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~* Two biopsies from normal squamous epithelium, and~* One biopsy from each area of esophageal nodularity seen during the procedure~* Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~* Up to 4 cytology brushes during the procedure."
48110724|NCT03768843|PROCEDURE|Harms technique|Atlantoaxial fusion
48110725|NCT04091152|OTHER|usability assessment|"Usability of ardoiz will be assesse using a validated usability questionnary"
48110726|NCT00479648|BIOLOGICAL|CSL412|
48640898|NCT06121284|DRUG|D-Cycloserine|Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
48110727|NCT00479648|BIOLOGICAL|Inactivated trivalent influenza vaccine|
48110728|NCT04330768|PROCEDURE|PRF pulp capping|PRF is injected in the site of exposure
48110729|NCT04330768|PROCEDURE|MTA pulp capping|conventional pulp capping procedure
48110730|NCT05635604|DRUG|Eptinezumab|Eptinezumab or ALD403 is a humanized anti-calcitonin gene-related peptide IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). It selectively binds human CGRP ligand to prevent activation of the CGRP receptor and blocks its binding to the receptor for the prevention of migraine.
48640899|NCT06121284|DEVICE|intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
48640900|NCT06121284|DRUG|Placebo oral tablet|Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
48640901|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 1
48640902|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 2
48110731|NCT05635604|DRUG|PACAP-38|PACAP-38 is a naturally occurring peptide diffusely expressed throughout the body. The Danish Headache Center has used infusion of PACAP-38 for several years and the first time in 2007 where infusion of PACAP-38 triggered headaches and migraines in migraine patients.
48640903|NCT05835895|GENETIC|GNSC-001|intra-articular injection
48640904|NCT05835895|DRUG|transient immune-modulation|oral
48640905|NCT05835895|DRUG|transient immune-modulation|intra-articular injection
48640906|NCT05835895|DRUG|Placebo|intra-articular injection
48640907|NCT06288711|BEHAVIORAL|Prolonged exposure therapy|Twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions provided by therapists trained in prolonged exposure therapy.
48640908|NCT06288711|BEHAVIORAL|Financial incentives|Financial incentives contingent upon completion of prolonged exposure therapy sessions
47957631|NCT00761631|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
47957632|NCT03992014|DRUG|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
47957633|NCT03992014|DRUG|[14C]-linerixibat intravenous infusion|\[14C\]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
48110732|NCT06312943|OTHER|Collection of joint fluid or tissue sample|During a puncture or joint surgery planned as part of the routine care of the patient, a part of the joint fluid or tissue sample will be collected in order to carry out the analyzes planned for the research.
48110733|NCT00153309|BEHAVIORAL|People with Arthritis Can Exercise|
48110734|NCT02616861|DRUG|IW-1973|IW-1973 Tablet
48110735|NCT02616861|DRUG|Matching Placebo Tablet|Matching placebo tablet
48110736|NCT02814643|DRUG|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
48110737|NCT02814643|DRUG|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
48110738|NCT02814643|DRUG|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
48110739|NCT05339477|OTHER|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
48640909|NCT06288711|BEHAVIORAL|Treatment as usual|Continued standard buprenorphine or methadone maintenance treatment from current treatment provider.
47957634|NCT03992014|DRUG|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
47957635|NCT03728920|OTHER|Muscle strength measurement|Patients awaiting hip arthroscopy will undergo muscle strength testing pre- and post-operatively. There will be no deviation of treatment from their NHS care. Validated outcome measure questionnaires will be completed at five months post-operatively. Magnetic resonance imaging and electromyography tests will be performed on a subset of patients post-operatively.
47957636|NCT03386318|DRUG|Oxycodone|Serum concentration per hour from 1 to 5 h
48110740|NCT03292315|DRUG|Semaglutide 1MG Injection [Ozempic]|Once weekly injection of 1mg of Semaglutide.
48110741|NCT03292315|OTHER|No Intervention|No injection will be administered
48110742|NCT01944319|DRUG|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
48304736|NCT06693128|DRUG|Camrelizumab|Camrelizumab 200mg
48110743|NCT01944319|DRUG|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
47957637|NCT01545804|DRUG|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
48110744|NCT01471392|DEVICE|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
48304737|NCT06693128|DRUG|Apatinib|Apatinib 250mg
48110745|NCT04873336|DEVICE|Intellivent ASV|A closed loop mechanical ventilation mode that adjusts oxygenization and ventilation automatically
48110746|NCT06174662|DEVICE|Music|The patient can decide the music genre (a standard playlist) and receives a noise-cancelling headphone playing the chosen music during mobilization.
48304738|NCT06693128|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
48304739|NCT01881620|DEVICE|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
48304740|NCT01697527|BIOLOGICAL|aldesleukin|Given SC
48304741|NCT01697527|DRUG|fludarabine phosphate|Given IV
48481550|NCT01961752|DRUG|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
47957638|NCT01752985|DRUG|BMS-813160|
47957639|NCT01752985|DRUG|Placebo matching with BMS-813160|
48304742|NCT01697527|DRUG|cyclophosphamide|Given IV
48304743|NCT01697527|OTHER|laboratory biomarker analysis|Correlative studies
48304744|NCT01697527|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
48304745|NCT01697527|BIOLOGICAL|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
47957640|NCT02248701|DRUG|Testosterone Enanthate|Subjects receive testosterone (125 mg/week) by intramuscular injection
47957641|NCT02248701|DRUG|Finasteride|Subjects receive finasteride (5 mg/day) orally
47957642|NCT02248701|DRUG|Placebo injection|Subjects receive placebo (weekly) by intramuscular injection
47957643|NCT02248701|DRUG|Placebo pill|Subjects receive placebo pill (daily) orally
47957644|NCT00687895|PROCEDURE|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides."
48304746|NCT01697527|RADIATION|fludeoxyglucose F 18|Undergo PET scan using \[18F\] FDG tracer
48304747|NCT01697527|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F18 PET
48640910|NCT04649242|DRUG|Rimegepant/BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
48304748|NCT03737149|OTHER|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
48304749|NCT06235463|OTHER|Osteopathic Pedal Pump|Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.
48481551|NCT01961752|DRUG|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
47957645|NCT01030536|DRUG|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
47957646|NCT01030536|DRUG|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
47957647|NCT01030536|DRUG|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
47957648|NCT01030536|DRUG|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
47957649|NCT01030536|DRUG|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
47957650|NCT00002982|BIOLOGICAL|filgrastim|
47957651|NCT00002982|DRUG|carboplatin|
47957652|NCT00002982|DRUG|carmustine|
47957653|NCT00002982|DRUG|cytarabine|
47957654|NCT00002982|DRUG|etoposide|
47957655|NCT00002982|DRUG|ifosfamide|
47957656|NCT00002982|DRUG|melphalan|
47957657|NCT00002982|PROCEDURE|autologous bone marrow transplantation|
47957658|NCT00002982|PROCEDURE|peripheral blood stem cell transplantation|
47957659|NCT00002982|RADIATION|radiation therapy|
47957660|NCT06556940|BIOLOGICAL|LMN-401|Orally delivered tablets and capsules
47957661|NCT05613361|DRUG|Colistin|added for infection with multi drug resistant bacteria
48304750|NCT06235463|OTHER|Light Touch Treatment|Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
48304751|NCT06693466|OTHER|Facial expression block|Data will be collected to assess the facial expression, body movements and vocalization of (non-) painful heat stimuli. The experiment includes individually tailored and randomly administered painful (perceived as moderate pain) and non-painful heat stimuli.
48304752|NCT06693466|OTHER|Conditioned pain modulation block|The conditioned pain modulation will be tested according to internationally agreed standards and includes a painful phasic heat (test stimulus) and a painful tonic cold stimulus (conditioning stimulus).
48304753|NCT06693466|OTHER|Pain facilitation block|Pain facilitation will be assessed by using painful mechanical pinprick stimuli. The magnitude of pain experienced after a single mechanical pinprick stimulus is compared to that of a train of 10 pinprick stimuli of the same force.
48304754|NCT03319940|DRUG|Tarlatamab|Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
48304755|NCT03319940|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
48304756|NCT03319940|DRUG|CRS Mitigation Strategies|Participants will be treated with one of the CRS mitigation strategies.
48304757|NCT02026908|DEVICE|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
48304758|NCT04814355|DRUG|Celecoxib 400 mg|Patients will receive 400 mg/day of celecoxib for 8 weeks.
48640911|NCT04649242|DRUG|Matching placebo|Matching 75 mg or 50 mg ODT placebo
48640912|NCT05095792|OTHER|Observational - no intervention|This is an observational study with no intervention.
48640913|NCT02100033|DEVICE|acupuncture|
47957662|NCT05613361|DRUG|Curcumin|added for the possible nephroprotective effect
47957663|NCT02707107|DRUG|Intravenous infusions of WCK 5222|
47957664|NCT02707107|DRUG|Placebo|
47957665|NCT01372592|PROCEDURE|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
47957666|NCT03555760|BEHAVIORAL|Observation of informed consent form readings of all patients who are scheduled for surgery|All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
47957667|NCT01374828|DRUG|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
47957668|NCT01538511|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
47957669|NCT01538511|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
47957670|NCT02762578|DRUG|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
47957671|NCT02762578|DRUG|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
47957672|NCT01581710|DRUG|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
47957673|NCT01581710|DRUG|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
47957674|NCT04402918|DIAGNOSTIC_TEST|biological samples day of delivery|mother samples: serology, viremia, nasopharyngeal swab, vaginal swab, placenta swab, piece of placenta newborn: serology, viremia, nasopharyngeal aspiration
47957675|NCT06103539|DEVICE|Cardiac catheterization and evoked response to cardiac stimulation|Cardiac catheterization with a combined elecrtophysiology and pressure sensing catheter to perform multisite stimulation and measure the evoked pressure response in a connected software.
47957676|NCT05595096|PROCEDURE|General anesthesia with preservation of spontaneous breathing|non-intubation group, thoracic paravertebral nerve block was performed before anesthesia induction,when the BIS value drops to between 40 and 60, laryngeal mask airway(LMA) is placed,and observation of breathing
47957677|NCT05622695|DEVICE|catheterization|Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.
47957678|NCT05875571|DRUG|Ketorolac|Patients will get IV ketorolac during IUD placement under sedation
47957679|NCT05875571|DRUG|Placebo|Patients will get IV placebo during IUD placement under sedation
47957680|NCT02006888|DRUG|IBI-10090|
47957681|NCT02006888|DRUG|Placebo|Placebo
47957682|NCT05715697|PROCEDURE|Sham procedure and maintenance of heart failure medications|Sham intervention, maintenance of heart failure medications
48110747|NCT05238194|OTHER|The Psychological Effects of The Covid-19 Pandemic Process|Investigation of The Psychological Effects of The Covid-19 Pandemic Process on The Health Staff Workıng in The Filation Team
48110748|NCT02804516|BEHAVIORAL|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
48110749|NCT02804516|BEHAVIORAL|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
48110750|NCT03208101|BIOLOGICAL|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
48110751|NCT03208101|BIOLOGICAL|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
48110752|NCT01063517|DRUG|olaparib|100mg BID oral tablet continuous
48110753|NCT01063517|DRUG|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
48110754|NCT01063517|DRUG|Placebo|100mg BID oral tablet to match olaparib tablet
48110755|NCT03919864|BEHAVIORAL|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
48110756|NCT03919864|BEHAVIORAL|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
48110757|NCT04010955|DRUG|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
48110758|NCT02665130|OTHER|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
48110759|NCT02665130|OTHER|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
48110760|NCT00878618|DRUG|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
48110761|NCT00878618|DRUG|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
48304759|NCT06693219|DIAGNOSTIC_TEST|ultrasonography to confirm the correct placement of a nasogastric tube in the stomach|The sonographic examination consisted of three parts: neck scan, epigastric scan, and injection test using a mixture of 25 mL NaCl 0.9% and 25 mL room air through the nasogastric tube to detect dynamic fogging
48304760|NCT06692465|DRUG|GT20029 Tincture|5mg (0.5%) and 10mg (1%) one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
48110762|NCT04190342|OTHER|control group|A booklet on the self-management of cancer symptoms. After the pilot RCT is completed, if the participants allocated to the control group are interested in practising tai chi, the intervention will be provided
48110763|NCT04190342|BEHAVIORAL|tai chi group|Around 60 minutes practising easy tai chi movements/postures twice per week
48304761|NCT06692465|DRUG|GT20029 matching placebo|5mg (0.5%) and 10mg (1%) matching placebo one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) matching placebo twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
47957683|NCT05715697|PROCEDURE|Renal denervation and maintenance of heart failure medications|Renal denervation and maintenance of heart failure medications
47957684|NCT03973710|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
47957685|NCT03973710|DIETARY_SUPPLEMENT|Placebo controls|placebo with a similar appearance to probiotics supplement
47957686|NCT04958668|OTHER|Post-operative intensive care using volatile sedation|Patients admitted after valve surgery are receiving intensive care using volatile sedative per anaesthetic conserving device. The subject of the study is medical and nursing time management..
47957687|NCT05330572|OTHER|No interventions were administered to the patients as a part of this study.|No interventions were administered to the patients as a part of this study. Patients who were under topical steroid regime as a part of their management plan for lichen planus will be enrolled on the study. Details of prescribed topical steroid regime for lichen planus: type of corticosteroid, formulation, frequency of application, duration of treatment will be recorded.
48110764|NCT02981706|PROCEDURE|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
48110765|NCT02981706|PROCEDURE|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
48304762|NCT06693726|DRUG|Angiotensin II Infusion|Angiotensin II continuous infusion
47957688|NCT06454019|BEHAVIORAL|Phone Outreach|Phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
47957689|NCT06454019|BEHAVIORAL|Standard Notice|Standard notification letter without phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
47957690|NCT05886504|OTHER|Community-based psychiatric intervention|intervention will take place in CBO offices instead of mental health department, medication will be given freely and psychiatric consultations will be free. Trained CBO members will provide individual and collective support including recall of appointments and tracing of those lost to follow-up, information on mental health, main psychiatric disorders, psychiatric medication, their potential side effects and expected benefits, contact with families and continuous support
47957691|NCT06251752|DIAGNOSTIC_TEST|X-rays: load bearing inferior limbs, lateral knee, axial patella|X-rays at 5 years follow-up minimum
47957692|NCT01686061|OTHER|No intervention- only one time survey|
47957693|NCT04824950|OTHER|Circulating tumor DNA monitoring|Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy
47957694|NCT05922111|DEVICE|cervical ripening balloon for one hour|The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
47957695|NCT05922111|DEVICE|cervical ripening balloon for twelve hours|The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
47957696|NCT04099628|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
47957697|NCT01738542|DRUG|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
47957698|NCT01738542|DRUG|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
48304763|NCT06321536|DRUG|Allogeneic Microbiota in Glycerol (9%) (AMG)|Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.
48304764|NCT04040088|PROCEDURE|Computed Tomography|Undergo PET/CT
48304765|NCT04040088|DRUG|Gallium Ga 68-DOTATATE|Given IV
48304766|NCT04040088|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48304767|NCT06690905|DRUG|Piperacillin-tazobactam administered in a prolonged infusion|For patients with the prolonged infusion intervention, the piperacillin-tazobactam dose will be administered via 100 ml 0.9% NaCl mini-bags infused and a volumetric pump over 3 hours for piperacillin-tazobactam dosages every 6 hours or overs 4 hours for piperacillin-tazobactam dosages every 8 hours.
48304768|NCT06690905|DRUG|Piperacillin-tazobactam administered in a standard infusion|For patients with the standard infusion intervention, the piperacillin-tazobactam dose will be administered over 30 minutes for every piperacilline-tazobactam administered in the study (as instructed by the drug's monograph)
48304769|NCT06689735|OTHER|schroth exercises|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
48304770|NCT06689735|OTHER|pilates exercises|The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively.
48110766|NCT02969954|OTHER|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
48304771|NCT04528082|DRUG|Apremilast|Participants will receive apremilast orally.
48304772|NCT04528082|DRUG|Placebo|Participants will receive the matching placebo orally.
47957699|NCT01738542|DRUG|Statins|
47957700|NCT01738542|DRUG|Antihypertensive therapy|
47957701|NCT04879628|DRUG|SAR441344 IV|Pharmaceutical form: Solution Route of administration: IV infusion
47957702|NCT04879628|DRUG|placebo IV|Pharmaceutical form: Solution Route of administration: IV infusion
47957703|NCT04879628|DRUG|SAR441344 SC|Pharmaceutical form: Solution Route of administration: SC injection
47957704|NCT04879628|DRUG|placebo SC|Pharmaceutical form: Solution Route of administration: SC injection
47957705|NCT04879628|DRUG|MRI contrast-enhancing preparations|gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
47957706|NCT05720208|DEVICE|SCiP|Noninvasive Spinal Cord Neuromodulator
47957707|NCT06558071|DRUG|Galatonol 300 mg/Striatin 30 mg|1 film-coated caplet of Herba Asimor, twice daily
47957708|NCT06558071|DRUG|Placebo|1 film-coated caplet of placebo Herba Asimor, twice daily
47957709|NCT01682954|BEHAVIORAL|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
47957710|NCT00053443|DEVICE|Medication Reminder System/Adherence Tracker|
47957711|NCT01332370|DRUG|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
47957712|NCT01332370|DRUG|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
47957713|NCT05706493|OTHER|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
47957714|NCT03428932|DEVICE|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
48110767|NCT01441934|DRUG|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
47957715|NCT03428932|OTHER|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
47957716|NCT04010695|DIAGNOSTIC_TEST|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
47957717|NCT04010695|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
47957718|NCT04010695|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
47957719|NCT02002091|OTHER|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
48110768|NCT01441934|DRUG|Sugar pills|placebo t.i.d.
48110769|NCT01801293|DRUG|GS-5806|
48110770|NCT03579368|DEVICE|Symfony implantation|Bilateral Symfony IOL Implantation
48110771|NCT02860884|PROCEDURE|liver biopsy|
48110772|NCT02860884|OTHER|infrared spectroscopy|
48640914|NCT06431386|BEHAVIORAL|Behavioural Activation (BA) Therapy|Participants will receive weekly one-hour BA sessions on a day they are not receiving esketamine, delivered virtually or in person as per participant preference. The aim is for participants to learn to observe the relationship between what they did, felt, and thought and what was happening around them, and to identify conditions which maintained, increased, or weakened maladaptive behaviours. Functional behaviour analysis will be used in problem and behaviour evaluation and in planning and reviewing changes introduced by participants between sessions. Other techniques include self-observation and self-report, elaboration of activity hierarchies, behaviour programming, rehearsal and behavioural modelling, and contingency management. Between-session homework will develop relevant and rewarding routines to offer reinforcement in each participant's environment. Participants will be offered 12 BA sessions in total.
47957720|NCT06546657|OTHER|Breakfast|Breakfast meal
48110773|NCT00001524|DRUG|Thalidomide|
48110774|NCT05480358|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet ProlonADTM|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
48304773|NCT06681740|DEVICE|Inspiratory muscle training|The control group will perform a standard cardiac rehabilitation program, consisting of 16 multicomponent exercise sessions, health education, and a weekly group of psychological therapy session. The intervention group will do the same program with the addition of Inspiratory Muscle Training (IMT). The following device will be used: Power Breath model: Medic Classic. The training will be performed by adjusting the device load to 70% of the Maximum Inspiratory Pressure value, performing 1 daily training session 4 days a week of 3 sets of 10 repetitions, with a rest of 3 minutes between sets, during 8 weeks. A physical therapist will teach participants how to use the device on the first day and they will be instructed to perform it at home. They will be given a diary to record their compliance. In addition, once a week the physiotherapist will supervise the execution of the IMT by the participants.
47957721|NCT00546104|DRUG|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
47957722|NCT05942560|BEHAVIORAL|Cognitive behavioural therapy-based intervention|"A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure."
47957723|NCT05942560|BEHAVIORAL|Educational group|The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
47957724|NCT00395681|DRUG|Diprivan|Propofol 200 mg versus 350 mg
47957725|NCT03240354|DEVICE|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
47957726|NCT03240354|DEVICE|Control|Cuff of endotracheal tube inflated with air
48110775|NCT04215406|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.
48110776|NCT02138006|DRUG|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
48110777|NCT02138006|DRUG|Standard insulin treatment|Insulin Mixtard
48110778|NCT06002542|BEHAVIORAL|Information provided|get information at every stage of care in emergency room
48304774|NCT06681740|DEVICE|Sham Inspiratory muscle training|The control group will be given the same device as experimental group, but the load for all of the participants of the control group will be 5cm de H2O. This load is so low that it´s not able to induce improvement of the inspiratory musculature.
48110779|NCT06002542|BEHAVIORAL|Control|Information is only provided when participants request it.
47957727|NCT02364726|PROCEDURE|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
47957728|NCT02364726|BEHAVIORAL|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
47957729|NCT02364726|BEHAVIORAL|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
47957730|NCT03889106|DRUG|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
47957731|NCT04803461|DIAGNOSTIC_TEST|serum and urinary catecholamines|estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.
48110780|NCT00004004|DRUG|procarbazine hydrochloride|
48110781|NCT02739035|DRUG|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
48110782|NCT02739035|DRUG|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
47957732|NCT01622231|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
47957733|NCT00001963|PROCEDURE|hemoglobin-transported nitric oxide|
48110783|NCT00506727|DRUG|Mixed amphetamine salts (ADDERALL XR)|
48110784|NCT00506727|DRUG|Atomoxetine hydrochloride|
48110785|NCT06121310|OTHER|Survey|Non interventional. Pediatric anesthesia satisfaction scale validity and reliability is going to investigate by survey analyses
48110786|NCT01382030|DRUG|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
48304775|NCT05635734|DRUG|Azeliragon 5 mg|"Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
48110787|NCT01712113|DRUG|Irbesartan|
48110788|NCT01712113|DRUG|Avapro|
48110789|NCT02033018|DRUG|Aflibercept Injection|Aflibercept intravitreal injection
47957734|NCT03585062|DRUG|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
47957735|NCT03585062|DRUG|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
47957736|NCT04558944|DEVICE|Extracorporal Shock Wave Therapy|Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
47957737|NCT03186495|DRUG|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
48110790|NCT02378155|DEVICE|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
48110791|NCT02589002|OTHER|Sucralose|
48110792|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
48110793|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
48110794|NCT00822055|DRUG|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
48110795|NCT00822055|DRUG|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
48110796|NCT02082158|OTHER|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
48110797|NCT05543915|DEVICE|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
48110798|NCT03907098|DRUG|Endostar|an anti-angiogenesis drug
48110799|NCT03907098|DRUG|Chemotherapy|Physician's choice
48110800|NCT04653935|BEHAVIORAL|Self-management app with all intervention components|A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
47957738|NCT00276497|DRUG|Pioglitazone|
47957739|NCT00375037|BEHAVIORAL|feedback|
47957740|NCT00375037|BEHAVIORAL|Education|
47957741|NCT00375037|OTHER|usual care|
47957742|NCT00983437|DRUG|Armodafinil|
47957743|NCT01021930|DEVICE|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
47957744|NCT04939116|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule
47957745|NCT04939116|DRUG|Placebo|Orally administered placebo capsule
47957746|NCT00078182|DRUG|Tenofovir DF|
47957747|NCT05905900|COMBINATION_PRODUCT|Emergent IV Dye Preparation|Diphenhydramine 50 mg IV once, famotidine 20 mg IV once, and dexamethasone 10 mg IV once
47957748|NCT01052571|PROCEDURE|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
47957749|NCT00293033|DRUG|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
47957750|NCT00293033|DRUG|Placebo|
48110801|NCT04653935|BEHAVIORAL|Self-management app with Information component only|self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
48110802|NCT05790616|PROCEDURE|Arterial blood draw|"For the IN(Fast-Sitting) arm arterial blood will be collected to derive Gold-standard SaO2 reference values."
48110803|NCT05790616|OTHER|Oxygen reduction|Volunteers undergo an ambient oxygen decrease from 21% to 10%
48304776|NCT05635734|DRUG|Azeliragon 10 mg|"Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
48481552|NCT01961752|DRUG|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
48481553|NCT00058214|DRUG|perifosine|Given orally
48481554|NCT00058214|OTHER|laboratory biomarker analysis|Correlative studies
48655978|NCT03449576|OTHER|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
48110804|NCT04465734|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
48110805|NCT04465734|DRUG|HLX04|HLX04 is an recombinant anti-VEGF humanized monoclonal antibody ，developed by Shanghai Henlius Biotech, Inc.
48110806|NCT04465734|DRUG|Sorafenib|Sorafenib is a multi-target, multi-kinase inhibitor capable.The standard treatment of HCC.
47957751|NCT02633605|DEVICE|First Sense Medical®|
47957752|NCT02343237|PROCEDURE|Osteopathic treatment|osteopathic sessions of 20 minutes
47957753|NCT02343237|PROCEDURE|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
47957754|NCT02384161|OTHER|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
48110807|NCT05005065|DRUG|IN-C005 X mg|Oral capsule
48110808|NCT05005065|DRUG|IN-A001 Y mg|Oral tablet
48110809|NCT05005065|DRUG|IN-C005 Y mg|Oral capsule
48110810|NCT05005065|DRUG|IN-C005 Z mg|Oral capsule
48110811|NCT00240916|BIOLOGICAL|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
48110812|NCT00240916|BIOLOGICAL|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
48110813|NCT04662840|PROCEDURE|Geniculate artery embolization|Under fluoroscopic guidance and angiographic imaging, a microcatheter is used to select all the arteries feeding the affected knee and Embosphere (100-300um) particles are injected to obtaining pruning of the hypervascular tissues arteries.
48481555|NCT01933919|DRUG|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
48481556|NCT01933919|DRUG|Placebo|Placebo tablet matching to fluvoxamine maleate
48481557|NCT00148720|DRUG|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
48481558|NCT05846464|DEVICE|Meta Quest 2|The Meta/Oculus Quest (along with the SignWave software) delivers an immersive audio/visual-based game environment where the users hand is created and displayed in the virtual environment and matches target gestures to the beat of the music.
47957755|NCT05455268|OTHER|eHOPE|"e-Haematological Oncology Parents Education (eHOPE) consists of caregiving information for parents of children with leukaemia and lymphoma, presented in multimedia format through an online learning platform. The contents are developed in Malay language, encompassing basic information on disease and treatment, medical caregiving, emotional caregiving, appraising information, communication and self-care. Parents will be able to access multimedia information designed to support them in the care of their sick child. There are 4 self-paced activities in eHOPE with the following objectives:~1. Parents should be able to outline key tasks related to care for their child at home.~2. Parents should be able to outline strategies to initiate discussions with their child's healthcare providers.~3. Parents should be able to appraise reliability of information sources.~4. Parents should be able to identify coping strategies that they can use when faced with stressful situations."
47957756|NCT05455268|OTHER|Usual care|Face-to-face verbal discussions and caregiver training will be provided as deemed necessary by the clinicians.
47957757|NCT02000180|BEHAVIORAL|Progressive Group|
47957758|NCT00335361|DEVICE|Intra Vas Device (IVD)|
47957759|NCT01095211|DRUG|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
47957760|NCT05964101|DRUG|Nivolumab Injection [Opdivo]|Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
47957761|NCT00109122|BIOLOGICAL|zoster vaccine live (Oka/Merck)|
48110814|NCT04662840|PROCEDURE|Geniculate nerve ablation|Under fluoroscopic guidance, a Cool-tip RFA ablation needle is advanced such that it touches the femur at the condylar convexity on each side and the tibia at the tibial plateau convexity on the medial side. The ablation is performed to obtain an approximate zone of ablation of 2cm.
48110815|NCT04662840|PROCEDURE|Skin infiltration of local anesthetic at groin and knee|Freezing of the skin will be performed at the groin (as prior to an arterial access for embolization procedure) and at three areas around the knee (as prior to insertion of the ablation needles for nerve ablation procedure).
48304777|NCT05635734|DRUG|Azeliragon 20 mg|"Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
48304778|NCT04662710|BIOLOGICAL|Pembrolizumab|400 mg Q6W by IV infusion
48304779|NCT04662710|BIOLOGICAL|Lenvatinib|Administered PO QD, 8 mg induction/20 mg consolidation.
48304780|NCT04662710|DRUG|Oxaliplatin|130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
48304781|NCT04662710|DRUG|Capecitabine|1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.
48304782|NCT04662710|DRUG|Leucovorin (or Levoleucovorin)|Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
48304783|NCT04662710|DRUG|5-FU|400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
48304784|NCT06586320|DRUG|150% of their routine home dopaminergic medications dose right in the clinic|IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar to home dose with no change. This will be under the supervision of their treating movement disorders specialist and study PI.
48304785|NCT06586320|DEVICE|Evaluation of mathematical models|Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
48304786|NCT05024045|DRUG|LOXO-338|Oral
48304787|NCT05024045|DRUG|Pirtobrutinib|Oral
47957762|NCT00109122|BIOLOGICAL|Comparator: placebo (unspecified)|
47957763|NCT00119431|DRUG|C1 inhibitor concentrate|
47957764|NCT01580085|OTHER|polysomnography|full night supervised laboratory polysomnography
47957765|NCT00250055|PROCEDURE|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
47957766|NCT03925857|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
47957767|NCT03530969|BEHAVIORAL|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
47957768|NCT03530969|BEHAVIORAL|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
47957769|NCT03530969|BEHAVIORAL|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
47957770|NCT03530969|BEHAVIORAL|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
47957771|NCT03530969|BEHAVIORAL|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
47957772|NCT03530969|BEHAVIORAL|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
47957773|NCT03855865|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
47957774|NCT03855865|DRUG|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
47957775|NCT03855865|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
47957776|NCT02917733|DRUG|LY3039478|Administered orally
47957777|NCT01577368|DRUG|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
47957778|NCT01577368|DRUG|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
47957779|NCT03353246|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
47957780|NCT06066125|DRUG|AK111|AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
47957781|NCT06066125|DRUG|AK111|AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
47957782|NCT06066125|DRUG|Placebo|Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
47957783|NCT01747148|DRUG|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
47957784|NCT04878497|DRUG|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
48110816|NCT03662048|BEHAVIORAL|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
48110817|NCT00212784|DRUG|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
48110818|NCT00212784|DRUG|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
48110819|NCT01828320|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
48110820|NCT01828320|BEHAVIORAL|Psychoeducation|
48481559|NCT02676284|DEVICE|Durolane SJ|DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
48110821|NCT05503212|OTHER|Conservative treatment (CT)|Best medical treatment without intravenous thrombolysis nor endovascular thrombectomy
48110822|NCT05503212|OTHER|Intravenous thrombolysis (IVT)|Best medical treatment with intravenous thrombolysis but without endovascular thrombectomy
47957785|NCT04878497|DRUG|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
47957786|NCT04878497|DRUG|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
47957787|NCT04878497|DRUG|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
47957788|NCT04878497|DRUG|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
47957789|NCT01993706|DRUG|VRC-HIVMAB060-00-AB|
47957790|NCT05580393|DIAGNOSTIC_TEST|RFLP analysis of SSU rRNA|"1. Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~2. PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~3. The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
48481560|NCT04837079|OTHER|Clinical observational study|Clinical observational study
48640915|NCT06431386|DRUG|Esketamine|Participants will receive intranasal esketamine twice weekly during the induction phase (first 4 weeks of treatment). Maintenance treatments are administered once per week or once every two weeks at the discretion of the treating physician for 8 additional weeks, totaling 12 weeks of esketamine treatment. Dosing for esketamine usually starts at 56mg on Day 1, followed by 56 or 84mg doses for subsequent treatments.
47957791|NCT03791138|OTHER|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
48110823|NCT05503212|OTHER|Endovascular thrombectomy (EVT) ± intravenous thrombolysis (IVT)|Best medical treatment with endovascular thrombectomy with or without intravenous thrombolysis
48110824|NCT01764451|DRUG|Simvastatin|
48110825|NCT00993850|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
48304788|NCT06663358|DRUG|Pegunigalsidase-alfa|Administered via intravenous (IV) infusion under conditions of routine clinical care
48304789|NCT02071134|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
48304791|NCT02325674|DRUG|Metreleptin|
48304792|NCT02411812|DEVICE|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
48481561|NCT06105164|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher."
48481562|NCT06105164|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
47957792|NCT04811885|OTHER|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
48110826|NCT00993850|OTHER|Bipolar education|Psychoeducation
48304793|NCT02411812|DEVICE|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
48304794|NCT02411812|DEVICE|Twin-Block appliance|Group treated with Twin-Block appliance
48304795|NCT03558893|BEHAVIORAL|Forced Desynchrony|All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
47957793|NCT04027543|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
48304797|NCT06348420|PROCEDURE|anti-reflux mucosal valvuloplasty (ARMV)|During the ARMV procedure, a segment of the mucosa at the esophagogastric junction (EGJ) is released and reconstructed to form a mucosal flap. Cautery markings are made on 3/4-4/5 of the mucosa along the lesser curvature, approximately 2 cm below the dentate line. After submucosal injection of saline with indigocarmine, the premarked mucosa is dissected from the caudal to cranial side using an endoscopic submucosal dissection technique. The cranial edge of the released mucosa is left in place, and the semi-free mucosa naturally curls to form a double-layer flap. Metal clips are then used to anchor the free edge of the mucosa to the exposed submucosa/smooth muscle to prevent flattening of the mucosal flap. Any visible bleeding on the exposed submucosa is coagulated using electric forceps.
48304798|NCT04809467|DRUG|tafasitamab|tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.
47957794|NCT04027543|PROCEDURE|Oesophagectomy|Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
48304799|NCT04809467|DRUG|parsaclisib|parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.
48304801|NCT06692218|DEVICE|Leadless pacemaker|Patients who will implant leadless pacemakers or already implanted leadless pacemakers since 1 Jan 2015 will be recruited. After the implantation, patients will be invited back for a noncontrast, ECG-gated CT heart. It will be timed at the end diastole and a 3D reconstruction will be performed.
48304802|NCT06693492|DEVICE|Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention|Both chronic and post-acute patients are evaluated through the ultrasound technique to further characterize the mechanisms underlying DOC following acquired brain injuries (e.g., stroke, traumatic brain injury, anoxic events). Furthermore, the predictive value of structural and functional markers for DOC chronicization is explored by following up post-acute DOC patients 1 year after the acute event. Finally, to innovate the therapeutic approach to DOC patients, we adopt the low-intensity focused ultrasound (FUS) on a group of selected 10 patients out of the 100 DOC patients enrolled in the study to modulate brain networks' functioning targeting key brain structures for the recovery of consciousness.
48304803|NCT06486636|PROCEDURE|Left Posterior Pericardiotomy|The surgeon will perform a left posterior pericardiotomy while the patient is on cardiopulmonary bypass. A soft channel drain will be put into place at an angle directed toward the posterior pericardium. The surgeon will grasp the pericardium and use cautery to make a 4- to 5-cm opening between the left inferior pulmonary vein and the diaphragm. The previously prepared channel drain is cut to the desired length and placed through the pericardiotomy along the diaphragm and into the pleural space.
48304804|NCT06388590|OTHER|Dragons|The Dragons Script will be read to the subjects by the provider administering treatment. Subjects will receive their Acupuncture treatment with Dragons protocol.
48304805|NCT06388590|OTHER|Standard of Care|Standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention.
48304806|NCT06693609|DRUG|EMP-01|EMP-01 capsules
48481563|NCT04490226|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate as Ca-Mg-salt, active|24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
48304807|NCT06693609|DRUG|EMP-01 Placebo|EMP-01 placebo capsules
47957795|NCT04027543|DRUG|Neoadjuvant chemotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
47957796|NCT03421535|PROCEDURE|Sleeper Stretch|Internal Range of motion of dominant shoulder
47957797|NCT03421535|PROCEDURE|Opposite SI joint Stretch|Internal range of motion of dominant shoulder
47957798|NCT00018031|DRUG|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
48304808|NCT06235099|DRUG|Copper Cu 64 PSMA I&T|Radiopharmaceutical PET imaging tracer injected intravenously for the detection of PSMA expression.
48304809|NCT05606965|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
48304810|NCT05606965|BIOLOGICAL|Egg-based Quadrivalent Influenza Vaccine|Sterile suspension for injection
48304811|NCT05606965|BIOLOGICAL|Adjuvanted Quadrivalent Influenza Vaccine|Sterile injectable emulsion
47957799|NCT00018031|DRUG|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
47957800|NCT03700593|DEVICE|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
47957801|NCT06483178|DEVICE|Attune knee implant|Attune cementless cruciate retaining rotating platform implant (DePuy Synthes) with a standard gap balancing cruciate sacrificing surgical technique
47957802|NCT06483178|DEVICE|Triathlon knee implant|Triathlon cementless condylar stabilised implant (Stryker) with a standard gap balancing cruciate sacrificing surgical technique
47957803|NCT02005731|DEVICE|Low intensity linear focused shockwave device ('Renova')|
47957804|NCT00797771|DEVICE|"Adi Insulin pump"|insulin delivery will be defined by the physician
47957805|NCT05898685|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of eight 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with normoxic cycles to resaturation.
47957806|NCT05898685|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of eight 4-minute normoxic cycles (compressed air) interspersed with 1-minute normoxic cycles (room air)
47957807|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
47957808|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
47957809|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
47957810|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
47957811|NCT05763693|DRUG|Azithromycin at Baseline|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at baseline
47957812|NCT05763693|DRUG|Azithromycin at Day 21|this group will be randomized to receive a single oral dose of azithromycin (20mg/kg) at the day 21 visit
47957813|NCT05763693|OTHER|Placebo at Baseline|this group will be randomized to receive Placebo at baseline
47957814|NCT05763693|OTHER|Placebo at Day 21|This group will be randomized to receive Placebo at the day 21 visit
47957815|NCT05664607|OTHER|for excise, nutrition consultant, nutrition supplement and psychologic intervention.|for excise, nutrition consultant, nutrition supplement and psychologic intervention.
47957816|NCT03286738|DRUG|FOLFIRI, target agent|"* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
47957817|NCT04258865|DRUG|CKD-348 F1|QD, PO
47957818|NCT04258865|DRUG|CKD-348 F2|QD, PO
47957819|NCT04258865|DRUG|CKD-828, D097, D337|QD, PO
48110827|NCT04477538|OTHER|Post-mastectomy breast reconstruction physical well-being survey|-The survey will ascertain: function status (BREAST Q - Physical Well Being Module and PROMIS upper extremity function), former interaction with physical or occupational therapy, amount of narcotics taken weekly due to chest/neck/breast pain, amount of Tylenol or similar anti-inflammatories taken weekly due to chest/neck/breast pain, and amount of muscle relaxants taken weekly due to chest/neck/breast pain.
47957820|NCT02721160|OTHER|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~* nb of cases screened and referred to HC for acute malnutrition (AM)~* nb of classes promoting good nutrition~HC level~* nb of cases screened and cared for severe and moderate AM~* nb of growth follow-ups~Hospital level~* nb of treated severe AM cases with complications~* length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
47957821|NCT03298906|DRUG|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
47957822|NCT03298906|DRUG|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
47957823|NCT05140785|DIAGNOSTIC_TEST|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
47957824|NCT01004965|OTHER|laboratory biomarker analysis|
47957825|NCT01887665|BEHAVIORAL|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
48304812|NCT05606965|BIOLOGICAL|Inactivated Influenza Vaccine|Sterile suspension for injection
48304813|NCT05606965|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
48304814|NCT05606965|BIOLOGICAL|mRNA-1045|Sterile liquid for injection
47957826|NCT01237821|DRUG|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
47957827|NCT01237821|DRUG|Effaclar|Topical, Bid, 12 weeks
47957828|NCT00141843|GENETIC|ReFacto AF|
47957829|NCT00141843|GENETIC|B-Domain deleted Recombinant Factor VIII|
47957830|NCT00141843|GENETIC|BDDrFVIII|
47957831|NCT02234388|OTHER|Observation|There are no interventions associated with this registry as it is purely observational.
47957832|NCT00842582|DRUG|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
47957833|NCT00842582|DRUG|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
47957834|NCT00842582|DRUG|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
47957835|NCT03641339|OTHER|One vector feeding|Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
47957836|NCT03641339|OTHER|Four vector feeding|Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
47957837|NCT05351502|DRUG|Nitric Oxide 25,000 ppm|Intratumoral injection of 25,000 gNO
47957838|NCT05351502|DRUG|Nitric Oxide 50,000 ppm|Intratumoral injection of 50000 gNO
47957839|NCT05351502|DRUG|Nitric Oxide 100,000 ppm|Intratumoral injection of 100,000 gNO
47957840|NCT05351502|DRUG|Nitric Oxide selected dose|Intratumoral injection of selected does on gNO
48304815|NCT04736173|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
48304816|NCT04736173|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
48304817|NCT04736173|DRUG|Carboplatin|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
48304818|NCT04736173|DRUG|Paclitaxel|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
48304819|NCT04736173|DRUG|Pemetrexed|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
48304820|NCT04736173|DRUG|Pembrolizumab|Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
48304823|NCT05720611|BEHAVIORAL|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
48481564|NCT04490226|DIETARY_SUPPLEMENT|ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active|24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
47957841|NCT03062982|DRUG|Fluzoparib|2 doses separated by 7 days.
47957842|NCT05832801|OTHER|( Traditional dietary advice )|traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
47957843|NCT05832801|OTHER|(Pilates exercises)|Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (first- eighth session) composed of one set of eight repetitions Second month (eighth-sixteenth session) composed of two sets of ten repetitions
47957844|NCT03556735|DEVICE|Treatment with PEMF equipment|Treatment with PEMF in 8 weeks
47957845|NCT03859778|OTHER|survey|French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
47957846|NCT00880984|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
47957847|NCT03940287|OTHER|Muscle Energy Technique|"Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times."
48110828|NCT06291233|BEHAVIORAL|Virtual Interview Training (VIT)|Teachers will administer the intervention (Virtual Interview Training) with the student participants. University of Michigan research staff will train all teachers (including sites in California) and will provide support as necessary throughout the intervention delivery process. Surveys will be captures several times throughout delivery as delivery is expected to be anywhere between 4 to 6 weeks long.
48110829|NCT06291233|BEHAVIORAL|Services-as-usual|Participants will receive services-as-usual at participants school or program for approximately 6 weeks. Those that are in the active control group will receive access to the e-learning content of the Rita/Travis intervention (not the practice interviews) and will be able to review the e-learning content with teacher's supervision. In addition, this group will review a series of video conversations with autistic adults about navigating the pathway to a career. Surveys will be collected at different time points after randomization.
48481565|NCT04490226|DIETARY_SUPPLEMENT|fasting, active|36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
48481566|NCT04490226|DIETARY_SUPPLEMENT|fasting, inactive|"36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later."
48481567|NCT02504814|DEVICE|Nasal Highflow (NHF)|changes in breathing physiology in NHF
47957848|NCT03940287|OTHER|Kinesiotape application|"Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur."
47957849|NCT03940287|OTHER|Conventional physiotherapy|Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
47957850|NCT05009264|PROCEDURE|OMT|OMT will be performed on identified areas of trapezius trigger points
47957851|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
47957852|NCT01206075|DRUG|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
47957853|NCT01206075|DRUG|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
47957854|NCT02573168|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
47957855|NCT02573168|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
47957856|NCT02573168|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
47957857|NCT05241743|OTHER|radiological examination, pain, nomophobia, phone addiction|120 patients who applied to the clinic with the complaint of neck pain and were diagnosed with cervical hypolordosis by radiological examination will be included in the study. After giving the necessary verbal and written information about the study, a link will be sent to the phones of the patients whose informed consent was obtained. Patients will access evaluation questions and survey questions via this link. Personal information with the Sociodemographic Data Form prepared by us; pain severity by Visual Analogue Scale (VAS); phone addiction level with the Smartphone Addiction Questionnaire (Young Population); nomophobia levels will be evaluated with the Nomophobia Scale.
48110830|NCT04635267|OTHER|Prone position in patients with ARDS|Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
48110831|NCT04736849|DEVICE|Percutaneous epidural and dorsal root stimulation|"Abbott percutaneous trial lead for dorsal root ganglion neurostimulation (Model MN10350)~Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
48481568|NCT04530279|PROCEDURE|Clinical assessment|Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
48640916|NCT06089980|BEHAVIORAL|Effects from acute kratom exposure|Participants who regularly use commercial Kratom products will orally consume a known quantity of kratom under direct observation on first study day; following this, participants will stop kratom use for approximately 2 nights and 2.5 days for the duration of the study.
48640917|NCT03019653|DRUG|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
48481569|NCT06312423|DRUG|Oligonucleotides, Phosphorothioate|Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
48481570|NCT02638519|OTHER|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
48481571|NCT02638519|OTHER|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
48640918|NCT03019653|DRUG|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
48640919|NCT06120504|DRUG|SGN-35T|Given into the vein (IV; intravenously)
48640920|NCT02269774|PROCEDURE|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
47957858|NCT01995110|OTHER|high-fat meal A|
47957859|NCT01995110|OTHER|high-fat meal B|
47957860|NCT01995110|OTHER|high-fat meal C|
47957861|NCT01284101|DEVICE|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
47957862|NCT01284101|DEVICE|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
47957863|NCT01590459|DRUG|VX-509|50 mg oral tablet
47957864|NCT01590459|DRUG|VX-509 matching placebo|0 mg oral tablet
47957865|NCT05167929|BEHAVIORAL|Self-determination Enhancement Group|The self-determination enhancement group - Each group has eight participants. There will be 10 sessions per group and each session will last 1.5 hours.
47957866|NCT05167929|BEHAVIORAL|Self-determination Enhancement Plus Group|The self-determination enhancement PLUS group - Each group has eight participants and their caregivers. There will be 10 sessions per group and each session will last 1.5 hours. Meanwhile, their caregivers will attend four sessions separately and each session will last 1.5 hours.
47957867|NCT05167929|BEHAVIORAL|Leisure activity group|Leisure activity group - Leisure activity group is the comparison group. Each group will consist of eight adults with mild intellectual disability. There will be 10 sessions for the group and each session will last for 1.5 hours.
47957868|NCT05615168|DIAGNOSTIC_TEST|"Acumen IQ guided hemodynamic optimization"|"Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions."
47957869|NCT05615168|DIAGNOSTIC_TEST|"Flotrac guided hemodynamic optimization"|"Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor."
48110832|NCT03311113|OTHER|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
48110833|NCT02961127|OTHER|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
48110834|NCT05417542|OTHER|EEG|EEG recording during prematurity or around term
48110835|NCT05417542|OTHER|NIRS|NIRS recording during prematurity or around term
48640921|NCT06490874|DEVICE|CGM device - Metformin group|Individuals randomized to metformin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
47957870|NCT03180073|DIAGNOSTIC_TEST|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
47957871|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
47957872|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
47957873|NCT03566784|PROCEDURE|Inguinal hernia repair|Standard procedure for inguinal hernia repair
47957874|NCT04794309|OTHER|Circuit training exercise|"circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks."
47957875|NCT04794309|DIETARY_SUPPLEMENT|Healthy high Fiber diet|The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
47957876|NCT01275820|DIETARY_SUPPLEMENT|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
47957877|NCT04437563|BEHAVIORAL|HERMES|Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
47957878|NCT06361433|DRUG|HUFF-01|autologous MSC combined with scaffold
47957879|NCT00106197|DRUG|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
47957880|NCT05428046|BEHAVIORAL|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
47957881|NCT05428046|BEHAVIORAL|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
48640922|NCT06490874|DEVICE|CGM device - Insulin group|Individuals randomized to insulin will be provided with a CGM device (Dexcom, Inc, San Diego, CA) to be worn for up to 10 days (minimum \>5 days) at two pregnancy (randomization to metformin or insulin, late third trimester \> 340/7 weeks) and three postpartum timepoints (immediately after delivery, \~6 weeks, and \~2 years).
48640923|NCT05293314|DIAGNOSTIC_TEST|An exhaled breath test|All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.
48640924|NCT05187910|BEHAVIORAL|Speech Therapy|Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
48640925|NCT05187910|BEHAVIORAL|Swallowing Therapy|Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
48640926|NCT05187910|BEHAVIORAL|Upper Airway Therapy|Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
48640927|NCT06526078|BEHAVIORAL|Cognitive Training|Sessions of cognitive training exercises (15-20min each) self-administered via a web app
48640928|NCT06526078|BEHAVIORAL|Sham Training|Sessions of sham training exercises (15-20min each) self-administered via a web app
48110836|NCT05516654|DIAGNOSTIC_TEST|Routine bacteriological cultures|culture of different samples on different culture media as nutrient agar, blood agar, MacConkey agar, EMB agar, TSI
47957882|NCT01267045|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
47957883|NCT00728793|DRUG|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
47957884|NCT03084770|DIAGNOSTIC_TEST|Radiological imaging studies|Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67\> 2%) a high quality imaging (CT scan or MRI) is required.
48110837|NCT05516654|DIAGNOSTIC_TEST|Identification of the organism and antibiotic sensitivity will be done by VITEK II|Automated identification of the organism and antibiotic sensitivity will be done by VITEK II
48110838|NCT05516654|DIAGNOSTIC_TEST|Detection of biofilm formation|Detection of Biofilm formation to the collected organism by tissue culture plate method.
48110839|NCT05516654|DIAGNOSTIC_TEST|Molecular detection by PCR|Molecular detection of Type VI Secretion System genes, capsular serotyping( k1, k2), and FimH genes by PCR.
48481572|NCT02638519|DRUG|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
48110840|NCT00739518|PROCEDURE|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
48110841|NCT04050631|BEHAVIORAL|maternal arrest simulation on L&D floor|AFE on L\&D
48110842|NCT04554628|DIAGNOSTIC_TEST|ELISA test in urine|enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients
48304825|NCT06691269|DEVICE|Photobiomodulation|Photomodulation (PBM) is a promising non-tissue penetrating (i.e. minimally invasive) approach for achieving tooth and soft tissue anesthesia/analgesia in dental patients. A patent pending near-infrared laser technology that aims to provide dental analgesia will be used for PBM. This intra-oral PBM device comes with a tip comprising of a series of photonic emitters with specific wavelengths that can go through the tooth structure and bone, blocking the nerve conduction like local anesthetics. Research has shown that one burst of light application (for about 20 second) can provide up to 15-20 minutes of pain relief. Based on existing research PBM does not present a serious risk to health, safety, or welfare of a subject.
48640929|NCT05945355|DEVICE|Pro2 - Low Dose - 40% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
47957885|NCT03084770|OTHER|Quality of Life Assessment|quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
47957886|NCT03209531|BEHAVIORAL|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
47957887|NCT03209531|BEHAVIORAL|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
47957888|NCT03209531|DEVICE|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
47957889|NCT02768363|BIOLOGICAL|aglatimagene besadenovec|Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
47957890|NCT02768363|BIOLOGICAL|placebo|Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
48481573|NCT02638519|DEVICE|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
48481574|NCT04884061|OTHER|NBI images and/or videos|A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
48640930|NCT05945355|DEVICE|Pro2 - High Dose - 75% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
47957891|NCT02768363|DRUG|valacyclovir|Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
48110843|NCT02239796|DEVICE|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
47957892|NCT03519620|OTHER|SWWSV|Behaviours to prevent child obesity
48110844|NCT02239796|DEVICE|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
48110845|NCT03016455|OTHER|Presence of DSA w/ cAMR|
47957893|NCT02917850|PROCEDURE|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
48110846|NCT03016455|OTHER|Presence of DSA w/o cAMR|
47957894|NCT02917850|PROCEDURE|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
47957895|NCT00384657|DRUG|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
47957896|NCT04111575|BEHAVIORAL|Music Therapy|Music Therapy
48110847|NCT03016455|OTHER|No DSA No cAMR|
48110848|NCT05390736|BEHAVIORAL|Gait and balance assessment|Patients are given Time Up and Go (TUG) tests, 30-second chair test, and 4-stage balance test (side-by-side, instep, tandem, and one foot).
48304826|NCT06691269|DRUG|Topical Benzocaine|Topical Benzocaine at injection site to reduce discomfort of local infiltration
48304827|NCT06691269|DRUG|Local Anesthesia|Local infiltration using local anesthetics with epinephrine
48304828|NCT06692101|OTHER|oral care|We prepared the necessary tools and suction devices, then helped patients sit upright before starting oral care. Using a flashlight and toothbrush, we assessed the mouth and removed any food debris, aspirating saliva if needed. We cleaned the teeth using a toothbrush, dental floss, and an interdental brush with a small amount of fluoridated toothpaste. The Bass method was used for brushing. Finally, we cleaned the front two-thirds of the tongue with a damp toothbrush.
47957897|NCT05624281|DRUG|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
47957898|NCT00199875|DRUG|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
47957899|NCT02114801|DEVICE|manual brushing|Tooth brushing
47957900|NCT02114801|DEVICE|electric toothbrush linked|Tooth brushing
47957901|NCT02114801|DEVICE|off electric toothbrush|Tooth brushing
47957902|NCT01449539|DRUG|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
48110849|NCT05390736|BEHAVIORAL|Medication review|Patients' medication history in the EHR is assessed for polypharmacy (using 5 or more medications concurrently) and use of medication in the following classes: tricyclic antidepressants, antihistamines, antiemetics, antipsychotics, antispasmotics, muscle relaxants, benzodiazepines, hypnotics, and opioids. The CRN confirms prescriptions with the patient. The CRN reports the medication risk in her provider report and provides medication management educational materials to the patient. At the patient's upcoming primary care visit, providers evaluated whether the medications associated with increased fall risk could be adjusted.
48110850|NCT05390736|BEHAVIORAL|Comorbidity review|The clinical research nurse reviews the patient's EHR problem list for diagnoses of comorbidities associated with increased fall risk including: cognition problems, Parkinson's disease, cardiac issues, depression, or incontinence. Comorbidities are shared with providers in the recommendation statement.
48110851|NCT05390736|BEHAVIORAL|Fall history|The CRN asks how many times the patient had fallen in the past 12 months, whether those with falls sought medical attention, and if they experienced blackouts, loss of consciousness, or a broken/fractured bone(s) resulting from a fall. Fall history information is added to the provider report to increase the salience of fall prevention information.
48304829|NCT06692101|DEVICE|Neuromuscular Electrical Stimulation (NMES)|We used the VitalStim® device to deliver neuromuscular electrical stimulation (NMES). Before placing the electrodes, participants were asked to shave any facial hair and clean their neck skin with alcohol wipes. We positioned four electrode pads horizontally, above and below the hyoid bone. The device provided stimulation at a pulse rate of 80 Hz with a biphasic pulse duration of 300 microseconds. Each session lasted 30 minutes, with the intensity gradually increased in 0.5 mA intervals, based on the patient's comfort level, and adjusted to their maximum tolerance.
48640931|NCT05945355|DEVICE|Pro2 - SHAM - 15% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
48640932|NCT01856192|DRUG|Cyclophosphamide|Given IV
48640933|NCT01856192|DRUG|Doxorubicin Hydrochloride|Given IV
48640934|NCT01856192|OTHER|Laboratory Biomarker Analysis|Correlative studies
47957903|NCT06306820|OTHER|Fixed PEEP|Patients will receive a fixed positive end-expiratory pressure (PEEP) of 5 cmH2O throughout the surgical procedure.
47957904|NCT06306820|OTHER|Ultrasound-guided lung recruitment|Patients will receive ultrasound-guided lung before pneumoperitoneum, after pneumoperitoneum then once an hour, until the end of surgery. Alveolar recruitment will be conducted the same as that for the conventional manoeuvre with a simultaneous continuous ultrasound assessment if atalectasis is detected until no collapsed areas are visualized. When the collapsed lung areas are absent on the sonogram, positive end-expiratory pressure (PEEP) can no longer increase at this point. Subsequently, the pressure will be maintained for approximately 10 breaths.
48481575|NCT03652831|OTHER|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
48481576|NCT03652831|OTHER|Soft Tissue Mobilization without Neural Mobilization|"* Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
48481577|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
48481578|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
47957905|NCT06306820|OTHER|Individualized PEEP|Patients will receive individualized positive end-expiratory pressure (PEEP). After the first recruitment Maneuvere (RM), titration of PEEP will be performed by setting the initial PEEP to 5 cm H2O, then increasing PEEP according to the gradient of 2 cmH2O every 3 min, calculating static compliance (Cstat) according to the formula: \[Cstat = VT/Pplat - PEEP\] (Pplat = plateau pressure), then gradually increasing PEEP, until the calculated Cstat shows a downward trend, the we set its previous PEEP (corresponding to PEEP for high Cstat) as the optimal PEEP for this patient. The highest PEEP is limited to 15 cmH2O.
48481579|NCT06458153|BEHAVIORAL|Neural responses to speech functional localizer|Measuring speech-related brain activity using fMRI during a speech listening task.
48481580|NCT06458153|BEHAVIORAL|Neural responses to silent articulation|Measuring speech-related brain activity using fMRI during a silent articulation task.
48481581|NCT06458153|BEHAVIORAL|Neural responses to self vs. externally generated speech|Measuring speech-related brain activity using fMRI during self-generated vs. externally-generated speech.
48640935|NCT01856192|DRUG|Lenalidomide|Given PO
48640936|NCT01856192|DRUG|Prednisone|Given PO
48640937|NCT01856192|BIOLOGICAL|Rituximab|Given IV
48640938|NCT01856192|DRUG|Vincristine Sulfate|Given IV
47957906|NCT06303908|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
47957907|NCT04693988|BEHAVIORAL|Case Management|a case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as provide advice about cardiac symptoms and behavioral life style changes
47957908|NCT02298530|OTHER|Combination of caffeine and theanine|Beverage containing caffeine and theanine
48110852|NCT05390736|BEHAVIORAL|Assessment of feet/footwear|The CRN observes or asks about the patient's current footwear, asks about foot pain or loss of sensation, and notes a diabetes diagnosis when applicable. Patient reports of foot pain, loss of sensation or diabetes result in a CRN note to the provider to examine the patient's feet and the potential need for a referral to podiatry. The CRN also reviewed a safe footwear handout with all patients regardless of their responses and emailed it to patients with other patient information following the call.
48481582|NCT06458153|BEHAVIORAL|Event-related potentials for speech|Measuring electroencephalography (EEG) based evoked potentials for self vs. externally generated speech
47957909|NCT02298530|OTHER|Caffeine|Beverage containing caffeine
47957910|NCT00722423|BEHAVIORAL|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
47957911|NCT00722423|BEHAVIORAL|Usual Care Model|
47957912|NCT02191137|DRUG|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
47957913|NCT05072704|DRUG|Sufentanil|Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
47957914|NCT05072704|DRUG|Dexmedetomidine|Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
47957915|NCT00929383|DEVICE|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
47957916|NCT01790854|DRUG|Prasugrel dose 5 mg/day|
47957917|NCT01790854|DRUG|Prasugrel dose 10 mg/day|
47957918|NCT04103983|DEVICE|Sensory retraining device|All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
47957919|NCT00850343|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
47957920|NCT01199965|DRUG|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
48481583|NCT06458153|BEHAVIORAL|Neural responses to induced speech errors|Measuring speech-related brain activity using fMRI during conditions that induce auditory speech errors.
48481584|NCT06458153|BEHAVIORAL|Neural responses to sensory-motor adaptation|Measuring brain activity using fMRI during a learning task with sustained altered auditory feedback.
48640939|NCT06455280|DRUG|Siplizumab|Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
48481585|NCT06458153|BEHAVIORAL|Speech production behaviors|Behavioral measurements of speech during reading passages and words
47957921|NCT01199965|DRUG|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
47957922|NCT03196856|BEHAVIORAL|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
48481586|NCT06458153|BEHAVIORAL|Auditory acuity testing|Measurements of auditory acuity during listening tasks.
48481587|NCT06458153|BEHAVIORAL|Neural responses to learning a non-speech auditory motor behavior|Mapping of brain areas using fMRI during learning of non-speech sound-evoking movements.
48481588|NCT04912115|DRUG|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
48481589|NCT04912115|DRUG|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
48481590|NCT01135628|OTHER|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
48481591|NCT01135628|DIETARY_SUPPLEMENT|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
48481592|NCT01135628|DRUG|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
48481593|NCT05501808|PROCEDURE|cerasmart|the patient received a crown made of cerasmart ceramic
48481594|NCT05501808|PROCEDURE|enamic|the patient received a crown made of enamic ceramic
48481595|NCT03918941|DEVICE|Carey|mobile application
48481596|NCT03918941|OTHER|conventional information|leaflet, internet link and oral information
48481597|NCT06175936|OTHER|Laugther Yoga|Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session).
48481598|NCT01321281|DIETARY_SUPPLEMENT|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
48481599|NCT01321281|DIETARY_SUPPLEMENT|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
48481600|NCT00872924|DRUG|sumatriptan 100mg|
48481601|NCT05767203|OTHER|Biological samplings|Blood and/or skin samples
48640940|NCT05380453|BIOLOGICAL|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
48640941|NCT05380453|DRUG|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
48640942|NCT03294954|GENETIC|GINAKIT Cells|"Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~* Dose Level 5 = 3 x 10\^8~* Dose Level 6 = 1 x 10\^9"
48481602|NCT05430841|DIAGNOSTIC_TEST|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
48481603|NCT03112148|DRUG|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
48481604|NCT00699530|OTHER|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
48481605|NCT01199120|DIETARY_SUPPLEMENT|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
48481606|NCT00732524|DRUG|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
48481607|NCT00732524|DRUG|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
48481608|NCT05304026|DEVICE|Technique 1|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F pigtail catheter placed at the level of renal arteries to identify the lowest renal artery.
48481609|NCT05304026|DEVICE|Technique 2|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F introducer placed at the end of the proximal sealing zone to identify the lowest renal artery.
48481610|NCT05304026|DEVICE|Technique 3|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F pigtail catheter through the pigtail catheter placed at the level of renal arteries.
48481611|NCT05304026|DEVICE|Technique 4|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F introducer placed at the level of the contralateral iliac limb.
48640943|NCT03294954|BIOLOGICAL|GINAKIT cells + Etanercept|"At the time of the amendment version 13.0, we have treated 6 patients on DL4 without DLT. With Etanercept, we plan to start from DL4. Three dose levels of GINAKIT cells in combination of Etanercept will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Combination Dose level 4 = 1 x 108 + Etanercept~* Combination Dose level 5 = 3 x 108 + Etanercept~* Combination Dose level 6 = 1 x 109 + Etanercept"
48640944|NCT06274047|DRUG|Apalutamide|Given by PO
48640945|NCT06274047|DRUG|Androgen Deprivation Therapy|Given by PO
47957923|NCT03196856|DIETARY_SUPPLEMENT|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
48304830|NCT04510857|DEVICE|MOVE-IT Intervention|The MOVE-IT device comprises a custom smart toy and therapy game software to enable repetitive task practice involving the arm and hand.
48304831|NCT04510857|BEHAVIORAL|UCT Control|Participants assigned to the UCT control group will continue to receive their previously prescribed therapy services.
48304832|NCT06611748|DEVICE|Key Grip|KeyGrip is an implantable peripheral nerve stimulator that is being studied for its ability to provide coordinated activation of innervated paralyzed muscles. KeyGrip will be configured to activate nerves of the upper extremity (arm and hand) in order to facilitate movements such as hand opening and/or closing
48304833|NCT06692426|DRUG|MyoPAXon|MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2
48304834|NCT06692426|DRUG|Tacrolimus|Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.
48304835|NCT03440372|DRUG|Ozanimod|Specified dose on specified days
48304836|NCT03440372|OTHER|Placebo|Specified dose on specified days
48304837|NCT04026503|OTHER|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
47957924|NCT03196856|DIETARY_SUPPLEMENT|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
48304838|NCT06692283|DRUG|denifanstat|Tablet
47957925|NCT02655133|DRUG|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
47957926|NCT02655133|DRUG|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
48304839|NCT06692283|DRUG|Placebo|Matching tablet
47957927|NCT02470832|DRUG|RG1662|
48110853|NCT05390736|BEHAVIORAL|Assessment of visual acuity|The CRN projects a Banner eye chart on Zoom for the patient to read with their contacts or glasses from five feet away for both eyes together and each eye individually. Phone patients are asked to self-report any vision problems. If either the video screening or patient self-report indicated any vision problems, the CRN notes the result and recommendation for eye care referral for the patient's provider to review and order.
48304840|NCT06688032|OTHER|Jarlsberg cheese|Jarlsberg cheese contains Propionebacterium freudenreichii (PF) producing the K2-vitamer MK-9(4H) and DHNA in addition to the K2-vitamers found in Norvegia cheese
48304841|NCT06688032|OTHER|Norvegia|Cheese with different content of K2 vitamers
48640946|NCT06001775|BEHAVIORAL|Patient Priorities Care|According to patientprioritiescare.org a Patient Priorities Care conversation helps to align healthcare decision-making and care by all clinicians with patients' own health priorities. Patient Priorities Care involves not only the health outcome goals that patients want to achieve, but also their preferences for healthcare.
48655979|NCT06525727|OTHER|Falls Decision Rule|The Falls Decision Rule is a rule used to assess the risk of intracranial haemorrhage in geriatric patients and to prevent brain tomography (CT) in low-risk patients. This rule recommends that brain CT is not necessary in patients who do not have significant head trauma, memory loss or newly developing neurological examination disorder after a fall.
48655980|NCT05656664|DIETARY_SUPPLEMENT|Folic Acid|Folic acid supplementation to assess for increased arsenic metabolite excretion
48655981|NCT05656664|OTHER|Placebo|Placebo group to assess arsenic metabolite excretion
47957928|NCT02470832|DRUG|itraconazole|
47957929|NCT03300284|BEHAVIORAL|Questionnaires|Quality of Life Questionnaires
47957930|NCT04759573|BEHAVIORAL|Early Vocal Contact|Mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.
47957931|NCT04759573|BEHAVIORAL|Behavioral Observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
47957932|NCT03597880|OTHER|obese patients|underwent bariatric surgery
48304846|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (active)|non-invasive active repetitive stimulation applied to the scalp surface
48304847|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (sham)|non-invasive active repetitive stimulation applied to the scalp surface
48304848|NCT06693895|BIOLOGICAL|Investigational varicella vaccine|1 dose of investigational varicella vaccine administered subcutaneously.
48304849|NCT06693895|BIOLOGICAL|Marketed varicella vaccine|1 dose of marketed varicella vaccine administered subcutaneously.
48304850|NCT06693895|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.
48304851|NCT06693895|BIOLOGICAL|Hepatitis A vaccine|1 dose of hepatitis A vaccine co-administered intramuscularly.
48304852|NCT06693895|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
48304853|NCT06693895|BIOLOGICAL|PCV 20|1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
48304854|NCT06693895|BIOLOGICAL|Vaxneuvance|1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
48304855|NCT06691334|DEVICE|PRP injection|Active comparator: PRP 3 cycles of platelet-rich plasma injection treatment in 4 weeks intervals. Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under the urethra. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
48640947|NCT05770622|OTHER|First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)|CALCULATOR: A 'First-dose trough dose adjustment calculator' was developed based on a population pharmacokinetic model. A participant's post-menstrual age, weight, creatinine, target trough concentration, dose, dosing interval and first-dose trough concentration (taken immediately before the second dose is due) are entered into the calculator. The calculator determines if a dose adjustment is required (based on whether the predicted steady-state trough concentration is \<10mg/L or \>20mg/L) and, if required, recommends a new adjusted dose.
48640948|NCT06468176|OTHER|Cognitive Behavioral Therapy (CBT) neuropsychologist|"* CBT: at least 3 teleconsultations by the neuropsychologist (up to 1/week maximum)~* Brain Head Quarters (BrainHQ) Digital program: 4 sessions of 40 minutes / week"
48640949|NCT05516966|DRUG|HRS9531|Administrated SC
47957933|NCT00094172|DRUG|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
48304856|NCT06691334|DEVICE|Hifu procedure and PRP injection|Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under urethra.And intravaginal Hifu in4 weeks intervals. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
48304857|NCT06692543|OTHER|Active population|1 blood withdraw, questionnaire and tests
48304858|NCT06692543|OTHER|Inactive population|1 blood withdraw, questionnaire and tests
48304859|NCT06217536|DRUG|Lurbinectedin|Given intravenously (IV)
48304860|NCT06217536|RADIATION|Radiotherapy|Conventionally fractionated radiotherapy or external beam radiation
48304861|NCT06217536|PROCEDURE|Non-investigational surgery|Non-investigational surgical procedure on tumor tissue
48640950|NCT05516966|DRUG|Placebo|Administrated SC
48640951|NCT05516966|DRUG|Dulaglutide Injection|Administrated SC
48640952|NCT06311175|BEHAVIORAL|Dietary Tracking Prescription|Dietary tracking prescriptions to follow during a digital weight loss intervention.
48640953|NCT06140238|DRUG|Parecoxib|Parecoxib administration 15 minutes before start surgical operation
48640954|NCT06140238|DRUG|Normal saline|Normal saline administration 15 minutes before start surgical operation
47957934|NCT00094172|DRUG|Placebo|tablet form
47957935|NCT00223015|DRUG|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
47957936|NCT03754569|PROCEDURE|Peritoneal biopsies after complete macroscopic cytoreduction|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
48110854|NCT05390736|BEHAVIORAL|Home safety risk assessment|"The CRN reviews the CDC brochure Check for Safety: A Home Fall Prevention Checklist for Older Adults with each patient. Check for Safety asks 17 questions about the home's floors, stairs and steps, kitchen, bathrooms, and bedrooms and suggests ideas for removing or reducing fall hazards. The CRN communicates home safety risks and a recommendation for occupational therapy to the provider for indicated patients."
48110855|NCT05390736|BEHAVIORAL|Vitamin D Deficiency|The CRN asks the patient if they usually take a Vitamin D supplement with their other medications. If the patient does not take a Vitamin D supplement, the CRN recommends the provider check Vitamin D levels and consider supplementation if Vitamin D levels are less than 20 ng/mL.
48304862|NCT06534944|DRUG|Nicotinamide riboside|NR 1g daily for 4 weeks
48304863|NCT03616080|BEHAVIORAL|soccer play program|once a week for an hour of a soccer program for 8 weeks
48304864|NCT02685384|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
48304865|NCT04472923|PROCEDURE|Traditional Treatment|"Patients belonging to the control group received conventional physical therapy program in the form of:~1. Dietetic Regulation: The diet was given in the form of the bulk-forming diet, fruits, vegetables, cereals, and bran.~2. Pelvic floor muscle exercises (Kegal exercises): The patient was instructed to lie crock lying position with knees bent. He/she was instructed to pull his/her pelvic muscles upward and inward and hold the contraction for 6 seconds as if to hold back a defecation movement, followed by relaxation for 6 seconds. The exercise was repeated 25 times. Gradually increase the time until reaching 10 seconds of contraction and relaxation for each with repetition up to 30 times. The exercises applied twice per week for 3 months."
48304866|NCT04472923|DEVICE|Biofeedback|"Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months."
48304867|NCT02136823|DRUG|sugar pill|
48304868|NCT02136823|DRUG|Riluzole|
48304869|NCT02136823|DRUG|Isradipine|
48481612|NCT05205018|BEHAVIORAL|Motivational interviewing performed remotely through videocalls|Remote motivational interviewing will be performed seven time over 12 months, through videocalls. The first four interventions will be performed within two months and the following three will be performed at five, eight and eleven months from enrollment.
48640955|NCT06694311|DEVICE|CPAP|"12 cmH2O for 48 hours (at least 10 hours of therapy per day). Nasobucal interface will be the preferred route with complete facial mask being also an acceptable device. If needed, therapy breaks will be delivered with HFNO at 50 L/min.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although CPAP will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
48110856|NCT04047784|DEVICE|Endobronchial ultrasound (EBUS)|"An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn."
48110857|NCT02534350|DRUG|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
48110858|NCT02534350|DRUG|Placebo|Tablets administered orally or via NG tube once daily
48110859|NCT05014516|DRUG|129Xenon gas|Observational
48110860|NCT02949583|DRUG|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
48110861|NCT02949583|DRUG|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
48110862|NCT03895034|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
48110863|NCT05283616|DRUG|Pegfilgrastim|Pegfilgrastim 3mg per chemotherapy cycle
48110864|NCT05608369|DRUG|Cisplatin|Cisplatin100 mg/m2 every 3 weeks or 40 mg/m2 weekly
48110865|NCT05608369|RADIATION|Radiation therapy|Radiation therapy (70 Gy) for total of 7 weeks
48110866|NCT05608369|DRUG|Vorinostat|Pre-treatment; 300 mg every other day and ends with the dose closest to the last fraction of radiation (total of 8 weeks)
48110867|NCT06376357|OTHER|Foot Massage with roller|The intervention group is expected to apply roller massage to the soles of both feet in a sitting position on a chair (8 hours apart at 08.00, 16.00, 24.00 hours) every day for 6 weeks, 3x5 minutes a day. Video recording will be used as a reminder in the application.
48304870|NCT02136823|DRUG|Memantine|
48304871|NCT02136823|PROCEDURE|Therapeutic muscle stretching|
48304872|NCT05756673|DRUG|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
48304873|NCT05756673|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
48304874|NCT05756673|DRUG|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
48481613|NCT03662308|DEVICE|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
48481614|NCT03662308|DEVICE|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
48481615|NCT00147160|DRUG|Temozolomide, Cisplatinum|
48481616|NCT04658316|BEHAVIORAL|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
48481617|NCT03768284|OTHER|Saliva or buccal sample|Saliva or buccal sample
48640956|NCT06694311|DEVICE|HFNO 50 L/min|"HFNO 50 L/min for 48 hours. Therapy breaks with oxygen facemask will be allowed as per clinician decision but the protocol will advise against this practice.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although HFNO will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
48640957|NCT06694298|DRUG|SYS6020|BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion
48304875|NCT05756673|DEVICE|TePe Original Interdental Brush|Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
48110868|NCT06234644|OTHER|Standardized Walking Obstacle Course (SWOC)|The Standardized Walking Obstacle Course (SWOC) is a test that allows interaction of a child with environmental demands and obstructions while examining differences in functional ambulation performances. The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC), the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of SWOC training and 5 minutes of cool down period.
48110869|NCT06234644|OTHER|Conventional Gait Training|Conventional gait training protocol including walking on a treadmill, parallel bar walk, seated marching. The Group B (Control group) will receive the treatment with conventional Gait training, the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of Conventional gait training and 5 minutes of cool down period.
48110870|NCT01189513|DRUG|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
48110871|NCT00793754|DRUG|Aspirin|100 mg / day for 8 weeks
48110872|NCT00793754|DRUG|Atorvastatin|40 mg / day for 8 weeks
48110873|NCT00793754|DRUG|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
48110874|NCT00696280|BEHAVIORAL|Functional Living Index - Emesis|
48110875|NCT00211913|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
48110876|NCT00211913|BIOLOGICAL|placebo|single IM dose
48110877|NCT05635162|DRUG|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
48110878|NCT05635162|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
48110879|NCT03346018|DIAGNOSTIC_TEST|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
48110880|NCT00002632|DRUG|paclitaxel|
48110881|NCT02905812|OTHER|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
48110882|NCT00281008|DRUG|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
48110883|NCT00281008|DRUG|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
48110884|NCT00281008|DRUG|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
48110885|NCT00281008|DRUG|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
48110886|NCT04557488|OTHER|Music therapy|Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
48110887|NCT04557488|BEHAVIORAL|Behavioral-based social skill training|Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
48481618|NCT01051713|BEHAVIORAL|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
48640958|NCT03039985|DEVICE|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
48640959|NCT03039985|DEVICE|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
48110888|NCT05605444|OTHER|Single bout of exercise|isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
48110889|NCT01083342|DRUG|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
48110890|NCT05388565|BEHAVIORAL|Domestic Violence Enhanced Perinatal Care Program|Our intervention consists of four major components: a) information about IPV and its effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
48110891|NCT05388565|BEHAVIORAL|Standard of Care|Usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV and mental health resources)
48304876|NCT05725798|DRUG|Sitagliptin|Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
48640960|NCT06549114|DRUG|Leniolisib|The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).
47957937|NCT05664490|BEHAVIORAL|Youth Friendship Bench SA|The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
47957938|NCT04841538|DRUG|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
47957939|NCT05749107|DIAGNOSTIC_TEST|Echocardiography|Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm
48640961|NCT05898646|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48640962|NCT05898646|BIOLOGICAL|Daratumumab|Given SC
48640963|NCT05898646|PROCEDURE|Echocardiography|Undergo echocardiography
48640964|NCT05898646|OTHER|Questionnaire Administration|Ancillary studies
48640965|NCT05898646|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
48640966|NCT05898646|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48640967|NCT05132582|DRUG|Tucatinib|300mg given by mouth (orally) twice daily
47957940|NCT05749107|COMBINATION_PRODUCT|Proteomic analyses|To identify the mechanisms leading to moderate/severe STR during AF.
47957941|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times
47957942|NCT05809882|DEVICE|"Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil"|frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
47957943|NCT01880281|OTHER|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
47957944|NCT02343107|BEHAVIORAL|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
48304877|NCT03229759|DRUG|Octenidine Dihydrocloride in aqueous solution|application of investigational product
48640968|NCT05132582|DRUG|Trastuzumab|6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
48640969|NCT05132582|DRUG|Pertuzumab|420mg given by IV every 21 days
48640970|NCT05132582|DRUG|Combination product: Trastuzumab + Pertuzumab|600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
48640971|NCT05132582|DRUG|Placebo|Given orally twice daily
48640972|NCT01550575|DEVICE|Non Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc.
48640973|NCT01550575|DEVICE|Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc
47957945|NCT05211115|PROCEDURE|Split thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the split thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a micro-blade, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
47957946|NCT05211115|PROCEDURE|Full thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the full thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a fine periosteal elevator, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
48110892|NCT04300426|DRUG|"ACHIM as solute (10^9 intestinal microbes/ml)"|Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
48110893|NCT01610479|DRUG|TAS-114 + S-1|
48304878|NCT03229759|OTHER|Vehicle Control|application of vehicle control
48304879|NCT03229759|OTHER|Saline Control|application of placebo
48304880|NCT02851680|BIOLOGICAL|blood samples|
48304881|NCT06126653|DRUG|Low Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.
48304882|NCT06126653|DRUG|High Dose ARD-501|Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.
48640974|NCT05964868|DRUG|Liposomal Bupivacaine|Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
48640975|NCT05964868|DRUG|0.25% bupivacaine with 1:200,000 epinephrine|Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.
48640976|NCT05964868|OTHER|Placebo - Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
48640977|NCT04317534|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
48640978|NCT05445804|DRUG|300 mg Cannabidiol|300 mg CBD in Medium Chain Triglyceride oil b.i.d.
48640979|NCT05445804|DRUG|600 mg Cannabidiol|600 mg CBD in Medium Chain Triglyceride oil b.i.d.
48640980|NCT05445804|DRUG|Placebo|Medium Chain Triglyceride oil
48640981|NCT00569127|BIOLOGICAL|Bevacizumab|Given IV
48640982|NCT00569127|OTHER|Laboratory Biomarker Analysis|Correlative studies
48640983|NCT00569127|DRUG|Octreotide Acetate|Given IM
48640984|NCT00569127|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
47957947|NCT05211115|PROCEDURE|Autogenous sub epithelial connective tissue graft|Harvest of a sub epithelial connective tissue graft using a double incision technique, approximately 2-3 mm apical to the palatal gingival margins of the first and second premolars. Graft dimension standardised as 10mm (mesio-distally) by 6-8mm (apico-coronally) by 1,5mm (thickness). Graft stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
47957948|NCT05211115|PROCEDURE|Volume stable collagen matrix|Geistlich Fibro-Gide® matrix shaped at a standardised dimension of 10mm (mesio-distally) by 6-8mm (apico-coronally) by 6mm (thickness). Matrix stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
47957949|NCT01854242|OTHER|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
47957950|NCT05875428|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Be given intravenously at 20 mg/m\^2 on days 1 of each treatment cycle.
47957951|NCT03781427|DEVICE|Cardiac resynchronization therapy|Left ventricular pacing
48640985|NCT05337696|PROCEDURE|Vertebral Implant PEEK Procedure|Vertebral Implant PEEK (VIP) procedure is a minimally invasive/percutaneous vertebral augmentation (PVA), image guided procedure. Two VIP devices are implanted in each to be treated vertebra. A cavity is drilled allowing the introduction of the implant posteriorly through the pedicle and the vertebral body upto the anterior wall. A part of the implant is embedded into the pedicle, thus providing posterior support. The other part of the device, located in the vertebral body, presents a central canula and lateral perforations, which allow acrylic bone cement diffusion, filling of the vertebral body, filling and fixing the implant, and supporting of the upper endplate. The combination of the implant and the cement allows the treatment of vertebral fractures.
48640986|NCT05337696|DEVICE|Vertebral Implant PEEK (VIP) implant|The study device is V-STRUT© Vertebral Implant manufactured by Hyprevention (VIP -Vertebral Implant PEEK), FDA cleared under K191709, indicated for use in the treatment of vertebral fractures in the thoracic and lumbar spine from T9 to L5. It is intended to be used in combination with PMMA bone cement.
48640987|NCT01872208|BIOLOGICAL|HAV implantation|Patients will be implanted with a Human Acellular Vessel (HAV) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques.
48640988|NCT05157893|DEVICE|Virtual reality based analgesic therapy|The intervention is a single 15 min VR therapy. The VR therapy is consisted of VR device and software. The model of VR device used is Pico Neo 3 Pro. The software run on the VR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.
48640989|NCT04379271|DRUG|IMU-838|"Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube."
48640990|NCT04379271|OTHER|Placebo|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
48640991|NCT05449132|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
48640992|NCT05449132|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
48640993|NCT03278340|BEHAVIORAL|Sun Safe Workplaces - Technology|After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
48640994|NCT03278340|BEHAVIORAL|Sun Safe Workplaces -In Person|After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
47957952|NCT02428270|DRUG|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
48640995|NCT02618187|DRUG|SER-287|
48640996|NCT02618187|DRUG|Placebo|
48640997|NCT02618187|DRUG|Placebo Pre-Treat|
48640998|NCT02618187|DRUG|Vancomycin Pre-Treat|
48640999|NCT05783960|OTHER|administration questionary|Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
48641000|NCT05701917|DEVICE|ClotTriever System|Mechanical thrombectomy
47957953|NCT02428270|DRUG|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
47957954|NCT01338103|DRUG|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
47957955|NCT04534543|RADIATION|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
47957956|NCT05757596|DRUG|VSA001 injection|The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
47957957|NCT05757596|DRUG|Placebo|0.9% Saline, volume matched
47957958|NCT02158975|DRUG|MLN9708|
48304883|NCT06126653|DRUG|Placebo|Titratable, liquid formulation, taken orally.
48304884|NCT06338553|DRUG|Placebo|placebo capsule or tablet once before the pre-TZIELD® MMTT and once before one of the post-TZIELD® MMTTs.
48641001|NCT05701917|DRUG|Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.|Anticoagulants are a group of medications that decrease your blood's ability to clot.
48641002|NCT05673200|PROCEDURE|Biopsy|Undergo biopsy
48641003|NCT05673200|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48641004|NCT05673200|PROCEDURE|Computed Tomography|Undergo CT
48641005|NCT05673200|DRUG|Decitabine and Cedazuridine|Given PO
48304885|NCT06338553|DRUG|Semaglutide (Rybelsus®)|7 mg single dose of Rybelsus® by mouth once before one of the post-TZIELD® MMTTs
48304886|NCT01583322|DRUG|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
48641006|NCT05673200|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48641007|NCT05673200|DRUG|Paclitaxel|Given IV
48641008|NCT05673200|BIOLOGICAL|Pembrolizumab|Given IV
48641009|NCT03004131|DRUG|Azelastine hydrochloride + fluticasone propionate nasal spray|
48641010|NCT03004131|DRUG|Placebos|
48641011|NCT03004131|DRUG|fluticasone propionate nasal spray + loratadine|
48641012|NCT05507164|DRUG|Temporomasseteric Nerve Block|The TMNB injection is a local anesthetic injection technique that targets the anterior deep temporal and masseteric branches of the mandibular division of the Trigeminal Nerve. The surface landmark for the twin block injection site is located by palpating for the depression created by the greater wing of the sphenoid bone at the superior border of the zygomatic process and approximately 1 cm posterior to the posterior border of the frontal process of the zygomatic bone. This site is first disinfected with alcohol wipes prior to inserting a 27- or 25-gauge long dental needle (32 mm). Angled 35-45° away from the calvarium (skull) and perpendicular to the zygomatic arch (along the coronal plane), the needle is advanced to its length before injecting 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
48641013|NCT05705271|DRUG|Finerenone (Kerendia, BAY94-8862)|Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
48641014|NCT03620981|DRUG|Brexpiprazole|Drug: 1 tablet /day Once daily for 10 weeks
48641015|NCT03620981|DRUG|Placebo|Placebo: 1 tablet /day Once daily for 10 weeks
48641016|NCT00021359|DRUG|dexamethasone|
48641017|NCT00021359|DRUG|isotretinoin|
48641018|NCT01064622|DRUG|Gemcitabine Hydrochloride|Given IV
48641019|NCT01064622|OTHER|Hydrocortisone/Placebo|Given PO
47957959|NCT06301334|DRUG|Bupivacaine 0.25% Injectable Solution|Group CTB (n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25% Group ESPB (n=30): patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
47957960|NCT03884959|BIOLOGICAL|HepaStem Infusion|HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
47957961|NCT02585843|DRUG|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
47957962|NCT02585843|DRUG|Spironolactone 25mg|25mg/day of spironolactone
47957963|NCT02579837|DEVICE|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
48481619|NCT01051713|BEHAVIORAL|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
48481620|NCT00483587|DRUG|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
48481621|NCT02130531|DRUG|Emixustat HCl Tablet|Tablet for oral administration
48641020|NCT01064622|DRUG|Vismodegib|Given PO
48641021|NCT04572230|DEVICE|Endovascular treatment of intracranial aneurysms using a flow-diverting stent|The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
48641022|NCT04428281|DRUG|RO7248824|In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
48641023|NCT04297761|OTHER|Filtered Air|Ambient air will be filtered and used for control exposure.
48641024|NCT04297761|OTHER|Wood Smoke|Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m\^3 for 2 hours.
47957964|NCT02579837|DEVICE|Zeiss Cirrus|optical coherence tomographer (OCT)
47957965|NCT03596008|DIETARY_SUPPLEMENT|Active drink|The freeze-dried strawberry powder (25 g) in active drink
47957966|NCT03596008|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink
47957967|NCT01866774|OTHER|Fecal calprotectin level|
47957968|NCT02693119|DRUG|elamipretide (MTP-131) 1% topical ophthalmic solution|
47957969|NCT02693119|DRUG|Vehicle topical ophthalmic solution|
47957970|NCT06132295|OTHER|Nursing care|"1. Consistent Schedule for the Replacement of Positioning Line Pens~2. Tailored Educational Content~3. Hypoallergenic Adhesive Patches~4. Enriched Treatment Care Platform~5. Participants with BMI \> 25 and an education level of high school or below, without specific caregivers, were identified by placing a red dot on the treatment record and on the patient's happiness card. Patients with BMI \< 25 and an education level of high school or above, with specific caregivers, were identified by placing a green dot on their records.~6. Individual interventions, educational pamphlets prepared in-house were added, to assess the maintenance status of the positioning marks."
47957971|NCT02421471|DRUG|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
48641025|NCT06638307|DRUG|MEN2312|MEN2312 administered as oral tablets.
48641026|NCT06638307|DRUG|Elacestrant|Elacestrant administered as oral tablets.
48641027|NCT04181762|DRUG|secukinumab|STUDY DRUG
48641028|NCT04181762|DRUG|Placebo|Placebo
48641029|NCT01386385|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
48641030|NCT01386385|DRUG|Carboplatin|Given IV
48641031|NCT01386385|OTHER|Laboratory Biomarker Analysis|Correlative studies
48304887|NCT01583322|DRUG|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
48641032|NCT01386385|DRUG|Paclitaxel|Given IV
47957972|NCT01868464|BIOLOGICAL|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.
47957973|NCT05607615|DRUG|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
47957974|NCT05607615|DRUG|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
47957975|NCT05961579|DRUG|Barrier Renew|RoC Skincare (New York, New York, USA) has developed a gentle cleanser and moisturizer that are free of exfoliants, astringents, and other abrasive ingredients. The moisturizer contains emollients, humectants, and silicones to improve the functioning of the skin barrier while antioxidants protect against environmental damage and inflammation
47957976|NCT05552521|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
47957977|NCT04259567|DEVICE|Cytokine absorption|Use of CytoSorb absorber
48304888|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more"
48304889|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
47957978|NCT06257628|DEVICE|Index Event|Patients with at least one Beckman High Sensitivity Troponin test at the Emergency Department visit
48481622|NCT02130531|OTHER|Placebo Tablet|Tablet for oral administration
48641033|NCT01386385|OTHER|Placebo Administration|Given PO
48641034|NCT01386385|DRUG|Veliparib|Given PO
48641035|NCT05974111|DIAGNOSTIC_TEST|blood sampling|At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation
48641036|NCT06460051|PROCEDURE|Maxillary nerve block|Ultrasound-guided, suprazygomatic approach, infrazygomatic window
48641037|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) powder formulation|T-P-S-10 Caliper powder - 30 mg CBD in the form of 300 mg of 10% CBD isolate (Formulation 725: Water soluble.Contains sorbitol)
47957979|NCT04803539|DRUG|capecitabine|capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
47957980|NCT04803539|DRUG|capecitabine + camrelizumab + apatinib|Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
48481623|NCT00165230|DRUG|Thalidomide|
48481624|NCT00165230|DRUG|Temodar|
48481625|NCT01849016|DRUG|N-Acetylcysteine|
48481626|NCT01849016|DRUG|Placebo|
48641038|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Oil based tincture formulation|30 mg CBD isolate in MCT oil,1:1 ratio of CBD to Medium Chain Triglycerides oil. (Formulation 088: Not water soluble. Contains medium chain triglyceride coconut oil.)
48641039|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation|10% CBD Gum Arabic, maltodextrin base(Formulation 126: Water soluble. Contains gum arabic and maltodextrin)
48110894|NCT01833364|PROCEDURE|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
48641040|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Gum Arabic, sorbitol base formulation|10% CBD Gum Arabic, sorbitol base (Formulation 213: Water soluble. Contains gum arabic and sorbitol)
48641041|NCT04971837|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Isolate in water formulation|Pure CBD as crystalline powder (\>99% purity) (Formulation 625 Not water soluble)
48641042|NCT04971837|DIETARY_SUPPLEMENT|CBD matching Placebo|Matching Placebo
48641043|NCT06643689|DRUG|Tranilast|Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.
48655982|NCT02475356|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|The treatment of Mirena should comply with the local product information.
48641044|NCT06643689|DRUG|Dexamethasone|Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
48641045|NCT05703256|DEVICE|Amygdala real-time fMRI neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
48641046|NCT05703256|DEVICE|Sham feedback|Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
48641047|NCT04518657|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
48641048|NCT04518657|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing wellness in people with MS.
48641049|NCT05001165|OTHER|Proactive Panel Management Clinics for HFrEF|Novel clinic based on review of panel HFrEF data and impromptu telephone or video patient contacts/visits.
48641050|NCT05903131|BEHAVIORAL|Telemedicine behavioral weight intervention|Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (12 months total). Each telephone session will be 30 minutes long.
48641051|NCT05903131|DRUG|Progestin|Released via the levonorgestrel-releasing IUD.
48641052|NCT05903131|BEHAVIORAL|Enhanced usual care|1-3 page handouts
48641053|NCT05903131|DRUG|Levonorgestrel-releasing IUD.|Standard of care
48641054|NCT05860400|BEHAVIORAL|Healthy life style|Healthy diet, regular exercise, and quitting smoking
47957981|NCT06334887|DEVICE|Use of esTOCma|"Participants of the experimental group will use the esTOCma mobile app until completion, within a set period of 10 days.~EsTOCma is a a serious game with 10 missions where users have to free 10 characters who have been imprisoned by a monster called esTOCma, which metaphorically represents the stigma in OCD. With each mission, users will gain knowledge about OCD and free an imprisoned character until the tenth mission, when they will defeat the monster. This game has three modules: (1) Psychoeducation (missions 1-5), where general information about OCD, OCD treatments and where to seek help is provided; (2) Indirect Contact (missions 6 and 7), which consists of a series of audio-visual recordings in which OCD patients report their symptoms and the impact the disorder has had on their lives; and finally, (3) Cognitive Restructuring (missions 8-10), where common dysfunctional beliefs about OCD and OCD treatment are challenged."
47957982|NCT05232071|DRUG|IVA337|800 mg
47957983|NCT05232071|DRUG|Placebo|Placebo to match
47957984|NCT05232071|DRUG|Empagliflozin|10 mg
48641055|NCT05860400|DRUG|Secondary prevention for atherosclerotic coronary artery disease|Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
48641056|NCT05860400|DRUG|Immunosuppressive therapy|Glucocorticoids and/or immunosuppressive agents
48641057|NCT05860400|PROCEDURE|Coronary revascularization|Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
48641058|NCT05860400|DRUG|Supportive therapies|Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
48641059|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF5993 pMDI
48641060|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF1535 pMDI or CHF5993 pMDI
48641061|NCT05882058|DRUG|BI 764532, formulation 1|BI 764532, formulation 1
48641062|NCT05882058|DRUG|BI 764532, formulation 2|BI 764532, formulation 2
47957985|NCT01924000|DRUG|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
48641063|NCT00660959|DRUG|lixivaptan|oral capsule
47957986|NCT01924000|DRUG|Placebo|
47957987|NCT04383483|OTHER|COVICU|COVICU
47957988|NCT03095885|OTHER|Test Meal|
48481627|NCT00699478|DRUG|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
48641064|NCT00660959|DRUG|placebo|oral capsule
48641065|NCT04088292|DRUG|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
48641066|NCT04088292|DEVICE|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
48641067|NCT04439903|OTHER|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
48641068|NCT05026385|BEHAVIORAL|Intervention|Targeted nutrition advice, progressive resistance training exercise, and self-management support
48641069|NCT06695585|DRUG|Lidocaine 2% without vessel constrictor|different volumes of intravesical 2% lidocaine without epinephrine, all patients will be receiving bladder botox but this will not be compared
48641070|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 1|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
48641071|NCT06466603|DIETARY_SUPPLEMENT|GABA Probiotic Dose 2|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
48304890|NCT00832754|DEVICE|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
48481628|NCT00288665|DEVICE|Export catheter (Medtronic)|
48641072|NCT06466603|DIETARY_SUPPLEMENT|Placebo Group|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
48641073|NCT04997018|RADIATION|Radiation Therapy|"Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted."
48641074|NCT04135443|BEHAVIORAL|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-19. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
48641075|NCT04135443|BEHAVIORAL|General Health Materials Website|The control group will receive access to a website containing general health promotion materials.
48641076|NCT05243290|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
48641077|NCT05243290|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
48641078|NCT05463952|DRUG|vepdegestrant|ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
47957989|NCT02351375|OTHER|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
48481629|NCT05150756|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]|At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
47957990|NCT02351375|DEVICE|IntelliCap® system|
47957991|NCT04996017|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
48481630|NCT05150756|DRUG|morphine sulphate (10mg/ ml ampoule)|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
48110895|NCT05379491|DRUG|3 L PEG + linaclotide|Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
48110896|NCT05379491|DRUG|3 L PEG + placebo|Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
47957992|NCT04996017|DRUG|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
48481631|NCT02588547|DRUG|Granisetron|IV granisetron 1 mg before spinal anethesia
48481632|NCT02588547|DRUG|Granisetron|IV granisetron 0.7 mg before spinal anethesia
48481633|NCT02588547|DRUG|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
48481634|NCT05336435|DIAGNOSTIC_TEST|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
47957993|NCT02241252|DEVICE|iPhone ECG|Please see detailed description for additional information.
47957994|NCT04793087|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
48110897|NCT03097744|DEVICE|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
48110898|NCT00269516|DRUG|pardoprunox|fixed dose 6 mg
47957995|NCT06357858|DRUG|INQOVI (decitabine and cedazuridine)|Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
47957996|NCT06357858|DRUG|Nivolumab|Nivolumab will be administered on D8 with every 4 week cycle.
47957997|NCT01613300|DRUG|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
47957998|NCT06128473|DEVICE|Soft Contact Lens|Vision Correction
48110899|NCT00269516|DRUG|Pardoprunox|fixed dose 12 mg
48110900|NCT00269516|DRUG|Pardoprunox|12-42mg
48110901|NCT00269516|DRUG|Placebo|Placebo
48110902|NCT02817724|DEVICE|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
48110903|NCT02817724|OTHER|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
48110904|NCT04554082|PROCEDURE|laparoscopic sleeve gastrectomy|bariatric surgery to loss weight
48110905|NCT06089954|OTHER|private web-portal eHealth disclosure of genetic results|The intervention involves delivering actionable genetic research results to participants via a secure, private web-portal.
48110906|NCT06089954|OTHER|eHealth education intervention (web or chatbot)|The intervention involves pre-disclosure education via an eHealth intervention (web or chatbot). The intervention will review the types of actionable results being returned, the method of return, the differences between research and clinical testing, the need for confirmation testing and the benefits, risks and limitations of receiving actionable genetic research results and study steps and procedures.
48481635|NCT05719831|DRUG|vonoprazan fumarate + high dose amoxicillin（H-10d）|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
47957999|NCT05364190|DRUG|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
47958000|NCT05364190|DRUG|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
47958001|NCT03772925|DRUG|Belinostat|Given IV
47958002|NCT03772925|DRUG|Pevonedistat|Given IV
48641079|NCT04281576|DEVICE|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
48641080|NCT04281576|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
48641081|NCT04281576|DRUG|Capecitabine|Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
48641082|NCT04281576|DRUG|Trastuzumab|Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
48641083|NCT05257018|DRUG|R-CDOP+intrathecal MTX|"R-CDOP+intrathecal MTX：~* Rituximab 375 mg / m\^2，D1~* Cyclophosphamide 750 mg / m\^2，D2~* Doxorubicin Hydrochloride Liposome Injection 35mg / m\^2，D2~* Vincristine 1.4mg/m\^2 (dose capped at 2 mg)，D2~* Prednisone 50 mg， bid D2-6~* Cycle1-5：Intrathecal MTX 12 mg + DXM 5 mg after chemotherapy （PK patients will be given 24 h after chemotherapy）"
48304891|NCT00832754|OTHER|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
48304892|NCT01109901|PROCEDURE|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
48641084|NCT05726630|DRUG|Divozilimab|anti CD20 monoclonal antibody
47958003|NCT02027207|BIOLOGICAL|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
48304893|NCT01109901|PROCEDURE|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
48304894|NCT02230124|DEVICE|MRE|
48304895|NCT03524677|DIAGNOSTIC_TEST|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
48304896|NCT03479879|DRUG|Estradiol|Estradiol
48304897|NCT03479879|DRUG|Placebo Oral Tablet|Placebo
48304898|NCT03479879|DRUG|Misoprostol|Misoprostol
48641085|NCT05726630|DRUG|Placebo|Placebo
48641086|NCT00917020|DRUG|Nasal CO2|As-Needed during the 14 day Treatment Period
48641087|NCT00917020|DRUG|Inactive Placebo Gas|Placebo
48641088|NCT05957367|DRUG|DCC-3116|Oral Tablet Formulation
48641089|NCT05957367|DRUG|Ripretinib|Oral Tablet Formulation
48641090|NCT04576117|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48641091|NCT04576117|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48641092|NCT04576117|OTHER|Quality-of-Life Assessment|Ancillary studies
48641093|NCT04576117|OTHER|Questionnaire Administration|Ancillary studies
48641094|NCT04576117|DRUG|Selumetinib Sulfate|Given PO
48641095|NCT04576117|DRUG|Vinblastine Sulfate|Given IV
47958004|NCT02027207|BIOLOGICAL|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
47958005|NCT05108285|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
47958006|NCT01703325|DRUG|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group"
47958007|NCT00390065|DRUG|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
47958008|NCT02110238|DEVICE|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
48304899|NCT04717843|OTHER|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
48304900|NCT04717843|OTHER|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
48304901|NCT04717843|OTHER|Holter ECG|48 hours ECG recording
48304902|NCT04717843|OTHER|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
48304903|NCT04717843|BIOLOGICAL|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
48304904|NCT04717843|OTHER|Standard MRI|Acquisitions of MR imagining
48304905|NCT00308542|DRUG|dexamethasone|
48304906|NCT05314166|OTHER|meditation practice|Description: meditation practice
48304907|NCT00424580|DRUG|Montelukast (10mg) and Desloratadine (5mg)|
48304908|NCT03126136|DEVICE|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
48641096|NCT05993234|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC."
48304909|NCT03997539|DRUG|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
48481636|NCT05719831|DRUG|vonoprazan fumarate + low dose amoxicillin（L-10d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
48641097|NCT05350267|BEHAVIORAL|HALO|"Health and Lifestyle Behaviors in Offspring, or HALO is designed for mothers who recently had bariatric surgery who have a school-aged child. HALO focuses on providing each mother with education and parenting strategies to improve her child's healthy lifestyle behaviors, such as her child's eating and physical activity, while she is engaged in her own lifestyle behavior change after bariatric surgery."
48641098|NCT05350267|BEHAVIORAL|Enhanced Standard of Care|The comparator group will receive monthly mailings of publicly available and age-appropriate handouts on healthy eating, physical activity, screen time, and healthy sleep habits
47958009|NCT02110238|DEVICE|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
47958010|NCT00622284|DRUG|Placebo identical to BI 1356 5mg|Placebo tablet once daily
47958011|NCT00622284|DRUG|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
47958012|NCT00622284|DRUG|BI 1356|5mg, once daily in the morning for 104 weeks
48304910|NCT03997539|DRUG|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
48304911|NCT03997539|DRUG|vinorelbine|vinorelbine
48481637|NCT05719831|DRUG|vonoprazan fumarate + amoxicillin（H-14d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
48481638|NCT04592523|OTHER|No Intervention|This is a non-interventional study.
48641099|NCT03750513|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Given LET optimized IMPT
48641100|NCT03750513|OTHER|Quality-of-Life Assessment|Ancillary studies
47958013|NCT00622284|DRUG|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
47958014|NCT02004483|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
47958015|NCT05912244|DRUG|IO102/IO103|IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.
47958016|NCT05912244|DRUG|Nivolumab-Relatlimab|Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.
47958017|NCT04087265|DIAGNOSTIC_TEST|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
47958018|NCT00457301|BEHAVIORAL|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
47958019|NCT00769210|DRUG|Simvastatin|Simvastatin 40 mg tablet
47958020|NCT01447433|DRUG|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
47958021|NCT01447433|BEHAVIORAL|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
47958022|NCT06273462|DRUG|Palmitoylethanolamide 600mg twice a day|600mg palmitoylethanolamide twice a day
47958023|NCT06273462|OTHER|placebo|visually identical placebo capsule
47958024|NCT01481597|DRUG|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
47958025|NCT01481597|DRUG|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
47958026|NCT01481597|DRUG|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
48641101|NCT03750513|OTHER|Questionnaire Administration|Ancillary studies
48641102|NCT05807893|DRUG|Serplulimab combined with bevacizumab and first-line chemotherapy|Serplulimab combined with bevacizumab and first-line chemotherapy
48641103|NCT05047172|DRUG|Ticagrelor + Aspirin|ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
48641104|NCT05047172|DRUG|Rivaroxaban + Aspirin|low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
48641105|NCT05047172|DRUG|Clopidogrel + Aspirin|clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)
47958027|NCT01481597|DRUG|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
47958028|NCT01481597|DRUG|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
47958029|NCT06090396|DIAGNOSTIC_TEST|cardiac output monitoring with electrical cardiometry|comparison of limits of agreement between the two monitoring modalities
47958030|NCT00673504|DRUG|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
47958031|NCT00673504|DRUG|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
48641106|NCT05047172|OTHER|Risk Factor Management|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
48641107|NCT03855839|DEVICE|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
48641108|NCT03855839|DEVICE|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
48641109|NCT06051968|BEHAVIORAL|Online hearing support for first-time hearing aid users|Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.
48641110|NCT06051968|BEHAVIORAL|Hearing rehabilitation according to common practice.|Participants get hearing rehabilitation according to common practice.
48641111|NCT06295159|DRUG|Nivolumab|Nivolumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
48641112|NCT06295159|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a combination formulation composed of nivolumab, a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), and relatlimab-rmbw, a human IgG4 monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3). Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response. Relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs) and prevents LAG-3 binding to major histocompatibility complex (MHC) class II. This prevents LAG-3-mediated signaling and LAG-3-mediated inhibition of the immune response.
48641113|NCT06295159|DRUG|Ipilimumab|Ipilimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor that may block CTLA-4 and help the immune system kill cancer cells. Ipilimumab binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that have certain mutations (changes) in genes involved in DNA repair.
48641114|NCT06431646|BEHAVIORAL|A web-based education intervention developed for university students with PMS|The web-based education program includes the definition, prevalence, importance, causes, symptoms, diagnosis, risk factors, management strategies and treatment options of PMS. The education emphasizes non-pharmacological strategies for managing PMS, including diet, exercise and body mass index (BMI), sleep hygiene, smoking cessation, stress management, as well as vitamin and mineral supplements, herbal therapy, acupuncture, acupressure and reflexology.
48641115|NCT02060188|DRUG|Ipilimumab|Specified dose on specified days
48641116|NCT02060188|DRUG|Nivolumab|Specified dose on specified days
47958032|NCT02322346|OTHER|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
48110907|NCT00509769|DRUG|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
48304912|NCT00075348|GENETIC|mutation analysis|
48304913|NCT02648048|DRUG|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
48304914|NCT02648048|DRUG|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
48304915|NCT00540449|DRUG|TMC278|25 mg tablet once daily for 96 weeks
48304916|NCT00540449|DRUG|Efavirenz|600mg once daily for 96 weeks
48304917|NCT00079612|DRUG|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
48641117|NCT02060188|DRUG|Cobimetinib|Specified dose on specified days
48641118|NCT02060188|DRUG|Daratumumab|Specified dose on specified days
48641119|NCT02060188|DRUG|BMS-986016|Specified dose on specified days
48641120|NCT06695325|DIAGNOSTIC_TEST|HbA1c test|Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm draw. They will do the latter again at home.
48304918|NCT00079612|DRUG|Placebo|2x 400mg tabs daily
48304919|NCT02948140|PROCEDURE|MRI|
48304920|NCT02948140|PROCEDURE|Abdominal scanner|
48304921|NCT01897415|BIOLOGICAL|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
48304922|NCT03569423|PROCEDURE|Transepithelial photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
48304923|NCT03569423|PROCEDURE|Alcohol assisted photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
48110908|NCT06071624|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
48304924|NCT02859545|BEHAVIORAL|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
48304925|NCT02859545|BEHAVIORAL|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
48304926|NCT00141635|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|
48304927|NCT01419366|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
48304928|NCT03762525|RADIATION|ECG gated CTA|"Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings."
48304929|NCT00298610|DRUG|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
48304930|NCT00298610|DRUG|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
48304931|NCT00591227|DRUG|insulin aspart|"insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
48481639|NCT06406322|OTHER|PFMT|Pelvic floor muscle training will be given to patients with strengthening and endurance exercises for 8 weeks. PFMT will be applied at a patient-specific progression for 8 weeks.Exercises will be given in different positions (supine, sitting, etc.).
48304932|NCT00591227|DRUG|insulin detemir|"insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
48304933|NCT00406640|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
48304934|NCT00406640|DRUG|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
48304935|NCT02024711|DEVICE|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
48304936|NCT02024711|DEVICE|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
48304937|NCT02086565|BEHAVIORAL|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
48304938|NCT02086565|BEHAVIORAL|Portal training|training in use of patient portal
48304939|NCT01262261|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
48304940|NCT06511713|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
48481640|NCT06406322|OTHER|Aerobic Exercise|Aerobic exercise will be applied as a progressive program in the form of a walking program, at least 4 days a week for 8 weeks. There will be 5-minute warm-up and cool-down periods (walking at a light pace) before and after exercise.
48481641|NCT00236249|DRUG|Lidocaine|
48481642|NCT02293473|DEVICE|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
48110909|NCT04201249|DRUG|Piroxicam, lidocaine|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
48481643|NCT02293473|DEVICE|BIS-Bispectral Index Monitor|Depth of anaesthesia
48481644|NCT02293473|DEVICE|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
48481645|NCT02293473|OTHER|Standard of care|Using standard of care
48641121|NCT06529692|BEHAVIORAL|Placebo Split-Belt Training|Walking on a split-belt treadmill in which the belt under the ACL leg will move at a speed that is minimally slower than the other belt.
48110910|NCT04201249|DEVICE|Mesotherapy without drug administration|Patients will be randomized to 2 groups group A - mesotherapy with piroxicam (20mg/ml, 1ml) and lidocaine (1%, 1.5ml) (treatment arm); group group B - mesotherapy without piroxicam
48110911|NCT01556971|DRUG|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
48110912|NCT01556971|DRUG|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
48110913|NCT05697081|OTHER|Medical doctors infected with COVID-19|web-based survey
48110914|NCT03546907|DRUG|SAR440340|Pharmaceutical form: Solution for injection; Route of administration: SC
48481646|NCT06245759|OTHER|This was a retrospective study and no patient intervention was performed|This was a retrospective study and no patient intervention was performed
48481647|NCT02779751|DRUG|Abemaciclib|Administered orally
48481648|NCT02779751|DRUG|Pembrolizumab|Administered IV
48481649|NCT02779751|DRUG|Anastrozole|Administered orally
48481650|NCT03441295|PROCEDURE|Dynamic Intraligamentary Stabilization|DIS, Ligamys
48481651|NCT03441295|PROCEDURE|Internal Brace Ligament Augmentation|IBLA
48481652|NCT03441295|PROCEDURE|ACL Reconstruction|Conventional
48481653|NCT01386502|BIOLOGICAL|p53: 264-272 peptide|
48481654|NCT01386502|DRUG|CT-011|
48481655|NCT04206722|DEVICE|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
48481656|NCT04206722|DEVICE|Ultrasound|Ultrasound 0.7W/cm2
48481657|NCT06184295|DEVICE|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
48481658|NCT02914249|OTHER|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
48481659|NCT00338130|DRUG|AZD6244|Oral liquid or Capsule
48481660|NCT00338130|DRUG|Temozolomide|oral
48110915|NCT03546907|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: SC
48481661|NCT02746627|BEHAVIORAL|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
48481662|NCT02746627|BEHAVIORAL|Education|Educational materials on diabetes management
48481663|NCT04492852|PROCEDURE|Polypropylene (PROLENE) sutures|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
48481664|NCT04492852|PROCEDURE|Staple Sutures|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
48481665|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
48481666|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
48481667|NCT00897949|DRUG|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
48481668|NCT00897949|DRUG|Comparator: placebo|Placebo to rizatriptan
48481669|NCT05848401|DEVICE|Biosound Therapy System|Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
48641122|NCT06529692|BEHAVIORAL|Split-Belt Training|Walking on a split-belt treadmill in which the treadmill belt under the ACL leg will move at a speed faster or slower than the belt under the Non-ACL leg.
48641123|NCT04522375|DRUG|FP-045|activator of aldehyde dehydrogenase
48641124|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
48641125|NCT02628067|BIOLOGICAL|pembrolizumab|intravenous infusion
47958033|NCT02322346|DRUG|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
47958034|NCT02322346|DRUG|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
47958035|NCT02791997|OTHER|Neuropsychological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
47958036|NCT02791997|OTHER|Neurophysiological tests|Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
48110916|NCT03546907|DRUG|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
48110917|NCT03546907|DRUG|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
48110918|NCT03546907|DRUG|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
48110919|NCT03546907|DRUG|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: inhaled
48110920|NCT01029093|OTHER|no intervention, MRI and motor skill test|Two MR Investigations at two different times
48481670|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.
48481671|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
48481672|NCT05909917|OTHER|Half-Day First Responder Training|Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.
48481673|NCT02947620|DRUG|Metformin/Atorvastatin 1500mg/40mg, QD|
48641126|NCT04666155|DEVICE|Intermittent Colonic Exoperistalsis with MOWOOT device|"Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both."
48110921|NCT00723450|DRUG|lamictal|Flexible Dosing
48304941|NCT05556382|RADIATION|radiation of brain tissue specimen and dna damage analysis|increasing doses of radiation on brain tissue specimen and analysis of related dna damage.
48110922|NCT00372450|PROCEDURE|management of therapy complications|
48110923|NCT00372450|PROCEDURE|quality-of-life assessment|
48481674|NCT02947620|DRUG|Metformin 1500mg, QD|
48481675|NCT02947620|DRUG|Atorvastatin 40mg, QD|
48110924|NCT05426057|BEHAVIORAL|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
48110925|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive BBT-CI
48110926|NCT04829539|BEHAVIORAL|Behavioral Intervention|Receive HEAL
48110927|NCT04829539|OTHER|Quality-of-Life Assessment|Ancillary studies
48481676|NCT05605912|OTHER|Control|Participants perform five one-hour conventional training sessions at the Sint Maartenskliniek in which they perform functional exercises. After the conventional training program, the control group will receive a recommendation for physical activity at home for six weeks.
48481677|NCT05605912|DEVICE|Myosuit|Participants perform five one-hour Myosuit training sessions at the Sint Maartenskliniek in which they perform functional exercises and learn to don, doff and use the device for standing, walking, climbing the stairs and sit-to-stand transitions. After the clinical Myosuit training program, participants receive the Myosuit at their disposal at home and a recommendation for physical activity at home for six weeks.
48481678|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules|As previously published
48481679|NCT01205841|PROCEDURE|Buffalo Rule|As previously published
48110928|NCT04829539|OTHER|Questionnaire Administration|Ancillary studies
48110929|NCT05603520|OTHER|Collection of Clinical Data|prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
48481680|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
48481681|NCT01205841|PROCEDURE|Thompson Test|As previously published
48481682|NCT01205841|PROCEDURE|Palpation of the fibula|Palpation of the fibula over its entire length.
48481683|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
48481684|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
48481685|NCT01205841|PROCEDURE|Malleolar Zone Algorithm|As previously published
48481686|NCT01205841|PROCEDURE|Low Risk Exam|As previously published
48481687|NCT01205841|PROCEDURE|Bernese Ankle Rules|As previously published
48110930|NCT05297448|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
48110931|NCT05297448|DRUG|Placebo|Placebo Twice Daily
48110932|NCT04493242|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
48110933|NCT04493242|OTHER|Intravenous normal saline|Placebo
48110934|NCT03703518|OTHER|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
48304942|NCT03908138|DRUG|RDD|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
48304943|NCT03908138|DRUG|VDD|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
48304944|NCT06219317|DRUG|Cemiplimab|Cemiplimab is provided in a 10 ml glass vial
48304945|NCT06219317|DRUG|Placebo|standard saline solution
48481688|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
48481689|NCT03808584|OTHER|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
48481690|NCT03581188|DEVICE|Patient-led surveillance|Usual care plus reminders, ASICA instructional videos, a mobile dermatoscope, an app that facilitates store-and-forward teledermatology, and fast-tracked unscheduled clinic visits.
48481691|NCT03581188|BEHAVIORAL|Clinician-led surveillance|Usual care (scheduled clinician visits)
48481692|NCT04464109|PROCEDURE|Evisceration with orbital implantation|Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
48481693|NCT04910828|OTHER|Common foods of varying glycemic indices|Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
48641127|NCT04666155|DEVICE|Standard of care with Trans-Anal Irrigation|Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
48641128|NCT04401475|BIOLOGICAL|SOC plus 15mg/kg EB05 IV|Standard of care plus single IV infusion of 15mg/kg of EB05.
47958037|NCT06270771|DEVICE|OURA Ring|The OURA ring (https://ouraring.com) is a light-weight wearable device in the form of a ring that has several microsensors enabling detection of heart rate, blood oxygen level, skin temperature, and movement. The OURA ring and application can synthesize the sensory data to generate physiologic information such as sleep, activity level, resting heart rate, heart rate variability, respiratory rate, and more. The OURA ring is water resistant and has up to 5-7 days of battery life and can be fully charged in 20-80 minutes. It communicates with the OURA app and commonly used Smartphone health apps via Bluetooth connectivity with automatic syncing every week.
47958038|NCT05542160|DIETARY_SUPPLEMENT|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
47958039|NCT00450255|BIOLOGICAL|ziv-aflibercept|Given IV
47958040|NCT00450255|OTHER|pharmacological study|Correlative studies
47958041|NCT00407329|PROCEDURE|transurethral resection of the prostate|resection of prostate
47958042|NCT01981980|OTHER|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
47958043|NCT01981980|OTHER|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
47958044|NCT02027519|OTHER|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~* Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~  * Self-administer HIV rapid test and read test results~ * Provide study staff with self-testing result~ * Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
47958045|NCT04549857|BEHAVIORAL|aromatherapy|"The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment."
47958046|NCT00298584|PROCEDURE|Percutaneous Suprapubic Aspiration|
47958047|NCT00298584|PROCEDURE|Urethral Catheterization|
47958048|NCT04689009|DEVICE|EmoLED|The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.
47958049|NCT04689009|PROCEDURE|current Standards Of Care|"The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out."
47958050|NCT01409434|DRUG|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
47958051|NCT05115669|DEVICE|Wortie freeze plus|treatment of common and plantar warts
47958052|NCT01722123|OTHER|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
47958053|NCT00229073|DRUG|dapoxetine|
47958054|NCT00508755|DEVICE|Gait Robot|gait training with the use of a gait robot
48304946|NCT04151017|OTHER|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
48641129|NCT04401475|OTHER|SOC plus Placebo IV|Standard of care plus a single IV infusion of placebo.
48641130|NCT06070350|BIOLOGICAL|Low Titer Group O Whole Blood (LTOWB)|LTOWB is whole blood from group O donors with low titer (\<200) anti-A and anti-B antibodies. Up to 8 units of LTOWB will be allowed unless local clinical practice allows for a higher maximum dose.
48641131|NCT06070350|DRUG|Placebo|Placebo will be provided to the research pharmacy at each of the clinical sites
48641132|NCT06070350|DRUG|Tranexamic Acid (TXA)|TXA is a synthetic lysine analog that competitively inhibit activation of plasminogen, thereby decreasing the conversion of plasminogen to plasmin, preventing degradation of fibrin's matrix structure. Dose is 25mg/kg IV or IO (maximum 2 grams).
47958055|NCT00508755|DEVICE|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
48110935|NCT03703518|OTHER|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
48110936|NCT04892290|OTHER|Conservative Treatment for Postdural Puncture Headache|The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
48110937|NCT02488200|OTHER|No intervention|No intervention
48110938|NCT04528264|DEVICE|Intraoperative ultrasound guided|Samsung Mysono U6 machine with LN 15 linear (https://www.samsunghealthcare.com/en/products/UltrasoundSystem/MySono%20U6/General%20Imaging/transducers) probe capable of Musculoskeletal imaging will be used for visualization and location of fracture after which elevation and reduction of fracture will be attempted. The ultrasound probe will be used as described by McCann. Radiographic continuity of periosteal shadow without any step will be taken as end point for reduction and the procedure will be terminated.
48110939|NCT04528264|OTHER|Conventional blind reduction technique|Conventional blind reduction technique
48110940|NCT00889694|DRUG|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
48110941|NCT00889694|DRUG|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
48304947|NCT04151017|OTHER|Suture|Graft fixation using 10.0 mononylon
48110942|NCT00889694|DRUG|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
48110943|NCT05727397|DRUG|RC28-E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
48110944|NCT05727397|DRUG|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.
48110945|NCT04520880|DIAGNOSTIC_TEST|Testing procedure for Binding antibodies|Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
48110946|NCT04520880|DIAGNOSTIC_TEST|Neutralizing antibodies|Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
48110947|NCT02129049|OTHER|educational intervention|Participate in the Enhancing Connections Telephone Program
48304948|NCT05922267|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUES|"The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~* Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing"
48481694|NCT01398202|DIETARY_SUPPLEMENT|vitamin D3|20 micrograms per day for 10 weeks
48481695|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
47958056|NCT00736944|DRUG|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
47958057|NCT00736944|DRUG|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
48110948|NCT02129049|BEHAVIORAL|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
48481696|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
48481697|NCT01398202|DIETARY_SUPPLEMENT|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
48641133|NCT06070350|BIOLOGICAL|Component Therapy (CT)|Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio. This will be given with Placebo
47958058|NCT00736944|DRUG|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
47958059|NCT00736944|DRUG|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
47958060|NCT00736944|DRUG|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
47958061|NCT00736944|RADIATION|Radiation (Post induction)|Monday-Friday, weeks 1-7
47958062|NCT00736944|DRUG|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
48641134|NCT01783236|DRUG|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
48641135|NCT01783236|DRUG|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
48641136|NCT01272037|DRUG|Anastrozole|Given PO
48481698|NCT01668121|DRUG|Symbicort Turbohaler|
48641137|NCT01272037|DRUG|Exemestane|Given PO
48641138|NCT01272037|OTHER|Laboratory Biomarker Analysis|Correlative studies
48641139|NCT01272037|DRUG|Letrozole|Given PO
48641140|NCT01272037|OTHER|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
47958063|NCT00736944|DRUG|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
47958064|NCT06377475|PROCEDURE|Jaw relation|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
47958065|NCT06377475|PROCEDURE|Questionnaire|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
47958066|NCT00699569|DIETARY_SUPPLEMENT|hyperimmune colostrum|hyperimmune colostrum
47958067|NCT00699569|DIETARY_SUPPLEMENT|Placebo|
47958068|NCT05374733|DIAGNOSTIC_TEST|Coronary Physiology assessment|"1. Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~2. Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention."
48481699|NCT01668121|DRUG|Budesonide/formoterol Easyhaler|
48481700|NCT06372925|DRUG|atorvastatin|20mg atorvastatin PO
48481701|NCT06372925|PROCEDURE|IVUS/OCT|performed the IVUS/OCT at baseline and Day 360
48481702|NCT06372925|DRUG|inclisiran|Inclisiran 284mg SC
48481703|NCT02270424|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
48481704|NCT02270424|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
48481705|NCT02270424|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
48481706|NCT02270424|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
48481707|NCT02270424|DRUG|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
48481708|NCT02270424|DRUG|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
48481709|NCT02270424|DRUG|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
48481710|NCT05246787|BEHAVIORAL|breastfeeding|nonphamacological methods
48481711|NCT05246787|COMBINATION_PRODUCT|Breastfeeding and Shotblocker|combined Breastfeeding and Shotblocker device
48481712|NCT05246787|DEVICE|shotblocker|it is a small plastic tool
48481713|NCT02561234|DRUG|Co-ArgI-PEG|Administered IV
48481714|NCT01021267|DRUG|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
48481715|NCT03087786|DRUG|Nicotine Bitartrate Lozenge 4mg|Test Product
48481716|NCT03087786|DRUG|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
48481717|NCT02010294|GENETIC|DNA samples, GAS strains|DNA samples,GAS strains
48641141|NCT01272037|DRUG|Systemic Chemotherapy|Given IV
48641142|NCT01272037|DRUG|Tamoxifen Citrate|Given PO
48641143|NCT04969770|OTHER|Ultrasound elastography (USE)|"Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation."
48641144|NCT05350592|DRUG|Tocilizumab|Single bolus
48641145|NCT05350592|DRUG|Dobutamine|Continous weight-adjusted infusion
48641146|NCT05350592|DRUG|NaCl 0.9%|Placebo comparator and diluent
48641147|NCT05566054|DRUG|Chidamide|Chidamide 10mg orally daily for 7 days (d1-d7)
48641148|NCT05566054|DRUG|Azacitidine|azacytidine 75mg/m2 daily for 7 days (d1-d7)
48641149|NCT05566054|DRUG|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28)
48641150|NCT06075745|DRUG|CMV-MVA Triplex|The dosage used will be 5.0 x 10\^8 pfu, administered under sterile conditions intramuscularly. The CMV-MVA Triplex vaccine lots range in titre from 5.0 to 9.0 x 10\^8 pfu/mL in a supplied volume of 1.0 mL
48641151|NCT06075745|DRUG|Placebo for CMV-MVA Triplex|Arm 2 participants receive two doses of matching placebo CMV-MVA Triplex
48641152|NCT04319198|DRUG|Sacituzumab Govitecan-hiy|Administered intravenously
47958069|NCT06315959|PROCEDURE|Bilateral ultrasound guided erector spinae plane block|"Bilateral ultrasound-guided ESP(total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS).~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
48110949|NCT02129049|OTHER|questionnaire administration|Ancillary studies
47958070|NCT06315959|DRUG|morphine PCA|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
48110950|NCT00497991|DRUG|AZD1152|
48110951|NCT01091454|DRUG|brostallicin|Given IV
48110952|NCT01091454|DRUG|cisplatin|Given IV
48110953|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
48110954|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
48110955|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
48110956|NCT01365637|DRUG|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
48110957|NCT06466564|DEVICE|Nufairy® Coil embolization system for intracranial aneurysm|Nufairy® Coil embolization system for intracranial aneurysm
48110958|NCT04164680|DIAGNOSTIC_TEST|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
48110959|NCT03768869|DRUG|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
48110960|NCT03768869|DRUG|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
48110961|NCT03768869|DRUG|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
48110962|NCT04775290|BEHAVIORAL|Yoga lessons|2 weekly yoga classes during the 5 weeks of radiotherapy
48110963|NCT06174337|BEHAVIORAL|Use of Video Connection with Family via Robot|A remote family member is able to connect via video with a nursing home resident.
48110964|NCT04905225|PROCEDURE|Ascending aortic replacement|Surgical access will be performed through a median sternotomy. Ascending aortic repair is performed under conditions of cardiopulmonary bypass (CPB) and MHCA with unilateral ACP via innominate artery with a flow rate of 8-10 ml/kg/min and perfusion pressure of 60-80 mmHg. Once CPB is instituted, the aortic cross-clamp is applied, and the heart is arrested with antegrade cardioplegia. Hemiarch replacement involves resection lesser curve of the aortic arch from the base of the innominate artery (Zone 0) to a point immediately distal to the nadir of the lesser curvature (Zone 3 or Zone 2 if the left subclavian artery was too far).
48110965|NCT05827393|PROCEDURE|muscle transplantation|the resected extra stump of rectus muscle was transplanted to the other horizontal rectus muscle which was recessed by a standard recession technique
48110966|NCT03196167|DRUG|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
48110967|NCT03196167|OTHER|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
48110968|NCT02847117|OTHER|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
48110969|NCT00933088|OTHER|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
48110970|NCT03629444|RADIATION|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
48110971|NCT05651399|DRUG|Remimazolam|Patients receive remimazolam at a rate of 1 mg/kg/hr. When a patient's MOAA/S reaches 3 or less, the rate of remomazolam is maintained at a rate between 0.3 mg/kr/hr and 1.0 mg/kg/hr until the end of surgery.
48110972|NCT05651399|DRUG|Propofol|Patients are administered propofol with an effect-site concentration of 1.0 mcg/mL to 2.5 mcg/mL by target controlled infusion.
48110973|NCT05310136|BEHAVIORAL|BBTi|On the arrival for the baseline appointment, participants will receive workbooks which include an outline and content of BBTi, sleep diaries, and adherence record. In the end of weeks 1 and 3, nurse interventionist will meet participants to review their sleep diary data and negotiate their bedtime and wake-time schedule. During the weeks 2 and 4, participants will receive planned follow-up phone calls to assess their adherence and review progress and challenges.
48110974|NCT03070483|DRUG|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
48110975|NCT04132518|DEVICE|Sculptra|Initial injection and optional 3 injections with Sculptra in Midface.
48481718|NCT02419924|DEVICE|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
47958071|NCT06315959|OTHER|Control group|"Patients in this group will not be performed plane blocks. Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS) .~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
47958072|NCT06315959|DRUG|morphine PCA|V PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
48641153|NCT05675020|BEHAVIORAL|Zoom Intervention|"This educational program will be delivered via a 45-minute presentation via Zoom.~* The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~* The educational program will promote a healthy lifestyle knowledge and behaviors through education evidenced by the CDC, WHO, and the American Academy of Pediatrics. Educational sessions will include the importance of healthy lifestyle modifications in the adolescent population with a mental health condition(s), lifestyle recommendations versus reality, nutrition, physical activity, screen time, and sleep recommendations and guidelines.~* We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."
47958073|NCT03617185|OTHER|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
47958074|NCT03617185|OTHER|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
48641154|NCT06293365|BIOLOGICAL|VAY736 1ml PFS|Solution for injection.
47958075|NCT03617185|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
47958076|NCT03698409|DRUG|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
47958077|NCT02331342|DEVICE|NICOM cardiac output measurement|
47958078|NCT02331342|DEVICE|Innocor cardiac output measurement|
47958079|NCT00693849|DRUG|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
47958080|NCT00693849|DRUG|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
47958081|NCT00693849|DRUG|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
47958082|NCT01072422|BEHAVIORAL|smoking cessation|Use of trying to quit smoking instrument and quit smoking advice
47958083|NCT00607984|DRUG|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
48304949|NCT05922267|OTHER|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
48304950|NCT01107977|BEHAVIORAL|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
48304951|NCT00259259|BEHAVIORAL|SALATRIM|
48481719|NCT05146726|OTHER|BARMER anemia treatment|BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
48641155|NCT06293365|BIOLOGICAL|VAY736 2 ml PFS|Solution for injection
48641156|NCT06293365|BIOLOGICAL|VAY736 2ml AI|Solution for injection.
48641157|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
48641158|NCT04573946|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
48641159|NCT04573946|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
48304952|NCT02725892|OTHER|NIS observational stud|NIS observational study : Epidemiologic registry
48304953|NCT01507584|DEVICE|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
48304954|NCT00814073|DRUG|Masitinib|Masitinib 6 mg/kg/day
48304955|NCT00814073|DRUG|Placebo|Matching placebo
48641160|NCT04573946|DIETARY_SUPPLEMENT|Vitamin D3|"Vitamin D3 (cholecalciferol), 2000 IU per day.~Other Names: cholecalciferol"
48641161|NCT05901597|DEVICE|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer
48641162|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
48641163|NCT05886881|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
47958084|NCT06144281|BEHAVIORAL|Nudge for PHPC NP Referral|The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
47958085|NCT02850601|DRUG|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
47958086|NCT04067700|PROCEDURE|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
47958087|NCT00492531|DRUG|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
47958088|NCT00492531|DRUG|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
47958089|NCT03361163|BIOLOGICAL|emm75 Streptococcus pyogenes (GAS M75, strain 611024)|Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
48110976|NCT03329144|BEHAVIORAL|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
48110977|NCT01849055|DRUG|Placebo|Administered orally
48110978|NCT01849055|DRUG|LY3023703|Administered orally
47958090|NCT04478266|DRUG|Amcenestrant-matching placebo|Pharmaceutical form: Tablets Route of Administration: Oral
48110979|NCT01849055|DRUG|Celecoxib|Administered orally
48110980|NCT02631148|DRUG|Melatonin|2mg controlled release melatonin tablet
48110981|NCT02631148|DRUG|Placebo|placebo tablet identical to circadin
48110982|NCT01131494|OTHER|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
48110983|NCT03802266|DEVICE|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
47958091|NCT04478266|DRUG|SAR439859|Pharmaceutical form: Tablets Route of Administration: Oral
47958092|NCT04478266|DRUG|Palbociclib|Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
47958093|NCT04478266|DRUG|Letrozole|Pharmaceutical form: Capsules Route of Administration: Orally
47958094|NCT04478266|DRUG|Goserelin|Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
47958095|NCT04478266|DRUG|Letrozole-matching placebo|Pharmaceutical form: Capsules Route of Administration: Orally
47958096|NCT02195336|DEVICE|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
47958097|NCT02195336|DRUG|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
47958098|NCT02195336|DRUG|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
47958099|NCT05136703|BEHAVIORAL|Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)|CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months.
47958100|NCT05136703|BEHAVIORAL|Antiretroviral Therapy (ART) Adherence Counseling|"This treatment involves a single session integrating CBT for depression with CBT for adherence following our Life-Steps approach."
48110984|NCT03802266|DEVICE|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
48110985|NCT04807725|GENETIC|Analysis of genetic polymorphisms|For the investigation of genetic polymorphisms, it will be collected a sample of cells from the jugal mucosa with the aid of a swab. The genetic analysis will be done with the DNA extraction technique followed by PCR-RFLP techniques (polymerase chain reaction followed by restriction fragment length polymorphism).
48110986|NCT04807725|OTHER|Biochemical analysis|For the biochemical analysis of the inflammatory mediators IL-1beta, TNF-alpha and PGE2 a peri-implant crevicular fluid collection will be performed by inserting paper strips into peri-implant sulcus or pocket, in situations of peri-implantitis from the most affected location, while in situations of peri-implant health from the mesio-buccal location.
48110987|NCT05482399|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
48481720|NCT05146726|OTHER|NON-BARMER anemia treatment|Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability\> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
48481721|NCT02450877|DRUG|Azacitidine|
48110988|NCT04431388|DEVICE|ultrasound device|We performe a differnt analgesic techniques to know if some of then are better
48110989|NCT04431388|DRUG|Levobupivacaine|using the same AL
48110990|NCT06376513|OTHER|Evaluation|Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
48110991|NCT03299816|BEHAVIORAL|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
48110992|NCT03299816|BEHAVIORAL|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
48110993|NCT00976625|PROCEDURE|Aortic Valve Replacement|Surgical valve replacement of the aorta
48110994|NCT00246012|DRUG|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
48110995|NCT00246012|DRUG|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
48110996|NCT00246012|DRUG|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
48110997|NCT05814211|DEVICE|Investigational device - newly developed intermittent catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
48110998|NCT05814211|DEVICE|Comparator device #1 - SpeediCath Eve|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
48110999|NCT05814211|DEVICE|Comparator device #2 - SpeediCath Compact Plus Female|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
48111000|NCT01924975|PROCEDURE|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
48111001|NCT01924975|DEVICE|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
48111002|NCT01924975|DEVICE|A 22 or 24 G intravenous catheter|
48111003|NCT04779333|BEHAVIORAL|LEAP|LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker \& facebook group.
48111004|NCT04779333|BEHAVIORAL|Standard BMT|Weekly BMT groups sessions which follow the Barkley curriculum
48111005|NCT02474147|OTHER|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
48111006|NCT02474147|OTHER|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
48481722|NCT02450877|OTHER|Control Arm|
48481723|NCT00692315|DRUG|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
48111007|NCT04215471|DRUG|PD-L1 Antibody SHR-1316|Neoadjuvant therapy with immunoreagent (PD-L1 antibody SHR-1316) for resectable oesophageal squamous cell carcinoma
48481724|NCT05343221|DEVICE|High Fidelity Simulator|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the High Fidelity CPR Simulator. This simulator is adult human sized and specialized for CPR practice. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
48641164|NCT05886881|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
48304956|NCT00814073|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
47958101|NCT01706822|DEVICE|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
47958102|NCT04798755|DRUG|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
47958103|NCT04798755|DRUG|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
47958104|NCT04798755|DRUG|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
47958105|NCT05036590|OTHER|control group|The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
47958106|NCT05036590|OTHER|Intervention group|The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
47958107|NCT06378580|DRUG|Surufatinib combine immune checkpoint inhibitor|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip"
47958108|NCT06378580|DRUG|AG/FOLFIRINOX|"Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity."
47958109|NCT00487175|DRUG|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
47958110|NCT06176521|PROCEDURE|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
47958111|NCT05954975|COMBINATION_PRODUCT|BabyCheck and pulse oximetry|"The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained."
47958112|NCT03750955|DEVICE|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
47958113|NCT03750955|DEVICE|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
47958114|NCT03869983|OTHER|Omnipaque™ (iohexol) Injection|755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
48304957|NCT00002572|BIOLOGICAL|aldesleukin|
47958115|NCT03869983|OTHER|CE-Iohexol|755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
48111008|NCT02500654|DEVICE|Emdogain®|Surgery and Emdogain®
48304958|NCT00002572|BIOLOGICAL|muromonab-CD3|
48304959|NCT00002572|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
48304960|NCT00002572|PROCEDURE|conventional surgery|
48304961|NCT04498533|OTHER|forearm strap (counterforce brace)|
48304962|NCT04498533|OTHER|Kinesio tape application|
48304963|NCT00549237|DIETARY_SUPPLEMENT|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
48304964|NCT00549237|OTHER|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
48304965|NCT03233490|OTHER|web course|Web course Help Brain Heart was conducted Before CPR training.
48304966|NCT03233490|OTHER|CPR training|No web course was conducted
48304967|NCT03865017|BIOLOGICAL|Regulatory T cells|The trial will be carried out in Alzheimer's disease patients. The investigators will isolate CD4+CD25+ Tregs from these patients, expand and injection.
48304968|NCT03865017|OTHER|Saline|Saline+cell suspension solution infusion
48304969|NCT03441191|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
47958116|NCT04432025|PROCEDURE|Bariatric surgery + goal directed medical therapy|Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
47958117|NCT04432025|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
47958118|NCT01133873|DRUG|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
48111009|NCT02500654|DEVICE|Surgery alone|Surgery alone
48111010|NCT02457117|RADIATION|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
48111011|NCT03702673|DRUG|K-877 CR Tablet A|K-877 Controlled Release Tablet A
48111012|NCT03702673|DRUG|K-877 CR Tablet B|K-877 Controlled Release Tablet B
48111013|NCT03702673|DRUG|K-877 CR Tablet E|K-877 Controlled Release Tablet E
48111014|NCT03702673|DRUG|K-877 IR Tablet|K-877 Immediate Release Tablet
48111015|NCT05404906|DRUG|Azacitidine|Given SC
48111016|NCT05404906|DRUG|Venetoclax|Given PO
48111017|NCT05404906|OTHER|Supportive care|Patients will receive disease monitoring and supportive care for any complication.
48111018|NCT00928213|DRUG|Progesterone|40 units daily admission
48111019|NCT00928213|DRUG|Low molecular weight Heparin|40-80 mg/day
48111020|NCT00928213|DRUG|No Drug|no treatment
48111021|NCT04507945|DRUG|Nutritional Therapy, Metabolic Disorder, Regular|According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
48111022|NCT05315180|DRUG|BPI-421286|Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
47958119|NCT01133873|DRUG|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
48111023|NCT01494246|OTHER|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
48111024|NCT03983889|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
48111025|NCT03983889|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
47958120|NCT01549678|OTHER|Total contact insole|EVA insole shaped on patient´s foot.
47958121|NCT01549678|OTHER|placebo insole|EVA insole flat
47958122|NCT02654314|DRUG|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
47958123|NCT02654314|OTHER|Placebo|Blue capsule matching the melatonin arm
47958124|NCT04734938|DIETARY_SUPPLEMENT|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
47958125|NCT00002688|DRUG|cyclosporine|
47958126|NCT00002688|DRUG|etoposide|
47958127|NCT00002688|DRUG|mitoxantrone hydrochloride|
48111026|NCT03983889|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
48111027|NCT03983889|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
48111028|NCT03983889|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
48111029|NCT04893213|OTHER|Manipulation of availability of lower energy meal options|Menus provided differ in % of menu options that are higher vs. lower in energy
48111030|NCT03909477|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
48111031|NCT03909477|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
48111032|NCT03909477|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
48111033|NCT03909477|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants \>35 years of age will perform the six minute walk test as a measure of exercise capacity
48111034|NCT03909477|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants \<35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
48111035|NCT03909477|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
48111036|NCT03909477|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
48111037|NCT04133740|DRUG|Oxygen|Liberal versus conservative oxygen therapy.
48111038|NCT02045836|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
48111039|NCT02045836|BIOLOGICAL|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
48304970|NCT06034704|OTHER|Plantar fascia self massage with a magnetic fascia ball|Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
48304971|NCT06034704|OTHER|Plantar fascia self massage with a non-magnetic fascia ball|Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
48304972|NCT06386653|DRUG|Diagnostic injection of [123I]I-DARPIN-Ec1|A single intravenous injection of \[123I\]I-DARPIN-Ec1
48304973|NCT06386653|DIAGNOSTIC_TEST|Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1|Gamma camera-based whole-body planar scintigraphy imaging 2, 4, 6, and 24 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
48304974|NCT06386653|DIAGNOSTIC_TEST|Whole-body SPECT with [123I]I-DARPIN-Ec1|Whole-body SPECT at 2, 4, and 6 hours after a single intravenous injection of \[123I\]I-DARPIN-Ec1
48304975|NCT05239286|PROCEDURE|General anaesthesia|"All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia."
48304976|NCT05239286|DRUG|Conventional fluid managment|Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
48304977|NCT05239286|DRUG|PVI dependant goal directed fluid therapy|"After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated."
48304978|NCT01502657|DEVICE|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
48304979|NCT03014219|DRUG|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
48481725|NCT05343221|DEVICE|Haptic|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the 3D technology Haptic Device Simulator. This tool has a computer screen and a swing haptic pen. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
48481726|NCT01470196|DRUG|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
48481727|NCT01470196|DRUG|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
48481728|NCT01470196|DRUG|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
48481729|NCT01046630|DRUG|AZD6765|single infusion
48481730|NCT01046630|DRUG|Ketamine|single infusion
48481731|NCT01046630|DRUG|Placebo|single infusion
48481732|NCT05602402|OTHER|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
48481733|NCT05602402|OTHER|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
48481734|NCT04553913|DEVICE|cooling device|device placed on patient in recovery on non surgical side to determine resolution of spinal anesthetics.
48481735|NCT04385524|BIOLOGICAL|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
48481736|NCT00880087|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
48481737|NCT00880087|PROCEDURE|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
48481738|NCT03178721|DIAGNOSTIC_TEST|blood sample|study B regulatory in blood and its correlation with atherosclerosis
48481739|NCT04184999|DRUG|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
47958128|NCT04346082|BEHAVIORAL|online mindfulness group|Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
47958129|NCT02221830|DRUG|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
47958130|NCT02221830|DRUG|Placebo|This intervention utilizes a Placebo Camparator
47958131|NCT01406743|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
47958132|NCT04029506|OTHER||this is an obsevational study which needs no interventions
47958133|NCT03840798|OTHER|Child Abuse Clinical Decision Support system|"The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~1. a universal child abuse screen (CAS)~2. an embedded child abuse alert system~3. alerts to physicians and advanced practice providers~4. physical abuse order sets"
47958134|NCT02369016|DRUG|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
47958135|NCT05642988|DEVICE|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
47958137|NCT03434197|DRUG|Esflurbiprofen|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
47958138|NCT03434197|DRUG|Diclofenac diethylamine|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
47958139|NCT05476406|OTHER|äKwä skincare system products|The skincare product system tested in this study was äKwä 6-step skincare system from 4Life Research USA, LLC ( https://www.4life.com/6613461/page/äKwä). Product directions state to use the following products morning and night in sequential order: First Wave Oil-to-Foam Cleanser, Glacier Glow Four-Way Toner, Precious Pool Vitamin Essence, Ripple Refine Eye Cream, and RainBurst Moisture Cream.
48111040|NCT05209386|BEHAVIORAL|Dimension-Based Statistical Learning|"Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant."
48641165|NCT05886881|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
47958140|NCT05476406|OTHER|competitor products (control)|Participants use whatever their normal daily routine of skincare products, which are commercially available competitor products from the marketplace.
47958141|NCT05182190|DIETARY_SUPPLEMENT|White bread|Toasted white bread
47958142|NCT05182190|DIETARY_SUPPLEMENT|Black beans whole boiled|Whole boiled black beans with spaghetti sauce
48111041|NCT02715258|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
48111042|NCT02715258|DRUG|Placebo|tablets matching the appearance of bexagliflozin tablets
48481740|NCT04184999|DRUG|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
48481741|NCT03367689|DRUG|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
48481742|NCT03703024|DIETARY_SUPPLEMENT|Raspberry Leaf Extract|Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
48481743|NCT03703024|DIETARY_SUPPLEMENT|Placebo|Delivered in a capsule
48481744|NCT01959490|BIOLOGICAL|trastuzumab|Given IV
48481745|NCT01959490|BIOLOGICAL|Pertuzumab|Given IV
48111043|NCT02995096|PROCEDURE|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
48111044|NCT02995096|DRUG|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
48481746|NCT01959490|DRUG|docetaxel|Given IV
48481747|NCT01959490|DRUG|carboplatin|Given IV
47958143|NCT05182190|DIETARY_SUPPLEMENT|Knife Mill pasta|Black bean pasta (KM) with spaghetti sauce
47958144|NCT05182190|DIETARY_SUPPLEMENT|Combo Flour Pasta|Black bean pasta (Combo) with spaghetti sauce (medium protein flour)
47958145|NCT05182190|DIETARY_SUPPLEMENT|Cyclone Flour Pasta|Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
47958146|NCT00586625|DRUG|Bepreve|One drop, both eyes, twice a day
47958147|NCT00586625|DRUG|Placebo|One drop, both eyes, twice a day
47958148|NCT05527197|DEVICE|Lapiplasty|The Lapiplasty® System instruments and implants will be retrospectively evaluated in patients previously surgically treated with the Lapiplasty® Procedure for Triplane MTP and TMT joint arthrodesis.
48304980|NCT02510235|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
48304981|NCT02510235|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
48481748|NCT01959490|DRUG|doxorubicin|Given IV
48481749|NCT01959490|DRUG|cyclophosphamide|Given IV
48641166|NCT05886881|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
48641167|NCT03533491|BEHAVIORAL|Rewire App|A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
48641168|NCT06401733|OTHER|Intensive Aerobic and Resistance Exercise Program (IAREP)|"IAREP is a combined aerobic exercise and resistance training program that developed by qualified exercise professionals. It encompasses a 12-week exercise intervention, conducted in a blended mode which consists of face-to-face exercise, Zoom exercise, and pre-recorded video exercise.~Frequency: 3 times exercise per week. Intensity: moderate to vigorous exercise. Time of the exercise: 45-60 mins. Type of exercise: combined aerobic and resistance training.~Warm-up: aerobic workout with dynamic stretch (for targeted muscles). Aerobic exercise: each session encompasses 5 exercise. Resistance training: each session encompasses 4 exercise, 2 upper body exercise and 2 lower body exercise.~Cool-down: relax targeted muscles."
48111045|NCT06336486|DEVICE|intermittent pneumatic compression +pregabalin group|The investigators divided the patients into two equal groups , some of the patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
48641169|NCT04130867|PROCEDURE|pHRM|Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.
48641170|NCT04130867|PROCEDURE|VFSS|Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
48641171|NCT03704922|BIOLOGICAL|Transfusion|Red cell units for transfusion
48641172|NCT04938466|DRUG|Long-Acting Growth Hormone (LAGH)|Long-acting growth hormone (LAGH) treatment
48641173|NCT06580899|DEVICE|Intra-articular catheter|Intra-articular catheter pump with existing standard-of-care multimodal pain management protocol in the immediate post-op period
48641174|NCT06580899|OTHER|Routine Standard of Care Treatment|No changes to what would occur outside of the study.
48641175|NCT05389150|DRUG|Fixed dose combination Pregabalin 150 mg / Tramadol 50 mg|Pregabalin/Tramadol (Laboratorios Silanes S.A. de C.V.), Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
48641176|NCT05389150|DRUG|Pregabalin 150mg|From Pfizer S.a. de C.V. Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
48641177|NCT05389150|DRUG|Tramadol 50 mg|From Grünenthal de México, S.A. de C.V. Pharmaceutical Form: Capsule Dosage: 50 mg Administration way: oral
48641178|NCT06547996|DEVICE|tES-tDCS group|2mA/20mins/session
48111046|NCT06336486|OTHER|pregabalin group|only pregabalin treatment was continued.
48111047|NCT05862454|DRUG|Magnesium|Magnesium injection therapy
48111048|NCT04668742|DEVICE|DYNAtraq|Tracheostomy alignment with DYNAtraq
48111049|NCT01495936|PROCEDURE|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
48111050|NCT01495936|PROCEDURE|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
48111051|NCT03371966|DIETARY_SUPPLEMENT|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
48111052|NCT03371966|DIETARY_SUPPLEMENT|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
48111053|NCT04792554|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
48111054|NCT04665661|BEHAVIORAL|High-intensity aerobic training|Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
48111055|NCT04665661|BEHAVIORAL|Wait-list control|Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
48111056|NCT03766711|OTHER|Physical Therapy|Repetitive bimanual task training for upper limb motor function recovery.
48304982|NCT00758927|DRUG|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
48481750|NCT01959490|DRUG|paclitaxel|Given IV
48111057|NCT00036036|DRUG|CP-461|
48304983|NCT00758927|DRUG|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
48304984|NCT00820703|DRUG|Nexagon®|
48481751|NCT01959490|DRUG|Bevacizumab|
48641179|NCT06547996|DEVICE|tES-tACS group|2mA/40Hz/20mins/session
48641180|NCT06547996|DEVICE|tES-sham group|0mA/20mins/session
48641181|NCT01989585|PROCEDURE|Biopsy|Undergo biopsy
48641182|NCT01989585|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48641183|NCT01989585|PROCEDURE|Computed Tomography|Undergo CT
48641184|NCT01989585|DRUG|Dabrafenib|Given PO
48641185|NCT01989585|PROCEDURE|Echocardiography|Undergo echocardiography
48641186|NCT01989585|OTHER|Laboratory Biomarker Analysis|Correlative studies
48641187|NCT01989585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48641188|NCT01989585|PROCEDURE|Multigated Acquisition Scan|Undergo multigated acquisition scan
48641189|NCT01989585|BIOLOGICAL|Navitoclax|Given PO
48641190|NCT01989585|OTHER|Pharmacological Study|Correlative studies
48641191|NCT01989585|DRUG|Trametinib|Given PO
48641192|NCT05847686|OTHER|Counseling|Participate in therapy visits
48641193|NCT05847686|DRUG|Psilocybin|Given PO
48641194|NCT05847686|OTHER|Questionnaire Administration|Ancillary studies
48641195|NCT06333158|DIETARY_SUPPLEMENT|Cholesfytol NG|3 capsules a day with dinner.
48641196|NCT06333158|OTHER|Placebo|3 capsules a day with dinner
47958149|NCT01315665|DIETARY_SUPPLEMENT|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
47958150|NCT05274737|DEVICE|Novel sling|The novel sling was designed and created by the principal investigator to address these concerns of the traditional slings that are currently available for postsurgical protection and immobilization after shoulder surgery. It is anticipated that the novel sling will allow the patient to be more active and more comfortable while still providing a safe healing environment after a shoulder injury or shoulder surgery.
47958151|NCT05274737|DEVICE|Traditional abduction sling|An abduction sling is the most common type of sling utilized to protect patients after rotator cuff surgery and total shoulder of arthroplasty and can be considered the current standard of care.
47958152|NCT03881475|OTHER|questionnaire|"During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes."
47958153|NCT05040048|OTHER|Clinical, biological and imaging assessment|
47958154|NCT05065281|OTHER|Education|Training for health care professionals on how to identify and manage cases of elder abuse among their patients
47958155|NCT04304742|PROCEDURE|hip standard radiography/ CT scan/ MRI|hip standard radiography/ CT scan/ MRI
47958156|NCT00570570|PROCEDURE|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
47958157|NCT00570570|OTHER|conventional physiotherapy|trice a week during 6 weeks
47958158|NCT02824575|DRUG|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
47958159|NCT02824575|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
47958160|NCT02824575|DRUG|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
47958161|NCT05981339|OTHER|breathing exercises|For the diaphragmatic breathing exercise, patients are asked to perform a nasal inspiration and expiration that moves predominantly the abdomen by reducing the movement of the thorax in the semi-supine position. To give tactile stimulation, one hand of the patient is placed on the chest with the other hand on the abdominal region. Continue this exercise for three minutes.
47958162|NCT05981339|OTHER|osteopathic manual therapy techniques|"* Sacral release: While the patient is in the side lying position, the physiotherapist goes behind the patient, one hand is placed on the lower abdominal area, and the thenar and hypothenar areas of the other hand are placed on the basis of the sacrum. It is waited until a general relaxation is felt in the tissue under the hands (Stone, C., 2006).~* Bladder mobilization: Two hands are placed just above the pubic region and gently pressed down first to test the surface protrusion of the uterus. During the application, the pressure of the hand is adjusted according to the tension of the tissue. Hand contact is not interrupted until the fascial tissue under the hand is relaxed (Stone, C., 2006)."
47958163|NCT01170143|DRUG|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
48481752|NCT02524184|DRUG|sildenafil|sildenafil 100 mg per day for 7 days.
48481753|NCT02524184|DRUG|placebo|an identical placebo per day for 7 days
47958164|NCT00154635|DRUG|DCB-AD1|
47958165|NCT01188421|DRUG|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
47958166|NCT01188421|DRUG|Clonidine|up to 0.8 mg per day (oral)
48481754|NCT01998243|DEVICE|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
48481755|NCT01998243|OTHER|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
47958167|NCT01188421|DRUG|Tramadol ER|up to 600 mg per day
47958168|NCT05406778|DEVICE|SPARK Test|Twenty (20) minutes of resting state EEG data collection.
48111058|NCT03070938|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
48111059|NCT01222910|DRUG|Valacyclovir hydrochloride|
48481756|NCT00804206|DRUG|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
48481757|NCT00804206|DRUG|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
48481758|NCT05601076|PROCEDURE|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
48641197|NCT06224348|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
48641198|NCT06224348|DRUG|Placebo|Pharmaceutical form: injection solution Route of administration: SC injection
48641199|NCT06224348|DRUG|Topical corticosteroids|Pharmaceutical form: Topical formulation Route of administration: Topical
47958169|NCT01272674|OTHER|exercise training|4 weeks supervised physical exercise training
47958170|NCT06403228|OTHER|Mindfulness Based Structured Nursing Interventions|In the study, 8 days of mindfulness-based structured nursing interventions were applied to high-risk pregnant women. The program lasts 60 minutes each day. The program includes short body scanning meditation, breath awareness meditation, sitting meditation, compassion meditation.
48111060|NCT02009839|BEHAVIORAL|Meeky Mouse program|
48111061|NCT02009839|OTHER|Computer Games|
48304985|NCT00820703|DRUG|Nexagon® vehicle|
47958171|NCT04617587|BEHAVIORAL|Early Intervention|The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
47958172|NCT00082979|GENETIC|cytogenetic analysis|
47958173|NCT00082979|GENETIC|proteomic profiling|
47958174|NCT00082979|OTHER|cytology specimen collection procedure|
47958175|NCT00082979|OTHER|immunohistochemistry staining method|
47958176|NCT00082979|OTHER|laboratory biomarker analysis|
47958177|NCT00082979|PROCEDURE|breast duct lavage|
47958178|NCT01360593|DRUG|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
47958179|NCT01360593|DRUG|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
47958180|NCT01360593|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
47958181|NCT05123820|DRUG|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
47958182|NCT05123820|DRUG|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
47958183|NCT04061265|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|Local anesthetic agent
47958184|NCT04061265|DRUG|lidocaine hydrochloride 2% and epinephrine 1:100000|Local anesthetic agent
48111062|NCT05126004|DRUG|Azacitidine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
48111063|NCT05126004|DRUG|N Acetyl L Cysteine|28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.
48304986|NCT02514512|DEVICE|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
48304987|NCT02137772|DRUG|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
48481759|NCT05601076|PROCEDURE|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
48481760|NCT00792519|BEHAVIORAL|HIV support group|group support
48481761|NCT00792519|BEHAVIORAL|CBT|group cognitive behavioral treatment
48481762|NCT05487755|DRUG|Tadalafil 20Mg Oral Tablet|Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
48481763|NCT05487755|DRUG|Pentoxifylline 400 MG Oral Tablet|Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
48481764|NCT04186559|DRUG|Topical Pentoxifylline Gel (Vehicle +PTX)|Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
48641200|NCT06224348|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical formulation Route of administration: Topical
48641201|NCT02620852|OTHER|Complete a health questionnaire|Complete a health history questionnaire.
48641202|NCT02620852|DEVICE|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
48641203|NCT02620852|OTHER|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
48641204|NCT02620852|OTHER|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
48641205|NCT03812172|DRUG|99mTc-PYP or 99m Tc-HDP|10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
47958185|NCT03805399|DRUG|Pyrotinib with Capecitabine|If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
47958186|NCT03805399|DRUG|AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)|B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
47958187|NCT03805399|DRUG|anti PD-1 with nab-paclitaxel|If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
47958188|NCT03805399|DRUG|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
47958189|NCT03805399|DRUG|BLIS with anti-VEGFR included therapy|"If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w"
47958190|NCT03805399|DRUG|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
47958191|NCT03805399|DRUG|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
47958192|NCT05594056|PROCEDURE|Transorbital ultrasound of the optic nerve sheet|Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
47958193|NCT04795960|DIETARY_SUPPLEMENT|Low serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
47958194|NCT04795960|DIETARY_SUPPLEMENT|High serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
47958195|NCT04164355|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
47958196|NCT05000281|DRUG|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
47958197|NCT00547495|DRUG|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
47958198|NCT00547495|DRUG|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
47958199|NCT00547495|DRUG|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
47958200|NCT00547495|DRUG|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
47958201|NCT06405958|OTHER|gut microbiome|Obtaining new gut microbiome data in organ transplantation
47958202|NCT04397601|DRUG|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
48641206|NCT04032470|DEVICE|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
48641207|NCT04710303|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
48641208|NCT00972478|DRUG|Cyclophosphamide|Given IV
48304988|NCT02137772|DRUG|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
48304989|NCT03611959|OTHER|Non Applicable|
47958203|NCT04397601|DRUG|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
48304990|NCT05348265|OTHER|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
48304991|NCT05348265|OTHER|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
47958207|NCT02434978|DEVICE|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
47958208|NCT02434978|DRUG|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
48481765|NCT04186559|DRUG|Topical Placebo Gel (Vehicle)|Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.
48641209|NCT00972478|DRUG|Doxorubicin Hydrochloride|Given IV
48641210|NCT00972478|OTHER|Laboratory Biomarker Analysis|Correlative studies
48641211|NCT00972478|DRUG|Prednisone|Given IV
47958209|NCT02434978|OTHER|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
47958210|NCT02146664|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
47958211|NCT02146664|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
47958212|NCT02974283|OTHER|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:"
47958213|NCT04396301|DRUG|Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).|Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
47958214|NCT04883229|DEVICE|Halo Neuroscience Neurostimulator|"Experimental: Neurostimulation of 2 milliamps anodal (active) tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework.~Active comparator: Experimental: Sham tDCS stimulation for 20 mins during 1 hour speech therapy sessions, 3 times a week for 8 weeks, plus daily homework. Then a washout period of no treatment, followed by a 8 weeks of neurostimulation of 2 milliamps anodal (active) sham tDCS treatment during 1 hour speech therapy sessions, 3 times a week for 8 weeks."
47958215|NCT04497935|DRUG|PLENVU|Bowel preparation for a colonoscopy
47958216|NCT04497935|DRUG|MoviPrep|Bowel preparation for a colonoscopy
48304992|NCT01998581|DEVICE|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
48304993|NCT01998581|DEVICE|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
47958217|NCT00431769|DRUG|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
47958218|NCT03398044|DRUG|Dexamethasone|Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
47958219|NCT03398044|DRUG|Placebo|Placebo will be administered to patients randomised into the control group arm.
47958220|NCT04209192|DRUG|Fosfomycin Tromethamine 3G Sachet|Is the prophylactic drug which will be used in the intervention group.
47958221|NCT04209192|DRUG|Amikacin|Is the prophylactic drug which will be used in the control group.
48304994|NCT00690716|DRUG|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
48304995|NCT00690716|DRUG|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
48304996|NCT05886647|OTHER|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
48304997|NCT05886647|OTHER|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
48304998|NCT04964219|DRUG|S-ketamine|"After anesthesia induction, a bolus of 0.15 mg/kg S-ketamine is injected intravenously about 30 min before incision; this is followed by a continuous infusion at a rate of 0.15 mg/kg/h until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 25 mg, dexmedetomidine 100 microgram, and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
48304999|NCT04964219|DRUG|Placebo|"After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval."
47958222|NCT02244112|DRUG|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
47958223|NCT02244112|DRUG|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
47958224|NCT03768232|OTHER|ultrasound asessment|US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
48481766|NCT03444441|PROCEDURE|Foot or ankle surgery|Surgery for foot or ankle
48481767|NCT05273931|OTHER|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
47958225|NCT02831140|BEHAVIORAL|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
47958226|NCT02831140|BEHAVIORAL|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
47958227|NCT02831140|BEHAVIORAL|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
47958228|NCT02831140|BEHAVIORAL|commun interventions|"* In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~* In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~  , preservation of Serratus anterior and the front part of Latissimus Dorsi ).~* In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
47958229|NCT05953311|OTHER|Blood analysis|Blood analysis for neurological biomarkers measurements
47958230|NCT05953311|OTHER|Cognitive tests|Questionnaires assessing cognitive function
47958231|NCT00180050|DRUG|Budesonide|
47958232|NCT02607930|DRUG|ABC/DTG/3TC|600/50/300 milligrams (mg) tablets administered orally, once daily
47958233|NCT02607930|DRUG|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
47958234|NCT02607930|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally, once daily
47958235|NCT02607930|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
47958236|NCT03619278|OTHER|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 doses of 10-1074 antibodies and 3 doses of romidepsin
48305000|NCT05853562|OTHER|structured vestibular rehabilitation program|The structured Vestibular rehabilitation protocol consisted of a structured vestibular rehabilitation program that included vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises, and posture exercises.
48305001|NCT02015598|DRUG|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
48305002|NCT02015598|DEVICE|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
48305003|NCT00003342|BIOLOGICAL|filgrastim|
48481768|NCT02842684|DEVICE|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
47958237|NCT03619278|OTHER|placebo|Participants will receive 5 vaccines of placebo of HIVACAR01, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
47958238|NCT01956435|DEVICE|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
47958239|NCT00581243|DRUG|SLV-313 SR|sustained relase tablets taken once daily for 14 days
47958240|NCT04111198|RADIATION|Cardiac MRI|Cardiac MRI
47958241|NCT02787382|DEVICE|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
47958242|NCT00261222|DRUG|Amodiaquine|
47958243|NCT02675985|OTHER|Physical Therapy|Early Intensive Physical therapy in the ICU
47958244|NCT06378931|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life.
47958245|NCT01785264|PROCEDURE|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
48305004|NCT00003342|DRUG|carboplatin|
48305005|NCT00003342|DRUG|doxorubicin hydrochloride|
48305006|NCT00003342|DRUG|gemcitabine hydrochloride|
48305007|NCT00003342|DRUG|paclitaxel|
48305008|NCT01366222|DIETARY_SUPPLEMENT|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
48305009|NCT03704792|DEVICE|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
48481769|NCT01077817|DRUG|Alendronate|
48481770|NCT01077817|DRUG|Etidronate|
48481771|NCT01077817|DRUG|Ibandronate|
48481772|NCT01077817|DRUG|Risedronate|
48481773|NCT01077817|DRUG|Raloxifene|
48481774|NCT01904422|PROCEDURE|conventional periodontal treatment|
47958246|NCT01785264|PROCEDURE|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
47958247|NCT01785264|PROCEDURE|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
47958248|NCT05176743|BEHAVIORAL|Unconditional Cash Transfer (UCT)|The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.
47958249|NCT03504059|BEHAVIORAL|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
47958250|NCT03504059|BEHAVIORAL|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
47958251|NCT05890508|DEVICE|Acupuncture|Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
47958252|NCT05890508|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
47958253|NCT00850070|DRUG|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
47958254|NCT00850070|DRUG|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
47958255|NCT00686283|BEHAVIORAL|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
48111064|NCT03996083|OTHER|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
48305010|NCT05511753|DEVICE|electroacupuncture|Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
48305011|NCT04030481|OTHER|inhalation anesthesia|sevoflurane was used to maintain anesthesia
48641212|NCT00972478|BIOLOGICAL|Rituximab|Given IV
47958256|NCT03636984|DRUG|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
47958257|NCT03996733|OTHER|Lecture|Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
47958258|NCT03996733|OTHER|Demo Video|Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
47958259|NCT03996733|OTHER|UltrasoundImaging|Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
48305012|NCT04030481|OTHER|Total intravenous anesthesia|propofol was used to maintain anesthesia
48305013|NCT01579539|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
48305014|NCT01579539|DRUG|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
48305015|NCT03601416|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
48641213|NCT00972478|DRUG|Vincristine Sulfate|Given IV
48641214|NCT00972478|DRUG|Vorinostat|Given PO
48641215|NCT05116644|OTHER|NONE - this is a cross-sectional survey design|NONE - this is a cross-sectional survey design
48641216|NCT02730286|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
47958260|NCT03996733|OTHER|ModelTraining|"Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy."
47958261|NCT05508711|DEVICE|FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device|Concomitant cardiac output measurement with transesophageal echocardiography and with the FloTrac/Vigileo system (© Edwards Lifesciences) (Edwards Lifesciences, Irvine, CA) device in 3 different positions (horizontal supine, Trendelenburg and reverse Trendelenburg position).
47958262|NCT03485391|BEHAVIORAL|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
47958263|NCT01015209|DEVICE|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
47958264|NCT02322476|OTHER|No intervention will be performed|No intervention will be performed
47958265|NCT00985478|DRUG|SLV342|25 mg once daily - Maximal Tolerated Dose
47958266|NCT00985478|DRUG|placebo|matching placebo
47958267|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
48111065|NCT03996083|OTHER|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
48111066|NCT01942707|PROCEDURE|abdominoplasty with Scarpa's Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
48111067|NCT01942707|PROCEDURE|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
48111068|NCT04117724|OTHER|Survey|Patients will be asked to complete a 4 question survey assessing adherence. Follow up via patient's preferred method of contact will be conducted after the patient's intended antibiotic completion date and covariates for antibiotic regimens will be recorded including antibiotic type, number of doses, antibiotic duration, reason for non-adherence, pills remaining, and number of other medications.
48111069|NCT01899027|DRUG|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
48111070|NCT01899027|DRUG|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
48111071|NCT01987154|OTHER|Marketed cow milk-based premature infant formula|
48111072|NCT01987154|OTHER|Marketed extensively hydrolyzed casein infant formula|
48111073|NCT04566042|BEHAVIORAL|Acceptance and commitment therapy video game|The intervention is a videogame which teaches the participant about acceptance and commitment therapy.
47958268|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
47958269|NCT00942448|DRUG|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
47958270|NCT00942448|OTHER|Placebo s.c.|1 single injection at day of dental surgical extraction
47958271|NCT06203171|OTHER|Observational|Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.
47958272|NCT00469378|DRUG|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
47958273|NCT01784445|DRUG|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
47958274|NCT00815698|PROCEDURE|suture|suture for mesh fixation
48111074|NCT06201819|DRUG|Liraglutide injection|Liraglutide (GLP-1 analog) injection during 3 months
48111075|NCT04442919|DRUG|Ticagrelor followed with Methoxyflurane|patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina
48111076|NCT04442919|DRUG|Ticagrelor followed with Morphine|patients who received ticagrelor followed with intravenous morphine due to unstable angina
48111077|NCT04442919|DRUG|Ticagrelor alone|patients who received ticagrelor without any analgesia due to unstable angina
47958275|NCT00815698|PROCEDURE|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
48111078|NCT02032329|DEVICE|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
48111079|NCT05603338|PROCEDURE|LSG with omental band|LSG with omental band
48111080|NCT05603338|PROCEDURE|LSG|just to do sleeve gastrectomy
48111081|NCT06339489|DIAGNOSTIC_TEST|Testing the serum levels of bone metabolic markers|Testing serum levels of TRACP-5b and BALP, BMD values of lumbar spine L1-L4, left and right hip, left and right femoral neck et.al.
47958276|NCT03217357|DEVICE|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
47958277|NCT03534414|DIETARY_SUPPLEMENT|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~1. plant sterols (sterol-enriched margarine or supplement)~2. viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~3. plant protein (soy products and pulses), and~4. nuts (tree nuts and peanuts)"
47958278|NCT03534414|DIETARY_SUPPLEMENT|NCEP Based Diet|A low saturated fat, low cholesterol diet.
48111082|NCT04455399|DEVICE|Intravitreal injection guide (Malosa)|A single use, multifunction device will be used to push away an eyelid to expose injection site, indicate injection point about 4 millimeters from surgical limbus, and directs needle perpendicular to the ocular surface while limiting intraocular needle incursion
48111083|NCT04455399|DEVICE|Dual Blade Eyelid Speculum|A conventional dual blade eyelid speculum will be use to push away eyelids. A Castroviejo surgical caliper will be used to mark the injection site.
48111084|NCT05345119|DRUG|Sirolimus|2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
48111085|NCT05345119|DRUG|Methylprednisolone|500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
48111086|NCT02888249|OTHER|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
48111087|NCT00422019|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
48111088|NCT00422019|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
48111089|NCT01628237|DEVICE|comparison of spinal cord stimulation|
48111090|NCT04998318|DEVICE|Pocket Colposcope|Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.
48111091|NCT04998318|PROCEDURE|Standard of Care Colposcopy|VIA and VILI as previously described,
48111092|NCT05340244|DEVICE|Investigational ultrasound exam|"Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device."
48111093|NCT02212054|BEHAVIORAL|conservative|anal dilatation; colonic lavage; oral probiotic
48111094|NCT02212054|PROCEDURE|operative|one stage pull through radical colectomy
48111095|NCT00521833|PROCEDURE|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
48111096|NCT02994719|DRUG|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
48111097|NCT02994719|DEVICE|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
48111098|NCT06513806|DRUG|Granisetron 1 Mg/mL Intravenous Solution|will receive granisetron 3 mg iv bolus
48305016|NCT03601416|DRUG|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
48305017|NCT00086840|DRUG|temsirolimus|Given IV
47958279|NCT00809354|DRUG|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
47958280|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
48111099|NCT06513806|DRUG|Pethidin|will receive pethidine 25 mg iv bolus
48111100|NCT06313125|OTHER|3-dimensional foot-ankle extension exercises|In three-dimensional foot-ankle extension exercises, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
48305018|NCT00086840|OTHER|laboratory biomarker analysis|Correlative studies
48305019|NCT00088634|DRUG|Lurasidone|80 mg AM dosing once daily
48305020|NCT00088634|DRUG|Placebo|Matching Placebo to 40mg lurasidone tablets
48305021|NCT02065947|PROCEDURE|paravertebral block|catheter with 3-level-injection
48305022|NCT02065947|DRUG|fentanyl, propofol, atracurium|endotracheal intubation
48305023|NCT02065947|DRUG|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
48305024|NCT02065947|DEVICE|catheter with 3-level-injection|
48305025|NCT02065947|DRUG|sevoflurane and 50% oxygen in air|
48305026|NCT06184269|DRUG|BR1017-1|One tablet administered alone
48305027|NCT06184269|DRUG|BR1017-1A|One tablet administered alone
48305028|NCT06184269|DRUG|BR1017-1B|One tablet administered alone
48305029|NCT06472258|DRUG|IV Artesunate|IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.
48481775|NCT02825576|DRUG|Sugammadex|Sugammadex 2mg/kg given for reversal agent
47958281|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
47958282|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
47958283|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
47958284|NCT00809354|BIOLOGICAL|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
47958285|NCT00809354|DRUG|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
48111101|NCT06313125|OTHER|Clam exercise|In three-dimensional foot-ankle extension exercises and clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
48111102|NCT06313125|OTHER|Short-foot exercise|In clam exercise, an elastic band will be used to create resistance to the movement and the intensity/severity of the exercise will be between 13 (somewhat difficult) and 15 (difficult) according to the perceived difficulty level on the Borg scale. Exercises will begin with red (light) tape; Progression will be achieved by moving to a higher level band color \[green (medium) and blue (difficult) in that order\] every two weeks. Exercises will be performed 3 days a week (2 days supervised, 1 day at home), in 3 sets of 10 repetitions, and a 1-minute rest period will be given between sets to reduce fatigue. Short-foot exercises will be performed in 3 sets of 15 repetitions, with a 45-second rest period between sets, every day a week (2 days/week with a physiotherapist; 5 days/week at home) for 6 weeks.
48111103|NCT03182959|DRUG|Avmacol®|Avmacol® tablets
48111104|NCT05865379|DEVICE|BUFY01 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
48111105|NCT05865379|DEVICE|SVS20 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
48305030|NCT06472258|DRUG|IV Quinine Hydrochloride|IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
48305031|NCT02556645|OTHER|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
48305032|NCT02556645|OTHER|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
48481776|NCT02825576|DRUG|Neostigmine/Glycopyrrolate|Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
48641217|NCT03979794|BEHAVIORAL|Behavioral Intervention for Wellness and Engaged Living (Be-WEL)|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
48641218|NCT06451770|DRUG|VERVE-201|Intravenous (IV) infusion
48641219|NCT05158166|DRUG|DaxibotulinumtoxinA|This is a long-acting alternative to traditional Botox A treatment.
48641220|NCT04876391|DRUG|Spesolimab|Spesolimab
48305033|NCT05488561|DIAGNOSTIC_TEST|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
48305034|NCT00003753|DRUG|dexamethasone|
48305035|NCT00003753|DRUG|floxuridine|
48305036|NCT00003753|DRUG|irinotecan hydrochloride|
48481777|NCT02953678|DRUG|Ruxolitinib|
48481778|NCT02953678|DRUG|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
48481779|NCT02480426|DEVICE|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
48641221|NCT02332668|BIOLOGICAL|Pembrolizumab|IV infusion
47958286|NCT04792008|BIOLOGICAL|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
47958287|NCT04792008|BIOLOGICAL|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
47958288|NCT04763668|OTHER|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
47958289|NCT04763668|OTHER|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
47958290|NCT02465515|BIOLOGICAL|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
47958291|NCT02465515|BIOLOGICAL|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
47958292|NCT02465515|BIOLOGICAL|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
47958293|NCT00091442|DRUG|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
47958294|NCT00091442|DRUG|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
48481780|NCT02480426|DRUG|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
47958295|NCT06438302|DEVICE|EEG activity measurement|"The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 37°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition."
47958296|NCT02164214|DRUG|etanercept Treatment|
47958297|NCT06556303|OTHER|Acupressure|Acupressure
47958298|NCT04782661|DRUG|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
47958299|NCT04782661|DRUG|Placebo|Placebo solution will be administered orally.
47958300|NCT02007993|OTHER|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
47958301|NCT02007993|OTHER|Tongue Scraper|The pacient will scrap the tongue 10 times.
47958302|NCT02944032|OTHER|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
47958303|NCT02944032|OTHER|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
47958304|NCT06246929|BEHAVIORAL|MBCT+w|MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
48111106|NCT01885845|DEVICE|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
48111107|NCT01885845|OTHER|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
48111108|NCT05763290|OTHER|Affective Response to Exercise|Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
48111109|NCT03197246|DEVICE|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
48111110|NCT03197246|DEVICE|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
48111111|NCT05590650|DRUG|SZKJT(San-Zhong-Kui-Jian-Tang)|The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
48111112|NCT01230840|DIETARY_SUPPLEMENT|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
48111113|NCT01230840|DIETARY_SUPPLEMENT|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
48111114|NCT00420654|DRUG|Growth Hormone|1.25 mg, 6 months
48111115|NCT00420654|DRUG|Placebo|Equivalent to 1.25 mg, 6 months
48111116|NCT00420654|OTHER|Healthy controls|Healthy controls
48111117|NCT01808495|DRUG|Mitomycin C|
48111118|NCT03368378|PROCEDURE|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
47958305|NCT06246929|BEHAVIORAL|ALED|ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
47958306|NCT02269306|DRUG|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
47958307|NCT02911857|BIOLOGICAL|Canakinumab (AIN457)|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
47958308|NCT03875365|PROCEDURE|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
47958309|NCT04267822|DRUG|RV521 oral tablet|Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
47958310|NCT04267822|DRUG|Placebo oral tablet|Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
47958311|NCT01214343|DRUG|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
47958312|NCT01214343|DRUG|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
47958313|NCT05373277|DRUG|Placebo|one tablet of placebo twice daily for two days
47958314|NCT05373277|DRUG|Ticagrelor|Intervention Description: 90 mg tablet twice daily for two days
47958315|NCT05373277|DRUG|Rosuvastatin|10 mg tablet, single dose
47958316|NCT06192784|PROCEDURE|DEB-TACE|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
47958317|NCT06192784|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
47958318|NCT05203432|DEVICE|Red Light Intervention|Repeated Low-Level Red-Light Therapy
47958319|NCT05203432|DRUG|Atropine|0.01% atropine
47958320|NCT01453361|BIOLOGICAL|Vigil™ Vaccine|
47958321|NCT02294435|DEVICE|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
47958322|NCT02294435|DEVICE|Unitary Manifold|Unitary Manifold Endovascular stent graft system
47958323|NCT04216966|DEVICE|Control group|No intervention was given
47958324|NCT04216966|DEVICE|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
47958325|NCT04216966|DEVICE|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
47958326|NCT04216966|DEVICE|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
47958327|NCT04600141|DRUG|Tocilizumab|Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
47958328|NCT04600141|DRUG|Heparin - Therapeutic dosage|Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
47958329|NCT04600141|DRUG|Heparin - Prophylactic dosage|Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
47958330|NCT00440414|DRUG|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
47958331|NCT00440414|DRUG|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
47958332|NCT03095612|DRUG|Selinexor|Selinexor once weekly oral or twice weekly oral
47958333|NCT03095612|DRUG|Docetaxel|Docetaxel once every 3 weeks (75 mg/m2 IV)
47958334|NCT05862142|OTHER|No intervention|No intervention
47958335|NCT05446896|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
47958336|NCT05705388|DEVICE|POSE2.0 Endoscopic Gastric Remodeling|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
47958337|NCT05705388|DRUG|Liraglutide injection|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
47958338|NCT00619736|DRUG|NSA-789|
47958339|NCT00619736|OTHER|Placebo|
47958340|NCT03593096|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
47958341|NCT03593096|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
47958342|NCT00560105|DEVICE|Lung Flute|8 weeks home use, twice daily
47958343|NCT00560105|DEVICE|Acapella|8 weeks home use, twice daily
47958344|NCT02486523|BEHAVIORAL|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
47958345|NCT02486523|DEVICE|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
47958346|NCT02486523|BEHAVIORAL|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
47958347|NCT02486523|BEHAVIORAL|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
47958348|NCT02486523|PROCEDURE|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
48111119|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 1|6Gy x 2 fractions to all sites in 2 weeks
48111120|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 2|6Gy x 3 fractions to all sites in 3 weeks
48111121|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 3|6Gy x 4 fractions to all sites in 4 weeks
48111122|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 4|6Gy x 5 fractions to all sites in 5 weeks
48111123|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - De-escalation Level|6Gy x 1 fraction to all sites in 1 week
48111124|NCT04055766|DEVICE|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
48111125|NCT00391755|DRUG|ramelteon|"1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary"
48305037|NCT00003753|PROCEDURE|adjuvant therapy|
48305038|NCT00003753|PROCEDURE|conventional surgery|
48305039|NCT03900559|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes."
48305040|NCT05714306|BIOLOGICAL|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
48305041|NCT05714306|BIOLOGICAL|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
48305042|NCT05714306|BIOLOGICAL|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
48111126|NCT01688089|DRUG|ODM103|
47958349|NCT01593085|BEHAVIORAL|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~--------------------------------------------------------------------------------"
48111127|NCT01688089|DRUG|Placebo|
48305043|NCT05714306|DRUG|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
47958350|NCT01817530|OTHER|Elagolix placebo|oral coated tablet
47958351|NCT01817530|DRUG|Elagolix|oral coated tablet
47958352|NCT01817530|DRUG|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
47958353|NCT01817530|DRUG|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
47958354|NCT01817530|DRUG|E2/NETA placebo|oral hard capsule
48111128|NCT01688089|DRUG|Entacapone|
48111129|NCT01688089|DRUG|Levodopa/carbidopa|
48111130|NCT05131386|DRUG|Trabectedin|ET-743, Yondelis (vials of 1 mg). Route of administration: intravenous infusion
48111131|NCT00687622|DRUG|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
48111132|NCT02740530|DEVICE|Magstim® Rapid 2 machine|See Arms description
48305044|NCT02653378|BEHAVIORAL|DIET|25% Energy Depletion by Diet only for 3 Days
48305045|NCT02653378|BEHAVIORAL|EX|25% Energy Depletion by Exercise only for 3 Days
47958355|NCT03011710|DEVICE|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
48305046|NCT03251014|OTHER|YSS|Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks
48305047|NCT03251014|OTHER|Salmon|Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks
48305048|NCT01223976|OTHER|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.~QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
48641222|NCT06636487|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 3 - 5 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks.~Specific exercises are evidence-based; been used in several intervention studies on patients with CRD (eg. COPD). Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with CRD. Every sixth education session consists of 25 min Mindfulness exercises developed for CRD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
48305049|NCT03924674|OTHER|Education, clinical decision support tools|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
48481781|NCT06469762|OTHER|Dry Cupping|Dry cupping treatment session, using 4 regular plastic cups on the lumbar spine for 10 minutes.
48481782|NCT06469762|OTHER|Placebo Dry Cupping|Dry cupping treatment session, using 4 plastic cups with two 2 mm holes drilled in either side of them, on the lumbar spine for 10 minutes.
48481783|NCT05870488|DEVICE|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
48481784|NCT06097845|DIAGNOSTIC_TEST|Transcranial Ultrasound|Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.
48481785|NCT00017459|DRUG|cisplatin|
48305050|NCT04077203|BEHAVIORAL|Biofeedback / No biofeedback|Biofeedback / No biofeedback
48305051|NCT06090253|BEHAVIORAL|Gerotechnology enhanced multi-component exercise|Intervention courses will be divided into 3 categories: Musculoskeletal training course, Neuromuscular and fall prevention training course, and cardiometabolic training course. The courses will be enabled by wearable technology, digital platform and visual display. Each of the courses will be 8 weeks in length (1 session per week), and 60 minutes per session.
48481786|NCT00017459|DRUG|tirapazamine|
48481787|NCT00017459|DRUG|vinorelbine tartrate|
48481788|NCT02201979|PROCEDURE|Vertical breast lift with implants|
48481789|NCT05663372|DRUG|Efez 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
48481790|NCT05663372|DRUG|INSPRA® 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
48481791|NCT03716531|RADIATION|IORT|IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
48481792|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in EFT
48481793|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in ERT
48481794|NCT05012176|OTHER|Quality-of-Life Assessment|Ancillary studies
48481795|NCT05012176|OTHER|Questionnaire Administration|Ancillary studies
48481796|NCT01940302|DIETARY_SUPPLEMENT|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
48481797|NCT05736484|BEHAVIORAL|Social Support Gamification|Participants sign a pre-commitment contract agreeing to try their best to achieve their daily step goal. Over the 26-week intervention period, participants are endowed 70 points (10/day) weekly and informed they will lose 10 points each day goal is not met. Points are replenished at start of each week. At the end of each week, if the participant has 40 points or more, they will advance a level, or drop a level if they have less than 40 points. The levels include blue (lowest), bronze, silver, gold, platinum (highest). Participants select a family member or friend as a support partner to receive weekly email on participants' progress (points, game level, and average step count). Participants will also work with a virtual health coach by attending group sessions organized by them with other participants through video calls once a month to discuss ways to motivate participants to increase their physical activity.
48481798|NCT04610060|BEHAVIORAL|Power walking|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~* Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~* Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~* Week 3 70-75 % of the target heart rate (THR) \>=10,000 steps/day~* Week 4 75-80 % of the target heart rate (THR) \>12,500 steps per day"
47958356|NCT03011710|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
47958357|NCT03011710|DEVICE|Cigarette tip|Placebo device
48641223|NCT06636487|BEHAVIORAL|Home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle endurance based exercise; 3-days/weekly for 10-weeks. Exercises are evidence based; used in several intervention studies on patients with CRD (eg. COPD) and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of access to mindfulness exercises and an educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to CRD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
48641224|NCT06636487|BEHAVIORAL|Control|Receive usual care; medication, scheduled follow up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes their decision and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
48641225|NCT01829503|DRUG|decitabine and cytarabine|
48641226|NCT01829503|OTHER|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
48641227|NCT04718896|DRUG|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
48641228|NCT06177990|OTHER|Caregiver as Navigator: Develop Skills Online (CAN-DO) program|"Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~* The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~* The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~* The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively."
48641229|NCT06177990|OTHER|Healthy Living online course|"Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization."
48641230|NCT04899466|DEVICE|ActiGraft|Whole blood clot (WBC) gel
48641231|NCT06578338|OTHER|Physical height measurement|Physical height will be measured and images will be collected for AI to estimate the height
48641232|NCT06639503|DRUG|Bupivacain|5mL 0.25% bupivacain
48641233|NCT05848050|PROCEDURE|biological samples (blood test and lumbar puncture)|"On the day of excision of the cerebral metastasis, additional biological samples (blood test and lumbar puncture) will be taken in the operating room.~A biological sample of the tumor tissue (brain metastases of a solid cancer with contrast uptake of at least 1 cm accessible to surgical excision) will also be taken and preserved by freezing, in accordance with current practice and after obtaining their written agreement. .~Biological samples (liquid biopsies and tumour) from patients who have explicitly expressed their consent will be kept after the end of the research as part of a biobank in order to be able to carry out any additional analyses."
48641234|NCT05026619|OTHER|Information about age-related fertility|"The following information is provided:~Age and fertility IVF success rates and side effects"
48641235|NCT05026619|OTHER|Information about policy initiatives|"The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies"
48481799|NCT04610060|BEHAVIORAL|Standardised outpatient cardiac rehabilitation|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
48641236|NCT05026619|OTHER|Information about diabetes|"The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies"
48641237|NCT00816673|DRUG|placebo Circadin|Placebo tabs of Prolonged release melatonin
48641238|NCT00816673|DRUG|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
48481800|NCT06133218|OTHER|Mepitel Film|A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
48481801|NCT03717493|BEHAVIORAL|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking \& Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
48481802|NCT06060548|OTHER|Monitoring of patients presenting with PVCs|Patients presenting with PVCs and ventricular arrhythmias will be monitored using ILRs from the time of their initial presentation of PVCs to assess for the incidence of all cardiac arrhythmias. They will also be evaluated for clinical, biomarker and radiological evidence of myocarditis to understand association with incident arrhythmias.
48481803|NCT05119660|DEVICE|Intermittent Theta Burst Stimulation|iTBS
48481804|NCT01063959|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
48111133|NCT04052919|OTHER|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
48111134|NCT00116623|DRUG|Indomethacin|
48111135|NCT00116623|DRUG|Magnesium sulfate|
48111136|NCT05262478|DEVICE|Alpha-D CDP|Alpha-D cervical disc prosthesis was developed jointly by the Spine Center of Koç University Faculty of Medicine and Toledo University Bioengineering Department. It was designed as a single unit to ensure user-friendly administration for surgeons, and it was designed and manufactured to reproduce the movements of the normal cervical movement segment.
48111137|NCT01434134|DRUG|Metoprolol|Tablet, target dose 100 mg once daily
48111138|NCT01434134|DRUG|Placebo|Tablet, target dose 100 mg once daily
48111139|NCT01434134|DRUG|Candesartan|Tablet, target dose 32 mg once daily
48111140|NCT01434134|DRUG|Placebo|Tablet, 32 mg once daily
48111141|NCT02754479|DEVICE|Nd:YAG laser|Treatment of lower extremity spider veins
48481805|NCT01063959|PROCEDURE|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
48111142|NCT02076451|DRUG|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
48111143|NCT01611467|DRUG|CC-223|20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution
48481806|NCT00186823|DEVICE|Miltenyi Biotec CliniMACS|A stem cell selection device.
48481807|NCT00186823|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
48111144|NCT01611467|DRUG|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
48111145|NCT04277299|DEVICE|IcorySolution|The ICory-solution programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery. The healthcare professional have received face-to-face training on how to use the BuddyCare dashboard and BuddyCare has been in the hospital in earlier studies.The Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support, games and distraction to children and a virtual tour to the hospital before children´s operation.
48111146|NCT05641363|DRUG|Ketorolac Tromethamine|ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
48111147|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on breast cancer tissues|Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.
48111148|NCT06555354|DIAGNOSTIC_TEST|miRNA targeted analysis on plasma samples|miRNAs extracted from plasma samples are analysed by QPCR and/or ddPCR .
48481808|NCT00186823|DRUG|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
47916864|NCT05758636|BEHAVIORAL|Emotional Freedom Technique|"Before starting the EFT session, the participants were asked to identify the problem that aroused their anxiety. After the common point of the problems was determined, the ORDS level of all participants was determined. Next, the EFT session explained traditional acupressure meridian points on the head, face, neck, chest, and hands. Next, they were asked to repeat the phrase, Even though I have this feeling of stress and anxiety, I accept myself deeply and completely, while gently applying to the acupuncture points with their index and middle fingers. While using this expression, the participants hit each acupuncture area seven times. After the first round of hits accompanied by this phrase, participants were asked to abbreviate this feeling of anxiety, stress with another short phrase. The participants then repeated rounds of this process until they noticed that their anxiety had decreased"
47958358|NCT02179866|DRUG|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
48111149|NCT06555354|DIAGNOSTIC_TEST|miRNA profiling of breast cancer tissues|Selected samples from the retrospective cohort are profiled for miRNA expression by using GeneChip® miRNA 4.0 Array.
48111150|NCT01980641|BEHAVIORAL|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
48111151|NCT01980641|DEVICE|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
48111152|NCT00664430|DRUG|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
48481809|NCT02580084|PROCEDURE|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
48481810|NCT02580084|PROCEDURE|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
48481811|NCT04307472|BEHAVIORAL|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
48481812|NCT04307472|BEHAVIORAL|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
48481813|NCT01937819|DEVICE|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
48481814|NCT03258879|PROCEDURE|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
48481815|NCT03258879|PROCEDURE|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
48481816|NCT06616064|BEHAVIORAL|personalised feedback and brief motivational|personalised feedback and brief motivational
48481817|NCT06616064|OTHER|routine lifestyle advice|routine lifestyle advice
48481818|NCT06616064|OTHER|questionnaire CliniCAP|questionnaire CliniCAP
48481819|NCT00991510|DRUG|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
48481820|NCT00991510|DRUG|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
47958359|NCT01128842|DRUG|Neratinib|240 mg once daily by mouth.
47958360|NCT01128842|DRUG|Capecitabine|1500 mg/m\^2 twice daily by mouth.
48111153|NCT00664430|DRUG|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
48111154|NCT05394896|DEVICE|ACUMEN (Edwards Lifesciences, Irvine, USA)|ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
47958361|NCT04286399|DRUG|Renin-angiotensin-aldosterone system inhibitors|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
48641239|NCT05948943|DRUG|Alpelisib|"In Stage 1: adult participants (≥18 years of age) will receive dose 1 or dose 2 of alpelisib; pediatric participants (6-17 years of age) will receive dose 2 or dose 3 of alpelisib.~In Stage 2: Adult participants will receive alpelisib at the dose selected for confirmatory phase in adult participants; pediatric participants (6-17 years of age) will will receive alpelisib at the dose selected for confirmatory phase in pediatric participants; and pediatric participants of 2-5 years of age will receive dose 3 of alpelisib"
48641240|NCT05948943|DRUG|Placebo|In Stage 2, participants will receive matching placebo for 24 weeks of the study
48305052|NCT06090253|BEHAVIORAL|Home-based exercise|The proposed elderly home gym training services will be conducted by professional fitness instructors and tailor-made for the participants. 4 personal training sessions will be assigned (once per week, 45 to 60 minutes per session).
48305053|NCT06090253|BEHAVIORAL|Walking exercise|Two interventions will be provided: A) Walk-focused intervention, B) Disease-related walk intervention for participants with chronic diseases.
48305054|NCT06090253|BEHAVIORAL|Slow sports and exercise|Participants will receive 10 training sessions (once or twice per week, 2 hours per session) conducted by professional fitness instructors. The training programs can be selected according to the participants' preference, including water exercises, stretching/fitness/gymnastics, slow walking/jogging, sports massage, Tai Chi, Yoga, etc.
48305055|NCT06090253|BEHAVIORAL|Football|The Football Training Programme will be arranged (10 training sessions+1 game day per stage, 4 stages per season). held on artificial turf football pitch or indoor sport facilities in 5 regions
48305056|NCT04352634|OTHER|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
48305057|NCT02572830|BEHAVIORAL|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
48305058|NCT02572830|BEHAVIORAL|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
48305059|NCT04723524|COMBINATION_PRODUCT|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
48305060|NCT04723524|OTHER|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
48305061|NCT00457054|DRUG|Lithium|starting dose 600 mg increase as tolerated
48305062|NCT01123278|DRUG|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
48305063|NCT01123278|DRUG|Placebo|Placebo transdermal gel (5 gr)
48641241|NCT06522568|BEHAVIORAL|MyMammogram|An online breast cancer screening decision aid
48641242|NCT06522568|OTHER|Provider communication|Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
48641243|NCT05828901|OTHER|S1PR analysis on immune cells|S1P receptor 1 and 5 expression will be measured on immune cells
48111155|NCT05394896|DEVICE|Invasive Blood Pressure|Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
48111156|NCT05632731|PROCEDURE|double cleavage-stage or single blastocyst stage embryos transfer|Infertile women requesting in vitro fertilization treatment were randomly assigned to undergo transfer of either two cleavage-stage embryos or a single blastocyst-stage embryo.
48305064|NCT00110656|OTHER|Observations|This is a non-interventional study- only observational.
48481821|NCT06103279|DRUG|Empagliflozin 10 MG|1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol
48481822|NCT02695719|DRUG|Placebo|Lubiprostone placebo-matching capsules
48305065|NCT04838691|BEHAVIORAL|interpersonal counseling|In the intervention group, it will be administered for 40 minutes for 8 weeks to people with symptoms of premenstrual syndrome.
48305066|NCT05881551|DEVICE|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
48641244|NCT05980403|OTHER|no intervention|no intervention
48305067|NCT05881551|OTHER|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
48305068|NCT04150640|DRUG|Nal-IRI|chemotherapy drug
48305069|NCT04150640|DRUG|Oxaliplatin|chemotherapy drug
48305070|NCT04150640|DRUG|5-FU|chemotherapy drug
48305071|NCT04150640|DRUG|Trastuzumab|immunotherapy
48481823|NCT02695719|DRUG|Lubiprostone|Lubiprostone capsules
48641245|NCT02098538|DRUG|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
48481824|NCT05887219|DRUG|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
48481825|NCT05887219|DRUG|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
48305072|NCT04150640|DRUG|Pembrolizumab|immunotherapy
48305073|NCT04150640|DRUG|Nivolumab|immunotherapy
48481826|NCT05429697|DRUG|SMT-NK inj.+Pembrolizumab|"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."
48481827|NCT05429697|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
48481828|NCT04756778|PROCEDURE|Aortic surgery +/- aortic valve replacement|Replacement of aneurysmal proximal thoracic aorta +/- replacement of diseased bicuspid aortic valve
48305074|NCT00624130|DRUG|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
48305075|NCT00624130|DRUG|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
48641246|NCT06646276|BIOLOGICAL|BMS-986489 (BMS-986012+Nivolumab)|Specified dose on specified days
48641247|NCT06646276|BIOLOGICAL|Atezolizumab|Specified dose on specified days
48305076|NCT04350658|PROCEDURE|Transcatheter aortic valve implantation required for symptomatic aortic stenosis|The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.
48305078|NCT05331612|BEHAVIORAL|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
48305079|NCT06472895|DRUG|AK112 monotherapy|A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W
48305080|NCT04992832|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.
48305081|NCT04992832|OTHER|human serum albumin|Saline solution containing 1 percent human serum albumin will be infused to the control group.
48305082|NCT00102505|DRUG|Motexafin Gadolinium Injection|
48305083|NCT02761993|BIOLOGICAL|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
48305084|NCT02761993|DRUG|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
48305085|NCT04483739|DRUG|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
48305086|NCT04483739|DRUG|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
48305087|NCT03209544|BEHAVIORAL|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
48305088|NCT02226094|DEVICE|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
48305089|NCT02226094|DEVICE|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
48481829|NCT04156412|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
48481830|NCT02341521|DRUG|OC000459|Taken orally for 8 days
48481831|NCT05329818|DEVICE|high definition transcranial direct current stimulation|"Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down."
48481832|NCT01067716|DEVICE|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
48481833|NCT06218745|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
48481834|NCT02610270|DIETARY_SUPPLEMENT|2 Gums|760 mg DHA
47958362|NCT04286399|DRUG|Beta blocker|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
47958363|NCT04286399|DRUG|SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product|Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
47958364|NCT01286233|DRUG|Metformin|
47958365|NCT01286233|DRUG|Placebo|
47958366|NCT02898129|OTHER|Questionnaire|
47958367|NCT02898129|DEVICE|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
47958368|NCT03734575|DEVICE|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
47958369|NCT02010710|DEVICE|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
47958370|NCT06450821|PROCEDURE|PRIOR [Proactive Intensive Oral Review & Treatment]|Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \[Proactive Intensive Oral Review \& Treatment\] prior to chemotherapy.
47958371|NCT03740633|BEHAVIORAL|passive ankle pump motions on the day of surgery|Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
47958372|NCT03740633|BEHAVIORAL|active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery|Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
47958373|NCT03740633|COMBINATION_PRODUCT|Regular care|Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
48305090|NCT02226094|DEVICE|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
48305091|NCT02226094|DEVICE|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
48305092|NCT05578651|DEVICE|SternaLock XP|Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
47958374|NCT03685123|BEHAVIORAL|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
47958375|NCT03685123|BEHAVIORAL|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
47958376|NCT03685123|BEHAVIORAL|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
48305093|NCT01975935|DRUG|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
48305094|NCT01975935|DRUG|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
48305095|NCT00092586|DRUG|MK0653, ezetimibe|
48111157|NCT00319436|BEHAVIORAL|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
47958377|NCT03505190|DRUG|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
48111158|NCT00319436|BEHAVIORAL|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
48111159|NCT00148291|DRUG|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
48111160|NCT06048991|DIAGNOSTIC_TEST|Thermographic assessment|Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
48111161|NCT02041104|DIETARY_SUPPLEMENT|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
48111162|NCT02041104|DIETARY_SUPPLEMENT|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
48111163|NCT05684042|OTHER|Data analysis: Accuracy measurement of the classifications of the distal radius fracture in the fracture database.|An expert panel (3 in-house experienced specialists) carries out a new fracture classification based on the anonymous radiological images in the interface of the REDCap fracture database. The degree of discrepancy between the expert panel and the database in fracture classifications is analyzed. By evaluating the extracted data, it is analyzed how valid the quality of the collected fracture classifications are, which the medical staff carry out in everyday clinical practice.
48111164|NCT00625937|DRUG|cisplatin|
48111165|NCT00625937|DRUG|docetaxel|
48111166|NCT00625937|DRUG|tegafur-gimeracil-oteracil potassium|
48111167|NCT00625937|RADIATION|radiation therapy|
48111168|NCT03441763|DEVICE|Emed foot device|foot pressure will be measure by using emed foot pressure system
48111169|NCT04801836|DRUG|Estetrol monohydrate 15 mg|One Estetrol monohydrate (E4) 15 mg tablet once per day
48111170|NCT04801836|DRUG|Placebo|One placebo tablet once per day
48111171|NCT04867291|DIETARY_SUPPLEMENT|Pizza|Portion equivalent to 200 µg of iodine (half a pizza), consumed with \~450mL of water.
48111172|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Sheets|Portion equivalent to 200 µg of iodine (\~10g), consumed with two slices of white bread and \~450mL of water.
48111173|NCT04867291|DIETARY_SUPPLEMENT|Seaweed Powder|Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \~450mL of water.
48111174|NCT04867291|DIETARY_SUPPLEMENT|Potassium iodide|Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \~450mL of water.
48111175|NCT00748410|DRUG|SB-656933|7 days repeat dose
48111176|NCT03510949|DEVICE|Nasopharyngeal airway or laryngeal mask airway|Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
48111177|NCT04925739|OTHER|Self-questionnaire on the comfort and general appreciation of a nasal mask|Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use
48111178|NCT04925739|OTHER|Self-questionnaire on the appearance of CPAP side effects related to the mask|Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use
48111179|NCT04925739|OTHER|Self-questionnaire on the patient's appreciation of the mask headgear,|Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.
48111180|NCT04925739|OTHER|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction|Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.
48111181|NCT04925739|OTHER|Self-questionnaire Epworth on the daytime sleepiness|"Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment."
48111182|NCT04925739|OTHER|To study the CPAP compliance|To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
47916865|NCT05926518|PROCEDURE|blood sampling|Blood sampling for the determination of anti-Xa peak levels 4 hours after administration of nadroparin sc.
47958378|NCT03505190|DRUG|Placebo|Matching placebo will be administered subcutaneously (SC).
47958379|NCT01907581|OTHER|Quality of life questionnaires|
47958380|NCT01797731|DEVICE|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
47958381|NCT01797731|DEVICE|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
47958382|NCT00766025|DRUG|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
48641248|NCT06646276|DRUG|Carboplatin|Specified dose on specified days
47958383|NCT01010373|DRUG|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
47958384|NCT00074269|BIOLOGICAL|anti-thymocyte globulin|
48111183|NCT04925739|OTHER|To study the unintentional leakage|To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.
48111184|NCT04925739|OTHER|To study the therapeutic pressures of CPAP|To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
48111185|NCT04670159|BEHAVIORAL|Online Education|Online ergonomics, exercise and physical activity training will be provided 3 times a week for 6 weeks. The trainings it is planned to be made with a video-based online platform called Edpuzzle. With the online classroom created, the student education will be provided. A total of 18 training videos will be prepared, each video is 6-10 minutes. After the training there will be an individual motivational interview with the students in the this group with the zoom application. With motivational interview solutions by revealing the willingness, obstacles and indecision of the student to transfer the learned information to his daily life will be recommended.
48111186|NCT04670159|BEHAVIORAL|Information With Brochure|An e-brochure will be prepared for students in this group to provide information on ergonomics, physical activity and exercise. and the e-brochure will be sent to the students via e-mail after the initial evaluation.
48111187|NCT01794936|DEVICE|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
48111188|NCT06231277|DRUG|BH002|Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle
48111189|NCT04669171|BIOLOGICAL|EO2463|Multiple dose of EO2463
48111190|NCT04669171|DRUG|lenalidomide|D1-21 of 4-weekly cycles
48111191|NCT04669171|BIOLOGICAL|rituximab|Multiple doses of rituximab
48111192|NCT02008084|DRUG|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
48641249|NCT06646276|DRUG|Etoposide|Specified dose on specified days
48641250|NCT03210662|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48641251|NCT03210662|BIOLOGICAL|Pembrolizumab|Given IV
47958385|NCT00074269|BIOLOGICAL|filgrastim|
47958386|NCT00074269|BIOLOGICAL|graft-versus-tumor induction therapy|
47958387|NCT00074269|BIOLOGICAL|therapeutic allogeneic lymphocytes|
47958388|NCT00074269|DRUG|cyclosporine|
47958389|NCT00074269|DRUG|fludarabine phosphate|
47958390|NCT00074269|DRUG|melphalan|
47958391|NCT00074269|DRUG|methotrexate|
48111193|NCT02008084|DRUG|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
48111194|NCT01301469|DRUG|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
48111195|NCT01301469|DRUG|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
48111196|NCT03201562|DRUG|Aceclidine+tropicamide combination|Ophthalmic Solution
48111197|NCT03201562|DRUG|Aceclidine|Ophthalmic Solution
48111198|NCT03201562|DRUG|Vehicle|Ophthalmic Solution
48111199|NCT05483335|OTHER|No intervention but assessing for burnout syndrome in all group|Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
48111200|NCT01229358|OTHER|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
48305096|NCT00092586|DRUG|Comparator: statins|
48641252|NCT06378190|BIOLOGICAL|CAR-T cells therapy|CAR-T cells therapy
47958392|NCT00074269|PROCEDURE|peripheral blood stem cell transplantation|
47958393|NCT03076320|COMBINATION_PRODUCT|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
47958394|NCT03076320|COMBINATION_PRODUCT|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
47958395|NCT03562910|OTHER|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
47958396|NCT04749875|OTHER|blood sample|sampling of blood for research during routine care
48641253|NCT02572687|DRUG|Ramucirumab|Administered IV
48641254|NCT02572687|DRUG|MEDI4736|Administered IV
48641255|NCT06215118|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
48641256|NCT06215118|DRUG|Iberdomide|cereblon-modulating agent
48641257|NCT05818943|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
48641258|NCT00225602|BEHAVIORAL|Assertive Community Treatment|
48641259|NCT00225602|BEHAVIORAL|Treatment in Community Mental Health Center|
48641260|NCT05970497|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
48641261|NCT05970497|DRUG|Opdualag|Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
48305097|NCT02664636|PROCEDURE|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care."
48305098|NCT02664636|PROCEDURE|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care."
48305099|NCT02664636|PROCEDURE|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
48305100|NCT01913210|DIETARY_SUPPLEMENT|Ginseng|
48305101|NCT06332144|BEHAVIORAL|Structural vs. Random sequences of stimuli|Participants will see or listen to sequences of sounds and images either in a structured condition or a random condition.
48305102|NCT06332144|BEHAVIORAL|Intact vs. Degraded speech|"Participants will listen to an audiobook Alice in Wonderland in the MRI scanner. The speech is either intact or degraded."
48305103|NCT06332144|BEHAVIORAL|Repeating 5-syllable nonwords or 2-syllable nonwords|Participants will listen to nonwords (either 5-syllable or 2-syllable) and then repeat them as accurately as possible in the MRI scanner.
48305104|NCT06332144|BEHAVIORAL|Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data.|Participants will read (orthographic serial recall) or listen to (phonological serial recall) strings.
48305105|NCT06263426|OTHER|HIV D+/R+|Receipt of kidney transplant from a deceased donor with HIV.
48305106|NCT06263426|OTHER|HIV D-/R+|Receipt of kidney transplant from a deceased donor without HIV.
48305107|NCT00130208|DRUG|Sulodexide|100 mg sulodexide gelcaps
48305108|NCT00130208|DRUG|Placebo|0 mg gelcap
48305109|NCT05833893|DRUG|XPO1 inhibitor|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
48305110|NCT05926986|OTHER|Exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
48305111|NCT05926986|OTHER|control|No additional treatment will be practiced to the control group.
48305112|NCT01180140|DEVICE|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
48305113|NCT04018963|PROCEDURE|Single nostril approach endoscopic transsphenoidal pituitary surgery|Single nostril approach endoscopic transsphenoidal pituitary surgery
48305114|NCT04018963|PROCEDURE|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
48305115|NCT00415714|DEVICE|Portable Biofeedback|
48305116|NCT04520113|BEHAVIORAL|Household contact tracing|Household contact tracing to test and diagnose Tuberculosis of household contacts of Tuberculosis patients.
48305117|NCT05526170|DEVICE|Devices for long-term monitoring of objective and subjective parameters of the body|Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
48305118|NCT03506698|OTHER|Kangaroo Mother Care (KMC)|Skin to skin contact of newborns with mothers or caregiver for a minimum of at least eight hours over a 24-hours period, along with exclusive breastfeeding or breast milk feeding via tube or spoon
48641262|NCT05436444|BIOLOGICAL|A/Mallard/Ohio-99/MM4/1989 H10N7|The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.
47958397|NCT03886480|DEVICE|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
48111201|NCT05790096|BIOLOGICAL|Granulokine|Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
48111202|NCT05790096|BIOLOGICAL|Filgrastine|Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
48111203|NCT00427752|PROCEDURE|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
48111204|NCT05304546|DRUG|Pembrolizumab|Solution for IV
48111205|NCT05304546|DRUG|Encorafenib|Oral QD
48305119|NCT02887534|DRUG|SPARC1401-low dose|SPARC1401- low dose
48305120|NCT02887534|DRUG|SPARC1401-mid dose|SPARC1401- mid dose
48305121|NCT02887534|DRUG|SPARC1401-high dose|SPARC1401-high dose
48111206|NCT05304546|DRUG|Binimetinib|Oral BID
48111207|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir|"Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
48111208|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
48111209|NCT04962906|DRUG|Gam-COVID-Vac / Gam-COVID-Vac|A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.
48111210|NCT01321606|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10\^10 organisms
48111211|NCT01321606|DIETARY_SUPPLEMENT|sugar pill (placebo)|Placebo identical to the active product will be given
48111212|NCT00703625|DRUG|Temsirolimus|
48111213|NCT00703625|DRUG|Docetaxel|
48111214|NCT03400124|PROCEDURE|ISBCS|The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
48111215|NCT03400124|PROCEDURE|DSBCS|The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
48111216|NCT00761436|BIOLOGICAL|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
48305122|NCT02887534|DRUG|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
48305123|NCT02887534|DRUG|Placebo1401|Placebo
47958398|NCT04704544|OTHER|Tele-rheumatology|Participants will receive virtual visits via video conferencing and/or phone.
48305124|NCT02817555|DRUG|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin \> 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
48481835|NCT02610270|DIETARY_SUPPLEMENT|3 Gums|1140 mg DHA
48481836|NCT05717270|PROCEDURE|Two-layered suture repair|The ruptured Achilles tendon will be sutured in two-layer.
47958399|NCT05929157|DRUG|artesunate-pyronaridine|Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.
47958400|NCT05822661|DIETARY_SUPPLEMENT|Black Seed Oil|Dietary supplement
48111217|NCT00270803|DRUG|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
48111218|NCT04825184|BEHAVIORAL|Body image chatbot|See arm/group description.
48111219|NCT03429062|OTHER|Personal training exercises|Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
48111220|NCT03906968|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
48111221|NCT05949749|DIAGNOSTIC_TEST|Epitope exploration|Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
48111222|NCT04497727|OTHER|Gene Expression|Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
48111223|NCT04108754|OTHER|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
48641263|NCT06292325|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard therapy for Obstructive Sleep Apnea. It consists of a machine that delivers a constant and steady air pressure through a mask worn over the nose or both nose and mouth during sleep. This continuous flow of air helps to keep the airway open, preventing episodes of airway collapse and obstruction characteristic of OSA. CPAP therapy is highly effective in reducing symptoms such as snoring, daytime sleepiness, and fatigue, as well as improving overall sleep quality and decreasing the risk of complications associated with untreated OSA, such as cardiovascular issues. It is considered the gold standard treatment for moderate to severe OSA and is often prescribed after a sleep study confirms the diagnosis. CPAP machines come in various designs and features to suit individual needs and preferences, and proper adjustment and compliance are essential for optimal treatment outcomes.
48641264|NCT06548971|DRUG|Aspirin|Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.
48641265|NCT06548971|DRUG|Placebo|Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
48641266|NCT06548971|OTHER|Best medical management|Patients in both groups will receive the best medical management according to the guidelines.
48641267|NCT06633666|DEVICE|Acupuncture|"1. Fatigue Principal points: Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Baihui (GV 20), Guanyuan (RN 4), Zusanli (ST 36), Sanyinjiao (SP 6)~2. Anxiety/ depression Principal points: Yintang (EX-HN3), Baihui (GV 20), Taichong (LR 3), Neiguan (PC 6), Danzhong (RN 7)~3. Cognitive impairment/ memory loss Principal points: Baihui (GV 20), Sishencong (EX-HN1), Fengfu (GV 16), Taixi (K 13), Xuanzhong (GB 39), Zusanli (ST 36)~4. Insomnia Principal points: Zhaohai (K 16), Shenmai (BL 62), Shenmen (HT 7), Sanyinjiao (SP 6), Anmian (EX-HN22), Sishencong (EX-HN1)"
47958401|NCT05822661|DIETARY_SUPPLEMENT|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
48481837|NCT05445531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Functional and morphologic imaging of the lungs
47958402|NCT00158574|DRUG|sulphadoxine-pyrimethamine|
47958403|NCT00158574|DRUG|mefloquine|
47958404|NCT00158574|DRUG|Chlorproguanil-dapsone|
47958405|NCT00158574|DRUG|Placebo|Placebo
48481838|NCT05445531|DIAGNOSTIC_TEST|Nailfold capillaroscopy|Imaging of nailfold microvasculature
47958406|NCT00158574|DRUG|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
47958407|NCT00158574|DRUG|IPTi mefloquine|IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
47958408|NCT00158574|DRUG|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
47958409|NCT00855673|DEVICE|Intermittent Mechanical Compression|FM220 device
47958410|NCT00855673|DRUG|Control|Standard medical treatment
47958411|NCT00443092|OTHER|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
48481839|NCT05445531|DIAGNOSTIC_TEST|Spiroergometry|Cardiopulmonary exercise testing
48481840|NCT05445531|DIAGNOSTIC_TEST|Realtime deformability cytometry|High-throughput measurement of cell deformability and physical properties
48481841|NCT03176355|PROCEDURE|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
48481842|NCT04281732|DEVICE|Virtual Reality Headset based tests|Visual task tests based on Oculus Rift
48481843|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|"Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
48481844|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy|"Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
48481845|NCT05190523|DRUG|ASC42 5 mg|5 mg of ASC42 tablets orally once daily for 12 weeks.
48481846|NCT05190523|DRUG|ASC42 10 mg|2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.
48481847|NCT05190523|DRUG|ASC42 15 mg|15 mg of ASC42 tablets orally once daily for 12 weeks.
48481848|NCT05190523|DRUG|Placebo|Placebo tablets orally once daily for 12 weeks.
48481849|NCT05533099|OTHER|Observational study|Observational study of a device implanted in a previous clinical study
48481850|NCT06253338|RADIATION|genomic alterations|Alteration of the genome under radiotherapy
48481851|NCT05384886|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
48481852|NCT02230618|DRUG|insulin degludec/insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
48641268|NCT04941898|BIOLOGICAL|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
48641269|NCT06634849|DRUG|PTT-4256|Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohort 1-3 will receive 10mg, 20mg \& 40mg.
48641270|NCT05803551|DRUG|Ketamine Hydrochloride|Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight
48641271|NCT05803551|DRUG|Placebo|Intravenous 0.9% saline infusions for three consecutive days.
48641272|NCT05284513|BEHAVIORAL|FH diagnosis program|Uptake of screening, diagnosis, and initiation of care management for FH
48641273|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop and implement tools for quality monitoring|EHR tools to order labs, record results, and document FH care
48641274|NCT05284513|BEHAVIORAL|Implementation strategy package: Develop educational materials|Education regarding guidelines for identification and treatment of FH
48641275|NCT05284513|BEHAVIORAL|Implementation strategy package: Conduct educational outreach visits|Continuing medical education (CME) material for FH that is presented to
48641276|NCT05284513|BEHAVIORAL|Implementation strategy package: Intervene with clinicians and patients to enhance|Notify patients simultaneously with clinicians about the need for screening
48641277|NCT05284513|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions|Clinical lipid champions
48641278|NCT05284513|BEHAVIORAL|Implementation strategy package: Audit and provide feedback|Provide aggregate level feedback to clinics on diagnosing FH
47958412|NCT00443092|OTHER|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
47958413|NCT02933606|DRUG|BNC210|
47958414|NCT02933606|DRUG|Placebo|
47958415|NCT01853423|DRUG|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
47958416|NCT02061774|DRUG|Acetaminophen|1 gram of intravenous Acetaminophen
47958417|NCT02061774|DRUG|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
47958418|NCT05737589|RADIATION|Whole-brain radiotherapy|Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
47958419|NCT01168141|DRUG|ZD4054|10mg ZD4054 daily in tablet form
48641279|NCT05284513|BEHAVIORAL|Implementation strategy package: Stage implementation scale up|Develop the timeline for the stepped-wedge rollout to primary care
47958420|NCT02432482|BEHAVIORAL|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
47958421|NCT02432482|BEHAVIORAL|Standard care|Brief advice to quit (\<5 minutes) Self-help brochure Offer of nicotine patches
47958422|NCT05345977|DEVICE|eMotiph|Mobile application for patients with schizophrenia.
47958423|NCT00532558|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
47958424|NCT00532558|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
47958425|NCT02391701|BEHAVIORAL|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
48641280|NCT05990738|DRUG|BI 764532|BI 764532
48641281|NCT05990738|DRUG|Topotecan|Topotecan
48641282|NCT05990738|DRUG|Single agent chemotherapy|single agent chemotherapy
48641283|NCT06483828|BEHAVIORAL|Dental Anxiety Coping Module|Dental tour where participants will be introduced to the dental clinic setting while Expressive Art Therapy, participants will engage with activity of making collage and finger painting.
47958426|NCT03461978|DEVICE|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
47958427|NCT02221687|DIETARY_SUPPLEMENT|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
48641284|NCT06644768|DRUG|valemetostat tosylate|Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
47958428|NCT02221687|DIETARY_SUPPLEMENT|Control formula|Standard milk formula without pre and probiotic
47958429|NCT03711318|DRUG|Buprenorphine/naloxone|3 week treatment with buprenorphine/naloxone
47958430|NCT03464071|DEVICE|Hyperinflation with mechanical ventilator|increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
48111224|NCT01740063|DRUG|DAS181-F02 formulation|
48111225|NCT01740063|DRUG|DAS181-F04 formulation|
48641285|NCT06644768|DRUG|pembrolizumab|One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
48641286|NCT06085625|BEHAVIORAL|Pre-Surgery Survey|Participants will be asked to complete a survey 3 times (before surgery, after surgery, and 2 weeks after surgery). You will be monitored for up to 1 month after your surgery, where you may be contacted by a study provider virtually or in person to ask you about medication usage and heath care needs.
48641287|NCT06085625|BEHAVIORAL|Post-Surgery Surveys|"After surgery, Participants will complete the same survey as in the pre-surgery visit about 1 day and then 2 weeks after surgery. These surveys will be completed electronically through the MyChart system. They will take about 5-10 minutes to complete and must be done within 24 hours after receiving the survey.~Participants will be monitored for 1 month after your surgery, including your standard-of-care postoperative visit at about 2 weeks. You may be contacted by a provider for a phone or in person visit at the 1-month time point to ask how you are doing."
47958431|NCT03464071|DEVICE|Manual hyperinflation|the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
47958432|NCT04312750|DRUG|Lidocaine topical system 1.8%|
48481853|NCT03233451|BEHAVIORAL|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
48111226|NCT01740063|DRUG|Placebo|
48481854|NCT04750382|DRUG|HX008+Cisplatin+Gemcitabine|Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
48641288|NCT06313957|BIOLOGICAL|LUCAR-20SP cells|Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
48641289|NCT05614336|BIOLOGICAL|Blood sample|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
48641290|NCT03241550|DRUG|isavuconazonium sulfate - intravenous|IV infusion
48641291|NCT03241550|DRUG|isavuconazonium sulfate - oral|Oral
48481855|NCT03092882|BEHAVIORAL|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
48641292|NCT05026632|DRUG|NPI-002 Intravitreal Implant|Implant inserted during vitrectomy.
48481856|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
47958433|NCT05921201|BEHAVIORAL|Relax, Reflect, and Empower mobile application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
47958434|NCT04204343|DRUG|Bupivacaine 0.7 ml/kg|Bupivacaine 0.25% 0.7 ml/kg
47958435|NCT04204343|DRUG|Bupivacaine 0.5 ml/kg|Bupivacaine 0.25% 0.5 ml/kg
47958436|NCT06086171|DRUG|Methadone Hydrochloride|Methadone hydrochloride (0.10 mg/kg) administered intravenously at the induction of anaesthesia
47958437|NCT06086171|OTHER|Placebo|Saline solution
47958438|NCT02040948|DEVICE|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
48111227|NCT05674370|DEVICE|GRIP Electronic Diagnostic Chip|Graphene-based point-of-care device for detection of respiratory viruses (e.g., COVID-19 and influenza) from a nasal swab
48111228|NCT05674370|DIAGNOSTIC_TEST|Laboratory-based nucleic acid amplification tests (NAATs)|Polymerase Chain Reaction (PCR) analysis for detection of viruses (e.g., Roche cobas SARS-CoV-2 or influenza A/B) from nasal swab
48111229|NCT03837028|OTHER|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
48481857|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
48641293|NCT06623409|BIOLOGICAL|GARDASIL®9 (G9)|Suspension administered via intramuscular (IM) injection
48641294|NCT06623409|BIOLOGICAL|V540B|Experimental vaccine and adjuvant administered via IM injection
48641295|NCT05572216|PROCEDURE|Robot assisted partial nephrectomy with 3D image guidance|patient have a partial nephrectomy for renal complex tumor
47958439|NCT04234022|DRUG|Zn-DDC|Zn-DDC added to myeloma samples for culturing
48641296|NCT04889950|DEVICE|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
48641297|NCT04889950|DEVICE|LipiFlow|LipiFlow
48641298|NCT06688851|DIAGNOSTIC_TEST|Preoperative Cone Beam Computed Tomography (CBCT) scan|A CBCT scan is performed before the surgical intervention.
48641299|NCT06688851|PROCEDURE|Cystostomy|Under local anesthesia, a full-thickness flap is prepared and cystostomy is performed.
48641300|NCT06688851|DIAGNOSTIC_TEST|Histology to confirm the initial diagnosis|A sample of the cyst lining is sent for histologic diagnosis.
48641301|NCT06688851|DEVICE|Patient Specific Implant|The PSI is fixed on the surface of the bone using osteosynthesis screws.
48641302|NCT06688851|PROCEDURE|Cyst decompression|The PSI enables the discharge of the cystic liquid into the oral cavity. The resulting decrease in cystic pressure induces bone healing. Patients are recalled monthly for controls and panoramic X-rays are performed to monitor the decompression.
47958440|NCT04234022|DRUG|Lanalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
47958441|NCT04234022|DRUG|Pomalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
47958442|NCT06463834|DRUG|Sintilimab|"Sintilimab: 200mg, iv, D1, Q3W;~DCF chemotherapy:~docetaxel 70mg/m2，iv，d1，Q3W； cisplatin 75mg/m2，iv，d1，Q3W； 5-fluorouracil 750-800mg/m2，iv，d1-d5，Q3W"
47958443|NCT01932307|PROCEDURE|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
47958444|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
47958445|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
47958446|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
47958447|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
48111230|NCT00558363|DRUG|Avodart|0.5 mg administered orally once daily
48111231|NCT00558363|OTHER|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
48111232|NCT06375291|OTHER|splint /steroid injection/both|pregnant women treated in pain department by splint /steroid injection/both
48305125|NCT02817555|DRUG|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin \>150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
48111233|NCT00688948|DRUG|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
48111234|NCT05967338|DEVICE|using McGrath Video Laryngoscope|glottis visualization in indirect and direct lifting methods by using McGrath Video Laryngoscope
48111235|NCT00002527|DRUG|aspirin|
48111236|NCT00002527|OTHER|placebo|
48305126|NCT01278680|BEHAVIORAL|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
48305127|NCT04424433|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
48305128|NCT02654327|DEVICE|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
48305129|NCT00544128|DRUG|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
48305130|NCT00544128|DRUG|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
48305131|NCT00200278|BEHAVIORAL|PROJECT STRIDE|
48305132|NCT02519075|OTHER|No intervention|Observational study
48305133|NCT02399813|DRUG|Axalimogene filolisbac|
47958448|NCT00491764|DRUG|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
47958449|NCT00491764|DRUG|Placebo|Placebo for 24 weeks.
47958450|NCT04614558|DRUG|Isatuximab|"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."
47958451|NCT05306977|DEVICE|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by \~50 min rest intervals.
48111237|NCT03580798|PROCEDURE|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
48111238|NCT03580798|PROCEDURE|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
48111239|NCT06486987|OTHER|Constraint induced movement therapy delivered by televideo|In-home Constraint induced movement therapy delivered by a therapist participating by televideo
48111240|NCT02639013|PROCEDURE|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
48111241|NCT05159297|OTHER|Reference values|Normative reference values of coordination tests will be obtained
48111242|NCT01787240|DRUG|Escitalopram 10mg|
48111243|NCT01787240|DRUG|Placebo|
48111244|NCT01182116|PROCEDURE|J Pouch|Comparing J pouch, side to end coloanal surgery
48111245|NCT00864786|DRUG|PF03635659|Inhaled doses of 200 mcgQD
48111246|NCT00864786|DRUG|PF03635659|Inhaled doses of 600 mcg QD
48111247|NCT00864786|DRUG|PF03635659|Inhaled doses of 1000 mcg QD
48111248|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
48111249|NCT00864786|DRUG|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
47958452|NCT03676283|OTHER|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
47958453|NCT06341075|DEVICE|Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
47958454|NCT00799422|DEVICE|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
47958455|NCT00799422|DEVICE|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
47958456|NCT00799422|DEVICE|Clear Care|Commercially marketed contact lens solution for contact lens care
48305134|NCT04712578|DIETARY_SUPPLEMENT|Caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
48305135|NCT04712578|DIETARY_SUPPLEMENT|Non-caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
48305136|NCT04712578|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of consuming a standardized meal followed by a placebo beverage.
48305137|NCT02949765|DRUG|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
48305138|NCT02949765|DIETARY_SUPPLEMENT|Iron-rich diet|
48305139|NCT04906239|PROCEDURE|Erector Spinae Plane Block|A high-frequency ultrasound linear probe, covered with a sterile sheath, will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After showing the T 4-5 transverse process and the erector spinae muscle on top of it, a 22-gauge, 80 mm insulated quincke type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal, using the in-plane technique. When the transverse process is touched, the needle will be pulled out and after a negative aspiration test with 0.5 mL of normal saline and after the demonstration of a hypo-echogenic image and hydro dissection, a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.
48305140|NCT03166436|PROCEDURE|Radiofrequency ablation|radiofrequency ablation
48305141|NCT03166436|PROCEDURE|Biliary stenting|biliary stenting
48481858|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
48641303|NCT06688851|DIAGNOSTIC_TEST|CBCT|Post-operative CBCT is performed six months after cystostomy to assess whether the cyst volume has been sufficiently reduced for enucleation, minimizing the risk of damage to anatomical landmarks.
47958457|NCT00799422|DEVICE|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
47958458|NCT01446107|OTHER|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
47958459|NCT01446107|OTHER|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
47958460|NCT01446107|OTHER|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
47958461|NCT01446107|OTHER|placebo control|application of water onto tooth surface every year
47958462|NCT04479930|OTHER|Pulmonary Care Web-Based App (HappyAir App)|The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
48305142|NCT06024577|BEHAVIORAL|Walking|Prescribed 150 minutes per week of moderate to vigorous walking.
48305143|NCT06024577|BEHAVIORAL|Variety|Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
48305144|NCT06024577|BEHAVIORAL|Progressive|Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
48305145|NCT00257192|DRUG|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
48641304|NCT06688851|PROCEDURE|Enucleation|Under local anesthesia a full-thickness flap is raised and the PSI is removed by unscrewing the osteosynthesis screws. The wall of the cyst is completely enucleated and the flap is sutured.
48641305|NCT06688851|DIAGNOSTIC_TEST|Histology performed on the entire lining of the cyst|The residual cyst wall is sent for histopathologic examination.
47958463|NCT05956691|DIETARY_SUPPLEMENT|AllerPops|Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
47958464|NCT06556992|BEHAVIORAL|FIT Teens|This intervention will consist of 16 in-person and remote group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
47958465|NCT02055833|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
47958466|NCT02055833|OTHER|Nutritional counseling|Nutritional counseling
47958467|NCT05562414|BEHAVIORAL|HIIT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes."
47958468|NCT05562414|BEHAVIORAL|MCT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes."
48305146|NCT00257192|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
48305147|NCT01842620|DRUG|Metformin|Oral antidiabetic agent
48305148|NCT01676480|BEHAVIORAL|Endurance training|12 weeks of endurance training 3 times per week
48305149|NCT02882399|OTHER|Shortystrap|
48481859|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
48481860|NCT03378414|PROCEDURE|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)
48481861|NCT03378414|PROCEDURE|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)
48481862|NCT03378414|BIOLOGICAL|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
48481863|NCT02815202|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-034)
48481864|NCT04837027|BEHAVIORAL|Aerobic training|Aerobic training on stationary bike 5x a week for 30 minutes a day
48481865|NCT04837027|BEHAVIORAL|Balance training|Training 5x a week for 30 minutes. Standard of care
48481866|NCT02459418|DRUG|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
48481867|NCT02459418|DRUG|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
48481868|NCT06218121|DIAGNOSTIC_TEST|Instrumental and Functional Tests that Assess Functional Capacity|The correlation between all functional, ultrasound, nutritional, and psychological variables will be analyzed. Through GLIM diagnosis, anthropometric data (weight, height, BMI) as well as analytical data including inflammation information (CRP and albumin) will be used to reach a diagnosis that allows comparison/correlation with the rest of the variable parameters.
48481869|NCT04071054|DIAGNOSTIC_TEST|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
48481870|NCT01058551|DEVICE|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
48481871|NCT05657106|BEHAVIORAL|Harm reduction kiosk|The intervention involves enhancing an existing staffed harm reduction program (syringe service program) located in a local health department with a Kentucky Outreach Service Kiosk (KyOSK).
48481872|NCT00962884|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
48481873|NCT00962884|DEVICE|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
48481874|NCT01561794|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2) Hospital-acquired pneumonia (HAP): For the patient with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
48481875|NCT00004294|GENETIC|human glucocerebrosidase gene into autologous peripheral blood stem cells|
48481876|NCT03282006|DRUG|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
48481877|NCT00108576|DRUG|Divalproex|anticonvulsant; mood stabilizer
48481878|NCT00108576|OTHER|placebo|Look-a-like placebo
47958469|NCT06217341|OTHER|In the study, bispectral index monitoring and follow-up will be applied to both groups.|Perioperative Bispectral Index Monitoring (BIS) monitor and Bispectral Index suppression Rate (BIS-SR) monitoring will be applied. The duration and magnitude of BIS-SR values will be examined together with BIS values in terms of recovery agitation.
47958470|NCT04456257|DEVICE|fractional picosecond 1,064 nm laser|The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
47958471|NCT03359772|OTHER|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
47958472|NCT00154622|BEHAVIORAL|work hardening program|
47958473|NCT05938842|BEHAVIORAL|Online DBT-Mindfulness Intervention|"The whole intervention exists of 10 sessions, one session a week for at least one hour and a half. The session 1 is tailored to address specific issues to people with MS, whereas the sessions 2 to 7 are based on DBT and mindfulness contents, and in sessions 7 to 10 introduced some contents of ACT. The program is based in teaching two different sets what and how (Linehan, 1993). The first skill what, teaches patients to simply observe; in a second level, to describe, which implies the ability to put the name to what one has observed; and in the third, what skill patients learn to fully participate in their actions in the current moment and without self-consciousness (Soler et al., 2012). In the other hand, the skills of how are related to how observe, how to describe and how to participate. Moreover, some mindfulness skills such as Observing the breath, Half-smiling, Awareness are practice introduced as homework tasks."
47958474|NCT05938842|BEHAVIORAL|Online psychoeducational intervention|The active control group intervention will be based on a psycho-educational framework and will involve MS-related topics (Oz \& Oz, 2020). The psychoeducational intervention will be conducted by a psychologist with experience in working with pwMS through group videoconference and will follow similar format as the DBT-Mindfulness intervention, except for the homework tasks. The participants will receive information about different aspects related to the disease (e.g., disease progression, disease-symptoms, stress management, nutrition, sleep hygiene, physical activity, social relationships). The content of the sessions of the psychoeducation program was created based on the current literature about MS. Similar psychoeducational programs were used in other studies before (Oz \& Oz, 2020; Dowd et al., 2015).
48111250|NCT03629730|BEHAVIORAL|Coordination training|The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
48111251|NCT00305591|DRUG|l-ornithine l-aspartate|
48111252|NCT04567888|BEHAVIORAL|Happify Teens|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
48111253|NCT03848234|DRUG|Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
48111254|NCT03848234|DEVICE|Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
48481879|NCT00958802|OTHER|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
48111255|NCT04783610|OTHER|Ethanol|Ethanol will be administered via oral route.
48111256|NCT00727038|DRUG|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
48111257|NCT06467279|DEVICE|Target Controlled İnfusion|TCI (Target-Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
48111258|NCT06467279|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
48111259|NCT03034681|OTHER|Physiotherapy technique: TENS|
48481880|NCT00958802|OTHER|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
48481881|NCT00682617|BEHAVIORAL|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
48111260|NCT03034681|OTHER|Physiotherapy technique: Vojta Therapy|
48111261|NCT00158054|BEHAVIORAL|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
48111262|NCT00158054|BEHAVIORAL|Referred depression care|Physician notified of depression symptoms, usual care followed.
48111263|NCT00126308|DEVICE|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
48111264|NCT00126308|DEVICE|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
48111265|NCT04747756|OTHER|Virtual Village|The purpose of this study is to create a virtual village for people aging with HIV, and to pilot test the virtual village intervention as a final step.
48111266|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
48111267|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
47958475|NCT00679666|DRUG|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
47958476|NCT00679666|DRUG|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
47958477|NCT02399553|OTHER|Soccer boot intervention|
47958478|NCT01033760|DRUG|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
47958479|NCT01033760|DRUG|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
47958480|NCT00132652|DRUG|Lamivudine|
47958481|NCT00132652|DRUG|Telbivudine|
47958482|NCT05158465|BEHAVIORAL|Motivational Interviewing|Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
48481882|NCT00682617|BEHAVIORAL|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
48481883|NCT06483087|BEHAVIORAL|Animated Education Program|Eight minutes animated vedio; presented individually to children in their rooms. The vedio explains specific aspectsof the cardiac cathetrization procedure.
48481884|NCT03532230|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
48481885|NCT02278458|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
48641306|NCT06691919|DEVICE|Direct Endoscopic Necrosectomy with Powered Endoscopic Debridement|Patients will first undergo endoscopic ultrasound-guided cystgastrostomy using an electrocautery-enhanced lumen apposing metallic stent to gain access to the necrosum. Direct Endoscopic Necrosectomy will be performed using the EndoRotor® NecroMax 6.0 PED Catheter which has an outer diameter of 5.1 mm and is compatible with endoscopes that have a working channel of ≥6.0 mm.
48641307|NCT06691919|PROCEDURE|Transgastric Surgical Necrosectomy|Patients randomized to the surgical arm will undergo open or minimally invasive (laparoscopic) transgastric SN with the aim of creating an ample size cystgastrostomy to perform a complete debridement. In either approach, the peritoneal cavity is entered to identify the stomach through which an anterior gastrotomy is made. The retrogastric necrosum is identified either using a finder needle or ultrasound and accessed through a posterior cystgastrostomy. Transgastric SN is then manually performed, and any cyst fluid fully evacuated. The anterior gastrotomy is then closed allowing any residual necrosis or pancreatic enzyme to efflux into the stomach and enter the upper GI tract. As with endoscopy, patients with retrogastric collections are observed for a sufficient period to ensure full maturation of the necrosum.
47958483|NCT02327689|DRUG|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
47958484|NCT06097169|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
47958485|NCT06097169|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
47958486|NCT04149379|DRUG|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
47958487|NCT05717179|DIAGNOSTIC_TEST|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
47958488|NCT04046055|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
47958489|NCT04046055|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
47958490|NCT04046055|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
47958491|NCT02821169|DRUG|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
48481886|NCT02278458|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
47958492|NCT02821169|DRUG|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
47958493|NCT04147702|OTHER|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
47958494|NCT01194466|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
47958495|NCT03605407|OTHER|Patient visit prior to hospital admission|Patient and family receiving one visit prior to hospital admission for surgery
47958496|NCT06151132|PROCEDURE|Direct current cardioversion|Direct current cardioversion to maintain sinus rhythm during rhythm control strategy
47958497|NCT03144921|BEHAVIORAL|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
47958498|NCT00389597|DEVICE|Cervical Artificial Disc|Cervical artificial disc mechanical device
47958499|NCT03801460|OTHER|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
47958500|NCT03820141|DRUG|Durvalumab|programmed cell death-ligand 1 inhibitor
47958501|NCT03820141|DRUG|Trastuzumab|anti-HER2 monoclonal antibody
47958502|NCT03820141|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
47958503|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct external drainage|"Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve."
47958504|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct internal drainage|"Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures."
48111268|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (COVID active device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
48111269|NCT03356444|DRUG|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
48481887|NCT03013881|BIOLOGICAL|UB-921|150 mg/vial
47958505|NCT02283619|OTHER|None - no intervention, observational study|No intervention, observational study
48111270|NCT03356444|DRUG|Docetaxel|"Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
48111271|NCT02105064|DEVICE|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
48111272|NCT02105064|DEVICE|SHAM rTMS|Sham rTMS, without brain stimulation
48481888|NCT03013881|BIOLOGICAL|Herceptin|440 mg/vial
48481889|NCT00453817|DRUG|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
48481890|NCT00453817|PROCEDURE|Islet transplantation|intraportal percutaneous islet transplantation
47958506|NCT03089320|BEHAVIORAL|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
47958507|NCT03089320|BEHAVIORAL|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
48111273|NCT00585533|DRUG|Erlotinib (Tarceva)|Erlotinib
48111274|NCT02847312|OTHER|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
48111275|NCT02847312|OTHER|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
48481891|NCT00453817|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
48481892|NCT02172352|DRUG|Ba 679 BR low dose|
48481893|NCT02172352|DRUG|Ba 679 BR middle dose|
48481894|NCT02172352|DRUG|Ba 679 BR high dose|
48481895|NCT02172352|DRUG|Placebo inhalation powder|
48481896|NCT04744324|BEHAVIORAL|Self-supporting Care|Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)
47958508|NCT03089320|BEHAVIORAL|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth \> 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
47958509|NCT02074930|DEVICE|Microporation by P.L.E.A.S.E. Professional / Prick needle|
47958510|NCT00191269|DRUG|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
47958511|NCT00191269|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
47958512|NCT01431170|DRUG|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
47958513|NCT01431170|DRUG|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
47958514|NCT00001067|DRUG|Lamivudine|
48111276|NCT02847312|OTHER|Control|Control are matched with energy and insoluable fibre.
48111277|NCT03456336|OTHER|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
48111278|NCT03456336|OTHER|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
48111279|NCT00765934|DRUG|Rapydan|lidocaine / tetracaine 70/70 mg patch
48111280|NCT01964937|BIOLOGICAL|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
48111281|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10\^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10\^8 PFU.
48111282|NCT01964937|BIOLOGICAL|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10\^6 PFU IM, for a planned maximum dose of 1.1×10\^7 PFU.
48481897|NCT04744324|BEHAVIORAL|Home health education|Individualized home health education
48481898|NCT04673708|DIAGNOSTIC_TEST|H - Test|Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
48111283|NCT01964937|BIOLOGICAL|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
48111284|NCT01964937|BIOLOGICAL|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
48111285|NCT04102371|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
48481899|NCT06021678|DRUG|EX103 injection|Administered as specified in the treatment arm.
48481900|NCT00273234|PROCEDURE|Autologous Platelet Gel (APG)|
48481901|NCT01154959|DRUG|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
48481902|NCT06400108|OTHER|Dementia Moves|"Dementia Moves: Dementia Moves is a multicomponent exercise program that can be individually tailored to the abilities of LTC residents with more advanced dementia and focuses on moderate- to high-intensity strength and balance activities with an aim to improve ADLs. Individualized strategies are implemented throughout the intervention to support and promote participation of individuals with more advanced dementia.~Each exercise will be individually prescribed for each participant by the physiotherapists (PT) at the beginning of the program. The intensity of the exercise will be adjusted throughout the program by the PT to ensure the target intensity of moderate to high intensity balance and strength exercises. The intervention will be provided face to face in groups of 4 residents with the PT, PTA, and three volunteers. Though the intervention is delivered in a group setting, the specific exercises that the participants complete are individualized based on their abilities."
48481903|NCT00594113|OTHER|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
48481904|NCT00594113|OTHER|Touch screen intervention|Touch screen intervention
48481905|NCT00078507|BEHAVIORAL|Sensory Re-training|
48481906|NCT00078507|BEHAVIORAL|Sensory Retraining|Facial Exercises
48481907|NCT00078507|BEHAVIORAL|Opening Exercises|
47958515|NCT00001067|DRUG|Stavudine|
47958516|NCT00001067|DRUG|Zidovudine|
47958517|NCT00931879|DRUG|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.
47958518|NCT00931879|DRUG|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
47958519|NCT01435603|BEHAVIORAL|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
48641308|NCT04210089|DEVICE|Total Contact Soft Cast|"The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~* Unna boot from MPJs to just below the knee,~* Sterile Kerlix from MPJs to just below the knee~* Sterile 4 inch Kling wrap from the MPJs to just below the knee,~* Four inch coban from MPJs to just below the knee, and~* Ace wraps from MPJs to just below the knee"
47958520|NCT01435603|BEHAVIORAL|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
47958521|NCT04085393|DRUG|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
48641309|NCT04210089|DEVICE|Cam Boot|Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
48641310|NCT05618626|OTHER|Physical exercise and dietary intervention for NAFLD|Investigators will assess the efficiency of the intervention by measuring adherence to physical exercise and nutritional diet.
47958522|NCT03734042|BIOLOGICAL|Platelet rich plasma intrauterine infusion|platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
47958523|NCT03734042|BIOLOGICAL|Normal saline|Intrauterine infusion of normal saline at day 11
47958524|NCT01232595|DRUG|LFF571|
47958525|NCT01232595|DRUG|Vancomycin (POC)|
47958526|NCT04321070|DRUG|Clindamycin Phosphate|A thin film of investigation product will be applied to the affected areas of the face once daily
47958527|NCT04321070|DRUG|Clindamycin Phosphate RLD|A thin film of investigation product will be applied to the affected areas of the face once daily
48111286|NCT04102371|DRUG|Normal Saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
48111287|NCT04102371|DRUG|Plasma-lyte|PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
48111288|NCT03709758|DRUG|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
47958528|NCT04321070|DRUG|Placebos|A thin film of investigation product will be applied to the affected areas of the face once daily
48111289|NCT03709758|DRUG|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
48481908|NCT03988517|OTHER|timing of receiving the drug|each group took levothyroxine in different timing
48481909|NCT06456879|OTHER|extra-coronal restoration type|primary molar crown type
48481910|NCT02148913|DRUG|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
48481911|NCT02148913|DRUG|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
48111290|NCT03709758|DRUG|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
48481912|NCT02148913|DRUG|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
48481913|NCT02148913|DRUG|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
48481914|NCT01923584|DRUG|EPI-743 400mg|
48481915|NCT01923584|DRUG|EPI-743 200mg|
48641311|NCT02613507|DRUG|Nivolumab|
48111291|NCT05561036|DRUG|Liposome doxorubicin|Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
48111292|NCT05561036|DRUG|Saline Solution|saline solution
48111293|NCT05056051|DEVICE|WATS-3D tissue sampling prior to forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells.
48481916|NCT04948957|DRUG|Esmolol|
48641312|NCT02613507|DRUG|Docetaxel|
47958529|NCT05004077|DRUG|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
47958530|NCT00660699|DRUG|Gemcitabine|
47958531|NCT00660699|DRUG|Docetaxel|
47958532|NCT00660699|RADIATION|Radiation|
48481917|NCT04948957|DRUG|Nitroglycerin|
48481918|NCT02470091|BIOLOGICAL|Denosumab|Given SC
47958533|NCT06183177|OTHER|Whole-Body Vibration|10 minutes of whole-body vibration when performing semi-squatting or forward lunges (12-16 Hz, varying intensity from low to high depending on patients' tolerance
47958534|NCT06183177|OTHER|Exercise|Four to five sessions of a physiotherapist-led exercise program with education talk (20 minutes), group exercises (30 minutes) and individual exercises (30 minutes) per week supplemented with home exercises
47958535|NCT02845934|OTHER|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
47958536|NCT03576612|BIOLOGICAL|AdV-tk|Given IT
47958537|NCT03576612|DRUG|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
47958538|NCT03576612|RADIATION|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
48111294|NCT05056051|DEVICE|WATS-3D tissue sampling following forceps biopsies|WATS-3D is a brush-based tissue sampling technique. Abrasive brush sampling of large areas of the esophagus pick up cells to obtain trans-epithelial specimens. This technique samples much larger tissue areas than standard forceps biopsies. Analysis is then done by proprietary neural-network based computer scanning and molecular diagnostics to identify abnormal cells. This will be done after forceps biopsies in this arm.
48111295|NCT05360043|DEVICE|laser treatment|All subjects were treated with a 1565-nm NAFL on their left faces for one pass, A 34-40 mJ per microbeam laser was used, and density was 250-300 microbeam per cm2. Their right faces were treated with a 1064-nm LPNY for one pass. We used a spot size of 10 mm in diameter, an energy density of 45-50 J/cm2, pulse width of 300 microseconds, and a repetition rate of 2 Hz. 1064-nm LPNY was equipped with a dynamic cooling device (DCD), the parameter was set as 40/20/0 ms. A total of 5 treatments were carried out at 2-week intervals, and one follow-up session at two months after last treatment. Before each treatment, subjects were asked to wash their face with clean water, and no topical lotion was applied. For post-treatment care, all subjects were advised to use their own moisturizing cream and avoid sun exposure.
48305150|NCT04420871|DRUG|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
48111296|NCT02081274|PROCEDURE|Surgery for congenital heart disease|
48111297|NCT04755530|DIETARY_SUPPLEMENT|Regular whole milk|400 g/day of regular whole milk
48111298|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with live bacteria|400 g/day of yogurt with live bacteria
48305151|NCT04420871|DRUG|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
48305152|NCT03328130|BIOLOGICAL|AAV2/5-hPDE6B|Subretinal administration in one eye
48305153|NCT03238144|OTHER|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
48305154|NCT05055739|DEVICE|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
48305155|NCT02717871|DEVICE|PACK-CXL|"Local anesthesia~- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~* 3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~* Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~* Homatropin or Scopolamin, if anterior chamber reaction~* Systemic NSAID/NSAR, if substantial pain~* Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
47958539|NCT03576612|DRUG|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
48481919|NCT02470091|OTHER|Laboratory Biomarker Analysis|Correlative studies
48481920|NCT02470091|OTHER|Pharmacological Study|Correlative studies
48481921|NCT04297995|DRUG|HLX10|Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
47958540|NCT03576612|BIOLOGICAL|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
47958541|NCT03576612|OTHER|Laboratory Biomarker Analysis|correlative studies
47958542|NCT04105582|BIOLOGICAL|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
47958543|NCT03116360|DIAGNOSTIC_TEST|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
47958544|NCT02114671|DRUG|Faldaprevir high dose|capsules, oral
47958545|NCT02114671|DRUG|Placebo|capsule, oral
47958546|NCT02114671|DRUG|Ciprofloxacin|tablets, oral
47958547|NCT02114671|DRUG|Faldaprevir low dose|capsules, oral
47958548|NCT04785248|PROCEDURE|Three-step disinfection|"Three step disinfection method can be divide in three part. The first step of disinfection: scalp dandruff removal + disinfection The second step of disinfection: whole head Use 2% iodine tincture to smear the whole head skin, the assistant helps to lift the head to expose the surgical field, from both eyebrows to the occipital hairline, from both sides to the neck, after the iodine tincture dry out, use 75% alcohol to deionize. Then placing more than 4 layers of operation towel under the head.~The third step of disinfection: neck chest abdomen disinfection."
48111299|NCT04755530|DIETARY_SUPPLEMENT|Yogurt with inactivated bacteria|400 g/day of yogurt with inactivated bacteria
48111300|NCT04755530|DIETARY_SUPPLEMENT|Acidified whole milk|400 g/day of yogurt with acidified whole milk
48111301|NCT03754218|DRUG|Amnion Membrane Powder|This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
47958549|NCT02459301|DRUG|IPH2201|
48305156|NCT02717871|DRUG|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
48305157|NCT02717871|DRUG|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
48305158|NCT02717871|DRUG|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
48305159|NCT02717871|DRUG|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
48481922|NCT04297995|DRUG|HLX07|Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
48305160|NCT00695084|BEHAVIORAL|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
48481923|NCT04297995|DRUG|HLX07 placebo|HLX07 placebo 1000 mg every three weeks
48481924|NCT04297995|DRUG|Cisplatin/Carboplatin|Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
48481925|NCT04297995|DRUG|5-FU|5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
48481926|NCT03447340|BEHAVIORAL|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
48481927|NCT03447340|OTHER|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
48481928|NCT00717184|DRUG|Interleukin, NK cells|
48481929|NCT00737737|DRUG|MS Contin|
48481930|NCT00737737|DRUG|Placebo|
48481931|NCT06250036|DRUG|Single agent zimberelimab|Single agent zimberelimab (PD-1 inhibitor) Q3W
48481932|NCT06250036|DRUG|Combination zimberelimab + domvanalimab|Combination zimberelimab + domvanalimab (TIGIT inhibitor) Q3W
48481933|NCT03492970|BIOLOGICAL|Hourly dosing of the nychtemeral secretion of melatonin|Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
48481934|NCT01885416|OTHER|consumption of test meal based on dairy products|
48481935|NCT01885416|OTHER|consumption of high fat test meal without dairy products|
48481936|NCT01885416|OTHER|consumption of high fat test meal with dairy products|
48481937|NCT06180408|OTHER|manual therapy and exercise for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
48481938|NCT06180408|OTHER|lumbar stabilization exercise|core training and myofascial release therapy
47958550|NCT05771012|DRUG|0.05% cyclosporin (Restasis®, Allergan Inc)|study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)
47958551|NCT05771012|DEVICE|mini-monoka stent|insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
48305161|NCT03817593|OTHER|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
48305162|NCT01925001|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
48305163|NCT01925001|DRUG|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
48481939|NCT04854564|BEHAVIORAL|Prehabilitation intervention|The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
47958552|NCT04894448|BIOLOGICAL|COVID-19 Vaccine|Any COVID-19 vaccine (1 or more doses)
47958553|NCT04391361|DRUG|Scopolamine, atropine, edaravone and dexmedetomidine|The patients were treated with scopolamine, atropine, edaravone and dexmedetomidine dissolved in saline.
47958554|NCT04391361|DRUG|Edaravone|The patients was treated with edaravone dissolved in the same volume of saline as the intervention applied in the experimental group.
47958555|NCT03605589|DRUG|Blinatumomab|Continuous IV infusion
47958556|NCT03605589|DRUG|Pembrolizumab|IV infusion
47958557|NCT04344548|BIOLOGICAL|Allogeneic NK transfer|Three doses of allogeneic NK cell transfer
47958558|NCT01980940|DRUG|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
47958559|NCT01980940|DRUG|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
47958560|NCT01980940|DRUG|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
47958561|NCT01980940|DRUG|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
47958562|NCT01980940|DRUG|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
47958563|NCT01980940|DRUG|Placebo|Placebo gel applied topically.
47958564|NCT01980940|DRUG|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
47958565|NCT01980940|DRUG|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
47958566|NCT04337268|DRUG|Glucagon-Like Peptide 1|Intravenous infusion (1.5 pmol/kg/min) for 60 min.
47958567|NCT04337268|DRUG|saline 0.9%|Intravenous infusion for 60 min.
47958568|NCT04664192|OTHER|Patient Biospecimen Registry (observational and blood sampling)|Clinical data collected at every blood sample collection visit.
47958569|NCT03133130|DRUG|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
47958570|NCT03133130|DRUG|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
47958571|NCT04728399|DIETARY_SUPPLEMENT|Experimental group|Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits
48305164|NCT04635696|DRUG|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
48305165|NCT04635696|OTHER|Tissue culture grade water|Pressurized water mist
48305166|NCT05690412|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary neoplasm
48305167|NCT05645484|DRUG|18F-PFPN|18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
48305168|NCT05645484|DRUG|18F-FDG|18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
48481940|NCT04854564|BEHAVIORAL|Caregiver intervention|The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
47958572|NCT04728399|DIETARY_SUPPLEMENT|Control group|Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits
47958573|NCT00573183|BEHAVIORAL|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
47958574|NCT00573183|BEHAVIORAL|Treatment as Usual|
47958575|NCT03802695|BIOLOGICAL|OrcaGraft (Orca-Q)|engineered donor allograft
47958576|NCT00763711|DEVICE|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
47958577|NCT04813640|DEVICE|Spectacles|Novel spectacles for myopia control
47958578|NCT06107504|DRUG|Sucralfate|2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
47958579|NCT05899985|COMBINATION_PRODUCT|FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System|"FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H\&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry)."
47958580|NCT02793544|DRUG|Fludarabine|"* Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~* The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~* creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
47958581|NCT02793544|DRUG|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"* Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
47958582|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy on Day -1|"* 200 cGy TBI is administered in a single fraction on Day -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
47958583|NCT02793544|PROCEDURE|Infusion of non-T-cell depleted bone marrow on Day 0|"* On Day 0, the harvested bone marrow is infused.~* Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~* The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
47958584|NCT02793544|DRUG|Busulfan|"* Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min (Perkins et al., 2012))~* Busulfan dosing is based on adjusted IBW (Appendix K)"
47958585|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
47958586|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
47958587|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"* 200cGy TBI is administered in twice daily on Days -3, -2, and -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
48111302|NCT03754218|PROCEDURE|SOC Wound Covering|Institutional standard of care wound covering.
48305169|NCT03649100|PROCEDURE|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
48305170|NCT05921006|DRUG|RJ4287|Oral，tablets，Once daily for 14 days
48305171|NCT05921006|DRUG|Placebo|Oral，tablets，Once daily daily for 14 days
48305172|NCT02618850|PROCEDURE|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
47916866|NCT04796194|COMBINATION_PRODUCT|LTX-315 in combination with pembrolizumab|"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."
48305173|NCT02618850|DRUG|first-line chemotherapy|as prescribed by oncologist
48305174|NCT05465733|DRUG|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
48305175|NCT04914637|PROCEDURE|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
48305176|NCT04914637|PROCEDURE|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
47916867|NCT00375609|DRUG|Betrixaban|Capsule
48111303|NCT05222087|RADIATION|Radiotherapy|35Gy/5# Central 40Gy/5# Large Tumours \>5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm
48305177|NCT04914637|PROCEDURE|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
48305178|NCT06480513|BEHAVIORAL|live yoga|following live yoga classes twice a week and using yoga video's at home once a week
48305179|NCT06480513|BEHAVIORAL|live remote yoga|The control group will be offered live remote yoga classes after the intervention period
48481941|NCT00596206|DRUG|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
47916868|NCT00375609|DRUG|Enoxaparin|Administered subcutaneously
48111304|NCT05222087|DRUG|SoC systemic therapy|Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
48111305|NCT04573803|DRUG|Phenytoin Sodium|Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
48305180|NCT03468192|OTHER|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
48305181|NCT04421989|BEHAVIORAL|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
48305182|NCT04421989|OTHER|Support Group|Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
48305183|NCT03175744|DEVICE|Stellarex DCB|Intervention with the Stellarex DCB
48111306|NCT04573803|DRUG|Levetiracetam|Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
48111307|NCT04440046|OTHER|Manual therapy thoracic spine|Manual therapy mobilization directed to the costovertebral joint.
48111308|NCT04440046|OTHER|Manual therapy glenohumeral joint|Manual therapy mobilization directed to the glenohumeral joint.
48305184|NCT03175744|DEVICE|PTA Catheter|Intervention with an uncoated Standard PTA
48305185|NCT04290650|BEHAVIORAL|Modified CBT for insomnia|Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.
47916869|NCT02465424|OTHER|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
48111309|NCT04440046|OTHER|Sham thoracic manual therapy|Sham manual therapy directed to the costovertebral joint.
48111310|NCT04440046|OTHER|Sham glenohumeral manual therapy|Sham manual therapy directed to the glenohumeral joint.
48111311|NCT04440046|OTHER|Therapeutic exercise|Therapeutic exercise program consisting on isometric exercise with progressive load.
48111312|NCT01315314|DRUG|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
48111313|NCT06549582|OTHER|Taohong Tongluo Xiaoban Prescription|"Chinese herbal medicine Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose"
48305186|NCT04290650|BEHAVIORAL|Treatment as usual|All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
48305187|NCT02549690|DRUG|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
48305188|NCT02549690|DRUG|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
48305189|NCT04484519|OTHER|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging
48305190|NCT04941378|DRUG|OTL38|One time infusion of OTL38
48305191|NCT04941378|DEVICE|intraoperative imaging camera system|intraoperative imaging camera system
48305192|NCT03613415|OTHER|Expansion|non invasive technique to increase thickness of thin ridge
48305193|NCT04830995|DIETARY_SUPPLEMENT|moderate restricted diet (1800-2000 kcal/day) for four weeks|high intensity interval training 3 sessions for four weeks
48305194|NCT04399967|BEHAVIORAL|Chat-based support|Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
48641313|NCT06471998|DRUG|Sodium Chloride injection|"Patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard treatment including stage I and II analgesics and physiotherapy in line with the recommendations of the French National Authority for Health.~At each session, 250ml to 500ml of physiological serum will be injected subcutaneously using a Meso-Kit-Perfuser\* or injection octopus positioned by the nurse according to the injection points defined by the investigating physician during the inclusion visit, with a dermographic tracer for surgical use."
48641314|NCT06587386|DRUG|First patient Bupivacaine liposome|This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome concentration depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a concentration of 0.443% w/v (15ml). Subsequently, if motor function was preserved, the next patient received a lower concentration (increased by 0.05% w/v) with a probability of b=0.11; or the same concentration with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower concentration (decreased by 0.05% w/v).
48641315|NCT06587386|DRUG|Next patients Bupivacaine liposome|This study was conducted using the biased coin method, where each patient's use of bupivacaine liposome concentration depended on the previous patient's response. Based on previous research and our past experience, the first recruited patient used a concentration of 0.443% w/v (15ml). Subsequently, if motor function was preserved, the next patient received a lower concentration (increased by 0.05% w/v) with a probability of b=0.11; or the same concentration with a probability of 1-b=0.89. If motor function was blocked, the next patient received a lower concentration (decreased by 0.05% w/v).
48641316|NCT02520154|DRUG|Carboplatin|Given IV
48641317|NCT02520154|OTHER|Laboratory Biomarker Analysis|Correlative studies
48641318|NCT02520154|DRUG|Paclitaxel|Given IV
48641319|NCT02520154|BIOLOGICAL|Pembrolizumab|Given IV
48641320|NCT02520154|OTHER|Pharmacological Study|Correlative studies
48641321|NCT06115967|DRUG|AZD6912|AZD6912 will be administered as a single sub-cutaneous dose.
48305195|NCT04399967|BEHAVIORAL|AWARD plus COVID-specific advice|Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention
48305196|NCT04399967|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
48305197|NCT04399967|BEHAVIORAL|COVID-19 related health warning leaflet|The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation
48641322|NCT06115967|DRUG|Placebo|Placebo will be administered as a single sub-cutaneous dose.
48641323|NCT04975997|DRUG|Dexamethasone|Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
48641324|NCT04975997|DRUG|Daratumumab|Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7 of a 28-day cycle
48641325|NCT04975997|DRUG|Bortezomib|Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
48641326|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
48641327|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
48641328|NCT04975997|DRUG|Iberdomide|Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
47916870|NCT00609531|DRUG|Citalopram|Pill, 5-20mg once a day for twelve weeks
48305198|NCT04399967|BEHAVIORAL|Health warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.
48305199|NCT04399967|BEHAVIORAL|SMS-based support|Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.
48305200|NCT04399967|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
48305201|NCT04399967|BEHAVIORAL|COSH Self-help smoking cessation booklet|A general smoking cessation self-help booklet
48305202|NCT04987983|OTHER|Experimental SLP-R|SLP-R will be given to the infant during bottle-feeding.
47958588|NCT02793544|DRUG|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"* Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
48111314|NCT06549582|OTHER|Fundamental medical treatment|The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
48111315|NCT03615924|DRUG|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~* \>48 kg: Ticagrelor 45 mg, twice a day."
48305203|NCT04987983|OTHER|Experimental SLP-L|SLP-L will be given to the infant during bottle-feeding.
48111316|NCT03615924|DRUG|Placebo|"The double-blinded study drug dose will be weight dependent:~* ≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~* \>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~* \>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
48111317|NCT00783354|DRUG|desloratadine|"Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months."
48111318|NCT00783354|DRUG|desloratadine|"Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months."
48305204|NCT01137331|DRUG|K301|Liquid- applied once daily prior to bed
48305205|NCT01137331|DRUG|Placebo|Liquid- applied once daily prior to bed
48305206|NCT03569111|DEVICE|Bronchoscopic ablation catheter|The Emprint™ Ablation Catheter Kit with Thermosphere™ Technology is deployed endoscopically and will be used to conduct bronchoscopic ablations in the lung using the superDimension™ navigation system.
48305207|NCT05951738|PROCEDURE|Blood and saliva collection|Blood and saliva samples from pregnant women; saliva samples from babies.
48305208|NCT05951738|BEHAVIORAL|Psychometric scales|A battery of psychometric scales and questionnaires.
48305209|NCT05951738|OTHER|Smartphone app|A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.
48305210|NCT00928473|BEHAVIORAL|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
48305211|NCT02017678|BIOLOGICAL|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
48305212|NCT02824380|DRUG|DA-4001 H|5% minoxidil / high dose of finasteride
48305213|NCT02824380|DRUG|DA-4001 L|5% minoxidil / low dose of finasteride
48305214|NCT03271931|BEHAVIORAL|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
48111319|NCT04128319|DRUG|T-Guard|Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days (no less than 40 hours) apart. Each dose consists of 4 mg/m\^2 Body Surface Area (BSA).
48305215|NCT03271931|BEHAVIORAL|Passive choice|EHR passive alert to cardiologists about prescribing a statin
48305216|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
48305217|NCT06298370|DRUG|Intrathecal bupivacaine and morphine|Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
48305218|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine and morphine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
47916871|NCT00609531|DRUG|Placebo|Placebo pill once a day for twelve weeks
48111320|NCT00475501|DRUG|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
48111321|NCT00475501|DRUG|Finasteride|5 mg, oral, once/day, for 52 weeks
48111322|NCT00475501|OTHER|Placebo|Placebo
48111323|NCT01537003|DEVICE|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
48111324|NCT01537003|DEVICE|Coban 2 layer|Compression bandage
48305219|NCT00399269|DRUG|Recombinant Human Erythropoietin alpha|
48305220|NCT04065022|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
48305221|NCT04705025|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
48305222|NCT04705025|OTHER|Interview|Complete interview
48305223|NCT04705025|OTHER|Quality-of-Life Assessment|Ancillary studies
48305224|NCT04705025|OTHER|Questionnaire Administration|Ancillary studies
48305225|NCT01921270|DRUG|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
48305226|NCT05856799|DEVICE|Leadless Micra AV Transcatheter Pacing System|Patients are implanted with a leadless Micra AV TPS
48305227|NCT05856799|DEVICE|Transvenous Azure XT DR dual chamber pacemaker|Patients are implanted with a transvenous Azure XT DR pacemaker
48305228|NCT00918476|DRUG|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
48305229|NCT05514717|DRUG|XMT-2056|XMT-2056 will be administered through a vein in your arm or port catheter (intravenously)
48305230|NCT00012727|PROCEDURE|Matching Symptom Severity to Service Intensity|
48305231|NCT01400334|RADIATION|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine \[HED, 20 mCi (740 MBq)\] to quantify sympathetic nerve function, b) 13N-ammonia \[NH3, 20 mCi (740 MBq)\] for regional perfusion, and c) 18F-2-deoxyglucose \[FDG; 6.5 mCi (241 MBq)\] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
48305232|NCT05388435|DRUG|SKL27969|SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
48305233|NCT04591314|BEHAVIORAL|Neurofeedback|The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
48305234|NCT02740569|OTHER|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
48305235|NCT05121077|OTHER|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
48305236|NCT06516796|OTHER|No intervention|Patients were retrospectively screened.
48305237|NCT01916122|DRUG|Fluorestradiol (FES)|
48305238|NCT01916122|PROCEDURE|PET/CT Imaging|
48305239|NCT05940844|DRUG|OB-002|The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
48305240|NCT01217658|BEHAVIORAL|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
48305241|NCT01217658|BEHAVIORAL|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
48305242|NCT05103319|OTHER|Data collection for statistical analysis to identify patterns of treatment response/ non-response|All data are restricted from the patient physical and electronic record of the Pain Management-Unit of the University Hospital Basel. No external data sources will be used. Records will be screened from 2012- May 2021. Variables collected are e.g. demography, medical diagnosis, psychological diagnosis, infusion therapy, medication, pain.
48305243|NCT01468727|DIETARY_SUPPLEMENT|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
48305244|NCT01468727|DIETARY_SUPPLEMENT|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
48305245|NCT00921856|OTHER|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
48305246|NCT02142179|BEHAVIORAL|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
48305247|NCT02402218|OTHER|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
48305248|NCT02402218|OTHER|Usual care plus incentives|Participants are given incentives after completing treatment goals.
48305249|NCT02402218|OTHER|Usual Care|Participants receive standard of care in the clinic from their health care team.
48305250|NCT02426983|DEVICE|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
48305251|NCT02426983|DRUG|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
48305252|NCT02835638|DEVICE|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
48305253|NCT05380414|BIOLOGICAL|Tumor samples (archival FFPE) and blood samples|Molecular screening
48305254|NCT01103349|DRUG|BI 671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
48641329|NCT05865535|BIOLOGICAL|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
48641330|NCT04912531|DEVICE|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
48305255|NCT01103349|DRUG|Placebo|Patients receive placebo capsules and/or encapsulated tablets
48305256|NCT01103349|DRUG|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
48305257|NCT02697955|DRUG|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
48305258|NCT02697955|OTHER|Placebo|9 mg sodium chloride pr. ml (0,9 %)
48305259|NCT06073002|OTHER|home-based concurrent exercise|3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
48305260|NCT03026543|PROCEDURE|Pulmonary Recruitment Maneuver|
48305261|NCT03026543|PROCEDURE|Laparoscopic cholecystectomy|
48305262|NCT03026543|DEVICE|Ventilator|
48305263|NCT03864263|OTHER||
48305264|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (10 mg)|A low dose of 10 mg 2C-B will be administered.
48305265|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (20 mg)|A medium dose of 20 mg 2C-B will be administered.
48305266|NCT05523401|DRUG|4-bromo-2,5-dimethoxyphenethylamine (30 mg)|A high dose of 30 mg 2C-B will be administered.
48481942|NCT02521181|DRUG|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
48481943|NCT02521181|DRUG|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
48481944|NCT02521181|DRUG|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
48481945|NCT03720574|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
48481946|NCT03720574|DRUG|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
48481947|NCT05114759|DRUG|SHR-A2009|"In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
48481948|NCT00493454|DRUG|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
48481949|NCT00493454|DRUG|Rituximab|250 mg/m\^2 IV Over 6 to 8 Hours
48481950|NCT00493454|DRUG|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
48641331|NCT04912531|DEVICE|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, \>97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
48305267|NCT05523401|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 125 mg MDMA will be administered.
48305268|NCT05523401|DRUG|Psilocybin|A moderate dose of 25 mg psilocybin will be administered.
48641332|NCT04912531|DEVICE|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
48641333|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral tablet.
48305269|NCT05523401|OTHER|Placebo|Placebo (Mannitol)
48305270|NCT00629694|PROCEDURE|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
48305271|NCT00629694|PROCEDURE|A-M|adenoidectomy and myringotomy alone
48305272|NCT05344079|DEVICE|18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
48305273|NCT05344079|DEVICE|20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump|spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.
48305274|NCT03641469|DEVICE|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
48641334|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral capsule.
48305275|NCT06074458|OTHER|Glucosano|Glucosano is a remote patient monitoring diabetes dashboard with a patient facing Smartphone application
48305276|NCT06074458|BEHAVIORAL|Community Health Worker diabetes technology coach|Community Health Workers will work with participants as a diabetes technology coach during scheduled and as needed visits
48305277|NCT04793672|OTHER|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
48305278|NCT05639920|COMBINATION_PRODUCT|Scoreing|Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
48305279|NCT03914820|PROCEDURE|HIPEC CO2 surgery|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
48305280|NCT03914820|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
48305281|NCT03914820|DRUG|Mitomycin|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
48305282|NCT04969016|PROCEDURE|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
48305283|NCT04969016|PROCEDURE|stapler|surgical wound closure with stapler
48305284|NCT00199264|DRUG|Albaconazole oral solution|
48305285|NCT06552585|OTHER|12-weeks weight prevention program|Twice a week, over 12-weeks, the weight program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with two weights Domyos with 1, 2, 3, 4, or 5 kg.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
48641335|NCT06036836|BIOLOGICAL|favezelimab/pembrolizumab|IV infusion
48641336|NCT06036836|BIOLOGICAL|pembrolizumab|IV infusion
48641337|NCT06036836|DRUG|lenvatinib|Oral administration of capsule
48641338|NCT02315612|BIOLOGICAL|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
48641339|NCT06368622|DEVICE|Surpass Evolve Flow Diverter System|Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms
48641340|NCT03609944|PROCEDURE|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
48641341|NCT03609944|PROCEDURE|EUS|Endoscopic ultrasound
48641342|NCT04040231|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
48641343|NCT04040231|DRUG|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
47958589|NCT02793544|DRUG|Sirolimus|"* Sirolimus dosing is based on adjusted IBW (Appendix K).~* Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~* A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects \< 18 years old:~* A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
47958590|NCT02793544|DRUG|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
47958591|NCT02793544|DRUG|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
47958592|NCT02793544|DRUG|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
47958593|NCT02793544|DRUG|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
47958594|NCT02793544|DRUG|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
47958595|NCT02793544|DRUG|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
48641344|NCT04040231|BIOLOGICAL|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
48641345|NCT05658510|DRUG|BXCL501|Sublingual Film
47958596|NCT02323243|DEVICE|"Allium  Bulbar Urethral Stent  (BUS) system"|
47958597|NCT01533077|DRUG|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
47958598|NCT01533077|DRUG|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
47958599|NCT02554695|DRUG|placebo|subcutaneous saline injection
48111325|NCT05150613|OTHER|No Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
48111326|NCT05150613|OTHER|Surgical Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
48641346|NCT05658510|DRUG|Matching Placebo|Sublingual Placebo Film
48641347|NCT01602666|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
48641348|NCT01602666|DRUG|Carboplatin|Given IV
48641349|NCT01602666|DRUG|Etoposide|Given IV
48641350|NCT01602666|DRUG|Ifosfamide|Given IV
47958600|NCT02554695|DRUG|denosumab|single subcutaneous injection of denosumab 60 mg
47958601|NCT02004522|DRUG|Duvelisib|PI3K Inhibitor
47958602|NCT02004522|DRUG|Ofatumumab|monoclonal antibody
48641351|NCT01602666|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48641352|NCT02705820|DRUG|Pembrolizumab|Switch maintenance pembrolizumab treatment
48641353|NCT05639114|DRUG|Ianalumab|ianalumab s.c. monthly or quarterly
48641354|NCT05639114|DRUG|Placebo|placebo s.c. monthly
48641355|NCT06503250|DRUG|Atezolizumab|Observational Study
48641356|NCT06503250|DRUG|Bevacizumab|Observational Study
48641357|NCT06503250|RADIATION|Transarterial Chemoembolization|Observational Study
48641358|NCT03917498|RADIATION|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
48641359|NCT04564547|DRUG|Islatravir|ISL capsule taken by mouth.
48641360|NCT04564547|DRUG|Ulonivirine|Ulonivirine tablet taken by mouth.
48641361|NCT04564547|DRUG|BIC/FTC/TAF|BIC/FTC/TAF tablet taken by mouth.
48641362|NCT04564547|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
48641363|NCT04564547|DRUG|Placebo to Ulonivirine|Placebo tablet matched to ulonivirine taken by mouth.
48641364|NCT04564547|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
48641365|NCT03740165|BIOLOGICAL|Pembrolizumab|IV infusion
48641366|NCT03740165|DRUG|Placebo for pembrolizumab|IV infusion
48641367|NCT03740165|DRUG|Carboplatin|IV infusion
48641368|NCT03740165|DRUG|Paclitaxel|IV infusion
48641369|NCT03740165|DRUG|Olaparib|Oral tablet
48641370|NCT03740165|DRUG|Placebo for olaparib|Oral tablet
48641371|NCT03740165|BIOLOGICAL|Bevacizumab|IV infusion
48641372|NCT03740165|DRUG|Docetaxel|IV infusion
48641373|NCT06543758|DEVICE|Wearable exoskeletal robot|Participants will wear a wearable exoskeletal robot for gait training and undergo 10 sessions of 30-minute gait training over 4 weeks at home or in nearby indoor spaces. Participants will participate in physical function assessments, including the 10-meter walk test, Timed Up and Go (TUG) test, and Berg Balance Scale, both before and after the intervention. Additionally, participants will complete quality of life and depression inventories before and after the intervention.
48641374|NCT06114485|BEHAVIORAL|VIPA Treatment Program|Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program
48641375|NCT06114485|BEHAVIORAL|Alexa with Guidebook|Participants will receive an Alexa device with a detailed guidebook on how to use the device.
48641376|NCT05649540|DRUG|Vonoprazan|Potassium-competitive acid blocker
48641377|NCT05649540|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
48641378|NCT03695601|OTHER|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
48641379|NCT06564818|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
48641380|NCT06564818|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
48641381|NCT06564818|DRUG|Placebo|Placebo
48641382|NCT06545500|DRUG|Glycopyrrolate (85 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
48641383|NCT06545500|DRUG|Glycopyrrolate (42.5 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
48641384|NCT06545500|DRUG|Glycopyrrolate (14 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
48641385|NCT06545500|DRUG|Placebo|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
48641386|NCT05441345|OTHER|questionnaires with collection of stool and urine|questionnaires will be completed (GPAQ, SarQoL, EQ-5D-3L, SF36), with collection of stool (for care and research) and urine
48641387|NCT01907789|OTHER|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
48641388|NCT01907789|PROCEDURE|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
48641389|NCT01907789|PROCEDURE|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
48641390|NCT01907789|BEHAVIORAL|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
48641391|NCT01907789|PROCEDURE|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
48641392|NCT01907789|BEHAVIORAL|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
48641393|NCT06496230|BEHAVIORAL|Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder|Two-pronged intervention model: 1) behavioral intervention utilizing interoceptive exposures and cognitive behavioral therapy for insomnia and, 2) mobile application that facilitates medication adherence.
48641394|NCT06446778|DEVICE|Pipeline embolization device with or without shield technique|The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.
48641395|NCT04191096|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
48641396|NCT04191096|DRUG|Enzalutamide|Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
48641397|NCT04191096|DRUG|Androgen Deprivation Therapy (ADT)|Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
47958603|NCT05993819|OTHER|pilates based core stability training and congnitive therapy|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all.the patients also will receive cognitive behavioural therapy.The CBT manual was written specifically for this trial. The sessions were collaborative in style, and the therapist used Socratic questioning wherever possible. The main aim was to challenge any behavioral, cognitive, emotional and external factors that may be contributing to MS fatigue.
47958604|NCT05993819|OTHER|Pilates based core stability training|Exercises were structured in different conditions such as supine, side-lying, prone, quadruped, sitting, and standing positions. The various variations of each exercise were created so that the easier or more difficult versions of the exercises were selected according to the level of the patients, basically in the same training plan for all. The exercises were gradually made more difficult to increase the stabilization of the trunk by gradually reducing the support surface, increasing the extremity loading, and adding various materials.Exercises were progressed every 2 weeks in both groups and were performed with 10 repetitions for the first 4 weeks and 15 repetitions for the next 4 weeks.
48305286|NCT06552585|OTHER|12-weeks elastic band prevention program|Twice a week, over 12-weeks, the elastic band program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with an elastic band Bodytone Power Band with 10, 15, 20, 25, or 30 kg weights Domyos.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
48305287|NCT06552585|OTHER|sham intervention|The control group performed a sham intervention, twice a week, for 12-weeks. This intervention consisted of 2 sets of 10 repetitions of 5 shoulder mobility exercises, without preventive aim, normally carried out in warm-up before training: shoulder maximum flexion and extension, horizontal abduction and adduction starting from 90º of shoulder abduction, maximum internal/external rotation starting from 90º of shoulder abduction, circumduction of the shoulder in a clockwise direction and circumduction of the shoulder in a counterclockwise direction. There was no progression after 6-weeks of this sham intervention. The coach of the respective team checked the execution of the exercises, but there was no individualized monitoring with a regular exercise technique correction by a physiotherapist.
48305288|NCT05657743|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
47958605|NCT01349088|DRUG|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
48305289|NCT00102453|DRUG|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
48305290|NCT05536713|DEVICE|Guardant SHIELD blood-based colorectal cancer screening test|The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
48305291|NCT00501033|DEVICE|Mechanical induction of labor|
47958606|NCT01349088|DRUG|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
47958607|NCT01349088|DRUG|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
48111327|NCT05150613|OTHER|N95 Mask|Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
47958608|NCT02505906|RADIATION|Simultaneous Integrated Boost Technique|
48111328|NCT03109795|DRUG|Clonidine Pill|sympathetic nerve activity blockade
48111329|NCT03109795|DRUG|Hydrochlorothiazide|Blood pressure-lowering control condition
48305292|NCT00501033|DEVICE|Double Balloon|
48305293|NCT00501033|DEVICE|Foley Catheter|
48305294|NCT05894278|OTHER|Prescription data collection|Prescription data collection
48305295|NCT06554314|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and once a day
48641398|NCT04191096|OTHER|Placebo|Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
48641399|NCT06034275|DRUG|VIP943 (QW)|VIP943 will be administered by IV Infusion weekly
48111330|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
48111331|NCT01623336|DRUG|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
48111332|NCT01623336|DRUG|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
47958609|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
48305296|NCT02126904|DRUG|IVA group|
48305297|NCT06179654|BEHAVIORAL|Preoperative pelvic floor physical therapy|Pelvic floor physical therapy to start before prostate surgery rather than after surgery.
47958610|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
47958611|NCT03391089|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
47958612|NCT04808544|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
47958613|NCT04808544|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
47958614|NCT06324812|DRUG|Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)|subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks
47958615|NCT06044454|OTHER|qXR|a software product that uses artificial intelligence to triage, prioritise, and (for tuberculosis only) diagnose based upon identified abnormalities within the CXR.
47958616|NCT03320057|DRUG|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
47958617|NCT03320057|OTHER|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
47958618|NCT04528732|BEHAVIORAL|Group Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
47958619|NCT04528732|BEHAVIORAL|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
47958620|NCT06558305|OTHER|blood sample|Total RNA will be extracted from the whole blood using a commercial extraction kit (RNA Extraction Kit, applied biotechnology Co.Ltd, Egypt) according to the manufacturer's instructions. RNA will be stored at -80°C.The extracted RNA will be used for cDNA synthesis using commercial kits (cDNA Synthesis Kit, applied biotechnology Co.Ltd, Egypt), according to the manufacturer's instruction.
47958621|NCT05614232|RADIATION|Chest X-ray|Chest radiographs
47958622|NCT04142632|PROCEDURE|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
47958623|NCT03939026|GENETIC|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
47958624|NCT03939026|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
47958625|NCT03939026|DRUG|Fludarabine|Chemotherapy for lymphodepletion
47958626|NCT03939026|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
48305298|NCT04769583|DRUG|metronidazole based quadriple therapy|patient randomized in QC will be treated by a double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day)
47958627|NCT00645112|DRUG|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
47958628|NCT00645112|DRUG|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
47958629|NCT02513342|BIOLOGICAL|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
47958630|NCT02513342|DRUG|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
47958631|NCT02513342|DRUG|Cisplatin|d4，cisplatin，75（mg/m2），iv；
47958632|NCT04374071|DRUG|Methylprednisolone|IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
47958633|NCT00435864|PROCEDURE|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
47958634|NCT00252746|DRUG|ZD6474 (vandetanib) 100mg|once daily oral dose
47958635|NCT00252746|DRUG|ZD6474 (vandetanib) 200mg|once daily oral dose
47958636|NCT00252746|DRUG|ZD6474 (vandetanib) 300mg|once daily oral dose
48305299|NCT04769583|DRUG|placebo based quadriple therapy|patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
48305300|NCT02345642|DEVICE|ActiveCare+SFT Supine|
48305301|NCT02345642|DEVICE|VenaFlow Elite Supine|
48305302|NCT02345642|DEVICE|ActiveCare+SFT Standing|
48305303|NCT02345642|DEVICE|VenaFlow Elite Standing|
48305304|NCT05085392|BEHAVIORAL|Trauma-Informed Yoga|6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
48305305|NCT06397729|BEHAVIORAL|Wait-List Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
48305306|NCT06397729|BEHAVIORAL|PREVENT Tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help the care team link patients to resources in their community. PREVENT follows up with patients electronically and communicates progress on behavior change to the care team.
48305307|NCT00815412|BEHAVIORAL|Counseling in use of health care|
48305308|NCT00815412|BEHAVIORAL|Counseling in diet, exercise|
48641400|NCT06034275|DRUG|VIP943 (BIW)|VIP943 will be administered by IV Infusion bi-weekly
47958637|NCT04200950|DEVICE|Previse|Machine learning algorithm for early acute kidney injury (AKI) prediction.
48305309|NCT00815412|OTHER|Control|
48641401|NCT06695949|OTHER|Percutaneous neuromodulation|Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
47958638|NCT01725711|DEVICE|OPRA Implant System|
47958639|NCT01970657|BIOLOGICAL|No treatment specified|No intervention
47958640|NCT01970657|BIOLOGICAL|No treatment|None specified
47958641|NCT04253262|DRUG|Rucaparib|Rucaparib (PO twice daily continuous)
47958642|NCT04253262|DRUG|Copanlisib|Copanlisib (IV day 1, 8, 15; 28 day cycle)
47958643|NCT04076878|DEVICE|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
47958644|NCT01330030|DRUG|Selegiline|6mg/24 hrs for 8 weeks
47958645|NCT01330030|OTHER|matching placebo|placebo/24hrs for 8 weeks
47958646|NCT05468060|DRUG|PA1010|Placebo as control
47958647|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation|The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.
47958648|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct Auditory Intervention|The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
47958649|NCT06169046|DRUG|Clenbuterol|tablets
47958650|NCT06169046|DRUG|Placebo|tablets
47958651|NCT06042504|OTHER|Survey|"Subjects will complete a survey. The survey consists of two parts, A and B. During part A subjects will indicate which of the 5 cohorts they identify as. Successively in part B, subject will complete a survey known as the Perceived Stress Scale (PSS)."
47958652|NCT05867303|DRUG|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
47958653|NCT00319501|DRUG|Placebo|Intramuscular autoinjector; administered at onset of an episode
47958654|NCT00319501|DRUG|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
47958655|NCT03748693|PROCEDURE|Hysterectomy|Surgery performed on women with a variety of gynecological indications
47958656|NCT03748693|PROCEDURE|Colporrhaphy|Surgery performed on women with POP
47958657|NCT00935948|DRUG|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
47958658|NCT00935948|DRUG|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
47958659|NCT04515394|DRUG|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
47958660|NCT04515394|BIOLOGICAL|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
47958661|NCT00261274|BIOLOGICAL|A-ECO|
47958662|NCT00261274|BIOLOGICAL|Saline|
48111333|NCT02563613|BEHAVIORAL|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
48111334|NCT02563613|BEHAVIORAL|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
48111335|NCT02563613|OTHER|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
48305310|NCT02255851|DEVICE|SENTINEL (Cerebral Protection System)|
48305311|NCT02045277|DRUG|IDP-118 Lotion|Lotion
48305312|NCT02045277|DRUG|IDP-118 Monad HP Lotion|Active Comparator
48305313|NCT02045277|DRUG|IDP-118 Monad Taz Lotion|Active Comparator
48305314|NCT02045277|DRUG|IDP-118 Vehicle Lotion|Vehicle
48305315|NCT02532634|DRUG|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
48305316|NCT02532634|DRUG|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
48305317|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
48305318|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
48305319|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
48305320|NCT03934593|BEHAVIORAL|Faith-Based (FB, BHT DSMS)|BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.
48305321|NCT03934593|OTHER|Faith-Placed (FP, Stanford DSMP)|Standard Stanford DSMP delivered by health professional
48641402|NCT03037008|DEVICE|Perineal Sonography|In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
48111336|NCT04733534|DRUG|Dasatinib plus Quercetin|Dasatinib (100 mg/day) plus Quercetin (500 mg twice daily) on days 1, 2, 3, 30, 31, 32 taken orally under observation of the study nurse.
48305322|NCT02293954|PROCEDURE|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
48305323|NCT02293954|PROCEDURE|positron emission tomography|Undergo PET
48305324|NCT02293954|OTHER|laboratory biomarker analysis|Correlative studies
48305325|NCT02293954|OTHER|pharmacological study|Correlative studies
48305326|NCT02293954|DRUG|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
48305327|NCT01911624|DRUG|direct thrombin inhibition|
48305328|NCT01911624|DRUG|enoxaparin|
48305329|NCT00443404|PROCEDURE|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
48641403|NCT06695117|BIOLOGICAL|IIV-HD|Inactivated, split-virion
48641404|NCT06695117|BIOLOGICAL|rC19 (dose 1)|Protein subunit
48641405|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 1)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
48641406|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 2)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
48641407|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 3)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
48641408|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 4)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
48641409|NCT06695117|OTHER|Placebo (0.9% NaCl)|Normal saline
48305330|NCT04468958|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
48305331|NCT04468958|OTHER|Normal saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
48305332|NCT05657288|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
48305333|NCT01518582|DEVICE|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
48305334|NCT04703660|PROCEDURE|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
48305335|NCT04297384|OTHER|Informational Intervention|Receive standard chemotherapy educational materials
48305336|NCT04297384|OTHER|Informational Intervention|Receive personalized information about cancer, treatment, and side effects
48481951|NCT06615765|OTHER|Acupuncture|"Acupuncture sessions will use sterile, disposable stainless-steel needles (0.3 mm × 40 mm and 0.3 mm × 75 mm). Each session has two phases:~Supine Position:~* Needles (0.35 mm × 75 mm) are inserted into ST25, ST15, and SP14, reaching the abdominal muscle layer.~* Needles (0.30 mm × 40 mm) are inserted into CV12, CV4, ST36, ST37, and SP6.~* Electroacupuncture (EA) at ST25, SP15, and ST36 uses a continuous 5 Hz wave, 0.1 to 2.0 mA.~Prone Position:~* Needles are inserted into BL32, BL33, and BL35 with precise angles and depths.~* EA at BL32, BL33, and BL35 uses a continuous 5 Hz wave, 2.0 to 6.5 mA. Sessions occur three times a week for the first 4 weeks, then twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions."
48481952|NCT06615765|OTHER|Sham acupuncture|Sterile, disposable stainless-steel needles (0.30 mm × 25 mm) will be used. After skin sterilization, needles will be inserted into the same points as the acupuncture group but to a shallow depth of 2 to 3 mm and lightly manipulated for blinding. Paired alligator clips will be attached to the same points, but the sham EA apparatus will have no current output, though it mimics the active EA apparatus in appearance and sound. Sham sessions will follow the same schedule as the acupuncture group: three times a week for the first 4 weeks and twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions.
48481953|NCT01564459|DRUG|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
48481954|NCT01564459|DRUG|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
48481955|NCT02858648|BEHAVIORAL|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
48481956|NCT02858648|BEHAVIORAL|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
48481957|NCT02177006|BEHAVIORAL|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
48481958|NCT05813938|DEVICE|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
48481959|NCT01929395|DEVICE|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
48481960|NCT06013917|DEVICE|Cardiac Monitoring|FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
48481961|NCT05815082|PROCEDURE|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
48481962|NCT05815082|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
48305337|NCT04297384|OTHER|Quality-of-Life Assessment|Ancillary studies
48305338|NCT04297384|OTHER|Survey Administration|Complete surveys
48305339|NCT03933917|PROCEDURE|Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
47958663|NCT02537106|PROCEDURE|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
48305340|NCT04598165|BEHAVIORAL|Interactive two-way SMS dialogue|We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
48305341|NCT00194636|PROCEDURE|nerve block|
48305342|NCT03362346|DEVICE|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
48305343|NCT05326750|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
48305344|NCT01340235|DRUG|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
48305345|NCT00475280|PROCEDURE|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
48305346|NCT00475280|PROCEDURE|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
48305347|NCT06297460|BEHAVIORAL|Systems Training for Emotional Predictability & Problem Solving (STEPPS)|STEPPS is based on a cognitive-behavioral and skills training approach divided into three major components. The first component (sessions: 1-2) teaches participants to replace misconceptions about the presented issues with greater awareness of thoughts, feelings, and behaviors that characterize them. It also helps them identify their own thought patterns driving their behaviors. The second (sessions 3-12) teaches skills to more effectively manage the cognitive and emotional effects of the issues, such as distancing, communication, challenging, distraction, and problem-solving. The third component (sessions 13-19) teaches behavioral skills where participants are encouraged to master habits of healthy eating, sleep hygiene, regular exercise, leisure activities, health monitoring, self-harm prevention, and interpersonal effectiveness. The therapeutic objectives of the three blocks are awareness of illness (1), emotional regulation (2), and behavioral regulation (3).
48305348|NCT02674737|DRUG|dexmedetomidine, tramadol and flurbiprofen|
48305349|NCT02674737|DRUG|tramadol and flurbiprofen|
48305350|NCT05009823|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
48305351|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
47958664|NCT02537106|PROCEDURE|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
48111337|NCT04733534|DRUG|Fisetin|Fisetin (20mg/kg/day) on days 1, 2, 30 and 31 taken orally under observation of the study nurse. Fisetin will be dispensed based on weight of 20 mg/kg/day on the four separate days.
48111338|NCT00979563|DRUG|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
48305352|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
48305353|NCT05009823|DIETARY_SUPPLEMENT|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
48305354|NCT05009823|DIETARY_SUPPLEMENT|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
48305355|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
48111339|NCT03774459|DRUG|High dose ANAVEX2-73|Active oral capsule
48111340|NCT03774459|DRUG|Mid dose ANAVEX2-73|Active oral capsule
48305356|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
48111341|NCT03774459|DRUG|Placebo oral capsule|Placebo oral capsule
48111342|NCT00318019|DIETARY_SUPPLEMENT|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
48111343|NCT00318019|OTHER|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
48111344|NCT05598151|DRUG|HM97662|To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
48305357|NCT03329937|DRUG|Niraparib|Niraparib is a potent, orally active, highly selective poly adenosine diphosphate (\[ADP\]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
48305358|NCT04041388|OTHER|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
48305359|NCT03568149|PROCEDURE|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
48305360|NCT03568149|PROCEDURE|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
48305361|NCT01241513|DRUG|NAC|NAC provided to determine if beneficial at altitude
48305362|NCT01241513|DRUG|Placebo|Placebo
48305363|NCT03959540|DRUG|Opicapone|Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
48305364|NCT03959540|DRUG|Levodopa (L-DOPA) + Standard care|Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
48305365|NCT05897138|DRUG|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle|"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"
48305366|NCT03474133|DRUG|Brentuximab Vedotin|brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
48305367|NCT03237832|DRUG|ARN-6039|Ascending doses per Cohort
48305368|NCT03237832|OTHER|Placebo|Placebo to match ARN-6039
48481963|NCT05814432|DRUG|Single high dose of liposomal amphotericin B|Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
48481964|NCT05814432|DRUG|L-AmB standard dose|Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
48481965|NCT02965872|OTHER|No intervention|
47958665|NCT03267017|OTHER|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
47958666|NCT00302185|PROCEDURE|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
47958667|NCT00302185|BEHAVIORAL|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
47958668|NCT00989105|OTHER|immunohistochemistry staining method|
47958669|NCT00989105|OTHER|laboratory biomarker analysis|
47958670|NCT00989105|OTHER|pharmacological study|
47958671|NCT00989105|PROCEDURE|computed tomography|
47958672|NCT00989105|PROCEDURE|magnetic resonance imaging|
47958673|NCT00989105|PROCEDURE|single photon emission computed tomography|
47958674|NCT00989105|RADIATION|technetium Tc 99m demobesin-4|
47958675|NCT00150709|DRUG|Levetiracetam|"* Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use"
47958676|NCT01500031|DEVICE|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
48111345|NCT02538263|DEVICE|Volume-targeted noninvasive ventilation|
48111346|NCT03083119|DRUG|Xuesaitong soft capsule|Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
48305369|NCT05511246|DRUG|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
48305370|NCT05511246|PROCEDURE|Catheter ablation|Endocardial catheter ablation of VT substrate
48305371|NCT05474040|DRUG|Morphine versus multimodal analgesia for post elective craniotomy pain|To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
48305372|NCT04813237|OTHER|n a|the participants are not subjected to any type of intervention
48305373|NCT00073333|BEHAVIORAL|Social Skills Training|Social skills training once per week
48305374|NCT00073333|BEHAVIORAL|Exposure Treatment|Exposure once per week
48305375|NCT00073333|BEHAVIORAL|Placebo|Placebo
48305376|NCT01920620|BEHAVIORAL|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
48305377|NCT01920620|BEHAVIORAL|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
48305378|NCT05676489|DRUG|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
47958677|NCT04776109|PROCEDURE|erector spinae block|"Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours."
48111347|NCT03083119|DRUG|Placebo oral capsule|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
48305379|NCT02733692|BEHAVIORAL|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
48305380|NCT05142657|OTHER|diet survey|Dietary survey applied to all participants
48305381|NCT03614429|DRUG|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
48305382|NCT03125746|DRUG|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
48305383|NCT03125746|DRUG|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
48111348|NCT00361283|DRUG|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
48305384|NCT00746577|OTHER|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
48305385|NCT06324487|OTHER|Progressive Exercises|Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises
48305386|NCT06324487|OTHER|Blood Flow Restriction Therapy|Strengthening exercises performed by using cuff surrounding proximal part of the arm.
48481966|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 2 doses alternate timing|Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
48481967|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|This will be the comparison group for the 2-dose group.
48481968|NCT01010126|BIOLOGICAL|Bevacizumab|Given IV
48481969|NCT01010126|DRUG|Temsirolimus|Given IV
48481970|NCT03545191|DRUG|Daridorexant 25 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
48481971|NCT03545191|DRUG|Daridorexant 50 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
48481972|NCT03545191|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
48641410|NCT06695975|BEHAVIORAL|Occupational self-analysis|"Occupational self analysis program is delivered in group sessions, each session lasting 45 minutes, twice a week. Also Individual sessions are held throughout the program with each participant, with the intention of clarifying certain concepts and resolving specific difficulties that were occurring.The thematic modules worked are 5; occupation-health and difficulty, occupational balance, adaptation strategies to difficulties, social relationships and knowing other realities.~The methodological strategies used to structure the program were the Model of Human Occupation (MOHO) and the See-Judge-Act methodology"
48641411|NCT04869449|DRUG|Ketoconazole|400 mg (two 200 mg tablets) orally
48111349|NCT01126112|BIOLOGICAL|Panitumumab|Panitumumab: 6 mg/Kg Q2W
48111350|NCT00815750|OTHER|Information Gathering|An information gathering phase leading to development of a new decision aid.
48481973|NCT04736108|DRUG|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
48111351|NCT00815750|OTHER|Decision Aid|To test the newly developed decision aid.
48481974|NCT04736108|DRUG|Prednisolone|5 mg oral low dose prednisone, once daily
48481975|NCT04736108|DRUG|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
48481976|NCT02597582|PROCEDURE|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
48305387|NCT00748826|BIOLOGICAL|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
48305388|NCT04066816|OTHER|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
48641412|NCT05655169|PROCEDURE|Piezosurgery and GaALAs diode laser|"One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied."
48305389|NCT00788658|BEHAVIORAL|Diet modifications|Diet consultation
48305390|NCT00788658|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
48305391|NCT06175650|PROCEDURE|Cardiac surgery|Cardiac surgery of all types
48305392|NCT06334029|DIAGNOSTIC_TEST|Functional and structural Connectome|Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)
48305393|NCT03411746|OTHER|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
48305394|NCT03666260|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
48305395|NCT03666260|PROCEDURE|femoral block|femoral block with echography
48305396|NCT04429503|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
48305397|NCT04429503|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
48641413|NCT05655169|PROCEDURE|Piezosurgery|One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
48641414|NCT05655169|OTHER|Fixed orthodontic appliance|"After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side."
48641415|NCT05792930|BEHAVIORAL|cognitive-behavioral therapy and biofeedback therapy|Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.
48305398|NCT02602236|DEVICE|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
48305399|NCT02945449|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
48305400|NCT01173627|DRUG|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
48305401|NCT01173627|DRUG|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
48305402|NCT00511589|OTHER|chagas disease diagnostic|
48305403|NCT03389126|DRUG|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
48305404|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
48305405|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
48305406|NCT00589888|DRUG|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
48305407|NCT00589888|DRUG|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
48305408|NCT00589888|DRUG|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
48305409|NCT00589888|DIETARY_SUPPLEMENT|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
48481977|NCT01316419|DRUG|Telmisartan|Telmisartan 40mg or 80mg
48481978|NCT01316419|DRUG|amlodipine|amlodipine 5mg or 10mg
48481979|NCT02155374|DRUG|Sliding scale insulin|
48641416|NCT02650414|BIOLOGICAL|Cohort 1|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22 cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22 cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22 cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22 cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22 cells/kg"
48305410|NCT00589888|DIETARY_SUPPLEMENT|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
48305411|NCT06323330|OTHER|Speech rehabilitation|Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
48111352|NCT06556160|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests to search synaptopathie. During the surgery, stimuli are delivered."
48305412|NCT02566330|DEVICE|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
48305413|NCT06156111|DEVICE|Transepithelial abutment group|Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments on the implants randomized to this group will be put at the torque the manufacturer recommends (30 Ncm typically), according to the appropriate gingival height and then the fixed implant-supported monolithic zirconia will be placed at the torque of 15 Ncm
48305414|NCT06156111|DEVICE|Direct to implant group|It will be registered the essential clinical data registration to produce an individual patient-oriented prosthesis, and then the fixed implant-supported monolithic zirconia will be placed at the torque of 30 Ncm.
48305415|NCT03293199|PROCEDURE|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
48305416|NCT03293199|PROCEDURE|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
48305417|NCT04615689|OTHER|The collection of feces|When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.
48305418|NCT03318107|DEVICE|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
48305419|NCT00243230|DRUG|Vicriviroc 30 mg|Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
48305420|NCT00243230|DRUG|Vicriviroc 20 mg|Two tablets of vicriviroc 10 mg once daily for 48 weeks.
48305421|NCT00243230|DRUG|Placebo|Three tablets of placebo once daily for 48 weeks.
48305422|NCT00243230|DRUG|Placebo|Two tablets of placebo once daily for 48 weeks.
48305423|NCT00243230|DRUG|Background ART Regimen|"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
48305424|NCT05108909|DEVICE|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
48305425|NCT00538876|DRUG|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
48305426|NCT03653611|OTHER|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
48305427|NCT03653611|OTHER|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
48305428|NCT03653611|OTHER|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
48305429|NCT03653611|OTHER|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
48481980|NCT02155374|DRUG|Intermediate acting insulin|
48111353|NCT02964195|DRUG|Rifaximin|ALFA WASSERMANN S.p.A.
48111354|NCT00644475|DRUG|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
48111355|NCT00644475|DRUG|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
48111356|NCT03923491|BEHAVIORAL|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
48111357|NCT03923491|BEHAVIORAL|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
48305430|NCT03653611|OTHER|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
48305431|NCT02269059|DRUG|MK-7680|MK-7680 10 mg and 100 mg capsules
48305432|NCT05516901|PROCEDURE|The erector spinae plane block group|The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
48305433|NCT05516901|PROCEDURE|Control group|Patients in this group will receive general anesthesia alone.
48481981|NCT02155374|BEHAVIORAL|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
48641417|NCT02650414|BIOLOGICAL|Cohorts 2|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22-65s cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22-65s cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22-65s cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22-65s cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22-65s cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22-65s cells/kg"
48641418|NCT02650414|BIOLOGICAL|Cohort 3|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.5-2.5x10\^6 CAR T cells/kg Day 2, 75% fraction: 1.5-7.5x10\^6 CAR T cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.25-1.25x10\^8 CART22-65s cells Day 2, 75% fraction: 0.75-3.75x10\^8 CART22-65s cells"
48641419|NCT06676085|DRUG|Nafamostat|Nafamostat combined with unfractionated heparin for anticoagulation
48641420|NCT06676085|DRUG|Heparin|unfractionated heparin for anticoagulation
48641421|NCT06222424|OTHER|outpatient prescription issues|Evaluation of utility will involve describing all Emergency Medicine Pharmacist (EMP)-written prescriptions pursuant to resolution of prescription issues realized after discharge
48641422|NCT06191315|DRUG|Dupilumab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
48641423|NCT06191315|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
48641424|NCT06565546|OTHER|Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin|CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication
48481982|NCT02155374|DRUG|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
47958678|NCT05281679|OTHER|Low-intensity resistance exercise with blood flow restriction group (L-BFR)|The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.
48481983|NCT02155374|DRUG|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
48481984|NCT02921503|OTHER|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
48481985|NCT02577224|OTHER|Patient-initiated treatment|Please see Intervention Arm
48481986|NCT03456024|OTHER|Questinnaire|
48481987|NCT03081039|DRUG|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
48481988|NCT03081039|DRUG|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
48481989|NCT03081039|DRUG|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
48481990|NCT05256472|DRUG|AK104|anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
48481991|NCT05256472|DRUG|axitinib|an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
48481992|NCT04948294|DEVICE|Channeled blade|In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation
48481993|NCT04948294|DEVICE|Non-channeled blade|In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
48481994|NCT03409991|BEHAVIORAL|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
48481995|NCT04732988|DRUG|HSG4112|Once-daily oral administration
48481996|NCT04732988|DRUG|Placebo|Once-daily oral administration
48481997|NCT01905709|BIOLOGICAL|Human fecal matter|
48481998|NCT01382745|DRUG|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
48481999|NCT01382745|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
48482000|NCT03141879|OTHER|HUR equipment resistance training intervention|Resistance training intervention
48482001|NCT03554252|OTHER|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
48305434|NCT05609747|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
48305435|NCT00000849|DRUG|Aldesleukin|
48305436|NCT00138099|DRUG|Fragmin (dalteparin sodium)|
48305437|NCT03719560|DRUG|Methotrexate|Systemic methotrexate
48305438|NCT03719560|DRUG|Cytarabine|Systemic cytarabine
48305439|NCT02371759|DRUG|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
48305440|NCT02371759|DRUG|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
48305441|NCT02371759|DRUG|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
48305442|NCT02371759|DRUG|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
48305443|NCT00442247|DEVICE|Pelvicol|
48305444|NCT04652063|OTHER|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
48305445|NCT00956475|BEHAVIORAL|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
48305446|NCT00956475|OTHER|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
48305447|NCT00956475|PROCEDURE|assessment of therapy complications|questionnaire via telephone
48305448|NCT00956475|PROCEDURE|fatigue assessment and management|questionnaire via telephone
48305449|NCT00956475|PROCEDURE|psychosocial assessment and care|questionnaire via telephone
48305450|NCT00956475|PROCEDURE|quality-of-life assessment|questionnaire via telephone
48305451|NCT04548089|BEHAVIORAL|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
48305452|NCT00942045|BIOLOGICAL|Biologic - Osteocel Plus|Osteocel Plus
48305453|NCT05692193|BEHAVIORAL|pain education|Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
48482002|NCT03554252|OTHER|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
48482003|NCT00101413|DRUG|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
47958679|NCT05281679|OTHER|High-intensity resistance exercise without blood flow restriction group (H-BFR).|The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
47958680|NCT02137265|DRUG|Clomiphene|Clomiphene citrate 50 mg orally daily
47958681|NCT02137265|DRUG|Placebo|One pill every other day
47958682|NCT05159284|DRUG|Hydrocortisone Ophthalmic|1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
47958683|NCT05159284|DEVICE|MGD Rx EyeBag® eyelid warming device|Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
48305454|NCT04346628|DRUG|Favipiravir|Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
48641425|NCT06565546|OTHER|Acetaminophen and Gabapentin: standard postoperative pain medications|Participants will receive standard postoperative pain medications
48305455|NCT04346628|DRUG|Placebo|Placebo to match favipiravir administered orally through day 10.
48305456|NCT04346628|OTHER|Standard of care treatment|Standard of care treatment for COVID-19 infection
48305458|NCT00347711|DRUG|Intravitreal injection|
48305459|NCT05320770|PROCEDURE|US guided TMJ intra articular injection|therapeutic TMJ intra articulatr injection of blood under sonography guidance to reduce joint hyper mobility
48641426|NCT06693921|PROCEDURE|AI/guided block graft|The allo-dentin tooth graft will be prepared by placing a dentin block from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template.
48641427|NCT06693921|PROCEDURE|AI/guided shell graft|The allo-dentin shell graft will be prepared by placing a dentin shell from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template
48641428|NCT06670586|PROCEDURE|conventional in vitro fertilization|Fertilization via conventional In Vitro Fertilization
48641429|NCT06670586|PROCEDURE|intracytoplasmic sperm injection (ICSI)|Fertilization via intracytoplasmic sperm injection
48641430|NCT05250583|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
48641431|NCT06011252|DEVICE|Solia S lead with any BIOTRONIK Pacemaker|"* Name: Solia S lead with any BIOTRONIK Pacemaker~* Model: Solia S45/S53/S60~* Manufacturer: BIOTRONIK SE \& Co. KG~* Method of use: LBBAP implantation for all bradycardia indications.~* Mechanism of action: (1) Pacemaker stimulates the cardiac tissue to keep stable heart beats in patients with bradycardia. (2) LBBAP can be an alternative to right ventricular (RV) pacing to reduce RV pacing-induced ventricular dyssynchrony.~* Device category and grade: E3610 Cardiovascular devices, Class III"
48641432|NCT06161025|DRUG|R-DXd|R-DXd will be administered as an intravenously (IV) infusion
48641433|NCT06161025|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion
48641434|NCT06161025|DRUG|Paclitaxel|Paclitaxel will be administered as an IV infusion
48641435|NCT06161025|DRUG|Topotecan|Topotecan will be administered as an IV infusion
48641436|NCT06161025|DRUG|PLD|PLD will be administered as an IV infusion
48641437|NCT02467881|BEHAVIORAL|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
48641438|NCT02467881|BEHAVIORAL|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
48641439|NCT02467881|OTHER|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
48641440|NCT04994483|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
48641441|NCT04994483|DRUG|Placebo|Matching placebo given b.i.d. for 52 weeks.
48641442|NCT05385692|DRUG|BL-M02D1|Administration by intravenous infusion
48641443|NCT06504394|BIOLOGICAL|Pembrolizumab Coformulated With Hyaluronidase|SC injection
48641444|NCT03918278|BIOLOGICAL|MK-0482|IV infusion
48641445|NCT03918278|BIOLOGICAL|pembrolizumab|IV infusion
48641446|NCT03918278|DRUG|Paclitaxel|IV infusion
48641447|NCT03918278|DRUG|Nab-paclitaxel|IV infusion
48641448|NCT03918278|DRUG|Gemcitabine|IV infusion
48641449|NCT03918278|DRUG|Carboplatin|IV infusion
48641450|NCT03918278|DRUG|Pemetrexed|IV infusion
48641451|NCT06694675|DRUG|Sevoflurane (Volatile Anesthetic)|Sevoflurane 1%\~3.5%
47958684|NCT05159284|DEVICE|Lephanet® lid wipes|Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
47958685|NCT05159284|DEVICE|Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%|Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
48641452|NCT06694675|DRUG|propofol|Propofol 9\~15mg/kg/h
48641453|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
48641454|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
48641455|NCT02853773|OTHER|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
48641456|NCT06559241|DEVICE|14-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 14 days post-thrombectomy.
48641457|NCT06559241|DEVICE|30-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 30 days post-thrombectomy.
48641458|NCT06559241|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.
48305460|NCT01231633|DRUG|Ozurdex|Ozurdex, 0.7mg dexamethasone
48305461|NCT01231633|DRUG|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
48305462|NCT02656992|DEVICE|Inspiratory muscle training group|
48641459|NCT06559241|DRUG|Best medical management|Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.
48305463|NCT05704543|DRUG|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
48482004|NCT03729154|BEHAVIORAL|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
48305464|NCT02330627|BEHAVIORAL|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
48482005|NCT00678626|DRUG|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
47958686|NCT06057831|RADIATION|Total Neo-adjuvant Therapy|"* TNT incorporates chemotherapy with concurrent chemoradiotherapy (CRT) in any order.~* Radiotherapy includes 5000 cGy/25 fractions over 5 weeks.~* Chemotherapy regimen for Concurrent CRT: Capecitabine~* Chemotherapy regimens used with TNT are: FOLFIRINOX x 6 cycles, 8-9 courses FOLFOX or 5-6 courses of CAPEOX delivered over 4-6 months.~* The chemotherapy regimen or the order of treatment will be decided at the discretion of the patient's medical oncologist"
48305465|NCT02929563|DRUG|Pantoprazole|
48305466|NCT02929563|DRUG|Placebo (for pantoprazole)|
48305467|NCT03782740|DRUG|Melatonin 10 mg|Melatonin capsule
48482006|NCT00678626|DRUG|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
48482007|NCT05692999|DRUG|Pembrolizumab 200 mg Q6W|Pembrolizumab 200mg Q6W
48482008|NCT05692999|DRUG|Pemetrexed 500 mg/m^2 Q3W|Pemetrexed 500 mg/m\^2 Q3W
48482009|NCT05692999|DRUG|Pembrolizumab 200 mg Q3W or 400 mg Q6W|Pembrolizumab 200 mg Q3W or 400 mg Q6W
48482010|NCT03629028|DIAGNOSTIC_TEST|Residual myometrium thickness|The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
48482011|NCT03629028|DIAGNOSTIC_TEST|Niche Presence|The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.
48305468|NCT03782740|DRUG|Placebo|Sugar pill manufactured to mimic Melatonin capsule
48482012|NCT03629028|DIAGNOSTIC_TEST|Adjacent myometrium thickness|The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
48482013|NCT03629028|DIAGNOSTIC_TEST|Niche Measurements (depth of niche, width of niche, length of niche)|The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
47958687|NCT06057831|OTHER|18FDG-PET/MRI scan|18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
47958688|NCT06366932|DRUG|Second-line systemic treatment|Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in whom the use of cyclosporine is considered inappropriate due to contraindication or intolerance, are candidates for treatment with other alternatives (Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib).
47958689|NCT06366932|OTHER|Folllow-up of second-line systemic treatment already started|If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
47958690|NCT00087503|DRUG|Edotecarin|
47958691|NCT01604408|BIOLOGICAL|LY2495655|Administered SC
47958692|NCT01604408|DRUG|Placebo|Administered SC
47958693|NCT02628470|PROCEDURE|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
47958694|NCT02628470|PROCEDURE|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
47958695|NCT02628470|PROCEDURE|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
47958696|NCT02624752|DIETARY_SUPPLEMENT|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
47958697|NCT03294759|OTHER|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
48305469|NCT03782740|DRUG|Melatonin 20 mg|Melatonin capsule
48305470|NCT00003982|DRUG|sabarubicin|
48482014|NCT06503107|DRUG|Nanobody-based biepitope BCMA-targeting CAR-T cells|Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.
48482015|NCT00668720|DEVICE|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
48482016|NCT00668720|DEVICE|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
48482017|NCT03968497|OTHER|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
48482018|NCT03968497|OTHER|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
48482019|NCT04747704|BEHAVIORAL|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
48641460|NCT04597112|OTHER|Myofascial Release Technique|Myofascial release focuses on reducing pain by easing the tension and tightness in the trigger points. Therapist will gently massage the myofascia and feel for stiff or tightened areas. Normal myofascia should feel pliable and elastic. The therapist will begin massaging and stretching the areas that feel rigid with light manual pressure. The therapist then aids the tissue and supportive sheath in releasing pressure and tightness. The process is repeated multiple times on the same trigger point and on other trigger points until the therapist feels the tension is fully released.
48482020|NCT05646628|BEHAVIORAL|Qualitative Interviews|Semi-structured Qualitative Interviews
48641461|NCT04597112|OTHER|Exercise|"Exercise is recommended by physical therapists for most cervical radiculopathy patients.~In this study, a customized exercise program will be applied for patients with cervical radiculopathy."
48641462|NCT04769986|BEHAVIORAL|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
48641463|NCT04769986|BEHAVIORAL|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
48641464|NCT06398418|DRUG|R-5780|Probiotic
48641465|NCT06658249|OTHER|Core Stabilization Exercises with Foot-Ankle Strengthening Program|Core Stabilization Exercises and Foot-Ankle Strengthening Program with the frequency of 3 sets of 10 repetitions 3 times per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
48482021|NCT00002702|BIOLOGICAL|aldesleukin|
48482022|NCT00002702|PROCEDURE|adjuvant therapy|
48482023|NCT00002702|PROCEDURE|conventional surgery|
48482024|NCT00002702|PROCEDURE|neoadjuvant therapy|
48482025|NCT00002702|RADIATION|radiation therapy|
48482026|NCT04701034|DRUG|Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)|infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
48482027|NCT04701034|DRUG|Prednisolone Tablets|5 mg before ET and 10 mg after ET until gestational week 8+0
48305471|NCT03651999|OTHER|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
48305472|NCT01834924|OTHER|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
48305473|NCT00363805|DIETARY_SUPPLEMENT|green tea|Given orally
48305474|NCT00363805|DRUG|Polyphenon E|Given orally
48305475|NCT00363805|OTHER|placebo|Given orally
48305476|NCT05437224|DRUG|Ambrisentan|eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
48305477|NCT04133779|PROCEDURE|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
48305478|NCT04133779|PROCEDURE|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
48305479|NCT04133779|PROCEDURE|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
48305480|NCT01467908|DEVICE|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
48305481|NCT00993603|BEHAVIORAL|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
48305482|NCT04040712|OTHER|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
48641466|NCT06658249|OTHER|Foot-Ankle Strengthening Program|Foot-Ankle Strengthening Program along with common conventional treatment with the frequency of 3 sets of 10 repetition thrice per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
48641467|NCT01381887|DRUG|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
48641468|NCT01381887|DRUG|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
48482028|NCT04701034|DRUG|Human Albumin Solution|Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
48482029|NCT04701034|DRUG|Placebo tablet|1 tablet before ET and 2 tablets after ET until gestational week 8+0
48482030|NCT00809315|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
48482031|NCT00809315|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
48482032|NCT01345318|BIOLOGICAL|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
47958698|NCT03294759|OTHER|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
47958699|NCT03949972|OTHER|Biosampling|Biosampling at initial visit and follow-up visits
48111358|NCT00012935|BEHAVIORAL|Help with decision making on prostate cancer treatment|
48305483|NCT04040712|OTHER|Sham FMT|Sham fecal microbiota transplantation
48305484|NCT02053272|DRUG|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
48305485|NCT02053272|DRUG|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
48641469|NCT01381887|DRUG|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
48111359|NCT00509535|DRUG|vitreoscilla filiformis cream|
48111360|NCT00666094|BEHAVIORAL|Endurance training|supervised endurance training. Three sessions per week in three months.
48641470|NCT01381887|DRUG|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
48111361|NCT00666094|BEHAVIORAL|strength training|Supervised strength training. Three sessions per week in three months.
48111362|NCT05570019|PROCEDURE|Revascularization|Open surgery (arterial endarterectomy with or without bypass surgery) and/or angioplasty (with or without stent placement)
48111363|NCT02587130|DRUG|Ketamine|ketamine administered in bolus by subcutaneous injection
48111364|NCT05589506|DEVICE|Removable partial denture PEEK|A removable partial denture incorporating PEEK and acrylic resin in its composition used as definitive prosthesis to rehabilitate partial edentulism in the maxilla or mandible.
48111365|NCT03368937|DEVICE|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
48111366|NCT03598478|BEHAVIORAL|TC-MPT|Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.
48111367|NCT03598478|BEHAVIORAL|TC|Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.
48111368|NCT03598478|BEHAVIORAL|MPT|Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
48111369|NCT03703037|DIAGNOSTIC_TEST|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
48111370|NCT01513135|BIOLOGICAL|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
48111371|NCT01513135|BIOLOGICAL|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
48111372|NCT03414736|DRUG|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
48111373|NCT03760419|BEHAVIORAL|Clinical Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
48305486|NCT01821170|DRUG|Methylphenidate|Patient will take treatment during two months
48305487|NCT01821170|DEVICE|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
48305488|NCT01821170|BEHAVIORAL|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
48305489|NCT01821170|OTHER|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
48305490|NCT05240950|DRUG|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\^6/kg, 3×10\^6/kg, and 6×10\^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
48305491|NCT00002263|DRUG|Zidovudine|
48305492|NCT00002263|DRUG|Sargramostim|
48305493|NCT01617434|DRUG|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
48305494|NCT01617434|DRUG|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
48305495|NCT00121355|DEVICE|safety glide|
48305496|NCT00121355|DEVICE|autocover needle|
48305497|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
48305498|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
48482033|NCT01345318|BIOLOGICAL|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
48641471|NCT03975829|DRUG|dabrafenib|dabrafenib oral, twice daily
48641472|NCT03975829|DRUG|trametinib|trametinib oral, once daily
48641473|NCT05230407|OTHER|Visual analog scale (VAS) assesment of pain|Post operation VAS score will be assessed before discharge from hospital and 24 hours post operation
48641474|NCT04816292|PROCEDURE|Active Comparator: Hot Snare Polypectomy|Hot Snare Polypectomy with the use of electrocautery for the resection of polyps.
48641475|NCT04816292|PROCEDURE|Experimental: Cold Snare Polypectomy|Cold Snare Polypectomy without the use of electrocautery for the resection of polyps.
48641476|NCT04227522|DRUG|Rucaparib|A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
48305499|NCT01135953|OTHER|Transcranial direct Stimulation (tDCS) and D-cycloserine|"Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session."
48305500|NCT01592851|DRUG|Stannous Fluoride|dentifrice containing stannous fluoride
48305501|NCT01592851|DRUG|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
48305502|NCT04126369|OTHER|mindfulness intervention|The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
48305503|NCT04126369|OTHER|psycho educative programme|The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
48482034|NCT06163872|BEHAVIORAL|survey study|survey study
48111374|NCT02828423|PROCEDURE|EMD|Regenerative surgery with EMD
48111375|NCT02828423|PROCEDURE|BC|Regenerative surgery with BC
48111376|NCT01663519|OTHER|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
48111377|NCT01663519|OTHER|Prefabricated insoles|Prefabricated insoles
48111378|NCT01663519|OTHER|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
48111379|NCT03802032|DRUG|Lidocaine Gel|topical lidocaine gel
48111380|NCT03802032|DRUG|KY jelly|topical KY jelly
48111381|NCT05188781|DRUG|Pembrolizumab combined Anlotinib|Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off
48111382|NCT03534869|PROCEDURE|Ear acupuncture|French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
48111383|NCT03534869|DRUG|Analgesics|Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
48111384|NCT02599818|BEHAVIORAL|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
48305504|NCT02122861|BIOLOGICAL|ID-LV305|pembrolizumab
48305505|NCT05049512|OTHER|Multi-nut OIT|Finely ground pure peanut, almond, cashew, hazelnut, and walnut.
48305506|NCT06552520|DRUG|TQH2722 injection|Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
48305507|NCT06552520|DRUG|Placebo of TQH2722 injection|Placebo without drug substance
48305508|NCT05988541|DIAGNOSTIC_TEST|Ultrasonography imaging|Ultrasonography: rotator cuff tendons (supraspinatus, infraspinatus, subscapularis) integrity, long head of the biceps tendon integrity and location, SASD (subacromial-subdeltoid) bursitis, synovitis and muscle atrophy.
48305509|NCT05988541|DIAGNOSTIC_TEST|American Shoulder and Elbow Surgeons (ASES) Score|"The patient self-assessment (pASES) includes 6 pain items and 10 functional items that are shoulder specific (Angst, 2008).~The pASES form has 3 sections: pain, instability, ADLs (Goldhahn, 2008).~1. Pain section: 4 questions with yes/no responses, 1 question covering number of pain tablets per day, and a VAS (visual analogue scale) from 0 (no pain) to 10 (worst pain).~2. Instability section: 2 questions (1. Response yes/no about feelings of instability, 2. Quantify instability from 0 (stable) to 10 (very unstable)).~3. Activities of daily living (ADLs): Each shoulder is included (affected/non affected), 10 items, with a 4 point ordinal scale, range: 0 (unable to perform activity) to 3 (no difficulty in doing activity) (Goldhahn 2008)."
48305510|NCT05988541|DIAGNOSTIC_TEST|The Constant-Murley score (CMS)|The test is divided into four subscales: pain (15 points), activities of daily living (ADL) (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points).
48305511|NCT05988541|DIAGNOSTIC_TEST|The Disabilities of the Arm, Shoulder and Hand (DASH)|"30-item self-report questionnaire designed to assess symptoms and function of the entire upper extremity.~Total scores range from 0 (minimum) to (100) maximum."
48305512|NCT01518608|DRUG|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
48482035|NCT03916042|DRUG|Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
48482036|NCT03916042|DRUG|Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
48641477|NCT04227522|DRUG|Placebos|Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
48641478|NCT00658814|DRUG|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
48641479|NCT00658814|DRUG|Gemtuzumab Ozogamicin|Given IV
48641480|NCT04712227|OTHER|intubation|intubation
48111385|NCT03289611|BIOLOGICAL|sFlt-1 / PlGF ratio|"* Ambulatory management if sFlt-1 / PlGF ratio is below 38~* usual management if sFlt-1/PlGF is between 38 and 85.~* If the ratio is \> 85, monitoring will be intensified and patient hospitalization will be continued"
48111386|NCT03706261|DRUG|18F-MK-6240|Administration of 5 mCi of 18F-MK-6240 for tau PET.
48111387|NCT03706261|DRUG|18F-Florbetaben|Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
48111388|NCT00922207|DRUG|Adefovir|From week -4 to week 2
48111389|NCT00922207|DRUG|Entecavir|From week -4 to week 2
48111390|NCT00922207|DRUG|Placebo|From week -4 to week 2
48111391|NCT00922207|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
48111392|NCT00373555|PROCEDURE|Bronchoscopy|
48111393|NCT04675944|DRUG|BIA 5-1058|200 mg (2 x 100 mg tablets), oral route
48111394|NCT04675944|DRUG|treprostinil|1 mg (1 extended-release tablet), oral route
48305513|NCT05436613|DEVICE|Transcranial Direct Current Stimulation|tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
48305514|NCT06338865|OTHER|Carbon dioxide|Gas used for insufflation pressure
48305515|NCT06338865|DRUG|Bupivacaine|Local subcutaneous infiltration of all port sites with 0.25% bupivacaine will be performed prior to each incision. Remaining local anesthetic will be administered into the incision sites prior to the conclusion of the case (30cc total).
48305516|NCT06338865|DRUG|Oxycodone|All patients will be prescribed a total of 10 pills of oxycodone 5mg, which is the standard amount that our practice prescribes for patients after laparoscopic surgery.
48305517|NCT03987412|BEHAVIORAL|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
48305518|NCT00239200|DRUG|Lapatinib|
48305519|NCT06300762|DEVICE|Superabsorbent dressing application|Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
48305520|NCT00252486|DRUG|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
48305521|NCT04581980|OTHER|Exercise|Participants will exercise on a cycle ergometer
48305522|NCT04718987|RADIATION|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
48305523|NCT03686254|COMBINATION_PRODUCT|RFA, bevacizumab and second-line chemotherapy|Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
48305524|NCT03686254|DRUG|Bevacizumab and second-line chemotherapy|Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
48305525|NCT00717418|DRUG|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
48305526|NCT00177541|BEHAVIORAL|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
48305527|NCT04141345|DIAGNOSTIC_TEST|cardiopulmonary exercise test|Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
48305528|NCT04875819|DRUG|Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine|One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
48305529|NCT04875819|DRUG|13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine|One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
48641481|NCT04712227|OTHER|mask ventilation|mask ventilation
48305530|NCT02620332|DRUG|MultiPepT1De injection|A mix of peptides
48305531|NCT02620332|OTHER|Placebo|Water for injection
48305532|NCT02899793|DRUG|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
48305533|NCT00034970|BEHAVIORAL|Mindfulness-based at therapy|
48305534|NCT02236546|DIAGNOSTIC_TEST|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
48305535|NCT02236546|OTHER|Molecular assays on biopsied tissue|Correlative studies
48305536|NCT02236546|DEVICE|positron emission tomography|Undergo FDG-PET/CT
48305537|NCT02236546|DEVICE|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
48305538|NCT00833248|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
48305539|NCT00833248|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
48305540|NCT00833248|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
48305541|NCT03119376|OTHER|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
48305542|NCT02558738|DEVICE|ear spray|
48305543|NCT03041116|DRUG|Fosmetpantotenate|Daily dosing
48305544|NCT03041116|DRUG|Placebo|Daily dosing
48305545|NCT05828264|BEHAVIORAL|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
48305546|NCT03032068|OTHER|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
48305547|NCT05405296|DEVICE|Truenat™ MTB Plus/COVID-19|Truenat™ MTB Plus/COVID-19is a disposable, room temperature stable, chip-based Real Time duplex PCR test, along with freeze dried PCR reagents provided in microtube for performing Real Time PCR for infectious disease and runs on the Truelab® Real Time micro-PCR Analyzer.
48305548|NCT06041698|OTHER|Planned Notification|Receive text notification
48305549|NCT06041698|OTHER|Survey Administration|Complete surveys
48305550|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in TXT-Chatbot
48305551|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
48111395|NCT03956641|OTHER|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
48111396|NCT04286529|DRUG|Calcitriol capsules|0.25micrograms, taken daily for eight weeks, orally
48305552|NCT06041698|OTHER|Interview|Ancillary studies
48305553|NCT06041698|OTHER|Survey Administration|Complete surveys
48305554|NCT06041698|OTHER|Planned Notification|Receive email notification
48305555|NCT06041698|BEHAVIORAL|Behavioral Intervention|Participate in MyChart/Patient Portal
48305556|NCT06041698|OTHER|Electronic Health Record Review|Ancillary studies
48482037|NCT01768819|BEHAVIORAL|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
48482038|NCT00932282|DRUG|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
48111397|NCT04286529|DRUG|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
48111398|NCT00839371|DRUG|Propofol|i.v. propofol titration until adequate depth of sedation
48111399|NCT00839371|DRUG|Midazolam|i.v. midazolam titration until adequate depth of sedation
48111400|NCT06318104|DRUG|Tegoprazan|Tegoprazan 50 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
48111401|NCT06318104|DRUG|Esomeprazole 40mg|Esomeprazole 40 mg BID + amoxicillin 1 gr BID + clarithromycin 500 mg BID all for 14 days.
48111402|NCT00282971|DRUG|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
48111403|NCT00282971|OTHER|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
48111404|NCT06513442|OTHER|Trabecular bone score software|To assess the clinical utility of trabecular bone score (TBS) on fracture risk prediction including the new version (TBS V4) and future TBS versions at the spine and hip.
48305557|NCT06041698|OTHER|Interview|Ancillary studies
48305558|NCT01993329|DRUG|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
48305559|NCT01993329|DRUG|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
48305560|NCT01993329|DRUG|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
48305561|NCT01993329|DRUG|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
48305562|NCT01073696|DRUG|granisetron IV|IV
48305563|NCT01073696|DRUG|granisetron patch|patch
48305564|NCT05259553|OTHER|Blood samples|"Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~* Sampling before MM treatment,~* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis."
48305565|NCT01205191|BEHAVIORAL|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
47958700|NCT00533897|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
48111405|NCT01965119|DRUG|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
48111406|NCT04009642|OTHER|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
48111407|NCT03789786|DIAGNOSTIC_TEST|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
48305566|NCT01205191|BEHAVIORAL|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
48305567|NCT01205191|BEHAVIORAL|CBT|CBT for anxiety disorders
48305568|NCT06290830|BEHAVIORAL|Abdominal massage group|abdominal massage creates reflex and mechanical movement of the intestines by applying pressure to the rectum and changing intra-abdominal pressure.
48305569|NCT06290830|BEHAVIORAL|Kegel Exercises group|Kegel exercises (also called pelvic floor exercises) have a functional connection with other core muscles and contribute to the synergistic effect of the abdominal and pelvic floor muscles
48305570|NCT06290830|BEHAVIORAL|Both abdominal massage and kegel exercises to gether|with both exercises are performed to accelerate the peristalsis movement by mechanical movements
48305571|NCT03709888|DRUG|Memantine XR-pregabalin combination therapy|Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
48305572|NCT02085239|DRUG|Lidocaine Ropivacaine|"* 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection"
48305573|NCT02085239|DRUG|Lidocaine alone|
48305574|NCT00817986|DRUG|Arbaclofen placarbil, 20 mg|tablets
48111408|NCT03789786|DIAGNOSTIC_TEST|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
48305575|NCT00817986|DRUG|Placebo|tablets
48305576|NCT00817986|DRUG|Arbaclofen placarbil, 30 mg|tablets
48305577|NCT00817986|DRUG|Arbaclofen placarbil, 40 mg|tablets
47958701|NCT00533897|DRUG|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
48305578|NCT00697047|BEHAVIORAL|Automated Mailing|Usual Care plus Automated mailing
48111409|NCT03789786|BEHAVIORAL|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
48305579|NCT00697047|BEHAVIORAL|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
48305580|NCT00697047|BEHAVIORAL|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
48482039|NCT00932282|DRUG|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
48482040|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
48305581|NCT04126070|DRUG|Androgen Deprivation Therapy|Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
48305582|NCT04126070|DRUG|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
48305583|NCT04126070|DRUG|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
48305584|NCT03095183|DEVICE|Grape flavored Puritan Junior tongue depressor|
47958702|NCT02336373|DRUG|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
47958703|NCT02041078|PROCEDURE|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
47958704|NCT02041078|PROCEDURE|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
47958705|NCT03651505|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
47958706|NCT00306189|DRUG|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
47958707|NCT00306189|DRUG|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
48111410|NCT04225780|DRUG|Low-dose IL-2 and ganciclovir|If patients are eligible, which CMV-DNA are more than 10\^3 copies, it will be randomly distributed in low-dose IL-2 and ganciclovir group, or ganciclovir group. Low-dose IL-2 is defined as 1 million IU per day subcutaneously.
48305585|NCT03095183|DEVICE|Traditional unflavored Puritan Regular Tongue Depressor|
48305586|NCT03868228|PROCEDURE|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
48305587|NCT04567966|PROCEDURE|Split-block technique|Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
48305588|NCT04567966|PROCEDURE|Cortico-cancellous block graft|Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
48305589|NCT02003651|DIETARY_SUPPLEMENT|Quick Defense|Echinacea product from Gaia Herbs.
48305590|NCT02003651|DIETARY_SUPPLEMENT|Placebo|Placebo
48305591|NCT05769842|DRUG|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
48305592|NCT05769842|DRUG|normal saline|Same dose as propofol.
48305593|NCT04174638|OTHER|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
48305594|NCT05356624|OTHER|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
48305595|NCT05356624|OTHER|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
48305596|NCT02574780|OTHER|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
48305597|NCT02574780|OTHER|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
48305598|NCT04417088|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
48305599|NCT04417088|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
48305600|NCT01596075|DRUG|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
48305601|NCT03416582|BEHAVIORAL|Symptom Management Education and Nurse Coaching|"The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration."
48305602|NCT03416582|BEHAVIORAL|Drinks Diary|The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
47958708|NCT00306189|DRUG|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
47958709|NCT00306189|DRUG|Placebo|Placebo SC every 6 months
47958710|NCT00069940|BIOLOGICAL|sargramostim|
47958711|NCT00069940|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
47958712|NCT05114070|OTHER|Decision of hypothermia|Decision of hypothermia thanks to EEG signal
48305603|NCT00380354|DRUG|GSK256066|
48305604|NCT02242890|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
48305605|NCT05831059|RADIATION|Pulsed radio frequency therapy|Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue
48305606|NCT05831059|OTHER|sham operation|The means to achieve double-blind treatment had no practical effect on the subjects
48482041|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
47958713|NCT00311844|DRUG|desloratadine|
47958714|NCT04167982|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
47958715|NCT04167982|DRUG|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
48305607|NCT06390982|RADIATION|Radiotherapy|45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
48305608|NCT06390982|DRUG|Tislelizumab|200 mg IV on Day 1 of each 21-day cycle.
48305609|NCT06390982|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
48305610|NCT06390982|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1 of each 21-day cycle in CAPOX regimen
48305611|NCT06390982|DRUG|Capecitabine|825 mg/m2 orally twice daily (bid) 5 days/week during radiotherapy.
48305612|NCT06017063|OTHER|Psychological intervention|The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
48482042|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
48482043|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
47958716|NCT04167982|DRUG|Oral low-dose isotretinoin|low-dose isotretinoin
47958717|NCT03857399|DRUG|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
47958718|NCT06161870|DRUG|individualized vancomycin dosing based on the population pharmacokinetics (PK) model|The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
47958719|NCT06161870|DRUG|empirical vancomycin dosing|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
48482044|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
48482045|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
48482046|NCT04944082|DRUG|Ivermectin|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
48111411|NCT04951518|OTHER|VAN Stroke Scale|V.A.N Stroke Assessment measures unilateral weakness with visual deficits, aphasia, and neglect in possible stroke patients
48305613|NCT02320799|BEHAVIORAL|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
48305614|NCT02320799|BEHAVIORAL|treatment as usual|Clinic psychosocial treatment as usual
47958720|NCT01216631|DRUG|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
47958721|NCT01216631|DRUG|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
47958722|NCT01216631|DRUG|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
47958723|NCT01332643|GENETIC|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
47958724|NCT04289142|DRUG|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
47958725|NCT05847855|DIAGNOSTIC_TEST|Blood collection|Blood collection for fragmentomic profiles of plasma cell-free DNA
47958726|NCT04905888|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Subjects randomized to treatment will receive up to ten 90 minute treatments with hyperbaric oxygen over a 2-3 week period.
47958727|NCT02836093|BEHAVIORAL|FACIT-Fatigue 52-point questionnaire|
47958728|NCT06557226|OTHER|oral and nutritional examination|Participants will receive a comprehensive oral examination, nutritional examination and will fill an oral health related quality of life questionnaire.
47958729|NCT01203631|DRUG|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
47958730|NCT01203631|DRUG|Placebo|A single dose administered subcutaneously (s.c., under the skin)
47958731|NCT06021288|OTHER|Effluent dose of CRRT|The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
47958732|NCT05521620|BEHAVIORAL|The father-friendly NICU|"* Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker"
47958733|NCT04334057|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available Esperoct® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
47958734|NCT00481143|DRUG|ICL670/Deferasirox|
48305615|NCT00296959|DRUG|topiramate (drug)|
48305616|NCT05714020|OTHER|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
48305617|NCT05714020|OTHER|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
48305618|NCT03288779|DEVICE|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
47958735|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm1|Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
47958736|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm2|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
47958737|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm3|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
47958738|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm4|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
47958739|NCT00806351|DRUG|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
48111412|NCT02035735|PROCEDURE|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
48305619|NCT02676310|DRUG|Bimatoprost|
48305620|NCT06176963|COMBINATION_PRODUCT|SB11 PFS|SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection
48305621|NCT03527056|BIOLOGICAL|Fecal Microbiota Transplantation|This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
48305622|NCT04454996|DRUG|tong-jiang granules|This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
48305623|NCT04454996|DRUG|Chang 'an II Recipe|This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
48305624|NCT04454996|DRUG|The placebo of tong-jiang granules|This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
48305625|NCT04454996|DRUG|The placebo of Chang 'an II Recipe|This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
48305626|NCT04562064|DEVICE|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
48305627|NCT04904653|DEVICE|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~* HEMOPATCH 27 x 27 mm~* HEMOPATCH 45 x 45 mm~* HEMOPATCH 45 x 90 mm"
48305628|NCT04904653|OTHER|Control group|No sealant (liquid, gel or patch) + suction drain
48305629|NCT05469932|DEVICE|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
48305630|NCT06215339|BEHAVIORAL|diet therapy training|diet education
48305631|NCT06517615|BEHAVIORAL|Home Visit Supported Nursing Training Program|Individualized Nurse Education Program with Home Visit Support (• Walking and exercise programs, Disease self-management training for those with chronic diseases, techniques and practices that facilitate medication compliance, vital sign monitoring, • • • Nutrition charts and follow-ups, food characteristics information and weight tracking, cooking activities in the kitchen,• Helping to create family and friend systems, creating neighbor communication mechanisms
48305632|NCT05523362|DEVICE|Dexcom continuous glucose monitor|The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.
48111413|NCT03091010|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
48305633|NCT04975607|BEHAVIORAL|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
48305634|NCT02196194|DRUG|Tiotropium|
48305635|NCT04201769|DRUG|Netupitant/Palonosetron|NEPA is adiministered 60 minutes before chemotherapy, on day 1
48305636|NCT04201769|DRUG|Dexamethasone|"Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm"
48305637|NCT01495897|DEVICE|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
48305638|NCT01495897|DEVICE|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
48305639|NCT05275153|OTHER|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
48305640|NCT00692900|DRUG|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
48305641|NCT00692900|DRUG|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
48305642|NCT06189001|DRUG|Oxytocin|Intravenous oxytocin 0.2 IU/min during experimental days
48305643|NCT06189001|OTHER|Placebo (saline)|Intravenous saline during experimental days
48305644|NCT06222372|DRUG|Rifampin|antibiotic
48305645|NCT04137276|DRUG|vitamin C, vitamin B1|vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
48305646|NCT04137276|DRUG|vitamin B1|thiamine 200 mg/12 hours for 3 days
48305647|NCT05368428|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
48305648|NCT01234402|BIOLOGICAL|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
48305649|NCT01234402|BIOLOGICAL|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
48305650|NCT01234402|DRUG|Capecitabine|"1000 mg/m\^2 orally~Twice a day for 14 days"
48482047|NCT00710749|DEVICE|Disposable device|Disposable urine flow meter
48482048|NCT00710749|DEVICE|Digital device|Digital urine flowmeter
48111414|NCT03091010|DRUG|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
48482049|NCT00710749|DEVICE|Clinic flow measurement|Clinic gold standard flow measurement
48641482|NCT05200780|DEVICE|ultrasound|All subjects will undergo the tests with the same machine. Transverse ultrasound images were obtained using the Philips HD with a 4-12 MHz probe. in neurosonology unit in neurology department.
48641483|NCT05130463|DRUG|empagliflozin/linagliptin|tablet
48641484|NCT04257513|DIAGNOSTIC_TEST|Brain MRI|Neurological and Cognitive evaluation; Brain MRI
48641485|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 1|Participants will use their Radicle Rest Placebo Control Form 1 as directed for a period of 6 weeks.
48305651|NCT04065880|OTHER|TachoSil®|topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
48305652|NCT04065880|OTHER|Neoveil®|bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
48305653|NCT03363048|BEHAVIORAL|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
48305654|NCT03363048|BEHAVIORAL|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
48305655|NCT00137774|DRUG|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
48305656|NCT00137774|DRUG|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
48305657|NCT04356144|DIAGNOSTIC_TEST|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
48305658|NCT04356144|DIAGNOSTIC_TEST|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
48305659|NCT00501566|DRUG|satavaptan (SR121463B)|
48305660|NCT03553329|DRUG|dabrafenib|Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.
48305661|NCT01276067|DRUG|Donepezil|10 mg Tablet
48641486|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 1.1 Usage|Participants will use their Radicle Rest Active Study Product 1.1 as directed for a period of 6 weeks.
47958740|NCT00806351|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
47958741|NCT02433457|DRUG|CC-292|
47958742|NCT02433457|DRUG|Oral Omeprazole (OMP)|
47958743|NCT02060123|BEHAVIORAL|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
48111415|NCT04570631|DRUG|Eftozanermin alfa|Intravenous (IV) infusion
48111416|NCT04570631|DRUG|Bortezomib|Intravenous (IV) or Subcutaneous (SC) injection
48111417|NCT04570631|DRUG|Dexamethasone|Oral Tablet
48111418|NCT06178354|PROCEDURE|Cryosurgery|Undergo focal cryotherapy ablation
48111419|NCT06178354|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo high intensity frequency ultrasound ablation
47958744|NCT02060123|OTHER|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
48111420|NCT06178354|OTHER|Survey Administration|Ancillary studies
48305662|NCT02471248|DEVICE|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
48305663|NCT02471248|DEVICE|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
48641487|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 2|Participants will use their Radicle Rest Placebo Control Form 2 as directed for a period of 6 weeks.
48305664|NCT06196476|BEHAVIORAL|Interactive digital-based educational program|"The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session"
48305665|NCT02891031|DRUG|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
48305666|NCT02891031|DRUG|Placebo|500 mg twice daily after meal for 6 weeks
48305667|NCT03144141|OTHER|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
48305668|NCT03927534|BEHAVIORAL|Mindful Eating|The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
48305669|NCT04160468|DRUG|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
48305670|NCT04160468|DRUG|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
48305671|NCT06556056|OTHER|SesZen-Bio Serum|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liduid Frequency: Daily Night application. Route of administration: Topical"
48305672|NCT06556056|OTHER|Minoxidil hair serum (1%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
48305673|NCT06556056|OTHER|Placebo|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
48305674|NCT03742336|DRUG|PF-04965842|Single oral 200 mg dose of PF-04965842
48305675|NCT03742336|DRUG|Dabigatran|Single 75 mg dose of dabigatran
48305676|NCT00843297|DEVICE|Coolgard|invasive Cooling via femoral ICY-catheter
48305677|NCT00843297|DEVICE|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
48305678|NCT00843297|OTHER|Conventional treatment|Intensive care-treatment without cooling
48305679|NCT01879605|DRUG|Docusate natrium and sorbitol|
48305680|NCT01879605|DRUG|Bisacodyl|
48305681|NCT03968367|PROCEDURE|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
48305682|NCT01045772|DRUG|rilonacept|160mg of rilonacept 1x/week
48305683|NCT03984318|PROCEDURE|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
48305684|NCT01971476|DRUG|volasertib|intravenous administration on day 1of a treatment course
48305685|NCT06429683|OTHER|Sexually transmitted diseases training for young adolescents aged 17-21|Education
48305686|NCT05818293|DEVICE|radiofrquency device|• The radiofrequency system has been used for treatment of subcutaneous fat layers.
48305687|NCT03011840|OTHER|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
48305688|NCT02214186|OTHER|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
48305689|NCT05346601|DRUG|Chiauranib|50mg po only once
48305690|NCT05495074|OTHER|ATP III dietary intervention|The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.
48305691|NCT01358500|DRUG|Fentanyl|Intravenous infusion using STANPUMP
48305692|NCT03492463|DRUG|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
48305693|NCT03492463|OTHER|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
48305694|NCT03492463|OTHER|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
48305695|NCT03492463|OTHER|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
48305696|NCT01543464|DRUG|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
48305697|NCT02298270|BEHAVIORAL|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
47958745|NCT04391491|DIAGNOSTIC_TEST|Neuregulin-1β level in plasma|Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP
47958746|NCT03519178|DRUG|PF-06873600|PF-06873600 tablet for oral dosing
47958747|NCT03519178|DRUG|Endocrine Therapy 1|Endocrine Therapy 1
47958748|NCT03519178|DRUG|Endocrine Therapy 2|Endocrine Therapy 2
47958749|NCT01688518|DRUG|Heated Lidocaine/Tetracaine Patch|
47958750|NCT01688518|DRUG|5% Lidocaine Patch|
47958751|NCT05251246|BEHAVIORAL|recovery management program|The recovery management program consists in training the nurses and physicians during a 15-day training course to optimize their recovery abilities : sleep management according to the schedules by anticipation and recovery, and stress management through cardio-feedback techniques (cardiac coherence) also called controlled breathing techniques and mental imagery.
47958752|NCT03221270|DEVICE|tACS treatment week|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 20 minutes twice for 5 consecutive days.
47958753|NCT03221270|DEVICE|tACS sham week|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds twice a day for 5 consecutive days.
47958754|NCT03221270|DEVICE|Maintenance tACS|10 Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes once a weekly for 8 weeks.
47958755|NCT03221270|DEVICE|Maintenance Sham tACS|10Hz sine wave stimulation with a peak-to-peak amplitude of 2 mA for 10 seconds once a week for 8 weeks.
47958756|NCT05757102|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered.
47958757|NCT05757102|DEVICE|ELLIPTA|FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
47958758|NCT05757102|DRUG|FF/VI|FF/VI will be administered.
47958759|NCT02364492|DRUG|MAG-TN3 + AS15|
47958760|NCT05820945|OTHER|Pharmacist-led medication review|Clinical review by a primary care pharmacist of the primary care clinical history and the pharmacological treatment plan. After the review process, a meeting will be held between the pharmacist and the responsible physician in order to present proposals for pharmacotherapeutic optimization.
47958761|NCT06489925|DRUG|Cerebrolysin|The Cerebrolysin will be administered at least one hour after the standard treatment and no later than 24 hours after the stroke symptom onset.
47958762|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
47958763|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
48111421|NCT05657795|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
48111422|NCT03335969|DEVICE|colon irrigation|Study is to compare bowel movement patterns before and after colon irrigation.
48641488|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 2.1 Usage|Participants will use their Radicle Rest Active Study Product 2.1 as directed for a period of 6 weeks.
48641489|NCT04924075|DRUG|Belzutifan|Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
48641490|NCT05037500|DRUG|Decitabine and Cedazuridine|Given PO
48641491|NCT05037500|DRUG|Enzalutamide|Given PO
47958764|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
47958765|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
47958766|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
47958767|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
47958768|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
47958769|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
47958770|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
47958771|NCT01446926|BIOLOGICAL|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
47958772|NCT01446926|BIOLOGICAL|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
47958773|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
47958774|NCT03236285|BEHAVIORAL|Continous exercise training in the fed state|Continous exercise training in the fed state
47958775|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
47958776|NCT03236285|BEHAVIORAL|Continous exercise training in the fasting state|Continous exercise training in the fasting state
47958777|NCT06005571|PROCEDURE|composite restoration repair by traditional acid etch treatment procedure and adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid and adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
48305698|NCT05880368|OTHER|Patient partnership tools|The intervention consists of two patient partnership tools: (1) a one-page 'visit prep guide' given to relevant patients by clinic staff before seeing the primary care provider, with the intention to improve communication and shared decision-making; and (2) a series of short educational videos that clinic staff can encourage patients to watch. The interventions will be included in the workflow of the clinics during the intervention periods (i.e., clinics either do not use the intervention or use them for all relevant patients depending on study period).
48305699|NCT06368921|BIOLOGICAL|VRT106|intratumoral injection
48305700|NCT00928616|DIETARY_SUPPLEMENT|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
48305701|NCT00928616|DIETARY_SUPPLEMENT|margarine (placebo)|non-sterol ester supplemented margarine
48305702|NCT00520676|DRUG|pemetrexed|500 mg/m\^2, IV, q 21 days x 6 cycles maximum
48305703|NCT00520676|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days x 6 cycles maximum
48305704|NCT00520676|DRUG|carboplatin|AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
48305705|NCT01449591|DRUG|BFH772 1% ointment|
48305706|NCT01449591|DRUG|Vehicle ointment|
48305707|NCT01449591|DRUG|Noritate® 1% cream|
48111423|NCT02048592|DIETARY_SUPPLEMENT|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support \|(Nutridrink) for another 8 weeks."
48111424|NCT02048592|DIETARY_SUPPLEMENT|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
48111425|NCT03141333|BEHAVIORAL|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
48111426|NCT00519129|DEVICE|3D-imager|3D-imager vs fluoroscopy during coloscopy
48111427|NCT05871346|BEHAVIORAL|Complementary feeding counseling|Complementary Feeding Counseling to Improve Appropriate Complementary Feeding Practices and Reduce Child Undernutrition
48111428|NCT01750307|DIETARY_SUPPLEMENT|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
48111429|NCT01750307|DIETARY_SUPPLEMENT|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
48111430|NCT02641990|DRUG|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
48111431|NCT02641990|DRUG|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
48111432|NCT03943459|DRUG|Quercetin|Quercetin 250 mg BID
48111433|NCT00002472|DRUG|cisplatin|
48111434|NCT00002472|DRUG|etoposide|
48111435|NCT00002472|PROCEDURE|conventional surgery|
48111436|NCT00002472|PROCEDURE|neoadjuvant therapy|
48111437|NCT00002472|RADIATION|radiation therapy|
48111438|NCT05774717|DRUG|Tranexamic acid|1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
48305708|NCT05238896|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
48305709|NCT05238896|DRUG|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
48305710|NCT03191396|DRUG|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
48305711|NCT03191396|DRUG|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
48305712|NCT00849979|BEHAVIORAL|Questionnaire|Day 1 MDASI-GI Questionnaire
48305713|NCT00849979|OTHER|Interview|Open-ended, audiotaped interviews
48305714|NCT05935904|OTHER|Exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
48305715|NCT05935904|OTHER|Non exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
48305716|NCT05332067|DRUG|Omalizumab|"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"
48305717|NCT05332067|DRUG|Placebo|Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
48305718|NCT06042699|DIETARY_SUPPLEMENT|Oral ferrous sulfate|Oral ferrous sulfate 325mg is used as a dietary supplement providing 65mg elemental iron.
48305719|NCT06042699|DIETARY_SUPPLEMENT|Oral placebo tablet|Oral placebo tablet provided as placebo comparator.
48111439|NCT04913779|DRUG|Anti-SARS-CoV-2|Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)
48305720|NCT02145299|DEVICE|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
48305721|NCT02145299|DEVICE|CROSSER CTO Device|
48641492|NCT01331330|DEVICE|Deep Brain Stimulation|Normal DBS Programming
48305722|NCT05427825|OTHER|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
48305723|NCT05427825|OTHER|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
48305724|NCT03357276|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
48305725|NCT03550326|PROCEDURE|airway management|patients will be intubated or will be placed an airway device
48305726|NCT04120792|BEHAVIORAL|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
48305727|NCT04120792|BEHAVIORAL|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
48305728|NCT04120792|BEHAVIORAL|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
48305729|NCT04120792|BEHAVIORAL|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
48305730|NCT02775864|DRUG|Antipsychotic|New initiation of any antipsychotic medication
48305731|NCT02775864|DRUG|Antidepressant|New initiation of any antidepressant medications
48305732|NCT02775864|DRUG|Benzodiazepine|New initiation of any benzodiazepine
48305733|NCT02775864|DRUG|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
48305734|NCT04757935|BEHAVIORAL|Yoga|Yoga for 30 minutes three times weekly for 8 weeks in addition to three, 1-hour in-studio yoga sessions.
48305735|NCT05490953|DRUG|Pentoxifylline|Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
48305736|NCT05490953|DRUG|Placebo|Patients will be treated with placebo during the first two chemotherapy cycles of their respective treatment.
48641493|NCT01331330|DEVICE|Deep Brain Stimulation|Low Programming
48111440|NCT04913779|DRUG|Placebo|Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
48305737|NCT04891250|DRUG|Ivermectin|Treatment of SARS Cov-2 patients with Ivermectin
48305738|NCT04891250|OTHER|Prophylaxis|Treatment of high risk population with Ivermectin as prophylaxis
48305739|NCT06350539|OTHER|Biological Sample Collection|Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
48641494|NCT05867940|BEHAVIORAL|Physical activity on prescription|"Physical activity on prescription (PAP) is a well-established method to enhance physical activity in adults in primary care. The prescribed activity should lead to moderate increase of the pulse, such as walking, cycling, swimming, or gardening, and should be performed over a longer period of time in order to achieve a change towards a more active lifestyle. The activity may be prescribed by a physiotherapist, physician, nurse, or other health professional. PAP has shown to be feasible to increase participation in physical activity and to reduce sedentary behaviour in children with cerebral palsy.~Motivational interviewing is used for our PAP with participants with disabilities. During PAP-period, the participants are asked to fill in an activity logbook."
48641495|NCT06642168|GENETIC|Whole exome sequencing to detect myocardial genetic mutations (SCA group only)|Whole exome sequencing to detect myocardial genetic mutations
48641496|NCT03924869|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
48305740|NCT00850759|DEVICE|virtual pedestrian environment|a computer-driven virtual pedestrian environment
48305741|NCT00850759|DEVICE|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
48305742|NCT00850759|BEHAVIORAL|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
48305743|NCT00705224|BIOLOGICAL|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
48305744|NCT00705224|DRUG|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
48305745|NCT00000404|BEHAVIORAL|Patient education in self-care of knee OA|
48305746|NCT06112340|DRUG|linsitinib|Study medication taken twice daily by mouth
48305747|NCT04099316|DEVICE|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
48305748|NCT04099316|DEVICE|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
48305749|NCT03734107|BEHAVIORAL|Plan, Reflect, and Engage with Providers for Diabetes Care|Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
48305750|NCT03912922|OTHER|Activity regime|Activity regime of 4 days followed by a test day.
48305751|NCT01532323|OTHER|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
48641497|NCT03924869|BIOLOGICAL|Pembrolizumab|IV infusion
48305752|NCT03415919|OTHER|no intervention will be given to patients.|samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
48305753|NCT00982306|BEHAVIORAL|Brief intervention|20 minute one to one counseling session
48305754|NCT02884791|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
48305755|NCT00003546|DRUG|gemcitabine hydrochloride|given IV
48305756|NCT00003546|RADIATION|radiation therapy|1.8 Gy to tumor bed
48305757|NCT01595737|DRUG|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
48305758|NCT01595737|DRUG|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
48305759|NCT02796924|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
48305760|NCT00397969|OTHER|counseling intervention|
48305761|NCT00397969|PROCEDURE|screening colonoscopy|
48305762|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
48305763|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
48305764|NCT01318083|DRUG|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
48305765|NCT03552549|BIOLOGICAL|PEG-Intron|Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
48305766|NCT03552549|BIOLOGICAL|INTRON A|Interferon alfa-2b, recombinant for intravenous injection.
48305767|NCT02674997|BIOLOGICAL|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
48305768|NCT03013777|BEHAVIORAL|8-week CBT Program|
48305769|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
48305770|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
48305771|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
48305772|NCT03253406|BEHAVIORAL|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
48305773|NCT03253406|BEHAVIORAL|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
48305774|NCT00005022|DRUG|cisplatin|
48305775|NCT00005022|DRUG|etoposide|
48305776|NCT00005022|RADIATION|radiation therapy|
48305777|NCT00916955|OTHER|Observation|Observe development of syndrome over time
48305778|NCT04438603|DRUG|Intervention for incipient patients at low risk of disease progression|Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
48305779|NCT04438603|DRUG|Intervention for patients at high risk of disease progression|"BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks."
48305780|NCT04503486|DIAGNOSTIC_TEST|handgrip strength|measure of handgrip strength using Jamar Dynamometer and a standardized protocol, strength expressed in kg
48482050|NCT00606502|DRUG|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
48305781|NCT04503486|DIAGNOSTIC_TEST|quadriceps strength|maximal isometric quadriceps strength measured using a handheld dynamometer and a standardized protocol, strength expressed in Newton
48305782|NCT03743584|PROCEDURE|Targeted temperature management|Target temperature management at 33°C
48305783|NCT03743584|PROCEDURE|Standard care, early treatment of fever|Standard of care with early treatment of fever
48305784|NCT06243757|OTHER|MDASI-GI|"The MDASI-GI assesses 5 symptoms specific to gastrointestinal cancer:~constipation diarrhea or watery stools difficulty swallowing change in taste feeling bloated~Using this questionnaire, participants score the severity of their symptoms over the previous 24 hours on a scale of 0 (not present) to 10 (as bad as you can imagine)."
48305785|NCT02329795|RADIATION|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
48305786|NCT02329795|DRUG|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
48305787|NCT00107770|DRUG|sodium phenylbutyrate|histone deacteylase inhibitor
48482051|NCT00606502|DRUG|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
48305788|NCT00985855|DRUG|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
48305789|NCT00985855|DRUG|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
48305790|NCT04215354|DEVICE|Magnetic field|Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
48305791|NCT04215354|DEVICE|Virtual reality|Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
48305792|NCT03124615|DRUG|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
48305793|NCT05925816|BEHAVIORAL|Video|Video uses BA techniques for approximately 5 minutes
48305794|NCT05925816|BEHAVIORAL|Active game|Game provides positive feedback in response to decisions made by participants
48305795|NCT05925816|BEHAVIORAL|Neutral game|Game without feedback
48305796|NCT04229550|BEHAVIORAL|Festival participation|One week's participation in Roskilde Festival 2016 or living a normal daily life.
48305797|NCT01931462|DEVICE|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
48305801|NCT00941616|BIOLOGICAL|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
48305802|NCT00941616|BIOLOGICAL|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
48305803|NCT02889510|DRUG|liraglutide|7-week subcutaneous liraglutide once daily
48305804|NCT02889510|DRUG|placebo|7-week subcutaneous placebo once daily
48305805|NCT00914199|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
48305806|NCT02839967|OTHER|Photobiomodulation|Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
48305807|NCT02839967|OTHER|Photobiomodulation placebo|The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
48305808|NCT02075502|BEHAVIORAL|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
48305809|NCT02075502|PROCEDURE|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
48482052|NCT00606502|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
48482053|NCT00606502|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
48482054|NCT04831086|DRUG|Steroid Drug|Steroids doses will be optimized in the intervention group according the risk based on predictive models
48482055|NCT04831086|DRUG|Tocolytic Agents|Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
48482056|NCT01448356|PROCEDURE|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~1. 25°C and 45% humidity;~2. 25°C and 65% humidity;~3. 30°C and 45% humidity;~4. 30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
48641498|NCT03924869|DRUG|Placebo|IV infusion
48305810|NCT02075502|PROCEDURE|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
48305811|NCT06050863|BIOLOGICAL|silk fibroin|silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films
48305812|NCT06050863|DRUG|Chlorhexidin|chlorhexidine is used
48305813|NCT06050863|BIOLOGICAL|combination of silk fibroin and chlorhexidine|combination of silk fibroin and chlorhexidine is used
48305814|NCT00899743|GENETIC|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
48305815|NCT00899743|GENETIC|western blotting|western blotting
48305816|NCT00899743|OTHER|immunologic technique|immunologic technique
48305817|NCT00899743|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
48305818|NCT04552535|DRUG|Second line (2L) afatinib|Afatinib
48305819|NCT04552535|DRUG|Second line chemotherapy|Chemotherapy
48305820|NCT06554301|DRUG|empagliflozin in treatment pulmonary aerterial hypertension|On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
48305821|NCT06554301|DRUG|placebo in treatment pulmonary aerterial hypertension|On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
48305822|NCT03204838|GENETIC|IDH mutation test performed at diagnosis|Observation of the test result
48305823|NCT05816239|PROCEDURE|Dual Energy CT|Patient will receive Dual Energy CT
48305824|NCT00151762|DRUG|Colesevelam hydrochloride|
48305825|NCT05859880|BEHAVIORAL|Expressive writing intervention|4 videoconference-delivered group-based expressive writing sessions
48305826|NCT01614769|DRUG|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
48305827|NCT01614769|DRUG|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
48305828|NCT01614769|DRUG|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
48305829|NCT01614769|PROCEDURE|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
48482057|NCT02954159|DRUG|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
48482058|NCT02954159|DRUG|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
48305830|NCT00235846|PROCEDURE|vein harvest|Conventional open vein harvest or endoscopic vein harvest
48305831|NCT02512263|PROCEDURE|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
48305832|NCT00026468|DRUG|exisulind|
48305833|NCT05221645|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
48305834|NCT05221645|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
48305835|NCT05221645|DRUG|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
48305836|NCT05221645|DRUG|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
48305837|NCT05221645|DRUG|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
48305838|NCT04180813|DRUG|Linagliptin|drug
48305839|NCT04180813|DRUG|Acarbose|drug
48305840|NCT03415477|DRUG|Denosumab (Xgeva)|Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
48305841|NCT04806932|PROCEDURE|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
48305842|NCT04806932|PROCEDURE|The conventional approach|The conventional approach
48305843|NCT03153215|OTHER|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
48305844|NCT03153215|OTHER|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
48482059|NCT02954159|OTHER|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
48482060|NCT02864004|DRUG|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
48482061|NCT02864004|OTHER|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
48482062|NCT03382431|DRUG|PC786|Repeat doses
48305845|NCT06270940|PROCEDURE|Pulsed Radiofrequency (PRF) Treatment|PRF treatment maintains a temperature below 42°C and does not produce structural tissue damage around the needle. PRF exposure to the Dorsal Root Ganglion (DRG) induces c-Fos gene expression in the dorsal horn, which suggests a cellular response to the electric forces generated within the DRG. PRF has been found to relieve neuropathic pain by inducing long-term depression of synaptic transmission in the spinal cord, leading to a decrease in allodynia and hyperalgesia. It also modulates the inflammatory response in the injured area by decreasing the expression of pro-inflammatory cytokines, such as TNF-α, in the peripheral nerve and spinal cord, which is a major player in the development and maintenance of neuropathic pain. PRF is characterized by a 500 kHz current applied for 2 pulses per second, with each pulse lasting 20 milliseconds.
48305846|NCT04831216|BEHAVIORAL|Type 2 Diabetes Appropriate Food Boxes + Diabetes Education|All participants will be assigned to a single intervention arm. The intervention includes weekly delivery of type 2 diabetes-appropriate food boxes that include diabetes self-management education materials.
48305847|NCT06034834|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
47958778|NCT06005571|PROCEDURE|Composite restoration repair by acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
47958779|NCT06005571|PROCEDURE|Composite restoration repair by sandblasting first, then acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed, the old restoration surface were sandblasted, and the tooth and restoration surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was added to repair the old restoration and restore the carious cavity.
48111441|NCT04613024|DRUG|Topamax|Experiment randomized group will be prescribed Topamax before and after surgery with follow up at regular interval
48111442|NCT04613024|DRUG|Gabapentin|Control group will be prescribed gabapentin after surgery with follow up at regular interval
48111443|NCT05128019|BEHAVIORAL|ICIT|Patients in the intervention group will receive a number of consultations with their GP based on the ICIT
48111444|NCT00929721|PROCEDURE|Blood draw|culture for Streptococcus pneumoniae Frequency-1
48111445|NCT00929721|PROCEDURE|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
48111446|NCT00929721|PROCEDURE|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
48111447|NCT00929721|PROCEDURE|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
48111448|NCT00929721|PROCEDURE|sputum|culture for Streptococcus pneumoniae Frequency-1
48111449|NCT06333132|BEHAVIORAL|Weight loss-induced Diabetes Remission|Patients will undergo a dietary intervention plus drugs (if needed) with the purpose to obtain a 10% (or at least 10 kg) body weight reduction to achieve diabetes remission
48305848|NCT03242278|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
48111450|NCT06237868|DEVICE|rTMS Active|The participants undergo Active rTMS, approximately 10-15 min and then complete tasks and questionnaires.
48305849|NCT05464758|OTHER|Repeated cold exposure|8 consecutive days of exposure to 8°C air for 120 minutes each day
48305850|NCT04017533|PROCEDURE|GMK Sphere TKR|Se earlier
48305851|NCT06242236|OTHER|The respiratory effort parameters guide sedative dosage.|The intervention involves the measurement of respiratory effort using P0.1 and Pocc then calculating to dynamic transpulmonary pressure swing (Predicted ΔPL) to adjust sedative drug dosage.
48305852|NCT01370278|OTHER|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
48305853|NCT01370278|OTHER|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
48305854|NCT04470310|DRUG|Glimepiride|
48305855|NCT04470310|DRUG|Alogliptin 25Mg Tab|
48305856|NCT04470310|DRUG|Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet|
48305857|NCT02482363|RADIATION|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
48482063|NCT03382431|DRUG|Placebo/vehicle|Repeat doses
48482064|NCT03349827|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
48482065|NCT03349827|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
48641499|NCT04651296|BEHAVIORAL|compassion meditation|manualized compassion meditation training
47958780|NCT02178735|PROCEDURE|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
47958781|NCT02178735|PROCEDURE|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
47958782|NCT00828412|DEVICE|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
47958783|NCT00828412|DRUG|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
48111451|NCT06237868|DEVICE|rTMS Sham|The participants undergo Sham rTMS, approximately 10-15 min and then complete tasks and questionnaires.
48111452|NCT00851708|DRUG|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
48111453|NCT05237921|BEHAVIORAL|Combined Exercise and Dietary Intervention (CEDI)|"Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status.~Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Forticare®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake."
48305858|NCT02482363|RADIATION|Sham Control|20 minutes of sham control exposure
48482066|NCT03349827|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
47958784|NCT04941560|OTHER|No intervention|No intervention
47958785|NCT02050243|DRUG|5ALA|20mg/kg of oral suspension of 5ALA
48305859|NCT04339075|OTHER|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
48482067|NCT03349827|DRUG|Apatinib|500mg, once daily, day 1 to day 21.
48482068|NCT01978899|BEHAVIORAL|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
48482069|NCT01978899|BEHAVIORAL|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
48641500|NCT04651296|BEHAVIORAL|health education|manualized health education group
47958786|NCT05395689|BIOLOGICAL|House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
47958787|NCT05395689|BIOLOGICAL|Placebo|The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
47958788|NCT05405868|DRUG|Nicotinomide|Nicotinamide tablets (750mg)
47958789|NCT05405868|DRUG|Matching placebo|Matching placebo
47958790|NCT00545766|DRUG|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
47958791|NCT03070366|DRUG|Chemotherapy|"* cisplatin~* 5FU~* carboplatin~* cetuximab"
47958792|NCT03070366|RADIATION|Stereotactic radiotherapy|Stereotactic radiotherapy
47958793|NCT04613050|OTHER|Respiratory Training|"Respiratory training in form of :~Diaphragmatic breathing,Segmental breathing, Incentive spirometer:"
47958794|NCT04613050|OTHER|Aerobic training|aerobic exercises are customized according to the patient's underlying disease and residual dysfunction. These exercises will include walking on treadmill. After an initial, 5-minute warm-up phase performed on the treadmill at a low load, each endurance training session lasted 30 minutes and ended with 5-minute recovery and relaxation phase. A total of 3-5 sessions are carried out per week. Patients who are prone to fatigue should perform intermittent exercises
47958795|NCT05738603|DEVICE|Hypotension Prediction Index|Hemodynamic perioperative monitoring with the Hypotension Prediction Index
47958796|NCT03841812|DRUG|5mg/kg/h Propofol|5mg/kg/h Propofol continuously infused during intre-operation
47958797|NCT03841812|DRUG|Sevoflurane|1% Sevoflurane continuously using during intre-operation.
47958798|NCT03841812|DRUG|2 mg/kg/h Propofol|2mg/kg/h Propofol continuously infused during intre-operation
47958799|NCT04710264|OTHER|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
47958800|NCT04310046|PROCEDURE|PCI before TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
47958801|NCT04310046|PROCEDURE|PCI after TAVI|TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
47958802|NCT03147677|DRUG|Alfacalcidol|
47958803|NCT03147677|DRUG|Irbesartan|
47958804|NCT05142111|BEHAVIORAL|Therapy|Discussion with therapist
47958805|NCT04021771|OTHER|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
47958806|NCT01984411|PROCEDURE|Radial Technical|Vascular Access for cardiac catheterization
47958807|NCT01984411|PROCEDURE|Femoral Technical|Vascular Access for cardiac catheterization
47958808|NCT01984411|DRUG|Omnipaque|
47958809|NCT06341101|DRUG|Perindopril|In case of side effects Perindopril will be replaced by Valsartan
47958810|NCT03750617|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
47958811|NCT03616275|OTHER|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
47958812|NCT03493607|DRUG|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
48305860|NCT06316258|BEHAVIORAL|Compassion focused therapy group|6 session compassion focused therapy group for adults with ABI
48305861|NCT05399706|DIAGNOSTIC_TEST|CTA Aorta|Computed Tomography Angiography - Aorta Whole
48305862|NCT02041715|DRUG|TKM-100802 for Injection|IV infusion
48305863|NCT02041715|DRUG|Placebo|IV infusion
48641501|NCT00736736|OTHER|Additional Hip Muscle Strengthening to Leg Press Exercise|
48641502|NCT00736736|OTHER|Leg Press Exercise|
47958813|NCT02695901|DRUG|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
47958814|NCT02695901|DRUG|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
47958815|NCT06558591|DEVICE|Telerehabilitation intervention|"Inclusion will take place within the framework of routine care for individuals with chronic diseases in rehabilitation services, hospitals, institutions, etc. The study will be offered to patients with chronic illnesses who are being cared for by their therapists. Data collection will be conducted in two sessions. The period between the two sessions will be determined based on the patient's availability, not exceeding a period of 12 weeks:~1. 1st session at 0 week : Conducting activities and initial evaluation at their usual care center. Therapists will perform the various planned tests and evaluations.~2. 2nd session at 12 weeks : This session will take place under the same conditions as the first one and without any potential health risks to the participants.~3. A final evaluation will be carried out at the 18-week follow-up. A telephone call will be made between sessions to check in and assist participants in case of any issues during the study."
47958816|NCT02898805|OTHER|Placebo|
48305864|NCT01815710|OTHER|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
48305865|NCT01815710|OTHER|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
48305866|NCT02621268|DRUG|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
48305867|NCT05826197|OTHER|Radiomics|PET Radiomics
48305868|NCT01032512|DIETARY_SUPPLEMENT|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
48305869|NCT01032512|DIETARY_SUPPLEMENT|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
48305870|NCT02951988|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
48305871|NCT02951988|DRUG|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
48305872|NCT03344601|BEHAVIORAL|physical activity|The program will consist of 18 face-to-face coaching sessions (\~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
48305873|NCT03781882|PROCEDURE|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
48305874|NCT03781882|PROCEDURE|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
48305875|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact|The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
48482070|NCT02681484|BEHAVIORAL|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
48641503|NCT06132893|DRUG|BHV-7000|BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
47958817|NCT02898805|OTHER|Prescribed Diet|
47958818|NCT02898805|DIETARY_SUPPLEMENT|LopiGLIK®|
47958819|NCT02898805|DIETARY_SUPPLEMENT|Armolipid Plus|
47958820|NCT06220773|DRUG|BR1019A|Subjects take the investigational products once a day for 12 weeks.
47958821|NCT06220773|DRUG|BR1019B|Subjects take the investigational products once a day for 12 weeks.
47958822|NCT06220773|DRUG|BR1019C|Subjects take the investigational products once a day for 12 weeks.
48111454|NCT05237921|BEHAVIORAL|Standard Care|Standard Care
48111455|NCT01624168|BEHAVIORAL|Anxiety Management Education|written materials on management of anxiety for self-study
48111456|NCT01624168|BEHAVIORAL|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
48641504|NCT06132893|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
48641505|NCT06132893|DRUG|Placebo|Matching placebo taken once daily
48641506|NCT05644977|DRUG|Emraclidine|Oral tablets
48641507|NCT05644977|DRUG|Placebo|Oral tablets
48305876|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing|Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
48305877|NCT03288272|RADIATION|Whole Brain Radiotherapy|Radiotherapy of the whole brain
48305878|NCT03288272|OTHER|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
48305879|NCT05055635|RADIATION|Pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
48305880|NCT03615755|OTHER|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
48305881|NCT02422953|DIETARY_SUPPLEMENT|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
48305882|NCT02422953|DIETARY_SUPPLEMENT|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
48305883|NCT02422953|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
48305884|NCT02422953|BEHAVIORAL|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
48305885|NCT03092258|OTHER|Questionnaire|Questionnaire to be completed by staff
48305886|NCT03930212|DRUG|Progesterone|received rectal progesterone suppositories 400 mg once daily
48305887|NCT03930212|DRUG|Placebos|received placebo suppositories rectally once daily.
48305888|NCT01850849|DRUG|LEO 39652 cream|
48305889|NCT01850849|DRUG|cream vehicle|
48641508|NCT04103645|DRUG|Vactosertib|This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
48641509|NCT04105634|DRUG|FNOS|The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
48641510|NCT04105634|DRUG|Florbetaben|The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
48305890|NCT01168713|DRUG|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
48305891|NCT01168713|DRUG|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
48305892|NCT01477190|DRUG|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
48305893|NCT01477190|DRUG|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
48305894|NCT05478044|DRUG|Ascorbic acid|Ascorbic acid IV ampoules (20%).
48305895|NCT05478044|OTHER|saline|saline (0.9%)
48305896|NCT01940757|BIOLOGICAL|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
48305897|NCT05121727|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
48305898|NCT05121727|PROCEDURE|Deep and Superficial Serratus Anterior Plane Block|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
48305899|NCT02689336|BIOLOGICAL|Erlotinib|
48305900|NCT02689336|DRUG|Temozolomide|
48305901|NCT04181567|OTHER|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
48305902|NCT04181567|DRUG|agomelatine|agomelatine
48305903|NCT04181567|DRUG|Placebo|placebo
48305904|NCT03689283|OTHER|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
48305905|NCT03689283|OTHER|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
48305906|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
48305907|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
48305908|NCT00495560|DRUG|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
48305909|NCT02384499|BIOLOGICAL|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
48305910|NCT02384499|DRUG|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
48305911|NCT03756974|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
48305912|NCT03756974|DRUG|Placebo|Placebo of BX-1, oral solution
48305913|NCT05727566|OTHER|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
48305914|NCT03736837|DRUG|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
48305915|NCT03484000|BEHAVIORAL|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
48305916|NCT06168864|DIAGNOSTIC_TEST|Artificial intelligence models for segmentation and characterization of prostate cancer|rtificial intelligence algorithms for the automatic segmentation of prostate cancer lesions on medical images.
48305917|NCT03201198|BEHAVIORAL|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
48305918|NCT03201198|BEHAVIORAL|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
48305919|NCT04366986|OTHER|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
48305920|NCT04366986|OTHER|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
48305921|NCT03295097|OTHER|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
47958823|NCT06220773|DRUG|BR1019A-1|Subjects take the investigational products once a day for 12 weeks.
48305922|NCT03548597|DEVICE|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
48305923|NCT06499545|OTHER|Pressure release|Release of pre-pressure at the latent trigger point of flexor digitorum brevis
47958824|NCT06220773|DRUG|BR1019B-1|Subjects take the investigational products once a day for 12 weeks.
48305924|NCT06499545|OTHER|Non emision Laser|Non emision laser in Flexor digitorum brevis latent trigger point
48305925|NCT04090931|PROCEDURE|Orthodontic treatment|leveling and aligning stage in orthodontics
48305926|NCT04090281|GENETIC|CYP2C19 genotyping|Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
48305927|NCT05367687|DRUG|Camrelizumab、Rivoceranib|Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.
48305928|NCT05367687|DRUG|Camrelizumab|Camrelizumab: 200 mg, intravenous infusion.
47958825|NCT06220773|DRUG|BR1019C-1|Subjects take the investigational products once a day for 12 weeks.
47958826|NCT02367443|RADIATION|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
47958827|NCT00552565|DRUG|Rezular 15mg|Oral Tablets
47958828|NCT00552565|DRUG|Placebo|placebo
47958829|NCT00552565|DRUG|Rezular|Rezular 37.5mg 3xday up to 12 weeks
47958830|NCT00552565|DRUG|Rezular|Rezular 75mg 3xday up to 12 weeks
47958831|NCT02938104|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
48305929|NCT05257239|OTHER|no intervention|National University Health System,
48305930|NCT01849250|DRUG|Docosahexaenoic Acid|Given PO
48305931|NCT01849250|OTHER|Placebo|Given PO
48305932|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with a marked tip
48305933|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with an unmarked tip
48305934|NCT04150874|DIAGNOSTIC_TEST|Lumason®|Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
48305935|NCT06401512|BEHAVIORAL|Guided self-determination (GSD) follow-up approach by primary care nurses.|The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.
48305936|NCT03190720|DEVICE|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
48305937|NCT00530322|PROCEDURE|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
48305938|NCT01783626|DEVICE|Evodial|
48305939|NCT01783626|DEVICE|Evodial+ Condition B1|
48305940|NCT01783626|DEVICE|Evodial+ Condition B2|
48305941|NCT01783626|DEVICE|Evodial+ Condition C|
48305942|NCT03156556|BEHAVIORAL|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
48305943|NCT04081844|DRUG|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
48305944|NCT04081844|DRUG|HGP0904|Amlodipine 5mg(Norvasc)
48305945|NCT04081844|DRUG|HGP0608|Losartan 100mg(Cozaar)
48305946|NCT00959296|DEVICE|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
48305947|NCT01926041|DRUG|Varenicline for tobacco smoking cessation|The 16-week varenicline course conforms to real-practice government regulations in Taiwan.
48305948|NCT01926041|BEHAVIORAL|Individualized counseling about both smoking cessation and weight control techniques|The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.
48305949|NCT02379156|DRUG|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
48305950|NCT02379156|OTHER|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
48305951|NCT02223221|PROCEDURE|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
48305952|NCT02223221|GENETIC|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
48305953|NCT02223221|OTHER|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
48305954|NCT01241838|DEVICE|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
48305955|NCT01954121|DRUG|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~* Down-titration Period (Week 30 up to Week 33)"
48305956|NCT01954121|DRUG|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~* Down-titration Period (Week 30 up to Week 33)"
48305957|NCT05972135|DRUG|Teclistamab|Teclistamab will be administered subcutaneously at step-up doses on Day 1, Day 4 and Day 8, one week after first treatment dose and weekly thereafter. In participants who have a partial response (PR) or better after 6 months of therapy, dosing frequency may be reduced to every 2 weeks.
48305958|NCT05972135|DRUG|Talquetamab|Talquetamab will be administered subcutaneously at step-up doses on Day 1, Day 4, Day 8 and Day 15, one week after first treatment dose and every 2 weeks thereafter. In participants who have a very good partial response (VGPR) or better after Cycle 4, dosing frequency may be reduced to every 4 weeks
48305959|NCT05972135|DRUG|Tocilizumab|Tocilizumab will be administered as a pretreatment medication in advance of administration of the first step-up dose of teclistamab or talquetamab on Cycle 1 Day 1.
48305960|NCT04478292|DRUG|Sodium Thiosulfate Injection|Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
48305961|NCT04478292|PROCEDURE|Primary surgery resection|Resection of the primary tumor up-front
48305962|NCT04478292|DRUG|mono CDDP-Group A2|Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
48305963|NCT04478292|DRUG|Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C|All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
48305964|NCT04478292|PROCEDURE|Biopsy|Tumors are deemed unresectable at diagnosis.
48305965|NCT04478292|PROCEDURE|Resection or transplant|Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
48305966|NCT04478292|PROCEDURE|Resection of pulmonary nodules|Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
48305967|NCT04478292|DRUG|mono CDDP- Group B|Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
48305968|NCT04478292|DRUG|Block 1 to 3 (Cisplatin, Doxorubicin) Group D|Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
48305969|NCT04478292|DRUG|Consolidation (Carboplatin, Doxorubicin) -Group D1|Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
48305970|NCT04478292|DRUG|Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2|"Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;"
48305971|NCT03357822|DRUG|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
48305972|NCT03357822|DRUG|Entecavir|0.5mg entecavir is orally taken every day
48305973|NCT03357822|DRUG|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
48305974|NCT05183958|RADIATION|Radiotherapy group|Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 \>60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;
48305975|NCT05183958|DRUG|Camrelizumab|4 cycles for combined therapy. Camrelizumab maintenance.
48111457|NCT01624168|BEHAVIORAL|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
48305976|NCT05183958|DRUG|Chemotherapy|4 cycles for combined therapy.
48305977|NCT04610242|DIAGNOSTIC_TEST|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
48305978|NCT06059378|DEVICE|Artificial intelligence-assisted classification (CADx)|CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
48305979|NCT03535701|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
48305980|NCT03535701|OTHER|Laboratory Biomarker Analysis|Correlative studies
48111458|NCT05219617|DRUG|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\])."
48305981|NCT03535701|DRUG|Paclitaxel|Given standard of care therapy with paclitaxel
48305982|NCT03535701|OTHER|Quality-of-Life Assessment|Ancillary studies
48305983|NCT03535701|OTHER|Questionnaire Administration|Ancillary studies
48305984|NCT03919253|COMBINATION_PRODUCT|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
48305985|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
48305986|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
48305987|NCT04922892|PROCEDURE|Parathyroidectomy|Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
48305988|NCT03534258|DEVICE|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
48305989|NCT00084682|DRUG|romidepsin|Given IV
48305990|NCT03641989|OTHER|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
48305991|NCT03641989|OTHER|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
48305992|NCT04964830|DEVICE|Orthodontic treatment with functional appliance (MAD)|Expansion plate and z-activator (MAD)
48305993|NCT06306612|DRUG|Systemic Chemohormonal Therapy|Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
48305994|NCT06306612|DRUG|Systemic Hormonal Therapy|Under continuous ADT, oral darolutamide 600mg twice per day
48305995|NCT06306612|PROCEDURE|Cytoreductive Prostatectomy|Cytoreductive prostatectomy was performed after six cycles of neoadjuvant systemic chemohormonal therapy.
48305996|NCT06306612|PROCEDURE|Postoperative Adjuvant Radiotherapy|Postoperative adjuvant radiotherapy of prostate bed is performed, if margin positive, with conventional segmentation and the dose of 64-72Gy.
48305997|NCT05572229|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
48305998|NCT05572229|DRUG|Daratumumab|Daratumumab will be administered via a subcutaneous injection (SC)
48305999|NCT05572229|DRUG|Lenalidomide|Lenalidomide will be administered orally
48306000|NCT04558645|OTHER|Online Survey|Online surveys will be applied to all participants
47958832|NCT02938104|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
48111459|NCT04459819|OTHER|Respiratory physiotherapy|"Respiratory physiotherapy consists of:~* early mobilization (passive and active mobilization, muscle-strengthening exercises, mobilization out of bed, standing, walking, ADL)~* patients positioning~* non-invasive mechanical ventilation / CPAP~* tracheostomy management~* invasive mechanical ventilation weaning~* airway clearance~* oxygen titration"
47958833|NCT02938104|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
47958834|NCT02632331|DRUG|ASP8825|Oral
48306001|NCT03950570|DRUG|Abraxane|"The doses of ORIN1001 in both dose escalation and dose expansion will be 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600mg, 800 mg, 1,000 mg, 1,200 mg Weekly paclitaxel will be 80 mg/m2 given intravenously for the dose escalation and dose expansion phases.~cohorts as follows: 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,300 mg and 1,500 mg administered for 21 days (one cycle)."
48306002|NCT01740622|OTHER|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
48306003|NCT04420481|DRUG|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
48306004|NCT04420481|DRUG|Placebo|Placebo
47958835|NCT05178888|DRUG|MRTX849|KRAS G12C inhibitor
47958836|NCT05178888|DRUG|Palbociclib|CDK 4 and 6 inhibitor
48306005|NCT05547763|PROCEDURE|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
48306006|NCT02016417|DRUG|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
48306007|NCT02016417|DRUG|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
48306008|NCT01587872|PROCEDURE|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
48306009|NCT02750813|DEVICE|Delefilcon A contact lenses|
48306010|NCT02750813|DEVICE|Senofilcon A contact lenses|
48306011|NCT01984346|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax|Convergent Epicardial Endocardial Ablation Procedure
48306012|NCT01984346|DEVICE|Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering|Endocardial Catheter Ablation Procedure
48111460|NCT00929617|BEHAVIORAL|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
48306013|NCT02179515|BIOLOGICAL|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
48306014|NCT01348282|DRUG|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
48306015|NCT01348282|DRUG|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
48306016|NCT01996345|PROCEDURE|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
48306017|NCT05005208|OTHER|rehabilitation program with the support of the technological platform SI-ROBOTICS|"A 16-treatment session will be conducted, divided into 2 training sessions per week, for 8 weeks. The therapy sessions last 60 minutes; each session will involve 2 patients at time. Cardiac and respiratory activity monitoring is planned during robotic treatments in order to detect the heart rate during physical activity. Individual participants must complete at least 80% of the sessions. Recovery of 2 sessions will be possible.~Each session involves the following activities:~* Breathing, relaxation and postural harmonization exercises;~* Active mobility and stretching exercises;~* Irish dance with the SI-ROBOTICS system;~* Relaxation exercises."
48306018|NCT01096082|DRUG|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
48306019|NCT01096082|DRUG|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
48306020|NCT02597842|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
48306021|NCT03321552|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
48306022|NCT03321552|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
48306023|NCT02535949|DRUG|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
48306024|NCT02535949|OTHER|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
48306025|NCT00872170|DRUG|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
48306026|NCT04617613|DRUG|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
47958837|NCT05246683|OTHER|observational|registry
47958838|NCT03252860|OTHER|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
47958839|NCT00400764|DRUG|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
48111461|NCT00929617|OTHER|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
48306027|NCT04617613|DRUG|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
47958840|NCT00400764|DRUG|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
47958841|NCT05084131|OTHER|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
48306028|NCT01295905|DEVICE|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
48111462|NCT04881318|OTHER|Waist-High Compression Tights|Waist-high compression tights providing 15-40 mmHg of pressure.
48306029|NCT01295905|DEVICE|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
48306030|NCT04114994|DIAGNOSTIC_TEST|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
48306031|NCT05379361|BEHAVIORAL|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
48306032|NCT05379361|BEHAVIORAL|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
48306033|NCT06554223|BEHAVIORAL|SUSTAIN-DSD|"Participants randomized to SUSTAIN-DSD will be enrolled into an Adherence Club and will have 6 months of ART dispensed through a pre-packed dispensing service. Participants may choose to use the decentralized pick-up point solely for medication retrieval or may opt into the peer-support aspect of the Clubs by attending the group session of up to 30 PWH, who will meet once every 6 months in a safe space (e.g., clinic meeting room, church, or local library).~At 6 months, 12 months, and every 12 months thereafter, a visiting nurse will draw a blood specimen for viral load. Optional process uptake will be recorded. Participants with a raised viral load will be called and offered enhanced adherence counselling; then recalled for a repeat viral load in 3 months."
48306034|NCT06554223|OTHER|Enhanced (guideline-driven) Standard of Care (E-SoC)|"As per current SA ART guidelines, all patients who are \>28 days late for a scheduled visit are offered enhanced adherence counselling (EAC) at reengagement and restarted on ART. Patients who are \>90 days late also have blood drawn for a CD4 count to test for advanced HIV disease. Individual clinic visits occur every 3 months, with 3-month ART dispensing. VL testing is repeated 3 months after restart, then at 12 months and annually there-after, if suppressed.~These visits will be managed by clinic staff (nurse or doctor). EAC is a single counselling session delivered by a lay counsellor.~The study team will ensure all SoC processes are complete as per the guidelines; and reported to the COCT team as appropriate."
48111463|NCT04881318|OTHER|Abdominal Compression Garments|Abdominal compression garment compressing the abdomen, buttocks, and upper thighs.
48306036|NCT02869867|OTHER|refrigerated cushion|refrigerated cushion
48306037|NCT05323786|PROCEDURE|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
48306038|NCT05323786|PROCEDURE|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
48306039|NCT03536429|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
48306040|NCT03536429|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
48306041|NCT02461914|DRUG|PEX168|200µg,injected subcutaneously,once a week.
48306042|NCT02461914|DRUG|Warfarin|5mg,oral,two times.
48111464|NCT04881318|DRUG|Medications that modulate heart rate and blood pressure|Medications that modulate heart rate and blood pressure that participants regularly take. These medications include beta-blockers, midodrine, ivabradine and stimulants.
48306043|NCT02030561|DRUG|Trastuzumab + NK cells|
48306044|NCT00483288|OTHER|educational intervention|
48306045|NCT00483288|OTHER|questionnaire administration|
48306046|NCT00483288|OTHER|study of socioeconomic and demographic variables|
48306047|NCT00483288|OTHER|survey administration|
48306048|NCT03958617|DEVICE|Bilateral Deep brain stimulation of the thalamus, Medtronic Device|
48306049|NCT01879618|DRUG|Fragmin|variable dosing regimen
48306050|NCT05170893|DIETARY_SUPPLEMENT|Coenzyme Q10|Oral capsules
48306051|NCT05170893|OTHER|Placebo|Oral capsules
47958842|NCT06177522|DRUG|Adebrelimab|1200mg，i.v. , q3w
47958843|NCT06177522|DRUG|albumin-bound paclitaxel|125 mg/m2, i.v.,d1,d8, q3w
47958844|NCT06177522|DRUG|Gemcitabine|1.0 g/m2, i.v.,d1, d8, q3w
47958845|NCT05749965|PROCEDURE|Unicompartmental knee arthroplasty|medial unicompartmental knee arthroplasty
47958846|NCT01402765|DEVICE|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
47958847|NCT01402765|DEVICE|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
47958848|NCT02703831|PROCEDURE|Dual attending|Two attending spine surgeons perform surgery
47958849|NCT02703831|PROCEDURE|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
47958850|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
47958851|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
48482071|NCT00725621|BIOLOGICAL|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
47958852|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
47958853|NCT06043726|DIAGNOSTIC_TEST|Laboratory testing: D-dimeer and astrup|Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
47958854|NCT05849701|DEVICE|Shock wave therapy|using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session for 6 weeks.
47958855|NCT05849701|DEVICE|Vacuum-assisted closure|Using KCI's Vacuum Assisted Closure Device for six weeks, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, the dressings were changed on the fourth day.
47958856|NCT05913258|DEVICE|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
47958857|NCT05913258|DEVICE|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
47958858|NCT03719586|DRUG|ZMapp|Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
47958859|NCT03719586|DRUG|Remdesivir|Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight \>= 40 kg and for pediatric patients weighing \< 40 kg remdesivir 2.5 mg/kg)
47958860|NCT03719586|DRUG|MAb114|50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
47958861|NCT03719586|DRUG|REGN-EB3|150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
47958862|NCT01630642|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
47958863|NCT02592525|BEHAVIORAL|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
47958864|NCT04281303|PROCEDURE|Endoscopic vertical gastroplasty|endoscopic vertical gastroplasty + lifestyle modification
47958865|NCT00372671|BEHAVIORAL|Survey|
47958866|NCT00372671|BEHAVIORAL|Survey and videotape|
47958867|NCT02698046|DIETARY_SUPPLEMENT|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
47958868|NCT02698046|DIETARY_SUPPLEMENT|Placebo starch|200mg of placebo starch three times a day for 4 months
47958869|NCT01631110|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
47958870|NCT05668884|COMBINATION_PRODUCT|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab|Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
47958871|NCT00811759|DRUG|sorafenib tosylate|
48306052|NCT03274336|BEHAVIORAL|questionnaire|questionnaire post preanesthetic interview
47958872|NCT00811759|DRUG|temozolomide|
47958873|NCT00811759|GENETIC|gene expression analysis|
47958874|NCT00811759|GENETIC|mutation analysis|
47958875|NCT00811759|OTHER|laboratory biomarker analysis|
47958876|NCT00811759|OTHER|pharmacological study|
47958877|NCT00811759|PROCEDURE|biopsy|
48306053|NCT03274336|BEHAVIORAL|face-to-face interview|Group A = face-to-face interview
48306054|NCT03274336|BEHAVIORAL|brochure|after reading a brochure a face to face interview will take place
48306055|NCT03274336|BEHAVIORAL|movie|after seeing a film about the procedure a face-to-face interview will take place
48482072|NCT03179449|DIAGNOSTIC_TEST|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
48482073|NCT03179449|PROCEDURE|Surgery|Undergo surgical resection
48482074|NCT03179449|DRUG|Ferumoxytol|Given IV
48482075|NCT03179449|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
48482076|NCT04254640|DRUG|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
47958878|NCT05582473|BEHAVIORAL|LST-LC Education|"Testing the LST-LC intervention with cultural adaptations integrated through Stage 2 (Adaptation Design). There are 9 modules.~Session 1, we describe the principles underlying the program (safety, hygiene, dignity, comfort, and independence), discuss self-care, and introduce a vignette of caring for a person with dementia, designed to generate conversation around the caregiving role.~Other modules focus on 1) behavioral and 2) communication challenges in the context of dementia; 3) home safety, transfers, and adaptable medical equipment; 4) managing nutrition needs; 5) swallowing challenges; 6) supporting oral hygiene; 7) dealing with incontinence, including preventing and recognizing urinary tract infections; 8) medication management and 9) managing comorbidities including assessing and managing pain"
47958879|NCT06057844|OTHER|Additional blood sampling|Once you have been informed and have given your consent, 2 tubes of venous blood (citrated tubes of approximately 5 milliliters (ml) each) will be taken after the blood donation to enable in vitro thrombus formation. The entire sample will be used, and no surplus will be kept in the bank.
47958880|NCT04887844|DRUG|Lidocaine injection|Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
48111465|NCT02753413|BIOLOGICAL|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
48111466|NCT02753413|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
48111467|NCT02245334|DRUG|Povidone-Iodine|1 pill per biopsy
48111468|NCT03941912|DEVICE|Erchonia EVRL|Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
48111469|NCT02778958|DRUG|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
48111470|NCT02778958|DRUG|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
48111471|NCT02910635|DRUG|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
48641511|NCT04755062|BEHAVIORAL|Micronutrient-dense plant-rich Intervention|"The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes."
48641512|NCT04951206|DEVICE|Fractionated CO2-laser|All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.
48641513|NCT04951206|DRUG|Clobetasol Propionate 0.05% Ointment|Clobetasol propionate 0.05% ointment obtained from a commercial manufacturer
48111472|NCT02910635|DRUG|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
48111473|NCT02910635|DRUG|Placebo|
48111474|NCT04560855|DEVICE|Connected devices measurements|The patient has to measure everyday several vital parameters like respiration and heart rate during the night with Withings Sleep, temperature with Withings Thermo, arterial pressure with Withings Tensiometer and physical activity with Withings smartwatch.
48111475|NCT04378062|PROCEDURE|Digital nerve procedure|The type of procedure performed on the digital nerve at the time of amputation
48111476|NCT01157182|DRUG|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
48482077|NCT04254640|DRUG|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
48482078|NCT04254640|DRUG|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
48482079|NCT04254640|DRUG|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
48641514|NCT02271919|DRUG|Nicotine Lozenge|Given PO
48111477|NCT01157182|DRUG|Activella®|1/0.5 mg Tablets
48111478|NCT00903266|BEHAVIORAL|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
48111479|NCT00903266|BEHAVIORAL|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
48111480|NCT01546155|RADIATION|PET imaging|Up to a 120 minute PET scan using \[11C\]diprenorphine as the radiotracer
48111481|NCT00521937|OTHER|Dermagen®|Weekly topical applications
48111482|NCT00476333|DEVICE|APOS biomechanical gait system|
48111483|NCT01196936|DRUG|Tamoxifen Citrate|5 mg PO Daily
48111484|NCT01196936|DRUG|Placebo|1 tablet daily
48111485|NCT01196936|PROCEDURE|Digital mammography|Correlative studies
48111486|NCT01196936|OTHER|immunohistochemistry staining method|Correlative Studies
48111487|NCT01196936|OTHER|pharmacological study|Correlative Studies
48111488|NCT01196936|OTHER|laboratory biomarker analysis|Correlative Studies
48111489|NCT01196936|GENETIC|protein expression analysis|correlative studies
48111490|NCT01196936|OTHER|pharmacogenomic studies|correlative studies
48111491|NCT01196936|OTHER|questionnaire administration|Ancillary studies
48111492|NCT01196936|PROCEDURE|Fine needle aspiration|
48482080|NCT06014528|DRUG|IN10018|100mg QD orally (PO)
48482081|NCT06014528|DRUG|Placebo of IN10018|100mg QD orally (PO)
48482082|NCT06014528|DRUG|Pegylated Liposomal Doxorubicin|40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
48482083|NCT02946684|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
48111493|NCT01196936|OTHER|Quality of Life Assessment|Ancillary Studies
48306056|NCT02954835|DEVICE|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
48306057|NCT02954835|DEVICE|Traditional Dressing|Sterile gauze dressing secured by tape.
48306058|NCT03471754|DEVICE|TESA-HB Transcranial Electronic Stimulation Device|Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
48306059|NCT02998008|BEHAVIORAL|high intensity interval training|
48306060|NCT00386893|PROCEDURE|simultaneous EEG/fMRI|fMRI/EEG recordings
48306061|NCT00386893|DEVICE|fMRI|
48306062|NCT05687994|BEHAVIORAL|Audiovisual Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, auditory, and visual cues for speaking
48306063|NCT05687994|BEHAVIORAL|Auditory Speech Entrainment Practice|Speech Entrainment Practice is an aphasia rehabilitation treatment based on imitation of recorded speech in real time. Treatment includes repeated practice of speaking along with a recorded model, which provides contextual, temporal, and auditory cues for speaking
48306064|NCT05375903|DRUG|UGN-301|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
48306065|NCT05375903|DRUG|UGN-201|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
48306066|NCT05375903|DRUG|Gemcitabine|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
48306067|NCT00112151|DRUG|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
48306068|NCT00112151|BEHAVIORAL|Resistance Training|Weight training 45-60 minutes 3 times per week
48306069|NCT00112151|DRUG|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
48306070|NCT00112151|DRUG|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
48111494|NCT00000635|DRUG|Trifluridine|
48111495|NCT00000635|DRUG|Bacitracin zinc/Polymyxin B sulfate|
48111496|NCT00545077|DRUG|Letrozole|
48111497|NCT00545077|DRUG|Bevacizumab|
48111498|NCT00545077|DRUG|Fulvestrant|
48306071|NCT00540436|DRUG|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
48306072|NCT04451434|DRUG|Danicopan|Oral tablet
48306073|NCT05396066|DIAGNOSTIC_TEST|Muscle evaluation|Repeated maximal voluntary contraction
48306074|NCT00918528|PROCEDURE|Internal urethrotomy|
48306075|NCT00918528|DRUG|Mitomycin C - local injection|
48306076|NCT04385797|OTHER|Telephone interview|Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
48306077|NCT02041546|DRUG|Lung lavage with surfactant|
48306078|NCT02041546|DRUG|Bolus surfactant|
48306079|NCT02610556|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
48641515|NCT02271919|DRUG|Nicotine Patch|Given via patch
48641516|NCT02271919|OTHER|Placebo|Given PO or via patch
48111499|NCT00354406|DRUG|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
48111500|NCT03005678|DRUG|Denosumab|active treatment group
48111501|NCT03005678|DRUG|Alendronate|comparator
48111502|NCT04812938|DIAGNOSTIC_TEST|Patients with Ovarian cancer and pap test available|Define the possibility to detect through the pap test the presence of ovarian cancer cells in vaginal smear in patients with no evidence of ginecological malignancies.
48111503|NCT00228007|DRUG|Antidepressant Medication|
48306080|NCT02610556|DRUG|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
48111504|NCT04871750|DIETARY_SUPPLEMENT|Soy protein|Daily consumption for 24 weeks
48111505|NCT04871750|DIETARY_SUPPLEMENT|Casein protein|Daily consumption for 24 weeks
48306081|NCT02610556|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
48306082|NCT02610556|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
48306083|NCT05727163|DRUG|Dexamethasone|25mg via HAI (Pre-chemotherapy)
48306084|NCT05727163|DRUG|Anisodamine|10 mg via HAI (Pre-chemotherapy)
48306085|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 via HAI over 3 hours
48306086|NCT05727163|DRUG|Leucovorin|200 mg/m2 via HAI
48306087|NCT05727163|DRUG|Fluorouracil|400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
48306088|NCT05727163|DRUG|Irinotecan|150 mg/m2 intravenously
48306089|NCT05727163|DRUG|Bevacizumab|5 mg/kg intravenously
48306090|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 intravenously over 3 hours
48306091|NCT05727163|DRUG|Leucovorin|200 mg/m2 intravenously
48306092|NCT05727163|DRUG|Fluorouracil|400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
48306093|NCT03476018|DRUG|Z-100|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
48306094|NCT03476018|DRUG|Placebos|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
48482084|NCT02946684|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
48641517|NCT02271919|OTHER|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
48641518|NCT02271919|DRUG|Varenicline|Given PO
47958881|NCT04887844|DRUG|Corticosteroid injection|Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
47958882|NCT04887844|OTHER|Conventional Physical therapy|The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
47958883|NCT05257655|PROCEDURE|MRI after ganglionic local opioid analgesia (GLOA)|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
48306095|NCT04713020|OTHER|Intervention:APP educational programs|Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression
48482085|NCT01918579|PROCEDURE|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
47958884|NCT00049192|BIOLOGICAL|oblimersen sodium|Given IV
47958885|NCT00049192|DRUG|imatinib mesylate|Given PO
47958886|NCT00049192|OTHER|laboratory biomarker analysis|Correlative studies
47958887|NCT00312559|BEHAVIORAL|Yoga Training|
47958888|NCT05213481|DRUG|Tepotinib|Participants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
48111506|NCT03988569|OTHER|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
48111507|NCT02931383|DRUG|Liraglutide 3 mg (Saxenda)|
48111508|NCT02931383|DRUG|Liraglutide 3 mg placebo|
48111509|NCT03040661|PROCEDURE|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
48111510|NCT03631537|OTHER|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
48306096|NCT04713020|OTHER|No Intervention:general care|general care
48306097|NCT00003943|BIOLOGICAL|filgrastim|5 ug/kg
47958889|NCT05213481|DRUG|Carbamazepine|Carbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.
48306098|NCT00003943|DRUG|carboplatin|AUC 5
48306099|NCT00003943|DRUG|cyclophosphamide|3 gm/m2
48306100|NCT00003943|DRUG|paclitaxel|250 mg/m2
48482086|NCT05198882|PROCEDURE|Laser technology for intracerebral thermocoagulation|One intervention : LITT (Laser Interstitial Thermal Treatment), technology that uses laser energy to thermally destroy (photo-thermal treatment) a brain injury under continuous MRI control (Validated by FDA - CE marking). The operator console + surgical laser generator + software that manages the power delivered by the laser is connected to an MRI - Provided by MEDTRONIC - FDA approved and CE certified.
48482087|NCT06415214|DRUG|Placebo|Placebo
48482088|NCT06415214|DRUG|HRS-7535|HRS-7535
47958890|NCT00702039|OTHER|No Music|No music will be played in patients in arm 2 of the study.
47958891|NCT00702039|OTHER|Music Therapy|Classical music being played during intravitreal injection.
47958892|NCT03296098|DRUG|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
48111511|NCT04372394|DRUG|surufatinib|Surufatinib: 300 mg as a single dose on Days 1 and 8 with or without food
48111512|NCT02403219|DRUG|Botulinum toxin type A injection|Injection of botulinum toxin type A
48111513|NCT02403219|OTHER|Saline solution injection|Injection of saline solution
48111514|NCT06374732|BEHAVIORAL|High-intensity interval training|The experimental group will perform 6-to-10-minute of high-intensity interval training at the beginning of their physical education lessons or physical activity lessons.
48111515|NCT06374732|BEHAVIORAL|Control group|The control group will maintain their normal behaviour, including regular physical education lessons and physical activity lessons.
48111516|NCT00043264|DRUG|Rifampin|
48111517|NCT00043264|DRUG|Azithromycin|
48111518|NCT03291470|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
48111519|NCT03291470|BIOLOGICAL|Placebo Control|2 mL normal saline intraarticular injection
48111520|NCT06245746|BIOLOGICAL|umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)|UCMSC-Exo will be infused intravenously.
48306101|NCT00003943|DRUG|topotecan hydrochloride|10 mg/m2
48306102|NCT00003943|PROCEDURE|peripheral blood stem cell transplantation|harvest via apheresis
48306103|NCT01082913|DEVICE|SSE|Use of SSE or not use of SSE
48306104|NCT01829035|OTHER|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~  1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
47958893|NCT06289569|OTHER|Home telerehabilitation therapy|Occupational therapist prescribed hand/arm exercises will be assigned to patients. Records of each subject's motor tasks, number of repetition and level of performance will be kept. Standard of care home therapy will be performed Monday-Friday for approximately 4 weeks, followed by 4 weeks of application-driven home teletherapy. It is expected that approximately 20 treatments will be finished in 4weeks, however the amount of therapy completed will be recorded to accommodate patients' schedules. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
48306105|NCT04561843|DIAGNOSTIC_TEST|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
47958894|NCT02233114|OTHER|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
48111521|NCT01771666|DEVICE|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
48111522|NCT01771666|DRUG|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
48111523|NCT01771666|DRUG|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
48111524|NCT01771666|DRUG|99technetium-sulfur colloid radiolabel|
48306106|NCT01566123|RADIATION|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
48306107|NCT01566123|RADIATION|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
48306108|NCT05844800|PROCEDURE|Nuss repair of Pectus Excavatum|The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.
47958895|NCT02233114|OTHER|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
47958896|NCT03847714|DIETARY_SUPPLEMENT|Omni-Biotic Stress Repair|The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).
47958897|NCT03847714|DIETARY_SUPPLEMENT|placebo|similar looking and tasting powder
47958898|NCT01754870|DRUG|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
48111525|NCT05125133|OTHER|ITENs + ITWS|A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
48111526|NCT01760837|OTHER|Baked milk products to cow's milk allergic patients|
48111527|NCT02578108|PROCEDURE|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
48111528|NCT02578108|PROCEDURE|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
48111529|NCT06392633|PROCEDURE|spastic hand sugery|Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.
48111530|NCT06392633|DRUG|Botulinum Toxin A|Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
48111531|NCT01180153|DRUG|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
48111532|NCT02010372|OTHER|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
48111533|NCT02010372|OTHER|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
48111534|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with TPRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the TPRF as a sole grafting material.
48111535|NCT05721612|OTHER|Flapless transcrestal sinus lift approach with PRF|Including 8 patients who will be treated by flapless transcrestal sinus floor elevation using the PRF as a sole grafting material.
48306109|NCT05844800|DRUG|Epidural anesthesia|The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
48306110|NCT06194435|OTHER|Remote Monitoring of Participant Progress and Well-being via Video Calls|Participants with Rotator Cuff Syndrome undergo remote evaluations via video calls with a physician. On the same day, they receive an asynchronous exercise brochure containing instructions for performing home exercises three times a day. They are also provided with an exercise diary to track their daily exercise sessions. Follow-up assessments and discussions about their condition take place remotely on video calls with the physician on the 7th and 15th days. During the final video call on the 15th day, participants are asked to submit their exercise diaries via WhatsApp for assessment of exercise adherence.
47958899|NCT03329508|DRUG|P2B001 0.6/0.75 mg|Fixed low dose extended release combination capsule of pramipexole and rasagiline
47958900|NCT03329508|DRUG|Rasagiline 0.75 mg|Rasagiline 0.75 mg oral extended release capsule, component
47958901|NCT03329508|DRUG|Pramipexole 0.6 mg|Pramipexole 0.6 mg oral extended release capsule, component
47958902|NCT03329508|DRUG|Marketed Pramipexole ER|Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
47958903|NCT04328766|DRUG|DWC202005, alone|DWC202005, as a single dose
48111536|NCT01287052|DRUG|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
48111537|NCT04955119|DIAGNOSTIC_TEST|Fusion imaging contrast-enhanced ultrasound|"Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue"
48111538|NCT00910754|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
48111539|NCT00910754|DRUG|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
48306111|NCT06194435|OTHER|Face-to-Face Clinic-based Monitoring of Participant Progress and Well-being|Participants with Rotator Cuff Syndrome undergo in-clinic evaluations by a physician, during which they receive an exercise brochure with instructions for performing home exercises three times a day. They are also given an exercise diary to track their daily exercise sessions. On the 7th and 15th days, participants return for follow-up assessments and discussions about their condition. During the final clinic visit, participants are requested to submit their exercise diaries for assessment of exercise adherence.
48306112|NCT05669482|DRUG|avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel|The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
48306113|NCT01823822|DIETARY_SUPPLEMENT|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
48306114|NCT01823822|DIETARY_SUPPLEMENT|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
48306115|NCT03175393|DEVICE|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
47958904|NCT04328766|DRUG|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
47958905|NCT04328766|DRUG|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
47958906|NCT00434954|DRUG|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
47958907|NCT00434954|DRUG|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
47958908|NCT05608759|BEHAVIORAL|Multimodal prehabilitation|4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
47958909|NCT03959553|DRUG|GV1001|Lyophilized peptide from hTERT
47958910|NCT03959553|DRUG|Normal saline|0.9% normal saline
47958911|NCT04210596|PROCEDURE|Soft tissue augmentation at the buccal aspect of single implants|Soft tissue augmentation is performed following mucoperiosteal flap elevation at the buccal aspect of single implants. The connective tissue graft (control) or collagen matrix (test) is inserted in the buccal pouch and attached with monofilament sutures.
47958912|NCT02500160|DEVICE|Patient specific instrumentation (MRI)|
47958913|NCT02500160|DEVICE|Patient specific instrumentation (CT)|
47958914|NCT00001071|DRUG|Filgrastim|
47958915|NCT00831025|BIOLOGICAL|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
48111540|NCT01492218|DRUG|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
48111541|NCT02128607|DEVICE|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
48111542|NCT02128607|DEVICE|Sham|
48111543|NCT02987530|DRUG|Dolutegravir|Oral use, 50mg/day
48111544|NCT02987530|DRUG|Darunavir-cobicistat|Oral use, 800-150mg/day
48111545|NCT02987530|DRUG|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
48111546|NCT04940117|DIETARY_SUPPLEMENT|Eefooton oral solution|Check eGFR value, liver and kidney function every month
47958916|NCT00831025|BIOLOGICAL|Placebo|Placebo for subcutaneous monthly administration
47958917|NCT01196507|DRUG|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
47958918|NCT01196507|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
47958919|NCT01289080|DRUG|OPC-34712|administered orally
48306116|NCT02567344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
48306117|NCT02567344|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
48306118|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
48306119|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
48306120|NCT04000672|PROCEDURE|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
48306121|NCT04000672|PROCEDURE|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
48306122|NCT02219555|DRUG|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
48111547|NCT02298140|OTHER|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
48111548|NCT04676984|OTHER|Consultations|The intervention will comprise a series of consultations between the patient and general practitioner (at least three), where the patient and general practitioner will continuously adjust the patient's medication according to the patient's goals, needs, and preferences.
48482089|NCT00369382|DRUG|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
48482090|NCT00369382|DRUG|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
47958920|NCT02911220|GENETIC|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
48111551|NCT04353037|DRUG|Group 1 HCQ|Enrolled participants randomized in Group 1 receive the HCQ drug
48111552|NCT04353037|DRUG|Group 2 Placebo|Enrolled participants randomized in Group 2 will receive a placebo drug
48111553|NCT01239563|DRUG|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
48306123|NCT02219555|PROCEDURE|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
48482091|NCT05298787|DRUG|RLS-0071|RLS-0071 is administered as an IV infusion
48482092|NCT05298787|DRUG|Saline Placebo|Placebo is administered as an IV infusion
48111554|NCT01239563|DRUG|Basiliximab|Intravenous 20mg, day 0\&4
48111555|NCT01334320|PROCEDURE|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
48111556|NCT04533464|BIOLOGICAL|MultiStem|Intravenous Infusion
48306124|NCT04761094|DEVICE|Insulin pump|Treatment with continuous subcutaneous insulin infusion
48306125|NCT05249543|BEHAVIORAL|Unified protocol|Transdiagnostic cognitive-behavioral therapy
48306126|NCT05249543|BEHAVIORAL|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
48306127|NCT00676481|BEHAVIORAL|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
48111557|NCT04533464|BIOLOGICAL|Placebo|Intravenous Infusion
48306128|NCT00757562|DRUG|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
48306129|NCT00757562|DRUG|Placebo|placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
48482093|NCT04115709|DEVICE|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
48482094|NCT04115709|DEVICE|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
47958921|NCT03055156|DEVICE|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
47958922|NCT03055156|DEVICE|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
47958923|NCT03191422|BEHAVIORAL|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
47958924|NCT06139965|OTHER|Validity and Reliability|Assessment study
48111558|NCT01025843|DRUG|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
48111559|NCT01025843|DRUG|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
48111560|NCT01025843|DRUG|Comparator: Pbo|Placebo
48306130|NCT04769960|DIAGNOSTIC_TEST|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
48306131|NCT04769960|BEHAVIORAL|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
48306132|NCT05179369|BEHAVIORAL|Standard Care with Well-Mama Intervention|The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
48306133|NCT03222479|BEHAVIORAL|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
48111561|NCT06552884|BEHAVIORAL|(Maternity Identity Development Training)|Monitoring the Effect of the Education Given to Parents According to Maternal Role Ability Theory on Maternal Role Mother-Baby and Father-Infant Attachment
48111562|NCT04484402|BIOLOGICAL|mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells mixed with sodium hyaluronate 1% solution
48111563|NCT04484402|BIOLOGICAL|limbal stem cells|Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution
48111564|NCT04484402|OTHER|standard treatment|Standard treatment according to the Clinical protocols
47958925|NCT06157359|PROCEDURE|scalp nerve block|In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.
47958926|NCT03816384|DEVICE|Standard of Care|Standard of care urinary drainage system.
47958927|NCT03816384|DEVICE|DLC Group|Urinary drainage system with active drain line clearance and plain silicone catheter.
48111565|NCT04333758|DEVICE|Jintronix Virtual Reality Telerehabilitation System|"System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training."
48111566|NCT03776890|BEHAVIORAL|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
48111567|NCT02329613|OTHER|Standard evening meals.|Patients will receive usual evening meals.
48111568|NCT02329613|OTHER|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
47958928|NCT03816384|DEVICE|DLCS Group|Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
48306134|NCT06498739|DRUG|Erector spinae plane block(15 ml bupivacaine 0.5%)|Patients will preoperatively receive high concentration-low volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% }, for each patient).
48111569|NCT06040333|OTHER|Exercise|Dynamic Neuromuscular Stabilisation Exercise
48111570|NCT06040333|OTHER|Standard therapy|Patient education, massage, diaphragmatic breathing, kegel exercise
48111571|NCT05172752|OTHER|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
47958929|NCT02028754|DRUG|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
47958930|NCT02028754|DRUG|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
48111572|NCT05172752|OTHER|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
48306135|NCT06498739|DRUG|Erector spinae plane block (15 ml bupivacaine 0.5% and 15ml normal saline)|Patients will preoperatively receive low concentration-high volume ultrasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline}, for each patient.
47958931|NCT02028754|DRUG|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
48306136|NCT01383200|DRUG|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
48306137|NCT01383200|DRUG|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
48306138|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to MC-EVOO|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
47958932|NCT04486911|DRUG|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
48306139|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to refined oil|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
48111573|NCT03126656|DRUG|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
48306140|NCT05994794|DIETARY_SUPPLEMENT|Alpha-GPC, Creatine and Ashwagandha (Sensoril®)|Other Ingredients: Microcrystalline Cellulose, Rice Fiber, Maltodextrin, Silica, Vegetable Stearate
48306141|NCT05994794|OTHER|Placebo|Microcrystalline Cellulose
48306142|NCT05557890|BEHAVIORAL|System Constellation VR-Seminar|individual-centered intervention in a group VR-setting, duration 2 to 3 days
48306143|NCT00797459|DEVICE|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
48306144|NCT01180374|DRUG|Cannabidiol|Active Cannabidiol 5mg.
48111574|NCT05501548|DRUG|Olaparib|Olaparib 300mg by mouth twice daily
48111575|NCT05501548|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid 1g/kg administered intravenously twice weekly
48306145|NCT01180374|DRUG|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
48306146|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
48111576|NCT04778917|DRUG|Low-Molecular-Weight Heparins Calcium Injection|We use different dose of low-molecular-weight heparins calcium injection to different interventions
48111577|NCT02577198|OTHER|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
47958933|NCT00099541|DRUG|zoledronic acid|
47958934|NCT05944211|DRUG|Hetrombopag Olamine|"The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator."
47958935|NCT01476956|OTHER|Observational study|RA patients on standard DMARD therapy
47958936|NCT00553943|DRUG|Rituximab|375 mg/m2 D1
47958937|NCT00553943|DRUG|Cytarabine|50 mg D3
47958938|NCT00000430|DRUG|Alendronate|
47958939|NCT00000430|DRUG|Estrogen/progestin therapy|
47958940|NCT02728596|OTHER|Preventive Intervention|Automated ordering system recommends prescribing or not prescribing CSF based on drug's risk level for FN
48111578|NCT06028282|RADIATION|SPECT|SPECT of thyroid traced with I-131
48111579|NCT04385355|DEVICE|Conventional transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
48111580|NCT04385355|DEVICE|Narrow transmucosal abutment design|The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
48306147|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
48306148|NCT03066817|DRUG|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
48306149|NCT03066817|DRUG|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
48306150|NCT03800706|DRUG|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
48306151|NCT06109116|OTHER|Self myofascial release+ Conventional PT|The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel Conventional PT including Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise concentrating on the medial arch for 2 minutes in sitting position,with as much pressure as they could, pushing into discomfort but not pain Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility
48306152|NCT06109116|OTHER|Conventional PT|"Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise .~Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins"
48641519|NCT06695715|BEHAVIORAL|Mindfulness Training Program|This mindfulness training program is based on the Mindfulness-Based Stress Reduction (MBSR) model developed by Jon Kabat-Zinn, incorporating elements of self-compassion and acceptance. What sets this program apart is its integration of both formal and informal practices. Participants engage in 45-minute guided sessions focused on breath awareness and the observation of thoughts, emotions, and physical sensations. Additionally, informal practices include brief daily moments of present-moment awareness. Participants will also receive 10 audio recordings for at-home practice, enhancing the program's accessibility and supporting consistency.
48641520|NCT06695715|BEHAVIORAL|HRV Biofeedback|This HRV biofeedback training program is distinguished by its combination of advanced technology and a novel at-home methodology. Participants will engage in five weekly sessions, with four conducted at home using a heart rate sensor and the EliteHRV mobile app, which provides real-time feedback on heart rate variability. One session per week will take place in the lab, utilizing the Procomp Infiniti biofeedback system. The at-home approach is based on recent research (Schumann et al., 2021), offering participants a flexible yet structured method to practice biofeedback and improve heart rate variability over the six-week program.
48111581|NCT00532220|DRUG|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
48111582|NCT00532220|DRUG|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
48111583|NCT02808039|OTHER|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
48111584|NCT06257693|DRUG|enzalutamide|Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy
48111585|NCT05672849|DEVICE|Modified Surgical Instruments/Devices (Sheaths and Irrigator)|Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
48111586|NCT06261775|OTHER|Red meat-based meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
48111587|NCT06261775|OTHER|Lacto-ovo-vegetarian meal|Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
48306153|NCT05480787|DRUG|Remimazolam 0.1mg/kg/h|Remimazolam Tosilate for Injection(36mg)
48306154|NCT05480787|DRUG|Remimazolam 0.3mg/kg/h|Remimazolam Tosilate for Injection(36mg)
48306155|NCT05480787|DRUG|Remimazolam 0.5mg/kg/h|Remimazolam Tosilate for Injection(36mg)
48306156|NCT05687201|DIAGNOSTIC_TEST|Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)|Non-surgical patients were followed up by CT on days 1 and 5-7 after ICH, and by CT or MRI on day 5-7. Surgical patients were followed up by CT before surgery and then transferred to the operating room. The first postoperative follow-up CT scan was performed on the second day after surgery, and the second postoperative CT scan was performed on the third day after surgery. Some patients need a third or even a fourth CT follow-up after surgery. The CT scan can be repeated at any time if the patient has neurologic deterioration.
47958941|NCT02728596|OTHER|Quality-of-Life Assessment|Ancillary studies
48111588|NCT04130165|OTHER|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
48111589|NCT06464172|OTHER|Acute Oral gamma-aminobutyric acid (Natural Health Product in Canada)|1800 mg (3 capsules of 600mg) of GABA taken at the research center under the supervision of the research team.
48111590|NCT06464172|OTHER|Acute Placebo|A capsule filled with powdered sugar taken under the supervision of the research team.
48306157|NCT02674581|DRUG|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
48306158|NCT05447377|BIOLOGICAL|SII Yellow Fever Vaccine|"SII YF vaccine:~Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-213 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 5 mg of sorbitol per dose."
48482095|NCT04076488|OTHER|Dividat Fit|tablet based, remote assisted home-training
48111591|NCT03068858|DIAGNOSTIC_TEST|real-time feedback of SYNTAX score category|
48111592|NCT04033042|DEVICE|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
48111593|NCT00179335|PROCEDURE|Blood drawing to determine drug levels|
47958942|NCT02728596|OTHER|Questionnaire Administration|Ancillary studies
47958943|NCT06095804|DEVICE|Percutaneous Ultrasound Jejunostomy|Placement of a jejunostomy tube using the PUMA-J System
47958944|NCT06013397|DIETARY_SUPPLEMENT|Ketogenic diet|"Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy."
47958945|NCT01796483|DEVICE|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
47958946|NCT01796483|DEVICE|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
47958947|NCT00968214|GENETIC|polymorphism analysis|
47958948|NCT00968214|OTHER|laboratory biomarker analysis|
47958949|NCT01062204|DEVICE|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
47958950|NCT01062204|DEVICE|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
47958951|NCT04432285|DEVICE|DBS-device, implanted in GPi bilaterally|Chronic/continuous bilateral GPi-DBS
47958952|NCT04432285|DRUG|Botulinum toxin|Repeated intramuscular injections at regular intervals of around 3 months
47958953|NCT06184386|OTHER|NIDCAPARENTALIM|PARENTALIM practice that strengthens the NIDCAP. It is proposed in a routine way in the NICU since 2019. PARENTALIM supports and monitors parental implication in nursing care. It is led by a speach language therapist specialized in early feeding development who proposes 5 individualized interviews and uses an educational booklet on eating development care with a lot of illustrations and few words.
47958954|NCT06184386|BEHAVIORAL|SOFS|SOFS is a behavioral practice of orofacial stimulations. Il has been mainly carried out by nurses or a speach language therapist specialized in early feeding development. SOFS has been applied through routine protocol in the NICU until 2018.
48111594|NCT04013646|DRUG|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
48306159|NCT05447377|BIOLOGICAL|STAMARIL®|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL® is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-204 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 8 mg of sorbitol (E420) per dose."
48306160|NCT02134314|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
48306161|NCT02134314|DRUG|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
47958955|NCT01507012|DIETARY_SUPPLEMENT|Berry Polyphenols|
47958956|NCT01507012|DIETARY_SUPPLEMENT|Placebo|Placebo control containing sugar and artificial flavouring.
48306162|NCT05146973|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
47958957|NCT00843856|DRUG|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
47958958|NCT00843856|DRUG|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
47958959|NCT00303901|PROCEDURE|cryosurgery|
47958960|NCT00303901|PROCEDURE|positron emission tomography|
47958961|NCT04530526|PROCEDURE|Regenerative Peripheral Nerve Interface|The regenerative peripheral nerve interface (RPNI) has emerged as a novel strategy to treat neuromas in peripheral nerves. The RPNI consists of the residual peripheral nerve end implanted in a skeletal muscle graft, following surgical resection of the injured terminal nerve portion (neuroma). The free muscle graft is separated from its native nerve innervation, leaving open neuromuscular junctions for ingrowth and attachment of nerve fibers from the implanted nerve.
47958962|NCT04057365|DRUG|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
47958963|NCT04057365|DRUG|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
47958964|NCT06294782|RADIATION|STereotactic Arhythmia Radioablation (STAR)|STereotactic Arhythmia Radioablation (STAR)
47958965|NCT03948672|DEVICE|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
47958966|NCT04368676|OTHER|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
47958967|NCT04368676|OTHER|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
47958968|NCT04450446|DRUG|Low molecular weight heparin|Anticoagulation therapy
48306163|NCT04249141|OTHER|Survey and concept mapping|ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
48306164|NCT00001262|DRUG|Copper Histidine|
48306165|NCT00006360|DRUG|radioprotection|
47958969|NCT02016001|OTHER|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
48306166|NCT00006360|RADIATION|radiation therapy|
48306167|NCT06233032|DRUG|Ephedrine|Patient Will receive 6mg IV
48306168|NCT06233032|DRUG|Dexmedetomidine|Patient Will receive 30mcg IV
48482096|NCT01371084|BEHAVIORAL|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
48482097|NCT01371084|BEHAVIORAL|Pedal@Work|Worksite wellness program.
48641521|NCT06695715|BEHAVIORAL|Interoception Training|The interoception training program stands out by its focus on developing internal body awareness through structured guided sessions. Participants will engage in weekly 45-minute formal sessions at the university, where they will learn to focus on internal sensations like breath and muscle tension using specific techniques. Additionally, participants will receive 10 guided interoceptive exercises to practice at home, four times a week. This program not only focuses on the physical sensations but also integrates these practices into daily life, aiming to improve self-care and self-regulation over the six weeks, with personalized feedback provided.
48641522|NCT06535139|BEHAVIORAL|Brief training|Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.
48306169|NCT03283163|BEHAVIORAL|Exercise Testing and Training|The study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
48641523|NCT06535139|BEHAVIORAL|Parent-targeted motivational aids|Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.
47958970|NCT02016001|OTHER|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
47958971|NCT06556589|BEHAVIORAL|Collaborative Care|Collaborative care components include patient-centered team care, population-based care, measurement-based treatment to target, evidence-based care, and accountable care.
47958972|NCT00241085|DRUG|valsartan|
47958973|NCT05057182|BIOLOGICAL|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
47958974|NCT05944887|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
47958975|NCT05944887|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
48306170|NCT01253512|DRUG|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
48306171|NCT01253512|DRUG|Placebo|Intravenous
48306172|NCT05769803|DIAGNOSTIC_TEST|Nasal and mouth swab|"Whinin 7 days from diagnosis, the subjects will be requested to sample another two specimens i.e. nasal swab and mouth swab, that will be tested for the presence of SARS-CoV-2 RNA. Results, expressed as cycle threshold will be then compared to analyze viral loads from the two different sites.~Moreover, an aliquot will be retro-transcribed into cDNA and sequenced by Next Generation Sequencing (NGS) to obtain the virus entire genome sequence or evaluated by RT-PCR for variantdetermination."
48306173|NCT02379234|OTHER|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
48306174|NCT03771144|PROCEDURE|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
48482098|NCT01937247|PROCEDURE|Patients will be inducted in the induction room|The patients will be inducted in the induction room
48482099|NCT01937247|PROCEDURE|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
48482100|NCT01937247|DRUG|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
48482101|NCT01937247|PROCEDURE|STANDARD PROCESS|standard process
47958976|NCT05944887|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol
47958977|NCT05944887|PROCEDURE|gastroscopy|esogastroduodenoscopy
47958978|NCT05675176|DRUG|BCG|Intravesical Instillation
47958979|NCT02985372|DRUG|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
47958980|NCT02985372|DRUG|Cytarabine|
47958981|NCT02369432|DRUG|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
48306178|NCT03544671|DIETARY_SUPPLEMENT|Vitamin D|
48306179|NCT06177834|DEVICE|Alisklamp|Alisklamp
48306180|NCT06177834|OTHER|Dorsal slit circumcision technique|In this group, included the patients who will operated with dorsal slit circumcision technique
48306181|NCT05054933|OTHER|ultrasound capsule endoscopy|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
48306182|NCT05329688|PROCEDURE|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
48306183|NCT01199263|OTHER|Laboratory Biomarker Analysis|Correlative studies
48306184|NCT01199263|DRUG|Paclitaxel|Given IV
48306185|NCT01199263|BIOLOGICAL|Pelareorep|Given IV
48306186|NCT02474940|BEHAVIORAL|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
48306187|NCT02474940|BEHAVIORAL|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
48306188|NCT02474940|BEHAVIORAL|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
48306189|NCT00505700|DRUG|velcade|
48306190|NCT00505700|DRUG|Idarubicin|
47958982|NCT05190588|OTHER|Mesotherapy|Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
48306191|NCT00505700|DRUG|Cytarabine|
48482102|NCT04047537|OTHER|Medical Food Formulation 1|WBF-0011
48482103|NCT04047537|OTHER|Medical Food Formulation 2|WBF-0011 (0.2X concentration)
48641524|NCT06535139|BEHAVIORAL|Healthcare access|Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.
48641525|NCT00792948|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
48641526|NCT00792948|DRUG|Cyclophosphamide|Given IV
48641527|NCT00792948|DRUG|Cytarabine|Given IT
48641528|NCT00792948|DRUG|Dasatinib|Given PO
47958983|NCT05095597|PROCEDURE|Injection of hUC-PRP by hysteroscopy|PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.
47958984|NCT05095597|DRUG|Oestraclin|Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
47958985|NCT05095597|PROCEDURE|Umbilical cord blood collection|The SCU will be collected using a blood collection bag containing anticoagulant. This step will be performed by the medical and nursing staff of the obstetrics service of the HUP La Fe. The blood collection bags will be the following, or similar: Cord Blood Collection Bags from MACOPHARMA; CPD Umbilical Cord Bag from GRIFOLS.
47958986|NCT05095597|PROCEDURE|Endometrial biopsy|Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.
47958987|NCT00384501|DEVICE|Intacs|
48641529|NCT00792948|DRUG|Dexamethasone|Given IV or PO
48641530|NCT00792948|DRUG|Doxorubicin Hydrochloride|Given IV
48641531|NCT00792948|DRUG|Etoposide|Given IV
47958988|NCT05686889|OTHER|Patient self-report|Simulated patient following structured script
47958989|NCT02128802|PROCEDURE|Gastric Bypass|
47958990|NCT02128802|OTHER|Weight Loss Program|
47958991|NCT00242437|DEVICE|Hemostatic matrix|
47958992|NCT00242437|DEVICE|bovine thrombin|
47958993|NCT03999177|BEHAVIORAL|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
47958994|NCT00644228|DRUG|Bortezomib|Given IV
47958995|NCT00644228|DRUG|Dexamethasone|Given PO
47958996|NCT00644228|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
47958997|NCT00644228|DRUG|Lenalidomide|Given PO
47958998|NCT01275040|OTHER|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
47958999|NCT01275040|OTHER|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
47959000|NCT01971840|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
47959001|NCT00463112|DRUG|Sibutramine|
47959002|NCT03045185|PROCEDURE|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
47959003|NCT04690933|OTHER|Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients|Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
47959004|NCT02789995|PROCEDURE|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
47959005|NCT01021722|PROCEDURE|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
47959006|NCT04925661|DRUG|HEC53856|Either dose of HEC53856 will be administered after fasting .
47959007|NCT04925661|DRUG|Roxadustat|Roxadustat will be administered after fasting .
47959008|NCT04925661|DRUG|Placebo|Either dose of placebo will be administered after fasting .
48306192|NCT05184296|PROCEDURE|Extracorporeal Membrane Oxygenation (ECMO)|All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
48306193|NCT06517953|DRUG|Icotinib|An orally first-generation EGFR inhibitior.
48641532|NCT00792948|BIOLOGICAL|Filgrastim|Given SC
48641533|NCT00792948|OTHER|Laboratory Biomarker Analysis|Correlative studies
47959009|NCT04330053|OTHER|Experimental|"* Training will address issues such as: environmental security, identifying hazards that can lead to a fall, psychological support, getting up from a fall, standing techniques and calling for help.~* The exercise program will last for six months and will be based on the OTAGO exercise program, which includes five exercise groups: general warm-up, muscle strengthening exercises, balance exercises, range of motion and stretching exercises. The program will be performed individually or in groups of two people at most and will be conducted once a week in one of the 5 outpatient clinics under the supervision of a specialized OTAGO trainer, while seniors should repeat the exercises twice a week alone at home and also walk twice a week for at least half an hour."
47959010|NCT04330053|OTHER|Control|"* Information / Education about falls The participants in this group will receive the same information - education as the participants of the 1st group.~* They will be given a leaflet with general gentle exercises (not fall prevention specific) for the home."
47959011|NCT00219973|DRUG|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
48482104|NCT04047537|OTHER|Placebo|Placebo Capsules identical to those containing Formulation 1 and 2
48482105|NCT00192673|DRUG|PEG-asparaginase|
48641534|NCT00792948|DRUG|Leucovorin Calcium|Given IV
48641535|NCT00792948|DRUG|Methotrexate|Given IV or IT
48641536|NCT00792948|DRUG|Methylprednisolone|Given IV
48641537|NCT00792948|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
48641538|NCT00792948|DRUG|Prednisone|Given PO
48641539|NCT00792948|DRUG|Sirolimus|Given PO
47959012|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
47959013|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
47959014|NCT00813020|DRUG|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
47959015|NCT05409495|PROCEDURE|periodontal surgical procedure (open flap debridement)|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
47959016|NCT05409495|PROCEDURE|periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))|All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
47959017|NCT05409248|OTHER|Personalized cognitive stimulation|Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
47959018|NCT05409248|OTHER|Sham cognitive stimulation|Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
47959019|NCT04121975|RADIATION|Radiotherapy|Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
47959020|NCT04121975|DRUG|Endostar|30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
47959021|NCT04121975|DRUG|Cisplatin|30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
47959022|NCT00951444|BIOLOGICAL|dalotuzumab|Given IV
47959023|NCT00951444|DRUG|carboplatin|Given IV
48111595|NCT04013646|DRUG|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
48111596|NCT04013646|DRUG|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
48111597|NCT04013646|DRUG|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
48111598|NCT04013646|PROCEDURE|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
48111599|NCT01500395|PROCEDURE|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
48482106|NCT02667002|PROCEDURE|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
48482107|NCT02667002|PROCEDURE|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
48482108|NCT02667002|OTHER|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
47959024|NCT00951444|DRUG|gemcitabine hydrochloride|Given IV
48482109|NCT04452279|DEVICE|iStent or iStent inject implantation with concomitant cataract surgery|Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
47959025|NCT05100459|DIETARY_SUPPLEMENT|Pasture-raised whey protein|25 grams of protein delivered 3 times daily
47959026|NCT05100459|DIETARY_SUPPLEMENT|Conventional whey protein|25 grams of protein delivered 3 times daily
48482110|NCT04781114|DRUG|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
48482111|NCT04781114|DRUG|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
47959027|NCT05100459|DIETARY_SUPPLEMENT|Placebo|Iso-caloric placebo taken 3 times daily like the protein supplementation
47959028|NCT00003257|BIOLOGICAL|Ad5CMV-p53 gene|
47959029|NCT03154164|DEVICE|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
47959030|NCT02300246|PROCEDURE|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
47959031|NCT01805375|DRUG|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
48482112|NCT00149526|BEHAVIORAL|Shared Decision-Making|
48641540|NCT00792948|DRUG|Tacrolimus|Given IV
48641541|NCT00792948|RADIATION|Total-Body Irradiation|Undergo TBI
47959032|NCT03565978|DEVICE|BAMA solution|Use of BAMA cardiac post-discharge management solution for patients education and follow up management
47959033|NCT04694781|DRUG|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
47959034|NCT04694781|DRUG|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
47959035|NCT00969696|DRUG|Placebo|8Mg a day of a sugar pill
47959036|NCT00969696|DRUG|Galantamine|8mg of Galantamine
47959037|NCT01542320|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
48111600|NCT04807322|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|Implantation of a Reverse Total Shoulder Arthroplasty
48111601|NCT00652301|DRUG|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
48111602|NCT00652301|DRUG|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
48111603|NCT00652301|DRUG|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
48111604|NCT04609618|DEVICE|Appscent Device|computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
48306194|NCT06517953|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
48111605|NCT00868192|DRUG|Pemetrexed|
48111606|NCT00868192|DRUG|Bevacizumab|
48111607|NCT01587755|OTHER|TTOP|Patient is taken care of in an intensified, optimised manner
48111608|NCT01587755|OTHER|non-TTOP|Standard medical care
48111609|NCT03610958|DEVICE|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
48306195|NCT05876780|GENETIC|SRP-9003|Single IV infusion of SRP-9003
48306196|NCT06324747|PROCEDURE|Vestibular socket therapy|Vestibular socket therapy will be used for the intervention.
48306197|NCT06324747|PROCEDURE|conventional full thickness flap|reflecting the mucoperiosteum to access the extraction socket
48482113|NCT06402344|OTHER|Hormonal implant|History of at least 1 hormonal implant with gestrinone in the last 6 months, applied by the participant's private doctor.
48482114|NCT06402344|OTHER|Control group|Young women who never used any hormonal implant.
48482115|NCT06155773|PROCEDURE|Highly viscous glass ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
48482116|NCT06155773|PROCEDURE|Low shrinkage Flowable Composite (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
48111610|NCT04036630|DEVICE|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
48111611|NCT04036630|DEVICE|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
48111612|NCT01162876|DRUG|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
48111613|NCT03183999|DIETARY_SUPPLEMENT|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
48111614|NCT03183999|DIETARY_SUPPLEMENT|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
48482117|NCT06155773|PROCEDURE|Resin Modified Glass Ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
47959038|NCT01542320|OTHER|Placebo|Solution without active Lactobacillus reuteri
47959039|NCT00419276|PROCEDURE|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
47959040|NCT06114160|OTHER|Data collection|Data collection
47959041|NCT05947045|OTHER|Cognitive training via iPad|Participants will complete five sessions of the Cogmed training program on an iPad. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
48111615|NCT05563246|DRUG|LY3473329|Administered orally
48111616|NCT05563246|DRUG|Placebo|Administered orally
48111617|NCT00050375|DRUG|oregovomab|
48111618|NCT03007836|BIOLOGICAL|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
48111619|NCT04028336|OTHER|TITRATION|PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
48306198|NCT03393013|DRUG|KZR-616|Subcutaneous Injection of KZR-616
48482118|NCT06155773|PROCEDURE|Bioactive Ionic Resin (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
48641542|NCT00792948|DRUG|Vincristine Sulfate|Given IV
47959042|NCT05947045|OTHER|Cognitive training via virtual reality|Participants will complete five sessions of the Cogmed training program within virtual reality. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
47959043|NCT04094129|DIETARY_SUPPLEMENT|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
47959044|NCT04094129|DIETARY_SUPPLEMENT|Placebo|placebo
47959045|NCT01928173|BEHAVIORAL|Abbreviated cognitive behavioral therapy|see arm description
47959046|NCT01928173|BEHAVIORAL|Sleep education/sleep hygiene|see arm description
47959047|NCT05210907|BIOLOGICAL|SNUH-CD19-CAR-T|SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
47959048|NCT02741856|DRUG|Carboplatin|For more information please see the arm descriptions section.
47959049|NCT02741856|DRUG|Paclitaxel|For more information please see the arm descriptions section.
47959050|NCT02741856|DRUG|Cisplatin|For more information please see the arm descriptions section.
47959051|NCT02741856|DRUG|Capecitabine|For more information please see the arm descriptions section.
47959052|NCT02741856|RADIATION|Radiotherapy|For more information please see the arm descriptions section.
47959053|NCT00385762|DRUG|paroxetine|paroxetine 10-40mg daily x 5 weeks
48306199|NCT02276157|DEVICE|Direct peroral cholangioscopy|"The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary."
48306200|NCT03889093|OTHER|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
48306201|NCT04014153|PROCEDURE|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
48306202|NCT00833235|OTHER|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
47959054|NCT03539328|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
47959055|NCT03539328|DRUG|Gemcitabine|Chemotherapy medication
47959056|NCT03539328|DRUG|Paclitaxel|Chemotherapy medication
47959057|NCT03539328|DRUG|Liposomal Doxorubicin|Chemotherapy medication
47959058|NCT01446315|BEHAVIORAL|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
48111620|NCT03408925|OTHER|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
48111621|NCT01698255|BEHAVIORAL|ENGAGE|
48111622|NCT01698255|BEHAVIORAL|Standard of Care Psychotherapy|
47959059|NCT01446315|BEHAVIORAL|Asthma APGAR tools|Usual care
48111623|NCT00002450|DRUG|Tenofovir disoproxil fumarate|
48482119|NCT03940482|BEHAVIORAL|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
47959060|NCT03583697|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
47959061|NCT03583697|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
47959062|NCT01984788|DRUG|BCX4161|
47959063|NCT01984788|DRUG|Placebo|
47959064|NCT03254875|BEHAVIORAL|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
47959065|NCT05170464|BEHAVIORAL|Acute Exercise|Brisk walking on a treadmill at ⅔ maximum heart rate as defined by 220-age (in years).
47959066|NCT05170464|DRUG|Caffeine Powder|Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
47959067|NCT02858960|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
47959068|NCT02858960|DEVICE|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
47959069|NCT05333016|BEHAVIORAL|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
47959070|NCT00245661|DRUG|Temazepam|
47959071|NCT06365112|PROCEDURE|Endoscopy assisted|Endoscopy
47959072|NCT00366574|DEVICE|Amadeus Microkeratome|
47959073|NCT00366574|DEVICE|IntraLase|
47959074|NCT04312048|DRUG|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
48111624|NCT03207568|DEVICE|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
48111625|NCT00414648|DRUG|Sirolimus|A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
48306203|NCT05858736|DRUG|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
47959075|NCT04312048|DRUG|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
47959076|NCT05116215|DRUG|Hydrogen|Hydrogen supplement
47959077|NCT03057678|OTHER|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
47959078|NCT06558292|OTHER|Virtual Reality Group|Students will experience the operating room environment with virtual reality glasses before clinical practice.
47959079|NCT00678093|OTHER|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
47959080|NCT02683720|DIETARY_SUPPLEMENT|ONS|randomized clinical trial involving different ONS strategies
47959081|NCT05840640|DRUG|Standard Medical Therapy|Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
48111626|NCT00414648|DRUG|Placebo|A placebo dose of 2 tablets per day for 1 year.
47959082|NCT05840640|DRUG|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
47959083|NCT05840640|DRUG|G-CSF and NAC|Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
47959084|NCT05944289|BEHAVIORAL|Acceptance and Commitment Therapy|a four-week workshop based on the principles and procedures of Acceptance and Commitment Therapy
47959085|NCT05944289|BEHAVIORAL|Caregiver Support Group|Caregiver support group to run parallel to the ACT intervention group.
48111627|NCT01125761|DRUG|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
48111628|NCT01125761|DRUG|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
48482120|NCT04073017|DIETARY_SUPPLEMENT|Enterade®|Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
47959086|NCT03555032|DRUG|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
48111629|NCT05581654|PROCEDURE|Salpingectomy|Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
48111630|NCT04424641|BIOLOGICAL|GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.|GEN1044 will be administered intravenously in cycles of 21 days.
48111631|NCT05650268|DRUG|Vitamin D3|Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
48111632|NCT05650268|OTHER|95% MCT|95% MCT supplement 3-7 day before surgery
48111633|NCT01669382|DEVICE|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
48482121|NCT04073017|OTHER|Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)|Ancillary studies
48482122|NCT00767520|DRUG|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
48482123|NCT00767520|DRUG|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
47959087|NCT03069443|OTHER|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
47959088|NCT04912193|DRUG|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
47959089|NCT00769392|DRUG|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
47959090|NCT00769392|DRUG|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
47959091|NCT00769392|DRUG|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
47959092|NCT00769392|DRUG|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
47959093|NCT03661671|DIAGNOSTIC_TEST|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
47959094|NCT03477097|OTHER|Nutrition, exercise and social network intervention|
47959095|NCT00846235|OTHER|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
47959096|NCT03373292|PROCEDURE|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
47959097|NCT03373292|PROCEDURE|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
47959098|NCT06354309|OTHER|Virtual reality game|Pre and post control study after use virtual reality game
48482124|NCT00419887|DRUG|Vildagliptin (LAF237)|
48641543|NCT04596631|DRUG|Oral semaglutide|Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
48641544|NCT04596631|DRUG|Placebo (semaglutide)|Placebo treatment for 52 weeks.
48641545|NCT05997615|DRUG|AMX-500 (SAR446329)|Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
47959099|NCT06081712|DRUG|TNP-2198|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
47959100|NCT06081712|DRUG|TNP-2198 Placebo|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
47959101|NCT00972582|DIETARY_SUPPLEMENT|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
47959102|NCT01902199|BEHAVIORAL|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
47959103|NCT02059408|OTHER|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
47959104|NCT02059408|OTHER|Screen-Educate and Intensify Treatment|This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys \<45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
47959105|NCT03717246|BEHAVIORAL|Sleep Smart Latino|A culturally tailored group intervention aimed at improving sleep duration and quality for Latino middle school students.
47959106|NCT03717246|BEHAVIORAL|Basic Sleep Hygiene and Child Health|A group intervention providing sleep hygiene and child health topics education to Latino middle school students.
47959107|NCT03756077|DIAGNOSTIC_TEST|68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT|0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
47959108|NCT00392015|BIOLOGICAL|NMRC-M3V-Ad-PfCA|Malaria Vaccine
47959109|NCT00392015|BIOLOGICAL|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA|Malaria Vaccines
47959110|NCT02449252|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
47959111|NCT02449252|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
47959112|NCT02449252|DRUG|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
48306204|NCT03241797|PROCEDURE|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
48306205|NCT04869956|OTHER|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
48306206|NCT04869956|OTHER|Dietary pattern: Standard diet|standard nutritional recommendations
47959113|NCT02449252|DRUG|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
47959114|NCT02449252|DRUG|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
48306207|NCT01455428|DRUG|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
47959115|NCT02449252|DRUG|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
47959116|NCT02272660|DRUG|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
48482125|NCT05604937|OTHER|Shi's traumatology osteopathic manipulation|Patients receive treatment twice a week and continues for 2 weeks. Receive a total of 4 manipulative treatments. The manipulation intervention has mainly two steps: First, doctors perform soft-tissue manipulation on neck and shoulders to relax for 10 min; Second, doctors perform manipulation to reconstruct atlantoaxial joint. The strength of manipulation is based on the patient's tolerance. Do not use too much force.
48482126|NCT05604937|DRUG|Merislon|Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks, 6mg a day, three times a day.
48641546|NCT05594589|DRUG|Lemborexant|Lemborexant oral tablet.
47959117|NCT02272660|DRUG|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
48306208|NCT01455428|DRUG|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
48641547|NCT05594589|OTHER|PBO|Lemborexant-matched PBO tablet.
48641548|NCT06006585|DRUG|BI 771716|BI 771716
47959118|NCT04905758|PROCEDURE|platform switching|reduced implant abutment interface
47959119|NCT04905758|PROCEDURE|platform amtching|matched implant abutment interface
47959120|NCT05532917|OTHER|Gupta score|The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (\>130 mmol/L or \>1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
47959121|NCT00006477|DIETARY_SUPPLEMENT|mistletoe extract|
47959122|NCT01443078|DRUG|pemetrexed|
47959123|NCT01443078|DRUG|cisplatin|
47959124|NCT01443078|DRUG|Carboplatin|
47959125|NCT01443078|DRUG|Gemcitabine Hydrochloride|
48111634|NCT02533713|DEVICE|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
48111635|NCT01583712|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
48111636|NCT01583712|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
48111637|NCT01801410|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
48111638|NCT01801410|DRUG|Misoprostol|25mcg every 2 hours for maximum of 12 doses
48111639|NCT05593159|OTHER|Dentin Conditioning|After washing and drying -but not desiccating- Dentin Conditioner 20% (GC, Japan) will be applied using a cotton pellet for 20 seconds then rinsed thoroughly and gently dried
48111640|NCT05593159|OTHER|RM-GIC|RM-GIC (Fuji II LC) will be applied in \<2mm incremental layers afterword light-cured for 10 sec (1,000 mW/cm2) per increment to fill the cavity.
47959126|NCT01443078|DRUG|Vinorelbine Tartrate|
47959127|NCT01443078|DRUG|Docetaxel|
47959128|NCT00392860|DEVICE|Natural-Fit|Ergonomic handrim for wheelchairs
47959129|NCT00392860|DEVICE|PalmRim|Ergonomic handrim for wheelchair
47959130|NCT00392860|DEVICE|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
47959131|NCT02460445|PROCEDURE|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
47959132|NCT02460445|DRUG|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
47959133|NCT02460445|DRUG|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
47959134|NCT03948711|DEVICE|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
47959135|NCT04843137|DEVICE|Cervical Transcutaneous Electrical Spinal Cord Stimulation|Surface electrodes are placed over the cervical spinal cord. Constant current is delivery through these electrodes. Stimulation frequency and electrode configuration are manipulated, and outcome measures are recorded.
48111641|NCT05593159|OTHER|1-step adhesive|A universal adhesive system (Tetric® N-Bond Universal) will be applied on both enamel and dentin and gently scraped for 20 sec, then dispersed with oil-free gentle air stream, then light-cured for 10 sec (1,000 mW/cm2).
48111642|NCT05593159|OTHER|Cention N|The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
48306210|NCT02864745|DEVICE|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
48641549|NCT05494736|DRUG|MK-8527|MK-8527 capsule taken by mouth.
47959136|NCT03204201|DRUG|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
47959137|NCT00668707|DIETARY_SUPPLEMENT|melatonin|20 mgs ingested nightly
47959138|NCT00668707|DIETARY_SUPPLEMENT|placebo|similar to experimental in all ways except for lack of active ingredient
47959139|NCT01934946|OTHER|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
47959140|NCT01934946|OTHER|home rehabilitation|6 times home rehabilitation services within 3 months
47959141|NCT02138682|DRUG|l-123 Ioflupane|5 millicuries of Ioflupane
47959142|NCT06224257|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
47959143|NCT01061411|DRUG|Dalteparin|Given SC
47959144|NCT01061411|OTHER|Pharmacological Study|Correlative studies
47959145|NCT01061411|DRUG|Sunitinib Malate|Given PO
47959146|NCT01484223|BEHAVIORAL|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
47959147|NCT00400283|DRUG|NNC 55-0414|
48111643|NCT05593159|OTHER|Dentin roughness|Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)
48111644|NCT05593159|OTHER|Gingival retentive groove preparation|Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
48111645|NCT01630564|BIOLOGICAL|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
48111646|NCT01630564|PROCEDURE|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
48111647|NCT01630564|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
48111648|NCT04305574|BEHAVIORAL|Use of social media during COVID-19|Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
47959148|NCT02234232|BEHAVIORAL|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
47959149|NCT05216783|BEHAVIORAL|Motivational Interviews|The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
47959150|NCT01953107|OTHER|Oral Ferrous Fumarate|
47959151|NCT01953107|OTHER|Placebo|
47959152|NCT04203654|BEHAVIORAL|cognitive-behavior group therapy|cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
47959153|NCT04203654|BEHAVIORAL|Individual supportive psychotherapy|Individual supportive psychotherapy 3 sessions during the 16-week treatment period
47959154|NCT02904889|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
47959155|NCT02904889|OTHER|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
47959156|NCT00105417|DRUG|IL-7|
47959157|NCT01393301|BEHAVIORAL|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
47959158|NCT01393301|BEHAVIORAL|Control|Enhanced standard smoking cessation treatment and NRT.
47959159|NCT02609204|DIAGNOSTIC_TEST|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
48111649|NCT01669148|DEVICE|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
48111650|NCT01669148|DEVICE|Conventional|conventional (2D) imaging (standard mammography)
48111651|NCT06398912|OTHER|Music Based Intervention|Measuring how the fundamental frequency of differential music facilitators (mother, father, male and female music therapist) impacts the premature infant brain
48111652|NCT04521192|DRUG|Fluzoparib|the first period: test preparation; the second period: reference preparation
48111653|NCT04521192|DRUG|Fluzoparib|the first period: reference preparation the second period: test preparation
48111654|NCT00844636|DEVICE|Sharp needle|
48111655|NCT00844636|DEVICE|Blunt needles|
48111656|NCT01534910|DRUG|aged garlic extract|2400 mg a day
48111657|NCT01534910|DRUG|placebo|placebo
48111658|NCT02602743|DRUG|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
48111659|NCT02602743|DRUG|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
48111660|NCT02602743|DRUG|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
48111661|NCT01033058|DRUG|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
48111662|NCT01033058|DRUG|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
48111663|NCT01121549|DRUG|Aromasin|25 mg daily continuously
48111664|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
47959160|NCT00182884|DRUG|Donepezil|
47959161|NCT06503913|BEHAVIORAL|Cognitive Muscular Therapy|Psychologically informed physiotherapy which integrates training to reduce overactivity of postural muscles which can interfere with the mechanics of breathing.
48111665|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
48306211|NCT02864745|OTHER|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
47959162|NCT06503913|BEHAVIORAL|Breathing visualisation|Breathing visualisation; Data from two 3D camera are combined and used to calculate respiratory volumes. These volumes are then used to drive an animation of breathing so that the patient can understand how their breathing pattern compares to an optimal pattern. Note this is not a medical device as data from this system is only used for education and not for diagnostic or treatment decisions.
47959163|NCT03041857|RADIATION|Observational use of fluoroscopy|
47959164|NCT01760629|DEVICE|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
47959165|NCT01622803|PROCEDURE|parallel stent|bilateral parallel stent insertion (right and left side)
47959166|NCT01622803|DEVICE|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
47959167|NCT06212154|BIOLOGICAL|ThisCART19A|Participants will receive ThisCART19A cell infusion after preconditioning, and they need to be closely monitored for 28 days following CAR-T cell infusion.
47959168|NCT03789214|DRUG|Placebo oral capsule|Placebo Sleep Medication
47959169|NCT03789214|DRUG|Low Dose Suvorexant|Low Dose Suvorexant
47959170|NCT03789214|DRUG|High Dose Suvorexant|High Dose Suvorexant
47959171|NCT04676178|DRUG|PRA023|PRA023
47959172|NCT04676178|OTHER|Placebo|Placebo
48306212|NCT01736202|BIOLOGICAL|fat orally|Oral ingestion of palm oil or canola oil or water at timepoint zero
48306213|NCT05067790|DRUG|Nusinersen|Administered as specified in the treatment arm
48306214|NCT00013403|PROCEDURE|Blindness|
47959173|NCT03719612|DRUG|DEFINITY®|All subjects will receive a single dose of DEFINITY®
47959174|NCT06209931|PROCEDURE|RIRS|RIRS with tip flexible pressure-controlling ureteral access sheath versus mini PCNL for the treatment of 2-3-cm kidney stones
47959175|NCT05253638|DIAGNOSTIC_TEST|Macrophage migration inhibitory factor|Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
47959176|NCT02260544|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
47959177|NCT00762229|DRUG|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
47959178|NCT00762229|DRUG|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
47959179|NCT05227183|BEHAVIORAL|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
47959180|NCT01414660|PROCEDURE|transplantation|transplantation of islet, kidney or liver
48111666|NCT02675348|DIETARY_SUPPLEMENT|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
48111667|NCT04023916|DRUG|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m\^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
48111668|NCT00831272|DRUG|naltrexone|50mg/day
48306215|NCT03468283|OTHER|mobile application for diabetes|Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
48111669|NCT00831272|DRUG|Placebo|Placebo
48111670|NCT00490685|DRUG|Sorafenib (BAY-43-9006)|
48111671|NCT02965248|DRUG|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
48111672|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
48111673|NCT02965248|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
48111674|NCT01689272|PROCEDURE|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
48111675|NCT02964780|PROCEDURE|Gastric bypass surgery|
48306216|NCT03080220|DEVICE|Astym|therapeutic massage instrument
48306217|NCT03080220|DEVICE|Stick|massage instrument
48306218|NCT03080220|DEVICE|Massage|massage instruments
48306219|NCT00017316|DRUG|semaxanib|
48306220|NCT00017316|DRUG|thalidomide|
48306221|NCT03458000|DEVICE|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
48306222|NCT03458000|OTHER|Standard of Care|Patient was admitted to hospital for care and received in-patient EGD.
47959181|NCT01602120|DRUG|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
47959182|NCT03892070|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB will be provided for 12 weeks twice daily
47959183|NCT03892070|DIETARY_SUPPLEMENT|Mannitol|1.5 g twice daily for 12 weeks
47959184|NCT04647864|DEVICE|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
47959185|NCT00687960|DIETARY_SUPPLEMENT|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
47959186|NCT00687960|DIETARY_SUPPLEMENT|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
47959187|NCT00687960|DIETARY_SUPPLEMENT|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
47959188|NCT00687960|DIETARY_SUPPLEMENT|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
47959189|NCT01049100|PROCEDURE|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
47959190|NCT01049100|OTHER|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--\> CT controlled biopsy
48497873|NCT04791475|PROCEDURE|adding Dexmedetomidine and dexamethasone to bupivacaine in USG guided supraclavicular brachial plexus block.|The linear transducer probe (frequency 4 -12 Hz) of USG machine will be used. A superficial skin wheal will be made by 2ml of 1% lignocaine subcutaneously at the point of needle insertion. USG guided Brachial plexus block will be performed by supraclavicular route via the subclavian perivascular approach in in-plane technique from lateral to medial using 22 gauge spinal needle. Study Drug will be administered via Pressure Monitoring line connected to syringe according to the allocated group with repeated aspiration and incremental dosing. • Intercostobrachial nerve block will be performed to alleviate the tourniquet pain. A 25 G needle will be inserted at the level of axillary fossa. The entire width of the medial aspect of arm, starting at the deltoid prominence and proceeding inferiorly, will be infiltrated with 5ml of 1% Lignocaine with Epinephrine (1:4,00,000) to raise a subcutaneous wheal. •
48111676|NCT02964780|BEHAVIORAL|Conservative weight loss program|
48111677|NCT00702806|DRUG|Org 36286|Intra-abdominal injection of Org 36286
48306223|NCT02672319|PROCEDURE|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices \> 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
48306224|NCT02930655|DRUG|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
48306225|NCT02930655|DRUG|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
48306226|NCT03572543|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
48306227|NCT02431585|DIETARY_SUPPLEMENT|gluten|
48306228|NCT02431585|DIETARY_SUPPLEMENT|placebo|
48306229|NCT02920684|OTHER|Passive legs mobilisation|A physiotherapist performs a passive leg movement
48641550|NCT06244199|BEHAVIORAL|T2CR Intervention|The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.
48111678|NCT00702806|DRUG|Puregon®|Subcutaneous Puregon® 150 IU
48306230|NCT02920684|OTHER|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
48306231|NCT02920684|OTHER|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
48306232|NCT02920684|OTHER|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
48306233|NCT05092815|DRUG|HLX208|HLX208 450mg bid po
47959191|NCT06069908|OTHER|Complex Decongestive Treatment|Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach. It will be applied 5 days a week for 3 weeks
48111679|NCT00702806|DRUG|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
47959192|NCT06069908|OTHER|Sham transcutaneous vagus nerve stimulation|In sham transcutaneous vagus nerve stimulation application, the device electrode will be placed in the superior scapha region of the outer ear, where the vagus nerve has no innervation, and no current will be given.Complex Decongestive Therapy and sham transcutaneous vagus nerve stimulation.It will be applied 5 days a week for 3 weeks.
47959193|NCT06069908|OTHER|Transcutaneous Auricular Vagus Nerve Stimulation|Transcutaneous vagus nerve stimulation will be applied in addition to Complex Decongestive Therapy.It will be applied 5 days a week for 3 weeks.
47959194|NCT06069908|OTHER|Exercise|Patients will undergo lymphedema-specific exercises 5 days a week for 3 weeks.
47959195|NCT01034631|DRUG|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
47959196|NCT01034631|DRUG|BNC105P|BNC105P, up to 16 mg/m\^2
48111680|NCT00702806|DRUG|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
48111681|NCT04531137|DIETARY_SUPPLEMENT|CLA-fortified milk powder|3.4 gram of CLA-fortified milk powder one a day for 12 weeks
48111682|NCT04531137|OTHER|Placebo|Placebo milk powder one a day for 12 weeks
48111683|NCT04531137|OTHER|Nutrition Counseling|Individualized nutrition counseling using nutrition module at week 0, 4, and 8 for 30-45 minutes each session
48306234|NCT01449019|DRUG|exendin(9-39)amide|intravenous infusion of exendin(9-39)
48306235|NCT01449019|DRUG|saline|intravenous infusion of saline
48306236|NCT01449019|OTHER|duodenal meal|duodenal perfusion of a meal
47959197|NCT03780543|DRUG|standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)|Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
47959198|NCT05654935|RADIATION|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
47959199|NCT05654935|RADIATION|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
47959200|NCT02023593|DRUG|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
47959201|NCT02980783|DEVICE|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
47959202|NCT04007926|BEHAVIORAL|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
48111684|NCT03375255|DRUG|SRP-5051|Single dose of SRP-5051 administered as an intravenous (IV) infusion.
48111685|NCT02315391|DIETARY_SUPPLEMENT|isolated whey protein|isolated whey protein
48111686|NCT02315391|DIETARY_SUPPLEMENT|micellar whey protein|micellar whey protein
48111687|NCT02315391|DIETARY_SUPPLEMENT|glycine|glycine
48306237|NCT01449019|OTHER|duodenal saline|duodenal perfusion of saline
48306238|NCT00416637|BIOLOGICAL|Bevacizumab (Avastin)|
48306239|NCT00005655|BIOLOGICAL|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
48306240|NCT00005655|BIOLOGICAL|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
48306241|NCT02460822|DEVICE|MyChemoCare iPad application|
48111688|NCT02315391|DIETARY_SUPPLEMENT|citrulline|citrulline
48111689|NCT06491212|DIAGNOSTIC_TEST|Determination of Foot Deformity Level|One of the methods used in our study to determine the presence and degree of pes planus is the navicular drop test.
48111690|NCT06491212|DIAGNOSTIC_TEST|Foot Function Index|Evaluation of Foot Function
48111691|NCT06491212|DIAGNOSTIC_TEST|UFAA-International Physical Activity Questionnaire|To determination of physical activity level.
48306242|NCT04748276|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.
48111692|NCT06491212|DIAGNOSTIC_TEST|Diaphragm ultrasound measurements|Rehabilitative ultrasound imaging is a method frequently used by physiotherapists to assess muscle function.
48111693|NCT06491212|DIAGNOSTIC_TEST|NeuruCom Balance Master Balnce and Performans Test|Balance master will be used for postural stability, static and dynamic balance measurements.
48111694|NCT06491212|DIAGNOSTIC_TEST|Plantar Pressure Assessment|When assessing plantar pressure, postural control will be evaluated statically or dynamically, through examination of the behavior of the center of plantar pressure (COP).
48111695|NCT03085316|DEVICE|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
48111696|NCT02026778|DRUG|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
48111697|NCT02026778|DRUG|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
48306243|NCT05682664|OTHER|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
48306244|NCT05682664|OTHER|Usual care|Routine outpatient clinical visits every 3 months.
48306245|NCT04527016|PROCEDURE|Microbiota and eosinophils based therapy|"1. Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~2. Blood eosinophils\<3%+ Moraxella species\>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~3. Blood eosinophils ≥3%+ Moraxella species\>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~4. Blood eosinophils\<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention."
48497874|NCT01150318|DRUG|Administration of 131 iodine|100 mCi 131 iodine irradiation
48497875|NCT00157079|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
48497876|NCT01172821|DRUG|placebo|Placebo that represents BI drug
48497877|NCT01172821|DRUG|placebo|Placebo that represents comparator
47959203|NCT04007926|BEHAVIORAL|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
47959204|NCT04969575|OTHER|Insemination and culture|All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
47959205|NCT04969575|OTHER|Media refreshment Group 1|Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).
47959206|NCT04969575|OTHER|Culture media preparation and refreshment|"30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator."
47959207|NCT04969575|OTHER|Embryo grading|Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.
47959208|NCT04969575|OTHER|Media refreshment Group 2|Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
47959209|NCT03665454|DRUG|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
47959210|NCT03665454|DRUG|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
47959211|NCT04352569|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
47959212|NCT01805440|DRUG|Uridine|Uridine is the active treatment in this clinical trial.
47959213|NCT01805440|DRUG|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
47959214|NCT00369707|DRUG|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
48482127|NCT05510024|PROCEDURE|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy|The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
47959215|NCT00369707|DRUG|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
47959216|NCT05128500|PROCEDURE|Total Shoulder Arthroplasty with Permedica's MIRAI|Total Shoulder Arthroplasty with Permedica's MIRAI Modular Shoulder Prosthesis System
47959217|NCT06311786|DRUG|[14C]-BIIB091|Administered as specified in the treatment arm.
47959218|NCT05781620|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
47959219|NCT05781620|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
47959220|NCT06098092|OTHER|Long-term non-invasive Blood pressure monitoring|All measurements during the experiment include only non-invasive Blood pressure and Heart rate measurements. Measurements will be taken using a smartwatch attached to the wrist and a digital tonometer with a cuff placed on the other arm. Paired readings will be compared.
47959221|NCT00310401|DRUG|Albuterol|5 mg nebulized q4h
47959222|NCT00310401|DRUG|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
48306246|NCT04527016|DRUG|Clinical guidelines based therapy|"The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~1. regular inhaled FP 50 ug twice daily via spacer for 3 months;~2. montelukast(4mg od for 3 months)~3. intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention."
47959223|NCT05101642|PROCEDURE|Guided Creeping Technique (GCT)|Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
47959224|NCT01686308|PROCEDURE|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
48306247|NCT00677027|OTHER|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
48306248|NCT00677027|OTHER|placebo|Placebo
48497878|NCT01172821|DRUG|placebo|Placebo that represents comparator
48497879|NCT01172821|DRUG|tiotropium Respimat® low dose|IMP
48306249|NCT02892123|DRUG|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
48306250|NCT02892123|DRUG|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
48306251|NCT02892123|DRUG|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
48306252|NCT02892123|DRUG|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
48306253|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
48306254|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
48306255|NCT05874219|DRUG|Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU|The intervention Sprayed 1 to 3 times /day
48306256|NCT05874219|DRUG|Mupirocin 2% ointment|10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
48306257|NCT05774457|BEHAVIORAL|Voice training|Traditional vs. virtual reality
48306258|NCT02046343|BEHAVIORAL|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
48306259|NCT02046343|BEHAVIORAL|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
48306260|NCT02046343|OTHER|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
48306261|NCT02046343|OTHER|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
48306262|NCT03955107|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
48306263|NCT05545813|DIETARY_SUPPLEMENT|Probiotic|Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
48306264|NCT05545813|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
48306265|NCT02558153|DEVICE|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
48306266|NCT02558153|DEVICE|standard PTA|Percutaneous angioplasty performed with a standard balloon
48306267|NCT04961840|OTHER|No Intervention|This is a non-interventional study.
48306268|NCT00006222|DRUG|cilengitide|
48306269|NCT02754778|BEHAVIORAL|conditional workout|6 month of regular conditional workout 1-3 times a weak
48306270|NCT03557398|DEVICE|Hydeal-D vaginal pessaries|One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
48306271|NCT03975868|OTHER|Analysis of associated factors for cut-out in internal fixation of extracapsular proximal femoral fracture.|Identification of factors for mechanical failure of internal fixation of extracapsular proximal femoral fracture in over 75 year olds
48306272|NCT00124267|DRUG|Intrarectal quinine|
48306273|NCT00287833|OTHER|placebo|Given orally
48306274|NCT00287833|DRUG|Bowman-Birk inhibitor concentrate|Given orally
48306275|NCT02159963|OTHER|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
48306276|NCT02159963|OTHER|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
48306277|NCT02159963|OTHER|Optional training|8 weeks of optional home based, unsupervised training.
48306278|NCT02159963|OTHER|Control|8 weeks of control period. Participants are doing daily living.
48306279|NCT04722393|OTHER|Exercise|Exercise training
48306280|NCT04171544|DEVICE|Streamline Occipito-Cervico-Thoracic Spinal Fixation System|Spinal Fixation
47959225|NCT01686308|PROCEDURE|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
48306281|NCT04649528|BEHAVIORAL|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
48306282|NCT04649528|DEVICE|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
48306283|NCT00834002|BIOLOGICAL|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
48306284|NCT02797106|OTHER|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
48306285|NCT03394170|OTHER|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
48306286|NCT06410781|OTHER|Radial Extracorporeal Shockwave|Treatment procedure will be initiated by palpation to locate the painful area around the lateral femoral condyle and the lateral side of the thigh. The therapist uses the principle of clinical focusing where the patient guides the therapist to the most painful area. The area will be treated in a circumferential pattern, starting at the point of maximum pain. At each of the session a total of 4600 pulses will be applied. RESWT will start with 500 pulses at (2 Bar) with the frequency of 15 Hz to the lateral femoral condyle to adjust to treatment.An additional 2000 pulses will be applied at (2- 4 Bar), 15 Hz, depending on pain tolerance. in addition,stretching exercise, manual therapy, and ultrasound on the iliotibial band.
48306287|NCT06410781|OTHER|traditional therapy|the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
48306288|NCT00269191|DRUG|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
48306289|NCT00269191|DRUG|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
48306290|NCT02142192|DRUG|natalizumab|Administered as specified in the treatment arm
48497880|NCT01172821|DRUG|placebo|Placebo that represents BI drug
48497881|NCT01172821|DRUG|tiotropium Respimat® high dose|IMP
48306291|NCT02415296|OTHER|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
47959226|NCT02056938|DRUG|Anti-Thymocyte Globulins treatment|
47959227|NCT02056938|DRUG|Basiliximab treatment|
47959228|NCT06213246|BEHAVIORAL|Sleep Hygiene Strategies|"The sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the following guidelines recommended by the National Sleep Foundation~* Maintain a consistent wake-up and bedtime schedule during workdays.~* Do not delay/advance excessively (no more than 2 hours) the wake-up and bedtime - schedule during weekends.~* Keep the bedroom temperature below 22°C.~* Avoid sources of light and noise in the bedroom.~* Use the bed only for sleeping, avoiding other activities before bedtime.~* Avoid daytime naps during workdays.~* Refrain from using electronic devices (PC, laptop, cellphone, television) at least 30 minutes before bedtime.~* Expose yourself to natural light in the morning and reduce artificial lights in the evening.~* Avoid consuming alcoholic beverages and caffeine in the afternoon.~* Have a moderately sized dinner at least 3 hours before bedtime."
47959229|NCT04749706|BEHAVIORAL|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
47959230|NCT04749706|BEHAVIORAL|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
47959231|NCT02902432|DRUG|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
47959232|NCT05159219|DRUG|Colchicine Pill|Anti-inflammatory
47959233|NCT05159219|OTHER|Placebo|Inert ingredients
47959234|NCT05343442|PROCEDURE|Percutaneous tracheostomy|"Guidewire dilating forceps (Grigges') technique was the method which has been applied during our work. Proper positioning: patient's neck was extended as much as possible by placing a rolled towel between the shoulder blades, the patient's neck and the bed were maintained in neutral position. The operative site was sterilized before draping with 10% povidone iodine solution. Lidocaine 2% was used as local anesthetic prior to beginning the intervention.~Transverse (1 cm) skin incision was made midway between the cricoid cartilage and the suprasternal notch, i.e., opposite the 2nd - 3rd or 3rd - 4th tracheal rings. Blunt dissection of subcutaneous fat and pre-tracheal tissue with mosquito clamp in a vertical direction was done till the tracheal rings were palpable."
47959235|NCT04937231|OTHER|Aerobic exercises|"For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes"
47959236|NCT04937231|OTHER|Resistance exercises|"For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls"
47959237|NCT04937231|OTHER|Combined training|For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
47959238|NCT05236296|BEHAVIORAL|EASE-CG|EASE-CG is an adapted brief psychotherapeutic intervention with relational support and trauma-based cognitive behavioral therapy (CBT) components.
47959239|NCT02962388|DRUG|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
48306292|NCT02415296|OTHER|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
48306293|NCT02415296|OTHER|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
48306294|NCT00398619|DRUG|INCB13739|
48306295|NCT01191294|OTHER|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
48482128|NCT05510024|PROCEDURE|SCIT|Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
48497882|NCT01172821|DRUG|50 mcg salmeterol HFA MDI|Active comparator
48497883|NCT01172821|DRUG|placebo|Placebo that represents comparator
48306296|NCT04163146|DIAGNOSTIC_TEST|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
48306297|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-L|Low dose: 2x1010 CFU/day
48306298|NCT04893746|DIETARY_SUPPLEMENT|Maltodextrin|0x1010 CFU/day
48306299|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-H|High dose: 6x1010 CFU/day
48306300|NCT04684485|DRUG|Placebo|Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.
48482129|NCT01609621|DEVICE|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
48482130|NCT04217655|DIAGNOSTIC_TEST|Low-dose computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
48482131|NCT04217655|DIAGNOSTIC_TEST|Standard-dose computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
48482132|NCT02404519|DIETARY_SUPPLEMENT|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
48306301|NCT04684485|DRUG|SCD-044_Dose 1|SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.
48306302|NCT04684485|DRUG|SCD-044_Dose 2|SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.
48306303|NCT04684485|DRUG|SCD-044_Dose 3|SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.
48306304|NCT01629485|BEHAVIORAL|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
48306305|NCT01629485|BEHAVIORAL|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
48306306|NCT01629485|BEHAVIORAL|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
48306307|NCT06048055|OTHER|Transcutaneous auricular vagus nerve stimulation|Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
48306308|NCT06048055|OTHER|selected physical therapy program|The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
48306309|NCT03778177|PROCEDURE|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
48306310|NCT05920187|OTHER|Mediterranean diet and Anti-inflammatory diet|"Cases will be randomly allocated to two groups: Mediterranean diet group (following dietary intervention based on MD), and Anti_inflammatory diet group(following dietary intervention based on IBD-AIF). Patients of the control group will not be instructed to follow a specific dietary intervention.~Evaluation of adherence of cases to dietary intervention will be at two points of time: after four weeks and after 12 weeks by using Mediterranean Diet Serving Score (MDSS) for MD adherence and Anti- Inflammatory Diet Serving Score for IBD- AID adherence. The AID Serving Score (AIDSS) is based on the latest update of the Anti-Inflammatory Diet Pyramid, using the recommended consumption frequency of foods and food group."
47959240|NCT02962388|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
47959241|NCT02962388|DRUG|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
47959242|NCT05662345|DIAGNOSTIC_TEST|CellSearch Circulating Tumor Cells|Serial CTC enumeration
47959243|NCT05740124|BEHAVIORAL|slip recovery training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after slipping.
47959244|NCT05740124|BEHAVIORAL|alternative balance training|Participants practice standing and walking under varied sensory conditions.
48306311|NCT03919916|PROCEDURE|Serratus plane block|Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
48306312|NCT03919916|OTHER|Patient controlled analgesia|Computerised pump device facilitating the patient self administration and titration as needed of morphine
48306313|NCT02490150|DRUG|Corifollitropin alfa|
48482133|NCT02404519|DIETARY_SUPPLEMENT|Placebo|1 tablet without MK-7 taken orally every day during 1 year
48482134|NCT00705120|OTHER|Bone Marrow Cell Transplantation|
48482135|NCT00705120|RADIATION|Irradiation, Total Body|
48482136|NCT00705120|DRUG|Cyclophosphamide|
48482137|NCT00705120|DRUG|Cyclosporin|
48482138|NCT00705120|PROCEDURE|Mesenchymal Stem Cell Transplantation|
48482139|NCT00705120|DRUG|Busulfan|
48482140|NCT00000486|PROCEDURE|coronary artery bypass|
47959245|NCT04089475|DEVICE|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
48641551|NCT06244199|OTHER|Usual Care|Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.
48306314|NCT02294721|DEVICE|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
48306315|NCT02294721|DEVICE|The CPREazy|feedback device-1
48306316|NCT02294721|DEVICE|TrueCPR|feedback device -2
48306317|NCT02294721|DEVICE|The CPR PRO APP|feedback device -3
48306318|NCT02294721|DEVICE|The CardioPump|feedback device- 4
47959246|NCT04633577|DRUG|Lidocaine IV|A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
48306319|NCT00780468|BEHAVIORAL|Existing diet plan|
48306320|NCT00780468|BEHAVIORAL|New diet plan|
48641552|NCT04933227|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously (IV) on Day 1 of each 21-day cycle.
47959247|NCT04633577|DRUG|0.9% normal saline|0.9% normal saline
47959248|NCT01519232|RADIATION|Liver Irradiation|Patients already scheduled to undergo radiation treatment
47959249|NCT02218749|OTHER|Initially triaged to physiotherapist|
47959250|NCT02218749|OTHER|Initially triaged to physician|
47959251|NCT01817829|DRUG|paracetamol|500 mg oral tablet
47959252|NCT01817829|DRUG|placebo|
47959253|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.
47959254|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.
47959255|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
47959256|NCT00593502|DRUG|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; \> 40 kg, 75 mg twice daily, for 5 days
47959257|NCT00593502|DRUG|placebo|The dosage of placebo will be similar to the active drug
48111698|NCT01640821|BEHAVIORAL|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
48306321|NCT01038284|BEHAVIORAL|Patient education|Pharmaceutical care of patients with PAH
48306322|NCT01038284|OTHER|Data collection|Clinical and biological data, treatment, medication errors and ADEs
48306323|NCT04655495|DIETARY_SUPPLEMENT|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet
48306324|NCT03207022|PROCEDURE|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
48306325|NCT05628467|DRUG|Antidepressive Agents|Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
48306326|NCT03739944|PROCEDURE|Laparotomic radical hysterectomy|Laparotomic radical hysterectomy for patients without fertility requirement
48306327|NCT03739944|PROCEDURE|Laparotomic radical trachelectomy|Laparotomic radical hysterectomy for patients with fertility requirement
48641553|NCT04933227|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered IV on Day 1 of each 21-day cycle.
48641554|NCT04933227|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle during Cycles 1-4.
48641555|NCT04933227|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2/d will be administered orally (PO) twice daily (bid) on Days 1-14 during Cycles 1-4.
48641556|NCT04026412|BIOLOGICAL|nivolumab|Specified dose on specified days
48306328|NCT03739944|PROCEDURE|Laparoscopic radical hysterectomy|Laparoscopic radical hysterectomy for patients without fertility requirement
48306329|NCT03739944|PROCEDURE|Laparoscopic radical trachelectomy|Laparoscopic radical hysterectomy for patients with fertility requirement
48306330|NCT06554626|DRUG|Dexamethasone|Glucocorticoids
48306331|NCT06554626|DRUG|Blinatumomab|Bi-specific anti CD19/CD3 antibody
48306332|NCT06554626|DRUG|Venetoclax|BCL-2 inhibotor
48306333|NCT06554626|DRUG|Inotuzumab ozogamicin|a humanized monoclonal antibody-drug conjugate targeting CD22
48306334|NCT06554626|DRUG|Methotrexate|antifolate antineoplastic drug
48306335|NCT06554626|DRUG|Pegaspargase|antitumor drug
48306336|NCT06554626|DRUG|Cytarabine|Pyrimidine, antimetabolites
48306337|NCT01734187|DIETARY_SUPPLEMENT|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
48306338|NCT01734187|DIETARY_SUPPLEMENT|Placebo|Placebo (30g/day)
48306339|NCT04374825|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention consists of 8, 90-minute online group sessions delivered via video conference. Content will be developed by tailoring an ACT intervention to the specific needs of women with MBC, by using qualitative data gathered in patient focus groups. The intervention will incorporate key concepts of ACT (i.e., creating meaning and purpose in life via coping skills, activities in line with patients' values, and mindfulness meditation).
48641557|NCT04026412|BIOLOGICAL|ipilimumab|Specified dose on specified days
48306340|NCT04374825|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|This intervention consists of 8, 90-minute online group sessions delivered via videoconference. Content is drawn from a standard published CBSM intervention previously tested in other studies. The intervention incorporates key concepts of CBSM (i.e., managing stress via deep breathing and relaxation, identifying distorted thoughts,cognitive restructuring, and effective interpersonal communication).
48306341|NCT02027298|DRUG|Abatacept|by SC injection of 125 mg weekly for 6 months
48306342|NCT03443726|PROCEDURE|Nerve block technique|Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
48306343|NCT03443726|PROCEDURE|Infiltrative technique|Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
48306344|NCT03443726|DRUG|4% articaine 1:100.000 epinephrine|Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
48306345|NCT03443726|PROCEDURE|Third molar extraction|Third molar extraction under local anesthesia.
48306346|NCT03408496|OTHER|Myofascial release|Manual therapy
48306347|NCT03408496|OTHER|Muscle stretching|Muscle stretching
48306348|NCT03408496|OTHER|Control|Medical appointment
48111699|NCT00030888|DRUG|7-hydroxystaurosporine|
48306349|NCT01930799|BEHAVIORAL|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
48306350|NCT01051375|BEHAVIORAL|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
48306351|NCT00389896|DRUG|MK0733 / Duration of Treatment: 18 Weeks|
48306352|NCT00389896|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
48306353|NCT03580577|DEVICE|thromboelastography|thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
48482141|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
48482142|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
48482143|NCT00759720|DRUG|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
48482144|NCT06167954|DEVICE|EXPLORER|8 sessions of use of the device in the home and the community of the participants
48482145|NCT05818982|DRUG|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
48482146|NCT05818982|DRUG|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
48482147|NCT00856505|DRUG|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
48482148|NCT01884688|DRUG|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
48482149|NCT00706992|BIOLOGICAL|ALVAC-MART-1 vaccine|Given subcutaneously
48482150|NCT00706992|BIOLOGICAL|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
48482151|NCT00706992|BIOLOGICAL|Aldesleukin|Given subcutaneously
48482152|NCT00706992|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
48482153|NCT00706992|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
48482154|NCT00388895|DRUG|chemotherapy|
48482155|NCT00388895|DRUG|Glivec|
48482156|NCT06318039|OTHER|Novel program|Applying new training method; the Nordic hamstring exercise
48482157|NCT06318039|OTHER|Traditional program|Conventional rehabilitation training administered
48482158|NCT01884584|DRUG|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
48482159|NCT01862419|OTHER|Alert|
48482160|NCT04780334|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
48482161|NCT04780334|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
48111700|NCT02808585|DRUG|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
48111701|NCT02808585|DRUG|Placebo Injection|Four weekly subcutaneous injections of placebo.
48482162|NCT02062801|DRUG|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (\<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
48111702|NCT03426839|DIAGNOSTIC_TEST|Coagulation tests|
48306354|NCT01427569|DRUG|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
48306355|NCT01427569|OTHER|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
48306356|NCT02934776|DEVICE|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
48482163|NCT02062801|DRUG|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
48482164|NCT03123783|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
48641558|NCT04026412|BIOLOGICAL|durvalumab|Specified dose on specified days
48306357|NCT01766830|DEVICE|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
48306358|NCT01766830|DEVICE|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
48306359|NCT01766830|DEVICE|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
48306360|NCT01766830|DEVICE|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
48306361|NCT01766830|DEVICE|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
48306362|NCT01766830|DEVICE|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
48482165|NCT03123783|DRUG|Nivolumab|Nivolumab is an immune checkpoint (PD-1) blocking antibody
48482166|NCT01201759|DRUG|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
48482167|NCT01201759|DRUG|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
48482168|NCT03042468|DRUG|177Lu-PSMA-617|177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
48482169|NCT03042468|DRUG|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
48482170|NCT00378950|BEHAVIORAL|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
48482171|NCT00378950|BEHAVIORAL|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
48482172|NCT04792879|DIAGNOSTIC_TEST|Peripheral veins Doppler ultrasound|Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
48482173|NCT01615887|DRUG|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
48482174|NCT01615887|DRUG|placebo|sugar pill
48482175|NCT05045313|DRUG|Warfarin sodium tablets|Drug: Warfarin sodium, tablet, oral
48482176|NCT05045313|DRUG|Digoxin tablet|Drug: Digoxin, tablet, oral
48482177|NCT05045313|DRUG|Probenecid tablets|Drug: Probenecid, tablet, oral
48482178|NCT05045313|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
48482179|NCT00845325|BEHAVIORAL|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
48482180|NCT00845325|BEHAVIORAL|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
48306363|NCT01766830|DEVICE|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
48306364|NCT01766830|DEVICE|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
48306365|NCT01766830|DEVICE|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
48306366|NCT01766830|DEVICE|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
48306367|NCT01999413|DRUG|OMEGAVEN|AML Study treatment induction phase
48306368|NCT01999413|DRUG|Daunorubicin|AML Study treatment induction phase
48306369|NCT01999413|DRUG|Cytarabine|AML Study treatment induction phase
48306370|NCT02739334|BEHAVIORAL|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
48497884|NCT04126213|BIOLOGICAL|RSV MAT 60 µg|One single dose of RSV MAT 60 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
48497885|NCT04126213|BIOLOGICAL|RSV MAT 120 µg|One single dose of RSV MAT 120 µg vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
48306371|NCT02739334|BEHAVIORAL|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
48306372|NCT04208867|BEHAVIORAL|QI Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH services
48306373|NCT00392171|DRUG|Temozolomide|Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
48306374|NCT05960344|PROCEDURE|Spirometry|Supervised v unsupervised spirometry
48306375|NCT02372825|PROCEDURE|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
48306376|NCT05984381|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 40mg at baseline) orally
48306377|NCT05984381|DRUG|Dapsone|Dapsone 100 mg/day
48306378|NCT05984381|DRUG|Methotrexate|Methotrexate 15 mg weekly
48306379|NCT03581773|DRUG|Folic Acid|5 mg pr day for 12 weeks
48306380|NCT03581773|DRUG|Placebo Oral Tablet|1 placebo pill pr day for 12 weeks
48306381|NCT02945761|PROCEDURE|High concentration of sugar solution|
48306382|NCT02945761|PROCEDURE|conventional surgical dressing change|
48306383|NCT01712386|DIETARY_SUPPLEMENT|Beetroot|
48306384|NCT01712386|DIETARY_SUPPLEMENT|Beetroot placebo|
48306385|NCT02272322|DEVICE|cystocele repair with biomesh soft prolaps and endofast reliant|
48306386|NCT04254289|BEHAVIORAL|Usual Care|Usual care
48306387|NCT04254289|BEHAVIORAL|Home-based exercise program|Home-based program determined by exercise physiologist
48306388|NCT06463769|BEHAVIORAL|8 week predominantly plant-based New Nordic LPF-diet program|An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.
48306389|NCT06463769|BEHAVIORAL|maintenance of the predominantly plant-based New Nordic LPF-diet|Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.
48306390|NCT02708043|OTHER|Flexible-Laryngeal Mask Airway|
48306391|NCT01257646|OTHER|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
48306392|NCT04105543|DRUG|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
48306393|NCT02520804|DRUG|sterofundin|sterofundin for shock patients in the first 72 hours
48306394|NCT02520804|DRUG|normal saline|Normal saline for shock patients in the first 72 hours
48306395|NCT06195384|BIOLOGICAL|Neoantigen mRNA Vaccine|Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
48306396|NCT03588767|DRUG|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
48306397|NCT03588767|OTHER|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
48641559|NCT05196724|BEHAVIORAL|Mentalization Based Therapy MBT|The focus is on improving the core components of secure attachment, particularly by developing the reflective functioning for all professionals working with children in out-of-home care, which is subsequently proposed to increase the psychosocial adjustment of the child and decrease emotional and behavioral problems. MBT treatment consists of up to 12 weekly sessions with the foster parents and child covering three core components: 1) psycho-education about mentalizing, trauma, and attachment for foster parents; 2) support for reflective practice in the professional network, and 3) mentalization-based therapy for the foster family \[41\].
48641560|NCT05196724|BEHAVIORAL|Usual care|The control group will receive the usual care offered to foster families such as supervision
48641561|NCT06565663|BEHAVIORAL|MaPGAS Decision Aid|This intervention involves a novel, web-based decision aid tool specifically designed to support transgender and non-binary individuals assigned female at birth in making informed decisions about Metoidioplasty and Phalloplasty Gender Affirming Surgeries (MaPGAS). The tool includes comprehensive information on surgical options, risks, benefits, and medical illustrations to aid in aligning surgical decisions with the individual's personal values and goals.
48641562|NCT05639647|DRUG|ATM-AVI|A drug specifically designed to treat resistant gam-negative bacterial infections
48641563|NCT05639647|DRUG|BAT|BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
48641564|NCT04935359|DRUG|NIS793|Concentrate for solution infusion (Liquid in Vial)
48641565|NCT04935359|DRUG|Nab-paclitaxel|Per locally approved formulation
48306398|NCT05782920|DEVICE|Platelet rich plasma|PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
48306399|NCT05782920|DEVICE|non cross-linked hyaluronic acid|HA filling is a known modality for rejuvenation
48306400|NCT05782920|DEVICE|topical HA gel|the standard treatment of vaginal atrophy and dryness
48641566|NCT04935359|DRUG|Gemcitabine|Per locally approved formulation
48641567|NCT04935359|DRUG|Placebo|Dextrose 5% in water (D5W) solution for infusion
48306401|NCT04960345|DEVICE|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
48306402|NCT03536312|PROCEDURE|Thoracic Aortic Surgery|Thoracic aortic surgery to treat thoracic aortic aneurysm
48306403|NCT05029544|OTHER|Dynamic taping|The intervention of this experimental study was therapeutic taping (dynamic tape) on the symptomatic shoulders of the participants.
48306404|NCT05029544|OTHER|Kinesio taping|The intervention of this experimental study was therapeutic taping (kinesio tape) on the symptomatic shoulders of the participants.
48306405|NCT05029544|OTHER|Physiotherapy and Rehabilitation|exercise, manuel therapy, mobilization, massage, sensorimotor control
48306406|NCT04015947|DEVICE|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
48306407|NCT04687202|OTHER|follow up and record|None additional intervention was applied to the subjects.
48306408|NCT05493787|BEHAVIORAL|Reminder|Patient portal, SMS, email, and/or another modality
48306409|NCT05470036|BEHAVIORAL|Educational intervention.|Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
48306410|NCT00166010|DRUG|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
48306411|NCT04653909|OTHER|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
48306412|NCT04516486|OTHER|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
48306413|NCT05916833|OTHER|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
48306414|NCT05916833|OTHER|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
48306415|NCT04030052|DRUG|Nuwiq (low dose protocol)|After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
48306416|NCT04030052|DRUG|HEMLIBRA|Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
48306417|NCT04030052|DRUG|Nuwiq (Atlanta protocol)|After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
48482181|NCT06341049|PROCEDURE|Intraperitoneal local anasthetic application + local anesthetic wound infiltration|For Group Intraperitoneal local anasthetic+ loal anesthetic wound infiltration, after the birth of the newborn and placenta, the uterus is taken out and closed, the blood accumulated in the pelvis is carefully wiped with surgical towels, and after complete hemostasis is achieved, sterilely prepared 20 ml 0.5% bupivacaine + 20 ml 2% lidocaine +1 A total of 40 ml of solution containing 200,000 epinephrine will be given to the surgeon. 10 ml of this solution will be instilled into all four quadrants of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer will be sutured or left open, depending on the surgeon's preference. 10 ml will be infiltrated around the edges of the rectus aponeurosis, and the remaining 20 ml will be infiltrated subcutaneously into the wound area.
48482182|NCT06341049|PROCEDURE|Intrathecal morphine application|Group Morphine will be given 11.2 mg hyperbaric bupivacaine + 15 µg fentanyl + 150 µg morphine into the spinal space.
48111703|NCT03751150|OTHER|Exercise program|The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
48111704|NCT00718406|DRUG|Metoprolol|
48111705|NCT00718406|DRUG|metoprolol plus morphine|
48111706|NCT02808338|DEVICE|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
48111707|NCT02808338|DEVICE|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
48306418|NCT03430882|DRUG|Carboplatin|Given IV
48306419|NCT03430882|DRUG|Paclitaxel|Given IV
48306420|NCT03430882|DRUG|Sapanisertib|Given PO
48306421|NCT04068558|DEVICE|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
48306422|NCT04068558|DEVICE|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
48482183|NCT06341049|PROCEDURE|Quadratus lumborum block tip 1 application|In Group Quadratus lumborum block, Quadratus lumborum block type I, a total of 40 ml of a solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200,000 epinephrine will be applied bilaterally under ultrasound guidance.
48111708|NCT02808338|DEVICE|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
48306423|NCT01884454|BEHAVIORAL|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
48306424|NCT02448901|DRUG|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
48306425|NCT01253681|DRUG|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
48306426|NCT00606762|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
48306427|NCT03132792|GENETIC|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
48111709|NCT02808338|DEVICE|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
48306428|NCT05703802|DIAGNOSTIC_TEST|Procalcitonin-variants ELISA-Assay|Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
48306429|NCT02148458|OTHER|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
48306430|NCT02148458|OTHER|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
48306431|NCT04436822|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
48306432|NCT04897503|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
48306433|NCT03623984|DRUG|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
48306434|NCT04438746|BEHAVIORAL|Emotion discussion|General discussion of emotions; no therapy or training is offered
48306435|NCT04438746|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger
48482184|NCT03870477|DEVICE|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
48482185|NCT01757899|DRUG|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
48111710|NCT02168751|DRUG|propofol|
48111711|NCT02168751|DRUG|Sevoflurane|
48111712|NCT05939063|PROCEDURE|LRAMPS|For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
48111713|NCT05939063|PROCEDURE|LDP|For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
48306436|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
48306437|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
48306438|NCT00321984|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
48306439|NCT04280601|DIETARY_SUPPLEMENT|vitamin D|Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
48306440|NCT02423824|BIOLOGICAL|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
48111714|NCT00444990|DEVICE|Magnetic Flex Pad|
48482186|NCT01757899|DRUG|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
48482187|NCT02839668|DRUG|Lidocaine|Continuous infusion of lidocaine
48482188|NCT02839668|DRUG|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
48482189|NCT02839668|DRUG|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
48482190|NCT02839668|DRUG|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
48482191|NCT02839668|DRUG|Tramadol|administration of tramadol for postoperative analgesia
48306441|NCT05270538|DEVICE|Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane|The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
48306442|NCT02439281|DRUG|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
48306443|NCT02439281|DRUG|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
48306444|NCT03532945|DEVICE|Bioactive Glass-Ceramic Spacer|
48306445|NCT03532945|DEVICE|Titanium cage|
48306446|NCT01721408|DRUG|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
48306447|NCT01721408|DRUG|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
48306448|NCT02532595|PROCEDURE|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
48306449|NCT02532595|PROCEDURE|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
48306450|NCT01850563|DEVICE|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
48306451|NCT06462586|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
48306452|NCT06462586|DRUG|Placebo|Matching capsules administered orally, once daily
48306453|NCT05115500|DRUG|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2
48306454|NCT03212404|DRUG|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
48306455|NCT04095988|PROCEDURE|Allogeneic microbiota reconstitution|gastroscopic microbiota Infusion (Verum)
48306456|NCT04095988|PROCEDURE|Placebo-Allogeneic microbiota reconstitution|gastroscopic saline Infusion (placebo)
48306457|NCT03945045|PROCEDURE|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
48306458|NCT03945045|PROCEDURE|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
48306459|NCT03796156|DRUG|Aspirin|75mg low dose non enteric coated or dispersible
48306460|NCT02796690|OTHER|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
48306461|NCT01741272|PROCEDURE|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
48306462|NCT01741272|PROCEDURE|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
48306463|NCT04165343|RADIATION|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
48306464|NCT04165343|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
48482192|NCT02839668|DRUG|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
48306465|NCT04165343|DIAGNOSTIC_TEST|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
48306466|NCT04165343|DIAGNOSTIC_TEST|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
48306467|NCT05239949|OTHER|Hypopressive exercises|For hypopressive exercises, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage.
48306468|NCT05239949|OTHER|Pelvic floor exercises|For pelvic floor exercises, the patient is instructed to hold each contraction for 6 seconds.
48482193|NCT02839668|DRUG|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
48306469|NCT05338294|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
48306470|NCT00387660|DRUG|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
48306471|NCT00387660|DRUG|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
48306472|NCT03140800|DEVICE|intrauterine device|a method of contraception inserted in the uterus
48306473|NCT05399238|DEVICE|The objective is to measure the temperature of the lingual dorsum|Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
48306474|NCT02118610|DRUG|L-tetrahydropalmatine (30mg)|Active comparator
48306475|NCT02118610|DRUG|Sugar pill|Placebo
48306476|NCT00253617|DRUG|porfimer sodium|
48306477|NCT00253617|PROCEDURE|adjuvant therapy|
48306478|NCT00253617|PROCEDURE|laser therapy|
48306479|NCT00253617|PROCEDURE|photodynamic therapy|
48306480|NCT00253617|PROCEDURE|phototherapy|
48306481|NCT02238028|BEHAVIORAL|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
48306482|NCT05420519|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
48306483|NCT04341597|OTHER|cervical ultrasound|All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.
48306484|NCT02318914|DRUG|gevokizumab|
48306485|NCT00668434|DRUG|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
48306486|NCT00668434|DRUG|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
48482194|NCT02839668|DEVICE|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
48482195|NCT06446310|DRUG|QLG2198|Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
48306487|NCT00900380|OTHER|flow cytometry|
48306488|NCT00900380|OTHER|immunological diagnostic method|
48306489|NCT00900380|OTHER|laboratory biomarker analysis|
48306490|NCT05296850|OTHER|Manual Release|Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.
48306491|NCT05296850|OTHER|Kinesio Taping|"In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension."
48306492|NCT01643915|BEHAVIORAL|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
48306493|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
48482196|NCT06446310|DRUG|Placebo|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
48482197|NCT04039919|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
48482198|NCT04039919|DRUG|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
48306494|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
48482199|NCT04154826|DRUG|Recombinant human interleukin-7|weekly intra-muscular (IM) administration
48482200|NCT00466726|BIOLOGICAL|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
48482201|NCT00466726|BIOLOGICAL|sargramostim|
48482202|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy|The Food Farmacy arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective.
48482203|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes|The Food Farmacy + Cooking for Diabetes Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention.
48482204|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Health Impact Ohio Pathways Hub|The Food Farmacy + Health Impact Ohio Pathways Hub Arm receives weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective and has social needs address through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
48306495|NCT06555003|DRUG|Drug-Eluting Embolic Bead|A minimum of 2 sessions of DEBIRI treatment and 2-4 cycles of systemic chemotherapy are administered (based on tumor size, bilobar or unilobar involvement of the liver, treatment response rate, treatment tolerance, occurrence of side effects, and liver function). Prior to performing DEBIRI, initial angiography is done via the femoral or axillary artery to determine the anatomy of the right and left hepatic arteries as well as the arteries supplying the tumor. Subsequently, a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor. The intervention will be repeated to deliver 200 mg of irinotecan intravascularly to the liver mass. A 14-day interval between the procedures is established to minimize side effects. Targeted therapy administration for each treatment group based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status as explained in control arm.
48306496|NCT06555003|DRUG|Chemotherapy drug|Control group will receive 2-4 cycles of systemic chemotherapy based on functional status of the patient, adverse event rate and treatment tolerance, tumor size and characteristics. Targeted therapy administration for each treatment group in based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status (e.g., administration of Pembrolizumab for patients with high rosatellite instability (MSI-H) or Bevacizumab for tumors harboring KRAS mutations). Due to the targeted nature of these therapies, they can not be administered to all participants of the trial, while It is not ethically justifiable to withhold targeted therapies from patients who are candidates for these treatments based on their tumor characteristics and deprive them of potentially life-extending options.
48306497|NCT05505578|BEHAVIORAL|GamerFit Condition|Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.
48306498|NCT05505578|BEHAVIORAL|Comparator Condition|Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
48306499|NCT00235339|BEHAVIORAL|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
48306500|NCT00235339|BEHAVIORAL|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
48306501|NCT00843310|DRUG|Lenalidomide (Revlimid)|
48306502|NCT00843310|DRUG|Melphalan|
48306503|NCT00843310|DRUG|Dexamethasone|
48306504|NCT06346028|DEVICE|Brainsway H4 deep rTMS coil and Brainsway stimulator system|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC."
48306505|NCT00787696|BEHAVIORAL|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
48306506|NCT00868959|DRUG|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
48306507|NCT01996735|DRUG|Ticagrelor 180 mg single dose|
48306508|NCT01996735|DRUG|Placebo|
48306509|NCT03062904|DRUG|Inhaled Bronchodilators +/- Inhaled Methacholine|"1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations"
48482205|NCT05472441|BEHAVIORAL|Mid-Ohio Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub|The Food Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub Arm receives all 3 interventions. Participants receive weekly produce through a consortium of local food banks at the direction of the Mid-Ohio Food Collective, Cooking for Diabetes, a 6-week diabetes self-management education and support and culinary education intervention and has social needs addressed through a community health worker model at the direction of Health Impact Ohio. The community health worker meets with participants, evaluates and addresses non-medical, health-related social needs.
48482206|NCT06468306|PROCEDURE|non-invasive ventilation teraphy, NIV|Routine management regimes of NIV
48482207|NCT06437106|BEHAVIORAL|A blanket impregnated with the mother's odor|Intervention group 1 consists of premature babies who receive a blanket impregnated with the mother's odor.
48482208|NCT06437106|BEHAVIORAL|blanket without mother's smell|Intervention group two consists of preterm infants who receive blanket without mother's odor.
48482209|NCT06437106|BEHAVIORAL|control group|The control group includes premature babies who are not subjected to any intervention and receive the usual care.
48482210|NCT05750147|OTHER|Blood Sample Collection|Blood for DNA and biomarker analysis
48482211|NCT04825015|DEVICE|VEnaRt Cardiac Output|Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
48482212|NCT01524302|DRUG|Ceftaroline|600 mg Q12h
48482213|NCT01524302|DRUG|Levofloxacin|750 mg QD
48482214|NCT05567939|OTHER|Natural course of disease|Sample and questionnaire collection
48482215|NCT01473576|DIETARY_SUPPLEMENT|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
48482216|NCT01473576|DIETARY_SUPPLEMENT|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
48482217|NCT04760392|BEHAVIORAL|Goal-directed mobilization|"* A short educational intervention with handout of a leaflet on GDM.~* Definition of personal mobility goal level.~* Communication of the mobility goal level to involved stakeholders.~* Regular reassessment of the mobility goal level and booster sessions by physiotherapists."
48482218|NCT01886482|OTHER|nutrition intervention|high protein diet
48482219|NCT01513031|OTHER|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
48306510|NCT01240122|DEVICE|Biotrue MPS|Multi-purpose contact lens care solution
48306511|NCT01240122|DEVICE|Investigational MPS|Multi-purpose contact lens care solution
48306512|NCT00148460|DRUG|TNK-tPA|
48306513|NCT00148460|DRUG|rt-PA|
48306514|NCT02634918|OTHER|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
48306515|NCT02409784|DIETARY_SUPPLEMENT|Pre-KD|Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
48641568|NCT02367040|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
48306516|NCT02409784|DIETARY_SUPPLEMENT|Post-KD|After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
48482220|NCT04399642|PROCEDURE|Arthroplasty|All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision
48482221|NCT00731549|DRUG|Aripiprazole IM Depot|300mg or 400mg
48641569|NCT02367040|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
48641570|NCT02367040|DRUG|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
48641571|NCT01924065|PROCEDURE|Cardioversion|Electrical cardioversion
48641572|NCT01924065|DRUG|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
48641573|NCT02016599|OTHER|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
48641574|NCT03680508|DRUG|TSR-022 and TSR-042|immunotherapy
48482222|NCT03752554|PROCEDURE|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
48482223|NCT01095419|OTHER|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
48306517|NCT03166358|BEHAVIORAL|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
48306518|NCT02512003|DEVICE|Fantom Scaffold|
48306519|NCT06036433|DEVICE|Infrared laser photobiomodulation device|904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.
48306520|NCT06036433|DEVICE|Infrared & Red LED photobiomodulation device|Infrared \& red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
48641575|NCT06168578|DEVICE|ultrasound|Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
48641576|NCT06572449|DRUG|KarXT|Specified dose on specified days
48641577|NCT05995353|DRUG|Risankizumab|Intravenous (IV) Infusion
48641578|NCT05995353|DRUG|Risankizumab|Subcutaneous (SC) Injection
48306521|NCT00443339|DRUG|Darbepoetin|
48306522|NCT01327040|OTHER|light exposure|12-hour light exposure of approximately 200 lux
48306523|NCT04867655|OTHER|Orange Juice|Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
48306524|NCT04867655|OTHER|Orange juice with either 6g or 3 g of β-Glucan|Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
48306525|NCT02897973|OTHER|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
48306526|NCT02811458|BEHAVIORAL|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
48306527|NCT04349254|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
48306528|NCT04857073|OTHER|Glucose Monitoring|Glucose monitoring consists of finger stick fasting and 2 hours post prandial
48306529|NCT05641818|OTHER|Screening tool for vitamin D deficiency|(1) Determination of 25(OH) Vitamin D3 in human serum samples and (2) Question based screening tool with personal (age, gender,...), lifestyle (e.g. sun exposure, outdoor activity) and dietary factors that affect the status of vitamin D in the human body.
48641579|NCT04877691|DRUG|Medi-546|Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
48306530|NCT02642887|PROCEDURE|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
48306531|NCT01912729|BEHAVIORAL|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
48306532|NCT01912729|BEHAVIORAL|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
48641580|NCT04877691|DRUG|Placebo|Solution for injection in aPFS
48641581|NCT05495230|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
48641582|NCT05495230|OTHER|Usual care|See arm description.
48641583|NCT06375863|DIAGNOSTIC_TEST|QT and QTc interval|measuring of QT and QTc on ECG
48482224|NCT01095419|OTHER|Control|no intervention
48641584|NCT03328273|DRUG|Ceralasertib|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
48641585|NCT03328273|DRUG|Acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
48641586|NCT05877547|DRUG|Efinopegdutide|Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg
48641587|NCT05877547|DRUG|Semaglutide|SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg
48641588|NCT05877547|DRUG|Placebo|SC injection of matching placebo
48111715|NCT01305434|DIETARY_SUPPLEMENT|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
48111716|NCT03221569|DRUG|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
48641589|NCT06435520|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Adaptive cloud-based software delivering cognitive behavioral therapy tailored to the needs of the individual patient.
48641590|NCT06435520|BEHAVIORAL|Structured Medication Tapering|A structured tapering of hypnotic (or other) medication to promote successful discontinuation by patients seeking to discontinue use.
48641591|NCT05998642|DRUG|Methotrexate|3.5mg/m2 IV
48641592|NCT05998642|DRUG|Rituximab (where available)|375mg/m2 / 1400mg IV or SC
48641593|NCT05998642|DRUG|Ibrutinib|Dose and schedule assigned at enrollment
48641594|NCT02656173|DRUG|Mirabegron|Oral tablet
48641595|NCT02656173|DRUG|Placebo|Oral tablet
48641596|NCT02656173|DRUG|Tamsulosin|Oral tablet
48111717|NCT03221569|DRUG|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
48111718|NCT03221569|DRUG|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
48111719|NCT03221569|DRUG|Normal saline|1ml intravenous push as placebo for double-blinding purposes
48111720|NCT06191159|DEVICE|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
48111721|NCT06191159|DEVICE|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
48641597|NCT06106984|DEVICE|Graded motor imagery mobile app|The Graded Motor Imagery mobile app is a mobile app designed for intervention in phantom limb pain.
48641598|NCT05018091|DRUG|Dexamethasone 4mg|4mg intravenous dexamethasone, administered shortly after induction of anesthesia
48641599|NCT05018091|DRUG|Dexamethasone 8 Mg/mL Injectable Suspension|8mg intravenous dexamethasone, administered shortly after induction of anesthesia
48641600|NCT05018091|DRUG|Dexamethasone 16mg|16mg intravenous dexamethasone, administered shortly after induction of anesthesia
48641601|NCT00775853|DRUG|6-[18F]Fluorodopamine|
48641602|NCT00775853|DRUG|6-[18F]Fluorodopa|
48641603|NCT00775853|DRUG|13N-Ammonia|
48641604|NCT06689631|PROCEDURE|Respiratory Physiotherapy|Mucociliary clearance techniques (prolonged slow expiration and provoked cough), bronchodilator when prescribed and nebulisation with 3% hypertonic saline.
48641605|NCT06688721|DEVICE|Driving a bus equipped with EDA|Eco-driving assistance (EDA) systems is a technology integrated into vehicles that helps drivers to optimize fuel efficiency and reduce emissions by providing real-time feedback and guidance on driving behaviors. The system typically analyzes several driving behaviours that are measured using different captors and sensors. These systems aim to reduce the overall carbon footprint of driving, leading to cost savings for the public transport company and reduced environmental impact.
48111722|NCT06191159|DEVICE|Standard Electrocautery|Standard Electrocautery for entire surgery.
48306533|NCT00303108|DRUG|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
48306534|NCT00303108|DRUG|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
48306535|NCT00303108|DRUG|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
48306536|NCT03347331|DRUG|[18F]F13640|"Radiotracer injection and PET scan acquisition of 90 min:~\*150 Mbq + 1 MBq/Kg of \[18F\]F13640 at t=0 min~Arterial Blood Sampling during the 90min acquisition"
48482225|NCT03138824|PROCEDURE|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
48111723|NCT05786456|PROCEDURE|Discussion|Participate in group and web-based self-study sessions
48482226|NCT03138824|PROCEDURE|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
48111724|NCT05786456|OTHER|Informational Intervention|Receive handouts
48111725|NCT05786456|OTHER|Media Intervention|View videos
48111726|NCT05786456|OTHER|Questionnaire Administration|Ancillary studies
48306537|NCT03347331|DRUG|[18F]F13640|2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of \[18F\]F13640 at t=0 min
48306538|NCT02742649|DRUG|Fixed Combination|Continuous elution from the ocular insert.
48306539|NCT02742649|DRUG|Bimatoprost|Continuous elution from the ocular insert. This is an active control arm.
48306540|NCT02742649|DRUG|Timolol|Continuous elution from the ocular insert. This is an active control arm.
48306541|NCT02742649|DEVICE|Placebo Segment|One segment of placebo (no drug product)
48306542|NCT02742649|DRUG|Timolol 0.5%|0.5% timolol drops twice daily.
48306543|NCT05029596|DRUG|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
48306544|NCT05029596|DRUG|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
48482227|NCT01714050|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
48482228|NCT01714050|DEVICE|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
48641606|NCT06588400|DEVICE|AOSEPT Plus and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
48641607|NCT06588400|DEVICE|AOSEPT Plus with HydraGlyde and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus with HydraGlyde) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
48641608|NCT06588400|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
48111727|NCT05786456|BEHAVIORAL|Telephone-Based Intervention|Participate in check-in calls
48111728|NCT05757310|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
48111729|NCT05757310|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48111730|NCT05757310|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
48111731|NCT05757310|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48111732|NCT05757310|DRUG|Cyclophosphamide|Given PO and IV
48111733|NCT05757310|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo CD4+ T-cell depleted haploHCT
48111734|NCT05757310|DRUG|Pentostatin|Given IV
48111735|NCT05757310|OTHER|Questionnaire Administration|Ancillary studies
48111736|NCT05149313|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
48111737|NCT05149313|DRUG|Lebrikizumab-matching Placebo|Matching Placebo solution for injection administered subcutaneously.
48111738|NCT00193297|DRUG|Topotecan|
48111739|NCT00193297|DRUG|Paclitaxel|
48111740|NCT00193297|DRUG|Carboplatin|
48111741|NCT06015750|DRUG|methotrexate|Methotrexate will be administered SC or orally weekly for 104 weeks.
48482229|NCT02234206|DRUG|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940"
48482230|NCT05616078|OTHER|laser treatment|a maximum of 4 sessions, with an interval of 3 to 4 weeks
48482231|NCT05616078|OTHER|cryotherapy|a maximum of 4 sessions, with an interval of 3 to 4 weeks
48111742|NCT06015750|DRUG|rituximab|Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
48306545|NCT02918487|DRUG|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
48306546|NCT02918487|DRUG|Placebo|Inactive compound that is similar looking as the intervention
48306547|NCT02322320|DRUG|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
48306548|NCT00944606|DIETARY_SUPPLEMENT|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
48482232|NCT02190448|DIETARY_SUPPLEMENT|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
48482233|NCT02190448|DIETARY_SUPPLEMENT|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
48482234|NCT05307159|DIETARY_SUPPLEMENT|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
48482235|NCT01720420|DEVICE|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
48641609|NCT06624670|DRUG|Spesolimab|Solution for infusion
48641610|NCT06624670|DRUG|Placebo matching to spesolimab|Placebo matching to spesolimab
48306549|NCT00944606|OTHER|Placebo candy|candy gum drops
48306550|NCT03442335|DIAGNOSTIC_TEST|Chromohysteroscopy|Standard hysteroscopy followed by injection of a dye, in this case iodine.
48306551|NCT03442335|DIAGNOSTIC_TEST|Endometrial biopsy (Pipelle)|A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
48306552|NCT05122663|BEHAVIORAL|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
48306553|NCT05122663|OTHER|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
48306554|NCT05293132|DRUG|Montelukast Sodium 10 mg|Film coated tablets containing 10 mg montelukast
48306555|NCT05293132|DRUG|Co-Enzyme Q10|Capsules contain 210 mg Co-Enzyme Q10
48306556|NCT05293132|DRUG|Standard Treatment|Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
48306557|NCT04307147|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
48306558|NCT04307147|DRUG|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
48306559|NCT00595699|DRUG|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
48306560|NCT00595699|DRUG|placebo|Placebo
48306561|NCT01680406|DRUG|Artemether-lumefantrine combination|
48306562|NCT01680406|DRUG|Primaquine|
48306563|NCT01680406|DRUG|Chloroquine|
48306564|NCT06368739|BEHAVIORAL|Nurture program|"1. Nurture Monthly Packages: Sent every four weeks until the member reaches the end of pregnancy (delivery or other reasons, e.g., miscarriage), with a maximum of eight packages. Each package includes:~   * A US$40 gift card (2 x $20 each) to a grocery store.~  * A healthy eating information sheet selected from Brighter Bites project (https://brighterbites.org/).~  * A set of three recipes.~  * Nutrition-related Frequently Asked Questions (included in four out of the eight packages).~2. Two 30-Minute Nutritional Consultations over the phone: Designed by a Registered Dietitian Nutritionist (RDN) who trained a bilingual nutrition specialist to deliver the consultations. Topics revolved around healthy eating during pregnancy, such as food choices, portion sizes, budget-friendly shopping, food safety, and food preparation. No nutrition therapy advice to manage diseases was provided."
48306565|NCT06368739|OTHER|Regular benefits|Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP.
48306566|NCT05012319|DRUG|to be given as a treatment|"Nitric Oxide Nasal Spray Enovid"
48306567|NCT03914287|OTHER|Self-Myofascial release|The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
48306568|NCT06150690|OTHER|No intervention|The participants did not receive any study-specific intervention
48306569|NCT05644665|DRUG|Ozanimod|Specified dose on specified days
48306570|NCT05644665|DRUG|Placebo|Specified dose on specified days
48306571|NCT05618457|DRUG|Aminoglycoside dose adjustment|Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
48306572|NCT01035606|BEHAVIORAL|training in goal-directed attention regulation|training in goal-directed attention regulation
48306573|NCT01035606|BEHAVIORAL|brain health education|brain health education workshops
48482236|NCT03357887|OTHER|Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples
48641611|NCT06624670|DRUG|Prednisone|Prednisone
47959258|NCT06263556|BEHAVIORAL|Pelvic floor exercises|"Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day"
47959259|NCT06263556|DEVICE|Transcutaneous posterior tibial nerve stimulation|Patients in TTSN group will receive posterior tibial nerve stimulation based on the protocol explained before.
47959260|NCT06263556|DEVICE|Sham stimulation|Patients in sham stimulation group will receive sham stimulation based on the protocol explained before.
47959261|NCT01195246|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injection on Day1
48306574|NCT01035606|BEHAVIORAL|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
48306575|NCT01333982|OTHER|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
48641612|NCT06624670|DRUG|Prednisolone|Prednisolone
48306576|NCT01333982|OTHER|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
48306577|NCT00206999|DRUG|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
48306578|NCT01801137|DRUG|Everolimus (Afinitor®)|
48306579|NCT00981383|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
48306580|NCT00981383|OTHER|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
48306581|NCT03072719|DRUG|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
48306582|NCT03072719|DRUG|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
48306583|NCT03988829|BEHAVIORAL|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
48306584|NCT03988829|BEHAVIORAL|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
48306585|NCT03988829|BEHAVIORAL|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
48306586|NCT00004895|DRUG|octreotide acetate|
48306587|NCT05811494|DEVICE|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
48306588|NCT05811494|DEVICE|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
48306589|NCT05811494|DEVICE|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
48306590|NCT05811494|DEVICE|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
48306591|NCT06555692|BIOLOGICAL|Transplant acellular dermal matrix(ADM)|The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.
48306592|NCT00527111|DRUG|Cetuximab|
48482237|NCT00611884|DRUG|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
48306593|NCT00527111|DRUG|5-fluorouracil|
48482238|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
48482239|NCT00611884|DRUG|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
48306594|NCT00527111|RADIATION|Pelvic irradiation|
48306595|NCT01601054|DEVICE|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
48306596|NCT01623817|DRUG|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
48306597|NCT01629342|BEHAVIORAL|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~* treadmill walking (5 minutes, 1 and 2km/h)~* staircase walking (1 floor, normal pace)~* cycling with fixed load (5 minutes)~* standing up from sitting position and sitting down again (x5)~* standing up from supine position~* turning from left to right and back while lying in bed~* raising outstretched arm 90° (x5, standing position)~* eating (5 minutes, sitting position)~* drinking a glass of water~* sleeping (6 hours)"
48306598|NCT00000748|DRUG|Sulfamethoxazole-Trimethoprim|
48306599|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
47959262|NCT01195246|BIOLOGICAL|Engerix-B|Intramuscular (IM) injection on Day 1
47959263|NCT01195246|BIOLOGICAL|Fendrix|Intramuscular (IM) injection on Day 1
48306600|NCT01109004|DRUG|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
48306601|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
48482240|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
48482241|NCT00611884|DRUG|metformin|Tablets, 1500-2000 mg/day
48306602|NCT03063775|DEVICE|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
48306603|NCT03063775|OTHER|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
48306604|NCT03063775|OTHER|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
48306605|NCT03063775|DEVICE|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
48306606|NCT06265077|DRUG|Placebo|Placebo
48306607|NCT06265077|DRUG|famotidine and loratadine|famotidine 20 mg once daily and loratadine 10 mg once daily
48306608|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
48306609|NCT01301742|DRUG|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
48306610|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
48306611|NCT02915861|OTHER|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
48306612|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
48306613|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
48306614|NCT02915861|OTHER|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
48306615|NCT05437172|PROCEDURE|injectable platelet rich fibrin with demineralized dentin graft|after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
48306616|NCT05437172|PROCEDURE|demineralized dentin graft|"after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures."
48306617|NCT04290962|BEHAVIORAL|Lifestyle Therapy|Complete web-based lifestyle intervention
48306618|NCT04290962|OTHER|Quality-of-Life Assessment|Ancillary studies
48306619|NCT04290962|OTHER|Questionnaire Administration|Ancillary studies
48306620|NCT00175175|BEHAVIORAL|"Allied health professional-run osteoporosis service (case-management)"|
48306621|NCT06227390|PROCEDURE|partial pulpotomy|2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
48306622|NCT03551301|OTHER|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
48306623|NCT06336577|OTHER|lower respiratory tract disease|lower respiratory tract disease
48306624|NCT03075397|OTHER|blood sample|A sample of HIV-1 infected patients's blood is collected
48306625|NCT03075397|OTHER|sperm sample|A sample of HIV-1 infected patients's sperm is collected
48497886|NCT04126213|DRUG|Placebo|One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
48497887|NCT01689818|OTHER|exercise training|exercise training program which included aerobic exercise for 3 times per week.
48641613|NCT05576207|DIETARY_SUPPLEMENT|Balanced energy and protein supplement for pregnant women|A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.
48641614|NCT05576207|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement for pregnant women|"Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group."
48306626|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
48306627|NCT03009331|PROCEDURE|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
48306628|NCT02435277|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
48306629|NCT02435277|DRUG|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
48306630|NCT02435277|DRUG|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
48306631|NCT02435277|DRUG|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
48306632|NCT03403504|DRUG|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
48306633|NCT03403504|DRUG|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
48306634|NCT01563562|DRUG|Bardoxolone Methyl|Oral, Single dose
48497888|NCT02554136|DRUG|HGP0918|
48497889|NCT02554136|DRUG|HGP0816|
48641615|NCT06445166|DRUG|Propranolol Hydrochloride|"Dosing is as follows:~* Patients who weigh 40 to 59 kg:~  * 40 mg BID (target)~ * 20 mg BID (half the target)~* Patients who weigh ≥ 60 kg:~  * 60 mg BID (target)~ * 30 mg BID (half the target)"
47959264|NCT06250777|DRUG|Trastuzumab deruxtecan|"Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg"
48306635|NCT06512415|DRUG|10 mcg Norepinephrine|The assigned dose (10 mcg) will be diluted with normal saline in a 10-cc syringe
48306636|NCT06512415|DRUG|15 mcg Norepinephrine|The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
48306637|NCT02687594|DRUG|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
48306638|NCT00008294|DRUG|FOLFOX regimen|
48306639|NCT00008294|DRUG|dexamethasone|
48306640|NCT00008294|DRUG|floxuridine|
48306641|NCT00008294|DRUG|fluorouracil|
48482242|NCT05342207|PROCEDURE|Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy|A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
48482243|NCT02610920|PROCEDURE|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
48482244|NCT02610920|DRUG|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
48482245|NCT06616012|DEVICE|Neosense umbilical catheter|The Neosense umbilical catheter is used instead of a standard umbilical catheter
48482246|NCT05082363|COMBINATION_PRODUCT|C4d evaluation in lupus nephritis in serum and renal tissue|C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)
48482247|NCT00393120|DRUG|INCB009471|100mg SR (sustained release) orally once daily
48497890|NCT02554136|DRUG|HGP0918 + HGP0816|
48641616|NCT06681727|OTHER|Accessible Video Mental Healthcare Triage and Assessment (IP)|Patients aged 18 years and older who were registered at participating primary care centers were eligible to access the IP through a regional healthcare app. IP comprised a brief digital screening followed by a 45-minute video consultation with a mental health professional. Eligible patients could thereafter schedule appointments at cooperating healthcare centers and clinics through the app used for video consultations.
48641617|NCT05108974|DRUG|Choline Bitartrate|Powdered drink mix for daily consumption
48306642|NCT00008294|DRUG|leucovorin calcium|
47959265|NCT03175757|DIETARY_SUPPLEMENT|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
48306643|NCT00008294|DRUG|oxaliplatin|
48306644|NCT00307060|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
48306645|NCT00307060|DRUG|losartan / Duration of Treatment: 6 weeks|
48306646|NCT04477304|BEHAVIORAL|Opioid Naive, OR|Visits where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days and clinician is on the clinic list as a treating member of the clinic
48306647|NCT04477304|BEHAVIORAL|At-risk for long-term use, OR|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days and clinician is on the clinic list as a treating member of the clinic
47959266|NCT03175757|DIETARY_SUPPLEMENT|Placebo|Placebo
48306648|NCT04477304|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days and clinician is on the clinic list as a treating member of the clinic
48306649|NCT05863689|DIAGNOSTIC_TEST|Spectralis SD-OCT|Optical Coherence Tomography
48306650|NCT05597436|DRUG|Trehalose|Once weekly 0.75g/kg administration
48306651|NCT00748540|DEVICE|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
48111743|NCT06015750|DRUG|bortezomib|Bortezomib will be administered via IV bolus or SC, as needed.
48111744|NCT06015750|DRUG|IVIg|IVIg will be administered via IV monthly through initial 74 weeks.
47959267|NCT06277557|OTHER|Virtual Reality|Virtual reality learning platform as intervention in this study
48306652|NCT03025048|BEHAVIORAL|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
48306653|NCT04111276|DEVICE|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
48306654|NCT04111276|OTHER|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
48482248|NCT00393120|DRUG|INCB009471|300mg SR (sustained release) orally once daily
48482249|NCT00393120|DRUG|Placebo comparator|Orally once daily
48482250|NCT00734110|DEVICE|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
48482251|NCT04694612|DRUG|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
48482252|NCT04694612|DRUG|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
48482253|NCT04694612|DRUG|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
48482254|NCT03617627|BEHAVIORAL|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
48641618|NCT04964466|BIOLOGICAL|Amount of PDGF-BB in PRF preparation vs. GEM21|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
47959268|NCT06350396|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
48482255|NCT03405376|DRUG|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
48482256|NCT01320020|DRUG|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
48482257|NCT05732181|DRUG|The skin lidocaine patch.|The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.
48482258|NCT05732181|DRUG|Placebo|patch without drugs
48482259|NCT00311350|DRUG|MOA-728|
48111745|NCT06015750|DRUG|Folic Acid|Folic acid will be given orally as long as methotrexate is being dosed.
48306655|NCT04111276|DIAGNOSTIC_TEST|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
48306656|NCT04111276|DIAGNOSTIC_TEST|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
48306657|NCT04082364|BIOLOGICAL|margetuximab|margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
48306658|NCT04082364|BIOLOGICAL|Retifanlimab|Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
48306659|NCT04082364|BIOLOGICAL|Tebotelimab|Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
48306660|NCT04082364|BIOLOGICAL|Trastuzumab|Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
48497891|NCT00752830|DRUG|AZD0328|Oral capsule, single dose
48497892|NCT01732874|DRUG|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
47959269|NCT06350396|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
47959270|NCT03960814|DRUG|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
47959271|NCT05962931|BIOLOGICAL|Bioengineered Artificial Mesenchimal Sheet (BAMS)|Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
47959272|NCT05962931|PROCEDURE|Standard treatment (Control)|Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
47959273|NCT05350410|BEHAVIORAL|HALT-AD|HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
47959274|NCT00362557|DEVICE|MRI|Magnetic resonance imaging
47959275|NCT03214315|PROCEDURE|Visceral adipose tissue specimen|specimen
48306661|NCT04082364|OTHER|Chemotherapy|"Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6~Chemotherapy~XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion~mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion."
48306662|NCT02292303|DIETARY_SUPPLEMENT|zinc-enriched yeast|
48306663|NCT02292303|DIETARY_SUPPLEMENT|Zinc references|
48306664|NCT00913978|DEVICE|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
48306665|NCT00913978|DEVICE|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
48111746|NCT06435273|DRUG|AZD4604|Janus kinase 1 (JAK1) inhibitor
48111747|NCT06435273|DRUG|Placebo to AZD4604|Placebo to AZD4604
48306666|NCT00366730|DRUG|Nitazoxanide|
48306667|NCT05892133|BEHAVIORAL|Maximal strength training|3 sessions/ week. leg press at \~85% of one repetition maximum for 8 weeks
48482260|NCT02331238|BEHAVIORAL|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
48482261|NCT01413282|RADIATION|Cardiac CT|Calcium scan and CT coronary angiography
48482262|NCT01807117|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
48482263|NCT01807117|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
48482264|NCT01807117|PROCEDURE|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
48482265|NCT01807117|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
48482266|NCT04301245|OTHER|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
48482267|NCT06064734|DEVICE|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
48482268|NCT06172413|DEVICE|transcranial alternating current stimulation (tACS)|"Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min."
48482269|NCT06172413|DEVICE|Sham tACS|Sham tACS
48111748|NCT04035291|OTHER|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
48111749|NCT04743973|DEVICE|Muse S™ Headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
48111750|NCT02637687|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
48111751|NCT04136912|DRUG|Definity|Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information. When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
48111752|NCT04136912|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8).~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
48482270|NCT01551147|DRUG|ONO-6950|200 mg QD for 8 days
48482271|NCT01551147|DRUG|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
48482272|NCT01551147|DRUG|Montelukast|10 mg Montelukast QD for 8 days
48482273|NCT00640263|DRUG|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
48306668|NCT06086639|OTHER|Online Occupational Therapy Group Training|In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
48306669|NCT04053179|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
48306670|NCT02932475|DRUG|Metformin|1000 mg twice a day
48306671|NCT02932475|DRUG|Placebo|Delivered to match active drug
48306672|NCT04669678|DRUG|Etonogestrel (ETG) implant|Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
48306673|NCT04669678|DRUG|Intramuscular depo-medroxyprogesterone acetate (IM DMPA)|DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
48306674|NCT04669678|DRUG|Sub-cutaneous medroxyprogesterone acetate (SC MPA)|SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
48306675|NCT04669678|DEVICE|Non-hormonal intrauterine device (IUD)|The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
48306676|NCT03169738|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
48306677|NCT03169738|BIOLOGICAL|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
48111753|NCT06070415|DEVICE|Chatbot|12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform
48111754|NCT06070415|OTHER|Home exercise, usual care|12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
48111755|NCT06070415|OTHER|Education|One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home
48306678|NCT03169738|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
48306679|NCT03169738|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
48306680|NCT03169738|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48306681|NCT03169738|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48306682|NCT03169738|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
48482274|NCT00640263|DRUG|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
48111756|NCT06368089|OTHER|Inspiratory muscle training (IMT) group|The IMT group receives inspiratory muscle training of 50%MIP, 6 breaths/set 10 sets/day for 7 days combined with conventional chest physiotherapy including; percussion, vibration, postural draining, positioning, and passive range of motion.
48111757|NCT06368089|OTHER|Early mobilization (EM) group|The ER group received active exercise in sitting, standing, and marching 30 minutes/day for 7 days with conventional chest physical therapy
48111758|NCT05831202|DEVICE|The SEAL™ Saccular Endovascular Aneurysm Lattice System|All adult subjects between 22 and 80 years of age and presenting with an unruptured or ruptured saccular Wide Neck intracranial aneurysm with less or equal to 19 mm in its equatorial width (2mm-19mm range) that in the opinion of the Principal Investigator (PI) requires treatment and suitable candidate for intrasaccular flow diversion treatment, who meet all eligibility criteria, will be considered for study enrollment.
48111759|NCT06100705|DRUG|Testosterone Cypionate|Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.
48641619|NCT04964466|BIOLOGICAL|Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation|Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
48641620|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes|The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
48641621|NCT04964466|BIOLOGICAL|Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes|The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
48641622|NCT05027139|DRUG|Zanidatamab|Administered intravenously (IV)
48641623|NCT05027139|DRUG|Evorpacept|Administered IV
48641624|NCT04132505|DRUG|Binimetinib|Given PO
48641625|NCT04132505|DRUG|Hydroxychloroquine|Given PO
48641626|NCT03625648|DRUG|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
48641627|NCT03625648|DRUG|Placebo|placebo
48641628|NCT04746183|DRUG|CST-2: EIDD-2801|"CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
48641629|NCT04746183|DRUG|CST-2: Placebo|CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).
48306683|NCT03169738|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
48306684|NCT03169738|DRUG|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
48306685|NCT03169738|BIOLOGICAL|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
48306686|NCT03169738|DRUG|Lovaza|Omega-3-acid ethyl esters
48306687|NCT03169738|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
48306688|NCT03169738|RADIATION|Stereotactic Body Radiation Therapy|(SRBT)
48306689|NCT03169738|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL15N72D:IL-15RαSu/IgG1 Fc complex\]
48306690|NCT03169738|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
48306691|NCT03169738|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
48306692|NCT03169738|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
48306693|NCT03169738|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
48306694|NCT03169738|BIOLOGICAL|GI-4000|Ras yeast vaccine
48306695|NCT03169738|BIOLOGICAL|GI-6207|CEA yeast vaccine
48306696|NCT03169738|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
48641630|NCT04746183|DRUG|Nitazoxanide|"CST3A \& CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.~Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose."
48641631|NCT04746183|DRUG|VIR-7832|"CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.~Phase II: As per Phase I, with the dose determined by the recommended phase II dose."
48641632|NCT04746183|DRUG|VIR-7831|CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.
48641633|NCT04746183|DRUG|CST-5: Placebo|CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour
48641634|NCT04746183|DRUG|Favipiravir|CST-6: Multiple doses of IV Favipiravir will be administered by intravenous (IV) infusion over 1 hour. Dosing regimen will be every 12 hours for 7 days duration. The starting dose will be 600mg (BID), and dose escalations to 1200mg (BID), 1800mg (BID) and 2400mg (BID) are anticipated as well as a de-escalation dose of 300mg (BID) if necessary, with de-escalation and escalation guided by emerging safety data and decision by the Safety Review Committee (SRC).
48641635|NCT04746183|DRUG|Molnupiravir|Molnupiravir 800mg Twice a day (BD) for 5 days as starting dose, with a de-escalation protocol reducing in increments of molnupiravir to 600mg BD, then 400mg BD if required.
48641636|NCT04746183|DRUG|Paxlovid|Paxlovid® (300mg nirmatrelvir + ritonavir 100mg) twice a day (BD) for 5 days. The dose of Paxlovid® will be fixed for all cohorts.
48306697|NCT03169738|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
48306698|NCT02261870|DEVICE|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
48306699|NCT02088684|DRUG|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
48306700|NCT02088684|DRUG|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
48306701|NCT02088684|DRUG|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
48306702|NCT02088684|DRUG|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
48306703|NCT00683358|BIOLOGICAL|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A\*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
48306704|NCT03184909|DRUG|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
48306705|NCT03184909|DRUG|Placebo|Placebo capsules of look alike inert substance for control
48306706|NCT02362308|OTHER|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
48641637|NCT04746183|DRUG|ALG-097558|ALG-097558 600 mg Twice a day (BD) for 5 days
48641638|NCT04746183|DRUG|ALG-097558 and Remdesivir|ALG-097558 600 mg Twice a day (BD) for 5 days Remdesivir will be administered once daily by intravenous infusion over 30 to 120 minutes. 200 mg will be given on day 1 and 100 mg on day 2 and day 3.
48641639|NCT04746183|DRUG|NHS standard of care as per COVID-19 treatment guidelines|NHS standard of care as per COVID-19 treatment guidelines
48641640|NCT06690580|OTHER|Motivational interviewing based on the knowledge motivation behavior skills model|Breastfeeding education that includes motivational interviews based on the knowledge motivation behavior skills model
48641641|NCT06585423|DIAGNOSTIC_TEST|Sterile commercially available bandage contact lens|Medical grade acrylic tip covered by a sterile commercially available bandage contact lens
48641642|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness <100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \<100 µm
48641643|NCT06585423|DIAGNOSTIC_TEST|Medical grade silicone of a thickness >100 µm|Medical grade acrylic tip coated with medical grade silicone of a thickness \>100 µm
48641644|NCT05996068|DEVICE|arterial line|insert arterial line for patients who meet major trauma criteria
48306707|NCT02362308|DRUG|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
48306708|NCT06198621|DEVICE|cardiometry|cardiometry is noninvasive method, while swan ganz is invasive method in hemodynamic parameters assessment
48306709|NCT00041613|GENETIC|INGN 201|
48306710|NCT05128435|DIAGNOSTIC_TEST|Blood sample|Blood sample taken 3 to 5 months after the infection
48306711|NCT00745485|DRUG|zoledronic acid|
48306712|NCT01823627|PROCEDURE|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
48306713|NCT04089605|DRUG|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
48306714|NCT04089605|DRUG|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
48306715|NCT03220048|DRUG|PrEP-001|
48306716|NCT03220048|OTHER|Placebo Comparator|
48306717|NCT05195333|OTHER|The exercise program|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
48306718|NCT05195333|OTHER|The exercise program|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
48306719|NCT05201859|DRUG|Sintilimab|Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
48306720|NCT05201859|DRUG|Capecitabine|An oral anticancer agent that can be converted into 5-Fu in vivo.
48641645|NCT06393985|DRUG|Decitabine, venetoclax and blinatumomab|"Cycle1 and cycle3： Decitabine monotherapy,20 mg/m2 qd, d1-5,intravenous infusion;~Cycle2 and cycle4:~Venetoclax 200mg qd, d1-14, orally; Blinatumomab d4-17(Weight ≥45 kg, 9ug d4-6, 28ug d7-17; Weight \<45 kg, 5ug/m2 d4-6, 15ug/m2 d7-17;continuous intravenous infusion)"
48641646|NCT05466799|DRUG|FOLFIRINOX chemotherapy|Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
48641647|NCT05466799|DEVICE|OncoSil™|Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance
48641648|NCT05554003|DRUG|Temozolomide capsule|Metronomic temozolomide 60 mg/die continuously
48641649|NCT06171737|BEHAVIORAL|Decision Aid|The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery
48641650|NCT06171737|BEHAVIORAL|Shared Decision Making Skills Training|60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
48641651|NCT06592521|DEVICE|OPTI-FREE EXPRESS MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
48641652|NCT06592521|DEVICE|OPTI-FREE PureMoist MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
48111760|NCT06100705|DRUG|Sipuleucel-T|Sipuleucel-T is the first FDA-approved immunotherapy in treatment of mCRPC. It is a therapeutic cancer vaccine composed of activated autologous dendritic cells loaded with an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, PAP-GMCSF, also called PA2024. This cellular product is prepared in three steps: (1) leukapheresis to isolate CD54+ dendritic cells, (2) the cells and harvested and cultured with PA2024 ex vivo, and (3) re-infusion of the activated DC into the original patient. The preparation and administration of this autologous cellular product are done every 2 weeks for a total of three infusions and is designed to elicit an immune response to prostatic acid phosphatase.
48111761|NCT06677112|PROCEDURE|Selective surgical staging|Intraoperative Consultation, performed by pathologist and surgeon jointly. The uterus is inspected for extra-corpus spread (cervix, parametria, adnexa, distant). The surgical pathologist will evaluate the uterus according to the IOC Worksheet and promptly notify the surgeon of the results. The IOC will include evaluation for extra-corpus disease, lesion measurement, frozen section (to confirm measured lesion is malignant, cell type, and re-grading of tumor). Non-sentinel nodes will be handled according to institutional standard-of-care practice.
48111762|NCT06677112|PROCEDURE|REFLEX|The surgeon will perform a side-specific lymphadenectomy when there is no mapping on a hemipelvis (no tracer uptake in nodes). If neither side has successful Sentinel Node mapping, the surgeon performs a complete pelvic lymphadenectomy. Surgeons will remove the para-aortic lymph nodes at their discretion.
48111763|NCT05062577|DRUG|ASP8062|oral
48111764|NCT05062577|DRUG|Placebo ASP8062|oral
48111765|NCT05062577|DRUG|buprenorphine/naloxone|sublingual
48111766|NCT06101992|DRUG|Mesoglycan|Mesoglycan capsules 50 mg are composed by heparan sulphate 47.5%, dermathan sulphate 35.5%, chondroitin sulfate 8.5%,slow heparin 8.5%, excipients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine
48641653|NCT06592521|DEVICE|OPTI-FREE REPLENISH MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
48641654|NCT06592521|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
48641655|NCT06113614|PROCEDURE|Physiotherapy|All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019. To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.
48641656|NCT06113614|DEVICE|Photobiomodulation|The PBM will be applied with LED devices in the form of a shoulder brace. The applications will occur every day starting 24 hours after the surgical procedure. The shoulder brace from the brand Cosmedical (Mauá, SP, Brazil) contains 70 red LEDs and 70 infrared LEDs. The area corresponding to the fixation plate will not be irradiated (no LEDs will be placed). PBM will be applied every day for 10 minutes using a device containing 318 light-emitting diodes (LEDs), including 159 LEDs at 660 nm (28.5 mW; 12 J/cm2 to 17 J) and 159 LEDs at 850 nm (23 mW; 10 J/cm2 to 14 J).
48641657|NCT06113614|DEVICE|Simulation of photobiomodulation|The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
48641658|NCT05784597|DRUG|[68Ga]Ga-OncoFAP administration|All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
48641659|NCT00708448|RADIATION|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
48641660|NCT00708448|DRUG|Erlotinib|150 mg/day
48111767|NCT06101992|OTHER|Placebo|placebo capsules are composed by lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate
48111768|NCT06532435|DIETARY_SUPPLEMENT|DHA & ARA Candy|Parpicipants need to eat 1-2 candy daily, for 4 consective weeks
48306721|NCT03046472|OTHER|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
48482275|NCT05631249|DRUG|Sotorasib 120Mg Tab|Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
48482276|NCT00116519|DRUG|PPAR alpha|
48482277|NCT00116519|DRUG|placebo|
48482278|NCT05941273|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
48482279|NCT01980342|DRUG|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
48306722|NCT02329873|BEHAVIORAL|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
48306723|NCT03455478|DEVICE|spectacles|dispending spectacles for uncorrected refractive error
48306724|NCT04623190|BEHAVIORAL|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
48306725|NCT04623190|BEHAVIORAL|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
48306726|NCT04152005|OTHER|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
48306727|NCT03161678|DRUG|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
48306728|NCT03161678|DRUG|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
48306729|NCT03929588|DEVICE|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
48306730|NCT03929588|DEVICE|Phoropter|Manual refraction and ETDRS chart
48306731|NCT03929588|DEVICE|Autorefractor|Automated refraction
48306732|NCT01739777|BIOLOGICAL|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
48306733|NCT01739777|OTHER|Controls|Autologous Serum will administrated as placebo
48306734|NCT00601588|DRUG|Sertraline|
48482280|NCT04054284|DIETARY_SUPPLEMENT|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
48482281|NCT04054284|DIETARY_SUPPLEMENT|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
48641661|NCT00708448|DRUG|Bevacizumab|15mg/kg q 21 days
48641662|NCT05799625|BEHAVIORAL|StepOne Smartphone Application|This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.
48641663|NCT06654297|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
48641664|NCT06654297|DRUG|Palbociclib(100mg)|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
48306735|NCT04371172|OTHER|cognitive research battery, MRI, laboratory values|cognitive research battery, MRI, laboratory values
48306736|NCT06175611|DEVICE|COVID-19/Flu A/Flu B/RSV Test Kit|"The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants."
48306737|NCT05050630|DRUG|TR2-ICE|Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
48641665|NCT06654297|DRUG|Palbociclib(125mg)|Palbociclib will be given at a dose of 125 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
48482282|NCT06465732|DRUG|Dupilumab|the active comparator arm receive dupilumab only
48482283|NCT06465732|DRUG|Tofacitinib|the experimental arm receive dupilumab plus tofacitinib.
48482284|NCT04633642|PROCEDURE|Ultrasound group|Every week during a six-week treatment period
48482285|NCT04633642|PROCEDURE|Surgical group|Every week during a six-week treatment period
48482286|NCT01749748|PROCEDURE|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
48306738|NCT03236350|DEVICE|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
48306739|NCT03236350|DEVICE|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
48306740|NCT04975256|DRUG|MRTX849|KRAS G12C inhibitor
48306741|NCT04975256|DRUG|BI 1701963|SOS1 Inhibitor
48306742|NCT03414840|DRUG|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
48306743|NCT05397613|BEHAVIORAL|STAIR|Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials. STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
48306744|NCT02560688|DRUG|DS-1040b|20 mg single 12-hour intravenous infusion
48306745|NCT02560688|DRUG|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
48111769|NCT06496958|DEVICE|CO2 insufflation with an abdominal compression device|For participants randomized to the intervention group, the back brace support belt, Maxbelt (me3 type, Nippon Sigmax Co., Tokyo, Japan), will be applied around the circumference of the lower abdomen. Five sizes of Maxbelt will be employed in this study. According to the manufacturer, the ultra small-size (XS-size) belt will be used in those patients with an abdominal circumference of 55 cm-65 cm, the small-size (S-size) belt will be used in those patients with an abdominal circumference of 65 cm-75 cm, the medium-size (M-size) belt will be used for a circumference of 75 cm-85 cm, the large-size (L-size) belt will be used for a circumference of 85 cm-95 cm, and the ultra large-size (XL-size) will be used for a circumference of 95 cm-105 cm. Once applied, participants will be asked to assess and confirm that the belt is fastened tightly but not uncomfortably.
48111770|NCT06496958|DEVICE|CO2 insufflation with a sham abdominal compression device|The study coordinator will fit the sham device in a private bay alone with the patient. For participants randomized to the sham control group, a larger-sized Maxbelt with loose fitting will be used as a sham device. The L-size Maxbelt will be used in those patients with an abdominal circumference of 55 cm-71 cm, the XL-size Maxbelt will be used in in those patients with an abdominal circumference of 72 cm-88 cm, and the 2 XL-size Maxbelt will be used in in those patients with abdominal circumference 89 cm-105 cm.
48306746|NCT02519751|DIETARY_SUPPLEMENT|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
48306747|NCT02519751|DIETARY_SUPPLEMENT|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
48306748|NCT04541849|OTHER|Critical Care|Critical care in the intensive care units
48306749|NCT01958736|OTHER|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
48306750|NCT01958736|OTHER|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
48306751|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
48306752|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
48306753|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
48306754|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
48306755|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
48306756|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
48306757|NCT01142219|DRUG|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
48306758|NCT01142219|DRUG|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
48306759|NCT04224740|DRUG|Pembrolizumab|Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
48306760|NCT04224740|DRUG|Standard of care therapy|Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
48306761|NCT03293095|PROCEDURE|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
48306762|NCT05091489|OTHER|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
48306763|NCT03308084|DRUG|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
48306764|NCT03308084|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
48306765|NCT02411201|DRUG|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
48306766|NCT05980117|DRUG|Remimazolam|Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
48306767|NCT05980117|DRUG|Midazolam|Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
48306768|NCT05740436|OTHER|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
48306769|NCT05862324|BIOLOGICAL|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
48306770|NCT05187806|BEHAVIORAL|motivational interview|After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
48306771|NCT00571363|PROCEDURE|standard surgery|excision with 4 mm margins
48306772|NCT00571363|PROCEDURE|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
48306773|NCT03241758|DIAGNOSTIC_TEST|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
48306774|NCT01395095|OTHER|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
48306775|NCT01395095|OTHER|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
48482287|NCT05179694|DIAGNOSTIC_TEST|Prostate biopsy|Prostate biopsy via either the Transrectal route (comparator) or Transperineal route (experimental), each under local anaesthetic.
48482288|NCT02707926|DRUG|Anti-HIV Agents|Therapy to treat HIV infection
48482289|NCT01276717|DRUG|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
48482290|NCT01276717|DRUG|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
48482291|NCT03845413|BEHAVIORAL|Control|Schedule an appointment to attend tobacco cessation at Basic Health Unit
48482292|NCT03845413|BEHAVIORAL|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
48482293|NCT00911599|DIAGNOSTIC_TEST|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
48482294|NCT04062994|BEHAVIORAL|Nudge to reduce intraoperative hypotension|Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
48482295|NCT02713815|RADIATION|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
48482296|NCT02713815|RADIATION|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
48482297|NCT06546007|DIAGNOSTIC_TEST|CTC-DNA|ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
48482298|NCT06617442|PROCEDURE|Pulmonary vein isolation|First pulmonary vein isolation performed for atrial fibrillation.
48482299|NCT03935022|OTHER|Rice|"Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration."
48482300|NCT04086771|BEHAVIORAL|Navigation|Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
48482301|NCT04086771|OTHER|Information only|American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
48482302|NCT01583257|BEHAVIORAL|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
48482303|NCT02403739|OTHER|No Intervention|No Intervention
48482304|NCT01859767|DRUG|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
48111771|NCT06496958|DEVICE|Water exchange colonoscopy|In those patients assigned to the water exchange (WE) group, the air pump will be turned off during the insertion phase of colonoscopy, while the colon is irrigated with warm-to-touch distilled water or half normal saline using a flushing pump. The WE approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Any encountered air pockets will be aspirated to ensure optimal WE maneuvers in salvage cleaning.
48111772|NCT06620406|DIETARY_SUPPLEMENT|Synbiotic IVS-1|A mixture of the prebiotic potato resistant starch (RS, Bobs Red Mill) and the probiotic IVS-1 (Bifidobacterium adolescentis).
48111773|NCT06620406|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, a carbohydrate packaged similarly to the study intervention
48482305|NCT01312181|BEHAVIORAL|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
48111774|NCT06454721|DRUG|[89Zr]Zr-DFO-BIIB080|Administered as specified in the treatment arm.
48111775|NCT06454721|DRUG|BIIB080|Administered as specified in the treatment arm.
48111776|NCT06357910|DRUG|HCP2303|Take 1 tablet once per period
48111777|NCT06357910|DRUG|RLD2302|Take 1 tablet once per period
48111778|NCT06357910|DRUG|RLD2102|Take 1 tablet once per period
48111779|NCT01374893|BEHAVIORAL|Exercise|The intervention group will perform the multi-session per day training program
48111780|NCT01374893|BEHAVIORAL|Control|Usual care
48111781|NCT00307463|PROCEDURE|strict volume control policy|strict volume control by UF and dietary salt restriction
48482306|NCT01312181|BEHAVIORAL|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
48111782|NCT00307463|PROCEDURE|antihypertensive drugs administration|continue antihypertensive medications
48111783|NCT04706026|OTHER|Open Inguinal Hernia Repair - Local Anesthesia|Patients in the local anesthesia arm will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (Propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
48111784|NCT04706026|OTHER|Inguinal Hernia Repair - General Anesthesia|General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
48111785|NCT01117584|DRUG|ipragliflozin|oral tablet
48111786|NCT01117584|DRUG|Placebo|oral tablet
48111787|NCT01117584|DRUG|Metformin|oral tablet
48111788|NCT06390267|DEVICE|Sparrow Hawk (Active)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.
48111789|NCT06390267|DEVICE|Sparrow Hawk (Sham)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.
48111790|NCT06676488|DEVICE|Re-Timer glasses|Morning bright light therapy (BLT) will be administered through a safe wearable glasses device called a Re-Timer, purchased from the manufacturer Re-Timer.
48111791|NCT06676488|DEVICE|Placebo Device|Placebo glasses not providing Bright Light Therapy
48111792|NCT06251193|BEHAVIORAL|E-CBSST|E-CBSST is a blended intervention that combines Cognitive Behavioral Social Skills Training and Executive Function Training.
47959276|NCT04211883|BEHAVIORAL|ACTIVE intervention|The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
47959277|NCT00639431|BEHAVIORAL|direct observation|direct observation of another person's foot moving
47959278|NCT00639431|BEHAVIORAL|mental visualization|mentally imagining moving one's phantom foot/feet
47959279|NCT05723302|DIAGNOSTIC_TEST|MIP/MEP|MIP/MEP
47959280|NCT01086761|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye.
47959281|NCT00825682|OTHER|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
47959282|NCT05638178|OTHER|No intervention|No intervention, cohort study.
47959283|NCT02715180|RADIATION|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
47959284|NCT05310838|BEHAVIORAL|Behavioral Activation for First Episode Psychosis|Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.
47959285|NCT05310838|BEHAVIORAL|Treatment As Usual|Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
47959286|NCT00324610|DRUG|capecitabine|
48111793|NCT06676826|DEVICE|Infrabony defects will be filled with a volume-stable collagen matrix (VCMX)|Infrabony defects will be filled with a volume-stable collagen matrix
48111794|NCT06676826|DEVICE|Infrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen|Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen
48482307|NCT01312181|BEHAVIORAL|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
48482308|NCT01464554|BEHAVIORAL|Usual care|alcohol and drug education
48482309|NCT01464554|BEHAVIORAL|Project Free Talk|motivational interviewing alcohol and drug program
47959287|NCT06004128|DRUG|VYD222|Monoclonal antibody
47959288|NCT01492985|BIOLOGICAL|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
47959289|NCT01492985|BIOLOGICAL|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
47959290|NCT00282412|BIOLOGICAL|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
47959291|NCT00282412|DRUG|Fludarabine|inhibits DNA synthesis or repair
47959292|NCT00282412|DRUG|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
47959293|NCT00282412|DRUG|Campath 1H|humanized monoclonal antibody against CD52 antigen
47959294|NCT00282412|DRUG|GCSF|Hematopoietic growth factor
47959295|NCT00282412|DRUG|Cyclosporins|immune suppressive drug
48111795|NCT04172246|DRUG|Zanubrutinib|Zanubrutinib at 160 mg orally twice daily
48111796|NCT02621424|DEVICE|RTMS|stimulation of the brain with magnetic pulses
48111797|NCT02621424|DEVICE|sham|sham noise to block the sound of stimulation
48111798|NCT04244604|OTHER|Acute Salt (sodium chloride)|Varied amounts of salt (sodium chloride) will be added to a very low sodium soup to determine the effects of a single high sodium meal on measures of vascular function and autonomic regulation of blood pressure
48111799|NCT06676605|DIETARY_SUPPLEMENT|Withania somnifera|The experimental supplement administered to patients in this study was Withania somnifera, commonly known as ashwagandha. It is classified as a dietary supplement and is regulated similarly to pharmaceutical medications. The supplement has been authorized for commercialization and use by the Food and Drug Administration (FDA). Participants received the supplement in the form of 500 mg capsules, taken daily over a 40-day period, following the manufacturer's instructions. The range of the recommended daily dose is between 240 and 600 mg. The purpose of administering this supplement was to evaluate its impact on various health parameters, including serum lipid concentrations and body composition, in the study's participants.
48497893|NCT01732874|DRUG|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
48497894|NCT01725776|DRUG|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
47959296|NCT00282412|DRUG|Mycophenolate Mofetil|immune suppressive drug
47959297|NCT01488370|DEVICE|Endotracheal intubation|Endotracheal intubation
47959298|NCT06383936|PROCEDURE|intensive rehabilitation after uncemented TKA|patients undergoing an intensive rehabilitation protocol after uncemented tka
47959299|NCT06050005|DIAGNOSTIC_TEST|Diagnostic test through functional tests and comparison of scales applied to participants in the pre-surgical and post-surgical period.|The protocol is based on the ligamentization stages, since the bibliography relates the ligamentization process with rehabilitation. These stages are necrosis, revascularization, cellular priorities and collagen formation, and different care is required for each stage. Taking these aspects into account, the authors developed recommendations to establish a protocol divided by the evaluation phases of the present work. Users should only move on to the next phase if they achieve the expected results, or that makes the total duration of each protocol vary from user to user. tests and scales will be evaluated before surgery, after 6 weeks of surgery and at the end of treatment.
47959300|NCT00313261|DRUG|Clevudine|
47959301|NCT02672826|PROCEDURE|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
47959302|NCT00313300|DRUG|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
47959303|NCT00313300|DRUG|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
47959304|NCT00313300|DRUG|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
47959305|NCT00313300|DRUG|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
47959306|NCT00528463|PROCEDURE|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
47959307|NCT05232175|DRUG|ALT-BB4|Recombinant Hyaluronidase
47959308|NCT05232175|DRUG|0.9%NaCl|Normal Saline
47959309|NCT01972568|DRUG|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
47959310|NCT01972568|DRUG|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
48111800|NCT06676605|OTHER|Placebo Intervention|The product administered to the placebo group was designed to simulate the appearance and administration of the experimental supplement but without containing any active ingredients. Participants in the placebo group received capsules/tablets filled with starch rice. These capsules were taken daily over the same 40-day period as the experimental group, ensuring that the placebo group followed identical administration and monitoring procedures. The use of starch rice capsules aimed to serve as a neutral control, allowing for a comparison between the effects of the actual Withania somnifera supplement and the placebo.
48111801|NCT04157855|PROCEDURE|Abdominal Plane Block(s) with depot Steroids|APB Steroids treatment: under real time ultrasound guidance, a 100 mm needle is introduced into the specified plane (subcostal TAP for upper abdomen pain, posterior TAP for lower abdomen pain or TQL for flank and lower abdominal pain). Normal saline (10 ml) is used to open the fascial plane (saline hydrodissection). Then 40 mg of depomedrone diluted in 10 ml of 0.25% levo-bupivacaine is injected into the plane. . A total of 80 mg of depomedrone (steroid) will be used.
48111802|NCT05228691|OTHER|Evaluation and Education|A functional physical evaluation will be carried out and they will be informed about the characteristics of their symptoms. After the evaluation, they will be taught a guideline of exercises and recommendations.
47959311|NCT01972568|DRUG|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
47959312|NCT00003487|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
47959313|NCT05799170|OTHER|regional trauma care|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment. Taking 5 to 6 hospitals with certain trauma treatment capacity as the trauma treatment point, the trauma treatment network is formed relying on the treatment point hospitals within the range of one trauma treatment center.
47959314|NCT03722823|DRUG|Tucatinib|300mg oral single dose
47959315|NCT06068608|DRUG|TNM005|single,intramuscular injection
47959316|NCT06068608|DRUG|Placebo|single,intramuscular injection
47959317|NCT06068608|DRUG|VariZIG|a single dose of VARIZIG 625 IU,intramuscular injection
47959318|NCT00431288|BEHAVIORAL|diet high in fruits, vegetables, and dairy|
47959319|NCT00431288|OTHER|Routine nutrition care|
48306776|NCT01395095|OTHER|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
48306777|NCT04070313|DRUG|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
48306778|NCT05689021|DRUG|Abiraterone Acetate/Niraparib|Given PO
48306779|NCT05689021|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
47959320|NCT01172236|DRUG|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
47959321|NCT01172236|DRUG|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
47959322|NCT05146895|DRUG|Imiquimod treatment|As an control arm, for patients with flat warts
47959323|NCT05146895|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
47959324|NCT00446251|DRUG|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
47959325|NCT00446251|DRUG|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
47959326|NCT01216748|OTHER|quiet breathing|Subjects were instructed to breath normally at room air.
47959327|NCT01216748|OTHER|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
48306780|NCT05689021|PROCEDURE|Bone Scan|Undergo technetium-99m bone scan
47959328|NCT01216748|OTHER|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
47959329|NCT01216748|OTHER|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
48111803|NCT06247085|DRUG|Pegtibatinase|Full Target Dose of pegtibatinase BIW
48306781|NCT05689021|PROCEDURE|Computed Tomography|Undergo CT scan
48306782|NCT05689021|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48497895|NCT01475058|BIOLOGICAL|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
48497896|NCT03617757|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
47959330|NCT03944421|OTHER|Red and Processed Meat|Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
47959331|NCT03944421|OTHER|Quorn|Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
47959332|NCT02255903|OTHER|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
47959333|NCT05276037|OTHER|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
48111804|NCT06247085|OTHER|Placebo|volume-matched saline SC BIW
48111805|NCT00281424|DEVICE|pedometer|gave pedometer and info
48111809|NCT06677541|OTHER|Instructional handout|A handout on how to improve sexual dysfunction/function will be provided
48306783|NCT05689021|DRUG|Prednisone|Given PO
48306784|NCT01798784|BEHAVIORAL|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
48306785|NCT01798784|BEHAVIORAL|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
48306786|NCT01798784|BEHAVIORAL|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
48497897|NCT03617757|DIAGNOSTIC_TEST|HbA1c|2mL blood will be taken for analysis of HbA1c.
47959334|NCT00231842|DRUG|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
47959335|NCT00231842|DEVICE|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
47959336|NCT00231842|DRUG|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
47959337|NCT05986786|DEVICE|Patients will receive 1 IVT injection of AVT06 PFS depending on their chorioretinal vascular disease schedule|Patient will receive AVT06 (proposed aflibercept biosimilar) PFS injection
47959338|NCT05514483|DRUG|Placebo|Single intravenous dose of 10 mL of sodium chloride (NaCl) 0.9% over 15 minutes.
47959339|NCT05514483|DRUG|Ondansetron|Single intravenous dose of ondansetron hydrochloride dihydrate 0.15 mg/kg (maximum 16 mg) in 10 mL of NaCl 0.9% over 15 minutes.
47959340|NCT01083485|DRUG|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
47959341|NCT01083485|DRUG|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
48111810|NCT06677541|DEVICE|Vibrator|An FDA approved vibrator device to improve sexual function will be provided
48111811|NCT06632379|DRUG|Atorvastatin 10 mg|Participants will be assigned to 10 mg Atorvastatin
48111812|NCT06632379|DRUG|Placebo|Participants will be assigned to identical appearing placebo
48111813|NCT06675955|DRUG|Ocrelizumab|Ocrelizumab will be administered according to the regimen in the parent study.
48111814|NCT06221566|OTHER|Muscle Energy Technique|"Muscle energy technique (MET) for upper trapezius and levetor scapulae muscle of neck with 7 to 10 second hold, 3 to 5 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
48641666|NCT06266403|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
47959342|NCT06024460|PROCEDURE|non-pharmacological treatment strategy|Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
48306787|NCT02338076|DRUG|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
47959343|NCT06024460|PROCEDURE|pharmacological treatment strategy|"Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified."
48111815|NCT06221566|OTHER|Stretching Exercises|"Stretching exercises program for upper trapezius and levetor scapulae muscle of neck with 10 second hold, 15 repetitions.~Transcutaneous electrical nerve stimulation (TENS) with Cold pack.~Home exercise program (HEP) will receive by both the groups which will be not supervised by the principal investigator or any other investigator."
48482310|NCT05540652|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
48482311|NCT05766020|BEHAVIORAL|Listen training|Auditory skills with the inclusion of cognitive control.
47959344|NCT00412542|DRUG|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
47959345|NCT00412542|DRUG|CPT-11|125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
48111816|NCT05523674|OTHER|Warm-up exercise|The warm-up exercise will be performed on a treadmill.
48306788|NCT01476176|DRUG|Experimental paracetamol|experimental paracetamol with caffeine
48306789|NCT01476176|DRUG|Paracetamol marketed formulation|marketed formulation containing caffeine
48641667|NCT06266403|BEHAVIORAL|Clear Speech|"PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the ___ this time. Participations will be instructed to overenunciate the critical words."
47959346|NCT00412542|PROCEDURE|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
47959347|NCT00412542|PROCEDURE|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
48111817|NCT05523674|OTHER|Warm-up exercise with Blood Flow Restriction|The warm-up exercise will be performed on a treadmill and pressure cuffs will be used for the blood flow restriction technique.
48111818|NCT06643377|DRUG|Enlicitide|Oral tablet
48111819|NCT06501586|DRUG|SGB-3908|SGB-3908 for sc injection
48111820|NCT06501586|OTHER|SGB-3908-Matching placebo|Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered
48111821|NCT05294731|DRUG|BGB-16673|Orally administered
47959348|NCT06464796|OTHER|Motor Imagery Techniques|"* Play a video of person doing a toe-raise exercise where carrying a big barbell on his shoulders.~* The individual in the video proceeded from a neutral upright position to a tiptoe standing while loud a heavy barbell; the plantar-flexors are used in this workout.~* The members were said to imagine engaging their ankle flexor muscles in an effort to generate ankle flexion. Both limbs were used during the 10-second imaginary contraction, which was tailed by a 10-second rest. Subsequently five repetitions of the contraction, there was a 30 second pause. Two-minutes of rest were interspersed between five-sets of five-contractions. Fifty imaginary contractions in total."
47959349|NCT06464796|OTHER|Conventional Exercise Therapy|"1. ROM drills for pronation, flexion and extension.~2. Ankle strengthening trainings include stand-up on tiptoe, walking on toe-tip, hopping on single foot, and resistance exercise with a latex elastic band.~3. Proprioceptive exercise include the following exercises: (a) sit on a proprioception board and move the injured limb in a round motion; (b) stand-up with both legs on the board while performing both eyes open and closed; (c) standing with single leg on the board while performing both eyes open; and (d) exercises on a mini-tramp (stand-up on double legs, single leg stances, hops on both left and right legs and on single leg).~4. Strengthening of the muscles of ankle completed with flexible bands at moderate Intensities.~5. Training on a stationary bicycle.~6. lunges forward into a wall.~7. Steps up and down on the transverse or sagittal plane."
47959350|NCT01480089|DRUG|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
48482312|NCT05696080|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
48111822|NCT05870241|OTHER|Ga-As Laser|Patient sits on a chair with back support and the two GA-AS laser ( 5 milli Watts \& 904 nm) probe will be applied one on the shoulder tip for 5 minutes and the other application another 5 minutes will be on the center of deltoid muscle. The main power of the laser switch will be turned on. The duration of the treatment will be 10 minutes.
47959351|NCT01480089|DRUG|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
47959352|NCT01899261|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
48111823|NCT05870241|OTHER|Microcurrent Electrical Stimulation|The patient sits on a chair with back support and the two electrodes from Microcurrent 850 unit device will be applied one on the shoulder tip and the other electrode on the center of the deltoid muscle. A wet cloth was placed between the electrode and the patient's skin. An adhesive tape was used to hold the electrode over the treated areas. The main power switch will be turned on. The treatment duration will be for 10 minutes.
48111824|NCT05870241|OTHER|traditional therapy|the patients will receive traditional physical therapy in the form of manual lymphatic drainage , compression bandage, exercise to increase lymphatic drainage, skin care. and ROM exercises to improve shoulder mobility
48111825|NCT02571816|DRUG|ASP2215|oral
48111826|NCT01350804|BIOLOGICAL|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
48111827|NCT01350804|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
48111828|NCT01350804|BIOLOGICAL|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
48111829|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks|
48111830|NCT00221234|BEHAVIORAL|Print materials, pedometers/logbooks, telephone counselling|
48111831|NCT04540497|DRUG|Inebilizumab|Inebilizumab is a monoclonal antibody that depletes B cells.
48482313|NCT05696080|DRUG|Placebo for PCV15 + PPSV23|Saline in each 0.5 mL sterile solution
48482314|NCT05696080|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
48111832|NCT04540497|OTHER|Placebo|Placebo
48111833|NCT04047862|DRUG|Ociperlimab|Administered as an intravenous (IV) injection
48111834|NCT04047862|DRUG|Tislelizumab|Administered as an IV injection
48111835|NCT04047862|DRUG|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
48111836|NCT04047862|DRUG|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
48111837|NCT04047862|DRUG|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
48111838|NCT04047862|DRUG|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
48111839|NCT04047862|DRUG|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
48111840|NCT04047862|DRUG|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
48111841|NCT04047862|DRUG|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
48111842|NCT04047862|DRUG|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
48111843|NCT04047862|DRUG|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
47959353|NCT04548037|OTHER|PET-CT examination|The subject is placed in supine position, the head immobilized in a headrest. The imaging sequence begins with a scout view (viewing angle 90 °, 120 kV, 20 mA), then an X-ray scan is performed for the attenuation correction (120 kV, 5 mAs per slice, pitch 0.531, collimation 40 mm , FOV 70) and diagnostic CT scan (120 kV, 100-250 mA: auto mA, pitch 0.531, 40 MM, DFOV 25, ASIR 60%, thickness 1.25 mm). Finally, the positron emission tomography is acquired: static in 3D mode for 15 minutes, 30 minutes after the injection of 18 FDG, the axial field of view is 25, the matrix in 256 x 256, OSEM reconstruction 6 iterations 24 subsets, attenuation correction, diffused, and PSF. Gaussian filter, cutoff frequency of 4. Obtaining forty-seven contiguous sections of 3.26 mm thick.
47959354|NCT01201785|DRUG|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
47959355|NCT04512014|DIAGNOSTIC_TEST|serum lactate|perioperative measurement of lactate levels
47959356|NCT02623023|DRUG|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
47959357|NCT02623023|OTHER|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
48111844|NCT06674538|DRUG|Moonshot antibodies|Chimeric antibodies
48111845|NCT03646123|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion
48111846|NCT03646123|DRUG|doxorubicin|25 mg/m\^2 by IV infusion
48111847|NCT03646123|DRUG|vinblastine|6 mg/m\^2 by IV infusion
48306790|NCT01255397|PROCEDURE|Male Infertility Protocol|"1. Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~2. Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~3. When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~4. 35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~   1. If the follicle has collapsed than IUI will be performed~  2. It the total motile sperm count is above 5 million sperm/ml then IUI will be done~  3. If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
48111848|NCT03646123|DRUG|dacarbazine|375 mg/m\^2 by IV infusion
48111849|NCT03646123|DRUG|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
48111850|NCT03646123|DRUG|nivolumab|240 mg by IV infusion
48111851|NCT06049732|DEVICE|PainChek®|Both PainChek® and the Abbey Pain Scale are observational pain assessment tools which have been designed to assist healthcare professionals and profession caregivers assess pain in people who cannot self-report their pain
48111852|NCT03110458|DRUG|SENS-111 100mg|SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
48111853|NCT03110458|DRUG|SENS-111 200mg|SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
48111854|NCT03110458|DRUG|Placebo Oral Tablet|Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
48111855|NCT06677216|PROCEDURE|Botulinum Toxin, Type A|All participants will receive a solution of BTX-A (Xeomin, Merz Pharma GmbH, Frankfurt am Main, Germany) in the masseter and temporalis muscles (total of 100 units reconstituted with 4cc unpreserved 0.9% sodium chloride). The injection will be provided by the same maxillofacial surgeon. The participants are asked to clench their teeth to determine the site of the most intense muscle activity in the masseter and temporal muscles with palpation. Intramuscular BTX-A injections are administered on both sides at the location of the most intense muscle activity of the masseter (80 units) and temporalis (20 units).
48111856|NCT06097260|DRUG|PLN-74809|PLN-74809
48111857|NCT06097260|DRUG|Placebo|Placebo
48111858|NCT06676748|DRUG|Benzydamine Hydrochloride|The Difflam Forte Anti-Inflammatory Throat Spray (iNova Pharmaceuticals Pte Ltd, Singapore) is an over-the-counter medication indicated for temporary relief of painful mouth and throat conditions. It contains benzydamine hydrochloride (BH) 3 mg/mL, a non-steroidal anti-inflammatory agent (NSAID), and is recommended for adults to spray 2 to 4 times to the affected throat every 1.5 to 3 hours as needed.
48111859|NCT06588855|DRUG|RO7790121|RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
48111860|NCT06588855|DRUG|Placebo|Placebo matching IV RO7790121. Placebo matching SC RO7790121.
48111861|NCT00210509|DRUG|almotriptan malate|
48111862|NCT03047083|OTHER|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
48111863|NCT03047083|OTHER|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
48111864|NCT05715268|DEVICE|WeB|"Participants will be given WeB devices and trained on the use of these devices for home therapy, including the associated mobile applications. Participants will be given home programs and given a schedule to use the WeB devices at home on their own time. At their standard visit participants will have their WeB device use checked and progressed as the therapist deems appropriate.~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
47959358|NCT04850820|DIETARY_SUPPLEMENT|Novel essential amino acid supplementation|This intervention will determine the impact of EAA+ on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
47959359|NCT04850820|DIETARY_SUPPLEMENT|Branched-chain amino acid supplementation (BCAA)|This intervention will determine the impact of the BCAA supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
47959360|NCT04850820|DIETARY_SUPPLEMENT|Isocaloric carbohydrate supplementation|This intervention will determine the impact of an isocaloric carbohydrate placebo supplement (to be compared to EAA+) on markers of whole-body net protein balance, protein synthesis, and protein breakdown following home-based resistance exercise in a free-living setting.
47959361|NCT01137396|DRUG|Modafinil|Modafinil 400mg PO QDaily following up-titration for \~8weeks
47959362|NCT01137396|BEHAVIORAL|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
47959363|NCT00428792|DRUG|Methylphenidate 20 mg long-acting capsules|
47959364|NCT02874157|BIOLOGICAL|blood draw|
47959365|NCT00633750|DRUG|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
47959366|NCT00633750|GENETIC|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
47959367|NCT00633750|GENETIC|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
47959368|NCT00633750|OTHER|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
47959369|NCT00633750|OTHER|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
47959370|NCT00633750|OTHER|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
47959371|NCT00633750|OTHER|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
47959372|NCT00633750|OTHER|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
48111865|NCT05715268|OTHER|Standard pelvic floor physical therapy|"Baseline will consist of a standard PFPT evaluation. Regular visits (tele-video visits or in-person depending on the patients preference) will be scheduled every week for the first 4 weeks and then every other week at the discretion of the therapist. A total of 8-10 visits will be scheduled over the 12 weeks of the study. Participants will be given home exercise programs (as per standard PFPT).~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
47959373|NCT00633750|PROCEDURE|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
47959374|NCT03625622|DRUG|AR1001|AR1001 Active Oral Tablet
48306791|NCT04691752|OTHER|Audit|Audit from clinical records
47959375|NCT03625622|DRUG|Placebo|Placebo Oral Tablet
47959376|NCT02508857|DRUG|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
47959377|NCT02508857|DRUG|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
47959378|NCT02508857|DRUG|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
47959379|NCT00142298|DRUG|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
47959380|NCT06467968|OTHER|Cardiac ECG-gated PET imaging will added|Blood sample will be used to measure troponin, BNP and CRP . After 68Ga-DOTATOC PET/CT whole body recording, a cardiac ECG-gated PET imaging will added
47959381|NCT02447939|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
47959382|NCT02447939|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
47959383|NCT01586065|DEVICE|Continuous Glucose Monitor (CGM)|CGM during 24-hr CRC stay.
47959384|NCT01803061|BEHAVIORAL|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
47959385|NCT00321308|DRUG|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
47959386|NCT00321308|DRUG|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
47959387|NCT04766060|OTHER|Fluorescent Imaging|Fluorescense imaging used to evaluate blood perfusion
47959388|NCT06557044|DRUG|Ropivacaine|PENG block with ropivacaine
47959389|NCT06557044|OTHER|Physiological saline|Placebo control
48306792|NCT03649958|DEVICE|HIRREM-SOP or Cereset|HIRREM-SOP for ten 90 minute sessions
48306793|NCT03649958|DEVICE|Cereset 2x|Cereset 2x for five 90 minute sessions
47959390|NCT00579137|BIOLOGICAL|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients \>15 kg to 30 kg the dose 5 mg; for patients \> 30 kg the dose is 10 mg"
47959391|NCT00579137|DRUG|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
47959392|NCT00579137|BIOLOGICAL|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
47959393|NCT00579137|PROCEDURE|Stem cell infusion|stem cells are infused on day 0
47959394|NCT05868395|DRUG|Polatuzumab, bendamustin und rituximab|"* Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle~* Bendamustine 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle~* Rituximab 375 mg/m2 i.v. on day 1 of each cycle~* Each cycle is 21 days long~* Up to 6 cycles per patients planned"
47959395|NCT00939640|BEHAVIORAL|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
47959396|NCT02202525|DRUG|Micardis®|
47959397|NCT02202525|DRUG|Other hypertensives|
47959398|NCT02204956|BEHAVIORAL|Sustained Care|The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.
47959399|NCT02204956|BEHAVIORAL|Usual Care|Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
47959400|NCT03771820|DRUG|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
47959401|NCT03771820|DRUG|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
47959402|NCT01139983|GENETIC|DNA analysis|
47959403|NCT01139983|GENETIC|RNA analysis|
47959404|NCT01139983|GENETIC|fluorescence in situ hybridization|
47959405|NCT01139983|GENETIC|microarray analysis|
47959406|NCT01139983|GENETIC|polymerase chain reaction|
47959407|NCT01139983|GENETIC|reverse transcriptase-polymerase chain reaction|
47959408|NCT01139983|OTHER|laboratory biomarker analysis|
47959409|NCT00325273|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
47959410|NCT03831789|DEVICE|Cerebellar targeted rTMS|10 Hz cerebellar rTMS (250 pulses)
47959411|NCT03913988|BEHAVIORAL|Lucid Dream|Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
47959412|NCT03913988|BEHAVIORAL|Stress Reduction|Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
47959413|NCT03913988|BEHAVIORAL|Sleep Hygiene Techniques|Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
48111866|NCT04743765|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of eligibility criteria criteria met.
48111867|NCT00475319|DRUG|placebo|comparison of different dosages of drug
48482315|NCT05696080|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
47959414|NCT02982668|OTHER|Initial enteral feeding|
47959415|NCT02982668|DRUG|metoclopramide or mosapride|gastrointestinal (GI) motility improving
47959416|NCT04116788|DEVICE|Artefact IRM assessment|IRM
47959417|NCT02326792|OTHER|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
47959418|NCT01907997|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
47959419|NCT01907997|DRUG|normal saline infusion|In group C, the patients receive same volume of normal saline
47959420|NCT06282510|DRUG|Povidone Iodine Topical|Topical intranasal povidone iodine (10%) twice daily for 5 days
47959421|NCT01626430|DIETARY_SUPPLEMENT|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
47959422|NCT01626430|DIETARY_SUPPLEMENT|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
48111868|NCT00475319|DRUG|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
48111869|NCT00475319|DRUG|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
47959423|NCT02564497|BIOLOGICAL|Process E Belatacept|
47959424|NCT02564497|BIOLOGICAL|Process C Belatacept|
47959425|NCT02672800|BEHAVIORAL|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
47959426|NCT02846831|OTHER|12-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."
47959427|NCT02846831|OTHER|12-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."
47959428|NCT02846831|DEVICE|Insulin pump|Tandem Diabetes Care
47959429|NCT02846831|DEVICE|Continuous glucose monitoring system|Dexcom G5 Platinum
47959430|NCT02846831|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
47959431|NCT02899299|BIOLOGICAL|Nivolumab|
47959432|NCT02899299|BIOLOGICAL|Ipilimumab|
47959433|NCT02899299|DRUG|Pemetrexed|
47959434|NCT02899299|DRUG|Cisplatin|
47959435|NCT02899299|DRUG|Carboplatin|
47959436|NCT04046692|OTHER|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
47959437|NCT04046692|OTHER|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
47959438|NCT04046692|OTHER|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
47959439|NCT04046692|OTHER|Hospital School Experience, point of view of parents|Operators interview parents
47959440|NCT01851460|DEVICE|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of \>75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
48306794|NCT03758378|OTHER|Dietary intervention|Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
47959441|NCT04821648|DRUG|RJV001|Subcutaneous injection in the abdomen
47959442|NCT04821648|DRUG|Placebo|The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
47959443|NCT05469581|OTHER|A set of preventive interventions to improve adherence in vulnerable elderly people|"* reviewing the list of medications, delivery of an ordered list of medications, and checking medication regimen understanding;~* delivering a leaflet on the correct/safe taking of medications, discussion, explanation, and verification of understanding of the content;~* a counseling about the importance of adherence;~* handing over the medication dispenser (if the elderly person does not have one yet),~* delivering of a personal medication card, which shows the timeline of taking prescribed medication."
48306795|NCT04811313|DRUG|Tranexamic acid|patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
48306796|NCT04811313|PROCEDURE|caudal epidural block|regional anesthesia in orthopedic procedures are known to help reduction of intraoperative blood loss
48306797|NCT04811313|OTHER|Placebo|participants will receive standard care but neither TXA nor caudal epidural block
48306798|NCT01975766|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
47959444|NCT01263977|DEVICE|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
47959445|NCT01198678|DIETARY_SUPPLEMENT|Boost Nutritional Supplement|Boost- Nutritional Supplement
47959446|NCT03782961|DEVICE|sodium lactate and combination of polymers|sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
47959447|NCT00000842|DRUG|Nerve Growth Factor, Recombinant Human|
48111870|NCT05832086|BEHAVIORAL|Fasting Mimicking Diet (FMD)|Consume the FMD (Xentigen, L-Nutra, Los Angeles, CA) for 5 days every monthly cycle for 6 cycles total in 6 months.
48306799|NCT01975766|DEVICE|External beam radiation therapy|
48306800|NCT05796258|DIAGNOSTIC_TEST|NTRK fusion assessment|To evaluate NTRK fusion presence by MCG, Immunohistochemistry or NGS
48306801|NCT03977285|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
48306802|NCT01543490|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
48306803|NCT01543490|OTHER|Vehicle|Vehicle twice daily for 2 weeks
48306804|NCT05431413|DRUG|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
48306805|NCT05431413|DRUG|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
47959448|NCT05893355|BEHAVIORAL|Acupressure group|"Application to Acupressure Group~* Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed."
47959449|NCT00316472|DRUG|Niacinamide|
47959450|NCT03758066|DEVICE|PlusCare|PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
47959451|NCT05205525|OTHER|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
47959452|NCT05205525|OTHER|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
47959453|NCT03851757|DEVICE|waist-shaped interdental brush|use four times each per interdental space
47959454|NCT03851757|DEVICE|cylindric interdental brush|use four times each per interdental space
47959455|NCT03483025|OTHER|Skin Testing of Hair cleansing products|6 different commercially available shampoos
47959456|NCT03460938|PROCEDURE|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
47959457|NCT00816296|OTHER|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
47959458|NCT00816296|OTHER|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
47959459|NCT00816296|OTHER|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
47959460|NCT00816296|OTHER|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
47959461|NCT00089414|DRUG|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
47959462|NCT00089414|DRUG|Placebo|
47959463|NCT00089414|DRUG|CDB 2914|
47959464|NCT04932993|BEHAVIORAL|Writing down goals|Patient will write their health goals down before the visit.
47959465|NCT05021601|PROCEDURE|Bi-atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.
47959466|NCT05021601|PROCEDURE|Left atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
47959467|NCT05367492|DRUG|Double Blind Varenicline|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
47959468|NCT05367492|DRUG|Double Blind Placebo|"For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks"
47959469|NCT05367492|BEHAVIORAL|QuitVaping|QuitVaping is a manualized intervention based on the American Lung Association smoking cessation program modified with adolescent appropriate content and language for vaping cessation from the vaping section of teen.smokefree.gov and the Truth Initiative. These behavioral support sessions will be delivered weekly during the 12-week treatment phase via videoconference or in- person.
47959470|NCT05367492|BEHAVIORAL|This Is Quitting|A free, publicly available text message vaping cessation program from Truth Initiative, designed specifically to help adolescents who vape nicotine quit. Participants who set a quit date receive messages for a week preceding it and 30 days afterward that include encouragement and support, skill- and self-efficacy building exercises, coping strategies, and information about the risks of vaping, benefits of quitting and cutting down to quit.
47959471|NCT06044831|BEHAVIORAL|Expanded Population Health Model|This intervention includes the current population health model in addition to expanded programming from a local community organization. The current population health model with Baylor Scott \& White Health and Wellness Center includes access to primary care, general wellness programs such as cooking classes and nutritional counseling, and evidence-based disease management and prevention. The additional programs from a local community organization focus on human essentials integral to improving health and quality of life and include: health and wellness, economic stability, safe and affordable housing, transportation, a sense of belonging, education, and access to fair credit.
47959472|NCT02420522|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
47959473|NCT02420522|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
47959474|NCT02518256|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
48306806|NCT05431413|DRUG|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
47959475|NCT01721993|DRUG|T121|
47959476|NCT01721993|DRUG|Zoledronic acid|
47959477|NCT04079946|PROCEDURE|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
47959478|NCT04079946|PROCEDURE|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
47959479|NCT06558266|OTHER|Since this was an observational study, no intervention was performed.|Since it is an observational study, only evaluation will be made. Each participant s mental imagery ability will be evaluated with the Movement Imagery Vividness Questionnaire-2 four times, follicular phase, ovulation, luteal phase and menstrual phase. In addition, the pain intensity experienced during menstruation will be evaluated with the Numerical Classification Scale-11, and the symptoms experienced due to menstruation will be evaluated with the Menstruation Symptom Scale.
47959480|NCT06445296|OTHER|High-fat meal containing beef|High-fat meal (eggs cooked in butter, croissant) with 80% ground beef.
47959481|NCT06445296|OTHER|High-fat meal containing Beyond Meat|High-fat meal (eggs cooked in butter, croissant) with Beyond Meat Cookout Classic.
47959482|NCT04798963|PROCEDURE|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
47959483|NCT04798963|PROCEDURE|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
47959484|NCT02222740|DRUG|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
47959485|NCT02222740|DRUG|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
47959486|NCT01555450|OTHER|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
47959487|NCT01546805|DRUG|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
47959488|NCT01546805|DRUG|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
47959489|NCT02620657|OTHER|Non interventional study|Non interventional study
47959490|NCT03206411|DIAGNOSTIC_TEST|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
47959491|NCT01742000|DIETARY_SUPPLEMENT|Karinat|
48111871|NCT05832086|BEHAVIORAL|Standard Anti-Cancer Diet|Will receive standard of care diet and exercise recommendations from the study dietitian. The diet advice will be consistent with the American Cancer Society for cancer survivors and exercise recommendation of a goal of 150 minutes/week of cardiovascular exercise and weight resistance training at least twice a week.
48111872|NCT05985356|DEVICE|iTBS|iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
48111873|NCT06069726|DRUG|Atezolizumab|One dose of atezolizumab will be given prior to resection.
48111874|NCT03900793|DRUG|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments per Table 1 of the protocol. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily and dose levels 2 and 3 dosing will not exceed 100 mg daily. Doses should be taken at approximately the same time daily and patients should fast for \> 4 hours prior to dosing
48111875|NCT03900793|DRUG|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2 per Table 1 of the protocol. Doses should be taken at approximately the same time daily.
48111876|NCT03174054|PROCEDURE|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
48111877|NCT05521880|DRUG|Oritavancin|Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder
48111878|NCT06444451|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
48111879|NCT06444451|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
47959492|NCT01742000|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
47959493|NCT03087643|OTHER|Passive mobilization - PM|
47959494|NCT01787331|DRUG|Itraconazole|Given PO
47959495|NCT01787331|OTHER|Laboratory Biomarker Analysis|Correlative studies
47959496|NCT01787331|OTHER|Pharmacological Study|Correlative studies
47959497|NCT00133029|DRUG|Timing of prophylactic antibiotic administration|
47959498|NCT05846204|BEHAVIORAL|Progressive Muscle Relaxation|"The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks.~DB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught."
47959499|NCT05846204|BEHAVIORAL|Deep Breathing Exercise Group-DBE|Breathing exercise is an exercise to improve breathing and functional performance. deep breathing exercise; It is a nursing intervention that helps to increase the function of respiratory muscles and improve ventilation and oxygenation.
48111880|NCT00790790|DRUG|Placebo|LY545694 placebo BID po for 5 weeks
48111881|NCT00790790|DRUG|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
48111882|NCT00790790|DRUG|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
48111883|NCT01356758|DRUG|biological treatment|patients treated with anti-psoriatic biological agents
48111884|NCT02867670|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
48111885|NCT00003292|DRUG|ifosfamide|
48111886|NCT06677268|PROCEDURE|rehabilitation|Patients will undergo a respiratory rehabilitation program (24 exercise sessions of 90 minutes each, three times a week for 8 weeks and up to 9 therapeutic education workshops of 1 hour of the patient\&#39;s choice)
48111887|NCT02557542|OTHER|One Stop Vein Clinic|Same day diagnosis and treatment
48111888|NCT02557542|DEVICE|Radiofrequency ablation|Venous ablation
48111889|NCT02557542|DEVICE|Endovenous laser ablation|Venous ablation
48111890|NCT02557542|DRUG|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
48641668|NCT06266403|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
48306807|NCT06131346|OTHER|Evaluation of clinical and paraclinical data.|Retrospective data collection from available medical files of patient.
48306808|NCT03121222|DRUG|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
48306809|NCT03121222|DRUG|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
48641669|NCT06266403|BEHAVIORAL|Clear Speech Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success."
48641670|NCT04166864|DEVICE|Transcranial magnetic Stimulation|Transcranial magnetic stimulation delivered at the Subject's SCC-determined frequency. Each Subject will receive 40 pulses every 26 seconds, over 75 trains.
48641671|NCT06643598|BEHAVIORAL|Abecedarian Approach|The Abecedarian Approach is an early childhood behavioral education program that aims to improve the learning and cognitive development of children in high-risk or at-risk communities. This study will test the efficacy of implementing this approach in a virtual format.
48641672|NCT06587139|BEHAVIORAL|Teen Connection Project (TCP)|The Teen Connection Project (TCP) includes seven 90-minute sessions facilitated by transgender and/or gender minority (TGM) adults. Each transgender and/or gender minority youth (TGMY) will be paired with a TGM adult mentor based on TGMYs' rank-ordered preference for mentors. The research team seeks to match mentors \& mentees such that each TGMY is matched with one of their top 3 preferred mentors. Mentors and mentees participate together in each session along with other mentors \& mentees. Facilitators direct activities/discussion to promote TGMY social-emotional skills acquisition and facilitate mentor-mentee conversations. TCP sessions also include mentor-mentee breakout sessions where mentors share challenges they personally faced as TGMY and how they overcame them. Break-out discussions focus on self-acceptance, coming out, dating questions, hopes and goals for the future, \& how other marginalized social identities, such as race and ethnicity, intersect with identifying as TGMY.
48641673|NCT05309746|PROCEDURE|Laparoscopic surgery|Surgery used to remove the child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into the child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of the child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
48641674|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional impression technique|surgical procedures: Implant installation Prosthetic procedures: Conventional impression fabrication of full arch implant supported screw-retained restoration evaluation: Accuracy, Passive fit
48641675|NCT06067334|OTHER|full arch implant supported screw retained restoration with conventional digital technique|surgical procedures: Implant installation Prosthetic procedures: Digital impression fabrication of full arch implant-supported screw-retained restoration evaluation: Accuracy, Passive fit
48111891|NCT03396692|PROCEDURE|Intravenous morphine patient-controlled analgesia (PCA)|"Group 1 control:~* Morphine titration at 0.1 mg/kg~* Establishment of PCA morphine:~* concentration 1mg/ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg"
48111892|NCT03396692|PROCEDURE|Block of the posterior exo-thoracic fascia with Ropivacaine|"Group 2 PEF block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia."
47959500|NCT05545709|PROCEDURE|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
47959501|NCT06095583|DRUG|Tifcemalimab injection|200mg once every 3weeks
47959502|NCT06095583|DRUG|toripalimab injection|240mg once every 3 weeks
47959503|NCT06095583|DRUG|Placebo for Tifcemalimab|every 3weeks
47959504|NCT06095583|DRUG|Placebo for toripalimab|every 3weeks
47959505|NCT01577420|OTHER|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
47959506|NCT01577420|OTHER|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
47959507|NCT00002734|BIOLOGICAL|recombinant interferon alfa|
47959508|NCT00002734|DRUG|chemotherapy|
47959509|NCT00002734|DRUG|paclitaxel|
47959510|NCT00002734|DRUG|topotecan hydrochloride|
48306810|NCT02614872|DRUG|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
48306811|NCT01617681|DRUG|VAL489|Valsartan 3mg/kg oral solution
48306812|NCT01617681|DRUG|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
48306813|NCT02844101|DEVICE|GT3X Actigraph accelerometer.|
48306814|NCT06142253|BEHAVIORAL|WATER+CT|This is an 8-month long two phase intervention. The first phase consists of 6 months of thrice weekly pool-based exercise occurring at VA Palo Alto. After completion of the 6 month long pool based exercise, participants transition to ten sessions of cognitive training that will occur over 2 months at the VA Palo Alto.
48306815|NCT06142253|BEHAVIORAL|Usual Care|This condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
48306816|NCT03229915|BEHAVIORAL|cognitive processing therapy|Group therapy for PTSD patients
48306817|NCT03481881|DRUG|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
48482316|NCT03353402|PROCEDURE|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
48482317|NCT00004810|DRUG|-aminosalicylic acid|
48641676|NCT04150757|DRUG|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
47959511|NCT00002734|RADIATION|lutetium Lu 177 monoclonal antibody CC49|
47959512|NCT00002734|RADIATION|yttrium Y 90 monoclonal antibody CC49|
48306818|NCT00883558|DRUG|Insulin Lispro|
48306819|NCT00883558|DRUG|regular human insulin|
48306820|NCT00883558|DRUG|recombinant human hyaluronidase PH20|
48306821|NCT00883558|DRUG|Insulin glargine|
48306822|NCT02778516|DIETARY_SUPPLEMENT|Sodium Restriction|
48482318|NCT05098457|DEVICE|GP0112|Injectable gel
48482319|NCT05098457|DEVICE|Restylane Lyft Lidocaine|Injectable gel
48482320|NCT05503251|OTHER|Best Practice|Receive usual care
48482321|NCT05503251|BEHAVIORAL|Neuropsychological Assessment|Undergo neuropsychological evaluation
48482322|NCT05503251|OTHER|Quality-of-Life Assessment|Ancillary studies
47959513|NCT06326385|OTHER|no intervention|no intervention
47959514|NCT02094183|OTHER|GLP-1|GLP-1
47959515|NCT02094183|DIETARY_SUPPLEMENT|low calorie diet|low calorie diet
47959516|NCT00651352|DRUG|4 mg nicotine lozenge|marketed formulation
47959517|NCT00651352|DRUG|2 mg nicotine lozenge|marketed formulation
47959518|NCT00651352|DRUG|2 mg nicotine prototype|2 mg
47959519|NCT00651352|DRUG|4 mg nicotine prototype|4 mg
47959520|NCT03726307|BIOLOGICAL|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
47959521|NCT03726307|BIOLOGICAL|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
48482323|NCT05503251|OTHER|Questionnaire Administration|Ancillary studies
48482324|NCT05881642|PROCEDURE|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
47959522|NCT03726307|BIOLOGICAL|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
47959523|NCT00168870|DRUG|Gemcitabine|
47959524|NCT00168870|DRUG|Treosulfan|
47959525|NCT03138603|DRUG|Metoprolol Tartrate|Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
47959526|NCT03138603|DRUG|Placebo|Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
47959527|NCT00570765|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
47959528|NCT00570765|DRUG|Obeticholic Acid (OCA)|Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
47959529|NCT02328300|DRUG|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
47959530|NCT06095947|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|A total of 652326 healthy children with immunization history and no immunization history aged 3-8 years who met the program requirements received two doses of normally commercially available quadrivalent influenza vaccine according to the 0,30-day procedure.
48111893|NCT03396692|PROCEDURE|Block of paravertebral space with Ropivacaine|"Group 3 paravertebral block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse."
48111894|NCT01839903|OTHER|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
48111895|NCT01839903|OTHER|Care as usual|Care as usual in the ED will be tracked
48111896|NCT01281813|DRUG|Darunavir|Participants will receive darunavir (per parent study) as oral suspension.
48111897|NCT01281813|DRUG|Ritonavir|Participants will receive ritonavir (per parent study) as oral solution/suspension.
48111898|NCT03542630|DIAGNOSTIC_TEST|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
48306823|NCT02996539|OTHER|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
48111899|NCT03542630|OTHER|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
48111900|NCT03542630|OTHER|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
48111901|NCT05889195|DIAGNOSTIC_TEST|Cxbladder urine test|Cxbladder tests uses mRNA and DNA biomarkers in the urine to direct the management of UC from diagnosis to surveillance for disease recurrence.
48111902|NCT06520345|DRUG|177Lu-TLX591|Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
48306824|NCT04310163|OTHER|Natural history|Parent interview and video capture
48111903|NCT06520345|DRUG|Enzalutamide|Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.
48111904|NCT06520345|DRUG|Abiraterone|Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
48111905|NCT06520345|DRUG|Docetaxel|Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
48111906|NCT01418118|DRUG|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
48306825|NCT03462446|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
48111907|NCT01418118|DRUG|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
48306826|NCT03462446|DRUG|Vitamin K antagonists (VKAs)|As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
48306827|NCT00965705|BEHAVIORAL|Therapy|Individual Therapy and Group Therapy
48306828|NCT01630044|DEVICE|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
48306829|NCT03022305|BEHAVIORAL|Group one - standard therapy|Group two - standard physical therapy treatment for shoulder and hip maladjustment.
48306830|NCT03022305|BEHAVIORAL|Group two - neuromuscular therapy|Use of physical therapy treatment for shoulder and hip maladjustment.
48482325|NCT05881642|PROCEDURE|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
47959531|NCT04816266|DEVICE|Iol master|Iol master measures the distance between anterior pole of the cornea and the anterior surface of the lens to calculate the anterior chamber depth
47959532|NCT04816266|DEVICE|Pentacam|The Pentacam HR calculates Anterior chamber depth from the corneal endothelial layer along a line from the apex of the cornea to the anterior surface of the lens
47959533|NCT03677921|DIETARY_SUPPLEMENT|Investigational Product (Bio-Germanium)|"* Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
48111908|NCT01418118|DRUG|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
48306831|NCT04574284|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48306832|NCT04574284|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
48111909|NCT01418118|DRUG|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
48111910|NCT05486260|DIETARY_SUPPLEMENT|DMB lowest dose|Intake of 150 mg of DMB
48111911|NCT05486260|DIETARY_SUPPLEMENT|DMB highest dose|Intake of 300 mg of DMB
48111912|NCT05486260|DIETARY_SUPPLEMENT|Strawberry lyophilisate|Intake of 300 mg of strawberry lyophilisate
48111913|NCT01800513|PROCEDURE|Endometrial Biopsy|
48111914|NCT01800513|PROCEDURE|Sham Procedure|
48111915|NCT04823663|DEVICE|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
48306833|NCT00860340|DRUG|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
47959534|NCT03677921|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
48306834|NCT00875017|DRUG|Lanthanum Carbonate|1 x 1000mg tablet
48641677|NCT05330546|PROCEDURE|Densah burs|using Densah burs to prepare implant osteotomy
48641678|NCT05330546|PROCEDURE|Ridge expansion screws|using Ridge expansion screws to prepare implant osteotomy
47959535|NCT00717093|DRUG|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
48306835|NCT00875017|DRUG|Sevelamer|3 x 800mg tablets
48306836|NCT04867135|DRUG|Amikacin Sulfate Injection|The dose and frequency of amikacin was defined by each hospital.
48306837|NCT02991053|DRUG|ketamine|
48340215|NCT05430204|DEVICE|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~* Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~* Average glucose≥130 mg/dL or~* Any glucose value ≥200 mg/dL"
48641679|NCT05640999|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
48641680|NCT05640999|RADIATION|Adjuvant radiotherapy (EBRT +/- brachytherapy)|Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
48641681|NCT05640999|OTHER|Observation|Observation
48111916|NCT04823663|PROCEDURE|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
47959536|NCT00717093|DRUG|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
48111917|NCT06672042|DEVICE|CHAMP App|"CHAMP® App is a proprietary, downloadable, mobile Software Application and software platform designed and developed by the Children's Mercy Hospital of Kansas City (CMH), that permits parents and caregivers to transmit to the care team data to permit remote monitoring of the patient's condition. The parent or caregiver enters into the CHAMP App data including vital signs, intake and output, video, and images of patients (collectively, CHAMP® Data), which operates on computers, mobile devices, and handheld computers. The CHAMP® App is intended to be used in the clinical care of pediatric patients in the home setting that are followed by specialty health care teams to improve patient self-management through the use of asynchronous data. Videos and data related to the patient are entered by the parent and sent electronically to the Clinical Care Team as recommended by the clinical team."
48111918|NCT06243588|OTHER|clinical records review|review the medical records, radiological imaging, and histological data of these patients
48111919|NCT01392313|DIETARY_SUPPLEMENT|Carnitine|Carnitine Ingestion
48111920|NCT01392313|DIETARY_SUPPLEMENT|Placebo|Carnitine placebo
47959537|NCT03509558|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
47959538|NCT03509558|OTHER|Physical Therapy|physical therapy to improve walking and standing functions
47959539|NCT05210335|OTHER|Clinical pharmacist's recommendation to physicians about drug related problems|Clinical pharmacist's recommendation to physicians about drug related problems
47959540|NCT04764279|DIETARY_SUPPLEMENT|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
47959541|NCT03736733|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
47959542|NCT03736733|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
47959543|NCT01218113|BIOLOGICAL|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
47959544|NCT01218113|DRUG|Placebo|1 or 3 doses according to protocol schedule
47959545|NCT05409326|DRUG|TQH2722 injection|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
47959546|NCT05409326|DRUG|Placebo to match TQH2722|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
47959547|NCT02606448|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
47959548|NCT02606448|PROCEDURE|Femoral nerve block|Pre-operative femoral nerve block
48111921|NCT02894749|RADIATION|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
48111922|NCT06408259|DRUG|Ozanimod|Specified dose on specified days
48111923|NCT06408259|DRUG|Fingolimod|Specified dose on specified days
48111924|NCT06408259|OTHER|Placebo|Specified dose on specified days
48111925|NCT05570994|DRUG|177Lu HTK03170|Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
48482326|NCT04831138|PROCEDURE|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
48111926|NCT05570994|DRUG|68Ga-HTK03149|68Ga-HTK03149 PET/CT imaging; intravenous during screening
48111927|NCT05845645|DRUG|UCB0599|Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
48111928|NCT05845645|OTHER|Esomeprazole|Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
48641682|NCT06662292|BEHAVIORAL|Mobile STRIDES app (psychoeducation features)|Twelve theory-based physical activity behavior change lessons/modules during the course of the 3-month intervention.
47959549|NCT02606448|DRUG|Ropivacaine|Ropivicaine was used in all femoral nerve blocks
48111929|NCT05845645|OTHER|Placebo|Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
48111930|NCT05678972|OTHER|Self-help online mindfulness-based intervention|"This self-help online mindfulness-based intervention is comprised of four weekly modules on education about mindfulness, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and videos are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.~Participants will be asked to meditate daily and complete a daily log on their mindfulness practice during this 8-week period."
48340216|NCT02524535|OTHER|Therapeutic alliance|
48340217|NCT03713827|DEVICE|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
48340218|NCT00116324|DRUG|Montelukast|
48340219|NCT00424346|DRUG|Canakinumab|
48340220|NCT00424346|DRUG|Placebo|
47959550|NCT02050841|BIOLOGICAL|octaplas|Octaplas S/D Plasma
47959551|NCT03212924|BEHAVIORAL|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
47959552|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
47959553|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
47959554|NCT03212924|BEHAVIORAL|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
48111931|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
48111932|NCT00736853|DRUG|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
48111933|NCT00736853|DRUG|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
48111934|NCT06378528|DRUG|Ketamine|3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks
48111935|NCT06378528|DEVICE|SmartSleep EEG recording headband|Participants will complete 7 nights of at-home sleep recordings for exploratory analysis
48111936|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions)|
48111937|NCT02562391|DEVICE|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
48111938|NCT05853978|DRUG|BSS Plus|BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)
48111939|NCT05853978|DRUG|BSS|BSS® Sterile Irrigating Solution (balanced salt solution)
48111940|NCT05319353|DRUG|Maribavir|Participants will receive maribavir.
48111941|NCT03874650|BEHAVIORAL|Activity Planning Group|Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
48111942|NCT03874650|BEHAVIORAL|Activity Engagement Group|Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
48111943|NCT03874650|BEHAVIORAL|Waitlist Group|Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
48111944|NCT03945942|DEVICE|Near infrared spectroscopy with INVOS device|somatic and cerebral oximetry by INVOS in pediatric liver transplantation
48111945|NCT03945942|DEVICE|Near infrared spectroscopy with Foresight device|somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
48111946|NCT03206736|OTHER|Loop DS surgery|these patients will receive a loop DS bariatric procedure
48111947|NCT06675968|PROCEDURE|Direct Suture|A capsular closure will be performed, closure of the gluteus medius with a direct tendon and absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
48340221|NCT00914238|BEHAVIORAL|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
48482327|NCT06293326|DRUG|bi-layer calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
48482328|NCT06293326|DRUG|Immediate release calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
48482329|NCT01845402|BIOLOGICAL|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
48482330|NCT04567576|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure."
48482331|NCT04659551|DRUG|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
48482332|NCT04659551|DRUG|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
48111948|NCT06675968|PROCEDURE|Transosseus Suture|A capsular closure will be performed, transosseous suture with a non-absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
48111949|NCT03499236|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
48111950|NCT03499236|OTHER|Control|Right heart catheterization, invasive echocardiography.
48111951|NCT06554093|DEVICE|Medical Device - PKS|The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.
48111952|NCT01720563|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
48111953|NCT01720563|DRUG|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
48111954|NCT01720563|PROCEDURE|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
48111955|NCT04153435|DRUG|Calcium Chloride|Calcium chloride 5 mmol
48111956|NCT04153435|DRUG|Sodium chloride 0.9%|Placebo
48111957|NCT02427633|OTHER|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
48111958|NCT02427633|OTHER|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
48340222|NCT00914238|BEHAVIORAL|OPUS 5 years|
48340223|NCT02999815|PROCEDURE|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
48482333|NCT04659551|DRUG|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
48482334|NCT04659551|DRUG|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
48482335|NCT04659551|DRUG|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
48482336|NCT04918160|OTHER|Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)|The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
48641683|NCT06662292|BEHAVIORAL|Mobile STRIDES app (self-regulation features)|Personalized physical activity goals focused on moderate-to-vigorous intensity aerobic physical activity and steps. Physical activity (tracked with a Fitbit wearable smartwatch and synced with the Mobile STRIDES app) tracking component, displaying team and individual progress. Weekly individualized feedback messages crafted by a trained professional for the first month of the intervention.
48306838|NCT05629416|BEHAVIORAL|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"1. Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~2. Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~3. Support simplified and improved strategies for booking an interpreter to increase uptake.~4. Implement retention strategies to ensure interpreters receive workplace support.~5. Provide training in health terminology for interpreters.~6. Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~7. Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
48306839|NCT03032185|DEVICE|Transcutaneous Elevtrical Nerve Stimulation|
48306840|NCT04109625|DIAGNOSTIC_TEST|Demonstrator MAGIA|test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
48306841|NCT05129813|BEHAVIORAL|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
48306842|NCT01234012|BIOLOGICAL|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
48306843|NCT04182659|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
48306844|NCT04182659|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
48306845|NCT04357353|BIOLOGICAL|Platelet rich plasma|PRP will be used in the experimental arm.
48306846|NCT04357353|OTHER|Placebo Sham Injection|sham injection
48306847|NCT02659683|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
48306848|NCT02659683|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
48306849|NCT05992519|DIAGNOSTIC_TEST|¸FeNO|FeNO measured with a NIOX VERO device after the methacholine challenge
48306850|NCT04852588|PROCEDURE|Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)|Chest lymph node sampling procedure by EBUS
48306851|NCT04852588|PROCEDURE|Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)|Chest lymph node sampling procedure by EUS
48306852|NCT03240211|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV
48306853|NCT03240211|DRUG|Pralatrexate|Pralatrexate 20 or 30 mg/m2 IV push
48306854|NCT03240211|DRUG|Decitabine|Decitabine 10 mg/m2
48306855|NCT03160404|DRUG|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg/night
48482337|NCT01652729|DRUG|Exenatide once weekly suspension|
48482338|NCT01652729|DRUG|Sitagliptin|
48482339|NCT01652729|DRUG|Placebo|Placebo oral capsule once daily
48482340|NCT00152191|DRUG|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
48482341|NCT00152191|DRUG|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
48482342|NCT04776057|OTHER|catarct surgery with toric intra ocular lenses|rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
48306856|NCT03160404|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
48306857|NCT02234583|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
48306858|NCT03065712|DRUG|F-18 Fluoroestradiol|F-18 Fluoroestradiol will be administered for PET/CT scan.
48306859|NCT03065712|PROCEDURE|Computed Tomography|Undergo PET/CT
48306860|NCT03065712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48306861|NCT03065712|OTHER|Laboratory Biomarker Analysis|Correlative studies
48306862|NCT05217680|BIOLOGICAL|Bevacizumab|Administration of monthly intravitreal bevacizumab (4-12 injections)
48306863|NCT05217680|BIOLOGICAL|Lucentis®|Administration of monthly intravitreal ranibizumab (4-12 injections)
48306864|NCT05549063|OTHER|Mobility and Stability Exercise|Mobility and stability exercises
48306865|NCT05549063|OTHER|Stretching Exercise|Balance and reaching exercise
48306866|NCT03204227|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
48306867|NCT03204227|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
48306868|NCT02269111|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
48482343|NCT01167517|OTHER|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
48482344|NCT06615791|BEHAVIORAL|FIT FIRST Teen|High intensity sports drills and games.
48482345|NCT02471079|RADIATION|Radiotherapy|
47959555|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
48306869|NCT02269111|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
48306870|NCT02269111|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
48641684|NCT06662292|BEHAVIORAL|Mobile STRIDES app (social support training features)|For the experimental group, the Mobile STRIDES app also includes five social support training lessons/modules (during the course of the 3-month intervention) focused on providing guidance related to effective communication when exchanging social support for physical activity within a team. In addition, six team feedback messages will be delivered to respective teams throughout the course of the 3-month intervention to reinforce content taught via the training lessons/modules. A weekly poll will also be administered that complements the social support training lessons, with cumulative results displayed.
47959556|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
47959557|NCT03525171|DIAGNOSTIC_TEST|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
47959558|NCT00608660|OTHER|acupuncture|staging acupuncture
47959559|NCT00608660|OTHER|acupuncture and moxibustion|staging acupuncture and moxibustion
47959560|NCT00608660|OTHER|electroacupuncture|staging electroacupuncture
48111959|NCT04549532|BEHAVIORAL|Targeted Multidomain|Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.
48111960|NCT04549532|BEHAVIORAL|Behavioral Management|1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
48111961|NCT04191486|DRUG|T-817MA|224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
48306871|NCT02269111|PROCEDURE|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
48641685|NCT06696040|DEVICE|Passive mobilization using a device|"The protocol consists of three moments: initial assessment, use of the device, and final assessment.~In the initial assessment, participants will be positioned supine on a stretcher, where the muscle tone of the lower limb(s) will be tested using the Modified Ashworth Scale. After the physical test with the Modified Ashworth Scale, the TUG test will be carried out, and, finally, gait assessment with the BAIOBIT Inertial Meter with Accelerometer and Gyroscope.~At the end of the initial assessment, the Autofisio500 device will be used. To do this, the participant will be positioned again and comfortably supine on the stretcher, and the previously tested lower limb will be attached to the device for movement, between the knee and ankle joints, for 30 minutes, at maximum speed (11 RPM).~For the final assessment, the Modified Ashowrth Scale, TUG and gait assessment with the Inertial Meter with Accelerometer and BAIOBIT Gyroscope will be applied again."
48641686|NCT06375772|DRUG|2-Deoxy-D-glucose|Intranasal administration
48306872|NCT02028429|DRUG|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
48306873|NCT01264250|DRUG|AZD2927|Single dose of AZD2927
48306874|NCT01264250|DRUG|Placebo|Single dose of placebo
48306875|NCT04792853|BEHAVIORAL|Tab-G|Participants receive a tablet preloaded with Tab-G application and an accelerometer.
48641687|NCT06375772|OTHER|Placebo|Intranasal administration
47959561|NCT00608660|OTHER|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
47959562|NCT00608660|OTHER|acupuncture|non-staging acupuncture
47959563|NCT05344911|DRUG|Propofol combined with alfentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
48482346|NCT03046719|DRUG|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
47959564|NCT05344911|DRUG|Propofol combined with remifentanil|Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
48111962|NCT04191486|DRUG|Placebo|Placebo once daily
48111963|NCT06390943|OTHER|Facility-based feeding support package plus (FB-FSP+)|Package of materials to support facility-based feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
48111964|NCT06390943|OTHER|Transition-to-home feeding support package plus (TTH-FSP+)|Package of materials to support transition-to-home feeding and lactation, KMC and WASH, including a training curriculum, training guide, and implementation materials, such as Standard Operating Procedures (SOPs) and job aides
48111965|NCT01205620|DEVICE|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
48306876|NCT06331065|OTHER|Information session on mindfulness meditation and questionnaires|"The information session on mindfulness meditation is an information meeting on the PROMIND study opened to all hospital professionals from the 8 participating departments, i.e. the intervention and control groups.~During this information session, it is specified that it is desirable for the non-intervention groups to maintain their usual practice (or non-practice) during the study, without starting a new practice of mindfulness meditation.~Before this meeting, the baseline questionnaires are administered. Immediately after this time, the questionnaire on representations of mindfulness meditation is administered."
48340224|NCT02999815|PROCEDURE|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
48482347|NCT03046719|DRUG|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
47959565|NCT02624609|OTHER|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
47959566|NCT02624609|OTHER|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
48306877|NCT06331065|DEVICE|Mindfulness meditation experimentation, practice program, questionnaires, individual interview and focus group|"After randomization, a mindfulness meditation trial session is offered to all professionals in the intervention group follow by the questionnaire on representations of mindfulness meditation administration.~Then, interdepartmental focus groups is conducted with leaders. The following mindfulness meditation program consists of 10 1-hour sessions within 15 days, in groups of up to 15 professionals, conducted at the participants' place and time of work, by a certified mindfulness meditation trainer with a recommended daily practice of 10-20 minutes with the possibility of a longer duration, and an audio guidance tool adapted to the study.~After the program, and 3 months later, questionnaires are administered for both groups.~For the intervention group, individual interviews, and inter-departmental focus groups (leaders) are carried out at the end of the intervention, and intra-departmental focus groups are conducted 3 months after the end."
48306878|NCT06052735|OTHER|Correlation research|The relationship among pain perception, temporomandibular disorder severity and spine health
48306879|NCT01892033|BEHAVIORAL|Aerobic Exercise|12 weeks of brisk walking
48306880|NCT04720508|DIAGNOSTIC_TEST|blood sample collection.|venipuncture procedure
48306881|NCT05517603|DRUG|AJ201|Administered orally
48306882|NCT05517603|DRUG|Placebo|Administered orally
48306883|NCT03640806|OTHER|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
48306884|NCT02738827|PROCEDURE|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
48306885|NCT01196169|DRUG|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
48306886|NCT01196169|DRUG|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if \> one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
48306887|NCT00972400|GENETIC|protein analysis|
48482348|NCT01996059|PROCEDURE|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
48482349|NCT01996059|PROCEDURE|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
48482350|NCT01694017|DRUG|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
48482351|NCT01694017|DRUG|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
48306888|NCT00972400|OTHER|laboratory biomarker analysis|
48306889|NCT00972400|OTHER|mass spectrometry|
47959567|NCT00916942|DRUG|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
47959568|NCT00916942|DRUG|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
47959569|NCT04121026|OTHER|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~* history of contact~* suggestive TB symptoms~* tachycardia~* chest radiography~* abdominal ultrasound~* Xpert MTB/RIF Ultra. A score of \>100 is highly predictive of TB. In children with a score \>100, anti-TB treatment will be initiated immediately. In children with a score of \<100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
47959570|NCT04470323|DIAGNOSTIC_TEST|Flow cytometry|Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
48111966|NCT01205620|OTHER|No intervention|No intervention will be performed in the control group
48306890|NCT00972400|OTHER|questionnaire administration|
48306891|NCT00972400|PROCEDURE|assessment of therapy complications|
48306892|NCT00972400|PROCEDURE|cognitive assessment|
48306893|NCT00972400|PROCEDURE|quality-of-life assessment|
48306894|NCT06208982|DIAGNOSTIC_TEST|Colonoscopy images and videos|A CADx system in real-time characterization of colonic ulcer diseases was constructed using artificial intelligence to extract endoscopic features from the training set. Subsequently, the performance of the CADx system was preliminarily tested through the validation set.
48306895|NCT03827473|DRUG|Abiraterone Acetate|Given PO
48306896|NCT03827473|DRUG|Antiandrogen Therapy|Given per standard of care
48306897|NCT03827473|DRUG|Docetaxel|Given IV
48306898|NCT03827473|DRUG|Prednisone|Given PO
48306899|NCT03827473|OTHER|Quality-of-Life Assessment|Ancillary studies
48306900|NCT03827473|OTHER|Questionnaire Administration|Ancillary studies
48482352|NCT01001260|DRUG|No ASA|Alternative antiplatelet therapy instead of aspirin
47959571|NCT05259514|DEVICE|CytoSorb|The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
47959572|NCT01437969|GENETIC|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
47959573|NCT05962957|DRUG|carbidopa-levodopa|Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication
47959574|NCT05962957|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy via suppression of the TLR4/NF-κB network signaling pathway. Moreover, Pentoxifylline has a potential antioxidant capacity mostly via nuclear erythroid 2-related factor 2 (Nrf2) activation with subsequent up-regulation and expression of several antioxidant enzymes
47959575|NCT05962957|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
47959576|NCT03949309|OTHER|Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.|It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
47959577|NCT03334539|BIOLOGICAL|HL036 ophthalmic solution|HL036 ophthalmic solution
47959578|NCT03334539|OTHER|Placebo vehicle solution|Placebo vehicle solution
47959579|NCT00055250|DRUG|Gemcitabine|
48111967|NCT06677138|DRUG|gefurulimab|Participants will receive gefurulimab subcutaneously (SC).
48111968|NCT02383108|DRUG|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
48111969|NCT02383108|DRUG|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
48111970|NCT00535977|DIETARY_SUPPLEMENT|Broccoli|400g ITC-enriched broccoli per week for 12 months
48641688|NCT05090566|DRUG|Elranatamab + Nirogacestat|BCMA-CD3 bispecific antibody + gamma secretase inhibitor
48111971|NCT00535977|DIETARY_SUPPLEMENT|Peas|400g frozen garden peas per week for 12 months
48111972|NCT04013555|DRUG|N-acetylcysteine (NAC)|Flavored effervescent formulation
47959580|NCT00055250|DRUG|LY293111|
48111973|NCT04013555|DRUG|Placebo|Flavored effervescent formulation designed to mimic NAC
48111974|NCT04013555|DRUG|Tryptophan|Oral slurry form
48111975|NCT02277288|OTHER|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
48111976|NCT02086370|PROCEDURE|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
48111977|NCT02086370|PROCEDURE|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
48111978|NCT06265636|PROCEDURE|Percutaneous nerve stimulation|Percutaneous nerve stimulation (PENS) involves inserting a dry needling needle through muscle tissue until it reaches a nerve branch. At this point, a bipolar TENS current with different parameters is applied to the needle with the goal of improving the patient's pain perception.
48111979|NCT06265636|OTHER|Manual therapy|Digital pressure techniques in muscle areas with the aim of reducing the perception of stiffness and pain
48111980|NCT06265636|OTHER|exercise|Exercises for improving mandibular mobility, occlusion coordination and regulation of temporomandibular muscle tone
48641689|NCT05090566|DRUG|Elranatamab + lenalidomide + dexamethasone|BCMA-CD3 bispecific antibody + immunomodulatory
47959581|NCT00055250|DRUG|placebo|
48111981|NCT04577612|DRUG|CHI-554|hemp-derived CBD in MCT oil
48482353|NCT01001260|DRUG|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
48641690|NCT06694246|DIAGNOSTIC_TEST|Pipelle outpatient endometrial biopsy|This quality improvement project aims to improve the adequacy and sufficiency of outpatient endometrial biopsy results.
47959582|NCT03208712|DRUG|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
47959583|NCT03208712|DRUG|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
47959584|NCT02824614|DIETARY_SUPPLEMENT|E967-Xylitol|
48111982|NCT04541901|OTHER|Massage|12 minutes of effleurage and petrissage on the upper limbs
48111983|NCT04541901|OTHER|Cold water immersion|12 minutes of cold water immersion at the shoulder level with water temperature between 11 to 15°C
48111984|NCT00756730|DRUG|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
48641691|NCT03575364|DEVICE|ClotTriever|Thrombectomy
48641692|NCT06694129|DRUG|Entrectinib|Patients in each cohort were treated with Entrectinib.
48641693|NCT06372483|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
48641694|NCT06372483|DRUG|Placebo|VMX-C001 matched placebo
48641695|NCT06372483|DRUG|Rivaroxaban 20 mg Oral Tablet|Fxa DOAC
47959585|NCT02824614|DIETARY_SUPPLEMENT|E968-Erythritol|
47959586|NCT06069505|DIAGNOSTIC_TEST|Aspergillus PCR|Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.
47959587|NCT05334966|OTHER|Maternal Hyperoxygenation|Oxygen is given to mothers at 8L through a non-rebreather mask.
47959588|NCT04988139|OTHER|individualized educational training|50 min per session, one session per week, 4 sessions per month, of individualized educational training to preschool children with developmental delays under traditional rehabilitation programs
47959589|NCT02055417|BEHAVIORAL|Personal Approaches to Treatment Choices for HIV|
47959590|NCT02055417|BEHAVIORAL|Stress Reduction Skills Program|
47959591|NCT06082492|DIAGNOSTIC_TEST|18F FDG PET/CT|Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
47959592|NCT06082492|DIAGNOSTIC_TEST|CT scan|CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
47959593|NCT00078793|DRUG|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
47959594|NCT03350581|PROCEDURE|FAM 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
47959595|NCT03350581|PROCEDURE|FAM-CT 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
47959596|NCT03836248|OTHER|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
48111985|NCT00756730|DRUG|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
48111986|NCT05261568|BEHAVIORAL|PROGRESSIVE RELAXATION EXERCISE|Progressive relaxation exercise will be done for 6 weeks by watching the animation video in the mobile application program.
48111987|NCT04544592|DRUG|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
48111988|NCT02537704|BEHAVIORAL|Group Lifestyle Balance Program|
48111989|NCT06676111|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
48641696|NCT06372483|DRUG|Apixaban 5 mg Oral Tablet|Fxa DOAC
48641697|NCT06372483|DRUG|Edoxaban 60 mg Oral Tablet|Fxa DOAC
48641698|NCT06560307|DEVICE|Enterra Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
47959597|NCT03836248|OTHER|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
47959598|NCT03836248|OTHER|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
47959599|NCT04497831|DRUG|Morphine hydrochloride|5 mg milligram(s) per day per two days of dosage
47959600|NCT04497831|DRUG|Placebo|Inhalation use
47959601|NCT01539538|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
47959602|NCT01539538|DRUG|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
47959603|NCT06298331|OTHER|Aerobic Exercise|Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down). Walking speed in the clinic will be determined according to the Heart Rate Reserve(HRR) method. In the warm-up and cool-down phases in the clinic, the walking speed will be adjusted in the range of 20-40% of HRR, while in the loading phase it will be adjusted in the range of 40-60% of HRR. Heart rate will be monitored with a monitor that detects heart rate by hand contact on the treadmill. Outside the clinic, walking speed will be determined according to the level of fatigue perceived on the Borg Scale. Outside the clinic, walking speed will be regulated as 10-12 (light) on the Borg scale during warm-up and cool-down phases and 12-14 (slightly difficult) during the loading period.
47959604|NCT06298331|OTHER|Abdominal Massage|Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
48641699|NCT03703167|DRUG|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
47959605|NCT06298331|OTHER|Patient Education|Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
47959606|NCT02646384|PROCEDURE|Ovarian tissue cryopreservation|Ovarian tissue will be removed
47959607|NCT06187584|DRUG|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen 0.15mg/kg PO q6
47959608|NCT06187584|DRUG|Acetaminophen|15mg/kg PO q6 hours
47959609|NCT06187584|DRUG|Ibuprofen|10mg/kg PO q6 hours
47959610|NCT05768217|BEHAVIORAL|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention \& Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
47959611|NCT05768217|BEHAVIORAL|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
48111990|NCT06676111|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
48111991|NCT03902236|OTHER|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
48306901|NCT04054778|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
48306902|NCT04054778|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
48306903|NCT04381819|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 E gene
48306904|NCT04301882|DRUG|interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
47959612|NCT03989700|DRUG|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
48111992|NCT03902236|OTHER|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
47959613|NCT06247514|BEHAVIORAL|The BEET Diabetes Program|The BEET Diabetes program is an adapted CBT program specifically designed to treat disordered eating and improve diabetes self-management. Participants receive support from BHPs to guide them through the program, maintain motivation, and facilitate appropriate goal setting.
48111993|NCT03902236|OTHER|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
48306905|NCT04301882|DRUG|direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
48306906|NCT06363448|PROCEDURE|Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia|Patients were divided into two groups to undergo classic ab externo two-point scleral fixation or flanged haptics as described by Yamani or the 2\*2 proline mesh technique.
48306907|NCT04355091|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage forms, rather than using acupuncture needles.
48306908|NCT01355068|DRUG|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
48306909|NCT01355068|DRUG|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
48306910|NCT00046319|DRUG|BSF 208075|
47959614|NCT06247514|BEHAVIORAL|Cognitive Behavioral Therapy Guided Self-Help|"6-session cognitive behavioral therapy delivered through the self-help book Overcoming Binge Eating Self-help by Christopher G. Fairburn.~The manual focuses on reducing binge-eating episodes. Guided support sessions can be provided by personnel with no background training or knowledge of CBT or disordered eating behaviors, as the book acts as the expert."
47959615|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
47959616|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
47959617|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
47959618|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
47959619|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
47959620|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
48111994|NCT03902236|OTHER|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
48111995|NCT06178822|OTHER|No intervention|There is no intervention
48111996|NCT01435395|DRUG|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
48111997|NCT02576821|OTHER|Neurological examinations|
48111998|NCT02576821|OTHER|Neuropsychological examinations|
48111999|NCT02576821|OTHER|Clinical examinations|
48112000|NCT02576821|RADIATION|MRI 3T|
48112001|NCT02576821|RADIATION|MRI 7T|
48112002|NCT06369922|PROCEDURE|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
48112003|NCT06369922|PROCEDURE|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
48112004|NCT03512756|DRUG|SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)|Daily oral therapy for cancer
48112005|NCT03512756|DRUG|Capecitabine, Gemcitabine, and 5-FU|"Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU"
48112006|NCT02749578|DRUG|Atorvastatin|
48112007|NCT02749578|DRUG|MGL-3196|
48112008|NCT00839241|DEVICE|Bellovac ABT|Bellovac ABT (autologous blood)
48306911|NCT06515652|DRUG|rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun|Comparing allopathic and herbal group of drugs for metabolic syndrome
47959621|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
48482354|NCT01001260|DRUG|325 mg ASA|high dose of aspirin prior to PTCA
48112009|NCT00839241|PROCEDURE|Allogenic Blood Transfusion|"Transfusion of allogenic (bank) blood."
48112010|NCT03959839|PROCEDURE|ESD|Rectal Endoscopic Submucosal Dissection
48112011|NCT03959839|PROCEDURE|TAMIS|Transanal Minimally Invasive Surgery
48112012|NCT03959839|PROCEDURE|TEO|Transanal Endoscopic Operation
48112013|NCT05686421|DEVICE|OCT Imaging Using Device N|Standard conventional OCT imaging device equipped with extendable and comfortable chin and forehead rest.
48112014|NCT05686421|DEVICE|OCT Imaging Using Device C|Standard conventional OCT imaging device.
48112015|NCT01175317|PROCEDURE|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
48112016|NCT01175317|OTHER|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
48112017|NCT00478335|DRUG|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
48112018|NCT00478335|DRUG|calcitonin|one nasal spray daily for 4 days
48112019|NCT00478335|DRUG|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
48112020|NCT00478335|DRUG|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
47959622|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
47959623|NCT03773263|DRUG|sequential IVM system|The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
47959624|NCT03773263|PROCEDURE|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
47959625|NCT03773263|PROCEDURE|Thawed embryo transfer (TET)|Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
47959626|NCT03773263|DRUG|traditional IVM system|COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
47959627|NCT03848429|PROCEDURE|Surgery for mechanical complications of acute myocardial infarction|Surgical treatment of post-AMI left ventricular free-wall rupture: sutured and sutureless repair. Surgical treatment of post-AMI ventricular septal defect: infarctectomy and infarct exclusion repair. Surgical treatment of post-AMI papillary muscle rupture: mitral valve repair and replacement
47959628|NCT05086848|DRUG|Irinotecan liposome、5-fluorouracil、Leucovorin|Irinotecan liposome、5-fluorouracil、Leucovorin
47959629|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
47959630|NCT01681472|DRUG|Levoleucovorin 200 mg/m2|i.v. bolus injection
47959631|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
47959632|NCT01681472|DRUG|Levoleucovorin 60 mg/m2|i.v. bolus injection
47959633|NCT00287482|DRUG|Essiac|
48112021|NCT00478335|DRUG|Placebo for sildenafil|one tablet daily for 4 days
48112022|NCT00478335|DRUG|placebo for calcitonin|one nasal spray daily
48112023|NCT04628026|DRUG|Venetoclax|Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
48112024|NCT04628026|DRUG|Placebo|Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
48112025|NCT04628026|COMBINATION_PRODUCT|Standard chemotherapy|"Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6, and daunorubicin 60 mg/m2 IV (days 1-3). Patients \>60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-6 without daunorubicin.~Consolidation chemotherapy option 1 consists of one cycle of mitoxantrone (10mg/m2 IV) and etoposide (100mg/m2 IV) (ME) days 1-5 (patients ≤60 yrs) or days 1-3 (patients \>60 yrs). Consolidation chemotherapy option 2 consists of intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are \>60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients \>60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment."
48112026|NCT04628026|OTHER|Autologous stem cell transplantation|Busulfan/Cyclophosphamide will be administered as conditioning regime. Patients may proceed to autologous HCT when they have reached CR/CRi/MLFS after at least two cycles of chemotherapy and performance status permits continuation with high-dose chemotherapy. Venetoclax will not be added to or given after the conditioning regimen.
48112027|NCT04628026|OTHER|Allogeneic stem cell transplantation|Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
48306912|NCT03100435|DEVICE|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
48306913|NCT03100435|OTHER|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
47959634|NCT02780375|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
47959635|NCT02714374|BIOLOGICAL|GL-ONC1|"Dose and Regimen:~1. Single dose group: Cohort 1 dose is 1 × 109 pfu~2. Multiple dose groups:~   * Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~  * Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~  * Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
47959636|NCT05057975|DEVICE|Sunrise|Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.
47959637|NCT05057975|DEVICE|polysomnography|Reference protocol to diagnose OSA (in-lab or outpatient PSG)
47959638|NCT03748784|BIOLOGICAL|ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
48112028|NCT05819099|DIAGNOSTIC_TEST|An Intelligent Endoscopic Diagnosis System Developed and Verified Based on Deep Learning|This study will compare the established AI model with the diagnostic results of endoscopists to evaluate the clinical auxiliary value of the model for endoscopists.
48112029|NCT00846066|OTHER|Hands on training|Hands on training by a pediatric dentist on preventive oral health
48112030|NCT00846066|OTHER|Web based training|Web based training alone
48112031|NCT01026064|OTHER|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
48112032|NCT01026064|DRUG|Azithromycin|Zithromax (250 mg oral capsule).
48112033|NCT01026064|DRUG|Placebo|Matching placebo
48112034|NCT00345761|DRUG|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
48112035|NCT00345761|DRUG|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
48112036|NCT00345761|DRUG|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
48112037|NCT05485402|DIETARY_SUPPLEMENT|Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
48112038|NCT05485402|DIETARY_SUPPLEMENT|Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)|The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).
48112039|NCT05485402|DIETARY_SUPPLEMENT|Maltodextrin|The dosage will be 7,5 g/day of maltodextrin.
48112040|NCT05485402|DIETARY_SUPPLEMENT|Prebiotic (FOS and inulin)|The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).
48112041|NCT05485402|OTHER|Nutritional and physical activity recommendations|The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
48112042|NCT02346006|BEHAVIORAL|More physical activity.|Subjects receiving more physical activity in school.
48112043|NCT02401646|DIETARY_SUPPLEMENT|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
48112044|NCT02401646|DIETARY_SUPPLEMENT|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
48112045|NCT04100148|DEVICE|SyncAV programmed ON|For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
48112046|NCT04100148|DEVICE|Fixed AV delay|For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
48112047|NCT03280017|DRUG|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
48306914|NCT04492956|DRUG|Ecopipam|Oral tablet
48306915|NCT04492956|DRUG|Placebo|Oral tablet
48112048|NCT03280017|DRUG|Normal saline|normal saline infusion
48112049|NCT06153641|OTHER|N/A-Observational Study|N/A-Observational Study
48112050|NCT01259102|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
48112051|NCT00188461|DEVICE|CT Thorax|
48112052|NCT03062137|DIAGNOSTIC_TEST|blood gas sampling|
48112053|NCT02418013|OTHER|Fresh cord blood(experimental group A)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
48112054|NCT02418013|OTHER|Frozen cord blood(experimental group B)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
48112055|NCT02418013|OTHER|Frozen plasma(experimental group C)|"1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
48112056|NCT02418013|OTHER|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
48112057|NCT00813904|BIOLOGICAL|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
48112058|NCT06390826|PROCEDURE|Biopsy|Undergo biopsy
48112059|NCT06390826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48112060|NCT06390826|PROCEDURE|Computed Tomography|Undergo CT scan
48112061|NCT06390826|PROCEDURE|Echocardiography|Undergo ECHO
48112062|NCT06390826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48112063|NCT06390826|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
48112064|NCT06390826|DRUG|Sunitinib|Given PO
48112065|NCT06677463|DEVICE|Virtual Reality|Studying the effect of virtual reality glasses on women during pregnancy, for the first time, it is also used to facilitate the birth process
48112066|NCT01748318|DRUG|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
48112067|NCT01748318|DRUG|Bactrim DS|Bactrim DS
48112068|NCT01990924|RADIATION|15 FPS|X-ray pictures
48112069|NCT01990924|RADIATION|7.5 FPS|X-ray pictures
48306916|NCT04297670|OTHER|Measurement of HPV types prevalence|Self collected genital samples to be tested for the presence of different HPV types.
48306917|NCT03554538|BEHAVIORAL|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
48306918|NCT03554538|BEHAVIORAL|Exercise program|Exercise on an evidence based program for shoulder pain
48306919|NCT02738437|DEVICE|Kryptonite-bone cement|
48306920|NCT05058131|DIETARY_SUPPLEMENT|Dietary fibre|Dietary fibre as a powder, 24 g per day for 6 weeks
48306921|NCT05058131|DIETARY_SUPPLEMENT|Placebo compound|Maltodextrin powder, 24 g per day for 6 weeks
48306922|NCT00713401|DRUG|Tecadenoson|Tecadenoson administered intravenously (i.v.)
48112070|NCT06199648|OTHER|web-based documentation and advice|Caregivers will be supported with a web-based documentation and advice system for home care for elderly people
48112071|NCT01886625|PROCEDURE|unilateral single-port VATS sympathicotomy|
48112072|NCT05506943|DRUG|CTX-009|IV infusion on day 1 and 14 of every 28 day cycle
48112073|NCT05506943|DRUG|Paclitaxel|IV infusion on day 1, 8, and 15 of every 28 day cycle
48112074|NCT00395603|DRUG|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
48112075|NCT00395603|DRUG|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
48112076|NCT03655938|PROCEDURE|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
48112077|NCT03443037|DRUG|amantadine sulphate|
48112078|NCT06043128|OTHER|Patients With Stroke With Different Trunk Impact Levels|"Before the study, written and verbal Informed Consent Form will be obtained from all participants who meet the inclusion criteria.Trunk Impairment Scale (TRS) will be used to measure trunk control, which is our independent variable. Scores close to 23 points on the TIS will constitute the group with high trunk control, and those with scores close to 0 will constitute the group with low trunk control. Spasticity of the participants, Modified Tardiue Scale (MTS), cervical proprioceptive awareness cervical joint error test, lower extremity proprioceptive awareness Proprioception test in Technobody Prokin 252 Isokinetic Balance Platform, balance skills Dynamic and static balance in Tecnobody Prokin 252 Isonkinetic Balance Platform will be evaluated by tests. The patients' quality of life will be evaluated with the stroke-specific quality of life scale. All data obtained will be noted on a prepared evaluation form."
48112079|NCT01640678|PROCEDURE|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
48306923|NCT00713401|DRUG|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
48306924|NCT01513798|BEHAVIORAL|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
48306925|NCT01513798|BEHAVIORAL|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
48306926|NCT02280681|OTHER|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
48641700|NCT03703167|DRUG|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 \& 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
48641701|NCT03703167|DRUG|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
48641702|NCT06694324|DRUG|Liposomal Doxorubicin (Doxil)|30 mg/m2, d1, IV
48641703|NCT06694324|DRUG|Apatinib|250 mg, qd
48641704|NCT06694324|DRUG|Camrelizumab|200 mg, d1, IV
48641705|NCT05739643|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
48112080|NCT01640678|PROCEDURE|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
48112081|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|solution for intramuscular injection, 1 dose (0.5 mL)
48112082|NCT05739474|BIOLOGICAL|Influenza vaccine [inactivated]|suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
48112083|NCT02834884|GENETIC|RP-1828 IMMUcan|WES, lcWGS and RNAseq, multiplex IF and IMC
48112084|NCT02834884|GENETIC|RP-1759 AYA/TYA|WES, RNAseq and EPIC array
48112085|NCT02834884|GENETIC|RP-1843 Arcagen|NGS panel
48112086|NCT02834884|GENETIC|RP-1920 BioRadon|NGS panel
48112087|NCT00396851|DRUG|Gurmar|
48112088|NCT00396851|DRUG|Metformin|
48112089|NCT06214117|DRUG|Remimazolam|Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
48112090|NCT06214117|DRUG|Sevoflurane|Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min).
48306927|NCT02702908|OTHER||Historical Reference group.
48306928|NCT05922423|BEHAVIORAL|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
47959639|NCT03919331|DIAGNOSTIC_TEST|Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)|After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
47959640|NCT06191640|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|HEMT's are prescribed at the discretion of the treating physician and is not dictated by the principal investigator of this study.
47959641|NCT02027961|BIOLOGICAL|Durvalumab|Intravenous dose of 3 or 10 mg/kg durvalumab.
47959642|NCT02027961|DRUG|Dabrafenib|Oral dose of 150 mg dabrafenib capsule.
47959643|NCT02027961|DRUG|Trametinib|Oral dose of 2 mg trametinib tablet.
47959644|NCT04261868|DEVICE|Virtual Reality|New treatment for amblyopia therapy using playing games
47959645|NCT04261868|OTHER|Patching|Patching
47959646|NCT00868985|DRUG|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
47959647|NCT00868985|DRUG|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
47959648|NCT02261896|DRUG|Placebo|Evaluate usefullness of antibiotic prophylaxis
47959649|NCT02261896|DRUG|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
47959650|NCT01889238|DRUG|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
47959651|NCT00719108|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
47959652|NCT00719108|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
47959653|NCT05428631|DEVICE|Implantation of the CARDIOMEMS™ HF device|The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
47959654|NCT02721485|OTHER|Ringer's Lactate|After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
47959655|NCT02721485|OTHER|Normal Saline|After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
48306929|NCT05922423|BEHAVIORAL|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
47959656|NCT05191771|DEVICE|Neovis Total Multi|1 drop in each eye, 4 times per day
47959657|NCT05191771|DEVICE|Systane Balance|1 drop in each eye, 4 times per day
47959658|NCT00675948|DRUG|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
47959659|NCT00675948|DRUG|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
47959660|NCT03538002|DEVICE|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
48641706|NCT05249426|DRUG|BI 765063|BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
48641707|NCT05249426|DRUG|Ezabenlimab|Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
47959661|NCT00884169|DRUG|M518101|Proper quantity twice a day
47959662|NCT00884169|DRUG|placebo|Proper quantity twice a day
47959663|NCT02021032|DEVICE|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
47959664|NCT04152473|DRUG|Proglumide|oral CCK receptor antagonist
47959665|NCT06049238|OTHER|Maitland Mobilization|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
48306930|NCT04230486|DEVICE|Cross-model Visual Auditory Rehabilitation|Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
48306931|NCT01661400|DRUG|Metronomic Cyclophosphamide|
48306932|NCT01661400|DRUG|Thalidomide|
47959666|NCT06049238|OTHER|Post facilitation stretch|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
47959667|NCT05629169|OTHER|No intervention applied - observational study only|Observational study only. All head impacts will be assessed using video footage.
47959668|NCT00437983|DIETARY_SUPPLEMENT|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
47959669|NCT00437983|DIETARY_SUPPLEMENT|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
48112091|NCT04408937|DRUG|triopifexor|Tropifexor as a dry blend in hard gelatin capsules for oral administration
48112092|NCT04408937|DRUG|Placebo|Placebo capsules for oral administration
48112093|NCT03769506|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|Use of ASP-1929 PIT therapy
48112094|NCT03769506|DRUG|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
48112095|NCT03973944|DEVICE|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
48112096|NCT01343342|DIETARY_SUPPLEMENT|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
48306933|NCT01967667|DIETARY_SUPPLEMENT|Liposomal glutathione|Escalating dose steps
48112097|NCT06677203|DRUG|ASN51|Oral capsules
48112098|NCT06677203|DRUG|Placebo|Oral capsules
48112099|NCT00097188|DRUG|rituximab|
48112100|NCT01353170|OTHER|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
48112101|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
48112102|NCT03582410|PROCEDURE|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
48112103|NCT00834834|DRUG|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
48641708|NCT05249426|DRUG|BI 836880|BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
48112104|NCT00834834|BEHAVIORAL|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
48112105|NCT00834834|DRUG|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
48112106|NCT04908371|PROCEDURE|Selective Trunk Block|"It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL)."
48112107|NCT04908371|PROCEDURE|Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)|"It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA."
48112108|NCT02425111|DRUG|Vedolizumab|Vedolizumab intravenous injection
48112109|NCT06466980|OTHER|Ventilator associated event|Measure of incidence of Ventilator associated event
48112110|NCT04020718|BEHAVIORAL|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
48306934|NCT01967667|DIETARY_SUPPLEMENT|Placebo|escalating dose steps
48306935|NCT03356158|BIOLOGICAL|CPGJ602|Injection, q.w., 20 mg: 100 ml
48306936|NCT03356158|BIOLOGICAL|Cetuximab|Injection, q.w., 20 mg: 100 ml
48306937|NCT03382899|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Pembrolizumab
48306938|NCT03382899|DRUG|Pembrolizumab|Pembrolizumab Alone
48306939|NCT02756390|BEHAVIORAL|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
48306940|NCT02756390|BEHAVIORAL|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
48482355|NCT03971487|BEHAVIORAL|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
48641709|NCT05249426|DRUG|Cetuximab|Cetuximab
48641710|NCT05249426|OTHER|Investigator´s Choice Chemotherapy|Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
48641711|NCT04107285|BEHAVIORAL|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
47959670|NCT06356519|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
47959671|NCT01869439|DEVICE|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
47959672|NCT01869439|DEVICE|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
48306941|NCT02756390|BEHAVIORAL|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
47959673|NCT01869439|DEVICE|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
48112111|NCT04020718|DRUG|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
48112112|NCT04020718|BEHAVIORAL|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
48112113|NCT02994017|OTHER|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
48112114|NCT04257435|BEHAVIORAL|Positive Psychological Group Treatment|Positive psychological group treatment will involve engagement in traditional behavioral health treatment, as well as a group treatment focusing on previously researched exercises that have been demonstrated to relate to reduced depression and increased positive emotionality (Seligman, Rashid, Parks, et al., 2005; Seligman, Rashid, \& Parks, 2006; Rashid, 2015).
48112115|NCT04257435|BEHAVIORAL|Traditional Behavioral Health Treatment|Treatment will include traditional individual behavioral health treatment, involving CBT-based therapeutic interventions for presenting diagnoses (typically depression, anxiety, or PTSD-related symptomatology).
48112116|NCT01038011|DRUG|drug treatment|
48112117|NCT05777317|DEVICE|10 kHz SCS|Spinal cord stimulation programmed to a frequency of 10 kHz
48112118|NCT05777317|OTHER|CMM alone|Conventional medical management alone
48112119|NCT05585775|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
48112120|NCT05585775|BEHAVIORAL|Wellness for Wellbeing|Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
48306942|NCT01797107|DRUG|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
48306943|NCT06428643|OTHER|Chlamydia, gonorrhea, syphilis, and HIV screening|Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
48306944|NCT02216253|DRUG|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
47959674|NCT01869439|DEVICE|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
47959675|NCT03247751|DEVICE|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
47959676|NCT02014571|DRUG|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
47959677|NCT02014571|DRUG|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
47959678|NCT06342752|DIAGNOSTIC_TEST|Breath test|Early detection of volatile organic compounds (VOCs) in breath from preterm infants, collected at several timepoints within the first 4 weeks of life to predict BPD before diagnosis is made at 36 weeks PMA.
48641712|NCT04107285|DIAGNOSTIC_TEST|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
47959679|NCT06342752|OTHER|Throat swabs|A throat swab will be taken on several timepoints within the first 4 weeks of life to detect airway mucin expression. A second throat swab will be taken as proxy for the airway microbiome.
47959680|NCT06342752|OTHER|Placental samples|After birth, placental biopsies will be collected for headspace VOCs analysis. A placental swab and a biopsy will be taken for microbiome analysis.
47959681|NCT06342752|OTHER|Vaginal swab|A vaginal swab will be taken before birth for microbiome analysis.
47959682|NCT06342752|OTHER|Endotracheal aspirates|Collection of aspirates, as part of routine care, to detect mucin expression and the lung microbiome.
47959683|NCT01890941|DRUG|KCT-0809 ophthalmic solution|
47959684|NCT01890941|DRUG|Placebo|
47959685|NCT01099137|DRUG|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
47959686|NCT01099137|DRUG|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
47959687|NCT00531934|DRUG|Doxycline|100mg po daily
47959688|NCT00531934|DRUG|erlotinib [Tarceva]|150mg po daily
48112121|NCT04576858|DIAGNOSTIC_TEST|Circulating tumor DNA|Measurement of circulating tumor DNA from plasma over a period of 2 years.
48112122|NCT00346684|DRUG|Rituximab|
48641713|NCT04107285|OTHER|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
48641714|NCT05445323|GENETIC|Low dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
48641715|NCT05445323|GENETIC|Mid Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
47959689|NCT05469191|OTHER|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
47959690|NCT05469191|OTHER|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
47959691|NCT02664259|PROCEDURE|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
47959692|NCT02664259|PROCEDURE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
47959693|NCT02664259|PROCEDURE|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
47959694|NCT04080375|DRUG|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
48112123|NCT01091831|DRUG|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
48306945|NCT02216253|OTHER|Placebo|Placebo tablet twice a day 7 days before and after surgery
48641716|NCT05445323|GENETIC|High Dose LX2006|Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
47959695|NCT04080375|DRUG|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
47959696|NCT06291974|DIAGNOSTIC_TEST|electromyography|"Surface Electromyography (SEMG) is a measurement of the electrical activity in muscles as a byproduct of contraction.~It is the summation of action potentials from the muscle fibers under the electrodes placed on the skin"
47959697|NCT01313858|DRUG|Simponi®|
47959698|NCT01313858|DRUG|Methotrexate|Given concomitantly with Simponi®
47959699|NCT03681665|OTHER|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80\~90% reduced radiation dose compared to standard dose CT.
47959700|NCT02758990|DIETARY_SUPPLEMENT|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
47959701|NCT02758990|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
47959702|NCT02758990|DIETARY_SUPPLEMENT|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
47959703|NCT02758990|DIETARY_SUPPLEMENT|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
47959704|NCT02758990|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
47959705|NCT02758990|DIETARY_SUPPLEMENT|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
47959706|NCT02758990|OTHER|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.
47959707|NCT02758990|OTHER|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.
47959708|NCT02758990|DIETARY_SUPPLEMENT|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
47959709|NCT02758990|OTHER|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
48112124|NCT01091831|DRUG|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
47959710|NCT02758990|DEVICE|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
47959711|NCT02758990|OTHER|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
47959712|NCT00004762|DRUG|cladribine|
47959713|NCT02967731|DRUG|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
47959714|NCT03704480|DRUG|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
47959715|NCT03704480|DRUG|Tremelimumab|300mg by IV infusion on D1 at cycle 1 only
47959716|NCT03758001|DRUG|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
47959717|NCT03758001|DRUG|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
48306946|NCT04527172|DIAGNOSTIC_TEST|neuromuscular ultrasound|ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
48306947|NCT01675804|OTHER|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
47959718|NCT03758001|DRUG|Sintilimab|200mg iv infusion day 1 of every 21 days
47959719|NCT03591991|DRUG|Empagliflozin|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
47959720|NCT03591991|OTHER|placebo|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
47959721|NCT01849783|DRUG|dexamethasone|Given PO
47959722|NCT01849783|DRUG|cisplatin|Given IV
47959723|NCT01849783|DRUG|doxorubicin|Given IV
47959724|NCT01849783|DRUG|cyclophosphamide|Given IV or PO
47959725|NCT01849783|DRUG|etoposide|Given IV
48482356|NCT03971487|BEHAVIORAL|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
48482357|NCT03971487|DIAGNOSTIC_TEST|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
48482358|NCT03971487|BIOLOGICAL|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
48482359|NCT02839421|DRUG|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
47959726|NCT01849783|DRUG|bortezomib|Given IV
47959727|NCT01849783|DRUG|thalidomide|Given PO
47959728|NCT01849783|DRUG|melphalan|Given IV
48482360|NCT00135382|DRUG|Videx EC|
48482361|NCT00135382|DRUG|Epivir|
48482362|NCT00135382|DRUG|Sustiva|
48641717|NCT01747213|DRUG|BNC|
47959729|NCT01849783|PROCEDURE|autologous stem cell transplant|
47959730|NCT06492967|BEHAVIORAL|Systematic Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
47959731|NCT06492967|BEHAVIORAL|Flexible Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
47959732|NCT02759783|RADIATION|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
48482363|NCT03978091|DRUG|AZACTAM|A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
48482364|NCT03978091|DRUG|Ceftazidime-Avibactam|An antibacterial combination product containing ceftazidime and avibactam
48641718|NCT01747213|OTHER|Placebo|Microcrystalline cellulose fiber
47959733|NCT02759783|OTHER|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
47959734|NCT02302807|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
47959735|NCT02302807|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
47959736|NCT02302807|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
47959737|NCT02302807|DRUG|Vinflunine|Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
47959738|NCT01126801|DRUG|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
47959739|NCT01126801|OTHER|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
47959740|NCT01645345|DEVICE|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
47959741|NCT03714971|BEHAVIORAL|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
47959742|NCT00724932|DRUG|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
47959743|NCT00724932|DRUG|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
47959744|NCT00724932|DRUG|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
47959745|NCT00724932|DRUG|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
48112125|NCT01091831|DRUG|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
47959746|NCT04396340|BIOLOGICAL|XMT-1592|XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
47959747|NCT05182905|DRUG|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
47959748|NCT01998776|DRUG|Misoprostol|Misoprostol 200ug four times daily
47959749|NCT01998776|DRUG|Placebo|Placebo Starch four times daily
47959750|NCT05600452|OTHER|Heat acclimation|Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
47959751|NCT00025363|DRUG|vincristine sulfate|Given IV
47959752|NCT00025363|DRUG|irinotecan hydrochloride|Given IV
47959753|NCT00025363|DRUG|cyclophosphamide|Given IV
47959754|NCT00025363|DRUG|doxorubicin hydrochloride|Given IV
48112126|NCT01091831|DRUG|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
48112127|NCT06242899|OTHER|Exercise|"Exercise with a cycle ergometer in three phases:~* Warm-up: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes.~* Short exercise at moderate intensity for 8, 10 or 15 minutes according to group allocation. The exercise was cycling at 75% HRmax determined with an effort test.~* Cool down: the exercise intensity was determined at 50-60% of HRmax obtained in the effort test, and lasted 2 minutes."
48112128|NCT06544161|DEVICE|CPMX2|The CPMX2 is a point-of-care device for non-invasive, real-time, and intermittent monitoring of vascular occlusion pressure.
48306948|NCT01675804|DRUG|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
48306949|NCT01675804|OTHER|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
48306950|NCT03121183|DEVICE|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
48482365|NCT05506358|DIAGNOSTIC_TEST|High performance liquid chromatography|High performance liquid chromatography (HPLC) using the D10 System by Bio-Rad Laboratories will be used as the gold standard test.
48482366|NCT05506358|DEVICE|Automated sickling test|The standard sickling test using 2% sodium metabisulphite will be augmented using an automated microscope (such as Octopi) and machine learning, and will be used as one of the low-cost tests.
47959755|NCT00025363|DRUG|ifosfamide|Given IV
47959756|NCT00025363|DRUG|etoposide|Given IV
47959757|NCT00025363|DRUG|tirapazamine|Given IV
47959758|NCT00025363|BIOLOGICAL|filgrastim|Given SC
47959759|NCT00025363|BIOLOGICAL|sargramostim|Given SC
47959760|NCT00025363|OTHER|pharmacological study|Correlative studies
47959761|NCT00025363|OTHER|pharmacogenomic studies|Correlative studies
47959762|NCT00025363|OTHER|laboratory biomarker analysis|Correlative studies
47959763|NCT01446978|BIOLOGICAL|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
47959764|NCT01446978|BIOLOGICAL|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
47959765|NCT05995483|OTHER|Early Diagnosis on BSE|the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
47959766|NCT01387932|DEVICE|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
47959767|NCT01387932|PROCEDURE|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
47959768|NCT02116946|BIOLOGICAL|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
47959769|NCT02116946|OTHER|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
47959770|NCT00236444|DRUG|risperidone|
47959771|NCT04257981|DEVICE|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
47959772|NCT04257981|OTHER|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
47959773|NCT00037596|DRUG|Gemtuzumab Ozogamicin|
47959774|NCT00037596|DRUG|cytarabine.|
47959775|NCT03694587|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
47959776|NCT03694587|DRUG|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
47959777|NCT06426810|DEVICE|Electrosurgical bipolar system (LigaSure)|Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
47959778|NCT00915278|DRUG|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
47959779|NCT00092612|DRUG|MK0653, ezetimibe|
47959780|NCT00092612|DRUG|Comparator: ezetimibe, placebo|
47959781|NCT02980497|OTHER|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
47959782|NCT02980497|OTHER|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
47959783|NCT00853775|OTHER|No intervention, observational study|
47959784|NCT04574011|DIAGNOSTIC_TEST|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
47959785|NCT06061536|DRUG|Lipovirtide 10mg|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
47959786|NCT06061536|DRUG|Lipovirtide 40mg|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
47959787|NCT06061536|DRUG|Lipovirtide 60mg|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
48641719|NCT04480450|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
48641720|NCT04519619|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
48641721|NCT03865355|OTHER|Non- interventional|Translational, observational study
48641722|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 1|Pharmaceutical form:liquid Route of administration: intramuscular
47959788|NCT06061536|DRUG|DTG|DTG +3TC + TDF（once daily）.
47959789|NCT01259596|BEHAVIORAL|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
48112129|NCT06676800|DRUG|Yiqi Gubiao pill|Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
48112130|NCT06676800|DRUG|Yiqi Gubiao Pill placebo|The placebo's appearance and content color are similar to that of Yiqi Gubiao Pill, with the main ingredients being starch and caramel. Take 10 pills orally each time, three times a day, after meals, for a continuous period of 12 weeks. Receiving basic treatment: standardized quadruple anti-tuberculosis therapy is administered, with Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide used for the first 2 months, followed by Rifampicin and Isoniazid for the next 4 months.
48112131|NCT05049538|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48112132|NCT05049538|PROCEDURE|Liquid Biopsy|Undergo liquid biopsy
48112133|NCT05049538|OTHER|Pap Smear|Undergo Pap smear
48112134|NCT04643470|DRUG|Zanubrutinib|Administered as specified in the treatment arm
48112135|NCT04643470|DRUG|Placebo|Placebo to match zanubrutinib
48112136|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
47959790|NCT01259596|BEHAVIORAL|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
48482367|NCT05506358|DIAGNOSTIC_TEST|HbS solubility test|Standard HbS solubility test currently used in Nepal (e.g. Sicklevue) will be used as one of the low-cost tests
48482368|NCT05506358|DEVICE|HemoTypeSC|A point-of-care lateral flow assay, HemoTypeSC (https://www.hemotype.com/), will be used as one of the low-cost tests
48482369|NCT05506358|DEVICE|Sickle SCAN|A point-of-care lateral flow assay, Sickle SCAN (https://www.biomedomics.com/products/hematology/sicklescan/), will be used as one of the low-cost tests
48482370|NCT05506358|DEVICE|Gazelle Hb Variant Test|A portable electrophoresis machine, Gazelle diagnostic device (https://hemexhealth.com/), will be used as one of the low-cost tests
47959791|NCT00143182|DRUG|Asenapine|Asenapine , 9 weeks
48482371|NCT05841147|DRUG|Tirofiban|Intravenous administration of tirofiban
47959792|NCT00143182|DRUG|Olanzapine|Olanzapine, 9 weeks
47959793|NCT00334958|DRUG|Placebo|For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
48112137|NCT00258895|BIOLOGICAL|DAPTACEL®: DTaP|0.5 mL, Intramuscular
48482372|NCT05841147|DRUG|normal saline|Intravenous administration of normal saline
48641723|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 2|Pharmaceutical form:liquid Route of administration: intramuscular
48112138|NCT04299984|PROCEDURE|Open Conversion after EVAR|"See Open Conversions group description."
48112139|NCT04299984|PROCEDURE|SemiConversion after EVAR|"See SemiConversions group description."
48112140|NCT02886858|DEVICE|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
48112141|NCT02886858|DEVICE|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
48641724|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 3|Pharmaceutical form:liquid Route of administration: intramuscular
48641725|NCT04398706|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
48641726|NCT04398706|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
48641727|NCT04398706|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Pharmaceutical form:liquid Route of administration: intramuscular
48641728|NCT04398706|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|Pharmaceutical form:liquid Route of administration: intramuscular
48641729|NCT04398706|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:liquid Route of administration: oral
48641730|NCT04398706|BIOLOGICAL|Hepatitis B Vaccine* [Recombinant] *as applicable|Pharmaceutical form:liquid Route of administration: intramuscular
48306951|NCT03121183|BEHAVIORAL|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
47959794|NCT00334958|DRUG|Rufinamide|For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
47959795|NCT01597401|DRUG|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
47959796|NCT01597401|DRUG|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
47959797|NCT01597401|DRUG|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
47959798|NCT01597401|DRUG|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
47959799|NCT01597401|DRUG|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
47959800|NCT03041883|PROCEDURE|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
47959801|NCT03041883|PROCEDURE|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
48112142|NCT05520086|DRUG|Single Dose|Single Dose: Administration of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
48112143|NCT05520086|DRUG|Double Dose|Repetead Dose: Administration of 2 doses, separated by 14 days, of 12,5 million allogeneic mesenchymal stem cells derived from adipose tissue by subcnjunctival injection and topical conjunctival injection.
48112144|NCT03672773|DRUG|Talazoparib|Given PO
48112145|NCT03672773|DRUG|Temozolomide|Given PO
48306952|NCT03277950|OTHER|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
48306953|NCT03277950|OTHER|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
48306954|NCT03277950|OTHER|Healthy|Healthy do not play game
48306955|NCT05302739|OTHER|Facial cooling|30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
48641731|NCT06147869|DEVICE|phonophoresis|Phonophoresis is a method of driving topically applied substances across tissues using ultrasound (US) to enhance percutaneous absorption of selected drugs such as corticosteroids, local anaesthetics, and salicylates
48641732|NCT06147869|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
48641733|NCT03535129|BEHAVIORAL|Real time fMRI neurofeedback|During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
48306956|NCT03960138|DEVICE|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
48306957|NCT03960138|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
48306958|NCT03879668|DEVICE|eIPOS|Electronic version of IPOS
48306959|NCT00740779|DRUG|Silodosin 8 mg|Silodosin 8 mg daily
48306960|NCT00740779|DRUG|Placebo|Placebo
48306961|NCT00740779|DRUG|Silodosin 4 mg|Silodosin 4 mg daily
48306962|NCT04729088|DRUG|Isosorbide mononitrate|Intra-anal application performed by the study physician of 2 g of the study drug
48306963|NCT05520996|BEHAVIORAL|Cyberball|Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
48641734|NCT05261139|DRUG|nirmatrelvir|PF-07321332
48641735|NCT05261139|DRUG|ritonavir|ritonavir
47959802|NCT04751565|OTHER|Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy|Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
47959803|NCT04105270|DRUG|Oral Restorative Microbiota Therapy (RMT) Capsules|Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
47959804|NCT04105270|DRUG|Durvalumab 1500 mg IV|Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
48112146|NCT05454163|OTHER|SNOT 22 questionnaire|22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
48112147|NCT00476255|BEHAVIORAL|Enhanced Standard Care (ESC)|Reading material
48112148|NCT00476255|BEHAVIORAL|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
48112149|NCT05093478|DRUG|Intranasal capsaicin|Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
48112150|NCT05093478|DRUG|topical lidocaine|The nose will be pre-treated with topical lidocaine 15 minutes before each application
48641736|NCT06419660|DRUG|BI 300202|BI 300202
48641737|NCT06419660|DRUG|esomeprazole|esomeprazole
47959805|NCT04105270|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
47959806|NCT04105270|OTHER|Placebo|Sixteen doses of oral placebo capsules given weekly
47959807|NCT05378178|DRUG|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2...) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
47959808|NCT02385942|DEVICE|Smart phone|"* measure the Live assessed wound size and the transmitted Smart phone-based wound size~* determine dressing materials using Smart phone-based tele-consultation"
47959809|NCT05637866|OTHER|Soy milk|Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
47959810|NCT02492269|DRUG|Dexmedetomidine|
47959811|NCT02492269|DRUG|Placebo|
47959812|NCT00601211|DRUG|Pilocarpine|
47959813|NCT05938517|DRUG|Betahistine dihydrochloride|Each subject received single dosages of Betahistine (24 mg, 48 mg, 96 mg) for pharmacokinetic serum draw with at least two days between the different dosages.
47959814|NCT05938517|DRUG|Selegiline-hydrochloride|In the second period, each subject was pre-treated with Selegiline (5 mg/day) for one week and treated continuously with Selegiline (5 mg/day) in combination with the single dosages of Betahistine (24 mg, 48 mg, 96 mg) with at least two days between the different dosages.
47959815|NCT00654017|DRUG|placebo|Placebo comparator to be given per protocol.
47959816|NCT00654017|DRUG|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
47959817|NCT02941991|BIOLOGICAL|hESC-RPE|sub-retinal injection
47959818|NCT02707939|OTHER|Observation|Patients will be observed before and after they receive anesthesia
47959819|NCT05133232|DEVICE|SynPhNe physio-neuro platform|"The SynPhNe device training protocol lasting approximately 60 mins:~1. Preparation for setup (\~5 mins)~2. Instruction video led warm up with active single and multi-joint movements - (\~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~3. Rest break - (\~5 mins)~4. Video led task practice as per the tasks below (any 4 tasks only) - (\~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object."
47959820|NCT00977860|RADIATION|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
47959821|NCT01831648|OTHER|Blood sample|
47959822|NCT03037775|OTHER|Baseline|measurement of baseline hemodynamic parameters
47959823|NCT03037775|DEVICE|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
48112151|NCT01948648|DRUG|Colesevelam|Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
48112152|NCT01948648|DIETARY_SUPPLEMENT|Fish Oil|In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
48112153|NCT01948648|DRUG|Combination of fish oil and colesevelam|combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
48306964|NCT01598584|DRUG|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
48306965|NCT01598584|DRUG|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
48306966|NCT06342804|DRUG|4-MUST, 2 tablets, fasted|2 tablets (256 mg), fasted
48306967|NCT06342804|DRUG|4-MUST, 2 tablets, after meals|2 tablets (256 mg), after meals
48306968|NCT02334332|OTHER|Educational Intervention|Receive educational brochure
48112154|NCT00971022|BEHAVIORAL|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
48112155|NCT00971022|BEHAVIORAL|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
48306969|NCT02334332|PROCEDURE|Standard Follow-Up Care|Receive standard post-operative care
48306970|NCT02334332|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
48306971|NCT02008929|BIOLOGICAL|MG4101|Ex vivo expanded allogeneic NK cell
47959824|NCT03037775|DEVICE|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
47959825|NCT03037775|DEVICE|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
48306972|NCT06365814|OTHER|enhanced recovery after surgery|ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery
47959826|NCT03068260|DRUG|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
47959827|NCT03068260|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
47959828|NCT03068260|DRUG|Acetaminophen|1 g orally administered postoperatively
47959829|NCT03068260|DRUG|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
47959830|NCT03068260|DEVICE|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
48306973|NCT06365814|OTHER|conventional perioperative management|conventional perioperative management
48306974|NCT01029288|OTHER|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
47959831|NCT03068260|DRUG|Morphine|intravenously administered morphine via PCA-pump
48306975|NCT01029288|OTHER|Statin Choice Decision Aid|Statin Choice Cards
47959832|NCT03068260|DEVICE|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
48306976|NCT01029288|OTHER|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
47959833|NCT00317512|PROCEDURE|Percutaneous Coronary Revascularization|
48112156|NCT05061641|DRUG|Progesterone|The delivery outcomes of the three groups were compared, including the rate of premature delivery (\<37 weeks of gestation), the rate of early premature delivery (\<32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (\<37 weeks), neonatal perinatal mortality and morbidity.
48112157|NCT01340261|BEHAVIORAL|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
48641738|NCT06245603|DEVICE|Hydeal Cyst®|"BCG or MMC will be started within 1-2 weeks from randomization (within 4-6 weeks after TURB).~BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes.~IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment.~48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation.~BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation."
48641739|NCT03911271|DRUG|0.1% atropine and 0.01% atropine|0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
48641740|NCT03911271|DRUG|0.01% atropine|0.01% atropine for 24 months
48641741|NCT03911271|DRUG|0.9% Sodium-chloride|Placebo for 24 months
48641742|NCT06564142|DRUG|Povetacicept|Subcutaneous injection administration.
48112158|NCT02620410|DEVICE|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
48112159|NCT04756323|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
48112160|NCT04756323|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
48112161|NCT04756323|BIOLOGICAL|Placebo|placebo
48112162|NCT01263730|BEHAVIORAL|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
48112163|NCT03546998|DIAGNOSTIC_TEST|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
48112164|NCT04148040|PROCEDURE|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
48112165|NCT06450041|DRUG|Universal Donor (UD) TGFβi NK Cells|Patients will receive a dose of 1x108 UD TGFβi NK cells/kg per treatment cycle on day 8 of each cycle
48112166|NCT06450041|DRUG|Temozolomide|Enteral or IV daily on days 1-5 of each cycle For patients ≥ 0.5 m2: 100 mg/m2/dose For patients \< 0.5 m2: 3.3 mg/kg/dose MAXIMUM dose = 200 mg
48112167|NCT06450041|DRUG|Irinotecan|50mg/m2/dose IV daily on days 1-5 of each cycle
48112168|NCT06450041|DRUG|Dinutuximab|17.5mg/m2/dose IV daily on days 2-5 of each cycle
48112169|NCT06450041|DRUG|GM-CSF|250mcg/m2/dose subcutaneous (preferred) or IV daily on days 6-12 of each cycle
48112170|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
48112171|NCT04764448|OTHER|Placebo|Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
48112172|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
48112173|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
48306977|NCT01029288|OTHER|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
48306978|NCT00004013|BIOLOGICAL|trastuzumab|
48306979|NCT00004013|DRUG|paclitaxel|
48641743|NCT06564142|DRUG|Placebo (matched to Povetacicept)|Placebo matched to Povetacicept subcutaneous injection administration.
48641744|NCT02662907|PROCEDURE|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
48641745|NCT02662907|BEHAVIORAL|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
48641746|NCT02662907|DEVICE|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
47959834|NCT00317512|DRUG|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
47959835|NCT00317512|DRUG|Voluven|
47959836|NCT06267105|PROCEDURE|Longitudinal incision|Incision performed longitudinally
47959837|NCT06267105|PROCEDURE|Transverse incision|Incision performed transversally
47959838|NCT03837860|DRUG|Oxycodone/Placebo|Oxycodone 20 mg plus placebo
47959839|NCT03837860|DRUG|Oxycodone/Risperidone|Oxycodone (20mg) plus Risperidone (2 mg)
47959840|NCT03837860|DRUG|Oxycodone/Ziprasidone|Oxycodone (20mg) plus Ziprasidone (80 mg)
47959841|NCT01142271|PROCEDURE|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
47959842|NCT01142271|PROCEDURE|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
47959843|NCT05047835|DIAGNOSTIC_TEST|electrocardiogram|Prone position electrocardiogram
47959844|NCT01642979|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
47959845|NCT01642979|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
48482373|NCT04059549|BEHAVIORAL|PartnerCHESS|"Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each."
48482374|NCT04059549|BEHAVIORAL|A-CHESS|A-CHESS control group
47959846|NCT01642979|DRUG|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
47959847|NCT04868214|DEVICE|coagulation measurements|peak and trough coagulation measurements of patients treated with Xarelto, Eliquis, or Lixiana and coagulation measurements of healthy proband blood spiked with eiter Xarelto, Eliquis or Lixiana.
47959848|NCT03885258|DRUG|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
47959849|NCT00557128|DRUG|COREG CR and lisinopril (FDC)|
47959850|NCT00209534|DRUG|fospropofol disodium|
47959851|NCT02015754|DRUG|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
47959852|NCT02015754|DEVICE|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
47959853|NCT02015754|PROCEDURE|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
48641747|NCT02662907|DEVICE|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
48306980|NCT03431675|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
48306981|NCT05433389|BEHAVIORAL|Breath Counting|Patients will listen to a 5-minute, audio-recorded breath counting practice.
48641748|NCT02662907|BEHAVIORAL|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
48482375|NCT02596386|PROCEDURE|sialometry|potassium evaluation
48306982|NCT05433389|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
48306983|NCT05433389|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
48306984|NCT05433389|BEHAVIORAL|Mindfulness of Pain|Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.
48306985|NCT05433389|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
48641749|NCT02662907|DRUG|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
48641750|NCT06117540|DRUG|WX390|WX390 tablet, 1.1 mg once a day
47959854|NCT06271122|OTHER|Voluntary activation assessed by magnetic stimulation|"Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau."
47959855|NCT00518687|BIOLOGICAL|V710|0.5-mL single injection of V710 (60 µg)
47959856|NCT00518687|BIOLOGICAL|Placebo|0.5-mL single injection of matching placebo
47959857|NCT04372082|OTHER|Standard of care (SOC)|SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen...) during the whole study duration
47959858|NCT04372082|DRUG|Hydroxychloroquine|200 mg x 3 per day during 10 days in addition to SOC
48306986|NCT01951014|OTHER|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
48306987|NCT02254668|OTHER|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
48482376|NCT02596386|PROCEDURE|blood test|potassium evaluation
48482377|NCT06365099|DEVICE|Single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere while participants rest quietly with their eyes open
48482378|NCT01795742|DEVICE|Human-Powered Nebulizer|
48482379|NCT03498599|BEHAVIORAL|Novelty facilitated extinction|In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
48641751|NCT05960929|COMBINATION_PRODUCT|Infasurf Aero™|A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
48641752|NCT06250257|DRUG|Bromocriptine mesylate plus standard GDMT|The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
48641753|NCT06555731|GENETIC|Ultra rapid genome sequencing|DNA extraction from blood sample and whole genome sequencing
47959859|NCT04372082|DRUG|Association of diltiazem and niclosamide|niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
47959860|NCT01815801|OTHER|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
47959861|NCT01815801|OTHER|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
47959862|NCT04614597|BIOLOGICAL|Sabin strain inactivated polio vaccine|Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
48112174|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
48112175|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.
48112176|NCT06677372|DIAGNOSTIC_TEST|Body temperature measurement|Comparative analysis of temperature between esophageal temperature and skin temperature
48112177|NCT05499559|BEHAVIORAL|Joint Academy digital treatment|The Joint Academy® (www.jointacademy.com) program for people with hand OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons, possibility for a social chat group with other patients and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period. The program also contains three telephone consultations with a physiotherapist that were compulsory, one at the start, one after six weeks and one after three months.
48112178|NCT03380390|DRUG|Oxymetazoline HCL 1.0% Cream|Oxymetazoline HCl cream 1.0% once daily application
48482380|NCT03498599|BEHAVIORAL|Standard Extinction|During standard fear extinction the expected aversive outcome is omitted.
47959863|NCT01972113|DIETARY_SUPPLEMENT|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
48641754|NCT05101798|DRUG|5-Aminolevulinic acid Hydrochloride|The closure consists of colorless glass vial (Type II, Ph Eur) and bromobutyl-rubber stopper ø 20 mm (Type I, Ph Eur) and flip cap. The powder for oral solution is intended for single (partial) use. To prepare the ready-to-use solution the content of one vial is dissolved in 50 ml of water or apple juice. The concentration of the reconstituted solution is 3%. Gleolan® is administered orally to patients prior to tumor removal by surgery (20 mg/kg BW). The reconstituted solution may be prepared up to 24 hours prior to use if protected from light. It should be given 3 hours (range 3-5 hours) prior to planned induction of anesthesia for surgery, although its effect is present for up to 8-12 hours. This step is critical for an optimal visualization of tumor tissue due to pharmacokinetic properties of Gleolan®.
48641755|NCT00540761|DEVICE|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
48641756|NCT06365853|DRUG|Mirvetuximab Soravtansine|Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
48641757|NCT06365853|DRUG|Lubricating Eye Drops|Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.
48641758|NCT06365853|DRUG|Prednisolone acetate ophthalmic suspension 1% eye drops|Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
48641759|NCT06365853|DRUG|Brimonidine tartrate ophthalmic solution eye drops|Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
48641760|NCT06665789|BEHAVIORAL|Mindfulness-based Stress Reduction|An 8-week Mindfulness-based stress reduction training programme
48641761|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination A|Combined influenza and Pfizer-BioNTech COVID-19 Vaccine
48641762|NCT06178991|BIOLOGICAL|Licensed influenza vaccine|Licensed influenza vaccine
48641763|NCT06178991|BIOLOGICAL|COVID-19 Vaccine|Pfizer-BioNTech COVID-19 vaccine
48641764|NCT06178991|BIOLOGICAL|Influenza and COVID-19 Combination B|Combined influenza and Pfizer-BioNTech COVID-19 vaccine
48641765|NCT06178991|BIOLOGICAL|Placebo|Saline Solution
47959864|NCT01972113|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
48112179|NCT03380390|DEVICE|Energy-Based Therapy|Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])
48306988|NCT02254668|OTHER|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
48306989|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
48482381|NCT03146637|BIOLOGICAL|Activated CIK|Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days
48482382|NCT03146637|BIOLOGICAL|CIK|Traditional CIK were infused for 3 days
48482383|NCT00379223|PROCEDURE|vitrectomy with radial optic neurotomy|
48482384|NCT05563181|BEHAVIORAL|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
48482385|NCT05563181|BEHAVIORAL|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
48482386|NCT05563181|BEHAVIORAL|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
48482387|NCT01057927|DRUG|OC000459|OC000459 capsules 2x100mg BID for 28 days
48482388|NCT01057927|DRUG|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
48482389|NCT03311308|DRUG|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years; After the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
48641766|NCT06178991|BIOLOGICAL|Investigational influenza vaccine|Investigational influenza vaccine
48641767|NCT04009499|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
48641768|NCT01174108|DEVICE|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
48641769|NCT01174108|OTHER|Donor derived G-CSF mobilized PBC|Cell Therapy
48641770|NCT05677451|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
48641771|NCT05677451|DRUG|placebo|matching active drug
48641772|NCT06662422|DEVICE|Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System|The Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System is a single-use electrode placed on and around the ear which provides transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN).
48641773|NCT06590558|PROCEDURE|Biopsy|Undergo tissue biopsy
48641774|NCT06590558|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48641775|NCT06590558|PROCEDURE|Computed Tomography|Undergo CT
48641776|NCT06590558|DRUG|Eribulin Mesylate|Given IV
47959865|NCT01972113|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
47959866|NCT05546502|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
47959867|NCT05546502|BIOLOGICAL|Active Comparator|Covovax
47959868|NCT00457925|DRUG|GSK221149A|
47959869|NCT04737382|DIAGNOSTIC_TEST|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
48112180|NCT05857813|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills (PEERS®)|developed at the University of California, Los Angeles (E. A. Laugeson \& F. Frankel, 2010). This is a parent-assisted, manualized social skills training program that addresses crucial areas of social functioning for adolescents. Psycho-education and cognitive-behavioral therapy techniques are employed to help adolescents develop ecologically valid skills for making and maintaining friendships.
48306990|NCT01323257|DRUG|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
48306991|NCT01323257|DRUG|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
48306992|NCT01323257|DRUG|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
48306993|NCT01323257|DRUG|TMC435|50 mg capsule once daily for 7 days (Trt F)
48306994|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
48306995|NCT04676750|BEHAVIORAL|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
48306996|NCT02998437|DRUG|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
48306997|NCT02998437|DRUG|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
48306998|NCT02998437|DRUG|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
48306999|NCT06350227|COMBINATION_PRODUCT|the absorbable hemostat and suture|The hemostasis method of the experimental group is to use both the absorbable hemostat and suture.
48307000|NCT06350227|COMBINATION_PRODUCT|electrocoagulation and suture|The active comparator group is to use electrocoagulation and suture simultaneously to stop bleeding.
48307001|NCT06350227|OTHER|suture|The placebo comparator is to use suture alone for hemostasis.
48307002|NCT00255684|BIOLOGICAL|graft-versus-tumor induction therapy|
48307003|NCT00255684|DRUG|cyclophosphamide|
48641777|NCT06590558|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48641778|NCT06590558|DRUG|Tolinapant|Given PO
48641779|NCT06590558|PROCEDURE|X-Ray Imaging|Undergo chest X-ray
48641780|NCT06048588|DRUG|YN001|In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.
48641781|NCT06048588|DRUG|Placebo for YN001|The injection solution to mimic the YN001
48641782|NCT06048588|DRUG|rosuvastatin calcium tablets|In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
48641783|NCT06686537|DRUG|Estradiol Patches|Estradiol patched will be worn for 7 days.
48307004|NCT00255684|DRUG|cyclosporine|
48307005|NCT00255684|DRUG|fludarabine phosphate|
48307006|NCT00255684|DRUG|mycophenolate mofetil|
48307007|NCT00255684|PROCEDURE|umbilical cord blood transplantation|
48307008|NCT00255684|RADIATION|radiation therapy|
48307009|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
48307010|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
48307011|NCT02151409|DRUG|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
48307012|NCT02633995|PROCEDURE|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
47959870|NCT04737382|DIAGNOSTIC_TEST|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
47959871|NCT00005044|DRUG|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
47959872|NCT00005044|DRUG|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
48307013|NCT03502252|BEHAVIORAL|Semillas de Apego|Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
48307014|NCT02226042|BEHAVIORAL|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
48307015|NCT02388061|DRUG|Tenecteplase|
48482390|NCT03311308|DRUG|Metformin|500 mg, by mouth, twice a day for nine weeks.
48482391|NCT02587312|OTHER|Very low nicotine content cigarettes|
48112181|NCT05078424|BEHAVIORAL|Cognitive Behavioural Therapy|CBT is a well-established, evidence-based intervention frequently used for easing depressive and anxiety symptoms. The intervention will be delivered for 6-7 sessions, each session lasts for 1.5 hours, in the format of a group for a period of 6-7 weeks by frontline social or youth workers trained by professional CBT clinicians. Core treatment components include mood monitoring, emotion education, behavioural activation, emotion cycle/ ABC model, identification of automatic thoughts, and cognitive restructuring. It is designed to improve youths' abilities/ skills in handling their moods to have better emotional management.
48112182|NCT00866866|DRUG|N-Acetyl Cysteine|600 mg PO BID
48112183|NCT00866866|DRUG|Placebo|1 tab PO BID
48482392|NCT02587312|OTHER|Standard nicotine content cigarettes|
48482393|NCT04877587|DRUG|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)"
48482394|NCT04877587|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
48641784|NCT06446258|OTHER|Manual therapy (myofascial release, soft tissue mobilization)|Soft tissue mobilization will be performed by a team of experienced manual therapists.
48641785|NCT05532657|OTHER|Hearing intervention|The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
48112184|NCT01328418|PROCEDURE|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
48112185|NCT06237751|DRUG|Sildenafil 100 MG|Sildenafil 100mg orally half an hour before surgery
48112186|NCT00413595|OTHER|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
48307016|NCT02388061|DRUG|Tissue Plasminogen Activator|
47959873|NCT00005044|DRUG|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
48307017|NCT03047993|DRUG|Azacitidine|Given IV or SC
48307018|NCT03047993|DRUG|Glutaminase Inhibitor CB-839|Given PO
48307019|NCT03375112|PROCEDURE|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
48307020|NCT03375112|DRUG|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
48307021|NCT03375112|DRUG|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
47959874|NCT00005044|RADIATION|radiation therapy|\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
47959875|NCT00365508|DRUG|nicotine lozenge|nicotine lozenge
47959876|NCT00365508|DRUG|nicotine patch|transdermal nicotine patch
47959877|NCT01262131|DEVICE|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
47959878|NCT01262131|DEVICE|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
47959879|NCT01262131|DEVICE|placebo therapy|Application of inactive magnetic fields using the Resonator device
47959880|NCT03690531|DEVICE|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
48112187|NCT02949206|DRUG|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
48112188|NCT02949206|DRUG|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
48112189|NCT02949206|DRUG|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
48112190|NCT00000251|DRUG|30% N2O|
48112191|NCT00000251|DRUG|0.2% isoflurane|
48641786|NCT05532657|OTHER|Successful aging/delayed hearing intervention|The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
48112192|NCT00000251|DRUG|0.4% isoflurane|
48112193|NCT00000251|OTHER|100% oxygen|Placebo
48112194|NCT00172185|DRUG|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
48112195|NCT00172185|DRUG|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
48112196|NCT04183959|DEVICE|video stylet|trachea will be intubated using laryngoscopic assisted video stylet device in lateral position
48641787|NCT06646042|DRUG|ibuzatrelvir|2x 300 mg tablet
47959881|NCT03690531|DEVICE|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
47959882|NCT03999593|PROCEDURE|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
47959883|NCT03863665|DEVICE|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
48112197|NCT04183959|DEVICE|fiberoptic|intubation will be done using fiberoptic device by the same anesthesiologist in lateral position
48112198|NCT05311319|DRUG|HAIC+TQB2450+Anlotinib|HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
48112199|NCT03961633|BEHAVIORAL|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
48112200|NCT00801983|DEVICE|Alternative Keyboard|Subjects use either a typical or alternative keyboard
48482395|NCT05123729|BEHAVIORAL|Crowdsourced campaign package|COVID-19 prevention intervention developed using a crowdsourcing process.
48641788|NCT06646042|DRUG|carbamazepine ER|100 mg BID (Day 1-3) 200 mg BID (Day 4-7) 300 mg BID (Day 8-15)
48641789|NCT06302621|DRUG|Afatinib|Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
48641790|NCT06302621|DRUG|Pemigatinib|Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
48641791|NCT02112916|DRUG|Bortezomib|Given IV
47959884|NCT01064596|OTHER|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
47959885|NCT03095339|OTHER|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
47959886|NCT03405584|DRUG|Esomeprazole|Proton pump inhibitor
47959887|NCT03405584|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
47959888|NCT03405584|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
48112201|NCT06640387|DIAGNOSTIC_TEST|Daily Influenza, RSV or SARS-CoV-2 PCR testing for 10 days|Each participant will undergo daily PCR testing for Influenza, RSV or SARS-CoV-2 to assess viral dynamics
48112202|NCT02326649|DEVICE|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
48112203|NCT02089698|DEVICE|Mini-flared|Mini-flared Kelman tip
48112204|NCT02089698|DEVICE|Reversed tip|Reversed Kelman tip
48112205|NCT02279017|BEHAVIORAL|mHealth Texting for Weight Loss|
48641792|NCT02112916|DRUG|Cyclophosphamide|Given IV
47959889|NCT03894800|DRUG|Methoxyflurane (M)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
47959890|NCT03894800|DRUG|Fentanyl (F1)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
47959891|NCT03894800|DRUG|Fentanyl (F2)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
48112206|NCT06319586|PROCEDURE|Radial Forearm Flap|"* Elevate the flap from ulnar to radial side toward the FCR~* Elevate flap from radial to ulnar side to the brachioradialis tendon. Ligate and divide the radial artery and venae comitantes distally.~* incise the skin over the cephalic vein proximally to the cubital fossa. Identify the venous branching pattern and perforating vein.~* Elevate the skin and subcutaneous paddles proximally off of the FCR and brachioradialis.~* Define the venous anatomy at the cubital fossa. In most cases, the median basilic vein and continuation of the median vein contribution to the cephalic vein can be harvested proximal to the perforating vein. This anatomy allows two large veins to be harvested that drain both the deep and superficial systems. Occasionally, one large vein will be identified.~* Closure is performed by harvesting a 0.018-inch skin graft to cover the donor defect. The radial skin edge should be advanced to cover the exposed radial nerve."
48112207|NCT04426045|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
48112208|NCT04426045|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected."
48112209|NCT06148935|DRUG|Vericiguat (Verquvo, BAY1021189)|Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
47959892|NCT03894800|DRUG|NaCl (C)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
48112210|NCT02171104|BIOLOGICAL|Stem Cell Transplantation|Infusion given on Day 0
48112211|NCT02171104|DRUG|IMD Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan"
48112212|NCT02171104|DRUG|Osteopetrosis Only Preparative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Thiotepa"
48112213|NCT02171104|DRUG|Osteopetrosis Haploidentical Only Preparative Regimen|"* Rituximab~* Alemtuzumab~* Busulfan~* Fludarabine"
48112214|NCT02171104|DRUG|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
48112215|NCT02171104|DRUG|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
48641793|NCT02112916|DRUG|Cytarabine|Given IT, IV, or SC
48307022|NCT04283994|BEHAVIORAL|Survey-based Patient/Clinician Jumpstart|"The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families."
48307023|NCT04283994|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
47959893|NCT06295302|DRUG|HWH486|HWH486 capsule was administrated orally
47959894|NCT06295302|DRUG|Placebo|Matching placebo was administrated orally
48112216|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
48112217|NCT02171104|DRUG|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
48112218|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with LMA Gastro
48112219|NCT04740164|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with standard nasal cannula
48307024|NCT00422838|PROCEDURE|fine-needle aspiration biopsy|aspiration of intrahepatic cells
48112220|NCT05019417|DRUG|Glycerol Phenylbutyrate 1100 MG/ML|Daily adminisitraion of the study drug (three times a day) in escalting dose over 4 months
48641794|NCT02112916|DRUG|Daunorubicin|Given IV
48112221|NCT00149838|PROCEDURE|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
48112222|NCT00149838|DRUG|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
48112223|NCT00149838|PROCEDURE|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
48112224|NCT06089694|DEVICE|Enabling Sensor Research Holter Mode feature|The Sensor Research Holter Mode feature within the Crome and Cobalt ICD and CRT-D devices will be enabled for a short period of time at the In-clinic Testing Visit to allow for desired data collection.
48112225|NCT06258668|DRUG|Deucravacitinib|As per product label
48112226|NCT03150238|OTHER|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
48641795|NCT02112916|DRUG|Daunorubicin Hydrochloride|Given IV
47959895|NCT02680717|DRUG|Clobetasol|ointment, twice daily (alternating weeks)
47959896|NCT02680717|DRUG|Calcipotriene|ointment, twice daily
47959897|NCT02680717|DRUG|Tacrolimus|ointment, 0.1%, twice daily
47959898|NCT02732756|BEHAVIORAL|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
48112227|NCT02205307|DEVICE|PINPOINT|
48112228|NCT02205307|DEVICE|SPY Elite|
48112229|NCT00993369|OTHER|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
48112230|NCT00636064|DRUG|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
48641796|NCT02112916|DRUG|Dexamethasone|Given PO or IV
48641797|NCT02112916|DRUG|Doxorubicin|Given IV
48641798|NCT02112916|DRUG|Doxorubicin Hydrochloride|Given IV
48641799|NCT02112916|DRUG|Etoposide|Given IV
48641800|NCT02112916|DRUG|Hydrocortisone Sodium Succinate|Given IT
48641801|NCT02112916|DRUG|Ifosfamide|Given IV
48641802|NCT02112916|DRUG|Leucovorin Calcium|Given PO or IV
48641803|NCT02112916|DRUG|Mercaptopurine|Give PO
48641804|NCT02112916|DRUG|Methotrexate|Given IT, IV, or PO
48641805|NCT02112916|DRUG|Pegaspargase|Given IV
48641806|NCT02112916|RADIATION|Radiation Therapy|Undergo radiation therapy
48641807|NCT02112916|DRUG|Thioguanine|Given PO
47959899|NCT02732756|BEHAVIORAL|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
47959900|NCT01397890|DRUG|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
47959901|NCT01397890|DRUG|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
47959902|NCT03954197|OTHER|No hormone|No hormonal injection before oocytes retrieval
47959903|NCT03954197|OTHER|hCG|a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
47959904|NCT03954197|OTHER|GnRH a|a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
47959905|NCT01443182|BEHAVIORAL|STAIR|Skills Training in Affective and Interpersonal Regulation
47959906|NCT01443182|BEHAVIORAL|MPE|Modified prolonged exposure (MPE)
47959907|NCT01443182|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing
47959908|NCT04678856|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
47959909|NCT04678856|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
47959910|NCT05399641|DRUG|Ibrexafungerp|Each day dosing will consist of two 150mg tablets taken BID.
47959911|NCT05412615|PROCEDURE|Meniscus Allograft Transplantation with Proximal Row Carpectomy|Supplementing the wrist reconstruction with a meniscal allograft to improve wrist function and pain scores.
47959912|NCT05412615|PROCEDURE|Proximal Row Carpectomy|Standard proximal row carpectomy with no tissue or synthetic adjuncts
48112231|NCT00636064|DRUG|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
48112232|NCT00636064|OTHER|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
48112233|NCT05136092|DIETARY_SUPPLEMENT|Cohort 1: HFCS (fructose) fed|"Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
48307025|NCT03714113|DIAGNOSTIC_TEST|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
48307026|NCT03705962|DRUG|Tobramycin|
48307027|NCT03705962|OTHER|Placebo: normal saline|
48307028|NCT05304871|DRUG|Cefazolin|infusion
48307029|NCT05304871|OTHER|saline|infusion
48307030|NCT05517525|DRUG|Brensocatib|Oral tablet.
48307031|NCT02772354|PROCEDURE|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
48307032|NCT02772354|DRUG|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg"
48307033|NCT02772354|DRUG|Verapamil|Verapamil 20-240 mg
48307034|NCT02772354|DEVICE|NAVI-STAR® RMT ThermoCool|
48307035|NCT05131451|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
48482396|NCT05123729|BEHAVIORAL|Standard information|Standard informational videos promoting the adoption of health-protective behaviors and COVID-19 testing
48482397|NCT01946984|PROCEDURE|ERCP|endoscopy, retrograde cholangio-pancreaticography.
48482398|NCT01946984|DRUG|Diclofenac hydroxyethylpyrrolidine|
47959913|NCT03108677|OTHER|Blood samples|15 ml peripheral blood
47959914|NCT02467075|DRUG|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
47959915|NCT02467075|DRUG|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
47959916|NCT06484738|OTHER|transcriptomic analysis|to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq
47959917|NCT05550285|DEVICE|orbital floor recontriction|Guided Calvarial Graft Harvesting vs 3D Printed Titanium mesh
48482399|NCT01946984|DRUG|Normal Saline|
48641808|NCT02112916|DRUG|Vincristine|Given IV
48307036|NCT03285217|DIETARY_SUPPLEMENT|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
48307037|NCT03285217|DIETARY_SUPPLEMENT|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
48641809|NCT02112916|DRUG|Vincristine Sulfate|Given IV
48641810|NCT01266083|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
48641811|NCT01266083|BIOLOGICAL|GM-CSF|subcutaneous injection
48641812|NCT01266083|OTHER|Montanide|adjuvant
48641813|NCT06160440|DRUG|SC1011|Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
48641814|NCT04375033|DRUG|Sublingual buprenorphine with naloxone|The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit.
48307038|NCT03227848|DEVICE|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
48641815|NCT04375033|DRUG|Injectable subcutaneous buprenorphine|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit.
48641816|NCT00059267|DRUG|HBIG, Epivir, Hepsera|
48641817|NCT05358639|DRUG|Olaparib tablet|Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
48641818|NCT05358639|DRUG|Navitoclax|For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
48641819|NCT06687681|BIOLOGICAL|NK cell therapy|Active NK cell injection through lumbar puncture in patient with Astrocytoma IDH-mutant, Oligodendroglioma IDHmutant, Glioblastoma IDH-wild type, Diffuse midline glioma, Diffuse hemispheric glioma, Diffuse pediatrictype high-grade glioma IDH-wild type
47959918|NCT03039140|OTHER|Educational Intervention|Attend weekly educational sessions
47959919|NCT03039140|BEHAVIORAL|Exercise Intervention|Participate in CR program
48641820|NCT05825742|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
48641821|NCT05825742|OTHER|Standard oral health instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
48641822|NCT05626114|BIOLOGICAL|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
47959920|NCT03039140|OTHER|Quality-of-Life Assessment|Ancillary studies
47959921|NCT03039140|OTHER|Questionnaire Administration|Ancillary studies
47959922|NCT01762878|DRUG|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
47959923|NCT01762878|DRUG|Placebo|Dry powder for oral inhalation once daily using DIKUS device
48641823|NCT05097950|DRUG|Administration of 1 gr paracetamol I.V|Administration of 1 gr paracetamol I.V
48641824|NCT03964233|DRUG|BI 907828|Film-coated tablets
48641825|NCT03964233|DRUG|ezabenlimab|Solution for infusion
48641826|NCT03964233|DRUG|BI 754111|Solution for infusion
48641827|NCT01902173|PROCEDURE|Biopsy|Undergo a biopsy
48641828|NCT01902173|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48641829|NCT01902173|PROCEDURE|Computed Tomography|Undergo a CT scan
48641830|NCT01902173|DRUG|Dabrafenib Mesylate|Given PO
47959924|NCT05239975|BIOLOGICAL|SCTV01C|intramuscular injection
47959925|NCT05239975|BIOLOGICAL|Comirnaty|intramuscular injection
47959926|NCT04888468|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
47959927|NCT01676571|DRUG|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
48482400|NCT02505152|PROCEDURE|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
48482401|NCT04916496|BEHAVIORAL|Acceptance and Commitment Therapy-based lifestyle counselling programme|"The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change."
48482402|NCT04916496|BEHAVIORAL|Healthy lifestyle talk|"The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change."
48482403|NCT03026907|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
48482404|NCT03026907|DRUG|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
48482405|NCT00921037|PROCEDURE|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
48482406|NCT02283450|DRUG|Qiliqiangxin Capsule|
48482407|NCT04364737|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
48307039|NCT02053389|BEHAVIORAL|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
48307040|NCT02053389|BEHAVIORAL|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
48307041|NCT04289129|DIAGNOSTIC_TEST|Myotonometric evaluation|Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
48307042|NCT02636348|DIETARY_SUPPLEMENT|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
48482408|NCT04364737|OTHER|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
48482409|NCT00140413|DRUG|Nutropin AQ|Daily injection. Dosage dependent on weight.
48482410|NCT03165955|DRUG|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
48482411|NCT05043259|BIOLOGICAL|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
48482412|NCT05043259|BIOLOGICAL|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
48482413|NCT05043259|BIOLOGICAL|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
48482414|NCT06403683|DIAGNOSTIC_TEST|WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test|Case control trial study
48482415|NCT06338735|OTHER|Ultra-High Frequency Ultrasound scan of minor salivary glands|Patients will undergo ultra-high frequency ultrasonography (70 MHz) of minor salivary glands, and the scans will be assessed using the OMERACT scoring system. Score 0 will be assigned in the presence of normal glandular tissue, Score 1 will correspond to mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 will be assigned to moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, while in Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis will be observed.
48482416|NCT04594915|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics \[SmPC\]).
48482417|NCT06489834|OTHER|Group Drumming|Weekly group drumming for 8 weeks
48482418|NCT01754506|DIETARY_SUPPLEMENT|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
48482419|NCT06612203|DRUG|Debio 0123 and Sacituzumab govitecan|Debio 0123 will be administered orally during 6 days of each 21-day cycle in combination with 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first.
48641831|NCT01902173|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48641832|NCT01902173|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
48641833|NCT01902173|DRUG|Uprosertib|Given PO
48641834|NCT06689865|DEVICE|HA-HCP|Prescription hearing aid fit by a hearing healthcare professional using audiology best practices.
47959928|NCT06535425|OTHER|Platelet-Rich Plasma|The PG and JG were injected with autologous PRP at baseline. The injection was performed by the same clinician with 10 years of experience in knee joint injections. Participants were seated with their knees extended, and the needle was inserted through the joint space into the intra-articular cavity of the knee, administering approximately 2.5 mL of PRP into each knee joint. Thirty millilitres of venous blood were drawn from the participant's elbow vein, and approximately 5 mL of PRP was obtained for bilateral knee joint injection by using a TD5A tabletop low-speed centrifuge manufactured in China. The first centrifugation was performed at 2500 revolutions per minute (rpm) for 3 minutes, followed by a second centrifugation at 2300 rpm for 6 minutes.
48307043|NCT02636348|DIETARY_SUPPLEMENT|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
48482420|NCT03544151|DEVICE|Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion
48482421|NCT05442203|DEVICE|Zio Patch Monitor|Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
48482422|NCT05442203|DEVICE|Echocardiogram|Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
48482423|NCT03201354|PROCEDURE|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
48482424|NCT03201354|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
48482425|NCT03201354|PROCEDURE|Cataract extraction|Cataract surgery and IOL implantation
48482426|NCT05991596|BEHAVIORAL|Psychodramatic psychotherapy|"The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows:~* 1 individual motivational interview;~* 1 weekly group session lasting 2 hours for 1 month (total 4 meetings);~* 1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings).~Patients will also receive the pharmacological treatment usually recommended for vitiligo."
48482427|NCT05991596|BEHAVIORAL|Self-help activities|"The self-help activities will include:~* 1 individual motivational interview;~* 1 weekly, 2 hours group meeting, for 1 month (total 4 meetings);~* 1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings).~Patients will also receive pharmacological treatment usually recommended for vitiligo."
47959929|NCT06535425|OTHER|Isometric Contractions of Quadriceps|The IG and JG exercises followed the methods of our previous research, with participants undergoing an 16-week ICQ intervention five times per week. Each session consisted of isometric contractions and relaxations of the quadriceps muscle for 5 seconds each, in sets of 30 repetitions, for a total of 10 sets, with a 30-second rest between sets. During this period, researchers conducted weekly follow-up calls or face-to-face interviews with participants to understand their living conditions, ensuring that they did not change their original lifestyle habits and did not engage in any other form of regular fitness activities. Participants who did not comply were not included in the final data analysis.
47959930|NCT06535425|OTHER|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps|Platelet-Rich Plasma Combined with Isometric Contractions of Quadriceps
48641835|NCT06689865|DEVICE|OTC-HCP|Over-the-counter hearing aids fit by a hearing care professional using audiology best practices.
48641836|NCT06689865|DEVICE|OTC-R|OTC fit to an individual using some best practices via remote consultation.
48641837|NCT06689865|DEVICE|OTC-SF|Self-fit OTC hearing aids without any clinical support from HCPs.
48641838|NCT03390686|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
48641839|NCT03390686|DRUG|HD204|15 mg/kg IV every 3 weeks on Day 1
48641840|NCT03390686|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
48641841|NCT03390686|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
48641842|NCT05648500|DRUG|Cenerimod|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
48641843|NCT05648500|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
48641844|NCT05868148|DEVICE|Shoulder iD™ Primary Reversed Glenoid|Device implant via reversed total shoulder arthroplasty
48307044|NCT00539630|DRUG|Docetaxel|
48307045|NCT02342561|DEVICE|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
48482428|NCT06226948|DEVICE|CGM|Participants will wear CGM monitors for 10 days.
48482429|NCT06226948|DIAGNOSTIC_TEST|Visualization|Enriched visualization of SCORE2 CVD risk.
48482430|NCT06231459|DRUG|Evolocumab|Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
48641845|NCT05431556|OTHER|Virtual mind-body group exercise classes|"Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~* Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~* Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)"
48641846|NCT05431556|OTHER|Enhanced usual care|EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
48641847|NCT01778621|DEVICE|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
47959931|NCT06535425|OTHER|Control|Initially, all participants received identical health education in the form of thematic lectures once per week for 40 minutes each. The content included the following aspects: emphasising the importance of close cooperation with physicians as key to maintaining health; the process of the occurrence and development of KOA, along with its treatment methods; the role of family and social support in improving the condition; establishing a reasonable daily activity routine, such as protecting the affected knee joint, avoiding long-distance fatigue, mountain climbing, ascending and descending high-rise stairs and various adverse body postures (prolonged standing, kneeling and squatting); and advising those who are overweight to reduce their body weight. On this foundation, the four groups of participants underwent the following interventions.
47959932|NCT02416570|DRUG|Clarithromycin|
47959933|NCT02416570|DRUG|Placebo|
47959934|NCT06099366|DRUG|induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate|vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
48641848|NCT05478707|DRUG|Dulaglutide|GLP1-RA
47959935|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
47959936|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
47959937|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
47959938|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
47959939|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
47959940|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
48307046|NCT02042404|DEVICE|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
48641849|NCT05478707|DRUG|Placebo|Saline placebo
48307047|NCT04095286|DRUG|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
48307048|NCT04095286|DRUG|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
47959941|NCT06099366|DRUG|Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
47959942|NCT01596478|BEHAVIORAL|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
47959943|NCT01596478|BEHAVIORAL|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
47959944|NCT01596478|BEHAVIORAL|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
48307049|NCT01831934|BIOLOGICAL|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
48641850|NCT05478707|BEHAVIORAL|exercise training|supervised high intensity interval training
48641851|NCT04191616|DRUG|Carfilzomib|Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m\^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m\^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.
48641852|NCT04191616|DRUG|Dexamethasone|Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.
48641853|NCT04191616|DRUG|Pomalidomide|Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.
47959945|NCT05570292|DRUG|Domperidone|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet
48641854|NCT02181413|DRUG|Ixazomib Citrate|Ixazomib citrate capsules
48641855|NCT02181413|DRUG|Placebo|Ixazomib citrate placebo-matching capsules
48641856|NCT04902066|OTHER|Cognitive Behavioural Virtual Reality Therapy.|Cognitive Behavioural Therapy augmented with Virtual Reality.
48641857|NCT04902066|OTHER|Traditional Cognitive Behavioural Therapy|Traditional Cognitive Behavioural Therapy for psychosis.
48641858|NCT03615326|BIOLOGICAL|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
48641859|NCT03615326|BIOLOGICAL|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
47959946|NCT05570292|DRUG|Folic acid|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
48641860|NCT03615326|DRUG|Cisplatin|80 mg/m\^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
47959947|NCT05919888|DRUG|Povidone-Iodine|Applied to skin incision.
47959948|NCT05919888|DEVICE|SURGX Wound Gel|Applied to skin incision.
48307050|NCT03702582|DRUG|Rivaroxaban|Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
48482431|NCT04317313|OTHER|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
48482432|NCT01594047|DRUG|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
47959949|NCT05993377|OTHER|Logistic regression Cross validation Area under the RIC curves Machine learning analysis. .|we will use robust machine learning approaches, such as Random Forest and XGBoost.
48482433|NCT01594047|DRUG|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
48482434|NCT04965857|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
48482435|NCT04747314|DRUG|Antidepressant|"The antidepressant treatment utilizes antidepressant medication to improve pain, function, and depression outcomes.~The Antidepressant Treatment History Form (ATHF) will be used to assess adequacy of any prior antidepressant medication treatment and to assist the decision regarding which antidepressant to start. A medication flowchart will help serve as a guideline throughout the drug selection and dosing determination. Weekly assessments completed by subjects will help determine response, tolerability, and necessity for dose adjustment or medication change."
48482436|NCT04747314|OTHER|Enhanced Fear Avoidance Rehabilitation|The EFAR treatment utilizes physical therapy, pain education, and motivational messaging to improve pain, function, and depression outcomes. Subjects will engage in gradual exposure to exercises and activities they are apprehensive about, such as standing to wash dishes.
48482437|NCT01084382|DIETARY_SUPPLEMENT|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks."
48482438|NCT02874014|RADIATION|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
48482439|NCT05681312|DRUG|systemic proteolytic enzyme (Tibrolin)|Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)
48482440|NCT05681312|DRUG|Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg|Amoxicillin is given with metronidazole 500mg 1\*3' Doliprane 1000mg is given 1\*1
48482441|NCT01956448|DEVICE|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
48641861|NCT03615326|DRUG|5-FU|800 mg/m\^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
48641862|NCT03615326|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
48641863|NCT03615326|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
48482442|NCT04413734|DRUG|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
48482443|NCT04413734|DRUG|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
48482444|NCT00591435|OTHER|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
48641864|NCT03615326|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
48641865|NCT03615326|BIOLOGICAL|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
48641866|NCT06286098|DRUG|Alpha lipoic acid|THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA
47959950|NCT02408627|DEVICE|EEG|
47959951|NCT03989895|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
47959952|NCT01334164|BEHAVIORAL|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
47959953|NCT01334164|OTHER|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
47959954|NCT00017446|DRUG|CP4071|
47959955|NCT04311502|DRUG|Clofazimine (CFZ)|Administered orally once daily
47959956|NCT04311502|DRUG|Rifapentine (RPT)|Administered orally once daily
47959957|NCT04311502|DRUG|Isoniazid (INH)|Administered orally once daily
48307051|NCT03702582|DRUG|Warfarin|Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
48307052|NCT00019513|DRUG|fluorouracil|
47959958|NCT04311502|DRUG|Pyrazinamide (PZA)|Administered based on weight orally once daily
48307053|NCT00019513|DRUG|gemcitabine hydrochloride|
48307054|NCT00019513|DRUG|leucovorin calcium|
48307055|NCT01054677|BEHAVIORAL|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
48307056|NCT02288767|DEVICE|Conventional arterial blood pressure monitoring|
48307057|NCT02288767|DEVICE|Stroke volume variation monitoring with arterial blood pressure monitoring|
48307058|NCT04645017|BEHAVIORAL|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
48307059|NCT04247022|OTHER|Health care product (intimate gel)|heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
48307060|NCT05070273|DIAGNOSTIC_TEST|Hypoglossal nerve conduction study|"NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~1. angle of the lower jaw (proximal point),~2. the area of the carotid triangle (distal point),~3. directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms."
48307061|NCT05070273|DIAGNOSTIC_TEST|Transcranial magnetic stimulation of hypoglossal nerve|"TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold."
48307062|NCT04332029|BEHAVIORAL|CBT + WGP + CM|The intervention will be implemented in 8-week group-based sessions and includes: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating, and 3) a Contingency Management procedure reinforcing smoking abstinence. This component will consist on providing vouchers to reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
48307063|NCT04332029|BEHAVIORAL|CBT + WGP|The intervention will be implemented in 8-week group-based sessions and will include only the first two components of the experimental intervention: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating.
48307064|NCT02634879|BEHAVIORAL|Incentive Change|
48307065|NCT02191917|PROCEDURE|Respiratory muscle strength measurements by different techniques.|
48482445|NCT03203772|OTHER|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
48482446|NCT02582372|DRUG|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
48482447|NCT02582372|DRUG|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
48482448|NCT06085573|DRUG|Dexmedetomidine Hydrochloride|"\<Sedation of non-invasive procedures and tests without intubation in pediatrics\> For children aged 2 years or older, the usual dosage of dexmedetomidine is 12 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~For children aged 1 month to \< 2 years old, the usual dosage of dexmedetomidine is 9 μg/kg/hr given as a continuous intravenous infusion over 10 minutes (initial loading dose) followed by a maintenance dose of 1.5 μg/kg/hr (maintenance dose).~The infusion rate should be reduced according to patient's condition."
48641867|NCT06286098|OTHER|Placebo|Placebo identical Tablets are manufactured by EVA PHARMA containing the same excipients without Alpha Lipoic Acid.
48307066|NCT01315119|PROCEDURE|SPY Intra-Operative Angiography|Calculated per patient
48307067|NCT03013322|DRUG|Physostigmine|
48641868|NCT04523207|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
48641869|NCT04523207|DRUG|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
47959959|NCT04311502|DRUG|Ethambutol (EMB)|Administered based on weight orally once daily
47959960|NCT04311502|DRUG|Rifampicin (RIF)|Administered orally once daily
48307068|NCT03013322|DRUG|Isotonic Saline|
48307069|NCT00543829|DRUG|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
48482449|NCT03939988|RADIATION|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
48641870|NCT04523207|DRUG|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
48641871|NCT04880356|OTHER|collection of data|collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
47959961|NCT04311502|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
47959962|NCT06556979|RADIATION|Radiotherapy|Review imaging and medical record of head and neck cancer patient who recieve radiotherpy to find out the incidence of ischemic cerebrovascular event and carotid artery stenosis. The risk factor that influence new carotid artery stenosis was claculated
47959963|NCT02519257|PROCEDURE|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
47959964|NCT02519257|PROCEDURE|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
47959965|NCT04258163|DRUG|Capecitabine|1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
47959966|NCT04258163|DRUG|Liposomal doxorubicin|50 mg/m 2 IV day 1, cycled every 28 days
47959967|NCT04258163|DRUG|Gemcitabine|800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
47959968|NCT04258163|DRUG|Fulvestrant|500mg IH Days 0, 14, 28, then every 28 days
47959969|NCT04258163|DRUG|Anastrozole|1mg PO qd
47959970|NCT04258163|DRUG|Letrozole|2.5mg PO qd
47959971|NCT06469593|DEVICE|Automated insuling delivery system|Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS
47959972|NCT01577680|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
47959973|NCT01577680|DRUG|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
47959974|NCT02021773|DRUG|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
47959975|NCT02021773|DRUG|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
47959976|NCT02021773|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
47959977|NCT06315348|PROCEDURE|flapless alveolar decortication with augmentation|piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane. Piezocisions will be performed using a piezoelectric device.
47959978|NCT04601415|DIAGNOSTIC_TEST|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
47959979|NCT05397431|DRUG|Lanadelumab|Lanadelumab 300 mg, subcutaneous injection every 2 weeks
48307070|NCT00543829|DRUG|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
48307071|NCT06227234|OTHER|Dechoker|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
48482450|NCT03939988|RADIATION|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
48482451|NCT04077047|BEHAVIORAL|iEngage|The intervention is a network-based, social support intervention to improve Adolescents living with HIV (ALWH) retention in HIV care and antiretroviral therapy (ART) adherence
48482452|NCT00000239|DRUG|Buprenorphine|
48482453|NCT02332213|PROCEDURE|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
47959980|NCT01041326|RADIATION|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
47959981|NCT01041326|PROCEDURE|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
47959982|NCT00303173|BEHAVIORAL|Guided Imagery|
47959983|NCT06069882|BEHAVIORAL|Cognitive Rehabilitation|"Cognitive Rehabilitation is a person-centred, goal-oriented, problem-solving therapy aimed at managing or reducing functional disability, mitigating excess disability, and maximising engagement and social participation (Clare et al., 2019, p. 710). For this multiple-baseline SCED, there will be a baseline phase where participants will be assessed on goal attainment without an intervention. This phase will be either 3, 4, 5 weeks long and be determined for the participants using an electronic randomiser programme. Thereafter, facilitators will help participants devise personal rehabilitation plans to achieve one of these goals using evidence-based rehabilitative methods. These methods may include the use of environmental adaptations and prompts, introduction of compensatory strategies, procedural learning of skills, and methods for learning or relearning relevant information. The personal rehabilitation plan is put into practice for 6 weeks during the intervention phase of the study."
47959984|NCT03847246|DRUG|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
47959985|NCT03847246|DRUG|Entecavir tablets,1.0 mg|oral,once,under fasting condition
47959986|NCT04822324|OTHER|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion. shoulder flexion with elbow extension. circumduction with compression circumduction with distraction shoulder abduction and internal rotation with elbow flexion. shoulder adduction and external rotation with elbow flexion stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
48641872|NCT03882034|DRUG|Pegvisomant|A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.
47959987|NCT04822324|OTHER|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
48112234|NCT05136092|DIETARY_SUPPLEMENT|Cohort 2: D-Xylose (xylose-fed)|"Two to three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml"
48112235|NCT02298751|BEHAVIORAL|Cue Exposure Treatment|
48112236|NCT02670525|GENETIC|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
48112237|NCT06448364|BIOLOGICAL|PF-07329640|an anti-lymphotoxin beta receptor agonist
48112238|NCT06448364|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
48112239|NCT06448364|BIOLOGICAL|bevacizumab|a monoclonal antibody that blocks VEGF
48641873|NCT06681428|OTHER|Allograft|Placental-based Allografts
48112240|NCT03694288|PROCEDURE|Implant removal|Surgical Implant removal
48112241|NCT02425449|DRUG|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
48112242|NCT05175248|BEHAVIORAL|Plant-based Intervention Group|Participants in the intervention group will be instructed in ways to adopt a plant-based diet, use appropriate methods of food preparation, and make meals enjoyable and appetizing. The plant-based diet primarily emphasizes whole grains, vegetables, beans and legumes, and fruits. Animal products and added oils will be proscribed and the use of ultra-processed foods, sugar, and sugar-sweetened beverages will be discouraged. Fat intake will be limited to 20-30 g/day.
48112243|NCT01063036|DRUG|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
48112244|NCT01063036|DRUG|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
48112245|NCT04299230|DEVICE|Cortium C3|
48112246|NCT02894151|DRUG|Depot medroxyprogesterone acetate|
48112247|NCT02894151|DEVICE|LNG-IUS|
48112248|NCT01245452|DRUG|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
48112249|NCT01245452|DRUG|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
48112250|NCT03691428|BEHAVIORAL|Wish Outcome Obstacle Plan|"1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan."
48641874|NCT06656702|DRUG|Psilocybin|Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
47959988|NCT04171440|PROCEDURE|robotic pancreaticoduodenectomy|The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
47959989|NCT00134459|DRUG|Bifeprunox|
47959990|NCT00134459|DRUG|Placebo|
48112251|NCT00920725|DRUG|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"
48112252|NCT03781336|BEHAVIORAL|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
48112253|NCT05204615|OTHER|Collection of clinical, psychometric and biometric data|Wearable devices and a mobile app will be used to collect real-time data for 4 weeks to detect physiological and psychological complications based on biometric and psychometric (patient-reported outcomes) information.
48112254|NCT04584489|OTHER|iron stores assessment.|assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.
48112255|NCT02118077|BIOLOGICAL|G17DT|
48482454|NCT02332213|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
48641875|NCT05908656|PROCEDURE|Investigational procedure|Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
48307072|NCT06227234|OTHER|LifeVac|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
48307073|NCT06227234|OTHER|Abdominal Thrusts|"Participants will be shown a short educational video for each intervention. A research assistant acting as an instructor will be present to answer any questions that the students have about each of the techniques.~After training of all three techniques is complete, participants will be asked to respond to a choking scenario, using an assigned technique (the first one in their randomized order). Participants will use a mannequin (Choking Charlie, Laerdal Medical AS, Stavanger, Norway), with a simulated food bolus placed per manufacturer's directions, to complete each scenario. Participants will have up to four minutes to complete the intervention.~Each participant will repeat the two more times so that they attempt each intervention."
48112256|NCT03916835|DEVICE|Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.|"Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized."
48307074|NCT06404125|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities. Flexion, extension, abduction, adduction, internal and external rotation angles of the shoulder complex will be evaluated in the measurement.
48307075|NCT06404125|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 10 seconds. The test will be repeated for both upper extremities separately.
48307076|NCT06404125|DIAGNOSTIC_TEST|Numeric Rating Scale|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
48307077|NCT06404125|DIAGNOSTIC_TEST|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral shoulder region and left forearm as control region and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~1. Bilateral supraspinatus muscle: 1 cm cranial to the midpoint of the spina scapulae~2. Bilateral infraspinatus muscle: Medial edge of the scapula, intersection of the spina scapula and the inferior scapular angle~3. Bilateral upper trapezius muscle: MidN point of the line joining the acromion and C7 spinous process~4. Left forearm volar face center as control point"
48307078|NCT06404125|DIAGNOSTIC_TEST|Quick DASH|The arm, shoulder and hand problems rapid questionnaire is a shortened version of a questionnaire designed to detect symptoms and loss of function secondary to musculoskeletal problems of the upper extremity. The questionnaire will be used to assess quality of life related to upper extremity function.
48307079|NCT06404125|DIAGNOSTIC_TEST|SF-36|The scale was developed by Ware in 1987 and consists of 36 questions in which 8 sub-parameters related to the health status of the person are questioned. These parameters are physical function, pain, limitation due to physical and emotional problems, emotional well-being, social function, fatigue and general health perception. The Turkish validity and reliability of the scale was performed by Pınar et al. It is one of the leading methods used in the evaluation of quality of life in our country as well as all over the world.
48482455|NCT02332213|PROCEDURE|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
48482456|NCT02332213|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
48482457|NCT02332213|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
48482458|NCT02332213|PROCEDURE|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
48641876|NCT06267508|PROCEDURE|Maternal HIV viral load testing at delivery for VHT risk assessment|Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.
48641877|NCT03745313|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
48641878|NCT04825262|DRUG|Tacrolimus|Starting dose based on CYP3A5 genotype
48641879|NCT04744831|DRUG|DS-8201a 5.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
48112257|NCT02448446|DRUG|ranibizumab 0.3mg|intravitreally administered
48112258|NCT00176371|BEHAVIORAL|physical exercise|
48112259|NCT04402957|DRUG|LSALT peptide|LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
47959991|NCT00137579|PROCEDURE|Influenza vaccine intramuscular administration route|
48641880|NCT04744831|DRUG|DS-8201a 6.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
48641881|NCT05572632|BEHAVIORAL|COPD Wellness|COPD Wellness consists of 10 weekly sessions led by the COPD Wellness Coach. The intervention was designed to be portable, rely on little equipment, and require limited space (\~300sqft). The curriculum was iteratively developed with patient input and builds behavioral capability and self-efficacy through 30 minutes blocks of disease education and self-management skill building, exercise training, and social support.
48641882|NCT05572632|BEHAVIORAL|COPD Wellness Plus+|Couples COPD Wellness with the ZSFG Health Advocates Program. The HA will help the participant prioritize identified needs and, using an algorithm informed approach to connect the individual to the needed resource, this includes providing referrals to outside social or legal service agencies, help with applications for social benefits, or other services. The HA will use a checklist to track activities including review and prioritization of needs, referrals or resources provided, and contacts/contact attempts.
48641883|NCT05572632|BEHAVIORAL|Usual Care|Includes access to comprehensive primary care services that is standardized across the SFHN. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
48641884|NCT06586164|BEHAVIORAL|Targeted Cognitive Training|TCT is a computer-based cognitive training program in which participants train on progressively more difficult auditory processing exercises in order to improve speed, accuracy and fidelity of auditory information processing in order to generate gains in cognition and functioning.
48641885|NCT05016245|COMBINATION_PRODUCT|TheraSphere™ Yttrium-90 Glass Microspheres|"TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit"
48641886|NCT05016245|PROCEDURE|conventional Transarterial Chemoembolization(cTACE)|conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
48641887|NCT06541301|DEVICE|PICC-port|Implantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols
48641888|NCT06541301|DEVICE|Chest-port|Implantation of a Chest-port device by expert physicians or certified expert nurses, following predefined evidence-based international guidelines and protocols
48641889|NCT05657639|DRUG|CAV Regimen|Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
48641890|NCT05657639|DRUG|MEC Regimen|Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
48641891|NCT02844075|DRUG|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
48641892|NCT06670755|BIOLOGICAL|ID93/GLA-SE|"ID93/GLA-SE is a protein-adjuvant vaccine which has been purposefully designed to elicit a diverse immune response against M.tb bacterial antigens, improve treatment outcomes and prevent TB disease in people already infected with M.tb.~ID93/GLA-SE will be administered intramuscularly."
48641893|NCT06670755|BIOLOGICAL|BCG Danish|"BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.~For the challenge, aerosol BCG will be administered via nebulizer."
48641894|NCT05453357|DEVICE|iGlucose|The patient will use the monitor as instructed by their healthcare team to monitor their blood glucose.
48641895|NCT05855135|DEVICE|OPTIMIZER® Integra CCM-D System (Treatment Arm)|"The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a Cardiac Contractility Modulation - Defibrillator. All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years."
48641896|NCT05652140|OTHER|Data collections|Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.
48641897|NCT06651554|BEHAVIORAL|Digital Platform Intervention|Key features of the digital platform include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements. Youth will be able to access the digital platform as often as they like during their assigned 3-month intervention period.
48641898|NCT01385995|DEVICE|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
48641899|NCT01385995|DEVICE|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
48641900|NCT05584631|DRUG|Intravenous immune globulin G|Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
48641901|NCT05584631|DRUG|Subcutaneous immune globulin G|Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
48641902|NCT04380753|DRUG|AMG 510|Subjects will be enrolled and will receive AMG 510 PO QD.
48641903|NCT04677595|DRUG|Capmatinib|400 mg of capmatinib tablets, administered orally twice daily
48641904|NCT06001320|DRUG|Letermovir 480 mg once daily|We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 30 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 30 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 60 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.
48641905|NCT06001320|OTHER|Historical/Control|The control study group will include high-risk African American kidney transplant recipients cared for with Valganciclovir in the 5 years prior to the enrollment start for the study group. This time frame is based upon the current volume of transplants done at VCU. On average 30 liver and/or kidney transplants are done per month. Thus, 5 years should be an adequate time frame to mine enough number of participants to answer our primary research hypothesis.
48641906|NCT06675019|OTHER|Manual therapy|Manual therapy group: will have manual therapy and relaxation training three times per week in addition to their medications as needed. Manual therapy will include stretching exercises, strengthening exercises, soft tissue manipulation in the form of myofascial release and deep friction massage, and postural correction.
48641907|NCT06675019|OTHER|Kinesio taping|Kinesio taping group: will have kinesio taping (KT), and relaxation exercises three times per week in addition to their medication as needed, One I-shaped tape was used to apply KT to the upper trapezius muscle that was 50 mm broad and 0.5 mm thick. The tape was measured from the acromion to the hairline in the back, and the upper trapezius fibers were stretched in the extended position, i.e., the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation positions. The band was secured to the acromion's insertion site in its first resting position. The muscle was lengthened, and the band was fixed with the initial skin shift, after which the band was fixed to the origin of the hairline from the muscle with a 10% stretch. The tape was massaged with the muscle in the extended position.
48641908|NCT06675019|OTHER|Control (Standard treatment)|The control group will just receive relaxation exercises three times per week, in addition to their medications as needed.
48641909|NCT04952753|DRUG|NIS793|Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
48641910|NCT04952753|DRUG|Bevacizumab|Bevacizumab will be administered IV
48641911|NCT04952753|DRUG|Modified FOLFOX6|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
48641912|NCT04952753|DRUG|FOLFIRI|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
48641913|NCT04952753|DRUG|Tislelizumab|Investigational drug tislelizumab will be administered intravenously (IV).
48641914|NCT05756829|OTHER|High frequency, low touch virtual health care|Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
48641915|NCT05618847|DEVICE|Acapella,ACBTS|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
48641916|NCT05618847|OTHER|ACBTs|Every subject will perform supervised ACBTs with and without acapella for four weeks. Three sessions per week will be given with 20 repetitions in two sets
47959992|NCT03988088|DRUG|Lasmiditan|Administered orally.
47959993|NCT06533917|DEVICE|Main Group|Thoracolumbar spine AP, Thoracolumbar spine LAT
47959994|NCT01500577|DRUG|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
47959995|NCT01500577|DRUG|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
47959996|NCT01500577|OTHER|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
47959997|NCT01344785|PROCEDURE|Intramedullary nailing|All patients will be treated with Intramedullary nailing
47959998|NCT04999488|DRUG|BPM31510|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
47959999|NCT04999488|OTHER|Placebo|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
48112260|NCT04402957|DRUG|Placebo|0.9% saline solution
48112261|NCT01235884|DIETARY_SUPPLEMENT|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
48112262|NCT01235884|DIETARY_SUPPLEMENT|Placebo|5 drops daily for 28 days
48112263|NCT02485444|DRUG|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
48112264|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
48112265|NCT01039688|DRUG|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
48112266|NCT01039688|DRUG|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
48307080|NCT06404125|DIAGNOSTIC_TEST|Central Sensitization Scale|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization are questioned. In part B, the presence of diseases with a well-defined relationship with central sensitization is questioned without participating in the scoring. Patients who score 40 points or more out of a total of 100 points are considered to have central sensitization. Düzce et al. stated that the Central Sensitization Scale can be used as a valid method in the Turkish population to screen the presence of central sensitization in patients presenting with chronic pain.
48307081|NCT06404125|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|This scale was developed by Zigmond and Snaith in 1983 to screen anxiety and depression in individuals with physical illness. The scale consists of fourteen questions, seven for anxiety and seven for depression, to be answered on a four-point Likert scale. The Turkish validity and reliability of the scale has been demonstrated and a score above ten for anxiety and seven for depression is considered significant.
48307082|NCT03736746|BEHAVIORAL|Motivational Interviewing|An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
48307083|NCT06234735|BEHAVIORAL|Physical activity in the community|Supervised and guided PA sessions in the community setting using public resources such as parks, sports facilities, etc.
48641917|NCT05157789|OTHER|SMS|In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
48641918|NCT03468465|DRUG|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
48641919|NCT03468465|DEVICE|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
48482459|NCT03588052|PROCEDURE|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
48112267|NCT05242653|PROCEDURE|pressure by a cotton swab|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with pressure by a cotton swab.
48482460|NCT03588052|PROCEDURE|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
48482461|NCT03384706|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week."
48482462|NCT03384706|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week."
48482463|NCT00393536|BEHAVIORAL|Educational outreach visiting|
48482464|NCT02632734|DEVICE|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
48482465|NCT02632734|DEVICE|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
48482466|NCT05206422|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
48482467|NCT00913198|DRUG|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48482468|NCT05386524|DRUG|sintilimab|sintilimab 200mg, ivgtt，d1
48482469|NCT05386524|DRUG|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
48482470|NCT05386524|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
48482471|NCT02790541|DEVICE|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
47960000|NCT04536701|BEHAVIORAL|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
47960001|NCT00913172|OTHER|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
47960002|NCT05004103|OTHER|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
48112268|NCT05242653|PROCEDURE|stromal hydration with the balanced salt solution（BSS）|All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag. Finally, the clear corneal incision is closed with stromal hydration.
48307084|NCT06234735|BEHAVIORAL|Conventional intervention|Conventional protocol for lung cancer and PA recommendations.
48112269|NCT01567683|DRUG|Imiquimod (topical use)|
48112270|NCT03830658|BEHAVIORAL|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
48112271|NCT05752136|BIOLOGICAL|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
48112272|NCT06504368|DRUG|DCR-PDL1|Solution for IV Infusion
48307085|NCT02353351|DEVICE|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
48307086|NCT01193348|DRUG|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
48112273|NCT06676384|DRUG|Oral prednisolone and SoC|Oral prednisolone 0.5 mg/kg per day (maximum, 40 mg/day) for two months, followed by dose tapering by 5mg per day each month for six to nine months. All participants in this arm will receive SoC and oral cotrimoxazole prophylaxis.
48112274|NCT06676384|DRUG|Gut-directed budesonide and SoC|Gut-directed Budesonide 12 mg once daily for nine months and tapered to 9mg once daily for the next three months, 6mg once daily for the next three months and 3mg once daily for the next three months and stopped (total 18 months). All participants in this arm will receive SoC.
48112275|NCT06676384|DRUG|Mycophenolate mofetil (MMF) and SoC|Mycophenolate mofetil (MMF) 1.5g/ day for twelve months, followed by 1g/ day for six months (total 18 months). All participants in this arm will receive SoC.
48112276|NCT06676384|DRUG|Hydroxychloroquine and SoC|Hydroxychloroquine (HCQ) 6.5 mg/kg/day (maximum 400 mg daily) for 24 months. All participants in this arm will receive SoC.
48112277|NCT06676384|DRUG|Non-steroidal mineralocorticoid receptor antagonist and SoC|Generic drug not available currently. All participants in this arm will receive SoC.
48112278|NCT06676384|DRUG|SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)|Maximal labelled or tolerated dose of ACEi/ ARB and a steady dose of SGLT2i (10mg/d of dapagliflozin).
48112279|NCT02227771|DEVICE|Percutaneous coronary intervention|
48112280|NCT02562352|OTHER|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
48112281|NCT00898846|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
48307087|NCT05158595|OTHER|Exergaming low intensity group|wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
48307088|NCT05158595|OTHER|Exergaming moderate intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
48307089|NCT05158595|OTHER|Exergaming high intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
48307090|NCT05158595|OTHER|control group exergaming|Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
48307091|NCT02624401|DRUG|Dexmedetomidine|Intravenous infusion
48307092|NCT02624401|DRUG|Propofol|Intravenous infusion
48307093|NCT02624401|DRUG|S-ketamine|Intravenous infusion
48307094|NCT02624401|DRUG|Sevoflurane|Inhalation
48307095|NCT02624401|DRUG|Placebo|Intravenous infusion of saline (Ringer's Acetate)
48482472|NCT05356936|DIETARY_SUPPLEMENT|Vitamin K2 (MK-7)|Participants will receive Vitamin K2 (MK-7) daily by mouth.
48641920|NCT02899754|BEHAVIORAL|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
47960003|NCT04636229|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
47960004|NCT04636229|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
47960005|NCT04824352|DRUG|apatinib|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
47960006|NCT05247775|PROCEDURE|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
48307096|NCT02029404|PROCEDURE|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
48482473|NCT05356936|DIETARY_SUPPLEMENT|Vitamin D3|Participants will receive Vitamin D3 daily by mouth.
48482474|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
48482475|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
48482476|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
48482477|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
48482478|NCT06194006|OTHER|Follow-up|Follow-up grafted patients as long as their condition allows
48482479|NCT01722682|BIOLOGICAL|Human pancreatic islet transplantation|
48482480|NCT04415008|DRUG|HAD induction with intermediate dose cytarabine|daunorubicin,cytarabine,homoharringtonine
48482481|NCT03864042|DRUG|losartan|taken orally
48482482|NCT03864042|DRUG|dextromethorphan|taken orally
48482483|NCT03864042|DRUG|caffeine|taken orally
48482484|NCT03864042|DRUG|omeprazole|taken orally
48641921|NCT02899754|BEHAVIORAL|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
47960007|NCT04873115|OTHER|Placebo|Sialanar placebo
47960008|NCT04873115|DRUG|Sialanar|Sialanar - a licensed glycopyrronium bromide product
47960009|NCT04873115|OTHER|Oral Rehabilitation|Standard oral rehabilitation for provided drooling
47960010|NCT06210971|DRUG|liposomal irinotecan|Liposomal irinotecan: 50mg/m\^2 or 70mg/m\^2
47960011|NCT06210971|DRUG|Capecitabine|Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.
47960012|NCT06210971|RADIATION|Radiation threapy|50.4Gy/28 fractions
47960013|NCT06166589|DRUG|Zimberelimab|Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.
47960014|NCT06166589|DRUG|Oxaliplatin|Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.
47960015|NCT06166589|DRUG|S-1|S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.
47960016|NCT06166589|DRUG|Irinotecan|Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.
47960017|NCT06323057|DEVICE|Single pulse TMS to the frontal cortex|Single pulse TMS will be delivered to the left frontal cortex, and stimulation intensity will be at 110% of resting motor threshold.
47960018|NCT05777746|BEHAVIORAL|12-week plant-based dietary program|a 12-week plant-based dietary program consisting of information via an online platform, online guidance by dieticians and in online peer support groups. Patients will aim to maximize their intake of plant-based products while reducing their of animal products as much as possible.
47960019|NCT05777746|BEHAVIORAL|Usual Diet|Patients in the control group continue with their usual diet and/or usual dietary care. Patients in the control group will be offered access to the online platform at 24 weeks.
48482485|NCT03864042|DRUG|midazolam|taken orally
48482486|NCT03864042|DRUG|rosuvastatin|taken orally
48482487|NCT03864042|DRUG|bupropion immediate release (IR)|taken orally
48482488|NCT03864042|DRUG|encorafenib|taken orally
48482489|NCT03864042|DRUG|binimetinib|taken orally
48482490|NCT03864042|DRUG|modafinil|taken orally
48482491|NCT06122233|BEHAVIORAL|Pulmonary Fibrosis self-management package and smartphone application|"The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis.~The RE-BUILD app is used as a tool for data collection and to help participants self-monitor their disease over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data close to the participant as well as physical activity level (step count). The app also has links to ILD-related educational resources."
47960020|NCT00965315|DRUG|Rosuvastatin,SFC fenofibrate|"1. Rosuvastatin 10 mg once daily~2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
47960021|NCT06441448|BEHAVIORAL|case focus groups|The study is in a monocentric, exploratory, participatory study conceptualization phase. Within the study, a mixed-methods assessment involves various interview and group exercise formats among scientists, medical personnel, affected individuals, and their caregivers to develop components for a future psychotherapeutic program for ALS patients and their caregivers. Therapists provide an overview of therapy forms by presenting components based on format, content, and applied techniques. Case studies and focus groups are used for practical experience for the participants. Participants qualitatively assess the significance of therapeutic approaches and make a quantitative prioritization to establish a ranking of therapy components.
48482492|NCT05760352|DEVICE|Eccentric bike|Received eccentric cycling exercise
48482493|NCT05760352|DEVICE|Helmet ventilation|Using helmet ventilation during eccentric cycling exercise
47960022|NCT01643356|BEHAVIORAL|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
47960023|NCT03115086|DRUG|Cholbam|Cholbam prescribed according to the approved label.
47960024|NCT01373242|DRUG|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
47960025|NCT01423318|DRUG|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
47960026|NCT01423318|DRUG|placebo|single dose subcutaneously
48112282|NCT01562925|DIETARY_SUPPLEMENT|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
48112283|NCT01562925|DIETARY_SUPPLEMENT|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
48112284|NCT01562925|DIETARY_SUPPLEMENT|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
48112285|NCT04116203|DRUG|Metformin|Manufacturer's standard 500 mg. Submission Control No.:128147
48307097|NCT02029404|PROCEDURE|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
47960027|NCT01976338|DRUG|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
48307098|NCT02786355|OTHER|Frova bougie|Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
47960028|NCT01976338|OTHER|Sham injection|Sham intravitreal injection
47960029|NCT04343469|PROCEDURE|Bariatric Surgery (RYGB or LSG)|Morbidly obese subjects will receive either RYGB or LSG, and the effect of bariatric surgery-induced weight loss on brain inflammation will be assessed
47960030|NCT06143813|DIAGNOSTIC_TEST|Selective nerve root block (SNRB)|CT/Fluoroscopy guided nerve root block
47960031|NCT01007539|DIETARY_SUPPLEMENT|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
47960032|NCT01007539|DIETARY_SUPPLEMENT|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
48112286|NCT04116203|COMBINATION_PRODUCT|Fish Oil and Metformin|Combo of 2 other arms
48112287|NCT04116203|DIETARY_SUPPLEMENT|Fish Oil|NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
48112288|NCT06498895|RADIATION|lung ultrasound|"Lung ultrasound score will be done within one hour of admission,12 hours post admission then 24 hours in intensive care unit,follow up of patients will continue for 72 hours .~a complete lung ultrasound evaluation will be performed using low frequency curved probe (2MHz-5MHz) according to the lung ultrasound score . The external lung fields will be examined by longitudinal and transverse plane scans, dividing the surface of the thorax into 12 zones: 6 on the right (anterior: upper R1 and lower R2; lateral; upper R3 and lower R4; posterior: upper R5 and lower R6) and 6 on the left side (front: upper L1 and lower L2; lateral: upper L3 and lower L4; rear: upper L5 and lower L6). LUS assigns 0 points to A lines or \< 2 separate B lines plus regular sliding; 1 point with lines B ≥ 3 or spaced focal points plus regular sliding; 2 points with coalescing B lines, and 3 points to pulmonary consolidations for each zone with a score ranging from 0 (normal lungs) to 36 (worst case scenario)"
48112289|NCT04187326|BEHAVIORAL|Facial Microexpression Training|The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
48307099|NCT00466999|DRUG|misoprostol|single dose of 400 mcg misoprostol administered sublingually
48307100|NCT00466999|PROCEDURE|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
48307101|NCT00003750|BIOLOGICAL|hu14.18-IL2 fusion protein|
48307102|NCT06555367|DEVICE|scleral lenses|Wear scleral lenses
48307103|NCT05328921|DRUG|Antihypertensive Agents|Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
48307104|NCT05328921|DRUG|Antihistaminics|Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
47960033|NCT00144391|DRUG|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
47960034|NCT04862117|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
47960035|NCT04789135|DRUG|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
47960036|NCT05371431|OTHER|Traditional rehabilitation training|The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
48482494|NCT01094028|DRUG|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
48482495|NCT00919984|DRUG|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
48482496|NCT02607423|DRUG|Cisplatin|Given IV
48112290|NCT04058990|DEVICE|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
48112291|NCT04058990|DEVICE|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
48112292|NCT04707313|DRUG|Placebo (Cohorts 1 and 2)|4 matching placebo tablets taken twice daily
48482497|NCT02607423|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
48482498|NCT02607423|DRUG|Docetaxel|Given IV
48482499|NCT02607423|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
48482500|NCT02607423|DRUG|Gemcitabine Hydrochloride|Given IV
48482501|NCT02607423|DRUG|Pemetrexed Disodium|Given IV
48482502|NCT02607423|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
48307105|NCT06364228|DRUG|Placebo|Placebo intranasal spray liquid administration. Oxytocin delivered 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
48482503|NCT01333072|DRUG|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
47960037|NCT05371431|OTHER|Blood flow restriction combined with traditional rehabilitation training|BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
48307106|NCT06364228|DRUG|Oxytocin Intranasal Spray 12 International Unit (12IU)|Oxytocin intranasal spray liquid administration. Subjects weighing \< 40 kg will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
47960038|NCT03190590|PROCEDURE|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
48307107|NCT06364228|DRUG|Oxytocin Intranasal Spray 24 International Unit (24IU)|Oxytocin intranasal spray liquid administration. Subjects weighing \> 40 kg will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (visit 1).
48307108|NCT06364228|PROCEDURE|Functional MRI|Functional MRI (fMRI) scan with affective Stroop and EmpaTom task (Empathy and Theory of Mind task). fMRI scan will administered pre and post-administration of oxytocin.
48307109|NCT00041717|DRUG|Fampridine-SR|25mg bid (twice daily)
48307110|NCT00041717|OTHER|Placebo|Placebo
48482504|NCT01333072|DRUG|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
48482505|NCT01443559|GENETIC|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
48482506|NCT01443559|GENETIC|homogenic cornea|homogenic corneas were sterilised by radiation
48482507|NCT05407506|DIAGNOSTIC_TEST|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
48482508|NCT04557176|DEVICE|CRP, point-of-care assay|CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
48482509|NCT02808208|BIOLOGICAL|Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.
48482510|NCT02808208|DRUG|Placebo|5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
48482511|NCT02808208|BIOLOGICAL|Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)|Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
48482512|NCT05915286|DRUG|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
48482513|NCT05915286|DRUG|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
48482514|NCT03113526|PROCEDURE|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
48482515|NCT06274866|OTHER|exercise program|Study group were followed up with a personalized home-based exercise program for 6 weeks. IThe exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program
48641922|NCT05694637|BEHAVIORAL|Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)|"Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline."
48641923|NCT05694637|DRUG|Varenicline|Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
48641924|NCT06544148|DEVICE|Electrical impedance tomography|In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
48641925|NCT05132075|DRUG|JDQ443|JDQ443 tablets, orally administered
48641926|NCT05132075|DRUG|docetaxel|docetaxel concentrated solution for infusion, intravenously administered
48641927|NCT03973489|BEHAVIORAL|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
48482516|NCT06274866|OTHER|control group|Individuals in the control group were followed up with an exercise training brochure.
48112293|NCT04707313|DRUG|PF-06882961 (Cohorts 1 and 2)|Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
48112294|NCT04707313|DRUG|Placebo (Cohort 3)|2 matching placebo tablets taken twice daily
47960039|NCT03190590|PROCEDURE|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry \[this is not repetitive TMS and so does NOT modulate brain excitability
47960040|NCT03190590|PROCEDURE|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
48112295|NCT04707313|DRUG|PF-06882961 (Cohort 3)|Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
48482517|NCT04030520|BEHAVIORAL|POPPi behavioral intervention|behavioral intervention with offer of HIV self test
47960041|NCT02539446|BEHAVIORAL|stable condition|
47960042|NCT02539446|BEHAVIORAL|unstable condition|
47960043|NCT02539446|BEHAVIORAL|attentional focus|
47960044|NCT02053051|DEVICE|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
47960045|NCT02053051|DEVICE|Standard bolus calculator|
48112296|NCT05503446|OTHER|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
48482518|NCT04030520|BEHAVIORAL|POPPi behavioral intervention|behavioral intervention
47960046|NCT03307967|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
47960047|NCT00767962|OTHER|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
48112297|NCT06262139|DRUG|MT218 injection|a targeted magnetic resonance imaging contrast agent
48112298|NCT06167265|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
48112299|NCT06167265|DRUG|PMR Tablet 145 mg|Single oral dose (total daily dose of 290 mg)
48112300|NCT04407780|OTHER|No interventions are planned|Non applicable
48112301|NCT03413748|PROCEDURE|Elective Cesarean Section|lower segment cesarean section
48112302|NCT03413748|OTHER|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
48112303|NCT04933123|DEVICE|indirect restorative treatement with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
48307111|NCT00200525|DRUG|apomorphine HCl injection|
48307112|NCT02484196|BEHAVIORAL|Questionnaires|Questionnaires
48482519|NCT00896194|BEHAVIORAL|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
48641928|NCT03973489|DRUG|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
48641929|NCT03973489|DRUG|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
48641930|NCT02142803|BIOLOGICAL|Bevacizumab|Given IV
48641931|NCT02142803|OTHER|Laboratory Biomarker Analysis|Correlative studies
48641932|NCT02142803|OTHER|Pharmacological Study|Correlative studies
48641933|NCT02142803|DRUG|Sapanisertib|Given PO
48641934|NCT05605509|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
48641935|NCT05605509|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
48112304|NCT06677086|DEVICE|Treatment with BTL-899|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 device will be applied over the designated area. Each treatment session will last 30 minutes.
48112305|NCT02206672|OTHER|Micro reinjection of autologus adipose tissue|
48112306|NCT02553460|DRUG|ITMHA|Given intrathecally (IT).
48112307|NCT02553460|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
48112308|NCT02553460|DRUG|Mitoxantrone|Given IV.
48112309|NCT02553460|DRUG|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
48112310|NCT02553460|DRUG|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
48482520|NCT00896194|BEHAVIORAL|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
48482521|NCT04811014|DRUG|Buprenorphine, Naloxone Drug Combination|8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
48482522|NCT04811014|BEHAVIORAL|Individual Counseling|One-on-one counseling with a licensed chemical dependency counselor
48482523|NCT04811014|BEHAVIORAL|Peer Recovery Support Services|24/7 support from our team of certified peer recovery support specialists to assist with emotional support and case management
48482524|NCT04811014|BEHAVIORAL|Support Group|Referrals to youth-focused support groups and eventual creation of in-house youth-focused support groups
48641936|NCT05605509|DRUG|FOLFIRI Protocol|Irinotecan Leucovorin FU
48641937|NCT05605509|DRUG|Trastuzumab|standard doses q3weekly
48641938|NCT04248829|DRUG|Lazertinib 240 mg/160 mg|The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
48641939|NCT04248829|DRUG|Gefitinib 250 mg|The initial dose for Gefitinib (250 mg once daily) cannot be reduced to a lower dose
48641940|NCT04248829|DRUG|Lazertinib-matching placebo 240 mg/160 mg|The initial dose of lazertinib-matching placebo 240 mg (3 tablets of 80 mg lazertinib-matching placebo) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib-matching placebo) under specific circumstances
48641941|NCT04248829|DRUG|Gefitinib-matching placebo 250 mg|The initial dose for Gefitinib-matching placebo (250 mg once daily) cannot be reduced to a lower dose
48641942|NCT03142958|DEVICE|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
48641943|NCT03816826|OTHER|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
47960048|NCT00767962|OTHER|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
47960049|NCT04076475|DEVICE|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
47960050|NCT05435677|DRUG|IcoSema|One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
47960051|NCT05435677|DRUG|insulin icodec|One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh
47960052|NCT05435677|DRUG|semaglutide|One single dose of semaglutide administered subcutaneously, S.c. into the left thigh
47960053|NCT02840955|DEVICE|Staphefekt SA.100|
47960054|NCT02840955|OTHER|Placebo|
47960055|NCT04301037|PROCEDURE|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
48112311|NCT02553460|DRUG|Bortezomib|Given IV.
48307113|NCT04051021|BEHAVIORAL|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
48112312|NCT02553460|DRUG|Vorinostat|Taken PO or NG.
48307114|NCT04051021|OTHER|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
48641944|NCT06327490|PROCEDURE|ICG-guided manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using ICG lymphography images of the lymphatic pathway in their affected arm as guidance once daily for 2 years post-surgery.
48307115|NCT05868993|DRUG|Dose of 0.5% Ropivacaine|Dose varied by 5mL of 0.5% Ropivacaine
47960056|NCT04301037|PROCEDURE|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
47960057|NCT02126917|DRUG|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
47960058|NCT02126917|DRUG|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
48112313|NCT02553460|DRUG|Cyclophosphamide|Given IV.
48112314|NCT02553460|DRUG|Mercaptopurine|Given PO or NG.
48112315|NCT02553460|DRUG|Methotrexate|Given IV, IM or PO.
48112316|NCT02553460|DRUG|Leucovorin Calcium|Leucovorin rescue PO or IV.
48307116|NCT04559152|DIETARY_SUPPLEMENT|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
48641945|NCT06327490|PROCEDURE|Traditional manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using traditional technique once daily for 2 years post-surgery.
48641946|NCT06327490|DRUG|Indocyanine green|All participants will be injected with indocyanine green for lymphatic mapping of the affected upper extremity, however this mapping will only be used to guide manual lymphatic drainage for participants on the ICG-guided manual lymphatic drainage arm.
48641947|NCT05937165|OTHER|Freeze-dried Blueberry Powder|Three day consumption of two doses of freeze-dried blueberry powder
48641948|NCT05555732|DRUG|Datopotamab Deruxtecan|Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
47960059|NCT02126917|DRUG|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
47960060|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
47960061|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
48112317|NCT02553460|DRUG|Cytarabine|Given IV.
48112318|NCT02553460|DRUG|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
48112319|NCT02553460|DRUG|Vincristine|Given IV.
48641949|NCT05555732|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
48112320|NCT03597100|DEVICE|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
48112321|NCT04238000|DEVICE|repetitive transcranial magnetic stimulation|Cerebellar repetitive theta Burst stimulation will be performed as detailed in the Real arm description
48112322|NCT04798248|BEHAVIORAL|Momentary Affect Regulation - Safer Sex Intervention (MARSSI)|MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
48307117|NCT04559152|DIETARY_SUPPLEMENT|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
48482525|NCT04811014|BEHAVIORAL|Referral to Medication Management|Study staff will refer patients to long-term MOUD providers in the community
47960062|NCT00751933|DIETARY_SUPPLEMENT|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
48307118|NCT05267353|BEHAVIORAL|Exercise intervention program|"It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention."
48307119|NCT02963727|BIOLOGICAL|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
48307120|NCT03757481|OTHER|no intervention|SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
48307121|NCT01526018|BEHAVIORAL|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
47960063|NCT00751933|OTHER|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
48307122|NCT02928406|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
48307123|NCT00429377|DRUG|tacrolimus|
48307124|NCT04718181|DRUG|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
48307125|NCT04718181|DRUG|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
48307126|NCT00409422|BEHAVIORAL|weight management program|
48482526|NCT04811014|BEHAVIORAL|Assertive Outreach|The investigators will conduct weekly outreach to youths who experienced an opioid overdose and attempt to initiate treatment. Outreach is completed by a paramedic and peer coach.
48641950|NCT05555732|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
48641951|NCT05555732|DRUG|Carboplatin|Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
47960064|NCT01629992|OTHER|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
47960065|NCT04158492|DIAGNOSTIC_TEST|real-time multiplex PCR|Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
47960066|NCT04158492|DIAGNOSTIC_TEST|Standard diagnostic procedures|Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
47960067|NCT02834039|PROCEDURE|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
47960068|NCT02834039|PROCEDURE|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
47960069|NCT01458236|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
47960070|NCT01458236|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
47960071|NCT00423904|BEHAVIORAL|Brief intervention|
48112323|NCT04798248|BEHAVIORAL|Podcast Health Group|Participants assigned to the Podcast Health Group will listen to \~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
48112324|NCT04785989|OTHER|[U-13C]glucose|\[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
48112325|NCT04785989|OTHER|[13C5]glutamine|6mg/kg of body weight of \[13C5\]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
48307127|NCT00039273|BIOLOGICAL|panitumumab|
48307128|NCT02307019|OTHER|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
48307129|NCT02307019|OTHER|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
48307130|NCT04808154|DRUG|SNP-630|Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
48482527|NCT05052242|DIAGNOSTIC_TEST|primary angle closure disease|2 swept source OCT biometers, IOL Master700 and Anterion
48482528|NCT04290286|OTHER|i2TransHealth|i2TransHealth: online intervention for TGD people
48641952|NCT05555732|DRUG|Cisplatin|Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
48641953|NCT05704244|DRUG|FE 999326|75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
47960072|NCT01204554|DRUG|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
48307131|NCT04276311|DEVICE|Percutaneous transluminal angioplasty|The purpose of this study is to evaluate the efficacy and the feasibility of atherectomy, using the Jetstream™ artery preparation associated to DCB treatment (Ranger™ Paclitaxel-Coated balloon), in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo femoropopliteal arterial lesions (TASC C).
48307132|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
48307133|NCT01703286|DRUG|Linagliptin|given once daily for 28 days
48307134|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
48307135|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
48307136|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
48307137|NCT01703286|DRUG|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
48307138|NCT00506051|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
47960073|NCT03466567|DRUG|Semaglutide|A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
48307139|NCT00506051|DRUG|pemetrexed|intravenous infusion
48307140|NCT00506051|DRUG|ZD6474 (vandetanib) 300mg|
48307141|NCT02929095|DRUG|dexmedetomidine|
48307142|NCT02929095|DRUG|midazolam|
48307143|NCT02929095|DRUG|remifentanil|- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
48307144|NCT02731508|DEVICE|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
47960074|NCT03466567|DRUG|Probenecid|A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
47960075|NCT03466567|DRUG|Ciclosporin|A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
47960076|NCT01147523|DRUG|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
48307145|NCT02304783|DRUG|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
48307146|NCT02304783|DRUG|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
48307147|NCT02304783|DRUG|paracetamol|Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
48641954|NCT03964909|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
48641955|NCT03964909|PROCEDURE|Magnetic Resonance Imaging|Undergo CVR MRI
48641956|NCT03964909|PROCEDURE|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
47960077|NCT01972100|DEVICE|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
48307148|NCT03400696|BEHAVIORAL|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
48307149|NCT03400696|BEHAVIORAL|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
48307150|NCT03400696|BEHAVIORAL|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov\>
48641957|NCT05909397|DRUG|ARV-471 (PF-07850327)|Pharmaceutical form: Tablets. Route of Administration: Oral
48307151|NCT01673724|DRUG|pramipexole|pramipexole
48641958|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
47960078|NCT01972100|OTHER|isokinetic exercise|
47960079|NCT01972100|DEVICE|Placebo low-level laser therapy|
48307152|NCT01673724|DRUG|Bromocriptine|bromocriptine
48307153|NCT00047281|DRUG|celecoxib|
48641959|NCT05909397|DRUG|Letrozole|Pharmaceutical form: Capsules. Route of Administration: Orally
47960080|NCT02984111|DRUG|normal saline|
47960081|NCT02984111|DRUG|erythropoietin|
47960082|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
48307154|NCT00047281|DRUG|cyclophosphamide|
48307155|NCT00047281|DRUG|etoposide|
48307156|NCT00047281|DRUG|thalidomide|
48307157|NCT01402284|DRUG|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
48307158|NCT01402284|DRUG|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
48307159|NCT01402284|DRUG|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
48307160|NCT01402284|DRUG|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
48307161|NCT01402284|DRUG|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
48307162|NCT00083239|DRUG|talabostat (PT-100) tablets|
48307163|NCT04437017|DRUG|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
48307164|NCT04437017|DRUG|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
48307165|NCT04368806|DRUG|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
48307166|NCT04368806|OTHER|Placebo Control|Normal Saline with autologous Serum
48307167|NCT05994014|DIAGNOSTIC_TEST|PET/CT|Experimental test for detecting atherosclerosis
48307168|NCT06245018|BIOLOGICAL|iNK Injection|Subjects will receive about 4 cycles of iNK
48641960|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
48307169|NCT04453839|DRUG|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
48307170|NCT04841382|OTHER|Supporting information.|CardioSolv Software System is a software-based medical device meant which creates a patient-specific 3D heart model that provides physiologic information.
48307171|NCT02069223|PROCEDURE|Gastrectomy|
48307172|NCT02069223|PROCEDURE|BPD-DS|
48307173|NCT01929044|DRUG|654-II (anisodamine)|10mg injection
48307174|NCT01929044|DRUG|Buscopan® (hyoscine butylbromide)|20mg injection
48112326|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|mitral valve replacement
48307175|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
48307176|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
48307177|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
48307178|NCT03712163|DRUG|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
48307179|NCT03712163|DRUG|Placebo Oral Capsule|Placebo
48307180|NCT05878808|DIAGNOSTIC_TEST|Psychometric assessment|Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
48307181|NCT02626819|BEHAVIORAL|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
48641961|NCT05429502|DRUG|Topotecan|Starting out dose of topotecan administered at standard dose given to neuroblastoma patients (0.75 mg/m2/day).
47960083|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
47960084|NCT01186965|BEHAVIORAL|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
47960085|NCT05346874|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
47960086|NCT05346874|DRUG|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
48641962|NCT05429502|DRUG|Temozolomide|Starting out dose of temozolomide for first two cohorts for Phase 1-Part A: 150mg/m2/day. Starting out dose for subsequent cohorts in Phase 1-Part A will initiate at 100mg/m2/day and will be determined for Phase 1-Part B depending on safety outcome and for phase II.
48641963|NCT05429502|DRUG|Ribociclib|Ribociclib administered at the RP2D defined from Phase I-Part A.
48641964|NCT01817452|DRUG|Trastuzumab|
47960087|NCT05346874|PROCEDURE|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
47960088|NCT05439941|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
47960089|NCT05075902|BEHAVIORAL|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
48482529|NCT03446352|OTHER|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
48482530|NCT03446352|OTHER|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
48641965|NCT01817452|DRUG|Pertuzumab|
48641966|NCT01817452|DRUG|Paclitaxel|
48307182|NCT02626819|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
48112327|NCT03242642|DEVICE|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement
48641967|NCT04691492|BEHAVIORAL|Friend-Based Motivational Interview|The intervention will use Motivational Interviewing's (MI) collaborative conversation style for strengthening commitment to change, to motivate and prepare women to work together to reduce Sexual Assault (SA) risk. This intervention will target ways that the friend dyad may support, encourage, and share responsibility with one another in protecting against SA. The Friend-based MI (FMI) will then use the responsibility and relationship of friends as a framework to foster collaborative efforts to increase readiness and decrease barriers to helping behavior. As part of this, the FMI will focus on the identification and implementation of skills friends can use to help one another prevent sexual assault. FMI will include a focused discussion of the ways drinking may impede helping efforts. Moreover, the FMI will encourage women to identify personal, specific strategies for reducing the effects of alcohol on helping.
48112328|NCT01061424|BEHAVIORAL|community health worker|community health worker provides home visits for education
48112329|NCT01061424|BEHAVIORAL|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
48112330|NCT00281996|DRUG|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
48112331|NCT00281996|DRUG|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
48307183|NCT02184143|BEHAVIORAL|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
48482531|NCT03341000|DEVICE|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.
48482532|NCT03431064|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
48307184|NCT02184143|OTHER|Education|Patient education
48307185|NCT01648608|DRUG|Exemestane|Exemestane for neoadjuvant chemotherapy
48307186|NCT03003143|DRUG|Vigabatrin 500 MG|
48307187|NCT04506827|PROCEDURE|Maxillary Sinus Augmentation|Biomaterial Graft into the Maxillary Sinus
48307188|NCT04506827|DEVICE|Maxillary Sinus Graft with ABBM|The maxillary sinuses in the control group are grafted with ABBM
48482533|NCT03431064|OTHER|Fluid Administration|Administration of IV Fluid by Anesthesiologist
48482534|NCT03407612|DEVICE|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
47960090|NCT02225561|PROCEDURE|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~* Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~* The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~* Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
48112332|NCT05746247|BEHAVIORAL|Testing centralized referral mechanism for PCPs|"For patients with a Penn PCP, we are testing a centralized referral mechanism to increase the number of referrals to preventive cardiology (default/opt out referrals)~For default/opt out: PCPs will receive a pended order for a referral for their patient to see a lipid specialist for a formal FH evaluation. Not interacting with the pended order or accepting the pended order will indicate that the referral to a lipid specialist should be placed."
48307189|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP|The maxillary sinuses in the test1 group are grafted with TCP
48307190|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP + HA|The maxillary sinuses in the test1 group are grafted with TCP + HA
48307191|NCT03097328|DRUG|TAK-228|TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
47960091|NCT02225561|PROCEDURE|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
47960092|NCT00876057|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy
47960093|NCT00876057|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
47960094|NCT05139121|DRUG|MR-100A-01|Transdermal contraceptive delivery system
47960095|NCT04997083|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
47960096|NCT04997083|DEVICE|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
47960097|NCT00822042|OTHER|Samples and procedures|"* Scanner, histomorphometry : at the inclusion and M3 visits~* whole blood samples, cytoponction : at the inclusion and M3 visits"
47960098|NCT01077570|DRUG|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
47960099|NCT04808999|DRUG|Pembrolizumab Injection|200 mg IV infusion
47960100|NCT01045525|PROCEDURE|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
47960101|NCT01045525|BEHAVIORAL|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
47960102|NCT04152655|DRUG|Idebenone|30mg tablets three times a day
47960103|NCT04152655|DRUG|Placebo oral tablet|placebo tablets three times a day
47960104|NCT02128971|DIETARY_SUPPLEMENT|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
47960105|NCT02128971|DIETARY_SUPPLEMENT|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
47960106|NCT02128971|DIETARY_SUPPLEMENT|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
47960107|NCT02128971|DIETARY_SUPPLEMENT|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
47960108|NCT02128971|DIETARY_SUPPLEMENT|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
47960109|NCT02128971|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
48307192|NCT00002410|DRUG|Indinavir sulfate|
48307193|NCT00002410|DRUG|Lamivudine|
47960110|NCT02144623|DRUG|Valproate|
47960111|NCT02504684|DEVICE|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
47960112|NCT02504684|DEVICE|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
48307194|NCT00002410|DRUG|Zidovudine|
48307195|NCT03445013|DRUG|SB414 6%|Twice daily
48307196|NCT03445013|DRUG|Vehicle|Vehicle Comparator
48307197|NCT01066078|OTHER|Echocardiography and SonR recording|
47960113|NCT06318429|BEHAVIORAL|stretching exercise group|stretching exercise group
47960114|NCT04674644|BEHAVIORAL|The psychosocial effects of COVID-19 pandemic on dental professionals|Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
47960115|NCT00734175|BIOLOGICAL|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
47960116|NCT02564237|BIOLOGICAL|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
48307198|NCT01096446|DRUG|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
48482535|NCT02744755|BIOLOGICAL|Adalimumab - GP2017|Adalimumab - GP2017
48482536|NCT02744755|BIOLOGICAL|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
48482537|NCT06104631|OTHER|BK003|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.
47960117|NCT02564237|BIOLOGICAL|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
47960118|NCT02564237|BIOLOGICAL|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
48112333|NCT05746247|BEHAVIORAL|Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation|All eligible patients will be informed that they have been identified by the FIND FH tool as potentially having familial hypercholesterolemia. All patients will be invited to schedule a telehealth appointment with a lipid specialist for a formal evaluation for FH.
48307199|NCT03002116|OTHER|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
48307200|NCT01958671|DRUG|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
48307201|NCT01958671|DRUG|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
48307202|NCT01958671|DRUG|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
48307203|NCT01958671|DRUG|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
48307204|NCT01958671|DRUG|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
48307205|NCT01958671|DRUG|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
48307206|NCT00988559|BIOLOGICAL|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
48307207|NCT00988559|DEVICE|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
48307208|NCT00988559|BIOLOGICAL|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
48307209|NCT00988559|BIOLOGICAL|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
48307210|NCT00988559|PROCEDURE|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
48307211|NCT00988559|DRUG|imiquimod|imiquimod applied to the cervix by the physician
48307212|NCT00108849|DRUG|estradiol, 10 mcg|
48307213|NCT03680794|OTHER|sampling of ophthalmic liquid|aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
48307214|NCT02776696|DEVICE|Advanced Hybrid Closed Loop System|
48307215|NCT02776696|DEVICE|Hybrid Closed Loop System|
48307216|NCT03924024|DEVICE|Accelerated intermittent theta burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator."
48307217|NCT06332781|DRUG|Gentamicin|administered via bladder
48307218|NCT06332781|DRUG|Nitrofurantoin|administered PO
48307219|NCT01798134|DEVICE|TANDEM™|
48307220|NCT06551077|PROCEDURE|POSTERIOR RECTUS SHEATH HIATAL AUGMENTATION (PORSHA)|Use of a novel permanent autologous vascularized biologic fascial flap to reconstruct the diaphragmatic hiatus following standard hiatal hernia repair in selected patients. This technique is called a posterior rectus sheath flap hiatal augmentation or PoRSHA.
48307221|NCT04964063|OTHER|Potassium Nitrate + Sodium Fluoride|Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
48307222|NCT02692820|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
48482538|NCT06104631|OTHER|Placebo|The placebo product has the same composition in excipient, same form and same posology as BK003.
48112334|NCT06258031|DRUG|Psilocybin (COMP360)|Up to 10mg on two occasions
48112335|NCT06676423|BIOLOGICAL|Lenzumestrocel|1.0 ⅹ 10\^6 cells/kg of Neuronata-R mixed with HTS-FRS suspension are administered twice in the cerebrospinal fluid at intervals of 26 days
48307223|NCT02692820|OTHER|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
48307224|NCT06242665|OTHER|Low UPF Meals (Study Provided)|Meals provided through delivery service
48307225|NCT06242665|OTHER|Low UPF Nutritional Guidance|Self-guided instructions from study team.
48307226|NCT06242665|OTHER|Low UPF Snacks (Study Provided)|Low UPF snacks provided to participant
48307227|NCT00673998|DEVICE|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
48307228|NCT01743586|OTHER|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
48307229|NCT01201096|RADIATION|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
48307230|NCT01201096|PROCEDURE|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
48307231|NCT00305643|DRUG|Capecitabine|Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
48307232|NCT00305643|DRUG|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
48482539|NCT01926275|DEVICE|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
48482540|NCT01926275|DEVICE|NPPV|noninvasive positive pressure ventilation
47960119|NCT02564237|BIOLOGICAL|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
47960120|NCT02903355|DRUG|D-methionine|D-methionine, oral liquid suspension
47960121|NCT02903355|DRUG|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
48112336|NCT06676423|DRUG|Riluzole|In the case of a subject who is not taking Riluzole at the time of screening (visit 1), Riluzole should be taken except when discontinued due to Adverse events. The dose can be changed within the authorization according to the medical expert's judgement
48112337|NCT06676852|BEHAVIORAL|Primary palliative care|Enrolled patient participants will receive Sentinel prior to and during their hospitalization for HCT. Prior to HCT, a transplant clinician (nurse practitioner - NP) will conduct a focused PC visit to build rapport, manage expectations regarding HCT, review anticipated symptoms, and discuss illness coping strategies. During the HCT hospitalization, HCT physicians and advanced practice providers will incorporate PC domains into their routine care of patients undergoing HCT.
48112338|NCT05491317|BIOLOGICAL|GEN1042|Intravenous
48112339|NCT05491317|DRUG|Pembrolizumab|Intravenous
48112340|NCT05491317|RADIATION|Radiotherapy|Radiotherapy
48307233|NCT00305643|PROCEDURE|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
48307234|NCT00305643|DRUG|Placebo|Oral placebo twice daily on days 1-21
48307235|NCT04378309|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
48112341|NCT05494762|DRUG|BGB-B167|Intravenous administration
48112342|NCT05494762|DRUG|Tislelizumab|Intravenous administration
48112343|NCT05256641|DRUG|Acalabrutinib|Given PO
48307236|NCT02795351|DRUG|Sildenafil|Single oral administration of active or placebo one week apart
48307237|NCT02795351|DRUG|Placebo|
48307238|NCT05723549|DRUG|HCP1803-3|Take it once per period
48307239|NCT05723549|DRUG|RLD2002|Take it once per period
48307240|NCT05723549|DRUG|HCP1904-1|Take it once per period
48482541|NCT01926275|DEVICE|IMT|inspiratory muscle training
47960122|NCT00882063|DRUG|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
47960123|NCT00968201|DRUG|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
47960124|NCT00968201|DRUG|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
47960125|NCT00967057|DRUG|asparaginase|Given intramuscularly
47960126|NCT00967057|DRUG|dexamethasone|Given orally
47960127|NCT00967057|DRUG|idarubicin|Given IV
47960128|NCT00967057|DRUG|methotrexate|Given intrathecally
47960129|NCT00967057|DRUG|mitoxantrone hydrochloride|Given IV
47960130|NCT00967057|DRUG|pegaspargase|Given intramuscularly
47960131|NCT00967057|DRUG|vincristine sulfate|Given IV
48112344|NCT01740310|BEHAVIORAL|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
48307243|NCT05039580|DRUG|PD-1 monoclonal antibody|PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
48307244|NCT02075762|PROCEDURE|Transbronchial biopsy|
48307245|NCT02075762|PROCEDURE|Cryoprobe biopsy|
48307246|NCT02075762|PROCEDURE|VATS biopsy|
48307247|NCT05260931|DIAGNOSTIC_TEST|Fetal echocardiography|Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
47960132|NCT04242719|DEVICE|Electromagnetic stimulation|Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.
48112345|NCT00092027|DRUG|MK0217, alendronate sodium/Duration of Treatment: 6 months|
48112346|NCT00092027|DRUG|Comparator: placebo / Duration of Treatment: 6 months|
48112347|NCT04415086|BIOLOGICAL|convalescent plasma|The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
48112348|NCT04077151|BEHAVIORAL|PrEP Demonstration Project|In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
48112349|NCT06297135|BEHAVIORAL|Behavioral Parent Training|Teaches parents antecedent- and reinforcement-based behavior management techniques and provide support to manage their stress
48112350|NCT00014599|DRUG|paclitaxel|
48307248|NCT03665350|DRUG|Insulin|"Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile."
48112351|NCT02894463|OTHER|questionnaire|
48307249|NCT00326105|DRUG|Quetiapine fumarate|
48307250|NCT02493309|OTHER|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
48307251|NCT02493309|OTHER|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
48307252|NCT01058369|DRUG|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
48307253|NCT01814800|BIOLOGICAL|RI-002|Immune Globulin Intravenous (IGIV)
48307254|NCT03282201|OTHER|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
48307255|NCT01029002|DRUG|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
48307256|NCT01029002|OTHER|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
48307257|NCT05380297|DEVICE|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
48307258|NCT04421196|OTHER|Exclusion of opioid analgesics|The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.
48307259|NCT00337467|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
48641968|NCT06564623|DRUG|mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]|Patients will receive treatment on Day 1, 8, 15 and 22 of cycle 1 and on day 1 of remaining cycles (C2-C4) in Prime Phase. In the Boost Phase - every 2 cycles (8 weeks) beginning from C6D1.
48112352|NCT01234844|BEHAVIORAL|care of guinea pigs|twice weekly sessions of care with guinea pigs
48112353|NCT01234844|BEHAVIORAL|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
48112354|NCT00326924|BIOLOGICAL|Transfusion|PRBC blood transfusions.
48112355|NCT01305733|DRUG|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
48112356|NCT01305733|OTHER|saline injection|saline
48307260|NCT02667990|OTHER|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
48641969|NCT06564623|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV every 4 weeks in both the Prime and Boost Phase.
48112357|NCT05881577|OTHER|Observational|Impact of AR on educational outcomes
48112358|NCT00468910|DRUG|acetylsalicylic acid|Given orally
48112359|NCT00468910|DRUG|placebo|Given orally
48112360|NCT00468910|OTHER|laboratory biomarker analysis|Correlative study
48112361|NCT04266795|DRUG|Pevonedistat|Pevonedistat IV infusion.
48112362|NCT04266795|DRUG|Venetoclax|Venetoclax tablets.
48112363|NCT04266795|DRUG|Azacitidine|Azacitidine IV or SC injection.
48112364|NCT00079183|DRUG|sirolimus|Given PO
48307261|NCT02667990|OTHER|standard stiletto|standard stiletto without insole
48307262|NCT02667990|OTHER|comfy trainer|comfy trainer
48307263|NCT00767156|OTHER|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
48307264|NCT00767156|OTHER|Base cream|The subjects use the base cream on the face, twice per day
48112365|NCT03978468|OTHER|Interagency Collaboration (ICollab)|The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.
48112366|NCT03978468|OTHER|Usual Care|The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare \& Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
48112367|NCT06676514|DIETARY_SUPPLEMENT|Butirrisan®|Probiotic Clostridium butyricum CBM588®
48112368|NCT03703297|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
48112369|NCT03703297|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
48112370|NCT03703297|OTHER|Placebo|Placebo IV (intravenous infusion)
48112371|NCT03444701|DRUG|E7130|Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.
48112372|NCT03444701|DRUG|E7130|Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
48112373|NCT03618134|BIOLOGICAL|Durvalumab|Given IV
48112374|NCT03618134|PROCEDURE|Modified Radical Neck Dissection|Undergo modified radical neck dissection
48112375|NCT03618134|OTHER|Quality-of-Life Assessment|Ancillary studies
48112376|NCT03618134|OTHER|Questionnaire Administration|Ancillary studies
48112377|NCT03618134|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48112378|NCT03618134|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
48112379|NCT03618134|BIOLOGICAL|Tremelimumab|Given IV
48482542|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
48112380|NCT04587908|DRUG|TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]|・Treatment period：oral administration for 52 weeks, BID after meal
48112381|NCT04587908|DRUG|Placebo [Ambulatory Cohort] only|"* Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal"
48112382|NCT05247749|DEVICE|CONVIVO Confocal Endomicroscopy System|Confocal Laser Endomicroscopy (CEM) system intended for viewing intra-operative blood flow in the cerebral vascular area. Manufacturer - Zeiss
48112383|NCT00000646|DRUG|Pentoxifylline|
48482543|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
48641970|NCT06564623|DRUG|Tremelimumab|Patients will receive treatment on C1D1. Tremelimumab (300 mg) will be administered IV as a single dose on Day 1 of Cycle 1.
48641971|NCT03997383|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
48641972|NCT03997383|DRUG|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
48482544|NCT03226171|DRUG|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
48641973|NCT01044693|DRUG|Placebo|Placebo capsule
48641974|NCT01044693|DRUG|Nebivolol 5 mg|Nebivolol 5mg single oral dose
48641975|NCT01044693|DRUG|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
48641976|NCT01044693|DRUG|Sildenafil25 mg|Sildenafil 25 mg single oral dose
48641977|NCT05002816|DRUG|Elotuzumab|Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
48641978|NCT05002816|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered via IV infusion on day 1 of each 28 day cycle. There will be 3 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested, further dose reduction to 1.4mg/kg every 8 weeks will be administered. Following the dose evaluation, there will be a dose expansion cohort wtih 12 additional subjects. There is no dose escalation planned in this study.
48641979|NCT06525870|DRUG|85%TCA topical application|85%TCA topical application is done at cervical lesion and transformation zone. Application of TCA will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of TCA will be applied to cover the lesion and transformation zone.
48641980|NCT06525870|DRUG|3% acetic acid|3% acetic acid topical application is done at cervical lesion and transformation zone. Application will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators. A thin film of acetic acid will be applied to cover the lesion and transformation zone.
48641981|NCT06654089|DIETARY_SUPPLEMENT|Emergen-C Core Super Orange Powder|A dietary supplement powder containing vitamin C, zinc, vitamin B6, vitamin B12, folate, and manganese.
48641982|NCT06654089|DIETARY_SUPPLEMENT|Placebo|A study product identical to the test product without active ingredients.
48641983|NCT05877599|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R175H|"* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)"
47960133|NCT04242719|BIOLOGICAL|Platelet rich plasma|About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
47960134|NCT01942343|DRUG|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
47960135|NCT06129175|BIOLOGICAL|Neuroncell-EX|Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
47960136|NCT06129175|OTHER|Placebo|Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
47960137|NCT05340075|PROCEDURE|Patients who underwent percutaneous nephrolithotomy|Patients who underwent percutaneous nephrolithotomy to the contralateral kidney 2-4 weeks and 4-6 weeks after the percutaneous nephrolithotomy operation
47960138|NCT04420442|PROCEDURE|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
47960139|NCT03385564|DRUG|BI 655064|subcutaneous injection
47960140|NCT03385564|DRUG|Placebo|subcutaneous injection
47960141|NCT01631773|GENETIC|microRNA|Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
47960142|NCT04158752|DRUG|Galcanezumab|Injection of study drug at 3 timepoints (day 30, day 60, day 90)
47960143|NCT03273270|RADIATION|transcranial magnetic stimulation|transcranial magnetic stimulation
47960144|NCT00917397|DRUG|Sertraline|varies
47960145|NCT00917397|BEHAVIORAL|trauma-focused cognitive behavioural therapy|once a week
47960146|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung impedence|the changes of end expiratory lung impedence measured by EIT
47960147|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung volume|the changes of end expiratory lung volume measured by apnea method
47960148|NCT01479478|DRUG|Placebo|One placebo capsule daily.
47960149|NCT01479478|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
47960150|NCT02653872|DRUG|AZD7986|Oral solution, single dose, dilution from concentrate
47960151|NCT02653872|DRUG|Verapamil|Extended release tablet for oral use
48112384|NCT06656377|BEHAVIORAL|exercise intervention|A total of 25 prediabetic adults of either gender will participate in the study they will engage in exercise at intensities of 50%, 60%, 70%, or 80% of their predicted maximum heart rate (PMHR). In duration they will exercise for 15, 30, 45 and 60 minutes, and in timing protocol they will exercise at various time points after having breakfast. Blood samples were collected at four time points i.e. at fasting, pre-exercise and post-exercise at 30 and 60 minutes to measure glucose, insulin, and C-peptide levels.
48112385|NCT01701453|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
48112386|NCT03236064|DRUG|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
48112387|NCT00386516|DRUG|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
48482545|NCT02619682|DRUG|Ixazomib Citrate|Given PO
48112388|NCT00386516|DRUG|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
48112389|NCT05863195|BIOLOGICAL|Bevacizumab|Given IV
48112390|NCT05863195|BIOLOGICAL|Cetuximab|Given IV
48112391|NCT05863195|PROCEDURE|Computed Tomography|Undergo SPECT/CT and/or CT
47960152|NCT02653872|DRUG|Itraconazole|Oral solution
47960153|NCT02653872|DRUG|Diltiazem|Extended release capsule
47960154|NCT01788228|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
47960155|NCT00868608|DRUG|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
48112392|NCT05863195|DRUG|Floxuridine|Given via HAI pump
48112393|NCT05863195|DRUG|Fluorouracil|Given IV
48482546|NCT02619682|OTHER|Laboratory Biomarker Analysis|Correlative studies
48482547|NCT02619682|DRUG|Lenalidomide|Given PO
48641984|NCT05569954|BIOLOGICAL|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
48641985|NCT05569954|BIOLOGICAL|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
48482548|NCT00717496|OTHER|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
47960156|NCT05274061|BEHAVIORAL|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
48482549|NCT03447886|OTHER|Phone interview|Collecting clinical and socio-demographic information.
48482550|NCT00922259|BIOLOGICAL|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10\^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
47960157|NCT01237743|DEVICE|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
47960158|NCT00684099|DRUG|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
47960159|NCT00684099|DRUG|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
47960160|NCT00255112|BEHAVIORAL|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
47960161|NCT01543958|DRUG|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
47960162|NCT01543958|DEVICE|Sevelamer carbonate|
47960163|NCT02041832|OTHER|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
47960164|NCT02041832|DEVICE|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
47960165|NCT02296320|DRUG|MEDI4893|Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
47960166|NCT02296320|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
47960167|NCT01296217|PROCEDURE|lymph nod detection|
47960168|NCT01828736|BIOLOGICAL|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
47960169|NCT01828736|DRUG|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
47960170|NCT01828736|DRUG|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
47960171|NCT01828736|DRUG|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
48112394|NCT05863195|PROCEDURE|Implantation|Undergo surgery to place the HAI pump
48112395|NCT05863195|PROCEDURE|Intrahepatic Infusion Procedure|Undergo HAI
48482551|NCT06552104|BEHAVIORAL|ACUPRESSURE APPLI ACUPRESSURE APPLICATION|Pre-test data were collected from participants who met the inclusion criteria and volunteered to participate in the study by researcher BI in the LDP rooms during the latency period of labor. Post-test data were obtained by the same researcher 16 hours after the cesarean section. Data were obtained using the Personal Information Form, Episiotomy Evaluation Form (EEF), Visual Analog Scale (VAS), and Spielberger Manual for State-Trait Anxiety Inventory (STAI).
48482552|NCT02315066|DRUG|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
47960172|NCT02702219|BEHAVIORAL|Mobility of the hamstrings muscles|
47960173|NCT03484377|DEVICE|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
47960174|NCT03484377|DEVICE|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
47960175|NCT05097274|OTHER|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
47960176|NCT05097274|OTHER|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
47960177|NCT05097274|OTHER|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
47960178|NCT03998930|OTHER|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
47960179|NCT01234441|DIETARY_SUPPLEMENT|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
47960180|NCT01234441|DIETARY_SUPPLEMENT|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
47960181|NCT01234441|BEHAVIORAL|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
47960182|NCT05857059|DRUG|Misoprostol 25 mcg|Misoprostol 50 mcg every 2 hours
47960183|NCT05857059|DRUG|Misoprostol 50 mcg|Misoprostol 50 mcg every 2 hours
48112396|NCT05863195|DRUG|Irinotecan|Given IV
48112397|NCT05863195|DRUG|Leucovorin|Given IV
48112398|NCT05863195|DRUG|Oxaliplatin|Given IV
48112399|NCT05863195|BIOLOGICAL|Panitumumab|Given IV
48307265|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
48307266|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
48307267|NCT02252874|BEHAVIORAL|Slow-paced action video game|20 hours slow-paced action video games
48307268|NCT02252874|BEHAVIORAL|Fast-paced action video game|20 hours fast-paced action video games
48307269|NCT02252874|BEHAVIORAL|Control|20 hours leisure activities
48307270|NCT00050349|DRUG|EPO906 epothilone B|
48307271|NCT03968861|DRUG|Xenon|Inhaled xenon gas given via purposely designed ventilator
48307272|NCT00159744|DRUG|Asenapine|Asenapine, 3 weeks
48307273|NCT00159744|DRUG|Olanzapine|Olanzapine, 3 weeks
47960184|NCT01752270|DRUG|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
47960185|NCT01752270|DRUG|Diane-35 pretreatment|
47960186|NCT05236400|DEVICE|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
47960187|NCT05236400|PROCEDURE|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
48482553|NCT02315066|DRUG|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
47960188|NCT04203797|DRUG|dupilumab|Pre-filled syringe administered by subcutaneous (SC) injections
47960189|NCT04203797|DRUG|Matching placebo|Pre-filled syringe administered by subcutaneous (SC)
47960190|NCT03884491|DRUG|Vortioxetine IV|an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
47960191|NCT03884491|DRUG|Vortioxetine SLA|5-25 mg of sublingual formulation A of vortioxetine
47960192|NCT03884491|DRUG|Vortioxetine SLB|5-25 mg of sublingual formulation B of vortioxetine
47960193|NCT03884491|DRUG|Vortioxetine SLC|formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
47960194|NCT03172442|DEVICE|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
47960195|NCT03172442|DEVICE|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
48112400|NCT05863195|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
48307274|NCT00159744|DRUG|Placebo|placebo, 3 weeks
48307275|NCT04045249|DIETARY_SUPPLEMENT|Home based food|Home based food is compare able to RUTF
48482554|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
47960196|NCT03172442|DEVICE|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
48112401|NCT03416842|DEVICE|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
48112402|NCT00046995|DRUG|carboplatin|
48307276|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 1|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar among all three arms.
48307277|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 2|Patients will undergo imaging on a modern 128 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
48307278|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 3|Patients will undergo imaging on a modern 20 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
48307279|NCT01864759|BIOLOGICAL|ICOVIR-5|
48307280|NCT03312777|DRUG|Omnitram|Omnitram tablets overencapsulated
48307281|NCT03312777|DRUG|Tramadol|Tramadol tablet overencapsulated
48307282|NCT03312777|DRUG|Placebo|Microcrystalline powder overencapsulated
48307283|NCT03564171|COMBINATION_PRODUCT|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
48307284|NCT00441558|DRUG|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
48307285|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic, Polyphenol-rich Extracts|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day"
48307286|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day"
48307287|NCT05990764|OTHER|Placebo|"placebo~Once a day"
48307288|NCT02361203|BEHAVIORAL|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
48307289|NCT01957826|OTHER|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
48307290|NCT01957826|OTHER|placebo intervention|placebo administration
48307291|NCT02548104|OTHER|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
48482555|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
48112403|NCT00046995|DRUG|fluorouracil|
48482556|NCT02116517|DIETARY_SUPPLEMENT|green tea extract|500 mg three times per day
48482557|NCT02116517|DIETARY_SUPPLEMENT|Placebo|cellulose 500mg three times a day for 6 weeks
48482558|NCT00617370|DRUG|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
47960197|NCT02021227|PROCEDURE|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for \> 1 hour
48112404|NCT00046995|DRUG|leucovorin calcium|
48112405|NCT00046995|PROCEDURE|adjuvant therapy|
48112406|NCT02969863|DEVICE|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
48112407|NCT02969863|DEVICE|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
48112408|NCT02969863|OTHER|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
48112409|NCT02969863|OTHER|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
47960198|NCT02560909|BIOLOGICAL|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
47960199|NCT02560909|BIOLOGICAL|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
47960200|NCT00508365|DRUG|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
47960201|NCT00508365|DRUG|Placebo|Placebo capsules to match each dose level will be provided.
47960202|NCT00508365|DRUG|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
47960203|NCT06455176|PROCEDURE|alveolar cleft Grafting from the symphysis|grafting using particulate bone from the symphysis
47960204|NCT06455176|PROCEDURE|alveolar cleft Grafting from the iliac cancellous bone|grafting using iliac cancellous bone
47960205|NCT05802212|DRUG|Metformin intervention for 12 weeks|PCOS patients were treated with metformin orally for 12 weeks, and various indicators related to fertility were observed.
47960206|NCT00899769|GENETIC|protein expression analysis|
47960207|NCT00899769|GENETIC|proteomic profiling|
47960208|NCT00899769|OTHER|immunoenzyme technique|
47960209|NCT00899769|OTHER|laboratory biomarker analysis|
47960210|NCT00899769|OTHER|liquid chromatography|
47960211|NCT00899769|OTHER|mass spectrometry|
48112410|NCT06552702|OTHER|There is no intervention|There is no intervention.
48112411|NCT01385891|DRUG|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
48112412|NCT04926571|DRUG|Dexamethasone Oral|New users of Dexamethasone
48482559|NCT01233843|DRUG|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
48482560|NCT01233843|DRUG|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
47960212|NCT03697473|OTHER|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
47960213|NCT03697473|OTHER|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
47960214|NCT00540774|DEVICE|detection of oral pathology|detection of oral pathology
47960215|NCT03569085|DRUG|Sevoflurane|The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
47960216|NCT03569085|DRUG|Isoflurane|The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
47960217|NCT05412303|OTHER|data collection|age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
47960218|NCT06557707|OTHER|Childhood stress|Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.
48112413|NCT03350542|DEVICE|SYNERGY 48 mm|A drug eluting coronary stent system
48482561|NCT01233843|RADIATION|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
48482562|NCT06026813|DEVICE|test pressure alternating shoes|test pressure alternating shoes
48641986|NCT05696782|DRUG|Durvalumab|Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
48307292|NCT02548104|OTHER|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
48307293|NCT01589068|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
48307294|NCT01589068|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
48307295|NCT01052168|OTHER|skills training|participants will train using different performance goals (based on different metrics)
48307296|NCT02639793|PROCEDURE|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
48307297|NCT05698771|DIETARY_SUPPLEMENT|nicotinamide riboside|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6-10 healthy individuals (3-5 men and 3-5 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using HPLC-MS. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans. Based on these results we will determine the optimal dosing frequency of NRT in healthy individuals.
48307298|NCT05698771|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6-10 healthy individuals (3-5 men and 3-5 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using HPLC-MS. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans. Based on these results we will determine the optimal dosing frequency of NRT in healthy individuals.
48482563|NCT05385848|PROCEDURE|Autologous Platelet-rich Plasma (PRP) Injection|PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
48641987|NCT05696782|OTHER|the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)|Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (
47960219|NCT04049760|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
47960220|NCT04775407|PROCEDURE|blood sampling|IgM og IgG analysis
47960221|NCT02564549|PROCEDURE|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
48112414|NCT02550197|BIOLOGICAL|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
48482564|NCT00078481|DRUG|Idebenone|
48482565|NCT00890552|DRUG|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
47960222|NCT02564549|PROCEDURE|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
47960223|NCT01776411|DRUG|forodesine hydrochloride|
48112415|NCT02550197|BIOLOGICAL|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
48112416|NCT04501276|DRUG|ADG116|For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
48112417|NCT04501276|DRUG|ADG106|For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
48112418|NCT04501276|DRUG|anti PD1 drug|For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
48307299|NCT05137509|DEVICE|Computerized Tomography|Using Computerized Tomography for diagnosis COVID -19 patients
48641988|NCT05696782|DIAGNOSTIC_TEST|COPD Assessment Test (CAT)|Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
48641989|NCT05696782|DIAGNOSTIC_TEST|Modified Medical Research Council (mMRC) dyspnea scale|Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
48641990|NCT06007794|OTHER|JUMP group|patients will have a femoral ultrasound and blood tubes in addition to the blood sample taken as part of the treatment
47960224|NCT01694264|DRUG|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
48641991|NCT05249348|DRUG|PC14586|An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
47960225|NCT01694264|DRUG|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
47960226|NCT04722887|BIOLOGICAL|Alpha-1 15%|Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
47960227|NCT04722887|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion
47960228|NCT03844880|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
47960229|NCT03844880|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
47960230|NCT03724032|DEVICE|HD-tDCS*|Non-invasive brain stimulation (active protocol)
47960231|NCT03724032|DEVICE|Sham HD-tDCS*|Non-invasive brain stimulation (sham protocol)
47960232|NCT04214171|DIAGNOSTIC_TEST|Gait and muscle strength will be assessed|The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
47960233|NCT03922997|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
47960234|NCT04534582|DRUG|HLX14|healthy volunteers receive HLX14 (60mg) once
47960235|NCT04534582|DRUG|EU-Prolia®|healthy volunteers receive EU-Prolia® (60mg) once
48112419|NCT02537769|DEVICE|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
48112420|NCT02537769|PROCEDURE|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
48307300|NCT02425267|OTHER|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
47960236|NCT04534582|DRUG|US-Prolia®|healthy volunteers receive US-Prolia® (60mg) once
48307301|NCT00972244|DRUG|Dapagliflozin|once daily, 12 weeks
48307302|NCT00972244|DRUG|Placebo|once daily, 12 weeks
47960237|NCT04534582|DRUG|CN-Prolia®|healthy volunteers receive CN-Prolia® (60mg) once
47960238|NCT06223737|DIAGNOSTIC_TEST|EOS x-ray|After marking the anatomical landmarks where later on skin markers will be placed, radiopaque markers are attached for the radiographic examination with the EOS system. Images are taken from the positions standing and sitting
47960239|NCT06223737|DIAGNOSTIC_TEST|Motion capture|"The used marker set is the IfB marker set (List et al. 2013), consisting of 40 skin markers on the lower extremities, 7 on the pelvis, 24 on the trunk and 6 on the upper extremities. For the later musculoskeletal modelling the IfB marker set is extended with 7 additional markers on the spinal thoracic processes. All markers will be placed by skilled operators.~The test procedure consists of six trials, namely a standing trial in an anatomic upright position and a calibration motion as well as four basic motion tasks to define functional estimated joint axis, respectively centers (each performed twice).~Tasks: standing, maximal flexion-extension, lateral bending, axial rotation, lifting, holding load, walking, step up, sitting and sit-to-stand"
47960240|NCT04527315|OTHER|Questionnaires|Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
47960241|NCT05464810|DRUG|Letrozole|Given PO
47960242|NCT05464810|DRUG|Simvastatin|Given PO
48112421|NCT01886430|OTHER|Functional electrical stimulation|Functional electrical stimulation for 10 days
48112422|NCT01886430|OTHER|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
48112423|NCT00716144|DRUG|Talarozole|Oral Capsule Once Daily
48112424|NCT02960269|OTHER|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
48112425|NCT02878330|DRUG|MEDI8897|A single IM dose of 50 mg on Day 1 of the study.
48112426|NCT02878330|DRUG|Placebo|A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
48307303|NCT01572532|OTHER|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
48641992|NCT06565936|RADIATION|PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG|Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.
48641993|NCT03191032|OTHER|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
48641994|NCT06654271|DEVICE|Robotic assisted bronchoscopy (RAB)|Participants allocated to the robotic assisted bronchoscopy arm will undergo robotic assisted bronchoscopy with integrated cone beam computed tomography
48307304|NCT01966562|BEHAVIORAL|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
48307305|NCT01966562|BEHAVIORAL|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
48641995|NCT06654271|DEVICE|Electromagnetic navigation bronchoscopy (ENB)|Participants allocated to the electromagnetic navigation bronchoscopy arm will undergo electromagnetic navigation bronchoscopy with integrated digital tomosynthesis
48641996|NCT04850274|BEHAVIORAL|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
48641997|NCT04850274|BEHAVIORAL|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
48641998|NCT04609566|DRUG|brentuximab vedotin|1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks
48641999|NCT04609566|DRUG|pembrolizumab|200 mg given intravenously every 3 weeks
48642000|NCT06351189|DEVICE|Observation|Patients will be filmed in sitting position in the NETTI DYNAMIC chair, either in static mode or dynamic mode for a period of 3 hours each time.
48307306|NCT02588248|DRUG|Peppermint Oil|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).
48482566|NCT00890552|DRUG|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
48642001|NCT06196879|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) formulated solution
48112427|NCT02602106|BEHAVIORAL|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
48642002|NCT06196879|DRUG|Placebo|Verekitug (UPB-101) matching placebo
48112428|NCT00420316|BIOLOGICAL|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
48112429|NCT00420316|BIOLOGICAL|Placebo (primary vaccination study)|Two liquid oral doses of placebo
48112430|NCT00903019|BEHAVIORAL|Tele-Problem-Solving Therapy|Six sessions of tele-PST
48112431|NCT00903019|BEHAVIORAL|In-Person PST|Six sessions of in person PST
48112432|NCT00903019|BEHAVIORAL|Attention control|Six weekly telephone calls
48112433|NCT00143234|DRUG|Amlodipine/atorvastatin single pill|
48112434|NCT06000072|OTHER|Core Exercise Program|Core exercises
48307307|NCT02588248|OTHER|Placebo|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 80 ml of Solution B, also has 0 mg of L-Menthol).
48307308|NCT03645408|DRUG|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
48307309|NCT03645408|OTHER|Sham injection|Subjects received a sham injection with no study drug.
48307310|NCT03384290|DRUG|PRS-060|Drug
48307311|NCT03384290|DRUG|Placebo|PRS-060 Matching Placebo
48307312|NCT01150994|BEHAVIORAL|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
48307313|NCT03587675|DIAGNOSTIC_TEST|EVH test|
48307314|NCT02432001|PROCEDURE|Image-Guided Biopsies|
48307315|NCT01313104|PROCEDURE|colposcopy|Undergo colposcopy
48307316|NCT01313104|OTHER|cervical Papanicolaou test|Undergo cervical Pap smear
48307317|NCT01313104|PROCEDURE|screening method|Undergo anal Pap smear
48307318|NCT01313104|PROCEDURE|screening method|Undergo high resolution anoscopy
48307319|NCT05702684|OTHER|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
48307320|NCT06241599|DRUG|GP/PFLL+AK104|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks)."
48307321|NCT06241599|DRUG|GP/PFLL+placebo|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks)."
48307322|NCT06155266|DIAGNOSTIC_TEST|2 additional whole blood samples of 6mL each will be taken|"As part of the initial blood work-up, 2 additional samples of 6mL each of whole blood will be taken, to which 1mL of Cytodelics® Stabiliser will be added. The tubes will be mixed by inverting 10 to 15 times, incubated at +20°C for 10 minutes, then transported within 1 to 2 hours at 4°C by courier to the CRB at Pitié-Salpêtrière for aliquoting and freezing at -80°C . The expression level of cell surface markers will then be measured in series on an Aurora spectral cytometer, after frozen samples (1 to 2 aliquots) have been sent from the CRB-PSL to CIMI (INSERM U1135) at -80°C approximately once a month.~Any remaining samples sent to CIMI will be destroyed once the analyses have been completed."
48307323|NCT05540613|BEHAVIORAL|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
48307324|NCT05540613|BEHAVIORAL|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
48307325|NCT05540613|BEHAVIORAL|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
48307326|NCT02683915|PROCEDURE|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
48307327|NCT01386580|DRUG|2B3-101|IV every 21 days
48307328|NCT01386580|DRUG|Trastuzumab|IV every 21 days
48307329|NCT01386580|DRUG|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
48307330|NCT01386580|DRUG|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
48307331|NCT03112213|DRUG|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
48307332|NCT03112213|DRUG|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
48307333|NCT05896761|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
48307334|NCT05896761|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
47960243|NCT00478231|DRUG|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
47960244|NCT06533722|DRUG|Gemcitabine, Vinorelbine, or Eribulin|Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
47960245|NCT06547099|DIAGNOSTIC_TEST|Clinical tau PET|Tau PET (flortaucipir)
47960246|NCT06547099|DIAGNOSTIC_TEST|Clinical amyloid test|Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
47960247|NCT06547099|OTHER|Research blood collection|Research blood assays for amyloid, tau, and neurodegeneration
47960248|NCT06547099|OTHER|Cognitive assessments|Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
47960249|NCT01206348|DRUG|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
47960250|NCT04974983|OTHER|Observation of neurological deficits|Observation of neurological deficits
47960251|NCT04944420|BEHAVIORAL|Health enSuite Caregivers|"Advice within Health enSuite Caregivers is organized into 5 priority areas: Taking Care of Yourself (Self-care), Support for You (Support), Supporting the Person Living with Dementia (Characteristics of Persons Living with Dementia), Communication, and Time Management.~Under My Priority Areas, participants will see these in order from highest to lowest need, based on their answers to the needs assessment. Each priority area contains small subtopics and specific tips for things to Try or Avoid. Navigation through the priority areas is user directed and at the participant's discretion. The goal is to make the information they need easy to access."
47960252|NCT06110078|DRUG|Acetazolamide|Oral rinse with acetazolamide (not taken orally)
47960253|NCT05086926|COMBINATION_PRODUCT|Exercises and CSI|"Corticosteroid injection:~The project manager will give the participants one injection with cortisone and lidocaine in the lateral hip at baseline. The procedure will be performed aseptically.~Home exercise program:~The exercise programis based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of 8 weeks. Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled."
47960254|NCT01059591|DRUG|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
47960255|NCT01059591|DRUG|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
47960256|NCT01059591|RADIATION|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
48307335|NCT03087825|PROCEDURE|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
48307336|NCT03087825|PROCEDURE|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
48307337|NCT01958606|OTHER|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
48307338|NCT01958606|OTHER|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
48307339|NCT00122005|BIOLOGICAL|GM-CSF gene transduced allogeneic vaccine GVAX|
48307340|NCT03184298|OTHER|Surveys|The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
48307341|NCT03184298|OTHER|Interviews|These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
48307342|NCT03184298|OTHER|Group Discussions|The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
48307343|NCT03575091|OTHER|Non-individualized|Comparing two experimental interventions with standard care
48307344|NCT03575091|OTHER|Individualized|Comparing two experimental interventions with standard care
48307345|NCT06459531|BEHAVIORAL|Virtual Reality (VR) Therapy|"Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
48307346|NCT06459531|OTHER|Conservative Treatment|"Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
48307347|NCT04357379|BEHAVIORAL|IQOS|Participants will try an IQOS product and then take home the IQOS to sample for one week.
48307348|NCT02002442|OTHER|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
48307349|NCT00000271|DRUG|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
48112435|NCT00886145|DEVICE|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
48112436|NCT01787760|DEVICE|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
48112437|NCT01787760|DEVICE|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
48307350|NCT00000271|DRUG|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
48307351|NCT02742077|DEVICE|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
48307352|NCT03464708|DIETARY_SUPPLEMENT|HMB|Powder form
48307353|NCT03464708|OTHER|Lactose (placebo)|Powder form
48307354|NCT02462304|PROCEDURE|End-Point-Management grid laser|
48307355|NCT02462304|DRUG|ranibizumab|
48482567|NCT00890552|DRUG|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
48112438|NCT01787760|DEVICE|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
48112439|NCT05148780|DIAGNOSTIC_TEST|Nasal Swab Sample|Nasal swab sample will be used to screen participants for detection of viral pathogens. No intervention or study drug will be administered as part of this study.
48307356|NCT02462304|DRUG|Bevacizumab|
48307357|NCT00540722|DRUG|R-(-)-gossypol acetic acid|Given PO
48307358|NCT00540722|OTHER|laboratory biomarker analysis|Correlative studies
48307359|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
48307360|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
48307361|NCT00426049|DRUG|Everolimus|
48307362|NCT03161769|PROCEDURE|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
48307363|NCT03161769|DEVICE|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
48642003|NCT04195685|PROCEDURE|Neurofeedback (NFB)|Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
48642004|NCT05199155|BIOLOGICAL|NerVFIX|Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
48642005|NCT04634331|BEHAVIORAL|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
48642006|NCT04634331|BEHAVIORAL|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
47960257|NCT02856035|OTHER|Neural feedback plus FES and motor training|We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
48112440|NCT06489899|BEHAVIORAL|PEGISUS|PEGISUS is an 8-session intervention for substance use and gender equitable beliefs.
48112441|NCT03691922|PROCEDURE|Erector Spinae Plane (ESP) Block|"1. Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~2. PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
48112442|NCT03691922|PROCEDURE|Periarticular Infiltration (PAI)|"1. Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~2. PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
48112443|NCT06024369|DEVICE|CPM Device|Wearable monitor used for 5 minutes per day.
48112444|NCT05739903|DRUG|DA-1229_01 5/1000mg (Before)|single dose administration (one tablet once a day)
48112445|NCT05739903|DRUG|DA-1229_01 5/1000mg (After)|single dose administration (one tablet once a day)
48307364|NCT05155787|DEVICE|Neurofeedback|Neurofeedback training as a method is going to let the brain producing the alpha signal (8-13 Hz).
48307365|NCT05155787|DEVICE|Shame neurofeedback|shame neurofeedback
48307366|NCT03477565|DEVICE|Kinesio tape lymphatic drainage technique application|Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
48307367|NCT04162886|OTHER|Exercise|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
48307368|NCT03213626|DRUG|Cabozantinib 40 MG|To be taken orally once daily
48307369|NCT03213626|DRUG|Erlotinib 100Mg Tab|To be taken orally once daily
48307370|NCT06125054|DRUG|Ketamine|single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
48307371|NCT06125054|DRUG|Placebo|single dose of placebo (0.9% saline solution i.v. over 40 minutes)
48307372|NCT06125054|BEHAVIORAL|real-time fMRI neurofeedback training|Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated twice.
48307373|NCT06125054|BEHAVIORAL|sham real-time fMRI neurofeedback training|Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated twice.
48307374|NCT03140254|DRUG|Chlorhexidine gluconate|
48307375|NCT03140254|DRUG|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
48307376|NCT03140254|DRUG|Placebo|
48307377|NCT00362063|DRUG|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
48307378|NCT03637842|DRUG|Lorcaserin|Lorcaserin XR 20mg per day
48307379|NCT03637842|DRUG|Placebo oral capsule|Placebo
48307380|NCT01608789|DEVICE|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
48307381|NCT02344628|DRUG|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
48482568|NCT05460559|PROCEDURE|Group A (p-PCNL) procedure|In lithotomy position, ureteric catheter will be inserted allowing injection of contrast to obtain a pyelogram. Shifting the patients in prone position will be done. Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
48482569|NCT05460559|PROCEDURE|Group B (s-ECIRS) procedure|The patients will be in Galdakao-Modified Supine Valdivia (GMSV) position . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out till 30 Fr. Amplatz sheath will be inserted to allow a 26 Fr nephroscope to enter the collecting system. Retrograde intrarenal surgery will be applied simultaneously by a second surgeon using flexible ureteroscopy. The stones will be fragmented with holmium-yttrium-aluminum-garnet (YAG) laser and stone fragments will be evacuated by basket or removed through PCNL tract under nephroscopy.
48482570|NCT04233086|OTHER|No intervention, observational only|No intervention, observational only
48482571|NCT05735964|DRUG|Indocyanine green|Intravenous and endoluminal dosing
48482572|NCT01915342|DEVICE|Focal muscular vibration|
48482573|NCT02187107|DRUG|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
48642007|NCT05570318|DRUG|Polyethylene Glycols|To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
47960258|NCT06474702|DEVICE|'Fitbit charge 4' 'smart-watch'-|smartwatch device that collects physiological measures
47960259|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
47960260|NCT00330746|DRUG|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
47960261|NCT00330746|DRUG|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
48112446|NCT00992238|DRUG|Flavoxate Hydrochloride Tablets, 100mg|
48112447|NCT00992238|DRUG|Urispas® Tablets, 100mg|
48112448|NCT02427698|PROCEDURE|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
48112449|NCT02427698|PROCEDURE|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
48112450|NCT04440124|OTHER|Incremental shuttle walk test|All patients were reviewed by a physiotherapist during their pre-assessment clinic one week prior to surgery to complete an incremental shuttle walk test (ISWT). The ISWT was completed according to a standardised protocol and involved patients walking around 2 cones set up 9 metres apart. Patients were asked to cover the distance between the cones in time to auditory cues. Oxygen levels and heart rate were recorded during the assessment with the use of a portable pulse oximeter. The test was stopped when patients could no longer keep pace with the auditory cues or were too breathless to continue. The total distance mobilised was recorded.
48112451|NCT01203618|DRUG|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
48112452|NCT05874986|OTHER|Resistance training|12-week resistance training intervention
48112453|NCT06677515|OTHER|VR training|The different VR scenarios comprise the following learning goals: 1) Social cognition. Interpreting social situations, understanding others; 2) Social communication. Express oneself, being understood by others; 3) Social competence. Interacting with others The investigators will use an MSI Raider GE78HX with a GeForce RTX4080 12GB GPU, running Windows 11, Unreal Engine 5.4, and the Meta Quest Link app, with a Meta Quest Pro as a PCVR headset connected via a Meta Quest Link cable. The setup works 100% locally, and no Wi-Fi or internet connection is used on the head-mounted-display or PC. The VR program itself does not store any data and will discard all that has happened inside the program, when restarted.
48482574|NCT02187107|DRUG|rtv|100 mg tablet of Norvir®
48482575|NCT02589158|DRUG|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
48482576|NCT02589158|DRUG|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
48482577|NCT05380323|DRUG|LY3541105|Administered SC.
48482578|NCT05380323|DRUG|Placebo|Administered SC.
48642008|NCT05570318|DEVICE|Low volume trans anal irrigation|To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
48642009|NCT03626662|DRUG|AMG 890|Ascending Single Doses of AMG 890
48642010|NCT03626662|DRUG|Placebo|Calculated volume to match experimental drug.
48642011|NCT05226078|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral treatment of insomnia
48642012|NCT06575595|BIOLOGICAL|Tulisokibart|single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)
48642013|NCT00401830|DRUG|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
48642014|NCT00401830|OTHER|Placebo|Matching placebo tablet administered twice daily
48642015|NCT03228537|DRUG|Atezolizumab|Given IV
48642016|NCT03228537|DRUG|Cisplatin|Given IV
47960262|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
47960263|NCT05821478|DRUG|ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy|a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin
47960264|NCT05821478|DRUG|Lymecyclin and corresponding placebos of the experimental arm|12-week course of oral lymecycline.
47960265|NCT05234996|DEVICE|3 Virtual Reality headset (VR Headset),|The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
48642017|NCT03228537|PROCEDURE|Extrapleural Pneumonectomy|Undergo EPP
48307382|NCT02647762|DRUG|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
48307383|NCT02647762|DRUG|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
48307384|NCT02647762|DRUG|Placebo|Placebo tablets, 1mg BID for 12 weeks
48307385|NCT02647762|DRUG|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
48307386|NCT02167568|GENETIC|Genetic|
48307387|NCT05901714|DRUG|Afimetoran|Specified dose on specified days
48307388|NCT05901714|DRUG|Phenytoin|Specified dose on specified days
48307389|NCT05901714|DRUG|Midazolam|Specified dose on specified days
48307390|NCT01869829|DRUG|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
48307391|NCT06215898|OTHER|LSVT-BIG Group via Telerehabilitation|An aerobic supervised exercise protocol was implemented four times a week for four weeks in LSVT-BIG Group via a Tele-rehabilitation model.
48307392|NCT01267097|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
48307393|NCT01267097|BEHAVIORAL|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
48307394|NCT02704728|OTHER|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
48307395|NCT02704728|OTHER|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
48307396|NCT05264571|DIAGNOSTIC_TEST|calscreener|The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.
48307397|NCT05264571|OTHER|Metabolic profile|"The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria"
48307398|NCT05264571|OTHER|optical microscopy|To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture
48307399|NCT05264571|OTHER|RTqPCR|To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
48307400|NCT01105416|BEHAVIORAL|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
48307401|NCT01105416|BEHAVIORAL|ESC|Enhanced standard care
48307402|NCT05307822|OTHER|Non-combusted cigarette variant 42001401|Menthol flavor variant of a non-combusted cigarette (42001401)
48307403|NCT05307822|OTHER|Non-combusted cigarette variant 42001399|Menthol flavor variant of a non-combusted cigarette (42001399)
48307404|NCT05307822|OTHER|Non-combusted cigarette variant 40007386|Menthol flavor variant of a non-combusted cigarette (40007386)
48307405|NCT05307822|OTHER|Non-combusted cigarette variant 42001402|Non-Menthol flavor variant of a non-combusted cigarette (42001402)
48642018|NCT03228537|DRUG|Pemetrexed Disodium|Given IV
48112454|NCT05495334|PROCEDURE|Treatment for Knee OA|Pain management treatment for knee OA.
48112455|NCT02449070|DRUG|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
48307406|NCT05336526|DEVICE|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Bilateral brest augmentation in primary intention
48307407|NCT04478682|OTHER|Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application|Breastfeeding support provided to mothers through WhatsApp messaging application will be maintained for the first 6 months after birth. In the first 1 month, standard information sharing will be made through whatsApp. Also, for the first 6 months, solutions generating shares will be made according to the problems and questions of the mother regarding breastfeeding.
48307408|NCT05966909|DIAGNOSTIC_TEST|Doppler Ultrasound|Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
48307409|NCT03887559|BEHAVIORAL|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
48307410|NCT03887559|OTHER|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
48307411|NCT04284982|BEHAVIORAL|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
48307412|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
48642019|NCT03228537|PROCEDURE|Pleurectomy|Undergo PD
48642020|NCT03228537|RADIATION|Radiation Therapy|Undergo RT
48307413|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
48307414|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
48307415|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
48307416|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
48307417|NCT03963245|BEHAVIORAL|Meaningful Activities and Recovery|"MA\&R is a new rehabilitation program for people with psychiatric disabilities. MA\&R aims to enable participation in everyday activities that are meaningful to the individual.~MA\&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA\&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA\&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery."
48482579|NCT04321798|BEHAVIORAL|Physical Activity|Four group sessions and one individual session delivered over a period of 12 weeks in a primary care setting. Each session includes patient education and support for behaviour change as well as a supervised practical exercise component. The intervention is based upon a combination of self-determination theory and COM-B framework (capability, opportunity, motivation and behaviour) and employs motivational interviewing techniques.
48307418|NCT03963245|BEHAVIORAL|Standard Care and Treatment|"For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support"
48482580|NCT02941510|DRUG|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
48482581|NCT02941510|OTHER|Placebo|Subject(s) will participate in all study activities but will receive placebo.
48482582|NCT02152202|OTHER|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
48482583|NCT02152202|OTHER|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
48482584|NCT03420768|DRUG|BMS-986263|Administered by intravenous (IV) infusion
48482585|NCT03420768|OTHER|Placebo|Administered by intravenous (IV) infusion
48482586|NCT04442724|PROCEDURE|Fiducial marker placement|placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection
48482587|NCT04442724|DIAGNOSTIC_TEST|Multiparametric MRI (mpMRI)|In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.
48482588|NCT04745208|BEHAVIORAL|Simulation based education|high fidelity simulation with moulage
48482589|NCT05185258|DRUG|Enstilar|Topical foam
48482590|NCT05185258|DRUG|Placebo-vehicle|Topical foam
48482591|NCT03163849|DRUG|Sofosbuvir , daclatasvir|Tablets
48482592|NCT03163849|DRUG|Placebos|oral tablets
48482593|NCT05104099|DRUG|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
48482594|NCT03798379|OTHER|Exercise|Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
48482595|NCT03328728|DEVICE|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
48482596|NCT03328728|DEVICE|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
48307419|NCT03575520|DRUG|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
47960266|NCT03243071|BEHAVIORAL|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
48307420|NCT03575520|DRUG|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
48307421|NCT00926055|DRUG|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
48307422|NCT00926055|DRUG|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
48307423|NCT01145027|OTHER|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
48307424|NCT02840487|BIOLOGICAL|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
48307425|NCT02021058|OTHER|Experimental Formula|Experimental formula
48307426|NCT02021058|OTHER|Standard control formula|Standard Infant formula
48307427|NCT06470100|DRUG|0.9% Sodium Chloride Injection|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
48307428|NCT06470100|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
48307429|NCT06470100|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
48307430|NCT05956249|OTHER|Online group therapy|Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.
48307431|NCT05956249|OTHER|Control Group|Without intervention at the first moment, but the control group will receive the intervention after the reassessment of the scales by the scholarship holder was done.
48307432|NCT05160701|OTHER|Medherent|Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
48307433|NCT05553756|DIETARY_SUPPLEMENT|Maltodextrin|200 ml maltodextrin given 2 hours before cesarean section
47960267|NCT03243071|BEHAVIORAL|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
47960268|NCT02489760|BIOLOGICAL|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
48307434|NCT04446234|DRUG|Risperidone|Use medicine according to patients condition
48307435|NCT04446234|DRUG|Aripiprazole|Use medicine according to patients condition
48307436|NCT04446234|DRUG|Ziprasidone|Use medicine according to patients condition
48112456|NCT04943770|PROCEDURE|Spinal cord stimulator implant|"Patients will undergo spinal cord implant procedures as per standard of care and be implanted with the WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system.~Implant Procedures will be followed by a healing period (4-6 weeks) during which patients will be offered therapy (up to one 1Khz). Patients will then be randomised to receive therapy at four different rates (A, B, C, D) in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit."
48112457|NCT04943770|DIAGNOSTIC_TEST|Healing period|Acute opioid pain medications may be continued. No additional scheduled assessments will be completed during this period.
48307437|NCT04446234|DRUG|Amisulpride|Use medicine according to patients condition
48307438|NCT04446234|DRUG|Quetiapine|Use medicine according to patients condition
48307439|NCT01701583|DRUG|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
48307440|NCT04706182|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.
48482597|NCT06106451|BEHAVIORAL|Standard of Care plus Enhanced Patient Education|Patients in this arm will receive a pamphlet explaining the benefits of cardiac rehabilitation. This pamphlet will be given in addition to standard of care patient education. The research team will also call the patient at four specified time points to provide additional information.
48482598|NCT06106451|BEHAVIORAL|Motivational Interviewing Intervention|Patients in this arm of the study will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
48112458|NCT04943770|DEVICE|WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system|Patients will then be randomised to receive therapy (up to 1KHz) at four different rates in no particular order for 3-6 weeks each. Patients will then be followed up at 3 and 6 months after the last randomization visit.
47960269|NCT02489760|BIOLOGICAL|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
47960270|NCT01431989|DRUG|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
47960271|NCT01431989|DRUG|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
48307441|NCT04706182|PROCEDURE|Proximal segment grooving (PSG)|Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
48307442|NCT02496728|BEHAVIORAL|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
48307443|NCT02496728|BEHAVIORAL|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
48307444|NCT02496728|BEHAVIORAL|Social Support|Participants may interact with each other through a private Facebook group.
48307445|NCT02496728|BEHAVIORAL|Educational Materials|Educational materials regarding healthy behaviors.
48307446|NCT00385567|DRUG|PEHRG214|
48307447|NCT05075096|OTHER|No intervention.|No intervention observational study.
47960272|NCT03078244|OTHER|N/A, observational study|
47960273|NCT03185871|DRUG|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
48307448|NCT06255561|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
48307449|NCT05681741|PROCEDURE|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
48307450|NCT04747548|BEHAVIORAL|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
48307451|NCT04747548|BEHAVIORAL|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
48307452|NCT00711399|DEVICE|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
48307453|NCT01251172|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
48307454|NCT01251172|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
48307455|NCT01251172|PROCEDURE|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
47960274|NCT02568774|OTHER|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
47960275|NCT02568774|OTHER|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
47960276|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pilot (two iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screen Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
48307456|NCT01251172|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
48112459|NCT05609032|BEHAVIORAL|Sense2Quit App|Participants in the intervention arm will receive access to Sense2Quit, a smartphone app that links to a smartwatch.
48307457|NCT01251172|OTHER|Laboratory Biomarker Analysis|Correlative studies
48307458|NCT01251172|DRUG|Melphalan|Given IV
48307459|NCT03008408|DRUG|Everolimus|Given PO
48307460|NCT03008408|DRUG|Letrozole|Given PO
48307461|NCT03008408|DRUG|Ribociclib|Given PO
48307462|NCT05169645|OTHER|Physical activity monitoring - Symptom monitoring|"This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~* Physical activity using daily step count~* Additional physical activity entries~* Heart rate~* Sleep quality~* Calories burned~* Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~* Urticaria symptomatology using the urticaria control test~* Symptoms of depression using 2 items from the PHQ 9~* Symptoms of anxiety using two items from the GAD~* Short form self-compassion scale"
48307463|NCT03393364|DRUG|Oxycodone|Patients receive oxycodone for pain control after outpatient urologic surgery.
48307464|NCT03393364|DRUG|Ketorolac|Patients receive ketorolac for pain control after outpatient urologic surgery
48307465|NCT03167580|PROCEDURE|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
48307466|NCT03167580|PROCEDURE|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
48307467|NCT01840176|PROCEDURE|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
48307468|NCT04406246|DRUG|Nitazoxanide 500Mg Oral Tablet|Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.
48307469|NCT01647594|BEHAVIORAL|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
48482599|NCT06106451|BEHAVIORAL|Home-Based Activity Program plus Motivational Interviewing Intervention|Patients in this arm will be evaluated on postoperative day 1 by a physical therapist on the study team. After the evaluation, the physical therapist will use the information from the evaluation to make a tailored home-based physical activity program for the patient. The patient will begin the home-based physical activity program on the day of their 1-month post-operative cardiology clinic appointment. In addition to the home-based activity program, patients will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
48482600|NCT05125731|BEHAVIORAL|Parental absence|Parent does not accompany the child during dental treatment
48482601|NCT05125731|BEHAVIORAL|Parental visual support|The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.
48112460|NCT05952206|DEVICE|Angiolite: Sirolimus-eluting stent|The angiolite stent (iVascular, Barcelona, Spain) is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design containing a durable biostable coating composed of three layers - acrylate to ensure adhesion to the metal surface, fluoroacrylate that carries the sirolimus, and a top layer of fluoroacrylate to control drug release.
48307470|NCT01647594|BEHAVIORAL|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
48307471|NCT02996695|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
48307472|NCT02996695|DRUG|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
48307473|NCT02996695|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
48307474|NCT02996695|OTHER|Placebo|Placebo
48307475|NCT04405804|DRUG|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight \> 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight \> 40 kg"
48307476|NCT00856271|DRUG|olmesartan medoxomil|oral tablets, once daily for 8 weeks
48307477|NCT00856271|DRUG|losartan potassium|capsules, once daily for 8 weeks
48307478|NCT03969901|DRUG|IMI/REL|"Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 2 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
48307479|NCT03969901|DRUG|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
48307480|NCT04060173|DRUG|ABP-671|ABP-671 is an investigational drug
48307481|NCT04060173|OTHER|Placebo|Matching placebo
48307482|NCT03408574|DRUG|Nicotine patch, oral mecamylamine, placebo|Each participant randomly receives one active drug or placebo on each of three study days.
48307483|NCT03212131|DRUG|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
48112461|NCT05952206|DEVICE|Xience: Sirolimus-eluting stent|The Xience stent family (Abbott vascular, California, United States of America), characterized by an L-605 cobalt-chromium (CoCr) is a thin-strut cobalt-chromium everolimus-eluting stent with an open-cell design containing a nonerodable polymer made of PBMA, a reservoir made of a fluorinated copolymer of vinylidene fluoride and hexafluoropropylene monomers. Xience™ stent family includes XIENCE Skypoint™ and XIENCE Sierra™
48307484|NCT03636776|OTHER|Quality of life in metastatic BC|"1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II"
48307485|NCT01803763|DRUG|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
48307486|NCT01803763|DRUG|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
48307487|NCT06377800|OTHER|navicular mobilization along conventional therapy.|"In the prone position, when the foot is stabilized by a towel underneath, navicular mobilization is administered. The therapist's fixing hand wraps the calcaneus, grasps the talus bone, and fixes it.~By placing the thumb on the plantar surface of the foot and pushing with the thumb of the other hand in a dorsal direction, navicular mobilization is provided.~This dorsal glide will be given with 2 sets of 5 minutes. Each session will be of 30 minutes."
48307488|NCT06377800|OTHER|conventional therapy|ultrasound therapy at 1.5 w/cm2 for 7 minutes in continuous mode at a 3MHz frequency. Stretching targets the medial arch and surrounding muscles like calf and tibialis posterior with exercises such as arch lift, heel raise, towel pickup, and toe lift. Additionally, strengthening exercises for intrinsic foot muscles like standing toe curls and towel toe curls are included. Ice pack application for 10 minutes follows
48307489|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
48307490|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan|Pre-treatment scan
48307491|NCT01253421|DRUG|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
48482602|NCT05125731|BEHAVIORAL|Parental presence|Parent accompanies the child during dental treatment
48482603|NCT00726102|OTHER|Meat|2 0z of locally available meat per day
48482604|NCT00726102|OTHER|Cereal|Daily provision of cereal to infants from 6-18 mos
48482605|NCT00726102|OTHER|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
48482606|NCT03515902|DEVICE|mouthguard|mouthguard
48307492|NCT01253421|DRUG|placebo|single-dose placebo capsule
48482607|NCT03515902|DEVICE|mouthguard with desensitizing toothpaste|mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
48482608|NCT04430127|OTHER|No supplementary intervention is performed|No supplementary intervention will be applied
48307493|NCT01461954|DRUG|FST-100|FST-100
48307494|NCT01461954|DRUG|FST-100 Vehicle|FST-100 Vehicle
48482609|NCT03424850|RADIATION|HDR brachytherapy|"* Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%"
48482610|NCT01084434|DIETARY_SUPPLEMENT|probiotic|Bifidobacterium lactis HN019 10\^9 CFU/day 1 sachet once a day for 7 weeks
48482611|NCT01084434|DIETARY_SUPPLEMENT|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
48482612|NCT01084434|DIETARY_SUPPLEMENT|Synbiotic|(Bifidobacterium lactis 10\^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
48482613|NCT01084434|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
48482614|NCT05836415|PROCEDURE|Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation
48482615|NCT04689347|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
48482616|NCT04689347|DRUG|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
48482617|NCT04689347|DRUG|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
48642021|NCT05940246|BEHAVIORAL|Motivational Interviewing|"MI was introduced by William Miller in 1983 as a strategy to promote behavioral changes that would make people drink less. It is well established that MI can be successfully applied to many areas across the medical disciplines. Although the aim of MI is behavioral changes toward a specific goal it is necessary to understand the essence of MI with the four key interrelated elements of the spirits of MI. These are partnership, acceptance, compassion, and evocation. Together they form an equal and respectful collaboration between the MI practitioner and the patient wherein empathy and acknowledgment are important pillars. Moreover, an important message derived from the spirit of MI is the belief that patients in themselves have and know what is needed and get support from the MI practitioner to find it."
48642022|NCT06604598|DRUG|IBU-PCT-DEX|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.
48307495|NCT03699852|RADIATION|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
48307496|NCT03699852|OTHER|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
48307497|NCT03233100|OTHER|FMT|fecal microbiota transplantation
48307498|NCT03972592|DRUG|Topical 0.1% Sirolimus|The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.
48307499|NCT03972592|DRUG|Topical Vehicle|The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
48307500|NCT04937478|OTHER|Observation|Only observational study, no intervention.
48307501|NCT02659111|OTHER|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
48307502|NCT02659111|OTHER|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
48307503|NCT05794932|DIAGNOSTIC_TEST|Stress test|"Diagnostic Test:~* Maximum effort test (CPET) on a cycloergometer~* Leg muscle strength assessment~* Leg muscle mass, composition and water compartments (segmental bioelectrical impedance)~* Spirometry, arterial blood gaz, NO/CO transfer"
48307504|NCT00536978|DRUG|ARA-C|100 mg/m\^2 IV Daily Over 1 Hour for 4 Days
48307505|NCT00536978|DRUG|BCNU|300 mg/m\^2 IV Over 1 Hour for 1 Day
48307506|NCT00536978|DRUG|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
48307507|NCT00536978|DRUG|Cyclophosphamide|1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
48482618|NCT04689347|DRUG|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
48482619|NCT04689347|DRUG|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
48482620|NCT03155737|OTHER|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
48307508|NCT00536978|DRUG|Etoposide|100 mg/m\^2 IV Daily Over 3 Hours for 4 Days
48307509|NCT00536978|DRUG|Fludarabine|30 mg/m\^2 IV Daily Over 1 Hour for 3 Days
48307510|NCT00536978|DRUG|Melphalan|100 mg/m\^2 IV Over 30 Minutes for 1 Day.
48307511|NCT00536978|DRUG|Rituximab|375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.
48642023|NCT06604598|DRUG|IBU-PCT-placebo|Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention
48642024|NCT06604598|DRUG|PCT-placebo-placebo|Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
48642025|NCT06581666|OTHER|No special intervention, all participants will be asked to complete same set of questionnaire.|No special intervention, all participants will be asked to complete same set of questionnaire.
48307512|NCT00536978|OTHER|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
48307513|NCT00536978|RADIATION|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
48307514|NCT00536978|DRUG|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
48482621|NCT03155737|OTHER|Knee health education|A course regarding knee health will be offered to the subjects in this group.
48307515|NCT00536978|DRUG|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
48307516|NCT00536978|PROCEDURE|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
48307517|NCT00421343|DRUG|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
48307518|NCT00421343|DRUG|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
48307519|NCT00421343|BEHAVIORAL|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
48307520|NCT04308512|DEVICE|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
48307521|NCT00092040|DRUG|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
48307522|NCT00092040|DRUG|Comparator: risedronate / Duration of Intervention: 12 mo|
48307523|NCT01850784|DIETARY_SUPPLEMENT|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
48307524|NCT01850784|DIETARY_SUPPLEMENT|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
48307525|NCT00395252|DRUG|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion"
48307526|NCT02083510|DRUG|Colchicine|
48307527|NCT03886727|DEVICE|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
48307528|NCT03886727|DEVICE|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
48307529|NCT02805868|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48307530|NCT02805868|OTHER|Laboratory Biomarker Analysis|Correlative studies
48307531|NCT02805868|BIOLOGICAL|Siltuximab|Given IV
48307532|NCT05874063|DRUG|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
48307533|NCT02404155|DRUG|Clozapine|
48482622|NCT00949988|DRUG|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
48482623|NCT06242743|OTHER|Scalpel blade needles|Patients were assigned to IANB injection by double scalpel blade bevel needles.
48112462|NCT05952206|DRUG|1-month DAPT|"DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Then, only the same oral P2Y12 inhibitor (clopidogrel, prasugrel, and ticagrelor) up to 12 months.~The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC"
48307534|NCT00718419|DRUG|Enzastaurin|"Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression."
48307535|NCT04933305|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic surgical procedure
48307536|NCT00300300|PROCEDURE|Computer-assisted surgery|no description
48307537|NCT05841134|DRUG|Tislelizumab|"Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months."
48307538|NCT05831670|DRUG|KSP-0243|Oral administration
48482624|NCT06242743|OTHER|standard blade needles|Patients were assigned to IANB injection by standard blade bevel needles.
48482625|NCT02617082|RADIATION|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
48482626|NCT01613664|DRUG|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
48482627|NCT01613664|OTHER|no tisseel|the surgeon does not applied tissucol during the surgery
48482628|NCT03738527|DRUG|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
48482629|NCT03738527|DRUG|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
48307539|NCT05831670|DRUG|Placebo|Oral administration
48307540|NCT04183842|DIETARY_SUPPLEMENT|LACIME Anti-hangover|"LACIME Anti-hangover contains the following excipients:~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~LACIME Anti-hangover contains the following plant extracts and vitamin:~* Curcuma longa rhizome extract (Curcuma),~* Panax quinquefolius extract (Ginseng panax),~* Malpighia punicifolia extract (Acerola),~* Silybum marianum extract (Milk thistle),~* Desmodium adscendens extract (Desmodium),~* Pyridoxine chlorhydrate (Vitamin B6)."
48307541|NCT04183842|OTHER|Placebo|"Placebo contains the following excipients :~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~Placebo contains :~- Carrot juice"
48307542|NCT05048823|OTHER|Visceral Osteopathic Techniques|Generalized Discharge Technique of the Peritoneum and Intestinal Wings, Mobilization of the Cecum, Technique for the Root of the Mesentery, Release of the D1-D2 Angle, Technique for the Sigmoid Colon
48307543|NCT05048823|OTHER|Simulated visceral techniques|Simulated visceral techniques in the region of the gastrointestinal system
48307544|NCT03542071|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
48307545|NCT03542071|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
48307546|NCT06198049|OTHER|Pilates Training|This group will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week
48307547|NCT06198049|OTHER|Balance Proprioception Exercises|This group will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
48307548|NCT02600026|DEVICE|DriveCam|Video event monitoring device
48307549|NCT02600026|BEHAVIORAL|Feedback|Video feedback intervention
48307550|NCT04032743|OTHER|ICU treatment|any treatment available by ICU
48307551|NCT03977727|DRUG|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
48307552|NCT03977727|DRUG|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
48307553|NCT03977727|DEVICE|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
48307554|NCT01598857|DRUG|Blisibimod|
48307555|NCT01598857|DRUG|Placebo|
48307556|NCT06168721|OTHER|Expert survey|The expert group will participate in a two-round survey using the Delphi method. The first round aims to assess the relevance of the proposed ICF categories and to identify missing concepts. The second round will aim to confirm the appropriateness of including the selected categories in the ICF core set. Each round will last 3 weeks and the experts will be provided with feedback on the results obtained.
48307557|NCT01300611|DRUG|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
48307558|NCT01300611|DRUG|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
48307559|NCT01707069|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
48307560|NCT05273749|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
48307561|NCT05273749|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
48307562|NCT04969822|DEVICE|iDAScore®|A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
48307563|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
48307564|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
48307565|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
48307566|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
48307567|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
48307568|NCT03516292|DIAGNOSTIC_TEST|Urinary Nerve Growth Factor|The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume \<30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
48307569|NCT03694574|BEHAVIORAL|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, \& Hoffmann, 2011)"
48307570|NCT03694574|BEHAVIORAL|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
48307571|NCT03694574|BEHAVIORAL|control|No instruction
48307572|NCT05832164|OTHER|Multifactorial intervention|"* Adherence to a Mediterranean diet.~* Progressive aerobic and anaerobic exercise program.~* Review of polypharmacy~* Group socialization activities"
48307573|NCT06257238|DEVICE|Fully immersive Head-Mounted Display Virtual Reality|patients are asked to wear the Oculus Quest VR on their heads and to hold the hand controllers by their hands and start the game exercises (Dance loop, Tennis ball and Boxing) with 10 min. for each game with 1 min. rest in between, plus the traditional PT program:(Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
48307574|NCT06257238|BEHAVIORAL|Traditional Physical Therapy Program|patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.
48307575|NCT00878540|DRUG|mirtazapine|30 mg mirtazapine once daily for 7 days
48307576|NCT00344149|DRUG|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
48482630|NCT01017419|BEHAVIORAL|Counseling|Informational Counseling provided after hearing aid fitting
48642026|NCT05958225|BEHAVIORAL|SEE Change Business and Personal Agency Training|"A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals."
48642027|NCT01505426|DRUG|ASP1941|oral
48642028|NCT01505426|DRUG|metformin|oral, concomitant use
48642029|NCT01505426|DRUG|Placebo|oral
48642030|NCT05325944|BEHAVIORAL|Self-guided digital intervention for NSSI|"Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies."
48642031|NCT05325944|BEHAVIORAL|Digital intervention for NSSI with coaching|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.
48112463|NCT05952206|DRUG|12-month DAPT (Standard of care)|DAPT with acetylsalicylic acid and prasugrel or ticagrelor up to 12 months. The type of agent and treatment duration will be selected according to the clinical characteristic of the patient: Acute coronary syndrome or Chronic coronary syndrome and Need for OAC or No need for OAC
48307577|NCT00150371|DRUG|atorvastatin|
48307578|NCT05807724|OTHER|Phone-based fall-prevention strategy|Written education material and Phone-Based Fall-Prevention Strategy
48307579|NCT05807724|OTHER|Home-visit fall prevention strategy|Written education material and Home visit-Based Fall-Prevention Strategy
48497898|NCT01992523|DRUG|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
48307580|NCT04993950|OTHER|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
48307581|NCT04993950|OTHER|SNAGS with thoracic postural correction techniques|thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
48307582|NCT06275971|DEVICE|Dexcom G6|Glycemic control was monitored using CGM data for seven days following cardiac surgery
48307583|NCT06275971|DEVICE|SMBG or venous/arterial blood glucose|Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
48307584|NCT04068467|OTHER|Smartphone App|The application consists of content areas focused on mental health.
48307585|NCT04068467|OTHER|Waitlist Control|Waitlist control
48307586|NCT05590195|DRUG|Preforpro|Preforpro will be investigated to improve vaginal health in women with BV.
48307587|NCT05590195|OTHER|Placebo|Placebo capsules manufactured to look like Preforpro capsules
48307588|NCT05725057|DRUG|AX-158|Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
48307589|NCT05725057|DRUG|Placebo|Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
48307590|NCT04152525|OTHER|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
48307591|NCT01452126|DRUG|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
48307592|NCT01785433|DRUG|Tiotropium HFA BAI 4.5 mcg|
48307593|NCT01785433|DRUG|Tiotropium HFA BAI 9.0 mcg|
48307594|NCT01785433|DRUG|SPIRIVA® HandiHaler® 18 mcg/day|
48307595|NCT01785433|DRUG|Spiriva® Respimat® 5 mcg/day|
48307596|NCT02592603|DEVICE|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
48307597|NCT02005653|DRUG|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
48307598|NCT02005653|DRUG|Albendazole|Experimental
48307599|NCT02005653|DRUG|Doxycycline|Experimental
48497899|NCT01992523|DRUG|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
48642032|NCT05325944|BEHAVIORAL|Active control|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
47960277|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pre-Injury (one iteration)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
48307600|NCT00041223|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|
48307601|NCT04982432|DRUG|Orismilast|Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
48307602|NCT04593940|DRUG|Infliximab|study drug or matching placebo
48307603|NCT04593940|DRUG|Abatacept|study drug or matching placebo
48112464|NCT06677294|PROCEDURE|Placenta remove|This is an observational study. No intervention was performed
48307604|NCT04593940|DRUG|Remdesivir|Standard of Care
48307605|NCT04593940|DRUG|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
48307606|NCT00553059|DRUG|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
48307607|NCT00553059|DRUG|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
48307608|NCT00553059|DRUG|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
48307609|NCT00553059|OTHER|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
48307610|NCT04951336|DIETARY_SUPPLEMENT|FoTv|Fomitopsis Officinalis and Trametes Versicolor
48307611|NCT00887718|BIOLOGICAL|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
48307612|NCT02692339|DRUG|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
48307613|NCT02692339|DRUG|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
48307614|NCT04426123|DRUG|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
48307615|NCT04426123|OTHER|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
48307616|NCT01333267|DRUG|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
48642033|NCT03706833|DEVICE|Edwards PASCAL System|Transcatheter mitral valve repair with the Edwards PASCAL System
48112465|NCT04597125|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection
48112466|NCT04597125|DRUG|NAH therapy|Participants will receive continuous NAH (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily
48307617|NCT01333267|DRUG|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
48307618|NCT01333267|DRUG|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
48307619|NCT03885726|DEVICE|Precision Flow Plus|High velocity nasal insufflation
48307620|NCT03885726|DEVICE|Treatment as Usual|Conventional therapy per institution
48307621|NCT01008254|BEHAVIORAL|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
48307622|NCT01008254|BEHAVIORAL|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
48307623|NCT01008254|OTHER|No musical prompt|No intervention.
48307624|NCT01952197|OTHER|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
48307625|NCT03165136|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
48307626|NCT03165136|DRUG|Placebo|placebo of hydroxychloroquine
48307627|NCT05794516|DRUG|ZB004|ZB004 single doses administered subcutaneously as solution
48307628|NCT05794516|DRUG|Placebo|Placebo single doses administered subcutaneously as solution
48307629|NCT02446730|DEVICE|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
48307630|NCT02446730|DRUG|Prasugel|
48307631|NCT02446730|DRUG|Clopidogrel|
48307632|NCT02460926|PROCEDURE|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
48482631|NCT03902652|PROCEDURE|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
48482632|NCT03902652|PROCEDURE|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
48642034|NCT03706833|DEVICE|Abbott Mitraclip System|Transcatheter mitral valve repair with the Abbott Mitraclip System
48307633|NCT01273688|BEHAVIORAL|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
48307634|NCT01273688|DEVICE|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
48307635|NCT03514303|DIAGNOSTIC_TEST|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
48307636|NCT02149654|DEVICE|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
48112467|NCT04970810|BEHAVIORAL|My Diabetes Goal|Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.
48307637|NCT04140708|BEHAVIORAL|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
48307638|NCT04158908|BEHAVIORAL|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
48307639|NCT03987620|DRUG|Ibrexafungerp|Ibrexafungerp 300mg BID for one day
48307640|NCT03987620|DRUG|Placebo|Matching Placebo
48307641|NCT00500786|BIOLOGICAL|CYT006-AngQb|
48307642|NCT03273738|DIAGNOSTIC_TEST|folate level measurement|the level of folate measured in plasma with homocysteine
47960278|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report thee most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
48307643|NCT03273738|DIAGNOSTIC_TEST|B12|B12 measurement in blood
48307644|NCT05118958|DRUG|KVD824 Prototype 1 modified-release tablet|300 mg modified-release tablet
48307645|NCT05118958|DRUG|KVD824 Prototype 2 modified-release tablet|300 mg modified-release tablet
48307646|NCT05118958|DRUG|KVD824 Immediate-Release Capsule|300 mg immediate-release capsule
48307647|NCT05118958|DRUG|Placebo to KVD824 Prototype 1|Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
48307648|NCT05118958|DRUG|KVD824 Prototype 3 modified-release tablet|300 mg modified-release tablet
48307649|NCT01350037|DRUG|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
48307650|NCT01350037|DRUG|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
48307651|NCT03794141|BEHAVIORAL|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
48307652|NCT03794141|BEHAVIORAL|life style advise|all test persons were given information on healthy diet and life style
48307653|NCT00907881|DRUG|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
48307654|NCT01433627|OTHER|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
48482633|NCT06257316|DRUG|EPHEDrine Hydrochloride 5 mg/ml|"In the present study, the expected rate of recovery of the internal carotid artery according to the dose of the inotropic agent was similar to that in a previous study in which the fraction maintaining mean arterial pressure within 80% of baseline by dose of inotropic agent was 0.9% for the ephedrine 0.1, 0.6, 0.8, 1. 0, 1.2, and 1.4 doses (mg/kg) were 9.9%, 21%, 41%, 47%, 65.5%, and 40%, respectively (Br J Anaesth. 2023 May;130(5):603-610), and it was assumed that the rate of internal carotid artery recovery by inotrope dose would be 90% of that result.~The study will randomize to dose in six cohorts and will include dose group and cohort variables in a logistic regression model to assess the trend between inotropic dose and rate of carotid revascularization after correcting for cohort effects on the outcome variable."
48307655|NCT01433627|OTHER|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
48307656|NCT01433627|OTHER|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
48482634|NCT00920088|DRUG|darunavir/ritonavir|DRV/RTV 600/100mg
48482635|NCT00920088|DRUG|lopinavir/ritonavir|LPV/RTV 400/100mg
48642035|NCT01946100|GENETIC|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
48482636|NCT00920088|DRUG|Midazolam|Midazolam 3mg
48642036|NCT04787042|BIOLOGICAL|ST-067|ST-067 is an engineered variant of human interleukin-18.
47960279|NCT05111925|OTHER|PREPARE Optimized Clinical Assessment|"Participants will complete an optimized set of clinical assessments that may include semi-automated field-expedient functional movement quality, joint ranges of motion, and/or psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
47960280|NCT00875992|DEVICE|ETN with ASLS|Angle stable locking of ETN using ASLS
47960281|NCT00875992|DEVICE|ETN locked with conventional locking bolts|Conventional surgical procedure
47960282|NCT01216761|DRUG|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
47960283|NCT01216761|DRUG|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
47960284|NCT01216761|DRUG|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
47960285|NCT06000332|DEVICE|InogenOne Rove 6 Portable Oxygen Concentrator|overnight use of Portable Oxygen Concentrator, 6 hours minimum
47960286|NCT01435278|DEVICE|Glucosanol|2 tablets taken 3 times a day.
48307657|NCT01433627|OTHER|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
48307658|NCT01433627|OTHER|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
48482637|NCT00920088|DRUG|Dextromethorphan|Dextromethorphan 30mg
48482638|NCT00920088|DRUG|Flurbiprofen|Flurbiprofen 50mg
48482639|NCT00920088|DRUG|GSK2248761|NNRTI under investigation
48482640|NCT06454942|DIETARY_SUPPLEMENT|Nutrient-fortified egg|Consumption of nutrient-fortified eggs with habitual diet
48482641|NCT06454942|DIETARY_SUPPLEMENT|Regular egg with habitual diet|Consumption of regular egg with habitual diet
48482642|NCT05527691|BEHAVIORAL|SupportGroove|"An app-delivered program consisting of positive psychology-based activities, such as expressing gratitude, finding meaning, savoring, and fostering connections. Participants complete daily quests suggested through the app, some of which are completed on their own, and some with their partner."
48482643|NCT04832048|OTHER|Therapeutic physical exercise|"The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF)."
48482644|NCT04832048|OTHER|No physical exercise|No programmed physical exercise
48482645|NCT06617767|OTHER|Reiki|The Reiki group received distant Reiki application to their energy centers for 20 minutes, once a day, for 4 consecutive days, by researchers with Reiki Stage II training under the guidance of a researcher with the Usui Reiki Master \& Teacher degree.
48482646|NCT04593212|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
48642037|NCT04787042|BIOLOGICAL|Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]|Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
48482647|NCT03070691|DRUG|LDE225B|Cream, 2x daily
48642038|NCT04787042|BIOLOGICAL|pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
48642039|NCT04310774|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
47960287|NCT00178633|PROCEDURE|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
47960288|NCT01931592|DRUG|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
48482648|NCT03070691|DRUG|Vehicle|cream, 2x daily
48482649|NCT05604079|DEVICE|Electrolarynx|The device transmits electronic sound source vibrations through soft tissue, either the neck at the level of the glottis, or less commonly the check. Speech is created through movements of articulators including the lips, tongue and jaw.
48482650|NCT01726114|DEVICE|Non-invasive Optical Glucose Monitor™|Test device
47960289|NCT01931592|DRUG|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
47960290|NCT05400746|BIOLOGICAL|Pfs48/45 in Matrix-M|Three doses of Pfs48/45 in Matrix-M at different doses
47960291|NCT03694002|DRUG|Carboplatin|Given IV
48482651|NCT01726114|DEVICE|YSI blood glucose analyzer|Reference device
48482652|NCT05543694|DRUG|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
47960292|NCT03694002|DRUG|Paclitaxel|Given IV
48307659|NCT01433627|OTHER|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
48307660|NCT02274324|DIETARY_SUPPLEMENT|different diets|3 different diets: A\\B\\C
48307661|NCT01512394|PROCEDURE|standard bowel prep|standard bowel prep
48307662|NCT01512394|PROCEDURE|no bowel prep|no bowel prep
48307663|NCT03175380|BIOLOGICAL|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
48307664|NCT01554956|BIOLOGICAL|Human Plasminogen|Eye Drops
48307665|NCT00006708|BIOLOGICAL|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
48307666|NCT00006708|BIOLOGICAL|rituximab|
48307667|NCT00006708|DRUG|carboplatin|
48307668|NCT00006708|DRUG|etoposide|
48307669|NCT00006708|DRUG|ifosfamide|
48307670|NCT04460378|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy with Focus on guided exposure
47960293|NCT03694002|BIOLOGICAL|Ramucirumab|Given IV
47960294|NCT03469934|BIOLOGICAL|Etokimab|Administered on Day 1 over 1 hour by IV infusion
47960295|NCT03469934|DRUG|Placebo|Administered on Day 1 over 1 hour by IV infusion
48307671|NCT04439630|DIETARY_SUPPLEMENT|Nopal fractions|Nopal flour were divided in two fractions and mixed in two different test breads
47960296|NCT05977140|DRUG|CDI-988|SARS-CoV-2 3CL protease inhibitor
47960297|NCT05977140|DRUG|Placebo|matching placebo
47960298|NCT00576784|DRUG|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
47960299|NCT02422303|DRUG|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
47960300|NCT05222737|DEVICE|medency diode laser|intra pocket application of diode laser
47960301|NCT05222737|DRUG|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
47960302|NCT05046899|DEVICE|BIOpH+ Psoriasis Medical Bath|20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
47960303|NCT05046899|DEVICE|Cetaphil Moisturizing Lotion|Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
47960304|NCT03607487|DRUG|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
47960305|NCT03607487|DRUG|Placebo|Placebo tablet administered orally once daily.
47960306|NCT02946528|DEVICE|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
47960307|NCT02946528|DEVICE|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
48307672|NCT04439630|DIETARY_SUPPLEMENT|Test product without the active components|Test product without the active components
48307673|NCT03698604|PROCEDURE|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
48307674|NCT01101568|DRUG|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
48307675|NCT01101568|DRUG|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
48307676|NCT01101568|DRUG|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
48307677|NCT01005732|DEVICE|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and \<5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
48307678|NCT02680847|DRUG|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
48307679|NCT03566693|DEVICE|Dexcom G6 CGM System|continuous glucose monitor
48307680|NCT03566693|DEVICE|Blood glucose meter|Blue-tooth enabled blood glucose meter
48307681|NCT06554938|DEVICE|water pik|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
48307682|NCT06554938|DEVICE|Super floss|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
48307683|NCT00252902|BEHAVIORAL|Behavior change counseling|
48307684|NCT04425421|OTHER|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
48307685|NCT04664920|DEVICE|exergame|motor-cognitive training device
48307686|NCT04775797|DRUG|AB-836|Capsules or Tablets
48307687|NCT04775797|DRUG|Placebo|Capsules of Tablets
48307688|NCT04775797|DRUG|AB-836|Tablets
48307689|NCT04775797|DRUG|Placebo|Tablets
48307690|NCT04775797|DRUG|Nucleos(t)ide Analogue|Tablets
48307691|NCT03105440|OTHER|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
48307692|NCT03105440|OTHER|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
48307693|NCT03105440|OTHER|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
48307694|NCT03105440|OTHER|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
48112468|NCT04970810|BEHAVIORAL|My Diabetes Goal + CommunityRx|"Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations."
47960308|NCT03651544|BIOLOGICAL|GamFluVac|1 dose (0,5 ml)
47960309|NCT05252455|BEHAVIORAL|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
48482653|NCT00775788|PROCEDURE|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
47960310|NCT05578170|DRUG|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
47960311|NCT01122771|DRUG|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
47960312|NCT01122771|DRUG|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
47960313|NCT01122771|DRUG|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
48112469|NCT06677528|OTHER|Questionnaire|Questionnaire on Aortic Valve Disease, HADS-D, SCL-27, MLHFQ
48112470|NCT06676865|DIAGNOSTIC_TEST|the palm print test|"The patient's dominant hand was pressed firmly against a blue ink pad, then onto a white sheet of paper without applying body weight. The palm prints were scored as follows:~* Grade 0: All phalangeal areas visible~* Grade 1: Deficiency in the interphalangeal areas of the 4th and 5th digits~* Grade 2: Deficiency in the interphalangeal areas of the 2nd to 5th digits~* Grade 3: Only the tips of the digits visible The palm print test was scored from 0 to 3. Grades 2 and 3 were considered indicators of difficult intubation."
48112471|NCT05053503|DEVICE|Sparrow Ascent Therapy System|Transcutaneous auricular neurostimulation (tAN)
48482654|NCT05064748|DRUG|Benvitimod|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
48482655|NCT06308835|OTHER|questionnaires|BREF(Batterie d'efficience Frontale), SDMT (Symbol Digit Modalities Test), TMT (Trail making test), Empans verbaux et BNT (Boston naming Test)
48482656|NCT01569347|OTHER|Interviews|Interviews
48112472|NCT05053503|DRUG|Lofexidine|Participants will receive 3 lofexidine 0.18 mg/tablets four times per day (daily dose of 2.16 mg) for 7 days.
48112473|NCT05053503|DRUG|Extended-release injectable naltrexone|Participants will receive extended-release injectable naltrexone based on the clinical site's standard of care.
48482657|NCT01569347|OTHER|Blood sample|Blood sample
48482658|NCT01569347|OTHER|Hair sample|Hair sample
47960314|NCT01122771|DRUG|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
47960315|NCT04239859|BIOLOGICAL|secukinumab|Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.
47960316|NCT04239859|DRUG|Methotrexate|Oral tablet up to 15mg per week
47960317|NCT04239859|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
47960318|NCT04239859|DRUG|Acitretin|Oral capsule up to 25mg per day
47960319|NCT00951548|DIETARY_SUPPLEMENT|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
47960320|NCT00951548|DIETARY_SUPPLEMENT|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
47960321|NCT00285233|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
48112474|NCT00861549|DRUG|Phencynonate hydrochloride|2mg/tablet
48112475|NCT03688659|DRUG|Vancomycin and gentamycin|intravenous
48112476|NCT06487858|DRUG|BGB-R046|Intravenous administration
48112477|NCT06487858|DRUG|Tislelizumab|Intravenous administration
48112478|NCT05930496|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48482659|NCT04081441|DEVICE|Inyenyeri clean cookstove and fuel system|The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
48482660|NCT04081441|BEHAVIORAL|I-ACT (Individual, Agency-Centered Training) workshop|The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
47960322|NCT01269411|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
47960323|NCT01269411|PROCEDURE|therapeutic conventional surgery|Undergo surgery
47960324|NCT01269411|OTHER|pharmacological study|Correlative studies
47960325|NCT01269411|OTHER|laboratory biomarker analysis|Correlative
47960326|NCT02702453|BEHAVIORAL|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
47960327|NCT04292483|DRUG|Nitric Oxide|Inhaled vasodilator to increase pulmonary capillary perfusion
47960328|NCT04261036|DRUG|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
47960329|NCT04261036|OTHER|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
48112479|NCT05930496|OTHER|Exercise Intervention|Receive exercise intervention
48112480|NCT05930496|OTHER|Exercise Intervention|Receive tele-coaching intervention
48112481|NCT05930496|BEHAVIORAL|Health Education|Receive health-related information
48112482|NCT05930496|OTHER|Interview|Ancillary studies
48482661|NCT02456649|DEVICE|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to \< 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as \< 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
48482662|NCT06615843|DEVICE|Participants will receive post-emergency gynecological follow-up at home using a connected health app|The app will facilitate data collection and communication, including logging of vital signs, symptoms (such as pain, bleeding, and vomiting), and uploading of test results. Medical professionals will review the health data twice daily and provide care instructions through instant messaging. The app will also alert the medical team of any urgent updates or deviations from expected health patterns
48482663|NCT01602172|BEHAVIORAL|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
48112483|NCT05930496|OTHER|Questionnaire Administration|Ancillary studies
48112484|NCT05174065|DRUG|Apremilast|Oral tablets
48482664|NCT01602172|OTHER|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
47960330|NCT01262911|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
47960331|NCT01262911|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
47960332|NCT02288052|BEHAVIORAL|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
47960333|NCT02288052|BEHAVIORAL|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
47960334|NCT06050148|BIOLOGICAL|Feacal microbial transplantation (FMT)|Feacal microbial transplantation (FMT)
47960335|NCT06050148|OTHER|Placebo transplantation (PT)|Transplantation with coloured 0,9% NaCl-solution
47960336|NCT01158157|BIOLOGICAL|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
47960337|NCT01949831|OTHER|Assessment of functional ability in combination with follow-up at home|
47960338|NCT01857856|DRUG|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
47960339|NCT01186536|DIETARY_SUPPLEMENT|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
47960340|NCT01186536|DIETARY_SUPPLEMENT|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
47960341|NCT01186536|DIETARY_SUPPLEMENT|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
48112485|NCT05174065|DRUG|Placebo|Oral tablets
48112486|NCT00597038|DRUG|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m\^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m\^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m\^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m\^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m\^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m\^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m\^2."
48112487|NCT05799963|DEVICE|BioMatrix Alpha|Patient will be treated with BioMatrix Alpha
48112488|NCT01779999|OTHER|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
48112489|NCT05105646|PROCEDURE|Knee Arthroplasty, knee revision arthoplasty|Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
48112490|NCT02675309|DRUG|MT-8554|
48112491|NCT02675309|DRUG|rosuvastatin|
48112492|NCT02675309|DRUG|simvastatin|
48307695|NCT03105440|OTHER|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
48307696|NCT03105440|OTHER|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
48307697|NCT05308225|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
48307698|NCT01797198|DRUG|ASP3652|Oral
48307699|NCT01797198|DRUG|Gemfibrozil|Oral
48642040|NCT02714543|DRUG|aloevera juice|aloevera juice to drink twice daily for 3 months.
48642041|NCT02714543|DRUG|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
48642042|NCT02714543|DRUG|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
48642043|NCT02714543|DRUG|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
48642044|NCT02714543|DRUG|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
47960342|NCT05728021|BEHAVIORAL|Recovery Record Aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16."
47960343|NCT05728021|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
48112493|NCT05674357|BEHAVIORAL|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~* Cognitive Behavioral Therapy (CBT)~* Acceptance Commitment Therapy (ACT)~* Mindfulness-Based Cognitive Therapy (MBCT)~* Mindfulness-Based Stress Reduction (MBSR)~* Meaning-Centered Psychotherapy (MCP)~* Cognitive Behavioral Therapy for Insomnia (CBT-I)~* CBT for pain~* CBT for fatigue~* CBT for nausea"
48112494|NCT05674357|BEHAVIORAL|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
48307700|NCT01797198|DRUG|Repaglinide|Oral
48307701|NCT04192448|OTHER|Alcohol Administration|The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
48307702|NCT04192448|OTHER|Mood Induction|The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
48307703|NCT00025532|OTHER|iodine I 131 monoclonal antibody CC49-deltaCH2|
48307704|NCT03811223|DRUG|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
48307705|NCT03811223|DRUG|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
48307706|NCT03657914|PROCEDURE|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
48307707|NCT00002157|DRUG|Thalidomide|
48307708|NCT00086957|BIOLOGICAL|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
48307709|NCT00086957|DRUG|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
48307710|NCT00086957|DRUG|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
48642045|NCT06003621|BIOLOGICAL|Tiragolumab|600mg IV every 21 days from Cycle 1 Day 1
48642046|NCT06003621|BIOLOGICAL|Atezolizumab|1,200mg IV every 21 days from Cycle 2 Day 1
48642047|NCT04980872|DRUG|Miransertib|Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
48642048|NCT06123468|DRUG|Sacituzumab govitecan|10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
48642049|NCT05741710|DRUG|Methylone|Methylone capsules, given orally, once a week for 4 weeks
48642050|NCT05741710|DRUG|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
48642051|NCT03266627|DRUG|cytotoxic t-lymphocytes|adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
48642052|NCT06400511|DRUG|Pimecrolimus 0.3% Ophthalmic Ointment|Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
48642053|NCT06400511|DRUG|Placebo Ophthalmic Ointment|Placebo will be applied twice a day to both eyelid margins.
48307711|NCT03986346|DEVICE|pulsed dye laser|The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
48307712|NCT03986346|OTHER|standardized care|the scar will receive standardized care such as scar massage.
48307713|NCT02191085|PROCEDURE|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
48307714|NCT03158688|DRUG|Dexamethasone|Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
48307715|NCT03158688|DRUG|Daratumumab|Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
48307716|NCT03158688|DRUG|Carfilzomib|"Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity."
48307717|NCT04129684|OTHER|Probiotics|subgingival delivery and lozenges
48307718|NCT01536977|OTHER|quality-of-life assessment|Ancillary studies
48307719|NCT01536977|OTHER|questionnaire administration|Ancillary studies
48307720|NCT01536977|BEHAVIORAL|management of therapy complications|Undergo BBT-I
48307721|NCT01536977|BEHAVIORAL|cognitive assessment|Ancillary studies
48307722|NCT01536977|BEHAVIORAL|educational intervention|Undergo BBT-I
48307723|NCT04446793|DRUG|Onvansertib|15 mg/m\^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
48307724|NCT04446793|BIOLOGICAL|Bevacizumab|5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
48307725|NCT04446793|DRUG|FOLFIRI|FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
48307726|NCT05288634|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
48482665|NCT01731249|BIOLOGICAL|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
48482666|NCT01731249|BIOLOGICAL|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
48482667|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
48642054|NCT06562985|DRUG|BAY3018250 Dose 1|Infusion, single dose
48307727|NCT03859986|DRUG|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle
48307728|NCT03859986|DRUG|ALX-101 Gel 5%|ALX-101 Gel 5%
48307729|NCT00601523|DRUG|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
48307730|NCT00601523|DRUG|Pramipexole|ER 0.375-4,5 mg
48307731|NCT04946136|OTHER|Gait modification|Individualized gait modifications guided by real-time visual feedback of knee load
48307732|NCT03883022|DRUG|with U-VANCO (vancomycin hydrochloride)|1 gm or 2 gm mixed with autogenous cancellous bone graft
48307733|NCT03883022|DRUG|without U-VANCO (vancomycin hydrochloride)|no vancomycin added
48307734|NCT00702052|DRUG|Everolimus|Everolimus tablets
48307735|NCT04032496|BEHAVIORAL|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
48307736|NCT04032496|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
48307737|NCT01096771|DRUG|ClinOleic 20%|96 hour continuous infusion.
48307738|NCT01096771|DRUG|Intralipid 20%|96 hour continuous infusion.
48307739|NCT06190210|DIAGNOSTIC_TEST|electroencephalography|Pre-, per- and postoperative electroencephalography
48482668|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
48482669|NCT00020267|DRUG|interleukin-2|
48482670|NCT00020267|DRUG|MAGE-12 peptide vaccine|
48482671|NCT00020267|DRUG|Montanide ISA-51|
48482672|NCT04517929|OTHER|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
48497900|NCT01118897|RADIATION|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
48497901|NCT03322618|BIOLOGICAL|blood samples|7 tubes of 6 ml (42 ml of blood )
48112495|NCT00630786|DRUG|Panitumumab|Administered by intravenous infusion
48307740|NCT06190210|DIAGNOSTIC_TEST|Near-Infrared Spectroscopy|Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
48307741|NCT06190210|DIAGNOSTIC_TEST|neuronal cell-free DNA|CfDNA which is characterized based on methylation patterns to determine the tissue of origin
48307742|NCT04723108|OTHER|Destek V4 Virtual Reality Headset|The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
48307743|NCT05664048|BEHAVIORAL|Dry heat application|Self- dry heat application on the foot during menstrual period with pain.
48307744|NCT03293277|DRUG|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
48307745|NCT03293277|DRUG|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
48307746|NCT03293277|DRUG|Intranasal Placebo|Intranasal Placebo
48307747|NCT03293277|DRUG|Intravenous Placebo|Intravenous Placebo
48307748|NCT03785717|PROCEDURE|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
48307749|NCT03785717|PROCEDURE|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
48307750|NCT05610462|BEHAVIORAL|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
48307751|NCT05610462|BEHAVIORAL|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
48307752|NCT01967420|BEHAVIORAL|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
48307753|NCT01967420|BEHAVIORAL|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
48307754|NCT03428412|DRUG|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
48307755|NCT03428412|DRUG|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
48307756|NCT04419064|DIAGNOSTIC_TEST|Point of care ultrasound|Tracheal and lung ultrasonography
48307757|NCT00532883|DRUG|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
48307758|NCT00532883|DRUG|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
48307759|NCT00532883|OTHER|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
48307760|NCT03596177|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
48112496|NCT00630786|DRUG|Conatumumab|Administered by intravenous infusion
48307761|NCT03596177|DRUG|Placebo|Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
48307762|NCT02280967|BEHAVIORAL|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
48307763|NCT00210080|DRUG|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
48482673|NCT01957345|OTHER|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
48497902|NCT00050323|DRUG|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
48642055|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, infusion
48642056|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, injection
48112497|NCT05550740|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
48112498|NCT06676462|DEVICE|Video laryngoscopy with visionPRO|Video laryngoscopy to be performed using the visionPRO (HEINE® Optotechnick, Gilching, Germany) during intubation.
48112499|NCT06676462|DEVICE|Video laryngoscopy with Glidescope|Video laryngoscopy to be performed using theGlideScope (Verathon Inc., Bothell, USA) during intubation.
48307764|NCT03737968|DRUG|Durvalumab|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
47960344|NCT06117163|BEHAVIORAL|Collaborative Care Model|"The investigators propose a CCM called Tunawiri, meaning thrive in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics. CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication."
47960345|NCT06125561|OTHER|Probing depth and Clinical attachment loss|CPTIN probe will be used for the clinical examination
48112500|NCT01159704|BEHAVIORAL|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
48112501|NCT01159704|BEHAVIORAL|HIV Counseling and Education Model|"The C \& E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
48307765|NCT03737968|DRUG|durvalumab + tremelimumab|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
48307766|NCT02426658|OTHER|Laboratory Biomarker Analysis|Correlative studies
48307767|NCT02426658|DRUG|Pemetrexed Disodium|Given IV
48307768|NCT02426658|OTHER|Quality-of-Life Assessment|QOL studies
48482674|NCT01381263|BEHAVIORAL|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
48482675|NCT01381263|OTHER|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
48482676|NCT05752916|DRUG|rhTNK-tPA|Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
48482677|NCT05752916|DRUG|Antiplatelet Agents|Patients will receive single antiplatelet therapy-choice at the discretion of the clinician. Aspirin will be the choice of most physicians, some will choose clopidogrel.
48482678|NCT01120769|DRUG|Acetaminophen|single dose
48482679|NCT01120769|DRUG|Placebo|single dose
48482680|NCT01293552|BIOLOGICAL|ANT-1207|single dose application
48482681|NCT01293552|BIOLOGICAL|Vehicle|
48482682|NCT00727077|BIOLOGICAL|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
48482683|NCT00727077|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
48482684|NCT00128934|DRUG|levonorgestrel/ethinyl estradiol|
48482685|NCT01329224|OTHER|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
48482686|NCT05886270|OTHER|Housing Assessment/Safety Modifications|A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
48482687|NCT04953078|BIOLOGICAL|Baiya SARS-CoV-2 Vax 1|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
48642057|NCT06562985|DRUG|BAY3018250 Dose 2 infusion|Infusion, single dose
48642058|NCT06562985|DRUG|BAY3018250 Dose 2 injection|Injection, single dose
48642059|NCT05849662|DRUG|Trametinib|"PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day"
48642060|NCT05849662|DRUG|Azacitidine|"IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day"
48642061|NCT05849662|DRUG|Fludarabine|"IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)"
47960346|NCT01086085|DRUG|Adefovir|Adefovir 10 mg po once daily for 36 weeks
47960347|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
47960348|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
47960349|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
48482688|NCT04351841|OTHER|arabinogalactan|A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
48482689|NCT04351841|OTHER|maltodextrin|A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
48642062|NCT05849662|DRUG|Cytarabine|"IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)"
48642063|NCT04340843|DRUG|Belinostat|Given IV
48642064|NCT04340843|PROCEDURE|Biopsy|Undergo biopsy
48642065|NCT04340843|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48642066|NCT04340843|PROCEDURE|Computed Tomography|Undergo CT
48642067|NCT04340843|DRUG|Decitabine and Cedazuridine|Given PO
47960350|NCT00753571|DRUG|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2"
47960351|NCT05248867|DRUG|Placebo|Placebo solution for injection
48642068|NCT04340843|DRUG|Guadecitabine|Given SC
47960352|NCT05248867|DRUG|AGN-151586|AGN-151586 solution for injection
47960353|NCT00677131|OTHER|Reading the package insert of the drug|package insert of the drug
47960354|NCT00677131|OTHER|Reading the education information provided by the Pharmacy of NTUH|education information
47960355|NCT00677131|OTHER|Oral education provided by the pharmacist|Oral education provided by the pharmacist
47960356|NCT04721171|DEVICE|The Bridge device|he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
48482690|NCT01771315|BEHAVIORAL|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
48482691|NCT01476228|DEVICE|EEG recording|EEG recording
48482692|NCT00167128|DEVICE|hearing aid, Phonak EduLink-FM System|
48307769|NCT06100471|OTHER|Observational study|Observational study in different tissues in identifing new genetic markers related to endometriosis disease
48307770|NCT01099839|DRUG|ASP1941|oral
48307771|NCT01099839|DRUG|Miglitol|oral
48307772|NCT04950881|PROCEDURE|Ultrasound guided vagus nerve block|Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
47960357|NCT06040840|PROCEDURE|BAX|Injection of 30 mL of lidocaine (10 mg/ml) around the median, radial, ulnar and musculocutaneous nerves.
48307773|NCT04950881|DRUG|Bradycardia Treatment|If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
48482693|NCT01049412|DRUG|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
47960358|NCT06040840|PROCEDURE|Tourniquet|Inflation pressure 75 to 100 mmHg above the patient's systolic blood pressure.
48482694|NCT01049412|DRUG|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
48482695|NCT01682148|BIOLOGICAL|Botulinum toxin type A|
48482696|NCT01546649|DRUG|TAP-144-SR(6M)|
47960359|NCT06040840|DRUG|Lidocaine|Axillary block with Lidocaine (10 mg/ml).
47960360|NCT06040840|PROCEDURE|WALANT|"Preparation of a mixture of 20 ml of lidocaine (10 mg/ml) with epinephrine (0.005 mg/ml) + 3 ml Na bicarbonate (84 mg/ml) + 17 ml sterile normal saline.~The ultrasound probe will be placed to obtain a transverse image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 5 ml of the solution posterior and then anterior to the median nerve under the annular carpal ligament.~Then the ultrasound probe will be placed to obtain a longitudinal image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 15 ml of the solution anterior to the median nerve towards the carpal tunnel.~At last, a local infiltration with 5 ml of the solution will be performed around the surgical incision."
48307774|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
48307775|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
48307776|NCT04594239|DEVICE|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
48307777|NCT04594239|DEVICE|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
48482697|NCT01546649|DRUG|TAP-144-SR(3M)|
48482698|NCT00221962|DRUG|Aripiprazole|Open label
48482699|NCT03100890|OTHER|Preoperative training (hospital)|Preoperative hospital training
47960361|NCT06040840|DRUG|Lidocaine + Epinephrine|WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
48112502|NCT06512961|DEVICE|Tissue Flossing|Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
48112503|NCT06512961|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
48482700|NCT03100890|OTHER|Preoperative training (home)|Preoperative in-home training
48642069|NCT04340843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48642070|NCT03304639|BIOLOGICAL|Pembrolizumab|Given IV
48642071|NCT03304639|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48642072|NCT06559150|DRUG|Nebulized Ensifentrine Suspension; 3 mg|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
48642073|NCT06559150|DRUG|Nebulized Placebo Solution|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
47960362|NCT05960552|DIAGNOSTIC_TEST|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.
47960363|NCT05960552|DIAGNOSTIC_TEST|The conventional TEE group|Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
48642074|NCT06141031|DRUG|TTI-101|TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
48642075|NCT05685160|DIAGNOSTIC_TEST|MRI with contrast|MRI of the forefoot with contrast (Gadovist)
47960364|NCT01136148|BEHAVIORAL|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
48112504|NCT06512961|OTHER|Training Protocol|The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.
48112505|NCT06241989|OTHER|health education supported by motivational interviewing|The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
48112506|NCT05700513|COMBINATION_PRODUCT|Capsules containing the combination products|Capsules containing dog-rose, Cranberry leaves, Cranberry Berries, Alfalfa, Fenugreek, Lemon Beebrush, Urtica, and Sumac
48112507|NCT05700513|DRUG|Placebo capsules|Placebo capsules containing maltodextrin
48307778|NCT06302933|BIOLOGICAL|Blood sampling|Blood samples collected from children followed in the Pediacam III ANRS12225 cohort
48307779|NCT05927727|DIAGNOSTIC_TEST|Ultrasound and biyopsy|Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
48307780|NCT04125797|OTHER|Application of adhesive|Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
48307781|NCT02058927|DRUG|Measles vaccine|measles revaccination administered at 12 months from start of ART
48307782|NCT03825601|DIAGNOSTIC_TEST|PET with [11C]Flumazenil|7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
48307783|NCT01752842|DRUG|Fenofibrate|
48482701|NCT05859399|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
48482702|NCT05487365|DEVICE|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
48482703|NCT05487365|OTHER|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
48482704|NCT05365152|DIETARY_SUPPLEMENT|Meal Replacement|Meal Replacement
48482705|NCT02906865|OTHER|Proximal hamstring tendons repair|Proximal hamstring tendons repair
48482706|NCT04252482|DEVICE|CPAP|CPAP useg 3month
48482707|NCT06067451|BEHAVIORAL|SMART GOALS Setting Tool/ Protocol|The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.
48482708|NCT02385201|DEVICE|Senza|Spinal Cord Stimulation
48482709|NCT04243096|BEHAVIORAL|Exercise-based Physical Therapy|Exercises for pain modulation, strengthening, and neuromuscular control
48482710|NCT02477852|DRUG|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
48642076|NCT05685160|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging of the forefoot
48642077|NCT03672981|BEHAVIORAL|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
48642078|NCT03672981|OTHER|Quality-of-Life Assessment|Ancillary studies
48642079|NCT03672981|OTHER|Questionnaire Administration|Ancillary studies
48642080|NCT03672981|BEHAVIORAL|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
48642081|NCT06054815|DRUG|DA-1241|Route of Administration: Oral, with subjects in a fasting state
48642082|NCT06054815|DRUG|Sitagliptin|Route of Administration: Oral, with subjects in a fasting state
47960365|NCT06275347|OTHER|Low-fat normoprotein Controlled Ketogenic Diet.|Frank ketosis will consist of between 650 and 730 kcal/day in 5 meal times, based on commercial and vegetable preparations with low glycemic index, an average of 1.2 g of protein/kg of ideal weight/day, 20 g/day of lipids based on essential fatty acids and less than 60 g/day of absorbable carbohydrates. Patients will receive vitamin and sodium chloride, magnesium oxide, calcium carbonate. Mixed Ketosis one or two intakes of commercial preparations will be progressively replaced by proteins, which will increase by 100 to 150 Kcal/day, supplementation of vitamins and minerals will continue. Transition Stage simple carbohydrates and some complex carbohydrates are added to the previous program, in an approximate proportion of 30 to 35% protein, 25% fat and 40 to 45 % carbohydrates. Integral and maintenance phase: may vary between 1300 and 2250 kcal/day, with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats.
47960366|NCT06275347|OTHER|Hypocaloric Balanced Diet|Balanced hypocaloric diet (caloric intake 20% below basal metabolic expenditure measured by Multifrequency Bioelectrical Impedance or calculated according to the FAO/WHO/UN formula (FAO/WHO/UNU (1985). Energy and Protein requirements. Technical Report Series No 724, World Health Organization, Geneva). The usual caloric intake of a balanced hypocaloric diet is between 1,200 and 1,400 kcal per day with a macronutrient distribution of 50% carbohydrates, 25% proteins and 25% fats, according to the Diogenes study
47960367|NCT02412995|OTHER|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
47960368|NCT02412995|OTHER|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
47960369|NCT02412995|OTHER|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
47960370|NCT02412995|OTHER|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
47960371|NCT02412995|OTHER|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
48112508|NCT03491696|DRUG|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
48112509|NCT01866566|BIOLOGICAL|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
48307784|NCT01752842|DRUG|Placebo for fenofibrate|
48482711|NCT02477852|DRUG|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
48307785|NCT05794152|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
48307786|NCT05794152|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
48307787|NCT05794152|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
48307788|NCT06409052|BEHAVIORAL|Qualitative interviews|Interviews will be conducted for approximately 45-60 minutes
48307789|NCT01290081|OTHER|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
48642083|NCT06054815|DRUG|DA-1241 Placebo|Route of Administration: Oral, with subjects in a fasting state
48482712|NCT02477852|DRUG|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
48482713|NCT02477852|DRUG|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
48482714|NCT01727349|OTHER|HbA1c measurement|
48482715|NCT01727349|OTHER|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
48482716|NCT04786977|OTHER|No Intervention, Observational Study|No Intervention
48482717|NCT03393416|BIOLOGICAL|MASCT-I|The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
48642084|NCT06054815|DRUG|Sitagliptin Placebo|Route of Administration: Oral, with subjects in a fasting state
47960372|NCT02412995|OTHER|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
47960373|NCT02700113|OTHER|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
48307790|NCT00830037|DRUG|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
47960374|NCT02418078|PROCEDURE|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
47960375|NCT00072566|BIOLOGICAL|Bevacizumab|Given IV
47960376|NCT00072566|DRUG|Cyclophosphamide|Given PO
47960377|NCT00072566|OTHER|Laboratory Biomarker Analysis|Correlative studies
47960378|NCT02530684|OTHER|insole|Insoles available on the market without prescription
47960379|NCT02398578|DEVICE|Amphora OAB Device|Cystoscopic procedure to treat OAB
47960380|NCT02562534|DEVICE|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
47960381|NCT06193317|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
47960382|NCT03314194|OTHER|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
48307791|NCT00830037|DRUG|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
48307792|NCT04093739|DEVICE|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
48307793|NCT02064439|DRUG|BAY 59-7939|10 mg tablet once daily for 12 months
47960383|NCT06246175|DRUG|HRS9531|Receive a single dose of HRS9531 injection
47960384|NCT00003710|DRUG|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
48482718|NCT03393416|DRUG|PD1 antibody|"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
48482719|NCT00793741|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
48482720|NCT02457884|OTHER|Temporal Group|Visual Processing Training
48482721|NCT02457884|OTHER|Spatial Group|Spatial visual span training
48482722|NCT02457884|OTHER|Combined Group|Visual processing speed and spatial visual span training
48482723|NCT02457884|OTHER|Control Group|Leisure reading activities
47960385|NCT00003710|DRUG|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
47960386|NCT02544399|OTHER|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
47960387|NCT01696695|DRUG|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
47960388|NCT01696695|DRUG|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
47960389|NCT01485575|PROCEDURE|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
48307794|NCT02064439|DRUG|BAY 59-7939|20 mg tablet once daily for 12 months
48307795|NCT02064439|DRUG|ASA|100 mg tablet once daily for 12 months
48307796|NCT03523832|DRUG|Celecoxib and Pregabaline|Single dose versus repetition dose
48307797|NCT03523832|OTHER|Placebo|Placebo
48307798|NCT05155696|DIETARY_SUPPLEMENT|Experimental: Kefir probiotic drink (supplied by Nourish)|125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.
48307799|NCT05155696|DIETARY_SUPPLEMENT|Placebo comparator|125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
48482724|NCT00789113|DRUG|Extended Release Lamotrigine|
48482725|NCT04355949|DIAGNOSTIC_TEST|Serum vitamin D, vitamin B12, folic acid|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
48482726|NCT04611984|PROCEDURE|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
48642085|NCT06284252|OTHER|Virtual Gaming Simulation|Two-dimensional virtual game simulations that can be played on computers will be developed using the recorded videos. Games will focus on physical examination of the heart, abdomen and respiratory system. The developed games will be played to the intervention group.
47960390|NCT04273204|DIAGNOSTIC_TEST|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
47960391|NCT01760720|BEHAVIORAL|MMT CARE|
47960392|NCT03875339|BEHAVIORAL|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
47960393|NCT02187497|DRUG|Low dose of BIBR 277|
47960394|NCT02187497|DRUG|Medium dose of BIBR 277|
47960395|NCT02187497|DRUG|High dose of BIBR 277|
47960396|NCT02990689|DEVICE|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
47960397|NCT02990689|DEVICE|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
47960398|NCT02990689|DEVICE|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
47960399|NCT00259610|DRUG|methotrexate|varies
47960400|NCT00259610|DRUG|sulfasalazine|varies
47960401|NCT00259610|DRUG|hydroxychloroquine|varies
48307800|NCT02372292|DRUG|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
48482727|NCT04611984|PROCEDURE|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
47960402|NCT00259610|DRUG|etanercept|varies
47960403|NCT06085378|DRUG|Urinary Kallidinogenase for injection|The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
47960404|NCT06085378|OTHER|Placebo|The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
47960405|NCT04148352|DRUG|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
47960406|NCT04148352|OTHER|Placebo|Placebo injected every 2 weeks for 18 weeks
48307801|NCT01724736|DRUG|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
48307802|NCT01724736|DRUG|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
48307803|NCT03139955|DEVICE|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
48482728|NCT05357859|DIETARY_SUPPLEMENT|solubilized vitamin D3|solubilized vitamin D3
48482729|NCT05357859|DIETARY_SUPPLEMENT|medium chain triglyceride|MCT with same amount
48482730|NCT03585907|DIETARY_SUPPLEMENT|MAD|A high fat, low carbohydrate diet
48482731|NCT03585907|DIETARY_SUPPLEMENT|MIND|A combination of the Mediterranean and DASH diets
48482732|NCT01793818|BIOLOGICAL|Tat Oyi|Three injections in the arm
48482733|NCT00180076|DRUG|Budesonide|
48482734|NCT01008384|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units taken orally once a week for 8 weeks
48482735|NCT04303702|DRUG|Continue Oxytocin|The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
47960407|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
47960408|NCT00087607|DRUG|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
47960409|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
47960410|NCT00087607|DRUG|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
47960411|NCT02384486|BEHAVIORAL|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
47960412|NCT02384486|OTHER|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
47960413|NCT01180985|DEVICE|galyfilcon A prototype lens|silicone hydrogel contact lens
47960414|NCT01180985|DEVICE|comfilcon A|silicone hydrogel contact lens
47960415|NCT02242266|DRUG|Tiotropium low dose|inhalation powder, hard PE capsule
47960416|NCT02242266|DRUG|Tiotropium medium dose|inhalation powder, hard PE capsule
47960417|NCT02242266|DRUG|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
47960418|NCT02242266|DRUG|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
47960419|NCT02242266|DRUG|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
47960420|NCT00371826|DRUG|Everolimus (RAD001)|
47960421|NCT00371826|DRUG|Cyclosporine (Calcineurin Inhibitor (CNI))|
47960422|NCT00371826|DRUG|Methylprednisone/prednisone|
47960423|NCT00371826|DRUG|Mycophenolate sodium (MPA)|
47960424|NCT03812471|DEVICE|3D volume acquisitions|2 abdominal volumes 2 thigh volumes 2 head volumes
47960425|NCT03812471|DEVICE|2D standard measurements and 3D volumes acquisitions|"* 1 abdomen circumference measurement~* 1 femur length measurement~* 1 head circumference measurement~* 1 bi-parietal diameter measurement~* 1 abdominal volume~* 1 thigh volume~* 1 head volume"
47960426|NCT00785265|BEHAVIORAL|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
47960427|NCT00785265|BEHAVIORAL|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
47960428|NCT01217801|DRUG|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
47960429|NCT01217801|DRUG|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
48642086|NCT06395324|OTHER|High arabinose diet|Participants will consume a high arabinose diet for 18 consecutive days.
48642087|NCT04506775|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
48642088|NCT04506775|PROCEDURE|Radial artery catheterization|Radial artery catheterization is the standard of care for measuring blood pressure continuously throughout surgery.
47960430|NCT02426944|DRUG|NOAC|Medical arm, patients will be treated by NOAC.
47960431|NCT02426944|DEVICE|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
47960432|NCT01164930|BEHAVIORAL|Acceptance and Commitment Therapy|8-week ACT group
47960433|NCT02989545|DEVICE|Anal Tape|
47960434|NCT03659500|DIAGNOSTIC_TEST|Four-week routine bloodwork|Routine hemodialysis bloodwork done every 4 weeks
47960435|NCT03659500|DIAGNOSTIC_TEST|Six-week routine bloodwork|Routine hemodialysis bloodwork done every 6 weeks
47960436|NCT00531973|DRUG|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
47960437|NCT00531973|DRUG|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
47960438|NCT01921387|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
47960439|NCT01921387|DRUG|Carmustine|Given IV
47960440|NCT01921387|DRUG|Cytarabine|Given IV
47960441|NCT01921387|DRUG|Etoposide|Given IV
47960442|NCT01921387|OTHER|Laboratory Biomarker Analysis|Correlative studies
47960443|NCT01921387|DRUG|Melphalan|Given IV
47960444|NCT01921387|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
47960445|NCT01921387|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
47960446|NCT04996043|DIETARY_SUPPLEMENT|Collagen Peptide Drink|Testing product
47960447|NCT04996043|DIETARY_SUPPLEMENT|Placebo drink|Blank
47960448|NCT01146834|DRUG|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
47960449|NCT01146834|DRUG|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
47960450|NCT01146834|DRUG|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
47960451|NCT01146834|DRUG|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
48112510|NCT01866566|BIOLOGICAL|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
48307804|NCT03037658|OTHER|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
48307805|NCT02267863|DRUG|APTO-253|APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
48307806|NCT06555055|OTHER|CT trochlear thickness change|"Preoperative and postoperative CT scan measuring trochlear thickness of PFJ was defined as distance from deepest part of trochlea and line tangential to the anterior aspect of the femoral cortex. It was assessed on the sagittal cuts.~CT images will be viewed using Sante DICOM viewer version 5.4.2 and image fusion will be done using Overlay multiple image software.~Two observers will measure the angles and the intraobserver and interobserver reliabilities will be assessed for consistency by the intraclass correlation coefficient (ICC) and reliability coefficient using the SPSS software"
48307807|NCT02500199|DRUG|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
47960452|NCT04747080|DRUG|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
47960453|NCT04747080|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
47960454|NCT00318448|DRUG|Zolpidem (SL800750)|
47960455|NCT03059758|OTHER|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
47960456|NCT03969732|DRUG|1. amyloid PET；2. T807 PET|"1. Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
47960457|NCT03407625|OTHER|Foley bulb plus Oral Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States."
48307808|NCT01574222|BIOLOGICAL|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
48307809|NCT03253991|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
48307810|NCT01896037|DIETARY_SUPPLEMENT|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
48307811|NCT03899194|DIETARY_SUPPLEMENT|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
48307812|NCT03899194|DRUG|escitalopram|escitalopram 10-20 mg/d
48307813|NCT01428063|DRUG|Daclatasvir|
47960458|NCT03407625|OTHER|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
48482736|NCT04303702|OTHER|Discontinue Oxytocin|Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
47960459|NCT03745131|OTHER|Blood draw|Blood draw to obtain serum to determine anti-orthopox antibody titres.
47960460|NCT06558123|PROCEDURE|block|Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block
48307814|NCT01428063|DRUG|Asunaprevir|
48307815|NCT01428063|DRUG|Pegylated interferon alfa-2a|
48482737|NCT06389513|BIOLOGICAL|MCV4|4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
47960461|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
48112511|NCT01866566|BIOLOGICAL|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
48307816|NCT01428063|DRUG|Ribavirin|
48307817|NCT04352322|DIETARY_SUPPLEMENT|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
47960462|NCT00795145|DRUG|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
47960463|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
48112512|NCT01866566|BIOLOGICAL|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
48307818|NCT04352322|DIETARY_SUPPLEMENT|Placebo|oral solution with no active ingredients
48307819|NCT04527224|DRUG|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
48307820|NCT04065230|DRUG|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
48307821|NCT04266860|OTHER|Experimental - Test Results and Education|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case."
48642089|NCT04381559|BEHAVIORAL|Cognitive Behavioural Therapy|In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.
47960464|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
47960465|NCT00795145|DRUG|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
48307822|NCT01655264|BEHAVIORAL|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
48307823|NCT01655264|BEHAVIORAL|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
48307824|NCT04446936|PROCEDURE|Flap covering for pressure ulcer|Flap covering for pressure ulcer
47960466|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
47960467|NCT00795145|DRUG|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
47960468|NCT02419105|DRUG|Testosterone|transdermal gel, 75 mg daily
47960469|NCT02419105|DRUG|Colecalciferol|drink solution, 24000 IU once per month
47960470|NCT02419105|DRUG|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
48112513|NCT05947305|PROCEDURE|Surgical Blade|Using a 15c blade to de-epithelialize the soft tissue extra-orally
48112514|NCT05947305|PROCEDURE|Mucotome|Using Megagen Mucotome to de-epithelialize the soft tissue intra-orally
48112515|NCT05947305|PROCEDURE|Diamond Bur|Using a surgical diamond bur to de-epithelialize the soft tissue intra-orally
48307825|NCT02773719|OTHER|True Biofield therapy|
48112516|NCT05947305|PROCEDURE|Er:YAG Laser|Using an Er:YAG Laser to de-epithelialize the soft tissue intra-orally
48112517|NCT02431663|DRUG|Ketamine|Intravenous administration in continuous
48307826|NCT02773719|OTHER|Fake Biofield therapy|
48307827|NCT00631488|DRUG|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
48307828|NCT00631488|DRUG|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
47960471|NCT02419105|DRUG|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
47960472|NCT01065597|DEVICE|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
47960473|NCT03844932|DRUG|ST-0529|ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
47960474|NCT01355757|DEVICE|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
47960475|NCT01355757|DRUG|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
47960476|NCT04532047|DRUG|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
47960477|NCT05663567|BEHAVIORAL|solution oriented approach|Implementing a solution-focused approach to support breastfeeding
47960478|NCT02652832|DEVICE|non invasive brain stimulation|non invasive brain stimulation
47960479|NCT02916589|DIETARY_SUPPLEMENT|Diet|
48112518|NCT05025267|OTHER|Medical Food: Peptide-Based Enteral Formula|Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
48112519|NCT04263480|DRUG|Carfilzomib + Ibrutinib|"Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
48112520|NCT04263480|DRUG|Ibrutinib|"Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
48307829|NCT00631488|DRUG|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
48307830|NCT00631488|DRUG|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
48307831|NCT00631488|DRUG|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
48307832|NCT00631488|DRUG|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
48307833|NCT01848964|DEVICE|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
48307834|NCT06291103|DRUG|Conversion to Belatacep|CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
48307835|NCT06291103|DRUG|Standard of care treatment (SOC regimen) with Tacrolimus|Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
48307836|NCT03091062|DEVICE|Vest® Airway Clearance System|High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
48307837|NCT03091062|DEVICE|Monarch™ System|Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
48307838|NCT02549911|OTHER|HIPEC,Chemotherapy AND surgery|"1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
48307839|NCT06141213|DIAGNOSTIC_TEST|Ultrasound screening|Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.
48642090|NCT04381559|BEHAVIORAL|Applied Relaxation|12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
47960480|NCT04302896|DRUG|dolutegravir oral tablet 50mg|"Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets \[GlaxoSmithKline\] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide."
48482738|NCT06368557|BEHAVIORAL|CoolMinds: Internet-based cognitive behavioral therapy (iCBT)|The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.
48482739|NCT01815112|OTHER|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
48482740|NCT01815112|OTHER|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
48642091|NCT03735979|DRUG|Argatroban|Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
48112521|NCT03276104|PROCEDURE|IOL repositioning|Intraocular lens repositioning by scleral suturing
48482741|NCT01407224|BEHAVIORAL|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
48482742|NCT00002351|DRUG|Indinavir sulfate|
48307840|NCT03341897|PROCEDURE|endovasculer embolization of varicocele|"Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting \< 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise."
48307841|NCT00830661|PROCEDURE|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
48307842|NCT00830661|PROCEDURE|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
48307843|NCT03527446|BEHAVIORAL|Sprint Interval Training|The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
48307844|NCT04039685|OTHER|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
48307845|NCT04039685|OTHER|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
48642092|NCT03735979|DRUG|Eptifibatide|GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
48642093|NCT03735979|DRUG|Placebo|IV placebo solution
48642094|NCT04718675|DRUG|KB-0742|Oral capsules
48642095|NCT06126276|PROCEDURE|Biopsy|Undergo tumor biopsy
48642096|NCT06126276|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48642097|NCT06126276|PROCEDURE|Computed Tomography|Undergo CT scan
48642098|NCT06126276|PROCEDURE|Echocardiography|Undergo ECHO
48642099|NCT06126276|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48642100|NCT06126276|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48642101|NCT06126276|DRUG|Neratinib Maleate|Given PO
48642102|NCT06126276|DRUG|Palbociclib|Given PO
48642103|NCT05608291|DRUG|Fianlimab|Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
48307846|NCT04039685|OTHER|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
48307847|NCT04486443|BEHAVIORAL|music therapy|patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
48307848|NCT05858944|DRUG|Intensive Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
48307849|NCT05858944|DRUG|Standard Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
48307850|NCT01180413|DRUG|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
48307851|NCT01180413|DRUG|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
48307852|NCT01180413|DRUG|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
48642104|NCT05608291|DRUG|Cemiplimab|Cemiplimab will be administered by IV infusion Q 3 weeks
48642105|NCT05608291|DRUG|Pembrolizumab|Pembrolizumab will be administered by IV infusion Q 3 weeks
48642106|NCT05608291|DRUG|Placebo|Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
48642107|NCT06567327|DRUG|Danuglipron|Danuglipron oral tablets
48642108|NCT06567327|DRUG|Atorvastatin|Atorvastatin oral tablets
48642109|NCT06567327|DRUG|Rosuvastatin|Rosuvastatin oral tablets
48642110|NCT05930067|DEVICE|Pinnacle Gription Acetabular Cup|Pinnacle Gription cup with Corail/ACTIS stem
48642111|NCT05930067|DEVICE|Pinnacle Dual Mobility|Bi-Mentum AltrX liner
48642112|NCT06651190|OTHER|Pain Caregiver Resource (PainCaRe)|The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home. The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed. Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents. The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT. Please find attached the study protocol for reference.
48642113|NCT04835428|DEVICE|Treatment Group: AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
48642114|NCT04835428|DEVICE|Control Group: PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
48307853|NCT01180413|DRUG|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
48307854|NCT02918188|DRUG|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
48307855|NCT02734602|DRUG|Ketamine|Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
48307856|NCT02166593|DRUG|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
48307857|NCT02166593|DRUG|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
48307858|NCT06512818|DIETARY_SUPPLEMENT|Psiguavin|A purified guava extract will be used, enriched in psiguavin
48482743|NCT01131299|OTHER|Placebo|2 tablets PO 3 times a day for 12-14 weeks
48307859|NCT06512818|DRUG|Placebo|Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
48307860|NCT00398710|DRUG|Perifosine|150 mg daily (100 mg daily in case of dose reduction)
48307861|NCT02200458|DEVICE|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
48482744|NCT01131299|DRUG|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
48307862|NCT00368134|DRUG|Vildagliptin|
48307863|NCT02327286|BEHAVIORAL|Promote and support healthy behaviors|"* Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~* Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~* Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~* A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
48307864|NCT00011765|DRUG|Fluoxetine|
48307865|NCT03971461|DRUG|Lutathera|administered intravenously every 8 weeks for a total of 4 doses
48307866|NCT06416059|BEHAVIORAL|Mobile Application|The mobile application is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety,
48307867|NCT05599126|DRUG|Mianserin|Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
48307868|NCT05599126|DRUG|Lorazepam|Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
48307869|NCT03744676|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
48307870|NCT00756587|DEVICE|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
48307871|NCT00756587|DEVICE|Bottle Feeding|receiving all feeding by bottle
48307872|NCT03801304|DRUG|Atezolizumab|Atezolizumab in IV infusions
48307873|NCT03801304|DRUG|Vinorelbine|Vinorelbine capsules
48307874|NCT03472378|DRUG|DFN-15|Oral Solution of 4.8 mL containing 120 mg of DFN-15
48307875|NCT03472378|OTHER|Placebo|Oral Solution of 4.8 mL containing 0 mg of DFN-15
48307876|NCT04752579|OTHER|Pilates exercise program|"The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts \& Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes."
48482745|NCT00427674|DRUG|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
48482746|NCT01739634|DRUG|CASAD|CASAD is provided in 500mg capsules.
48642115|NCT03334305|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
48642116|NCT03334305|DRUG|Dose-intensified TMZ|After chemoradiation, subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
48642117|NCT03334305|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Prior to chemoradiation, enrolled subjects will undergo a mobilized leukapheresis for collection of PBSCs and PBMCs for generation of DCs. One group will receive recommended dose of \> 2 x 106 CD34+ HSCs/kg. Subjects enrolled in Group B will receive HSCs during TMZ Cycle 6 before receiving DC vaccine and T-cell infusion.
48112522|NCT03276104|PROCEDURE|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
48307877|NCT06330272|PROCEDURE|Application of dental mousse based on CPP-ACPF|"Treatment will begin with pumice prophylaxis of incisors with IMH lesions. After this step, the teeth will be dried before applying dental foam based on CPP-ACPF (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).~The application of Tooth Mousse PlusTM to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute, which will be timed. The application will be carried out once a week, for four consecutive weeks."
48307878|NCT05673005|DEVICE|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
48307879|NCT02504476|DRUG|AMG 581|Active drug
48307880|NCT02504476|DRUG|Placebo|Placebo
48307881|NCT02504476|DRUG|Midazolam|Interaction
48307882|NCT03537820|OTHER|questionnaire|questionnaire EVAN-G
48307883|NCT03587558|DRUG|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
48307884|NCT03587558|DRUG|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
48307885|NCT03359005|DRUG|Vincristine|vincristine 1.5mg/m2 iv D1,D8
48307886|NCT03359005|DRUG|Temozolomide|Temozolomide 100mg/m2/d iv on days 1-5.
48307887|NCT01290484|DRUG|Sildenafil|Sildenafil oral tablet three times daily
47960481|NCT04302896|DRUG|emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg|"Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets \[Gilead\] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide."
48112523|NCT01443117|BIOLOGICAL|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
48307888|NCT03000309|DRUG|Apremilast|
48307889|NCT02577250|DRUG|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
48307890|NCT03653702|DRUG|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
48307891|NCT03695432|BIOLOGICAL|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
48307892|NCT03695432|DIETARY_SUPPLEMENT|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
48307893|NCT03695432|OTHER|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
48307894|NCT03695432|OTHER|Placebo probiotic|Capsul
48307895|NCT05179031|DIETARY_SUPPLEMENT|First Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
48307896|NCT05179031|DIETARY_SUPPLEMENT|Second Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
48307897|NCT05179031|DIETARY_SUPPLEMENT|Third Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
48307898|NCT05179031|DIETARY_SUPPLEMENT|High protein tube feed|Nutritional product containing 25 g of available carbohydrates
48307899|NCT05179031|DIETARY_SUPPLEMENT|High-protein tube feed with additional amino acid|Nutritional product containing 25 g of available carbohydrates
48307900|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients|Nutritional product containing 25 g of available carbohydrates
48307901|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients (new formula)|Nutritional product containing 25 g of available carbohydrates
48112524|NCT01443117|BIOLOGICAL|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
48112525|NCT01443117|BIOLOGICAL|Placebo Vaccine|Administered as a 0.5 mL IM dose
48307902|NCT05179031|DIETARY_SUPPLEMENT|ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
48307903|NCT05179031|DIETARY_SUPPLEMENT|Plantbased ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
48307904|NCT00905879|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
48307905|NCT05112458|OTHER|Cope 360 mobile health application|Cope 360 is a mHealth (mobile health) app designed to support caregivers of children with cancer with symptom tracking, medication management, and emergency preparedness. We will evaluate Cope 360 via a pilot, randomized control trial in which some caregivers will receive the app and some will not. The purpose of this study is to assess: 1) feasibility of caregiver use over extended period of time, 2) acceptability of the mHealth tool by caregivers in a real-world setting, 3) impact of the mHealth tool on caregiver self-efficacy, mastery of caregiving skills/knowledge, and caregiver stress, and 4) effect on healthcare utilization of the child with cancer (i.e. preliminary data about sick visits and ED encounters).
48307906|NCT05112458|OTHER|Usual care|Caregivers of children with cancer will receive the usual clinical care provided to our patient population.
48307907|NCT01959386|DRUG|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
48307908|NCT00426985|DRUG|Ketoprofen Topical Patch 20%|
48307909|NCT04680286|DRUG|Methadone Hydrochloride|Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.
48112526|NCT02571387|BEHAVIORAL|Mindfulness-based intervention|
48112527|NCT02571387|BEHAVIORAL|Sham meditation|
48112528|NCT01075217|DRUG|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
48307910|NCT04680286|OTHER|Placebo|Single dose, intravenous bolus. Administered as the experimental arm.
48307911|NCT05473624|DRUG|HRS-1167|Participants will receive HRS-1167.
48307912|NCT01064453|DRUG|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
48307913|NCT02739594|DRUG|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
48307914|NCT02739594|DRUG|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
48307915|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
48307916|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
48307917|NCT00848692|DRUG|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
48307918|NCT00848692|DRUG|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
48307919|NCT01444495|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
48307920|NCT01444495|PROCEDURE|Surgery|Total mesorectal excision of rectal cancer
48307921|NCT03559244|OTHER|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
48307922|NCT03559244|OTHER|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
48112529|NCT01075217|DRUG|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
48112530|NCT06013878|OTHER|Transfer Training with clinician|Participants will undergo transfer training with a clinician who is an expert on assisted transfer techniques if they are found to have skill deficits during the study. After training, a transfer assessment will be conducted to examine if the transfer skills of the caregiver have improved
48112531|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
48112532|NCT00892593|DEVICE|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
48307923|NCT02597023|DRUG|MitoQ|Mitoquinone pill, 20 mg/day
48307924|NCT02597023|DRUG|Placebo|Placebo pill with inert excipient, 1 time/day
48307925|NCT03488472|DEVICE|NovoTTF-200A|Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.
48307926|NCT03488472|RADIATION|Stereotactic Radiosurgery (SRS)|SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
48307927|NCT05509205|OTHER|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
48307928|NCT02232672|DEVICE|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
48307929|NCT05636579|BIOLOGICAL|EO2002|Intracameral injection of magnetic human corneal endothelial cells (EO2002)
48307930|NCT05636579|DRUG|Ripasudil|Daily use of Ripasudil drops
48307931|NCT01364571|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
48307932|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
48307933|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
48112533|NCT01029717|DEVICE|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
48112534|NCT01029717|DEVICE|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
48112535|NCT01029717|DEVICE|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
48112536|NCT04998799|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge
48112537|NCT02762006|DRUG|Durvalumab|Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
48307934|NCT01364571|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
48307935|NCT01364571|PROCEDURE|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
48307936|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
48307937|NCT01364571|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
48307938|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
48307939|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
48307940|NCT01364571|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
48307941|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
47960482|NCT04302896|DRUG|tenofovir disoproxil fumarate oral tablet 300mg|"Viread® (tenofovir DF, TDF) is a nucleotide analog HIV-1 reverse transcriptase inhibitor and a hepatitis B reverse transcriptase inhibitor FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents and for the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg. Viread® 300mg tablets \[Gilead\] are almond-shaped, light blue, film-coated tablets containing 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with GILEAD and 4331 on one side and with 300 on the other side. The inactive ingredients in each tablet are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Viread® 300mg tablets are coated with Opadry II Y-30-10671-A, which contains FD\&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin."
47960483|NCT04302896|DRUG|lamivudine oral tablet 300mg|"Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets \[Apotex Inc.\] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide."
47960484|NCT04680091|DRUG|Pyrotinib Maleate|single oral dose, 400 mg, fed.
47960485|NCT04680091|DRUG|Efavirenz|single oral dose, 600 mg, fasted, at bedtime.
47960486|NCT01228643|BIOLOGICAL|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
47960487|NCT01228643|DEVICE|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
48307942|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
47960488|NCT06154187|DRUG|PBK_L2201|Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
47960489|NCT06154187|DRUG|Placebo|Placebo was formulated similar to abaloparatide-SC.
47960490|NCT00310167|RADIATION|radiation therapy|
47960491|NCT02025322|BEHAVIORAL|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
48112538|NCT02762006|DRUG|Tremelimumab|Tremelimumab is a CTLA-4 monoclonal antibody.
48112539|NCT01845532|DRUG|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25\~0.5% lidocaine, 0.125% bupivacaine)
48112540|NCT01845532|DRUG|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
47960492|NCT04696055|DRUG|Pembrolizumab|Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
48112541|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
48112542|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
48112543|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
48112544|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
48112545|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
48307943|NCT00193440|DRUG|Rituximab|
48307944|NCT00193440|DRUG|CHOP|
48307945|NCT00193440|DRUG|CVP|
48307946|NCT00193440|DRUG|Ibritumomab Tiuxetan|
48307947|NCT03871140|OTHER|diagnosis|therre is no intervention diagnosis or treatment for patients
48307948|NCT01300468|DRUG|PHA-848125AC|
48112546|NCT01924767|DRUG|BI 10773 Placebo|po taken fasting with 240 mL water
48307949|NCT00859898|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
48307950|NCT00859898|DRUG|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
48307951|NCT00859898|DRUG|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
48307952|NCT00859898|DRUG|dapagliflozin matching Placebo|Tablets
48307953|NCT00859898|DRUG|metformin HCl Modified Release matching Placebo|Tablets
48112547|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
48112548|NCT01924767|DRUG|BI 10773|po taken fasting with 240 mL water
48307954|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.
48642118|NCT03334305|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 6 and with DC vaccine #8, an infusion of T-cells will be administered to all subjects.
47960493|NCT04696055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
47960494|NCT00229593|DRUG|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
48642119|NCT03334305|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
47960495|NCT00229593|DRUG|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
47960496|NCT05457426|PROCEDURE|robotic right hemicolectomy with CME|The distribution of trocars was placed according to the position of Intuitive Surgical Inc. for robotic colectomy. The robot was set to come and dock from theright shoulder of the patient. Three robotic 8-mm trocars (R1, R2 and R3) and two 12-mm trocars (camera and assistant port) were used for the robotic procedure. One working arm carrying a monopolar cautery hook for dissection was located in the left upper quadrant port (R1). The other two working arms carried bipolar forceps in the suprapubic port (R3), and Cadiere's fenestrated forceps in the right lower quadrant port (R2) that was used to keep the superior mesenteric axis in traction. After gentle cephalad traction on the transversemesocolon with the grasp in R2, the assistant grasped the ileocecal valve through the assistant port to put the ileocolic vascular pedicle on tension and the ileocolic vessels were identified and lifted up with R3.
47960497|NCT02256657|BEHAVIORAL|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
47960498|NCT03602820|BIOLOGICAL|AAV2-hRPE65v2|
47960499|NCT01880502|DRUG|Belviq 10mg|Belviq 10mg single dose administration
47960500|NCT01880502|DRUG|Belviq 20mg|Belviq 20mg single dose administration
48307955|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS) sham|"TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle."
48307956|NCT06512441|DRUG|Vitamin B6 Tablets|The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
48307957|NCT06512441|DRUG|Placebo|The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
48307958|NCT01640587|DRUG|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
48307959|NCT01640587|DRUG|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
48642120|NCT06433557|DRUG|Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections|For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.
47960501|NCT01880502|DRUG|Placebo|Placebo single dose administration
47960502|NCT01839123|DEVICE|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
47960503|NCT01839123|DEVICE|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
47960504|NCT05087108|DEVICE|OsciPulse system|The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.
47960505|NCT05087108|DEVICE|Reference Therapy 1|The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
48307960|NCT04137133|DIAGNOSTIC_TEST|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
48307961|NCT02688842|DEVICE|Rapamycin target-eluting coronary stent systems (38mm)|
48307962|NCT00245193|BEHAVIORAL|Motivationally-Enhanced Interpersonal Psychotherapy|
48307963|NCT01474746|DRUG|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
48642121|NCT06138067|BEHAVIORAL|High intensity approach|PEM, cancer center support services material, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the participants appointment with the medical oncologist. If enrolled in a clinical trial, the patient navigator will call the participant biweekly, or more often if they are working to resolve any needs identified in the needs assessment) until the participant is successfully enrolled in the therapeutic clinical trial. The patient navigator will call the participant once weekly for 4 weeks, or less than 4 weeks in other cases including withdrawal from the clinical trial or this navigation study, disease progression, or death. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
48307964|NCT01474746|DRUG|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
48307965|NCT05918874|OTHER|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
48307966|NCT05629533|DEVICE|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
48307967|NCT04293042|BIOLOGICAL|BK-virus specific CTLs|"HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
48307968|NCT03659747|DIETARY_SUPPLEMENT|Probiotic|- 6 g sachet containing probiotic powder (1.8 x 10\^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
48307969|NCT03659747|DIETARY_SUPPLEMENT|Lactrase|- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
48307970|NCT03659747|OTHER|Placebo|- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
48307971|NCT01893190|DRUG|Nimodipine|Based upon Investigator Judgement
48307972|NCT01893190|DRUG|Nimodipine Microparticles|Based upon Investigator Judgement
48307973|NCT04031378|RADIATION|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
48307974|NCT04031378|DRUG|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
48307975|NCT03000816|RADIATION|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
48307976|NCT01230671|OTHER|Yoga|A 12 week yoga session will be offered to women with breast cancer.
48482747|NCT04986852|DRUG|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
48482748|NCT04577885|DRUG|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
47960506|NCT05087108|DEVICE|Refence Therapy 2|The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
48482749|NCT05587972|OTHER|survey|Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic PRO surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.
48482750|NCT01611207|DEVICE|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
48307977|NCT02193269|DRUG|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
48307978|NCT02193269|DRUG|Minocycline|you will receive 200 mg as a single daily dose for 4 days
48307979|NCT00277316|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
48307980|NCT01734941|DRUG|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
48307981|NCT01734941|DRUG|Placebo|
48307982|NCT01675219|PROCEDURE|white light TUR-BT|traditional transurethral bladder tumor resection
48307983|NCT01675219|PROCEDURE|blue light TUR-BT|photodynamic transurethral bladder tumor resection
48307984|NCT01675219|DRUG|optimized MMC|six weekly optimized mitomycin-C instillations
48307985|NCT01675219|DRUG|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
48482751|NCT01611207|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
48482752|NCT03399617|DIETARY_SUPPLEMENT|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
48307986|NCT03832062|OTHER|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
48307987|NCT06347276|DEVICE|PFO occluder; ASD occluder|Transcatheter closure of atrial septal defect (ASD) and patent foramen ovale (PFO) All cases will be examined with DW-MRI preoperatively, and DW-MRI will be repeated 24 hours and 4 weeks after the transcatheter closure procedure.
48307988|NCT02335216|DEVICE|Implantation with the commercially available Axium neurostimulator|
48307989|NCT04420455|DRUG|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
48307990|NCT03779425|OTHER|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
48307991|NCT04077970|BIOLOGICAL|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
48307992|NCT00934557|DRUG|ATG Fresenius|
48307993|NCT00934557|DRUG|ATG Fresenius|
48307994|NCT00934557|DRUG|ATG Fresenius|
48307995|NCT00934557|DRUG|ATG Fresenius|
48307996|NCT00934557|DRUG|ATG Fresenius|
48307997|NCT00934557|DRUG|ATG Fresenius|
48307998|NCT00934557|DRUG|ATG Fresenius|
48307999|NCT00934557|DRUG|ATG Fresenius|
48308000|NCT01244542|OTHER|unpleasant stimuli|
48308001|NCT00932139|PROCEDURE|Electro-acupuncture control|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
48308002|NCT00932139|PROCEDURE|Electro-acupuncture test|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
48308003|NCT06458140|PROCEDURE|Cardioneuroablation|Radiofrequency ablation of ganglionated plexi of the heart
48308004|NCT00758914|DIETARY_SUPPLEMENT|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
48642122|NCT06138067|BEHAVIORAL|Low intensity approach|The participant will receive PEM, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the appointment with the medical oncologist. The patient navigator will call the participant 4 weeks after enrollment on the trial. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
48642123|NCT06029998|DRUG|Bortezomib|sub-cutaneous injection of bortezomib for 6-8 cycles of treatment.
48642124|NCT05535244|DRUG|Cevostamab|Cevostamab will be administered by IV infusion in 21-day cycles.
48308005|NCT03003416|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
48642125|NCT05535244|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
48642126|NCT00742742|BEHAVIORAL|healthy life style education|healthy life style education
48308006|NCT03849040|PROCEDURE|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
48308007|NCT05670964|DEVICE|Connecting valve system|UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
48308008|NCT05670964|DEVICE|Central haemodialysis Venous Catheter|Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
48308009|NCT02364193|DEVICE|MRI|"Cardiac MRI for LVEF and segmentation.~* Phase-contrast MRI for CO in aorta and each pulmonary vein.~* DCE-MRI for bolus kinetic parameter analysis."
47960507|NCT03459170|BIOLOGICAL|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
48308010|NCT02364193|DRUG|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
48308011|NCT02364193|DEVICE|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
48308012|NCT02364193|DEVICE|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
48308013|NCT04523844|DRUG|Brinzolamide-brimonidine Fixed Combination|In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
48308014|NCT04833985|PROCEDURE|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
48308015|NCT03352414|DRUG|Alvimopan|alvimopan pill
48308016|NCT03352414|DRUG|Placebo|placebo pill
48308017|NCT01143350|OTHER|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
48308018|NCT01143350|OTHER|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
48308019|NCT05569304|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty
48308020|NCT00953550|DRUG|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
48308021|NCT00953550|DRUG|Succinylcholine|1 mg/kg
48308022|NCT04640324|DRUG|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
48308023|NCT05871125|BEHAVIORAL|Reimbursement|Patients will be dosed in cohorts of 5, with a maximum available sample size of 30. The first cohort of 5 patients will be enrolled at the first reimbursement dose level of $1000 per month for 4 months ($4000 per patient in total). At the end of the 4-month period, reimbursement dose suitability will be determined as suitable by a cumulative negative financial toxicity screen and reimbursement dose deemed acceptable and appropriate in at least 4 patients. If the reimbursement dose is found suitable, we will de-escalate the reimbursement dose for the next cohort of 5 patients. If the reimbursement dose is found unsuitable, the next cohort of 5 patients will be enrolled at the same reimbursement amount ($1000 per month for 4 months).
48308024|NCT04615962|DRUG|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
48482753|NCT03399617|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
48308025|NCT04615962|DRUG|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
48308026|NCT04615962|DRUG|SNG100|A combination of low potency steroid and skin barrier repair agent
48308027|NCT01060735|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
48308028|NCT04702555|DRUG|VTS-K|An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
48308029|NCT01912768|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
48308030|NCT01912768|DEVICE|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
48308031|NCT01912768|DEVICE|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
48482754|NCT03399617|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
48308032|NCT02689219|DRUG|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
48482755|NCT03184532|DIAGNOSTIC_TEST|ultrasound|ultrasound examination of pyloric antrum
48482756|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg on alternate weeks
48482757|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg every other week
48482758|NCT05421793|OTHER|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
48308033|NCT01655823|DRUG|Placebo|Sham treatment acting as control arm
48308034|NCT01655823|DRUG|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
48308035|NCT04169334|BEHAVIORAL|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
48308036|NCT02191202|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
48308037|NCT04329611|DRUG|Hydroxychloroquine|COVID19
48308038|NCT02464787|DIETARY_SUPPLEMENT|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
48308039|NCT02222012|DEVICE|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
48308040|NCT02222012|DEVICE|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
48308041|NCT05118386|DRUG|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM"
48308042|NCT05118386|OTHER|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
48308043|NCT02477085|OTHER|all women with an induced labor|all women who have an induced labor
48308044|NCT02557971|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
48308045|NCT05058664|BEHAVIORAL|A-F texting component|Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
48308046|NCT05058664|BEHAVIORAL|P-F texting component|Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
48308047|NCT03833674|OTHER|Daily AIH Block|Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
48308048|NCT03833674|OTHER|Sham dAIH Block|Daily sessions of sham dAIH which includes breathing room air (21% O2)
48308049|NCT03833674|OTHER|Respiratory Strength Training Block|Respiratory strength training using a hand-held device that resists inspiration or expiration.
48308050|NCT03833674|OTHER|AIH + Strength Training Block|AIH followed by respiratory strength training.
48642127|NCT06213636|BIOLOGICAL|CD19/CD22-CAR T cells|"The intervention in this clinical trial involves a novel approach using CD19/CD22-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/CD22-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/CD22-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/CD22-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
48308051|NCT02329522|DEVICE|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
48308052|NCT02329522|DEVICE|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
48308053|NCT02344069|DRUG|Fibrinogen|Human fibrinogen concentrate as a injection
48308054|NCT02344069|DRUG|Placebo|Saline 0.9% as a injection
48308055|NCT04285346|DRUG|Ganaxolone|titration followed by maintenance and extension period
48308056|NCT06336031|OTHER|blood-injection-injury (BII) phobia stimuli|498 seconds of BII phobia-related images and videos will begin two-minutes prior to head-up tilt test, while in supine.
48308057|NCT06336031|OTHER|neutral stimuli|498 seconds of neutral images and videos will begin two-minutes prior to head-up tilt test, while in supine.
48308058|NCT03218293|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
48308059|NCT06285474|DEVICE|Low Intensity Focused Ultrasound Pulsation (LIFUP)|All participants will undergo 3 identical LIFUP sessions. All sessions must occur at least 1 day apart, and no more than 3 days apart, such that sessions may occur at minimum on days 1, 3, 5 and at maximum may occur on days 1, 5, 9.
48308060|NCT02973464|DRUG|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
48308061|NCT02973464|DRUG|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
48308062|NCT05300100|BEHAVIORAL|sensorimotor activities|"The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~* Trial 1 : Straightening: passage from sitting to sitting.~* Trial 2 : Movement with difficulty of balance: heel-toe walking~* Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~* Trial 4 : Move to a target, 5 m away~* Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~* Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. ."
48308063|NCT00473161|DEVICE|surface EMG biofeedback|
48308064|NCT04775212|DRUG|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
48308065|NCT04775212|DRUG|Sevoflurane|Sevoflurane
48308066|NCT01742468|DIETARY_SUPPLEMENT|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
48308067|NCT01742468|DIETARY_SUPPLEMENT|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
48308068|NCT05567835|DRUG|Fluorouracil|2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
48308069|NCT05567835|DRUG|Leucovorin|200 mg mg/m2 IV over 2 hours Day 1,15
48308070|NCT05567835|DRUG|Oxaliplatin|85 mg/m2 IV over 2 hours Day 1,15
48308071|NCT05567835|DRUG|Docetaxel|60 mg/m2 IV over 60 minutes Day 1,15
48308072|NCT05567835|BIOLOGICAL|GSCF|Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
48308073|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
48308074|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
48308075|NCT05635552|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.
48308076|NCT05635552|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.
48308077|NCT05635552|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.
48308078|NCT05635552|DIAGNOSTIC_TEST|Handgrip strength test|Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.
48308079|NCT05635552|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
48308080|NCT02934412|DRUG|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
48308081|NCT02934412|DRUG|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
48308082|NCT00130299|BEHAVIORAL|low glycemic load diet|
48308083|NCT00130299|BEHAVIORAL|low fat diet|
48308084|NCT05320458|OTHER|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
48308085|NCT03023982|DRUG|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
47960508|NCT03459170|DRUG|rimiducid|administered to eliminate BPX-501 cells in the event of GVHD
47960509|NCT01468883|PROCEDURE|M|Modified radical mastectomy
47960510|NCT01468883|RADIATION|X|Excisional biopsy plus radiation
48308086|NCT03023982|DEVICE|Ultrasound|All blocks will be done under ultrasound
48497903|NCT04791423|BIOLOGICAL|GRAd-COV2|GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues
48497904|NCT04791423|OTHER|Placebo|Saline solution
48642128|NCT05092516|DEVICE|Active tDCS|2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.
48308087|NCT03023982|PROCEDURE|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
48482759|NCT04776954|DEVICE|Forced Air Warming System|"The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin."
48482760|NCT04776954|DEVICE|Resistive Blanket Warming System|This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
48482761|NCT06211413|OTHER|no intervention|no intervention
48482762|NCT00155233|DRUG|Nalbuphine and morphine|
48642129|NCT05092516|DEVICE|Sham tDCS|Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.
48642130|NCT05672576|DRUG|Cenerimod|Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.
48482763|NCT03239236|PROCEDURE|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
47960511|NCT02886832|DIETARY_SUPPLEMENT|Prostate Health formulation|
48308088|NCT03023982|DRUG|Opioids|standard pain control with opioids
48482764|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
48642131|NCT05672576|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
48642132|NCT03648372|DRUG|TAK-981|Intravenous infusion.
48642133|NCT06407934|DRUG|Amlitelimab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous (SC) injection"
48642134|NCT06407934|DRUG|Placebo|"Pharmaceutical form: Injection solution~Route of administration: SC injection"
48642135|NCT06196138|OTHER|Gum|In the postoperative period, starting from the 4th hour, chewing gum is done 3 times a day, morning, noon and evening, for 30 minutes each, until the patient passes the first flatus.
48308089|NCT03023982|DRUG|NSAID|standard pain control with NSAIDs
48308090|NCT00138710|DRUG|Letrozole (Femara)|
48308091|NCT06092242|DRUG|Tas-102(Suyuan) combined with bevacizumab|Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks.
48308092|NCT04964024|DIAGNOSTIC_TEST|SARS-CoV-2 antibodies|Analysis of the results of the serological response to COVID-19 and/or Vaccine
48308093|NCT04044391|DIAGNOSTIC_TEST|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
48308094|NCT01403740|DRUG|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
48308095|NCT02857907|OTHER|Blood sample|A blood sample is performed one year after kidney transplantation.
48308096|NCT01474330|DRUG|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
48308097|NCT01474330|DRUG|Placebo|Placebo capsule
48642136|NCT06196138|OTHER|Hot Compress|Starting from the 1st postoperative day, patients will receive hot application (to the lumbar region) for 10 minutes in the morning and evening. The hot application is applied by wrapping 2 towels in a water bag containing 55 ± 2 °C hot water. The water bag is applied to the lumbar region for 10 minutes with the patient in the supine position. The application is continued until the patient passes the first flatus.
48642137|NCT06276348|GENETIC|Whole genome sequencing|Standard diagnostic whole genome sequencing will be performed.
48642138|NCT06276348|GENETIC|BeginNGS test|Genomic sequencing that screens for 434 genetic diseases.
48642139|NCT06276348|GENETIC|WES|Whole exome sequencing will be performed.
48642140|NCT06225531|OTHER|Autobiographical Memory Based Intervention|"The intervention involves 6 sessions of therapeutic input based around autobiographical memories. Memory based activities will broadly follow the 5 stages outlines in the broad-minded affective coping (BMAC) procedure, but with a focus on specific memories. It will follow the following structure:~Session 1 - Introduction and Familiarisation Session 2 - Neutral Memories Session 3 - Positive Memories Session 4 - Memories of Moves Away from Suicidality Session 5 - Practice of Preferred Memory (from Sessions 2-4) Session 6 - Continued Practice and Post-Intervention Planning"
48642141|NCT05876312|DRUG|ADX-038|siRNA duplex oligonucleotide
48642142|NCT05876312|DRUG|Placebo|Saline
48642143|NCT05300737|OTHER|intensive medical therapy|Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification
48642144|NCT02614066|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
48642145|NCT02614066|DRUG|Cyclophosphamide|Administered intravenously.
48642146|NCT02614066|DRUG|Fludarabine|Administered intravenously.
48642147|NCT05034887|DRUG|Trastuzumab Deruxtecan (T-DXd) monotherapy|T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
48642148|NCT05034887|DRUG|T-DXd, Durvalumab and Capecitabine Combination|Administer each cycle over 21 days. T-DXd is administered by intravenous infusion at 5.4 mg/kg every 21 days (every 3 weeks). Capecitabine is given at 750 mg/m2 BID, taken orally for 14 days, followed by a drug holiday from the evening of Day 15 to the morning of Day 22 (Day 1 of the next cycle). Durvalumab is administered at 1500 mg by intravenous infusion over 60 minutes every 21 days (every 3 weeks). As neoadjuvant chemotherapy, administer T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles. As adjuvant chemotherapy consists of T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles, followed by Durvalumab monotherapy on a q4w schedule until 10 cycles are completed.
48642149|NCT06695156|BEHAVIORAL|Meditation|The objective of this study is to assess the safety, feasibility, and effects of the practice of the Transcendental Meditation technique in adults with migraines. This study will involve 30 male and female participants recruited from migraine treatment facilities and migraine support groups in the US. The study will span three months, with all participants practicing Transcendental Meditation (TM) while continuing their usual lifestyle and medication regimen. Pre-data will be collected through symptom analysis, headache patterns, and evaluation questionnaires. All potential subjects will use a migraine App for 30 days prior to inclusion in the study, both as a means of assessing migraine status and of ability to adhere to study protocols during the study. In addition, all subjects will take the PHQ-9 to screen for levels of depression that might impair participation in the study. All the subjects will receive TM instruction, followed by bi-weekly
48642150|NCT06694870|DIAGNOSTIC_TEST|Transcutaneous CO2 monitoring|Transuctaneous CO2 monitoring
48642151|NCT05726227|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
48642152|NCT05726227|DRUG|Placebo|Placebo will be administered subcutaneously once-weekly.
48642153|NCT06567860|BIOLOGICAL|Influenza Fluzone vaccine|Fluzone vaccine administered in both May-June and in September-October for each participant.
48642154|NCT04344860|DRUG|Recombinant Von Willebrand factor|Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
48642155|NCT04344860|DRUG|Tranexamic Acid Injection [Cyklokapron]|Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
48642156|NCT04903197|DRUG|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
48642157|NCT04903197|DRUG|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
48642158|NCT04209855|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
48642159|NCT04209855|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
47960512|NCT01162460|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
48112549|NCT06054867|DEVICE|Robotic Waterjet Treatment|"The Aquablation therapy is a minimally invasive, image-guided, heat-free robotic therapy delivered by the AQUABEAM Robotic System.~During Aquablation therapy, the AQUABEAM Handpiece is inserted transurethrally into the prostatic urethra. The operating physician then utilizes cystoscopy in conjunction with transrectal ultrasound (TRUS) imaging for real-time visualization. The AQUABEAM Robotic System utilizes high-velocity sterile saline waterjet to resect and remove the prostate tissue according to the operating physician's treatment plan."
48112550|NCT00238212|DRUG|sorafenib tosylate|Given orally
48308098|NCT01457118|DRUG|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
48308099|NCT01457118|DRUG|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
48308100|NCT01457118|DRUG|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
48308101|NCT01457118|DRUG|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
48308102|NCT02764632|PROCEDURE|Digital facilitation|
48308103|NCT01057199|GENETIC|RNA analysis|
48308104|NCT01057199|GENETIC|gene expression analysis|
48308105|NCT01057199|GENETIC|mutation analysis|
48308106|NCT01057199|GENETIC|protein expression analysis|
48308107|NCT01057199|OTHER|fluorescence activated cell sorting|
48308108|NCT01057199|OTHER|laboratory biomarker analysis|
47960513|NCT01685944|DIETARY_SUPPLEMENT|Live Pediococcus pentosaceus LP28|
48308109|NCT03257072|BIOLOGICAL|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
48308110|NCT03257072|BIOLOGICAL|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
48308111|NCT03257072|BIOLOGICAL|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
48308112|NCT02159391|BEHAVIORAL|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
48308113|NCT02756715|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
48308114|NCT02756715|DRUG|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
48308115|NCT00594152|DRUG|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
48308116|NCT00947570|BEHAVIORAL|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
48642160|NCT04209855|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
48308117|NCT02437097|OTHER|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
48308118|NCT02437097|OTHER|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
48482765|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
48642161|NCT04209855|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
48482766|NCT03239236|PROCEDURE|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
48482767|NCT03239236|PROCEDURE|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
48482768|NCT03239236|DRUG|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
48642162|NCT04094090|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
48642163|NCT03288025|BEHAVIORAL|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
48642164|NCT04681313|PROCEDURE|High-risk percutaneous coronary intervention|Percutaneous coronary interventions (PCI) deemed high risk based on patient-related risk features, hemodynamic criteria, clinical presentation and complexity of coronary anatomy.
48642165|NCT05648214|DRUG|ALN-PNP - Part A|Administered by subcutaneous (SC) single ascending dose (SAD)
48642166|NCT05648214|DRUG|ALN-PNP - Part B|Administered by SC parallel single dose
48642167|NCT05648214|DRUG|Placebo (PB)|Administered by SC injection
48642168|NCT01740427|DRUG|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
48642169|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
48642170|NCT01740427|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
48482769|NCT03239236|DIAGNOSTIC_TEST|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
48482770|NCT03239236|DIAGNOSTIC_TEST|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
48482771|NCT03239236|DIAGNOSTIC_TEST|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
48642171|NCT01740427|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
48642172|NCT04042311|OTHER|High-intensity interval training|a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.
48642173|NCT06318416|DIAGNOSTIC_TEST|urine spectrophotometry for rifampin absorbance|All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.
48642174|NCT06072586|DRUG|BDTX-1535|BDTX-1535 is an inhibitor of EGFR mutations
48642175|NCT05776277|BIOLOGICAL|Iltamiocel|Single external anal sphincter (EAS) injection of 300 x 10\^6 cells.
47960514|NCT01685944|DIETARY_SUPPLEMENT|Heat-killed Pediococcus pentosaceus LP28|
47960515|NCT01685944|DIETARY_SUPPLEMENT|Placebo|
48112551|NCT00238212|OTHER|laboratory biomarker analysis|Correlative studies
48482772|NCT00824369|DRUG|No drug will be administered|No drug will be administered.
48497905|NCT03713775|OTHER|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
48642176|NCT05776277|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
48642177|NCT05573906|COMBINATION_PRODUCT|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
48642178|NCT05573906|COMBINATION_PRODUCT|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
48642179|NCT06657976|BEHAVIORAL|Supervised Treadmill Exercise|This is a 12 week intervention where participants will walk for exercise 3 times a week on a treadmill at a center while being supervised by healthcare personnel.
48642180|NCT06657976|BEHAVIORAL|Attention Control|This group will attend weekly one-hour educational sessions either on Zoom or in-person for 12 weeks. These sessions are on topics of interest to the typical PAD patient and may be led by study staff, physicians, or other health care workers.
48642181|NCT06657976|COMBINATION_PRODUCT|Nitrate-Rich Beetroot Juice + supervised exercise therapy|Participants randomized to this group will drink nitrate-rich beetroot juice while engaged in supervised exercise.
47960516|NCT03966144|DEVICE|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
47960517|NCT05900271|DEVICE|rTMS|10 Hz repetitive-transcranial-magnetic-stimulation
47960518|NCT05900271|DEVICE|iTBS|neuronavigated intermittent theta burst transcranial-magnetic-stimulation
48308119|NCT02437097|OTHER|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
48497906|NCT03713775|OTHER|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
48642182|NCT06657976|COMBINATION_PRODUCT|Placebo + supervised exercise therapy|Participants randomized to this group will drink placebo while engaged in supervised exercise.
48642183|NCT05656573|DRUG|CART-PSMA cells|"This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2 (body surface area); Cohort 3： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 4： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^8/M\^2 (body surface area)."
48308120|NCT02437097|OTHER|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
48308121|NCT00511407|DEVICE|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
48308122|NCT03072017|BEHAVIORAL|MBAT|Breathing-based intervention
48308123|NCT02908958|BIOLOGICAL|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
48308124|NCT02908958|BIOLOGICAL|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
48497907|NCT03172663|DEVICE|pure tone audiometry|for estimate the type and degree of hearing loss
48497908|NCT01484262|DRUG|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
47960519|NCT00992290|BIOLOGICAL|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
47960520|NCT00992290|BIOLOGICAL|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
47960521|NCT03352349|DRUG|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
47960522|NCT00180622|PROCEDURE|Spirometry|
48308125|NCT05821257|OTHER|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
48308126|NCT05821257|OTHER|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
48308127|NCT03154723|DRUG|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
47960523|NCT00180622|PROCEDURE|Exhaled Nitric Oxide and Carbon Monoxide|
47960524|NCT00180622|PROCEDURE|Exhaled Breath Condensate|
48112552|NCT04291586|OTHER|Virtual reality|Virtual Reality Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
48497909|NCT01484262|DRUG|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
48497910|NCT00145275|DRUG|zoledronic acid|
47960525|NCT00180622|PROCEDURE|Induced Sputum|
48112553|NCT04291586|OTHER|Paper and Pencil|Paper and Pencil Intervention of 30 minutes, 3 times a week until reaching 24 sessions.
48112554|NCT04242264|OTHER|Placebo|0.9% Sterile Normal Saline, USP
48112555|NCT04242264|BIOLOGICAL|Shigella sonnei strain 53G|1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
48308128|NCT00403858|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
48308129|NCT00403858|DRUG|Lactulose|
48308130|NCT03064776|DEVICE|m-RESIST Patients|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
48308131|NCT03064776|DEVICE|m-RESIST Caregivers|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
47960526|NCT00180622|PROCEDURE|CT Scan|
48112556|NCT04242264|BIOLOGICAL|WRSs2|10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
48308132|NCT00909142|DRUG|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
48308133|NCT05663996|OTHER|locally applied to the skin|Applying St John's wort oil locally on the knee three times a day for three weeks.
48308134|NCT05663996|OTHER|locally applied to the skin|Applying olive oil locally on the knee three times a day for three weeks.
48308135|NCT05276713|DRUG|Tucidinostat|Tucidinostat in combination with endocrine drugs
48308136|NCT01728584|DRUG|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
48308137|NCT01728584|OTHER|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~* Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~* Low insufflation pressure - a starting pressure of 8 mmHg will be used."
48112557|NCT02006940|DEVICE|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
48112558|NCT03026036|RADIATION|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
48112559|NCT01685606|BIOLOGICAL|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
48112560|NCT03587363|DRUG|Erdafitinib|Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
48112561|NCT01806454|DRUG|calcium|
48112562|NCT02307565|DRUG|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
48308138|NCT01728584|DRUG|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
48308139|NCT02629523|DRUG|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
48308140|NCT01544777|DEVICE|Study IOL|Aspheric IOL for correction of aphakia
48308141|NCT01544777|DEVICE|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
48308142|NCT01544777|DEVICE|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
47960527|NCT00180622|PROCEDURE|Blood test|
47960528|NCT00180622|PROCEDURE|St Georges Questionnaire|
47960529|NCT00180622|PROCEDURE|Bodypletysmography|
47960530|NCT05254886|OTHER|NEMO nurse-led program|"The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will:~* Report the presence of pre-existing comorbidities/EIMs~* Detect the presence of risk factors~* Implement recommendations for the detection and/or management of comorbidities/EIMs."
47960531|NCT00674362|BIOLOGICAL|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
47960532|NCT00674362|BIOLOGICAL|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
47960533|NCT04502433|DRUG|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
47960534|NCT05186025|DRUG|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
47960535|NCT02352129|OTHER|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
47960536|NCT01504620|OTHER|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
48112563|NCT02307565|DRUG|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
48482773|NCT06496074|DIAGNOSTIC_TEST|Head-up Tilt Test|Two protocols for the head-up tilt test (HUTT) are used in our center and in the collaborating centers: (1) passive or prolonged inclination protocol \[40 minutes\], (2) mixed protocol: passive phase \[first 20 minutes\] plus nitrate-provoked phase \[last 20 minutes\], with the use of 1.25 mg sublingual isosorbide dinitrate. All patients are submitted to 10 minutes of rest in the supine position at zero degree before the tilt phase of the HUTT. During this period, HR and systolic (SBP) and diastolic (DBP) measurements are obtained every 2 minutes. After this phase, the table is tilted at an angle of 70° with measurement of SBP / DBP and HR every minute. Patients older than 60 years are routinely investigated for carotid sinus hypersensitivity by carotid sinus massage during the passive phase of the HUTT. The exam is considered positive according to the criteria defined in guidelines.
48482774|NCT06183450|DIAGNOSTIC_TEST|auditory level|"* Evaluation of auditory thresholds through audiometric tests.~* Evaluation of speech comprehension in noise through a vocal audiometry test in noise (FraMatrix).~* Evaluation of spatial auditory behavior and spatial precision using a spatial discrimination test (Minimum Audible Angle) and a static sound localization test in virtual reality."
48482775|NCT06183450|DIAGNOSTIC_TEST|cognitive level|"* Evaluation of attention and short-term memory functions with verbal and non-verbal tasks: Digit Span Test and Reading Span Test.~* Evaluation of inhibition capacities using the Stroop Test.~* Evaluation of executive functions, visual attention, reasoning, and mental arithmetic using the Raven's Matrix test."
48482776|NCT06183450|DIAGNOSTIC_TEST|quality of life level|- Evaluation of quality of live level via Speech, Spatial and Qualities of Hearing Scale (SSQ-12) and EuroQol-5D questionnaires.
48308143|NCT01540188|BEHAVIORAL|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
48482777|NCT00452608|DRUG|amido pill|one pill of amido/d by mouth for 10 days
48482778|NCT00452608|DRUG|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
48482779|NCT03910764|OTHER|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
48482780|NCT01302847|DRUG|DTG film-coated tablets|DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
48482781|NCT01302847|DRUG|DTG granules for suspension|DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
47960537|NCT01504620|DRUG|insulin infusion|i.v. infusion of insulin
48112564|NCT03752385|BEHAVIORAL|reducing smartphone screen time|"Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time."
48112565|NCT04313543|DIETARY_SUPPLEMENT|Glucose and Longan syrup|Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
48112566|NCT02805439|DRUG|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
48112567|NCT02805439|DRUG|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
48112568|NCT02805439|DRUG|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
48112569|NCT01278888|PROCEDURE|Anterolateral thoracotomy|Standard anterolateral thoracotomy
48112570|NCT01278888|PROCEDURE|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
48308144|NCT01519622|OTHER|Questionnaire|Questionnaire to be distributed among sick elderly in the community
48308145|NCT06434103|DRUG|SHR-A1921；Adebrelimab；SHR-8068；carboplatin|SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
48308146|NCT01247220|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
48308147|NCT01247220|PROCEDURE|Peripheral Laser|Angiography-directed peripheral laser
48308148|NCT03342469|OTHER|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
48308149|NCT03342469|OTHER|Placebo|Placebo chocolate cookies
48308150|NCT05355090|DIETARY_SUPPLEMENT|PP|Protein Pacing three times per day
48308151|NCT06182072|DRUG|ProAgio Dose Levels (DL) 1,2,3,4|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
48308152|NCT06182072|DRUG|Gemcitabine, nab paclitaxel|ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
48308153|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
48308154|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
48308155|NCT00369668|BEHAVIORAL|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
48308156|NCT02801097|DRUG|RRx-001|
48308157|NCT02801097|DRUG|Irinotecan|
48308158|NCT04360187|DRUG|Crisaborole Ointment|Crisaborole ointment 2%
48308159|NCT04360187|DRUG|Crisaborole Placebo Vehicle|Placebo for crisaborole ointment
48642184|NCT06484517|DEVICE|Hugemed Videolaryngoscope|After general anesthesia induction, the first group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope. For the second group (Group H, n=20), the Hugemed videolaryngoscope was used. Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age.
48112571|NCT01278888|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
48308160|NCT01596842|DRUG|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
48308161|NCT01596842|OTHER|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
48308162|NCT01596842|OTHER|cholecalciferol|if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
48308163|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - Remote|Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
48308164|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - In Person|Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
48308165|NCT03834129|DRUG|Dexmedetomidine|Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
48308166|NCT03834129|DRUG|sodium chloride 0.9%|Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
48308167|NCT00532948|DRUG|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
48308168|NCT02469831|DRUG|Rocuronium|
48308169|NCT05092971|DEVICE|Shock or startle device|Shock and startle devices were used as aversive stimulus (shock and startle)
48112572|NCT01278888|PROCEDURE|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
48112573|NCT03030248|DRUG|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
48308170|NCT00258089|DRUG|Levofloxacin|
48308171|NCT01516164|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
48308172|NCT04119726|BEHAVIORAL|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
48308173|NCT04119726|BEHAVIORAL|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
48642185|NCT06695650|OTHER|Mandala Coloring|Students in the intervention group will be provided with mandala templates and coloring materials. They will be asked to color for 15 minutes twice a week over a two-month period
48642186|NCT05962138|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
48642187|NCT04238624|DRUG|Dabrafenib|Participants will receive dabrafenib 150 mg orally twice a day
48642188|NCT04238624|DRUG|Trametinib|Participants will receive trametinib 2 mg orally once a day
47960538|NCT03689530|BEHAVIORAL|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery."
47960539|NCT03689530|BEHAVIORAL|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
47960540|NCT02929914|PROCEDURE|Local anesthesia and rubber dam isolation|Local anesthesia was performed. Tooth was isolated using a rubber dam isolation in order to collect the dentin samples.
48642189|NCT06695988|BEHAVIORAL|Time Restricted Eating|The intervention group will eat and drink in a prescribed daily feeding window of 8-hour between 6 a.m. to 8 p.m. for 8 weeks and follow their normal exercise and resistance training routines. We will allow +/-1 hour starting and ending times for the eating window while aiming for an 8-hour eating window
48642190|NCT01937468|OTHER|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
48642191|NCT01937468|DRUG|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
48642192|NCT06542289|DEVICE|BlinkER device.|Participants will use the BlinkER System for 8-16 hours daily (removed during sleep) at approximately 10 blinks/minute. The stimulation cycle will be ON and OFF to achieve the desired blink rate. Participants will receive training on device usage before starting the study.
48642193|NCT04236804|DEVICE|Flowly (TMC-CP01)|TMC-CP01 is a device designed specifically for pain management and is tailored for low back pain. The treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain over time guidelines.
48642194|NCT06333860|DRUG|Risankizumab|Solution for Subcutaneous (SC) injection
48642195|NCT06333860|DRUG|Deucravacitinib|Oral tablet
48642196|NCT06276023|BEHAVIORAL|Mindful and Self-Compassionate Care Program (MASC)|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
48642197|NCT06276023|BEHAVIORAL|Health Education Program (HEP)|"The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives."
48642198|NCT05776160|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
48642199|NCT05860296|DRUG|SLC-391|SLC-391 is an AXL inhibitor
48642200|NCT05860296|BIOLOGICAL|pembrolizumab|Immunotherapy
48642201|NCT06100172|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Use of tAN for pain relief is an attractive alternative to pharmacologic and opioid-based approaches because it is safe and effective and presents no addiction liability.
48642202|NCT06100172|DEVICE|Sham Control Device|This device looks like the active device, but no stimulation will be delivered.
47960541|NCT02929914|PROCEDURE|Incomplete caries removal and microbiological samples collection|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed.
47960542|NCT02929914|PROCEDURE|Dentin washed with sodium 0.9% saline|The remaining dentin was dipped in sodium 0.9% saline for 2min.
47960543|NCT02929914|PROCEDURE|Antimicrobial Photodynamic Therapy|The remaining dentin was disinfected with aPDT for 2 min.
47960544|NCT02929914|PROCEDURE|Microbiological samples collection and Indirect pulp treatment|A new dentin collection was performed after this treatment at another site of the cavity. Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin (Z350,3M).
47960545|NCT01235624|GENETIC|genetic analysis|
48112574|NCT03030248|DRUG|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
48308174|NCT04119726|BEHAVIORAL|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
48308175|NCT03182205|OTHER|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
48308176|NCT03182205|OTHER|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
48308177|NCT06018584|OTHER|Tooth extraction|Tooth extractions were performed by a single physician. Topical anesthesia (Xylo-caine, Astra, Södertalje, Switzerland) was applied to the dried mucosa in the area to be lo-calized with the help of an ear stick for 1 minute. Posterior-superior-alveolar nerve block anesthesia and palatal anesthesia were applied for the upper primary molars; Inferi-or-alveolar nerve block anesthesia and lingual anesthesia (Ultracain, Aventis Pharma, Is-tanbul, Turkey) were applied for the lower primary molars. After anesthesia control was achieved, a randomly selected tooth was extracted. Tooth extraction on the other side was performed two weeks later. During the shootings, attention was paid to the traumatic ap-proach. After the control of bleeding was achieved, data were recorded for each group.
48308178|NCT04802876|DRUG|Spartalizumab|Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
48308179|NCT04802876|DRUG|Tislelizumab|Tislelizumab 300mg will be given intravenously every 28 days
48308180|NCT04313335|DRUG|Duloxetine|Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
48308181|NCT00146393|BEHAVIORAL|People with Arthritis Can Exercise program|
48112575|NCT03804918|OTHER|VitalTips mobile application|VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
48482782|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~0.8 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
48482783|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets; Weight band 10 to \<14 kg: 20 mg DTG dispersible tablets; Weight band 14 to \<20 kg: 25 mg DTG dispersible tablets; Weight band ≥20 kg: 30 mg DTG dispersible tablets."
48642203|NCT06695559|OTHER|Labrida Bioclean|Debridement on the active comparator group will be implemented on the implant surface with Labrida Bioclean (i.e. the chitosan brush).
48642204|NCT06695559|COMBINATION_PRODUCT|Labrida Bioclean and tetracycline slurry|On the experimental group debridement of the implant surface will be carried out with Labrida Bioclean and thereafter irrigation of the periimplant sulcus with tetracycline slurry will take place.
48642205|NCT05261490|DRUG|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
48642206|NCT05261490|DRUG|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
48308182|NCT03901287|OTHER|dual energy CT scans|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
48642207|NCT02657551|DRUG|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
48308183|NCT02782663|DRUG|ABT-494|Tablet: Oral
48308184|NCT04009174|OTHER|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~* \[18F\]-FCH PET + Dynamic CT~* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~* 3D-Transrectal ultrasound~* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~* \[18-F\]-DCFPyL PET+Dynamic CT~* PET/MRI with endorectal coil~* 3D-Transrectal Ultrasound~* Optional Sodium (23Na) MRI"
48308185|NCT00257387|DRUG|Cyclosporine|
48308186|NCT05522335|BIOLOGICAL|BBV154(Intranasal) & covaxin|Intervention Covaxin
48482784|NCT01302847|DRUG|DTG dispersible tablets|"DTG dispersible tablets initial starting dose of \~1.25 mg/kg with a maximum dose of 30 mg; orally once daily. The proposed weight-band dosing was:~Weight band 3 to \<6 kg: 5 mg DTG dispersible tablets; Weight band 6 to \<10 kg: 15 mg DTG dispersible tablets."
48642208|NCT05698992|OTHER|evidence-based individualized rehabilitation|The experimental group will receive structured individualized assessment based on physical, psychological or social needs and will be offered evidence-based interventions to promote rehabilitation and recovery.
48642209|NCT06658080|DIAGNOSTIC_TEST|organoid drug test|Before initiating therapy, patients diagnosed with metastatic breast cancer patients with hydrothorax and ascite fluid. The hydrothorax and ascite fluid is utilized to establish organoids and conduct drug testing.
48642210|NCT06558279|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
48308187|NCT03569293|DRUG|Placebo for Upadacitinib|Tablets taken orally once a day
48308188|NCT03569293|DRUG|Upadacitinib|Tablets taken orally once a day
48482785|NCT04681625|BEHAVIORAL|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
48482786|NCT02560428|BEHAVIORAL|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
48482787|NCT06084741|OTHER|Omitting of usage of intraabdominal drains after repair of peptic ulcer perforations|omitting the intraabdominal drains
48308189|NCT01044381|DRUG|Luliconazole Solution, 10%|28 days of daily application
48308190|NCT00678509|BIOLOGICAL|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
48308191|NCT02032537|DRUG|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
48308192|NCT02032537|DRUG|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
48340225|NCT04432571|BEHAVIORAL|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
48482788|NCT06084741|OTHER|Using intraabdominal drains|The investigators will put intraabdominal drains
48482789|NCT04554706|BEHAVIORAL|Mobile-phone delivered Treatment for Excessive Rumination|This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
48482790|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .23s|Aortic CTA performed with short (0.23 sec) gantry rotation time.
48482791|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .28s|Aortic CTA performed with standard (.28 sec) gantry rotation time.
48482792|NCT06423157|OTHER|Intervention|The intervention period will last 6 weeks, with a periodicity of 2 weekly sessions of 20 minutes each. All interventions will take place at the Palacio de los Deportes de Murcia. All interventions will be carried out by the same physiotherapist, following the same protocol. The intervention of the experimental group will consist of a protocol using plyometric and stability exercises.
48482793|NCT03501537|PROCEDURE|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
48482794|NCT04825717|OTHER|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
48642211|NCT06558279|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
48642212|NCT05763420|DEVICE|AH Plus Bioceramic Sealer|A bioactive, calcium silicate-based sealer will be used in combination with the core root canal filling material (gutta-percha). It's premixed and is dispensed in the root canal via a fine disposable syringe.
48482795|NCT03748394|BEHAVIORAL|Work-directed rehabilitation|Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work
48642213|NCT05763420|DEVICE|AH Plus Sealer (resin-based)|A resin-based sealer will be used in combination with the core root canal material (gutta-percha). It consists of two pastes that are mixed together in equal amounts prior to application.
48642214|NCT03396575|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
48642215|NCT03396575|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
48112576|NCT01325558|BIOLOGICAL|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
48482796|NCT03748394|BEHAVIORAL|Physical activity|In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
48482797|NCT00254020|DRUG|Citalopram|Patients who are found to have major depression will be referred to a psychologist
48482798|NCT04013074|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
48482799|NCT04013074|OTHER|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
48482800|NCT01972035|DRUG|Valacyclovir|Experimental Arm
48482801|NCT01972035|DRUG|Valganciclovir|Standard of care
48482802|NCT01868763|DEVICE|telemedical devices (weighing machine and step counter)|
48482803|NCT01868763|BEHAVIORAL|care calls once per week for 12 weeks|
48482804|NCT02948257|DEVICE|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
48482805|NCT04558333|OTHER|blood and exhaled breath specimens|identification of possible biomarkers
48482806|NCT02303886|DRUG|Methylene blue|In NaCL0.9% 100 ml
48482807|NCT02303886|DRUG|Methylene blue|in NaCl 0.9% 100 ml
48482808|NCT03897478|DIAGNOSTIC_TEST|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
48482809|NCT03696355|DRUG|GDC-0084|Given PO
48482810|NCT03696355|RADIATION|radiation therapy|Both photon and proton therapy modalities will be allowed.
48482811|NCT03015714|OTHER|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
48642216|NCT03396575|DRUG|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
48642217|NCT03396575|DRUG|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
48112577|NCT02110056|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
48642218|NCT03396575|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
48642219|NCT03396575|BIOLOGICAL|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
48642220|NCT03784326|DRUG|Atezolizumab|Given IV (vein)
48642221|NCT03784326|PROCEDURE|Conventional Surgery|Undergo surgical resection
48642222|NCT03784326|DRUG|Fluorouracil|Given IV (vein)
48642223|NCT03784326|DRUG|Oxaliplatin|Given IV (vein)
48642224|NCT03784326|DRUG|Tiragolumab|Given IV (vein)
48642225|NCT03967522|DRUG|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
48642226|NCT06224153|OTHER|3-day dietary record|This is the conventional ingesta assessment. It will be performed twice during the study.
48642227|NCT06224153|OTHER|Food Frequency Questionnaire (FFQ)|This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
48642228|NCT03004144|OTHER|FLOAT|
48642229|NCT06494761|DRUG|zongertinib|zongertinib
48642230|NCT06494761|DRUG|midazolam|midazolam
48642231|NCT06494761|DRUG|omeprazole|omeprazole
48642232|NCT06494761|DRUG|repaglinide|repaglinide
48112578|NCT02110056|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
48642233|NCT05833945|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of biomarkers associated to Large Vessel Occlusion in blood samples used in combination with an APP.
48642234|NCT06282159|DRUG|DNTH103|Day 1: IV loading dose Week 1 to Week 11: DNTH103 administered SC every 2 weeks
48642235|NCT06282159|DRUG|Placebo|Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks
48642236|NCT05766254|DEVICE|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
48642237|NCT05766254|DEVICE|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
48642238|NCT02757768|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
48642239|NCT02757768|DRUG|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
48642240|NCT02757768|DRUG|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
48112579|NCT05223205|PROCEDURE|Air|Test if air is sufficient for macular hole closure.
48112580|NCT05223205|PROCEDURE|10% SF6 and 90% air|Test if 10% SF6 and 90% air is sufficient for macular hole closure.
48112581|NCT02943629|DEVICE|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
48308193|NCT04755296|DEVICE|Low level laser therapy|Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
48308194|NCT04755296|OTHER|Aerobic exercises|Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
48308195|NCT04755296|OTHER|Traditional physical therapy program|Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
48308196|NCT05079282|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
48308197|NCT02013024|OTHER|cryopreservation technique|
48308198|NCT01351077|OTHER|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
48308199|NCT04645472|DEVICE|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
48308200|NCT00520195|BEHAVIORAL|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
48308201|NCT01889199|DRUG|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
48308202|NCT01889199|OTHER|Placebo|Placebo orally each 28 day cycle for 6 cycles
48308203|NCT02026622|BEHAVIORAL|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
48308204|NCT02026622|DEVICE|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
48308205|NCT02026622|DEVICE|transcranial doppler and TPI|transcranial doppler TPI
48308206|NCT02026622|BEHAVIORAL|explicitative interview|
48308207|NCT06133647|PROCEDURE|managing Male Breast Cancer Patients at Methodist Health System|To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
48308208|NCT03123354|DEVICE|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
48308209|NCT04514237|DRUG|BOS172767 enantiomer E1 or E2|Oral tablets
48308210|NCT04514237|DRUG|Placebo|Oral tablets
48308211|NCT00333268|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
48308212|NCT00333268|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
48308213|NCT01619384|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
48308214|NCT03311607|DRUG|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
48308215|NCT00174616|DRUG|Oxaliplatin, capecitabine, radiotherapy|"* Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
48308216|NCT05903300|OTHER|Surveys and Questionnaires|The intervention consists of completing the MIPIM-P, QuickDash, and Brief Pain Inventory questionnaires.
47960546|NCT03366038|PROCEDURE|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
47960547|NCT00679432|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
47960548|NCT00679432|DRUG|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
47960549|NCT00679432|DRUG|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
47960550|NCT00679432|DRUG|Placebo|Placebo
48308217|NCT03445052|BEHAVIORAL|XPAND|The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
48497911|NCT02130583|BEHAVIORAL|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
47960551|NCT00679432|DRUG|Asacol® 400 mg|2400 mg/day, 400 mg tablets
48308218|NCT04929262|BEHAVIORAL|Supporting Anxious Youth: Strategies for Caregivers|The outreach presentation will last 75 minutes with an additional 15 minutes for caregiver questions. The presentations will occur in the evening via Zoom. The presentation will include information about identifying anxiety disorders, strategies for caregivers to help their youth with anxiety, evidence-based practices to treat youth anxiety, and strategies for finding a therapist who uses cognitive behavior therapy with exposures. The text on the presentations is written at a 5.3 grade reading level. Presentations will incorporate stigma reduction strategies, such as education to dispel myths, and behavioral decision-making tools to elicit hope, empowerment, and motivation.
48308219|NCT02072317|DRUG|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
48308220|NCT02072317|DRUG|taxol|taxol 135 mg/m2, every three weeks for a cycle
48308221|NCT04363086|BEHAVIORAL|iFightDepression online self-help tool|Computerized cognitive behavior therapy
48308222|NCT04363086|BEHAVIORAL|Treatment as Usual|TAU
48308223|NCT04363086|BEHAVIORAL|phone call|phone call
48308224|NCT01293396|DRUG|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
48308225|NCT01293396|DRUG|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
48308226|NCT01293396|DRUG|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
48308227|NCT01158495|PROCEDURE|Intubation with a cuffed ET Tube|
48308228|NCT01158495|PROCEDURE|CT scan Radiation|
48308229|NCT02087319|OTHER|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
48308230|NCT01665417|DRUG|Experimental|Icotinib: 125mg, oral administration, three times per day.
47960552|NCT00036270|DRUG|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
48308231|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
48482812|NCT03015714|OTHER|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
48482813|NCT01787279|DRUG|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
47960553|NCT00036270|DRUG|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
48308232|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
48308233|NCT00465153|DIETARY_SUPPLEMENT|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
47960554|NCT06343740|BEHAVIORAL|COMET-Y|Competitive memory training (COMET) is a transdiagnostic intervention first developed for adults and later adapted to be used in children and adolescents. The adapted version for youth consists of 7 sessions in which participants learn to facilitate activation of functional/positive thoughts instead of relying on dysfunctional/negative thoughts by using positive self-verbalizations, imagery, body posture, and music. In addition, they are challenged to reformulate dysfunctional/negative thoughts into more functional/positive thoughts. As an addition to the original COMET protocol, there is a parent session in which parents receive psycho-education about their influence on self-esteem. Parents learn to be a 'co-therapist' and to support practicing at home and improve generalization.
47960555|NCT03805269|DRUG|TAP block|TAP block: local anesthetics infiltration at trans abdominis plane
47960556|NCT03805269|DRUG|wound infiltration|wound infiltration: local anesthetics infiltration at surgical incision
47960557|NCT05140915|BEHAVIORAL|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
47960558|NCT05140915|BEHAVIORAL|Peer Coaching via Text|Peer coaching, facilitated by texting
47960559|NCT05140915|BEHAVIORAL|Gamification|Gamification, designed to motivate participation
48112582|NCT02943629|DEVICE|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
48308234|NCT00465153|BEHAVIORAL|Resistance exercise training|Resistance training
48308235|NCT05625425|BEHAVIORAL|LabyrinthVR software|Head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, highly engaging regimen of wayfinding in novel urban and village neighborhoods.
48308236|NCT05625425|BEHAVIORAL|Placebo Games software|Commercially-available, narrative computer games marketed as cognitively enriching. Can be tablet-based or wireless VR headset-based.
48308237|NCT05625425|BEHAVIORAL|Labyrinth Tablet software|Tablet computer playing Labyrinth spatial wayfinding game in 2.5D
48308238|NCT05625425|BEHAVIORAL|Labyrinth VR wireless|Wireless head-mounted display virtual reality game designed to induce environmental enrichment in an adaptive, engaging regimen of wayfinding in novel urban and village neighborhoods.
48308239|NCT05873101|DIAGNOSTIC_TEST|Mobilization With Movement (MWM)|Mobilization With Movement
48308240|NCT05873101|DIAGNOSTIC_TEST|Kelternborn Treatment Technique|Kelternborn Treatment Technique
48308241|NCT06016608|DIAGNOSTIC_TEST|Magnetic Resonance Angiography, Ocular OCTA, CT Angiography|Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery
48308242|NCT00610935|DRUG|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
48308243|NCT00610935|DRUG|Placebo|Single intramuscular injection
48497912|NCT02130583|BEHAVIORAL|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
48308244|NCT01124058|DRUG|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
48308245|NCT01124058|DRUG|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
48308246|NCT06130696|OTHER|Clamshell exercises|Group A will receive treatment with Clamshell exercises Change sides and do 3 sets. Total of 6 session were given.
48308247|NCT06130696|OTHER|Isometric and muscle strengthen exercise|"group B will receive simple exercises also with clamshell 10 to 20 times. Change sides and do 3 sets.~Total 6 session were given"
48308248|NCT03785873|DRUG|Nivolumab|Intravenous (IV) infusion
48308249|NCT03785873|DRUG|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
48308250|NCT03785873|DRUG|5-Fluorouracil|Intravenous (IV) infusion
48308251|NCT03785873|DRUG|Leucovorin|Intravenous (IV) infusion
48308252|NCT00002058|DRUG|Clofazimine|
48308253|NCT02607969|OTHER|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
48308254|NCT02177851|DIETARY_SUPPLEMENT|Single oral iron dose of 120 mg per day for 3 consecutive days|
48308255|NCT02177851|DIETARY_SUPPLEMENT|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
48308256|NCT05339438|RADIATION|functional MRI|Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
48308257|NCT03901612|DRUG|Ropivacaine 0.2%|Continuous post operative regional analgesia
48308258|NCT03901612|DRUG|saline 09%|Continuous post operative regional analgesia
48308259|NCT05373706|BEHAVIORAL|Alcohol Cue Reactivity Personalized Feedback Intervention|This online brief intervention provides personalized feedback using EMA data focused on alcohol cue reactivity to reduce alcohol misuse among young adults.
48308260|NCT02715960|DRUG|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
48308261|NCT06484530|DRUG|N acetyl cysteine|1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
48482814|NCT06471920|BEHAVIORAL|Educational Control|Patients randomized to the educational control group will receive registered access to a study website with access to evidence-based education for patients with chronic LBP. Each participant will have unique login credentials to allow for tracking of individual patient use. The website will include important education on the etiology of chronic LBP and evidence-based suggestions for self-management of symptoms. Education will focus on the importance of maintaining healthy levels of physical activity and avoiding bedrest.
48642241|NCT02704832|OTHER|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
48642242|NCT04250766|PROCEDURE|Echo-guided uterine biopsy|"Echo-guided uterine biopsy will be performed by a specialized radiologist by transvaginal and exclusive transuterine approach. 4 to 5 samples will be made.~Local anesthesia will be performed. A pain assessment will be performed during the biopsy (visual or verbal scale)."
48642243|NCT06695533|BEHAVIORAL|Diabetes self management workbook|The diabetes self-management workbook section used in this pilot study will focus on diet management, specifically carbohydrates, following ADA guidelines. It will include exercises based on the ADA diabetes plate method, aimed at helping subjects understand meal planning, food categories, portion sizes, goal setting, and the impact of foods on blood glucose levels. Activities will include word searches, crosswords, and goal-setting exercises. Subjects will begin the first section during a clinic visit. They can complete the workbook at home over three months, with input from subjects and Certified Diabetes Care and Education Specialists to refine the content.
47960560|NCT05140915|OTHER|E-Cigarette Cessation Materials|Written e-cigarette cessation materials by the Research Coordinator at the time of study enrollment. The written materials will consist of two pamphlets from Journeyworks, selected based on: (1) their clear and attractive layout designed for a low-literacy audience, and (2) their providing both information re: e-cigarette use with a strong message about nicotine and nicotine addiction, E-Cigarettes: 8 Things Everyone Should Know, and support in quitting, How to Quit Vaping.
48308262|NCT04253301|DEVICE|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
48308263|NCT00038701|DRUG|TNP-470|
48308264|NCT00619411|BEHAVIORAL|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
48308265|NCT01125176|DRUG|thalidomide|50 mg oral dosing every other day
48308266|NCT01125176|DRUG|lenalidomide|varying oral doses every other day (max 25 mg/day)
48308267|NCT01125176|BIOLOGICAL|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
48308268|NCT00398541|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
48308269|NCT00524316|DRUG|doxorubicin hydrochloride|Transarterial chemoembolization
48308270|NCT00524316|DRUG|sunitinib malate|Given Orally
48308271|NCT00524316|OTHER|laboratory biomarker analysis|Correlative Study
48308272|NCT00524316|PROCEDURE|hepatic artery embolization|Surgical procedure
48308273|NCT00524316|PROCEDURE|quality-of-life assessment|Correlative Study
48308274|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 200 mL tap water via nasogastric tube|
48308275|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
48308276|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
48308277|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
48308278|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
48308279|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
48308280|NCT01343134|DEVICE|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
48308281|NCT05883592|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
48308282|NCT01574313|PROCEDURE|stellate ganglion block|stellate ganglion block
48308283|NCT01574313|DRUG|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
48308284|NCT01574313|DRUG|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
48308285|NCT01574313|DRUG|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
48308286|NCT06002282|BEHAVIORAL|Tailored messages|Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.
48308287|NCT06002282|BEHAVIORAL|Standard messages|Generic reminder/recall HPV vaccination messages.
48308288|NCT00366834|DRUG|Casopitant (GW679769) oral tablets|
48308289|NCT00366834|DRUG|Casopitant (GW679769) intravenous|
48642244|NCT05058040|DRUG|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
47960561|NCT03392467|BIOLOGICAL|PNEUMOSTEM|human umbilical cord blood-derived mesenchymal stem cells
48308290|NCT00366834|DRUG|Dexamethasone intravenous|
48308291|NCT00366834|DRUG|Ondansetron oral tablets|
48308292|NCT00366834|DRUG|placebo|casopitant placebo
48308293|NCT03084575|PROCEDURE|Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy|Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
48308294|NCT03084575|DRUG|hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)|L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
48642245|NCT01719055|DEVICE|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
48642246|NCT05115110|DRUG|RO7204239|"RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1."
48642247|NCT05115110|DRUG|Placebo|Placebo will be administered Q4W by SC injection into the abdomen.
48642248|NCT05115110|DRUG|Risdiplam|Risdiplam will be administered orally once daily (QD) for the duration of the study.
48642249|NCT04504812|DRUG|Duloxetine|Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
48308295|NCT03084575|DEVICE|Thermal RF lesioning is done using Bailys RF generator|
48308296|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily
48308297|NCT02150824|DRUG|Placebo|BI 187004 medium dose matching placebo once daily
48308298|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
48308299|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily add on to background metformin
48308300|NCT02150824|DRUG|Placebo|BI 187004 low dose matching placebo once daily
48308301|NCT02150824|DRUG|BI 187004|BI 187004 medium dose once daily
48308302|NCT02150824|DRUG|BI 187004|BI 187004 low dose once daily
48308303|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily
48308304|NCT01987986|BIOLOGICAL|Collagenase Clostridium Histolyticum|injectible intervention
48308305|NCT01987986|BIOLOGICAL|Placebo|
48308306|NCT02938065|PROCEDURE|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
48308307|NCT02938065|OTHER|2% milk|16 participants will drink 10 ounces of 2% milk
48308308|NCT02938065|OTHER|apple juice|16 participants will drink 10 ounces of apple juice
48308309|NCT02938065|OTHER|ensure clear|16 participants will drink 10 ounces of ensure clear
48308310|NCT02917187|DRUG|BIIB074|Administered as specified in the treatment arm
48308311|NCT02917187|DRUG|Placebo|Matched placebo
48308312|NCT02588274|DEVICE|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
48308313|NCT02588274|DEVICE|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
48308314|NCT03571334|DRUG|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
48308315|NCT03571334|DRUG|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
48308316|NCT00188877|PROCEDURE|intensity modulated radiation therapy|
48308317|NCT00188877|DRUG|cisplatinium and fluorouracil - standard treatment|
48308318|NCT02759146|OTHER|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
48308319|NCT02759146|OTHER|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
48308320|NCT03165591|BIOLOGICAL|V3-P|one tablet of V3-P given once daily for 2 months
48308321|NCT02673593|DRUG|DS102|
48308322|NCT02673593|DRUG|Placebo|
48308323|NCT00590018|DRUG|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.
48308324|NCT00590018|DRUG|Placebo|Placebo for 5 days intravenously.
48482815|NCT06471920|BEHAVIORAL|Telerehabilitation|Based on prior SBTS risk stratification, participants in the risk-informed telerehabilitation group will receive subsequent care using an evidence-based treatment protocol designed for video visits to be informed by a participant's baseline risk score with elements ranging from standard physical therapy telehealth visits (low-to-medium risk) to PIPT telehealth visits (high-risk).
48482816|NCT00002360|DRUG|Didanosine|
48482817|NCT05319613|OTHER|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
48112583|NCT02943629|DEVICE|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
48308325|NCT00088803|GENETIC|molecular genetic technique|
48308326|NCT00088803|GENETIC|polymerase chain reaction|
48308327|NCT00088803|GENETIC|polymorphism analysis|
48308328|NCT06531382|OTHER|Nurses attitudes toward adressing sexual health in patients with cancer|"Health professionals, within the field of cancer, attitude towards addressing sexual health with patients is unknown.~The aim is to investigate the attitudes of Danish cancer nurses towards addressing sexual health in their clinical work, as well as to assess differences in perceived competences and knowledge.~Method: The questionnaire Health professionals Attitudes towards Sexual Health-Danish version (PA-SH-D) is sent out to Danish cancer nurses via the Professional Society for Cancer Nurses. The questionnaire is sent out via a link via the RedCap database.~The questionnaire link is sent out to members of the Professional Association for Cancer Nurses under the Danish Nursing Council, and it is sent out via their membership register."
48308329|NCT02801630|DEVICE|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
48482818|NCT04357613|DRUG|Experimental drug|Imatinib 800mg/d during 14days
48482819|NCT06389916|DEVICE|Euclid orthokeratology MAX (current design)|The current lens design
48482820|NCT06389916|DEVICE|Euclid orthokeratology MAX Phoenix (new design)|The new lens design
48482821|NCT03519984|DRUG|Cytarabine|Given IV
48482822|NCT03519984|OTHER|Laboratory Biomarker Analysis|Correlative studies
48482823|NCT03519984|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
48482824|NCT03519984|DRUG|Vincristine Liposomal|Given IV
47960562|NCT03392467|OTHER|Placebo|normal saline
48112584|NCT06271304|DEVICE|Blue blocking eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
48112585|NCT06271304|DEVICE|Low filtration eyewear|Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
48112586|NCT03727854|DIETARY_SUPPLEMENT|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
48308330|NCT05345834|BEHAVIORAL|Patient Navigation|Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.
48308331|NCT05345834|BEHAVIORAL|Adapted Cognitive-Behavioral Therapy|Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
47960563|NCT02746146|OTHER|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
48308332|NCT00466128|DRUG|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
48308333|NCT03754283|DEVICE|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
48308334|NCT04632095|PROCEDURE|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
48308335|NCT04632095|PROCEDURE|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
48308336|NCT02819648|DRUG|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
48308337|NCT02819648|OTHER|Control|Milk Tablet
48308338|NCT01103817|DIETARY_SUPPLEMENT|Vitamin D|"Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.~If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily."
48482825|NCT03416491|DRUG|KW-136|KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
48482826|NCT03416491|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
48482827|NCT00642421|DRUG|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
48642250|NCT04504812|COMBINATION_PRODUCT|Intra-Articular Injection|Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.
48642251|NCT04504812|PROCEDURE|Nerve Procedure with long acting blocks|People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
47960564|NCT05903170|DEVICE|360J LifePak Monitor/Defibrillator|The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.
47960565|NCT05903170|DEVICE|200J Philips HeartStart MRx Monitor/Defibrillator|The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
47960566|NCT01102517|PROCEDURE|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
47960567|NCT01102517|PROCEDURE|axillary thoracotomy|axillary thoracotomy lobectomy
48308339|NCT05655390|BEHAVIORAL|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
48308340|NCT00926796|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
48308341|NCT00926796|DRUG|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
48308342|NCT00926796|DRUG|Gemifloxacin|One 320 mg tablet administered orally.
48308343|NCT00836680|DEVICE|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
48308344|NCT00109317|DRUG|Raptiva (efalizumab)|
48308345|NCT05475262|DEVICE|Active white noise|Active white noise of 57 dB - 60 dB from 10 pm to 6 am
48308346|NCT05475262|DEVICE|Inactive white noise|Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
48308347|NCT03100942|DRUG|Lanraplenib|1 x 30 mg tablet administered orally once daily
48308348|NCT03100942|DRUG|Filgotinib|1 x 200 mg tablet administered orally once daily
48308349|NCT03100942|DRUG|Tirabrutinib|1 x 40 mg tablet administered orally once daily
48308350|NCT03100942|DRUG|Lanraplenib placebo|1 x tablet administered orally once daily
48308351|NCT03100942|DRUG|Filgotinib placebo|1 x tablet administered orally once daily
48308352|NCT03100942|DRUG|Tirabrutinib placebo|1 x tablet administered orally once daily
48308353|NCT04098952|OTHER|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
48308354|NCT04098952|OTHER|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
48308355|NCT06329141|DRUG|Vutiglabridin|Once-daily oral administration
48308356|NCT06329141|DRUG|Placebo|Once-daily oral administration
48308357|NCT04735367|DRUG|palbociclib plus letrozole|palbociclib plus letrozole
48308358|NCT00043875|DRUG|lamotrigine|
48308359|NCT05145504|DIAGNOSTIC_TEST|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
48482828|NCT00642421|DRUG|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
48482829|NCT02046668|DRUG|spironolactone|spironolactone 25mg daily for 12 weeks
48642252|NCT04504812|PROCEDURE|Nerve Procedure with nerve ablation|People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
48642253|NCT04504812|BEHAVIORAL|Pain Coping Skills Training|Participants will be provided with a written manual that includes login information for the pain coping skills training website. The participants will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
48642254|NCT04504812|OTHER|Best Practices|Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
48642255|NCT04022239|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
48642256|NCT04022239|DRUG|Bendamustine|Given IV
48642257|NCT04022239|DRUG|Cyclophosphamide|Given IV
48642258|NCT04022239|BIOLOGICAL|Filgrastim-sndz|Given SC
48642259|NCT04022239|DRUG|Fludarabine|Given IV
48642260|NCT04022239|DRUG|Melphalan|Given IV
48642261|NCT04022239|DRUG|Mycophenolate Mofetil|Given PO
48642262|NCT04022239|BIOLOGICAL|Rituximab|Given IV
48642263|NCT04022239|DRUG|Tacrolimus|Given IV and PO
48642264|NCT04022239|RADIATION|Total-Body Irradiation|Undergo TBI
48642265|NCT06479707|BEHAVIORAL|Digital Literacy Intervention|This intervention consists of 4-6 home visits with 3-4 interim phone calls based on the participant's individual digital literacy needs and goals. Each participant will receive internet connectivity (if not already available), a tablet (if not already available) and tailored action plans co-developed by the participant and the interventionist.
48642266|NCT03772990|DRUG|Calcium Chloride|Calcium Chloride
48642267|NCT03772990|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride
48308360|NCT02241395|BIOLOGICAL|Intrathecal autologous bone marrow mononuclear cell transplantation|
48308361|NCT05465603|DEVICE|ETDNO (Elastic Tension digital neoprene orthosis)|A bespoke orthosis created from neoprene.
48308362|NCT00269074|DRUG|IDEA-070|
48308363|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation using surgical guide|The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.
48308364|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation without surgical guide|The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
48308365|NCT05087602|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
48308366|NCT02830841|DEVICE|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
48308367|NCT02830841|DEVICE|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
48308368|NCT01668563|PROCEDURE|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
48308369|NCT01668563|PROCEDURE|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
48482830|NCT06412042|DIETARY_SUPPLEMENT|Probiotic BLa80|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
48112587|NCT03727854|BEHAVIORAL|Dietary modification|Subjects in this group will follow diabetes diet education.
48112588|NCT04104698|DIAGNOSTIC_TEST|Quantitative EEG|"1. Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~2. Both groups will be assessed for psychological \& cognitive contributes respectively using:~   A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~3. Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~4. The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
48112589|NCT03444506|DRUG|Molo 1 (also referred as GSP 301-2 NS)|
48112590|NCT03444506|DRUG|Molo 2 (also referred as GSP 301-1 NS)|
48308370|NCT01666236|OTHER|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
48482831|NCT06412042|OTHER|Placebo Maltodextrin|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
47960568|NCT05695352|DRUG|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
47960569|NCT05695352|DRUG|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
48482832|NCT00506506|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
47960570|NCT05695352|OTHER|Placebo|Each tablet contains Calcium Carbonate 1000 mg
47960571|NCT06178289|DEVICE|3M Cavilon Advanced Skin Protectant|3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
47960572|NCT06178289|DEVICE|Standard hospital wound treatment protocol|Comparator: Standard hospital wound treatment protocol
47960573|NCT00807170|DRUG|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
47960574|NCT00807170|RADIATION|Whole Brain Radiotherapy (WBRT)|
47960575|NCT00807170|DRUG|ZD6474|200 mg as a once daily oral dose, 21 days
47960576|NCT00807170|DRUG|ZD6474|300 mg as a once daily oral dose, 21 days
47960577|NCT01506258|PROCEDURE|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
47960578|NCT01506258|PROCEDURE|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
48112591|NCT03444506|DRUG|Placebo nasal spray|
48112592|NCT03444506|DRUG|DYMISTA nasal spray|
48112593|NCT03444506|DRUG|PATANASE nasal spray|
48112594|NCT02984319|DIETARY_SUPPLEMENT|Cherry versus placebo concentrate|Acute cherry concentrate
48112595|NCT03612882|OTHER|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
48112596|NCT06524375|DRUG|Venetoclax|Venetoclax tablets will be administered as per the schedule specified in the arm.
48482833|NCT00506506|DRUG|Placebo|
48482834|NCT01048502|DRUG|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
47960579|NCT00316719|DRUG|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
47960580|NCT00316719|DRUG|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
47960581|NCT04760821|DRUG|Trimetazidine|Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
47960582|NCT05801133|DRUG|Pirfenidone|200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
47960583|NCT03912168|OTHER|Question Prompt List|Question prompt list for common orthopaedic conditions
47960584|NCT03912168|OTHER|3 questions list|3 questions from the AskShareKnow model
47960585|NCT06451003|BEHAVIORAL|Exposure to clinical decision support system and education|"Surgeons will receive education regarding post-discharge venous thromboembolism after cancer surgery. An electronic medical record based decision support tool with be initiated that will identify patients who have undergone major abdominopelvic cancer surgery. The tool will permit use of a risk stratification score and advise guideline concordant post-discharge venous thromboembolism prophylaxis strategies.~Patients will receive dedicated venous thromboembolism education at the time of discharge."
47960586|NCT05073601|DIAGNOSTIC_TEST|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)\& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (\< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (\> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested \[Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)\] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
47960587|NCT01723345|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
47960588|NCT01421914|OTHER|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
47960589|NCT03219541|BEHAVIORAL|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
47960590|NCT03219541|BEHAVIORAL|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
47960591|NCT02293057|BEHAVIORAL|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
47960592|NCT02293057|BEHAVIORAL|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
47960593|NCT00014937|DRUG|lopinavir/ritonavir|
47960594|NCT00014937|DRUG|lamivudine/zidovudine|
47960595|NCT00014937|DRUG|efavirenz|
47960596|NCT00014937|DRUG|lamivudine|
47960597|NCT00014937|DRUG|stavudine|
47960598|NCT00014937|DRUG|zidovudine|
47960599|NCT00014937|DRUG|didanosine|
47960600|NCT05043909|BEHAVIORAL|VR-based training|Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
48482835|NCT01048502|DRUG|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
48112597|NCT06524375|DRUG|cBTKi Monotherapy|Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
48112598|NCT01560416|DRUG|Fulvestrant|
48112599|NCT01560416|DRUG|Ganetespib|
48112600|NCT06677060|DRUG|Baxdrostat and dapagliflozin|baxdrostat tablet and dapagliflozin tablet
48112601|NCT06677060|OTHER|Placebo and dapagliflozin|placebo tablet and dapagliflozin tablet
48112602|NCT06554353|DEVICE|Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
48112603|NCT05573035|BIOLOGICAL|LYL845|LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
48482836|NCT01048502|DRUG|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
48482837|NCT01219452|BIOLOGICAL|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
48482838|NCT04075552|BEHAVIORAL|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
48112604|NCT03409263|OTHER|Observational study|Not applicable (observational registry study)
48112605|NCT00176813|DRUG|Gemcitabine|
48112606|NCT00176813|DRUG|Cisplatin|
48112607|NCT00176813|DRUG|Celecoxib|
48308371|NCT04072146|DRUG|Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Cross over bioavailability study
48308372|NCT04072146|DRUG|OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg|Cross over bioavailability study
48308373|NCT01448291|DRUG|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
48308374|NCT04746612|DRUG|HH30134|HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
48308375|NCT01233401|OTHER|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
48308376|NCT05512130|DRUG|Empagliflozin 25 mg|Participants will take empagliflozin daily for 2 weeks.
48308377|NCT05512130|DRUG|Placebo|Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
48308378|NCT01419249|OTHER|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
48308379|NCT05304182|DEVICE|EYESTAR 900|The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
48642268|NCT06643962|DRUG|Venetoclax|Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.
48642269|NCT06643962|DRUG|Idarubincin|Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
47960601|NCT04306848|DEVICE|Temporary Continuous Glucose Monitoring System|This is a feasibility study evaluating the potential to utilize a continuous glucose monitoring system (CGMs) on a temporary basis, during participation in an intensive therapeutic lifestyle medicine program, to help improve the compliance with healthy lifestyle changes for people with Type 2 diabetes (T2DM) and prediabetes (PD).
48308380|NCT05304182|DEVICE|LENSTAR LS 900|"The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'."
48642270|NCT06643962|DRUG|Cytarabine|During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age \>55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.
48308381|NCT01615224|DRUG|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
48308382|NCT04022174|BEHAVIORAL|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
48308383|NCT04022174|BEHAVIORAL|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
48308384|NCT04022174|BIOLOGICAL|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
48308385|NCT04022174|BEHAVIORAL|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
48308386|NCT01441440|DRUG|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
48308387|NCT01441440|DRUG|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
48642271|NCT03386513|DRUG|IMGN632|CD123-targeted ADC
48642272|NCT01226316|DRUG|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
48642273|NCT01226316|DRUG|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
48642274|NCT01226316|DRUG|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
47960602|NCT03397537|DRUG|Letrozole 2.5Mg Tablet|letrozole 2.5mg p.o.qd
47960603|NCT03397537|DRUG|GnRH analogue|3.75 mg triptorelin im. q28d
47960604|NCT00293215|DRUG|111-Indium-CMD-193|111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
47960605|NCT00293215|DRUG|CMD-193|CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
48308388|NCT01441440|DRUG|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
48308389|NCT05178953|DRUG|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
48308390|NCT05178953|DRUG|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
48308391|NCT04009096|BIOLOGICAL|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
48308392|NCT06116461|DRUG|Nivolumab|Participants receive three reduced doses of 240 mg every four weeks
48308393|NCT05942339|DEVICE|Procedure/Surgery|The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.
48308394|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
48308395|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
48308396|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
48308397|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
48308398|NCT02194400|BIOLOGICAL|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
48308399|NCT03016442|DEVICE|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
48308400|NCT03016442|DRUG|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
48308401|NCT05684120|BEHAVIORAL|Mood Lifters for Undergraduates|Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
47960606|NCT05026411|DIAGNOSTIC_TEST|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
47960607|NCT05026411|DIAGNOSTIC_TEST|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
48308402|NCT04209296|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
48308403|NCT00977327|DEVICE|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
48308404|NCT00977327|DEVICE|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
48308405|NCT03793816|DEVICE|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
48308406|NCT03215264|DRUG|hydroxychloroquine|600-1200mg daily
48308407|NCT03215264|DRUG|entinostat|3-5mg weekly
48308408|NCT03215264|DRUG|regorafenib|160mg daily
48308409|NCT01833273|DRUG|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
48308410|NCT04917835|DEVICE|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
47960608|NCT05026411|DIAGNOSTIC_TEST|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
48308411|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
48308412|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
48308413|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
48308414|NCT02100748|DRUG|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
48308415|NCT02100748|DRUG|Morphine|Morphine 4 mg will be administered every 4 hours
47960609|NCT01209611|PROCEDURE|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
47960610|NCT01209611|PROCEDURE|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
47960611|NCT01480752|DRUG|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
47960612|NCT01480752|DRUG|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
47960613|NCT01480752|DRUG|no injection|inject nothing after inferior alveolar injection and before root canal therapy
47960614|NCT03326544|OTHER|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
47960615|NCT03326544|OTHER|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
47960616|NCT01070498|DRUG|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
48308416|NCT02100748|DRUG|Placebo|Placebo will be administered every 4 hours
47960617|NCT06349330|DEVICE|Test: 3D intra-oral scanner|"3D intra-oral scanner will be used to scan the subjects after plaque staining is performed. Subsequently, a 3D rendered image will be produced. Participants will be given oral hygiene education and instruction before being instructed to brush.~A cooling-off period of 30 minutes is given before participants are instructed to brush."
47960618|NCT06349330|OTHER|Control: Standard oral hygiene|Standard oral hygiene instructions will be delivered using a hand mirror. No 3D intraoral scanner will be used.
47960619|NCT04286750|DRUG|ACT-1004-1239|ACT-1004-1239 administered as hard capsules for oral use.
47960620|NCT04286750|DRUG|Placebo|Matching placebo administered as hard capsules for oral use.
47960621|NCT00880542|DRUG|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
47960622|NCT00880542|DRUG|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
47960623|NCT04489797|DRUG|Acalabrutinib|Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
47960624|NCT04489797|DRUG|Rabeprazole|Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
47960625|NCT01441180|DRUG|GS7977|drug intervention
47960626|NCT01441180|DRUG|RBV|drug intervention
47960627|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
47960628|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
47960629|NCT00510497|BIOLOGICAL|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
47960630|NCT02737397|DRUG|JMI-001 (SJP-304 and SJP-223)|
47960631|NCT02737397|DRUG|SJP-304|
47960632|NCT02737397|DRUG|SJP-223|
47960633|NCT02737397|DRUG|placebo|
48112608|NCT05702996|DRUG|Eculizumab administration|Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab
48112609|NCT05883644|DRUG|Durvalumab|Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
48642275|NCT01226316|DRUG|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
47960634|NCT03191188|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
47960635|NCT03191188|DRUG|Placebo Oral Tablet|Placebo
48112610|NCT05883644|DRUG|Tremelimumab|Participants will receive single dose of 300 mg through IV infusion at Day 1
47960636|NCT03127410|OTHER|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
48112611|NCT06478238|DRUG|calcium folinate|Intravenous infusion and/or oral therapy
47960637|NCT00399750|DRUG|oxaliplatin|
47960638|NCT00399750|DRUG|fluoropyrimidine|
47960639|NCT00399750|DRUG|bevacizumab|
47960640|NCT03207477|DIAGNOSTIC_TEST|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
47960641|NCT02652754|DRUG|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
47960642|NCT05165836|PROCEDURE|Erector Spinae Plane block without Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
48112612|NCT04025359|DRUG|Dronabinol|Dronabinol 2.5 mg
48112613|NCT04025359|DRUG|Dronabinol|Dronabinol 5 mg
48112614|NCT04025359|DRUG|Placebo|Placebo
48112615|NCT03833804|OTHER|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
48112616|NCT06656689|PROCEDURE|Rezum (water vapor thermal therapy)|Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.
48112617|NCT01811407|BEHAVIORAL|Precommitment announcement|
48112618|NCT01811407|BEHAVIORAL|Results announcement|
48112619|NCT01811407|BEHAVIORAL|Walking program|
48308417|NCT04890574|DEVICE|CellMist™ System|Open Label, Safety and Feasibility
48308418|NCT00086658|DRUG|mepolizumab|
48308419|NCT06390579|OTHER|Deep learning algorithm applied on retrospectively collected color fundus photographs|Deep learning algorithm applied on retrospectively collected color fundus photographs
48308420|NCT06257706|BIOLOGICAL|Vedolizumab|All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
48308421|NCT01977053|OTHER|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:~* Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~* Nominative notebook containing details of chemotherapy administered and medical contacts.~* Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
48308422|NCT06397391|DEVICE|TREM-AB|Wearing medical device on site during 1 hour
48308423|NCT00456963|BEHAVIORAL|Diet|total fat \< 5%, saturated fat \< 10%, vegetables, fruit
48308424|NCT00456963|BEHAVIORAL|Moderate exercise|30 min at least 5 times/week
48308425|NCT00456963|DRUG|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
48308426|NCT00456963|DRUG|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
48308427|NCT00456963|DRUG|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
48308428|NCT01597622|DRUG|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
48308429|NCT02916498|DEVICE|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
48308430|NCT00151060|DRUG|Estramustine|
48308431|NCT00151060|DRUG|Etoposide|
48308432|NCT00151060|DRUG|Paclitaxel|
48308433|NCT05676528|OTHER|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
48308434|NCT00433732|DRUG|sumatriptan|
48112620|NCT04177017|BEHAVIORAL|Mindfulness-based intervention|"The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no."
48112621|NCT03895268|DEVICE|ALiA Analyser|NPS specimens shall be tested with the investigational device
48112622|NCT03895268|DEVICE|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
48112623|NCT01793441|DRUG|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
48112624|NCT01793441|DRUG|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
48308435|NCT00433732|DRUG|naproxen sodium|
48308436|NCT06387888|OTHER|Listening to mother's voice|During the care, from the beginning to the end, mother's voice was played to the newborns. It took about 20 minutes. The mini Bluetooth speaker and the decibel meter were disinfected with the rapid surface disinfectant used in the clinic. The speaker was placed 30 cm away from the infant's ear and the sound level in the incubator was adjusted to be 50-60 dB by using a decibel meter (Official Gazette, 2018). Mother's voice was played from the beginning of the provision of care and continued for 15 minutes after the end of the provision of care. During the provision of care, COMFORTneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.
48308437|NCT04755543|DRUG|LP002|600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
48308438|NCT04755543|DRUG|Cisplatin|50mg/m2 IV on Day 1, Q2W
48112625|NCT02319122|OTHER|High Intensity Interval Training|See arm description
48112626|NCT02319122|OTHER|Progressive Resistance Training|See arm description
48112627|NCT06511817|OTHER|No intervention will be performed|No intervention will be performed
48308439|NCT04755543|DRUG|Fluorouracil|2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
48308440|NCT04755543|BIOLOGICAL|OH2 oncolytic virus|106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
48308441|NCT06550141|DRUG|Emapalumab|An interferon gamma (IFNγ) blocking antibody
48308442|NCT06550141|DRUG|Cyclophosphamide|Alkylating agent
48308443|NCT06550141|DRUG|Fludarabine Phosphate|Purine antagonist antimetabolite
48308444|NCT06550141|DRUG|Axicabtagene Ciloleucel|Autologous treatment
48308445|NCT03583762|DIAGNOSTIC_TEST|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
48308446|NCT03583762|DIAGNOSTIC_TEST|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
47960643|NCT05165836|PROCEDURE|Erector Spinae Plane block with Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
47960644|NCT02837289|OTHER|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
48112628|NCT01230047|BEHAVIORAL|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
48112629|NCT00711126|DRUG|GW642444|2.5mcg IV
48112630|NCT00711126|DRUG|GW642444|5mcg IV
48112631|NCT00711126|DRUG|GW642444|10mcg IV
48308447|NCT01841658|DIETARY_SUPPLEMENT|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
48308448|NCT01507610|DRUG|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
48308449|NCT02123160|BEHAVIORAL|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
48308450|NCT02123160|BEHAVIORAL|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
48482839|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
48482840|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
48482841|NCT02358850|DRUG|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
48482842|NCT02358850|DRUG|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
48482843|NCT02358850|DRUG|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
48482844|NCT02358850|DRUG|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
47960645|NCT02837289|OTHER|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
48112632|NCT00711126|DRUG|GW642444|100mcg inhaled
48112633|NCT00711126|DRUG|GW642444|20mcg IV
48112634|NCT00711126|DRUG|GW642444|500mcg oral
48112635|NCT05857267|DRUG|Dorzolamide / Timolol Ophthalmic Solution|Dorzolamide-timolol fixed combination in a preservative-free multidose device
48112636|NCT05857267|DRUG|dorzolamide/timolol|Dorzolamide-timolol BAK-preserved fixed combination
48112637|NCT03330418|BIOLOGICAL|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
48112638|NCT03330418|BIOLOGICAL|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
48112639|NCT04808505|BIOLOGICAL|Cipaglucosidase alfa|Sterile lyophilized powder intravenous (IV) infusion
48112640|NCT04808505|DRUG|Miglustat|65 mg oral capsules
48112641|NCT03903081|DRUG|HEC110114 tablet|administered orally once daily
48112642|NCT03903081|DRUG|Placebo Oral Tablet|Placebo will be administered orally at a dose and frequency matched to HEC110114
48642276|NCT05673291|OTHER|No intervention|Volunteers who will be included in the research will be informed about the research and an informed consent form will be signed. Questionnaire evaluating sociodemographic characteristics and working positions; The Extended Nordic Musculoskeletal Questionnaire (7) and measurements made with the Spinal Mouse device for posture analysis will be applied when individuals feel comfortable. Questionnaires and device and posture analysis will be carried out after the purpose of the research is explained to the individuals and their consent is obtained. The data will be analyzed in the SSPS program. Number, percentage, standard deviation and mean from descriptive statistics will be used in the evaluation of the data. The relationship between posture and musculoskeletal pain will be evaluated by correlation analysis. The confidence interval of the research will be 95% and the significance level will be considered as p\<0.05.
48308451|NCT05804305|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue
48642277|NCT06695897|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
48112643|NCT02539212|DEVICE|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
48308452|NCT05804305|DRUG|Placebo|Placebo contained substance that has no therapeutic value.
48308453|NCT03430687|OTHER|Laboratory Biomarker Analysis|Correlative studies
48308454|NCT03430687|BIOLOGICAL|Talimogene Laherparepvec|Given intravesically
48308455|NCT00454064|BEHAVIORAL|cognitive-behavioral treatment|
48308456|NCT04156750|DRUG|LY3556050|Administered orally.
48308457|NCT04156750|DRUG|Placebo|Administered orally.
48308458|NCT04156750|DRUG|Iohexol|Administered IV.
48308459|NCT04156750|DRUG|Metformin|Administered orally.
48308460|NCT05679687|DRUG|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
48308461|NCT05508776|DRUG|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
48308462|NCT05508776|DRUG|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
48308463|NCT05508776|DRUG|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
48112644|NCT02539212|DEVICE|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
48308464|NCT02353260|DEVICE|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
48308465|NCT02353260|DRUG|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
48308466|NCT04932525|PROCEDURE|Biopsy|Blood and tumor samples for Genetic Profiling research
48308467|NCT02258009|DRUG|Ranibizumab|0.5 mg intravitreal injections
48308468|NCT02258009|DRUG|Aflibercept|2 mg intravitreal injections
48308469|NCT02909673|BEHAVIORAL|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
48308470|NCT02840058|OTHER|Biological samples|blood and tumor tissue samples
48308471|NCT02840058|DRUG|Anti PD1/PDL1 treatment|
48308472|NCT02693483|DRUG|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
48308473|NCT01662297|DRUG|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
48308474|NCT01662297|DRUG|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
48308475|NCT04053543|DRUG|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
48308476|NCT06203730|BEHAVIORAL|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
48308477|NCT01883323|DRUG|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
48308478|NCT01883323|DRUG|Fludarabine|i.v., 25mg/m2 per day for 5 days
48308479|NCT01883323|BIOLOGICAL|Tumor-Infiltrating Lymphocytes|i.v., 1x10\^10 - 1.6x10\^11 cells
48308480|NCT01883323|BIOLOGICAL|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
48308481|NCT03856086|BEHAVIORAL|Baseline questionnaire|Baseline questionnaire on the day of the patient's surgery.
48308482|NCT03856086|BEHAVIORAL|NCCN Problem List|NCCN Distress Thermometer
48308483|NCT03856086|BEHAVIORAL|FACT-GP|Greater overall quality of life
48308484|NCT03856086|BEHAVIORAL|HADS|Lower anxiety and depression
48308485|NCT03856086|BEHAVIORAL|CSS-CG|web-based CSS-CG
48308486|NCT03027804|PROCEDURE|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
48482845|NCT02262858|DRUG|Telmisartan and HCTZ|
47960646|NCT04691271|PROCEDURE|Stellate ganglion block|"After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care."
47960647|NCT00404235|DRUG|carboplatin|
47960648|NCT00404235|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
47960649|NCT02462252|DRUG|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
47960650|NCT02462252|DRUG|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
48642278|NCT06462573|DRUG|locally infilterating anaethesia like lidocaine|which patients will undergo ESWL under locally infiltrated anaesthetic. Using ultrasound guidance, the quadratus lumborum muscle will be identified. Then a mixture of 0.5 % bupivacaine (10 ml) and 2 % lidocaine (10 ml) will be injected into the muscle as a single shot 20 minutes before the procedure.
48308487|NCT04845698|DEVICE|i-Dashboard|i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
48308488|NCT02544971|BEHAVIORAL|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
48308489|NCT02544971|OTHER|Control|Treatment as usual
48308490|NCT04683198|DRUG|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
48308491|NCT04683198|DRUG|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
48308492|NCT04683198|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
48308493|NCT04683198|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
48308494|NCT03343431|DRUG|Anti-HBV antiviral prophylaxis|Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum
48482846|NCT02262858|DRUG|Telmisartan|
47960651|NCT02462252|DRUG|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
48482847|NCT02262858|DRUG|HCTZ|
48642279|NCT06462573|DRUG|general anaethesia|"which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session."
48642280|NCT04619888|DIAGNOSTIC_TEST|HeartLogic|In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
48642281|NCT04857671|DRUG|Botulinum Toxin Type A in saline water|"100 Allergan units Botulinum toxin A in a total of 2 ml sodium chloride (NaCl) 0,9% Braun.~5 IU of Botox per injection point (0,1ml); in total 100 IU per 20 injections points."
47960652|NCT02462252|DRUG|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
47960653|NCT04599140|DRUG|CXCR1/2 Inhibitor SX-682|Given PO
48308495|NCT01727635|OTHER|body-mind-spirit group therapy|8-session therapy
48308496|NCT03599141|BEHAVIORAL|Trust-building Self-management Together|Trust building plus depression self-management
48308497|NCT03599141|BEHAVIORAL|Depression Management|Traditional depression self-management
48308498|NCT03065504|DIETARY_SUPPLEMENT|Turmeric|
48308499|NCT03065504|DIETARY_SUPPLEMENT|Turmeric-containing combination tablet|
48642282|NCT04857671|DRUG|Isotone saline water|2ml Na Cl (sodium chloride) 0,9% Braun. 0,1ml per injection point in total 20 injections points
48642283|NCT05238220|DRUG|Valganciclovir|continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity
48642284|NCT04082572|BIOLOGICAL|Pembrolizumab|Given IV
48642285|NCT03976323|BIOLOGICAL|Pembrolizumab|IV infusion
47960654|NCT04599140|BIOLOGICAL|Nivolumab|Given IV
47960655|NCT04623112|DEVICE|Hearing aid feature: Frequency Compression|FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
47960656|NCT06175455|DEVICE|dynamic chest radiography|A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images
48308500|NCT03065504|DIETARY_SUPPLEMENT|Placebo tablets|
48482848|NCT03245034|BEHAVIORAL|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
48482849|NCT05394766|OTHER|Omada Hypertension Program|The Omada Program: an online program that offers comprehensive lifestyle self-management support for hypertension.
47960657|NCT02701023|DRUG|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
47960658|NCT00894166|DRUG|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
47960659|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
48482850|NCT05064774|OTHER|myofascial release technique|myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.
47960660|NCT00894166|DRUG|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
47960661|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
47960662|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
47960663|NCT00894166|DRUG|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
47960664|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
47960665|NCT06013904|PROCEDURE|Difficult PIV placement personnel|Patients randomized to this group will have their difficult PIV placed following the usual protocol for pediatric ED patients.
47960666|NCT06013904|PROCEDURE|US-trained PEM Fellows|US-trained PEM Fellows
47960667|NCT03398785|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
47960668|NCT01673217|DRUG|decitabine|Given IV
47960669|NCT01673217|BIOLOGICAL|NY-ESO-1 peptide vaccine|Given SC
47960670|NCT01673217|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
47960671|NCT01673217|BIOLOGICAL|sargramostim|Given SC
47960672|NCT01673217|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
47960673|NCT01673217|OTHER|immunohistochemistry staining method|Correlative studies
47960674|NCT01673217|OTHER|liquid chromatography|Correlative studies
47960675|NCT01673217|OTHER|mass spectrometry|Correlative studies
47960676|NCT01673217|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
48308501|NCT02709434|BEHAVIORAL|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
48308502|NCT02709434|OTHER|Standard care|Usual IBD management
48482851|NCT05064774|OTHER|physiotherapy|patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
48642286|NCT03976323|DRUG|Pemetrexed|IV infusion
48642287|NCT03976323|DRUG|Carboplatin|IV infusion
48642288|NCT03976323|DRUG|Cisplatin|IV infusion
48642289|NCT03976323|DRUG|Olaparib|Tablets
47960677|NCT01673217|OTHER|laboratory biomarker analysis|Correlative studies
47960678|NCT01673217|GENETIC|DNA methylation analysis|Correlative studies
47960679|NCT01673217|OTHER|enzyme-linked immunosorbent assay|Correlative studies
47960680|NCT05624593|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
48308503|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
48308504|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
48308505|NCT03651193|DIAGNOSTIC_TEST|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
48642290|NCT06695078|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
48642291|NCT00702533|DEVICE|Pentagastrin Injection BP|
48308506|NCT04991506|DRUG|ES102|The active ingredient of ES102 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4)
48308507|NCT04991506|DRUG|JS001|JS001 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
48482852|NCT02847208|OTHER|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
48482853|NCT02477241|PROCEDURE|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
47960681|NCT05624593|DEVICE|Predicate|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
47960682|NCT03941405|DRUG|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
47960683|NCT01945528|DRUG|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
47960684|NCT01945528|DRUG|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
47960685|NCT03836599|DRUG|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
47960686|NCT03836599|DRUG|Allopurinol|Participants will receive allopurinol 300 mg once daily.
47960687|NCT03836599|DRUG|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
47960688|NCT04412434|DIAGNOSTIC_TEST|Electroencephalography (EEG)|"Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies."
48482854|NCT02477241|DEVICE|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
48482855|NCT03734887|BEHAVIORAL|Social Network Feedback|Social networks are cost-free and highly influential social relationships and interactions that influence behavior and conversely are influenced by a patient's behavior. In addition to receiving a private text message regarding their medication adherence rate, participant's feedback will also be shared to a loved-one or friend that the participant is willing to share medical information with.
48482856|NCT03734887|BEHAVIORAL|Private Feedback|Participant will receive medication adherence feedback from a pharmacist at the start of the study.
48482857|NCT04414475|DRUG|Selinexor|Participants will receive Selinexor oral tablets.
48482858|NCT04414475|DRUG|Dexamethasone|Participants will receive Dexamethasone oral tablets.
48482859|NCT04414475|DRUG|Bortezomib|Participants will receive Bortezomib SC injection.
48482860|NCT04414475|DRUG|Pomalidomide|Participants will receive Pomalidomide oral tablets.
47960689|NCT00628056|DRUG|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
47960690|NCT03433157|DEVICE|Hall technique|Metal Stainless stain crown placed with Hall technique
47960691|NCT03433157|DEVICE|Traditional technique|Metal Stainless stain crown placed with Traditional technique
47960692|NCT00003568|BIOLOGICAL|aldesleukin|
47960693|NCT00003568|BIOLOGICAL|gp100 antigen|
47960694|NCT00003568|BIOLOGICAL|incomplete Freund's adjuvant|
48482861|NCT00004481|PROCEDURE|genetic testing|
48482862|NCT04798482|DRUG|Dexmedetomidine|Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
47960695|NCT04775069|BIOLOGICAL|BNT162b2|Intramuscular injection
47960696|NCT04775069|BIOLOGICAL|CoronaVac|Intramuscular injection
47960697|NCT04775069|BIOLOGICAL|AZD1222|Intramuscular injection
48112645|NCT02633423|PROCEDURE|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
48308508|NCT04372576|DIAGNOSTIC_TEST|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
48308509|NCT05490628|OTHER|Cognitive Rehabilitation|Language, memory, attention and executive function exercises are performed for the participants' deficient cognitive functions.
48308510|NCT05490628|OTHER|Conventional Therapy|Strengthening, walking, balance and coordination exercises are performed according to the needs of the participants.
48308511|NCT02191423|DRUG|Oxytocin|administered pre-fMRI assessment
47960698|NCT03374969|BEHAVIORAL|Attachment and Biobehavioral Catch-Up|Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
48112646|NCT02633423|PROCEDURE|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
48112647|NCT02633423|PROCEDURE|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
48308512|NCT02191423|DRUG|placebo|administered pre-fMRI assessment
48308513|NCT02191423|BEHAVIORAL|Dyadic psychotherapy|
48308514|NCT01003561|PROCEDURE|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
48308515|NCT03648476|BEHAVIORAL|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
48308516|NCT00048594|DRUG|aprepitant|
48308517|NCT00048594|DRUG|Comparator: placebo (unspecified)|
48482863|NCT05057052|DRUG|Sintilimab|Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
48482864|NCT05057052|DRUG|Regorafenib|Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48482865|NCT05057052|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
48482866|NCT04995120|DRUG|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
48482867|NCT01008137|BIOLOGICAL|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
48482868|NCT01008137|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
48482869|NCT06460961|BIOLOGICAL|MK-6837|IV Infusion
48482870|NCT06460961|BIOLOGICAL|Pembrolizumab|IV Infusion
48482871|NCT01045707|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
48482872|NCT01045707|DRUG|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
48482873|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30)
48308518|NCT01146067|DRUG|Rivastigmine|Rivastigmine capsules 1.5 mg
48308519|NCT01577160|DRUG|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
48308520|NCT04420416|OTHER|Survey|The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
48482874|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30-200,201)
48482875|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30)
48642292|NCT00702533|DRUG|Pentagastrin|
48642293|NCT04775524|BEHAVIORAL|Storytelling Through Music (STM)|6 week expressive arts-based program
48112648|NCT02633423|PROCEDURE|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
48308521|NCT03709810|COMBINATION_PRODUCT|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
48308522|NCT03709810|OTHER|No Adhesive|No adhesive will be applied.
48308523|NCT02858609|OTHER|Nasopharyngeal Swab|
48308524|NCT02394444|OTHER|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
48308525|NCT01956409|DRUG|18F-FCH|
48308526|NCT01956409|DRUG|Magnevist|
48308527|NCT05392127|DRUG|SHR0302 Tablets|SHR0302 Tablets once daily
48308528|NCT05392127|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
48308529|NCT05392127|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
47960699|NCT03374969|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
47960700|NCT03629431|PROCEDURE|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
48308530|NCT05392127|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
48308531|NCT05392127|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
48112649|NCT01285830|DIETARY_SUPPLEMENT|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
48112650|NCT01285830|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
48112651|NCT04518748|DRUG|Yttrium-90|Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
48112652|NCT04518748|DEVICE|Selective Internal Radiation Therapy|SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
48112653|NCT04518748|RADIATION|Stereotactic Body Radiation Therapy|3-5 fractions over 1-2 weeks, after Y-90 SIRT
48112654|NCT04518748|DIAGNOSTIC_TEST|PET/CT|Within 3 hours of completing Y-90 SIRT
48308532|NCT05392127|DRUG|Repaglinide Tablets|Repaglinide Tablets single dose
48308533|NCT04527354|DRUG|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
48308534|NCT04527354|DRUG|Placebo|Participants will receive Placebo once a day during 4 weeks
48308535|NCT03010995|DRUG|Prazosin|Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
48308536|NCT01241851|BEHAVIORAL|Aerobic exercise|
48308537|NCT01241851|BEHAVIORAL|Resistance exercise|
48308538|NCT06042751|BEHAVIORAL|Exercise Therapy|Six online consultations will take place on the basis of the sports medicine assessment every two weeks, resulting in 300 min in 3 months. For the home-based implementation, participants receive wearables with which the activity and training data are collected. In conjunction with feedback, the goal is to ensure that the interventions lead to improvements in self-control, reduced resilience, and fatigue without overwhelming participants with volume or intensity. Due to the expected large differences in personal performance, determined in the initial assessment, the exercise plan is individually designed and regularly adjusted. This includes control of everyday activity as well as moderate endurance and strengthening exercises totalling up to 30min daily. The individual training intensity is below the aerobic lactate threshold so that overload is avoided. The average training heart rate is planned to be in the range between 50 and 70% of the maximum heart rate.
48482876|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30-200,201)
48482877|NCT01072786|BIOLOGICAL|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
47960701|NCT03629431|PROCEDURE|postoperative standard care|Standard care received postoperatively
47960702|NCT03385200|DRUG|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
48112655|NCT04518748|DEVICE|Therasphere|Glass microspheres containing Y-90, administered at day 0 by SIRT
48112656|NCT01830946|OTHER|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
48266642|NCT02419976|OTHER|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
47960703|NCT02124525|DRUG|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
48266643|NCT02419976|DEVICE|Aeonose|
48308539|NCT06042751|BEHAVIORAL|Psychotherapy|Six online consultations will take place based on the psychosocial assessment and the initial psychosomatic interview every two weeks, resulting in 300 min in 3 months. A structured, telemedicine-supported, modularized, brief psychosomatic intervention is planned with a focus on psychoeducational elements, promotion of self-management, improvement of illness acceptance, modification of self-monitoring, and learning to cope with altered performance levels. The six modularized telemedical sessions taking into account the specific deficits identified in the psychosomatic evaluation. Within the sessions, starting points are identified with the patients, which the patients can work on independently between the sessions.
48308540|NCT00005117|DRUG|pravastatin|
48308541|NCT05607290|BEHAVIORAL|Cognitive-Behavioral Treatment|12 sessions of Cognitive-Behavioral Treatment for Alcohol Use Disorder
48482878|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
48642294|NCT04775524|BEHAVIORAL|Wait List / Storytelling Through Music-Hybrid|2 week song listening program
47960704|NCT06129838|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
47960705|NCT04560036|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
47960706|NCT00887874|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
47960707|NCT00003473|DRUG|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
47960708|NCT00003473|DRUG|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
47960709|NCT05058820|OTHER|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
47960710|NCT05058820|OTHER|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
47960711|NCT04252781|OTHER|Exhaustive exploration|"* clinical investigations~* imagery~* blood assessment~* functional respiratory investigations~* muscle function / skeletal muscle index"
48112657|NCT01830946|OTHER|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
48112658|NCT01830946|OTHER|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
48482879|NCT05854459|OTHER|HIIT and Nordic Curl exercise program|The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
48482880|NCT05854459|OTHER|HIIT-only program|The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.
48482881|NCT05704972|OTHER|the operating room environment risk|in determining the risks they face in the operating room environment.
48642295|NCT05965466|PROCEDURE|Distal gastrectomy and radical resection|Distal gastrectomy and Roux-en-Y anastomosis
47960712|NCT06027294|PROCEDURE|Ischemic Conditioning|A cuff will be inflated to a pressure of 225 mmHg.
47960713|NCT05116878|DIETARY_SUPPLEMENT|Omega-3|One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
47960714|NCT05116878|DIETARY_SUPPLEMENT|Placebo|One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
47960715|NCT00057889|BIOLOGICAL|ipilimumab|
48112659|NCT01101685|DRUG|Escitalopram|7 days dosing of 10mg per day
48112660|NCT01101685|DRUG|Placebo|7 days dosing at 10mg daily
48112661|NCT06461624|BIOLOGICAL|anti-GPC3 CAR-T|All subjects were intravenous administrated with CBG166.
48112662|NCT06450730|BEHAVIORAL|Cognitive-Behavioral Therapy: face-to-face + app|"This group will receive three 1-hour face-to-face CBT sessions (1,3,8). Participants will be involved in psychoeducation and practical activities related to psychological variables crucial for the adequate management of the disease (emotion regulation, self-efficacy, psychological flexibility, decision-making, etc.). These activities will include role-playing, discussions, and assignments to highlight the importance of emotions, thoughts, and healthy behaviors in managing diabetes and and their impact on the quality of life.~For the online sessions, an app will be developed to complement the face-to-face intervention. Participants will engage in 5-weeks of exercises with weekly activities related to the intervention content (2,5,6,7). The structure of the activities will mirror that of the face-to-face sessions and will include tasks, self-report instruments, reinforcement and activity monitoring. In addition, the app will incoportate multiple resources (texts, slides, videos)."
48112663|NCT06203639|OTHER|UR Caregiver|The UR Caregiver app was informed by previous research and developed in collaboration with caregiver partners. The app utilizes cognitive behavioural principles and is consistent with models of stress and coping. The app consists of seven modules. The app is available on IOS and Googe Play store. In addition to the didactic information provided in the app, worksheets are available in each module to practice the strategy/skill provided.
48482882|NCT04663438|DRUG|Chemotherapy Drugs, Cancer|Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
48482883|NCT02623452|DRUG|Insulin Lispro|Administered subcutaneously (SC)
48482884|NCT03360357|PROCEDURE|Guided drills|"These residents will perform 5 set of exercises:~1. Needle Dance (Learning to manipulate the suture)~2. Loopy Loop (Learning to place needle through a loop)~3. Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~4. Dense Matter (Passing the needle through dense material without losing control of the needle)~5. Respect for tissue (Passing the needle through flimsy material without tearing)"
48642296|NCT05965466|PROCEDURE|Total gastrectomy and radical resection|Total gastrectomy and Roux-en-Y anastomosis
47960716|NCT01325961|RADIATION|Intensity-Modulated Radiation Therapy|
47960717|NCT00324792|DRUG|intensive insulin therapy|
47960718|NCT03318510|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
47960719|NCT04710394|BEHAVIORAL|Smell Training|Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
47960720|NCT02018068|OTHER|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
47960721|NCT02018068|OTHER|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
47960722|NCT06557200|BEHAVIORAL|Digital Infant- parents support|A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
47960723|NCT05456165|DRUG|GRT-C901|An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
47960724|NCT05456165|DRUG|GRT-R902|An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
47960725|NCT05456165|DRUG|Atezolizumab|Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.
47960726|NCT05456165|DRUG|Ipilimumab|Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.
47960727|NCT05456165|DRUG|Adjuvant chemotherapy|Administered according to standard of care.
47960728|NCT04960631|DIAGNOSTIC_TEST|Double site CT guided needle biopsy|Double site CT guided needle biopsy
48112664|NCT06203639|OTHER|CLEAR Dementia Care|A subset of participants will be randomly assigned to use the CLEAR Dementia Care app as part of an active control group. The app consists of features that primarily address care-related needs (as opposed to stress management strategies) allowing for a comparison with the UR Caregiver app. The app was developed by the Northern Health and Social Care Trust (Northern Ireland) and is freely available on both IOS and Google Play stores. The CLEAR Dementia Care app provides users with information about dementia (e.g., the different types of dementia, how dementia affects the brain, and symptoms associated with dementia). The app offers suggestions and alternative approaches to various care-related situations through illustrations/images that caregivers may experience.
48112665|NCT06397105|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy will comprise a digital support program that participants can access via the internet."
48112666|NCT01711710|DEVICE|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
48112667|NCT05011734|OTHER|Fast Track recovery pathway|Multidisciplinary approach alongside the orthopedic surgeon
48112668|NCT03053388|DRUG|Nitric Oxide|Nitric Oxide given via inhalation in cycles
48112669|NCT03053388|OTHER|Supportive treatment|Supportive treatment (including oxygen)
48482885|NCT04893122|OTHER|COVID-19 pandemic|Study focuses on the impact of the COVID-19 pandemic on emergency attendances and admissions.
48482886|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
48482887|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
47960729|NCT03584178|DEVICE|Budesonide via MAD device|Delivery through Mucosal Atomization Device
48482888|NCT05742919|DRUG|NC0194-0499|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
48482889|NCT04424849|DIAGNOSTIC_TEST|CT-Scan|Chest CT scan on admission to the intensive care unit
48482890|NCT01983514|DRUG|8IU intranasal oxytocin|
48482891|NCT01983514|DRUG|24 IU intranasal oxytocin|
47960730|NCT03584178|DEVICE|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
47960731|NCT00509444|BEHAVIORAL|Educational materials|
47960732|NCT00509444|BEHAVIORAL|educational materials, plus patient navigation|
48482892|NCT01983514|DRUG|1 IU intravenous oxytocin|
48482893|NCT01983514|DRUG|Placebo|
48482894|NCT00149149|OTHER|Zinc Carnosine coadministered with Indomethacin|
48482895|NCT00149149|OTHER|Placebo coadministered with Indomethacin|
48308542|NCT02883582|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
48308543|NCT02883582|DEVICE|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
48308544|NCT00343304|DEVICE|Robot|
47960733|NCT05200832|OTHER|Online questionnaire|Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.
47960734|NCT05200832|OTHER|Semi-structured interview|20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
48308545|NCT00343304|DEVICE|Ergometer|
48308546|NCT05420272|BEHAVIORAL|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
48308547|NCT02834052|DRUG|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
48308548|NCT02834052|DRUG|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
47960735|NCT03218709|COMBINATION_PRODUCT|High-dose multi-vitamins with minerals|The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
48112673|NCT03594396|DRUG|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
48112674|NCT03594396|DRUG|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
48308549|NCT05740449|DRUG|Decitabine|intravenous
48112675|NCT02044588|BIOLOGICAL|HBsAg positive kidney allograft donor|
48112676|NCT05263037|DEVICE|EaseVRx|VR software with interactive content
48112677|NCT05263037|DEVICE|Sham VR|VR with neutral non-interactive content
48112678|NCT00715494|BEHAVIORAL|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
48266644|NCT01823068|DRUG|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
48308550|NCT05740449|DRUG|Venetoclax|oral
48308551|NCT05740449|DRUG|Navitoclax|oral
48308552|NCT05740449|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
48308553|NCT04005209|DRUG|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
48308554|NCT04005209|OTHER|Pain management|Pain management
48308555|NCT04212793|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
48308556|NCT04212793|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
48308557|NCT05813327|DRUG|ADI PEG20|ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.
48642297|NCT05787483|BEHAVIORAL|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
48308558|NCT05813327|DRUG|Ifosfamide|Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
48308559|NCT05813327|RADIATION|Radiotherapy|Radiotherapy will begin on C2D1 and will continue as per institutional practice.
48642298|NCT05787483|BEHAVIORAL|active control group|business as usual; regular wellness or SEL classes
48642299|NCT06411860|OTHER|Placebo|Participants will receive a subcutaneous (SC) injection of placebo.
48642300|NCT06411860|DRUG|Olpasiran|Participants will receive a SC injection of olpasiran at dose level 1 or 2.
48642301|NCT06411860|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
48642302|NCT00049283|DRUG|erlotinib hydrochloride|Given orally
48266645|NCT02250209|DRUG|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14\~16 cycles.
48308560|NCT05813327|DRUG|Mesna|Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
48308561|NCT06424873|RADIATION|PET/CT with FDG or FES|The study consists of an additional 50 minutes of imaging during the radiotracer's uptake phase prior to their clinical scan (standard of care).
48482896|NCT04618978|PROCEDURE|PSG and actigraphy recording|"Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record)."
48642303|NCT00049283|DRUG|docetaxel|Given IV
48642304|NCT00049283|RADIATION|radiation therapy|Undergo radiotherapy
48642305|NCT00049283|PROCEDURE|therapeutic conventional surgery|Undergo neck dissection
48642306|NCT00049283|OTHER|laboratory biomarker analysis|Correlative studies
48308562|NCT01576016|DEVICE|Accent MRI system (lead safety)|Patients implanted with an Accent MRI system
48308563|NCT01576016|DEVICE|Accent MRI system (with MRI scan)|Patients implanted with an Accent MRI system will receive an MRI scan
48482897|NCT01602016|DRUG|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
48482898|NCT01602016|DRUG|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
48482899|NCT00141141|DRUG|Atorvastatin|
48482900|NCT00141141|DRUG|Simvastatin|
48482901|NCT01891812|DRUG|Nitrous oxide 50%|
48482902|NCT01026259|OTHER|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
48642307|NCT00049283|OTHER|pharmacological study|Correlative studies
48642308|NCT05720884|DEVICE|acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used.
47960736|NCT03218709|COMBINATION_PRODUCT|Low-dose multi-vitamins with minerals|The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
48642309|NCT05720884|DEVICE|placebo acupuncture|Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used but in differene location.
48308564|NCT06103695|DRUG|Tapinarof|Add on Vtama (tapinarof) to biololgic therapy
47960737|NCT03218709|COMBINATION_PRODUCT|Hypouricemic tablets|The hypouricemic tablets contained skipjack,salvia and rosemary extract.
48308565|NCT04227249|PROCEDURE|no lymph node dissection|do not undergo lymph node dissection
47960738|NCT03218709|COMBINATION_PRODUCT|Placebo|The placebo tablets contained maltodextrin and tartrazine.
48308566|NCT00648843|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
47960739|NCT04335097|DEVICE|Biosensors|Sensor that detect vital signs
47960740|NCT01812031|OTHER|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
47960741|NCT05882942|DIETARY_SUPPLEMENT|Matcha green tea|This is the condition with the Matcha green tea
47960742|NCT05882942|DIETARY_SUPPLEMENT|Placebo|This is the condition with the placebo
48112679|NCT00992173|DRUG|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
47960743|NCT04526860|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
47960744|NCT00828997|BIOLOGICAL|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
48308567|NCT00648843|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
48308568|NCT02912000|BEHAVIORAL|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
48482903|NCT01026259|OTHER|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
48482904|NCT04510129|DIAGNOSTIC_TEST|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
47960745|NCT03423082|DRUG|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
47960746|NCT03423082|DEVICE|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
48112680|NCT06385886|BEHAVIORAL|Linkage Coordinator|The Linkage Coordinator (LC) will be the initial contact with unaffiliated SCD patients to establish a relationship, champion preventative services, and support them in engaging with an SCD specialist by helping patients address barriers to care. Study staff will provide initial and ongoing training to the LC to ensure they have adequate support to effectively engage with patients.
48112681|NCT04184336|OTHER|surveillance|
48642310|NCT03802799|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
48642311|NCT05655507|DRUG|Zuranolone|Administered as capsules
48642312|NCT05143957|DRUG|sapablursen|Sapablursen will be administered by SC injection.
48642313|NCT06694051|PROCEDURE|marking|axis marking
48642314|NCT06121635|COMBINATION_PRODUCT|Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation|At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.
47960747|NCT05979259|OTHER|Serious game nutrition education intervention|"Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will play the Foodbot Factory nutrition education serious game for 10-15 minutes. The Foodbot Factory serious game and lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide."
47960748|NCT05979259|OTHER|Conventional nutrition education intervention|Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will use conventional learning activities, such as worksheets, sourced from an online teaching resource repository. The lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide.
47960749|NCT00242216|DRUG|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
47960750|NCT00242216|DRUG|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
47960751|NCT03070028|PROCEDURE|crystallised phenol|crystallised phenol will be applied to sinus cavity
47960752|NCT03070028|PROCEDURE|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
47960753|NCT02292121|PROCEDURE|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
47960754|NCT02292121|OTHER|a solution of mannitol and lactitol|
47960755|NCT02481908|DEVICE|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
47960756|NCT01553383|DEVICE|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
48112682|NCT00491517|DRUG|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
48112683|NCT00491517|DRUG|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
48112684|NCT01720550|DRUG|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
48112685|NCT01720550|DRUG|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
48642315|NCT06121635|COMBINATION_PRODUCT|Sham ts-DCS and sham t-DCS|Sham ts-DCS and sham t-DCS
48642316|NCT03508700|DRUG|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
47960757|NCT04827381|OTHER|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
47960758|NCT04827381|OTHER|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
47960759|NCT05231057|OTHER|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
47960760|NCT05231057|OTHER|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
47960761|NCT04399226|DRUG|Dexmedetomidine|Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine).
48112686|NCT00666276|DRUG|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
48112687|NCT04567407|DRUG|Bilateral erector spinae blocks using ropivacaine|Bilateral chest wall nerve blocks using ropivacaine.
48112688|NCT00777816|DRUG|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
48112689|NCT00777816|DRUG|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
48112690|NCT01970358|BIOLOGICAL|Poly-ICLC|
48112691|NCT01970358|BIOLOGICAL|Peptides|
48112692|NCT05821322|OTHER|Physical activity trial intervention|60 minutes aerobic ergocyle exercice at 60% VO2 Peak
48112693|NCT06676397|PROCEDURE|Blood Punction|venous blood sampling
48642317|NCT06305767|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every 3-week cycle for up to 4 neoadjuvant cycles, and up to 13 adjuvant cycles for Perioperative Cohort participants.
47960762|NCT03998488|DRUG|Fecal Microbiota Transplantation|"The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery."
47960763|NCT03998488|DIETARY_SUPPLEMENT|Psyllium Husk Powder|"All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat."
48112694|NCT06500962|BEHAVIORAL|Usual Care|Participants will receive a message sent to their electronic health record portal with instructions about how to sign up for a food is medicine program.
48112695|NCT06500962|BEHAVIORAL|Navigation|Participants will receive a weekly phone call from a navigator to promote enrollment in the food is medicine program and address any barriers to participation.
48112696|NCT06500962|BEHAVIORAL|Text Messaging|Participants will receive two text messages per week to promote healthy eating, enrolling in a food is medicine program, and continuing to participate in a food is medicine program.
48112697|NCT03854253|PROCEDURE|Long introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
48112698|NCT03854253|PROCEDURE|Short introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
48112699|NCT01872403|DRUG|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
48112700|NCT05007678|DRUG|leflunomide|leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days
48112701|NCT04217850|OTHER|250 kcal Dietary Energy Restriction|The nutrition intervention will be individualized and implemented as a free-living energy-restricted eating plan where energy intake will be based on a mild restriction (approx. 250 kcal/day).
48112702|NCT04217850|OTHER|Aerobic Exercise|Supervised aerobic exercise will be combined with the energy restriction. Individuals will perform aerobic exercise (treadmill, cycle, or rower or combination) 4-5 days per week for 12 weeks. At each session they will expend 250 or more calories to further meet or exceed the 500 kcal energy deficit.
48112703|NCT06668597|BEHAVIORAL|Motivational educational program to improve sleep quality in OSA patients through adherence to CPAP|Phase 1 (Pre-adaptation Psychoeducation): The participant will be shown, within two days prior to the home visit by the provider, which usually takes place within three days of the visit with the pulmonologist, the necessary materials (device, masks, and tubing), along with an educational video on the topic of OSA (duration 25 minutes); Phase 2 (Motivational Interview): Following the first night of titration and use of the CPAP, the participant will be contacted by phone for a brief motivational interview (duration 25 minutes); Phase 3 (Psychological Support Interview): One week after the provider's intervention and the start of the CPAP adaptation period, the participant will be contacted again for a support interview regarding the adaptation process to CPAP (duration 40 minutes). The first week of adaptation is considered a high-risk period for abandonment of device use; Phase 4 (Monitoring Interview): Two weeks after the provider's intervention and the start o
48112704|NCT05440981|DEVICE|iTind device|Cystoscopy will be performed to assess the anatomy of the bladder and prostate. The iTind device would be inserted under visual guidance into the bladder. The device will then be deployed and under visual guidance, it will be positioned at the prostatic lumen. After confirming the position of the device, cystoscopy will be withdrawn and the position will be finished.
48482905|NCT05506878|DEVICE|NSS-2 BRIDGE|"NBD® will be applied to either the right or left ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.~Once the device is placed, subjects will be asked to perform a pinch test throughout the duration of their time wearing the device. To perform the pinch test subjects must pinch down on the electrodes and ground to ensure the electrodes are still placed in their designated locations and have not come loose."
48642318|NCT06305767|BIOLOGICAL|V940|Administered via IM injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.
48642319|NCT06305767|OTHER|Placebo|V940 diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.
48482906|NCT05506878|DEVICE|Sham NSS-2 BRIDGE|Sham NBD® will be applied to either the left or right ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.
47960764|NCT04465110|DIETARY_SUPPLEMENT|Grape Seed Extract|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
47960765|NCT04948528|OTHER|Active Comparator: Surgery Pathology or Cystoscopy|Case group will be followed up with surgery pathology or cystoscopy.
47960766|NCT04948528|OTHER|Active Comparator: Clinical Diagnosis|Control group will be diagnosed in clinical.
47960767|NCT00372762|DRUG|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
47960768|NCT00372762|DRUG|Bumetanide|Equivalent dose to pre-existing furosemide will be used
47960769|NCT00372762|DRUG|furosemide|20mg to 80mg orally once or twice daily
47960770|NCT00372762|DRUG|bumetanide|0.5mg to 2mg orally once or twice daily
47960771|NCT03307681|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
47960772|NCT03307681|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
47960773|NCT03307681|OTHER|Mashed potato served hot|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
47960774|NCT03307681|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
48482907|NCT01098994|DIETARY_SUPPLEMENT|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
48482908|NCT01098994|OTHER|Dummy pills|Daily placebo administration for 8 weeks
48482909|NCT02562417|DRUG|Normal saline|
48482910|NCT02562417|DRUG|IV dexamethasone|
48482911|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
48482912|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
48482913|NCT03311152|DIAGNOSTIC_TEST|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
48482914|NCT06061406|DEVICE|smart visit app|"Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician."
48482915|NCT01975194|DRUG|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
48482916|NCT00138957|PROCEDURE|Laparoscopic parastomal hernia repair with mesh|
48482917|NCT05274672|DRUG|Nitrofurantoin|Prophylactic postoperative antibiotic use
48482918|NCT05274672|DRUG|Cephalexin|Prophylactic postoperative antibiotic use
48482919|NCT05274672|DRUG|Sulfamethoxazole Trimethoprim Combination|Prophylactic postoperative antibiotic use
48482920|NCT05274672|DRUG|Ciprofloxacin|Prophylactic postoperative antibiotic use
48482921|NCT05274672|PROCEDURE|Holmium Laser Enucleation of prostate|Endoscopic transurethral Holmium Laser enucleation of enlarged prostate followed by morcellation of prostatic tissue
48482922|NCT00869986|DRUG|dirucotide|500mg, intravenous, every 6 months for 15 months
48482923|NCT00869986|DRUG|placebo|intravenous, once every six months for 15 months
47960775|NCT03307681|OTHER|Meal skipping|No food given
47960776|NCT01000402|DRUG|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
47960777|NCT05106517|DRUG|Denosumab|Denosumab 60mg/6 months subcutaneously + placebo iv
47960778|NCT05106517|DRUG|Zoledronic acid|Iv zoledronic acid and placebo /6 months subcutaneously
47960779|NCT02265068|DRUG|Ticagrelor|Treatment of ACS patients with Ticagrelor
47960780|NCT04953754|DIETARY_SUPPLEMENT|Melatonin|The melatonin group will receive 5mg melatonin nightly
47960781|NCT04953754|DEVICE|Phillips Actiwatch Spectrum Plus|Both groups will be monitored by the FDA-cleared Actigraph
47960782|NCT01466153|DRUG|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
47960783|NCT01466153|DRUG|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
47960784|NCT01466153|DRUG|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
47960785|NCT05693948|OTHER|Other: Serum X|Serum X contain arbutin and glutathione
47960786|NCT01842022|DIETARY_SUPPLEMENT|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
47960787|NCT01842022|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
48112705|NCT03343938|OTHER|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
48112706|NCT01820195|DRUG|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
48112707|NCT01820195|DRUG|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
47960788|NCT01842022|DIETARY_SUPPLEMENT|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
47960789|NCT01215565|DRUG|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
47960790|NCT05817643|DRUG|BMS-984923|Oral capsule
47960791|NCT01686828|DRUG|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
47960792|NCT01686828|DRUG|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
47960793|NCT01686828|DRUG|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
47960794|NCT01686828|DRUG|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
47960795|NCT01686828|DRUG|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
47960796|NCT06222190|RADIATION|online-adaptive radiotherapy|A conebeam CT is taken to determine the current tumour extent and the deformations occurring in comparison to the dose distribution to be applied. Normal tissues heart, lung and tracheal tree are automatically contoured by the Ethos therapy system in that cone-beam CT. A specialist physician and a physicist are present during this process. These organ contours are used to determine the extent of the current target volume and the adaptive radiotherapy plan is adjusted to the new target volume. If the current tumour extent is not sufficiently covered by the initial radiotherapy plan planned for the series with its planned tolerances, or if the surrounding normal tissue is exposed to too much radiation, then the online adaptive radiotherapy plan for the current treatment is selected by the specialist. Otherwise, the initial radiotherapy plan is used for IGRT.
47960797|NCT05163236|DIAGNOSTIC_TEST|Positive fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
47960798|NCT05163236|DIAGNOSTIC_TEST|Negative fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
47960799|NCT05163236|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT) not performed|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
47960800|NCT00919425|OTHER|biologic sample preservation procedure|
47960801|NCT06021197|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of CIAS
48112708|NCT01820195|DRUG|Placebo group|The patients in this group will be received both oral placebo and IV placebo
48112709|NCT05789472|BEHAVIORAL|Assessment|Executive functions and reaction times of all participants will be measured.
48112710|NCT04650386|BEHAVIORAL|Psychosocial support determined by adaptive treatment algorithm|Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
48112711|NCT02570542|PROCEDURE|leukapheresis|
48112712|NCT02570542|DRUG|Plerixafor|Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
48112713|NCT02570542|DRUG|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
48112714|NCT02570542|PROCEDURE|Autologous Stem Cell Transplantation|
48482924|NCT01387425|DRUG|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
47960802|NCT06021197|DRUG|Placebo Cap|Use of placebo as a comparator
47960803|NCT00001880|DRUG|methotrexate|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
47960804|NCT00001880|DRUG|Cyclosporin|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
47960805|NCT00244062|BEHAVIORAL|counseling|
47960806|NCT00252915|BIOLOGICAL|GM-CSF (verum)|sagramostim
47960807|NCT04437186|BEHAVIORAL|Recovery program|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
47960808|NCT06402071|DIAGNOSTIC_TEST|Ascitic fluid study|Ascitic fluid study will be obtained from all participants
47960809|NCT02358174|PROCEDURE|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
48112715|NCT05776680|OTHER|Psychological support|60-minute once or twice a week for 6 months of Initial Remote Psychological Support Course .
48112716|NCT01305291|OTHER|placebo|
48112717|NCT01305291|DIETARY_SUPPLEMENT|digestion-resistant maltodextrin|
48112718|NCT03347942|BEHAVIORAL|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
48112719|NCT03347942|OTHER|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
48308569|NCT02466737|PROCEDURE|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
48482925|NCT01387425|DRUG|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
47960810|NCT02358174|OTHER|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
47960811|NCT02358174|OTHER|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
48112720|NCT04290117|BEHAVIORAL|Acceptance and Commitment Training|During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
48308570|NCT02466737|PROCEDURE|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
48308571|NCT01324583|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
48482926|NCT05306951|DIAGNOSTIC_TEST|Computed tomography|Head computed tomography
47960812|NCT05436093|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
47960813|NCT03857893|DEVICE|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
47960814|NCT03857893|DRUG|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
47960815|NCT02538029|BEHAVIORAL|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
47960816|NCT02538029|BEHAVIORAL|Single Task Group|Performing motor or cognitive tasks alone.
48112721|NCT04290117|BEHAVIORAL|Sleep Hygiene and bright light in the morning|During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
48112722|NCT06164327|DRUG|BEBT-908 for Injection|BEBT-908 for Injection,dosage of administration:15mg/m\^2 or 22.5mg/m\^2，frequency and duration of administration:on the 1st,3rd,5th,8th,10th and 12th days of each cycle,and 21 days as a cycle.
48112723|NCT06164327|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:on the 1st day of each cycle, and 21 days as a cycle.
48112724|NCT06164327|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection，dosage of administration:1g/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
48112725|NCT06164327|DRUG|Oxaliplatin Injection|Oxaliplatin Injection，dosage of administration:100mg/m\^2,frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
48308572|NCT01324583|DRUG|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
48482927|NCT06449872|DEVICE|Obstetrics and Gynecology clinical applications for ultrasound diagnostic systems|Up to 5 healthcare professionals trained and experienced in Obstetrics and Gynaecology ultrasound qualitatively assessed the diagnostic image quality of the Kosmos Diagnostic Ultrasound System against the benchmark Mindray M9 Ultrasound System.
48482928|NCT01453621|OTHER|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
48482929|NCT03121014|DRUG|Fludarabine|40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
48482930|NCT03121014|DRUG|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
48482931|NCT03121014|DRUG|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
48482932|NCT03121014|RADIATION|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
48482933|NCT03121014|PROCEDURE|Stem Cell Product Infusion|Day 0 according to BMT unit policy
48482934|NCT03121014|DRUG|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
48482935|NCT03121014|DRUG|Methotrexate|5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
48482936|NCT04686513|OTHER|Observation|observational study
48482937|NCT00006143|DRUG|Somatropin|
48482938|NCT04569513|BIOLOGICAL|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
47960817|NCT03006107|PROCEDURE|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
47960818|NCT03006107|PROCEDURE|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
48482939|NCT01419587|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
48482940|NCT00977548|DRUG|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
48112726|NCT06164327|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2，frequency and duration of administration:on the 1st,2nd and 3rd days of each cycle,and 21 days as a cycle.
48308573|NCT01537770|PROCEDURE|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
48308574|NCT01537770|PROCEDURE|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
48482941|NCT04703621|DRUG|Daratumumab Injection|subcutaneious daratumumab administration
48482942|NCT06363253|OTHER|No specific intervention|"Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).~Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention~Control subjects will have no interventions performed as well."
48482943|NCT05893446|DIETARY_SUPPLEMENT|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
48482944|NCT03326986|DRUG|MK-7252|1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
48482945|NCT03326986|DRUG|Placebo|Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
47960819|NCT04226872|BEHAVIORAL|My Tools for Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
47960820|NCT02023606|DRUG|SPN-810M|
47960821|NCT04388878|DRUG|PF-07054894|Participants will receive oral ascending doses
47960822|NCT04388878|DRUG|Placebo|Participants will receive matching placebo
47960823|NCT04131426|DRUG|Remune|Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
47960824|NCT04131426|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
47960825|NCT06557590|DIAGNOSTIC_TEST|18F-FAPI-04|18F-FAPI-04 was injected into the patients before the PET/CT or PET/MR scans
47960826|NCT03475823|DIETARY_SUPPLEMENT|Sideritis Scardica|Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
47960827|NCT03475823|DIETARY_SUPPLEMENT|Ginkgo biloba|Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
47960828|NCT03475823|DIETARY_SUPPLEMENT|Placebo control|An inert encapsulated powder provided by Finzelberg.
47960829|NCT03119233|DEVICE|PQ Bypass System|Intended use from CLN114 Rev F (CLN114 is the DETOUR2 protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
47960830|NCT00223262|DRUG|Lamotrigine (Drug)|
48642320|NCT06305767|BIOLOGICAL|Enfortumab Vedotin|Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every 3-week cycle for up to 4 neoadjuvant cycles, and up to 5 adjuvant cycles for Perioperative Cohort participants.
48642321|NCT06305767|PROCEDURE|Surgery (RC plus PLND)|Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines.
47960831|NCT05679323|OTHER|KATZ index of independence in activities of daily living|KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
48112727|NCT06164327|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,24 hours of continuous intravenous drip，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
48642322|NCT06290128|DRUG|Riliprubart|Pharmaceutical form:Solution-Route of administration:IV Infusion
48642323|NCT06290128|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:IV Infusion
48266646|NCT02250209|DRUG|Capecitabine|"Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles."
48482946|NCT04639297|DEVICE|NeuroVision® IONM|Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
48642324|NCT06290128|DRUG|Riliprubart|Pharmaceutical form:Solution-Route of administration:SC Injection
47960832|NCT03975036|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules
48482947|NCT04639297|DEVICE|Hospital Based IONM|Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
47960833|NCT03975036|DRUG|pd-1 antibody|Pembrolizumabinjection
47960834|NCT06074198|BEHAVIORAL|SuCCESs|strengthening and endurance exercises
47960835|NCT06506110|OTHER|Retrieving of retrospective data from Epic|Retrospective data from Epic will be extracted to determine the Patient Acceptable Symptom State (PASS) for the numeric rating scale (NRS) pain score in the first 48 hours after surgery in patients who received intravenous Patient Controlled Analgesia.
48482948|NCT00530543|PROCEDURE|Robot-assisted gait training|
48482949|NCT03323723|DEVICE|SUI Device|Pessary SUI device
48482950|NCT04685694|DRUG|Misoprostol|sl 800 mcg misoprostol
48482951|NCT02613078|BEHAVIORAL|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
48482952|NCT02613078|DIETARY_SUPPLEMENT|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10\^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
48482953|NCT02613078|BEHAVIORAL|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
48482954|NCT02502734|DRUG|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
48482955|NCT02502734|DRUG|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
48482956|NCT02502734|DRUG|Salbutamol|Salbutamol will be provided as a inhaler.
48482957|NCT02782091|BEHAVIORAL|Multiple Errands Test (MET)|1 hour assessment in an unknown district with 2 independent raters.
47960836|NCT03803995|PROCEDURE|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
47960837|NCT03803995|PROCEDURE|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
48482958|NCT01947478|DEVICE|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
48482959|NCT01947478|DEVICE|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
48642325|NCT06290128|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:SC Injection
48642326|NCT06593665|DRUG|Inrathecal Morphine|Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
48642327|NCT06593665|DRUG|Intravenous Methadone|Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
47960838|NCT06544889|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
48642328|NCT05367076|BEHAVIORAL|Web-based Aerobic Exercise Program|"Community based FTTs will use a web-based platform to deliver a 12-week exercise training program (120-minute group sessions of aerobic activity 3 times/week). Each session will include:~* Warm-up activities~* Aerobic activities and fitness training in a game-like fashion~* Organized sports/games~* Cool down activity~* Snack/reward time"
48642329|NCT04846881|DRUG|Iclepertin|Iclepertin
48642330|NCT04846881|DRUG|Placebo|Placebo
48642331|NCT04832854|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.
47960839|NCT00189995|DRUG|clozapine|
47960840|NCT00189995|DRUG|haloperidol|
48112728|NCT06164327|DRUG|Carboplatin Injection|Carboplatin Injection，dosage of administration:based on AUC=5, single dose ≤800 mg，frequency and duration of administration:on the 2nd day of each cycle, and 21 days as a cycle.
48112729|NCT04572191|DIAGNOSTIC_TEST|CERAMIDE LEVEL IN BLOOD|BY ELISA ASSAY TO DETECT CERAMIDE LEVEL IN BLOOD IN ANTERIOR STEMI PATIENTS
48112730|NCT06225427|PROCEDURE|Biopsy|Undergo tissue biopsy
48112731|NCT06225427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48112732|NCT06225427|PROCEDURE|Computed Tomography|Undergo CT scan
48112733|NCT06225427|PROCEDURE|Echocardiography|Undergo echocardiography
48112734|NCT06225427|DRUG|Gilteritinib|Given PO
48112735|NCT06225427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48112736|NCT06225427|OTHER|Questionnaire Administration|Ancillary studies
48112737|NCT04169399|DRUG|Toripalimab|240mg intravenously every 3 weeks
48482960|NCT03928535|DEVICE|High-FlowNasal Cannula|High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
48482961|NCT03928535|DEVICE|Noninvasive Ventilation|Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation \[SaO2\] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
48482962|NCT05788575|PROCEDURE|surgery|any surgery that an inpatient has undergone
48482963|NCT04025138|OTHER|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)"
48112738|NCT04169399|RADIATION|Stereotactic body radiotherapy|Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
48112739|NCT01387334|BEHAVIORAL|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
48112740|NCT04429230|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline soaked (0.9% NaCl) surface sponge electrodes. Anodal stimulation will be given to brain area based on qEEG findings
48112741|NCT04429230|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Electrode placement will be the same as active stimulation but the electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
48642332|NCT04832854|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
48112742|NCT02916758|OTHER|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
48482964|NCT04025138|DEVICE|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
48642333|NCT04832854|DRUG|Carboplatin|Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.
48642334|NCT04832854|DRUG|Cisplatin|Cisplatin at 75 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
48112743|NCT00870207|BEHAVIORAL|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
48112744|NCT00323752|PROCEDURE|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
48112745|NCT02139748|PROCEDURE|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
48266647|NCT02250209|DRUG|Oxaliplatin|"Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles."
48642335|NCT04832854|DRUG|Pemetrexed|Pemetrexed at 500 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
48642336|NCT04832854|DRUG|Gemcitabine|Gemcitabine at 1000 or 1250 mg/m\^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
47960841|NCT05845736|DRUG|Antihypertensive Agents|number of hypertensive drugs
47960842|NCT01400763|DIETARY_SUPPLEMENT|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
47960843|NCT01400763|DIETARY_SUPPLEMENT|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
48642337|NCT04832854|DRUG|Paclitaxel|Paclitaxel at 175 or 200 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
48642338|NCT04211870|RADIATION|LED clusters|Each LED board contains six (6) LEDs with a wavelength of 660nm and a duration of seven (7) minutes in each muscle. The treatment was carried out in a total of four (4) sessions, one (1) session per week.
48642339|NCT04674306|BIOLOGICAL|α-lactalbumin vaccine|"α-lactalbumin vaccine will be administered subcutaneously in rotating sites (vaccine will not be administered in the arms of any participant, due to likelihood of prior bilateral mastectomy).~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 100 mcg~DL3: 500 mcg~D1b: 50 mcg~D1e: 10 mcg~D1f: 20 mcg~D1g: 20 mcg (D1g will only be utilized if D1c is deemed too toxic)"
48642340|NCT04674306|BIOLOGICAL|Zymosan|"Adjuvant used in vaccine preparation~DL1: 10 mcg~DL Original 2: 100 mcg~DL2: 10 mcg~DL3: 10 mcg~D1b: 10 mcg~D1e: 20 mcg~D1f: 20 mcg~D1g: 1o mcg (D1g will only be utilized if D1c is deemed too toxic)"
48642341|NCT03072849|PROCEDURE|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
47960844|NCT01400763|DIETARY_SUPPLEMENT|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
47960845|NCT01400763|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
47960846|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
47960847|NCT00934089|DRUG|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
47960848|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
47960849|NCT00934089|DRUG|latanoprost|Topical ocular solution, once-daily for 14 days
47960850|NCT05207046|OTHER|Mechanical Ventilation|Patients will be assessed and measurements will be taken during controlled ventilation (most likely \<72 hours of ICU admission), during partially assisted ventilation, and until spontaneous unassisted breathing is reached.
48112746|NCT02139748|PROCEDURE|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
48112747|NCT03546634|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
48482965|NCT04025138|OTHER|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
48482966|NCT04025138|OTHER|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
48482967|NCT04025138|BIOLOGICAL|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
48482968|NCT04025138|BIOLOGICAL|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
48482969|NCT03987555|OTHER|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
48482970|NCT03987555|OTHER|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
48482971|NCT03987555|OTHER|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
48482972|NCT00467831|DRUG|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
48482973|NCT00467831|DRUG|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
47960851|NCT05499858|OTHER|Spiced|Vegetables provided to volunteers will be spiced.
47960852|NCT05499858|OTHER|Plain|Vegetables provided to volunteers will be plain.
47960853|NCT05497609|OTHER|no intervention. Care as ususal|No intervention
47960854|NCT04216238|BEHAVIORAL|quasi-experimental Pre-test/Post-test design|surveys to document progress
48112748|NCT04448158|DIAGNOSTIC_TEST|Genotypic Resistance Test|"A Genotypic Resistance Test by Sanger sequencing will be done after the period of virological suppression.~* If M184V is still present no additional test will be performed.~* If M184V is absent, we will go back in the previous samples (one per year) to determine the time point where the mutation has been cleared by sanger and UDS sequencing."
48482974|NCT00467831|DRUG|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
48482975|NCT00467831|DRUG|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
48482976|NCT00467831|DRUG|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
48482977|NCT06061783|DRUG|Hypotonic Solution|"Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily."
48482978|NCT06061783|DRUG|Water Purified|administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
47960855|NCT04747509|OTHER|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
47960856|NCT04747509|OTHER|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
47960857|NCT03338010|DRUG|LY2963016|Administered SC
47960858|NCT03338010|DRUG|Lantus®|Administered SC
47960859|NCT03352297|BIOLOGICAL|Unfiltered Nanofat Graft|Nanofat created from microfat, skipping the filtration step. Intradermal and subdermal injections in post burn scars on the face.
47960860|NCT02573688|BEHAVIORAL|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
48112749|NCT05339763|RADIATION|chemoradiotherapy|exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
48112750|NCT02845063|BEHAVIORAL|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
48112751|NCT02845063|BEHAVIORAL|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
48112752|NCT02845063|GENETIC|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
48112753|NCT06302491|DRUG|AND017 capsules|Administer AND017 capsules once per day (QD)
48112754|NCT06302491|DRUG|AND017 Placebo|Administer AND017 matching placebo capsules once per day (QD)
48308575|NCT01839188|BIOLOGICAL|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Hepatitis B \[HB; Recombinant DNA\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
48308576|NCT01839188|BIOLOGICAL|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
47960861|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL) admixed with 0.47µg of recombinant double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant.
47960862|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL).
47960863|NCT05327426|BIOLOGICAL|Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain|Monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity.
48112755|NCT06338241|COMBINATION_PRODUCT|Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin|The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.
48112756|NCT06338241|OTHER|Bovine Hydroxyapatite|The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.
48112757|NCT00903227|DRUG|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
48112758|NCT00903227|DRUG|Placebo|1 puff of inhaled Placebo twice a day
48112759|NCT00903227|DRUG|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
48112760|NCT00903227|DRUG|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
48308577|NCT01839188|BIOLOGICAL|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
48308578|NCT01839188|BIOLOGICAL|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
48308579|NCT01839188|BIOLOGICAL|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine \[PCV; 13-valent, adsorbed\]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
48642342|NCT03072849|DRUG|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
48642343|NCT03976375|BIOLOGICAL|Pembrolizumab|IV infusion of pembrolizumab at 200 mg
48642344|NCT03976375|DRUG|Lenvatinib|Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.
48642345|NCT03976375|DRUG|Docetaxel|IV infusion of docetaxel at 75 mg/m\^2.
48642346|NCT06089746|OTHER|NIPT|Coordinated suite of DME and training to support continuous maintenance of flexion posture during the 6 week trial.
48642347|NCT02522611|DRUG|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
48642348|NCT06694428|OTHER|Reinterpretation of CMV serology results using the MyCMV tool on the basis of the serology results performed|"The CMV serology results of the patients will have been previously interpreted as part of the care on the basis of the entire virological file according to the reference method.~These results will be reinterpreted using the MyCMV tool on the basis of the serology results performed (IgM, IgG, avidity), CMV PCR, the date of sampling and the date of the start of pregnancy (or last period). This reinterpretation by the tool will be carried out as part of the study and will not be communicated to the patient or to the doctor prescribing the virological analyses."
47960864|NCT01536470|OTHER|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
47960865|NCT01536470|OTHER|Ephedryne chorydrate|
47960866|NCT03402646|BEHAVIORAL|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
47960867|NCT03402646|BEHAVIORAL|Photovoice|Same as described under arm/group descriptions
47960868|NCT01365052|DRUG|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
47960869|NCT01365052|DRUG|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
47960870|NCT02349061|DRUG|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
47960871|NCT02349061|DRUG|Placebo Infusion|Placebo intravenously at Week 0.
47960872|NCT02349061|DRUG|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
47960873|NCT02349061|DRUG|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
47960874|NCT02349061|OTHER|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
47960875|NCT01523262|PROCEDURE|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
47960876|NCT01523262|PROCEDURE|Normal surgery, with sham intervention without inflating arm cuff|
47960877|NCT03000569|DRUG|SAGE-217|
47960878|NCT03000569|DRUG|Levodopa|Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
48112761|NCT00903227|DRUG|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
48308580|NCT03417284|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HSCT
47960879|NCT03000569|DRUG|Antiparkinsonian Agent(s)|Antiparkinsonian agent(s) were administered as a clinical practice as standard of care, which includes levodopa (i.e. levodopa/carbidopa) or dopamine agonists or catechol-O-methyltransferase (COMT) inhibitors or monoamine oxidase (BMAO-B) inhibitors.
47960880|NCT00133913|PROCEDURE|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
47960881|NCT03840174|BIOLOGICAL|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
48112762|NCT01111526|DRUG|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m\^2 IV; DL 1: 2.5 mg/m\^2 IV; DL 2: 5 mg/m\^2 IV; DL 3: 7.5 mg/m\^2 IV; DL 4: 10 mg/m\^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
48112763|NCT04206215|DEVICE|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
48642349|NCT06694753|BIOLOGICAL|mRNA-1645-eODGT8|eOD-GT8 60mer is a self-assembling nanoparticle composed of 60 subunits of the engineered HIV-1 gp120 outer domain germline targeting version 8 (eOD-GT8) fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 15-amino acid Glycine-Serine linker. eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform. To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.
48112764|NCT04206215|DEVICE|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
48308581|NCT03417284|BIOLOGICAL|Filgrastim-sndz|Given SC
48308582|NCT03417284|DRUG|Melphalan Hydrochloride|Given IV
48308583|NCT06514885|OTHER|SDF solution application|silver diamine fluoride (SDF) solution is highly effective in stopping and arresting the progress of decay in dental roots of older adults. The American Dental Association (ADA) has published a guideline based on the up-to-date evidence to support the use of SDF for managing tooth decay. As a non-invasive procedure, application of SDF is simple, quick, painless and non-aerosol generated.
48112765|NCT06676774|DRUG|Oxytocin nasal spray|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.
48112766|NCT06676774|OTHER|Placebo|Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of placebo (0.9% normal saline) under the supervision of unblinded study personnel.
48112767|NCT03201549|DIETARY_SUPPLEMENT|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
48112768|NCT06023186|DRUG|mavacamten|Study participants will receive mavacamten under the standard of care
48112769|NCT03702647|DRUG|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
48112770|NCT03702647|DRUG|Normal saline|30mL of normal saline placed in the POEM tunnel
48308584|NCT06514885|OTHER|Tonic water|Tonic water will be used as a placebo to mimic the SDF solution.
48642350|NCT06694753|BIOLOGICAL|mRNA-1645-CoreG28v2|core-g28v2 60mer is a nanoparticle composed of 60 protein subunits of an engineered core-gp120 fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 21-amino acid Glycine-Serine linker. Core-g28v2 60mer will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.
47960882|NCT03840174|OTHER|Placebo|Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection
47960883|NCT00702195|DRUG|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
47960884|NCT00702195|DRUG|Placebo|single dose of placebo (administered under protocol 38805)
48112771|NCT03635294|OTHER|Blood sample|combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
48112772|NCT04713371|DRUG|Keytruda Injectable Product|"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."
48112773|NCT04713371|DRUG|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."
48112774|NCT04713371|DRUG|Cytoxan|Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.
48112775|NCT04713371|PROCEDURE|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.
48112776|NCT04713371|DRUG|GM-CSF Injectable|Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.
48112777|NCT05076318|OTHER|Aminoacid, alanine-infusion|During 3 hours, patient will receive alanine-infusion, while amino-acid and urea will be monitored by blood samples.
48112778|NCT04352803|BIOLOGICAL|Autologous Adipose MSC's|Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
48266648|NCT05902000|DEVICE|Carotid Stenting|Emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first) the extracranial carotid artery lesion will be left to the interventionist discretion.
48266649|NCT05902000|PROCEDURE|Thrombectomy|Intracranial thrombectomy is an endovascular procedure. In the experimental group, thrombectomy will be completed with extracranial carotid stenting.
48308585|NCT04583566|GENETIC|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
47960885|NCT00702195|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
47960886|NCT02489162|DEVICE|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
48642351|NCT06694753|BIOLOGICAL|mRNA-1645-N332GT5|"N332-GT5 gp151 is an HIV envelope glycoprotein gp151 trimer based on BG505 SOSIP MD39 (clade A) trimer with germline-targeting mutations added that confer the ability to bind germline precursors of BG18 class B cells. N332-GT5 gp151 will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg."
48642352|NCT06694753|BIOLOGICAL|Placebo|Saline
47960887|NCT02489162|DEVICE|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
47960888|NCT06254651|OTHER|High resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
47960889|NCT06254651|OTHER|Low resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
47960890|NCT01559467|OTHER|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
48308586|NCT00556361|DRUG|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
48112779|NCT05216692|PROCEDURE|La Tour Hospital Foot Strengthening Protocol|"First exercise : NMES forward lean doming. Doming exercise assisted by NMES placed on the IFM. 8 sec of contraction (6 sec rest) moving the trunk forward. 12 repetitions, 3 sets. Progressive increase of the intensity of NEMS during 4 weeks and increase of body load while decreasing the number of repetitions.~Second exercise : MTP joint flexion. Isometric MTP joint flexion contractions. 4 contractions of 5 sec (10 sec rest), 3 sets. Progressive increase of the number of MVIC during 4 weeks and of increase body load while keeping the same intensity.~Third exercise : Foot-ankle rebound. Multiple jumps with only plantar flexion. Keeping the knee stiff and straight and pushing off the ground with only ankle and MTP plantar flexion by a forefoot contact with the ground. 10 seconds of jump (1 min of rest) during 5 sets. Progressive increase of body load while keeping the same intensity."
48308587|NCT00556361|DRUG|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
48308588|NCT01670513|DRUG|IDP-118 Low Strength|8 weeks
48482979|NCT03104348|DIAGNOSTIC_TEST|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
48482980|NCT03665948|OTHER|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
47960891|NCT01559467|OTHER|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
47960892|NCT02398396|BIOLOGICAL|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
47960893|NCT05178771|OTHER|Platelet rich fibrin|"1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted."
47960894|NCT03026660|DIETARY_SUPPLEMENT|Moringa Oleifera|
47960895|NCT03026660|DIETARY_SUPPLEMENT|Cabbage Placebo|
47960896|NCT03128411|DRUG|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
47960897|NCT05013489|BEHAVIORAL|Mindfulness and intercare based intervention|"Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare."
48308589|NCT01670513|DRUG|IDP-118 High Strength|8 weeks
48482981|NCT03665948|OTHER|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
48482982|NCT02560441|OTHER|chemotherapy followed by radiotherapy|
48308590|NCT00659919|DRUG|Placebo|
48308591|NCT00659919|DRUG|Trazodone|
48308592|NCT02951611|PROCEDURE|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
48308593|NCT02951611|PROCEDURE|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
48308594|NCT03484923|DRUG|PDR001|400 mg of PDR001 administered every 4 weeks intravenously
48308595|NCT03484923|DRUG|LAG525|600 mg of LAG525 administered every 4 weeks intravenously
48308596|NCT03484923|DRUG|INC280|400 mg of INC280 administered twice daily orally
48482983|NCT02560441|OTHER|radiotherapy followed by chemotherapy|
48482984|NCT02560441|DRUG|IPGDP regimen chemotherapy|
48482985|NCT04446988|DEVICE|Sacroiliac joint injection|Injection of sacroiliac joint with local anesthetic and steroid
48482986|NCT01323452|DRUG|Entecavir|once daily
48482987|NCT03116061|OTHER|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
48482988|NCT02194569|DRUG|Citrate|
48482989|NCT06203912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48482990|NCT06203912|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48482991|NCT06203912|DRUG|Cyclophosphamide|Given IV
47960898|NCT04840004|DRUG|PVT-1|Since there is no specific dose range is available for testing the anti-tumor effects of PVT-1 in clinical trials settings, in the present study the dose of PVT-1 will be up-titrated 250/160/160 mg to maximum 1000/640/640 mg as described in study methodology section.
47960899|NCT03838952|DRUG|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
47960900|NCT03817879|PROCEDURE|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
47960901|NCT03817879|PROCEDURE|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
48112780|NCT05216692|PROCEDURE|Standard Literature Foot Strengthening Protocol|"During the 1st week, the participants will perform the Short foot exercise (SFE) during 3 series of 10 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 2nd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in sitting position. 1 minute of rest will be give between series.~During the 3rd week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing bipedal position. 1 minute of rest will be give between series.~During the 4th week, the participants will perform the SFE during 3 series of 15 repetitions of 5 seconds of contractions in standing unipedal position. 1 minute of rest will be give between series.~The progression of the exercise during the protocol will be based on passing from a sitting position to a unipedal standing position."
48112781|NCT05016713|COMBINATION_PRODUCT|Chlorhexidine mouthwash|"Chlorhexidine mouthwash is added to the oral hygiene protocol being used beside fluoride-based toothpaste and interdental brushes. CHX mouthwash is used by patients according to the manufacturer's instructions 15 min after tooth-brushing: 5 mL of 0.2% CHX was applied for 60s in the morning and at bedtime. The patients will be instructed not to consume any liquid or food at least 30 min after using the prescribed mouthwash. All patients are asked to bring the mouthwash bottle, so we could determine patient compliance based on how much liquid was left.~If any participant shows any signs of CHX hypersensitivity, the intervention will be discontinued."
48112782|NCT05016713|DEVICE|Interdental brush|Fluoride-based toothpaste is used for tooth-brushing beside using interdental brushes.
48112783|NCT05016713|OTHER|Fluoride-based toothpaste|Regular tooth-brushing is carried out using fluoride-based toothpaste supplied only.
48308597|NCT03484923|DRUG|ACZ885|200 mg of ACZ885 administered every 4 weeks subcutaneosuly
48308598|NCT03484923|DRUG|LEE011|600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
47960902|NCT02616081|OTHER|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
47960903|NCT02616081|OTHER|Indwelling Catheter|Indwelling catheterization is a standard of care.
47960904|NCT02616081|OTHER|Surgery|Bladder surgery is a standard of care.
47960905|NCT02616081|OTHER|Voiding|Voiding spontaneously is a standard of care.
47960906|NCT01769807|DEVICE|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
47960907|NCT05947383|DRUG|Psilocybin|Psilocybin 25 mg oral capsule
47960908|NCT05947383|DRUG|Placebo|Niacin 100 mg oral capsule
47960909|NCT03226860|DEVICE|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
48112784|NCT02914951|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
48308599|NCT03909763|DRUG|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
48308600|NCT03631862|DRUG|Apatinib|Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
48308601|NCT03631862|DRUG|CHOP Regimen|CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
48308602|NCT00462696|DRUG|docetaxel|
48308603|NCT00462696|DRUG|epirubicin hydrochloride|
48308604|NCT00462696|PROCEDURE|conventional surgery|
47960910|NCT03226860|OTHER|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
47960911|NCT03410329|OTHER|Resistance training|Physical activity
47960912|NCT03928496|DRUG|AbobotulinumtoxinA|Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
47960913|NCT03928496|DRUG|Normal saline|Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
47960914|NCT00232973|DRUG|ICXP007|
48308605|NCT00462696|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
48308606|NCT00462696|PROCEDURE|neoadjuvant therapy|
48482992|NCT06203912|DRUG|Dexamethasone|Given PO
47960915|NCT00037141|DRUG|dehydrated alcohol|
47960916|NCT02925520|DRUG|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
48308607|NCT00462696|PROCEDURE|radiomammography|
48308608|NCT00003117|DRUG|carboplatin|
48308609|NCT00003117|DRUG|paclitaxel|
48308610|NCT04026438|DRUG|Potassium Phosphate Injection|One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
48482993|NCT06203912|PROCEDURE|Echocardiography|Undergo echocardiography
48482994|NCT06203912|BIOLOGICAL|Isatuximab|Given IV
48482995|NCT06203912|OTHER|Questionnaire Administration|Ancillary study
48482996|NCT06203912|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
47960917|NCT00479726|DRUG|duloxetine hydrochloride|
48308611|NCT05906641|DIETARY_SUPPLEMENT|High-protein diet|Protein intake will be increased to be 30% calories from protein with calcium caseinate.
48308612|NCT01120093|DRUG|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
47960918|NCT02994992|DRUG|BAY 987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
48308613|NCT01120093|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
48308614|NCT01120093|DRUG|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
48308615|NCT01120093|DRUG|Placebo|Placebo via inhalation in the morning and evening for 7 days
47960919|NCT02994992|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
47960920|NCT03214146|BIOLOGICAL|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.
48266650|NCT05902000|DRUG|Dual antiplatelet treatment|Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.
48308616|NCT01120093|DRUG|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
47960921|NCT04532970|BEHAVIORAL|Cessation Counseling|Two different types of smoking cessation counseling
48308617|NCT00488033|PROCEDURE|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
48308618|NCT03650348|DRUG|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
48308619|NCT03873467|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
48308620|NCT03873467|OTHER|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
48308621|NCT05368285|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
48308622|NCT05368285|DRUG|Matching Placebo|Subcutaneous Administration
48308623|NCT02590016|DRUG|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
48308624|NCT01515176|DRUG|Dinaciclib|Given IV
48308625|NCT01515176|OTHER|Laboratory Biomarker Analysis|Correlative studies
48308626|NCT01515176|BIOLOGICAL|Ofatumumab|Given IV
47960922|NCT05198999|OTHER|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
47960923|NCT05198999|OTHER|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
47960924|NCT02933723|PROCEDURE|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
47960925|NCT02467400|DRUG|Atenolol|beta blocker
47960926|NCT02467400|DRUG|Nebivolol|beta blocker
47960927|NCT02467400|DRUG|Propranolol|beta blocker
47960928|NCT02467400|DRUG|placebo|placebo
48112785|NCT02914951|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
48112786|NCT04222959|BEHAVIORAL|Girls Invest Intervention|"App-based trainings: The first 2 modules cover gender and cultural norms related to girls' social and economic empowerment, increasing girls' recognition of the importance of financial literacy and independence. The last 3 modules cover finance, educational loans, and employment.~Savings account: Participants receive $100 deposited into a savings account we set up for them, conditional upon completion of app-based trainings."
48112787|NCT01755897|PROCEDURE|radical hysterectomy + pelvic lymph node dissection|
48112788|NCT01755897|DRUG|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
48112789|NCT01755897|DRUG|Cisplatin|75 mg/m(2) IV on day 2 and 3
48112790|NCT01755897|DRUG|Cisplatin|35 mg/m(2) IV once a week
48112791|NCT01755897|RADIATION|Pelvic RT|IMRT
48112792|NCT00943735|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
48112793|NCT00943735|BEHAVIORAL|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
48112794|NCT02881944|BEHAVIORAL|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
48112795|NCT02881944|BEHAVIORAL|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
48112796|NCT06055985|OTHER|Placebo|Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
48112797|NCT06055985|DRUG|UCB0022|Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
48112798|NCT00405951|DRUG|Obatoclax mesylate 250 ml|
48112799|NCT00405951|DRUG|Docetaxel|
48112800|NCT05899179|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein|"Dosage form:injection. Main ingredients and contents: Recombinant Mycobacterium tuberculosis fusion protein, 0.3ml, 0.5ml, 1.0ml per bottle.~1. This product is used alone: 0.1ml (5U) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method. 2. This product combined with TB-PPD: 0.1ml(5U) of this product and 0.1ml(5U) of TB-PPD were inhaled respectively, and the product was injected intradermally into the volar side of the left forearm by the Mondu's method. After observing no abnormality for 5 minutes, TB-PPD was injected intradermally into the volar side of the right forearm."
48112801|NCT05899179|BIOLOGICAL|Purified Protein Derivative of Tuberculin|"Dosage form:injection. Main ingredients and contents:Pure protein derivatives of tuberculin,0.1ml per bottle.~Usage:0.1ml (5IU) of this product is inhaled and injected into the palmar skin of the forearm by the Mondu's method."
48308627|NCT01515176|OTHER|Pharmacological Study|Correlative studies
47960929|NCT00695409|BIOLOGICAL|rituximab|Given IV
47960930|NCT00695409|DRUG|carmustine|Given IV
47960931|NCT00695409|DRUG|cytarabine|Given IV
47960932|NCT00695409|DRUG|etoposide|Given IV
47960933|NCT00695409|DRUG|melphalan|Given IV
47960934|NCT00695409|PROCEDURE|ASCT|Undergo autologous peripheral blood stem cell transplant
47960935|NCT00695409|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
47960936|NCT05230420|OTHER|Clamping|Clamping of chest tube
47960937|NCT05230420|OTHER|Urine bag|Attachment of a urine bag to chest tube
47960938|NCT06533254|OTHER|Predicting choice of dialysis|"Language data collected using survey 1, will be analyzed using Scaled Insights Behavioral AI solution to identify personality attributes and values. The resulting individual scores will be plotted on a graph and be used to identify specific personality clusters of patients.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses.~The open-ended questions will gather a natural language sample of 100-300 words for analysis using Scaled Insights Behavioral AI approach. This language sample will be analyzed using Scaled Insights Behavioral AI system to identify personality attributes and values. Patients will also be asked their likelihood of selecting PD over HD."
47960939|NCT06533254|BEHAVIORAL|Behavioral nudges|"Patients with Chronic Kidney Disease, participants will be provided with their predicted personalized nudge to increase their likelihood of either maintaining their choice of peritoneal dialysis, or switching from hemodialysis to peritoneal dialysis.~Participants will respond to a survey that utilizes open and closed ended questions, asking broad questions about kidney failure and associated behaviors (e.g. diet, attitudes towards treatment). The open-ended questions will gather a natural language sample of 100-300 words whilst closed questions will capture data using Likert scale and multiple-choice responses."
47960940|NCT02481583|DRUG|Levosulpiride|different formulations of levosulpiride
48308628|NCT03332108|OTHER|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past \[x\] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
48308629|NCT03332108|OTHER|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
47960941|NCT00981370|DRUG|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
48308630|NCT03897920|OTHER|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
48308631|NCT04019093|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
48308632|NCT04019093|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
48308633|NCT00002333|DRUG|Saquinavir|
48308634|NCT00002333|DRUG|Zalcitabine|
48308635|NCT03681652|DRUG|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
48308636|NCT03681652|DRUG|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
48308637|NCT05087628|BIOLOGICAL|PRV-3279|Bi-specific antibody-based molecule
48308638|NCT05087628|OTHER|Placebo|Placebo
48308639|NCT05183048|DRUG|[89Zr]Panitumumab Tracer|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
48308640|NCT02690233|PROCEDURE|Elective Surgery|Elective laparoscopic inguinal hernia repair
48482997|NCT04339426|DRUG|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
47960942|NCT04773756|DRUG|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
48308641|NCT06317857|OTHER|Centio Forte|A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
48308642|NCT02427256|DEVICE|Topcon Specular Microscope SP-1P|
48482998|NCT01084018|BEHAVIORAL|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
47960943|NCT03854201|BEHAVIORAL|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
47960944|NCT05792501|DEVICE|Mechanical ventilation|type of therapy that helps you breathe or breathes for you when you can't breathe on your own
48112802|NCT00005772|DEVICE|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
48112803|NCT00005772|DEVICE|Control|Control group: standard care
48112804|NCT06676306|OTHER|Non-Interventional Study|Non-Interventional Study
48642353|NCT06694987|OTHER|Non-Physician Health Worker|"NPHW will aid participants in accessing a family doctor if required. The family doctor will receive a letter from the study, with suggested medication, based on the HOPE-4 algorithm. The family doctor may decide not to prescribe the recommended treatment or give another treatment (medication). In such case, the participant will still be part of the study and family physician's decision and reason why will be recorded. Follow-up will occur as per the visit schedule. All participants will attend a 20-minute follow-up visits in person at 0, 6 and 12 months, and via telephone at 3 and 9 months.~Participants will be assessed to determine if: i. the patient was assessed by their family physician, ii. the family doctor initiated recommended medication treatment(s), iii. they are adhering to the medications as prescribed, iv. they implemented what the NPHW has recommended about dietary and lifestyle changes, using the specific, measurable, achivable, relevant, time-bound (SMART) for goals."
48642354|NCT05964166|DEVICE|TetraGraph NMT Monitor|TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
48308643|NCT02427256|DEVICE|Konan Specular Microscope CELLCHEK XL|
48308644|NCT01806246|BEHAVIORAL|integrative rehabilitation program|
48308645|NCT04211610|DIAGNOSTIC_TEST|Blood and urine sampling|"* Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin."
48308646|NCT01469013|DRUG|Placebo|
48308647|NCT01469013|DRUG|Baricitinib|
48308648|NCT01469013|DRUG|Baricitinib|
48308649|NCT01469013|DRUG|Baricitinib|
48308650|NCT01469013|DRUG|Methotrexate|Administered orally as background therapy
48112805|NCT04603625|OTHER|postural management|postural management in sitting position
48112806|NCT01638039|OTHER|Laboratory Tests|Stool, blood, urine and saliva samples
48112807|NCT06676189|DEVICE|total knee arthroplasty with medial pivot polyethylene|total knee arthroplasty with medial pivot polyethylene
48112808|NCT06676189|DEVICE|total knee arthroplasty with ultra-congruent polyethylene|total knee arthroplasty with ultra-congruent polyethylene
48112809|NCT02472782|DRUG|Teriparatide|The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
48112810|NCT06277401|OTHER|Neuromuscular training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
48112811|NCT06277401|OTHER|High-load strength training for the knee|The exercise programme includes exercises identified in literature to target muscles around the knee.
48112812|NCT05731466|DEVICE|CardioMems HF System|"1. Implantation CardioMems device.~2. Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements."
48308651|NCT01081223|BIOLOGICAL|Cancer vaccine plus immune adjuvant|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
48308652|NCT05828186|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) catheter|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of Shockwave IVL catheter treatment by their physicians.
48308653|NCT01399801|PROCEDURE|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
48308654|NCT01399801|PROCEDURE|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
48308655|NCT00870948|DRUG|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
48308656|NCT00331370|BEHAVIORAL|GP training and Health Education|
48308657|NCT06553144|PROCEDURE|control|Canals were irrigated with only10 mL of 5% NaOCl
48308658|NCT06553144|PROCEDURE|methylene blue|0.1 mg/mL methylene blue solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
48308659|NCT06553144|PROCEDURE|erythrosine b|0.3 mg/mL eryrhtosine b solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
48308660|NCT06553144|PROCEDURE|curcumin|5.0 mg/mL curcumin solition delivered into the canal and irradiated with a 200mW diode laser at a wavelength of 450 nm
48308661|NCT01936285|DRUG|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
48308662|NCT01936285|DRUG|Placebo|
47960945|NCT04090866|OTHER|PET/MRI|Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy
47960946|NCT00133328|DRUG|valsartan|
47960947|NCT01918384|DRUG|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
47960948|NCT01918384|DRUG|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
47960949|NCT05509036|OTHER|No interventions|No interventions
47960950|NCT02599714|DRUG|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
47960951|NCT02599714|DRUG|Palbociclib|cyclin dependent kinase inhibitor
47960952|NCT02599714|DRUG|Fulvestrant|Fulvestrant hormonal therapy as background
47960953|NCT02875054|BEHAVIORAL|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
47960954|NCT02875054|BEHAVIORAL|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
48112813|NCT00360451|BEHAVIORAL|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
48112814|NCT00360451|BEHAVIORAL|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
48112815|NCT00891176|BIOLOGICAL|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
48308663|NCT05678413|PROCEDURE|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
48308664|NCT05678413|PROCEDURE|DVIU|DVIU
48642355|NCT04114084|PROCEDURE|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
48642356|NCT03249558|DRUG|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
48308665|NCT04604106|DIAGNOSTIC_TEST|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
48308666|NCT04604106|DIAGNOSTIC_TEST|Ages & Stages questionnaire|The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
48308667|NCT04604106|DIAGNOSTIC_TEST|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
48308668|NCT03259334|DRUG|Ontamalimab|Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
48308669|NCT03259334|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
48308670|NCT05962996|DEVICE|Pupillometry|Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
48642357|NCT03249558|DRUG|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
47960955|NCT05597371|OTHER|the use of the platform|the use of the platform
47960956|NCT05451225|BEHAVIORAL|Targeted Educational Campaign|"Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the Correction Health Services staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times; pre-exposure, after 6 months, and after 12 months from the beginning of the TEC."
47960957|NCT05593588|DRUG|Fisetin|20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
47960958|NCT05593588|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
47960959|NCT04312880|DRUG|Tranexamic Acid|IV and topical form of TXA will be administered to patients in the respective groups.
47960960|NCT04916821|DIETARY_SUPPLEMENT|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
47960961|NCT01387620|DRUG|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
47960962|NCT01634334|BEHAVIORAL|Real-Time Intervention|Lights and Sound Brief Coaching
47960963|NCT01634334|BEHAVIORAL|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
47960964|NCT03555916|DRUG|BOTOX®, Allergan|50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
47960965|NCT03555916|DRUG|Placebo|2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
47960966|NCT06376292|DRUG|Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases|Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa. The injection was administered by qualified individuals (certified personnel in the radiotherapy department of our hospital) twice a week for a total of 4 weeks. Thiotepa was injected 10mg each time, mixed with cerebrospinal fluid, and then injected slowly for 5-10 minutes.
47960967|NCT04043286|DEVICE|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
47960968|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles|Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.
47960969|NCT01950975|BIOLOGICAL|Peripheral blood samples in EDTA tubes|
47960970|NCT01950975|PROCEDURE|Skin biopsies|
47960971|NCT02257307|PROCEDURE|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
47960972|NCT05269823|OTHER|Ice-therapy|Ice therapy will be provided prior to intravitreal injection provision
47960973|NCT05269823|OTHER|No Ice-therapy|No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
48112816|NCT00891176|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
48112817|NCT00891176|BIOLOGICAL|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
48112818|NCT00891176|BIOLOGICAL|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
48112819|NCT00891176|BIOLOGICAL|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
48112820|NCT00891176|BIOLOGICAL|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
47960974|NCT02577549|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
47960975|NCT02577549|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
47960976|NCT06505174|OTHER|Hydroxypropyl Guar-based artificial tears four times per day|Use of hydroxypropyl Guar-based artificial tears four times per day
47960977|NCT06255964|DRUG|IAP0971|Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
48112821|NCT00891176|BIOLOGICAL|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
48112822|NCT00891176|BIOLOGICAL|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
48112823|NCT00891176|BIOLOGICAL|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
48112824|NCT04382365|OTHER|Sleep Health Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness|Cognitive-Behavioral Treatment for insomnia (CBT-I) is a non-pharmacological intervention that is effective in treating insomnia in older adults, even when present with comorbid medical and psychological conditions.25 CBT-I focuses on the maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems, and typically consists of five primary treatment components: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
48112825|NCT06545994|OTHER|Observation|It's a observational cohort study and no interventions are performed.
48112826|NCT00410124|DRUG|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
48112827|NCT00410124|DRUG|Placebo|
48112828|NCT01316263|BIOLOGICAL|Olaratumab|Administered IV
47960978|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
47960979|NCT06255964|COMBINATION_PRODUCT|IAP0971＋BCG|Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
47960980|NCT04004130|OTHER|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
47960981|NCT01778972|OTHER|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
47960982|NCT01778972|OTHER|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
47960983|NCT06053996|RADIATION|Hepatopulmonary radio-sterilization|Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
47960984|NCT00956969|BEHAVIORAL|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
47960985|NCT00956969|BEHAVIORAL|Relaxation Training|Teaches patients relaxation training
47960986|NCT00809393|DRUG|tranexamic acid|10 mg/kg
47960987|NCT00809393|DRUG|tranexamic acid|30 mg/kg
47960988|NCT06134752|OTHER|Pulse field ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
47960989|NCT06134752|OTHER|Radiofrequency ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
47960992|NCT01131611|BEHAVIORAL|CBPT|Cognitive-Behavioral Based Physical Therapy
47960993|NCT01131611|OTHER|Control-Attention|Standard of Care + weekly phone calls
48112829|NCT06673602|DRUG|FCYC+Conventional treatment|Conventional treatment combined with oral administration of FCYC (four capsules, three times a day, orally) for a 12-week course of treatment.
48112830|NCT06673602|DRUG|conventional treatment|The control group will receive the current gold standard treatment for ICH according to the guidelines (AHA/ASA 2022). This involves blood pressure and care.
48112831|NCT01199705|BIOLOGICAL|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
48266651|NCT05902000|DRUG|Intraoperative Drug Treatment|Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
48266652|NCT03931356|OTHER|Pulmonary function tests|analysis of lung volume and diffusion capacity
48266653|NCT02881034|DRUG|Triple therapy|
48266654|NCT02249702|DRUG|gemcitabine + docetaxel|
48266655|NCT02249702|DRUG|trabectedin|
48308671|NCT01270581|OTHER|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
48340226|NCT04432571|BEHAVIORAL|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following per current MOH guidelines).
47960994|NCT04505865|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being."
47960995|NCT05309408|DIAGNOSTIC_TEST|Venipuncture|Venipuncture
47960996|NCT05309408|DIAGNOSTIC_TEST|Lumbar Puncture|Lumbar Puncture
47960997|NCT01423370|DRUG|YHD1023|5g oral once daily
47960998|NCT01423370|DRUG|YHD1023|5g oral twice a day
47960999|NCT01423370|DRUG|YHD1023|10g oral once daily
47961000|NCT01423370|DRUG|Cialis|5mg oral once daily
47961001|NCT01423370|DRUG|Placebo|Oral
47961002|NCT01934023|DRUG|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
47961003|NCT01934023|DRUG|Placebo|
47961004|NCT04882618|DRUG|Indocyanine green|indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
47961005|NCT05039073|DRUG|Brentuximab Vedotin|Given IV
47961006|NCT05039073|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
47961007|NCT05039073|BIOLOGICAL|Nivolumab|Given IV
47961008|NCT05039073|OTHER|Quality-of-Life Assessment|Ancillary studies
47961009|NCT05039073|OTHER|Questionnaire Administration|Ancillary studies
48266656|NCT03720457|DRUG|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
48266657|NCT03286673|DIETARY_SUPPLEMENT|calcium phosphate|
47961010|NCT05764421|BEHAVIORAL|motor-cognitive intervention|The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
47961011|NCT05493475|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at court sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
47961012|NCT00362310|DRUG|indinavir|
47961013|NCT02122172|DRUG|afatinib dimaleate|Given PO
48266658|NCT03286673|DIETARY_SUPPLEMENT|Tricalcium Phosphate|
48308672|NCT01270581|OTHER|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
47961014|NCT02122172|OTHER|laboratory biomarker analysis|Correlative studies
47961015|NCT00074204|DRUG|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
47961016|NCT00074204|DRUG|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
47961017|NCT00074204|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
47961018|NCT03763175|DRUG|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
48266659|NCT03286673|DIETARY_SUPPLEMENT|Calcium carbonate|
48266660|NCT03286673|DIETARY_SUPPLEMENT|Placebo|
48266661|NCT01984021|DEVICE|Acupuncture|
48266662|NCT01984021|DEVICE|Sham acupuncture|
48266663|NCT04241965|DRUG|OPC-214870|Tablet(s)
48266664|NCT04241965|OTHER|Placebo|Tablet(s)
48266665|NCT04408807|OTHER|Speculum-free (SpF) fundoscopy|Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation
48266666|NCT04408807|OTHER|Speculum (Sp) fundoscopy|Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
47961019|NCT03763175|DRUG|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
47961020|NCT03763175|DRUG|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
47961021|NCT04425512|DIAGNOSTIC_TEST|Complete Blood Count|Complete Blood Count samples
48642358|NCT03249558|DRUG|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
47961022|NCT06435676|DRUG|HRS9531|Single dose escalation of HRS9531 tablets in healthy subjects
47961023|NCT06435676|DRUG|Placebo|Single dose of placebo in healthy adults
47961024|NCT06435676|DRUG|HRS9531|Multiple dose escalation of HRS9531 tablets in healthy subjects
47961025|NCT06435676|DRUG|Placebo|Multiple dose of placebo in healthy adults
47961026|NCT04232254|BEHAVIORAL|Animal-based Protein Foods|Participants will consume animal-based protein foods.
47961027|NCT04232254|BEHAVIORAL|Skewed Protein Distribution|Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
47961028|NCT04232254|BEHAVIORAL|Plant-based Protein Foods|Participants will consume plant-based protein foods.
47961029|NCT04232254|BEHAVIORAL|Balanced Protein Distribution|Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
47961030|NCT01861860|DEVICE|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain \> 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
47961031|NCT05808114|BEHAVIORAL|Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
48112832|NCT05286632|DEVICE|KidneYou APP|KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
48112833|NCT02240550|DEVICE|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
47961032|NCT05808114|BEHAVIORAL|TAU|Individually tailored and delivered specialized child psychiatric care
47961033|NCT04028778|DRUG|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
47961034|NCT04028778|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
47961035|NCT04028778|OTHER|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
48308673|NCT03440216|DRUG|blood sampling|"* temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7"
47961036|NCT05222269|DRUG|68Ga-PTF|68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.
48112834|NCT02240550|DEVICE|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
48308674|NCT03440216|DRUG|Tissue sampling (lung)|Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
48482999|NCT05134194|DRUG|Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
48642359|NCT03192332|DEVICE|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
48642360|NCT03192332|DRUG|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
48642361|NCT02091960|DRUG|Enzalutamide|Capsules for oral administration
48642362|NCT02091960|DRUG|Trastuzumab|Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
48642363|NCT02257528|OTHER|Laboratory Biomarker Analysis|Correlative studies
48642364|NCT02257528|BIOLOGICAL|Nivolumab|Given IV
47961037|NCT03478930|DRUG|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
47961038|NCT03478930|DRUG|Placebo|Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
47961039|NCT04899869|OTHER|Faecal microbiota transplantation with active study microbiota first|2x enema with active study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
47961040|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota first|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with active study microbiota
47961041|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota only|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
47961042|NCT03416725|DEVICE|Otoscope|Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
47961043|NCT05610683|DEVICE|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
47961044|NCT04447651|OTHER|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
48112835|NCT03504644|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48112836|NCT03504644|PROCEDURE|Computed Tomography|Undergo CT scan
48112837|NCT03504644|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48112838|NCT03504644|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48112839|NCT03504644|DRUG|Venetoclax|Given PO
48308675|NCT03440216|DRUG|Collection of fluid samples|Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
48308676|NCT02411227|BEHAVIORAL|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
48308677|NCT04611711|DRUG|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
48642365|NCT05195632|DRUG|Encorafenib|Hard capsule
48112840|NCT03504644|DRUG|Vincristine Liposomal|Given IV
48112841|NCT03504644|DRUG|Vincristine Sulfate|Given IV
48112842|NCT05014828|DRUG|lenvatinib|Capsules administered orally
48112843|NCT05014828|DRUG|Tislelizumab|intravenous (iv) infusion
48112844|NCT04686942|DIAGNOSTIC_TEST|After sonazoid|0.015ml/mg sonazoid enhanced US to detection of liver metastases.
48112845|NCT05722106|BEHAVIORAL|Persuasive Appeal|Persuasive appeals were manipulated using promotional flyers ostensibly distributed by the Public Health Agency of Canada.
48112846|NCT05898152|OTHER|Data collection|A collection about patient's data demographic, neurologic and gynecologic follow-up and satisfaction will be review by questionnaire. And a calendar of epileptic seizures will be completed by patients on 4 months
48308678|NCT04611711|DRUG|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
48642366|NCT05195632|DRUG|Binimetinib|Film-coated tablet
48642367|NCT05075577|DRUG|Enzalutamide|Daily oral dose of enzalutamide
48642368|NCT05075577|DRUG|EPI-7386 with Enzalutamide|Daily oral dose of EPI-7386 in combination of enzalutamide
48642369|NCT05987449|DRUG|NXT007|Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.
47961045|NCT00492141|DRUG|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
48112847|NCT00576134|DEVICE|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
48112848|NCT06676579|DRUG|Avacopan|Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.
48112849|NCT06676579|DRUG|Prednisone|0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months
48112850|NCT06676579|DRUG|Methylprednisolone (drug)|Methylprednisolone 1g intravenous on day +1
48112851|NCT06676579|DRUG|Prednisolone|Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
48112852|NCT05206773|DRUG|Venglustat (GZ402671)|Pharmaceutical form: Tablet Route of administration: Oral
48112853|NCT05206773|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
47961046|NCT00492141|DRUG|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
48308679|NCT04126967|DIAGNOSTIC_TEST|NGS patients|The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
48308680|NCT01252797|RADIATION|Stereotactic Radiosurgery (15 Gy)|"Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy"
48308681|NCT01252797|RADIATION|Stereotactic Radiosurgery (12 Gy)|Group B will start at Dose Level I: 12 Gy
48308682|NCT06471465|DRUG|Bevacizumab|Drug: bevacizumab IV
48308683|NCT06471465|DRUG|Placebo|Drug: placebo IV
48308684|NCT06471465|DRUG|Prednisolone|Drug: corticosteroids IV
48308685|NCT04088851|DRUG|On Metformin|Oral intake of Metformin (1 g / day) for 2 weeks
48308686|NCT04088851|DRUG|Off Metformin|No oral intake of Metformin (1 g / day) for 2 weeks
48308687|NCT00002452|DRUG|L-756423|
48642370|NCT04736121|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
48308688|NCT00002452|DRUG|Indinavir sulfate|
48642371|NCT06439082|BIOLOGICAL|Crizanlizumab|Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
48642372|NCT06439082|DRUG|Placebo|Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
48642373|NCT03916419|DEVICE|ViewRay MR-Linear Accelerator|-Radiation will be delivered by this machine
48642374|NCT03916419|RADIATION|Radiation therapy|-60Gy in 15 fractions
48642375|NCT03916419|DRUG|Paclitaxel|-50 mg/m\^2 intravenous
48642376|NCT03916419|DRUG|Carboplatin AUC|-2 mg/mL/min intravenous over 30 minutes
48642377|NCT03916419|BIOLOGICAL|Durvalumab|-10 mg/kg
48308689|NCT01009801|DRUG|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
48642378|NCT05898594|PROCEDURE|Low-dose Computed Tomography|Per standard care
48308690|NCT01009801|DRUG|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
48308691|NCT01009801|OTHER|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
48308692|NCT01757639|BIOLOGICAL|Ipilimumab|Given IV
48308693|NCT01757639|OTHER|Laboratory Biomarker Analysis|Correlative studies
48308694|NCT02610400|COMBINATION_PRODUCT|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) \> 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
48483000|NCT05134194|DRUG|Capecitabine/eribulin/gemcitabine/vinorelbine|Capecitabine or eribulin or gemcitabine or vinorelbine
48483001|NCT04211519|DIAGNOSTIC_TEST|sampling|sampling from endodontically infected primary and permanent teeth by using paper point method
47961047|NCT01489397|DEVICE|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
48112854|NCT06648759|DEVICE|Vagal Nerve Stimulator|The vagal nerve stimulator device is a nonsignificant risk device that provides electrical impulses to the vagus nerve, located in the neck and ear regions. The device (pulse generator) and a wire lead (insulated wire) with electrodes on the end of the wire will send the electrical signals along the vagus nerve to your brainstem to activate various neurochemical coordinates.
48112855|NCT06648759|DEVICE|Placebo Vagal Nerve Stimulator|The sham vagal nerve stimulator device is a nonsignificant risk device that mirrors that of the active stimulator but does not provide electrical impulses to the vagus nerve.
47961048|NCT01238510|PROCEDURE|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
47961049|NCT01238510|PROCEDURE|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
47961050|NCT03883711|OTHER|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
47961051|NCT06169384|DEVICE|Endoscopic adenoidectomy|Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
47961052|NCT00991731|BEHAVIORAL|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
47961053|NCT00991731|BEHAVIORAL|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
47961054|NCT00736424|DEVICE|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
47961055|NCT01719978|DRUG|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
47961056|NCT01719978|PROCEDURE|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
48112856|NCT01672619|PROCEDURE|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
48112857|NCT05370430|BIOLOGICAL|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
48112858|NCT01703897|DEVICE|Manometry and Impedance analysis|
47961057|NCT01719978|DRUG|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
47961058|NCT01719978|DRUG|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
48112859|NCT00000760|DRUG|Ro 24-7429|
48112860|NCT00000760|DRUG|Zidovudine|
48112861|NCT00000760|DRUG|Didanosine|
48112862|NCT03593317|DRUG|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
48112863|NCT03593317|DRUG|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
48112864|NCT01188499|DRUG|Birinapant|
48112865|NCT06515210|DIETARY_SUPPLEMENT|Acacia Gum|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
48112866|NCT06515210|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
47961059|NCT05352100|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
47961060|NCT01457144|DRUG|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
47961061|NCT03658239|OTHER|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
48483002|NCT05978739|DRUG|Orelabrutinib High dose|Orelabrutinib will be administered as 3 tablets once per day
48483003|NCT05978739|DRUG|Orelabrutinib Low dose|Orelabrutinib will be administered as 1 tablet once per day
47961064|NCT04923061|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
48112867|NCT06515210|DIETARY_SUPPLEMENT|Placebo|Participants (n=23) incorporate the placebo into their usual diet daily.
48112868|NCT02888080|DRUG|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
48112869|NCT02888080|DRUG|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
48112870|NCT06456190|BEHAVIORAL|Skills Training in Active Recovery (STAR) Video|a 12-15 minute video that includes psychoeducation about ptsd and substance misuse plus tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
48112871|NCT06456190|BEHAVIORAL|Text Skills Training in Active Recovery (TextSTAR) program|a 3-week daily text program that includes supportive/empowering messages along with brief coping tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
48112872|NCT06643507|OTHER|Connective tissue graft|regenerative properties
48112873|NCT06643507|BIOLOGICAL|ALB-PRF|regenerative properties
48112874|NCT05636852|DRUG|Altropane (123I) Injection|Each subject will receive a single IV administration of 5 mCi (185 MBq) Altropane.
48112875|NCT01725854|BEHAVIORAL|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
48112876|NCT03703219|OTHER|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
48112877|NCT03812978|OTHER|Smart phone application|Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
48112878|NCT00082810|DRUG|fulvestrant|Given intramuscularly
48112879|NCT00082810|DRUG|tipifarnib|Given IV
48112880|NCT00922649|DEVICE|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on \>2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
48112881|NCT06062212|PROCEDURE|Transpulmonary pressure|Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
48483004|NCT01747382|PROCEDURE|Renal denervation|
48483005|NCT04574128|PROCEDURE|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
48483006|NCT01279252|DRUG|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
48112882|NCT03760627|BEHAVIORAL|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
48483007|NCT04451187|DRUG|Seltorexant Dose 1|Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.
48483008|NCT04451187|DRUG|Seltorexant Dose 2|Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.
48308695|NCT02610400|COMBINATION_PRODUCT|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
48308696|NCT02610400|COMBINATION_PRODUCT|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) \> 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
47961065|NCT04923061|OTHER|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
48308697|NCT00461955|PROCEDURE|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
48308698|NCT03892785|DRUG|Prednisone treatment|tapering prednisone regimen
48308699|NCT03892785|DRUG|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
48308700|NCT03892785|DRUG|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
48308701|NCT03892785|OTHER|Questionnaires|HAQ, SF-36, FACIT-fatigue
48308702|NCT03892785|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
48308703|NCT05498961|OTHER|Gallstone characteristics|stone size, number, the thickness
48308704|NCT02046265|BEHAVIORAL|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
48308705|NCT02046265|BEHAVIORAL|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
48308706|NCT02046265|BEHAVIORAL|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
48308707|NCT02046265|BEHAVIORAL|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
48308708|NCT06199440|DRUG|Group I|First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
48308709|NCT06199440|DRUG|Group II|Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
48308710|NCT06199440|DRUG|Group III|"Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol."
48308711|NCT01341431|DRUG|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
47961066|NCT05018975|DRUG|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
48308712|NCT02984826|OTHER|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
48308713|NCT02984826|OTHER|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
48308714|NCT06085352|DRUG|TetraLens bandage contact lens|Methafilcon-A contact lens eluding tetracaine ophthalmic solution
48308715|NCT06085352|DEVICE|Control Acuvue Oasys Bandage contact Lens|Standard of care bandage contact lens
47961067|NCT01529047|BEHAVIORAL|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
47961068|NCT05170984|DEVICE|CACIPLIQ20®|Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
47961069|NCT03424200|BEHAVIORAL|Routine care|Participants will receive routine care
47961070|NCT03424200|OTHER|Coaching plus routine care|Participants will receive coaching plus routine care
47961071|NCT01945281|DRUG|Caspofungin|
48483009|NCT04451187|DRUG|Placebo|Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
48483010|NCT04451187|DRUG|Zopiclone|Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.
47961072|NCT01945281|DRUG|Amphotericin B Deoxycholate|
48266667|NCT06351930|BEHAVIORAL|CBT-I + UC group|Refer to the arm description
48112883|NCT03760627|BEHAVIORAL|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
48112884|NCT02655835|BEHAVIORAL|Internet Mindfulness Meditation|
48112885|NCT02655835|BEHAVIORAL|Access|
48112886|NCT04030767|DRUG|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
48112887|NCT02839369|OTHER|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
48112888|NCT02839369|OTHER|walking under varies conditions|walking on electronic walkway under different conditions
48112889|NCT02348658|DRUG|TAK-536TCH|TAK-536TCH tablets
48112890|NCT06491888|DIAGNOSTIC_TEST|Detection of Cervical Lesions by Fluorescence Photoelectric Image|Photoelectric detection was carried out on the subjects of the experimental group.
48112891|NCT01637662|DRUG|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
48112892|NCT00316316|BEHAVIORAL|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
48112893|NCT00316316|BEHAVIORAL|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
48112894|NCT05135013|DRUG|Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol|"History of hormonal use as follows:~1. Reason for hormonal use: contraception, fertility promotion, Polycystic ovary syndrome (PCOS)~2. Duration of hormonal use~3. Type of hormonal drug used: dose, hormone type, route of administration"
48112895|NCT05054764|DEVICE|Promus PREMIER BTK DES|Collect one year data of the Promus PREMIER BTK drug eluting stent in CLTI patients
48112896|NCT02098382|DEVICE|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
48112897|NCT01948960|DRUG|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
48112898|NCT05288868|OTHER|Educational Intervention: online didactic lecture and educational simulation activity|"The didactic was created by the research team and provides information on Autism Spectrum Disorder (ASD) and an approach to taking vital signs in these children. The didactic will be pre-recorded and sent by email to employee study participants. The didactic will last about 10 minutes.~The simulation activity will have the premise of a child with ASD and their caregiver at clinic visit. The employee participant will be asked to take vital signs on the patient. The caregiver will be played by an actor and the child will be played by a mannequin. An iterative script will be used by the actor during the scenario. The simulation will last about 20 minutes and will be followed by a 10 minute debrief."
48112899|NCT00588666|DRUG|Bevacizumab|
48112900|NCT00588666|DRUG|Carboplatin|
48112901|NCT00588666|DRUG|Gemcitabine|
48112902|NCT06136897|PROCEDURE|Biopsy|Undergo biopsy
48112903|NCT06136897|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48112904|NCT06136897|PROCEDURE|Echocardiography|Undergo ECHO
48112905|NCT06136897|BIOLOGICAL|Pertuzumab|Given IV
48112906|NCT06136897|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
48112907|NCT06136897|BIOLOGICAL|Trastuzumab|Given IV
48112908|NCT04313868|DRUG|GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)|GEN2 is an investigational drug combining cytotoxic and immunotherapy.
48112909|NCT04853602|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses. In addition to priming anti-tumor immunity in immune checkpoint inhibitor (ICI)-naïve patients, this could re-sensitize patients with primary or secondary ICI clinical resistance."
48112910|NCT04618224|DIAGNOSTIC_TEST|DDART Testing|One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
48112911|NCT04618224|DIAGNOSTIC_TEST|wDDART Testing|One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
48112912|NCT05691738|OTHER|Exercise Group|The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).
48112913|NCT05691738|OTHER|Control Group|The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
48112914|NCT06225882|DRUG|Oxaluria evolution.|To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
48112915|NCT06629155|DIAGNOSTIC_TEST|Infrared oculography|Eye movements will be captured through infrared oculography and processed via in-house algorithms.
48112916|NCT04222686|DRUG|Perindopril Arginine|10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
48112917|NCT04222686|DRUG|Losartan Potassium|100 mg Losartan tablet will be added to the usual treatment for each patient for a period of 08 weeks.
48112918|NCT00552942|PROCEDURE|laparoscopic gastric bypass plus omentectomy|
48266668|NCT01904981|DRUG|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
48308716|NCT04397393|DRUG|Midazolam|Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU
48308717|NCT00798213|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
48308718|NCT00798213|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
48308719|NCT01242020|DRUG|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
48308720|NCT06239909|OTHER|24-h pad-weight test|The patients will be asked to perform the 24-h pad-weight test
48308721|NCT06239909|OTHER|Patient Global Impression - Improvement Questionnaire|The patient-reported outcome, as measured by PGI-I (Patient Global Impression - Improvement Questionnaire)
48308722|NCT01766336|DRUG|Group 1 ELND005|
48308723|NCT01766336|DRUG|Group 2 ELND005|
48308724|NCT02028546|PROCEDURE|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
48308725|NCT05515601|DRUG|Mirikizumab|Administered SC.
48308726|NCT02069782|OTHER|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
47961073|NCT04010058|DEVICE|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
47961074|NCT00222443|DRUG|Irinotecan|
47961075|NCT05303181|DEVICE|Russian Current|"The patient will be placed in sitting position, hip at 90-degree flexion, knee at 60°, the upper body supported by the backrest, cross belt support the trunk and cross belt support the pelvis. The dynamometer rotating axis will be aligned with knee joint axis and the resistance lever arm will place in the distal leg above the malleolus. The angle of the joints adjustment considering the joint's range of motion and the device's user's manual, any movement other than the range of motion determined by the mechanical limit will be not allowed~All electrical induced contraction will last 4 second each, with characteristics of 75 bursts; 4 second time on, 400 μs pulse width and 10 second time off. The greatest electrically induced torque by the quadriceps muscle at the maximum current output from the stimulator will be recorded for each subject to be used in data analysis. The same procedure will be done on the 3rd week and after 6th week."
47961076|NCT03557853|DRUG|Golimumab Injection|Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
47961077|NCT03473535|COMBINATION_PRODUCT|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
48308727|NCT02166021|BIOLOGICAL|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
48308728|NCT00722553|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
48308729|NCT00722553|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
48483011|NCT01418677|DRUG|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
47961078|NCT03473535|BEHAVIORAL|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
48112919|NCT00411138|RADIATION|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
48308730|NCT00722553|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
48308731|NCT04008589|DEVICE|repetitive transorbital AC Stimulation|Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
48308732|NCT04008589|DEVICE|combination of transcranial direct current stimulaton and rtACS|Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
48308733|NCT04864912|OTHER|Questionnaires and survey|Questionnaires: Health Utilities Index Mark III, Chronic Otitis Media Outcome Test-15 and Speech, Spatial, and Qualities of Hearing Scale-12 Survey: Client Service Receipt Inventory (adapted version)
48308734|NCT00322595|DRUG|Quetiapine fumarate|
48308735|NCT00322595|DRUG|Paroxetine|
48308736|NCT04802850|OTHER|Mulligan mobilization with movement|
48308737|NCT05888428|DEVICE|MyoTrain|MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
48308738|NCT05888428|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
48308739|NCT02210871|DRUG|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
48308740|NCT01977209|DRUG|Gossypol|
48308741|NCT01977209|DRUG|Placebo|
48308742|NCT05022771|DRUG|PMG1015 Dose 1|Dose level 1 of PMG1015
48308743|NCT05022771|DRUG|PMG1015 Dose 2|Dose level 2 of PMG1015
48308744|NCT05022771|DRUG|PMG1015 Dose 3|Dose level 3 of PMG1015
48308745|NCT05022771|DRUG|PMG1015 Dose 4|Dose level 4 of PMG1015
48308746|NCT05022771|DRUG|PMG1015 Dose 5|Dose level 5 of PMG1015
48308747|NCT05022771|DRUG|PMG1015 Dose 6|Dose level 6 of PMG1015
48308748|NCT05022771|DRUG|Placebo|Placebo to match
48308749|NCT05022771|DRUG|PMG1015 Dose 7|Dose level 7 of PMG1015
48308750|NCT00809172|DRUG|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
48308751|NCT00809172|DRUG|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
48308752|NCT03696303|OTHER|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
48308753|NCT00093080|DRUG|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
47961079|NCT00169026|DRUG|Clozapine versus typical (conventional) and atypical antipsychotic medications|
48308754|NCT00704509|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
47961080|NCT01669226|DRUG|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
47961081|NCT01669226|DRUG|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
47961082|NCT03094429|DRUG|NaBen®|2000 mg/day or 1000 mg/day, twice daily
47961083|NCT03094429|OTHER|Placebo|0 mg total, twice daily
47961084|NCT03195764|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
47961085|NCT01466335|DRUG|Ronacaleret (100mg tablet)|100mg tablet
47961086|NCT01466335|DRUG|Placebo|matching placebo tablet
47961087|NCT03137537|DRUG|Ivabradine|lower heart rate in heart failure patients.
47961088|NCT03137537|DRUG|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
47961089|NCT01741974|DIETARY_SUPPLEMENT|Karinat|
47961090|NCT01741974|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
47961091|NCT03105583|DRUG|Medication use during pregnancy|
47961092|NCT03105583|DIETARY_SUPPLEMENT|Supplement use during pregnancy|
47961093|NCT03105583|OTHER|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
48112920|NCT00411138|DRUG|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
48112921|NCT00411138|DRUG|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
48308755|NCT00704509|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
48308756|NCT00704509|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
48308757|NCT04837534|BEHAVIORAL|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
48308758|NCT04837534|BEHAVIORAL|SMS and phone call reminder group|In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
48308759|NCT03225781|DEVICE|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
48308760|NCT02256332|DIETARY_SUPPLEMENT|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
48308761|NCT02256332|DIETARY_SUPPLEMENT|High dose plant based ingredient|Reference food with high dose of plant based ingredient
47961094|NCT03703622|BEHAVIORAL|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, \& OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
47961095|NCT00096798|DRUG|Ethyl-eicosapentanoic acid (ethyl-EPA)|
47961096|NCT04621630|DRUG|PN-235|Active Drug
47961097|NCT04621630|DRUG|Placebo|Matching Placebo
47961098|NCT05325788|OTHER|e-Covery|Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.
47961099|NCT05325788|OTHER|Comparator Condition|Through the e-Covery app, participants will receive a single general message sent daily in the morning.
47961100|NCT03265639|DIETARY_SUPPLEMENT|P-inulin|
47961101|NCT03713892|DRUG|CKD-504|orally administered once with investigational drug assigned on 1d morning with 240 mL of water
47961102|NCT03713892|DRUG|Placebo|orally administered
47961103|NCT02656732|BIOLOGICAL|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
47961104|NCT02656732|PROCEDURE|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
47961105|NCT04094883|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
48642379|NCT06229080|DEVICE|NexGel|When a planned perfused area includes three or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
48642380|NCT03163264|BEHAVIORAL|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
47961106|NCT03342183|OTHER|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
47961107|NCT03342183|OTHER|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
47961108|NCT01242462|PROCEDURE|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
47961109|NCT01242462|OTHER|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is \>/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH \>/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
48112922|NCT00411138|DRUG|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
48112923|NCT00711217|OTHER|Medical Food|twice daily
48112924|NCT00711217|OTHER|Drink mix calorically similar to experimental product|twice daily
48112925|NCT06068244|OTHER|3D printed crowns|3D printed crowns
48308762|NCT02256332|DIETARY_SUPPLEMENT|Reference food format|Reference food without plant-based ingredient
48112926|NCT06068244|OTHER|Zirconia crowns|Nu smile zirconia crowns
48266669|NCT01904981|DRUG|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
48266670|NCT02529579|OTHER|iAPA-DC/CTL adoptive cellular immunotherapy|twice DC cell infusion and CTL cell infusion for 6 times
48266671|NCT02529579|DRUG|Gemcitabine|standard Gemcitabine therapy
48266672|NCT01777763|DRUG|Posaconazole 200 mg|
48266673|NCT01777763|DRUG|Posaconazole 300 mg|
48266674|NCT03176316|DRUG|Naloxone|Naloxone is an opioid antagonist (i.e., a medication used to reverse or reduce the effects of opioids)
48483012|NCT01418677|DRUG|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
48483013|NCT01418677|DRUG|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
48483014|NCT01363141|OTHER|Regular AGE Diet|Regular AGE Diet
48308763|NCT03816306|DRUG|LCZ 696|LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
48308764|NCT03223324|DEVICE|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
48308765|NCT04641364|DRUG|recombinant human albumin injection|single dose or multiple doses of intravenous infusion
48308766|NCT04641364|DRUG|Placebo|Single dose intravenous infusion of 0.9% sodium chloride injection
48308767|NCT04641364|DRUG|human albumin injection|multiple doses of intravenous infusion
48308768|NCT03200457|DEVICE|1,5 Tesla abdominal MRI|Measurement of the fat and iron
48308769|NCT03200457|DEVICE|3 Tesla abdominal MRI|Measurement of the fat and iron
48308770|NCT04304755|DRUG|Zoledronic Acid 5 MG in 5 ML Injection|Zoledronic acid
48308771|NCT04304755|DRUG|Placebos|NaCl 0.9%
48308772|NCT00344617|DRUG|Bevacizumab (tradename: Avastin)|
48308773|NCT02218814|PROCEDURE|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
48308774|NCT02218814|PROCEDURE|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
48308775|NCT00694512|DIETARY_SUPPLEMENT|Low fat diet|20% fat diet
48308776|NCT00694512|DIETARY_SUPPLEMENT|High fat diet|40% fat diet
48308777|NCT00694512|DIETARY_SUPPLEMENT|MCT diet|Medium chain triglyceride diet
48308778|NCT00118482|DRUG|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
48308779|NCT02973529|DEVICE|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
48308780|NCT02973529|DEVICE|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
48308781|NCT02575079|DEVICE|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
48642381|NCT03163264|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
48642382|NCT06241482|PROCEDURE|Enhanced recovery after surgery|"The technologies, processes and measures of enhanced recovery after surgery focus on the following aspects:~1. Early assessment and treatment~2. Optimized anesthetic protocol~3. Reducing surgical stress~4. Multi-modal comprehensive monitoring~5. Comprehensive diagnosis and treatment in neurosurgical intensive care~6. Intensive early rehabilitation treatment"
48308782|NCT03463616|RADIATION|CT abdomen|CT scan of abdomen for metastasis staging of rectal cancer
48308783|NCT03463616|RADIATION|MRI abdomen|MRI of abdomen for metastasis staging of rectal cancer
48308784|NCT06055881|OTHER|Non-Interventional Study|Non-interventional study
48308785|NCT02310971|BIOLOGICAL|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
48308786|NCT01081873|DRUG|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
48308787|NCT04006899|DEVICE|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
48308788|NCT02074579|DRUG|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
48308789|NCT02074579|DRUG|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
48308790|NCT00807846|DRUG|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
48308791|NCT00807846|DRUG|Naproxen|Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
48308792|NCT04356755|DRUG|AdMSC|At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks
48308793|NCT04356755|DRUG|Placebo|At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
48308794|NCT05126524|OTHER|NO INTERVENTION|Observational study, no intervention performed
48308795|NCT00285298|DRUG|Pentoxifylline|
48308796|NCT00285298|DRUG|Placebo|
48308797|NCT06250530|PROCEDURE|High tibial osteotomy using TOMOFIX|TOMOFIX: A guidepin is placed to determine the level and length of the osteotomy with an appropriate hinge position selected. The oscillating saw is then used along with osteotomes to complete the osteotomy under image intensifier guidance. This is opened to the desired width of correction with a trapezoidal gap noted when using laminar spreader in the posterior position to avoid slope change. The plate is then applied and secured as per manufacturers operative technique.
48308798|NCT06250530|PROCEDURE|High tibial osteotomy using BodyCAD|BodyCAD: The patient specific cutting block is applied to the proximal tibia and secured in placed. The osteotomy is then created with sequential drills and osteotome and opened to the predetermined correction as per the manufacturer's guidelines. The plate is applied and secured with the supplied screws.
48308799|NCT03451864|PROCEDURE|Vaginal delivery|classic vaginal delivery
48308800|NCT03451864|PROCEDURE|Cesarean Section|routine lower segment cesarean scetion
48308801|NCT00340314|PROCEDURE|Circumferential Pulmonary Vein Ablation|
48308802|NCT00340314|DRUG|Antiarrhythmic Drug Therapy|
48308803|NCT06463158|DEVICE|Family Room App|The Family Room is a dynamic, point of care tool. It guides families on how best to contribute to patient care by providing real time education, a sense of connection, emotional support, and resources that enable meaningful caregiving. Importantly, family caregivers receive virtual training on comfort-focused care activities that can be done at the bedside, as well as a mechanism within the electronic health record (EHR) to measure and record the effectiveness of the care they provide.
48308804|NCT03664193|RADIATION|SIBRT|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
48308805|NCT00161980|DRUG|Fibrin Sealant VH S/D|
48308806|NCT00161980|PROCEDURE|Surgical intervention alone without Fibrin Sealant VH S/D application|
48308807|NCT00108927|BEHAVIORAL|TRANSLATE|
48308808|NCT00490373|DRUG|pemetrexed|
48308809|NCT04422665|OTHER|Resistance exercise|Single-legged resistance exercise
48308810|NCT02266901|PROCEDURE|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
48308811|NCT05785117|DEVICE|Vagal Stimulation|ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
48642383|NCT06241482|PROCEDURE|Conventional therapy|Conventional therapy in neurocritical care.
48642384|NCT03921541|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
48308812|NCT05785117|OTHER|Circuit training program|The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
48642385|NCT03921541|DRUG|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
48642386|NCT05633355|DRUG|Rocatinlimab|Subcutaneous (SC) injection
48642387|NCT06517927|DIAGNOSTIC_TEST|Clinical and radiographic dental examination|complete clinical oral examination + intra-oral and panoramic x-rays
48642388|NCT05278104|DRUG|Zentiva®|Zentiva®
48642389|NCT05278104|DRUG|Placebo|Placebo
48642390|NCT06097364|DRUG|Odronextamab|Administered by intravenous (IV) infusion
48642391|NCT06097364|DRUG|Rituximab|Administered by IV infusion, or subcutaneous (SC)
48642392|NCT06097364|DRUG|Cyclophosphamide|Administered by IV infusion
48266675|NCT00699348|DRUG|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
48308813|NCT01742624|DRUG|Advagraf|oral
48308814|NCT01742624|DRUG|Prograf|oral
48308815|NCT01742624|DRUG|Corticosteroid|oral
48308816|NCT01742624|DRUG|Mycophenolate mofetil|oral
48308817|NCT02487849|PROCEDURE|HIPEC|secondary cytoreductive operation
48308818|NCT02487849|DRUG|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
48308819|NCT00924976|BEHAVIORAL|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
48308820|NCT04749979|DRUG|Agonist (decapeptyl )|giving agonist
48308821|NCT04749979|DRUG|HCG ( eg. Choriomon )|giving HCG
48308822|NCT03136549|OTHER|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
48308823|NCT03136549|OTHER|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
48308824|NCT02270892|DEVICE|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
48308825|NCT05425238|OTHER|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
48308826|NCT05425238|OTHER|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
48308827|NCT05151770|OTHER|Measure of glycemia levels and comparison to algorithm predictions|The study aims to evaluate the efficacy of a new algorithm in predicting the evolution of glycemia levels after a full meal. Glycemia levels measured during and after a full meal will be compared to the values predicted by the algorithm. Composition of the meals will also be collected.
48308828|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
48642393|NCT06097364|DRUG|Doxorubicin|Administered by IV infusion
48642394|NCT06097364|DRUG|Vincristine|Administered by IV infusion
48642395|NCT06097364|DRUG|Prednisone/Prenisolone|Administered orally (PO)
48642396|NCT03049462|DRUG|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50 mg tablets.
48308829|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
48308830|NCT03062319|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
48642397|NCT03049462|OTHER|B Complex Plus Vitamin C Tablets|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
48642398|NCT03798626|DRUG|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
48642399|NCT03798626|DRUG|Bevacizumab|25 mg/mL concentration; administered IV
48308831|NCT03062319|DRUG|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
48308832|NCT06492785|BIOLOGICAL|High Hyaluronic Acid concentrations (0.5 mg/ml)|Hyaluronic Acid(EmbryoGlue®)
48308833|NCT06492785|BIOLOGICAL|Low Hyaluronic Acid concentrations (0.125 mg/ml)|Hyaluronic Acid (G2 medium)
48308834|NCT01331239|DRUG|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
48308835|NCT02750800|BIOLOGICAL|Adalimumab|Pre-filled syringe or pen, administered by subcutaneous injection
48308836|NCT02750800|BEHAVIORAL|AbbVie Care 2.0|Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
48308837|NCT03661268|OTHER|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
48308838|NCT02427477|DEVICE|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
48308839|NCT02427477|DEVICE|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
48308840|NCT00597935|PROCEDURE|SSLF|sacrospinous ligament fixation (SSLF)
48308841|NCT00597935|PROCEDURE|ULS|uterosacral vaginal vault ligament suspension (ULS)
48308842|NCT00597935|BEHAVIORAL|PMT|Pelvic muscle training and exercises (PMT)
48308843|NCT01606592|BEHAVIORAL|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
48308844|NCT01606592|BEHAVIORAL|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
48308845|NCT01606592|OTHER|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
48308846|NCT05162950|DIAGNOSTIC_TEST|physical exercise as a standardized high intensity exercise test|High intensity exercise test, cycling, performed at the Karolinska University Hospital
48308847|NCT05162950|BEHAVIORAL|Stress vulnerability|Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
48308848|NCT02307344|DIETARY_SUPPLEMENT|Nigella Sativa|
48308849|NCT02307344|DIETARY_SUPPLEMENT|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
48308850|NCT05475821|DRUG|ABBV-990|Oral Tablet
48112927|NCT06167525|DEVICE|Real-time feedback through the device. Bio-feedback signals will be given once deviated from a neutral posture for >1 minute. Response of surgeons to bio-feedback signals will be recorded|"During the first stage of the study the device will be set to record cervical spine positioning without bio-feedback signals. This will be used to record duration of time surgeons held maladaptation postures.~The second stage will involve real-time feedback through the device. For surgeons who consent, bio-feedback signals will be given once deviated from a neutral posture for \>1 minute. Response of surgeons to bio-feedback signals will also be recorded.~The Neck Disability index score will be used to assess for neck pain and the functional implications in relation to reported neck pain. This will be completed following study completion."
48308851|NCT05475821|DRUG|Placebo for ABBV-990|Oral Tablet
48308852|NCT03751995|BEHAVIORAL|Mindfulness meditation|"Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in."
48308853|NCT05130333|OTHER|No intervention|No intervention
48308854|NCT00603980|DRUG|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
48308855|NCT00603980|DRUG|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
48308856|NCT00603980|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
48308857|NCT00603980|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
48308858|NCT00603980|DRUG|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
48308859|NCT00603980|DRUG|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
48308860|NCT00603980|DRUG|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
48308861|NCT00603980|DRUG|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
48308862|NCT00603980|DRUG|Oral placebo qualifying session|Qualifying control session (oral placebo)
48308863|NCT06105879|DEVICE|covered or open skin|transcutaneous mesarument of covered or open skin area
48308864|NCT06108427|OTHER|Renin measurements|Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
48308865|NCT02280291|DRUG|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
48308866|NCT02280291|DRUG|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
48308867|NCT02280291|DRUG|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
48308868|NCT02280291|DRUG|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
48642400|NCT03798626|DRUG|Modified FOLFOX6|Oxaliplatin \[5 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
47961110|NCT02747875|DRUG|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
47961111|NCT02747875|DRUG|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
47961112|NCT01786941|OTHER|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
47961113|NCT01786941|OTHER|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
47961114|NCT00080470|DEVICE|bion|battery powered microstimulator
47961115|NCT03916991|OTHER|Exercise|Hip focused Neuromuscular Activation Exercise
48642401|NCT03798626|DRUG|FOLFIRI|Irinotecan \[20 mg/mL concentration; administered IV\], leucovorin \[10 mg/mL concentration; administered IV\] (or levoleucovorin \[10 mg/mL concentration; administered IV\]), and 5-fluorouracil \[50 mg/mL concentration; administered IV\]
47961116|NCT00398918|DRUG|zonisamide|zonisamide (100 mg)one time
47961117|NCT00398918|DRUG|Placebo|Placebo Comparator
47961118|NCT00807378|OTHER|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
47961119|NCT04044378|DRUG|Famitinib|famitinib with RP2D orally daily
47961120|NCT04044378|DRUG|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
47961121|NCT04044378|DRUG|Camrelizumab|camrelizumab 200mg infusion once Q2W
48642402|NCT03798626|DRUG|Ramucirumab|10 mg/mL concentration; administered IV
48642403|NCT03798626|DRUG|Paclitaxel|6 mg/mL concentration; administered IV
47961122|NCT02273778|PROCEDURE|MRI Scan|
48112928|NCT04143126|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
48308869|NCT00146705|PROCEDURE|blood samples are taken once|
48642404|NCT03798626|DRUG|Cabozantinib|60 mg tablet; administered orally
48642405|NCT05730478|DEVICE|ASOCT&UBM|glaucoma assesment by ASOCT \&UBM
47961123|NCT02273778|PROCEDURE|PET-CT Scan|
47961124|NCT02273778|OTHER|No intervention|
47961125|NCT03534960|DEVICE|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
47961126|NCT03534960|DEVICE|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
47961127|NCT04899154|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
47961128|NCT04899154|OTHER|stool sampling|Participants will provide one stool sample at inclusion
47961129|NCT06199596|DIETARY_SUPPLEMENT|alpha-s1 casein hydrolysate|150mg of Prelactium per capsule
47961130|NCT06199596|DIETARY_SUPPLEMENT|Maltodextrin|150mg of Maltodextrin per capsule
47961131|NCT02265874|DRUG|Habitrol|Patch used daily for 28 weeks
47961132|NCT02265874|DRUG|Placebo to Habitrol|
47961133|NCT00252395|DEVICE|PDA-based Electronic Prescribing Software|
48642406|NCT05730478|DRUG|Glaucoma therapy|ASOCT and UBM parameters Comparison
47961134|NCT00382304|DRUG|tolevamer potassium-sodium (GT267-004)|
47961135|NCT05821400|OTHER|observational study|observational study
48112929|NCT04143126|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
48308870|NCT01808118|BIOLOGICAL|adalimumab|40 mg every other week
48308871|NCT01808118|BIOLOGICAL|Placebo|every other week
48642407|NCT05730478|DRUG|Glaucoma therapy|Comparison
48642408|NCT06549049|BEHAVIORAL|TranS-C for PTSD|The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for veterans in the VA healthcare system.
48308872|NCT03491722|OTHER|risk factors and revascularization procedures|arterial revascularizations needed since index procedure
48308873|NCT03951857|OTHER|Resistance exercise with a gym stick|Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
48308874|NCT05590663|OTHER|Physiotherapy|routine referral-based physiotherapy treatment for patients with knee osteoarthritis
48308875|NCT02151006|DRUG|DHEA|
48308876|NCT03950245|OTHER|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
48308877|NCT03950245|OTHER|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
48308878|NCT03950245|OTHER|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
48308879|NCT03950245|OTHER|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
47961136|NCT01268969|PROCEDURE|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
47961137|NCT01268969|PROCEDURE|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
47961138|NCT00318422|DRUG|liraglutide|
47961139|NCT00318422|DRUG|rosiglitazone|
47961140|NCT00318422|DRUG|glimepiride|
47961141|NCT04749277|OTHER|CAD EYE® (Fujifilm, Europe, Gesellschaft mit beschränkter Haftung, Dusseldorf, Germany)|"Methods plan~Phase 1. Brief virtual chromoendoscopy training on the characterization of colorectal polyps (WLI, LCI and BLI)~Phase 2. CAD EYE® system applied during colonoscopy retrieval:~2.1. CAD EYE® system OFF: Virtual chromoendoscopy (BLI) - independently characterization of a suspected polyp in WLI and BLI by the first endoscopist and by the second endoscopist (iconographic record) 2.2. CAD EYE® system ON: Characterization mode (BLI): Characterization of a suspected polyp by CAD EYE® and respectively level of characterization (1 to 3) (iconographic record) Phase 3. Histopathological evaluation (pathologist with gastrointestinal expertise): Resection and recovery of a suspected polyp for anatomopathological characterization"
48112930|NCT01568918|DRUG|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
48112931|NCT01568918|OTHER|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
48112932|NCT00000699|DRUG|Inosine pranobex|
48112933|NCT00000699|DRUG|Ribavirin|
48308880|NCT04885491|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
48308881|NCT04885491|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
48308882|NCT00735124|DRUG|Gabapentin|1200 mg single dose gabapentin
48308883|NCT00735124|OTHER|placebo|Injection of placebo/sham
48112934|NCT04234048|DRUG|Fenretinide|"Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort"
48112935|NCT06677008|DEVICE|Disposable endoscopic linear cutter stapler|Investigational devices of all the models of the staplers and its cartridge listed in Study Plan(Plan number: CAK-PMCF)
48112936|NCT06677411|OTHER|Observention of vitamin D|It is an observational study
48308884|NCT03397277|BEHAVIORAL|Safety behaviour promoting video|A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence
48308885|NCT03397277|BEHAVIORAL|Control video|A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
48308886|NCT02283606|DEVICE|Accuvix SnonAce UGEO|vaginal ultrasonography
48308887|NCT02053220|BIOLOGICAL|Colo-Ad1|Oncolytic virus
48308888|NCT01205672|DRUG|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
48308889|NCT05868941|DEVICE|Broncho Muco Cleaner|"The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally."
48308890|NCT01073956|PROCEDURE|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
48308891|NCT01073956|PROCEDURE|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
48308892|NCT01073956|PROCEDURE|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
48308893|NCT01893944|OTHER|virtual reality|customized applications using virtual and augmented reality to be developed.
48308894|NCT02180503|DRUG|BI 1356 BS PIB - low dose|
48308895|NCT02180503|DRUG|BI 1356 BS tablet - low dose|
48308896|NCT02180503|DRUG|BI 1356 BS PIB - high dose|
48308897|NCT02180503|DRUG|BI 1356 BS tablet - high dose|
47961142|NCT00242320|DRUG|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
48112937|NCT06673147|OTHER|Prenatal Nordic Walking|Traditional Nordic walking poles will be modified according to International Nordic Walking Federation guidelines, which meant that the elbows were bent at a 90°angle when holding the poles in a vertical position. Nordic Walking will be conducted in two phases consisting of a 4-week learning phase followed by an 8-week main phase of intervention.
48112938|NCT04868188|OTHER|5 blood samples|5 blood samples across 3 occasions/sampling windows (Day 1-4, Day 6-9 and Day 11-14) to determine plasma concentrations of voriconazole
48112939|NCT04868188|GENETIC|Determination of CYP2C19 genotype|A single buccal swab to determine the CYP2C19 genotype will be undertaken during the course of ICU stay.
48112940|NCT04870645|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
48308898|NCT02180503|DRUG|BI 1356 BS tablet - high dose with food|
48308899|NCT00518219|DRUG|TW|TW,120mg/d
48112941|NCT04870645|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo conventional MRI
48112942|NCT04870645|DRUG|Gadolinium-Chelate|Contrast agent
48308900|NCT04056364|BIOLOGICAL|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
48308901|NCT06373614|OTHER|foot massage|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
48308902|NCT06373614|OTHER|bed bath|Interventions are to be performed in the evening before bedtime for 4 consecutive days.
48308903|NCT00789477|PROCEDURE|Laser Photocoagulation|laser every 16 weeks as needed
48308904|NCT00789477|DRUG|Intravitreal Aflibercept Injection|
48308905|NCT00620321|DRUG|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
48308906|NCT00620321|DRUG|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
48308907|NCT00620321|DRUG|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
48308908|NCT01913249|PROCEDURE|LIFT|Ligation of intersphincteric fistula tract
48112943|NCT04870645|DRUG|Iopamidol|Contrast agent
48308909|NCT06031480|DRUG|Anlotinib and TQB2450|"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."
47961143|NCT00242320|DRUG|Placebo|
47961144|NCT04118439|OTHER|Motor Imaginery and Action Observation|A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
47961145|NCT06199154|DRUG|Misoprostol|Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
47961146|NCT05250778|BEHAVIORAL|Nudge|Room intervention
47961147|NCT05344170|DRUG|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
48112944|NCT00001304|DRUG|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
48308910|NCT03593967|BEHAVIORAL|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~* Week 1: Food and Play as our National Heritage~* Week 2: Our Voices, Our Singapore: Strengthening Bonds~* Week 3: Overcoming Adversities: Stories of Resilience~* Week 4: Beholding the Future: Dreams and Aspirations~* Week 5: Passing It On: The Stories We Share"
48308911|NCT00417976|DRUG|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
48308912|NCT00417976|DRUG|Bevacizumab|10 mg/kg every 2 weeks.
48308913|NCT00417976|DRUG|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
48308914|NCT05923489|DIAGNOSTIC_TEST|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
48483015|NCT01363141|OTHER|Low AGE Diet|One year reduction in dietary AGE intake.
48483016|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
48483017|NCT02985619|DRUG|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
48112945|NCT00001304|DRUG|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
48112946|NCT05295134|DIETARY_SUPPLEMENT|Placebo|Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
48308915|NCT05923489|DIAGNOSTIC_TEST|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
48308916|NCT00307515|DRUG|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
48308917|NCT00307515|DEVICE|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
48308918|NCT00214851|DRUG|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
48308919|NCT02294149|DRUG|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
48308920|NCT02294149|DRUG|placebo|
47961148|NCT05344170|DRUG|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
47961149|NCT05344170|DRUG|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
47961150|NCT00479193|DRUG|bacitracin/xeroform|single layer, change every 3 days
47961151|NCT00479193|DRUG|Polymem|single layer of Polymen, change every 3 days
47961152|NCT03616626|RADIATION|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
47961153|NCT03616626|RADIATION|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
48308921|NCT00916123|DRUG|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
48308922|NCT00916123|DRUG|Prednisone|10 mg per day starting on cycle 1, day 1
48308923|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
48308924|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
48308925|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
48308926|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
48642409|NCT06549049|BEHAVIORAL|Sleep Psychoeducation Control|Participants will receive psychoeducation about sleep.
48642410|NCT06694961|OTHER|Online Educational Material|Online educational material will be an easy way to reach large number of physicians
48642411|NCT06695507|DRUG|Ruxolitinib|Participants will receive ruxolitinib for 6 months.
47961154|NCT03616626|RADIATION|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
47961155|NCT00119834|DEVICE|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
47961156|NCT02699814|BEHAVIORAL|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
47961157|NCT04993820|BEHAVIORAL|Physical activity|The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.
48642412|NCT05954312|DRUG|VVD-130037|Oral tablets
48642413|NCT05896124|DRUG|2mg CS0159|Oral QD
48642414|NCT05896124|DRUG|Placebo|Oral QD
47961158|NCT04993820|BEHAVIORAL|Education control|Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
47961159|NCT00670150|DRUG|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
48308927|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
48308928|NCT03487380|PROCEDURE|Fecal sample collection|Fecal sample collection
48308929|NCT04430049|PROCEDURE|Covid ICU containment measures|The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
48308930|NCT01592890|DRUG|RO4917523|\[14C\]-labeled RO4917523, single oral dose
48308931|NCT01592890|DRUG|RO4917523|\[13C\]-labeled RO4917523, single intravenous tracer dose
48483018|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
48483019|NCT01145924|PROCEDURE|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
48483020|NCT05305560|DRUG|Ivermectin Tablets|Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
48483021|NCT05305560|DRUG|Matching placebo tablets|Daily placebo tablets intake for 28 days
48642415|NCT05087680|BEHAVIORAL|ACTPrEP|ACTPrEP will include a 60-minute initial session and a series of 30-minute follow-up sessions. Sessions will focus on the Thoughts, Emotions, Associations, Memories, and Sensations (TEAMS) relevant to PrEP uptake and adherence.
48642416|NCT05087680|BEHAVIORAL|Enhanced Standard of Care|Enhanced Standard of Care (ESOC) will include one 30-minute PrEP education session.
48642417|NCT06003790|DEVICE|MR-001|Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
47961160|NCT00670150|DRUG|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
47961161|NCT05462483|OTHER|Rice Sock and Instructions to heat the quadriceps.|A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
47961162|NCT02849431|BEHAVIORAL|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
47961163|NCT03031197|COMBINATION_PRODUCT|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
47961164|NCT00666172|BEHAVIORAL|Exercise|
47961165|NCT00666172|BEHAVIORAL|Weight Loss|
47961166|NCT04253444|BEHAVIORAL|slow deep breathing|Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
47961167|NCT04253444|BEHAVIORAL|sham breathing|Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
47961168|NCT02543710|PROCEDURE|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with \<50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with \<50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 \<50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
48112947|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (225,000 FIP lipase units per day)|Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
48112948|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (450,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
48112949|NCT05295134|DIETARY_SUPPLEMENT|Candida cylindracea lipase (675,000 FIP lipase units per day)|Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.
48308932|NCT01603316|BEHAVIORAL|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
48112950|NCT01714882|BEHAVIORAL|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
48308933|NCT01603316|BEHAVIORAL|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
48112951|NCT01714882|BEHAVIORAL|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
48112952|NCT05394779|DEVICE|DTXO APP|DTXO is an investigational therapeutic intervention (Digital Therapeutics - DTx) for obese patients, under clinical validation with a randomized and placebo-controlled clinical trial for confirmatory purposes. It is intended to improve weight loss, weight-loss maintenance, and overall health in patients with obesity by increasing their self-engagement, self-monitoring and adherence to dietary/exercise and behavioral programs. The App integrates different non-pharmacological approaches, engaging the patient through monitoring of her/his non-vital parameters, monitoring of patient diet and exercise, monitoring of patient psychological status, prescription of exercise and diet in a weight-loss program.
48112953|NCT05394779|DEVICE|PLACEBO APP - Control group|The placebo App will include only the non-medical modules of the digital therapy and has been introduced to make the experience of subjects in the control arm more similar to that of subjects in the experimental arm; moreover, data collection through the placebo app (questionnaires) will streamline the data collection process, avoiding manual data entry and reducing the possibility of entry errors.
48308934|NCT06448312|DRUG|SKB264|IV Infusion
48308935|NCT06448312|DRUG|Pembrolizumab|IV Infusion
48308936|NCT03697967|PROCEDURE|supine or prone position|"Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth.~The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished.~All subsequent nursery care are conducted according to hospital protocol."
47961169|NCT02543710|DRUG|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
47961170|NCT02051686|DRUG|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
47961171|NCT02051686|DRUG|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
47961172|NCT05864755|DRUG|HAIC+Durvalumab+Tremelimumab+Bevacizumab|Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
47961173|NCT01895062|DEVICE|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
47961174|NCT01399814|BEHAVIORAL|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000\~1500ml crystalloid was administered on the days following operation
48266676|NCT02648126|PROCEDURE|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
48308937|NCT05800444|DRUG|BAY3283142|Oral administration as tablet.
48308938|NCT05800444|OTHER|Placebo|Oral administration as tablet.
48308939|NCT05602259|DIAGNOSTIC_TEST|induced sputum|After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.
48308940|NCT05602259|DIAGNOSTIC_TEST|lung biopsy|As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.
48308941|NCT05602259|DIAGNOSTIC_TEST|bronchoalveolar lavage|When available, the remaining material from a patient's bronchoalveolar lavage will be collected.
48308942|NCT05602259|DIAGNOSTIC_TEST|blood draw|As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.
48308943|NCT03302793|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
48308944|NCT03302793|DEVICE|tDCS|tDCS will be applied for 20 minutes.
48308945|NCT03302793|DEVICE|tDCS sham|
48308946|NCT03471767|DRUG|AXS-05|Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
48308947|NCT03471767|DRUG|Bupropion SR|Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
48308948|NCT03572270|DIAGNOSTIC_TEST|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
48308949|NCT03572270|DIAGNOSTIC_TEST|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
48308950|NCT03268668|OTHER|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase \> 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
48308951|NCT02794051|BEHAVIORAL|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
48483022|NCT02021253|DIETARY_SUPPLEMENT|Probiotic|Lactibiane TOLERANCE vs Placebo
48483023|NCT02021253|DIETARY_SUPPLEMENT|Placebo|
47961175|NCT01399814|BEHAVIORAL|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000\~2500ml crystalloid was administered on the days following operation
47961176|NCT03571425|OTHER|Oral Placebo|A placebo beverage will be consumed orally
47961177|NCT03571425|OTHER|Oral Protein|A protein beverage will be consumed orally
48642418|NCT02628145|BEHAVIORAL|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
47961178|NCT03571425|OTHER|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
47961179|NCT00129428|PROCEDURE|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
47961180|NCT05087459|DRUG|Avatrombopag|On the basis of conventional treatment, Avatrombopag was added, 30×10\^9/L \< platelet count \< 50×10\^9/L patients received Avatrombopag 60mg/d, 50×10\^9/L≤ platelet count \< 75×10\^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
47961181|NCT00179556|DRUG|Isoflavone supplement|
47961182|NCT05719662|OTHER|Weight bearing exercises|Weight bearing exercises
47961183|NCT05719662|OTHER|Jaffrey's core stability exercises|Jaffrey's core stability exercises
48112954|NCT06212141|DEVICE|VisCalor Bulk,VOCO,Germany|"It was placed class II restorations.Before applying it, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 15 sec. and Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Then light air pressure will be applied for 5 sec., and then polymerization will be carried out for 10 sec. using LED light.~When it comes to the application of VisCalor , the VisCalor Gun , heating device will be used. A disposable composite capsule will be placed into the device, and it will be heated by selecting program 1 (65°C) for 30 sec. The material will remain hot for 2.5 min.~The nozzle of the capsule on the gun will be directly applied to the deepest part of the cavity, ensuring that the material is placed from bottom to top without exceeding 4 mm. Polymerization will be carried out with LED for 10 sec."
48642419|NCT02628145|BEHAVIORAL|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
47961184|NCT03813069|OTHER|IR3535|The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only
47961185|NCT03813069|OTHER|Permethrin lower dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
47961186|NCT03813069|OTHER|Permethrin higher dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
47961187|NCT02569658|DRUG|Tranexamic Acid|
47961188|NCT02569658|DRUG|Placebo|
47961189|NCT03862222|OTHER|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
47961190|NCT03862222|OTHER|Pupillometry|Participants will complete a task studying pupillary response to light
47961191|NCT03862222|OTHER|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
48642420|NCT02953457|BIOLOGICAL|Durvalumab|Given IV
48308952|NCT03657680|OTHER|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
48483024|NCT05403710|DRUG|Botulinum toxin|Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
48483025|NCT02575508|DRUG|Fluorouracil|Given IV
48483026|NCT02575508|DRUG|Irinotecan Hydrochloride|Given IV
48642421|NCT02953457|OTHER|Laboratory Biomarker Analysis|Correlative studies
48642422|NCT02953457|DRUG|Olaparib|Given PO
48642423|NCT02953457|BIOLOGICAL|Tremelimumab|Given IV
47961192|NCT03862222|DIAGNOSTIC_TEST|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
47961193|NCT03862222|GENETIC|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
47961194|NCT03862222|OTHER|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
47961195|NCT03862222|OTHER|Gait Assessment|Gait assessment will be conducted by trained researcher
47961196|NCT03862222|OTHER|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
47961197|NCT05435495|PROCEDURE|Single-photon emission computed tomography|Imaging procedure
47961198|NCT05435495|PROCEDURE|Blood Draw|Blood draw for future research tests (45-60 mL).
47961199|NCT05435495|PROCEDURE|Tumor Biopsy|Guided biopsy of lesion
47961200|NCT05541120|DEVICE|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
48308953|NCT05589116|OTHER|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
48642424|NCT05370144|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiation 23 Gy in 5 fractions with a simultaneous integrated boost of 26 Gy in 5 fractions to the gross tumor volume (GTV) given concurrently over 1 week during week 3 of chemotherapy.
48112955|NCT06212141|DEVICE|Admira Fusion x-tra,VOCO,Germany|"Admira Fusion x-tra composite resin was placed class II restorations. Before applying it an orthophosphoric acid with a concentration of 37% will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin. Then, cavity will be rinsed with pressurized air and water for 20 sec. And Futura Bond U adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec. using LED light with a power of 1200 mW/cm².~Afterwards bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light for 20 seconds."
48642425|NCT02900404|OTHER|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
48642426|NCT02900404|OTHER|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
48642427|NCT06163807|DRUG|Antiasthmatic|real-life
48308954|NCT04626024|OTHER|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal|Stop taking TKI medication
48642428|NCT01435746|BEHAVIORAL|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
48642429|NCT02926196|DRUG|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
47961201|NCT04523220|DRUG|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
47961202|NCT04523220|DRUG|Placebo|Subcutaneous administration in the same manner as Osocimab.
47961203|NCT01664546|PROCEDURE|Trophectoderm biopsy|
47961204|NCT02702804|OTHER|High Intensity Interval Training|High Intensity Interval Training
47961205|NCT02785120|DRUG|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
47961206|NCT03092921|DEVICE|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
47961207|NCT03092921|DEVICE|F&P Mask|Investigative Mask to be used for OSA therapy
48308955|NCT04626024|DRUG|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation|Re-start TKI medication
48308956|NCT01249183|BIOLOGICAL|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
48308957|NCT01249183|BIOLOGICAL|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
48483027|NCT02575508|OTHER|Laboratory Biomarker Analysis|Correlative studies
48483028|NCT02575508|DRUG|Oxaliplatin|Given IV
48483029|NCT02575508|DRUG|pan FGFR Kinase Inhibitor BGJ398|Given IV
48483030|NCT02575508|OTHER|Pharmacological Study|Correlative studies
48483031|NCT04822376|DRUG|ansuvimab|Human monoclonal antibody to Zaire strain GP (EBOV GP)
48483032|NCT04822376|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
48483033|NCT02710682|PROCEDURE|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~1. Skin disinfection; Local anesthesia (lidocaine 1%).~2. Skin incision, slightly anterior to lateral epicondyle.~3. Exposure of the plane between the tendon and fascia.~4. Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~5. Excision of diseased tissue of the ECRB tendon.~6. ECRL tendon is sutured back to the fascia. The skin is closed.~7. Patient is monitored for 30 minutes after procedure."
47961208|NCT05947175|BIOLOGICAL|Vertebral bone marrow (vBMA) clot|The clotted vBMA will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
48308958|NCT00109187|DRUG|Xolair (omalizumab)|
48308959|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
48308960|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
48308961|NCT02638805|DRUG|Metformin|Stable dose for at least 3 months (at least 1000 mg/day)
48308962|NCT02638805|DRUG|Liraglutide|Stable dose for at least 3 months (at least 1.2 mg/day)
48308963|NCT04491786|DRUG|Gabapentin|Gabapentin plus nefopam
48308964|NCT00205725|DRUG|Ziprasidone, Olanzapine|
48308965|NCT01041690|DRUG|Bevacizumab|
47961209|NCT05947175|OTHER|Bone allograft chips|Bone allograft chips will be obtained from Musculoskeletal Tissue Bank at IRCCS Istituto Ortopedico Rizzoli.
47961210|NCT03245684|DIAGNOSTIC_TEST|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
47961211|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
47961212|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
47961213|NCT01529502|DRUG|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
48308966|NCT02746393|OTHER|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
48308967|NCT02746393|OTHER|211 Information Sheet|Receive a printed list of community resources to address social needs.
48308968|NCT02099916|DRUG|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
48308969|NCT02099916|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
48308970|NCT00086710|DRUG|Fuzeon|
48308971|NCT02218658|DRUG|WE941 OD tablets|
48308972|NCT02218658|DRUG|Brotizolam|
48308973|NCT04950582|DIAGNOSTIC_TEST|Spectral characteristics assessment|Urine sample analysis for evidence of urinary tract infection
48308974|NCT06553417|OTHER|Aqua posae and microresyl|"* This intervention involves the use of two topical products:~  * Aqua posae - a moisturizing agent~ * Microresyl - an active ingredient with potential therapeutic effects~* Subjects in Group A will be instructed to apply these two products (aqua posae and microresyl) twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
48308975|NCT06553417|OTHER|Urea 10%|"Intervention 2: Urea 10%~* This intervention involves the use of a 10% urea-based topical moisturizing product.~* Subjects in Group B will be instructed to apply the 10% urea moisturizer twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
48308976|NCT01429987|DRUG|plecanatide|Subjects receive experimental study drug for 12 weeks.
48308977|NCT01429987|OTHER|Placebo|Subjects receive experimental study drug for 12 weeks.
48308978|NCT06346288|PROCEDURE|Breast Milk Sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of commercial risankizumab at pre-dose and 1 hour after dosing on Day 1, on Days 4 (± 1), 8 (± 2), 15 (± 3), 29 (± 3), and pre-dose on Day 57 (± 3)
47961214|NCT02657369|DRUG|Lenvatinib 24 mg|
47961215|NCT01995474|OTHER|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
47961216|NCT01995474|OTHER|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
47961217|NCT00275457|DRUG|pramipexole|
47961218|NCT05618366|DRUG|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
47961219|NCT05618366|DRUG|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
48308979|NCT06346288|DRUG|Risankizumab|Participants will have already been taking commercial risankizumab and will continue on commercial risankizumab. Participants will not be provided risankizumab from the study. Participants must have received at least 2 doses of 360 mg of risankizumab SC every 8 weeks postpartum prior to start of participation in this study.
48308980|NCT00323505|DRUG|Pegylated Interferon|
48308981|NCT00323505|DRUG|Interferon-alpha2a|
48308982|NCT04452591|BIOLOGICAL|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
48112956|NCT06212141|DEVICE|Filtek One Bulk,3M,Germany|"Filtek One Bulk composite resin was placed class II restorations. Before applyingthe material, a 37% orthophosphoric acid will be injected into the cavity for 30 sec. on the enamel and 15 sec. on the dentin, followed by rinsing the cavity with pressurized air and water for 20 sec.Then , adhesive agent will be applied to the enamel and dentin surfaces using a disposable applicator for 20 sec. Following the manufacturer's recommendations, light air pressure will be applied for 5 sec, and then polymerization will be carried out for 10 sec using LED light .~Afterwards, bulk-fill composite will be placed in the cavity, ensuring that each layer does not exceed 4 mm, and appropriate occlusal shaping will be performed. Polymerization will be carried out with LED light at a power of 1200 mW/cm² for 10 sec from all directions, following the manufacturer's recommendations."
48112957|NCT06122727|PROCEDURE|total knee arthroplasty|In detail, in the STANDARD group, patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of guide intramedullary of femur and extramedullary of tibia); in the PERSONALIZED group, patients will undergo a primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with design based specifically on each patient's actual knee morphology and using PSI surgical technique and instrumentation. In both groups, the approach of the basic prosthetic design base will be of the Cruciate-Retaining (CR) type with congruent polyethylene (PE), with standard and customized for the STANDARD and CUSTOM group, respectively.
48112958|NCT05789485|BEHAVIORAL|structured treadmill walking|Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
48112959|NCT03984617|OTHER|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
47961220|NCT04159571|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
48642430|NCT04097860|BEHAVIORAL|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
48642431|NCT06694688|DIAGNOSTIC_TEST|the supine/standing postural change test|The prevalence of orthostatic hypotension will be characterized by the percentage of patients with a decrease of ≥ 20mmHg in systolic blood pressure or ≥ 10mmHg in diastolic blood pressure following the supine/standing postural change position.
48642432|NCT06660446|OTHER|Exercise|The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new PE project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic.
48642433|NCT05623514|COMBINATION_PRODUCT|Trans-vaginal ultrasound|Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
48642434|NCT05990465|DRUG|Pirtobrutinib|Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.
48642435|NCT05990465|DRUG|LV20.19 CAR T cells|Subjects will receive a dose of 2.5x10\^6 CAR-T cells/kg as a previously identified safe in a Phase 1 protocol at the Medical College of Wisconsin.
48642436|NCT06036810|OTHER|Shared Medical Decision Tool|standard of care
48642437|NCT06036810|BEHAVIORAL|Engaging Patients in Decision Making|standard of care
48642438|NCT06036810|BEHAVIORAL|Literacy Spanish Language|standard of care
48642439|NCT06044714|PROCEDURE|Manual Standardized Stress Acupuncture (MSSA)|Participants in the experimental group will receive 4 weekly sessions of MSSA, which consists of 8 acupuncture points: bilateral auricular (ear) shen men, GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. Needles are left in situ for 30 minutes per session.
48112960|NCT05196438|OTHER|Collecting statistics about congenital heart patterns and investigations done and interventions done to them|Collecting statistics about congenital heart patterns and investigations done and treatment given or interventions e.g. catheterization or surgical operations done to them
48308983|NCT04452591|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
48483034|NCT02710682|DEVICE|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.~1. Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~2. Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~3. Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~4. Patient monitored for 30 minutes, before being discharged."
48483035|NCT01253395|BEHAVIORAL|Strength training|Daily supervised strength training.
48483036|NCT01253395|BEHAVIORAL|Aerobic exercise|Daily supervised aerobic exercise.
48642440|NCT06044714|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will receive four sessions of MBSR group psychotherapy (no more than 10 participants per group session) via Microsoft Teams. The first session will be 90 minutes followed by three 60-minute weekly sessions.
47961221|NCT04159571|DEVICE|Sham cTBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
47961222|NCT06471829|DRUG|Lu AG13909|Solution for injection/infusion
47961223|NCT03737942|DEVICE|monitoring of neuromuscular function|started by percutaneous stimulation of the cubital nerve at the wrist level
47961224|NCT02655640|OTHER|Questionnaires|Questionnaires will be provided to patients
47961225|NCT02423759|DRUG|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
47961226|NCT02423759|DRUG|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
47961227|NCT02423759|DRUG|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
47961228|NCT04511546|DEVICE|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
47961229|NCT02368015|OTHER|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
47961230|NCT02368015|DRUG|cefazolin|
47961231|NCT00544830|DRUG|Bicalutamide|Given PO
47961232|NCT00544830|DRUG|Goserelin Acetate|Given SC
47961233|NCT00544830|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
47961234|NCT00544830|OTHER|Laboratory Biomarker Analysis|Correlative studies
47961235|NCT00544830|DRUG|Leuprolide Acetate|Given via injection
47961236|NCT01016197|PROCEDURE|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
47961237|NCT01016197|PROCEDURE|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
47961238|NCT04925583|RADIATION|Stereotactic body radiotherapy (SBRT)|"* level 0 (de-escalation): 10 x 5.0Gy~* level 1 (start): 10 x 5.5Gy~* level 2: 10 x 6.0Gy~* level 3: 10 x 6.5Gy"
47961239|NCT06037070|BIOLOGICAL|Platelet Rich Fibrin|PRF will be injected inside the hole that prepared to place dental implant
47961240|NCT02144415|DRUG|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
47961241|NCT02144415|DRUG|EB-1020 800 mg|8 x EB-1020 100-mg capsules
47961242|NCT02144415|DRUG|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
47961243|NCT02144415|DRUG|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
47961244|NCT02144415|DRUG|Placebo|8 x matching placebo capsules
47961245|NCT05911529|BEHAVIORAL|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
47961246|NCT05911529|BEHAVIORAL|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
47961247|NCT04745130|DRUG|Sintilimab，regofinib，cetuximab|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
47961248|NCT04745130|DRUG|KRAS BRAF mutant Sintilimab + regafinil|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
47961249|NCT04394117|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
47961250|NCT04394117|OTHER|Placebo|Placebo
47961251|NCT03081988|OTHER|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
47961252|NCT06429748|DEVICE|rTMS|repetitive Transcranial Magnetic Stimultion
47961253|NCT05274880|DRUG|CKD-393|PO, QD
47961254|NCT03175978|DRUG|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
47961255|NCT02901405|DEVICE|Negative Pressure Wound Therapy (ActivVAC, KCI)|
47961256|NCT02901405|DEVICE|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
47961257|NCT03050099|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
47961258|NCT01300650|DRUG|Anakinra|Anakinra 100 mg subcutaneous injection daily
47961259|NCT03225885|OTHER|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
47961260|NCT03225885|OTHER|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
47961261|NCT00845858|DRUG|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
47961262|NCT00845858|DRUG|Placebo|30 minutes before meals and at bedtime
47961263|NCT06492317|DRUG|Disitamab Vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)
47961264|NCT06492317|DRUG|Cadonilimab|Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)
47961265|NCT00329004|DRUG|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
47961266|NCT03396185|DRUG|Icotinib|Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
47961267|NCT00566995|DRUG|ZACTIMA (Vandetanib) (ZD6474)|
47961268|NCT04033575|DRUG|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
47961269|NCT04033575|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
47961270|NCT04555343|DRUG|Tranexamic acid|1gm instilled instravesically
47961271|NCT06127654|DEVICE|Healthy lung sparing treatment plan|CT Ventilation imaging will be used to create a healthy lung sparing treatment plan for patients who will receive radiation therapy treatment for their lung cancer.
47961272|NCT06204887|PROCEDURE|Manual dynamic activation|The root canals were filled with irrigation solutions. A main gutta percha cone was positioned 1 mm shorter than the working length and 2 mm coronal-apical direction movement was performed at a rate of 100 strokes per minute during 60 s.
48308984|NCT05956886|BEHAVIORAL|sleep chatbot|Personalized intervention algorithms will be developed based on CBT-I guidelines, focus group data, individual sleep baseline information and self-reported prioritized sleep goals. The CBT-I intervention will focus on principles of sleep restriction and stimulus control, with other CBT-I components used as on-demand content. The sleep chatbot system will facilitate sleep goal-setting with the participant and communicate weekly behavioral prescriptions and educational modules. After baseline data collection, the research coordinator will provide intervention orientation and set up the first-week sleep modification goal during the in-person/Zoom meeting. Sleep modification goals in the remaining weeks will be developed through the participant-chatbot interaction. The Chatbot system will send sleep-related information and behavioral reminders/feedback based on the interactive conversation with participants. Participants will also complete a sleep diary prompted by a chatbot.
48308985|NCT00331825|DRUG|Risperidone and Olanzapine|
48308986|NCT05493865|BEHAVIORAL|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.
48308987|NCT02884817|DRUG|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
48308988|NCT02884817|OTHER|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
48308989|NCT02884817|OTHER|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
48308990|NCT04145830|DEVICE|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
48308991|NCT06555926|OTHER|Acupressure|The pregnant women will receive acupressure on the (Pc-6/Lung-7 )acupoints one minute for each point with 3 repetitions on both side( about 30minutes /session),2 times per week in addition to advices for 12 weeks.
48308992|NCT06555926|OTHER|advices for relieving carpal tunnel syndrome|"The pregnant women will receive advices for 12 weeks as follows:~* Avoid heavy lifting.~* Avoid repetitive tasks.~* Sit on chairs with armrests and elevate affected hand on the armrest~* Avoid sleeping on the side of the affected hand.~* Keep the wrist in a neutral (straight) position.~* Avoid positions of full flexion and extension.~* Reduce general swelling by:~  * eating less salty food .~ * elevating legs when sitting .~ * wearing compression garments.~* Apply cold water over the wrist."
48308993|NCT04118686|OTHER|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
48308994|NCT04118686|OTHER|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
48308995|NCT06262555|PROCEDURE|Transbronchial PDT peripheral lung tumor ablation|Transbronchial lung tumor ablation with Photodynamic therapy
48642441|NCT03971045|DRUG|Pembrolizumab|Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
47961273|NCT06204887|PROCEDURE|Passive ultrasonic activation|A non-cutting ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) coupled to an ultrasonic device (DTE S6 Led, Guilin Woodpecker Co., Guilin, Guangxi, China) (mode: E, setting: 6) was used according to the manufacturer's recommendations.
48308996|NCT02671890|DRUG|Chemotherapy|
48308997|NCT02671890|DRUG|Disulfiram|Given PO
48483037|NCT00573170|DRUG|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
47961274|NCT06204887|PROCEDURE|Laser activation|A 2940 nm Er:YAG-laser device (Lightwalker, Fotona, Ljubljana, Slovenia), equipped with a handpiece (H14, Fotona) holding a 8.5 mm long and 600 µm diameter-tapered fiber tip (SWEEPS 600, Fotona) was used for irrigation activation. The device was set to AutoSWEEPS mode with two ultrashort micropulse durations (25 μs) continuously varying at 0.3 W, 20 mJ, 15 Hz settings. The air and water sprays were turned off.
47961275|NCT03928158|DRUG|LCZ 696|50-100-200 mg tablet
47961276|NCT03928158|DRUG|Valsartan|40-80-160 mg tablet
47961277|NCT00589992|DRUG|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
47961278|NCT03566160|DEVICE|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
47961279|NCT06477198|OTHER|QLB|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the convex probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the quadratus lumborum muscle, the needle will be punctured and 5 ml of saline will be injected into the posterior border of the quadratus lumborum muscle between QLM and latissimus dorsi muscle.. After the block location is confirmed, 30 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (60 ml totally).
47961280|NCT06477198|OTHER|ESPB|ESP block will be performed. Convex probe will be placed longitudinally 4 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle, 2 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for the block in each side (total 60 mL).
48308998|NCT02671890|DRUG|Gemcitabine Hydrochloride|Given IV
48308999|NCT02671890|OTHER|Laboratory Biomarker Analysis|Correlative studies
48309000|NCT00101192|BIOLOGICAL|cetuximab|
48309001|NCT00101192|DRUG|cisplatin|
48309002|NCT01689207|DRUG|Avibactam (AVI)|PART A: AVI IV infusion
48309003|NCT01689207|DRUG|Aztreonam (ATM)|PART A: ATM IV infusion
48309004|NCT01689207|DRUG|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
48309005|NCT01689207|DRUG|Placebo|PART A, PART B, PART C: matching placebo IV infusions
48309006|NCT04708392|DEVICE|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
48309007|NCT05160077|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography (MSOT)|MSOT Acuity Echo, iThera medical, Munich
48309008|NCT03255291|BEHAVIORAL|Risk Assessment App|The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
48309009|NCT03255291|BEHAVIORAL|Audio Recording - Sleep|-Participants imagine themselves improving sleep hygiene
48309010|NCT03255291|OTHER|Surveys|Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
48309011|NCT03255291|BEHAVIORAL|Audio Recording - Exercise|Participants imagine themselves improving exercise
48309012|NCT03255291|OTHER|Text message reminders|-Reminders to practice mental imagery
48642442|NCT06368427|DRUG|budesonide / glycopyrronium / formoterol|"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria"
47961281|NCT06477198|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
48309013|NCT03255291|OTHER|Text Message Survey|-Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
47961282|NCT01478880|PROCEDURE|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
48309014|NCT05745896|OTHER|Telemedicine appointment|Three online appointments for pregnancy monitoring at prenatal care.
48309015|NCT05745896|OTHER|Face-to-face appointment|Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
48309016|NCT01652248|PROCEDURE|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
47961283|NCT01478880|PROCEDURE|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
47961284|NCT06547450|BEHAVIORAL|5-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session
48309017|NCT03132805|BEHAVIORAL|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
48309018|NCT03132805|BEHAVIORAL|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
48309019|NCT03392155|BEHAVIORAL|Training & Nutrition|Exercise at moderate to high intensities and diet education/counseling
48309020|NCT03965988|DRUG|DHA|Docosahexaenoic acid
48309021|NCT03965988|DRUG|Placebo|Placebo
48309022|NCT01452958|BIOLOGICAL|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
48309023|NCT01452958|BIOLOGICAL|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
48309024|NCT01295112|DRUG|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
48309025|NCT01295112|DRUG|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
48309026|NCT05836818|OTHER|Question (Q)|Flu vaccine acceptance question: a question asked of participants about their willingness to accept a flu vaccine
48309027|NCT05836818|OTHER|Messaging (M)|Flu vaccine educational materials -videos and flyers containing flu vaccine educational information
48309028|NCT04023513|OTHER|High protein intake|6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
48309029|NCT04023513|OTHER|Control, no intervention|No Intervention, control
48309030|NCT04023513|OTHER|Low protein intake|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
48309031|NCT04023513|OTHER|Strength training|6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
48309032|NCT02196142|DRUG|Cortisol 20mg|Drug: Cortisol 20mg
48309033|NCT02196142|DRUG|Placebo Mannitol|Drug: Placebo Mannitol
48309034|NCT00377624|DRUG|sodium hyaluronate|
48309035|NCT04182620|DEVICE|renal denervation|Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy
48309036|NCT04182620|DEVICE|Catheter ablation|Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation
48309037|NCT05164861|DIETARY_SUPPLEMENT|kombucha-based beverage|"kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%\*), vitamin B1 - 0.4 mg (29%\*), B2 - 0.21 mg (13%\*), B6 - 0.48 mg (24%\*), niacin - 2.74 mg (15%\*), folic acid - 24.0 mcg (12%\*). Energy value/Caloric content - 54 kilojoules/13 kcal (\* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries \& juniper berries, or strawberries \& lime leaves, or passion fruit \& mango.~Portion's volume - 220 ml. Daily intake: 1 portion"
48309038|NCT05158205|BEHAVIORAL|Yoga|12-week yoga intervention in which 60-minute classes are completed at Texas State University 3 times per week
48309039|NCT05158205|BEHAVIORAL|Slow, deep breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
48309040|NCT05158205|BEHAVIORAL|Control breathing|12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
48309041|NCT02580916|OTHER|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
48309042|NCT00638326|DRUG|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
48309043|NCT00638326|DRUG|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
48309044|NCT00435032|PROCEDURE|early appendectomy|Appendectomy within 24 hours of admission
48112961|NCT06676332|OTHER|motor imagery training|"Children in the study group will receive multisensory motor imagery training program 45 minutes. The training protocol consists of several parts that will be run through every training session according to Kumar et al. (2016):~* Watching videos of selected multisensory motor skills for 10 minutes.~* Mental rehearsal of these motor skills 10 minutes.~* Overt practice of the multisensory motor skills for 25 minutes. On the videos, the performance of the skill by a child aged 8-12 years will be shown. All the exercises will be looped to repeat for six to seven times. While projecting the video on the laptop screen, it will be ensured that the children are in a comfortable seating position and the screen is in their visual field. Repetition of the exercises was based on their ability which could be a minimum of five repetitions per session to a maximum of ten repetitions per exercise session."
48309045|NCT00435032|PROCEDURE|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
47961285|NCT06547450|BEHAVIORAL|8-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session
47961286|NCT04184713|DIETARY_SUPPLEMENT|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
48309046|NCT04261387|DRUG|LUT014 Gel|Topical application qd for 28 days
48309047|NCT04261387|DRUG|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
48309048|NCT03463694|OTHER|Na Cl solution|\~2.6% NaCl solution prepared from sea salt
47961287|NCT04184713|DIETARY_SUPPLEMENT|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
48309049|NCT04956822|OTHER|Basic information|Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
48309050|NCT04956822|OTHER|Functional scores|depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores
48309051|NCT04956822|DEVICE|MINUX|MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.
47961288|NCT04979468|DRUG|DOVATO|Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
47961289|NCT04516174|PROCEDURE|Transversus abdominis plane block using ropivacaine|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using 0.25% ropivacaine was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
48112962|NCT06676332|OTHER|traditional physical therapy|traditional physical therapy training program
48309052|NCT02205827|OTHER|Single-arm|collection of blood for assessment of whole blood clotting time
48483038|NCT00573170|DRUG|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
47961290|NCT04516174|DRUG|Dexmedetomidine|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of dexmedetomidine.
47961291|NCT04516174|PROCEDURE|Transversus abdominis plane block using saline|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using saline was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
48642443|NCT04906187|OTHER|Arm A : intraoperative ANI monitoring of nociception|For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
47961292|NCT04516174|DRUG|Saline|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of saline, dosage and infusion method of saline are consistent with dexmedetomidine.
48483039|NCT00573170|DRUG|placebo|placebo
48112965|NCT02763033|DRUG|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
48112966|NCT02763033|OTHER|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
48112967|NCT05657496|DRUG|Triamcinolone Acetonide 40 mg/ml Inj, Susp|Prepared in clinic by physician or medical staff
48112968|NCT05657496|BIOLOGICAL|Platelet-rich plasma Inj|Produced from participant's whole blood venous draw of approximately 15 mL. Prepared by centrifuge in clinical office
48112969|NCT05181254|BEHAVIORAL|health dialogue|The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.
48112970|NCT04202393|BEHAVIORAL|Integrated Treatment Adherence Program (ITAP)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
48112971|NCT04202393|BEHAVIORAL|Safety Assessment and Follow-up Evaluation (SAFE)|Enhanced assessment and evaluation with clinician feedback.
48112972|NCT05991908|DRUG|Fludarabine, busulfan and melphalan|FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2
48112973|NCT05991908|DRUG|Fludarabine and Busulfan|FLudarabine 150mg/m2 + Busulfan 12.8mg.kg
48112974|NCT02078804|PROCEDURE|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
48112975|NCT05567822|DRUG|Esmolol Hydrochloride|In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
48112976|NCT05567822|DRUG|normal saline|In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively
48642444|NCT04906187|OTHER|Arm B : no specific monitoring of nociception|For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.
48112977|NCT00634452|BIOLOGICAL|MDX-1401|IV weekly for 4 weeks
48112978|NCT04661150|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.
48112979|NCT04661150|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
48112980|NCT04661150|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
48112981|NCT04661150|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
48483040|NCT02075606|DRUG|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
48483041|NCT05618535|DEVICE|Transcranial Doppler.|"Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler."
48483042|NCT04913207|PROCEDURE|method of device size selection|device size selection based on 3D-CTA
48483043|NCT00207194|BEHAVIORAL|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
48642445|NCT06354777|PROCEDURE|Ablation Procedure|Left atrial radiofrequency ablation for the treatment of atrial fibrillation. This may include pulmonary vein isolation with or without additional ablation lesions as warranted during the procedure.
48642446|NCT06513416|PROCEDURE|Elective upper abdominal surgery|The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.
48642447|NCT05213429|OTHER|non interventional study|non interventional
48642448|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 2-dose regimen|Investigators will randomly assign patients into a 2-dose regimen.
48642449|NCT04588077|BIOLOGICAL|Heplisav-B Injectable Product, 3-dose regimen|Investigators will randomly assign patients into a 3-dose regimen.
48642450|NCT06694077|DRUG|Bupivacaine with Dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
47961293|NCT04567498|OTHER|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
47961294|NCT01337700|DRUG|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
47961295|NCT01337700|DRUG|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
47961296|NCT01364649|DRUG|Vortioxetine|Vortioxetine tablets
47961297|NCT01364649|DRUG|Escitalopram|Escitalopram tablets
47961298|NCT01364649|DRUG|Placebo|Vortioxetine Placebo-matching capsules
47961299|NCT05282329|DEVICE|Transcranial alternating Current Stimulation (tACS)-active|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with gamma frequency, delivered over the temporal lobe.
47961300|NCT05282329|DEVICE|Transcranial Alternating Current Stimulation (tACS)-sham|Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.
47961301|NCT00034541|BIOLOGICAL|cetuximab|400 mg/m2 i.v. over 120 minutes
47961302|NCT00034541|DRUG|paclitaxel|225 mg/m2, infusion
47961303|NCT00034541|DRUG|carboplatin|30-minute AUC = 6, infusion.
47961304|NCT00144196|DRUG|tiotropium (Spiriva)|
47961305|NCT05219175|DRUG|MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)"
47961306|NCT01878279|OTHER|Underlying medical illness|
47961307|NCT01258582|PROCEDURE|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
47961308|NCT01258582|PROCEDURE|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
47961309|NCT00002914|DRUG|piritrexim|
48112982|NCT01366664|DRUG|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
48112983|NCT01366664|DRUG|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days)
48112984|NCT06072105|OTHER|Telemedicine visits|Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
48112985|NCT06072105|OTHER|Multidisciplinary, personalized symptomatic treatment|Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
48112986|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
48112987|NCT05232669|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
48112988|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
48112989|NCT05232669|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
48112990|NCT00288392|DRUG|Soluble beta-1,3/1,6-glucan|
48112991|NCT03365622|DRUG|acetaminophen|Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
48309053|NCT00190203|PROCEDURE|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
48309054|NCT00190203|PROCEDURE|hemicraniectomy|hemicraniectomy
48642451|NCT06694077|DRUG|Bupivacaine only|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline
47961310|NCT03478657|DRUG|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
47961311|NCT03478657|DEVICE|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
47961312|NCT03478657|OTHER|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
47961313|NCT03857958|PROCEDURE|endoscopic retrograde cholangio-pancreatography|In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
47961314|NCT06557564|GENETIC|TruGraf liver gene expression|Blood from the patients undergoing graft liver biopsy will be collected on the day of the liver biopsy, preferable prior to tissue collection or within 48 hours following the biopsy. Two specialized PaxGene tubes containing 2.5mL of blood each will be filled and will be sent to TGI laboratory in USA for processing, storage, and analysis using TGI's proprietary bioinformatics TruGraf will provide UHN with a Liver binary result: ACR or non-ACR. The results data will be batched and sent to UHN at agreed upon timepoints.
47961315|NCT04275531|DRUG|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
47961316|NCT06004336|DRUG|Pembrolizumab|Given by vein (IV)
47961317|NCT06004336|RADIATION|Radiation therapy|Given by vein (IV)
47961318|NCT02184481|BEHAVIORAL|Working memory training|
47961319|NCT02184481|BEHAVIORAL|Placebo training|
48309055|NCT00138151|BIOLOGICAL|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
48309056|NCT00138151|DRUG|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
48309057|NCT00138151|DRUG|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
48309058|NCT03777579|DRUG|JS001，an engineered anti-PD-1 antibody|JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
48309059|NCT03777579|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
48309060|NCT03777579|DRUG|Placebo|Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
48309061|NCT02848690|BEHAVIORAL|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
48309062|NCT02848690|OTHER|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI\> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
48309063|NCT03055104|OTHER|management of severe malnutrition|multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
48309064|NCT01667575|DRUG|Esomeprazole|antisecretary drug of the quadruple therapy
48309065|NCT01667575|DRUG|Amoxicillin|antibiotic of the quadruple therapy
48309066|NCT01667575|DRUG|Clarithromycin|antibiotic of the quadruple therapy
48309067|NCT01667575|DRUG|Bismuth Potassium Citrate|one of a component of a quadruple therapy
48309068|NCT01667575|OTHER|long duration (14 day)|
48309069|NCT03516019|OTHER|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
47961320|NCT05856071|DEVICE|goniometer|to measure the range of motion
48309070|NCT03516019|OTHER|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
48309071|NCT03516019|OTHER|am notices|notifications sent at 7 am.
48309072|NCT03516019|OTHER|pm notices|notifications sent at 7 pm.
48309073|NCT03516019|OTHER|weekday notices|notifications sent on Wednesday
48309074|NCT03516019|OTHER|weekend notices|notifications sent on Saturday
47961321|NCT05856071|OTHER|clamshells exercises|clamshells exercises
47961322|NCT05856071|OTHER|traditional physical therapy|traditional physical therapy
48112992|NCT03365622|DRUG|Acetaminophen|500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
48309075|NCT02231658|DRUG|Liraglutide|
48309076|NCT02231658|DRUG|Lixisenatide|
48309077|NCT01497314|OTHER|Low Lactose Infant Formula|Low Lactose Infant Formula
48309078|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
48309079|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
48309080|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
48642452|NCT06695793|PROCEDURE|Interrupted Sutures|The first layer of uterine incision will be closed using individual, separate sutures placed at regular intervals along the incision line. Each suture will be tied independently, ensuring adequate apposition of uterine tissue, followed by a second layer of running continuous sutures.
48309081|NCT04921345|DRUG|Nemolizumab|Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
48642453|NCT06695793|PROCEDURE|Locked Sutures|The first layer of uterine incision will be closed using continuous sutures placed along the uterine incision, incorporating a locking technique at specified intervals to prevent unraveling. The knots will be securely tied to maintain tissue approximation, followed by a second layer of running continuous sutures.
47961323|NCT02592252|BEHAVIORAL|Participatory gender training|10 sessions of participatory gender training
47961324|NCT02592252|OTHER|Microfinance|Microfinance loan
47961325|NCT00191139|DRUG|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
47961326|NCT00191139|DRUG|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
47961327|NCT00191139|DRUG|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
48112993|NCT03365622|DRUG|Placebos|Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
47961328|NCT00191139|DRUG|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
47961329|NCT00191139|RADIATION|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
47961330|NCT01358045|DRUG|Diclofenac|Application on the lesion 2 times a day 8 weeks.
47961331|NCT01358045|DRUG|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
47961332|NCT01358045|DRUG|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
47961333|NCT04850001|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
47961334|NCT01720056|DRUG|Verapamil|
48112994|NCT03365622|DRUG|Placebo Oral Tablet|Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
48112995|NCT06676410|OTHER|ICF|Application of Informed Consent Form.
48112996|NCT06676410|BEHAVIORAL|Eligibility Assessment|Assessment of inclusion, exclusion and discontinuation criteria.
48112997|NCT06676410|OTHER|Demographic data|Collection of demographic data.
48112998|NCT06676410|DIAGNOSTIC_TEST|Weight, height and BMI|Weight and height measurement and body mass index calculation.
48112999|NCT06676410|OTHER|Vital Signs|HR, BP and FR and T°, in addition to oximetry.
48113000|NCT06676410|DIAGNOSTIC_TEST|Medical evaluation|Medical history and physical examination at screening. In other consultations, the medical evaluation is focused on viral load, CD4+ and new complaints.
48113001|NCT06676410|DIAGNOSTIC_TEST|Safety exam|Blood collection for safety laboratory exams. Blood count, Na, K, U, C, amylase, total cholesterol and fractions, triglycerides, coagulation tests (TTTP, TT, platelets), TGO, TGP, AP, GGT, glycated hemoglobin, total bilirubin and fractions, creatine kinase and CKmB and urine I.
48309082|NCT04921345|DRUG|Nemolizumab|Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
48642454|NCT06695793|BIOLOGICAL|Running Continuous Sutures|Double layer closure of uterine incision using running continuous suture used to close the uterine incision without interruption, providing seamless tissue approximation throughout the incision length.
48642455|NCT06232252|DRUG|BI 765423|BI 765423
48642456|NCT06232252|DRUG|Placebo matching BI 765423|Placebo matching BI 765423
48642457|NCT06019832|PROCEDURE|Total Knee Arthroplasty (TKA)|Both study arms will undergo TKA
48642458|NCT06019832|DEVICE|Stemmed Tibial Implant|A stemmed tibial implant
48642459|NCT06019832|DEVICE|Non-stemmed tibial implant|non-stemmed tibial implants
47961335|NCT01720056|DRUG|Kenalog 10|
47961336|NCT04984330|DRUG|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
48642460|NCT03540485|DRUG|Melatonin|Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
48642461|NCT03540485|OTHER|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
47961337|NCT04984330|DRUG|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
47961338|NCT00990405|DRUG|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
47961339|NCT02403986|DEVICE|Restylane Vital Skinboosters Lidocaine|
47961340|NCT06202430|PROCEDURE|High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
48113002|NCT06676410|DIAGNOSTIC_TEST|Pregnancy test|β-HCG in urine in non-sterile women
48113003|NCT06676410|DIAGNOSTIC_TEST|Serology|HBV (HBsAg, Anti-HBc) and HCV (anti-HCV-Ab).
48113004|NCT06676410|OTHER|Randomization|Assignment to the Standard Antiretroviral Treatment + Codivir® group or the Standard Antiretroviral Treatment only group
48113005|NCT06676410|DIAGNOSTIC_TEST|Apoptosis markers|Caspases and Annexin V.
48113006|NCT06676410|DIAGNOSTIC_TEST|Cell activation markers|PBMCs will be isolated by density gradient centrifugation. The cells will then be tested for CD4+, CD8+, CD38 and HLA DR
48113007|NCT06676410|DIAGNOSTIC_TEST|Inflammation markers|ultrasensitive CRP, D-dimer.
48113008|NCT06676410|DIAGNOSTIC_TEST|Proviral DNA:|Total HIV DNA will be measured to estimate the size of the viral reservoir throughout the preparation.
48113009|NCT06676410|DIAGNOSTIC_TEST|HIV-specific antibodies|Anti-HIV-1 specific antibody titers in plasma.
48113010|NCT06676410|DIAGNOSTIC_TEST|HIV viral load (RNA)|Performed on plasma.
48113011|NCT06676410|BEHAVIORAL|Codivir® Training|The participant is trained to self-inject Codivir®
48113012|NCT06676410|DRUG|Dispensing Codivir®|the participant receives Codivir®
48113013|NCT06676410|OTHER|Codivir® Accounting|The Codivir® used since the last visit is accounted for
48113014|NCT06676410|OTHER|Concomitant medication|Record of concomitant medications used.
48113015|NCT06676410|OTHER|Adverse events|Collection and recording of adverse events.
48309083|NCT04967508|DRUG|Stelara® (Ustekinumab)|Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
48309084|NCT04967508|DRUG|SB17 (Proposed Ustekinumab Biosimilar)|"Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.~Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection."
48309085|NCT02998554|DRUG|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
47961341|NCT06202430|PROCEDURE|Shoulder Block|"Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus."
47961342|NCT01064310|DRUG|pazopanib|oral anti-angiogenic treatment
47961343|NCT01064310|DRUG|sunitinib|oral anti-angiogenic treatment
47961344|NCT04337801|OTHER|Acupressure|The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
47961345|NCT04337801|OTHER|Placebo|The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
47961346|NCT03453008|OTHER|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
47961347|NCT00622401|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
47961348|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 30ng/kg
47961349|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 100ng/kg
48113016|NCT06676410|DRUG|Antiretrovirals|"Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day"
48113017|NCT05216120|DRUG|Pemigatinib 4.5 MG|"Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles~Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food."
48113018|NCT00444769|DRUG|GW842166|
48113019|NCT00658996|DEVICE|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
48113020|NCT00658996|DEVICE|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
48113021|NCT03253848|OTHER|Best Practice|Discussion between doctors and APL expert
48113022|NCT03253848|OTHER|Laboratory Biomarker Analysis|Correlative studies
48113023|NCT03253848|PROCEDURE|Supportive Care|Receive simplified guidelines and support
48113024|NCT06312618|DRUG|Propofol|"After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive propofol~1mg/kg over 10 minutes (group 1) ."
48113025|NCT06312618|DRUG|Dexmedetomidine|After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive dexmedetomidine 0.2 mcg/kg over 10 minutes (group 2).
48113026|NCT02896699|BEHAVIORAL|PrEP Intervention Group|
48113027|NCT02896699|OTHER|Control Group|
48113028|NCT02957981|BEHAVIORAL|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
48113029|NCT02957981|BEHAVIORAL|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
48113030|NCT01826695|OTHER|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
48113031|NCT01826695|OTHER|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
48113032|NCT00626418|DRUG|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
48309086|NCT02998554|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
47961350|NCT00053937|DRUG|pirfenidone|
48113033|NCT00626418|DRUG|Placebo|Placebo tablets
48113034|NCT01964469|BEHAVIORAL|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
48113035|NCT05434611|DIAGNOSTIC_TEST|S100A12|The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
48113036|NCT05741996|BEHAVIORAL|Taping|Taping types and brace acute effects for knee osteoartritis
48309087|NCT00894413|DRUG|Tadalafil|20 mg once daily for 10 - 14 days
48309088|NCT00894413|OTHER|Placebo Pill|Placebo
48309089|NCT00528346|BEHAVIORAL|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
47961351|NCT01964833|PROCEDURE|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT."
47961352|NCT01964833|PROCEDURE|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
47961353|NCT02530359|DRUG|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
47961354|NCT02530359|DRUG|Placebo equivalent|Placebo equivalent per mouth
47961355|NCT02486497|BIOLOGICAL|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
47961356|NCT06192277|OTHER|Screening|Patients are screened to confirm they are low risk for a penicillin allergy
48309090|NCT00528346|BEHAVIORAL|placebo|Some participants will see simulated data that does not come from their own brains.
48309091|NCT05528497|OTHER|VR+|Use of a virtual reality helmet during ovocyte retrieval
48309092|NCT05874401|DRUG|Trilaciclib|Participants will receive intravenous trilaciclib infusion
48309093|NCT05874401|DRUG|Placebo|Participants will receive intravenous placebo infusion
48309094|NCT05874401|DRUG|Topotecan|Participants will receive intravenous topotecan infusion
48309095|NCT00308425|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
48309096|NCT04911270|DEVICE|Computer Decision Support Tool Intervention Group|Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC
48309097|NCT04911270|OTHER|Matched Historical Controls|Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
48309098|NCT00559052|DRUG|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
48642462|NCT06471751|OTHER|Inspiratory and Oropharyngeal Muscle Strengthening|"Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises.~The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device."
48113037|NCT03932188|BEHAVIORAL|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
48113038|NCT03932188|DEVICE|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
48113039|NCT03663842|OTHER|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
48309099|NCT01515982|BEHAVIORAL|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
48309100|NCT01515982|BEHAVIORAL|Control Group|All participants were asked not to commence any new exercise regimen.
48309101|NCT01860053|BEHAVIORAL|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
48309102|NCT02391506|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
48309103|NCT03398018|DRUG|repository corticotropin injection|80 units twice per week as a subcutaneous injection
48309104|NCT03555903|OTHER|Endometriosis cohort|"The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison."
48309105|NCT05616767|OTHER|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
48309106|NCT03584854|DRUG|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
48309107|NCT03584854|DRUG|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
48309108|NCT02566525|DEVICE|CytoSorb|Cytosorb device use during cardiopulmonary bypass
48309109|NCT03114982|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
48642463|NCT05544929|DRUG|KFA115|Immunomodulatory agent
48642464|NCT05544929|DRUG|pembrolizumab|Anti-PD-1 antibody
48309110|NCT03114982|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
48309111|NCT04671914|DRUG|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
48309112|NCT04671914|OTHER|Dilation and curretage|After abortion in II trimester we do D\&C.
48309113|NCT03716232|DEVICE|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
48309114|NCT03716232|DEVICE|Multiple plastic stents|"Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
47961357|NCT06192277|DRUG|Low dose Penicillin|Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
48309115|NCT00850460|DRUG|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
47961358|NCT06192277|DRUG|Standard dose Penicillin|Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
47961359|NCT06192277|OTHER|Remove allergy label|Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
47961360|NCT03110094|OTHER|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
48309116|NCT00850460|DRUG|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
48309117|NCT00942773|DRUG|Voriconazole|
48309118|NCT00112099|PROCEDURE|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
48113040|NCT02329132|DRUG|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
48309119|NCT00112099|PROCEDURE|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
48642465|NCT05621044|BEHAVIORAL|FitBrothers smartphone active app|The FitBrothers smartphone active app is designed to assist African American men with adopting and maintaining PA. The app will be developed with significant input from African American men and contain self-monitoring, goal setting, reward, and educational components. The app will include additional elements including PA adoption strategies, competitions, incentives, health information, and greater compatibility with activity monitoring devices. The intervention is based on the Social Cognitive and Self-Determination theories and is culturally tailored.
47961361|NCT03110094|OTHER|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
47961362|NCT05892120|BEHAVIORAL|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
48309120|NCT01225640|DRUG|PNU-100480|600 mg twice daily (BID) for 14 days
47961363|NCT00261144|DRUG|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
47961364|NCT00261144|BIOLOGICAL|Biological|Collagenase injection
48309121|NCT01225640|DRUG|PNU-100480|1200 mg once daily (QD) for 14 days
48309122|NCT01225640|DRUG|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
48483044|NCT00207194|BEHAVIORAL|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
47961365|NCT02981264|DRUG|Transcricoid Injection|
47961366|NCT02981264|DRUG|Spray as you go|
47961367|NCT06371443|BEHAVIORAL|Sucking and swallowing exercises|Sucking-swallowing exercises were applied to premature infants in the experimental group (n=41) for 14 days, once a day, 12 minutes before feeding.
47961368|NCT05707975|OTHER|Identifying a relationship between the intensity of eco-anxiety and the severity of suicide risk in adolescents|Relationship between the intensity of eco-anxiety with the 13-item CAS score, and the seriousness of the suicide risk with the C-SSRS score
47961369|NCT04329403|DRUG|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
47961370|NCT04329403|DRUG|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
47961371|NCT04329403|OTHER|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
47961372|NCT06171295|DIAGNOSTIC_TEST|Blood draw|The blood draws in specified time points
48113041|NCT05943171|DEVICE|Cognitive Behavioral Therapy|All participants will receive Cognitive Behavioral Therapy. They will be randomized to either Digital RITch®CBT or Standard CBT
48309123|NCT01524172|BEHAVIORAL|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
48309124|NCT01524172|BEHAVIORAL|Standard Mental Health Treatment|Trauma and evidence informed therapy
48309125|NCT02253706|DEVICE|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
48309126|NCT02253706|DEVICE|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
48309127|NCT04322630|OTHER|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
48309128|NCT03546387|OTHER|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability
48309129|NCT03546387|OTHER|California Verbal Learning Test, Children's Version|Used to assess verbal learning and memory in children and adolescents
48309130|NCT03546387|OTHER|Beery Developmental Test of Visual Motor Integration, 6th edition|Helps assess visual-motor skills in children and adults.
48309131|NCT03546387|OTHER|Grooved Pegboard Test|Measures dexterity
48309132|NCT03546387|OTHER|Behavior Assessment System for Children/Parent Report|The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.
48309133|NCT04146272|DEVICE|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
48309134|NCT04146272|DEVICE|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
48309135|NCT04146272|DEVICE|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
48309136|NCT04146272|DEVICE|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
48309137|NCT05828238|DRUG|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
48309138|NCT05828238|DRUG|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
48642466|NCT05621044|BEHAVIORAL|Nike Training Club|The app is designed to increase fitness in users through a variety of mechanisms. Users are able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior.
47961373|NCT04336306|OTHER|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
48309139|NCT00952289|DRUG|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
48309140|NCT00952289|DRUG|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
48309141|NCT01529476|DRUG|Levofloxacin|levofloxacin 500 mg,QD,7\~10 days
48642467|NCT04002063|BEHAVIORAL|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
48309142|NCT01529476|DRUG|Nemonoxacin|Nemonoxacin 500mg,QD,7\~10 days
48309143|NCT05205434|OTHER|Synchronous telerehabilitation programme|Exercise program and educational program
48309144|NCT05205434|OTHER|Asynchronous telerehabilitation programme|Exercise program educational program
48309145|NCT04688346|DRUG|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
48309146|NCT03879148|OTHER|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
48309147|NCT03744780|BEHAVIORAL|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
48309148|NCT06187844|PROCEDURE|Inguinal exploration|Inguinal exploration will be done for all the included patients.
48309149|NCT06187844|PROCEDURE|Laparoscopy|All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
48309150|NCT01062451|DRUG|Perindopril|8 mg taken orally from days 0 through 7.
48642468|NCT04002063|BEHAVIORAL|CBT alone|CBT therapy individual
48309151|NCT01062451|DRUG|Placebo|Placebo treatment daily.
48309152|NCT01062451|DRUG|Candesartan|16 mg taken orally from days 0 through 7.
48309153|NCT02631135|DRUG|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
48309154|NCT02631135|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation
48309155|NCT02631135|DRUG|Dexmedetomidine|0.5 microgram/kg infusion, no changes
48309156|NCT02631135|DRUG|Rocuronium|0.5 mg/kg iv for intubation, no changes
48309157|NCT02256865|DRUG|Ketoconazole|Ketoconazole is taken 4 times a day
48309158|NCT02256865|DRUG|Hydrocortisone|Hydrocortisone is taken 3 times a day
47961374|NCT00003805|DRUG|piperacillin sodium|
47961375|NCT00003805|DRUG|piperacillin-tazobactam|
48309159|NCT02256865|DRUG|Testosterone|Testosterone gel is applied once a day
48309160|NCT02256865|DRUG|Placebo for ketoconazole|Placebo for ketoconazole
48309161|NCT02256865|DRUG|Placebo for hydrocortisone|Placebo for hydrocortisone
48309162|NCT02256865|DRUG|Placebo for testosterone|Placebo for testosterone
48309163|NCT03828006|DIETARY_SUPPLEMENT|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
48309164|NCT03828006|OTHER|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
48309165|NCT03566524|DIETARY_SUPPLEMENT|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
47961376|NCT00003805|DRUG|tazobactam sodium|
47961377|NCT00003805|DRUG|vancomycin|
48309166|NCT03566524|DIETARY_SUPPLEMENT|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
48309167|NCT01463072|OTHER|Laboratory Biomarker Analysis|Correlative studies
48309168|NCT01463072|DRUG|Nab-paclitaxel|Given IV
48309169|NCT01463072|OTHER|Questionnaire Administration|Ancillary studies
48309170|NCT02110810|DRUG|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
48309171|NCT02110810|DRUG|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
48309172|NCT05429723|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
48309173|NCT05429723|DRUG|HS-10383 Placebo|Placebo for HS-10383
47961378|NCT02655796|DEVICE|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
47961379|NCT03452423|PROCEDURE|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
47961380|NCT03236025|COMBINATION_PRODUCT|Video+brief smoking cessation+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.
47961381|NCT03236025|COMBINATION_PRODUCT|Text-message+brief smoking cessation+pamphlet|The text -message contains the same content with the videos
47961382|NCT03236025|OTHER|brief smoking cessation+pamphlet|"The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking."
47961383|NCT04253223|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for three weekly doses
48309174|NCT02648035|BIOLOGICAL|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
48309175|NCT03591679|DRUG|Oxytocin|20 units by slow intravenous drip injection
48309176|NCT03591679|PROCEDURE|bilateral uterine artery ligation|• The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
48309177|NCT04739657|DEVICE|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
48309178|NCT04739657|DEVICE|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
48309179|NCT00818324|DRUG|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
47961384|NCT04495270|DIAGNOSTIC_TEST|"Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale"|Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
48309180|NCT03738566|DEVICE|Esophageal self-dilation therapy|Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
48309181|NCT03738566|PROCEDURE|Endoscopic therapy with esophageal dilation|A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
48309182|NCT02349334|DEVICE|Percutaneous Tibial Nerve Stimulation|
48309183|NCT02781467|BIOLOGICAL|PNK-007|
48309184|NCT02781467|DRUG|Cyclophosphamide|
48309185|NCT02781467|DRUG|Fludarabine|
48309186|NCT02781467|DRUG|Human recombinant Interleukin-2 (rhIL-2)|
48483045|NCT00053235|GENETIC|Comparative Genomic Hybridization|Correlative studies
48309187|NCT01375504|BEHAVIORAL|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
48309188|NCT01375504|BEHAVIORAL|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
48642469|NCT05758545|DEVICE|COMS One device|The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The COMS One is a lightweight, portable device. The device is locally applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific feature that has been modified for the purpose of blinding is sensor detecting whether the device is lying on the skin.
48642470|NCT05758545|DEVICE|Sham device|The Sham device is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
48642471|NCT03640624|COMBINATION_PRODUCT|Multidisciplinary treatment|"1. Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~2. Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~3. Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
48642472|NCT03640624|COMBINATION_PRODUCT|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
48642473|NCT04673032|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation for treatment of chronic pain
48642474|NCT01122368|DRUG|micafungin|IV
48642475|NCT01122368|DRUG|placebo|IV
48642476|NCT05263206|DRUG|Dupilumab|Injection solution subcutaneous
48642477|NCT05263206|DRUG|Placebo|Injection solution SC
48642478|NCT05263206|DRUG|Fexofenadine (loratadine if not available)|Tablet or capsule Oral
48642479|NCT05263206|DRUG|Moisturizer|Topical
48642480|NCT06005610|DRUG|Estradiol|Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
48642481|NCT03238196|DRUG|Erdafitinib|4mg - 8mg
48642482|NCT03238196|DRUG|Palbociclib|125 mg
48642483|NCT03238196|DRUG|Fulvestrant|500 mg
47961385|NCT04372901|PROCEDURE|Digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
47961386|NCT04372901|PROCEDURE|Digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
48642484|NCT06004674|DRUG|Lovenox 40mg|Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
48642485|NCT06210009|OTHER|DASH-Style Diet|Participants will be randomized to a DASH-style diet
48642486|NCT06210009|OTHER|Western-Style Diet|Participants will be randomized to a Western-style diet
48642487|NCT05942040|OTHER|Tailored Palliative Care Information|This study test feasibility and acceptability of implementing tailored informational materials into clinician's discussions about CBPC with MA plan members who are eligible for the service.
48642488|NCT05714384|DEVICE|CeraSeal (Calcium Silicate-based Root Canal Sealer)|A calcium silicate-based root canal sealer will be used in cases requiring root canal retreatment.
48642489|NCT04115241|DEVICE|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
48642490|NCT04115241|OTHER|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
48642491|NCT06151574|DRUG|zongertinib|zongertinib
47961387|NCT02453178|BEHAVIORAL|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
47961388|NCT00289133|DEVICE|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
48113042|NCT03221023|DRUG|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
48113043|NCT03221023|DRUG|Saline Solution|Individuals in the control arm will receive intrawound saline solution
48642492|NCT06151574|DRUG|pembrolizumab|pembrolizumab
48642493|NCT06151574|DRUG|cisplatin|platinum-pemetrexed chemotherapy
48642494|NCT06151574|DRUG|carboplatin|platinum-pemetrexed chemotherapy
48642495|NCT06151574|DRUG|pemetrexed|platinum-pemetrexed chemotherapy
48642496|NCT06324370|DIETARY_SUPPLEMENT|Virgin Coconut Oil|"Virgin Coconut Oil (VCO) will be administered with 240 mL water and standardized food during dosing periods.While the participant is standing up, each dose will be administered orally with at least 240 mL of water and standardized meal after an overnight fast of at least 10 hours on each occasion. The time of dosing will be recorded to the nearest minute in the case report form (CRF).~No other liquid or solid food intake is permitted during this time. Fluid intake will be ad libitum 4 hours post-dose. There will be a washout interval of 7 days between the single- and multiple-dose studies.~Participants will not be permitted to take any prescribed medication or over-the-counter products (including vitamins and herbal supplements) within 14 days prior to dosing or during the course of the study."
48642497|NCT06444542|BEHAVIORAL|Guardant Shield|Blood-based colorectal cancer screening
48642498|NCT03688139|BEHAVIORAL|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
48642499|NCT03688139|BEHAVIORAL|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
48642500|NCT06695871|OTHER|Patient navigation-based health management|A patient navigation-based health management model for individuals with cervical lesions post-LEEP procedure, encompassing healthcare consultation services, personalized health guidance, and routine follow-up assessments.
48642501|NCT06269107|DRUG|IcoSema|IcoSema will be administered subcutaneously.
48642502|NCT06269107|DRUG|Insulin glargine|Insulin glargine will be administered subcutaneously.
48642503|NCT05228015|DRUG|IK-930|tablets for oral administration
48642504|NCT05228015|DRUG|Osimertinib|tablets for oral administration
48642505|NCT04209153|OTHER|Transcranial Direct Current Stimulation|tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
48642506|NCT06222957|OTHER|None (Observational study)|Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
48642507|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for cough|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation. Patients will be assessed for their comfort with undergoing the procedure and clinicians will be surveyed on the ease and benefit of performing the procedure under ultrasound guidance.
48642508|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.
48642509|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphagia|Patients with and without swallowing complaints will be enrolled to assess their tongue, suprahyoid and infrahyoid musculature, including muscle identification, bulk and function.
47961389|NCT00289133|DEVICE|total knee arthroplasty|cross-linked polyethylene tibial insert
47961390|NCT06304428|OTHER|Deprescribing Care Model|The Deprescribing Care Model is designed to deprescribe fall related medications (FRIDs)
48113044|NCT01679951|DRUG|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
48642510|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphonia|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have muscle tension dysphonia will undergo ultrasonography during their visit with laryngology or speech language pathology.
48642511|NCT06514898|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|"After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.~up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment)"
48642512|NCT06514898|BIOLOGICAL|TTRNA-xALT|All participants will receive a single infusion of T-cells.
47961391|NCT06304428|OTHER|Bone Health Service Model|The Bone Health Service Model is designed to provide osteoporosis evaluation and management
48642513|NCT06514898|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #5, #7 and #9.
47961392|NCT06304428|OTHER|Injury Prevention Service Model|The Injury Prevention Service Model provides both the Deprescribing Care Model and the Bone Health Service Model.
47961393|NCT05190237|DIETARY_SUPPLEMENT|TMD21-16 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
47961394|NCT05190237|DIETARY_SUPPLEMENT|TCD21-55 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
47961395|NCT05190237|DIETARY_SUPPLEMENT|TFD21-1 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
48113045|NCT01679951|DRUG|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
48113046|NCT01679951|DRUG|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
47961396|NCT06506682|BEHAVIORAL|Constraint Induced Movement Therapy|CIMT is an intensive upper limb therapy for children with unilateral (one sided) cerebral palsy where the child wears a constraint (splint or mit) on their dominant hand so that they use the involved (weaker) side to do activities
48309189|NCT04870112|DRUG|Durvalumab|Anti-PD-L1 antibody
48309190|NCT04870112|DRUG|Cisplatin|Chemotherapy
48309191|NCT04870112|DRUG|Carboplatin|Chemotherapy
48309192|NCT04870112|DRUG|Etoposide|Chemotherapy
48309193|NCT05387915|RADIATION|Radiation Therapy|Undergo reduced dose radiation therapy
48309194|NCT01984541|BIOLOGICAL|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
47961397|NCT06506682|BEHAVIORAL|CIMT + VR|Participants in the CIMT+VR group of this study protocol will do everything the CIMT group does PLUS will utilize at least 4 of the following VR technologies each day of intervention: FitMi, Tyromotion Pablo® UpperExtremity, Hocoma Armeo® Spring Pediatric, Nintendo Wii, and Parrot Drone.
48309195|NCT02486510|DRUG|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
48309196|NCT06462417|DRUG|Arbidol|Arbidol Hydrochloride Tablets 0.2g/d for 2 weeks
48309197|NCT01477151|DRUG|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
48309198|NCT05784948|OTHER|Virtual Reality Mindfulness Treatment|once a week for 30 minutes, over 8 weeks
48309199|NCT05784948|OTHER|Experience relaxing scenery and music|once a week for 30 minutes, over 8 weeks
48309200|NCT05135130|DRUG|ON101 Cream|Not applicable in this retrospective study
48642514|NCT06514898|BIOLOGICAL|autologous HSCs|All participants will receive a single intravenous infusion of autologous HSCs.
48309201|NCT05158309|OTHER|8% Capsaicin patch|Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.
48309202|NCT05158309|OTHER|placebo patch|A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
48309203|NCT06312267|DEVICE|Bioelectric dressing|Participants randomized into the experimental arm will have a bioelectric dressing applied 3 days before surgery, and 3 days post-surgery.
48309204|NCT04367116|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
48309205|NCT04544709|DRUG|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
48309206|NCT03152136|DEVICE|Cala ONE device|The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
48483046|NCT00053235|OTHER|Laboratory Biomarker Analysis|Correlative studies
48642515|NCT06514898|DRUG|Pembrolizumab|Participants will receive PD-1 blockade IV starting with ACT continuing for up to 2 years as long as tolerable and without disease progression.
48642516|NCT06695611|OTHER|Increase systolic blood pressure|"To increase systolic blood pressure, treating physicians can consider the following options:~1. Withdraw blood pressure medications, reducing dose of medications that are not indicated for other reasons, or down titrate medication.~2. Increase estimated dry weight (EDW) by 0.5 kg increments if the participant is hypovolemic or euvolemic"
47961398|NCT03809676|OTHER|periodontal examination|clinical measurements were recorded
48309207|NCT06296628|DEVICE|Miraπ|"This device has tiny sensors that measure the movement of the healthy fingers and tiny motors that move the affected fingers of the patient.~The device is connected to a specially designed finger mechanism that moves the affected fingers of the patient. This opening mechanism is designed in a way that it prevents the fingers from being forced into any hurting position. If the patient moves the healthy fingers during training, also the fingers of the affected hand are moved by the device at the same time. This creates the effect of mirror therapy for the brain as the patient can see both hands moving."
48309208|NCT06296628|BEHAVIORAL|Mirror Therapy|Current standard of care using MT.
47961399|NCT04682028|OTHER|professional care|The trained nurses provide professional care for the patients.
47961400|NCT04682028|OTHER|coventional care|nurses provide coventional care for the patients.
48309209|NCT04286542|DIAGNOSTIC_TEST|Cold, dry air|Participants will be exposed to cold (\<-10°C, \<10% relative humidity), dry air for 15 minutes.
48309210|NCT01187901|DRUG|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
48483047|NCT00053235|GENETIC|Polymerase Chain Reaction|Correlative studies
48483048|NCT00462891|OTHER|IT System|
48309211|NCT01187901|DRUG|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
48309212|NCT01187901|DRUG|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
48309213|NCT01187901|DRUG|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
48113047|NCT01679951|DRUG|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
47961401|NCT06199817|BEHAVIORAL|occupational therapies|music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
47961402|NCT02294955|DEVICE|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
47961403|NCT02294955|DRUG|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
47961404|NCT02294955|DRUG|Sotalol|Dosage orally 80-160 mg twice daily
48113048|NCT01679951|DRUG|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
48113049|NCT04045886|BEHAVIORAL|Online Educational Modules (Videos)|5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
47961405|NCT02294955|DRUG|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
47961406|NCT02294955|DRUG|Propafenone|Dosage orally 300 mg twice daily
47961407|NCT02294955|DRUG|Disopyramide|Dosage orally 250-375 mg twice Daily
47961408|NCT02294955|DRUG|Dronedarone|Dosage orally 400 mg twice daily
47961409|NCT02021331|DEVICE|immediate implant placement without provisionalization|
47961410|NCT02021331|DEVICE|immediate implant placement with immediate provisionalization|
47961411|NCT06270810|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on the treadmill at 40-60% of the participants' heart rate reserves. Each aerobic exercise session will last for 40 minutes. All participants will be monitored with a heart rate monitor throughout the exercise sessions. During the first three-week, participants will exercise on the treadmill at intensities between 40-50%, and between fourth and eighth weeks, 50-60% of their heart rate reserves. Participants will wear an accelerometer on their non-dominant wrist during the intervention to monitor the physical activity and sedentary behavior data. At the same time, these participants will be asked not to change their routine diet during the intervention period.
47961412|NCT06270810|BEHAVIORAL|Increasing non-Exercise Physical Activity|Participants who will carry out this intervention will increase their non-exercise physical activities. Before intervention period, participants will receive face-to-face training to increase their non-exercise physical activities. This training will generally consist of recommendations based on the study which effectively reduced sedentary behavior (SB) with non-exercise physical activities (Sarah Kozey-Keadle et al. 2012). A one-on-one interview will be held with each participant every week to learn about strategies by which the volunteers successfully increased their non-exercise physical activities in the previous week, and the difficulties or barriers they encountered. New strategies to overcome these difficulties and barriers will be discussed and suggestions will be made. Participants will wear an accelerometer on their non-dominant wrist to monitor the physical activity and SB data, and will be asked not to change their routine diet during the intervention period.
47961413|NCT06405451|OTHER|Conventional treatment|Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, and six times per week.
48309214|NCT02028104|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
48309215|NCT03840668|DEVICE|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 2 months.
48309216|NCT01248234|DRUG|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
47961414|NCT06405451|OTHER|Experimental treatment|"Respiratory muscle training will be conducted using the Threshold IMT-Philips inspiratory training device and the Threshold PEP expiratory training device, both from Respironics®. Participants will be comfortably seated in a chair with their feet on the ground, without back support, and with the trunk at a 90° angle to the hips. A conventional nasal clip will be used to prevent air leaks. During forced expiratory training, participants will use the ThresholdPEP® with a customized mouthpiece and perform forced expiration through the resistance device. Inspiratory muscle training will follow the same procedure using the Threshold IMT® (45).~Both inspiratory and expiratory trainings will be repeated 10-15 times, 5 sets for 20 minutes in one session, with a rest time of 30-60 seconds between each set."
47961415|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 1
47961416|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 2
47961417|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 3
47961418|NCT02092831|DRUG|GDC-0941|Single dose Phase 2 tablet formulation
48113050|NCT05117372|OTHER|treatment with immunotherapy and diffuse infiltrative lung disease|Patients treated with with immunotherapy and developing diffuse infiltrative lung disease
48113051|NCT05117372|OTHER|Patients requiring carcinologic lobectomy|Patients requiring carcinologic lobectomy
48113052|NCT04126109|OTHER|questionaire|A questionaire will be offered to every parents
48309217|NCT01248234|DRUG|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
48309218|NCT01248234|DRUG|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
48309219|NCT05553431|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
48309220|NCT06317272|OTHER|DIBH using ABC technique|Deep breath inspiration hold (DIBH) using Active Breathing Control (ABC) technique
48309221|NCT06317272|OTHER|DIBH using VC technique|Deep breath inspiration hold (DIBH) using Voluntary Coaching (VC) technique
48309222|NCT02380430|OTHER|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
48309223|NCT03860311|DEVICE|Bladder Ultrasound|"Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound."
48309224|NCT03860311|OTHER|Standard of Care|Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
48309225|NCT04661930|DRUG|TriCor® 145mg tablets|Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
48309226|NCT04661930|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
48309227|NCT04661930|OTHER|Usual care|All participants will otherwise receive usual medical care
48309228|NCT00000461|DRUG|pravastatin|
48309229|NCT00000461|DRUG|niacin|
48309230|NCT00000461|DRUG|cholestyramine|
48309231|NCT00000461|DRUG|gemfibrozil|
48309232|NCT00000461|DRUG|fatty acids, omega-3|
48309233|NCT00626912|PROCEDURE|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
48309234|NCT03407196|DRUG|Forxiga|Oral antidiabetics
48309235|NCT05128253|OTHER|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
48309236|NCT00052169|DRUG|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
48309237|NCT02924506|DEVICE|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
48309238|NCT02924506|DEVICE|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
48309239|NCT04987060|DEVICE|Intrastromal Fresh Human Lenticule Implantation|The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
47961419|NCT00919919|DRUG|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
48113053|NCT05168553|OTHER|Revascualrization|Regain pulp vascularity for mature permenant teeth
48309240|NCT05279833|DRUG|dronedarone|Pharmaceutical form is tablet and route of administration is oral
48309241|NCT05279833|DRUG|sotalol|Pharmaceutical form is tablet and route of administration is oral
47961420|NCT00919919|DRUG|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
47961421|NCT03145233|OTHER|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
48113054|NCT05168553|OTHER|Conventional endodontic treatment|Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
48309242|NCT05078333|OTHER|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
48309243|NCT05078333|DEVICE|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
48309244|NCT02227017|DRUG|TPV capsule|
48309245|NCT02227017|DRUG|TPV solution|
48113055|NCT00588809|DRUG|selumetinib|Given PO
48113056|NCT03444649|DRUG|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
48113057|NCT03444649|DRUG|Idarubicin|Standard chemotherapy d1-d3 cycle 1
48113058|NCT03444649|DRUG|Cytarabine|Standard chemotherapy d1-d7 cycle 1 and 2
48113059|NCT03444649|DRUG|Daunorubicin|Standard chemotherapy d1-3 cycle 2
48113060|NCT06113692|BIOLOGICAL|mRNA-1273|intramuscular injection
48309246|NCT02227017|DRUG|RTV capsule|
48309247|NCT02227017|DRUG|RTV solution|
48309248|NCT02227017|OTHER|standard meal|
48309249|NCT04331873|DIAGNOSTIC_TEST|Ultrasound|An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
48309250|NCT01716468|OTHER|Ketogenic Diet|modified ketogenic diet
48309251|NCT01228071|DRUG|testosterone gel 2%|40 mg testosterone gel 2%
48309252|NCT02519244|DEVICE|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
48309253|NCT03126929|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
47961422|NCT03145233|OTHER|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
47961423|NCT00268359|BIOLOGICAL|bevacizumab|
47961424|NCT00268359|DRUG|irinotecan hydrochloride|
47961425|NCT05984095|OTHER|Telerehabilitation|The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
47961426|NCT01696084|DRUG|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
47961427|NCT01696084|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
47961428|NCT03691155|OTHER|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
47961429|NCT03308032|BEHAVIORAL|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
47961430|NCT03308032|BEHAVIORAL|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
47961431|NCT06120296|DEVICE|Acumen Hypotension prediction Index software|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
47961432|NCT06385951|DIAGNOSTIC_TEST|Procedure for patients|We will screen patients who undergo an MRI and neuropsychological examination as part of their diagnostic workup. If inclusion and exclusion criteria are met, patients will be asked to undergo additional investigations (FDG-PET, lumbar puncture, tau and amyloid PET and the ALLO iVR task).
48113061|NCT05591144|DRUG|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose based on weight for 4 days, followed by a taper every 2 days, with the maximum duration to 14 days.
48113062|NCT05591144|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
48113063|NCT03015454|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
48113064|NCT03015454|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
48113065|NCT06297070|BEHAVIORAL|Whole Health Lifestyle Care for Reproductive Well-being pilot program|The program consists of an individual Integrative Health and Medicine (IHM) consultation with a CWH IHM provider, 4 Shared Medical Appointments (SMA), and 4 individual Health and Wellness Coaching (HWC) sessions. The SMA sessions occur at the UH CWH Beachwood office conference and movement rooms. The HWC sessions are virtual. The consultations are either virtual or in person at UH CWH Beachwood.
48113066|NCT04634617|OTHER|Questionnaire Administration|Complete questionnaires
48113067|NCT05452941|DIAGNOSTIC_TEST|Diagnostic test on urine samples|Testing by BinaxNOW® S. pneumoniae and serotype-specific urine antigen detection (UAD) assays (UAD-1 and UAD-2).
48113068|NCT01552980|DRUG|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
48113069|NCT03178110|BEHAVIORAL|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
48113070|NCT02824939|OTHER|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
48113071|NCT02824939|OTHER|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
48113072|NCT02200159|DRUG|Sedation with dexmedetomidine|
48113073|NCT02507336|DRUG|Thalidomide|100-300 mg capsule taken by mouth once daily.
48113074|NCT06673316|OTHER|Design thinking workshop|The workshop will cover the five stages of design thinking, allowing students to apply these principles to real-world healthcare challenges in their future practice.
48113075|NCT02208258|DEVICE|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
48113076|NCT06612762|DIETARY_SUPPLEMENT|The daily ingestion of capsules containing naringenin|Following surgical intervention, patients will be administered two capsules (equivalent to 500 mg) daily for a period of 14 days. Subsequently, patients will ingest the maintenance dose of 250 mg per day until the 90th day post-surgery.
48113077|NCT06612762|DIETARY_SUPPLEMENT|Placebo|The daily ingestion of capsules containing placebo
48309254|NCT04349306|DRUG|RASBURICASE SR29142|Pharmaceutical form:solution for infusion Route of administration: intravenous
48309255|NCT05313932|OTHER|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
48309256|NCT02401750|DRUG|Oxycodone Naltrexone (a)|
48309257|NCT02401750|DRUG|Oxycodone Naltrexone (b)|
48309258|NCT02401750|DRUG|Placebo|Matches both experimental drugs
48309259|NCT02955654|BEHAVIORAL|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
48309260|NCT02955654|DRUG|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
48309261|NCT02955654|BEHAVIORAL|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
48309262|NCT02385825|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
48309263|NCT00292474|DEVICE|percutaneous coronary intervention|
48113078|NCT06147401|PROCEDURE|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
48642517|NCT06695611|OTHER|Decrease systolic blood pressure|"To decrease SBP, treating physicians can consider the following options:~1. Adjust blood pressure medications. This could be accomplished by increasing the dose of current medications, and/or adding an additional medication class. Choice of medication will be dependent on current medications, contraindications, age, comorbidities, and cardiovascular indications. Adherence to blood pressure medications should be reviewed.~2. Reduce EDW by 0.1 - 0.5 kg~3. Reduce sodium levels. This could be accomplished through a reduction in dietary sodium intake to \<2 gm/day and fluid intake to \<1.5 L per day. Adherence to dietary sodium restrictions should be reviewed with the participant~4. Extend dialysis time or adding an additional dialysis session if needed to achieve target dry weight"
47961433|NCT06385951|DIAGNOSTIC_TEST|Procedure for healthy controls|Healthy controls will be asked to undergo a neuropsychological examination, the ALLO iVR task, an MRI, FDG-PET and tau-PET.
47961434|NCT00307645|DRUG|Cyclophosphamide|
47961435|NCT00307645|DRUG|Mycophenolate mofetil|
47961436|NCT00307645|DRUG|Azathioprine|
47961437|NCT00307645|DRUG|Prednisone (and methylprednisolone)|
47961438|NCT01256801|BIOLOGICAL|cytokine|interleukin 2 2 million unit every week
47961439|NCT00067405|DRUG|Intravenous micronutrient therapy|
47961440|NCT01146665|BEHAVIORAL|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
48113079|NCT06147401|PROCEDURE|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
48309264|NCT01985009|DEVICE|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
48309265|NCT05686616|DRUG|Dapagliflozin Propanediol Hydrate 12.3 mg|Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
48309266|NCT00580177|PROCEDURE|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
48309267|NCT00580177|PROCEDURE|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
48309268|NCT00580177|PROCEDURE|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
47961441|NCT01146665|BEHAVIORAL|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
47961442|NCT00696800|DRUG|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
47961443|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
47961444|NCT00696800|DRUG|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
47961445|NCT00696800|DRUG|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
48309269|NCT03252704|OTHER|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
48309270|NCT03252704|OTHER|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
48309271|NCT05323968|DIAGNOSTIC_TEST|Abdominal Ultrasonography|The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
47961446|NCT00696800|BIOLOGICAL|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
47961447|NCT00696800|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
48309272|NCT05323968|DIAGNOSTIC_TEST|Abdominal Computerized Tomography|The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
47961448|NCT00696800|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
48309273|NCT02388516|DIETARY_SUPPLEMENT|Vitamin D3|
47961449|NCT00696800|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
47961450|NCT04482257|DRUG|Irinotecan Liposome Injection combined with 5-FU/LV|Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
47961451|NCT06032468|DEVICE|ARC Intellicare|wearable devices to guide rehabilitation exercise
47961452|NCT06032468|OTHER|Rehabilitation sheets|rehabilitation exercise sheets to guide rehabilitation exercise
47961453|NCT00662246|RADIATION|respiratory gated proton beam radiotherapy|- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
47961454|NCT06004362|BEHAVIORAL|Complementary and Integrative Medicine online intervention, routine care and book|"The online program takes place in a multiprofessionally guided online group setting once a week for up to 180 minutes (including several breaks) over a period of 10 weeks:~* Basic principles of a plant-based whole-food nutrition~* Procedures of hydrotherapy according to Kneipp~* Self-help strategies (e.g. teas, wraps, compresses etc.)~* Methods of mind-body medicine (mindfulness, meditation, breathing, yoga etc.)~* Methods of extended Complementary and Integrative Medicine (e.g. acupressure)~It is recommended to practice a part of the taught exercises at home for about 30 minutes daily. In addition, the patients receive a book for the treatment of post-covid syndrome complaints. Group 1 additionally uses the already existing routine care (e.g. general practitioner)."
47961455|NCT06004362|BEHAVIORAL|Routine care and book|Participants in the second study arm receive routine care, e.g. from their general practitioner. In addition, the patients receive the same book as group 1 for the treatment of post-covid syndrome complaints. The participants of the second study arm will be offered to participate in the Complementary and Integrative Medicine online intervention after 4 months within the study.
47961456|NCT06071208|DRUG|Gliflozin|to study whether the use of gliflozin prevented diabetic complications
47961457|NCT04812899|BEHAVIORAL|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
47961458|NCT00214344|BEHAVIORAL|family preparation for withdrawing life support|
47961459|NCT01390129|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
47961460|NCT01390129|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
47961461|NCT01750983|DRUG|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
47961462|NCT01750983|DRUG|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
48309274|NCT02388516|DIETARY_SUPPLEMENT|Placebo|
48309275|NCT03433287|DIAGNOSTIC_TEST|18F-NaF-PET/MRI|PET/MRI scan after injection of 18F-labelled sodium fluoride
48642518|NCT05149768|DRUG|Brentuximab vedotin|Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)
47961463|NCT05746793|PROCEDURE|endometrium biopsy|"The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle."
47961464|NCT05746793|DIAGNOSTIC_TEST|Transabdominal ultrasound|Evaluation of fetal biometry and doppler flow study using ultrasound.
48642519|NCT04138277|DRUG|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
48642520|NCT04138277|BIOLOGICAL|ATB200|Enzyme Replacement Therapy via intravenous infusion
47961465|NCT05746793|DIAGNOSTIC_TEST|Peripheral phlebotomy|single puncture collection of peripheral venous blood.
48309276|NCT02773069|BEHAVIORAL|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
48309277|NCT06282497|RADIATION|Optimised neck CTV|neck CTV delineation extends from the lateral process of C1
48309278|NCT06282497|RADIATION|standard neck CTV|neck CTV delineation extends from skull base
48309279|NCT02619019|DRUG|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
47961466|NCT05746793|DIAGNOSTIC_TEST|Urine collection|Collection of urine in a plastic cup.
48113080|NCT05599256|DRUG|Ruxolitinib|"Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens."
48113081|NCT05284812|BIOLOGICAL|Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
48113082|NCT05284812|BIOLOGICAL|High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
48113083|NCT05284812|BIOLOGICAL|High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)|Subjects receive high-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02) injection into the deltoid muscle of the upper arm
48113084|NCT05284812|BIOLOGICAL|Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo|Subjects receive Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo injection into the deltoid muscle of the upper arm
48113085|NCT06604871|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
48113086|NCT01257074|DRUG|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
48113087|NCT01257074|DRUG|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
48113088|NCT00281489|DEVICE|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
48113089|NCT00281489|BEHAVIORAL|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
48113090|NCT02508038|PROCEDURE|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
48642521|NCT03143322|RADIATION|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
47961467|NCT05746793|OTHER|MOCK frozen embryo transfer preparative cycle.|Start with daily estradiol (progynova, oestrogel) administration at hormonal baseline (day 2 of the cycle or with confirmation using endocrine evaluation). When adequate thickness (≥6.5 mm) of the endometrium is achieved (usually after 10-14 days), progesterone is administered daily. 6 days after progesterone administration, the pipelle biopsy will be performed. When this test cycle has ended and menstruation starts, patients will be asked to collect their menstrual flow, during the first night of heavy/red flow, in a menstrual cup. The next day patients will be asked to bring their collected menstrual blood to our center and they will undergo a blood analysis needed for the start of their ART treatment.
48113091|NCT02508038|DRUG|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
48113092|NCT00959946|DRUG|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
48113093|NCT00959946|DRUG|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
48113094|NCT04456218|DEVICE|NCKU-scope-01 (a custom-made biliary endoscope system)|The NCKU-scope-01 is a custom-made endoscope system for this study and it will be applied to help biliary disorders diagnosis
48113095|NCT00918957|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
48309280|NCT02619019|DRUG|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
48642522|NCT05750498|OTHER|No interventions|There are no interventions
48642523|NCT06384157|DRUG|INDV-2000|INDV-2000 is a highly potent and selective OX1R antagonist that is being developed as a therapy for the treatment of OUD.
47961468|NCT05746793|DIAGNOSTIC_TEST|Baseline questionnaire|questionnaire the patient has to fill in
47961469|NCT05746793|OTHER|collection of menstrual blood|collection of menstrual blood during the first day of heavy menstrual flow for at least 6 hours
47961470|NCT05746793|DIAGNOSTIC_TEST|nutritional and metabolic work-up|Including body composition analysis by BIA/whole body MRI and analysis of resting energy expenditure (REE).
47961471|NCT05746793|DIAGNOSTIC_TEST|cardiac work-up|Using transthoracic ultrasound.
47961472|NCT05746793|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement
47961473|NCT00250120|DRUG|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
47961474|NCT04446000|BIOLOGICAL|CSL730|solution for injection and infusion
47961475|NCT04446000|DRUG|Placebo|A solution matching the excipient profile of CSL730 without the active substance
47961476|NCT05746195|BEHAVIORAL|Dietary intervention via Text Messaging|Text messages will be sent to participants cell phones using the HealthySMS platform
47961477|NCT05746195|OTHER|Survey Administration|Various questionnaires evaluating participants dietary habits and use of study intervention will be administered
47961478|NCT05746195|BEHAVIORAL|Nutrition Education|Participants will receive nutrition education materials
47961479|NCT00319995|DRUG|loratadine; montelukast|
47961480|NCT01352104|BEHAVIORAL|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
48113096|NCT00918957|DRUG|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
48113097|NCT02705937|OTHER|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
48113098|NCT02705937|DEVICE|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
47961481|NCT02130232|BEHAVIORAL|Lifestyle Intervention|
47961482|NCT02130232|OTHER|Usual Care|
48113099|NCT01592448|BEHAVIORAL|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
48113100|NCT01714193|DRUG|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
48113101|NCT01714193|DRUG|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
48113102|NCT06182423|BEHAVIORAL|STEPS-CI (Support, Training, and Education for Pain Self-management- Cognitively Inclusive version)|This intervention is a community health worker (CHW)-led chronic pain self-management program designed for older adults with chronic pain and mild to moderate cognitive impairment. It is a 7-week intervention that includes two primary components: a website that includes brief instructional videos on pain management skills as well as testimonials from individuals living with the two target health conditions; and weekly telephone sessions with a CHW to support and motivate participants in setting goals related to pain management. Reminder strategies and content addressing pain management challenges related to cognitive impairment are incorporated throughout. Participants may choose to work with a care partner during intervention activities.
48113103|NCT06512545|OTHER|second allogeneic stem cell transplantation|"1. Change another donor if possible~2. Conditioning regimen: fludarabine (30mg/m2/day, days -6 to -2 )/cyclophosphamide (1g/m2/day, days -5 to -4)/rabbit antithymocyte globulin (1.5mg/kg/day, days -4 to -2)~3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng/ml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)"
48309281|NCT02619019|DRUG|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
48113104|NCT06404710|BEHAVIORAL|Exercise|Participants in this group will be given a gradual muscle relaxation exercise.
48642524|NCT06384157|OTHER|Placebo|This is a randomized, double-blind, placebo-controlled study.
48642525|NCT02119611|DEVICE|Deep Brain Stimulation management|The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
47961483|NCT02107170|DRUG|Sevoflurane|sevoflurane-based general anesthesia
47961484|NCT02107170|DRUG|Propofol|total intravenous anesthesia
47961485|NCT02107170|DRUG|Remifentanil|
47961486|NCT01848691|OTHER|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
47961487|NCT00911547|DRUG|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
47961488|NCT00911547|DRUG|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
47961489|NCT00911547|DRUG|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
48309282|NCT02892461|PROCEDURE|Umbilical cord milking|As same as that in arm descriptions.
48309283|NCT03243513|OTHER|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
48642526|NCT05128448|OTHER|Cross-body stretch (CBS)|CBS is a self administered stretch that aims to stretch posterior shoulder structures
47961490|NCT00911547|DRUG|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
47961491|NCT00013962|DRUG|Vitamin D|
47961492|NCT01783431|DRUG|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
47961493|NCT01783431|PROCEDURE|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
47961494|NCT01607242|OTHER|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
47961495|NCT01607242|OTHER|Voice Handicap Index|Subjective Evaluation of Voice disorders
48642527|NCT05128448|OTHER|Mobilisation with movement (MWM)|WMW is a musculoskeletal procedure that aims to improve restricted and/or painful range of movement
48642528|NCT05751941|DRUG|Abiraterone|1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
48642529|NCT05751941|DRUG|Enzalutamide|160 mg of Enzalutamide will be given orally daily ending at week 4
48642530|NCT05751941|DRUG|Apalutamide|240 mg of Apalutamide will be given orally daily ending at week 4
47961496|NCT01607242|OTHER|Swallowing Assesment|Swallowing function questionnaire
48309284|NCT03726671|OTHER|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
48309285|NCT03726671|OTHER|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
48642531|NCT05751941|DRUG|Sipuleucel-T|Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
48642532|NCT05032911|DIAGNOSTIC_TEST|sensorimotor control analysis using inertial sensor technology|Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns
48642533|NCT05816590|OTHER|Med@HOME Mobile App|Meds@HOME is a software application designed for use on a personal mobile device. The app allows primary caregiver to create routines where they can detail how to perform the routine, start date and time, and frequency (daily, weekly, monthly). Optional push notifications can be set so that users are alerted to an upcoming routine. Only primary caregivers can create, edit, and delete routines. All caregivers can check off on routines and receive notifications. Caregivers can also post notes related to routines or events. App enables an inventory of caregiver troubleshooting strategies and inventory reminders.
48642534|NCT01046994|PROCEDURE|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
48642535|NCT01046994|DRUG|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
48642536|NCT06431633|DRUG|Zimberelimab|"Zimberelimab is a fully human IgG4 monoclonal antibody targeting human PD-1. PD-1 is a type I transmembrane protein that is part of the immunoglobulin gene superfamily and the CD28 family of cell surface receptors. PD-1 is an inhibitory immune checkpoint protein that is expressed on activated B cells, T cells, and myeloid cells, and it plays a key role in limiting the activity of effector T cells.~Zimberelimab is formulated at 30 mg/mL in a buffer solution containing histidine/histidine-HCl buffer solution, sucrose, sodium chloride, and polysorbate 80, at pH 5.5. The investigational product is supplied as a vial contains 120 mg of active Zimberelimab at a concentration of 30mg/mL.~No premedication nor profilaxis is needed before Zimberelimab administration. Zimberelimab doses are administered by IV infusion over 60 minutes, followed by a 30- to 60-minute observation period, on D1 of each 21-day cycle."
48642537|NCT06431633|DRUG|Sacituzumab govitecan|"Sacituzumab govitecan (SG) is an ADC composed of the following 3 components:~o The humanized monoclonal antibody hRS7 IgG1κ, which binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers.~o The camptothecin-derived agent SN-38, a topoisomerase I inhibitor. o A hydrolyzable linker, with the company designation as CL2A that links the humanized monoclonal antibody to SN-38.~Sacituzumab govitecan is approved globally for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and HR+ breast cancer."
48642538|NCT06431633|DRUG|Cisplatin|"Cisplatin-based adjuvant chemotherapy~Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation."
48642539|NCT06431633|DRUG|Carboplatin|Cisplatin-based adjuvant chemotherapy Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin. Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center. Other Name: ATC code: L01XA02
48642540|NCT06690853|OTHER|Experimental Coordinative training|The warm-up protocols of the Experimental Group included four types of upper and lower limb coordination exercises using different-sized balls, with intensity increasing week by week.
48642541|NCT06690853|OTHER|Traditional training (control group)|The Control Group warm-up protocol only involved joint mobility exercises and muscle activation, as used in their regular training activities.
48642542|NCT03495635|BEHAVIORAL|Big Brothers Big Sisters Community-Based Mentoring Program|One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
48483049|NCT04514055|PROCEDURE|De-epithelialized connective tissue graft wall|A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
48483050|NCT00270933|DEVICE|Registry|
48642543|NCT06026332|DRUG|ADSTILADRIN|Non-interventional
48642544|NCT05596240|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
48642545|NCT05596240|OTHER|Sham Dry Needling|Streitberger Placebo-needles (Asia-med, Las Vegas, NV) will be used to perform the intervention for participants in the sham DN group. These needles have been reported to be indistinguishable from real needles. The device consists of a plastic tube with a blunted tip needle that allows for the sensation of a prick without penetrating the skin. The sham needle produces a sensation, which causes the participant to feel as if the needle enters the skin, while maintaining similar patient-therapist contact time and total intervention time.
48642546|NCT05220098|DRUG|TAK-280|Participants will receive TAK-280 as IV infusion.
48642547|NCT06083493|DEVICE|LIFUP excitation|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-excitation) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
47961497|NCT03985904|OTHER|ART THERAPY|ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
47961498|NCT02327065|DEVICE|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
48642548|NCT06083493|DEVICE|LIFUP inhibition|The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-inhibition) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
48642549|NCT06432725|BEHAVIORAL|JUNTOS|HIV test counselor and Latino MSM participants will be given access to the JUNTOS website/app, which shows information about local HIV and ancillary services. HIV test counselor participants will also be given access to a training video explaining how to use the JUNTOS website/app. HIV test counselors are encouraged to use the website/app for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the website/app to locate HIV and ancillary services as needed.
47961499|NCT02327065|DEVICE|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
47961500|NCT00544518|DRUG|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
47961501|NCT00544518|DRUG|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
47961502|NCT04424888|OTHER|WB-011|WB-011 medical food product.
47961503|NCT04424888|OTHER|Placebo|Placebo Capsules identical to those containing WB-011.
47961504|NCT04424888|DEVICE|Continuous Glucose Monitor|Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
47961505|NCT04058730|PROCEDURE|Laparoscopic Roux en Y Gastric by pass surgery|
47961506|NCT04058730|PROCEDURE|Laparoscopic Sleeve Surgery|
48113105|NCT05987878|PROCEDURE|single minimal conjunctival incision|A 5-0 PGA traction suture was used near the corneal limbus corresponding to the operated muscle. A 3-4 mm single conjunctival incision posterior and parallel to the insertion in medial, lateral or superior rectus muscle was used. A hang-back recession of the muscle was done using 6-0 PGA suture. The conjunctiva was closed by an 8-0 PGA single stitch with knot burial
48113106|NCT05348876|DRUG|Darolutamide (Nubeqa, BAY1841788)|600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
48113107|NCT05719558|DRUG|ASP1002|intravenous (IV) infusion
48113108|NCT05612048|OTHER|Survey|This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
48113109|NCT05612048|OTHER|Intra-oral camera|Intraoral pictures of molars and incisors in 13 key regions
48113110|NCT05612048|OTHER|Optional Salvia sample|Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
48113111|NCT03359460|DRUG|Ibrutinib|Given PO
48113112|NCT03359460|DRUG|Lenalidomide|Given PO
48113113|NCT03393377|DRUG|fluvastatin 10 mg and valsartan 20 mg|
48113114|NCT03393377|DRUG|placebo|
48642550|NCT06432725|BEHAVIORAL|Referral Sheet|HIV test counselor and Latino MSM participants will be given access to referral sheet, which is a list of local HIV and ancillary services. HIV test counselors are encouraged to use the referral sheet for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the referral sheet to locate HIV and ancillary services as needed.
48642551|NCT06694766|PROCEDURE|Blood sample collection|A blood sample collection of 18.5 mL will be required for the immunogenicity component.
48642552|NCT06083142|BIOLOGICAL|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules
48113115|NCT02329457|BIOLOGICAL|Zostavax|varicella zoster vaccine
48113116|NCT02329457|BIOLOGICAL|Normal Saline|normal saline placebo vaccine
48113117|NCT06173258|DEVICE|Water exchange alone|During the insertion phase of water exchange colonoscopy, the air pump will be turned off, while the colon will be irrigated with warm-to-touch water using a flushing pump. The water exchange approach involves the simultaneous infusion of water to facilitate luminal expansion and suction of unclean water during insertion. Upon reaching the cecum, where most of the water is suctioned to collapse the cecal lumen, the air pump will be opened. Withdrawal from the cecum will begin in the left lateral position. Similar withdrawal techniques with adequate luminal distention and comprehensive examination behind the folds will be emphasized. Any position change away from the original left lateral position in any colon segment during the withdrawal phase will be recorded. Tandem examination of specific colon segments, including the right colon, either in the standard modality or retroflexion, is prohibited.
47961507|NCT04058730|OTHER|Standard Medical Management|
47961508|NCT01399515|DRUG|Valproic Acid|One 500mg tablet by mouth daily
47961509|NCT05477693|BIOLOGICAL|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
47961510|NCT05477693|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
47961511|NCT01041833|DRUG|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
47961512|NCT01041833|DRUG|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
47961513|NCT04443010|DRUG|Onfekafusp alfa|"This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone."
47961514|NCT04443010|DRUG|Temozolomide|Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
48309286|NCT03726671|OTHER|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
48309287|NCT05347069|DRUG|Aspirin|Aspirin 100 mg/day
48309288|NCT05347069|DRUG|No aspirin|No aspirin administered
47961515|NCT01236482|DRUG|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
48113118|NCT06173258|DEVICE|Water exchange plus Artificial Intelligence (AI)|Similar water exchange technique as the active comparator will be employed during insertion. Similar withdrawal inspection techniques as the active comparator will be used. During withdrawal phase, commercially available AI system (GI Genius, Medtronic, USA; CAD-EYE, Fujifilm, EU and Taiwan; Endo-AID, Olympus, EU and Taiwan) will be activated, providing a bounding box as output any time a lesion that is suspected to be a polyp is recognized by the AI device. False positive activation is defined as the identification by AI systems of an area during the withdrawal phase that is not deemed to be a colorectal lesion after re-examination by the colonoscopist. Real-time flagging of FP activation will be recorded by investigators and study staff.
48113119|NCT01607372|DRUG|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
48113120|NCT01607372|DEVICE|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
48113121|NCT01607372|OTHER|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
48113122|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 800 IU/day|Higher dose of enteral vitamin D supplementations (800 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
48113123|NCT06674122|DIETARY_SUPPLEMENT|Enteral vitamin D supplementation of 400 IU/day|Standard recommended dose of enteral vitamin D supplementations (400 IU/day) are given for 28 days, and vitamin D status are examined before and after supplementation
48113124|NCT06600425|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
48642553|NCT05324371|DEVICE|Watchman FLX Device|Left atrial appendage closure using the Watchman FLX device
47961516|NCT01523535|BEHAVIORAL|repeated cycles of short sleep|- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
47961517|NCT03783364|RADIATION|Radiotherapy|Pre- or postoperative acellerated irradition in 5 fractions
47961518|NCT03593603|DEVICE|Nellcor™ Bedside Respiratory Monitoring System|Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
47961519|NCT03713359|BIOLOGICAL|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
47961520|NCT03713359|BIOLOGICAL|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
47961521|NCT03515278|PROCEDURE|SCNB group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
47961522|NCT03515278|PROCEDURE|IACI group|SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
48113125|NCT05251207|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
48113126|NCT05251207|DIETARY_SUPPLEMENT|L-leucine|L-leucine
48113127|NCT05251207|BEHAVIORAL|Change of the circadian cycle|Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
48113128|NCT04756063|DRUG|Ascorbic acid|Intravenous vitamin C
48113129|NCT04756063|OTHER|Placebo|Normal Saline
48113130|NCT00457769|DRUG|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
48113131|NCT00457769|DRUG|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
48113132|NCT02630719|DRUG|Timolol eye drops|eye drops
48113133|NCT02630719|DRUG|Artificial tears|Placebo drop
48309289|NCT04008433|DRUG|Lidocaine|Advanced intravenous injection of lidocaine before the propofol injection
48309290|NCT03739463|DIETARY_SUPPLEMENT|MAG-DHA|375 MG of MAG-DHA per capsules, two capsules BID
48309291|NCT03739463|DIETARY_SUPPLEMENT|Oleic acid|375 MG of sunflower oil (oleic acid) per capsules, two capsules BID
48309292|NCT05238948|DRUG|Midazolam|Substrate of CYP3A4
48113134|NCT06085755|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
48309293|NCT05238948|DRUG|CKD-506|Perpetrator of CYP3A4
48309294|NCT05277155|DIETARY_SUPPLEMENT|BEJO Red Ginger Extract|"BEJO Red Ginger Extract ingredients:~* Zingiber officinale var. rubrum (Rhizome extract) 80 mg~* Foeniculi vulgare Fructus (Fennel) 25 mg~* Menthae arvensis Folium (Mint) 5 mg~* Piper retrofractum Fructus (Javanese long pepper) 12.5 mg~* Honey 7500 mg"
48309295|NCT05277155|OTHER|Placebo|Placebo composition: Substance without active ingredient
48309296|NCT05391984|OTHER|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
48309297|NCT05391984|OTHER|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
48642554|NCT05359016|BEHAVIORAL|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
48642555|NCT06109272|DRUG|Livmoniplimab|Intravenous (IV) Solution
48642556|NCT06109272|DRUG|Budigalimab|Intravenous (IV) Solution
48642557|NCT06109272|DRUG|Durvalumab|Intravenous (IV) Solution
48642558|NCT06109272|DRUG|Atezolizumab|Intravenous (IV) Solution
48642559|NCT06109272|DRUG|Bevacizumab|Intravenous (IV) Solution
48642560|NCT06109272|DRUG|Tremelimumab|Intravenous (IV) Solution
48642561|NCT05248386|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
47961523|NCT03241875|DRUG|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
48113135|NCT06085755|DRUG|Afatinib|Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.
48113136|NCT02613871|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
47961524|NCT03241875|DRUG|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
48113137|NCT04874415|BEHAVIORAL|1RLD|1RLD=One text per day, ramped goal, loss incentive, daily goal time period
48113138|NCT04874415|BEHAVIORAL|1RLW|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
48113139|NCT04874415|BEHAVIORAL|1RGD|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
48113140|NCT04874415|BEHAVIORAL|1RGW|One text per day, ramped goal, gain incentive, weekly goal time period.
48113141|NCT04874415|BEHAVIORAL|2RLD|Two texts per day, ramped goal, loss incentive, daily goal time period.
48113142|NCT04874415|BEHAVIORAL|2RLW|Two texts per day, ramped goal, loss incentive, weekly goal time period.
48113143|NCT04874415|BEHAVIORAL|2RGD|Two texts per day, ramped goal, gain incentive, daily goal time period.
48113144|NCT04874415|BEHAVIORAL|2RGW|Two texts per day, ramped goal, gain incentive, weekly goal time period.
48113145|NCT04874415|BEHAVIORAL|1FLD|One text per day, fixed goal, loss incentive, daily weekly goal time period.
48113146|NCT04874415|BEHAVIORAL|1FLW|One text per day, fixed goal, loss incentive, weekly goal time period.
48642562|NCT05248386|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
47961525|NCT03241875|DRUG|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
48309298|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
48309299|NCT01386710|DRUG|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
48309300|NCT01597557|DRUG|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
48309301|NCT01597557|OTHER|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
48642563|NCT04991454|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
47961526|NCT03218514|DRUG|Dalteparin|
48113147|NCT04874415|BEHAVIORAL|1FGD|One text per day, fixed goal, gain incentive, daily goal time period.
48113148|NCT04874415|BEHAVIORAL|1FGW|One text per day, fixed goal, gain incentive, weekly goal time period.
48113149|NCT04874415|BEHAVIORAL|2FLD|Two texts per day, fixed goal, loss incentive, daily goal time period.
48113150|NCT04874415|BEHAVIORAL|2FLW|Two texts per day, fixed goal, loss incentive, weekly goal time period.
48113151|NCT04874415|BEHAVIORAL|2FGD|Two texts per day, fixed goal, gain incentive, daily goal time period.
48113152|NCT04874415|BEHAVIORAL|2FGW|Two texts per day, fixed goal, gain incentive, weekly goal time period.
48642564|NCT05669352|DRUG|CA-4948|Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.
48642565|NCT05669352|DRUG|Pembrolizumab|Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
48642566|NCT06307015|RADIATION|De-escalation|Surgical resection of primary oropharyngeal tumour followed by de-escalated radiation therapy (30Gy) with concurrent platinum-based chemotherapy to oropharynx + neck, followed by surgical neck dissection
47961527|NCT05604677|PROCEDURE|Breast Surgery|Breast-conserving Surgery or modified radical mastectomy
47961528|NCT05618860|OTHER|Questionnaire|eligible participants in the radiology department waiting rooms will be asked to complete a questionnaire after taking consent.
47961529|NCT03454542|DEVICE|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
47961530|NCT05419999|DEVICE|Soterix 1x1 tDCS mini CT|During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
47961531|NCT05419999|OTHER|Sham Soterix 1x1 tDCS Mini CT|Sham setting is used on the Soterix transcranial electrical stimulator
47961532|NCT05419999|BEHAVIORAL|Written Exposure Therapy (WET)|An exposure-based, behavioral psychotherapy for PTSD.
47961533|NCT01184391|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
47961534|NCT01184391|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
47961535|NCT06210607|DRUG|HS-10511 Tablets|HS-10511 tablets for 5\~6 SAD cohorts and 4 MAD cohorts
47961536|NCT06210607|DRUG|HS-10511 Tablets Placebo|HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
47961537|NCT00917995|DEVICE|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
48266677|NCT03094000|BEHAVIORAL|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
48113153|NCT05926596|DEVICE|Wearable Robotic Exoskeleton|"* Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~* Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~* Treadmilll and Overground Walking (60-90 minutes including rest periods)~* Cool down (5-10 minutes)"
48113154|NCT00306449|BEHAVIORAL|Small group seminar-based educational intervention|
48113155|NCT00221208|BEHAVIORAL|Resistance Training|
48113156|NCT06188611|DRUG|Huazhi Rougan Granule Placebo granule|Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
48113157|NCT04580901|BEHAVIORAL|Group Interpersonal Psychotherapy|Group IPT consists of 12 weeks of virtually delivered therapy by two co-therapists via Zoom to a group of 6-8 women. The 12 weeks consist of 15 sessions over 12 weeks of group IPT taking place virtually via Zoom (2 sessions per week for the first 4 weeks (acute phase) then once a week for 6 weeks, then a two-week space before the last session).
48113158|NCT04144322|DEVICE|Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition|Placement of a short implant
48642567|NCT06307015|RADIATION|Standard of care|Radiation therapy (70Gy) with concurrent platinum-based chemotherapy to oropharynx + neck
48642568|NCT06167317|DRUG|GS-0201|Pill administered orally
48642569|NCT06167317|DRUG|Sacituzumab Govitecan|Administered intravenously
47961538|NCT03362008|DRUG|Zeropix|administration of Zeropix
48642570|NCT04007549|BEHAVIORAL|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
48642571|NCT06695663|BEHAVIORAL|Referral and communication skills learning|assigned to receive a brief, live, experiential training on the referral process and communication strategies.
47961539|NCT03362008|DRUG|Champix®|administration of Champix®
47961540|NCT03447704|DRUG|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
47961541|NCT03447704|OTHER|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
47961542|NCT04180358|BEHAVIORAL|Native STAND|Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
47961543|NCT04180358|BEHAVIORAL|Regular Health/Physical Education Curriculum|General health and physical education curriculum provided by New Mexico's Public Education Department.
47961544|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus MIND diet|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.
47961545|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus Health Education|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
47961546|NCT02856178|DRUG|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
47961547|NCT02856178|DRUG|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
47961548|NCT01675791|BIOLOGICAL|ALK tree AIT 0.5 DU|
47961549|NCT01675791|BIOLOGICAL|ALK tree AIT 1 DU|
48642572|NCT06695663|BEHAVIORAL|Written guide to the referral process|assigned to receive only written information about the referral process
48113159|NCT04144322|DEVICE|Zimmer T3 with DCD Ex Hex Parallel Walled implants|Placement of a long implant with sinus lift and bone graft
48113160|NCT00412321|DRUG|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
47961550|NCT01675791|BIOLOGICAL|ALK tree AIT 2 DU|
47961551|NCT01675791|BIOLOGICAL|ALK tree AIT 4 DU|
47961552|NCT01675791|BIOLOGICAL|ALK tree AIT 7 DU|
47961553|NCT01675791|BIOLOGICAL|ALK tree AIT 12 DU|
47961554|NCT01675791|BIOLOGICAL|ALK tree AIT Placebo|
47961555|NCT01317485|PROCEDURE|Laparoscopic lavage and drainage|"\[CLOSED\] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~\*\*\*This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
47961556|NCT01317485|PROCEDURE|Sigmoidectomy with primary anastomosis|\[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
47961557|NCT01317485|PROCEDURE|Sigmoidectomy with end-colostomy|\[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
47961558|NCT02167087|PROCEDURE|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
47961559|NCT01826188|DRUG|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
47961560|NCT01826188|DRUG|Placebo|olive oil without cannabis
48113161|NCT06023589|BIOLOGICAL|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
48113162|NCT06023589|OTHER|Placebo|Participants will be receiving subcutaneous injection of matching placebo
48309302|NCT03399175|DRUG|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
48309303|NCT01121159|PROCEDURE|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
47961561|NCT03681431|DRUG|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
47961562|NCT03681431|DRUG|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
48309304|NCT01117688|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
48309305|NCT03894527|BEHAVIORAL|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
47961563|NCT05869266|DEVICE|professional fitting vs. self fitting|Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
48113163|NCT03903900|BEHAVIORAL|Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain|The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
48309306|NCT03894527|BEHAVIORAL|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
48113164|NCT03522467|DRUG|MRCP001|MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
48113165|NCT06079320|DRUG|Sisunatovir|Participants will receive tablets from Day 1 to Day 5
48113166|NCT06079320|DRUG|Placebo|Participants will receive matching placebo tablets from Day 1 to Day 5
48309307|NCT03141060|DRUG|Delamanid|Administered orally; dosing will be based on participants' age and weight.
48309308|NCT03141060|DRUG|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
48309309|NCT00002118|DRUG|Zalcitabine|
48642573|NCT06695663|BEHAVIORAL|Empowered Generations (eGen): parent training|eGen is a six-session parent training program provided by therapists via video chat online to parents with a child between the ages of 3-8 years.
48113167|NCT02140138|BIOLOGICAL|CV9104|
48113168|NCT02140138|DEVICE|needle free injection device (Tropis®)|
48113169|NCT04301596|OTHER|Collection of data|different set of data will be collected over a 6 months period
48113170|NCT02347436|PROCEDURE|24-hr ambulatory blood pressure measurement|
48309310|NCT00334932|DRUG|bortezomib|
48309311|NCT00334932|DRUG|melphalan|
48642574|NCT06695663|BEHAVIORAL|control|The control condition consists of a single scripted session, in which therapists guide the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) vetted parenting advice websites; (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools; and (d) a list of culturally tailored parenting advice websites.
48642575|NCT06205485|DRUG|Leucovorin|400 mg/m2
48642576|NCT06205485|DRUG|Oxaliplatin|85 mg/m2 or 130 mg/m2 on day 1
48642577|NCT06205485|DRUG|Fluoruracil|bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2
47961564|NCT04247880|BEHAVIORAL|Mentoring program|Apprentice-level female construction workers will be assigned to a mentor who has gone through a rigorous mentorship training. Participants will be asked to meet with a mentor at least 4 times/year in person to discuss the challenges of being a female in construction, learn coping mechanisms, and otherwise discuss the unique challenges of the job environment.
47961565|NCT01048177|DRUG|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
47961566|NCT04758104|RADIATION|Yttrium90|Intracystic implantation of 90yttrium colloid
47961567|NCT02552875|OTHER|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
47961568|NCT02552875|OTHER|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
47961569|NCT00496470|DRUG|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
47961570|NCT00496470|DRUG|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
47961571|NCT05269043|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smart inhaler, spirometer, blood pressure monitor, pulse oximetry device, particulate matter sensor.
47961572|NCT01933061|DRUG|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
47961573|NCT01933061|DRUG|Abraxane|Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
48113171|NCT00971711|BIOLOGICAL|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
48642578|NCT06205485|DRUG|Capecitabine|1,000 mg/m2 twice daily for 14 days
48642579|NCT06205485|RADIATION|Radiation|54 Gy (27-30 fractions)
48642580|NCT06345118|BEHAVIORAL|Otago exercise program|"The OEP consists of 17 strength and balance exercises and a walking program performed thrice a week by the older adult at home.~Program Prescription The program is designed to be delivered over 6 months and includes a minimum of 5 visits. The first visit is Day 1 of Otago when performance of the functional measures is assessed, and the exercises are prescribed at the Rehabilitation Center of the National Geriatric Hospital. Then, the therapist will see the patient for 4 visits over an 8-week period (typically every other week). This is considered the initial bolus of Otago. Then, the therapist will follow the patient via phone calls every week and make a visit at three months, four months, five months, and six months to reassess the patient's training ability and compliance.~Monitoring:~Calendars can be completed each month to document any falls. A calendar or diary can be used to monitor compliance with the exercise programme"
47961574|NCT05210673|OTHER|ERAS|Preoperative: Preoperative explanation of ERAS. Preoperative medical optimization. Smoking cessation 4-8 weeks before surgery. Nutritional status assessment. Preoperative fasting: 2hours for Clear fluids and water, 6hours for Semi-solid foods and 8 hours for Solid food. Preoperative carbohydrate loading. Pre-anesthetic medication: Avoid long active sedatives. Thromboembolic prophylaxis and Compression stockings Intraoperative: Antimicrobial prophylaxis and skin preparation. Epidural analgesia. Prevention of intraoperative hypothermia. Intraoperative fluid management. Minimize incision. Drain strategy Postoperative: Nasogastric intubation. Early oral intake. Early mobilization. Prevention of postoperative ileus through. Prevention of postoperative nausea and vomiting. Multimodal opioid sparing analgesia. Discharge criteria: Patients have resumed adequate oral intake and normal bowel function, Effective oral pain management and No other clinical or biochemical concerns
47961575|NCT05210673|OTHER|Non ERAS pathway|standard preoperative preparation intraoperative: combined general and epidural anesthesia postoperative standard care
47961576|NCT01805804|DRUG|placebo/valsartan|
47961577|NCT02500420|OTHER|Diagnosis examens|"* Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~* Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
47961578|NCT03351933|BIOLOGICAL|Immune Globulin (Human)|A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
48113172|NCT02482519|OTHER|High calorie diet|High calorie diet for 10 days
48113173|NCT02482519|OTHER|Fasting|10 day fast
48113174|NCT01165658|RADIATION|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
48113175|NCT02181660|DRUG|Gilteritinib|oral
48113176|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
48113177|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
48309312|NCT00334932|DRUG|pegylated liposomal doxorubicin hydrochloride|
48642581|NCT00986102|DRUG|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
48642582|NCT05677126|DRUG|Tralement|Tralement with Manganese
48642583|NCT05677126|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese
48642584|NCT05799157|DRUG|VDMN-21 Patch Low Dose|Microneedle patch containing 125 mcg of active drug
47961579|NCT00508716|BEHAVIORAL|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
48309313|NCT05851508|DRUG|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
48309314|NCT05851508|DRUG|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
48113178|NCT00493402|PROCEDURE|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
48113179|NCT00346333|DRUG|Lutein|12mg/d
48113180|NCT00346333|DIETARY_SUPPLEMENT|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
48309315|NCT02871180|DIETARY_SUPPLEMENT|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
48309316|NCT02871180|OTHER|No late night snack|Patient consumed no nutrients at late night.
48642585|NCT05799157|DRUG|VDMN-21 Patch High Dose|Microneedle patch containing 250 mcg of active drug
48642586|NCT05799157|DRUG|Vehicle Patch|Placebo microneedle patch containing no active drug (i.e., placebo)
48642587|NCT06311513|BIOLOGICAL|Concentrated Bone Marrow Aspirate Injection|Intraoperatively, bone marrow will be harvested from the iliac crest with a commercial kit, it will then be prepared via centrifugation and an injection of the resulting concentrated product (cBMA) will be administered in the operative knee. cBMA is an autologous biologic product.
48642588|NCT06311513|PROCEDURE|Sham Incision|A 2 mm sham incision will be made in the anatomical site where bone marrow would be harvested.
48642589|NCT06311513|PROCEDURE|Revision Anterior Cruciate Ligament Reconstruction|This is the standard-of-care surgical procedure.
48642590|NCT04179448|PROCEDURE|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
48642591|NCT04179448|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
48642592|NCT05179408|BEHAVIORAL|Targeted-telerehabilitation|Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/stept count; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)
48309317|NCT05909566|OTHER|Clinical Decision Support (CDS)|Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.
48642593|NCT05179408|BEHAVIORAL|Waitlist|8-week waiting period prior to targeted telerehabilitation
47961580|NCT02930330|BEHAVIORAL|INT|"* 5 min warm-up (40% Pmax\*)~* 30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
47961581|NCT02930330|BEHAVIORAL|CONT|"* 5 min warm-up (40% Pmax\*)~* 30 min moderate intensity continuous training (60% Pmax)~* 10 min cool-down (30% Pmax)~Pmax\*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
47961582|NCT00891592|BIOLOGICAL|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~* 1xE5 cells/kg~* 2xE6 cells/kg~* 3xE7 cells/kg~* 4xE8 cells/kg"
47961583|NCT00891592|OTHER|Observation Arm|Single infusion of Cord Blood Cells
47961584|NCT01813188|PROCEDURE|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
47961585|NCT01813188|PROCEDURE|autologous bone graft|autologous bone graft
48113181|NCT02907398|DEVICE|Inspire therapy|
48113182|NCT02907398|OTHER|No intervention|
48113183|NCT04852302|BEHAVIORAL|CALM Therapy|The CALM intervention is a brief, individualized psychotherapeutic intervention established to meet an unmet need to address psychological distress and promote well-being in advanced cancer patients.
48113184|NCT06664762|BEHAVIORAL|Left lateral position intervention|Patients will be randomized and asigned to start and remain in left lateral position during the colonoscopy
48113185|NCT06664762|BEHAVIORAL|Supine position intervention|Patients will be randomized and asigned to start and remain in supine position during the colonoscopy
48113186|NCT03798080|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48113187|NCT03798080|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48309318|NCT05909566|DEVICE|HHFNC Weaning|Wean patient off oxygen and flow as oxygenation and work of breathing improves.
48309319|NCT00219336|BEHAVIORAL|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
48642594|NCT05528588|COMBINATION_PRODUCT|Furoscix|"Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours)."
48642595|NCT05528588|DRUG|Diuretic Therapy|Patients will receive home dose oral furosemide or oral furosemide per standard of care.
48642596|NCT04837547|BIOLOGICAL|Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)|There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.
48309320|NCT00219336|BEHAVIORAL|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
48642597|NCT05649306|OTHER|Additional Education|Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services
48642598|NCT05649306|OTHER|Questionnaires|Female Sexual Function Index, Demoralization Scale-II
48642599|NCT05649306|OTHER|Attendance Diary|Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized
48642600|NCT06655896|BIOLOGICAL|rapcabtagene autoleucel|single infusion of rapcabtagene autoleucel
47961586|NCT04315883|BEHAVIORAL|Quality of Life Assessment|"Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
47961587|NCT04315883|RADIATION|Transarterial Radioembolization|"Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~* Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~* Resection Rate following treatment~* Transplant Rate following treatment~* Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~* Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~* Review of clinical course post-treatment-rehospitalization rate"
48309321|NCT01104584|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
48309322|NCT01797276|DRUG|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
48642601|NCT06655896|BIOLOGICAL|rituximab|rituximab intravenous infusion (i.v.) as per protocol
47961588|NCT01332903|DRUG|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
47961589|NCT04360668|OTHER|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
48113188|NCT03798080|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
48113189|NCT03777696|DRUG|Misoprostol|400 μg of buccal misoprostol
48642602|NCT05106764|OTHER|No intervention|This is non-interventional study.
48642603|NCT06297213|DRUG|R-2487|R-2487 DP
48642604|NCT03491085|DRUG|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
48642605|NCT03196089|PROCEDURE|Oxygen application|Supplemental oxygen via mask
48642606|NCT06647628|DRUG|MK-1708|MK-1708 oral suspension
48642607|NCT06647628|DRUG|Placebo|Placebo oral suspension
48642608|NCT04995419|DRUG|Enfortumab vedotin|Intravenous Infusion
48642609|NCT06101069|PROCEDURE|MRF in conjunction with IVIM MRI without contrast|MRF in conjunction with IVIM MRI scan, without contrast.
48642610|NCT02040376|DRUG|Metformin|Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
48113190|NCT03777696|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
48113191|NCT03777696|DRUG|placebo to misoprostol|placebo tablets to misoprostol buccal
48642611|NCT02040376|DRUG|Placebo|Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
48642612|NCT06683599|PROCEDURE|Apneic oxygenation|1 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with conventional nasal cannula during tracheal intubation performed with a video laryngoscope with Miller-blade or Macintosh-blade size No. 0 or No. 1.
47961590|NCT04360668|OTHER|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
47961591|NCT04360668|OTHER|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
47961592|NCT03360604|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
47961593|NCT03360604|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
47961594|NCT06504706|PROCEDURE|Matcha Tea|Japanese tea rich in antioxidants and Catechins
47961595|NCT06504706|PROCEDURE|Green Tea|Green tea rich in catechins
47961596|NCT05536583|PROCEDURE|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
47961597|NCT00714883|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
47961598|NCT04036019|BIOLOGICAL|CD20-directed CAR-T cells with CliniMACS Prodigy® system|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
47961599|NCT00691314|DEVICE|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex\&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1"
47961600|NCT00691314|DRUG|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
47961601|NCT04733404|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
47961602|NCT04790773|OTHER|Amazon Alexa based voice recording patient education|Amazon Alexa based voice recording of medication education material
47961603|NCT00622817|DRUG|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
47961604|NCT00622817|DRUG|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
47961605|NCT05898113|OTHER|EXTRA VIRGIN OLIVE OIL|Participants will consume a daily amount of extra virgin olive oil. Can consume the oil either raw or cooked
47961606|NCT05898113|OTHER|OLIVE OIL LOW POLYPHENOL|Participants will consume a daily amount of olive oil low polyphenol. Can consume the oil either raw or cooked
47961607|NCT01918436|BEHAVIORAL|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
47961608|NCT01918436|OTHER|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
47961609|NCT05209425|DIETARY_SUPPLEMENT|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
48483051|NCT05810025|BEHAVIORAL|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
48483052|NCT03301818|DEVICE|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
48483053|NCT02758860|PROCEDURE|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
48483054|NCT01613378|OTHER|No intervention|No intervention administered in this study
48483055|NCT03629600|DRUG|Lactated Ringer|High-volume Lactated Ringer Solution
48483056|NCT03629600|DRUG|Rectal Form Indometacin|Post-ERCP rectal administration of 100 MG Indomethacin
47961610|NCT00358371|DRUG|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
47961611|NCT00358371|DRUG|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
47961612|NCT05596344|OTHER|Hospital Anxiety and Depression Scale|The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
47961613|NCT03832777|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
47961614|NCT01898637|OTHER|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
47961615|NCT01898637|DEVICE|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
47961616|NCT04493073|PROCEDURE|Trabectulectomy|decrease IOP
48113192|NCT03777696|DRUG|placebo to TA|110 ml saline iv
48113193|NCT01161563|DRUG|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
48309323|NCT05264090|OTHER|Ambulatory blood pressure monitoring|The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
48113194|NCT01161563|DRUG|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
48309324|NCT05264090|OTHER|Combined aerobic-resistance exercise|Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).
48309325|NCT05264090|OTHER|The cardiovascular exercise|The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
47961617|NCT04493073|DRUG|Mitomycin|Decrease bleb failure
48113195|NCT06211907|DEVICE|Postoperative intraocular tamponade|Flushing the eye cavity with a tamponade at the end of surgery
47961618|NCT04493073|DEVICE|Ologen Collagen Implant|Ologen Collagen Implant (Aeon Astron Europe, Netherlands)
47961619|NCT04493073|DEVICE|Mitomycin-C Kyowa®|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
47961620|NCT06284031|PROCEDURE|3 fractions HDR brachytherapy|"The 3 fractions of HDR brachytherapy may be delivered in the following ways:~Option 1: 3 insertions over 2 non-consecutive days:~Option 2: 3 insertions over 3 non-consecutive days"
47961621|NCT01483755|PROCEDURE|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
47961622|NCT01483755|PROCEDURE|Percutaneaous intervention|Conventional primary percutaneaous intervention
47961623|NCT00001381|DRUG|suramin|
47961624|NCT02577978|DEVICE|Medacta GMK posterior stabilized prosthesis|
47961625|NCT02577978|DEVICE|Medacta GMK Sphere prosthesis|
47961626|NCT06450353|BEHAVIORAL|Patient Ancestry Questionnaires|Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
47961627|NCT03471520|BEHAVIORAL|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
48113196|NCT05300035|DRUG|Recombinant human monoclonal antibody (bNAbs)|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
48266678|NCT03094000|BEHAVIORAL|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
48266679|NCT01756729|DEVICE|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
47961628|NCT03312478|DRUG|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
47961629|NCT04449601|OTHER|clinical assesment|Comparison of Hypertensive group and normotensive group
47961630|NCT03217656|OTHER|No intervention|
47961631|NCT04144660|DEVICE|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
47961632|NCT03224715|OTHER|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
48309326|NCT03201172|DEVICE|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
48309327|NCT05803720|BEHAVIORAL|Provider Intervention on Addressing Intersectional Stigma and Medical Mistrust in Patients with HIV|The intervention will consist of psychoeducation and skills-building for HIV care providers to gain knowledge and skills needed to address intersectional stigma and medical mistrust with patients. The intervention will be online and conducted in groups.
47961633|NCT04719286|DEVICE|MinSafeStart app|The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
47961634|NCT03348150|PROCEDURE|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
47961635|NCT03348150|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
47961636|NCT03389620|DRUG|dexamethasone|0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
47961637|NCT05722197|BEHAVIORAL|Crisis Response Planning and Lethal Means Safety Counseling|Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
47961638|NCT03801343|DIETARY_SUPPLEMENT|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
47961639|NCT01977742|OTHER|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
47961640|NCT01977742|OTHER|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
48309328|NCT05151328|DRUG|Plecanatide|Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 3mg, dosage form oral; Frequency of administration: QD
48309329|NCT03119116|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
47961641|NCT05374369|DIAGNOSTIC_TEST|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
47961642|NCT05374369|PROCEDURE|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
47961643|NCT06044883|PROCEDURE|Injection of Botulinum neurotoxin (BoNT)|"Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder."
48113197|NCT05300035|DRUG|Placebo|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
48113198|NCT05862285|DRUG|Ipatasertib|Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
48113199|NCT05862285|DRUG|Tiragolumab|Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
48113200|NCT05862285|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy and in combination with tiragolumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
48266680|NCT03416283|BEHAVIORAL|Remote Monitoring|Remote BP monitoring and medication adherence
48309330|NCT03119116|DRUG|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
48309331|NCT03119116|DRUG|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
48309332|NCT02856581|DRUG|Varenicline|Given PO
48309333|NCT02856581|DRUG|Placebo|Given PO
48309334|NCT02856581|OTHER|Tobacco Cessation Counseling|Complete counseling session
48309335|NCT00051558|DRUG|Teriparatide|20 micrograms/day, injection, 36 months
48309336|NCT00051558|DRUG|Alendronate Sodium|10 mg/day, oral, 36 months
48309337|NCT00051558|DRUG|Placebo|Oral placebo, daily, 36 months
48309338|NCT00051558|DRUG|Placebo|Injection placebo, daily, 36 months
48309339|NCT01528800|DRUG|Vitamin K1|10mg orally three times a week for 12 months
48309340|NCT01528800|DRUG|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
48309341|NCT00896987|DRUG|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg\~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
48309342|NCT00896987|DRUG|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg\~600 mg) and maintenance for 40 weeks (600 mg)
48309343|NCT02532361|DEVICE|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
47961644|NCT06044883|DIAGNOSTIC_TEST|Penile duplex and shear wave elastosonography (SWE).|Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
47961645|NCT00870441|DRUG|ASP2151|Oral
47961646|NCT00870441|DRUG|Valacyclovir|Oral
48113201|NCT03199781|DEVICE|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
48309344|NCT02532361|PROCEDURE|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
47961647|NCT00870441|DRUG|Placebo|Oral
47961648|NCT00443495|DRUG|Chitin microparticles by nasal route|
48113202|NCT05601830|DRUG|QN-030a|NK cell therapy
48113203|NCT05601830|DRUG|Cyclophosphamid|Lympho-conditioning Agent
48113204|NCT05601830|DRUG|Fludarabine|Lympho-conditioning Agent
48113205|NCT05601830|DRUG|Cytarabine|Lympho-conditioning Agent
48113206|NCT06542133|DEVICE|AVEIR remote care system|In-clinic or an at-home system designed to support remote follow up in Aveir leadless pacemaker patients
48113207|NCT06488625|DRUG|Low-Dose CICR-NAM|2 g/d CICR-NAM (blinded)
48113208|NCT06488625|DRUG|High-Dose CICR-NAM|3 g/d CICR-NAM (blinded)
48113209|NCT06488625|DRUG|0 g/d CICR-NAM (blinded)|Placebo (blinded)
48113210|NCT06488625|DRUG|Open-Label|3 g/d CICR-NAM (open label)
48309345|NCT01905319|OTHER|Blood collecting for storage of samples|
48309346|NCT04757779|DRUG|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
48309347|NCT05346952|DRUG|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
47961649|NCT01201850|DRUG|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
48113211|NCT04080258|OTHER|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
48113212|NCT04080258|OTHER|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
48113213|NCT02577419|OTHER|Target Fortification|
48309348|NCT06101173|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
48309349|NCT06101173|BIOLOGICAL|Inactivated poliomyelitis vaccine (IPOL)|1 dose of IPOL vaccine (0.5ml) on Visit 1
47961650|NCT02051504|BEHAVIORAL|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
47961651|NCT02051504|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
47961652|NCT02051504|PROCEDURE|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
47961653|NCT02051504|PROCEDURE|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
47961654|NCT02051504|PROCEDURE|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
47961655|NCT02051504|PROCEDURE|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
47961656|NCT02051504|OTHER|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
47961657|NCT01186471|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
47961658|NCT01186471|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
47961659|NCT01186471|DRUG|placebo|placebo - three times daily during each treatment period
47961660|NCT02218320|DRUG|Raltegravir|
47961661|NCT02218320|DRUG|Dolutegravir|
48113214|NCT02577419|OTHER|Higher Initial Concentration|
48113215|NCT02577419|OTHER|Portagen Formula|
48113216|NCT03951649|DRUG|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
48113217|NCT06538558|DRUG|Tezampanel|Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
47961662|NCT02218320|PROCEDURE|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
47961663|NCT01850628|DRUG|Paclitaxel|
47961664|NCT01850628|BIOLOGICAL|trastuzumab|
47961665|NCT01850628|BIOLOGICAL|pertuzumab|
47961666|NCT02850965|DRUG|BI 695501|
48309350|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
48113218|NCT06538558|DRUG|Placebo|Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
48113219|NCT06170593|DRUG|Triamcinolone Injection|0.1mL of triamcinolone 1% solution per lesion
48113220|NCT01102049|DIETARY_SUPPLEMENT|fish, beef, fruit|
48113221|NCT05638945|BEHAVIORAL|ED Delirium Screening and Detection Program (ED-DDP)|The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
48113222|NCT04744402|DRUG|Autologous Chondrocyte Implantation (CartiLife®)|CartiLife consists of small beads (1 mm in diameter) in suspension, developed from pellet culture of autologous costal chondrocytes after multiplication. The beads are implanted in an injective manner with fibrin glue through minimal arthrotomy. The dose depends on the size (volume) of the defect, recommended dose is 480 pellets/cm\^3 defect
48113223|NCT01523158|BIOLOGICAL|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
48113224|NCT01522092|DRUG|escitalopram|5mg-20mg, tablet, od, 12 months
48113225|NCT04705376|DEVICE|Breg Polarcare|The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
48113226|NCT04705376|DEVICE|Thermazone|ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
48113227|NCT03119558|DRUG|18F-Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
48113228|NCT04276402|PROCEDURE|Irradiation of implants with 808nm laser|Irradiation of implants with 808nm laser
48113229|NCT04255888|PROCEDURE|Laterally positioned flap in thick periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
48113230|NCT04255888|PROCEDURE|Laterally positioned flap in thin periodontal phenotype.|Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
48483057|NCT00836147|DRUG|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
48642613|NCT05296798|DRUG|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
48642614|NCT05296798|DRUG|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
48642615|NCT05296798|DRUG|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
47961667|NCT02850965|DRUG|Humira|
47961668|NCT00318123|DRUG|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
47961669|NCT00515411|DRUG|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
47961670|NCT00515411|DRUG|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
47961671|NCT00515411|DRUG|Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
48309351|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
47961672|NCT00543010|DRUG|MK0767|
48309352|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
48309353|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
48309354|NCT00551824|DRUG|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
48309355|NCT01072097|DRUG|Atorvastatin|Atorvastatin 20mg/day for 6 months
48309356|NCT01072097|DRUG|Placebo|Placebo for 6 months
48309357|NCT03218254|DRUG|Methylphenidate|Titration of MTP for treatment of fatigue
48309358|NCT03218254|DRUG|Placebo|Placebo
48113231|NCT02999477|DRUG|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
48642616|NCT05296798|DRUG|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
47961673|NCT05745493|BEHAVIORAL|Social Engage Coaching (S-ENG)|Social Engage Coaching (S-ENG) involves 10 individual coaching sessions focused on increasing social connection. S-ENG is a stepped, modular intervention that was developed to allow personalization to a given subject's needs, preferences, and individualized barriers to social connection. Early sessions include psychoeducation on the importance of social connection; a values clarification exercise on aspects of connection most important to subjects; and assessment of current social networks and social activities. Together, the coach and subject create a conceptualization of reasons for loneliness and identify personalized activities most likely to impact loneliness. The primary activity is 'action planning,' which involves selecting a social goal for the week, brainstorming ways to meet the goal, identifying barriers, and selecting specific actions to take before the next session. The first 8 sessions are offered weekly and the final two are monthly booster sessions.
47961674|NCT03804697|DRUG|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
47961675|NCT02548416|PROCEDURE|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI\>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
47961676|NCT02548416|PROCEDURE|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
47961677|NCT06557746|OTHER|Coca-Cola|100 ml Coca-Cola every 30 minutes during the operation
47961678|NCT06557746|OTHER|Supplemental oxygen|Continuous supply of oxygen (2 L/min) during the operation
47961679|NCT04862819|DRUG|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
47961680|NCT04862819|PROCEDURE|scaling root planing|In the second group, on one side of the dental arch srp will be performed
47961681|NCT03158025|DRUG|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
48113232|NCT02999477|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
48113233|NCT02999477|PROCEDURE|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
48113234|NCT00551876|DRUG|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
48113235|NCT00551876|DRUG|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
48113236|NCT02430740|DRUG|recFSH|
48113237|NCT02304952|PROCEDURE|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
48113238|NCT02304952|OTHER|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
48113239|NCT02304952|DEVICE|Arthrocare Topaz MicroDebrider|
48113240|NCT03281694|DRUG|Placebo|placebo skin patch and placebo oral solution
48483058|NCT00836147|DRUG|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
48113241|NCT03281694|DRUG|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
48113242|NCT03281694|DRUG|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
48483059|NCT04788446|BEHAVIORAL|Mini-flipped Game-based Learning|The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
48483060|NCT04788446|BEHAVIORAL|Balanced diet|Given a balanced diet nutrition health education manual for the aged.
48483061|NCT06210802|OTHER|Korean version of Defense and Veterans Pain Rating Scale|Defense and Veterans Pain Rating Scale translated into Korean
48483062|NCT00120276|DEVICE|Less invasive mitral valve repair|
48483063|NCT02092883|DRUG|ACTH|PK PET scan before and after ACTH treatment
48483064|NCT05420779|DRUG|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
48483065|NCT05420779|DRUG|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
48642617|NCT05296798|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
48642618|NCT05296798|DRUG|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
47961682|NCT03158025|DRUG|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
47961683|NCT03158025|DRUG|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
47961684|NCT03158025|DRUG|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
47961685|NCT03158025|DRUG|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
47961686|NCT03158025|DRUG|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
47961687|NCT00394823|BEHAVIORAL|Set of supportive tools/measures vs. standard care|
47961688|NCT00818597|DEVICE|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
47961689|NCT05223933|BEHAVIORAL|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
47961690|NCT05799586|BEHAVIORAL|Traditional Chinese Medicine health preservation group|The traditional Chinese medicine health preservation intervention for depression was developed based on a previous systematic review and meta-analysis of Traditional Chinese medicine based integrated health interventions for depression, traditional Chinese medicine health preservation textbooks, clinical practice guidelines related to traditional Chinese medicine health preservation and traditional Chinese medicine treatment for depression. The content and structure of traditional Chinese medicine health preservation for depression was achieved among Hong Kong traditional Chinese medicine experts via a Delphi study.
47961691|NCT05799586|BEHAVIORAL|Waitlist control group|Usual care
47961692|NCT02378961|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
47961693|NCT02378961|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
47961694|NCT05292508|DIAGNOSTIC_TEST|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
47961695|NCT00837057|PROCEDURE|crrt|early CRRT (35 ml/kg/h)\& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
47961696|NCT02334358|DEVICE|YVOIRE Classic s|
47961697|NCT06114225|COMBINATION_PRODUCT|metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy|participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
47961698|NCT06134622|DRUG|Intravenous thrombolysis plus tirofiban|Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
47961699|NCT06134622|DRUG|Intravenous thrombolysis plus placebo|placebo (saline)
47961700|NCT05647460|PROCEDURE|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~* Preoperative CT.~* Virtual reduction of broken segments on software.~* Gain occlusion.~* Design surgical screw holes locating guide.~* Design the custom-made plates.~* Print the screw holes locating guide and the custom-made plate.~* Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
47961701|NCT05647460|PROCEDURE|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
48113243|NCT03281694|DRUG|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
48113244|NCT05534984|DRUG|Tecovirimat Oral Capsule|"Drug: Tecovirimat Oral capsules~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
48113245|NCT05534984|DRUG|Placebo|"Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days"
48113246|NCT05534984|DRUG|Tecovirimat Oral Capsule (Open Label)|"* Participants weighing 4 to \<6kg and \>7 days old - Tecovirimat 50mg every 12 hours for 14 days~* Participants weighing 2.5 to \<4kg and \>7 days to \<4 weeks old - Tecovirimat 20 mg every 12 hours for 14 days~* Participants weighing 4 to \<6kg and ≤7 days old - Tecovirimat 50mg every 24 hours for 14 days~* Participants weighing 2.5 to \<4 kg and ≤7 days old - Tecovirimat 20mg every 24 hours for 14 days~* Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days~* Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days~* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg (2 capsules) every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days"
48113247|NCT05141149|DRUG|PBP1510 (400mg/16mL)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
48113248|NCT05141149|DRUG|Gemcitabine (1000 mg/m^2)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
48113249|NCT03511651|PROCEDURE|PEEP|Two PEEP levels will be used during mechanical ventilation.
48642619|NCT01944761|BEHAVIORAL|Exercise Program|"Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week."
47961702|NCT03875651|DEVICE|SYNERGY 4.50 mm and 5.0 mm Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
47961703|NCT05887414|OTHER|Baseline|Measure Ottawa Decisional Regret at baseline when patients receive a diagnosis of appendicitis.
47961704|NCT05887414|OTHER|30 Day Follow Up|Measure Ottawa Decisional Regret after 30 days.
47961705|NCT00951223|DRUG|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
48266681|NCT03416283|BEHAVIORAL|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
48309359|NCT04355312|DIAGNOSTIC_TEST|Use of Indocyanine Green in laparoscopic ovarian cystectomy|"During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH \& Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized."
48309360|NCT01830361|DRUG|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
48309361|NCT04398719|RADIATION|[11C]PBR28|The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
48309362|NCT04398719|DRUG|Low-dose lipopolysaccharide|Subjects will receive intravenous lipopolysaccharide.
48309363|NCT04398719|DRUG|Intradermal Capsaicin|A small dose of capsaicin will be administered by intradermal injection.
48309364|NCT02353637|DIETARY_SUPPLEMENT|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
48309365|NCT06316791|BIOLOGICAL|single dose of CNCT19|Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
48309366|NCT00431847|PROCEDURE|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
48309367|NCT00431847|PROCEDURE|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
48642620|NCT05117125|DIAGNOSTIC_TEST|Heparin-binding protein|Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
47961706|NCT02516046|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
47961707|NCT02516046|PROCEDURE|PET Scan|positron emission tomography (PET) scan
47961708|NCT03582189|OTHER|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
47961709|NCT06437496|DRUG|68Ga-AAZTA-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
48113250|NCT04977856|BEHAVIORAL|Behavioral activation (BA)|The main goal of the BA is to increase engagement in values-based activities and decrease avoidant behaviors that serve to maintain depression. The adolescent will learn about depression, how behavioral activations works, monitor their own activities, plan and do more values-based activities and deal with obstacles to getting in touch with positive reinforcement, such as avoidance behaviors.
48113251|NCT04977856|OTHER|Regular care within primary or secondary mental health care for children|Regular care (supportive therapy, waitlist, psychological treatments, drugs, or a combination of different interventions)
48309368|NCT04345991|DRUG|Transfusion of COVID-19 convalescent plasma|Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
48113252|NCT04762875|BIOLOGICAL|MGTA-145|MGTA-145 will be be administered as an IV infusion
48113253|NCT04762875|BIOLOGICAL|Plerixafor|240 µg/kg subcutaneously
48309369|NCT06355557|OTHER|AI enabled ultrasound system for self-directed learning|use of the AI enabled ultrasound system for self-directed learning
48309370|NCT06355557|OTHER|Simulator for self-directed learning|use of the simulator for self-directed learning
48113254|NCT05819775|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
48113255|NCT04857502|DRUG|99mTc-based PSMA Imaging and Surgery Agent|Given via IV injection
48113256|NCT04857502|PROCEDURE|Computed Tomography|Undergo SPECT/CT
48113257|NCT04857502|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
48309371|NCT06355557|OTHER|traditional with human instructors|Medical students who are randomised to this arm
48309372|NCT05808348|OTHER|Scales and questionnaires|"We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively."
48309373|NCT01593683|BEHAVIORAL|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
48309374|NCT00029848|DRUG|Rimonabant (SR141716)|
48309375|NCT01542476|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
48309376|NCT02249286|BEHAVIORAL|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
48309377|NCT02249286|OTHER|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
48309378|NCT01835496|DRUG|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
48309379|NCT00187837|PROCEDURE|SW|Stepwise removal of carious tissue in 2 stages
48642621|NCT05117125|DIAGNOSTIC_TEST|Interleukin-26|Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
48642622|NCT05117125|DIAGNOSTIC_TEST|Microbiome|Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
48113258|NCT06113146|OTHER|ultra-processed slow eating rate diet|Consuming ultra-processed slow eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a hard texture that require a long chewing duration before a bite of food can be swallowed.
48113259|NCT06113146|OTHER|Ultra-processed fast eating rate diet|Consuming ultra-processed fast eating rate meals (served ad libitum) and snacks. Eating rate is manipulated through food texture, for example foods with a soft texture that require little chewing before a bite of food can be swallowed.
48113260|NCT06513455|DRUG|Irinotecan liposome（40mg/m2）|irinotecan Liposome was administered 40mg/m2, D1，iv. q2w
48113261|NCT06513455|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered 125mg/m2 D1、D8、D15，iv. q4w
48642623|NCT05117125|DIAGNOSTIC_TEST|Bacterial transcriptome|Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
48113262|NCT06513455|DRUG|Gemcitabine|gemcitabine was administered 1000 mg D1、D8、D15，iv. q4w
48309380|NCT00187837|PROCEDURE|DCE|one complete excavation
48309381|NCT05768620|OTHER|CAVE|The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
48113263|NCT06513455|DRUG|Irinotecan Liposome（60mg/m2）|irinotecan Liposome was administered 60mg/m2, D1，iv. q2w
48113264|NCT03009864|DRUG|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
48113265|NCT03009864|DRUG|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
48113266|NCT03394365|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
48113267|NCT05707871|DRUG|SPECTRUM cigarettes|SPECTRUM cigarettes have varying amount of nicotine content
48113268|NCT05707871|OTHER|usual brand of Cigarettes|Usual Brand of Cigarettes
48113269|NCT05571722|DRUG|Vancomycin Injection|Patients receive a dose of 30 mg/kg of vancomycin (2 hours infusion) starting 2.5 hours before the scheduled time of surgical incision as defined in the French guidelines.
48113270|NCT05571722|DRUG|Linezolid Injection|Patients receive a dose of 1200 mg of linezolid (30 minutes infusion) 30 minutes before the scheduled time of surgical incision.
48309382|NCT05768620|OTHER|TAU|This is the usual care used to train visuospatial processes
48309383|NCT02408796|DRUG|OTO-201|
48309384|NCT03099369|BEHAVIORAL|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
48309385|NCT03099369|BEHAVIORAL|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
48309386|NCT03099369|OTHER|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
48309387|NCT04076722|BEHAVIORAL|Stress reactivity stimuli|An evaluated speech task delivered to participants after baseline testing.
48483066|NCT05420779|DRUG|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
48483067|NCT01790113|DEVICE|Univers™|Control
48483068|NCT01790113|DEVICE|Eclipse™ Total Shoulder Replacement|Investigational
48483069|NCT04713514|DRUG|OSE2101|subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
48483070|NCT04713514|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
48483071|NCT00604903|DEVICE|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
48642624|NCT05117125|DIAGNOSTIC_TEST|Proteome|Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
48309388|NCT00676273|DEVICE|TVT-Obturator (TVT-O)|sub urethral sling
48642625|NCT00558207|DRUG|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
48309389|NCT00676273|DEVICE|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
48309390|NCT04097756|DRUG|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
48309391|NCT02196038|BEHAVIORAL|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
48309392|NCT02196038|BEHAVIORAL|Attention Control|Usual care with bi-weekly contact from study staff
48309393|NCT00237796|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
48309394|NCT00237796|BEHAVIORAL|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
48309395|NCT02249234|DRUG|Botox|
48309396|NCT02249234|DRUG|Placebo|
48309397|NCT01839292|DEVICE|uncovered D-type stent insertion|
48309398|NCT01839292|DEVICE|double-layered ComVi stent insertion|
48483072|NCT03261479|DIAGNOSTIC_TEST|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
48483073|NCT05365659|DRUG|IKS03|IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
48483074|NCT00227266|DRUG|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
48483075|NCT00227266|DRUG|Placebo|
48483076|NCT03914118|DRUG|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
48483077|NCT03914118|DRUG|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
48483078|NCT03914118|DRUG|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
48483079|NCT02556892|DRUG|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
48483080|NCT04233879|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
48483081|NCT04233879|DRUG|BIC/FTC/TAF|BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.
48483082|NCT04233879|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
48483083|NCT04233879|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL taken by mouth.
48483084|NCT04815694|RADIATION|RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT|The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
48483085|NCT00909584|DRUG|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
48483086|NCT01674439|PROCEDURE|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
48483087|NCT01674439|PROCEDURE|Without supplementation of ADRC|Standard fat graft preparation
48642626|NCT00558207|DRUG|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
48309399|NCT05722899|OTHER|Football training|10-week progressive football training with small-sided games, 2x/week, 45min-1h sessions
48309400|NCT01585961|DEVICE|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
48309401|NCT03387904|DRUG|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
48309402|NCT03387904|DRUG|Irinotecan|Irinotecan Day 1,8 ivgtt
48309403|NCT01380106|DRUG|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
48309404|NCT01380106|DRUG|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
48309405|NCT02020031|DRUG|Vancomycin|
48309406|NCT00398151|DRUG|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
48309407|NCT01419665|BIOLOGICAL|GP2013|Type: Biological/Vaccine
48309408|NCT01419665|BIOLOGICAL|rituximab|Type: Biological/Vaccine
48309409|NCT03272854|OTHER|No intervention performed, the study is observational|
48309410|NCT01514188|DRUG|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
48309411|NCT01514188|DRUG|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
48309412|NCT02458690|BEHAVIORAL|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
48309413|NCT02458690|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
48309414|NCT02458690|DRUG|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
48309415|NCT02458690|OTHER|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
48309416|NCT02713230|DRUG|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
48309417|NCT02713230|DRUG|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
48309418|NCT02713230|DRUG|Placebo|20 mL normal saline as single-injection
48309419|NCT01248624|BEHAVIORAL|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
48309420|NCT03252496|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
48309421|NCT03252496|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
48309422|NCT03252496|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
48309423|NCT03252496|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
48309424|NCT03252496|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
48309425|NCT03252496|DRUG|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
48309426|NCT03252496|DRUG|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
48309427|NCT03252496|DRUG|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
48309428|NCT03252496|DRUG|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
48309429|NCT03252496|DRUG|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
48309430|NCT03252496|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
48309431|NCT03252496|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
48309432|NCT01986569|DRUG|[18F]fluoroestradiol (FES)|\[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
48309433|NCT02191787|DRUG|Seresis®|
48309434|NCT02191787|DRUG|Placebo|
48309435|NCT04423926|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
48309436|NCT04423926|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
48309437|NCT04423926|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
48309438|NCT04423926|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
48309439|NCT04423926|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
47961710|NCT06437496|DRUG|68Ga-PSMA-11//68Ga-PSMA-617|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
48113271|NCT06676124|DIETARY_SUPPLEMENT|Piper crocatum Extract Cookie|Participants in the intervention group will receive cookies containing a standardized 10% ethyl acetate extract of Piper crocatum, known for its antioxidant and anti-inflammatory properties. These cookies will be consumed twice daily for 12 weeks. The intervention aims to assess the effects of Piper crocatum on renal biomarkers, such as MMP-9 and NGAL, in diabetic patients with early renal dysfunction
48113272|NCT06676124|DIETARY_SUPPLEMENT|Placebo Comparator|Participants in the placebo group will receive cookies that are identical in appearance, taste, and texture to the active Piper crocatum cookies but do not contain the Piper crocatum extract. These cookies will be consumed twice daily for 12 weeks, serving as a control to assess the effects of the active intervention on renal biomarkers associated with diabetic nephropathy.
48113273|NCT01977638|DRUG|CXD101|Capsules, administered orally
48113274|NCT06583460|OTHER|Early and systematic oncosexological supporting care|"Each patient included in the study will be cared by an anthropologist and a sexologist.~This therapeutic support care will be based on :~* 2 qualitative semi-directive interviews (Baseline and M18),~* 2 individual consultations with questionnaires (Baseline and M18).~The qualitative semi-structured interviews will be conducted with the anthropologist, and the individual consultations with the sexologist.~At the end of the first oncosexology consultation, patients will be given the opportunity to decide whether or not to accept further systematic oncosexology support care, which will be based on :~* 3 individual and/or couple consultations,~* 3 group workshops.~Patients are under no obligation to accept this additional oncosexology support care."
48113275|NCT02173444|OTHER|Blood test|
48642627|NCT06496178|DRUG|Petosemtamab|MCLA-158
48642628|NCT06496178|DRUG|Investigator's Choice|Cetuximab
47961711|NCT03372044|DRUG|PF-06865571 Immediate release suspension|Suspension
47961712|NCT03372044|DRUG|PF-06865571 Slow release MR tablets|Modified release tablets
47961713|NCT03372044|DRUG|PF-06865571 Fast release MR tablets|Modified release tablets
47961714|NCT03372044|DRUG|PF-06865571 Immediate release tablets|Immediate release tablets
47961715|NCT03789474|DEVICE|HUNTLEIGH FLOWTRON ACS900|
47961716|NCT01655914|DRUG|Flumazenil|
47961717|NCT03159624|OTHER|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
47961718|NCT03159624|OTHER|Doyle silastic sheet|Doyle silastic sheet
47961719|NCT01005108|DRUG|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
47961720|NCT02654834|OTHER|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
47961721|NCT04157491|DRUG|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
47961722|NCT00366132|DEVICE|Extracorporeal Shockwaves|
47961723|NCT00353795|PROCEDURE|MR Imaging of the Coronary Arteries|
47961724|NCT02571075|OTHER|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
47961725|NCT04017078|OTHER|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
47961726|NCT02435446|DEVICE|Cone-beam computed tomography|Cone-beam computed tomography
47961727|NCT04179708|OTHER|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
48113276|NCT01373346|PROCEDURE|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
48113277|NCT03105219|DRUG|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
48309440|NCT05868876|DRUG|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
48642629|NCT06496178|DRUG|Investigator's Choice|Methotrexate
48642630|NCT06496178|DRUG|Investigator's Choice|Docetaxel
48642631|NCT05490875|PROCEDURE|Carotid ultrasound|Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
48309441|NCT06342726|DEVICE|PAX Warming Blanket|Electric resistive active external warming blanket
48642632|NCT05490875|OTHER|Blood draw|This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
48642633|NCT05490875|OTHER|Survey|Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
48642634|NCT06272058|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
48309442|NCT06342726|DEVICE|Passive insulation|3-layered wrapping model
48309443|NCT03817567|DRUG|recombinant anti-EGFR monoclonal antibody|Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
48309444|NCT00120120|DRUG|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
48309445|NCT04686006|DRUG|Potassium Iodide|
48309446|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
48309447|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
48309448|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
48309449|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
48309450|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
48309451|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
48309452|NCT04799405|DEVICE|tDCS|"Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~1. First taper phase: three 30 minutes tDCS sessions applied every other day;~2. Second taper phase: three 30 minutes tDCS sessions applied one every third day;~3. Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day."
48309453|NCT00943319|DRUG|Busulfan|Daily intravenous dosing to target AVC
48309454|NCT00943319|DRUG|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
48309455|NCT00943319|DRUG|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
48309456|NCT00943319|PROCEDURE|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
48309457|NCT05742464|BEHAVIORAL|RUBI|"RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials."
47961728|NCT04179708|OTHER|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
47961729|NCT03268993|DIETARY_SUPPLEMENT|Avmacol|Avmacol is a dietary supplement available over the counter
48309458|NCT00837512|DEVICE|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
48309459|NCT00837512|DEVICE|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
48309460|NCT02540252|OTHER|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
48309461|NCT04415489|DEVICE|Office hysteroscopy|Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
48309462|NCT02954003|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
48309463|NCT01762293|DRUG|Famitinib|Famitinib 25 mg p.o. qd
48642635|NCT06605534|BEHAVIORAL|LungTalk|Tailored lung screening intervention
47961730|NCT05544734|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
47961731|NCT05544734|DRUG|Acetaminophen 1000mg|1000 mg tablet
47961732|NCT05544734|DRUG|Ibuprofen 400 mg|400 mg tablet
47961733|NCT03572972|DRUG|Apixaban|Treatment for NVAF patients
47961734|NCT03572972|DRUG|Dabigatran|Treatment for NVAF patients
47961735|NCT03572972|DRUG|Rivaroxaban|Treatment for NVAF patients
47961736|NCT03572972|DRUG|warfarin|Treatment for NVAF patients
47961737|NCT03572972|DRUG|Antiplatelets|Treatment for NVAF patients
47961738|NCT00237094|BEHAVIORAL|Nurse Practitioner led multidisciplinary team approach|
48309464|NCT01762293|OTHER|placebo|p.o. qd
48309465|NCT05111496|RADIATION|Gafchromic film|Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
47961739|NCT00005073|DRUG|zoledronic acid|
48309466|NCT03807739|DRUG|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
48309467|NCT03807739|DRUG|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
48309468|NCT03807739|DRUG|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
48309469|NCT02472548|BIOLOGICAL|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
48309470|NCT02472548|BIOLOGICAL|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
48309471|NCT02472548|OTHER|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
48309472|NCT02711761|DEVICE|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
48309473|NCT05808998|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
47961740|NCT03196726|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
48309474|NCT06018467|DRUG|Dasatinib 100 Mg Oral Tablet|"Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb"
48309475|NCT06018467|DIETARY_SUPPLEMENT|Quercetin 1.250 mg (oral)|five 200mg Quercetin Phytosome capsules, from Thorne
48309476|NCT06018467|DIETARY_SUPPLEMENT|Nicotinamide Riboside 1g (oral)|four 250mg Nicotinamide Riboside Capsules, from Elysium Health
48309477|NCT00012337|DRUG|gefitinib|
48309478|NCT03611933|OTHER|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
48309479|NCT02580487|PROCEDURE|appendicectomy|Appendix was removed either laparoscopically or open surgery
48309480|NCT05445622|OTHER|learning spinal mobilization with a force sensor|Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
48309481|NCT01833767|DRUG|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
48309482|NCT04951648|DRUG|Almonertinib|Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
48309483|NCT04951648|DRUG|chemotherapy|Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
48309484|NCT00170248|DEVICE|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
48309485|NCT00399984|BEHAVIORAL|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
48309486|NCT04586894|DIAGNOSTIC_TEST|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
48309487|NCT04586894|DEVICE|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
48309488|NCT04586894|OTHER|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
48483088|NCT06090682|DEVICE|Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)|We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
48483089|NCT01552967|DRUG|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
48483090|NCT01797926|DRUG|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
48483091|NCT01797926|DRUG|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
47961741|NCT03196726|BEHAVIORAL|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
47961742|NCT06233617|DRUG|0.9% Sodium Chloride Injection|biliteral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
47961743|NCT06233617|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|biliteral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
47961744|NCT06233617|DRUG|Dexmedetomidine injection|biliteral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
47961745|NCT01099553|OTHER|Educational video|Instructions to view an educational video about preparing for a colonoscopy
47961746|NCT01099553|OTHER|Written instructions|Written instructions on preparing for a colonoscopy
47961747|NCT05747430|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
47961748|NCT05747430|DRUG|Providone-Iodine|5% Providone-Iodine
48309489|NCT04980846|OTHER|Driving under the influence of alcohol with a driving simulator|"Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected."
48113278|NCT03105219|OTHER|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
48113279|NCT03229044|GENETIC|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
47961749|NCT04383262|DRUG|Fosamprenavir Calcium|A repurposing approach, prospective, placebo-controlled clinical trial of FOS-SA (used at 1,400 mg fosamprenavir calcium and 24.5 mg sodium alginate, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI \> 13, RFS \> 7 and MII-pH confirmed laryngeal reflux event\[s\]).
48309490|NCT01989546|DRUG|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
48309491|NCT02473133|RADIATION|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
48309492|NCT02473133|RADIATION|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
48309493|NCT03127215|DRUG|Olaparib|Olaparib 150 mg tablet
47961750|NCT04383262|OTHER|Placebo|Sodium Alginate: 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate morning and night.
48113280|NCT02055794|PROCEDURE|Suturing of the perineal skin|
48113281|NCT02055794|PROCEDURE|Closing perineal skin with surgical glue|
48309494|NCT03127215|DRUG|Physician's choice|treatment according to current guidelines
48309495|NCT03127215|DRUG|Trabectedin|Trabectedin 1.1mg/m² infusional solution
48309496|NCT05110183|DEVICE|electrical stimulation|A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.
48309497|NCT05110183|OTHER|optical stimulation|Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.
48309498|NCT05110183|OTHER|combined optical and electrical stimulation|A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.
48309499|NCT04158024|OTHER|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
48309500|NCT01204840|DRUG|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
48113282|NCT02055794|PROCEDURE|No suturing of the perineal skin|
48113283|NCT01980069|DRUG|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
48113284|NCT01980069|DRUG|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
48113285|NCT00362869|DRUG|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
48113286|NCT00362869|DRUG|Placebo|Sodium bicarbonate solution
47961751|NCT04417361|DRUG|Galcanezumab Prefilled Syringe|Galcanezumab will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
48309501|NCT01204840|DRUG|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
48309502|NCT02902016|DRUG|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
48309503|NCT01397071|OTHER|Avocado|Fresh Avocado
48309504|NCT02361762|BEHAVIORAL|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
48309505|NCT02437448|OTHER|No intervention|
48309506|NCT01580592|DRUG|Omalizumab|150mg, s.c., every 4 weeks
48309507|NCT01580592|DRUG|Omalizumab|300mg, s.c., every 4 weeks
48309508|NCT01580592|DRUG|Placebo|Placebo, s.c., every 4 weeks
48309509|NCT00149656|DIETARY_SUPPLEMENT|Multivitamins|dietary supplement of multivitamins
48309510|NCT00149656|DIETARY_SUPPLEMENT|Selenium|dietary supplement of selenium only
48309511|NCT00149656|OTHER|Placebo|placebo pill
48309512|NCT03517748|DEVICE|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
48309513|NCT03517748|DEVICE|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
47961752|NCT04417361|DRUG|Placebo|Placebo will be supplied in preloaded syringes, each with a dose of 120 mg. Participants will first receive the first month's supply (240 mg) at study visit 2, and then will receive a two month supply at study visit 3. So, at study visit 2 and 3, each participant will get two pre-filled syringes.
47961753|NCT03340688|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
48309514|NCT05807334|OTHER|DASH eating plan with eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.
48309515|NCT05807334|OTHER|DASH eating plan without eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
48309516|NCT01840020|PROCEDURE|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
48309517|NCT01840020|PROCEDURE|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
48309518|NCT05624684|DIAGNOSTIC_TEST|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
48309519|NCT01784406|BEHAVIORAL|Autonomy supportive counselling|
47961754|NCT00036517|DRUG|PHY906|
47961755|NCT03133169|DIAGNOSTIC_TEST|blood sample|blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
47961756|NCT03133169|DIAGNOSTIC_TEST|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
48309520|NCT00541086|DRUG|anastrozole|1 mg per day, orally
48309521|NCT00541086|DRUG|exemestane|25 mg per day, orally
48309522|NCT00541086|DRUG|letrozole|2.5 mg per day, orally
48309523|NCT00541086|DRUG|tamoxifen citrate|20 mg per day, orally
48309524|NCT00788515|DRUG|Volinanserin (M100907)|2 mg tablets QD
48309525|NCT00788515|DRUG|Lormetazepam|1 mg tablets (overencapsulated) QD
48309526|NCT05255055|OTHER|Physical Therapy|A manual therapy protocol and a therapeutic exercise protocol
48309527|NCT04236206|BEHAVIORAL|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~* The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~* The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~* Patients will be encouraged to send messages/call the researcher for any queries encountered."
48309528|NCT00455247|DRUG|Glutamine|
48309529|NCT00290576|DIETARY_SUPPLEMENT|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
48309530|NCT05645029|OTHER|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
48309531|NCT05645029|OTHER|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
48309532|NCT05645029|OTHER|glass ionomer|glass ionomer will be used without any additives
48309533|NCT03792776|OTHER|cuff inflation with air|Endotracheal tube cuff inflation with air
48309534|NCT03792776|DRUG|cuff inflation with lidocaine 1%|Endotracheal tube cuff inflation with lidocaine 1%
48309535|NCT03792776|DRUG|cuff inflation with lidocaine 2%|Endotracheal tube cuff inflation with lidocaine 2%
48309536|NCT03792776|OTHER|Induction of anesthesia|The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
48309537|NCT03792776|OTHER|Maintenance of anesthesia|Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
48309538|NCT03792776|OTHER|Endotracheal intubation|The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept \< or = 20 centimeter of water (cmH2O).
48309539|NCT03792776|OTHER|Systematic post-operative analgesia|All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
48309540|NCT00845923|DRUG|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
48309541|NCT00169494|BIOLOGICAL|HPV-16/18 L1/AS04|
48309542|NCT02531035|DRUG|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
48309543|NCT02531035|DRUG|Placebo|Placebo, once daily, before the first meal of the day
48309544|NCT00587418|DIETARY_SUPPLEMENT|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
48309545|NCT00587418|DIETARY_SUPPLEMENT|Placebo|Placebo powder 9.2g bid for 7 days
47961757|NCT01430000|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
47961758|NCT04224480|DRUG|Pembrolizumab|200mg of intravenous infusion every 3 weeks
47961759|NCT00603174|DEVICE|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
48113287|NCT00362869|BIOLOGICAL|Enteroaggregative E. coli (EAEC)|Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution
48309546|NCT05006898|COMBINATION_PRODUCT|PBO to control presbyopia symptoms|Low dose PBO to control presbyopia symptoms
48309547|NCT00940342|DRUG|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
48309548|NCT00940342|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly for four weeks
48309549|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
48309550|NCT03691610|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
48309551|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
48309552|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
48309553|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
48309554|NCT03691610|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
47961760|NCT02352974|DRUG|GAD-Alum|
47961761|NCT02352974|DRUG|Vitamin D|
47961762|NCT05032664|OTHER|Home-based aromatherapy programme|1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.
47961763|NCT05032664|OTHER|Control Group|Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
47961764|NCT05693389|BEHAVIORAL|acceptance and commitment therapy|ACT attempts to encourage psychological flexibility, acceptance of one's own experiences, and dedication to behaviours that are consistent with one's own values. ACT therapies focus on six key processes to improve psychological flexibility: engagement with the present moment, acceptance, defusion, self as context, values clarification, and committed action.
47961765|NCT05693389|OTHER|routine hospital care|the patients with bipolar disorders who receive routine pharmacological treatment
48113288|NCT00984737|DRUG|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
48309555|NCT03691610|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
48309556|NCT03691610|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
48309557|NCT03691610|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
48309558|NCT03691610|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
48309559|NCT03691610|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
48309560|NCT01552928|DRUG|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
48309561|NCT01552928|DRUG|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
48309562|NCT01552928|DRUG|Moxifloxacin|400 mg Moxifloxacin single oral dose
48309563|NCT01552928|DRUG|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
48309564|NCT04408859|DRUG|Neoadjuvant Chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
48309565|NCT00002250|DRUG|CD4-IgG|
48309566|NCT03782818|DRUG|Olaparib|Olaparib up to 300 mg BID for 24 weeks
48309567|NCT01863849|BIOLOGICAL|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
48309568|NCT01004783|GENETIC|DNA methylation analysis|
48309569|NCT01004783|GENETIC|gene expression analysis|
48309570|NCT01004783|GENETIC|loss of heterozygosity analysis|
48309571|NCT01004783|GENETIC|microarray analysis|
48309572|NCT01004783|GENETIC|mutation analysis|
48309573|NCT01004783|GENETIC|polymerase chain reaction|
48309574|NCT01004783|GENETIC|reverse transcriptase-polymerase chain reaction|
48309575|NCT01004783|OTHER|laboratory biomarker analysis|
48309576|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler|
48483092|NCT01797926|DRUG|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
48483093|NCT01797926|DRUG|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
48483094|NCT05985382|OTHER|Lower Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
48483095|NCT05985382|OTHER|Upper Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
48483096|NCT01981499|DRUG|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
48483097|NCT01981499|DRUG|Placebo|Placebo tablets
48483098|NCT01981499|DRUG|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
48113289|NCT04551794|BEHAVIORAL|Selfapy with therapeutic guidance|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to talk about personal experiences with a therapeutic guide.
48113290|NCT04551794|BEHAVIORAL|Selfapy with additional peer support|The program consists of 9 modules with many interactional exercises. Themes that are addressed in the online-program are for example self-esteem, coping with relapse, establishing a structure for daily life and attention and breathing exercises as well as depression-specific topics such as negative thoughts management and arranging and maintaining social contacts. In addition, participants were able to participate in exchange with peers via an internal closed forum.
48309577|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
48309578|NCT02162485|DRUG|Seretide Diskus|
48309579|NCT02162485|DRUG|Seretide Diskus with charcoal|
48309580|NCT04106427|DEVICE|continuous theta burst stimulation (cTBS)|"cTBS stimulation of 17 mins over right inferior parietal lobe (IPL) with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 100% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
48309581|NCT04106427|DEVICE|placebo cTBS|"Placebo stimulation of 17 mins over right IPL with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 0% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
48309582|NCT04106427|BEHAVIORAL|social cognitive remediation therapy (SCRT)|16 sessions of group SCRT will be scheduled within 8 weeks, comprising 6-8 participants per group with 2 therapists. Duration of group sessions will be 60-90 mins. The content will follow the manual of SCRT and we will add a short intervention to practice the use of co-speech gestures at each session
48309583|NCT04106427|BEHAVIORAL|Sham group therapy|Group activities in closed groups of 6 participants. Schedule of two sessions per week for 8 weeks. Two therapists are guiding different leisure activities, e.g. group walks, going to museums/movies, games.
48309584|NCT01881594|PROCEDURE|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
48309585|NCT04598581|RADIATION|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
48309586|NCT04598581|OTHER|Sham irradiation|Sham irradiation
48309587|NCT00236639|DRUG|topiramate|
48309588|NCT03916250|DRUG|PF-06700841 cream|PF-06700841 will be applied topically
48309589|NCT03916250|DRUG|White petrolatum|White petrolatum will be applied topically
48309590|NCT05110040|DRUG|immunosuppressive agent|patients with TAO recruited in this study will administrated with immunosuppressive agent per day
48309591|NCT05478343|BIOLOGICAL|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
48309592|NCT03355599|OTHER|3d camera|3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
48309593|NCT04673526|PROCEDURE|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
48309594|NCT04673526|PROCEDURE|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
48309595|NCT00100633|DRUG|CpG7909 oligodeoxynucleotides (ODN)|
48309596|NCT00100633|BIOLOGICAL|Hepatitis B virus vaccine|
48309597|NCT04183205|DIAGNOSTIC_TEST|LDAEP|This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
48309598|NCT04183205|DRUG|Placebo|placebo pills of the same size, color and taste as the active drug will be administered
48483099|NCT01981499|DRUG|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
48483100|NCT01981499|DRUG|10 mg cetirizine|Single 10 mg dose of cetirizine
48483101|NCT01981499|DRUG|Placebo|Placebo tablets
48483102|NCT05410054|OTHER|no intervention|observational research
48483103|NCT00233987|DRUG|carmustine|150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.
48483104|NCT00233987|DRUG|cyclophosphamide|100 mg/kg IV 2 days before transplant.
48113291|NCT03653013|BEHAVIORAL|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
48309599|NCT04183205|DRUG|sertraline|Sertraline is an FDA approved SSRI for treatment of PTSD.
48309600|NCT03992768|DEVICE|Hamamatsu NanoZoomer S360MD Digital Slide Scanner System|Detection of pathology features using whole slide imaging
48309601|NCT05228444|BEHAVIORAL|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
48309602|NCT00377143|DRUG|Warfarin Dosing|
48309603|NCT04971395|DRUG|XTMAB-16 2mg/kg|Biological XTMAB-16 IV infusion single dose
48309604|NCT04971395|DRUG|Placebo|Placebo; IV infusion single dose
48309605|NCT04971395|DRUG|XTMAB-16 4mg/kg|Biological XTMAB-16 IV infusion single dose
48309606|NCT03696069|OTHER|Non-Interventional|Non-Interventional
48309607|NCT05228730|BIOLOGICAL|Tozinameran - Standard dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A standard dose will be administered on day 0 of the study.
48309608|NCT05228730|BIOLOGICAL|Tozinameran - fractional dose|Tozinamrean is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2). A fractional dose (15mcg) of the intervention will be administered on day 0 of the study.
48309609|NCT05228730|BIOLOGICAL|Elasomeran - standard dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A single standard dose (50mcg) of the intervention will be administered on day 0 of the study."
48309610|NCT05228730|BIOLOGICAL|Elasomeran - fractional dose|"Elasomeran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2).~A fractional dose (20mcg) of the intervention will be administered on day 0 of the study."
48309611|NCT03679663|DEVICE|Ultrasound|Use of ultrasound to identify pre-puncture site
48309612|NCT04906889|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
48309613|NCT04906889|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
48309614|NCT04906889|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
48309615|NCT02388529|DRUG|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
48309616|NCT02388529|DRUG|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
48309617|NCT02388529|DRUG|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
48266682|NCT06419764|DRUG|Spleen Invigorating and Weight Reducing Decoction|"Composition: Raw Astragalus (Huang Qi) 5g, Cang Zhu 5g, Fructus Aurantii Immaturus (Zhi Shi) 3g, Prepared Rhubarb (Shu Jun) 3g, Red Peony Root (Chi Shao Yao) 3g, Crataegus (Shan Zha) 3g, Tribulus (Bai Jie Li) 2g, Cimicifuga (Sheng Ma) 1g.~Granule form, for oral administration. Take 1 dose daily (2 bags, once in the morning and once in the evening, dissolved in water), for a course of 1 month."
48309618|NCT02388529|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
48309619|NCT03141086|DRUG|LML134|LML134
48309620|NCT03141086|DRUG|Placebo|placebo
48309621|NCT03541512|BEHAVIORAL|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
48309622|NCT03541512|BEHAVIORAL|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
48309623|NCT04353960|DIAGNOSTIC_TEST|electrocardiograph|electrocardiograph monitor during strabismus surgery
48309624|NCT05038163|OTHER|Nutrition Facts|The nutritional information label for each beverage is enlarged.
48309625|NCT05038163|OTHER|Text Warning|The health risks of sugary beverages are communicated to subjects using words/text and simple images.
48309626|NCT05038163|OTHER|Graphic Warning|The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
48309627|NCT04645459|OTHER|low phosphorus meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
48483105|NCT00233987|DRUG|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
48483106|NCT00233987|DRUG|melphalan|150 mg/m\^2 IV 1 day before transplant.
48483107|NCT00233987|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
48483108|NCT00233987|RADIATION|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
48483109|NCT02197026|DRUG|Hylan G-F 20|
48483110|NCT02197026|DRUG|Standard treatment|Standard drug treatment at the discretion of the investigator
48483111|NCT02197026|PROCEDURE|Physiotherapy|
47961766|NCT01876420|DEVICE|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
47961767|NCT01854658|DRUG|GFF MDI (PT003)|GFF MDI administered as two puffs BID
47961768|NCT01854658|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
47961769|NCT01854658|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
47961770|NCT01854658|DRUG|Placebo|
47961771|NCT03481075|OTHER|Biomechanical computer program|Fusion assisting software for image-guided intervention
47961772|NCT00150202|DRUG|pegaptanib sodium|
48642636|NCT06605534|OTHER|Non-tailored lung screening|Non-tailored lung screening. It involves the addition of education to Social Determinants of Health (SDOH) screening and referral with patient navigation. Patients will be identified, and screened for SDOH needs using the UniteUs SDOH screener that is embedded in the Electronic Health Record (EHR), and connected to geographically-tailored resources (as described above under Arm 1). Participants will then be sent a non-tailored lung screening educational brochure via email to review that details lung cancer risk, lung screening facts, benefits, and potential harms. Within 48 hours, the Community Outreach and Engagement (COE) Patient Navigator will contact the patient to answer questions and provide navigation services as described above in Arm 1.
48642637|NCT05324787|DEVICE|Grency venous stent system|Venous stent implantation during the index procedure
48642638|NCT05800002|PROCEDURE|Intravascular ultrasound|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on intravascular ultrasound.
48642639|NCT05800002|PROCEDURE|Angiography|Pretreatment strategy, stent size, stent landing zone and post-dilation balloon size are depended on angiography.
47961773|NCT03747458|DRUG|OPN-375|OPN-375, BID
47961774|NCT05626803|DRUG|Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
47961775|NCT05626803|DRUG|Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
47961776|NCT05626803|DRUG|Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose|50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
48483112|NCT02197026|PROCEDURE|Hydrotherapy|
48483113|NCT02792348|OTHER|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
48483114|NCT03347513|DRUG|triple attack therapy|eradication of H-pylori using triple attack therapy.
48483115|NCT03347513|DRUG|Ferrous(II)-glycine-sulphate complex 567.7 mg capsules|Iron therapy will be given to both groups twice daily for one month.
48483116|NCT00706355|DRUG|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
48483117|NCT00946049|DEVICE|Vicryl Plus|
48483118|NCT00946049|DEVICE|Vicryl|
48483119|NCT02617524|DEVICE|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
48483120|NCT00472797|DRUG|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
48483121|NCT00472797|DRUG|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
48483122|NCT04668976|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
48483123|NCT04668976|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
48483124|NCT04668976|DRUG|Gemcitabine|Please see Detailed Description.
48483125|NCT04668976|DRUG|Oxaliplatin|Please see Detailed Description.
48483126|NCT04668976|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
48483127|NCT04668976|DRUG|Fluorouracil|Please see Detailed Description.
48483128|NCT04668976|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
48483129|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
48483130|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
48483131|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
48483132|NCT02784782|DEVICE|Orthesis|
48483133|NCT02784782|BEHAVIORAL|No orthesis|
48483134|NCT01823276|OTHER|Tyrosine-Containing Bar|
48483135|NCT01823276|OTHER|Placebo Bar|
48642640|NCT06357078|OTHER|Art Therapy|Caregivers in the art therapy group will be given art therapy practices, lasting approximately 45 minutes-1 hour, twice a week for 4 weeks. Visual and handicraft practices (painting work, collage work, mandala work, painting with felt, clay work, painting and storytelling) are done in art therapy activities that will last for 4 weeks, and it is aimed to develop personal and emotional awareness, reduce stress and increase general well-being.
48642641|NCT04550728|COMBINATION_PRODUCT|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
48309628|NCT04645459|OTHER|control meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
48309629|NCT06491953|DRUG|SGLT-2 inhibitors|SGLT-2 inhibitors use or not use； the duration of SGLT-2 inhibitors use
48309630|NCT04575857|DRUG|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
48309631|NCT04575857|DRUG|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
48309632|NCT04242017|DRUG|Triptoreline|Comparison of the duration of ADT (Triptoreline)
48309633|NCT01044173|DEVICE|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
48309634|NCT02844023|BEHAVIORAL|Clinical evaluation|With questionnaire.
48309635|NCT02844023|OTHER|Paraclinical evaluation|Symptom inflammatory, biomarkers.
48309636|NCT02844023|DEVICE|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
48309637|NCT02844023|OTHER|Ophthalmologic examination|
48309638|NCT02844023|BIOLOGICAL|Dosage of biomarkers|Control patients.
48309639|NCT05256277|DRUG|CT101a|cytokine-induced memory-like NK cells
48483136|NCT03758482|OTHER|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
47961777|NCT05626803|DRUG|Placebo|25 subjects will receive matching placebo
47961778|NCT06468566|DIAGNOSTIC_TEST|Ultrasound light scattering imaging equipment|Radiologists use ultrasound light scattering imaging to evaluate the benign and malignant nature of breast nodules
47961779|NCT05679583|RADIATION|Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy|"1. Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~2. Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~3. Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX."
47961780|NCT05282862|PROCEDURE|Horizontal bone augmentation|Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
47961781|NCT03131778|PROCEDURE|Liver resection|liver resections for colorectal liver metastases
47961782|NCT05751265|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
48642642|NCT04550728|COMBINATION_PRODUCT|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
48642643|NCT05212337|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
48642644|NCT05212337|DRUG|Sodium chloride|Subcutaneous injection with NaCl once
47961783|NCT05751265|DRUG|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
47961784|NCT05751265|DRUG|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
47961785|NCT02241629|DRUG|placebo|placebo of levo phencynonate hydrochloride
47961786|NCT02241629|DRUG|levo phencynonate hydrochloride|levo phencynonate hydrochloride
47961787|NCT03964623|DIAGNOSTIC_TEST|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
48309640|NCT01793051|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
48309641|NCT01793051|OTHER|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
48309642|NCT01793051|BEHAVIORAL|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
48309643|NCT03766750|DRUG|LIMA association|1 coated tablet, oral, once a day.
48309644|NCT03766750|DRUG|Tradjenta|1 coated tablet, oral, once a day.
48309645|NCT03766750|DRUG|Forxiga|1 coated tablet, oral, once a day.
48309646|NCT02931695|OTHER|evaluation of QT interval duration|ECG to evaluation of QT interval duration
48309647|NCT02931695|OTHER|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
48309648|NCT02819310|DRUG|BLI400 Laxative|oral laxative
48483137|NCT03068650|BIOLOGICAL|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
48642645|NCT04886063|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
48309649|NCT00256867|DRUG|GSK523338|
48309650|NCT02697461|OTHER|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
47961788|NCT06438458|PROCEDURE|Postural change from supine to sitting|Patients go from supine to sitting position in bed (passive)
48309651|NCT02697461|OTHER|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
48309652|NCT03798444|RADIATION|dual energy X-ray absorptiometry|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis
48309653|NCT03798444|RADIATION|lateral spine imaging from T4 to L4 on X-ray|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio \<0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
48309654|NCT06269341|OTHER|No intervention|No intervention
48309655|NCT00436969|DEVICE|Orthovisc|Orthovisc injection
48309656|NCT00436969|DRUG|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
48309657|NCT05754190|DEVICE|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
48309658|NCT05549141|OTHER|treadmill gait training with gait facilitators|6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
48309659|NCT05549141|OTHER|treadmill gait training not-associated with gait facilitators|6 sessions of 30 minutes each of treadmill gait training
48309660|NCT06092138|DEVICE|Wearable Device|Whether to use wearable devices.
48309661|NCT01688167|BEHAVIORAL|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
48642646|NCT03918408|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
48642647|NCT06343792|DRUG|RLS-0071|RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.
48642648|NCT06055920|DEVICE|FlowTriever System|Mechanical Thrombectomy for pulmonary embolism
48642649|NCT06055920|DRUG|Anticoagulation Agents|"Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot."
48642650|NCT06542484|DRUG|Gefapixant Citrate|An additional treatment of gefapixiant will be performed for 12 weeks.
47961789|NCT06438458|PROCEDURE|Mobilization to a chair|Patients go from the bed to sitting in a chair (active)
47961790|NCT04970355|BIOLOGICAL|Erenumab|Pre-filled syringe; s.c. injection
47961791|NCT04970355|DRUG|Placebo|Pre-filled syring; s.c. injection
48113292|NCT03653013|BEHAVIORAL|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
48113293|NCT00785863|OTHER|Placebo|Placebo IV before placebo infusion
48113294|NCT00785863|DRUG|Remifentanil|placebo IV and remifentanil infusion
48113295|NCT00785863|DRUG|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
48309662|NCT00825383|OTHER|High Fiber and Moderate Fiber Diets|Dietary
48483138|NCT04310306|DEVICE|Thrombectomy using EmboTrap II|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
48483139|NCT05992948|DEVICE|Transanal stapling device|Transanal stapling device used in low anterior- or anterior rectum resection, sigma resection, left hemicolectomy and intestinal reconstruction operations
48483140|NCT03417791|OTHER|no intervention|no intervention
48483141|NCT01587131|BIOLOGICAL|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
48113296|NCT00785863|DRUG|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
48113297|NCT03094013|OTHER|Assessment|Assessment
48113298|NCT02488980|DRUG|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
48113299|NCT02488980|DRUG|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
48642651|NCT02021318|DRUG|Roxadustat|Oral tablet.
48642652|NCT02021318|DRUG|Darbepoetin alfa|Subcutaneous or intravenous injection.
48309663|NCT02941107|DRUG|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P\[8\] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
48309664|NCT02941107|DRUG|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
48309665|NCT01863407|DRUG|DAM|composed of dexamethasone, allantoin and metronidazole
48309666|NCT01863407|DRUG|Normal Saline|Normal Saline 250ml
47961792|NCT03162588|DRUG|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
48309667|NCT03537339|OTHER|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
48309668|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
48309669|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
48309670|NCT01160055|PROCEDURE|Middle ear fluid and urine.|Middle ear fluid and urine collection.
48309671|NCT01876732|DRUG|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
48309672|NCT02116660|DRUG|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
48309673|NCT02116660|DRUG|Nevirapine|Nevirapine (NVP) 200 mg tablets
48309674|NCT02116660|DRUG|Lamivudine|Lamivudine (3TC) 150 mg tablets
48309675|NCT02116660|DRUG|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
48309676|NCT02116660|DRUG|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
48309677|NCT02116660|DRUG|Lopinavir|Lopinavir (LPV) 200 mg tablets
48309678|NCT02116660|DRUG|Ritonavir|Ritonavir (r) 100 mg tablets
48309679|NCT02116660|DRUG|Atazanavir|Atazanavir (ATV) 300 mg tablets
48309680|NCT02116660|DRUG|Darunavir|Darunavir (DAR) 400 mg tablets
48309681|NCT00198445|DRUG|Bromfenac|One drop in study eye every 12 hours for 14 days
47961793|NCT03751696|BEHAVIORAL|Group Coaching|4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
48309682|NCT00198445|DRUG|Placebo|One drop in study eye every 12 hours for 14 days
48309683|NCT04321694|DRUG|KHK2455|
48309684|NCT00264316|PROCEDURE|bone marrow-derived stem cell transfer|
48309685|NCT05699746|DRUG|Capecitabine tablets|Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
48309686|NCT05699746|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
47961794|NCT03751696|BEHAVIORAL|SMS self-help tips|4 mental well-being tips through sms within 8 weeks
47961795|NCT01823978|BIOLOGICAL|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
48309687|NCT01685632|PROCEDURE|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
48309688|NCT01685632|PROCEDURE|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
48309689|NCT05640713|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .
48309690|NCT05640713|DRUG|Fludarabine Pill|Fludarabine is used for lymphodepletion.
48309691|NCT05640713|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
48309692|NCT05640713|DRUG|VP-16 Protocol|VP-16 is used for lymphodepletion.
48309693|NCT03093493|DIAGNOSTIC_TEST|Genotyping|Genotyping by next generation sequencing
48309694|NCT02128620|BEHAVIORAL|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
48309695|NCT02934048|OTHER|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
47961796|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
47961797|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
47961798|NCT04863040|BEHAVIORAL|MOVI intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 10 at high intensity (85-90% of HR max) followed by 20 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities. To increase the workload, and after evaluation of cardiorespiratory capacity, after 12 weeks of program, the HIIT protocol will be changed to 20 of high intensity work alternating with 10 of recovery."
48309696|NCT02934048|OTHER|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
48309697|NCT02934048|OTHER|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
48483142|NCT01129453|BIOLOGICAL|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10\^6, 10\^7, 10\^8, or 10\^9 CFU per mL. Route: oral.
47961799|NCT04290780|OTHER|nosocomial infection/hospital acquired infection|"When there is suspicion of a community-acquired case (admission of an infected patient) or nosocomial case (infection of a patient already hospitalized), a case report form including demographic data, medical history, and clinical and biological data on the infectious episode will be completed for each case, either patient, caregivers or health care professionals, presenting clinical signs or symptoms compatible with SARS-CoV-2 infection. The suspected cases will undergo nasopharyngeal swab collection and detection of SARS-CoV-2 in nasopharyngeal swabs will be done by real-time RT-PCR assay.~Hygiene measures applied by the service will be collected using a questionnaire as well as recommendations of the learned societies within the country regarding the risk of infection by coronavirus. In addition, data characterizing the service and hospital will also be collected (specialty, number of beds, number of nurses, doctors, etc.)."
47961800|NCT00945893|BIOLOGICAL|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
48113300|NCT02488980|DRUG|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
48113301|NCT03853109|DRUG|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
48113302|NCT04414098|DRUG|INC424 / Ruxolitinib|"1. Ruxolitinib 5 mg orally every 12 hours during 14 days.~2. Total Follow-up time will be of 45 days.~3. The reduction of ruxolitinib dose will be considered in cases of drug-related cytopenias.~4. During hospitalization, clinical and laboratory evolution parameters will be recorded daily in the medical history of the patient and in the data collection table of the study. Upon patient's discharge, a follow-up will be conducted until day +45~5. During hospitalization, adverse events will be monitored daily by means of clinical assessment and laboratory data.~6. After discharge, monitoring of adverse events will continue during the outpatient follow-up.~7. Pro-inflammatory parameters will be assessed at baseline, after one week (day +7) and at the end of treatment (day +14)~8. Ruxolitinib will be associated to the standard of care for COVID-19 of each center.~9. In case of an adverse effect or a need to discontinue the treatment, ruxolitinib should be suspended."
48113303|NCT05656846|DEVICE|PulseNmore ES™|The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.
48113304|NCT05656846|DEVICE|Standard Ultrasound|These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
48113305|NCT02744521|OTHER|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
48309698|NCT01470573|PROCEDURE|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
48309699|NCT00813514|GENETIC|VEGF genotyping|blood sample for gene analysis
48483143|NCT01129453|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
48113306|NCT03483519|OTHER|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
48483144|NCT00685490|PROCEDURE|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
48483145|NCT03687879|OTHER|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
48483146|NCT00643214|DEVICE|Tetrix|Twice daily topical application
48483147|NCT00643214|DEVICE|Tetrix|Twice daily topical application
47961801|NCT00945893|OTHER|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
48113307|NCT03483519|OTHER|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
48113308|NCT02274896|DEVICE|PD Catheter group|PD catheter
48113309|NCT01557855|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
47961802|NCT03673046|DEVICE|Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
47961803|NCT05089149|PROCEDURE|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
47961804|NCT05089149|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
47961805|NCT05089149|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
47961806|NCT05089149|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
47961807|NCT05089149|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
47961808|NCT04042896|BEHAVIORAL|exergame|Exergame is 'exercise + game'.
47961809|NCT04042896|BEHAVIORAL|treadmill exercise|traditional aerobic exercise
47961810|NCT05744284|DEVICE|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
47961811|NCT03391037|DIAGNOSTIC_TEST|Internal Jugular Vein Distensibility|. 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
47961812|NCT00386048|BEHAVIORAL|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
47961813|NCT05332197|BIOLOGICAL|17D Yellow fever vaccine|This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
47961814|NCT00489138|DRUG|Ertapenem|1g a day by drip of 30 min
48113310|NCT01951508|DRUG|Methylphenidate|60mg per os, single dose
48113311|NCT01951508|DRUG|Modafinil|600mg per os, single dose
48113312|NCT01951508|DRUG|MDMA|125mg per os, single dose
48113313|NCT01951508|DRUG|Placebo|per os
48113314|NCT05650125|OTHER|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
48113315|NCT01801449|DRUG|Rilonacept|
48113316|NCT03145480|DRUG|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
48113317|NCT03145480|DRUG|Ibrutinib|560mg po daily
48113318|NCT03145480|OTHER|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
48113319|NCT01191892|DRUG|carboplatin|
48113320|NCT01191892|DRUG|gemcitabine hydrochloride|
48113321|NCT01191892|DRUG|vandetanib|
48113322|NCT01191892|DRUG|Placebo|Placebo of vandetanib tablet
48113323|NCT05865314|OTHER|Optimisation of nutrition therapy coupled with early mobilisation|"Optimisation of nutrition therapy coupled with early mobilisation with:~* Optimisation of nutrition therapy during ICU stay~* Optimisation of physiotherapy during ICU stay~* Better communication and closer collaboration between physiotherapy and nutrition teams.~* Optimisation of continuity of the care."
48483148|NCT04916483|OTHER|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
48113324|NCT05865314|OTHER|Standard care|Patients will receive nutritional therapy and mobilisation according to local standard procedures.
48113325|NCT02705586|BEHAVIORAL|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
48113326|NCT02801071|DRUG|15g L-citrulline daily p.o.|
48309700|NCT04520516|DEVICE|Active VAGUSTIM device|Settings: 25 Hz stimulation, 100 microsec pulse width, intensity escalation up to 8 mA or below if tingling sensation, 20 min/day of stimulation in one daily session
48309701|NCT04520516|DEVICE|Sham VAGUSTIM device|The sham device : no electrical signal for VNS will be delivered.
48309702|NCT01720615|DRUG|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
48309703|NCT01720615|DRUG|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
48309704|NCT02396823|BEHAVIORAL|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
48309705|NCT01883440|DRUG|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
48309706|NCT01883440|DRUG|Saline+glucose|Placebo arm
48309707|NCT00121303|DRUG|cytarabine|
48309708|NCT00121303|DRUG|daunorubicin hydrochloride|
48309709|NCT00121303|DRUG|gemtuzumab ozogamicin|
48309710|NCT05169307|DRUG|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
48309711|NCT04463329|PROCEDURE|conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage|on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
48309712|NCT04413435|OTHER|File Scanning|The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
48309713|NCT02284958|BEHAVIORAL|Standard|Back care advice
48309714|NCT02284958|BEHAVIORAL|Walking|Back care advice, individualized 12 week pedometer-driven walking program
48309715|NCT03284619|DEVICE|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
48309716|NCT06071494|OTHER|Tropical fruits|papaya, mango, banana, orange
48309717|NCT02024893|OTHER|Observational study|"Observation and type of data collected are listged in detail under 'description"
48309718|NCT00632463|BIOLOGICAL|RI-001|Dose 1
48113327|NCT02801071|DRUG|Placebo|
48483149|NCT04916483|OTHER|usual care|The control group maintains the unit routine treatment.
48113328|NCT01228916|BEHAVIORAL|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
48113329|NCT02574026|BEHAVIORAL|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
48113330|NCT01093430|PROCEDURE|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
48113331|NCT01093430|PROCEDURE|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
48113332|NCT00035542|DRUG|Glucovance (metformin HCl/glyburide)|
48309719|NCT00632463|BIOLOGICAL|RI-001|Dose 2
48113333|NCT00035542|DRUG|metformin HCl|
48113334|NCT00035542|DRUG|glyburide|
48309720|NCT00632463|BIOLOGICAL|RI-001|Placebo
48309721|NCT03927937|PROCEDURE|AUTOTRANSPLANTATION TOOTH|Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
48309722|NCT06288672|OTHER|True avoidance diet|Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
48309723|NCT06288672|OTHER|Sham avoidance diet|Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
48309724|NCT04804722|DEVICE|18F-FDG PET-CT (fluorodesoxyglucose positron emission tomography)|18F-FDG PET-CT exams during 30 minutes with injection of radiopharmaceutical product
48309725|NCT04041778|OTHER|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
48309726|NCT05946135|DRUG|Lansoprazole|taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
48309727|NCT05946135|DRUG|Fexuprazan Hydrochloride|taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
48309728|NCT04527562|DRUG|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
48483150|NCT00836719|DRUG|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
48483151|NCT05497141|DEVICE|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
48309729|NCT04527562|DRUG|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
47961815|NCT05694767|DRUG|CM313 Injection|"intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
47961816|NCT01021046|PROCEDURE|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
47961817|NCT01021046|PROCEDURE|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
47961818|NCT06111807|DIAGNOSTIC_TEST|ctDNA|ctDNA will be tested retrospectively, no treatment decisions will be made prospectively
47961819|NCT03722966|DRUG|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
47961820|NCT03722966|DRUG|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
47961821|NCT03722966|BEHAVIORAL|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
47961822|NCT03722966|BEHAVIORAL|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
47961823|NCT03573739|PROCEDURE|low-calorie low-protein|In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
47961824|NCT03573739|PROCEDURE|standard-calorie/standard-protein|In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
47961825|NCT05751902|OTHER|Arabic version of OHIP questionnaire|Translated Arabic version of Oral Health Impact Profile questionnaire
47961826|NCT03120000|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
47961827|NCT01916720|DRUG|SB-480848 40 mg|Study Drug
47961828|NCT01916720|DRUG|SB-480848 80 mg|Study Drug
47961829|NCT01916720|DRUG|Placebo|Study Drug
47961830|NCT03574831|DEVICE|Stretta|Stretta
47961831|NCT01517711|DRUG|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
47961832|NCT01517711|DRUG|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
47961833|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
47961834|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
47961835|NCT05711784|OTHER|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
47961836|NCT02000583|OTHER|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
48309730|NCT05130164|RADIATION|CBCT|Cone beam computed tomographic images selected for age estimation
48309731|NCT03181165|BEHAVIORAL|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
48483152|NCT05473000|BEHAVIORAL|Exercise|Submaximal and maximal exercise
47961837|NCT02000583|OTHER|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
48113335|NCT00478738|DRUG|GSK961081|
48483153|NCT05473000|OTHER|Ozone|Delivery of ozone air pollution at 170ppb
48483154|NCT05473000|OTHER|Room air|Delivery of room air
48113336|NCT04783454|OTHER|Exercise program|educational video on training program design and healthy lifestyle 24 training sessions (12 on cardiovascular endurance training, 12 on mobility and strength)
48113337|NCT02631343|BEHAVIORAL|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
47961838|NCT03228433|DRUG|TAK-418|TAK-418 Capsule.
48309732|NCT02155296|BEHAVIORAL|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
47961839|NCT03228433|DRUG|TAK-418 Placebo|TAK-418 placebo-matching capsules.
47961840|NCT03750708|DEVICE|Ara® KOLIBREE tooth brush|"Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data."
48309733|NCT06430047|DRUG|EsoDuo® Tablet|QD, PO
48309734|NCT01258348|DRUG|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
48309735|NCT01258348|DRUG|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
48309736|NCT02108951|DRUG|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
47961841|NCT00727493|DRUG|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
47961842|NCT00727493|DRUG|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
48113338|NCT02631343|OTHER|Essential newborn care|
48113339|NCT02473419|DRUG|Vayarin|
48113340|NCT02473419|DRUG|Placebo|
48113341|NCT01220336|BEHAVIORAL|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model \[Bodenheimer 2007\] for 12 months.
48113342|NCT04781439|PROCEDURE|IV-to-PO conversion of antibiotics|IV-to-PO switching of antibiotics treatment
48113343|NCT03737240|DRUG|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
48113344|NCT03737240|DRUG|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
48309737|NCT04776356|DEVICE|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
48309738|NCT06064786|DIAGNOSTIC_TEST|GCF levels of fetuin A and hsCRP evaluation|ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation
48309739|NCT03057834|BEHAVIORAL|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
48309740|NCT00089843|DRUG|Testosterone|Testosterone patch 150mcg daily
48309741|NCT00089843|DRUG|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
48309742|NCT00089843|DRUG|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
48309743|NCT00089843|DRUG|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
48309744|NCT00305851|PROCEDURE|Music Therapy|Undergo therapeutic music video therapy
48309745|NCT00305851|PROCEDURE|Psychosocial Assessment and Care|Undergo books on tape therapy
48309746|NCT00305851|OTHER|Quality-of-Life Assessment|Ancillary studies
48309747|NCT01831973|DRUG|Lipotecan|
48309748|NCT06060275|DIAGNOSTIC_TEST|serum sample and nerve conduction study and cerebrospinal fluid study|serum sample and cerebrospinal fluid study to detect Neurofilament light chain Nerve conduction study
48483155|NCT00654654|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm biopsies~2. Two injection treatments of facial wrinkles and creases~3. Conduct of study assessments"
48483156|NCT03804164|OTHER|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
48483157|NCT03804164|OTHER|Quality-of-Life Assessment|Ancillary studies
48483158|NCT03804164|OTHER|Survey Administration|Ancillary studies
48483159|NCT03421704|DEVICE|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
47961843|NCT05235555|DEVICE|Transcatheter heart valve (THV) with CE approval|TAVI trough femoral access or alternative routes
47961844|NCT05776615|OTHER|mobile application|"In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months.Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied."
47961845|NCT03811028|DRUG|SOBI003|weekly i.v. infusion
48266683|NCT06419764|OTHER|Diet and meal replacements|The dietitian provides recommended meal plans based on body weight, and meal replacements are used postoperatively.
48266684|NCT04451330|DRUG|Trifarotene cream|Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
47961846|NCT03493399|BEHAVIORAL|Interference|"The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, \& Kavanagh, 2012; May, Andrade, Panabokke, \& Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, \& May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text."
48113345|NCT03737240|DRUG|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
48113346|NCT00971906|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups
48113347|NCT06456970|DEVICE|fibroscan|"Fibroscan examination with controlled attenuation parameterCAP (Echosens FibroScan ® Compact 530) for evaluation of steatosis and its degree (by CAP score) and fibrosis stage by liver stiffness measurement(LSM)"
48113348|NCT01161498|BIOLOGICAL|Talimogene Laherparepvec|Administered by intratumoral injection
48113349|NCT01161498|RADIATION|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
48113350|NCT01161498|DRUG|Cisplatin|Administered by intravenous infusion
48113351|NCT05285891|DRUG|Ocrelizumab|Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
48113352|NCT05285891|DRUG|Placebo for Ocrelizumab|Placebo infusions every 6 months from Month 30 through Month 48.
48113353|NCT04381143|DRUG|Aspirin 100 mg Oral Tablet|Aspirin 100 mg tablet daily
48113354|NCT04381143|DRUG|Matching Placebo|Matching Placebo 1 pill daily
48113355|NCT05579366|DRUG|PRO1184|Intravenous infusion of PRO1184
48113356|NCT05579366|DRUG|PRO1184 intravenous infusion of PRO1184|Carboplatin intravenous infusion
48113357|NCT05579366|DRUG|PRO1184 intravenous infusion of PRO1184|Bevacizumab intravenous infusion
48309749|NCT01769690|OTHER|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
48483160|NCT03159286|BEHAVIORAL|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
47961847|NCT00816595|BIOLOGICAL|bevacizumab|Given IV
47961848|NCT00816595|BIOLOGICAL|pegfilgrastim|Given subcutaneously
47961849|NCT00816595|BIOLOGICAL|rituximab|Given IV
47961850|NCT00816595|DRUG|cyclophosphamide|Given IV
47961851|NCT00816595|DRUG|pentostatin|Given IV
47961852|NCT03757325|DRUG|DNL747|DNL747
47961853|NCT03757325|DRUG|Placebo|Placebo
48113358|NCT05579366|DRUG|PRO1184 intravenous infusion of PRO1184|Pembrolizumab intravenous infusion
48113359|NCT06461455|DEVICE|Lehfilcon A multifocal for astigmatism contact lenses|Investigational multifocal contact lenses for astigmatism
48113360|NCT06461455|DEVICE|Samfilcon A multifocal for astigmatism contact lenses|Commercially available multifocal contact lenses for astigmatism
48113361|NCT06461455|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfection system
48113362|NCT01145170|RADIATION|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
48113363|NCT01145170|BIOLOGICAL|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
48113364|NCT06628869|DIETARY_SUPPLEMENT|Fructanase|Participants will consume one capsule containing 400 INU inulinase (325 mg, includes maltodextrin) with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The fructanase was obtained from Aspergillus tubingensis.
48113365|NCT06628869|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing 300 mg maltodextrin with a mixture of oatmeal (40 grams) and inulin (25 grams). Participants will be directed to consume the capsule after two spoonfuls of oatmeal. The maltodextrin was obtained from tapioca.
48113366|NCT06390995|DRUG|TAK-853|TAK-853 intravenous injection
48113367|NCT04396730|DRUG|Cannabidiol Oil|400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.
48113368|NCT04396730|DRUG|Placebo|Placebo will be administered daily along with oral contraceptives daily for 24 days.
48309750|NCT01769690|OTHER|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
48309751|NCT03104335|DRUG|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
48309752|NCT04898907|DRUG|ANG-3777 (Therapeutic Dose)|Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
48309753|NCT04898907|DRUG|ANG-3777 (Supra-therapeutic Dose)|Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
48309754|NCT04898907|DRUG|Placebo|Arms assigned to this intervention will receive normal saline, IV, Fasted
48309755|NCT04898907|DRUG|Moxifloxacin Hydrochloride|Arms assigned to this intervention will receive 400 mg, Oral, Fasted
48309756|NCT05903196|DEVICE|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
48309757|NCT02244723|OTHER|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
48309758|NCT05257720|DIAGNOSTIC_TEST|GFAP, S100B|It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
48309759|NCT04436224|DRUG|Hydromorphone|Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)
48309760|NCT04436224|DRUG|Fentanyl|Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
48309761|NCT04436224|DRUG|Butorphanol|Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
48309762|NCT05056467|PROCEDURE|Induction of Labor|Induction of Labor at 39 weeks of gestation
48309763|NCT02523326|DEVICE|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
48309764|NCT03740841|BEHAVIORAL|Interactive story teller LUNII|Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
48309765|NCT06185218|OTHER|Intravesical Botulinum Toxin|Botulinum Toxin injections will be made into the bladder.
48642653|NCT06690216|DIAGNOSTIC_TEST|PET/CT （[18F]AlF-NOTA-PCP2）|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
47961854|NCT00550524|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
48113369|NCT04396730|DRUG|Combined oral contraceptive pill|All participants will receive oral contraceptives
48113370|NCT02879695|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48113371|NCT02879695|BIOLOGICAL|Blinatumomab|Given IV
48309766|NCT01924910|DIETARY_SUPPLEMENT|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
48309767|NCT01924910|DIETARY_SUPPLEMENT|Placebo|
48309768|NCT04065477|BEHAVIORAL|computer-based cognitive rehabilitation (CBCR)|Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
48309769|NCT05736588|BEHAVIORAL|Elimisha HPV|Elimisha HPV is a multi-level stigma-responsive cervical cancer prevention service delivery model that incorporates stigma-responsive education, peer navigation and a patient-centered delivery strategy, addressing drivers while mitigating harms from stigma.
48309770|NCT02843867|OTHER|blood sample|36 ml of blood sample at D0 and 1 year after transplantation
48309771|NCT00736710|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
48483161|NCT03159286|BEHAVIORAL|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
48309772|NCT00736710|PROCEDURE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
48642654|NCT06690216|DIAGNOSTIC_TEST|[18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
48642655|NCT01603251|DRUG|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
48309773|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
48309774|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
48483162|NCT03159286|BEHAVIORAL|Control|Participants view social networking site profiles with no alcohol content.
48483163|NCT06304909|DRUG|Dexmedetomidine injection|Dexmedetomidine group will receive 0.5 mcg/kg
48483164|NCT02355756|DRUG|Maxadilan|
48483165|NCT02355756|DRUG|Placebo|
48483166|NCT06297655|DRUG|Recombinant human activated coagulation factor VIII for injection|Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.
48483167|NCT06322459|BEHAVIORAL|Sport Education Curriculum|The six characteristics of The Sport Education Model include season, affiliation, formal competition, culminating event, Record-keeping, and Festivity. The intensity of the training is increasing in the first 30 minutes, and the intensity is gradually decreasing in the next 10 minutes.
48483168|NCT06322459|BEHAVIORAL|Normal teaching|The intervention content, frequency, and intensity were the same as those in the experimental group, but the type of intervention was different. The most significant difference between the two teaching methods lies in delivering basic content. The Sport Education Model includes Teacher-directed learning (10 minutes) and Team practice (10 minutes); Normal Teaching includes Teacher-directed learning (10 minutes) and Individual practice (10 minutes).
48483169|NCT03977259|OTHER|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
48483170|NCT00561314|OTHER|questionnaire administration|
48483171|NCT00561314|PROCEDURE|biopsy|
48483172|NCT00561314|PROCEDURE|high-intensity focused ultrasound ablation|
48483173|NCT00561314|PROCEDURE|magnetic resonance imaging|
47961855|NCT05739188|BIOLOGICAL|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%."
47961856|NCT01205711|DRUG|FOLFIRI regimen|
48483174|NCT00561314|PROCEDURE|quality-of-life assessment|
48483175|NCT04331964|PROCEDURE|partial pulpotomy|Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
48483176|NCT03128684|OTHER|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
48483177|NCT03128684|OTHER|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
48483178|NCT03128684|OTHER|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
48483179|NCT03128684|OTHER|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
47961857|NCT01205711|DRUG|fluorouracil|
47961858|NCT01205711|DRUG|irinotecan hydrochloride|
47961859|NCT01205711|DRUG|leucovorin calcium|
47961860|NCT01205711|DRUG|zibotentan|
48483180|NCT03128684|OTHER|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
48483181|NCT03128684|OTHER|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
47961861|NCT01205711|OTHER|laboratory biomarker analysis|
47961862|NCT01205711|OTHER|pharmacogenomic studies|
48113372|NCT02879695|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48113373|NCT02879695|BIOLOGICAL|Ipilimumab|Given IV
48113374|NCT02879695|BIOLOGICAL|Nivolumab|Given IV
47961863|NCT02072083|DRUG|Dexmedetomidine|via intranasal route 1 mcg/kg
47961864|NCT02072083|DRUG|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
47961865|NCT02499822|DRUG|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
47961866|NCT02499822|DRUG|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
47961867|NCT00882895|PROCEDURE|Stem cell infusion|
47961868|NCT00882895|PROCEDURE|TLI|
48113375|NCT00298597|DRUG|granulocyte - colony stimulating factor (G-CSF)|
48113376|NCT00298597|DRUG|erythropoetin (EPO)|
48113377|NCT06051786|DRUG|azelastine/fluticasone 137/50 mcg nasal spray|AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. AFC is administered intranasally and is used to treat Allergic Rhinitis (AR).
48113378|NCT06051786|DRUG|Dymista™|Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
48113379|NCT04010318|PROCEDURE|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
48113380|NCT04663464|COMBINATION_PRODUCT|abaloparatide-sMTS|Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
48113381|NCT04663464|COMBINATION_PRODUCT|abaloparatide-SC|Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
48113382|NCT02975310|PROCEDURE|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
48113383|NCT02975310|PROCEDURE|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
48113384|NCT02975310|OTHER|General Anesthesia|ESS will be performed under general anesthesia in the operating room
48113385|NCT02975310|OTHER|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
47961869|NCT00882895|DRUG|Anti-thymocyte globulin|
48113386|NCT04594759|DRUG|Isotretinoin|Participants will be getting isotretinoin (1-1.5 mg/kg/week)
48113387|NCT05527717|PROCEDURE|Culprit lesion only PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken culprit-lesion only PCI during primary PCI."
48642656|NCT01603251|DRUG|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
47961870|NCT00882895|DRUG|Solumedrol|
47961871|NCT00882895|DRUG|Tacrolimus|
47961872|NCT00882895|DRUG|Mycophenolate mofetil|
47961873|NCT02545556|PROCEDURE|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
47961874|NCT04642443|DEVICE|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
47961875|NCT04794842|DRUG|Tetracaine 5% drops|same as information in the arm/group description
47961876|NCT04794842|DRUG|Phenol 90% concentration|same as information in the arm/group description
47961877|NCT05001256|OTHER|questionnaire study|Participants will be surveyed through face-to-face interviews.
47961878|NCT01370330|DRUG|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Jubilant DraxImage (Quebec, Canada) with specific activities of 9-18 Ci/mmole, or at Progenics with specific activity of 2,500 mCi/mg. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25-50 ml of normal saline for either preparation, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present.If Azedra is used, the dose will be infused over 30-60 minutes; the low specific activity preparation from Draximage will be infused over 90-120 minutes. For patients with pheochromocytoma or paraganglioma, the recommended maximum dose is 500 mCI or 12 mCi/kg.
47961879|NCT03210246|DRUG|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
48642657|NCT01603251|DRUG|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
47961880|NCT03210246|DRUG|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
47961881|NCT03210246|DRUG|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
47961882|NCT03210246|DRUG|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
48642658|NCT06693141|OTHER|ESP block|ESP block was applied to the patients.
47961883|NCT04377620|DRUG|Placebo|Placebo administered BID approximately 12 hours apart
48642659|NCT06693141|OTHER|ITM|ITM was applied to the patients.
48642660|NCT03834662|DRUG|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
48642661|NCT05336409|BIOLOGICAL|CNTY-101|CNTY-101 cells for intravenous (IV) infusion
48642662|NCT05336409|BIOLOGICAL|IL-2|IL-2 subcutaneous (SQ) injection
48642663|NCT05336409|DRUG|Lymphodepleting Chemotherapy|LDC as prespecified in the protocol.
47961884|NCT04377620|DRUG|Ruxolitinib|Ruxolitinb administered BID approximately 12 hours apart
47961885|NCT04390191|DEVICE|Continuous Positive Airway Pressure|CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
47961886|NCT00327275|BEHAVIORAL|strength training|
47961887|NCT02271568|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
47961888|NCT02271568|OTHER|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
47961889|NCT01223430|DRUG|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
47961890|NCT06475586|DRUG|Semaglutide|0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks
47961891|NCT06349772|DRUG|Zynrelef|Zynrelef will be injected at the 12mm port site
48113388|NCT05527717|PROCEDURE|Immediate multi-vessel PCI|"Randomization will be done after coronary angiography before or during primary PCI for IRA. Patients will be randomized to either immediate multi-vesesl PCI group or culprit-lesion only PCI group with 1:1 ratio.~This group will be taken immediate multi-vesesl PCI during primary PCI."
48266685|NCT04451330|DRUG|Doxycycline hyclate|Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
48266686|NCT04451330|DRUG|Trifarotene Vehicle|Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
48266687|NCT04451330|DRUG|Doxycycline Placebo|Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
48266688|NCT06487546|DIETARY_SUPPLEMENT|Ergothioneine|This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.
48266689|NCT05220267|DRUG|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
48642664|NCT05497882|BEHAVIORAL|E-Learning Prototype for Dementia Care|Usability testing System Usability Scale
48642665|NCT05829330|OTHER|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
48642666|NCT05829330|OTHER|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
48642667|NCT06258785|DRUG|Tizanidine|Tizanidine 2mg will be given preoperatively prior to scheduled sacrospinous ligament suspension
47961892|NCT06349772|DRUG|Exparel|Exparel will be injected at the 12mm port site
47961893|NCT06142071|BEHAVIORAL|Telephone questionnaire|Telephone questionnaire, which includes questions on participant's demographics, anxiety/depression scores, what support they find helpful and what additional support they feel would be beneficial
47961894|NCT01809106|DRUG|Morphine|60 mg /24 ore
47961895|NCT01809106|DRUG|Fentanyl|25 microg/h
47961896|NCT01809106|DRUG|Buprenorphine|35 microg/h
47961897|NCT01809106|DRUG|Oxycodone|40 mg /24 ore
47961898|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 1|milk supplement with probiotics
47961899|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 2|milk supplement without probiotics
47961900|NCT04751526|DEVICE|BreEStim 240|240 BreEStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
47961901|NCT04751526|DEVICE|EStim 240|240 EStim stimuli/visit will be applied for 10 sessions to test any accumulated analgesic effect.
47961902|NCT00932100|DRUG|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
47961903|NCT00932100|DRUG|Heparin|IV dose per standard of care at the local institution
47961904|NCT02201641|RADIATION|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
47961905|NCT02201641|RADIATION|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
47961906|NCT02201641|DEVICE|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
47961907|NCT02201641|DEVICE|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
48642668|NCT02549638|GENETIC|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
48642669|NCT03747757|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
48642670|NCT03747757|OTHER|Quality-of-Life Assessment|Ancillary studies
47961908|NCT01814631|OTHER|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
47961909|NCT01814631|OTHER|image quality and resolution|image quality and resolution will be viewed on the EU-me2
47961910|NCT05876975|PROCEDURE|laparoscopic pectopexy|Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
47961911|NCT04655638|DEVICE|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
48309775|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
48309776|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
48309777|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
48309778|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
48309779|NCT01073527|DRUG|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
48309780|NCT01073527|DRUG|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
48483182|NCT02276079|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
48483183|NCT02276079|BEHAVIORAL|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
48483184|NCT03508687|DRUG|300mg Gemcabene|300mg Gemcabene
48483185|NCT03508687|DRUG|600mg Gemcabene|600mg Gemcabene
48483186|NCT04344457|DRUG|Hydroxychloroquine|200 mg PO BID 7 days
48483187|NCT04344457|DRUG|Indomethacin|50 mg PO TID 14 Days
48483188|NCT04344457|DRUG|Zithromax Oral Product|500 mg PO QD 3 Days
48483189|NCT04399265|DIETARY_SUPPLEMENT|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
48483190|NCT04399265|DIETARY_SUPPLEMENT|Maltose|Maltose power
47961912|NCT04655638|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
47961913|NCT05205811|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
47961914|NCT05205811|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 7 weeks.
48266690|NCT03152240|OTHER|Non intervention|Non intervention
48266691|NCT00427856|DRUG|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
48266692|NCT00427856|DRUG|Rituximab|Rituximab
48266693|NCT05809531|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
48266694|NCT04909905|DIETARY_SUPPLEMENT|Standard enteral nutrition|Standard enteral nutrition according to ICU nutrition protocol for 7 days
48309781|NCT03381924|OTHER|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
48309782|NCT03381924|OTHER|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
48309783|NCT00935142|DRUG|[18F]VM4-037|Bolus IV injection of \[18F\]VM4-037
48309784|NCT01599754|DRUG|Axitinib|Axitinib 5 mg twice daily
48309785|NCT01599754|DRUG|Placebo|Placebo twice daily
48309786|NCT02422927|DIETARY_SUPPLEMENT|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
48309787|NCT02422927|OTHER|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
48309788|NCT02422927|OTHER|Placebo|placebo
48309789|NCT02514928|PROCEDURE|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
48309790|NCT02514928|PROCEDURE|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
48309791|NCT04697472|DEVICE|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
48309792|NCT05596968|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
48309793|NCT04358094|OTHER|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
48309794|NCT04358094|OTHER|Standard script|Standard script during peripherical veinous catheter set up
48309795|NCT01881035|PROCEDURE|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
48309796|NCT03650452|DRUG|TAK-935|TAK-935 tablets or mini-tablets.
48309797|NCT03650452|DRUG|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
48309798|NCT01487668|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
48309799|NCT04208763|DRUG|Imipenem|Inj Imipenem 1gm i.v. TDS
48309800|NCT04208763|DRUG|Tigecycline|Inj Tigecycline 100mg stat f/b 50mg i.v. OD
48309801|NCT04208763|DRUG|GMCSF|Inj GM-CSF 500mcg s.c. OD
48309802|NCT04208763|DRUG|Colistin|Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
48309803|NCT05607940|PROCEDURE|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
48309804|NCT05607940|PROCEDURE|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
48309805|NCT00045682|DRUG|Paclitaxel Poliglumex|Given IV
48309806|NCT02242825|DRUG|Micardis®|
48309807|NCT02242825|DRUG|MicardisPlus®|
48309808|NCT00861484|DRUG|GSK958108|Coated Tablets 1 mg
48309809|NCT00861484|DRUG|Placebo|Coated tablets
48309810|NCT02805556|DRUG|BMS-663068|Single oral dose of BMS-663068
48309811|NCT02805556|DRUG|BMS-626529|Single intravenous dose of \[13C\]BMS 626529
48309812|NCT01550718|BEHAVIORAL|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
48309813|NCT01550718|BEHAVIORAL|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
48309814|NCT04644289|DRUG|olaparib|Olaparib tablets are administrated orally 300 mg twice daily.
48309815|NCT04644289|DRUG|durvalumab|Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
48309816|NCT02417870|BIOLOGICAL|aldesleukin|
48309817|NCT03239756|BIOLOGICAL|TK006|Subcutaneous injection
48309818|NCT00316303|DRUG|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
48309819|NCT00316303|BEHAVIORAL|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
48309820|NCT05365620|DEVICE|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
48483191|NCT03458247|DRUG|Abiraterone acetate standard dose|1000 mg/day
48483192|NCT03458247|DRUG|Abiraterone acetate escalated dose|2000 mg/day
47961915|NCT05205811|DRUG|Placebo bupropion|Placebo bupropion for 7 weeks.
47961916|NCT05205811|DRUG|Placebo zonisamide|Placebo zonisamide for 7 weeks.
47961917|NCT05205811|OTHER|E-cigarette|e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
48113389|NCT01385384|DEVICE|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
48309821|NCT05365620|PROCEDURE|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
48309822|NCT03605810|OTHER|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
48309823|NCT00482872|GENETIC|gene expression analysis|
47961918|NCT03246893|DEVICE|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
47961919|NCT03246893|DEVICE|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
47961920|NCT01954992|DRUG|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
47961921|NCT01954992|DRUG|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
47961922|NCT04846296|OTHER|Questionnaire|The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
47961923|NCT03974191|OTHER|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
47961924|NCT01100541|DEVICE|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
47961925|NCT05509114|DEVICE|Virtual Reality Glasses|The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
47961926|NCT05561738|DIETARY_SUPPLEMENT|Nicotinamide Riboside Chloride|The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.
47961927|NCT05561738|DIETARY_SUPPLEMENT|Placebo|The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.
47961928|NCT05561738|OTHER|Standard of Care|Standard of Care
47961929|NCT02287857|DRUG|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
47961930|NCT02287857|DRUG|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
48309824|NCT00482872|GENETIC|mutation analysis|
48309825|NCT00482872|GENETIC|polymerase chain reaction|
48309826|NCT00482872|GENETIC|polymorphism analysis|
48309827|NCT00482872|OTHER|flow cytometry|
48309828|NCT00482872|OTHER|laboratory biomarker analysis|
48309829|NCT06224894|OTHER|Music Therapy|Music Therapy
48309830|NCT06224894|OTHER|antiemetic treatment|antiemetic treatment
48309831|NCT03762122|DRUG|Rogaratinib|Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
47961931|NCT01197560|DRUG|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
47961932|NCT01197560|DRUG|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
47961933|NCT01197560|DRUG|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
48309832|NCT02446054|DIETARY_SUPPLEMENT|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
48309833|NCT00013624|DRUG|IV Levodopa|
48309834|NCT03570281|DRUG|Edoxaban|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
48309835|NCT03570281|DRUG|Enoxaparin|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
48642671|NCT03747757|OTHER|Questionnaire Administration|Ancillary studies
48642672|NCT01299532|DEVICE|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
48642673|NCT05009069|RADIATION|Radiotherapy|Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
48642674|NCT05009069|DRUG|Capecitabine|Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
48642675|NCT05009069|DRUG|Fluorouracil|Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
48642676|NCT05009069|DRUG|Atezolizumab|Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
48642677|NCT05009069|DRUG|Tiragolumab|Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
48642678|NCT04130022|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
48642679|NCT02056951|PROCEDURE|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~* health education~* exercise therapy~* back school~* physical treatments~* psychological interventions in groups and individual counselling~* rehabilitation/social counselling."
48642680|NCT02056951|PROCEDURE|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~* education about low back pain~* behavioural exercise therapy~* coping with pain~* relaxation~* work related informations"
47961934|NCT01197560|DRUG|Rituximab|Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
47961935|NCT01197560|DRUG|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles"
47961936|NCT04066023|DRUG|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
47961937|NCT04066023|DRUG|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
47961938|NCT02188108|OTHER|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
48113390|NCT05857436|OTHER|apical periodontitis|Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
48113391|NCT03921450|DEVICE|1 Hz rTMS|1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
48642681|NCT06695962|DRUG|Domperidone 10mg|30 mg per day for 21 days
48642682|NCT06695962|DRUG|Placebo|3 per day for 21 days
48483193|NCT00485927|BEHAVIORAL|stress|
48642683|NCT06695962|DIAGNOSTIC_TEST|gastric emptying test|gastric emptying test
48642684|NCT06161194|OTHER|Supervised group exercise therapy|Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.
48642685|NCT05284747|DRUG|Evolocumab|Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
48642686|NCT05284747|DRUG|Routine Lipid Management|Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
48309836|NCT00846079|DEVICE|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
48309837|NCT04798885|BEHAVIORAL|GAIN 2.0|1) three structured group sessions of two hours duration performed jointly by a neuropsychologist, an occupational therapist and a physiotherapist. Relatives are also invited. 2) Up to five weekly semi-structured individual sessions of 30 min. duration with an allocated therapist
48309838|NCT00537550|DRUG|Vincristine|Steroids pre-treatment
48309839|NCT00537550|DRUG|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
48309840|NCT04314167|DRUG|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
48309841|NCT00137852|DRUG|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
48309842|NCT00137852|DRUG|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
48309843|NCT00137852|DRUG|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
48309844|NCT00137852|PROCEDURE|Radiation Therapy|5 days a week for 5-6 weeks
48309845|NCT00137852|PROCEDURE|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
48309846|NCT02969343|BEHAVIORAL|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
48483194|NCT02787317|DRUG|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
48642687|NCT06444633|BEHAVIORAL|Community Sensitization + Household visit + Information + Free pre-emptive distribution of ORS+Zinc|The intervention will involve the following: 1) The communities will be sensitized on the importance of ORS and Zinc use for the treatment of child diarrhea, by the Clinton Health Access Initiative (CHAI). 2) Campaigners recruited by CHAI will visit each household in their catchment area that contain at child under 5 years old. 3) During the distribution visits, the campaigners will train caregivers on the dangers of diarrhea and the importance of ORS and zinc use, among other things (including how to prepare, use, and store ORS/zinc, benefits of the treatments, recommended health behaviors such as seeking care, and encouraging basic handwashing and hygiene practices). The caregivers will also receive a flyer describing the same information in their local language, for future reference. 4) Campaigners will then distribute two ORS and zinc co-packs (each co-pack contains two sachets of ORS and 10 tablets of zinc) for free for each child under the age of five in the household.
48642688|NCT05198830|DRUG|Carboplatin|Given IV
48113392|NCT03921450|DEVICE|iTBS|50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
48113393|NCT03921450|DRUG|Placebo|1 Hz stimulation with the placebo TMS coil without any magnetic emission
48113394|NCT03244579|BEHAVIORAL|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
48309847|NCT02632110|DRUG|ALA|20% ALA applied to face prior to light treatment
48309848|NCT02632110|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
48309849|NCT02632110|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10 mW/cm2 for 16 minutes 40 seconds
48309850|NCT02632110|PROCEDURE|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
48309851|NCT02632110|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20 mW/cm2 for 8 minutes 20 seconds
48309852|NCT03797040|BIOLOGICAL|Cell therapy|PLX-R18: Allogeneic ex vivo expanded placental stromal cells
48642689|NCT05198830|DRUG|Cisplatin|Given IV
48309853|NCT02596711|DRUG|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
48642690|NCT05198830|PROCEDURE|Computed Tomography|Undergo CT and FDG-PET/CT
48642691|NCT05198830|BIOLOGICAL|Durvalumab|Given IV
48642692|NCT05198830|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET/CT
48642693|NCT05198830|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48309854|NCT02596711|BEHAVIORAL|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
48309855|NCT02596711|OTHER|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
48309856|NCT02596711|BEHAVIORAL|Health Education and Handouts|Participants receive general health education and handouts.
48309857|NCT02596711|BEHAVIORAL|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
48309858|NCT02596711|BEHAVIORAL|Counseling Sessions|Participants attend 3 counseling sessions during the study.
48309859|NCT05126368|OTHER|Cataract surgery|During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
48309860|NCT06165484|PROCEDURE|laparoscopy and hysteroscopy|laparoscopy and hysteroscopy for patient with failed IVF
48309861|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy|Derazantinib was administered orally at a dose of 300 mg once daily
48309862|NCT04045613|DRUG|Derazantinib 200 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
48309863|NCT04045613|DRUG|Derazantinib 300 mg once daily+ atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
48483195|NCT02787317|DRUG|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
48483196|NCT01397617|DEVICE|NobelActive Internal implant|Dental implant
48483197|NCT01397617|DEVICE|NobelActive External implant|Dental implant
48483198|NCT01397617|DEVICE|NobelReplace Tapered Groovy implant|Dental implant
47961939|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
47961940|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
48113395|NCT05076435|DRUG|Isotonic crystalloids|"Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy."
48113396|NCT06676930|DEVICE|Colonoscopy With Computer-Aided Detection|Use of Computer-Aided Detection During Colonoscopy
48309864|NCT04045613|DRUG|Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
48309865|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy (QD)|Derazantinib was administered orally at a dose of 300 mg once daily
48309866|NCT04045613|DRUG|Derazantinib 300 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
48309867|NCT04045613|DRUG|Derazantinib 200 mg twice daily monotherapy|Derazantinib was administered orally at a dose of 200 mg twice daily
48309868|NCT04953949|DEVICE|NU-MAX®|Topical Hemostat
48309869|NCT00374153|BEHAVIORAL|Feedback|Online personal feedback report
48309870|NCT00374153|BEHAVIORAL|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
48309871|NCT00374153|BEHAVIORAL|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
48309872|NCT05072769|DIETARY_SUPPLEMENT|Date Fruit|Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
48309873|NCT00004284|DRUG|potassium citrate|
48113397|NCT06676930|PROCEDURE|Colonoscopy without Computer-Aided Detection|Colonoscopy without Computer-Aided Detection (AI)
48266695|NCT04909905|COMBINATION_PRODUCT|Glutamine|Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
48309874|NCT00004284|DRUG|potassium phosphate|
48309875|NCT04719338|DIAGNOSTIC_TEST|presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .|samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
48309876|NCT02555644|DRUG|Prexasertib|Administered IV
48309877|NCT02555644|DRUG|Cisplatin|Administered IV
48642694|NCT05198830|DRUG|Methoxyamine|Given PO
48642695|NCT05198830|DRUG|Pemetrexed|Given IV
48642696|NCT05198830|RADIATION|Radiation Therapy|Undergo thoracic radiation
48642697|NCT03702738|DRUG|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
48642698|NCT05869825|PROCEDURE|High Flow Nasal Canula following extubation|Participants in this group will be randomized to receive High Flow Nasal Cannula support after extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
48309878|NCT02555644|DRUG|Cetuximab|Administered IV
48309879|NCT02555644|RADIATION|Intensity Modulated Radiation Therapy|
48309880|NCT04836143|DRUG|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
48309881|NCT04111887|BEHAVIORAL|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
48309882|NCT01434472|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
48309883|NCT01434472|DRUG|Cyclosporine|Given PO
48309884|NCT01434472|DRUG|Fludarabine Phosphate|Given IV
48309885|NCT01434472|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
48309886|NCT01434472|DRUG|Mycophenolate Mofetil|Given PO
48309887|NCT01434472|OTHER|Pharmacological Study|Correlative studies
48309888|NCT01434472|BIOLOGICAL|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
48309889|NCT01434472|RADIATION|Total-Body Irradiation|Undergo TBI
48309890|NCT01434472|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
48309891|NCT01434472|DRUG|Fludarabine|Given IV
48309892|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
47961941|NCT04188847|DRUG|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
47961942|NCT01546883|DRUG|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
47961943|NCT01552941|DEVICE|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
47961944|NCT01274078|BIOLOGICAL|Blueberries|150 grams of frozen blueberries on the same day as exercise
48113398|NCT05129020|DEVICE|Sparrow Fledging Therapy System|tAN sessions will be administered up to four times per day for up to 20 days total. Active tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
48113399|NCT05129020|DEVICE|Sham Sparrow Fledging Therapy System|Participants randomized to the sham group will have the device earpiece applied at the same timepoints and for the same duration as the active group, but stimulation will not be turned on. tAN sessions will be administered up to four times per day for up to 20 days total. Sham tAN will be set to run for 30 minutes one hour prior to each planned morphine dose. When the 30-minute tAN session is complete, the system will be turned off and unplugged.
48113400|NCT00103025|DRUG|Sodium Nitrite|
48113401|NCT00103025|DRUG|Sodium Nitrite Injection|
48113402|NCT03614546|RADIATION|SBRT|Stereotactic Body Radiation Therapy (SBRT)
48113403|NCT03614546|RADIATION|IMRT|Intensity-modulated Radiation Therapy (IMRT)
48113404|NCT03614546|PROCEDURE|Hepatectomy|Hepatectomy
48642699|NCT05869825|PROCEDURE|Non-Invasive Positive Pressure Ventilation following extubation|Participants in this group will be randomized to receive NIPPV respiratory support following extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
47961945|NCT05915078|COMBINATION_PRODUCT|Iontophoresis and tube placement|Iontophoretic delivery of TYMBION™ otic anesthetic using the Tula Iontophoresis System and tube insertion using the Tula Tube Delivery System
47961946|NCT00726375|DRUG|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
47961947|NCT04242329|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases aimed at R0 resection.
47961948|NCT04242329|DRUG|Immunotherapy|Continued PD1-inhibitor treatment according to current treatment standards.
48113405|NCT03614546|PROCEDURE|TACE|transarterial chemoembolization (TACE)
48113406|NCT05018754|DEVICE|TREATMENT OF ORAL MUCOSITIS USING PLATELET-RICH-FIBRIN (PRF)|All patients were affected by oral mucositis (9 RIOM, 6 chemotherapy-related oral mucositis). They were treated with almost 2 different systemic therapies before and during platelets gel applications. Median of time before the lesions were treated with platelets gel were 7 days. Lesions affected buccal mucosa, tongue, labial commissure and lower lip. Preliminar parameters were the microbiological contamination of lesions and presence of pain. Patients refer spontaneous widespread pain worsened by swallowing and feeding. Response to treatment has been evaluated in relation to the reduction of lesions dimensions, to the involution of pain and presence of granulation tissue after every application of platelet gel.
48113407|NCT04548830|PROCEDURE|Transbronchial cryobiopsy|After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
48113408|NCT05132348|DIAGNOSTIC_TEST|Immunological markers|Markers of blood samples of patients suffering from osteoporosis will be analyzed
48113409|NCT04683718|DEVICE|Permanent implant of a BIOTRONIK Prospera SCS (Spinal Cord Stimulation) System with HomeStream Remote Management|The Prospera SCS System is a rechargeable, 16-electrode, MRI conditional Spinal Cord Stimulation system that delivers electrical stimulation to the dorsal column of the spinal cord for the treatment of chronic intractable pain of the trunk and/or limbs.
48642700|NCT05965167|DRUG|EBP05|Oral tablets
48113410|NCT03967626|DEVICE|external cooling with the xxxxx device|external cooling with the xxxxx device
47961949|NCT02109211|DEVICE|Intubation with Magill forceps|
48113411|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
48113412|NCT00542035|DRUG|Placebo; oral|dose 1, dose 2
48113413|NCT00542035|DRUG|Placebo; oral|dose 1
48113414|NCT00542035|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
48113415|NCT02613676|DEVICE|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
48309893|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
47961950|NCT02109211|DEVICE|Intubation with altered Magill forceps|
47961951|NCT05016999|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
47961952|NCT04563611|OTHER|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
48113416|NCT02613676|OTHER|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
48309894|NCT04398017|PROCEDURE|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
48642701|NCT05965167|DRUG|Forteo 20 mg|Subcutaneous injection
48642702|NCT05965167|DRUG|EBP11|Oral tablets
48642703|NCT05965167|DRUG|EBP22|Oral tablets
48309895|NCT00968253|DRUG|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
48309896|NCT00968253|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
48309897|NCT00968253|DRUG|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
48642704|NCT02719366|DEVICE|comfilcon A Extended Range test lens|contact lenses
48642705|NCT02719366|DEVICE|comfilcon A control lens|contact lenses
48309898|NCT00968253|DRUG|Doxorubicin|50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
48309899|NCT00968253|DRUG|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
48309900|NCT00968253|DRUG|Mesna|600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.
48309901|NCT00968253|DRUG|Methotrexate|200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
48309902|NCT00968253|DRUG|Ara-C (Cytarabine)|3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
48309903|NCT00968253|DRUG|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
48309904|NCT00968253|DRUG|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
48309905|NCT00358618|DRUG|Propofol|See Detailed Description.
48642706|NCT05076175|DRUG|Ozanimod|Specified dose on specified days
47961953|NCT04563611|OTHER|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
47961954|NCT04563611|OTHER|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
48309906|NCT01661361|PROCEDURE|blood levels|
47961955|NCT04563611|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
47961956|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
48309907|NCT01379534|DRUG|TKI258|
48309908|NCT03866863|OTHER|Intrauterine growth restriction (IUGR)|Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight \< 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight \< 10th centile combined with umbilical artery pulsatility index \> 95th centile or breakage of growth.
48309909|NCT05523713|BIOLOGICAL|Peripheral venous blood samples|10 ml in a sodium heparin tube and 5 ml in an EDTA tube
48309910|NCT04894786|OTHER|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
48309911|NCT04894786|OTHER|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
47961957|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
47961958|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
48113417|NCT05588193|BEHAVIORAL|PVO|post-visit outreach
48483199|NCT04821388|DEVICE|Rontis DCB|"The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries"
48483200|NCT04546932|PROCEDURE|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O \[24\]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
48483201|NCT02694549|DEVICE|CaveoVasc|
48483202|NCT04854252|DRUG|Fentanyl|TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
48113418|NCT05588193|BEHAVIORAL|TSH|tele-sexual health visit during the ED visit
48113419|NCT01354769|DEVICE|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
47961959|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
47961960|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
48113420|NCT02449863|OTHER|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
47961961|NCT05641519|BEHAVIORAL|SERVE OC Intervention|"SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings"
47961962|NCT05641519|BEHAVIORAL|Enhanced Standard Intervention|Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
48113421|NCT02925351|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48113422|NCT02925351|RADIATION|Fluorine F 18 Clofarabine|Given IV
48113423|NCT02925351|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48113424|NCT01199783|DRUG|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
48113425|NCT01199783|DRUG|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
48113426|NCT00126997|BIOLOGICAL|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
48113427|NCT05752006|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
48642707|NCT06397183|OTHER|Mulligan Strech with Traction (TSLR) Technique|The Mulligan traction straight leg raise (TSLR) technique is a mobilization technique that can increase hamstring flexibility and range of motion.
48642708|NCT06397183|OTHER|Post-Isometric Relaxation Technique|Post-Isometric Relaxation Technique is a Muscle Energy Technique which increases hamstring flexibility and range of motion.
48113428|NCT00590707|DEVICE|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
48642709|NCT05979818|DRUG|Propranolol hydrochloride|10 mg, PO, BID, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
48113429|NCT00590707|DEVICE|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
48113430|NCT06301841|OTHER|experimental|"At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation.~Discontinuation is encouraged in case of no bacteria documentation and a procalcitonin \< 1 ng/L; discontinuation is even encouraged if a viral documentation is concurrently obtained. In case of no bacteria documentation and a procalcitonin \> 1 nd/L, antibiotic continuation is encouraged for additional two days.~In case of bacteria documentation, antibiotic continuation is encouraged, but with narrowing the spectrum as much as possible. The duration of antibiotics is based on a procalcitonin algorithm: procalcitonin \< 0.1 nd/l: discontinuation; 0.1 ng/l \< procalcitonin \< 0.25 ng/l: additional 1 day; procalcitonin \> 0.25 ng/l: additional 2 days."
48113431|NCT02139046|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
48113432|NCT02139046|DRUG|Febuxostat XR|Febuxostat XR over-encapsulated capsules
48113433|NCT02139046|DRUG|Febuxostat placebo|Febuxostat placebo-matching capsules
48483203|NCT05010733|DEVICE|Total hip arthroplasty using the Exeter V40 cemented femoral stem|Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.
48483204|NCT05010733|DEVICE|Total hip arthroplasty using the Müller Straight Stem|Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
48113434|NCT02139046|DRUG|Colchicine|Colchicine tablets
48113435|NCT02139046|DRUG|Naproxen|Naproxen tablets
48113436|NCT02139046|DRUG|Lansoprazole|Lansoprazole capsules
48113437|NCT03761108|DRUG|Linvoseltamab|Administered by IV infusion and/or SC
48483205|NCT01509482|OTHER|blood samples|blood samples to test for primary and secondary outcome measures
48483206|NCT01509482|OTHER|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
48483207|NCT05840094|DRUG|18F-FDG|18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
48483208|NCT05840094|DEVICE|MR STIR|The overall scanning time of MR is about 13min.
48483209|NCT05840094|PROCEDURE|EBUS-TBNA|Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
48483210|NCT02377921|DRUG|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
48483211|NCT02377921|DRUG|Placebo|tablets for oral use
48309912|NCT05185752|PROCEDURE|SIFP Block Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
48309913|NCT05185752|PROCEDURE|PECS II block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
48309914|NCT05185752|PROCEDURE|ESP block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
48309915|NCT01093924|BEHAVIORAL|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
48309916|NCT00347555|BIOLOGICAL|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
48309917|NCT00347555|DRUG|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
48309918|NCT00347555|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
48309919|NCT03008746|OTHER|water used for oral wash|
48309920|NCT03008746|OTHER|sputum|
48309921|NCT03008746|OTHER|oral wash|
48309922|NCT05820100|OTHER|Observational|"The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel."
48309923|NCT01762540|DRUG|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
48309924|NCT01762540|DRUG|Calcium Supplement|Placebo
48309925|NCT02351245|OTHER|observation|
48309926|NCT02814968|DRUG|Enzalutamide|
48309927|NCT02814968|DEVICE|18-FDG PET/CT|
48309928|NCT02814968|DEVICE|Whole body MRI|
48309929|NCT02814968|DEVICE|Bone scan|
48309930|NCT04547738|DRUG|TB treatment according to national guidelines|National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
48309931|NCT04035135|DRUG|ANX005|investigational drug
48309932|NCT04035135|DRUG|Intravenous immunoglobulin|investigational drug
48309933|NCT00219765|DRUG|Imatinib mesylate 600 mg|
48113438|NCT06676696|DRUG|Continue low dose calcineurin inhibitor (CNI)|CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study
48113439|NCT06676696|DRUG|Calcineurin inhibitor withdrawal at 6 months|CNI dose (tacrolimus or cyclosporine) will be reduced to one-half on month 3 visit and completely withdrawn on month 6 visit.
48309934|NCT00219765|DRUG|Cytarabine|
48309935|NCT00219765|DRUG|Daunorubicine|
48309936|NCT05034484|DRUG|ALPN-303|Multiple dose levels will be evaluated.
48309937|NCT05034484|DRUG|Placebo|Placebo will be administered
48309938|NCT00746031|DRUG|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
48309939|NCT00746031|DRUG|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
48266696|NCT03459573|BEHAVIORAL|"One Drop | Experts On Track"|Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
48266697|NCT03459573|BEHAVIORAL|"One Drop | Experts On Call"|Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
48309940|NCT02311855|BIOLOGICAL|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
48309941|NCT01570712|OTHER|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~* Support in the development and the maintenance of the housing;~* Support in the diverse steps (administrative, judicial, financiers, etc.);~* Support around addictions / alcohol;~* Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~* to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
48309942|NCT01570712|OTHER|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\\or the restoring, but this by means of the existing devices"
48309943|NCT00819624|OTHER|Interactive Voice Response System (IVRS)|Telephone based system
48309944|NCT00819624|OTHER|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
48309945|NCT06536153|COMBINATION_PRODUCT|Amaranth grain flat bread|The recipe will be produced according to the recommended dietary allowance (RDA); based on RDA, 200 g of flat-bread (30% chickpea and 70% amaranth grain) comprised 30 mg of iron, which can satisfy 50% of RDA supposing 15-20% iron absorption (54). A prior study concluded that the acceptability was satisfactory in the community (55). Also, a study from the Hawassa University Department of Food Sciences reported that amaranth-grain flat-bread was safe for consumption for 48 hours after preparation and improved the nutritional values (56). To lower the phytate levels in the amaranth grain, home-level processing will be used. For 24 hours, amaranth grain will be soaked in water with 5 milliliters of lemon juice per 100 milliliters of water, and it will germinate for 72 hours. It will be sun-dried, roasted, and ground using a nearby electrical mill before fermented bread is made
48309946|NCT03152916|DEVICE|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
48642710|NCT05979818|DRUG|Sintilimab|intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
48483212|NCT03513042|RADIATION|Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy|"Standard of care:~* IMPT (conventional fractionation \[35x1,55/2Gy, 5 fractions/week\] or accelerated fractionation \[35x1,55/2Gy, 6 fractions/week\])~* with or without concurrent cisplatin (100 mg/m2 \[d1, d22 and d43\] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)"
48642711|NCT05979818|DRUG|Chemotherapy|"Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent."
48483213|NCT01176019|DEVICE|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
48483214|NCT06397820|DEVICE|Percutaneous coronary intervention (PCI)|Revascularization by percutaneous coronary intervention for vessels with decreased PET-derived flow indexes
48642712|NCT01887600|DRUG|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
48642713|NCT01887600|DRUG|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
48483215|NCT02722252|DEVICE|Embryoscope|
48483216|NCT02722252|DEVICE|Embryo culture system without incorporated camera|
48642714|NCT06465966|DEVICE|iRAI|Ionizing-radiation photo acoustic imaging (iRAI) is a method of collecting images from inside the body using acoustic (sound) waves. Researchers will collect iRAI during a participant's radiation treatments. Researchers will use this imaging to examine the delivery and dose of the radiation to the participant's prostate. Researchers will also compare the delivery and dose calculated from iRAI to the expected doses that were calculated from CT images which are done as standard of care.
48642715|NCT02080000|OTHER|Optimisation of V-V timing using R wave on surface ECG|
48642716|NCT02080000|OTHER|Standard V-V timing settings|
48642717|NCT05530707|OTHER|Moisturizer containing saccharide isomerate and niacinamide|Moisturizer containing saccharide isomerate and niacinamide
48642718|NCT06566768|DRUG|Deucravacitinib|Specified dose on specified days
48642719|NCT06694402|DEVICE|focal muscle vibration combined with exercise|The treatment group will receive a 30-minute intervention in each session. Focal muscle vibration will be applied to the anterior and lateral parts of shoulder to give a sensory stimulation while participants are doing eaercise.
48642720|NCT06694402|OTHER|exercise|The control group will receive 30-minute exercise without focal muslce vibration.
48266698|NCT03459573|BEHAVIORAL|"One Drop | Experts Revive"|Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
48266699|NCT03791333|OTHER|injury severity score|injury severity score of multi trauma patients
48266700|NCT04233515|DRUG|Oral anticoagulant|Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
48266701|NCT05660304|DEVICE|Cortico-cortical paired associative stimulation|Two brain areas will be stimulated with transcranial magnetic stimulation pulses. The pulses will be delivered with a time difference, on other words, one pulse after another.
48309947|NCT05839431|BEHAVIORAL|Virtual Reality for Youth Phobias|The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
48309948|NCT01368341|DRUG|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
48309949|NCT01368341|DRUG|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
48309950|NCT01368341|DRUG|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
48309951|NCT06478758|DRUG|Ibuprofen 400 mg|The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
48309952|NCT06478758|DRUG|Acetaminophen 100 MG/ML|The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
48309953|NCT03839147|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
48309954|NCT03531437|DRUG|1.5 mg estradiol and 2.5 mg nomegestrol acetate|
48309955|NCT03531437|DRUG|15 µg ethinylestradiol and 60 µg gestodene|
48309956|NCT05858294|BEHAVIORAL|Cognitive Behavioral Therapy programme|This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
48309957|NCT06177054|BEHAVIORAL|Rotation guided by ultrasound|Instruction to avoid areas with hyperechogenicity - after two weeks observation
48309958|NCT01524445|OTHER|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
48309959|NCT02046031|DRUG|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
48309960|NCT01133210|DRUG|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
48309961|NCT01133210|OTHER|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
48309962|NCT04495361|OTHER|E-learning portal|An online learning portal for the identification and management of pneumonia in under five children
48642721|NCT03776240|DRUG|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
48642722|NCT03776240|DRUG|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
48642723|NCT03776240|DRUG|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
48266702|NCT05660304|DEVICE|Sham cortico-cortical paired associative stimulation|Two brain areas will be stimulated with sham transcranial magnetic stimulation. The sham pulses will be delivered with a time difference, on other words, one pulse after another.
48309963|NCT02164513|DRUG|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
48309964|NCT02164513|DRUG|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
48309965|NCT02164513|DRUG|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
48309966|NCT06305104|BIOLOGICAL|2.5μg/ml EEC|0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
48309967|NCT06305104|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
48642724|NCT03153202|DRUG|Ibrutinib|once daily oral intake ibrutinib
48642725|NCT03153202|DRUG|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
48642726|NCT05068830|DRUG|ExPlas|"ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
48266703|NCT03696992|PROCEDURE|Tandem colonoscopy|Tandem colonoscopy with different image modalities
47961963|NCT03533868|DIAGNOSTIC_TEST|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
47961964|NCT03680560|BIOLOGICAL|ACTR T Cell Product|Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
47961965|NCT03680560|DRUG|Trastuzumab|monoclonal antibody targeting HER2
48309968|NCT06305104|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
47961966|NCT01847378|PROCEDURE|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
48309969|NCT02145156|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
48309970|NCT02145156|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
48309971|NCT02145156|BEHAVIORAL|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
48309972|NCT05298033|DRUG|Crisaborole 2 % Topical Ointment|Twice daily crisaborole 2% topical ointment
47961967|NCT00702923|DRUG|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
47961968|NCT00702923|DRUG|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
48309973|NCT05298033|DRUG|PF-07038124 0.01% topical ointment|Twice daily PF-07038124 0.01% topical ointment
47961969|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
47961970|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
47961971|NCT00702923|DRUG|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
47961972|NCT01429415|DRUG|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
47961973|NCT01429415|DRUG|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
47961974|NCT03764696|DEVICE|tight-fitting simple facemask|Oxygen will be administered by facemask at 10 L/min oxygen. The therapy will continue until after delivery
48309974|NCT05298033|DEVICE|NBUVB phototherapy|Home narrow band UVB phototherapy exposure sessions 3 times per week
48483217|NCT01191528|DEVICE|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.~End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
48309975|NCT05298033|DEVICE|Sham phototherapy|Non-NBUVB visible light radiation exposure sessions 3 times per week
47961975|NCT02736760|DRUG|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
47961976|NCT02736760|PROCEDURE|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
48483218|NCT01421199|PROCEDURE|Myringotomy|tube placement for children with multiple ear infections
48483219|NCT00688428|DRUG|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
48483220|NCT00688428|DRUG|Esomeprazole|40mg capsule, administered as a single dose
48483221|NCT00688428|DRUG|ASA|325mg tablet, administered as a single oral dose
48483222|NCT01369017|DRUG|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
47961977|NCT04173559|BEHAVIORAL|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
47961978|NCT00037804|DRUG|Irinotecan|
47961979|NCT02925923|DRUG|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
47961980|NCT02925923|DRUG|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
47961981|NCT02925923|DRUG|Clopidogrel|
47961982|NCT05250882|OTHER|Enhanced perioperative care protocol|See arm/group description
47961983|NCT02601391|BEHAVIORAL|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
47961984|NCT04720066|DIAGNOSTIC_TEST|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
47961985|NCT05789160|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
47961986|NCT05820672|OTHER|No intervention|No intervention
47961987|NCT04208633|PROCEDURE|Horizontal placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
47961988|NCT04208633|PROCEDURE|Vertical placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
47961989|NCT00840892|OTHER|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
47961990|NCT01002222|DRUG|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
47961991|NCT00850590|DRUG|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
47961992|NCT04338074|DRUG|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
47961993|NCT04338074|DRUG|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
47961994|NCT03203616|DRUG|KADCYLA 160 MG Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
47961995|NCT01020175|PROCEDURE|Bone marrow transplantation|Patients received bone marrow transplantation
48642727|NCT05068830|DRUG|Octaplasma|"Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
48642728|NCT05068830|DRUG|Saline|"Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline."
48642729|NCT06695624|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganglion block group 4cc (80mg) 2% lidocaine + 1cc (4mg) dexamethasone in total 5cc volume will be prepared under sterile conditions before the procedure, 2.5 cc will be given to both nostrils. Sphenopalatine ganglion block will be applied by transnasal endoscopic method.
48309976|NCT05298033|DRUG|Vehicle|Twice daily vehicle ointment
47961996|NCT01020175|PROCEDURE|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
47961997|NCT02321410|OTHER|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
48309977|NCT05232942|OTHER|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
48309978|NCT02000986|BEHAVIORAL|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
48309979|NCT03326219|PROCEDURE|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
48309980|NCT02564159|OTHER|Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels|"* Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~* Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels"
48309981|NCT01337531|DRUG|Gonal-F, Fostimon|dosage form
48309982|NCT01337531|DRUG|Gonal-F, Fostimon|injection, daily, 10-15 days
48309983|NCT03192982|DEVICE|A-V impulse 6000 Series|foot pad and pump
48309984|NCT03192982|DEVICE|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
48309985|NCT02397993|PROCEDURE|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
48309986|NCT02397993|PROCEDURE|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
48309987|NCT02397993|PROCEDURE|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
48309988|NCT06084390|OTHER|Interdisciplinary care + booster session (intervention)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden + one extra booster-session 3 months after the standard care rehabilitation. At the booster-session, the participant´s individual rehabilitation plan is followed-up and adjusted. This extra period also includes extended access to the team, meaning that the participants have the possibility to contact the team and, if needed, have digital or telephone contact.
48309989|NCT06084390|OTHER|Interdisciplinary care (control)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden.
48309990|NCT05024123|DIETARY_SUPPLEMENT|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
47961998|NCT02321410|OTHER|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
48309991|NCT05024123|DIETARY_SUPPLEMENT|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
48309992|NCT02275689|PROCEDURE|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
48309993|NCT02275689|PROCEDURE|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
48642730|NCT06694220|OTHER|Tailored preventive exercises|Players in the experimental group will be asked to perform the tailored preventive program 2-3 times per week for 1 hour for at least 6 weeks preseason which includes warming up for 10 mins, flexibility exercises, strengthening exercises, core and lower body stability and balance exercises and drills all these exercises for 1-4 sets x 10-20 reps and cooling down stretches for the last 10 mins.
47961999|NCT04742985|DIETARY_SUPPLEMENT|Green tea combined extracts group|Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks
48309994|NCT00584220|DEVICE|senofilcon A toric|contact lens
48309995|NCT00584220|DEVICE|alphafilcon A toric|contact lens
48309996|NCT04176432|OTHER|No intervention|Retrospective observational study with no intervention
47962000|NCT04742985|DIETARY_SUPPLEMENT|Placebo group|Placebo 320 mg/day during 8 weeks
47962001|NCT04218630|OTHER|Reformer pilates exercises|The program consisted of 10 minutes warm-up exercises, reformer pilates exercises for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week and applied to be 12-15 repetitions in the last week. Increasing the resistance of the springs and adding different positions were used for progression of exercises.
47962002|NCT04218630|OTHER|Home mat pilates exercises|The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week, and applied to be 12-15 repetitions in the last week.
47962003|NCT06022744|DRUG|LX109|LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
48483223|NCT01369017|DRUG|Placebo|Injection of NS
47962004|NCT05218135|OTHER|Intervention|Learning session 1: explain key interventions, explain BIC methodology, retrospective patient record analysis Learning session 2: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 3: feedback report, share best practices, discussion, set priorities, teaching and improvement, retrospective patient record analysis Learning session 4: feedback report
47962005|NCT04456530|DRUG|Aveed 750 MG in 3 ML IM Injection|Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
47962006|NCT04456530|OTHER|Normal Saline 3 ML IM Injection|Participants in the Control Group will receive two IM normal saline injections 1 month apart.
47962007|NCT01450995|DRUG|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
47962008|NCT01450995|DRUG|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
47962009|NCT04612673|DRUG|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
47962010|NCT00397345|BIOLOGICAL|Trovax|1ml IM injection 2-8 weeks apart.
47962011|NCT00397345|BIOLOGICAL|Placebo|Placebo
47962012|NCT00397345|BIOLOGICAL|Standard of care therapy|subcutaneous low dose IL-2, interferon-α or sunitinib
47962013|NCT02011971|DRUG|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
47962014|NCT02527135|BEHAVIORAL|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
47962015|NCT02796469|DRUG|Pentoxifylline|
47962016|NCT02796469|DRUG|Corticosteroid|
47962017|NCT02796469|DRUG|Placebo|
47962018|NCT05999929|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
47962019|NCT05085873|DRUG|Sodium Oxybate injection|"* Induction dosage : 60 mg/kg by direct intravenous injection.~* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death."
47962020|NCT05085873|DRUG|Midazolam injection|"* Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death."
47962021|NCT00433121|DRUG|Risperidone|
47962022|NCT00433121|DRUG|Olanzapine|
47962023|NCT00433121|DRUG|Haloperidole|
47962024|NCT00433121|DRUG|Quetiapin|
47962025|NCT00433121|DRUG|Escitalopram|
47962026|NCT00433121|DRUG|Citalopram|
47962027|NCT00433121|DRUG|Sertralin|
47962028|NCT01790880|BEHAVIORAL|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
47962029|NCT01790880|BEHAVIORAL|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
47962030|NCT02560532|DRUG|Clazosentan|Concentrated solution for intravenous injection
48113440|NCT06318624|OTHER|Mobilisation with Movement and Taping|For MWM for the talocrural joint, the hemiparetic side of the participant is positioned in a standing position on a stool. A non-elastic belt is passed behind the patient's distal tibia and secured around the therapist's pelvis. The patient is asked to perform active knee flexion and ankle dorsiflexion with weight on the hemiparetic side. Meanwhile, the therapist performs forward sliding of the tibia with the help of the belt. For 10 seconds active and painless sliding takes place and then return to the starting position. This application is applied as 10 repetitions, 6 sets, and 1 minute rest between sets. Following the MWM application, Mulligan talus stabilization taping is performed. For this taping, the participants' ankles are placed on a stool at a height of 30 cm and their feet are placed in the dorsiflexion position. The therapist starts taping from the plantar surface of the calcaneus using rigid tape and will wrap and stabilize the talus.
47962031|NCT01550731|BEHAVIORAL|PREPARE website|Advance care planning website and materials plus an advance directive.
47962032|NCT01550731|BEHAVIORAL|Advance directive|The control group will only receive an advance directive.
48483224|NCT04621916|DRUG|FVIII|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
47962033|NCT02121431|BEHAVIORAL|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
47962034|NCT03538548|BEHAVIORAL|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
48113441|NCT06318624|OTHER|Sham|During joint mobilization with movement, the therapist will stabilize the ankle while performing knee flexion and ankle dorsiflexion by actively moving the center of mass to the affected side, but the shear force required to slide the tibia forward with the belt will not be given. Placebo taping following the application will be applied in such a way that there is no stabilization effect without tension between the same start and end points.
47962035|NCT01213329|DRUG|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
47962036|NCT03081533|OTHER|Circle Dance Program (CircleCare)|Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
47962037|NCT00493025|DRUG|cisplatin|Cisplatin IV
47962038|NCT00493025|DRUG|gefitinib|Gefitinib IV
47962039|NCT00493025|DRUG|paclitaxel|Paclitaxel IV
47962040|NCT00493025|PROCEDURE|adjuvant therapy|Postoperative ZD1839
47962041|NCT00493025|RADIATION|radiation therapy|Radiotherapy
47962042|NCT02354495|DIETARY_SUPPLEMENT|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
47962043|NCT01408927|OTHER|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
47962044|NCT01408927|OTHER|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
47962045|NCT01408927|OTHER|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
47962046|NCT00453063|DRUG|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
47962047|NCT00453063|DRUG|Placebo|Two sprays in each nostril once daily in the morning
47962048|NCT00000557|BEHAVIORAL|social support|
47962049|NCT02021578|BEHAVIORAL|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
47962050|NCT02021578|BEHAVIORAL|Written information|Reading materials about depression
47962051|NCT06469216|DRUG|Hyaluronic Acid|Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
47962052|NCT06469216|OTHER|Placebo|Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
47962053|NCT01827956|OTHER|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
47962054|NCT04868175|DRUG|Timolol|Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
47962055|NCT04868175|DRUG|Travatan|Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
47962056|NCT04868175|DRUG|Hypromellose|Placebo eye drop, lubricant
48113442|NCT05507749|PROCEDURE|cryoballoon ablation|Cryoballoon ablation for the treatment of atrial fibrillation
47962057|NCT03424408|DRUG|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
47962058|NCT01352546|BIOLOGICAL|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
47962059|NCT03046758|DRUG|A combination of fosfomycin, metronidazole and GM-CSF i.p.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
47962060|NCT01388738|DRUG|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
47962061|NCT01388738|DRUG|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
47962062|NCT01388738|DRUG|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
48113443|NCT05507749|DEVICE|implantable loop recorder insertion|The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.
48483225|NCT04621916|DRUG|Emicizumab|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
48309997|NCT02030145|PROCEDURE|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
48642731|NCT06694220|OTHER|Traditional exercises|The players will be warmed up as usual, with jogging and ball-based exercises following FIFA 11+ warming up program which consist of three steps with 15 specific exercises running exercises for 8 mins, starting warming up in pairs; Path consists of 6-10 pairs of parallel cones: (Running Straight Ahead, Running Hip Out, Running Hip In, Running Circling Partner, Running Shoulder Contact, Running Quick Forwards and Backwards, Rep. x2). Strength, plyometric, balance for 10 minutes (The Bench, Sideways Bench, Single-leg Stance, Squats, Jumping Rep. 2x 30 sec each side). Running Exercises for 2 minutes (End of heating): (running across the pitch, running bounding, running plant, and cut. Rep x 2). Techniques need to be performed correctly and with an emphasis on maintaining the correct posture of the body. This exercise program should be done at least twice a week
48642732|NCT05353829|DRUG|Methotrexate|When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
48309998|NCT02030145|PROCEDURE|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
48309999|NCT06447025|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
48310000|NCT01245426|DRUG|GW870086 2mg|oral inhalation
48310001|NCT01245426|DRUG|GW870086 4mg|oral inhalation
47962063|NCT02324257|DRUG|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
48642733|NCT05877846|DIETARY_SUPPLEMENT|Beta-hydroxymethyl butyrate supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
47962064|NCT02324257|DRUG|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
47962065|NCT02324257|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
47962066|NCT05984472|PROCEDURE|Edelweiss prefabricated veneers|Individual Randomized Clinical Trial
47962067|NCT05984472|PROCEDURE|Ceram-X Duo SphereTec with U-Veneer|Ceram-X Duo SphereTec with U-Veneer
48310002|NCT01245426|DRUG|GW870086 Placebo|oral inhalation
48310003|NCT01245426|DRUG|GW870086 1mg|oral inhalation
47962068|NCT02646657|DRUG|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
47962069|NCT02004119|DRUG|KHK4577|
47962070|NCT02004119|DRUG|Placebo|
47962071|NCT02639767|DRUG|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m\^2 for pemetrexed in combination with 75 mg/m\^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
48310004|NCT01245426|DRUG|GW870086 3mg|oral inhalation
48310005|NCT02195791|DRUG|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
48310006|NCT02195791|DRUG|Placebo|Placebo (oral) 1 tab once daily for 7 days
48483226|NCT04363749|OTHER|hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint|the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
48483227|NCT02948725|OTHER|Cross-education + standard rehabilitation|
48483228|NCT03054831|DRUG|liquid oxycodone|"The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).~In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU)."
48483229|NCT03921151|DRUG|Mirtazapine 15 MG Oral Tablet|The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
48483230|NCT03413384|DRUG|Ceftriaxone|1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
48483231|NCT03413384|OTHER|Placebo|Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
48483232|NCT04693338|OTHER|Quality-of-Life Assessment|Ancillary studies
48483233|NCT04693338|OTHER|Questionnaire Administration|Ancillary studies
48483234|NCT04693338|OTHER|Supportive Care|Receive ICP tasks
48483235|NCT01688726|OTHER|SYSTANE® BALANCE eyedrops|
48483236|NCT01688726|OTHER|Minims® Saline 0.9% eyedrops|
48483237|NCT06401967|BEHAVIORAL|Pivot Clear|A mobile app and program for alcohol reduction.
48483238|NCT06401967|DEVICE|BACtrack breathalyzer|Personal breathalyzer device that measures blood alcohol content.
48642734|NCT05877846|DIETARY_SUPPLEMENT|Vitamin D supplement|Beta-hydroxymethyl butyrate (750 mg) - Vitamin D3 (200 IU) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate with 200 IU of vitamin D3 per capsule. Frequency is 2 capsules twice daily (morning, evening)
48310007|NCT04800419|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a third generation cognitive behavioral approach which uses acceptance and mindfulness processes, and commitment and behavior change processes to produce psychological flexibility. ACT increase adaptive coping through acceptance, cognitive defusion, mindfulness, and perspective-taking exercises while supporting cancer survivors in aligning behavior with their personal values. The objectives of the therapy are for client to learn to focus on behaviors and actions that are in line with their individual values - the things they care about most. ACT facilitates development and maintenance of health behavioral improvements by targeting internal barriers, such as emotional discomfort and self-defeating thoughts, and by fostering connection and commitment to personal values associated with self-management of positive health behaviors. ACT is useful in cancer patients, because it can help them to deal with the negative emotions caused by cancer instead of avoiding these.
48310008|NCT04800419|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|The term 'mindfulness' refers to mindful awareness as a way of being - a knowing and experiencing of feelings, thoughts, and perceptions as they arise and pass away each moment. It is a way of relating to all experiences in an open, receptive way, without judging experiences as good or bad (grasping at them or pushing them away). Mindfulness employed two styles of meditations: concentrative meditation involves intentionally focusing attention on a chosen object (e.g. the sensations of breathing) in a sustained way, while receptive meditation involves monitoring the content of experience (e.g. sensations, emotions, thoughts, sounds, etc.) in a non-reactive and non-judgmental way, from moment to moment, with the goal being to recognize the nature of emotional and cognitive patterns. Mindfulness-based stress reduction (MBSR) is an 8-week, standardized group intervention consisting of mindfulness meditation and gentle yoga that is designed to have applications for stress, pain, and illness
48310009|NCT02795195|RADIATION|Carbon ion radiotherapy (CIRT)|Four dose levels (54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., maximal tolerated dose, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the gross tumor volume plus 3\~5mm.
48310010|NCT01515306|BIOLOGICAL|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
48310011|NCT01515306|DRUG|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
48310012|NCT05381376|DIAGNOSTIC_TEST|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
48310013|NCT05381376|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
48310014|NCT04698213|DRUG|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
48483239|NCT04825041|DIAGNOSTIC_TEST|Patency test|Successive flow test, bubble flow test and peristalsis test
48483240|NCT04149028|PROCEDURE|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
48483241|NCT01418716|OTHER|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
48113444|NCT06306313|DEVICE|ReoGo|ReoGo is a fixed arm rehabilitation exoskeleton that comes on a small and compact wheeled platform. The end-effector extension is capable of producing a wide range or repeatable movements in 3D space. ReoGo can be used by both adults and children. It is an arm rehabilitation exoskeleton with a fixed base. Its design allows limited controlled movements of the shoulder as well as the elbow and wrist.
48113445|NCT06306313|OTHER|Conventional Physiotherapy|Physiotherapy protocols will be created with traditional physiotherapy practices such as neurodevelopmental techniques based on muscle strengthening and task-oriented exercises. Protocols in general terms; It will include passive and active joint range of motion exercises, stretching exercises, stimulation and facilitation techniques, strengthening exercises, fine motor skills and functional task training for daily living activities. Protocols will be tailored to each patient's level of motor impairment and functional needs.
48483242|NCT01418716|OTHER|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
48113446|NCT06534983|DRUG|Autogene Cevumeran|Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
48113447|NCT06534983|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
48483243|NCT02231424|DRUG|Drug: Berodual®|
48483244|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
48310015|NCT04698213|DRUG|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
48310016|NCT02779192|DRUG|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
48310017|NCT02779192|DRUG|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
48310018|NCT02779192|DRUG|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
48310019|NCT04341675|DRUG|Sirolimus|Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
48642735|NCT05877846|DIETARY_SUPPLEMENT|Matching Beta-hydroxymethyl butyrate supplement without Vitamin D|Beta-hydroxymethyl butyrate (750 mg) capsules. The formulation is 750 mg of Beta-hydroxymethyl butyrate per capsule. Frequency is 2 capsules twice daily (morning, evening)
48310020|NCT04341675|DRUG|Placebo|Matching placebo
48310021|NCT06231199|OTHER|gastrocnemius release|The patient will be prone to lying and the therapist will stand at the side of the patient's leg. The therapist uses both hands in cross-hand pattern (Figure 10a and 10b). Myofascial Release will be performed for 20 repetitions, then gastrocnemius release by foam roller;This involved long sitting, with the affected leg will be extended on the foam roller and foot relaxed. The non-affected leg will be flexed at knee so that the foot will be rested on the floor. The participants will be instructed to use their arms and non_affected foot to propel their body back and forth from the popliteal fossa to Achilles tendon in continuous motion. then patients perform plantar fascia realise from standing by foam roller
48310022|NCT06231199|OTHER|conventional treatment|the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
48310023|NCT01815333|DRUG|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
48310024|NCT01815333|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
48310025|NCT00279968|DEVICE|ICD|
48310026|NCT00149604|DRUG|conjugated estrogens|
48310027|NCT00149604|DRUG|Raloxifene|
48310028|NCT00149604|BEHAVIORAL|exercise plus mild caloric restriction for weight loss|
48310029|NCT00429065|DRUG|Rituximab|
48310030|NCT04516018|OTHER|Cold exposure|Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
48310031|NCT03136185|DRUG|Bomedemstat|Oral (capsule) administration according to dose allocation.
48310032|NCT00313534|DRUG|masoprocol|
48113448|NCT06534983|DRUG|Saline|Saline solution for intravenous infusion
48310033|NCT02081339|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|
48113449|NCT01809392|DRUG|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
48310034|NCT04786873|DRUG|Macimorelin|Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
48310035|NCT04786873|DIAGNOSTIC_TEST|Arginine|For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.
48310036|NCT04786873|DIAGNOSTIC_TEST|Clonidine|"For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally."
48310037|NCT00003636|DRUG|carboplatin|
48310038|NCT00003636|DRUG|cisplatin|
48310039|NCT00003636|PROCEDURE|conventional surgery|
48310040|NCT00003636|PROCEDURE|neoadjuvant therapy|
48310041|NCT02488551|DEVICE|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
48310042|NCT02488551|OTHER|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
48310043|NCT01345123|BEHAVIORAL|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
48483245|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
48642736|NCT03845166|DRUG|XL092|oral doses of XL092
48642737|NCT03845166|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
48642738|NCT03845166|DRUG|Avelumab|Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
48642739|NCT04308590|DRUG|relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
48642740|NCT04308590|OTHER|Placebo|Placebo is supplied as 100 mg capsules for oral dosing.
48310044|NCT01345123|BEHAVIORAL|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
48310045|NCT05959772|RADIATION|Photobiomodulation|"Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape"
48310046|NCT05224869|DEVICE|Medical Device Usage and Evaluation|Undergo hydrogel rectal spacer placement
48310047|NCT05224869|PROCEDURE|CT simulation|CT simulation of radiation treatment planning 2-7 days after hydrogel placement
48310048|NCT05224869|PROCEDURE|Stereotactic body radiation therapy|SBRT in 5 fractions over 1 week, 7 days after CT simulation
48642741|NCT06695429|DIETARY_SUPPLEMENT|Beetroot juice|Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.
48310049|NCT05224869|RADIATION|Brachytherapy|one month after completing SBRT
48310050|NCT05224869|PROCEDURE|Post-implant dosimetry scan|one month after brachytherapy
48310051|NCT05080179|BEHAVIORAL|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
48310052|NCT05080179|BEHAVIORAL|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
48310053|NCT05080179|BEHAVIORAL|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
48310054|NCT05080179|BEHAVIORAL|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
48113450|NCT00492791|DEVICE|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
48113451|NCT05486364|DIAGNOSTIC_TEST|Digital Monitoring|Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
48310055|NCT01918098|DRUG|Oxycodone/naloxone prolonged release tablets|
48310056|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
48310057|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
48310058|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
48310059|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
48310060|NCT06440369|OTHER|Training group|"The patient will perform an intermittent exercise which consists of nine 5-minute cycles with a succession of work (top: 1 minute; bottom: 4 minutes). The high-intensity work phase will be adjusted so as to achieve a target Heart Rate (HR) corresponding to resting HR + 80% reserve HR (reserve HR = (200 - age) - resting HR). The low-intensity work phase will be adjusted to achieve a target maximum HR corresponding to resting HR + 60% reserve HR. In total duration, the exercise presents a submaximal intensity, commonly used in exercise rehabilitation studies carried out with various pathologies. It is an intensity capable of promoting benefits on the cardiovascular aspect without representing a severe intensity for the patient.~In order to adapt the training and guarantee patient safety, the first exercise session will be carried out with an alternation between a high-intensity work phase of resting HR + 70% reserve HR and a work phase. at low intensity of resting HR + 50% reserve HR."
48310061|NCT06440369|OTHER|Physical activity orientation group|Every week, for around ten minutes, patients in the AP orientation group will be contacted by telephone. The main objective of this exchange is to provide targeted advice on physical activity, its role, its objectives as well as its different ways of carrying it out. The second objective is to provide each week a personalized objective for each patient which can evolve over the weeks to increase levels of physical activity as far as possible. During each call, the evaluator will practice reflective listening, ask open-ended questions to facilitate the exchange, value and summarize the patient.
48310062|NCT02362087|OTHER|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
48310063|NCT04178681|OTHER|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
48310064|NCT04178681|OTHER|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
48310065|NCT04178681|OTHER|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
48113452|NCT05486364|DIAGNOSTIC_TEST|Standard of care|Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
48310066|NCT05390450|DEVICE|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
48310067|NCT05390450|DEVICE|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
48310068|NCT00307593|DRUG|Infliximab|Infliximab
48310069|NCT00307593|DRUG|Rituximab|Rituximab
48483246|NCT02677259|DRUG|17-beta estradiol|
48483247|NCT02677259|DRUG|Micronized progesterone|
48483248|NCT02854696|PROCEDURE|Islet graft|Patients will be transplanted with pancreatic islet cells
48642742|NCT06694519|DEVICE|manometry through the PHENIX series device (model: PHENIX LIBERTY; manufacturer: ELECTRONIC CONCEPT LIGNON INNOVATION, Montpelier, France).|For this manometry the air probe, connected to the Phenix biofeedback system, covered by a latex probe cover lubricated with gel, will be used. In the procedure, the labia majora are opened with one hand and slowly rotated into the vagina while holding the back of the manometric probe with the other hand. Basal tone in g will be measured prior to pelvic floor muscles force measurements. The manometry probe will extract pelvic floor pressure signals by measuring both your basal tone and the maximum pressure held for 10 seconds in three measurements, the average of the three being calculated at the command, 'contract as hard as you can for as long as possible'.
47962072|NCT02639767|RADIATION|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
47962073|NCT02639767|DEVICE|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
48113453|NCT01793662|PROCEDURE|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
48113454|NCT03616639|DRUG|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
47962074|NCT00760123|OTHER|Early Physical Therapy and Educational strategy|"Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy"
48310070|NCT03082495|BEHAVIORAL|Exercise|Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
48483249|NCT02854696|DRUG|best medical care|Patients will continue their insulin treatment
48483250|NCT00986453|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
48483251|NCT00986453|PROCEDURE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
48310071|NCT02332356|DRUG|azathioprine or adalimumab and infliximab|
48310072|NCT00120445|PROCEDURE|air|0.3 ml of filtered air
48310073|NCT00120445|PROCEDURE|expansile gas|0.3 ml of perfluoropropane gas
48483252|NCT06175429|DIAGNOSTIC_TEST|Physical performance testing|Assessment of physical performance using established clinical tests and scoring systems
48483253|NCT06175429|DIAGNOSTIC_TEST|Breath sampling and VOC analysis|Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.
48483254|NCT06175429|DIAGNOSTIC_TEST|Muscle ultrasound|Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.
48483255|NCT06175429|DIAGNOSTIC_TEST|Blood-based biomarker analysis|Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)
48483256|NCT04807751|DRUG|Delgocitinib cream|Cream for topical application
48483257|NCT04807751|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
48483258|NCT04553224|OTHER|Clinical evaluations|SCORAD and target SCORAD
48483259|NCT04553224|OTHER|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
47962075|NCT01404858|BEHAVIORAL|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
48483260|NCT04553224|OTHER|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
48483261|NCT01706016|PROCEDURE|Thermic destruction of tissue by Laser using the Novilase device|
48310074|NCT03088293|DRUG|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
48310075|NCT03088293|DRUG|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
48310076|NCT01401816|OTHER|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
48310077|NCT04556084|DRUG|Blinatumomab|"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
48310078|NCT00218036|DRUG|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
48310079|NCT00218036|DRUG|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
48310080|NCT00218036|DRUG|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
48310081|NCT00218036|DRUG|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
48310082|NCT00218036|DRUG|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
48310083|NCT02666092|OTHER|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
48310084|NCT02666092|BIOLOGICAL|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
48310085|NCT04738500|PROCEDURE|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
48310086|NCT04738500|PROCEDURE|PCA|PCA will be applied after surgery
48310087|NCT04188340|BEHAVIORAL|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
48310088|NCT02476981|DRUG|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
48310089|NCT02476981|DRUG|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
48642743|NCT06694519|DIAGNOSTIC_TEST|PFIQ-20 questionnaire (Pelvic Floor Impact Questionnaire Short Form)|This questionnaire allows assessment of the impact of urinary symptoms, colo-rectal-anal symptoms and genital prolapse symptoms. This questionnaire will also be used as an inclusion criterion, to homogenise the characteristics of the population in terms of pelvic dysfunction prior to the intervention, as indicated above.
48642744|NCT06694519|DIAGNOSTIC_TEST|ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)|a four-question self-administered questionnaire that identifies individuals with urinary incontinence by assessing frequency, severity and impact on quality of life. It is composed of five questions assessing frequency, severity and impact of UI, plus a set of eight self-diagnostic items related to UI situations experienced by patients. The maximum sum of the response values indicates a score of 21 points, referring to the high impact of UI on an individual's life.
48642745|NCT06694519|DIAGNOSTIC_TEST|Sandvik's test|It provides information on the severity of the UI by means of two questions. The interpretation based on the score is classified as: 1-2 mild UI, 3-6 moderate UI, 8-9 severe UI, 12 very severe UI.
48642746|NCT06694519|DIAGNOSTIC_TEST|vaginal health index (VHI)|this index consists of a graduated scale from 1 to 5 for each item (vaginal elasticity, fluid volume, pH, epithelial integrity and moisture).Vaginal elasticity ranges from 1 (no elasticity) to 5 (excellent elasticity), assessed by distension of the mucosa on palpation and speculum placement. The volume of fluid, assessed during inspection, varies between 1 (no discharge) and 5 (normal discharge) (white flocculent). The integrity of the epithelium varies between 1 (petechiae already detected on inspection) and 5 (non-friable tissue and normal mucosa). Moisture ranges from 1 (no moisture detected on inspection and presence of inflamed mucosa) to 5 (normal moisture). The pH will be quantified using a pH indicator strip between 0 and 14 (MColorpHast™-PH indicator strips) to be placed directly on the right lateral vaginal wall for one minute, giving 1 point for pH 6.1, 2 for pH 5.6-6.0, 3 for pH 5.1-5.5, 4 for pH 4.7-5.0 and 5 for pH ≤ 4.6. The sum of all items represents the vaginal health
48310090|NCT02476981|DRUG|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
48310091|NCT02476981|DRUG|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
48310092|NCT02476981|DRUG|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
48310093|NCT02774226|DRUG|Tetrahydrobiopterin (BH4)|12 week intervention
48310094|NCT02774226|DIETARY_SUPPLEMENT|Antioxidant Cocktail|12 week intervention
48310095|NCT02514460|DEVICE|plaque excision system|
48310096|NCT02514460|DEVICE|Stent|
48310097|NCT02661607|PROCEDURE|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
48310098|NCT02661607|DEVICE|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
48310099|NCT02661607|PROCEDURE|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
48310100|NCT04355156|DRUG|Axitinib|"* All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated"
48310101|NCT04355156|DRUG|Placebo|"* All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)"
48310102|NCT05789264|DEVICE|Nasal Compression Device|Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.
48310103|NCT05789264|DIAGNOSTIC_TEST|Routine Care|Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
48310104|NCT00997048|PROCEDURE|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
48310105|NCT00997048|PROCEDURE|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
48310106|NCT01778387|PROCEDURE|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
48310107|NCT01425190|DRUG|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
48310108|NCT04719169|DIAGNOSTIC_TEST|Dynamic MRI enema|Dynamic MRI enema
48310109|NCT04719169|DIAGNOSTIC_TEST|Fluoroscopic enema|Fluoroscopic enema
48310110|NCT00633438|OTHER|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
48310111|NCT00633438|DRUG|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
48310112|NCT04387058|DEVICE|TIPS|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
48310113|NCT02960932|DEVICE|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
48310114|NCT01675531|DRUG|Targin|Single arm for Targin
48310115|NCT00664092|OTHER|Residential|living in a democratic, resident-run setting
48310116|NCT00664092|OTHER|Residential|Professionally-run substance abuse recovery setting
48310117|NCT03904446|DRUG|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
48310118|NCT03904446|DRUG|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
47962076|NCT02572401|BEHAVIORAL|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
47962077|NCT02572401|BEHAVIORAL|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
48310119|NCT00488618|DRUG|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
48310120|NCT00488618|DRUG|Placebo|Dose-matched placebo oral administration, once per day.
47962078|NCT00352339|DRUG|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
48310121|NCT00145548|DEVICE|Intra Bronchial Valve|
48310122|NCT02654704|BIOLOGICAL|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
48310123|NCT00266721|DRUG|Pancrelipase (Creon) 2 tablets with each meal|
48310124|NCT03276936|DRUG|FMX103 1.5%|FMX103 1.5% minocycline foam
48310125|NCT03830008|BEHAVIORAL|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
48310126|NCT00390000|DRUG|vatalanib|Given orally
48310127|NCT00390000|DRUG|pemetrexed disodium|Given IV
48310128|NCT00390000|OTHER|pharmacological study|Correlative study
47962079|NCT00352339|DRUG|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
48310129|NCT00390000|PROCEDURE|ultrasound imaging|Correlative study
48310130|NCT02432287|DRUG|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
48310131|NCT02432287|DRUG|Placebo|there is no other name we used for the placebo
48310132|NCT04388280|DIAGNOSTIC_TEST|Echocardiography|Functional assessment of coronary artery disease
48310133|NCT04388280|DIAGNOSTIC_TEST|CT angiography|Anatomical assessment of coronary artery disease
48310134|NCT05687695|OTHER|backward walking program|six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
48310135|NCT05687695|OTHER|core training|six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
48310136|NCT00719576|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
48310137|NCT00719576|PROCEDURE|Microfracture|Microfracture performed by arthroscopic surgery
48310138|NCT03590262|DRUG|Metformin|take the metformin 500mg twice or three times a day
48310139|NCT03021798|OTHER|No Drug and no aspecific intervention|No intervention
48310140|NCT01028651|DRUG|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
48310141|NCT04443127|DEVICE|Virtual Reality Training Session|VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
48310142|NCT04443127|BEHAVIORAL|Motor-Relearning Program|Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
48310143|NCT01825590|OTHER|Dialysate and serum sodium concentration aligned|
48310144|NCT00313807|DRUG|Amino Acid|7% amino acid infusion
48310145|NCT00313807|DRUG|Placebo|0.9% Saline Infusion
48310146|NCT05073458|DRUG|parsaclisinib|parsaclisib will be administered QD orally
48310147|NCT05073458|DRUG|placebo|placebo will be administered QD orally follwed by Parsaclisinib in the open label period
48310148|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
48310149|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
48642747|NCT06694519|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|This scale allows the intensity of pain described by the patient to be measured with maximum reproducibility between observers. It consists of a horizontal line of 10 centimetres, at the ends of which are the extreme expressions of a symptom. At the left end is the absence or lowest intensity and at the right end the highest intensity. The patient is asked to mark on the line the point that indicates the intensity of the pain during sexual intercourse and it is measured with a millimetres ruler. The intensity is expressed in centimetres or millimetres. The rating will be: 1 Mild pain if the patient scores the pain as less than 3; 2 Moderate pain if the rating is between 4 and 7; 3 Severe pain if the rating is equal to or greater than 8.
47962080|NCT00352339|DRUG|Abilify|Start with abilify and keep it through the end of study
47962081|NCT01988688|DEVICE|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
47962082|NCT01926015|BIOLOGICAL|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
47962083|NCT01926015|BIOLOGICAL|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
47962084|NCT05902520|BIOLOGICAL|DP CD8 TIL|intravenous infusion of T cell suspension
47962085|NCT05902520|BIOLOGICAL|DP CD8 TIL KD|intravenous infusion of T cell suspension
47962086|NCT05902520|BIOLOGICAL|Low dose IL-2|Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
47962087|NCT05020782|DRUG|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
47962088|NCT05705518|DRUG|Systane Complete PF|3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
47962089|NCT05705518|DRUG|Refresh Relieva PF|3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
47962090|NCT05705518|DRUG|Refresh Optive Mega-3 PF|3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
47962091|NCT05705518|DRUG|CVS Health Lubricant Eye Drop (PG 0.6%)|3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
48310150|NCT03165513|BEHAVIORAL|mhGAP-IG|psychosocial interventions
48310151|NCT03648840|BEHAVIORAL|Aversive cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
48310152|NCT03648840|BEHAVIORAL|Neutral cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
48310153|NCT01921257|DRUG|Cat-PAD|
48310154|NCT01921257|DRUG|Placebo|
48310155|NCT05787834|OTHER|Best Practice|Receive usual care
48310156|NCT05787834|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
48310157|NCT05787834|PROCEDURE|Respiratory Muscle Training|Undergo RMT
48310158|NCT05787834|OTHER|Survey Administration|Ancillary studies
48310159|NCT03419767|DRUG|Melatonin|Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
48310160|NCT03419767|OTHER|blank|Patients under carotid revascularization surgery without taking melatonin
48310161|NCT02261168|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
48310162|NCT00000539|DRUG|niacin|
48310163|NCT00000539|DRUG|pravastatin|
48310164|NCT00000539|DRUG|beta-carotene|
48310165|NCT00000539|DRUG|vitamin E|
48310166|NCT00000539|BEHAVIORAL|dietary supplements|
48310167|NCT00000539|DRUG|vitamin C|
48310168|NCT00000539|DRUG|warfarin|
48310169|NCT00003019|DRUG|methotrexate|
48310170|NCT00003019|DRUG|vinblastine sulfate|
48310171|NCT03851276|RADIATION|Multi-sliced computed tomography (MSCT)|Surgery planning done based solely on MSCT.
48310172|NCT04462718|OTHER|Radiofrecuency|EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
48310173|NCT04462718|OTHER|Therapeutic Exercise|CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
48310174|NCT05208424|DIAGNOSTIC_TEST|Coronary angiography|Invasive coronary angiography
48310175|NCT04655950|OTHER|protocols and practices for the immobilization of vertebral osteomyelitis in different French hospitals and bone and joint infections Centers|"Evaluation of the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications.~We search for association between type and duration of spine immobilization and neurological status at the end of follow-up"
48310176|NCT02990637|DIETARY_SUPPLEMENT|OLECOL|Olive leaf extract
48310177|NCT02990637|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48483262|NCT02167542|DEVICE|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2\>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
48483263|NCT02167542|DEVICE|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2\>92%."
47962092|NCT02012283|OTHER|Food consumption|Cooked vegetables with spices or without spices
47962093|NCT05405374|OTHER|OSTEOAMP|OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
47962094|NCT05405374|DEVICE|Infuse|The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
47962095|NCT05344365|DRUG|Iloperidone|oral tablet
47962096|NCT01253408|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
47962097|NCT01253408|DRUG|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
47962098|NCT01466647|DRUG|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
47962099|NCT04405414|OTHER|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
47962100|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
47962101|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
47962102|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
47962103|NCT01534962|DRUG|Placebo|Oral administration, BID; for a maximum of 112 days.
47962104|NCT04449081|BEHAVIORAL|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
47962105|NCT04981548|OTHER|no intervention|no intervention
48310178|NCT04758273|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
48310179|NCT04758273|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
48310180|NCT04758273|BIOLOGICAL|Placebo|placebo
48310181|NCT06457984|DIETARY_SUPPLEMENT|Selenium nutritional supplementation|Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
48310182|NCT03121872|PROCEDURE|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
48310183|NCT03121872|PROCEDURE|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
48310184|NCT01786616|DRUG|Formoterol|
48310185|NCT04972032|DEVICE|Estrogen Intrauterine Stent System|A Estrogen Intrauterine Stent System（E-IUS）will be introduced post-operatively. The E-IUS will be removed 60 days after surgery with continuous dydrogesterone administration for 5 days at 20 mg/d, and routine management.
48310186|NCT04972032|DEVICE|Foley balloon combined with self-cross-link sodium hyaluronate gel|Foley balloon combined with self-crosslinking sodium hyaluronate gel will be introduced post-operatively，2 cycles of estrogen-progestin sequential therapy comprised of continuous estrogen and progestin added in the second half of the cycle or continuous estradiol valerate for 60 days, followed by dydrogesterone for 10 days
48310187|NCT01836575|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
48310188|NCT01836575|DRUG|Carboplatin|Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
48310189|NCT04856436|DRUG|Benzodiazepine|Exposure to benzodiazepine during early pregnancy
48310190|NCT06363045|DEVICE|NIDEK TONOREF III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
48310191|NCT06363045|DEVICE|Haag-Streit, PERKINS HAND-HELD APPLANATION TONOMETER|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
48310192|NCT06363045|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
48310193|NCT03783650|BEHAVIORAL|Control condition|Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.
48310194|NCT03783650|BEHAVIORAL|QIC with PCP and without subspecialist|During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).
48310195|NCT03783650|BEHAVIORAL|QIC with Subspecialist|Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
48483264|NCT05410028|OTHER|No intervention in clinical treatment|No intervention in clinical treatment
47962106|NCT04263077|OTHER|PLACEBO|The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.
47962107|NCT04263077|OTHER|50% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 50% tension.
47962108|NCT04263077|OTHER|75% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
47962109|NCT04263077|OTHER|100% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
48310196|NCT03783650|BEHAVIORAL|Hub and Spoke co-management|Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.
48310197|NCT03783650|BEHAVIORAL|Sustainability of changes|Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
48310198|NCT04561635|DIETARY_SUPPLEMENT|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
48483265|NCT00494624|DRUG|prednisolone|
48483266|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Placebo|Colored water
48483267|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
48483268|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
48483269|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8_TCID50
48483270|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8_TCID50
48483271|NCT00686582|PROCEDURE|Blood Draw Only|
48483272|NCT00396461|DRUG|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
48483273|NCT00396461|DRUG|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
48483274|NCT05113459|DRUG|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
48483275|NCT04523610|BEHAVIORAL|Telehealth phone calls|The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
48483276|NCT04523610|OTHER|Volunteer of TIP-OA Program|Participant is a volunteer of the TIP-OA Program
48310199|NCT04604236|BEHAVIORAL|Mapping Enhanced Counseling|Practitioner-led, collaborative discussion with the youth and their caregiver on co-creating guide maps for decision making around starting treatment and continuing substance use that can help users organize information and think through a series of steps, questions, and behavior choices. encountered when attempting to initiate substance use treatment services. MEC is a communication and decision-making approach that uses graphic visualization tools to train individuals to monitor and control their decision making, improve judgment and behavioral choices (self-regulation), and improve communication and mutual understanding.
48310200|NCT04604236|BEHAVIORAL|Active Linkage|Practitioner-led, collaborative discussion with the youth and their caregiver on how to overcome barriers encountered when attempting to initiate substance use treatment services. Discussion focuses around the top barriers identified through assessment and identification of 1 or more treatment agency/options that fit the family's needs. Practitioner takes a more active role in addressing barriers to treatment by helping the family find ways to access resources for payment, childcare, or other needs, and actively linking them to the treatment provider (e.g., scheduling the initial appointment with family present).
48310201|NCT03727321|COMBINATION_PRODUCT|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
48310202|NCT03727321|DIETARY_SUPPLEMENT|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
48310203|NCT03727321|DIETARY_SUPPLEMENT|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
48310204|NCT01321996|PROCEDURE|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
48310205|NCT06504173|PROCEDURE|diced cartilage|In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.
48310206|NCT04200105|DEVICE|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
48310207|NCT04200105|DEVICE|Acquire TBNB|Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
48310208|NCT00184106|DRUG|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
48310209|NCT03808623|DEVICE|MAC with NOVOCART Basic|"NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called matrix associated chondrogenesis (MAC). It is a single-step procedure.~NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue."
48310210|NCT00332514|BEHAVIORAL|telephone call by a pharmacist|
48310211|NCT01186146|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
48310212|NCT01186146|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
48310213|NCT06381648|DIAGNOSTIC_TEST|LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)|A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
48310214|NCT03218423|DEVICE|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
48310215|NCT03476785|BEHAVIORAL|High intensity exercise|Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.
48310216|NCT03476785|BEHAVIORAL|Yoga|Subjects will perform strength and flexibility exercises.
48310217|NCT03546725|DEVICE|Compression stocking|Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
48310218|NCT05554159|BEHAVIORAL|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
48310219|NCT05554159|BEHAVIORAL|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
48310220|NCT03055403|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
48310221|NCT03055403|DRUG|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
48310222|NCT06482554|DRUG|Lumateperone 42 mg|Standard treatment with lumateperone
48310223|NCT06482554|DRUG|Risperidone 2 mg|Standard treatment with other antipsychotic drugs
48310224|NCT06518109|OTHER|Zarit Caregiver Burden Scale|The Zarit Caregiver Burden Scale (ZCBS) is a widely used instrument for assessing the burden experienced by caregivers of individuals requiring long-term care. It consists of 22 items and the total score ranges from 0 to 88 (low/no burden to severe burden)
47962110|NCT00286312|DRUG|Atorvastatin|
48310225|NCT05460871|DRUG|Pregabalin 75mg|participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
48483277|NCT04523610|OTHER|Stakeholder of TIP-OA Program|Participant is a stakeholder of the TIP-OA Program
47962111|NCT03484091|DRUG|Hyruan-One|single dose intra-articular injection
48310226|NCT00634244|DRUG|alvocidib|Given IV
48310227|NCT00634244|DRUG|mitoxantrone hydrochloride|Given IV
48310228|NCT00634244|DRUG|carboplatin|Given IV
48310229|NCT00634244|DRUG|cytarabine|Given IV
48310230|NCT00634244|DRUG|sirolimus|Given PO
48310231|NCT00634244|DRUG|etoposide|Given IV
48310232|NCT00634244|DRUG|topotecan hydrochloride|Given IV
48310233|NCT05388708|DEVICE|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
48310234|NCT05388708|OTHER|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
48310235|NCT06287736|DEVICE|Spinal Cord Stimulator Implantation (SCS)|Spinal cord stimulator implantation is broken up into two parts. The first part involves placement of temporary SCS leads for a one-week trial. If the participants respond favorably to the SCS, then they will undergo the second part and the device is implanted
48310236|NCT04962542|OTHER|ventilation|low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
48310237|NCT06113185|OTHER|survey|Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To record the presence and severity of pain behaviors exhibited during physical performance tests, patients will be asked to complete 5 functional tests (repetitive trunk flexion, repetitive sit-to-stand, timed get-up-and-go test, reach with load, 50-step walk test) and observers will simultaneously complete the Pain Behavior Scale. Each participant will be asked to attend two testing sessions separated by one week and occurring before the start of treatment.
48310238|NCT01426425|DEVICE|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
48310239|NCT00192335|BIOLOGICAL|CAIV-T|
48310240|NCT00192335|BIOLOGICAL|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
48310241|NCT00192335|BIOLOGICAL|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
48310242|NCT04286412|BIOLOGICAL|Nonacog alfa|Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
48310243|NCT02487628|DEVICE|HQ® Matrix Soft Tissue Mesh|
48310244|NCT02487628|DEVICE|ULTRAPRO® Partially Absorbable Lightweight Mesh|
48310245|NCT06331923|DEVICE|Continuous glucose monitoring (CGM) device|Continuous glucose monitoring (CGM) will be prescribed by the attending physician for at least 6 hours before surgery. The supervising nurse will educate the patient and their family on the correct wearing and connection of the CGM device. The calibration frequency and interval of glucose monitoring devices before and after surgery should be determined according to institutional treatment guidelines and the requirements of the monitoring device used. Intraoperative glucose calibration should be done immediately upon entering the operating room, immediately after skin incision, every 2 hours after skin incision, and at the end of wound closure. Glucose monitoring should be continued until the 7th day after surgery or discharge.
47962112|NCT03484091|DRUG|Hylan G-F 20|single dose intra-articular injection
47962113|NCT03484091|DRUG|Normal saline|single dose intra-articular injection
47962114|NCT05406141|DIETARY_SUPPLEMENT|Amino acid formula (Neocate Jr)|"Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~* Sole source of nutrition: as far as possible \>7 days, especially newly diagnosed allergy children~* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)"
47962115|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
48310246|NCT01458444|DEVICE|Non invasive ventilation (VNI)|BIPAP® vision
48310247|NCT01458444|DEVICE|Non invasive ventilation|OPTIFLOW system
48483278|NCT01415050|DEVICE|Whole body vibration|15 times WBV
48483279|NCT06420830|PROCEDURE|SAPIEN 3 Ultra RESILIA Valve|Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.
48483280|NCT01002794|PROCEDURE|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital and Martina Hansens Hospital.
47962116|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
48113455|NCT03616639|DRUG|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
48113456|NCT00949975|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
48113457|NCT00949975|DRUG|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
48113458|NCT00949975|DRUG|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
47962117|NCT01403181|DRUG|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
47962118|NCT05679219|PROCEDURE|Structured Pes Planus Exercises|Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. the purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
48483281|NCT01002794|OTHER|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training. Carried out at Nimi Ullevaal Oslo or Gnist trending- og fysioterapi, Baerum
48310248|NCT06217458|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|The CEM performance protocol involves the intravenous administration of non-ionic, low-osmolarity iodinated contrast medium using an automatic syringe that delivers the required bolus of contrast medium at a dose of 1.5 ml/kg body weight at a rate of 3 ml/s without compressing the breast. After a two-minute pause, necessary to allow the breast parenchyma to absorb (stain) the contrast agent, the patient is positioned for the mammogram and the breast is compressed. First the symptomatic and then the non-symptomatic breast is imaged in two or a total of four standard projections: craniocaudal (CC) and oblique mediolateral (MLO) projections of the breast. The delayed CC and MLO projections of the symptomatic breast are taken within eight minutes of the start of the examination. The delayed mammograms are used to assess the dynamics of the contrast uptake of the lesion and are compared to the same parameters of the breast MRI. The time required to perform the CEM is 8-10 minutes.
48310249|NCT00367640|DRUG|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
48310250|NCT00367640|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
48310251|NCT00367640|DRUG|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
48310252|NCT00367640|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
48310253|NCT04982120|DEVICE|Repris Needle|Injection of Botox
48310254|NCT03439748|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
48310255|NCT03439748|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
48310256|NCT01746732|DRUG|Ortho-Cyclen|Oral administration
48310257|NCT01746732|DRUG|Evacetrapib|Oral administration
48310258|NCT05149794|OTHER|Calisthenic Exercises|Bunny Jumps, Bear Crawls, Bear Crawls, Bird Dog . these intervention were used
48310259|NCT02160379|OTHER|standard test meal|
48310260|NCT06376214|DRUG|Dratumumab / Hyaluronidase Injection [Darzalex Faspro]|Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.
48310261|NCT06376214|DRUG|Pomalidomide 4 MG|Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.
48310262|NCT06376214|PROCEDURE|autologous stem cell transplantation (ASCT)|"The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~."
48310263|NCT00003648|GENETIC|DNA stability analysis|
47962119|NCT05679219|PROCEDURE|Wii Based Exergame|Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
48310264|NCT00003648|GENETIC|gene rearrangement analysis|
48310266|NCT02801162|DEVICE|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
48310267|NCT02801162|DEVICE|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
48310268|NCT05212168|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
48310269|NCT05212168|OTHER|Placebo Tablets|Oral tablets similar in appearance and number to active vaccine tablets
48310270|NCT05212168|BIOLOGICAL|Norovirus GI.1 Norwalk Virus Inoculum|Norwalk Virus Inoculum Lot 01-09NV
48310271|NCT02632708|DRUG|AG-120|
48310272|NCT02632708|DRUG|AG-221|
48310273|NCT02632708|DRUG|cytarabine|
48310274|NCT02632708|DRUG|daunorubicin|
48310275|NCT02632708|DRUG|idarubicin|
48310276|NCT02632708|DRUG|mitoxantrone|
48310277|NCT02632708|DRUG|etoposide|
48310278|NCT01986634|PROCEDURE|Laser Treatment|Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
48310279|NCT00142519|DRUG|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
48310280|NCT00142519|DRUG|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
48310281|NCT03364426|OTHER|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
48310282|NCT04397406|DRUG|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
48310283|NCT04397406|DRUG|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
48310284|NCT04397406|DRUG|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
48310285|NCT02568033|DRUG|Pemetrexed|
48310286|NCT02568033|DRUG|Carboplatin|
48310287|NCT02568033|DRUG|Cisplatin|
48310288|NCT02568033|DRUG|Docetaxel|
48310289|NCT02568033|DRUG|Paclitaxel|
48310290|NCT02568033|RADIATION|stereotactic radiosurgery|
48310291|NCT03196505|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
48310292|NCT03196505|DRUG|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
48310293|NCT01855542|OTHER|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
48310294|NCT01855542|OTHER|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
48483282|NCT05430945|BIOLOGICAL|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
48113459|NCT00949975|DRUG|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
48310295|NCT03323229|DIAGNOSTIC_TEST|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (\<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
48310296|NCT04883580|DEVICE|Navigation and Positioning System for Orthopedic Surgeries|"Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation"
48113460|NCT00464399|DRUG|everolimus|
48310297|NCT04346069|OTHER|PCIT (parent child interaction therapy)|Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas \&amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
48310298|NCT06441812|DRUG|SHR-1703 Injection|SHR-1703 Injection
48310299|NCT04591912|BEHAVIORAL|mind. body. voice|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
48310300|NCT02724774|BEHAVIORAL|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
48310301|NCT02849990|DRUG|Abiraterone Acetate|Given PO
48310302|NCT02849990|DRUG|Apalutamide|Given PO
48310303|NCT02849990|DRUG|Degarelix|Given SC
48310304|NCT02849990|DRUG|Indomethacin|Given PO
48310305|NCT02849990|OTHER|Laboratory Biomarker Analysis|Correlative study
48310306|NCT02849990|DRUG|Prednisone|Given PO
48310307|NCT01551758|DRUG|FF/VI|FF/VI
48483283|NCT02504723|DRUG|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure \>90 mm Hg.
48483284|NCT02504723|DRUG|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
48483285|NCT03232099|DIETARY_SUPPLEMENT|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
48113461|NCT03179969|OTHER|paravalvular leak|Observational study on patients with paravalvular leak
48113462|NCT01304277|BIOLOGICAL|agalsidase alfa|
48310308|NCT01551758|OTHER|Existing Maintenance Therapy|"Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy"
48113463|NCT05909761|DRUG|UPLIZNA|Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed. No study drug will be administered.
48310309|NCT03920982|DIAGNOSTIC_TEST|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
48310310|NCT01014637|DRUG|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
48310311|NCT01014637|DRUG|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
48310312|NCT03437772|BEHAVIORAL|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
48310313|NCT03278080|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
48310314|NCT03278080|OTHER|Car-following test|Driving with simulator program for DCV measurement
48310315|NCT03278080|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
48310316|NCT05545267|PROCEDURE|Angioplasties|Transluminal angioplastie
48310317|NCT06554925|PROCEDURE|Cardiac surgery|The difference in males and females undergoing cardiac surgery of all types
48310318|NCT04591470|DIAGNOSTIC_TEST|Mar test|Study of antisperm antibodies
48310319|NCT04202562|PROCEDURE|Ab interno trabeculectomy|Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
48483286|NCT03232099|OTHER|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
48483287|NCT05768126|DRUG|Rivastigmine Transdermal Product|The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).
48483288|NCT05768126|OTHER|Sham|The sham patches will be administered during the same period of time as the rivastigmine.
48483289|NCT06234774|PROCEDURE|Robot-assisted laparoscopic surgery|
48483290|NCT06234774|PROCEDURE|Conventional (non-robotic) laparoscopic surgery|
48642748|NCT06694519|DIAGNOSTIC_TEST|Body Image Scale (S-BIS)|It consists of 10 items assessing various dimensions of body image in cancer patients, evaluating: affective, behavioural and cognitive. The items are scored on a four-point scale (0: not at all; 1: a little; 2: quite a lot; 3: a lot) with a maximum possible score of 3 points. The higher the score, the higher the body image problem. Its brevity facilitates rapid assessment in both clinical and research settings. It shows a stable factor structure between samples, and good psychometric properties with high reliability (Cronbach's alpha=0.93), suggesting that it is a suitable and useful measure for assessing body image in breast cancer patients.
48642749|NCT06694519|DIAGNOSTIC_TEST|Likert's scale questionnaire|five-point Likert scale for satisfaction with treatment to be classified as: 1 (very dissatisfied), 2 (dissatisfied), 3 (no change), 4 (satisfied), 5 (very satisfied). Women who miss any of the RF sessions and/or whose attendance at the face-to-face physiotherapy sessions (RF and/or PFMT) does not reach 80% will be considered as not complying with the study protocol and their participation will be terminated, although they will be included in the analysis (by intention to treat).
48310320|NCT04202562|PROCEDURE|Cataract|Cataract surgery with minimal clear cornea incision and phacoemulsification
48310321|NCT04319562|PROCEDURE|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
48310322|NCT04319562|DEVICE|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
48310323|NCT01294891|OTHER|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
48483291|NCT02018094|DRUG|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
48483292|NCT02018094|DRUG|Iodine|Intra-operative skin preparation prior to incision to skin.
48483293|NCT02018094|DRUG|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
48483294|NCT02018094|DRUG|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
48483295|NCT02018094|DRUG|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
48483296|NCT02018094|DRUG|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
48483297|NCT05580952|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
48483298|NCT01534078|DRUG|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
48483299|NCT01534078|DRUG|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
48483300|NCT01976455|OTHER|20% fewer calories|
48483301|NCT01976455|OTHER|40% fewer calories|
48310324|NCT05436197|BEHAVIORAL|PLAYshop Program|The intervention includes: 1. Educational Training - the 60 min virtual/hybrid workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be provided with physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
48310325|NCT01887249|DRUG|Clarithromycin|
48310326|NCT01887249|DRUG|metronidazole|
48310327|NCT01887249|DRUG|esomeprazole|
48310328|NCT02657668|BEHAVIORAL|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
48642750|NCT06694519|DIAGNOSTIC_TEST|Oxford's Scale|It allows the contractile capacity of the pelvic floor muscles to be assessed. It scores from 0 to 5, as follows: if there is no contraction it is 0, if the contraction is very weak it is 1, if the contraction is weak it is 2, if the contraction is moderate/with tension/and maintained it is 3, if the contraction is good and maintains tension with resistance it is 4, and if the contraction is strong and maintains tension against a resistant force it is 5.
48642751|NCT06694519|DIAGNOSTIC_TEST|Sexual function and self-esteem|The Female Sexual Function Index (FSFI) questionnaire consists of 19 items that assess sexual function over the past 4 weeks and performance in six domains: sexual desire, arousal, lubrication, orgasm, satisfaction and pain. A cut-off point ≤ 26.5 is considered sexual dysfunction and an increase in score is considered an improvement.
48642752|NCT05735652|DEVICE|SpaceOAR Hydrogel|The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum
48310329|NCT02539082|DEVICE|Regenseal|Regenseal, collagen, injection in the defect area
48310330|NCT02539082|DRUG|normal saline|placebo, normal saline, injection in the defect area
48310331|NCT00975702|PROCEDURE|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
48310332|NCT01847833|OTHER|MRI scan|
48310333|NCT04511234|DEVICE|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
48310334|NCT04511234|DEVICE|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
48310335|NCT05913960|DEVICE|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
48310336|NCT05913960|DEVICE|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
48310337|NCT05913960|DEVICE|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
48310338|NCT03075462|DRUG|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
48310339|NCT03075462|DRUG|Apatinib|Apatinib at 250mg once daily, tablet oral
48310340|NCT02520622|BEHAVIORAL|Digital photographs loaded onto a mobile device|
48310341|NCT02520622|BEHAVIORAL|Skin exam reminders|
47962120|NCT05679219|PROCEDURE|Wii Based Serious Game|The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
47962121|NCT01264757|BEHAVIORAL|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
48642753|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
48113464|NCT05133063|BEHAVIORAL|Gratitude letter|"Participants are given the following instructions:~Think of someone in your life who you feel like you have never fully or properly thanked for something meaningful or important that they did for you. . . . In the space provided below, please write a note to this person that describes why you feel like you never properly thanked them and letting them know why you feel thankful for something important that they did for you. Though this letter will not actually be sent to this person and is simply an exercise for you, please use this as an opportunity to really explore those feelings surrounding how you feel about what they have done for you and write honestly and openly from your heart. You have ten minutes."
48310342|NCT02520622|BEHAVIORAL|Social support network|
48310343|NCT00263302|DRUG|dexamethasone|
48310344|NCT03670641|DRUG|Glargine|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
48310345|NCT03670641|DRUG|Lispro|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
48310346|NCT03670641|DEVICE|Dexcom G6|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
48310347|NCT01443455|BEHAVIORAL|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
48642754|NCT06694701|DRUG|Emapalumab-Izsg|The drug is administered at a dose of 10mg/kg of body weight on day 0, 6mg/kg of body weight on day 3 and repeated dosing of 3mg/kg of body weight is provisioned for days 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
48642755|NCT06694701|DRUG|Placebo|250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply
47962122|NCT01264757|BEHAVIORAL|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
47962123|NCT06194630|DRUG|68Ga-A3|Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
48483302|NCT02523937|OTHER|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
48483303|NCT02430805|OTHER|dna extraction and genotyping|blood and urine sample
48483304|NCT04380675|OTHER|Music|Music listening during ESWL
48483305|NCT03030716|DIETARY_SUPPLEMENT|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
48483306|NCT00040430|DRUG|111In-DAC|
48483307|NCT00040430|PROCEDURE|Diagnostic|
48483308|NCT04628104|RADIATION|cardiac magnetic resonance|"o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation"
48483309|NCT00127517|DRUG|peptide-nucleic acid solution AVR118|
48483310|NCT03136874|OTHER|Interview and questionaires|"* Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~* Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
48483311|NCT01376310|DRUG|GSK1120212|up to 2 mg/day
48483312|NCT01376310|DRUG|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
48483313|NCT01376310|DRUG|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
48483314|NCT01376310|DRUG|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
48483315|NCT01376310|DRUG|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
48483316|NCT01376310|DRUG|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
48310348|NCT01443455|BEHAVIORAL|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
48310349|NCT01443455|BEHAVIORAL|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~--------------------------------------------------------------------------------"
48310350|NCT01790893|DRUG|aflibercept|
48310351|NCT06261099|OTHER|control + working group|Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to in 5 sessions per week for 6 weeks.
48483317|NCT01376310|DRUG|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
47962124|NCT05014893|COMBINATION_PRODUCT|multi-modal targeted intervention (e.g., cognitive training, exercise, games)|The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
47962125|NCT00420693|DRUG|sevoflurane|
47962126|NCT02501226|OTHER|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
47962127|NCT02501226|BEHAVIORAL|ENVIE psychoeducational program|"The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.~The sessions may be carried out remotely, by videoconference."
47962128|NCT06290661|DEVICE|Active electrostimulation|Maintain the electrical stimulation state, and according to the patient's feeling to set the appropriate stimulation parameter range (pain relief and no obvious numbness and discomfort), the programme will be written into the patient's self-control remote control, by the patient according to their own pain situation for the independent control of the stimulation current.
47962129|NCT06290661|DEVICE|Placebo electrostimulation|No actual electrostimulation
47962130|NCT00143637|OTHER|Office dust|airborne office dust spiked with glucan
47962131|NCT00143637|OTHER|clean air|Clean air
47962132|NCT06557187|RADIATION|ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost|hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
48113465|NCT05133063|BEHAVIORAL|Control intervention|"Participants receive the following instructions:~Think of the room you are in.... In the space below, please provide a description of the room you are in. Try to focus on the specific elements in the room, the colours of the wall or objects in the room. Use this writing session as an opportunity to paint a detailed picture of this room and include as much specific information as you can. You have ten minutes."
48113466|NCT04102462|DRUG|BI 764198|Capsules
48113467|NCT04102462|DRUG|Matching placebo|Capsules
48113468|NCT05668819|DEVICE|TH-001|TH001 is a software program intended to treat adults with prediabetes.
48113469|NCT06086080|OTHER|Standard care|Bracing and physical therapy
48113470|NCT06086080|OTHER|Taping|The patient is treated with tape in special configuration (McConell modified) for the patella + standard care
48483318|NCT01376310|DRUG|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
48483319|NCT00938145|PROCEDURE|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
48483320|NCT00938145|DRUG|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
47962133|NCT02592356|PROCEDURE|Computed Tomography|Correlative studies
48113471|NCT06086080|DEVICE|Sham taping|Taping with no treatment disposition
48113472|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
48113473|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.
48113474|NCT04623541|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.
48113475|NCT04623541|DRUG|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
48113476|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
48113477|NCT04623541|DRUG|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
48113478|NCT02398565|OTHER|No intervention|
48113479|NCT00389012|PROCEDURE|exercise therapy|
48113480|NCT00389012|PROCEDURE|walking rehabilitation|
47962134|NCT02592356|PROCEDURE|Dual X-ray Absorptiometry|Correlative studies
47962135|NCT02592356|PROCEDURE|Physical Examination|Correlative studies
47962136|NCT02592356|OTHER|Quality-of-Life Assessment|Ancillary studies
47962137|NCT02592356|OTHER|Questionnaire Administration|Ancillary studies
47962138|NCT02592356|DRUG|Cabozantinib|
48310352|NCT03126539|DRUG|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
48310353|NCT03126539|RADIATION|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
47962139|NCT02592356|DRUG|Lenvatinib|
47962140|NCT00511446|DRUG|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
47962141|NCT01577108|DIETARY_SUPPLEMENT|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
47962142|NCT01577108|DIETARY_SUPPLEMENT|Placebo|oral taking 2 capsules before sleeping per day for 14 days
47962143|NCT06136078|OTHER|rate of appropriate and inappropriate transfers from Methodist interfacility transfers|Evaluating rate for patients experiencing traumatic intracranial subarachnoid hemorrhage or spontaneous bleeds
47962144|NCT05191342|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay for PCSK9|Enzyme-linked immunosorbent assay for plasma PCSK9
47962145|NCT06442280|DRUG|Dapagliflozin tablet|Dapagliflozin 10 mg 1 tablet once daily
47962146|NCT06442280|DRUG|Hypertonic Saline Solution, 1 Ml|Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
47962147|NCT06442280|DRUG|Furosemide Injection|Furosemide 20 mg
47962148|NCT05710042|DEVICE|Revivent TC System|The Revivent TC System is indicated for patients suffering from symptomatic heart failure referred for treatment of left ventricular antero-septal aneurysms/scars that are contiguous and includes both anterior and septal components.
48483321|NCT00938145|PROCEDURE|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
47962149|NCT05490810|OTHER|Trunk stabilization|"Trunk stabilization exercises with~* Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~* Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~* Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~* Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~* SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
47962150|NCT05490810|OTHER|Activation exercises|"Activation exercises with~* Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~* External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~* Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
47962151|NCT03221283|BEHAVIORAL|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
47962152|NCT05530759|PROCEDURE|Biopsy Specimen|Undergo collection of tissue samples
48113481|NCT00548574|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
48483322|NCT00003293|DRUG|leflunomide|
48483323|NCT00003293|DRUG|procarbazine hydrochloride|
48483324|NCT02938520|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
47962153|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal swab samples
47962154|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of archived tissue and blood samples
47962155|NCT05530759|OTHER|Medical Chart Review|Review of medical record
47962156|NCT03824730|DEVICE|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
48113482|NCT00548574|DRUG|Mesalazine|
48113483|NCT06677398|OTHER|Debriefing Method 1|The researchers used a debriefing method that they chose after a virtual simulation
48113484|NCT06677398|OTHER|Debriefing Method VP|The researchers used the debriefing method that virtual patient simulator presents
48113485|NCT06677398|OTHER|Debriefing Method 2|The researchers used a debriefing method that they chose after a virtual simulation
48113486|NCT03003637|DRUG|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
48483325|NCT02938520|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
48642756|NCT06695546|OTHER|VExUS evaluation ultrasound|"VExUS evaluation by ultrasound will be performed before the filling/bleeding/cleaning procedure, and again after the procedure:~* Inferior vena cava measurement in Time-Motion (TM) mode, 1-2 cm from the right atrial orifice.~* Hepatic venous Doppler measurement in pulsed Doppler mode.~* Renal vein Doppler measurement in pulsed Doppler mode. Each measurement is performed three times consecutively (to average the results), then the ultrasound measurements are compiled into a score according to the degree of doppler severity."
48642757|NCT06313346|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules
48642758|NCT06313346|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
48642759|NCT06694116|DIAGNOSTIC_TEST|sentinel lymph node biopsy using carbon dye|Sterile Charcoal carbon dye peritumoral injection will be performed around vulvar tumor and inguinofemoral lymph node dissection will be done 20 min later (unilateral or bilateral)
47962157|NCT00880997|DRUG|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
47962158|NCT00880997|OTHER|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
47962159|NCT04333550|DRUG|Deferoxamine|Intravenous infusion of Deferoxamine
47962160|NCT00709761|DRUG|Lapatinib/nab-Paclitaxel|This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
47962161|NCT00012311|BIOLOGICAL|filgrastim|
47962162|NCT00012311|DRUG|CMF regimen|
47962163|NCT00012311|DRUG|carboplatin|
47962164|NCT00012311|DRUG|cyclophosphamide|
47962165|NCT00012311|DRUG|docetaxel|
47962166|NCT00012311|DRUG|doxorubicin hydrochloride|
47962167|NCT00012311|DRUG|etoposide|
47962168|NCT00012311|DRUG|fluorouracil|
47962169|NCT00012311|DRUG|ifosfamide|
47962170|NCT00012311|DRUG|methotrexate|
47962171|NCT00012311|DRUG|thiotepa|
47962172|NCT00012311|PROCEDURE|peripheral blood stem cell transplantation|
48310354|NCT03126539|PROCEDURE|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
48310355|NCT00880672|DRUG|dutasteride|5mg, oral, daily, 2-4 weeks
48310356|NCT06417931|BEHAVIORAL|Patient education and counselling|The pharmacist intervention was aimed at identifying and addressing barriers to treatment adherence through tailored strategies
47962173|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Peach Pod|Participants in this arm will use the air up® drinking system with a peach-flavored pod.
47962174|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Orangeade Pod|Participants in this arm will use the air up® drinking system with an orangeade-flavored pod.
47962175|NCT01463488|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
48483326|NCT02938520|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
48483327|NCT02938520|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
48483328|NCT02938520|DRUG|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
48483329|NCT02938520|DRUG|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
47962176|NCT01463488|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
47962177|NCT00035997|DRUG|Zometa|
48113487|NCT03003637|DRUG|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
48483330|NCT03923231|DRUG|Atazanavir 300mg/ Ritonavir 100 mg once daily|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
48483331|NCT03923231|DRUG|Atazanavir 250 mg / ritonavir 80 mg|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
48483332|NCT01965184|BEHAVIORAL|Cognitive-Behavioral Therapy for Anger and Aggression|
48483333|NCT01965184|BEHAVIORAL|Supportive Psychotherapy (SPT)|
48483334|NCT05607251|OTHER|No intervention|There is no intervention as this is an observational study
48483335|NCT00359788|DRUG|tiotropium|
48642760|NCT05568459|OTHER|Non-Interventional|No study treatment will be administered in this study.
48642761|NCT06694233|DRUG|Aspirin prescription on outpatient basis|Improving aspirin prescription rates for candidate patients (moderate- and high-risk obstetric population)
48642762|NCT03166631|DRUG|BI 891065|Part A, Part B
48310357|NCT02007785|BEHAVIORAL|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
48310358|NCT02150187|DIETARY_SUPPLEMENT|HCap Formula|Pill should be taken every other day during the treatment phase.
48642763|NCT03166631|DRUG|BI 754091|Part B
48642764|NCT05145413|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
48642765|NCT05145413|DRUG|Placebo|Placebo Capsules
48642766|NCT04328727|DRUG|eltrombopag|Tablet 25mg and 12.5mg
48642767|NCT04328727|DRUG|rabbit anti-thymocyte globulin (r-ATG)|r-ATG 25 mg sterile lyophilized powder in 10 mL vials for IV use
48642768|NCT04328727|DRUG|cyclosporine A (CsA)|CsA 25mg Capsule or CsA 5.0g/50mL solution for oral use
48642769|NCT05064709|DEVICE|Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
48642770|NCT05064709|DEVICE|OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
48642771|NCT06126575|DRUG|Elacestrant dihydrochloride|A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
48642772|NCT06689722|OTHER|chiropractic|Chiropractic practice was applied using the diversified technique, which is one of the types of chiropractic techniques.
48642773|NCT06689722|OTHER|sham|The patient was asked if he/she had any pain or other complaints during the trial mobilization. High-velocity, low-amplitude impulses were applied to the inferior and lateral directions for patients who did not describe any complaints.
48642774|NCT06689722|OTHER|ergonomics|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
48642775|NCT04739059|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
48642776|NCT05815784|DRUG|Atropine|0.05% atropine. One drop per eye per day for 2 years.
48642777|NCT05815784|DEVICE|MiSight contact lenses|Daily wear for 2 years.
48642778|NCT01844986|DRUG|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
48642779|NCT06222736|OTHER|Rocabado Exercises|Patients trained by Rocabado Exercises
48642780|NCT06222736|OTHER|Servical Core Exercises|Servical Core Exercises
47962178|NCT04578639|DRUG|Rituximab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
48310359|NCT02150187|DIETARY_SUPPLEMENT|Placebo|Similar pills without active ingredients
48642781|NCT06404684|BEHAVIORAL|Cognitive behavioral therapy (CBT)|se above
48642782|NCT05776381|OTHER|Shared Decision Making using a Patient Decision Aid.|The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.
48642783|NCT06077071|RADIATION|ViewRay MRIdian Stereotactic Radiosurgery|Participants will undergo stereotactic radiosurgery of the spinal cord on the ViewRay MRIdian, a hybrid MRI-linac platform, with 40 Gy in 5 fractions prescribed to the planning target volume (PTV).
48642784|NCT06637332|DRUG|Daptomycin for Injection|Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
48642785|NCT06637332|DRUG|Vancomycin (IV)|Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
48642786|NCT04743206|DEVICE|Standard Airway Clearance device|Subjects will be using their home standard airway clearance device, VEST (High Frequency Chest Wall Oscillation VEST) for 2 weeks followed by PIAPD.
48642787|NCT04743206|DEVICE|Portable Internal Airway Percussion device|Subjects will be using the investigational device, PIAPD (Portable Internal Airway Percussion Device) for 2 weeks.
48642788|NCT05656274|DRUG|JS1-1-01|Oral tables
48642789|NCT05656274|DRUG|Placebo|Oral tables
48642790|NCT06541964|OTHER|Parent-Provide Distraction|The children will be asked riddles by their parents for 5 seconds before and during the blood collection procedure.
48310360|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
48310361|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
48642791|NCT06541964|OTHER|Windmill Toy Blowing|The children will blow on the windmill toy for 5 seconds before and during the blood collection procedure.
48642792|NCT06541964|OTHER|Control|No intervention will make on the children.
48642793|NCT05019521|DRUG|Danicopan|Oral tablet.
48642794|NCT05019521|DRUG|Placebo|Oral tablet.
48642795|NCT06025578|DRUG|BMS-986278|Specified dose on specified days
47962179|NCT04578639|DRUG|Ocrelizumab|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years. Active substance is biosimilar rituximab iv infusion and comparator is ocrelizumab (Ocrevus ®) iv infusion. Both treatments are given as infusion at month 0, month 6, month 12, month 18 and month 24. Randomization rituximab: ocrelizumab is 3:2. The primary end-point is proportion of patients with no new or enlarging T2-weighted brain MRI lesions between re-baselining at month 6 and month 24.
48310362|NCT03162783|DRUG|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
48483336|NCT00359788|DRUG|Combivent (Ipratropium/Albuterol)|
48483337|NCT00692146|DRUG|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
48483338|NCT00692146|DRUG|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
47962180|NCT04342377|DIAGNOSTIC_TEST|Selective Targeted Sampling|Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
48310363|NCT02538588|DEVICE|Nebulizer 1|
48483339|NCT05592353|OTHER|Brace|Brace following hip arthroscopy
48642796|NCT06025578|DRUG|BMS-986278 Placebo|Specified dose on specified days
48642797|NCT06283589|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
48642798|NCT04224142|DIETARY_SUPPLEMENT|PKU sphere|"PKU sphere is a Food for Special Medical Purposes (FSMP). This product is for use in the dietary management of phenylketonuria (PKU).~It is a powdered, low phenylalanine medical food containing a balanced mix of GMP, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and DHA.~It is available in 27g sachets providing 15g PE and contains 28mg Phe and 35g sachets providing 20g PE and contains 36mg Phe."
48642799|NCT05175105|DRUG|Mitapivat|Tablets or granules
47962181|NCT04342377|DIAGNOSTIC_TEST|Systematic Sampling|All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
48310364|NCT02538588|DEVICE|Nebulizer 2|
48310365|NCT00623454|BEHAVIORAL|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
48310366|NCT02343536|DRUG|Oral Azacitidine|
48310367|NCT02343536|DRUG|Rituximab|
48310368|NCT02343536|DRUG|cyclophosphamide|
48310369|NCT02343536|DRUG|Vincristine|
48310370|NCT02343536|DRUG|Prednisone|
48310371|NCT04743245|DEVICE|TherOx DownStream System|SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)
48483340|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
48642800|NCT05175105|DRUG|Mitapivat-matching placebo|Tablets or granules
48642801|NCT06159725|DRUG|CMTX-101|CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
48642802|NCT06159725|DRUG|Placebo|Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.
48642803|NCT04798339|DRUG|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
48642804|NCT04798339|DRUG|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
48642805|NCT06383598|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
48310372|NCT04743245|DEVICE|PCI|Standard Care of PCI
48310373|NCT00139854|DRUG|Alprazolam orally disintegrating tablets|
48310374|NCT03436446|OTHER|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
48310375|NCT04652336|PROCEDURE|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
48483341|NCT00865631|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
48483342|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
48483343|NCT02759341|OTHER|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
48642806|NCT04547712|DEVICE|Adaptive DBS|Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
48310376|NCT04652336|PROCEDURE|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
48310377|NCT04151537|BEHAVIORAL|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
48310378|NCT04151537|BEHAVIORAL|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
48310379|NCT06293625|DRUG|Folfox|Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.
48310380|NCT06293625|PROCEDURE|Surgery|Experimental arm: Surgery should take place 21 days after the last dose of neoadjuvant chemotherapy Control arm: upfront surgery as soon as possible
48642807|NCT05950659|DEVICE|Orpyx Sensory Insole System|The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
48642808|NCT05059522|DRUG|Avelumab|oral
48113488|NCT06677125|PROCEDURE|Electrical Mallet|The osteotome will be directly attached and pushed by magnetic mallet and a shock wave will be pushed on their tip. The electrical mallet will be imparted to osteotomes a longitudinal movement along a central axis moving up and down toward pilot bone hole providing a driving mechanism of longitudinal movements. Then the sinus lift instruments (Sweden and Martina) will be used to slowly lift the sinus. After that implant will be placed with the help of implant drilling device.
48310381|NCT04836455|BEHAVIORAL|The FDA's The REal Cost vaping prevention ads - Health harms theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about the health harms of vaping will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
48310382|NCT04836455|BEHAVIORAL|The FDA's The Real Cost vaping prevention ads - Addiction theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about vaping addiction will be shown to participants at week 0, 1, and 2. Ads will be shown in a random order.
48310383|NCT04836455|BEHAVIORAL|Neutral vaping ads|Three neutral (i.e., purely informational and without graphics) vaping video ads developed by the Investigators will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
48310384|NCT04753203|DRUG|Alpelisib plus Capecitabine combination|Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
48310385|NCT01280890|BEHAVIORAL|Staff training using VIPS|Staff training using the VIPS framework
48483344|NCT02759341|OTHER|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
48483345|NCT02759341|OTHER|State-Trait Anxiety Inventory form Y (STAI-Y)|
48483346|NCT02759341|OTHER|SF-36 Health-Related Quality of Life|
48642809|NCT05059522|DRUG|Lorlatanib|oral
48310386|NCT01280890|BEHAVIORAL|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
48310387|NCT01280890|BEHAVIORAL|Control group|Filmed traditional Lectures will be given to care staff
48310388|NCT05050721|OTHER|CT imaging|clinical, radiological and biochemical parameters associated with disease progression
48310389|NCT06554470|DRUG|Systemic Methotrexate|Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
48483347|NCT02759341|OTHER|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
48483348|NCT02412462|DRUG|AB-16B5|
48483349|NCT03003260|OTHER|CBD chewing gum|
48483350|NCT03003260|OTHER|Placebo|
48483351|NCT04637126|OTHER|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
48642810|NCT05059522|DRUG|Talazoparib|oral
48642811|NCT05059522|DRUG|Pemetrexed|IV (intravenous) infusion
48642812|NCT05059522|DRUG|Axitinib|oral
48642813|NCT05059522|DRUG|CMP 001|IT (intratumoral) or SC (subcutaneous)
48642814|NCT05059522|DRUG|Utomilumab|IV infusion
48642815|NCT05059522|DRUG|PF04518600|IV infusion
48642816|NCT06063031|DIETARY_SUPPLEMENT|Active|Active nutritional supplement plus telerehabilitation
48642817|NCT06063031|OTHER|Placebo|Placebo nutritional supplement plus telerehabilitation
48642818|NCT02390635|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
48642819|NCT02390635|PROCEDURE|Diffusion Weighted Imaging|Undergo whole body PET/MRI
48642820|NCT02390635|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
48642821|NCT02390635|DRUG|Gadolinium|Given IV
48642822|NCT02390635|PROCEDURE|Magnetic Resonance Imaging|Undergo whole body PET/MRI
48642823|NCT02390635|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT and whole body PET/MRI
48642824|NCT02390635|PROCEDURE|Three-Dimensional Spoiled Gradient MRI|Undergo whole body PET/MRI
48642825|NCT06203210|DRUG|Ifinatamab deruxtecan|12 mg/kg intravenous dose on Day 1 of each 21-day cycle
48642826|NCT06203210|DRUG|Topotecan|Topotecan will be administered per local SoC.
48642827|NCT06203210|DRUG|Amrubicin|Amrubicin will be administered per local SoC.
48642828|NCT06203210|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SoC
48642829|NCT04739800|PROCEDURE|Biospecimen Collection|Undergo collection of blood
47962182|NCT00536679|DRUG|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
48113489|NCT06677125|PROCEDURE|Densah bur|The implant motor will be adjusted on reverse-densifying mode with 800 to 1200 rpm. According to the desired implant dimension, it will be started with the smallest densah bur. The first densah bur will advanced in densifying mode with bouncing motion in and out movement with copious irrigation until.
48483352|NCT02771041|PROCEDURE|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
48642830|NCT04739800|DRUG|Cediranib Maleate|Given PO
48642831|NCT04739800|PROCEDURE|Computed Tomography|Undergo CT
48642832|NCT04739800|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
48642833|NCT04739800|BIOLOGICAL|Durvalumab|Given IV
48642834|NCT04739800|PROCEDURE|Echocardiography|Undergo ECHO
48642835|NCT04739800|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48642836|NCT04739800|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48642837|NCT04739800|DRUG|Olaparib|Given PO
47962183|NCT00536679|DRUG|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
47962184|NCT00536679|DRUG|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
47962185|NCT03935360|OTHER|Oakland-Jairath Risk Score|Oakland and Jairath developed a clinical prediction rule for safe discharge among patients with LGIB using data from their UK National Audit. They defined safe discharge as the absence of rebleeding, blood transfusion, need for endoscopic/radiologic/surgical intervention for hemostasis, readmission with LGIB, and death and developed a seven variable risk score: age, sex, previous history of LGIB admission, presence of blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin. Using a cut-off score ≤8, they reported excellent discrimination (AUC 0.84, 95% CI 0.82-0.86), good calibration, and a 95% probability of safe discharge.
47962186|NCT02425020|DIETARY_SUPPLEMENT|Meat Protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
47962187|NCT02425020|DIETARY_SUPPLEMENT|Whey protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
47962188|NCT02425020|DIETARY_SUPPLEMENT|Carbohydrate|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
47962189|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
47962190|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
47962191|NCT03893370|DEVICE|RejuvenAir System|RejuvenAir Metered CryoSpray
48113490|NCT06677281|OTHER|Systematic Review of COVID-19's Impact on Pregnancy Outcomes|This study is a systematic review of existing literature that examines the effects of COVID-19 on pregnancy outcomes, including maternal health, neonatal health, and obstetric complications. It synthesizes data from various studies to provide an overview of the potential risks associated with COVID-19 infection during pregnancy. This intervention does not involve any new clinical trials or direct patient interaction.
48113491|NCT01807546|DRUG|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
48113492|NCT06334549|DRUG|Ephedrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
48113493|NCT06334549|DRUG|Phenylephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
48642838|NCT04739800|DRUG|Paclitaxel|Given IV
48642839|NCT04739800|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48483353|NCT06355479|DRUG|OsrHSA|Recombinant Human Serum Albumin from Oryza Sativa
48483354|NCT06355479|DRUG|Plasbumin®-20|Albumin (Human) 20%, USP
48642840|NCT04739800|DRUG|Topotecan Hydrochloride|Given IV
48642841|NCT06110689|OTHER|VU-AMS device|Patients will wear the VU-AMS monitor prior to MRI.
48642842|NCT03673072|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
48642843|NCT03673072|DRUG|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
47962192|NCT03893370|DEVICE|Sham Control Procedure|Sham Control Procedure
47962193|NCT00324909|DRUG|Hyperbaric Oxygen Therapy|
48483355|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
48483356|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
48483357|NCT00812422|DRUG|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
48483358|NCT03647631|PROCEDURE|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
48483359|NCT05235659|BEHAVIORAL|Basic modules|Caregivers will only have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.
48113494|NCT06334549|DRUG|Norepinephrine-P|after induction of anesthesia, use total intravenous anesthesia maintained with propofol
48113495|NCT06334549|DRUG|Ephedrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
48310390|NCT06554470|DRUG|Local Methotrexate|Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
48113496|NCT06334549|DRUG|Phenylephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
48310391|NCT03466489|DEVICE|Floraseal|FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
48310392|NCT00734773|BIOLOGICAL|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
48310393|NCT00734773|DRUG|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
48310394|NCT00734773|DRUG|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
48310395|NCT00734773|DRUG|Motexafin gadolinium|"* Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~* For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~* During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
48310396|NCT00734773|DRUG|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
48310397|NCT00734773|DRUG|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
48310398|NCT00734773|RADIATION|Radiation therapy|Given at weeks 11 through 16.
48310399|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Contour® Next One|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
48310400|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect|
48310401|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing FreeStyle Freedom Lite|
48310402|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing OneTouch® Verio|
48310403|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing GlucoMen® areo|
48310404|NCT02241044|DEVICE|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
48642844|NCT03673072|PROCEDURE|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
48642845|NCT03673072|DRUG|Adjuvant chemotherapy|Can be selected by Investigator's Choice
48642846|NCT04274218|OTHER|Perturbation|Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
47962194|NCT02918201|DRUG|Tranexamic Acid|TXA 25 mg/ml applied topically to moisten the wound
47962195|NCT02918201|DRUG|saline|Saline solution (0.9% NaCl) applied topically to moisten the wound
47962196|NCT03981770|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
48113497|NCT06334549|DRUG|Norepinephrine-S|after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
47962197|NCT02057731|GENETIC|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
47962198|NCT03267108|COMBINATION_PRODUCT|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
47962199|NCT03267108|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
48113498|NCT06300489|DRUG|irinotecan liposomes+capecitabine|"Radiotherapy：IMRT DT 50Gy/25Fx. Capecitabine: 625mg/m2 bid po d1-5 qw. For patients are double sites mutant (GG+7/7 or AA+6/6 or GA+6/7)，the intial dose of Irinotecan liposomes is 25mg/m2 weekly，for four weeks。 This study stratify cases by the 3+3 rule according to UGT1A1 \* 6 and UGT1A1 \* 28 phenotypes. Three cases were enrolled in each dose group, and if there was no DLT, they were promoted to the next dose group（an increase of 5mg/m2）; If there is 1 case of DLT, 3 cases will be reenrolled in the same dose group. If there is no new occurrence of DLT, it will be promoted to the next dose group. Otherwise, the study will be terminated; If there are 2 cases of DLT, the study will be terminated, and the previous dose group will be the maximum tolerated dose (MTD)."
48113499|NCT01926977|DRUG|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
48113500|NCT01926977|DRUG|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
48113501|NCT05799261|PROCEDURE|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
48310405|NCT02241044|DEVICE|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
48113502|NCT05799261|PROCEDURE|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~1. Staining of all tooth surfaces to detect soft and hard deposits.~2. Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~3. If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~4. Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
48113503|NCT06676098|PROCEDURE|IANBD 3D guided approach|The IANBD will be used to administer the dental anesthetic 2mm medial to the lingula
48113504|NCT05148897|OTHER|Questionnaire|a self-administered questionnaire. Based on extensive literature review no questionnaire was found that specifically related to knowledge evaluation. The basic theme of the questionnaire was taken from Diabetes Knowledge Questionnaire (DKN), a well validated tool for knowledge assessment among type 1 and type 2 diabetes mellitus patients. Some modifications were made and new questions particularly related to GDM were included.
48310406|NCT00375882|PROCEDURE|hypothermia|
48310407|NCT00375882|PROCEDURE|cochlear implantation with mild hypothermia|
48310408|NCT01388582|DEVICE|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
48310409|NCT01388582|DEVICE|Implanon|60 mcg/day contraceptive implant
48310410|NCT01388582|DRUG|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
48483360|NCT05235659|BEHAVIORAL|"Basic modules and experimental condition My coach"|Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.
47962200|NCT03267108|COMBINATION_PRODUCT|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
47962201|NCT04562688|OTHER|CICADAS and then PEERS|Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. After 16 weeks, participants will then crossover to PEERS, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians.
48310411|NCT01388582|DEVICE|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
48310412|NCT01388582|DEVICE|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
47962202|NCT04562688|OTHER|PEERS + CICADAS and then no-contact|Participants will complete both PEERS and CICADAS study activities. Participants will complete sensory processing assessments and neuroplasticity-based social cognitive training (NB-SCT) exercises on a digital device for a total of 40 hours. The CICADAS app captures user-specific sensory processing abnormalities (SPA) through 10 brief computerized assessments. The data from these assessments guide and personalize the delivery of 10 NB-SCT exercises. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
47962203|NCT04562688|OTHER|PEERS + Active Comparator and then no-contact|Participants will complete both PEERS and Active Comparator study activities. Participants will engage in computerized, casual video games for a total of 40 hours. Participants will also complete the 10 sensory processing abnormalities (SPA) computerized assessments. In addition, participants will be asked to attend weekly 1-hour group sessions led by a PEERS clinician. Each PEERS group session will consist of a minimum of 3 participants and will meet as a group using Zoom. PEERS teaches how to solve real-life social dilemmas, appraise affect and social contexts, and initiate and maintain conversations while receiving feedback from peers and clinicians. After 16 weeks, participant will crossover to No-Contact with no active intervention.
48310413|NCT02245568|DRUG|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
48310414|NCT01076842|DRUG|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
48310415|NCT01076842|DRUG|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
48310416|NCT01076842|DRUG|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
48642847|NCT06420063|BIOLOGICAL|CD123/CD33 CART|"The intervention in this clinical trial involves a novel approach using CD22/123-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD33/123-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD33/123-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD33/123 CAR-T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
47962204|NCT04376463|DIETARY_SUPPLEMENT|Branched Chain Aminoacid|It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.
48483361|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
48642848|NCT06003829|DRUG|Sinsunatovir|Single dose, to be spit out after tasting
48642849|NCT06003829|OTHER|Bitrex|Single dose, to be spit out after tasting
47962208|NCT02561611|BEHAVIORAL|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
47962209|NCT04930965|BEHAVIORAL|Community health worker engagement|3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
47962210|NCT01708161|DRUG|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
47962211|NCT01708161|DRUG|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
47962212|NCT02834260|DRUG|Dexamethasone implant OZURDEX|
47962213|NCT04336540|OTHER|Menu configuration (presence of energy labelling)|Restaurant menus are altered to accommodate energy labelling intervention
48310417|NCT01076842|DEVICE|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
48310418|NCT01076842|DEVICE|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
48642850|NCT04963413|BIOLOGICAL|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
47962214|NCT04336540|OTHER|Menu configuration (more lower energy options added)|Restaurant menus are altered to include more lower energy options
47962215|NCT06444971|PROCEDURE|Post isometric Relaxation|"Post isometric relaxation technique: It is defined as a manual procedure which involves the precisely controlled and specifically directed active contraction of a muscle at varying levels of intensity against a counterforce applied by the therapist.~PIR will be applied to following muscles~1. scalene (anterior, middle and posterior)~2. sternocleidomastoid"
47962216|NCT04128085|DRUG|TQB3804|A kind of tyrosine kinase inhibitor.
47962217|NCT00415168|DRUG|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
47962218|NCT00415168|DRUG|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
47962219|NCT01171430|DEVICE|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:~* 1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~* 1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~* 1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
47962220|NCT02914119|DRUG|Rocuronium|
47962221|NCT02914119|DRUG|Succinylcholine|
47962222|NCT02914119|DRUG|Cisatracurium|
47962223|NCT02914119|DRUG|Mivacurium|
47962224|NCT02914119|DEVICE|Objective neuromuscular monitoring (acceleromyography)|
47962225|NCT02914119|DRUG|Sugammadex|
47962226|NCT02914119|DRUG|Neostigmine|
47962227|NCT04468854|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
47962228|NCT04468854|OTHER|Placebo|mannitol formulated for oral administration (capsules)
47962229|NCT03240484|DIAGNOSTIC_TEST|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
48113505|NCT00598208|DRUG|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
48310419|NCT01626183|GENETIC|RNA analysis|
48310420|NCT01626183|GENETIC|proteomic profiling|
48310421|NCT01626183|OTHER|laboratory biomarker analysis|
48310422|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
48310423|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
48310424|NCT02391090|DEVICE|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
48310425|NCT02391090|DEVICE|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
48310426|NCT02391090|PROCEDURE|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
48310427|NCT02391090|OTHER|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
48310428|NCT02391090|PROCEDURE|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
48483362|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Who am I and where do I belong? and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules."
47962230|NCT03240484|OTHER|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
47962231|NCT01667484|DRUG|Adderall XR 5mg|
47962232|NCT01667484|DRUG|Adderall XR 10 mg|
47962233|NCT01667484|DRUG|Placebo|
47962234|NCT00210483|DRUG|almotriptan malate|
47962235|NCT00820846|BIOLOGICAL|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
47962236|NCT00820846|BIOLOGICAL|Placebo|1 mL of sodium chloride for injection
47962237|NCT00820846|BIOLOGICAL|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
47962238|NCT00003433|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
47962239|NCT06535542|GENETIC|Whole Genome Sequencing|Participants in this arm will have their blood sample analyzed by whole-genome sequencing (WGS) and will be given access to Predictiv™ Deoxyribonucleic acid (DNA)-based digital twin platform, a web-based interactive application with WGS results. The platform will include positive monogenic and polygenic Familial Hypercholesterolemia results and pharmacogenomics results on statins and clopidogrel. A report of positive monogenic variants will be included in their medical record. This may also include genes on the American College of Medical Genetics and Genomics (ACMG) secondary findings (SF) version 3.2 list if the participant consents to receive these incidental findings. The report will only include pathogenic, likely pathogenic, and variant of uncertain significance (VUS) results.
47962240|NCT05894408|OTHER|this is no intervention|this is no intervention
47962241|NCT00002711|DRUG|chemotherapy|
47962242|NCT00002711|DRUG|cisplatin|
47962243|NCT00002711|DRUG|paclitaxel|
47962244|NCT00002711|RADIATION|low-LET electron therapy|
47962245|NCT00002711|RADIATION|low-LET photon therapy|
47962246|NCT04707508|DRUG|Valsartan 80 mg and metformin|Valsartan 80 mg once daily in addition to metformin monotherapy
47962247|NCT04707508|DRUG|Metformin|Metformin monotherapy
47962248|NCT03454711|DEVICE|fMRI|Brain MRI
47962249|NCT03454711|DEVICE|Indirect calorimetry|Resting energy expenditure
47962250|NCT03454711|DEVICE|Bioimpedance|Measurement of body composition
47962251|NCT03454711|BIOLOGICAL|Lipid profile, glucose, HBA1c, metabolomic analysis|Blood sample
47962252|NCT03454711|BEHAVIORAL|YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)|Questionnaires to characterize eating habits and depression
47962253|NCT01468363|DEVICE|Dry weight adjustment|Dry weight adjustment according to BCM results
47962254|NCT05121896|DEVICE|MRI Scan|7.0 tesla functional MRI scan
47962255|NCT05239208|OTHER|Oral Nutrition Supplement (ONS) Group|Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling
47962256|NCT05239208|OTHER|Control Group|Dietary counseling
47962257|NCT01695187|DRUG|NB-001 (0.3%)|Topical administration at least five times throughout the day
48310429|NCT02391090|PROCEDURE|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
47962258|NCT01695187|DRUG|Placebo|
48310430|NCT02391090|PROCEDURE|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
48310431|NCT04682834|DRUG|Sulopenem Etzadroxil/Probenecid|Individual Patients
48310432|NCT01687738|OTHER|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
48310433|NCT01687738|OTHER|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
48483363|NCT05235659|BEHAVIORAL|"Basic modules and experimental module You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
48483364|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules."
48483365|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
48642851|NCT05940649|PROCEDURE|Continuous norepinephrine administration|In patients randomized to continuous norepinephrine administration, hypotension (= mean arterial pressure \< 65mmHg) will be treated with continuous norepinephrine infusion. The norepinephrine perfusion line will be connected to the saline infusion line using a three-way valve. Treating anesthesiologists will be free to reduce or increase the norepinephrine infusion rate anytime.
48642852|NCT04070027|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty following standard procedures.
48642853|NCT04070027|OTHER|Progressive Resistance Training|"Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power."
48642854|NCT06323473|DIETARY_SUPPLEMENT|Black Maitake Prothera|Mushroom extract; liquid
48642855|NCT06487286|OTHER|observational study|observational study
48642856|NCT03422731|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow and blood samples
48642857|NCT03422731|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
47962259|NCT02008760|DIETARY_SUPPLEMENT|Omega Krill with D3|
47962260|NCT06245031|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
47962261|NCT01218243|DEVICE|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
48113506|NCT00598208|DRUG|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
48310434|NCT05787912|DEVICE|Photobiomodulation|The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.
48310435|NCT05787912|OTHER|Hyaluronic acid after photobiomodulation|The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
48310436|NCT02739022|BEHAVIORAL|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
48310437|NCT05632458|DEVICE|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
48310438|NCT04517617|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
48310439|NCT02755844|DRUG|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
48310440|NCT02755844|DRUG|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
48642858|NCT03422731|DRUG|Fluorothymidine F-18|Undergo FLT PET
48642859|NCT03422731|OTHER|Laboratory Biomarker Analysis|Correlative studies
48642860|NCT03422731|PROCEDURE|Magnetic Resonance Imaging|Undergo water-fat MRI
48642861|NCT03422731|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
47962262|NCT03282682|PROCEDURE|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
48310441|NCT02755844|DRUG|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
48642862|NCT06526169|OTHER|Food Frequency, Social, Lifestyle, Demographic Questionnaires and Blood Collection|Questionnaires on food frequency, social, lifestyle, and demographics will be administered to participants and will be correlated with the presence of chemical hazards in the blood. The chemical hazards analyzed will be referenced from Singapore's Total Diet Study, based on the prioritized chemical hazards of interest to investigate the distribution of risk in the population.
48642863|NCT06246409|BEHAVIORAL|Modernized patient instructions|Patients will be given modernized patient instructions prior to radiotherapy treatment.
48642864|NCT06246409|BEHAVIORAL|Existing patient instructions|Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
48642865|NCT04267848|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48642866|NCT04267848|DRUG|Carboplatin|Given IV
47962263|NCT06395545|DEVICE|Electronic injector|At room temperature, 1% lidocaine combined with 1:100,000 epinephrine was used as a local anesthesia. The electronic constant-speed injector, i-JECT® (MediHub Inc., Gyeonggi-do, Korea) (Figure 1) was used, and the injection speed of the injector was set at level 1 (0.25 mL/s) or level 2 (0.4 mL/s). The injection site in a patient was divided into two sides (left and right). The method of local infiltration (manual or using the electronic injector) was randomly assigned to each side of the surgical field, and 2.5 cc (0.5 cc at five separate areas) of local anesthetic was injected individually using a 5 cc syringe with a 31-gauge needle. All injections were administered by a single surgeon (Sung Joo Tommy Hwang) to reduce inter-operator variation.
47962264|NCT01908283|BIOLOGICAL|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
47962265|NCT02032225|OTHER|Skin biopsy|
48113507|NCT06676007|OTHER|Gd-IgA1 test|collect and test Gd-IgA1 test in enrolled subjects
48310454|NCT06206668|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
48310455|NCT06425783|PROCEDURE|Warmed Blood Transfusion|"The erythrocyte suspension will be heated between 34-36 C⁰, which is the determined physiological temperature.~Before giving it to the baby, 2 ml of blood will be taken through a triple tap and its hematocrit and K value (blood gas) will be checked. It will be given to the baby after the temperature is checked with a body fluid thermometer and determined to be within the appropriate range and if hemolysis is not observed.~At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K."
48310456|NCT01043185|DRUG|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
48642867|NCT04267848|DRUG|Cisplatin|Given IV
48642868|NCT04267848|PROCEDURE|Computed Tomography|Undergo CT
48310457|NCT01043185|DRUG|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
48310458|NCT01043185|DRUG|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
48310459|NCT01043185|DRUG|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
48310460|NCT01043185|DRUG|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
48310461|NCT02734719|DEVICE|Bonestim|Bonestim is the multipad electrical stimulation device.
48310462|NCT05999474|DRUG|Topical tioconazole|Laser
48310463|NCT04229589|OTHER|Clinic follow-up|Patients are regularly evaluated to asses the occurrence of syncopal relapses
48310464|NCT00251407|DRUG|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
48310465|NCT00251407|DRUG|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
48310466|NCT00251407|DRUG|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
48310467|NCT04022811|DRUG|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
48310468|NCT02541838|OTHER|Muscle power|
48310469|NCT02541838|OTHER|balance perturbation|
48310470|NCT02541838|OTHER|aerobic exercise|
48642869|NCT04267848|PROCEDURE|Echocardiography|Undergo ECHO
48642870|NCT04267848|DRUG|Gemcitabine Hydrochloride|Given IV
48642871|NCT04267848|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48642872|NCT04267848|OTHER|Observation|Undergo observation
48642873|NCT04267848|DRUG|Paclitaxel|Given IV
48642874|NCT04267848|BIOLOGICAL|Pembrolizumab|Given IV
47962266|NCT05278767|OTHER|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
48310471|NCT04536740|DEVICE|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
48310472|NCT01387295|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
48310473|NCT06553339|DRUG|Oral HS-10516|Oral HIF-2α inhibitor
48310474|NCT03563703|DEVICE|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
48310475|NCT03563703|DEVICE|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
48310476|NCT02529761|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
48310477|NCT02529761|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
48310478|NCT00339183|DRUG|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
48310479|NCT00339183|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
48310480|NCT04875039|DRUG|Dexamethasone|dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
48310481|NCT04875039|DRUG|Dexmedetomidine-Dexamethasone|A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
48310482|NCT00186745|DRUG|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
48642875|NCT04267848|DRUG|Pemetrexed Disodium|Given IV
47962267|NCT03851523|OTHER|No intervention|No intervention
47962268|NCT00251784|DRUG|Sildenafil|
47962269|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
48642876|NCT04267848|OTHER|Quality-of-Life Assessment|Ancillary studies
48642877|NCT04267848|OTHER|Questionnaire Administration|Ancillary studies
47962270|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
48310483|NCT03524833|DRUG|Metronidazole|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
48310484|NCT03524833|DRUG|Lansoprazole, Amoxicillin, Metronidazole|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
48310485|NCT03965663|DEVICE|Vibro-tactile Feedback|The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
48310486|NCT00076219|PROCEDURE|renal replacement therapy|renal replacement therapy
48310487|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement A|1, 2 or 4 capsules daily of oral supplement A for 3 days
48642878|NCT03213704|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48113508|NCT06553547|DRUG|Tenapanor|Tenapanor 5 mg/mL solution
48642879|NCT03213704|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
48642880|NCT03213704|PROCEDURE|Bone Scan|Undergo a bone scan
48642881|NCT03213704|PROCEDURE|Computed Tomography|Undergo a CT scan
48642882|NCT03213704|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
48642883|NCT03213704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48642884|NCT03213704|PROCEDURE|Radionuclide Imaging|Undergo a MIBG scintigraphy
48642885|NCT03213704|PROCEDURE|X-Ray Imaging|Undergo an x-ray
48642886|NCT05093166|DRUG|"Ex vivo expanded autologous human oral epithelium containing stem cells"|The treatment includes a single administration of investigational product through a dedicated surgical procedure of penis wound bed preparation, epithelial surface adaption and product application followed by urethra tubularization and penis reconstruction.
48642887|NCT02838706|PROCEDURE|Surgery for hip fracture|
48642888|NCT02344927|OTHER|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
48642889|NCT02344927|OTHER|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
48642890|NCT05269940|DRUG|ZX-101A|oral dosing, once daily
48642891|NCT03285893|OTHER|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
48642892|NCT02302833|DRUG|Cabozantinib S-malate|Given PO
48642893|NCT02302833|OTHER|Laboratory Biomarker Analysis|Correlative studies
48642894|NCT02302833|OTHER|Questionnaire Administration|Ancillary studies
48642895|NCT03643588|DEVICE|HYAJOINT Plus|Single-injection, 60 mg / 3 ml (2%) cross-linked hyaluronan
48642896|NCT03643588|DEVICE|Hyalgan|Three-injection, 20 mg / 2 ml (1%) linear hyaluronan
48642897|NCT05785767|DRUG|fianlimab|Every three weeks (Q3W) as intravenous (IV) co-infusion
48642898|NCT05785767|DRUG|cemiplimab|Q3W as IV co-infusion
48642899|NCT05785767|DRUG|Placebo|Q3W as IV co-infusion
48642900|NCT04429087|DRUG|BI 764532 - parenteral 1|BI 764532 - parenteral 1
47962271|NCT05656495|DRUG|Standard of care|The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
47962272|NCT02937675|DRUG|Tomivosertib (eFT-508)|eFT508
47962273|NCT04305418|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
47962274|NCT04649320|OTHER|questionnaire|"1. 13-item questionnaire about cancer patient's distress and everyday life,~2. EORTC-QLQ-C30"
48642901|NCT04429087|DRUG|BI 764532 - parenteral 2|BI 764532 - parenteral 2
48642902|NCT05112965|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
48642903|NCT05112965|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
48642904|NCT05112965|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
48642905|NCT05112965|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
48642906|NCT05112965|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
48642907|NCT04621929|DRUG|Phentermine / Topiramate Oral Product|All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)
47962275|NCT01509092|PROCEDURE|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
47962276|NCT00845104|DRUG|fludarabine phosphate|Given IV
48113509|NCT06553547|DRUG|Placebo|Matching Placebo solution
48642908|NCT04621929|COMBINATION_PRODUCT|Citrate Salts, Allopurinol, Diet|Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
48642909|NCT06601335|DRUG|AK117 in combination with AK112|Following a predefined dose and date.
48642910|NCT06601335|DRUG|Placebo in combination with Pembrolizumab|Following a predefined dose and date.
48642911|NCT06082960|DRUG|GS-9911|Tablets administered orally
48642912|NCT06082960|DRUG|Zimberelimab|Administered intravenously
48642913|NCT05745883|DRUG|DISC-0974|DISC-0974 is administered subcutaneously
48642914|NCT05745883|DRUG|Placebo|Placebo is administered subcutaneously
48642915|NCT04303169|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
47962277|NCT00845104|BIOLOGICAL|rituximab|Given IV
47962278|NCT00845104|BIOLOGICAL|bevacizumab|Given IV
47962279|NCT00845104|OTHER|laboratory biomarker analysis|Correlative studies
48642916|NCT04303169|BIOLOGICAL|Vibostolimab|Administered via IV infusion at a specified dose on specified days
48310488|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement B|4 capsules daily of oral supplement B for 3 days
48310489|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement C|1,2 or 4 capsules daily of oral supplement C for 3 days
47962280|NCT00845104|OTHER|flow cytometry|Correlative studies
48310490|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement D|1 or 2 tablets daily of oral supplement D for 3 days
48310491|NCT03707652|DIETARY_SUPPLEMENT|Oral Supplement D in combination with oral supplement C|1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
48310492|NCT01073345|PROCEDURE|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
48310493|NCT01073345|PROCEDURE|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
47962281|NCT00845104|GENETIC|polymerase chain reaction|Correlative studies
47962282|NCT00845104|GENETIC|fluorescence in situ hybridization|Correlative studies
47962283|NCT04779125|PROCEDURE|Gluteus plasty enhanced with Progrip self gripping mesh|Intervention group will be compared to historical patients in a case-control setting. Intervention group will have a mesh enhanced gluteus plasty made to reconstruct perineum after abdominoperineal resection.
47962284|NCT02649595|OTHER|Red Cross Respite care|See detailed description.
47962285|NCT02130297|DEVICE|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
47962286|NCT03438929|DEVICE|Diode laser|Diolaze XL blended modes diode laser
47962287|NCT03142178|DRUG|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
48113510|NCT02770495|OTHER|blood sample|
48113511|NCT05717751|PROCEDURE|surgical staging|para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
48113512|NCT04484480|PROCEDURE|Balance training|Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
48310494|NCT01073345|PROCEDURE|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
48310495|NCT01613287|DEVICE|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
48310496|NCT05434247|DEVICE|Needle choice|The type of needle use was the only intervention
48310497|NCT00308438|DRUG|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
48310498|NCT04043338|DRUG|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
48310499|NCT04043338|DRUG|Placebo|Placebo supplied as matching capsules or tablets
48310500|NCT01496430|DRUG|Placebo|
47962288|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
48310501|NCT01496430|DRUG|Azilsartan medoxomil|
47962289|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
48310502|NCT01496430|DRUG|Azilsartan medoxomil|
48310503|NCT02473159|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
48310504|NCT04846751|BEHAVIORAL|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
48310505|NCT04148924|OTHER|Questionnaire|"Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~* HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~* BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~* Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours)."
48642917|NCT04303169|BIOLOGICAL|Gebasaxturev|Administered via IT injection at a specified dose on specified days
48642918|NCT04303169|BIOLOGICAL|MK-4830|Administered via IV infusion at a specified dose on specified days
47962290|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
47962291|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
48113513|NCT04063410|PROCEDURE|Angiography|Undergo standard of care CTA
48113514|NCT04063410|PROCEDURE|MRI-Based Angiogram|Undergo pPCA
48113515|NCT04063410|OTHER|Quality-of-Life Assessment|Ancillary studies
48113516|NCT01261234|DRUG|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
48113517|NCT05774951|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
48113518|NCT05774951|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered per local approved label
48113519|NCT05774951|DRUG|Anastrozole|Anastrozole. Comparator. Administered per local approved label
48113520|NCT05774951|DRUG|Letrozole|Letrozole. Comparator. Administered per local approved label
48113521|NCT05774951|DRUG|Exemestane|Exemestane. Comparator. Administered per local approved label
47962292|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
47962293|NCT05759078|DRUG|Ferinject|The first dose of FCM will be administered during the first visit on the day of randomisation (V1). Then, the participants will be reassessed at 4 and 8 months (visits V2, V3) for: haemoglobin, serum ferritin and TSAT. They will receive an additional dose of 1000 mg of FCM during these visits if ferritin \<100 ng/mL or/and TSAT \<20% (ferritin cannot exceed 400 ng/dL, TSAT cannot exceed 40%, haemoglobin cannot exceed 15 g/dL). If these criteria are not fulfilled, a patient in the active study arm will receive i.v. NaCl 0.9% during the particular visit.
47962294|NCT05759078|DRUG|Sodium Chloride 0.9% Inj|The first dose of placebo will be administered during the first visit on the day of randomisation (V1). During visits V2 i V3 (at 4 and 8 months) they will receive next dose of placebo.
47962295|NCT01057095|GENETIC|RNA analysis|
47962296|NCT01057095|GENETIC|gene expression analysis|
47962297|NCT01057095|GENETIC|reverse transcriptase-polymerase chain reaction|
47962298|NCT01057095|OTHER|laboratory biomarker analysis|
47962299|NCT03356756|DIAGNOSTIC_TEST|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
48113522|NCT05695911|BEHAVIORAL|Limb Load Biofeedback Training Intervention|Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.
48113523|NCT05695911|OTHER|Attention Control|The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).
48642919|NCT04303169|BIOLOGICAL|Favezelimab + Pembrolizumab|Administered via IV infusion at a specified dose on specified days
48642920|NCT04303169|DRUG|ATRA|Administered via oral capsules at a specified dose on specified days
48642921|NCT06059846|DRUG|TBP-PI-HBr|TBP-PI-HBr film-coated immediate-release tablets.
47962300|NCT05002452|OTHER|Search of factors predicting therapeutic effects and prognosis|There factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
48113524|NCT03655626|OTHER|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
48113525|NCT03081949|DRUG|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
48113526|NCT03689699|DRUG|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
48642922|NCT06059846|DRUG|Imipenem-cilastatin|Sterile powder for reconstitution administered as IV.
48642923|NCT06059846|DRUG|Dummy Infusion|0.9% sodium chloride administered as IV infusion.
48642924|NCT06059846|DRUG|Dummy Tablets|TBP-PI-HBr matching dummy tablets.
48642925|NCT06389591|BIOLOGICAL|pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)|pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously
48642926|NCT06389591|BIOLOGICAL|RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)|personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously
48642927|NCT05739942|DRUG|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
48642928|NCT05739942|DRUG|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
48642929|NCT05739942|OTHER|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
47962301|NCT03145974|DEVICE|mechanical ventilation|ventilatory support
47962302|NCT00183677|DRUG|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
47962303|NCT00985023|PROCEDURE|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
48642930|NCT06380751|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
48642931|NCT06380751|DRUG|Camizestrant|Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
47962304|NCT00985023|PROCEDURE|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
47962305|NCT04084431|RADIATION|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
47962306|NCT04084431|OTHER|OSC|optimal supportive Care (OSC) alone
48642932|NCT06380751|DRUG|Abemaciclib|CDK4/6 Inhibitor
48642933|NCT06380751|DRUG|Ribociclib|CDK4/6 Inhibitor
47962307|NCT04966039|OTHER|No intervention.|There was no intervention.
47962308|NCT03566888|DEVICE|Blood pressure assessment|Validation of an automated blood pressure device
47962309|NCT04153942|BEHAVIORAL|Mobilization|Any movement out of bed
47962310|NCT06556615|BEHAVIORAL|Interview|Interviews, presentation of questionnaires
47962311|NCT01374997|OTHER|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
47962312|NCT00094705|BIOLOGICAL|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
47962313|NCT00094705|BIOLOGICAL|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
47962314|NCT03219138|DEVICE|Acceleromyography|Use of an uncalibrated acceleromyography
47962315|NCT03892096|DIAGNOSTIC_TEST|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
47962316|NCT06313775|PROCEDURE|bilateral orchiectomy|Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
48310506|NCT04148924|OTHER|Medical staff questionnaire|"Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms"
48310507|NCT01675011|DEVICE|Embozene® Microspheres|
47962317|NCT02087735|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
47962318|NCT02056977|OTHER|Titration|Individualized PEEP according to PEEP titration monitored by EIT
47962319|NCT02056977|OTHER|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
47962320|NCT04898595|PROCEDURE|Discontinuation of CRRT|Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
47962321|NCT04470141|DRUG|SHC014748M treatment|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
48113527|NCT03689699|DRUG|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
48113528|NCT03689699|DRUG|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
48113529|NCT00001637|PROCEDURE|Blood cell transplantation|
48113530|NCT06271590|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
48113531|NCT06271590|DEVICE|Drug eluting stents (DES)|For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES (ZES or EES) and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.
48113532|NCT06677502|DRUG|Cerebrolysin|Patients were randomized into two groups: CBL - patients treated with cerebrolysin at the daily dose of 50 mL, and K - control patients treated without cerebrolysin. Cerebrolysin was administrated intravenously on the day the delirium was detected and then for seven consecutive days.
48642934|NCT06380751|DRUG|Palbociclib|CDK 4/6 Inhibitor
48113533|NCT06677502|OTHER|Saline Solution - IV|Patients enrolled in group K received the infusion of 0.9% Saline solution at a volume of 250 mL.
47962322|NCT00115739|DRUG|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
47962323|NCT00541684|DRUG|MK0954, /Duration of Treatment : 16 Weeks|
47962324|NCT00541684|DRUG|Comparator : atenolol /Duration of Treatment : 16 Weeks|
47962325|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
47962326|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
47962327|NCT05161767|DIAGNOSTIC_TEST|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
47962328|NCT02973061|OTHER|Questionnaires|All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
47962329|NCT02158234|DRUG|Cisplatin|Cisplatin 15 mg/m\^2 prior to each fraction
48113534|NCT01287286|DIETARY_SUPPLEMENT|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
48113535|NCT01287286|DIETARY_SUPPLEMENT|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
48113536|NCT00376519|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
48113537|NCT00376519|DRUG|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of \>200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
48310508|NCT01675011|DEVICE|Embosphere®|
48310509|NCT04316689|BIOLOGICAL|S-488210|S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
48310510|NCT04316689|BIOLOGICAL|S-488211|S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
48642935|NCT06380751|DRUG|Fulvestrant|Endocrine Therapy
48642936|NCT06380751|DRUG|Letrozole|Endorcine Therapy
48642937|NCT06380751|DRUG|Anastrozole|Endocrine Therapy
48642938|NCT06380751|DRUG|Exemestane|Endocrine Therapy
48642939|NCT05809596|DEVICE|WATCHMAN FLX Pro LAAC Device|Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device
47962330|NCT02158234|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
48113538|NCT00376519|DRUG|fludarabine phosphate|Fludarabine 25 mg/m\^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
48113539|NCT00376519|DRUG|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
48113540|NCT00376519|PROCEDURE|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10\^6/kg, 0.3 x 10\^6/kg, 1 x 10\^6/kg and 3 x 10\^6/kg weight (determined on the day prior to administration of the preparative therapy).
48310511|NCT03191656|DEVICE|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
48310512|NCT00875784|DRUG|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
48642940|NCT06207227|DEVICE|VITA AV Clinical System|The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
48642941|NCT06425588|OTHER|Surgical/Procedure Mask Fit Testing|All participants will wear a surgical/procedure mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
48642942|NCT06425588|OTHER|KN95 Mask Fit testing|All participants will wear a KN95 mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
48642943|NCT04973293|DRUG|sintilimab|Sintilimab 200 mg, 4 cycles of treatment before surgery
48642944|NCT04973293|DRUG|bevacizumab|bevacizumab 15 mg/kg, 4 cycles of treatment before surgery
48642945|NCT05514535|DRUG|Semaglutide|Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
48642946|NCT05514535|DRUG|Insuline glargine U100 (reduced)|Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
48642947|NCT05514535|DRUG|Insuline glargine U100 (titrated)|Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
48642948|NCT06150183|BIOLOGICAL|BNT314|Intravenous infusion
48642949|NCT06150183|BIOLOGICAL|Pembrolizumab|Intravenous infusion
48642950|NCT06125327|DRUG|SC1011|Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
47962331|NCT01389388|DRUG|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
47962332|NCT03880734|DRUG|Cholecalciferol|ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
47962333|NCT03880734|OTHER|Placebo oral capsule|ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
47962334|NCT01544283|DRUG|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
48113541|NCT00376519|PROCEDURE|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
48113542|NCT00376519|RADIATION|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
48310513|NCT00875784|DRUG|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
48310514|NCT00875784|DRUG|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
48310515|NCT00875784|DRUG|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
48310516|NCT00107068|PROCEDURE|[A] Aerobic isokinetic cycling exercise|
48310517|NCT00107068|PROCEDURE|[B] Progressive Resistance Training|
48642951|NCT06125327|DRUG|Placebo comparator|Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
48642952|NCT05560763|DEVICE|FlowTriever2 Catheter|The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism
48642953|NCT04895956|PROCEDURE|Intra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
48642954|NCT04895956|PROCEDURE|Extra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
48642955|NCT04895956|DEVICE|Ultrasound|To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
48310518|NCT00107068|PROCEDURE|[A] + [B]|
48310519|NCT03765541|DRUG|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~* Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV \[10 minutes\])~* Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[10 minutes\])~In combination with azacitidine:~* Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV \[10 minutes\]).~* Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV \[10minutes\])."
48310520|NCT03765541|DRUG|Amsacrine|"* Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV \[3 hours\])~* Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV \[3 hours\])"
48310521|NCT03765541|DRUG|Cytarabine|"Patients \< 60 years of age:~* Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV \[2 hours\])~* Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[2 hours\]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
48310522|NCT03765541|DRUG|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle \[or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle\] (SC)
48310523|NCT02557386|DRUG|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
48310524|NCT02557386|DRUG|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
48310525|NCT02557386|DRUG|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
48310526|NCT02557386|DRUG|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
48310527|NCT02557386|DRUG|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
48310528|NCT02557386|DRUG|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
48642956|NCT06420076|BIOLOGICAL|CD5/CD7 CAR-T|"The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
48310529|NCT05884411|DEVICE|Left bundle branch area pacing|A cardiac pacing electrode is inserted into the left bundle branch area of the myocardium via a transvenous approach.
48310530|NCT05884411|DIAGNOSTIC_TEST|Cardiac MRI|A diagnostic imaging test using magnetic resonance imaging to evaluate cardiac function.
48310531|NCT04680663|DIAGNOSTIC_TEST|Peripheral Perfusion index|Peripheral Perfusion index is the ratio between pulsatile blood flow to non pulsatile blood flow or static blood in the peripheral tissue
48310532|NCT04680663|DIAGNOSTIC_TEST|serum lactate level|Blood lactate (product of metabolism) level is maintained by a cycle of continuous production and metabolism allowing it to be kept within normal values
48310533|NCT01762657|DRUG|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
48113543|NCT03122574|OTHER|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
48113544|NCT03122574|OTHER|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
48113545|NCT01170299|DIETARY_SUPPLEMENT|dietary intervention|
48310534|NCT01762657|DRUG|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
48310535|NCT04666324|DRUG|Simethicone Solution|Oral daily treatment for four weeks
48310536|NCT04666324|DIETARY_SUPPLEMENT|Multilac Baby|Oral daily treatment for four weeks
48310537|NCT04592432|OTHER|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
48310538|NCT04592432|OTHER|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
48310539|NCT03268070|DEVICE|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
48310540|NCT03268070|DEVICE|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
48310541|NCT03268070|DEVICE|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
48310542|NCT03268070|DEVICE|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
48310543|NCT03268070|DEVICE|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
48310544|NCT02040194|DRUG|AM-101|AM-101 gel for intratympanic injection
48642957|NCT04331769|DEVICE|AccuCinch Ventricular Restoration System|AccuCinch Ventricular Restoration System
48310545|NCT02040194|DRUG|Placebo|Placebo gel for intratympanic injection
48642958|NCT04331769|DRUG|Guideline-Directed Medical Therapy|Guideline-Directed Medical Therapy
48642959|NCT04584320|OTHER|Stool sample|Stools samples taken daily to test for present of Clostridium butyricum and Clostridium neonatale
48642960|NCT06120582|GENETIC|ANB-002, dose 1|Adeno-associated viral vector carrying the FIX gene single infusion at dose 1.
48642961|NCT06120582|GENETIC|ANB-002, dose 2|Adeno-associated viral vector carrying the FIX gene single infusion at dose 2.
48642962|NCT04770779|DRUG|Placebo Matching Mitapivat|Tablets
48642963|NCT04770779|DRUG|Mitapivat|Tablets
48642964|NCT03555994|DRUG|MEDI0382|MEDI0382 administered subcutaneously
48642965|NCT03555994|DRUG|Placebo|Placebo administered subcutaneously
48642966|NCT03555994|DRUG|Liraglutide|Liraglutide administered subcutaneously
48642967|NCT06136819|COMBINATION_PRODUCT|RT-310|Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
48642968|NCT03035097|OTHER|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
47962335|NCT01544283|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
47962336|NCT03033004|DEVICE|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
47962337|NCT03033004|DEVICE|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
47962338|NCT03033004|DEVICE|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
47962339|NCT02939430|DRUG|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
48642969|NCT05930444|DIAGNOSTIC_TEST|Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases|Patients presenting with eye-related chief complaints initially complete a mobile phone application. This application utilizes patient medical history and relevant images (such as selfies and photos from eye examinations) to provide intelligent diagnosis. The diagnosis remains undisclosed to the patients. Subsequently, patients seek medical attention and undergo clinical examination by a skilled clinician. The clinical diagnosis is subsequently reviewed by a second experienced clinician. If the diagnoses align, it is considered the gold standard. In cases of discrepancy, the consensus reached by the two clinicians becomes the gold standard.
47962340|NCT02939430|DRUG|Intravenous neostigmine and atropine|
47962341|NCT01471678|DRUG|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
47962342|NCT01471678|DRUG|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
47962343|NCT01471678|DRUG|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
47962344|NCT04449926|BIOLOGICAL|Bacillus of Calmette and Guerin (BCG)|Prime and boost vaccination
48113546|NCT01170299|OTHER|laboratory biomarker analysis|
48113547|NCT01170299|PROCEDURE|gastrointestinal complications management/prevention|
48642970|NCT06522503|BEHAVIORAL|stress ball|The intervention group was provided with a stress ball to be held in both hands for a period of five minutes prior to the insertion of the port catheter needle. They were instructed to squeeze the ball in their hands at regular intervals until the conclusion of the procedure.
48642971|NCT05836259|GENETIC|TN-201|TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene. It is a single (one-time) intravenous dose.
48642972|NCT05377216|DRUG|Stellate Ganglion Block|Left sided percutaneous stellate ganglion block
48642973|NCT04474301|OTHER|Survey Administration|Complete survey
48642974|NCT06240208|BEHAVIORAL|Inactivity|Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
48642975|NCT04725071|DIETARY_SUPPLEMENT|Impact Advanced Recovery|L-arginine and omega-3 rich supplement
48642976|NCT04725071|DIETARY_SUPPLEMENT|Boost High Protein|conventional supplement
48642977|NCT05025605|DRUG|BXCL501 80 Micrograms|Sublingual film containing 80 Micrograms BXCL501
48642978|NCT05025605|DRUG|Placebo Film|Matching Sublingual Placebo film
48642979|NCT05025605|DRUG|BXCL501 120 Micrograms|Sublingual film containing 120 Micrograms BXCL501
48642980|NCT05025605|DRUG|BXCL501 60 Micrograms|Sublingual film containing 60 Micrograms BXCL501 Europe Only
48310546|NCT05072548|BEHAVIORAL|The ABCs of SLEEPING|"The intervention is comprised of three components. The first is a sleep check-in which is a questionnaire that is evidence based and evaluates what areas of sleep parents can work on. The second component is the sleep report which summarizes to the parent what areas they're doing well in (i.e., within the ABCs of SLEEPING mnemonic described above) and what areas they can improve on. The third component of this intervention are the sleep tips which are sleep recommendations that are customized based on the identified areas of sleep the parents are suggested to work on."
48310547|NCT06255470|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
47962345|NCT00032409|BEHAVIORAL|Music therapy-based relaxation/stress reduction|
48310548|NCT02274584|GENETIC|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
48310549|NCT01887899|DEVICE|transcranial direct current stimulation|
48310550|NCT01887899|DEVICE|sham stimulation|
48310551|NCT06316622|DEVICE|ultrasound|measured by ultrasound
48310552|NCT02767141|BEHAVIORAL|Coping Strategies|Coping strategies for households in the US with food insecurity
48310553|NCT06271200|OTHER|Intermittent fasting and 10,000 steps per day|"Reduce calories intake and eat as 168 pattern, namely, eating foods for 8 hours while fast for 16 hours at daily basis plus walking more than 10,000 steps per day."
48310554|NCT05822895|DEVICE|CADe enabled programme (GI Genius)|CADe enabled programme (GI Genius)
48310555|NCT01810198|PROCEDURE|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
48310556|NCT01810198|PROCEDURE|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
48310557|NCT01252134|DEVICE|Biotrue multipurpose solution|Contact lens care solution
48642981|NCT06606119|OTHER|Data and tissue collection|Collection of bone marrow, blood, feces, medical record data, and patient response surveys.
47962346|NCT03638609|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
47962347|NCT01121653|DRUG|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
47962348|NCT06088108|DEVICE|Cornell treadmill exercise protocol|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
47962349|NCT01208792|PROCEDURE|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
47962350|NCT01208792|OTHER|Blood Sample|a blood sample will be collected
47962351|NCT03136354|PROCEDURE|Endoscopic Submucosal Dissection|
47962352|NCT03136354|PROCEDURE|Laparoscopic assisted Gastrectomy|
48310558|NCT01252134|DEVICE|Sauflon Synergi multipurpose solution|Contact lens care solution
48310559|NCT01252134|DEVICE|OTE Elements multipurpose solution|Contact lens care solution
48310560|NCT01252134|DEVICE|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
48310561|NCT03129581|BEHAVIORAL|Dietary Counseling|Counseling to only eat during a restricted amount of time.
48310562|NCT03017924|DEVICE|Q collar|q-collar concussion prevention device
48310563|NCT02963714|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
48310564|NCT02963714|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
48310565|NCT03914443|BIOLOGICAL|Nivolumab|240 mg or 360 mg
48310566|NCT03914443|DRUG|5-FU|750 or 800 mg\^2
48310567|NCT03914443|DRUG|CDDP|70 or 80 mg/m\^2
48310568|NCT03914443|DRUG|DTX|70 mg/m\^2
48310569|NCT01055808|DRUG|Insulins|Individual dose and frequency and duration as determined by the treating physician
48310570|NCT03750032|PROCEDURE|Stapler appendectomy|The patients randomised for this intervention will undergo stapler appendectomy.
48310571|NCT03750032|PROCEDURE|Endoloop|The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
48642982|NCT05029999|DRUG|PLD Chemotherapy|PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
48642983|NCT05029999|DRUG|CDX-1140|CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
48310572|NCT03750032|PROCEDURE|Hem-O-Lock|The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
48310573|NCT04056013|DEVICE|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
48310574|NCT01241669|DRUG|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
48642984|NCT05029999|DRUG|CDX-301|CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
48642985|NCT06439329|BEHAVIORAL|Standard PN|Standard of care
47962353|NCT00092638|DRUG|MK0653, ezetimibe|
47962354|NCT00092638|DRUG|Comparator: ezetimibe, placebo|
47962355|NCT05622175|DRUG|F8IL10|"The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10"
47962356|NCT04800744|OTHER|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
47962357|NCT04800744|OTHER|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
47962358|NCT04020380|DRUG|Azithromycin 250Mg Capsule|250 mg OD
47962359|NCT03021941|DRUG|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
47962360|NCT00716703|OTHER|CT Scan using IV contrast alone|CT scan using IV contrast alone
47962361|NCT03656432|DRUG|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
47962362|NCT04401423|DRUG|TXA127|0.5 mg/kg per day
47962363|NCT04401423|DRUG|Placebo|0.5 mg/kg per day
48642986|NCT06439329|BEHAVIORAL|Patient Choice|Participants can select from a menu of options including brick and mortar services, Mobile Health Unit (MHU) or telehealth services.
48642987|NCT05912166|BEHAVIORAL|Wakeful Spanish|"Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~1. Write what they observed during meditations.~2. Be guided by videos/audios through breathing exercises and gentle stretching.~3. See what others experienced and their tips for overcoming challenges.~4. Access videos/audios that explain how mindfulness benefits the body and mind.~5. Receive suggestions on meditations to do during the week~6. Set an intention for the week based on class content."
48642988|NCT05223829|DRUG|Brexanolone|Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
48642989|NCT02446600|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48642990|NCT02446600|DRUG|Carboplatin|Given IV
48642991|NCT02446600|DRUG|Cediranib Maleate|Given PO
48642992|NCT02446600|PROCEDURE|Computed Tomography|Undergo CT
48642993|NCT02446600|PROCEDURE|Echocardiography|Undergo ECHO
48642994|NCT02446600|DRUG|Gemcitabine|Given IV
47962364|NCT02805010|DRUG|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
47962365|NCT02805010|OTHER|Placebo|On Day 1, subjects will receive a single SC dose of placebo
47962366|NCT06044610|OTHER|GENPOP Passive dehydration (75% reduction in fluid intake|Over 24-hours
48642995|NCT02446600|DRUG|Gemcitabine Hydrochloride|Given IV
48642996|NCT02446600|OTHER|Laboratory Biomarker Analysis|Correlative studies
48642997|NCT02446600|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48642998|NCT02446600|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48642999|NCT02446600|DRUG|Olaparib|Given PO
47962367|NCT06044610|OTHER|GENPOP Ad lib fluid intake|Over 24 hours
48643000|NCT02446600|DRUG|Paclitaxel|Given IV
47962368|NCT06044610|OTHER|EXERCISE without fluid replacement|90-min standard cycling exercise trial in heat chamber
47962369|NCT06044610|OTHER|EXERCISE with fluid replacement|90-min standard cycling exercise trial in heat chamber
47962370|NCT01826630|OTHER|CLn BodyWash|Comparing two washes to determine change in bacterial load.
47962371|NCT01826630|OTHER|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
48113548|NCT01170299|PROCEDURE|management of therapy complications|
48643001|NCT02446600|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48643002|NCT02446600|OTHER|Pharmacological Study|Correlative studies
48643003|NCT02446600|OTHER|Quality-of-Life Assessment|Ancillary studies
48643004|NCT03996018|OTHER|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
48643005|NCT01746069|BEHAVIORAL|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
48643006|NCT01746069|BEHAVIORAL|health advice|routine clinical practice
47962372|NCT01282632|DRUG|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
48113549|NCT01170299|RADIATION|selective external radiation therapy|
48113550|NCT06677320|OTHER|Exercise|Patients with rotator cuff disease will receive exercise treatment for two months.
47962373|NCT01282632|DRUG|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
47962374|NCT04809285|DEVICE|Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app|Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.
47962375|NCT05853185|DRUG|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
47962376|NCT05853185|DRUG|EBRRM®|Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
47962377|NCT01646307|DRUG|Atorvastatin|
47962378|NCT01646307|DRUG|Rosuvastatin|
47962379|NCT00531271|DRUG|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
47962380|NCT01930123|DRUG|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
47962381|NCT01930123|OTHER|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
47962382|NCT06040931|PROCEDURE|Bronchoscopy|Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
47962383|NCT03325127|DRUG|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
47962384|NCT03325127|DRUG|Zytiga|Abiraterone 1000 mg per day orally
47962385|NCT03325127|DRUG|Xtandi|Enzalutamide 160 mg per day orally
48113551|NCT00662480|PROCEDURE|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
48113552|NCT03749044|OTHER|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
48113553|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
48113554|NCT02393001|OTHER|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
48310575|NCT01241669|DRUG|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
47962386|NCT03498144|DEVICE|Anterior segment OCT|lower punctum examination by AS-OCT
47962387|NCT04821115|DEVICE|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
47962388|NCT04821115|DEVICE|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
47962389|NCT00746083|BEHAVIORAL|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
47962390|NCT03507803|OTHER|Gait Biofeedback|Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
47962391|NCT02118883|OTHER|Essentia Water|
47962392|NCT02118883|OTHER|Bottled water|
47962393|NCT04340180|DRUG|Standard of Care (SOC) gadolinium Breast MRI|Standard of Care (SOC) gadolinium Breast MRI
47962394|NCT04340180|DRUG|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
47962395|NCT01647646|DRUG|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
47962396|NCT02607150|OTHER|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
48113555|NCT02393001|OTHER|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
48113556|NCT02393001|OTHER|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
48113557|NCT05724472|DRUG|rVSV∆G-SEBOV-GP Vaccine or Placebo|rVSV∆G-SEBOV-GP Vaccine or Placebo
48113558|NCT05845528|DEVICE|s-tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
48310576|NCT06006858|BIOLOGICAL|Moderna COVID-19 Vaccine|Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
47962397|NCT04351685|BIOLOGICAL|VPM1002|"The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial"
48113559|NCT05845528|DEVICE|a- tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
47962398|NCT04351685|BIOLOGICAL|BCG SII|"Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection"
47962399|NCT04858633|DRUG|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
47962400|NCT04858633|OTHER|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
48113560|NCT06483308|RADIATION|Radiotherapy|Radiotherapy using 30Gy in 6 fractions (alternate days) over 12 days.
48310577|NCT02426411|DRUG|EMA401 200 mg|
48310578|NCT02426411|DRUG|EMA401 600 mg|
48310579|NCT02426411|DRUG|Placebo|
48643007|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 1 (nOPV1)|Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10\^6.0, or high-dose (HD) 10\^6.5 CCID₅₀/dose
48643008|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 2 (nOPV2)|Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10\^5.3 and HD 10\^5.6 CCID₅₀/dose.
47962401|NCT04858633|OTHER|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
47962402|NCT03807518|BEHAVIORAL|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
47962403|NCT05528185|OTHER|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
47962404|NCT05442814|PROCEDURE|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
47962405|NCT05442814|PROCEDURE|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
48113561|NCT00920257|DRUG|GSK2141795|GSK2141795 is an oral AKT inhibitor.
48113562|NCT03547752|OTHER|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
48113563|NCT03148496|DEVICE|Biologic Mesh|Biologic mesh placed during surgery
48113564|NCT03148496|PROCEDURE|Small Bites|0.5 cm x 0.5 cm sutures used
48113565|NCT03148496|PROCEDURE|Large Bites|1.0 x 1.0 sutures used
48113566|NCT04016870|DEVICE|Reconditioned Pacemaker|Devices from the three manufacturers below will be used.
48113567|NCT04016870|DEVICE|New Pacemaker|Devices from the four manufacturers below will be used.
48643009|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 3 (nOPV3)|Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10\^6.0, or HD 10\^6.5 CCID₅₀/dose.
47962406|NCT03864978|DRUG|Rifaximin delayed release 400 mg tablet|Rifaximin delayed release
47962407|NCT03864978|DRUG|Placebo|Placebo
48113568|NCT03354039|DRUG|Tamoxifen|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
48113569|NCT03354039|DRUG|Matching placebo|Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
48113570|NCT02957812|DEVICE|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
48113571|NCT04358354|DRUG|Irinotecan|Irinotecan 150 mg/m2
48113572|NCT04358354|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
48113573|NCT04358354|DRUG|5-fluorouracil|5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
48643010|NCT06137664|BIOLOGICAL|Bivalent Oral Poliomyelitis Vaccine (bOPV)|Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10\^6.0 infective units of type 1 and 10\^5.8 of type 3.
48310580|NCT05747131|BEHAVIORAL|Emotion Detectives In-Out|Emotion Detectives In-Out is a blended cognitive-behavioral intervention for children with emotional disorders aged between 7 to 12 years and their parents. It contains group sessions, online self-guided sessions and videoconference sessions. The groups will consist of about 5 to 7 children. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists with specific training in the program. The online sessions were developed by the research team and are completely self-guided. These sessions last approximately 45 minutes. Parents will be asked to participate in 2 face-to-face sessions, 4 videoconference sessions and 10 self-guided online sessions. It is a transdiagnostic and emotion-focused manualized cognitive-behavioral therapy designed to help children reduce the intensity and frequency of strong and aversive emotional experiences and to help parents reduce parental emotional behaviors.
48310581|NCT05747131|BEHAVIORAL|Coping Cat|Coping Cat is a cognitive behavioral therapy for children with anxiety aged between 7 to 13 years. Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists.
47962408|NCT00725374|DRUG|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
47962409|NCT00725374|DRUG|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
47962410|NCT02831452|OTHER|pelvic floor muscle strength evaluation|
47962411|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
47962412|NCT06507787|DIAGNOSTIC_TEST|EDIT-B test (without giving result)|"EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%.~For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY.~The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact."
47962413|NCT06097286|PROCEDURE|external oblique intercostal plane block|o EOIP Group (ŋ=25): Patients will receive ultrasound guided External oblique intercostal plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
48310582|NCT00486538|DRUG|ABT-869|One oral dose daily.
48310583|NCT05649072|BEHAVIORAL|Genetic Testing and Counseling|Participants will be asked to collect a saliva sample for hereditary cancer and genetic testing
48113574|NCT03477149|DEVICE|Easyx|Embolization will be done with Easyx liquid agent.
47962414|NCT06097286|PROCEDURE|erector spinae plane block|o ESP Group (ŋ=25): Patients will receive ultrasound guided Erector spinae plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
47962415|NCT01864655|DRUG|saracatinib|oral drug given to experimental group
47962416|NCT01864655|DRUG|Placebo|Placebo given to placebo group
48113575|NCT03637231|DIAGNOSTIC_TEST|Ultra low-dose CTAC|All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
48113576|NCT06400719|BIOLOGICAL|AVT16|Single intravenous administration of 300mg of AVT16
48113577|NCT00947817|OTHER|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
48113578|NCT04656886|DRUG|Intravenous Infusion|
48310584|NCT05649072|BEHAVIORAL|Screening Form|Participant will be answering demographic details
48310585|NCT00016874|DRUG|cisplatin|
48310586|NCT00016874|DRUG|paclitaxel|
48310587|NCT00016874|DRUG|triapine|
48310588|NCT02197039|DRUG|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
48643011|NCT04295759|DRUG|INCB7839|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
48643012|NCT06308965|PROCEDURE|Vessel sparing technique|Vessel sparing
48643013|NCT06308965|PROCEDURE|Vessel ligation technique|Vessel ligation
48643014|NCT00233961|BIOLOGICAL|filgrastim|
48266704|NCT02260518|BEHAVIORAL|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
48310589|NCT02197039|PROCEDURE|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
47962417|NCT04076397|PROCEDURE|autologous transplant reinjection|The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
48310590|NCT05930392|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
48310591|NCT05930392|PROCEDURE|Conventional surgical depigmentation|GINGIVAL DEPIGMENTATION USING CONVENTIONAL SURGICAL TECHNIQUE
48310592|NCT04716192|OTHER|Positional release technique|"Positional Release Technique The subject lies supine with therapist standing on the affected side; tender points are located along the upper fibres of the trapezius. Pressure will applied by pinching the muscle between the thumb and fingers. The subject's head is laterally flexed toward the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90° a slight flexion or extension is added to obtain fine-tune. The ideal position of comfort achieved is held for a period of 90 seconds and followed by a passive return of the body part to an anatomically neutral position continued for 5 minutes.~Mayofascial Release Technique Therapeutic Ultrasound"
48310593|NCT04716192|OTHER|Myofascial release technique & Ultrasound|"Myofascial Release Technique~* Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~* Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest."
48310594|NCT05977517|BEHAVIORAL|Sleep and well-being tracking|This study will track sleep, learning and wellbeing of 500 freshmen under free-living conditions for 20 weeks
48310595|NCT00683956|DEVICE|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
48310596|NCT00683956|DRUG|Propofol|
48310597|NCT06263634|OTHER|Hand exercises|30-45 minutes of home exercises consisting of stretching, mobility and strengthening
48310598|NCT02669797|BEHAVIORAL|In-home Visits and Food Preparation Activities|"Families will participate in eight in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally ,a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits."
48310599|NCT02669797|BEHAVIORAL|Ecological Momentary Intervention|Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
48643015|NCT06227026|BIOLOGICAL|Anti-CD19 CAR-T cells|Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
47962418|NCT04076397|OTHER|desensitization|Patients will have to stimulate the pulp of your finger on a daily basis
47962419|NCT03209661|DRUG|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
47962420|NCT03209661|DRUG|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
47962421|NCT03209661|DRUG|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
47962422|NCT00986830|DEVICE|FinESS Sinus Treatment|
47962423|NCT05599191|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
47962424|NCT05599191|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
48113579|NCT05985824|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
47962425|NCT00785694|DRUG|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
48113580|NCT06194734|DRUG|KC1036|KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle
48113581|NCT06194734|DRUG|Irinotecan|Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks
48113582|NCT06194734|DRUG|Docetaxel|Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；
48113583|NCT06194734|DRUG|S-1|S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
47962426|NCT03795454|BEHAVIORAL|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
48113584|NCT00748150|BIOLOGICAL|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
48113585|NCT05751499|DIAGNOSTIC_TEST|• Blood Markers CRP, TNFα, IL-6, IL-8, IL-1, and IL-1β AND FIBRINOGEN|"* Low Back Outcome Scale~* Center for Epidemiological Studies-Depression Scale (CES-D)~* International Physical Activity Questionnaire~* Roland-Morris Disability Questionnaire~* Force Platform~* Pain Self-Efficacy Questionnaire (PSEQ)~* Numeric Rating Scale~* Job Content Questionnaire~* Pits Burgh Sleep Quality Index (PSQI)~* Orebo Musculoskeletal Pain Screening Questionnaire~* Gait \& Balance App~* Keele STarT Back Screening Tool (SBST)~* Fear-Avoidance Beliefs Questionnaire (FABQ)~* Pain Catastrophizing Scale"
48113586|NCT03160781|BIOLOGICAL|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
48113587|NCT00617201|DRUG|atomoxetine|Once daily oral dosing
48113588|NCT00617201|DRUG|placebo|Once daily oral dosing - matched placebo
48497913|NCT04544501|BEHAVIORAL|Culturally-Targeted Video|"Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling."
48310600|NCT02669797|BEHAVIORAL|Feedback on Video-recorded Family Meals|Parents will video-record and upload via their cellphone one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
47962427|NCT06045546|PROCEDURE|5-5-5-8 technique|the new technique of 5-5-5-8 for laparoscopic cholecystectomy
47962428|NCT06045546|PROCEDURE|10-10-10-5 technique|the standard technique of 10-10-10-5 for laparoscopic cholecystectomy
47962429|NCT01896050|DRUG|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
47962430|NCT01896050|DRUG|Tamoxifen|Patients were treated with tamoxifen for up to one year
47962431|NCT03572244|DEVICE|Laser-Lok|A microgrooved abutment will be placed
47962432|NCT03572244|DEVICE|Machined|A machined transmucosal healing abutment will be placed
47962433|NCT00818480|DRUG|YM155|continuous infusion
47962434|NCT05814289|OTHER|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.|To assess telephone head tilt and cervical, thoracic, and lumbar spine mobility and disturbances.
47962435|NCT01006174|OTHER|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
47962436|NCT01006174|OTHER|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
48113593|NCT05443126|DRUG|EP0031|EP0031 is a potent next-generation selective RET-inhibitor (SRI)
48113594|NCT05092139|DEVICE|endovascular treatment|all enrolled patients must receive endovascular treatment
48643016|NCT05353751|BEHAVIORAL|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
48643017|NCT02686125|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
48643018|NCT06290011|DEVICE|Pain key group|mixed real pain treatment software, pain treatment scenarios in MR
48643019|NCT06009978|DEVICE|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) 2 times a day á 15 minutes from the third to the eight week after injury. The additional treatment will be perform in the patients home by themselves
48643020|NCT06079398|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
48643021|NCT06079398|DRUG|Placebo for Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
48643022|NCT06555783|DRUG|ALKS 2680|Oral tablet containing ALKS 2680
48643023|NCT06555783|DRUG|Placebo|Oral tablet containing placebo for once daily administration
48113595|NCT01178632|DRUG|Passiflora|01 tablet Passiflora p.o., b.i.d.
48113596|NCT01178632|DRUG|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
48497914|NCT04544501|OTHER|FORCE Fact Sheet|A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
48497915|NCT03206463|DRUG|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
48497916|NCT03206463|DRUG|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
47962437|NCT01006174|OTHER|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
47962438|NCT04209517|OTHER|Filming|Behavioural markers selection from video-recordings of the interview
47962439|NCT06438068|OTHER|Modern Colon Hydrotherapy plus probiotic product intake|Colonic cleansing through 3 interventions of Modern Colon Hydrotherapy separated by 48 hours. In addition, a daily intake of a product with prebiotic and prebiotic properties for 30 days.
47962440|NCT03802760|DEVICE|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
48497917|NCT03206463|DRUG|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
47962441|NCT00762385|DEVICE|galyfilcon A|galyfilcon A
47962442|NCT00762385|DEVICE|comfilcon A|comfilcon A
47962443|NCT06115252|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.
48643024|NCT01659151|DRUG|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
48643025|NCT01659151|PROCEDURE|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
48643026|NCT01659151|DRUG|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
48643027|NCT01659151|DRUG|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
48643028|NCT06694636|PROCEDURE|endovascular radiofrequency ablation and desympathetic nerve surgery|endovascular radiofrequency ablation and desympathetic nerve surgery
48310601|NCT02669797|BEHAVIORAL|Maintenance|After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
48310602|NCT01002859|DRUG|Sandimmum|Intravenous injection of cyclosporine
48310603|NCT01002859|DRUG|Placebo|Intravenous Injection of NaCl solution
48310604|NCT02829177|DRUG|Allopurinol|
48310605|NCT02829177|DRUG|Placebo|
48310606|NCT00704743|DEVICE|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
48643029|NCT04943068|DRUG|Bremelanotide|Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
48643030|NCT04943068|DRUG|Placebo|Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
47962444|NCT05091359|DEVICE|Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste|Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
48643031|NCT06078514|PROCEDURE|Loop electrosurgical excision procedure (LEEP)|The affected area of cervix is excised under local anesthesia using a small thin electrically charged hardwire loop for simultaneous cutting and electrocoagulation.
48643032|NCT01340170|DEVICE|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
47962445|NCT00654680|DRUG|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
47962446|NCT00654680|DRUG|Placebo|Matching placebo
47962447|NCT03104543|BEHAVIORAL|Education|30 minute education session; 15 minute booster session at 4 months
47962448|NCT03104543|BEHAVIORAL|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
47962449|NCT04755790|DEVICE|Point Digit|Patient is fit with Point Digit partial hand prosthetic system
47962450|NCT01259128|DRUG|SER120 Nasal Spray 500 ng/day|SER120 Level 1
47962451|NCT01259128|DRUG|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
47962452|NCT05560477|DRUG|AM3101|Injectable drug product.
47962453|NCT05560477|DRUG|Saline Placebo|2 mL 0.9% normal saline
47962454|NCT00499499|DRUG|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
47962455|NCT06447740|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
47962456|NCT06447740|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
47962457|NCT06447740|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
48113597|NCT06612879|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
47962458|NCT00762060|DEVICE|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
47962459|NCT00762060|DRUG|Patient controlled analgesia|IV opioids delivered via PCA
47962460|NCT01593657|OTHER|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
47962461|NCT01593657|OTHER|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
48310607|NCT00704743|DEVICE|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
48310608|NCT00704743|DEVICE|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
48310609|NCT04486924|DEVICE|Globe Mapping and Ablation System|Prospective, non-randomized, open-label clinical study.
48310610|NCT04404595|BIOLOGICAL|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
48310611|NCT01963299|DRUG|5 ml Ropivacaine 10% + physiological saline|
48310612|NCT01963299|DRUG|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
48310613|NCT04020484|BEHAVIORAL|Making Mindfulness Matter© (M3)|Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
48310614|NCT00685620|BEHAVIORAL|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
48310615|NCT05117229|DEVICE|MetaWear Sensor|Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
48310616|NCT02510729|DEVICE|Neurostimulation|
48310617|NCT02510729|DEVICE|Sham stimulation|
48310618|NCT02464397|DEVICE|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
48310619|NCT03092869|OTHER|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
48310620|NCT03092869|OTHER|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
48310621|NCT05431140|DEVICE|CloudCare|Only eligible subjects to whom CloudCare is introduced as part of their new standard care will be enrolled. Participants will not be subjected to extra procedures on top of their standard of care, except that they will be asked to fill out short questionnaires about their treatment satisfaction and the emotional burden caused by diabetes, which are not standard in the participating study locations.
48310622|NCT04970771|BEHAVIORAL|Solving Wellness platform|Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
48310623|NCT02787434|OTHER|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
48310624|NCT05233696|DRUG|Nab-paclitaxel|All patients are encouraged to receive nab-paclitaxel 100 mg/m2 IV D1 and D8 every 21 days (in combination with pembrolizumab) for at least 4-6 cycles per institutional standards and treating physicians' recommendations.
48310625|NCT05233696|DRUG|Paclitaxel|Paclitaxel can be substituted for nab-paclitaxel at the discretion of the treating physician 80 mg/m2 IV D1 and D8 every 21 days.
48310626|NCT05233696|RADIATION|Radiation Therapy|The treating radiation oncologist will select 1-4 sites of metastatic disease to target with radiation. All sites of disease may be targeted with radiation. Sites of metastatic disease planned to be biopsied should not be radiated.
48310627|NCT05233696|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200 mg D1 every 21 days.
48113598|NCT01962844|DIETARY_SUPPLEMENT|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
48113599|NCT01962844|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months
47962462|NCT01593657|PROCEDURE|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
47962463|NCT01593657|PROCEDURE|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
47962464|NCT03831399|DIETARY_SUPPLEMENT|Leucine|Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
47962465|NCT03831399|DIETARY_SUPPLEMENT|Placebo|Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
48113600|NCT04482400|BEHAVIORAL|NEAT!2|8 week sedentary reduction program
48310628|NCT00002288|DRUG|Zidovudine|
48310629|NCT04500314|DEVICE|whole body vibration device|20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
48113601|NCT04482400|BEHAVIORAL|MyKneeGuide|8 week surgery recovery education program
48113602|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
48113603|NCT01461655|DRUG|marketed topical NSAID|once daily application, 4 weeks
48113604|NCT01461655|DRUG|vehicle gel|once daily application, 4 weeks
48113605|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
48113606|NCT02139943|DRUG|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
48310630|NCT04500314|OTHER|routine physical therapy treatment|The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
48310631|NCT03167086|BEHAVIORAL|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
48310632|NCT03167086|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) \[1\& 2\], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner \[3\].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk \& Winter \[4\] for optional reading."
48310633|NCT03167086|BEHAVIORAL|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
48310634|NCT06247059|DEVICE|Box Fan|Classrooms assigned to this arm will be equipped with 2 - 8 box fans each with a single minimum efficiency reporting value-14 (MERV-14) filter sufficient to increase effective air changes per hour to 12 based on the clean air delivery rate measured in cubic feet per minute of the box fan + filter \* 60 divided by the room volume.
48310635|NCT06247059|DEVICE|UV Germicidal Irradiation Lamp Unit|Classrooms assigned to this arm will be equipped with one or two 222nm wavelength light ultraviolet germicidal irradiation lamp units (number of units per classroom based on room volume).
48310636|NCT06247059|DEVICE|Combined: Box Fan and UV Germicidal Irradiation Lamp Units|Classrooms assigned to this arm will be equipped with both box fans and UV germicidal irradiation lamp units.
48310637|NCT00300469|DRUG|ABT-335|135 mg, daily, 12 weeks
48310638|NCT00300469|DRUG|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
48310639|NCT00300469|DRUG|Placebo|daily, 12 weeks, see Arm Description for placebo information
48310640|NCT04969640|OTHER|Optical coherence tomography|Anterior segment optical coherence tomography examination of corneas with infective keratitis
48310641|NCT01924546|OTHER|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
48310642|NCT04929340|OTHER|Probiotic bacteria|The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
48310643|NCT04929340|OTHER|Placebo|Children in control group are given 5 drops per day (containing no bacteria).
48310644|NCT05076851|OTHER|placebo|placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
48310645|NCT05076851|DRUG|Proxalutamide|Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
47962466|NCT05146167|BEHAVIORAL|Bodhi AIM (intervention group)|"Bodhi AIM (Action In Mindfulness) is a smartphone-based app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations (e.g., attending a party)."
48497918|NCT05061186|OTHER|Resistive Expiratory muscle Training Group|"Mild Resistive Expiratory Technique \[Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day\] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
47962467|NCT05146167|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone-based app that is matched to Bodhi AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in Bodhi AIM. Like Bodhi AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
48113607|NCT02139943|DRUG|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
48113608|NCT02139943|DRUG|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
48310646|NCT05322863|DEVICE|High-definition Transcranial Direct Current Stimulation|The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
48310647|NCT05535127|DIAGNOSTIC_TEST|"Palpation with  laryngeal handshake technique"|Information alredy included
48310648|NCT05535127|DIAGNOSTIC_TEST|Palpation strategy plus sequential ultrasound|Information alredy included
48310649|NCT05535127|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
48310650|NCT01679080|DRUG|Zoledronic acid|antiresorptive and calcium and vitamin D
48310651|NCT01679080|DRUG|Teriparatide|anabolic and calcium and vitamin D
48310652|NCT01679080|OTHER|No active treatment|Calcium and vitamin D
48310653|NCT03661827|DIAGNOSTIC_TEST|Stress Cardiac MRI|Dobutamine and adenosine stress MRI
48310654|NCT04926194|BIOLOGICAL|Decidual stromal cells (DSC)|DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
48310655|NCT02076555|BEHAVIORAL|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
48310656|NCT01735747|RADIATION|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
48310657|NCT01735747|DRUG|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
48310658|NCT01735747|DRUG|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
48310659|NCT01735747|DRUG|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
48310660|NCT05111899|BEHAVIORAL|Newborn Health Education|Community influencers will receive training and give community education to women and their families regarding newborn health.
48310661|NCT03928834|BEHAVIORAL|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
48310662|NCT02714673|DRUG|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
48310663|NCT06004141|BEHAVIORAL|Laguna Health|Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
48310664|NCT02526927|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
48310665|NCT02526927|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
48310666|NCT02526927|OTHER|Blood samples|
48310667|NCT01815892|DRUG|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
48310668|NCT01815892|DRUG|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
48310669|NCT00248313|DRUG|Rapamune®|
48310670|NCT00035425|DRUG|linezolid|600mg every 12 hours
48310671|NCT00035425|DRUG|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
48643033|NCT03487510|OTHER|NO interventions apply|does not apply
48643034|NCT02375802|BIOLOGICAL|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
48113609|NCT06288932|DRUG|Mycophenolate Mofetil (MMF) Treatment|The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.
48113610|NCT00188604|DRUG|sodium selenite|
48310674|NCT01227538|OTHER|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
48310675|NCT01880255|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
48310676|NCT04829383|DRUG|Atezolizumab|1,200 mg
48310677|NCT04829383|DRUG|Bevacizumab|15 mg/kg
48310678|NCT01579981|PROCEDURE|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
48310679|NCT05369117|BEHAVIORAL|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
48310680|NCT02939144|DIETARY_SUPPLEMENT|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
48310681|NCT01750398|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
48310682|NCT01750398|DRUG|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
47962468|NCT03277664|BEHAVIORAL|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
48113611|NCT03915886|DRUG|JNJ-0440|JNJ-0440 tablets will be administered orally.
48113612|NCT03915886|DRUG|Placebo|Matching placebo tablets will be administered orally.
48310683|NCT01750398|DRUG|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
48310684|NCT01423617|DIETARY_SUPPLEMENT|Zenoctil|3 tablets 2 times daily
48310685|NCT01423617|OTHER|Placebo|3 tablets 2 times daily
48310686|NCT03554005|DRUG|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
48310687|NCT03554005|DRUG|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
47962469|NCT05134675|DIETARY_SUPPLEMENT|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
47962470|NCT02776865|DRUG|suprascapular nerve block|4ml 2% xylocaine
48113613|NCT01125319|OTHER|blood sample|
48113614|NCT06513936|PROCEDURE|The skin care Bundle|S- Secure device and protect the skin with dressings K- Keep repositioning more frequently than twice daily Inspect the skin under the device more than twice daily N- Nutrition and hydration C- Choose the correct size and type of medical device A- Avoid placing devices over sites of prior or existing pressure injury R- Report MDRPI correctly and immediately E- Educate staff on the correct use of devices and prevention of skin breakdown
48310688|NCT02217319|DRUG|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
48310689|NCT02217319|DRUG|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
48310690|NCT05149937|OTHER|interprofessional, person-centered care concept|interprofessional, person-centered care concept
48310691|NCT02143362|DRUG|Anesthesia induction,propofol, remifentanil ,cisatracurium|"1. Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~2. Intermittent injection cisatracurium (0.15mg/kg).~3. A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
48643035|NCT02375802|DRUG|Adipose-derived stromal cells|
48643036|NCT04984590|DEVICE|IOPCL AMD MAG|The IOPCL MAG (intraocular pseudophakic capsular lens magnifier) consists of a 4.5 mm diameter optic. The central 1.8mm of the anterior surface has a power of 10.0 diopters. This IOPCL MAG will be implanted over an Alcon Model SN60WF or SA60AT intraocular lens to improve near vision.
48310692|NCT02143362|DRUG|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg)."
48310693|NCT02143362|PROCEDURE|Awaken test|"1. Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~2. In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~3. Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~4. Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~5. Patients will receive initial anesthesia after finish awaken test."
48310694|NCT05113368|DRUG|Regorafenib|Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
48310695|NCT05113368|DRUG|Fulvestrant|500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
48310696|NCT04414657|OTHER|blood sampling for biobank|blood sampling for biobank
48310697|NCT01412645|DIETARY_SUPPLEMENT|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
48310698|NCT00028366|DRUG|Fosamprenavir|
48497919|NCT05061186|OTHER|Conventional Breathing Exercise Group|"Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)"
48643037|NCT06691594|RADIATION|neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy|"Eligible participants will receive neoadjuvant treatment consisting of:~SBRT: One session of 10Gy radiation to the primary tumor, followed by a 150mg subcutaneous injection of pembrolizumab (PD-1 inhibitor).~Chemotherapy and Immunotherapy: One week after SBRT, participants will undergo 6 cycles of pembrolizumab (400mg), albumin-bound paclitaxel (250mg/m²), and carboplatin (AUC=5).~Surgery: Surgery will be performed 21 days after the last chemotherapy cycle, with either breast-conserving surgery or modified radical mastectomy. Pathological evaluation will assess the treatment response.~Adjuvant Immunotherapy: Four weeks post-surgery, patients will receive pembrolizumab every 3 weeks for up to 1 year."
48643038|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
48643039|NCT05545306|DIETARY_SUPPLEMENT|fasting|Fasting for at least 24 hours
47962471|NCT02776865|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
47962472|NCT05667844|BEHAVIORAL|interoceptive mind-body exercise|A interoceptive mind-body exercise program in a patient with Generalized Anxiety Disorder and Major Depressive Disorder based on a Multidimensional Assessment of Interoceptive Awareness. Each session of the body-mind intervention lasts 80 minutes and is supervised by physical education professionals. The intervention is divided in 4 parts, that are: Preparatory phase (reception) the subjects will be welcomed through subjective analyzes of the researcher; Initial phase (preliminares) Mindfulness, grounding, sensory stimulation and joint warm-up exercises are performed; main phase (exercises) stretching, mobility, posture and balance exercises are performed with full attention and listening after each exercise; Final phase (relaxation) breathing exercises, stretching exercises, body scanning and relaxation are performed.
48310699|NCT00028366|DRUG|Lopinavir/Ritonavir|
48310700|NCT00028366|DRUG|Ritonavir|
48310701|NCT00028366|DRUG|Tenofovir disoproxil fumarate|
48310702|NCT02593747|DRUG|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
48310703|NCT02593747|DRUG|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
48310704|NCT04705558|OTHER|continuous moderate intensity aerobic training|continuous moderate intensity aerobic exercises with ketogenic diet group underwent supervised moderate-intensity exercised on a treadmill at 50%-70% of heart rate reserve for three month
48310705|NCT04705558|OTHER|ketogenic diet|Ketogenic diet: a low carbohydrate high-fat diet consisted of the following nutrient conformation: 80% fat, 15% protein and 5% carbohydrates, entire daily intake was estimated to be 20-30 g of carbohydrates for three month.
48310706|NCT06505057|OTHER|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
48310707|NCT05116540|BIOLOGICAL|HB-adMSCs|Autologous product
48310708|NCT05116540|DRUG|Placebo|Normal Saline
48310709|NCT03668691|DEVICE|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
48310710|NCT05948657|DIAGNOSTIC_TEST|PSMA-PET CT|Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
48310711|NCT04801537|OTHER|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
48310712|NCT04801537|OTHER|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
48310713|NCT00455260|DRUG|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
48310714|NCT00455260|DEVICE|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).~The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
48310715|NCT05894473|OTHER|Motor-Motor Dual Task Physical Exercises|Only physical exercise and motor dual tasks will be given
47962473|NCT01012271|OTHER|MRI|MR arthrography is used to evaluate wrist abnormalities
48310716|NCT03553433|DRUG|Apremilast 30mg|Anti-psoriatic drug
47962474|NCT00040365|DRUG|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
47962475|NCT00040365|RADIATION|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
48113615|NCT06513936|PROCEDURE|Routine care|Routine care delivered in the unit
48113616|NCT02350842|DEVICE|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
48310717|NCT03553433|DRUG|Placebo Oral Tablet|Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
48310718|NCT03136757|OTHER|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~* to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~* to identify new intracellular signaling pathways that could lead to new therapeutic"
47962476|NCT04923438|OTHER|Telerehabilitation|The exercise program will begin with a warm-up, followed by a stretching exercise and an alphabetical exercise game called what's your name, and will end with a cool-down. The exercises will be performed 2 times a week for a total of 12 weeks, and each program will last for roughly 30 minutes. it will last. In what is your name game, 10 5-letter words containing the whole alphabet were produced and children will work out the exercises corresponding to each letter with a word they choose for each day.
47962477|NCT04923438|OTHER|Control|The same exercise program will be prepared and given to the patients who are offered and not accepted telerehabilitation, and they will be asked to do their own exercises at home. This group will also be included in the study as a control group.
47962478|NCT02343679|DRUG|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
47962479|NCT04057612|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
48113617|NCT02350842|DEVICE|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
48113618|NCT02167867|DEVICE|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
48310719|NCT00087737|DRUG|DVS-233 SR|
48310720|NCT00087737|DRUG|Venlafaxine ER|
48310721|NCT00675558|PROCEDURE|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) \& fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
48310722|NCT00675558|PROCEDURE|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
47962480|NCT04057612|OTHER|Carotid artery temperature monitoring|Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
47962481|NCT03954665|BEHAVIORAL|10 km time trial|10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
48310723|NCT02763878|PROCEDURE|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
48310724|NCT02763878|PROCEDURE|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
48310725|NCT02833649|DEVICE|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
48310726|NCT00267280|DRUG|torcetrapib/atorvastatin|
48310727|NCT00267280|DRUG|simvastatin|
48310728|NCT04005820|OTHER|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
48310729|NCT04005820|OTHER|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
47962482|NCT03954665|BEHAVIORAL|30s Wingate|30s all-out test to measure peak power output
47962483|NCT03954665|DIETARY_SUPPLEMENT|Ketone|Supplement containing exogenous ketone salts
47962484|NCT03954665|BEHAVIORAL|Baseline 10 km time trial|A baseline 10 km Cycling time trial test will be conducted
47962485|NCT03954665|BEHAVIORAL|Baseline 30s Wingate|A baseline 30s all-out test to measure peak power output
47962486|NCT04665700|DRUG|BI 764198|BI 764198
47962487|NCT04665700|DRUG|Placebo|Placebo
47962488|NCT04022850|BEHAVIORAL|A non-reflective decision assistance strategy|A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
47962489|NCT04022850|BEHAVIORAL|A both reflective and non-reflective decision information strategy|"This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients."
48113619|NCT02167867|DEVICE|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
48310730|NCT05888467|OTHER|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
48310731|NCT05888467|OTHER|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
48310732|NCT05888467|OTHER|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
48310733|NCT02641236|DRUG|Vancomycin-polymyxin B|
48310734|NCT01934192|DRUG|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
48310735|NCT01934192|DRUG|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
48310736|NCT01934192|DRUG|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
48310737|NCT01934192|DRUG|Placebo IV|Placebo will be administered IV every 6 hours
48310738|NCT05722236|BEHAVIORAL|IBD Strong Peer2Peer|Mentee participants will experience the intervention: this group will partake in peer-led sessions (peer calls) consisting of up to 10 virtual sessions on Zoom lasting approximately 20-30 minutes in duration over eight weeks. Individual peer calls will be unstructured whereby trained mentors (patients with IBD who have undergone training to be a mentor) and mentees will be given the freedom to discuss whatever issues they choose. Psychological and emotional support is provided to the mentee by the mentor.
48310739|NCT05722236|OTHER|Waitlist control|Wait list controls will be offered participation in the IBD Strong Peer2Peer intervention once post-control outcome measures have been completed.
48497920|NCT01965392|OTHER|Health education intervention|'Health education intervention'
47962490|NCT04022850|BEHAVIORAL|A reflective decision structure strategy|The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.
47962491|NCT01940601|DRUG|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
47962492|NCT01940601|DRUG|Filgrastim|Filgrastim 5 μg/kg
47962493|NCT01319890|PROCEDURE|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
47962494|NCT06063278|BEHAVIORAL|l Group Therapy for BN.|9 to 10 group sessions of 90 to 120min each
47962495|NCT00149201|DRUG|5-FU continuous infusion|
47962496|NCT00149201|DRUG|MTX + 5-FU sequential therapy|
47962497|NCT02859311|DRUG|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
48113620|NCT00835380|BIOLOGICAL|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
47962498|NCT04874584|BEHAVIORAL|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
47962499|NCT04874584|BEHAVIORAL|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
47962500|NCT04614220|BEHAVIORAL|Presence of Family member|The correlation between presence of the Family member and the consent for regional anaesthesia for Caesarean Section
47962501|NCT01999868|BIOLOGICAL|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh \> 100 kg at study entry will receive 90 mg of ustekinumab."
47962502|NCT01999868|BIOLOGICAL|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
47962503|NCT01999868|DRUG|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
47962504|NCT01999868|DRUG|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
47962505|NCT04624646|DEVICE|Discontinuous monitoring|Discontinuous ECG monitoring by finger contact every day
47962506|NCT04624646|DEVICE|Continuous single-lead ECG Patch|Continuous 72hr ECG monitoring by a single-lead patch at 3, 6, 9, 12 months after stroke
47962507|NCT04624646|DEVICE|24-hour Holter monitoring|Continuous 24-hour monitoring by Holter monitor at 1, 6, 12 month after stroke
47962508|NCT01796509|OTHER|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
47962509|NCT01652209|BIOLOGICAL|Hearticellgram-AMI|
47962510|NCT02044393|DRUG|itraconazole|multiple doses of itraconazole given as capsules
47962511|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
48310740|NCT03862690|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
48310741|NCT00002340|DRUG|Atovaquone|
48310742|NCT00002340|DRUG|Pentamidine isethionate|
48310743|NCT00021697|DRUG|AVP-923|
47962512|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
47962513|NCT03386448|DRUG|Scopolamine and naltrexone|participants will receive scopolamine and naltrexone in buccal drops
47962514|NCT03386448|DRUG|placebo arm|participants will receive placebo medications
47962515|NCT04774796|OTHER|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
47962516|NCT00330070|DRUG|IPL512,602 20 mg once daily|
47962517|NCT00330070|DRUG|IPL512,602 Matching Placebo once daily|
47962518|NCT02605070|DRUG|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
47962519|NCT05241912|DRUG|Dobutamine|administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
48113621|NCT01852526|DEVICE|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
48113622|NCT01852526|DEVICE|Active Comparator: Plif|monosegmental PLIF
48113623|NCT00034463|DRUG|ALIMTA|
48113624|NCT00034463|DRUG|folic acid|
48310744|NCT02623036|DRUG|Equivalent dose enalapril|Chronotherapy with enalapril.
48310745|NCT02623036|DRUG|Equivalent dose lisinopril|Chronotherapy with lisinopril
48497921|NCT04364425|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
48497922|NCT04364425|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
48113625|NCT00034463|DRUG|multi-vitamins|
48113626|NCT02957006|DEVICE|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
48497923|NCT04364425|DRUG|Normal saline|Ultrasound guided injection using 15ml or 12 ml of normal saline
48113627|NCT06079840|DEVICE|mindfulness-based stress reduction app|mobile application (app) for caregivers
48310746|NCT02775552|BEHAVIORAL|A&T community-based interventions|"1. Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~   - Increase mothers' knowledge about adequate child feeding practices~2. Interpersonal communication delivered by agricultural extension workers to:~   - Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~3. Community mobilization activities to:~   * Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~  * Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~  * Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~4. Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~   * Improve their ability to provide timely and appropriate information and support to mothers and families"
48310747|NCT02775552|BEHAVIORAL|Mass media|Radio campaign - radio drama series, spots, and jingles
48310748|NCT00187239|DEVICE|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
48310749|NCT03059810|DEVICE|etafilcon A|Investigational Contact Lens
48310750|NCT06128590|DEVICE|Photobiomodulation|"Photobiomodulation was applied before the procedures at an infrared wavelength of 808nm, at a power of 100mW, 1 point with a total energy of 8J, time of 80s, irradiance of 3.33W/cm² and radiant exposure of 266.66 J/cm2. The application point was on the retromolar region where the needle was inserted to perform the anesthetic, in a single application before the procedure.~The patient and operator were properly protected with goggles in both the control and experimental groups."
48310751|NCT06128590|DRUG|Mepivacaine hydrochloride in combination with epinephrine|"The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure."
48310752|NCT06128590|DEVICE|Photobiomodulation simulation|The participants will be treated in the same manner as in group A. The person responsible for the application of FBM will simulate the irradiations by placing the device in the same location described for the experimental group, but the equipment will remain turned off. To prevent the participant from identifying their group, the activation sounds of the devices (beeps) will be recorded to simulate the device's operation.
48310753|NCT00862966|OTHER|citrate|comparison of different catheter lock solutions
48310754|NCT00862966|OTHER|heparin|comparison of different lock solutions
48310755|NCT01912937|DEVICE|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
48310756|NCT01660087|DEVICE|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
48310757|NCT03194152|DIETARY_SUPPLEMENT|Peanut|Dietary Supplement: Peanut
48310758|NCT03194152|DIETARY_SUPPLEMENT|Control|Dietary Supplement: High carbohydrate snacks
48310759|NCT00660036|DRUG|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
48310760|NCT00660036|DRUG|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
48310761|NCT00660036|DRUG|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
48310762|NCT06553456|DRUG|Recombinant Human Serum Albumin|The experimental drug was administered at a dose of 20 g/ day for 7 days.
48310763|NCT06553456|DRUG|Human Serum Albumin|The positive control drug was administered at a dose of 20 g/ day for 7 days.
48310764|NCT01325480|DEVICE|Cardiac Pacing|
48310765|NCT04657016|DRUG|Tirzepatide|Administered SC
48310766|NCT04657016|OTHER|Placebo|Administered SC
48497924|NCT05249530|OTHER|Chiropractic spinal adjustment|Chiropractic spinal adjustment
48497925|NCT05249530|OTHER|Non-force simulation|Non-force simulation
47962520|NCT01944696|OTHER|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
48113628|NCT06103669|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
48113629|NCT03384069|BEHAVIORAL|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
48113630|NCT03384069|BEHAVIORAL|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
48113631|NCT03802149|DRUG|Ulipristal Acetate|90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
47962521|NCT02425371|OTHER|Screening and treatment of comorbidities|Screening and treatment of comorbidities
47962522|NCT02425371|OTHER|Placebo Comparator|No screening of comorbidities
47962523|NCT04538430|DEVICE|SPRINT percutaneous peripheral nerve stimulator placed|Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
48310767|NCT03734081|DEVICE|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
48310768|NCT03734081|DEVICE|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
48310769|NCT01613014|DRUG|ABT-436|Target dose - 400mg BID
48310770|NCT01613014|DRUG|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
48310771|NCT03393052|PROCEDURE|Coronary Angiography|Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
48310772|NCT03910933|OTHER|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
48310773|NCT06382974|PROCEDURE|Cyst enucleation and bone grafting|cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.
48310774|NCT01189435|DRUG|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
48310775|NCT00827996|DRUG|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
48310776|NCT04766203|BEHAVIORAL|Treatment of REDS using a holistic treatment arm|This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
48310777|NCT02804880|BEHAVIORAL|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
48310778|NCT02804880|BEHAVIORAL|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
48310779|NCT02804880|BEHAVIORAL|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
48310780|NCT02804880|OTHER|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
48310781|NCT02804880|OTHER|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
48310782|NCT02804880|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
48113632|NCT02342119|OTHER|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
48310783|NCT02804880|OTHER|12-page booklet|12-page smoking cessation self-help booklet
48310784|NCT03355287|OTHER|Traditionally Threshed Teff (TTT)|The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
48310785|NCT03355287|OTHER|Lab Threshed Teff (LTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
48310786|NCT03355287|OTHER|Fortified Lab Threshed Teff (FTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
48310787|NCT03266484|DIETARY_SUPPLEMENT|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
48310788|NCT03266484|DIETARY_SUPPLEMENT|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
48310789|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Low Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 2 consecutive minutes for each side, only once for the experiment duration.
48497926|NCT04502823|PROCEDURE|Management based on sFlt-1/PlGF values|"In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks."
48310790|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Intermediate Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 3 sessions of 2 minutes, with 2 minutes of rest for each side. stimulation will be provided only once for the experiment duration.
48310791|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (High Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 8 consecutive minutes for each side, only once for the experiment duration.
48310792|NCT00615290|DRUG|tipranavir|
47962524|NCT05022082|OTHER|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
48113633|NCT02342119|OTHER|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
48310793|NCT00320736|DRUG|galantamine|
48310794|NCT05196243|OTHER|Patients diagnosed as gastrointestinal mucosal lesions|Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer
48310795|NCT02973841|DEVICE|Sono-ease device|insertion of US guided IJV using sono-ease device
48310796|NCT03647371|PROCEDURE|Macintosh laryngoscopy|intubation with MAcintosh laryngoscopy after anesthetic induction
48310797|NCT03647371|PROCEDURE|McGrath MAC video laryngoscopy|intubation with McGrath MAC videolaryngoscopy after anesthetic induction
48310798|NCT00069576|BEHAVIORAL|nutritional counseling|
48310799|NCT00069576|BEHAVIORAL|self blood glucose monitoring|
48310800|NCT00506077|DRUG|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
48310801|NCT00506077|DRUG|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
48310802|NCT03430245|DEVICE|VelaShape III|The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.
48310803|NCT03430245|DEVICE|UltraShape Power|The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
48310804|NCT03347604|DIAGNOSTIC_TEST|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
48310805|NCT01790737|DRUG|Cyclophosphamide|
48310806|NCT01790737|DRUG|Filgrastim|
48310807|NCT00498108|DRUG|Rotigotine|
48310808|NCT01236612|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
48310809|NCT01236612|BIOLOGICAL|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
48310810|NCT01236612|BIOLOGICAL|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
48310811|NCT01236612|BIOLOGICAL|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
48497927|NCT02032706|DEVICE|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
48643040|NCT05545306|DIETARY_SUPPLEMENT|-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-50% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
47962525|NCT00194285|PROCEDURE|FDG-PET Imaging|
47962526|NCT04453722|DEVICE|Oxalert Monitor Mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.
47962527|NCT04453722|DEVICE|Oxalert Normal mode|The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode
48113634|NCT00092885|DRUG|MK0476, montelukast sodium|
47962528|NCT00437177|DRUG|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
47962529|NCT00437177|DRUG|[(123)I] iodobenzamide|\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
47962530|NCT04802317|DIAGNOSTIC_TEST|Identification of the composition of the intestinal microbiota|Identification of the composition of the intestinal microbiota
48310812|NCT01236612|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
48310813|NCT04648423|DRUG|Sodium Oxybate|solution for oral administration
48310814|NCT04648423|DRUG|Placebo|solution for oral administration
48310815|NCT03311490|DEVICE|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
48310816|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
48310817|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
47962531|NCT06492759|RADIATION|Radiation Therapy|Undergo radiation therapy
47962532|NCT06492759|BIOLOGICAL|Pembrolizumab|Given IV
47962533|NCT06492759|DRUG|Nab-paclitaxel|Given IV
47962534|NCT06492759|DRUG|Paclitaxel|Given IV
47962535|NCT06492759|DRUG|Carboplatin|Given IV
47962536|NCT06492759|DRUG|Gemcitabine|Given IV
47962537|NCT06492759|PROCEDURE|Biopsy|Undergo biopsy
47962538|NCT06492759|PROCEDURE|Computed Tomography|Undergo CT
47962539|NCT06492759|PROCEDURE|Bone Scan|Undergo bone scan
47962540|NCT06492759|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47962541|NCT06492759|OTHER|Medical Chart Review|Ancillary studies
47962542|NCT00261469|DRUG|topiramate|
47962543|NCT00731627|DRUG|placebo|one tablet a day for up to 21 days
47962544|NCT00731627|DRUG|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
47962545|NCT00740389|DRUG|TMC125|
47962546|NCT05998044|OTHER|Pilates Based Exercises|"The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~* Arm Circles~* Toe Touch~* bridge~* Shoulder Bridge~* Chest Lift~* Hundred~* Roll Up~* Leg Circles~* Chris Cross~* Side Kick~* Side Leg Circles~* one leg kick~* double leg kick~* Swan~* Single leg Stretch~* Double leg Stretch~* saw~* Spine Stretch"
48310818|NCT04840992|BIOLOGICAL|Placebo for Inhalation|Aerogen Solo
48310819|NCT04840992|BIOLOGICAL|Placebo|Intramuscular administration
48310820|NCT01849835|PROCEDURE|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
48310821|NCT01849835|PROCEDURE|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
48310822|NCT05913934|BEHAVIORAL|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
48310823|NCT05864443|PROCEDURE|Severe complications following emergency surgery|The respondents are limited to surgeons who had previously experienced severe complications following emergency surgery as chief surgeons.
47962547|NCT05998044|OTHER|control|They will be asked not to participate in any regular exercise for 8 weeks.
47962548|NCT01581775|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
47962551|NCT01460004|DEVICE|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
47962552|NCT00455078|PROCEDURE|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
47962553|NCT00455078|OTHER|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
47962554|NCT00455078|PROCEDURE|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
48310824|NCT04058262|OTHER|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
48310825|NCT04058262|OTHER|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
48310826|NCT04058262|OTHER|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
48310827|NCT04058262|OTHER|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
48310828|NCT04523441|OTHER|Focus group|Holding of a focus group by a sociologist
48310829|NCT04523441|OTHER|Semi-directive interview|Conducting a semi-directive interview by a sociologist after discharge from hospital
48310830|NCT05890287|DRUG|Chidamide|Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
48310831|NCT03916809|OTHER|EMST|Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
48310832|NCT01778088|DRUG|I-131-CLR1404 Injection|
48310833|NCT04789642|OTHER|blood pressure measurement whatsapp educational program|educational
47962555|NCT00455078|PROCEDURE|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
48310834|NCT05978830|DEVICE|Transcranial ultrasound stimulation|In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.
48310835|NCT00119301|DRUG|leucovorin calcium|
48310836|NCT00119301|DRUG|methotrexate|
48310837|NCT00119301|DRUG|trimetrexate glucuronate|
48310838|NCT03168256|DRUG|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
48310839|NCT03168256|DRUG|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
48310840|NCT03168256|DRUG|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
47962556|NCT00455078|PROCEDURE|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
47962557|NCT06557083|BEHAVIORAL|Polyvagal Breathing Exercises|Breathing exercises provided include, square breathing, modified Qigong breathing, and three step breathing
48310841|NCT03168256|DRUG|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
48497928|NCT00003521|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
47962558|NCT06557083|OTHER|No Intervention|The control group will not perform any intervention.
47962559|NCT05116475|DRUG|Darolutamide 300 mg|Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
47962560|NCT05116475|DRUG|Placebo of Darolutamide|Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
47962561|NCT03533296|PROCEDURE|Positive end expiratory pressure (PEEP)|The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
47962562|NCT05327257|DEVICE|iTBS rTMS|Repetitive transcranial magnetic stimulation (rTMS) intermittent Theta Burst Stimulation (iTBS)
48310842|NCT05020652|DRUG|TQ05105 tablets|TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
48310843|NCT05020652|DRUG|Hydroxycarbamide tablets|Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.
48310844|NCT05362851|DRUG|YYC301-1 & YYC301-2 & YYC301-3|"YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day"
48497929|NCT05854888|PROCEDURE|Perineal Massage and Warm Compresses (PeMWaC)|Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
47962563|NCT05512767|OTHER|Best Practice|Undergo self-manual lymphatic drainage
47962564|NCT05512767|OTHER|Consensus Auditory-Perceptual Evaluation of Voice|Ancillary studies
47962565|NCT05512767|PROCEDURE|Diagnostic Imaging|Undergo photographs of face and neck
47962566|NCT05512767|OTHER|Lymphedema Management|Undergo skilled lymphedema treatment by a therapist
47962567|NCT05512767|PROCEDURE|Modified Barium Swallow|Undergo swallow study
47962568|NCT05512767|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo Nasolaryngoscopy
47962569|NCT05512767|DEVICE|Pneumatic Compression Therapy|Undergo compression therapy - Flexitouch Plus System is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides systematic and sequential pressure changes to move fluid to intact lymphatic chains.
47962570|NCT05512767|OTHER|Quality-of-Life Assessment|Ancillary studies
47962571|NCT05512767|OTHER|Questionnaire Administration|Ancillary studies
47962572|NCT05512767|OTHER|Voice Handicap Index-10|Ancillary studies
47962573|NCT01766596|PROCEDURE|Optical Coherence Tomography|
47962574|NCT01402011|PROCEDURE|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
48113635|NCT00092885|DRUG|Comparator: placebo|
48310845|NCT05362851|DRUG|YYC301 placebo & Celecoxib 200mg|comparator medication
48310846|NCT02850887|OTHER|general endotracheal anesthesia|sedation with the use of endotracheal intubation
48310847|NCT02850887|OTHER|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
48310848|NCT01737840|DRUG|Pantoprazole|33 patients
48310849|NCT01737840|DRUG|Ranitidine|33 patients
48310850|NCT05329181|BEHAVIORAL|Integrated cognitive behavioral treatment|Integrated cognitive behavioral treatment adapted specifically for homeless individuals and developed to treat substance use and depressive symptoms simultaneously
48310851|NCT00920608|DRUG|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
48310852|NCT00920608|DRUG|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
48310853|NCT00294008|DRUG|Risperdal Consta|flexible dosage for 24 months
48310854|NCT02583945|PROCEDURE|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
48310855|NCT06254105|OTHER|HANDY programme|The manualised HANDY program includes descriptions of procedures related to the GP's evaluation of the client's need for referral to occupational therapy, procedures for referral from the GP to community-based occupational therapy, the group-based occupational therapy programme, and recommendations related to collaboration and communication between GP and occupational therapist.
48643041|NCT05545306|DIETARY_SUPPLEMENT|+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
48310856|NCT01401010|DRUG|Doripenem|500 mg every 8 hours
48310857|NCT01401010|DRUG|doripenem|1000 mg every 8 hours
48310858|NCT03657368|PROCEDURE|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
48310859|NCT03657368|PROCEDURE|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
48113636|NCT02620618|DRUG|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
48113637|NCT02744859|OTHER|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
48310860|NCT03657368|PROCEDURE|Low PEEP|PEEP = 5 cm H2O
48310861|NCT03657368|PROCEDURE|High PEEP|PEEP = 8 cm H2O
48310862|NCT03517683|OTHER|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
48310863|NCT03517683|OTHER|High speed|speed of intrathecal injection will be 1ml in 5 seconds
48310864|NCT01468909|OTHER|Laboratory Biomarker Analysis|Correlative studies
48310865|NCT01468909|DRUG|Paclitaxel|Given IV
48310866|NCT01468909|DRUG|Pazopanib Hydrochloride|Given PO
48310867|NCT01468909|OTHER|Placebo|Given PO
47962575|NCT01402011|PROCEDURE|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
47962576|NCT01402011|PROCEDURE|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
48113638|NCT06426602|DEVICE|mindBEAGLE daily device use|If participants are considered responsive, they will continue to use the device daily for the remainder of their stay at inpatient rehab, or until they regain consciousness.
48310868|NCT02817815|DEVICE|Electrocardiogram (ECG)|
48113639|NCT00246714|DRUG|repeated injections of endotoxin during 5 days|
48310869|NCT02817815|BIOLOGICAL|Blood sampling from the cephalic vein|
48643042|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
47962577|NCT06558409|BEHAVIORAL|" Safer Still  Interactive Intervention"|An interactive intervention will be developed to help promote safe storage of firearms during the critical period immediately following high-risk care transitions.
48113640|NCT06410144|BEHAVIORAL|Program A|Subjects in the Control group will receive 1) National Kidney Foundation information, and 2) support from a kidney therapy educator.
48113641|NCT06410144|BEHAVIORAL|Program B|Subjects in the intervention group will receive 1) a video and paper decision aid, and 2) coaching from a palliative care clinician. The visits will be aimed at supporting patients with kidney therapy decision-making.
48113642|NCT06677099|PROCEDURE|chest physiotherapy|Two sessions of CPT (morning and afternoon, 20 minutes each) were conducted. The CPT session consisted of modified postural drainage, assisted cough technique , positive expiratory pressure and chest percussion, vibration. The appointed therapist performed pulmonary auscultation and thoracic palpation to assess the status of pulmonary ventilation and secretion retention, and whether the patient's cough ability can complete effective airway clearance. Individualized program was formed according to the assessment, internal guidelines, the patient's tolerance, education level, and patient's preference prior to the randomization. All CPT sessions were performed by the same physiotherapist to avoid potential bias.
48310870|NCT02817815|BIOLOGICAL|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
48310871|NCT02817815|BIOLOGICAL|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
48310872|NCT02817815|PROCEDURE|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
48310873|NCT02817815|BIOLOGICAL|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
48310874|NCT03665376|DIETARY_SUPPLEMENT|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
48310875|NCT03665376|COMBINATION_PRODUCT|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
48310876|NCT03747835|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
48310877|NCT03747835|BEHAVIORAL|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
48310878|NCT02993224|DRUG|Deferasirox dispersable tablet (DT)|"Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water."
48310879|NCT02993224|DRUG|Deferasirox film coated tablet (FCT)|"Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree)."
48310880|NCT05905211|OTHER|Observational Tests|The Berg Balance Scale was used to evaluate the balance levels, the Timed Up and Go Test was used to evaluate the functional mobility levels, and the Functional Independence Scale was used to evaluate the activities of daily living. The World Health Organization Quality of Life Instrument-Older Adults Module (WHOQOL-OLD) was used to evaluate the quality of life, the Fear of COVID-19 Scale was used to evaluate the COVID-19 fear levels, the Geriatric Depression Scale was used to evaluate the symptoms of depression.
48310881|NCT00314756|DRUG|imiquimod|
48310882|NCT05263440|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
48310883|NCT06409078|DEVICE|repeated transcranial magnetic stimulation treatment group|Patients with irritable bowel syndrome received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 1 week.
48310884|NCT06409078|DRUG|Western medicine group|Patients with irritable bowel syndrome were given pivotal ammonium bromide tablets orally at 50 mg three times daily for seven days in the Western medicine group.
48310885|NCT02537314|DRUG|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
48310886|NCT02537314|OTHER|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
48310887|NCT04769635|DEVICE|CPAP therapy|All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of \>70% nights \[380\] obtained from device download with AHI\<5 /hr
48310888|NCT05550948|DEVICE|Transcranial photobiomodulation (tPBM) - Mobile System|The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
48310889|NCT02686606|DIETARY_SUPPLEMENT|Vital 1.5|Oral nutritional supplement
48310890|NCT02686606|DIETARY_SUPPLEMENT|Ensure Plus|Oral nutritional supplement
48310891|NCT00287326|DRUG|Bupivacaine, Clonidine, Morphine|
48310892|NCT02676076|DRUG|CHF 5993 100/6/12.5 µg|
48310893|NCT02676076|DRUG|CHF 1535 100/6 µg|
48310894|NCT04709991|PROCEDURE|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
48310895|NCT01465711|PROCEDURE|All abdominal surgical procedures|Laparotomy, Laparoscopy
48310896|NCT01465711|PROCEDURE|Intubation|Ventilatory support
48310897|NCT01465711|RADIATION|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
48310898|NCT05837026|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts."
48310899|NCT05837026|OTHER|Care as Usual (CAU)|Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
48310900|NCT04495452|DRUG|Fentanyl Drug Administration|Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
48310901|NCT03614091|PROCEDURE|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
48310902|NCT03614091|PROCEDURE|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
48310903|NCT01959737|PROCEDURE|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
48310904|NCT05908344|DEVICE|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
48310905|NCT05908344|DEVICE|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
48310906|NCT06555614|OTHER|Acellular Dermal Matrix(ADM)|A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.
48310907|NCT02423434|OTHER|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
48310908|NCT03147144|OTHER|Ultrasonographic imaging|Ultrasound pelvic scan
48310909|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
48310910|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
48310911|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
48310912|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
48310913|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
48310914|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
48310915|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
48643043|NCT05545306|DIETARY_SUPPLEMENT|-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
48113643|NCT06677099|PROCEDURE|EIT-guided chest physiotherapy|EIT-guided modified postural drainage combined with vibrations and chest percussion: tidal variation images in EIT reveals heterogeneously ventilated regions. Physiotherapist identified such regions at the bedside and instructed the patient to take the appropriate drainage position, so that the poorly ventilated regions became gravity non-dependent regions. Subsequently, the physiotherapist put her hands on the poorly ventilated area with a vibratory force. A compressive pressure was produced by the therapist's arms.
48113644|NCT04141943|OTHER|Virtual reality|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
48113645|NCT00318253|PROCEDURE|cranberry juice|
48113646|NCT02095899|DRUG|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
48113647|NCT04997746|BEHAVIORAL|Multiprofessional educational interventions|Preventive educational interventions
48113648|NCT04997746|OTHER|Measurement of anthropometric measurements|Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
48113649|NCT04367415|DIAGNOSTIC_TEST|Darwish test for a free endometrial cavity|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis). If the uterine cavity is normal the patient will be allocated as group A
48310916|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
48310917|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
48310918|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
48310919|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
48310920|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
48310921|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
48310922|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
48310923|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
48310924|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
48310925|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
48310926|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
48310927|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
48310928|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
48310929|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
48310930|NCT03116399|BEHAVIORAL|PRISM 2.0 Condition|Access to the PRISM 2.0 program
48310931|NCT03116399|BEHAVIORAL|Tablet Condition|Access to the tablet
48310932|NCT01771718|DEVICE|MPTflex-multiphoton microscopy-based tomograph.|non-invasive optical biopsy
48310933|NCT01693458|BEHAVIORAL|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
48310934|NCT04906655|DRUG|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
48310935|NCT04043182|PROCEDURE|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
48310936|NCT00409604|DEVICE|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
48310937|NCT00004735|BIOLOGICAL|Tetanus toxoid|
48310938|NCT00004735|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
48310939|NCT04534439|DRUG|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
48310940|NCT04534439|DRUG|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
48310941|NCT03136081|DIAGNOSTIC_TEST|Candidiasis infection occurence|Candidiasis infection occurence
48310942|NCT01557608|PROCEDURE|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
48310943|NCT01557608|PROCEDURE|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
48310944|NCT02038296|PROCEDURE|transarterial chemoembolization|
48310945|NCT03798912|COMBINATION_PRODUCT|RaniPill capsule containing octreotide|Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
48310946|NCT03637192|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
48310947|NCT03637192|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
48310948|NCT02187094|DRUG|TC-6499|
48310949|NCT02187094|DRUG|Placebo|
48310950|NCT01834144|OTHER|Exercise Training|
48310951|NCT03685799|DIAGNOSTIC_TEST|Pathological revision|Pathological revision
48310952|NCT05218850|DRUG|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
48310953|NCT03927248|DRUG|Nivolumab|See description in Arms/Groups section
48310954|NCT05729217|OTHER|SBQ-LC survey|Symptom burden questionnaires of Long COVID
48310955|NCT05428072|OTHER|Sugar test|All participants will take two sugar tests ( sugar cocktail consisting of mannitol \& lactulose) subjects within 2-3 days of the initial sugar test.
48310956|NCT05428072|DRUG|Aspirin Challenge|All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 \& 1 hour before the sugar drink.
48310957|NCT00941954|BEHAVIORAL|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
48310958|NCT00941954|BEHAVIORAL|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
47962578|NCT06558409|OTHER|Enhanced Usual Care (EUC):|Families randomly assigned to the control condition will receive a psychological placebo that will feature an education only website developed by NCH's web design team. This website will cover warning signs for suicide, the leading methods of suicide - so that both conditions have content that features information about firearms - and locating professional help. The control website will NOT feature these three behavioral economic strategies--namely (a) multiple suggested alternatives for means restriction, (b) requests to justify inaction regarding means restriction, and (c) normative feedback about means restriction.
48310959|NCT01031524|BIOLOGICAL|PfCS102|Antigen of the sporozoite protein
48310960|NCT01031524|BIOLOGICAL|Montanide ISA 720|adjuvant alone
48643044|NCT05545306|DIETARY_SUPPLEMENT|+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
48113650|NCT04367415|DIAGNOSTIC_TEST|Darwish test for an endometrial cavity with endometrial polyps|Darwish test (Office hysteroscopic bubble suction and tubal peristalsis).If there is one or more polyp(s) the patient will be allocated as group B.
48310961|NCT02287012|OTHER|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
48310962|NCT00127504|DRUG|Rifampin|
48310963|NCT00127504|DRUG|Azithromycin|
48310964|NCT04438889|OTHER|Non-interventional|Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
48310965|NCT05430451|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
48310966|NCT05430451|BEHAVIORAL|Referral card|The content consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information, and strong supporting messages or slogans.
48310967|NCT05430451|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
48310968|NCT05430451|BEHAVIORAL|Simple physical exercise training|The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises, and c) resistance exercises. Participants will receive handgrips and elastic bands, and trained smoking cessation ambassadors will demonstrate and encourage the use of handgrip and elastic bands onsite with an instruction leaflet.
48643045|NCT02629809|DRUG|Cyclophosphamide|Given IV
48643046|NCT02629809|DRUG|Fludarabine Phosphate|Given IV
48643047|NCT02629809|DRUG|Ibrutinib|Given PO
48310969|NCT05430451|BEHAVIORAL|Simple physical exercises with instant messaging support|During the 3-month instant messaging support, smoking cessation counselors will deliver regular messages to encourage the practices of simple physical exercise, provide strategies for managing craving and withdrawal symptoms, and provide information on smoking-related knowledge and available smoking cessation services. Our trained smoking cessation counselors will also provide real-time support upon participants' inquiries.
48310970|NCT05430451|BEHAVIORAL|SMS|SMS on follow-up survey reminders
48310971|NCT01395589|DRUG|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
48310972|NCT06442852|OTHER|exposure|The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers
48310973|NCT06553326|DEVICE|EndoStyle|The EndoStyle system is able to transform the style of the different video-processor images.
48310974|NCT00440427|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
48310975|NCT01300897|PROCEDURE|Cortical Evoked Potentials|A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
48310976|NCT01300897|PROCEDURE|Transcranial motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
48310977|NCT01300897|PROCEDURE|Translumbosacral motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
48310978|NCT04234815|BEHAVIORAL|CETA Short Session (CSS)|CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.
48310979|NCT04234815|BEHAVIORAL|Psychoeducation and Safety|This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
48310980|NCT00406952|PROCEDURE|electronic diary|
48310981|NCT00406952|DRUG|Sertraline|
48113651|NCT01402830|OTHER|Visual analogue scales (EVAs)|This scale measures the pain intensity.
48310982|NCT00406952|DRUG|Placebo|
48310983|NCT00406952|PROCEDURE|voice acoustics|
48310984|NCT06085846|DEVICE|Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application|Vivally® System Wearable, Non-Invasive Neuromodulation System and Mobile Application to treat patients with the conditions of urinary incontinence and urinary urgency.
48310985|NCT00305006|PROCEDURE|Constraint-Induced Movement Therapy (CIMT)|90 hours
48310986|NCT00305006|PROCEDURE|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
48310987|NCT03526003|DIAGNOSTIC_TEST|Measurement of esophageal pressure|Measurement of esophageal pressure during posture changes and pneumoperotoneum
48310988|NCT01188382|PROCEDURE|CSF dynamic investigation|
48643048|NCT02629809|BIOLOGICAL|Obinutuzumab|Given IV
48643049|NCT06689696|DEVICE|miLens system|The miLens system consists of the miLens contact lens made of soft, biocompatible materials, the miLens imaging system, and miLens analysis software.
48643050|NCT06695234|BEHAVIORAL|Meditation Awareness Training|A second-generation mindfulness-based intervention that reincorporates Buddhist wisdom concepts into mindfulness-based intervention.
48643051|NCT06695039|DIAGNOSTIC_TEST|Fluoroestradiol (18F)|images for 90 minutes after F-18 FES injection
48113652|NCT00572078|DRUG|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
48113653|NCT03399370|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
48113654|NCT03399370|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
48643052|NCT06694506|OTHER|Biological Sample|Clinical examination and blood test. The clinical examination and blood test are considered standard-of-care as they could be performed annually or bi-annually as part of an adult GHD follow-up. Subsequently, the data will be collected directly from the patient's chosen physician.
48113655|NCT01081145|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
48310989|NCT02076256|BEHAVIORAL|The helping relationships intervention program|
48310990|NCT02522962|BEHAVIORAL|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
48643053|NCT06695338|PROCEDURE|Guided Bone Regeneration (Submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (submerged approach)
48643054|NCT06695338|PROCEDURE|Guided Bone Regeneration (Non-submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (Non submerged Approach)
48310991|NCT02522962|BEHAVIORAL|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
48310992|NCT04716166|OTHER|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
48310993|NCT04716166|OTHER|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
48113656|NCT01081145|OTHER|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
48310994|NCT05415540|OTHER|Questionnaires|Subjects included in the study will answer questionnaires
48310995|NCT06317233|BEHAVIORAL|Chronic Pelvic Pain Treatment Guide|The treatment guide includes mobile and web-based resources and applications specifically chosen to empower patients with information and to promote self-efficacy. The treatment guide is designed to be easily understood, visually appealing, and largely translatable from institution to institution. Patients using the treatment guide will be followed with a clearly defined follow up schedule, which includes touch points between appointments to aid with resource navigation.
48310996|NCT05051865|DRUG|camrelizumab|camrelizumab combined with SHR1020 for advanced melanoma
48310997|NCT05051865|DRUG|SHR1020|camrelizumab combined with SHR1020 for advanced melanoma
48310998|NCT00260637|PROCEDURE|Acupuncture|
48310999|NCT04848584|BIOLOGICAL|Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine|prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
48311000|NCT04848584|BIOLOGICAL|BNT162b2 BA.4/5 bivalent|Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
48311001|NCT04848584|BIOLOGICAL|XBB.1.5-adapted vaccinated|Vaccinated with XBB.1.5-adapted vaccine
48311002|NCT03885739|OTHER|Continuous Pericapsular Nerve Group block|Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
48311003|NCT03179514|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
48311004|NCT03179514|DRUG|Lipid Regulating Drugs|Mainly including statins
48311005|NCT03179514|DRUG|Coronary Vasodilator|Mainly including nitrates
48311006|NCT03179514|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
48311007|NCT01152333|DRUG|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
48311008|NCT01152333|DRUG|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
48311009|NCT02000570|PROCEDURE|Sitting position (neurosurgery)|
48311010|NCT05397886|DRUG|Remimazolam Besylate|Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
48311011|NCT05397886|DRUG|Flumazenil|Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
48311012|NCT05397886|DRUG|Propofol|Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
48311013|NCT00791713|DRUG|Paliperidone ER|
48311014|NCT02392039|DRUG|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
48311015|NCT02392039|DRUG|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
48311016|NCT02392039|OTHER|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
48311017|NCT02392039|BEHAVIORAL|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
48311018|NCT00958308|OTHER|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
48113657|NCT05491031|OTHER|magnetic resonance spectroscopy|Investigation of the association, in patients with multiple sclerosis, between MRI biomarker data at inclusion and progression of physical disability during follow-up (6, 12, 18 and 24 months) assessed by a composite endpoint EDSS plus (EDSS, 9HPT, T25FW)
48311019|NCT00958308|OTHER|Placebo|Placebo is devoid of microorganisms.
48311020|NCT03182400|BEHAVIORAL|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
48311021|NCT03182400|BEHAVIORAL|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
48311022|NCT01810042|DRUG|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
48643055|NCT06696053|OTHER|Transversal therapeutic education|Additional patient consultation for therapeutic education with nurses.
48311023|NCT06146712|OTHER|Asutra's 'Dream the night away' nighttime lotion|Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
48311024|NCT01115569|DRUG|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
48311025|NCT04288804|DEVICE|Smartphone microphone sensor|The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
48311026|NCT04288804|DEVICE|Smartphone accelerometer sensor|The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
48311027|NCT04323748|DRUG|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
48311028|NCT02421367|BIOLOGICAL|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
48311029|NCT03766334|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet(20g, thrice-daily)
48311030|NCT02215421|BEHAVIORAL|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
48311031|NCT05868213|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
48311032|NCT06053827|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
48311033|NCT05420688|OTHER|Heart Failure Group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
48311034|NCT03477526|PROCEDURE|Pulmonary rehabilitation program|3 weeks, ...
48311035|NCT02915367|BEHAVIORAL|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
48643056|NCT04284969|BEHAVIORAL|PROADAPT program|"* A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~* Pre-operative physical training including strength, endurance and breathing exercises.~* A nutrition activity.~* An activity to educate patients (on nutrition, exercise).~* The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~* A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~* A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
47962579|NCT02717520|DEVICE|EQUIA Forte and Tetric EvoCeram|"GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished."
47962580|NCT01161459|DRUG|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
47962581|NCT01161459|DRUG|FK506|capsule
47962582|NCT01999114|DRUG|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
47962583|NCT01999114|DRUG|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
47962584|NCT01999114|DRUG|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
47962585|NCT01999114|DRUG|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
48311036|NCT03913624|OTHER|Neuromuscular electrical stimulation|
48311037|NCT01023399|DRUG|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
48311038|NCT02352051|DRUG|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
47962586|NCT03460730|BIOLOGICAL|Pneumovax|23-valent pneumococcal polysaccharide vaccine
47962587|NCT03295084|DRUG|Irinotecan|Dose Escalation
48311039|NCT02352051|DRUG|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
48311040|NCT03741894|DRUG|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
48311041|NCT03741894|OTHER|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
48311042|NCT03741894|DRUG|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
48311043|NCT05197595|BEHAVIORAL|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
48311044|NCT05197595|BEHAVIORAL|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
48311045|NCT00516269|DRUG|Methylphenidate|18 mg by mouth daily for 2 weeks
48311046|NCT00516269|DRUG|Placebo|Capsule by mouth daily for 2 weeks
48311047|NCT05241015|OTHER|Control Group|Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
48311048|NCT05241015|OTHER|Exercises Group|In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
48311049|NCT05655156|DEVICE|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~* Size 5~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 6~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 8~  * Primary ACL reconstruction where autograft tissue is not suitable~ * Revision ACL reconstruction~ * Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 10~  * Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
48311050|NCT01620632|PROCEDURE|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
48311051|NCT01555112|DRUG|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
48311052|NCT03699787|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
48311053|NCT05560841|DEVICE|topical treatment|Topical application of Nailner brush 2in1 for toenail onychomycosis
48311054|NCT01662700|DRUG|Artesunate|
48311055|NCT01662700|DRUG|Chloroquine|
48497930|NCT05854888|PROCEDURE|Control Group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum."
48497931|NCT04078126|COMBINATION_PRODUCT|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
48497932|NCT04078126|COMBINATION_PRODUCT|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
48643057|NCT02595879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47962588|NCT03295084|DRUG|Capecitabine|Dose Escalation
47962589|NCT05401357|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
47962590|NCT05401357|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
48113658|NCT05020756|DIETARY_SUPPLEMENT|Isosource Junior Mix|Single arm study, collecting data on those who have been on Isosourcr Junior mix tube feed formula for 30 days
48311056|NCT01341652|BIOLOGICAL|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
48311057|NCT01341652|BIOLOGICAL|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
48311058|NCT03969043|OTHER|MRI|"The MRI examination will consist of a series of acquisition scans:~* Scanning Scan: for positioning the functional volume of interest.~* Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~* Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~* Resting state functional scan: for exploring cerebral activation during a rest activity.~* Diffusion Tension Imaging: for measuring structural connectivity.~* Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast."
48311059|NCT03934086|DRUG|rimegepant|rimegepant 75 mg
48311060|NCT00210340|DRUG|intrathecal rituximab|
48643058|NCT02595879|RADIATION|Brachytherapy|Undergo LDR brachytherapy
48643059|NCT02595879|DRUG|Cisplatin|Given IV
48643060|NCT02595879|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
48643061|NCT02595879|RADIATION|External Beam Radiation Therapy|Undergo pelvic EBRT
48643062|NCT02595879|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
48643063|NCT02595879|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
48643064|NCT02595879|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48113659|NCT02852681|DRUG|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
47962591|NCT05871775|BEHAVIORAL|Personalized exercise|After selective functional movement evaluation, customized interventions for each patient
47962592|NCT05871775|BEHAVIORAL|Stabilization exercise|Neck stabilization exercise and sensorimotor program
48113660|NCT05265559|PROCEDURE|Partial Indirect Restoration|Dental restorative treatment
48113661|NCT02902471|OTHER|Forced oscillations measure|
48113662|NCT05504941|DIAGNOSTIC_TEST|Diagnostic, cerebral Digital Subtraction Angiography (DSA)|The DSA is the goldstandard for the visualization of brain vessels. For performing a diagnostic cerebral DSA, the femoral artery of the patient will be punctured in the groin. Over this arterial access a catheter will be advanced under fluoroscopy guidance to the target vessel in the brain. After navigation to the targeted brain vessel, contrast media will be injected over the catheter into the vessel. The efflux of the contrast media will be monitored and visualized with fluoroscopy. The additional radiation to the patient due to the DSA will be approx. 1.1 mSv. The duration of the DSA will be 15 to 20 minutes.
48113663|NCT00445952|OTHER|clinical observation|
48113664|NCT00445952|PROCEDURE|management of therapy complications|
48113665|NCT02419261|DRUG|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
48113666|NCT02419261|PROCEDURE|Arthroscopic surgical repair of the anterior cruciate ligament|
48113667|NCT02754999|DRUG|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
48113668|NCT01365208|DRUG|Chemotherapy|platinum-based chemotherapy
48113669|NCT04709055|OTHER|Co-management|Personalized and intensive geriatric peri-operative care
48113670|NCT04709055|OTHER|Usual care|Pre-operative and post-operative geriatric care as per usual practice
48113671|NCT00787033|DRUG|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
48113672|NCT05732701|OTHER|Algorithm-guided DAPT duration|"PRECISE-DAPT score ≥25~* Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy~* Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy~PRECISE-DAPT score \<25:~* Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy~* Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy~* Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)"
48113673|NCT05732701|OTHER|Standard-of-care DAPT duration|DAPT strategy at the operators´ discretion in accordance with applicable guidelines
48113674|NCT00190931|DRUG|Atomoxetine Hydrochloride|
48113675|NCT00190931|DRUG|placebo|
48113676|NCT02281838|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
48643065|NCT02595879|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47962593|NCT05871775|BEHAVIORAL|General exercise|General mobility exercise and strength exercise program
47962594|NCT01205204|DRUG|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
47962595|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
47962596|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
47962597|NCT01205204|DRUG|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
48113677|NCT06219187|OTHER|Questionnaire completion|"To meet the study's objective, patients will be asked to complete a questionnaire characterizing their environmental and psychosocial context.~The questionnaire is to be completed by the patients themselves, or by their trusted support person as recorded in their medical records (in the particular case of a deceased patient).~It is estimated that the questionnaire will take around 30 minutes to complete.~Data will also be collected from the medical records of included patients:~* Demographics~* Disease data"
48113678|NCT06073860|DRUG|Luspatercept|According to the approved label
48113679|NCT05542862|BIOLOGICAL|SpikoGen vaccine|Recombinant spike protein based Covid-19 vaccine
48113680|NCT03999866|DEVICE|airtraq|airtraq videolaryngoscope
48113681|NCT03999866|DEVICE|mcgrath mac x-blade|mcgarth mac videolaryngoscope
48113682|NCT03999866|DEVICE|storz c-mac|storz c-mac videolaryngoscope
48113683|NCT03999866|DEVICE|storz d-blade|storz d-blade video laryngoscope
48113684|NCT06014827|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48497933|NCT01239875|BIOLOGICAL|dendritic cell vaccine therapy|Given intratumorally
48497934|NCT01239875|PROCEDURE|cryotherapy|Undergo cryoablation
48497935|NCT01239875|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
48497936|NCT01239875|OTHER|laboratory biomarker analysis|Correlative studies
48497937|NCT01239875|OTHER|immunoenzyme technique|Correlative studies
48643066|NCT02595879|OTHER|Pharmacological Study|Correlative studies
48643067|NCT02595879|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
48643068|NCT02595879|DRUG|Triapine|Given IV and PO
48643069|NCT02019706|RADIATION|DOTATATE PET-CT|68Ga-DOTATATE PET/CT
48113685|NCT06014827|PROCEDURE|Computed Tomography|Undergo CT or PET/CT scan
48113686|NCT06014827|DRUG|Osimertinib|Given PO
48497938|NCT01239875|OTHER|immunohistochemistry staining method|Correlative studies
48497939|NCT01239875|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given intradermally
48497940|NCT00914953|DRUG|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
48643070|NCT02019706|RADIATION|F-DOPA PET CT|68Ga-DOTATATE PET/CT
48643071|NCT02019706|RADIATION|CT scan|routine CT scan
48643072|NCT02019706|DIAGNOSTIC_TEST|Routine MRI scan|routine 1.5 or 3T MRI scan
48311061|NCT00672529|DIETARY_SUPPLEMENT|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
47962598|NCT02631759|DRUG|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
48113687|NCT06014827|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48311062|NCT00882726|DRUG|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
48311063|NCT00882726|DRUG|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
48311064|NCT00882726|DRUG|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
48311065|NCT00882726|DRUG|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
48311066|NCT02680223|DEVICE|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
48311067|NCT02680223|DEVICE|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
48113688|NCT06014827|RADIATION|Stereotactic Body Radiation Therapy|Undergo BgRT/SBRT
48113689|NCT06014827|OTHER|Survey Administration|Ancillary study
48113690|NCT01282346|DEVICE|SOLX Gold Shunt|Single use implant
48113691|NCT04911933|BEHAVIORAL|Family Therapy|There will be systemic family psychotherapy sessions every two weeks. Families and individuals who require a more intensive service will be referred to a higher level of care.
48113692|NCT02740595|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cig vapor with nicotine
48113693|NCT02740595|OTHER|one time exposure to e-cig without nicotine|one time exposure to e-cig without nicotine
48113694|NCT02740595|OTHER|one time exposure to empty e-cig|one time exposure to empty e-cig (sham control
48311068|NCT02600325|DRUG|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
48311069|NCT03271385|DIAGNOSTIC_TEST|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
48311070|NCT05055115|PROCEDURE|Balloon Eustachian Tuboplasty|Balloon Eustachian Tuboplasty of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
48311071|NCT06060223|OTHER|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
48311072|NCT01880268|DEVICE|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
48311073|NCT01880268|BEHAVIORAL|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
48311074|NCT03161639|OTHER|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
48311075|NCT06376474|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
48643073|NCT02019706|DIAGNOSTIC_TEST|Gated MRI scan|Cardiac gated MRI scan
48643074|NCT02019706|DRUG|68Ga-DOTATATE|68Ga-DOTATATE radioligand
48113695|NCT03094663|DRUG|Bupivacaine with epinephrine|bupivacaine 0.5% with epinephrine 30cc
48113696|NCT03094663|DRUG|Methylprednisolone|40 mg/ml, 1 ml
48113697|NCT03094663|DRUG|Cefazolin|500 mg in 10 ml
48113698|NCT03094663|DEVICE|8 MHz. Chiba needle|22G/ 4 inches
48113699|NCT03094663|DRUG|Bupivacaine with Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
48113700|NCT03094663|DRUG|Bupivacaine 25cc|25 cc 0.25% bupivacaine
48113701|NCT03094663|DRUG|Bupivacaine 20cc|20cc 0.25% bupivacaine
48113702|NCT03094663|DRUG|Dexamethasone|2 mg IV dexamethasone.
48113703|NCT02452918|DRUG|Oritavancin|Administered intravenously
48113704|NCT02452918|DRUG|Warfarin|Administered as a concomitant medication at a standard dose and dosing schedule
48113705|NCT02474394|DEVICE|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
48113706|NCT02474394|DEVICE|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
48311076|NCT01053546|BEHAVIORAL|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
48311077|NCT01053546|OTHER|questionnaire administration|Ancillary study
48311078|NCT01053546|PROCEDURE|quality-of-life assessment|Ancillary study
48311079|NCT03638947|DEVICE|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
48311080|NCT00348634|DRUG|Tegaserod|
48311081|NCT03047863|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
48311082|NCT03047863|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
48311083|NCT05142332|OTHER|Covid-19 vaccine education materials|videos and flyers containing Covid-19 vaccine educational information
48311084|NCT00074100|DRUG|amonafide dihydrochloride|
48311085|NCT01139385|PROCEDURE|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
48311086|NCT01139385|PROCEDURE|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
48311087|NCT05663359|PROCEDURE|EVLA 1940 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
48311088|NCT05663359|PROCEDURE|EVLA 1470 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
48311089|NCT01680094|DRUG|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
48311090|NCT03173820|GENETIC|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5\*1/\*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5\*1/\*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5\*3/\*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
48311091|NCT03173820|GENETIC|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
47962599|NCT02631759|DRUG|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
47962600|NCT01685892|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
47962601|NCT01685892|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
47962602|NCT05499715|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
48113707|NCT05072743|DEVICE|Photobiomodulation Therapy|PBMT will be applied to the cervical spine using the BIOFLEX® DUO+ system that utilizes a Light Emitting Diode (LED) array pad followed by laser probes. Both delivery methods will be applied to the cervical spine and will entail the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided twice per week for 6 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for the treatment of the cervical spine soft tissue injuries.
47962603|NCT04340648|DEVICE|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
48311092|NCT05579093|COMBINATION_PRODUCT|Cognitive test + Pupillary measure|"Patients will be put into a quiet room with a computer and a webcam for a five minute assessment with the NeuroTrack™ testing. Study personnel will stay in the room, and be available for answering questions about using the online testing tool.~After Neurotrack, pupillary responses will be recorded with the pupillometer with the PLR -3000TM. In brief, an eye cup attached to a pupillometer will be placed over one eye to allow measurement of the pupillary response to light. Once the eye cup is properly positioned, the reading takes approximately 5 seconds, after which time the eye cup will be removed. The reading will then be taken in the contralateral eye."
48311093|NCT01433458|DRUG|RLX030A|RLX030 is administered as a continuous 24 hour infusion
48311094|NCT00681967|DRUG|Gefitinib|250 mg; oral
48311095|NCT00681967|DRUG|Gefitinib|250mg; oral
48311096|NCT03217578|OTHER|SMA Newborn Screening|
48311097|NCT04961372|OTHER|Survey|PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
48311098|NCT05990660|DEVICE|JuxtaFlow System|Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
48311099|NCT02729558|RADIATION|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
48311100|NCT01212172|DEVICE|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
48311101|NCT01212172|DEVICE|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
48643075|NCT02019706|DRUG|18F-DOPA|18F-DOPA radioligand
48311102|NCT05323903|OTHER|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
48311103|NCT05323903|OTHER|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
48311104|NCT00055822|BIOLOGICAL|oblimersen sodium|
48311105|NCT00055822|DRUG|fluorouracil|
48311106|NCT00055822|DRUG|leucovorin calcium|
48643076|NCT06374459|DRUG|Zumsemetinib|Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.
48643077|NCT06374459|DRUG|Capecitabine|Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
48113708|NCT03130439|DRUG|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
48113709|NCT06554769|PROCEDURE|non rigid indirect anchorage connection|a nonrigid connection is placed between the miniscrews and the second premolar to prevent mesial tooth movement.
48643078|NCT06374459|DRUG|Zoledronic acid|Standard of care. Will receive zoledronic acid or denosumab.
47962604|NCT06326099|BEHAVIORAL|Brief Online Binge Eating and Drinking Intervention|The intervention is an online mobile phone program developed by our research team. It builds upon efficacious brief alcohol interventions with college students by addressing underlying loss of control, impulsivity, and emotion regulation through the use of videos, interactive activities, and psychoeducation.
47962605|NCT03191279|PROCEDURE|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
47962606|NCT05801965|DEVICE|A digital solution for patients with Cancer|A digital program that provides holistic lifestyle intervention as well as disease education.
47962607|NCT05801965|OTHER|Standard of care for patients with Cancer|Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
47962608|NCT04929574|DIAGNOSTIC_TEST|Echocardiogram and Hematological Analysis|Echocardiogram and Hematological Analysis
47962609|NCT06409923|DEVICE|Stimulation of mandibular growth.|orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance
47962610|NCT00487877|DEVICE|SenseWear Pro3 Armband|
48113710|NCT06554769|PROCEDURE|rigid indirect anchorage connection|a rigid connection is placed between the miniscrews and the first molar to prevent mesial tooth movement.
47962611|NCT00487877|DEVICE|i-button DS2191 H|
47962612|NCT05852015|BEHAVIORAL|Treatment-as-Usual (TAU)|TAU consists of weekly outpatient-based group therapy for substance use disorder
47962613|NCT05852015|BEHAVIORAL|Digital Mindfulness Treatment|The digital mindfulness-based treatment is a multimedia app-based program teaching mindfulness skills to facilitate recovery from substance use disorder
48113711|NCT05404958|OTHER|Systems Analysis and Improvement Approach (SAIA)|"What is SAIA? It is a 5-step cycle that is repeated every 4-6 weeks for continuous quality improvement, implemented by Kenyan public health workforce and FP clinic staff, and monitored by Mombasa DOH.~Step 1: Understanding the cascade from FP clinic enrollment to HIV testing to linkage to treatment and prevention services.~Step 2: Use process mapping to identify modifiable bottlenecks. Step 3: Define and implement workflow adaptations to eliminate modifiable bottlenecks.~Step 4: Monitor change in performance. Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
48113712|NCT04296019|DRUG|Fruquintinib|Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
48113713|NCT02764307|DEVICE|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
48113714|NCT02764307|DEVICE|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
48113715|NCT02764307|DEVICE|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
48311107|NCT00055822|DRUG|oxaliplatin|
48311108|NCT03491553|DRUG|Selgantolimod|Tablet(s) administered orally once weekly
48311109|NCT03491553|DRUG|Placebo|Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
48311110|NCT03491553|DRUG|Hepatitis B virus (HBV) OAV Therapy|"Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)"
48311111|NCT05304910|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
48643079|NCT06374459|DRUG|Denosumab|Standard of care. Will receive zoledronic acid or denosumab.
48311112|NCT05304910|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
48311113|NCT04279561|PROCEDURE|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
48311114|NCT04279561|DRUG|Gallium Ga 68 Gozetotide|Given IV
48311115|NCT04279561|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
48497941|NCT05295238|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
48497942|NCT03169712|BEHAVIORAL|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
47962614|NCT05806073|PROCEDURE|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
48311116|NCT02018952|OTHER|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~* Information of patient and no opposition getting~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~* Functional outcome"
47962615|NCT05806073|PROCEDURE|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
47962616|NCT02147470|DRUG|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
48113716|NCT02764307|DEVICE|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
48113717|NCT04603417|DIAGNOSTIC_TEST|Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI|This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
48113718|NCT03316482|DRUG|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
48113719|NCT03934658|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
48113720|NCT03934658|DEVICE|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
48497943|NCT03169712|BEHAVIORAL|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
48643080|NCT05715281|BIOLOGICAL|Atezolizumab|Given IV
48643081|NCT05715281|PROCEDURE|Biopsy|Undergo tumor biopsy
48643082|NCT05715281|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48643083|NCT05715281|PROCEDURE|Computed Tomography|Undergo CT scan
47962617|NCT00384566|DRUG|Carvedilol|anit hypertensive medication
47962618|NCT00384566|DRUG|Metoprolol|Anti hypertensive medication
47962619|NCT04674410|DRUG|Antibiotic|Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
47962620|NCT06487585|DRUG|Angiotensin II|Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
47962621|NCT03233607|PROCEDURE|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
47962622|NCT00436839|DRUG|Docetaxel|75mg/m² intravenously (day 1) every 21 days
47962623|NCT00436839|DRUG|Mitoxantrone|12mg/m² intravenously every 21 days
47962624|NCT00436839|DRUG|Prednisone|10mg orally given daily
48497944|NCT01455311|PROCEDURE|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
48643084|NCT05715281|PROCEDURE|Echocardiography|Undergo ECHO
48643085|NCT05715281|DRUG|Tiragolumab|Given IV
48643086|NCT06656221|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 2000mg on Cycle 1 Days 1-2
48311117|NCT06552611|COMBINATION_PRODUCT|Transcutaneous electrical spinal cord stimulation + therapy|A two-channel transcutaneous spinal cord stimulator (SCONE, SpineX, Inc.) will deliver non-invasive electrical stimulation during hand therapy sessions. For each session, two self-adhesive hydrogel electrodes will be positioned along the midline of the C3-C4 and C6-C7 spinous processes over the skin as cathodes to stimulate the cervical spinal cord at two vertebral levels. An additional pair of electrodes will be symmetrically positioned over either the iliac crests or shoulders, functioning as anodes. The electrical current employed for the transcutaneous spinal cord stimulation is biphasic, featuring a 1-millisecond pulse width, a base frequency of 30 Hz, and an overlapping frequency of 10 kHz. Stimulation intensity will range from 0 to 120 milliamperes (mA), with incremental increases of 5 mA until reaching the level that facilitates voluntary movement. The stimulation amplitude will be fine-tuned for each specific activity based on the therapist's observation.
48311118|NCT06552611|OTHER|Occupational Therapy|The hand therapy program is comprised of intensive, progressive, functional task practice following a standardized protocol. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance. Several activities with various difficulty levels are designated for each category, and the participant will perform 1-2 activities within each category in each training session. Activities are chosen according to the participant's ability, interests, and needs and are modified as function progresses over time.
48311119|NCT05689658|BEHAVIORAL|Brazilian Diabetes Prevention Program|A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity
48311120|NCT05689658|BEHAVIORAL|Diet|Hypocaloric diet prescription
48311121|NCT01914705|PROCEDURE|Landmark Procedure|Using Landmarks to guide SCVC placement
47962625|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.
48311122|NCT01914705|PROCEDURE|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
48311123|NCT02370849|DRUG|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
48311124|NCT02370849|DRUG|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
48311125|NCT02370849|DRUG|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
48311126|NCT00024076|PROCEDURE|radiofrequency ablation|
48311127|NCT02731703|DEVICE|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
48311128|NCT02932722|OTHER|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
47962626|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field automatic microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.
47962627|NCT03873974|DIAGNOSTIC_TEST|Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
47962628|NCT03873974|DIAGNOSTIC_TEST|Bózsik Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
47962629|NCT03873974|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay (ELISA) IgM and IgG|Standard ELISA test for Lyme borreliosis.
47962630|NCT03873974|DIAGNOSTIC_TEST|DualDur Polymerase chain reaction|DualDur PCR test for Lyme borreliosis.
47962631|NCT05560360|DRUG|SHR1459 tablet|100 mg/tablet; administered orally
47962632|NCT05560360|DRUG|Efavirenz tablet|600 mg/tablet; administered orally
47962633|NCT05145595|DEVICE|Thermal Sensory Analyzer|Thermal stimuli: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
48113721|NCT05143255|BEHAVIORAL|KNOW|KNow the Optimal Way (KNOW) is a manualized ADRD patient-care partner intervention designed to increase engagement in advance care planning (ACP) and completion of advance directives among early stage ADRD patients and their care partners using theoretically grounded distress tolerance techniques (inhibitory learning theory) and communication skills (cognitive-social processing theory) consistent with recommended guidelines for discussions about ACP in ADRD care.
48113722|NCT01428297|DRUG|BPR277 ointment (controlled application)|
48113723|NCT01428297|DRUG|Placebo (Vehicle)|
48311129|NCT02932722|DRUG|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
48311130|NCT02932722|DRUG|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
48311131|NCT00922194|DRUG|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
48311132|NCT03803540|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via duodenal infusion
48311133|NCT03847155|DRUG|Nicotine patch|The patients will receive a nicotine patch for the period of a maximum of 7 days.
48311134|NCT03847155|OTHER|Placebo patch|The patients will receive a placebo patch for the period of a maximum of 7 days.
48311135|NCT02458079|DRUG|Pentoxiphylline|
48311136|NCT02458079|DRUG|Stool microbiota transplantation|
48311137|NCT01087528|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
48311138|NCT02433288|OTHER|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
48497945|NCT01455311|PROCEDURE|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
48311139|NCT02433288|OTHER|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
48311140|NCT02754934|OTHER|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
48311141|NCT00372190|DEVICE|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
47962634|NCT05145595|DEVICE|Pressure Stimuli|Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
47962635|NCT05145595|DEVICE|Mechanical Stimuli|Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture.
47962636|NCT05145595|BEHAVIORAL|Pain Ratings|Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
48311142|NCT00372190|PROCEDURE|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
48311143|NCT06330948|DIETARY_SUPPLEMENT|SugarCut® Unripe Guava Fruit Extract|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the SugarCut® Guava Extract group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
48311144|NCT06330948|DIETARY_SUPPLEMENT|Placebo group|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
48311145|NCT03018626|DRUG|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
48311146|NCT03018626|DRUG|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
48311147|NCT03018626|DRUG|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
48643087|NCT06656221|DRUG|Glofitamab|Glofitamab is given intravenously at a dose of 2.5mg on Cycle 1 Day 8. Glofitamab is given intravenously at a dose of 10mg on Cycle 1 Day 15. Glofitamab is given intravenously at a dose of 30mg on Day 1 of Cycles 2-6
48643088|NCT06656221|DRUG|Bortezomib|Bortezomib is given intravenously at a dose of 1.6 mg/m² on Days 1, 8, and 15 of Cycles 1-12.
48311148|NCT03018626|DRUG|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
48643089|NCT06656221|DRUG|Orelabrutinib|Orelabrutinib is given orally at a dose of 150 mg daily on Days 1-21 of Cycles 1-12.
48643090|NCT06566716|DIAGNOSTIC_TEST|CleoDX ovarian cancer test|A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.
48643091|NCT06695390|OTHER|Nursing students' humanistic care competence|A cross-sectional study with nursing students
47962637|NCT05145595|BEHAVIORAL|Thermal pain thresholds|Cold and heat pain thresholds (CPT and HPT, respectively) will be determined \[22; 55\]. Thresholds are determined by continuous ramping of temperature from 32°C baseline temperature until the participant press a button at the first moment he/she feels pain from the stimulus. Cut-off temperatures are 0°C and 50°C, to minimize potential damage to the skin. The baseline temperature to which the thermode returns before each test is 32°C. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
47962638|NCT05145595|BEHAVIORAL|Pressure pain thresholds (PPT)|Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus. The first threshold measurement will be used as a familiarization. The average threshold is calculated from three measurements.
48113724|NCT01428297|DRUG|BPR277 ointment|
48643092|NCT02923778|PROCEDURE|Biopsy|Undergo tumor biopsy
48113725|NCT01428297|DRUG|Placebo (Vehicle)|
48643093|NCT02923778|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48113726|NCT01428297|DRUG|BPR277|
48113727|NCT01428297|DRUG|Placebo (Vehicle)|
48113728|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
48311149|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
48311150|NCT03018626|DRUG|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
48311151|NCT03018626|DRUG|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
48311152|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
48311153|NCT03018626|DRUG|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
48311154|NCT03018626|DRUG|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
48643094|NCT02923778|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48643095|NCT02923778|RADIATION|Radiation Therapy|Undergo radiation therapy
48643096|NCT02923778|BIOLOGICAL|Talimogene Laherparepvec|Given IT or via intralesional injection
48643097|NCT05040542|OTHER|maternal exposure during pregnancy|maternal exposure during pregnancy (e.g., environmental exposures and maternal inflammatory states)
48643098|NCT02571543|DRUG|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
48311155|NCT02831634|PROCEDURE|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
47962639|NCT05145595|BEHAVIORAL|Mechanical temporal summation|A pinprick stimulus with standardised intensity (#6.10 or #6.45 von Frey filament) and a flat contact area of 0.25mm diameter will be used. In this test, participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli. The 10 identical pinprick stimuli are applied with a frequency of 1 s-1 within an area of 1 cm2. Immediately following the single stimulus and series of stimuli, an evaluation of the pain will be collected. The difference in pain ratings evoked with the one stimuli vs. the 10 stimuli is the temporal summation value.
47962640|NCT05145595|BEHAVIORAL|Conditioned pain modulation (CPM) efficiency|"The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information. CPM testing includes the application of a test stimulus without conditioning (control run) and a subsequent application of the same test stimulus together with a conditioning stimulus (conditioning run). Heat-CPM and pressure-CPM. Heat and pressure CPM will be tested in random order.~The difference between the pain ratings/thresholds of the test stimulus with vs. without the concomitant conditioning stimulus is the CPM magnitude. CPM\<0 (reduction in pain) implies efficient inhibitory pain modulation of spatial filtering."
47962641|NCT05145595|BEHAVIORAL|Offset analgesia efficiency|"Offset analgesia (OA) paradigm assesses endogenous inhibitory pain modulation efficiency of temporal filtering of nociceptive information. The mechanisms underlying OA are distinct from the CPM mechanisms \[41\]. OA is characterized by a disproportionately large reduction in pain perception after a small decrease in temperature during noxious thermal stimulation.~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). The T1 will be noxious heat (44-48°C) delivered to the hand or leg. During the OA paradigm, real time pain intensity ratings will be obtained using the computerized VAS.~The difference between the pain ratings of the 10-20 seconds noxious stimulus in the OA paradigm compared to a control paradigm (30 seconds of T1) is the OA magnitude. OA\<0 (reduction in pain) implies efficient inhibitory pain modulation of temporal filtering."
48311156|NCT03957109|PROCEDURE|general anesthesia|
48311157|NCT03264508|BEHAVIORAL|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
48311158|NCT03264508|BEHAVIORAL|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature \>0.2°C.
48311159|NCT04369430|DRUG|AKST4290|Oral AKST4290
48311160|NCT04369430|DRUG|Placebo|Oral Placebo
48311161|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
48311162|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
48311163|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
48311164|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
48113729|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
48113730|NCT03608839|DRUG|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
48113731|NCT06060210|DRUG|normal Saline|50-ml Saline
48311165|NCT00586924|DRUG|CAT 8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
48311166|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
48311167|NCT00279552|DRUG|Recombinant human intrinsic factor|
48311168|NCT01119274|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
48311169|NCT01119274|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
48497946|NCT03823495|OTHER|12-week PAP|It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
48497947|NCT06060808|GENETIC|gene polymorphism|gene polymorphism of NFKBIA and PTPN22 genes
48311170|NCT04415567|DRUG|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW \<60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
48311171|NCT03897673|DIETARY_SUPPLEMENT|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
48311172|NCT03897673|DIETARY_SUPPLEMENT|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
48311173|NCT04123756|BEHAVIORAL|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
48497948|NCT05476913|DEVICE|geko™ device|Neuromuscular electrical stimulation of the peroneal nerve
47962642|NCT05145595|BEHAVIORAL|Cold pain tolerance|Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold (4-12°C) water bath. Tolerance will be defined by the time of hand withdrawal. VAS ratings of cold pain intensity might be obtained periodically, and both pain intensity and pain unpleasantness will be recorded upon hand withdrawal. Limb immersion in the cold water bath will be terminated after 120 s if participants do not withdraw their hand before then.
47962643|NCT04638257|BIOLOGICAL|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =\<18 weeks of gestation in singleton pregnancy
48113732|NCT06060210|DRUG|Ketamine|50-ml volumes, and the ketamine concentration is 1 mg/ml
47962644|NCT04638257|OTHER|Placebo|Daily oral placebo starting at =\<18 weeks of gestation in singleton pregnancy
47962645|NCT00153907|DRUG|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
48643099|NCT06453486|RADIATION|High dose radiation therapy|"High dose radiation refers to the administration of a concentrated beam of radiation to target and treat the tumor. High dose radiation therapy typically involves delivering radiation in fractions over a set period. For instance, options such as:~* 50Gy/5Fx: 50 Gray delivered over 5 fractions, administered every other day over 2 weeks.~* 67.5Gy/15Fx: 67.5 Gray delivered over 15 fractions, administered once a day over 3 weeks.~* 75Gy/25Fx: 75 Gray delivered over 25 fractions, administered once a day over 5 weeks.~These numbers denote the total dose of radiation (in Gray, abbreviated as Gy) delivered over a specific number of fractions (abbreviated as Fx), and the respective time frames for administration. The selection of radiation therapy (RT) dose levels for participants is guided by the expertise and evaluation of the radiation oncologist."
48643100|NCT06223698|DRUG|Letrozole|Letrozole 2.5 mg daily
47962646|NCT00153907|DRUG|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
47962647|NCT02124083|DRUG|Vorinostat|Histone deactylase inhibitor
48643101|NCT06223698|DRUG|Anastrozole|Anastrozole 1 mg daily
48113733|NCT05973812|DIETARY_SUPPLEMENT|Infant formula supplemented with Bifidobacterium breve PS1|Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.
48113734|NCT05973812|DIETARY_SUPPLEMENT|Infant formula NOT supplemented with Bifidobacterium breve PS1|Feeding with the same infant formula but without supplementation with the B. breve strain
48113735|NCT06676228|BEHAVIORAL|Fear of cancer recurrence therapy (FORT)|"FORT consists of 6 sessions in total, the scopes of the sessions are detailed below:~Session 1 (Acquiring new skills to cope with Fear of Cancer Recurrence (FCR)) HOMEWORK: Daily practice of progressive muscle relaxation exercise; creation of a thought record~Session 2 (Providing information on symptoms of cancer recurrence and increasing tolerance to uncertainty) HOMEWORK: Listening to recordings of relaxation exercises every day; practising self-calming, keeping a record of thoughts~Session 3 (Developing coping skills) HOMEWORK: Practise guided imagery daily; debunk erroneous beliefs about the benefits of worrying; keep a thought log~Session 4 (Deepening the underlying fears) HOMEWORK: Reading the worst case fear scenario every day, practising daily self-care and mindfulness practices~Session 5 (Moving beyond specific fears) HOMEWORK: Writing goals and priorities for the future~Session 6 (Review and conclusion) Reviewing all the discussed content"
48113736|NCT06676228|BEHAVIORAL|cognitive-behavioural therapy (CBT) group|"The cognitive-behavioural therapy (CBT) oriented control group consisted of a total of 6 sessions. The scopes of the sessions are given in detail below.~Session 1: Introduction and cancer-focused psychoeducation with CBT HOMEWORK: Keeping a thought diary~Session 2: Addressing the underlying causes of thoughts HOMEWORK: Keeping a thought diary about underlying beliefs~Session 3: Recognising conflicts HOMEWORK: Task: Keep a diary of thoughts about disagreements (what gives us pleasure and what we should master)~Session 4: Effective communication techniques HOMEWORK: Keeping a diary about the use of the word good enough~Session 5: Discussion of the definitions of anxiety and depression~Session 6: Anger Management HOMEWORK: HOMEWORK: Keeping a diary about the use of the breathing exercise"
48113737|NCT05437783|DRUG|Azithromycin Dihydrate|exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
48113738|NCT06386627|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
48643102|NCT06223698|DRUG|Exemestane|Exemestane 25 mg daily
48643103|NCT06223698|DRUG|Tamoxifen|Tamoxifen 20 mg daily
48643104|NCT05262764|DRUG|JARDIANCE®|JARDIANCE®
47962648|NCT06055101|DRUG|DEXMEDETOMIDINE|"DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water."
48643105|NCT04180462|OTHER|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
48643106|NCT04180462|OTHER|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
48643107|NCT04180462|OTHER|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
48643108|NCT04180462|OTHER|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
47962649|NCT06055101|DRUG|Neostigmine|Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
47962650|NCT06055101|DRUG|Bupivacaine|"The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane."
47962651|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
48113739|NCT06386627|DIAGNOSTIC_TEST|Transcranial magnetic stimulation|Transcranial magnetic stimulation to assess the integrity of corticospinal connections
48113740|NCT00995306|DRUG|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
48113741|NCT06512714|OTHER|A diagnosis of mycetoma in a medical, radiologic, or laboratory record.|For each patient, data will be extracted for each clinical, laboratory or radiologic visit related to the condition that may meet this study's case definition.
48113742|NCT04559659|OTHER|Respiratory muscle strength|Pimax and Pmax will be performed according to the (ATS) and (ERS). A Manovacuometer (Analog M 120, GlobalMed) with a range between 0-120cmH2O will be used. The elderly should undergo forced inspiration after maximal expiration and forced expiration after maximal inspiration through a mouthpiece with a hole to prevent closure of the glottis to evaluate Pimax and Pmax. The elderly should sustain the inspiration for 1 second. Three measurements will be performed, with a one-minute interval between them, with less difference equal to 10% between them, the higher value will be used.
48113743|NCT06392451|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV, & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 real-time (RT) PCR assay is a Point of Care (POC) system that enables the extraction, amplification, detection and differentiation of influenza A, Influenza B, respiratory syncytial virus (RSV) and SARS-CoV-2 viral RNA from dry nasal swabs (NS). The system consists of the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, the LIAISON® NES system (with LIAISON® NES Software), and associated accessories. In the LIAISON® NES FLU A/B, RSV \& COVID-19 cartridge, extraction reagents and lyophilized fluorescent probes are used together with corresponding forward and reverse primers to extract and amplify influenza A, influenza B, RSV, SARS-CoV-2 and internal control RNA targets.
48483366|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 4, and 5. Finally, they will receive text messages or emails with the core message of the modules."
48643109|NCT06693947|OTHER|Alpine dairy products|The intervention group will be instructed to eat three portions of alpine dairy products daily. The proposed three portions represent an estimated mean consummation in the study population, taking into consideration the national statistics.
48643110|NCT06345703|DRUG|Placebo|NS-136 matching placebo
48643111|NCT06345703|DRUG|NS-136 tablet|Investigational product NS-136
48643112|NCT06694818|BEHAVIORAL|trauma film paradigm|Use the trauma films as stressors to induce stress and evaluate how it affects sleep reactivity in healthy subjects with insomnia symptoms compared to healthy subjects without insomnia symptoms
48643113|NCT05430919|DRUG|REGN5713|Administered subcutaneously (SC)
48643114|NCT05430919|DRUG|REGN5714|Administered SC
48643115|NCT05430919|DRUG|REGN5715|Administered SC
48643116|NCT05430919|OTHER|Placebo|Administered SC
48643117|NCT06133712|DRUG|Dexmedetomidine|Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
48643118|NCT06133712|DRUG|Ozone|Participants will receive a single local injection of 4 ml ozone (10 micrograms/dl) plus to 1 ml lidocaine (1%) using a 25 G needle.
48643119|NCT06133712|DRUG|Dexamethasone|Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
48643120|NCT05539352|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"All caregivers are assigned to this condition and receive EUC and PST. EUC is delivered along with the treatment to ensure the safety of all caregivers enrolled in the study. In addition to EUC, caregivers receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by caregivers and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
48643121|NCT06694337|DIETARY_SUPPLEMENT|300 mg Palmitoylethanolamide (PEA) Phytosome® (contain120 mg mg pure PEA)|300 mg Palmitoylethanolamide (PEA) Phytosome®
48643122|NCT06694337|DIETARY_SUPPLEMENT|450 mg Palmitoylethanolamide (PEA) Phytosome® (contain180 mg mg pure PEA)|450 mg Palmitoylethanolamide (PEA) Phytosome®
48643123|NCT06694337|OTHER|Control group|Placebo
48643124|NCT02928497|DEVICE|WATCHMAN LAAC Device Implant|WATCHMAN LAAC Implant
48311174|NCT04296500|OTHER|Decision tree modeling|"A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied."
48311175|NCT00313599|DRUG|lapatinib|
48311176|NCT00313599|DRUG|paclitaxel|
48311177|NCT02898025|DEVICE|Active Interferential Current|Involves the application of medium frequency alternating currents
48311178|NCT02898025|DEVICE|Active Laser|Involves the application of low level laser over the knee
48311179|NCT02898025|DEVICE|Placebo Interferential Current|It is a sham interferential therapy
48311180|NCT02898025|DEVICE|Placebo Laser|It is a sham laser therapy
48311181|NCT05177952|OTHER|Blood Flow Restriction|Resistance training with BFR
48311182|NCT05177952|OTHER|Standard of Care|Resistance Training with no BFR
48311183|NCT05256056|DRUG|Bupivacain|efficacy of bupivacaine in different volumes
48311184|NCT04698590|DEVICE|Wavefront Guided Scleral Lenses|Custom wavefront guided, higher order aberration correcting scleral lenses
48311185|NCT04698590|DEVICE|Traditional Scleral Lenses|Traditional scleral lenses
48311186|NCT02536170|DRUG|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
48311187|NCT02536170|DRUG|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
48311188|NCT02536170|OTHER|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
48643125|NCT02928497|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
47962652|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
48113744|NCT06392451|DIAGNOSTIC_TEST|LIAISON PLEX Respiratory Flex Assay|"The LIAISON PLEX® (also known as VERIGENE® II) RSP Flex Assay is an automated test for the detection and identification of common viruses and bacteria, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, from upper respiratory specimens. The VERIGENE® II Respiratory Flex (RSP Flex) Assay is performed on the VERIGENE® II System. The VERIGENE® II System is an automated platform that performs sample preparation and is capable of polymerase chain reaction (PCR) for the detection of target-specific nucleic acids. The VERIGENE® II System is a fully automated, bench-top sample-to-answer device. The test reagents are supplied in a single, disposable test cartridge."
48113745|NCT06673628|DRUG|Pembrolizumab plus Lenvatinib|"One course is fixed at 21 days, and the length of course is not extended or shortened.~Participants receive 200 mg of pembrolizumab injection intravenously over approximately 30 minutes on day 1 of each course, and take 20 mg of lenvatinib capsules orally once daily, preferably at the same time each day.~Treatment with pembrolizumab and lenvatinib will be continued for up to 35 courses unless the criteria for termination of protocol treatment are met."
47962653|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
47962654|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
47962655|NCT03711461|DEVICE|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
48113746|NCT05089084|DRUG|Plozasiran|ARO-APOC3 injection
48311189|NCT05252884|DIAGNOSTIC_TEST|calcium correction according to PTH levels|A PTH blood test will be performed 4 hours post-thyroidectomy. If the PTH result is \>15 pg/mL, the patient will be discharged without calcium intake; if PTH \< 15 pg/mL, start a dose of 1200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days
48311190|NCT05252884|DRUG|routine postoperative calcium and calcitriol|The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
47962656|NCT03711461|DEVICE|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
47962657|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
47962658|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
47962659|NCT02509273|DRUG|Clonidine|
47962660|NCT02509273|DRUG|Midazolam|
48311191|NCT01868178|DEVICE|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
48311192|NCT01519245|DRUG|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
48311193|NCT01519245|DRUG|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
48311194|NCT03765801|DRUG|GRTA9906 60 mg PR tablet|GRTA9906 60 mg PR tablet
48311195|NCT03765801|DRUG|GRTA9906 60 mg IR capsule|GRTA9906 60 mg IR capsule
48311196|NCT02577406|DRUG|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
47962661|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of original formulation.
48311197|NCT02577406|OTHER|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
48311198|NCT02577406|DRUG|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
47962662|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of new formulation.
48113747|NCT05089084|DRUG|Placebo|sterile normal saline (0.9% NaCl)
48113748|NCT06508658|DRUG|Epcoritamab|Subcutaneous Injection
48113749|NCT06508658|DRUG|Rituximab|Intravenous (IV) Infusion
48113750|NCT06508658|DRUG|Lenalidomide|Oral Capsule
48113751|NCT06508658|DRUG|Oxaliplatin|IV Infusion
48311199|NCT02577406|DRUG|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
48311200|NCT02577406|DRUG|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
48311201|NCT03333057|DRUG|NOV03|Perfluorohexyloctane
48311202|NCT03333057|DRUG|Placebo|Saline solution (0.9% sodium chloride solution)
48311203|NCT01158833|OTHER|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
48311204|NCT01165021|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
48311205|NCT01165021|DRUG|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
48311206|NCT01165021|DRUG|Folic Acid|Administered orally.
48311207|NCT01165021|DRUG|Vitamin B12|Administered Intramuscular injection.
48311208|NCT01165021|DRUG|Dexamethasone|Administered orally.
48311209|NCT00207103|DRUG|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
48311210|NCT00207103|DRUG|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
47962663|NCT05195671|OTHER|Review|Reviewing all protocols
47962664|NCT01160315|DRUG|Triptorelin|Triptorelin: intramusculAR injection every 3 months
47962665|NCT01160315|DRUG|Norethisterone acetate|5 mg/day per os until during chemotherapy
47962666|NCT03375606|BIOLOGICAL|CSL730|Solution for IV infusion
47962667|NCT03375606|OTHER|Placebo|Saline solution for IV infusion
47962668|NCT02438020|DRUG|Metformin|One tablet of 500 mg will be ingested before the main meal
47962669|NCT02438020|OTHER|Placebo|A placebo tablet will be ingested daily before main meal.
47962670|NCT00690274|DRUG|BF2.649|up to 20mg per day
47962671|NCT00690274|DRUG|Placebo|up to 20mg per day
47962672|NCT02027883|DEVICE|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
48113752|NCT06508658|DRUG|Gemcitabine|IV Infusion
48113753|NCT01892553|DEVICE|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~* Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~* Cathodal tDCS: Intensity of 1.25 mA during 15 min~* Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
48113754|NCT06547840|DRUG|MOv18 IgE|MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class
48113755|NCT06555380|BEHAVIORAL|The one-year intervention|A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
48113756|NCT06555380|BEHAVIORAL|The three-year intervention|A multifactorial family-centered lifestyle intervention extending up to three years, with clinical visits at local healthcare centers which included repeatedly visits (up to 8 times / year). The intervention was managed by specialized nurses.
48113757|NCT06400745|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
48311211|NCT00207103|DRUG|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
48311212|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
48311213|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
48311214|NCT00207103|DRUG|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
48311215|NCT01605565|PROCEDURE|A nasal brushing|A nasal brushing in every nostril
48311216|NCT02077075|BEHAVIORAL|Web-based weight loss program|A 4-week web-based wellness program.
48311217|NCT02077075|BEHAVIORAL|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
48311218|NCT00038688|BEHAVIORAL|Peer HIV Education Program|
48311219|NCT06224699|DRUG|Toothpaste Product|Use of toothpaste with or without sodium carbonate at 67%
48311220|NCT05916677|OTHER|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
48311221|NCT05916677|OTHER|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
48311222|NCT00511524|DRUG|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
48311223|NCT00511524|DRUG|[carbonyl-^11C]GW842166|\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
48483367|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Watch out!"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior."
48483368|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 3. Finally, they will receive text messages or emails with the core message of the modules."
48643126|NCT06324110|OTHER|Electronic Health Record Review|Ancillary studies
47962673|NCT02027883|DEVICE|Educated T shock setting|Experimental Parameter Set 2 Programming Values
47962674|NCT06313489|PROCEDURE|Biopsy of EPL tendon and muscle during the operation|Biopsy of EPL tendon and muscle
47962675|NCT00765557|DRUG|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
47962676|NCT00765557|DRUG|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
48497949|NCT06390644|DIAGNOSTIC_TEST|Periorbital Massage Therapy|Participants in this arm will receive periorbital massage therapy administered by a trained practitioner. The massage technique will involve gentle circular motions around the eye sockets and brow bone area, aiming to improve eyelid and tear gland function.
47962677|NCT02772107|DRUG|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
47962678|NCT02772107|DRUG|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
47962679|NCT02772107|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
47962680|NCT02772107|RADIATION|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
47962681|NCT01139931|GENETIC|DNA methylation analysis|
47962682|NCT01139931|GENETIC|gene expression analysis|
47962683|NCT01139931|GENETIC|microarray analysis|
47962684|NCT01139931|GENETIC|polymorphism analysis|
47962685|NCT01139931|OTHER|laboratory biomarker analysis|
47962686|NCT01684956|PROCEDURE|Intradermal injection|
47962687|NCT01684956|PROCEDURE|Subcutaneous injection|
47962688|NCT02544360|BEHAVIORAL|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
47962689|NCT01628978|OTHER|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
47962690|NCT01628978|OTHER|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
47962691|NCT02675283|DEVICE|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
47962692|NCT06557629|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of gastric residual volume
47962693|NCT05795075|PROCEDURE|Computerized Modified Paramedian Approach Technique|Computerized Modified Paramedian Approach Technique ( CMPAT )
47962694|NCT05795075|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
47962695|NCT04341077|DRUG|SHR3162|A single oral dose of fluzoparib on Day 1
48311224|NCT02259036|OTHER|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
48311225|NCT03076047|DEVICE|end-tidal CO2 (ETCO2) monitoring|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
48643127|NCT06324110|OTHER|Interview|Ancillary studies
48643128|NCT06324110|BEHAVIORAL|Patient Navigation|Receive lung cancer screening care coordination services
48643129|NCT06399289|BIOLOGICAL|Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)|Lyophilized powder for solution for intravenous injection
48311226|NCT00943293|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
48311227|NCT00943293|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
48311228|NCT00943293|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
48311229|NCT04212338|OTHER|Before intravitreal injection music intervention|The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.
48311230|NCT04212338|OTHER|during intravitreal injection music intervention|The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
48311231|NCT03823417|DRUG|Tranexamic Acid|Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
48311232|NCT03823417|DRUG|Normal saline|Normal saline infusion
48311233|NCT04477824|DIAGNOSTIC_TEST|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
48311234|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
48311235|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
48311236|NCT00909766|DRUG|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
48311237|NCT00909766|DRUG|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
48311238|NCT00909766|DRUG|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
48311239|NCT00909766|DRUG|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
48311240|NCT00909766|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
48311241|NCT03560193|DRUG|2%Chlorhexidine-70%Isopropanol|2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
48311242|NCT03560193|DRUG|5%Povidone Iodine- 69%Ethanol|5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
48311243|NCT00002663|BIOLOGICAL|Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
48311244|NCT01250093|DEVICE|acupuncture|
48311245|NCT05238467|OTHER|COVID antibody titers in the blood|COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
48311246|NCT04332640|DEVICE|VERITAS Vision System|The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.
48311247|NCT04585399|BEHAVIORAL|Contingency management|Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
48311248|NCT02434627|DRUG|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
48311249|NCT01094717|DRUG|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
48311250|NCT01094717|DEVICE|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
48311251|NCT01094717|DRUG|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
48311252|NCT01094717|DEVICE|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
48311253|NCT01240811|DRUG|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
48311254|NCT01240811|DRUG|Levonorgestrel IUD|
48497950|NCT06390644|OTHER|Control Group (Standard Care)|"Participants in this arm will receive standard care for dry eye disease, which include artificial tears. They will not receive periorbital massage therapy."
47962696|NCT05806450|BEHAVIORAL|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
48311255|NCT01240811|DRUG|Copper T380A IUD|
48311256|NCT01218932|DRUG|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
48311257|NCT01218932|DRUG|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
48497951|NCT02717897|OTHER|No intervention|This study is not interventional
48311258|NCT04190784|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
48311259|NCT04190784|OTHER|Placebo stretching|The therapist maintains the same manual contact without stretching force.
48311260|NCT01588145|DRUG|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
48311261|NCT02231255|DRUG|Sifrol®|
48311262|NCT02800564|BEHAVIORAL|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
48311263|NCT02800564|BEHAVIORAL|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
48311264|NCT01743339|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
48311265|NCT01743339|BEHAVIORAL|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
48311266|NCT01532700|DRUG|Ofatumumab with GSK2110183|"* GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
48311267|NCT00961337|BIOLOGICAL|Trivalent inactivated influenza vaccine|one dose
48311268|NCT02773238|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
48311269|NCT02773238|PROCEDURE|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
48311270|NCT02773238|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
48311271|NCT02773238|OTHER|Laboratory Biomarker Analysis|Correlative studies
48311272|NCT02773238|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
48311273|NCT02773238|RADIATION|Radiation Therapy|Undergo functional avoidance radiation therapy
48311274|NCT02773238|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
48113758|NCT06400745|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
48113759|NCT06400745|PROCEDURE|Cataract surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
48311275|NCT02773238|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
48311276|NCT02773238|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
48311277|NCT04393636|OTHER|Digital cardiac Counseling|"* Screening for reduced physical fitness and digital counseling.~* Screening for smoking and digital counseling.~* Screening for malnutrition and obesity and digital counseling.~* Screening for anxiety and depression and digital counseling.~* Screening for elevated pulmonary risk score and digital counseling."
48311278|NCT01350349|BEHAVIORAL|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
48311279|NCT01350349|BEHAVIORAL|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
48311280|NCT06101394|DRUG|Cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
48311281|NCT05803889|OTHER|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
48311282|NCT05803889|OTHER|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
48311283|NCT05253313|OTHER|MRI scan|Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
48311284|NCT04817085|DEVICE|Visant Medical Canalicular Plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
48311285|NCT04817085|DEVICE|Commercially available canalicular plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
48497952|NCT03021109|DEVICE|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
47962697|NCT05806450|OTHER|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
48311286|NCT02787993|BEHAVIORAL|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
48311287|NCT00470353|DIETARY_SUPPLEMENT|calcium carbonate|
48311288|NCT00470353|DIETARY_SUPPLEMENT|cholecalciferol|
48311289|NCT00470353|OTHER|immunohistochemistry staining method|
48311290|NCT00470353|OTHER|laboratory biomarker analysis|
48311291|NCT00470353|OTHER|pharmacological study|
48311292|NCT00470353|PROCEDURE|biopsy|
48311293|NCT01002534|DRUG|Vardenafil|Nasal instillation of Vardenafil
48311294|NCT01002534|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
48497953|NCT00374426|DRUG|sertraline|
48311295|NCT02306187|DRUG|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
48311296|NCT01935687|DEVICE|Using of instrumented wheel|Using of instrumented wheel
48311297|NCT01935687|DEVICE|Using of ergometer roller|Using of ergometer roller
47962698|NCT04923256|BEHAVIORAL|AAT-APP: A novel smart-phone approach-avoidance bias modification intervention|Participants allocated to the intervention group will be required to upload photos of drinks they wish to avoid, as well as activities they wish to engage in more, and be trained to avoid and approach by repeatedly 'swiping' images away from and towards themselves, respectively.
48113760|NCT03165071|DRUG|ACT-132577|Capsule
48311298|NCT03766087|PROCEDURE|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
48311299|NCT03826355|PROCEDURE|CO2 (carbon dioxide) laser vaporisation|CO2 (carbon dioxide) laser is used to vaporise the inner wall of the endometrioma
48113761|NCT00007956|BIOLOGICAL|monoclonal antibody mono-dgA-RFB4|
48113762|NCT03216538|DRUG|AS101 1% oral solution|0.4 ml daily p.o.
48311300|NCT03826355|PROCEDURE|Stripping technique|Identification of a cleavage plane and perform the cystectomy removing all the wall of the endometrioma from the healthy ovarian tissue
48311301|NCT03154632|DEVICE|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
48311302|NCT03154632|DEVICE|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
48311303|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
48483369|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
47962699|NCT04923256|BEHAVIORAL|Sham training control|Complete an AAT on a weekly basis for four weeks
47962700|NCT01176383|GENETIC|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
47962701|NCT02283385|BEHAVIORAL|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
47962702|NCT03334630|DEVICE|DiamondTemp Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
48311304|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
48311305|NCT00533637|DRUG|Placebo|Citrate buffer with preservatives
48497954|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and delivery of systemic oxygen|CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
47962703|NCT03334630|DEVICE|TactiCath Quartz Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
48113763|NCT03216538|DRUG|Placebo|0.4 ml daily p.o.
48497955|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and without additional oxygen therapy|corneal collagen cross linking with accelerated protocol without additional oxygen therapy
48113764|NCT03734692|DRUG|Rintatolimod|200 mg by IP administration over 1-2 hours
48113765|NCT03734692|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion
48311306|NCT02848300|DRUG|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
48311307|NCT02848300|DRUG|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
48113766|NCT03734692|DRUG|Cisplatin|50mg/m\^2 solution
48113767|NCT05261399|DRUG|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
48113768|NCT05261399|DRUG|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
48113769|NCT05261399|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
48113770|NCT05261399|DRUG|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
48113771|NCT05261399|DRUG|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
48113772|NCT06323356|DRUG|TAK-279|Specified drug on specified days.
48113773|NCT00703911|DRUG|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
48311308|NCT06381518|OTHER|Switch to SC CT-P13.|all patients in the study will switch from IFX to SC CT-P13
48311309|NCT01912430|BEHAVIORAL|ICC (Integrated Care Coaching) Intervention Group|
48311310|NCT00410501|DRUG|Indacaterol (QAB149)|
48311311|NCT00828087|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
48311312|NCT00828087|DEVICE|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
48311313|NCT05281601|DRUG|AZD7442|"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."
48311314|NCT01540461|DRUG|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
48311315|NCT05610774|DRUG|Dexmedetomidine|pre-eclamptic Patients will receive a loading dose of iv dexmedetomidine (0.5 ug/kg) diluted in 50 ml saline and given over 10 min, followed by a maintenance infusion of (0.2 ug/kg/h) diluted in 200 ml saline till The sedation scores on the Richmond Agitation and Sedation Scale was -2 to +1 (lightly sedated to restless).
48311316|NCT05610774|DRUG|Saline|pre-eclamptic patients will receive 50 ml saline loading for 10 min followed by 200 ml saline infusion
48311317|NCT01523808|DRUG|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
48311318|NCT05428748|OTHER|1 serving of test product|Participants will consume 1 serving/day of the test product for 28 days
48311319|NCT05428748|OTHER|2 servings of test product|Participants will consume 2 servings/day of the test product for 28 days
48311320|NCT05428748|OTHER|3 servings of test product|Participants will consume 3 servings/day of the test product for 28 days
47962704|NCT04889807|OTHER|measure of EtCO2 variation|measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
48311321|NCT05428748|OTHER|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
48311322|NCT05974735|BEHAVIORAL|Wellness trail|"Setting up wellness trails based on four distinct themes:~* Food, Nutrition and Micronutrition~* Physical activity~* Sleep~* Stress and well-being"
48643130|NCT04589988|BEHAVIORAL|Removing Environmental Barriers to Independent Living (REBIL)|REBIL is a complex intervention with two essential components: (1) removing environmental barriers and home hazards in the home tailored to the participant's unique abilities and limitations and (2) strategy training with the participant to help participant to be able to identify barriers in the home and community and identify potential resources and strategies to remove the barriers. Treatment includes one assessment session and four 75-minute visits in the home with an occupational therapist over 8 weeks, followed by a 6 -month assessment session by a blinded rater.
47962705|NCT01610661|OTHER|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
48113774|NCT04088032|DRUG|Abemaciclib, durvalumab and aromatase inhibitor|Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
48113775|NCT05660967|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.
48311323|NCT06179550|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48311324|NCT06179550|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm (Appendix). However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48311325|NCT04875975|DRUG|Rozanolixizumab|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive rozanolixizumab in a pre-specified sequence during the Treatment Period."
48311326|NCT04875975|DRUG|Placebo|"* Pharmaceutical form: Solution for infusion~* Route of administration: Subcutaneous use~Subjects will receive placebo in a pre-specified sequence during the Treatment Period."
48311327|NCT02915406|DEVICE|CliniMACs|
48311328|NCT01560546|DRUG|Testosterone|50 mg/dose/day for 24 weeks
48311329|NCT01560546|DRUG|Placebo|placebo on the skin for 24 weeks
48311330|NCT04017988|DIETARY_SUPPLEMENT|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
48311331|NCT04017988|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
48311332|NCT02935634|BIOLOGICAL|Nivolumab|Specified dose on specified days
48311333|NCT02935634|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48311334|NCT02935634|BIOLOGICAL|Relatlimab|Specified dose on specified days
48311335|NCT02935634|BIOLOGICAL|BMS-986205|Specified dose on specified days
48311336|NCT02935634|DRUG|Rucaparib|Specified dose on specified days
48311337|NCT04282226|DEVICE|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
48311338|NCT04282226|DEVICE|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
47962706|NCT03308201|DRUG|Hemay022+exemestane|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane."
48311339|NCT05151341|DIAGNOSTIC_TEST|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
48311340|NCT05151341|OTHER|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
48311341|NCT00771407|DEVICE|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
48311342|NCT00771407|OTHER|Standard ostomy creation|Ostomy will be created as routinely performed
48311343|NCT06534424|OTHER|Best Practice|Receive standard care
48311344|NCT06534424|PROCEDURE|Biospecimen Collection|Undergo collection of blood or mouthwash sample
48311345|NCT06534424|OTHER|Counseling|Receive tailored counseling
48311346|NCT06534424|PROCEDURE|Discussion|Participate in phone discussion
48311347|NCT06534424|PROCEDURE|Genotyping|Undergo genotyping
48311348|NCT06534424|PROCEDURE|Molecular Risk Assessment|Undergo enhanced risk assessment
48311349|NCT06534424|OTHER|Questionnaire Administration|Ancillary studies
48311350|NCT01856595|DRUG|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
48311351|NCT01856595|DRUG|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
48311352|NCT01477892|DRUG|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
48311353|NCT05764356|GENETIC|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
48311354|NCT05764356|OTHER|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
48311355|NCT05764356|OTHER|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
48483370|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 5. Finally, they will receive text messages or emails with the core message of the modules."
47962707|NCT03308201|DRUG|Hemay022+letrozole|Part two: Hemay022 combination with letrozole.
47962708|NCT03308201|DRUG|Hemay022+ fulvestrant|Part two: Hemay022 combination with fulvestrant.
48113776|NCT05660967|DRUG|Lenalidomide|Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
48113777|NCT05251259|DRUG|Atuliflapon|Randomised participants will receive Atuliflapon
48311356|NCT05021536|OTHER|Placebo|Matching Placebo Comparator
48311357|NCT05021536|DRUG|AMX0035|Proprietary formulation of taurursodiol and sodium phenylbutyrate
48497956|NCT04343326|PROCEDURE|perform Conventiona corneal collagen cross linking|Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
47962709|NCT02774954|BEHAVIORAL|Change the Cycle|See previous response
48113778|NCT05251259|DRUG|Placebo|Randomised participants will receive placebo
48311358|NCT02857855|PROCEDURE|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
48311359|NCT02857855|PROCEDURE|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
48311360|NCT01598727|DEVICE|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
48311361|NCT05337813|DEVICE|"Storz Medical Extracoporeeal Shock Wave Therapy System"|A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
48311362|NCT02082314|PROCEDURE|RFA Vertebroplasty|
48311363|NCT05474508|OTHER|Diaphragmatic breathing|Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
48311364|NCT05474508|OTHER|Aerobic exercises|Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
48311365|NCT02736292|BEHAVIORAL|Mindfulness Practices for Healthcare Professionals|
48311366|NCT04730986|BEHAVIORAL|ED GOAL Nursing|A brief (\<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
48497957|NCT05759143|BEHAVIORAL|Nest Platform|Patient- and clinician-facing portal via secure link
48311367|NCT04622787|OTHER|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
47962710|NCT04661904|DEVICE|Continuous theta burst stimulation (cTBS)|Our active treatment will consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
48311368|NCT02380352|DRUG|Amoxicillin|
48311369|NCT02380352|DRUG|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
48311370|NCT04379934|DIETARY_SUPPLEMENT|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
48311371|NCT01228266|BIOLOGICAL|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
48311372|NCT02496637|BEHAVIORAL|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
48311373|NCT02496637|BEHAVIORAL|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
48311374|NCT04939077|BIOLOGICAL|Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|In CABG with hUC-MSC treatment group, 1×10\^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
48311375|NCT05853523|COMBINATION_PRODUCT|Gas ozone|The application of ozone was performed with the HealOzone System X4 (HealOzon, Kavo, Germany). The dentist adapted the silicon cup stricken on the cervical surface of the teeth. The pumping system created the vacuum and the machine applied high dosage of ozone, equal to 32 g/m3, for 30 second.
48311376|NCT05853523|COMBINATION_PRODUCT|Diode laser and desensitized gel|"The dentist applied desensitized gel (JW-Desensitizing Gel, Heydent Gmbh, Germany) directly on the cervical zone of the teeth. Subsequently the irradiation was performed with Wiser III (Wiser, Doctor Smile, Italy) in the desensitizing assisted mode (preprogramed protocol). The protocol provides consecutively steps (not in contact) with 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. radiating the entire desensitize surface second using the black tip (400 micron). The procedure continued maintaining the tip of the laser on contact with the dentine surface making movement of lawn mowing (brushing technique) for 30 second. Then the surface was rinsed, and the irradiation applied again without the gel."
48483371|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
47962711|NCT04661904|DEVICE|Sham stimulation|The sham stimulation group will receive a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 4 days) with the coil set at 90 against the skull. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
47962712|NCT01270516|DRUG|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
47962713|NCT01270516|DRUG|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
47962714|NCT01270516|DRUG|Saline|Control
47962715|NCT01496248|DIETARY_SUPPLEMENT|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
47962716|NCT00509041|DRUG|dasatinib|50 mg PO bid
47962717|NCT05938491|DIAGNOSTIC_TEST|OCT and OCT-A|OCT and OCT angiography for the macula
47962718|NCT03204578|DRUG|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
48113779|NCT01359436|DEVICE|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
48113780|NCT01984086|DRUG|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
48497958|NCT01642914|DRUG|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
48497959|NCT01642914|DRUG|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
48311377|NCT01290172|DRUG|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
47962719|NCT03204578|DRUG|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
47962720|NCT01418170|OTHER|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
47962721|NCT00989560|PROCEDURE|endoscopy|patients receive best treatment and care with an additional endoscopy
47962722|NCT00567307|DRUG|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
47962723|NCT00567307|OTHER|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
47962724|NCT00273546|DRUG|XRP6976 (Docetaxel/Taxotere)|
47962725|NCT01477593|PROCEDURE|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
47962726|NCT01477593|PROCEDURE|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
47962727|NCT01477593|PROCEDURE|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
47962728|NCT04002661|DRUG|Flibanserin|Flibanserin tablet
47962729|NCT04002661|DRUG|Placebo|Oral Tablet
48113781|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
48113782|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
48113783|NCT01984086|DRUG|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
48113784|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
48497960|NCT01642914|DRUG|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
48497961|NCT05453773|OTHER|Questionnaire Administration|Ancillary studies
48497962|NCT05453773|BEHAVIORAL|Tobacco Smoking|Smoke waterpipe tobacco
47962730|NCT05617469|OTHER|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
48113785|NCT01984086|DRUG|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
48113786|NCT01984086|DRUG|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
48113787|NCT01984086|DRUG|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
48311378|NCT01290172|DRUG|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
47962731|NCT00356291|BEHAVIORAL|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
48311379|NCT04989829|DRUG|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
47962732|NCT00356291|BEHAVIORAL|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
47962733|NCT04589455|DIETARY_SUPPLEMENT|Hennep extract|Hennep extract from Becanex containing 70 mg CBD
47962734|NCT04926428|DRUG|tPA|Selectively catheter thrombolysis with alteplase in each main pulmonary
47962735|NCT05136404|DRUG|Selpercatinib|Administered orally
48311380|NCT03633227|DRUG|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
48311381|NCT03633227|DRUG|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
48311382|NCT02325635|OTHER|Educational Training|Intervention/Training offered to endoscopists only.
48483372|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 4. Finally, they will receive text messages or emails with the core message of the modules."
48311383|NCT03951961|DRUG|Midostaurin|50mg Midostaurin bid for 12 months
48311384|NCT00040833|PROCEDURE|complementary or alternative medicine procedure|
48643131|NCT04589988|BEHAVIORAL|Waitlist Attentional Control|The waitlist attentional control group will receive an initial assessment session then four 75 minute interview visits from an occupational therapy graduate assistant, followed by a 6-month assessment session by a blinded rater. After the 6-month follow-up is completed this group will receive the REBIL intervention.
48643132|NCT06694896|DIAGNOSTIC_TEST|Microarray Application|Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.
47962736|NCT06257797|DIAGNOSTIC_TEST|Skin prick test|Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
47962737|NCT03470870|OTHER|Comparative analysis of the characteristics|"* Predictive nomogram of short-term hospitalization (less than two days after surgery)~* Factors influencing the variations of average stay lenght~* Morbidity of the ERAS program"
47962738|NCT03712956|DRUG|Caelyx®|Caelyx® every two weeks for 8 courses
48113788|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
48311385|NCT00040833|PROCEDURE|pain therapy|
47962739|NCT00113022|DRUG|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
48311386|NCT04323761|DRUG|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
47962740|NCT00113022|DRUG|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
47962741|NCT00991718|DRUG|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
47962742|NCT00991718|DRUG|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
47962743|NCT00991718|DRUG|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
47962744|NCT01578187|DEVICE|Hair2Go|Treatment with the device once under observation
47962745|NCT01939808|OTHER|Splint Neutral|
47962746|NCT01939808|OTHER|Splint Extended|
47962747|NCT01139489|OTHER|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
47962748|NCT00231205|PROCEDURE|Revascularization|
47962749|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
48311387|NCT03418402|DEVICE|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
48311388|NCT03418402|DEVICE|Standard insufflator|Standard insufflator
48311389|NCT05836532|PROCEDURE|Central edge-to-edge|Suture of free margins of the mitral leaflets in central position to restore coaptation
48311390|NCT03764215|DRUG|Nilotinib 150 MG|10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
48311391|NCT06144528|OTHER|QT robot|In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
48311392|NCT05464446|DEVICE|Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices|Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
48311393|NCT05329987|OTHER|Rehabilitation|Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
48311394|NCT01740037|OTHER|Specialized outpatient AF Clinic|
48311395|NCT01740037|OTHER|Usual Care|
48311396|NCT00002533|DRUG|fluconazole|
48311397|NCT00002533|RADIATION|radiation therapy|
48311398|NCT03934892|DIAGNOSTIC_TEST|serum lactate|check lactate levels during cardiopulmonary bypass in adult cardiac operations
48311399|NCT03572439|DIAGNOSTIC_TEST|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
48311400|NCT03122028|DEVICE|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
48483373|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
48497963|NCT01254266|BEHAVIORAL|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
48643133|NCT06695013|DRUG|zanubrutinib|zanubrutinib 160 mg BID orally
47962750|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
47962751|NCT04548583|OTHER|Placebo|Normal saline
47962752|NCT00401531|BIOLOGICAL|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
47962753|NCT00401531|BIOLOGICAL|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
48113789|NCT01984086|DRUG|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
48311401|NCT05379426|OTHER|Impact COVID-19 pandemic|Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
48311402|NCT04276220|DIAGNOSTIC_TEST|Tenosynovial biopsy|Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
48311403|NCT00654511|DRUG|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
48311404|NCT00654511|DRUG|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
48113790|NCT01984086|DRUG|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
48113791|NCT01984086|DRUG|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
48311405|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
48311406|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
48311407|NCT00125658|OTHER|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
48311408|NCT00125658|OTHER|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
48311409|NCT04194658|DRUG|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
48311410|NCT03644940|DIAGNOSTIC_TEST|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
48311411|NCT02115815|BIOLOGICAL|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
48113792|NCT01909258|OTHER|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
48113793|NCT01909258|OTHER|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
48113794|NCT01909258|OTHER|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
48113795|NCT05415449|DEVICE|Gus gear protective wearable device|Gus gear protective wearable device for central line.
48311412|NCT02115815|BIOLOGICAL|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
48311413|NCT02115815|BIOLOGICAL|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
48311414|NCT02115815|BIOLOGICAL|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
48311415|NCT02115815|BIOLOGICAL|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
48311416|NCT02115815|BIOLOGICAL|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
48311417|NCT02115815|BIOLOGICAL|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
48311418|NCT05504148|DRUG|crocin|Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
48113796|NCT00664404|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
48497964|NCT01254266|BEHAVIORAL|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
48497965|NCT01254266|PROCEDURE|bariatric surgery|bariatric surgery.
48497966|NCT01254266|BEHAVIORAL|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
48113797|NCT06220071|OTHER|Case series review of clinical and radiographic data|Extraction of clinical and radiographic data related to patients' history from medical records
48113798|NCT05505799|OTHER|Intubation Checklist|A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
48113799|NCT05505799|OTHER|Standard Care|Clinicians will intubate as per their usual practice
48113800|NCT06225388|OTHER|Compression socks|A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
48311419|NCT05504148|DRUG|Placebo|Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
48311420|NCT06276608|DIAGNOSTIC_TEST|Iron status|Iron status will be based on preoperative ferritin levels: a ferritin \< 10 mcg/L will be considered as iron deficiency, ferritin levels \> 10 mcg/L will be considered normal
48311421|NCT05369416|OTHER|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
48311422|NCT05369416|OTHER|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of \> 4200 mg/Day) for two weeks.
48311423|NCT01996137|DEVICE|VASST II treadmill|Supervised treadmill training under physiotherapist
48311424|NCT04740268|DEVICE|Straberi|"The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
48497967|NCT02958982|DRUG|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
48643134|NCT06695013|DRUG|CAR-T|CAR-T Cell therapy
48643135|NCT06695013|RADIATION|Bridging radiotherapy|For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.
48311425|NCT02405234|DEVICE|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
48497968|NCT02958982|DRUG|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
48643136|NCT06695013|DRUG|Tislelizumab|200mg IV Q3-4W
48643137|NCT06350630|DRUG|Hydroxychloroquine Oral Tablet|Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
48643138|NCT06350630|DRUG|Placebo oral tablet|placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
48643139|NCT06693960|DIETARY_SUPPLEMENT|Oregano|Oil of oregano administered as a softgel (180 mg).
48643140|NCT06693960|DRUG|Drug cocktail|Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
47962754|NCT04709107|OTHER|Quality of life assessment - elective|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. To assess reliability and systematic shift and variation between the two assessments, elective patients will be asked to fill the VascuQoL-6 again at the admission to hospital, as well as 1 week after the 30-days follow-up vie an e-mail link for a test-retest assessment. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
48311426|NCT02405234|DEVICE|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
48311427|NCT04105556|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
47962755|NCT04709107|OTHER|Quality of life assessment - emergent|"Patients will be asked to fill up both VascuQoL-6 and SF-36 questionnaires before the procedure, as well at 30-days and 1-year follow-up visit while they are sitting in the waiting room. All questionnaires will be administered on a tablet.~During the 30-days follow-up 4 extra questions concerning patient related outcomes and occurrence of major complication will be added to the VascuQoL-6 questionnaire in the App. During every visit (preoperatively, at 30-days and 1-year follow-up) the stage of the lower limb peripheral artery disease will be noted according to the WIfI-Classification."
48497969|NCT03517696|PROCEDURE|Membrane sweeping|Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
47962756|NCT01968759|DRUG|Sevelamer|
48311428|NCT03367130|BEHAVIORAL|Mobile phone reminder|Intervention described already in arm/group descriptions.
48311429|NCT00678587|DRUG|Eltrombopag|75 mg, once daily, oral
48311430|NCT00678587|DRUG|Placebo|placebo, once daily, oral
48311431|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Unilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
47962757|NCT01968759|DRUG|Ramipril and Irbesartan|
47962758|NCT01519271|DRUG|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
47962759|NCT01519271|DRUG|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
47962760|NCT04473391|DEVICE|Cycle-ergometer training assisted by FES for lower extremities|The intervention consists of FES treatment sessions on a cycle ergometer for the lower extremities. Each subject received 24 sessions lasting 45 minutes each and a frequency of 3 sessions per week. The sessions will be applied by a physiotherapist with experience in electrotherapy. A 6-channel FES device (TrainFES, Biomedical Devices SpA, Chile) will be used, which consists of a stimulator unit of 95x50x30mm and 100g of weight coupled to the motorized cycle ergometer (MOTOmed Viva 2, Reck GmbH., Germany), a remote user interface consisting of an android application for the configuration of the stimulation via Bluetooth 3.1, and an inertial measurement unit positioned on the rotation axis of the cycle ergometer to detect the rotations and trigger the synchronized electrical stimulation according to the stimulation pattern pre-configured for the pedaling exercise
47962761|NCT05113758|DIAGNOSTIC_TEST|muscle ultrasound|All participants will undergo a muscle ultrasound on admission and at discharge
47962762|NCT05108662|PROCEDURE|Surgery method|Patients were subdivided into two groups according to their prostate volume
47962763|NCT01723488|RADIATION|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
47962764|NCT00925041|DEVICE|Vedera KXS|one treatment with the Vedera KXS
48311432|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Bilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
48311433|NCT04801342|DRUG|Memantine Hydrochloride|Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks
48311434|NCT02836990|DEVICE|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
48311435|NCT02836990|DEVICE|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
48311436|NCT03862079|OTHER|Best Practice|Given standard of care
48497970|NCT03627520|DRUG|[14C]Sulfatinib|300 mg Sulfatinib with 100 µCi \[14C\]
48497971|NCT04192279|DIAGNOSTIC_TEST|lactate clearance|Lactate clearance rate was monitored within 6 hours after admission
48643141|NCT05843721|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
48643142|NCT06425029|OTHER|Experimental Intervention (Music A)|Participants will be asked to listen to Music A on their personal device daily, at a time most convenient for them.
47962765|NCT06006741|BIOLOGICAL|MM-specific universal CAR T cells|Infusion of MM-specific universal CAR T cells
47962766|NCT01786668|DRUG|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
47962767|NCT01786668|DRUG|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
47962768|NCT01786668|DRUG|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
47962769|NCT01786668|DRUG|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
47962770|NCT03641859|DEVICE|virtual reality|"The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain)."
47962771|NCT03928353|DRUG|PB2452 Infusion|30 minute - 24 hour infusion
47962772|NCT03928353|DRUG|Placebo - Sodium Chloride|30 minute - 24 hour infusion
47962773|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
47962774|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
47962775|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
47962776|NCT03928353|DRUG|PB2452 Infusion|30 minute - 16 hour infusion
47962777|NCT03928353|DRUG|Placebo - Sodium Chloride|Placebo - Sodium Chloride
47962778|NCT00000371|DRUG|D-cycloserine|50 mg/daily by mouth
48311437|NCT03862079|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
47962779|NCT00000371|DRUG|Placebo|50 mg/day of placebo by mouth
47962780|NCT02867462|OTHER|Standard care|standard care
47962781|NCT02867462|OTHER|manipulator consultation radiotherapy added to standard care|
47962782|NCT06143644|OTHER|Serial ctDNA monitoring|Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
47962783|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
48311438|NCT03862079|DRUG|Nystatin|Given PO
48311439|NCT03862079|DRUG|Piperacillin-Tazobactam|Given PO
48311440|NCT03633786|PROCEDURE|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
48311441|NCT03633786|PROCEDURE|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
48311442|NCT03633786|DIAGNOSTIC_TEST|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
48311443|NCT03633786|DIAGNOSTIC_TEST|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
48311444|NCT03633786|DIAGNOSTIC_TEST|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
48311445|NCT03294681|DEVICE|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
48643143|NCT06425029|OTHER|Active Comparator Intervention (Music B)|Participants will be asked to listen to music B on their personal device daily, at a time most convenient for them.
48643144|NCT06425029|OTHER|Active Comparator Intervention (Music C)|Participants will be asked to listen to music C on their personal device daily, at a time most convenient for them.
48643145|NCT06068075|OTHER|FoundationOne Liquid CDx|a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
48311446|NCT02410707|DRUG|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
48311447|NCT02410707|DRUG|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
48311448|NCT02410707|DRUG|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
48311449|NCT05263102|DEVICE|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
48311450|NCT04217577|DIETARY_SUPPLEMENT|Dried plums|10-16 dried plums/day, approximately 100-120 g/day
48311451|NCT02586636|DRUG|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
48311452|NCT02586636|DRUG|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
48483374|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation. They will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Further access will be provided to module 4 You are safe here on improving children´s relationship-related safety and facilitating solid relationships. Access to module 5 Who am I and where do I belong? will support caregivers in helping their child develop an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support will be provided. They will receive four phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, 4, and 5. Text messages or emails with the core message of the modules will be provided."
48483375|NCT06115304|OTHER|Large liquid meal, spinal catheter and venous line|"Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying).~Spinal catheter for 4 hours, with samples taken at one hour interval.~2 venous lines, one for saline and one for venous sampling every half hour"
48483376|NCT03407118|DRUG|LY900014|Administered SC.
48483377|NCT03407118|DRUG|Insulin Lispro|Administered SC.
48483378|NCT00026871|PROCEDURE|Radiotherapy|
47962784|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
47962785|NCT00003165|DRUG|doxorubicin-HPMA conjugate|
47962786|NCT02198872|OTHER|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
47962787|NCT02198872|OTHER|Land Group|Patients of this group perform physical training on bicycle.
47962788|NCT05248048|BIOLOGICAL|CAR-T infusion|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
47962789|NCT00002946|DRUG|penclomedine|
47962790|NCT01842321|DRUG|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
47962791|NCT00349531|DRUG|Pramipexole|
47962792|NCT01503918|DRUG|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
47962793|NCT01503918|DRUG|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
47962794|NCT01317654|OTHER|Observation|Collection of mortality data at 5 years post trial
47962795|NCT00548223|DRUG|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid\*1year
47962796|NCT00548223|DRUG|placebo|Capsule, 0.18g, 2#, Bid\*1year
47962797|NCT05960799|DEVICE|CON - Contiplex C™ (CC)|This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.
47962798|NCT05960799|DEVICE|CTN - Contiplex|This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
47962799|NCT05781854|DRUG|Epidural analgesia with bupivacaine and dexmedetomidine|Epidural analgesia with bupivacaine and dexmedetomidine
47962800|NCT00745329|OTHER|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
47962801|NCT06273085|BEHAVIORAL|Patient education|3 sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
47962802|NCT02920385|DRUG|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
47962803|NCT02920385|DRUG|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
47962804|NCT02920385|DRUG|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
48311453|NCT02586636|DRUG|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
47962805|NCT02920385|DRUG|Placebo|Oral administration once daily together with semaglutide
47962806|NCT06504797|DEVICE|automatic massage|automatic massage
47962807|NCT04345042|OTHER|Classic Massage (Swedish Technique)|Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
47962808|NCT00568997|DRUG|Pimecrolimus|Pimecrolimus 1% cream
47962809|NCT04307303|DEVICE|abdominal functional electrical stimulation|functional electrical stimulation of the abdominal muscles
47962810|NCT05574738|OTHER|Observational|
47962811|NCT02200432|OTHER|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
48311454|NCT00808691|OTHER|Critical care|Standard care for each group of patients
47962812|NCT01040975|BEHAVIORAL|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
48113801|NCT06225388|OTHER|Placebo socks|The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
48483379|NCT06467565|DRUG|Liposomal irinotecan|NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
48643146|NCT06694207|DRUG|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients
47962813|NCT01906398|OTHER|ketogenic diet|KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction
48113802|NCT05190419|DRUG|Orismilast modified release tablets|Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.
48113803|NCT05190419|DRUG|Placebo|Matching placebo tablets
48113804|NCT06677450|OTHER|Pain neuoroscience education|Pain neurosicence education will be applied 1 day / 6 weeks at the beginning of one of the weekly exercise sessions in addition to the exercise program. The educations will include the definition and general characteristics of pain, pain physiology, peripheral neuropathic pain, the role of the brain in pain perception, tissue healing, peripheral and central sensitization, the effects of emotional, psychological and social factors on the pain process and pain coping strategies.
48311455|NCT03741582|OTHER|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station-from 32 to 6 minutes; 31 minutes saved from Manitas station-from 38 to 7 minutes and 49 minutes saved from Paraiso station-from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
48643147|NCT02707042|DRUG|Amoxicillin|7-day therapeutic oral course of twice daily amoxicillin
48643148|NCT02707042|DRUG|Azithromycin|5-day oral course of once-daily azithromycin
47962814|NCT05494931|PROCEDURE|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
47962815|NCT01744197|DRUG|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
47962816|NCT00304746|DRUG|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
47962817|NCT00304746|DRUG|Placebo|Placebo
47962818|NCT04431453|DRUG|Remdesivir|Administered as an intravenous infusion
47962819|NCT00462566|DEVICE|motor cortex stimulation|
47962820|NCT04597723|DRUG|oxygen|Patients will be given different concentrations of oxygen.
48113805|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
48643149|NCT02707042|OTHER|Control|A group of volunteers will receive no antibiotics and will serve as study controls.
48643150|NCT03664609|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
48643151|NCT05217966|RADIATION|Radiation: Single Pre-Operative Radiation Therapy|Ablative preoperative partial breast radiation therapy
47962821|NCT05196204|OTHER|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
47962822|NCT05196204|OTHER|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
47962823|NCT01517074|DRUG|Sirolimus|Subconjunctival injection
48483380|NCT02752841|DIETARY_SUPPLEMENT|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
48483381|NCT03736759|BEHAVIORAL|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
48483382|NCT05661734|DRUG|VX-548|Tablets for oral administration.
47962824|NCT00714441|BEHAVIORAL|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
47962825|NCT00714441|BEHAVIORAL|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
48483383|NCT02447926|PROCEDURE|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
48483384|NCT05282979|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
48483385|NCT00156715|DRUG|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
48483386|NCT00004876|DRUG|carboplatin|
48483387|NCT00004876|DRUG|thalidomide|
48483388|NCT00349726|DRUG|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
48483389|NCT00349726|DRUG|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
48483390|NCT00349726|DRUG|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
48483391|NCT00349726|DRUG|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
48483392|NCT00346892|BIOLOGICAL|Rotavirus (vaccine)|
48483393|NCT01430975|DRUG|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
48643152|NCT05835986|DRUG|RO7507062|RO7507062 solution for injection will be administered SC as specified in each treatment arm.
48643153|NCT05835986|DRUG|Tocilizumab|Tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
48643154|NCT02928822|BEHAVIORAL|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
48643155|NCT02928822|BEHAVIORAL|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
48643156|NCT05159960|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
48643157|NCT01627093|OTHER|Medical Chart Review|Review of medical records
48643158|NCT01627093|OTHER|Questionnaire Administration|Complete questionnaires
48311456|NCT04348487|OTHER|Modified cephalica venous access|This modified technique prioritized the safety in TIVAPS by using several modified landmarks and techniques. The catheter was inserted through cephalic vein in deltopectoral groove regio and implanted the port in the anteromedial of thorax. Generally, the percutaneous and Seldinger technique was used to ensure safety and minimal tissue disruption. To connect the trimmed catheter to port pocket, the author anchored a special trocar from anteromedial of thorax to the deltopectoral groove for guidance.
48311457|NCT04829955|OTHER|Eccentric manual resistance training|Eccentric bodyweight resistance training
48311458|NCT04829955|OTHER|Concentric manual resistance resistance training|Concentric bodyweight resistance training
48311459|NCT05872971|DEVICE|Dry Needling|Dry Needling: The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN. The application will be through the deep technique, above 10mm deep, the therapist will score trigger points regions of the muscles of the posterolateral region of the hip with application duration of 30 to 60 seconds. Eight points of application will be standardized in the region of the muscles of the posterolateral region of the hip.
48311460|NCT05872971|DEVICE|Lasertherapy|Lasertherapy: The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics. The equipment will be infrared laser (904 nm), by point technique. Eight points of application will be standardized in the region of muscles of the posterolateral region of the hip. The time, dose and amounts of application points will be guided according to the dosimetry criteria of the World Association for Photobiomodulation Therapy.
48311461|NCT01928108|BEHAVIORAL|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
48311462|NCT01928108|BEHAVIORAL|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
48311463|NCT02615535|DEVICE|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
48311464|NCT02615535|DEVICE|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
48311465|NCT03165721|DRUG|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
48483394|NCT01430975|DRUG|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
47962826|NCT00714441|BEHAVIORAL|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
48113806|NCT06677450|OTHER|Exercise|Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
48113807|NCT05667454|DRUG|Atropine Ophthalmic 0.05%|Atropine 0.05% sulphate ophthalmic solution
48113808|NCT05667454|DRUG|Atropine Ophthalmic 0.5%|Atropine 0.5% sulphate ophthalmic solution
48113809|NCT03151655|BEHAVIORAL|MATTeRS Video|Narrative-based video intervention and accompanying workbook
48113810|NCT03151655|BEHAVIORAL|Didactic Video|Education only video
48311466|NCT01151995|OTHER|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
48311467|NCT01151995|OTHER|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
48311468|NCT04439838|DRUG|BI 1595043|BI 1595043
48483395|NCT02904668|OTHER|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (...), which were complemented by a problem-based session.
48483396|NCT04704349|RADIATION|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
48483397|NCT04491357|DRUG|Calcium Gluconate|Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy
48643159|NCT04236414|DRUG|Olaparib|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.
48643160|NCT04586231|DRUG|Belzutifan|Immediate-release 40 mg tablet
48311469|NCT04439838|DRUG|Placebo|Placebo
48311470|NCT05910294|OTHER|questionnaires|Vaginal Assessment Scale (VAS) \& Vulvar Assessment Scale (VuAS) Breast survivorship Tool (MSK Engage Symptom Assessment) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
48311471|NCT05910294|OTHER|moisturizers|Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
48311472|NCT05910294|OTHER|moisturizers|potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules
48483398|NCT04491357|DRUG|Normal saline|Normal saline within 4 hours of skin closure after total thyroidectomy
48311473|NCT00175084|BEHAVIORAL|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
48311474|NCT00538980|DRUG|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
48311475|NCT05414708|BEHAVIORAL|Art Therapy|During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
48311476|NCT01276665|PROCEDURE|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
48311477|NCT01276665|PROCEDURE|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
48311478|NCT00635947|OTHER|isotonic solution|1.5 L- during 2-4hours
48311479|NCT00635947|OTHER|water|1.5 L- during 2-4hours
48311480|NCT00635947|OTHER|water|200mL- during 2-4hours
48311481|NCT03539172|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
48311482|NCT00174707|DRUG|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
48643161|NCT04586231|DRUG|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
48643162|NCT04586231|DRUG|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
48643163|NCT01445509|DRUG|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
48113811|NCT06333717|DIETARY_SUPPLEMENT|Whole grain bread|Consumption of high-fibre bread as a dietary supplementation
48113812|NCT06333717|DIETARY_SUPPLEMENT|Control bread|Consumption of control bread as a dietary supplementation
48113813|NCT00533013|OTHER|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
48113814|NCT00533013|OTHER|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
48113815|NCT00527540|DRUG|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
48311483|NCT00174707|DRUG|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
48311484|NCT00174707|DRUG|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
48311485|NCT05818124|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
48311486|NCT05818124|DRUG|Placebo molnupiravir|Four placebo capsules matched to molnupiravir taken twice daily by mouth.
48311487|NCT05818124|DRUG|Placebo oseltamivir|Placebo capsule matched to oseltamivir taken twice daily by mouth.
48311488|NCT05818124|DRUG|Oseltamivir|One capsule of oseltamivir 75 mg taken twice daily by mouth.
48311489|NCT05818124|BIOLOGICAL|Influenza A Virus|Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
48311490|NCT04760353|DIETARY_SUPPLEMENT|Probiotic mixture (OMNi-BiOTiC STRESS)|OMNi-BiOTiC STRESS containing 9 human bacterial strains \[Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)\] and vitamin B (B2, B6, B12),
48311491|NCT04760353|OTHER|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~* Powder portion bags are suitable for participants with intolerance to yeasts or lactose~* Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
48311492|NCT05118204|DRUG|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
48311493|NCT05118204|DRUG|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
47962827|NCT01109797|BEHAVIORAL|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
47962828|NCT01109797|BEHAVIORAL|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
47962829|NCT01667029|DRUG|Sulfasalazine|
48311494|NCT05118204|BEHAVIORAL|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
48311495|NCT03260205|DRUG|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
47962830|NCT01667029|DRUG|placebo|
47962831|NCT01837108|DRUG|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
47962832|NCT01837108|DRUG|Placebo|
48113816|NCT06676917|DRUG|Datopotamab deruxtecan|Trophoblast cell surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) consisting of a humanized anti-TROP2 monoclonal antibody (MAAP-9001a), a GGFG tetra-peptide linker, and a Topo I inhibitor (MAAA-1181a, derived from exatecan). Upon binding to TROP2 on the cell surface, Dato-DXd internalizes into the cells and releases MAAA-1181a in the cytoplasm which inhibits cell replication and promotes cell apoptosis.
48113817|NCT03590080|DRUG|Methylprednisolone|
48311496|NCT03260205|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
48311497|NCT03260205|DRUG|SPD489|SPD489
48113818|NCT00178399|PROCEDURE|Stereotactic Body Radiation Therapy|
48113819|NCT02038868|DRUG|ASP4901|oral
48311498|NCT01153763|DRUG|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
48643164|NCT01445509|DRUG|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
48643165|NCT06559176|BIOLOGICAL|PM359|Single dose of PM359 administered autologously by intravenous (I.V.) infusion following myeloablative conditioning with busulfan
48643166|NCT06695247|OTHER|Exercise Training|Patients will be recommended to exercise 3 days/week, 20 minutes per session, for 12 weeks using personalized intervention determined by a consultation with a clinical exercise physiologist (CEP)
48643167|NCT05051735|DRUG|Paracetamol|Paracetamol 500 mg
48311499|NCT02336594|DRUG|RDEA3170 10 mg|
48311500|NCT02336594|DRUG|RDEA3170 2.5 mg|
48311501|NCT04659226|GENETIC|Blood sampling for microRNA testing|Blood samples will be collected and analyzed for the microRNA profile by means of microfluidic cards
48311502|NCT05949099|DRUG|Nirogacestat|Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
48643168|NCT05051735|DRUG|Placebo|Placebo
48643169|NCT06324357|DRUG|Zongertinib|Zongertinib
48643170|NCT06324357|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan
48643171|NCT06324357|DRUG|Trastuzumab emtansine|Trastuzumab emtansine
48113820|NCT02038868|DRUG|Tamsulosin|oral
48113821|NCT02038868|DRUG|Placebo|oral
48113822|NCT04891458|DRUG|Patients received lighter sedation with propofol after spinal anesthesia.|MOAA/S 0-2.
48113823|NCT04891458|DRUG|Patients received heavier sedation with propofol after spinal anesthesia|MOAA/S 3-5.
48113824|NCT04891458|DRUG|Patients received lighter sedation with dexmedetomidine after spinal anesthesia|MOAA/S 0-2.
48113825|NCT04891458|DRUG|Patients received heavier sedation with dexmedetomidine after spinal anesthesia.|MOAA/S 3-5.
48113826|NCT00648011|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
48113827|NCT00648011|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
48113828|NCT06048835|DEVICE|Blood sample|For each patient, a 15 ml EDTA blood sample will be collected at different time-points
48311503|NCT05949099|PROCEDURE|Cryoablation|Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
48643172|NCT06041828|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
48643173|NCT06041828|OTHER|Standard oral hygiene|Standard oral hygiene instructions
48643174|NCT06442228|DIAGNOSTIC_TEST|spermiogram test|"Approximately 7 mL of blood sample will be taken by the health personnel in a vacuum gel tube for hormonal and biochemical analyses. The blood samples will be centrifuged at 1000xg for 20 minutes by the researchers. In the next step, the supernatant portion will be separated and transferred to 3 mL ependorfs. Serum samples will be stored in the -800C deep freezer of our hospital until the time of analysis.~Sperm samples from individuals will be collected in our hospital in accordance with the protocol and the results will be reported."
48643175|NCT03833583|DEVICE|Soterix Medical mini-CT tDCS stimulator|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
48643176|NCT05761951|DRUG|DKN-01|Given by IV (vein)
48643177|NCT05761951|DRUG|Pembrolizumab|Given by IV (vein)
48311504|NCT01175278|PROCEDURE|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
48311505|NCT01175278|OTHER|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
48311506|NCT01318473|DEVICE|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
48311507|NCT04335266|DRUG|SHR2554|SHR2554
48643178|NCT02677051|DRUG|Sulforaphane|Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
48643179|NCT02677051|DRUG|Placebo|
48311508|NCT06162260|PROCEDURE|ICU readmission|Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
48311509|NCT03637699|BEHAVIORAL|Positive Psychology|5-week positive psychology intervention
48311510|NCT00777491|DRUG|induction cisplatin|15 mg/m\^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
48311511|NCT00777491|DRUG|induction 5-fluorouracil|400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
48311512|NCT00777491|DRUG|induction gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
48311513|NCT00777491|RADIATION|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
48113829|NCT04679571|BIOLOGICAL|Albumin|Patients with serum albumin \<3 g/L with recurrent ascites - Will receive 20 % albumin at 60 grams/week until target serum albumin of 3.0 g/L is achieved following this patients would get 40 grams of albumin every week until ascites resolution or serum albumin \>3.5 g/L. Patients who achieve this target will continue with 20 gm/week until patient has complete resolution of ascites and serum albumin \>3.5 gm/L this patients would receive albumin 20 gms once every 2 weeks.
48311514|NCT00777491|RADIATION|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
48311515|NCT00777491|RADIATION|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
48311516|NCT00777491|RADIATION|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
48311517|NCT00777491|DRUG|consolidation gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
48311518|NCT00777491|DRUG|consolidation 5-fluorouracil|400 mg/m\^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
48311519|NCT00777491|DRUG|consolidation cisplatin|15 mg/m\^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
48311520|NCT00777491|PROCEDURE|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
48311521|NCT00777491|PROCEDURE|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
48311522|NCT00777491|DRUG|adjuvant gemcitabine|1000 mg/m\^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
48643180|NCT03734536|DEVICE|REGENETEN™ Bioinductive Implant|The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
48643181|NCT03734536|DEVICE|Arthroscopic repair of the high-grade (>50%) partial-thickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
47962833|NCT04784377|OTHER|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
48113830|NCT04679571|DRUG|Standard Medical Treatment|"Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year."
47962834|NCT04784377|OTHER|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
47962835|NCT04784377|OTHER|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
47962836|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
48311523|NCT00777491|DRUG|adjuvant cisplatin|70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
48311524|NCT06312449|OTHER|The side-lying position with the peanut ball during the second stage of labor.|"The usage of the peanut ball is divided into two stages:~Stage one: The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The peanut ball is placed between the legs, allowing for leg separation. The parturient can choose to lie on either the left or right side according to preference.~Stage two: When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides. The peanut ball is then positioned between the legs with the knees bent together, for pushing"
48311525|NCT06312449|OTHER|During the second stage, the patient is placed in a lateral position|The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The parturient can choose to lie on either the left or right side according to preference.When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides, for pushing
48311526|NCT04247750|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
48311527|NCT02125006|BEHAVIORAL|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
48311528|NCT05054673|OTHER|universal adhesive|PALFIQUE universal adhesive
48311529|NCT05054673|OTHER|universal adhesive|3M™ ESPE™ single bond Universal Adhesive
48643182|NCT03006315|DEVICE|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
48643183|NCT03006315|BEHAVIORAL|Mobile Health quality of life assessements|
47962837|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
48113831|NCT03938428|OTHER|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
48113832|NCT01518478|DRUG|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
48643184|NCT04600544|OTHER|Non-interventional|Translational, observational study
48643185|NCT02268851|DRUG|TGR-1202|Capsules taken whole daily with water and with food
47962838|NCT02138500|DRUG|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
47962839|NCT04633018|DEVICE|AsthmaMD mobile application|asthma management app with Spanish-language user interface
47962840|NCT04633018|OTHER|Usual care|Asthma management without the app
47962841|NCT04560660|DRUG|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
47962842|NCT04560660|DRUG|Midazolam|FDA approved sedative medication with dissociative effects.
48311530|NCT04628013|DEVICE|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
47962843|NCT02126995|DRUG|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
48311531|NCT04086563|OTHER|Action observation|look at a clip of a hand doing neurodynamic exercises.
48311532|NCT04086563|OTHER|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
48311533|NCT04086563|OTHER|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
48311534|NCT04086563|OTHER|Strength|Execute a short strength training for the dominant hand
48311535|NCT03235544|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
48311536|NCT05932511|DRUG|30% ascorbic acid in DMSO|see above
48311537|NCT04582734|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy intervention
48311538|NCT06210191|PROCEDURE|Intramedullary headless screw fixation|fixation of fractures of metacarpals and phalanges by intramedullary headless screws
48643186|NCT02268851|DRUG|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
48643187|NCT06695780|OTHER|survey on eating behavior, physical activity and health status|Participatory research: participants will carry out surveys, functional tests and urine and blood sampling completely independently
48643188|NCT06690944|OTHER|Proprioceptive Neuromuscular Facilitation|The following basic principles and procedures were emphasized when applying the techniques: manual contact, resistance, approximation, verbal commands, and therapist's body mechanics. During stages 1 and 2 of the intervention, the amount of PNF optimal resistance used was necessary to maintain a stable and safe position, with good body alignment, in a manner that produced coordinated movements to generate appropriate motor learning.
47962844|NCT06362577|DIAGNOSTIC_TEST|EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG|Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery
47962845|NCT02043171|DIETARY_SUPPLEMENT|Placebo|A Placebo comparator
47962846|NCT02043171|DRUG|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
47962847|NCT02043171|BEHAVIORAL|Non-Exercise|This group will not participate in 3 times per week strength training
48311539|NCT04985799|DEVICE|Gynecare TVT Exact Continence System|Participants will have placement of Gynecare TVT Exact sling.
47962848|NCT02043171|BEHAVIORAL|Exercise|This group will participate in a supervised 3 times per week strength training program
47962849|NCT01801878|BIOLOGICAL|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
47962850|NCT01801878|BIOLOGICAL|Normal saline|Normal saline inject to the half of irradiated breast
47962851|NCT05536050|OTHER|Migraine diary and Questionnaires|Patients who already have a prescription for low-dose naltrexone will be administered questionnaires twice during the trial. Additionally, patients will maintain migraine diary for the duration of the trial.
47962852|NCT00202800|DRUG|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
47962853|NCT00002554|DRUG|busulfan|
47962854|NCT00002554|DRUG|cyclophosphamide|
47962855|NCT00002554|DRUG|methotrexate|
47962856|NCT00002554|PROCEDURE|allogeneic bone marrow transplantation|
47962857|NCT00002554|RADIATION|radioimmunotherapy|
47962858|NCT04092400|DEVICE|Micro-invasive Glaucoma Surgical Devices|Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
47962859|NCT05792709|OTHER|Oral Motor Therapy|In Traditional therapy we will give cognitive and articulation therapy to the patients.
47962860|NCT01826877|BIOLOGICAL|AdGMCAIX-transduced autologous dendritic cells|Given ID
47962861|NCT01826877|BIOLOGICAL|therapeutic autologous dendritic cells|Given ID
48311540|NCT04985799|DEVICE|Neomedic KIM (Knotless Incontinence Mesh)|Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
48311541|NCT04358042|OTHER|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
48643189|NCT06690944|OTHER|Physical exercise without proprioceptive neuromuscular facilitation control group|The physical exercise without proprioceptive neuromuscular facilitation control group (CG) intervention consisted of the same activities carried out in the proprioceptive neuromuscular facilitation (PNF) group during Stages 1 and 2, during the same amount of minutes, sessions, and weeks; however, CG intervention did not include specific techniques and basic principles (i.e. approximation and optimal resistance) and procedures of the PNF concept. The activities were instructed and supervised by a trained professional through verbal command. The professional was at stand-by assistant position to prevent accidents.
48113833|NCT02886221|PROCEDURE|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
48483399|NCT05893511|PROCEDURE|Endoscopic ultrasound-guided gallbladder drainage|Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
48643190|NCT02370147|BEHAVIORAL|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
48643191|NCT02370147|BEHAVIORAL|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
48483400|NCT05893511|DRUG|Antibiotics first|Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
48643192|NCT05936138|DRUG|LY3502970|Administered orally.
47962862|NCT01826877|OTHER|laboratory biomarker analysis|Correlative studies
47962863|NCT06220565|DEVICE|"sensor and wearable device Graded Exercise"|"The program plans to use rational mechanism to provide safe and targeted exercise interventions to patients at different stages of their lives through three aspects: education, motivation and feedback. Through real-time collection of knee function parameters, real-time feedback on the effect of exercise intervention, and tracking the changes in the functional status of patients' knee joints. On the basis of improving knee function, we further improve patients' compliance with exercise intervention.~Considering the community scenario, we plan to use sensors and wearable devices to realize the function of the knee joint on the basis of the existing technology. wearable devices to realize the digital assessment of knee function to reduce patient's time and cost and improve efficiency. At the same time, this digital assessment will provide a basis for decision-making for patient self-management."
47962864|NCT06220565|OTHER|exercise|exercise
47962865|NCT06220565|OTHER|Educational Manual|Educational Manual
47962866|NCT04847856|BEHAVIORAL|Diabetic care Information, education, and communication intervention will be delivered by relevant and trained health animators working in chronic care clinic.|The training sessions and the IEC materials were adapted from John Hopkins University studies on self-care for diabetic patients.
47962867|NCT04173585|DRUG|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
48113834|NCT03481608|OTHER|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
48113835|NCT03481608|OTHER|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
48113836|NCT01787773|DEVICE|Veniti Inferior Vena Cava Filter|
48483401|NCT04734834|DIETARY_SUPPLEMENT|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
48483402|NCT04086641|DEVICE|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
48311542|NCT04358042|OTHER|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
47962868|NCT04173585|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
47962869|NCT03680690|PROCEDURE|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
47962870|NCT00042900|DRUG|pyroxamide|
47962871|NCT02718157|DEVICE|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
47962872|NCT06001645|DIAGNOSTIC_TEST|Blood and bronchoalveolar fluid collection and analysis|Blood and bronchoalveolar lavage fluid will be collected within 12 hours after intubation. Blood samples will be centrifuged, and the serum immediately stored at less than 70° C. The following biomarkers will be analysed in the serum and bronchoalveolar lavage fluid: Interleukin-8 (IL-8), Interleukin (IL)-6, IL-1Ra, IL-18, interferon (IFN ), Angiopoietin-2 (Ang-2), Tumour Necrosis Factor receptor-1 (TNFr1), Plasminogen Activator Inhibitor-1(PAI-1), Receptor for Advanced Glycation Endproducts (RAGE), Intercellular adhesion molecule-1 (ICAM-1), Surfactant Protein D (SPD), protein C, Von Willebrand Factor (VWF), CXCL10/CXCR3, and metalloproteases (MMP9, MMP10). Blood samples obtained from the patients will be placed in specimen tubes containing heparin, centrifuged at 1500 G for 10 minutes, and then the plasma will be aspirated and stored at -70° C. Bronchoalveolar lavage fluid will be centrifuged at 1500 G for 10 minutes to remove cellular contents and stored at -70° C.
47962873|NCT06001645|DIAGNOSTIC_TEST|Chest CT scan|Computed Tomography Scan per normal clinical practice
47962874|NCT00958100|DRUG|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
47962875|NCT00958100|DRUG|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
47962876|NCT00958100|DRUG|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
47962877|NCT04458597|RADIATION|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
47962878|NCT02019693|DRUG|INC280|Supplied by Novartis as film-coated tablet for oral use.
47962879|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
47962880|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
47962881|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
47962882|NCT01234285|DRUG|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
47962883|NCT02308605|DEVICE|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
47962884|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
48113837|NCT01240837|OTHER|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
48113838|NCT01240837|OTHER|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
48113839|NCT01240837|OTHER|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
48113840|NCT01325233|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
48113841|NCT01325233|DRUG|Placebo|500 ml normal saline, tiw, 2 weeks
48113842|NCT02534311|DRUG|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
48113843|NCT06259409|DEVICE|Regenn® Negative Pressure Therapy System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
48483403|NCT04086641|DEVICE|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
48483404|NCT02329119|OTHER|electrophysiological recordings|
48483405|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
48483406|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
47962885|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
47962886|NCT05845216|DEVICE|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
47962887|NCT05845216|DEVICE|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
47962888|NCT06101758|DIAGNOSTIC_TEST|Handgrip strength test|A handgrip strength test using a hydraulic hand dynamometer will be performed
47962889|NCT06101758|DIAGNOSTIC_TEST|total body Dual Energy X-Ray Absorptiometry (DXA)|A total body Dual Energy X-Ray Absorptiometry (DXA) to estimate muscle mass will be performed
47962890|NCT06101758|DIAGNOSTIC_TEST|Muscle ultrasound|A muscular ultrasound of abdominal muscles, forearm muscles, quadriceps and gastrocnemius will be performed
47962891|NCT01906632|BIOLOGICAL|DC-CIK Immunotherapy|
47962892|NCT02230800|DRUG|Tocovid SupraBio plus pentoxifylline|
47962893|NCT02230800|DRUG|Matching placebos|
47962894|NCT00791570|BIOLOGICAL|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
47962895|NCT05509270|BEHAVIORAL|Letter|Mailed letter about flu vaccination
47962896|NCT05509270|BEHAVIORAL|Patient portal|Patient portal message about flu vaccination
47962897|NCT05509270|BEHAVIORAL|SMS|SMS about flu vaccination
47962898|NCT01655771|DRUG|TD-1211 Dose 1|
47962899|NCT01655771|DRUG|TD-1211 Dose 2|
47962900|NCT01530360|DEVICE|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
47962901|NCT04123600|DEVICE|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
47962902|NCT04994600|OTHER|Reduces number of question items|The number of alarm fatigue questions are reduced to about 15 in the CFA_2nd_phase group.
47962903|NCT00383461|BEHAVIORAL|smoking cessation intervention|
47962904|NCT00383461|OTHER|counseling intervention|
47962905|NCT01419691|DRUG|auranofin|6 mg twice a day for a total of 12 mg total daily dose
47962906|NCT01844128|DIETARY_SUPPLEMENT|weight loss|
47962907|NCT02983825|DEVICE|Continuous positive airway pressure (CPAP); level changes|as per arm description
47962908|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
47962909|NCT01890369|DIETARY_SUPPLEMENT|3g Leucine|Dissolved in 250ml water.
47962910|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
48113844|NCT06259409|DEVICE|Prevena™ Incision Management System|Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
48113845|NCT03581357|BEHAVIORAL|Mobile Mindfulness Meditation|It is hypothesized that participants who are randomized in the app condition will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
47962911|NCT00004779|GENETIC|Ad5-CB-CFTR|
48113846|NCT03581357|BEHAVIORAL|Mindfulness Coach|It is hypothesized that participants who are randomized into treatment condition will have significantly less CIPN, anxiety, and fatigue, and improved anxiety, in comparison to their counterparts in the wait-list control condition.
48113847|NCT02502344|BEHAVIORAL|healthy lifestyle|food control and intensive exercise to lose weight
48113848|NCT02502344|DRUG|Metformin|use metformin to reduce insulin resistance
47962912|NCT06107400|GENETIC|RM-004|Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.
47962913|NCT04646837|DRUG|Durvalumab|Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months
47962914|NCT04646837|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
47962915|NCT04646837|DRUG|Carboplatin/Cisplatin|Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
47962916|NCT02347280|PROCEDURE|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
47962917|NCT02347280|PROCEDURE|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
47962918|NCT04510012|OTHER|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
47962919|NCT02911714|DRUG|Lumason Contrast-Enhanced Ultrasound|In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
47962920|NCT02198066|OTHER|Dry Sterile Dressing|Described in Arm Description.
47962921|NCT02198066|OTHER|Metallic Silver Dressing|Described in Arm Description.
47962922|NCT02198066|OTHER|Ionic Silver Dressing|Described in Arm Description.
47962923|NCT01901120|DRUG|Betanis|oral
47962924|NCT04454294|OTHER|Control|"Common Process Steps:~1. Informed consent forms will be signed by those who wish to take part in the research.~2. The form in which individual characteristics are questioned will be filled.~3. Hands will be washed, gloves will be worn.~4. Before the procedure, body temperature, heart rate, respiratory rate, blood pressure, oxygen saturation and bleeding amount will be recorded.~5. Drains will be kept parallel to the ground and upright.~6. Drainage hoses will not be bent and in-bed position will be provided in accordance with gravity.~7. It will be ensured that all connections between the chest tubes and drainage unit are tight and secure.~8. Dressings of the chest and mediastinum drains will be fixed on the patient's skin, so as not to interfere with drainage.~9. To prevent the tubes from coming out, they will be fixed to the patient bed.~Vital signs, Sp02 and bleeding amount will be recorded every hour for 6 hours after surgery"
48113849|NCT04693130|BEHAVIORAL|Mindfulness-based prenatal education|Mindfulness-based prenatal education involves mindfulness breathing and other skills with mindfulness meditations.
48113850|NCT04693130|BEHAVIORAL|Hospital-based antenatal care|Hospital-based antenatal care involves all aspects of pregnancy, childbirth and postpartum.
48483407|NCT01060475|DRUG|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
48311543|NCT04358042|OTHER|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
48311544|NCT04358042|OTHER|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
48311545|NCT02742870|OTHER|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
48311546|NCT02044159|DRUG|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
48311547|NCT02044159|OTHER|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
48311548|NCT00000309|DRUG|Risperidone|
47962925|NCT04454294|OTHER|Experimental Group (Absorption Group)|"1. Common process steps~2. Appropriate negative pressure monitoring system of the patient, who is admitted to the intensive care unit with underwater drainage system, will be established.~   * The suction control room combined with the vacuum regulator will be filled with sterile distilled water up to the specified level (20 cm H2O).~  * From the vacuum regulator, the drain or drains will be connected tightly and by preventing the crimping, from the aspirator receptor hoses.~3. Suction will begin with a low level and gradually increase the suction until a slight bubble is noticed in the suction control room.~4. Suction pressure will be maintained between 5 and 15 kPa (kilopascals) or 10-20 cm H20.~5. The application will continue without interruption until the patient's drain need and the doctor's request is ended.~6. During the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
48311549|NCT00657631|BEHAVIORAL|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, \& Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl \& Wilson, 1999)."
48311550|NCT00825955|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
48311551|NCT00825955|OTHER|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
48311552|NCT00825955|PROCEDURE|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
48311553|NCT04279912|DEVICE|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
48311554|NCT03174717|BEHAVIORAL|Music performance|residents of LTC will learn and perform songs with musicians from the community
48311555|NCT04042610|BEHAVIORAL|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
47962926|NCT04454294|OTHER|Experimental Group (Milking Group)|"1. Common process steps will be applied~2. Operation will start from the area near the drain entrance point~3. Latex tube will be folded into 12 cm long pieces and will be gripped with two hands~4. The procedure will be repeated 3 times by compressing the parts gripped by the nurse hand.~5. This process will be repeated in the distal part.~6. After the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
47962927|NCT01941875|DRUG|Progesterone Effervescent Vaginal Tablets|Experimental
47962928|NCT00903799|DEVICE|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
47962929|NCT03240965|DIAGNOSTIC_TEST|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
47962930|NCT03240965|OTHER|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
47962931|NCT03240965|DIAGNOSTIC_TEST|Taste-/smell-test|Taste-/smell-test
47962932|NCT03240965|DIAGNOSTIC_TEST|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
47962933|NCT04896541|BIOLOGICAL|AZD7442 300 mg IM(male)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
47962934|NCT04896541|BIOLOGICAL|AZD7442 600 mg IM (male)|Single dose of 600 mg of AZD7442 or saline placebo on Day 1.
47962935|NCT04896541|BIOLOGICAL|AZD7442 300 mg IV (male and female)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
47962936|NCT04896541|BIOLOGICAL|AZD7442 1000 mg IV (male)|Single dose 1000 mg of AZD7442 or saline placebo on Day 1.
47962937|NCT03056404|OTHER|additional blood sample|
47962938|NCT03056404|OTHER|respiratory functional exploration|
47962939|NCT00398580|DRUG|Nanomilled testosterone|
47962940|NCT00398580|DRUG|Nanomilled dutasteride|
47962941|NCT00398580|DRUG|commercially available dutasteride|
48311556|NCT02358330|OTHER|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
48311557|NCT04186000|BIOLOGICAL|Ad26.ZEBOV vaccine|The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.
48311558|NCT03803852|DEVICE|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric and Rayner RayOne EMV toric IOL on the axis according to the steep meridian of the cornea"
48311559|NCT04226859|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
48483408|NCT01060475|DRUG|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
48483409|NCT05612282|DIAGNOSTIC_TEST|body composition analysis|A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
48483410|NCT05612282|OTHER|anthropometric measurements|An assessment of the status of nutrition based on anthropometric measurements was carried out.
48483411|NCT05612282|OTHER|Interview questionnaire|An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
48643193|NCT05186077|OTHER|Magnetic Resonance Imaging|Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
48643194|NCT05186077|OTHER|Psychiatric testing|Subjects will be evaluated using psychiatric assessments
47962942|NCT00332163|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
47962943|NCT00332163|DRUG|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
47962944|NCT00332163|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
47962945|NCT00332163|DRUG|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
48113851|NCT05297864|DRUG|Niraparib|The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
48113852|NCT04838158|DIAGNOSTIC_TEST|Isokinetic measurements|Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
48113853|NCT05817630|OTHER|Silicone oil Tamponade for Retinal Detachment|eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
48311560|NCT03442413|DRUG|2-[18F]-FA PET/CT|2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
48483412|NCT05612282|DIAGNOSTIC_TEST|biochemical parameters|The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
48483413|NCT05612282|DIAGNOSTIC_TEST|cardiopulmonary fitness test|Cardiopulmonary fitness was assessed using the Modified Bruce protocol
48113854|NCT01885806|DEVICE|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
48113855|NCT01885806|DEVICE|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
48113856|NCT00485940|DRUG|Prucalopride|2 mg o.d.
48113857|NCT00485940|OTHER|Placebo|Placebo o.d.
48113858|NCT00485940|DRUG|Prucalopride|4 mg o.d.
48311561|NCT03442413|DRUG|I.V. Nicotine|Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
48311562|NCT02197429|OTHER|Acupuncture|
48483414|NCT05612282|OTHER|nutritional interview|A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
48483415|NCT00335335|DRUG|iodixanol|
48483416|NCT00802282|DRUG|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
48483417|NCT00802282|BEHAVIORAL|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
48643195|NCT05186077|OTHER|Eye-Tracking|Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
48311563|NCT01239186|OTHER|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
48483418|NCT00802282|BEHAVIORAL|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
48483419|NCT04851275|BEHAVIORAL|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
48483420|NCT04851275|BEHAVIORAL|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
48311564|NCT04263337|DRUG|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
48643196|NCT05186077|OTHER|Neuropsychology Evaluation|The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
48311565|NCT04263337|DRUG|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
47962946|NCT00332163|DRUG|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
47962947|NCT03147560|BIOLOGICAL|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
48311566|NCT04263337|DRUG|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
48311567|NCT01102153|DEVICE|Coolgard|invasive cooling via femoral ICY-catheter
48113859|NCT05865938|DEVICE|PASCAL vs. MitraClip|"transcatheter mitral valve repair of the mitral valve (M-TEER) using the Edwards PASCAL Transcatheter Valve Repair System or the Abbott MitraClip in patients with severe and symptomatic degenerative or functional mitral regurgitation (FMR).~The type of device system used was not randomized but was determined by the operational structuring of the mitral valve program such that patients were scheduled for the next available implantation date with weekly alternating time slots for MitraClip device and PASCAL device."
48311568|NCT01102153|DEVICE|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
48311569|NCT01982604|DRUG|TI-Inhalation Powder A|Inhaled Insulin
48311570|NCT01982604|DRUG|TI-Inhalation Powder B|Inhaled Insulin
48311571|NCT00158548|DRUG|SP, chloroquine, amodiaquine, primaquine, artesunate|
48311572|NCT00443378|BEHAVIORAL|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
48643197|NCT05012618|DRUG|LUNA18|LUNA18 Capsule
48643198|NCT05012618|DRUG|Cetuximab|Cetuximab as a IV infusion
48643199|NCT05478018|BEHAVIORAL|High Intensity Interval Training|Supervised high-intensity interval training for 12 weeks three times per week
48643200|NCT04062565|DRUG|Treprostinil Injectable Product|Injection
48643201|NCT04062565|DRUG|Riociguat Pill|Tablet
48643202|NCT04572243|DRUG|Placebo|Placebo matching to lorcaserin oral tablet, administered as oral suspension.
48643203|NCT04572243|DRUG|Lorcaserin|Lorcaserin oral tablet, administered as oral suspension.
48643204|NCT03258593|DRUG|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
48643205|NCT03258593|DRUG|Vicineum|Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
48643206|NCT03258593|DRUG|Acetaminophen|Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
47962948|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
47962949|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
48311573|NCT00376597|OTHER|quality of life assessment|Ancillary studies
48643207|NCT03258593|DRUG|Antihistamine|Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
48643208|NCT03258593|PROCEDURE|Bladder Biopsy|Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
48643209|NCT03258593|PROCEDURE|TURBT|Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
48643210|NCT03258593|PROCEDURE|Cystoscopy|Urine cytology at screening and every 3 months before each cystoscopy per schema.
48643211|NCT03258593|DIAGNOSTIC_TEST|Urine cytology|Urine cytology at baseline and every 3 months before each cystoscopy per schema.
48643212|NCT03258593|DIAGNOSTIC_TEST|Electrocardiogram|Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
48643213|NCT03258593|DIAGNOSTIC_TEST|CT|Computed tomography (CT) at screening and every 12 months while on study.
47962950|NCT00578708|DEVICE|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
47962951|NCT04561466|DRUG|Béfizal|600 mf befizal a day for one year
47962952|NCT00007683|DRUG|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
47962953|NCT00007683|DRUG|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
48483421|NCT06196593|DEVICE|AcrySof™ IQ Vivity™ Toric intraocular lens|Uneventful phacoemulsification and implantation of IOL
47962954|NCT00007683|DRUG|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
48113860|NCT03411291|DEVICE|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
48113861|NCT04093908|OTHER|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
47962955|NCT02694965|OTHER|observational|
47962956|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
47962957|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
47962958|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
47962959|NCT02400333|DRUG|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
48113862|NCT05276973|PROCEDURE|Biopsy|Undergo biopsy
48113863|NCT05276973|DRUG|Carboplatin|Given IV
48113864|NCT05276973|DRUG|Ipatasertib|Given PO
48113865|NCT05276973|DRUG|Paclitaxel|Given IV
48483422|NCT06615882|DEVICE|stent-angioplasty & nimodipine infusion (During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused)|"I. Procedure \& Intervention~1. Assess the presence and degree of cerebral vasospasm of the target vessel through cerebral angiography before the procedure.~2. Solitaire-X stent types are selected~3. During the stent-angioplasty, IA nimodipine was also infused.~4. Retrieve Solitaire-X after maintaining deployment for 3 minutes.~5. Additional procedures are determined through immediate post-procedure and 15-minute delayed cerebral angiography."
48483423|NCT02544542|DEVICE|Rectum cooling system|
48483424|NCT02544542|DEVICE|Hyper-hypothermia blanket|
48483425|NCT02170350|PROCEDURE|Meditation therapy|Use brief mindful meditation practice
48483426|NCT02170350|OTHER|Quality-of-life assessment|Ancillary studies
48483427|NCT02170350|OTHER|Questionnaire administration|Ancillary studies
47962960|NCT04312204|DRUG|Sintilimab combined with Gemcitabine and Carboplatin|"The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months."
47962961|NCT04669652|DEVICE|Piezo-ICSI|During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
47962962|NCT02348905|DRUG|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
47962963|NCT02348905|DRUG|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
47962964|NCT03438747|DEVICE|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
47962965|NCT03438747|OTHER|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
48113866|NCT04820361|DRUG|Cannabis sativa L., folium cum flore|Muscle Relaxation
48113867|NCT04820361|DRUG|Placebo|Muscle Relaxation
48113868|NCT03840486|DEVICE|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
48113869|NCT03840486|DEVICE|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 50% FiO2 for 3 minutes, 75% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
48113870|NCT03840486|DEVICE|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
48113871|NCT03840486|DRUG|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
48113872|NCT03840486|DRUG|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 50% FiO2, 75% FiO2 or 100% FiO2 for 3 minutes each.
48113873|NCT04200365|DRUG|Itacitinib|Itacitinib will be administered orally once daily for up to 24 months.
48113874|NCT04612348|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound to measure gastric contents.
48113875|NCT06441539|DEVICE|Bingo® Paclitaxel coated balloon|Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon
48483428|NCT03861663|DEVICE|Ultrasound|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
48483429|NCT05322629|BEHAVIORAL|PrEP adherence biofeedback|Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .
48483430|NCT05322629|BEHAVIORAL|Standard of care counseling|Adherence counseling based on self report and following national guidelines
48483431|NCT02948920|DRUG|Ephedrine|9 mg of ephedrine (3 ml)
48643214|NCT03258593|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
48311574|NCT00376597|OTHER|educational intervention|Receive lymphedema educational materials
47962966|NCT04361318|COMBINATION_PRODUCT|Hydroxychloroquine plus Nitazoxanide|Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients
48113876|NCT06441539|DEVICE|Xience® Alpine Everolimus Eluting Coronary Stent System|Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
48113877|NCT01827787|DRUG|Eribulin|
48311575|NCT00376597|PROCEDURE|Physical therapy|Complete physical therapy-focused intervention
48311576|NCT01869114|DRUG|Sirolimus|Given PO
48311577|NCT01869114|DRUG|Azacitidine|Given IV
48311578|NCT00708604|PROCEDURE|Islet Transplantation|Islet Transplantation
48311579|NCT00708604|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
48311580|NCT03108144|BEHAVIORAL|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
48311581|NCT02843334|BIOLOGICAL|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
48311582|NCT01806077|DRUG|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
48311583|NCT00543569|DRUG|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
48311584|NCT00543569|DRUG|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
47962967|NCT04361318|OTHER|Standard care|"Oxygen administered via ventilator. In addition, antipyretic paracetamol may be added if necessary"
48113878|NCT03897127|DRUG|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~* Patients age 18-60 years~  o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~* Patients age \>60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
48113879|NCT03897127|DRUG|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
48311585|NCT00543569|DRUG|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
48311586|NCT00543569|DRUG|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
48311587|NCT00543569|DRUG|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
48311588|NCT03677687|BEHAVIORAL|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
48311589|NCT05681195|DRUG|Pemetrexed|Participants will receive 900 mg/m\^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.
48311590|NCT05681195|DRUG|Zanubrutinib|"Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression."
48311591|NCT05681195|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols
48311592|NCT05681195|RADIATION|Whole Brain Radiation Therapy (WBRT)|WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
48311593|NCT03392753|PROCEDURE|Mechanochemical ablation|Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
48311594|NCT03392753|PROCEDURE|Cyanoacrylate adhesive|Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
48311595|NCT05941949|DIETARY_SUPPLEMENT|Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E|2 softgels per day
47962968|NCT00690105|DRUG|tacrolimus 0.1%|ointment
47962969|NCT00690105|DRUG|fluticasone 0.005 %|ointment
47962970|NCT06251648|DRUG|Lenalidomide|Patients exposed to LEN
47962971|NCT01190345|DRUG|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
48311596|NCT05941949|DIETARY_SUPPLEMENT|Placebo|2 softgels per day
48483432|NCT02948920|DRUG|NSS|3 ml of normal saline
48643215|NCT06011551|DEVICE|The ReGelTec HYDRAFIL™ System|The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
48643216|NCT06011551|OTHER|Conservative Care Management|Conservative care management (including physical therapy and/or pain medication)
48113880|NCT03897127|DRUG|CPX-351|"Induction 1:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3,5~Induction 2:~o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine \[100 U/m²\] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine \[65 U/m²\] i.v. (90 min) d1,3"
48643217|NCT05607849|OTHER|The decidons ensemble (let's decide together) leaflet and the discutons-mammo.fr (let's talk about breast cancer screening) online tool.|"The leaflet will include a link to access the discutons-mammo.fr DA aid tool, and will inform women about shared decision-making.~The GPs of women who are sent the leaflet will also be sent a letter encouraging shared decision-making. This material will be sent 3 months after women have received their breast cancer screening invitation letter.~Data related to primary and secondary objectives will be collected by questionnaire from the 2 groups. The questionnaire will be sent 2 months after participants are informed about the tool."
47962972|NCT01190345|DRUG|no bevacizumab|no bevacizumab
47962973|NCT01999179|DRUG|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
48113881|NCT01512810|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
47962974|NCT05833074|BEHAVIORAL|Couples HIV testing and counseling|Couples HIV testing follows a CDC published protocol for delivery of HIV testing to relationship partners. HIV test results are obtained from Oraquick (FDA approved for at home HIV testing)
47962975|NCT05833074|BEHAVIORAL|Individual HIV testing and counseling|Individual HIV testing and counseling uses a counseling protocol based on the standard of care for routine HIV pre- and post-test counseling. HIV test results are obtained from Oraquick (FDA approved for at home testing)
47962976|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
47962977|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
47962978|NCT01317030|OTHER|Non-Contact Lens Wear|No intervention
47962979|NCT00791856|DRUG|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
47962980|NCT00791856|DRUG|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
47962981|NCT06558513|DRUG|XNW5004 tablets|XNW5004 an EZH2 inhibitor, BID, administered in continuous
47962982|NCT02046161|PROCEDURE|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
47962983|NCT01513343|BEHAVIORAL|Parent and child groups focused on self-regulation of eating|
47962984|NCT03150017|OTHER|SPIRE|Online pain management programme.
47962985|NCT05754931|OTHER|Deep neck flexors training + Conventional therapy|Hold for 10 sec and repeated 10 times.Patients will be treated 3 times a week for 4 consecutive weeks
48113882|NCT05038228|DRUG|Apixaban|Anticoagulant
48113883|NCT05038228|DRUG|Rivaroxaban|Anticoagulant
48483433|NCT04555278|DEVICE|Active rTMS|"A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes."
47962986|NCT05754931|OTHER|Muscles energy techniques + conventional therapy|position of patient is in maximal comfort and lengthening After engaging the barrier use of an isometric contraction Feel the release and lengthen the muscle repeated for 4 time per session Patients will be treated 3 times a week for 4 consecutive weeks
47962987|NCT05723978|PROCEDURE|Selective extended dissection of pancreaticoduodenectomy|An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
48483434|NCT04555278|DEVICE|Sham rTMS|A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).
48483435|NCT04555278|OTHER|Motor Control Exercises|The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
48483436|NCT04421092|PROCEDURE|Superior laryngeal nerve block|Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
48483437|NCT04421092|PROCEDURE|Injection of placebo (saline)|Superior laryngeal nerve block using 1mL of saline as the injection.
48483438|NCT04421092|PROCEDURE|Injection of steroid-lidocaine mixture|Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
48643218|NCT03956108|DIAGNOSTIC_TEST|MRI+targeted biopsies+Stockholm3-test|MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
48643219|NCT03956108|DIAGNOSTIC_TEST|PSA + systematic biopsies|Systematic biopsies and PSA test
48643220|NCT03340935|OTHER|Fasting mimicking diet|Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
48311597|NCT02581319|PROCEDURE|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
48311598|NCT03221322|BEHAVIORAL|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
48311599|NCT04302610|DEVICE|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
48311600|NCT04302610|DEVICE|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
48311601|NCT05686473|BEHAVIORAL|Program of psychoeducation of parents and professionals|"The program consists of a standardized manual-based treatment package as an easily accessible treatment tool for use by professionals in the specialist health services, who have treatment responsibilities for children diagnosed with FASD in Norway.~The intervention program will last for about 2 months and includes eight sessions, including six digitally based, interactive psychoeducational sessions.~Topics will be:~1. General information about FASD~2. Intervention strategies in kindergartens/schools for children with FASD~3. Families living with FASD - activities of daily living~4. Self-regulatory deficits - how to cope~5. Executive functions in daily life~6. Social development in children with FASD~7. Guidance in social settings~8. Challenging behavior - what can be done"
48311602|NCT00059722|DRUG|ZD6474|
48311603|NCT00059722|DRUG|Placebo|
48311604|NCT00059722|DRUG|ZD1839|
48311605|NCT05009459|BEHAVIORAL|eVIS|To facilitate individualized physical activity levels within the Swedish IPRP setting, an eVISualisation (eVIS) of physical activity and pain intervention has been systematically developed. eVIS is designed to target facilitating mechanisms for behavior change, such as outcome expectations, self-monitoring, self-evaluation, and self-efficacy, which are theoretically framed by the Social Cognitive Theory by Bandura. In eVIS, objectively measured physical activity tracking using a wrist-worn activity tracker (Fitbit Versa 2) is combined with a daily activity goal (steps/day) and daily patient reports of known important clinical outcome assessments: pain intensity and its affect on daily activities30-34 and pharmaceutical consumption. Data is collected and visualized in a purpose-developed web application, Pin And TRaining ON-line (PATRON), which can be used by the patient and the IPRP-team to follow and adjust individual physical activity levels.
48311606|NCT05226819|DRUG|PPI quadruple therapy|Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.
48483439|NCT04888676|PROCEDURE|Class II Restoration|A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
48483440|NCT05019482|BEHAVIORAL|University-based intervention to promote PA and reduce ST|"This intervention was realized with all college student and involved:~1. Design-based innovative workshops during the first week;~2. 8-weeks program of Physical Activity constructed by users~3. Information session focusing on the promotion of active behaviors~4. Feedback provided to the users with an individualized report"
48483441|NCT03497832|OTHER|magnetic resonance spectroscopy (MRI)|Each healthy subject will get 3 MRI examinations at 7:30, 13:30 and 18:00. Each MRI scan lasts an average of 20 minutes.
48483442|NCT06193824|DEVICE|Experimental: downhill treadmill walking at -10% and -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)
48483443|NCT02531594|BEHAVIORAL|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
47962988|NCT00941005|DEVICE|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
48311607|NCT03215394|BEHAVIORAL|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
48483444|NCT02531594|BEHAVIORAL|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
48113884|NCT05038228|DRUG|Dabigatran|Anticoagulant
48311608|NCT03215394|BEHAVIORAL|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
48311609|NCT03215394|OTHER|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
48311610|NCT03215394|BEHAVIORAL|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
48311611|NCT06554392|DIAGNOSTIC_TEST|Blood sample|Blood sample from each subject to detect Glutathione Peroxidase 4.
48311612|NCT05047640|BIOLOGICAL|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
48311613|NCT05047640|BIOLOGICAL|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
48311614|NCT05120622|DRUG|Tremelimumab|"Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy."
48311615|NCT04762108|OTHER|Standard of care|Patients will be given standard of care as per their clinical needs
48311616|NCT06267092|OTHER|No treatment given|Participants will not get any medicine during this study.
48311617|NCT06267092|DRUG|Cagrilintide and Semaglutide|Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
48311618|NCT06267092|DRUG|Placebo|Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
48311619|NCT00411788|DRUG|Rapamycin|oral rapamycin 6 mg daily
48311620|NCT00411788|DRUG|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
48311621|NCT03286088|DIAGNOSTIC_TEST|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
48483445|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Survivors|"CBCT-S is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-S will be administered to breast cancer survivors and will not including supportive partners.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
47962989|NCT05648383|BEHAVIORAL|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
47962990|NCT05648383|BEHAVIORAL|Standard care|Participants will receive standard care, including lifestyle recommendations.
47962991|NCT04660877|DIETARY_SUPPLEMENT|Cheddar Cheese|20g of protein from cheddar cheese
47962992|NCT04660877|DIETARY_SUPPLEMENT|Milk|20g of protein from milk
48311622|NCT03286088|DIAGNOSTIC_TEST|Cardiac Magnetics Resonance|imaging as standard practice
48311623|NCT03286088|DIAGNOSTIC_TEST|MitraClip|imaging as standard practice
48311624|NCT00905021|DRUG|Exemestane|Exemestane 25 mg by mouth every day.
48311625|NCT00905021|DRUG|Sutent|Sunitinib 37.5 mg by mouth every day.
48311626|NCT03219749|BEHAVIORAL|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
47962993|NCT03464578|PROCEDURE|Therapy of proximal humeral fractures (irrespective conservative or operative)|
47962994|NCT02023281|BEHAVIORAL|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
47962995|NCT00004075|DRUG|tanespimycin|
48113885|NCT05038228|DRUG|Vitamin K antagonist (VKA)|Anticoagulant
48311627|NCT02528500|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
48311628|NCT03434964|DIAGNOSTIC_TEST|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
48311629|NCT04573452|DIAGNOSTIC_TEST|Galectin-3|Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
48643221|NCT06038487|PROCEDURE|Immediate loading of maxillary implant overdenture|The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
48483446|NCT05676255|BEHAVIORAL|Cognitively-Based Compassion Training for Dyads|"CBCT-D is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. CBCT-D will be administered to breast cancer survivors and supportive partners together.~Module 1 (Week 1): Overview and Connecting to A Moment of Nurturance~Module 2 (Week 2) Developing Stable and Clear Attention~Module 3 (Week 3): Enhancing Self Awareness~Module 4 (Week 4): Cultivating Self compassion Part 1: Accepting our Suffering~Module 5 (Week 5): Self Compassion Part 2: Finding Meaning in Suffering.~Module 6(Week 6): Expanding our Circle of Concern~Module 7 (Week 7): Deepening Gratitude and Tenderness~Module 8 (Week 8): Harnessing the Power of Compassion"
48483447|NCT05676255|BEHAVIORAL|Health Education|"HE focuses on topics relevant to health and cancer, but is also intended for individuals who are not cancer survivors themselves.~HE will be administered to both breast cancer survivors and supportive partners together.~Module I (Week 1): Cancer Advocacy.~Module II (Week 2): Health Through the Lifespan.~Module III (Week 3): Nutrition.~Module III (Week 4): Nutrition.~Module IV (Week 5): Physical Activity.~Module V (Week 6): Sleep.~Module VI (Week 7): Stress.~Module VII (Week 8): Mental Health and Social Support."
48483448|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
48483449|NCT01578668|DRUG|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
47962996|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
47962997|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
47962998|NCT04167579|DEVICE|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
48311630|NCT04573452|DIAGNOSTIC_TEST|Placental Galactin-3|Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
48311631|NCT02165657|DEVICE|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
48483450|NCT01578668|DRUG|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
48483451|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
48483452|NCT00085306|BIOLOGICAL|recombinant interferon beta|recombinant interferon beta
48483453|NCT02851719|OTHER|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
48483454|NCT02851719|OTHER|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
47962999|NCT02528396|DRUG|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
47963000|NCT02528396|DRUG|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
48483455|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
48483456|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
48113886|NCT02541916|OTHER|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy \& LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
48311632|NCT05745402|BEHAVIORAL|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
48113887|NCT00470704|DRUG|Lapatinib|
47963001|NCT05373745|BEHAVIORAL|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
47963002|NCT05373745|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
47963003|NCT02829697|DRUG|Ropivacaine|Perineural injection.
48113888|NCT00470704|DRUG|Herceptin|
48113889|NCT06676553|DEVICE|Radiofrequency ablation alone, re-denervation to main and/or branch renal artery|Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.
48113890|NCT06676553|PROCEDURE|Radiofrequency ablation alone, no further renal denervation|No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg
48311633|NCT00321100|DRUG|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
48311634|NCT00321100|DRUG|cetuximab|Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
48311635|NCT00321100|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
48311636|NCT00321100|DRUG|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
48483457|NCT00904748|DRUG|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
48483458|NCT04628936|DRUG|KZR-616|Subcutaneous 30 mg for 1 week, then 45 mg weekly
48483459|NCT05054894|OTHER|Therapeutic Plasma Exchange (TPE)|"Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion."
48483460|NCT02150772|PROCEDURE|Shear Wave Elastography (SWE)|
48483461|NCT00697216|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
48483462|NCT00697216|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
48483463|NCT06177314|OTHER|correlate the molecular signatures of active lesions of contact dermatitis with allergological results|Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
48483464|NCT01616121|OTHER|Usual treatment of patients with developing acute heart failure|
48483465|NCT01616121|DEVICE|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
48483466|NCT02655055|PROCEDURE|high frequency voluntary apheresis blood donation|
48483467|NCT04731584|BIOLOGICAL|Blood sample|Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
48113891|NCT00457743|DRUG|Sunitinib malate (SU011248)|SU011248
48113892|NCT00888979|DRUG|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
48311637|NCT00905307|DRUG|OPC-34712|oral, once daily
48311638|NCT00905307|DRUG|Placebo|Placebo
48311639|NCT00905307|DRUG|Aripiprazole|oral, once daily
48311640|NCT01740440|DEVICE|BMR Face|BMR Face used in accordance with manufacturer IFU
48483468|NCT01914172|OTHER|online questionairres|see group descriptions
48483469|NCT04800341|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
48483470|NCT03544814|DRUG|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
48483471|NCT03544814|DRUG|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
48483472|NCT05560724|DEVICE|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
47963004|NCT03033485|RADIATION|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
47963005|NCT02543437|DEVICE|Trident Acetabular X3 Insert|
47963006|NCT04526431|DRUG|Dosage Forms Oral|Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
47963007|NCT06467448|DEVICE|EMG Assessement of Recovery of Neuromuscular Function|EMG Train of Four Assessment of Recovery of Neuromuscular Function
47963008|NCT03024060|DRUG|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
47963009|NCT03024060|DRUG|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
47963010|NCT03024060|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
47963011|NCT03024060|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
47963012|NCT01552694|DRUG|Sitagliptin|Oral, 100 mg/day for 2 months
47963013|NCT01552694|DRUG|Placebo|oral, matching placebo daily for 2 months
47963014|NCT03994107|DRUG|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
47963015|NCT03994107|DRUG|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
47963016|NCT03994107|DRUG|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
47963017|NCT03963596|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
47963018|NCT03813849|DIAGNOSTIC_TEST|Sonographic examination of uterus after surgical evacuation|
47963019|NCT05683769|GENETIC|miRNA|Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
47963020|NCT01060813|DIETARY_SUPPLEMENT|Leucine supplements|leucine supplements
47963021|NCT00962910|OTHER|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
47963022|NCT00659997|DRUG|Albendazole|Single oral dose of 400mg
48113893|NCT05892055|OTHER|Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
47963023|NCT00659997|DRUG|Levamisole|Single oral dose of 2.5mg/kg
47963024|NCT02386735|DRUG|Placebo|Three days prednisone 40mg, two days placebo
47963025|NCT02386735|DRUG|Prednisone|Five days prednisone 40mg.
48483473|NCT02215148|DRUG|Tolvaptan|
48483474|NCT02335515|DEVICE|Soctec|Gastroretentive Drug Delivery System
48483475|NCT02612454|DRUG|Dupilumab|Weight-tiered dosing administered subcutaneous (SC)
48483476|NCT04995757|DEVICE|Stent Retriever|Stent Retriever for acute ischemic stroke
47963026|NCT05509920|OTHER|S-PRG barrier coat|S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
47963027|NCT03167905|DEVICE|Epidural delivery system|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
47963028|NCT03167905|DRUG|Entonox|Entonox will be given upon request in non-epidural group.
47963029|NCT03167905|DRUG|Meperidine|Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
47963030|NCT03167905|DRUG|Ultiva|Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
47963031|NCT03167905|DRUG|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
47963032|NCT03167905|DRUG|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
48113894|NCT04594798|DRUG|Polatuzumab vedotin|IV 1.8 mg/kg per cycle
48113895|NCT04594798|DRUG|Rituximab|IV 375 mg/m2 per cycle
48113896|NCT04594798|DRUG|Cyclophosphamide|IV 400 mg/m2 per cycle
48113897|NCT04594798|DRUG|Doxorubicin|IV 25 mg/m2 per cycle
48113898|NCT04594798|DRUG|Prednisone|PO 40 mg/m2 per cycle
48113899|NCT03187860|PROCEDURE|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
48483477|NCT01795079|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
48643222|NCT06038487|PROCEDURE|Delayed loading of maxillary implant overdenture|A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
48311641|NCT04983329|OTHER|Telemedicine intervention|Following education, the telemedicine center will subsequently monitor operating rooms included in this trial for protocol adherence for three-months. The telemedicine center is staffed by attending anesthesiologists, resident anesthesiologists, certified registered nurse anesthetists (CRNAs) and student registered nurse anesthetists (SRNAs) and is currently providing evidence-based support to clinicians in a subset of operating rooms and post-anesthesia care unit (PACU) beds at Barnes-Jewish Hospital.
48311642|NCT02417233|BEHAVIORAL|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
48311643|NCT02417233|BEHAVIORAL|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
48311644|NCT02778750|PROCEDURE|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
48311645|NCT02477722|OTHER|EFP-NF|
48311646|NCT02477722|OTHER|Sham|
48311647|NCT00741143|OTHER|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
48311648|NCT02493426|DRUG|Intranasal Oxytocin|
48311649|NCT02493426|DRUG|Placebo|
48311650|NCT03459131|DEVICE|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
48311651|NCT03459131|DEVICE|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
48311652|NCT02563288|DRUG|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
48311653|NCT02563288|DRUG|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
48311654|NCT05877885|BEHAVIORAL|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
48311655|NCT05877885|BEHAVIORAL|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
48311656|NCT02273440|DRUG|BIIL 284 BS|
48311657|NCT02273440|DRUG|Theophylline|
48643223|NCT03941860|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48113900|NCT03187860|OTHER|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
48113901|NCT06676527|OTHER|Follow-up study of the treated cohort|For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
48643224|NCT03941860|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
48643225|NCT03941860|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48643226|NCT03941860|PROCEDURE|Computed Tomography|Undergo CT scan
48643227|NCT03941860|DRUG|Ixazomib Citrate|Given PO
48643228|NCT03941860|DRUG|Lenalidomide|Given PO
48113902|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
48113903|NCT01430611|BIOLOGICAL|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
48311658|NCT02273440|DRUG|Placebo|
48311659|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
48311660|NCT00634959|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
48311661|NCT00634959|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
48643229|NCT03941860|OTHER|Placebo Administration|Given PO
48113904|NCT05296811|PROCEDURE|Lateral Arm Free Flap|Primary Reconstruction of intraoral defects by use of Lateral Arm Free Flap.
48113905|NCT03014973|BIOLOGICAL|intra-prostatic concentration of sexual steroids|
48113906|NCT03014973|PROCEDURE|Trans-rectal biopsy|
48113907|NCT05430334|COMBINATION_PRODUCT|e-liquid 1|30/70 PG/VG ratio with nicotine concentration 4mg/ml protonated
48113908|NCT05430334|COMBINATION_PRODUCT|e-liquid 2|30/70 PG/VG ratio with nicotine concentration 10mg/ml protonated
48311662|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
48311663|NCT00634959|OTHER|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
48311664|NCT05092737|PROCEDURE|Prone positioning|Prone position during invasive mechanical ventilation
48311665|NCT00114283|DRUG|lapatinib ditosylate|Given PO
48311666|NCT00114283|OTHER|laboratory biomarker analysis|Correlative studies
48311667|NCT00663728|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
48311668|NCT00663728|DRUG|Placebo|Matching placebo
48643230|NCT03941860|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48643231|NCT03941860|OTHER|Quality-of-Life Assessment|Ancillary studies
48311669|NCT01240044|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
48311670|NCT01240044|PROCEDURE|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
48311671|NCT01882998|BEHAVIORAL|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
48311672|NCT01933191|BEHAVIORAL|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
48311673|NCT01933191|BEHAVIORAL|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
48311674|NCT05901038|DEVICE|Wearing heart rate monitors|Participants will use 2 consumer wearable heart rate monitors: Polar H10 chest strap and Fitbit Inspire 2 fitness tracker.
48311675|NCT04182997|DRUG|Dexamethasone|Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery.
48311676|NCT04182997|DRUG|saline 0.9%|Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
48311677|NCT06198959|DEVICE|Adult blanket plus, MA2220 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Adult Blanket plus, MA2220 blanket connected to the Mistral Air, Blower. MA1200-PM system for 30 minutes.
48311678|NCT06198959|DEVICE|Premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the premium adult blanket, 3320 blanket connected to the Mistral Air, Blower MA1200-PM system.
48113909|NCT05430334|COMBINATION_PRODUCT|e-liquid 3|30/70 PG/VG ratio with nicotine concentration 4mg/ml free base
48113910|NCT05430334|COMBINATION_PRODUCT|e-liquid 4|30/70 PG/VG ratio with nicotine concentration 10mg/ml freebase
48311679|NCT06198959|DEVICE|Blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the blanket full body, 30000 blanket connected to the 3M, Bair Hugger, Blower 775 system.
48311680|NCT06198959|DEVICE|FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
48311681|NCT06198959|DEVICE|Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system|Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
48311682|NCT00002789|DRUG|busulfan|
48311683|NCT00002789|DRUG|cyclophosphamide|
48311684|NCT00002789|DRUG|cyclosporine|
48311685|NCT00002789|DRUG|methotrexate|
48311686|NCT00002789|PROCEDURE|allogeneic bone marrow transplantation|
48311687|NCT00002789|PROCEDURE|peripheral blood stem cell transplantation|
48311688|NCT03504774|DRUG|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
48483478|NCT05088031|DEVICE|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
48113911|NCT05430334|COMBINATION_PRODUCT|e-liquid 5|30/70 PG/VG ratio with nicotine concentration 0mg/ml (placebo)
48113912|NCT02101905|OTHER|Laboratory Biomarker Analysis|Correlative studies
48113913|NCT02101905|DRUG|Lapatinib|Given PO
48643232|NCT03941860|OTHER|Questionnaire Administration|Ancillary studies
48113914|NCT02101905|DRUG|Lapatinib Ditosylate|Given PO
48643233|NCT06568796|OTHER|randomize controlled study|eswt treatment
48311689|NCT03455309|BIOLOGICAL|NDV-3A|Single dose administered by intramuscular injection
48311690|NCT03455309|BIOLOGICAL|Placebo|Single dose administered by intramuscular injection
48311691|NCT05145075|OTHER|Survey|Patients are asked to fill in a survey concerning teleconsultations
48643234|NCT03639051|DEVICE|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
48643235|NCT03639051|OTHER|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
48643236|NCT02070549|DRUG|Trametinib|Given PO
48643237|NCT06484595|OTHER|Best Practice|Receive SOC supportive care services
48311692|NCT00337376|DRUG|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
48643238|NCT06484595|BEHAVIORAL|Patient Navigation|Receive clinical trial navigator guide services
48643239|NCT06157827|DRUG|LBL-024 for Injection|Initial dose-MTD; Q3W; intravenous infusion
48311693|NCT00337376|DRUG|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
48643240|NCT06157827|DRUG|Etoposide Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
48643241|NCT06157827|DRUG|Carboplatin Injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
48643242|NCT06157827|DRUG|Atezolizumab injection|Initial dose; Q3W; intravenous infusion
47963033|NCT03143413|OTHER|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
47963034|NCT03479970|OTHER|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
47963035|NCT03479970|OTHER|GNPT|It's a computeritzed program of cognitive telerehabilitation
47963036|NCT00465036|DIETARY_SUPPLEMENT|Whole flaxseeds, flaxseed mucilage, glucomannan|
48311694|NCT00071201|DRUG|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
48311695|NCT06369675|DRUG|MOB015B|Topical formulation
48643243|NCT06157827|DRUG|Cisplatin injection|Initial dose（Dose was decided by the investigator according to the subject's condition）; Q3W; intravenous infusion
48643244|NCT02025010|DRUG|abiraterone acetate|Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
48311696|NCT06369675|DRUG|0.2% SLS|Positive control
48311697|NCT06369675|DRUG|0.9% Saline|Negative control
48311698|NCT06369675|DRUG|MOB015B vehicle|Topical formulation
48311699|NCT01847664|DRUG|Rifamycin SV-MMX® 400 mg b.i.d.|
48113915|NCT02101905|OTHER|Pharmacological Study|Correlative studies
48113916|NCT02101905|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
48113917|NCT05800977|BIOLOGICAL|Prizloncabtagene autoleucel|Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
48311700|NCT01847664|DRUG|Rifamycin SV-MMX® 600 mg t.i.d.|
48311701|NCT01847664|DRUG|Rifamycin SV-MMX® Placebo|
48311702|NCT05595785|BEHAVIORAL|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
48311703|NCT05595785|BEHAVIORAL|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
48643245|NCT04136288|DEVICE|MoreNova|Shockwave therapy delivered to the genital area with low dose shocks
48643246|NCT03947385|DRUG|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
48643247|NCT03947385|DRUG|Binimetinib|Binimetinib dosed orally, twice daily for each 28-day cycle
48643248|NCT03947385|DRUG|Crizotinib|Crizotinib dosed orally, twice daily for each 28-day cycle
48643249|NCT05389371|BEHAVIORAL|Alberta Healthy Living Program|Weight management services
48643250|NCT05389371|BEHAVIORAL|Alberta Obesity Centre Program|Multi-disciplinary obesity management
48643251|NCT05389371|BEHAVIORAL|Osteoarthritis advice|Living Your Best Life with Osteoarthritis Handbook
48643252|NCT05389371|BEHAVIORAL|Physiotherapy|GLA:D physiotherapy programs.
48311704|NCT03899129|PROCEDURE|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
48311705|NCT03899129|PROCEDURE|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
48311706|NCT01425073|OTHER|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
48311707|NCT00901537|DRUG|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
48311708|NCT04610034|BEHAVIORAL|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
48311709|NCT04610034|OTHER|Care as usual|The control arm will receive usual care, which implies no systematic support.
48311710|NCT03057457|DEVICE|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
48311711|NCT05931016|DIAGNOSTIC_TEST|6-MWT|Measurement of saturation and blood gas parameters under 6-MWT with different masks.
48311712|NCT05931016|DIAGNOSTIC_TEST|Spiroergometry|Measurement of saturation and blood gas parameters under spiroergometry with different masks.
48311713|NCT02419183|OTHER|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
48311714|NCT02419183|OTHER|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
48311715|NCT03810690|BIOLOGICAL|mRNA-3704|mRNA-3704 dispersion for intravenous (IV) infusion
48311716|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
48311717|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
48311718|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
48311719|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
48311720|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
48311721|NCT06121063|COMBINATION_PRODUCT|CCT-102 A and CCT-102 B|2 day oral regimen
48311722|NCT03411213|DEVICE|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
48643253|NCT06219122|BEHAVIORAL|Creative arts and psychomotor therapies intervention for people with personality disorders|a Group (max of 9 participants) Creative arts and psychomotor therapies (CAPTS) intervention for people with personality disorders. Consisting of 10 sessions, where two CAPTS disciplines and therapists are represented each session. Each session lasts 90 minutes. Sessions are aimed at psychological adativity thru=ough the CAPTS. The sessions cover warming up in one of the CAPTS, short psycho education and a longer assigment focusing on the session goal. The first half of the interventions focusses mainly on listening to body signals, emotions and emotional needs and dealing in a healthy way with these. The second half will be more complex when dealing with challenges and adapting tot he context in a healthy way are goals of the sessions.
48643254|NCT05961709|DRUG|Cemiplimab|Given by IV (vein)
48643255|NCT04846868|DRUG|Iclepertin|Iclepertin
48643256|NCT04846868|DRUG|Placebo|Placebo
48643257|NCT06452277|DRUG|BAY2927088|Tablet, oral
48643258|NCT06452277|DRUG|Pembrolizumab|Intravenous (IV) infusion
48311723|NCT05641792|DEVICE|CGM (Dexcom G6)|Dexcom G6 system consists of a transmitter and sensor that measure interstitial glycaemia every 5 minutes. Measurements are transmitted via Bluetooth to a compatible device, that uploads the data on a virtual drive. This allows for remote real-time glycaemia monitoring on another device.
48311724|NCT00180596|DEVICE|Contak heart failure devices|
48643259|NCT06452277|DRUG|Cisplatin|IV infusion
48643260|NCT06452277|DRUG|Carboplatin|IV infusion
48311725|NCT01686022|OTHER|Immunoblot|serum specific IgE binds to grass extract by immunoblot
48311726|NCT01625598|PROCEDURE|Photography of the retina|Every subject will undergo photography of the retina in both eyes
48311727|NCT01625598|PROCEDURE|Retinal photography|"Device~Subjects will have photography of both eyes"
48311728|NCT06139679|PROCEDURE|ASD closure with fenestrated/non-fenestrated patch|A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
48311729|NCT00003243|BIOLOGICAL|aldesleukin|
48311730|NCT00003243|BIOLOGICAL|filgrastim|
48483479|NCT03319095|DEVICE|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
48113918|NCT05627336|DIAGNOSTIC_TEST|pregnant women in the 3rd trimester|Pregnant women who are in their third trimester and will give birth in the clinic will form the study group. These pregnant women will be measured by applying a set of questionnaires to measure their fear of childbirth.
48113919|NCT00233337|DRUG|Co-artemether|
48311731|NCT00003243|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48311732|NCT00003243|DRUG|cyclophosphamide|
48311733|NCT00003243|DRUG|etoposide|
48483480|NCT03721302|OTHER|Main study clinical sepsis|No intervention-Observational study
48483481|NCT03721302|OTHER|Microbiology sub study|Analysis of Bacterial isolates
48483482|NCT06234319|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.
48643261|NCT06452277|DRUG|Pemetrexed|IV infusion
48311734|NCT00003243|DRUG|pegylated liposomal doxorubicin hydrochloride|
48311735|NCT06020274|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
48311736|NCT01202227|DRUG|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
48643262|NCT04879940|DEVICE|Merit Medical Embospheres|Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
48483483|NCT05362006|DEVICE|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
48643263|NCT04879940|RADIATION|Radiation Therapy|Patients will undergo standard of care definitive radiation therapy.
48113920|NCT00553683|DRUG|cyclophosphamide|
48113921|NCT00553683|DRUG|poly ICLC|
48113922|NCT00553683|PROCEDURE|hepatic artery embolization|
48483484|NCT05362006|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
48113923|NCT00553683|RADIATION|3-dimensional conformal radiation therapy|
48311737|NCT05682820|DIAGNOSTIC_TEST|Measurements on knee MRI performed during routine clinical practice|Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
48311738|NCT01029886|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly
48483485|NCT02285634|DRUG|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
48483486|NCT02285634|DRUG|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
48483487|NCT02285634|DRUG|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
48483488|NCT02285634|DRUG|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
48483489|NCT02516384|BIOLOGICAL|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (\>18 year old) patients with active ulcerative colitis (UC).
48483490|NCT00888784|PROCEDURE|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
48483491|NCT00888784|DRUG|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
48483492|NCT00128037|DRUG|mitomycin C, vindesine, cisplatin and radiotherapy|
48483493|NCT03341546|OTHER|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
48483494|NCT02470117|DRUG|Alginate-based reflux suppressant|
48483495|NCT02470117|DRUG|magnesium-aluminium antacid gel|
48483496|NCT01705860|BIOLOGICAL|Santyl|
48483497|NCT01494441|PROCEDURE|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
48483498|NCT01494441|DEVICE|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
48483499|NCT01494441|DEVICE|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
48483500|NCT01700478|DRUG|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
48483501|NCT01700478|DRUG|Vasopressin|Vasopressin was used in all patients during surgery.
48483502|NCT04782128|BIOLOGICAL|RC28-E injection|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
48113924|NCT02343211|DRUG|Immunoglobulin|
48113925|NCT01531075|BIOLOGICAL|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
48113926|NCT01531075|BIOLOGICAL|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
48113927|NCT04393246|DRUG|EDP1815|EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
48311739|NCT01029886|DRUG|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
48483503|NCT03544359|DEVICE|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
48483504|NCT06292494|DEVICE|Exablate 4000 Transcranial MRgfUS System|Focused ultrasound interrupt structure of epilepsy network to improve seizure.
48311740|NCT05866835|OTHER|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~* digital recording of the maxillary and mandibular dental arches~* mandibular wedging performed with an inter-arch piece~* digital recording of the inter-arch position"
48311741|NCT05866835|OTHER|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~* At rest, standing still.~* During a 4 minute run on a treadmill at 50% of MAS.~* During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
48113928|NCT04393246|DRUG|Dapagliflozin|Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
48311742|NCT05866835|OTHER|Evaluation of comfort level:|Collection from participants (self-questionnaire)
48311743|NCT03272945|PROCEDURE|Linked-color imaging|Linked-color imaging colonoscopy
48311744|NCT03090620|DRUG|Physostigmine|Administration of physostigmine bolus followed by an infusion
48311745|NCT03090620|DRUG|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
48311746|NCT03041194|OTHER|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
48311747|NCT03660813|DIAGNOSTIC_TEST|Follicle measurment|Follicle will be measured before aspiration
48483505|NCT02165306|BEHAVIORAL|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
48483506|NCT02165306|BEHAVIORAL|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
48483507|NCT02291692|PROCEDURE|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
48483508|NCT03180801|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
48483509|NCT03180801|BIOLOGICAL|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
48483510|NCT03180801|OTHER|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
48483511|NCT05794724|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
48483512|NCT01901848|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
48483513|NCT01901848|DRUG|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
48483514|NCT01901848|DRUG|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
48311748|NCT03660813|DRUG|Ovitrelle ( Hcg 250 mcg)|Drug used for triggering
48311749|NCT03660813|DRUG|Decapeptyl ( GnRH Agonist 0.1 mg*2 )|Drug used for triggering
48311750|NCT05426707|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
48311751|NCT05426707|DEVICE|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
48311752|NCT01260467|DRUG|memantine|10 milligrams orally twice a day
48311753|NCT03397927|DEVICE|orthosis|
48311754|NCT05186883|BIOLOGICAL|Allogenic parathyroid cells|Allogenic parathyroid cells
48311755|NCT05186883|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
48311756|NCT06164444|OTHER|Intervention: Reusable drapes and gowns|Reusable drapes and gowns used during surgery.
48311757|NCT06164444|OTHER|Comparator: Disposable (single-use) drapes and gowns|Disposable drapes and gowns used during surgery.
48311758|NCT05968976|PROCEDURE|Awake DBS|55 patients receive awake DBS (current standard procedure)
48311759|NCT05968976|PROCEDURE|Asleep DBS|55 patients receive asleep DBS
48311760|NCT00786838|DRUG|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
48311761|NCT00786838|DRUG|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
48311762|NCT06156358|OTHER|No intervention|No intervention
48311763|NCT04783532|BEHAVIORAL|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
48483515|NCT01901848|BEHAVIORAL|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
48643264|NCT06196203|DRUG|AK117|AK117 IV injection
48643265|NCT06196203|DRUG|Placebo|Placebo IV injection
48113929|NCT04393246|DRUG|Ambrisentan|Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
48311764|NCT03955887|BIOLOGICAL|bronchoalveolar lavage fluid (BAL)|Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
48643266|NCT06196203|DRUG|Azacitidine|Azacitidine SC injection
48483516|NCT01901848|BEHAVIORAL|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
48643267|NCT06288659|DEVICE|Intraventricular intracranial pressure monitoring|The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.
48643268|NCT05726383|DRUG|Iscador*P|Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
47963037|NCT05386810|BIOLOGICAL|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
48113930|NCT04393246|OTHER|Standard of care|Regular standard of care for COVID-19 patients
48311765|NCT03955887|BIOLOGICAL|Venous blood|Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
48483517|NCT03452072|DRUG|0.25% Timolol gel with paraffin gauze dressings|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
48483518|NCT03452072|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
48483519|NCT01733147|DRUG|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
48483520|NCT01733147|DRUG|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
48483521|NCT01042535|BIOLOGICAL|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
48113931|NCT01884636|DRUG|isavuconazole|oral
48113932|NCT01884636|DRUG|methotrexate|oral
48113933|NCT05167877|OTHER|No intervention will be given to the participants|This is an observational feasibility study with no intervention.
48311766|NCT01886131|OTHER|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
48643269|NCT06656364|DEVICE|Esprit BTK System|The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
48643270|NCT05520762|PROCEDURE|A strategy of first choice supraglottic airway|See description in Arms section
48643271|NCT05520762|PROCEDURE|A strategy of first choice endotracheal intubation|See description in Arms section
48483522|NCT01042535|DRUG|1-methyl-d-tryptophan|Given orally (PO)
48483523|NCT01042535|OTHER|Laboratory biomarker analysis|Correlative studies
48483524|NCT03357081|DRUG|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
48113934|NCT05569837|OTHER|Regular meal pattern|6 meals every day
48113935|NCT05569837|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
48113936|NCT04297917|BIOLOGICAL|ChAdOx1-HBV|chimpanzee adenovirus-vectored hepatitis B virus vaccine
47963038|NCT05386810|BIOLOGICAL|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
48643272|NCT04569097|OTHER|standard of care lingual strengthening|standard or care lingual strengthening approaches with outcome measured with novel pressure metrics
48113937|NCT03799536|DRUG|Sotalol|Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
48113938|NCT03799536|DRUG|Sotalex|Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
48113939|NCT00166166|DRUG|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
47963039|NCT05386810|BIOLOGICAL|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
48113940|NCT00166166|DRUG|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
48113941|NCT00166166|DRUG|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
48113942|NCT00166166|DRUG|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
48113943|NCT00166166|DRUG|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
48113944|NCT00166166|DRUG|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
48113945|NCT00166166|DRUG|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
48113946|NCT03690037|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
48113947|NCT03690037|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
48113948|NCT02554240|DRUG|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
48113949|NCT02554240|DRUG|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
48113950|NCT02554240|DRUG|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
48113951|NCT05956626|GENETIC|OCU410ST|Subretinal Administration of OCU410ST
48311767|NCT02831075|BIOLOGICAL|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
48113952|NCT03770507|OTHER|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
48113953|NCT05573191|DRUG|Lidocaine|The experimental group was injected with lidocaine 1.5mg/kg, and propofol was pumped intravenously at 90s after lidocaine injection.The dose of propofol was further set according to groups. The heart rate, mean arterial pressure, pulse oxygen saturation and NTI values of subjects were recorded in tne basic state,during the 90s after lidocaine administration, 60s after propofol administration and consciousness loss.The control group simply replaced lidocaine with equal volume normal saline
48113954|NCT05573191|DRUG|Normal saline|Normal saline
48113955|NCT04617353|PROCEDURE|NO-based treatment of sterno-mediastinitis|"Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number."
48113956|NCT04617353|PROCEDURE|Treatment of sterno-mediastinitis|patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
48311768|NCT02831075|BIOLOGICAL|saline|
48113957|NCT01474707|BEHAVIORAL|Group one|Group 1 will view the knowledge-based video only
48113958|NCT01474707|BEHAVIORAL|Group two|Group two will view the motivational video only
48113959|NCT01474707|BEHAVIORAL|Group three|Group three will view both knowledge-based and motivational videos
48311769|NCT00978809|OTHER|Epley maneuver|
48311770|NCT00978809|OTHER|Semont maneuver|
48311771|NCT00127062|OTHER|Oxford street|2 h walk around Oxford street
48311772|NCT00127062|OTHER|Hyde park|2 h walk around Hyde park
48311773|NCT00162396|DRUG|Albuterol|
48311774|NCT02876055|DRUG|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
48311775|NCT02876055|DRUG|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
48311776|NCT02876055|DRUG|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
48643273|NCT05836220|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
48643274|NCT05836220|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
48643275|NCT05836220|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
48643276|NCT04058756|DRUG|PDR001|PDR001
48643277|NCT05516472|DRUG|Microbial Transplant Therapy|Participants will take microbial capsules, 2 capsules daily for 7 days
48643278|NCT05516472|DRUG|Placebo|Participants will take placebo capsules
48643279|NCT06649773|DRUG|Noiiglutide Injection|Experimental group
48643280|NCT06649773|DRUG|Noiiglutide Placebo|Placebo Comparator group
48113960|NCT01474707|BEHAVIORAL|Group four|Group four will view the printed educational pamphlet and will not view either video
48311777|NCT04068064|PROCEDURE|EABM training|"The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days."
48483525|NCT05692284|OTHER|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
48483526|NCT05692284|OTHER|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
48483527|NCT04812639|OTHER|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
48483528|NCT04812639|OTHER|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
48483529|NCT01770431|DRUG|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
48483530|NCT00307931|BIOLOGICAL|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."
48483531|NCT04062682|BEHAVIORAL|Healthy Diet|Receive counseling to meet guidelines for healthy dietary patterns
48483532|NCT04685551|BEHAVIORAL|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
48483533|NCT06308172|PROCEDURE|Hysterotomy closure|Hysterotomy closure is done in either one of two ways. Single layer closure consists in a single layer, unlocked suture. Double layer closure consists in a double layer, unlocked suture.
47963040|NCT04378556|BEHAVIORAL|Nutritional coaching|Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
47963041|NCT01944592|BEHAVIORAL|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
48311778|NCT04068064|PROCEDURE|sham training|In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
48311779|NCT04284956|PROCEDURE|Proximal and distal segment of saphenous vein harvested by No-Touch technique|two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
48113961|NCT05189340|OTHER|Educational Videos|Series of six videos each covering a specific aspect of post-transplant care related to medication use or monitoring
48113962|NCT05552508|COMBINATION_PRODUCT|Benralizumab|Participants will receive benralizumab subcutaneously.
48113963|NCT04705623|BEHAVIORAL|Iyengar Yoga|Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
48113964|NCT00732953|DEVICE|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
48311780|NCT04129749|PROCEDURE|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
48311781|NCT01175967|OTHER|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
48483534|NCT06347432|OTHER|Power wheelchair skills training using the IndieTrainer system|The IndieTrainer system will be used to provide the power wheelchair (PWC) skills training sessions. The IndieTrainer is comprised of a mobility device and an array of video-based gamified training modules designed to facilitate PWC training. The IndieTrainer mobility device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. Principles outlined in the Assessment of Learning Powered mobility use (ALP) Facilitating Strategies for each ALP Assessment phase will guide the intervention sessions.
48643281|NCT05852717|PROCEDURE|AutoSCT OR CAR T-cell Therapy|Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP
48643282|NCT05852717|DRUG|GDP|Gemcitabine Cisplatin Dexamethasone
48643283|NCT05852717|DRUG|Epcoritamab|Epcoritamab
48643284|NCT05083364|DRUG|ARO-C3|ARO-C3 for sc injection
48113965|NCT00732953|DEVICE|Genous stent implantation|Genous stent implantation
48113966|NCT05356572|DEVICE|Investigational Skin Preparation Device|Removal of hyperkeratotic skin with Investigational Skin Preparation Device
48113967|NCT05356572|DEVICE|GMDN 47102 / Electrode Skin Abrasive Pad|Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation
47963042|NCT01944592|BEHAVIORAL|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
47963043|NCT01699360|DRUG|Cyclosporine A, Tacrolimus, Sirolimus|
47963044|NCT02252913|DRUG|Volitinib|oral administration
48113968|NCT05356572|DEVICE|UMDNS 13-230 / Biopsy punch (Dermal Curette)|Removal of hyperkeratotic skin with Disposable Dermal Curette
48113969|NCT04485156|DRUG|High-dose rifampicin|30mg/kg
48113970|NCT04485156|DRUG|Isoniazid|300mg
48113971|NCT04485156|DRUG|Pyrazinamide|20-30mg/kg
47963045|NCT02252913|DRUG|Docetaxel|intravenous injection
47963046|NCT03188315|GENETIC|HPV oncogenes|PCR and oncogenes detection
47963047|NCT02157987|DRUG|bevacuzimab spray|
48643285|NCT05083364|DRUG|Placebo|sterile normal saline (0.9% NaCl) for sc injection
47963048|NCT02509767|DRUG|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
47963049|NCT04584151|PROCEDURE|regional analgesia|Insertion of bilateral ESP catheters
48113972|NCT04485156|DRUG|Ethambutol|15-20mg/kg
48113973|NCT04485156|DRUG|Rifampicin|10mg/kg
48643286|NCT03266653|DRUG|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
47963050|NCT04176497|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
48113974|NCT00131144|DRUG|Octreotide Acetate in Microspheres 20 mg|
48113975|NCT00131144|DRUG|Octreotide Acetate in Microspheres|
48113976|NCT00131144|DRUG|Placebo|
48113977|NCT00230399|DRUG|Celecoxib|
48113978|NCT00230399|DRUG|Capecitabine|
48113979|NCT00230399|DRUG|Irinotecan|
48113980|NCT04864925|DRUG|Colgate Total Clean Mint|2 minutes of whole mouth toothbrushing
48113981|NCT04864925|DRUG|Tom's Botanically Bright Peppermint|2 minutes of whole mouth toothbrushing
48113982|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 1|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil and nuts
48113983|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 2|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil, nuts, and medically tailored meals
48643287|NCT04365270|DRUG|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
48643288|NCT04365270|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
48643289|NCT04365270|DRUG|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
48643290|NCT04365270|DRUG|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), \>99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
48311782|NCT01175967|OTHER|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
48311783|NCT01175967|OTHER|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
48311784|NCT01175967|OTHER|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
48311785|NCT02669004|DRUG|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
48483535|NCT03166813|PROCEDURE|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
48483536|NCT03166813|OTHER|Control|Placement of blood pressure cuff without inflation for 30 minutes.
48113984|NCT05250336|OTHER|Observational Study|Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
48311786|NCT02669004|DRUG|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
48311787|NCT05906134|PROCEDURE|Thoracic epidural catheter|The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will be added as an adjunct to the study arm and will be noted in the data set. This will likely consist of a thoracic epidural catheter.
48311788|NCT05906134|PROCEDURE|Local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
48311789|NCT05906134|PROCEDURE|Cryo-analgesia and intercostal nerve block|The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
48311790|NCT05906134|PROCEDURE|Serratus plane catheter blocks and intercostal nerve blocks|A total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on POD #1, 2, 3, 4, and 5 by the pain service.
48311791|NCT01127126|DRUG|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
48311792|NCT01328249|DRUG|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
48311793|NCT02734589|OTHER|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
48311794|NCT02734589|OTHER|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
48311795|NCT02734589|OTHER|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
48311796|NCT05282264|OTHER|device|closed-loop insulin
48311797|NCT02042729|DRUG|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
48311798|NCT02042729|DRUG|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
48311799|NCT02042729|DRUG|E2022 Matching Placebo- Current Formula Tape|
48311800|NCT02042729|DRUG|E2022 Matching Placebo- New Formula Tape|
48311801|NCT02626533|PROCEDURE|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
48483537|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
48483538|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
48483539|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
48483540|NCT03439579|BEHAVIORAL|Home weight loss program|Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
48113985|NCT01271452|BIOLOGICAL|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
48483541|NCT02540447|PROCEDURE|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
48643291|NCT06411158|OTHER|Interventionist-guided training|Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
48643292|NCT06411158|DEVICE|Home pelvic floor exercises guided by the leva® device|Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
47963051|NCT05875363|OTHER|collect data|"The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure."
48113986|NCT01271452|BIOLOGICAL|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
48113987|NCT06676631|BIOLOGICAL|NK 010 or NK042|NK010 is an allogeneic non-genetically modified NK cell infusion. NKX010 will be administered at a dose of 2.5 × 109 NK cells, 5.0 × 109 NK cells and 7.5 × 109 NK cells by a dose-escalation design and administered IV. N042 is an allogeneic genetic modification of NK cell. NKX042 will be administered at a dose of 6 × 108 NKR positive NK cells, 1.2 × 109 NKR positive NK cells and 2.4 × 109 NKR positive NK cells by a dose-escalation design and administered IV.
48113988|NCT06676631|DRUG|Rituximab|RTX dose of 1 g administered IV over 60 minutes at the first day of the treatment phase.
48113989|NCT05715151|OTHER|CQI intervention|Activity 1: Reflective sessions and problem prioritisation. Activity 2: PDSA cycles. Activity 3: Group mentoring.
48113990|NCT05715151|OTHER|Audit and Feedback|Audit and Feedback on six key AA indicators, patients reported experience about access and selected AA processes.
48113991|NCT04390958|DRUG|nab-paclitaxel|125mg/m2 ivgtt d1、d8
48113992|NCT04390958|DRUG|Cisplatin|60mg/m2 ivgtt d1 or d1-2
48113993|NCT04390958|DRUG|Capecitabine|1750mg/m2 po bid d1-14
48113994|NCT05201976|OTHER|Virtually administered Cardiac Rehab program|Virtual cardiac rehab program delivered through the CardaHealth platform.
48113995|NCT05201976|OTHER|Standard of Care in person Cardiac Rehab Program|Clinically ordered standard of care cardiac rehab program (in-person).
48113996|NCT04703920|DRUG|Talazoparib|Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
48113997|NCT04703920|DRUG|Belinostat|Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
48113998|NCT03309579|OTHER|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
48113999|NCT03309579|OTHER|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
48643293|NCT06411158|OTHER|Education|Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
48114000|NCT05283395|DRUG|Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution|Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
48114001|NCT05677633|DRUG|Sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
48114002|NCT04614675|PROCEDURE|Distal soft tissue procedure with TALR|TALR group: Transarticular lateral release as the distal soft tissue procedure
48114003|NCT04614675|PROCEDURE|Distal soft tissue procedure with PCLR|PCLR: Percutaneous soft tissue procedures as the distal soft tissue procedure
48114004|NCT02872753|BIOLOGICAL|ACP|Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
48114005|NCT02872753|OTHER|Standard Meniscectomy|Patients will receive standard arthroscopic meniscectomy
48114006|NCT04729114|DRUG|PRL-02 injection|abiraterone decanoate for intramuscular injection
48114007|NCT04729114|DRUG|prednisone|Oral dose
48114008|NCT04729114|DRUG|dexamethasone|Oral dose
48114009|NCT04729114|DRUG|enzalutamide|Oral capsule
48114010|NCT03599453|PROCEDURE|Biopsy|Undergo Biopsy
48114011|NCT03599453|PROCEDURE|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
48114012|NCT03599453|DRUG|Celecoxib|Given by mouth
48114013|NCT03599453|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given intravenously
48114014|NCT03599453|DRUG|Rintatolimod|Given intravenously
48114015|NCT03599453|BIOLOGICAL|Pembrolizumab|Given intravenously
48114016|NCT06401551|DEVICE|CPO Pro IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.
48311802|NCT01975779|DRUG|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
48114017|NCT06401551|DEVICE|CPO IOL|Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.
48311803|NCT01975779|DRUG|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
48311804|NCT01975779|DRUG|Cohort B1: Lu AE58054|Two single oral doses 60 mg with \>=7 days washout.
48311805|NCT05594680|DRUG|Cilostazol|Cilostazol 50 MG
48311806|NCT05594680|DRUG|Methotrexate|Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
48311807|NCT05594680|DRUG|Placebo|Placebo
48311808|NCT00149851|DRUG|Tegaserod|
48311809|NCT01249872|DRUG|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
47963052|NCT03717818|BEHAVIORAL|Good Psychiatric Management - Brief|specific interventions as defined by Gunderson and Links (2014)
47963053|NCT03717818|BEHAVIORAL|treatment as usual|non-specific intervention
47963054|NCT05787275|OTHER|diaphragmatic positioning|Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
47963055|NCT05787275|OTHER|incentive spirometer|Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
47963056|NCT05787275|OTHER|Control|Traditional medical treatment
47963057|NCT04406376|DRUG|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
47963058|NCT00561808|OTHER|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
47963059|NCT03280901|OTHER|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
47963060|NCT05581628|DIAGNOSTIC_TEST|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
48114018|NCT06401551|PROCEDURE|Cataract Surgery|Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
48114019|NCT02799706|DRUG|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
48114020|NCT02799706|DRUG|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
48114021|NCT02799706|RADIATION|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
48114022|NCT05110534|BEHAVIORAL|additional oral hygiene appointments|Two additional preventive sessions including oral hygiene instructions one week before the date of the general anaesthesia treatment and at the control visit about a week after the general anaesthesia.
48311810|NCT01249872|DRUG|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
48311811|NCT01249872|DRUG|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
48311812|NCT01249872|DRUG|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
48311813|NCT01249872|DRUG|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
48311814|NCT01249872|DRUG|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
48311815|NCT03625362|DIETARY_SUPPLEMENT|Hydrogen|Hydrogen-rich water
48311816|NCT03625362|DIETARY_SUPPLEMENT|Placebo|Tap water
47963061|NCT05581628|DIAGNOSTIC_TEST|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
48311817|NCT03136705|DRUG|Nicotinamide|Nicotinamide tablet
48311818|NCT03136705|DRUG|Lanthanum Carbonate|Lanthanum Carbonate tablet
48311819|NCT03136705|DRUG|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
48311820|NCT03136705|DRUG|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
48311821|NCT03878017|PROCEDURE|skin marking of clip axillary lymph node for localisation|to determine the feasibility of skin marking to localize clipped ln
48311822|NCT04220489|DRUG|Ketamine|Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
48311823|NCT04220489|DRUG|Placebo Comparator|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
48311824|NCT02775760|BEHAVIORAL|Cardiovascular endurance|Physical exercise at the Boston University Fitness and Recreation Center
48311825|NCT02775760|BEHAVIORAL|Strength, balance, and flexibility|Physical exercise at the Boston University Fitness and Recreation Center
48311826|NCT04973033|DRUG|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
48311827|NCT03306134|DIAGNOSTIC_TEST|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire \[4\]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
48311828|NCT04991844|BEHAVIORAL|Intervention Group|Intervention group participants met once a week, for 2.5 hours, over a period of six weeks for the HES workshops. The HES workshops followed a scripted curriculum that incorporated information from the USDA's MyPlateTM, and the USDA 2015-2020 dietary guidelines. Participants were also taught goal-setting, problem-solving through brainstorming, group support, self-assessment and management of dietary and physical activity patterns.
48311829|NCT06284018|OTHER|Progressive Muscle Relaxation Exercises|"* Focus on the targeted muscle group.~* Take a slow, deep breath while squeezing on muscle group as hard as she can (not to the point of strain). Keep the muscle tensed for 5 seconds.~Hands and arms, forehead ,Eyes and Cheek, Mouth and Jaw , Neck and Shoulder ,Stomach , Leg and Toes"
48311830|NCT06284018|OTHER|Pilates Exercises|Pilates exercise program consisted of floor exercises on a rubber mat, including the following exercises: a- Pelvic Curl. b- Single-Leg Lift. c- Chest Lift. d- Supine Spine Twist. e- Basic Back Extension.
48311831|NCT02454218|DEVICE|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
48311832|NCT02427594|DRUG|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
48311833|NCT02427594|OTHER|Controlled diet|Diet without sodium bicarbonate supplementation
48311834|NCT00525148|DRUG|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
48311835|NCT04417777|GENETIC|Blood Test|Blood analysis
48311836|NCT02813798|DRUG|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
47963062|NCT05581628|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
48311837|NCT00521092|DRUG|sunitinib malate|Given orally
48311838|NCT00521092|PROCEDURE|laboratory biomarker analysis|Correlative study
48311839|NCT00521092|PROCEDURE|pharmacological study|Correlative study
48311840|NCT01922427|DRUG|RNS60|
47963063|NCT01691209|DEVICE|Phoenix (BAY81-2996)|Topical formulation applied to the skin
47963064|NCT01691209|DRUG|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
47963065|NCT06127680|BEHAVIORAL|Brief Health Promotion Advice|Brief Health Promotion advice on exercise and nutrition (protein intake) delivered by a health care professional during routine consultations
47963066|NCT03472183|OTHER|biopsies of colon|Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
47963067|NCT00378378|DRUG|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
47963068|NCT00378378|DRUG|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
47963069|NCT04571879|DRUG|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
48311841|NCT03775018|PROCEDURE|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
48311842|NCT03775018|DRUG|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
48311843|NCT00474162|DRUG|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
48311844|NCT00474162|DRUG|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
48311845|NCT05029115|DRUG|SGLT2 inhibitor|Dapagliflozin, Empagliflozin
48311846|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
48311847|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
48311848|NCT03927508|DRUG|r-tPA|Pulse spray and infusion
47963070|NCT04571879|DRUG|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
47963071|NCT04571879|OTHER|Placebo|Nebulized normal saline and intranasal normal sline
47963072|NCT01397162|DRUG|Fluticasone propionate|Fluticasone propionate
48311849|NCT03927508|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
47963073|NCT01397162|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
47963074|NCT01397162|DRUG|BI 54903|BI 54903
48311850|NCT01131221|OTHER|laboratory biomarker analysis|
48311851|NCT00900250|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48311852|NCT02153450|DRUG|metformin hydrochloride|Given PO
48311853|NCT02153450|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
48311854|NCT04258332|DIETARY_SUPPLEMENT|High Salt Diet|Patients will be randomized to be on a high salt diet for 7 days.
48311855|NCT04258332|DIETARY_SUPPLEMENT|Low Salt Diet|Patients will be randomized to be on a low salt for 7 days.
48311856|NCT03689725|OTHER|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
48311857|NCT02968043|OTHER|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
48311858|NCT02968043|OTHER|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
48311859|NCT05580172|DRUG|RH324|polymolecular
47963075|NCT05053100|PROCEDURE|Biospecimen Collection|Undergo collection of blood
47963076|NCT05053100|OTHER|Electronic Health Record Review|Undergo electronic health record review
47963077|NCT01698372|DEVICE|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
47963078|NCT02557555|OTHER|educational information|patients will receive pamphlet on labor analgesia options.
48311860|NCT05339724|OTHER|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
48311861|NCT02491437|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
48311862|NCT02491437|DRUG|intravaginal progesterone gel 90 mg|
47963079|NCT04464629|DRUG|Dextenza|Intracanalicular sustained release dexamethasone insert 0.4 mg
47963080|NCT04464629|DRUG|Prednisolone Acetate|Topical Prednisolone acetate 1% ophthalmic suspension
47963082|NCT02323867|DEVICE|Alpha Beta T cell depletion|
47963083|NCT01768286|DRUG|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
47963084|NCT01768286|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48311863|NCT04629989|OTHER|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
48311864|NCT04629989|OTHER|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
48311865|NCT04629989|OTHER|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
47963085|NCT00653120|DRUG|Propranolol|ER capsules, 160 mg, single-dose
47963086|NCT00653120|DRUG|Inderal-LA|ER capsules, 160 mg, single-dose
47963087|NCT04138810|OTHER|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
48311866|NCT05509231|BEHAVIORAL|High-intensity exercise|Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.
48311867|NCT05509231|DEVICE|Wearable glove and arm sleeve device to measure movement|Sign language and other fine motor skills activities using wearable technology.
48311868|NCT03051334|OTHER|diagnosed as bicuspid aortic valve|
48311869|NCT01218412|BEHAVIORAL|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
48311870|NCT00143221|DRUG|Viagra|
48311871|NCT00143221|DRUG|Placebo|
48311872|NCT00209599|DRUG|fospropofol disodium|
48311873|NCT02592629|DRUG|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
48311874|NCT02592629|DRUG|ethyl chloride|topical spray
48311875|NCT02592629|DRUG|Kenalog|used with lidocaine in shoulder injection
48311876|NCT04392102|DRUG|ZL-2306(Niraparib）|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
48311877|NCT04377594|PROCEDURE|Radio frequency ablation|Two different radio frequency ablation procedures
48311878|NCT05915754|OTHER|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
48311879|NCT05915754|OTHER|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
48311880|NCT02678741|DRUG|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
48311881|NCT06290895|OTHER|women having had a second IVF cycle with AOA|The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.
48311882|NCT03867669|OTHER|Open Bay Unit|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
48311883|NCT03867669|OTHER|Single patient room|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
48311884|NCT03073655|OTHER|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
48311885|NCT03073655|OTHER|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
48311886|NCT03073655|OTHER|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
48311887|NCT06273657|OTHER|Medisinstart|Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
48311888|NCT04699604|DRUG|Levocetirizine Dihydrochloride|At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children \>11 years per recommended doses) or placebo to their current asthma regimen.
47963088|NCT04138810|OTHER|Survey|Measure of satisfaction regarding post-op visit.
47963089|NCT06265246|OTHER|Habitual Diet + Milk|1.5 servings of milk \[providing approx. 500 mg Ca/day\] per day (either 1% fat milk, or 2% fat milk)
47963090|NCT06265246|OTHER|Habitual Diet + Yogurt|2 servings of yogurt \[providing approx. 500 mg Ca/day\] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
48311889|NCT04699604|DRUG|Placebo|Placebo
48311890|NCT03169452|DEVICE|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
48311891|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
48311892|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
48311893|NCT02421328|DEVICE|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
48311894|NCT02421328|DEVICE|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
48311895|NCT01696734|DRUG|Domperidone|Given PO
48311896|NCT01696734|OTHER|Questionnaire Administration|Ancillary studies
48311897|NCT04207957|DRUG|Olorofim|150 mg
47963091|NCT00002307|DRUG|Stavudine|
47963092|NCT00002307|DRUG|Zidovudine|
48311898|NCT01449357|DRUG|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
48311899|NCT03301766|DRUG|lidocaine 5% patch|transdermal patch
48311900|NCT03301766|DRUG|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
48311901|NCT03301766|DRUG|Non-medicated patch|non-medicated patch
48311902|NCT01599468|DRUG|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
48643294|NCT06116032|DIAGNOSTIC_TEST|Methylation Cytometry|Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
48311903|NCT01599468|DRUG|saline serum|The Placebo group received normal saline with the same volumes
48311904|NCT02262039|DEVICE|Valveless recirculating insufflation (VTI)|10 mmHg target pressure
48311905|NCT02262039|DEVICE|Conventional pressure|15 mmHg target pressure
48311906|NCT06266273|OTHER|No intervention|No intervention
48311907|NCT04497662|DRUG|KPL-404|humanized IgG4 monoclonal antibody
48311908|NCT04497662|OTHER|Matching Placebo|Placebo
48311909|NCT05462769|DEVICE|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
48311910|NCT04062851|OTHER|No Gastric residual volume monitoring|Gastric residual volumes will not be monitored
48311911|NCT05796453|DEVICE|Clareon Vivity IOL - Non Toric|Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
48311912|NCT05796453|DEVICE|Clareon Vivity IOL - Toric|Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
48311913|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Non Toric|Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.
48311914|NCT05796453|DEVICE|Clareon PanOptix Trifocal IOL - Toric|Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.
48311915|NCT00115349|DRUG|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
48311916|NCT00115349|DRUG|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
48311917|NCT00564954|DRUG|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
48311918|NCT00564954|DRUG|Placebo|orally once a day for 7 days
48311919|NCT02426554|DIETARY_SUPPLEMENT|DDU-supplement|DDU: Vitamin D, DHA, Uridine
48311920|NCT02426554|DIETARY_SUPPLEMENT|Placebo supplement|
48311921|NCT05539586|OTHER|Tecartherapy|Patients will receive therapeutic exercise sessions for 7 weeks and 7 tecartherapy sessions.
48311922|NCT05539586|OTHER|Sham|Patients will receive therapeutic exercise sessions for 7 weeks and 7 sessions of simulated tecartherapy.
48114023|NCT03833154|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
48311923|NCT03036332|BEHAVIORAL|Aerobic interval training|Carried out 3 times per week for 16 weeks
48311924|NCT02547831|OTHER|Observational approach|Patients will be placed under wait and see approach without any specific treatment
48311925|NCT03634358|PROCEDURE|Bipolar scissors|
48311926|NCT03634358|PROCEDURE|classic scalpel|
48311927|NCT03860545|DIAGNOSTIC_TEST|urine and blood analysis|concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively
48311928|NCT06318663|OTHER|Survivor Mom Companion|Weekly intervention sessions will follow the survivor Moms' Companion manualized modules. One module each week. The module centers on reinforcement of information introduced in each previous module, then emotional support, and referrals to additional services or specialists as needed. Participants in each session will practice applying knowledge and skills using the module's vignettes. Process guides prompt inquiry about in vivo management of post-traumatic stress disorder reactions and emotional and interpersonal responses to events since the last session. Each module may require 45 minutes of self-study before each session and 45 minutes of in-session time spent with the interventionist.
48311929|NCT05542303|DRUG|ZB001 for injection|Dose Cohort1 (3mg/kg) ZB001 of single IV injection
48114024|NCT03833154|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
48311930|NCT05542303|DRUG|ZB001 for injection|Dose Cohort2 (10mg/kg) ZB001 of single IV injection
48311931|NCT05542303|DRUG|ZB001 for injection|Dose Cohort3 (20mg/kg) ZB001 of single IV injection
48311932|NCT04004624|DEVICE|Ablation|Cardiac Ablation
48311933|NCT03435991|OTHER|Validation Experience Sampling Method 'Uromate'|In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
48311934|NCT06083246|OTHER|Hybenix gel|Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.
48311935|NCT06083246|OTHER|Chlosite gel|Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
48311936|NCT02370498|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
48311937|NCT02370498|DRUG|paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
47963093|NCT04872582|DRUG|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
47963094|NCT02085122|OTHER|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
47963095|NCT00000869|DRUG|Nevirapine|
47963096|NCT00871533|DRUG|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
47963097|NCT00871533|DRUG|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
47963098|NCT00871533|DRUG|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
47963099|NCT00871533|DRUG|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
47963100|NCT05212571|DRUG|S-ketamine infusion inpatient setting|S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
48114025|NCT03833154|DRUG|(Osimertinib cohort, single-arm, open-label separate cohort)|Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
48114026|NCT00951379|DRUG|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
48114027|NCT00951379|OTHER|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
48114028|NCT00951379|OTHER|laboratory biomarker analysis|Correlative studies
48114029|NCT00310154|DRUG|docetaxel|
47963101|NCT05212571|DRUG|S-ketamine infusion outpatient setting|S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
47963102|NCT05678777|DEVICE|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
47963103|NCT05267886|DRUG|Dobutamine|Dobutamine administered according to its clinical dose stage for cardiogenic shock
47963104|NCT05267886|DRUG|Milrinone|Milrinone administered according to its clinical dose stage for cardiogenic shock
47963105|NCT05267886|DRUG|Normal Saline|Normal saline running at a standardized rate
47963106|NCT01261910|BEHAVIORAL|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
48114030|NCT00310154|DRUG|gefitinib|
48114031|NCT00310154|OTHER|laboratory biomarker analysis|
48114032|NCT00310154|RADIATION|radiation therapy|
48114033|NCT03013504|DRUG|HD201|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
48114034|NCT03013504|DRUG|Herceptin|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
48311938|NCT00587821|OTHER|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
48114035|NCT03013504|DRUG|Docetaxel|75mg/m2 via i.v. infusion during cycles 1 to 4.
48114036|NCT03013504|DRUG|Epirubicin|75 mg/m2 via i.v. infusion during cycles 5-8.
48114037|NCT03013504|DRUG|Cyclophosphamide|500 mg/m2 via i.v. infusion during cycles 5-8.
48114038|NCT02999022|DRUG|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
48114039|NCT02999022|DRUG|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
48114040|NCT00596310|OTHER|CT|Screening CT
48114041|NCT02341625|DRUG|BMS-986148|
48114042|NCT02341625|BIOLOGICAL|Nivolumab|
48114043|NCT01320215|PROCEDURE|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
48114044|NCT01320215|PROCEDURE|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
48114045|NCT00861510|DRUG|ON01910 Na|
48311939|NCT01419275|DRUG|Xenon contrast agent|
48311940|NCT01419275|DEVICE|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
48311941|NCT06502470|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
48643295|NCT06466486|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
48643296|NCT06466486|DRUG|FE999302|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
48114046|NCT03778099|DRUG|Cinnamon Cap 500 MG|The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.
48311942|NCT04169594|DIAGNOSTIC_TEST|3D Gait Analysis with Statistical Parametric Mapping|A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
48311943|NCT01680419|BEHAVIORAL|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
48311944|NCT01680419|BEHAVIORAL|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
48311945|NCT00429039|DRUG|L-leucyl-L-leucine methyl ester (LLME)|
48311946|NCT02896907|DRUG|Oxaliplatin|Given IV
48311947|NCT02896907|DRUG|Irinotecan Hydrochloride|Given IV
48311948|NCT02896907|DRUG|Leucovorin Calcium|Given IV
48311949|NCT02896907|DRUG|Fluorouracil|Given IV
48311950|NCT02896907|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
48311951|NCT04539249|DRUG|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
48483542|NCT04625452|BEHAVIORAL|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
48483543|NCT01056094|DRUG|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
48483544|NCT02382549|DRUG|BRAF inhibitor|BRAF inhibitor
48483545|NCT02382549|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
48483546|NCT02382549|DRUG|MEK inhibitor|MEK Inhibitor
48483547|NCT00951626|BEHAVIORAL|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
48483548|NCT00951626|BEHAVIORAL|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
48643297|NCT06466486|DRUG|FE999302 Placebo|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
48643298|NCT06479863|COMBINATION_PRODUCT|Pozelimab/Cemdisiran|Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks
48643299|NCT05445843|DRUG|JDQ443|JDQ443 orally administered
48643300|NCT01708941|BIOLOGICAL|Ipilimumab|Given IV
48114047|NCT03778099|DRUG|Placebo|450 mg of starch and 50 mg of cinnamon powder
48114048|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
48483549|NCT00951626|DIETARY_SUPPLEMENT|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
48483550|NCT00951626|OTHER|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
47963107|NCT01848860|PROCEDURE|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
47963108|NCT01848860|BIOLOGICAL|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
47963109|NCT05002062|DEVICE|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning\& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
48483551|NCT00951626|OTHER|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
47963110|NCT05002062|OTHER|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
47963111|NCT04326556|OTHER|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
48114049|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
48114050|NCT01135511|DRUG|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
48114051|NCT01135511|DRUG|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
48114052|NCT01135511|DRUG|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
48311952|NCT04539249|DRUG|Pentazocine|"Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
48311953|NCT00335946|DEVICE|HANS non-needle acupuncture|
48311954|NCT00335946|PROCEDURE|Stimulation of two acupuncture points bi-lateral|
48311955|NCT02488759|DRUG|Nivolumab|
48311956|NCT02488759|DRUG|Ipilimumab|
48311957|NCT02488759|DRUG|Relatlimab|
48311958|NCT02488759|DRUG|Daratumumab|
48311959|NCT01134692|DRUG|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
48483552|NCT00951626|PROCEDURE|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
48483553|NCT00951626|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
48643301|NCT01708941|OTHER|Laboratory Biomarker Analysis|Correlative studies
48643302|NCT01708941|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV or SC
48114053|NCT06676371|PROCEDURE|Conventional hemiarch replacement|Conventional open hemiarch replacement
48114054|NCT06676371|PROCEDURE|E-vita® Open Neo; Artivion|E-vita® Open Neo is a hybrid stent graft system for aortic arch and descending thoracic aorta repair with Frozen Elephant Trunk Technique.
48483554|NCT00951626|PROCEDURE|assessment of therapy complications|Collected throughout the 12 month study period
48483555|NCT00951626|PROCEDURE|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
48311960|NCT02730845|DRUG|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
48311961|NCT02730845|DRUG|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
48311962|NCT04999826|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
48311963|NCT04999826|OTHER|Quality-of-Life Assessment|Ancillary studies
48311964|NCT04999826|OTHER|Questionnaire Administration|Complete questionnaires
48311965|NCT05340257|DRUG|Augmentin ES|Amoxicillin and clavulanic acid in fixed dose combination will be administered
48311966|NCT05667727|DRUG|nebulized epinephrine|we are using 1:1000 epinephrine into nebulization form
48311967|NCT05667727|DRUG|Salbutamol|Patient will receive salbutamol as 4th nebulization.
48311968|NCT02524860|DEVICE|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
48311969|NCT01636024|DRUG|AZD7594|Suspension inhaled via Spira nebuliser
48311970|NCT01636024|DRUG|Placebo to match|Matching placebo inhaled via Spira nebuliser
48311971|NCT05630404|DRUG|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
48311972|NCT05630404|DRUG|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
48311973|NCT01631279|DRUG|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
48311974|NCT00083070|DRUG|temozolomide|
48311975|NCT02651194|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
48311976|NCT06519006|PROCEDURE|Pelvic floor exercise|Exercises aimed at this issue consist of identification and isolated contraction of the pelvic floor muscles as well as their activation during complex movements and daily activities. During the engagement of the pelvic floor muscles, the correct engagement of the respiratory activity is important. Within the exercise units, exercises are used from sphincter contraction, through the gradual activation of individual pelvic floor layers in various ways, to their complex involvement in movement activities. Exercises are practiced repeatedly, at different frequencies and intensities that gradually increase, 4-5 times per day.
48311977|NCT02876939|OTHER|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
48311978|NCT02876939|OTHER|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
48311979|NCT03546179|OTHER|tidal volume challenge test|Tidal volume (VT) will be increased from 6 to 8 ml/kg of for one minute and hemodynamic variables, including PVI with 8 ml/kg tidal volume ventilation (PVI8) will be recorded.
48311980|NCT03546179|OTHER|Volume loading|After these two baseline hemodynamic measurements, volume expansion will be performed for 10 min using an infusion of balanced crystalloid solution (6ml/kg of predicted body weight).
48311981|NCT02426372|BIOLOGICAL|QBECO SSI|QBECO Site Specific Immunomodulators
48311982|NCT02665234|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
48311983|NCT02665234|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
48311984|NCT05127096|DIAGNOSTIC_TEST|FirstSight blood test|FirstSight blood test for colorectal cancer screening
48311985|NCT06072872|DEVICE|Use of portable CPAP|Patients use portable CPAP during exercise
48311986|NCT05610995|DEVICE|SENSIUM Patch|The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
48311987|NCT05605379|BIOLOGICAL|Next Generation Sequencing (DNA and RNA)|Targeted Next Generation Sequencing (DNA and RNA)
48311988|NCT02202031|BEHAVIORAL|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
48311989|NCT02202031|BEHAVIORAL|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
48311990|NCT05441137|BEHAVIORAL|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
47963112|NCT02211079|DRUG|JNJ-54861911|JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.
48311991|NCT05441137|BEHAVIORAL|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
48311992|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
48311993|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
47963113|NCT02211079|DRUG|Caffeine|Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
47963114|NCT02211079|DRUG|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
47963115|NCT02211079|DRUG|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
48311994|NCT02156869|OTHER|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
48311995|NCT06494878|DRUG|Aspirin|75-100 mg taken once daily by mouth.
48311996|NCT06494878|DRUG|Low-molecular-weight heparin|Low-molecular-weight heparin injections daily as prescribed by the treating physician.
48311997|NCT01803399|DRUG|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
48311998|NCT01803399|DRUG|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
48311999|NCT01803399|DRUG|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
48312000|NCT01803399|DRUG|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
48312001|NCT05277870|DEVICE|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
48312002|NCT05277870|DEVICE|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
48312003|NCT04770987|OTHER|lateral neck flexor endurance test|Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
48312004|NCT03334669|BEHAVIORAL|Parents Connect for Healthy Living (PConnect)|Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health; NOTE: The PConnect program was not implemented in 2019-2020 due to the coronavirus pandemic. In 2020-2021, PConnect was implemented virtually; these are pilot data and not part of the main trial.
48483556|NCT00951626|PROCEDURE|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
48483557|NCT00951626|PROCEDURE|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
48114055|NCT06676371|PROCEDURE|Thoraflex Hybrid; Terumo|The Thoraflex Hybrid is a device system designed to repair a weakened and bulging section (aneurysm) and/or a tear in the lining (dissection) of the aorta behind the heart (aortic arch). The system includes a polyester graft section that reinforces a weakened section of the blood vessel, a connected stented section (nitinol wire frame on polyester graft material) that holds the artery open, and a delivery catheter that is used to place the device. The polyester graft and stented sections are coated with a protein substance taken from animal body parts (gelatin) to seal the implant and prevent blood from leaking out.
48483558|NCT00951626|PROCEDURE|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
47963116|NCT03857048|OTHER|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
47963117|NCT03857048|OTHER|Exercise training|16-wk supervised endurance exercise training program
48312005|NCT03334669|BEHAVIORAL|Enhanced Nutrition Support|Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child has overweight or obesity. NOTE: Enhanced nutrition support was not implemented in spring 2020 due to the pandemic. In 2020-2021, it was moved to a virtual format in what will be a pilot virtual trial.
48312006|NCT03334669|BEHAVIORAL|Media Resources|Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families. NOTE: Due to the pandemic, media resources were not shared in spring 2020. They were implemented in virtual format in 2020-2021 in a pilot virtual trial.
47963118|NCT03857048|OTHER|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
48312007|NCT03540134|DEVICE|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
48312008|NCT00696657|DRUG|semaglutide|0.1 mg, once weekly, s.c. injection
48312009|NCT00696657|DRUG|semaglutide|0.2 mg, once weekly, s.c. injection
48312010|NCT00696657|DRUG|semaglutide|0.4 mg, once weekly, s.c. injection
48312011|NCT00696657|DRUG|semaglutide|0.8 mg, once weekly, s.c. injection
48312012|NCT00696657|DRUG|semaglutide|0.8 mg with titration, once weekly, s.c. injection
48312013|NCT00696657|DRUG|semaglutide|1.6 mg with titration, once weekly, s.c. injection
48312014|NCT00696657|DRUG|placebo|0.1 mg, once weekly, s.c. injection
48312015|NCT00696657|DRUG|placebo|0.2 mg, once weekly, s.c. injection
48312016|NCT00696657|DRUG|placebo|0.4 mg, once weekly, s.c. injection
48312017|NCT00696657|DRUG|placebo|0.8 mg with titration, once weekly, s.c. injection
48483559|NCT05674799|BEHAVIORAL|NDPP-NextGen|"NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) Pre-sessions to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance."
48312018|NCT00696657|DRUG|placebo|1.6 mg, once weekly, s.c. injection
48312019|NCT00696657|DRUG|liraglutide|1.2 mg with titration, once daily, s.c. injection
48312020|NCT00696657|DRUG|liraglutide|1.8 mg with titration, once daily, s.c. injection
48312021|NCT03029650|DRUG|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
48312022|NCT03029650|DRUG|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
48312023|NCT03989219|PROCEDURE|plasma cfDNA methylation|plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
48643303|NCT06585696|DRUG|CU-20101 treatment for Moderate to Severe Glabellar Striae|"Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36)."
48312024|NCT04772664|DIETARY_SUPPLEMENT|Multispecies-Probiotic|Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
48312025|NCT04772664|DIETARY_SUPPLEMENT|Placebo Supplement|Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
47963119|NCT04067674|BIOLOGICAL|Blood sampling|Blood sampling for biomarker measurement
47963120|NCT03742830|DEVICE|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
47963121|NCT03129178|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
48312026|NCT00233259|BEHAVIORAL|Mediterranean Diet|Mediterranean dietary program
48312027|NCT00233259|BEHAVIORAL|Physical Activity|Physical activity program
48312028|NCT00233259|BEHAVIORAL|Stress Management|Stress management program
48312029|NCT00233259|BEHAVIORAL|Social Support|Social support
48312030|NCT00233259|BEHAVIORAL|Smoking Cessation|Smoking cessation program
48312031|NCT00233259|OTHER|Control group|Usual Diabetes Care Control group
48312032|NCT04863014|DRUG|evinacumab|Intravenous infusion every 4 weeks (Q4W)
48312033|NCT04863014|OTHER|Placebo|Intravenous infusion Q4W
48312034|NCT06115161|DEVICE|Instrumented Orthosis|Gait analysis will be performed with the instrumented orthosis as well as the reference system.
48312035|NCT04860284|DRUG|Hydroxychloroquine tablets|Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
48312036|NCT02653105|BIOLOGICAL|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
48312037|NCT03071536|DRUG|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
48312038|NCT01465698|BEHAVIORAL|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
47963122|NCT05950256|DEVICE|N95 mask and surgical mask|Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
47963123|NCT03428724|DRUG|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
47963124|NCT03428724|DRUG|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age\>65, neurologic comorbidities)
47963125|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
48114056|NCT06186245|OTHER|Early feeding with an oral diet|Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.
48114057|NCT03289962|DRUG|Autogene cevumeran|Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.
48114058|NCT03289962|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
48114059|NCT00908817|DRUG|triamcinolone acetonide|paste applied over tracheal tube for lubrication
48114060|NCT00908817|DRUG|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
48114061|NCT06448598|OTHER|Exercise|The exercise protocol involved twice-weekly sessions, with aerobic exercises performed at 70% of the maximum heart rate achieved during the step test, and resistance exercises at 60% of 1RM. Participants self-selected their exercise timing, either intradialytic (during HDF sessions) or interdialytic (on non-dialysis days). For the intradialytic group, exercise was seamlessly integrated into the HDF session, excluding the initial and final two hours of dialysis.
48114062|NCT06651294|DIETARY_SUPPLEMENT|Neorenal Forte|This specialized formulation of phytotherapeutic extracts consists of proprietary Betula pendula leaves dry extract, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens. The product contains supplementary ingredients: microcrystalline cellulose, povidone, magnesium stearate, colorant film (brilliant blue FCF, iron dioxide).
48114063|NCT06651294|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical to the active form and will have the same composition but without the proprietary extract from Betula pendula, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens.
48114064|NCT04979299|OTHER|Wheelchair|Patient will be asked to sit in a wheelchair, and a 5-minute video recording of spontaneous speech capturing the semi-structured iCGI interview is made.
48114065|NCT05392946|DRUG|Bortezomib|Given SC
48312039|NCT01465698|BEHAVIORAL|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
48114066|NCT05392946|BIOLOGICAL|Daratumumab|Given SC
48312040|NCT01465698|BEHAVIORAL|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
48312041|NCT01465698|OTHER|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
48312042|NCT04362904|OTHER|acupressure|
48643304|NCT06026696|OTHER|follow-up|Long term follow-up
47963126|NCT01705990|BIOLOGICAL|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
47963127|NCT01705990|BIOLOGICAL|Ad35-GRIN (0.5mL)|(1x10\^10 vp) Delivered intramuscularly by standard syringe and needle injection
47963128|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)|100 mg subcutaneous (s.c) once
47963129|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)|200 mg subcutaneous (s.c) once
48114067|NCT05392946|DRUG|Dexamethasone|Given PO
48114068|NCT05392946|DRUG|Iberdomide|Given PO
48114069|NCT00473811|BEHAVIORAL|Low GI|low-GI education
48114070|NCT00473811|BEHAVIORAL|ADA diet|ADA dietary education
48114071|NCT03547479|BEHAVIORAL|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
48114072|NCT03547479|BEHAVIORAL|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
48114073|NCT02016352|BIOLOGICAL|patient CSF extraction with hydrocephalus|CSF extraction
48114074|NCT02016352|BIOLOGICAL|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
48114075|NCT05500807|DRUG|Emicizumab|Subcutaneous injection of emicizumab for prophylaxis
48114076|NCT01052233|PROCEDURE|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
48114077|NCT01052233|PROCEDURE|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
47963130|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)|300 mg subcutaneous (s.c) once
47963131|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
47963132|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
47963133|NCT05588908|DRUG|Compound Betamethasone Injection (phase II)|1 mL i.m. once on Day 1
47963134|NCT05588908|OTHER|Placebo (phase II)|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
47963135|NCT04214769|DIAGNOSTIC_TEST|Audiometry and tympanometry, vHIT, VEMP, ENG|Diagnostic tests
48643305|NCT00769379|OTHER|Laboratory Biomarker Analysis|Correlative studies
47963136|NCT04456946|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy
47963137|NCT04456946|DEVICE|Occlusal Splint Treatment|Occlusal Splint Treatment
47963138|NCT05107674|DRUG|NX-1607|Oral NX-1607
47963139|NCT05107674|DRUG|Paclitaxel|Paclitaxel IV
47963140|NCT01814384|DEVICE|prosthesis GMK ® without the ancillary MyKnee ® LBS|
47963141|NCT01814384|DEVICE|Matched patient cutting blocks MyKnee ® LBS|
47963142|NCT05700097|DRUG|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
47963143|NCT05700097|DRUG|Placebo injection|placebo control arm for the standard protocol
47963144|NCT03345914|DRUG|Dupilumab|"Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)"
47963145|NCT03345914|DRUG|Matching Placebo|"Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)"
47963146|NCT03345914|OTHER|Background Treatment: Topical Corticosteroids|All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
47963147|NCT03345914|OTHER|Background Treatment: Moisturizers|All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
47963148|NCT02527161|DEVICE|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
47963149|NCT00443261|DRUG|Azacitidine|SC azacitidine
47963150|NCT00443261|DRUG|Cisplatin|cisplatin 75 mg/m\^2 day 8 every 28 days
47963151|NCT04958135|DRUG|Acoramidis|Film-coated immediate release oral tablet.
47963152|NCT05456269|DRUG|Bisantrene Dihydrochloride (high dose)|Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
47963153|NCT05456269|DRUG|Bisantrene Dihydrochloride (low dose)|IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
47963154|NCT05456269|DRUG|Cytarabine Hydrochloride|Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
47963155|NCT05456269|DRUG|Decitabine and cedazuridine|PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
47963156|NCT02445508|DRUG|Sevelamer|
47963157|NCT02445508|DRUG|Cholecystokinin|
48643306|NCT00769379|BIOLOGICAL|Trastuzumab|Given IV
48643307|NCT00769379|RADIATION|Whole Breast Irradiation|Undergo standard whole breast irradiation
47963158|NCT02445508|DRUG|Sevelamer placebo|
47963159|NCT02445508|DRUG|Isotonic saline|
47963160|NCT06556732|DRUG|Eplereone|Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
47963161|NCT04375371|PROCEDURE|Bariatric surgery|Obese patients who haveundergone bariatric surgery as part of routine clinical management within the indication of this intervention.
47963162|NCT03642457|DRUG|Bupivacaine|20 cc 0.5%
47963163|NCT03642457|DRUG|Bupivacaine liposome|133mg liposomal bupivacaine
47963164|NCT00261183|DRUG|Melatonin|
47963165|NCT05598541|PROCEDURE|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
47963166|NCT03485339|DIAGNOSTIC_TEST|genome testing|blood sampling via venipuncture
47963167|NCT01185756|RADIATION|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
47963168|NCT02298608|DEVICE|Nano Knife|Percutaneous, CT guided, ablation of renal mass
47963169|NCT04843020|DRUG|ION 682884|Subcutaneous injection every month
47963170|NCT01091974|DRUG|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
47963171|NCT01091974|DRUG|Placebo Comparator|Placebo for 47 days
47963172|NCT01091974|BEHAVIORAL|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
47963173|NCT00926328|DRUG|Triclosan, fluoride|Six Month study, brush twice daily
47963174|NCT00926328|DRUG|Fluoride|twice daily usage
47963175|NCT04299074|OTHER|addiction|questionnaire
47963176|NCT01133522|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
47963177|NCT01133522|BIOLOGICAL|Placebo|Administered by subcutaneous injection
47963178|NCT00386438|PROCEDURE|Honan balloon application|
47963179|NCT01671800|DRUG|Botulinum Type B|
47963180|NCT01671800|DRUG|Placebo|
48312043|NCT01463904|PROCEDURE|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
48312044|NCT01035255|DRUG|LCZ696 200 mg BID|LCZ696 200 mg BID
48114078|NCT00959582|PROCEDURE|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
48114079|NCT00114244|DRUG|sorafenib tosylate|Given PO
48114080|NCT00114244|DRUG|gemcitabine hydrochloride|Given IV
48114081|NCT00114244|OTHER|laboratory biomarker analysis|Correlative studies
48312045|NCT01035255|DRUG|Enalapril 10 mg BID|Enalapril 10 mg BID
48312046|NCT06361329|DRUG|Homoharringtonine|Intravenous infusion
48312047|NCT06361329|DRUG|venetoclax|Orally by mouth
48312048|NCT06361329|DRUG|Cytarabine|subcutaneous injection or Intravenous infusion
48483560|NCT04310488|OTHER|The Centre of excellence self-administered (CESAM) questionnaire items|Complete a self-administered questionnaire within two days of their museum visit.
48483561|NCT00284804|DRUG|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
48483562|NCT05391711|BEHAVIORAL|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~1. Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~2. Culturally Smart Relationships Training (live, virtual)~3. JEDI enhanced monthly supervision from case managers~4. Monthly emails with activity suggestions for mentors and youth"
48483563|NCT02168725|DRUG|briciclib|
47963181|NCT02782637|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
47963182|NCT04765696|OTHER|No intervention is administered|No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.
47963183|NCT05561569|PROCEDURE|Pars plana vitrectomy|23 gauge pars plana vitrectomy for managing primary retinal detachment.
47963184|NCT01531595|DRUG|Bevacizumab plus alternating Xelox/Xeliri|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
48114082|NCT06676956|PROCEDURE|Order of bronchoscopy procedures for peripheral nodule biopsy|Patient scheduled to undergo peripheral nodule biopsy of the lung under bronchoscopy typically get both a nodule biopsy as well as a linear EBUS of the lymph nodes to assess for any disease spread. This procedure will randomize patients to either getting the peripheral nodule first or linear EBUS of the lymph nodes first and assess overall diagnostic yield as the primary outcome.
48114083|NCT05375188|DRUG|Dexmedetomidine|DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
48114084|NCT05375188|DRUG|Normal Saline|DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
48266705|NCT02260518|BEHAVIORAL|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
48312049|NCT06361329|DRUG|G-CSF|subcutaneous injection
48312050|NCT06361329|DRUG|Vindesine|Intravenous infusion
48312051|NCT06361329|DRUG|Daunorubicin|Intravenous infusion
48312052|NCT06361329|DRUG|cyclophosphamide|Intravenous infusion
48312053|NCT06361329|DRUG|Dexamethasone|Intravenous infusion or orally
48312054|NCT06361329|DRUG|L-ASP|subcutaneous injection
48312055|NCT06339736|OTHER|Questionnaires administered to all study participants|Ten treatment sessions were performed, which initially involved muscular stretching and relaxation exercises and then strengthening and endurance exercises to achieve stabilization. An oral splint was applied to he upper dental arch.
48312056|NCT00101803|DRUG|vildagliptin|
48312057|NCT02413125|DEVICE|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
48312058|NCT02413125|DRUG|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
48312059|NCT06554834|PROCEDURE|CV4 + RR|Participants in this group will undergo three 30-minute sessions of osteopathic therapy. The intervention will involve a combination of the Fourth Ventricle Compression (CV4) technique and the Rib Raising (RR) technique. These sessions will be administered once per week over three consecutive weeks. The CV4 technique involves gentle compression of the occiput to influence cranial rhythmic impulses, while the RR technique involves mobilization of the rib cage to impact autonomic nervous system function.
48312060|NCT06554834|PROCEDURE|CV4|Participants in this group will receive three 30-minute sessions focusing solely on the Fourth Ventricle Compression (CV4) technique. The sessions will be conducted once per week for three consecutive weeks. The CV4 technique involves applying gentle pressure to the occiput with the goal of affecting cranial rhythmic impulses and promoting autonomic nervous system balance.
47963185|NCT00425295|BEHAVIORAL|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
48312061|NCT06554834|DEVICE|sham ultrasound transducer|Participants in the placebo group will undergo three 30-minute sessions of a sham procedure using an ultrasound transducer. The transducer will be applied in a manner that mimics a therapeutic intervention, but without delivering any actual therapeutic effect. These sessions will also be conducted once per week for three consecutive weeks.
48312062|NCT06554834|DEVICE|Ultrasound Transducer Sham Procedure|Participants in the placebo group will undergo three 30-minute sessions using an ultrasound transducer as part of a sham procedure. The transducer will be applied to the body in a manner that mimics a therapeutic intervention, but it will not deliver any actual therapeutic effect. This procedure is designed to simulate the experience of receiving treatment without providing the physiological benefits associated with active ultrasound therapy. The sessions will be conducted once per week over three consecutive weeks.
48312063|NCT06554834|DEVICE|EEG/HRV/RSA (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring using Infiniti System|Participants in this study will undergo monitoring of Heart Rate Variability (HRV), and Respiratory Sinus Arrhythmia (RSA) using the Infiniti 8 measuring device. This system includes a ProComp Infiniti encoder, which is a versatile and advanced tool for capturing physiological signals, and the Biograph Infiniti software, which, along with the Physiology Suit, allows for detailed analysis and monitoring of autonomic nervous system function.
48312064|NCT03535233|DRUG|Triamcinolone Acetonide|
48312065|NCT03535233|DRUG|Minoxidil 5 % Topical Spray|
48312066|NCT03535233|DRUG|clobetasol propionate|
48312067|NCT03134950|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
48312068|NCT05583006|DRUG|tenofovir alafenamide (TAF)|TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
47963186|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|Temperature
47963187|NCT01935791|DRUG|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Hormone
48312069|NCT05966766|OTHER|Mozart selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections by Mozart of previously studied and shown to reduce anxiety.
48312070|NCT05966766|OTHER|Patient-preferred music selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections of patient choice.
48312071|NCT01332812|DRUG|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
48312072|NCT01332812|OTHER|control group|General anesthesia, without additional interventions
48312073|NCT01415037|PROCEDURE|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
48312074|NCT05505565|DEVICE|Abbott Freestyle Libre 2|Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
48312075|NCT05505565|OTHER|Standard physical activity and nutritional counseling for prediabetes management|Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
48312076|NCT02114567|OTHER|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
48312077|NCT00300651|BEHAVIORAL|Cognitive Behavioral Therapy|
47963188|NCT01935791|OTHER|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|Temperature
47963189|NCT01935791|DRUG|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|Hormone
47963190|NCT01935791|DRUG|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|Hormone
47963191|NCT01935791|DRUG|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|hormone
47963192|NCT01935791|DRUG|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|hormone
47963193|NCT01935791|DRUG|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|hormone
47963194|NCT01935791|DRUG|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|Hormone
47963195|NCT01489800|BEHAVIORAL|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
47963196|NCT01651039|DRUG|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
48483564|NCT02443545|DRUG|Deferiprone|
48114085|NCT02073123|DRUG|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~* If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~* If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~* If \> 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~* If \>1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If \>1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
48483565|NCT06205706|DRUG|BI-1910|BI-1910 administered as a flat-dose IV infusion once every 3 weeks
48483566|NCT06205706|DRUG|Pembrolizumab|Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
48483567|NCT05665959|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
48483568|NCT04711720|DEVICE|"VTS surgical navigation system"|"TheVTS surgical navigation system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track the surgical instruments during the operation, and update the position of the surgical instruments on the patient's image in real time, so that the doctor can clearly understand the position of the surgical instruments relative to the patient's anatomical structure, and make the operation procedure more accurate and safer."
48483569|NCT06484322|BEHAVIORAL|Strategies Empowering Activities in Everyday life (SEE 2.0)|SEEs internet-based intervention process begins with supporting the client to explore the need of and readiness for changes in everyday life. Thereafter, the client is supported to self-analyse their engagement in activities in everyday life along with use of management strategies in everyday life. Next, the client takes on web- modules including short educational movies with subsequent analyses and reflections. The modules aim to support the development of self-management by improving the knowledge of how strategies and changes in daily activities can prevent disabilities and contribute to improved health. After that, the focus is on establishing an activity plan with goals and activity-based management strategies to promote an active everyday life. The clients' implementation of the plan is supported through follow-up meetings. During the whole intervention process, the client is regularly supported by an occupational therapist through feedback and online guiding dialogues.
48483570|NCT05375019|BEHAVIORAL|Positive discipline program|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program
48483571|NCT05375019|BEHAVIORAL|active control group|free interaction group consisting of topics determined by the families.
48643308|NCT05546385|DEVICE|Partial Rebreathing Device|Partial Rebreathing Device
48643309|NCT05546385|DEVICE|Sham breathing device|Sham breathing device
48643310|NCT06153355|DRUG|LY3839840|Administered orally.
48643311|NCT06153355|DRUG|Placebo|Administered orally.
48643312|NCT02941783|DRUG|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
48312078|NCT01683110|DRUG|cabozantinib|
48312079|NCT01438749|DRUG|Placebo|Single dose
48312080|NCT01438749|DRUG|RO4917838|Single doses (3 dose levels)
48312081|NCT01438749|DRUG|diazepam|Single dose
48312082|NCT04691063|DRUG|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
48312083|NCT04691063|DRUG|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
48312084|NCT00000944|DRUG|Indinavir sulfate|
48312085|NCT00000944|DRUG|Lamivudine|
48312086|NCT00000944|DRUG|Zidovudine|
48312087|NCT02623634|BEHAVIORAL|Position, waveform|different positions and waveform
48312088|NCT02191709|DRUG|Dextromethorphan syrup|
48312089|NCT02191709|DRUG|Dextromethorphan soft pastilles|
48312090|NCT04851717|DRUG|Remimazolam|Remimazolam for intravenous sedation
48312091|NCT01163162|DRUG|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
48312092|NCT03617133|RADIATION|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of \~20% IB, \~50% IIB, \~20% IIIB and \~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
48643313|NCT06605027|OTHER|Therapeutic Ketogenic Diet|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
48114086|NCT02073123|DRUG|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
48114087|NCT02073123|DRUG|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
48114088|NCT02073123|DRUG|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
48114089|NCT06139315|DRUG|BI 765845|BI 765845
48114090|NCT06139315|DRUG|Placebo|Placebo
48114091|NCT00106054|DRUG|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
48114092|NCT03772457|DRUG|Rivaroxaban|new oral anticoagulant molecules which is the selective factor Xa inhibitor
48114093|NCT01064817|DRUG|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
48114094|NCT01064817|DRUG|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
48114095|NCT05261815|OTHER|Ultrasound Therapy|Ultrasound Therapy improves the pain management in patients with herniation. It eases down the severity of symptoms as well.
48114096|NCT05261815|OTHER|High Intensity Laser Therapy|Treatment of low disc herniation should be non-surgical, pharmacological and by physical therapy modalities. Laser radiation with high intensity used as a modality called high intensity laser therapy. It is used to relieve the pain by three process; Photo-chemical, Photo-thermal, Photo-mechanical. High Intensity Laser Therapy uses high intensity laser irradiation and low light absorption.
48114097|NCT03114904|OTHER|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
48114098|NCT05448807|DRUG|OraVerse|Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
48114099|NCT04780035|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
48483572|NCT06076551|DIAGNOSTIC_TEST|Adenosine stress echocardiography|Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood ﬂow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel ﬂow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary ﬂow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
48114100|NCT04780035|OTHER|Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)|The use of placebo: intramuscularly twice, given 21 to 28 days apart at a dose of 0.5 ml
48114101|NCT00623792|BEHAVIORAL|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
48483573|NCT04894084|DEVICE|CP321|The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
48483574|NCT00177463|DRUG|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
48483575|NCT03827018|COMBINATION_PRODUCT|mavrilimumab|1 mL of 150 mg in a pre-filled syringe
48483576|NCT03827018|COMBINATION_PRODUCT|placebo|1 mL of placebo in a pre-filled syringe
48643314|NCT06536530|BEHAVIORAL|Exergame-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
48643315|NCT06536530|BEHAVIORAL|Cognitive-Based Training|40-50 min sessions, two sessions per week, for a total of eight weeks.
48643316|NCT06536530|BEHAVIORAL|Wait-List|Participants will not train with any program and they will not assist to any specific session or intervention
48643317|NCT06467708|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).
48114102|NCT02779517|OTHER|Mobile Service Robot Survey|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
48114103|NCT02779517|OTHER|Mobile Service Robot Survey for Patients|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
48114104|NCT02960659|DRUG|Liraglutide|Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.
48114105|NCT02960659|DRUG|Metformin|Metformin 500mg oral tablet
48483577|NCT03827018|DRUG|prednisone|Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
48483578|NCT03512184|BEHAVIORAL|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
48114106|NCT05936411|DEVICE|Siemens Quadra PET/CT and [18F]FDG|The Siemens Quadra PET/CT, a clinically approved imaging device, is utilized in conjunction with the radiopharmaceutical tracer \[18F\]FDG in this study. The device allows for the acquisition of emission data across an extended axial field of view (axFOV) of 106 cm, covering an imaging range from the head to the thighs. The device's capabilities are leveraged to perform quantitative functional examinations of an extended axFOV. Subjects are scanned twice within a month for reproducibility standards. Each time, they are injected with 100MBq \[18F\]FDG and examined for 60 minutes in a dynamic scan. The tracer is used to build an atlas of normative glycolytic activities for most organs, excluding the brain. The glycolytic activities are measured as organ-based standardized uptake values. An ultra-low-dose CT scan is acquired to estimate mandatory attenuation correction factors.
48114107|NCT05936411|DEVICE|Apple i-Watch|The Apple i-Watch, a wearable smart device, is used to continuously monitor physiological signals from the subjects. These signals include heart rate, steps and distance, calories burned, sleep tracking, blood oxygen saturation (SpO2), electrocardiogram (ECG), and workout tracking. Subjects are required to wear the Apple i-Watch for three months prior to the first PET scan and up to three months after the second PET scan. The data collected from the Apple i-Watch is paired with the FDG-PET image readouts to identify relationships between lifestyle and glucose uptakes during the scan.
48114108|NCT04077632|DEVICE|Transcranial direct current stimulation|tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
48114109|NCT02972801|PROCEDURE|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
48114110|NCT00677391|DRUG|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
48114111|NCT00677391|DRUG|Placebo|Capsules, once daily
48266706|NCT01424735|DRUG|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
48266707|NCT03092050|BEHAVIORAL|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
48266708|NCT03092050|BEHAVIORAL|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
48266709|NCT06265844|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48266710|NCT06265844|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48266711|NCT06265844|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48266712|NCT02071433|PROCEDURE|Saphenous nerve blockade|
48266713|NCT02071433|PROCEDURE|Femoral nerve blockade|
48312093|NCT03617133|RADIATION|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
48312094|NCT03617133|RADIATION|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
48483579|NCT05073120|OTHER|Piqray Prescriber's/HCP guide for hyperglycemia|oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
48114112|NCT01234610|BEHAVIORAL|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
48312095|NCT03617133|RADIATION|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by \~50%.
48114113|NCT04895475|BEHAVIORAL|SARS-CoV-2 vaccine|Baseline demographics, baseline breast milk samples, and blood collection will be obtained at the initial visit. Serial collections of breastmilk and blood as well as weekly self-administered monthly surveys will occur
48312096|NCT03617133|RADIATION|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
48312097|NCT03617133|RADIATION|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
48312098|NCT03617133|RADIATION|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or \>2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
48483580|NCT00479388|DRUG|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
48483581|NCT00479388|DRUG|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
48483582|NCT00479388|DRUG|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
48483583|NCT04539626|DRUG|Estrogen Therapy|EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)
48483584|NCT04412057|DRUG|CERC-002|Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
48114114|NCT00206375|DRUG|Growth hormone|Growth hormone + Synthroid + Lupron
48114115|NCT00206375|DRUG|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
48312099|NCT03617133|DRUG|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
48312100|NCT03617133|OTHER|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of \<=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (\>80%) will adhere to the \<=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
48312101|NCT02843295|OTHER|blood samples|
47963197|NCT01651039|DRUG|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
48114116|NCT00971789|RADIATION|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
48312102|NCT01586156|DRUG|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
48312103|NCT01586156|DRUG|placebo|Placebo will be taken twice daily for 6 months
48312104|NCT05412394|DRUG|Prednisolone|Liquid, 5mg/kg per week, for one year
48312105|NCT04980924|OTHER|no intervention|no intervention
48312106|NCT04142307|DEVICE|Biofeedback Training|Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.
48312107|NCT04142307|DEVICE|Sham - simulated BT|The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
48312108|NCT02750657|GENETIC|Molecular Profiling|Whole Genome Sequencing
48312109|NCT00002057|DRUG|Nystatin|
48483585|NCT04412057|DRUG|Placebo|Administered once subcutaneously
48483586|NCT02484313|OTHER|dietary treatments|commercially available food products
47963198|NCT01651039|DRUG|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
47963199|NCT05662150|DIAGNOSTIC_TEST|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
47963200|NCT02228200|BEHAVIORAL|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
48114117|NCT00971789|DRUG|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
48312110|NCT04200716|BEHAVIORAL|Moderate intensity continuous training - session|Moderate exercise continuous exercise 30 minuts session
48483587|NCT04727684|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
48483588|NCT04727684|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
48483589|NCT04727684|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
48483590|NCT04727684|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
48483591|NCT03327714|BEHAVIORAL|Mindfulness and compassion|
48483592|NCT00809237|DRUG|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
48483593|NCT03452124|DEVICE|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
48483594|NCT03452124|OTHER|Conventional cigarette|Conventional cigarette smoking continuation
48483595|NCT02492841|DRUG|Mineral trioxide aggregate|Mineral trioxide aggregate
48483596|NCT02492841|DRUG|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
48483597|NCT02492841|DRUG|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
48312111|NCT04200716|BEHAVIORAL|High intensity interval training - session|The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.
48312112|NCT06367868|PROCEDURE|After 5 ml CSF Drainage|Optic Nerve Sheath Diameter and Intracranial Pressure measurements will be after 5 ml CSF drainage
48312113|NCT04480697|DRUG|HPG1860|6 subjects randomized to active compound and 2 subjects randomized to placebo
48312114|NCT00975195|DRUG|tiotropium inhalation|
48312115|NCT00975195|DRUG|salmeterol xinafoate|
48312116|NCT00975195|DRUG|fluticasone propionate|
48312117|NCT00975195|DRUG|placebo matched for fluticasone propionate|
48312118|NCT04100798|PROCEDURE|Entire Papilla Preservation technique|A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
48312119|NCT04100798|PROCEDURE|Modified Minimally invasive Surgical Technique|a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
48312120|NCT04850703|DEVICE|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
48312121|NCT04850703|DRUG|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
48312122|NCT04850703|COMBINATION_PRODUCT|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
48312123|NCT04850703|DIAGNOSTIC_TEST|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
48312124|NCT03233412|PROCEDURE|Control|Exertion of the cervix transformation zone
48312125|NCT03233412|DRUG|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
48312126|NCT00448253|BIOLOGICAL|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
48483598|NCT02282202|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
48483599|NCT04635332|BEHAVIORAL|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
48483600|NCT04635332|BEHAVIORAL|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
48312127|NCT00042354|DRUG|clofarabine (IV formulation)|
48312128|NCT05449613|DRUG|acupoint application|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
48483601|NCT03902899|OTHER|Educational intervention (oral presentation)|A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
48114118|NCT00971789|OTHER|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
48312129|NCT05449613|OTHER|placebo|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
48312130|NCT05822908|DRUG|VO659|VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
48312131|NCT03514758|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
48312132|NCT00252122|DRUG|Ketamine|Ketamine. 0.2 mg/kg, intravenously
48312133|NCT03355937|PROCEDURE|Sperm Chip|Sperm selection using by conventional or with sperm chip
48312134|NCT02008838|DIETARY_SUPPLEMENT|Synbiotic|
48483602|NCT03711214|PROCEDURE|Periodontal scaling|Periodontal scaling and root planing
48483603|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
48483604|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
48483605|NCT02450526|DRUG|Placebo|50 Units
48483606|NCT02450526|DRUG|Placebo|20 Units
48483607|NCT00006091|DRUG|arsenic trioxide|
48483608|NCT00363155|DRUG|KRN7000|
48114119|NCT04783012|PROCEDURE|Catheter removal|Catheter management strategy after surgery
48312135|NCT02008838|DIETARY_SUPPLEMENT|Placebo|
48312136|NCT03420716|DIETARY_SUPPLEMENT|yogurt|
48483609|NCT05842304|DEVICE|active cTBS|Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
48483610|NCT05842304|DEVICE|sham cTBS|Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
48483611|NCT06504498|DEVICE|0.5 mm-thick Duran® clear aligner|0.5 mm-thick clear aligner was used for orthodontic treatment.
48114120|NCT01985269|OTHER|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
48643318|NCT04256837|DEVICE|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
48114121|NCT05981157|DRUG|Anrotinib plus Tirelizumab|Subjects receive Anrotinib, 10mg, QD and Tirelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
48114122|NCT03393078|DEVICE|transcranial magnetic stimulation with real coil|TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
48114123|NCT03393078|DEVICE|transcranial magnetic stimulation with sham coil|TMS with sham coil is a placebo
48643319|NCT06466161|DEVICE|Upper Arm Cylindrical Blood Pressure Cuff|In Group 1, the upper arm cylindrical cuff is inflated first, followed by inflation of the forearm conical cuff.
48643320|NCT06466161|DEVICE|Forearm Conical Blood Pressure Cuff|In Group 2, the forearm conical cuff is inflated first, followed by inflation of the upper arm cylindrical cuff.
48114124|NCT01824030|DEVICE|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
48114125|NCT01824030|DEVICE|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
48483612|NCT06504498|DEVICE|0.75 mm-thick Duran® clear aligner|0.75 mm-thick clear aligner was used for orthodontic treatment.
48483613|NCT00028535|BIOLOGICAL|trastuzumab|Given IV
48114126|NCT01269749|RADIATION|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
48114127|NCT01269749|DRUG|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
48312137|NCT01841424|BEHAVIORAL|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
48312138|NCT04129606|DIAGNOSTIC_TEST|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
48312139|NCT02635737|DEVICE|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
48483614|NCT00028535|DRUG|paclitaxel|Given IV
48483615|NCT00028535|BIOLOGICAL|recombinant interleukin-12|Given SC
48483616|NCT03282734|OTHER|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
48312140|NCT03521687|DRUG|Apremilast|30 mg BID
48312141|NCT03699631|DRUG|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
48312142|NCT03699631|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
48312143|NCT03699631|DRUG|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
48312144|NCT04344405|DRUG|Vitamin D|vitamin D supplementation
48483617|NCT03282734|OTHER|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
48483618|NCT05139277|DIAGNOSTIC_TEST|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
48483619|NCT05139277|OTHER|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
48483620|NCT01232491|DRUG|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
48114128|NCT06501911|DRUG|Bicalutamide|Patients will receive daily oral bicalutamide for six (6) months. The dose will be determined by the cohort to which the participant is enrolled as well as the toxicities experienced by previously enrolled cohorts.
47963201|NCT02228200|BEHAVIORAL|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
47963202|NCT05499000|BEHAVIORAL|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
47963203|NCT00469274|DRUG|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
48312145|NCT04344405|DRUG|Steroid Drug|control
48312146|NCT04255550|DIAGNOSTIC_TEST|Esophageal doppler|It is a prospective observational clinical study to correlate hemodynamic monitoring between non-invasive Electrical Cardiometry and minimally invasive Esophageal Doppler during major abdominal surgery.
48312147|NCT03703375|DRUG|Azacitidine|Azacitidine
47963204|NCT00469274|DRUG|Antibiotic PEP|TMP-SMX DS po BID for 14 days
47963205|NCT01457469|OTHER|questionnaire administration|Ancillary studies
47963206|NCT01457469|PROCEDURE|quality-of-life assessment|Ancillary studies
47963207|NCT01457469|OTHER|counseling intervention|Undergo counseling session
47963208|NCT01457469|OTHER|internet-based intervention|Receive enhanced quitline intervention
47963209|NCT01457469|BEHAVIORAL|telephone-based intervention|Receive enhanced quitline intervention
47963210|NCT01457469|OTHER|educational intervention|Receive usual care plus
47963211|NCT01457469|DRUG|nicotine replacement therapy|Receive nicotine replacement patches
48114129|NCT06501911|RADIATION|Intensity-modulated radiation therapy (IMRT)|Participants will receive 35 Gy delivered in 10 fractions, administered once daily on weekdays.
48114130|NCT04152421|OTHER|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
48312148|NCT03703375|DRUG|Romidepsin|Romidepsin
48312149|NCT03703375|DRUG|Gemcitabine|Gemcitabine
48312150|NCT02278289|DEVICE|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
48312151|NCT02278289|PROCEDURE|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
48114131|NCT05766189|BEHAVIORAL|Wastewater vaccine prompts|Social media communications showing levels of SARS-CoV-2 in wastewater
48312152|NCT06420765|DRUG|VX-150|Suspension for oral administration.
48312153|NCT06420765|DRUG|VX-548|Solution or suspension for oral administration.
48312154|NCT06420765|DRUG|Placebo|Suspension for oral administration.
48312155|NCT03226080|DRUG|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
48312156|NCT03226080|DRUG|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
48312157|NCT03226080|DRUG|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
48312158|NCT00624572|DRUG|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
48312159|NCT01716533|PROCEDURE|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
48312160|NCT01716533|OTHER|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
48312161|NCT00915005|RADIATION|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
48312162|NCT00915005|RADIATION|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete."
48312163|NCT00915005|DRUG|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
48312164|NCT00915005|DRUG|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
48312165|NCT01308320|DRUG|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
48312166|NCT01308320|DRUG|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
48312167|NCT05224401|DRUG|Pivmecillinam and amoxicillin/clavulanic acid|1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.
48643321|NCT05397496|BIOLOGICAL|PIT565|Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
48312168|NCT05224401|DRUG|Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility|Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
48312169|NCT02021526|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
48312170|NCT06128005|BEHAVIORAL|knowledge translation in nursing for pressure injury care|Pressure injury's knowledge and healing of wound.
48312171|NCT00920595|DRUG|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
48312172|NCT02390336|OTHER|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
48312173|NCT02390336|OTHER|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
48312174|NCT04336397|DIAGNOSTIC_TEST|multi-target stool DNA test|Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care
48312175|NCT05795218|DEVICE|Deep Brain Stimulation|implant and DBS therapy with the directSTIM™ DBS system
48312176|NCT01597427|DRUG|Clonidine|Administration of 2 μg/kg of intravenous clonidine
48312177|NCT01597427|DRUG|Placebo|Injection of placebo solution.
48312178|NCT02061722|RADIATION|PET Imaging with [18F]MNI-659|"The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
48483621|NCT01232491|DIETARY_SUPPLEMENT|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
48483622|NCT03443193|OTHER|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
48483623|NCT01520636|PROCEDURE|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
48483624|NCT01520636|PROCEDURE|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
48483625|NCT00684567|RADIATION|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
48483626|NCT00684567|DRUG|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
48483627|NCT05122221|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
48483628|NCT05122221|DRUG|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
48483629|NCT05122221|BIOLOGICAL|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
48643322|NCT04887805|DRUG|Lenvatinib Mesylate|Given PO
48643323|NCT04887805|BIOLOGICAL|Pembrolizumab|Given IV
48643324|NCT06605118|DRUG|Azithromycin Injection|500mg azithromycin in 250 mL of normal saline
48643325|NCT06605118|DRUG|Placebo|250 mL of normal saline
48114132|NCT05575869|OTHER|(online) PRONEtect educational material|This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.
48312179|NCT03172221|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
48312180|NCT03374514|DRUG|Dexamethasone|instilation of the solution in the middle ear
48312181|NCT03374514|DRUG|Sterile isotonic saline solution|Sterile isotonic saline solution
48312182|NCT02130427|DIAGNOSTIC_TEST|CT scan|Weekly 3D/4D CT scan
48312183|NCT05366699|PROCEDURE|axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)|lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
48312184|NCT05366699|PROCEDURE|Axillary lymphadenetomy alone|oncologic axillary lymphadenectomy
48312185|NCT04855123|OTHER|retinal imaging|OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer
48312186|NCT04855123|OTHER|paraclinical surveillance|blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
48312187|NCT05491057|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
48312188|NCT05582811|DRUG|Dose Riociguat 2,5 or 5mg|A selective stimulator of soluble guanylate cyclase (sGC)
48312189|NCT05582811|DRUG|Riociguat|A selective stimulator of soluble guanylate cyclase (sGC)
48312190|NCT05582811|DRUG|Placebo|Placebo
48312191|NCT02347111|DRUG|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
48312192|NCT02347111|DRUG|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
48312193|NCT06515769|DIAGNOSTIC_TEST|TERMOGRAPHY|Obtaining an image of the foot using a thermographic camera
48483630|NCT00839059|DRUG|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
47963212|NCT01457469|OTHER|educational intervention|Receive enhanced quitline intervention
47963213|NCT01348165|DRUG|BI 137882|Powder for oral solution
47963214|NCT01348165|DRUG|Placebo|Powder for oral solution
48312194|NCT05929144|OTHER|MRI sequences testing|Testing different MRI sequences in order to optimize them
48312195|NCT01926054|DRUG|Acthar gel|
48483631|NCT05849012|OTHER|Low Sulfur Diet|"Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
48643326|NCT06605118|DRUG|Standard of Care Preoperative antibiotics|standard of care preoperative antibiotics (excluding azithromycin) prior to incision
48312196|NCT02874404|DRUG|Ibrutinib|Given PO
48312197|NCT02874404|OTHER|Laboratory Biomarker Analysis|Correlative markers
48312198|NCT02874404|DRUG|PI3K-delta Inhibitor TGR-1202|Given PO
47963215|NCT01251939|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
47963216|NCT00171483|DRUG|Tegaserod|
48114133|NCT05575869|OTHER|Classic (normal) one hour lesson/lecture|As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
48114134|NCT04663347|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
48114135|NCT04663347|DRUG|rituximab and lenalidomide|28-day cycles
48312199|NCT00964548|DRUG|Dantrolene|1.25 mg/kg IV once over 60 min
48312200|NCT00964548|DRUG|Dantrolene|2.5 mg/kg IV once over 60 min
48312201|NCT03577093|OTHER|There is no intervention at all.|There is no intervention at all.
48312202|NCT00127556|PROCEDURE|Label applied to blood bag|
48312206|NCT00932529|DRUG|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
48312207|NCT00932529|DRUG|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
48312208|NCT00932529|DRUG|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
48312209|NCT00932529|DRUG|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
48312210|NCT00688168|BEHAVIORAL|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
48312211|NCT00688168|BEHAVIORAL|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
48312212|NCT00688168|BEHAVIORAL|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
48312213|NCT01473628|OTHER|Clinical Observation|Undergo observation
48483632|NCT05849012|OTHER|Usual Diet|"Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy."
48483633|NCT05189314|PROCEDURE|Thyroidectomy|Surgical Resection of thyroid nodules
48483634|NCT05189314|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation of thyroid nodules
48483635|NCT00563017|DRUG|Long-acting Risperidone microspheres injection|
48483636|NCT04190563|BEHAVIORAL|Pain De-Catastrophizing|Experimenter-administered education and skill practice.
48483637|NCT04190563|BEHAVIORAL|Pain Education|Experimenter-administered education.
48483638|NCT04947501|DRUG|Cyclophosphamide|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg.~\*\*\*\*\*\*\* Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
48483639|NCT04947501|DRUG|Topotecan|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
48483640|NCT04947501|DRUG|Vincristine|"Administration of CTV - cycles 1 and 4~Days 1 \& 2: Cyclophosphamide 70 mg/kg/day (2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-4: Topotecan 2 mg/m2/day, IV over 30 minutes. Day 1: Vincristine 0.067 mg/kg (or 2 mg/m2, whichever is less) by IV piggyback; maximum dose is 2 mg."
48483641|NCT04947501|DRUG|Doxorubicin|"Administration of CDV - cycle 3 Days 1 \& 2: Cyclophosphamide 70 mg/kg/day ((2100 mg/m2/day for patients \>10 years old), IV over 6 hrs.~Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Days 1-3: Doxorubicin 25 mg/m2/day, by 24-hr IV infusion (total dose over 72 hr is 75 mg/m2).~Days 1-3: Vincristine 0.67 mg/m2/day or 0.022 mg/kg/day (whichever is less), by 24-hr IV infusion (total dose over 72 hr is 2 mg/m2 or 0.067 mg/kg); maximum dose is 0.67 mg/day, or 2mg over 72 hr."
48483642|NCT04947501|DRUG|Ifosfamide|Administration of ICE - cycle 2 Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs.
48483643|NCT04947501|DRUG|Etoposide|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
47963217|NCT00651560|DRUG|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
48114136|NCT04663347|DRUG|rituximab and bendamustine|28-day cycles
48114137|NCT04663347|DRUG|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|21-day cycles
48114138|NCT04663347|DRUG|gemcitabine and oxaliplatin|28-day cycles
48114139|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
48114140|NCT04663347|DRUG|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|21-day cycles
48312214|NCT01473628|RADIATION|Radiation Therapy|Undergo radiation therapy
48312215|NCT01473628|BIOLOGICAL|Rituximab|Given IV
48312216|NCT01548898|DEVICE|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
48312217|NCT02871115|OTHER|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
48114141|NCT04663347|DRUG|Lenalidomide|28-day cycles
48114142|NCT04663347|DRUG|rituximab, ifosfamide, carboplatin, and etoposide phosphate|21-day cycles
48114143|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
48312218|NCT02871115|OTHER|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
48312219|NCT03172611|OTHER|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
48312220|NCT02027116|BIOLOGICAL|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
48312221|NCT00200499|DRUG|Nebivolol|
48312222|NCT02260102|DRUG|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
48312223|NCT04070768|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 3mg/m\^2, Days 1,4,7
48312224|NCT04070768|DRUG|Venetoclax|Venetoclax, 100,200,400, or 600mg Daily Dose
48312225|NCT03928431|OTHER|Maternal microbiota|See arm descriptions
48312226|NCT00137436|DRUG|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
48312227|NCT00137436|DRUG|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
48312228|NCT00137436|DRUG|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
48114144|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.
48312229|NCT06131554|BIOLOGICAL|batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
48483644|NCT04947501|DRUG|Carboplatin|"Administration of ICE - cycle 2~Days 1-5: Ifosfamide 1500 mg/m2/day (50 mg/kg/day if weight is \<10 kg), IV over 6 hrs. Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion. Days 1-2: Carboplatin 400 mg/m2/day (13.3 mg/kg/day if weight is \<10 kg), IV over 1 hr. Days 1-5: Etoposide 100 mg/m2/day (3.3. mg/kg/day if weight is \<10 kg), IV over 2 hrs."
48643327|NCT05974540|DIAGNOSTIC_TEST|Determination of cricothyroid membrane|"After the patient's head is extended, the pediatric surgeon will be asked to mark the cricothyroid membrane with a pencil using traditional inspection and palpation methods. Then, the cricothyroid membrane will be determined by the Anesthesiology and Reanimation specialist by USG method and the difference will be determined. Demographic and morphometric characteristics of the patients will be recorded. In addition, the length of the cricothyroid membrane, the distance between the cricoid cartilage and the skin, the distance between the cricoid cartilage and the 2nd tracheal ring will be measured by USG.~Mallampati classes of patients with intubation, Cormack-Lehane (CL) glottic appearance grades, Likert scale with intubation difficulties (1: very easy, 2: easy, 3: medium, 4: difficult) will also be recorded."
48114145|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
48114146|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
48114147|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
48312230|NCT06131554|BIOLOGICAL|batch 2 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
48312231|NCT06131554|BIOLOGICAL|batch 3 of MCV4|1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
48643328|NCT06164756|OTHER|Cognitive Behavior Therapy (CBT)|Participants will receive 10 weeks of CBT
48114148|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
48312232|NCT06131554|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
48312233|NCT04213287|DRUG|Dexketoprofen Trometamol|Drug: Dexketoprofen Trometamol oral tablet
48312234|NCT04213287|OTHER|spinal anesthesia|Drug: heavy bupivacaine 2,5 ml 0,5%
48643329|NCT06164756|OTHER|Treatment As Usual (TAU)|Participants will receive standard of care treatment
48114149|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.
48114150|NCT05623007|DIETARY_SUPPLEMENT|Probiotics|Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
48114151|NCT05623007|BEHAVIORAL|Counselling on healthy eating, physical activity, and psychosocial stimulation|Counselling on healthy eating, physical activity, and psychosocial stimulation.
48114152|NCT05623007|DIETARY_SUPPLEMENT|Placebo probiotics|Maltodextrin
48312235|NCT04213287|OTHER|IPACK|Drug: bupivacaine 20 ml 0,025%
48312236|NCT04213287|OTHER|PAI|Drug: bupivacaine 30 ml 0,025%
48312237|NCT04213287|OTHER|Adductor canal block|Drug: bupivacaine 20 ml 0,025%
48312238|NCT01781429|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
48312239|NCT01369316|PROCEDURE|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
48312240|NCT01369316|PROCEDURE|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
48312241|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Behavioral Counseling|
48312242|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Attention Control|
48312243|NCT05181319|OTHER|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
48312244|NCT05996731|PROCEDURE|Skin biopsy|A punch biopsy is a 15-minute low-risk procedure performed through a sterile circular blade (usually 3-4 mm) under local anesthesia. Briefly, the instrument is rotated down through the forearm epidermis and dermis perpendicular to its physiological lines of relaxation and into the subcutaneous fat, by producing a cylindrical core. Punch biopsy site can be closed with a single suture and generally produce only a minimal scar.
47963218|NCT00899574|DRUG|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
47963219|NCT02711592|GENETIC|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
48114153|NCT05746325|OTHER|Digital Photography|Digital photographs taken of array placement
48114154|NCT05746325|PROCEDURE|Lumbar Puncture|Undergo LP
48114155|NCT05746325|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48312245|NCT05341505|BEHAVIORAL|Emotion Regulation Intervention|We will administer a cognitive-behavioral treatment targeting emotion dysregulation, including mindfulness skills and other cognitive and behavioral emotion regulation skills.
48312246|NCT03759457|DEVICE|High Flow Nasal Cannula (AIRVO2)|High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
48312247|NCT01216592|OTHER|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
48483645|NCT04947501|DRUG|Mesna|"Administration of CTV - cycles 1 and 4 Mesna 70 mg/kg (2100 mg/m2/day for patients \>10 years old) , by 24-hr IV infusion, starting with the cyclophosphamide infusion.~Administration of ICE - cycle 2 Mesna 1500 mg/m2/day, by 24-hr IV infusion, starting with the ifosfamide infusion.~Administration of CDV - cycle 3 Mesna 70 mg/kg ((2100 mg/m2/day for patients \>10 years old), by 24-hr IV infusion, starting with the cyclophosphamide infusion."
48483646|NCT05122767|DRUG|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B\*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
47963220|NCT05890885|PROCEDURE|Real left prefrontal tDCS - sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
48312248|NCT01152008|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
48483647|NCT05122767|DRUG|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, \>=30kg (P 900mg, H 900mg)
48483648|NCT06614660|OTHER|Metabolism genomics and imaging genomics|Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\&#39;s blood specimen was collected to collect metabolism genomics and imaging genomics.
48483649|NCT03543345|DIAGNOSTIC_TEST|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~* Written consent.~* Complete history.~* Complete physical examination.~* Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~* Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
48483650|NCT00865514|DRUG|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
48483651|NCT00865514|GENETIC|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
48114156|NCT05746325|DEVICE|Medical Device Usage and Evaluation|Transducer arrays applied and wear NovoTTF-200T
48114157|NCT02356549|BEHAVIORAL|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
48114158|NCT02356549|BEHAVIORAL|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
48114159|NCT02356549|BEHAVIORAL|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
48114160|NCT06068439|DRUG|Acetylsalicylic Acid|aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
48114161|NCT06068439|DRUG|Placebo|Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
48114162|NCT05921708|OTHER|Assessment1|International Physical Activity Questionnaire (IPAQ) (Short)
47963221|NCT05890885|PROCEDURE|Sham - Real left prefrontal tDCS|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
47963222|NCT00386659|DRUG|tenofovir + abacavir + lopinavir/ritonavir|
47963223|NCT00386659|DRUG|tenofovir + abacavir + efavirenz|
48114163|NCT05921708|OTHER|Assesment2|Physical Appearance Comparison Scale-Revised (PACS-R)
48114164|NCT05921708|OTHER|Assessment3|Sociocultural Attitudes Towards Appearance Questionnaire -4-Revised (SATAQ-4R)
48114165|NCT05921708|OTHER|Assessment4|Body-Cathexis Scale (BCS)
48114166|NCT05921708|OTHER|Assessment5|Mobile Health, Exercise Preferences and Social Media Questionnaire
48114167|NCT02707224|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
48114168|NCT02707224|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
48483652|NCT00865514|OTHER|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
48643330|NCT03382873|BEHAVIORAL|Group Lifestyle Balance (GLB)|The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.
47963224|NCT01610570|DRUG|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
47963225|NCT03217812|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
47963226|NCT03217812|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
47963227|NCT03217812|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
47963228|NCT03217812|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
47963229|NCT03552731|BEHAVIORAL|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
47963230|NCT06197971|OTHER|Instrument Assisted Soft Tissue Mobilization|Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied on hamstring muscles.
47963231|NCT06197971|OTHER|Therapeutic Cupping Technique|Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings.
47963232|NCT03476993|BIOLOGICAL|BCD-085|All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
47963233|NCT02644642|OTHER|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
47963234|NCT00129272|DRUG|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
47963235|NCT00129272|OTHER|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
47963236|NCT01189604|DRUG|Placebo|Infusion of placebo, same infusion rates as for arm 2
47963237|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
48483653|NCT00865514|OTHER|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
48483654|NCT00179868|BEHAVIORAL|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~1. Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~2. Acute GVHD \> grade II defined according to the Seattle criteria~3. VOD- defined according to the modified Seattle criteria"
47963238|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
47963239|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
47963240|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
47963241|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
47963242|NCT01189604|DRUG|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
47963243|NCT03274596|DRUG|Vitamin E|
47963244|NCT03274596|DRUG|Placebo|
48114169|NCT02707224|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
48483655|NCT01178164|GENETIC|Blood sampling for biological and genetic analysis|"* Clinical examination~* Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
48483656|NCT01372124|DRUG|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
48483657|NCT02857829|DIETARY_SUPPLEMENT|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
48483658|NCT02857829|DIETARY_SUPPLEMENT|Caffeine-alone|Caffeine (100 mg)
47963245|NCT02129114|DEVICE|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
47963246|NCT02129114|DEVICE|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
47963247|NCT02155790|DEVICE|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
47963248|NCT02349529|BEHAVIORAL|Psychosocial Intervention Group|6 group sessions
47963249|NCT02349529|OTHER|Waiting list control|Treatment as usual
47963250|NCT06317727|DEVICE|Irreversible Electroporation using EndoVE(Endoscopic Vacuum Electrode) and electrical pulses generated using ePORE(electroporation device)|The use of pulsed field ablation via irreversible electroporation delivered during flexible lower gastrointestinal endoscopy
47963251|NCT02099578|DIETARY_SUPPLEMENT|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
47963252|NCT02099578|DIETARY_SUPPLEMENT|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
47963253|NCT02099578|DIETARY_SUPPLEMENT|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
47963254|NCT05834374|OTHER|Contextual variation|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
47963255|NCT05834374|OTHER|Maximum affordances|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
47963256|NCT06535386|DRUG|Dexmedetomidine 0.004 MG/ML|Incidence of polyuria during the intraoperative period, associated with dexmedetomidine .
47963257|NCT06403449|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R (G-WET) is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete.The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
48312249|NCT03420131|DIAGNOSTIC_TEST|QFR and iFR|"iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland"
48312250|NCT03608553|DEVICE|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
48312251|NCT06555705|OTHER|Placebo|The control group will be given placebo for 3 months
48483659|NCT02857829|OTHER|Placebo|Rice flour
48483660|NCT00374582|DEVICE|Bodystat Quadscan 4000|device determining body composition and nutritional status
48483661|NCT00374582|DEVICE|bodystat quadscan 400|device determining body composition and nutritional status
48483662|NCT03421756|DRUG|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
48312252|NCT06555705|DIETARY_SUPPLEMENT|Omega 3|The interventional group will be given omega 3 for 3 months
48312253|NCT02449954|DRUG|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
47963258|NCT06403449|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
48312254|NCT02449954|DRUG|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
48483663|NCT03421756|RADIATION|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
47963259|NCT03947801|OTHER|Greek Yogurt|Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
47963260|NCT03947801|OTHER|Isoenergetic carbohydrate|Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
47963261|NCT02570074|DRUG|Fosfomycin|Broad spectrum antibiotic
47963262|NCT00776204|DEVICE|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
47963263|NCT00776204|DEVICE|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
47963264|NCT00776204|DEVICE|Taxus Libertè|Taxus Libertè stent placed in coronary artery
47963265|NCT04713930|DRUG|JNJ-61393215|JNJ-61393215 will be administered orally.
47963266|NCT04713930|DRUG|Placebo|Placebo will be administered orally.
47963267|NCT02420171|OTHER|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
47963268|NCT03741062|DEVICE|J. Morita AdvErl Evo Er:YAG laser|"Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s"
47963269|NCT03741062|DEVICE|Control|Sham treatment with laser unit turned off
47963270|NCT04459728|BEHAVIORAL|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
47963271|NCT04459728|BEHAVIORAL|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
47963272|NCT04459728|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
47963273|NCT04459728|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
48114170|NCT00463788|DRUG|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m\^2) followed by weekly doses of 250 mg/m\^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
48114171|NCT00463788|DRUG|cisplatin|"Subjects will receive cisplatin (75 mg/m\^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
48483664|NCT03421756|DRUG|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
47963274|NCT04459728|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
47963275|NCT04459728|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
47963276|NCT04459728|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
47963277|NCT02365831|OTHER|Observation of treatment management|Group/cohort
48312255|NCT02449954|DRUG|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
48312256|NCT06491628|BEHAVIORAL|Avoiding the risk factors|Exercise, Salt and lipid reduction in diet, smoking cessation
48312257|NCT01325831|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
48312258|NCT01325831|DEVICE|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
48483665|NCT00414349|DRUG|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
48483666|NCT00414349|DRUG|oral intake|300 to 600 mg per day taken orally
48483667|NCT00414349|DRUG|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
48483668|NCT00775606|DRUG|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
48483669|NCT00775606|DRUG|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
47963278|NCT03949530|DRUG|IDL-2965 Oral Capsule|Investigational drug
47963279|NCT03949530|DRUG|Placebos|Placebo
47963280|NCT06005480|DRUG|Mepivacaine|Injection of 1.5% Mepivacaine in nerve block
47963281|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
47963282|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
47963283|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
48483670|NCT00411957|DRUG|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
48312259|NCT05662137|BEHAVIORAL|Emotions Recognition and Expression|Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
47963284|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
47963285|NCT00071097|DRUG|TMC114/rtv|800mg TMC114/100mg rtv once daily
47963286|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
47963287|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv once daily
47963288|NCT00071097|DRUG|TMC114/rtv|600mg TMC114/100mg rtv twice daily
47963289|NCT00371280|PROCEDURE|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
47963290|NCT03166735|DRUG|BI 1467335|once daily
48114172|NCT03087084|DEVICE|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
48114173|NCT04384250|DIAGNOSTIC_TEST|Whole Exome Sequencing|Genetic study of patients
47963291|NCT03166735|DRUG|Placebo|once daily
48114174|NCT02613806|DRUG|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
48114175|NCT02613806|DRUG|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
48114176|NCT06272162|RADIATION|MR guided radiotherapy|5 fractions of 10 Gray MRgRT in addition to standard of care
48312260|NCT00579124|DEVICE|CliniMACs|T and B Cell depletion
48312261|NCT06520176|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
48312262|NCT06520176|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
48483671|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
48312263|NCT06520176|DRUG|Pegfilgrastim|Day 6: 6mg
48312264|NCT06520176|DRUG|Cyclophosphamide|Day 1\~Day 2: 1～2g/m\^2
48312265|NCT06520176|DRUG|G-CSF|Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.
48483672|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
48483673|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
48483674|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
48483675|NCT02172677|BEHAVIORAL|Episodic memory task|
48483676|NCT02172677|DEVICE|fMRI|
48483677|NCT05711342|BEHAVIORAL|Aggression|"The intervention consists of 10 lessons:~1. Motivation - where are you now?~2. Where do you want to go?~3. Circle of aggression.~4. Thoughts.~5. Emotions.~6. Bodily sensations.~7. Techniques for self-control.~8. Asking for help.~9. Assertiveness.~10. Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
48483678|NCT05711342|BEHAVIORAL|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
48483679|NCT01690975|DRUG|Placebo|Placebo - single dose at start of each treatment period
48483680|NCT01690975|DRUG|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
48483681|NCT01690975|DRUG|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
48483682|NCT05209828|DEVICE|pfmmedical implantable vascular access ports|Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
48483683|NCT01452594|DRUG|Diphenylcyclopropenone|Topical administration
48483684|NCT01452594|DRUG|Placebo|Placebo
47963292|NCT02341365|OTHER|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
47963293|NCT03018769|DRUG|Chinese Herb|
47963294|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
47963295|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Month 1, 7 and 13, respectively.
47963296|NCT02993757|BIOLOGICAL|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, IM injection at Day 0 and Month 6, respectively.
48312266|NCT06520176|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
48312267|NCT04436627|DEVICE|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
48114177|NCT00518869|DRUG|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
48114178|NCT06673277|DEVICE|Prolonged (2-hour) cryocompression therapy|The cuff of the device will be attached around the knee randomised to receive the treatment as per the manufacturer's instruction. Then the device will be set to apply a standard 30-minute treatment with a temperature of 8 ℃ and intermittent compression of 25-50 mmHg. Following this, and depending on the randomised condition, the treatment will continue for a further 90-minutes with a temperature of either 10 ℃ or 12 ℃ being applied by the device. The level of compression will remain the same (25-50 mmHg) throughout all tests.
48114179|NCT05150054|DEVICE|CardioFlux|Not an intervention
48114180|NCT04404881|DRUG|Bevacizumab|"* Induction Period (first 3 months of bevacizumab treatment):~  -- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~  * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
48114181|NCT05600855|DRUG|Ruxolitinib|"Model-predicted high-risk patients: ruxolitinib 5mg bid po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted moderate-risk patients: ruxolitinib 2.5mg bid p po until at least day 60 post-transplant and terminated after day 100. If severe hematological signs occur such as when there is severe neutropenia (\<0.1×10\^9/L), ruxolitinib can be used at half dose or discontinued as appropriate, and can continue to be used after hematology recovery.~Model-predicted low risk: regular aGVHD prophylactic regimens."
48114182|NCT01269853|DRUG|Bevacizumab|"Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
48114183|NCT01269853|DRUG|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
48114184|NCT01622075|DEVICE|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
48114185|NCT01622075|DEVICE|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
48114186|NCT02887625|DRUG|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
48114187|NCT02887625|DRUG|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c \<7.0%
48114188|NCT00333658|BEHAVIORAL|Goal setting and work feedback group|Goal setting and feedback using WBI
48312268|NCT04436627|DEVICE|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
48312269|NCT04436627|DEVICE|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
48312270|NCT02797704|DRUG|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
48312271|NCT00487084|DRUG|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
48312272|NCT00487084|DRUG|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
48312273|NCT00487084|DRUG|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
48312274|NCT03446937|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
47963297|NCT04754152|OTHER|θ burst transcranial magnetic stimulation|In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .
47963298|NCT04754152|DRUG|Pharmacotherapy|Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
48114189|NCT02806557|DEVICE|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
48312275|NCT03446937|DRUG|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
48312276|NCT03446937|DRUG|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
48312277|NCT05676320|DEVICE|V-Flex|Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture
48312278|NCT05676320|DEVICE|V-Steady|Bone Cement alone
48114190|NCT00842049|DEVICE|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
48114191|NCT00842049|OTHER|No lumbar drain|No lumbar drain
48114192|NCT00024141|DRUG|fluorouracil|
48312279|NCT04496895|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
48312280|NCT04496895|DIETARY_SUPPLEMENT|orange peel fermentation|consume 1 sachet per day for 2 months
48312281|NCT03235596|DEVICE|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
48312282|NCT00050999|DRUG|ONTAK|
48312283|NCT00764400|BEHAVIORAL|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
48312284|NCT01151592|DRUG|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
48643331|NCT03382873|BEHAVIORAL|Group Lifestyle Balance Plus (GLB+)|The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.
47963299|NCT05612711|DRUG|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
47963300|NCT00000409|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
47963301|NCT00000409|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
47963302|NCT00000409|PROCEDURE|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
47963303|NCT00000409|PROCEDURE|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
47963304|NCT00304291|DRUG|Mitoxantrone|
47963305|NCT05281211|DIETARY_SUPPLEMENT|Nutrition|6 weeks nutrition implementation in the form of branched chain amino acids and immune-system boosters twice daily for 4 weeks and once daily for 2 weeks
47963306|NCT05281211|BEHAVIORAL|Exercise|6 weeks exercise 30 minutes' walk/day or 2000 extra steps daily
47963307|NCT02329912|DEVICE|SmartPill|Application of the SmartPill at the end of surgery
47963308|NCT04568733|BEHAVIORAL|Pilates exercise session|The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.
47963309|NCT04568733|BEHAVIORAL|Treadmill walking at 3.2 kph|Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.
47963310|NCT04568733|BEHAVIORAL|Treadmill walking at 4.8 kph|Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
48312285|NCT02524652|DRUG|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
47963311|NCT04049357|DEVICE|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
48114193|NCT00024141|DRUG|irinotecan hydrochloride|
48114194|NCT00897546|OTHER|laboratory biomarker analysis|
48114195|NCT04525170|DEVICE|HPT treatment|
48114196|NCT04525170|DEVICE|untreated|
48114197|NCT06677333|OTHER|Whey Protein|This intervention will add 50 g of a whey or pea protein supplement to their usual dietary intake.
48114198|NCT06677333|OTHER|Pea protein|This intervention will add 50 g of a pea protein supplement to their usual dietary intake.
48114199|NCT05081713|BEHAVIORAL|high-intensity training focused on stepping in variable contexts|Approximately 10 weeks (\~30 sessions) of high-intensity training
48114200|NCT03250052|DRUG|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
48114201|NCT03250052|DRUG|(fimasartan and linagliptin) x 7days|Part A \& Part B: Co-administration of fimasartan and linagliptin
48114202|NCT06676215|DIETARY_SUPPLEMENT|IAA mix supplement|The intervention is a daily IAA dose that provides x1.5 the estimated average requirement (EAR) for a healthy child. This IAA dose will be mixed to the complementary food and will be taken once daily for 4 weeks (28 days) by the child in the intervention group.
48312286|NCT00064467|DRUG|Extended-release bupropion (HCl)|
48483685|NCT05693571|BEHAVIORAL|Valera Smart Phone Application and Care Manager Dashboard|Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
48483686|NCT01355159|DRUG|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
48483687|NCT01355159|DRUG|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
48643332|NCT06284564|DRUG|Evolocumab|Given by SC
48643333|NCT06284564|DRUG|Nivolumab|Given by IV
48643334|NCT06531538|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine.
48643335|NCT06531538|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
48483688|NCT04109859|DRUG|Saline|When using saline, if found mean arterial pressure \<65mmHg, Cardic Output\>4L/min, Sequential Vascular Response\<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
48483689|NCT04109859|DRUG|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
48114203|NCT06676215|OTHER|Complementary food comprised of rice and legumes|Each study child will receive standard complementary food which he/she will take once daily for 4 weeks (28 days)
48114204|NCT01180192|DRUG|oxygen|either 8 L/minute O2 via face mask for 2 hours
48114205|NCT02315469|OTHER|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
48114206|NCT02315469|OTHER|Questionnaire Administration|Ancillary studies
48312287|NCT05138185|DEVICE|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
48312288|NCT02982304|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation Electrode
48312289|NCT04542382|DRUG|Rosuvastatin|"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."
48483690|NCT05444322|DRUG|RD14-01 cell infusion|Autologous CAR T cells
47963312|NCT05865262|DIAGNOSTIC_TEST|ECG|"A triplicate ECG and a blood test will be done during a medical consultation as part of the usual endocrinology follow-up. Included individuals seen prior to initiation of GAHT, will be assessed a second time (at least one month after GAHT start) with a triplicate ECG and a blood test similar to inclusion visit. Included individuals already on GAHT will be seen only once at the inclusion visit.~Triplicates of 10seconds 12-lead digitized electrocardiogram will be recorded after few minutes of rest in the supine position. Electrocardiograms will be acquired with Mindray ECG BeneHeart R12. For each subject, RR, PR, QRS and QT interval durations will be assessed with a semiautomatic approach using the median representative beats (overlap method) generated from 10seconds ECG with a good quality (CalECG v3.7; AMPS, LLC). The QT interval will be measured and corrected for heart rate by Fridericia's formula."
47963313|NCT05865262|DIAGNOSTIC_TEST|blood test (assessing ionic and hormonal circulating levels)|Blood samples for the determination of serum concentrations of estradiol, progesterone, testosterone, FSH, and LH will be collected on the same day as the ECG, in a dry tube and further assayed in the immunology laboratory of Bordeaux University Hospital (France). Estradiol, progesterone, FSH, and LH plasma concentrations will be assayed by immunochemiluminescence (Architect i2000SR; Roche Diagnostics), and testosterone levels by liquid chromatography mass spectrometry. Kalemia and calcemia will be collected in a BD Vacutainer tube with heparin lithium and separator, further assayed at the biochemistry laboratory of Bordeaux University Hospital by indirect potentiometric measurement (Architect c16000) and Arsenazo III SRM 956 colorimetrie (Architect c16000).
47963314|NCT00786734|DRUG|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
47963315|NCT00786734|DRUG|Pitavastatin|4mg daily for 28 days after PCI
47963316|NCT05176145|DEVICE|VisioCyt®|"* Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~* Urine collection for conventional cytology and VisioCyt® test"
47963317|NCT01754701|DIETARY_SUPPLEMENT|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
47963318|NCT01754701|DIETARY_SUPPLEMENT|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
47963319|NCT06405230|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered.
47963320|NCT06405230|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
47963321|NCT06405230|DRUG|Pemetrexed+ (carboplatin or cisplatin)|PBCD consisting of pemetrexed+ (carboplatin or cisplatin) will be administered.
48114207|NCT05026476|DIETARY_SUPPLEMENT|Resource Thicken up Junior|Each infant and child will be switch over to receive for a period of 7 days (new thickener)
48114208|NCT03760835|DRUG|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
48114209|NCT03760835|DRUG|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
48114210|NCT05004935|DIETARY_SUPPLEMENT|beetroot juice|single intake of beetroot juice containing 800mg nitrates
48114211|NCT05004935|OTHER|nitrate|single intake of 800mg nitrates
48114212|NCT05630508|BEHAVIORAL|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
48114213|NCT05630508|OTHER|Sham|Receiving standard care, LIVEN educational material and access to the application
48114214|NCT00003339|BIOLOGICAL|gp100 antigen|
48114215|NCT00003339|BIOLOGICAL|incomplete Freund's adjuvant|
48114216|NCT00003339|BIOLOGICAL|recombinant interleukin-12|
48114217|NCT00003339|BIOLOGICAL|tyrosinase peptide|
48114218|NCT06041919|DRUG|RESP301|Nitric Oxide agent
48114219|NCT06041919|DRUG|HRZE|isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)
48114220|NCT04906954|OTHER|NMES|Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
48114221|NCT05838495|OTHER|formulated liquid diet|will be fed exclusively the pediatric enteral study formula with a feeding tube
48114222|NCT01199575|DRUG|Revlimid|
48114223|NCT01199575|DRUG|Rituximab|
48114224|NCT06647017|DEVICE|Volta tAN System|Transcutaneous auricular neurostimulation (tAN)
48483691|NCT01272921|DRUG|Bupivacaine|Varying doses to determine the duration of analgesia
48312290|NCT04542382|DRUG|Rosuvastatin (Inhibitor arm)|"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."
48312291|NCT04542382|DRUG|Eltrombopag|"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."
48114225|NCT06647017|DEVICE|SHAM Volta tAN System|Participants randomized to the sham group will have an earpiece applied, but stimulation will not be turned on.
48114226|NCT06360744|BIOLOGICAL|Johnson & Johnson|Vaccination with the Johnson \& Johnson vaccine which is NOT part of the Danish National Government programme
48312292|NCT04669314|PROCEDURE|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
48312293|NCT03857763|COMBINATION_PRODUCT|Apatinib,Paclitaxel,Cisplatin,RT|Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
48312294|NCT01532063|PROCEDURE|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
48643336|NCT04409418|DEVICE|Extended dwell catheters|EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
47963322|NCT06046885|DEVICE|Neuromuscular electrical stimulation|"As regards the electrodes position, one proximal electrode on the gastrocnemius, which will be located below the popliteal fossa (at least 5cm below it) for a better position on the muscle belly; and one distal electrode, located at least 10 cm from the calcaneus.~This protocol will last 20 minutes per session. The placement of the electrodes is as mentioned above, and the parameters to be used will be the following: a stimulation frequency between 35 and 80Hz, a pulse width between 150 and 200 µs, the intensity will be established individually using an intensity that generate a visible contraction of maximum intensity without generating pain. The duration of the contraction will be of 6 seconds with 30 seconds of rest."
47963323|NCT03895541|DIAGNOSTIC_TEST|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
47963324|NCT02208479|OTHER|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
48643337|NCT06115603|DRUG|Cannabigerol|1 mL of 80mg Cannabigerol once during experimental session
47963325|NCT01204437|DRUG|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
47963326|NCT01204437|DRUG|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
47963327|NCT01204437|DRUG|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
47963328|NCT02416401|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
47963329|NCT02416401|OTHER|Commercially available computerized training|
47963330|NCT03746457|BEHAVIORAL|Behavioral intervention|Individual counseling, group intervention, collective advocacy
47963331|NCT03674671|DRUG|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
48114227|NCT04040413|PROCEDURE|bariatric surgery|All bariatric procedures
48114228|NCT04360057|OTHER|PMD|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
48114229|NCT04360057|OTHER|PMDPlus|A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
48114230|NCT00997386|DRUG|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
48312295|NCT03886701|DRUG|Doravirine (DOR)|Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
48312296|NCT03886701|DRUG|Rifapentine (RPT)|Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
48312297|NCT03886701|DRUG|Isoniazid (INH)|Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
48312298|NCT01351766|DRUG|Transdermal Nicotine Patch|Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
48312299|NCT03161938|DRUG|Dexamethasone|intravenous
48312300|NCT03696758|PROCEDURE|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
48312301|NCT03696758|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
48312302|NCT03696758|PROCEDURE|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
48483692|NCT01272921|DRUG|Ropivacaine|Varying doses to determine the duration of analgesia
48483693|NCT04678401|RADIATION|Radiation|Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards
48643338|NCT06115603|OTHER|Placebo|1 mL of placebo once during experimental session
48643339|NCT03502590|DEVICE|IGEL Laryngeal mask|Insertion of an IGEL device in anaesthetised patients
48643340|NCT04658368|PROCEDURE|Primary TMR|TMR procedure as part of the primary major limb amputation surgery
48643341|NCT04658368|PROCEDURE|Secondary TMR|TMR procedure subsequent to major limb amputation surgery
48643342|NCT04153149|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
48643343|NCT04153149|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection.
48312303|NCT03696758|DRUG|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
48312304|NCT03696758|DRUG|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
48312305|NCT03412318|DEVICE|Twisted file|Use of twisted file during cleaning and shaping of root canals
48312306|NCT03412318|DEVICE|Mpro|Use of Mpro during cleaning and shaping of root canals
48312307|NCT02426060|DRUG|Imrecoxib|
48643344|NCT05795764|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.
48643345|NCT05795764|BEHAVIORAL|Treatment as Usual|Standard care provided for patients at risk for suicide
48643346|NCT06535646|OTHER|Home exercise program using Physitrack exercise program and a smart watch|Participants wear a smart watch to monitor activity levels while using a web based exercise program to follow along for 8 weeks.
48643347|NCT05672615|OTHER|Questionnaires|Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.
48643348|NCT05672615|OTHER|Daily Mood Diaries|Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.
48483694|NCT04678401|DRUG|Fludarabine|Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
48643349|NCT05672615|OTHER|Urine Specimen Collection|Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.
48643350|NCT05672615|OTHER|Research Blood Draw|Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.
48643351|NCT05672615|OTHER|Utilize excess tissue from a standard of care procedure|Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.
48643352|NCT05720520|OTHER|Technological education method|Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
48643353|NCT06333678|DRUG|Durvalumab|10 mg/kg IV every 2 weeks or 1500 mg/kg IV every 4 weeks for up to 12 months.
48643354|NCT06333678|DRUG|Sotorasib|960 mg, Patients who do not tolerate sotorasib at 960 mg can be dose reduced to 120 mg.
48643355|NCT06048705|DRUG|GSK3901961|GSK3901961 was administered.
48643356|NCT06048705|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
48643357|NCT06048705|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
48643358|NCT05289908|DRUG|Pemetrexed (1)|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
48643359|NCT05289908|DRUG|Pemetrexed (2)|The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
48312308|NCT02426060|DRUG|Warfarin|
48312309|NCT00454155|DRUG|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
48312310|NCT03354819|BEHAVIORAL|Modified MBCT|"Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion \& allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning"
48483695|NCT04678401|DRUG|Thiotepa|Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
48483696|NCT04678401|DRUG|Cyclophosphamide|Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
48483697|NCT04678401|DRUG|Mesna|Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
48483698|NCT04678401|BIOLOGICAL|Treg-enriched donor cell|Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)
48483699|NCT04678401|BIOLOGICAL|Unmodified donor T Cell|Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)
48483700|NCT04678401|PROCEDURE|CD34+ Haplo Peripheral Blood Stem Cell|CD34+ Haplo Peripheral Blood Stem Cell Transplantation
48114231|NCT05593523|DRUG|Indocyanine green (ICG)|ICG is a well, known, FDA-approved dye
48114232|NCT05593523|DEVICE|OnLume|The OnLume Clinical Imaging System (CIS), also known as the Asimov-MSK Imaging System, used in this study is a clinical fluorescence-guided imaging system.
48312311|NCT03354819|BEHAVIORAL|SIRE on dementia|"The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~1. Overview of dementia~2. Pharmacological and non-pharmacological treatment of dementia~3. BPSD in dementia care~4. Person center care~5. Advance planning in people with dementia~6. Principle of mindfulness~7. Non-pharmacological intervention on stress reduction"
48312312|NCT04053088|DEVICE|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
48312313|NCT03435172|DEVICE|Device-ADRCs intravenously infusion|Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
48312314|NCT04649203|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
48312315|NCT04649203|DRUG|Placebo|The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
48312316|NCT04177056|RADIATION|SBRT|Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
48312317|NCT01274442|OTHER|anamnesis|To update the anamnesis.
48312318|NCT01274442|PROCEDURE|oral examination|A brief clinical oral examination will be performed.
48312319|NCT01274442|PROCEDURE|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
48312320|NCT05939596|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
48643360|NCT05289908|DRUG|Folic Acid|Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
48643361|NCT05289908|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
47963332|NCT03674671|PROCEDURE|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
47963333|NCT00672646|DRUG|AZD1386|95mg, oral solution, single dose
47963334|NCT00672646|DRUG|Naproxen|500mg, capsule, single dose
48114233|NCT04016025|BEHAVIORAL|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
48114234|NCT02244411|BEHAVIORAL|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
48114235|NCT02244411|BEHAVIORAL|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
48114236|NCT02244411|BEHAVIORAL|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
47963335|NCT00672646|DRUG|Placebo|AZD1386 Placebo oral solution
48114237|NCT02244411|OTHER|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
48114238|NCT01147341|DRUG|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
48114239|NCT01147341|DRUG|Placebo|prefilled saline syringe
48483701|NCT00592202|DEVICE|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
48483702|NCT00336115|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
48483703|NCT05101993|DEVICE|AtriClip|Received AtriClip for exclusion of left atrial appendage during concomitant cardiac procedure
48483704|NCT00025129|DRUG|laromustine|
48114244|NCT05176964|RADIATION|split-course HFRT|7Gy/F, d7, q3w, 5 cycles
48114245|NCT05176964|DRUG|CAPOX chemotherapy|CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
48114246|NCT05176964|DRUG|Tislelizumab|Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
48114247|NCT00375453|DRUG|SH U04722|
48312321|NCT05939596|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
48312322|NCT05324332|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
48312323|NCT05324332|DRUG|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
48312324|NCT03140930|DIETARY_SUPPLEMENT|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
48312325|NCT03140930|DIETARY_SUPPLEMENT|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
48312326|NCT03140930|DIETARY_SUPPLEMENT|Placebo duodenal|Duodenal infusion of placebo (tap water)
48483705|NCT02986035|OTHER|ECA cream|
48114248|NCT05578053|DRUG|Dalpiciclib|a new, orally administered, selective CDK4/6 inhibitor
48114249|NCT05510245|DRUG|PF-07081532|One PF-07081532 20 mg tablet, administered orally
48114250|NCT00411099|DRUG|agomelatine|
48114251|NCT00411099|DRUG|placebo|
48114252|NCT04194749|OTHER|Digital Media Based Physical Therapy|This intervention is a modified post immobilization protocol. This will include giving the patients a USB drive loaded with a 12 week therapy protocol presented in digital form with videos and graphical representations of exercises to be done. They will also have access to the videos and multimedia on the Oregon Health \& Science University website.
48114253|NCT04194749|OTHER|Traditional Physical Therapy|This intervention is a 12 week therapist supervised clinic-based therapy protocol.
48114254|NCT05596994|DEVICE|Lighting Intervention Therapy|The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.
48114255|NCT05596994|DEVICE|Sham LIT|A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.
48114256|NCT00236340|DEVICE|syringe aspiration|
48114257|NCT00236340|DEVICE|Wall suction|
48114258|NCT02552186|OTHER|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
48643362|NCT05289908|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
48643363|NCT04590963|DRUG|Monalizumab|Participants will receive IV infusion of monalizumab as stated in arm description.
48114259|NCT06505187|DRUG|Celecoxib|200mg every 12 hours
48114260|NCT06505187|DRUG|Tylenol|650mg q6h
48114261|NCT06505187|DRUG|Oxycodone|5mg every 6 hours as needed
48114262|NCT06505187|DRUG|placebo|every 12 hours
48114263|NCT01667302|DRUG|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
48114264|NCT06555627|BEHAVIORAL|High Protein Breakfast|For 5 days children will receive a high protein breakfast comprised of baked items (i.e. waffles with syrup) and Greek yogurt. The high protein meal will aim for 40% protein, 40% carbohydrates, and 20% fat. Meals will be served with a cup of water.
48114265|NCT06555627|BEHAVIORAL|Morning Exercise|Exercise Intervention. For 5 days, a 30-min physical activity bout including a 5-minute warm up and cool down will be provided to participants in this group. The aim is for students to achieve an average heart rate above 150 for the session, not including warm up or cool down. To monitor intensity, the participant will wear heart rate monitors around their chest and waist-worn accelerometers.
48114266|NCT06555627|BEHAVIORAL|High Carb Breakfast|For 5 days children will receive a high carb breakfast that will be comprised of 15% protein, 65% carbohydrates and 20% fat. Total energy content, fat, sugar, fiber, energy density, are similar between the breakfast meals.
48114267|NCT04920032|DRUG|TAS-102|Given PO
48643364|NCT04590963|DRUG|Cetuximab|Participants will receive IV infusion of cetuximab as stated in arm description.
48643365|NCT04590963|OTHER|Placebo|Participants will receive IV infusion of placebo as stated in arm description.
48114268|NCT04920032|DRUG|Irinotecan|Given IV
48114269|NCT04920032|COMBINATION_PRODUCT|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
48114270|NCT04920032|DIAGNOSTIC_TEST|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
48114271|NCT02363192|BEHAVIORAL|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
48114272|NCT01638949|BEHAVIORAL|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
48114273|NCT01638949|BIOLOGICAL|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
48114274|NCT01638949|GENETIC|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
48643366|NCT06553625|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery
48643367|NCT05177328|BIOLOGICAL|S. hominis A 9 Product|Commensal staph species, phosphate buffered saline, and glycerol.
48114275|NCT01638949|OTHER|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
48114276|NCT03621917|DEVICE|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
48114277|NCT02751580|OTHER|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
48483706|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
48114278|NCT02751580|OTHER|Questionnaire Administration|Ancillary studies
48114279|NCT04906278|DEVICE|Foley catheter balloon|A Cusco speculum will be placed and a 16F Foley catheter will be inserted into the cervix using ring forceps. Then the balloon will be inflated with 40 ml of saline and it will be pulled out to ensure the balloon covered the internal os of the cervix
48114280|NCT04906278|PROCEDURE|Amniotomy|Amniotomy will be performed by toothed forceps. The handle of the device will be held with one hand outside the vagina while 2 fingers of the opposite hand will be placed in the vagina to guide the tip. Care should be taken to protect maternal vaginal tissues from the forceps. Once the forceps reach the amniotic sac, the tip is pushed up against the sac with the index or middle finger of the internal hand to pierce the membranes. The nature of amniotic fluid will be checked.
48114281|NCT04906278|DRUG|Oxytocin|The intravenous oxytocin infusion will be administered as 10 IU oxytocin/ 500 ml glucose/ 30 mIU/minute were every 6 hours till complete abortion occurs.
48114282|NCT06311760|DRUG|AZD0292|AZD0292 will be administered as single dose via IV infusion.
48114283|NCT06311760|DRUG|Placebo|Placebo will be administered as IV infusion.
48114284|NCT04302805|DRUG|Privigen|Patients randomized to PE/rATG/IVIG group will receive IVIG 0.5g/kg infusions, on 1st, 3rd and 5th postoperative day.
48114285|NCT04302805|DRUG|Thymoglobulin|All patients will receive 1.5 mg/kg intraoperatively and 1 mg/kg when possible daily within first week up to cumulative dose 5-7 mg/kg.
48312327|NCT03140930|DIETARY_SUPPLEMENT|Placebo ileal|Ileal infusion of placebo (tap water)
48643368|NCT05177328|DRUG|Placebo|Phosphate buffered saline and glycerol
48114286|NCT04302805|OTHER|Plasma Exchange|All patient will undergo Plasma Exchange before transplantation.
48114287|NCT06555848|DEVICE|CERAMENT G|CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.
48114288|NCT06127199|DEVICE|Ovaprene|Non-hormonal intravaginal ring
48312328|NCT03135587|PROCEDURE|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
48312329|NCT03571620|DRUG|Q301 Cream|1.0% or 1.4% Q301 Cream
48312330|NCT03571620|DRUG|Vehicle|Vehicle Control
48114289|NCT06332404|DEVICE|Hypoglossal nerve stimulation Inspire system (Inspire Medical Systems Inc., USA)|Hypoglossal nerve stimulation therapy
48114290|NCT04535544|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
48114291|NCT04535544|DRUG|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
48114292|NCT04535544|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
48114293|NCT04535544|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
48114294|NCT04535544|DRUG|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
48114295|NCT03387319|BEHAVIORAL|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
48312331|NCT00396708|DEVICE|myomo e100 neurorobotic elbow brace|
48312332|NCT02566941|DEVICE|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
48312333|NCT04910724|OTHER|Energy Deficit|A combination of individualized exercise performed on a cycle ergometer and individualized dietary prescriptions will be used to achieve energy balance or the assigned energy deficits throughout the controlled feeding and testing periods
48312334|NCT04767256|DRUG|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
48312335|NCT04767256|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
48483707|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
48483708|NCT03122587|DEVICE|Active sham transcranial alternating current stimulation|Active sham (placebo)
48643369|NCT05202301|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
48643370|NCT05202301|DRUG|Enzalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
48643371|NCT05202301|DRUG|Apalutamide|Retrospective cohort analysis, using the IQVIA Real-World Data Adjudicated Claims, US claims database
48643372|NCT03989674|DIETARY_SUPPLEMENT|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
48643373|NCT05975125|DRUG|Vitamin C 500 MG Oral Tablet|compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
48114296|NCT03387319|BEHAVIORAL|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
48114297|NCT02536430|DRUG|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
48643374|NCT04128228|BEHAVIORAL|8-week outpatient treatment|Individuals with AUD participated in an 8-week treatment program integrating cognitive behavioral techniques focused on emotion regulation with breathing-based stress management.
48643375|NCT06171802|DRUG|Empagliflozin|10 mg empagliflozin daily for six months
48643376|NCT06171802|DRUG|Placebo|Placebo capsule once daily for six months
47963336|NCT04795011|OTHER|exercise and manual lymphatic drainage|MLD will be launched with simple neck application. Hemodynamics of blood and lower extremity motoring will be increased by combining active bilateral shoulder-twisting with breathing after effleurage. Cervical lymph nodes will be stimulated. Back-up treatment will be applied for the abdominal area. Suction power in the ductus thoracicus will be increased with breathing exercises. Ventral drainage will be applied to the lower extremity in accordance with the surgery of the patient.
48114298|NCT02536430|DRUG|Placebo|buccal infiltration of Normal Saline.
48312336|NCT04767256|OTHER|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
48312337|NCT04767256|OTHER|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
48312338|NCT02433379|DEVICE|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
48312339|NCT00850018|PROCEDURE|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
47963337|NCT04795011|OTHER|exercise|range of motion and walking exercise
48114299|NCT06373744|DRUG|cyclophosphamide , methotrexate , vinorelbine ,capecitabine|The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
48483709|NCT06483256|DIAGNOSTIC_TEST|radiographic control|Radiographic study with standard projections (AP and LL) is used to assess any signs of anchor loosening and/or presence of heterotopic ossifications (which can restrict movement and is one of the main complications).
48483710|NCT00110188|DRUG|ridaforolimus|
48483711|NCT00115934|PROCEDURE|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
48483712|NCT00115934|PROCEDURE|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
48643377|NCT05159739|GENETIC|Blood Draw or Saliva/Cheek Cell Sample:|Collected samples will immediately undergo genetic analysis to determine the presence or absence of potential candidate genes responsible for the increased incidence of PJI.
47963338|NCT05010057|DIETARY_SUPPLEMENT|New Zealand blackcurrants (NZBC)|NZBC capsules containing anthocyanin-rich blackcurrant extract
47963339|NCT05010057|DIETARY_SUPPLEMENT|Placebo (PLA)|Placebo capsules containing microcrystalline cellulose
48643378|NCT05980299|BEHAVIORAL|Individualized Positive Psychosocial Interaction|The intervention involves a brief positive interaction around a preferred activity or personal care routine.
48114302|NCT01292681|OTHER|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
48114303|NCT03668288|OTHER|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
48643379|NCT06032715|BEHAVIORAL|BI (Brief Intervention)|Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
48643380|NCT06658756|BEHAVIORAL|internet-CBT|10 modules on line of I-CBT for OCD
48643381|NCT03539705|OTHER|There is no intervention|There is no intervention
48643382|NCT06297343|PROCEDURE|Creation of an arteriovenous fistula|Patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day (outpatient care, or an overnight stay in hospital if they live a long way from the hospital, have multiple pathologies or are socially isolated). An arteriovenous fistula is created under local or general anaesthetic. On the day of the operation, the type of arteriovenous fistula created, the side of the arteriovenous fistula, the location of the arteriovenous fistula and the patency of the arteriovenous fistula will be collected.
48643383|NCT05676450|DIAGNOSTIC_TEST|cell-free DNA|Given by IV (vein)
48114304|NCT06677073|BEHAVIORAL|High-intensity interval training|High-intensity interval training
48114305|NCT06677073|BEHAVIORAL|Maximal fat oxidation exercise|Maximal fat oxidation exercise
48114306|NCT05641311|DRUG|ALXN1840|Tablet for oral use.
48114307|NCT06259058|DRUG|Irinotecan liposome injection|50 mg/m² on Day 1 of a 14-day cycle
48114308|NCT06259058|DRUG|Oxaliplatin|60 mg/m² on Day 1 of a 14-day cycle
48114309|NCT06259058|DRUG|5-Fluorouracil|2400 mg/m² continuous IV infusion in 46 h
48114310|NCT06259058|DRUG|Leucovorin|400 mg/m² on Day 1 of a 14-day cycle
48312340|NCT00850018|BEHAVIORAL|Usual care|Participants will receive usual care for the treatment of SCD.
48312341|NCT03442829|BEHAVIORAL|Sweet food consumption|Sweet food consumption at breakfast
48312342|NCT03442829|BEHAVIORAL|Non-sweet food consumption|Non-sweet food consumption at breakfast
48312343|NCT04824196|OTHER|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear
48483713|NCT01680783|DEVICE|Non invasive ventilation using a helmet hyperbaric device|"Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.~If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay."
48483714|NCT01680783|OTHER|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
48483715|NCT05322902|DRUG|remimazolam group|Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
48483716|NCT05322902|DRUG|propofol group|Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
48483717|NCT02130167|DRUG|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
48483718|NCT01330667|DIETARY_SUPPLEMENT|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
48483719|NCT02401477|DRUG|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
48483720|NCT04617392|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
48643384|NCT05761301|DRUG|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
48643385|NCT05761301|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection.
48643386|NCT05591300|DIAGNOSTIC_TEST|Microparticles research|The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
48643387|NCT03595124|DRUG|Axitinib|Given PO
48643388|NCT03595124|BIOLOGICAL|Nivolumab|Given IV
48643389|NCT03761173|DEVICE|FlowTriever System|Thrombectomy
48643390|NCT03761173|DRUG|Anticoagulation Agents|Anticoagulation medication
48643391|NCT06557343|DIAGNOSTIC_TEST|Single Cell Sequencing|Sequencing of all viable single cells present in deep bronchial brushings using transcriptomics to identify what cells are present and what they are doing.
47963340|NCT03108183|DIAGNOSTIC_TEST|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
47963341|NCT06506656|DEVICE|Hyadrol®|Sterile single-use Medical Device for intra-articular injections
47963342|NCT06310317|BEHAVIORAL|Applied Behavior Analysis protocol|"The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. The use of Applied Behavior Analysis procedures, with the help of technological tools such as a tablet or robot can facilitate the increase of new knowledge and skills.~The criterion is acquired if the subject emits 8 out of 10 independent correct responses (90%) for 3 consecutive sessions.~The objective is to test whether the technological tool used (tablet or robot) can make the proposed learning procedure more effective. The experimental group carries out the procedure by means of stimuli presented on tablets or robots."
47963343|NCT06310317|BEHAVIORAL|Traditional intervention|The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. In this group the materials are traditional, such as image printed. The criterion is acquired if the subject emits 9 out of 10 independent correct responses (90%) for 3 consecutive sessions. The control group performs the procedure with images printed on A4 laminated sheets.
47963344|NCT01822171|OTHER|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
47963345|NCT01822171|OTHER|Home medication if needed|Patient will be provided with medication to take home, when needed.
48114311|NCT06259058|RADIATION|SBRT|30Gy/5Fx
48312344|NCT04824196|OTHER|propriocetion exercise|"1. Alternate knee flexion-extension with extended trunk posture using both hands for support.~2. Hip and knee flexion-extension with swiss ball between the back and wall.~3. Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball"
48312345|NCT02730507|DEVICE|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
48312346|NCT02730507|DEVICE|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
48312347|NCT06253286|DEVICE|clear aligner treatment for orthodontics patients|patient are instructed to wear aligners
48312348|NCT04549597|DRUG|Tenapanor|Use of tenapanor
48114312|NCT03981042|DEVICE|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
48312349|NCT02626104|DIETARY_SUPPLEMENT|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
48483721|NCT04617392|OTHER|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
48483722|NCT00314431|PROCEDURE|Care coordination by telephone contacts with a nurse|
48483723|NCT02994355|OTHER|Systems Analysis and Improvement Approach|"1. Understanding the cascade from FP clinic enrollment to HIV testing~2. Use process mapping to identify modifiable bottlenecks~3. Define and implement workflow adaptations to eliminate modifiable bottlenecks~4. Monitor change in performance~5. Repeat the analysis and improvement cycle (steps 1-4)"
47963346|NCT01822171|OTHER|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
48312350|NCT02626104|DIETARY_SUPPLEMENT|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
48312351|NCT04176055|DRUG|Haloperidol|haloperidol intervention
48312352|NCT04087343|BEHAVIORAL|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
48483724|NCT00345059|DRUG|docetaxel|
48114313|NCT06552624|DRUG|Magaldrate|A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
48114314|NCT06552624|DRUG|Magaldrate|A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
48114315|NCT04266951|BEHAVIORAL|Singstrong:|Group singing and breathing control training
48114316|NCT02304913|OTHER|Hypoglossal acupuncture|
48114317|NCT02304913|OTHER|Sham acupuncture|
48114318|NCT02304913|BEHAVIORAL|Dietary recommendations|
48483725|NCT00345059|DRUG|vinorelbine|
48483726|NCT00345059|DRUG|gemcitabine|
48483727|NCT00345059|DRUG|capecitabine|
48483728|NCT02592759|DEVICE|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
48483729|NCT00147849|BEHAVIORAL|mailing of printed educational materials|
48483730|NCT00147849|BEHAVIORAL|a combination of interactive educational meetings, educational outreach visits, and reminders|
48483731|NCT00147849|BEHAVIORAL|identification of local opinion leaders and establishment of local consensus processes|
48483732|NCT03528473|OTHER|Exercise|"The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines."
48483733|NCT00852917|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
48483734|NCT00852917|DRUG|Placebo|One Placebo tablet daily.
48483735|NCT03662906|OTHER|Electroacupuncture|"Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
48643392|NCT05852990|COMBINATION_PRODUCT|Glutamine plus L. reuteri|Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
48643393|NCT05559580|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
48643394|NCT05559580|DRUG|Placebo|Placebo
48312353|NCT04087343|BEHAVIORAL|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
48643395|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 1|Participants will use their Radicle Spark Placebo Control Form 1 as directed for a period of 6 weeks.
48643396|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 1.1 Usage|Participants will use their Radicle Spark Active Study Product 1.1 as directed for a period of 6 weeks.
48643397|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 2|Participants will use their Radicle Spark Placebo Control Form 2 as directed for a period of 6 weeks.
48312354|NCT00861367|DRUG|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
48312355|NCT02837692|DRUG|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
48312356|NCT02837692|DRUG|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
48312357|NCT02837692|DRUG|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
48312358|NCT02837692|DRUG|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
48312359|NCT01263691|BIOLOGICAL|BioThrax|BioThrax
48312360|NCT01263691|BIOLOGICAL|AV7909 Formulation 1|AV7909 Formulation 1
48312361|NCT01263691|BIOLOGICAL|AV7909 Formulation 2|AV7909 Formulation 2
48312362|NCT01263691|BIOLOGICAL|AV7909 Formulation 3|AV7909 Formulation 3
48312363|NCT01263691|BIOLOGICAL|AV7909 Formulation 4|AV7909 Formulation 4
48312364|NCT01263691|DRUG|Control|Saline control
48483736|NCT03662906|OTHER|Sham electroacupuncture|"Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
48483737|NCT01995721|BIOLOGICAL|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
48643398|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 2.1 Usage|Participants will use their Radicle Spark Active Study Product 2.1 as directed for a period of 6 weeks.
48643399|NCT05013905|DRUG|PRA023 IV|PRA023 administered at timepoints as directed by the protocol
48643400|NCT05013905|DEVICE|Companion diagnostic (CDx)|CDx+ or CDx-
48643401|NCT06643936|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, community health worker, and dietician working together to overcome barriers to diabetes control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
48643402|NCT06643936|BEHAVIORAL|E3 Self-Guided Type 2 Diabetes Education|Patients will receive timed, mailed educational materials on diabetes monitoring, diet and lifestyle modifications to supplement usual clinic based type 2 diabetes care with their primary care doctor. A registered nurse will ensure patients have glucometers and supplies, and remind patients to obtain A1C readings at 3 months and 6 months via phone call.
48643403|NCT05813093|DEVICE|rTMS|Accelerated iTBS treatment
48643404|NCT06521736|DEVICE|AAC-BCI device|Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
48643405|NCT00870324|DEVICE|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
48312365|NCT00884182|BIOLOGICAL|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
48312366|NCT00002887|DRUG|cisplatin|
48312367|NCT00002887|DRUG|etoposide|
48312368|NCT00002887|DRUG|hydroxyurea|
48312369|NCT00002887|DRUG|vinblastine sulfate|
48312370|NCT00002887|DRUG|vindesine|
48312371|NCT00002887|DRUG|vinorelbine tartrate|
48312372|NCT00002887|PROCEDURE|drug resistance inhibition treatment|
48643406|NCT00870324|DEVICE|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
48643407|NCT05297500|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
48312373|NCT06007482|DRUG|ES009|ES009 is administered via intravenous infusion, once every 21 days.
48312374|NCT02302794|PROCEDURE|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
48312375|NCT02302794|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
48312376|NCT04382859|PROCEDURE|Transversus abdominis plane (TAP) block with liposomal bupivacaine|Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
48312377|NCT01827059|DRUG|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
48312378|NCT01827059|DRUG|Placebo|
48114319|NCT01548846|RADIATION|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
48312379|NCT00016198|DRUG|FOLFOX regimen|
48312380|NCT00016198|DRUG|fluorouracil|
48312381|NCT00016198|DRUG|leucovorin calcium|
48312382|NCT00016198|DRUG|oxaliplatin|
48312383|NCT05357352|OTHER|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
48312384|NCT01758393|DRUG|Prednisone|
48312385|NCT00259220|DRUG|erythomycin|erythomycin
48312386|NCT00259220|PROCEDURE|gastric lavage alone|gastric lavage alone
48312387|NCT00259220|PROCEDURE|erythromycine and gastric lavage|erythromycine and gastric lavage
48312388|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
48312389|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
48312390|NCT01635751|DRUG|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
48312391|NCT00256048|PROCEDURE|Nasojejunal feeding|
48643408|NCT06612151|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.
48643409|NCT06612151|DRUG|topotecan hydrochloride for injection|Topotecan hydrochloride will be administered intravenously per prescribing information.
48643410|NCT02113813|DRUG|naquotinib|oral
48643411|NCT02113813|DRUG|midazolam|oral
48643412|NCT06229873|DEVICE|App-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by a smartphone application. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. All training sessions will be guided by the smartphone application.
48114320|NCT05590273|BEHAVIORAL|CALM Therapy|"The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention."
48312392|NCT05818527|DEVICE|Acceledent vibrating device|used to accelerated the movement of teeth during orthodontic treatment
48312393|NCT02280928|OTHER|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
48312394|NCT02280928|OTHER|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
48312395|NCT02280928|OTHER|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
48312396|NCT03060603|DRUG|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
48312397|NCT05974085|DRUG|Selinexor+RCHOP|XPO-1 inhibitor selinexor in combination with RCHOP
48312398|NCT04574297|BEHAVIORAL|smoking and alcohol assumption|documenting the change of smoking and drinking status during the follow-up period
48312399|NCT04574297|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
48312400|NCT04136561|DEVICE|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
48312401|NCT04059445|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Regenerative therapy with biphasic calcium phosphate + collagen membrane.
48312402|NCT04059445|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
48643413|NCT06229873|DEVICE|Clinic-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by researchers. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. One training session each week will be performed in the research clinic.
48643414|NCT03569891|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
48643415|NCT03569891|BIOLOGICAL|Factor IX (FIX)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
48643416|NCT06434363|DRUG|Tafasitamab|Given by vein (IV)
48643417|NCT06434363|DRUG|Fludarabine phosphate|Given by vein (IV)
48312403|NCT04576637|PROCEDURE|Neurophysiological monitoring during intubation|In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
48312404|NCT00234858|DRUG|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
48312405|NCT00234858|DRUG|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
48312406|NCT04084938|PROCEDURE|Prostate operation or prostate artery embolization|As described above.
48312407|NCT01213433|DRUG|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
48312408|NCT05342129|OTHER|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
48312409|NCT01026701|DRUG|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
48312410|NCT03606252|OTHER|Blood sampling|6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
48312411|NCT03606252|OTHER|urine sampling|2 urine sample (1 at J0 and 1 at J7)
48312412|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
48643418|NCT06434363|DRUG|Cyclophosphamide|Given by vein (IV)
48643419|NCT06586957|DRUG|NKT3964|Oral CDK2 Degrader
48643420|NCT06295120|DRUG|Phenoxymethylpenicillin 1.2 MIE 4 times daily|The intervention is the duration of treatment with phenoxymethylpenicillin from 3 to 7 days. Dose and frequency of the treatment is the same in the different arms.
48643421|NCT06686030|DRUG|AK112 low dose|10mg/kg, Q3W, ivgtt
47963347|NCT05510440|DIETARY_SUPPLEMENT|Alpha-amino acid derivatives|Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
47963348|NCT00002989|DRUG|busulfan|
47963349|NCT00002989|DRUG|cyclophosphamide|
47963350|NCT00002989|DRUG|idarubicin|
47963351|NCT00002989|DRUG|melphalan|
47963352|NCT00002989|RADIATION|radiation therapy|
47963353|NCT01101880|BIOLOGICAL|filgrastim|Given SC
48643422|NCT06686030|DRUG|Chemotherapy|ivgtt
48643423|NCT06686030|DRUG|Olaparib|bid, oral
48643424|NCT06686030|DRUG|AK112 high dose|20mg/kg, Q3W, ivgtt
48643425|NCT06685848|DEVICE|Hemanext ONE system|Hypoxic red blood cells
48643426|NCT06685848|DEVICE|Conventional RBCs|Conventional manufactured Red blood cells
48643427|NCT05569252|DRUG|DS-1211b|DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
47963354|NCT01101880|DRUG|clofarabine|Given IV
47963355|NCT01101880|DRUG|cytarabine|Given IV
47963356|NCT03691259|OTHER|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
47963357|NCT06065943|OTHER|Palpation and Fluoroscopy|Vessel puncture guided palpation and fluoroscopy only
47963358|NCT06065943|PROCEDURE|Ultrasound guidance|Vessel puncture guided by Ultrasound
47963359|NCT01753505|OTHER|64-slice Multidetector coronary CT angiography|
47963360|NCT02147236|BEHAVIORAL|Social Skills Training|
47963361|NCT06382259|OTHER|Movement breaks|Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.
47963362|NCT02378259|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
47963363|NCT02378259|PROCEDURE|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
47963364|NCT02140086|BEHAVIORAL|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
47963365|NCT02671305|PROCEDURE|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
47963366|NCT02671305|PROCEDURE|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
47963367|NCT01752361|DEVICE|Motilis-3D transit|
47963368|NCT00730145|DRUG|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
48114321|NCT04681079|DRUG|albuterol sulfate (MDI)|albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
48312413|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
48643428|NCT05569252|OTHER|Placebo|Placebo tablet administered once daily in the morning either in the fasted state or with a meal
48643429|NCT03797326|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
48643430|NCT03797326|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle.
47963369|NCT04847011|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
48312414|NCT00711269|DRUG|Placebo|
48312415|NCT00711269|DRUG|Risperidone|
48312416|NCT00258427|BIOLOGICAL|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
48312417|NCT00258427|BIOLOGICAL|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)
48312418|NCT00258427|DRUG|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)
48312419|NCT00258427|DRUG|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
48312420|NCT00258427|DRUG|fludarabine phosphate|35 mg/m\^2 intravenously (IV) on Days -5 through -2.
48312421|NCT00258427|DRUG|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
48312422|NCT00258427|BIOLOGICAL|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
48312423|NCT05954832|DIAGNOSTIC_TEST|Echocardiography|Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
48483738|NCT03813693|OTHER|towels impregnated with 2% chlorhexidine gluconate|"The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes."
48643431|NCT06316063|DEVICE|Apnoeic oxygenation with high-flow nasal oxygen|The subjects in the intervention group will be oxygenated with HFNO during the surgical procedure.
48643432|NCT06316063|OTHER|Mechanical ventilation|Study subjects in the comparator group will be tracheally intubated and mechanically ventilated
48643433|NCT06679543|OTHER|Partial sleep deprivation|Participants will be asked to come to the lab for testing after a night of partial sleep deprivation. Participants will be asked to fall asleep at their habitual bedtime but wake up early (\~40% of normal sleep duration).
48643434|NCT06683677|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to extremely preterm infants immediately after birth.
48643435|NCT03326921|BIOLOGICAL|CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|Given IV
48643436|NCT03326921|DRUG|Fludarabine|Given IV
48643437|NCT03326921|OTHER|Laboratory Biomarker Analysis|Correlative studies
48643438|NCT06164730|DRUG|VERVE-102|Intravenous (IV) infusion
48643439|NCT06687330|DEVICE|Tracking Mobility and Health Data with a Smartwatch in Discharged Oncology Patients to Predict Rehospitalization: A Prospective Study|The intervention involves daily monitoring of discharged oncology patients using a smartwatch (Huawei Watch Fit 2) to track physical activity (step count), heart rate, and sleep duration. Data is collected remotely via a smartphone app, allowing real-time tracking of health metrics post-discharge. This intervention is distinct in its focus on correlating mobility and physiological data with the risk of rehospitalization within a 30-90 day period. Patients will also receive recommendations to maintain daily walking routines as part of their post-discharge care. Additionally, quality of life and sleep quality assessments are conducted before discharge and at follow-up visits to provide a comprehensive overview of each patient's post-hospital recovery.
48643440|NCT06688305|DRUG|68Ga-NI-FAPI|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-NI-FAPI.
48643441|NCT05377489|DRUG|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
48643442|NCT03813290|DEVICE|Neuro-technological Intervention|During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
48643443|NCT06551961|DIETARY_SUPPLEMENT|methylcellulose|2.5 and 5 gm Methylcelllose heated to create a gel
47963370|NCT02661659|BIOLOGICAL|Multipeptide vaccine S-588210|
47963371|NCT04345809|PROCEDURE|MESH WHIT OMEGA-3|Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
48114322|NCT04681079|DRUG|albuterol sulfate (nebulizer)|albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece
48114323|NCT00881842|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
48312424|NCT06549023|PROCEDURE|Single-session panretinal PRP (SS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
48643444|NCT06551961|DIETARY_SUPPLEMENT|inulin|2.5 and 5 gm inulin powder dissolved in water
48312425|NCT06549023|PROCEDURE|Multiple-session panretinal PRP (MS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
48312426|NCT02315937|PROCEDURE|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
48312427|NCT03007745|DEVICE|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
48312428|NCT04628403|OTHER|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
48312429|NCT04628403|DEVICE|lasertherapy|lasertherapy
48312430|NCT04628403|DEVICE|shock waves|shock waves
48312431|NCT05799443|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
48312432|NCT05799443|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.
48643445|NCT06551961|DIETARY_SUPPLEMENT|maltodextrin|2.5 and 5gm maltodextrin dissolved in water
48483739|NCT03813693|OTHER|chlorhexidine gluconate 2% liquid|Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
48643446|NCT06685835|DRUG|Brensocatib|Film-coated Oral tablet
48114324|NCT05797519|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.
48114325|NCT02899000|DRUG|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
48643447|NCT06685835|DRUG|Placebo|Film-coated Oral tablet
48114326|NCT02899000|DRUG|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
48483740|NCT04531787|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
48643448|NCT05226884|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance and intermediate visual acuity at variety targeted correction.
48643449|NCT05226884|DIAGNOSTIC_TEST|Defocus Curve|Measurement of a defocus curve
48114327|NCT03227757|DEVICE|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
48114328|NCT04424303|DRUG|Tofacitinib|Observational study
48114329|NCT04287478|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
47963372|NCT04345809|PROCEDURE|MESH WITHOUT OMEGA-3|Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
47963373|NCT01495117|DRUG|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
47963374|NCT01495117|DRUG|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
48114330|NCT05430880|DIAGNOSTIC_TEST|impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)|"Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~1. st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~   CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~2. nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~3. rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli"
48114331|NCT06375668|DIETARY_SUPPLEMENT|Probiotic|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).
48114332|NCT06375668|OTHER|Placebo|The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
48114333|NCT04749017|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
48114334|NCT04749017|OTHER|Control product consumption|Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
48483741|NCT03301103|BIOLOGICAL|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
48483742|NCT03301103|DEVICE|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
48483743|NCT01685593|DEVICE|abdominal binder|
48483744|NCT01685593|OTHER|no binder|
48483745|NCT06108219|DRUG|Miricorilant (Cohort A)|Miricorilant 100 mg for oral dosing
48483746|NCT06108219|DRUG|Placebo (Cohort A)|Matching placebo for oral dosing for 48 Weeks
48483747|NCT06108219|DRUG|Miricorilant (Cohort B)|Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
48483748|NCT06108219|DRUG|Placebo (Cohort B)|Matching placebo for oral dosing for 24 Weeks
48483749|NCT01671982|OTHER|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to \<50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
48483750|NCT06296524|OTHER|Footcore exercises and conventional therapy|30 minutes exercises protocol will be provided
48643450|NCT03568058|DRUG|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
48643451|NCT03568058|DRUG|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
48643452|NCT06407427|DEVICE|App for in-bed conditioning exercises|Participants will use an application (app) in facilitating in-bed conditioning exercises for hospitalized patients
48643453|NCT06407427|OTHER|Usual care|All participants will receive usual care in the post-operative setting.
48643454|NCT04456517|DRUG|Ranolazine|500 mg tablet
48643455|NCT04456517|DRUG|Placebo|Ranolazine-matched placebo tablet
48643456|NCT06674772|DIAGNOSTIC_TEST|Saliva test|Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
48114335|NCT03706690|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.
48114336|NCT03706690|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
47963375|NCT00450281|GENETIC|chromogenic in situ hybridization|
48114337|NCT05260086|DEVICE|Neuronavigated aiTBS|Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
48114338|NCT01901510|DRUG|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
47963376|NCT00450281|GENETIC|gene expression analysis|
48114339|NCT01901510|OTHER|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
48114340|NCT03189316|OTHER|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
48483751|NCT06296524|OTHER|conventional therapy|conventional therapy will be provided.
47963377|NCT00450281|GENETIC|mutation analysis|
47963378|NCT00450281|GENETIC|polymerase chain reaction|
47963379|NCT00450281|GENETIC|polymorphism analysis|
47963380|NCT00450281|OTHER|fluorescent antibody technique|
48483752|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M2
47963381|NCT00450281|OTHER|immunohistochemistry staining method|
47963382|NCT00450281|OTHER|laboratory biomarker analysis|
47963383|NCT00450281|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
47963384|NCT00450281|OTHER|study of socioeconomic and demographic variables|
48114341|NCT03538912|OTHER|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
48114342|NCT03538912|OTHER|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
48114343|NCT03503084|BEHAVIORAL|Classical Yang's TCC exercise|
48114344|NCT00665444|DRUG|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
48114345|NCT05744193|OTHER|Exempt Infant Formula|Liquid human milk fortifier to be added to human milk daily
48114346|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
48483753|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M3
48483754|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
48483755|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
48483756|NCT02696031|DRUG|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
47963385|NCT00450281|PROCEDURE|study of high risk factors|
47963386|NCT05518019|DIETARY_SUPPLEMENT|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
47963387|NCT05094583|BEHAVIORAL|Use of SmokeFree app|Intervention Arm
47963388|NCT02696460|PROCEDURE|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
47963389|NCT02696460|PROCEDURE|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
47963390|NCT03021070|OTHER|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
48114347|NCT03270358|PROCEDURE|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
48114348|NCT06520865|OTHER|Acoustic paradigms|Acoustic oddball Gap detection
48483757|NCT02696031|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
48483758|NCT00799916|DRUG|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
48483759|NCT00799916|DRUG|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
48483760|NCT06142149|PROCEDURE|ultrasonographic evaluation|Screen the front of neck using ultrasound
48483761|NCT04823819|DEVICE|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
48483762|NCT04823819|DEVICE|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
48312433|NCT05799443|DRUG|cetuximab|cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
48483763|NCT02384850|DRUG|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
48483764|NCT02384850|DRUG|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
48483765|NCT02384850|DRUG|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
48643457|NCT06688006|OTHER|climate change short animation film|For the short animated film, a scenario will be created that describes climate change, risk factors that threaten human health as a result of climate change, adverse health effects of climate change, adverse effects on maternal and foetal health, precautions to be taken to protect against and adapt to the adverse effects of climate change. In the short animation film, visual materials will be created that show the adverse effects of climate change by using developing technology. The created scenario will be prepared as a two-dimensional (2D) animation film with the support of Selçuk University SERATEM (Selçuk University Radio and Television Application Center). All lines, colours, decorations and characters used in the creation phase of the short animation film will be determined by the researchers. Once the drawing and animation phases are complete, the voice-over actors will be selected after a further review. The short animated film should be about 2-3 minutes long.
48643458|NCT03233971|OTHER|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
48643459|NCT06380686|OTHER|data collection|Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
47963391|NCT06047483|DRUG|HRF2105 patch|HRF2105 patch ，external use，once a day
47963392|NCT06047483|DRUG|Loxoprofen patch|Loxoprofen patch ，external use，once a day
47963393|NCT06047483|DRUG|placebo|placebo ，external use，once a day
47963394|NCT02109380|BEHAVIORAL|Bed rest|
47963395|NCT01937416|BIOLOGICAL|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
47963396|NCT02554500|PROCEDURE|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
47963397|NCT04173104|DIAGNOSTIC_TEST|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
47963398|NCT04173104|DRUG|[18F]PARPi|Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
47963399|NCT05346770|BEHAVIORAL|Behavioral Intervention|A behavioral intervention could include changing the time of day a drug is taken.
47963400|NCT05346770|DIAGNOSTIC_TEST|Diagnostic Test|A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.
47963401|NCT05346770|OTHER|Data Analysis|Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
47963402|NCT02304679|OTHER|Pre-inclusion questionnaires|"(Month -2)~During this visit, the investigator will:~* Validate the patient's inclusion and exclusion criteria;~* Obtain informed consent from the patient;~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Prescribe 1 month of PDE5i treatment.~* The next visit will be scheduled"
48114349|NCT03071653|PROCEDURE|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
48483766|NCT02384850|DRUG|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
48643460|NCT06690528|PROCEDURE|Surgical resection of both the primary tumor and liver metastases|Surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
47963403|NCT02304679|DRUG|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
47963404|NCT02304679|OTHER|PDE5i follow-up questionnaires|"(Month -1)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~* The next visit will be scheduled"
48312434|NCT05799443|RADIATION|SBRT|8-10Gy×5F，QOD
48312435|NCT01202708|DEVICE|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
48312436|NCT01202708|DEVICE|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
48312437|NCT01172587|OTHER|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
48312438|NCT06186882|BEHAVIORAL|Action Video-Game|Thanks to their specific characteristics (presentation of multiple peripheral, rapidly moving, spatio-temporally unpredictable stimuli), Action Video-Games improve reading skills through their effects on the Magnocellular-Dorsal stream. Training will consist of 20 days of Action Video-Games sessions of 1 hour each, three times per week.
48483767|NCT01976728|DRUG|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
48643461|NCT06602752|BEHAVIORAL|Food system and demand generation|The Vegetables for All project will create FFZs in low-income urban and peri-urban areas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will link vendors and farmers through market facilitators, support the uptake of digital solutions for vendors to access vegetables, and support district governments to improve market infrastructure. To encourage BoP parents of children 3-9 years to buy and consume more vegetables, the program will include a demand generation component.
48643462|NCT06688227|OTHER|Isolated Core Stability Program|The control group consists of basic core exercises which include the activation of transversusabdominins and multifidus muscles and progressive strengethening of these muscles in all positions using swiss balls and floor mats. All exercises were done for at least 3 sets of 15 repetitions to build proper core stability.
48643463|NCT06688227|OTHER|Integrated Core Stability Program|"An individualized protocol was designed for these cricketers targeting static and dynamic core stability, with integration of balance, endurance and power component.~Tranversusabdominis and multifidus strengthening is combined with upper extremity motions to work on the fast bowling action i.e throwing of the players.~At the same time lower extremity balance and strengthening is also included to ensure the high speed of sprint."
47963405|NCT02304679|OTHER|Inclusion questionnaires|"(Day 0)~During this visit the investigator will:~* Verify inclusion and exclusion criteria, and proceed with final inclusion~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Randomize the patient at the end of the visit~* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
47963406|NCT02304679|DEVICE|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
47963407|NCT02304679|DEVICE|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
47963408|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 1|"(Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
47963409|NCT02304679|OTHER|Follow-up questionnaires 3 months after Wave 1|"(Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
47963410|NCT02304679|DEVICE|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
47963411|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 2|"(Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
47963412|NCT02304679|OTHER|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
47963413|NCT02304679|OTHER|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
48312439|NCT01104259|DRUG|veliparib|Given PO
48312440|NCT01104259|DRUG|cisplatin|Given IV
48312441|NCT01104259|DRUG|vinorelbine tartrate|Given IV
48312442|NCT01104259|OTHER|laboratory biomarker analysis|Correlative studies
48312443|NCT01104259|OTHER|pharmacological study|Correlative studies
48312444|NCT03798145|PROCEDURE|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
48312445|NCT00851734|DRUG|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
48312446|NCT01545908|OTHER|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
48312447|NCT01545908|OTHER|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
48312448|NCT00932152|DRUG|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
48312449|NCT00932152|DRUG|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
48312450|NCT00932152|DRUG|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
48312451|NCT00932152|DRUG|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
48312452|NCT01712087|DEVICE|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
48114350|NCT03071653|OTHER|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~1. A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~2. A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~3. A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~4. The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
48643464|NCT06690281|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine)
48643465|NCT06690281|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 3 doses)
48643466|NCT06690281|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 4 days
48643467|NCT06690281|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 30 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 7.5 mg/kg/day over 1 hour x 2 days
48643468|NCT06688344|OTHER|fESWT|fESWT will be applied for 1 session between weeks 4-9. The device will be set to low intensity at 0.20 mJ/mm2 - 4 Hz, 500 pulses will be applied from the tibiofemoral interval to the center of the tibiofemoral joint, and 1000 pulses will be applied to the soft tissues around the patella.
48643469|NCT06688344|OTHER|Conventional Physiotherapy|"Participants will be included in the traditional physiotherapy program for the first 9 weeks, and exercise progression will be provided in the form of weekly checks in the 10-12 week period. Between the 12-24th weeks, the exercise program will continue with face-to-face follow-up twice a month.~The traditional physiotherapy program to be applied in the first 9-week period will be as follows :~Week 1 Weight Transfer as Tolerable, NMES, Elevation, Cold Application, Ankle Pumping Exercises, Heel Slide Exercises, Isometric Quadriceps Exercises, Straight Leg Raise Exercises, Extension Brace~Week 2-3 Weight Transfer, Gait Training, NMES, Heel Slide Exercises, Straight Leg Raise, Quadriceps and Adductor Isometric Exercises, Extension Brace, Bicycle, Hip Abduction-Adduction Exercises~Week 4-8. week Mini Squat, Leg Press, Soft Ground Walking, Neuromuscular Training on Balance Board, Functional Strengthening with Elastic Band, Stair Climbing Up and Down"
48643470|NCT06688344|OTHER|shamfESWT|Participants in the control group will receive sham fESWT once a week in weeks 4-9. Participants will be prepared in the same way as the fESWT procedure, but the application will be done with a sham device.
48643471|NCT06241430|DEVICE|CardioMEMS|Hemodynamic-guided optimization will be performed using the CardioMEMS CardioClip device.
48643472|NCT06439771|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
48643473|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A|0,5 ml DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A injected three-dose regimen with 28 days interval between doses. Vaccine is injected intramuscularly in left anterolateral thigh.
48643474|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B|0,5 ml injected of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B three-dose regimen with 28 days interval between doses. Injected intramuscularly in left anterolateral thigh.
47963414|NCT04544397|PROCEDURE|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
47963415|NCT03004742|DIETARY_SUPPLEMENT|Flavonoid|Flavonoid rich supplement
47963416|NCT03004742|DIETARY_SUPPLEMENT|Placebo|Placebo
48312453|NCT04289415|BEHAVIORAL|Individual Placement and Support|Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
48312454|NCT04243135|DEVICE|ESWT|Extracorporeal shock wave therapy
48643475|NCT06690515|BIOLOGICAL|Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®|The control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml IPV (Sinovac)® injected in three-dose regimen with 28 days interval between doses. Registered DTwP-Hepatitis B-Hib Vaccine are injected intramuscularly into the left antero-lateral thigh region. IPV (Sinovac)® vaccine are injected intramuscularly into the right mid-lateral thigh region
47963417|NCT00000789|DRUG|Stavudine|
47963418|NCT00000789|DRUG|Zidovudine|
47963419|NCT00030290|PROCEDURE|high-intensity focused ultrasound ablation|
48312455|NCT02796534|OTHER|Diagnosis of sleep apnea by oxymetry|
47963420|NCT05419869|DRUG|ALTO-100 PO Tablet|Two tablets daily
48643476|NCT04212442|BEHAVIORAL|Independent Living Program for Affordable Housing.|"Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches."
48643477|NCT03159676|RADIATION|Proton beam|Proton beam
48114351|NCT02471755|DEVICE|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30\*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
48312456|NCT06033339|OTHER|Blood sampling|Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
48312457|NCT05924906|DRUG|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
48312458|NCT05867316|BEHAVIORAL|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
48312459|NCT01994226|DRUG|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
48312460|NCT01994226|DRUG|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
48483768|NCT01976728|DRUG|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
48643478|NCT01270555|DRUG|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
48643479|NCT03803943|BEHAVIORAL|Parent-Implemented Communication Intervention (PICT)|Weekly hour long intervention sessions for 6 months
48643480|NCT03803943|OTHER|No Intervention - Business-as-usual control|Does not receive PICT internvention
48643481|NCT06560879|BIOLOGICAL|Lactobacillus casei|Lacticaseibacillus casei is a species of Gram-positive anaerobic bacteria found in the intestine and mouth of humans. This lactic acid-producing bacterium is used in the dairy industry in the production of probiotic foods.
48312461|NCT03039127|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
48312462|NCT00226681|BEHAVIORAL|Nursing Telephone Support Protocol|
48483769|NCT01976728|DRUG|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
48483770|NCT01976728|DRUG|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
48643482|NCT06560879|BIOLOGICAL|Lactobacillus rhamnosus|A live form of a bacterium that makes lactic acid (a substance derived from milk sugars and also made by the body). Lactobacillus rhamnosus GG is given to help with digestion and normal bowel function. In addition, it may help maintain a healthy gastrointestinal tract. It is being studied for the prevention of infections in patients who received donor stem cell transplants and for other conditions.
48643483|NCT06560879|BIOLOGICAL|Bifidobacterium bifidum|B. bifidum is an essential bacteria found in the human intestine. When it is low or absent all together in the human intestine, it is an indication of being in an unhealthy state. Intestinal flora can be improved if someone takes oral B. bifidum. Also, oral B. bifidum is used for other things such as therapy for enteric and hepatic disorders, for activating the immune response, and for preventing some cancers
48312463|NCT00226681|BEHAVIORAL|Usual Care|
48312464|NCT06049771|OTHER|Collect blood sample|Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
48312465|NCT02348411|DEVICE|ExAblate|
48483771|NCT04920903|DRUG|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
48483772|NCT04920903|DRUG|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
48483773|NCT01731899|DRUG|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
48483774|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
48483775|NCT01012557|BIOLOGICAL|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
48483776|NCT01012557|BIOLOGICAL|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
48483777|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
47963421|NCT03775629|DRUG|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
47963422|NCT03775629|DRUG|Polmacoxib|Polmacoxib
48483778|NCT02264093|DRUG|Propranolol|
48483779|NCT02264093|DRUG|Talsaclidine|
47963423|NCT03775629|DRUG|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
47963424|NCT06135753|OTHER|psychosomatic intervention based on cognitive restructuring.|Participants will receive information on psychosomatic phenomena and over-listening of somatic manifestations (Session 1), interpretation and possible catastrophization of somatic manifestations even when they might be well-known health problems or potential physiological or para-physiological manifestations (Session 2), pain-proneness (Session 3) and mental pain and psychological distress in somatizers (Session 4). The second part of each session will be devoted to group cognitive restructuring, thus participants will be stimulated in verifying how the phenomena illustrated are in their lives and how they can be differently conceptualized in order to be less intrusive and less able to reduce their own functioning.
47963425|NCT06135753|BEHAVIORAL|Control condition|The control condition will include 4 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health.
47963426|NCT06135753|OTHER|Experimental and control condition: Museum therapy|"Session 5-6-7: preselected painting works from the Uffizi Galleries (Florence) will be presented to the participants in order to trigger reflections and emotional responses on specific pain related topics. Session 8: visit the Galleria di Arte Moderna at Palazzo Pitti, in person. Each session will be aimed at facilitating emotional expressions and partecipants' behavioral activation and identifying thoughts associated with those emotions and, if appropriate, remodulating them in a functional way (cognitive restructuring).~Session 9: share the experience of the previous meetings and to recap strategies and skills which could be implemented in FM participants' daily life to cope with their illness."
47963427|NCT02988843|DRUG|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
47963428|NCT02988843|DRUG|Bevacizumab|15 mg/kg every 21 days
47963429|NCT00787384|DRUG|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
47963430|NCT01989897|DRUG|saline with 1mg/ml Histamine base|
47963431|NCT01989897|DRUG|diluent, saline with HSA--phenol|
47963432|NCT00639678|DRUG|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
47963433|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
47963434|NCT00639678|DRUG|placebo|40 mg/kg placebo, single dose (day 0), Group 4
47963435|NCT00639678|DRUG|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
47963436|NCT04132258|OTHER|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
47963437|NCT04027062|BEHAVIORAL|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
48114352|NCT02471755|DEVICE|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
48114353|NCT00130117|DRUG|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
48114354|NCT00130117|DRUG|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
48114355|NCT00130117|OTHER|Placebo|placebo (no active medication)
48483780|NCT00754442|DRUG|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
48483781|NCT04458493|BEHAVIORAL|satiety|satiety ratings, appetite and desire to eat (10-point visual analogue scale) will be measured at 30, 60 and 120 minutes after each meal replacement drink
48483782|NCT04458493|DIETARY_SUPPLEMENT|Dietary Supplement: Generation UCAN supplementation|meal replacement, Generation UCAN supplement, 400ml, 20% solution
48483783|NCT03432234|OTHER|Biomarkers|This is an observational study, there is no intervention
48483784|NCT00768118|DIETARY_SUPPLEMENT|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
48483785|NCT00768118|GENETIC|electrophoretic mobility shift assay|
48483786|NCT00768118|OTHER|laboratory biomarker analysis|
48483787|NCT02373995|BIOLOGICAL|LAB4|Additional treatment with the specific LAB4 probiotic preparation
48483788|NCT01885702|BIOLOGICAL|DC vaccination|DC vaccination
47963438|NCT05248061|OTHER|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~- \*Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~\*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~\*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
48483789|NCT00669981|BEHAVIORAL|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
47963439|NCT05248061|OTHER|Group B|"The same exercises as in Group 1 will be suitable for the participants.~* PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~* Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
47963440|NCT02771431|OTHER|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
48483790|NCT06151782|DIETARY_SUPPLEMENT|Wheat gluten 1000 mg|Nothing to add here
48483791|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 1000 mg|Nothing to add here
48483792|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 50 mg|Nothing to add here
48483793|NCT06151782|DIETARY_SUPPLEMENT|Barley hydrolyzed gluten 50 mg|Nothing to add here
48643484|NCT06560879|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production.The most common form is used in vitamin supplements or tablets
47963441|NCT03173313|DEVICE|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
47963442|NCT04564261|BEHAVIORAL|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
47963443|NCT04564261|BEHAVIORAL|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
47963444|NCT03323541|DRUG|Filgrastim Prefilled Syringe [Zarzio®]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils \>1 giga/l)
47963445|NCT06062134|PROCEDURE|Pericapsular nerve group block|Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.
47963446|NCT06062134|DRUG|18 mL ropivacaine 0.5% + 2 mL radiopaque contrast|20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)
48483794|NCT00951184|BEHAVIORAL|telephone-based intervention|
48483795|NCT00951184|OTHER|screening questionnaire administration|
48483796|NCT00951184|OTHER|study of socioeconomic and demographic variables|
48483797|NCT00951184|PROCEDURE|assessment of therapy complications|
48483798|NCT00951184|PROCEDURE|psychosocial assessment and care|
48483799|NCT01298778|DRUG|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
48483800|NCT01298778|DRUG|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
48483801|NCT01298778|DRUG|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
48483802|NCT04199117|DRUG|Varenicline|Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
48643485|NCT06436742|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
48643486|NCT06436742|OTHER|Placebo|Intravenous infusion of placebo
48643487|NCT05712538|DRUG|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
48643488|NCT05712538|OTHER|Placebo|Normal saline
48643489|NCT06687122|DIETARY_SUPPLEMENT|3 whole eggs|Participants will be free-living and will not be supplied with any other food except for the eggs during the intervention period with no restrictions of energy intake.
48643490|NCT05538130|DRUG|PF-07799544|Tablet
48483803|NCT04199117|DRUG|Combination nicotine patch and nicotine mini-lozenge treatment|Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
48483804|NCT04199117|BEHAVIORAL|Monetary incentives for initiating treatment|Participants randomized to this intervention will earn an incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
48483805|NCT04199117|BEHAVIORAL|Automated tailored outreach|Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
48483806|NCT04199117|BEHAVIORAL|Care management|Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
47963447|NCT04755569|DEVICE|ODOCOR II CCM LEADS|ODOCOR II CCM LEADS Implantation
47963448|NCT00289965|BEHAVIORAL|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
47963449|NCT00289965|BEHAVIORAL|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
47963450|NCT00289965|BEHAVIORAL|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
47963451|NCT00592215|DRUG|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
47963452|NCT00007865|BIOLOGICAL|rituximab|
47963453|NCT00007865|DRUG|carboplatin|
47963454|NCT00007865|DRUG|etoposide|
47963455|NCT00007865|DRUG|ifosfamide|
47963456|NCT06139107|DRUG|Abemaciclib|150mg twice a day for 3 cycles prior to radiation.
47963457|NCT06139107|DRUG|Letrozole|Letrozole 2.5mg daily
47963458|NCT02151110|BIOLOGICAL|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
47963459|NCT02151110|BIOLOGICAL|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
47963460|NCT02151110|BIOLOGICAL|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
47963461|NCT02151110|BIOLOGICAL|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
47963462|NCT02151110|BIOLOGICAL|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
47963463|NCT02151110|BIOLOGICAL|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
47963464|NCT02151110|BIOLOGICAL|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
47963465|NCT02151110|OTHER|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
47963466|NCT05662007|OTHER||no intervention
47963467|NCT03194230|OTHER|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
47963468|NCT04194580|BEHAVIORAL|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
47963469|NCT03363958|PROCEDURE|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
47963470|NCT03363958|PROCEDURE|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
47963471|NCT01631344|OTHER|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
47963472|NCT04530916|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day wild blueberry powder
47963473|NCT04530916|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder
47963474|NCT04036903|RADIATION|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
47963475|NCT01313793|DRUG|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
47963476|NCT01313793|DRUG|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
47963477|NCT04600557|BEHAVIORAL|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
48114356|NCT06377111|DIETARY_SUPPLEMENT|C-PAN|C-PAN is an essential nutrient as it is required for the synthesis of CoA, a key cofactor in the tricarboxylic acid cycle and fatty acid metabolism, as well as for the synthesis of acyl carrier protein. Pantothenate appears to be safe in humans with studies describing the administration of doses up to 10 grams per day over prolonged periods of time; hence, no upper limit for tolerability has been established. In this study, oral supplement consisting of 2000 mg daily of C-PAN will be administered to a single cohort of patients.
48114357|NCT06377111|BIOLOGICAL|Nivolumab|Nivolumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Nivolumab 1 mg/kg every 3 weeks for up to 4 cycles (upon patient´s tolerability) followed by maintenance Nivolumab 3 mg/kg (or fixed dose 240 mg) every 2 weeks or Nivolumab 6 mg/kg (or fixed dose 480 mg) every 4 weeks.
48114358|NCT06377111|BIOLOGICAL|Ipilimumab|Ipilimumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein CTLA-4 on immune cells called T cells. Ipilimumab 3 mg/kg every 3 weeks for up to 4 cycles.
48114359|NCT05736497|OTHER|Digital Care Plans|Investigators will develop digital care plans for 10 common Cancer Predisposition Syndromes for patients diagnosed within 3 years.
48114360|NCT04723706|DIAGNOSTIC_TEST|COVID-19 serology IgG|patients with SCT or CART who decide to get their vaccines we will measure response by therapy by measuring COVID-19 serology IgG at the following schedule: Baseline +5 days after vaccination; 1 month +/- 10 days (after the first dose), 2 months +/- 10 days (after the 2nd dose), 3 months +/- 10 days, 6 months +/- 10 days and 12 months +/- 10 days
48114361|NCT04974008|DRUG|OST31-164|Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
48312466|NCT02290535|PROCEDURE|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
48312467|NCT02290535|PROCEDURE|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
48483807|NCT04199117|OTHER|Wisconsin Tobacco Quit Line referral|This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
48643491|NCT05538130|DRUG|PF-07799933|Tablet
47963478|NCT04600557|BEHAVIORAL|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
47963479|NCT04600557|BEHAVIORAL|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
47963480|NCT04600557|BEHAVIORAL|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
47963481|NCT02330237|DRUG|natural gels|whole fruits and vegetables
47963482|NCT02330237|DRUG|Placebo|
47963483|NCT00480883|DRUG|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
47963484|NCT00480883|DRUG|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
47963485|NCT00480883|DRUG|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
47963486|NCT00726986|DRUG|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
47963487|NCT00726986|DRUG|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
47963488|NCT00726986|DRUG|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
47963489|NCT02477150|BIOLOGICAL|Zostavax|Vaccination of a zoster vaccine (Zostavax)
48643492|NCT05538130|DRUG|encorafenib|Capsule
47963490|NCT02477150|BIOLOGICAL|placebo|placebo administration
47963491|NCT04806997|DIAGNOSTIC_TEST|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
47963492|NCT03734276|OTHER|High intensity activity|Cyclo-ergometer session in high intensity setting
47963493|NCT03734276|OTHER|control arm|Usual care
48114362|NCT03426228|DIAGNOSTIC_TEST|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~1. At baseline (second day of the menstrual period)~2. Triggering phase (post-egg retrieval procedure)~3. Embryo transfer phase (post-transfer procedure)~4. Week 4 (positive bHCG)~4. Week 8 of pregnancy"
48114363|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Pre-training)|handgrip and treadmill walking 4 days per week
48114364|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Post-training)|handgrip and treadmill walking 4 days per week
48114365|NCT00446550|DRUG|afegostat tartrate|
48114366|NCT05147662|BIOLOGICAL|Damoctocog alfa pegol (Jivi, BAY94-9027)|"Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion.~Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg."
48114367|NCT06127836|PROCEDURE|ICG guided sentinel lymph node biopsy|The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
48114368|NCT06647641|OTHER|Whole genome sequencing will be performed at the NIH|All samples will undergo non-CLIA approved whole genome sequencing on a research basis in collaboration with Sonja Scholz, MD, PhD at the Neurodegenerative Diseases Research Unit of the National Institutes of Health (Bethesda, MD). This sequencing method allows for the identification of not only variants known to be associated with these disorders but also potentially novel variants.
48114369|NCT05201248|DRUG|Epcoritamab|Subcutaneous Injection (SC)
48114370|NCT05201248|DRUG|Cyclophosphamide|IV Injection
48114371|NCT05201248|DRUG|Rituximab|Intravenous (IV) Infusion
48312468|NCT03898336|OTHER|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
47963494|NCT05276518|PROCEDURE|Closure of cesarean section incision|"After the delivery the first group will undergo Two Layer Uterine Closure:~Double-layer closure of the uterine incision will be performed using unlocked continuous Polyglactin thread sutures(1/0) for both layers, with a large portion of the myometrium and the endometrium included in the first layer. The second layer was a continuous running suture that imbricate the first layer, including serosal and myometrial tissue.~The second group will undergo continuous unlocked sutures in a single layer, Uterine closure will begin from one corner of the incision and then the uterine incision wound is closed using Polyglactin thread include endometrium, myometrium and serosa."
48643493|NCT05071027|OTHER|Endovascular Neurosurgery|Custom Dual Antiplatelet Therapy reminders for patients receiving endovascular treatment of cerebral unruptured aneurysms. The app utilized to generate reminders is available on the Apple app store.
47963495|NCT06260852|DIAGNOSTIC_TEST|Diagnostic Test: Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
47963496|NCT06306781|DRUG|HCL001 cell (homologous allogeneic hepatocytes) injection|The patient will undergo a DSA procedure in the hospital's operating room before infusion. A catheter will be inserted into the femoral artery and guided to the hepatic artery. Upon confirmation through imaging, HCL001 cell injection will be slowly infused through the catheter. During the infusion, the cells should be continuously agitated to prevent clumping. The infusion can be administered as a single dose or multiple doses, and after infusion, the patient will be closely monitored for at least one week.
47963497|NCT04269252|OTHER|CHI-907|CHI-907 is a high CBD extract.
47963498|NCT04269252|OTHER|CHI-804|CHI-804 is the placebo formulation.
47963499|NCT02527005|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
47963500|NCT02527005|DRUG|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
47963501|NCT03531697|DRUG|Generic Loteprednol Etabonate|Drug
47963502|NCT03531697|DRUG|Reference Listed Drug (RLD)|Drug
47963503|NCT06271382|OTHER|Acupressure Group|"In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes."
47963504|NCT06271382|OTHER|Sham Acupressure Group|"Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention."
48114372|NCT05201248|DRUG|Doxorubicin|IV Infusion
48114373|NCT05201248|DRUG|Vincristine|IV Infusion
48114374|NCT05201248|DRUG|Prednisone|Oral; Tablet
48114375|NCT05201248|DRUG|Lenalidomide|Oral; Capsule
48114376|NCT03445598|BEHAVIORAL|Interactive and personalized CCBT|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
48114377|NCT03445598|BEHAVIORAL|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
48114378|NCT03445598|OTHER|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
48114379|NCT06676202|BEHAVIORAL|Progressive Relaxation Exercises|It combines the contraction and relaxation of large muscle groups such as the face, arms, legs, neck and back with deep breathing exercises. Before applying progressive relaxation exercises, the environment should be quiet, dimly lit, a comfortable chair or armchair should be sat or lying down, and clothing should be loose and comfortable, and it is recommended to apply it one hour after eating. In the application of progressive relaxation exercises, it is first asked to breathe regularly. After our breathing rhythm is regulated, the hands, arm muscles, shoulder and neck muscles, chest, abdominal and hip muscles, legs, feet and facial muscles are contracted with a 5-7 second breathing exercise and relaxed during exhalation. This is repeated with 4-5 breathing exercises for each muscle and the exercise is ended when the eyelids are opened.
48114380|NCT00599716|DRUG|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
48114381|NCT00599716|DRUG|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
48643494|NCT01081262|BIOLOGICAL|Bevacizumab|Given IV
48114382|NCT02710708|DRUG|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
48643495|NCT01081262|DRUG|Capecitabine|Given PO
48114383|NCT00003728|DRUG|asparaginase|
48114384|NCT00003728|DRUG|cyclophosphamide|
48312469|NCT03898336|OTHER|placebo|daily intake of capsules
48312470|NCT05897346|OTHER|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
48643496|NCT01081262|DRUG|Carboplatin|Given IV
48643497|NCT01081262|OTHER|Laboratory Biomarker Analysis|Correlative studies
48643498|NCT01081262|DRUG|Oxaliplatin|Given IV
48643499|NCT01081262|DRUG|Paclitaxel|Given IV
47963505|NCT06271382|OTHER|Foot Ankle Exercise Group|Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
47963506|NCT03543150|DRUG|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
47963507|NCT04427371|OTHER|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
47963508|NCT00460096|DRUG|Kamada-API|
47963509|NCT03953196|BIOLOGICAL|Imvanex|Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
47963510|NCT03953196|BIOLOGICAL|Shingrix|Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
48312471|NCT05897346|OTHER|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
48312472|NCT01540916|OTHER|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
47963511|NCT03953196|BIOLOGICAL|LPS|LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
47963512|NCT03953196|BIOLOGICAL|Candin|Candin 0.1 mL solution for injection will be administered as one intradermal injection.
47963513|NCT03953196|OTHER|Skin Biopsy|3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
47963514|NCT03953196|OTHER|Saline Control|Saline control solution for injection will be administered as one intradermal injection.
47963515|NCT02998567|DRUG|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
47963516|NCT02998567|DRUG|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
48312473|NCT01540916|OTHER|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
48643500|NCT01081262|OTHER|Quality-of-Life Assessment|Ancillary studies
48643501|NCT03608007|DRUG|X-396 Capsule|225 mg once daily
48643502|NCT06668220|DRUG|Dexmedetomidine|Dexmedetomidine has become more popular as a caudal adjuvant in children; it is a highly selective α2 agonist with sedative and analgesic properties. Dexmedetomidine possesses anxiolytic, sedative, sympatholytic, and analgesic properties without respiratory depressant effects In addition; dexmedetomidine has the ability to reduce both the anesthetic and opioid analgesic requirements during the perioperative period.
48643503|NCT06668220|DRUG|Bupivacain|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
48643504|NCT06685796|DRUG|BEBT-209 capsules|BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.
48643505|NCT06685796|DRUG|Carboplatin injection|Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
48643506|NCT06685796|DRUG|Gemcitabine hydrochloride for injection|Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
48643507|NCT04779593|OTHER|Clinical examination|Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.
48114385|NCT00003728|DRUG|cytarabine|
48114386|NCT00003728|DRUG|daunorubicin hydrochloride|
48114387|NCT00003728|DRUG|dexamethasone|
48114388|NCT00003728|DRUG|doxorubicin hydrochloride|
48114389|NCT00003728|DRUG|etoposide|
48114390|NCT00003728|DRUG|leucovorin calcium|
48643508|NCT04779593|OTHER|SF36 questionnaire|"At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life)."
47963517|NCT02998567|DRUG|ASTX727|In arm B2 (lung expansion) replacing guadecitabine
48114391|NCT00003728|DRUG|mercaptopurine|
48114392|NCT00003728|DRUG|methotrexate|
47963518|NCT00004771|DRUG|leuprolide|
47963519|NCT00004771|DRUG|testosterone|
47963520|NCT02809612|BEHAVIORAL|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
47963521|NCT02985957|BIOLOGICAL|Nivolumab|Specified dose on specified days
47963522|NCT02985957|BIOLOGICAL|Ipilimumab|Specified dose on specified days
47963523|NCT02985957|DRUG|Cabazitaxel|Specified dose on specified days
47963524|NCT02985957|DRUG|Prednisone|Specified dose on specified days
47963525|NCT01841788|DEVICE|Thermal Adhesion Patch|
47963526|NCT01841788|DEVICE|Marketed Thermal Adhesion Patch|
48114393|NCT00003728|DRUG|methylprednisolone|
48114394|NCT00003728|DRUG|mitoxantrone hydrochloride|
48312474|NCT01790971|DRUG|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
48312475|NCT01790971|DRUG|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
47963527|NCT01841788|DEVICE|Placebo Patch|
48114395|NCT00003728|DRUG|prednisolone|
48114396|NCT00003728|DRUG|therapeutic hydrocortisone|
48312476|NCT00420394|PROCEDURE|Chemotherapy|
47963528|NCT00459225|DRUG|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
47963529|NCT01597960|OTHER|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
47963530|NCT03747588|PROCEDURE|Minimally-invasive pancreaticoduodenectomy|Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
47963531|NCT03747588|OTHER|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy for resection of pancreatic tumor
47963532|NCT01065259|DRUG|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
48114397|NCT00003728|DRUG|thioguanine|
48114398|NCT00003728|DRUG|vincristine sulfate|
48114399|NCT00003728|DRUG|vindesine|
48114400|NCT00003728|PROCEDURE|allogeneic bone marrow transplantation|
48114401|NCT00003728|PROCEDURE|peripheral blood stem cell transplantation|
48114402|NCT04054635|DEVICE|Silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
48114403|NCT06393244|BEHAVIORAL|a theory-based home-based multi-component exercise training|The participants in the intervention group will receive a 12-week theory-based home-based MCE program, which consists of three phases: exercise mobilization phase, exercise preparation phase (exercise instructions and exercise plan determination), and home-based autonomous exercise training. Structured guidelines have been developed for the intervention by the research team. This allowed interveners to deliver the intervention in a structured way with the same dosage.
48114404|NCT04957225|BEHAVIORAL|MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)|Multimodal intensive treatment of aphasia and AOS
48114405|NCT03126812|DRUG|Carboplatin|Carboplatin AUC=6
48114406|NCT03126812|DRUG|Paclitaxel|paclitaxel 80 mg/m2
48114407|NCT03126812|DRUG|Pembrolizumab|200 mg flat dose, starting cycle 2
48312477|NCT00420394|PROCEDURE|surgery|
48312478|NCT00420394|PROCEDURE|radiotherapy|
48312479|NCT03422406|OTHER|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
48643509|NCT04779593|OTHER|AIMS2_SF questionnaire|At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
48643510|NCT04779593|OTHER|WOMAC questionnaire|At D0, M12 and M24. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is a widely used questionnaires specifically assessing lower limb (hips and knee) osteoarthritis. It measures five items for pain, two for stiffness and 17 for functional limitation and had been translated in French.
48643511|NCT04779593|OTHER|EQ-5D-5L questionnaire|At D0, M12 and M24. The EQ-5D is a standardized instrument which evaluates the generic quality of life (http://www.euroqol.org/). It is a preference-based health-related quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers given to EQ-5D permit to find 243 health states that can be converted into utility score anchored at 0 for death and 1 for perfect health. EQ-5D is an instrument developed in Europe, widely used in cost-utility analysis. It has been validated in a representative sample of French population.
48643512|NCT04779593|BIOLOGICAL|Blood Sample Complete blood count|Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit
48643513|NCT04779593|BIOLOGICAL|Blood Sample Iron panel|Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
47963533|NCT01065259|DRUG|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
47963534|NCT05620771|DRUG|Atezolizumab and Bevacizumab|Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
47963535|NCT05620771|DRUG|Y90 + TKI|Patients will receive TKI for 21 days after standard of care therapy is complete.
47963536|NCT00307177|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
47963537|NCT00307177|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
47963538|NCT03198247|OTHER|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
47963539|NCT03198247|OTHER|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
47963540|NCT02106260|DRUG|CLS003|
47963541|NCT02814578|OTHER|Optical coherent tomography|comparative method for BVS
47963542|NCT02814578|OTHER|IntraVascular UltraSound|The method of goldstandard for decision stent choice
47963543|NCT04404205|DIAGNOSTIC_TEST|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
47963544|NCT06039397|BEHAVIORAL|Semifowler 30' Right Lateral Body Position|Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
48266714|NCT05886062|OTHER|Motor Imagery to Facilitate Sensorimotor Re-Learning Training|In order to motor imagery to facilitate sensorimotor re-learning training will be given for 20 minutes a day, 3 days a week, for a total of 8 weeks. Basketball-specific movement patterns will be used (squat, single leg jump, side stepping, standing on one leg, squat on one leg, etc.). Exercises will be started from easy and progressed to more advanced levels. During the exercise, the person will not only be physically active, but will be asked to dynamically visualize the determined scenario. Thus, a holistic exercise program will be applied both physically and psychologically.
48266715|NCT05886062|OTHER|Control Group|They will only continue their routine basketball technical-tactical training.
48312480|NCT04901403|OTHER|Education|Parents will be provided with information about Earned Income Tax Credits and budgeting
48312481|NCT04901403|OTHER|Home visiting|Parents as Teachers home visiting program
47963545|NCT02662829|BEHAVIORAL|Community-based intervention|
47963546|NCT02662829|OTHER|Standard of care|
47963547|NCT05431192|BEHAVIORAL|Mindfulness Training + Enhanced Usual Care|"Participants will receive a 30-minute, individual, phone-delivered session once a week for 8 weeks. MT involves training in the following (1) Awareness of breath; (2) Body scan; (3) Directing attention to simple activities of daily life; (4) Becoming aware of own thoughts and emotions; (5) Open awareness - a technique by which the participant is invited to direct his/her attention to any event arising in their field of experience at a given moment.~In addition, participants will practice mindfulness techniques for 20 minutes daily on their own with the guidance of a digitally recorded, standardized guided mindfulness practice."
47963548|NCT05431192|OTHER|Enhanced Usual Care|"Usual care will be enhanced in BOTH conditions with printed education materials provided to all participants using publicly available materials (the Healthier Living with Heart Failure guide available at the AHA Heart Failure Resource Center).66 The guide is organized in 7 chapters containing information on topics such as understanding HF, making healthy lifestyle changes, managing HF symptoms, taking medications, and living well with HF. Printed materials will be mailed weekly to all participants during the first 8 weeks of the study."
48266716|NCT03372239|DRUG|Indoximod base formulation|Specified dose on specified days
48114408|NCT04707729|DIAGNOSTIC_TEST|ROX index algorithm|"The thresholds of the ROX index for intubation are the following:~* After 2 hours of HFNC: ROX \<2.85.~* After 4 and 6 hours of HFNC: ROX \<3.47~* After 8, 10 and 12 hours of HFNC: ROX \<3.85 If the ROX index is between the abovementioned thresholds and 4.88, the NHF support will be also increased to the maximum tolerated flow (up to 60L/min) and FIO2 of 1 and subsequently titrated with the target SpO2. If the patient is already treated with to 60L/min) and FIO2 of 1 and no further increase could be done and the ROX index will be recalculated after 30 minutes of full NHF support. The ROX index will be recalculated in 30 minutes: 1) if the ΔROX is \<0 the patient will be intubated; 2) if the ΔROX is 0-0.5, the ΔROX will be reassessed in 20 minutes; and 3) if the ΔROX is \>0.5 the patient will not be intubated, NHF will be managed as protocolized and respiratory condition will be reassessed every two hours or at any new clinical deterioration."
48114409|NCT06131268|DRUG|Venlafaxine|we will recruit a cohort of 10 MDD patients currently receiving evidence-based treatments for depression (including treatment with an antidepressant drug such as SSRIs/SNRIs) who will be switched to the antidepressant venlafaxine and followed along for 4 weeks (Group 1). The switch from the ongoing treatment to venlafaxine will must be required by therapeutical needs (null or partial response and/or poor tolerability or compliance to ongoing therapy) according to the indications of the principle clinical guidelines for the treatment of MDD and it is independent of the decision of including the patient in the study.
48114410|NCT02765438|DEVICE|BOBO|"Each subject will play four games with the BOBO system."
48266717|NCT03372239|DRUG|Indoximod HCL (salt) formulation|Specified dose on specified days
48312482|NCT03732391|DRUG|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
48312483|NCT01321294|PROCEDURE|laparoscopic anti-reflux surgery|
48312484|NCT00849264|DRUG|chemotherapy with endostar|15mg/d×14d
48312485|NCT00849264|DRUG|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
48312486|NCT00849264|DRUG|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
48312487|NCT01521234|BEHAVIORAL|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
47963549|NCT04083196|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
47963550|NCT04083196|BIOLOGICAL|Placebo|Placebo
47963551|NCT06429436|BEHAVIORAL|VENDY|At least 1 machine (vending machine like a snack machine or a machine like a newspaper kiosk) will be placed in the respective community served by the participating organizations. Any person in the community can get naloxone from the machine. The vending machine will require a code that will be placed on the machine for anyone to use. The kiosks are a box that you simply pull open and naloxone can be obtained. Naloxone kits will be provided for free as part of the current naloxone distribution program within each respective organization.
47963552|NCT00272012|DRUG|Insulin glulisine|
47963553|NCT01205906|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
47963554|NCT01205906|BEHAVIORAL|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
47963555|NCT01205906|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
47963556|NCT03787732|DRUG|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
47963557|NCT03787732|OTHER|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
47963558|NCT04486105|DIETARY_SUPPLEMENT|sucrose|pure sucrose in water in addition to habitual diet
47963559|NCT05988008|DRUG|CCX168|Administered orally.
47963560|NCT05988008|DRUG|Placebo|Administered orally.
47963561|NCT05343845|OTHER|Observational study|After approval of the institution's ethics committee, 100 patients will be divided in two groups as pregnant women who did not smoke during pregnancy and pregnant women who smoked 5 or more cigarettes in a day. The local anesthetic, which dose will adjusted according to height and weight, and 20 µg fentanyl will be administered intrathecally to both groups. Results on the effectiveness of spinal anesthesia will be monitored.
47963562|NCT04505462|OTHER|Therapeutic diet|A special healthy diet for dialysis patients
47963563|NCT01725503|DIETARY_SUPPLEMENT|Creatine and Amino Acid supplement|
47963564|NCT00120731|DRUG|Potassium Citrate|
48312488|NCT00633581|DIETARY_SUPPLEMENT|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
48312489|NCT00633581|DIETARY_SUPPLEMENT|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
47963565|NCT00120731|DRUG|Acetazolamide|
47963566|NCT00120731|BEHAVIORAL|Diet low in oxalate and purines|
47963567|NCT02503657|DRUG|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
47963568|NCT02503657|DRUG|Placebo|Excipients of MN-001/tipelukast
48312490|NCT02251054|OTHER|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
48312491|NCT02251054|OTHER|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
48312492|NCT04265586|BEHAVIORAL|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
48312493|NCT04265586|BEHAVIORAL|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
48312494|NCT04507438|DRUG|Donepezil 5-10 Mg Oral Tablet|Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period
47963569|NCT00727428|BIOLOGICAL|FluLaval® TF|One IM injection.
48114411|NCT02838342|DRUG|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
48114412|NCT02838342|DRUG|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
48114413|NCT04378361|DEVICE|endovascular repair|Endovascular repair of complicated acute, subacute or chronic type B aortic dissection with double lumen
48114414|NCT03003845|OTHER|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
48114415|NCT03003845|OTHER|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
48312495|NCT04507438|DRUG|Placebo Oral Tablet|Placebo oral tablet administered daily for an 8 week period
48312496|NCT02242994|DEVICE|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
48312497|NCT02242994|DEVICE|Experimental App|Participant receives experimental app to test speed and error rate of communication.
48312498|NCT06187987|DEVICE|Mechanical thrombectomy|Aspirational mechanical thrombectomy
48312499|NCT06187987|DRUG|Intravenous thrombolysis|Intravenous thrombolysis with tissue-type plasminogen activator (tPA)
47963570|NCT00084383|BIOLOGICAL|GVAX pancreatic cancer vaccine|"Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination."
47963571|NCT03338374|DEVICE|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
48114416|NCT00523237|DRUG|Raltegravir|400 mg Twice daily for 24 weeks
48114417|NCT03024606|BEHAVIORAL|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
48114418|NCT06516042|DRUG|Dihydroartemisinin-piperaquine|Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.
48114419|NCT05474105|DIETARY_SUPPLEMENT|Oral nutritional supplement|Daily drink 125 ml together with meal
48312500|NCT01763281|DRUG|CRH|
48312501|NCT01763281|DRUG|Placebo|
48312502|NCT03998475|BEHAVIORAL|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
48340227|NCT04432571|BEHAVIORAL|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV). SOC-REC is a stage 1 intervention (routine care) to prevent lapses in HIV engagement. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement. Trained peer navigators will develop rapport with the participants and provide psychosocial support, case management, and assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers. The peer navigator will meet with the participant at least monthly, and no more than weekly, until HIV care engagement is demonstrated.
47963572|NCT02095977|PROCEDURE|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
48114420|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status"
48266718|NCT03372239|OTHER|Placebo|Specified dose on specified days
48114421|NCT01839578|DRUG|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
48114422|NCT03696966|DIETARY_SUPPLEMENT|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
48114423|NCT03696966|BEHAVIORAL|Low-Calorie Diet|Restrict calorie intake daily
48114424|NCT03696966|BEHAVIORAL|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
48114425|NCT03611205|PROCEDURE|Computed Tomography|Undergo dPET/CT
48114426|NCT03611205|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
48114427|NCT04053816|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
48114428|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
47963573|NCT02095977|PROCEDURE|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
47963574|NCT02095977|PROCEDURE|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
47963575|NCT03302234|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
47963576|NCT03302234|BIOLOGICAL|Ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
48114429|NCT06325761|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses separated by 7-days
47963577|NCT03302234|OTHER|Placebo|Normal saline solution administered as an IV infusion Q6W
48114430|NCT06353282|DRUG|MDMA|MDMA will be dosed in pre-filled capsules and administered orally to participants in two fixed doses - an 80mg dose following the fourth session and a 120mg dose following the ninth session of MDMA to each participant. MDMA experimental medication administration session 1 (8 hours); MDMA experimental medication session 2 (8 hours). Participants will be required to remain in the therapy room for the duration of the experimental medication sessions without the youths' parent/guardian present. The parent/guardian will be invited to attend integration sessions and must be available to drop off and pick up the participant.
48114431|NCT06353282|BEHAVIORAL|Psychotherapy|Treatment session order: Four weekly 90-minute experimental medication preparation psychotherapy sessions; four weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session; and Five weekly 90-minute psychotherapy integration sessions, starting the day following the preceding experimental medication session.
48114432|NCT02320123|BEHAVIORAL|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
48114433|NCT01239316|OTHER|Laboratory Biomarker Analysis|Correlative studies
48114434|NCT01239316|OTHER|Pharmacological Study|Correlative studies
48114435|NCT01239316|DRUG|Vismodegib|Given PO
48114436|NCT02272959|BEHAVIORAL|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
48114437|NCT02272959|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
47963578|NCT05638581|BIOLOGICAL|LTOWB|Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
47963579|NCT05638581|BIOLOGICAL|Components|Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
47963580|NCT02217878|DRUG|Morphine|IV bolus injection
47963581|NCT02217878|DRUG|Placebo|IV bolus injection
47963582|NCT02217878|DRUG|Ticagrelor|180 mg loading dose
47963583|NCT00207350|DEVICE|Interstitial Laser Therapy|Device
47963584|NCT00043771|DRUG|Tolvaptan|
47963585|NCT02050516|OTHER|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
48114438|NCT05601466|DRUG|QN-023a|NK cell therapy
48114439|NCT05601466|DRUG|Cyclophosphamid|Lympho-conditioning Agent
48114440|NCT05601466|DRUG|Fludarabine|Lympho-conditioning Agent
48114441|NCT05601466|DRUG|Cytarabine|Lympho-conditioning Agent
48114442|NCT05817968|DEVICE|intelligent Esophageal Pressure Catheter (iEPC)|"Placement of the iEPC nasogastric catheter with solid state sensor for esophageal manometry.~Comparator: Esophageal balloon catheter (NutriVent)."
48114443|NCT06397768|BIOLOGICAL|RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
48114444|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48114445|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48114446|NCT06397768|BIOLOGICAL|Hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48114447|NCT06397768|BIOLOGICAL|Streptococcus pneumoniae vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48114448|NCT06397768|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form:Oral solution-Route of administration:Oral
48114449|NCT06397768|BIOLOGICAL|Measles, mumps, and rubella vaccine|Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular
48114450|NCT06397768|BIOLOGICAL|Varicella virus vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular
47963586|NCT05780372|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
47963587|NCT05780372|DRUG|Chemotherapy|Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.
47963588|NCT05399732|DRUG|Luspatercept|Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
48114451|NCT06397768|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
48114452|NCT06173531|DRUG|Carbetocin|Carbetocin nasal spray 3.2 mg three times daily (TID)
48114453|NCT06173531|DRUG|Placebo|Placebo given TID, identical in appearance respective to carbetocin treatment
48114454|NCT05539755|PROCEDURE|Non surgical debridement of peri-implantitis|"The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed."
48483808|NCT04199117|OTHER|Primary care provider referral|This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
48483809|NCT04199117|BEHAVIORAL|Untailored outreach|Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
48483810|NCT04199117|BEHAVIORAL|Multiple smoking cessation coaching calls|Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
48483811|NCT01834781|DEVICE|Pulsed electromagnetic fields|
48114455|NCT00988637|DRUG|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
48114456|NCT00988637|DRUG|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
48114457|NCT01832480|DRUG|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
48114458|NCT01832480|DRUG|MTZ 2 g|MTZ 2 g
48114459|NCT01591733|DRUG|FOLFIRINOX|Up to Eight-14 day cycles
48114460|NCT01591733|DRUG|Capecitabine|Orally, for 10 days
48483812|NCT01834781|DEVICE|w/o pulsed electromagnetic fields|
48483813|NCT03327090|OTHER|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
48643514|NCT04779593|BIOLOGICAL|Blood Sample Fasting Glucose|Blood Sample Fasting Glucose at D0 and M24/end follow-up visit
48114461|NCT01591733|RADIATION|Short Course Radiation|Five or ten days
48114462|NCT01591733|PROCEDURE|Surgery|1-4 weeks after completion of capecitabine therapy
48114463|NCT00028678|DRUG|dalteparin|
48114464|NCT00028678|RADIATION|radiation therapy|
48114465|NCT00495417|BIOLOGICAL|AFFITOPE AD01|s.c. injection
48114466|NCT00495417|BIOLOGICAL|AFFITOPE AD01 adjuvanted|s.c. injection
48114467|NCT05992311|DRUG|Montelukast|This group will receive the montelukast treatment.
48114468|NCT05992311|OTHER|Placebo|This group will receive a placebo pill instead of montelukast
48114469|NCT00006276|DRUG|Micellar Paclitaxel|
48114470|NCT04795128|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
48114471|NCT02170324|DRUG|Exenatide|
47963589|NCT00334321|RADIATION|IMRT|
48114472|NCT02170324|DRUG|Placebo|
48114473|NCT06554860|OTHER|scapular Blackburn stabilization plus exercise|scapular Blackburn stabilization
48114474|NCT06554860|OTHER|PNF plus Exercise|PNF plus Exercise
48114475|NCT06554860|OTHER|exercise only|Exercise only
48114476|NCT05118581|DEVICE|ultrasound guided vascular access|Arterial or venous catheterization guided by ultrasound
47963590|NCT00334321|RADIATION|Intracavitary vaginal brachytherapy|
47963591|NCT00334321|DRUG|Paclitaxel|
47963592|NCT00334321|DRUG|Carboplatin|
47963593|NCT03894332|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|"After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT_0) and the last (SBT_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB_0) and 30 minutes after extubation (SB_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV)."
47963594|NCT03375775|DRUG|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy|According to standardized clinical protocol
47963595|NCT03375775|OTHER|No immunotherapy, symptomatic treatment|These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
47963596|NCT05399654|DRUG|TAC-001|TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)
47963597|NCT03990038|DRUG|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
47963598|NCT03990038|DRUG|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
47963599|NCT05209360|DEVICE|Medial or Lateral Wedge|A foam wedge that is placed inside the shoe under the CDO, that runs along the length of the foot. The tall side of the wedge will be placed on the medial (Medial Wedge) or lateral (Lateral Wedge) aspect of the shoe to preferentially load the medial or lateral side of the foot.
47963600|NCT05209360|DEVICE|Carbon Fiber Custom Dynamic Orthosis|A device that consists of a proximal cuff that wraps around the leg just below the knee, a posterior strut that runs the length of the leg, and a semi-rigid footplate that goes under the length of the foot.
47963601|NCT05626023|DRUG|Human TH-SC01 cell injection|Single injection of human TH-SC01 cell injection
47963602|NCT01919593|DRUG|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
47963603|NCT01919593|DRUG|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
47963604|NCT03917238|RADIATION|gallium-68-exendin injection followed by PET/CT scan|After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
47963605|NCT01376284|DRUG|Dutasteride|Collection of safety data
47963606|NCT01487200|DRUG|FX006 10 mg|single 3 mL IA injection
47963607|NCT01487200|DRUG|FX006 40 mg|single 3 mL IA injection
47963608|NCT01487200|DRUG|FX006 60 mg|single 3 mL IA injection
47963609|NCT01487200|DRUG|TCA IR 40|single 1 mL IA injection
47963610|NCT00249860|DRUG|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
47963611|NCT00249860|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
47963612|NCT00249860|DRUG|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
47963613|NCT03050554|DRUG|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
47963614|NCT03050554|RADIATION|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
47963615|NCT03209596|DIETARY_SUPPLEMENT|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
47963616|NCT03209596|DIETARY_SUPPLEMENT|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
47963617|NCT02185092|DIETARY_SUPPLEMENT|Lactobacillus GG|probiotic supplement
47963618|NCT02185092|OTHER|Sugar pill|placebo
48114477|NCT02749968|DRUG|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
48114478|NCT02749968|DRUG|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
48114479|NCT02378337|OTHER|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
48266719|NCT02672085|PROCEDURE|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
48266720|NCT02672085|PROCEDURE|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
48266721|NCT03196128|OTHER|Digital communication|Communicating with patients via email and text message.
48266722|NCT03196128|OTHER|Non digital|Communicating with patients via telephone and written appointment letters.
48266723|NCT00760981|DRUG|Imatinib|The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
48483814|NCT04797442|DRUG|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
48483815|NCT04797442|DRUG|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
48483816|NCT06126861|DRUG|[14C]LP-168|single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
48483817|NCT03099629|BEHAVIORAL|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
48483818|NCT00860691|PROCEDURE|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
48483819|NCT00860691|PROCEDURE|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
48643515|NCT04779593|BIOLOGICAL|Blood sample lipid panel|Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit
48643516|NCT04779593|BIOLOGICAL|Blood sample liver panel|Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit
48643517|NCT04779593|BIOLOGICAL|Blood sample C reactive protein|Blood sample C reactive protein at D0 and M24/end follow-up visit
47963619|NCT04833543|OTHER|Robotic Mobility Device (REX)|A self supporting robotic mobility device (REX) will be utilized. It is a Class I device, and it is classified as powered exercise equipment meant for anyone that requires use of a wheelchair for mobility who has difficulty with standing and walking. The participant will be supported securely within the device using a pelvic harness, and thigh and calf cuffs. The device will be operated under the supervision of a device trained physical therapist and therapy technician. The participant will be transferred into the device in a seated position. Once aligned properly and strapped in, the participant will be passively moved by the device into standing and walking positions. To provide constant vestibular input, a variety of mobility functions will be performed including standing, sitting, walking, turning, shuffling (side-stepping), and backwards stepping.
47963620|NCT04833543|OTHER|Tilt Table|A tilt table is a table with a footplate that can be tilted at different angles. The participant will lie flat on the table and straps will be placed to stabilize the trunk and lower extremities. The inclination of the tilt table will be adjusted from a horizontal to a vertical position to allow the participant to attain and maintain a standing or partial-standing position. Sessions will be supervised by a physical therapist and therapy technician.
47963621|NCT05276193|OTHER|Observational health care register - no applicable intervention at present|Observational health care register - no applicable intervention at present
47963622|NCT01737320|DRUG|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
47963623|NCT01737320|DRUG|accepted prolonged antibiotic treatment|
47963624|NCT03834441|OTHER|Oral HRSN screening|Verbal screening delivered by an RA
47963625|NCT03834441|OTHER|Written HRSN screening|Patient completes written screen on iPad.
47963626|NCT00168896|DRUG|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
47963627|NCT04498520|DRUG|Abexinostat Tosylate|Given PO
47963628|NCT04498520|DRUG|Fulvestrant|Given IM
47963629|NCT04498520|DRUG|Palbociclib|Given PO
47963630|NCT04023435|OTHER|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
47963631|NCT00402415|DRUG|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
47963632|NCT00402415|DRUG|Rapamycin|"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
47963633|NCT04051528|PROCEDURE|aerobic exercise training|The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
48266724|NCT00459992|DRUG|Betahistine Hydrochloride|
48114480|NCT01320657|DEVICE|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
47963634|NCT04051528|PROCEDURE|computerized cognitive training|The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
47963635|NCT04051528|PROCEDURE|guiding training|At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
47963636|NCT02083783|DRUG|TRI102|formulation containing active moiety (amphetamine)
47963637|NCT02083783|OTHER|Placebo|formulation without active moiety
47963638|NCT02236975|DEVICE|BuMA Supreme Biodegradable drug coating coronary stent system|
47963639|NCT02236975|DEVICE|Resolute Integrity durable polymer stent system|
47963640|NCT03501459|DRUG|Rituximab|
47963641|NCT03609905|BIOLOGICAL|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10\~7 diluted on 100 mL of normal saline
47963642|NCT03609905|OTHER|Conventional drugs|5-amino-salicylic acid or glucocorticoid
47963643|NCT00495365|DRUG|Epoetin alfa|
47963644|NCT06089499|BEHAVIORAL|Get Palliative Care: four educational learning module videos|Organizational Sponsored public domain educational videos
47963645|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
47963646|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.1%)|Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
47963647|NCT03404115|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered for approximately twelve weeks.
47963648|NCT01910025|DRUG|ADI-PEG 20|
48114481|NCT03336424|DIAGNOSTIC_TEST|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
48114482|NCT03336424|DIAGNOSTIC_TEST|Invasive investigations|Cystomanometry, pressure flow study, EMG
48114483|NCT01745016|DIETARY_SUPPLEMENT|Placebo|
47963649|NCT00134082|BIOLOGICAL|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.
47963650|NCT00134082|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is \>= 1000/mcL.
47963651|NCT00134082|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
47963652|NCT00134082|DRUG|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
47963653|NCT04742998|OTHER|Acoustic-phonetic decoding task (DAP)|Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
48114484|NCT01745016|DIETARY_SUPPLEMENT|Beta-alanine|
48114485|NCT06345495|DRUG|Ruxolitinib|Given by PO
48114486|NCT06345495|PROCEDURE|Allogeneic Stem Cell Transplantation|Given by Transplant
47963654|NCT05627323|BIOLOGICAL|CHM-1101 CAR-T cells|Administered via ICT/ICV dual delivery
47963655|NCT00200616|PROCEDURE|Antimicrobial prophylaxis|
47963656|NCT00847379|DRUG|Ataluren|Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
47963657|NCT00005814|BIOLOGICAL|cetuximab|
47963658|NCT00005814|DRUG|cisplatin|
47963659|NCT00005814|RADIATION|radiation therapy|
47963660|NCT03800797|DRUG|Loxoprofen sodium hydrogel patch|100 mg per day
48114487|NCT06345495|DRUG|Levetiracetam|Given by PO
48114488|NCT06345495|DRUG|Eltrombopag|Given by PO
48114489|NCT06345495|DRUG|Busulfan|Given by IV
48114490|NCT06345495|DRUG|Romiplostim|Given by IV
48114491|NCT06345495|DRUG|Fludarabine phosphate|Given by IV
48114492|NCT06345495|DRUG|Cyclophosphamide|Given by IV
48114493|NCT06345495|DRUG|Mesna|Given by IV
48114494|NCT06345495|DRUG|Tacrolimus|Given by IV or PO
48643518|NCT04779593|PROCEDURE|Bloodletting - control group|Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
48643519|NCT04779593|BIOLOGICAL|BioBank|Blood sample will be collected for BioBank at D0, M12 and M24.
48643520|NCT04779593|OTHER|Medico-economical|Medico-economic data will be collected at each follow up visit.
48643521|NCT04779593|PROCEDURE|Bloodletting - experimental group|"Patients treated with bloodletting according to transferrin saturation and serum ferritin. Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit."
48643522|NCT06337097|DIAGNOSTIC_TEST|Troponin surveillance|Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.
47963661|NCT03800797|DRUG|Loxoprofen sodium tablet|60 mg t.i.d.
48643523|NCT06337097|OTHER|Standard of care|Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.
47963662|NCT04119544|OTHER|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
47963663|NCT04119544|DEVICE|Intensive Visual Simulation|"* First week: observation, mentalization and then attempt to perform the movements on the screen.~* Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~* From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
48114495|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
48643524|NCT06691659|DIAGNOSTIC_TEST|CT-DACE|Photon Counting CT scan
48114496|NCT01530698|BIOLOGICAL|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
48114497|NCT05850091|DRUG|Rosuvastatin|Pharmacotherapy for reduction in LDL cholesterol level
48643525|NCT06169176|BIOLOGICAL|RAPA-501 Autologous T cells|Experimental: Intermediate size expanded access cohort. Single-agent RAPA-501 T cells, (80 x 106 cells per infusion; acceptable dose range of RAPA-501 is 20-to-80 x 106 cells per infusion, depending on manufacturing yield)
48312503|NCT05980832|OTHER|Peer practitioner training - Peer Education Supported Psychosocial Skills Education|"Psychosocial skills training-practitioner training will be given to 4 patients diagnosed with chronic mental disorder by the research psychiatry nurse.~Educational content~1. Getting acquainted - briefing about the study~2. The Importance, Aims and Objectives of Psychosocial Skills Education~3. The importance of peer support~4. The importance, aims and objectives of peer education supported psychosocial skills training~5. Management of the meeting game, warm-up games and role plays~6. 1st and 2nd session peer education supported psychosocial skills training~7. 3rd and 4th session peer education supported psychosocial skills training~8. The last 5th and 6th sessions of peer education are supported by psychosocial skills training.~9. Key points and termination in group management. The training will be planned to last 10-13 hours in total. Trainer's booklet prepared by the researcher psychiatric nurse."
48483820|NCT00860691|OTHER|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
48483821|NCT02299219|BEHAVIORAL|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
48643526|NCT05931965|DIETARY_SUPPLEMENT|L-methylfolate|Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
48643527|NCT05931965|DIETARY_SUPPLEMENT|Vitamin B12|Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
48643528|NCT05931965|DIETARY_SUPPLEMENT|magnesium|Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
47963664|NCT02782728|BEHAVIORAL|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
48643529|NCT06689657|BEHAVIORAL|Cognitive behavioral group therapy for adolescents and non violent resistance group for parents|"In the adolescents group, this cognitive-behavioral group therapy will include emotion regulation skills, distress tolerance skills, cognitive strategies, work on values and problem-solving strategies~Those sessions will include psychoeducation about adolescents, about suicidal ideation and suicidal behavior, coping with adolescent emotional distress, support on how to be a parent today (screen regulation...) and manage daily life"
47963665|NCT02782728|BEHAVIORAL|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
47963666|NCT00133471|BIOLOGICAL|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
48114498|NCT05850091|DRUG|Colchicine|Pharmacotherapy for inflammation inhibition
48114499|NCT05850091|DRUG|Placebo|Capsule with sugar pill that mimics active study drugs
48114500|NCT01613274|OTHER|gum chewing|gum chewing three times a day for up to 20 minutes
48643530|NCT06689657|OTHER|Adolescent group therapy (CARES) and parent group therapy (RNV)|"In the adolescent group, they will attend 8 group sessions during 1 month (2 sessions/week). There also will be a boost session 3 month after the last session. Parents will attend 4 group sessions during 1 month too (1 session/week). There will be 2 boost sessions : 1 month and 3 month after the last session Patients will be randomized in each group with blinded assessment"
48643531|NCT06686420|DIETARY_SUPPLEMENT|B. longum|On the first day of the intervention period, participants will be instructed to consume two capsules of the live B. longum strain daily with a glass of water before breakfast for the next eight weeks.
48643532|NCT06686420|DIETARY_SUPPLEMENT|Placebo|On the first day of the intervention period, participants will be instructed to consume two capsules, which are without any live bacteria, daily. They should take these before breakfast with a glass of water, for the following eight weeks.
48114501|NCT01613274|OTHER|no gum chewing|no gum chewing
48114502|NCT02474238|DEVICE|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
48114503|NCT02474238|DEVICE|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
48312504|NCT05980832|OTHER|Peer Education Supported Psychosocial Skills Education|"It is a psychosocial skills training that will be given to both experimental groups in 6 sessions within 6 weeks. 2 of the 4 peer trainers who received the practitioner training will conduct the training. During the training period, the research psychiatric nurse will support.~Session titles are as follows:~1. Session:Preparation Session~2. Session: Understanding Mental Disorders~3. Session: Developing Communication Skills~4. Session: Developing Emotion Recognition and Expression Skills~5. Session: Dealing with Daily Living Activities and Problems~6. Session: Understanding the Stigma Experience~The duration of each session is determined as 90 minutes. Taking into account the patient's opinions breaks not exceeding 15 minutes will be given as needed."
48312505|NCT05649618|BIOLOGICAL|Tumor Infiltrating Lymphocytes|On day 0 patients will be intravenous infusion of TILs
48312506|NCT05649618|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen
48312507|NCT05649618|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
48312508|NCT05649618|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
48643533|NCT06686186|OTHER|No Intervention: Observational Cohort|There were no interventions in our cohort. The subjects of our cohort were and will be followed up at the regular intervals.
48643534|NCT06689150|DRUG|Drospinetta|To evaluate the three different types of POPs, the new POPs Drosperinon 4 mg, Desogestrel 75 pg, and Levonorgestrel 30 pg in healthy female subjects as regard to the contraceptive efficacy, bleeding pattern, acceptability and safety
48312509|NCT00347854|OTHER|Systane Free lubricant eye drops|
48312510|NCT00347854|OTHER|Visine Tears Lubricant Eye Drops|
48312511|NCT00347854|OTHER|Refresh Liquigel Lubricant Eye Drops|
48312512|NCT00347854|OTHER|Refresh Plus Lubricant Eye Drops|
48312513|NCT03297099|PROCEDURE|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
48312514|NCT03297099|PROCEDURE|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
48312515|NCT00462098|DEVICE|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
48312516|NCT00462098|DEVICE|non-treated control group|no change from routine care, no HBO
47963667|NCT00133471|DRUG|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
47963668|NCT05251766|DRUG|Nab paclitaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
47963669|NCT05251766|DRUG|Docetaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
47963670|NCT03100500|DRUG|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
48312517|NCT03764202|OTHER|Detection of sufentanil concentration|"* Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point"
48312518|NCT02307721|DRUG|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
48312519|NCT02307721|DRUG|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
48312520|NCT02307721|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
48483822|NCT02299219|BEHAVIORAL|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
48483823|NCT04359563|BEHAVIORAL|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
48643535|NCT06684977|BEHAVIORAL|360 Video|360° Video consists of video recordings, made with a camera to simultaneously capture and combine scenes in a 360 degrees perspective such as Instant Google Street View Instant Google Street View (instantstreetview.com). When uploaded to a VR headset, 360° videos may provide a more cost-effective method for rapidly creating virtual environments in which users can experience a sense of immersion and the viewer can control and change the viewing angle at any stage through head movement. While photorealism may be superior, this option is known to be less interactive as the viewer can't move or walk around within the virtual space. In addition, the landscape and imagery may have been changed or developed meaning the recordings captured do not match the traumatic memory. Despite these limitations, the use of 360° video has been trialled in clinical mental health settings showing positive outcomes for both user and clinician.
48643536|NCT06684977|BEHAVIORAL|VR Photoscan|VR Photoscan creates immersive virtual environments by transforming real-world imagery into detailed 3D models. Using high-resolution images captured from a smartphone, these images are processed in 3D graphics software to sculpt realistic virtual scenes. The resulting 3D models are imported into a game engine, adding VR functionality, allowing users to navigate freely with six degrees of freedom. Interactive content, such as animated cars and people, can be added in real-time, while menu systems guide users through the experience. Environmental factors like lighting, weather, and time of day can be adjusted to simulate real conditions. Spatial 360° audio enhances immersion, providing sounds from various directions. This VR environment creation process is efficient and cost-effective, requiring no specialised equipment, and ensuring high-quality immersive experiences at minimal production time and cost.
48643537|NCT06684977|BEHAVIORAL|Standard TF-CBT|Ehlers and Clark's model follows the general style of reliving (recommended by NICE) suggested by Foa and Rothbaum with some fluidity and in vivo exposure (i.e., trauma site visit). During the treatment process of reliving, clients are asked to close their eyes and intentionally recall the traumatic memories, i.e., relive the trauma in their mind in detail and narrate their experience in present tense, including recalling images, sensory experiences, thoughts, and feelings. VR-based PTSD treatments can promote emotional engagement and the process of trauma via providing visual, auditory, and haptic sensory cues.
47963671|NCT01970397|DEVICE|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
48643538|NCT06686004|DIETARY_SUPPLEMENT|Carrots|Detection of polyacetylene and carotenoids in human biofluids
48643539|NCT06056570|DRUG|dontinurad|dotinurad alone
48643540|NCT06056570|DRUG|dotinurad + allopurinol|dotinurad + allopurinol 300mg
48643541|NCT06056570|DRUG|allopurinol|allopurinol 300 mg alone
48643542|NCT06688825|BEHAVIORAL|Education regarding Weight loss|Per American Association of Clinical Endocrinology (AACE) guidelines
47963672|NCT01970397|DEVICE|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
48114504|NCT06188754|BEHAVIORAL|Time restricted eating|Limiting food intake to 10 hours per day
47963673|NCT01927510|BEHAVIORAL|Early mobilisation|
48114505|NCT06188754|BEHAVIORAL|Mediterranean diet|Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
48312521|NCT02307721|DEVICE|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
48312522|NCT03417180|DRUG|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
48312523|NCT03417180|DEVICE|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
48312524|NCT03227562|DRUG|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
48312525|NCT02039180|DRUG|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
48312526|NCT02039180|DRUG|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
48312527|NCT02039180|DRUG|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
48312528|NCT01996202|DRUG|Ipilumimab|
48312529|NCT01996202|RADIATION|Radiation|
48312530|NCT03622593|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
48312531|NCT03622593|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
48312532|NCT03622593|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
48312533|NCT05673863|BEHAVIORAL|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
48643543|NCT06688825|BEHAVIORAL|Lifestyle tools for weight loss|Calorie App, Continuous GlucosWe Monitor (CGM), Weight Scale, Food Scale
47963674|NCT04324775|OTHER|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
47963675|NCT04324775|OTHER|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
48312534|NCT01389648|OTHER|Pre Operative|Pre operative chest physiotherapy treatment
47963676|NCT03019783|DRUG|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
48312535|NCT05525767|DRUG|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
48312536|NCT03772938|BIOLOGICAL|Stem/progenitor cells transplantation|Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
48312537|NCT02811536|DEVICE|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
48312538|NCT04222439|DEVICE|AI for the Diagnosis of Gastrointestinal Diseases|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
48312539|NCT01376713|BIOLOGICAL|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
48114506|NCT02731339|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
48312540|NCT01376713|BIOLOGICAL|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
48312541|NCT02356406|RADIATION|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
48643544|NCT06688825|BIOLOGICAL|Blood draw|Per American Association of Clinical Endocrinology (AACE) guidelines
48643545|NCT06618534|DRUG|Azithromycin|A standard dose of azithromycin (500 mg) will be delivered by oral route.
47963677|NCT03019783|OTHER|Placebo|The control group will stay on their baseline regimen
47963678|NCT04535648|OTHER|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
47963679|NCT04490343|DIAGNOSTIC_TEST|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
47963680|NCT03685968|DEVICE|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
47963681|NCT04451850|OTHER|Noninvasive actigraphy monitor|Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.
47963682|NCT03245515|DRUG|BMS-986195|specified dose on specified days
47963683|NCT05009654|DIETARY_SUPPLEMENT|L-carnitine|
47963684|NCT05009654|DIETARY_SUPPLEMENT|L-leucine|
47963685|NCT05645575|DEVICE|Open-label TMS|Customized, Open-Label Transcranial Magnetic Stimulation
47963686|NCT00032123|DRUG|erlotinib hydrochloride|
47963687|NCT01217359|DRUG|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
48483824|NCT05511220|BEHAVIORAL|PRIMeR|Virtual PRIMeR intervention consists of coaching parents to use strategies derived from Social Routines (to boost positive affect) and Reciprocal Imitation Training (to boost toy play)
48483825|NCT05511220|BEHAVIORAL|PRT|Virtual PRT intervention consists of coaching parents to use key PRT strategies to enhance children's communication skills
48483826|NCT00295139|BEHAVIORAL|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
48643546|NCT06686823|BEHAVIORAL|Health Education Program|n informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.
47963688|NCT05572320|DIAGNOSTIC_TEST|Platelet Aggregometry Testing|1.6 ml of blood collected in hirudin-coated tubes before the surgery
47963689|NCT02915016|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
47963690|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
47963691|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
47963692|NCT02915016|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
47963693|NCT00727636|BIOLOGICAL|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
47963694|NCT03909841|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB)|Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
47963695|NCT03909841|OTHER|Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)|Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
47963696|NCT00916097|DRUG|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
47963697|NCT02258698|PROCEDURE|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
48312542|NCT01590680|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
47963698|NCT02727361|RADIATION|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
48312543|NCT03956953|DRUG|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
48312544|NCT03956953|OTHER|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
48483827|NCT00295139|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
48483828|NCT00295139|BEHAVIORAL|Critical Time Intervention (CTI)|Case management component
48483829|NCT02581072|DRUG|SB204 4%|Applied topically once
47963699|NCT02727361|OTHER|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
47963700|NCT00635674|DEVICE|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
47963701|NCT02743169|OTHER|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
47963702|NCT03743623|DEVICE|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
47963703|NCT03743623|DEVICE|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
47963704|NCT00437307|DRUG|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
47963705|NCT06445881|DRUG|Modified Si Jun Zi Tang|Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
47963706|NCT00008372|DRUG|chloroquinoxaline sulfonamide|
48312545|NCT01090089|DRUG|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
48312546|NCT01090089|DRUG|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
48312547|NCT04393584|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
47963707|NCT04714957|OTHER|construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.|Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.
48312548|NCT04393584|DRUG|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
48312549|NCT04393584|DRUG|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
48312550|NCT04393584|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
48312551|NCT04393584|DRUG|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
48312552|NCT03518099|BIOLOGICAL|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
48312553|NCT03979105|DRUG|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
48312554|NCT05618899|OTHER|HIGH INTENSITY INTERVAL TRAINING|Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
48312555|NCT05618899|OTHER|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
48312556|NCT04748224|DRUG|Bupivacaine 0.25% Injectable Solution|a local anesthetic drug
48483830|NCT02581072|DRUG|SB204 8% or 12%|Applied once topically
48483831|NCT02581072|DRUG|Vehicle|Applied topically once
48483832|NCT04445064|BIOLOGICAL|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
48483833|NCT04445064|BIOLOGICAL|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
48483834|NCT03765086|PROCEDURE|Karydakis procedure|Pilonidal sinus will be excised by Karydakis procedure
48483835|NCT03765086|PROCEDURE|Limberg Flap|Pilonidal sinus will be excised by Limberg Flap
48483836|NCT00480623|DRUG|Satraplatin plus radiation therapy|
48483837|NCT00604201|BIOLOGICAL|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
48483838|NCT01473550|BEHAVIORAL|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
48483839|NCT06415695|BEHAVIORAL|Education sessions|Ten 40-minute education sessions appropriate to Saudi people will be developed and will cover essential topics for enhancing diet, lifestyle, and health. Each session comprises four modules, including activities and homework reviewed by a dietitian. Based on the EMPOWER weight loss program developed by the Nakamura lab for the US population, adjustments will be made to align with Saudi preferences, including food choices and cooking methods. Participants will access these materials online.
48483840|NCT03964636|DIAGNOSTIC_TEST|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
48483841|NCT00518622|DRUG|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
48483842|NCT00518622|DRUG|Comparator: Placebo|MK7009 Placebo
48483843|NCT04667247|DRUG|FoTv|8 capsules three times a day for 14 consecutive days.
47963708|NCT03806790|DRUG|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
47963709|NCT03806790|DRUG|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
48483844|NCT04449536|DRUG|Mesna|Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
47963710|NCT06201741|RADIATION|[131I]/[18F]/[68Ga]ZT-111|\[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
48483845|NCT02985879|DRUG|Placebo|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
47963712|NCT01375244|DRUG|Lisinopril|Tablets, 10 mg, single dose
47963713|NCT01375244|DRUG|Zestril|Tablets, 10 mg, single dose
47963714|NCT00417469|DEVICE|NADGL|
48114507|NCT02731339|BEHAVIORAL|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
48114508|NCT02731339|BEHAVIORAL|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
48312557|NCT04748224|DRUG|bupivacaine plus dexmedetomidine|bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
48312558|NCT00991380|BEHAVIORAL|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
48312559|NCT00991380|BEHAVIORAL|Usual Care|Control
48114509|NCT02731339|BEHAVIORAL|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
47963715|NCT03634657|RADIATION|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
48114510|NCT04848233|DIETARY_SUPPLEMENT|Drinks containing 5AA+CrPic and Placebo|Same diet will be repeated for 3 days in a row and the beverage switched every day. 3 periods of 3 days are included in the study.
48114511|NCT06007352|DRUG|Gentamicin|Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
48312560|NCT06502756|DEVICE|SOBER, mobile Application providing digital CBT|SOBER is a software application (Android) that delivers cognitive behavioral therapy (CBT) in a structured and interactive manner. It analyzes patterns in participants\&#39; lifestyles to identify problematic behaviors related to their alcohol consumption. By providing tailored guidance and support, the app aims to help individuals make sustainable changes, ultimately reducing hazardous drinking. This approach combines the principles of CBT with the convenience and accessibility of digital technology, offering a personalized experience to support the reduction of alcohol consumption.
48312561|NCT00771030|BIOLOGICAL|Brodalumab|Solution for subcutaneous or intravenous administration
48312562|NCT00771030|OTHER|Placebo|Solution for subcutaneous or intravenous administration
48312563|NCT04476355|OTHER|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
48312564|NCT03965832|DEVICE|HFNT during exercise|"6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions."
48312565|NCT03965832|DEVICE|Standard oxygen therapy/RA|6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
48312566|NCT03736538|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
48312567|NCT03736538|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
48114512|NCT06007352|OTHER|Placebo|3 L of NaCl irrigation typically used for ureteroscopy surgery
48312568|NCT01383395|DRUG|simvastatin/cilostazol|
48312569|NCT02919488|OTHER|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
48312570|NCT02919488|OTHER|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
48312571|NCT01962714|BEHAVIORAL|Loving-Kindness Meditation|12-week loving-kindness meditation course
48312572|NCT01962714|BEHAVIORAL|Cognitive Processing Therapy|12-week CPT course
48312573|NCT02416362|OTHER|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
48312574|NCT02416362|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
48312575|NCT04998045|BEHAVIORAL|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
47963716|NCT03634657|RADIATION|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield \& X-ray protective strips
47963717|NCT03634657|RADIATION|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield \& X-ray protective strips \& X-ray protection patient cut-outs
47963718|NCT04916431|DRUG|mRNA-6231|Sterile frozen liquid dispersion for injection
47963719|NCT00896571|DRUG|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
47963720|NCT03421665|DEVICE|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
48114513|NCT00138619|DRUG|vildagliptin|
48312576|NCT02460757|OTHER|Laryngoscopy|Observation of glottic width in different arms
48312577|NCT01809418|DEVICE|keePAP|
48312578|NCT05820256|DIETARY_SUPPLEMENT|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
48114514|NCT02520908|PROCEDURE|HSCT|Hematopoietic stem cell transplantation
48114515|NCT02520908|OTHER|Standard Care|
48114516|NCT01091233|PROCEDURE|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
48114517|NCT03220425|DRUG|Insulin detemir|
48114518|NCT03220425|DRUG|NPH insulin|
48114519|NCT06038617|BIOLOGICAL|mRNA COVID-19 Vaccine|ACIP Recommended Vaccine
48114520|NCT06038617|BIOLOGICAL|Routine Childhood Vaccinations|ACIP Recommended Vaccines
48312579|NCT05820256|DIETARY_SUPPLEMENT|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
48114521|NCT05537155|PROCEDURE|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
48114522|NCT05537155|OTHER|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
47963721|NCT00496652|RADIATION|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
47963722|NCT00496652|DRUG|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
48114523|NCT03615417|DEVICE|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
47963723|NCT01378637|DEVICE|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
47963724|NCT05267847|OTHER|Cryotherapy|local anesthetic injection with articaine 4% 1:100,000 epinephrine then an application ice packs
47963725|NCT05267847|OTHER|Traditional local anesthesia|local anesthetic injection with articaine 4% 1:100,000 epinephrine
47963726|NCT00138580|DRUG|vildagliptin|
47963727|NCT03315806|OTHER|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
47963728|NCT03315806|OTHER|Placebo|140 mL of beetroot juice isent of nitrate
47963729|NCT00667875|DRUG|Placebo|placebo
47963730|NCT00667875|DRUG|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
47963731|NCT00667875|DRUG|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
47963732|NCT06028139|BEHAVIORAL|Continuous glucose monitoring and health coaching|"Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial.~Participants will interact with health coach throughout the study duration."
47963733|NCT06028139|BEHAVIORAL|EMPOWER mobile app|Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.
47963734|NCT02951065|OTHER|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
47963735|NCT02951065|OTHER|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
48114524|NCT03615417|DEVICE|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
48114525|NCT05685316|DEVICE|COPLA® cartilage implant|In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
48483846|NCT02985879|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
48483847|NCT01556152|DRUG|GRC 17536 (Medium Dose)|1 BD for 28 days
47963736|NCT02030041|DRUG|Vitamin D|Vitamin D will be given to achieve normal serum levels
47963737|NCT02030041|DRUG|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
47963738|NCT02030041|DRUG|Placebo|Placebo will be provided to the study participants
47963739|NCT04933877|PROCEDURE|Fascial plane block|Serratus anterior plane block
47963740|NCT01727297|DEVICE|REVEAL Implantable Cardiac Monitor|
47963741|NCT00672932|DRUG|raltegravir|400 mg two times daily for three months
47963742|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
47963743|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
48114526|NCT03414658|DRUG|Vinorelbine|work by interfering with cell division, which leaves the tumor unable to grow and spread
48114527|NCT03414658|DRUG|Trastuzumab|trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
48483848|NCT01556152|DRUG|GRC 17536 (Low Dose)|1 BD for 28 Days
47963744|NCT03584360|DRUG|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
47963745|NCT02617381|OTHER|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
47963746|NCT01191229|DEVICE|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
47963747|NCT01191229|DEVICE|Crystalens AO|25 patients that are previously implanted
48312580|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
47963748|NCT04673422|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
48312581|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
48312582|NCT06553196|BEHAVIORAL|MATAspire Web-app|Substance misuse prevention education and adaptive coping skills
48312583|NCT00632190|OTHER|fluorophotometry|
48483849|NCT01556152|DRUG|Placebo|Matching Placebo for 28 Days
48483850|NCT01025219|GENETIC|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
48483851|NCT02747004|DRUG|Abemaciclib|Administered orally
48483852|NCT02747004|DRUG|Tamoxifen|Administered orally
47963749|NCT04673422|DRUG|Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
48114528|NCT03414658|DRUG|Avelumab|monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
48114529|NCT03414658|DRUG|Utomilumab|Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
48114530|NCT02692417|DEVICE|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
48114531|NCT00293293|OTHER|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
48114532|NCT00293293|OTHER|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
48312584|NCT00632190|PROCEDURE|colposcopic biopsy|
48312585|NCT00632190|PROCEDURE|colposcopy|
48312586|NCT00632190|PROCEDURE|light-scattering spectroscopy|
48483853|NCT02747004|DRUG|Prophylactic Loperamide|Administered orally
48483854|NCT05197829|DEVICE|Continuous Glucose Monitoring|Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
48483855|NCT05197829|OTHER|Care Coordination|All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
48312587|NCT03700476|DRUG|Sintilimab|Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
48312588|NCT03700476|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
48483856|NCT01417819|OTHER|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
47963750|NCT06074601|DIAGNOSTIC_TEST|Mirvie Predictive Test for Adverse Pregnancy Outcomes|This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
48483857|NCT04922684|BEHAVIORAL|Mimic facial expressions|16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
48483858|NCT01569776|OTHER|Amino Acid formula|Amino Acid baby formula
48483859|NCT01569776|OTHER|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
48483860|NCT00052416|DRUG|thalidomide|
48483861|NCT00778882|DRUG|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
48483862|NCT05283603|DIAGNOSTIC_TEST|ECG, Echocardiogram, Magnetic resonance|Clinical and instrumental follow-up
48643547|NCT06686823|BEHAVIORAL|Cognitive Training Program|The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
47963751|NCT01797744|OTHER|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
47963752|NCT02399722|DEVICE|WICVAC|combined wound therapy
47963753|NCT02399722|DEVICE|VAC mono therapy|mono therapy
47963754|NCT02914470|DRUG|carbplatin, cyclophophamide, atezolizumab|
47963755|NCT00247897|DRUG|Skin antisepsis|See Detailed Description
47963756|NCT01814514|DRUG|Timolol-trusopt|
47963757|NCT01814514|DRUG|placebo|
48312589|NCT03700476|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
48114533|NCT00293293|OTHER|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
47963758|NCT01392443|DRUG|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
48114534|NCT00293293|DRUG|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
48114535|NCT05425433|OTHER|Tailored serial casting intercention|Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
48114536|NCT04889131|BEHAVIORAL|Yoga Program Immediately|free 12 week yoga program, twice a week for 75 minutes each
48114537|NCT04889131|BEHAVIORAL|Wait-Listed Control|assigned to take the Yoga Program in 12-weeks
48114538|NCT04889131|OTHER|Activity Monitor|Garmin VivoSmart activity monitor throughout study
48114539|NCT01184508|DRUG|Placebo|Administered orally, once daily, for 12 weeks
48114540|NCT01184508|DRUG|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
47963759|NCT04992598|OTHER|Hypnosis session|Hypnosis session will precede therapeutic strategies and reduction
48114541|NCT05289466|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy (Xoft, 20 Gy single dose)
47963760|NCT04992598|PROCEDURE|Reduction|All dislocation would be reduced Under adequate analgesia and sufficient sedation. All methods for reduction can be used.
48114542|NCT05289466|PROCEDURE|Oncoplastic partial mastectomy|Breast Conserving Therapy
48114543|NCT05249036|PROCEDURE|Ultrasound guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using real-time ultrasound guidance
48114544|NCT05249036|PROCEDURE|Palpation guided arterial cannulation|Arterial cannulation will be attempted at the site of the radial artery of the non-dominant hand, using palpation technique (standard-of-care)
48114545|NCT01012388|DEVICE|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
48114546|NCT06246435|OTHER|moderate aerobic exercise|
48114547|NCT06081686|DRUG|Phase I:[177Lu]Lu-XT033 Injection|Six subjects were enrolled in the 1.11 Gbq (30 mCi) group of \[177Lu\] Lu-XT033 Injection. The last subject in this group completed the 4-week observation period after the first dose, With the consent of the Safety Monitoring Committee (SRC), 6 subjects were enrolled in the 1.85 Gbq (50 mCi) group. Both groups used 8 ± 1 weeks as the dosing interval .
48114548|NCT06081686|DRUG|Phase II:[177Lu]Lu-XT033 Injection|Patients received \[177Lu\]Lu-XT033 Injection every 8 weeks (+/- 1 week) for a maximum of 6 cycles.
48114549|NCT00364013|DRUG|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
48114550|NCT00364013|DRUG|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
48312590|NCT03700476|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
48483863|NCT02025231|RADIATION|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
47963761|NCT00742430|PROCEDURE|PCI|percutaneous coronary intervention in stable coronary artery disease
47963762|NCT06159985|PROCEDURE|left posterior pericardiostomy|In patients assigned to the study group, a 4-5 cm vertical incision posterior to the phrenic nerve and extending from the left inferior pulmonary vein to the diaphragm is performed.
47963763|NCT03036007|OTHER|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
47963764|NCT03036007|OTHER|Exercises with Internet support|Neck-specific exercise with Internet support
47963765|NCT06059794|OTHER|PUQE score|The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy (NVP). Based on quantification of the 3 physical symptoms of NVP (nausea, vomiting and retching)
47963766|NCT06059794|OTHER|GAD-7|"The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include not at all, several days, more than half the days and nearly every day"
48114551|NCT05496907|BEHAVIORAL|Diabetes specialist nurse-led collaborative care intervention|10 sessions with a diabetes nurse to help improve physical and mental health outcomes
48312591|NCT04030104|DEVICE|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
48312592|NCT04030104|DEVICE|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
48312593|NCT04030104|DEVICE|Mammography|Mammography as available per standard of care
48312594|NCT02728440|DRUG|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
48312595|NCT05844124|OTHER|Exercise for Knee Osteoarthritis -(Land Based Treadmill or Community Walking)|Standard-of-care Land-based walking exercise
48312596|NCT05844124|OTHER|Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)|Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise
48643548|NCT06689969|PROCEDURE|conventional implant placement method|Site marking was the first step in preparing the place for implantation. Subsequently, using a high speed surgical handpiece and a surgical motor, a pilot drill was revolved at 1200 RPM in a clockwise rotation to the desired depth, creating a 1.5 mm first pilot osteotomy. An X-ray was obtained using paralleling pins to validate the angle between the surrounding teeth and the implants. Eventually the implant's precise placement was established. To prepare the osteotomy site to the desired diameter, drills are used sequentially at 1200 RPM in a clockwise motion. Gradually bigger drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes were utilized in ascending order
48114552|NCT02384070|PROCEDURE|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
48114553|NCT02384070|DRUG|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
48114554|NCT02384070|DRUG|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
48114555|NCT02384070|DRUG|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
48114556|NCT06050109|DRUG|OFS continues to use group after 5 years use|Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
48114557|NCT06050109|DIAGNOSTIC_TEST|Immunohistochemical detection of HR status|Enrolled patients must be HR-positive premenopausal breast cancer patients
48114558|NCT03857971|DEVICE|Coronary Optical Coherence tomography|Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
48114559|NCT00006327|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
48114560|NCT01784653|BEHAVIORAL|iMET|Self-completed, computerized motivational enhancement therapy
48114561|NCT01784653|BEHAVIORAL|MET|Clinician-delivered Motivational Enhancement Therapy
48114562|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
48114563|NCT00885157|BIOLOGICAL|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
48114564|NCT00783133|DRUG|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
48114565|NCT00783133|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
48114566|NCT03863834|DEVICE|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
48114567|NCT04820439|DRUG|recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)|A single intravenous infusion of HS627 420mg
48114568|NCT04820439|DRUG|Perjeta ®|A single intravenous infusion of Perjeta ®420mg
48114569|NCT04349150|DEVICE|Virtual reality|Intervention consists of providing virtual reality in place of standard sedatives and narcotics for a portion or the duration of the colonoscopy
48114570|NCT01831284|PROCEDURE|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
48114571|NCT04000269|DEVICE|Soterix MxN Neuromodulation device|Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
48312597|NCT05844124|OTHER|Exercise for Knee Osteoarthritis - (Aquatic Walking)|Aquatic Walking exercise
48483864|NCT00396331|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
48114572|NCT04000269|DEVICE|Sham Stimulation|Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
48114573|NCT05991999|OTHER|Stretching|"Master swimmers will be taught iliopsoas, sternocleidomastoid and pectoralis major stretching exercises as stretching exercises. Participants will stretch daily for 3 repetitions, each stretching for 20 seconds.~Participants will continue their swimming training 2 days a week."
47963767|NCT05382663|DEVICE|Alio Device|Non-invasive device worn over vasculature.
47963768|NCT04752475|DRUG|Furosemide|Furosemide 20 mg pill taken daily for 5 days
48114574|NCT05991999|OTHER|Training|Participants continued their swimming training 2 days a week.
48114575|NCT06553911|OTHER|Artificial Intelligence-based medical imaging interpretation|In the AI interpretation group, using clinical information, imaging data, and corresponding etiological results of the study participants, an AI diagnostic tool is established to specifically recognize patients' chest medical imaging and construct corresponding diagnostic conclusions.
48114576|NCT05922046|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
48114577|NCT01348880|DRUG|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
48114578|NCT01348880|DRUG|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
48312598|NCT06503289|DEVICE|Cytosorb therapy|Extracorporeal treatment with cytosorb filter to patients diagnosed with rhabdomyolysis
48643549|NCT06689969|PROCEDURE|Osseodensification to implant placement using densah bur kit|"Beginning with site marking, the area was prepared for implantation. A high speed surgical handpiece and a surgical motor (surgic pro® NSK, Japan) were then used to construct a 1.5 mm initial pilot osteotomy using a pilot drill spun at 1200 RPM in a clockwise rotation to the desired depth. In order to verify the angle between the surrounding teeth and the implants, paralleling pins were used to capture an X-ray.~After it was determined that the implant was in the proper location, OD was used to extend the osteotomy using a Densah® Bur VT1525 2.0-mm (VersahTM, LLC, USA) in non-cutting anticlockwise rotation at 1200 RPM (Densifying Mode). The osteotomy was expanded to the desired diameter by repeatedly using a DensahTM Bur operating in a non-cutting anticlockwise (CCW) direction at 1200 RPM (Densifying Mode). Gradually increasing drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes (diameters) were utilised in ascending order"
48643550|NCT06689501|COMBINATION_PRODUCT|SPICE BLEND CAPSULE|The study product is a powder mix of L-carnitine tartrate yeast protein hydrolysate and dihydrocapsiate.in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
48643551|NCT06689501|OTHER|Placebo|The matching placebo is microcrystalline cellulose in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.
48643552|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule Placebo|Xiang Ju Ru Pi Ning capsule Placebo(0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
47963769|NCT04752475|OTHER|Placebo|Identical-appearing placebo pill taken daily for 5 days
47963770|NCT03873844|BEHAVIORAL|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
47963771|NCT03873844|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
47963772|NCT02285842|DEVICE|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
47963773|NCT01113567|DIETARY_SUPPLEMENT|Lactose-free milk|3.5 g of lactose
47963774|NCT01113567|DIETARY_SUPPLEMENT|Whole milk|Whole milk with 24 g lactose
47963775|NCT06261502|DRUG|CBD Oral Solution|Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
47963776|NCT06261502|DRUG|Placebo|Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
47963777|NCT06218485|PROCEDURE|Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making|"The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR \>0.80.~2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area"
47963778|NCT06218485|PROCEDURE|Fractional flow reserve-guided PCI strategy|"The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR \>0.80.~2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05"
47963779|NCT00092989|DRUG|montelukast sodium|Duration of Treatment: 1 dose
47963780|NCT00092989|DRUG|placebo|Duration of Treatment: 1 dose
47963781|NCT05214495|DRUG|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
47963782|NCT05214495|DRUG|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
47963783|NCT06524284|DEVICE|Releaf|10 days/35 minutes per day EVNS (non-invasive electrostimulation) treatment on lower legs and feet by the subject or its caregiver after instruction by the podiatrist.
47963784|NCT00440583|DRUG|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
47963785|NCT02701400|BIOLOGICAL|Durvalumab|Given IV
47963786|NCT02701400|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
47963787|NCT02701400|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
47963788|NCT02701400|BIOLOGICAL|Tremelimumab|Given IV
47963789|NCT05051371|DEVICE|Train of four monitoring|Train of four monitoring in postoperative care unit
47963790|NCT02201485|DEVICE|Stent|
48483865|NCT06326177|PROCEDURE|Spine Posture Assessment|Spine posture will be assessed with double inclinometer method. After determining landmarks for each assessment, inclinometers will be placed and degree will be noted. Both degree which are obtained with different inclinometers will be used to summed up for determining postural alteration degree. Cervical, thoracal, thoracolumbar and lumbar spinal postures will be used. Spine postures are going to be expressed as, cervical lordosis degree, thoracal kyphosis degree, thoracolumbar posture degree and lumbar lordosis degree. Landmarks for cervical lordosis are C2 and C7, for thoracal kyphosis are T1 and T12, for lumbar lordosis are T12 and S1, for thoracolumbar posture C7 and S1.
48483866|NCT06326177|PROCEDURE|Spine Movement Assessment|Spine movement will be assessed via using bubble inclinometer in terms of degree. Bony landmarks will be spotted like done in spine posture assessment after that full spinal flexion and extension wanted in order to record degrees in inclinometers at the end range. As a result the difference between two inclinometer will give the motion of that segment. Lumbar and thoracolumbar spinal movement will be assessed with this method. For thoracal and cervical range of motion values will be recorded separately without substruction from both inclinometer. Thoracal rotation range of motion will be assessed with two landmarks and will be recorded separately according to landmark. Thoracolumbar range of motion will be assessed with two substruction of degrees. Landmarks for cervical range of motion are vertex and C7, for thoracal range of motion are T1 and T12, for lumbar range of motion are T12 and S1, for thoracolumbar range of motion C7 and S1.
48643553|NCT06685978|DRUG|Xiang Ju Ru Pi Ning capsule|Xiang Ju Ru Pi Ning capsule (0.45g per capsule ) 4 capsules each time,p.o.,tid,for 3menstrual cycle.
48643554|NCT04193189|BIOLOGICAL|HEPLISAV-B|Administered by IM injection
48643555|NCT04193189|BIOLOGICAL|ENGERIX-B|Administered by IM injection
47963791|NCT02201485|DEVICE|Balloon|
47963792|NCT06018454|OTHER|Handout on PGT-A|Educational handout on PGT-A
47963793|NCT06018454|OTHER|Handout on PGT-A and genetic counseling|Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
47963794|NCT05865067|OTHER|Yoga Therapy|The intervention sessions will consist of 12 yoga therapy sessions, each one approximately 30 to 45 minutes long, it will be given once a week (on Saturdays) in a room in the building of the School of Health Professions in the Campus of Medical Sciences from the University of Puerto Rico.
48643556|NCT03227575|BEHAVIORAL|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
47963795|NCT05865067|OTHER|Exercise|The wait-list control group will be motivated to exercise at home (except for Yoga).
47963796|NCT01970215|DRUG|TA-8995|
47963797|NCT01970215|DRUG|Atorvastatin|
47963798|NCT01970215|DRUG|Rosuvastatin|
47963799|NCT01970215|DRUG|TA-8995 0mg (placebo)|
47963800|NCT01970215|DRUG|Placebo Statin|
47963801|NCT04219007|DRUG|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
47963802|NCT00363883|DRUG|vorinostat|Given orally
47963803|NCT00363883|OTHER|laboratory biomarker analysis|Correlative studies
47963804|NCT02969369|DRUG|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
47963805|NCT02969369|DRUG|Placebo capsule|Placebo once daily
47963806|NCT05378880|BEHAVIORAL|Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission|The study teams will work with communities and authorities to develop, implement and evaluate a multifaceted intervention bundle that will optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission, by targeting the general public (including farmers) and medicine stores.
47963807|NCT03445715|GENETIC|ART-I02|Single Intra-articular injection in the wrist joint
47963808|NCT03041077|DIETARY_SUPPLEMENT|Instaflex Advanced|Joint function
47963809|NCT03041077|DIETARY_SUPPLEMENT|Placebo|Placebo
47963810|NCT03290092|DRUG|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
47963811|NCT03290092|DRUG|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
47963812|NCT00190671|DRUG|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
48114579|NCT02701855|BEHAVIORAL|Cognitive tests|"Cognitive tests include:~* The MMSE (Mini Mental State Examination)~* Free and Cued Selective Recall Reminding Test (FCSRT).~* Executive functions (fluencies, TMT A and B, span).~* Tests of verbal fluency (literal and category)~* Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~* The Clinical Dementia Rating Scale~* The IADL scale evaluates autonomy.~* Geriatric Depression screening Scale (GDS)"
48114580|NCT02701855|BIOLOGICAL|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
48114581|NCT02701855|RADIATION|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
48114582|NCT02701855|OTHER|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
48643557|NCT06691009|PROCEDURE|Group 1 (mechanical pleurodesis)|pleural abrasions will be done by scrubbing the parietal and visceral pleura until a uniform aspect of bloody pleura by a piece of gauze attached to the end of a holding forceps , intercostal tube will then placed and monitoring of lung expansion will be done through serial CXR and chest ultrasound follow up and when the lung is fully expanded the tube will be clamped for two hours and follow up CXR will be done for follow up and then the tube removed
48114583|NCT06643728|DRUG|Bimagrumab|Administered SC
48114584|NCT06643728|DRUG|Tirzepatide|Administered SC
48114585|NCT06643728|DRUG|Placebo|Administered SC
48114586|NCT05355623|PROCEDURE|Vaginal Repair|Vaginal Repair will be done either by application of sterilized (gamma irradiated) amniotic membrane or by Classical repair
48114587|NCT04009577|DRUG|LEM 5 mg|LEM tablet.
48114588|NCT04009577|DRUG|LEM 10 mg|LEM tablet.
48643558|NCT06691009|PROCEDURE|Group 2 chemical pleurodesis by bleomycin)|Those Patients will have indwelling pleural catheter through which pleural fluid will be drained until dryness and then pleurodesis will be done by 60 mg bleomycin dissolved in 50 ml 0.9% saline and 10 ml 2% xylocaine solution then the catheter will be clamped for 6 hours
48643559|NCT06689891|DEVICE|Pelvic Floor Muscle Therapy Website|8-week video-based, self-directed PFMT course
47963813|NCT00190671|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
47963814|NCT00190671|DRUG|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
48114589|NCT06386237|OTHER|Dietary intervention: Standardized breakfast with varying amounts of macronutrients (in particular carbohydrate/protein ratios)|Participants receive a standardized meal with one type of macronutrient composition in one experimental session and the other type in a different experimental session a few days apart (within-subjects crossover design; i.e. order counterbalanced)
48114590|NCT00117130|DRUG|Aranesp®|
48114591|NCT01596946|BEHAVIORAL|Contact tracing mode test at clinic|
48114592|NCT01596946|BEHAVIORAL|Self-sampling at home - Sent Test Kit|
48114593|NCT03473522|DEVICE|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
48114594|NCT03473522|BEHAVIORAL|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
48114595|NCT05003570|DRUG|Remifentanil|Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
48114596|NCT05003570|DRUG|Fentanyl|Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
48114597|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
48114598|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
48114599|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
48114600|NCT03830736|COMBINATION_PRODUCT|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
47963815|NCT06085612|DIAGNOSTIC_TEST|Automated retinal oximetry|Non invasive standard examination on automated retinal oximetry.
47963816|NCT02575937|BEHAVIORAL|low glycemic diet|nutrition education-based low glycemic diet intervention
47963817|NCT04946747|DEVICE|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
47963818|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
48643560|NCT06442397|BEHAVIORAL|Anti-Inflammatory Lifestyle Intervention|Content includes training in empirically-supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with evidence-based behavior change content adapted to meet the needs of EACS. Participants will also receive digital tools to facilitate daily self-monitoring (Fitbit activity monitor, wireless scales, self-monitoring app) and generate information for tailored weekly e-coaching
48114601|NCT03830736|COMBINATION_PRODUCT|Control product|Glucose based beverage without added test components is used as control product
48114602|NCT02387099|DRUG|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
48312599|NCT02720016|BEHAVIORAL|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
48312600|NCT02720016|BEHAVIORAL|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
48483867|NCT06326177|PROCEDURE|Core Muscle Endurance Assessment|Core muscle endurance is divided into three components. Trunk anterior flexion test will be used to assess anterior core region endurance. Lateral plank test will be used to determine lateral core muscle endurance. Trunk posterior extensor test will be used to determine endurance of the posterior core musculature. All of these test are calculated in predetermined positions according to literature with static contractions. Maximum duration of maintaining that position is needed. In trunk anterior flexion test participant will sit with 60 degree inclination from the ground while making contact with their feet when hips and knees are flexed. In lateral plank test participants should place their elbow to ground and lift their hip while feet are in contact with ground in side lying position. In trunk extensor endurance test participants will lie prone to the bed while maintaining contact with their ASIS and lower extremity. The upper body should stay outside of the bed.
48312601|NCT02720016|BEHAVIORAL|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
48643561|NCT06673069|DRUG|ION269|Administered as intrathecal (IT) injection.
48643562|NCT06689930|OTHER|PDSA Cycles|Conduct PDSA cycle and follow-up interviews and surveys for patients (5 per cycle, 10 total) and CBO staff (no less than 2)
47963819|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
47963820|NCT01575587|DRUG|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
48312602|NCT01515995|DRUG|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
48312603|NCT04940871|DRUG|Favipiravir HU 200 mg hard capsules|Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
48312604|NCT04940871|DRUG|Placebo HU|Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
48312605|NCT01510808|PROCEDURE|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
48312606|NCT01251276|BIOLOGICAL|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
48643563|NCT06691607|OTHER|Serum NGAL level|serum NGAL level
48643564|NCT05908084|BIOLOGICAL|HAV|HAV implantation
47963821|NCT01575587|DRUG|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
47963822|NCT01575587|DRUG|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
47963823|NCT01575587|DRUG|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
47963824|NCT03118635|BEHAVIORAL|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
47963825|NCT05288244|OTHER|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
47963826|NCT05288244|OTHER|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
47963827|NCT05288244|OTHER|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
47963828|NCT04849754|DIAGNOSTIC_TEST|bone scintigraphy|Bone scintigraphy
47963829|NCT02450591|DRUG|Erlotinib|
47963830|NCT02450591|OTHER|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
47963831|NCT06332911|DEVICE|Shockwave™ Peripheral Intravascular Lithotripsy Balloon M5+|Cracking-not-debulking technique (SHOCKWAVE IVL)
47963832|NCT03562533|DRUG|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
48312607|NCT00859781|DRUG|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
48312608|NCT00859781|DRUG|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
48312609|NCT00859781|DRUG|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
48312610|NCT00859781|DRUG|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
48312611|NCT06043206|PROCEDURE|Bariatric Surgery|Bariatric Surgery
48312612|NCT02853734|OTHER|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
48312613|NCT02853734|OTHER|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
48312614|NCT05140005|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
48312615|NCT04611685|DRUG|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
47963833|NCT03562533|DRUG|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
48312616|NCT04611685|DRUG|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
48312617|NCT03056495|DRUG|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
48312618|NCT02273752|DRUG|Everolimus|Given PO
48312619|NCT00157092|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
48312620|NCT03825276|DIETARY_SUPPLEMENT|Mango consumption|Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
48643565|NCT05908084|OTHER|AVF|AVF creation procedure
48643566|NCT01724307|PROCEDURE|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
48643567|NCT06686498|BEHAVIORAL|Illness Management and Recovery adapted to suicidal behavior (IMR-ACS)|"Illness Management and Recovery adapted to suicidal behavior (IMR-ACS) is a protocolized clinical intervention in a brief group format aimed at people at risk of suicide. Specifically, people who have had more than two attempts in their lifetime are called repeaters. For its construction, we relied on the Spanish version of the Illness Management and Recovery IMR, developed by the Spanish Nursing Association, adapted to the field of suicidal behavior, taking as a reference the model of personal recovery from suicide attempt proposed by Sokol et al.~The goals of IMR-ACS are to 1) know the warning signs of a suicidal crisis, 2) implement strategies to manage the suicidal crisis, 3) foster social support among peers, 4) formulate goals for recovery from a suicidal crisis, and 5) seek help and make informed decisions in the event of a suicidal crisis.~IMR-ACS is a complementary intervention to the usual treatments."
47963834|NCT01212315|DEVICE|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
48312621|NCT00916500|DRUG|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
48312622|NCT01114958|DRUG|Cisplatin, Thiosulfate|Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
48312623|NCT01667068|OTHER|Comprehensive non invasive cardiovascular examination|"* Anamnesis with the participian~* File recherche,Physical examination~* Documentation of the carciovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Measuring of the arterial media thickness~* Exercise Montreal Cognitive Assesment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
48312624|NCT00488579|DRUG|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
48312625|NCT03297307|BEHAVIORAL|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
48312626|NCT01503073|DEVICE|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
48312627|NCT01773135|OTHER|collection of blood sample and tocolysis adminstration|"investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery \& preterm delivery) and investigators compare between these 2 groups by level of hormone."
48312628|NCT00176670|DRUG|midazolam or GameBoy or parental presence|
48312629|NCT05347498|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
48312630|NCT05347498|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
48312631|NCT00266019|BEHAVIORAL|Weight Management (diet, exercise, and behavior modification)|
48312632|NCT02576964|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
48312633|NCT02576964|DRUG|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
48483868|NCT06326177|PROCEDURE|Scapular Dyskinesia|Scapular dyskinesia will be assessed with scapular dyskinesia test. Dumbbells which are 1,5kg will be used in the testing setting. Participant will perform full shoulder abduction for 5 times while examiner assesses the movement quality by ranking it as subtle dyskinesis, obvious dyskinesis and no dyskinesis according to the movement of the scapula. After that participant will perform 5 repetitions of shoulder flexion.
48483869|NCT06326177|PROCEDURE|Shoulder Strength|Shoulder strength will be assessed via usage of microfet hand held dynamometer. Isometric shoulder strength will be calculated in supine lying position while participant holding their arm at side with 90 degree elbow flexion. After that participant will apply maximal contraction towards external rotation while examiner resists that motion in order to prevent any motion with dynamometer. Eccentric shoulder strength will be assessed in sitting position. Participant will hold their shoulder at 90 degrees of abduction with 90 degree external rotation. Also elbow should be in 90 degree flexed position. After that examiner will give force towards neutral rotation while holding the arm. Participant will resist this motion eccentrically until neutral rotation is reached. Velocity of the shoulder should be same throughout all motion due to creation of isokinetic environment.
48483870|NCT06445218|OTHER|Data collection|Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
48483871|NCT04150822|OTHER|Registry and Saliva sample|Non-interventional registry with saliva sample collected for DNA analysis
48643568|NCT06689319|BEHAVIORAL|Assessment of Artificial Intelligence Literacy|The Artificial Intelligence Literacy Scale will be used to determine the level of AI literacy.. The scale is a 12-item instrument designed to measure individuals' knowledge and skills in AI awareness, usage, evaluation, and ethical considerations. Items are rated on a Likert scale from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree), with some items reverse-coded (items 2, 5, and 11). The minimum possible score on the scale is 12, and the maximum score is 84; a higher score indicates a higher level of AI literacy. The Turkish version of the scale will be used in this study.
48643569|NCT06436183|DRUG|Camoteskimab|Drug Product
47963835|NCT02557711|DEVICE|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
47963836|NCT03339908|DEVICE|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
47963837|NCT00282984|DRUG|placebo|1 mg placebo twice daily by mouth for 12 weeks
47963838|NCT00282984|DRUG|Varenicline|1 mg twice daily by mouth for 12 weeks
47963839|NCT03758209|PROCEDURE|Prehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
47963840|NCT03758209|PROCEDURE|ERAS|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
48643570|NCT06436183|DRUG|Placebo|Inactive substance
48643571|NCT04130971|OTHER|No intervention, just observation|No intervention, just observation of the differences between groups and within patients.
47963841|NCT04457635|BEHAVIORAL|Psychotherapy|
47963842|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|30 µg
47963843|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|300 µg
47963844|NCT04224701|BIOLOGICAL|Placebo|Tris NaCl Diluent
47963845|NCT04944251|BEHAVIORAL|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
47963846|NCT05729646|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
47963847|NCT05729646|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
48114603|NCT02387099|DRUG|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
48312634|NCT00717262|DRUG|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
48312635|NCT00717262|DRUG|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
47963848|NCT05729646|DRUG|S1|S-1 orally intake as perioperative chemotherapy
47963849|NCT04533373|PROCEDURE|DIEP Flap Neurotization|"We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new source) that is being transferred and attaching it to a nerve in the chest wall."
47963850|NCT03796793|PROCEDURE|Wound Edge Debridement|Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.
47963851|NCT03796793|OTHER|Standard of Care Treatment|Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
47963852|NCT03965039|DEVICE|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
47963853|NCT03965039|DRUG|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
47963854|NCT03965039|DRUG|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
47963855|NCT03965039|DRUG|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
48312636|NCT03327753|BEHAVIORAL|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
48312637|NCT03327753|BEHAVIORAL|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
48312638|NCT01116219|BIOLOGICAL|bevacizumab, erlotinib|"* Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression."
48312639|NCT01116219|DRUG|bevacizumab, pemetrexed, cisplatin|"Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
48312640|NCT02002806|OTHER|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
48312641|NCT02002806|OTHER|Placebo Injection|
48312642|NCT05841602|OTHER|descriptive|This research was conducted to evaluate nursing care from the perspective of hospitalized children during the Covid-19 pandemic process and to determine their feelings during this process.
48312643|NCT01418664|DIETARY_SUPPLEMENT|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
48312644|NCT00916370|DEVICE|Core size Xience Prime|Core size includes a range of stent sizes.
48312645|NCT00916370|DEVICE|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
48312646|NCT05642013|PROCEDURE|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
48312647|NCT05642013|OTHER|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
48312648|NCT01831557|OTHER|Blood samples will be taken for gene sequencing|
48312649|NCT03632681|DRUG|Intranasal Insulin|Intranasal insulin
48312650|NCT03632681|DRUG|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
48312651|NCT00986258|DRUG|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
48312652|NCT02757066|DRUG|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
48483872|NCT03715322|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
48483873|NCT03715322|OTHER|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
48312653|NCT02757066|DRUG|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
48483874|NCT03715322|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
48483875|NCT02658916|DRUG|BIIB092|Same dose as corresponding CN002003 study panel.
48483876|NCT02098421|DRUG|Oxytocin|Use of oxytocin while the Foley bulb is in place
48483877|NCT05680779|OTHER|ultrasound-guided percutaneous neuromodulation|It´s an intervention of physiotherapy
48312654|NCT02757066|DRUG|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
48312655|NCT03869957|DIETARY_SUPPLEMENT|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
48312656|NCT04292405|DEVICE|Wearable Cardioverter Defibrillator|Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
48312657|NCT01754220|DRUG|Montelukast|Montelukast is a leukotriene receptor antagonist
48312658|NCT02802059|DRUG|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
48312659|NCT02802059|DRUG|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
48312660|NCT03191006|DEVICE|MEI BIN insoles|insoles
48312661|NCT00665496|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
48312662|NCT00665496|DRUG|Placebo|Matching Placebo
48312663|NCT05623904|PROCEDURE|Carotid Revascularization|Carotid Artery Stenting/Carotid Endarterectomy
48312664|NCT05623904|DRUG|Medical Treatment|"Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment."
48312665|NCT04460690|DEVICE|Rapid Onsite COVID-19 Detection|saliva assay test for high concentrations of SARS-CoV-2
48312666|NCT05157451|OTHER|Quality of Life|Ancillary studies
48312667|NCT05157451|OTHER|Questionnaire Administration|Ancillary studies
48312668|NCT05157451|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48483878|NCT05680779|OTHER|dry needling|It´s an intervention of physiotherapy
48312669|NCT05157451|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Given via injection
48312670|NCT04081883|OTHER|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
48312671|NCT00793676|OTHER|spirometry|
48312672|NCT00793676|OTHER|blood test|
48312673|NCT04655105|DEVICE|root canal rotary files|post operative pain evaluation using different rotary file system
48312674|NCT04807543|DRUG|17-hydroxyprogesterone caproate|intramuscular injection weekly
48312675|NCT04807543|DRUG|Castor Oil|intramuscular injection weekly
48114604|NCT02387099|DRUG|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
48114605|NCT02387099|DRUG|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
48114606|NCT00687388|DRUG|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
48312676|NCT00551720|BEHAVIORAL|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
48312677|NCT00551720|BEHAVIORAL|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
48114607|NCT00687388|DRUG|celecoxib|200mg daily for 8 weeks
48114608|NCT00687388|DRUG|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
48312678|NCT05954377|OTHER|Quarterly remote motivational interviews|Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
48312679|NCT06093763|PROCEDURE|Group without bone grafting|Open wedge corrective osteotomy and plate fixation without bone grafting.
48312680|NCT06093763|PROCEDURE|Group with bone grafting|Open wedge corrective osteotomy and plate fixation with harvesting and using bone from the iliac crest.
48312681|NCT03785496|DRUG|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
48312682|NCT04855565|DRUG|ALY688-SR|single dose subcutaneous injection
48312683|NCT02686697|DRUG|L-Carnosine|
48312684|NCT02686697|DRUG|Placebo|
48312685|NCT02686697|BEHAVIORAL|Cognitive Training|Cognitive Training for 2 weeks
48312686|NCT01269372|DEVICE|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
48312687|NCT01269372|DEVICE|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
48312688|NCT03003780|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
48312689|NCT01968096|DEVICE|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
48114609|NCT03264755|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
48114610|NCT00396084|DRUG|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
48114611|NCT00396084|DRUG|Isoniazid|Isoniazid 300 mg/day x 7 days.
48312690|NCT00883480|DRUG|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
48312691|NCT00883480|DRUG|Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
48312692|NCT00883480|DRUG|Gemcitabine|"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
48312693|NCT00883480|DRUG|Erlotinib|Erlotinib 150 mg/day x 21 days
48312694|NCT03242083|OTHER|quality of life questionnaire|quality of life questionnaire
48312695|NCT00748059|PROCEDURE|Standing or upright tilt|stand upright or tilt table test
48312696|NCT00748059|PROCEDURE|Microneurography|Recording from sympathetic nerve
48312697|NCT00748059|PROCEDURE|QSweat|quantitative sweat testing
48483879|NCT05683210|BEHAVIORAL|Cup feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The feeding process was completed at the end of 30 minutes even if the infant did not take all of the food. The infant was followed up for 30 minutes after the end of feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
48483880|NCT05683210|BEHAVIORAL|Bottle feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. During the feeding period, heart rate and oxygen saturation were continuously recorded. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The infant was followed up for 30 minutes after the end of the feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
48483881|NCT02340494|BEHAVIORAL|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
48483882|NCT02024373|DRUG|Atorvastatin|20 mg (every evening orally) for 8 weeks
48483883|NCT02024373|DRUG|placebo|20 mg (every evening orally) for 8 weeks
48483884|NCT01673698|DEVICE|ReShape Duo balloon|
48483885|NCT01673698|OTHER|Diet counseling|
48312698|NCT00748059|DEVICE|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
48312699|NCT00748059|DRUG|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
48312700|NCT00748059|DRUG|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
48312701|NCT00748059|PROCEDURE|BodPod|Determination of body composition
48312702|NCT00748059|PROCEDURE|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~1. 0.5% proparacaine (Alcaine, Allergan, Inc)~2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~3. 0.5%, 1% tropicamide (Mydriacyl, Alcon)~4. Over-the-counter preservative-free artificial tears~5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~6. 1% cyclopentolate hydrochloride (Alcon)"
48483886|NCT01673698|OTHER|Exercise counseling|
48312703|NCT00748059|PROCEDURE|Sleep study|Recording of sleep pattern overnight
48312704|NCT00748059|PROCEDURE|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
48312705|NCT00748059|PROCEDURE|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
48312706|NCT00748059|PROCEDURE|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
48114612|NCT00396084|DRUG|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
48114613|NCT00396084|DRUG|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
48312707|NCT00748059|PROCEDURE|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
48483887|NCT04762940|DEVICE|Robotic|"The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user."
48312708|NCT04907006|DRUG|SY-004 capsule|After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
48312709|NCT02969317|DRUG|Tiotropium|Fixed dose combination
48312710|NCT02969317|DRUG|Olodaterol|Fixed dose combination
48483888|NCT04762940|DEVICE|Vibration|Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
48483889|NCT01562626|DRUG|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
48483890|NCT01562626|DRUG|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
48643572|NCT06688279|OTHER|Plyometric Exercise|". The session will last for 60 minutes and 3 times per week. 5 minutes warm up with dynamic stretching and 5 minutes cool down period with static stretching and 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set (total 3 sets).~Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step. Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
48312711|NCT04360616|DIAGNOSTIC_TEST|imaging|perform US and mammography examination
48312712|NCT03096223|DRUG|KHK4083|IV administration
48312713|NCT02874690|DRUG|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
48312714|NCT02874690|DRUG|Placebo|Placebo pill identical in appearance to methylphenidate
48312715|NCT03972358|DRUG|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
48312716|NCT03972358|DRUG|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
48483891|NCT01562626|DRUG|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
48114614|NCT00396084|DRUG|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
48312717|NCT01979796|DEVICE|Ecig 24 mg nicotine|Cigalike
48312718|NCT01979796|DEVICE|Ecig 0 mg nicotine|Cigalike
48312719|NCT01979796|DEVICE|Nicotine free inhalator|Plastic CIG a Like
48312720|NCT04827836|PROCEDURE|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
48312721|NCT03437538|DEVICE|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
48312722|NCT03437538|DEVICE|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
48312723|NCT03029416|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
48312724|NCT05474690|DRUG|Docetaxel + Carboplatin + Trastuzumab + Pertuzumab|"Subjects who met the inclusion conditions were randomly divided into TCbHP group and ECHP-THP group according to 1:1.~Stratified at randomization by the following factors: T, N, HER2 expression (HER2 protein 3+ vs HER2 protein 2+ but FISH+), and hormone receptor status (HR positive vs HR negative).~TCbHP regimen drug dose: docetaxel 75 mg/m2 + carboplatin (AUC=6) + trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg) + pertuzumab Antibiotics (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle."
48312725|NCT05474690|DRUG|(Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)|Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
48312726|NCT05412719|BEHAVIORAL|THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS|the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization
48114615|NCT03762213|DEVICE|Oculus GO VR HMD, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
48312727|NCT04367025|DRUG|Camrelizumab|Camrelizumab: 200mg,iv drip for 1h,d1,q3w
48312728|NCT04367025|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
48312729|NCT04367025|DRUG|S1|S-1:40\~60mg Bid, d1\~14, q3w;
48312730|NCT00572806|DRUG|insulin aspart|
48312731|NCT00547378|DEVICE|InterStim|
48312732|NCT00547378|DRUG|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
48312733|NCT02227329|DRUG|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
48312734|NCT02227329|DRUG|Heparin Lock|3 mL of 100 U/ml heparin
48312735|NCT02227329|DRUG|Normal Saline|
48312736|NCT01999634|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
48312737|NCT05280041|BEHAVIORAL|SOLENA - Online self-help program for older adults who lost the partner|SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.
48312738|NCT03912025|OTHER|Relationship between positive mindset and exercise capacity|No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
48312739|NCT04371731|OTHER|Care4todayheart failure platform|Platform allowing patients to enter information about their health at home, namely weight and BP and medications
48312740|NCT00810719|DRUG|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
48643573|NCT06688279|OTHER|Standard exercises protocol|"The session will last for 60 minutes and 3 times per week. Following exercises would be performed.~* Push ups.~* Sit ups.~* Lunges~* 500 m running.~* Squats Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
48114616|NCT03762213|DEVICE|iPad, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
48114617|NCT04001517|DRUG|Neflamapimod|Double-Blind, Placebo-Controlled
48312741|NCT00810719|DRUG|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
48312742|NCT03706534|DEVICE|Ultrasound Image review with CADe|This software is a computer-aided detection (CADe) software application, designed to assist radiologist to analyze breast ultrasound images. S-Detect automatically segments and classifies shape, orientation, margin, lesion boundary, echo pattern, and posterior feature characteristics of user-selected region of interest. The device uses deep learning methods to perform tissue segmentation and classification of images.
48312743|NCT03706534|DEVICE|Ultrasound Image review with CADx|This software is also a computer-assisted diagnostic(CADx) software application, designed to assist a medical doctor in determining diagnosis by presenting whether a lesion is malignant in a breast ultrasound image obtained from an ultrasound imaging device.
48643574|NCT06605599|DRUG|ABBV-932|Oral Capsule
48643575|NCT06605599|DRUG|Placebo for ABBV-932|Oral Capsule
48643576|NCT06686966|DIAGNOSTIC_TEST|gastric cancer|be diagnosed as gastric cancer
48312744|NCT03706534|DEVICE|Ultrasound Image manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored.
48312745|NCT03706534|PROCEDURE|Biopsy|Suspicious lesions found on breast ultrasound are then followed either by ultrasound guided biopsy or ultrasound imaging every 6 months for two years. For those who undergo biopsy, ultrasound provides images which are used to localize the lesion and guide the placement of the biopsy needle. The sample is sent to pathology for diagnosis, while the ultrasound guidance images are stored. For those who have imaging follow-up, ultrasound images of the breast mass are obtained, digitally stored and interpreted by the radiologist typically using BIRADS scheme.
48312746|NCT02531373|BIOLOGICAL|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
48312747|NCT02531373|BIOLOGICAL|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
48643577|NCT03497117|DEVICE|Lung Clearance Index|To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
48312748|NCT02531373|BIOLOGICAL|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
48483892|NCT01555827|OTHER|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~* Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~* Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~* Wide-field colour and autofluorescence imaging (Optomap)~* Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~* Age, gender~* educational level~* smoking~* cardiovascular diseases, current medications~* scores at neuropsychological tests"
48483893|NCT01949714|PROCEDURE|Removal of adrenal tumor|
48483894|NCT02214719|BEHAVIORAL|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
48483895|NCT06290219|COMBINATION_PRODUCT|platelet-rich plasma combined with hyaluronic acid|The project investigator injects plasma mixed with hyaluronic acid into the nasal septum and the medial side of the middle turbinate of the patient's nasal cavity under a nasal endoscope.
48643578|NCT03497117|DRUG|MRI with PFP|"* Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
48483896|NCT06290219|DRUG|Zinc Gluconate 10 MG Oral Tablet|one tablet three times a day for a period of 12 weeks
48483897|NCT06290219|DEVICE|4 bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil|Sniffing each odorant for 10 seconds, twice a day for 12 weeks
48483898|NCT03119493|BEHAVIORAL|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
48483899|NCT04799613|OTHER|walking speed|walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
48643579|NCT02416388|DRUG|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
48643580|NCT02416388|DRUG|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
48643581|NCT02416388|DRUG|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
48643582|NCT02416388|DRUG|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
48114618|NCT05254171|DRUG|SBP-101|small molecule polyamine metabolic inhibitor for subcutaneous injection
48643583|NCT02416388|DRUG|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
48643584|NCT02416388|DRUG|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
48643585|NCT02416388|DRUG|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
48114619|NCT05254171|DRUG|Nab-paclitaxel|paclitaxel protein-bound particles for injectable suspension
48114620|NCT05254171|DRUG|Gemcitabine|gemcitabine for injection
48114621|NCT05254171|OTHER|Placebo|Normal Saline
48114622|NCT01590836|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
48114623|NCT01590836|DRUG|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
48312749|NCT02531373|BIOLOGICAL|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
48312750|NCT02531373|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
48114624|NCT01430858|DEVICE|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
48312751|NCT02290886|OTHER|Intravenous administration of placebo|
48312752|NCT02290886|DRUG|Intravenous administration of 1 million of MSC|
48312753|NCT02290886|DRUG|Intravenous administration of 2 million of MSC|
48312754|NCT02290886|DRUG|Intravenous administration of 4 million of MSC|
48312755|NCT01769417|DRUG|Placebo|Placebo
48312756|NCT01769417|DRUG|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
48312757|NCT03765476|BEHAVIORAL|SALIENCE|"3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)"
48312758|NCT03765476|BEHAVIORAL|TAU|treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
48312759|NCT04662242|DRUG|Selenium Supplement|Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
48312760|NCT04662242|DRUG|normal saline|normal saline 100ml iv infusion for 7 days
48312761|NCT02076321|DRUG|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
48312762|NCT02076321|DRUG|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
48312763|NCT00745368|DRUG|Raltegravir|400 mg tablets twice daily during duration of trial
48643586|NCT02416388|DRUG|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
48643587|NCT02416388|DRUG|Dexamethasone|"Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5"
48312764|NCT01759329|DIETARY_SUPPLEMENT|test coffee|test coffee with higher alkyl pyridine content
48312765|NCT01759329|DIETARY_SUPPLEMENT|control coffee|control coffee with regular alkyl pyridine content
47963856|NCT00911560|BIOLOGICAL|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, \& 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), \& continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic \& bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood \& bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or \>2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
47963857|NCT00911560|BIOLOGICAL|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
47963858|NCT03380403|RADIATION|PDT|clinical treatment of infected diabetic foot
48312766|NCT04987853|DIAGNOSTIC_TEST|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~* EchoCG + strain~* CT scan of the lungs~* Holter~* SMAD~* Kidney ultrasound~* Ultrasound~* Doppler ultrasonography of veins and arteries~* Chalder Scale, EQ Questionnaire"
48312767|NCT04987853|DIAGNOSTIC_TEST|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4. Laboratory research methods:~1. The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~2. Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
48312768|NCT04987853|DIAGNOSTIC_TEST|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
48312769|NCT04987853|DIAGNOSTIC_TEST|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
48312770|NCT04251208|OTHER|Observational Study|No intervention will be administered.
48312771|NCT06287502|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB)|Ensure NutriVigor, a nutritional supplement, was provided to subjects according to the manufacturer's recommendation of two servings per day. Each serving consists of 54.1g of powder which provides \~231kcal, 8.61g protein, 1.21 g β-hydroxy β-methylbutyrate, 130 IU vitamin D and 0.29 g omega-3 fatty acid.
47963859|NCT03380403|OTHER|Ciprofloxacin|antibiotics and or surgical debridment
47963860|NCT05762198|DEVICE|Rezūm|In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
48312772|NCT06287502|BEHAVIORAL|Resistance, aerobic, flexibility and balance exercise training|The exercise intervention consists of 75-minutes sessions delivered by physiotherapists at the Integrated Rehabilitation Day Centre (IRDC) in Kowloon Hospital, twice per week for 12 weeks with a total of 24 supervised sessions. Each exercise session consists of 5 minutes of warm up, 30 minutes of resistance training, 20 minutes of aerobic training, 15 minutes of balance or neuromuscular exercises and 5 minutes of cool down.
48312773|NCT02590445|DEVICE|deep brain stimulation system|
48312774|NCT02279433|DRUG|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
48312775|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (3mg/kg IV)|3/1 (6/2 if DLT)
48312776|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (10mg/kg IV)|3/1 (6/2 if DLT)
48483900|NCT04799613|OTHER|visual loading|visual loading (walking through narrow pathway using VR)
48483901|NCT04799613|OTHER|dual task|dual task (serial subtraction using VR)
48483902|NCT04799613|OTHER|best side reduction|best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
48483903|NCT04462016|OTHER|Calamansi|250 ml of a commercially sourced calamansi drink
47963861|NCT05762198|DEVICE|TURP|In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
47963862|NCT00695877|BIOLOGICAL|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
47963863|NCT00952978|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
47963864|NCT00952978|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
48312777|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (30mg/kg IV)|3/1 (6/2 if DLT)
48312778|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|3/1 (6/2 if DLT)
48312779|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|3/1 (6/2 if DLT);
48483904|NCT04462016|OTHER|Glucose|75 g of glucose dissolved in 250 ml of drinking water
48483905|NCT02489591|DEVICE|Oral appliance|Patients will bring their prescribed oral appliance.
48483906|NCT02489591|DEVICE|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
48483907|NCT05990842|DRUG|Antibiotic|the individual will receive 1 dose of antibiotic during anesthetic induction
48483908|NCT05990842|OTHER|placebo|the individual will receive 10 ml of saline during anesthetic induction
48483909|NCT02346682|DRUG|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
48643588|NCT02416388|DRUG|Venetoclax|"Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)"
48483910|NCT03023657|OTHER|Detection of arousal|Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
48483911|NCT03227224|DRUG|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
47963865|NCT00811369|DRUG|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
47963866|NCT00811369|DRUG|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
47963867|NCT05846971|OTHER|Educational materials on validated methylation assay|Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.
48114625|NCT01430858|OTHER|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion \& strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion \& strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low \& high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion \& strain gauge readings will be captured."
48483912|NCT03227224|DRUG|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
48114626|NCT00695071|DRUG|Itraconazole|Oral
48114627|NCT02400099|DIETARY_SUPPLEMENT|High-protein low calorie diet|
48114628|NCT02400099|DIETARY_SUPPLEMENT|Control low calorie diet|
48114629|NCT02400099|OTHER|Anthropometrical measurements|
48483913|NCT01014624|DRUG|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
48483914|NCT01014624|DRUG|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
48114630|NCT02400099|OTHER|Body composition|
48114631|NCT02400099|OTHER|8-h metabolic profile|
48483915|NCT00589849|PROCEDURE|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
48643589|NCT05896384|DRUG|BI 456906|BI 456906
48643590|NCT05896384|DRUG|Microgynon®|Ethinylestradiol (EE) and Levonorgestrel (LNG)
48114632|NCT02400099|OTHER|Liver biopsy|
48114633|NCT00705328|BEHAVIORAL|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
48114634|NCT00705328|BEHAVIORAL|Recreation Coordination Model (REC)|Recreation coordination service delivery
47963868|NCT00448981|BEHAVIORAL|Hand hygiene and educational material|
47963869|NCT00448981|DEVICE|Mask, alcohol and hand sanitizer|
47963870|NCT00001535|DRUG|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
47963871|NCT06324669|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
48114635|NCT00705328|BEHAVIORAL|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
48114636|NCT05925985|OTHER|NA-Observational Registry|NA Observational Registry
48114637|NCT05704751|DEVICE|spinal cord stimulation|EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
48114638|NCT02910388|DEVICE|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
48114639|NCT02910388|OTHER|LLETZ without colposcopy|Loop procedure without using a colposcope
48312780|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|3/1 (6/2 if DLT)
48312781|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|3 (max 9)
48643591|NCT03767231|DIAGNOSTIC_TEST|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
48643592|NCT06563349|DRUG|Intravenous magnesium sulfate|Intraoperative intravenous magnesium sulfate infusion.
47963872|NCT06324669|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with stevia and bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test, on 2 occasions during test day
47963873|NCT01337232|BEHAVIORAL|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
47963874|NCT00107393|BIOLOGICAL|trastuzumab|
47963875|NCT00107393|DRUG|capecitabine|
47963876|NCT04851080|DEVICE|Heart Rate Variability|"Heart rate variability is carried out using the complex of prenosological diagnostics VARICARD 2.51 with the ISCIM 6.2 program is methodically based on the technology of analysis of heart rate variability, it uses the original scientific and theoretical substantiation of HRV indicators, which is based on modern ideas about stress, functional state of the body and assessment of health levels. It is designed to assess the risk of developing diseases in persons who are in states bordering health and disease. A decrease in the adaptive capabilities of the organism is considered as the main risk factor, the results obtained with its help are considered from the point of view of the level of health or stressful effects. It can be successfully used to control the effectiveness of medical intervention. Functionally, the complex is designed to register an electrical signal and form conclusions about the functional state of the body, assess the level of stress and its effect on health."
48114640|NCT04426786|OTHER|Active exercise|Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.
48114641|NCT04426786|OTHER|Passive exercise|Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.
48114642|NCT01331863|PROCEDURE|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
48483916|NCT03418987|OTHER|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
48483917|NCT06102408|OTHER|second line investigations for uveitis etiological workup|Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
48483918|NCT02872792|DEVICE|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
48643593|NCT06563349|DRUG|Normal saline infusion|Intraoperative intravenous normal saline infusion.
48643594|NCT06691412|DRUG|Obeticholic Acid 5 mg|- Patients will be randomly divided into two groups , the first will receive obeticholic acid at a dose of 5 mg once daily and antiviral drug ,and the other will receive the antiviral drug only for six months
48114643|NCT04460612|DEVICE|Active IR sock|Subjects will be wearing the infrared socks for 60 minutes
48643595|NCT06687486|BEHAVIORAL|relaxin|caregivers relaxing and care burden
48643596|NCT06687486|OTHER|kontrol|no intervention
48643597|NCT01546779|DEVICE|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
48643598|NCT06689761|DIETARY_SUPPLEMENT|ColCT|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
48643599|NCT06689761|DIETARY_SUPPLEMENT|ColET|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
48114644|NCT04460612|OTHER|Placebo socks|Placebo Socks will be placed on participants feet first for 60 minute
48114645|NCT02694978|DRUG|Ferumoxytol|
48114646|NCT02694978|DRUG|FCM|
48312782|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 (MTD IV)|3 (max 9)
48312783|NCT00403559|DRUG|Elidel|
48312784|NCT00403559|DRUG|Ketoconazole Cream|
48312785|NCT03958682|DEVICE|AR smart wearing equipment combined with 4G + satellite information transmission system|"We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors."
48312786|NCT00736086|DEVICE|Vessel Closure (StarClose™)|
48312787|NCT02769845|DRUG|Hydroxyurea|drug to be administered
48312788|NCT02769845|PROCEDURE|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
48312789|NCT04261634|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
48312790|NCT04261634|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
48643600|NCT06689761|DIETARY_SUPPLEMENT|PlaCT|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
48643601|NCT06689761|DIETARY_SUPPLEMENT|PlaET|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
47963877|NCT04851080|DEVICE|Spirometry|Spirometry is carried out using the device Spirotest USPTs-01, equipped with liquid crystal indicators. It is non-invasive method for measuring air flows and volumes as a function of time using forced maneuvers. It is intended for functional diagnostics of the lungs, namely, indication and measurement of forced vital capacity and forced expiratory volume in the first second.
48312791|NCT00782665|PROCEDURE|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
48312792|NCT02260908|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
48312793|NCT02260908|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
48312794|NCT05194293|BIOLOGICAL|Durvalumab|Given IV
48312795|NCT05194293|DRUG|Regorafenib|Given PO
48312796|NCT02668107|OTHER|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
48312797|NCT01276457|DRUG|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
48312798|NCT01276457|DRUG|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
48312799|NCT01276457|DRUG|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
48312800|NCT01037504|DRUG|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
48114647|NCT00891930|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
48312801|NCT01037504|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
48312802|NCT02641366|DEVICE|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
48312803|NCT02641366|PROCEDURE|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
48312804|NCT02641366|PROCEDURE|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
48643602|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with a low or intermediate risk Decipher score will receive radiation targeting the seminal prostate and seminal vesicles to a dose of 40 Gy in 5 fractions delivered every other day.
48483919|NCT02872792|OTHER|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
48114648|NCT00891930|BIOLOGICAL|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
48114649|NCT00891930|DRUG|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
48114650|NCT02010138|PROCEDURE|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
48114651|NCT02010138|PROCEDURE|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
48483920|NCT03903159|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
48114652|NCT01420393|PROCEDURE|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
48114653|NCT01420393|OTHER|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR \< 80 bpm and 6-minute walk HR \< 110 bpm.
48114654|NCT02441036|DEVICE|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
48483921|NCT03746548|DEVICE|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
48643603|NCT05169970|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients with high risk Decipher scores will receive radiation targeting the prostate and seminal vesicles to a dose of 40 Gy in 5 fractions with a simultaneous integrated boost to 45 Gy of any dominant intraprostatic lesion as well as radiation to the pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered every other day.
48643604|NCT01097681|DRUG|ASP1941|oral
48114655|NCT02570711|DRUG|ACP-196|ACP-196 capsule
48114656|NCT02570711|DRUG|Nab-paclitaxel|Nab-paclitaxel infusion
48483922|NCT03746548|DEVICE|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
48483923|NCT00027794|PROCEDURE|conventional surgery|
48483924|NCT01967693|PROCEDURE|Retrospective analysis of data|Retrospective data analysis
48483925|NCT01568866|DRUG|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
48483926|NCT01568866|DRUG|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
48483927|NCT01568866|DRUG|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
48483928|NCT02879110|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
48483929|NCT02879110|OTHER|Placebo|Placebo tablet is composed of starch.
48483930|NCT01906086|OTHER|nutritional intervention|
48483931|NCT01906086|OTHER|life style intervention|
48483932|NCT02926781|DEVICE|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
48483933|NCT00933283|DRUG|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
48483934|NCT00933283|DRUG|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
48483935|NCT05206487|DIETARY_SUPPLEMENT|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
48114657|NCT02570711|DRUG|Gemcitabine|Gemcitabine infusion
48114658|NCT05371288|DRUG|NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)|Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
48114659|NCT03127995|RADIATION|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
48114660|NCT03127995|RADIATION|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
48114661|NCT05528341|BIOLOGICAL|NKG2D-CAR-NK92 cells|NKG2D-CAR-NK92 cells will be administered intravenously over 1h. The starting dose of NKG2D-CAR-NK92 cells will be 0.5×10\^6-2×10\^6/kg, twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
48114662|NCT06676761|PROCEDURE|nipple sparing mastectomy without reconstruction|nipple sparing mastectomy was conventionally performed with reconstruction. we aim to study the outcomes in the group of patients with Minimal scar mastectomy (MSM) who have nipple sparing mastectomy without reconstruction
48483936|NCT04440449|BEHAVIORAL|Lifestyle App|A mobile app used to assist with lifestyle changes
48483937|NCT04440449|BEHAVIORAL|Look AHEAD behavior lifestyle intervention|A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
48483938|NCT04440449|BEHAVIORAL|Abbreviated Look AHEAD behavior lifestyle intervention|An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
48483939|NCT02079168|DRUG|RXI-109|
48483940|NCT02079168|DRUG|Placebo|
48643605|NCT05090397|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
48643606|NCT05090397|DEVICE|Sham Transcranial Direct Current Stimulation|Sham Transcranial Direct Current Stimulation
48643607|NCT03867084|BIOLOGICAL|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
48643608|NCT03867084|DRUG|Placebo|IV infusion of 0.9% normal saline.
48114663|NCT03319680|OTHER|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
48114664|NCT01087762|BIOLOGICAL|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
48114665|NCT01087762|BIOLOGICAL|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
48114666|NCT01087762|OTHER|Placebo|Matching Placebo to CZP injection.
48114667|NCT02271971|DIETARY_SUPPLEMENT|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
48114668|NCT02271971|DIETARY_SUPPLEMENT|Placebo|A daily placebo capsule during 6 weeks.
48114669|NCT00086892|BIOLOGICAL|cetuximab|
48114670|NCT00086892|DRUG|carboplatin|
48114671|NCT03416465|BEHAVIORAL|medical questionnaire|The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
48114672|NCT06123208|OTHER|Whole cooked pinto bean|Meal comprised of whole cooked pinto beans
48114673|NCT06123208|OTHER|Pinto bean flour|Meal comprised of pinto bean flour
48114674|NCT06123208|OTHER|Control|Control meal
48114675|NCT04160429|PROCEDURE|Biospecimen Collection|Undergo collection of sweat, saliva, and blood samples
48114676|NCT04160429|OTHER|Medical Chart Review|Review of medical chart
48114677|NCT04160429|OTHER|Questionnaire Administration|Complete questionnaire
48114678|NCT06555510|OTHER|InBody|Bioelectrical impedance analysis
48114679|NCT06259474|COMBINATION_PRODUCT|Hypopressive Exercises and (heat therapy, medication, and progressive strength training)|20 subjects combined HE with traditional treatments for LBP (heat therapy, medication, and progressive strength training). Each session consisted of 5 to 10 HEs. Participants were instructed not to hold their breath or perform PFMS contractions during the HEs. Traditional treatment for low back pain typically involved using medications like acetaminophen (0.5-1 g three times daily) and heat therapy, which consisted of using a continuous heat wrap for 2 hours, 3 times per week at 40 °C, one hour before and after the session
48114680|NCT02327611|DRUG|Custodiol|
48114681|NCT02327611|DRUG|Enriched Ringer's lactate solution|
48114682|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
48114683|NCT04135989|DEVICE|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
48114684|NCT04135989|DRUG|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
48114685|NCT04135989|DRUG|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
48114686|NCT06676644|DRUG|adjuvanted|adjuvanted (aIIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
48114687|NCT06676644|DRUG|non-adjuvanted|non-adjuvanted (IIV4) influenza vaccine in the Taiwanses elderly with chronic medical conditions
48114688|NCT02694666|OTHER|Controlled whole-body vibration training|The intervention is an 8-week program
48114689|NCT05942963|DRUG|Empagliflozin 10 MG|10-25 mg/day
48114690|NCT05942963|DRUG|Pioglitazone 15mg|15-45 mg/day
48114691|NCT05942963|DRUG|Metformin|1000mg-2850mg/ day
48114692|NCT03161990|PROCEDURE|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
48114693|NCT03161990|PROCEDURE|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
48114694|NCT03328715|DEVICE|intraoperative OCT|before and after surgery intraoperative OCT is performed
48114695|NCT03328715|DEVICE|stand-alone OCT|before and after surgery stand-alone OCT is performed
48483941|NCT04892121|OTHER|Prevention exercises|Participants will have to follow a warm-up prevention program (15 minutes) twice a week
48483942|NCT00110344|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
48114699|NCT06370572|OTHER|PAINAD EHR Prompt|Implementation of PAINAD EHR prompt in the ED workflow for PLWD presenting to the ED with hip pain
48114700|NCT01591304|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
48114701|NCT03601910|DRUG|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
48114702|NCT03601910|DRUG|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
48114703|NCT05857371|PROCEDURE|lipoaspiration|The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
48114704|NCT05857371|PROCEDURE|urethrotomy|The urologist will perform an endoscopic urethrotomy (standard care).
48114705|NCT05857371|DRUG|autologous ADSVF administration|ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
48114706|NCT04505982|OTHER|Data extraction from medical files|Data extraction from medical files
48114707|NCT06375265|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)|Preoperative hybrid intervention (in-person or via phone/video) over 4 weeks using content from the CBT-I Coach app from Veteran Affairs.
48114708|NCT06375265|BEHAVIORAL|Sleep Health Education|Sleep Health Education materials provided
48114709|NCT00084903|PROCEDURE|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
48312805|NCT05148585|OTHER|physiotherapy|Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
48312806|NCT05148585|OTHER|activity-based therapy|patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
48312807|NCT01176097|DRUG|AZD5658|oral suspension, escalating single doses
48312808|NCT01176097|DRUG|Placebo|oral suspension,single doses
48312809|NCT03071705|DRUG|Metformin|500 mg PO BID
48312810|NCT03071705|DRUG|TKI|standard dose
48312811|NCT03357809|PROCEDURE|Endoscopic mucosal resection|"Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient."
48312812|NCT04264455|DEVICE|Biomonitor|Patients receive a Biomonitor only
48312813|NCT04264455|DEVICE|Life Vest|Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally
48312814|NCT04264455|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Patients receive an Implantable Cardioverter-Defibrillator (ICD)
48114710|NCT00084903|PROCEDURE|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
48114711|NCT02704741|DEVICE|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
48114712|NCT04352283|DEVICE|Preprocedural ultrasound exam of lumbar spine|Preprocedural ultrasound exam of lumbar spine used to determinate needle puncture site
48266725|NCT00652353|OTHER|44-55-66-PM|"The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar"
48312815|NCT01003080|DEVICE|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
48312816|NCT01003080|OTHER|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
48312817|NCT05781971|DIETARY_SUPPLEMENT|high protein|Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
48312818|NCT05781971|BEHAVIORAL|rehabilitation|In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
48312819|NCT05781971|DIETARY_SUPPLEMENT|standard protein|The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
48312820|NCT01152164|BEHAVIORAL|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
48312821|NCT04153006|DEVICE|POC troponin analysis.|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
48312822|NCT00586391|GENETIC|CD19CAR-28-zeta T cells|"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10\^7 cells/m\^2~Dose Level 2:~CD19CAR-28zeta - 1 x10\^8 cells/m\^2~Dose Level 3:~CD19CAR-28zeta - 2x10\^8 cells/m\^2"
48312823|NCT00586391|DRUG|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
48312824|NCT04010786|DRUG|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
48312825|NCT04010786|DRUG|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
48312826|NCT01975272|DRUG|Ferinject|
48312827|NCT01975272|DRUG|Ferrous fumarate|
48312828|NCT01975272|DRUG|Placebo for ferrous fumarate|
48312829|NCT01975272|DRUG|Placebo for ferinject|
48312830|NCT03740607|DEVICE|Virtual reality|Healthcare virtual reality software implemented during peripheral intravenous catheter placement
48312831|NCT03740607|PROCEDURE|Peripheral intravenous catheter placement|Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
48312832|NCT00319852|BIOLOGICAL|DTaP-IPV combined vaccine|0.5 mL, IM
48312833|NCT00319852|BIOLOGICAL|DTaP vaccine|0.5 mL, IM
48312834|NCT02170805|DRUG|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
48312835|NCT02170805|DRUG|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
48312836|NCT02170805|DRUG|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
48312837|NCT02170805|DRUG|Pantoprazole|Pantoprazole 40 mg
48312838|NCT00791440|BEHAVIORAL|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
48312839|NCT00791440|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
48312840|NCT02140359|BEHAVIORAL|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
48312841|NCT02530606|PROCEDURE|Photoacoustic Imaging|Undergo PAI
48312842|NCT00904826|DRUG|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
48312843|NCT01627067|DRUG|Everolimus|10 mg by mouth once daily.
48312844|NCT01627067|DRUG|Exemestane|25 mg by mouth once daily.
48312845|NCT01627067|DRUG|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
48312846|NCT01223872|OTHER|interview|"* Standard Interview (2-15 years from last treatment)~* Demographic data interview (pre-initial study interview)"
48312847|NCT01223872|OTHER|clinic visit and interview|"* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
48483943|NCT00110344|DRUG|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
48312848|NCT01223872|OTHER|interviews and clinic visit|"* Pre-REACH Clinic Interview(2-15 yrs from last treatment)~* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview(1mo from initial clinic visit)~* Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
48312849|NCT00970528|DRUG|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
48643609|NCT06691763|BEHAVIORAL|Pythagorean Self-Awareness Intervention for stress management and health promotion|Pythagorean Self-Awareness is a holistic stress magement program that combines cognitive reconstruction and the implementation of the 6 pillars of life-style medicine depending on the targeted population.
48266726|NCT00652353|OTHER|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
48312850|NCT00970528|DRUG|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
48312851|NCT04619875|OTHER|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
48312852|NCT04619875|OTHER|SG1|SG1 is a novel glycan
48483944|NCT00378651|PROCEDURE|Neck Auscultation|
48312853|NCT04619875|OTHER|Lactulose|Lactulose is a synthetic dissacharide
48312854|NCT02988466|BIOLOGICAL|Haplo HCT <55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
48312855|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel): Dose reduction by 30%~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion"
48312856|NCT02988466|DRUG|GVHD Prophylaxis|"* Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)"
48312857|NCT02988466|BIOLOGICAL|Haplo HCT ≥55 and < 65 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* non-T-cell depleted donor bone marrow stem cells"
48312858|NCT02988466|BIOLOGICAL|Haplo HCT ≥65 and ≤75 years old|"* Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Total body irradiation (TBI)"
48312859|NCT00649467|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
48312860|NCT00649467|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
48312861|NCT03144583|BIOLOGICAL|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
48483945|NCT03478228|OTHER|Multi-Sensory Training|
48483946|NCT02689245|DRUG|Tenofovir|
48483947|NCT02689245|DRUG|Fecal Microbiota Transplantation (FMT)|
48483948|NCT00384384|DRUG|oral 18B Glycyrrhetinic acid versus placebo|
48483949|NCT00112294|DRUG|Paclitaxel (Taxane)|IV, 225 mg/m\^2
48483950|NCT00112294|DRUG|Docetaxel (Taxane)|IV, 75 mg/m\^2
48483951|NCT00112294|DRUG|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
48483952|NCT00112294|DRUG|Cetuximab|Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2
48643610|NCT06691386|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
48643611|NCT06691386|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
48643612|NCT06691386|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
48643613|NCT06691386|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
48643614|NCT06691386|OTHER|Test Product E|Use of Test Product E in controlled use and ad libitum use sessions
48643615|NCT06691386|OTHER|Reference Product F: Subjects' OBMST|Use of Reference Product F in controlled use and ad libitum use sessions. The subjects' Own Brand Moist Smokeless Tobacco (OBMST) reference products used in this study were commercially available and had been reported by the subjects as the brands they usually consume.
48643616|NCT03898973|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
48114713|NCT01153451|OTHER|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
48266727|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
48312862|NCT01517945|BEHAVIORAL|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~* Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~* Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~* Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~* Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~* Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~* Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
48312863|NCT00582062|OTHER|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
48312864|NCT03279783|DEVICE|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
48483953|NCT00724373|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
48266728|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
48483954|NCT00724373|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
48483955|NCT00266240|DRUG|GK Activator (2)|Escalating doses po bid
48483956|NCT00266240|DRUG|Placebo|po bid
48483957|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
48483958|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
48483959|NCT00455442|DRUG|Mifepristone|
48483960|NCT02463305|DRUG|Creatine monohydrate|21 grams creatine monohydrate total per day
48483961|NCT02463305|OTHER|Placebo|7 grams of dextrose dissolved in 500mL water, taken three times daily
48483962|NCT06417164|BEHAVIORAL|Functional Movement Training Group|The program control group will use traditional physical training methods, while the experimental group will use a training program based on FMS functional movement design. The experimental group will receive a 12-week FMS functional movement training intervention, with each session lasting 40 minutes. The experimental group will be divided into two phases, a corrective intervention phase and a capacity enhancement phase, and the main assessment criteria will include the seven movements of the FMS Functional Movement Test (squat, hurdle step, deep squat, shoulder mobility, active straight leg raise, trunk stabilizing push-ups, and trunk rotational stabilization), as well as the ability to control the body's dynamic and static postures during aerobic exercise.
48312865|NCT00695591|OTHER|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
48312866|NCT02804412|OTHER|Control group|This is the control group with 14 h treatment over 10 workdays.
48312867|NCT02804412|OTHER|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
48312868|NCT02804412|OTHER|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
48312869|NCT03871517|DRUG|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
48312870|NCT03871517|DRUG|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
48312871|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
48312872|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
48312873|NCT01204658|BIOLOGICAL|Synflorix|Intramuscular injection
48312874|NCT01204658|BIOLOGICAL|Prevenar 13|Intramuscular injection
48312875|NCT01204658|BIOLOGICAL|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
48312876|NCT05742672|OTHER|ABDOMINAL MASSAGE APPLICATION|"* Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~* Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~* Routine treatment and care practices in the clinic will continue."
48312877|NCT02391844|DRUG|Oxycodone|Oxycodone with Acetaminophen Extended Release
48312878|NCT02669550|DEVICE|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
48312879|NCT02669550|DEVICE|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
48312880|NCT05489822|DEVICE|VERTICALE® Cervical System|"All measures and devices mentioned in the study protocol correspond to routine clinical practice with the exception of the following questionnaires:~NDI (Neck Disability Index) NRS (Numerical Rating Scale) neck pain (cervical spine) and NRS arm pain mJOA (modified Japanese Orthopaedic Association) Score"
48483963|NCT00279955|DEVICE|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
48483964|NCT06082674|DEVICE|Vayu bCPAP|The Vayu bCPAP uses a constant flow of dry oxygen from the source with an adjustable flow meter. Oxygen is blended by Venturi blender with ambient air to create a source of oxygen-enriched air of adjustable concentration.
48266729|NCT01463813|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
48312881|NCT03200873|DEVICE|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
48312882|NCT04064320|BEHAVIORAL|Lullaby intervention|Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
48483965|NCT06082674|DEVICE|Mechanical Ventilator Driven CPAP|Mechanical Ventilator Driven CPAP
48483966|NCT00868296|DRUG|pantoprazole|
48483967|NCT01972347|DRUG|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
48483968|NCT01972347|DRUG|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
48312883|NCT05700175|DIAGNOSTIC_TEST|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA_MFS_signature).~The obtained TAA_MFS_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
48312884|NCT05284578|OTHER|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
48312885|NCT05284578|OTHER|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
48312886|NCT05284578|OTHER|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
48312887|NCT01220648|DRUG|Nilotinib, interferon-alfa|
48312888|NCT00032968|DRUG|Buprenorphine/naloxone|
48312889|NCT01504854|DRUG|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
48312890|NCT01504854|DRUG|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
48312891|NCT05842564|OTHER|Blood samples|Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
48312892|NCT05842564|OTHER|Biopsies|5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
48312893|NCT04094350|OTHER|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
48312894|NCT04094350|OTHER|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
48312895|NCT04094350|OTHER|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
48643617|NCT06686043|DRUG|HPV vaccine, Imiquimod, and metformin combination therapy|Participants in the treatment arm will have visits during the 2nd and 4th weeks of radiation, and then at weeks 8, 10, 12, and 16 after radiation. At each visit, a blood sample will be taken, and tumor cells collected using a cytobrush (or directly from the tumor for vulvar cancer). An HPV vaccine will be injected into the tumor, imiquimod cream will be applied topically, and participants will receive a subcutaneous vaccine shot. They will also take metformin tablets twice daily for two weeks and apply imiquimod cream at home three nights per week. Follow-up PET/CT scans will occur at week 20 and two years post-treatment, with exams every three months for two years.
48114714|NCT02738372|OTHER|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
48114715|NCT04562636|OTHER|Environmental message|Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.
48114716|NCT04562636|OTHER|Health message|Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.
48114717|NCT04562636|OTHER|Neutral Message|Participants will be randomized to view a set of four messages about checking their credit score.
48312896|NCT04094350|OTHER|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
48312897|NCT02069496|BIOLOGICAL|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
48483969|NCT00963651|DEVICE|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
48643618|NCT06687473|DRUG|Bismuth-based susceptibility-guided treatment|"The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori.~A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens."
48643619|NCT06686810|PROCEDURE|Endoscopic Retrogradade CholangioPancreatography (ERCP)|ERCP is an endoscopic therapeutic procedure to drain the bile ducts in case of stones or biliary strictures that can be treated by balloon dilatation or stents (plastic or metal) insertion
48114718|NCT01535833|PROCEDURE|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
48114719|NCT05568264|OTHER|Physical Therapy intervention|The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
48114720|NCT06120699|OTHER|Pelvic floor muscle training with 360 degree expanded diaphragm exercises|Women in this group will be taught 360-degree expanded diaphragm exercises with the Ohmbelt device. Two Ohmbelt devices will be used in this study. The anterior sensor will be placed in the inguinal cavity to visualize the expansion of the anterior abdominal wall, and the posterior sensor will be placed contralaterally in the upper lumbar triangle to visualize the expansion of the posterior wall. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied.
48114721|NCT06120699|OTHER|Pelvic floor muscle training with standard diaphragm exercises|"Women in this group will be taught standard diaphragm exercises. In the supine position, with the head and knees supported by a pillow, the patient will first be asked to close his or her eyes to focus. With one hand on the chest and the other hand on the abdomen, Take a deep breath through your nose and direct all the air as much as possible under your lower hand. inflate your belly. Now exhale all the air slowly through your mouth. The protocol of breathing exercises is inspiration and expiration time of 6 seconds, 10 repetitions and 3 sets. Pelvic floor muscle training will be given with the NeuroTract Myoplus 4 PRO EMG biofeedback device. The training protocol: Each patient will be asked to contract close to the maximum pelvic floor muscle contraction for slow muscle contraction, maintain the contraction for 6-8 seconds, and then perform fast muscle contractions 3-4 times. This cycle is 1 set, 8-12 repetitions. A total of 3 sets will be applied."
48114722|NCT00006224|DRUG|gemcitabine hydrochloride|
48114723|NCT05516004|DEVICE|PXL Platinum 330 system|to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
48114724|NCT01694823|DRUG|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
48312898|NCT02756650|DRUG|Canakinumab|150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
48312899|NCT02011126|DRUG|Imetelstat Sodium|Given IV
48312900|NCT02011126|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48312901|NCT02733614|DRUG|SRX246|novel V1a receptor antagonist
48312902|NCT02733614|DRUG|Placebo|matching placebo
48483970|NCT04904016|DEVICE|FlowOx™|The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
48483971|NCT02059330|DRUG|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
48483972|NCT02059330|DRUG|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
48483973|NCT02059330|DRUG|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
48114725|NCT02547922|BIOLOGICAL|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
48114726|NCT02547922|DRUG|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
48312903|NCT01188915|PROCEDURE|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
48312904|NCT01938781|DRUG|entecavir|antiviral therapy
48312905|NCT01938781|DRUG|Peg-IFN|antiviral and antifibrosis therapy
48312906|NCT04484779|DEVICE|IIM System|IIM System
48312907|NCT04484779|DRUG|Insulin Lispro and/or Insulin Glargine|Administered subcutaneously (SC)
48312908|NCT02165800|PROCEDURE|L-PANP-TME|
48312909|NCT02165800|PROCEDURE|O-PANP-TME|
48312910|NCT01948284|PROCEDURE|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
48312911|NCT01948284|PROCEDURE|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
48483974|NCT02059330|DRUG|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
48483975|NCT02059330|DRUG|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
48483976|NCT03063424|DIAGNOSTIC_TEST|Eucapnic voluntary hyperventilation|
48483977|NCT03063424|DIAGNOSTIC_TEST|Exercise challenge on a cycle ergometer|
48483978|NCT03104621|DRUG|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
48483979|NCT03104621|DRUG|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
48483980|NCT02584088|OTHER|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
48643620|NCT06395415|BEHAVIORAL|EQUIP|The intervention is delivered directly to participants' mobile phones using the Insight® platform, which allows for the implementation of assessments and interventions. Insight has been used in prior mHealth studies and allows for the delivery of tailored content based on parameters, such as intervention stage. The intervention has two stages: 1) Motivational enhancement (weeks 1-2) and 2) Skills and information (weeks 3-6). The first stage of messages will utilize personalized feedback and motivational interviewing prompts, while the second stage will provide health information on ENDS and skills, such as deep breathing. Content is tailored to motivation level (low/medium or high) and dual use status.
48312912|NCT01948284|DEVICE|Suction Unit|
48312913|NCT05813171|DIETARY_SUPPLEMENT|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
48312914|NCT05813171|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
48312915|NCT02357849|DRUG|Aripiprazole|see arm description
48114727|NCT01764815|DEVICE|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
48114728|NCT04075318|BIOLOGICAL|UB-312|A synthetic peptide-based vaccine
48312916|NCT02357849|DRUG|Fluoxetine|see arm description
48312917|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
48312918|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
48312919|NCT03102944|DIAGNOSTIC_TEST|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
48312920|NCT02202096|OTHER|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
48312921|NCT02202096|OTHER|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
48312922|NCT02202096|OTHER|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
48312923|NCT02202096|OTHER|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
48114729|NCT04075318|BIOLOGICAL|Placebo|Matching placebo
48114730|NCT06612268|DRUG|Etavopivat|Etavopivat will be administered orally.
48114731|NCT06612268|DRUG|Placebo|Placebo matching Etavopivat will be administered orally.
48312924|NCT02202096|OTHER|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
48312925|NCT02202096|OTHER|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
48312926|NCT02202096|OTHER|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
48114732|NCT04802759|DRUG|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
48483981|NCT04818437|OTHER|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
47963878|NCT04851080|BEHAVIORAL|Testing of psycho-physiological functions using four questionnaires|Research of the behavioral time preferences by Composite Scale of Morningness (CSM, Smith C.S., Reilly C., Midkiff K., 1989). Translation into Russian by Kolomeichuk S., May 2015), of the chronotype by Munich ChronoType Questionnaire (MCTQ, Roenneberg T., Merrow M., LMU München, 2006, 2008. Translation into Russian by Putilov A.A., Danilenko K.V., approved by the authors October 2007, updated 2010), of the seasonal pattern by Seasonal Pattern Assessment Questionnaire (SPAQ, Rosenthal N.E., Genhart M., Sack D.A., Skwerer R.G., Wehr T.A., 1987.Translation into Russian by Putilov A.A., Danilenko K.V., Korneeva N.I. 1988, 2002), of the sleep quality by Pittsburgh Sleep Quality Index (PSQI, Russian edition Semenova E.A., Danilenko K.V., October 2009)
48114733|NCT04802759|DRUG|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
48114734|NCT04802759|DRUG|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
48114735|NCT04802759|DRUG|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
48643621|NCT06395415|BEHAVIORAL|Standard Care|Those in the standard advice group will be given offered a sample of NRT, instruction on its use, and will be encouraged to use in conjunction with standard web-based resources on ENDS and cessation over the course of a ten minute walk-through with study staff.
48114736|NCT04802759|DRUG|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
48643622|NCT06290635|DIAGNOSTIC_TEST|Breathlessness Assessment Tool|Participants will complete a breathlessness assessment tool (questionnaire) at three timepoints over the study duration, among other validated questionnaires.
48643623|NCT06356350|OTHER|Conventional neuromuscular exercises|Conventional neuromuscular exercises represent a contemporary physiotherapeutic approach. These exercises aim to improve neuromuscular control, strength, and endurance in various muscles surrounding the included joint, contributing to the correction and maintenance of proper posture.
47963879|NCT00145522|DRUG|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
48114737|NCT04802759|DRUG|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
48114738|NCT04802759|DRUG|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
48114739|NCT04802759|DRUG|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
48643624|NCT06356350|OTHER|Core based exercises|Core based exercises increase overall mobility, relieve pain, improve posture, and support spinal alignment. Especially important for children who are still growing is to slow or stop the progression of deformities because of the asymmetrical loading pattern.
48643625|NCT06496659|PROCEDURE|Segmentectomy|A segmentectomy is a surgical procedure to remove a segment of the lung. This surgery will be done on patients who have completed neoadjuvant therapy for diagnosis of Non-Small Cell Lung Cancer.
48114740|NCT04802759|DRUG|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
48114741|NCT04802759|DRUG|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
48312927|NCT02202096|OTHER|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
48312928|NCT02202096|OTHER|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
48312929|NCT02202096|OTHER|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
48312930|NCT02202096|OTHER|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
48312931|NCT04115696|DEVICE|Percutaneous placement of biodegradable biliary stents|The bening biliary strictures stents used in this register are made of polydioxanone (PPDX) (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography using the standard micropuncture technique. Before stent implantation, balloon bilioplasty may be performed.
48312932|NCT03007953|BEHAVIORAL|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
48312933|NCT04431661|PROCEDURE|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
48312934|NCT04431661|PROCEDURE|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
48483982|NCT04818437|OTHER|CORE STABILITY EXERCISES|"1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
48483983|NCT05114382|PROCEDURE|EP Procedure|Intracardiac signals will be passively recorded using CathVision Cube® System in parallel with the commercial (CE marked) EP recording system during a scheduled electrophysiology procedure
48483984|NCT04818749|DRUG|Saline|Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
48483985|NCT04818749|DRUG|Dexamethasone 12 mg|Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
48483986|NCT04818749|DRUG|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
48483988|NCT01566019|PROCEDURE|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
48483989|NCT01129934|DRUG|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
48483990|NCT01129934|DRUG|morphine|Administration of intravenous morphine 0.1 mg/kg
47963880|NCT00145522|DRUG|Tibolone|2,5 mg/day for 12 cycles of 28 days
48114742|NCT06676891|DRUG|RZ-001|Participants will receive a single intracerebral injection of RZ-001, Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
47963881|NCT06147362|DRUG|68Ga-NOTA-PEG2-RM26|Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
47963882|NCT02295488|PROCEDURE|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
48312935|NCT04431661|PROCEDURE|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
48312936|NCT00408421|DRUG|Duloxetine|
48312937|NCT00408421|DRUG|placebo|
48312938|NCT05362643|OTHER|Acupuncture|Manual acupuncture on acupoint Tai Xi(KI3), bilateral;Sanyinjiao (SP6), bilateral; Zusanli (ST36), bilateral; Shenmen (HT7) unilateral, in the arm without arteriovenous fistula;Guan Yuan (CV4), unilateral, attempt to achieve De qi sensation. After generating needling sensation, needles were manipulated for one minute, every ten minutes during needle retention (20 minutes), using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
48312939|NCT05362643|OTHER|Sham Acupuncture|Manual acupuncture performed as superficial needling (5mm depth) on non-acupuncture points without an attempt to achieve De qi sensation and without stimulation, lasting 20 minutes, using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
48312940|NCT01442740|PROCEDURE|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
48312941|NCT05427071|DEVICE|Magnetic seed localization|Magnetic seed guided localization
48312942|NCT01016106|GENETIC|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
48312943|NCT03223857|PROCEDURE|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
48312944|NCT03072121|DRUG|Shexiang Baoxin pill|Conventional western medicine \& shexiang baoxin pill
48483991|NCT03986450|OTHER|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~1. Preoperative care:~   Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~2. Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
48483992|NCT03708159|DEVICE|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
48312945|NCT03072121|DRUG|SBP placebo|Conventional western medicine \& placebo (for shexiang baoxin pill)
47963883|NCT02295488|BIOLOGICAL|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
48312946|NCT03072121|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
48312947|NCT03072121|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
48312948|NCT03072121|DRUG|Atorvastatin Calcium|10 mg tablet, two tablets each night.
48312949|NCT03072121|DRUG|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
48312950|NCT03072121|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
48312951|NCT03072121|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
48312952|NCT03246217|BEHAVIORAL|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
48312953|NCT03246217|BEHAVIORAL|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
48312954|NCT03246217|BEHAVIORAL|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
48312955|NCT05685641|DIAGNOSTIC_TEST|Histoplasma Urine Antigen Lateral Flow Antigen test|Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease
48312956|NCT05685641|DIAGNOSTIC_TEST|Cryptococcal Lateral Flow Antigen test|Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease
48312957|NCT05685641|DIAGNOSTIC_TEST|Tuberculosis-lipoarabinomannan Lateral Flow Antigen test|Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease
48312958|NCT04056455|DRUG|Mobocertinib|Mobocertinib capsule.
48312959|NCT06454604|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
48312960|NCT01480206|OTHER|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
48312961|NCT01633996|PROCEDURE|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
48312962|NCT02790671|DRUG|DS-8500a|DS-8500a 25mg tablet
48312963|NCT02790671|DRUG|Itraconazole|200mg itraconazole
48114743|NCT05127226|DRUG|ION582|ION582 will be administered by IT injection.
48312964|NCT00262418|DRUG|Administration of ivermectin or permethrin|
48312965|NCT05842070|PROCEDURE|Low-Intensity Egg Freezing Protocol|The low-intensity egg freezing protocol involves fewer ultrasounds, bloodwork and injections, contributing to a lower cost. Otherwise, this protocol does not differ significantly from the other routine high-intensity clinic protocols.
48312966|NCT05842070|PROCEDURE|High-Intensity Egg Freezing Protocol|The high-intensity egg freezing protocol is a routinely used clinic protocol where patients are coming for frequent ultrasounds and bloodwork, as well as more injections, contributing to a higher overall cost for egg-freezing.
48312967|NCT04541212|DIAGNOSTIC_TEST|Cardiac Imaging|Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test
48312968|NCT04541212|OTHER|Data Collection|Collection of retrospective data
48312969|NCT04374110|OTHER|Clinical data|Clinical characteristics from medical records
48312970|NCT01628016|BEHAVIORAL|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
48312971|NCT01768598|OTHER|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
48312972|NCT01768598|OTHER|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
48312973|NCT01768598|OTHER|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
48643626|NCT04460261|OTHER|Functional Inspiratory Muscle Training|Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT. Foundation IMT was applied during the first 4 weeks of training. The participants were asked to sit in a comfortable upright position. Following the foundation IMT, all participants underwent four weeks of functional IMT. Initially, all participants were taught diaphragmatic breathing and activating abdominal wall musculature. Each training session started with warm-up exercises and ended with cool-down exercises. During the loading phase, core stability, dynamic trunk activation and postural control exercises were applied together with IMT.
48114744|NCT00356265|DRUG|Procedure: Regional phenylephrine arterial infusion|
48114745|NCT03168048|OTHER|mobile application|Oncologic therapy support by means of a mobile application
48312974|NCT01768598|OTHER|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
48312975|NCT02104804|DRUG|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
48312976|NCT02104804|DRUG|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
48312977|NCT01294735|DRUG|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
48312978|NCT01294735|DRUG|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
48483993|NCT03708159|OTHER|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
48312979|NCT06530589|OTHER|Tupler's Technique|Patient will wear diastasis rehab splint and will follow Tupler's techniqe protocol for 6 weeks. In the first 2 weeks both elevator and contracting exercises will be performed and after 2 weeks in the 3rd week only contracting exercises will be perform and for these exercises we divide abdomen into 6 floors and will patient have to contract her tummy towards the 3rd to 5th floor in first week, towards the 4th to 5th floor in 2nd week and from 5th to 6th floor in the 3rd week. in the wek 4 to week 6 head lifts will also be started along with contracting exercises from 5th to 6th floor.
48312980|NCT06530589|OTHER|Traditional Exercises|The traditional treatment includes traditional abdominal exercises that patient will be perform for 6 weeks and three times per week with 15 repetitions of each exercise. These exercises includes posterior pelvic tilt' static abdominal contractions', reverse sit up exercise, kegals, russian twist , trunk twist and reverse trunk twist.
48312981|NCT02822339|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
48312982|NCT03270696|DRUG|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
48312983|NCT00819208|BEHAVIORAL|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
48312984|NCT00819208|OTHER|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
48312985|NCT00819208|OTHER|educational intervention|Once at the beginning of the program
48312986|NCT00819208|OTHER|laboratory biomarker analysis|Every 12 months
48312987|NCT00819208|OTHER|questionnaire administration|Every 6 months
48312988|NCT00819208|OTHER|study of socioeconomic and demographic variables|Every 6 months
48312989|NCT00819208|PROCEDURE|fatigue assessment and management|Every 6 months
48312990|NCT00819208|PROCEDURE|quality-of-life assessment|Every 6 months
48312991|NCT00819208|OTHER|Educational Intervention|For Arm 2 just once at beginning of program.
48312992|NCT00819208|OTHER|Fitness testing|Objective fitness testing for both arms
48643627|NCT06484400|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a well-established psychological treatment that focuses on identifying, understanding, and changing negative thinking and behavior patterns. The intervention involves structured sessions where participants are taught strategies to alter detrimental thoughts and behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, CBT will be delivered in 12 one-hour weekly sessions conducted in person and on a one-on-one basis. This intervention is designed to reduce symptoms of depression and anxiety through cognitive restructuring and behavioral adaptations.
47963884|NCT05096793|DIETARY_SUPPLEMENT|beta alanine|On day 1, all participants completed the 6-MRT corresponding to baseline. Then, on days 2 and 3, each participant performed the 6-MRT with 30 mg·kg-1 and 45 mg·kg-1 of BA (low and high-dose trials, respectively). BA was purchased in powder format from a factory specializing in sports supplements. BA was colorless when diluted in water and had a characteristic taste. This format of BA (powder) allowed personalized dosing for each participant. The research team performed the personalized dosing before the application of the treatment. Between the evaluation days, there was 72 hours difference. The 30 mg·kg-1 or 45 mg·kg-1 BA administration was done with a double-blind method. Thus, on day 2, 50% of the sample performed the 6-MRT supplemented with 30 mg·kg-1 BA, while the other 50% performed the 6-MRT with 45 mg·kg-1 BA. On day 3, those participants who completed the 6-MRT with 30 mg·kg-1 BA now performed with 45 mg·kg-1 BA and vice versa.
48643628|NCT06484400|BEHAVIORAL|Ericksonian Hypnotehrapy|Ericksonian Hypnotherapy is a form of psychotherapy using clinical hypnosis and indirect suggestion to modify unconscious behaviors and thought patterns. Named after Dr. Milton H. Erickson, this therapeutic approach emphasizes adaptability and utilizes the patient's own experiences and internal resources for healing. The therapy is known for its effectiveness in addressing anxiety and depression by encouraging flexibility in perception and behavior. Like CBT, this intervention will be administered over 12 one-hour sessions, each conducted in person and tailored to the individual's unique psychological landscape.
48643629|NCT03136094|BEHAVIORAL|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
47963885|NCT02356575|OTHER|Acupuncture|
47963886|NCT02356575|OTHER|Cognitive Behavior Therapy|
47963887|NCT00345839|DRUG|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
48483994|NCT04960319|DEVICE|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
48312993|NCT05537948|DRUG|Pitavastatin|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months."
48483995|NCT04882982|BEHAVIORAL|Caria app|App to improve symptoms of menopause
47963888|NCT00345839|DRUG|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
47963889|NCT00043901|DRUG|lamotrigine|
48114746|NCT06675994|DRUG|PCSK9 Antibody, PCSK9 Enzyme|In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
48114747|NCT06677476|OTHER|mobile application training|Researchers compiled literature information and used their expertise to create mobile application content. This content will be downloaded to mobile phones via mobile application software and participants will be trained.
48114748|NCT06384547|DRUG|VRDN-001 10 mg/kg|5 infusions of VRDN-001 10 mg/kg
48483996|NCT04882982|BEHAVIORAL|Menopause Education|Educational materials about symptoms of menopause
48483997|NCT05187611|DEVICE|Conduction system pacing|Lead placed in the His-Purkinje system in order to achieve QRS shortening.
48483998|NCT05187611|DEVICE|Biventricular pacing|Lead is placed in a tributary of the coronary sinus.
48483999|NCT06418425|BEHAVIORAL|counselling on home-based exercise program and dietary protein intake|Participants in the intervention group will be on a home-based exercise program and go through counselling on dietary protein intake with the aim of achieving prevention of frailty status. Participants will be required to attend the 3 study visits throughout the study period. Research procedures include physical measurements (eg. Weight, height, waist and hip circumference, calf circumference, hand grip strength, blood pressure, short physical performance battery tests), administration of questionnaires on sociodemographics, physical activity, dietary habits, smoking, alcohol, health conditions, health-related quality of life, clinical frailty status and sarcopenia screening. At three months and twelve months, the intervention group participants will see the care coordinators who will check their compliance to the exercise programme and high protein diet, reinforce the interventions.
48643630|NCT03136094|BEHAVIORAL|SBIRT+Usual Care|Patients receive usual SBIRT care
48643631|NCT06690424|DRUG|Remimazolam|remimazolam 0.2mg / kg was injected IV during the induction of anesthesia，and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.
48643632|NCT06690424|DRUG|Propofol|Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia，and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.
48643633|NCT04960943|DRUG|Pyrotinib with or without trastuzumab|After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
48643634|NCT02096159|DRUG|trimethoprim-sulfamethoxazole|
48643635|NCT02096159|OTHER|placebo|
48643636|NCT04255563|DEVICE|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
48114749|NCT06384547|DRUG|VRDN-001 3 mg/kg|5 infusions of VRDN-001 3 mg/kg
47963890|NCT03928119|BEHAVIORAL|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
48312994|NCT05537948|DRUG|PCSK9 inhibitor|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months."
48312995|NCT04953650|BEHAVIORAL|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
48312996|NCT04953650|OTHER|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
48312997|NCT01192217|PROCEDURE|Modified thoracoscopic technique|Two-port thoracoscopic technique
48114750|NCT05849233|OTHER|no intervention|no intervention
48312998|NCT01192217|PROCEDURE|Axillary mini-thoracotomy|Axillary mini-thoracotomy
48312999|NCT04818814|BEHAVIORAL|Mindfulness Meditation App|Listening to audio-guided meditation sessions using a mobile app.
48313000|NCT04818814|BEHAVIORAL|Engagement and Distraction App|Listening to engaging and distracting videos of interest to the participant using a mobile app.
48313001|NCT05834803|PROCEDURE|Renal artery stenting|Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.
48313002|NCT05834803|PROCEDURE|Sham treatment|Optimal medical therapy and sham treatment.
48313003|NCT03948659|PROCEDURE|Arterio ventricular coupling|We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
48313004|NCT06496321|PROCEDURE|Conventional Saphenous vein harvest|The conventional one involves harvesting only the vein, without perivascular tissue or the nerve.
48313005|NCT06496321|PROCEDURE|No touch Saphenous vein harvest|"During the extraction of the saphenous vein using the no touch technique, it is sectioned with the perivascular adipose tissue and the saphenous nerve of the leg."
48313006|NCT00540553|DRUG|placebo|
48313007|NCT00540553|DRUG|GSK971086|
48313008|NCT06553378|OTHER|Geriatric Oncology Supportive Clinic|Subjects in the intervention arm will be seen within four weeks of recruitment. Clinical assessment involves a Comprehensive Geriatric Assessment (CGA) and Supportive Care Assessment conducted by a geriatric-oncologist. Both clinical assessments and targeted interventions are supported by a multi-disciplinary team comprising the geriatrician, geriatric trained nurse, physiotherapist, occupational therapist, speech therapist, pharmacist, dietician, and medical social worker. We will conduct an initial GOSC assessment, with a follow up review during oncology treatment. Subsequently, further GOSC clinic sessions duration of follow up will be determined by the subject's underlying disease, symptom burden and clinical course during treatment.
48313009|NCT04175704|DRUG|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
48313010|NCT02112994|DRUG|Sebelipase Alfa|IV infusion of sebelipase alfa
48313011|NCT02916030|DIETARY_SUPPLEMENT|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
48313012|NCT00295698|DRUG|Diethylcarbamazine|
48484000|NCT00227331|DRUG|Oral amoxicillin|
48114751|NCT05432934|DRUG|Dexamethasone|Dexamethasone will be added to local anesthetic solution and injected at 4 site for for laparoscopically placed TAP blocks.
48114752|NCT04364594|DIAGNOSTIC_TEST|conjunctival swab|analysis of conjunctival cells (real time PCR) collected by conjunctival swabs in both eyes
48266730|NCT04373460|BIOLOGICAL|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
48313013|NCT04586868|BEHAVIORAL|An intervention development study|Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
48484001|NCT05342649|PROCEDURE|P-CTG|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
48313014|NCT04586868|BEHAVIORAL|A randomized feasibility study|Feasibility of virtual reality environment for adolescents with psychosis
48313015|NCT04586868|BEHAVIORAL|A single-case study|The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
48313016|NCT01871896|DEVICE|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
48313017|NCT04146467|DEVICE|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
48313018|NCT02745223|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
48313019|NCT02745223|DRUG|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
47963891|NCT05454098|DRUG|Clifutinib with fed state|40 mg Clifutinib with food
47963892|NCT05454098|DRUG|Clifutinib with fasted state|40 mg Clifutinib without food
47963893|NCT06558227|BIOLOGICAL|ZG005 for Injection|10 mg/kg or 20 mg/kg administered intravenously Q3w
47963894|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
48266731|NCT04373460|BIOLOGICAL|Plasma from a volunteer donor|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
47963895|NCT06558227|BIOLOGICAL|Sintilimab|200 mg administered intravenously Q3w
47963896|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
48313020|NCT05256069|DRUG|Propranolol Pill|Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
48643637|NCT06674265|BIOLOGICAL|Allogenic NK cells infusion|Natural Killer (NK) cells are extracted from a healthy donor through apheresis and processed in a clean room using the CLINIMACS device. After quality assessment, these cells are stored at -198°C until needed. When required, the cells are thawed, washed, and evaluated for viability and sterility before being administered to the patient at a dosage of 5 × 10\^6 cells per kilogram of body weight. Two further injections may be considered based on the patient's response and confirmed improvement via MRI MIBG. Injections are scheduled seven to ten days after each chemotherapy course according to the standard treatment protocol.
48643638|NCT04711889|DRUG|Ulinastatin|Ulinastatin is taken three times a day.
47963897|NCT00283452|BEHAVIORAL|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
47963898|NCT03868046|DRUG|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
47963899|NCT03868046|DIAGNOSTIC_TEST|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
47963900|NCT02697864|DRUG|tafamidis|
47963901|NCT06383078|DRUG|HR070803|HR070803 60 mg/\^2 D1 over 90 minutes.
47963902|NCT06383078|DRUG|Oxaliplatin|Oxaliplatin 85 mg/\^2 D1 over 2 hours.
47963903|NCT06383078|DRUG|Tegafur|initial dose of S-1 is determined according to the body surface area，orally, D1-7.
47963904|NCT06383078|DRUG|Folinic acid|Folinic acid 400 mg/\^2 D1
47963905|NCT06383078|DRUG|5-Fluorouracil|5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
48266732|NCT01864408|OTHER|"Usual practice counseling"|
48313021|NCT05256069|DRUG|Placebo|Participants will receive a placebo in pill form.
48313022|NCT03742401|PROCEDURE|Surgery|Traditional open excisional surgery
48313023|NCT03742401|DEVICE|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
48313024|NCT02306707|PROCEDURE|Endoscopic Mucosal Resection|
48313025|NCT05280431|DEVICE|AGREE exoskeleton|"Upper limb exoskeleton with four actuated degrees of freedom (shoulder horizontal adduction/abduction, shoulder flexion/extension, humeral rotation, elbow flexion/extension), and one passive degree of freedom (wrist pronation/supination), implementing different rehabilitative strategies.~The intervention consists of the execution of different exercises with the affected arm supported by the AGREE device. The subject is actively involved in the exercises and the system provides different kinds of assistance that can be tailored according to the patient's status.~The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects (on a plane or in the space)~* exergames.~A subset of exercises is defined based on the patient's capability."
48484002|NCT05342649|PROCEDURE|CTG|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
48484003|NCT06094049|OTHER|Preference test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
48643639|NCT04711889|DRUG|Blank control|Blank control
48643640|NCT01950390|BIOLOGICAL|Bevacizumab|Given IV
48643641|NCT01950390|BIOLOGICAL|Ipilimumab|Given IV
47963906|NCT04051866|PROCEDURE|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
47963907|NCT04051866|OTHER|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
47963908|NCT05958667|BEHAVIORAL|Quitxt text messaging or Chat|Mobile intervention using proven social cognitive, motivational interviewing, and brief intervention methods for promoting behavior change - blends bilingual text and social media messaging for smoking cessation tailored to the language and culture of young adult smokers in our vulnerable region of South Texas.
47963909|NCT05958667|OTHER|Usual care|Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit.
48266733|NCT01864408|OTHER|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
48643642|NCT03612583|PROCEDURE|Lung- and Diaphragm-Protective Ventilation|Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
48266734|NCT02244151|DRUG|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
48643643|NCT06687317|OTHER|Behavioral|KNAP
48643644|NCT06690879|DEVICE|Smartphone application AI Posture Evaluation and Correction System (APECS)|Mobile application APECS v. 6.2.0. is used to assess upper body posture during standing from back side and right side.
48643645|NCT06690112|PROCEDURE|Arm I (Removal of drainage)|During gastrectomy, a drainage tube is placed within the abdominal cavity. In Arm I (the intervention group), the drainage tube will be removed at the bedside. This procedure is a simple intervention that does not require local anesthesia and involves the removal of the drainage tube by cutting the nylon suture.
48643646|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Groin Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
48643647|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Conventional Multiple Access Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
48643648|NCT06690411|OTHER|Mulligan Concept|The participants of the Mulligan SNAG group will undergo the Mulligan SNAG technique. Mulligan's SNAG technique is a gentle manual therapy method. This technique is based on the correction of the joint position. There are 3 techniques specified for headache; Headache SNAG, Reverse Headache SNAG, and C1-C2 SNAG.
48643649|NCT06690411|OTHER|Myofascial Release Technique|Myofascial therapy can be described as massage-type manual therapy. The participants of the Myofascial Release Group will undergo the myofascial release technique.
48643650|NCT06520553|DRUG|BI 1569912 (C-14)|unlabelled BI 1569912 mixed with \[14C\]- labelled BI 1569912
48643651|NCT06520553|DRUG|BI 1569912 (C-13)|\[13C\]- labelled BI 1569912
48643652|NCT06088563|OTHER|Vaccine injection|Injection of the vaccine in renal transplant patients.
48643653|NCT06686719|OTHER|Post Facilitation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed to mid- range. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 30 % of the strength for 15 seconds by attempting to push the leg back toward the therapist and relax. The therapist then passively stretched the muscle until a mild stretch sensation was reported. The stretch was held for another 10 seconds. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
48643654|NCT06686719|OTHER|Post Isometric Relaxation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 25 % of the strength for 7-10 seconds by attempting to push the leg back toward the therapist and relax.After relaxation, the therapist further extends the knee for 3 to 5 seconds.. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
48643655|NCT06686719|OTHER|Myofascial Release|"MFR for Hamstring muscle will be given with patient in prone position with 120 second hold. For giving the MFR, the thumb of the therapist will be allowed to sink in to the central portion of the hamstring. It will held for 120 seconds to allow the tissue to soften and then myofascial structures will spread in a lateral direction until feeling of first fascial barrier. MFR will be performed for 15 mins.~Stretching of the hip adductors, hip flexors and plantar flexors. Functional training includes kneeling, bridging and sit to stand."
48643656|NCT06687512|OTHER|SaaTwae Bio-Natural Moisturizing Cream|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
48643657|NCT06687512|OTHER|Placebo|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
48643658|NCT06688500|PROCEDURE|Bowel function post Holmium Laser Enucleation of the Prostate|Observing post operative bowel functions among participants who have undergone a HoLEP procedure.
48643659|NCT06688643|DEVICE|ITM group|Patients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
48643660|NCT06688643|DEVICE|EA group|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
48643661|NCT03289195|PROCEDURE|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
48643662|NCT06687564|PROCEDURE|Biopsy|A skin biopsy and a blood sample will be taken to culture the iPS cells and intestinal organoids.
48643663|NCT00310180|DRUG|Anastrozole|Given PO
48643664|NCT00310180|DRUG|Exemestane|Given PO
48643665|NCT00310180|OTHER|Laboratory Biomarker Analysis|Correlative studies
48643666|NCT00310180|DRUG|Letrozole|Given PO
48643667|NCT00310180|OTHER|Quality-of-Life Assessment|Ancillary studies
48643668|NCT00310180|RADIATION|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
48643669|NCT00310180|DRUG|Tamoxifen Citrate|Given PO
47963910|NCT02615314|PROCEDURE|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
47963911|NCT04099147|OTHER|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
48266735|NCT02244151|DRUG|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
48484004|NCT06094049|OTHER|Triangle test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
48643670|NCT05950438|PROCEDURE|Esophagectomy|Esophagectomy is a complex surgical procedure performed to treat various esophageal disorders. The surgery involves the removal of all or part of the esophagus and reconstruction using other parts of the gastrointestinal tract.
48643671|NCT03807648|OTHER|Data Inclusion|Patients in this group will be included in the project
48643672|NCT03377998|OTHER|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
48114753|NCT06611839|DRUG|Ivosidenib,venetoclax,azacytidine,cytarabine|"phase I:Induction therapy：Ivosidenib 、Venetoclax、Cytarabine 、DNR or IDA~Dose climbing stage: adopt the 3 + 3 design principle, and the dose 0 group is set as follows~dose level 0: Ivosidenib 500mg d1-28 Venetoclax 100mg d-2，200mg d-1，400mg d1-7 Cytarabine 100mg/m2/d, d1-7 DNR 60mg/m2/d，d1-3 or IDA 12mg/m2/d，d1-3~dose level -1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-2，200mg d-1，400mg d1-7 Cytarabine 100mg/m2/d, d1-5 DNR 60mg/m2/d，d1-2 or IDA 12mg/m2/d，d1-2~dose level 1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1 800mg d1-7 Cytarabine 100mg/m2/d, d1-7 DNR 60mg/m2/d，d1-3 or IDA 12mg/m2/d，d1-3~Consolidation therapy intermediate-dose cytarabine regimen ： 3 courses~If IDH1 mutant residual disease was positive before consolidation chemotherapy, Ivosidenib was added;~Maintenance treatment:~Azacytidine、Venetoclax 、Ivosidenib： 6 courses~phase II: dose based on phase I results"
48313026|NCT05280431|DEVICE|FEXO exoskeleton|After patient's preparation (tDCS and FES) the FEXO assessment is conducted. The subject performs FEXO assessment games. This stage is also used to calibrate the reach and grasp movement intention EEG patterns. The movement is recorded using internal kinematic sensors; therefore, these measures can be extracted for both reaching and lifting movements. Trunk forward bending is measured to avoid compensatory movements when doing reaching assessment. The clinician then reviews the plan for today's session: game selection, number of repetitions and assistance levels. The patient gets ready to play the games and the clinician starts the first activity of the active stage of FEXO therapy. The patient plays the game and sees his own results. The clinician monitors patient activity, assistance levels, effort and signs of discomfort. The patient plays the next game and sees his own results, and the clinician checks the patient's progress with the results overview.
48313027|NCT05280431|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Occupational therapy exercises~* Constraint-induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training"
48313028|NCT03506399|DRUG|Lanabecestat|Administered orally
48313029|NCT03506399|DRUG|Oral Contraceptive|Administered orally
48313030|NCT01795222|DRUG|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
48114754|NCT02828254|DRUG|PRI-724|
48114755|NCT02135042|DRUG|Cisplatin|Given IV
48114756|NCT02135042|OTHER|Clinical Observation|Undergo clinical observation
48313031|NCT01795222|DRUG|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
48114757|NCT02135042|DRUG|Fluorouracil|Given IV
48484005|NCT05127694|OTHER|Vestibular Rehabilitation|Vestibular Rehabilitation which is consist of repetitive exercises and canalit repositioning maneuvers
48313032|NCT04813848|PROCEDURE|Application of varnish fluoride desensitizing agent on buccal surfaces of exposed dentin|"Varnish fluoride is a single dose transparent varnish with 5 % sodium fluoride (22.600 ppm fluoride) and 5 % calcium fluoride.~The application was performed according to the manufacturer's instructions. The varnish was applied on a clean and dry surface, then after 10-20 seconds to allow the fluoride varnish to be absorbed, was then dried with air."
48313033|NCT04813848|PROCEDURE|Application of bonding agent desensitizing agent on buccal surfaces of exposed dentin|Bonding agent is a single dose dual curing universal adhesive and its application was performed according to the manufacturer's instruction for cases with hypersensitive tooth necks. The bonding was applied without etching, on a clean and dry surface. After 10 s any excess material was removed and then light cured for 30 s.
48313034|NCT04699903|DIAGNOSTIC_TEST|POC SARS-Cov-2 IgG Antibody test|All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood
48313035|NCT03011034|DRUG|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
48313036|NCT03011034|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
48313037|NCT00660504|DRUG|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
48643673|NCT06214520|BEHAVIORAL|App-based Motivational Interviewing & Human health coaching|"Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.~App-based Motivational Interviewing \& Human health coaching:~The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call."
48643674|NCT06214520|BEHAVIORAL|Empower+ App & Smartwatch wearable tracker|Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.
48643675|NCT06687161|DEVICE|Transcranial Magnetic Stimulation (TMS) therapy|Each treatment consists of 600 TMS pulses (\~3 minutes) applied to the L-DLPFC
48643676|NCT06687161|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|9-week fully-automated, Internet-delivered CBT-I program: SHUTi OASIS (Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness)
48313038|NCT00660504|DRUG|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
48643677|NCT03649178|OTHER|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
48643678|NCT06674616|OTHER|Replicating Effective Programs|Replicating Effective Programs (REP), based on Social Learning Theory and Rogers' Diffusion of Innovations, incorporates program packaging, training, and technical support
48643679|NCT06674616|OTHER|Coaching|Coaching is based on the Positive Behavior Interventions and Supports model, addresses staff barriers by building implementers' evidence-based practice (EBP) knowledge, self-efficacy, and skills through clinical support and feedback.
48643680|NCT06674616|OTHER|Facilitation|Facilitation addresses potential organizational barriers to delivery, including leadership support and acceptance among other staff.
48643681|NCT01671774|DRUG|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
47963912|NCT02521545|DRUG|BIIB061|Capsule
47963913|NCT03822078|DRUG|Placebo|Administered by subcutaneous injection
48643682|NCT01671774|DRUG|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
48643683|NCT01671774|DRUG|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
48313039|NCT05390814|DRUG|PET-MRI|\[18F\]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
47963914|NCT03822078|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
47963915|NCT00592930|DRUG|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
48114758|NCT02135042|DRUG|Gemcitabine Hydrochloride|Given IV
48114759|NCT02135042|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48643684|NCT01671774|DRUG|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
48313040|NCT05737173|DRUG|Leukocyte-rich platelet-rich plasma|Intra-articular knee injection
48643685|NCT04448912|PROCEDURE|Damage control surgery|Surgery for non-traumatic abdominal emergencies using the damage control approach
47963916|NCT00592930|DRUG|placebo|
48643686|NCT04448912|PROCEDURE|Conventional surgery|Conventional surgery for non-traumatic abdominal emergencies
48643687|NCT06690086|PROCEDURE|Lesion biopsy|Lesions enrolled in the study are biopsied to confirm histopathology
47963917|NCT04957004|DEVICE|CPAP|CPAP ventilator was worn at nigh
47963918|NCT04205968|DRUG|Fluorouracil|Given IV bolus or IV
47963919|NCT04205968|DRUG|Irinotecan|Given IV
47963920|NCT04205968|DRUG|Irinotecan Hydrochloride|Given IV
47963921|NCT04205968|DRUG|Leucovorin|Given IV
47963922|NCT04205968|DRUG|Leucovorin Calcium|Given IV
47963923|NCT04205968|DRUG|Paclitaxel|Given IV
47963924|NCT04205968|BIOLOGICAL|Ramucirumab|Given IV
47963925|NCT02621697|OTHER|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
47963926|NCT02621697|OTHER|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
47963927|NCT02012101|DEVICE|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
47963928|NCT02012101|DEVICE|oxygen therapy|
48114760|NCT02135042|OTHER|Laboratory Biomarker Analysis|Correlative studies
48114761|NCT02135042|DRUG|Paclitaxel|Given IV
48114762|NCT02135042|OTHER|Quality-of-Life Assessment|Ancillary studies
48114763|NCT06261372|BEHAVIORAL|The mindfulness meditation combined with progressive muscle relaxation training .|The first part is progressive muscle relaxation training. The second part is mindfulness meditation training.
48266736|NCT06415721|DEVICE|Active Transcranial Magnetic Simulation|1 session of active continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. TMS will be delivered using the Magventure MagPro X100.
48313041|NCT05737173|DRUG|Leukocyte-poor platelet-rich plasma|Intra-articular knee injection
48313042|NCT05737173|DRUG|Corticosteroid|Intra-articular knee injection
48313043|NCT02375633|DRUG|DW-330SR2|
48313044|NCT02375633|DRUG|Pelubiprofen|
47963929|NCT02398760|OTHER|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
47963930|NCT01269463|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
48313045|NCT02047513|DRUG|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
48313046|NCT02047513|DRUG|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
48313047|NCT05763342|DEVICE|The Phoenix Research System|Focused Multipolar Stimulation (FMS) strategy in adult cochlear implant recipients.
48313048|NCT04005898|DEVICE|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
48313049|NCT04901065|DRUG|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
48643688|NCT06690086|DEVICE|DermaSensor Device Use|Users are blinded to the DermaSensor Device result
48643689|NCT06688812|OTHER|Perceptual Motor Training|"8 set of exercises~1. Balance training and related exercises~2. Tones of awareness training, body parts' role and related exercises~3. Space awareness training and related exercises~4. Perception of shape training and related exercises~5. Visual perception training and related exercise.~6. Kinesthetic-tactile perception training and related exercises~7. Auditory perception training and related exercises~8. Eye and hand coordination, ﬁne motor movements and related Exercises"
48643690|NCT06688812|OTHER|Repetitive Facilitation Exercises|"Eight set of exercises:~1. Shoulder Flexion with 90° Elbow Flexion (Supine).~2. Shoulder Horizontal Extension/Flexion with Elbow flexion (supine).~3. Complex Shoulder and Upper Limb Movements (Supine)~4. Shoulder Flexion/Abduction/External Rotation with Elbow and Forearm Supination (Supine)~5. Forearm Supination/Pronation with 90° Elbow Flexion (Sitting)~6. Wrist Extension and Forearm Pronation with Finger Extension (Supine)~7. Finger Extension with Wrist Flexion (Supine)~8. Finger Extension/Flexion with Wrist Flexion (Sitting) • Therapist facilitate the movement by rubbing, tapping and gentle stretching."
48643691|NCT06690333|DEVICE|Pacemaker|Transvenous pacemaker with left bundle area pacing
48643692|NCT06690333|DEVICE|Pacemaker|Transcatheter pacemaker with MICRA AV
47963931|NCT01269463|DRUG|Placebo|Capsule without active drug
47963932|NCT02586129|DRUG|YH14755|20/1500mg, QD
47963933|NCT02586129|DRUG|Metformin|1500mg, QD
47963934|NCT02586129|DRUG|Rosuvastatin|20mg, QD
47963935|NCT00060008|RADIATION|fludeoxyglucose F 18|
48313050|NCT04901065|DRUG|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
48313051|NCT05529940|DRUG|Folfirinox|The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
48313052|NCT03265509|DIETARY_SUPPLEMENT|glutamine supplementation|30 g/day glutamine supplementation for three months
48313053|NCT03265509|DIETARY_SUPPLEMENT|fantomalt supplementation|30 g/day fantomalt supplementation for three months
48313054|NCT02128763|DRUG|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
48313055|NCT02128763|DRUG|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
48313056|NCT03503149|OTHER|no intervention|observational study
48313057|NCT00207766|DRUG|infliximab or placebo|
48313058|NCT00267332|DRUG|Modafinil|
48313059|NCT02037802|DEVICE|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
48643693|NCT04939363|COMBINATION_PRODUCT|Obinutuzumab with Ibrutinib and Venetoclax|"1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:"
48643694|NCT06689683|DEVICE|Shock wave lithotripsy|SWL works on the principle of focusing on the calculus using fluoroscopy. There has yet to be a consensus on the optimal frequency of fluoroscopic monitoring in the literature.
48643695|NCT06686147|DIAGNOSTIC_TEST|Assessment of Joint Range of Motion|Joint range of motion (ROM) measurements will be conducted to assess the specific ranges of motion of participants' joints.
47963936|NCT00060008|RADIATION|gadopentetate dimeglumine|
47963937|NCT00814164|DRUG|clofarabine|IV
47963938|NCT00814164|DRUG|daunorubicin hydrochloride|IV
47963939|NCT00814164|GENETIC|cytogenetic analysis|Correlative study
47963940|NCT00814164|GENETIC|protein expression analysis|Correlative Study
47963941|NCT00814164|OTHER|immunologic technique|Correlative Study
47963942|NCT00814164|OTHER|pharmacological study|Correlative Study
47963943|NCT00156052|RADIATION|Conventional whole breast radiation schedule|
47963944|NCT00156052|RADIATION|Hypofractionated whole breast radiation schedule|
47963945|NCT00935363|DRUG|glyburide|single oral dose
47963946|NCT00935363|DRUG|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
47963947|NCT00935363|DRUG|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
47963948|NCT00935363|DRUG|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
48313060|NCT02037802|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
48313061|NCT02037802|DRUG|Propofol|fentanyl propofol atracurium besylate
48313062|NCT02037802|DRUG|Bupivacaine|
47963949|NCT04489628|DRUG|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
47963950|NCT04489628|DEVICE|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
48313063|NCT02037802|DRUG|Fentanyl|
48313064|NCT04091282|OTHER|No intervention|No intervention
48313065|NCT01201798|DRUG|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
48313066|NCT01201798|DRUG|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
48313067|NCT06553274|PROCEDURE|Individualized nutrition intervention|"After the patients were enrolled, they were given nutritional assessment by full-time clinical nutritionist and designed individualized nutritional management program, which included: Nutritional Assessment once a week for 4 weeks after Transplantation + 30 days, and nutritional assessment once a week for 4 weeks after Transplantation + 60 days, nutritional assessment every 2 weeks for 8 weeks; nutritional assessment every 4 weeks for 1 year after Transplantation + 120 days after transplantation; nutritional assessment during hospitalization in the ward and after discharge from the hospital, they were followed up in the nutrition counseling clinic or by telephone. The total energy intake was 25-35 kcal/kg/d and the protein intake was 1.2-1.5 g/kg/d. According to theFive-step nutritional treatment principle, individual nutritional prescriptions were designed by clinical nutritionists."
48313068|NCT03614442|OTHER|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
48313069|NCT01068041|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
48313070|NCT03790462|OTHER|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected."
48643696|NCT06686667|BEHAVIORAL|Time Restricted Eating|The intervention arm will consist of a time-restricted eating protocol with fasting between 11:00 PM to 6:00 AM. Ad libitum eating will be allowed outside these times and the protocol will be administered during day and night shifts over a 2 week period.
48313071|NCT02001116|OTHER|Quality Improvement intervention|"1. Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~2. Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
47963951|NCT04489433|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
47963952|NCT04489433|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
47963953|NCT04489433|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
48313072|NCT03696264|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
48484006|NCT03267420|DIAGNOSTIC_TEST|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
48313073|NCT05528003|PROCEDURE|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
48313074|NCT01807715|OTHER|survey|Survey before procedure to obtain demographic information and contraceptive information
48313075|NCT00077337|DRUG|romidepsin|
48313076|NCT01488825|BEHAVIORAL|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
48313077|NCT00004285|DEVICE|Standard dose, low flux hemodialysis|
48313078|NCT00004285|DEVICE|Standard dose, high flux hemodialysis|
48313079|NCT00004285|DEVICE|High dose, low flux hemodialysis|
48313080|NCT00004285|DEVICE|High dose, high flux hemodialysis|
48313081|NCT06370936|OTHER|Standardized diet with commercially available animal meats (comparator products)|Fully controlled standardized diet with commercially available meats from animal origin. Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
48313082|NCT06370936|OTHER|Standardized diet with commercially available PBMAs (intervention products)|Fully controlled standardized diet with commercially available Plant-Based Meat Analogues (PBMAs). Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
48313083|NCT01094002|OTHER|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
48313084|NCT00563836|DRUG|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
48313085|NCT01743963|BEHAVIORAL|Decision support|Clinical pharmacists mediated computerized decision support
48313086|NCT01743963|BEHAVIORAL|Usual Care|clinicians typical apporach for GID monitering
47963954|NCT04600375|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
48114764|NCT05471414|BEHAVIORAL|Whole-food, Plant-Based Diet|Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.
48313087|NCT02405052|OTHER|No intervention|Validation of the Panic Screening Score
48313088|NCT04069793|DEVICE|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
48643697|NCT06691620|PROCEDURE|Nasal irrigation with isotonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of isotonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
48313089|NCT04069793|DEVICE|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
48313090|NCT06063408|BEHAVIORAL|Cognitive Functional Therapy|"Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change."
48313091|NCT06063408|BEHAVIORAL|Conventional Therapy|Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
48313092|NCT04435262|OTHER|Remote Monitoring|Remote Monitoring Follow-up
48313093|NCT05841550|BIOLOGICAL|TG01|All participants will receive the same treatment as described under arm
48313094|NCT01842308|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
48313095|NCT01842308|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
48313096|NCT01842308|DRUG|Carfilzomib|Given IV
48313097|NCT01842308|OTHER|Laboratory Biomarker Analysis|Correlative studies
47963955|NCT04600375|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
47963956|NCT00303732|DRUG|RAD001 (everolimus)|
47963957|NCT00303732|DRUG|PTK787 (vatalanib)|
47963958|NCT01637935|DRUG|Pioglitazone|Pioglitazone tablets.
47963959|NCT05987228|DIETARY_SUPPLEMENT|Thymus vulgaris|500 mg of Thymus vulgaris (capsules) was given orally twice daily
47963960|NCT02537119|PROCEDURE|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
47963961|NCT02537119|PROCEDURE|Massage therapy|Rubbing on hamstrings
47963962|NCT05678933|DRUG|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
47963963|NCT05678933|DRUG|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
47963964|NCT05678933|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
48313098|NCT01842308|DRUG|Melphalan|Given IV
48313099|NCT05701969|DIETARY_SUPPLEMENT|Melatonin|Melatonin
48313100|NCT05701969|OTHER|Placebo|Placebo control
48313101|NCT05170659|DRUG|Relatlimab|
48313102|NCT01620385|DEVICE|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
48313103|NCT04288726|BIOLOGICAL|CD30.CAR-EBVST cells|"The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 108 cells/m2 and we did not reach an MTD. We will be splitting the total dose between 2 infusions three days apart to improve tumor exposure to CAR-T cells.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Days 0 and 3 ±1 of study, patients will receive half their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL."
48313104|NCT02399839|DRUG|lomitapide|As prescribed by Physician.
48313105|NCT05745324|PROCEDURE|Scaling and root planing|SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
48313106|NCT01438567|DRUG|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
48313107|NCT01438567|DRUG|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
48313108|NCT06254352|DIAGNOSTIC_TEST|scoring system|Clinical Risk Scores in Prediction of Outcome of Acute Upper Gastrointestinal Bleeding in Non Cirrhotic Patients.
48313109|NCT01512641|OTHER|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
48114765|NCT05471414|BEHAVIORAL|General Nutritional Counseling|"All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls."
48114766|NCT06475508|BIOLOGICAL|Complarate®|The investigational drug Complarate® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
48313110|NCT01512641|OTHER|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
48313111|NCT01725152|DRUG|Ganaxolone|oral suspension, given in 3 divided doses
48313112|NCT01725152|DRUG|Placebo|oral suspension, given in 3 divided doses
48313113|NCT02481726|RADIATION|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
48313114|NCT04612062|DRUG|CEE321|CEE321 administered to all subjects
48313115|NCT02390115|OTHER|Elastic tape application in shoulder|
48313116|NCT02515617|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
48313117|NCT02515617|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
48313118|NCT03555851|DRUG|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
48313119|NCT03555851|OTHER|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
48114767|NCT06475508|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
48313120|NCT01980108|OTHER|water|water
48313121|NCT01680588|DRUG|[18F]NAV4694|
48643698|NCT06691620|PROCEDURE|Nasal irrigation with hypertonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of hypertonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
48313122|NCT01082718|DRUG|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
48313123|NCT04721236|OTHER|hyperimmune plasma|plasma collected from convalescent Covid-19 donors with titre 1:80 or more
48313124|NCT00330655|DRUG|memantine|
48313125|NCT01053845|OTHER|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
48313126|NCT04905537|OTHER|No intervention|It's only observational study. No interventions.
48313127|NCT01952834|DIETARY_SUPPLEMENT|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
48313128|NCT01952834|DRUG|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
48313129|NCT01005719|DRUG|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
48313130|NCT01005719|DRUG|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
48313131|NCT04191577|DRUG|CVN424 Low Dose|CVN424
48313132|NCT04191577|DRUG|CVN424 High Dose|CVN424
48313133|NCT04191577|DRUG|Placebo|Placebo
48313134|NCT05781815|PROCEDURE|dynamic hip screw|using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
47963965|NCT05678933|DRUG|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
47963966|NCT05678933|DRUG|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
47963967|NCT05678933|DRUG|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
47963968|NCT03230097|DRUG|BI 409306|50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
47963969|NCT03230097|DRUG|Placebo|placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
47963970|NCT03424863|OTHER|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
47963971|NCT02803255|DEVICE|MAHI Exo-II|
47963972|NCT02767843|DEVICE|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
47963973|NCT02320669|DRUG|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
47963974|NCT02320669|DRUG|Placebo|Bolus of Placebo followed by infusion for 48 hours
47963975|NCT03243604|DRUG|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
47963976|NCT00808860|DIETARY_SUPPLEMENT|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
47963977|NCT00808860|DIETARY_SUPPLEMENT|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
47963978|NCT01160978|DRUG|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
47963979|NCT01160978|DRUG|Control Rx|The transplant recipients who have received an organ from non-treated donors.
47963980|NCT00259337|BIOLOGICAL|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
47963981|NCT05540457|DEVICE|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
47963982|NCT03503175|DEVICE|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
47963983|NCT03503175|DEVICE|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
47963984|NCT03298867|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
47963985|NCT03298867|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
48313135|NCT00696865|DRUG|AZD2624|oral suspension, 3 doses
48313136|NCT00696865|DRUG|Placebo|
48313137|NCT02583802|DRUG|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
48313138|NCT02583802|DRUG|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
48313139|NCT06523452|OTHER|Laser Speckle Imaging|At least three scans (four for skin sparing mastectomy) will be performed on participants randomised to the LSI Assisted Group. Further scans may be taken at the discretion of the surgeon.
48313140|NCT00439673|DRUG|5-Azacytidine|
48313141|NCT00439673|DRUG|Valproic Acid|
48313142|NCT00439673|DRUG|ATRA|
48313143|NCT02898207|DRUG|Olaparib|Given PO
48313144|NCT02898207|DRUG|Onalespib|Given IV
48313145|NCT00793702|BIOLOGICAL|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
48313146|NCT04496596|DRUG|Suramin|Suramin is administered via IV infusion as a single dose of 3 mg/kg
48313147|NCT04496596|DRUG|Placebo|Placebo
48313148|NCT00590915|DRUG|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
48313149|NCT05790811|OTHER|Physician-oriented Video|previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses
48313150|NCT05790811|OTHER|Patient-oriented video|"The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council."
48313151|NCT04281160|DEVICE|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
48313152|NCT05556733|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4, week 8
48313153|NCT01435239|DEVICE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
48313154|NCT01435239|DEVICE|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
48313155|NCT05556824|DRUG|MHS-1031|Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
48313156|NCT05556824|OTHER|Placebo|Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
48313157|NCT03959449|BEHAVIORAL|Action Observation plus motor imagery|Action observation (video) and motor imagery of running.
48313158|NCT03959449|BEHAVIORAL|Motor imagery|Motor imagery of running
48313159|NCT03959449|BEHAVIORAL|Exercise plus action Observation and motor imagery|Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
48313160|NCT00427583|DRUG|imatinib mesylate|
48313161|NCT02049255|DRUG|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
48313162|NCT02049255|DRUG|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
48313163|NCT01085305|BEHAVIORAL|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
47963986|NCT00365911|PROCEDURE|Taking blood sample|A blood sample will be taken.
48313164|NCT01085305|BEHAVIORAL|TAU|Usual treatment for behavioral disorders
48313165|NCT02403193|DRUG|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
48313166|NCT02403193|DRUG|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
48313167|NCT02403193|DRUG|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
48313168|NCT02403193|DRUG|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
48313169|NCT02403193|DRUG|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
48313170|NCT02403193|DRUG|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
48313171|NCT02403193|DRUG|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
48313172|NCT02403193|DRUG|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
48313173|NCT02403193|DRUG|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
47963987|NCT04467606|BEHAVIORAL|a discharge planning using the strategy of motivational interviewing|The experimental group will receive a discharge planning which use the strategy of motivational interviewing. The discharge planning will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, and then each month till one year.
48313174|NCT01805232|DRUG|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
48313175|NCT01805232|DRUG|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
48313176|NCT00103194|DRUG|lapatinib ditosylate|Given PO
48313177|NCT00103194|OTHER|laboratory biomarker analysis|Correlative studies
48313178|NCT05902507|DIAGNOSTIC_TEST|Magnetic Resonance Imaging Simulation|Radiographic Image Simulation
48313179|NCT06288776|DIAGNOSTIC_TEST|Herbal based mouthwash|Herbal based mouthwash will be used to treat the tooth sensitivity in participants having VAS score values of tooth sensitivity ranging between 30-80
48313180|NCT06473337|DIAGNOSTIC_TEST|Blood sample|Serum blood sample for Vitamin D testing
48313181|NCT00121069|DRUG|Escitalopram|
48313182|NCT03920826|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
48313183|NCT03920826|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
48313184|NCT03446534|DRUG|Amoxicillin|Imacillin mixture
48313185|NCT03446534|DRUG|Placebos|Placebo manufactured to mimic amoxicillin mixture (Imacillin)
48313188|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
48313189|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
48313190|NCT03834571|DRUG|Carboplatin|Given IV
48313191|NCT03834571|DRUG|Cisplatin|Given IV
48313192|NCT03834571|DRUG|Paclitaxel|Given IV
48313193|NCT03834571|PROCEDURE|Patient Monitoring|Undergo active monitoring
48313194|NCT03834571|RADIATION|Radiation Therapy|Undergo radiation
48313195|NCT03350750|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
48313196|NCT05158452|PROCEDURE|Discussion|Attend a focus group
48114768|NCT06010433|DEVICE|CERAMENT G|"* Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™\|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments.~* Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing."
48313197|NCT04482491|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
48313198|NCT04664595|DRUG|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
48313199|NCT05331950|OTHER|Office Workers|Office Workers which will be observed/exposed with different task and different factors
48313200|NCT03298412|DRUG|Blinatumomab|Blinatumomab is administered as a continuous IV infusion.
48313201|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
48313202|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
48313203|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
48313204|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
48313205|NCT04569474|DEVICE|Transparent dressing|Use of sterile transparente dressing
48313206|NCT03445897|DRUG|miltefosine plus intralesional pentamidine|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
48313207|NCT02467803|OTHER|Scapula mobilization|
48313208|NCT02467803|OTHER|Shoulder ROM exercises|
47963988|NCT04853550|DEVICE|Strattice Mesh|Subjects will be restrospectively identified has having undergone ventral hernia repair with Strattice mesh reinforcement. Once identified long term follow-up data will be collected.
48114769|NCT01895218|DRUG|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
48114770|NCT01895218|OTHER|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
48114771|NCT00422617|DRUG|Alefacept (Amevive)|
48313209|NCT06122428|DRUG|modified hyaluronic acid 0.1% covalently linked to Riboflavin|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
48313210|NCT06122428|DRUG|hyaluronic acid 0.1%|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
48313211|NCT00133237|DEVICE|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
48313212|NCT00133237|DEVICE|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
48313213|NCT02077634|DRUG|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
48313214|NCT02077634|DRUG|abiraterone acetate + prednisone|ormon therapy will be stopped
48313215|NCT06163456|OTHER|Acute submaximal exercise|30 min of treadmill running at 70% of the participants maximal oxygen consumption
48313216|NCT03314519|DIAGNOSTIC_TEST|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
48313217|NCT03314519|DIAGNOSTIC_TEST|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
48313218|NCT03578848|DEVICE|uAOBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
48313219|NCT03578848|DEVICE|Home BP|As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
48313220|NCT03578848|DEVICE|CBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
48313221|NCT00808327|DRUG|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
48313222|NCT00808327|DRUG|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
48313223|NCT02007330|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
48313224|NCT02007330|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
48313225|NCT05311280|OTHER|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
48313226|NCT05311280|OTHER|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
48313227|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
48313228|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
48643699|NCT06691620|PROCEDURE|Nontraumatic nasopharyngeal aspiration|After nasal irrigation, the secretions and saline solution from the underlying nasal cavity were nontraumatically aspirated from the entrance of the nasal cavity after the irrigation. The infant was positioned on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
48643700|NCT06434805|OTHER|sex workers and sexual minorities education workshop|The participants will receive a one-day workshop (four sessions). The generic content aims at enhancing the understanding of sexual orientation, gender identities, social stigma, sex work and sexual orientation and human rights (session 1), the lived experience of SWSM (session 2), the content specifically related to the medical and healthcare field, including be familiar with the professional and ethical obligations (session 3), the skills that can be adopted when providing services to SWSM (session 4).
48643701|NCT06626347|OTHER|TREAT-ED Virtual Group Diabetes Self-Management Education and Support|TREAT-ED is an innovative group telehealth delivery model designed to engage emerging adults in DSMES services. TREAT-ED sessions are facilitated by a Diabetes Care and Education Specialist and include content centered around the ADCES7 Self-Care Behaviors and applied learning strategies, e.g., case scenarios integrating glucose monitoring, and group discussions to drive knowledge transfer and skill development for diabetes self-care behaviors within the context of issues that are salient to the target population.
48643702|NCT06467864|PROCEDURE|bronchoscope|We will perform bronchoscopy and collect bronchoalveolar lavage fluid (BALF) samples at the time of patient enrollment and three days after the treatment.
48643703|NCT06613139|DRUG|YHP2305|Test drug: YHP2305 Comparator: YHR2404
48643704|NCT06613139|DRUG|YHR2404|Test drug: YHP2305 comparator: YHR2404
48313229|NCT05651139|DEVICE|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
48313230|NCT05147558|DRUG|Pembrolizumab|Pembrolizumab (200mg every 3 weeks, intravenously)
48313231|NCT05147558|DRUG|Lenvatinib|Lenvatinib (20mg once daily orally)
48643705|NCT06689709|OTHER|Serum Alkaline Phosphatase Levels|Venous blood was drawn from the patients
48643706|NCT06594159|DRUG|LY4065967|Administered orally
48313232|NCT03005977|PROCEDURE|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
48643707|NCT06594159|DRUG|Placebo|Administered orally
48643708|NCT06594159|DRUG|Rosuvastatin|Administered orally
48643709|NCT06688370|DEVICE|Petit Drill|Day 1: 2-4 doses, including one of the daily doses taken at bedtime. Days 2 and 3: 3 to 4 doses on days 2 and 3, including one of the daily doses taken at bedtime.
48643710|NCT03631056|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)|
48643711|NCT06687824|OTHER|Black Tea|Sterile gauze is impregnated into specific volume of black tea-extract
48643712|NCT06687824|OTHER|Colour-blinded Sterile Gauze|Diluted povidone-iodine is added into sterile gauze to colour blind the involved subject and the operator
48313234|NCT06519552|GENETIC|JWK008 Single intravenous infusion administration|"Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant."
48313235|NCT02875821|DRUG|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
47963989|NCT04920552|DEVICE|Elastic abdominal binder|"The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH)."
48313236|NCT02875821|DRUG|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
48313237|NCT01763905|BIOLOGICAL|Evolocumab|Subcutaneous injection
48313238|NCT01763905|DRUG|Placebo to Evolocumab|Subcutaneous injection
48313239|NCT01763905|DRUG|Ezetimibe|Tablet for oral administration
48313240|NCT01763905|DRUG|Placebo to Ezetimibe|Tablet for oral administration
48313241|NCT03169829|DIETARY_SUPPLEMENT|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~* Animal only Protein~* Refined only Grains~* Limit Dairy~* Low-k only"
48313242|NCT03169829|DIETARY_SUPPLEMENT|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~* Limit Dairy, provide Soymilk Dairy~* Low-k only Fruit and Vegetables"
48313243|NCT03169829|DIETARY_SUPPLEMENT|Standard|"•¼ Animal, ¾ Plant Proteins~* Refined, ½ Whole Grain~  •Limit Dairy, provide Soymilk Dairy~* Low-k, Fruit and Vegetables~* High-k Fruit and Vegetables"
48313244|NCT04075201|BIOLOGICAL|One dose of investigational vaccine|One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd.
48313245|NCT04075201|BIOLOGICAL|One dose of control vaccine|One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
48313246|NCT04075201|BIOLOGICAL|Three doses of investigational vaccine|Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd. on the schedule of month 0,1,2
48313247|NCT04075201|BIOLOGICAL|Three doses of control vaccine|Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
48313248|NCT05685368|BEHAVIORAL|ACT for Race Related Stress|This intervention will be guided by: Payne, J. S. (2022). Out of the Fire: Healing Black Trauma Caused by Systemic Racism Using Acceptance and commitment Therapy New Harbinger Publications, Inc.
48313249|NCT02946879|BIOLOGICAL|AAV OPTIRPE65|comparison of different doses of AAV RPE65
48313250|NCT00816907|DRUG|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
48313251|NCT00816907|DRUG|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
48313252|NCT01987349|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
48313253|NCT01987349|BIOLOGICAL|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
48313254|NCT03702530|BIOLOGICAL|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
48643713|NCT06132360|DRUG|RN0191|This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.
48313255|NCT03702530|OTHER|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
48643714|NCT06686589|DIAGNOSTIC_TEST|Intestinal ultrasound|Intestinal ultrasound performed by hand held ultrasound devices
48313256|NCT03702530|BIOLOGICAL|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
48313257|NCT03855137|DRUG|Atogepant 30 mg|Tablets containing 30 mg atogepant
48313258|NCT03855137|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
48313259|NCT03855137|DRUG|Placebo|30 mg/60 mg tablets containing atogepant-matching placebo
48313260|NCT00773760|OTHER|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
48313261|NCT04905381|BEHAVIORAL|Usual care|This arm receives usual care (control group)
48313262|NCT04905381|BEHAVIORAL|LENA Star Program sessions|LENA Start is an evidence-based community program designed to engage families and help them learn how to increase conversation with their children during the first few years of life.
48313263|NCT05041959|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours
48313264|NCT05041959|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
48313265|NCT02263482|OTHER|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
48643715|NCT06689644|DIETARY_SUPPLEMENT|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Commercially available product: Mind lab pro
48643716|NCT06689644|DIETARY_SUPPLEMENT|Placebo|A cellulose commonly used as a bulking agent in supplement products
48643717|NCT06689644|BEHAVIORAL|Perceptual decision-making performance|A computerised cognitive task involving rapid visual categorisation of images
48114772|NCT03611712|DRUG|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
48643718|NCT06689644|DEVICE|Electroencephalography|Brain signals are recorded from a 64 channel EEG system during the cognitive task
48114773|NCT06300996|DEVICE|Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)|Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
48114774|NCT06325111|OTHER|Determinants of T1D glycaemic control|DNA genotyping, microbiome, DNA methylation and microRNAs analysis
47963990|NCT04920552|DEVICE|Placebo binder|"Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer."
47963991|NCT00536185|DIETARY_SUPPLEMENT|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
47963992|NCT00536185|DIETARY_SUPPLEMENT|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
47963993|NCT03214939|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
47963994|NCT04153669|BEHAVIORAL|Exercise-NMES|Exercise-NMES
47963995|NCT04153669|BEHAVIORAL|Exercise-No NMES|Exercise-No NMES
47963996|NCT03513458|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
47963997|NCT03513458|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
47963998|NCT03513458|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
47963999|NCT01528475|BEHAVIORAL|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
47964000|NCT01628315|DEVICE|MRI|Annual MRIs as part of participation in the ASA study.
47964001|NCT00565045|DEVICE|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
47964002|NCT02363842|DEVICE|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
47964003|NCT02363842|OTHER|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
47964004|NCT00133497|BIOLOGICAL|MF-59|Microfluoridized adjuvant 59 (MF59).
47964005|NCT00133497|DRUG|Placebo|0.5 mL of saline placebo.
47964006|NCT00133497|BIOLOGICAL|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
47964007|NCT04889079|BEHAVIORAL|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
48114775|NCT02578615|OTHER|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
48114776|NCT04360681|DRUG|Lofexidine|BID dosing, and a max daily dose of 1.6 mg/day
48114777|NCT04360681|DRUG|Placebo oral tablet|Placebo
48313266|NCT02263482|OTHER|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
48313267|NCT02263482|OTHER|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
48313268|NCT02491073|OTHER|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
48313269|NCT05300243|DIAGNOSTIC_TEST|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
48313270|NCT01603641|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
48643719|NCT06686446|BEHAVIORAL|Enhanced Education Package|"Participants randomised to the intervention arm will receive an advanced patient education toolkit and reminders delivered by email/SMS in addition to the standard education provided by their treating clinician.~Weekly repeat reminders - these reminders will be sent via either SMS or email over a period of 3 months. They will instruct and remind the participant to take their INCS/INAH as per their treating clinician recommendation and why it is important to take it as instructed.~Education Toolkit - contains links to websites of key organisations including the National Allergy Council (NAC), Allergy \& Anaphylaxis Australia (A\&AA), Australasian Society of Clinical Immunology and Allergy (ASCIA), National Asthma Council Australia (NACA) and AusPollen which include educational videos and other resources."
48643720|NCT06681909|BEHAVIORAL|UB Campus Veggie Van|The UB Veggie Van is based on the Veggie Van, an evidence-based mobile produce market intervention. Mobile markets are like farmers' markets on wheels that travel to underserved communities selling high-quality, low-cost produce and healthy foods. The Veggie Van mobile market model was developed through multiple research studies on the efficacy, effectiveness, and implementation of the intervention, and is a multi-level intervention that addresses the five components of nutrition security (availability, accessibility, affordability, stability, and utilization). The UB Veggie Van is operated according to the Veggie Van model, with specific adaptations made to more effectively reach the campus community (Aim 1 of the larger funded study).
48313271|NCT00133900|PROCEDURE|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
48643721|NCT05513508|PROCEDURE|Protocolized rotational use of interfaces|The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.
48643722|NCT05513508|PROCEDURE|Standard of care|Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
48643723|NCT06617806|OTHER|Follow-up by the Advanced Practice Nurse|"At each follow-up (FU), the recommendations of an APN may include :~* Referral to a specialized memory assessment in case of cognitive impairment~* Psychological FU in the event that APN detects any mood complaints~* Ophthalmological and/or ear, nose, and throat consultation if any auditory or visual difficulties is observed~* Compression stockings use if orthostatic hypotension is present~* Nutritional counseling, with particular emphasis on the intake of protein, in combination with long-term assessment of weight~* Supplementation with vitamin D and calcium based to prevent osteoporosis in older adults, especially those at risk of recurrent falls~* Proposal of a standardized and personalized physical activity program~* Evaluation of medication therapies, especially antipsychotics, blood pressure medication or broad anticholinergics. The STOPPFall tool will be also proposed and coordinated by APN in accordance with the patient's physician~* A comprehensive social evaluative approach"
47964008|NCT05678569|DIAGNOSTIC_TEST|Dual Energy Xray Absorptiometry|DXA for diagnosis of osteoporosis
48643724|NCT05554393|DRUG|Azacitidine|Given IV or SC
48643725|NCT05554393|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48643726|NCT05554393|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48643727|NCT05554393|DRUG|Cytarabine|Given IV
48643728|NCT05554393|DRUG|Daunorubicin Hydrochloride|Given IV
48643729|NCT05554393|DRUG|Venetoclax|Given PO
48643730|NCT05204329|BIOLOGICAL|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
48643731|NCT01333826|BEHAVIORAL|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
48643732|NCT06690983|DIAGNOSTIC_TEST|18F-S16/T807|Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
48643733|NCT06668909|DEVICE|WaveLight® EX500|Phorcidies Planned Contoura LASIK
47964009|NCT04452682|OTHER|COVID 19 impact|The impact of COVID-19 pandemic on Critical limb threatening ischemia and emergency vascular practice
47964010|NCT01112358|DRUG|r-FSH|r-FSH will be administered as specified in the arm description.
47964011|NCT01112358|DRUG|r-hLH|r-hLH will be administered as specified in the arm description.
47964012|NCT01112358|DRUG|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
47964013|NCT01112358|DRUG|r-hCG|r-hCG will be administered as specified in the arm description.
47964014|NCT01112358|DRUG|Progesterone|Progesterone will be administered as specified in the arm description.
47964015|NCT00003331|DRUG|fluorouracil|
47964016|NCT00003331|DRUG|leucovorin calcium|
47964017|NCT00003331|DRUG|topotecan hydrochloride|
47964018|NCT01862900|BIOLOGICAL|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
47964019|NCT04054505|DIETARY_SUPPLEMENT|EZPAK|One packet with breakfast for three months
48313272|NCT04705324|PROCEDURE|Operative Hysteroscopy|Separation of the non-viable gestational sac from the uterine wall will through operative hysteroscopy
47964020|NCT04054505|DIETARY_SUPPLEMENT|Placebo|One packet with breakfast for three months
47964021|NCT00221403|DRUG|Risperidone oral solution|liquid, BID dosing.
47964022|NCT00221403|DRUG|Valproate Oral Solution|liquid, BID dosing.
47964023|NCT00221403|OTHER|Placebo|liquid, BID dosing.
48313273|NCT04705324|PROCEDURE|D&C|Separation of the non-viable gestational sac from the uterine wall through dilation and curettage
48313274|NCT04705324|PROCEDURE|Operative Hysteroscopy - safety and feasibility|Operative hysteroscopy - safety and feasibility phase
48114778|NCT06676839|OTHER|the complete ICOPE program|"The participant benefits from a personalized intervention, including 1) a screening to be repeated every 6 months, based on the use of the ICOPE tool, allowing an assessment of the 6 functions necessary for an autonomous lifestyle; 2) a comprehensive assessment step for the 6 functions 3) a personalized intervention step aimed at correcting the trajectory of functional decline, based on the participants' preferences; 4) a follow-up step for this intervention.~Participants will benefit from telephone follow-up 1.5 months after the start of the program and between each annual visit to support them in implementing their personalized intervention plan.~At each contact, the ICOPE nurse reviews the participant's implementation of the personalized intervention plan recommendations and their adherence to the program.~The results of the assessment and the proposed intervention are communicated and discussed with the primary care physician and a summary letter is also sent."
48114779|NCT04195568|DEVICE|Surpass Evolve Flow Diverter System|The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.
48114780|NCT03505801|DEVICE|Confirm Rx ICM insertion procedure|Insertion of Confirm Rx ICM device
48114781|NCT00657943|DRUG|metformin|metformin tablets 2 g x 2
48114782|NCT00657943|DRUG|insulin detemir|insulin as requested
48114783|NCT00657943|DRUG|insulin aspart + insulin aspart protamin|insulin as requested
48313275|NCT06206278|DRUG|Infigratinib|Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
48313276|NCT03969797|DEVICE|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
48313277|NCT03994263|DEVICE|ITind device implant|device implanted for 5-7 days
47964024|NCT03940222|DEVICE|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
48313278|NCT02891798|DRUG|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
48643734|NCT06689553|DEVICE|Automated Continual Fluid Removal System|The intraperitoneal device is percutaneously implanted via mini laparotomy, under local anaesthesia and sedation, and connected to the wearable rechargeable pump through extracorporeal tubing. The device aims to remove excess fluids in heart failure patients with diuretic resistance
48643735|NCT06607913|OTHER|Exercise|The participants will exercise 2 days a week for 16 weeks. The exercises will include 4 movements: squats, shoulder press, seated row, and bicep curl focusing on internal load and contraction velocity.
48643736|NCT04171869|OTHER|no intervention|observational study, no intervention
47964025|NCT03940222|PROCEDURE|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
47964026|NCT01029834|BEHAVIORAL|family based lifestyle and behavioral counseling|16 group meetings
48114784|NCT00657943|DRUG|Insulin aspart|insulin as requested
48114785|NCT02272452|DEVICE|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
48313279|NCT02891798|DRUG|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
48313280|NCT05505968|OTHER|Virtual Reality Headset|Virtual Reality Headset of the society Healthy Mind and is a CE Class 1 medical device. This virtual reality headset is a Pico G2 4K and corresponds to the model A7510 and is connected to a Bose Sound Link 2 AE headset.
47964027|NCT01029834|BEHAVIORAL|counseling focused on the child|16 meetings
47964028|NCT00004211|BIOLOGICAL|PSA RNA-pulsed dendritic cell vaccine|
48114786|NCT03399968|DEVICE|ESWT|at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
48114787|NCT03399968|DEVICE|Placebo ESWT|the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
48114788|NCT03427255|BEHAVIORAL|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
47964029|NCT06079021|DEVICE|CytoSorb|Application of CytoSorb treatment for 72 hours in patients with ACLF
47964030|NCT05840510|DRUG|Adagrasib|KRAS G12C inhibitor
47964031|NCT05840510|DRUG|nab-Sirolimus|mTOR inhibitor
47964032|NCT00045968|DRUG|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
48114789|NCT03427255|OTHER|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
48114790|NCT05835219|DRUG|REBYOTA™|REBYOTA™ is administered in the rectum
48114791|NCT02377726|BEHAVIORAL|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
48114792|NCT02377726|BEHAVIORAL|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
48313281|NCT02144454|DIETARY_SUPPLEMENT|Saturated fat|
48313282|NCT02144454|DIETARY_SUPPLEMENT|Monounsaturated fat|
48313283|NCT02144454|DIETARY_SUPPLEMENT|n-6 polyunsaturated fat|
48313284|NCT04757909|DIAGNOSTIC_TEST|Monthly Haemoglobinometry|"Monthly measurement of capillary hemoglobin with non-invasive techniques in primary health care.~Inclusion in a transfusion circuit with referral to a hospital day hospital if necessary."
48643737|NCT05218980|DIETARY_SUPPLEMENT|Olives|Organic olives (provided by Sakellaropoulos Organic Farms; Sparta, Greece)
48313285|NCT05008913|DRUG|[14C]Adavosertib|Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.
48313286|NCT06552312|OTHER|Delphi Questionnaire|"Experts will be asked to rate the importance of each item for ECPR for OHCA using the Grading of Recommendations Assessment, Development and evaluation scale from 1 (strongly disagree) to 9 (strongly agree). The median score (IQR) will be calculated after eliminating one lowest and one highest value after each survey round. Statements will be classified as strong agreement (median score 7-9), neither agree or disagree (median score 4-6), or strongly disagree (median score 1-3). Panel members were also provided an Unable to Score response to use if they did not feel comfortable rating any specific domain. Recipients will be asked to recommend any wording/phrasing changes and to suggest any additional items for inclusion."
48313287|NCT00678106|DRUG|Dalbavancin|Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV
48313288|NCT05600192|OTHER|Aerobic or anaerobic exercise|Aerobic or anaerobic exercise in the morning or in the afternoon
48313289|NCT05688579|DRUG|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
48313290|NCT05688579|OTHER|Blank control|Participants will be treated with the original antihypertensive drugs for 48 months.
48313291|NCT01940016|BEHAVIORAL|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
48484007|NCT03267420|DIAGNOSTIC_TEST|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
48643738|NCT01818648|DRUG|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
48643739|NCT01818648|DRUG|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
47964033|NCT05765396|DEVICE|imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope|The imPulse™ Systems are an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
47964034|NCT00757497|BEHAVIORAL|Electrical Polarization|
47964035|NCT04431180|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
47964036|NCT03643796|DRUG|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
47964037|NCT03643796|DRUG|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
47964038|NCT03643796|DRUG|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
47964039|NCT01459081|DRUG|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
47964040|NCT01459081|DRUG|Placebo|inhaled by mouth, twice daily, for 5 days
48114793|NCT02377726|BEHAVIORAL|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
48114794|NCT00777244|DRUG|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
48114795|NCT05721924|PROCEDURE|Pericapsular nerve group (PENG) block|In PENG group, the patient will be given PENG block 30mls of 0.2% ropivacaine
48114796|NCT05721924|PROCEDURE|Supra-inguinal fascia iliaca compartment (S-FICB) block|Patients in group B (S-FICB group) will be supra-inguinal fascia iliaca compartment block 30mls of 0.2% ropivacaine
48313292|NCT01940016|BEHAVIORAL|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
48313293|NCT02368340|OTHER|Pulmonary function test|Pulmonary function testing performed
48313294|NCT02368340|OTHER|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
48313295|NCT02368340|OTHER|Sample collection|Blood and urine sample collections
48313296|NCT03811678|DRUG|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
48313297|NCT03811678|DRUG|placebo|Tablet，administered orally once daily
48313298|NCT06391073|BEHAVIORAL|Self-Measured Blood Pressure Monitoring|Prompted SMBP with tailored feedback
48313299|NCT06391073|BEHAVIORAL|Physician appointment and transportation scheduling|Physician appointment and transportation scheduling or none dependent on current BP control
48643740|NCT06553898|BIOLOGICAL|anti-BCMA/CD70 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
48313300|NCT04068324|DIETARY_SUPPLEMENT|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
48313301|NCT00617409|DRUG|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
48313302|NCT00617409|BIOLOGICAL|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
48313303|NCT00617409|DRUG|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
48313304|NCT00239317|DRUG|Tamusulosin|
48313305|NCT06553924|DRUG|Macitentan and Tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
48313306|NCT06553924|DRUG|PrOpsynvi® macitentan and tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
48313307|NCT03533725|OTHER|Breastfeeding counseling and education services|Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
48313308|NCT03943758|DIETARY_SUPPLEMENT|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
48313309|NCT03943758|DIETARY_SUPPLEMENT|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
48313310|NCT00138034|PROCEDURE|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
48313311|NCT01731301|DRUG|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
48313312|NCT01731301|DRUG|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
48313313|NCT01731301|DRUG|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
48313314|NCT04196361|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound as part of routine physical examination
48313315|NCT01405846|DRUG|Gefitinib|250mg od for 6 months
48313316|NCT04611295|PROCEDURE|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
48313317|NCT00819533|DEVICE|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
48484008|NCT03267420|DIAGNOSTIC_TEST|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
48484009|NCT03390348|DEVICE|LENA Recorder|Use of the LENA recorder to document crying and fussing
48484010|NCT04652284|DRUG|Rifabutin|150 mg
48484011|NCT04652284|DRUG|Amoxicillin|1000 mg
48484012|NCT04652284|DRUG|Esomeprazole|40 mg
48484013|NCT04652284|DRUG|Clarithromycin|500 mg
48484014|NCT04652284|DRUG|Tinidazole|500 mg
48484015|NCT04952831|OTHER|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
47964041|NCT02339584|DRUG|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
47964042|NCT02339584|DRUG|Brinzolamide 10 mg/mL eye drops, suspension|
47964043|NCT02339584|DRUG|Brimonidine 2 mg/mL eye drops, solution|
47964044|NCT02339584|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
47964045|NCT02015572|BEHAVIORAL|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
47964046|NCT02015572|OTHER|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
47964047|NCT05045131|PROCEDURE|Left atrial combined pulmonary vein isolation and posterior wall isolation|
48313318|NCT04467177|OTHER|30% glucose|Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
48313319|NCT04467177|OTHER|Placebo|Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
48313320|NCT05516108|BEHAVIORAL|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
48313321|NCT05516108|BEHAVIORAL|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
48313322|NCT03505567|DEVICE|KOWA OCT Bi-µ|Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
48313323|NCT03505567|DEVICE|Optovue iVue 100|U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
48313324|NCT04004533|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
48313325|NCT04076150|DEVICE|Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System|Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.
48313326|NCT03086200|BEHAVIORAL|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
48313327|NCT03432910|OTHER|CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate|The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
48313328|NCT02969434|OTHER|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
48313329|NCT03695991|PROCEDURE|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
48313330|NCT05734326|DEVICE|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA \[18\].
48313331|NCT03251287|DRUG|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
48313332|NCT03251287|DRUG|Placebo|Single dose of oral matching placebo
48313333|NCT03251287|DIAGNOSTIC_TEST|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
48313334|NCT03251287|DIAGNOSTIC_TEST|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
48643741|NCT05921162|BIOLOGICAL|Gene Therapy product:vMCO-I|Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
48643742|NCT05333029|BIOLOGICAL|Allogeneic mesenchymal stromal cells (MSCs)|Treatment dose 2 x10\^6 cells/kg (+/- 20%)
48313335|NCT03317275|DEVICE|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
48313336|NCT03317275|PROCEDURE|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
48313337|NCT03317275|OTHER|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
48313338|NCT00603434|DRUG|OROS-MPH|18 mg bid on days 1 and 2
48313339|NCT00603434|DRUG|OROS-MPH|27mg bid on days 3 and 4
48313340|NCT00603434|DRUG|OROS-MPH|35 mg bid on days 5-9
48313341|NCT06555237|DRUG|Trametinib tablet|Trametynib orally once daily in 0,025mg/kg dose
48313342|NCT06555237|DRUG|Standard therapy|Disopiramide and Beta blockers orally
48313343|NCT02215993|DRUG|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
48313344|NCT02215993|DRUG|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
48313345|NCT00392262|DRUG|valsartan + amlodipine|
48313346|NCT01361009|DRUG|pramipexole|as prescibed by the investigator
48313347|NCT05250271|OTHER|15 g dextrose|15 g dextrose tablets
48313348|NCT05250271|OTHER|5 g dextrose|5 g dextrose tablets
48313349|NCT05250271|OTHER|Protein bar|5 g carbohydrates + 10 g protein
48313350|NCT05110716|BEHAVIORAL|Bundle-size 1|In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
48313351|NCT05110716|BEHAVIORAL|Bundle-size 3|In this condition, each choice in the adjusting-amount task produce a series of three consequences over time. o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
48313352|NCT05110716|BEHAVIORAL|Bundle-size 9|In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time. To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
48313353|NCT02108600|DRUG|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
48313354|NCT04505696|OTHER|Speech-Language Pathology Presentation|45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
48313355|NCT03779035|DRUG|Gemcitabine|1000mg/m2
48313356|NCT03779035|DRUG|Capecitabine|1250mg/m2
48313357|NCT04725370|OTHER|NA - survey instrument|Survey instrument was administered verbally to parents of the Guatemalan cohort.
48313358|NCT04263142|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
48313359|NCT04263142|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
48313360|NCT00202631|DEVICE|Surface Functional Electrical Stimulation|
48313361|NCT04053452|DIAGNOSTIC_TEST|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
48114797|NCT06306378|DIAGNOSTIC_TEST|social memory levels and spindle levels|Take a face recognition memory test, and a car recognition memory test as a control . Then record nighttime EEG recordings after the two tasks and performed subsequent spindle analysis.So conduct the correlation between social memory levels and the level of spindles in the EEG by using machine learning to model.
48313362|NCT04053452|DIAGNOSTIC_TEST|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
48313363|NCT03616665|OTHER|CBASPersonalized|"In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented."
48313364|NCT03176940|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
48313365|NCT04315376|BEHAVIORAL|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
48114798|NCT00719459|DRUG|Iron Sucrose|Venofer 20 mg/mL
48313366|NCT04315376|BEHAVIORAL|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
48313367|NCT01818050|OTHER|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
48313368|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
48313369|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
47964048|NCT06275724|OTHER|inclisiran|Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
47964049|NCT00978198|DRUG|ASP1517|oral
47964050|NCT00978198|DRUG|Placebo|oral
48114799|NCT00719459|DRUG|Iron Sucrose|Iron sucrose 20 mg/mL
47964051|NCT06064812|DRUG|FWD1802|"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."
48313370|NCT04058119|BEHAVIORAL|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
48313371|NCT05059652|DEVICE|Ischemic Preconditioning|The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
48313372|NCT03209180|DRUG|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
48313373|NCT03209180|DRUG|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
48643743|NCT05333029|BIOLOGICAL|Extracorporeal photopheresis (ECP)|Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
48313374|NCT00444223|PROCEDURE|fluorine F 18 FEQA + positron emission tomography|
48643744|NCT04462393|OTHER|Admission to ICU for COVID-19|All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
48643745|NCT06132399|DEVICE|META QUEST 3 virtual reality glasses|The RESET virtual reality software will be integrated into META QUEST 3 glasses (Meta Platforms, San Francisco, CA, US) by DYNAMICS.
48643746|NCT06132399|DEVICE|Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan)|This group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the Sports package games.
48643747|NCT06132399|OTHER|Usual care|The UC intervention consists of 3 sessions/week of 90' of physical therapy and occupational therapy conducted by a physiotherapist and an occupational therapist.
48313375|NCT05717452|DIETARY_SUPPLEMENT|Blueberry drink|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.
48313376|NCT05717452|DIETARY_SUPPLEMENT|Placebo drink|22 g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
48313377|NCT02273050|DRUG|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
48313378|NCT02273050|DRUG|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
48313379|NCT02273050|DRUG|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
48313380|NCT02273050|DRUG|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
48313381|NCT01914887|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
48313382|NCT00006054|DRUG|anti-thymocyte globulin|
48643748|NCT05127785|PROCEDURE|LVAD or Heart Transplant|Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
47964052|NCT06064812|DRUG|palbocilib|"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."
48114800|NCT04370418|DRUG|short course chemo-radiation with 5-fluorouracil|neo-adjuvant short course chemo-radiation in locally advanced rectal cancer patients followed by delayed surgery
48114801|NCT01755949|DRUG|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
48313383|NCT00006054|DRUG|busulfan|
48313384|NCT00006054|DRUG|cyclophosphamide|
47964053|NCT05703516|OTHER|Capmatinib|There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis
47964054|NCT04972292|DRUG|FDC of codeine 30 mg/dipyrone 500 mg|Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
47964055|NCT04972292|DRUG|Tylex|Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
48114802|NCT01755949|DRUG|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
48114803|NCT00705588|DRUG|Tadalafil|Orally, titrated to maximum 20mg od
48114804|NCT00705588|DRUG|Vardenafil|Orally, titrated to 10 mg bid
48114805|NCT06353165|DRUG|Stannous fluoride toothpaste|product containing 0.45% stannous fluoride
48313385|NCT00006054|DRUG|cyclosporine|
48313386|NCT00006054|DRUG|etoposide|
48313387|NCT00006054|DRUG|methotrexate|
48313388|NCT00006054|DRUG|methylprednisolone|
48313389|NCT00006054|DRUG|prednisone|
48313390|NCT00006054|PROCEDURE|Allogeneic Bone Marrow Transplantation|
48313391|NCT05728671|DRUG|IP2015|Test drug
48484016|NCT04818996|BEHAVIORAL|Mediterranean Diet|"While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).~In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated."
47964056|NCT04573712|OTHER|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
47964057|NCT03206775|BEHAVIORAL|Cognitive Assessments (Phase 1)|"Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~* Visual Sweeps~* Sustained Visual Attention~* Associative Learning--Visual~* Associative Learning--Auditory~* Emotion Motion~* Voice Choice"
47964058|NCT03206775|BEHAVIORAL|Cognitive Battery A (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~* On trails: Learning~* Line Length Discrimination~* Tap the Emotion~* Sound Sweeps~* BIS/BAS~* TEPS~* Feasibility survey"
47964059|NCT03206775|BEHAVIORAL|Cognitive Battery B (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~* Visual Time Order Judgment~* Target Tracker~* Emotional Face~* Auditory Sound Discrimination~* BIS/BAS~* TEPS~* Feasiblity assessment"
47964060|NCT03206775|BEHAVIORAL|Cognitive Battery C (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~* Stroop 2AFC~* Visual Task Switcher~* Beep Seeker~* Voice Choice~* BIS/BAS~* TEPS~* Feasibility Survey"
47964061|NCT03859193|BEHAVIORAL|Nutritional Video|A 10 - 15 minute video
47964062|NCT03918785|DIETARY_SUPPLEMENT|Rice germ|25 g twice a day.
47964063|NCT03918785|DIETARY_SUPPLEMENT|Wheat-based supplement|25g twice a day.
47964064|NCT03475368|OTHER|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
47964065|NCT03475368|OTHER|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
47964066|NCT03475368|OTHER|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
47964067|NCT05595941|OTHER|tele-yoga|"Each session will include postural exercises (asanas), standing, sitting and lying down, in order to work on balance, muscular strength and endurance, as well as flexibility. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, cushions, blocks (provided free to each participant). In addition, breathing work will accompany these postures. A relaxing passive meditation is practiced at the end of each session, in a lying posture called Savasana. The complexity of the postures, their holding time, or the number of repetitions will increase as the program progresses, relative to the abilities of each participant."
47964068|NCT03600818|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48114806|NCT06353165|DRUG|Colgate Dental Cream|product containing 0.76% sodium monofluorophosphate
48484017|NCT03360175|OTHER|No intervention - observational study|No intervention - observational study
48643749|NCT06686212|OTHER|Sensory re-education+ strengthening exercises+ kinesio taping|"Sensory re-education. Splinting: as constant maintained touch with wrist holding in neutral position for 15 minutes.~Topical anesthesia spray on affected area for 10 minutes. Massage: apply massage over sensitive areas with same speed and pressure, then the light pressure with cotton, velvet, terry cloth, polyester and wool over sensitive area for 10 minutes.~PNF using upper extremity (D2) pattern including shoulder extension, adduction, internal rotation, wrist and fingers flexed and wrist ulnar deviated. 10-15 repetitions for 5 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions of each exercise for 20 minutes.~Kinesio taping: Taping will be applied twice a week for 12 weeks."
48484018|NCT06094907|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.
48643750|NCT06686212|OTHER|Neural mobilization+ Strengthening exercises+ Kinesio taping.|"The median nerve is mobilized through wrist flexion and extension with elbow straight and palm facing up.~Wrist flexion and extension with elbow flexed to 90 degrees with palm facing up 10-15 repetitions.~Wrist flexors stretch with extended arm and palm facing down 10-15 repetitions. Straight fist: hold your hand up with fingers straight. Full fist: bend your fingers to form a full fist. Median nerve stretch and wrist extension exercises for 30 minutes. Free the bird exercises, busy bee flexion shape of Z exercises and wall stretch exercise. (10-15 repetitions) for 10 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions each for 20 minutes.~Kinesio taping: The taping will be applied twice a week for 12 weeks."
47964069|NCT03600818|DRUG|Sarilumab-matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
47964070|NCT03600818|DRUG|Prednisone|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
47964071|NCT03600818|DRUG|Prednisone-matching placebo|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
47964072|NCT03600818|DRUG|Prednisone|Pharmaceutical form:tablets Route of administration: oral administration
47964073|NCT00967603|DRUG|sunitinib|oral sunitinib 37.5 mg daily
48313392|NCT01641549|PROCEDURE|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
48313393|NCT01641549|DRUG|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
48313394|NCT05414617|DEVICE|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
48313395|NCT05414617|DEVICE|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
48313396|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every other day.|6mg/kg of oral iron as ferrous sulfate administered every other day instead of 6 mg/kg of oral iron daily supplementation.
48484019|NCT03465748|DEVICE|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
48484020|NCT06273020|DRUG|Cerebrolysin|Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
48484021|NCT06273020|PROCEDURE|Brain-MRI with contrast after 10-14 days of cerebrolysin|Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
47964074|NCT02609009|OTHER|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
47964075|NCT02609009|OTHER|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
47964076|NCT02099708|DRUG|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
47964077|NCT01281865|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
47964078|NCT01281865|DRUG|everolimus|Given PO
47964079|NCT01281865|DRUG|imatinib mesylate|Given PO
48114807|NCT03948997|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
48313397|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every day.|6 mg/kg of oral iron as daily ferrous sulfate instead of 6mg/kg of oral iron supplementation administered every other day.
48114808|NCT04669249|BEHAVIORAL|PROCare|PROCare is a reward-based digital recovery management platform for individuals receiving medication treatment for opioid use disorder. Patients have the opportunity to earn both non-monetary and monetary incentives via smart debit card for a variety of clinically-indicated behaviors, including taking their medication (buprenorphine) as directed, attending clinic appointments and community-based mutual-help support group meetings, participating in routine outcomes monitoring surveys using validated measures, accessing the curated psychoeducation content library, and engaging in other recovery-oriented activities within the smartphone app.
48313398|NCT02594475|PROCEDURE|Endoscopic retrograde cholangiopancreatography|"1. Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~2. Selective bile duct cannulation is performed using wire-guided cannulation.~3. In case of difficult cannulation, precut is performed using a needle-knife.~4. After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
48643751|NCT06615726|BEHAVIORAL|Regular physical activity|Best medical treatment plus regular physical activity. Each subject is equipped with an exercise guidance expert to regularly guide and adjust the exercise plan according to the subject's personal conditions throughout the trial period. After randomization, the exercise guidance expert formulated an individualized aerobic exercise plan based on the subject's preferences and their own exercise abilities. After each exercise, subjects filled out the exercise diary , and reported back to the exercise guidance expert.
48484022|NCT00757614|GENETIC|DNA analysis|
48484023|NCT00757614|GENETIC|polymorphism analysis|
48484024|NCT00757614|OTHER|laboratory biomarker analysis|
48114809|NCT02616263|OTHER|Foot exercise|
48114810|NCT02616263|OTHER|Shoulder exercise|
48114811|NCT05079919|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
48114812|NCT05079919|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
48114813|NCT01856335|OTHER|Patient Education|
48484025|NCT00757614|OTHER|questionnaire administration|
48484026|NCT05877079|DRUG|Menthol|Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
48484027|NCT05877079|DRUG|Placebo|Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
48484028|NCT00846859|DRUG|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
48114814|NCT01856335|OTHER|exercise: increase physical activity/goal setting|
48484029|NCT00846859|DRUG|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
48484030|NCT05236842|DRUG|Sulthiame|oral
48114815|NCT05948358|OTHER|Menstrual Distress Questionnaire|The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.
48114816|NCT03102710|DEVICE|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
48114817|NCT03102710|OTHER|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
48114818|NCT03102710|OTHER|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
48114819|NCT03102710|OTHER|Control cream|A neutral cream will be applied on the arm as a control.
48114820|NCT05085990|BIOLOGICAL|TARA-002|Phase 1b, Dose Expansion Phase: All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)
48114821|NCT06390852|PROCEDURE|Biopsy|Undergo biopsy
48114822|NCT06390852|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48114823|NCT06390852|PROCEDURE|Computed Tomography|Undergo CT scan
48484031|NCT03969199|BEHAVIORAL|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
48484032|NCT00402220|DRUG|TMS|Active Transcranial Magnetic Stimulation
48484033|NCT00402220|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
48484034|NCT05294419|DEVICE|CVD Integrated Risk Test|CVD IRT (IVD regulations with a software device)
48484035|NCT01398059|OTHER|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
48643752|NCT06615726|OTHER|Control group|Best medical treatment
48643753|NCT05690204|DRUG|SAP-001|Test the efficacy and safety of SAP-001 versus placebo
48643754|NCT01829763|DRUG|injection botox|
48114824|NCT06390852|DRUG|Larotrectinib|Given PO
48114825|NCT06390852|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48114826|NCT02376517|BEHAVIORAL|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
48114827|NCT06676722|DRUG|SBRT combined with Nimotuzumab followed by Tislelizumab|BRT combined with 3 cycles of Nimotuzumab 400mg qw followed by maintain Tislelizumab for 2 years or until disease progression
47964080|NCT02695225|BEHAVIORAL|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
47964081|NCT02695225|BEHAVIORAL|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
48114828|NCT02705183|RADIATION|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
48114829|NCT03443453|DRUG|MIV-711|MIV-711 administered as tablets and capsules at four occasions
48114830|NCT06602479|DRUG|MEDI0618|MEDI0618 per protocol
48114831|NCT06602479|DRUG|Placebo|Volume-matched placebo for all arms
48114832|NCT02971488|OTHER|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
48484036|NCT01398059|OTHER|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
48484037|NCT01398059|OTHER|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
48114833|NCT05989646|DEVICE|Sacral TENS|Sacral TENS applied two hours daily for 10 weeks
48484038|NCT06309316|BEHAVIORAL|Person-centred care (PCC)|In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. Primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.
48484039|NCT00093951|DRUG|SGS742|
48484040|NCT04633655|OTHER|outcome measures for CIPN testing|questionnaires administration, physician based scales for CIPN data collection
47964082|NCT04068935|PROCEDURE|fracture immobilization after reduction of displaced finger fractures|After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
47964083|NCT00077961|DRUG|CAMPATH (alemtuzumab)|
47964084|NCT03331367|PROCEDURE|Blood draw|Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
47964085|NCT03331367|PROCEDURE|Urine sample|Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
48114834|NCT02126878|DRUG|Kenalog|
48114835|NCT06675539|DIAGNOSTIC_TEST|French version PAWSS|French version of the Prediction of Alcohol Withdrawal Severity Scale
48114836|NCT03501173|OTHER|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
48114837|NCT03745001|DRUG|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
48484041|NCT04158817|DRUG|68Ga-Labeled PSMA|All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
48484042|NCT04158817|DRUG|Non-labeled PSMA|Patient will be injected with microdose (\<100 ug) of THP-PSMA
47964086|NCT04218422|PROCEDURE|Battlefield Acupuncture|Acupuncture at 5 points on the ears
48114838|NCT03745001|DRUG|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
48114839|NCT03745001|DRUG|Matching placebo|Oral liquid administration daily
48114840|NCT01190007|DRUG|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
48114841|NCT00448721|DRUG|Perifosine|Perifosine will be administered orally at 100mg PO daily with food.
48313399|NCT02146079|DRUG|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
48313400|NCT02146079|DRUG|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
48313401|NCT03623139|BEHAVIORAL|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
47964087|NCT04218422|PROCEDURE|Sham Acupuncture|Sham acupuncture in 2 points for liver and 1 point for stomach
47964088|NCT05038631|DRUG|Ribociclib|Patients receive ribociclib
47964089|NCT03703115|BEHAVIORAL|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
47964090|NCT00114530|BIOLOGICAL|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
47964091|NCT00114530|DRUG|cyclophosphamide|An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
47964092|NCT04352816|DEVICE|Magnetocardiogram|Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
47964093|NCT04005911|DEVICE|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
47964094|NCT03069300|DRUG|N-acetyl cysteine (NAC)|
47964095|NCT02695329|DEVICE|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
47964096|NCT02966431|BEHAVIORAL|Counseling|
47964097|NCT02966431|BEHAVIORAL|No Counseling|
47964098|NCT02095093|DEVICE|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
47964099|NCT02095093|DEVICE|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
47964100|NCT05306275|DRUG|CSL312|Factor XIIa antagonist monoclonal antibody for subcutaneous use
47964101|NCT01699906|OTHER|Diet regimen to induce weight loss|Diet regimen to induce weight loss
47964102|NCT00783237|DRUG|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
47964103|NCT00783237|DRUG|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
47964104|NCT00843947|PROCEDURE|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
47964105|NCT02346552|DEVICE|AutoLap|
47964106|NCT02610725|OTHER|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
47964107|NCT03752983|DIAGNOSTIC_TEST|blood samples|blood samples
47964108|NCT04907903|OTHER|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
47964109|NCT01628133|PROCEDURE|ultrasound|sonographic evaluation of intestinal blood flow
47964110|NCT05827731|BEHAVIORAL|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
48643755|NCT06508450|BEHAVIORAL|Just Do You|Just Do You Core Intervention utilizes creative arts and a provider team of a licensed clinician and professional peer to increase young adult engagement in adult outpatient mental health programs. Content addresses recovery, advantages of using mental health services, working with providers, stigma, and mental health literacy.
48643756|NCT06508450|BEHAVIORAL|Component A|Content addresses participant cultural identities and how they may be barriers and facilitators to on-going engagement with services.
48643757|NCT06508450|BEHAVIORAL|Component B|Content addresses identity-based motivations for on-going engagement with services and hope for the future.
47964111|NCT03434093|DEVICE|Transcranial Magnetic Stimulation (TMS)|Description: This will comprise single and repeated paired-pulses delivered over motor and non-motor areas.
47964112|NCT03434093|BEHAVIORAL|Working Memory Task|This will consist in remembering an item presented 1 to 5 steps before the inquiry. This task will span the whole duration of the functional MRI acquisition.
47964113|NCT03342677|DIAGNOSTIC_TEST|Primovist MRI|Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
47964114|NCT01149226|DRUG|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
47964115|NCT06358820|DRUG|Amino acid peritoneal dialysis solution|Each subject received treatment with 1 bag of amino acid peritoneal dialysis daily and 2-4 bags of glucose peritoneal dialysis solution daily for 6 months
47964116|NCT02178371|PROCEDURE|mCIMT|affected upper limb use with constraint of the healthy hand
47964117|NCT02178371|PROCEDURE|Unimanual therapy without constraint UTWC|affected upper limb use without constraint of healthy hand
48114842|NCT04577014|DRUG|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
48114843|NCT04577014|DRUG|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
48643758|NCT06508450|BEHAVIORAL|Component C|Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.
47964118|NCT00388596|DRUG|SB-751689|
47964119|NCT06278350|DRUG|D-2570|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
47964120|NCT06278350|DRUG|Placebo|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
47964121|NCT01919606|DRUG|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
47964122|NCT03993795|OTHER|A19010-W|A snus product
47964123|NCT03993795|OTHER|B19010-F|A snus product
47964124|NCT01323283|DIETARY_SUPPLEMENT|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
47964125|NCT01323283|DIETARY_SUPPLEMENT|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
47964126|NCT04688970|OTHER|no intervention|no intervention
47964127|NCT04145557|DEVICE|diode laser 980nm|Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
47964128|NCT04145557|DEVICE|scaling root planing|scaling and root planing
47964129|NCT04836572|OTHER|3M 1529 Adhesive Tape|5-12 hour adhesive wear
47964130|NCT00760097|DEVICE|Transcranial direct stimulation|sessions of 20 minutes each
48114844|NCT04577014|DRUG|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
48114845|NCT06088225|DEVICE|distance-image screen|Distance-image screen is a screen make each image at distance of 6-meters to reduce the accommodation and convergence for eyes during the reading and learning with screens.
48643759|NCT06691048|OTHER|Description of an adult population diagnosed late with a neurodevelopmental disorder|Clinical description during diagnostic interview
48643760|NCT04840875|BIOLOGICAL|chimeric antigen receptor T cell treatment|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
48484043|NCT04702724|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
48484044|NCT06305520|DEVICE|Investigational medical device (SkinPlus-HYAL Implant Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
48484045|NCT06305520|DEVICE|Active Comparator: Active Comparator Medical Device (RESTYLANE Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
47964131|NCT04365296|OTHER|Experimental|The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
47964132|NCT03842514|DIETARY_SUPPLEMENT|Soya lecithin|The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
47964133|NCT00196755|DRUG|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
47964134|NCT00196755|DRUG|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
47964135|NCT01781975|DRUG|Imatinib Mesylate|
47964136|NCT01781975|DRUG|Placebo (For imatinib mesylate)|
47964137|NCT00261807|DRUG|Daptomycin 6mg/kg/day|
47964138|NCT05106686|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan group|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
47964139|NCT05106686|DIETARY_SUPPLEMENT|placebo group|Placebo 300 mg/day for 12 weeks
47964140|NCT05561049|DRUG|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
47964141|NCT05036759|DRUG|68Ga-FAPI|intravenously injected with 68Ga-FAPI
47964142|NCT04741282|OTHER|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
47964143|NCT04741282|OTHER|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
47964144|NCT00082251|DRUG|Niacin extended release and simvastatin tablets|
47964145|NCT04966624|PROCEDURE|"LUVS ventilatory strategy composed of a bundle of measures"|Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
47964146|NCT04966624|PROCEDURE|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
48484046|NCT02529202|DRUG|Dexmedetomidine|Dexmedetomidine infusion
48484047|NCT06048094|DRUG|18F fluciclovine|Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
48484048|NCT01090999|OTHER|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
47964147|NCT02742441|DRUG|122-0551 Foam|Topical Foam containing active drug
47964148|NCT02742441|DRUG|Vehicle Foam|Topical Foam containing no active drug
48313402|NCT03623139|BEHAVIORAL|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
48313403|NCT00058734|BIOLOGICAL|Dendritic Cells Pulsed with HIV antigens|
47964149|NCT05825339|DIAGNOSTIC_TEST|Coronary Flow Reserve|Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve
47964150|NCT03652597|DEVICE|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
47964151|NCT06043531|OTHER|Experimental: EVOO|Subjects will consume 50g of cold pressed EVOO per day for 28 days.
47964152|NCT01270412|BIOLOGICAL|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
47964153|NCT01270412|DRUG|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
47964154|NCT05496400|RADIATION|Echocardiographic and Doppler studies|"Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~1. Cardiac output:~2. Cerebral, intestinal and renal blood flow velocities:"
48114846|NCT01141010|OTHER|Language|Plain language without psychological intervention
48114847|NCT01141010|OTHER|Language|Psychological linguistic intervention will be given
47964155|NCT05482412|DEVICE|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
48313404|NCT06285929|OTHER|ACS CARES Student Navigation|Student volunteers providing navigation support to patients, families and caregivers with a cancer diagnosis through an SDOH assessment.
48313405|NCT00575952|DRUG|Cisplatin|Given IV or IP
48313406|NCT00575952|DRUG|Doxorubicin Hydrochloride|Given IV
48313407|NCT00575952|BIOLOGICAL|Filgrastim|Given SC
48313408|NCT00575952|DRUG|Paclitaxel|Given IV or IP
48484049|NCT02776813|BIOLOGICAL|ACTR087|
47964156|NCT01822795|PROCEDURE|Lung volume reduction coïl treatment|
47964157|NCT01822795|OTHER|Regular medical treatment|
48643761|NCT03084900|OTHER|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
48643762|NCT05494697|DRUG|Rintatolimod|Rintatolimod (poly I : poly C12U)
47964158|NCT03692130|BEHAVIORAL|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
48114848|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
48114849|NCT04880694|DRUG|STC3141|"To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care."
48313409|NCT00575952|BIOLOGICAL|Pegfilgrastim|Given SC
48313410|NCT02529241|DRUG|Group 1:LCB01-0371|"1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg"
48313411|NCT02529241|DRUG|Group 2:LCB01-0371|"1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg"
48484050|NCT02776813|BIOLOGICAL|rituximab|
48643763|NCT05783596|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.
48643764|NCT05783596|DRUG|Glofitamab|T-cell bispecific humanized monoclonal antibody, via IV infusion.
48313412|NCT02238496|PROCEDURE|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
48313413|NCT02238496|DRUG|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
47964159|NCT03692130|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson
48114850|NCT05984784|DRUG|Placebo|Drug: Placebo Intravenous Infusion
48114851|NCT05984784|DRUG|IMG-007|Drug: IMG-007 Intravenous Infusion
48114852|NCT04045977|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
48266737|NCT06415721|DEVICE|Sham|1 session of sham continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. The MagVenture MagPro x100 is capable of administering a sham stimulation. The reverse side of the TMS coil is plated with a magnetic shield such that electromagnetic energy cannot stimulate the brain. The device offers compatibility with Transcutaneous Electrical Nerve Stimulation devices such that titrated electrical pulses can be delivered to the scalp location to mimic the sensation of a TMS pulse without stimulating the brain.
48313414|NCT02238496|DRUG|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
48313415|NCT06291116|DRUG|standard care + rotigotine at 4 mg/24h for 24 months.|standard care + rotigotine at 4 mg/24h for 24 months.
48313416|NCT06291116|DRUG|standard care for 24 months.|standard care for 24 months.
48313417|NCT05136248|PROCEDURE|intraarticular injection|Ultrasound-guided intraarticular injection
48313418|NCT05136248|PROCEDURE|peng block|Ultrasound-guided PENG block
48313419|NCT06270693|PROCEDURE|Endodontic treatment|Root canal treatment
48313420|NCT03498781|OTHER|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
48313421|NCT03498781|OTHER|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
48313422|NCT05705570|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
48313423|NCT05705570|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
48313424|NCT05705570|BIOLOGICAL|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0"|"Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
48484051|NCT03816813|OTHER|blood and saliva sampling|blood and saliva sampling
48484052|NCT06007651|DRUG|LY3885125|Administered SC
48484053|NCT06007651|DRUG|Placebo|Administered SC
48484054|NCT05116748|BIOLOGICAL|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
47964160|NCT02793921|BEHAVIORAL|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment or home exercise. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check (in-person) and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety when sessions are completed in-person, or through regular communication when home-based exercise is warranted (due to COVID-19).
47964161|NCT00204230|DRUG|mycophenolate mofetil (drug)|
47964162|NCT05141591|OTHER|Anxiety level assessment|To investigate the impact of psychological variables e.g. pre-surgical anxiety on postoperative opioid consumption and pain level, the investigators will perform the STOA, APAIS, PCS and the VAS-A anxiety questionnaires before surgery.
47964163|NCT02166905|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
47964164|NCT02166905|DRUG|Epacadostat|Given PO
47964165|NCT02166905|OTHER|Laboratory Biomarker Analysis|Correlative studies
47964166|NCT02166905|OTHER|Pharmacological Study|Correlative studies
47964167|NCT02166905|DRUG|Poly ICLC|Given SC
47964168|NCT03144947|BIOLOGICAL|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
47964169|NCT03144947|BIOLOGICAL|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
47964170|NCT03144947|BIOLOGICAL|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
47964171|NCT03144947|DRUG|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
47964172|NCT03556774|BEHAVIORAL|'WeChat WeQuit' smoking cessation training program|Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
47964173|NCT04556188|PROCEDURE|Cardiac surgery|
47964174|NCT02846584|BIOLOGICAL|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
47964175|NCT00115752|DRUG|Valdecoxib|
47964176|NCT00115752|DRUG|COX Inhibitor|
47964177|NCT02963792|OTHER|Preventing Professionals burnout|
48266738|NCT00214461|BIOLOGICAL|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
48313425|NCT03940924|OTHER|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
48313426|NCT02843373|DEVICE|TMS|
47964178|NCT04185428|BEHAVIORAL|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
47964179|NCT05164796|DEVICE|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~* IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~* IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~* In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
47964180|NCT00005639|DRUG|Azacitidine Injection|subcutaneous injection (SC)
47964181|NCT00005639|DRUG|sodium phenylbutyrate|continuous intravenous (CIV)
47964182|NCT01065285|BIOLOGICAL|Evaluation of vaccines against flu|evaluate efficacy and tolerance
47964183|NCT03986398|OTHER|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
47964184|NCT02542904|PROCEDURE|mesenteric excision|
47964185|NCT00538291|BIOLOGICAL|cetuximab|
48266739|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
48266740|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
48266741|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
48313427|NCT03854643|OTHER|Pilates group|Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
48266742|NCT03002974|DRUG|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
48266743|NCT03002974|DRUG|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
48266744|NCT03002974|DRUG|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
47964186|NCT00538291|DRUG|capecitabine|
47964187|NCT00538291|GENETIC|gene expression analysis|
48313428|NCT03854643|OTHER|Control group|These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
47964188|NCT00538291|GENETIC|microarray analysis|
47964189|NCT00538291|GENETIC|polymorphism analysis|
48484055|NCT01194973|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
48484056|NCT03316378|DRUG|Ropivacaine injection|single dose, subcutaneous injection
48484057|NCT00350155|DRUG|Lumiracoxib|
48484058|NCT01583218|DRUG|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
48484059|NCT01583218|DRUG|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
48484060|NCT06327802|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the Beck, Zarit, HAD, FAS CARERQOL-7D questionnaires
48484061|NCT02553278|DEVICE|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
48643765|NCT02577302|DEVICE|CAN-Stim - Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.
47964190|NCT00538291|GENETIC|reverse transcriptase-polymerase chain reaction|
47964191|NCT00538291|OTHER|immunohistochemistry staining method|
47964192|NCT02088710|BEHAVIORAL|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
47964193|NCT03022136|OTHER|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
48484062|NCT02553278|DEVICE|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
48484063|NCT00253981|DEVICE|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
48484064|NCT06110247|DEVICE|NIRS|After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
48484065|NCT06110247|OTHER|Taking a blood sample|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
48484066|NCT01378741|DRUG|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
47964194|NCT00777114|DRUG|bortezomib, tositumomab|"1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
47964195|NCT03980041|DRUG|IPI-549 (eganelisib)|IPI-549 (40mg QD) administered orally in 28-day cycles
47964196|NCT03980041|DRUG|Nivolumab|Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
47964197|NCT03980041|DRUG|Placebos|Placebo administered orally in 28-day cycles
47964198|NCT00040573|DRUG|131I-TM-601|
47964199|NCT05042154|DEVICE|WatchPAT|The WatchPAT One can detect the presence of OSA based on measurement of peripheral arterial tone (PAT), pulse rate, oxygen saturation, actigraphy, snoring, and body position.
47964200|NCT01881347|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
47964201|NCT01881347|DIETARY_SUPPLEMENT|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
48266745|NCT03002974|DRUG|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
48266746|NCT02953145|DRUG|Tisseel|Tisseel will be applied to open areas lateral to the cleft palate repair
48313429|NCT04037436|OTHER|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
48313430|NCT04037436|OTHER|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
48313431|NCT01469494|PROCEDURE|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
48484067|NCT01378741|DRUG|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
48313432|NCT01469494|PROCEDURE|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
48313433|NCT01272297|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
48313434|NCT03868007|DEVICE|RIC|The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
48313435|NCT03868007|DEVICE|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
48313436|NCT03744884|BEHAVIORAL|Force efforts with haptic feedback in virtual reality.|A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
48313437|NCT05016947|DRUG|Venetoclax|Tablet, taken by mouth
48313438|NCT05016947|DRUG|Dexamethasone|Taken orally
48313439|NCT05016947|DRUG|Inotuzumab Ozogamicin|Intravenous infusion
48313440|NCT01453569|DRUG|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
48313441|NCT01453569|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
48313442|NCT01453569|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
48484068|NCT06108258|DRUG|IV iron administration|IV iron administration during pregnancy
48484069|NCT01491035|DRUG|Vortioxetine|5 mg tablets for 14 days; orally; once daily
48484070|NCT01491035|DRUG|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
48484071|NCT01491035|DRUG|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
48484072|NCT01491035|DRUG|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
48484073|NCT04353024|DRUG|Dimethyltryptamine (DMT)|Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min
48484074|NCT04353024|DRUG|Saline|Intravenous saline bolus and/or saline maintenance perfusion over 90 min
48484075|NCT04801667|BIOLOGICAL|Coronavac|The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
48114853|NCT04045977|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
48313443|NCT01947049|OTHER|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
48313444|NCT00195260|DRUG|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
48313445|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
48313446|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
48313447|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
48484076|NCT05221424|OTHER|Patient Education|"The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training."
48484077|NCT04477551|PROCEDURE|Diode laser (device) with scaling and root planing|Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
48484078|NCT04477551|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
48484079|NCT02497794|OTHER|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
48484080|NCT01792414|DEVICE|Sham TES|Neuroconn Eldith device
48484081|NCT01792414|DEVICE|Active TES|Neuroconn Eldith device
48484082|NCT06288191|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
48484083|NCT06331520|DRUG|Netupitant / Palonosetron Oral Capsule [Akynzeo]|Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).
48484084|NCT06331520|DRUG|Olanzapine|Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.
48484085|NCT06331520|DRUG|Dexamethasone Oral|synthetic glucocorticoids
48484086|NCT00553449|DRUG|rabeprazole|
48484087|NCT03135652|RADIATION|adjuvant SBRT|adjuvant SBRT of liver lesions
48484088|NCT03135652|DRUG|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
48484089|NCT03095898|DEVICE|Electroacupuncture|Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
48484090|NCT00613834|DRUG|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
48484091|NCT00613834|DRUG|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
48484092|NCT00567437|OTHER|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
48484093|NCT00609388|DRUG|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
48484094|NCT00609388|OTHER|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
48484095|NCT03496857|DEVICE|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
48114854|NCT04045977|BEHAVIORAL|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
48313448|NCT05787353|OTHER|Exercise programme|Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
48313449|NCT03487900|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
48313450|NCT05132816|DIAGNOSTIC_TEST|high-resolution manometry|"High-resolution manometry is an outpatient examination and part of our routine diagnostic or pre-operative evaluation in GERD.~A thin catheter is placed through the nose into the esophagus, local anaesthesia can be used if the patient experiences a discomfort. Once the tip of the manometry catheter is placed below the esophagogastric junction, the patient is asked to take in water and bread. In rest and during deglutition, pressure measurements are registered with the manometry catheter, allowing the investigator to detect IEM. The examination takes about 1.5 hours. The manometry is a standard and routine intervention being performed for over 30 years with minimal risks.~The GSRS questionnaire pre- and postoperatively is part of our standard workup, no additional assessment for this study is needed."
48313451|NCT05314218|DEVICE|Electrophysiology catheters and cables|"The Xtrem electrophysiology catheter was developed for diagnosis of cardiac arrhythmias. Their function is to collect by contact, electrical signals generated by the heart muscle.~Xtrem are inserted via femoral vena cava or via artery and can be used in two occasions:~* Exploration procedures for diagnosis alone~* Diagnosis before ablation procedure An extension cable is used to connect the catheter to a stimulation/ recording device."
48313452|NCT03111134|PROCEDURE|modified component separation technique|a new abdomen closure technique based on component separation technique
48313453|NCT00547599|DRUG|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
48313454|NCT05877534|OTHER|Individual tailored exercise|A 16 week period of progressive exercise, supervised by a physiotherapist once a week.
48313455|NCT01346371|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|
48313456|NCT01346371|DRUG|Bepreve 1.5% Ophthalmic Solution|
48313457|NCT02687230|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
48484096|NCT03496857|OTHER|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
48484097|NCT05518448|DIETARY_SUPPLEMENT|Ketone - beta-hydroxybutyrate (β-OHB)|Ketone - beta-hydroxybutyrate (β-OHB)
48484098|NCT02112721|DIETARY_SUPPLEMENT|Vitamin D|
48484099|NCT02112721|DIETARY_SUPPLEMENT|Placebo|
48484100|NCT04754802|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
48484101|NCT04754802|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
48484102|NCT00766155|DRUG|capecitabine|Given orally
48484103|NCT00766155|DRUG|oxaliplatin|Given IV
47964202|NCT06393829|BEHAVIORAL|Applying the Early Mobilization Program|A mobilization intervention based on the level of function (LOF) ( i.e. patients should be assessed for mobilization status within 24 hours of admission; mobilization should occur at least three times a day, and mobility should be progressive and scaled, tailored to the patient's abilities); The frequency of patient mobilization (primary outcome) will be assessed 20 weeks before implementation, during the 20 weeks of implementation and 20 weeks after the end of implementation (60 weeks in total).
47964203|NCT03164135|GENETIC|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
47964204|NCT01284829|OTHER|FDG-PET scan|
47964205|NCT02066142|DEVICE|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
47964206|NCT02066142|DEVICE|Ultrasound|
48313458|NCT02687230|DRUG|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
48313459|NCT05622383|OTHER|aromatherapy|aromatherapy,
48484104|NCT03978312|OTHER|Nominal consensus group|NLit-UK linguistic and cultural adaptation (NLit-UK) 2 x nominal consensus groups evidence review and topic expert engagement
48484105|NCT03978312|OTHER|Observational cohort (validity and reliability testing)|Nutrition Literacy Measurement Tool validation (NLit-UK). Target sample 366 on treatment cancer patients confirmatory binary analysis for validity and reliability.
48484106|NCT06317584|OTHER|Experimental: Empowerment Application for CAM Health Education|Using empowerment software application for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of assistive tool of the empowerment software application
47964207|NCT03873831|BEHAVIORAL|Animal-assisted intervention|The therapy dog is present during the session.
47964208|NCT03873831|BEHAVIORAL|Social skills group|"The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists."
47964209|NCT02968797|DEVICE|SafeSed|Monitor respiratory parameters
47964210|NCT04838483|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
47964211|NCT03708081|PROCEDURE|ProTaper Next|Root canal instrument
47964212|NCT03708081|PROCEDURE|TF Adaptive|Root canal instrument
48114855|NCT03401190|DRUG|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
48313460|NCT05622383|OTHER|music concert|music concert
48484107|NCT06317584|OTHER|Written Paper for CAM Health Education|Using written paper for complementary and alternative therapy education and explaining the risk factors that need to be considered
48484108|NCT00251641|DRUG|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
48484109|NCT00251641|DRUG|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
48484110|NCT03479931|PROCEDURE|Without placement of a catheter|Elective cesarean section without preoperative placement of a urinary catheter.
48484111|NCT03479931|PROCEDURE|With placement of a catheter|Elective cesarean section with preoperative placement of a urinary catheter.
48484112|NCT00103402|DRUG|Alfuzosin|
48484113|NCT00103402|DRUG|Placebo|
47964213|NCT06556446|DRUG|Tenecteplase and Alteplase|The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
47964214|NCT02532088|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
48114856|NCT03401190|DRUG|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
48114857|NCT01521624|DRUG|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
48484114|NCT01947231|OTHER|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
48484115|NCT01947231|OTHER|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
48114858|NCT05800405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48313461|NCT05622383|OTHER|aromatherapy and music concert,|aromatherapy and music concert,
48484116|NCT05519657|OTHER||
47964215|NCT02532088|DIETARY_SUPPLEMENT|Placebo|Placebo
47964216|NCT03550456|OTHER|ECC|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
47964217|NCT03550456|OTHER|ECC with CLE|Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
48313462|NCT03188679|DEVICE|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
47964218|NCT03550456|OTHER|Speech therapy|Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
47964219|NCT06310538|BEHAVIORAL|kou sha|Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.
48313463|NCT05604469|DIAGNOSTIC_TEST|Isolation of skin microbiota|Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.
48484117|NCT03523247|BEHAVIORAL|whole food, plant based diet|whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
48484118|NCT04194684|DRUG|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
48484119|NCT04203160|DRUG|CPI 613|Given intravenously
48484120|NCT04203160|DRUG|Gemcitabine|Given intravenously
48484121|NCT04203160|DRUG|Cisplatin|Given intravenously
48484122|NCT00334256|DRUG|Tenofovir (TDF)|
48484123|NCT00334256|DRUG|Emtricitabine (FTC)|
48484124|NCT02226731|DEVICE|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
47964220|NCT06310538|DRUG|Hongjin Xiaojie Capsules|The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
48114859|NCT05800405|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR-T per standard of care
48313464|NCT00088868|DRUG|alvespimycin hydrochloride|
47964221|NCT00180544|DEVICE|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
48313465|NCT04060264|BIOLOGICAL|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
48484125|NCT02226731|DEVICE|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
48484126|NCT05333224|OTHER|Telerehabilitation|Family-centered, goal-oriented early physiotherapy approaches will be applied.
48484127|NCT05333224|OTHER|Control|Family-centered, goal-oriented early physiotherapy approaches will be applied.
48484128|NCT02794155|DRUG|HDV Insulin Lispro|HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
48484129|NCT02794155|DRUG|Insulin LISPRO|Insulin Lispro: no bound insulin
48484130|NCT06233110|DRUG|Fostamatinib|Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.
48484131|NCT06233110|DRUG|Ruxolitinib|Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
47964222|NCT04315909|DRUG|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
47964223|NCT04315909|DIETARY_SUPPLEMENT|Vitamin E and C|Vitamin E and vitamin C
47964224|NCT04315909|OTHER|Placebo|Placebo
47964225|NCT02497339|BEHAVIORAL|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
47964226|NCT04279457|DEVICE|DyeVert Plus System|The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure. At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved
48484132|NCT05476614|OTHER|Yoga (Robot-instructed)|Yoga that is instructed by a social robot
48484133|NCT05476614|OTHER|Yoga (Human-instructed)|Yoga that is instructed by a human
48484134|NCT06044194|DRUG|L-arginine and liposomal vitamin C|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
48484135|NCT01795248|DRUG|Liraglutide|1.8 mg liraglutide
47964227|NCT04279457|OTHER|Standardized hydration protocol|hydration protocol based up on the Poseidon protocol
47964228|NCT00705484|BIOLOGICAL|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
47964229|NCT00705484|DRUG|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
47964230|NCT00004132|BIOLOGICAL|filgrastim|
47964231|NCT00004132|BIOLOGICAL|palifermin|
47964232|NCT00004132|DRUG|cyclophosphamide|
47964233|NCT00004132|DRUG|etoposide|
47964234|NCT00004132|DRUG|ifosfamide|
47964235|NCT00004132|PROCEDURE|quality-of-life assessment|
48484136|NCT01795248|DRUG|Placebo|Liraglutide without the GLP-1 analogue
48484137|NCT05800899|BEHAVIORAL|Brief Motivational Interviewing|Standard non-adapted brief motivational interviewing based on motivational interviewing.
47964236|NCT00004132|RADIATION|radiation therapy|
48484138|NCT05800899|BEHAVIORAL|Culturally adaptation brief motivational interviewing|culturally adapted brief motivational interviewing based on motivational interviewing.
48484139|NCT05547334|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
48114860|NCT05800405|PROCEDURE|Computed Tomography|Undergo PET/CT
48114861|NCT05800405|RADIATION|External Beam Radiation Therapy|Undergo radiation therapy
48114862|NCT05800405|PROCEDURE|Leukapheresis|Receive leukapheresis
48484140|NCT05016622|BIOLOGICAL|BNT162b2 vaccine|Administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
48484141|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.|Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).
48484142|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.|dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
48484143|NCT05213260|OTHER|Flipped Teaching method|Before the clinical skill laboratory session, the students will receive the learning materials that they have to read and assimilate before the in-class part which will include interactive, discussion-oriented, and practice-oriented activities.
48484144|NCT01999426|OTHER|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
48484145|NCT03795584|PROCEDURE|sterile repositionable hemostasis clipping device close the large duodenal papilla incision|After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
47964237|NCT04036890|DRUG|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
47964238|NCT04036890|DRUG|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
47964239|NCT02738060|DIETARY_SUPPLEMENT|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
47964240|NCT06260332|BEHAVIORAL|Supportive Care (Fitbit)|Wear Fitbit, Use Fitbit application, Receive educational materials, attend coaching calls, Ancillary studies
47964241|NCT02893670|PROCEDURE|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
47964242|NCT00515346|DEVICE|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
47964243|NCT04556513|OTHER|Paraclinical examination|Respiratory functional tests
47964244|NCT04556513|OTHER|Clinical Examination|Clinical Examination
47964245|NCT04556513|OTHER|Semi-directive interview|By phone
47964246|NCT04556513|OTHER|quality of life questionnaires|SF36, VSRQ, IESR, HADS
47964247|NCT03289858|DRUG|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
47964248|NCT03289858|DRUG|Sodium Chloride|Saline Injection
47964249|NCT03026322|OTHER|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
47964250|NCT03026322|OTHER|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
47964251|NCT04977193|BIOLOGICAL|LY011|CAR-T
47964252|NCT05535699|OTHER|exercises|scapular exercise
47964253|NCT02829528|BEHAVIORAL|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
47964254|NCT02179489|PROCEDURE|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
48114863|NCT05800405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48114864|NCT05800405|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48114865|NCT00605982|PROCEDURE|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
48114866|NCT06469684|BEHAVIORAL|Health education session|1 hour health education session religious teaching promoting health-seeking behaviour, and question and answer session with healthcare professional.
48313466|NCT04060264|BIOLOGICAL|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
48484146|NCT03351387|COMBINATION_PRODUCT|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
47964255|NCT04655378|OTHER|Mass Sepctrometry|Mass spectrometry (LC/MS) of purified immunoglobulins
47964256|NCT02487667|DEVICE|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
47964257|NCT06241833|DRUG|PPI|use of PPI concomitant with DAPT
47964258|NCT01552200|PROCEDURE|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
47964259|NCT01552200|PROCEDURE|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
47964260|NCT05965492|DRUG|Acetaminophen|"Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg."
47964261|NCT05965492|DRUG|Celebrex|"Day 1: 200 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 400 mg.~Day 2 and Day 3: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 4: 100 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 5: 50 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 100 mg.~Not prescribed on Days 6 and 7."
47964262|NCT05965492|DRUG|Gabapentin|"Day 1 and Day 2: 300 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 900 mg.~Day 3: 200 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 600 mg.~Day 4: 200 mg two times a day and 100mg once a day administered via tablet by mouth for a total cumulative daily dose of 500 mg.~Day 5: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 6: 100 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 7: 100 mg once a day administered via tablet by mouth for a total cumulative daily dose of 100 mg."
47964263|NCT05965492|DRUG|Famotidine|Day 1- Day 7: 20 mg once a day administered via tablet by mouth for a total cumulative daily dose of 20 mg.
48114867|NCT00182845|DRUG|Donepezil|
48114868|NCT01282944|BEHAVIORAL|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
48114869|NCT01282944|BEHAVIORAL|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
48114870|NCT04818255|BEHAVIORAL|PET Biomarker Disclosure|Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
48114871|NCT01970618|DRUG|RV1162 single dose|Safety and tolerability of single escalating doses
48114872|NCT01970618|DRUG|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
48114873|NCT01970618|DRUG|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
48484147|NCT03418168|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
48114874|NCT01970618|DRUG|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
48313467|NCT06467643|PROCEDURE|non-instrumented root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were irrigated with room temperature 5.25% sodium hypochlorite which was activated ultrasonically for 30 seconds and then intra-canal heated using a heat carrier to a temperature fixed at 150 degree celsius. Three consecutive cycles of PAU and intra-canal heating of sodium hypochlorite were performed. After the first and the last cycle, root canals were irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) and kept in the canal for 60 seconds and then flushed out with 5 mL of saline. Root canals of this group were kept un-instrumented.
48313468|NCT06467643|PROCEDURE|conventional root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were convetionally prepared using Reciproc Blue rotary files according to the manufacturer's instructions. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
48313469|NCT01592279|DRUG|liraglutide|
48484148|NCT01988168|PROCEDURE|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
47964264|NCT05965492|DRUG|Decadron|"Day 1: 4 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 12 mg.~Day 2: 4 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 8 mg.~Day 3: 2 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 4 mg.~Not prescribed on Days 4 through 7."
47964265|NCT05965492|DRUG|Oxycodone|A prescription of oxycodone as per standard of care will be provided to participants in case of breakthrough pain.
47964266|NCT01100671|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
47964267|NCT04945122|DRUG|Pitavastatin|Pitavastatin 4mg Qn
47964268|NCT04945122|DRUG|Atorvastatin|Atorvastatin 20mg Qn
47964269|NCT05717946|DIETARY_SUPPLEMENT|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
47964270|NCT05717946|OTHER|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
47964271|NCT04974840|BEHAVIORAL|Treadmill training combined with/ without thera-band|Treadmill walking training with thera-band Treadmill walking training without thera-band
47964272|NCT02582983|DRUG|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
47964273|NCT03482544|DRUG|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
47964274|NCT03482544|OTHER|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
47964275|NCT00976040|OTHER|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
48114875|NCT01970618|DRUG|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
48114876|NCT01970618|DRUG|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
48114877|NCT05516641|DIETARY_SUPPLEMENT|Soluble Corn Fiber|once daily additive to diet
48114878|NCT05516641|DIETARY_SUPPLEMENT|Maltodextrin|once daily additive to diet
48313470|NCT01592279|DRUG|Insulin injections|
48313471|NCT03349541|OTHER|Complex Care Curriculum|"A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations."
48313472|NCT05366972|DEVICE|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
48313473|NCT02678234|DRUG|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
48313474|NCT04548687|PROCEDURE|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
48313475|NCT04548687|PROCEDURE|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
48313476|NCT02629601|BEHAVIORAL|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
48313477|NCT02629601|BEHAVIORAL|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
48313478|NCT02629601|BEHAVIORAL|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
48313479|NCT02629601|BEHAVIORAL|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
48313480|NCT02629601|BEHAVIORAL|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
48313481|NCT04689750|DIAGNOSTIC_TEST|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
48313482|NCT06527612|OTHER|Pulmonary rehabilitation exercise programme|In addition to standard medical treatment, the EGr will undergo an exercise program. The initial exercise training will be conducted in the hospital, followed by online exercise sessions via video conferencing three times a week during the first week. From the second week onwards, they will be asked to perform their exercises at home three times a week using provided exercise videos and will be monitored for one year. Compliance with the exercise regimen will be assessed through a weekly survey shared in a WhatsApp group established for the exercise group patients.
48313483|NCT01005537|BIOLOGICAL|aldesleukin|Given IV and orally
48313484|NCT01005537|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
48313485|NCT01005537|DRUG|cyclophosphamide|Given IV
48313486|NCT03799718|BIOLOGICAL|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
48313487|NCT00005050|DRUG|ethynyluracil|
48313488|NCT00005050|DRUG|fluorouracil|
48313489|NCT00005050|DRUG|oxaliplatin|
48313490|NCT01622920|OTHER|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
48313491|NCT03073681|DEVICE|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
48313492|NCT00764959|DEVICE|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
48313493|NCT01887028|DEVICE|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
48313494|NCT00139334|BIOLOGICAL|Rotavirus|
48313495|NCT01370096|DRUG|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
48313496|NCT01370096|DRUG|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
47964276|NCT05195580|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
47964277|NCT02971254|DRUG|Sevoflurane|
47964278|NCT02971254|DRUG|Desflurane|
48114879|NCT02783235|OTHER|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
48114880|NCT02928874|BEHAVIORAL|% COMPX (low ED vs. high ED preload)|
48114881|NCT02928874|BEHAVIORAL|EAH (low ED vs. high ED snacks)|
48114882|NCT04298788|OTHER|Blue dishware|blue dishware is used for plates and bowls
48114883|NCT06112977|PROCEDURE|Prepectoral implant-based immediate breast reconstruction|Prepectoral implant based breast reconstruction is an immediate breast reconstruction whereby a fixed volume implant or expander is placed on top of the chest wall muscle (Pectoralis Major) to reconstruct the breast after mastectomy.
48114884|NCT06068699|OTHER|Postcard|Participants received a postcard asking them to address non-adherence to remote monitoring.
48114885|NCT02827617|DRUG|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
48114886|NCT04956757|OTHER|Exercise Intervention|Scapula retraction exercises at varying shoulder abduction angles will be applied
48114887|NCT02692105|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
47964279|NCT02119364|OTHER|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
48114888|NCT02692105|RADIATION|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
48313497|NCT06279130|DRUG|botensilimab|Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)
48643766|NCT02577302|DEVICE|SNS - InterStim® System|"Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months."
48643767|NCT06254950|DRUG|TAK-279|TAK-279 capsules.
47964280|NCT02598804|OTHER|5 educational workshop|
47964281|NCT02598804|OTHER|written information booklet|
47964282|NCT02983344|DRUG|Ropivacaine|Fascia iliaca compartment block using ropivacaine
48114889|NCT03737682|DIAGNOSTIC_TEST|ENzyme linked immunity-sorbet assays|Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
48114890|NCT00861458|DRUG|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
48313498|NCT06279130|DRUG|balstilimab|Anti programmed cell death protein-1 (anti-PD1)
48313499|NCT06422351|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
48313500|NCT01672996|DRUG|Ioforminol 160 mgI/mL|Given as s single administration to the subject
48313501|NCT01672996|DRUG|Ioforminol 200 mgI/mL|Given as a single administration to the subject
48313502|NCT01672996|DRUG|Iopamidol 300 mgI/mL|Given as a single administration to the subject
48313503|NCT02474667|DRUG|ANG-3777|
48643768|NCT06254950|DRUG|Placebo|TAK-279 placebo-matching capsules.
47964283|NCT02983344|DRUG|Fentanyl|Intravenous fentanyl
47964284|NCT02983344|DEVICE|Ultrasound|Ultrasound-guided fascia iliaca compartment block
47964285|NCT02840500|OTHER|No intervention|No intervention
48114891|NCT04432688|DRUG|Lurasidone HCl|This is a non-interventional, observational study
48114892|NCT02599935|DIETARY_SUPPLEMENT|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
48114893|NCT02599935|OTHER|standard treatment|No other than standard treatment
48114894|NCT02599935|OTHER|educational structured counseling|Nutritional counseling leaded to patient and caregivers
48114895|NCT04228536|PROCEDURE|Totally ExtraPeritoneal (TEP) repair|
48114896|NCT04228536|PROCEDURE|TransAbdominal PrePeritoneal (TAPP) repair|
48114897|NCT04228536|PROCEDURE|Open anterior mesh repair (OAM)|
48114898|NCT04228536|PROCEDURE|Combined Anterior and Posterior technique (CAP)|
48114899|NCT04228536|PROCEDURE|Open PrePeritoneal Mesh technique (OPPM)|
48114900|NCT04228536|PROCEDURE|Sutured Repair|
48114901|NCT02412748|BEHAVIORAL|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
48114902|NCT02412748|BEHAVIORAL|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
48114903|NCT04810793|DRUG|Amoxicillin , Levofloxacin and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens
48114904|NCT04810793|DRUG|Amoxicillin , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens
48114905|NCT04810793|DRUG|Tetracycline , Furazolidone and Esomeprazole|Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens
48114906|NCT04810793|DRUG|Amoxicillin,Levofloxacin and Vonoprazan fumarate|Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group
48313504|NCT02474667|OTHER|Placebo|
48313505|NCT05429372|GENETIC|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
48313506|NCT01853111|BIOLOGICAL|Interleukin-2|
48313507|NCT04770610|DRUG|OT-101 Ophthalmic Solution|Atropine 0.01%
48313508|NCT04770610|DRUG|Vehicle|Investigational Product minus active ingredient
48643769|NCT06228326|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
48643770|NCT06228326|DRUG|Pembrolizumab (KEYTRUDA®)|PD-1 immune checkpoint inhibitor
48643771|NCT06228326|DRUG|Chemotherapy|SOC chemotherapy
48643772|NCT06599073|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the carotid artery during cardiac arrest
48114907|NCT04810793|DRUG|Amoxicillin,Furazolidone and Vonoprazan fumarate|Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group
48114908|NCT04810793|DRUG|Tetracycline,Furazolidone and Vonoprazan fumarate|Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group
48114909|NCT02620761|DRUG|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
48114910|NCT02620761|DRUG|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
48114911|NCT05618236|DRUG|Group N; neostigmine+atropine|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
48114912|NCT05618236|DRUG|GROUP S; decurarized with sugammadex.|"The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no."
48643773|NCT06599073|DEVICE|Rescue|RescueDoppler patch with probe is attached on the left side of the neck during the cardiac arrest. Operative health personell are blinded for the velocity curves that are post-processed by the research team after the cardiac arrest and synchronised with ECG.
48643774|NCT06685913|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test
48643775|NCT06685913|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test
48643776|NCT05162794|OTHER|Laparoscopy with excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
48643777|NCT05162794|OTHER|Laparoscopy without excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
48643778|NCT05162794|OTHER|Medical treatment-as-usual|Patients continue their hormonal and analgesic treatment-as-usual.
48643779|NCT05810038|DRUG|Rimegepant|Rimegepant
47964286|NCT00149162|DRUG|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
47964287|NCT00002588|DRUG|etoposide|
48114913|NCT01684397|BIOLOGICAL|Bevacizumab|Given IV
48114914|NCT01684397|OTHER|Laboratory Biomarker Analysis|Correlative studies
48114915|NCT01684397|DRUG|Pazopanib Hydrochloride|Given PO
48114916|NCT01684397|OTHER|Pharmacological Study|Correlative studies
48114917|NCT00004124|DRUG|bicalutamide|
48313509|NCT06400836|OTHER|Carbohydrate timing - carbohydrate intake before or after exercise|The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
48643780|NCT05810038|DRUG|Placebo|matching placebo
48643781|NCT06626711|DRUG|Propofol|Propofol as a part of total venous anesthesia
48643782|NCT06626711|DRUG|Sevoflurane|Sevoflurane as a part of intravenous anesthesia
47964288|NCT00002588|DRUG|topotecan hydrochloride|
47964289|NCT04152278|DIAGNOSTIC_TEST|cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
48114918|NCT00004124|DRUG|goserelin|
48643783|NCT04210115|BIOLOGICAL|pembrolizumab|IV infusion
48643784|NCT04210115|DRUG|placebo|IV infusion
48114919|NCT00004124|DRUG|mitoxantrone hydrochloride|
48114920|NCT00004124|DRUG|prednisone|
48114921|NCT00232895|DRUG|lipuro propofol|
48114922|NCT00232895|DRUG|standard formulation propofol|
48114923|NCT06666725|OTHER|Menu label|Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group
48114924|NCT00344994|DRUG|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
48114925|NCT01573130|BEHAVIORAL|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
48114926|NCT00028769|DRUG|bicalutamide|
48114927|NCT00028769|DRUG|estramustine|
48114928|NCT00028769|DRUG|etoposide|
48114929|NCT00028769|DRUG|flutamide|
48114930|NCT00028769|DRUG|goserelin|
48114931|NCT00028769|DRUG|leuprolide|
48114932|NCT00028769|DRUG|nilutamide|
48114933|NCT00028769|DRUG|paclitaxel|
48114934|NCT01716858|DIETARY_SUPPLEMENT|Sulforaphane-rich Broccoli Sprout Extract|
48313510|NCT00437606|DRUG|GK Activator (2)|100mg po
48643785|NCT04210115|DRUG|cisplatin|IV infusion
48643786|NCT04210115|DRUG|5-FU|IV infusion
48643787|NCT04210115|RADIATION|radiotherapy|external radiation
48643788|NCT04210115|DRUG|leucovorin|IV infusion
48643789|NCT04210115|DRUG|levoleucovorin|IV infusion
48643790|NCT04210115|DRUG|oxaliplatin|IV infusion
48643791|NCT00005898|DRUG|anti-thymocyte globulin|
48114935|NCT06216730|PROCEDURE|Endoscopic papillectomy|"patients undergoing endoscopic papillectomy will be included and treated according to the study algorithm.~* A papillary adenoma (abnormal tissue growth/ tumour at junction of bile duct \& intestines) will be removed completely by cutting \& removing abnormal tissue growth using a flexible tube containing a camera through the mouth.~* After the procedure you will be admitted in the hospital for at least 24 hours for observation,~* You will be asked to use medications which decrease acid production (PPIs- proton pump inhibitors) in stomach for 2 weeks to decrease the risk of bleeding."
48313511|NCT00437606|DRUG|Ethanol|40g po
48114936|NCT02748265|DRUG|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
48114937|NCT02748265|DRUG|Sevoflurane|Volatile maintenance anesthesia
48114938|NCT02748265|DRUG|Propofol|Intravenous maintenance anesthesia
48114939|NCT02158754|DIAGNOSTIC_TEST|Corus CAD (ASGES)|
48114940|NCT06467253|DEVICE|1. rTMS + CS|"In the first phase each participant will receive 15 sessions of rTMS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of rTMS and 1 session of CS per week for 12 weeks. Each session will consist of 10 trains of 10 stimuli, at a 5-Hz frequency and a stimulation intensity of 120% of the resting motor threshold.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The rTMS condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
48114941|NCT06467253|DEVICE|2. rTMS Sham + CS|"In the first phase each participant will receive 15 sessions of rTMS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham rTMS and 1 session of CS per week for 12 weeks.~In total, each participant will receive 27 sessions of Sham rTMS and 21 sessions of CS.~rTMS will be administered by a MagPro R30 stimulator (MagVenture) and an active/placebo 8-shape coil model MCF-B70.~Two surface electrodes will be employed to replicate rTMS skin sensations near the stimulation site. The sham condition will be double-blinded through the use of a USB stick.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of rTMS and 21 sessions of CS."
48313512|NCT01316991|DIETARY_SUPPLEMENT|Chewing Gum|chewing gum will be provided
48313513|NCT01316991|DIETARY_SUPPLEMENT|No Gum|no chewing gum will be provided
48313514|NCT00001439|BIOLOGICAL|gp100 human melanoma peptide|
48313515|NCT00978861|DRUG|Hydrogen Peroxide|Whitening product syringe type
48484149|NCT01988168|PROCEDURE|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
48484150|NCT00290251|DRUG|ulipristal acetate 20 mg|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
48484151|NCT00290251|DRUG|ulipristal acetate 10 mg|10 mg given daily for three menstrual cycles or 90 - 102 days
48484152|NCT00290251|DRUG|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
48484153|NCT01124695|DRUG|tamoxifen|PO
48114942|NCT06467253|DEVICE|3. tDCS + CS|"In the first phase each participant will receive 15 sessions of tDCS and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of tDCS and 1 session of CS per week for 12 weeks. Each session will consist of the delivery of a weak direct current of 2mA for 30 minutes.~tDCS will be administered by the Sooma tDCS stimulator. The tDCS condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of tCDS and 21 sessions of CS."
48313516|NCT05481203|BEHAVIORAL|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
48313517|NCT05481203|BEHAVIORAL|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
48313518|NCT01687413|RADIATION|Intensity-modulated radiation therapy (IMRT)|
48313519|NCT01687413|DRUG|Cisplatin|
48484154|NCT00932945|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
48484155|NCT02056470|DEVICE|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
48484156|NCT02056470|DEVICE|Total Knee Replacement|total Knee replacement implant
48484157|NCT02056470|DEVICE|Freedom Total Knee System|Total Knee replacement implant
48484158|NCT00005119|PROCEDURE|Measures of calcium and bone turnover|
48484159|NCT02396173|OTHER|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
48484160|NCT00722631|DRUG|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
48114943|NCT06467253|DEVICE|4. tDCS Sham + CS|"In the first phase each participant will receive 15 sessions of tDCS Sham and 9 sessions of CS divided in 3 weeks, in the maintenance phase each participant will receive 1 session of Sham tDCS and 1 session of CS per week for 12 weeks.~tDCS will be administered by the Sooma tDCS stimulator. The sham condition will be double-blinded, and a third operator will program the stimulator.~Cognitive stimulation will be a Mexican adaptation of the Memory Training and Cognitive Stimulation for Mild Cognitive Impairment from the Center for the Prevention of Cognitive Impairment of the Madrid City Council.~In total, each participant will receive 27 sessions of Sham tDCS and 21 sessions of CS."
48114944|NCT05241847|BEHAVIORAL|PeLTQL delivery via electronic means|Delivery of PeLTQL scoring information to clinicians via electronic means.
48114945|NCT03078634|OTHER|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
48313520|NCT03836976|OTHER|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
48484161|NCT00722631|DRUG|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
48484162|NCT03499119|DRUG|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
48484163|NCT03499119|DRUG|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
48484164|NCT03499119|DRUG|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
48484165|NCT05727475|PROCEDURE|Minimal invasive restorative treatment|Composite veneer facing without drilling or removal of enamel
48484166|NCT05727475|PROCEDURE|Fluoride gel application|Fluoride gel application 1.23%
48643792|NCT00005898|DRUG|cyclophosphamide|
47964290|NCT01256008|BEHAVIORAL|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
48114946|NCT03078634|OTHER|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
48114947|NCT06676787|OTHER|Transportation Voucher, Comunity engagement and microplannnig support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. This is in addition to support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
48340228|NCT04432571|BEHAVIORAL|E-NAV/SOC-OIC|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
48484167|NCT02150759|DRUG|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
48484168|NCT02150759|DRUG|Fentanyl|add dexmedetomidine during position change
48484169|NCT02150759|DRUG|Ketamine|add dexmedetomidine during position change
48484170|NCT03643679|OTHER|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
48484171|NCT01202071|DRUG|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
48484172|NCT01202071|DRUG|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
48643793|NCT00005898|DRUG|cyclosporine|
48643794|NCT00005898|DRUG|filgrastim|
48643795|NCT00005898|DRUG|fludarabine|
48643796|NCT00005898|DRUG|methylprednisolone|
48114948|NCT06676787|OTHER|Direct Facility Funding, Community Engagement, and Microplaning Support|Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly performance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
48114949|NCT06676787|OTHER|Transportation Voucher, Direct Facility Funding, Community engagement and Microplanning support|Transportation vouchers will be provided to caregivers of eligible children after vaccination at designated routine immunisation health facilities. Direct funding will be provided to designated routine immunisation health facilities monthly, in addition to weekly oerformance monitoring and quarterly financial capacity building. Also, there will be support for microplaning (technical assistance) for these routine immunisation health facilities and comunity engagement at their catchment areas.
48114950|NCT00628862|DRUG|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
48114951|NCT00628862|DRUG|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
48313521|NCT03533140|DEVICE|DUCEST Neurostimulator V Group A|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
48313522|NCT03533140|DEVICE|DUCEST Neurostimulator V Group B|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
48313523|NCT04188951|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
48484173|NCT01202071|DRUG|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
47964291|NCT01256008|BEHAVIORAL|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
47964292|NCT00564772|DRUG|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
47964293|NCT03400878|BIOLOGICAL|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
47964294|NCT03400878|BIOLOGICAL|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
47964295|NCT05791175|DEVICE|Teeth scan with intraoral scanner (Trios, 3 Shape, Denmark)|Intraoral scanner will be use to monitor the changes of the teeth over time. Intraoral scanners are devices that capture three-dimensional images of teeth and are used as an alternative to conventional dental impressions.
47964296|NCT05089877|DEVICE|Surgical Ablation|The AtriCure cryoICE® cryoFORMTM cryoablation probe is used in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway.
47964297|NCT03255798|DEVICE|G2 and G3|Two iStent inject devices and one iStent supra device
47964298|NCT05397964|DEVICE|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
47964299|NCT04790929|DEVICE|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
47964300|NCT04790929|BEHAVIORAL|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
48114952|NCT00628862|DRUG|Turbuhaler® placebo|placebo inhaled twice daily
48114953|NCT04738565|DIETARY_SUPPLEMENT|Probiotic preparation|The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
48114954|NCT04738565|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
48114955|NCT03151590|BEHAVIORAL|exercise training|
48114956|NCT04084080|BIOLOGICAL|Red Blood Cell|Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of \<20% and a pre-transfusion hemoglobin S of \<30%.
48114957|NCT04084080|OTHER|Standard of care|NHLBI/ASH/ATS Expert Panel recommended guidelines
48266758|NCT03760484|DRUG|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
47964301|NCT04561830|PROCEDURE|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
47964302|NCT00451308|PROCEDURE|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
47964303|NCT00451308|PROCEDURE|Induction of labor with foley balloon with 30cc|30cc of saline in foley
47964304|NCT00920998|DRUG|Z-338|oral
47964305|NCT03739593|DRUG|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
48114958|NCT05561452|OTHER|Single PRP Injection|"In single-PRP injection group, 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
48484174|NCT01202071|DRUG|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast."
48114959|NCT05561452|OTHER|Multiple PRP Injections|"In multiple-PRP injection group, two PRP injections will be performed with an interval of 3 weeks. 10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged at 3850 rpm for 8 minutes. Approximately 4 ml of the PRP obtained is planned to be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
47964306|NCT03739593|DRUG|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
48114960|NCT05561452|OTHER|Placebo Injection|"In placebo-injection group,10 ml of venous blood will be taken and after the same waiting time 4 ml of 0.9% saline will be injected into the subacromial space using the lateral subacromial injection method under ultrasound guidance. All injections will be performed in the sagittal axis with the long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe).~A physical therapy program including Codman pendulum exercises, shoulder range of motion, stretching and strengthening exercises will be given and be performed at least for 20 minutes daily."
48484175|NCT03346252|DRUG|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
48643797|NCT05988931|BEHAVIORAL|Web Program + App|Youth receive a brief interactive web program made available online to prevent alcohol misuse. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
47964307|NCT05410483|DRUG|Docetaxel|Hyperthermic Intraperitoneal Docetaxel
47964308|NCT05197556|DRUG|HSG4112|Once-daily oral administration
47964309|NCT05197556|DRUG|Placebo|Once-daily oral administration
48114961|NCT01505881|DRUG|dabigatran etexilate low dose|active treatment (low)
48114962|NCT01505881|DRUG|warfarin 5mg|comparator warfarin
48114963|NCT01505881|DRUG|dabigatran etexilate intermediate dose|active treatment (medium)
48114964|NCT01505881|DRUG|warfarin 1mg|comparator warfarin
48114965|NCT01505881|DRUG|dabigatran etexilate high dose|active treatment (high)
48114966|NCT01505881|DRUG|warfarin 3mg|comparator warfarin
48114967|NCT00482378|DRUG|Pamidronate|90 mg by IV monthly.
48114968|NCT00482378|DRUG|Zoledronic acid|4 mg by IV monthly.
48114969|NCT00482378|RADIATION|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
48266759|NCT03760484|BIOLOGICAL|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
48266760|NCT00308607|DRUG|Bevacizumab (Avastin)|
47964310|NCT05037071|DEVICE|Upper body graduated compression sleeve|An over the counter light compression sleeve will be worn during game training
47964311|NCT03222960|DRUG|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
47964312|NCT03222960|DRUG|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
47964313|NCT06400862|COMBINATION_PRODUCT|eOCT implantation|eOCT is regarded as an Advanced Therapy Product (ATP).
47964314|NCT00272740|DRUG|Fulvestrant|
47964315|NCT04138238|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
47964316|NCT01802801|OTHER|embryo development|intra- and inter-observator analysis
48266761|NCT00308607|DRUG|dacarbazine|
48266762|NCT00308607|DRUG|interferon-alfa-2a (Roferon-A)|
48266763|NCT02388373|DRUG|Fluticasone 250/formoterol 10|
48266764|NCT02388373|DRUG|Fluticasone 250/salmeterol 25|
48266765|NCT02388373|DRUG|Fluticasone 125/formoterol 5|
48114970|NCT06354283|BEHAVIORAL|Progressive Muscle Relaxation Exercises|Progressive muscle relaxation techniques were explained to the women from the couples assigned to the Intervention Group by a researcher. In addition to relaxation exercises, deep breathing movements were also explained to the women and progressive muscle relaxation exercises and breathing exercises were performed together. The importance of the exercises and how to do them were explained to the women by the researcher for about 30 minutes and then demonstrated practically for 30 minutes. Each progressive muscle relaxation exercise session lasted approximately 20-25 minutes. The women in the intervention group continued the exercises at home three times a week for four weeks.
48643798|NCT05988931|BEHAVIORAL|Web Program + App + Text Messages|Youth receive a brief interactive web program made available online to prevent alcohol misuse. This is followed by 8 weeks of supportive text messages. The parent/caregiver app addresses monitoring and skill building for parents to communicate with the child about preventing underage drinking and drug use.
47964317|NCT01728909|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
47964318|NCT01728909|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
47964319|NCT01637272|DRUG|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
47964320|NCT05626855|DRUG|Apitegromab|Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.
47964321|NCT01837433|DRUG|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
47964322|NCT01837433|DRUG|Prednisone 6 weeks|Guidelines recommend
47964323|NCT06045351|DRUG|Vitamin D|"Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day"
47964324|NCT06045351|OTHER|Active Comparator|"Active Comparator (Group B; n=71):~Initial-- 12 weeks;~* Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~* VD supplementation (600,000 IUI/M) once during the study period~* Calcium 1000 mg/day~* Standard PCOS Continued"
47964325|NCT03306563|DIAGNOSTIC_TEST|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
47964326|NCT04617171|DRUG|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
47964327|NCT04617171|DRUG|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
47964328|NCT02050191|BEHAVIORAL|www.princetonlivingwell.com|
47964329|NCT02753114|DRUG|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
47964330|NCT02753114|DRUG|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
47964331|NCT01780077|DRUG|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
47964332|NCT01780077|DRUG|Placebo|Multiple intradermal injections of placebo at incision sites
47964333|NCT04198298|DRUG|EndoSequence|The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
47964334|NCT04198298|DRUG|ProRoot MTA|The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
47964335|NCT04198298|DRUG|Biodentine|The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
47964336|NCT01372696|OTHER|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
47964337|NCT04257734|OTHER|observation|different serum antibodies status
47964338|NCT03942666|DRUG|Treatment A|tablet of CHF 6532
47964339|NCT03942666|DRUG|Treatment B|tablet of CHF 6532
47964340|NCT03942666|DRUG|Treatment C|tablet of CHF 6532
47964341|NCT03942666|DRUG|Treatment D|tablet of CHF 6532
47964342|NCT03942666|DRUG|Treatment E|Placebo tablet of CHF 6532
47964343|NCT03942666|DRUG|Treatment F|tablet of CHF 6532
48484176|NCT04132401|DIAGNOSTIC_TEST|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
48484177|NCT00401284|DRUG|EVT 201|
48484178|NCT00572117|DRUG|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
48484179|NCT01739725|DEVICE|Stent insertion|The patient will receive the helical stent
48484180|NCT02135120|DRUG|Combined spinal epidural anesthesia technique with intrathecal morphine|
48484181|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
47964344|NCT01581788|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
47964345|NCT01471808|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
47964346|NCT01471808|DRUG|CSII, Metformin, Pioglitazone|CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
47964347|NCT01471808|DRUG|CSII, Sitagliptin|CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months
48114971|NCT05766969|DRUG|CBD/PEA|A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
48114972|NCT05766969|DRUG|Placebo|An inactive compound.
48313524|NCT03510611|DRUG|Ensartinib with fed or fasting|The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
48313525|NCT01473810|BIOLOGICAL|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
48313526|NCT01473810|BIOLOGICAL|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
48313527|NCT01473810|BIOLOGICAL|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
48484182|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
48484183|NCT06142370|OTHER|Descriptive|The patients will be asked by the recruiting physicians to perform a clinical examination looking for the LCV, which will take a total of five seconds. This is a self-test and not part of a regular clinical examination
48484184|NCT04070339|OTHER|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
48484185|NCT04009889|DIETARY_SUPPLEMENT|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
47964348|NCT03342365|DIAGNOSTIC_TEST|Evaluation of microbial translocation and microbiota|Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis
48484186|NCT04009889|OTHER|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
47964349|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 1|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964350|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 2|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964351|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 3|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964352|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 4|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964353|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 5|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964354|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 6|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964355|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 7|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964356|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 8|Liquid formula produced by several food ingredients to provide a balance nutrient intake
47964357|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 9|Liquid formula produced by several food ingredients to provide a balance nutrient intake
48114973|NCT02195713|DEVICE|Accuryn|Accuryn is a novel electronic urine output monitor
48114974|NCT02651233|OTHER|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
48114975|NCT01424540|DRUG|GSK2336805 150mg|Single Dose
48114976|NCT01424540|OTHER|Placebo|Single Dose
48114977|NCT03601780|DRUG|local wound infiltration plus usual care|local wound infiltration plus usual care
48114978|NCT03601780|DRUG|usual care only|usual care only
47964358|NCT06358716|DIETARY_SUPPLEMENT|Glucose|25 mg of glucose dissolved in 200 mL
47964359|NCT01011777|DRUG|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10\^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10\^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
47964360|NCT00828932|DRUG|Lorcaserin|
48114979|NCT04470258|OTHER|ELMO PROJECT AT COVID-19: STUDY IN HUMANS|The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.
48114980|NCT04470258|DEVICE|ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY|After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
48313528|NCT01473810|BIOLOGICAL|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
48313529|NCT00129805|DRUG|MCI-9042|
48313530|NCT00129805|DRUG|Aspirin|
48313531|NCT02942849|DRUG|r-hFSH|As per standard clinical practice
48114981|NCT03470142|PROCEDURE|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
48114982|NCT03470142|PROCEDURE|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
48114983|NCT05322837|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires related to upper limb function and quality of life will be used
48313532|NCT06444243|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.
48313533|NCT06444243|DRUG|Niacin|"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacin helps some enzymes work properly and helps skin, nerves, and the digestive tract stay healthy. Niacin is found in many plant and animal products.~Niacin will be used at a concentration of 250mg as an active control."
48313534|NCT00103805|DRUG|levodopa|
48313535|NCT04680078|PROCEDURE|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
47964361|NCT03368794|BEHAVIORAL|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
47964362|NCT03368794|BEHAVIORAL|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
48313536|NCT04680078|PROCEDURE|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
48313537|NCT04434053|DEVICE|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
48313538|NCT04434053|DEVICE|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
48484187|NCT05449093|OTHER|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
48484188|NCT00500279|DRUG|Celecoxib|
47964363|NCT04471142|DEVICE|neuromuscular bandage|After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
47964364|NCT03959943|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
47964365|NCT01915082|DRUG|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
47964366|NCT01915082|DRUG|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
48484189|NCT05295654|OTHER|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
48484190|NCT04623021|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
47964367|NCT03372096|DEVICE|Prostatic Artery Embolization|LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
47964368|NCT06273410|OTHER|Cention N|Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds
48484191|NCT04784884|DEVICE|HSI|diagnostic hyperspectral imaging
48114984|NCT04510454|DIAGNOSTIC_TEST|Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR|Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
48114985|NCT00161733|DRUG|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
48114986|NCT00161733|DRUG|TISSEEL VH fibrin sealant|
48313539|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
47964369|NCT06273410|OTHER|Cention N + Adhesive|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds
48114987|NCT06676592|DIAGNOSTIC_TEST|Preoperative imaging|Preoperative imaging will be performed as part of the standard of care. Imaging data from US, CT, MRI, and/or PET performed for routine care will be used for this study.
48313540|NCT06536335|DEVICE|Biomax Nuvola aligners|All patients will be treated with Biomax Nuvola aligners built based on the individual atient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
48313541|NCT01204619|BEHAVIORAL|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
48313542|NCT05279612|RADIATION|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
48313543|NCT03817255|OTHER|Substance use questionnaire|Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
48313544|NCT03817255|OTHER|Physical activity|Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
48313545|NCT02117167|DRUG|AZD2014|Target: m-TOR
48313546|NCT02117167|DRUG|AZD4547|Target: FGFR
48313547|NCT02117167|DRUG|AZD5363|Target: AKT
48313548|NCT02117167|DRUG|AZD8931|Target: HER2, EGFR
48114988|NCT06676592|DIAGNOSTIC_TEST|3D framework|3D images of surface landmarks will be acquired by use of US and the Scaniverse app before surgery, in conjunction with the participant's standard-of-care US or US-guided biopsy procedure
48114989|NCT02080650|DEVICE|Mesenchymal-marker based ferrofluid (c-MET)|
48114990|NCT02080650|DEVICE|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
48114991|NCT06184152|DIAGNOSTIC_TEST|CEUS imaging|Contrast-enhanced ultrasound (CEUS)
48114992|NCT06184152|DIAGNOSTIC_TEST|aMRI imaging|contrast enhanced abbreviated MRI (AMRI)
48313549|NCT02117167|DRUG|Selumetinib|Target: MEK
48313550|NCT02117167|DRUG|Vandetanib|Target : VEGF, EGFR
48313551|NCT02117167|DRUG|Standard maintenance for squamous NSCLC|
48313552|NCT02117167|DRUG|Pemetrexed|Standard maintenance for non squamous NSCLC
48313553|NCT02117167|DRUG|Durvalumab|Target: PD-L1
48313554|NCT02117167|DRUG|savolitinib|target : MET
48313555|NCT02117167|DRUG|Olaparib|target : PARP
48313556|NCT06337292|DEVICE|Incisional Negative Pressure Wound Therapy (NPWT)|Participants in the treatment group will be standardized and will receive incisional NPWT using the any incisional VAC system that can apply 75-125mmHg continuous suction to the incision. The VAC sponge will be placed over the surgical wound at least 2cm in width and \>3cm in length.
48313557|NCT03614169|PROCEDURE|Implantation of a HIS-pacing lead|This intervention is attempted first
48114993|NCT06335628|DEVICE|Geistlich Fibro-Gide®|Geistlich Fibro-Gide® is intended to be used as an implantable device for regeneration and augmentation of soft tissue in oral and maxillofacial surgery.
48114994|NCT02888808|OTHER|Gastroscopy|Upper gastrointestinal endoscopy procedure
48114995|NCT05518396|DIAGNOSTIC_TEST|CoDE-HF decision support tool|We will assess the diagnostic performance of the CoDE-HF decision support tool
48114996|NCT06588257|BIOLOGICAL|Non-infectious adjuvanted recombinant nonavalent HPV vaccine|Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).
48114997|NCT00917241|DRUG|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
48114998|NCT00917241|DRUG|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
48114999|NCT00296751|PROCEDURE|ECG recording|
48115000|NCT00296751|PROCEDURE|Epidural catheter insertion|
48313558|NCT03614169|PROCEDURE|Implantation of a LV-pacing lead|This intervention is attempted first
48313559|NCT00731393|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
48313560|NCT00731393|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
48313561|NCT03623126|OTHER|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
48484192|NCT03596619|DEVICE|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
47964370|NCT06273410|OTHER|Bulk Fill Composite|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
48643799|NCT04980963|BEHAVIORAL|Cognitive Support Technology (CST)|Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
47964371|NCT00823095|DRUG|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
48643800|NCT05773586|DRUG|APG-5918|oral tablets 10mg, 50mg.
48643801|NCT05773586|DRUG|Placebo|Matching placebo
48643802|NCT06687941|DRUG|AST-201|AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
47964372|NCT02237131|DRUG|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
47964373|NCT02237131|DRUG|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
48115001|NCT00296751|DRUG|Intravenous meperidine injection|
48115002|NCT00296751|DRUG|Epidural Bupivacaine and fentanyl injection|
48115003|NCT02390544|DRUG|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
48115004|NCT05552469|DRUG|DFV890|DFV890 Single Agent
48115005|NCT05519813|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
48115006|NCT05519813|DRUG|Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets|Use Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets for 3 months to treat PCOS
48115007|NCT06357754|BIOLOGICAL|Idecabtagene vicleucel|As per product label
48313562|NCT00620971|DRUG|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
48313563|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
48643803|NCT06686082|DRUG|Biologics|The ultrasonic changes of synovitis and enthesitis were observed after 12 weeks of treatment with biologic agents
48643804|NCT05704036|DRUG|Transdermal estrogen|Transdermal estradiol 0.1 mg/day, applied once weekly
48643805|NCT05704036|DRUG|Progesterone|Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
48643806|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated|Antihypertensive therapy utilizing atrioventricular interval modulation.
47964374|NCT01425996|DRUG|Lipotecan® (TLC388)|"* Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~* Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~* Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~* Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~* Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
47964375|NCT00002190|DRUG|Saquinavir|
47964376|NCT00002190|DRUG|Lamivudine|
47964377|NCT00002190|DRUG|Zidovudine|
47964378|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
47964379|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
48115008|NCT06357754|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
48115009|NCT01283750|BEHAVIORAL|care coordination|dementia-related care coordination
48313564|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
48313565|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
48313566|NCT00620971|DRUG|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
48313567|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
48313568|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
48313569|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
48313570|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
48313571|NCT02024204|DRUG|Fluticasone propionate 230mcg for 3 Months|
48313572|NCT02024204|DRUG|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
48115010|NCT02050763|BEHAVIORAL|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau \& Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska \& DiClemente, 1983; Prochaska \& Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
48115011|NCT04883957|DRUG|BGB-11417|Film-coated tablets administered orally as specified in the treatment arm.
48115012|NCT04121858|OTHER|Brain Safe App|The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.
48115013|NCT04121858|OTHER|Attention Control App|The attention control app, called Med Safe, includes only the medication list feature.
48313573|NCT02024204|DRUG|Salmeterol 21mcg for 3 Months|
48313574|NCT02826733|DEVICE|Electroencephalogram (EEG)|
48313575|NCT02826733|DEVICE|Near Infra Red Spectroscopy (NIRS)|
47964380|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
47964381|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
47964382|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
48115014|NCT00938535|BEHAVIORAL|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
48115015|NCT00837746|DRUG|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
48266766|NCT05752214|OTHER|WEB Register|Observational, non-profit, multicentre longitudinal study on the assessment of quality of life and its association with demographic variables and visual function of visually impaired patients attending the visual rehabilitation service.
48266767|NCT05836454|OTHER|Progressive Muscle Relaxation Group:|Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.
48313576|NCT02826733|DEVICE|magnetic resonance imaging (MRI)|
48313577|NCT02979886|DRUG|GnRH-a|the hormone reaction to the down regulation of the patients
48313578|NCT02979886|DRUG|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
47964383|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
47964384|NCT01382095|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
47964385|NCT00726869|DRUG|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
47964386|NCT01594983|DRUG|LCQ908|
48313579|NCT06440161|OTHER|Primary exposures were venous congestion defined by central venous pressure (CVP) and mean arterial pressure (MAP).|"After the induction of anaesthesia, a central venous or pulmonary artery catheter was positioned. Based on prior studies, thresholds for central venous pressure were set at 10, 12, 16, and 20 mm Hg. Venous congestion was quantified by time exceeding each CVP threshold and the area under the curve (AUC) surpassing each CVP threshold in mmHg × min. Assessments were limited to pre- and post-CPB periods, as the venous drainage cannulate generated negative CVP during CPB.~An arterial catheter was installed upon room admission. Continuous arterial blood pressure monitoring commenced after exposure to atmospheric pressure and calibration to zero. The MAP was determined using the formula: 2/3 × diastolic blood pressure + 1/3 × systolic blood pressure. Data were logged by automated software every minute. Established thresholds for MAP were 55, 65, and 75 mm Hg. Hypotension was quantified as (1) time under each MAP threshold in minutes and (2) the AUC below each MAP threshold in mmHg × min."
47964387|NCT01594983|DRUG|Fenofibrate|Fenofibrate once daily 12 weeks
47964388|NCT01594983|DRUG|Fish Oil|Fish Oil once daily for 12 weeks
47964389|NCT01594983|DRUG|Placebo of LCQ908|Matching placebo of LCQ908
47964390|NCT01594983|DRUG|Placebo of fenofibrate|Matching placebo of fenofibrate
47964391|NCT01594983|DRUG|Placebo of fish oil|Matching placebo of fish oil capsule
48115016|NCT04051255|DRUG|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
48643807|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated|AVIM therapy is deactivated
48643808|NCT06650592|OTHER|All patients who were candidates for immediate lymphatic reconstruction (ILR)|All patients who were candidates for immediate lymphatic reconstruction (ILR)
48643809|NCT05743140|DIAGNOSTIC_TEST|CaIMR|Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.
47964392|NCT03795623|OTHER|Voice-Weaning|Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
47964393|NCT03795623|OTHER|Sham control|Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
47964394|NCT06376396|DRUG|albendazole and praziquantel|Combination of albendazole plus praziquantel
47964395|NCT06376396|DRUG|Albendazole|Albendazole alone
47964396|NCT01682109|DRUG|Valacyclovir|
47964398|NCT02040493|RADIATION|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
47964399|NCT02464020|DRUG|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
48115017|NCT05017571|DRUG|Colchicine|Colchicine 1 capsule (0.6 mg) per day
48313580|NCT02322892|DRUG|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
48313581|NCT02322892|DRUG|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
48313582|NCT01755494|DRUG|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
48313583|NCT01755494|DRUG|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
48313584|NCT01755494|DRUG|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
48313585|NCT01755494|DRUG|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
48313586|NCT01755494|DRUG|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
48643810|NCT06616272|OTHER|Cervical rehabilitation|"* Manual joint mobilization (Grades I-V) of painful and restricted cervical spine segments.~* Supine manual cervical traction to stretch and mobilize the cervical spinal tissues.~* Manual soft tissue mobilization of the cervical, upper thoracic and/or shoulder muscles.~* Passive stretching of hypertonic muscles and active strengthening of hypotonic muscles.~* Motor-control and isometric exercises to activate the deep neck flexors."
47964400|NCT01634009|DIETARY_SUPPLEMENT|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
47964401|NCT04712994|OTHER|PrEP Optimization Interventions|A bundle of strategies (video-based PrEP counselling, HIV Self-Testing \[HIVST\] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes) will be implemented in the intervention group.
48115018|NCT05017571|DRUG|Placebo|Placebo 1 capsule per day
48115019|NCT06172699|DEVICE|Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device|All enrolled subjects who meet eligibility criteria will undergo an attempted implant within 30 days of consent. After successful device implant, subjects will be followed at 1 and 12 months. Subjects will be fitted with a Holter monitor during the 1m follow-up visit and will complete a minimum of 72 hours and maximum of up to 7 days of Holter monitoring.
48313587|NCT01609803|OTHER|laboratory biomarker analysis|Correlative studies
48313588|NCT04500041|PROCEDURE|Casting|Use of casts applied using corrective maneuvers
48643811|NCT06616272|OTHER|Standard Concussion Care|"Standard Concussion Care interventions are individualized to each patient and their adjudicated profile(s)/moderating factor(s) and may include any/all of the following:~* Behavioral regulation~* Vestibular rehabilitation~* Oculomotor rehabilitation~* Exertion rehabilitation~* Pharmacological management~* Behavioral sleep intervention~* \*Cervical spine rehabilitation (the variable of interest in this study)~* Psychotherapy"
48643812|NCT06268678|OTHER|Phase of the menstrual cycle|Follicular or luteal phase
47964402|NCT02627521|PROCEDURE|PRU guided CABG|Coronary Artery Bypass Surgery
47964403|NCT02627521|PROCEDURE|CABG per standard of care|Coronary Artery Bypass Surgery
47964404|NCT02627521|DEVICE|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
47964405|NCT02627521|DRUG|Ticagrelor|Ticagrelor administration prior to randomization
47964406|NCT02717585|DEVICE|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
48313589|NCT04500041|DEVICE|Bracing|Use of full-time spinal orthosis
48313590|NCT03174821|DEVICE|Insulin pump|Blood glucose management device
48313591|NCT03671824|OTHER|Measurements|Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
48115020|NCT06611059|DEVICE|PSG|Two replicas of each scapula are made. The scapulae are drilled with a commercial guide and with an in-house guide separately
48115021|NCT01772420|DRUG|Eltrombopag Olamine|Given PO
48115022|NCT01772420|OTHER|Laboratory Biomarker Analysis|Correlative studies
48115023|NCT01772420|DRUG|Lenalidomide|Given PO
48115024|NCT02133404|DRUG|ASP7991|oral
48115025|NCT02133404|DRUG|Cinacalcet|oral
48115026|NCT02133404|DRUG|Placebo|oral
48115027|NCT05463549|OTHER|Informative video|An informative instructional film regarding the amniocentesis procedure including answers to frequently asked questions.
48115028|NCT03477695|DEVICE|ambulatory use of the Upright device|Patients will wear the UpRight for a period of two month
48115029|NCT04825366|DEVICE|Continuous glucose monitoring device|Participants will have to wear their continuous glucose monitoring device throughout the study.
48115030|NCT04825366|OTHER|Gold method|The Gold method will be used to assess impaired awareness of hypoglycemia
47964407|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (active)|The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.
48115031|NCT04825366|OTHER|Clarke questionnaire|The Clarke questionnaire will be used to assess impaired awarness of hypoglycemia
48115032|NCT04825366|OTHER|Edinburgh Hypoglycemia Symptom Scale|The Edinburgh Hypoglycemia Symptom Scale will be used to assess symptoms of hypoglycemia
48643813|NCT06343610|DIETARY_SUPPLEMENT|Active product|Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.
47964408|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (Sham)|"The tDCS Acti- Sham montage is developed to recreate the cutaneous sensations associated with tDCS, yet essentially a null electrical field over the networks of interest."
47964409|NCT02158273|DRUG|Sugar Pill|145 mg/day, oral pill, 9 days
47964410|NCT02158273|DRUG|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
48115033|NCT04825366|OTHER|BAPAD questionnaire|The BArriers to Physical Activity in type 1 Diabetes (BAPAD) questionnaire will be used to assess barriers of physical activity
48115034|NCT04825366|OTHER|Hypoglycemia Fear Survey II|The Hypoglycemia Fear Survey II will be used to assess fear of hypoglycemia
48115035|NCT04825366|OTHER|Physical activity questionnaire|The International Physical Activity Questionnaire will be used to assess physical activity practice
48115036|NCT04825366|OTHER|Well-being|The WHO-5 well-being index will be used to assess well-being.
48115037|NCT04825366|OTHER|Treatment satisfaction|The Diabetes Treatment Satisfaction Questionnaire will be used to assess treatment satisfaction.
48115038|NCT04825366|OTHER|Hypoglycemia diary|Participants will be asked to record in a diary treatments for hypoglycemic events
48115039|NCT04825366|DEVICE|Piezo RxD|Participants will be asked to wear a pedometer throughout the study
47964411|NCT02657915|DRUG|Placebo|Administered as specified in the treatment arm.
47964412|NCT02657915|DRUG|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
48115040|NCT04825366|DEVICE|Heart rate monitor|During training sessions, participants will be asked to wear a heart rate monitor
48115041|NCT04825366|OTHER|Exercise diary|Before each training session, participants will be asked to note in a diary their glucose levels, if they have taken a snack or not and if insulin was administered. After each training session, participants will be asked to note that same information. In addition, they will be asked to note their bedtime blood glucose, if they have taken a bedtime snack and if adjustment to insulin doses was made.
48115042|NCT01386138|BEHAVIORAL|Psycho-education|Receive RBT education and peer-support in a group format.
48115043|NCT01386138|BEHAVIORAL|Experimental|Receive RBT education and a pro-active counseling method
48115044|NCT03753841|OTHER|Adjustment of oral diet|Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
48115045|NCT05774444|DIETARY_SUPPLEMENT|Krill oil|Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.
48115046|NCT05774444|DIETARY_SUPPLEMENT|Krill protein|Krill protein will be given to the participant following a resistance exercise bout.
48115047|NCT05774444|DIETARY_SUPPLEMENT|Vegetable oil|This will be the control against the Krill oil
48115048|NCT05774444|DIETARY_SUPPLEMENT|Carbohydrate|This will be the control for the Krill protein
48115049|NCT06545214|PROCEDURE|Video-EEG monitoring|Video-EEG monitoring
48115050|NCT06545214|PROCEDURE|Respiratory monitoring and polysomnography|heart rate, pulse oximetry (oxygen levels in the blood), nasal airflow, respiratory effort (thoracic and abdominal) and capnography (carbon dioxide (CO2) levels in exhaled air)
48266768|NCT05836454|OTHER|Myofascial Release Technique Group|It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
48266769|NCT06028633|DRUG|pembrolizumab|pembrolizumab 200mg IV on day 1 for every 3 weeks
48266770|NCT06028633|DRUG|lenvatinib|lenvatinib 8mg taken orally every day
48266771|NCT06028633|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
48266772|NCT05057455|PROCEDURE|cytokine hemadsorption|the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
47964413|NCT05898360|COMBINATION_PRODUCT|Time Restricted Eating|time restricted eating
47964414|NCT05898360|OTHER|normal diet|normal diet
47964415|NCT02383498|OTHER|Placebo|Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
47964416|NCT02383498|BIOLOGICAL|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
47964417|NCT02383498|RADIATION|Radiotherapy|Standard of care
48115051|NCT06545214|PROCEDURE|1 Hypercapnic challenge while participant is awake|The healthy patient/subject breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the healthy patient/subject breathes ambient air and his or her breathing is measured. Then, after a few minutes, the healthy patient/subject is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
48115052|NCT06545214|PROCEDURE|2 Hypercapnic challenges while participant is sleeping|"In the evening, as soon as the doctor detects on the EEG that the patient/subject is in deep sleep, various tests will be carried out to assess reactivity to wakefulness.~Two hypercapnic challenges will be carried out during sleep, using the same procedure as for wakefulness. The test will be stopped when the healthy patient/subject wakes up, or when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in case of intolerance."
48115053|NCT06545214|PROCEDURE|Auditory stimulus|Two auditory stimulus tests will be carried out during the patient's sleep. Using headphones, the investigator will administer auditory stimuli at regular, progressively louder intervals to determine the ability of the patient/ healthy subject to awaken to an auditory stimulus.
47964418|NCT02383498|DEVICE|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
47964419|NCT05581862|BEHAVIORAL|3 meals+3 snacks|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
48484193|NCT04641793|DEVICE|Motion and Emg Control|"We will consider two methods for integrating motions and EMG signals:~1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.~2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty."
48115054|NCT06545214|OTHER|Questionnaires|Questionnaire to assess caffeine consumption habits Quality of life questionnaires QOLIE-31 Anxiety and depression questionnaires HADS
48115055|NCT06676267|PROCEDURE|Laparoscopic surgery|The laparoscopic surgery system is applied to gynecology and 5G remote surgical treatment.
48115056|NCT03922334|BEHAVIORAL|Patient Navigation Program|A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.
48484194|NCT01145131|OTHER|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
47964420|NCT05581862|BEHAVIORAL|3 meals|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
47964421|NCT03646318|DRUG|Ketanserin|"The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours"
47964422|NCT03646318|OTHER|Placebo|Glucose 5% solution
47964423|NCT00934830|DRUG|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
48115057|NCT03098810|DRUG|Zinc sulphate|Oral syrup zinc sulphate
48484195|NCT05161819|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
48484196|NCT05161819|DEVICE|Sham stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
48484197|NCT03660215|OTHER|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
47964424|NCT00934830|OTHER|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
47964425|NCT02605824|DRUG|n-acetylcystine|NAC is a mucolytic drug.
47964426|NCT02605824|DRUG|0.9% saline|Normal saline is a placebo agent.
48115058|NCT03098810|OTHER|Placebo|Oral syrup placebo
48115059|NCT02129582|RADIATION|total marrow irradiation|Undergo TMI
48643814|NCT06343610|DIETARY_SUPPLEMENT|Placebo|No active ingredients.
48115060|NCT02129582|DRUG|fludarabine phosphate|Given IV
48115061|NCT02129582|DRUG|busulfan|Given IV or PO
48313592|NCT06257498|PROCEDURE|MRI scan|MRI scan on open scanner and some questionnaires
48313593|NCT03758430|OTHER|Meal-Tagging App|Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
48313594|NCT03758430|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 16 weeks.
48643815|NCT06608472|DRUG|N0877|1 tablet of N0877 and 1 tablet of Placebo of Benicar HCT®
48643816|NCT06608472|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877
48643817|NCT06500442|DRUG|NEU-111|Oral Doses
48643818|NCT06500442|DRUG|Placebo|Oral Doses
47964427|NCT06065397|PROCEDURE|Goal setting improvement program|A improvement program how to optimalize patient-centered goal setting in rehab care is being implemented.
47964428|NCT01245621|BEHAVIORAL|Later entry group|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
48115062|NCT02129582|PROCEDURE|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
48313595|NCT02078713|BEHAVIORAL|Contraceptive Decision Support Tool|"The decision support tool:~* Provides an educational session about different aspects of contraception~* Elicits patient preferences about different aspects of contraception~* Identifies potential contraindications to certain contraceptive methods~* Allows the patient to view details about and compare available contraceptive methods~* Suggests methods most appropriate based on the patient's preferences~* Collects questions the patient may have for her provider~* Generates a printout the patient can bring to her contraceptive counseling visit"
48115063|NCT02129582|BIOLOGICAL|anti-thymocyte globulin|Given IV
48115064|NCT02129582|DRUG|tacrolimus|Given IV or PO
48115065|NCT02129582|DRUG|methotrexate|Given IV
48115066|NCT02129582|OTHER|laboratory biomarker analysis|Correlative studies
48313596|NCT02221180|DRUG|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
48115067|NCT05960695|OTHER|Stretching|"Among the stretching exercises, iliopsoas, adductor, and hamstring stretches will be taught. Participants will repeat the stretches 3 times a week with 3 repetitions of each stretch for 20 seconds. The exercises will be done online by the physiotherapist.~The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises."
48115068|NCT05960695|OTHER|Relaxation|Diaphragmatic breathing will be taught as a relaxation exercise. The experimental group will be given both stretching and relaxation exercises. The Control group will be given only stretching exercises.
48115069|NCT05276310|BIOLOGICAL|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
48115070|NCT00629941|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
48313597|NCT02221180|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
48313598|NCT02221180|DRUG|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
48313599|NCT04997889|COMBINATION_PRODUCT|Artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
48313600|NCT04997889|OTHER|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
48313601|NCT05763160|DRUG|RZL-012|Ready to use drug product for injection into the subcutaneous fat
48313602|NCT02508688|PROCEDURE|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
48643819|NCT02213107|DRUG|Enzalutamide and Dutasteride or finasteride|"Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily"
48643820|NCT06375655|BEHAVIORAL|Team2BF|Team2BF includes 3-4 breastfeeding-supportive messages per time interval, sent weekly from 28 weeks gestation through delivery, daily through 2 weeks postpartum, weekly from 2 to 10 weeks, and then monthly to one year. Other maternal health topics are not addressed.
48115071|NCT01923012|DRUG|Vitamin K2 (Menaquinone)|
48115072|NCT05918861|DRUG|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
48115073|NCT05918861|DRUG|Placebo|matching placebo tablets
48115074|NCT02950779|OTHER|Handgrip Strength Measurement|
48115075|NCT06405880|OTHER|Pharmacist-led care pathway|Participants in the intervention arm will receive the care using a shared decision-making pharmacist-led care pathway designed to guide the cardiovascular (CV) risk reduction process. The pharmacist-led care pathway is modelled after the largest CV risk reduction randomized controlled trial in a community pharmacy setting (RxEACH Study), and based upon the latest CV risk reduction guidelines, such as C-CHANGE. This pathway will be built into a computer web-based program and include step-by-step, algorithm-guided patient assessment to calculate the participant's estimated CV risk. The participant and pharmacist will be guided by the care pathway to review the participant's estimated CV risk and contributing CV risk factors and engage in shared decision-making to manage the participant's CV risk factors using lifestyle changes and/or pharmacological treatment as clinically appropriate.
48115076|NCT06677229|DRUG|Eletriptan HBr 40 mg|Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.
48115077|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (TUS)|tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
48115078|NCT03519737|DEVICE|tPA in combination with the Sonolysis Headframe (Sham TUS)|tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
48313603|NCT05532098|PROCEDURE|Dry Needling|Dry Needling will be done for the patients with ADD of TMJ in the retrodiscal tissue and superior joint space .
48313604|NCT05532098|PROCEDURE|PRP|Patients with ADD are administered with 1ml of PRP into the retrodiscal tissue and the superior joint space. PRP will be prepared by method proposed by Okuda et al., 2003. Reinjection will be given after 2 weeks if required.
48313605|NCT06360874|DRUG|ND-003 40mg|Participants receive 40mg ND-003 tablets once.
48643821|NCT06375655|BEHAVIORAL|Bright By Text|Bright By Text sends 2-4 messages per week from the first trimester through and beyond one year postpartum about a wide range of maternal and child health topics as outlined on their website; 8 messages are specifically about breastfeeding.
48115079|NCT02353988|DRUG|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade \>= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
48115080|NCT02353988|OTHER|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
47964429|NCT01245621|BEHAVIORAL|Early palliative care intervention|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
48115081|NCT03596268|DIAGNOSTIC_TEST|Imaging|3T Prisma MRI
48115082|NCT03596268|DIAGNOSTIC_TEST|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
48115083|NCT03596268|DIAGNOSTIC_TEST|Lumbar Puncture|CSF will be collected
48115084|NCT06056830|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
48115085|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Hita, Oita, Japan)|
48115086|NCT00812617|DIETARY_SUPPLEMENT|Mineral water (Aso-gun, Kumamoto, Japan)|
48643822|NCT05786131|PROCEDURE|Culprit-lesion revascularization|Percutaneous coronary intervention of culprit-lesion
47964430|NCT00753415|BIOLOGICAL|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).
48643823|NCT05786131|PROCEDURE|Non-culprit-lesion revascularization|Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
47964431|NCT00753415|BIOLOGICAL|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
47964432|NCT02099994|BIOLOGICAL|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo
47964433|NCT02099994|BIOLOGICAL|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo
47964434|NCT02099994|BIOLOGICAL|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
47964435|NCT02099994|BIOLOGICAL|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
47964436|NCT05975892|BIOLOGICAL|Transplantation of allogeneic MSCs in periodontal disease|Oral surgery is performed in patients with periodontal disease, under local anesthesia. An incision will be made on the periodontal lesion, A full-thickness flap is elevated on both the buccal and lingual areas and the inner epithelium of the flap removed. Granulation tissue is removed from bone defect area, and a root planning is performed. MSC construct is placed around the bone defect and a collagen membrane is used to cover and close off the bone defect site. The flap will be repositioned and the wound closed by a suture
47964437|NCT02091492|DRUG|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
47964438|NCT02091492|DRUG|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
48115087|NCT01532310|DRUG|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
48115088|NCT05880472|DEVICE|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
48115089|NCT04737681|OTHER|body composition|This is an observational study to determine immune response and skin barrier restoration in individuals with and without obesity.
48115090|NCT05886049|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48115091|NCT05886049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
48643824|NCT06672575|DRUG|Ivonescimab|Participante will recived an infusion by vein
48643825|NCT06690996|DRUG|LY4005130|Administered IV
48643826|NCT06690996|DRUG|LY4005130|Administered SC
47964439|NCT04029831|DRUG|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
47964440|NCT05005793|DRUG|Sodium bicarbonate|Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
47964441|NCT05005793|DRUG|Placebo|Placebo at 0.5 mEq/kg-lean body weight/day
47964442|NCT01936805|DRUG|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
47964443|NCT02376231|DEVICE|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
47964444|NCT04138121|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
47964445|NCT00006161|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
47964446|NCT00006161|PROCEDURE|Distal Splenorenal Shunt|
47964447|NCT00524862|DRUG|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
48115092|NCT05886049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
48115093|NCT05886049|DRUG|Cytarabine|Given IV
48643827|NCT06690996|DRUG|Placebo|Administered IV
48643828|NCT06690996|DRUG|Placebo|Administered SC
48643829|NCT06689293|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Self-collected sample from stool collected into testing kit
48643830|NCT04754074|BEHAVIORAL|Education|Weekly education related to behavior change
48643831|NCT04754074|BEHAVIORAL|Personalized coaching|Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
48643832|NCT04754074|BEHAVIORAL|Weekly behavior modification challenges|Weekly challenges to address behavior change
48643833|NCT02620865|BIOLOGICAL|Aldesleukin|Given SC
48115094|NCT05886049|DRUG|Daunorubicin|Given IV
48115095|NCT05886049|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48115096|NCT05886049|DRUG|Revumenib|Given PO
47964448|NCT00524862|DEVICE|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
47964449|NCT01704378|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
48115097|NCT05886049|PROCEDURE|Transthoracic Echocardiography|Undergo transthoracic ECHO
48115098|NCT04722003|BIOLOGICAL|Meningococcal Group B Vaccine|A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.
48115099|NCT04722003|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
48115100|NCT05752513|PROCEDURE|Late bladder dissection|The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
48115101|NCT05752513|PROCEDURE|early bladder dissection|The bladder dissection is early as in classic cesarean hysterectomy
48115102|NCT02711293|OTHER|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count \>350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been \>350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
48115103|NCT02711293|OTHER|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
48115104|NCT06369220|DIAGNOSTIC_TEST|cobas® liat CT/NG/MG nucleic acid test|The cobas® CT/NG/MG nucleic acid test for use on the cobas® Liat® System is an investigational, automated, qualitative in vitro nucleic acid diagnostic test that utilizes real-time polymerase chain reaction (PCR) for the direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) nucleic acid in male/female urine and vaginal swabs (clinician-collected and self-collected) in cobas® PCR Media.
48313606|NCT06360874|DRUG|ND-003 placebo 40mg|Participants receive placebo tablet matching to receive 40mg of ND-003.
48313607|NCT06360874|DRUG|ND-003 80mg|Participants receive 80mg ND-003 tablets once.
48484198|NCT05516459|BIOLOGICAL|Pfizer BNT162b2 Vaccine|The Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada
48484199|NCT05275972|DRUG|Ripasudil|Topical Ripasudil 0.4%
48484200|NCT05275972|DRUG|Placebo|Topical Placebo
47964450|NCT02571777|DRUG|QVM149 150/50/160|
47964451|NCT02571777|DRUG|QVM149 150/50/80|
47964452|NCT02571777|DRUG|QMF149 150/320|
47964453|NCT02571777|DRUG|QMF149 150/160|
47964454|NCT02571777|DRUG|salmeterol/fluticasone|
47964455|NCT02074644|PROCEDURE|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
47964456|NCT02074644|PROCEDURE|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
47964457|NCT04746963|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
47964458|NCT04746963|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
47964459|NCT04746963|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
48115105|NCT06369220|OTHER|Standard of Care (SOC): Clinician's Standard Practice|Standard of care (SOC) is defined as the traditional/typical diagnosis and treatment steps in practice recommended by the CDC guidelines that rely upon clinical syndromic presentations and/or external laboratory testing.
48115106|NCT06510348|DIETARY_SUPPLEMENT|Supplemental Parenteral Nutrition (SPN)|Nutritional targets are based on ESPEN guidelines recommendation (calories administration based on indirect calorimetry study, proteins 1.3 g/kg/day). From the first day of ICU admission indirect calorimetry will be performed daily in order to evaluate energy requirements. On the fourth day, the patient will undergo a gastric residual volume measurement and a paracetamol absorption test. If gastrointestinal dysfunction is detected, the patient will be assigned to a study group based on the randomization protocol. The SPN group will gradually initiate supplemental parenteral nutrition in order to achieve the target of 80% by the fifth day. Trophic feed will be administered to cover the remaining 20% of the targeted nutrition intake.
48313608|NCT06360874|DRUG|ND-003 placebo 80mg|Participants receive placebo tablet matching to receive 80mg of ND-003.
48313609|NCT06360874|DRUG|ND-003 160mg|Participants receive 160mg ND-003 tablets once.
48484201|NCT02002000|DRUG|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
48313610|NCT06360874|DRUG|ND-003 placebo 160mg|Participants receive placebo tablet matching to receive 160mg of ND-003.
47964460|NCT05547685|DIAGNOSTIC_TEST|Methylene blue intradermal injection|Methylene blue intradermal injection
48484202|NCT02002000|DRUG|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
48313611|NCT06360874|DRUG|ND-003 240mg|Participants receive 240mg ND-003 tablets once.
48484203|NCT06394726|BEHAVIORAL|Exercise İntervention|Aerobic and Core Stabilization Exercise Intervention
48484204|NCT01922752|DRUG|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
48484205|NCT04031612|DRUG|Neoadjuvant therapy|Neoadjuvant therapy
48484206|NCT03475134|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
48484207|NCT03475134|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
48484208|NCT03475134|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
48484209|NCT03475134|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
48484210|NCT03475134|DRUG|Nivolumab|Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
47964461|NCT00260481|DRUG|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
48484211|NCT00990587|DRUG|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
48643834|NCT02620865|BIOLOGICAL|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
48643835|NCT02620865|DRUG|Fluorouracil|Given IV
48643836|NCT02620865|DRUG|Gemcitabine Hydrochloride|Given IV
47964462|NCT00260481|DRUG|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
47964463|NCT03812107|OTHER|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
47964464|NCT03812107|OTHER|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
47964465|NCT01095055|BIOLOGICAL|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly
47964466|NCT01095055|BIOLOGICAL|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly
47964467|NCT04229420|DEVICE|Ultrasound guided Rectus sheath block vs Erector spinae plane block|Ultrasound guided Rectus sheath block vs Erector spinae plane block
47964468|NCT02041884|BEHAVIORAL|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
47964469|NCT02041884|BEHAVIORAL|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
47964470|NCT02041884|OTHER|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
47964471|NCT03288129|DRUG|Perampanel|film-coated tablets
47964472|NCT05650775|DRUG|Concerta|3-week trial of oral methylphenidate extended release
48266773|NCT03390413|PROCEDURE|Robot|Renal cancer treated with robotic surgery
48266774|NCT03390413|PROCEDURE|Cryoablation|Renal cancer treated with cryoablation
48313612|NCT06360874|DRUG|ND-003 placebo 240mg|Participants receive placebo tablet matching to receive 240mg of ND-003.
48313613|NCT06360874|DRUG|ND-003 300mg|Participants receive 300mg ND-003 tablets once.
48313614|NCT06360874|DRUG|ND-003 placebo 300mg|Participants receive placebo tablet matching to receive 300mg of ND-003.
48313615|NCT06360874|DRUG|MAD_ND003_Dose 1|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
48313616|NCT06360874|DRUG|MAD_placebo_Dose 1|Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 1
48643837|NCT02620865|DRUG|Irinotecan Hydrochloride|Given IV
48643838|NCT02620865|OTHER|Laboratory Biomarker Analysis|Correlative studies
48643839|NCT02620865|DRUG|Leucovorin Calcium|Given IV
48643840|NCT02620865|DRUG|Oxaliplatin|Given IV
48643841|NCT02620865|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
48643842|NCT02620865|BIOLOGICAL|Sargramostim|Given SC
48643843|NCT06480591|OTHER|Blood Draw|The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.
48115107|NCT06675942|DEVICE|Oscillation and Lung Expansion|The OLE device (MetaNeb system) is a newer, noninvasive physiotherapy tool that combines mechanical and pharmacological interventions (aerosols) to help mobilize endobronchial secretions.
48313617|NCT06360874|DRUG|MAD_ND003_Dose 2|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
48115108|NCT06675942|DEVICE|High-frequency chest wall oscillation|High-frequency chest wall oscillation (HFCWO) is an airway clearance technique that uses external forces applied to the chest via an inflatable vest connected to a device that generates vibrations at varying frequencies and pressures.
48115109|NCT03887624|DRUG|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
48115110|NCT03887624|DRUG|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
48115111|NCT03887624|DRUG|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
48115112|NCT06257888|OTHER|patient navigation|two trained patient navigators will admit breast cancer patients to HCM, navigate them from admission to commencement of first treatment and will collect all pertinent epidemiological data and variables
48115113|NCT06447987|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
48115114|NCT06447987|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48115115|NCT06447987|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48115116|NCT06447987|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48115117|NCT06447987|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
48115118|NCT06447987|BIOLOGICAL|Cetuximab|Given IV
48115119|NCT06447987|PROCEDURE|Computed Tomography|Undergo CT and PET
48115120|NCT06447987|DRUG|Cyclophosphamide|Given IV
48115121|NCT06447987|PROCEDURE|Echocardiography|Undergo ECHO
48313618|NCT06360874|DRUG|MAD_placebo_Dose 2|Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 2
48484212|NCT03433755|DRUG|evolocumab|Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
48643844|NCT06687837|BIOLOGICAL|autologous dopaminergic cell implantation|Dopaminergic progenitor cells derived from autologous induced pluripotent stem cells will be injected into the brain in two cohorts of Parkinson's patients, one receiving low dose and the other high dose (4 and 8 million cells, respectively)
48313619|NCT06360874|DRUG|MAD_ND003_Dose 3|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
48313620|NCT06360874|DRUG|MAD_ placebo_Dose 3|Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 3
48484213|NCT03433755|DRUG|placebo|Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
48643845|NCT06686628|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
48643846|NCT06686628|DRUG|Midazolam|Pharmaceutical form: Solution Route of administration: Oral
48643847|NCT06686628|DRUG|Caffeine|Pharmaceutical form: Tablet Route of administration: Oral
48115122|NCT06447987|DRUG|Fludarabine|Given IV
48115123|NCT06447987|PROCEDURE|Leukapheresis|Undergo leukapheresis
48643848|NCT06686628|DRUG|Metoprolol|Pharmaceutical form: Tablet Route of administration: Oral
48643849|NCT06686628|DRUG|Omeprazole|Pharmaceutical form: Capsule Route of administration: Oral
48643850|NCT06686628|DRUG|Warfarin|Pharmaceutical form: Tablet Route of administration: Oral
48115124|NCT06447987|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48115125|NCT06447987|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48115126|NCT06447987|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48115127|NCT00494780|DRUG|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
48115128|NCT00494780|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
48115129|NCT00494780|DRUG|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
48115130|NCT00494780|DRUG|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
48115131|NCT00494780|DRUG|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
48115132|NCT03942835|OTHER|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
48115133|NCT03942835|OTHER|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
48115134|NCT03942835|OTHER|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
48115135|NCT04759066|DEVICE|HEALiX|HEALiX is a non-restraint patient safety device
48115136|NCT02599142|DEVICE|Group A: Closed-face shell|As for arm description
48643851|NCT03849235|DIETARY_SUPPLEMENT|Standardised meal or glucagon|Standardised meal (Nutridrink, Nutricia, 300 kcal, 18.4 g carbohydrates, 5.8 g fat, 12 g protein) or 1mg glucagon
48643852|NCT01366014|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
48313621|NCT06360874|DRUG|Food effect_Cohort 1|Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
48313622|NCT06360874|DRUG|Food effect_Cohort 2|Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
48313623|NCT03870711|DRUG|lidocaine spray|10% lidocaine spray 4 puffs
48313624|NCT03870711|DRUG|Placebo|Sterile water 4 puffs
48313625|NCT05005741|DRUG|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
48115137|NCT02599142|DEVICE|Group B: Open-face shell|As for arm description
48313626|NCT05005741|DRUG|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
48313627|NCT04898374|DRUG|Gemcitabin/cisplatin|chemotherapy combination
48313628|NCT06280157|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
48313629|NCT03375359|DIAGNOSTIC_TEST|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
48313630|NCT03226223|DRUG|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
48313631|NCT01155648|DEVICE|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
48313632|NCT01155648|DEVICE|Chest wall compression for ten minutes in chest|
48313633|NCT06072001|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
48484214|NCT03959215|BEHAVIORAL|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
48484215|NCT03959215|OTHER|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
48313634|NCT06072001|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
48313635|NCT05522712|DEVICE|Acapella user|"The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~* Breathing control~* 10 breaths through the Acapella® device~* Inhaling up to approximately three - quarter maximum breathing capacity~* 2-3 second breath hold~* Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~* The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle."
48313636|NCT05522712|DEVICE|Incentive spirometer user|"1. Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~2. Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~3. Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~4. Try to get the ball as high as possible.~5. When getting it, hold breath for 10 seconds, or as long as possible.~6. Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~7. Repeat 10 times. Try to get the ball to the same level or higher with each breath.~8. repeat 10 times for 3 sets."
48484216|NCT02593227|BIOLOGICAL|Low dose FRα vaccine|165ug per peptide ID injection
48484217|NCT02593227|DRUG|Cyclophosphamide|IV infusion over 1 hour
48484218|NCT02593227|BIOLOGICAL|High dose FRα vaccine|500ug per peptide ID injection
48484219|NCT05462730|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
48484220|NCT05462730|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
48484221|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
48484222|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
48484223|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
47964473|NCT05650775|DRUG|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
48115138|NCT03204396|DRUG|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
48115139|NCT03204396|DRUG|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
48313637|NCT05522712|PROCEDURE|Control|This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
48313638|NCT02145091|DRUG|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
48313639|NCT02145091|DRUG|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
48313640|NCT02145091|DRUG|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
48643853|NCT01366014|DRUG|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
48643854|NCT01366014|DRUG|Placebo; oral|matching placebo
48115140|NCT05056753|DEVICE|HWBV chair|vibration-actuated, saddle-seat type stool
48115141|NCT04961047|BEHAVIORAL|Digital neurotherapy (DNT) Treatment|The experimental group will have 8 weeks of DNT 4 times a week for 30 minutes in the participant's home. The computer-presented training will be done on the participants' tablets or personal computers with the Rejuvenate brain training program
48115142|NCT04961047|BEHAVIORAL|Wait list control group|Waiting-list control group participants will be offered 8 weeks of DNT training at the completion of the final outcome assessment.
48313641|NCT02145091|DRUG|Placebo|An oral placebo (lactose pill).
48313642|NCT01649739|DRUG|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
48313643|NCT03988257|DIETARY_SUPPLEMENT|Imunoglukan PH4|Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
48313644|NCT03988257|DIETARY_SUPPLEMENT|Placebo (vitamin C syrup)|Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
48484224|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
48115143|NCT04956679|DIAGNOSTIC_TEST|carbon 13 breath test|Patients with positive Helicobacter pylori infection were determined by carbon 13 breath test ,The diagnosis and treatment of positive patients were followed up without other intervention.
48115144|NCT01645098|DRUG|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
48484225|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp once daily for 24 weeks
48484226|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily for 24 weeks
48484227|NCT01466322|DRUG|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
48643855|NCT06686459|RADIATION|ALL-in-one radiotherapy|ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)
48643856|NCT06686459|RADIATION|IMRT|IMRT (breast + supraclavicular + internal mammary lymph node drainage area)
48115145|NCT01645098|DRUG|Dexmedetomidine|0.5 mcg/kg/hr IV
48115146|NCT05758597|DRUG|Remazolam besylate|Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.
48115147|NCT05758597|DRUG|midazolam|Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.
48313645|NCT04704999|DRUG|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
48313646|NCT04704999|DRUG|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
48313647|NCT04704999|DRUG|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
48313648|NCT01437670|DRUG|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
48115148|NCT05790408|DEVICE|Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG)|The Zeiss Artevo digital microscope integrated with iOCT (Zeiss Artevo 800, Carl Zeiss Meditec AG) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb during transconjunctival needle revision of trabeculectomy bleb.
48115149|NCT05790408|DEVICE|Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)|The Spectralis Anterior-segment OCT (AS-OCT) is a commercially available, FDA approved device that can be utilized to visualize and evaluate the morphology of the trabeculectomy bleb in the office.
48115150|NCT00675246|DRUG|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
48115151|NCT06170450|DEVICE|Cyclic SNM|SNM cycling: 8 hours on, 16 hours off
48115152|NCT06170450|DEVICE|Continuous SNM|Continuous SNM: on continuously, no 'off' period
48115153|NCT03471611|DRUG|Autologous CD34+ Cells|The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min
48115154|NCT03471611|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
48115155|NCT05938894|OTHER|online games with various food images|Participant will play a series of online games with various food images.
48266775|NCT00401063|DEVICE|Acupuncture|Acupuncture treatment twice a day for eight weeks
48313649|NCT01187108|DRUG|N-acetylcysteine|NAC 600 mg oral once daily
48313650|NCT01187108|DRUG|Acetazolamide|Acetazolamide 250 mg oral once daily
48484228|NCT02172482|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
48484229|NCT00003621|DRUG|carmustine|
48484230|NCT00003621|DRUG|cisplatin|
48484231|NCT00003621|DRUG|etoposide|
48484232|NCT00003621|RADIATION|radiation therapy|
48484233|NCT01876849|DRUG|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
48643857|NCT06690203|COMBINATION_PRODUCT|NRICM102|A traditional Chinese medicine formula
48643858|NCT06691750|DEVICE|Barbed suture|Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.
48643859|NCT06691750|DEVICE|Conventional smooth suture|Size 1 smooth multifilament absorbable polyglactin suture.
48643860|NCT06689111|DEVICE|Left bundle branch pacing lead|Use of LBBp Vs the standard method of BiVp in resynchronization therapy
48643861|NCT06689111|DEVICE|CRT with the standard method through cs|standard CRT procedure
48115156|NCT05938894|OTHER|online games with images of flowers and songbirds|Participant will play a series of online games with images of flowers and songbirds.
48643862|NCT03621254|OTHER|[LO-LONG]|Both interventions are different modalities of FES-evoked leg exercise, three-four times per week for 6-8 weeks (24 therapy sessions). The comparator intervention (\[LO-LONG\]) uses 20-40 min (patient state of fitness dependent) of continuous leg exercise of lower intensity.
48115157|NCT02425917|DEVICE|geko|neuromuscular electrostimulator
48115158|NCT02425917|DEVICE|IPC-Calf|IPC used on calf with or without geko
48643863|NCT03621254|OTHER|[HI-SHORT|One intervention (\[HI-SHORT\]) uses a variety of leg exercise interval training of higher intensity for 10 x 2-min intervals.
48643864|NCT05640635|PROCEDURE|Ventilator weaning first|Ventilator weaning initiated and completed before start of ECMO weaning.
48643865|NCT05640635|PROCEDURE|ECMO weaning first|ECMO weaning initiated and completed before start of ventilator weaning.
48643866|NCT03031730|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48643867|NCT03031730|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48643868|NCT03031730|DRUG|Carfilzomib|Given IV
48115159|NCT05756010|DEVICE|EMG|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises
48115160|NCT04136470|BIOLOGICAL|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
48115161|NCT04004468|BEHAVIORAL|Resistance Training|Standard barbell resistance training programs
48643869|NCT03031730|DRUG|Dexamethasone|Given PO
48643870|NCT03031730|DRUG|Dexamethasone Sodium Phosphate|Given IV
47964476|NCT05199181|PROCEDURE|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
48115162|NCT06570473|DRUG|Empagliflozin|Tablet
48115163|NCT06570473|DRUG|Ranolazine|Tablet
48115164|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
48115165|NCT04045106|OTHER|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
48115166|NCT04045106|OTHER|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
48115167|NCT01897298|BEHAVIORAL|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
48115168|NCT01790529|PROCEDURE|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
48115169|NCT01790529|PROCEDURE|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
48115170|NCT01065220|DRUG|Testolactone undecanoate|4ml i.m.
48115171|NCT01065220|DRUG|Lynestrenol|2/day
48115172|NCT01065220|DRUG|Cyproterone Acetate|50mg per day
48115173|NCT01065220|DRUG|Estradiol|100 microgram TTS twice a week
48643871|NCT03031730|PROCEDURE|Echocardiography|Undergo echocardiography
48643872|NCT03031730|DRUG|Lenalidomide|Given PO
48643873|NCT03031730|DRUG|Navtemadlin|Given PO
48643874|NCT06687057|BEHAVIORAL|HRV Biofeedback Training|The intervention involves 5 training sessions lasting 45 minutes (specifically, 5-minute baseline and 5 HRV biofeedback trials lasting 5 minutes each) according to the protocol published by Lehrer et al. (2013). Physiological signals (ECG and respiratory rate) will be recorded during all sessions. During the training, participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing. They will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle in order to maximize the difference between the maximum and minimum heart rate within each respiratory cycle \[i.e., respiratory sinus arrhythmia (RSA), an index of vagal modulation on the heart\] (Lehrer et al., 2003; Lehrer et al., 2000).
48313651|NCT01187108|DRUG|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
48313652|NCT04526756|PROCEDURE|Mechanical Thrombectomy|Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
48313653|NCT00658372|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
48313654|NCT00658372|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
48313655|NCT00658372|DRUG|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
48313656|NCT00658372|DRUG|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
48313657|NCT05096871|GENETIC|Genotyping by Real Time PCR|"3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA)."
48313658|NCT00312884|DEVICE|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
48313659|NCT02297334|DEVICE|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
48313660|NCT01255046|DRUG|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
48313661|NCT01255046|DRUG|STA-1|300mg/tab, 2 tab/tid for 72 weeks
48313662|NCT01255046|DRUG|placebo|2 tab/tid for 72 weeks
48313663|NCT00853333|DRUG|dexmedetomidine|
48313664|NCT00853333|DRUG|midazolam|
48313665|NCT00853333|DRUG|propofol|
48313666|NCT03879317|DEVICE|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
48313667|NCT01079962|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
48313668|NCT01079962|DRUG|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
47964477|NCT03166384|DEVICE|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
48313669|NCT02367170|PROCEDURE|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation \>92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
48313670|NCT02367170|DRUG|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
48313671|NCT02367170|PROCEDURE|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
48313672|NCT02367170|DEVICE|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
48484234|NCT00207948|DRUG|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
47964478|NCT03166384|PROCEDURE|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
47964479|NCT04458883|PROCEDURE|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging - Cardiac Scan
47964480|NCT04458883|PROCEDURE|Fast Field Cycling - Magnetic Resonance Imaging|Fast Field Cycling - Magnetic Resonance Imaging Cardiac Scan
47964481|NCT04458883|PROCEDURE|Electrocardiogram|Electrocardiogram
48115174|NCT01065220|DRUG|5-alpha reductase inhibitor|1mg daily
48115175|NCT05001477|DEVICE|TULSA Procedure|Transurethral ultrasound ablation procedure
48313673|NCT02367170|DEVICE|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
48313674|NCT02367170|PROCEDURE|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
48313675|NCT02367170|OTHER|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
48313676|NCT00246467|BIOLOGICAL|Alhydrogel|
48313677|NCT00246467|BIOLOGICAL|rF1 and rV protein antigens|
48313678|NCT00019500|DRUG|raloxifene|
48313679|NCT00019500|PROCEDURE|evaluation of cancer risk factors|
48313680|NCT05565300|OTHER|Cycling exercise|30 minutes of cycling (90 rpm).
48313681|NCT05565300|OTHER|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
48313682|NCT04684550|DRUG|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
48313683|NCT04684550|DRUG|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
48313684|NCT04626843|OTHER|Intermittent fast|16/8 fasting method: fast for 16 hours of the day with an 8 hours feeding window for a duration of 3 months.
48313685|NCT04253977|BEHAVIORAL|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
48313686|NCT04253977|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
48484235|NCT01584531|DRUG|rigosertib|"Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake."
47964482|NCT04458883|PROCEDURE|Echocardiogram|Echocardiogram
48266776|NCT04357106|BIOLOGICAL|Convalescent plasma|Convalescent plasma obtained by aphaeresis from recovered patients.
48266777|NCT05357131|BEHAVIORAL|Hypnosis without VR (HYP)|"HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used."
48313687|NCT05115279|PROCEDURE|breast conservative surgery for post chemotherapy tumour size|"* Skin preparation by povidine iodine.~* Excision of the mass with safety margin.~* Sentinel axillary lymph node or complete axillary clearance depend on axillary lymph node status~* All specimens were oriented with sutures~* A frozen section examination of the specimen was performed intraoperative~* When the margin status was inadequate, a re-excision was performed~* Closure as drawn by different oncoplastic technique"
48313688|NCT01258972|DEVICE|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
48313689|NCT01258972|DEVICE|POBA|Balloon angioplasty
48340229|NCT04432571|BEHAVIORAL|E-NAV/CCT|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following current MOH guidelines).
48484236|NCT02680418|DRUG|FDL169|
48484237|NCT04131231|DRUG|microparticles packaging methotrexate (MPs-MTX)|50ml, intrapleural infusion, day5,6,7,8
48484238|NCT04131231|DRUG|recombinant human interleukin-2(rhIL-2)|50ml, intrapleural infusion, day5,8,11
47964483|NCT00194571|BEHAVIORAL|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
47964484|NCT05947825|DRUG|Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug1: Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug2: Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug3: Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
47964485|NCT06557460|DEVICE|Surgical implantation of the CPCB-RPE1 implant|Surgical implantation of the CPCB-RPE1 implant
47964486|NCT02318771|RADIATION|Radiation Therapy (RT)|Undergo RT
47964487|NCT02318771|DRUG|MK-3475|Given IV
47964488|NCT06262516|PROCEDURE|Nephroureterectomy|Participants will undergo standard-of-care nephroureterectomy for UTUC.
47964489|NCT06262516|PROCEDURE|Lymph Node Dissection|Participants will receive lymph node dissection alongside nephroureterectomy for UTUC.
47964490|NCT03266965|DRUG|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
48115176|NCT05274334|OTHER|Assessment of de novo lipogenesis non-invasively in exhaled breath|"1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~4. Participants execute several exhalation sets over time.~5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~6. Participants execute several exhalation sets over time.~7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded."
48115177|NCT06674525|DRUG|626|Single subcutaneous injection
48115178|NCT06674525|DRUG|Placebo|Single subcutaneous injection
48313690|NCT05452057|BEHAVIORAL|Prehabilitation|"A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods."
48313691|NCT04597034|PROCEDURE|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
48313692|NCT04597034|PROCEDURE|AN69-Standard|Standard treatment.
48313693|NCT02683525|DRUG|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
48313694|NCT02653976|DRUG|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
48313695|NCT06088316|DRUG|group A : Amoxicillin Esomeprazole HDDT|"Group A - Amoxicillin 1gm 8 hourly after meal \& esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days."
48313696|NCT06088316|DRUG|group-B : Levofloxacin triple therapy|Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
48313697|NCT05970744|BIOLOGICAL|RSV/Flu-01E low dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
48313698|NCT05970744|BIOLOGICAL|RSV/Flu-01E high dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
48313699|NCT05970744|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of Placebo
48313700|NCT03481127|BEHAVIORAL|Integrated psychological care|Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
48115179|NCT03705442|DIETARY_SUPPLEMENT|Omni-Biotic 10|All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
48115180|NCT03705442|DRUG|"loperamide (Seldiar)"|All the patients will have access to standard drugs for diarrhoea
48115181|NCT05036746|OTHER|No intervention|No intervention
48484239|NCT04216420|DEVICE|MERM-observed self-administered therapy|The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
48484240|NCT03106558|DEVICE|Total Knee Arthroplasty using Manual Instrumentation|
48484241|NCT03106558|DEVICE|Total Knee Arthroplasty using Robotic Arm|
48484242|NCT01056640|DEVICE|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
48115182|NCT03883542|GENETIC|genomic mutations study|"Sequencing of the DNA samples extracted from the subgroups~1. serous BOT tissue,~2. serous BOT tissue with non-invasive implants and~3. serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)"
48115183|NCT00739765|BEHAVIORAL|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
48643875|NCT06687057|OTHER|Placebo Training|The Placebo procedure requires participants to attend 5 sessions lasting 45 minutes during which they perform a task. Physiological signals (ECG and respiration rate) will be recorded during all sessions. Participants will see on the screen a graph representing heart rate superimposed on a graph representing abdominal breathing but these will not directly reflect the subject's cardiorespiratory activity. Participants in the control group will be asked to synchronize the two signals so that the changes in heart rate are in phase with the respiratory cycle, but the feedback on the screen will not reflect that subject's RSA changes.
48643876|NCT02905591|DRUG|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
48643877|NCT02905591|DRUG|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~* the dose is 45 mg/m2 (standard dose)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standardized dose reductions are used"
48643878|NCT02905591|DRUG|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~* Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~* Administered weekly~* 6 to 7 weeks of therapy, depending on when radiation starts~* Standard dose reductions are used"
48643879|NCT02905591|DRUG|Ascorbic Acid|"Administered intravenously~* 75 grams per infusion; each infusion is about 2 hours~* 3 infusion per calendar week~* The infusion is actively running for at least 20 minutes when radiation begins~* May be given while chemotherapy is delayed due to low counts~* Dose reductions are not used~* Given for 6 to 7 weeks, depending on when radiation starts"
48643880|NCT06351761|DEVICE|Investigational Device (Withings SCT02) 30 second Electrocardiogram recording|30 second ECG recording with investigational device (Withings SCT02)
48115184|NCT00739765|BEHAVIORAL|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
48115185|NCT00739765|BEHAVIORAL|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
48484243|NCT01056640|OTHER|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
48643881|NCT06351761|DEVICE|Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording|30 second ECG recording with reference device (Schiller Cardiovit FT-1)
48313701|NCT03481127|OTHER|Surveys|"* NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey"
48643882|NCT06675773|OTHER|Conscious Awareness Development Psychoeducation Program|The Conscious Awareness Development Psychoeducation Program consists of nine sessions. The sessions will be applied once a week and last 90 minutes. The psychoeducation program is prepared based on conscious awareness. Conscious awareness and self-compassion techniques will be used in the sessions. Homework will be given to the participants in each session.
48643883|NCT06685822|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
48484244|NCT05457517|DRUG|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
48484245|NCT00344851|DRUG|metformin, exenatide or combined (metformin & exenatide )|
48484246|NCT02475382|DRUG|Nivolumab|Specified dose on specified days
48484247|NCT02621801|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
48266778|NCT05357131|DEVICE|Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort.
48266779|NCT04669990|DRUG|Remdesivir|The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
48313702|NCT03481127|PROCEDURE|Blood draw|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment"
48313703|NCT03481127|PROCEDURE|Fresh tissue from ovary|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery"
48313704|NCT00169988|DRUG|risperidone|
48643884|NCT05019807|OTHER|WhatsApp group|Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
48643885|NCT05019807|OTHER|Control group|Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
48643886|NCT06690762|OTHER|Education|It consists of nutrition, physical activity, stress management, relaxation exercises and defecation training.
48643887|NCT06688682|OTHER|PRP joint injection combined with acupoint injection|PRP acupoint injection
47964491|NCT03266965|DIETARY_SUPPLEMENT|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
47964492|NCT04158115|OTHER|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
47964493|NCT04158115|OTHER|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
47964494|NCT03733470|DRUG|Sildenafil study group|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
48115186|NCT06676735|DEVICE|Inflatable warming system|Inflatable warming system, including a forced air warming system (IOB, WU505) and forced air warming blanket (IOB-001, IOB-006, IOB-011), is employed for prewarming before anesthesia initiation and for maintaining body temperature throughout the operation. During the surgery, the insulation blanket will be applied to non surgical areas, and the host temperature will be adjusted to 38 ℃ for warming. If the temperature of the patient is lower than 36 ℃, the temperature of the system can be adjusted to 43 ℃; if the temperature of the patient is higher than 37 ℃, the temperature of the system can be adjusted to 32 ℃. After the patient\&#39;s temperature is normal, it can be adjusted back to 38 ℃.
48115187|NCT06676735|DIAGNOSTIC_TEST|Prediction of intraoperative hypothermia risk|According to the Intelligent Care For The Elderly (ICE, an optimized model based on the existing prediction model of our research group after dynamic incremental training), patients are divided into intraoperative hypothermia lowrisk group and intraoperative hypothermia high risk group.
48313705|NCT00169988|DRUG|sertraline-primary|
47964495|NCT00923156|DRUG|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
47964496|NCT00923156|DRUG|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
47964497|NCT00923156|DRUG|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
47964498|NCT00923156|DRUG|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
47964499|NCT04650490|RADIATION|Stereotactic Radiosurgery|Timing of stereotactic radiosurgery relative to immunotherapy
47964500|NCT04650490|DRUG|Immunotherapy|Physician's choice of immunotherapy per standard of care
47964501|NCT06415487|DRUG|Cyclophosphamide|Lymphodepleting agent
47964502|NCT06415487|DRUG|Fludarabine|Lymphodepleting agent
47964503|NCT06415487|DRUG|ACE2016|Allogeneic gamma delta T (gdT) cell therapy
47964504|NCT06415487|DRUG|Pembrolizumab|Immune checkpoint anti-PD-1 antibody
47964505|NCT02784431|DEVICE|Contour Neurovascular System placement|Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
48484248|NCT00653991|BEHAVIORAL|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
48484249|NCT01283815|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
48484250|NCT01283815|PROCEDURE|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
48643888|NCT06689124|DRUG|Nebulized fentanyl|After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
48643889|NCT05704049|DRUG|Isatuximab|Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
47964506|NCT06506344|BEHAVIORAL|5S Trial|Participants will receive caring contacts/recruitment outreach, suicide risk screening, suicide safety planning, and, if indicated, connection to healthcare services, resources and the CLASP virtual outreach intervention.
47964507|NCT03044678|BEHAVIORAL|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
47964508|NCT03044678|BEHAVIORAL|Self-Study|Books for youth about anxiety management
47964509|NCT06248801|DRUG|Vildagliptin and Metformin-Test product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by Mylan Laboratories Limited, India
47964510|NCT06248801|DRUG|Vildagliptin and Metformin-Reference product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by NOVARTIS PHARMA PRODUKTIONS GmbH, Germany.
47964511|NCT00004037|DRUG|docetaxel|
47964512|NCT04232995|OTHER|Balance Training|Balance enhancing exercises
47964513|NCT04232995|OTHER|General Exercises|General Exercises
47964514|NCT00763620|DEVICE|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
47964515|NCT02276001|DRUG|K-877|
47964516|NCT02276001|DRUG|Cyclosporine|
47964517|NCT05229237|DRUG|Conbercept|Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)
47964518|NCT01225432|OTHER|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
47964519|NCT04742959|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
47964520|NCT04742959|COMBINATION_PRODUCT|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
48484251|NCT05491239|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
48643890|NCT05704049|DRUG|Carfilzomib|Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
48643891|NCT05704049|DRUG|Dexamethasone|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
48643892|NCT05704049|DRUG|Dexamethasone IV|Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
48643893|NCT05704049|DRUG|Montelukast|Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
47964521|NCT00825578|DEVICE|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
47964522|NCT00798980|DRUG|Mirena (BAY86-5028)|Nulliparous Women
47964523|NCT00749645|DRUG|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
47964524|NCT00749645|DRUG|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
48484252|NCT05491239|PROCEDURE|Continuous regional paravertebral block|"The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter.~Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour."
48484253|NCT05491239|PROCEDURE|Single shot intercostal nerve block|At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
48484254|NCT03451240|BEHAVIORAL|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~1. Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~2. Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
48484255|NCT04702347|DIAGNOSTIC_TEST|Urine biomarker|Bladder urine samples (\> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
48484256|NCT02208115|DIETARY_SUPPLEMENT|Meal composition - Low versus high GI.|
47964525|NCT03718832|OTHER|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
47964526|NCT00672243|DRUG|Erlotinib + sirolimus|Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
47964527|NCT02493140|DIETARY_SUPPLEMENT|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
47964528|NCT02493140|DIETARY_SUPPLEMENT|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
47964529|NCT06300931|OTHER|educational lecture|An Educational lecture about SDF
48115188|NCT06676735|OTHER|The difference between axillary temperatature and esophageal temperature in elderly patients|Previous studies have shown that the difference and standard deviation between esophageal temperature and axillary temperature are approximately 0.05 ℃ and 0.26 ℃, respectively. In light of 10% dropout rate, a integer sample size of 400 achieves 95% power to detect a mean of paired differences of 0.05 with an estimated standard deviation of paired differences of 0.26 and with a significance level (alpha) of 0.05 using a two-sided paired t-test. So 400 patients in the Model optimization group need to undergo esophageal temperature.
48115189|NCT06676735|OTHER|Measurement of tympanic membrane temperature|As a intraoperative core temperature reference (measure every 15 minutes) for patients without esophageal temperature monitoring.
48115190|NCT05185921|BEHAVIORAL|Trial-based Cognitive therapy|The virtual CBT will be provided by 02 psychotherapists, who will follow a protocol developed for this study. The number of sessions will be eight, which will be held weekly, projecting an intervention time of 2 to 3 months considering the possibility of rescheduling any of the sessions for reasons derived from the participant People with relevant cognitive impairment that prevents them from answering the questionnaire questions or providing informed consent are excluded.
47964530|NCT00549081|DIETARY_SUPPLEMENT|DHEA|oral DHEA tablets 75 mg daily
47964531|NCT00244010|DEVICE|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
47964532|NCT03533543|DEVICE|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
47964533|NCT04070885|PROCEDURE|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
47964534|NCT04070885|PROCEDURE|Urine sample|The urine will be taken from three 15 ml tubes.
47964535|NCT00870883|DRUG|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
47964536|NCT02619175|DEVICE|Stroke Subjects Perturbation-Based Balance Training|
47964537|NCT02619175|DEVICE|Stroke Subjects Weight Shifting and Gait training|
47964538|NCT03502083|DRUG|GLP-1 (7-36)Amide|IV infusion
48115191|NCT04516564|DRUG|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
48643894|NCT05704049|DRUG|Acetaminophen|Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
48313706|NCT00904540|DRUG|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
48313707|NCT03523221|DRUG|Dexamethasone Oral|use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
48313708|NCT04423900|DIAGNOSTIC_TEST|smart phone application|Participants will be asked to provide information about their sociodemographic characteristics, chronic diseases, the history of the ankle injury, trauma, and surgery, the severity of the foot pain via using the mobile application.The app will be downloaded from the Google Play Store and available offline. Information from the patient will be stored in an SQLite database.The usability test will be carried out on the mobile application so that the latest releases contain clear, effective, loyal to the strategy, and easily understood messages by the intended audience and do not produce unwanted responses.Direct observation, individual interviews, and satisfaction surveys will be used to identify areas of improvement in a cross-sectional manner.Investigation of pes cavus, pes planus and ankle range of motion will be determined by image processing.All data can be analyzed and stored by Heel Analysis Systems established on an external server.The data will be transferred securely over HTTPS.
48313709|NCT03041909|DRUG|GBT440|Oral drug
48313710|NCT00465491|DRUG|picoplatin|IV picoplatin 150mg/m2 q3wk
48484257|NCT00502801|DRUG|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
48484258|NCT01582984|OTHER|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
47964539|NCT03617497|DIAGNOSTIC_TEST|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
47964540|NCT03617497|DIAGNOSTIC_TEST|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
47964541|NCT03830424|PROCEDURE|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
47964542|NCT03830424|DIETARY_SUPPLEMENT|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
47964543|NCT03365492|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
47964544|NCT00824720|DRUG|High Dose Device|inserted for 14 days
48313711|NCT00465491|OTHER|best supportive care|best supportive care
48313712|NCT05094999|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
48313713|NCT05094999|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
48313714|NCT01156597|DRUG|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
48313715|NCT01154972|PROCEDURE|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
48484259|NCT05472402|BEHAVIORAL|LADIES online intervention (R33 phase)|Participants will participate weekly online group sessions over 6 months. Participants will also receive access to written intervention materials, access to an online walking program, and access to weekly podcasts that are aligned with the intervention sessions and that support physical activity lessons with biblical scriptures.
48484260|NCT05472402|BEHAVIORAL|LADIES online control (R33 phase)|Participants will receive online access to a written self-guided curriculum that is self-paced and teaches participants how to increase physical activity. Participants will be encouraged to complete the self-guided curriculum within 6 months.
48484261|NCT00958867|BEHAVIORAL|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
47964545|NCT00824720|DRUG|Low Dose Device|inserted for 14 days
48484262|NCT00958867|BEHAVIORAL|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
48643895|NCT05704049|DRUG|Diphenhydramine|Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
48643896|NCT05704049|DRUG|Methylprednisolone|Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
47964546|NCT00824720|DEVICE|Placebo Device|inserted for 14 days
47964547|NCT01292811|DEVICE|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
48115192|NCT04516564|DRUG|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
48115193|NCT04820933|DRUG|Doravirine 100 Mg|Doravirine 100 Mg orally dail
48115194|NCT03573999|DRUG|Mannitol|4.6 ml/kg will be administered before dura opening
48115195|NCT03573999|DRUG|NaCl 7.5%|2 ml/kg will be administered before dura opening
48313716|NCT05526794|PROCEDURE|Analgesic consumption|1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
48484263|NCT00958867|BEHAVIORAL|Exercise training (S & R; control)|Six-month, twice-weekly stretch \& relax (S \& R; control) program
48484264|NCT02988479|OTHER|Out of pocket payments in patients|
48484265|NCT03128736|DRUG|Esomeprazole group|Esomeprazole 40mg qd
48484266|NCT03128736|DRUG|Dexlansoprazole group|Dexlansoprazole 60mg qd
48484267|NCT04978636|OTHER|Continuous low-tidal volume ventilation with using FiO2 of 0.21|The continuous low-tidal volume ventilation with using FiO2 of 0.21 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 0.21 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
48484268|NCT04978636|OTHER|Continuous low tidal volume ventilation with using FiO2 of 1.0|The continuous low-tidal volume ventilation with using FiO2 of 1.0 will be defined as the tidal volume of 3 mL/kg IBW (up to maximum 200 mL), 1.0 of FiO2, respiratory rate of 5 per minute, and PEEP 5 cm H20). A recruitment maneuver with 30 cm H2O for 10 seconds will be performed before starting the selected ventilation mode in all patients. During the sub-study extra blood samples will be drawn before and after CPB.
47964548|NCT01292811|OTHER|Conventional Occupational therapy|"The Control group will receive conventional occupational therapy pertaining to hand function \[15\].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
47964549|NCT00257374|DRUG|Gatorade, Pedialyte and New Solution|
47964550|NCT04922970|OTHER|Strength training|The interventon consist of 3 weekly, supervised group sessions for 4 months (16 weeks). The sessions consist of progressive full body strength training with a primary focus on lower extremity muscle strength. The leg exercises are leg press, knee extension and leg curl. In addition, participants will perform two upper body exercises. Physical assessment will take place immediately and monthly until 4 months.
47964551|NCT00002133|DRUG|Itraconazole|
47964552|NCT01599767|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
47964553|NCT02685410|OTHER|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
47964554|NCT01350297|PROCEDURE|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
47964555|NCT03821649|BEHAVIORAL|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
47964556|NCT03821649|BEHAVIORAL|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
47964557|NCT05923983|OTHER|Clinical decision support|In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
47964558|NCT05923983|OTHER|Will not receive Clinical Decision Support|In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
48115196|NCT04484415|COMBINATION_PRODUCT|Cevira®|The device is a single-use, disposable, LED-based red light source. The device will automatically switch on the light 5 hours after administration, and provide continuous photoactivation of 125 J/cm2 over 4.6 hours before automatically shutting down.
48484269|NCT04978636|OTHER|Apnea During CPB|There will be no ventilation used. But, during the sub-study part of the Apnea CPB extra blood samples will be drawn before and after CPB.
48484270|NCT01477814|BEHAVIORAL|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
48115197|NCT04484415|COMBINATION_PRODUCT|Placebo|The placebo device is identical in appearance as the Cevira® device, but does not provide light.
48115198|NCT04949607|DIETARY_SUPPLEMENT|Inulin fructooligosaccharide|Subjects will be administered inulin at a starting dose of 1g twice daily (2g/day) and ramping up an additional 2g/day until the final dose of 4g twice daily (8g/day), which will continue on until the end of month 3 (week 12). After the month 3 study visit, inulin dosing will begin to ramp down over the next week.
48115199|NCT01918644|RADIATION|stereotactic body radiation therapy|Undergo SBRT
48115200|NCT01918644|DRUG|capecitabine|Given PO
48115201|NCT01918644|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
48115202|NCT01918644|PROCEDURE|magnetic resonance imaging|Optional correlative studies
48115203|NCT01918644|OTHER|laboratory biomarker analysis|Optional correlative studies
48115204|NCT04542824|BIOLOGICAL|epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
48115205|NCT04542824|BIOLOGICAL|epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
48313717|NCT01100996|OTHER|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
48313718|NCT01100996|OTHER|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
48313719|NCT06371651|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing creatine and guanidinoacetic acid
48313720|NCT06371651|DIETARY_SUPPLEMENT|Placebo|Inert substance
48643897|NCT06162312|OTHER|Antenatal perineal massage|Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
48643898|NCT06673589|BEHAVIORAL|Transcendental Meditation|meditation practice
48643899|NCT06687083|DEVICE|nasal high frequency oscillatory ventilation mode|"Preterm neonates who will be allocated will start nHFOV: (CNO, Medin, Germany). nHFOV will be provided via binasal prongs (Size: small, medium, large; Diameter according to its chart; Medin, Germany).~The initial parameters will be mean airway pressure (MAP) of 6 cm H2O (range 6-10), frequency of 8 Hz (range 8-12) and amplitude will be adjusted until infant's chest showed slight oscillations and amplitude will be 7 (range 7-10).~The fraction of inspired oxygen (FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter."
48643900|NCT06687083|DRUG|nasal continuous positive pressure ventilation mode|Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
47964559|NCT06506721|DEVICE|Double ballon device, Cook|"Cook double balloon will be introduced transcervically. The double balloon will be inflated with sterile 0-9% saline solution (maximum 80 ml in each balloon of the double device), then the catheter will be fixed with a tape at the women's thigh without traction. The catheter will remain in place until spontaneously expelled or start of active labour.~If neither happens, the device will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
47964560|NCT06506721|DEVICE|Hygroscopic cervix dilators, Dilapan-S|"A maximum number of 5 hygroscopic cervical dilator rods will be inserted transcervically, after humidification with sterile 0.9% saline solution. They will be fixed in this position by inserting a humidified compress into the vagina. They will remain in place until spontaneously expelled or until start of active labour.~In neither happens, the devices will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
47964561|NCT01564914|DRUG|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
48484271|NCT01477814|BEHAVIORAL|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
48643901|NCT02844816|DRUG|Atezolizumab|Given IV
47964562|NCT01564914|DRUG|Bevacizumab|IV
47964563|NCT02000479|OTHER|training|
47964564|NCT06506747|DEVICE|Navigated Photogrammetry|Navigated Photogrammetry shall be performed following implant surgery, rather than standard stereophotogrammetry. The patient will then receive a provisional that was manufactured using the data from FastMap Navigated Photogrammetry.
47964565|NCT06506747|DEVICE|Standard Photogrammetry|The patient will receive the existing patient care protocol that includes anatomy information for the manufacturing of the provisional. Specifically, the patient will receive a preoperative IntraOral Scan (IOS) anatomy scan with IOS-compatible fiducials. Following implant surgery, the patient will receive a scan with a standard stereophotogrammetry device. Additionally, they will receive a post-op alignment IOS with IOS-compatible anatomy fiducials and IOS-compatible implant scan bodies. The patient will then receive a provisional that was manufactured using the data from the standard stereophotogrammetry device.
47964566|NCT00270790|DRUG|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
47964567|NCT00270790|DRUG|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
47964568|NCT00270790|DRUG|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
48313721|NCT00412698|DRUG|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
48313722|NCT00412698|DRUG|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
48643902|NCT06546735|DRUG|N0728|1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.
48643903|NCT06546735|DRUG|Vesomni®|1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
48643904|NCT06087328|DRUG|Regular Nicotine patch and lozenge dose|1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
47964569|NCT00270790|DEVICE|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
47964570|NCT02200211|DEVICE|iPad®|Binocular therapy on iPad®
47964571|NCT02200211|OTHER|Patching 2 hours per day, 7 days per week|
48313723|NCT06106321|PROCEDURE|Transalveolar crest maxillary sinus floor lift|Transalveolar crest maxillary sinus floor lift + bone grafting + implant implant is used
48643905|NCT06087328|DRUG|Augmented Nicotine patch and lozenge dose|21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
48643906|NCT05919823|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
48643907|NCT05919823|DRUG|Placebo|Placebo Capsules
48643908|NCT03057301|DEVICE|iCare home tonometer|All subjects will be taught to use the home care tonometer.
48313724|NCT06106321|PROCEDURE|transalveolar crest parietal maxillary sinus floor secondary lift|Transalveolar crest parietal maxillary sinus floor secondary lift + bone grafting + implant implantation were used body
48313725|NCT03745196|DRUG|PC945|Study drug under investigation
48484272|NCT01477814|BEHAVIORAL|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
48484273|NCT02740179|DRUG|Eplerenone|Eplerenone 50mg by mouth twice daily
48484274|NCT02740179|DRUG|Placebo|Placebo by mouth twice daily
48484275|NCT02740179|BEHAVIORAL|Lifestyle Modification|Counseling regarding diet and healthy activity
48484276|NCT05623631|OTHER|Survey|Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
48484277|NCT04588441|DRUG|Adenosine|Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
48484278|NCT00038987|BIOLOGICAL|Wetvax (APSV)|
48484279|NCT03109119|DRUG|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
48484280|NCT03109119|DRUG|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
48484281|NCT02601274|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
48643909|NCT06686680|DEVICE|extracorporeal shockwave therapy (ESWT)|Participants will receive ESWT administered by research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-top focus.Radial pressure waves will be applied using the Extracorporeal Pressure Activation Treatment (EPAT) device. For the anterior knee, patella tendon, vastus lateralis, and vastus medialis, treatment will aim for 1500 strikes at induction dose of 1.5 bars and titrating up by 0.5 bars to 3 bars and this will be performed to participant tolerance to pain, as pain is experienced due to clinical focusing technique which is standard of care in delivering effective treatment. For the calf muscles, the patient will be positioned prone and a similar protocol of starting at 1.5 and titrating up as tolerated to 3 bars. Focused shockwave therapy will be applied for 1000 shocks to four anatomical locations for a total of 4000 shocks. Each site will receive 1000 shocks: medial and lateral tibial plateau and medial and lateral femoral condyle.
48313726|NCT03745196|DRUG|Placebo|Placebo control
48313727|NCT03452553|DEVICE|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
48484282|NCT01715896|BIOLOGICAL|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
48484283|NCT01715896|BIOLOGICAL|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
48484284|NCT03507413|DRUG|Metformin Glucophage 500mg (IR) tablets M90|oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
48484285|NCT03507413|DRUG|Placebo Oral Tablet|Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
48484286|NCT05156424|OTHER|Exercise|An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.
48484287|NCT03744078|DEVICE|Foley balloon catheter|18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
48484288|NCT00281476|DRUG|Simvastatine|
48484289|NCT02936687|DRUG|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure \~8-15 mmHg that is within the range observed during exercise.
48484290|NCT02936687|DRUG|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
48484291|NCT02936687|DRUG|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
48484292|NCT02936687|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
48484293|NCT02936687|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
48484294|NCT02936687|OTHER|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
48484295|NCT02936687|DRUG|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
48484296|NCT01812135|BIOLOGICAL|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
48484299|NCT00300326|PROCEDURE|Computer assist|same implant using a computer-assisted surgical technique.
48484300|NCT05975177|DEVICE|Sterify Gel|A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate
48484301|NCT05975177|PROCEDURE|Scaling and root planing|The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
48484302|NCT05470933|DRUG|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
48484303|NCT00430950|DRUG|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
48484304|NCT00430950|DRUG|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
48484305|NCT00635830|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
48643910|NCT06686680|DEVICE|Sham Comparator|All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 day. Sham ESWT will administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
48643911|NCT04944017|DRUG|Ketamine Infusion|Participants will receive 6 infusions of ketamine (0.5 mg/kg IV, up to 60 mg total) , administered over 40 minutes while on continuous cardiac monitoring and oximetry
47964572|NCT02412618|DRUG|Mifepristone|Progesterone antagonist
48484306|NCT06098287|DEVICE|Residential mechanical ventilation system (Exhaust)|Exhaust-only ventilation system
48484307|NCT06098287|DEVICE|Residential mechanical ventilation system (CFIS) and air filtration upgrades|Central-fan-integrated-supply ventilation system and air filtration upgrades (MERV 10)
48484308|NCT06098287|DEVICE|Residential mechanical ventilation system (ERV) and air filtration upgrades|Balanced energy recovery ventilation system and air filtration upgrades (MERV 10)
48484309|NCT04289454|OTHER|Flavor additive|Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
48484310|NCT01526460|DRUG|Atorvastatin|80 mg
48484311|NCT01526460|DRUG|Rosuvastatin|40 mg
48484312|NCT01526460|DRUG|Placebo|no statin loading dose
48484313|NCT02551393|BEHAVIORAL|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
48484314|NCT05962502|DRUG|Cetuximab and irinotecan|chemotherapy plus targeted therapy
48484315|NCT02433119|DRUG|OROSARTAN® 5/160mg|
48484316|NCT02433119|DRUG|CODIOVAN® 160/12.5mg|
48643912|NCT04944017|OTHER|Placebo - Saline Infusion|Participants will receive 6 infusions of saline administered over 40 minutes while on continuous cardiac monitoring and oximetry
47964573|NCT02412618|DRUG|Misoprostol|Prostaglandin E1
47964574|NCT02412618|DIETARY_SUPPLEMENT|Placebo|Tasteless, odorless, sugar based pill
47964575|NCT01347944|DRUG|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
48484317|NCT05173870|DEVICE|Wearable device|The wearable devices has a biosensor able to daily collect,in a remote way, many biometric measurements such as: blood pressure, blood oxygenation, heart and respiratory rate
48484318|NCT02331693|BIOLOGICAL|anti-EGFR CAR T|
48484319|NCT05829759|BEHAVIORAL|Tele-B6|Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
48484320|NCT05829759|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
48484321|NCT00003014|DRUG|carboplatin|
48484322|NCT00003014|RADIATION|radiation therapy|
48484323|NCT05811702|OTHER|A randomized acute controlled trial of twenty-eight healthy overweight or obese women|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
48643913|NCT06603831|PROCEDURE|patients treated using 3D technology and Patient-Specific Instrumentation|"3D Digital surgery includes:~* 3D Surgical Planning using biomedical engineering software; 3D visualization of the patients anatomy and surgical simulation.~* Use of personalized surgical guides created through additive manufacturing.~* Use of personalized implants created through additive manufacturing.~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
48643914|NCT06603831|PROCEDURE|Patients treated with conventional surgery, without using 3D technology|"Conventional surgery includes:~* 2D planning using TC and x-rays~* Free-hand surgery~* Use of generic, non-personalized implants~  3 surgical procedures are studied in this study; radius osteotomy, acetabular arthroplasty and spinal arthrodesis"
48643915|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive sulfentanil for PCIA.
48643916|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive oxycodone for PCIA.
48643917|NCT06687707|OTHER|Attitude Scale towards Physiotherapy Profession|It is a questionnaire that evaluates the attitudes of physiotherapists with 35 questions under 3 headings: professional satisfaction, qualifications required by the profession, and concerns about the profession. It was developed in 2018 by Begümhan Turhan. In this scale, which is a Likert-type questionnaire, each question is scored between 0 and 5 points. The minimum score that can be obtained from the scale is 35 and the maximum score is 175. A high score indicates that physiotherapists have a positive attitude towards their profession
48643918|NCT06687707|OTHER|Minnesota Job Satisfaction Scale|It is a 20-item Likert-type questionnaire. Scores less than 3 points indicate low job satisfaction. Turkish validity and reliability studies were conducted. The validity and reliability study in Turkey was conducted by Baycan and the Cronbach's alpha value of the scale was found to be 0.77. It is a tool consisting of 20 items with features that reveal internal and external job satisfaction factors. The neutral satisfaction score of the scale is 3. If the score obtained from the scale is less than 3, job satisfaction is considered low, and if it is greater than 3, job satisfaction is considered high.
48643919|NCT06687707|OTHER|Maslach Burnout Scale|The Burnout Inventory, which was developed by Maslach and Jackson (1981) and introduced to the literature under Maslach's name, is a seven-point Likert-type scale and consists of a total of 22 items and three subscales. Among these subscales, emotional exhaustion subscale consists of 9 items, depersonalisation subscale consists of 5 items and personal accomplishment subscale consists of 8 items. Scale items are scored as '1 never' and '7 always'. The Turkish validity and reliability of the questionnaire was conducted by Burhan Çapri. It is a 5-point Likert-type scale measured with 0: never 4: always options. High scores are expected
48643920|NCT06678581|DRUG|SAP-001|Solid Oral Tablet
48643921|NCT06678581|DRUG|Placebo|Solid Oral Tablet
48115206|NCT04542824|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
48115207|NCT04542824|DRUG|gemcitabine and oxaliplatin|28-day cycles
48484324|NCT05759117|PROCEDURE|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
48484325|NCT05440630|DIETARY_SUPPLEMENT|Probiotics|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
48115208|NCT04542824|BIOLOGICAL|epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
48313728|NCT05172193|BIOLOGICAL|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
48313729|NCT00240630|DRUG|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
48313730|NCT00240630|DRUG|placebo|placebo to match
48313731|NCT02199301|PROCEDURE|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7\~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6\~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5\~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
48313732|NCT05000814|DEVICE|DLT|VDLT versus the use of DLT with fiberoptic bronchoscope
48313733|NCT02125487|BEHAVIORAL|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
48313734|NCT02125487|BEHAVIORAL|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
48313735|NCT02955134|DRUG|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
48313736|NCT02955134|DRUG|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
48313737|NCT02955134|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
48313738|NCT02955134|DRUG|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
48313739|NCT00423410|DRUG|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
48313740|NCT03157154|OTHER|Non interventional study|A query form to all concerned patients by each investigating centre will be send
48313741|NCT05520814|DRUG|PD-1 inhibitors|treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg \* q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
48313742|NCT05520814|RADIATION|chemoradiotherapy|"Chemotherapy：~1. GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~   \* Treatment courses every 3 weeks~2. Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min \* Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites."
48313743|NCT04724382|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
48313744|NCT04724382|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
48484326|NCT05440630|DIETARY_SUPPLEMENT|Postbiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.
48484327|NCT05440630|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
47964576|NCT02958514|DEVICE|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of \*500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
47964577|NCT02958514|DRUG|Tobramycin and Dexamethasone Ophthalmic Ointment|
47964578|NCT00133952|DRUG|Ruboxistaurin|Administered orally
48484328|NCT04608799|DRUG|Perampanel|Efficacy of epilepsy drugs
48484329|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
47964579|NCT00133952|DRUG|Placebo|Administered orally
47964580|NCT02749071|PROCEDURE|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
47964581|NCT02749071|DEVICE|EndoStim stimulation for first six months of study|Lower esophageal stimulation
47964582|NCT02749071|DEVICE|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
47964583|NCT02749071|DEVICE|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
48115209|NCT04542824|DRUG|rituximab and lenalidomide|28-day cycles.
48115210|NCT02618018|PROCEDURE|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
48484330|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
48643922|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White colored oval three-layer tablet
48115211|NCT06063733|OTHER|Digital pursed lip breathing intervention|"After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities."
48266780|NCT05698667|DIAGNOSTIC_TEST|Transoral ultrasound|Under local anesthetic with xylocaine spray in the oropharynx, the tonsils and tongue base are scanned with small-footprint, high-frequency ultrasound transducers (such as the 18XL5s hockey-stick from BK Medical)
48313745|NCT01626911|PROCEDURE|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
48313746|NCT01626911|OTHER|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
48313747|NCT00065741|DRUG|silymarin|
48313748|NCT00355212|PROCEDURE|percutaneous ablation of hepatocellular carcinoma|
48313749|NCT03725995|DRUG|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
48313750|NCT03725995|DRUG|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
48313751|NCT03725995|DRUG|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
48313752|NCT05795114|BEHAVIORAL|Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program|A 5-part interpersonal therapy based intervention
48313753|NCT04864652|DEVICE|CHILLS Procedure|CHILLS Cryotherapy procedure
48313754|NCT03150108|DRUG|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
48313755|NCT03150108|DRUG|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
48484331|NCT05695872|PROCEDURE|subtarsal approach|surgical approach
48643923|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White and pink colored oval two-layer tablet
48313756|NCT03150108|DRUG|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
48313757|NCT03001310|BIOLOGICAL|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
48643924|NCT06690866|BEHAVIORAL|Stress|Montreal Imaging Stress Task is a stress paradigm in the scanner to examine neuronal correlates of acute psychosocial stress.
48484332|NCT05695872|PROCEDURE|conventional transconjunctival approach|surgical approach
48484333|NCT05695872|PROCEDURE|transconjunctival approach with Y- modification|surgical approach
48484334|NCT00877357|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
48313758|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is \< 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
48115212|NCT04835181|BEHAVIORAL|Electroacupuncture combined with umbilical moxibustion|"①Umbilical moxibustion intervention: point selection: Shenque point Operation: Place the aconite cake on the Shenque point, place the Aizhu in the middle of the aconite cake, ignite the Aizhu and apply moxibustion to make the local warm sensation without burning pain, until the skin is flushed.~②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
48313759|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
48313760|NCT02710266|DRUG|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
48484335|NCT01747122|DEVICE|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
48484336|NCT01747122|DEVICE|Epidural|
48643925|NCT06689982|DRUG|Tofacitinib tablets|All patients should be closely monitored for signs and symptoms of infection during and after treatment with tofacitinib tablets. If a patient develops a severe infection, opportunistic infection, or sepsis, medication should be discontinued. During treatment, patients with lymphocyte counts \< 500 cells/mm\^3 or ANC \< 500 cells/mm\^3 confirmed by repeated testing should be stopped. When 500≤ANC≤1000 cells/mm\^3, administration should be interrupted, and if ANC returns to more than 1000 cells/mm\^3, administration should be resumed. When hemoglobin \< 8 g/dL or decreases by more than 2 g/dL, administration should be interrupted until hemoglobin values return to normal.
48643926|NCT06690268|DIAGNOSTIC_TEST|Multimodal AI-driven predictive model|This intervention involves a multimodal artificial intelligence (AI) model that integrates clinical data, imaging results, and pathology findings to predict the risk of postoperative recurrence in patients with locally advanced gastric cancer. Unlike traditional methods that may rely on single data sources, this AI-driven model synthesizes multiple types of patient information, offering a comprehensive and personalized prediction of recurrence risk. This approach aims to improve accuracy in identifying high-risk patients, allowing for more tailored follow-up and treatment planning to enhance patient outcomes.
48643927|NCT06690060|BEHAVIORAL|Mind-Body Intervention|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
48484337|NCT00795808|DRUG|Metformin|500mg tds for 6 months
48484338|NCT00795808|DRUG|Placebo|One tablet tds for 6 months
48484339|NCT00795808|DRUG|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
48484340|NCT00795808|DRUG|Metformin|500mg tds for 6 months
48484341|NCT00795808|DRUG|Clomiphene|Ovulatory dose for 6 months
48484342|NCT01514994|DEVICE|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
47964584|NCT01140893|DRUG|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
48115213|NCT04835181|BEHAVIORAL|Electroacupuncture|"②Electro-acupuncture intervention: Acupoint selection: Tianshu, Zusanli, Zhongwan, Moisture, Daheng, Vein, Waterway, Huaroumen, Abdominal Knot.~Operation: supine position, routine skin disinfection. After routine acupuncture at the acupoints, apply the technique of flattening, replenishing, relieving, and relieving qi. Tianshu and Daheng points, respectively, were horizontally connected to the electrodes of the electroacupuncture instrument on the needle handles of the bilateral Tianshu and Daheng points.~Electroacupuncture parameters: density wave, current intensity 1-5mA, electroacupuncture intensity is subject to patient tolerance."
48313761|NCT02710266|DRUG|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
48313762|NCT02710266|DRUG|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
48313763|NCT05632575|BEHAVIORAL|Virtual Promotoras Program|"Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~1. Educational Modules (8 evidence-based educational modules made by the VPs),~2. Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~3. Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider."
48313764|NCT01822691|DRUG|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
48313765|NCT00798694|DRUG|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
48313766|NCT00798694|DRUG|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
48313767|NCT06522581|DRUG|Citicoline Sodium|one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
48313768|NCT00751530|DRUG|raltegravir|New combination ART incorporating raltegravir with other ARVs.
48313769|NCT02509598|DRUG|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
48115214|NCT00952263|BIOLOGICAL|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
48313770|NCT02509598|DRUG|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
48313771|NCT02509598|PROCEDURE|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
47964585|NCT01140893|DRUG|Placebo|Placebo
47964586|NCT06558552|OTHER|transcutaneous pulsed radiofrequency|Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.
47964587|NCT06558552|OTHER|extracorporeal shock wave therapy (ESWT)'|A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.
47964588|NCT05495620|DRUG|Carfilzomib|"Intravenous~carfilzomib, lenalidomide, dexamethasone"
47964589|NCT05495620|DRUG|Lenalidomide|Oral
48115215|NCT03314675|DEVICE|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
48115216|NCT00223795|DEVICE|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
48115217|NCT00530517|DEVICE|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
48115218|NCT03547804|DRUG|Apatinib|500 mg qd/250mg
48115219|NCT03547804|DRUG|chemotherapy|Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
48313772|NCT06452628|OTHER|Mulligan mobilizations|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Mulligan mobilizations.
48313773|NCT06452628|OTHER|Active Release Technique|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with the Active release technique.
48313774|NCT06452628|OTHER|Mulligan mobilizations with active release technique|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with mulligan mobilizations with active release technique.
48313775|NCT03009201|DRUG|Doxorubicin Hydrochloride|Given IV
48313776|NCT03009201|OTHER|Laboratory Biomarker Analysis|Correlative studies
47964590|NCT05495620|DRUG|Dexamethasone|Oral or intravenous
47964591|NCT00256750|DRUG|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
48115220|NCT04795544|PROCEDURE|Intracuff pressure measurement|Intracuff pressure is measured by a pressure manometer.
48313777|NCT03009201|OTHER|Pharmacological Study|Correlative studies
48313778|NCT03009201|DRUG|Ribociclib|Given PO
48484343|NCT00107718|DRUG|SB-485232|
47964592|NCT00256750|DRUG|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
47964593|NCT00256750|DRUG|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
47964594|NCT00935571|DRUG|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
47964595|NCT04586907|DRUG|LY3537021|Administered SC.
47964596|NCT04586907|DRUG|Placebo|Administered SC.
47964597|NCT00160290|DRUG|Lactulose|15 mL / 12 hours
47964598|NCT00160290|DRUG|Plantago ovata|3,5 g / 12 hours
47964599|NCT00039975|DRUG|Indinavir sulfate|
48115221|NCT02032069|OTHER|no intervention|
48115222|NCT04125433|BEHAVIORAL|Peer Integrated Care Services|The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
48115223|NCT03411278|DEVICE|Deep Oscillation (DO)|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
48115224|NCT00080639|OTHER|physiologic testing|
48115225|NCT00080639|PROCEDURE|study of high risk factors|
48115226|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 1 month|temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.
48115227|NCT00117663|OTHER|temporary discontinuation of hormone therapy for 2 months|temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram
48115228|NCT04694885|BEHAVIORAL|Structured Hypnotherapy|"The Intervention includes 10 structured hypnotherapy sessions lasting 45 to 60 minutes. During hypnosis, patients reach a trance-like state comparable to a deep relaxation. The therapist guides the patient verbally and also communicates with the patient.~Patients will be supported to use their own imagination without suggesting any imagery. By repeatedly asking what the patient is perceiving, and by verbally repeating what the patient is saying, the therapist can help the patient to go deeper into trance. In these trance states the patient learns to reduce negative side effects of the chemotherapy and increase the quality of life by activating both physical and mental resources using imagination and focusing on positive memories and feelings."
48115229|NCT03617978|PROCEDURE|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
48115230|NCT02052375|DRUG|ASP2408|subcutaneous injection
48115231|NCT02052375|DRUG|Placebo|subcutaneous injection
48313779|NCT05674344|DEVICE|Masimo Temperature device|Non-invasive temperature device
48313780|NCT00848549|DRUG|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
48484344|NCT00964288|DRUG|GSK1014802 low dose|oral tablet
48484345|NCT00964288|DRUG|Lidocaine|positive control
48484346|NCT00964288|DRUG|GSK1014802 high dose|oral tablet
48484347|NCT00964288|DRUG|Placebo|To match GSK drug and positive control
47964600|NCT00039975|DRUG|Ritonavir|
47964601|NCT00039975|DRUG|Amlodipine|
47964602|NCT00039975|DRUG|Diltiazem HCl|
47964603|NCT06292520|OTHER|Portage Guide Protocol|Portage Guide Protocol will be given to this group The study will follow the Randomized control trial study design and a purposive sampling technique will be used. Data will be collected from a special education centre BASES (Behaviour and special education services), Lahore. Children with autism spectrum disorder with mild to moderate severity level will be included in the study. The age range of the children will be from three years to seven years. Children with other neurological disorders or any comorbid conditions will be excluded from the study. The consent form will be filled out by parents of children who meet the inclusion criteria. The autism screening tool will apply by the speech and language pathologist. Half of the total number of children will receive therapeutic intervention under ABL
47964604|NCT06292520|OTHER|ABLLS-R protocol|ABLLS-R protocol will be given to this group
48313781|NCT00848549|DRUG|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
48313782|NCT00003539|BIOLOGICAL|trastuzumab|
48313783|NCT00003539|DRUG|paclitaxel|
48313784|NCT04343521|BIOLOGICAL|Targeted Indoor Residual Spraying (TIRS)|Spraying of insecticide Actellic 300CS will start May-June and extend for 1-2 months. Residents will be asked to temporarily leave the house during treatment and wait 0.5-1 h for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed in CDC-Emory-UADY collaboration.
48313785|NCT05448560|BEHAVIORAL|Multi-level Intervention of shared model of survivorship care|1) Patient survivorship education via telehealth with the cancer center- The research registered nurse (RN) will discuss the contents of the survivorship care plan and coordination between the cancer center and PCP clinic. 2) Ongoing patient-tailored education program by MyChart within the EHR patient portal- Patients will be asked to select survivorship topics of interest from a panel (e.g. school issues, fertility, fatigue, physical activity, single kidney health, emotions/coping) that will then be sent over 1 year. 3) Structured interactive phone communication between the research RN at the cancer center and community PCP clinic- The discussion will explain the patient's cancer history, tumor recurrence monitoring schedule, individualized risk of late effects and surveillance schedule, psychosocial challenges, health behaviors, and coordination between the cancer center and PCP clinic. 4) In-person visit with the PCP clinic for survivorship care.
48313786|NCT05448560|OTHER|Comparison Group|Participants will be contacted by study staff at their cancer center to schedule an in-person visit at the survivorship clinic that will include a comprehensive history focused on cancer-related medical and psychosocial issues, physical examination, ordering of recommended surveillance for late effects, and delivery of hard copy of their survivorship care plan.
48313787|NCT02660333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin - 11g/day
48313788|NCT02660333|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharide - 11g/day
48313789|NCT02660333|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
48313790|NCT03848221|DRUG|Systane Complete|Systane Complete is an artificial tear.
48313791|NCT03848221|DRUG|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
48313792|NCT05123651|BIOLOGICAL|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
48313793|NCT02310802|DRUG|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
48313794|NCT02310802|DRUG|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
48313795|NCT02310802|DRUG|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
48313796|NCT02310802|DRUG|Placebo|Placebo dispersible tablets for single oral administration
48313797|NCT06330662|PROCEDURE|Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only|The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
48643928|NCT06689007|OTHER|Implementation Intervention|The intervention employs four established implementation strategies according to the Expert Recommendations for Implementing Change: conduct educational meetings, provide ongoing consultation, provide technical assistance, and change physical structure and equipment. The first component is a six-week online course led by the PI that combines weekly pre-recorded lectures, hands-on activities, group mentoring sessions and a reflective assignment. The second component of the intervention is ensuring access to the equipment needed for FES. The third component of the intervention is access to the FES Toolkit.
48643929|NCT06690827|DRUG|Anti-CD123 CAR NK cells|Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
48313798|NCT00409201|DRUG|reboxetine adjuvant therapy|
48313799|NCT01657448|DRUG|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
48313800|NCT01657448|DRUG|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
48115232|NCT02964429|DEVICE|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
48115233|NCT01502969|BIOLOGICAL|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
48115234|NCT01502969|BIOLOGICAL|cell culture medium in absence of virus|Placebo
48115235|NCT06181318|DIAGNOSTIC_TEST|Multiparametric MRI scan of the liver|MRI scans will be performed at the Champalimaud Foundation using a 1.5T scanner after patients have fasted for 4 hours. Transverse abdominal T1 maps will be acquired to estimate extracellular fluid (which increases in cases of fibrosis and inflammation) and T2\* maps will be acquired to estimate liver iron levels. These quantitative MRI maps will be laid onto the volumetric images of Couinaud segments. Multi-slice quantitative maps will be generated using Liver MultiScan software (Perspectum, UK) with operators blinded to patient status. T1 measurements will be adjusted for the iron level to give iron-corrected T1 maps (cT1). Reference ranges for cT1 have been defined in the general population. PDFF maps of the liver will be calculated using MRI multi-echo and spoiled-gradient-echo acquisition. No intravenous contrast agents will be used in Liver MultiScan maps and the total scan duration will be approximately 30 minutes.
48313801|NCT02878733|DRUG|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
48643930|NCT06526520|DRUG|Exposure to progesterone or HRT medication|to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
48643931|NCT06691776|DEVICE|online CBCT-guided adaptive radiation therapy using a new software|Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.
47964605|NCT01125267|BEHAVIORAL|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
47964606|NCT01125267|BEHAVIORAL|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
47964607|NCT04736030|BEHAVIORAL|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
47964608|NCT02730429|DRUG|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
48115236|NCT06076980|DRUG|Paracetamol|compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
48115237|NCT06076980|DRUG|Normal saline|as placebo
48115238|NCT00624026|DRUG|Memantine-HCl|20 mg per day (once daily)
48115239|NCT02444130|DEVICE|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
48313802|NCT03893773|DEVICE|doppler ultrasonagraphy|"The following parameters will be measured:~Hepatic artery Resistance index (HARI), Diameter, peak systolic velocity (HAPSV, cm/s).~Portal vein peak velocity (PVPV) and diameter at the anastomotic and non-anastomotic sites.~Hepatic vein peak velocity and wave form"
48313803|NCT00148733|DRUG|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
48313804|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
48313805|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
48115240|NCT01266265|DRUG|inhaled prostacyclin|Tyvaso
48115241|NCT01266265|DRUG|inhaled prostacyclin|As prescribed by the physician
48115242|NCT01266265|DRUG|prostacyclin|As prescribed by the physician
48115243|NCT01266265|DRUG|subcutaneous and intravenous prostacyclin|As prescribed by physician
48115244|NCT01266265|DRUG|oral ERA|As prescribed by physician
48115245|NCT01266265|DRUG|oral PDE5 inhibitors|As prescribed by physician
48115246|NCT05549869|DIAGNOSTIC_TEST|serum leptin|Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators
48313806|NCT02738996|BEHAVIORAL|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
48313807|NCT06365671|OTHER|autologous stem-cell transplantation|high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)
48313808|NCT06365671|DRUG|Relmacabtagene autoleucel (relma-cel)|relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
48313809|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day,|
47964609|NCT02730429|DRUG|Letrozole|Letrozole is standard of care in both arms
47964610|NCT01657669|DRUG|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
48115247|NCT01544270|DIETARY_SUPPLEMENT|Yogurt-like snacks|twice a day 120 g for four weeks
48313810|NCT00200694|DRUG|ramipril 10 mg + valsartan 160 mg/day,|
48643932|NCT06688916|BEHAVIORAL|Behavioral assessment|A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.
48313811|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
48313812|NCT00028002|PROCEDURE|Conventional Surgery|Undergo surgical resection
48313813|NCT00028002|DRUG|Imatinib Mesylate|Given orally
48313814|NCT03176277|DRUG|ONO-7475 3mg once daily|Part A initial dose level
48313815|NCT03176277|DRUG|ONO-7475 6mg once daily|Part A 2nd dose level
48313816|NCT03176277|DRUG|ONO-7475 10mg once daily|Part A 3rd dose level
48313817|NCT03176277|DRUG|ONO-7475 6mg + Venetoclax (70-400mg)|Part D ONO-7475 + Venetoclax Combination
48313818|NCT05726019|DRUG|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
48313819|NCT02528097|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
48313820|NCT02528097|DRUG|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
48313821|NCT00903032|BEHAVIORAL|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
48313822|NCT00903032|BEHAVIORAL|Usual care|Usual care following ACS hospital discharge.
48313823|NCT00824187|DRUG|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
48313824|NCT00824187|DRUG|Placebo|Inert tablet
48313825|NCT04484818|DRUG|Darolutamide|Given PO
48313826|NCT04484818|DRUG|Goserelin Acetate|Given via injection
48643933|NCT06688916|BEHAVIORAL|Functional Magnetic Resonance Imaging (fMRI)|"Neural mechanisms of embodiments will be explored with MRI sequences including structural MRI, resting-state and task-based fMRI of the head.~The task will be a modified version of the rubber hand illusion, previously used to asess embodiment. Participants will be required to lay in the MRI with their legs bended upright and a screen placed at the level of their hips, which will show a pair of legs. The participant's leg will be stroked with a paintbrush while the image on the screen will be showing the virtual legs being stroked. Participants will be required to report how strongly they perceive the virtual legs as their own, as a measure of embodiment."
47964611|NCT02576795|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
48115248|NCT05988307|DEVICE|Percussion massage gun|Percussion massage gun on hamstrings flexibility in patients with knee Osteoarthritis.
48313827|NCT04484818|DRUG|Leuprolide Acetate|Given IV
48313828|NCT04484818|DRUG|Placebo Administration|Given PO
48313829|NCT04484818|OTHER|Quality-of-Life Assessment|Ancillary studies
48313830|NCT04484818|DRUG|Triptorelin|Given via injection
48313831|NCT00952237|DRUG|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
48313832|NCT00952237|DRUG|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
48313833|NCT00364845|DRUG|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
47964612|NCT06298591|PROCEDURE|co2 laser|laser
48313834|NCT00364845|DRUG|Placebo|Prefilled syringe placebo, to match active arm
48313835|NCT03009539|BEHAVIORAL|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
48313836|NCT02330549|DRUG|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
48643934|NCT06686550|OTHER|This is a observational study and there is no intervention.|This is a observational study and there is no intervention.
48313837|NCT02330549|DRUG|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
48313838|NCT03102177|DRUG|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
48313839|NCT02074774|DEVICE|IntellO2|Automated FiO2 regulator that responds to pulse oximetry measures
48313840|NCT02074774|OTHER|Manual control|Standard practice of manually titrating FiO2 as needed.
48313841|NCT04599205|DRUG|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
48313842|NCT00000513|BEHAVIORAL|diet, reducing|
48313843|NCT00000513|BEHAVIORAL|diet, sodium-restricted|
48313844|NCT00000513|DRUG|chlorthalidone|
48313845|NCT00000513|DRUG|atenolol|
48643935|NCT05766280|BEHAVIORAL|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
48643936|NCT06679855|DRUG|Milrinone infusion|An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes).
48313846|NCT02200367|BEHAVIORAL|e-mental health collaborative programme|
48643937|NCT06679855|DRUG|Placebo infusion|An iv infusion of placebo (0.9% saline) of equivalent volume will be administered. The infusion will be accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes) to ensure blinding is maintained.
48643938|NCT06682650|BEHAVIORAL|NPT-PLA|"NPT-PLA was developed and initially tested in 5 European countries in the EU-funded RESTORE study. PLA Participatory Learning in Action is a set of participatory research techniques in which participants use democratic processes to identify key actions needed to achieve a specific goal e.g. implementation of a tested decision making tool such as I2; and prioritize which of these need to be acted upon first and subsequently (in which order). Normalization Process Theory (NPT) is combined with PLA to help implementation teams using PLA to assess organization capacity and readiness to enact the selected action steps vis-a-vis NPT constructs, iteratively. These are coherence does everyone understand what needs to be done?; Cognitive participation Does everyone who needs to act 'buy in' to take action; collective action Is everyone who needs to act taking steps to make the change?'; and reflexive monitoring After the step has been taken, has it had the desired impact on the goal?"
48643939|NCT06682650|BEHAVIORAL|Usual Quality Improvement|Usual quality improvement includes principles of continuous quality improvement, such as Plan-Do-Study-Act cycles, to implement a specific goal. In this study, 'usual QI' methods already in use in 'active comparator' arm will be documented during the baseline assessment of clinical workflows in clinics assigned to that arm; and will be provided with a 'preset protocol' to implement the study shared decision-making tool (I2). Processes that implementation teams in these clinics use to achieve implementation will be documented.
47964613|NCT03794271|PROCEDURE|Pupilometer guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
48115249|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization."
48115250|NCT06280950|DRUG|Tacrolimus (continued reduction)|"* Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction"
47964614|NCT03794271|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
47964615|NCT01930864|DRUG|metformin|metformin up to 2500mg/d
47964616|NCT01930864|DRUG|irinotecan|Irinotecan 350 mg/m² IV q21d
47964617|NCT03781869|DRUG|Anlotinib Hydrochloride; etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
47964618|NCT03781869|DRUG|etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
48115251|NCT06280950|DRUG|Tacrolimus (maintain 50% reduction)|- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
48313847|NCT02200367|OTHER|Usual Care|
48313848|NCT06249256|BIOLOGICAL|Fast CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of Fast CAR T cells. During Fast CAR T cells production, subjects will receive cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with Fast CAR T cells by intravenous (IV) injection.
47964619|NCT04271527|PROCEDURE|cognitive fusion targeted biopsy|A cognitive fusion targeted biopsy
47964620|NCT04092582|DRUG|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
47964621|NCT04092582|DRUG|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
48115252|NCT06280950|DRUG|Everolimus|"* The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen."
48115253|NCT02492048|DEVICE|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
48115254|NCT02492048|PROCEDURE|Split Thickness Skin Graft|Split Thickness Skin Graft
48115255|NCT03567798|DIETARY_SUPPLEMENT|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
48115256|NCT03567798|OTHER|Placebo|Placebo
48115257|NCT01603784|BEHAVIORAL|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at \~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
48115258|NCT01603784|BEHAVIORAL|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
48115259|NCT01603784|BEHAVIORAL|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
48643940|NCT06691347|BEHAVIORAL|Eye movement desensitization and reprocessing|Psychotherapy with EMDR. A therapist guides the client in recalling distressing events while simultaneously following a stimulus, like a moving light or tapping. The idea is that this bilateral stimulation helps reduce the intensity of the traumatic memory, allowing clients to gain perspective and lessen emotional distress associated with it. The standard treatment protocol includes up to 24 weekly sessions.
47964622|NCT00934492|DRUG|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
47964623|NCT00934492|DRUG|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
47964624|NCT00541593|PROCEDURE|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
47964625|NCT03415334|BEHAVIORAL|behavioral development for change|"1. Social Marketing Principles (4 Ps) Product, price, place and promotion~2. Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events"
47964626|NCT00303784|DRUG|Goserelin|3.6mg implant, in pre-filled syringe
47964627|NCT00303784|DRUG|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
47964628|NCT05683964|DRUG|Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]|per standard care
47964629|NCT05683964|DIAGNOSTIC_TEST|Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan|Per standard care
47964630|NCT04607954|BIOLOGICAL|Durvalumab|Given IV
47964631|NCT04607954|DRUG|Lurbinectedin|Given IV
47964632|NCT05493046|BEHAVIORAL|Interactive Hand Exercise Game|Interactive Hand Exercise Game to Improve Vascular Maturity and Grip Strength in Patients undergoing Arteriovenous Fistula Surgery
47964633|NCT05493046|BEHAVIORAL|Soft ball exercise ( routine care)|Soft ball exercise ( routine care)
47964634|NCT03597776|DRUG|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
48313849|NCT02597673|OTHER|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
48313850|NCT02597673|DEVICE|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
48313851|NCT02597673|DEVICE|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
48313852|NCT00760227|OTHER|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
48484348|NCT05356806|OTHER|Supportive periodontal and periimplant care|"Periodontal and peri-implant maintenance therapy will be carried out at baseline, 3 and 6-month visit. This session will include the removal of biofilm and calculus on teeth and implants (except those that have just been restored) with an ultrasonic device using a plastic tip ( for implants. and a conventional metal tip ( for teeth. At the end, polishing will be done with a rubber cup~Subsequently, patients will be explained that they must continue with their usual oral hygiene technique on their teeth, using the same type of brush (which can be electric or manual), interproximal devices, toothpaste or mouthwash used to date. Finally, they will receive specific instructions for the supragingival biofilm control in the area of the new restoration and will be given interdental brushes that suit to the space"
48484349|NCT00734201|DRUG|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
48484350|NCT01231750|DRUG|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
48484351|NCT01231750|OTHER|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
48484352|NCT02152735|PROCEDURE|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
48484353|NCT02336516|DRUG|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
48484354|NCT02336516|DRUG|Placebo (glucose solution 10%)|
48484355|NCT01414751|BEHAVIORAL|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
48484356|NCT01414751|BEHAVIORAL|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
48484357|NCT00338052|DRUG|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
48484358|NCT01974908|PROCEDURE|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
47964635|NCT03597776|DRUG|Saline|Bolus of saline will be given over 5 minutes before skin incision
47964636|NCT02871414|BEHAVIORAL|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
47964637|NCT02871414|BEHAVIORAL|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
47964638|NCT00560781|DRUG|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
48643941|NCT06691347|BEHAVIORAL|Cognitive therapy for PTSD|"Psychotherapy with CT-PTSD. A therapist works with the client to understand how they interpret their trauma and identify distorted thinking patterns that fuel their PTSD symptoms. Through guided discussions, written exercises, and sometimes re-living the trauma in a controlled way, clients learn to reshape these beliefs, gain a more balanced perspective, and reduce symptoms like hypervigilance, flashbacks, and avoidance behaviors. The standard treatment protocol includes up to 24 weekly sessions."
48484359|NCT04844021|BEHAVIORAL|Nudge|"EHR-based nudge"
48484360|NCT04844021|BEHAVIORAL|Nudge+|"EHR-based nudge plus facilitation"
48484361|NCT00261131|DRUG|Botulinum Toxin A|
48484362|NCT03984045|DRUG|Lidocaine topical|Intranasal 2% lidocaine delivered directly to SPG
48484363|NCT03984045|DRUG|Prochlorperazine Injection|intravenous prochlorperazine at 0.15mg/kg max 10 mg
48484364|NCT04636593|DRUG|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
48484365|NCT03913182|DRUG|apatinib|500mg po Qd
48643942|NCT06691399|OTHER|Oral care|Oral care done twice daily with chlorhexidine oral care solution (concentration 1.2%)
47964639|NCT03726411|PROCEDURE|non-surgical periodontal therapy|scaling and root planing
48313853|NCT00760227|OTHER|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
48313854|NCT00760227|OTHER|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
48313855|NCT03327181|DIETARY_SUPPLEMENT|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
48313856|NCT00121030|DRUG|darbepoetin alfa|
48313857|NCT00121030|DRUG|recombinant human erythropoietin (rHuEPO)|
48313858|NCT05610852|PROCEDURE|Transvesical Single Port Robotic Partial Prostatectomy|A foley catheter is inserted on the sterile field. A suprapubic midline incision is made and the da Vinci SP surgical system is docked percutaneously directly to the bladder. Prior to the operation, a radiologist identifies and segments tumors and the urethra. A transrectal ultrasound probe is inserted and secured into a fixed position. The Koelis software is utilized to fuse MRI and ultrasound images to identify the target lesion in real-time, allowing for intraoperative guidance. The ultrasound probe rotates automatically, allowing for localization of the tumor intraoperatively. Then depending on the area of the tumor, a Hemi or quadrant resection is completed while preserving the nerves, vas deferens, and seminal vesicles. The urethrovesical anastomosis is then performed.
48313859|NCT05610852|PROCEDURE|High-intensity focused ultrasound (HIFU)|Three contoured measurements are required for the MR fusion system to reproduce the volume of the prostate. Following this, the area to be targeted will be selected in graded fashion from the anterior to posterior of the prostate. Once planning of ROI (region of interest) is complete, the HIFU treatment may begin. Quadrant or hemi ablation will be performed based on the size and complexity of the tumor. The distal margin of the ablation will be kept at least 4 mm away from the external sphincter. The rectal temperature and its distance from the probe will be carefully monitored throughout the procedure.
48313860|NCT02711215|DIAGNOSTIC_TEST|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
48313861|NCT02711215|DRUG|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
48313862|NCT02711215|DRUG|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
48313863|NCT02711215|DRUG|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
48313864|NCT03605719|DRUG|Carfilzomib|Given IV
48313865|NCT03605719|DRUG|Dexamethasone|Given IV
48313866|NCT03605719|BIOLOGICAL|Nivolumab|Given IV
48313867|NCT03605719|BIOLOGICAL|Pelareorep|Given IV
48313868|NCT02893527|BEHAVIORAL|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
48313869|NCT06226506|DRUG|Test (T) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
48313870|NCT06226506|DRUG|Reference (R) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
48313871|NCT03682510|PROCEDURE|stepwise devascularization|stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc
48313872|NCT03682510|PROCEDURE|B-Lynch Transverse Compression Suture group|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity."
48313873|NCT03682510|PROCEDURE|N&H sandwich technique|In the N\&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
48484366|NCT04577573|DEVICE|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
48643943|NCT06688669|OTHER|Fabrication of suitable complete or removable partial dentures for the patient|Fabrication of suitable complete and partial dentures for the patient. The study will not interfere with this treatment process; only follow-up assessments will be conducted at specific intervals after the dentures are fabricated, and surveys will be administered to the patient.
48643944|NCT04677153|OTHER|Test and treat plus peer mentors|Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
48643945|NCT04677153|OTHER|Usual care|Participants are referred to another location for HCV treatment.
48643946|NCT06616766|DRUG|YH42946|YH42946
48643947|NCT06682975|DRUG|ZP9830|Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
48643948|NCT06682975|DRUG|Placebo|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
48643949|NCT06686381|PROCEDURE|Maximum TURBT|Total removal of the bladder tumor through TURBT
48484367|NCT04577573|DEVICE|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
48484368|NCT02276898|DRUG|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
48484369|NCT02276898|DRUG|Isotonic Saline 0.9% (Placebo)|
48484370|NCT05703035|PROCEDURE|standby while firing staple|VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.
47964640|NCT04725461|DEVICE|Low cost lower limb prosthetic socket|"A pre-made 3D printed cylinder used as an outer shell is selected for each subject based on their measurements. The space between the residual limb and the outer shell will be filled with an expanding polyurethane foam (Foam IT 8, Smooth On Inc.) that conforms to the residual limb and bonds with the outer shell to form a strong and lightweight socket. The foam forms a smooth surface against the protective sheath; the socket is fully formed once the foam has hardened to the 3D printed cylinder.~A prefabricated supracondylar suspension cuff made of Dacron or nylon, or a commercially available suspension sleeve may be will be applied to the prosthetic socket to aid in suspension. Commercially available components, including the International Committee of the Red Cross (ICRC) transtibial polypropylene component system will be attached to the bottom of the socket to allow the patient to ambulate in the prosthesis."
47964641|NCT01114256|PROCEDURE|FNA Biopsy|
47964642|NCT00788567|DRUG|mycophenolate mofetil|1
48484371|NCT03898102|DRUG|Regorafenib|regorafenib plus zinc gluconate
48484372|NCT03898102|DIETARY_SUPPLEMENT|Zinc gluconate supplement|Zinc gluconate supplement
48484373|NCT04208126|DEVICE|ECMO|ECMO implantation immediately after ICU admission
48484374|NCT00256711|DRUG|Gefitinib|
47964643|NCT05026255|PROCEDURE|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
47964644|NCT01201005|DIETARY_SUPPLEMENT|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
47964645|NCT01201005|DIETARY_SUPPLEMENT|Sham injection|needle injection without any substance given
47964646|NCT04875182|DIAGNOSTIC_TEST|Evaluation of Delirium development|Postoperative pain scores of the patients will recorded by using a numerical rating scale.
47964647|NCT02959307|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
47964648|NCT02959307|DEVICE|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
47964649|NCT02515825|DEVICE|CADence|
47964650|NCT00826943|DRUG|Cetirizine|Cetirizine 10 mg tab daily x 7 days
47964651|NCT00826943|DRUG|Levocetirizine|5 mg tab daily x 7 days
47964652|NCT00826943|DRUG|Placebo|Placebo tablet daily x 7 days
47964653|NCT05947396|DIETARY_SUPPLEMENT|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
47964654|NCT05947396|OTHER|placebo|The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
47964655|NCT00491816|DRUG|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
47964656|NCT04524546|DIAGNOSTIC_TEST|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
47964657|NCT00005571|DRUG|h5G1.1-mAb|
47964658|NCT05367622|BEHAVIORAL|Self-regulation health education|"1. Insert the continuous blood glucose monitor~2. Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~3. Use Telecommunications on the modifications of health promotion behaviors for 7 days"
47964659|NCT05367622|BEHAVIORAL|Usual diabetes health education|"1. Practice self-monitoring of blood glucose~2. Give usual diabetes health education"
48484375|NCT00256711|DRUG|Vinorelbine|
48484376|NCT00433316|DRUG|ropivacaine|1% ropivacaine
48484377|NCT00433316|DEVICE|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
48484378|NCT02712437|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
48484379|NCT06357949|DEVICE|High-intensity laser|"All patients will receive a rehabilitation program consisting of stretching, strengthening, balance, and walking exercises targeting the lower extremities for 45 minutes, 5 days a week, for 6 weeks. Walking training will initially begin on level ground and gradually progress to different levels and surfaces.~High-intensity laser will be applied continuously in biostimulation mode 3 days a week, once a day, for a total of 9 sessions over 3 weeks"
48484380|NCT06357949|DEVICE|Sham laser|The same procedure will be followed, but sham laser will be applied at 0 j/cm2 for 10 minutes.
48313874|NCT05431517|PROCEDURE|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
48313875|NCT00548080|DRUG|MK0991, caspofungin acetate / Duration of Treatment:|
48313876|NCT03509207|DRUG|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
48313877|NCT00946946|DRUG|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
48313878|NCT00946946|DRUG|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
48313879|NCT00946946|DRUG|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
48313880|NCT00946946|DRUG|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
48313881|NCT04962737|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.
48313882|NCT05067335|DRUG|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
48313883|NCT05067335|DRUG|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
48313884|NCT02149836|DRUG|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
48313885|NCT00004038|BIOLOGICAL|Ad5CMV-p53 gene|
48313886|NCT00004038|DRUG|chemotherapy|
48313887|NCT00882102|DRUG|Decitabine|Decitabine 20 mg/m\^2 IV over 1-1/2 hours daily for 5 days.
48313888|NCT00882102|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m\^2 IV on day 5.
48313889|NCT00646971|DEVICE|CPAP device|for 4 weeks
48484381|NCT05871086|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
48313890|NCT00646971|DEVICE|Placebo device|for 4 weeks
48313891|NCT03768830|BEHAVIORAL|Exercise training|Exercise program includes breathing and upper and lower limbs exercise.
48313892|NCT05960188|BEHAVIORAL|AI Opinion|For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
48313893|NCT02820376|OTHER|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
48313894|NCT01291329|GENETIC|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
48313895|NCT02822404|DIETARY_SUPPLEMENT|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
48313896|NCT02660619|OTHER|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
48313897|NCT05603039|DRUG|QL1706|5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
48313898|NCT05603039|DRUG|QL1604|200mg#D1#Q3W IV
48313899|NCT05603039|DRUG|Bevacizumab|15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
48484382|NCT05871086|OTHER|Placebo|Placebo Capsules
48643950|NCT06686381|DRUG|Chemotherapy + Immunotherapy Induction|Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)
48643951|NCT06686381|RADIATION|Radiotherapy|Hypofractionated radiotherapy: 20 fractions, 55 Grays
48643952|NCT06686381|DRUG|Immunotherapy Maintenance|Maintenance Avelumab every 2 weeks for 12 months
48643953|NCT06686381|OTHER|Watchful waiting with supportive care|1 year watch and wait
48313900|NCT00304265|BIOLOGICAL|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
48313901|NCT01156038|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
48313902|NCT04930783|DRUG|CDX-301|Administered as an injection given underneath the skin
48313903|NCT04930783|BIOLOGICAL|NEOVAX|Personalized neoantigen vaccine administered as an injection given underneath the skin
48313904|NCT04930783|DRUG|Nivolumab|Administered intravenously (IV)
48313905|NCT04930783|DRUG|Pembrolizumab|Administered intravenously (IV)
48313906|NCT01057719|OTHER|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
48313907|NCT02862821|OTHER|HR-EEG|
48313908|NCT05027529|DEVICE|CytoSorb|An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
48313909|NCT05027529|OTHER|VA-ECMO only|only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
48313910|NCT03259997|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
48313911|NCT03259997|DIETARY_SUPPLEMENT|Placebo|Placebo
48313912|NCT01614236|DRUG|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
48313913|NCT01614236|DRUG|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
48313914|NCT01193192|OTHER|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
48313915|NCT01193192|OTHER|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
48313916|NCT01718509|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
48313917|NCT01718509|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
48313918|NCT01214746|DRUG|Placebo|1 tablet Unikalk 1 time pr day for 5 days
48313919|NCT01214746|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
48313920|NCT05220228|DRUG|Prucalopride|1mg prucalopride x 2d, 2mg prucalopride x 5-8d
48313921|NCT05220228|DRUG|Placebo|Lactose / sucrose placebo
48313922|NCT05986097|BEHAVIORAL|Breakfast|We will provide participants recipes and information to support this dietary change.
48313923|NCT05463874|BEHAVIORAL|Mindful Self-Compassion Program|The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
48484383|NCT05871086|DRUG|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~* Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~* Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~* Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~* Leflunomide - Weight based, 10-20 mg once daily~* Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~* Etanercept - 0.8 mg/kg/dose once weekly~* Adalimumab - Weight based, 10-40 mg every other week"
48313924|NCT06310785|DRUG|Esketamine|The esketamine group used esketamine as an analgesic during induction and maintenance of anesthesia.
48313925|NCT06310785|DRUG|Sufentanil|In the opioid group, sufentanil was used as an analgesic during anesthesia induction and remifentanil was used as an analgesic during anesthesia maintenance.
48313926|NCT01422811|BEHAVIORAL|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~1. Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~2. Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
47964660|NCT05379738|OTHER|6 sessions of adapted physical activity after stem cell transplant|"physical assessement before and after stem cell transplant:~* weight loss~* brachial muscle circumference~* grip strength evaluation~* short physical battery test~psychometric assessment before and after stem cell transplant:~* quality of life questionary~* physical activities questionary"
48313927|NCT01422811|OTHER|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
48313928|NCT02175771|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
48484384|NCT00010166|DRUG|gemcitabine hydrochloride|
48484385|NCT00010166|PROCEDURE|adjuvant therapy|
47964661|NCT04352712|OTHER|blood sampling|blood sampling
47964662|NCT00833794|DRUG|Tramadol Once a day|
48313929|NCT02175771|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
48313930|NCT02175771|DRUG|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
48313931|NCT02175771|DRUG|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
48313932|NCT02175771|DRUG|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
48484386|NCT00010166|RADIATION|radiation therapy|
48313933|NCT06129318|BEHAVIORAL|Clinical Pharmacist Led Pharmaceutical Care|Within the scope of pharmaceutical care, medication review services for past and current medication use were provided by the clinical pharmacist. The patients in the intervention group were given verbal information about the definition of stroke, symptoms, how to manage risk factors, and their medications by the clinical pharmacist on the day of discharge, in addition to the neurologist. Each patient in the intervention group had a scheduled meeting with the clinical pharmacist. During the 1-year follow-up the patient education given by the clinical pharmacist was repeated every 3 months.
48313934|NCT05422352|DIETARY_SUPPLEMENT|Carnosine|Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
48115260|NCT01603784|BEHAVIORAL|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
48313935|NCT05364879|BEHAVIORAL|Prehabilitation Exercise Intervention|The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.
48313936|NCT05844345|OTHER|Hydrocolloid barrier group|In the hydrocolloid barrier group, Comfeel Plus brand hydrocolloid tape will be used. Hydrocolloid tape is a dressing cover made of soft, flexible and economic material in the form of a semi-permeable film or foam-supported gel. Air exchange continues due to the semipermeable film on the top, while entry of harmful microorganisms to the region is prevented, healing is accelerated by creating a humid environment for the wound and exudate from the wound is absorbed. These features reduce the risk of developing infection and ensure patient comfort. There is no specific change time, though generally the tape is changed every 3-5 days; however, it may remain in place for up to 7 days.
48484387|NCT06074302|DEVICE|RHA Redensity|RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.
48484388|NCT02577341|DRUG|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
47964663|NCT00833794|DRUG|Placebo|
47964664|NCT01546207|PROCEDURE|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
47964665|NCT04263220|DEVICE|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
48484389|NCT02577341|DRUG|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
48484390|NCT02577341|RADIATION|daily RT to the chest|Patients received daily RT to the chest
48484391|NCT01510652|PROCEDURE|BiP Group|Implantation of standard Left Ventricular (LV) lead
48643954|NCT06686199|DIETARY_SUPPLEMENT|steamed potato|135 g per day 4-5 times per week for 8 weeks
48115261|NCT00338299|DRUG|Epoetin alfa|
48484392|NCT01510652|DEVICE|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
48484393|NCT02547402|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
47964666|NCT04263220|OTHER|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
47964667|NCT05371691|DEVICE|Myofunctional appliance|Myifunctional appliance will be used for growing patients who have Cl.II div.1 malocclusion, two types of appliances are involved myobrace and twin=block appliance
47964668|NCT02838381|OTHER|Additional biological samples|blood and tissue samples
47964669|NCT03385460|OTHER|ESWL BOTOX|ESWL after intrravesical BOTOX
47964670|NCT04505189|DRUG|Psilocybin|Psilocybin assisted psychotherapy
47964671|NCT03256097|DEVICE|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
47964672|NCT03256097|DEVICE|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
48115262|NCT06231355|DRUG|Performing paravertebral nerve block with lipo-bupivacaine|Paravertebral block is performed using liposomal bupivacaine.
48115263|NCT06231355|DRUG|Performing paravertebral nerve block with bupivacaine|Paravertebral block is performed using bupivacaine.
48115264|NCT02716220|DEVICE|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
48115265|NCT01464736|OTHER|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
48643955|NCT06686199|DIETARY_SUPPLEMENT|fried potato|135 g per day 4-5 times per week for 8 weeks
48643956|NCT06691139|PROCEDURE|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia graft in patients ages from 12 years to 40 years|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia
48643957|NCT06691139|OTHER|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft|Group (A) Myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft
48313937|NCT05844345|OTHER|Facial Massage group|Premature infants in the facial massage group will have facial massage applied by the researcher. For facial massage, physiological serum used for routine moisturizing in the clinic will be used. When performing facial massage, the fingers will be placed in the middle of the infant's forehead and massage will be performed towards the temples. The eyelids will be lightly rubbed toward the temples. Both thumbs will be placed in the center of the eyebrows and the ridge of the nose will be rubbed toward the lips. The sides of the nose will be rubbed with light pressure. The nasal septum will be rubbed toward the tip of the nose along the philtrum. The fingers will be placed on the philtrum region above the gums and the mouth will be rubbed toward the ears to make a smiling expression. The chin will be lightly massaged toward the back of the ears. The thumbs of both hands will rub from under the infant's chin toward the temples to give make a smiling face (smiling motion).
48313938|NCT05214898|BEHAVIORAL|24/7 Dad|"The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships."
48313939|NCT00228306|BEHAVIORAL|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
48313940|NCT03416738|BEHAVIORAL|Semantically focused treatment|"Tasks are as follows:~1. Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~2. Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~3. Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
48313941|NCT03416738|BEHAVIORAL|Phonologically focused treatment|"Tasks are as follows:~1. Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~2. Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~3. The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
48313942|NCT06014710|OTHER|Swallowing evaluation|"For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)"
48313943|NCT01027208|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
48484394|NCT02547402|DRUG|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
48484395|NCT02547402|DRUG|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
48643958|NCT06691139|PROCEDURE|Myringoplasty operation using periosteal graft and myringoplasty using Temporalis fascia graft|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft in age from 12years to 40 years
48643959|NCT06691139|PROCEDURE|Group (A) myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft|Myringoplasty operation using Temporalis fascia graft and Myringoplasty using periosteal graft in patients from 12 years to 40 years
48643960|NCT06691802|DRUG|Shu Fei Tie|Optimize the extraction process and matrix formulation, and combine the use of traditional Chinese medicine volatile oil and chemical transdermal enhancers to develop adermal patch（Shu Fei Tie）
48643961|NCT06691802|DRUG|Shu Fei Tie placebo|Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
48115266|NCT01013012|DRUG|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
48115267|NCT01013012|DRUG|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
48643962|NCT06691061|DRUG|Vedolizumab|UC patients treated with vedolizumab
48643963|NCT06691061|DRUG|Ustekinumab - Standard Dosage|UC patients treated with ustekinumab
48643964|NCT06691061|DRUG|JAK Inhibitor|UC patients treated with JAK inhibitors
48643965|NCT06691685|DRUG|ESO-T01 Injection|ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
48643966|NCT05787119|OTHER|Conventional therapy|The CT consists of 1 session of 30 minutes of physical therapy (type of re-education established according to the pain at rest and during movement assessed every day) and 1 session of 30 minutes of occupational therapy (type of re-education established according to the pain at rest and during movement assessed every day). CT is performed 5 days a week.
48115268|NCT06115993|DRUG|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
48115269|NCT06115993|DRUG|Placebo|Placebo will be administered subcutaneously.
48115270|NCT06524700|PROCEDURE|pectopexy mesh|pectopexy with mesh
48115271|NCT06524700|PROCEDURE|pectopexy autologous|pectopexy using autologous graft
48115272|NCT03183518|OTHER|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
48115273|NCT03183518|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
48115274|NCT05570188|BIOLOGICAL|anti-CD19 UCAR-NK cells|"Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells:~Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg."
48115275|NCT03264846|DIAGNOSTIC_TEST|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
48115276|NCT01573598|DRUG|Placebo|Matching placebo given orally, once per day
48115277|NCT01573598|DRUG|Vilazodone|Vilazodone, 20 mg per day, oral administration
48115278|NCT01573598|DRUG|Vilazodone|Vilazodone, 40 mg once per day, oral administration
48313944|NCT04400409|OTHER|Intervention A - Vascular Care + site 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
48313945|NCT04400409|OTHER|Intervention B - Standard Care + site 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
48313946|NCT04400409|OTHER|Intervention A - Vascular Care + CPC EQuIP 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
48313947|NCT04400409|OTHER|Intervention B - Standard Care + CPC EQuIP 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
48313948|NCT04386564|DIAGNOSTIC_TEST|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
48313949|NCT00568958|BEHAVIORAL|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
48313950|NCT00568958|DRUG|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
48313951|NCT00568958|DRUG|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
48313952|NCT00118027|DRUG|sulphadoxine-pyrimethamine intermittent preventive treatment|
48313953|NCT02667860|PROCEDURE|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
48313954|NCT02667860|PROCEDURE|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
48313955|NCT02667860|DEVICE|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
48313956|NCT02667860|DEVICE|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
48313957|NCT05633147|DRUG|Linaprazan glurate|"Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days."
48313958|NCT05633147|DRUG|Drug drug interaction (DDI) - Clarithromycin (Part I)|Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
48313959|NCT05633147|DRUG|Drug drug interaction (DDI) - Midazolam (Part 2)|Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
48313960|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg|Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
48313961|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Placebo (tablet)|Selective serotonin reuptake inhibitor (SSRI) + placebo
48484396|NCT03695705|DRUG|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
48484397|NCT00822393|DRUG|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
48643967|NCT05787119|OTHER|ARMT|The ARMT consists of 1 session of 30 minutes (type of rehabilitation established according to the pain at rest and during movement evaluated daily). ARMT is performed 5 days a week for 1 month.
48115279|NCT02510534|DRUG|Menopur 150 international units|Menopur 150 international units given x 1 dose
48115280|NCT02510534|DRUG|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
48115281|NCT05887180|OTHER|PräVaNet-Intervention|interdisciplinary and digitally supported prevention concept
48313962|NCT03262532|OTHER|Web-base simulator|Training manipulation of TEE using a Web-based simulator
48313963|NCT03262532|OTHER|No web-base simulator|Training manipulation of TEE with out a web-base simulator
48313964|NCT05142514|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
48313965|NCT05142514|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive 2 injections of Cominarty administered 21 days apart
48313966|NCT02260245|BEHAVIORAL|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
48313967|NCT04099732|DRUG|Rosuvastatin|Tablet
48313968|NCT04099732|DRUG|BI 1358894|Tablet
48313969|NCT04099732|DEVICE|Dabigatran etexilate|Capsule
48313970|NCT04501679|DRUG|Nemolizumab|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
48313971|NCT04501679|DRUG|Placebo|Participants received matching placebo as SC injection.
48313972|NCT01424826|DRUG|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
48313973|NCT01424826|DRUG|Rifampicin|\< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days \> 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
48313974|NCT01424826|DRUG|Raltegravir|800 mg bd for 4 days
48484398|NCT00822393|DRUG|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
48484399|NCT04900909|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
48484400|NCT05998551|DRUG|Dexmedetomidine|intrathecal injection of dexmedetomidine added to hyperbaric bupivacaine
48484401|NCT05998551|DRUG|Fentanyl|intrathecal injection of fentanyl added to hyperbaric bupivacaine
48484402|NCT05998551|DRUG|Bupivacaine Hcl 0.5% Inj|intrathecal injection of hyperbaric bupivacaine only
48484403|NCT04283916|DRUG|Botulinum Toxins|Botulinum toxin injection to abdominal wall
48484404|NCT05613751|BEHAVIORAL|Nudge|Three text messages that are sent four weeks apart reminding to obtain the vaccines
48484405|NCT04667702|BEHAVIORAL|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
48484406|NCT01364324|DRUG|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
48643968|NCT05787119|OTHER|cortical reactivity|An electroencephalogram was taken at the start and end of the study to study cortical reactivity during the performance of 3 different tasks repeated 30 times: a resting task (consisting of looking at a cross on a screen), a motor imagery task (consisting of imagining performing wrist flexions/extensions) and a motor execution task (consisting of performing wrist flexions/extensions).
47964673|NCT03256097|DEVICE|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
47964674|NCT03256097|DEVICE|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
47964675|NCT03256097|DEVICE|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
48313975|NCT05381012|OTHER|Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization|All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.
48313976|NCT05381012|OTHER|Fibromyalgia syndrome|Patients who meet the diagnostic criteria for fibromyalgia syndrome will be evaluated with the Fibromyalgia Impact Questionnaire.
48313977|NCT05155475|PROCEDURE|Ultrasound endoscopy|After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver
48313978|NCT01457859|DRUG|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
48313979|NCT01457859|OTHER|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
48313980|NCT02913222|OTHER|Rehabilitation|Comparison of two rehabilitation approaches
48313981|NCT00673478|DRUG|Tiotropium+Salmeterol|
48313982|NCT00673478|DRUG|Salmeterol|
48313983|NCT00673478|DRUG|Tiotropium|
48313984|NCT00605410|DRUG|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
48313985|NCT00605410|DRUG|placebo|Matched placebo
48313986|NCT04105205|DRUG|Apramycin injection|30-min infusion
48313987|NCT04105205|DRUG|Placebo injection|30-min infusion
48313988|NCT00753935|DRUG|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
48313989|NCT00753935|DRUG|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
48313990|NCT02085876|OTHER|2 additional MRI sequences|
48313991|NCT02085876|OTHER|An additional blood sample|
48484407|NCT01091103|DRUG|Enzalutamide|
48484408|NCT05044884|OTHER|Otago Exercise training|"1. Warm-up exercises. Chair March, Arm swings ( 30 second), Head movement, neck movement, back extension, trunk movement, ankle movement (repeat 5 times).~   Back of thigh stretch, calf stretch, (hold for 8 seconds).~2. Strengthening exercises Front knee strengthening, back knee strengthening, side hip strengthening (2 or more sets of 10 reps) Calf raises, toe raises (repeat this exercises 10 to 20 times)~3. Balance improvement exercises Knee bends, heel-toe standing, heel toes walking, one leg stand ( start with 5 sec move up to 10 sec) Side walk, heel walking, sit to stand, backwards walking, heel toes walking backwards, walking and turning around, stair walking (10 steps).~4. Cool-down session Back of thigh stretch, calf stretches ( 10 to 20 sec hold, 1 to 3 reps)~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles."
48643969|NCT05787119|OTHER|Fluidity of movement|Motion capture at the start and end of the study to study the fluidity of movement during 3 different tasks repeated 30 times: a resting task (looking at a cross on a screen), a motor imagery task (imagining wrist flexions/extensions) and a motor execution task (performing wrist flexions/extensions).
48313992|NCT02918266|DRUG|Scopolamine|Scopolamine subcutaneous injection
48313993|NCT02918266|DRUG|TAK-071|TAK-071 DIC
48313994|NCT02918266|DRUG|Donepezil|Donepezil over-encapsulated tablet
48313995|NCT02918266|DRUG|Scopolamine Placebo|Scopolamine placebo-matching subcutaneous injection
48313996|NCT02918266|DRUG|TAK-071 Placebo|TAK-071 placebo-matching DIC
48313997|NCT02918266|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
48313998|NCT00173251|PROCEDURE|obtain surgical specimen for analysis|
48313999|NCT05749926|BIOLOGICAL|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
48314000|NCT05749926|BIOLOGICAL|VidPrevtyn® Beta vaccine (Sanofi/GSK)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
48314001|NCT05127421|DRUG|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
48314002|NCT05127421|DRUG|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
48314003|NCT01085058|DRUG|lenograstim|
48314004|NCT01917110|DEVICE|omafilcon A|
48314005|NCT01917110|DEVICE|Spectacle|
48314006|NCT00239772|BEHAVIORAL|Cognitive Processing Therapy|
48314007|NCT00239772|BEHAVIORAL|Prolonged Exposure Therapy|
47964676|NCT03256097|DEVICE|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
48314008|NCT00004880|BIOLOGICAL|dendritic cell vaccine therapy|
48314009|NCT00004880|PROCEDURE|conventional surgery|
48314010|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314011|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48484409|NCT05044884|OTHER|Circuit training|"1. Functional strength exercises Heel raise, toe raise, walking on toes, step ups in all directions ( forward, backward and sideways) (2 sets and 8 reps)~2. Stance exercises Tandem, narrow, one leg stance, and stand on uneven surfaces with open eyes (each exercise 30 seconds) Tandem, narrow, one leg stance, and stand on uneven surfaces with eyes closed (each exercise 15seconds).~3. Transition exercises Sit to stand from chair with arms (10 reps) and then without arms support (5 reps).~   Sit on floor and stand up with assistance and then without assistance.~4. Gait training Walking tandem, sideway and backward with arm support. Walking tandem, sideway and backward without arm support Walking tandem, sideway and backward over obstacles~5. Pulmonary rehabilitation program~   * Daily breathing exercises (e.g. diaphragmatic, pursed lip breathing).~  * Stretch exercise for major respiratory muscles"
47964677|NCT03256097|DEVICE|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
48314012|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314013|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
47964678|NCT03256097|DEVICE|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
47964679|NCT04367428|BIOLOGICAL|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
48484410|NCT05208658|OTHER|Experimental: Classical Vision Therapy Treatment|Do classical vision therapy treatment for improve vergence
48314014|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314015|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314016|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314017|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314018|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314019|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
48314020|NCT00228254|DRUG|Zinc (12.5 mg/day)|
48314021|NCT00228254|DRUG|vitamin A 10,000 IU per week|
48314022|NCT01928043|DRUG|Curcumin|
48314023|NCT03044015|BEHAVIORAL|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
48314024|NCT03044015|BEHAVIORAL|as usual|
48314025|NCT01107756|DRUG|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
48314026|NCT04601142|DRUG|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
48314027|NCT05297422|PROCEDURE|Forearm surgey|Microsurgery Clinic , KAT Hospital Athens
48314028|NCT05297422|DRUG|Ropivacaine|Ropivacaine
48314029|NCT05297422|DRUG|Ketamine|Ketamine
48314030|NCT01907594|DRUG|D-cycloserine|
48314031|NCT01907594|DRUG|Nicotine Replacement Therapy (patch)|
48314032|NCT01907594|BEHAVIORAL|Smoking Cue Exposure|
48484411|NCT05208658|OTHER|Control: Eye Movement Therapy Treatment|Do eye movement therapy treatment in order not to improve vergence
48484412|NCT03363477|DRUG|Enoxaparin|
48484413|NCT03363477|DRUG|Clexane|
48484414|NCT01010022|DRUG|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
47964680|NCT05523752|DEVICE|Proseal Laryngeal Mask|insertion of Proseal Laryngeal Mask
47964681|NCT05523752|DEVICE|Classic Laryngeal Mask|insertion of Classic Laryngeal Mask
47964682|NCT05523752|DEVICE|I-gel|insertion of I-gel
48643970|NCT06617364|PROCEDURE|gastrointestinal transit time measurement using MSOT and ICG contrast agent|The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
48314033|NCT01907594|BEHAVIORAL|Progressive Muscle Relaxation|
48314034|NCT01907594|DRUG|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
48314035|NCT04979832|DRUG|GM-CSF, fosfomycin and metronidazole|GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
48314036|NCT06445101|OTHER|Participatory Approach|The participatory approach is a stepwise, collaborative approach to the analysis and solvation of bottlenecks that cause stress in employees.
48643971|NCT01064648|DRUG|Cediranib Maleate|Given orally
48314037|NCT00668655|DRUG|Metronidazole Gel|Topical, Once daily for 2 weeks
48314038|NCT03231085|DRUG|Ferrous fumarate or ferrostrane|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
48314039|NCT00757939|OTHER|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
48314040|NCT00757939|OTHER|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
48314041|NCT00436566|BIOLOGICAL|trastuzumab|
48115282|NCT04782635|DEVICE|mobile based application|Application basic function would be support and improve nutrition status of children. Personalization of goals and challenges, daily intake of calories, carbohydrates, proteins, fats, minerals and vitamins will be tracked, food logging, food tracking, meal and supplement reminders, recipes, visual cues (remaining calories) will be notified, episodes of vomiting, meals missed, diarrhea, nausea will be recorded , meal planned according to the food preferences of child, food composition table, nutrition blogs and articles
48115283|NCT04782635|BEHAVIORAL|Pamphlet|A pamphlet which will be provide knowledge to the patients
48643972|NCT01064648|DRUG|Cisplatin|Given IV
48643973|NCT01064648|OTHER|Laboratory Biomarker Analysis|Correlative studies
48643974|NCT01064648|DRUG|Pemetrexed Disodium|Given IV
48115284|NCT05235698|PROCEDURE|Ophthalmological examinations|Visual acuity, slit lamp examination, eye pressure, retinophotography, indocyanine green retinal angiography, OCT-A( Optical Coherence Tomography- Angiography), adaptive optics, automated visual field
48115285|NCT05235698|PROCEDURE|GlycoCheck|"Evaluation of the glycocalyx of sublingual capillaries with the GlycoCheck :~A sidestream dark field camera, coupled with GlycoCheck™ software is used to visualize the patient's sublingual microvascularization"
48115286|NCT06323902|PROCEDURE|Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation|In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.
48115287|NCT06073769|DRUG|Oral azacitidine|Maintenance therapy according to the approved label
48115288|NCT00042198|BEHAVIORAL|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
48115289|NCT00042198|BEHAVIORAL|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
48314042|NCT00436566|DRUG|cyclophosphamide|
48314043|NCT00436566|DRUG|doxorubicin hydrochloride|
48314044|NCT00436566|DRUG|lapatinib ditosylate|
48314045|NCT00436566|DRUG|paclitaxel|
48314046|NCT00436566|GENETIC|gene expression analysis|
48314047|NCT00436566|GENETIC|reverse transcriptase-polymerase chain reaction|
48314048|NCT00436566|OTHER|fluorophotometry|
48643975|NCT01064648|OTHER|Placebo Administration|Given orally
48643976|NCT06690346|OTHER|Systematic oral health education|Provide systematic oral health education to patients in experimental group, including oral hygiene instruction and dietary instruction
48643977|NCT06690346|OTHER|Routine oral health education|Provide routine oral health education to patients in control group, including routine oral self-care instruction
48643978|NCT06687928|BIOLOGICAL|CT-P6 SC|A single fixed dose (600 mg) of CT-P6 subcutaneous
48314049|NCT00436566|OTHER|laboratory biomarker analysis|
48314050|NCT00436566|OTHER|mass spectrometry|
48314051|NCT00436566|PROCEDURE|adjuvant therapy|
48314052|NCT00436566|PROCEDURE|quality-of-life assessment|
48314053|NCT01986218|DRUG|BMS-986115|
48314054|NCT00094341|DRUG|Etanercept|
48314055|NCT06197945|OTHER|Mulligan bent leg raise|Mulligan bent leg raise
48314056|NCT06197945|OTHER|Mulligan bent leg raise with Bowen therapy|Mulligan bent leg raise with Bowen therapy
48314057|NCT01380158|DEVICE|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
48314058|NCT02632695|DEVICE|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
48314059|NCT03448718|DRUG|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
48314060|NCT05912413|OTHER|there is no intervention|there is no intervention
48314061|NCT05580861|DRUG|Sulfasalazine|Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
48314062|NCT04654000|PROCEDURE|Rheopheresis procedure|rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins
48314063|NCT04654000|PROCEDURE|Sham-apheresis|Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
48314064|NCT00104494|DRUG|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
48314065|NCT01670214|PROCEDURE|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
48314066|NCT00931580|DIETARY_SUPPLEMENT|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
48314067|NCT03765619|DRUG|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
48314068|NCT01372111|DRUG|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
48314069|NCT01372111|RADIATION|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
48314070|NCT00276978|DRUG|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
48314071|NCT03628430|PROCEDURE|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
48314072|NCT03628430|PROCEDURE|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
48314073|NCT03628430|PROCEDURE|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
47964683|NCT05523752|DEVICE|Suprema Laryngeal Mask|insertion of Suprema Laryngeal Mask
48115290|NCT05339893|DEVICE|In Motion Rehabilitation Robot|Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
48115291|NCT00414544|DEVICE|CosmetaLife|Dermal filler
48314074|NCT02868216|BEHAVIORAL|anger management training|
48643979|NCT06687928|BIOLOGICAL|EU-Approved Herceptin SC|A single fixed dose (600 mg) of EU-approved Herceptin subcutaneous
48643980|NCT01647256|DRUG|Nikkomycin Z|Capsule, 500 mg, single-dose
48643981|NCT04857983|DRUG|Memantine|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
48643982|NCT04857983|DRUG|Placebo|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
48115292|NCT00414544|DEVICE|Restylane|Dermal filler
48115293|NCT00092274|DRUG|HuMax-CD20|
48115294|NCT01979393|DRUG|Cabozantinib|
48115295|NCT01979393|DRUG|Placebo|
48115296|NCT02014766|PROCEDURE|Interscalene block|Ultrasound-guided interscalene block is performed.
48314075|NCT02233400|DRUG|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
48314076|NCT05740293|PROCEDURE|VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism|Bilateral treatment with the approved VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism.
48314077|NCT02430662|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
48115297|NCT02014766|PROCEDURE|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
48115298|NCT03247543|DRUG|Placebo|Placebo was administered once daily
48115299|NCT03247543|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
48115300|NCT03247543|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
48115301|NCT04734730|DRUG|Abiraterone Acetate|Given PO
48115302|NCT04734730|DRUG|Bicalutamide|Given PO
48115303|NCT04734730|DRUG|Degarelix|Given SC
48115304|NCT04734730|DRUG|Goserelin Acetate|Given SC
48115305|NCT04734730|DRUG|Leuprolide Acetate|Given IM
48115306|NCT04734730|DRUG|Prednisone|Given PO
48115307|NCT04734730|OTHER|Questionnaire Administration|Ancillary studies
48115308|NCT04734730|DRUG|Talazoparib|Given PO
48115309|NCT06172517|OTHER|Orthosis intervention|Clinical feasibility trial with one group using a custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
48314078|NCT02430662|DEVICE|NanoKnife|
48314079|NCT03689504|DIETARY_SUPPLEMENT|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
48314080|NCT03689504|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
48314081|NCT03689504|BEHAVIORAL|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
48314082|NCT05219422|BEHAVIORAL|Project ALERT|14 session drug prevention program for 7th and 8th grade youth.
48314083|NCT05219422|BEHAVIORAL|Getting to Outcomes|The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
48314084|NCT04442958|OTHER|Convalescent Immune Plasma|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
48314085|NCT05557773|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
48484415|NCT01010022|DRUG|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
48643983|NCT06690788|BEHAVIORAL|Individual intervention condition (PreventT2)|PreventT2 will be delivered by a team of trained CDC National Diabetes Prevention Program (NDPP) Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the lifestyle intervention curriculum to be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has Full recognition from the CDC based on outcome data over the course of a number of years.
48115310|NCT05824546|PROCEDURE|Intervention Arm (uSINE-PAMS-technique)|Patients will be lying in a lateral recumbent position and in a fetal position with the neck, back and limbs held in flexion. L3-L4 inter-vertebral space will be identified by palpation of external landmarks of the patients' iliac crests and spinous process of lumbar vertebrae L3, L4 and L5 and confirmed using uSINE-integrated ultrasound. The angle of needle during needle advancement will also be determined using the uSINE-integrated ultrasound. Markings on the patients' skin surface will be made using PAMS (non-sterile component) to enable relocation of the site and angle of the needle entry. Patients' back will be cleaned and draped using aseptic technique. Next, local anaesthesia is infiltrated into the previously identified needle entry site before the LP needle is inserted with location and angulation according to PAMS (sterile component) guidance.
48115311|NCT01665092|DRUG|Levo-Carnitine|
48115312|NCT01665092|DRUG|placebo|
48115313|NCT03911479|PROCEDURE|Bariatric Surgery|Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
48115314|NCT00989183|OTHER|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
48115315|NCT03185156|DRUG|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
48314086|NCT05557773|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
48314087|NCT03450369|BIOLOGICAL|NB01|Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
48314088|NCT02147704|DIETARY_SUPPLEMENT|High-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
48314089|NCT02147704|DIETARY_SUPPLEMENT|low-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet"
48314090|NCT01901731|PROCEDURE|transjugular coil embolisation of pelvic veins|
48314091|NCT01901731|PROCEDURE|endovenous treatment of leg varicose veins|
48484416|NCT03442881|PROCEDURE|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
48484417|NCT05992428|DRUG|DA-8010 5mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
48484418|NCT05992428|DRUG|Paroxetine 20mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg
48484419|NCT05992428|DRUG|Mirabegron 50mg|\[Part 2\] DA-8010 5mg + Mirabegron 50mg
48484420|NCT04158336|DRUG|ZN-c3|ZN-c3 is a study drug
48115316|NCT03185156|DRUG|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
48115317|NCT00119951|BEHAVIORAL|Participation on the ACOR Listserv|
48115318|NCT05245786|BIOLOGICAL|Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|Given IV
48314092|NCT03648281|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
48314093|NCT05744115|DRUG|Ga-68-PSMA-11|Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
48314094|NCT02324842|DRUG|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
48314095|NCT02324842|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
48643984|NCT06690788|BEHAVIORAL|Couple-based intervention condition (PreventT2 Together) (couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP|PreventT2 Together will be delivered by a team of trained CDC National DPP Lifestyle Coaches to adults at high risk for diabetes and their partners. The lifestyle intervention curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (Diabetes Prevention Program) (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevent type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
48314096|NCT03791645|BEHAVIORAL|Sky Intervention|SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (\~3 hours/day), followed by 4 weekly follow-ups (\~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
48314097|NCT00757770|BIOLOGICAL|Rotarix|Two oral doses.
48314098|NCT00757770|BIOLOGICAL|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
48314099|NCT03639883|DRUG|AIV001|Intradermal injection
48115319|NCT05245786|PROCEDURE|Imaging Technique|Undergo imaging
48115320|NCT05355116|DEVICE|Physiolab S1|A cryocompression device capable of circulating ice-water through a cuff at 6-12℃ with either a static pressure of 25mmHg or dynamic pressure of 25-50 mmHg or 25-75mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
48115321|NCT05355116|DEVICE|Breg Vpulse|A cryocompression device capable of circulating ice-water through a cuff at no lower than 5.5℃ with a dynamic peak pressure of 50 mmHg. The temperature of the ice-water, and the applied pressure, is not modifiable by the user.
48115322|NCT05355116|DEVICE|Aircast Cryo/Cuff|A cryocompression device capable of circulating ice-water through a cuff at an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
48115323|NCT05355116|DEVICE|GameReady|A cryocompression device capable of circulating ice-water through a cuff at 1-12℃ with a dynamic pressure of 5-15 mmHg, 5-50 mmHg, or 5-75 mmHg. The lowest temperature setting, and highest pressure setting will be used for this study.
48314100|NCT04564209|OTHER|Info Viz for Health|During the intervention, health care providers provide HIV-related health education using a mobile app that contains a bilingual database of relevant infographics.
48314101|NCT04426825|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
48314102|NCT04426825|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
48314103|NCT03364608|DRUG|AS MDI 90 μg|AS MDI 90 μg (2 actuations of 45 μg/actuation)
48314104|NCT03364608|DRUG|AS MDI 180 µg|AS MDI 180 μg (2 actuations of 90 μg/actuation)
48643985|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT) and Eccentric Exercise Training Group (NDT+EE)|Including Functional Eccentric Exercises Applied to Individuals with Cerebral Palsy
48643986|NCT06676540|OTHER|Neurodevelopmental Therapy (NDT)|This application includes rehabilitation methods frequently used in pediatric rehabilitation.
48484421|NCT04265690|BEHAVIORAL|Cooking classes|Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.
48484422|NCT04265690|BEHAVIORAL|Text messages|Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
48484423|NCT03064087|DEVICE|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
48484424|NCT03064087|DEVICE|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH \& Co. KG, Wiesbaden, Germany).
48484425|NCT03064087|DEVICE|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
48484426|NCT03064087|DEVICE|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
48484427|NCT03064087|DIAGNOSTIC_TEST|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH \& Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
48484428|NCT04787770|OTHER|non-intervention|non-intervention
48115324|NCT05355116|DEVICE|Physiolab Gel Therapy Wrap|A cryocompression cuff that applies an undefined, non-modifiable temperature with a static pressure that is also undefined and non-modifiable. The device will be applied as per the manufacturer's instructions, which will represent its maximum capability.
48115325|NCT04486222|DEVICE|Repeated Transcranial Magnetic Stimulation|Magstim® Super Rapid² Transcranial Magnetic Stimulation System
48643987|NCT05995665|DEVICE|EsoGLOVE with Trigno Biofeedback (EMG sensors)|The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVETM with Trigno Biofeedback (EMG sensors) training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day. A total of 15 sessions (5 session per week for a total of 3 weeks) of a minimum of 30 mins. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).
48643988|NCT05995665|OTHER|Graded Repetitive Arm Supplementary Program (GRASP)|Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
48643989|NCT06691165|OTHER|Low oxygen therapy (LOT)|"Participants will breathe variable concentrations of inspired oxygen, carbon dioxide, and nitrogen. The concentrations will be adjusted on a breath-by-breath basis to maintain end-tidal targets.~Each daily session of the intervention will consist of forty 1-minute intervals. Each 1-minute interval will consist of 40 seconds of hypercapnic hypoxia, increasing the partial pressure of end-tidal carbon dioxide by +4 mmHg and decreasing the partial pressure of end-tidal oxygen to 45 mmHg, followed by 20 seconds in simulated room air to return to baseline carbon dioxide and oxygen levels."
48643990|NCT06141460|DRUG|RRG001|Administered via Subretinal injection. Dosage form: injection solution.
48115326|NCT00570219|DRUG|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
48314105|NCT03364608|OTHER|Placebo MDI|Placebo MDI (2 actuations)
48484429|NCT00733031|DRUG|AZD6918|liquid suspension, daily, oral dose
48484430|NCT00733031|DRUG|gemcitabine|intravenous, doses are on an intermittent schedule
48314106|NCT03364608|DRUG|Proventil 90 μg|Proventil 90 μg (1 actuation of 90 μg/actuation)
48314107|NCT03364608|DRUG|Proventil 180 μg|Proventil 180 μg (2 actuations of 90 μg/actuation)
48484431|NCT00733031|DRUG|pemetrexed|intravenous, dose administered every 21-days
48314108|NCT02458157|DRUG|Furosemide (Furix)|"* Loading dose: 40 mg I.V.~* Infusion rate 40 mg/h~* Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
48314109|NCT02458157|OTHER|Continuous renal replacement therapy (CRRT)|"* Initiated in case of contraindications or inadequate effect of furosemide.~* Fluid removal is started at 2 ml/kg/h~* The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
48484432|NCT06091748|DRUG|68Ga-DOTATOC|Detection of somatostatin positive lesions in GEP-NETs
48314110|NCT02458157|OTHER|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:~* Mottling beyond the edge of kneecaps~* Hypotension (MAP \< 50) resistant to inotropes and vasopressors~* Plasma lactate ≥ 4 mmol/l~Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:~1. Fluid removal is paused~2. A crystalloid fluid bolus of 250-500 ml is given~3. Circulatory status is reevaluated within 30 minutes~4. Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour~5. Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
48314111|NCT02458157|OTHER|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:~* Hyperkalaemia (p-K+ \> 6 mmol/l)~* Severe metabolic acidosis attributable to AKI (pH \< 7.25 and standard base excess \< -10 mmol/l) resistant to IV bicarbonate infusion~* Severe respiratory failure with PaO2/FiO2 \< 13 kPa and bilateral infiltrates/oedema on the chest x-ray.~* Progressive azotaemia and a blood urea nitrogen (BUN) \> 25 mmol/l."
47964684|NCT06506136|DRUG|Fluoxetine|"Participants will receive fluoxetine tablets, 20 mg each, taken orally twice a day (total daily dose of 40 mg) for 12 weeks. Tablets should be taken with water at the same times daily.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
48115327|NCT04014803|DRUG|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm"
48115328|NCT01241435|DRUG|LY2216684|Administered orally
48115329|NCT00036933|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
48484433|NCT05678855|BEHAVIORAL|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
48643991|NCT06690554|OTHER|Education Group|"Women will be given a five-day training in line with the health promotion model.~Information will be provided to women who apply to the hospital. Written consent documents will be obtained from women who agree to participate in the study.~Women assigned to the intervention group will attend classes in groups of 8-10. Women will be given a 60-minute training once a day for five days. The total training duration is five hours. Scales will be applied to women who complete the training at the end of the fifth day.~Women who have completed the training will be contacted by phone at the end of the first and second months, reminded of health promotion behaviors and their questions will be answered and follow-ups will be carried out.~At the end of the third month, women who have received training will be invited to the institution and the Fertility Awareness, Preconceptional Knowledge and Attitude will be filled out face-to-face for the final test."
48643992|NCT06470919|OTHER|SMS reminders for upcoming vaccination(s)|All parents/caregivers of children in participating villages will receive access to a digital vaccine card. This will be used for record-keeping application (digital vaccine registry). Selected parents/caregivers of children will receive SMS messages and reminders related to vaccination.
48643993|NCT05950360|DEVICE|Electromagnetic tracking system, surface electromyography|arm elevation in the scapular plane, overhead reaching to the target 15° backward to the frontal plane, pull-up with overhead reaching forward and backward.
48643994|NCT05465408|BEHAVIORAL|Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention|One-to-One virtual (videoconference) behavioral intervention.
48643995|NCT06688903|BEHAVIORAL|App-based diabetes management and community-based health coaching|All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.
48643996|NCT06688838|DRUG|Tofacitinib|If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.
48643997|NCT05490446|DRUG|Tebapivat|Tebapivat Tablet
48643998|NCT06438250|DRUG|68Ga-JH04|The dose will be 148-222 MBq given intravenously.
48643999|NCT04901078|DRUG|KNX100|KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
48644000|NCT05965479|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
48644001|NCT06691841|DRUG|Chlorhexidine Gluconate|oral wiping and oral care solution rinsing, oral care solution was 0.12% chlorhexidine gluconate, and the frequency of oral care was 3 times a day.
48644002|NCT06691841|OTHER|normal saline|oral wiping and oral care solution rinsing, oral care solution was 0.9% normal saline, and the frequency of oral care was 3 times a day.
48644003|NCT06686641|DRUG|Local and systemical treatment|Evaluating the management of the edema including topical/local treatment (dexamethasone and NSAID, periocular injections, and dexamethasone intravitreal implant) and systemic treatment (prednisolone, DMARD, and biological agents, for example TNF-alpha inhibitors and interleukin-6 inhibitors). Moreover, the duration of any treatment as well as numbers of injections or implants.
48115330|NCT00036933|BIOLOGICAL|QS21|
48115331|NCT05786898|OTHER|NEAR-TSA|"Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes"
48314112|NCT03993964|DRUG|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
48314113|NCT05955586|DRUG|SPR720|SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
48314114|NCT02123563|OTHER|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
48484434|NCT04686656|OTHER|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
47964685|NCT06506136|DRUG|Placebo|"Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
47964686|NCT04856189|BIOLOGICAL|Pembrolizumab|Given IV
47964687|NCT04856189|DRUG|Selinexor|Given PO
47964688|NCT02385500|DRUG|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
47964689|NCT02385500|DRUG|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
47964690|NCT05856032|DEVICE|Acapella device|Acapella is one of the Oscillatory Positive Expiratory Pressure (OPEP) device used in mobilization of peripheral secretions to the central trachea. It consists of a mouth piece and metal strip that is attached to a magnet which oscillates upon exhalation of the patient into the device results in oscillations. This helps in generating positive expiratory pressure (PEP) and oscillations of the magnetic ball assist in mucus collection and expectoration. Pulmonary functions are greatly reduced in patients undergone CABG surgery due to prolong effects of anaesthesia and muscle relaxants administered prior to surgery.
48484435|NCT04686656|OTHER|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
48644004|NCT06686927|DRUG|corticosteroids combined with immunoglobulin and romiplostim|"Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.~IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.~Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month."
48644005|NCT06686472|DRUG|TL-925|TL-925 is an eye drop.
47964691|NCT05856032|OTHER|Conventional Treatment|Conventional chest physiotherapy techniques
47964692|NCT00647881|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
47964693|NCT00647881|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fed
47964694|NCT00001190|DRUG|Deslorelin|
47964695|NCT00615511|DIETARY_SUPPLEMENT|placebo pregnenolone|Sugar pill, taken twice a day
47964696|NCT00615511|DIETARY_SUPPLEMENT|pregnenolone|500mg in tablet form taken orally twice a day
47964697|NCT02996513|OTHER|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
47964698|NCT02563743|BEHAVIORAL|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
48644006|NCT06686472|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
47964699|NCT02563743|BEHAVIORAL|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
48115332|NCT05952557|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
48115333|NCT05952557|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered orally
48115334|NCT05952557|DRUG|Anastrozole|Anastrozole. Comparator. Administered orally
48484436|NCT03832738|DRUG|JTE-451 Tablets|Active drug tablets containing JTE-451
48484437|NCT03832738|DRUG|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
48484438|NCT02428179|PROCEDURE|StOP? - Control group|Control group - Surgical procedure without Study Intervention
48484439|NCT02428179|PROCEDURE|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
48484440|NCT04392557|DRUG|Metformin / alogliptin Oral Product|850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
48314115|NCT02123563|OTHER|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
48314116|NCT02648412|DRUG|ketamine|bolus 1 mg/kg
48314117|NCT02648412|PROCEDURE|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
48314118|NCT03106493|OTHER|None (observational)|None (observational)
48314119|NCT06260644|PROCEDURE|VertiseTM flowable composite (Kerr,USA)|self adhesive flowable resin composite restoration.
48314120|NCT04972344|DIAGNOSTIC_TEST|Ionized magnesium|Assessment of ionized magnesium level
48314121|NCT02132234|DRUG|Etanercept|biological treatment according to rheumatologic indication
48314122|NCT02132234|DRUG|Adalimumab|biological treatment according to rheumatologic indication
48314123|NCT02132234|DRUG|Certolizumab|biological treatment according to rheumatologic indication
48314124|NCT02132234|DRUG|Infliximab|biological treatment according to rheumatologic indication
48314125|NCT04200677|OTHER|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following NMES parameters: (Monophasic Current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
48314126|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
48314127|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
48314128|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
48314129|NCT04200677|OTHER|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Monophasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
48314130|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
48314131|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
48314132|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
48314133|NCT04200677|OTHER|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 25 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
48314134|NCT02493816|DRUG|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
48314135|NCT05523063|OTHER|Quality of life questionnaire|"The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator."
48314136|NCT06472700|OTHER|No intervention|No intervention
48314137|NCT01259752|DEVICE|compression stockings|compression stockings
48314138|NCT01259752|OTHER|standard non compressive stockings|standard non compressive stockings
48314139|NCT01144078|BEHAVIORAL|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
48314140|NCT01144078|BEHAVIORAL|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
48314141|NCT02555566|PROCEDURE|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
48314142|NCT02555566|PROCEDURE|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
48484441|NCT04392557|DRUG|Metformin / Pioglitazone Pill|(850 mg/15 mg every 12 hours) for 12 months
48115335|NCT05952557|DRUG|Letrozole|Letrozole. Comparator. Administered orally
48314143|NCT02304536|DRUG|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
48314144|NCT02304536|PROCEDURE|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
47964700|NCT04891952|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|Functional precision medicine test to predict response to candidate chemotherapeutic agents
47964701|NCT02975518|BIOLOGICAL|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
48314145|NCT02137590|DIETARY_SUPPLEMENT|Spanish Black Radish product|
48314146|NCT00472472|DEVICE|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
48314147|NCT03284242|DRUG|Treg|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
48484442|NCT04392557|DRUG|triple therapy|Metformin / Alogliptin/ Pioglitazone
48484443|NCT02631837|PROCEDURE|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
48484444|NCT02631837|PROCEDURE|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
47964702|NCT01203098|DRUG|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
47964703|NCT01203098|DRUG|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
47964704|NCT01203098|DRUG|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
47964705|NCT00773656|OTHER|Whole blood sample|70 ml per patient for collection of biological sample
47964706|NCT01372267|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
47964707|NCT01372267|BEHAVIORAL|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
47964708|NCT04731181|BEHAVIORAL|mobile application (little lovely dentist).|mobile application
47964709|NCT04650711|DIAGNOSTIC_TEST|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
47964710|NCT00980057|DEVICE|Adaptive CRT (aCRT)|Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function
47964711|NCT00980057|DEVICE|Echo|Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
47964712|NCT02790931|OTHER|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
48484445|NCT00021060|DRUG|paclitaxel|Given IV
47964713|NCT06440720|OTHER|ELDOA ,UPPER THORACIC MOBILIZATION AND MOBILITY EXERCISE|Already mentioned
47964714|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
47964715|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
47964716|NCT01475994|OTHER|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
47964717|NCT01475994|OTHER|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
47964718|NCT05332665|DEVICE|AS-OCT|Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.
47964719|NCT05332665|PROCEDURE|YAG laser PI|medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block
47964720|NCT01748084|DRUG|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
47964721|NCT01748084|DRUG|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
47964722|NCT02828696|DEVICE|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
47964723|NCT02981017|DEVICE|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
48484446|NCT00021060|DRUG|carboplatin|Given IV
48484447|NCT00021060|BIOLOGICAL|bevacizumab|Given IV
47964724|NCT06264414|DRUG|DTT106|oral route
47964725|NCT06264414|DRUG|Dutasteride-Tamsulosin|oral route
48115336|NCT05952557|DRUG|Exemestane|Exemestane. Comparator. Administered orally
48314148|NCT02020096|PROCEDURE|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
48314149|NCT02020096|PROCEDURE|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
48314150|NCT01413048|DRUG|Carvedilol 25mg|Tablet, q.d.
48314151|NCT01413048|DRUG|AGSCT101 12.5mg|Tablet, q.d.
48314152|NCT03535038|DIAGNOSTIC_TEST|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
48314153|NCT03535038|DIAGNOSTIC_TEST|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
48314154|NCT06450691|PROCEDURE|biopsy|skin biopsy and blood sampling
48314155|NCT01869062|DEVICE|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
48314156|NCT01869062|DEVICE|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
47964726|NCT04238260|BEHAVIORAL|Enhancing Physical Therapy Usual Care|The protocol is focused on the completion of a minimum of 30 minutes of weight-bearing, walking-related activities that progressively increase in intensity informed by heart rate and step counters over 4 weeks.
48115337|NCT05952557|DRUG|Abemaciclib|Abemaciclib adjuvant treatment Administered orally
48314157|NCT02537301|OTHER|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
48314158|NCT00294502|DRUG|Gentamycin/citrate, Minocycline/EDTA|
48314159|NCT05655637|OTHER|Exercise|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
48314160|NCT01226420|DRUG|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
48314161|NCT03346369|DRUG|Lanthanum Carbonate|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
48314162|NCT02645058|PROCEDURE|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
48314163|NCT02645058|PROCEDURE|ESWL|Treatment by extracorporeal shock waves lithotripsy
48314164|NCT02645058|DEVICE|Rigid and flexible ureteroscope|
48314165|NCT02645058|DEVICE|Lithotripter|
48314166|NCT02645058|DEVICE|Holmium laser|
47964727|NCT04238260|BEHAVIORAL|Physical Therapy Usual Care|Usual physical therapy
47964728|NCT05500105|OTHER|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
47964729|NCT01325584|DRUG|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
47964730|NCT02226146|BIOLOGICAL|Bertilimumab|
47964731|NCT02100514|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
47964732|NCT02100514|OTHER|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
48314167|NCT02645058|DEVICE|Basket for fragment removal|
48314168|NCT02645058|PROCEDURE|General or spinal anesthesia|
48314169|NCT02645058|DRUG|Intravenous pain medication|If required by the patient
48314170|NCT02645058|DEVICE|X-ray|To focus the stone
48314171|NCT02645058|DEVICE|Ultrasound|To focus the stone
48314172|NCT00064129|BIOLOGICAL|Ipilimumab|Given IV
48314173|NCT00064129|OTHER|Laboratory Biomarker Analysis|Correlative studies
48314174|NCT00064129|OTHER|Pharmacological Study|Correlative studies
48314175|NCT00064129|BIOLOGICAL|Sargramostim|Given SC
48484448|NCT00021060|OTHER|laboratory biomarker analysis|Correlative studies
48314176|NCT02942095|DRUG|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
48314177|NCT02942095|DRUG|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
48314178|NCT04721015|DRUG|ABBV-637|Intravenous (IV) Infusion
48314179|NCT04721015|DRUG|Docetaxel|Intravenous (IV) Infusion
48314180|NCT04721015|DRUG|Osimertinib|Oral Tablets
48314181|NCT00526149|DRUG|BI 2536|
48314182|NCT00526149|OTHER|high performance liquid chromatography|
48314183|NCT00526149|OTHER|mass spectrometry|
48314184|NCT00526149|OTHER|pharmacological study|
48314185|NCT03185455|OTHER|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
48314186|NCT03118531|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
48314187|NCT06336551|BEHAVIORAL|Acceptance and Commitment Therapy for insomnia (ACT-I)|During ACT-I patients are encouraged to let go of the struggle to control sleep and to focus on meaningful daytime activities. Treatment goals are addressed through ACT processes of creative hopelessness and self-as-context (session 1), acceptance (session 2), defusion (session 3), followed by values, committed action, and present moment awareness (sessions 4 and 5).
48314188|NCT01897961|OTHER|Anticorps anti-PLA2R1|
48314189|NCT05518734|DRUG|VX-708|Solution for intravenous (IV) administration.
48314190|NCT05518734|DRUG|Itraconazole|Solution for oral administration.
48314191|NCT05518734|DRUG|Midazolam|Solution for oral administration.
48314192|NCT05518734|DRUG|Placebo|Placebo matched to VX-708 for IV administration.
48314193|NCT00510328|DEVICE|Whole Body Vibration|
48314194|NCT01406847|OTHER|Spinal Manipulation|High velocity low amplitude joint-biased intervention
48314195|NCT01406847|OTHER|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
48314196|NCT01406847|OTHER|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
48314197|NCT02340819|DRUG|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
48314198|NCT04087421|DEVICE|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
48314199|NCT04087421|DRUG|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
47964733|NCT03005314|PROCEDURE|chemotherapy|chemotherapy before surgery
48314200|NCT05459389|OTHER|targeted antibiotics therapy|targeted antibiotics therapy guided by resistance genotyping (n=24)
48314201|NCT00986427|DRUG|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
48314202|NCT00986427|DRUG|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
47964734|NCT03005314|PROCEDURE|Surgery|chemotherapy after surgery
48314203|NCT04958863|OTHER|Surgical mask|Use of a surgical mask during test
48314204|NCT04958863|OTHER|Polyester reusable mask|Use of a polyester reusable mask during test
47964735|NCT02022852|DRUG|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
48314205|NCT00462020|DRUG|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
48314206|NCT00462020|DRUG|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
48314207|NCT04451655|DRUG|Continuous insulin infusion|This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
48314208|NCT01157416|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
48314209|NCT01157416|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
48314210|NCT01157416|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
48314211|NCT03213613|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
47964736|NCT02022852|DRUG|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
48115338|NCT04320186|BEHAVIORAL|Entertainment education|
48115339|NCT04320186|OTHER|video|video
48115340|NCT00976937|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
48115341|NCT00976937|DRUG|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
48115342|NCT00976937|DEVICE|Pen auto-injector|
48314212|NCT03213613|BEHAVIORAL|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
48314213|NCT03213613|BEHAVIORAL|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
48314214|NCT06468982|OTHER|Intra-aortic Balloon Pump|in patients with acute myocardial infarction involving elevated troponin levels and recurrent or persistent chest pain at rest, hemodynamic instability, multivessel disease, left main coronary artery disease, and narrow and/or tortuous coronary artery anatomy in which PCI has failed or is not feasible.
48314215|NCT05962814|DEVICE|EarGenie MVP test|The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
48314216|NCT01525849|DEVICE|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
48314217|NCT01525849|PROCEDURE|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
48314218|NCT02684019|DRUG|Dexmedetomidine|added to propofol sedation
48314219|NCT02684019|DRUG|Magnesium Sulphate|added to propofol sedation
48314220|NCT01996904|PROCEDURE|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
48314221|NCT01996904|PROCEDURE|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
48644007|NCT06689137|OTHER|mini mental state assessment test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used. With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
47964737|NCT02737696|BEHAVIORAL|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
47964738|NCT02737696|BEHAVIORAL|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
47964739|NCT05032859|DRUG|tapinarof cream, 1%|applied topically once daily
47964740|NCT05032859|DRUG|vehicle cream|applied topically once daily
47964741|NCT02085083|BEHAVIORAL|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
48115343|NCT00976937|DRUG|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
48314222|NCT01182623|OTHER|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
48314223|NCT06121700|RADIATION|Radiotherapy targeted to the primary lesion|5 to 7 fractions of short course hypofractionated radiotherapy (HFRT) targeted to the primary lesion.
48314224|NCT06121700|RADIATION|Radiotherapy targeted to the metastatic lesions|Hypofractionated radiotherapy (HFRT) or stereotactic body radiotherapy (SBRT) targeted to metastatic lesions. The target dose will be adjusted based on the lesion's site and diameter and organs at risk, with high-dose irradiation of 4-8 fractions. All metastatic lesions should be irradiated as much as possible, and partial lesion irradiation should be allowed when technically impractical.
48314225|NCT06121700|BIOLOGICAL|Anti-PD-1 monoclonal antibody|"The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status.~The commonly used anti-PD-1 mAb usages are as follows: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W."
47964742|NCT02085083|BEHAVIORAL|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
47964743|NCT01354340|DIETARY_SUPPLEMENT|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
47964744|NCT01354340|DIETARY_SUPPLEMENT|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
47964745|NCT01354340|OTHER|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
47964746|NCT02761252|DRUG|Bilastine 20mg|
47964747|NCT02761252|DRUG|Montelukast 10mg|
47964748|NCT02761252|DRUG|Placebo Bilastine 20mg|
47964749|NCT02761252|DRUG|Placebo Montelukast 10mg|
47964750|NCT00675493|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
47964751|NCT04407364|DEVICE|CoMatryx Surgical Bovine Collagen|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
47964752|NCT00939770|DRUG|Crizotinib|Given PO
47964753|NCT00939770|OTHER|Laboratory Biomarker Analysis|Correlative studies
47964754|NCT00939770|OTHER|Pharmacological Study|Correlative studies
47964755|NCT00939770|OTHER|Questionnaire Administration|Ancillary studies
47964756|NCT04442867|OTHER|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
47964757|NCT04442867|OTHER|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
47964758|NCT04380415|DIAGNOSTIC_TEST|Single lead ambulatory ECG patch|Single lead ambulatory ECG patch worn on the chest
47964759|NCT03322631|DRUG|Tirzepatide|Administered SC.
47964760|NCT03322631|DRUG|Placebo|Administered SC.
47964761|NCT02726152|PROCEDURE|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
47964762|NCT02726152|PROCEDURE|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
47964763|NCT00354536|DRUG|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
47964764|NCT00354536|BIOLOGICAL|placebo injection|placebo injection
47964765|NCT01007266|BEHAVIORAL|Assignment of a Lay Patient Partner|
47964766|NCT05251987|BIOLOGICAL|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
47964767|NCT03390816|OTHER|Nutritional assessment|Observational
47964768|NCT01758562|DEVICE|Caphosol|
47964769|NCT06556407|DEVICE|renal denervation|ultrasound based renal denervation
47964770|NCT03787264|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
47964771|NCT03787264|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
47964772|NCT03787264|BIOLOGICAL|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
47964773|NCT03787264|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
47964774|NCT02656537|DEVICE|EnSite™ HD Grid Catheter mapping system|
47964775|NCT02370134|DEVICE|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
47964776|NCT02370134|DEVICE|sham glove|
47964777|NCT04113109|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
47964778|NCT04113109|DRUG|Icatibant|Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
47964779|NCT04113109|DRUG|placebo|Placebo (vehicle) will be given at the same rate as icatibant.
47964780|NCT04113109|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
47964781|NCT04113109|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
47964782|NCT01606800|DRUG|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
47964783|NCT01606800|DRUG|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
48314226|NCT06121700|BIOLOGICAL|Trastuzumab|For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. The 3-weekly schedule of trastuzumab starts with a loading dose of trastuzumab of 8 mg/kg, followed by 6 mg/kg trastuzumab every 21 days.
48314227|NCT06121700|DRUG|Chemotherapy|"The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks."
47964784|NCT04815681|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 40-50 minutes.
48115344|NCT00976937|DRUG|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
48314228|NCT06121700|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For primary lesions, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper-third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle-third tumors, the gastric margin is recommended to be more than 5 cm, and total gastrectomy is performed. For lower-third tumors, a 2 cm duodenal margin is recommended, and subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
48314229|NCT06121700|PROCEDURE|Metastasectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For metastatic lesions, the surgical procedure and resection range are determined by the surgeon.
48314230|NCT06121700|PROCEDURE|Local ablative therapies|Local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) achieve high rates of complete tumor eradication of small metastases, and can be seen as alternatives if a widely invasive surgical approach is required or patient is inoperable.
48314231|NCT05093413|BEHAVIORAL|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
48314232|NCT01542359|OTHER|Yogic practice|breathing, meditation, physical postures
48314233|NCT01542359|OTHER|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
48314234|NCT03064295|DEVICE|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
48314235|NCT03064295|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
48314236|NCT03064295|DRUG|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
48314237|NCT00319228|DRUG|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
48314238|NCT03673241|DEVICE|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
47964785|NCT04815681|BEHAVIORAL|Active Control|The active control condition includes an online self-awareness program that lasts approximately 40-50 minutes. Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
48314239|NCT04579679|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
48644008|NCT06689137|OTHER|mini-cog test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
47964786|NCT00993200|GENETIC|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
47964787|NCT00993200|DRUG|Warfarin|Usual care warfarin dosing
47964788|NCT02362269|DIETARY_SUPPLEMENT|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
48115345|NCT00976937|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
48115346|NCT06110416|OTHER|nausea relief inhaler|Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
48115347|NCT04949035|DIAGNOSTIC_TEST|Assessment of mental state and quality of life|Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
48115348|NCT03105505|DRUG|Permethrin 5%|Facial skin application once a night for 3 months.
48115349|NCT03105505|DRUG|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
48484449|NCT05408182|PROCEDURE|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
48314240|NCT04158713|DRUG|Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine|Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
48644009|NCT06691503|PROCEDURE|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)|mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)
48644010|NCT03764033|BEHAVIORAL|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
48644011|NCT03764033|BEHAVIORAL|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
48644012|NCT06513312|DRUG|Lenacapavir Injection|Administered subcutaneously
48644013|NCT06513312|DRUG|Lenacapavir Tablet|Administered orally
48644014|NCT06513312|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
48644015|NCT06686758|DIETARY_SUPPLEMENT|Sugar cane polysaccharide|Sugar cane polysaccharide
48644016|NCT06686758|DIETARY_SUPPLEMENT|Control|placebo
48644017|NCT06596772|DRUG|MB04 (proposed biosimilar to etanercept)|MB04 50 mg/week via subcutaneous injection
48644018|NCT06596772|DRUG|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
48644019|NCT06296706|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
48644020|NCT06296706|DRUG|Taxotere (docetaxel)|Taxotere, by intravenous infusion, every 3 weeks.
48644021|NCT05457140|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
48644022|NCT05457140|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
48644023|NCT01105832|DRUG|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
48644024|NCT06686160|OTHER|Plyometrics Training|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise, Plyometrics are primarily used by athletes to improve performance and are used in the fitness field to a much lesser degree. This training focuses on learning to move from a muscle extension to a contraction in a explosive way, for example repeated jumping.
48644025|NCT06686160|OTHER|Theraband Resistance Exercise|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise Therabands is a Set of bands which are primarily use for resistance Training for strength and Power.
48644026|NCT06015165|DRUG|Analgesia plan for Anes. Group|For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.
48644027|NCT06015165|DRUG|Analgesia plan for Surg. Group|For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.
48644028|NCT06015165|PROCEDURE|Multi-modal analgesia during the surgery|Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.
48644029|NCT05998616|BEHAVIORAL|Exercise Training Program|The intervention group will be encouraged to complete aerobic and resistance training exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment for monitoring walking and complete resistance training will be provided to the intervention group. The exercise training prescription involves 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and resistance training consisting of 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.
48644030|NCT05998616|BEHAVIORAL|Flexibility Program|The control group will be encouraged to complete stretching and range of motion exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment (yoga mat) for monitoring walking and complete flexibility training will be provided to the control group. The flexibility training prescription involves stretches from the Stretching for People with MS: An Illustrated Manual from the National MS Society.
48644031|NCT06660030|OTHER|No intervention|No intervention
47964789|NCT00300274|DRUG|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
47964790|NCT00300274|DRUG|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
48314241|NCT00715611|PROCEDURE|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
48115350|NCT03105505|DRUG|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
48644032|NCT06656507|PROCEDURE|Quadro Iliac Plane Block (QIPB)|The Quadro Iliac Plane Block (QIPB) will be performed pre-awakening in patients undergoing lumbar vertebra surgeries. Using a low-frequency convex ultrasound transducer (2-6 MHz), the spinal process will be identified at the L3 level in a prone-positioned patient. The transducer will be moved laterally to locate the transverse process within the erector spinae muscle and then rotated to the parasagittal plane to identify the Quadratus Lumborum Muscle (QLM) attachment to the iliac crest. A 22G x 100 mm block needle will be advanced under ultrasound guidance, and 50 mg (0.25%) bupivacaine will be injected bilaterally into the fascia beneath the QLM. This technique is designed to provide effective postoperative pain control by blocking the nerves in the quadratus lumborum plane.
48644033|NCT06656507|PROCEDURE|Erector Spinae Plane Block (ESP)|The Erector Spinae Plane Block (ESP) will also be performed pre-awakening. A linear ultrasound probe will be placed transversely at the level of the L3 vertebra to visualize the transverse process. A block needle will be advanced under ultrasound guidance until it touches the transverse process, after which the needle will be withdrawn 1 mm. Fifty milligrams (0.25%) bupivacaine will then be administered bilaterally. The ESP block aims to provide postoperative analgesia by blocking sensory nerves in the erector spinae plane.
48644034|NCT03573024|DRUG|Azacitidine|On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
48644035|NCT03573024|DRUG|Venetoclax|Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
48644036|NCT05895045|BEHAVIORAL|Yoga|Restorative Vinyasa Yoga
48644037|NCT06645678|DRUG|Elranatamab|"Elranatamab: Participants will receive SC administration of elranatamab QW or Q2W. The initial doses of elranatamab will be 12mg (C0D1), 32mg (C0D4), and 76mg (C0D8) and will serve as the 2 step-up priming regimen (Cycle 0). Then, 76mg weekly C1-C6 \> then 76mg bi-weekly from C7 for those achieving PR or better \> then 76mg q4weeks from C12 for those achieving CR or better response. If the participant subsequently begins to have an increase of disease burden not yet qualifying as PD according to IMWG criteria, dose intervals will return to weekly dosing.~premedication for Elranatamab: Acetaminophen 650mg (or paracetamol 500mg), Diphenhydramine 25mg (or equivalent), Dexamethasone 20mg (or equivalent).~In case of mezigdomide discontinuation due to reasons other than disease progression, elranatamab continuation +/- dexamethasone will be allowed until loss of response. The administration of elranatamab +/- dexamethasone will continue per study protocol schedule."
48115351|NCT01292252|BIOLOGICAL|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
48115352|NCT01292252|BIOLOGICAL|Placebo|Saline solution
48484450|NCT00621920|DRUG|FM-601|Dose-escalation, split dosage, liquid
48115353|NCT03493269|DRUG|BAY1834845|Orally administered.
48115354|NCT03493269|OTHER|Matching Placebo|Orally administered.
48115355|NCT03493269|DRUG|Midazolam|Part 1: Orally administered 1mg as a single dose.
48314242|NCT00715611|DRUG|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
48115356|NCT06342063|DEVICE|Blood Flow Restriction Therapy|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is inflated.
48115357|NCT06342063|DEVICE|Blood Flow Restriction Therapy Sham|Patients wear a personalized tourniquet pressure system on their involved thigh while they perform a series of leg press machine exercises. This tourniquet is not inflated.
48115358|NCT02999581|DIETARY_SUPPLEMENT|C4 Extreme, C4 Extreme (without Advantra Z)|
48115359|NCT01104415|DRUG|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
48484451|NCT04159519|DRUG|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation and Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
48484452|NCT04159519|DRUG|Fasenra®|Participants received Benralizumab 30 mg/mL, 1 mL fill volume via Subcutaneous every 4 weeks for first 3 doses.
48484453|NCT04159519|DRUG|Ventolin®|Participants received Salbutamol sulfate 100 μg per inhalation as needed.
48314243|NCT00715611|RADIATION|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
48314244|NCT05653739|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
48314245|NCT02408055|DRUG|TA-8995|
48314246|NCT04427787|DRUG|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day
48314247|NCT04427787|DRUG|Lanreotide|Lanreotide will be administrated 120 mg injection every 28 days
48314248|NCT02860637|OTHER|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
48314249|NCT06447116|DEVICE|CGuard Prime™ Carotid Stent System|CGuard Prime™ Carotid Stent System
48314250|NCT01260766|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
48314251|NCT01260766|DEVICE|Placebo Patch|same as active patch
48314252|NCT00632541|DRUG|Sorafenib|Sorafenib 200mg po daily
48314253|NCT00632541|DRUG|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
48314254|NCT00632541|OTHER|Imaging|Imaging every third cycle
48314255|NCT03247660|OTHER|PFM training|See information included in arm/group descriptions.
48314256|NCT03247660|OTHER|HE|See information included in arm/group descriptions.
48314257|NCT03247660|BEHAVIORAL|Educational strategy|See information included in arm/group descriptions.
48314258|NCT01150955|DIETARY_SUPPLEMENT|Resveratrol|500 mg three times a day for five weeks.
48314259|NCT01150955|OTHER|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
48314260|NCT04041076|PROCEDURE|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
47964791|NCT00300274|DRUG|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
47964792|NCT00300274|DRUG|corticosteroids|Corticosteroids standard dose.
48314261|NCT03926559|DRUG|Morphine.|Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
48314262|NCT03284294|DRUG|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
48314263|NCT03284294|DRUG|Placebo|Oral placebo daily for 8 weeks
48314264|NCT02620462|DEVICE|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
48314265|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
48314266|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
48314267|NCT04860661|DRUG|Esketamine|After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
48314268|NCT04860661|DRUG|Normal saline|10 ml normal saline
48314269|NCT03163199|DEVICE|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
48314270|NCT00385268|DRUG|acamprosate|1998 mg/dau fpr 8 weeks
48314271|NCT00385268|DRUG|placebo|placebo pills
48314272|NCT01770873|BEHAVIORAL|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
48314273|NCT04708652|OTHER|No intervention|No intervention
48314274|NCT01972880|DRUG|ASP1941|Oral
48314275|NCT01735617|DRUG|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
48314276|NCT02481037|OTHER|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
48314277|NCT02481037|OTHER|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
48314278|NCT02481037|OTHER|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
48314279|NCT03108651|OTHER|Case|Motivational message will be administrated.
48314280|NCT01795287|PROCEDURE|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
48314281|NCT01795287|PROCEDURE|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
48314282|NCT04745793|OTHER|Hyperspectral and Fluobeam acquisition|"Once enough exposure of the operative site is achieved, an RGB (Red Green Blue) picture will be taken and the surgeon will depict the parathyroid glands on it, this picture will act as ground truth. At this point, without changing the surgical exposure, a second surgeon involved in the study will attempt once to detect the parathyroid glands intraoperatively using the HSI system and the Fluobeam® alternatively. The number and the position of the parathyroid glands visualized with each tool will be compared to the number and position of the glands previously visualized by the operating surgeon. The procedure will be repeated every time the surgeon attempts to visualize the parathyroid glands. The order of the detection tools randomized for each case will be preserved in case of repeated visualizations."
48314283|NCT04811521|BEHAVIORAL|Primary care follow-up|Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.
48314284|NCT04811521|BEHAVIORAL|Online Self-Administered Anxiety Management Program plus Peer Support Guidance|Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.
48314285|NCT04811521|BEHAVIORAL|Therapist-Administered Cognitive Behavioral Therapy|Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
48314286|NCT03628508|OTHER|Exercise|Comprehensive exercise program including strengthening, stretching, gait modification etc.
48314287|NCT00372034|DEVICE|Temporary Collagen Inserts|
48314288|NCT05796427|BEHAVIORAL|SupporT for ADHD and Related Treatment|Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
48314289|NCT00625365|DRUG|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
48314290|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
48314291|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
48314292|NCT02436577|DRUG|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
48314293|NCT06354270|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2.
48314294|NCT06354270|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
48314295|NCT01073280|PROCEDURE|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
48314296|NCT01485926|DRUG|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
48484454|NCT03177382|RADIATION|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
48644038|NCT06645678|DRUG|Mezigdomide|"The first day of study treatment dosing with mezigdomide is considered Day 1 of a cycle. (per recommended phase 2 dose, daily \[qd\], D1-21, q 4weeks). Capsules of mezigdomide will be taken by mouth with or without food.~In case of elranatamab discontinuation due to reasons other than disease progression, mezigdomide continuation +/- dexamethasone will be allowed until loss of response. The administration of mezigdomide will continue per study protocol."
48644039|NCT06645678|DRUG|Dexamethasone|"Administered at the dose of 20 mg/day from C1-3, then 10mg/day from C4-6 as a premedication for elranatamab.~(for those \>=75 yrs, with uncontrolled diabetes mellitus, history of intolerance: 10mg/day -\> 5mg/day)"
48644040|NCT06400121|DRUG|Apimostinel Infusion, Intravenous|Single injection of Apimostinel (10mg)
48314297|NCT01485926|DRUG|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
48314298|NCT01921933|DEVICE|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
48314299|NCT03047148|OTHER|Data mining from records|The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
48314300|NCT05407090|DIETARY_SUPPLEMENT|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
48314301|NCT05407090|DIETARY_SUPPLEMENT|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
48314302|NCT00841503|OTHER|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
48314303|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation active stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
48314304|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation sham stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
48314305|NCT05249088|OTHER|Protocolised reduction of non-resuscitation fluids|"* Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~* Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~* Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~* Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~* Parenteral nutrition is administered according to local protocol~* Intravenous medications are concentrated according to a predefined protocol~* Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
48484455|NCT03177382|RADIATION|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
48484456|NCT03177382|PROCEDURE|TME|The TME operation will be given after the end of the neoadjuvant treatment.
48644041|NCT06400121|BEHAVIORAL|Cognitive Training|8 sessions of digital active training
48644042|NCT06400121|BEHAVIORAL|Sham Training|8 sessions of digital sham training
48484457|NCT03177382|DRUG|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
48484458|NCT00500552|DRUG|Perhexiline/Placebo|
48644043|NCT06400121|DRUG|Isotonic Solution, Intravenous|Single injection of placebo
48644044|NCT03069924|BEHAVIORAL|Gain-framed messaging|Gain-framed messaging materials
48644045|NCT03069924|COMBINATION_PRODUCT|Unframed messaging materials|Unframed smoking cessation materials
48644046|NCT06055608|DRUG|Sirolimus|Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight \>= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily
48644047|NCT06055608|BIOLOGICAL|Belatacept|Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
48644048|NCT06055608|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID
48644049|NCT06055608|DRUG|Tacrolimus (Group1)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
48644050|NCT06055608|DRUG|Anti-Thymocyte Globulin (ATG)|Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
48644051|NCT06055608|DRUG|Tacrolimus (Group 2)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
48644052|NCT04330339|BEHAVIORAL|Fasting|Fasting
48644053|NCT06528184|DIAGNOSTIC_TEST|Self-sampled HPV DNA testing|Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)
48644054|NCT06528184|DIAGNOSTIC_TEST|Clinician-sampled HPV DNA test|Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
48484459|NCT05449782|DIETARY_SUPPLEMENT|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
48484460|NCT05449782|OTHER|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
48314306|NCT05249088|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~* Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~* Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~* Medications are concentrated according to local protocol"
48314307|NCT06335368|OTHER|Nutrition and Growth Status|Nutrition and Growth Status
48644055|NCT06670313|OTHER|postop Erector spinae plane block|Postoperative ESP block was performed as the control group
47964793|NCT03824314|DRUG|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
48314308|NCT00003353|BIOLOGICAL|filgrastim|
48314309|NCT00003353|DRUG|melphalan|
48484461|NCT03650959|OTHER|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
48484462|NCT05351814|OTHER|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
48484463|NCT04030494|DIAGNOSTIC_TEST|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
47964794|NCT03824314|DRUG|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
48484464|NCT04030494|DIAGNOSTIC_TEST|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
48314310|NCT00003353|PROCEDURE|bone marrow ablation with stem cell support|
48314311|NCT00003353|PROCEDURE|peripheral blood stem cell transplantation|
48484465|NCT04030494|DIAGNOSTIC_TEST|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
48484466|NCT06451718|DEVICE|Intracorneal implantation|Intracorneal implantation of the nitinol investigational device
47964795|NCT05120778|BEHAVIORAL|exercise training|as appear in arm description.
47964796|NCT05120778|OTHER|conventional medical treatment|participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
47964797|NCT04355520|DRUG|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
47964798|NCT04355520|DRUG|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
47964799|NCT06014203|DIAGNOSTIC_TEST|Edema measurement|"Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~1. Midpoint of the upper trapezius muscle~2. 5 cm distal to anterior acromion~3. 5cm distal to lateral acromion~4. 5cm distal to posterior acromion~5. 3cm medial to the axilla~6. Anterior cubital fossa~7. Carpal tunnel"
47964800|NCT05756491|OTHER|24 months of inclusion of unaccompanied patients|inclusion for 6 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 24 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
47964801|NCT05756491|OTHER|18 months of inclusion of unaccompanied patients|inclusion for 12 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 18 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
48314312|NCT05242549|BEHAVIORAL|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors uses the Trans-Theoretical Model (TTM) as the framework, which includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance).~Physical activity training comprised muscle training, joint strengthening, and upper and lower limb resistance exercises for older adults who were frail. After administering nutrition education- nursing Information, participants were encouraged to set their own goals to improve their diet. Home-based training and telecare group care depends on the stages of TTM behavior change of the elderly."
48484467|NCT01373060|DRUG|ASP1941|oral
48484468|NCT01373060|DRUG|Placebo|oral
48484469|NCT06160414|DRUG|Metformin|Participants will receive Metformin orally, after fasting.
48484470|NCT06160414|DRUG|Rosuvastatin|Participants will receive Rosuvastatin orally, after fasting.
48484471|NCT06160414|DRUG|ALXN2080|Participants will receive ALXN2080 orally, after fasting.
48484472|NCT04142242|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
48484473|NCT04142242|OTHER|Blood sample|Blood sample for assessment of antibody persistence.
48484474|NCT03490474|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
48484475|NCT03490474|OTHER|Pain Free Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
48644056|NCT04063462|DRUG|Pyrotinib|pyrotinib, single agent, 400mg p.o once daily until disease progressed
48644057|NCT03692052|DRUG|AG-348|AG-348 tablet orally BID
48644058|NCT06535893|DRUG|TN|Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
48644059|NCT06535893|DRUG|TN-1|Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
48314313|NCT01966575|DRUG|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
48314314|NCT02728258|DRUG|Copanlisib|Given IV
48314315|NCT02728258|OTHER|Laboratory Biomarker Analysis|Correlative studies
48314316|NCT02159326|DRUG|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
48314317|NCT02159326|DRUG|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
48314318|NCT05912855|DEVICE|qNOX|Non
48314319|NCT04823208|DRUG|LY3437943|Administered SC
48314320|NCT04823208|DRUG|Placebo|Administered SC
48314321|NCT06291181|DIAGNOSTIC_TEST|antibiotic sensitivity test|"Disc diffusion method using modified Kirby-Bauer technique on Muller Hinton agar (MHA) will be carried out for antimicrobial susceptibility of S. aureus isolates. The following antibiotics will be tested: cefoxitin (30 µg ), Tetracyclin 30 µg (TE), Chloramphenicol 30 µg (C), Gentamycin 10µg (CN), Erythromycin 15µg(E),Clindamycin 2 µg (DA), Ciprofloxacin 5 µg (CIP), Trimethoprim/sulphamethoxazole 1.25/23.75 µg (SXT), Rifampin 5µg (RA), Linezolide 30µg (LZD); cefoxitin disc (FOX 30 g)~zone diameters interpretation will be done according to Clinical and Laboratory Standard Institute (CLSI 2018),"
48314322|NCT04229498|DRUG|Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)|In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
48314323|NCT02175173|DRUG|Rufinamide|Administration of Inovelon 100mg or 200mg Tablets
48314324|NCT04737031|OTHER|Clinician Nudge|"Investigators will use the Best Practice Alert functionality within the EMR as the conduit to the point of decision-making. Epic currently fires a BPA for each new patient presenting to ACC within the Medical Assistant check-in and vital sign workflow, requiring that medical assistants assess tobacco use status within the past 30 days and satisfy the alert with one of three possible answers. Upon opening the Epic Order tab at a patient's next visit after the screening encounter, clinicians will receive the implementation strategy, placed directly over the order interface. The clinician will be required to acknowledge or opt-out when presented with the order. Opting-out will require clinicians to acknowledge a reason for opt-out using a checklist or free text."
48314325|NCT04737031|OTHER|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status (at the screening encounter). In all cases, the message will include information specific to the upcoming appointment with the oncology clinician.
48314326|NCT01413984|BEHAVIORAL|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
48314327|NCT02960048|DEVICE|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
48314328|NCT02960048|DEVICE|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
48314329|NCT04260334|OTHER|Preoperative Education|The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.
48314330|NCT00782015|DIETARY_SUPPLEMENT|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
48314331|NCT00782015|DIETARY_SUPPLEMENT|Placebo Comparator:|NCEP Step 2 diet
48314332|NCT05977699|DRUG|salbutamol aqueous solution|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
48314333|NCT05977699|DRUG|salbutamol pressurized metered dose inhaler|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
48314334|NCT05977699|OTHER|placebo|matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
48314335|NCT05909215|DRUG|Normal saline|Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
48314336|NCT05909215|DRUG|Dexmedetomidine 0.5 microgram/kg|Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
48314337|NCT05909215|DRUG|Dexmedetomidine 0.75 microgram/kg|Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
48314338|NCT00208312|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
48314339|NCT00208312|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
48314340|NCT00562003|PROCEDURE|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
48314341|NCT00562003|DRUG|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
48314342|NCT03204721|OTHER|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
47964802|NCT05756491|OTHER|12 months of inclusion of unaccompanied patients|inclusion for 18 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 12 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
48484476|NCT03490474|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
48314343|NCT05209932|BEHAVIORAL|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
48314344|NCT04161586|DRUG|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
48314345|NCT02768649|DRUG|RBP-7000|Sequential dosing of each cohort
48314346|NCT02768649|DRUG|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
48314347|NCT05167500|DRUG|Lorlatinib|"No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily."
48314348|NCT03016299|PROCEDURE|microfracture techniques|Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
48314349|NCT04339569|DIAGNOSTIC_TEST|Biomechanical analysis|3D analysis of landing manoeuvres.
48314350|NCT04339569|OTHER|Fatigue protocol|A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
48484477|NCT01071447|OTHER|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
48484478|NCT03656549|DRUG|Pemetrexed|3+3 dose escalation study of pemetrexed in patients with impaired renal function
47964803|NCT05756491|OTHER|6 months of inclusion of unaccompanied patients|inclusion for 24 months of accompanied patients in conventional outpatient care (observational period) and then inclusion for 6 months of unaccompanied with remonte surveillance patients and accompanied patients (interventional period)
48314351|NCT03196271|DIETARY_SUPPLEMENT|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
47964804|NCT00519402|OTHER|tonsillar examination and questionnaire completion|
48314352|NCT05457933|DRUG|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
48314353|NCT05457933|DRUG|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
48314354|NCT01830543|DRUG|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
48314355|NCT01830543|DRUG|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
48314356|NCT01830543|DRUG|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
48314357|NCT01830543|DRUG|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
48314358|NCT01830543|DRUG|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
48314359|NCT01830543|DRUG|clopidogrel|One 75 mg tablet once daily for up to twelve months
48314360|NCT01830543|DRUG|prasugrel|One 10 mg tablet once daily for up to twelve months
48314361|NCT01830543|DRUG|ticagrelor|One 90 mg tablet twice daily for up to twelve months
48314362|NCT05171231|DEVICE|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
48314363|NCT00389740|DRUG|MK0217, /Duration of Treatment : 12 Months|
48314364|NCT00389740|DRUG|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
48314365|NCT01774344|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
48314366|NCT01774344|DRUG|Placebo|Placebo tablets matching in appearance
48314367|NCT00683241|BIOLOGICAL|DCVac-L|Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
48314368|NCT00000741|DRUG|Methylprednisolone|
48314369|NCT01163253|DRUG|CP-690,550|5 mg oral BID
48314370|NCT01163253|DRUG|CP-690,550|10 mg oral BID
48314371|NCT05825651|OTHER|no interventions|This is an observational study without any intervention.
48314372|NCT04931316|OTHER|antiglaucoma|use antiglaucoma in ocular hypertension
48314373|NCT00202111|PROCEDURE|Laparoscopic-assisted colectomy|
48314374|NCT00202111|PROCEDURE|Conventional open colectomy|
48314375|NCT02912806|PROCEDURE|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
48314376|NCT02266186|BEHAVIORAL|Traditional Cognitive behavioural therapy|Therapist supported live therapy
48314377|NCT02266186|BEHAVIORAL|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
47964805|NCT01954719|PROCEDURE|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
48314378|NCT00578864|DRUG|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily"
48484479|NCT06063096|DIETARY_SUPPLEMENT|D-allulose|Fruit-flavoured drink with d-allulose at 2 dosages
48484480|NCT06063096|DIETARY_SUPPLEMENT|Placebo|Fruit-flavoured drink with high fructose corn syrup
47964806|NCT01954719|PROCEDURE|control group|surgeon not dilated cervix after surgery
47964807|NCT06506448|DIAGNOSTIC_TEST|CT Coronary Angiography|CTCA for anatomical, physiological, plaque composition and inflammatory assessment of coronary arteries
47964808|NCT00585143|DRUG|ABT-335|45 mg once daily for 10 consecutive days
47964809|NCT00585143|DRUG|Rosuvastatin|10 mg once daily for 10 days
47964810|NCT05747820|OTHER|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
48314379|NCT00578864|DRUG|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes"
48314380|NCT00578864|DRUG|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
48314381|NCT00578864|DRUG|Cisplatin|Cycle 1, 2, and 4
48314382|NCT00578864|DRUG|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
48314383|NCT00578864|DRUG|Mesna|Standard weight-based dosing with cyclophosphamide
48314384|NCT00578864|DRUG|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
48314385|NCT00578864|PROCEDURE|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
48314386|NCT01947608|DRUG|LDK378|750 mg. orally
48314387|NCT01594632|DRUG|Jadelle|LNG containing subdermal contraceptive implant
48314388|NCT01594632|DRUG|Sino-implant (II)|LNG containing subdermal contraceptive implant
48314389|NCT01975233|DEVICE|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
48314390|NCT02555761|DRUG|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
48314391|NCT00931671|OTHER|Exercise training|aerobic exercise training
48314392|NCT01852097|BEHAVIORAL|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~1. Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~2. Give feedback to individuals on their questionnaire responses.~3. Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~4. Provide advice on overcoming practical barriers.~5. Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~6. Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
48314393|NCT01196624|DEVICE|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
48484481|NCT04910516|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage fo
48484482|NCT01655524|DRUG|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
48484483|NCT03848247|OTHER|Injection of Isotonic saline|Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).
48484484|NCT03848247|OTHER|Injection of NGF|Half the participants will be injected in a neck muscle with NGF (Neck pain group).
48484485|NCT06427902|OTHER|Periodontal clinical measurements, Saliva sampling|Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque
48484486|NCT04637633|DRUG|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
48314394|NCT01196624|DEVICE|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
48314395|NCT02352610|PROCEDURE|LRTI|
48314396|NCT02352610|DEVICE|Biotenodesis Screw|
48314397|NCT04765826|PROCEDURE|Autologous mini punch grafting|"All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site"
48314398|NCT04343079|DIAGNOSTIC_TEST|PET CT|measurement of surgical margins during lumpectomy
48314399|NCT00611897|DRUG|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
48314400|NCT00611897|DRUG|placebo and ketamine|placebo N-acetylcysteine
48314401|NCT01520415|DRUG|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
48314402|NCT01520415|DRUG|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
48314403|NCT03978819|DEVICE|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI\>80 + Remifentanil \>6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
48314404|NCT04898426|OTHER|Enhanced bowel preparation instruction|Automated delivery of SMS, pre-recorded phone call, and link to an information website.
48314405|NCT02645656|DRUG|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
48314406|NCT02364947|DRUG|Nalmefene hydrochloride|As-needed; tablets, orally
48314407|NCT02364947|DRUG|Placebo|As-needed; tablets, orally
48314408|NCT04913714|BEHAVIORAL|3-month radio intervention on infant vaccination|Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners
48314409|NCT03391687|DIAGNOSTIC_TEST|Amylase Test|body fluid amylase will be tested after radical gastrectomy in scheduled interval
48314410|NCT00123851|DRUG|Tarceva (OSI-774)|
48314411|NCT00123851|DRUG|Capecitabine|
48314412|NCT00123851|DRUG|Oxaliplatin|
48314413|NCT04567602|DRUG|PAH medication|There will be no specific interventions.
48314414|NCT05753280|DRUG|Vitamin D|Patients take 800 mg vitamin D capsules daily during the whole treatment period
48314415|NCT02742922|BEHAVIORAL|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
48314416|NCT03483324|BIOLOGICAL|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
48314417|NCT03483324|BIOLOGICAL|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
48314418|NCT02062528|DIETARY_SUPPLEMENT|omega-3 fatty acids|highly dosed in EPA
48314419|NCT02062528|DIETARY_SUPPLEMENT|placebo|
48314420|NCT00752609|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
48314421|NCT03840083|BEHAVIORAL|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
48314422|NCT00394290|DEVICE|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
48314423|NCT00375115|DRUG|Sambucol|
48314424|NCT02467387|DRUG|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
48314425|NCT02467387|DRUG|Lactated Ringer's Solution|One time infusion 1.5mL/kg
48314426|NCT02005848|BIOLOGICAL|Alpha-1 Antitrypsin|
48314427|NCT02005848|OTHER|Placebo|Placebo
48314428|NCT03888391|DEVICE|Active TNS|
48314429|NCT06350344|DEVICE|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients with high-risk of VTE during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
47964811|NCT05690373|DIETARY_SUPPLEMENT|Probiotic effect on influenza vaccine response|Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from \>10 to 40 in Ab titre for seronegative subjects.
48314430|NCT00463658|OTHER|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
48314431|NCT05560815|PROCEDURE|Any surgical procedure|Might differ for substudies.
48314432|NCT01096849|DRUG|levofloxacin|
48314433|NCT01096849|DRUG|plazomicin|
48314434|NCT01096849|DRUG|placebo|
48314435|NCT01345877|PROCEDURE|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
48314436|NCT02627131|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
48314437|NCT00651976|DRUG|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
48314438|NCT00651976|OTHER|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
48314439|NCT00651976|PROCEDURE|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
48314440|NCT01072539|DRUG|tigecycline|As prescribed by physician in usual clinical practice
48314441|NCT00480922|BEHAVIORAL|Low glycemic load diet|Outpatient behavioral counseling
48314442|NCT00480922|BEHAVIORAL|Low fat diet|Outpatient behavioral counseling
48314443|NCT06555211|PROCEDURE|MRI|MRI will be performed
48314444|NCT06555211|PROCEDURE|PET/CT|PET/CT will be performed
47964812|NCT03144960|PROCEDURE|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
47964813|NCT02197520|DRUG|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
47964814|NCT02197520|DRUG|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
47964815|NCT02197520|DRUG|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
48314445|NCT02006667|DRUG|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
48314446|NCT02006667|DRUG|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
48314447|NCT02006667|DRUG|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
48314448|NCT00189241|DRUG|imiquimod|
48314449|NCT06552559|DRUG|Selinexor|Combination chemotherapy
48314450|NCT01672021|PROCEDURE|PET/MRI|PET/MRI
48314451|NCT03641209|DRUG|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
48314452|NCT03641209|OTHER|Placebo|Half physiological saline solution as the non-active placebo solution
48314453|NCT05931523|BEHAVIORAL|Stress First Aid|The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
48314454|NCT00492947|BIOLOGICAL|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
48314455|NCT03828084|DRUG|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
48314456|NCT05621824|DEVICE|Endoscopic ultrasound|Use endoscopic ultrasound to examine the pancreatic lesions.
48314457|NCT05621824|PROCEDURE|EUS-Fine needle aspiration|If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
48314458|NCT03192527|DRUG|KN015|experimental drug
48314459|NCT03192527|DRUG|Placebo|Comparator.
48314460|NCT03192527|DRUG|Triptorelin|The drug is used for down-regulation of endogenous FSH.
48314461|NCT01432197|OTHER|ADL intervention|1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
48644060|NCT06691724|OTHER|LLM-based transcription and reporting tool|"The LLM-based transcription and reporting tool works in three steps:~1. The conversation between patient and GP is transcribed to text with a speech-to-text LLM~2. The text is summarized according to the Subjective, Objective, Assessment, Plan (SOAP) rules~3. The SOAP summary is imported in the electronic health record of the GP"
48644061|NCT04105725|BEHAVIORAL|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
48314462|NCT03020758|DIETARY_SUPPLEMENT|Dried Fruit|Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.
48314463|NCT03020758|OTHER|High Carbohydrate Snack|Calorie-matched carbohydrate-rich snack.
48314464|NCT01656681|DIETARY_SUPPLEMENT|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
48644062|NCT04105725|OTHER|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
48644063|NCT06144853|OTHER|scan|Fluorodeoxyglucose (FDG)-positron emission tomography/Computed tomography scan
48314465|NCT01656681|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
48314466|NCT05485272|OTHER|Silver Diamine Fluoride combined with Potassium Iodide.|Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.
48314467|NCT05485272|OTHER|Silver Diamine Fluoride.|A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.
48644064|NCT02999360|BEHAVIORAL|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
48644065|NCT02999360|BEHAVIORAL|Background Music|30 minutes background music only
48644066|NCT02999360|BEHAVIORAL|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
48314468|NCT05485272|OTHER|High-Viscosity Glass Ionomer.|A Glass Hybrid material.
48314469|NCT04715230|BIOLOGICAL|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
48314470|NCT04715230|DRUG|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
48314471|NCT04715230|DRUG|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
48314472|NCT06121557|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
48314473|NCT06121557|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
48644067|NCT04567771|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
48644068|NCT04567771|OTHER|Questionnaire Administration|Complete adverse event assessments
48644069|NCT04567771|RADIATION|Radiation Therapy|Undergo proton or intensity modulated radiation therapy
48644070|NCT06315894|DEVICE|SuperCAP Program|"Distance program including tasks and exercises to improve cognitive, emotional, and functional status.~The intervention will be applied via cell phone and will have a duration of 3 months (12 weeks).~Tasks and exercises will be performed 5 days per week. Contents of the program will include daily exercises, daily games, daily videos, and weekly videos.~They will address cognitive functions, daily habits, and lifestyle factors in general.~Compliance will be monitored to control the adherence to the intervention. The program has been designed specifically for people with post-COVID syndrome."
48644071|NCT05836636|OTHER|Torque teno virus DNA measurement|Torque teno virus DNA level will be obtained from all study subjects upon recruitment, when subjects are admitted and when subjects undergo kidney allograft biopsies.
47964816|NCT03681405|OTHER|Informational Intervention|Given information about mindful movement and breathing
47964817|NCT03681405|OTHER|Questionnaire Administration|Ancillary studies
47964818|NCT03681405|BEHAVIORAL|Telephone-Based Intervention|Receive caring attention phone call
47964819|NCT02959320|PROCEDURE|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
48314474|NCT06121557|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
47964820|NCT03495219|PROCEDURE|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
48484487|NCT04815382|OTHER|Dynamic Upper Limb Orthosis|"The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months"
48484488|NCT00005090|BIOLOGICAL|bleomycin sulfate|10 U/m\^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
48484489|NCT00005090|DRUG|carmustine|150/m\^2 on days -6 to -4 (4-6 days before transplant).
48484490|NCT00005090|DRUG|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
48484491|NCT00005090|DRUG|dacarbazine|375 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
48484492|NCT00005090|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
48484493|NCT00005090|DRUG|etoposide|60 mg/kg on day -4 (4 days before transplant).
48484494|NCT00005090|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
48484495|NCT00005090|PROCEDURE|peripheral blood stem cell transplantation|2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight
48484496|NCT05017259|DIETARY_SUPPLEMENT|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
48484497|NCT00068081|DRUG|Capsaicin Dermal Patch|
48484498|NCT00750646|DEVICE|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
48484499|NCT02732691|DEVICE|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
48484500|NCT04882137|BEHAVIORAL|Education plus Coaching|Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
48484501|NCT00466973|DEVICE|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
48484502|NCT00466973|DEVICE|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
48484503|NCT00466973|DEVICE|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
48484504|NCT00466973|DEVICE|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
47964821|NCT05279339|OTHER|Exercise|Upper limb exercises using an elastic band.
47964822|NCT01737697|DRUG|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
47964823|NCT01737697|DRUG|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
48484505|NCT00466973|DEVICE|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
48484506|NCT00466973|DEVICE|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
48484507|NCT02257619|DRUG|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
48484508|NCT02257619|DRUG|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.
48484509|NCT03313882|OTHER|no intervention is involved|
48484510|NCT04119999|DEVICE|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
48484511|NCT04119999|DEVICE|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
48484512|NCT01857648|OTHER|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
48484513|NCT02611011|DEVICE|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
48484514|NCT03170388|DRUG|IDP-126 Gel|Gel
48484515|NCT03170388|DRUG|IDP-126 Component A|Component A
48484516|NCT03170388|DRUG|IDP-126 Component B|Component B
48484517|NCT03170388|DRUG|IDP-126 Component C|Component C
48484518|NCT03170388|DRUG|IDP-126 Vehicle Gel|Vehicle Gel
48484519|NCT00955721|DRUG|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
48484520|NCT00955721|DRUG|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
48484521|NCT00955721|DRUG|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
48484522|NCT00006387|BIOLOGICAL|QS21|
48484523|NCT00006387|BIOLOGICAL|ras peptide cancer vaccine|
48484524|NCT03235479|DRUG|Rimegepant|75 mg tablet QD
48484525|NCT03235479|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
48484526|NCT02662088|PROCEDURE|laparoscopic-lavage|
48644072|NCT04737603|DRUG|ED-Initiated treatment with buprenorphine / naloxone|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
48644073|NCT05624554|DRUG|Nemtabrutinib|65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
48115360|NCT05565859|BEHAVIORAL|Planetary Health Plate signage|A Planetary Health Plate graphic was developed based on the healthy reference diet proposed by the Eat Lancet Commission. The graphic was designed to capture the food groups and proportions of food groups promoted by the Planetary Health diet.
48644074|NCT05624554|DRUG|Fludarabine|25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
48644075|NCT05624554|DRUG|Cyclophosphamide|250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
48644076|NCT05624554|DRUG|Bendamustine|Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
48644077|NCT05624554|BIOLOGICAL|Rituximab|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
48115361|NCT03823534|DRUG|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
48115362|NCT03823534|DRUG|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
48484527|NCT01956019|DEVICE|MRI scanning|
48484528|NCT03083626|OTHER|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
48115363|NCT03823534|DRUG|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
48115364|NCT03823534|DRUG|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
48644078|NCT05624554|BIOLOGICAL|Truxima|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
48115365|NCT03823534|DRUG|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
48115366|NCT03823534|DRUG|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
48115367|NCT03823534|DRUG|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
48115368|NCT05755100|BEHAVIORAL|I MOVE!+UP|An individual psychotherapy that integrates behavioral weight management with evidence-based psychotherapy for PTSD (Cognitive Processing Therapy) for up to 6 months, augmented with evidence-based psychiatric and weight management medication management.
48484529|NCT00842530|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
48484530|NCT00842530|BIOLOGICAL|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
48484531|NCT00842530|BIOLOGICAL|Placebo|Sodium chloride 0.9%
48484532|NCT05877391|BEHAVIORAL|SGM Communication Intervention|Evaluate the feasibility and acceptability of the SGM communication intervention by hospice staff. I will pilot test the training with hospice staff to refine the content and delivery of the training. Outcomes in the pilot clinical trial will include feasibility, acceptability, and staff satisfaction with training.
48484533|NCT00403182|DRUG|chemotherapy|
48644079|NCT05624554|BIOLOGICAL|Ruxience|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
48644080|NCT05624554|BIOLOGICAL|Riabni|Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
48644081|NCT06278922|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|Signs of Safety is a Deaf-accessible toolkit to be used with the Seeking Safety treatment protocol. Seeking Safety is a manualized, non-exposure-based, cognitive behavioral therapy for trauma and addiction.
48644082|NCT06278922|BEHAVIORAL|Treatment as usual|NDT therapists come from a wide variety of training backgrounds, but each works with their clients to build on their existing strengths and provide support as clients develop new strategies and behaviors for overcoming adversity.
48115369|NCT04688801|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy± Radiotherapy after surgery
48115370|NCT04688801|DRUG|Immunotherapy|Chemotherapy + Immuonotherapy ± Radiotherapy after surgery
48115371|NCT01215552|DRUG|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
48115372|NCT00461747|DRUG|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
48115373|NCT00461747|DRUG|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity \< grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
48314475|NCT06121557|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|In the dose-escalation portion, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
48314476|NCT06121557|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
48314477|NCT06121557|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
48644083|NCT00872287|PROCEDURE|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
48314478|NCT06121557|DRUG|Chemotherapeutic drug, ADC or PARP inhibitor|Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
48314479|NCT04502810|RADIATION|High-level laser therapy|Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
48314480|NCT06552507|PROCEDURE|Duroplasty|The investigators open the dura from midline and repaired with fish mouth for dura augmentation
48314481|NCT01506778|DEVICE|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
48314482|NCT05271019|DEVICE|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
48314483|NCT02833116|DRUG|Betamethasone|
48644084|NCT00872287|PROCEDURE|SILS|Single transumbilical incision laparoscopic cholecystectomy
47964824|NCT01737697|DRUG|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
47964825|NCT01737697|DRUG|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
47964826|NCT04153331|OTHER|Nasal swab|Patient included in emergency with a nasal swab
47964827|NCT01683383|DEVICE|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
47964828|NCT01683383|OTHER|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
47964829|NCT00150748|DRUG|Levetiracetam 166 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use"
47964830|NCT00150748|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use"
47964831|NCT00150748|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use"
47964832|NCT03437096|OTHER|venipuncture pain|postoperative sleeve gastrectomy patients pain
47964833|NCT03047057|DRUG|Lidocaine|IV Lidocaine infusion
47964834|NCT03047057|DRUG|IV normal saline|IV normal saline infusion
47964835|NCT00199680|PROCEDURE|PET|
47964836|NCT02710474|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
47964837|NCT02710474|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
47964838|NCT05759247|DEVICE|BORA Band (wristband)|Wristband collecting patient vital signs and activity
47964839|NCT00886574|DRUG|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
47964840|NCT00886574|DRUG|Aspirin|100 mg once a day
47964841|NCT00779285|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
47964842|NCT02798601|OTHER|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
47964843|NCT05338515|DRUG|Selpercatinib|Administered orally.
47964844|NCT02277145|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
47964845|NCT04713215|OTHER|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
48314484|NCT02833116|DRUG|Dexamethasone|
48314485|NCT01201070|DRUG|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
48314486|NCT02410902|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
48644085|NCT06655194|DRUG|Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)|Chewable tablet, 81mg, oral
48644086|NCT06655194|DRUG|Acetylsalicylic Acid (BAYE004465, UI1615160)|Chewable tablet, 81 mg, oral
48644087|NCT03878342|RADIATION|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
48644088|NCT03878342|OTHER|No Radiotherapy|No Irradiation- Active surveillance
48115374|NCT00461747|DRUG|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is \< grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
48314487|NCT02410902|DRUG|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
48314488|NCT03026413|PROCEDURE|pulmonary vein antrum modification|
48644089|NCT00005880|DRUG|budesonide|
48644090|NCT01275677|DRUG|Cyclophosphamide|Given IV
48644091|NCT01275677|DRUG|Docetaxel|Given IV
48644092|NCT01275677|DRUG|Doxorubicin|Given IV
48484534|NCT00403182|DRUG|letrozole|
48115375|NCT04944446|OTHER|Treatment|Myofascial release of various muscle groups Treatment of mobilization of the shoulder joint
48266781|NCT05698667|DIAGNOSTIC_TEST|Transcervical ultrasound|The tongue base and tonsils are scanned externally via the neck, where a (preferably low-frequency) transducer is placed onto the skin above the hyoid bone to visualize the tongue base. The tonsils are visualized adjacent to the tongue base on either side and are located deep to the submandibular glands in a oblique coronal plane.
48266782|NCT00423059|DRUG|bevacizumab|
48314489|NCT01826422|DIETARY_SUPPLEMENT|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
48314490|NCT01826422|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
47964846|NCT03834597|DEVICE|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
47964847|NCT03834597|DEVICE|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
48314491|NCT05052775|OTHER|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
48314492|NCT05052775|OTHER|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
48314493|NCT05052775|OTHER|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
48314494|NCT00115804|DRUG|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
48314495|NCT03273205|DEVICE|Anodal tDCS|This group gets a real stimulation
48314496|NCT03273205|DEVICE|Sham tDCS|This group gets a sham stimulation
48314497|NCT00258102|DRUG|Levofloxacin|
48314498|NCT03378154|PROCEDURE|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
48484535|NCT02841748|DRUG|Pembrolizumab|200mg, every three weeks, iv, x 1 year
47964848|NCT02336971|BEHAVIORAL|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
47964849|NCT02336971|BEHAVIORAL|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
48314499|NCT03378154|PROCEDURE|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
48484536|NCT02841748|DRUG|Placebo|iv, every three weeks, x 1 year
48484537|NCT00164749|DRUG|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
48484538|NCT00164749|DRUG|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
48644093|NCT01275677|DRUG|Doxorubicin Hydrochloride|Given IV
48644094|NCT01275677|OTHER|Laboratory Biomarker Analysis|Correlative studies
48644095|NCT01275677|DRUG|Paclitaxel|Given IV
48644096|NCT01275677|OTHER|Quality-of-Life Assessment|Ancillary studies
48644097|NCT01275677|BIOLOGICAL|Trastuzumab|Given IV
48484539|NCT00164749|DRUG|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
48484540|NCT02673879|OTHER|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
48644098|NCT05668507|BEHAVIORAL|REACHOUT Virtual Mental Health Support|"REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~1. One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~2. Group support delivered via a 24/7 chat room~3. Face to face support delivered via virtual happy hours"
48644099|NCT05919030|RADIATION|Intensity-modulated radiotherapy (IMRT)|Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
47964850|NCT01646762|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
47964851|NCT01646762|OTHER|Laboratory Biomarker Analysis|Correlative studies
47964852|NCT04102787|OTHER|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
47964853|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
47964854|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
47964855|NCT02124330|DIETARY_SUPPLEMENT|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
47964856|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
47964857|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
47964858|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
47964859|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
47964860|NCT00217061|DEVICE|Decision Aid Statin Choice|
47964861|NCT00999089|PROCEDURE|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
47964862|NCT00999089|PROCEDURE|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
47964863|NCT00999089|PROCEDURE|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
47964864|NCT01116115|OTHER|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
47964865|NCT01116115|OTHER|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
47964866|NCT02123888|RADIATION|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
47964867|NCT05417139|OTHER|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
47964868|NCT01897844|DRUG|ITF2984 (100, 2000, 3000 mcg bid)|
47964869|NCT01897844|DRUG|Placebo|
47964870|NCT02851095|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
47964871|NCT02851095|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
47964872|NCT02851095|DRUG|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
47964873|NCT02339935|BEHAVIORAL|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
47964874|NCT02339935|OTHER|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
47964875|NCT02433405|BIOLOGICAL|Fetuin-A|Acute phase protein
47964876|NCT02433405|BIOLOGICAL|Serum Amyloid A|Acute phase protein
47964877|NCT02044705|BEHAVIORAL|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
47964878|NCT00266734|DEVICE|RPS Adeno Detector|
48484541|NCT02673879|OTHER|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
48644100|NCT05919030|DRUG|Tislelizumab|200 mg IV Q3W
48644101|NCT05919030|DRUG|Cisplatin|During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
48644102|NCT05919030|DRUG|Nab paclitaxel|During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
48644103|NCT06523387|BEHAVIORAL|Pivotal Response Treatment Online (PRT-O) Course|Pivotal Response Treatment - Parent Training
48644104|NCT05741372|DRUG|Rosuvastatin|Rosuvastatin
48644105|NCT05741372|DRUG|Digoxin|Digoxin
48644106|NCT05741372|DRUG|Metformin hydrochlorid|Metformin hydrochloride
48644107|NCT05741372|DRUG|Furosemide|Furosemide
48644108|NCT04190446|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48644109|NCT04190446|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
48314500|NCT03838172|OTHER|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
48314501|NCT05524441|OTHER|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
48314502|NCT01593501|DIETARY_SUPPLEMENT|vitamin D3|pharmaceutical grade D3
48484542|NCT06061705|PROCEDURE|Tumor Biopsy|"Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180. This will only be carried out if the tumour tissue is externalized and therefore accessible, and if the biopsy can be performed under local anaesthetic without any constraints for the patient (pain, risk of bleeding).~It consists of a superficial sampling of the externalized tumour lesion under local anaesthetic (xylocaine spray 5%, or xylocaine injectable 1%).~Biopsy of cervico-facial lesions under local anaesthetic is a commonly performed procedure. The main risk of this procedure is bleeding, which is very rare.~The biopsy will not be performed if the surgeon considers that the risk of bleeding is too great. Given the externalized nature of the lesion, biopsy does not entail any risk of tumour dissemination (possible for deep biopsies).~* Four 10-mL blood samples from two heparinized tubes~* Four 5-mL unstimulated saliva samples: non-invasive examination."
47964879|NCT05122533|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
48266783|NCT02266433|DRUG|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
48314503|NCT01182948|BEHAVIORAL|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
48314504|NCT01182948|BEHAVIORAL|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
48484543|NCT00690482|DRUG|AZD1981|Oral tablet, twice daily
48484544|NCT00690482|DRUG|Placebo|Placebo Oral tablet, twice daily
48484545|NCT03974165|OTHER|Cereal-legume product 1|The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
48484546|NCT03974165|OTHER|Cereal-legume product 2|The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
48484547|NCT03974165|OTHER|Cereal product|The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
48484548|NCT03974165|OTHER|Reference food|The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
48644110|NCT04190446|OTHER|Quality-of-Life Assessment|Ancillary studies
48644111|NCT04190446|OTHER|Questionnaire Administration|Ancillary studies
48644112|NCT04190446|PROCEDURE|Computed Tomography|Undergo CT scan
47964880|NCT05122533|DIAGNOSTIC_TEST|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position"
47964881|NCT04803071|DIETARY_SUPPLEMENT|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
47964882|NCT04803071|DIETARY_SUPPLEMENT|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
48314505|NCT00129350|PROCEDURE|Pulmonary rehabilitation programme|
48314506|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
48314507|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
48314508|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
48314509|NCT00162305|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
48644113|NCT04190446|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48644114|NCT04190446|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48644115|NCT05816083|BEHAVIORAL|Virtual Reality Tool|Virtual Reality Tool for At-Risk Trauma-Exposed Young People
48644116|NCT03429907|BEHAVIORAL|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
48644117|NCT03429907|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
48644118|NCT05062200|DRUG|JNJ-77242113|JNJ-77242113 will be administered as an oral tablet.
48644119|NCT05062200|DRUG|Placebo|Matching placebo will be administered as an oral tablet.
48644120|NCT05248009|DEVICE|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
48644121|NCT06422923|BIOLOGICAL|NRTX-1001|Cellular therapy consisting of GABAergic Inhibitory Interneurons
47964883|NCT04803071|DIETARY_SUPPLEMENT|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
48314510|NCT04353921|OTHER|No intervention will be administered as part of this study.|No intervention will be administered as part of this study.
48314511|NCT05099146|BEHAVIORAL|pictures|pictures with brushing technique demonstrated technique for proper brushing
48314512|NCT05099146|BEHAVIORAL|video|video of brushing technique demonstrated technique for proper brushing
48644122|NCT01150370|DEVICE|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
47964884|NCT03732235|DEVICE|TACE+ systemic Bevacizumab|PEG embolics
47964885|NCT03732235|DRUG|FOLFIRI+Bevacizumab|antiangiogenic factor
47964886|NCT03732235|DEVICE|TACE|PEG embolics
48484549|NCT06317948|OTHER|treatment plan comparison|In order to assess inter-Institute variability of DVH prediction of the various models, for the different situations and the different OARs, DVH and dose statistics (min, mean, median, max and SD of the dose received by each OAR) predicted on the patients owning to the different centers by the different models will be compared
48644123|NCT02783963|DEVICE|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
48484550|NCT06420414|OTHER|Virtual Reality|"Participants engaged in a 15-minute HIIT session using the Facebook Oculus Quest 2 VR headset with the FitXR fitness game. The advanced level workout (High Speed) was chosen, where participants performed functional movements like squats, lunges, and trunk rotations while punching virtual targets. The VR environment provided a 10-second rest period between intervals and featured a virtual trainer's guidance."
48644124|NCT06633042|DRUG|Universal BCMA-CD19 CART|1.0-4.0×10\^6 CAR-T cells/kg
48644125|NCT06686745|DRUG|SIM0508 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.
48644126|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0508 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
48644127|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0508 combination with olaparib established from SIM0508 combination dose escalation.
47964887|NCT05496530|DRUG|Suprachoroidal triamcinolone acetonide injection|Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.
48314513|NCT05099146|BEHAVIORAL|control|oral hygiene instructions provided
48644128|NCT04190771|BEHAVIORAL|TAU + multicomponent treatment NAT-FM|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30 min.)~* Mindfulness techniques (30 min.)~* Physical exercise in a natural environment / nature exposure (30 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
47964888|NCT05163977|PROCEDURE|Blumgart Anastomosis|The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
47964889|NCT05163977|PROCEDURE|Cattell Warren Anastomosis|It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
47964890|NCT05614505|DIETARY_SUPPLEMENT|Ready to use therapeutic foods|locally produced therapeutic foods
48314514|NCT06048237|DIAGNOSTIC_TEST|Diagnostic Ultrasound Imaging of the diaphragm|"In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications."
48314515|NCT04917744|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48484551|NCT06420414|OTHER|Traditional HIIT|"Participants followed a non-VR 15-minute HIIT programme designed to replicate the exercises and patterns seen in the FitXR game. The traditional exercises included squats, lunges, and punches, matching the VR programme's intensity and interval structure. Participants watched a pre-recorded video on a laptop, which guided them through the workout. The 10-second rest periods were also maintained for consistency."
48484552|NCT04734119|OTHER|Pre operative evaluation and anesthesia administration by the same anesthesiologist|Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
48644129|NCT04190771|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
47964891|NCT05929664|BIOLOGICAL|Cemiplimab|Given IV
47964892|NCT05929664|PROCEDURE|Computed Tomography|Undergo CT scan
47964893|NCT05929664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
47964894|NCT05929664|OTHER|Quality-of-Life Assessment|Ancillary studies
47964895|NCT05929664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47964896|NCT05929664|PROCEDURE|Biopsy|Undergo biopsy
47964897|NCT02045810|DRUG|Levobupivacaine|
47964898|NCT02045810|DRUG|Saline|
47964899|NCT01951274|DRUG|VPD-737|NK1 Receptor Antagonist
47964900|NCT01951274|DRUG|Placebo|
47964901|NCT04767568|DIAGNOSTIC_TEST|Blood sample|"In cohort A: Blood sample n°1 (PBMC, plasma, ctDNA) previous colonoscopy. If no cancer lesions: STOP. If cancer lesion detected : Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery.~In cohort B: Blood sample n°1 (PBMC, plasma, ctDNA) collected before surgery. Blood sample n°2 (PBMC, plasma, ctDNA) collected 1 month after surgery"
47964902|NCT04767568|OTHER|Tumor tissue|In each cohort, tumor tissue will be collected from the surgical specimen.
47964903|NCT04767568|OTHER|stool collection|In cohort B: Stool sample n°1 collected before surgery. Stool sample n°2 collected 1 month after surgery
47964904|NCT04456959|DRUG|Inotuzumab Ozogamicin|Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
47964905|NCT06234917|OTHER|EEG-based neurofeedback for brain activity modulation|NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
47964906|NCT06266910|OTHER|Visual training video|"The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment."
47964907|NCT03105791|OTHER|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
47964908|NCT00502047|DRUG|Plantago ovata husk|
47964909|NCT05309642|BEHAVIORAL|Intermittent calorie restriction|Recipes will be provided with suggestions of meals that would not exceed the calorie restriction. For the remaining 5 days of the week, they will receive instructions and recipes that follows the Korean Dietary Reference Intakes (KDRIs), with an intake limit of 2,000 kcal/day for women and 2,500 kcal/day for men. The percentage of energy (E%) from different macronutrients in the recipes will be 45-60 E% carbohydrates, 25 E% fat and 10-20 E% protein.
47964910|NCT05309642|BEHAVIORAL|Standard of care|They will receive individualized guidance from a hepatologist on how to choose a healthy diet, to reduce the intake of sweets and saturated fatty acids, increase sources of unsaturated fat, avoid large portions, and to regularly eat 3 meals per day. Each participant will be provided a written summary of the dietary advice.
47964911|NCT01865110|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
47964912|NCT01865110|DRUG|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
47964913|NCT01865110|DRUG|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
47964914|NCT01865110|DRUG|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
47964915|NCT05851066|DRUG|VSA003|sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
47964916|NCT05851066|DRUG|0.9% NaCl|placebo
48484553|NCT03330236|DEVICE|"Anesthetic depth management"|The propofol and remifentanil infusion rates will be adjusted to maintain the spectral edge frequency (SEF) value at 10-15 and the patient state index (PSI) value at 25-50 based on the SedLine EEG Brain Function Monitoring.
48484554|NCT01188265|DRUG|Valproate|
48484555|NCT01188265|DRUG|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
47964917|NCT06504836|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
47964918|NCT06504836|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
47964919|NCT03415568|DIETARY_SUPPLEMENT|LCT oil|LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
47964920|NCT03415568|DIETARY_SUPPLEMENT|MCDG oil|MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
47964921|NCT03266536|BEHAVIORAL|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with \< 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
48484556|NCT01188265|DRUG|Placebo|VPA plus placebo
48644130|NCT06603012|BEHAVIORAL|GET Up PD|"* The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-3 sets, 8-12 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.~* Other components of the GET Up PD program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters."
48484557|NCT01188265|DRUG|Dextromethorphan 30 mg|VPA \& Dextromethorphan 30 mg per day
48484558|NCT00682214|DRUG|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
48484559|NCT00682214|DRUG|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
48644131|NCT06603012|BEHAVIORAL|Stretching and Flexibility|"* The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GET Up PD program, and account for activity, social-contact, and attention.~* Other components of the Stretching and Flexibility program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GET Up PD program."
48314516|NCT04917744|OTHER|Laboratory Biomarker Analysis|Ancillary studies
48314517|NCT04917744|OTHER|Medical Chart Review|Review of medical charts
48314518|NCT04264767|PROCEDURE|Blood collection|Peripheral blood collection via routine venipuncture
48314519|NCT04715308|PROCEDURE|Urinary diversion|The formation of a stoma to divert urine to the skin because of the need to resect the bladder as part of surgery for advanced pelvic malignancy
48484560|NCT04375995|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry test will be applied to all groups.
48314520|NCT04363489|DEVICE|Wearable Medical Device (Empatica E4)|A wearable medical device (Empatica E4) which is a smart wristband that detects skin temperature, heart rate and sleep. It is CE and FDA approved.
48484561|NCT04375995|DIAGNOSTIC_TEST|Spirometric pulmonary function test|Spirometric pulmonary function test will be applied to all groups.
47964922|NCT06192134|DEVICE|CPM device|CPM brace
47964923|NCT01866930|BIOLOGICAL|Pegylated Interferon Lambda-1a|
47964924|NCT01866930|DRUG|Daclatasvir (DCV)|
47964925|NCT01866930|DRUG|Ribasphere (RBV)|
48314521|NCT04363489|DIAGNOSTIC_TEST|COVID-19 PCR Swab|COVID-19 PCR Swab will be self-taken by doctors every day. Fischer nasopharyngeal PCR Swabs
48314522|NCT04363489|DIAGNOSTIC_TEST|Pulse Oximeter|Participants will measure their oxygen saturations every day, and report them on the survey. Pulmolink A310 pulse oximeters
48484562|NCT04375995|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|FeNO test will be applied to asthma group.
48484563|NCT04375995|DIAGNOSTIC_TEST|Thorax Computed Tomography|Thorax Computed Tomography will be taken to the asthma group.
48484564|NCT04375995|DIAGNOSTIC_TEST|Blood eosinophil level|The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.
47964926|NCT04927260|DRUG|Patient treated by Avapritinib in real life|"The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA."
48314523|NCT05998954|PROCEDURE|transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block|Fifteen ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. Fifteen ml of 0.375% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.
48484565|NCT04375995|OTHER|Asthma control test|Asthma control test questions will be applied to the asthma group.
48484566|NCT04375995|OTHER|Asthma quality of life scale|Asthma quality of life scale (AQLQ) will be applied to the asthma group.
48484567|NCT04375995|DIAGNOSTIC_TEST|Chest X Ray|Chest X Ray will be applied to the healthy control group.
48484568|NCT01820858|DRUG|Paclitaxel|175 mg/m(2), intravenously (IV)
48484569|NCT01820858|DRUG|Paraplatin (Carboplatin Injection)|AUC=5, IV
48484570|NCT01820858|RADIATION|Pelvic Radiation|45-50 Gy
48484571|NCT01820858|RADIATION|Vaginal Brachytherapy 1|5 Gy, 3 times
48484572|NCT01820858|RADIATION|Vaginal brachytherapy 2|5 Gy, 2-4 times
48484573|NCT00609284|DRUG|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
48484574|NCT00609284|DRUG|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
48484575|NCT00609284|RADIATION|Radiotherapy|70 Gy in 7 weeks
48484576|NCT00692224|DRUG|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
48314524|NCT05998954|PROCEDURE|suprainguinal fascia iliaca block|Thirty ml of 0.375% ropivacaine will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
48115376|NCT04395235|OTHER|Survey|A multi-item survey was prepared to assess fellow's perception of residency training. The survey was utilized by our group, understanding of patient vascular anatomy, awareness of the changes based on variations, independent decision-making, differential diagnosis, plan on key surgical steps, and preparation for unexpected bleeding. The answers to the questions asked for each case were analyzed to include senior (3 years and over) - junior (1-2 years) residents.Assistants spend 45 minutes in the survey. Data are entered into SPSS 24.0 for statistical analysis. Wilcoxon Signed Ranks Test was used to determine any significant differences in the measurements between the original CT images, 3D rendered images, the 3D model and CT images of the 3D model. Statistical significance was defined as a p value of less than 0.05. Junior assistants stated that they perceived 2D image statistically better than 3D models compared to the senior assistants (Kruskal-Wallis Test).
48115377|NCT04809090|BEHAVIORAL|SMT|Standard 8 SMT (Stress Management Training) psychological interviews.
48314525|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
48644132|NCT06688422|DEVICE|incentive spirometry|The study will have one intervention group of patients using incentive spirometry in addition to standard of care treatment, including chemo/radiation and immunotherapy maintenance. Patients will use the incentive spirometer 10 times (10 breaths) every hour they are awake. Patients will be asked to start using the incentive spirometer as soon as they are enrolled in the study. Patients will be asked to continue to use incentive spirometry daily, including the duration of chemoradiation and up to three months post-treatment.
48314526|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
48314527|NCT04258059|DEVICE|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
48644133|NCT06622941|DRUG|ONO-4538|every 2 weeks
48644134|NCT03440190|DRUG|Methylphenidate|Patients are tested for their normal prescription methylphenidate medication
48115378|NCT04809090|DEVICE|App CA|An APP together a CA (Conversational Agent).
48314528|NCT04258059|DEVICE|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
48314529|NCT03860727|DIAGNOSTIC_TEST|Welch Allyn IExaminer|Fundus Examination
48115379|NCT04880434|DRUG|Fludarabine|Administered intravenously
48115380|NCT04880434|DRUG|Cyclophosphamide|Administered intravenously
48314530|NCT04543474|OTHER|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
48314531|NCT04543474|OTHER|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
48314532|NCT01043354|BEHAVIORAL|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
48314533|NCT01043354|BEHAVIORAL|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
48484577|NCT00692224|DRUG|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
48484578|NCT04528199|DRUG|[18F]FLOR (FC303) Injection|Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
48484579|NCT03744221|DIETARY_SUPPLEMENT|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
48484580|NCT03744221|DIETARY_SUPPLEMENT|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
48484581|NCT03744221|DIETARY_SUPPLEMENT|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
48484582|NCT03794791|BEHAVIORAL|education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
48484583|NCT03794791|BEHAVIORAL|no education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
48484584|NCT05558449|DEVICE|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
48115381|NCT04880434|BIOLOGICAL|Brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
48115382|NCT02462499|DRUG|Inspra (eplerenone)|
48484585|NCT05558449|DRUG|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
48484586|NCT05558449|DEVICE|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
48484587|NCT05601960|OTHER|anti-acne dermocosmetic|Topical application once daily for 2 months
48484588|NCT03570450|DRUG|Adipose derived Stem Cell|4 doses
48484589|NCT03570450|OTHER|placebo|placebo
48644135|NCT04277442|DRUG|Decitabine|Given IV
48644136|NCT04277442|BIOLOGICAL|Nivolumab|Given IV
48644137|NCT04277442|DRUG|Venetoclax|Given PO
48644138|NCT05358249|DRUG|JDQ443|KRAS G12C inhibitor, oral
48644139|NCT05358249|DRUG|trametinib|MEK inhibitor, oral
48644140|NCT05358249|DRUG|Ribociclib|CDK4/6 inhibitor, oral
48644141|NCT05358249|BIOLOGICAL|cetuximab|EGFR inhibitor, intravenous
48644142|NCT03822468|DRUG|Ribociclib|Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
48644143|NCT03822468|DRUG|Anastrozole|Anastrozole 1 mg tablets for oral use QD continuously
48644144|NCT03822468|DRUG|Letrozole|Letrozole 2.5 mg tablets for oral use QD continuously
48644145|NCT03822468|DRUG|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
48644146|NCT04803604|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
48644147|NCT06136884|DRUG|AO-252|AO-252 will be administered oral tablets or capsules daily
48115383|NCT05386498|PROCEDURE|precured composite insert technique|After curing of bonding agent a 2mm increment of composite will be placed on the gingival floor of the cavity and cured. a measured volume of composite(3mm height and 2mm width) will be cured outside the oral cavity on a flat plastic instrument for 40 seconds. a second increment of composite will be placed on the cavity and the precured composite will be pressed in the uncured increment and pressed outward against the matrix band and light cured for 20 seconds the rest of the cavity will be filled using the oblique layering technique.
48115384|NCT05386498|PROCEDURE|Contact making instrument|"a 1-2mm increment of the composite will be placed in the gingival floor of the proxial box.~a contact forming instrument will be placed in this uncured increment and an outward force will be applied using the instrument from the inside of the matrix band. The composite will then be cured for 20 seconds to achieve a tight contact."
48484590|NCT00591331|DRUG|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
47964927|NCT01500161|DRUG|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
47964928|NCT01500161|DRUG|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
48484591|NCT00591331|DRUG|placebo|
48484592|NCT04684524|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
48484593|NCT04684524|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
48484594|NCT00296491|DRUG|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
48484595|NCT00296491|DRUG|montelukast (MON)|montelukast capsule
48484596|NCT00296491|DRUG|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
48484597|NCT00296491|DRUG|placebo nasal|vehicle placebo nasal spray
48484598|NCT00296491|DRUG|ADVAIR DISKUS|ADVAIR DISKUS
48484599|NCT00296491|DRUG|placebo capsule|placebo capsule
48484600|NCT00296491|DRUG|placebo DISKUS|placebo DISKUS
48484601|NCT04273282|DRUG|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
48484602|NCT04273282|DRUG|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
48484603|NCT00347529|BIOLOGICAL|pPML7789 with and without pPJV2012 administered by PMED|
48484604|NCT02556307|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
48484605|NCT02556307|DRUG|Ribavirin|Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
48484606|NCT06208826|DRUG|Toripalimab|Toripamab, IV, 240mg, every 3 weeks for 15 cycles
48484607|NCT06208826|RADIATION|Radiation Therapy|Radiation Therapy
48484608|NCT06208826|DRUG|Cisplatin|Chemotherapy agent
48484609|NCT06454396|PROCEDURE|Endovascular therapy|Endovascular therapy is a minimally invasive interventional approach that utilizes the vascular system as a pathway to access and treat various pathological conditions within the body. By employing specialized catheters and devices, endovascular techniques enable precise delivery of therapeutic agents or interventional procedures directly to the target site, without the need for conventional open surgery.
48484610|NCT05393713|BIOLOGICAL|Anti-PD-L1 Monoclonal Antibody IMC-001|Given intra-lymphatically via DoseConnect device
48484611|NCT05393713|PROCEDURE|Punch Biopsy|Undergo punch biopsy
48484612|NCT06460441|DIAGNOSTIC_TEST|SUNRISE© device|"The device under study is the Sunrise© sensor, a single-use Class IIa medical device with CE marking and ISO 13485 certification.~The system combines a mandibular movement sensor with an artificial intelligence program to collect and interpret data. It consists of a three-gram device that is placed on the chin using an adhesive. The sensor is linked to a (free) mobile app, enabling data to be sent to the Sunrise© company's secured platform at the end of the night, and results to be transmitted to the prescribing physician."
48484613|NCT02707133|OTHER|No intervention|
48484614|NCT02760706|DEVICE|Computed Tomography scan|
48484615|NCT03262727|DRUG|BMS-986165|Oral administration of specified dose on specified days
48484616|NCT03262727|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
48115385|NCT05386498|PROCEDURE|Incremental composite layering technique|Increments will be placed in 1-2mm increments in oblique layering manner by a flat plastic instrument and condenser .Each increment will be cured for 20 seconds till the cavity is slightly overfilled.
48115386|NCT04563559|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.
48115387|NCT04563559|DRUG|Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]|The eye will be randomized to receive topical treatment with prednisolone acetate 1% on a tapering dose schedule
48115388|NCT01914913|BIOLOGICAL|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
48115389|NCT03233633|DRUG|Medical Marijuana|oral capsule, high ratio CBD:THC
48115390|NCT05068362|DEVICE|Auricular reconstruction|Medpor implant for treatment of microtia
48115391|NCT03410966|PROCEDURE|trans cateheter ablation|All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
48115392|NCT00012740|BEHAVIORAL|Casefinding and Referral System|
48115393|NCT04496362|DRUG|subcutaneous heparin anticoagulation|The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
48115394|NCT06347640|BIOLOGICAL|induced bleeding|revascularization of tooth is achieved by induced bleeding
48115395|NCT06347640|BIOLOGICAL|plasma rich fibrin|revascularization of tooth is achieved by plasma rich fibrin
48115396|NCT01689844|BEHAVIORAL|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
48115397|NCT01689844|BEHAVIORAL|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
48115398|NCT00316641|DRUG|Lipid-lowing Tea|
48115399|NCT06364696|DRUG|ASP4396|Intravenous (IV) infusion
48484617|NCT01560507|DRUG|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
48484618|NCT01560507|DRUG|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
48484619|NCT01560507|DRUG|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
48484620|NCT00969124|DEVICE|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
48484621|NCT05002686|DRUG|Sintilimab|200 mg Q3W on Day 1 by IV infusion
47964929|NCT01500161|DRUG|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
47964930|NCT01500161|DRUG|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
47964931|NCT01500161|DRUG|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
48115400|NCT04585412|DRUG|Palonosetron|Pharmacokinetic study under fasting conditions
48115401|NCT02997917|BEHAVIORAL|Education|
48115402|NCT02997917|BEHAVIORAL|Sham|
48115403|NCT05278871|DEVICE|Constructive Shearwave Interference (CSI)|handheld ultrasound
48115404|NCT05861063|DEVICE|Fractional CO2 laser|All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment
47964932|NCT01500161|DRUG|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
48314534|NCT01043354|BEHAVIORAL|attention placebo intervention|6 monthly counseling sessions about general health topics
47964933|NCT01500161|DRUG|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
47964934|NCT05465434|DRUG|Zinc Supplement|Zinc sulphate 50 mg
47964935|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation A
48484622|NCT05002686|DRUG|Albumin-Paclitaxel|200 mg/m\^2 Q3W on Day 1 by IV infusion
48484623|NCT05002686|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
47964936|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
48115405|NCT05861063|DRUG|Dezocine|Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)
48115406|NCT04134143|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
48115407|NCT05216510|BIOLOGICAL|TNX-2110|TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
48115408|NCT05216510|BIOLOGICAL|TNX-2120|TNX-2120 represents the spike protein and is administered intradermally.
48115409|NCT05216510|BIOLOGICAL|TNX-2130|TNX-2130 represents non-spike proteins and is administered intradermally.
48314535|NCT04232891|DIAGNOSTIC_TEST|liquid biopsy|detection of tumor DNA alteration in cf-DNA
48484624|NCT05002686|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
48314536|NCT01600183|DEVICE|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
48314537|NCT01600183|PROCEDURE|cast|casting of the infant legs
48314538|NCT03235570|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
48314539|NCT00074412|DRUG|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
48314540|NCT00074412|DRUG|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
48314541|NCT05056454|BEHAVIORAL|Online therapy with coaching within STAND|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or UCLA DGC's ParentMood course. The efficacy of each online course will be compared for equivalency.~Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
48314542|NCT05056454|BEHAVIORAL|Clinical care within STAND|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider.
48314543|NCT05056454|OTHER|Perinatal Psychiatric Care|Perinatal psychiatric care involves medication management and supportive therapy for up to six months, with referrals to relevant community resources by the final visit.
48314544|NCT00297362|DRUG|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
48314545|NCT00382980|BIOLOGICAL|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
48115410|NCT05216510|BIOLOGICAL|CANDIN|Candida albicans antigens to be administered intradermally as a positive control.
48314546|NCT00382980|BIOLOGICAL|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
48314547|NCT00382980|DRUG|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
48314548|NCT00219843|DRUG|PV-10 (rose bengal disodium, 10%)|
48314549|NCT00200252|DRUG|oxytocin|
48314550|NCT05213468|DEVICE|PainDrainerTM|Self management digital tool for chronic pain
48314551|NCT03545724|DEVICE|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
48314552|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
48314553|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
48314554|NCT04671316|DRUG|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
48314555|NCT01560728|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
48314556|NCT02817152|PROCEDURE|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
48314557|NCT02817152|DEVICE|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
48314558|NCT00088582|DRUG|Pasireotide (SOM230), Octreotide (Sandostatin)|
48314559|NCT00995345|DRUG|KRP-104|Tablet
48314560|NCT00995345|DRUG|Placebo|Tablet
48314561|NCT04894006|BEHAVIORAL|Community Health Worker (CHW) Home Visit Intervention|The on-site intervention will focus on stress reduction techniques and caregiving skills education for 4 weeks and two monthly caregiver-driven topics for the following two sessions. The education of dementia caregiving skills will include (1) understanding about Alzheimer's and dementias, (2) appropriate communication skills with PWD, (3) daily activities for or with PWD together (e.g., puzzles, writing, reading, singing, taking a walk, etc), and (4) care resources including support groups, adult day centers, or other dementia related social services (legal and financial matters). For stress reduction techniques to be effective, the investigators have installed an app on the smartwatch to remind them to practice mindful breathing exercises two times a day and when needed.
48314562|NCT04894006|BEHAVIORAL|Attention Control Group with WIoT Technology|The caregivers randomly assigned to the AC group will be asked to wear the smartwatch during the day time and the smartring during the night for 3 months in order to monitor their physiological measures (heart rate variability, heart rate, activities, and sleep quality). CHW will give AC participants an overview of WIOT instruction at the baseline home visit. Caregivers will also receive resource information regarding Alzheimer's association and local social service information. CHWs will contact them monthly via phone for 6 months answering general questions from participants. CHW will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
48314563|NCT04894006|BEHAVIORAL|Usual Care|The caregivers randomly assigned to UC group will receive resource information regarding Alzheimer's association and local social service information at the baseline home visit by CHW. CHWs will contact them monthly for 6 months by phone asking general questions from participants. CHWs will visit participants' home at baseline, 3 months, and 6 months to administer survey assessments.
48314564|NCT02630082|PROCEDURE|Circumcision|
48484625|NCT05002686|RADIATION|Radiation|Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy\*25.
48484626|NCT05002686|PROCEDURE|Radical gastric cancer surgery|Radical gastric cancer surgery with D2 lymph node dissection
48484627|NCT04216615|BEHAVIORAL|preoperative anxiety|patients who are anxious
47964937|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
48314565|NCT02630082|PROCEDURE|Flexible sigmoidoscopy|
48484628|NCT04507594|PROCEDURE|Lung lobectomy OR esophagus cancer resection|Lunge lobectomy (total) Resection of esophagus cancer
48484629|NCT04828798|DEVICE|Deep brain stimulation of the VIM Thalamic nuclei|Deep brain stimulation of the thalamus, in a directional and nondirectional manner
48115411|NCT05216510|BIOLOGICAL|Diluent|Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
48314566|NCT05909254|OTHER|Palatally impacted canine exposure using a surgical guide|Under local anaesthesia the tissues covering the palatally impacted canine are removed with the help of a surgical guide to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction.
47964938|NCT00720538|DRUG|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
48314567|NCT05909254|OTHER|Palatally impacted canine exposure using the conventional free.hand method|Under local anaesthesia the tissues covering the palatally impacted canine are removed to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction. The surgeon relies on the surgical plan and their experience to localize the impacted canine.
48314568|NCT02036593|BEHAVIORAL|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
48484630|NCT05396664|BEHAVIORAL|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
48484631|NCT03201211|BIOLOGICAL|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
48484632|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
48484633|NCT03201211|BIOLOGICAL|GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
48484634|NCT03201211|DRUG|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
48484635|NCT03657108|RADIATION|Civasheet 60 Gy|implantable proposed doses of Civasheet are 60 Gy
48484636|NCT03657108|RADIATION|Civasheet 75 Gy|implantable proposed doses of Civasheet are 75 Gy
48484637|NCT03657108|RADIATION|Adjuvant external beam radiation therapy|45 Gy in 25 fractions
48484638|NCT00362830|DRUG|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
48484639|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Quadriceps Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using only the tendon portion of the quadriceps tendon (without bone fragments) in this group.
48484640|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Hamstring Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using the hamstring tendon as a graft in this group.
48484641|NCT02490306|DEVICE|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
48484642|NCT03352895|DIETARY_SUPPLEMENT|resveratrol|Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
48484643|NCT03352895|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
48484644|NCT01932099|DEVICE|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
48484645|NCT01471899|DRUG|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
48484646|NCT01471899|DRUG|Naproxen|2 tablets every 8 hours for 4 days
48484647|NCT00365287|DRUG|anti-thymocyte globulin|
48484648|NCT00365287|DRUG|cyclophosphamide|
48484649|NCT00365287|DRUG|cyclosporine|
48484650|NCT00365287|DRUG|fludarabine phosphate|
48484651|NCT00365287|DRUG|mycophenolate mofetil|
47964939|NCT00720538|DRUG|placebo|placebo capsules
48484652|NCT00365287|PROCEDURE|radiation therapy|
48484653|NCT00365287|PROCEDURE|umbilical cord blood transplantation|
48484654|NCT01872052|DEVICE|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
48484655|NCT01065116|DRUG|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
48484656|NCT01065116|DRUG|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
48484657|NCT01631526|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
47964940|NCT02746796|DRUG|ONO-4538|
47964941|NCT02746796|DRUG|Oxaliplatin|
47964942|NCT02746796|DRUG|Tegafur- Gimeracil-Oteracil potassium|
47964943|NCT02746796|DRUG|Capecitabine|
47964944|NCT02746796|DRUG|Placebo|
48314569|NCT02772965|DRUG|Methotrexate|"1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
48484658|NCT05568979|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
48115412|NCT00869258|DRUG|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
48115413|NCT00869258|RADIATION|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
48115414|NCT03181763|DRUG|Placebo|Placebo given day after startle assessment
48115415|NCT03181763|DRUG|Midomafetamine|Participant will receive 100 mg MDMA one day after startle assessment
48115416|NCT03181763|BEHAVIORAL|Acoustic startle|Startle assessment
48115417|NCT05636332|DIAGNOSTIC_TEST|12 lead Electrocardiogram|12 lead Electrocardiogram
48484659|NCT05568979|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
48484660|NCT01404117|DRUG|Laquinimod 0.6|Laquinimod 0.6 capsule
47964945|NCT00259649|DRUG|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
47964946|NCT00758836|DRUG|placebo|
47964947|NCT00758836|DRUG|ibuprofen|
47964948|NCT00758836|DRUG|acetominophen|
47964949|NCT00758836|DRUG|telcagepant|
47964950|NCT05204238|DIAGNOSTIC_TEST|Transthoracic Echocardiography|LV dimensions, LV mass and indices of LV function LA area and volume Indices of diastolic function (E/A ratio, E/e' ratio) Heart valve assessment according to GL RV dimensions and indices of RV function PAPs (RV-RA gradient and vena cava dimensions and collapsibility) B-lines at lung ultrasounds (comet lung score) Speckle Tracking analysis of LV (GLS), LA (PALS) and RV (LS of free wall) Optional 3D analysis of left and right ventricle
47964951|NCT02510196|BEHAVIORAL|reminder|
47964952|NCT01695590|DRUG|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
48115418|NCT03184623|OTHER|muscle mass measurement|measurement of muscle mass by echocardiography
48115419|NCT01100125|DRUG|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
48115420|NCT01100125|DRUG|insulin dose increase|insulin dose increase
48314570|NCT02772965|OTHER|Sugar pill (placebo)|"1. Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~2. Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
48484661|NCT01404117|DRUG|Laquinimod 1.2|Placebo
48484662|NCT01404117|OTHER|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
48484663|NCT04523324|BIOLOGICAL|Flublok™ Quadrivalent by Sanofi, Inc.|0.5 mL intramuscular dose of Flublok
48484664|NCT04523324|BIOLOGICAL|VaxigripTetra™ by Sanofi, Inc.|0.5 mL intramuscular dose of Vaxigrip
48644148|NCT04870554|BEHAVIORAL|Enteric feeding|All subjects will be given nutrition enterally, corresponding to their calculated nutritional needs.
48644149|NCT05544396|OTHER|probiotic|probiotic group give probiotics (2 packs per day) for 6 months.
48644150|NCT04521361|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
47964953|NCT02598544|OTHER|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
47964954|NCT01341145|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
47964955|NCT01341145|BEHAVIORAL|Relaxation|12-week progressive muscle relaxation program (active control)
47964956|NCT04600128|OTHER|Dairy-based greek yogurt|Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
47964957|NCT04600128|OTHER|Dairy-based cheddar cheese|Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
47964958|NCT04600128|OTHER|Plant-based yogurt|Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
47964959|NCT04600128|OTHER|Plant-based cheese|Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
47964960|NCT01437462|DRUG|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
47964961|NCT01437462|DRUG|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
48115421|NCT03185338|BEHAVIORAL|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
48115422|NCT03185338|BEHAVIORAL|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
48115423|NCT03185338|BEHAVIORAL|Active school recess|Teachers will design games and activities and will encourage children for being active
48644151|NCT05911295|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks
47964962|NCT01581645|DEVICE|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
47964963|NCT04186728|DIETARY_SUPPLEMENT|Magnesium glycinate|Daily magnesium capsule.
47964964|NCT04186728|OTHER|Placebo|Daily placebo capsule.
47964965|NCT04961931|DRUG|Empagliflozin 10 MG|After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.
47964966|NCT02616406|DEVICE|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
47964967|NCT00033020|BEHAVIORAL|Behavior Therapy|
48484665|NCT05686148|OTHER|Vibration|The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
47964968|NCT04219657|BIOLOGICAL|mesenchymal stem cell application|
47964969|NCT03708016|DEVICE|Robot gait training|Lokomat robot training was applied to stroke patients.
47964970|NCT03708016|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
47964971|NCT01964430|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
48314571|NCT03480282|OTHER|Prognosis information and Provider Scripts|An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
48314572|NCT01794494|PROCEDURE|Bypass surgery|Patients are treated with femoro-popliteal bypass
48314573|NCT01794494|PROCEDURE|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
48314574|NCT02198287|DRUG|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
48314575|NCT02198287|DRUG|Placebo|
48314576|NCT04002154|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
48644152|NCT05911295|DRUG|pembrolizumab|400mg given by IV every 6 weeks
48644153|NCT05911295|DRUG|gemcitabine|1000 mg/m\^2 given by IV on days 1 and 8 of every 3-week cycle
48644154|NCT05911295|DRUG|cisplatin|70 mg\^2 given by IV on day 1 of every 3-week cycle
47964972|NCT01964430|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
47964973|NCT01244269|DRUG|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
47964974|NCT01244269|DRUG|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
47964975|NCT01244269|DRUG|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
47964976|NCT01244269|DRUG|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
47964977|NCT05663190|OTHER|mental foramen location|location of mental foramen in relation to primary molars
47964978|NCT01540838|DRUG|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
48644155|NCT05911295|DRUG|carboplatin|Area under the plasma concentration-time curve (AUC) 4.5 or 5 given by IV on day 1 of every 3-week cycle
48644156|NCT05827081|DRUG|Ribociclib|Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
48644157|NCT05827081|DRUG|Letrozole|Letrozole 2.5 mg orally once daily continuously
48644158|NCT05827081|DRUG|Ansastrozole|Anastrozole 1 mg orally once daily continuously.
48314577|NCT00527215|DRUG|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
48644159|NCT05827081|DRUG|Goserelin|Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
48644160|NCT05827081|DRUG|Leuprolide|Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
47964979|NCT01540838|DRUG|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
48115424|NCT03185338|BEHAVIORAL|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
48115425|NCT03185338|BEHAVIORAL|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
47964980|NCT01783262|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
48115426|NCT03958734|OTHER|High-fat meal|Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
48115427|NCT00232349|DRUG|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
48115428|NCT03950869|BEHAVIORAL|Positive Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
47964981|NCT01783262|DEVICE|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
48115429|NCT03950869|BEHAVIORAL|Negative Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
48644161|NCT05827081|DRUG|Exemestane|Exemestane 25 mg once daily continuously
47964982|NCT00250302|PROCEDURE|autologous mesenchymal stem cells implantation|
48115430|NCT00401206|DRUG|dexmedetomidine|
48115431|NCT05846841|BEHAVIORAL|Precision Treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.
48115432|NCT05846841|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
48115433|NCT04801563|OTHER|MDS and AlloHSCT|Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells
48115434|NCT04712851|BIOLOGICAL|Pembrolizumab|Given IV
48314578|NCT02003560|RADIATION|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
48314579|NCT03917719|DRUG|Edasalonexent|100 mg/kg/day
48314580|NCT04405505|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48314581|NCT04405505|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
48314582|NCT04405505|DRUG|Paclitaxel for Injection (albumin bound)|a anti-microtubule drug.
48644162|NCT06175065|DRUG|RLS-0071|RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.
48644163|NCT06175065|DRUG|Placebo|Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
48644164|NCT06528093|DRUG|BI 765883|BI 765883
47964983|NCT01322269|DRUG|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
47964984|NCT04289662|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
47964985|NCT04289662|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
47964986|NCT01893632|DRUG|gabapentin|
47964987|NCT01893632|DRUG|Placebo|
47964988|NCT05229406|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
47964989|NCT01948297|DRUG|Debio1347 (CH5183284)|Debio1347 (CH5183284) tablets for oral administration
47964990|NCT06258941|BEHAVIORAL|MF-HIIT|Two 10-min MF-HIIT sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
48115435|NCT03394976|DIAGNOSTIC_TEST|No intervention|No intervention
48115436|NCT06644430|PROCEDURE|Ablation|Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.
48115437|NCT06644430|DRUG|system therapy|Paticipants received systemic therapy according the instructions.
48115438|NCT04959136|DEVICE|Ambulatory Monitoring Solution|Aim is to evaluate PR; RR; NIBP, cNIBP, SpO2 and arterial blood pressure with investigational Ambulatory Monitoring Solution (AMS)
48115439|NCT01438086|DRUG|mecasermin|Intracoronary bolus
48314583|NCT03909191|DIAGNOSTIC_TEST|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
48644165|NCT06528093|DRUG|gemcitabine|gemcitabine
48644166|NCT06528093|DRUG|nab-paclitaxel|nab-paclitaxel
48644167|NCT04850118|BIOLOGICAL|rAAV2tYF-GRK1-hRPGRco|Adeno-associated virus vector expressing a human RPGR gene
48644168|NCT04850118|DRUG|Control|Untreated Control Group 3
48115440|NCT01438086|DRUG|mecasermin|Intracoronary bolus
48115441|NCT01438086|DRUG|0.9% sodium chloride injection|Intracoronary bolus
48314584|NCT00696111|DRUG|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
48314585|NCT00696111|DRUG|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
48314586|NCT00696111|DEVICE|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
48314587|NCT02786589|BIOLOGICAL|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
48314588|NCT04424355|DIAGNOSTIC_TEST|Chest MRI|Patients referred by the primary care physician with suspected pneumonia
48314589|NCT04720586|PROCEDURE|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
48314590|NCT04720586|PROCEDURE|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
48484666|NCT03196674|OTHER|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
48484667|NCT00484419|DRUG|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
48484668|NCT00484419|DRUG|rosiglitazone maleate|rosiglitazone tablets 4mg
48484669|NCT00484419|DRUG|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
48484670|NCT03362996|DIETARY_SUPPLEMENT|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
48484671|NCT03362996|COMBINATION_PRODUCT|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
48484672|NCT03362996|OTHER|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
48484673|NCT05730504|OTHER|Mobile app-based self-guided interventions|self-guided, app-based mobile psychological interventions based on CBT, meditation, mindfulness, journaling, and audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
48484674|NCT02458092|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
48484675|NCT02458092|BIOLOGICAL|Rabipur|Rabipur is a licensed rabies vaccine.
48115442|NCT06154239|DEVICE|DAYE Diagnostic Tampon|The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.
48115443|NCT06154239|DIAGNOSTIC_TEST|Vaginal self-swab|A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.
48484676|NCT02217696|OTHER|Computerized reading training|
48484677|NCT03750656|DRUG|Hyoscyamine|Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
48484678|NCT03750656|DRUG|Tamsulosin|Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
48484679|NCT04470531|DRUG|oral co-trimoxazole|oral co-trimoxazole + standard therapy
48484680|NCT00002869|BIOLOGICAL|recombinant interferon alfa|
48484681|NCT00002869|DRUG|cytarabine|
48115444|NCT06154239|DIAGNOSTIC_TEST|Clinician vaginal swab|A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.
48115445|NCT05978037|BIOLOGICAL|RH5.1 and/or RH5.2-VLP with Matrix-M|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial."
48115446|NCT01697969|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
48314591|NCT05837078|PROCEDURE|ridge splitting with implant placement|ridge splitting of mandibular denture followed by two implant placement
48314592|NCT02067091|DEVICE|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention"
48314593|NCT05233449|DEVICE|NoL monitor|NoL monitor : non invasive, adhesive digital device
48484682|NCT00002869|DRUG|hydroxyurea|
48484683|NCT03651726|DRUG|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
48484684|NCT03651726|DRUG|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
48484685|NCT04305379|PROCEDURE|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
48484686|NCT04305379|PROCEDURE|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
48115447|NCT05905172|DRUG|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.
48115448|NCT05905172|DRUG|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
48314594|NCT05233449|PROCEDURE|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
48115449|NCT04186546|DEVICE|Zephyr Valve Procedure|The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
48484687|NCT02855619|PROCEDURE|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
48644169|NCT06658067|DEVICE|Continuous Glucose Monitor (CGM)|The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.
48644170|NCT04779736|BEHAVIORAL|A set of implementation strategies to reduce sexual stigma|The intervention will be finalized based on formative interviews and consultation with an advisory board. It is likely to include an educational mHealth component followed by an in-person workshop for skills development, then supportive coaching components (i.e., coaching calls and an optional email listserve) to encourage and respond to the implementation of recommended practices.
47964991|NCT06258941|BEHAVIORAL|HIIT-only|Two 10-min HIIT-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
47964992|NCT06258941|BEHAVIORAL|MF-only|Two 10-min MF-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
47964993|NCT06258941|BEHAVIORAL|Sedentary activity|Two 10-min sedentary sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
47964994|NCT05179798|DEVICE|mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
47964995|NCT05909644|DRUG|Omaveloxolone|Omaveloxolone Capsules, 150 mg, administered orally
48115450|NCT05473260|OTHER|Control|In-patient care.
48115451|NCT05473260|OTHER|Experimental|Early discharge and outpatient follow-up.
48644171|NCT04418505|DEVICE|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
48644172|NCT05156203|DRUG|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
47964996|NCT05909644|DRUG|Efavirenz|Efavirenz Tablet, 600 mg, administered orally once daily
47964997|NCT04165200|DIAGNOSTIC_TEST|Blood and feces samples|"Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART."
47964998|NCT05593926|DIETARY_SUPPLEMENT|Myota Metabolic Regulator|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
47964999|NCT00418457|DRUG|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
47965000|NCT00418457|DRUG|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
47965001|NCT04563702|BIOLOGICAL|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
47965002|NCT00927602|DRUG|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
48115452|NCT05643560|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice.
48115453|NCT01304849|DRUG|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
48115454|NCT04735341|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
48314595|NCT00136773|DRUG|amlodipine/benazepril|
48314596|NCT05591599|DIAGNOSTIC_TEST|calponin 2|serum calponin 2 level
48314597|NCT04202861|DIAGNOSTIC_TEST|In vitro antibiotic combination testing (iACT)|CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
48314598|NCT04861480|BIOLOGICAL|C-4-29 Cells|Drug: C-4-29 Cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
48314599|NCT01908621|DRUG|G-CSF (filgrastim)|
48314600|NCT01908621|DRUG|Cytosine arabinoside + G-CSF (filgrastim)|
48314601|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
48314602|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
48314603|NCT00782418|DRUG|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
48484688|NCT02855619|PROCEDURE|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
47965003|NCT04534361|OTHER|CBCT measurements|No intervention will be performed on patients for this study. Based on the CBCTs already done previously of the patients in the sample, linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest in the CBCTs taken before and after implant explantation, 4-6 months apart.
47965004|NCT04911881|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
47965005|NCT04639375|BIOLOGICAL|Vaccinated with polio vaccine (IPV)|poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
47965006|NCT04720469|DEVICE|MRgFUS thalamotomy|Ablation of untreated thalamus using focused ultrasound to abate tremor.
48314604|NCT04461405|BEHAVIORAL|INTEGRATE-D|INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
48314605|NCT00475462|DRUG|metoprolol|
48314606|NCT00475462|DRUG|conventional treatment|
48314607|NCT04774042|DIETARY_SUPPLEMENT|Infloran probiotic|Infloran
48314608|NCT04774042|DIETARY_SUPPLEMENT|HAC probiotic|HAc probiotic
48314609|NCT04774042|DIETARY_SUPPLEMENT|Infloran placebo|Infloran placebo
48314610|NCT04774042|DIETARY_SUPPLEMENT|HAC placebo|HAC placebo
48644173|NCT00674843|RADIATION|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
47965007|NCT02476383|PROCEDURE|spinal manipulative therapy|refer to arm descriptions
47965008|NCT06022939|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Given IV
47965009|NCT06022939|PROCEDURE|Biopsy|Undergo fat pad biopsy
47965010|NCT06022939|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
47965011|NCT06022939|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
47965012|NCT06022939|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48314611|NCT02317406|DRUG|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
48314612|NCT02317406|DRUG|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
48314613|NCT01554540|DRUG|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
48644174|NCT06689488|DEVICE|Ablation|Bronchoscopy and microwave ablation prior to surgical resection.
47965013|NCT06022939|DRUG|Bortezomib|Given SC
47965014|NCT06022939|PROCEDURE|Computed Tomography|Undergo CT scan
47965015|NCT06022939|DRUG|Cyclophosphamide|Given PO or IV
47965016|NCT06022939|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
48644175|NCT02819518|BIOLOGICAL|Pembrolizumab|IV infusion
48644176|NCT02819518|DRUG|Nab-paclitaxel|IV infusion
48644177|NCT02819518|DRUG|Paclitaxel|IV infusion
48644178|NCT02819518|DRUG|Gemcitabine|IV infusion
48644179|NCT02819518|DRUG|Carboplatin|IV infusion
48644180|NCT02819518|DRUG|Normale Saline Solution|IV infusion
48644181|NCT05904548|DEVICE|RF Ablation|RF ablation for type I atrial flutter under iCMR guidance
48644182|NCT06143891|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:oral
48644183|NCT06143891|DRUG|Placebo|Pharmaceutical form:Table-Route of administration:oral
47965017|NCT06022939|DRUG|Dexamethasone|Given PO or IV
47965018|NCT06022939|PROCEDURE|Echocardiography|Undergo echocardiography
47965019|NCT06022939|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47965020|NCT06022939|DRUG|Melphalan|Given IV
47965021|NCT06022939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
47965022|NCT06022939|PROCEDURE|Stem Cell Isolation|Undergo stem cell collection
48115455|NCT05468411|OTHER|Oral application of miracle fruit pill|Miracle fruit has a taste modifying function from sourness to sweetness when it is exposed to an acidic environment. To activate the miracle fruit's function, a miracle fruit pill should be orally administered to coat taste buds prior to eating sour food. Thus, participants are instructed to place a miracle fruit pill is on their tongue, and roll the pill around their mouth to allow full contact of the pill with the surface of the oral cavity without chewing until the pill completely dissolved. A miracle fruit pill is administered prior to eating.
48314614|NCT04915677|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
48314615|NCT04915677|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
48644184|NCT06143891|DRUG|Prednisone|Pharmaceutical form:Tablet-Route of administration:oral
48644185|NCT06143891|DRUG|Prednisolone|Pharmaceutical form:Tablet-Route of administration:oral
48644186|NCT06006468|GENETIC|High genetic risk for type 1 diabetes|in individuals without diabetes comparison of prevalence of islet auto antibodies between individuals at high genetic risk of type 1 diabetes versus controls
47965023|NCT06022939|OTHER|Survey Administration|Ancillary study
47965024|NCT01408446|DRUG|Menthol|Capsule 48mg three times a day after meals 8 weeks
47965025|NCT01408446|DRUG|Placebo|Capsule 48mg three times a day after meals 8 weeks
47965026|NCT04967144|DIAGNOSTIC_TEST|Nerve conduction study|"Participants with carpal tunnel syndrome will consist of individuals whose diagnosis has been confirmed by an electrophysiological study.~Participants in the control group will consist of those who have been confirmed not to have carpal tunnel syndrome by nerve conduction study."
48644187|NCT06006468|GENETIC|High gentic risk for Coeliac disease|in individuals without Coeliac disease comparison of prevalence of anti tissue transglutaminase antibodies between individuals at high genetic risk of coeliac disease versus controls
48644188|NCT03228043|DRUG|Apatinib|Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
48644189|NCT03228043|DRUG|CAPEOX|CAPEOX adjuvant chemotherapy for resectable colorectal
48644190|NCT06192160|DRUG|Isoniazid|INH 300 mg will be administered as one tablet orally once daily.
48644191|NCT06192160|DRUG|Rifampicin|RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
48644192|NCT06192160|DRUG|Pyrazinamide|PZA will be administered as 500 mg tablets, based on weight, orally once daily.
47965027|NCT04967144|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Test|Montreal Cognitive Assessment Test evaluates eight separate cognitive functions. Thirty is the highest score. The scores equal to or above 26 are considered normal cognitive function.
47965028|NCT05772000|DIAGNOSTIC_TEST|cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry
47965029|NCT00714181|DRUG|hydroxychloroquine|
47965030|NCT00714181|DRUG|temozolomide|
47965031|NCT00714181|GENETIC|TdT-mediated dUTP nick end labeling assay|
47965032|NCT00714181|GENETIC|western blotting|
47965033|NCT00714181|OTHER|electron microscopy|
47965034|NCT00714181|OTHER|high performance liquid chromatography|
47965035|NCT00714181|OTHER|immunoenzyme technique|
47965036|NCT00714181|OTHER|immunohistochemistry staining method|
47965037|NCT00714181|OTHER|laboratory biomarker analysis|
47965038|NCT00714181|OTHER|mass spectrometry|
47965039|NCT00714181|OTHER|pharmacological study|
48644193|NCT06192160|DRUG|Ethambutol|EMB will be administered as 400 mg tablets, based on weight, orally once daily.
48644194|NCT06192160|DRUG|Bedaquiline|BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
48644195|NCT06192160|DRUG|Pretomanid|Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
48644196|NCT06192160|DRUG|Linezolid|LZD 600 mg will be administered as one 600 mg tablet orally once daily.
48644197|NCT06192160|DRUG|TBI-223|TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
48644198|NCT06192160|DRUG|Sutezolid|SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
48644199|NCT06192160|DRUG|TBI-223|TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
48644200|NCT06192160|DRUG|Sutezolid|SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
48314616|NCT01301560|RADIATION|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
48484689|NCT02855619|PROCEDURE|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
48484690|NCT02866240|DEVICE|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
47965040|NCT04978961|BEHAVIORAL|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
47965041|NCT04978961|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
47965042|NCT00375648|DRUG|Zoledronic acid|
47965043|NCT05607901|DRUG|Tacrolimus ointment|tacrolimus is an immunosuppressive drug acting as an immunomodulator to assist manage acute flares and reducing the severity of future flares
47965044|NCT05607901|DRUG|Hydrocortisone 1% cream|Topical corticosteroids (TCS) are the cornerstone for the management of AD to which other treatments are compared.
47965045|NCT06004999|OTHER|Whole body vibration|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program on the vibration platform will be applied to the 1st group.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
47965046|NCT06004999|OTHER|The exercise program on flat ground without a vibration platform|"All patients will be pedaling for 5 minutes, followed by a warm-up phase with 5 minutes of stretching for the hamstring, gastrocnemius, soleus, and quadriceps muscles.~Afterward, the following exercise program will be applied to the group.~The exercise program will be applied to the 2nd group (controls) on flat ground without a vibration platform.~* Lunge,~* Squat,~* Deep squat,~* Wide stance squat,~* Calves,~* Deep calves. The exercise time will be 6 minutes in the first week, and the exercise time will be increased in the following weeks, and the total exercise time will continue at 18 minutes in the last week."
47965047|NCT05825469|BEHAVIORAL|Nutrition Algorithm|A technology-based platform for a person-centered nutrition program, providing suggested foods and recipes from dietitians.
47965048|NCT00358852|OTHER|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
47965049|NCT05970185|DRUG|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
47965050|NCT05970185|DRUG|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
47965051|NCT04883931|DRUG|Normal Saline|0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
48484691|NCT02940678|OTHER|No intervention|
48484692|NCT02036450|DEVICE|Implantable loop recorder (Medtronic Reveal LINQ(TM))|The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
47965052|NCT04883931|BIOLOGICAL|Breast milk|0.5 ml breast milk from all infant's own mother will drop both eyes twice in a day
47965053|NCT04490850|PROCEDURE|Blood sample|Blood sample
47965054|NCT00109083|DRUG|RWJ-333369|
47965055|NCT01849198|DEVICE|accelerometry m. trapezius and m. adductor pollicis|
47965056|NCT04598230|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
47965057|NCT04598230|DRUG|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
47965058|NCT06373796|DEVICE|Echographic scan|Liver ultrasound exam
47965059|NCT00230204|PROCEDURE|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
48314617|NCT01301560|RADIATION|Observation|No local treatment
48314618|NCT03342482|OTHER|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
48314619|NCT04510350|OTHER|Biomarkers analysis|Genetic analysis of regions of interest
48644201|NCT03503799|OTHER|Observation|"Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy~Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival~Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone.~Status of Menopause Disease status Anti-tumor therapy Survival~Treatment after end of the study The patient will be treated during and after end of study by physician's choice."
48115456|NCT05468411|OTHER|Oral application of sugar candy|To simulate the miracle fruit's function as a placebo, a chewable sugar candy that has a similar appearance to miracle fruit pill is orally administered. The same protocol that is used in miracle fruit intervention is followed in this placebo intervention but with a chewable sugar candy. Participants are instructed to place a sugar candy is on their tongue, and roll the candy around their mouth to allow full contact of the candy with the surface of the oral cavity without chewing until the candy completely dissolved. A sugar candy is administered prior to eating.
48115457|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
48115458|NCT03768310|BIOLOGICAL|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
48115459|NCT04930718|OTHER|Thumb active Exercises|Active específico exercises; Reeducation program
48115460|NCT05200572|BEHAVIORAL|Dyadic Life Review (DLR)|DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
48115461|NCT03802318|DRUG|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
48115462|NCT02108106|DRUG|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
48115463|NCT02108106|DRUG|Placebo|
48115464|NCT06509841|OTHER|conventional rehabilitation treatment|Adopting conventional rehabilitation training methods for TSCI patients, including: ① posture training; ② Joint rehabilitation training; ③ Breathing training; ④ Muscle strength training, 7 times a week, with continuous treatment for 4 weeks.
48115465|NCT06509841|OTHER|Acupuncture treatment rehabilitation|Routine rehabilitation treatment combined with acupuncture and moxibustion treatment, the acupuncture measures taken are mainly Dumai points. Once a day. 5 times a week, continuous treatment for 4 weeks.
48314620|NCT02582580|OTHER|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
48484693|NCT04909541|OTHER|CEGSSS-Canadian Endourology Group Stent Symptom Score|Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
48484694|NCT00755768|BEHAVIORAL|additional review by dietician|
48484695|NCT05418075|OTHER|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
48484696|NCT03894241|BEHAVIORAL|physical activity|"Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)"
48484697|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
48644202|NCT05869604|BEHAVIORAL|HEALTHY AYA|8-session health lifestyle behavior intervention combining behavioral symptom management strategies with strategies to improve diet and increase physical activity.
48484698|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
48484699|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
48484700|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
48644203|NCT05869604|OTHER|Education Control|Participants will receive paper materials on topics of relevance to adolescent and young adult cancer survivors.
48115466|NCT04307407|BEHAVIORAL|Aerobic Exercise|Participants will be randomized to supervised aerobic exercise or standard care. Women with no current or past malignant disease will comprise the reference group and will be matched for age to participants in the Aerobic Exercise arm
48115467|NCT06182397|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|All patients must first be treated with pre dilatation with a standard balloon angioplasty using any standard balloon catheters at the discretion of the operator. Magic Touch PTA Sirolimus coated balloon catheter is an adjunct treatment that should be used in combination with standard balloon angioplasty. Following successful crossing of wire across the lesion and plain balloon angioplasty of arterial lesion with successful lesion preparation with residual lesion \<30%, subjects will be randomized to receive study device balloon. If patients are assigned to MagicTouch PTA Sirolimus DCB, the Angioplasty of lower limb will be performed with this device in addition to standard balloon angioplasty.
47965060|NCT02614092|BEHAVIORAL|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
47965061|NCT03423641|DRUG|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
48115468|NCT06182397|DEVICE|Placebo balloon angioplasty|For participants randomized to a Placebo balloon angioplasty group, a Placebo balloon angioplasty in addition to standard balloon angioplasty will be performed.
48115469|NCT05985512|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia is the main therapy for the patients. Medications include sedative-hypnotics and antidepressants with a sedative effect.
48484701|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
48484702|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
48644204|NCT03884920|DIETARY_SUPPLEMENT|Polyherbal formulation|Test candidate will be administered per oral before / with meal in two divided doses
48644205|NCT05541276|DRUG|Melatonin|Melatonin for injection 1 mg/mL
48644206|NCT05541276|DRUG|Isotonic sodium chloride solution|Sodium chloride 0.9 % for injection
48644207|NCT03844815|DRUG|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
48115470|NCT04529278|DRUG|Liraglutide|"Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26."
48115471|NCT06547151|DRUG|AMOR-1|Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).
48115472|NCT06547151|DRUG|Crystalline Calcium Carbonate|Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
48115473|NCT01624844|OTHER|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
48115474|NCT05433935|OTHER|Observation|This is an observational study.
48115475|NCT03494881|DRUG|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
48484703|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
48484704|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
48484705|NCT06310265|OTHER|Retrospective observational study|Our study includes child earthquake victims, regardless of gender, between the ages of 0-18, who applied to our clinic within six months after the February 6, 2023 earthquake and underwent surgery.
48484706|NCT01218984|DRUG|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
48484707|NCT01218984|DRUG|Medisorb naltrexone 150 mg|Single administration via IM injection.
48484708|NCT01218984|DRUG|Medisorb naltrexone 300 mg|Single administration via IM injection.
48644208|NCT03844815|DRUG|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
48644209|NCT04562090|DRUG|mirabegron|Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
47965062|NCT02687997|OTHER|poligraphy|Sleep study
47965063|NCT01957930|DRUG|Intensified insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
47965064|NCT01957930|DRUG|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
47965065|NCT01710969|BEHAVIORAL|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
47965066|NCT01710969|BEHAVIORAL|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
48644210|NCT01460537|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
48644211|NCT01460537|DRUG|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
47965067|NCT03730571|DEVICE|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
47965068|NCT05866900|DEVICE|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
47965069|NCT00006426|PROCEDURE|Achilles tendon-lengthening surgery|
47965070|NCT01925534|DEVICE|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
47965071|NCT01925534|DEVICE|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
47965072|NCT04405583|DEVICE|Occlutech Atrial Flow Regulator|The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.
47965073|NCT06241508|DEVICE|Transcranial magnetic stimulation|A standard 600-pulse TBS \[16\] will be administrated using a MagPro X100 stimulator (MagVenture, Denmark) and a 65-mm figure-of-eight coil. The measurement of the motor hotspot and individual RMT will be in accordance with our established methodology \[3, 9\]. For patients with stroke, the intensity of real stimulation will be 55% or 70% RMT of the unaffected M1 \[17\], depending on their assigned condition. Sham stimulation will be delivered using the same coil with 20% RMT of the unaffected M1 \[4, 6\]. The priming and conditioning sessions will be delivered to the ipsilesional M1 sequentially. In line with previous works, the interval between them will be 10 minutes \[2, 3\]. For healthy adults, the stimulation will be applied exclusively to the non-dominant (right) M1.
47965074|NCT03210571|DEVICE|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
47965075|NCT04676074|DEVICE|Electronic Upper limb( body) ergometer|Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
47965076|NCT05497154|BEHAVIORAL|Training Arm|The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
47965077|NCT04915144|DRUG|177Lu-DOTATOC|Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
47965078|NCT01084083|BIOLOGICAL|cetuximab|Given IV
47965079|NCT01084083|RADIATION|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
47965080|NCT01084083|DRUG|Paclitaxel|Given IV, 90 mg/m\^2 on days 1, 8 and 15
47965081|NCT01084083|DRUG|Cisplatin|Given IV, 75 mg/m\^2 on day 1
47965082|NCT02658903|DEVICE|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
47965083|NCT02658903|DEVICE|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
47965084|NCT03064997|DIETARY_SUPPLEMENT|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
47965085|NCT03064997|DIETARY_SUPPLEMENT|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
47965086|NCT02703662|DEVICE|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
47965087|NCT02703662|DEVICE|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
48115476|NCT01317446|DRUG|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
48115477|NCT00404417|DRUG|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
48115478|NCT00404417|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
48115479|NCT00404417|DRUG|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
48115480|NCT00404417|DRUG|Placebo / Placebo|Placebo at first injection / Placebo at second injection
48484709|NCT01218984|DRUG|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
48484710|NCT01218984|DRUG|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
48644212|NCT01460537|DRUG|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
48644213|NCT01460537|DRUG|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
48644214|NCT01460537|DRUG|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
48644215|NCT05137054|DRUG|Linvoseltamab|Linvoseltamab is administered by intravenous (IV) infusion
48644216|NCT05137054|DRUG|Daratumumab|Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
47965088|NCT05639426|BEHAVIORAL|Culturally Responsive Practices (CRP)|The CRP component of the intervention targets pedagogy, curriculum, and potential teacher biases and discriminatory behavior. This component will consist of two intensive 4-hour workshops delivered by Morton and Billingsley in each school's first intervention year as well as one-hour annual boosters (Backpacks for Success and Culturally Relevant Pedagogy). All teachers and school administrators will participate in the workshops. The purpose of Backpacks for Success is to increase participants' awareness of structural racism, empathy for students, and motivation to change, while identifying equity targets and strategies to reach those targets. Culturally Relevant Pedagogy comprises classroom based strategies to promote equity, including use of culturally responsive curriculum, language, attitudes, and actions, with the goal of reducing interpersonal and cultural racism. Ongoing group coaching sessions will provide a space for peer support and learning around increasing CRP.
47965089|NCT05639426|BEHAVIORAL|Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS)|We will implement SWPBS according to the equity-focused framework established by the Center on PBIS, with an increased emphasis on community integration. SWPBS involves creating a school team of 6-10 people, including at least one administrator, teachers, and staff members. We will include at least three community stakeholders on each C-SWPBS team to integrate the culture of the community, reducing institutional and cultural racism. Community stakeholders may be parents or other invested members of the local community not employed by the school district. The school climate specialists serve on the C-SWPBS team and provide consultation for the management of violence incidents and mental health concerns.
48484711|NCT02610816|OTHER|1 Food Elimination Diet|Participants eliminate milk from the diet for 12 weeks
48484712|NCT02610816|OTHER|4 Food Elimination Diet|Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks
47965090|NCT04729270|PROCEDURE|Physiotherapy treatment with physium device.|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
47965091|NCT04729270|PROCEDURE|Conventional physiotherapy treatment.|The intervention for this group consisted of 10 sessions with Electrical Nerve Stimulation (TENS) for a month.
47965092|NCT00753467|DRUG|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
48484713|NCT02610816|OTHER|4 Food Elimination Diet (post 1FED failure)|Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2
48115481|NCT03179722|BEHAVIORAL|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
48115482|NCT03179722|BEHAVIORAL|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~* before the medication review (T-1week)~* during the review (Tweek 3)~* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
48115483|NCT05706168|DEVICE|treadmill exercise|Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
48484714|NCT02610816|DRUG|Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)|Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
48484715|NCT05633914|DRUG|Tucidinostat|20mg, po., biw, q3w
48484716|NCT05633914|DRUG|nab-paclitaxel|125mg/m2, d1, iv.drip, q7d
48484717|NCT02083926|DRUG|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
48484718|NCT02083926|OTHER|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
48484719|NCT02883478|DEVICE|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
48484720|NCT02883478|PROCEDURE|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
48484721|NCT02883478|DRUG|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
48484722|NCT01435226|DRUG|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
48484723|NCT01435226|DRUG|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
48484724|NCT01435226|DRUG|tegobuvir|tegobuvir 30 mg BID
48484725|NCT01435226|DRUG|placebo to match tegobuvir|tegobuvir placebo BID
48484726|NCT01435226|DRUG|placebo to match RBV|Ribovirin placebo BID
48484727|NCT01435226|DRUG|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
48484728|NCT02266394|DRUG|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
48484729|NCT02266394|PROCEDURE|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
48484730|NCT04265950|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
48484731|NCT00002829|BIOLOGICAL|Recombinant Interferon Alfa|Daily
48484732|NCT00002829|DRUG|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
48484733|NCT00002829|DRUG|Etoposide|Administered intravenously on Day -8
48484734|NCT00002829|DRUG|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
48484735|NCT00002829|PROCEDURE|Bone Marrow Transplantation|Infusion on Day 0.
48484736|NCT00002829|RADIATION|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
48484737|NCT00003598|DRUG|tretinoin|
48644217|NCT05137054|DRUG|Carfilzomib|Carfilzomib is administered by IV infusion
48644218|NCT05137054|DRUG|Lenalidomide|Lenalidomide is administered by mouth (PO) as a capsule
48644219|NCT05137054|DRUG|Bortezomib|Bortezomib is administered by IV infusion or SC injection
48644220|NCT05137054|DRUG|Pomalidomide|Pomalidomide is administered by mouth (PO) as a capsule
48644221|NCT05137054|DRUG|Isatuximab|Isatuximab is administered by IV infusion
47965093|NCT00753467|DRUG|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
48644222|NCT05137054|DRUG|Fianlimab|Fianlimab is administered by IV infusion
48115484|NCT05706168|DEVICE|Cycle ergometer exercise|Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
48115485|NCT04152317|DRUG|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
47965094|NCT00753467|DRUG|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
47965095|NCT02579187|PROCEDURE|tooth extraction|The study tooth will be removed
47965096|NCT02579187|RADIATION|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
47965097|NCT02579187|DRUG|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
47965098|NCT02579187|OTHER|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
47965099|NCT02579187|DRUG|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
47965100|NCT02579187|DRUG|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
48115486|NCT04152317|DRUG|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
48115487|NCT03448653|OTHER|Colonoscopy with NBI|Colonoscopy with NBI
48115488|NCT01306864|DEVICE|Hemospray Kit|Hemostasis of Arterial GI Bleeding
48115489|NCT04782817|OTHER|Recommendation for high flow nasal cannula oxygen therapy order set|Participants will be assigned post extubation physician order set which recommends the administration of oxygen therapy via HFNC. HFNC is a heated and humidified system that allows prescribed fraction of inspired oxygen (FIO2) levels to be delivered at very high flow rates.
48314621|NCT02582580|DEVICE|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
48314622|NCT02582580|OTHER|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
48314623|NCT00195689|BIOLOGICAL|Human anti-TNF monoclonal antibody/adalimumab|
48314624|NCT00937560|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
48314625|NCT00937560|DRUG|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
48314626|NCT00937560|DRUG|Carboplatin|Carboplatin was supplied locally in commercial batches.
47965101|NCT02579187|PROCEDURE|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
47965102|NCT02579187|DRUG|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
47965103|NCT02579187|DRUG|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
47965104|NCT02579187|PROCEDURE|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
47965105|NCT02579187|OTHER|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
47965106|NCT02579187|PROCEDURE|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 \& 4 weeks post extraction
47965107|NCT02579187|PROCEDURE|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
47965108|NCT02579187|RADIATION|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
48115490|NCT04782817|OTHER|Provider choice standard care order set|Participants will receive order set with provider choice of standard care therapy.
48115491|NCT04022616|OTHER|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
48115492|NCT00923871|PROCEDURE|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
48115493|NCT03470662|OTHER|Care bundle|Care bundle
47965109|NCT02579187|OTHER|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
47965110|NCT02639065|DRUG|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
47965111|NCT05113017|OTHER|NO Intervention|NO Intervention
48314627|NCT05501574|DRUG|Tacrolimus Inhalation Powder|Tacrolimus powder for inhalation to prevent acute allograft rejection
48314628|NCT06419868|BEHAVIORAL|"Universal preventive intervention for depression and anxiety for university students"|"This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. It includes emotion regulation, mindfulness exercises, coping strategies, problem-solving strategies, psychoeducation of anxiety and depression, and the development of healthy behaviors, explained through the following theoretical components: mindfulness and cognitive behavioral therapy.~Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning."
47965112|NCT04178486|BEHAVIORAL|Hypnosis with amnesia suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
48484738|NCT04532398|OTHER|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
48484739|NCT04532398|OTHER|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
48484740|NCT00426010|DRUG|caffeine/placebo|caffeine or placebo, either overt or covert
48484741|NCT01976013|DEVICE|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
48484742|NCT04681651|DRUG|Normobaric Hyperoxia|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
48484743|NCT04681651|DRUG|Sham Normobaric Hyperoxia|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
48484744|NCT04681651|PROCEDURE|Endovascular Thrombectomy|EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
48484745|NCT01352728|DRUG|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
48484746|NCT04660305|DRUG|AT278|Concentrated rapid acting insulin aspart
48484747|NCT04660305|DRUG|NovoRapid|Rapid acting insulin aspart
48484748|NCT05397548|DIAGNOSTIC_TEST|Measurement of levels of circulating exosomal lncRNA-GC1|Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
48644223|NCT05137054|DRUG|Cemiplimab|Cemiplimab is administered by IV infusion
48644224|NCT05137054|DRUG|Nirogacestat|Nirogacestat is administered by mouth (PO) as a tablet
48644225|NCT06427577|DRUG|ZhenQi FuZheng granules (ShiDaiYangGuang)|1 bag at a time, twice a day. Oral orally for 4 weeks.
48644226|NCT03505424|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
47965113|NCT04178486|BEHAVIORAL|Hypnosis with cognitive rehearsal suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
47965114|NCT04178486|BEHAVIORAL|Hypnosis with memory substitution suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
48115494|NCT05791812|DEVICE|home-based transcranial direct current stimulation (tDCS)|2mA of tDCS for 20 min every weekday for six weeks
48115495|NCT06677385|RADIATION|diode laser as adjunctive to conventional scaling and debridement|diode laser as adjunctive to conventional scaling and debridement for old age patients
48314629|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 0 and 4
48314630|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
48314631|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 12
48314632|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
48314633|NCT03176797|DIAGNOSTIC_TEST|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
48115496|NCT06677385|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
48115497|NCT05201261|DEVICE|ltrasonic measure|In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
48484749|NCT05171673|DRUG|Licart™ (diclofenac epolamine) topical system|The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury through topical application. This investigational product (IP) is a 10 cm x 14 cm topical system comprised of an adhesive material containing 1.3% diclofenac epolamine that is bound to a non-woven polyester felt backing and covered with a polypropylene film release liner. The release liner is removed prior to topical application to the skin.
47965115|NCT04178486|BEHAVIORAL|Hypnosis with induction only|Participants received only hypnotic induction.
48484750|NCT00000334|DRUG|Buprenorphine|
47965117|NCT05504031|PROCEDURE|Hybrid coronary revascularization|Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
48484751|NCT01841216|DEVICE|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
47965118|NCT05504031|PROCEDURE|Conventional revascularization|Conventional revascularization with CABG of all significant stenoses through a sternotomy
48314634|NCT01326169|BEHAVIORAL|Brief intervention|Telephone-delivered counseling
48644227|NCT03505424|OTHER|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
48644228|NCT03505424|OTHER|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
48314635|NCT01326169|BEHAVIORAL|Standard care|No intervention
48314636|NCT01290120|DRUG|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
48314637|NCT05647902|DIAGNOSTIC_TEST|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
48644229|NCT03547973|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously.
48644230|NCT03547973|DRUG|Pembrolizumab|Administered per package insert
48644231|NCT03547973|DRUG|Cisplatin|Administered per package insert
48644232|NCT03547973|DRUG|Avelumab|Administered per package insert
48644233|NCT03547973|DRUG|Zimberelimab|Administered intravenously
48644234|NCT03547973|DRUG|Carboplatin|Administered per package insert
48644235|NCT03547973|DRUG|Gemcitabine|Administered per package insert
48644236|NCT03547973|DRUG|Domvanalimab|Administered intravenously
48644237|NCT03547973|DRUG|Enfortumab Vedotin|Administered intravenously
48644238|NCT05956535|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
48644239|NCT05956535|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
48644240|NCT03428828|DEVICE|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
47965119|NCT04465474|OTHER|Non Intervention|It's an observational study, no intervention involves.
47965120|NCT05219305|DEVICE|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
47965121|NCT02257008|DRUG|BILR 355 BS|
47965122|NCT02257008|OTHER|Grapefruit juice|
47965123|NCT02257008|DRUG|Nelfinavir|
47965124|NCT02257008|DRUG|Atazanavir|
47965125|NCT02257008|DRUG|Ritonavir|
47965126|NCT01909674|DEVICE|Switch CPAP mask type|
47965127|NCT02702154|DEVICE|High-frequency rTMS|20 Hz active stimulation, twice daily
47965128|NCT02702154|DEVICE|Low-frequency rTMS|1 Hz active stimulation, twice daily
48314638|NCT00583323|DRUG|Lomotil|Orally 10ml of Lomotil
48314639|NCT00583323|OTHER|Normal saline|10 ml orally
48314640|NCT02519049|OTHER|No intervention|This is an observational study
48314641|NCT02328989|DEVICE|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
48314642|NCT01262300|BIOLOGICAL|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
48314643|NCT02222038|OTHER|skin biopsy|
48314644|NCT05942937|OTHER|Education Intervention (The HepPEd Program)|"All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format."
48314645|NCT04778267|DRUG|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
48314646|NCT04778267|DRUG|Dexamethasone phosphate|used as additive to bupivacaine
48644241|NCT03428828|DEVICE|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
48314647|NCT05078463|DEVICE|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
48314648|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
47965129|NCT02702154|DEVICE|Sham rTMS|Sham stimulation, twice daily
48314649|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
48314650|NCT05078463|DRUG|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
48314651|NCT05078463|DEVICE|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
48314652|NCT03375905|DEVICE|cNEP|subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
48484752|NCT05048641|OTHER|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
48484753|NCT02162355|DRUG|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
48644242|NCT06656572|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
48644243|NCT06656572|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
48644244|NCT03915756|PROCEDURE|Drainage of surgical wound|Introduction of a drain before full fascial closure
48644245|NCT02344498|DRUG|Tenofovir disoproxil|
48484754|NCT02162355|DRUG|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
48314653|NCT02040818|DRUG|tigecycline, N-acetylcysteine, heparin combination|
48314654|NCT02040818|DEVICE|guide-wire exchange|
48314655|NCT04949841|DRUG|Delgocitinib|Delgocitinib cream 20 mg/g
48314656|NCT04489225|OTHER|Observational|Observational only without any intervention
48314657|NCT02752529|DRUG|Tacrolimus（FK506）|
48314658|NCT00006248|DRUG|cisplatin|
48314659|NCT00006248|DRUG|fluorouracil|
48314660|NCT00006248|DRUG|paclitaxel|
48314661|NCT02022696|GENETIC|Lentiviral Gene Transfer|
48314662|NCT06250127|DEVICE|Modified 3D printed facemask|modified 3D printed customized maxillary protraction facemask will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
48314663|NCT06250127|DEVICE|Conventional facemask appliance|Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
48314664|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review.
48314665|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review
48484755|NCT02162355|DRUG|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
48484756|NCT02162355|DRUG|Placebo|1 or 2 matching placebo tablets once daily for 10 days
48644246|NCT06306144|BEHAVIORAL|Psychoeducation|Arm 1 : Psychoeducation aims to inform patients about post-stroke cognitive impairment, teach them coping strategies to compensate for these difficulties, provide information on symptom recognition and management, and offer emotional and psychological support to help them meet the challenges associated with these potential cognitive impairments.
48644247|NCT06306144|BEHAVIORAL|Computerised Cognitive Stimulation|Arm 2 :Patients will participate in a 6-week cognitive stimulation telerehabilitation intervention, that will consist of two 45-minute sessions per week. Each week they will participate in a 45-minute on-line session with a rehabilitation clinician and later in the week will complete 45 minutes of on-line exercises set by the rehabilitation clinician
48484757|NCT04250831|DIETARY_SUPPLEMENT|agglomerated glucomannan, oligofructose and chromium mixture|Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
48484758|NCT03765996|OTHER|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
48644248|NCT06306144|BEHAVIORAL|Usual Care|Arm 3 : No specific care.
48644249|NCT05152524|DEVICE|Tigertriever 13|patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
48644250|NCT06083311|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
48644251|NCT06083311|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 28 days
48644252|NCT06413680|DRUG|REGN10597|Administered as an intravenous (IV) infusion
48644253|NCT06606600|OTHER|Intensive Kebbi robot interventions|The intensive Kebbi robot interventions will receive 30 minutes, 3 times per week for 12 weeks.
48644254|NCT03701334|DRUG|Ribociclib|Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
47965130|NCT03501290|DIETARY_SUPPLEMENT|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
47965131|NCT05490511|DRUG|Tacrolimus single dose|5 mg once
47965132|NCT05490511|DRUG|Epidiolex single dose|Epidiolex 5 mg/kg
47965133|NCT05490511|DRUG|Epidiolex steady-state and tacrolimus single dose|Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
47965134|NCT00804284|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
47965135|NCT00804284|BIOLOGICAL|Other DTap Vaccines|0.5 mL, Intramuscular
47965136|NCT02469298|DRUG|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
47965137|NCT02469298|DRUG|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
47965138|NCT02469298|DRUG|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
47965139|NCT02469298|DRUG|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
47965140|NCT06211166|DIAGNOSTIC_TEST|Digital PCR|digital Polymerase Chain Reaction (dPCR)
47965141|NCT06211166|DIAGNOSTIC_TEST|Quantitative PCR|Real-time Polymerase Chain Reaction (real-time PCR)
47965142|NCT06211166|DIAGNOSTIC_TEST|MFC|Multicolor Flow Cytometry
47965143|NCT05827380|BEHAVIORAL|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
47965144|NCT03194607|OTHER|Functional walk tests|
47965145|NCT03194607|OTHER|3D analysis of locomotion and posture|
47965146|NCT03194607|OTHER|questionnaires|
47965147|NCT03738683|DRUG|Piperacillin/tazobactam|Dose according to summary of product characteristics (SPC) or local protocols
47965148|NCT06223178|DEVICE|thumb-tack needle|Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
47965149|NCT06223178|DEVICE|sham thumb-tack needle|Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
47965150|NCT06223178|OTHER|Basic gynecological treatment|Gynecological health care guidance will be provided as patients needed.
47965151|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
47965152|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
47965153|NCT02601378|DRUG|LXS196|LXS196 as a single agent
47965154|NCT02601378|DRUG|LXS196 and HDM201|LXS196 in combination with HDM201
48115498|NCT05347108|PROCEDURE|laser-assisted neural decompression (LAND) procedure|"The LAND procedure is a minimally invasive spinal decompression procedure that uses a focused laser beam to reduce and remove disc herniations that are causing nerve compressions and impingements within the spinal canal. It is performed in an outpatient setting and the patient receives local anesthesia.~The LAND procedure has been performed extensively over the past 2-years on hundreds of patients, so including patients that have previously had the surgery allows for additional data points and improved reporting."
48115499|NCT00427323|PROCEDURE|light exposure|
48115500|NCT01052246|DRUG|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
48314666|NCT02953392|DEVICE|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
48314667|NCT02953392|DEVICE|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
48314668|NCT02953392|DEVICE|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
48314669|NCT02953392|DEVICE|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
48314670|NCT04246580|PROCEDURE|Indocyanine green-guided systematic pelvic lymphadenectomy|Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
48314671|NCT02768194|DEVICE|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
48314672|NCT02768194|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
48115501|NCT01052246|DEVICE|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~* Wavelength 585 nm~* Energy fluence 3 J/cm2~* Pulse duration 0.35 msec~* Spot size 7 mm"
48115502|NCT00011531|PROCEDURE|Prevention of Pressure Ulcers|
48115503|NCT04113707|BEHAVIORAL|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
48115504|NCT06216470|DRUG|VIR-3434|VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).
48115505|NCT01917097|DRUG|Dexmedetomidine|
48314673|NCT02768194|OTHER|Mineral water|Commercially available mineral water
48314674|NCT03071224|DRUG|[18F] MNI-946|Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
48314675|NCT03071224|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
48314676|NCT03262597|OTHER|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
48314677|NCT03262597|OTHER|Pedialyte|Subjects will consume Pedialyte
48314678|NCT03262597|OTHER|Gatorade|Subjects will consume Gatorade
48314679|NCT03262597|OTHER|Water|Subjects will consume water as the control beverage
48314680|NCT02776657|OTHER|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
48314681|NCT02776657|DEVICE|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
48314682|NCT02776657|PROCEDURE|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
48314683|NCT05180110|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
48314684|NCT05180110|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
48314685|NCT01064024|DRUG|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
48115506|NCT02561871|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on day 1 in Group 2.
48115507|NCT02561871|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11 virus particles \[vp\]) on day 85 in Group 2.
48115508|NCT02561871|DRUG|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
48115509|NCT00092781|DRUG|MK0663, etoricoxib|
48115510|NCT00092781|DRUG|Comparator: celecoxib|
48115511|NCT02731755|OTHER|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
48314686|NCT01064024|DRUG|Placebo|Tablets, every 8 hours for 48 hours
48314687|NCT02347241|OTHER|Educational intervention|Educational Debriefings and High frequency training and team reflection
48314688|NCT04069013|PROCEDURE|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
48644255|NCT03701334|OTHER|Endocrine Therapy|ET will be administered according to the local clinical guidelines and current local prescribing information
47965155|NCT00873912|BIOLOGICAL|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
47965156|NCT00873912|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
47965157|NCT03711110|OTHER|Intensive cardiovascular monitoring|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study."
47965158|NCT03711110|OTHER|No intervention|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria"
47965159|NCT00533598|DRUG|MK0557|
47965160|NCT03674684|OTHER|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
47965161|NCT04702061|OTHER|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
47965162|NCT04702061|OTHER|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
48644256|NCT06687044|BEHAVIORAL|Sleep restriction|Go to bed before 23pm
47965163|NCT00541710|DIETARY_SUPPLEMENT|genistein|pills of 27 mg, twice per day for 12 months
47965164|NCT00541710|DIETARY_SUPPLEMENT|placebo|sugar pills twice per day for 12 months
47965165|NCT05434000|DRUG|Hydroxyurea|Children at risk of developing stroke (TCD values\>200cm/s) will be given 20mg/kg of Hydroxyurea
47965166|NCT05846074|DIAGNOSTIC_TEST|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
47965167|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
47965168|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
48115512|NCT02731755|OTHER|Control|60g cream of rice
48115513|NCT03143348|PROCEDURE|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
48115514|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 6 peri-operative time points.
48115515|NCT03143348|PROCEDURE|Multiple blood draws|Blood draw at 7 peri-operative time points
48115516|NCT04086966|DRUG|[68Ga]PSMA-PET/MRI or PET/CT|\[68Ga\]PSMA-PET/MRI or PET/CT
48115517|NCT00065260|DRUG|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
48115518|NCT00065260|DRUG|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
48115519|NCT00065260|DRUG|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
48266784|NCT02266433|DRUG|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
48314689|NCT04889534|PROCEDURE|Analgesia|Patients will be observed during postoperative period,
48644257|NCT06687044|BEHAVIORAL|Stimulation control|Avoid drugs, alcohol, caffeine, and nicotine
48644258|NCT06687044|BEHAVIORAL|Cognitive therapy|Listen to 30 minutes of soothing music every night for 8 weeks
48644259|NCT06687044|BEHAVIORAL|Sleep principles discussion|The principles of sleep hygiene are discussed, but without the application of stimulus control or sleep restriction
48644260|NCT05804227|DRUG|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
48644261|NCT05673902|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
48644262|NCT05658640|DRUG|Trametinib|Oral
48644263|NCT05658640|DRUG|Dexamethasone|Oral/ Intravenous
48644264|NCT05658640|DRUG|Cyclophosphamide|Intravenous
48115520|NCT05858073|OTHER|Kinesio Taping|"Standard 5 cm Kinesio Tex will be used. Initially, a Y-strip was paper-off (without tension) from the starting point to the insertion of the supraspinatus, while the participants were reaching with their upper extremities behind their backs and flexing their necks to the contralateral side. Second, an I-strip from the coracoid process will be applied around the posterior deltoid using approximately 50% to 75% downward flexion. Initially, the shoulder will be externally rotated without elevation, and then slightly horizontally adduction and forward elevation as the end of the band is applied without stretching. This I strip is shaped like a Y at the end of the tape.~Finally, a Y-strip will be applied using paper-off tension from the T10-T12 region to the medial border of the scapula to facilitate the lower trapezius muscle. For this technique, the shoulder was adducted horizontally and the middle tail was applied with the hands crossed over the chest."
48115521|NCT05858073|OTHER|Placebo Kinesio Taping|Standard placebo taping will be applied to the placebo Kinesio taping group with a standard 5 cm Kinesio Tex. Two tension-free strips will be applied separately to the acromioclavicular joint and lower trapezius muscle. Suspicious participants will be excluded from the study.
48115522|NCT02328768|DRUG|Omegaven|
48115523|NCT01981837|DRUG|ALN-TTRSC (revusiran) for subcutaneous administration|
48115524|NCT02561949|BEHAVIORAL|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
48314690|NCT06177782|DEVICE|Tooth modified scan bodies|Tooth modified scan bodies are used during scanning for full arch implant cases.
48314691|NCT06177782|DEVICE|Conventional scan bodies|Conventional scan bodies will be used for scanning the full arch implant cases.
48314692|NCT01390116|DIETARY_SUPPLEMENT|Aged garlic extract|2 aged garlic extract capsules taken twice daily
48314693|NCT01390116|DIETARY_SUPPLEMENT|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
48314694|NCT02786732|BIOLOGICAL|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
48314695|NCT02786732|BIOLOGICAL|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
48314696|NCT02786732|BIOLOGICAL|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
48314697|NCT02786732|BIOLOGICAL|Placebo|Placebo administered subcutaneously
48314698|NCT02114333|BIOLOGICAL|Zostavax|0.65ml, subcutaneous
48484759|NCT03765996|OTHER|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
48644265|NCT05658640|DRUG|Cytarabine|Intravenous
48644266|NCT05658640|DRUG|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
48644267|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|"Treatment with baricitinib 4 mg daily~* Step 1 (after randomization): baricitinib 2mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): baricitinib 2mg every other day"
48314699|NCT02114333|BIOLOGICAL|HZ/su vaccine|0.5ml, intramuscular
48314700|NCT02114333|BIOLOGICAL|Placebo|0.65ml, subcutaneous
48314701|NCT04834882|OTHER|Data collection (|online survey
48314702|NCT01811849|DRUG|Insulin LISPRO|
48314703|NCT01811849|DRUG|Insulin LISPRO|
48314704|NCT01811849|DRUG|Insulin LISPRO|
48644268|NCT06687551|DRUG|filgotinib 200mg/day|"Treatment with filgotinib 200 mg daily~* Step 1 (after randomisation): filgotinib 100 mg daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): filgotinib 100mg every other day"
48644269|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|"Treatment with tofacitinib 5 mg twice daily or tofacitinib 11mg daily~* Step 1 (after randomisation): tofacitinib 5 mg once daily~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): tofacitinib 5 mg every other day"
48644270|NCT06687551|DRUG|Upadacitinib 15 MG|"Treatment with upadacitinib 15 mg daily~* Step 1 (after randomisation): upadacitinib 15 mg every other day~* Step 2 (in case of CDAI≤ 10 AND CRP level below the laboratory standard; 6 months after starting step1): upadacitinib 15 mg every 4 days"
48314705|NCT03594487|DRUG|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
48314706|NCT03594487|PROCEDURE|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
48314707|NCT03594487|OTHER|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
48115525|NCT02561949|OTHER|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
48115526|NCT01032486|DRUG|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
48115527|NCT02496702|DEVICE|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
48484760|NCT04917081|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
48115528|NCT03919292|DRUG|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
48484761|NCT04917081|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
48484762|NCT00006182|PROCEDURE|Blood Transfusion|
48644271|NCT06687551|DRUG|Baricitinib (LY3009104) 4 mg|use of JAK inhibitor at full dose until the end of the protocol
48484763|NCT05021913|DEVICE|DKL crosslinked sodium hyaluronate 23|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
48644272|NCT06687551|DRUG|filgotinib 200mg/day|use of JAK inhibitor at full dose until the end of the protocol
47965169|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
47965170|NCT04850521|OTHER|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
48115529|NCT03919292|DRUG|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
48115530|NCT05116085|DRUG|Tislelizumab|Administered intravenously
48115531|NCT01472003|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
48115532|NCT01472003|DRUG|ABT-806i|ABT-806i will be administered by intravenous infusion.
48484764|NCT05021913|DEVICE|Juvéderm Volift™ with lidocaine (Allergan, Inc)|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
48484765|NCT02201290|DRUG|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
48484766|NCT02201290|DRUG|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
48484767|NCT04172519|OTHER|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
48484768|NCT04172519|OTHER|Unsupervised PMFT|intervention after surgery, unsupervised exercises
48644273|NCT06687551|DRUG|Tofacitinib 5 mg twice daily|use of JAK inhibitor at full dose until the end of the protocol
48644274|NCT06687551|DRUG|Upadacitinib 15 MG|use of JAK inhibitor at full dose until the end of the protocol
48644275|NCT06078189|DEVICE|HORUS|"The trapezium-metacarpal arthroplasty consists of the installation of a bipolar prosthesis composed of a metacarpal implant and a trapezial implant articulated through a metacarpal head."
48644276|NCT06691191|DRUG|Ticagrelor 90 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
48644277|NCT06691191|DRUG|Prasugrel 10 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
48115533|NCT04468698|OTHER|Peritoneum insufflation|Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
47965171|NCT06297577|PROCEDURE|Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST)|Albumin-PRF will be placed into intrabony defect
47965172|NCT06297577|PROCEDURE|Minimally invasive surgical technique (MIST)|MIST will be the surgical access for treatment of Intrabony defect
47965173|NCT02898883|BEHAVIORAL|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
47965174|NCT05810883|DIAGNOSTIC_TEST|Blood Tests; Serum Fasting Insulin and Glucose|"Laboratory results of blood samples, for high-density lipoprotein (HDL), low-density protein (LDL), triglycerides, and total cholesterol (TC) will be evaluated for this study. Fasting Insulin and fasting glucose levels will be used to calculate IR.~Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (FPG (mmol/L) × FPI (mU/L)/22.5) \[21\] and defined as HOMA-IR ≥ 3.4"
47965175|NCT00484432|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
48314708|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
48314709|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
48314710|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
48484769|NCT04172519|OTHER|Supervised PMFT|intervention after surgery and supervised exercise
48484770|NCT05787002|DRUG|AZD0780|AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
48484771|NCT05787002|DRUG|Rosuvastatin|Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.
48484772|NCT00419549|DRUG|Glyceryl - trinitrate|Transdermal Patch once only
48484773|NCT00419549|DRUG|Valdecoxib|Single parenteral administration
48484774|NCT02667678|BIOLOGICAL|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
48484775|NCT03856593|BEHAVIORAL|Standard letter|The standard letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 morphine milligram equivalents (MME) per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking \> 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
48484776|NCT03856593|BEHAVIORAL|Comparator letter|"The comparator letter includes all the details in the standard letter plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation."
48484777|NCT04100824|PROCEDURE|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
47965176|NCT00484432|DRUG|doxorubicin|Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
47965177|NCT05438264|DRUG|Donepezil|acetylcholinesterase inhibitor
47965178|NCT05438264|DRUG|Placebo|placebo
47965179|NCT00189150|DRUG|Mycophenolate mofetil|
47965180|NCT00189150|DRUG|Valganciclovir|
48115534|NCT03297346|OTHER|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
48115535|NCT04833855|BIOLOGICAL|Tezepelumab Dose 1|Subcutaneous injection.
48644278|NCT05272579|OTHER|Fecal Filtrate Transfer|Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
48644279|NCT05272579|OTHER|Placebo|Saline solution
47965181|NCT03791489|DEVICE|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
47965182|NCT02485197|OTHER|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
47965183|NCT03414060|DEVICE|Menstrual Cup|
47965184|NCT03693300|DRUG|Durvalumab|Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
47965185|NCT00225069|PROCEDURE|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
48115536|NCT04833855|BIOLOGICAL|Tezepelumab Dose 2|Subcutaneous injection.
48115537|NCT04833855|BIOLOGICAL|Omalizumab|Subcutaneous injection.
48115538|NCT04833855|BIOLOGICAL|Placebo|Subcutaneous injection.
48115539|NCT06307548|DRUG|Aminolevulinic Acid|Given PO
48115540|NCT06307548|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48115541|NCT06307548|PROCEDURE|Computed Tomography|Undergo CT
48314711|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
48314712|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
48314713|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
48314714|NCT00703755|DRUG|Placebo|Placebo
48314715|NCT00780169|DRUG|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1"
48314716|NCT00400829|DRUG|eribulin mesylate|Given IV
48644280|NCT06685939|PROCEDURE|LPD|The patients who received the LPD
48115542|NCT06307548|PROCEDURE|Fluorescence-Guided Surgery|Undergo fluorescence-guided surgery
48115543|NCT06307548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47965186|NCT05746949|PROCEDURE|oxygenization techniques|to compare the effects of high-flow nasal oxygen and jet ventilation on oxygenation in patients who will receive general anesthesia for endolaryngeal surgery.
47965187|NCT06208683|BIOLOGICAL|Mumps vaccine, Live (MV)|0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
47965188|NCT06208683|BIOLOGICAL|Influenza Vaccine, inactivated, quadrivlent(QIV)|0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
47965189|NCT05111873|OTHER|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
48115544|NCT06307548|DRUG|Photodynamic Therapy|Undergo PDT
48115545|NCT06307548|PROCEDURE|Surgical Procedure|Undergo surgery
48115546|NCT03653169|DEVICE|Transcranial Magnetic Stimulation|TMS is a form of noninvasive brain stimulation. An external electromagnetic coil is placed on the head, and a large current is passed through an insulated wire coil held flat on the surface of a subject's scalp in a fraction of a millisecond. This pulse of current induces a weak electrical current within the surface brain cortex. Repetitive trains of TMS pulses (repetitive TMS or rTMS) can transiently modulate corticospinal excitability following the rTMS train. When current is delivered at high frequency (10 Hz), it may simultaneously increase the activity of the brain at this site. In this study, individuals will receive 10 treatments with intermittent theta burst stimulation (twice daily for 5 days).
48115547|NCT02519517|PROCEDURE|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
48115548|NCT05622786|OTHER|HIGT - physical rehab|High Intensity Gait Training using treadmill and overhead harness for fall prevention
48314717|NCT05291949|DEVICE|ATLASense RAPHAEL PolyMonitor|All patients will be monitored using the ATLASense RAPHAEL PolyMonitor during their surgery.
48314718|NCT00077805|DRUG|Enoxaparin sodium|
48314719|NCT04131517|DRUG|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
48484778|NCT04100824|DRUG|Nimodipine|Nimodipine 60mg every 4h
47965190|NCT02548780|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
48115549|NCT05622786|OTHER|Low intensity physical therapy|Low Intensity Gait Activities
48314720|NCT04131517|DRUG|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
48314721|NCT02618980|OTHER|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
48314722|NCT02902172|DRUG|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
48484779|NCT00382629|DRUG|BHT-3009 0.5 mg|
48644281|NCT05410860|DRUG|Etripamil NS 70 mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
48314723|NCT02902172|DRUG|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
48314724|NCT02634099|DEVICE|blood measurement|Hemoglobin measurement
48314725|NCT02634099|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
48314726|NCT02634099|DEVICE|hemoCue|non invasive method of hemoglobin measurement
48314727|NCT02472925|BEHAVIORAL|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
48314728|NCT03302416|DRUG|Hydrocortisone|
48314729|NCT03302416|RADIATION|[C-11]NOP-1A|
48484780|NCT00382629|DRUG|BHT-3009 1.5 mg|
48484781|NCT00382629|DRUG|Placebo|
48484782|NCT02243293|DRUG|ABT-493|Tablet
48484783|NCT02243293|DRUG|ABT-530|Tablet
48644282|NCT05410860|DRUG|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
48484784|NCT02243293|DRUG|ribavirin (RBV)|Tablet
48484785|NCT02243293|DRUG|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
48484786|NCT01626963|PROCEDURE|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
48484787|NCT01626963|PROCEDURE|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
48484788|NCT00604227|OTHER|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
48484789|NCT01931527|DRUG|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
48644283|NCT02575183|DRUG|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
48484790|NCT05439811|PROCEDURE|Swan-Ganz Catheter|Swan-Ganz Catheter
48484791|NCT01174355|DRUG|ND0801|Confidential
47965191|NCT02548780|OTHER|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
47965192|NCT05305820|BEHAVIORAL|Exercise|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
47965193|NCT05305820|BEHAVIORAL|Nutrition|Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
48484792|NCT01983319|DEVICE|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
47965194|NCT02478775|DRUG|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
47965195|NCT02478775|DRUG|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
48115550|NCT04655859|DIAGNOSTIC_TEST|saliva cotton swab|evaluate the role of thiol/disulfide homeostasis and oxidative stress in the saliva of children with severe early childhood caries and healthy group
48115551|NCT06016907|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
48115552|NCT06016907|BEHAVIORAL|In-person cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
48115553|NCT05588453|BIOLOGICAL|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
48115554|NCT05588453|DRUG|Temozolomide|Given PO
48484793|NCT01983319|DEVICE|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
48484794|NCT01983319|BEHAVIORAL|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
48484795|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF
48484796|NCT05681754|PROCEDURE|Experimental: RCT using conventional sealer and L-PRF + GTR|Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR
48484797|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only
48484798|NCT05681754|PROCEDURE|Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)|Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
48484799|NCT04269733|DEVICE|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
48484800|NCT03977701|BEHAVIORAL|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
48484801|NCT03977701|BEHAVIORAL|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
48314730|NCT04474899|DRUG|Moxonidine 0.4 MG|Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
48314731|NCT04474899|DRUG|Amlodipine 5mg|Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
48484802|NCT06126965|DRUG|KX-826-（5%） BID|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.
48484803|NCT06126965|OTHER|Placebo|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized matching placebo would be administered to the scalp once in the morning and once in the evening.
47965196|NCT02478775|DRUG|Cetrorelix|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
48314732|NCT02810262|OTHER|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
48484804|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
48484805|NCT01014962|DRUG|Placebo|Placebo oral once daily for 5 days
48484806|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
48484807|NCT01014962|DRUG|Placebo|Placebo oral every 12 hours for 5 days
48484808|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
48484809|NCT01014962|DRUG|Placebo|Placebo oral every 8 hours for 5 days
48484810|NCT04873531|DRUG|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
48484811|NCT04873531|DRUG|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
48484812|NCT05319834|DRUG|Aspirin tablet|group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
48484813|NCT05319834|DRUG|Placebo|group 2: oral placebo once daily at the same time with progesterone
48484814|NCT04432675|DRUG|hydroxyethl starch|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
48314733|NCT01710111|DEVICE|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
48314734|NCT03017248|DRUG|Ketamine|ketamine
48314735|NCT03017248|DRUG|Placebos|0.9% normal saline
48314736|NCT03017248|DRUG|Morphine|Morphine
48314737|NCT06046495|DRUG|PLB1004|PLB1004 will be orally self-administered by the patient as a mono-therapy.
48314738|NCT02511951|PROCEDURE|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
48314739|NCT05159596|DEVICE|In-Home Technology System|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages and alerts via cell phone when worrisome behaviors occur. Caregivers are able to: (a) select services (e.g., warnings for falls, wandering, late night activity); (b) access daily reports (summaries of daily activities that can also be shared with health care providers); and (c) obtain support (e.g. Caregiver Support Groups that connect caregivers with knowledgeable experts and other caregivers, Caregiver Events that provide virtual meetings about relevant topics, and Trusted Circle task management to distribute the caregiving work load).
48314740|NCT05159596|DEVICE|Limited In-Home Technology|Intelligent bots monitor the in-home water leak sensor and provide caregivers with text messages and alerts via cell phone when worrisome conditions occur.
48314741|NCT03785886|BEHAVIORAL|Walking group|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
48484815|NCT04432675|DRUG|Lactated Ringer's solution|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
48484816|NCT05162651|BEHAVIORAL|Contingency-management|In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
48484817|NCT05162651|OTHER|Enhanced usual care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
48484818|NCT01612416|DEVICE|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
47965197|NCT04489563|DEVICE|i-ACT|Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
47965198|NCT00401596|DRUG|Xolair (omalizumab)|
48115555|NCT00345007|PROCEDURE|Scleral buckling|
48644284|NCT02575183|DRUG|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
48644285|NCT02575183|BEHAVIORAL|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
48644286|NCT06424860|DIETARY_SUPPLEMENT|Fish oil|For 12 months
48644287|NCT06424860|DRUG|Metformin|12 months
48484819|NCT03557359|DRUG|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
48484820|NCT00387920|DRUG|sunitinib malate|Given orally
48115556|NCT06677437|OTHER|This is an observational and retrospective study|"It concerns all patients with chronic renal failure awaiting a kidney transplant, and presenting a contraindication to the transplant due to their anatomical constraints: major arterial calcifications, iliac dissections, iliac stenoses. They can only receive the kidney transplant after arterial preparation. These patients will be included and will benefit from endovascular preparation for the kidney transplant using a tailor-made arterial stent.~Imaging examinations and follow-up clinical data will be analyzed. Reinterventions and causes of death will be analyzed.~An information sheet will be given to patients; if the patient refuses the use of their data, it will not be collected.~Data collection will be carried out by ARCs or PIs of the centers from medical records. The data will be pseudo-anonymized, entered into a REDCAP database shared between each center."
48484821|NCT00387920|OTHER|pharmacological study|Correlative studies
48484822|NCT00387920|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
48484823|NCT00387920|OTHER|laboratory biomarker analysis|Correlative studies
48484824|NCT02766426|BEHAVIORAL|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
48484825|NCT03971149|BEHAVIORAL|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
48484826|NCT03235869|DRUG|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
48484827|NCT03235869|RADIATION|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
48484828|NCT05423470|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
48484829|NCT05423470|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
48484830|NCT03494543|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary of Vater neoplasms
48484831|NCT02572349|DRUG|IW-1701|
48484832|NCT02572349|DRUG|Matching Placebo|
48484833|NCT04507035|DRUG|Anlotinib hydrochloride capsules|Using anlotinib of 2 cycles as the first-line therapy.
48484834|NCT01741779|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
48484835|NCT01741779|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
48484836|NCT01741779|OTHER|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
48115557|NCT02874118|BEHAVIORAL|Fried scale for frailty assessement|
48115558|NCT01731041|DRUG|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
48115559|NCT01731041|DRUG|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
48484837|NCT05828355|OTHER|Knee Care@Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
48484838|NCT04998578|DEVICE|Comparison of aesthetic techniques|Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
48644288|NCT06424860|COMBINATION_PRODUCT|Fish Oil and Metformin|12 months
48115560|NCT02918279|DRUG|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
48115561|NCT02918279|DRUG|Placebo|Administered once daily subcutaneously (s.c., under the skin)
48115562|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
48484839|NCT06469177|DEVICE|Pain Coach App|Pain Coach App is a mobile application that offers patients undergoing shoulder, hip and knee arthroplasty surgery preoperative educational tools and questionnaires to provide patient specific details to their surgeons for prescribing purposes as well as post operative pain assessment and medication reminders/tracking, problem troubleshooting and a resource library for further pain management tools and education.
47965199|NCT02318251|OTHER|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
48115563|NCT00145314|DRUG|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
48115564|NCT00145314|DRUG|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."
48115565|NCT05147688|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48484840|NCT02237742|DRUG|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
48484841|NCT02211014|DRUG|acalabrutinib|
48115566|NCT00181753|DRUG|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for \> 3 days before we conduct stable isotope tracer measurements.
48115567|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant infusion
48484842|NCT02043613|OTHER|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study."
48484843|NCT02043613|OTHER|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
48484844|NCT03201679|PROCEDURE|Repair of hip fracture|Patients undergoing hip fracture surgery
48484845|NCT05888324|OTHER|Questionnaires|Questionnaires by phone at 1 and 6 months after inclusion
48115568|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
48115569|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
48115570|NCT00181753|DIETARY_SUPPLEMENT|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
48115571|NCT01843101|DEVICE|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
48115572|NCT04912791|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
48115573|NCT03648814|PROCEDURE|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
48115574|NCT03648814|PROCEDURE|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
47965200|NCT02318251|OTHER|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
47965201|NCT02160535|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
48115575|NCT03981822|COMBINATION_PRODUCT|VP-102 and applicator|In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.
48115576|NCT03981822|COMBINATION_PRODUCT|Placebo|The placebo single-use applicator contains the same formulation as the VP-102 applicator but does not contain the active pharmaceutical ingredient cantharidin
48115577|NCT04346732|OTHER|Vapocoolant spray|Vapocoolant spray
48115578|NCT05936333|PROCEDURE|Biological collection|up to 25 mL of blood collection for the adults and saliva collection for the minor at inclusion, and placenta collection at childbirth
48484846|NCT04294342|BEHAVIORAL|Active Comparator: Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
48115579|NCT02416076|DEVICE|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
48314742|NCT03785886|BEHAVIORAL|Chinese square dancing group|"Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13."
48314743|NCT03785886|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
48314744|NCT03150095|BEHAVIORAL|Health coaching|Patients will work with a health coach by telephone
48484847|NCT04428099|BEHAVIORAL|Lifestyle change promotion program|The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
48484848|NCT04428099|BEHAVIORAL|Mindfullness based cognitive program|The intervention consists of 8 group sessions with a mindfulness-based cognitive program
48115580|NCT02416076|DEVICE|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
48115581|NCT00609310|DIETARY_SUPPLEMENT|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
48115582|NCT02108236|DEVICE|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
48115583|NCT06107582|OTHER|data collection|The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
47965202|NCT00210405|DIETARY_SUPPLEMENT|"Sprinkles containing mulitple micronutrients"|
47965203|NCT00210405|BEHAVIORAL|Education/communication on use of micronutrient sprinkles|
48115584|NCT02957136|DEVICE|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
48115585|NCT00366873|PROCEDURE|Calcium absorption|formula with or without prebiotics
48314745|NCT04115046|DEVICE|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
48314746|NCT04115046|DEVICE|FibroScan|manufactured by Echosens
48115586|NCT05546359|DRUG|Amisulpride Injection|Dose finding treatment for continuation to phase 3
48314747|NCT04115046|DEVICE|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
48314748|NCT06405022|OTHER|Brain Endurance Training|Six week period with three weekly blocks with a 20 min brain endurance training program following a regular HIT session. Before the HIT session questionnaires are completed to measure the motivation for the HIT session and the current state of mood. In between the HIT session and the RCA session, questionnaires are completed to measure the experienced workload of the HIT session, the current state of mood, and the motivation for following the RCA session. Immediately after the RCA session, questionnaires are completed to measure the experienced workload of the RCA session and the current state of mood.
48314749|NCT06405022|OTHER|Control|No intervention
48314750|NCT06216015|OTHER|Exercise training|"Participants will engage in combined training five times a week, with activities including 2 minutes of stationary marching and a set of 15 repetitions for squats, bilateral hip abduction, plantar flexion, floor abdominal exercises, and arm flexion with the knee close to the ground. Additionally, twice a week on non-consecutive days, volunteers partake in 20 minutes of aerobic walking.~The second program starts with a 2-minute stationary march, followed by 2 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion with knee support, floor abdominal exercises, and concludes with 30 minutes of aerobic exercise.~The third program starts with a 2-minute stationary march, followed by 3 sets of 12 repetitions for free squats, hip abduction, plantar flexion, stiff-legged deadlifts, arm flexion, floor abdominal exercises, and includes thrice-weekly aerobic sessions lasting 30 minutes each."
48115587|NCT05546359|DRUG|Dexamethasone|Standard of care treatment
48115588|NCT00613782|DRUG|Reandron 1000|1000mg at 0,6,18,30 weeks
48314751|NCT06216015|OTHER|Continue exercising|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will include individuals who choose to persist with their exercise routine.
48484849|NCT04428099|BEHAVIORAL|Written Information|Written information about lifestyle change suggestions
48484850|NCT05424484|DEVICE|Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
48484851|NCT00210613|DRUG|Dapoxetine|
48115589|NCT00613782|DRUG|placebo|placebo injection 0,6.18.30 weeks
48115590|NCT06391775|BIOLOGICAL|GEN1055|Intravenous (IV) administration.
48115591|NCT06391775|BIOLOGICAL|Pembrolizumab|IV administration
48115592|NCT06391775|DRUG|Standard Chemotherapy|IV administration
48115593|NCT05254769|DEVICE|Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.|The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
48115594|NCT03845114|OTHER|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
48115595|NCT03845114|OTHER|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
48115596|NCT03845114|OTHER|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
48115597|NCT03845114|OTHER|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
48266785|NCT02141893|BEHAVIORAL|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
48266786|NCT02141893|BEHAVIORAL|CALMA|Family Education Intervention on management of pediatric asthma
48266787|NCT04993625|PROCEDURE|avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
48484852|NCT00465049|OTHER|PRIMARY CLOSRE|SUTURE
48484853|NCT00465049|OTHER|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
48484854|NCT00465049|OTHER|SPONTANEOUS HALING|SECONDARY HEALING AFTER I\&D
48484855|NCT04478461|DRUG|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
48484856|NCT02035020|DRUG|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
48644289|NCT04874428|DRUG|Rivaroxaban 10 mg Oral Tablet|Administration of one single dose of rivaroxaban (10 mg) in tablet form.
48115598|NCT06499246|PROCEDURE|Donor Parathyroid|Once a potential donor becomes available, the transplant team will assess if the donor is a match for our study participant using standardized transplantation protocols that include serology blood tests completed in the pre-operative setting. If the donor is a match, the procurement team will procure all parathyroid tissue using standard surgical techniques. The specimen will be kept in organ preservation solution for transport and transported to the operating room. The recipient (study participant) will be admitted to the hospital under and taken to the operating room for the surgical procedure. Once the procurement team arrives with the parathyroid tissue the procedure will be performed under local anesthesia using a well-established technique, for parathyroid auto transplant, of implanting parathyroid tissue in the non-dominant brachioradialis muscle. Immunosuppression medication protocols will be initiated.
48115599|NCT05688644|DEVICE|InterStim II|Sacral neuromodulation
48115600|NCT06555718|BEHAVIORAL|The Peer Support Program|Implementation of the research; Peer support programme for the intervention group will be carried out for 10 weeks in accordance with the peer guide-client implementation plan. Standard follow-up and training programme will be applied to the control group in accordance with the procedures of the institution.
48115601|NCT06555718|BEHAVIORAL|Standart care|The standard care provided by the institution will continue.
48115602|NCT03002805|DRUG|CBT-1®|"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
48115603|NCT00428519|DRUG|Placebo|Placebo for 14 days
48115604|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
48115605|NCT00428519|DRUG|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
48115606|NCT04674293|DRUG|Revelisa|Thrombolytic therapy for patients with ischemic stroke
48314752|NCT06216015|OTHER|Discontinue exercising|Following the 12-week training regimen, patients will have the option to decide whether they wish to continue their exercise training. This group will comprise individuals who opted not to continue their exercise routine.
48484857|NCT04343703|BEHAVIORAL|Telephone-based management|The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk. At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
48484858|NCT04343703|BEHAVIORAL|iFightDepression for Suicide|The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. The iFD-S also provides telephone guidance (2h per participant).
48484859|NCT04343703|BEHAVIORAL|Treatment as Usual|Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy. For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
48484860|NCT04343703|BEHAVIORAL|Self Awareness of Mental Health|The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
48484861|NCT04209010|PROCEDURE|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
48644290|NCT04874428|DRUG|Apixaban 2.5 mg Oral Tablet|Administration of one single dose of apixaban (2.5 mg) in tablet form.
48115607|NCT04302246|GENETIC|Biological testing on sequential blood sample|Biological characterization of various immune function and blood circulating leukocytes phenotyping before liver transplantation and therafter at day-3, -7, -14 postoperatively and if septic complication occurs.
48314753|NCT00121992|DRUG|Docetaxel|
48314754|NCT00121992|DRUG|5-fluorouracil|
48314755|NCT00121992|DRUG|Doxorubicin|
48314756|NCT00121992|DRUG|Cyclophosphamide|
48314757|NCT06011746|DRUG|Ketamine + Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with 1ml ketamine (50mg)
48115608|NCT02457845|BIOLOGICAL|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
48115609|NCT02772263|OTHER|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
48115610|NCT05206266|OTHER|Turmeric|Three amounts of dietary turmeric will be tested: 1) turmeric 300 mg/day, 2) turmeric 1 g/day, 3) turmeric 3 g/day.
48115611|NCT05206266|OTHER|Turmeric+Black Pepper|Three amounts of dietary turmeric (300mg/day, 1g/day or 3g/day) with black pepper (300 mg) added to the turmeric.
48115612|NCT03061552|DIAGNOSTIC_TEST|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
48115613|NCT01126918|BEHAVIORAL|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
48115614|NCT00488410|DEVICE|Doppler echocardiography|
48314758|NCT06011746|DRUG|Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with (50mg) or normal saline
48314759|NCT06137950|DRUG|gel Interferon arm|0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.
48314760|NCT06137950|DRUG|gel Interferon and interferon suppository arm|"0.2 ml gel interferon will be administered into vaginal using 1 ml syringe with measurement line. Patients will be trained how to fill the syringe and put into the vagina. Gel will be administered 2 times per day during the non menstruating day totally for 28 days.~3MIU suppository will be given to patients and will be trained how to use. Each patient in the arm will use the suppository twice a day for 10 days with vaginal therapy."
48314761|NCT06323915|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
48314762|NCT06520319|DRUG|68Ga-MGS5|Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
48314763|NCT05631015|OTHER|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
48484862|NCT04392284|BEHAVIORAL|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
48644291|NCT03361007|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
48644292|NCT04903093|DRUG|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
48644293|NCT04903093|DRUG|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
48644294|NCT04903093|DRUG|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
48115615|NCT06524973|OTHER|Telemedicine|Attend telehealth self-management coaching sessions
48115616|NCT06524973|OTHER|Counseling|Attend telehealth self-management coaching sessions
48115617|NCT06524973|OTHER|Best Practice|Receive standard of care
48115618|NCT06524973|OTHER|Questionnaire Administration|Ancillary studies
48115619|NCT06524973|OTHER|Inrweview|Ancillary studies
48115620|NCT05317572|DRUG|80 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 80 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
48644295|NCT04903093|DRUG|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
48644296|NCT04903093|DRUG|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
48644297|NCT04903093|DRUG|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
48314764|NCT04935125|PROCEDURE|Standard Program + Endurance and Strength training|Sessions of strength training added to a standard inpatient multidisciplinary programme
48314765|NCT04935125|PROCEDURE|Standard Program|Standard inpatient multidisciplinary programme (including endurance training)
48314766|NCT03754608|DIAGNOSTIC_TEST|MRI including cf-MRI, DTI, ASL and CVR.|A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
48644298|NCT04903093|DRUG|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
48644299|NCT04903093|DRUG|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
47965204|NCT00210405|DIETARY_SUPPLEMENT|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
47965205|NCT05707767|PROCEDURE|Resection surgery|Patients undergo resection surgery in our hospital.
48314767|NCT02683616|DEVICE|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
48644300|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 5-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 5 ounces.
48314768|NCT03487640|PROCEDURE|TARMR|Transanal resection of rectal mucosa for at least 5cm in length.
48314769|NCT03487640|PROCEDURE|LARSC|We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
48314770|NCT02058134|DEVICE|cardioPAT cell saver|
48314771|NCT00937768|DRUG|Goserelin Acetate|Given SC
48644301|NCT06690892|DIETARY_SUPPLEMENT|Ready-to-eat beef in frozen, 1-oz packages|The dietary intervention lasts 12 weeks for each individual. Participants in the control group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 1 ounces.
48644302|NCT02688166|OTHER|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
48644303|NCT01657942|DEVICE|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
48644304|NCT06690073|OTHER|Motor Relearning Program|"Total duration of the intervention is 45 minutes per session (30 minutes of CPT treatment followed by 15 minutes MRP), three sessions per week.~MRP of sitting and standing activities: The physical therapist will instruct the participant, who will be seated in an armrest-equipped chair, to keep their feet back and position their trunk forward.. The participant will then be guided to press down through the affected foot, stand up quickly, and move their hips forward. The therapist will suggest pressing down through the participant's knee along the leg while moving it forward through the affected foot.~MRP of standing to sitting: The participant will stand while the physiotherapist assists with anterior shoulder movement and knee bending at the start of the transition. The therapist will then help maintain weight on the affected leg while sitting. The participant will progress by standing and sitting at different seat heights, stopping at various points in the ROM, and changing speed."
47965206|NCT02231775|DRUG|Dabrafenib|Given PO
47965207|NCT02231775|OTHER|Laboratory Biomarker Analysis|Correlative studies
48266788|NCT02772861|DIETARY_SUPPLEMENT|Amino Acid Supplement - One dose|20gr
47965208|NCT02231775|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
47965209|NCT02231775|DRUG|Trametinib|Given PO
47965210|NCT04063930|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Sodium zirconium cyclosilicate (a hyperkalemia treatment)
48266789|NCT02772861|DIETARY_SUPPLEMENT|3-Methylhistidine|120mgr
48266790|NCT06391398|BEHAVIORAL|Stoma care education with the Stoma Care Training Belt|Stoma care education
47965211|NCT04063930|DRUG|Placebos|Matching placebo
47965212|NCT00917566|DEVICE|Airtraq|intubation with airtraq
47965213|NCT00917566|DEVICE|Macintoch|use Macintoch laryngoscope for intubation
48314772|NCT00937768|OTHER|Laboratory Biomarker Analysis|Correlative studies
48314773|NCT00937768|DRUG|Leuprolide Acetate|Given IM
48115621|NCT05317572|DRUG|120 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 120 micrograms of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
48115622|NCT05317572|DRUG|160 mcg intrathecal morphine|"İntraoperative Management:~Spinal anesthesia was administered to each patient in a sitting position, after aseptic conditions were achieved with a midline approach. A 25 gauge pencil point spinal needle was placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 10 mg of hyperbaric bupivacaine, 20 mcg of fentanyl and 160 mcg of morphine were injected into the intrathecal space together with the determined morphine doses.~Postoperative analgesia management:~Diclofenac sodium 2 × 75 mg was administered intramuscularly to all patients. All patients received iv Patient Controlled Analgesia (PCA) prepared with fentanyl postoperatively. For patients with pain VAS score of 5 or more, meperidine was administered at a rate of 25 mg each time and with a total daily dose of 200 mg."
48115623|NCT02986906|DRUG|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
48314774|NCT00937768|OTHER|Quality-of-Life Assessment|Ancillary studies
48314775|NCT04897555|DEVICE|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
47965214|NCT03021460|DRUG|Ibrutinib|Given PO
48644305|NCT06690073|OTHER|Conventional Physical Therapy|Conventional Physical Therapy (CPT) will be administered to the control group three times per week for six weeks (45 minutes per session). CPT treatments such as mat activities, assisted movements, weight-bearing strategies, and gymnasium training will be given to the control group.
47965215|NCT03021460|OTHER|Laboratory Biomarker Analysis|Correlative studies
47965216|NCT03021460|BIOLOGICAL|Pembrolizumab|Given IV
47965217|NCT06394817|OTHER|No intervention|No intervention
48115624|NCT02986906|DRUG|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
48115625|NCT02986906|DEVICE|Ultrasound|The ultrasound was used for injection guidance
48115626|NCT03231722|DRUG|Panitumumab|6 mg/kg iv over 60 minutes, day 1
48115627|NCT03231722|DRUG|Irinotecan|150 mg/sqm iv over 60 minutes day 1
48115628|NCT03231722|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
48115629|NCT03231722|DRUG|l-leucovorin|200 mg/sqm iv over 2 hours
48115630|NCT03231722|DRUG|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
48115631|NCT01778283|BIOLOGICAL|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
48115632|NCT02033148|DRUG|icotinib hydrochloride|Given PO
48115633|NCT02033148|OTHER|laboratory biomarker analysis|Correlative studies
48314776|NCT05950477|DIAGNOSTIC_TEST|Depression Questionnaires|Center of Epidemiological Studies-Depression Scale (CES-D) Patient Health Questionnaire (PHQ-9) Diabetes Treatment Satisfaction Questionnaire (DTSQ) Well-Being Index (WHO-5)
48644306|NCT06681220|COMBINATION_PRODUCT|PARP inhibitor/Temozolomide|PARP inhibitor 200mg/day +Temozolomide 40mg/day daily will be given in combination x21 days each cycle
47965218|NCT06008821|PROCEDURE|Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine|60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)
48115634|NCT02033148|OTHER|pharmacological study|Correlative studies
48115635|NCT04811950|DEVICE|Emerald|Complete blood countdevice
48115636|NCT04767698|DRUG|Belimumab|200 mg SC weekly for 36 months
48115637|NCT04767698|DRUG|Short-course Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
48115638|NCT04767698|DRUG|Continued Ocrelizumab|300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
48314777|NCT03342391|OTHER|Transnasal esophagoscopy|single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
48314778|NCT01891760|DEVICE|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
48314779|NCT01891760|DEVICE|Profore|Four-layer compression bandaging therapy.
48314780|NCT03768531|DRUG|Nivolumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
48314781|NCT03768531|DRUG|Cabrilizumab|Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
48314782|NCT04136353|DRUG|Darolutamide|2 x 300mg oral tablets twice daily for 96 weeks
48115639|NCT00484614|PROCEDURE|Positron Emission Mammography|Molecular Imaging Device
48115640|NCT00484614|PROCEDURE|Magnetic Resonance Imaging|Imaging Device
48115641|NCT02120911|DRUG|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
48115642|NCT03182010|DEVICE|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
48115643|NCT03182010|DEVICE|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
48115644|NCT01843569|BIOLOGICAL|In Vitro maturation|
48644307|NCT06681220|DRUG|Lurbinectedin|Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle
48314783|NCT04136353|DRUG|Placebo oral tablet|2 oral tablets twice daily for 96 weeks
48314784|NCT04136353|DRUG|Luteinizing Hormone-Releasing Hormone Analog|All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
48314785|NCT04136353|RADIATION|External Beam Radiotherapy|All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
48314786|NCT05060666|DRUG|Ivermectin|"2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~* 15 mg for 40-60 kg = 5 tablets à 3 mg~* 18 mg for 60-80 kg = 6 tablets à 3 mg~* 24 mg for \> 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg."
47965219|NCT06008821|PROCEDURE|Bilateral sham block with normal saline|10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)
47965220|NCT04962178|PROCEDURE|Primary PCI|The patients assigned to early invasive strategy group will receive the primary PCI.
47965221|NCT04962178|OTHER|Optimal medical therapy with primary PCI not performed|The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
47965222|NCT01524471|PROCEDURE|Per Oral Endoscopic Myotomy|
47965223|NCT00563498|DRUG|Glutamine|
47965224|NCT02817308|OTHER|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
47965225|NCT03673449|DEVICE|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
47965226|NCT04453371|DRUG|Tissue plasminogen activator|"In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
47965227|NCT04453371|DRUG|Ringer solution|"In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
47965228|NCT03974425|DRUG|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
48314787|NCT05060666|DRUG|Placebo|"An analogous number of tablets is administered for placebo:~* 5 tablets for 40-60 kg~* 6 tablets for 60-80 kg~* 8 tablets for \> 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin."
48314788|NCT02004587|DRUG|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
48484863|NCT04392284|BEHAVIORAL|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
48644308|NCT06688539|DRUG|Varenicline Pill|In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
48644309|NCT06688539|BEHAVIORAL|Contingency management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
48644310|NCT06688539|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.
48644311|NCT05302609|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
48644312|NCT06608927|DRUG|Quemliclustat|Administered as specified in the treatment arm
48115645|NCT01462058|DIETARY_SUPPLEMENT|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
48115646|NCT01462058|DRUG|Placebo|Placebo, daily, 12 weeks
48115647|NCT05726604|OTHER|Respiratory gating|10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality
48115648|NCT00159783|DRUG|asenapine|Asenapine, 40 weeks
48314789|NCT01683071|DRUG|Placebo|Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
48314790|NCT01683071|DRUG|EXPAREL 67 mg|5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
48314791|NCT01683071|DRUG|EXPAREL 133 mg|10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
48115649|NCT00159783|DRUG|Olanzapine|Olanzapine, 40 weeks
48266791|NCT00000815|BIOLOGICAL|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
48115650|NCT01638611|DRUG|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
48314792|NCT01683071|DRUG|EXPAREL 266 mg|20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
48314793|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
48484864|NCT01882179|DRUG|Mineralocorticoid receptor antagonist potassium-canrenoate|
48484865|NCT01882179|DRUG|placebo|
48484866|NCT04012372|OTHER|ROSA Water|Ad libitum hydration with ROSA oligomineral water
48484867|NCT04012372|OTHER|Control water|Ad libitum hydration with other waters
48484868|NCT03250975|DRUG|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
48484869|NCT03250975|OTHER|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
48644313|NCT06608927|DRUG|Placebo|Administered as specified in the treatment arm
47965229|NCT06111820|BEHAVIORAL|Improving Access to Community Therapies (iACT)|The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
47965230|NCT02579239|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
47965231|NCT02579239|BIOLOGICAL|Placebo|Concentrate for solution for infusion
47965232|NCT01702961|DRUG|Melphalan|"Given on Day -1~Melphalan is administered according to the current SOP."
47965233|NCT01702961|DRUG|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
47965234|NCT01702961|DRUG|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
48115651|NCT01638611|DRUG|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
48314794|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
47965235|NCT01702961|DRUG|BCNU|BCNU 300 mg/m2 IV given on Day -6
47965236|NCT01702961|DRUG|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
47965237|NCT01702961|DRUG|Stem Cells|Stem cells given on Day 0
47965238|NCT01927172|DEVICE|AirSonea|
47965239|NCT06005350|DIETARY_SUPPLEMENT|Niagen|Nicotinamide-Riboside-Chloride Preparation 1000mg/day
48115652|NCT05886491|DRUG|GDX012|GDX012 suspension for IV infusion.
48115653|NCT05886491|DRUG|Chemotherapy Agents|Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
48314795|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
48314796|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
47965240|NCT06005350|OTHER|Placebo|Placebo Preperation
48115654|NCT03157401|DRUG|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
48115655|NCT03157401|DRUG|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
48314797|NCT02163304|OTHER|Sucrose|
48314798|NCT02163304|OTHER|Artificial Sweetner|
48314799|NCT02163304|OTHER|Tasteless Solution|
48314800|NCT03994926|DEVICE|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
48314801|NCT03994926|DRUG|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
48314802|NCT00078962|BIOLOGICAL|GTI-2040|Given IV
48314803|NCT00078962|DRUG|gemcitabine hydrochloride|Given IV
48484870|NCT02573935|DRUG|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
48484871|NCT02573935|DRUG|Placebo|Placebo tablet twice daily for 63 days
48484872|NCT02573935|DRUG|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
48484873|NCT02489604|DRUG|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
48484874|NCT02489604|DRUG|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
48484875|NCT04142008|DEVICE|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
48644314|NCT06608927|DRUG|Nab-paclitaxel|Administered as specified in the treatment arm
48644315|NCT06608927|DRUG|Gemcitabine|Administered as specified in the treatment arm
47965241|NCT04971343|DIAGNOSTIC_TEST|Access HIV_blood donor|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
48115656|NCT03157401|DRUG|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
48115657|NCT01538914|PROCEDURE|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
48115658|NCT01538914|PROCEDURE|PCA|Postoperative pain is controlled with intravenous PCA.
48115659|NCT05640102|DRUG|Zanubrutinib|Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
48115660|NCT06619561|DRUG|Vimseltinib|Administered orally
48115661|NCT06090786|DIAGNOSTIC_TEST|MRD assessment|Bone marrow withdrawal for MRD quantification
48314804|NCT00078962|OTHER|laboratory biomarker analysis|Correlative studies
48484876|NCT00933959|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
48115662|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
48115663|NCT00981968|DRUG|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
48115664|NCT05957406|DEVICE|Acumen HPI Smart Alerts and Smart Trends Software|Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.
48115665|NCT05957406|DEVICE|The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff|Device: HemoSphere ClearSight Module and Pressure Controller, and adult Acumen IQ finger cuff
48115666|NCT06677164|PROCEDURE|Gluteus Maximus strengthening exercise|Maximus strengthening exercise for eight weeks using weight progression tools either elastic band or sand weight by assuming two modes of exercises (clamshell exercise, prone hip extension) with stretching exercise (hamstring, gastrocnemius, soleus, and plantar fascia) 2 sessions per week for 8 weeks
48115667|NCT06677164|DEVICE|high-intensity laser therapy|A 3-phase treatment program will be performed in each session on the plantar fascia area. Treatment of trigger points in phase 1 and 2 by using power of 9 watts, E2C mode for 6 minute of 2 phases. The draining and vascularization-promoting application involve the whole foot sole, starting from the heel area in phase three by using power of 9 watts, CW mode with energy of 100J/cm2.
48314805|NCT00078962|OTHER|pharmacological study|Correlative studies
48484877|NCT00933959|BEHAVIORAL|Sleep Hygiene|Treatment as usual
48484878|NCT04441099|DRUG|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
48484879|NCT05838521|DRUG|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
48484880|NCT00449319|PROCEDURE|Identification of appropriate therapies according to risks factors|
48484881|NCT00449319|DRUG|Daunorubicine|
48115668|NCT02302300|DEVICE|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
48115669|NCT05142878|DEVICE|Ultracore Repose® mattress|Residents will be placed on the Ultracore Repose® mattress during 14 days
48115670|NCT06666972|DIAGNOSTIC_TEST|PCR MTB/NTM|• The Polymerase chain reaction (PCR) MTB/NTM MDR-TB test is an innovative technology that offers a cutting-edge approach to the precise diagnosis of tuberculosis and nontuberculous mycobacterial infections (NTM).
48115671|NCT01171625|DEVICE|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
48115672|NCT03010553|PROCEDURE|Detection and resection of sentinel lymph node|
48115673|NCT04661410|BEHAVIORAL|Reward Re-Training|A brief, 10-session group-based behavioral treatment that is designed to indirectly change binge eating by directly focusing on building a more rewarding life. RRT hypothesizes that reductions in binge eating will occur as life becomes more rewarding because individuals will no longer need to rely on binge eating as a primary source of momentary reward. RRT notes that in order to live a satisfying life, individuals need to experience an adequate amount of reward in two overlapping yet distinguishable domains: momentary reward (i.e., the active experience of pleasure in the moment) and sustained reward (i.e., a deeper and more long-lasting sense of fulfillment and meaning that arises from building a personally valued life). A key aspect of RRT is an emphasize on building lasting and meaningful social relationships given the clear evidence that social connectedness can enhance both momentary reward and sustained reward.
48266792|NCT00000815|BIOLOGICAL|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
48314806|NCT00130806|DRUG|MK0478 (muraglitazar)|
48314807|NCT00130806|DRUG|Comparator: placebo|
48314808|NCT00469755|DRUG|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
48314809|NCT00469755|DRUG|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
48484882|NCT00449319|PROCEDURE|Transplant|
48484883|NCT03093818|OTHER|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
48484884|NCT00933881|OTHER|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
48115674|NCT04661410|BEHAVIORAL|Supportive Therapy|A brief, 10-session group-based treatment that is designed to instill hope and optimism and to increase social connection and support through a non-directive group leader that allows the patients to determine the focus of each session. The group leader will act as an empathetic provider by using reflective listening, eliciting and validating affect, and offering empathic comments.
48115675|NCT00257283|DRUG|Omega-3-acid ethyl esters 90|
48115676|NCT02120599|DIETARY_SUPPLEMENT|ready-to-use supplementary food|
48115677|NCT02120599|DIETARY_SUPPLEMENT|corn-soy blend|
48115678|NCT02120599|DIETARY_SUPPLEMENT|iron|
48115679|NCT02120599|DIETARY_SUPPLEMENT|folic acid|
48644316|NCT06142422|PROCEDURE|stimulation device|"The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation."
48115680|NCT02120599|DIETARY_SUPPLEMENT|UNIMMAP|
48115681|NCT03593213|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
48314810|NCT00469755|DRUG|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
48314811|NCT02389816|DRUG|Placebo|Placebo tablets
48484885|NCT02485002|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
48484886|NCT02485002|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
48484887|NCT04153448|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
48484888|NCT06304935|OTHER|Use of injectable platelet rich fibrin after tonsillectomy by injection of IPRF in one tonsillar bed and use of other side as control|Compare both sides of tonsillar beds in post operative healing, pain and hemostasis
48644317|NCT04575961|DRUG|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles
48115682|NCT03593213|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
48115683|NCT06019299|BEHAVIORAL|Mindfulness Practice|Participants were instructed to practice mindfulness daily using their instructed approaches for a period of 4 weeks.
48115684|NCT01048931|PROCEDURE|single-port LAVH|single-port LAVH
48115685|NCT05188118|DRUG|Cabozantinib|60mg oral once daily for 12 weeks
48115686|NCT05188118|DRUG|Ipilimumab|1mg/kg intravenous once every 3 weeks over 12 weeks
48115687|NCT05188118|DRUG|Nivolumab|3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after
48115688|NCT05188118|DRUG|Lenvatinib|18mg oral once daily for 12 weeks
48115689|NCT05188118|DRUG|Everolimus|5mg oral once daily for 12 weeks
48115690|NCT05796739|DIAGNOSTIC_TEST|Non-invasive stress test|Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
48115691|NCT05796739|DIAGNOSTIC_TEST|Medical treatment without further testing|Optimal medical treatment for primary prevention.
48115692|NCT01812148|PROCEDURE|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
48115693|NCT01919645|OTHER|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
48115694|NCT03583125|DRUG|EOC317|tablet(s) PO
48115695|NCT03933605|DRUG|midazolam and palonosetron group|intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
48115696|NCT03933605|DRUG|palonosetron group|intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
48115697|NCT02477670|DRUG|AVP-786|
48115698|NCT02477670|DRUG|Placebo|
48115699|NCT00826852|DRUG|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
48115700|NCT05165082|DRUG|Timolol maleate 0.5% ophthalmic solution|Apply on affected finger or toes twice daily for 8 weeks
48115701|NCT05165082|PROCEDURE|Cryotherapy with liquid nitrogen|Conducted on affected finger or toes every other week for four sessions.
48115702|NCT05082714|DRUG|Tocilizumab|tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)
48115703|NCT05082714|DRUG|Baricitinib|The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
48115704|NCT01185782|DRUG|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
48314812|NCT02389816|DRUG|Vortioxetine|Vortioxetine tablets
48314813|NCT05700071|DIAGNOSTIC_TEST|MRI|MRI without contrast agent
48314814|NCT06346457|DRUG|Tamoxifen|Tamoxifen is 20 mg once daily for two to three weeks.
48314815|NCT06346457|DRUG|Letrozole|Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.
48314816|NCT06346457|DRUG|Letrozole + GnRH|When they take Letrozole + GnRh, the GnRh is an injection once a month.
48314817|NCT06116877|PROCEDURE|implant supported overdenture|mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
48484889|NCT05310799|OTHER|Shared Decision Making (SDM)|The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
48484890|NCT01762124|DEVICE|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
48484891|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Amino Acid daily for 13 days|A 30 mg zinc amino acid supplement is taken p.o. in the fasted state for 13 days.
47965242|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Hospitalized patient|"All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested)."
47965243|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis"
48644318|NCT06187428|OTHER|PainSMART-strategy|"Be PainSMART:er is a seven minute long film developed by the research group based on modern pain science and previous qualitative studies.~The film is divided into three sections:~Section 1- Educates that MSKP is a complex protective system that does not reflect the anatomical state of the body and provides reassurance that MSKP is rarely caused by serious pathology.~Section 2- Provides advice on active MSKP coping, such as encouraging work despite some pain, in an attempt to reconceptualise the belief that a painful body part needs to be rested.~Section 3- Aims to prepare patients for a biopsychosocial physiotherapy consultation by encouraging them to reflect on the film's messages.~In addition to the film, the questions posed to the participant at the initial consultation aim to facilitate the discussion around the film and MSKP reflections. Management subsequent to the initial consultation will follow usual management."
47965244|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-2 antibody positives|"Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays."
47965245|NCT04971343|DIAGNOSTIC_TEST|Access HIV_known HIV-1 p24 Ag positive|"All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.~* Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays"
47965246|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_Blood donor|"To fit with Canada's requirements:~* 4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.~* Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements"
47965247|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_HIV positive|"To fit with Canada's requirements:~o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents."
47965248|NCT04971343|DIAGNOSTIC_TEST|Access HIV_Canada's requirements_P24 Positive|"To fit with Canada's requirements:~* HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.~* Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS"
47965249|NCT04137705|OTHER|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
47965250|NCT00730405|DRUG|Albaconazole 100mg|Albaconazole for 36 weeks
47965251|NCT00730405|DRUG|Albaconazole 200mg|Albaconazole for 36 weeks
47965252|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 36 weeks
47965253|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
47965254|NCT00730405|DRUG|Placebo 400 mg|Placebo for 36 weeks
48484892|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Gluconate daily for 13 days|A 30 mg zinc gluconate supplement is taken p.o. in the fasted state for 13 days.
48484893|NCT02079675|DRUG|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
48115705|NCT01185782|DRUG|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
48115706|NCT06266780|BEHAVIORAL|PROMPTS Enhanced Family Planning Counselling|Based on a targeted human-centered-design process with pregnant and early postpartum mothers, the intervention consists of informative messages, counselling and reminders regarding postpartum family planning and birth spacing, leveraging an existing mobile health platform (PROMPTS) for intervention delivery and Jacaranda's established partnership with the Kenyan Ministry of Health, county health offices and public maternity hospitals method options. The intervention includes several features: activation of family planning discussions between pregnant and postpartum women and their health care providers, information provision, method selection support to help women choose their preferred method, and reminders to follow-up. The key feature is to help women make an informed plan about family planning in the prenatal or early postpartum period and follow through with this plan.
48115707|NCT04353674|DEVICE|Control group|Patients randomized into this group will receive standard of care for COVID-19 infection
48115708|NCT04353674|DEVICE|SLEDD with a L-MOD|Patients randomized to this group will undergo slow low efficiency daily dialysis for approximately 12 hours, 2 days in a row with a leukocyte modulatory device.
48115709|NCT05457127|DEVICE|Automatic Positive Airway Pressure (APAP)|"If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise."
48115710|NCT06553209|BIOLOGICAL|CM512|CM512 injection
48115711|NCT06553209|DRUG|Placebo|Placebo
48115712|NCT03615495|DEVICE|Flourish Pediatric Esphogeal Atresia device|The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
48115713|NCT04970979|OTHER|survey|questionnaire about the influencing factors of home-based cardiac rehabilitation
48115714|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
48115715|NCT00831675|BIOLOGICAL|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
48115716|NCT03567369|DRUG|Dexamethasone|Dexamethasone 4,0 mg/mL
48115717|NCT03567369|DRUG|Traumeel S|Traummel S 2,2 mg/mL
48484894|NCT02079675|DRUG|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
48484895|NCT02079675|DRUG|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
48644319|NCT06187428|OTHER|Usual physiotherapy management|Patients randomised to the control group follow usual MSKP physiotherapy management. Specifically, patients first contact their physiotherapy department online or via telephone and are triaged by a certified physiotherapist and are booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients in the control group receive online data collection questionnaires identical to those of the intervention group at baseline and prior to the consultation, excluding the film and the questions linked to the film. The initial consultation will take place as usual according to the preferences of the physiotherapist. The physiotherapist will pose one question at start of the consultation to acknowledge the completion of control group questionnaires. Management subsequent to the initial consultation will follow usual management.
47965255|NCT05713175|DEVICE|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
48115718|NCT04056039|DRUG|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
48115719|NCT04056039|DRUG|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
48115720|NCT04988568|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where patients will be interviewed.
48115721|NCT03791892|OTHER|Shoulder mobilization Group|Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
48115722|NCT03791892|OTHER|Conventional Treatment Group|Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
48266793|NCT00868686|DEVICE|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
48484896|NCT04740931|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
48484897|NCT04740931|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
47965256|NCT05713175|DEVICE|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
48115723|NCT05527262|BEHAVIORAL|Queen Square Upper Limb Neurorehabilitation Programme|A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.
48115724|NCT05527262|DEVICE|Immersive gaming therapy|The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
48115725|NCT02354885|DRUG|Tranexamic Acid|Coagulation Management / Efficiency
48115726|NCT03089840|DEVICE|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
48115727|NCT03957798|BEHAVIORAL|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
48115728|NCT04114968|OTHER|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
48115729|NCT04036877|OTHER|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
48115730|NCT04464421|BEHAVIORAL|Contingency Management (CM)|Participants were able to draw a gift card from a virtual fishbowl when their urine toxicology results are positive for buprenorphine metabolites. Gift card values were $25, $50, or $100.
48115731|NCT04464421|BEHAVIORAL|Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)|Participants had one-on-one sessions with a behavioral interventionist to discuss their goals regarding treatment, how to reach these goals, the importance of substance-free activities, and mindfulness skills.
48115732|NCT05870579|DRUG|[68Ga]Ga-NeoB|"\[68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions, at screening.~\[68Ga\]Ga-NeoB will be administered as a single intravenous (i.v.) dose."
48115733|NCT05870579|DRUG|[177Lu]Lu-NeoB|Study participants will receive \[177Lu\]Lu-NeoB once every cycle
48115734|NCT05870579|DRUG|Ribociclib|600 mg once daily (OD) days 1 to 21 every 28 days
48115735|NCT05870579|DRUG|Fulvestrant|500 mg at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and every 28 days thereafter
48115736|NCT05870579|OTHER|Goserelin|For pre/peri-menopausal women only.
48484898|NCT04740931|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
48484899|NCT00002352|DRUG|Lobucavir|
48484900|NCT04625322|OTHER|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
47965257|NCT05713175|DEVICE|Fixtoe device|Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
48484901|NCT06147726|OTHER|Upper extremity position matching exercises in virtual reality|In addition to conventional treatment approaches for 20 minutes 2 days a week for 8 weeks, joint positioning exercises (4 different game sequences of 4 minutes, 1 minute rest between each sequence, total 20 minutes) designed specifically for the individual's existing range of motion will be applied to the VR group.
48484902|NCT06147726|OTHER|Conventional physiotherapy|proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises
48484903|NCT01264159|DEVICE|Lung impedence-guided therapy|
47965258|NCT06116760|DEVICE|Anodal or sham tDCS|"Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training."
48115737|NCT01219205|PROCEDURE|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
48484904|NCT01264159|OTHER|Usual treatment of patients with developing acute heart failure|
48484905|NCT04624347|BEHAVIORAL|Access to video and movement curves|intervention of caregivers with access to videos and motion curves of the premature infant
48484906|NCT02251119|DRUG|Tipranavir|
48115738|NCT00866203|DRUG|HDS vs ProMECE/CytaBOM|
48484907|NCT02251119|DRUG|Ritonavir|
48484908|NCT02251119|DRUG|Loperamide|
48484909|NCT04387734|DRUG|Ocrelizumab|Ocrevus will be administered following the FDA's regulations.
48115739|NCT04566458|OTHER|No intervention|retrospective chart review study
48115740|NCT06677424|DEVICE|NeuroCatch® Platform 2|The NeuroCatch® Platform 2, a medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information. The device is approved as a medical device by Health Canada.
48115741|NCT02846389|OTHER|Moderate Exercise|Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
48644320|NCT04782180|DRUG|Descovy 200Mg 25Mg Tablet|daily Descovy tab by mouth
48644321|NCT04782180|BEHAVIORAL|PrEP|PrEP will be provided in a community setting by community-based harm reduction program.
47965259|NCT06116760|BEHAVIORAL|Audio-visual training|"90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse."
47965260|NCT03557697|BEHAVIORAL|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
47965261|NCT03557697|BEHAVIORAL|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
47965262|NCT04141488|OTHER|experimantal group|Control Group
47965263|NCT05492838|PROCEDURE|Immediate implantation with the Socket Shield Technique|Immediate implant surgery applied with the Socket Shield Technique
47965264|NCT04503785|DIAGNOSTIC_TEST|Manometry|Transnasal Esophageal manometry and Endoflip Balloon distensibility
47965265|NCT03699657|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
47965266|NCT03699657|DEVICE|SSM|Monopolar RFA using single switching mode (SSM)
47965267|NCT03699657|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
47965268|NCT02282579|DRUG|Pazopanib|Non interventional study
47965269|NCT02993393|OTHER|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
47965270|NCT02993393|OTHER|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
47965271|NCT00750815|DRUG|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
47965272|NCT00750815|DRUG|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
47965273|NCT05192109|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
47965274|NCT05192109|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
47965275|NCT04340778|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
47965276|NCT04340778|DRUG|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
47965277|NCT04340778|DRUG|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
47965278|NCT02798874|DRUG|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
47965279|NCT02798874|DRUG|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
48266794|NCT00868686|DEVICE|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
47965280|NCT00925093|DRUG|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
47965281|NCT00925093|DRUG|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
47965282|NCT00925093|DRUG|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
47965283|NCT04269447|DIAGNOSTIC_TEST|Structured imaging follow-up|Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.
47965284|NCT01496612|DRUG|Buspirone|
47965285|NCT01496612|DRUG|Placebo|
47965286|NCT01678430|DRUG|Ofatumumab|
47965287|NCT01678430|DRUG|Chlorambucil|
47965288|NCT01678430|DRUG|Bendamustine|
48266795|NCT00868686|DEVICE|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
48484910|NCT04387734|DRUG|Platform|The applications of the platform DMTs will follow the FDA-approved regulations.
48484911|NCT00364806|DRUG|Prochlorperazine|
48484912|NCT00364806|DRUG|Metoclopramide|
48115742|NCT03161327|DEVICE|ABI using QuantaFlo™|"Perform Digital ABI:~* Will be performed by the nurse/medical assistant with training to perform this test~* The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~* The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~* Usually each digit takes about 15 seconds to obtain a waveform~* At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
48115743|NCT03309488|DIAGNOSTIC_TEST|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
48115744|NCT03178292|DRUG|Levofloxacin|Levofloxacin 500Mg daily for 5 days
48115745|NCT03178292|DRUG|Placebo|Placebo Oral Tablet daily for 5 days
48314818|NCT03054467|DRUG|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
48314819|NCT03054467|DRUG|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
48314820|NCT04018469|OTHER|No Interventions|No Interventions
48314821|NCT04279379|DRUG|Sintilimab|200mg d1,ivdrip, repeated every 3 weeks
48314822|NCT04279379|DRUG|Decitabine|10mg d1-5, ivdrip,repeated every 3 weeks
48484913|NCT03256422|DRUG|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
48484914|NCT05012202|DEVICE|Hemi device|A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.
48484915|NCT03060759|DEVICE|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
48484916|NCT06078813|RADIATION|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
48484917|NCT02689999|DRUG|Dexrabeprazole 10 mg Enteric-Coated Tablets|
48484918|NCT02253602|DRUG|Ferumoxytol|maximum rate of administration 1 ml/sec
48484919|NCT03336320|DEVICE|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
48484920|NCT00838942|BEHAVIORAL|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
48484921|NCT00817947|DEVICE|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
48484922|NCT04651322|DEVICE|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~\*Robot Assisted Arm training + Conventional occupational therapy"
48484923|NCT04651322|BEHAVIORAL|Conventional therapy|The control group received the usual conventional therapy \*Only Conventional occupational therapy
47965289|NCT03204019|DRUG|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
47965290|NCT03204019|DRUG|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
48484924|NCT01267006|DRUG|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
48484925|NCT01267006|DRUG|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
47965291|NCT04960501|PROCEDURE|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
47965292|NCT04861389|PROCEDURE|Arterial access|Arterial access for primary percutaneous coronary intervention in STEMI patients
47965293|NCT03655509|PROCEDURE|Dynamic test ACTH stimulation|
47965294|NCT03052491|DIETARY_SUPPLEMENT|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
48484926|NCT00027508|DRUG|trabectedin|
48644322|NCT06047717|OTHER|Virtual Reality Driving Task|"Participants will steer a virtual car with the goal of staying in the center of a single-lane roadway while traveling at a constant speed of 26.6 m/s (approximately 60 miles/hr). The roadway alternates between a series of straights and turns of different radii to both the left and the right. This allows for careful control of task difficulty, and for the repeated presentation of specific conditions across multiple trials (i.e. turns in the road) in a randomized order. In addition, the density of the visual texture elements in the virtual environment that provide optic flow (OF) signal is also varied. The low-density OF condition has no road texture or foliage, and only the solid road edges on a flat-black ground plane. The medium-density OF condition has sparse textural elements distributed on the ground plane, and the high-density OF condition has high density road texture and a canopy of road-side trees that provide texture extending far above the horizon."
48644323|NCT06222294|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
47965295|NCT01433705|OTHER|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
47965296|NCT01433705|OTHER|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
47965297|NCT01433705|OTHER|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
47965298|NCT01433705|DRUG|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
47965299|NCT00246155|BIOLOGICAL|Botulinum toxin type A|
47965300|NCT01370356|DRUG|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
47965301|NCT01370356|DRUG|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
47965302|NCT04014816|OTHER|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
47965303|NCT04014816|OTHER|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
47965304|NCT00395304|DRUG|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
47965305|NCT00395304|DRUG|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
47965306|NCT00395304|DRUG|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
47965307|NCT06359392|OTHER|No message|Participants will not be exposed to a message in this arm of the intervention.
47965308|NCT06359392|OTHER|Culture-centric message|Participants in this arm of the study will watch a 2-minute video on palliative care developed specifically for these American Indian communities.
47965309|NCT06359392|OTHER|General messge|Participants receiving this intervention will watch a 2-minute video developed by the National Hospice and Palliative Care Organization to teach about palliative care.
47965310|NCT02854631|DRUG|Selonsertib|18 mg tablet administered orally once daily
47965311|NCT02854631|DRUG|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
47965312|NCT02854631|DRUG|Placebo|Selonsertib placebo tablet administered orally once daily
47965313|NCT04903990|OTHER|Blood sample|As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
47965314|NCT05446805|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
47965315|NCT05446805|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
47965316|NCT03408483|DRUG|Quadratus Lumborum Block (QLB)|Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
47965317|NCT03408483|DRUG|Standard of Care|This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
48484927|NCT01468376|DIETARY_SUPPLEMENT|GLU-01|14 day dosing
48484928|NCT01468376|DIETARY_SUPPLEMENT|GLU-02|14 day dosing
48484929|NCT01468376|DIETARY_SUPPLEMENT|GLU-03|14 day dosing
48644324|NCT06222294|DRUG|Propofol Medium and Long Chain Fat Emulsion Injection|Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
48644325|NCT01788774|DRUG|Risperidone ISM 50 mg|
48314823|NCT03334162|BEHAVIORAL|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
48314824|NCT01952730|BIOLOGICAL|GVAX|
48314825|NCT01671969|OTHER|very low calorie diet|medically supervised diet
48314826|NCT04236479|BIOLOGICAL|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
48314827|NCT00414310|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days.
48484930|NCT01468376|DIETARY_SUPPLEMENT|GLU-04|14 day dosing
48484931|NCT01468376|DIETARY_SUPPLEMENT|GLU-05|14 day dosing
48484932|NCT01468376|DIETARY_SUPPLEMENT|GLU-06|14 day dosing
48484933|NCT00057486|DRUG|IL-12|
48484934|NCT00488813|DRUG|Third generation cephalosporins|
48484935|NCT02135965|DRUG|2mg of Albuterol|2mg of Albuterol on metabolic rate
48314828|NCT00414310|DRUG|Valproic Acid|50 mg/kg orally daily for 7 days
48484936|NCT02135965|DRUG|4mg of Albuterol|4mg of Albuterol on metabolic rate
48484937|NCT02135965|DRUG|100mg of Caffeine|100mg of caffeine on metabolic rate
48484938|NCT02135965|DRUG|200mg of Caffeine|200mg of Caffeine on metabolic rate
48484939|NCT02135965|DRUG|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
48484940|NCT02135965|DRUG|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
48484941|NCT02135965|DRUG|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
48484942|NCT02135965|DRUG|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
48484943|NCT04625075|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
48484944|NCT04625075|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to assess coronaries
48484945|NCT04625075|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|ECG to assess rhythm
48484946|NCT04625075|DIAGNOSTIC_TEST|Blood samples|renal function liver function full blood count, hematocrit glucose
48484947|NCT01300624|BEHAVIORAL|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
48484948|NCT02380079|DRUG|SCD-101|Administered as gelatin capsules
48484949|NCT02128555|PROCEDURE|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
48484950|NCT02128555|PROCEDURE|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
48484951|NCT04092920|DEVICE|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
48484952|NCT03675334|PROCEDURE|Root coverage with collagen matrix graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
47965318|NCT02723214|PROCEDURE|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
48314829|NCT03609528|DEVICE|CamPROBE|To be completed
48314830|NCT00471445|DRUG|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
48314831|NCT00471445|OTHER|placebo|Applied topically
48314832|NCT01897181|DEVICE|Hearing aids|Using hearing aids for 12 months
48484953|NCT03675334|PROCEDURE|Root coverage with subepithelial connective tissue graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
48484954|NCT03675334|OTHER|Basic periodontal treatment|profilaxis, coronary polishing and scaling and root planning
48484955|NCT04667936|OTHER|Treatment group|None, solely treatment documentation
48484956|NCT01345994|PROCEDURE|electro-acupuncture|acupuncture stimulation with electricity
48484957|NCT02293291|DIETARY_SUPPLEMENT|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
48644326|NCT01788774|DRUG|Risperidone ISM 75 mg|
48644327|NCT01788774|DRUG|Risperidone ISM 100 mg|
48314833|NCT03957655|BIOLOGICAL|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
48314834|NCT04233359|PROCEDURE|Local anesthetic thoracoscopy|Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
48314835|NCT04233359|PROCEDURE|US-guided pleural biopsy|In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
48314836|NCT04935060|BEHAVIORAL|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
48115746|NCT06588894|BEHAVIORAL|Questionnaire and Physical Exam|Individuals motor imagery skills will be assessed using a mental chronometer and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using the Montreal Cognitive Assessment questionnaire.
48314837|NCT04935060|BEHAVIORAL|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
48314838|NCT01596959|PROCEDURE|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
48314839|NCT01596959|PROCEDURE|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
48314840|NCT01281852|DRUG|Cisplatin|Given IV
48314841|NCT01281852|OTHER|Laboratory Biomarker Analysis|Correlative studies
48314842|NCT01281852|DRUG|Paclitaxel|Given IV
48314843|NCT01281852|DRUG|Veliparib|Given PO
48314844|NCT02034357|OTHER|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
48314845|NCT02034357|OTHER|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
48314846|NCT02814357|OTHER|Control (market standard)|
48314847|NCT02814357|OTHER|wheat flour|
48314848|NCT02814357|OTHER|chickpea flour|
48314849|NCT02814357|OTHER|guar gum|
48314850|NCT02814357|OTHER|barley|
48314851|NCT05191823|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
48314852|NCT05191823|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
48314853|NCT02515864|DRUG|FYU-981|
48314854|NCT02515864|DRUG|Placebo|
48314855|NCT02515864|DRUG|Moxifloxacin|
48314856|NCT02515864|DRUG|Moxifloxacin Placebo|
48484958|NCT02715219|OTHER|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
48484959|NCT03445299|BEHAVIORAL|Music|Listening to music for 30 minutes at bedtime
48644328|NCT04028063|DRUG|Balstilimab|Balstilimab (AGEN2034) is a human monoclonal antibody that targets programmed cell death 1 (PD-1). Engagement of PD-1 by its ligands, programmed death ligand (PD-L1) and PD-L2, leads to signal transduction that inhibits important aspects of T cell function including proliferation, cytokine production and cytolytic activity. Balstilimab (AGEN2034) potently inhibits PD-1 binding to PD- L1 and PD- L2 and is intended to reverse the immunosuppressive effects of this signaling pathway in the context of tumor immuno-surveillance by T cells. Balstilimab (AGEN2034) is intended for development as a treatment for advanced malignancies as a single agent or in combinations.
48644329|NCT04028063|DRUG|Zalifrelimab|Zalifrelimab (AGEN1884) is a fully human monoclonal immunoglobulin G1 κ subclass (IgG1κ) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152). Zalifrelimab (AGEN1884) is being developed as a monotherapy for cancer indications with potential for future development in combination with other immunotherapies.
48314857|NCT01651052|PROCEDURE|Heart Valve Surgery|Implant of an aortic valve, Model 11000
48314858|NCT03698513|DRUG|BMS-986177|BMS-986177 capsule
48314859|NCT03698513|OTHER|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
48314860|NCT03698513|DRUG|Clopidogrel|Clopidogrel tablet
48314861|NCT03698513|DRUG|Aspirin|Aspirin tablet
48314862|NCT00645567|DEVICE|Unassisted Manual Transfer|No device assistance
48314863|NCT00645567|DEVICE|Standard Transfer Board|Flat surface board
48314864|NCT00645567|DEVICE|Glide n' Go|Flip down power lift chair
48314865|NCT00645567|DEVICE|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
48314866|NCT00645567|DEVICE|Ryno lift|Lift for the wheelchair
48314867|NCT00093093|DRUG|Viramidine|
48314868|NCT00093093|DRUG|Ribavirin|
48314869|NCT00093093|DRUG|pegylated interferon alfa-2a|
48314870|NCT00657852|DRUG|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
48314871|NCT00657852|DRUG|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
48314872|NCT02426593|DEVICE|IMED-4|Non-invasive novel lung hydration status sensor.
48314873|NCT04378920|DRUG|LEAF-4L6715|LEAF-4L6715
48314874|NCT02617342|BEHAVIORAL|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
48314875|NCT06480305|DIETARY_SUPPLEMENT|Post dinner snack|one walnut, 2 cashews, 2 almonds, and 2 pistachios.
48314876|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-1|Prepackaged dose of 25 peanuts.
48314877|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-2|Prepackaged dose of 25 raisins
48314878|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-3|Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.
48314879|NCT05286073|PROCEDURE|Endodontic Root Canal Treatment|Root canal shaping procedures were performed. Irrigation was done after each three pecks of endodontic file. After instrumentation (Groups 1-3), the canals were dried with sterile paper points. The dentinal walls were then coated with Sealapex. For vertical root fracture resistance testing, sample preparation was done in acrylic blocks. Then roots were coated with polyvinylsiloxane impression material. After that roots were inserted again into acrylic resin blocks. The acrylic blocks with the vertically aligned roots were mounted in the Instron testing machine. 0.5 mm diameter round tip stainless-steel rod was fixed to the universal testing machine. The universal testing machine was adjusted and vertical compressive force was applied at a crosshead speed of 1mm/min. The Instron tester applied a slowly increasing force, until the root fractured. The maximum amount of force necessary to fracture every sample was recorded in Newton (N).
48314880|NCT03498417|DIAGNOSTIC_TEST|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
48314881|NCT05650073|OTHER|Immersive soundscapes|Audio technology used to create a three-dimensional sound experience in which the user is immersed in a virtual soundscape
48314882|NCT03744546|DRUG|ABBV-8E12|Solution for infusion
48314883|NCT01726920|DRUG|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
48314884|NCT01726920|DRUG|naratriptan|Tablets containing naratriptan 2,5 mg
48314885|NCT01726920|DRUG|naproxen|Tablets containing naproxen 500 mg
48314886|NCT01850745|OTHER|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
47965319|NCT01090843|PROCEDURE|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
48314887|NCT04586114|DRUG|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
48484960|NCT04306640|OTHER|Sagittal Cervical Posture Corrective Orthotic Device|The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
47965320|NCT01090843|DEVICE|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
48314888|NCT04868591|OTHER|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
48314889|NCT04868591|OTHER|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
48314890|NCT05848830|DIETARY_SUPPLEMENT|Mult-ingredient supplement|A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin
48314891|NCT05848830|DIETARY_SUPPLEMENT|Placebo|The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.
48314892|NCT05848830|BEHAVIORAL|Concurrent exercise training|All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
48314893|NCT05792670|PROCEDURE|Changing mechanic ventilatation parameters|The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
48314894|NCT00556218|BEHAVIORAL|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
48314895|NCT00556218|BEHAVIORAL|No Meditation|No meditation; usual care.
48314896|NCT04792437|PROCEDURE|surgery|surgery
48314897|NCT03591146|DRUG|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
48484961|NCT04882319|DRUG|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
48484962|NCT04882319|DRUG|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
48484963|NCT04882319|DRUG|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
48484964|NCT04036149|DEVICE|Intraocular lens|Implantation as part of cataract surgery
48644330|NCT04028063|DRUG|Doxorubicin|Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.
48644331|NCT04028063|DRUG|Botensilimab|Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.
47965321|NCT01090843|DEVICE|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
47965322|NCT00903396|DRUG|palonosetron hydrochloride|Given IV
47965323|NCT00903396|OTHER|placebo|Given IV
47965324|NCT03311633|PROCEDURE|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
47965325|NCT03675100|PROCEDURE|colonoscopic mucosal biopsy|colonoscopic mucosal biopsy was undertaken for every participant
47965326|NCT05780918|OTHER|Best Case/Worst Case-ICU Communication Tool|"This intervention uses scenario planning and a daily report of the interplay between major events and prognosis to illustrate a range of long-term outcomes and treatment experiences. By using a graphic aid to illustrate what we are hoping for, what we are worried about, and the evolution of the patient's story over time, the tool aims to facilitate dialogue among older adult trauma patients, their families, and the trauma team. Because the tool delivers critical prognostic information over the longitudinal course of care, subsequent treatment decisions can be made within the context of the patient's overall health status. This information alerts patients and families to the life-limiting nature of serious injury and provides an entrée for them to consider how comfort-focused strategies might better align with patients' end-of-life goals.~All clinicians will be trained to create, use, and/or reference the graphic aids with patients depending on their roles in the trauma ICU."
47965327|NCT02591290|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses with 8-week interval)
47965328|NCT00841646|BIOLOGICAL|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
47965329|NCT03725930|DRUG|Clonidine|clonidine intranasal premedication in preschool infants
47965330|NCT03725930|OTHER|Placebo|Placebo intranasal premedication
48314898|NCT03591146|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
48314899|NCT01511419|BIOLOGICAL|LAIV H7N3|2 doses of vaccine
48314900|NCT01511419|BIOLOGICAL|placebo|2 doses of placebo
48314901|NCT04538885|BIOLOGICAL|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
48314902|NCT04274166|DRUG|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
48314903|NCT01694576|DRUG|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
48314904|NCT04081935|DEVICE|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
48484965|NCT02560974|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
48484966|NCT02560974|DRUG|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.
48484967|NCT01508819|OTHER|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
48484968|NCT04851431|BEHAVIORAL|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
48484969|NCT01271179|PROCEDURE|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
48484970|NCT01271179|PROCEDURE|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
48484971|NCT00055484|DRUG|zonisamide|
48484972|NCT04686227|DIAGNOSTIC_TEST|3D Ultrasound|Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
48484973|NCT03744559|BEHAVIORAL|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
48644332|NCT02115282|PROCEDURE|Biospecimen Collection|Undergo collection of blood and archived tissue samples
48644333|NCT02115282|PROCEDURE|Computed Tomography|Undergo CT
48115747|NCT06588894|BEHAVIORAL|Motor Imagery Ability|Individuals motor imagery skills will be assessed using a mental stopwatch and mental rotation, body awareness will be assessed using the Body Awareness Questionnaire, and cognitive functions will be assessed using theMontreal Cognitive Assessment questionnaire.
48115748|NCT00569049|PROCEDURE|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
48115749|NCT00855686|DRUG|Memantine|20mg once daily oral dose
48115750|NCT00855686|DRUG|Placebo|Daily oral dose
48484974|NCT03744559|BEHAVIORAL|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
48115752|NCT06112899|BEHAVIORAL|Nordic Hamstring Exercise|The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
48115753|NCT06447675|OTHER|Hyperthermic Baths|The intervention will consist of 12 weeks of repeated (2x/day) 20-min body immersions.
48115754|NCT05817370|BEHAVIORAL|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
48115755|NCT02455752|PROCEDURE|LE-TME|Retroperitoneal approach for total mesorectal excision
48115756|NCT03895346|BEHAVIORAL|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
48314905|NCT05602441|BEHAVIORAL|VALID - diabetes supportive clubs|"The VALID - diabetes supportive clubs comprised diabetes classes and diabetes clubs, to highlight two prominent aspects of diabetes self-management: education and peer support.~The diabetes club meeting was held twice a month during a 9-month intervention, consisting of a focused delivery of the knowledge and discussion following the topic in the monthly class. Club meetings also included dedicated time for blood glucose testing and sharing experiences to deal with the difficulties of the periodic insurance examinations process. Finally, the club meetings provided the participants with emotional support to deal with the stigma and sadness in their daily lives.~Core messages aimed to strengthen daily self-management and boost the spiritual bond between individuals with T2D toward a healthy, happy life with T2DM. In addition, the intervention aimed to strengthen the capacities of grassroots health care workers in diabetes consultations and communication in rural communities."
48314906|NCT02928549|BEHAVIORAL|semi-structured interviews|
48314907|NCT02388022|DEVICE|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
48314908|NCT01672437|OTHER|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
48314909|NCT04568941|BEHAVIORAL|Vacuum-Assisted Biopsy|Vacuum-Assisted Biopsy
48314910|NCT04568941|BEHAVIORAL|Core Needle Biopsy|Core Needle Biopsy
48314911|NCT04568941|BEHAVIORAL|Intraoperative Excisional Biopsy|Intraoperative Excisional Biopsy
48314912|NCT05066828|OTHER|two pieces obturator|patient received two pieces obturator connecting by magnet attachment
48644334|NCT02115282|DRUG|Entinostat|Given PO
48644335|NCT02115282|DRUG|Exemestane|Given PO
47965331|NCT05353283|BEHAVIORAL|Motivational Interviewing Counselling|Motivational interviewing-based counseling will be provided to the participant based on the results of the urine test
47965332|NCT05353283|DEVICE|Point-of-care Urine Tenofovir Measurement|Urine will be collected and the presence or absence of tenofovir will be measured with the point-of-care urine tenofovir test.
47965333|NCT01847274|DRUG|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
47965334|NCT01847274|DRUG|placebo|
47965335|NCT06504914|BEHAVIORAL|Assigned Interventions|Behavioral: RN-CHeFRx The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
47965336|NCT06394297|RADIATION|SBRT|SBRT to reproduce HDR BT dose distribution in non-operated patients LACC
47965337|NCT04158297|PROCEDURE|ESWL vs SOPIL|To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
47965338|NCT00501670|PROCEDURE|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
47965339|NCT00501670|PROCEDURE|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
47965340|NCT04459533|DEVICE|TOF protocol|"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If \>=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."
47965341|NCT01734356|OTHER|Skin biopsies|
47965342|NCT05515081|PROCEDURE|blood sample collection|blood sample colletion at regular intervals
48314913|NCT05631327|DRUG|JZP341|JZP341 will be administered as a single, intravenous infusion over 2 hours.
47965343|NCT05459038|DIAGNOSTIC_TEST|C-Arm Rotational View (CARV)|CARV includes predefined fluoroscopy landmarks of the uninjured side to correct for rotational malalignment of the injured side in which the rotation of the C-Arm Image Intensifier is used
48314914|NCT01821820|OTHER|Pistachios|
48314915|NCT00617318|DIETARY_SUPPLEMENT|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
47965344|NCT01867437|DRUG|Placebo|Sterile solution (vehicle) for subcutaneous infusion
48314916|NCT00617318|DIETARY_SUPPLEMENT|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
48314917|NCT00264602|DRUG|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
48115757|NCT03895346|BEHAVIORAL|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
48314918|NCT05520268|BEHAVIORAL|Conventional music therapy (CMT)|CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
48314919|NCT05520268|BEHAVIORAL|Digital music rehabilitation (DMR)|DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
48484975|NCT03744559|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) will identify patterns of brain activity associated with RET and potentially predictive of treatment outcomes. The fMRI is used during the baseline and 24-hour follow-up test sessions while participants complete a cue-reactivity task. The collection of fMRI data is based on findings from human fear conditioning fMRI studies, in which groups receiving RET in the reconsolidation window exhibited less fear that was associated with attenuated BOLD response in the amygdala, relative to the control. We propose that the R-E arm will evidence attenuated cue reactivity in medial prefrontal cortex, limbic regions and ventral striatum, and that greater reduction in BOLD response in regions of interest will predict decreased smoking.
48484976|NCT03744559|OTHER|No functional magnetic resonance imaging (fMRI)|No functional magnetic resonance imaging (fMRI) serves as the control intervention to the fMRI intervention. Participants who are randomized to the no fMRI intervention or who have a contraindication to MRI will complete an identical cue-reactivity task in a cue-reactivity lab during the baseline and 24-hour follow-up test sessions.
48484977|NCT05442242|PROCEDURE|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
48484978|NCT05442242|PROCEDURE|High tibial osteotomy|Medial open wedge high tibial osteotomy
47965345|NCT01867437|DRUG|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
48115758|NCT00964197|DEVICE|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
48115759|NCT02218502|OTHER|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
48484979|NCT00731224|DRUG|Rivastigmine transdermal patch|
47965346|NCT03792698|OTHER|Aidcube digital app-based platform|Use of customizable, patient-specific mHealth home rehabilitation plan
47965347|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
47965348|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
48115760|NCT02218502|OTHER|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
47965349|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
47965350|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
48115761|NCT02218502|OTHER|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
48115762|NCT02218502|OTHER|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
48115763|NCT05660993|DRUG|Nivolumab|"Drug: Nivolumab Schedule: Nivolumab 3 mg/kg on day 0 of the Nivo-BeGEV or a maximum of 4 cycles Drug: Bendamustine~Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles Other Name: Ribomustin~Drug: Gemcitabine Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles Other Name: Gemzar~Drug: Vinorelbine Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles Other Name: Navelbine"
48115764|NCT05850026|PROCEDURE|Septal myectomy and mitral valve repair with edge-to-edge technique|Resection of the obstructing part of the interventricular septum and mitral repair using the edge-to-edge technique (suture of leaflets free margins in the regurgitation spot)
48314920|NCT00878917|DRUG|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
48484980|NCT04945772|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
48484981|NCT04945772|PROCEDURE|Sham Injection|Sham Injection
48484982|NCT01506908|DRUG|oral nicotine|oral nicotine replacement product
48484983|NCT01506908|DRUG|Placebo|no active
48484984|NCT02969772|OTHER|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
48644336|NCT02115282|DRUG|Goserelin|Given PO
48644337|NCT02115282|DRUG|Goserelin Acetate|Given SC
48644338|NCT02115282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48644339|NCT02115282|OTHER|Placebo Administration|Given PO
48644340|NCT02115282|OTHER|Quality-of-Life Assessment|Ancillary studies
48644341|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive APD for 12 weeks then switch to CAPD for another 12 weeks; Group B: Participants receive CAPD for 12 weeks and switch to APD for another 12 weeks.
48644342|NCT05078879|DRUG|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count \[ANC\] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
48644343|NCT06612281|DEVICE|colorectal cancer (CRC) screening|Gixam test
48644344|NCT06612281|DIAGNOSTIC_TEST|colorectal cancer screening|Fecal Immunochemistry Test (FIT)
48644345|NCT06612281|PROCEDURE|Colonoscopy after bowel cleansing|Standard of care optical colonoscopy for colorectal cancer screening
48644346|NCT06492291|DRUG|Enlicitide Decanoate|Oral tablet
48644347|NCT06052566|DRUG|Efinopegdutide|Subcutaneous injection administered at a dose of 7 mg
48644348|NCT06594913|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
48644349|NCT04974528|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
48644350|NCT04974528|BIOLOGICAL|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
48644351|NCT04974528|BIOLOGICAL|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48644352|NCT05094102|DEVICE|OnLume Imaging System|for fluorescence-guided surgery with ICG dye
48644353|NCT05094102|DRUG|Indocyanine green|Indocyanine green is a cyanine dye used in medical diagnostics
48644354|NCT06392230|DRUG|Oral [14C] PF-06821497|A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1
48644355|NCT06392230|DRUG|Oral PF-06821497|A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2
48314921|NCT04664855|OTHER|Trauma-Informed Yoga|8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
48314922|NCT02087384|BIOLOGICAL|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
48314923|NCT02087384|DRUG|Placebo|injection of 0.9% saline
48314924|NCT01366066|DEVICE|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
48314925|NCT05198752|DRUG|Neoantigen mRNA Personalised Cancer SW1115C3|Subcutaneous Injection
48314926|NCT00239187|DRUG|E1 and G1|
48314927|NCT02457182|OTHER|Mindfulness-based Stress Reduction (MBSR)|
48314928|NCT02457182|OTHER|Usual medical therapy|
48314929|NCT02855684|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48314930|NCT02855684|DRUG|Insulin glargine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48314931|NCT02855684|DRUG|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet~Route of administration: oral"
48314932|NCT03796091|BEHAVIORAL|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
48314933|NCT03796091|BEHAVIORAL|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).
48314934|NCT03796091|BEHAVIORAL|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
48314935|NCT06552442|DRUG|Methylprednisolone|High-dose intracoronary glucocorticoid methylprednisolone to abrogate no-reflow: a unique study for restoration of infarct-related artery patency and reduction of ischemia-reperfusion injury
48314936|NCT05698277|DIAGNOSTIC_TEST|Automated fetal cardiac function evaluation|"Evaluation of ultrasound parameters by automated algorithms.~Ultrasound assessed parameters are:~1. Pulsed wave Doppler Modified Left and Right Myocardial performance indices~2. Spatio-temporal image correlation Tricuspid, Mitral and Septal Annular Plane Systolic Excursion"
48484985|NCT02969772|OTHER|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
48484986|NCT01321021|DRUG|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
48115765|NCT06359327|DIETARY_SUPPLEMENT|Placebo|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given placebo for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
48314937|NCT00924352|DRUG|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
48484987|NCT04715776|DIETARY_SUPPLEMENT|Brown seaweed|Uptake of 1650 mg brown seaweed product twice daily
48484988|NCT04715776|DIETARY_SUPPLEMENT|placebo|Uptake of 1650 mg placebo twice daily
48484989|NCT03922074|PROCEDURE|Sedation directed by an endoscopist|"The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure."
48314938|NCT00924352|DRUG|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
48314939|NCT06155916|DRUG|Pregabalin|Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.
48314940|NCT00568880|DRUG|bortezomib|bortezomib 1.0-1.3mg/m2 IV
48484990|NCT03922074|PROCEDURE|Sedation directed by an anesthesiologist|The choice of the drugs and the target level sedation are directed by an anesthesiologist
48314941|NCT00568880|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg pill
48314942|NCT05834764|DRUG|Pyrotinib|Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
48314943|NCT06061887|OTHER|Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke
48314944|NCT00357526|DRUG|OCPs|
48314945|NCT00357526|DEVICE|vaginal ring|
48314946|NCT04580394|DRUG|AD109|Oral administration before bed
48314947|NCT04580394|DRUG|Atomoxetine|Oral administration before bed
48314948|NCT04580394|DRUG|R-oxybutynin|Oral administration before bed
48314949|NCT04580394|DRUG|Placebo|Oral administration before bed
48314950|NCT04580394|DIAGNOSTIC_TEST|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
48314951|NCT04402268|DEVICE|Cardioverter-defibrillator|We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
48314952|NCT05591898|BEHAVIORAL|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
48314953|NCT06242067|DRUG|Trifluridine/tipiracil|patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
48314954|NCT05924776|BIOLOGICAL|Plasmodium immunotherapy|Inoculation 1-5 × 10\^6 Plasmodium vivax once
48314955|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
48314956|NCT01458509|BEHAVIORAL|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
48314957|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
48314958|NCT01458509|BEHAVIORAL|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
48314959|NCT05311085|DRUG|Cytisine|"Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)"
48314960|NCT05311085|DRUG|Nicotine delivered via an e-cigarette|Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
48314961|NCT05311085|COMBINATION_PRODUCT|Cytisine plus nicotine delivered via an e-cigarette|"Cytisine: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco"
48314962|NCT00080366|DRUG|1-Octanol|
48314963|NCT06081998|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
48314964|NCT06081998|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
48314965|NCT01446952|DRUG|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
48314966|NCT03328585|BEHAVIORAL|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
48314967|NCT03328585|BEHAVIORAL|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
48314968|NCT03328585|OTHER|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
48314969|NCT03609658|BEHAVIORAL|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
48314970|NCT03609658|BEHAVIORAL|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
48644356|NCT06392230|DRUG|IV [14C] PF-06821497|A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
48644357|NCT06559969|DRUG|Intravenous administered opioid|Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion
47965351|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
48314971|NCT02500238|OTHER|Saliva sample|All participants will provide a saliva sample.
48115766|NCT06359327|DIETARY_SUPPLEMENT|Pep19 2 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 2 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
48314972|NCT02500238|OTHER|Urine Sample|All participants will provide a urine sample.
48314973|NCT02500238|OTHER|Toe nail clippings|All participants will provide toe nail clippings.
48314974|NCT02500238|OTHER|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
48314975|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
48314976|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
48314977|NCT02080689|OTHER|Decipher|
48314978|NCT04961814|OTHER|liberal fasting|preoperative fasting according to 6-4-0 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
48314979|NCT04961814|OTHER|standard fasting|preoperative fasting according to 6-4-2 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
48314980|NCT02220348|DRUG|linaclotide|
48314981|NCT05261672|DRUG|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
48314982|NCT05261672|DRUG|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
48314983|NCT02428530|OTHER|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
48314984|NCT01184716|OTHER|Vitamin D fortification|Bread and milk fortified with vitamin D3
48314985|NCT02456545|OTHER|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
48314986|NCT02456545|OTHER|depressive syndrome|in- and outpatients with depressive syndrome
48314987|NCT02456545|OTHER|ADHD|in- and outpatients with ADHD
48115767|NCT06359327|DIETARY_SUPPLEMENT|Pep19 5 mg|Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 5 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
48266796|NCT01256177|DRUG|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
48266797|NCT01256177|DRUG|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
48314988|NCT04143672|DEVICE|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
48314989|NCT04143672|DIAGNOSTIC_TEST|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
48314990|NCT01419483|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
48314991|NCT04554849|OTHER|Gender dysphoria psychosocial health|Retrospective analysis of medical records
48266798|NCT00732745|DRUG|docetaxel|Given IV
47965352|NCT03673215|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
47965353|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
47965354|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
48266799|NCT00732745|DRUG|oxaliplatin|Given IV
48266800|NCT00732745|DRUG|vandetanib|Given orally
48266801|NCT00732745|OTHER|placebo|Given orally
48266804|NCT04569838|DRUG|Bendamustine hydrochloride injection|Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
48266805|NCT03246828|OTHER|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
48266806|NCT01898182|OTHER|Kinetin, N6-furfuryladenine, 0.1%|
48314992|NCT06368687|OTHER|Anorexia nervosa plus autism|In the inpatient care the treatment model takes into account the patient's perception disorders, meaning e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
48314993|NCT00637364|PROCEDURE|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
48314994|NCT01260363|PROCEDURE|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
48314995|NCT01260363|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
48314996|NCT04050098|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
48314997|NCT04050098|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
48314998|NCT04387136|DRUG|Sublingual Sufentanil|15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
48314999|NCT00551538|DRUG|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
48315000|NCT00551538|DRUG|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
48315001|NCT03164512|DRUG|Oral or vaporized cannabidiol|Acute drug exposure
48315002|NCT03164512|DRUG|Placebo|Placebo capsule/vapor
48315003|NCT04310150|DRUG|Collastat|hemostatic agent that combine porcine-derived collagen thrombin
48315004|NCT04310150|DEVICE|Floseal|hemostatic agent that combine bovine-derived gelatin
48315005|NCT05742087|OTHER|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
48315006|NCT05742087|OTHER|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
48315007|NCT05276050|DEVICE|active F8-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
48315008|NCT05276050|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
48315009|NCT00913718|DRUG|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
48315010|NCT00913718|DRUG|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
48315011|NCT05700747|BEHAVIORAL|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
48315012|NCT04453696|BEHAVIORAL|Assessment scales-the Spielberger's State-Trait Anxiety Inventory, Modified Dental Anxiety Scale and a visual analog scale.|"STAI-S, like kinetic energy, refers to a palpable reaction or process taking place at a given time and level of intensity. STAI-T, like potential energy, refers to individual differences in reactions. Both of STAI-S and STAI-T scales includes 20 questions. For each question, the scores range from 1 (almost never) to 4 (almost always) points. For both scales, the sum of the scores ranges from 20 to 80. A score between 36 and 41 refers to a mean anxiety level, with values greater than 41 classified as a high level of anxiety.~The MDAS consists of 5 questions that measure anxiety at different stages of dental treatment. The options range from 1 (not anxious) to 5 (very anxious) for each question. The sum of the scores varies from 5 to 25; values between 19 and 25 indicate a high level of dental anxiety.~The VAS scale was included in the present study to determine how anxious the patients felt according to their own thoughts. Scores range from 0 (no anxiety) to 10 (extreme anxiety)."
48484991|NCT05177159|OTHER|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
48315013|NCT02648958|DRUG|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
48315014|NCT02648958|DRUG|normal saline|The control group received the normal saline infusion
48315015|NCT04240288|OTHER|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
48315016|NCT04240288|OTHER|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
48315017|NCT02142894|DEVICE|CST001|
48315018|NCT05835752|DRUG|RAY1225|Administered SC
48315019|NCT05835752|DRUG|Placebo|Administered SC
48315020|NCT05835752|DRUG|RAY1225|Administered SC
48315021|NCT05835752|DRUG|Placebo|Administered SC
48484992|NCT05177159|OTHER|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
48315022|NCT05835752|DRUG|RAY1225|Administered SC
48315023|NCT05835752|DRUG|Placebo|Administered SC
48315024|NCT03081286|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
48315025|NCT03081286|PROCEDURE|Fat graft|The harvested lipoaspirate is injected at the site of pain.
48315026|NCT03081286|PROCEDURE|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
48315027|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
48315028|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
48315029|NCT01511835|DRUG|Folic Acid|Folic Acid 400mcg; 1 cp/die
48315030|NCT01591226|DIETARY_SUPPLEMENT|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
48315031|NCT01591226|DIETARY_SUPPLEMENT|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
48315032|NCT01591226|DIETARY_SUPPLEMENT|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
48315033|NCT01591226|DIETARY_SUPPLEMENT|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
48315034|NCT02096146|PROCEDURE|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
48315035|NCT02096146|PROCEDURE|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
47965355|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
47965356|NCT02957669|BEHAVIORAL|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
48315036|NCT05881772|OTHER|Photobiomodulation|It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
48315037|NCT05627934|DIAGNOSTIC_TEST|qICG|Evaluation of bowel fluorescence by pixel software, qICG
48315038|NCT02704221|BEHAVIORAL|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
48315039|NCT02704221|BEHAVIORAL|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
48315040|NCT02704221|BEHAVIORAL|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
48315041|NCT02969850|DIETARY_SUPPLEMENT|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
48315042|NCT02969850|OTHER|Placebo|Subjects in this group will receive a placebo.
48315043|NCT02969850|DIETARY_SUPPLEMENT|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
48315044|NCT06226246|BEHAVIORAL|HEROS VR CPR training program|HEROS VR training program which combined video training and VR session
48315045|NCT06226246|BEHAVIORAL|Conventional HEROS CPR training program|Conventional HEROS training program using video learning
47965357|NCT02957669|BEHAVIORAL|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
47965358|NCT00514111|DRUG|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
48315046|NCT00649649|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
48315047|NCT00649649|DRUG|Accupril® Tablets 40 mg|40mg, single dose fed
48315048|NCT03877120|DRUG|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
48315049|NCT03877120|DRUG|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
48315050|NCT02893774|OTHER|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~* QLQ-C30~* SWLS (Satisfaction with Life Scale)~* PTGI (Post-Traumatic Growth Inventory)~* HADS (Hospital Anxiety and Depression Scale)~* Brief COPE~* MHLCS (Multidimensional Health Locus of Control Scale)"
48315051|NCT02393573|DRUG|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
48315052|NCT02393573|DRUG|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
48115768|NCT04339374|DEVICE|Photoacoustic imaging, photoacoustic microscopy|"* Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise~* The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers~* The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants"
48115769|NCT04339374|DEVICE|Endorectal photoacoustic imaging probe|"* Based on data gathered in the ex vivo cohort of patients, an endorectal imaging device using coregistered photoacoustic and ultrasound imaging will be constructed. This probe will then be used to perform in vivo imaging among patients with rectal pathology intraoperatively.~* The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants"
48315053|NCT01944969|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
48315054|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
47965359|NCT04342156|DRUG|Hydroxychloroquine Sulfate 200 milligram (mg) Tab|Oral tablet of Hydroxychloroquine sulfate
48315055|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
48315056|NCT05531058|BEHAVIORAL|AI-driven Vaccine Communicator|The intervention will include five modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes) and interact with an MI communication skills-based AI, digital assistant.
48315057|NCT05531058|BEHAVIORAL|Self-learning of COVID-19 vaccine knowledge|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
48315058|NCT01838967|DRUG|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
48315059|NCT01838967|DRUG|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
48315060|NCT01838967|DRUG|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
48315061|NCT01838967|DRUG|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
48484993|NCT05177159|OTHER|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
47965360|NCT04545060|BIOLOGICAL|VIR-7831 (sotrovimab)|VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
47965361|NCT04545060|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
47965362|NCT02590081|DRUG|Dextrose 5%|
47965363|NCT02590081|DRUG|normal saline|
47965364|NCT02168634|DRUG|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
48315062|NCT01838967|DRUG|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
48315063|NCT01838967|DRUG|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
47965365|NCT02168634|DRUG|Placebo|1cc normal saline, local injection
47965366|NCT00110838|PROCEDURE|Supplementation with fish oil versus placebo|
47965367|NCT03054441|OTHER|Actigraph|Actigraphs worn on wrists
47965368|NCT03147261|OTHER|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
47965369|NCT04902794|DEVICE|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
48315064|NCT01743014|DRUG|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
48315065|NCT01743014|DRUG|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
48315066|NCT05038033|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
48315067|NCT05038033|BEHAVIORAL|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
48315068|NCT04116814|DIAGNOSTIC_TEST|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
48315069|NCT00502307|DRUG|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
48315070|NCT00502307|DRUG|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
48315071|NCT02236728|DRUG|Pramipexole|
48315072|NCT05923476|DRUG|Lithium|Placebo + ECT
48315073|NCT03855748|OTHER|Healthy group|"Subjects undergo the following activities:~1. Walking~2. Jogging (8-11 km/h)~3. Maximal 5 meters sprint acceleration~4. Single leg drop jump from 35 cm height~5. Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~6. Maximal change of direction at 45, 135, 180 degrees~7. Single-leg cross-country skiing exercise"
48315074|NCT05102708|OTHER|Prognostic factors of severe COVID-19|prognostic factors: patients´ epidemiological characteristics (such as age, sex), comorbidities, length of hospitalization, critical care admission, treatments received, laboratory results, vital signs.
48315075|NCT03838770|DEVICE|Active tDCS|Active target 2.0mA tDCS (n=60)
48315076|NCT03838770|DEVICE|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
48315077|NCT02084784|DRUG|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
48315078|NCT02084784|DRUG|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
48315079|NCT01788306|DRUG|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
48315080|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
48315081|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
48315082|NCT01206010|DRUG|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
48315083|NCT01206010|DRUG|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
48315084|NCT01206010|DRUG|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
48315085|NCT04550793|DRUG|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
48315086|NCT03996434|DRUG|Gonadotropin|withholding gonadotropin administration for at least 24 hours
48315087|NCT03996434|DRUG|Antagonist|Cetrorelix acetate 0.25 mg
48315088|NCT06154031|BEHAVIORAL|Dyad learning|All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
48315089|NCT01928121|OTHER|Care provided by AF expert program|
48315090|NCT04524286|OTHER|Interviews only.|Interviews will be conducted with childbearing women and midwives.
48315091|NCT02819115|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
48484994|NCT00643734|DRUG|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
48315092|NCT05337527|DIETARY_SUPPLEMENT|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
48484995|NCT00643734|OTHER|placebo|placebo
48315093|NCT05625217|DIAGNOSTIC_TEST|Total Body PET/CT Imagin|Total-body PET imaging at different timepoints
48315094|NCT06280976|DRUG|Statin|high intensity statin (eg atorvastatin 80 mg daily)
48315095|NCT06280976|DRUG|Aspirin tablet|aspirin 81 mg po qd
48315096|NCT06280976|DRUG|Nexlizet|bempedoic acid-ezetimibe 180-10 mg po qd
48315097|NCT06280976|DRUG|LEQVIO|inclisiran SQ as per product insert
48315098|NCT06280976|DRUG|Vascepa|icosapent ethyl 2g PO BID
48315099|NCT06280976|DRUG|Jardiance|empagliflozin 10 mg PO QD
48315100|NCT06280976|DRUG|Colchicine|Colchicine 0.5 MG po qd
48315101|NCT03704441|DRUG|Bupivacaine|bupivacaine dose
48315102|NCT03775772|PROCEDURE|Oral Health|"* test group will receive an dental hygiene program for one year~* control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)"
48315103|NCT03775772|PROCEDURE|Bite Force|"* test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~* control group will remain without such training"
48484996|NCT00643734|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
48484997|NCT00643734|OTHER|placebo|placebo
48484998|NCT04897113|PROCEDURE|plasma exchange with albumin|plasma exchange with albumin, two per week, 110% of the circulating plasma volume
48484999|NCT04897113|PROCEDURE|plasma exchange without albumin|plasma exchange without albumin, two per week, 110% of the circulating plasma volume
48315104|NCT04761887|DRUG|Cool Ropivacaine Block|Ropivacaine is cooled.
48315105|NCT04761887|DRUG|Room Temp Ropivacaine Block|Room Temp Block
48315106|NCT00374374|BEHAVIORAL|Administration of probiotic|
48315107|NCT05209412|DEVICE|Lepu Paclitaxel coated balloon|Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.
48485000|NCT04452695|DEVICE|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
48485001|NCT03679273|DIETARY_SUPPLEMENT|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
48485002|NCT02249221|BIOLOGICAL|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
48485003|NCT02249221|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
48315108|NCT05209412|DEVICE|Resolute Integrity Zotarolimus eluting stents|The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).
48485004|NCT04049916|DRUG|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
48485005|NCT04049916|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
47965370|NCT04902794|DEVICE|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
47965371|NCT02381145|DIETARY_SUPPLEMENT|EGCG+RSV-supplementation|Teavigo (\~300mg/d) Resveratrol (\~80mg/d)
47965372|NCT02381145|DIETARY_SUPPLEMENT|Placebo|
47965373|NCT01218711|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
47965374|NCT04986423|DRUG|ZEN003694|72 mg PO QD
47965375|NCT04986423|DRUG|Enzalutamide|160 mg PO QD
47965376|NCT03218644|OTHER|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
47965377|NCT03218644|OTHER|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
47965378|NCT03445208|DRUG|BMS-986036|Crossover administration to abdomen then upper arm
47965379|NCT00003097|OTHER|preventative dietary intervention|
47965380|NCT00057317|DRUG|Ro 205-2349|
47965381|NCT01007773|DRUG|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
47965382|NCT01007773|DRUG|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP \< 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
47965383|NCT01007773|DRUG|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
47965384|NCT01007773|DRUG|Propofol|Propofol will be titrated to an ICP \< 20 mm Hg until achievement of sustained ICP control.
47965385|NCT03191994|BEHAVIORAL|Exercise|a structured, supervised eight week moderate intensity exercise intervention
47965386|NCT03931161|DRUG|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
47965387|NCT03931161|DRUG|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
47965388|NCT03280498|PROCEDURE|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
48315109|NCT05209412|DRUG|Aspirin|Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
48315110|NCT05209412|DRUG|Ticagrelor|Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
47965389|NCT03543475|DEVICE|arabin pessary|arabin pessary: silicon device
47965390|NCT03543475|DEVICE|no pessary|control group
47965391|NCT00967590|DRUG|RO5036505|380mg iv infusion once weekly for 8 weeks
47965392|NCT00967590|DRUG|placebo|iv infusion once weekly for 8 weeks
47965393|NCT02460627|DRUG|Lidocaine adhesive tape|700 mg for 12 hours
47965394|NCT02460627|OTHER|Adhesive tape|For 12 hours
47965395|NCT03839979|DIAGNOSTIC_TEST|BIOLINE HCV kits|We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.
47965396|NCT03839979|DIAGNOSTIC_TEST|ACCU-CHEK kits|For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
47965397|NCT03839979|DIAGNOSTIC_TEST|ErKameter 3000 mercury manometer|For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
47965398|NCT06409871|OTHER|Physiotherapy treatment.|-Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.
47965399|NCT06409871|OTHER|Physiotherapy treatment and modification of the biorhythm.|"* Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.~* Modification of the biorhythm will consist of eliminating methylxanthine-rich foods and/or beverages from their diet, as well as no exposure to electronic devices two hours before bedtime."
47965400|NCT00972868|DEVICE|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
47965401|NCT05847920|DRUG|SHR-2010 Injection|SHR-2010 Injection
47965402|NCT05847920|DRUG|Placebo|Placebo
48315111|NCT05209412|DRUG|Clopidogrel|Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
48315112|NCT04710524|DRUG|Placebo|Placebo BID for 13 weeks
48315113|NCT04710524|DRUG|FM101 150 mg BID|FM101 (150 mg) BID for 13 weeks
48315114|NCT04710524|DRUG|FM101 300 mg BID|FM101 (300 mg) BID for 13 weeks
47965403|NCT00851370|DRUG|Omalizumab (Xolair)|Bi-weekly
47965404|NCT00851370|DRUG|Placebo|Bi-Weekly
48315115|NCT01334372|BEHAVIORAL|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
48315116|NCT06347991|BEHAVIORAL|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
48315117|NCT02683226|DRUG|Vipdomet|
48315118|NCT02683226|DRUG|Incresync|
48315119|NCT04398849|BIOLOGICAL|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
48115770|NCT05727904|BIOLOGICAL|Lifileucel plus Pembrolizumab|A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
48115771|NCT05727904|BIOLOGICAL|Pembrolizumab with Optional Crossover Period|"Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2."
48115772|NCT05698069|DIAGNOSTIC_TEST|Pain Modulation Index|A 18 item questionnaire assessing patients' pain characteristics for the detection of disordered pain modulation processes.
48315120|NCT05388162|DEVICE|Mobile colposcope|It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
48315121|NCT03338751|DIAGNOSTIC_TEST|cognitive testing with HAD (PockeTalker) First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
48315122|NCT03338751|DIAGNOSTIC_TEST|Cognitive testing without HAD First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
48315124|NCT02471664|DEVICE|Mitral Loop Cerclage Annuloplasty|
48315125|NCT00882999|DRUG|LY2127399|Administered via Injection
48315126|NCT00882999|DRUG|Placebo|Administered via Injection
48485006|NCT04049916|DRUG|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
48115773|NCT05698069|OTHER|Pain Detect|A questionnaire that was validated for the assessment of neuropathic pain
48115774|NCT05698069|OTHER|Central sensitization inventory|A questionnaire developed for the detection of central sensitization.
48115775|NCT04898140|DIAGNOSTIC_TEST|SARS-CoV-2 specific IgM and IgG detection|Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).
48115776|NCT04898140|DIAGNOSTIC_TEST|ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins|Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.
48315127|NCT06411119|DEVICE|Meta Oculus Quest 2™ Virtual Reality Exergaming|Participants utilised the Meta Oculus Quest 2™ Virtual Reality headset to play the Beat Saber game, which involves striking blocks in time to music using hand controllers. Gameplay was configured at a moderate difficulty level in 'no-fail' mode to encourage continuous activity across pre-selected songs, requiring participants to perform movements such as lateral steps, squats, and arm motions. Each session lasted for 20 minutes, including 30-second rest intervals between songs, to maximise physical activity and monitor heart rate, perceived exertion, and technology acceptance.
48315128|NCT05120960|DRUG|tepotinib|Given by PO
48315129|NCT05120960|DRUG|tepotinib plus osimertinib|Given by PO
48315130|NCT03555084|DEVICE|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
48315131|NCT03555084|DEVICE|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
48315132|NCT02207699|DRUG|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
48315133|NCT02207699|DRUG|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
48315134|NCT02207699|DRUG|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
48315135|NCT02207699|DRUG|Placebo|8 placebo perles given by mouth once
48315136|NCT00908206|DRUG|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
48315137|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump in Auto Mode|This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.
48315138|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump without Auto Mode|Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
48315139|NCT01015664|DRUG|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
48315140|NCT01015664|DRUG|cisplatin|75 mg/m2 IV over 60 minutes on day 1
48315141|NCT01015664|DRUG|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
48315142|NCT01111539|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
48315143|NCT01111539|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
48315144|NCT01111539|DRUG|Blinded capsule|Blinded capsule administered orally, once daily.
48315145|NCT01097473|PROCEDURE|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
48315146|NCT00000728|DRUG|Zidovudine|
48315147|NCT00000728|DRUG|Aldesleukin|
48315148|NCT01980121|DEVICE|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
48315149|NCT05201183|COMBINATION_PRODUCT|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
48315150|NCT04093518|DRUG|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
48315151|NCT04093518|DRUG|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
48115777|NCT04898140|DIAGNOSTIC_TEST|Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes|Detection of peripheral blood T-helpers (CD45+CD3+CD4+)\* and cytotoxic T cells (CD45+CD3+CD8+)\* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. \* CD, cluster of differentiation
48315152|NCT04103255|OTHER|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
48315153|NCT00712322|DRUG|Darifenacin|Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
48315154|NCT00100724|BIOLOGICAL|rPA102|
48115778|NCT05318885|OTHER|A Randomized Controlled Study|For forward-leaning position, the child is first placed on a suitable chair with a soft pillow on their knees. The child will remain in the same position for the duration of the nebulization, and the pillow provides support, ensuring the child does not get tired. The child leans forward at an angle of 45°, places their arms on the pillow as shown in the figure and holds their head upright with their eyes facing forward (slight hyperextension). The upright head position of the child prevents spillage of the liquid medicine from the nebulizer chamber.
48115779|NCT03035123|BEHAVIORAL|Therapeutic education|Interventional arm
48315155|NCT02321137|PROCEDURE|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
48315156|NCT02321137|PROCEDURE|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
48315157|NCT02709993|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
48315158|NCT05281783|DEVICE|percutaneous radiofrequency ablation (RFA)|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
47965405|NCT02862444|OTHER|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
48315159|NCT02681952|DRUG|Renamezin capsule|
48315160|NCT02681952|DRUG|Kremezin granule|
48315161|NCT04313361|OTHER|No intervention|No drug will be administered as part of this study.
48315162|NCT03398369|DIAGNOSTIC_TEST|CMR/CTA Guidance for CRT|The intervention is the use of CMR and CTA to determine the optimal pacing site in the left ventricle for cardiac resynchronization therapy (CRT) and guide left ventricular lead placement.
48315163|NCT04389749|DEVICE|CPM|CPM-continuous passive motion device.
48315164|NCT03412474|DRUG|Bupivacaine|"The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%)."
48315165|NCT03412474|DRUG|Dexmedetomidine|Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
48315166|NCT03412474|DRUG|paracetamol|paracetamol
48485007|NCT03875014|DEVICE|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
48315167|NCT01368393|PROCEDURE|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
48315168|NCT01368393|PROCEDURE|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
48315169|NCT06217016|PROCEDURE|ICCAUT|In this study ,the ICCAUT strategy include intermittent catheter clamping and active urination training. For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
48315170|NCT06217016|PROCEDURE|Free drainage|For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
48315171|NCT06063252|BEHAVIORAL|NISMA|"The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention."
48315172|NCT05912959|OTHER|photo biostimulation|the intervention is a type of wavelength around 820 nm. this method of treatment is totally safe. yet, it has many therapeutic effects on the cellular level as well as tissue and organ level. during treatment with laser, the patient does not feel any specific sensation.
48315173|NCT03935087|DIAGNOSTIC_TEST|two-dimensional echocardiogram|two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction
48315174|NCT05312710|DRUG|APG-157|Treatment
48315175|NCT00014664|BIOLOGICAL|apolizumab|
48315176|NCT05211011|DRUG|Fosfomycin|Infectofos 5 g
48315177|NCT04182256|DEVICE|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
48315178|NCT04153617|DIETARY_SUPPLEMENT|Control honey|Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
48315179|NCT04153617|DIETARY_SUPPLEMENT|Modified honey with soluble fiber and polyphenols|Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
48315180|NCT05081648|PROCEDURE|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
48315181|NCT05081648|PROCEDURE|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
48315182|NCT02103790|DEVICE|Home NIV installation|
48315183|NCT01397305|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
48315184|NCT01397305|DRUG|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
48315185|NCT04891991|DRUG|Intravitreal infliximab|1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
48315186|NCT04891991|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy
48315187|NCT01794819|DEVICE|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
48315188|NCT06065527|BEHAVIORAL|Map Our Life|The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
48315189|NCT06065527|BEHAVIORAL|Attention Control|The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
48315190|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
48485008|NCT01627925|DEVICE|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
48485009|NCT04835649|OTHER|Exercise|Both groups will receive exercise-based training
48485010|NCT00834899|DRUG|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
48485011|NCT00834899|DRUG|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
47965406|NCT03978000|DRUG|IBP-9414|Oral suspension
47965407|NCT03978000|DRUG|Placebo|Sterile water
47965408|NCT04481854|PROCEDURE|cricoid pressure|cricoid pressure during laryngoscopy
47965409|NCT04481854|PROCEDURE|left paratracheal pressure|left paratracheal pressure during laryngoscopy
48315191|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
48315192|NCT01865435|GENETIC|cord blood sample|
48315193|NCT02150473|DRUG|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
48315194|NCT02150473|DRUG|Placebo|Placebo the same amount as adalimumab
48315195|NCT04472364|DEVICE|HemoPill Acute ®|Capsule positive: Endoscopy endoscopy will be performed within 12 hours. Capsule negative: Endoscopy will be performed after 48 to 96 hours.
48485012|NCT05553782|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~* Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~  * Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine"
48485013|NCT03857672|BEHAVIORAL|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
48315196|NCT03664973|PROCEDURE|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
48315197|NCT00066625|DRUG|oxaliplatin|Given IV
48485014|NCT00536484|DRUG|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
48485015|NCT00536484|DRUG|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
48485016|NCT01917968|DEVICE|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
48485017|NCT01917968|PROCEDURE|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
48485018|NCT02032355|PROCEDURE|spinal anesthesia|
48485019|NCT01351350|DRUG|MLN0128|MLN0128 capsules
48485020|NCT01351350|DRUG|paclitaxel|paclitaxel intravenous infusion
48485021|NCT01351350|DRUG|trastuzumab|trastuzumab intravenous infusion
48485022|NCT01908894|DRUG|BIOD-123|
48485023|NCT01908894|DRUG|BIOD-125|
48485024|NCT01908894|DRUG|Humalog|
48315198|NCT00066625|DRUG|bortezomib|Given IV
48315199|NCT00066625|OTHER|laboratory biomarker analysis|Correlative studies
48485025|NCT00456495|DRUG|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
48485026|NCT03432065|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
48485027|NCT03678779|BEHAVIORAL|Incentive|$5 grocery gift card
48485028|NCT03678779|BEHAVIORAL|Education|Video-based brief nutrition education
48485029|NCT03678779|BEHAVIORAL|Combined|Both Incentive and Education interventions received
48485030|NCT02166320|DEVICE|Partially covered SEMS|
48315200|NCT00066625|OTHER|pharmacological study|Correlative studies
48315201|NCT04897841|DRUG|Liposomal bupivacaine|20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
48315202|NCT04897841|DRUG|Bupivacaine Hydrochloride|30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
48315203|NCT04897841|OTHER|saline|post-surgical saline
48315204|NCT03700008|DIAGNOSTIC_TEST|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
48315205|NCT03700008|DIAGNOSTIC_TEST|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
48485031|NCT02166320|DEVICE|Fully covered SEMS|
48315206|NCT05403749|BIOLOGICAL|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
48315207|NCT05403749|DRUG|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
48315208|NCT05403749|BIOLOGICAL|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
48315209|NCT05625386|DEVICE|transcranial magnetic stimulation|TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
48315210|NCT03257930|DRUG|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
48315211|NCT05393817|DRUG|caffeine citrate|caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
48315212|NCT06273306|DEVICE|IMIDOC|Patient´s Mobile App for recording clinical data
48315213|NCT03921255|OTHER|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
48315214|NCT05062616|PROCEDURE|Toenail surgery|modified Winograd procedure
48115780|NCT04979988|DRUG|Lortlatinib|as provided in real world practice
48485032|NCT05215093|OTHER|Direct access physiotherapy for acute low back pain|Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
48315215|NCT06429878|DIAGNOSTIC_TEST|Biparametric prostatic MRI|
48315216|NCT01151579|DRUG|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
48315217|NCT01151579|DRUG|Albuterol|Nebulized albuterol 2.5mg
48315218|NCT04396743|PROCEDURE|Periapical surgery with use of prf-high clot and membrane|Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
48485033|NCT05215093|OTHER|Usual care for acute low back pain|Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
47965410|NCT01603056|BIOLOGICAL|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
47965411|NCT01603056|BIOLOGICAL|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
48115781|NCT00092105|DRUG|MK0476, montelukast sodium|
48115782|NCT00092105|DRUG|Comparator: placebo|
48315219|NCT04396743|PROCEDURE|Periapical surgery with use of prf-medium clot and membrane|Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
48315220|NCT04079894|OTHER|Standard Movement Protocol|Participant walking, cycling and sitting according to a pre-specified protocol.
48315221|NCT04079894|DEVICE|Accerelerometer Monitoring|7 days of accelerometer monitoring in participants home-environment.
48485034|NCT05859321|OTHER|Virtual reality Exercises|Virtual reality exercises along with transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
48485035|NCT05859321|OTHER|Routine Physiotherapy|transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
48115783|NCT06676345|PROCEDURE|Surgical treatment|Surgical repair of post-infarction mechanical complications (e.g. sutureless or sutured repair for LVFWR, David or Daggett technique for VSR, mitral valve repair or replacement for PMR)
48115784|NCT06676345|PROCEDURE|Percutaneous treatment|Percutaneous approach for the management of post-infarction mechanical complications (e.g. percutaneous closure with device for VSR, Mitraclip for PMR, PIFIT for LVFWR)
48115785|NCT03396848|OTHER|SHAReClinic|Online clinic with educational modules
48115786|NCT05001269|DRUG|nedosiran|Monthly subcutaneous dosing throughout study period
48115787|NCT03997682|OTHER|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
48115788|NCT02464852|BEHAVIORAL|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
48115789|NCT02464852|BEHAVIORAL|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
48315222|NCT06102252|DRUG|Paclitaxel/epirubcin/carboplatin|adjuvant treatment in endometrial carcinoma
48315223|NCT06102252|DRUG|Paclitaxel/carboplatin|Dose dense paclitaxel/carboplatin
48315224|NCT00742443|DRUG|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
48315225|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
48315226|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
47965412|NCT06556537|DEVICE|Face-to-face and video-assisted training|"During the first phase, the intervention group will receive face-to-face training over 12 weeks. Each session will last 60 minutes, and there will be five sessions per week, with three supervised and two unsupervised.~In the second phase, there will be 60 work sessions, divided into blocks of four weeks on three occasions, with one month of exercise and two months of non-exercise over the remaining 9 months. This phase will be conducted via video assistance. Each session will include a warm-up of 10-15 minutes, a main part of 20-40 minutes, and a cool-down of 10-15 minutes."
47965413|NCT03208205|PROCEDURE|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
47965414|NCT01427972|DRUG|LY2623091|Administered orally
47965415|NCT01427972|DRUG|Eplerenone|Administered orally
48315227|NCT02167841|BEHAVIORAL|Knee-Chest Position|
48315228|NCT03203889|BEHAVIORAL|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
48644358|NCT06559969|DRUG|Epidural administered opioid|Hydromorphone will be added to the bupivacaine in the epidural and will have a continuous infusion along with the ability for the patient to receive epidural boluses of the medications by a patient controlled epidural administration pump
48644359|NCT04564339|DRUG|Ravulizumab|Dosages (loading and maintenance) will be based on the participant's body weight.
48644360|NCT04564339|DRUG|Placebo|Dosages (loading and maintenance) will be based on the participant's body weight.
47965416|NCT05315544|DEVICE|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
48115790|NCT02464852|DEVICE|Sheffield Support Snood|
48315229|NCT03203889|BEHAVIORAL|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
48485036|NCT00782028|OTHER|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
48485037|NCT00782028|OTHER|Standard Care|
48485038|NCT06388837|OTHER|Injectable Platelet Rich Fibrin|Patients underwent mandibular symphysis Onlay bone graft mixed with injectable platelet rich fibrin (I-PRF) placement.
48115791|NCT02464852|DEVICE|sEMG|
48115792|NCT06335862|OTHER|Randomisation between the PPT- and no-PPT-group|Randomisation is performed between two possible treatment options for tracheomalacia in OA patients; the PPT or the wait-and-see policy (no-PPT).
48115793|NCT06335862|PROCEDURE|Primary Posterior Tracheopexy|The PPT involves fixating the posterior membrane of the trachea to the spinal ligament with sutures, to prevent the trachea from collapsing.
48315230|NCT00914836|DRUG|Betamethasone Sodium Phosphate|1cc:2cc
48315231|NCT00914836|DRUG|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
48315232|NCT00914836|DRUG|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
48315233|NCT04270994|DRUG|Misoprostol|
48315234|NCT00008138|DRUG|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
48315235|NCT00008138|DRUG|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
48315236|NCT00008138|PROCEDURE|debulking surgery|exploratory laparotomy, interval cytoreduction (to \< 1 cm residual)
48315237|NCT04185480|DEVICE|Hemopatch|Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
48315238|NCT00910429|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
48315239|NCT06152250|OTHER|Liver Fine-Needle Aspiration|"At the time of inclusion, when liver biopsy will be performed as part of routine medical management, fine-needle aspiration will also be made in all patients.~The procedure will be performed in the Day Hospital, immediately after the liver biopsy."
48315240|NCT03747224|DRUG|ARO-ANG3|single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
48315241|NCT03747224|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
48315242|NCT04848337|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
48315243|NCT04848337|DRUG|Lenvatinib|Lenvatinib 20 mg orally daily.
48485039|NCT06388837|OTHER|Xenograft|Patients underwent mandibular symphysis Onlay bone graft mixed with Xenograft (InterOss® Anorganic Cancellous Granules).
48485040|NCT00302549|DRUG|FK506|FK506,0.1mg/kg/d
48485041|NCT02640365|DRUG|MM-398|unresectable Advanced non-colorectal cancer
48485042|NCT02640365|DRUG|Irinotecan|unresectable metastatic colorectal cancer
48315244|NCT03922360|BEHAVIORAL|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
48315245|NCT03922360|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
48315246|NCT01763476|PROCEDURE|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
48315247|NCT01763476|PROCEDURE|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
48315248|NCT02533518|PROCEDURE|Rigid bronchoscopy with ultraviolet transmission|
48315249|NCT02533518|OTHER|Biopsy|
48485043|NCT02640365|DRUG|Leucovorin (LV)|unresectable metastatic colorectal cancer
48315250|NCT02930798|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)"
48315251|NCT02947516|PROCEDURE|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
48315252|NCT02947516|PROCEDURE|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
48315253|NCT03586882|DEVICE|Spinal Cord Stimulation|Stimulation provided by the generator to electrodes on the leads inhibits ascending pain signals, thereby decreasing pain perception.
48315254|NCT02586233|DRUG|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
48315255|NCT02586233|DRUG|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
48315256|NCT04048525|PROCEDURE|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
48315257|NCT04048525|PROCEDURE|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
48315258|NCT05238961|DRUG|[18F]DPA-714|Investigational PET Tracer \[18F\]DPA-714
48485044|NCT02640365|DRUG|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
48485045|NCT02640365|DRUG|bevacizumab|unresectable metastatic colorectal cancer
48485046|NCT02640365|DRUG|MM-398|unresectable metastatic colorectal cancer
48485047|NCT06012721|DRUG|ORIC-114|Food effect healthy subjects
48485048|NCT02332980|DRUG|Ibrutinib|Given PO
48485049|NCT02332980|DRUG|Idelalisib|Given PO
48315259|NCT05277649|OTHER|Exercise programme|Performing a programme of warm-up and stretching exercises for the cervico-mandibular region aimed at improving mobility and muscle condition.
48485050|NCT02332980|OTHER|Laboratory Biomarker Analysis|Correlative studies
48485051|NCT02332980|BIOLOGICAL|Pembrolizumab|Given IV
48485052|NCT03936179|RADIATION|high dose radiation therapy with concurrent chemotherapy|standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
48315260|NCT02529293|DRUG|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
48485053|NCT01679197|DRUG|Metreleptin|
48485054|NCT02235220|OTHER|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
48485055|NCT01477502|OTHER|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
48485056|NCT01477502|OTHER|standard treatment without homeopathy|participants receive standard UTI prophylaxis
48485057|NCT03585959|DEVICE|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
48485058|NCT06417333|DEVICE|xiaomi mi band 7 smart wristband|Patients with mild dementia have been distributed xiaomi mi band 7 smart wristbands for health data collection
48485059|NCT00183885|DRUG|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
48485060|NCT06301087|DEVICE|Web Application|web application for monitoring children's development and postnatal depression of mothers
48485061|NCT04754334|DRUG|ORMD-0801|Oral Insulin
48485062|NCT04754334|OTHER|Placebo|Fish Oil
48644361|NCT04564339|OTHER|Background Therapy|Participants will receive background therapy consistent with the standard of care.
48315261|NCT02529293|DRUG|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
48315262|NCT03777371|OTHER|Anti HIV Seropositive Pregnant Women|
48315263|NCT04980976|DEVICE|Blind insertion technique|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
48315264|NCT04980976|DEVICE|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique
48315265|NCT06053216|OTHER|Indirect calorimetry|Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.
48315266|NCT06053216|OTHER|Indirect calorimetry (Standard care nutrition arm)|Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
48315267|NCT01976819|DEVICE|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
48315268|NCT01344837|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48315269|NCT01344837|OTHER|Immunohistochemistry Staining Method|Correlative studies
48315270|NCT01344837|OTHER|Medical Chart Review|Correlative studies
48315271|NCT01344837|GENETIC|Microarray Analysis|Correlative studies
48315272|NCT01344837|OTHER|Study of Socioeconomic and Demographic Variables|Correlative studies
48315273|NCT01344837|GENETIC|Western Blotting|Correlative studies
48315274|NCT02876770|DIETARY_SUPPLEMENT|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
48315275|NCT02876770|DIETARY_SUPPLEMENT|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
48315276|NCT04852406|DRUG|Protocol-based management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
48315277|NCT04852406|DRUG|Routine management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to current routine practice.
48315278|NCT04220632|DRUG|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
48315279|NCT04220632|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
48315280|NCT04220632|DRUG|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
48315281|NCT02783794|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
48315282|NCT02783794|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
48115794|NCT06335862|DIAGNOSTIC_TEST|Preoperative tracheobronchoscopy|Prior to OA correction, a flexible and a rigid tracheobronchoscopy will be performed, in addition to a flexible tracheobronchoscopy through the endotracheal tube. Preoperative evaluation of TM through a tracheobronchoscopy is part of standard care for all participating centres.
48485063|NCT03432988|BEHAVIORAL|Nursing Solution-Focused|Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
48115795|NCT06335862|DIAGNOSTIC_TEST|Intraoperative tracheobronchoscopy|After the PPT is performed, or in case of the no-PPT group at the stage of the surgery when the PPT would usually be performed, a flexible tracheobronchoscopy through the endotracheal tube is carried out. This tracheobronchoscopy is routine care for all patients undergoing a PPT, and is additional for patients in the no-PPT-group.
48315283|NCT04989010|DRUG|89Zr-NY005|89Zr-NY005 injection followed by 89Zr-NY005 PET scan
48315284|NCT06430112|DRUG|Liposomal Bupivacaine|After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).
48315285|NCT06430112|DRUG|Ropivacaine|Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
48315286|NCT05973994|DEVICE|intravascular lithotripsy with Shockwave coronary system|OCT acquistion is performed at baseline. Then the IVL catheter will be passed across the lesion over the guidewire. Atherectomy or cutting/scoring balloons is not permitted per protocol. The IVL procedure is considered successful when a residual stenosis \<50% by visual estimate after IVL alone is achieved. After IVL procedure, one OCT imaging acquisition must be performed. If the residual stenosis is ≥50% following IVL, noncompliant balloon dilatation will be performed prior to stenting and OCT images repeated accordingly. Subsequent stent implantation will be performed per local standard of care at the discretion of the operator. Following stent implantation, high pressure post-dilatation is recommended and OCT imaging acquisition must be performed to assess stent apposition for secondary end point.
48315287|NCT05886634|DRUG|Etrumadenant|Will be administered PO daily for 24 weeks
48315288|NCT05886634|DRUG|Zimberelimab|Will be administered IV every 2 weeks for 24 weeks
48315289|NCT00099359|DRUG|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams
48315290|NCT00099359|DRUG|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams"
48315291|NCT00099359|DRUG|Epivir (3TC)|"Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams"
48315292|NCT00099359|DRUG|Nelfinavir (NFV)|200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
48315293|NCT01480141|DRUG|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
48315294|NCT02309164|PROCEDURE|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
48315295|NCT02309164|BEHAVIORAL|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
48315296|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 25 mg b.i.d
48315297|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg qhs
48315298|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg b.i.d.
48315299|NCT00360243|DRUG|placebo|placebo
48315300|NCT02857335|BEHAVIORAL|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
48315301|NCT00863837|DRUG|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
48315302|NCT00863837|DRUG|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
48315303|NCT01879670|DEVICE|CircuLite Synergy left ventricular assist device|
48315304|NCT02305901|DRUG|repaglinide|single dose on day 1 of visits 2 and 3
48315305|NCT02305901|DRUG|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
48315306|NCT02305901|DRUG|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
48315307|NCT04829019|RADIATION|Osimertinib and whole-brain irradiation|Osimertinib at a dose of 80 mg once per day, and WBI
48315308|NCT04829019|DRUG|Osimertinib|Osimertinib at a dose of 80 mg once per day, until unacceptable adverse events or disease progression occurred. WBI could be given to patients in experimental arm at any time base on investigator's decision after treatment initiated.
48315309|NCT01560897|DRUG|Oral C13|Ingestion of C13 and follow up of the ureogenesis
48315310|NCT03383718|PROCEDURE|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
48485064|NCT04438590|DIETARY_SUPPLEMENT|Kelulut Honey|The Substance being tested to be used as an alternative
48485065|NCT04438590|DIETARY_SUPPLEMENT|Carborie|The commercially available substance
48315311|NCT03383718|OTHER|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
48315312|NCT05216406|DIETARY_SUPPLEMENT|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
48315313|NCT05216406|OTHER|Placebo|Maltodextrin capsule
48315314|NCT01912716|DRUG|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
48315315|NCT01912716|DRUG|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
48315316|NCT04228692|PROCEDURE|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
48315317|NCT04228692|DEVICE|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
48315318|NCT05100654|DRUG|Doxycycline|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
48485066|NCT04088266|COMBINATION_PRODUCT|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA®
48315319|NCT05100654|DRUG|Ciprofloxacin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
48315320|NCT05100654|DRUG|Augmentin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
48315321|NCT05100654|DRUG|Bactrim|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
48315322|NCT05929417|OTHER|END-IT intervention for the community setting|The intervention was described in the arm/group descriptions.
48315323|NCT01253044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
48315324|NCT01253044|BEHAVIORAL|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
48315325|NCT02792322|DEVICE|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
48485067|NCT01663727|DRUG|Bevacizumab [Avastin]|Intravenous repeating dose
48485068|NCT01663727|DRUG|Paclitaxel|Intravenous repeating dose
48485069|NCT01663727|DRUG|Placebo|Intravenous repeating dose
48485070|NCT01774279|OTHER|Tissue, blood and clinical data collection|
48485071|NCT04684693|DEVICE|Laser|Laser puncture and exercise
48485072|NCT04684693|PROCEDURE|Control|Exercise
48315326|NCT03292679|PROCEDURE|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
48315327|NCT04018196|OTHER|motor imagery as training manual task|They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
48315328|NCT04018196|OTHER|motor imagery as training motor task|"They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
48315329|NCT04018196|OTHER|emotionally neutral film as training of manual task|"They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test)."
48315330|NCT04018196|OTHER|emotionally neutral film as training of motor task|"They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
48315331|NCT06014554|OTHER|Low-risk subgroup|Self-managed exercise programme.
48315332|NCT06014554|OTHER|Medium-risk subgroup|Education, goal-orientated mobility programme, and enhanced discharge planning.
48315333|NCT06014554|OTHER|High-risk subgroup|Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
48315334|NCT06014554|OTHER|Control group|Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
48315335|NCT02569411|OTHER|Financial Incentive|money
47965417|NCT05056545|BEHAVIORAL|C4 Intervention|"C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW."
47965418|NCT02165969|PROCEDURE|endoscopic endonasal surgery with UPSIT|
47965419|NCT00347568|DEVICE|TX-plore|PI has terminated at institution and there is no one available to report.
48315336|NCT02364167|DRUG|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
47965420|NCT05184985|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
47965421|NCT05184985|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
47965422|NCT03448783|DRUG|Apixaban|Patients are tested for their normal prescription apixaban medication
47965423|NCT02179242|OTHER|Cardiac rehab|
47965424|NCT04571814|BEHAVIORAL|Psycho-social, computerized intervention targeting error sensitivity|"A psycho-social, computerized intervention for parents and children targeting error sensitivity. This intervention will be based on the constructs in the Child Error Sensitivity Index, as well as other constructs, that relate to the error-related negativity - for example, perfectionism, fear of evaluation from others, and over-valuation of the negative consequences of errors. The parent version of the intervention will include these same basic concepts, but will also target parenting style and provide psychoeducation on the negative impact of over-reacting to children's mistakes.~The parent version will also include examples of how to model appropriate reactivity to mistakes, and provide video vignettes and examples of both critical and adaptive parenting reactions to mistakes."
47965425|NCT00000883|DRUG|Azithromycin|
48315337|NCT02364167|DEVICE|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
48315338|NCT02364167|OTHER|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
48315339|NCT05519371|DRUG|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
48315340|NCT05519371|DRUG|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
48315341|NCT02023164|DRUG|JDP-205 Injection|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
48315342|NCT02023164|DRUG|Diphenhydramine|Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
47965426|NCT00458211|DRUG|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
48315343|NCT02940626|DRUG|ASN100|monoclonal antibody combination of ASN-1 and ASN-2
48315344|NCT02940626|DRUG|Placebo|Placebo
48485073|NCT01659164|BEHAVIORAL|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
48485074|NCT04813016|DRUG|Tramal 1|Early intraperitoneal injection of tramal and bupivacaine
48315345|NCT03086317|DEVICE|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
47965427|NCT00957970|DEVICE|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
48315346|NCT03086317|DEVICE|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
48315347|NCT04195269|DRUG|Test Article|10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
48315348|NCT00003662|BIOLOGICAL|anti-thymocyte globulin|
48315349|NCT00003662|DRUG|busulfan|
48315350|NCT00003662|DRUG|cyclophosphamide|
48115796|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy through the endotracheal tube during extubation|A postoperative flexible tracheobronchoscopy is performed in the neonatal or pediatric intensive care unit (ICU), through the endotracheal tube during extubation. This procedure is a study intervention.
48115797|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy after 2-6 months|Two to six months after OA correction, a follow-up flexible and a rigid tracheobronchoscopy will be performed, under general anesthesia in the surgical theatre. This postoperative evaluation of TM through a tracheobronchoscopy is part of standard care for the Karolinska University Hospital and Great Ormond Street Hospital. At the University Medical Centre Utrecht and Erasmus Medical Centre Rotterdam, this tracheobronchoscopy is performed on indication in approximately half of patients. For the other half of patients, this is a study intervention.
47965428|NCT00957970|DEVICE|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
48115798|NCT00875160|DRUG|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
47965429|NCT05403281|DRUG|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
47965430|NCT00117481|DRUG|DR-2001a|DR-2001a administered vaginally each month
47965431|NCT00117481|DRUG|DR-2001b|DR-2001b administered vaginally each month
47965432|NCT00117481|OTHER|Placebo|Placebo administered vaginally each month
47965433|NCT05230290|BIOLOGICAL|KD6001 Injection|Solution for intravenous injection
48115799|NCT03072953|DRUG|APD334|APD334 active treatment
48115800|NCT04920149|DRUG|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
48115801|NCT04920149|DRUG|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
48115802|NCT02014142|DRUG|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
48115803|NCT00561886|DRUG|Formoterol|One inhalation of 24µg Formoterol
48115804|NCT06439901|OTHER|Screening|A first step to identify and recruit people eligible for screening,
48315351|NCT00003662|DRUG|cyclosporine|
48315352|NCT00003662|DRUG|melphalan|
48315353|NCT00003662|DRUG|methylprednisolone|
48315354|NCT00003662|PROCEDURE|umbilical cord blood transplantation|
48315355|NCT00003662|RADIATION|radiation therapy|
48315356|NCT01848054|DRUG|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
48315357|NCT01848054|DRUG|Buprenorphine|Buprenorphine sublingual tablets
48315358|NCT06518512|DEVICE|Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system|"AVIGA is an automated method and system for vision assessment of a subject. The method includes the following: determining a set of test patterns for the subject based on a preliminary assessment of an eye of the subject; displaying the set of test patterns sequentially to the subject; collecting data on the subject's gaze in response to each test pattern displayed; and correlating central vision function of the subjects to the collected gaze data.~Subjects perform the AVIGA test monocularly and pursue a pre-determined target moving in a customized waveform across the computer screen. The trail of the gaze points generated by the subject following the target is simultaneously recorded and stored.~1. Static Fixation Evaluation (SFE)~2. Static Perimetry Assessment (SPA)~3. Static Perimetry Sensitivity Assessment (SPSA)~4. Pursuit"
48315359|NCT01321931|DRUG|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
48315360|NCT01321931|DRUG|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
48315361|NCT01321931|DRUG|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
48315362|NCT00330720|DEVICE|Emergency Response System (Device)|
48315363|NCT06503861|BEHAVIORAL|Food Is Medicine intervention|The intervention provides regular meal kits as well as cooking and nutritional education.
48315364|NCT03404596|DRUG|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
48315365|NCT03404596|BEHAVIORAL|Counseling|Brief counseling sessions, 10-15 minutes each.
48485075|NCT04813016|DRUG|Tramal 2|Late intraperitoneal injection of tramal and bupivacaine
48315366|NCT03404596|BEHAVIORAL|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
48315367|NCT03404596|OTHER|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
48315368|NCT01943734|BEHAVIORAL|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
48315369|NCT00004986|DRUG|Nitazoxanide|
48315370|NCT00946777|OTHER|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
48315371|NCT01185145|RADIATION|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
48315372|NCT01185145|RADIATION|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
48315373|NCT02345252|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
48315374|NCT02345252|DRUG|FTC/RPV/TDF Placebo|Tablets administered orally once daily
48315375|NCT02345252|DRUG|FTC/RPV/TDF|200/25/300 mg FDC tablets administered orally once daily
48315376|NCT02345252|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
48315377|NCT03195062|OTHER|Test meal|Liquid test meal (fructose+glucose)
48315378|NCT03776643|DRUG|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
48315379|NCT02864537|OTHER|Training|Patients were trained to measure INR and dose warfarin
48315380|NCT04915664|DEVICE|Pessary|Use of Pessary as treatment of POP
48315381|NCT03470649|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
48315382|NCT06420648|OTHER|Early passive mobilization|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
48315383|NCT06420648|OTHER|Controlled active motion|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
48315384|NCT02987764|OTHER|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
48315385|NCT02125331|PROCEDURE|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
48315386|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
48315387|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
48315388|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
47965434|NCT03226483|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
47965435|NCT00113984|BIOLOGICAL|PROSTVAC-V/TRICOM|
48315389|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
48315390|NCT02689232|BIOLOGICAL|Fresh Frozen Plasma|
48315391|NCT02689232|BIOLOGICAL|Platelets Concentrate|
48315392|NCT02689232|BIOLOGICAL|Cryo Precitipitate|
48315393|NCT04913961|OTHER|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study
48315394|NCT04913961|OTHER|western medicine conventional therapy|The control group will get the western medicine conventional therapy with some additional tests for the study.
47965436|NCT00113984|BIOLOGICAL|PROSTVAC-F/TRICOM|
47965437|NCT00113984|DRUG|MDX-010|
47965438|NCT00113984|DRUG|Sargramostim|
48315395|NCT03414762|DEVICE|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
48315396|NCT03414762|DEVICE|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
48315397|NCT00849251|DRUG|cyclophosphamide|Given IV or PO
48315398|NCT00849251|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
48315399|NCT00849251|DRUG|bortezomib|Given IV
48315400|NCT00849251|DRUG|dexamethasone|Given IV or PO
48315401|NCT01021072|DRUG|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
48315402|NCT05667155|BIOLOGICAL|CB dualCAR-NK19/70|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19/CD70 CAR and IL15
48315403|NCT02998060|PROCEDURE|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
48315404|NCT02998060|DEVICE|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
48315405|NCT02998060|DEVICE|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
48315406|NCT03907982|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
48315407|NCT03907982|PROCEDURE|Pulmonary vein isolation|The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
48315408|NCT03907982|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.
48315409|NCT00005096|DRUG|docetaxel|
48485076|NCT04813016|DRUG|Dexmedetomidine 1|Early intraperitoneal injection of dexmedetomidine and bupivacaine
48485077|NCT04813016|DRUG|dexmedetomidine 2|Late intraperitoneal injection of dexmedetomedine and bupivacaine
48315410|NCT00962039|DRUG|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
48485078|NCT04958122|DRUG|Cefixime 400mg|Oral cefixime 400 mg, one capsule, twice a day for 10 days
48485079|NCT04958122|DRUG|benzathine penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
48485080|NCT04062149|OTHER|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
48485081|NCT04062149|OTHER|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
48485082|NCT00556101|PROCEDURE|Whole body magnetic resonance angiography|
48485083|NCT01366443|PROCEDURE|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
48485084|NCT01366443|PROCEDURE|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
48485085|NCT01366443|PROCEDURE|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
48315411|NCT00962039|DRUG|Placebo|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
48315412|NCT02375958|DRUG|PCA062|
48315413|NCT03760848|DRUG|Aramchol|Aramchol 600 mg
48315414|NCT03760848|DRUG|Midazolam|Midazolam 2 mg
48315415|NCT03760848|DRUG|Atorvastatin|atorvastatin 40 mg
48315416|NCT02560831|BEHAVIORAL|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
48315417|NCT02560831|BEHAVIORAL|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
48315418|NCT02312817|OTHER|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
48485086|NCT00168090|DRUG|Blood coagulation Factor VIII and vWF, human|
48485087|NCT03710590|OTHER|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
48485088|NCT03710590|OTHER|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
48485089|NCT03710590|OTHER|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
48485090|NCT03710590|OTHER|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
48485091|NCT03710590|OTHER|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
48315419|NCT02312817|OTHER|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
48315420|NCT03147274|BEHAVIORAL|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
48315421|NCT02856269|DIETARY_SUPPLEMENT|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
48485092|NCT03710590|OTHER|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
48485093|NCT02545647|DEVICE|BRYGB|65 patients undergo a banded RYGB
48485094|NCT02326974|DRUG|T-DM1|Neoadjuvant treatment is for a total of 18 weeks.
48485095|NCT02326974|DRUG|Pertuzumab|Neoadjuvant treatment is for a total of 18 weeks.
48485096|NCT02326974|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
47965439|NCT05473390|OTHER|functional electrical stimulation|functional electrical stimulation on back muscles
47965440|NCT05473390|OTHER|kinesotaping|no intervention
47965441|NCT03602482|BEHAVIORAL|Standing|Participants will stand and complete cognitive tests.
48315422|NCT02986893|BEHAVIORAL|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
47965442|NCT03602482|BEHAVIORAL|Supine|Participants will complete cognitive tests while supine.
48115805|NCT06439901|OTHER|Inclusion|A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,
48115806|NCT06439901|OTHER|Chest CTscan and follow-up|A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
48115807|NCT02771899|DEVICE|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
48315423|NCT02986893|BEHAVIORAL|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
48315424|NCT06378294|PROCEDURE|Mastectomy|Adjuvant postmastectomy radiotherapy
48315425|NCT06530602|OTHER|3 D SPA (shoulder complex pain alignment) Moblization|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
47965443|NCT02587234|DEVICE|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
47965444|NCT05417282|DRUG|MW151|Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.
47965445|NCT04527705|PROCEDURE|Non-surgical root canal retreatment|Non-surgical root canal retreatment
48115808|NCT02771899|DEVICE|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
48315426|NCT06530602|OTHER|Shoulder Moblization (KaltenBorn)|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
48315427|NCT03972644|PROCEDURE|Aortic valve replacement|Open heart surgery or transcatheter surgery
48315428|NCT05606224|BEHAVIORAL|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
48315429|NCT02921919|DRUG|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
48115812|NCT03315884|PROCEDURE|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
48115813|NCT03315884|PROCEDURE|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
48115814|NCT06382649|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
48115815|NCT06382649|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
48115816|NCT06522724|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information about self-management during the treatment process, the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise.
48315430|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
48485097|NCT02199015|DEVICE|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
48485098|NCT00293202|DRUG|Etanercept|Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
48485099|NCT00293202|DRUG|Placebo|Hemodialysis patients will receive Saline by subcutaneous injection twice a week
48315431|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
48315432|NCT04508673|OTHER|GH provocation tst|All patients underwent insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT), considered the 'gold standard' test for GHD diagnosis. Following insulin administration by venipuncture (1UI/mL), levels of hGH and glucose were monitored on serum and fluoride tube plasma, respectively, at intervals of 0, 30, 45, 60 and 90 minutes (T0, T30, T45, T60 and T90).
48315433|NCT01141634|OTHER|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
48485100|NCT00043537|BEHAVIORAL|Social Effectiveness Therapy for Children (SET-C)|
48644362|NCT05653752|DRUG|YL202|"YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle.~The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes."
48644363|NCT06255340|DRUG|BI 3031185|BI 3031185
48644364|NCT06255340|DRUG|Placebo matching BI 3031185|Placebo
48644365|NCT06253676|BEHAVIORAL|Problem Management Plus (PM+)|Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
48644366|NCT04725188|BIOLOGICAL|Pembrolizumab/Vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
48644367|NCT04725188|DRUG|Docetaxel|Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
48644368|NCT04725188|DRUG|Placebo|Normal saline IV infusion Q3W up to approximately 2 years
48644369|NCT06426381|BEHAVIORAL|Therapeutic Touch|Asymmetric energy fields can be balanced using the therapeutic touch method and treatment becomes easier. In this way, the person regains his health or can be helped to regain his health.
48644370|NCT06543381|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48644371|NCT06543381|DRUG|Olutasidenib|Given PO
48644372|NCT03413449|DIAGNOSTIC_TEST|Frailty model|"1. Grip strength~2. 30 second chair sit stand test~3. Psoas muscle area~4. Six minute walk"
48115817|NCT06522724|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of three hours daily. The program will be applied individually to each patient and include in-bed assisted exercises, airway clearance techniques, effective cough exercises, pursed-lips breathing, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
48315434|NCT02731391|PROCEDURE|Pelvic floor reconstruction（with or without mesh）|
48644373|NCT06315335|DRUG|UCB9741|Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
48315435|NCT01711320|DRUG|Placebo|
48315436|NCT01711320|DRUG|Omeprazole|
48315437|NCT05428800|BEHAVIORAL|Progressive Relaxation Exercises|Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
48315438|NCT04811469|DRUG|CBP-174|CBP-174 oral solution, given once
48315439|NCT04811469|DRUG|Placebo|Placebo oral solution, given once
48315440|NCT00152815|DRUG|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
48315441|NCT00152815|BEHAVIORAL|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
48315442|NCT05275738|DIETARY_SUPPLEMENT|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
48315443|NCT05275738|OTHER|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
48315444|NCT05342584|DRUG|Venetoclax Oral Tablet|Given PO
48315445|NCT05342584|DRUG|Daunorubicin|Given IV
48315446|NCT05342584|DRUG|Cytarabine|Given IV
48315447|NCT01333839|OTHER|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
48315448|NCT04428684|DRUG|Pepti 3.6 mg|Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
48485101|NCT00043537|DRUG|Fluoxetine|
48485102|NCT00043537|DRUG|Pill Placebo|
48485103|NCT03033719|PROCEDURE|Laparotomy|Open surgery
48485104|NCT03033719|PROCEDURE|Laparoscopy|Minimally invasive surgery
48485105|NCT00389779|DRUG|Darusentan|Darusentan capsules administered orally once daily
48485106|NCT00389779|DRUG|Guanfacine|Guanfacine capsules administered orally once daily
48485107|NCT00389779|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
48644374|NCT06315335|DRUG|Placebo|Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
48644375|NCT04452149|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download|Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.
48644376|NCT04452149|OTHER|Medication intervention|Risk status guided medication intervention.
48315449|NCT00005023|BIOLOGICAL|HER-2/neu peptide vaccine|
48315450|NCT00005023|BIOLOGICAL|sargramostim|
48315451|NCT03612180|DRUG|Metoprolol Succinate|Pharmacokinetics
48315452|NCT05091294|OTHER|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
48315453|NCT00786032|DEVICE|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
48315454|NCT05315232|OTHER|survey and interview|qualitative assessment
48315455|NCT02640846|DRUG|Norepinephrine|Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
48315456|NCT02640846|DRUG|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
48315457|NCT02640846|DRUG|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
48315458|NCT02121756|DRUG|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
48315459|NCT02121756|DRUG|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
48315460|NCT04546386|PROCEDURE|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
48315461|NCT03590522|GENETIC|Ryanodine Receptor 2 gene expression|Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
48315462|NCT00005986|DRUG|busulfan|
48485108|NCT06616948|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
48485109|NCT06616948|BEHAVIORAL|coaching calls|individuals will receive a phone call every 14 days to discuss ongoing exercise maintenance efforts.
48485110|NCT06616948|BEHAVIORAL|No coaching calls|Following completion of the 6-month cycling sessions, no maintenance calls will be placed.
48485111|NCT03482219|OTHER|Occupational therapy|The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
48315463|NCT00005986|DRUG|cyclophosphamide|
48315464|NCT00005986|DRUG|filgrastim|
48315465|NCT00005986|DRUG|recombinant interferon alfa|
48315466|NCT00005986|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48315467|NCT00005986|PROCEDURE|peripheral blood stem cell transplantation|
48315468|NCT00005986|PROCEDURE|radiation therapy|
48315469|NCT02010216|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
48315470|NCT05728086|OTHER|Group art therapy|The intervention is a manualised programme of group art therapy based on a bio-psychosocial therapeutic model. The programme is made up of six 60 - 90-minute art therapy group sessions facilitated by an experienced HCPC (Health and Care Professions Council) registered Art Therapists trained in the intervention.
48315471|NCT01727713|DRUG|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
48315472|NCT06371014|DRUG|Ondansetron oral membrane|A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy
48315473|NCT03531177|BEHAVIORAL|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
48315474|NCT03531177|BEHAVIORAL|Control|Participants receive usual care from their healthcare team.
48315475|NCT06383351|OTHER|Questionnaire|"Two sets of questionnaires will be administered to patients:~* Questionnaire about their perception of peri-implant disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire."
48315476|NCT05477342|BEHAVIORAL|Board Game|The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
48315477|NCT05477342|BEHAVIORAL|Tobacco Cesseation Education|The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.
48315478|NCT05477342|BEHAVIORAL|Combined İntervention|"The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale."
48315479|NCT02315287|DRUG|Pioglitazone|Comparison of two different thiazolidinediones
48315480|NCT02315287|DRUG|Lobeglitazone|Comparison of two different thiazolidinediones
48315481|NCT02410850|DEVICE|Oral Appliance|Mandibular Advancement Splints
48485112|NCT03482219|OTHER|Home app intervention|The app consists of videos depicting each exercise and ability to track adherence to exercises.
48485113|NCT02171390|DRUG|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
48485114|NCT02171390|DRUG|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
48485115|NCT04446039|DRUG|Escitalopram|Treatment for depression
48485116|NCT04446039|DRUG|Paroxetine|Treatment for depression
48485117|NCT04446039|DRUG|Fluoxetine|Treatment for depression
48485118|NCT04446039|DRUG|Mirtazapine|Treatment for depression
48485119|NCT04446039|DRUG|Duloxetine|Treatment for depression
48485120|NCT04446039|DRUG|Sertraline|Treatment for depression
48485121|NCT04446039|DRUG|Venlafaxine|Treatment for depression
48485122|NCT04446039|DRUG|Tianeptine|Treatment for depression
48485123|NCT04446039|DRUG|Vortioxetine|Treatment for depression
48115818|NCT05574192|BEHAVIORAL|Social Engagement Intervention|"The intervention includes social visiting with women affected by violence. Social visiting is carried out by trained peer-workers. Peers are women who share life histories with the target study population. Peer-workers will establish a visiting schedule (day/time) and provide a detailed list of activities in two categories:~1. arts-based activities.~2. physical activities.~The peer will meet with the participant at the scheduled place and times to accompany the participant and engage in the activities with the participant.~Participation in scheduled social activities that target the interest and ability of women affected by violence is considered to improve social connectedness by increasing the quality and quantity of a woman's social interactions with a supportive, trained person who shares life experiences. Shared, consistent and reliable social activities also are hypothesized to reduce loneliness by contributing to a sense of belonging and sense of being cared for."
48315482|NCT00756496|DEVICE|Mammography screening and diagnosis|Mammography screening and diagnosis
48315483|NCT00184249|PROCEDURE|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
48115819|NCT00420901|DRUG|sildenafil|
48115820|NCT03801967|DRUG|AZD9977|Randomized participants will receive oral dose of AZD9977.
48115821|NCT03801967|DRUG|Placebo|Randomized participants will receive oral dose of matching placebo.
48115822|NCT06209476|DIAGNOSTIC_TEST|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
48115823|NCT01117519|DRUG|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
48315484|NCT00002358|DRUG|Sorivudine|
48315485|NCT01604304|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
48315486|NCT01604304|PROCEDURE|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
48315487|NCT04359355|DEVICE|Artificial Intelligence System for Detection of colorectal polyps|In this group, an artificial Intelligence System will be used for computer-aided diagnosis of colorectal polyps. Diagnostic Performance of the artificial intelligence System for detection of polyps will be compared against Operator-based detection in the same group
48485124|NCT04446039|DRUG|Desvenlafaxine|Treatment for depression
48315488|NCT03320291|DEVICE|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
48315489|NCT01062594|OTHER|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
48315490|NCT01062594|OTHER|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
48315491|NCT01062594|OTHER|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
48315492|NCT00878657|DRUG|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
48315493|NCT00878657|RADIATION|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
48315494|NCT02662777|DEVICE|Eso-SPONGE® vacuum treatment|
48315495|NCT00062634|BEHAVIORAL|Female condom skills training|
48315496|NCT03050359|DRUG|TAK-438|TAK-438 tablets
48315497|NCT03050359|DRUG|Lansoprazole|Lansoprazole capsules
48315498|NCT03050359|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets.
48315499|NCT03050359|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
48315500|NCT03050359|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
48315501|NCT05564286|DRUG|Fosaprepitant|In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
48315502|NCT05564286|DRUG|tropisetron|All patients received tropisetron 5mg on day 1.
48315503|NCT05564286|DRUG|Dexamethasone|.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
48315504|NCT04777643|DRUG|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
48315505|NCT04777643|OTHER|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
48485125|NCT04446039|DRUG|Bupropion|Treatment for depression
48485126|NCT00995085|DRUG|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
48485127|NCT01484418|BEHAVIORAL|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
48485128|NCT01484418|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
48644377|NCT06472791|DIETARY_SUPPLEMENT|Centella Asiatica|Centella Asiatica is a perennial, herbaceous plant that is sold as a dietary supplement in the United States under the name Gotu Kola. It has been used for centuries in Ayurvedic and Chinese medicine. Evidence suggests it may help with resilience to aging and cognitive decline. The product for this study will be produced by Arjuna Natural.
48315506|NCT05398276|BEHAVIORAL|Behavioral Exposure For Introceptive Tolerance|BE-FIT will consist of a 6-session one-on one program with a clinician that are approximately 45 minutes delivered, over the course of 3 weeks (twice/week). Sessions will coincide with scheduled cardiac rehabilitation sessions at RWJ Cardiac Rehabilitation Program. The elements of BE-FIT are (1) psychoeducation about avoidance/anxiety and values clarification and committed action for exercise and lifestyle PA; (2) graded, repeated exposure to bodily sensations and exercise to build tolerance of discomfort; (3) fading safety behaviors and elimination of exercise avoidance behaviors to promote tolerance of uncertainty and reduce catastrophizing; and (4) use of Fitbit activity tracker to facilitate physical activity monitoring and provide physical activity feedback and goal-setting.
48115824|NCT04540822|OTHER|peripheral venous catheter with compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. Under the catheter-extension tube junction will be inserted a sterile non-woven compress, cut sterilely (3.5x1.5 cm). The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
48115825|NCT04540822|OTHER|peripheral venous catheter without compress under the catheter-extension tube junction|Placement of a BD Insyte® type catheter of 20 to 24 Gauge calibre on a peripheral vein located in the crease of the elbow or top of the hand or scalp or top of the foot. The catheter is placed while respecting the detersion and disinfection of the skin with the appropriate products and according to the procedure in force in the department. Once the venous return has been checked, a 10 cm extension with a BECTON-DIC® 3-way valve will be connected, which is previously purged with 0.9% Sodium Chloride. No compresses will be inserted under the catheter-extension tube junction.The assembly will be held in place by a transparent sterile semi-permeable adhesive dressing such as Tegaderm® (5x7 cm). This area will be secured by placing a crepe bandage (crepe bandage 4 m x7 cm).
48115826|NCT00144144|DRUG|Angiotensin II receptor antagonists, Calcium channel blocker|
48115827|NCT00534300|DRUG|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
48115828|NCT00534300|DRUG|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
48115829|NCT04996264|DRUG|Varespladib Methyl|Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.
48115830|NCT04996264|DRUG|Placebo|"The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate."
48115831|NCT04996264|DRUG|Standard of care (SOC)|SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
48115832|NCT06242782|PROCEDURE|VRA + d-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced d-PTFE membrane
48115833|NCT06242782|PROCEDURE|VRA + e-PTFE membrane|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Ti-Reinforced e-PTFE membrane
48115834|NCT06242782|PROCEDURE|VRA + customised Ti-mesh|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + 3D printed Titanium mesh
48115835|NCT06242782|PROCEDURE|VRA + RPM|VRA using a 50/50 particulate bone mix (xenograft+ autograft) + Reinforced PTFE mesh
48115836|NCT05734924|DEVICE|low Frequency High Intensity magnetic therapy|low Frequency High Intensity magnetic therapy with frequency 50 Hz and high intensity 60mT
48115837|NCT04122976|DRUG|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
48115838|NCT04239586|DRUG|Sulfonylurea|Starting treatment with sulfonylurea class of drug
48115839|NCT04019873|DRUG|Dolutegravir (DTG)|DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
48315507|NCT05398276|BEHAVIORAL|Health Education Control|HEC is a time-matched control intervention that will be administered on the same delivery schedule as BE-FIT. The intervention content includes: (1) educational information about health topics relevant to healthy aging, and (2) Use of the Fitbit activity watch for PA monitoring. The 6 topics introduced in the HEC include: nutrition, sleep, brain health, emotional health, living with chronic conditions, how to be a smart patient. The health information will be conveyed through lectures and handouts. The goal of sessions will be to provide education, particularly as it relates to healthy aging. Patients will be given the same Fitbit as in the BE-FIT but will not be given PA goals.
48644378|NCT06472791|DIETARY_SUPPLEMENT|Placebo Comparator|The comparator will contain microcystalline cellulose in matched capsules. The comparator product for this study will be produced by Arjuna Natural.
48115840|NCT04019873|DRUG|Lamivudine (3TC)|3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
48115841|NCT04019873|DRUG|Rilpivirine (RPV)|RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
48115842|NCT03267966|DIAGNOSTIC_TEST|Leeds Pathology Protocol (LEEPP)|LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
48115843|NCT02512965|RADIATION|20 Gy in 5 fractions|
48115844|NCT02512965|RADIATION|Conventional SBRT: 24 Gy in 2 fractions|
48115845|NCT00140088|DRUG|ALGRX 3268|
48115846|NCT06281808|DEVICE|Photon Counting Detector CT|Photon counting detector CT scan with dose arbitrarily reduced compared to EID CT scan (e.g., half the dose of EID CT)
48115847|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 25mg/dL≤ LDL-C\<70mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
48115848|NCT05765370|PROCEDURE|Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL|"Investigators initiated or adjusted lipid-lowering agents (drug and dosage) to achieve the target of 70mg/dL≤ LDL-C\<100mg/dL. The protocol encouraged, but did not mandate, the initiation of moderate-intensity statin therapy for secondary prevention with the evaluation of the potential for ASCVD risk reduction, adverse effects, and drug-drug interactions, as well as patient frailty and patient preferences. Statin monotherapy or in combination with ezetimibe, PCSK9 inhibitor or other drugs were adjusted on the basis of LDL-C levels.~At each follow-up visit, the investigators should verify whether the target LDL-C has been obtained. If the target level of LDL cholesterol was achieved, it is reasonable to continue to monitor adherence to lifestyle modiﬁcations, medication, and ongoing LDL-C response to therapy. If the target level of LDL cholesterol was not achieved, adjustment of the type and dose regimen of statin, or the additional of a nonstatin agent should be considered."
47965446|NCT04931407|OTHER|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
48115849|NCT00749749|DRUG|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
47965447|NCT05119517|OTHER|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
48115850|NCT00749749|DRUG|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
48315508|NCT05668260|DEVICE|Biodegradable Stent|A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
48315509|NCT05322018|DIAGNOSTIC_TEST|Faces Thermometer Scale (FTS)|The Faces Thermometer Scale (FTS) is a one-item measure with 11 numeric rating scale steps (0, no pain to 10, much pain). Each step is associated with different faces and colors. The app presents all information in text, sound, and picture. FTS is part of PicPecc, an application for mobile devices. The child/adolescent assesses their pain on a tablet by moving the finger on the scale and points to the color and face that represent their appraised level of pain.
48315510|NCT03172520|DEVICE|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
48315511|NCT03172520|DEVICE|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
48315512|NCT04336592|BEHAVIORAL|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
47965448|NCT05240313|BEHAVIORAL|kiR venezolano|A multi-week intervention focused on drug refusal skills and self-regulation.
48315513|NCT05696171|PROCEDURE|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
48315514|NCT05696171|PROCEDURE|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
48315515|NCT05437341|BIOLOGICAL|bi-4SCAR PSMA/CD70 T cells|Infusion of bi-4SCAR PSMA/CD70 T cells at 10\^6 cells/kg body weight via IV
48115851|NCT05949242|DEVICE|OMNI canaloplasty|OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal
48115852|NCT05949242|DEVICE|Hydrus microstent|Hydrus stent is introduced into Schlemm's canal to scaffold open the canal
48115853|NCT00259961|PROCEDURE|open fundoplication|
48485129|NCT06129344|OTHER|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
48315516|NCT03078036|GENETIC|Germline BRCA Test (blood)|If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
48644379|NCT06596759|BEHAVIORAL|Diaphragmatic Breathing|REDCap will be used to administer the Mayo Bloating Questionnaire (MBQ) and collect self-reported compliance to diaphragmatic breathing (DB) exercises over a 4 week follow up period. After completion of the MBQ, the patient will be taught DB techniques by an individual physical therapist face to face over a 30-minute session. The patient will be instructed to complete 5-10 minutes of diaphragmatic breathing twice a day for a period of 4 weeks. Patients will receive a telephone call and electronic health record portal message to check progress and answer any questions. At the end of the 4-week follow up period, patients will repeat the MBQ and self-report their adherence to daily diaphragmatic breathing. The questionnaire will include prompts investigating perceived side effects and attitudes towards therapy, willingness to perform DB therapy, likelihood to attempt self-guided DB in the future, and if the participant would recommend the therapy to a friend.
48315517|NCT03078036|GENETIC|FoundationOne Dx Genomic Profile (archival Tumour Specimen)|"Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:~* Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.~* Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile."
48315518|NCT03078036|OTHER|Follow-up|"Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.~- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study."
48315519|NCT02939924|DEVICE|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
48315520|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
48315521|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
48315522|NCT00783211|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
48315523|NCT00783211|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
48315524|NCT00783211|DRUG|placebo|placebo, once daily for 15 days
48315525|NCT00613418|DEVICE|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
48315526|NCT01902082|DRUG|Mesenchymal stem cells|
48315527|NCT01902082|DRUG|Placebo|
48315528|NCT01672606|DRUG|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
48315529|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
48315530|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
48315531|NCT02029508|PROCEDURE|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
48315532|NCT02029508|PROCEDURE|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
48315533|NCT02029508|PROCEDURE|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
48315534|NCT03071549|DRUG|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
48315535|NCT03071549|DRUG|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
48644380|NCT06456541|OTHER|Experimental Extensively Hydrolyzed Formula|Experimental powder formula
48644381|NCT06456541|OTHER|Placebo Extensively Hydrolyzed Formula|Placebo powder formula
48644382|NCT06577948|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
48644383|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 1|P.A.U.S.E. spectacle lens 1
48644384|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 2|P.A.U.S.E. spectacle lens 2
48115854|NCT00259961|PROCEDURE|laparoscopic fundopliaction|
48315536|NCT04685070|DRUG|HS-10296 (Almonertinib)|Neoadjuvant treatment stage: HS-10296 110mg, qd, po, 4 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: HS-10296 110mg, qd, po, up to 48 weeks (including neoadjuvant stage). PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
48315537|NCT03820037|DRUG|Ongentys|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
48315538|NCT03820037|DRUG|BIA 9-1067 (test)|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
48115855|NCT04776265|OTHER|Evaluation of therapeutical approach after ASCT|Evaluation of therapeutical approach after ASCT
48115856|NCT06204055|OTHER|Intramuscular Dry-Needling|It is a minimally invasive procedure where a solid filament needle is inserted deeply into a myofascial trigger point (MTrP) within a muscle in an attempt to abate it and illicit a desired treatment effect.
48315539|NCT02985905|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
48644385|NCT06034262|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
48115857|NCT02423291|DRUG|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
48115858|NCT03555214|OTHER|Manual Therapy based on soft tissues|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique."
48115859|NCT03555214|OTHER|Control group|"Placebo treatment:~The patient remains supine and the therapist sits on a stool at the bedside with the forearms resting on the couch. Both hands are placed on the posterolateral part of the patient's head and the position is maintained for 10 minutes without exerting any force or movement."
48115860|NCT03555214|OTHER|Manual Therapy based on structural techniques|"Manual Therapy:~1. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~2. Articulation technique of the high cervical spine (C0-C1).~3. Postero-anterior articular technique of C2-C7 in supine position.~4. Postero-anterior articular technique of C2-C7 in prone position.~5. Manipulative technique of the flapper C7-T1.~6. Dorsal spinal manipulative technique (T1-T8).~7. Lumbosacral global manipulative technique."
48115861|NCT03555214|OTHER|Manual Therapy based on soft tissues and structural techniques|"Manual Therapy:~1. Technique of suboccipital inhibition.~2. Cranial frontal technique.~3. Cranial sphenoid technique.~4. Cranial fourth ventricle technique.~5. Antero-posterior abdominal-sacral technique.~6. Technique of manipulation of the occipito-atlanto-axoidea joint (OAA).~7. Articulation technique of the high cervical spine (C0-C1).~8. Postero-anterior articular technique of C2-C7 in supine position.~9. Postero-anterior articular technique of C2-C7 in prone position.~10. Manipulative technique of the flapper C7-T1.~11. Dorsal spinal manipulative technique (T1-T8).~12. Lumbosacral global manipulative technique."
48115862|NCT02651480|DIETARY_SUPPLEMENT|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
48115863|NCT02651480|DIETARY_SUPPLEMENT|Control Group|Unrestricted diet with no instruction.
48115864|NCT03236909|DEVICE|MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System|Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.
48115865|NCT03801499|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48115866|NCT01297101|DRUG|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
48115867|NCT06106555|BEHAVIORAL|Dialectibal Behaviour Therapy|Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
48315540|NCT01563640|OTHER|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
48315541|NCT01563640|OTHER|washing|normal washing of school uniforms, without permethrin insecticide impregnation
48315542|NCT04743700|PROCEDURE|Piezocision|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.
48315543|NCT04743700|PROCEDURE|Micro-osteoperforations|Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP
48315544|NCT02909842|DIETARY_SUPPLEMENT|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
48315545|NCT02909842|DIETARY_SUPPLEMENT|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
48315546|NCT02909842|BIOLOGICAL|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
48644386|NCT06152575|DRUG|Elranatamab|Elranatamab will be administered subcutaneously
48644387|NCT06152575|DRUG|Elotuzumab|Elotuzumab will be administered intravenously
48644388|NCT06152575|DRUG|Pomalidomide|Pomalidomide will be administered orally
48644389|NCT06152575|DRUG|Dexamethasone|Dexamethasone will be administered orally
48644390|NCT06152575|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously
48644391|NCT06152575|DRUG|Carfilzomib|Carfilzomib will be administered intravenously
48644392|NCT03659721|BEHAVIORAL|FACAM|Support person
48644393|NCT03659721|BEHAVIORAL|Care as Usual|Usual care
48315547|NCT03765255|OTHER|In the Know: sexual health education|The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
48315548|NCT06170372|DRUG|200 ppm Nitric Oxide|NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
48315549|NCT06170372|DRUG|Sham treatment|Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
48485130|NCT06129344|OTHER|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
48485131|NCT05660031|PROCEDURE|LHB Tenotomy|Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors
48485132|NCT05660031|PROCEDURE|LHB Tenodesis|"ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique."
48485133|NCT02384694|OTHER|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
48315550|NCT02280941|OTHER|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
48315551|NCT04032171|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
48315552|NCT04032171|DRUG|Avonex®|Participants received avonex® IM injection once a week.
48315553|NCT04032171|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to avonex® once a week.
48315554|NCT04032171|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
48485134|NCT01931228|PROCEDURE|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
48485135|NCT01931228|PROCEDURE|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
48485136|NCT00764231|BEHAVIORAL|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
48315555|NCT03710941|DRUG|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
48315556|NCT03710941|DRUG|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
48315557|NCT01763268|BIOLOGICAL|Trivivac vaccine|Trivalent MMR vaccine
48315558|NCT01035242|BEHAVIORAL|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
48485137|NCT00764231|BEHAVIORAL|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
48485138|NCT02499224|DRUG|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
48485139|NCT04337684|DRUG|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
48485140|NCT04816747|BIOLOGICAL|Autologous PRP|Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
48485141|NCT02794935|OTHER|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
48644394|NCT03659721|BEHAVIORAL|COS-P|Attachment based therapy
48644395|NCT00912873|DRUG|0.1% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
48315559|NCT01035242|BEHAVIORAL|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
48315560|NCT00948818|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
48315561|NCT00948818|DRUG|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
48315562|NCT01259856|DRUG|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
48315563|NCT01259856|DRUG|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
48315564|NCT01259856|DRUG|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
48315565|NCT00163150|DRUG|Atorvastatin|
48315566|NCT04300062|PROCEDURE|Rebiopsy|Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
48315567|NCT01173341|DIAGNOSTIC_TEST|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
48315568|NCT01173341|OTHER|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
48315569|NCT01173341|OTHER|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
48315570|NCT04914078|DRUG|Mepolizumab 100 MG|The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
48315571|NCT01915004|OTHER|Educational Intervention|Bladder Training Video
48315572|NCT03861546|BEHAVIORAL|Healthy lifestyle Shared Medical Appointment (SMA) program|Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
48315573|NCT06552299|OTHER|Laypersons|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
48315574|NCT06552299|OTHER|Health-Care Providers|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
48315575|NCT04434820|DEVICE|External negative pressure dressing system (Yuwell 7E-A portable suction unit)|A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
48315576|NCT02093234|BEHAVIORAL|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
48315577|NCT02093234|BEHAVIORAL|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
48315578|NCT02093234|BEHAVIORAL|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
48315579|NCT02078882|BIOLOGICAL|abatacept|125 mg subcutaneously each week for 24 weeks
48315580|NCT03019770|BEHAVIORAL|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
48485142|NCT02794935|OTHER|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
48485143|NCT05182619|PROCEDURE|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
48485144|NCT06264479|PROCEDURE|Biopsy|Patients undergo a biopsy from a lesion, and give 40ml of blood
48485145|NCT05670782|DRUG|KM-819|Participants will receive oral doses of KM-819 once-daily
48485146|NCT05670782|DRUG|Placebo|Participants will receive matching placebo once-daily
48644396|NCT00912873|DRUG|0.4% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
48315581|NCT04742270|DEVICE|SIMEOX+ respiratory physiotherapy telecare|"Every 10 days, the patient's expert physiotherapist will contact the patient by video-transmission or telephone call for motivational reinforcement and technical support in the use of the device.~During these phone calls, a quick 3-question questionnaire will be administered to the patient to monitor events of hemoptysis, chest pain and clinical symptoms of gastroesophageal reflux disease: pyrosis.If patients report this type of event, the physiotherapist will inform the patient's physician for management at his/her discretion.~The expert physiotherapist will also conduct this sessions in order to increase the patient's motivation and compliance to the device. In order to do this, he will identify (in collaboration with the patient), the patient's difficulties and obstacles and he will try to find solutions with him."
48315582|NCT02512068|DRUG|Trelagliptin 25 mg|Trelagliptin 25 mg Tablets
48315583|NCT02512068|DRUG|Placebo|Placebo Tablets
48315584|NCT02730936|DEVICE|Antimicrobial Hernia Repair Device|hernia repair
48315585|NCT05007249|PROCEDURE|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
48315586|NCT04619121|DEVICE|NIR-tPBM|The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
48315587|NCT04619121|DEVICE|Sham device|The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
48315588|NCT04310215|BIOLOGICAL|CARTISTEM®|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture~2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
48315589|NCT04310215|PROCEDURE|Microfracture|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture"
48315590|NCT02518152|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
48315591|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
48315592|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
48315593|NCT01800006|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
48315594|NCT05346913|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
48315595|NCT05112016|PROCEDURE|Total mesorectal excision for rectal cancer|
48485147|NCT06384742|BEHAVIORAL|Shift Worker Intervention for Sleep Health|SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia that is individually administered via telehealth across seven approximately weekly sessions that range in length from 30-60 minutes
48485148|NCT05987735|BEHAVIORAL|BLAME-LESS|The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
48485149|NCT02903238|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
48485150|NCT02903238|DRUG|Placebo Oral Tablet|Lactose capsule
48485151|NCT06271902|OTHER|Singapore Youth Shoulder Overuse Injury Prevention Program|A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.
48315596|NCT00846261|DEVICE|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
48315597|NCT02199106|DEVICE|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS"
48485152|NCT06271902|OTHER|Lower body stretching program|A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
48485153|NCT03349359|DRUG|HIV antiretroviral therapy|HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
48485154|NCT04979884|DRUG|cyclosporine|Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
48485155|NCT05089695|DEVICE|Noninvasive respiratory support|Treatment of acute hypoxemic respiratory failure
48485156|NCT02777918|BEHAVIORAL|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
48644397|NCT04524871|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
48644398|NCT04524871|DRUG|Bevacizumab 15 mg/kg|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
48644399|NCT04524871|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
48644400|NCT04524871|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
48644401|NCT04524871|DRUG|TPST-1120|TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
48315598|NCT02199106|DEVICE|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS"
48315599|NCT02504268|DRUG|Abatacept|
48485157|NCT05198388|DIAGNOSTIC_TEST|βeta endorphins, interleukin 6 and interleukin 38|"* - Collection of peripheral blood samples in gel tube.~* - Creparation of samples in centrifuge to obtain serum.~* - Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
48644402|NCT04524871|DRUG|Tobemstomig 2100 mg|Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
48485158|NCT01370486|DRUG|melatonin|melatonin cp 2 mg 1x/d for 1 month
48485159|NCT01370486|DRUG|placebo|placebo cp 1x/d for 1 month
48315600|NCT02504268|DRUG|Methotrexate|
48315601|NCT02504268|OTHER|Abatacept Placebo|
48485160|NCT04104555|OTHER|Birthday card|Birthday card sent to participants in the post
48485161|NCT04104555|DEVICE|Prefabricated orthoses|Prefabricated insole
48644403|NCT04524871|DRUG|Bevacizumab 10 mg/kg|Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
48644404|NCT04524871|DRUG|Tobemstomig 600 mg|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
48644405|NCT04524871|DRUG|Tobemstomig 1200 mg|Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
48315602|NCT02504268|OTHER|Methotrexate Placebo|
48315603|NCT05339243|OTHER|ES 1|Two capsules orally once daily after breakfast for 84 days
48315604|NCT05339243|OTHER|HT ES1|Two capsules orally once daily after breakfast for 84 days
48315605|NCT05339243|OTHER|Placebo|Two capsules orally once daily after breakfast for 84 days
48485162|NCT04104555|OTHER|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
48485163|NCT04104555|OTHER|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
48644406|NCT04524871|DRUG|ADG126|ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
48644407|NCT04524871|DRUG|IO-108 1800 mg|IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
48644408|NCT04524871|DRUG|NKT2152|NKT2152 will be administered by mouth.
48644409|NCT04524871|DRUG|IO-108 1200 mg|IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
48644410|NCT06054880|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
48644411|NCT06054880|OTHER|Saline injection 0.9%|Placebo
48115868|NCT06666829|OTHER|Multidomain intervention|"treatment plan using combination of more than one technological or robotic devices, choosing from: Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~In this way, the child will be taken care of holistically, considering their needs from a motor, cognitive, and speech therapy perspective. The treatment plan will also include a conventional multi-level rehabilitation program."
48644412|NCT04020913|DRUG|Somatropin injection|"Boys with short stature will be studied for measures of:~1. skeletal muscle strength, power, and endurance~2. muscle agility~3. lean body mass accrual~4. bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
48644413|NCT05721729|DRUG|Mizagliflozin|Encapsulated
48644414|NCT05721729|DRUG|Placebo|Encapsulated
48644415|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 1|Soft gel capsule
48644416|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 2|Soft gel chewable
48644417|NCT06649721|DRUG|bedaquiline|400 milligrams (mg) daily for 2 weeks(w), then 200mg three times a week for 22 weeks (w)
48644418|NCT06649721|DRUG|delamanid|"* for participants weighing up to 33.9 kilograms (kg): 50mg two times a day for 24w~* for participants weighing 34kg or above: 100mg two times a day for 8w, then 200mg daily for 16w"
48644419|NCT06649721|DRUG|linezolid|"* for participants weighing up to 33.9kg: 450mg daily;~* for participants weighing 34kg or above: 600mg daily; for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
48315606|NCT01156610|BEHAVIORAL|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
48644420|NCT06649721|DRUG|Levofloxacin|"Only for participants with confirmed fluoroquinolone-susceptible TB or unknown fluoroquinolone susceptibility:~* for participants weighing up to 33.9kg: 500mg daily~* for participants weighing 34kg to 49.9kg: 750 daily~* for participants weighing 50kg or above: 1000mg daily for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
48644421|NCT06649721|DRUG|Clofazimine|"Only for participants with confirmed fluoroquinolone-resistant TB or unknown fluoroquinolone susceptibility:~100mg daily, for 24w if a negative culture is obtained from sputum collected at 16w, or else for 36w"
48644422|NCT06112418|DEVICE|The Cleerly CAD Staging System|The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.
48644423|NCT04389632|DRUG|sigvotatug vedotin|Administered into the vein (IV; intravenously)
48644424|NCT04389632|DRUG|pembrolizumab|200mg every 3 weeks or 400mg every 6 weeks, given by IV
48644425|NCT04389632|DRUG|cisplatin|75 mg/m2 every 3 weeks, given by IV
48644426|NCT04389632|DRUG|carboplatin|AUC 5 mg/mL per min every 3 weeks, given by IV
48644427|NCT01630083|DRUG|epirubicin|Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
48644428|NCT01630083|DRUG|oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
48644429|NCT01630083|DRUG|capecitabine|The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
48315607|NCT06065267|DRUG|sequential|amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
48315608|NCT06065267|DRUG|Levofloxacin 500Mg Oral Tablet|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
48115869|NCT06666829|DEVICE|Single domain intervention|"Treatment plan using only one of these technological or robotic device:~Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~Technological rehabilitation will focus on the main specific need for the child, it'll be chosen individually. The treatment plan will also include a conventional multi-level rehabilitation program."
48115870|NCT02034968|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
48115871|NCT03233919|DEVICE|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
48115872|NCT02789917|OTHER|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
48115873|NCT02789917|OTHER|Triple Therapy|"HAS-BLED-Score \<3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
48115874|NCT00014248|DRUG|adenosine triphosphate|
48115875|NCT00014248|PROCEDURE|quality-of-life assessment|
48115876|NCT05075694|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.
48115877|NCT05075694|OTHER|Sham Therapeutic Touch|The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
48115878|NCT06479187|DRUG|18F-rhPSMA-7.3|radiopharmaceutical targeting PSMA and used to image prostate cancer with PET scan.
48115879|NCT06479187|DEVICE|PET/CT|Diagnostic imaging test
48115880|NCT05488080|BEHAVIORAL|Department-level audit and feedback and electronic health record-embedded clinical decision support|This intervention will provide clinicians with Equity Report Cards and clinician decision support on mitigating disparities in quality of care.
48115881|NCT00235508|DRUG|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
48115882|NCT01274299|PROCEDURE|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
48115883|NCT02961569|PROCEDURE|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
48115884|NCT03623997|OTHER|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
48115885|NCT04487600|OTHER|Active voiding trial|
48115886|NCT00841035|DRUG|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
48315609|NCT03684291|PROCEDURE|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
48315610|NCT02364206|DRUG|LY2228820|
48315611|NCT02364206|DRUG|Temozolomide|
48315612|NCT02364206|RADIATION|radiotherapy|
48315613|NCT00628953|DRUG|Esomeprazole|40mg twice a day
48315614|NCT00628953|DRUG|Placebo|40mg twice a day
48315615|NCT02671695|DRUG|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
48315616|NCT02671695|DRUG|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
48315617|NCT05199350|OTHER|Device Name: ANSiscope|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
48315618|NCT02052843|BEHAVIORAL|Steps to Success|
48315619|NCT02052843|BEHAVIORAL|Traditional Healthy Families|
48315620|NCT06234618|OTHER|visual deprivation|A group of patients walking with eyes open and walking with visual deprivation.
48315621|NCT00116857|DRUG|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
48315622|NCT00116857|DRUG|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
48315623|NCT03463941|BEHAVIORAL|Peer Support Dyad Intervention|"Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed."
48315624|NCT01316601|DRUG|QAX567|
48315625|NCT05192174|BIOLOGICAL|NIB101|NIB101
48315626|NCT04209647|OTHER|REHIT Exercise|"-Start with warm-up period --\> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~* 15 seconds exercise period: %100 of maximum work rate~* 15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes"
48315627|NCT04209647|OTHER|Continuous Aerobic Exercise|At %50 of maximum heart rate, 30-60 minutes aerobic exercise
48315628|NCT03973684|DEVICE|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
48315629|NCT03973684|OTHER|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
48315630|NCT02014935|OTHER|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
48315632|NCT05745116|DEVICE|Notal Vision Home OCT|Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.
48315633|NCT04221906|DRUG|BOS-475|topical cream
48315634|NCT04221906|DRUG|Active ingredient-free vehicle cream|topical cream
48315635|NCT04221906|DRUG|Daivonex cream (calcipotriol 0.005%)|topical cream
48315636|NCT04221906|DRUG|Betnesol-V cream (betamethasone 0.1%)|topical cream
48315637|NCT05468944|PROCEDURE|Transanal specimen extraction robotic surgery|Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
48315638|NCT05468944|PROCEDURE|Transabdominal specimen extraction robotic surgery|Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
48315639|NCT01570400|BEHAVIORAL|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
48315640|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
48315641|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
48315642|NCT00414960|DRUG|Enzastaurin|500 mg po QD for 6 months
48315643|NCT00414960|DRUG|Placebo|po QD for 6 months
48315644|NCT03240393|DRUG|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
48315645|NCT04321317|OTHER|Measure of body composition by Air Displacement Plethysmography (ADP)|Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
48315646|NCT06254027|DEVICE|Forte|One application per day for a complete treatment period.
48315647|NCT06254027|DEVICE|Active Cover Light|One application per day for a complete treatment period.
48315648|NCT06254027|DRUG|Loceryl|One application per week for a complete treatment period.
48315649|NCT03850327|DEVICE|BIOMONITOR III|Patients with ICM indication receive a third-generation implantable cardiac monitor
48485164|NCT01310673|DRUG|Allopurinol|"Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
48315650|NCT06552598|DRUG|KD01(the recombinant oncolytic adenovirus)|"Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged."
48315651|NCT02857114|OTHER|massage|
48315652|NCT02145741|DRUG|Xentuzumab, low dose, every week (qw)|Patient to receive low dose of Xentuzumab IV
48315653|NCT02145741|DRUG|Xentuzumab, middle dose, qw|Patient to receive middle dose of Xentuzumab IV
48315654|NCT02145741|DRUG|Xentuzumab, high dose, qw|Patient to receive high dose of Xentuzumab IV
48315655|NCT02694211|BEHAVIORAL|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
48315656|NCT01724125|OTHER|personal electronic medical record|
48115887|NCT06677359|DIETARY_SUPPLEMENT|Creatine Group|Micronized creatine monohydrate supplementation.
48315657|NCT02849912|OTHER|questionnaire|
48315658|NCT04398199|DRUG|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
48315659|NCT04398199|RADIATION|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
48315660|NCT04747483|OTHER|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
48315661|NCT04747483|OTHER|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
48315662|NCT01450046|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
48315663|NCT02470052|DEVICE|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
48315664|NCT02410772|DRUG|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
48315665|NCT02410772|DRUG|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
48315666|NCT02410772|DRUG|control|standard six-month treatment
48315667|NCT02233205|DEVICE|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
48315668|NCT02233205|DRUG|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
48315669|NCT04825145|OTHER|Pregnancy|Pregnancies complicated by preeclampsia
48485165|NCT01310673|DRUG|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
48115888|NCT06677359|DIETARY_SUPPLEMENT|Placebo Group|Participants will recieved placebo supplementation
48115889|NCT06677359|OTHER|Multicomponent Training|Multicomponent physical exercise intervention
48115890|NCT04226664|PROCEDURE|Bariatric surgery|Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
48115891|NCT02582086|OTHER|BOR15001L7|Active cream with 5% 15019L0
48115892|NCT02582086|OTHER|Placebo|Placebo Cream with 0% 15019L0
48115893|NCT02838199|DEVICE|SAPIEN 3|
48115894|NCT02838199|PROCEDURE|SAVR|
48115895|NCT03865758|DEVICE|IN2L computer system|Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
48315670|NCT03054077|OTHER|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
48315671|NCT04975971|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
48315672|NCT03076190|BEHAVIORAL|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
48315673|NCT02288065|DRUG|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
48315674|NCT06087224|OTHER|Teleneonatology|Real-time, two way, audio-video telemedicine connection between the neonatologist located in the regional neonatal intensive care unit (NICU) and the physician located at the community hospital.
48315675|NCT02134327|DRUG|Combination of Dexmedetomidine with Midazolam|
48315676|NCT03918603|OTHER|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
48315677|NCT04786041|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
48315678|NCT02352792|RADIATION|radiochemotherapy with 70 Gy|
48315679|NCT02352792|RADIATION|radiochemotherapy with 77 Gy|
48315680|NCT05105438|DIETARY_SUPPLEMENT|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
48315681|NCT05105438|DIETARY_SUPPLEMENT|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
48315682|NCT02154126|DEVICE|Continuous Glucose Monitoring Device (Senseonics)|
48315683|NCT04430660|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
48315684|NCT04430660|DEVICE|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
48315685|NCT00808730|PROCEDURE|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
48315686|NCT01066195|DRUG|iressa|iressa 250mg per day every day
48315687|NCT01066195|DRUG|alimta|alimta 500mg/m2 every 3 weeks
47965449|NCT06094595|DIAGNOSTIC_TEST|MAS-p administration|Each patient will be assessed the first time at mealtime by two experienced speech therapists, and scores obtained on the MAS-p will be recorded independently and blinded to each other. The two scales selected for comparison will also be administered at the same time. The assessment with the MAS-p scale will be repeated 48 hours apart, a time considered optimal in order to avoid possible bias related to the clinical improvement of the patient undergoing rehabilitation treatment, by one of the two speech therapists.
48315688|NCT03709134|DIAGNOSTIC_TEST|Genomic Markers (CTC/ctDNA)|This is a non-interventional study.
48315689|NCT06148896|BEHAVIORAL|GrExPACT|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapy
48315690|NCT06148896|BEHAVIORAL|GrEx|Group physiotherapy exercise
48315691|NCT05637723|OTHER|schroth exercise|The schroth exercise program will be given 3 days a week for 6 weeks.
48315692|NCT05637723|OTHER|traditional scoliosis exercises|The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
47965450|NCT03944915|DRUG|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
47965451|NCT03944915|DRUG|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
48315693|NCT03488121|BEHAVIORAL|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
48315694|NCT03488121|BEHAVIORAL|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
48315695|NCT00547638|DEVICE|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
47965452|NCT03944915|DRUG|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
48115896|NCT06677034|OTHER|Exercise|Mobile Game-Based Exercise Training
48315696|NCT00547638|DEVICE|cyanoacrylate|Topical Skin Adhesive
48315697|NCT04987541|DEVICE|intermittent theta burst stimulation|stimulatory protocol
48315698|NCT03179592|DRUG|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
48115897|NCT04101968|DIAGNOSTIC_TEST|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
48115898|NCT04101968|DIAGNOSTIC_TEST|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
48115899|NCT05935527|DRUG|POLAT-001|Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.
48315699|NCT04839770|DEVICE|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
48315700|NCT03645772|OTHER|Exercise intervention|12-week progressive training intervention
48315701|NCT04657952|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine \& adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
48315702|NCT04657952|DRUG|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
48315703|NCT03282357|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
48315704|NCT03282357|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection
48315705|NCT00157937|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
48315706|NCT00157937|DRUG|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
48315707|NCT02279524|DRUG|Aramchol|"Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
48315708|NCT05948371|OTHER|High Intensity interval Training|"High Intensity interval Training~* Frequency: 3-5 day per week~* Intensity: 60 to 80% of HRR. If atrial fibrillation present use RPE of 11-14 on a 6-20 scale.~* Time: total 30 mint time.6 mint exercise with high intensity and 2 mints of low intensity for active recovery until 30 mints complete.~Type: walking and static cycling. Walking~* Frequency 3 -5 days per week Intensity : use RPE of 11-14.~* Time:30 mint total. 6 mint walk with high intensity and 2 mint walk with low intensity until 30mints completed."
48315709|NCT05948371|OTHER|Continuous Aerobic training|"Continuous Aerobic training~* Frequency : 3-5 days per week.~* Intensity:40-70% of HHR.~* Time : initial 5-10 then 10-15 until 30mints without rest interval~* Type : walking and static cycling."
48115900|NCT05935527|DRUG|Placebo|Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
48315710|NCT01360944|DRUG|LAS41004|once daily, topical, 100 microgram
48315711|NCT01360944|DRUG|reference|once daily, 100 microgram
48315712|NCT05380934|DRUG|TQH3821 tablets|TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
48315713|NCT05380934|DRUG|TQH3821 tablets (Placebo)|TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
48315714|NCT05380934|DRUG|Methotrexate tablets|Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
48115901|NCT02245581|PROCEDURE|SVV-guided fluid management|
48115902|NCT02245581|PROCEDURE|CVP-guided fluid management|
48115903|NCT01061151|DRUG|Zidovudine (ZDV)|300 mg twice daily
48115904|NCT01061151|DRUG|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
48315715|NCT00091845|DRUG|AVI-4020 Injection|
48315716|NCT06238245|DRUG|Cyclophosphamid|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
48315717|NCT02520518|DRUG|Dapagliflozin|
48315718|NCT02520518|DRUG|Placebo|
48315719|NCT02520518|BEHAVIORAL|Weight maintenance|
48315720|NCT02520518|BEHAVIORAL|Ad libitum dietary intake|
48485166|NCT05416463|PROCEDURE|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
48485167|NCT01764295|DRUG|DWJ1276|
48115905|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
48115906|NCT01061151|DRUG|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
48115907|NCT01061151|DRUG|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
48115908|NCT01061151|DRUG|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
48115909|NCT01061151|DRUG|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
48115910|NCT01061151|DRUG|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
48315721|NCT02520518|BEHAVIORAL|Dietary restriction|
48315722|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
48485168|NCT01764295|DRUG|Olmesartan|
48485169|NCT01764295|DRUG|Rosuvastatin|
48485170|NCT01764295|DRUG|Placebo|
48485171|NCT03329079|BEHAVIORAL|Mobile Technology Plus|The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
48315723|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
48315724|NCT04641312|DRUG|LY3457263|Administered SC
48315725|NCT04641312|DRUG|Dulaglutide|Administered SC
48315726|NCT04641312|DRUG|Placebo|Administered SC
48315727|NCT03456713|BIOLOGICAL|LY3074828|Administered SC
48315728|NCT00407264|DRUG|Fluticasone propionate|
48315729|NCT04538092|OTHER|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
48315730|NCT01113398|DRUG|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
48315731|NCT01113398|DRUG|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
48315732|NCT05137119|DRUG|Cefazolin|Cefazolin
48315733|NCT05137119|DRUG|Penicillin|benzylpenicillin
48315734|NCT05137119|DRUG|Clindamycin|Clindamycin
48315735|NCT05137119|DRUG|Vancomycin|Vancomycin or Daptomycin
48315736|NCT05137119|OTHER|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
47965453|NCT03944915|RADIATION|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
47965454|NCT03944915|DRUG|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
47965455|NCT03944915|DRUG|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
48315737|NCT05137119|RADIATION|Whole body FDG PET/CT Imaging|Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
48315738|NCT02983630|OTHER|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
48315739|NCT00610376|BEHAVIORAL|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
48315740|NCT00610376|BEHAVIORAL|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
48315741|NCT01320111|DRUG|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
48315742|NCT01320111|DRUG|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
48315743|NCT00032019|BIOLOGICAL|filgrastim|Cycle 1: 300 ug (BW \< = 70 kg) or 480ug (BW \>70 kg) sub Q injection Day 6 until ANC \> 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
48315744|NCT00032019|BIOLOGICAL|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
48315745|NCT00032019|DRUG|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
48315746|NCT00032019|DRUG|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
48315747|NCT00032019|DRUG|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
48315748|NCT00032019|DRUG|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
47965456|NCT03944915|DRUG|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
47965457|NCT03944915|DRUG|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
48315749|NCT00032019|DRUG|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
47965458|NCT00555971|DRUG|Omalizumab|Subjects randomized to Omalizumab prior to aspirin desensitization
47965459|NCT00555971|DRUG|placebo|Subjects randomized to Placebo prior to aspirin desensitization
48115911|NCT01061151|OTHER|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail."
48315750|NCT01778127|BEHAVIORAL|Activity Monitor|Measurement of physical activity.
48315751|NCT01778127|BEHAVIORAL|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
48315752|NCT01778127|BEHAVIORAL|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
48315753|NCT05341674|OTHER|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
48315754|NCT01911000|RADIATION|RT and hyperthermia after TACE|
48315755|NCT01434888|DRUG|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
48315756|NCT01434888|DRUG|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
48315757|NCT01434888|DRUG|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
48315758|NCT03014167|DRUG|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
48315759|NCT01791114|OTHER|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
48315760|NCT01791114|OTHER|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
48315761|NCT01791114|OTHER|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
48315762|NCT01791114|OTHER|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
48315763|NCT01791114|OTHER|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
48315764|NCT01791114|OTHER|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
48315765|NCT01791114|OTHER|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
48315766|NCT06516666|BEHAVIORAL|Music|"Participants went through four stages. In the rest stage, they were instructed to relax. In the neutral control stage, they watched an informative video about plastic injection molding. In the sadness induction stage, they viewed sad clips from either Hachi: A Dog's Tale or My Brother and Sister, with the order randomized across participants. In the music intervention stage, they listened to the cheerful Cuckoo Waltz. Each stage lasted for about 6 minutes.~The interventions for the two groups were exactly same.~PS: On the basis of the PHQ-9, this HAMD interview was conducted to further group the participants. So, following the experimental protocol, participants who scored ≥ 5 on the PHQ-9 measure underwent the HAMD interview, while the remaining individuals were simply interviewed about their feelings during the experiment."
48315767|NCT05524870|OTHER|Mobilization|Movement with mobilization plus exercise
48315768|NCT05283889|PROCEDURE|Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
48315769|NCT05283889|PROCEDURE|Sham Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
48315770|NCT02304315|BIOLOGICAL|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
48315771|NCT02304315|BIOLOGICAL|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
48315772|NCT00661245|DEVICE|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
48315773|NCT00661245|DEVICE|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
48315774|NCT05088616|BEHAVIORAL|Virtual Diabetes Wellness Classes and Medically Tailored Meals|Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
48315775|NCT01836887|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
48315776|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
48315777|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
48315778|NCT03838068|BIOLOGICAL|Biodentine|Biodentine is considered a calcium silicate cement
48115912|NCT01061151|OTHER|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
48115913|NCT01061151|OTHER|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
48315779|NCT03838068|BIOLOGICAL|mineral trioxide aggregate|calcium based silicate cement
48315780|NCT03838068|PROCEDURE|cervical pulpotomy|coronal pulp tissue was removed till the orifice
48315781|NCT03838068|DRUG|Local Anesthetics Procaine|40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
48315782|NCT03192072|DIAGNOSTIC_TEST|Host Gene Expression|comparison to retrospective clinical adjudication
48315783|NCT04435145|BEHAVIORAL|Sugar-sweetened beverage warning label|A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
48315784|NCT06280261|OTHER|parenting stress index, Zarit burden scale, Rosenberg self esteem scale, stait trait anxiety inventory, struggles and difficulties questionnaire|Scales and questionnaires
48315785|NCT00862849|DRUG|Insulin Lispro|
48315786|NCT00862849|DRUG|Regular Human Insulin|
48315787|NCT00862849|DRUG|rHuPH20|
48315788|NCT05400005|OTHER|Dietary protein|"Intervention of the study include consuming a higher protein diet. Depending on the group allocation, this is done by asking the subjects to follow My Healthy Plate diet and consumption of 20g of protein isolates (casein or soy)."
48315789|NCT04887103|OTHER|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
48315790|NCT03697928|OTHER|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
48315791|NCT00418834|DRUG|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
48315792|NCT00418834|DRUG|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
48315793|NCT00418834|DRUG|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
48315794|NCT05544422|OTHER|The Timed Up & Go Test and 30second Chair-Stand Test'|"Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other."
48315795|NCT03106194|OTHER|case management|
48315796|NCT00191074|DRUG|somatropin, rDNA origin, for injection|
48315797|NCT03573128|BEHAVIORAL|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
48315798|NCT03573128|OTHER|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
48315799|NCT01695057|DRUG|vorinostat|Given PO
48315800|NCT01695057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48315801|NCT01695057|OTHER|laboratory biomarker analysis|Correlative studies
48315802|NCT03331666|DRUG|Evolocumab|140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
48315803|NCT03477617|OTHER|Intraoperative Hemodynamic Algorithm|Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
48315804|NCT03477617|COMBINATION_PRODUCT|Usual hemodynamic management|Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
48315805|NCT00788775|DRUG|Nilotinib|
48315806|NCT01000194|DIETARY_SUPPLEMENT|High fat meal|A high fat milkshake containing 55g of fat
48315807|NCT01012193|DRUG|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
48315808|NCT05985122|DIAGNOSTIC_TEST|C3NEF assay|This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
48315809|NCT04065087|BIOLOGICAL|GX-I7|Investigational drug
48315810|NCT04065087|OTHER|Placebo|Placebo drug
48315811|NCT02438995|DRUG|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
48315812|NCT02900924|DEVICE|BioMimics 3D Stent|
48315813|NCT02855411|DRUG|PF-04958242|Administered as specified in the treatment arm
48315814|NCT02855411|DRUG|placebo|placebo, twice daily (BID) for 12 weeks, capsule
48315815|NCT02225873|OTHER|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
48315816|NCT02225873|OTHER|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
48315817|NCT05210205|DIETARY_SUPPLEMENT|EAA|EAA-enhanced protein snack bars
48315818|NCT05210205|DIETARY_SUPPLEMENT|Energy Dense|Energy dense snack bars (same calories in a smaller volume of food)
48315819|NCT05210205|DIETARY_SUPPLEMENT|Control|Low energy dense snack bars (same calories in a greater volume of food)
48315820|NCT06117800|OTHER|TeamSTEPPS|Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
48315821|NCT03427905|PROCEDURE|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
48315822|NCT03427905|PROCEDURE|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
48315823|NCT04471064|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
48644430|NCT01630083|DRUG|zolbetuximab|Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
48644431|NCT04839601|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
48644432|NCT04976322|DRUG|Dapirolizumab pegol|Subjects will receive dapirolizumab pegol at prespecified time-points.
48315824|NCT03982771|DRUG|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
48315825|NCT03982771|DRUG|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
48315826|NCT03982771|DRUG|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
48315827|NCT05009316|OTHER|Questionnaires|Online-based questionnaires
48315828|NCT01879956|OTHER|Craft Activities|There is no intervention method used to perform the task.
48315829|NCT01879956|BEHAVIORAL|OGI Method|metacognitive approach to assess executive functions.
48315830|NCT05877196|BEHAVIORAL|Moderate Intensity Continuous Training (MICT)|Aerobic cycling at a moderate intensity (50-75% of heart rate reserve) for 30-50 minutes, 3 times per week for 3-6 months.
48315831|NCT05877196|BEHAVIORAL|Chair-based Stretch|Stretching while seated for 30-50 minutes, 3 times per week for 6 months.
48315832|NCT05877196|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Aerobic cycling at a vigorous intensity (80-90% of heart rate reserve 4-minute bouts with 4-minute recovery intervals) for 40 minutes, 3 times per week for 3 months.
48315833|NCT05877196|BEHAVIORAL|Combined Aerobic Resistance Exercise (CARE)|6 full-body strength-building exercises followed by 30 minutes of MICT cycling (described above). Total duration is 60 minutes, 3 times per week for 3 months.
48315834|NCT01317667|BIOLOGICAL|RVEc|
48315835|NCT03629392|BEHAVIORAL|Low met/cys diet|Dietary intervention with low contents of methionine and cysteine
48644433|NCT06408298|DRUG|Hydroxychloroquine Sulfate 400Mg Tab|hydroxychloroquine sulfate tablet
48644434|NCT06408298|DRUG|Placebo|Inactive tablet
48644435|NCT01468961|BEHAVIORAL|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
48644436|NCT03945253|DRUG|ASP8374|Intravenous
48644437|NCT06589804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48315836|NCT03629392|BEHAVIORAL|Moderate met/cys diet|Dietary intervention with moderate contents of methionine and cysteine
48315837|NCT03629392|BEHAVIORAL|High met/cys diet|Dietary intervention with high contents of methionine and cysteine
48315838|NCT02860533|DEVICE|cuff device|Measurement of blood pressure during stress testing with cuff device
48315839|NCT02860533|DEVICE|iphone|Measurement of blood pressure during stress testing with iPhone
48315840|NCT06219616|DIAGNOSTIC_TEST|BKV immune monitoring|Blood will be drawn and investigated for BKV-specific T cell response.
48315841|NCT04838925|DEVICE|Mobile Neurofeedback App|Neurofeedback intervention delivered via mobile app. Participants wear an EEG headset which is connected to a mobile app that delivers feedback about brainwave data indicating whether they are in a calm, relaxed state. Participants hear a lower/simple sound when they are below a target level and higher/richer sound when they approach or achieve their target.
48315842|NCT04376606|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
48315843|NCT04376606|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
48485172|NCT03329079|BEHAVIORAL|Mobile Technology|The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
48485173|NCT03919448|BIOLOGICAL|Bevacizumab|Single-dose infusion
48485174|NCT04936776|BEHAVIORAL|Text messaging|Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
48644438|NCT06589804|BIOLOGICAL|Cetuximab|Given IV
48644439|NCT06589804|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48644440|NCT06589804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48644441|NCT06589804|BIOLOGICAL|Pembrolizumab|Given IV
48644442|NCT06589804|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48644443|NCT05287685|BEHAVIORAL|Screen media adapted School Readiness Parenting Program|For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
48315844|NCT04376606|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
47965460|NCT02279563|DRUG|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
48315845|NCT02559154|DRUG|Bortezomib|
48315846|NCT02559154|DRUG|Dexamethasone|
48315847|NCT02559154|DRUG|Doxorubicin|
48315848|NCT02559154|DRUG|Cyclophosphamide|
48315849|NCT02559154|DRUG|Mitoxsnteone|
48315850|NCT02559154|DRUG|Thalidomide|
48315851|NCT03902743|OTHER|Anticipatory Care Plan group|The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
48315852|NCT05607017|DRUG|Losartan|Taken Orally
48315853|NCT05607017|RADIATION|Radiation Therapy|Photon Radiation Therapy
48315854|NCT00703833|DRUG|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
48315855|NCT00703833|DRUG|Placebo (unspecified)|matching placebo
48315856|NCT06373042|DRUG|Intraarterial and intravenous tirofiban|Intraarterial and intravenous tirofiban after endovascular thrombectomy
48315857|NCT06373042|DRUG|Intraarterial and intravenous placebo|Intraarterial and intravenous placebo after endovascular thrombectomy
48315858|NCT01658696|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu heterologous prime-boost immunisation
48315859|NCT01658696|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
48315860|NCT04017442|DRUG|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
48315861|NCT04017442|DRUG|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
48315862|NCT04520763|OTHER|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
48315863|NCT04520763|OTHER|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
48644444|NCT05287685|BEHAVIORAL|School Readiness Parenting Program|The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
48644445|NCT05947890|BIOLOGICAL|MTBVAC|The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
48315864|NCT03280641|DRUG|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
48315865|NCT03280641|DRUG|Warfarin Sodium|Target INR:1.6-3.0
48315866|NCT04702217|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
48315867|NCT05081024|PROCEDURE|Biopsy|Undergo biopsy
48315868|NCT05081024|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or tissue samples
48315869|NCT05081024|OTHER|Electronic Health Record Review|Medical records are reviewed
48315870|NCT06166095|OTHER|high-dose|Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
48315871|NCT06166095|OTHER|Walking attention control|The attention control group will be asked to wear the Fitbit activity tracker to monitor their sleep each night for 10 weeks.
48485175|NCT06226922|OTHER|No intervention|No intervention
48485176|NCT01481740|DRUG|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
48485177|NCT01481740|DRUG|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
48315872|NCT06166095|OTHER|moderate-dose|Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
48315873|NCT05804006|OTHER|Conventional physiotherapy followed by HIIT-REC program|The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
48315874|NCT03153735|DEVICE|CMDHA0101|Maximum injection dose : 22 ml
48315875|NCT03153735|DEVICE|PowerFill®|Maximum injection dose : 22 ml
48315876|NCT04838106|OTHER|Not applicable as observational study|Not applicable as observational study.
48315877|NCT00536042|DRUG|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
48315878|NCT01636752|BEHAVIORAL|Deprexis|Online self-help with and without e-mail-support
48115914|NCT04730713|DEVICE|The morphology and parameters of cranial ultrasound spectrum based on cerebral artery|Subjects who meet the standards will undergo a full-body examination and basic life after entering the ICU Sign evaluation and monitoring, mainly including nervous system specialist physical examination, multi-modal brain function testing, Respiratory system monitoring and management, hemodynamic monitoring, APACHE Ⅱ score, GCS score, and routine general circulation, respiratory management, sedation and analgesia management, temperature management, infiltration Pressure management, lumbar pressure measurement The included subjects were monitored for optic nerve sheath diameter, TCD/TCCD before and after lumbar puncture, and recorded spectrum morphology: normal, high resistance state, ischemic topic, congestion state, spasticity, nail wave/oscillating wave state, S1S2 fusion high point state, and recording at the same time Parameters: systolic flow rate (Vs) Shu Tensile blood flow velocity (Vd), average blood flow velocity (Vm), pulsatility index (PI), impedance Index (RI)
48315879|NCT05574335|DRUG|Siplizumab|Weekly siplizumab doses for a total of 12 weeks
48315880|NCT06483516|PROCEDURE|Open repair|Open repair via median laparotomy or lumbotomy
48315881|NCT06483516|PROCEDURE|Endovascular repair|EVAR if AAA simple F-BEVAR if Complex AAA
48315882|NCT03085706|BIOLOGICAL|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
48315883|NCT04949880|DEVICE|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
47965461|NCT02279563|DRUG|Dymista™ Nasal Spray|
48115915|NCT04947072|PROCEDURE|Erector Spinae Plane Block|The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
48315884|NCT03319615|BEHAVIORAL|Dietary energy restriction|
48315885|NCT00103545|BIOLOGICAL|ACA 125|
48644446|NCT05947890|BIOLOGICAL|BCG|The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
48644447|NCT05931497|DEVICE|whole body hyperthermia|heat will be applied to the participant through a sauna to increase core body temperature
48644448|NCT05899868|DEVICE|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
48644449|NCT01473784|PROCEDURE|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
47965462|NCT02279563|DRUG|Placebo|
48315886|NCT02922634|OTHER|Mini Cog|short cognitive screen, short Frailty screen
48315887|NCT04400539|DEVICE|intrapleural photodynamic therapy with videothoracoscopy|MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
47965463|NCT03560232|DRUG|Ceftriaxone|See arm description
47965464|NCT03560232|DRUG|Ampicillin/sulbactam|See arm description
47965465|NCT03560232|DRUG|Piperacillin/tazobactam|See arm description
48115916|NCT04947072|PROCEDURE|Spinal anesthesia|Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
48644450|NCT01473784|PROCEDURE|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
48644451|NCT03682146|PROCEDURE|Prostatectomy|Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy
47965466|NCT03560232|DRUG|Cefazolin + Gentamicin|See arm description
47965467|NCT03560232|DRUG|Clindamycin + Gentamicin|See arm description
47965468|NCT01405456|DRUG|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
47965469|NCT01405456|OTHER|placebo and lifestyle|placebo pill daily and lifestyle counseling
48315888|NCT04400539|DRUG|Nivolumab Injection|Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
48315889|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
48315890|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
48115917|NCT00880477|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
48315891|NCT03771417|BEHAVIORAL|Exercise Intervention|The use of exercise to improve muscle and cardiometabolic health in older adults.
48315892|NCT03577912|PROCEDURE|TAP block administered by Surgery|TAP block administered by Surgery
48315893|NCT03577912|PROCEDURE|TAP block administered by Anesthesia|TAP block administered by Anesthesia
48315894|NCT03025217|BEHAVIORAL|Total Lifestyle Coaching (TLC)|
48315895|NCT03264482|PROCEDURE|M-TURP|endoscopic resection of the prostatic adenoma
48315896|NCT03264482|PROCEDURE|THUVAP|vaporization of prostatic adenoma via THULIUM laser
48315897|NCT02586753|OTHER|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
48315898|NCT02586753|OTHER|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
48315899|NCT04755712|DRUG|Rachianesthesia|Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
48315900|NCT04755712|DRUG|Sodium Chloride Injection|"Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2)."
48315901|NCT04755712|DRUG|Morphine|Morphine via pump (patient controlled analgesia)
48315902|NCT02754830|DRUG|LY3303560 - IV|Administered IV
48315903|NCT02754830|DRUG|Saline Solution - IV|Administered IV
48315904|NCT02754830|DRUG|LY3303560 - SC|Administered SC
48315905|NCT00459485|DIETARY_SUPPLEMENT|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
48315906|NCT00459485|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 3 weeks
48315907|NCT03114306|PROCEDURE|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
48315908|NCT03114306|PROCEDURE|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
48315909|NCT06146296|BIOLOGICAL|Local Vitamin C injection|An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.
48315910|NCT06146296|BIOLOGICAL|Oral Vitamin C supplement|Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
48315911|NCT01947244|BEHAVIORAL|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
48315912|NCT01947244|BEHAVIORAL|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
48315913|NCT01553916|DRUG|Lithium Carbonate|
48315914|NCT01553916|RADIATION|Prophylactic cranial irradiation|
48315915|NCT04788108|DRUG|Dydrogesterone|Dydrogesterone tablet
48315916|NCT04788108|DRUG|Placebo|Placebo tablet
48315917|NCT03972124|DRUG|CBD 100 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
47965470|NCT04245852|OTHER|Strength education video|The Strength education video must be watched by the patient at the University of Illinois at Chicago Faculty Practice (UICFP) prior to leaving from the 3rd physical therapy visit. The Experimental Group (EG) will watch the video in the waiting room or other quiet available rooms on the 3rd floor within the UICFP. The video will be watched from an iPad/tablet/laptop/desktop computer device as available in the clinic. The EG will also be provided a handout with a link and quick response code to the video on YouTube.com
47965471|NCT04245852|OTHER|standard PT care|standard PT care
47965472|NCT00608686|DIETARY_SUPPLEMENT|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
48115918|NCT00880477|BIOLOGICAL|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
48315918|NCT03972124|DRUG|CBD 200 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
48315919|NCT03972124|DRUG|Placebo|Soft-gel capsules containing placebo
48315920|NCT01628250|PROCEDURE|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
48315921|NCT01628250|PROCEDURE|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
48315922|NCT00147732|RADIATION|Accelerated radiotherapy|68 Gy over 5.5 weeks
48315923|NCT00147732|RADIATION|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
48315924|NCT03880240|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
48315925|NCT03880240|OTHER|Sham Transcranial Alternating Current Stimulation|Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
48315926|NCT06376266|COMBINATION_PRODUCT|nutritional supplements|a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
48315927|NCT02204241|DRUG|Carfilzomib|
48315928|NCT02204241|DRUG|Cyclophosphamide|
48315929|NCT02204241|DRUG|Dexamethasone|
48315930|NCT03780556|DRUG|Lornoxicam and mepridine|compare the effect of each to control pain
48315931|NCT02149056|BEHAVIORAL|observation|
48315932|NCT02149056|OTHER|Impaired Glucose Tolerance|Impaired Glucose Tolerance
48315933|NCT01522040|DRUG|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
48315934|NCT01522040|DRUG|Placebo|Simple saline drip, without active drug
48315935|NCT00288860|BEHAVIORAL|Telephone monitoring|Three months of biweekly telephone monitoring and support
48315936|NCT00288860|OTHER|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
48315937|NCT04169724|BEHAVIORAL|Calm Meditation|10 minutes per day of meditation via the Calm app.
48315938|NCT05443672|DEVICE|Yizhun BUSMS|During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.
48315939|NCT04027569|OTHER|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
48315940|NCT04027569|OTHER|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
48315941|NCT03579953|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).
48485178|NCT01004042|DRUG|Botulinum Toxin Type A|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
48644452|NCT05253651|DRUG|tucatinib|300mg given by mouth (orally) twice daily
48644453|NCT05253651|DRUG|trastuzumab|8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
48644454|NCT05253651|DRUG|bevacizumab|5mg/kg given by IV every 2 weeks
48644455|NCT05253651|DRUG|cetuximab|400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
48315942|NCT03579953|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
48315943|NCT05519046|DEVICE|Cardiac Contractility Modulation (CCM)|Cardiac Contractility Modulation (CCM) implantation
48315944|NCT05519046|DEVICE|CRT|Cardiac Resynchronization Therapy
48315945|NCT02681380|OTHER|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
48315946|NCT02681380|OTHER|Control group|No session will be planned for the participants.
48315947|NCT01911234|BIOLOGICAL|TNF-Kinoid|IM administration
48315948|NCT01911234|OTHER|Placebo|IM administration
48315949|NCT02696915|DRUG|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
48315950|NCT02696915|DRUG|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
48315951|NCT02696915|DEVICE|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
48315952|NCT02696915|DRUG|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
48315953|NCT00683475|BIOLOGICAL|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
48315954|NCT00683475|DRUG|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.
48485179|NCT01284855|DRUG|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
48644456|NCT05253651|DRUG|oxaliplatin|85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
48644457|NCT05253651|DRUG|leucovorin|400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
48644458|NCT05253651|DRUG|levoleucovorin|200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
48644459|NCT05253651|DRUG|fluorouracil|400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
47965473|NCT06060743|OTHER|INS-MOBILE: Mobile Application Developed for Insulin Use|After determining the application and control groups in the research, the purpose of the research was explained to both groups. Participants were informed that the application would last 1 month. It was explained that data collection forms would be filled out before the application (Z0), on the 14th day of the application (Z1), and on the 28th day of the application (Z2). On the 0th and 28th days of the follow-up, the participants' insulin administration skills were evaluated face-to-face by the researcher using the Insulin Therapy Skill Observation Form. In addition to the standard training given by diabetes training nurses, a mobile application on insulin use was sent to the application group, while the control group was given standard training only by diabetes training nurses.
48315955|NCT00683475|DRUG|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
48315956|NCT00683475|BIOLOGICAL|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
48315957|NCT00395408|DRUG|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
48315958|NCT00395408|DRUG|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
48315959|NCT01262755|BEHAVIORAL|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
48315960|NCT05583981|OTHER|Interview|Participate in interview
48315961|NCT00093678|DRUG|celecoxib|
48315962|NCT00093678|PROCEDURE|anticachectic therapy|
48644460|NCT05384223|BEHAVIORAL|RRFT (Risk Reduction through Family Therapy)|RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
48644461|NCT05384223|BEHAVIORAL|ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)|Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
48644462|NCT05139732|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
48644463|NCT06481813|OTHER|Blood Sampling (2*8mL Tubes)|Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)
48644464|NCT06481813|OTHER|PBMC Sampling (1*8mL Tubes)|Patients will be sampled from 1 x 8 mL PBMC
48644465|NCT06481813|OTHER|Paxgene Sampling|Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube
48115919|NCT00880477|BIOLOGICAL|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
48115920|NCT01582646|DRUG|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
48115921|NCT01296334|DRUG|morphine LO|intravenous infusion, 10 mg, once, 4 hours
48115922|NCT01296334|DRUG|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
48115923|NCT01296334|DRUG|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
48315963|NCT00093678|PROCEDURE|nutritional support|
48315964|NCT00093678|PROCEDURE|pain therapy|
48315965|NCT00093678|PROCEDURE|supportive care/therapy|
48315966|NCT03180489|DRUG|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
48315967|NCT03180489|DRUG|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
48315968|NCT00679679|DRUG|Metformin|Metformin 750 mg BID for 4 months
48315969|NCT00679679|DRUG|Placebo|Diet counseling and exercise
48315970|NCT00535015|DRUG|Betamarc|2 tabs BID
48315971|NCT04086069|DEVICE|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
48315972|NCT05345886|BEHAVIORAL|Hippotherapy|Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
48315973|NCT04574609|DEVICE|Oncomfort® clinical virtual reality|"hypnotherapy arm, patients will receive in addition to the care provided by the usual :~* for PAC insertion: a 45-minute hypnotherapy session 2 hours before the procedure in a room of the outpatient surgery unit (UCA).~* during the entire duration of chemotherapy (and/or immunotherapy for HER2+ patients) : one hypnotherapy session before the first treatment and then every 3 weeks. One hypnotherapy session before the first treatment and then every 3 weeks. Thus, sessions will take place before each treatment for 3-week inter-course regimens and every 3 treatments for chemotherapy administered on a weekly. Each session will last 20 minutes."
48315974|NCT00001019|BIOLOGICAL|rgp120/HIV-1 SF-2|
48315975|NCT00001019|BIOLOGICAL|MTP-PE/MF59|
48315976|NCT00621855|DRUG|placebo|matched placebo
48315977|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
48315978|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
48315979|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
48315980|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
48315981|NCT06054022|DEVICE|high flow nasal cannula|high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
48315982|NCT06054022|DEVICE|nasoprong oxyen 2Litres per minute|nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
48315983|NCT03445858|DRUG|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
48315984|NCT03445858|DRUG|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
48315985|NCT03445858|RADIATION|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
48315986|NCT05142540|PROCEDURE|blood and saliva samples will be taken|"For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2."
48315987|NCT03224975|OTHER|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
48315988|NCT03374748|OTHER|N/A - observational study|N/A - observational study
48315989|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
48315990|NCT01666678|DRUG|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
48315991|NCT01666678|DRUG|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
48315992|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
47965474|NCT00807729|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
48115924|NCT01296334|DRUG|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
48315993|NCT05656404|DEVICE|TorEx Lung Perfusion System|When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).
48315994|NCT00808782|DEVICE|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
48315995|NCT00808782|DEVICE|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
48115925|NCT01296334|OTHER|saline|intravenous infusion, 0.9% saline, once, 4 hours
48115926|NCT00010309|BIOLOGICAL|MART-1 antigen|
48115927|NCT00010309|BIOLOGICAL|gp100 antigen|
48315996|NCT04431154|BEHAVIORAL|Provision of HIV self-screen kit with incentives and linkage promotion|This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
48315997|NCT02964286|DEVICE|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
48315998|NCT01107275|BIOLOGICAL|rabies vaccine|intradermal vaccination
48315999|NCT00375817|PROCEDURE|Myoblasts injection with MyoCath catheter|
48644466|NCT06481813|PROCEDURE|Extended biopsies of tumor lesions|"Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology.~The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³.~For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³.~In the case of a complex biopsy, no additional sampling related to the research will be performed."
48644467|NCT05967455|BIOLOGICAL|Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
48644468|NCT05967455|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
47965475|NCT00807729|PROCEDURE|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
47965476|NCT05076292|DRUG|GlucaGen|150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
47965477|NCT05076292|DRUG|Saline|Saline will be used as placebo before and after exercise.
47965478|NCT03109249|DRUG|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
47965479|NCT03109249|DRUG|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
47965480|NCT06066164|DEVICE|Transcranial magnetic stimulation (TMS)|Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability
47965481|NCT03128567|DEVICE|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
48115928|NCT00507689|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
48316000|NCT03531333|PROCEDURE|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
48644469|NCT05999721|PROCEDURE|superficial parasternal intercostal plane block|Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1
48644470|NCT05999721|OTHER|Standard care|"Operating Room:~Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion.~Cardiothoracic Intensive Care Unit:~Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered.~Cardiothoracic ward:~The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered."
48644471|NCT02766478|DRUG|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
48644472|NCT02766478|DRUG|Placebo|A placebo pill will be taken orally for 12 weeks.
48644473|NCT04885530|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
48644474|NCT04885530|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
48644475|NCT04885530|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
48644476|NCT04885530|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
48644477|NCT04885530|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
48644478|NCT04885530|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
48644479|NCT02980185|PROCEDURE|Laparoscopic primary cytoreduction|Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
48644480|NCT03917836|DIAGNOSTIC_TEST|endoscopy and histology|diagnostic evaluation of chronic gastritis
48644481|NCT05712889|DRUG|VIP236 (Q3W)|VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.
47965482|NCT01929005|OTHER|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
48485180|NCT02987803|OTHER|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
48485181|NCT02038231|BEHAVIORAL|Parenting Mindfully Program|see Arm Description.
48485182|NCT02038231|OTHER|Parent Education Program|See Arm Description.
48485183|NCT02459145|BEHAVIORAL|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
48485184|NCT00965055|DRUG|Ezetimibe|10 mg
48644482|NCT05712889|DRUG|VIP236 (Q2W)|VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.
48644483|NCT02861573|BIOLOGICAL|Pembrolizumab 200 mg|IV Q3W
48644484|NCT02861573|DRUG|Olaparib 400 mg|Eight 50-mg capsules PO BID
48644485|NCT02861573|DRUG|Docetaxel 75 mg/m^2|IV Q3W
48644486|NCT02861573|DRUG|Prednisone 5 mg|One 5-mg tablet PO BID
48115929|NCT00507689|DRUG|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
48497972|NCT05390918|BEHAVIORAL|TAILOR|"The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the elicit-provide-elicit approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation."
48644487|NCT02861573|DRUG|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
48644488|NCT02861573|OTHER|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
48644489|NCT02861573|DRUG|Olaparib 300 mg|Two 150-mg tablets PO BID
48644490|NCT02861573|DRUG|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
48644491|NCT02861573|DRUG|Lenvatinib|20 mg PO QD
48644492|NCT02861573|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|IV Q3W
48644493|NCT02861573|DRUG|Carboplatin|IV Q3W
48644494|NCT02861573|DRUG|Etoposide|IV on Days 1, 2 and 3 of each cycle
48644495|NCT02861573|BIOLOGICAL|Belzutifan 120mg|PO QD
48644496|NCT06013969|DRUG|Spesolimab|Spesolimab intravenous (i.v.) infusion
48644497|NCT06117813|DEVICE|Nu.T|Participants receive visual perceptual training using the Nu.T software.
48644498|NCT06117813|OTHER|No-Treatment Control|No-treatment was administered during control period.
48644499|NCT05671861|DEVICE|Trismus Device Prototype|Device is noninvasive and will be inserted between patient's upper and lower teeth
47965483|NCT01350492|BEHAVIORAL|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
47965484|NCT03725852|DRUG|GLPG1205|GLPG1205 will be provided as an oral hard gelatin capsule.
47965485|NCT03725852|DRUG|Placebo|GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
47965486|NCT05943015|PROCEDURE|Quadratus Lumborum Block II|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the psoas major and the transverse process adjacent to the quadratus lumborum muscle, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle negative aspiration into the middle layer of the thoracolumbar fascia posterior to the quadratus lumborum muscle, then 0.5-1 ml of saline 20 ml of 0.25% bupivacaine will be injected after hydrodissection is observed. The same will be done to the other side.
47965487|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
48644500|NCT05671861|OTHER|Questionnaires|Surveys will be administered to participants
48644501|NCT05671861|OTHER|Mobile Application|A study-specific, accompanying secure mobile application for users to track progress will be created.
48644502|NCT06169527|DRUG|Dupilumab|Dupilumab cohort
47965488|NCT05943015|PROCEDURE|Quadratus Lumborum Block III|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
47965489|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
48644503|NCT06573242|OTHER|Home-based cardiac rehabilitation for people living with Heart Failure and their caregivers|Intervention DK:REACH-HF is a home-based 12-week CR program for people living with HF and their caregivers.
48644504|NCT06650098|OTHER|artificial intelligence-supported mobile application|It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
48644505|NCT06650098|OTHER|WEB based application|The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.
48644506|NCT04255043|DEVICE|IVUS guidance|IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
48644507|NCT04255043|DEVICE|Angiography guidance|DCB (Sequent® Please) treatment
48644508|NCT05761496|DEVICE|Biliary stents insertion|Endoscopic placement of plastic and metal biliary stents
48644509|NCT03708809|DEVICE|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
48644510|NCT03708809|OTHER|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
48644511|NCT05890755|OTHER|Mechanical pertubation|Acceleration or deacceleration of one treadmill gait belt.
48316001|NCT02194101|PROCEDURE|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
48316002|NCT00738543|OTHER|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
48316003|NCT01422278|OTHER|Rehabilitation|Three weeks of rehabilitation in Hospital.
48316004|NCT05864183|DIAGNOSTIC_TEST|HbA1c|HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .
48644512|NCT05886894|DEVICE|Lotrafilcon B multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
48644513|NCT05886894|DEVICE|Comfilcon A multifocal soft contact lenses|Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
48644514|NCT03053141|DEVICE|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
48644515|NCT06310824|DRUG|MAB-22|60mg dose of a single subcutaneous injection
48644516|NCT06310824|DRUG|EU-Prolia®|60mg dose of a single subcutaneous injection
47965490|NCT05943015|PROCEDURE|Paravertebral Block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. The linear ultrasound probe is placed longitudinally at the T6 level, 2-2.5 cm lateral to the spinous processes. Transverse process, superior costotransverse ligament and pleura are visualized, 22 gauge 80 mm peripheral block needle is passed with in-plane technique, superior costotransverse ligament is passed, negative aspiration into the paravertebral space under the ligament, followed by 0.5-1 ml of saline and hydrodissection of the pleura, followed by 20 ml of 0.25% bupivacaine is injected.The same is done to the opposite side.
47965491|NCT05943015|DRUG|Patient controlled intravenous analgesia|Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
47965492|NCT03481907|DEVICE|Nuvagen Collagen Powder|Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
47965493|NCT00115102|DRUG|fentanyl|
48316005|NCT05864183|DIAGNOSTIC_TEST|lipid profile|lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .
48316006|NCT05864183|DIAGNOSTIC_TEST|CBC|CBC will be measured for all patients to minimize the risk of developing diabetes or its complications
48316007|NCT05864183|DIAGNOSTIC_TEST|Alb/cr ratio|Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications
48644517|NCT06310824|DRUG|US-Prolia®|60mg dose of a single subcutaneous injection
48316008|NCT05864183|DIAGNOSTIC_TEST|serum creatinine .|serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications
48644518|NCT06054178|DRUG|Fluorescein Sodium|Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
48316009|NCT05864183|DIAGNOSTIC_TEST|CRP|CRP will be measured for all patients to minimize the risk of developing diabetes or its complications
48316010|NCT05864183|DIAGNOSTIC_TEST|urine analysis|urine analysis will be measured for all patients to minimize the risk of developing diabetes or its complications
48497973|NCT05390918|OTHER|Enhanced Usual Care|The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
48497974|NCT03692390|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
48497975|NCT04532801|DRUG|Kisspeptin-10|kisspeptin-10 IV infusion
48497976|NCT04532801|OTHER|mixed meal tolerance test|mixed meal tolerance test
48644519|NCT05224726|OTHER|Platelet Rich Plasma|Applying 5cc of PRP preparation on uterine incision after it has been sutured.
48644520|NCT04012710|PROCEDURE|Laparoscopy|Conventional abdominal laparoscopy
48644521|NCT04012710|PROCEDURE|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
48644522|NCT05586685|OTHER|effect of diaphragmatic release on upper crossed syndrome|"The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position"
48644523|NCT06035510|DIETARY_SUPPLEMENT|whey protein supplement|Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
48644524|NCT06143839|DRUG|Vyxeos liposomal|Standard of care JZP351 administered intravenously over 90 minutes.
47965494|NCT00115102|DRUG|S-ketamine|
48115930|NCT03522337|OTHER|Visual pedagogy (social stories)|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
48316011|NCT05864183|DIAGNOSTIC_TEST|ECG|ECG will be done for all patients to minimize the risk of developing diabetes or its complications
48644525|NCT06037083|DEVICE|Oxygen saturation probe|The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
48644526|NCT06037083|DEVICE|Near infrared spectroscopy sensors|The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
48644527|NCT06037083|DEVICE|Electrical impedance tomography|"The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~* From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~* Between 24 and 48 hours post extubation (total 3 hours)~* Between 72 and 96 hours post extubation (total 3 hours)"
48644528|NCT04199689|BIOLOGICAL|9vHPV Vaccine|9-valent human papillomavirus vaccine (9vHPV) is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
48644529|NCT04199689|OTHER|Placebo (Saline for Injection)|0.9% sodium chloride given as a 0.5-mL intramuscular injection
48316012|NCT05864183|DIAGNOSTIC_TEST|fundus examination|fundus examination will be done for all patients to minimize the risk of developing diabetes or its complications
48644530|NCT06398574|OTHER|Real dry needling|With the subject lying supine, a dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made
48644531|NCT06398574|OTHER|Sham dry needling|With the subject lying supine, a sham dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made, simulating the real technique
48316013|NCT05608317|DEVICE|ALLEVYN Non-Adhesive|"ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~* Breathable top film~* Highly absorbent foam core~* Non-adhesive wound contact layer"
48316014|NCT02141646|BEHAVIORAL|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
48644532|NCT04341012|DIAGNOSTIC_TEST|Collection of breath sample|Analysis of volatile organic compounds in breath
48644533|NCT05370209|DEVICE|Otinova® Ear Spray|Ear spray
48644534|NCT06690320|BEHAVIORAL|IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER|Description: By examining the parameters of the health belief model and fatalism scales, 6 targets were determined for these scale parameters. The targets were prepared to gain early diagnosis behaviors in breast cancer. By using the breast model, the behavior will be demonstrated in practice
48644535|NCT06690840|DRUG|Atezolizumab in combination with Cyclophosphamide and Vinorelbine|Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
48644536|NCT03260322|DRUG|ASP8374|intravenous
48644537|NCT03260322|DRUG|Pembrolizumab|intravenous
47965495|NCT04848298|BEHAVIORAL|mHealth Intervention|"The Mobile Health Arm will receive standard of care including tailored prescription of physical activity as well as the mobile health intervention, which will have the following features:~* Goal setting for frequency and duration of exercise sessions~* Graphic feedback and reinforcement with educational and motivational messages tailored to user's exercise adherence.~* Problem-solving support~* Library with educational tips and information regarding physical exercise."
48644538|NCT06256159|OTHER|12 MSWS questionnaire|The subject has to perform different gait assessments and fill out the 12-item multiple sclerosis walking scale questionnaire in one visit. Maximum 8 weekes after the first visit the subject has to fill out the same questionnaire again.
48644539|NCT06687265|DRUG|Metformin|one pill of 500 mg per os twice a day for 28 days.
48644540|NCT06687265|DRUG|Placebo|one pill per os twice a day for 28 days.
47965496|NCT05253729|DEVICE|Focused ESWT|F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
48115931|NCT03522337|OTHER|Conventional leaflets|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
48115932|NCT01976936|DRUG|Low Dose Lovastatin|80 mg daily for 3 days
48644541|NCT01575548|PROCEDURE|Computed Tomography|Undergo CT
48644542|NCT01575548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47965497|NCT05253729|BEHAVIORAL|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
48115933|NCT01976936|OTHER|Placebo|Placebo for 3 days
48115934|NCT01976936|DRUG|High Dose Lovastatin|640 mg daily for 3 days
48115935|NCT05849311|DRUG|Envafolimab with new manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
48115936|NCT05849311|DRUG|Envafolimab with old manufacturing process|"Dosage form:~Envafolimab is a monoclonal antibody drug administered subcutaneously in a minimum packaging unit of 1.0 ml solution in a single-use glass vial containing a total of 200 mg of Envafolimab.~Treatment method:~Envafolimab, single dose, 1 mg/kg, subcutaneously."
48316015|NCT02141646|BEHAVIORAL|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
48316016|NCT01554839|BEHAVIORAL|"Family of Heroes"|One hour online educational tool
48316017|NCT01554839|BEHAVIORAL|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
47965498|NCT05899036|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.
48115937|NCT00869323|BIOLOGICAL|rituximab|375 mg/m\^2 intravenously on Days 1,8, 15 and 22
48485185|NCT00965055|DRUG|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period"
48485186|NCT00288717|DRUG|Candesartan|
48485187|NCT00288717|DRUG|Telmisartan|
48485188|NCT02389101|OTHER|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
48485189|NCT05560789|BEHAVIORAL|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
48485190|NCT03923699|DEVICE|Anesthesia Control Tower monitoring|Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
48485191|NCT00257920|DRUG|Zemplar® injection|6 mcg QOD
48485192|NCT00257920|DRUG|Hectorol® injection|3.6 mcg QOD
47965499|NCT04177667|DIETARY_SUPPLEMENT|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
47965500|NCT04177667|OTHER|Placebo|Treatment with placebo for Placebo Arm
47965501|NCT03746652|DRUG|Daratumumab, Ixazomib, Dexamethasone|Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
47965502|NCT00843024|DRUG|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
47965503|NCT00843024|DRUG|Placebo|Placebo to match
47965504|NCT06024590|DEVICE|Irrisept|Standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.
47965505|NCT06024590|DEVICE|Saline|Standard of care wound treatment with 150 mL ration of Normal saline irrigation of the wound at each follow up visit
47965506|NCT05654220|BEHAVIORAL|Text Messaging Intervention|A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
47965507|NCT02458040|DRUG|Drug selected in the study|
47965508|NCT04360629|DRUG|Tranexamic Acid|Tranexamic Acid will be given through central vein
48115938|NCT00869323|DRUG|bortezomib|1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22
48316018|NCT05385042|DIETARY_SUPPLEMENT|Sangobion and Thiamine Hydrochloride|"Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery."
48316019|NCT05385042|DIETARY_SUPPLEMENT|Sangobion, Thiamine hydrochloride and Vitamin B12|"Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (\<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements."
48316020|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant IB160|H7N9 monovalent (fragmented and inactivated)
48316021|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant SE|H7N9 monovalent (fragmented and inactivated)
47965509|NCT04360629|DRUG|normal saline|normal saline will be given through central vein
47965510|NCT04826575|OTHER|High intensity inspiratory and expiratory muscle training|"Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).~Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.~Patients will train 2 times a day, 7 days per week, for 2 weeks."
47965511|NCT06515743|OTHER|Delayed surgical obturator|Prosthetic rehabilitation after surgical treatment of mucormycosis is essential for the early restoration of oral function and facial esthetics which is performed by using the surgical obturator.
47965512|NCT00804544|DEVICE|SPECT/CT|SPECT/Low-Dose MultiSclice CT
48316022|NCT03330899|BIOLOGICAL|H7N9 antigen without adjuvant|H7N9 monovalent (fragmented and inactivated)
48316023|NCT03330899|BIOLOGICAL|Placebo (PBS)|Placebo (Phosphate Buffered Saline -PBS)
48316024|NCT06295016|OTHER|High-intensity intensive training|"Participants will conduct a 3-weeks of 130% progressive high-intensity intensive training (increasing by 10% each week).~Week 1: Increase training to 110% of participants' regular training volume. Week 2: Increase training to 120% of participants' regular training volume. Week 3: Increase training to 130% of participants' regular training volume."
48115941|NCT04338893|PROCEDURE|Device: Persona Total Knee|The choice of intervention is defined by surgeons standard use of device 'Persona' in their standard of care practice
48115942|NCT04338893|PROCEDURE|Device: NexGen Total Knee|The choice of intervention is defined by surgeons standard use of device 'Nexgen' in their standard of care practice
48115943|NCT04338893|PROCEDURE|Device: Vanguard Total Knee|The choice of intervention is defined by surgeons standard use of device 'Vanguard' in their standard of care practice
48115944|NCT02971085|PROCEDURE|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
48115945|NCT02509585|DRUG|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
48115946|NCT03221478|OTHER|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
48115947|NCT03221478|OTHER|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
48115948|NCT03221478|OTHER|Kinesio Taping with tension|Kinesio Taping with tension
48316025|NCT06295016|OTHER|Taper|"Participants will conduct a 1-week taper phase by gradually reducing to 55% of their regular training volume.~Day 1: Decrease current training volume by 20%. Day 2: Decrease current training volume by 15%. Day 3: Decrease current training volume by 10%. Day 4: Decrease current training volume by 10%. Day 5: Decrease current training volume by 10%. Day 6: Decrease current training volume by 5%. Day 7: Decrease current training volume by 5%."
48316026|NCT01498081|DRUG|AZD2115|AZD2115 administered via inhalation
48316027|NCT01498081|DRUG|Placebo|Placebo administered via inhalation
48316028|NCT01498081|DRUG|Indacaterol|Indacaterol administered via inhalation
48316029|NCT01498081|DRUG|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
48316030|NCT04167306|DRUG|Varenicline Tartrate 1 mg b.i.d|Capsules for oral use
48316031|NCT04167306|DRUG|Bupropion Hydrochloride 150 mg b.i.d|Capsules for oral use
48316032|NCT04167306|OTHER|Placebo for varenicline|Capsules for oral use
47965513|NCT03692247|OTHER|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
48316033|NCT04167306|OTHER|Placebo for bupropion|Capsules for oral use
48316034|NCT03021434|OTHER|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
48316035|NCT03021434|OTHER|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
48316036|NCT03021434|OTHER|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
48316037|NCT02776410|BEHAVIORAL|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
47965514|NCT00462618|DRUG|Quetiapine|
48316038|NCT03389061|DRUG|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
48316039|NCT03389061|DRUG|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
48316040|NCT00005612|BIOLOGICAL|filgrastim|
48316041|NCT00005612|DRUG|carboplatin|
48316042|NCT00005612|DRUG|cyclophosphamide|
48316043|NCT00005612|DRUG|etoposide|
48316044|NCT00005612|DRUG|paclitaxel|
48485193|NCT03840252|DIAGNOSTIC_TEST|3D gait analysis|Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics
48644543|NCT01575548|DRUG|Pazopanib Hydrochloride|Given PO
48644544|NCT01575548|OTHER|Placebo Administration|Given PO
48644545|NCT01575548|OTHER|Questionnaire Administration|Ancillary studies
47965515|NCT00462618|BEHAVIORAL|Cogntive behavioral therapy|
47965516|NCT01523171|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
48115949|NCT05610280|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
48115950|NCT05610280|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
48115951|NCT00523107|DRUG|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
48115952|NCT00523107|DRUG|Placebo|500 ml normal saline t.i.w. per week
48115953|NCT06552663|DEVICE|CCTA|Coronary CT angiography
48115954|NCT03100227|OTHER|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
48115955|NCT03100227|OTHER|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
48115956|NCT04627493|BEHAVIORAL|Online exercise|Participants will participate in an online exercise program on Zoom delivered by Registered Kinesiologists and Physiotherapists three times a week.
48115957|NCT02174393|DRUG|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
48316045|NCT00005612|DRUG|topotecan hydrochloride|
48316046|NCT00005612|PROCEDURE|peripheral blood stem cell transplantation|
47965517|NCT05459272|DIETARY_SUPPLEMENT|Aquilea Sueno Forte|"The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
47965518|NCT05459272|OTHER|Placebo|"The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
47965519|NCT02154178|OTHER|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
47965520|NCT01475357|OTHER|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
47965521|NCT01475357|OTHER|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
48115958|NCT02174393|PROCEDURE|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
48115959|NCT02174393|DRUG|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):~* Gentle Antioxidant Soothing Cleanser daily~* Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~* AM: Physical sheer sunscreen and recovery ointment~* PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~* AM: BD Hydrating Day/Night Cream~* PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
48316047|NCT01136421|DRUG|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
48316048|NCT01136421|DRUG|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
48485194|NCT03840252|DIAGNOSTIC_TEST|rsfMRI|MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).
48485195|NCT03840252|DIAGNOSTIC_TEST|Montreal Cognitive assesment (MoCA)|Standard clinical questionnaire
48485196|NCT03532633|PROCEDURE|cord blood|collection of cord blood
48644546|NCT06041802|BIOLOGICAL|MK-3475A|MK-3475A is a fixed-dose formulation of pembrolizumab and MK-5180 for SC administration.
48644547|NCT00001595|PROCEDURE|MRI|
48115960|NCT02174393|DRUG|Post-Universal Peel Skin Care|"* Gentle Antioxidant Soothing Cleanser daily~* Physical Sunscreen daily~* Soothing recovery ointment fortified with silver only when peeling occurs~* After completely peeling, vitamin c product in the morning and the retinol in the evening"
48485197|NCT03532633|PROCEDURE|blood sample infant|collection of remnant of clinically indicated blood sample
48644548|NCT00001595|PROCEDURE|Tissue specimen collection|
48644549|NCT06687616|BEHAVIORAL|SynerGI|Standardized 8-week CBT program, used for 5-20 minutes daily
47965522|NCT02885103|DEVICE|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
47965523|NCT02885103|DEVICE|Nebulizer|Inhalation will be done will Nebulizer and via mouth
47965524|NCT01212523|DRUG|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
47965525|NCT02033109|DRUG|PC-1005|Intravaginal use
48485198|NCT03532633|PROCEDURE|blood sample mother|collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
48485199|NCT03532633|PROCEDURE|breast milk|collection of breast milk 1/week during neonatal care (maximum 8 weaks)
47965526|NCT02033109|DRUG|HEC gel|
48485200|NCT00821002|DRUG|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
48485201|NCT06525272|DRUG|Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.
48644550|NCT06687616|BEHAVIORAL|Sham VR|Distraction-based VR program with 2D nature videos to be used for 8 weeks, 5-20 minutes daily
48644551|NCT05026736|OTHER|Quality-of-Life Assessment|Ancillary studies
48644552|NCT05026736|BIOLOGICAL|Sintilimab|Given IV
48644553|NCT06688292|DRUG|Taneasy 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
48644554|NCT06688292|DRUG|Actein effervescent 600mg|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis.
48644555|NCT06055569|OTHER|Rehabilitation protocol: AOT+NMES|Action observation and neuromuscular electrical stimulation followed by motor execution
48644556|NCT06055569|OTHER|Rehabilitation protocol: Action Observation Therapy (AOT)|Action observation followed by motor execution
48644557|NCT06055569|OTHER|Observation of motor-neutral stimuli (MNO)|Motor-neutral observation followed by motor execution
48644558|NCT05021562|DRUG|Niraparib|Niraparib capsules
48644559|NCT06619860|DRUG|VX-993|Tablets for oral administration.
48644560|NCT06619860|DRUG|Pregabalin|Capsules for oral administration.
48316049|NCT00625521|DRUG|ASF 1096 0.5 % cream applied twice daily|
48316050|NCT00625521|DRUG|Cream vehicle for ASF 1096 cream applied twice daily|
48316051|NCT02042495|DRUG|Metformin|
48316052|NCT04173442|DRUG|dupilumab|Dupilumab cohort
48644561|NCT06619860|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
48115961|NCT05583539|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography is a viscoelastic test that measures the dynamics of blood clotting on whole blood samples.
48115962|NCT03565939|BIOLOGICAL|Trichuris suis ova|Eggs from the pig whipworm
48316053|NCT03237988|DRUG|CPI-444 Capsules|100mg Capsule
48316054|NCT03237988|DRUG|CPI-444 Tablets|100mg Tablets
48316055|NCT01902953|DRUG|Lymphoseek and VBD Sln dissection|See detailed description of study design
48316056|NCT05806047|DRUG|chidamide combined with fulvestrant|chidamide combined with fulvestrant
48316057|NCT06330597|DIAGNOSTIC_TEST|Echocardiography and lung ultrasound|All patients will undergo non-invasive echocardiogram and lung ultrasound at times of assessment of hemodynamic parameters as needed by usual clinical management.
47965527|NCT00842608|BEHAVIORAL|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol"
47965528|NCT00842608|PROCEDURE|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
47965529|NCT00842608|DRUG|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
47965530|NCT00842608|PROCEDURE|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
47965531|NCT02250781|DRUG|Oral ONC201|Given PO
47965532|NCT01265368|BIOLOGICAL|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
47965533|NCT02325037|DRUG|GLPG1837 single ascending doses|Single dose, oral suspension
47965534|NCT02325037|DRUG|Placebo single dose|Single dose, oral suspension matching placebo
47965535|NCT02325037|DRUG|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
48115963|NCT03565939|BIOLOGICAL|Placebo|Solution without TSO
48115964|NCT06131359|DIAGNOSTIC_TEST|Fine wire EMG and Force Frame muscle strength testing|Insertion of fine wires for EMG study of tibialis posterior and assessment of muscle strength using a force frame
48115965|NCT05125029|DRUG|Botulinum toxin|Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
48115966|NCT01489982|DEVICE|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
48115967|NCT01489982|BEHAVIORAL|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
48316058|NCT03574935|DRUG|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
48316059|NCT03574935|DRUG|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
48485202|NCT06525272|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.
48644562|NCT06619860|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
47965536|NCT02325037|DRUG|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
48115968|NCT01489982|DRUG|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
48115969|NCT01489982|DEVICE|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
48115970|NCT04567043|BEHAVIORAL|MORE+JITAI|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.
48115971|NCT04567043|BEHAVIORAL|Supporive Psychotherapy|A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
48485203|NCT02728011|OTHER|Scientific Brain Training (SBT)|Cognitive training
48644563|NCT06634004|OTHER|BOLD MRI|The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.
48115972|NCT02565069|DEVICE|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
48316060|NCT02730338|BEHAVIORAL|High intensity aerobic and resistance training|
48316061|NCT02730338|BEHAVIORAL|Psychosocial support|
48485204|NCT02728011|OTHER|Tetris|
48485205|NCT03399240|DEVICE|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
48644564|NCT06688461|OTHER|Experimental group: Exercise training|HIIT program, 3 times per week for 12 weeks
48115973|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
48115974|NCT00311363|DRUG|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
48115975|NCT00311363|DRUG|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
48115976|NCT05658341|BEHAVIORAL|ADA|"The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase."
48115977|NCT05658341|BEHAVIORAL|Usual Care|"Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization."
48316062|NCT01984034|BEHAVIORAL|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
48316063|NCT01984034|OTHER|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
48316064|NCT01893658|DRUG|Omalizumab|administration of a single dose together with the standard treatment
48644565|NCT06476392|DRUG|Melatonin 10 MG|2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
48316065|NCT01893658|DRUG|Prednisone|standard treatment
47965537|NCT00477256|BEHAVIORAL|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
48115978|NCT03207672|DRUG|E7389-LF|intravenous infusion
48316066|NCT03128216|PROCEDURE|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
48316067|NCT03128216|PROCEDURE|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
48316068|NCT03128216|PROCEDURE|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
48644566|NCT06476392|DRUG|Placebo|2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
48644567|NCT06113562|PROCEDURE|PFO closure|The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
48644568|NCT06688149|DIAGNOSTIC_TEST|Derivation algorithms|Derivation algorithm based on non-invasive methods, to standardise the continuum of care for diabetic patients with NAFLD from primary care and endocrinology settings to NAFLD specialised units (NSU)
48644569|NCT06592794|BIOLOGICAL|mRNA-1403|Intramuscular (IM) injection.
48644570|NCT06592794|BIOLOGICAL|Placebo|0.9% sodium chloride solution by IM injection.
48644571|NCT06290687|DRUG|Neoadjuvant Chemotherapy|"Standard of care neoadjuvant systemic therapy is currently cisplatin-based chemotherapy in cisplatin-eligible participants. Participants will start treatment within 60 days of Transurethral Resection of Bladder Tumor. Regimens may include:~* Cisplatin - Gemcitabine (Gem/Cis)~* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)"
48644572|NCT06290687|PROCEDURE|Partial cystectomy with Extended pelvic lymph node dissection|Partial cystectomy will then be performed using the surgical technique at the discretion of the treating Urologic Oncologist. Extended pelvic lymphadenectomy will then be performed at the discretion of the treating Urologic Oncologist. Surgery will be performed within 60 days of Transurethral Resection of Bladder Tumor for Cisplatin-ineligible participants. Surgery will be performed within 60 days of completing neoadjuvant chemotherapy for Cisplatin-eligible participants.
48644573|NCT06290687|DRUG|Adjuvant systemic therapy|Standard of care adjuvant systemic therapy in eligible participants. The choice of adjuvant systemic therapy will be left to the discretion of the treating Medical Oncologist but must fall within the SOC as outlined in NCCN guidelines.
47965538|NCT03978832|DRUG|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
47965539|NCT03978832|DRUG|Risperidone|Oral risperidone
47965540|NCT00966329|DRUG|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
47965541|NCT00966329|DRUG|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz)."
48316069|NCT03128216|DRUG|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
48115979|NCT00833365|DRUG|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
47965542|NCT04786990|DRUG|SPN-812|Viloxazine extended-release capsule
48115980|NCT00833365|DRUG|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
48485206|NCT04013113|DRUG|Haemoperfusion|"Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required."
48485207|NCT04013113|DRUG|Standard Medical Treatment|Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
48644574|NCT02145520|DRUG|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
47965543|NCT04960514|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
47965544|NCT01227434|DRUG|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
47965545|NCT01227434|DRUG|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
47965546|NCT01227434|PROCEDURE|Resection as clinical care|Indicated, intended, surgical resection as clinical care
47965547|NCT04579575|DEVICE|Trans-abdominal Ultrasound|"All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position.~The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions.~* The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system.~* The definite diagnoses of AM were preferentially established based on~Histo-pathological findings and other modalities."
47965548|NCT06505044|PROCEDURE|aerobic exercise|"aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase. There was 30 minutes of conditioning exercise including increasing the treadmill speed till reaching (60-75%) of the maximum heart rate.~* Frequency: 3 times/week for 12 weeks in addition to their usual daily calcium intake."
47965549|NCT06505044|PROCEDURE|resistance exercise|resisted exercise program for 12 weeks
47965550|NCT03258268|DEVICE|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
47965551|NCT03258268|OTHER|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
47965552|NCT00003931|GENETIC|reverse transcriptase-polymerase chain reaction|
47965553|NCT02900339|DEVICE|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
48316070|NCT03128216|DRUG|Bupivacaine|Local anesthetic used for Spinal Anesthesia
48316071|NCT01866878|DEVICE|equipment rehabilitation stereognosis|
48316072|NCT01866878|DEVICE|TENS|
48316073|NCT02969447|DRUG|Administration of 10 units of intra venous oxytocin after fetal expulsion|
48316074|NCT00661401|BIOLOGICAL|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
48316075|NCT02034474|DRUG|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
48316076|NCT02034474|DRUG|Placebo|intravenously via iv drip over 60 min
48316077|NCT05086289|DRUG|LY3526318|Administered orally
48644575|NCT02145520|OTHER|placebo|use of placebo with standard therapy
48644576|NCT04349371|DRUG|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
47965554|NCT01220050|DRUG|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
47965555|NCT01220050|DRUG|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
47965556|NCT05548816|OTHER|Handheld Dynamometer , Special tests and Modified DASH questionarre .|A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
48316078|NCT05086289|DRUG|Placebo|Administered orally
48316079|NCT04419285|BEHAVIORAL|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
48316080|NCT04419285|BEHAVIORAL|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
48316081|NCT04419285|BEHAVIORAL|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
48316082|NCT03513965|BEHAVIORAL|Symptoms as Positive Signals Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
48316083|NCT03513965|BEHAVIORAL|Symptoms as Side Effects Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
48316084|NCT00007904|BIOLOGICAL|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC \> 10,000/uL x1 day after the nadir cycles 1-3.
48644577|NCT04349371|DRUG|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
48644578|NCT05360888|BEHAVIORAL|Tools for Life|Tools for Life focuses on empowering youth to learn more about their culture and their identity.
48644579|NCT05360888|BEHAVIORAL|Tools for Life + MISN|Tools for Life focuses on empowering youth to learn more about their culture and their identity. MISN focuses on helping youth get support from their community and social networks.
48644580|NCT06687720|OTHER|MetBroma|Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
48644581|NCT05226338|DRUG|D-0502|Formulation 1 Formulation 2 Formulation 3
48644582|NCT06681558|DEVICE|Group Nasal Cannula|"Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a conventional oxygen mask.~The nasal cannula is a device that provides oxygen to patients through the nasal passages."
48644583|NCT06681558|DEVICE|Group Procedural Oxygen Mask|Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a Procedural Oxygen Mask (POM® ELITE MF). The procedural oxygen mask is a device that covers both the mouth and nose to deliver oxygen to the patient. Its reservoir feature increases the concentration of delivered oxygen
47965557|NCT05487144|BEHAVIORAL|Learning in a Virtual Environment (LIVE)|Phase 1 of the study will be a one-time meeting, either remote or in-person to complete V.E. training and fill out questionnaires. Phase 2 of the study is the 8 week intervention implementation.Participants will access the V.E. community from their homes on a computer with broadband internet. During the first four weeks of the intervention, participants will be required to come into the V.E. at least once per week for at least one hour. For the last four weeks, V.E. participation is strongly encouraged, but not required. The content in the V.E. will focus on psychosocial health and stroke recovery, and the messaging in the VE will be updated bi-weekly to encourage retention and engagement. Group meetings led by the study PI, a psychologist, or another trained member of the research team at least once a week will be offered. During the intervention period, VE-specific data will be collected continuously. Phase 3, will include a survey and a focus group interview via online platform.
47965558|NCT04389853|PROCEDURE|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
47965559|NCT04389853|PROCEDURE|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
47965560|NCT03507231|BEHAVIORAL|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
47965561|NCT03507231|BEHAVIORAL|Incentive for Vaccination|$5 gift card offered for vaccination
47965562|NCT03507231|BEHAVIORAL|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
47965563|NCT04185545|BIOLOGICAL|Rotavirus RV3 Vaccine (Bio Farma)|Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3
47965564|NCT04185545|OTHER|Placebo|Each 1 mL dose of placebo contains 30% of sucrose in DMEM
48316085|NCT00007904|DRUG|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
48316086|NCT00007904|DRUG|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
48316087|NCT00007904|DRUG|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
48316088|NCT00007904|DRUG|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
48316089|NCT00007904|PROCEDURE|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
48316090|NCT00007904|RADIATION|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
48316091|NCT03515434|PROCEDURE|ESP Block|ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
48644584|NCT06687200|OTHER|Setup with neutral pelvic positioning technique|Setup with neutral pelvic positioning technique (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT Mega Voltage Computed Tomography)
48644585|NCT06687200|OTHER|Standard setup|Standard setup (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT)
47965565|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
47965566|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
47965567|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
47965568|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
47965569|NCT00227097|BEHAVIORAL|Education Notebook for anticoagulant treatment|
47965570|NCT02443766|OTHER|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
47965571|NCT00238004|DRUG|Nicotinic acid|
47965572|NCT05853068|DEVICE|Mechanical ventilation|Need for endotracheal intubation and invasive mechanical ventilation
47965573|NCT04524910|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
47965574|NCT04201093|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 mg QD or 15 mg QD tablet once daily orally for 27 weeks.
47965575|NCT04201093|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
47965576|NCT00297583|DRUG|Insulin Glulisine|
47965577|NCT03760978|DRUG|Dexmedetomidine|
47965578|NCT01132430|BEHAVIORAL|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
47965579|NCT01132430|BEHAVIORAL|Usual care|Standard medical care within 4-6 week period
47965580|NCT01211730|DRUG|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
47965581|NCT02437266|OTHER|Scapular mobilization|
47965582|NCT03600571|PROCEDURE|medial midpatellar (MMP) portal|injection medial under horizontal patella midline was administrated with the lower limb extension
47965583|NCT03600571|PROCEDURE|anteromedial (AM) portal|injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
47965584|NCT01269632|BIOLOGICAL|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires"
47965585|NCT02367937|DRUG|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
47965586|NCT06284291|DIAGNOSTIC_TEST|transcranial magnetic stimulation (TMS)|The STM9000 Standard-BI stimulator with 70 mm refrigerated butterfly stimulator (EB Neuro, Florence, Italy) controlled by Galileo Netbrain 9000 hardware and software (EB Neuro, Florence, Italy) is used. EMG data are recorded from the contralateral dorsal first interosseous muscle using gelled surface electrodes. EEG data are recorded by using the BE PLUS PRO Advanced EEG/EMG/EP amplifier (EB Neuro, Florence, Italy IT).
47965587|NCT05116618|DIAGNOSTIC_TEST|InVisionFirst-Lung ctDNA assay|An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.
47965588|NCT01154582|DIETARY_SUPPLEMENT|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
47965589|NCT01154582|DIETARY_SUPPLEMENT|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
47965590|NCT04700371|DEVICE|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
47965591|NCT04700371|DEVICE|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
48316092|NCT03515434|PROCEDURE|TAP Block|TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
48316093|NCT03515434|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
48316094|NCT03407924|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
48644586|NCT05114291|OTHER|Explorations are planned as part of the one-day hospitalization|"* Clinical parameters : Interrogation, physical examination, morphological data measurements (weight, height, waist circumference, hip circumference) and impedencemetry (body composition).~* Biological samples : Blood and urine exam, fasting urine sample (urinary osmolarity)~* Standardized blood pressure measurement :~  * After 5 to 10 minutes of rest, with automated measurements at 1 minute intervals : un-attended, then attended~* Hemodynamic parameters :~  * Sphygmocor® : measure of the central blood pressure and pulse wave velocity~ * MESI® tool : measure of the Systolic Pressure Index (PSI or IPS)~ * pOpmetre® : Calculation of the speed of the pulse wave by the pOpmetre® device~* Others : if indicated (echocardiography, ABPM)"
48644587|NCT06690151|BEHAVIORAL|Neurodevelopmental assessment (Bayley-IV)|Assessment of developmental delays through administration of the Bayley-4 test by a neuropsychologist
47965592|NCT05160493|DRUG|S-ketamine and pregabalin|"S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
47965593|NCT05160493|DRUG|Normal saline and placebo capsule|Normal saline and placebo capsule
47965594|NCT00003997|DRUG|irofulven|
47965595|NCT00481078|DRUG|vorinostat|Given PO
47965596|NCT00481078|DRUG|paclitaxel|Given IV
47965597|NCT00481078|DRUG|carboplatin|Given IV
47965598|NCT00481078|OTHER|placebo|Given PO
47965599|NCT00481078|OTHER|laboratory biomarker analysis|Correlative studies
47965600|NCT06044090|DRUG|Minocycline|Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
47965601|NCT06044090|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
47965602|NCT05698030|OTHER|Food allergy|Oral immunotherapy to pistachio
48316095|NCT03407924|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
47965603|NCT04188782|DRUG|Sevoflurane|Describe how a reiterative anesthesia exposure could induce tolerance to the anesthetic.
47965604|NCT04739904|OTHER|Normoxia|48 hours experimental protocol conducted at sea level
47965605|NCT04739904|OTHER|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
47965606|NCT04739904|OTHER|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
47965607|NCT00687466|DRUG|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
47965608|NCT03530878|PROCEDURE|Hip Arthroscopy|Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
47965609|NCT05722782|DRUG|Piroxicam|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
47965610|NCT05722782|DRUG|Acetaminophen|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
47965611|NCT05722782|DRUG|Placebo|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
48316096|NCT04452227|OTHER|questionnaire|Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
48316097|NCT03499821|DEVICE|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
48316098|NCT02938585|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
48316099|NCT02938585|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
48316100|NCT00069420|BEHAVIORAL|Cognitive Motivational Behavior Therapy|
48316101|NCT00790738|DRUG|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
48115981|NCT02342210|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
48115982|NCT02220478|DEVICE|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
48316102|NCT00790738|DRUG|placebo|placebo
48316103|NCT05960019|DIETARY_SUPPLEMENT|Fermented milk product|This is a type of cultured bovine milk, that is prepared through mesophilic fermentation of milk, that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
48485208|NCT04013113|OTHER|Plasma Exchange|"Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier)."
48485209|NCT02773199|OTHER|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
48644588|NCT06690151|OTHER|Biological sampling|"The samples to be collected at delivery will include:~* A 4 ml maternal blood sample in an EDTA tube for lipidomic and metabolomic analyses at delivery~* A 6 ml maternal blood sample in an EDTA tube (2 tubes of 3 ml) for genetic analysis~* A 4 ml venous cord blood sample in an EDTA tube for transcriptomic and epigenetic analysis; and a 2 ml EDTA tube for metabolomic/lipidomic analysis~* Samples from fresh placenta for transcriptomic, epigenetic, metabolomic, and lipidomic analyses~* A meconium sample collected as soon as possible after birth in a dry tube for microbiome analysis~During hospitalization for the cardiac surgery:~* Genome analysis samples will be collected from the father and the infant. These samples will be taken in two EDTA tubes of 3 ml each.~* Perioperative neurobiomarker samples will be collected (one EDTA tube of 500 μL preoperatively and postoperatively on Day 1 and Day 2).~At 1 month, a stool sample will be collected from the infants for microbiome analysis."
48644589|NCT06690151|BEHAVIORAL|ELFE dietary questionnaire|Questionnaire on diet and lifestyle during pregnancy (only for the mother)
48644590|NCT06690151|BEHAVIORAL|Post-Traumatic Stress Questionnaire IES-R (Impact of Event Scale - Revised)|The IES-R is a 22-item self-report measure (for DSM-IV) that assesses subjective distress caused by traumatic events.
47965612|NCT05907876|OTHER|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
47965613|NCT02764060|DEVICE|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
47965614|NCT02764060|DEVICE|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
47965615|NCT04303819|DRUG|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
47965616|NCT03123913|DRUG|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
47965617|NCT03123913|DRUG|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
47965618|NCT01036893|DRUG|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
47965619|NCT03569618|DEVICE|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
48316104|NCT05960019|DIETARY_SUPPLEMENT|Fermented cereal based product|This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
48316105|NCT05960019|BEHAVIORAL|Behavioural modification counselling|Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the patients prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
48316106|NCT03370991|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day freeze-dried blueberry powder for 12 weeks
48316107|NCT03370991|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder for 12 weeks
48316108|NCT03489616|BIOLOGICAL|rhGM-CSF|rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
48316109|NCT03489616|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
48644591|NCT06690151|OTHER|Data collection for the study (Cardiovascular, developemental, fetal, pregnancy, MRI)|"* Cardiovascular follow-up data collection~* Developmental follow-up data collection~* Collection of postoperative brain MRI data, scheduled between Day 5 post-surgery and the end of the hospital stay~* Collection of data on pregnancy exposure, obstetric events, and delivery data.~* Collection of fetal ultrasound data (T2 and T3).~* Collection of fetal echocardiography data (T2 and T3)."
47965620|NCT03615378|DIETARY_SUPPLEMENT|5000 IU D3|Daily
47965621|NCT03615378|DIETARY_SUPPLEMENT|1000 IU D3|Daily
47965622|NCT03615378|DIETARY_SUPPLEMENT|Placebo|lactose/sugar tablet
47965623|NCT00626223|DRUG|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
47965624|NCT00626223|DRUG|folic acid|5 mg per day of oral folic acid
47965625|NCT06149832|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10\^6/ml) dressing was applied 4 times/day for 2 weeks.
47965626|NCT05488730|DIAGNOSTIC_TEST|passive leg raising test and fluid challenge|"Shocked patients were subjected to echocardiographic examination if (EF \<52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness)."
47965627|NCT00172133|DRUG|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
47965628|NCT00489346|DRUG|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
47965629|NCT00489346|DRUG|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
47965630|NCT02285192|RADIATION|18F-Fluorodeoxyglucose (18F-FDG)|
47965631|NCT02285192|DEVICE|PET/CT imaging|
47965632|NCT02285192|DEVICE|PET/MRI imaging|
47965633|NCT05880680|DEVICE|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
47965634|NCT02671175|DRUG|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
47965635|NCT02671175|DRUG|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
48115983|NCT03834792|OTHER|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
47965636|NCT00795496|PROCEDURE|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
47965637|NCT00795496|PROCEDURE|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
47965638|NCT00795496|PROCEDURE|Serum IgE blood testing|One blood test to measure total serum IgE
47965639|NCT00795496|PROCEDURE|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
47965640|NCT03906838|DRUG|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
47965641|NCT04444388|DIETARY_SUPPLEMENT|cocoa|Sachets of 5 grams of cocoa daily supplementation
47965642|NCT04444388|DIETARY_SUPPLEMENT|Placebo|Sachets of 5 grams of maltodextrin daily supplementation
48115984|NCT05124847|BEHAVIORAL|Standard Care|Participants will receive nutritional education sessions and will be instructed to maintain an intake window of at least 13 hours a day, preferably every day of the week and in any case at least 6 days a week.
47965643|NCT04028921|OTHER|No intervention|This is a cross-sectional study; no intervention
48316110|NCT03489616|RADIATION|Local Radiotherapy|Radiotherapy promotes the release of tumor antigen
48316111|NCT03489616|DRUG|Single agent|Other chemotherapy drugs,such as Docetaxel, gemcitabine
48316112|NCT03791437|DEVICE|Digital chest drainage system|patients who received Digital chest drainage system
48316113|NCT03791437|DEVICE|Not use Digital chest drainage system|patients who not received Digital chest drainage system( traditional drainage system)
48644592|NCT02850406|DRUG|Voxelotor|"* Part A: Voxelotor will be administered as oral capsules or tablets~* Part B: Voxelotor will be administered as oral capsules or tablets~* Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension~* Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension"
48644593|NCT06690814|OTHER|Ficus septica exudate (antiseptic plant exudates)|F. septica sap contains the antibacterial alkaloid ficuseptine which exhibits activivity agaisnt S. pyogenes and H. ducreyi, two pàthogens associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
47965644|NCT03048331|DEVICE|Functional Electrical Stimulation|"Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:~300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause."
48115985|NCT05124847|BEHAVIORAL|Time restricted eating|A personalized progression will be established to progressively reduce the intake window during the first 10 days of intervention. After these first 10 days, the participants will be prescribed to limit food intake to a maximum of 10 hours a day, at least 5 days a week. Participant can freely select the time of day to place the intake window. However, it will be recommended to avoid making the last intake in the 3 hours before going to bed. After 4 weeks of intervention, the dietitian will invite them to reduce the intake window to 9 or 8 hours, if they consider it feasible, maintaining this new intake window during the last 4 weeks of intervention. The intake window can be maintained at 10 hours until the end of the study.
48644594|NCT06690814|OTHER|Pterocarpus indicus exudate|P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).
47965645|NCT00689234|PROCEDURE|diaphragm plication 6 months after inclusion|thoracotomy
47965646|NCT00689234|PROCEDURE|diaphragm plication at time of inclusion|thoracotomy
47965647|NCT04590222|OTHER|blood sample|One blood sample of 60 mL (EDTA)
47965648|NCT03896386|OTHER|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
47965649|NCT06164678|BEHAVIORAL|OMSC|The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.
47965650|NCT04149626|DRUG|Dexmedetomidine|Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
47965651|NCT04149626|DRUG|Midazolam|Sedation using midazolam (initial bolus dose followed by continuous infusion)
47965652|NCT04149626|DRUG|Remifentanil|Sedation using remifentanil (initial bolus dose followed by continuous infusion)
47965653|NCT06266169|OTHER|making artificial intelligence based decisions of gamete, embryo and endometrial potential|The method of Raman spectroscopy is based on the registration of inelastic scattering of photons. Each compound has its own spectral pattern when using a certain type of monochromatic radiation (laser). With this method, it is possible to obtain metabolic fingerprints from the objects being studied. Luminescent spectroscopy is a type of spectroscopy used to register emission from objects that occurred after absorbing the exciting (primary) radiation. Spectrophotometry is the detection of radiation in the visible area of the spectrum. Raman spectroscopy is used for the spent medium and semen to build artificial intelligence model and make prognosis of function for each object. For endometrium, luminescent spectroscopy and spectrophotometry are used to build the model and test its clinical relevance
48115986|NCT04227288|DRUG|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
48115987|NCT01906788|DRUG|Artemether Lumefantrine|
48485210|NCT02773199|OTHER|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
48485211|NCT02773199|DRUG|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
48485212|NCT06284447|OTHER|Non-Interventional Study|Non interventional study
48485213|NCT03182894|DRUG|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
47965654|NCT03024619|OTHER|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
48485214|NCT05609916|BEHAVIORAL|Cognitive Behavioral Therapy|"During Phase I, participants will receive open label (no blinding) CBT during their study participation for 12 to 18 weeks.~During Phase II, participants will continue receiving CBT maintenance sessions every two weeks for the first 4 weeks, followed by sessions every four weeks. They will also meet with the study physician every 2 weeks via telepsychiatry appointments for clinical and scalar assessment."
48485215|NCT04778293|OTHER|Diacutaneous fibrolysis|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized, in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
48485216|NCT01304420|DEVICE|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
48485217|NCT02510014|DRUG|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
47965655|NCT03493594|OTHER|Nutrition education program|online platform support, workshop, seminar and cooking demo etc
47965656|NCT02062021|OTHER|No intervention|
47965657|NCT05147025|OTHER|Revascularization|Regain pulp vascularity for young permenant teeth
48115988|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
48115989|NCT01906788|DRUG|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
48115990|NCT05393726|PROCEDURE|Ultrasound-Guided Suprainguinal Fascia Iliaca Block Versus Lumbar Erector Spinae Plane Block|"Suprainguinal Fascia Iliaca Block group will receive ultrasound-guided suprainguinal fascia iliaca block injection 40 ml of bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~Lumbar Erector Spinae Plane Block group will receive ultrasound-guided lumber erector spinae plane block (L-ESPB) injection 40 ml bupivacaine 0.25% mixed with 2 ml of dexamethasone 4 mg/ml.~control group will underwent surgery under general anesthesia and receive the perioperative routine protocol of analgesia"
48115991|NCT02860910|BEHAVIORAL|Cognitive Behavioral Group Therapy|
48115992|NCT05500664|DRUG|Lavender Oil|three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
48316115|NCT00538824|DRUG|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
48316116|NCT00538824|DRUG|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
48485218|NCT02510014|DRUG|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
48485219|NCT04840784|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
48485220|NCT05195749|DRUG|101-PGC-005 ('005) + SOC|Three consecutive days of '005 administration
48485221|NCT05195749|DRUG|Placebo + SOC|Three consecutive days of placebo administration
48644595|NCT06690814|OTHER|Curcuma longa aqueous extract|C. longa is a culinary herb that contains the antibatieral compound curcumin. Curcumin exhibits antibacterial activity agasint S. pyogenes and has profound effects on bacterial biofilms. This intervention uses a mulch of the rhizome that has been sqeeezed to produce a curcumin containing aqueous fluid.
48485222|NCT03560921|DIAGNOSTIC_TEST|urinary NGAL|measurement urinary NGAL using the ARCHITECT technique
48485223|NCT02774486|DEVICE|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
48485224|NCT01996384|PROCEDURE|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
48644596|NCT06690814|DRUG|Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)|Common over the counter antiseptic cream
48644597|NCT06618664|DRUG|SHR-8068|SHR-8068: injection, 50 mg/10 mL, intravenous infusion
48644598|NCT06618664|DRUG|Adebrelimab|Adebrelimab: injection, 600 mg/12 mL, intravenous infusion
48644599|NCT06618664|DRUG|Bevacizumab|Bevacizumab: injection, 100 mg/4 mL, intravenous infusion
48644600|NCT06618664|DRUG|Sintilimab|Sintilimab: injection, 100 mg/10 mL, intravenous infusion
47965658|NCT02998944|OTHER||not any intervention for this study
47965659|NCT02192359|BIOLOGICAL|Carboxylesterase-expressing Allogeneic Neural Stem Cells|Given intracranially
47965660|NCT02192359|DRUG|Irinotecan|Given IV
47965661|NCT02192359|DRUG|Irinotecan Hydrochloride|Given IV
47965662|NCT02192359|OTHER|Laboratory Biomarker Analysis|Correlative studies
47965663|NCT02192359|OTHER|Pharmacological Study|Correlative studies
47965664|NCT01471171|DRUG|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
47965665|NCT01471171|DRUG|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
47965666|NCT04193332|DEVICE|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
47965667|NCT01326143|DEVICE|ORM Narval MRD|
47965668|NCT04946383|DRUG|Dasatinib plus Quercetin|Dasatinib plus Quercetin
48115993|NCT06676943|PROCEDURE|XEOS AURA 10 specimen PET-CT scan of tumour specimens|Participants will be injected with a small amount of radioactive tracer at the beginning of their cancer operation. This tracer will attach itself to the cancer cells. Once the surgical specimen is removed it will be placed into the specimen PET-CT scanner so that the surgeon can see the cancer within the specimen and assess the margin.
48115994|NCT02178020|DEVICE|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
48115995|NCT02178020|DEVICE|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
48316117|NCT00538824|DRUG|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*"
48485225|NCT01996384|PROCEDURE|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
48485226|NCT01996384|DRUG|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
48485227|NCT01921491|PROCEDURE|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
48115996|NCT06245863|DEVICE|Negative pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 milliwatts (mW) per laser. Vacuum therapy: 60 mm suction cup, pulsed mode (MP9, 50 pulsations per minute) and pressure of -150 at -350 mbar. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
48115997|NCT06245863|DEVICE|Positive Pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Positive Pressure: Massage with rollers. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
48485228|NCT01921491|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
48485229|NCT01092078|BEHAVIORAL|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
48115998|NCT06245863|DEVICE|Ultrasound and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Ultrasound: 1 megahertz (MHz), continuous mode and 1 milliwatts per square centimeter (mW/cm2). The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
48115999|NCT06245863|DEVICE|Laser|Infrared Laser (808 nm), continuous mode, 100 mW. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
48116000|NCT06245863|DEVICE|Placebo Laser|Laser: off mode. The placebo treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
48485230|NCT01092078|BEHAVIORAL|Patient Navigation|Patient navigation for colonoscopy.
48485231|NCT05739968|OTHER|Usual care + oncology case manager (OCM) care|Usual care + oncology case manager (OCM) care
48485232|NCT05739968|OTHER|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
48485233|NCT04051684|PROCEDURE|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
48485234|NCT04051684|DRUG|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
48116001|NCT03697876|DRUG|PRO-165|PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
48116002|NCT03697876|DRUG|Artelac|Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.
47965669|NCT01434667|BEHAVIORAL|APOE genotype and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
47965670|NCT01434667|BEHAVIORAL|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
48116003|NCT00113971|DRUG|epratuzumab|
48116004|NCT03264261|DEVICE|robotic training|robotic training, 3 times/week for 6 weeks
48116005|NCT03264261|DEVICE|treadmill training|treadmill training only, 3 times/week for 6 weeks
48116006|NCT02345018|PROCEDURE|Mechano-chemical ablation|Treatment with mechano-chemical ablation
48116007|NCT03949855|DRUG|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
48116008|NCT03949855|DRUG|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
48116009|NCT03949855|DRUG|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
48116010|NCT04409912|DEVICE|Sirolimus coated balloon|"Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety."
48116011|NCT04409912|DEVICE|Plain balloon|Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
48116012|NCT01379014|BEHAVIORAL|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
48116013|NCT01379014|OTHER|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
48316118|NCT04620915|BEHAVIORAL|High-level construal|"In the high-level construal condition, participants will be sent messages asking them to consider why they are quitting (What are your main reasons for quitting?) and to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014). The corpus for this condition is 100 messages composed by a large independent sample of mTurk workers who are smokers and validated by a team of RAs trained to 0.8 reliability on ratings of high-level construal. To meet criteria for inclusion, a message must be rated as significantly closer to high-level (vs. low-level) on a rating scale of construal level.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
48485235|NCT05123313|BEHAVIORAL|Deprescribing intervention|"The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal."
48485236|NCT02606526|BIOLOGICAL|BCG at birth|See previous description
48485237|NCT02606526|BIOLOGICAL|Control arm: Delayed BCG|See previous description
47965671|NCT01861964|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
47965672|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
47965673|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
48116014|NCT04725305|DEVICE|BiZact|It has been described as describes a bipolar device that continuously measures impedance of clamped tissue, adjusting energy levels in real time and automatically stopping energy delivery when a seal is established. Their literature suggests the device permanently seals vessels up to 3mm with less thermal damage, resulting in less intraoperative blood loss, more efficient procedures, and possibly less pain
48116015|NCT04725305|PROCEDURE|Standard of care|This method would involve removal of tonsils using electrocautery technique
48116016|NCT01813812|DRUG|DA-6034|
48116017|NCT01813812|DRUG|Rebamipide 300mg|
48116018|NCT03352778|RADIATION|IMRT|66Gy by intensity-modulated radiotherapy
48116019|NCT03352778|RADIATION|2DRT|66Gy by 2-dimensional radiotherapy
48316119|NCT04620915|BEHAVIORAL|Down-regulation of craving for cigarettes|"In the down-regulation of craving condition, participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences). The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability on ratings of plausibility AND effortful cognitive inhibition or control.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text."
48485238|NCT02116699|OTHER|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
48644601|NCT06691854|OTHER|The group that applied the Intrapartum Care Model|"Pregnant women who apply to the hospital for delivery, have cervical dilatation of 5 cm and above, agree to participate in the study and are assigned to the intervention group;~A Personal Information form will be applied at the first clinic admission. All primiparous pregnant women assigned to the intervention group will be applied the intrapartum care model by the research midwife during the labor process and after birth in line with the WHO positive birth recommendations.~The labor process of the pregnant woman will be recorded on the birth experience follow-up form.~After birth, the Respectful maternity care scale, Birth experience scale, Traumatic birth perception scale will be applied."
48644602|NCT02653755|DEVICE|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
48485239|NCT02116699|OTHER|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
48485240|NCT02549794|PROCEDURE|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
48644603|NCT04411199|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
48644604|NCT04411199|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
48644605|NCT05379725|OTHER|Mediterranean Dietary Pattern|The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
48644606|NCT05379725|OTHER|High Fermented Food Dietary Pattern|Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
48644607|NCT06687538|OTHER|Mobile application|The content of the mobile application training to be developed for patients who will undergo transurethral prostate resection will consist of 3 modules including preoperative, postoperative and discharge training process.
48644608|NCT01117662|DRUG|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
48116020|NCT00889499|DRUG|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
48116021|NCT00889499|DRUG|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
48644609|NCT01117662|DRUG|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
47965674|NCT02908360|GENETIC|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
47965675|NCT03949374|DRUG|CRESTOR, reference formulation of rosuvastatin|Use of ROVASRO for hypercholesterolemia
48116022|NCT00889499|DRUG|Placebo|NHCL 0,9%
48116023|NCT02192606|DEVICE|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
48116024|NCT02192606|DEVICE|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
48116025|NCT03185780|OTHER|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
48485241|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
48485242|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
48485243|NCT00522444|DRUG|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
48485244|NCT00522444|OTHER|Nebulized normal saline|standard of care
48644610|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
48116026|NCT03290248|BIOLOGICAL|B244 suspension|B244 suspension in 30ml/bottle
48116027|NCT03290248|BIOLOGICAL|Vehicle|Vehicle, 30ml/bottle
48116028|NCT05848583|OTHER|Compleat 1.5|EN Formula
48116029|NCT05153135|DRUG|Ribociclib|Participants who initiated CDK4/6i therapy
48116030|NCT05153135|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
48116031|NCT05153135|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
48116032|NCT05130450|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
48316120|NCT04620915|BEHAVIORAL|Up-regulation of goal energization|"In the up-regulation of goal energization condition, participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking. These messages will name a specific core value that the participant rated in the top three (of 19) during the baseline session, and will draw a connection between quitting and the core value. For example, a message for a person who nominated family as one of her top three core values might read, Quitting will help you model a healthy lifestyle for your family. This intervention is grounded in robust theory and evidence supporting Self-Affirmation Theory. The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability in correctly identifying to which core value the message is tied.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics."
47965676|NCT03949374|DRUG|ROVASRO, generic formulation of rosuvastatin|Use of CRESTOR for hypercholesterolemia
47965677|NCT04191031|DEVICE|ioveraº|Cryoneurolysis
47965678|NCT04191031|DEVICE|ioveraº sham|ioveraº sham
47965679|NCT05164185|PROCEDURE|Remote ischemic conditioning|Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
47965680|NCT01458938|OTHER|treatment plan|Data Collection Study
47965681|NCT02705469|DRUG|ZEN003694|
47965682|NCT03260309|PROCEDURE|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
47965683|NCT03260309|PROCEDURE|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
47965684|NCT04080128|DEVICE|Contact lenses|Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
47965685|NCT01979887|PROCEDURE|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
47965686|NCT04038684|BEHAVIORAL|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
47965687|NCT04038684|BEHAVIORAL|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
47965688|NCT01605162|DRUG|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
47965689|NCT01605162|DRUG|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
47965690|NCT03539471|DIAGNOSTIC_TEST|interview, Tridimensional Personality Questionnaire|interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
47965691|NCT00299104|DRUG|folate|Intravenous repeating dose
47965692|NCT00299104|DRUG|methotrexate|Oral or parenteral repeating dose
47965693|NCT00299104|DRUG|methylprednisolone|Intravenous repeating dose
47965694|NCT00299104|DRUG|placebo|Intravenous repeating dose
47965695|NCT00299104|DRUG|rituximab|Intravenous repeating dose
48116033|NCT03830866|BIOLOGICAL|Durvalumab|IV infusion every 4 weeks
48116034|NCT03830866|DRUG|Cisplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
48116035|NCT03830866|DRUG|Carboplatin|For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
48316121|NCT01820078|DRUG|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
48316122|NCT01820078|OTHER|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
48116036|NCT03830866|RADIATION|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
48116037|NCT06142851|OTHER|Data collection|data collection
48116038|NCT05283720|DRUG|Epcoritamab|Subcutaneous Injection (SC)
48116039|NCT05283720|DRUG|Lenalidomide|Oral; Capsule
48316123|NCT03321214|OTHER|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
48316124|NCT02607358|OTHER|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
48316125|NCT00783341|DRUG|GAP-134|
48316126|NCT00783341|DRUG|placebo|
48316127|NCT06121336|DIAGNOSTIC_TEST|Plasma levels of BD-tau|Plasma levels of BD-tau will be assessed using a single-molecule array assay.
48316128|NCT04830800|BIOLOGICAL|COVIVAC|COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19
48644611|NCT00951873|DRUG|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
47965696|NCT04534959|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \>100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
47965697|NCT00873197|DRUG|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
47965698|NCT03298815|BIOLOGICAL|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
48316129|NCT04830800|BIOLOGICAL|Phosphate-buffered saline|Phosphate buffer solution (pH 7.2), manufactured by IVAC
48316130|NCT04969497|DRUG|"Treatment A: M207 3.8 mg MiniMac"|"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"
48644612|NCT00951873|DRUG|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
47965699|NCT03298815|OTHER|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
47965700|NCT05391516|DIAGNOSTIC_TEST|Evaluation of shoulder problems|The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
47965701|NCT06557070|OTHER|The Emotional Freedom Technique|Emotional freedom technique (EFT) is a method to help manage emotions and troubling thoughts and lower stress and anxiety. EFT is applying by tapping. To do EFT, you tap your fingertips on certain points on your hand, head, and torso which are used in acupuncture.
47965702|NCT02140372|DRUG|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
47965703|NCT03533764|BEHAVIORAL|ASMA|ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
47965704|NCT01600469|DRUG|DAOI-B|250-1500 mg/day, oral, for 24 weeks
47965705|NCT01600469|OTHER|Placebo|placebo, oral, for 24 weeks
47965706|NCT06557655|DIETARY_SUPPLEMENT|caffeinate chewing gum|participants either chewed caffeinated gum (CAF) containing 3 mg/kg caffeine or a caffeine-free placebo gum (PLA) for 10 minutes prior to undertaking a series of tests on-ice and off-ice.
47965707|NCT04636190|DEVICE|Triathlon All-Polyethylene Tibia Knee|Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
47965708|NCT05112471|DEVICE|Airflow, Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
47965709|NCT05112471|DEVICE|Ultrasonic debridement and curettes|traditional Scaling and Root Planing with curettes and ultrasonic scaler
47965710|NCT04848597|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|200mg , once every 3 weeks
47965711|NCT01219569|DRUG|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
47965712|NCT01219569|DRUG|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
47965713|NCT05972876|BEHAVIORAL|Blood flow restriction training|BFR will be achieved using an automatic personalized tourniquet system (MAD-UP, Angers, France) designed to automatically calculate limb occlusion pressure
47965714|NCT05972876|BEHAVIORAL|Resistance training|Resistance training will be performed without any blood flow restriction
47965715|NCT01304316|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
47965716|NCT01925937|DRUG|Atorvastatin|
47965717|NCT01925937|DRUG|Coenzyme Q10|
47965718|NCT01925937|DRUG|placebo for coenzyme Q10|
47965719|NCT02541682|OTHER|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
47965720|NCT00816764|BIOLOGICAL|AGS-8M4|IV Infusion
47965721|NCT02837445|DEVICE|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
48116040|NCT05283720|DRUG|Ibrutinib|Oral; Capsule
48644613|NCT06690437|DEVICE|Galaxy Fixation System and Orthofix implantable devices|"It is planned to include 118 patients in 3 sites in Italy treated with GALAXY FIXATION™ System and Orthofix implantable devices for the following indications:~* fractures of the long bones or;~* Vertically stable pelvic fractures or vertically unstable pelvic fractures as a treatment adjunct Clinical data will be collected only from patients with a regular indication for GALAXY FIXATION™ System and Orthofix implantable devices as per IFUs (no off-label use will be included) and who underwent surgery performed with the specific devices."
47965722|NCT02837445|DEVICE|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
47965723|NCT03338998|DRUG|BAF312 solution|Solution for intravenous (IV) infusion - 4.5mg/4.5mL
47965724|NCT03338998|DRUG|Matching Placebo for BAF312 solution|Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
47965725|NCT03338998|DRUG|BAF312 tablet|2 mg film-coated tablet
47965726|NCT03338998|DRUG|Matching Placebo for BAF312 tablet|0 mg film-coated tablet matching placebo
48485245|NCT01164306|BEHAVIORAL|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
47965727|NCT05129215|OTHER|Questionnaire|The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.
48116041|NCT05283720|DRUG|Rituximab|Intravenous (IV); Injection
48116042|NCT05283720|DRUG|Cyclophosphamide|IV; Injection
48116043|NCT05283720|DRUG|Doxorubicin Hydrochloride [HCl]|IV; Injection
48116044|NCT05283720|DRUG|Prednisone|Oral; Tablet
48485246|NCT01164306|BEHAVIORAL|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes."
48485247|NCT01164306|BEHAVIORAL|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
48485248|NCT04665206|DRUG|VT3989|25, 50, 100,150 or 200 mg capsules for oral administration.
48485249|NCT02171767|DRUG|BIBW 2992 MA2 - single rising dose|
48485250|NCT04126616|DIAGNOSTIC_TEST|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
48485251|NCT02287324|PROCEDURE|Manipulation|
48644614|NCT06509074|DRUG|Beta blocker|Pragmatic design. Any beta-blocker with alpha or NO activity may be used
48116045|NCT05283720|DRUG|Polatuzumab Vedotin|IV; Injection
48116046|NCT05283720|DRUG|Venetoclax|Oral; Tablet
48116047|NCT05283720|DRUG|CC-99282|Oral; Capsule
48116048|NCT05283720|DRUG|Pirtobrutinib|Oral; Tablet
48485252|NCT02287324|PROCEDURE|Manual Contact|
48485253|NCT05025579|OTHER|Aerobic Exercise|"Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done."
48485254|NCT01261741|DRUG|Memantine|Each subject will receive memantine 10mg tablets once daily
48485255|NCT01261741|DRUG|Placebo|Each subject will receive matching placebo tablets once daily
48644615|NCT06421454|DRUG|Melatonin|Pressure Ulcer will be treated with a melatonin cream daily
48116049|NCT02456506|RADIATION|Hyperfractionated IMRT|
48116050|NCT02456506|RADIATION|Conventional Fraction IMRT|
48116051|NCT06102525|DRUG|RZ-001|Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
48116052|NCT06102525|COMBINATION_PRODUCT|VGCV|VGCV, used in a subject after RZ-001 administration, is a nucleoside analog that is metabolized by HSV-tk and other cellular kinases to form the cytotoxic nucleotide analog ganciclovir triphosphate. An approved oral VGCV will be used in the proposed clinical study of RZ-001.
48116053|NCT03498651|BEHAVIORAL|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
48116054|NCT03498651|BEHAVIORAL|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
48116055|NCT03498651|BEHAVIORAL|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
48316131|NCT04969497|DRUG|"Treatment B: M207 3.8 mg MACAP"|"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"
48116056|NCT05692908|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
48116057|NCT06671717|OTHER|Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation|"Drug: Pralatrexate, Chidamide~1. Pralatrexate: 30 mg/m2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment)~2. After the 6-week therapy, the patients should receive PET/CT evaluation.~3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week.~4. After the second cycle of 6-week therapy, the patients should receive PET/CT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies."
48485256|NCT04979273|DRUG|Dextrose 40 % in Water|injection of adrenaline 1:20.000, followed by dextrose 40% spray
47965728|NCT00694174|DRUG|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
47965729|NCT00694174|DRUG|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
47965730|NCT01784159|DRUG|Aspirin|Aspirin administration for 7 days
47965731|NCT02439138|DRUG|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
47965732|NCT04502693|COMBINATION_PRODUCT|rMenB+OMV NZ vaccine|rMenB+OMV NZ vaccine was administered intramuscularly.
47965733|NCT04502693|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|MenACWY vaccine was administered intramuscularly.
47965734|NCT04502693|COMBINATION_PRODUCT|Placebo|Placebo was administered intramuscularly.
47965735|NCT04502693|COMBINATION_PRODUCT|MenABCWY-1|Lot 1 of the MenABCWY vaccine was administered intramuscularly.
47965736|NCT04502693|COMBINATION_PRODUCT|MenABCWY-2|Lot 2 of the MenABCWY vaccine was administered intramuscularly.
47965737|NCT04502693|COMBINATION_PRODUCT|MenABCWY-3|Lot 3 of the MenABCWY vaccine was administered intramuscularly.
48116058|NCT03520413|OTHER|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
48116059|NCT03520413|OTHER|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
48116060|NCT04705922|DRUG|TT-00420 Capsule|TT-00420 capsule formulation, administered orally
48116061|NCT04705922|DRUG|TT-00420 Tablet|TT-00420 tablet formulation, administered orally
48116062|NCT01818713|DRUG|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
48116063|NCT04722237|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an evidence-based psychological therapy that has been used to improve physical and mental health among adults with health conditions, including cancer (Graham, Gouick, Krahe, \& Gillanders, 2016). It fosters engagement with, rather than avoidance of, painful experiences, to move towards acceptance of unchangeable difficulties alongside building a rich and meaningful life despite the presence of ongoing problems.
48316132|NCT04969497|DRUG|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
48316133|NCT04069741|OTHER|Decision Aid|A website that contains information about de Quervain's tenosynovitis and the options for treatment
48485257|NCT04979273|DRUG|Adrenaline 1 Mg/mL Solution for Injection|injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip
48485258|NCT04979273|PROCEDURE|argon plasma coagulation|Thermocoagulation
48485259|NCT04979273|PROCEDURE|Hemoclip|Hemoclip
48644616|NCT06421454|DRUG|Hydrogel|Pressure ulcer will be treated with hydrogel daily as a comparator
48644617|NCT06483217|BEHAVIORAL|Patient-directed follow up|Patients will be instructed to follow up for repeat injection based on bladder symptomatology at their own self-determined time interval.
48116064|NCT04631744|DRUG|Cabozantinib|Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
48116065|NCT02825485|PROCEDURE|Voiding cystourethrogram|
48116066|NCT00638963|DRUG|temozolomide|Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles
48644618|NCT06686940|DEVICE|intervention group|The monitoring effect of a smart electrocardiogram watch based on the PPG algorithm on atrial fibrillation burden.
47965738|NCT00289783|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
47965739|NCT00289783|BIOLOGICAL|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
47965740|NCT00289783|BIOLOGICAL|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
47965741|NCT00289783|BIOLOGICAL|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
47965742|NCT00289783|BIOLOGICAL|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
47965743|NCT00289783|BIOLOGICAL|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
47965744|NCT00289783|BIOLOGICAL|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
47965745|NCT01162512|BEHAVIORAL|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
47965746|NCT01390805|DRUG|Valaciclovir Hydrochloride.|
47965747|NCT00158990|DRUG|triiodothyronine|
47965748|NCT00158990|DRUG|sertraline|
47965749|NCT03863054|DEVICE|NATROX™ Topical Oxygen Therapy System|"A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system"
47965750|NCT06557447|DIAGNOSTIC_TEST|Immunological and microbiological sample of peri-implant crevicular fluid; clinical evaluation|"Immunological sample collection involves placing a Periopaper strip in the peri-implantar sulcus for 30 seconds. If sample is contaminated with blood, sample will be discarded and another sample will be collected (a different surface of the same implant/tooth can be used).~Microbiological sample collection involves collecting subgingival dental plaque by sliding the end of the STERILE curette (Gracey) inside the peri-implant sulcus. In case of slight bleeding following the first sample, dry the site again before collection. In case of profuse bleeding, collect a sample from another site (by site mean mesial/buccal/distal/lingual) of the same implant.~Both immunological and microbiological samples will be sent for respective laboratories for the analysis.~Clinical evaluation will assess presence of dental plaque, bleeding on probing and gingival status."
47965751|NCT03522389|PROCEDURE|AOT with gait training|"AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
47965752|NCT03522389|PROCEDURE|Gait training|"To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
48485260|NCT04845906|DEVICE|StatLock™ Catheter Stabilization Device and the StatLock™ stabilization device accessory (Foam Strip)|Each participant will have 2 separate devices applied, one to each arm, with or without a Foam Strip.The participant will also wear a dressing over top of a StatLock™ compatible catheter, which will be connected to an extension set. For this study, the catheter will not be inserted into the study participant but instead will be shortened or modified and placed on the skin and secured with the StatLock™ Stabilization Device. The use of the catheters, extension set, and the dressing represents how the device would be used in a clinical setting.
48485261|NCT02856009|OTHER|completion of a quality of life questionnaire|
47965753|NCT03522389|OTHER|Education|There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
47965754|NCT02940912|DRUG|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
47965755|NCT02940912|DRUG|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
47965756|NCT01832974|DRUG|IL-13-PE|IL-13-PE intravenous infusion
47965757|NCT05566743|DRUG|Capecitabine|maintenance capecitabine after 4 months of FOLFRINOX
47965758|NCT05566743|OTHER|follow up|follow up after 4 months of FOLFRINOX
47965759|NCT01322139|DRUG|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
48116067|NCT03814265|BEHAVIORAL|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
48116068|NCT00559286|DRUG|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
48644619|NCT06465290|DEVICE|Motor relearning training with wearable ankle robot|Ankle motor control relearning training under real-time feedback
48644620|NCT06465290|DEVICE|Passive stretching with wearable ankle robot|Passive stretching under intelligent robotic control
47965760|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
47965761|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
47965762|NCT01322139|DRUG|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
47965763|NCT02428517|PROCEDURE|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
47965764|NCT02428517|PROCEDURE|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
47965765|NCT02428517|PROCEDURE|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
47965766|NCT02428517|PROCEDURE|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
47965767|NCT04853212|PROCEDURE|Biopsy|Biopsy during recto-coloscopy
47965768|NCT03193203|DRUG|Etanercept|50 mg/mL PFS and AI
47965769|NCT01343420|BIOLOGICAL|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
47965770|NCT03727230|OTHER|Blood transfusion|Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients
47965771|NCT02170597|DRUG|BIBR 1048 MS HPMC capsule|
47965772|NCT02170597|DRUG|BIBR 1048 MS gelatine capsule|
47965773|NCT04496271|DEVICE|RIC (Receiver in channel)- device|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
47965774|NCT05719766|OTHER|education ,psycological support and social support|we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
47965775|NCT03172624|DRUG|Nivolumab|nivolumab 3 mg/kg every 2 weeks
47965776|NCT03172624|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
47965777|NCT04274413|COMBINATION_PRODUCT|Beta Adrenergic Sweat Test|"In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab.~1. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site.~2. Under the first probe, injection atropine will be given in one small area of the skin.~3. Under the second probe, first injection carbachol will be given in one small area of the skin.~4. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine.~5. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded."
47965778|NCT05230303|DIETARY_SUPPLEMENT|Caffeine supplementation|Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
47965779|NCT05230303|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
47965780|NCT05840367|BEHAVIORAL|Partner present in the operation room|The partner (father, co-mother or other close relative present for the birth) is present in the operation room during the entire category 1 cesarean section. This is standard clinical practice in this particular hospital since June 2021.
47965781|NCT04667871|PROCEDURE|cataract surgery|Eyes for cataract surgery
48316134|NCT04069741|BEHAVIORAL|Toolkit for de Quervain's|A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
47965782|NCT05776498|PROCEDURE|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
47965783|NCT05776498|PROCEDURE|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
47965784|NCT06264375|BEHAVIORAL|Physical exercise|see group description
47965785|NCT01771952|DEVICE|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
47965786|NCT01771952|OTHER|Sham Treatment|A single needle stick without arthrocentesis or injection.
48316141|NCT01914419|DRUG|Oxytocin|
48316142|NCT00717366|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
48316143|NCT04884815|GENETIC|UX701|Nonreplicating, recombinant gene transfer vector
48316144|NCT04884815|OTHER|Placebo|Normal saline
48316145|NCT03105700|DEVICE|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
48644621|NCT06465290|DEVICE|Gamed-based active movement training with wearable ankle robot|Active movement training through movement games with robotic assistance
48644622|NCT06465290|DEVICE|Passive movement with limited wearable ankle robot|Passive movement in the joint middle range of motion
47965787|NCT05866796|DIAGNOSTIC_TEST|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
47965788|NCT02077920|DRUG|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
47965789|NCT02077920|DRUG|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
47965790|NCT02077920|DEVICE|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
47965791|NCT02077920|DEVICE|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
48116069|NCT03784768|OTHER|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
48316146|NCT03858062|DEVICE|Insulin pump therapy (with or without glucose sensor)|Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
47965792|NCT04563351|OTHER|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
47965793|NCT01623583|OTHER|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~* The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~* Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
48644623|NCT06465290|DEVICE|Active movement training with limited wearable ankle robot|Active movement training without robotic assistance
48644624|NCT06465290|DEVICE|Ankle torque and motion measurement with limited wearable ankle robot|Ankle torque and motion measurement with no real-time feedback
48644625|NCT06689904|DEVICE|Nanodropper|One eye is randomly selected to be dilated with the nanodropper
48644626|NCT06689904|DEVICE|Standard eye drop bottle|eye is dilated with the standard eye drop bottle
48644627|NCT03616093|OTHER|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
48644628|NCT03616093|OTHER|Placebo Beverage|Placebo supplement containing negligible nitrate
48644629|NCT00306280|DEVICE|Phototherapy|
48116070|NCT03784768|OTHER|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
48116071|NCT06576726|OTHER|This study involves no intervention.|This study involves no intervention.
48644630|NCT06538987|PROCEDURE|percutaneous epicardial ablation|Epicardial catheter ablation is often necessary for the successful treatment of scar-induced ventricular tachycardia (VT), especially in patients with nonischemic cardiomyopathy (NICMP) where scarring is more extensive on the mid-myocardial or epicardial surface. Because epicardial mapping can be painful and patient movement can limit mapping and safe epicardial access, a common strategy for these patients is general anesthesia.
48116072|NCT05206617|OTHER|No intervention - pure observational study|No intervention
48116073|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
48116074|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
48116075|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
48116076|NCT00986466|DIETARY_SUPPLEMENT|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
48116077|NCT00502736|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
48116078|NCT00425152|DRUG|fluorouracil|
48116079|NCT00425152|DRUG|leucovorin calcium|
48116080|NCT00425152|DRUG|levamisole hydrochloride|
48316147|NCT03858062|DEVICE|Artificial pancreas (Inreda Diabetic)|Bi-hormonal reactive closed loop system without mealtime announcement
47965794|NCT01623583|OTHER|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~1. Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~2. Basic training on relaxation breathing~3. Brief video of a patient overcoming needle phobia~4. Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
47965795|NCT00786500|DIETARY_SUPPLEMENT|Gynostemma pentaphyllum tea|3 grams twice daily, orally
47965796|NCT00786500|DIETARY_SUPPLEMENT|Placebo tea|3 grams twice daily, orally
47965797|NCT05777850|PROCEDURE|Conventional cavotricuspid isthmus ablation|Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.
47965798|NCT05777850|PROCEDURE|High-power short-duration ablation|Point-by-point 90W applications at the CTI ablation during 4 seconds.
48116081|NCT03737097|OTHER|Online Spaced Education|Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
48116082|NCT03737097|OTHER|Brochure Education|The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
48116083|NCT02971176|RADIATION|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
48116084|NCT02971176|RADIATION|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
48116085|NCT00006517|DEVICE|bright light box|10,000 lux bright light therapy
48116086|NCT00006517|DEVICE|dawn simulator|gradual rise in bedroom illumination prior to wake-up
48116087|NCT00006517|DEVICE|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
48116088|NCT00006517|DEVICE|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
48116089|NCT00006517|DEVICE|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
48116090|NCT03451799|OTHER|Ketogenic Diet|A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
48116091|NCT03451799|RADIATION|Standard-of-care radiation|Patients will receive standard-of-care radiation. Radiation is not protocol directed.
48116092|NCT03451799|DRUG|Standard-of-care Temozolomide|Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
48316148|NCT04790552|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
48316149|NCT04790552|OTHER|Fasting|Subjects will be asked to fast overnight for approximately 15 hours.
48316150|NCT04790552|OTHER|Fast Bar|Subjects will be asked to consume a Fast Bar.
48316151|NCT04790552|OTHER|Bar with Coffee|Subjects will be asked to consume a Fast Bar with coffee.
48316152|NCT04790552|OTHER|Bar with Tea|Subjects will be asked to consume a Fast Bar with tea.
48316153|NCT01441921|DIETARY_SUPPLEMENT|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
48316154|NCT01441921|OTHER|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
48644631|NCT02349828|DRUG|Acyclovir|
48116093|NCT00718939|DEVICE|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
48116094|NCT04813419|DEVICE|1927nm thulium laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. The left face of subjects were treated with fractional 1927nm thulium laser(Lavieen, korea). Parameters were set as stamp mode, a spot size of 5\*5mm, a pulse time of 1000us, an energy intensity of 3645mJ/cm2 and a repetition of 1-3 times. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
48116095|NCT04813419|DEVICE|2940nm Er:YAG laser|The right face of subjects were treated with fractional 2940nm Er:YAG laser(MCL 31 Asclepion Laser Technologies, Germany), N25 mode. Energy was adjusted from 12 to 27J according to the severity of scarring. All patients received 3 treatment sessions totally at an average interval of 4 to 6 weeks.
48485262|NCT04425889|DIAGNOSTIC_TEST|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
48485263|NCT00676325|PROCEDURE|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
48116096|NCT03932981|DRUG|Temozolomide|Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
47965799|NCT00717197|DRUG|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
47965800|NCT06413563|DIAGNOSTIC_TEST|Complete blood count|"Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker"
47965801|NCT05909150|DRUG|Sodium chloride solution 3,5%|Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
48116097|NCT03062358|BIOLOGICAL|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
48116098|NCT03062358|DRUG|placebo|Normal saline solution administered as an IV infusion Q3W
48116099|NCT03062358|OTHER|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
47965802|NCT05909150|DRUG|Sodium chloride solution 0,9%|Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
48116100|NCT02880241|DRUG|MMV390048|Tablets of 20mg each
48116101|NCT04925765|OTHER|Virtual Reality Biofeedback Session|"The Flowly intervention treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression."
47965803|NCT02927730|OTHER|no interventions|no interventions
47965804|NCT00232609|DEVICE|GameCycle Exercise System|
47965805|NCT01221792|DRUG|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
47965806|NCT01221792|DRUG|Placebo|Non active comparator
47965807|NCT02792881|PROCEDURE|Laparoscopic completion total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
47965808|NCT04837261|DRUG|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
47965809|NCT04837261|DRUG|Flecainide|80 mg/m2/d
47965810|NCT04837261|DRUG|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
47965811|NCT04790422|DIETARY_SUPPLEMENT|Dietary fiber supplement|Dietary fiber
47965812|NCT04790422|DIETARY_SUPPLEMENT|Caseine protein hydrolisate|Dietary supplement
48116102|NCT00681525|DRUG|ABT-335|One ABT-335 135 mg capsule QD for 10 days
48116103|NCT00681525|DRUG|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
48116104|NCT00681525|DRUG|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
48116105|NCT04167163|DRUG|Abaloparatide|18 month ABL treatment
48116106|NCT05452720|DEVICE|Surgical Right Ventricular Outflow Tract Reconstruction|Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)
48316155|NCT05044260|PROCEDURE|Direct sinus lift with titanium reinforced PTFE membrane|Implants will be placed immediately after sinus lifting procedure and maintaining the sinus membrane in position using PTFE titanium reinforced membrane.
48485264|NCT00676325|DEVICE|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
48485265|NCT00676325|PROCEDURE|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
47965813|NCT04790422|DIETARY_SUPPLEMENT|Maltrodextrine|Placebo comparator
47965814|NCT02929667|DRUG|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
47965815|NCT02929667|DRUG|Placebo|Standard 6 weeks titration.
47965816|NCT03589560|DRUG|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
47965817|NCT03589560|DRUG|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
48116107|NCT01719666|PROCEDURE|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
47965818|NCT05492344|OTHER|Personalized ventilation|"Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~* Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~* Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~* Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~* PEEP ≥ 15 cm H2O~* Tidal volume: 4 to 6 mL/kg PBW~* Daily recruitment maneuver"
47965819|NCT05492344|OTHER|Standard care|"Patient who are randomized in the control group will receive standard care~* Tidal volume: 6 mL/kg PBW~* PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~* Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg"
47965820|NCT00040482|DRUG|Cyclophosphamide|
47965821|NCT00040482|DRUG|ATG|
47965822|NCT00040482|DRUG|MESNA|
47965823|NCT00040482|PROCEDURE|Radiation therapy|
47965824|NCT05979558|DRUG|ropivacaine with dexmedetomidine|this group received with ropivacaine with dexmedetomidine
47965825|NCT05979558|DRUG|Ropivacaine with placebo|this group received with ropivacaine with normal saline
47965826|NCT02643680|DEVICE|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
47965827|NCT02643680|DEVICE|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
47965828|NCT00067600|BEHAVIORAL|Diet with increased fruits, vegetables, and calcium|
47965829|NCT00067600|BEHAVIORAL|Increased high impact activity and resistance training|
48116108|NCT01719666|PROCEDURE|conventional surgery|conventional surgery: MPFL reconstruction
47965830|NCT02876211|DRUG|Paricalcitol|Paricalcitol 2 capsules/three times per week
47965831|NCT02876211|DRUG|Epoetin beta|epoetin 1-3 times per week
47965832|NCT02876211|DRUG|Placebo|Placebo 2 capsules/three times per week
47965833|NCT01302756|OTHER|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
47965834|NCT01302756|DIETARY_SUPPLEMENT|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
47965835|NCT00955071|OTHER|Exercise: LVLI|low volume, low intensity
47965836|NCT00955071|OTHER|Exercise: HVLI|high volume, low intensity
47965837|NCT00955071|OTHER|Exercise: LVHI|low volume, high intensity
47965838|NCT04948710|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
47965839|NCT04778930|OTHER|Physical Therapy|"FACE-TO FACE SESSIONS: approximately 90 minutes of Goal-directed training (activities for the activation of the muscles of the trunk, pelvis and lower limbs; and training of activities will be carried out in a functional and meaningful context, aimed at specific functional objectives, according to the interests of each participant and agreed with the participants and their families) and gait training on the treadmill for 20 minutes.~TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation."
47965840|NCT04778930|OTHER|THERAPEUTIC EDUCATION PROGRAM|TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation.
48116109|NCT01059877|DEVICE|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
48116110|NCT01059877|DEVICE|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
48116111|NCT05072171|PROCEDURE|Inguinal hernia repair with dynamic prosthesis|Tissue specimens excised at the above defined postoperative stages were fixed in neutral-buffered 10% formalin and routinely processed to paraffin wax. Sections (4 μm thick) were cut and stored at room temperature until use. Sections were stained with hematoxylin and eosin (H\&E) for histological analysis and Azan trichrome (Bioptica) staining to evaluate muscular tissue in the implant fabric.
48116112|NCT01925469|DRUG|Benzocaine|
48116113|NCT01925469|DRUG|Saline spray|A saline spray will be used in the placebo group
48116114|NCT02750072|PROCEDURE|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
48116115|NCT02750072|PROCEDURE|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
48116116|NCT04481672|DRUG|Magnesium Sulfate|Intravenous infusion of magnesium sulfate prior to intraoperative chemotherapy with cisplatin.
48485266|NCT01465282|DRUG|CT327 0.05%|0.05% CT327 (w/w) ointment
48485267|NCT01465282|DRUG|CT327 0.1%|0.1% CT327 (w/w) ointment
48485268|NCT01465282|DRUG|CT327 0.5%|0.5% CT327 (w/w) ointment
48485269|NCT01465282|DRUG|Placebo|Placebo
48485270|NCT02602834|OTHER|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
48116117|NCT05176106|BEHAVIORAL|CHW Incentives Intervention|The intervention comprises of an incentives package provided to VHTs who are active in the intervention-randomized parishes. It will comprise of items that will motivate them and support their work as VHTs in the community.
48116118|NCT01291615|DRUG|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
48116119|NCT01291615|DRUG|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
48116120|NCT05414786|BIOLOGICAL|eOD-GT8 60mer mRNA Vaccine (100µg)|"* 2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart~* No control group. There is no blinding and no randomization in this open label study"
48116121|NCT06491732|DEVICE|Electrical Impedance Myography|EIM is an impedance-based technology in which an imperceptible, high-, multi-frequency (e.g., 1 kHz to 10 MHz) electrical current is applied across two electrodes; the resulting voltage signals are measured across two sense electrodes
48116122|NCT00988975|PROCEDURE|Insertion of pelvicol graft|Pelvicol graft
48116123|NCT01317719|PROCEDURE|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
48116124|NCT04816487|DRUG|Potassium Iodide or Glutathione|Patient will receive either Glutathione or Potassium iodide
48116125|NCT00192491|BIOLOGICAL|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
48116126|NCT00192491|BIOLOGICAL|FluMist|Nasal sprayer of FluMist
48644632|NCT05174312|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
48116127|NCT00192491|OTHER|Placebo|Nasal Sprayer of Placebo
48116128|NCT03762291|BIOLOGICAL|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
48116129|NCT02238418|DRUG|Cholecalciferol vial (100 000 UI)|"VISIT 1:~Patient \> 60 kg and initial 25OHD serum concentration \< 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration \< 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient \< 20 kg and initial 25OHD serum concentration \< 75 nmol/L: prescription of 1 single vial~A local lab will performed urinary dosage of calciuria and creatininuria:~* at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial~* at days 0, 2 and 4 after other intakes (when applicable)~VISIT 2:~25OHD serum concentration will then be dosed at month 2 after visit 1"
48116130|NCT06488079|OTHER|Summary Label|The Nutri-Score Front-of-Pack nutritional label
48116131|NCT06488079|OTHER|Nutrient-specific label|The NutrInform Battery Front-of-Pack nutritional label
48116132|NCT06488079|OTHER|No label|Conventional food educational flyer
48116133|NCT06279728|DRUG|Datopotamab deruxtecan|6 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)
48116134|NCT06546384|DRUG|Liraglutide|"Treatment with liraglutide, following standard clinical practice as per below schedule:~Week 1: Injected dose of 0,6 mg once daily Week 2: Injected dose of 1,2 mg once daily Week 3: Injected dose of 1,8 mg once daily Week 4: Injected dose of 2,4 mg once daily From week 5 onwards: Injected dose of 3,0 mg once daily"
48116135|NCT06546384|BEHAVIORAL|Weight reduction recommendations (nutritional and exercise)|Participants will receive nutritional and exercise recommendations and 2 telephone consultations
48485271|NCT02602834|OTHER|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
48485272|NCT00646620|DRUG|budesonide/formoterol (Symbicort)|
48644633|NCT05174312|DRUG|Diuretic|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
48644634|NCT04733482|BEHAVIORAL|Cosmetic care|
48116136|NCT04788836|OTHER|Questionnaire (Survey and Food Frequency Questionnaire (FFQ))|Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
48116137|NCT04788836|OTHER|Collection of digital receipts from grocery shopping|"Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation"
48116138|NCT06324240|BIOLOGICAL|Ipilimumab|Given IV
48116139|NCT06324240|BIOLOGICAL|Pembrolizumab|Given IV
48116140|NCT06324240|BIOLOGICAL|Vaccine Therapy|Given TMV vaccine ID
48116141|NCT00661778|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
48116142|NCT00661778|DRUG|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
48116143|NCT00661778|DRUG|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
48116144|NCT01959126|BEHAVIORAL|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
48116145|NCT06198712|DRUG|Etavopivat|Participants will receive oral tablets of etavopivat once daily.
48116146|NCT06674473|DEVICE|With robot assistance|Use a portable isokinetic device
48116147|NCT06674473|BEHAVIORAL|traditional bodyweight rehabilitation|Use traditional bodyweight rehabilitation
48116148|NCT04563156|DIAGNOSTIC_TEST|Lung Function Test|Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
48116149|NCT01723410|BEHAVIORAL|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
48116150|NCT01723410|OTHER|Writing about places, objects|
48116151|NCT03603184|DRUG|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
48116152|NCT03603184|DRUG|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
48116153|NCT03603184|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
48116154|NCT03603184|DRUG|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
48116155|NCT05081570|DEVICE|telecare consultation|Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
48116156|NCT03260647|OTHER|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
48116157|NCT06195891|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48116158|NCT06195891|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48116159|NCT06195891|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48116160|NCT06195891|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT/MRI scan
48116161|NCT06195891|PROCEDURE|Echocardiography|Undergo echocardiography
48116162|NCT06195891|DRUG|Fludarabine|Given IV
48116163|NCT06195891|PROCEDURE|Magnetic Resonance Imaging|Undergo DECT/MRI scan
48116164|NCT06195891|DRUG|Melphalan|Given IV
48116165|NCT06195891|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48116166|NCT06195891|BIOLOGICAL|Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Given IV
48316156|NCT03896880|DIAGNOSTIC_TEST|blood culture|"During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~1. Isolation of microorganisms:~2. Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~1. Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~2. Culture on Brilliance Candida differential agar"
48116167|NCT06195891|DRUG|Tacrolimus|Given tacrolimus
48644635|NCT06686277|OTHER|Gong's Mobilization Technique|The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand.
48644636|NCT06686277|OTHER|Mulligan Mobilization Technique|Mulligan Mobilization Technique
48644637|NCT06623422|BIOLOGICAL|Pembrolizumab|IV Infusion
48644638|NCT06623422|DRUG|Cisplatin|IV infusion
48644639|NCT06623422|DRUG|Carboplatin|IV infusion
48644640|NCT06623422|DRUG|Pemetrexed|IV infusion
48644641|NCT06623422|DRUG|Gemcitabine|IV infusion
48644642|NCT06623422|DRUG|Paclitaxel|IV infusion
48644643|NCT06623422|BIOLOGICAL|V940|IM injection
48644644|NCT06623422|OTHER|Placebo|IM injection
48644645|NCT06622408|OTHER|HypnoVR© virtual reality headset|Adherence to the use of the virtual reality headset will be reported by a percentage of use at each stage of care.
48116168|NCT06195891|DRUG|Thiotepa|Given IV
48644646|NCT06673199|DIETARY_SUPPLEMENT|Washoku diet|The Washoku diet will consist of following the principles of a healthy eating plate, which will be supplemented with elements of the Washoku diet (30g of roasted black soybeans and 5g of wakame). Food products will be given to women on the day of the first meeting. The Washoku diet will be used for 7 days a week for a period of 1 month (4 weeks).
48644647|NCT04999020|DRUG|Ravulizumab|Intravenous dosing will consist of a loading dose followed by maintenance doses administered every 8 weeks (q8w). The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
48644648|NCT04999020|DRUG|Placebo|Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
48644649|NCT04652765|DRUG|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
48644650|NCT04652765|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
48644651|NCT06691243|DRUG|Semaglutide|The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
48116169|NCT06195891|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
48116170|NCT00002919|BIOLOGICAL|filgrastim|
48116171|NCT00002919|DRUG|cisplatin|
48116172|NCT00002919|DRUG|doxorubicin hydrochloride|
48116173|NCT00002919|DRUG|methotrexate|
48116174|NCT00002919|DRUG|vinblastine sulfate|
48116175|NCT00002919|PROCEDURE|conventional surgery|
48116176|NCT05702658|BEHAVIORAL|CAPS|Community Autism Peer Support is a one-to-one autistic-delivered peer support, community-based intervention focused on independent living and participation.
48116177|NCT01699152|DRUG|TG02 citrate|TG02 citrate capsules
48116178|NCT01796782|DRUG|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
48116179|NCT01796782|DRUG|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
48485273|NCT00646620|DRUG|fluticasone/salmeterol (Advair Diskus)|
48316157|NCT03896880|OTHER|Anti fungal susceptibility testing or antibiotic susceptibility testing|isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
48316158|NCT03896880|OTHER|phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)|The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
48485274|NCT00646620|DRUG|albuterol (Ventolin)|
48644652|NCT06691243|DRUG|Placebo|Patients randomized to placebo arm will receive placebo injection every week.
48644653|NCT01232582|DEVICE|Exablate treatment|MR guided Focused Ultrasound treatment
47965841|NCT04749615|DRUG|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
47965842|NCT04749615|DRUG|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
47965843|NCT00794378|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
47965844|NCT00794378|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
47965845|NCT03217630|OTHER|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
48316159|NCT03896880|OTHER|Identification of the isolated organism by multiplex PCR|FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
48485275|NCT01025674|BEHAVIORAL|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
48644654|NCT04417621|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
48644655|NCT04417621|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
48644656|NCT04417621|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
48644657|NCT04417621|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
48644658|NCT02771145|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
48644659|NCT02771145|DEVICE|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
47965846|NCT00048321|DRUG|ISIS 104838|
47965847|NCT05751460|OTHER|Straight leg raise|Diagnostic test, tool for \*g\*
47965848|NCT06443944|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
47965849|NCT06443944|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
47965850|NCT06081868|BEHAVIORAL|Use of toothbrush/toothpaste/fluoride varnish|Children receive information about the use of toothbrush/toothpaste/fluoride varnish.
48316160|NCT02605447|DRUG|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
48316161|NCT02605447|DEVICE|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
48316162|NCT00666133|DEVICE|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
48485276|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
48485277|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
48485278|NCT00062751|DRUG|Letrozole|Letrozole 2.5 mg daily
48485279|NCT06036888|OTHER|questionaries completion|Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
48485280|NCT02217631|DRUG|BI 653048 BS H3PO4|
48485281|NCT02217631|DRUG|Prednisolone low dose|
48485282|NCT02217631|DRUG|Prednisolone high dose|
48485283|NCT02217631|DRUG|Placebo|
48644660|NCT02771145|DEVICE|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
47965851|NCT06081868|BEHAVIORAL|Education on nutrition/oral hygiene|Children receive education on nutrition/oral hygiene.
47965852|NCT03692468|BEHAVIORAL|Psychotherapy|Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
47965853|NCT00296881|DEVICE|PERIOWAVE|
47965854|NCT00197639|DRUG|Ritonavir-boosted indinavir|
47965855|NCT03355716|DRUG|bupivacaine|Bupivacaine 25 ml (0.25%)
47965856|NCT03355716|DRUG|morphine|Morphine (3.0 mg)
47965857|NCT03355716|DRUG|fentanyl|fentanyl (30.0 Mc)
48485284|NCT06374966|DRUG|Zonisamide|This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication
48644661|NCT06685991|DRUG|Dexamethasone|Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
48116180|NCT03881449|COMBINATION_PRODUCT|ABILIFY MYCITE|Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
48116181|NCT03946046|PROCEDURE|Clinical targeting|The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
48116182|NCT03946046|PROCEDURE|Ultrasonography targeting|The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
48116183|NCT03621826|OTHER|Questionnaire/Interview|A convenience sample of patients/parents and stakeholders will be asked to participate in a survey and/or interview to evaluate barriers to care in sickle cell.
48116184|NCT05814328|OTHER|Transitional Care|Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
48116185|NCT03703856|DRUG|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
48116186|NCT03703856|DRUG|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 32 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
48116187|NCT03085498|OTHER|No intervention|no intervention
48644662|NCT06606158|OTHER|Exercises program|Strength, mobility, and balance exercises described within the standardized Physiotherapy plan.
48644663|NCT06606158|OTHER|App exercises program|A strength, mobility, and balance exercise program delivered through a mobile app.
48644664|NCT06057337|BEHAVIORAL|"Families with Pride (Familias con Orgullo)"|Families with Pride (Familias con Orgullo) aims to prevent the co-occurring epidemics of drug use and depression in Hispanic sexual minority youth. It focuses on improving parent support for the adolescent, parent acceptance of the adolescent, family functioning (e.g., communication), and decreasing stress and sexual minority stress. The program consists of 11 weekly, in-person sessions: 7 parent group sessions, 3 concurrent adolescent group sessions, both lasting two hours, 4 family sessions lasting 1 hour in either Spanish or English, depending on participant language preference. In the parent group sessions, parents come together to foster social support, family functioning, and increase parental support and acceptance for the adolescent. In the adolescent sessions, adolescents build skills in confronting and managing stressors related to being a sexual minority.
48644665|NCT06682637|DRUG|Melflufen|Pepaxti 20 mg powder for concentrate for solution for infusion
48644666|NCT06682637|DRUG|Dexamethasone|SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution
48644667|NCT06017115|DEVICE|Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)|Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
48644668|NCT06689943|DRUG|Tylenol|Tylenol for children
48644669|NCT03023683|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
47965858|NCT03355716|DRUG|Ketamine:|ketamine (0.5 mg/kg).
47965859|NCT03633656|DEVICE|Model predictive control|Computer aided dose selection for the treatment of iron deficient anemia.
47965860|NCT03633656|DEVICE|Model Predictive Control of Iron Dosing|Model Predictive Control of Iron Dosing
47965861|NCT00896246|DRUG|Klean-Prep®|Four litres of solution administered orally as a divided dose.
47965862|NCT00896246|DRUG|Moviprep®|Two litres of solution administered orally as a divided dose
47965863|NCT00636558|DRUG|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
47965864|NCT01306903|DEVICE|MECC|Minimized extracorporeal circulation
47965865|NCT01306903|DEVICE|MOPS|Modified and optimized perfusion system Frankfurt
47965866|NCT01306903|DEVICE|Super MOPS|Super modified and optimized perfusion system Frankfurt
47965867|NCT02054260|DRUG|Surgicel|
47965868|NCT05698797|OTHER|Hip strengthening exercises|Hip abductor and external rotator strengthening exercises were performed for 4 weeks.
47965869|NCT05698797|OTHER|Proprioceptive training|Proprioceptive training consisted of eight exercises was performed for 4 weeks.
47965870|NCT05698797|OTHER|Conventional physical therapy|Conventional physical therapy included interferential therapy and two types of knee-strengthening exercises.
47965871|NCT05775874|DRUG|AZD4547|Initiation dose: 80mg BID,po.
47965872|NCT05775874|DRUG|Tislelizumab|Tislelizumab:200mg Q3W
48316163|NCT04569331|PROCEDURE|Stimulation of efferent loop|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery."
48316164|NCT04569331|PROCEDURE|Rehabilitation pelvic floor|3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
48316165|NCT05770050|OTHER|No intervention|No intervention
48644670|NCT06687863|OTHER|Exercise training|Includes aerobic exercise, strength training, streching
48644671|NCT06686251|DEVICE|App LuAna|Inclusion of chest x-ray images in the LuAna app to receive feedback on lung findings.
48644672|NCT02567032|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
47965873|NCT03638297|DRUG|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
47965874|NCT05797675|PROCEDURE|prf + osseodensification|prf+ osseodensification in close sinus lift
47965875|NCT02642328|OTHER|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
47965876|NCT02642328|OTHER|Control|Continuous aerobic exercise at 65% of VO2Max
47965877|NCT04243798|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark)."
47965878|NCT04243798|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
47965879|NCT02197130|DRUG|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
47965880|NCT02197130|DRUG|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
47965881|NCT02197130|OTHER|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
47965882|NCT00283400|DRUG|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
48116188|NCT03082846|RADIATION|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
48116189|NCT03082846|DRUG|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
48116190|NCT06676501|PROCEDURE|ExAblate|Transcranial focused ultrasound thalamotomy
48644673|NCT02567032|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
48644674|NCT04015141|DRUG|Perampanel Oral Suspension|Perampanel oral suspension.
48644675|NCT04015141|DRUG|Perampanel Tablet|Perampanel tablet.
48644676|NCT06691438|DEVICE|prostate biopsy|prostate biopsies with virtual reality hypnosis headset
48644677|NCT06632418|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
48644678|NCT06597942|DEVICE|TMS|rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates
48644679|NCT06597942|DEVICE|Transcranial Magnetic Stimulation Sham|Sham coil placed in same location and set with same parameters as active treatment coil. However, this device will not output active treatment and scalp electrodes will mimic the sensation of rTMS for the participant.
48644680|NCT06687772|DRUG|Thiotepa|Thiotepa will be given intravenously twice daily on Days -5 and -4 over 120 minutes at a dose of 5 mg/kg.
48116191|NCT05470517|DRUG|Ceftriaxone|"Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed."
48116192|NCT05470517|PROCEDURE|Intra-peritoneal Fluid Aspiration|Intra-operative aspiration of intra-peritoneal fluid after successful appendectomy.
48116193|NCT05086159|BEHAVIORAL|Pain Neuroscience Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1: the nervous system is like an alarm to protect.~Session 2: common ways the nervous system becomes sensitive.~Session 3: importance of gradual conditioning and neuroplasticity.~Session 4: common ways to decrease nervous system sensitivity."
48116194|NCT05086159|BEHAVIORAL|Exercise|"The exercise protocol for each group will be identical and modeled after the Back to Fitness program. This program will consist of a 5-10-minute cardiovascular warm-up of walking in place or riding an exercise bike. Next is a 15-minute circuit consisting of 10 different general exercises for 1-minute each. Finally, a 5-minute cool down will consist of light stretching and trunk range of motion exercises. Each exercise will be tailored as easy, medium, or hard depending on the individual patient's tolerance. This program has been shown to be equally as effective as motor control exercises for long-term outcomes in patients with non-specific LBP."
48316166|NCT06349733|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
48485285|NCT03071328|DRUG|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
48644681|NCT06687772|DRUG|Carmustine|Carmustine will be given intravenously on Day -6 over 120 minutes at a dose of 400 mg/m\^2.
48644682|NCT06687772|PROCEDURE|Autologous Stem Cell Transplant|Infusion of autologous peripheral blood stem cells on Day 0.
48644683|NCT06687772|DRUG|Anthracycline-based induction chemotherapy|Standard of care, not dictated by protocol.
48644684|NCT01003964|DRUG|IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
48644685|NCT01003964|DRUG|GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
47965883|NCT05802511|DEVICE|Exablate treatment|Exablate treatment for Neuropathic Pain
47965884|NCT00905411|BEHAVIORAL|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
47965885|NCT00182286|BEHAVIORAL|Assessment of continuity of care from the patient perspective|
47965886|NCT00182286|BEHAVIORAL|Relationship between continuity of care, patient outcomes, and costs|
47965887|NCT01696825|DRUG|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
47965888|NCT01696825|DRUG|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
47965889|NCT01696825|DRUG|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
47965890|NCT06354400|OTHER|Core stabilization training|Isometric exercises of the abdominal muscles in the supine, prone, and squatting positions; isotonic exercises in the supine, prone, squatting, and side-lying positions; isotonic exercises in coordination with the extremity movements in the supine, prone, and crawling positions; and trunk rotation exercises in the sitting position will be performed. The Swiss ball will be used for dynamic exercises. It will include isometric and isotonic exercises of the abdominal muscles. Exercises will start with 3 sets of 20 repetitions, gradually increase in intensity on static and dynamic surfaces, and progress towards difficulty. Each exercise will be performed in coordination with breathing control. Breathing control will be coordinated with every exercise.
47965891|NCT00820560|DRUG|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
47965892|NCT02956421|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
47965893|NCT02956421|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
47965894|NCT02849041|DEVICE|medical imaging|Low-dose CT-scanner
47965895|NCT02849041|BIOLOGICAL|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
47965896|NCT02849041|PROCEDURE|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
47965897|NCT05206578|DRUG|AGT2, AGZ|Tablet, q.d.
47965898|NCT05206578|DRUG|AGT2|Tablet, q.d.
48644686|NCT06683248|OTHER|Investigate sleep deprivation|"Sleep deprivation~Devices used:~Dreem band for EEG Actiheart Tobii Eye tracker Blood glucose monitor Blood pressure cuff Mira fertility tracker Galvanic skin response K5: wearable metabolic system Fitbit: wearable technology Withings sleep analyzer Body composition monitor"
48116195|NCT05086159|BEHAVIORAL|Traditional Education|"Weekly education sessions lasting approximately 30 minutes each, once a week for four weeks.~Session 1 will include a basic overview of the anatomy of the spine.~Session 2 will discuss an overview of stress symptoms to include hypervigilance, avoidance, and re-experiencing.~Session 3 will cover common recommendations delivered in stress education: the do's and don'ts of stress management.~Session 4: review and mindfulness."
48644687|NCT06686225|OTHER|Bowen's technique.|"This group will receive 20 mint per session for 6 weeks of bowen's technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 20 mints~* Type: Bowen's technique"
48644688|NCT06686225|OTHER|Mulligan bent leg raise technique|"This group will receive 15 mints per session for 6 weeks of mulligan's bent leg raise technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 15 mints~* Type: Mulligan bent leg raise technique"
48644689|NCT06627595|DRUG|Immunotherapy|Patients will be treated in accordance with the guidelines for melanoma treatment.
47965899|NCT05206578|DRUG|AGT4, AGZ|Tablet, q.d.
47965900|NCT05206578|DRUG|AGT4|Tablet, q.d.
47965901|NCT01482845|DRUG|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
47965902|NCT01482845|DRUG|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
47965903|NCT06180772|BEHAVIORAL|FIT FIRST|High intensity sports drills and games
47965904|NCT04974697|DEVICE|JJVC Investigational Multifocal Toric Contact Lens|TEST
47965905|NCT02644135|DRUG|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
47965906|NCT02644135|DRUG|Halo Placebo|Three sprays per use, total = 9 sprays per day
47965907|NCT05473910|DRUG|SOC + TSC-100|HA-1 positive
47965908|NCT05473910|DRUG|SOC + TSC-101|HA-2 positive or HA-1 negative
47965909|NCT05473910|OTHER|Control|SOC alone
47965910|NCT03045315|OTHER|IVF Procedure|
47965911|NCT02956239|PROCEDURE|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
47965912|NCT02956239|PROCEDURE|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
47965913|NCT02956239|PROCEDURE|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
47965914|NCT04343963|DRUG|Pyridostigmine Bromide|One 60mg tablet P.O. once per day for 14 days
47965915|NCT04343963|DRUG|Placebo|One tablet P.O. once per day for 14 days
48116196|NCT02993588|DRUG|Melatonin|Melatonin 6 mg tablet once daily
48116197|NCT02993588|OTHER|Placebo|one tablet once daily
47965916|NCT04524897|DRUG|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
47965917|NCT00764283|DEVICE|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
47965918|NCT00764283|DEVICE|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
47965919|NCT00764283|DEVICE|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
47965920|NCT01197261|DRUG|Oxycodone naloxone prolonged release tablets|2 tablets/ day
47965921|NCT01197261|DRUG|Placebo tablets|2 tablets/ day
48485286|NCT04299659|DIAGNOSTIC_TEST|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
48485287|NCT00270049|DRUG|epoetin alfa|
47965922|NCT03855969|PROCEDURE|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
47965923|NCT04177797|DRUG|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
47965924|NCT01007084|DRUG|Propranolol|40 mg
47965925|NCT01007084|DRUG|Propranolol ER|120 mg twice per day
47965926|NCT01007084|DRUG|Sugar pills|sugar pill
47965927|NCT03879278|DRUG|NPT189|NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
48485288|NCT05367414|OTHER|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
48485289|NCT05367414|OTHER|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
47965928|NCT05745571|OTHER|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
47965929|NCT00844896|BEHAVIORAL|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
47965930|NCT00844896|BEHAVIORAL|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
47965931|NCT02186990|DRUG|propofol|2,5 mg/kg
47965932|NCT02186990|DRUG|etomidate|0,3 mg/kg
48644690|NCT06689332|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is performed by a geriatrician and a geriatric nurse. CGA in this study includes: Assessment of coexisting diseases and treatments. Review of medications and adjustments as needed. Assessment of symptoms and health related issues including screening for depression, dementia, delirium, nutritional problems, falls, polypharmacy and fatigue. Objective examination including blood tests and electrocardiogram. Assessment of activities of daily living and instrumental activities of daily living through standardized questionnaires. Assessment of domestic conditions, including need for assistance from community-based health care services. Assessment of physical function through history and physical tests. Based on the CGA findings, the geriatrician will initiate relevant interventions (including investigations or treatments) and follow-up as required.
47965933|NCT02186990|DRUG|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
47965934|NCT02267083|DRUG|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
47965935|NCT04109183|DRUG|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
47965936|NCT06495827|OTHER|No different intenvention|No different intenvention
47965937|NCT06556316|BEHAVIORAL|Cognitive Intervention with the Categorization Program|Cognitive intervention delivered individually. This is a hierarchical cognitive rehabilitation program
47965938|NCT06556316|BEHAVIORAL|Social Cognitive Communication Program|An 11 week group intervention targeting social and cognitive-communication abilities
47965939|NCT06556316|DEVICE|Non-Invasive Brain Stimulation with tDCS|20 minute tDCS intervention as a non-invasive neuromodulation treatment
47965940|NCT06505512|DIAGNOSTIC_TEST|No intervention|No intervention
47965941|NCT01063452|DEVICE|Truvalve|Atkinson Product Design urinary slide valve
47965942|NCT01063452|OTHER|Control (catheter drainage bag)|urinary catheter drainage bag
47965943|NCT00171353|DRUG|valsartan|
47965944|NCT04427566|RADIATION|Radiation therapy|Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
47965945|NCT00691860|DEVICE|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
47965946|NCT00691860|PROCEDURE|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
47965947|NCT01786083|BEHAVIORAL|Application of Problem Solving Technique|
48485290|NCT02984774|PROCEDURE|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
48485291|NCT02984774|PROCEDURE|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
48644691|NCT06689813|DIETARY_SUPPLEMENT|Vitamin D tablets|Vitamin D supplements is thought to reduce the severity of urinary incontinence.Vitamin D supplements were given to Group A
48644692|NCT06689813|OTHER|Ispaghula husk|Ispaghula husk tablets were given to Group B participants
48644693|NCT05421858|DRUG|Fosmanogepix|IV infusion
48644694|NCT05421858|DRUG|Fosmanogepix|Oral tablet
48644695|NCT05421858|DRUG|Caspofungin|IV infusion
48644696|NCT05421858|DRUG|Fluconazole|Fluconazole oral capsule
48644697|NCT05421858|DRUG|Placebo|Matching placebo for caspofungin (IV infusion)
48644698|NCT05421858|DRUG|Placebo|Matching placebo for fluconazole (oral capsule)
48644699|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (IV infusion)
48644700|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (oral tablet)
48644701|NCT03193437|DRUG|Open Label Selinexor|Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
48644702|NCT06608277|PROCEDURE|Group A active comparator|Group A placebo comparator. Stellate Ganglion Block plus placebo (.9 normal saline) infusion
48644703|NCT06608277|DRUG|Group B active comparator|Active Comparator: Group B = Sham Stellate Ganglion Block plus ketamine infusion
47965948|NCT05124314|DRUG|Mifepristone, Oral, 200 Mg|Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg
47965949|NCT05124314|DRUG|Misoprostol Pill|Regular treatment with vaginal Misoprostol 800 mcg
48116198|NCT00107796|DRUG|Modafinil|
48116199|NCT02308618|OTHER|Traditional Immobilization|"After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed~The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises"
48116200|NCT02308618|OTHER|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
48316167|NCT04941352|BEHAVIORAL|6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.|6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
48316168|NCT01149642|DIETARY_SUPPLEMENT|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
48316169|NCT01149642|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
48485292|NCT02984774|PROCEDURE|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
48485293|NCT02984774|PROCEDURE|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
47965950|NCT05043129|BIOLOGICAL|Biological/Vaccine: SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
48485294|NCT02334865|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
48485295|NCT02334865|OTHER|Laboratory Biomarker Analysis|Correlative studies
48485296|NCT02334865|DRUG|Lenalidomide|Given PO
48485297|NCT02334865|BIOLOGICAL|Sargramostim|Given SC
48485298|NCT02334865|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
48485299|NCT01155778|BIOLOGICAL|Recombinant human heparan N-sulfatase (rhHNS)|
48485300|NCT00971737|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
48485301|NCT00971737|BIOLOGICAL|trastuzumab|Given IV
48485302|NCT00971737|DRUG|cyclophosphamide|Given IV
48485303|NCT05336305|DIETARY_SUPPLEMENT|Polydextrose|Administration of 3g polydextrose per day, for 2 months
48485304|NCT01254682|DEVICE|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
48485305|NCT01254682|PROCEDURE|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
47965951|NCT04922775|PROCEDURE|conventional taping|Participants will accept conventional taping before muscle fatigue exercise.
48485306|NCT03893734|DRUG|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
48485307|NCT03893734|DRUG|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
48485308|NCT02546349|DRUG|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
47965952|NCT04922775|PROCEDURE|Chinese medicine technique taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
48116201|NCT05604885|DRUG|AP1189, 60 mg|AP1189 tablets for oral use
47965953|NCT04575116|DRUG|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
47965954|NCT04575116|DRUG|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
47965955|NCT02192138|PROCEDURE|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
47965956|NCT02192138|DEVICE|Pleural catheter|
47965957|NCT02192138|DEVICE|Pleural manometer|
47965958|NCT04344509|OTHER|Bacterial species isolated|in the respiratory specimen
47965959|NCT02547844|DRUG|efavirenz + emtricitabina + tenofovir|
47965960|NCT02547844|DRUG|rilpivirina + emtricitabina + tenofovir|
48116202|NCT05604885|DRUG|AP1189, 80 mg|AP1189 tablets for oral use
48116203|NCT05604885|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
47965961|NCT00404261|DRUG|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
48116204|NCT05604885|DRUG|Placebo|Matching placebo tablets for oral use
48116205|NCT06676683|DRUG|Usage of Statin in diabetic patients|The use of statin in diabetic patients not known to have Atherosclerotic cardiovascular disease in a low income community
48116206|NCT06457178|BEHAVIORAL|Acceptance and Commitment Therapy-Based Intervention for Oncology Patients|An intervention program was prepared for oncology patients aiming to reduce psychological distress and increase participation in normal life.
48116207|NCT06457178|BEHAVIORAL|Psychoeducation for Oncology Patients|A program was prepared to support oncology patients in physical and psychological symptom management.
48116208|NCT04484701|DRUG|68Ga-PSMA-11|PET/CT scan with radiotracer 68Ga-PSMA-11
48316170|NCT01605591|PROCEDURE|the DLT bending to the right|bending the bronchial lumen of DLT 60\~90 degrees in the same side with the tracheal lumen
48485309|NCT02059720|PROCEDURE|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
48485310|NCT03883282|OTHER|Not Provided|Not Provided
48485311|NCT00602134|DRUG|6-Mercaptopurine|
48644704|NCT06608277|COMBINATION_PRODUCT|Group C Experimental|Group C experimental Stellate Ganglion Block plus ketamine infusion
48644705|NCT06608277|OTHER|Group D Placebo Comparator|Group D Placebo Comparator: Sham Stellate Ganglion Block plus placebo normal saline
48644706|NCT06627478|DRUG|NKF-INS(G)|Single subcutaneous dose of 0.5 IU/kg administered over three periods
48644707|NCT06627478|DRUG|US-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
48644708|NCT06627478|DRUG|EU-Lantus®|Single subcutaneous dose of 0.5 IU/kg administered over three periods
48644709|NCT05900830|OTHER|play therapy|A combined program based on physical and occupational therapy techniques within a play context
48644710|NCT05900830|OTHER|common educational methods|the child will receive his education in a passive manner
47965962|NCT03616600|OTHER|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
47965963|NCT06015685|OTHER|Embedded Clinic|Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
47965964|NCT06015685|OTHER|Routine Care|Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population \[patients who receive routine care (i.e., referral to subspecialty care)\], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
47965965|NCT03197597|OTHER|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
47965966|NCT00158834|DRUG|Salmeterol/Fluticasone propionate combination product|
47965967|NCT00158834|DRUG|Fluticasone propionate|
47965968|NCT00008203|BIOLOGICAL|aldesleukin|
47965969|NCT00008203|BIOLOGICAL|recombinant interferon gamma|
47965970|NCT00008203|DRUG|carboplatin|
47965971|NCT00008203|DRUG|cyclophosphamide|
47965972|NCT00008203|DRUG|cyclosporine|
47965973|NCT00008203|DRUG|thiotepa|
47965974|NCT00008203|PROCEDURE|autologous bone marrow transplantation|
47965975|NCT00008203|PROCEDURE|peripheral blood stem cell transplantation|
47965976|NCT02216734|BEHAVIORAL|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
48116209|NCT02683811|BEHAVIORAL|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
48116210|NCT03870607|DIETARY_SUPPLEMENT|prebiotics in combination with probiotics|Administration of prebiotics in combination with probiotics before the start of Ch-RT
48116211|NCT02323529|DRUG|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
48116212|NCT00000338|DRUG|Lisuride|
48116213|NCT03461575|DRUG|HU007|cyclosporine 0.02%, trehalose 3%
48116214|NCT03461575|DRUG|Restasis|cyclosporine 0.05%
48116215|NCT03461575|DRUG|Moisview|trehalose 3%
48316171|NCT01605591|PROCEDURE|the DLT bending to the left|bending the bronchial lumen of DLT 60\~90 degree opposed to the tracheal lumen
48316172|NCT02517593|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40%).
48316173|NCT00578799|DIETARY_SUPPLEMENT|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
48316174|NCT00578799|DIETARY_SUPPLEMENT|placebo|placebo capsules (potato starch
48316175|NCT01260376|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
48316176|NCT04593693|DEVICE|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
48316177|NCT00701727|DRUG|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
48316178|NCT00701727|DRUG|Placebo|1 tablet, once a day, for 7 weeks
48485312|NCT00537108|BEHAVIORAL|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support \& skills-building for school continuation, higher education, and job readiness.
48644711|NCT06686732|OTHER|Multimodal physiotherapy|Experimental group included cold pack over lateral epicondyle. Passive stretching exercises in trapezius and levator scapulae and upper ECRB,ECRL,ECU,Extensor Digitorum, Extensor Digiti Minimi. Eccentric exercise of the extensor muscles associated with mobilization with movement. Neuromusclar Rehabilitation Excersise. In the region of origin of the tendons of the extensor muscles of the wrist and fingers for 2 min and inhibition of points of tension in the belly of the extensor region. Early mobilization with movement with the wrist in extension. Lateral sustained glide will be give at humeroradial joint during movement.
48485313|NCT03581513|PROCEDURE|Deferred or Immediate Stent Implantation|IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
48644712|NCT06686732|OTHER|Conventional physiotherapy|Control group included Cold pack for 10 mins on the lateral epicondylitis, Extensor carpi radialis brevis stretching (hold for 15 seconds x 4 reps) Active ROM of wrist flexion and extension (10 reps x 3 sets) Active ROM of elbow flexion, extension, supination and pronation (10 reps x 3 sets) . Manually resisting wrist extensors (10 second hold x 5 reps x 3 sets) 4 sets of Maitland elbow joint mobilization with 1 min of rest between sets. Baseline Dynamometer for grip strength and VAS for pain. These pre and post intervention values were mentioned in questionnaire. The participants were administered with the protocol and data was collected again immediately after the interventions without any delay.
48644713|NCT05039632|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally
48644714|NCT05039632|RADIATION|Radiation Therapy|Undergo Abscopal radiation therapy
47965977|NCT03129750|DEVICE|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
47965978|NCT05389397|BEHAVIORAL|Outreach|Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
47965979|NCT05747209|OTHER|Observation of Exercise Program Adherence|Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
47965980|NCT01957722|PROCEDURE|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
48316179|NCT04551573|DRUG|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
48316180|NCT04551573|DRUG|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
48316181|NCT02477228|PROCEDURE|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
48316182|NCT02477228|PROCEDURE|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
48316183|NCT00004816|DRUG|monoclonal antibody M-T412|
47965981|NCT01957722|BIOLOGICAL|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
47965982|NCT04568070|DIAGNOSTIC_TEST|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
47965983|NCT04568070|DIAGNOSTIC_TEST|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
48316184|NCT04729491|DRUG|Dutasteride 0.5 mg|Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
48316185|NCT04729491|DRUG|Azithromycin|Azithromycin 500mg/day for 05 days
48316186|NCT04729491|DRUG|Nitazoxanide|500mg twice daily for 06 days
48316187|NCT04729491|DRUG|Placebo|Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
48316188|NCT04767633|DRUG|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
48316189|NCT00002833|BIOLOGICAL|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
48116216|NCT06199323|BEHAVIORAL|Routine rehabilitation training|"1. Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~2. Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~3. Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~4. Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
48316190|NCT00002833|DRUG|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
48316191|NCT00002833|DRUG|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
48316192|NCT00002833|DRUG|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
48316193|NCT00002833|DRUG|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
48316194|NCT00002833|DRUG|Idarubicin|IV Days -6, -5 and -4.
48316195|NCT00002833|DRUG|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
48316196|NCT00002833|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
48485314|NCT01005706|DRUG|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
48485315|NCT01005706|DRUG|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
48485316|NCT01900496|BIOLOGICAL|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
48485317|NCT01900496|BIOLOGICAL|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m\^2 IV. Additional doses are given at three and six months post week 27.
48485318|NCT05887349|OTHER|Neck Stabilization Exercise|"1. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
48485319|NCT05887349|OTHER|Neck Stabilization Exercise + Rocabado Exercises|"2. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~1. Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~2. When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~3. When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
48644715|NCT05039632|RADIATION|Radiation Therapy|Undergo RadScopal radiation therapy
48644716|NCT02527083|DRUG|Propofol|
48644717|NCT02527083|DRUG|Sevoflurane|
48644718|NCT02527083|DRUG|Remifentanil|
48644719|NCT02527083|DRUG|Ketamine|
48644720|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET|Prostate specific membrane antigen positron emission tomography
48644721|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/MRI|Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging
48644722|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/CT|Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
48644723|NCT02773823|BEHAVIORAL|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
48644724|NCT06687655|DIETARY_SUPPLEMENT|Ketone-IQ|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Ketone-IQ (1,3 Butanediol) intervention.
48644725|NCT06687655|DIETARY_SUPPLEMENT|Placebo|This is a crossover study where participants will ingest either Ketone-IQ for 2 nights, or placebo for 2 nights before sleep. This is the Placebo intervention.
48644726|NCT06469281|OTHER|27T51|Intravenous (IV) infusion
48316197|NCT04513834|OTHER|GP will receive the educational outreach visit by a DAM (healthcare representative).|GP will receive the educational outreach visit by a DAM (healthcare representative).
48316198|NCT04513834|OTHER|Patient education material on PPI deprescribing will be sent to the patients|Patient education material on PPI deprescribing will be sent to the patients
48316199|NCT00804258|DRUG|intraperitoneal chemotherapy|
48316200|NCT00804258|OTHER|educational intervention|
48316201|NCT00804258|OTHER|medical chart review|
48316202|NCT00804258|OTHER|questionnaire administration|
48316203|NCT00804258|PROCEDURE|assessment of therapy complications|
48316204|NCT00804258|PROCEDURE|end-of-life treatment/management|
48316205|NCT00804258|PROCEDURE|psychosocial assessment and care|
48316206|NCT00804258|PROCEDURE|quality-of-life assessment|
48316207|NCT04748406|DEVICE|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
48316208|NCT04748406|OTHER|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
48116217|NCT06199323|BEHAVIORAL|Swallowing rehabilitation training|"1. Swallowing-related organ training: including movement training of lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises of vocal cord closure, laryngeal lifting and pharyngeal muscle training. 5-15 minutes/time, 1-2 times/day, 5-7 days/week.~2. Sensory stimulation training: With the self-made popsicle, medical staff slowly and gently stimulated the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface and sublingual area repeatedly. 5-25 minutes/time, 1-3 times/day, 3-7 days/week.~3. Direct training: When the patient's swallowing function improves to a certain extent of which the safety of oral intake can be basically ensured, oral feeding training (direct training) can be attempted gradually.~4. Mendelsohn maneuver: During the Mendelsohn maneuver, the patient consciously prolonged the duration of the muscle contraction in the throat during swallowing.15-30 minutes/time, once per day, 5 days/week."
48116218|NCT06199323|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
48116219|NCT02748954|BEHAVIORAL|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
48644727|NCT06469281|DRUG|Cemiplimab|IV infusion
48644728|NCT06469281|DRUG|Bevacizumab|IV Infusion
48644729|NCT04087876|DRUG|derazantinib|derazantinib will be administered orally
48644730|NCT02867423|DEVICE|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
48644731|NCT06691633|DRUG|Preoperative Methadone|patient receives a one-time preoperative dose of 10 mg of methadone
48644732|NCT06691633|DRUG|Preoperative Oxycodone|patient receives a one-time preoperative dose of 10 mg of oral oxycodone
48644733|NCT06355284|OTHER|Functional MRI|While in the MRI scanner, participants will complete several classic experimental tasks designed to capture brain activity related to core cognitive features of overcontrol that impact social functioning. Tasks include the Stop Signal Task (error monitoring), Delay Discounting Task (valuation, impulsivity), and Reversal Learning (cognitive flexibility).
48116220|NCT02748954|BEHAVIORAL|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
48116221|NCT02748954|BEHAVIORAL|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
48644734|NCT06685380|OTHER|Not applicable- observational study|For observational studies, participants are not assigned an intervention as part of the study
48644735|NCT00860431|DRUG|AST-120|6g/day (3 times a day)
48644736|NCT05250557|DIAGNOSTIC_TEST|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
48644737|NCT03280615|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
48644738|NCT03280615|DIETARY_SUPPLEMENT|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
48644739|NCT06678503|OTHER|balance exercise|Balance exercises are physical activities designed to improve stability, coordination, and posture by challenging the body's ability to maintain an upright position. These exercises target the muscles and systems involved in balance, particularly the core, legs, and the sensory systems (like vision and proprioception).
47965984|NCT04568070|DIAGNOSTIC_TEST|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
47965985|NCT04568070|DIAGNOSTIC_TEST|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
47965986|NCT04109456|DRUG|IN10018|100 mg or 50mg, orally once daily continuously;
47965987|NCT04109456|DRUG|Cobimetinib|60mg , orally once daily from day 1 to day 21 in a 28-day cycle
47965988|NCT04109456|BIOLOGICAL|Atezolizumab|biweekly 840 mg dose will be used in this study starting from Cycle 2.
47965989|NCT01962896|DRUG|Erlotinib|
47965990|NCT01962896|DRUG|Sirolimus|
47965991|NCT03223142|DEVICE|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
47965992|NCT02200562|DRUG|ipilimumab and dabrafenib|
47965993|NCT00036712|PROCEDURE|management of therapy complications|
47965994|NCT00036712|PROCEDURE|pain therapy|
47965995|NCT01866293|DRUG|Cabozantinib (XL184)|
47965996|NCT05342194|DRUG|Toripalimab|240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
47965997|NCT05342194|DRUG|Lenvatinib mesylate capsules|8 mg orally (po) once daily (QD)
47965998|NCT05342194|DRUG|Placebo IV|Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
47965999|NCT05342194|DRUG|Oral placebo|Oral placebo po QD continuously
48644740|NCT06678503|OTHER|Core stability exercises|"Core stability exercises are physical activities designed to improve the strength, endurance, and coordination of the muscles that support and stabilize the spine, pelvis, and torso. These exercises specifically target the muscles of the abdomen, lower back, hips, and pelvis, collectively referred to as the core. The goal is to enhance overall posture, prevent injury, and improve performance in daily activities or sports by increasing the body's ability to stabilize itself during movement."
48644741|NCT06604442|DRUG|Flotufolastat (18F)|Positron emission tomography (PET)
47966000|NCT05342194|DRUG|Oxaliplatin for injection|85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
48644742|NCT06604442|DRUG|piflufolastat (18F)|Positron emission tomography (PET)
48316209|NCT04748406|OTHER|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
48316210|NCT04748406|OTHER|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
48316211|NCT05202093|DEVICE|Oclean electric toothbrush A|Use Oclean electric toothbrush to brush teeth twice a day for 8 weeks
48316212|NCT05202093|DEVICE|Oral B manual toothbrush|Use Oral B manual toothbrush to brush teeth twice a day for 8 weeks
48485320|NCT03623464|OTHER|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
48485321|NCT03623464|OTHER|Standard of care|Post-operative standard of care information
48485322|NCT00619359|DRUG|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
48485323|NCT00619359|DRUG|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
48485324|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
48485325|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
48485326|NCT00619359|DRUG|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
48485327|NCT04808882|DRUG|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
48485328|NCT04808882|DRUG|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
48644743|NCT05094037|DEVICE|Removable cam walker boot|Standard of care device given to diabetic foot ulcer patients.
48644744|NCT05094037|OTHER|Counseling|Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
48644745|NCT06668025|OTHER|MxA tests|Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing. MxA measurements on Days 4, 7, and 10 will be performed only for patients still hospitalized on antiviral thearpy or at the attending physician's discretion.
48644746|NCT06668025|OTHER|MxA feedback|MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.
48644747|NCT06668025|OTHER|Follow-up at Day 30|A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.
48644748|NCT06687811|OTHER|preoperative carbohydrate loading|Patients receive 200 ml drink containing Maltodextrin 12.5%, 2 hours prior to surgery
48644749|NCT06687811|OTHER|Placebo|Patients receive 200 ml regular drinking water with zero-calorie sweetener, 2 hours prior to surgery
47966001|NCT05342194|DRUG|Gemcitabine hydrochloride|1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
47966002|NCT05342194|DRUG|Cisplatin|25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
47966003|NCT04452240|DEVICE|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
48316213|NCT05202093|DEVICE|Oclean electric toothbrush B|Use Oclean electric toothbrush B to brush teeth twice a day for 8 weeks
48316214|NCT05889507|PROCEDURE|Whole body hypothermia|Whole-body hypothermia (33.5±0.5°C) initiated within 6 hours of birth and continued for 72 hours. The rectal temperature will be maintained at 33.5±0.5°C using a servo-controlled cooling machine.
48116222|NCT02748954|BEHAVIORAL|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
48116223|NCT02748954|BEHAVIORAL|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
48116224|NCT03696771|DRUG|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
48116225|NCT04934904|DRUG|Ropivacaine injection|On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
48116226|NCT05000944|OTHER|breakfast omission (BO)|this group will not be provided with a breakfast until lunch time (at 12:30).
48116227|NCT05000944|OTHER|early-morning breakfast consumption (EM-BC)|this group will be provided with an early morning breakfast (at 08:30).
48116228|NCT05000944|OTHER|mid-morning breakfast consumption (MM-BC)|this group will be provided with a mid (late) morning breakfast (at 10:30).
48116229|NCT05723133|DEVICE|Electric toothbrush|Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).
48116230|NCT05723133|BEHAVIORAL|Oral hygiene instructions|The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
48116231|NCT04129658|BEHAVIORAL|Educational outreach visit|Two-four hours of discussion between a cardiologist and the primary care physicians at the PHCC encompassing evidence-based treatment guidelines and counseling upon specific patient cases and their diagnose and treatment for congestive heart failure.
48485329|NCT04808882|DRUG|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
48485330|NCT03487848|DRUG|Daclatasvir|Specified dose on specified days for specified duration
48485331|NCT03487848|DRUG|Sofosbuvir|Specified dose on specified days for specified duration
48485332|NCT02884323|DEVICE|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
48485333|NCT04349631|BIOLOGICAL|HB-adMSCs|Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
48485334|NCT02857556|BIOLOGICAL|Blood sample|
48485335|NCT02857556|OTHER|Retinal photography:|
48485336|NCT02857556|OTHER|dialyse|
48644750|NCT06184763|OTHER|6-minute walk test|"6-minute walk test in a 40-metre corridor. Included patients are used to performing this test, which is part of the standard care performed during patient follow-up, at least once a year.~Parameters collected during the test: distance walked, minimum SpO2, average SpO2, maximum heart rate, average heart rate, average heart rate over the last 2 minutes, dyspnea scale."
48644751|NCT03104517|BIOLOGICAL|AMDC-USR (iltamiocel)|Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
48644752|NCT03104517|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
48644753|NCT06691126|OTHER|Terpinolene in olive oil|Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil
48644754|NCT06688513|DEVICE|Carealth Phone App|The goal for this study is to assess Carealth app's ability to connect patients to resources to meet patient's identified SDH needs, with the end goal of assessing reduction in 30-day readmission and missed visits by connecting patients to resources to meet their social needs in a way that enables them to receive care earlier or avoid complications.
48644755|NCT06688513|BEHAVIORAL|Let's Talk: Sharing information about Family Cancer Risk|An interactive tool that patients can use to learn about how to talk with their family members about the family member's cancer risk
48644756|NCT06688955|PROCEDURE|Colonoscopy with Bacteriological Controlled Water|Patient with coloscopy which used Bacteriological Controlled Water : Collection of 250 ml of bacteriologically controlled water from the wash bottle at the end of each water-assisted colonoscopy to test for enterobacteria and fecal streptococci
48644757|NCT03581292|RADIATION|Radiation Therapy|Undergo radiation therapy
48644758|NCT03581292|DRUG|Temozolomide|Given PO
48644759|NCT03581292|DRUG|Veliparib|Given PO
48644760|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter|catheter ablation
48116232|NCT01622413|PROCEDURE|joimax TESSYS|Transforaminal Endoscopic Surgery System
47966004|NCT05963594|DIETARY_SUPPLEMENT|Oligomalt|The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
47966005|NCT05963594|DIETARY_SUPPLEMENT|maltodextrin|The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
48116233|NCT01622413|PROCEDURE|Microdiscectomy|Standard procedure for disc surgery
48116234|NCT01147380|BIOLOGICAL|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
48116235|NCT04878991|DIAGNOSTIC_TEST|Overture Metabolomics Embryo Selection|Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
48644761|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter
47966006|NCT01333254|PROCEDURE|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
48116236|NCT04229004|DRUG|Gemcitabine combined with nab-paclitaxel|"Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
48116237|NCT04229004|DRUG|Dose -mFOLFIRINOX|The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines.
48116238|NCT04229004|DRUG|Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel|"Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle"
48116239|NCT04229004|DRUG|Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine|"Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle"
48116240|NCT04229004|DRUG|Drug: Dose -SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus."
48316215|NCT05889507|PROCEDURE|Targeted normothermia|The rectal temperature will be maintained at 36.5±0.5°C using servo-controlled incubators for the first 80 hours and any hyperthermia will be treated with a standardised protocol.
48485337|NCT05712642|DRUG|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
48485338|NCT03738176|DRUG|Sesame Oil|Sesame oil(80 gm NaCMC-20 gmSesame oil)
48485339|NCT03738176|DRUG|triamcinolone in orabase|triamcinolone 140 gm-Na CMC 50 gm
48485340|NCT00569790|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
48644762|NCT06689787|OTHER|Self-Guided STAIR Coach with Real-Time Assessment|Two mobile apps to be used as one intervention package to support participants in their progress through STAIR (Skills Training in Affective and Interpersonal Regulation) with self-monitoring of symptoms and functioning
48644763|NCT06689787|OTHER|Real-Time Assessment|One mobile app to support participants in self-monitoring of symptoms and functioning
47966007|NCT05343598|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses."
47966008|NCT05343598|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
48316216|NCT05889507|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
48316217|NCT05889507|DIAGNOSTIC_TEST|Follow up assessment at 2 years of age|The assessment will be carried out using the Bayley Scales of Infant and Toddler Development IV. In addition, all infants will have a detailed neurological examination, including Gross Motor Function Classification System (GMFCS) for cerebral palsy, vision, and hearing assessment. Babies who die or who cannot be assessed with the Bayley-IV due to severe disability will be allocated a Cognitive Scale Composite score one point below the basal test score. PARCA-R will be completed by the parents immediately.
48316218|NCT01336556|PROCEDURE|Oral appliance|Anterior mandibular repositioner: used for two months
48485341|NCT01706848|OTHER|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
48485342|NCT01706848|OTHER|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
48485343|NCT02065713|DRUG|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
48116241|NCT05882266|DIETARY_SUPPLEMENT|Plant Omega|A commercial plant-based omega-3 beverage consumed once daily during breakfast
48116242|NCT05882266|OTHER|Dietary therapy only|Standard dietary therapy
48116243|NCT06575413|OTHER|Direct Electrical Stimulation|The patients underwent SEEG with at least one electrode targeting the claustrum. The investigators used the claustrum as a target for both mapping and CCEP, recording changes in cortical electrical activity.
48116244|NCT01735019|DRUG|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
48644764|NCT06688214|OTHER|Kinesio Taping treatment|Therapeutic KT application administered to patients in group A. The KT treatment was completed in compliance with Kase's recommended methodology for rotator cuff tendinitis/impingement. Initially, an inhibitory approach was used to apply a supraspinatus Y-strip from its insertion to its origin. The measurement of the strip's length was taken from the acromion to the scapular spine. The base of the strip was later applied to the tuberculum major while the patient was seated; the superior tale of the Y-strip was then terminated at the superomedial angle of the scapula, passing between the middle and superior fibers of the trapezius with light tension (% 15-25); the shoulder was then extended, adducted, and internally rotated with cervical contralateral bending; the final portion of the tape (2.5-5 cm) was applied painlessly.
47966009|NCT01960400|DEVICE|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
48116245|NCT05408559|DRUG|Sulforaphane|Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
48116246|NCT00980330|DRUG|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
48116247|NCT00980330|DRUG|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
48116248|NCT00980330|DRUG|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
48116249|NCT00980330|DRUG|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
48644765|NCT06688214|OTHER|Scapular Stabilization Exercises|"Participants in Group B engage in a twice-weekly, supervised SSE exercise program that is based on the clinical decision algorithm that has been recommended by an expert panel. The goal of scapular orientation training was to normalize the scapula's resting posture and enhance proprioception. Subsequently, three scapular control exercises were executed: a closed kinetic chain exercise known as the unilateral bench press, bilateral shoulder flexion up to 60°, and a scapular control exercise including bilateral shoulder retraction and extension in the prone position. There was no discomfort involved in performing the exercises, and each session may consist of no more than four exercises. The dosage and progressions were based on the objectives of each exercise; each exercise was performed 8-10 times with a 5- to 10-second hold in between, and there was a 30-to 1-minute rest period."
48316219|NCT01167465|OTHER|Moussik Diaper Rash Mousse|To be used as instructed
48116250|NCT06227637|OTHER|Local Muscle Vibration compared to Muscle energy technique in SIJD|Apply Local Muscle Vibration compared to Muscle energy technique on patients with sacroiliac joint dysfunction and note the effect on pain intensity, pain pressure threshold, functional disability, and innominate angle tilt in SIJD.
48116251|NCT00006035|BIOLOGICAL|bleomycin sulfate|
48316220|NCT01167465|OTHER|Desitin Creamy Ointment|To be used as instructed
48316221|NCT06059300|DIAGNOSTIC_TEST|Digital Breast Tomosynthesis|Screening with Digital Breast Tomosynthesis instead of Digital Mammography, for two screening rounds
48485344|NCT02065713|DRUG|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
48116252|NCT00006035|DRUG|electroporation therapy|
48116253|NCT03989986|BEHAVIORAL|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
48485345|NCT02065713|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
48644766|NCT06686901|BEHAVIORAL|Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)|Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
48644767|NCT06686901|BEHAVIORAL|Smartphone-delivered inactive Therapeutic Evaluative Conditioning|Therapeutic Evaluative Conditioning (inactive TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair positive and negative stimuli (pictures, words) with each other.
48644768|NCT03769467|BIOLOGICAL|Tabelecleucel|Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
47966010|NCT01960400|DEVICE|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
48116254|NCT04305405|DRUG|Benralizumab|Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
48116255|NCT05516927|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
48116256|NCT03901937|DRUG|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
48116257|NCT03901937|PROCEDURE|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
48116258|NCT00212056|DRUG|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
48116259|NCT00212056|DRUG|Control|placebo
48116260|NCT01538719|DRUG|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
48116261|NCT01538719|OTHER|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
48116262|NCT03284086|DIAGNOSTIC_TEST|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
48116263|NCT03284086|DIAGNOSTIC_TEST|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
48316222|NCT03629041|DEVICE|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
48316223|NCT03629041|DEVICE|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
48316224|NCT01155297|BEHAVIORAL|Physical training|"The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration."
48485346|NCT00867841|PROCEDURE|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
48485347|NCT05364008|DRUG|Green Tea Extract|Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
48485348|NCT05364008|OTHER|Placebo|Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
48644769|NCT03769467|BIOLOGICAL|Pembrolizumab|pembrolizumab IV infusion
48644770|NCT01798823|PROCEDURE|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
48116264|NCT04949581|OTHER|bioelectric therapy|the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.
48316225|NCT01155297|BEHAVIORAL|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
48316226|NCT00914602|DRUG|Sinemet 25-100 Oral Tablet|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
48316227|NCT00914602|DRUG|XP21279|Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
48316228|NCT00914602|DRUG|Carbidopa Pill|
48316229|NCT01952457|DEVICE|Zilver PTX|
48316230|NCT01952457|DEVICE|prosthetic bypass|
48316231|NCT03346447|OTHER|Artificial Fecal Enzyme|Artificial Fecal enzyme Trypsin/Chymotrypsin mixture
48316232|NCT05364905|DRUG|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
48316233|NCT00636376|PROCEDURE|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
48316234|NCT01842607|BIOLOGICAL|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
48316235|NCT02370355|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
48316236|NCT02370355|OTHER|Laboratory Biomarker Analysis|Correlative studies
48316237|NCT04633473|BEHAVIORAL|SIB-Time Web-Application Tool|Parents used the dual-language SIBTime app to watch video stories about common sibling experiences, respond to question prompts, track connection routines, and listen to guided Acceptance and Commitment Therapy (ACT) exercises for parents. During the 4-week intervention period, parents used the app at their convenience.
48485349|NCT02522403|PROCEDURE|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
48485350|NCT02522403|DEVICE|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
48485351|NCT02234752|DRUG|Galantamine ER|
47966011|NCT03228264|DEVICE|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
47966012|NCT03228264|DEVICE|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
47966013|NCT04503902|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
47966014|NCT04503902|DRUG|Toripalimab Injection|JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
47966015|NCT06204601|OTHER|Education According to Meleis' Transitional Theory to Patients With Pacemaker|Patients in the experimental group will be trained according to Meleis's Transition Theory.
47966016|NCT05543733|BEHAVIORAL|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
47966017|NCT00530309|DRUG|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
47966018|NCT00530309|DRUG|Placebo|Subjects will also receive placebo.
47966019|NCT03675477|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
47966020|NCT03675477|DRUG|Placebo|Placebo Oral Tablet
47966021|NCT05901428|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
47966022|NCT05901428|DRUG|Carboplatin|Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
47966023|NCT05901428|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
48316238|NCT02096861|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
48316239|NCT02096861|BIOLOGICAL|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
48316240|NCT02834546|BIOLOGICAL|Sorafenib plasma concentration 4 weeks after treatment initiation|Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
48316241|NCT01874652|DEVICE|Light Weight Breast Implants|Light Weight Breast Implants
48644771|NCT06679660|OTHER|inferior alveolar nerve block with 4% articaine|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Inferior Alveolar Block anesthesia via the mandibular foramen.
48644772|NCT06679660|OTHER|Mental/Incisive Nerve Block (%4 Articaine)|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Mental or Incisive Nerve Block anesthesia via the mental foramen.
48644773|NCT06686355|DRUG|Yiqilishui formula|Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;
48644774|NCT06686355|OTHER|Placebo|5% Yiqilishui Granules + 95% Dextrin;
48644775|NCT06197711|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants; PRISMA has four sessions."
48644776|NCT06687746|DEVICE|Bili-ruler|The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.
48644777|NCT06189846|DEVICE|International Cohort|"Assessing tumour response following neoadjuvant treatment in rectal cancer include :~* Digital rectal examination~* Rectal MRI~* Rectoscopy ( Lumeneye device)~The monitoring of tumour response intervals up to 6 months following completion of the neoadjuvant treatment at 8 weeks, at 16 weeks, at 24 weeks after the end of neoadjuvant treatment."
47966024|NCT05901428|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
47966025|NCT06556342|DRUG|FRD001|FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
48316242|NCT00208741|DRUG|Gabitril|
48485352|NCT02234752|DRUG|Memantine XR|
48644778|NCT06688526|OTHER|Quiet Sounds|Quiet sounds are played during sleep
48644779|NCT06688526|OTHER|Sham sounds|No sounds are played during sleep
48644780|NCT06686069|DIETARY_SUPPLEMENT|bioarginina zero|treatment
47966026|NCT01423305|DRUG|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
47966027|NCT01423305|DRUG|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
47966028|NCT02034383|OTHER|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
48316243|NCT00895518|BEHAVIORAL|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
48644781|NCT06686069|DIETARY_SUPPLEMENT|Placebo|absence of treatment
48644782|NCT06689579|DEVICE|Unipolar hemiarthroplasty|
48644783|NCT06689579|DEVICE|Bipolar hemiarthroplasty|
47966029|NCT02034383|OTHER|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
48316244|NCT02466321|PROCEDURE|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
48485353|NCT02032251|DRUG|oral administration of ginger|Oral administration of ginger in patients with infertility.
48485354|NCT02032251|DRUG|Placebo|
48485355|NCT01322971|DRUG|Metronidazole|Metronidazole 500mg orally twice daily for seven days
48485356|NCT01322971|DRUG|Placebo|Placebo will be administered orally twice daily for seven days
48485357|NCT03204474|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
47966030|NCT02034383|OTHER|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
47966031|NCT02034383|OTHER|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
47966032|NCT02034383|OTHER|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
48116265|NCT04949581|OTHER|cardiac rehabilitation program|the patient will receive cardiac rehabilitation program
48116266|NCT00922220|OTHER|stationary bike|Participants rode a stationary bike for five minutes
48316245|NCT01899404|BIOLOGICAL|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
48316246|NCT01098838|DRUG|LCL161|
48485358|NCT03204474|DRUG|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
48485359|NCT04352465|DRUG|Methotrexate|Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
48485360|NCT04352465|DRUG|Methotrexate|Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
48485361|NCT04352465|DRUG|Methotrexate|Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
48316247|NCT06200987|DEVICE|Penile vibrator|In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
48316248|NCT03151148|BIOLOGICAL|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
48316249|NCT03151148|DRUG|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
48316250|NCT06553443|DEVICE|Angioplasty of all peripheral AVF stenosis|All peripheral AVF stenosis are to be treated with the same type of balloon depending on allocation
48316251|NCT01870024|DRUG|Clonazepam|clonazepam 0,015 mg/kg
48316252|NCT01870024|DRUG|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
48316253|NCT01870024|DRUG|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
48316254|NCT01870024|DRUG|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
48316255|NCT04634773|RADIATION|Low-dose CT|"A low-dose, or quantitative (q) CT scan will be performed on the shoulder. This CT scan will be done to assess the bony structure of the shoulder, as well as bone strength, which can influence the health of the cartilage.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
48316256|NCT04634773|OTHER|T1Rho MRI|"A T1Rho MRI will be performed on the shoulder. This imaging technique uses a special sequence and will be used to assess the muscles and tendons around the shoulder.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
48316257|NCT04634773|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Group 1 participants will complete this scan at baseline, 2-years and 4-years in the affected shoulder, and at baseline and 4-years in the opposite, unaffected shoulder.~Group 2 participants will complete this scan at baseline, 2-years and 4-years."
48316258|NCT02223455|OTHER|Hand Hygiene Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
48316259|NCT02040883|DRUG|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
47966033|NCT06055010|OTHER|No interventions|Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
47966034|NCT04850937|DRUG|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
47966035|NCT04850937|DRUG|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
47966036|NCT04467060|DRUG|Anaprazole Sodium|2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.
47966037|NCT04467060|DRUG|Placebo|single dose, fasting oral administration
47966038|NCT04668625|BEHAVIORAL|Participate in a massive musical event|Participate in a massive musical event
47966039|NCT03291730|BEHAVIORAL|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
47966040|NCT03291730|OTHER|Art-therapy|May help reduce anxiety of receiving chemotherapy
48116267|NCT00922220|OTHER|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
47966041|NCT03572764|DRUG|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
47966042|NCT03572764|PROCEDURE|Research skin biopsy|"-And/or buccal swab~* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
47966043|NCT03572764|PROCEDURE|Research blood draw|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
47966044|NCT03572764|PROCEDURE|Research bone marrow aspirate|"* Pre-treatment~* Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~* Post-consolidation 1 (if applicable)~* Post-consolidation 2 (if applicable)~* Post-transplant Day 30 (if applicable)~* Post-transplant Day 100 (if applicable)"
47966045|NCT05829304|OTHER|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
48116268|NCT00922220|OTHER|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
48116269|NCT04529382|DIAGNOSTIC_TEST|Cognitive testing (Bayley III, WPPSI III and WISC V)|Parents and children will be invited to come for an outpatient clinic visit where cognitive testing and neurologic examination will be performed. In addition to this parents will be asked to fill in questionnaires, provide latest school results and medical files will be requested from treating physicians.
48316260|NCT02040883|DRUG|Tandospirone|Tandospirone，30mg per day
48316261|NCT06064708|BEHAVIORAL|Mindfulness-based intervention|"The experimental group received 30 minutes of MBI according to Smith's (2005) MBI protocol, which is a standardized theory-based intervention.~Smith's (2005) MBI protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes)."
48316262|NCT04933721|DRUG|berotralstat|BCX7353 capsules administered orally once daily
48316263|NCT05344144|OTHER|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
48316264|NCT05344144|OTHER|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
48316265|NCT03480607|DRUG|Dexmedetomidine group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
48485362|NCT01138826|DRUG|Amlodipine - reference|10 mg tablet, single dose, with water
48644784|NCT06688799|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
48485363|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
48644785|NCT02633527|DRUG|Placebo|Placebo was administered once daily
48644786|NCT02633527|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
48644787|NCT02633527|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
47966046|NCT05829304|OTHER|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
47966047|NCT06504940|DRUG|Orelabrutinib combined with bendamustine and rituximab|they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).
47966048|NCT06504940|DRUG|Orelabrutinib combined with obinutuzumab|they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
47966049|NCT03178903|OTHER|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
48116270|NCT06608368|DRUG|Test Dentifrice (Sensodyne Repair and Protect Original Mint)|Dentifrice containing 5% w/w NovaMin (Calcium Sodium Phosphosilicate) and 1040 ppm fluoride as sodium fluoride.
48316266|NCT03480607|DRUG|Dexamethasone group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
48316267|NCT00803010|DRUG|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
48316268|NCT00803010|DRUG|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
48485364|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
48485365|NCT00472875|DRUG|Glibenclamide|
48644788|NCT02633527|DRUG|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
48644789|NCT02633527|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
48644790|NCT06689618|DEVICE|Exercise|The WB-EMS Device is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs. After donning a base layer consisting of fitted shorts and shirt, a vest, shorts, and arm straps with integrated electrodes mapped to major muscle groups (biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings) are donned. The suit connects to an impulse pack that communicates with the Katalyst iPad App to deliver the programmed stimulation to the participant. Within the Katalyst App, there are leveled exercise programs where low levels (i.e. Level 1 and 2) are simple movements and higher levels (i.e. Levels 3, 4, and 5) have more complex and dynamic movements. There is complete user control of the stimulation level of each individual muscle group to tailor to participant responses and tolerance.
48644791|NCT05426681|DRUG|GlyBURIDE Oral Tablet|"Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide"
48644792|NCT06690372|OTHER|virtual reality exercise|"Over the 12-weeks, participants will be instructed to exercise with the VR-Move 3x/week for 30 minutes for 12-weeks total, with modules presented in a prescribed weekly sequence to provide novel and re-enforcement of modules, while ensuring all modules are performed. Further, participants will be provided the opportunity of a 30 minute free-play of module of choice once a module has been introduced."
48485366|NCT01425723|BIOLOGICAL|rFIXFc|Administered as specified in the treatment arm.
48116271|NCT06608368|DRUG|Positive Control Dentifrice (Sensodyne Fresh Mint)|Dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride.
48485367|NCT00992368|PROCEDURE|reduction mammaplasty|patients submitted to reduction mammaplasty
48644793|NCT05483400|DRUG|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
48644794|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Low Dose Radiotherapy|in experimental arm 1
48644795|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Double upper neck lymph node dissection|in experimental arm 2
48644796|NCT06586606|DRUG|MK-1708|Oral administration
48644797|NCT06586606|DRUG|Itraconazole|Oral administration
48316269|NCT00803010|DRUG|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
48485370|NCT05557448|DRUG|TYNADOTE|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
48116272|NCT06608368|DRUG|Reference Dentifrice (Crest Cavity Protection Regular)|Dentifrice containing 1100 ppm fluoride as sodium fluoride.
48116273|NCT00590551|OTHER|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
48116274|NCT02494999|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
48116275|NCT02494999|BIOLOGICAL|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
48116276|NCT06472206|BEHAVIORAL|CHW Sessions|Sessions with a Community Health Worker (CHW).
48116277|NCT06472206|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
48316270|NCT02307669|BEHAVIORAL|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
48316271|NCT02307669|BEHAVIORAL|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
48316272|NCT04217889|OTHER|Questionnaire|Short questionnaire that can be completed during the usual consultation.
48316273|NCT03025334|DEVICE|High-definition transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
48316274|NCT04061681|BEHAVIORAL|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
48116278|NCT03316521|DRUG|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
48116279|NCT05715957|OTHER|No intervention|No intervention
48116280|NCT01041417|DRUG|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
48116281|NCT01041417|DRUG|Placebo|Saline injection
48116282|NCT05495477|DEVICE|EIT|Evaluation of ventilation distrinution during deep sedation through EIT
48116283|NCT02695381|DRUG|Etodolac-lidocaine topical patch|Once daily
48116284|NCT02695381|DRUG|Placebo|Once daily
48316275|NCT04895163|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed for acute appendicitis
48316276|NCT00132236|DRUG|nicotine sublingual tablets|
48316277|NCT00132236|BEHAVIORAL|low and high behavior support|
48316278|NCT00003444|BIOLOGICAL|recombinant interferon alfa|
48316279|NCT00003444|RADIATION|radiation therapy|
47966050|NCT03178903|OTHER|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
47966051|NCT03178903|BEHAVIORAL|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
47966052|NCT03760783|OTHER|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
47966053|NCT02981420|BEHAVIORAL|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
47966054|NCT02711397|OTHER|Observational study|Comparison excretion levels of gluten immunogenic peptides
47966055|NCT01626456|DRUG|ALKS 9072, Low|IM injection, given monthly
47966056|NCT01626456|DRUG|ALKS 9072, High|IM injection, given monthly
47966057|NCT05969145|PROCEDURE|application of thermophor|The experimental group will be given hot and cold application to the bladder
47966058|NCT00602797|DRUG|Paclitaxel|Given IV
47966059|NCT00602797|OTHER|Quality-of-Life Assessment|Ancillary studies
47966060|NCT00602797|OTHER|Questionnaire Administration|Ancillary studies
47966061|NCT00602797|DRUG|Vinorelbine Tartrate|Given IV
47966062|NCT02688205|OTHER|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
47966063|NCT02688205|DEVICE|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
47966064|NCT01753271|OTHER|thoracic mobilization & shoulder mobilization & exercise|
47966065|NCT01753271|OTHER|shoulder mobilization & exercise|
47966066|NCT03312101|OTHER|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
47966067|NCT01169493|DEVICE|VVI-40|Pacing mode set to VVI-40, RV only pacing
48116285|NCT05688592|PROCEDURE|PET-CT|"This is a before-and-after study (not a clinical trial)~* in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT.~* in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT"
48485371|NCT05557448|DRUG|Placebo Oral Tablet|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
48485372|NCT06468423|DRUG|Deferasirox (DFX)|Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
48485373|NCT06468423|DRUG|Deferoxamine (DFO)|DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
47966068|NCT01169493|DEVICE|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
47966069|NCT01169493|DEVICE|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
47966070|NCT02607033|OTHER|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
47966071|NCT02607033|OTHER|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
47966072|NCT01471470|DRUG|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
47966073|NCT04176705|DRUG|Lidocaine Cream|Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
47966074|NCT04176705|DRUG|Triamcinolone Acetonide Cream|Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
47966075|NCT04176705|DEVICE|Fractional Ablative Laser|Applied to only site that is randomized to laser intervention
47966076|NCT02459210|BEHAVIORAL|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
47966077|NCT02459210|BEHAVIORAL|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
48116286|NCT01859416|DIETARY_SUPPLEMENT|Oral nutritional supplement|
48116287|NCT05446363|DEVICE|Medimonitor|A digital solution consisting of web based portal gathering data from mobile fundus camera and intraocular tonometer provided to the physicians located remotely to the University hospital that provides consults and analyses of on-site gathered data.
48116288|NCT04042545|DRUG|PPP001|1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device
48116289|NCT04042545|DRUG|Placebo|1 placebo dosing capsule inhaled 3 times a day with a vaporizer device
48116290|NCT01426178|DEVICE|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
48316280|NCT05437757|DEVICE|Surgical implantation of the PCL Breast scaffold with autologous fat grafting|Single shot of prophylactic perioperative antibiotics is given to the patient. A suitable incision is made to provide access followed by mobilisation of the breast gland.If present, the silicone implant is removed and capsulectomy performed. The implant pocket shall be rinsed with saline or antiseptic and a surgical drain shall be placed in the pocket at the discretion of the PI. The PCL Breast scaffold shall be inserted into the pocket and fixed using 2 to 4 sutures. The incision is closed. Liposuction is performed from another area of the body and lipofilling is performed within the breast scaffold. Sterile bandaging is applied and a daily wound revision is performed whilst an inpatient. A prophylactic antibiotic shall be administered to the patient.The patients shall be hospitalized overnight for clinical observation.
48485374|NCT04714970|DEVICE|iTBS|Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
47966078|NCT04083430|DRUG|Yellow Fever Vaccine|"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."
47966079|NCT00518284|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
47966080|NCT04281810|DEVICE|transcutaneous electric diaphragm stimulation|The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
47966081|NCT00205881|DEVICE|HiRes 90K Bionic Ear System|Cochlear implant system
47966082|NCT03432702|PROCEDURE|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
47966083|NCT02803632|BEHAVIORAL|questionnaires|
47966084|NCT02803632|DEVICE|actigraphic recording|
47966085|NCT05907512|DRUG|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
47966086|NCT05907512|DRUG|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
48116291|NCT01645423|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
48116292|NCT01446068|DIETARY_SUPPLEMENT|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
48116293|NCT02864238|OTHER|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
48116294|NCT00021008|DRUG|picoplatin|
48116295|NCT01681251|OTHER|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
48116296|NCT01681251|OTHER|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
48116297|NCT01347125|DEVICE|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
48116298|NCT01177696|BEHAVIORAL|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
48116299|NCT05712941|DRUG|Lerociclib|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
48116300|NCT05712941|DRUG|Letrozole 2.5mg|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
48116301|NCT05712941|DRUG|Placebo|"All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)"
48116302|NCT05305846|DEVICE|TENA-PROTO2|During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
48116303|NCT04461197|DEVICE|customised foot orthoses|The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.
48116304|NCT04461197|DEVICE|orthotic insole|For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
48116305|NCT02815566|DRUG|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
48116306|NCT02815566|DRUG|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
48116307|NCT00818805|DRUG|Olopatadine 0.1%|one drop in one eye
48116308|NCT00818805|DRUG|Tranilast 0.5%|one drop in one eye
48116309|NCT00818805|DRUG|Placebo (Olopatadine)|one drop in contralateral eye
48116310|NCT00818805|DRUG|Placebo (Tranilast)|one drop in contralateral eye
48485375|NCT04714970|DEVICE|Shame stimulation|TMS coil vertical to the brain surface, with same protocol as iTBS
48485376|NCT03361384|DRUG|Alcohol|
48485377|NCT03361384|OTHER|Placebo (non-alcoholic beverage)|
48644798|NCT06606405|DIAGNOSTIC_TEST|scapular dyskinesis test|Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).
48644799|NCT06686693|DRUG|Injectafer|Injectafer - 15 mg/kg up to 1000 mg
48644800|NCT06686693|OTHER|Placebo|Placebo
48644801|NCT04619147|OTHER|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
48644802|NCT06691373|OTHER|Static Stretching|"Static stretching of the quadriceps and hamstrings which was performed in the dominant limb, and held in a position where the participants referred discomfort:~* Quadriceps - participants were in the standing position, with one hand holding the back of a chair to maintain the balance, and were instructed to pull the ankle of the lower limb to be stretched, pressing the heel towards the buttocks and, at the same time, extending the thigh;~* Hamstrings - participants were also in the standing position, with the heel resting on a chair. They were then instructed to lean the body forward keeping the spine erect and the pelvis in anteversion, to obtain a stretch over the knee and hip."
47966087|NCT05433493|BEHAVIORAL|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
47966088|NCT05802056|BIOLOGICAL|Aldesleukin|Given IP
47966089|NCT05802056|PROCEDURE|Biopsy|Undergo biopsy
47966090|NCT05802056|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
47966091|NCT05802056|PROCEDURE|Computed Tomography|Undergo PET/CT
48116311|NCT05253664|BEHAVIORAL|Woman-Centered Care Group|Each woman in the experimental group was given woman-centered care as from 2 hours postpartum and this process continued until 24 hours postpartum. Physiological parameters (systolic-diastolic blood pressure, pulse, body temperature) of women assigned either to the experimental group or the control group were measured at 2 hrs postpartum. The State, Trait Anxiety, and Postpartum Comfort Scales were pretested. A dynamic interaction was ensured between the researcher and the women in the experimental group who received woman-centered care. In the processes of determining and meeting the care needs of women in the early postpartum period, both the women and the researcher took equal responsibilities and the common goal of achieving safe results was shared. Clinical guidelines were used while providing woman-centered care.
47966092|NCT05802056|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
47966093|NCT05802056|DRUG|Fluorouracil|Given IV
47966094|NCT05802056|DRUG|Leucovorin Calcium|Given IV
47966095|NCT05802056|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
47966096|NCT05802056|BIOLOGICAL|Nivolumab|Given IV
47966097|NCT05802056|DRUG|Oxaliplatin|Given IV
47966098|NCT05802056|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
47966099|NCT03925480|DRUG|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
47966100|NCT03925480|DRUG|Matching Placebo|Matching Placebo
48316281|NCT02492997|DEVICE|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
48316282|NCT02492997|OTHER|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
48316283|NCT01640925|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
48316284|NCT01640925|OTHER|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
48316285|NCT03508635|DRUG|CORT125134|Oral capsules
48644803|NCT06623266|PROCEDURE|Neck management|"In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions."
48316286|NCT03508635|DRUG|Matching Placebo of CORT125134|Placebo
48316287|NCT03508635|DRUG|Mifepristone|Active comparator
48116312|NCT00768235|OTHER|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
48116313|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
48316288|NCT03508635|DRUG|Prednisone|Challenge agent
48316289|NCT03508635|DRUG|Glucose|
48485378|NCT05901259|DEVICE|Exopulse Mollii Suit|The registry is designed to demonstrate the impact of Exopulse Mollii Suit on improvement of muscle relaxation, muscle activation, local blood circulation and/or chronic pain relief. The subjects included use the suit for 60 minutes every other day, unless other is specified by the Investigator, in their home environment for up to a maximum of 12 consecutive weeks. Qualitative and quantitative measures will be collected at baseline (T0), after 60 minutes stimulation (T1), after 4 weeks (T4) and at the end of the 12-week intervention period (T12).
48485379|NCT03971578|OTHER|No Intervention Provided|No Intervention Provided
48485380|NCT06389006|DRUG|Disitamab Vedotin for Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed
47966101|NCT03335098|DRUG|Bortezomib|Six 4-week cycles
48116314|NCT00724217|OTHER|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
48116315|NCT04003805|DRUG|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (\~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
48316290|NCT03976115|DRUG|DDO-3055|Oral
48316291|NCT03976115|DRUG|Placebos|Oral
48485381|NCT06389006|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
48644804|NCT06687967|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
48116316|NCT04003805|DRUG|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
48116317|NCT04632368|BEHAVIORAL|Transcendental Meditation|TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
48116318|NCT00539799|DRUG|prednisolone|5 - 7.5 mg/day
48116319|NCT00539799|DRUG|Placebo|Matched placebo to prednisolone
48316292|NCT00244894|PROCEDURE|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
48316293|NCT00244894|PROCEDURE|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
48316294|NCT00244894|PROCEDURE|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
48316295|NCT00244894|PROCEDURE|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
48316296|NCT00244894|PROCEDURE|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
48316297|NCT00143260|DRUG|Viagra (Sildenafil Citrate) 100 mg|
48316298|NCT03340181|OTHER|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
47966102|NCT02516163|DEVICE|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
48316299|NCT04969133|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
48316300|NCT01987167|DRUG|ACTHAR|Injectable Gel
48316301|NCT05618496|DEVICE|Sodium Hyaluronate Lyophilizate|Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression.
48316302|NCT02854137|DRUG|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
48485382|NCT06389006|DRUG|Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.
48485383|NCT06389006|DRUG|Cyclophosphamide|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
48485384|NCT03811626|PROCEDURE|cognitive-behavioral rehabilitation|Combination of clinical examination and neuropsychological and psychological tests
48485385|NCT03500042|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
48485386|NCT00769626|OTHER|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
48644805|NCT06687967|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
47966103|NCT02151383|DRUG|Serelaxin|Serelaxin was administered intravenously for up to 48 hours.
47966104|NCT02801383|DRUG|Yallaferon®， the recombinant human interferon α-2b gel|
47966105|NCT02801383|OTHER|gel without active ingredient|
47966106|NCT04504357|BEHAVIORAL|Tablet based U=U app|"Tablet based app focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing."
47966107|NCT04504357|BEHAVIORAL|U=U videos played in clinic waiting rooms and integrated into HIV counseling session|TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing.
48116320|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 0|10 (8-12) x 10\^6 MSCs
48116321|NCT06392711|BIOLOGICAL|Mesenchymal Stromal Cells (MSC) Dose Level 1|20 (16-24) x 10\^6
48116322|NCT01691963|DEVICE|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
48316303|NCT02854137|DRUG|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
48316304|NCT01143168|BIOLOGICAL|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
48316305|NCT05204511|OTHER|endurance training|endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 30-60 minutes per session
48316306|NCT05204511|OTHER|concurrent training|combination of endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 20-40 minutes per session and resistance training of moderate intensity performing 2-3 sets of leg press, leg curls, chest press and seated horizontal rows
48316307|NCT05947747|DRUG|EXO-CD24|Twice a day for 5 days, dose 10\^10
48316308|NCT05947747|OTHER|Placebo|Twice a day for 5 days
48316309|NCT04534569|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
48316310|NCT02361658|OTHER|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
48116323|NCT00390299|BIOLOGICAL|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
48116324|NCT00390299|OTHER|Laboratory Biomarker Analysis|Correlative studies
48116325|NCT00390299|PROCEDURE|Therapeutic Conventional Surgery|Undergo en bloc resection
48116326|NCT04651881|DRUG|Reference drug|1 Cap., single oral administration under fed condition
48116327|NCT04651881|DRUG|Test drug 1|1 Tab., single oral administration under fed condition
48116328|NCT04651881|DRUG|Test drug 2|1 Tab., single oral administration under fed condition
48116329|NCT03997916|DEVICE|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
48116330|NCT03997916|DIAGNOSTIC_TEST|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
48116331|NCT06676904|PROCEDURE|Higher Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 50 x 10\^9/L up to 7 days of life, and then for a platelet transfusion threshold of 35 x 10\^9/L at 7 or more days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
48116332|NCT06676904|PROCEDURE|Lower Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 25 x 10\^9/L up to 7 days of life, and then for a platelet transfusion threshold of 20 x 10\^9/L at 7 or more days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
48116333|NCT01284907|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
48116334|NCT01284907|DIETARY_SUPPLEMENT|Placebo Drops|
48116335|NCT06554041|DEVICE|Dental Crown with Titanium-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
48116336|NCT06554041|DEVICE|Dental Crown with PEEK (Polyetheretherketone)-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
48316311|NCT02361658|OTHER|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
48316312|NCT02361658|OTHER|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
47966108|NCT04504357|OTHER|Text messages|Monthly text messages reinforcing intervention content
47966109|NCT03721744|DRUG|GB201|GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
47966110|NCT03721744|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 will be administered intravenously starting on Day 1 of Cycle 1. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle
47966111|NCT03721744|DRUG|Gemcitabine|Low-dose gemcitabine 600 mg/m\^2 will be administered intravenously following completion of paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle.
47966112|NCT03721744|OTHER|Standard of care treatment options|Patients will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including Gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5-FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC).
47966113|NCT04444102|PROCEDURE|Yoga-based stretching|"Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators."
47966114|NCT04998786|DRUG|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
47966115|NCT04998786|DRUG|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
47966116|NCT04998786|DRUG|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
47966117|NCT02946944|DRUG|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
48316313|NCT03132480|OTHER|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
48316314|NCT02702427|BIOLOGICAL|virus-specific T-Cells|infusion
47966118|NCT02946944|DRUG|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
48316315|NCT06495307|DRUG|rhPRG4|Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
48316316|NCT05638906|DEVICE|MINT|Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.
48316317|NCT05249231|DRUG|Silver diamine fluoride|Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
48316318|NCT05249231|DEVICE|Hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
48316319|NCT00242580|DRUG|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
48316320|NCT00242580|DRUG|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
48316321|NCT00242580|DRUG|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
48316322|NCT02281903|DEVICE|The TrueCPR feedback device|feedback devices
48316323|NCT02281903|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
48316324|NCT03589105|DRUG|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
48316325|NCT03589105|DRUG|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
48316326|NCT01953536|DRUG|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
48316327|NCT01953536|DRUG|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m\^2.
48316328|NCT01953536|DRUG|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
48316329|NCT01953536|DRUG|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
48316330|NCT01953536|DRUG|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
48316331|NCT01630096|DRUG|Nu-Lytely|Bowl prep solution.
48485387|NCT00769626|OTHER|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
47966119|NCT06505889|OTHER|Local anesthesia methods|Local pain control method before arterial blood sampling procedure
47966120|NCT01193595|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
47966121|NCT01193595|DRUG|bevacizumab|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
47966122|NCT02989714|DRUG|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
48316332|NCT03892330|DRUG|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
48316333|NCT03892330|DRUG|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
48316334|NCT03892330|DRUG|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
48316335|NCT03892330|DRUG|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
48316336|NCT03892330|DRUG|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
48316337|NCT03892330|DRUG|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
48316338|NCT03562585|DIAGNOSTIC_TEST|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
48316339|NCT03329651|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2"
48316340|NCT03329651|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2"
48316341|NCT03773341|OTHER|research questionnaire|Patient personal data History taking clinical knee examination
48485388|NCT01699529|DEVICE|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
48316342|NCT05940727|OTHER|Habitual macroalgae consumption|The participant have a habitual macroalgae consumption at baseline.
48316343|NCT05940727|OTHER|No macroalgae consumption|The participants exclude any macroalgae products from their diet
48316344|NCT03146052|DRUG|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
48316345|NCT01621152|OTHER|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
48316346|NCT01621152|OTHER|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
48316347|NCT04026152|BEHAVIORAL|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
48485389|NCT02408328|DRUG|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
48485390|NCT02408328|DEVICE|Home monitor|Use of home monitor until 44 weeks postmenstrual age
48485391|NCT02408328|OTHER|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
48485392|NCT00761449|DRUG|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
48485393|NCT04794387|BIOLOGICAL|Amended LLS COVID-19 Registry|Do people with blood cancer who did not develop antibodies after a complete COVID-19 vaccination, develop antoibodies after a COVID-19 booster?
48485394|NCT00001007|DRUG|Zidovudine|
48485395|NCT03574922|OTHER|Balance exercises|Balance Exercises
48485396|NCT03574922|OTHER|Core Stabilization exercises|Core Stabilization exercises
48485397|NCT01978210|DEVICE|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
48485398|NCT00621036|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
48485399|NCT00621036|BIOLOGICAL|sargramostim|
48485400|NCT00621036|DRUG|methotrexate|
48485401|NCT00621036|DRUG|thiotepa|
48485402|NCT00621036|RADIATION|radiation therapy|
48485403|NCT05365841|DRUG|Mepolizumab 100 MG|Patients with SEA eligible to receive anti-IL5 treatment, which is a biologic treatment for SEA
48485404|NCT03050034|DEVICE|WIN @ Hospital system|WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
48485405|NCT03050034|OTHER|Traditional monitoring|Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
48485406|NCT02554734|DRUG|levodopa, carbidopa, ODM-104|
47966123|NCT02989714|DRUG|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
47966124|NCT03392701|BIOLOGICAL|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
48485407|NCT02554734|DRUG|levodopa, carbidopa, entacapone|
48485408|NCT02777684|OTHER|Qualitative study|
48485409|NCT03338179|BEHAVIORAL|Judgement of learning evaluation|The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.
48644806|NCT01008046|DRUG|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
48644807|NCT01008046|DRUG|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
48316348|NCT04026152|BEHAVIORAL|Unified Protocol|This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
48316349|NCT03596359|BEHAVIORAL|Education with Teach-Back method|
48316350|NCT03596359|OTHER|Received routine treatment|
48316351|NCT05236881|DEVICE|ANíMATE mobile application|mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
48316352|NCT06411808|BEHAVIORAL|Sensory-Adapted Dental Environment|The Sensory-Adapted Dental Environment (SADE) involves altering the dental setting to reduce sensory stimuli that can cause discomfort or anxiety in children with sensory processing disorders. This includes the use of controlled lighting, ambient sounds, and non-threatening tools to create a calming atmosphere conducive to positive dental experiences.
48316353|NCT01970514|DEVICE|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
48316354|NCT04019275|BEHAVIORAL|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
48316355|NCT03371160|DEVICE|Nutriplace™ System|The Nutriseal™ Nutriplace™ System is an electromagnetic tracking system for feeding tube placement designed to aid qualified operators in the placement of the Nutriseal™ Enteral Feeding Tube™ into the stomach or small intestine.
48316356|NCT06553534|OTHER|SAMURAI PICU Bundle|"The proposed multifaceted SAMURAI PICU Bundle is an intervention with the following core elements: 1) PICU Warning Tool: an automated clinical decision support (CDS) tool to provide a non-interruptive interprofessional predictive alert, 2) twice daily safety huddles with unit leadership, and 3) bedside assessment including the care team and patient's family to complete and display a bedside mitigation plan to prevent deterioration. This intervention combines the automated accurate prediction of the PICU Warning Tool with the use of provider intuition or a gut feeling from huddles to improve decision making at the bedside. Peripheral elements and possible adaptations will be suggested during Aim 1 and additional peripheral elements may be added by local sites after discussion with the PI through a user-centered design approach."
48316357|NCT03369106|OTHER|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
48316358|NCT01389622|OTHER|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
48316359|NCT01389622|OTHER|acupuncture|random points + digital pressure
48316360|NCT04899791|OTHER|Wheat bread enriched with hydroxytyrosol|Wheat bread enriched with hydroxytyrosol
48316361|NCT04899791|OTHER|Wheat bread|Wheat bread
48316362|NCT00796601|DRUG|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
48316363|NCT00796601|DRUG|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
48316364|NCT01954303|OTHER|Progress of CHD|
48316365|NCT00869765|DRUG|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
48316366|NCT00869765|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
48485410|NCT03676751|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
48485411|NCT03676751|DRUG|Placebo|Oral suspension of placebo for azithromycin
48644808|NCT01855503|PROCEDURE|Core Biopsy|
48316367|NCT03378726|DIETARY_SUPPLEMENT|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
48316368|NCT03378726|BEHAVIORAL|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
48316369|NCT03378726|BEHAVIORAL|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
48316370|NCT03378726|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
48485412|NCT03410043|DRUG|Osimertinib|Given PO
48644809|NCT06689852|DEVICE|Enriched|To be used twice a day
48644810|NCT06689852|DRUG|Loceryl 5%|To be used once a week
48644811|NCT06389682|DRUG|68Ga-NYM005 injection|he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.
48644812|NCT06688565|DEVICE|Hativ® electrocardiogram monitoring|Using Hativ®, a currently commercially available class II medical device, ECGs are measured every day at home and before and after dialysis
48316371|NCT03378726|BEHAVIORAL|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
48316372|NCT06281886|DRUG|Induction Immunotherapy-Toripalimab|Toripalimab 240mg iv. drip, Q3W, 2 cycles
48316373|NCT06281886|DRUG|Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin|Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.
48316374|NCT06281886|RADIATION|Radiotherapy|Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.
48316375|NCT06281886|DRUG|Apatinib|Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.
48316376|NCT06281886|DRUG|Capecitabine|Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy
48316377|NCT03229083|OTHER|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
48644813|NCT05970796|BEHAVIORAL|Pelvic floor muscle training|"The pelvic floor muscle training program will be provided via an intra-vaginal biofeedback device - Smart Kegel Trainer, which will be connected to the product application installed on the mobile phone or tablet so the participants can monitor their pelvic floor contractions in real time and directly in the application. Participants will be asked to complete three sets of 8 to 12 maximal pelvic floor muscle contractions and three to ten fast contractions per training session. The home program will be tailored to each participant and include pelvic floor safe exercises recommended by the Continence Foundation of Australia."
48316378|NCT01699620|PROCEDURE|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
48316379|NCT04102878|DRUG|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
48316380|NCT04102878|PROCEDURE|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
48316381|NCT04102878|PROCEDURE|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
48316382|NCT04102878|OTHER|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
48316383|NCT04102878|OTHER|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
48316384|NCT04102878|PROCEDURE|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
48316385|NCT04346134|PROCEDURE|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
48316386|NCT04346134|PROCEDURE|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
48316387|NCT05989490|OTHER|Static stretching|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
48485413|NCT03410043|RADIATION|Radiation Therapy|Undergo radiation therapy
48485414|NCT03410043|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48485415|NCT02693431|OTHER|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
48644814|NCT06687018|OTHER|Kaltenborn mobilisation|Kaltenborn mobilisation Grade 3 along with common treatment for 3 minutes, repeated 3 sets with rest of 1 minutes, three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises.
48644815|NCT06687018|OTHER|Mulligan mobilisation|Mulligan mobilisation with 10 repetitions with 3 sets and three sessions per week for four weeks. Conventional treatment comprises a hot pack for 10 minutes, SWD for 5 minutes, and nerve and tendon gliding exercises
47966125|NCT02650856|DRUG|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
47966126|NCT02650856|BIOLOGICAL|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
48316388|NCT06049290|DRUG|LBL-034 for Injection|Initial dose - MTD; Q2W; intravenous infusion
47966127|NCT01603498|DRUG|Dexamethasone|Dexamethasone 8mg
48316389|NCT02509494|BIOLOGICAL|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
48316390|NCT02509494|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).
48316391|NCT02509494|BIOLOGICAL|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
48316392|NCT02509494|BIOLOGICAL|Placebo|0.9% saline for injection.
48316393|NCT01767194|BIOLOGICAL|Dinutuximab|Given IV
48316394|NCT01767194|DRUG|Irinotecan Hydrochloride|Given IV
48316395|NCT01767194|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48316396|NCT01767194|BIOLOGICAL|Sargramostim|Given SC or IV
48316397|NCT01767194|DRUG|Temozolomide|Given PO
48316398|NCT01767194|DRUG|Temsirolimus|Given IV
48316399|NCT02771249|DRUG|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
48485416|NCT02540499|RADIATION|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
48644816|NCT06170606|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
48644817|NCT02536339|DRUG|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
48644818|NCT02536339|DRUG|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
48644819|NCT06688877|DEVICE|headphones with activated noise cancelling|noise cancelling is new
48644820|NCT06688877|DEVICE|headphones with activated noise cancelling and soft 60 bpm musc|noise cancelling is new
48644821|NCT06688877|DEVICE|heart rate measurement|three times (before, during and after surgery)
48316400|NCT02771249|DRUG|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
48316401|NCT02771249|DRUG|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
48316402|NCT02771249|DIETARY_SUPPLEMENT|Pyridoxine|
48316403|NCT00740168|DRUG|bevacizumab treatment|single infusion 10 mg/kg
48316404|NCT02257164|PROCEDURE|Femoral nerve block|2 mg/ml
48316405|NCT02257164|PROCEDURE|obturator nerve block|
48316406|NCT02257164|PROCEDURE|intraarticular injection|
48316407|NCT00966758|PROCEDURE|Computed Tomography|1 low dose CT scan is taken
48316408|NCT00966758|PROCEDURE|Single Photon Emission Computed Tomography|1 SPECT scan is taken
48316409|NCT01123122|OTHER|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
48485417|NCT03554603|BEHAVIORAL|Modified Report|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
48485418|NCT04718129|BEHAVIORAL|Youth Mindful Awareness Program (YMAP)|The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
48644822|NCT06688877|OTHER|Questionnaire|two times (before and after surgery)
48644823|NCT05943990|DRUG|GSK3845097|GSK3845097 was administered.
48316410|NCT04946019|COMBINATION_PRODUCT|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
48485419|NCT02972177|PROCEDURE|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
48644824|NCT05943990|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
48644825|NCT05943990|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
48644826|NCT06678984|PROCEDURE|with treated umbilical vein allograft|Surgical treatment of female stress urinary incontinence using a treated allogeneic umbilical vein sling
48644827|NCT06678984|PROCEDURE|with autologous fascial pubovaginal sling|Surgical treatment of female stress urinary incontinence using a autologous fascial pubovaginal sling
48644828|NCT04038008|DRUG|Fluconazole|Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
48644829|NCT04038008|DRUG|Diflucan®|Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
48644830|NCT06689527|DRUG|Vamorolone|Days 3 to 14: 6 mg/kg vamorolone once daily.
48316411|NCT00077376|BIOLOGICAL|trastuzumab|Given IV
48316412|NCT00077376|DRUG|ixabepilone|Given IV
48316413|NCT00077376|DRUG|carboplatin|Given IV
48316414|NCT00077376|OTHER|laboratory biomarker analysis|Correlative studies
48316415|NCT02308345|OTHER|Pre-chemotherapy visit summary Video|
48316416|NCT01753076|DRUG|Ozanezumab|Ozanezumab injection solution
48316417|NCT01753076|DRUG|Placebo|Normal saline (0.9% sodium chloride) infusion
48485420|NCT02972177|PROCEDURE|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
48485421|NCT02375919|OTHER|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
48485422|NCT03654664|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
48485423|NCT03654664|BIOLOGICAL|Havrix Inj|720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
48116337|NCT06554041|DEVICE|Dental Crown with Zirconia-Abutment|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
48316418|NCT04813159|DEVICE|Remote Ischaemic Conditioning (RIC)|The RIC protocol will comprise inflation of the automated RIC device to 20 mmHg above systolic blood pressure for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total. The RIC protocol will be repeated daily for the next 2 days.
48316419|NCT04813159|DEVICE|Sham-control|The sham protocol will comprise low-pressure inflation to 20 mmHg for 5 minutes and deflation for a further 5 minutes, a cycle which will be completed four times in total by a visually identical pneumatic cuff used in the active arm. The sham control protocol will be repeated daily for the next 2 days.
48316420|NCT00663455|DRUG|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
48316421|NCT04141787|DRUG|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
48316422|NCT04141787|DRUG|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
48316423|NCT01666418|DRUG|Pazopanib/Paclitaxel|
48316424|NCT01104558|DRUG|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
48316425|NCT05059418|DRUG|Clonazepam 0.5 MG|Topical treatment of oral mucosa with lozenge pill
48316426|NCT05059418|DRUG|Capsaicin Topical|Topical treatment of oral mucosa with capsaicin rinse
48316427|NCT05059418|OTHER|Placebo|Mouth rinse with no capsaicin
48316428|NCT00495495|DEVICE|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
48316429|NCT00495495|DEVICE|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
48316430|NCT04676464|DIAGNOSTIC_TEST|Ultra- sound|Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
48316431|NCT04183699|DIAGNOSTIC_TEST|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
48644831|NCT06689527|DRUG|Midazolam|Day 1 and 14: Single doses of 2.5 mg midazolam
48316432|NCT00306917|DEVICE|non-coated femoral hip stem|total hip replacement
48316433|NCT00306917|DEVICE|coated femoral hip stem|total hip replacement
48316434|NCT02415439|DRUG|VBP15|
48316435|NCT02415439|DRUG|Placebo|
48644832|NCT06688175|DRUG|IMRT combined with lobaplatin-based concurrent chemotherapy|IMRT combined with two cycles of lobaplatin-based concurrent chemotherapy
48644833|NCT06686524|DRUG|Anti-CD19 UCAR-T cells|A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy.
48316436|NCT02546674|DRUG|Nilotinib|A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
48316437|NCT04058054|DEVICE|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
48316438|NCT04058054|DEVICE|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
48316439|NCT04058054|DEVICE|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
48316440|NCT04058054|DRUG|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
48316441|NCT04058054|DRUG|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
48316442|NCT05092399|PROCEDURE|Bariatric Surgery|No study interventions
48316443|NCT00094887|DRUG|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
48644834|NCT06686368|DEVICE|I-DROP MGD|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
48644835|NCT06686368|DEVICE|Theloze Duo|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
48644836|NCT06686368|DEVICE|Systane Complete PF|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
48644837|NCT06290193|BIOLOGICAL|Acute Normovolemic Hemodilution/ANH|For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.
48644838|NCT06690775|DRUG|TORL-1-23|2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.
48644839|NCT06690775|DRUG|TORL-1-23|3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
48644840|NCT06690775|DRUG|TORL-1-23|3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
48644841|NCT06690775|DRUG|Pegfilgrastim (drug)|6 mg subcutaneous injection on Day 4 of each cycle.
48316444|NCT00094887|DRUG|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
48316445|NCT05633134|PROCEDURE|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
48316446|NCT05633134|PROCEDURE|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
48316447|NCT05917366|OTHER|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
48316448|NCT05917366|OTHER|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
48316449|NCT04596280|PROCEDURE|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
48316450|NCT04631120|OTHER|Integrated Dementia Practice Unit Design|"* Dementia Central: monthly review of participant progress~* Dementia Mobile: monthly nurse/lay health educator visits for assessments, education and coaching~* Dementia Link: communication between Dementia Central and Dementia Mobile using the eTransX mHealth platform and HealthStream educational interface for care providers and the patient/caregiver dyad."
48316451|NCT04631120|OTHER|Standard of Care|Standard clinical practices of the physician and institution including an initial assessment, Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard patient- and caregiver-centered educational material. Two phone sessions with a study nurse post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment.
48316452|NCT02527551|OTHER|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
48316453|NCT06554002|OTHER|Control|Participants will be asked to consume glucose on a daily basis (twice per day) for the entire 8 weeks. The supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
48316454|NCT06554002|OTHER|Treatment|Participants will be asked to consume a resistant dextrin on a daily basis (twice per day) for the entire 8 weeks. The test supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
48316455|NCT00585923|DEVICE|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
48316456|NCT00585923|DEVICE|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
48316457|NCT04729920|DEVICE|Mechanical insufflation/exsufflation device (MI-E)|download of device (MI-E) data and self-reported satisfaction with the device
48316458|NCT05550194|DRUG|ValACYclovir 1000 MG|Valacyclcovir is a targeted anti-viral for varicella zoster virus (VZV).
48316459|NCT05550194|BIOLOGICAL|Shingrix|Vaccine indicated for prevention of herpes zoster
48316460|NCT05295368|OTHER|Multicomponent intervention|Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
48316461|NCT00953043|DRUG|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
48316462|NCT00953043|DRUG|Placebo|Placebo medication given for three days
48316463|NCT00953043|OTHER|Bowel preparation|Polyethylene glycol-based bowel preparation
48316464|NCT00407914|DEVICE|Aquamid|Subcutaneous injection
48316465|NCT00407914|DEVICE|Restylane|Injection in dermis
48316466|NCT00471536|DRUG|pazopanib hydrochloride|800 mg Given orally
48316467|NCT05201274|BEHAVIORAL|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
48316468|NCT05201274|BEHAVIORAL|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
47966128|NCT01603498|DRUG|Methylprednisolone|Methylprednisolone 40mg
47966129|NCT03478020|DRUG|AQX-1125|Investigational Drug
47966130|NCT03478020|DRUG|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
47966131|NCT01752998|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|
47966132|NCT01752998|BEHAVIORAL|Health Education|
48316469|NCT06553066|DRUG|Deep neuromascular blockage|"maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)"
48316470|NCT06553066|DRUG|Moderate neuromascular blockage|maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
48316471|NCT05582265|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48316472|NCT05582265|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48316473|NCT05582265|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48316474|NCT05582265|PROCEDURE|Surgical resection|Standard of care
48316475|NCT05582265|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48316476|NCT05582265|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48316477|NCT05582265|RADIATION|Radiation|Recommended, standard of care
48316478|NCT05582265|DRUG|Carboplatin (neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48316479|NCT05582265|DRUG|Carboplatin (adjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48316480|NCT00406783|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
48316481|NCT00406783|DRUG|Placebo|Placebo tablet, once daily for 15 days
48116338|NCT06554041|DEVICE|Dental Crown with Lithium-Disilicate-Abutment (e.max)|Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
48316482|NCT06282471|BEHAVIORAL|Expressive Writing and Problem-Solving Therapy (EW+PST)|Participants will undergo a 6-week self-guided EW+PST. Participants will be provided with 6 printed journals (one for each week of the study) and instructed to write at least 2 entries per week.
48316483|NCT05869487|RADIATION|Dual-energy X-ray absorptiometry|Whole body x-ray absorptiometry
48316484|NCT01858610|DRUG|Irbeasartan/hydrochlorothiazide|
48316485|NCT01858610|DRUG|Irbesartan|
48644842|NCT04695119|OTHER|Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.|Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
48316486|NCT01858610|DRUG|Hydrochlorothiazide|
48316487|NCT02131948|DRUG|Intranasal insulin|Intranasal spray
48316488|NCT02131948|DRUG|Intranasal placebo|Intranasal spray
48316489|NCT03730883|PROCEDURE|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
48316490|NCT03730883|PROCEDURE|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
48316491|NCT00718757|DRUG|Dexamethasone|5 doses given on Days 6-10
48316492|NCT00718757|DRUG|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
48316493|NCT00718757|DRUG|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg"
48316494|NCT05906056|DEVICE|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
48316495|NCT05906056|OTHER|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
48116339|NCT04561544|BEHAVIORAL|Knowing Who You Are (Becoming): Cultural Identity Intervention|8-week cultural identity development program led by Alaska Native Elders
48316496|NCT05906056|DRUG|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
48644843|NCT05431088|DRUG|Osivelotor|Tablets which contain drug substance
48316497|NCT02526758|DRUG|beclomethasone|
48644844|NCT06671665|DRUG|calcium supplementation|Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
48316498|NCT02526758|DRUG|formoterol|
48316499|NCT02526758|DRUG|budesonide|
48485424|NCT03707041|DRUG|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
48485425|NCT03707041|DRUG|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
48485426|NCT03707041|DRUG|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
48116340|NCT04647786|DEVICE|Prototype medical device (SEA CtV)|A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube. Gas flow may be timed, warmed and/or humidified.
48316500|NCT04552379|BIOLOGICAL|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at \~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
48316501|NCT06023173|DIAGNOSTIC_TEST|Deep radiomics-based fusion model|This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
48316502|NCT02562248|OTHER|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
48485427|NCT03707041|BIOLOGICAL|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
48485428|NCT04773717|DRUG|Ascorbic acid|200mg/kg/24h in four equal parts
48485429|NCT04773717|DRUG|Placebo|The same regimen as ascorbic acid.
48485430|NCT00002199|DRUG|Indinavir sulfate|
48485431|NCT00002199|DRUG|Lamivudine/Zidovudine|
48485432|NCT00002199|DRUG|Abacavir sulfate|
48316503|NCT02562248|OTHER|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
48316504|NCT03134651|DEVICE|Monitoring brain function|
48316505|NCT03134651|DRUG|propofol|
48316506|NCT01782456|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
48316507|NCT00230100|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
48316508|NCT00230100|BEHAVIORAL|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
48316509|NCT01237808|DRUG|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
48316510|NCT01237808|DRUG|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
48316511|NCT01237808|DRUG|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
48316512|NCT03335852|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
48316513|NCT04191967|DEVICE|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
48316514|NCT03363711|OTHER|AYA STEPS|a mobile health application
48316515|NCT04068311|OTHER|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
48316516|NCT02432248|DRUG|Dehydroepiandrosterone|75mg/day, PO for 90 days
48316517|NCT02432248|OTHER|placebo(medical starch)|75mg/day, PO for 90 days
48316518|NCT01822041|DRUG|ARN-509|Single oral dose of 240 mg ARN-509
48316519|NCT00446446|DRUG|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
48316520|NCT00004993|DRUG|Parathyroid hormone (hPTH 1-34)|
48316521|NCT03627910|DIETARY_SUPPLEMENT|symbiotic|Feed supplementation
48316522|NCT03627910|DIETARY_SUPPLEMENT|zinc and arginine|Feed supplementation
48316523|NCT00622869|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
48316524|NCT00622869|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
48316525|NCT00622869|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
48316526|NCT00622869|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
48316527|NCT00622869|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
48316528|NCT00622869|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
48316529|NCT01337011|OTHER|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
48116341|NCT03020745|DRUG|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
48316530|NCT01989234|DRUG|YKP10811|
48316531|NCT01989234|DRUG|Placebo|
48316532|NCT00840944|DRUG|somatropin|somatropin 0.050 mg/kg/day
48316533|NCT00840944|DRUG|triptorelin|triptorelin 3.75 mg each month
48316534|NCT01067508|OTHER|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
48316535|NCT02366663|RADIATION|90-Yttrium Ibritumomab tiuxetan|0.4 mCi/kg given IV
48316536|NCT02366663|DRUG|Carmustine|Given IV
48316537|NCT02366663|DRUG|Etoposide|Given IV
48316538|NCT02366663|DRUG|Cytarabine|Given IV
48116342|NCT03020745|DRUG|Placebo|Placebo is available as a Clear colorless solution.
48116343|NCT04414683|PROCEDURE|staging surgery|laparoscopic or laparotomic staging surgery
48116344|NCT06174636|PROCEDURE|Application of abdominal weight|Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
48116345|NCT00848627|OTHER|Specimen and questionnaires only|Specimen and questionnaires only
48116346|NCT02904759|DRUG|Desmopressin|
48116347|NCT02904759|DRUG|Placebo|
48316539|NCT02366663|DRUG|Melphalan|Given IV
48316540|NCT02366663|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplantation (ASCT)
48316541|NCT02366663|BIOLOGICAL|Rituximab|Given IV
48316542|NCT00504335|DRUG|BIO 300 Capsules|
48316543|NCT02065622|DRUG|Adalimumab|
48316544|NCT02065622|OTHER|Placebo|
48316545|NCT06290947|DEVICE|BFR Cuffs for Intervention Group|"The intervention consists of supervised treadmill sessions incorporating specialized BFR cuffs, branded as H+ Curve, tailored for Blood-Flow Restriction Walk Training (BFRw). These cuffs are strategically positioned on the upper portion of the lower limbs to induce muscle adaptations and~improve metabolic health outcomes. The innovative protocol is designed to probe the potential benefits of BFRw in ameliorating insulin sensitivity and enhancing aerobic capacity, thus presenting a pioneering exercise approach for individuals with Type 2 Diabetes."
48316546|NCT06290947|OTHER|Standard Walking Training Program|"The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention."
48316547|NCT02985450|BIOLOGICAL|Engerix-B|Hepatitis B Vaccine
48316548|NCT00444626|DEVICE|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
48316549|NCT00444626|DEVICE|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
48316550|NCT00444626|DRUG|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
48316551|NCT00039442|DRUG|Capecitabine|Given orally
48316552|NCT00039442|OTHER|Laboratory Biomarker Analysis|Correlative studies
48316553|NCT03505138|DEVICE|Group intervention|"GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year."
48316554|NCT03505138|OTHER|health care system|"GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year."
48316555|NCT05383729|OTHER|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
48316556|NCT05383729|OTHER|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.\[1\]
48316557|NCT03077126|OTHER|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
48116348|NCT03441204|DRUG|LTOT 24 h/day|LTOT prescribed for 24 h/day.
48116349|NCT03441204|DRUG|LTOT 15h/day|: LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
48316558|NCT03077126|DEVICE|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
48316559|NCT03077126|DIAGNOSTIC_TEST|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
48485433|NCT06427525|OTHER|Mobile application-based adolecent obesity education|Mobile application-based adolecent obesity education
48116350|NCT05904340|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) uses machines to generate electric current, flows through the skin and conducts to the nerves, triggers a chain reaction of nerves through a new stimulus source, and achieves the effect of pain relief. Using different frequencies and intensities will Produce different effects and trigger different physiological mechanisms.
48116351|NCT00019747|DRUG|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
48116352|NCT00019747|PROCEDURE|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
48116353|NCT00019747|OTHER|Placebo|oral placebo once daily
48316560|NCT03077126|PROCEDURE|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
48316561|NCT00001261|DRUG|Gamma Globulin|
48316562|NCT05067062|DIETARY_SUPPLEMENT|New Zealand blackcurrant extract|Capsules taken daily or intermittent
48316563|NCT00285974|DEVICE|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
48316564|NCT02902913|OTHER|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
48316565|NCT02902913|OTHER|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
48116354|NCT00939419|OTHER|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
48316566|NCT02902913|OTHER|D2i0|No oleocanthal and no oleacein
48316567|NCT02902913|DRUG|Ibuprofen|400 mg of Ibuprofen
48316568|NCT05688410|OTHER|Exercise|"Participants who are randomized to exercise will be perform exercise on stationary bikes. Participants randomized to Voluntary Exercise will exercise on a standard stationary bike where they will pedal at their voluntary rates. Participants randomized to Assisted Exercise will exercise on a special bike that assists them to pedal faster than they do voluntarily on their own (assisted (exercise) bike)."
48316569|NCT05688410|BEHAVIORAL|Psychotherapy Pain and Addiction (I-STOP)|"Participants who are randomized to receive I-STOP will receive the Self-regulation Treatment for Opioid addiction and Pain (STOP) program modified for inpatients/residential drug treatment (I-STOP). I-STOP uses empirically validated pain psychotherapy approaches targeted to patients with an OUD using psycho-physiological self-regulation components and biofeedback with Bio-dots."
48316570|NCT02550314|DRUG|fiblast,gelatin sponge,fibrin glue|
48316571|NCT05821621|OTHER|no intervention|observational study : there is no intervention
48316572|NCT02808533|DRUG|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
48316573|NCT02808533|OTHER|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
48316574|NCT01232894|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
48644845|NCT06671665|OTHER|Manual therapy|Manual therapy treatment will be in the form of craniosacral techniques and visceral manipulation techniques for 8 sessions in 12 weeks. Sessions will be divided into one session per week for the first 4 weeks then one session every two week for the next 8 weeks. Each session lasts for 45 minutes.
48644846|NCT06688578|DEVICE|Subperceptual Stimulus|For each test participants will be stimulated using a subperceptual electric signal that is optimized to improve their gait.
48116355|NCT00939419|OTHER|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
48316575|NCT01232894|DRUG|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
48316576|NCT03219593|DRUG|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
48316577|NCT03245723|PROCEDURE|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
48485434|NCT01360866|DRUG|OPC-34712|Tablet
48316578|NCT03245723|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
48316579|NCT03245723|PROCEDURE|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
48485435|NCT01360866|DRUG|Escitalopram|Tablet
48485436|NCT01360866|DRUG|Fluoxetine|Capsule
48644847|NCT06688578|DEVICE|Sham Comparator|During intervention trial, sham comparator will consist of same stimulation device but no actual electrical stimulation will be provided by device during intervention trial.
48316580|NCT03245723|PROCEDURE|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
48316581|NCT03314441|BEHAVIORAL|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
48316582|NCT00084916|DRUG|temsirolimus|Given IV
48316583|NCT00084916|OTHER|laboratory biomarker analysis|Correlative studies
48485437|NCT01360866|DRUG|Paroxetine CR|Controlled-release tablets
48485438|NCT01360866|DRUG|Sertraline|Tablets
48644848|NCT06691516|PROCEDURE|horizontal and vertical bone augmentation using computer guided cortical shell technique|Computer-guided cortical shell technique in anterior mandible 3d defect using bone harvesting guide and fixation guides
48485439|NCT01360866|DRUG|Duloxetine|Delayed-release capsules
48485440|NCT01360866|DRUG|Venlafaxine XR|Extended-release capsules
48485441|NCT01123317|DRUG|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
48316584|NCT02719470|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
48316585|NCT01908959|BEHAVIORAL|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
48316586|NCT02792010|DEVICE|Hip cartilage MRI|Hip cartilage MRI
48316587|NCT04108585|PROCEDURE|HFO therapy|HFO therapy from mechanical ventilation
48316588|NCT04108585|PROCEDURE|CPAP therapy|CPAP therapy from mechanical ventilation
48316589|NCT04773899|DIAGNOSTIC_TEST|Procedure : Multimodal microvascular assessment at study inclusion|"* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy."
48316590|NCT01200615|BEHAVIORAL|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
48316591|NCT00125190|DRUG|rhIGF-1 (mecasermin) for a period of 86 weeks|Once a day rhIGF-1 injections
48485442|NCT01078129|BEHAVIORAL|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
48485443|NCT01078129|BEHAVIORAL|non-CRT|waiting list
48485444|NCT02960438|DRUG|E6011|subcutaneous administration
48485445|NCT02960438|DRUG|Placebo|subcutaneous administration
48485446|NCT03041168|DEVICE|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
48485447|NCT04688580|DRUG|XW10172|Various formulations
48485448|NCT03102593|DRUG|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
48485449|NCT03102593|OTHER|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
48485450|NCT04313049|DEVICE|JACO2|Performing tasks using joystick control
48485451|NCT04313049|DEVICE|VOCAL CONTROL|Performing tasks using vocal control
48316592|NCT03204435|PROCEDURE|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
48316593|NCT03204435|PROCEDURE|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
48316594|NCT03204435|PROCEDURE|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
48316595|NCT03204435|PROCEDURE|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
48316596|NCT06457035|DRUG|immunosuppressant|No intervention was performed in this retrospective cohort study.
48316597|NCT01513226|OTHER|Cycled light|lights on at daytime, lights off at nighttime
48316598|NCT04281745|BIOLOGICAL|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
48316599|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume
48316600|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume
48316601|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume
48316602|NCT06142461|DEVICE|PharmaJet Stratis® Needle-Free Injection System|0.5mL dose injection
48316603|NCT06142461|DEVICE|PharmaJet Tropis® Needle-Free Injection System|0.1mL dose injection
48316604|NCT01488318|DRUG|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
48316605|NCT01488318|DRUG|Dasatinib|Dasatinib 150 mg po
48316606|NCT04423614|OTHER|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
48316607|NCT04423614|OTHER|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
48316608|NCT05008705|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive diary 2 doses of the protein supplement
48316609|NCT05008705|DEVICE|Neuromuscular electrostimulation.|Patients will receive diary sessions of neuromuscular electrostimulation.
48316610|NCT05008705|DIETARY_SUPPLEMENT|Placebo (isocaloric supplement)|Patients will receive diary 2 doses of the isocaloric supplement
48316611|NCT05008705|DEVICE|Sham for neuromuscular electrostimulation.|Patients will not receive neuromuscular electrostimulation.
48316612|NCT05656716|BEHAVIORAL|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
48316613|NCT05656716|BEHAVIORAL|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
48316614|NCT00011713|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
48316615|NCT04141852|DEVICE|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
48316616|NCT05509218|BEHAVIORAL|Mobile-delivered personalized feedback|Following each daily survey on which a participant indicates prior day drinking, personalized feedback will be provided on how their most recent behavior (e.g., drinks last night, drinking days so far this week) compare/contrast with personal goals. Participants will then choose whether to receive additional feedback in any of 7 areas: blood alcohol concentrate on, high risk behaviors, consequences of drinking, caloric intake, spending, how drinking compares to peers, and safe drinking strategies. All participants will receive feedback on drinks consumed, and then be asked to choose at least one additional topic for feedback (following each drinking day). In addition to day-level feedback, an aggregate feedback report on drinking patterns and related behaviors will be delivered twice, once at the end of each 2-week period. Once again, they will have the option to view feedback across the range of topics noted above.
48485452|NCT01007474|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
48485453|NCT01007474|DEVICE|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
48485454|NCT01007474|DEVICE|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
48316617|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
48316618|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
48316619|NCT02213302|DRUG|placebo administration|
48316620|NCT02213302|DRUG|midazolam intravenous administration|
48316621|NCT02548572|DEVICE|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
48316622|NCT02522832|OTHER|Titre 1|Virus infection
48116356|NCT00939419|OTHER|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
48644849|NCT06691516|PROCEDURE|free hand cortical shell technique in anterior 3d defect|vertical and horizontal ridge augmentation in anterior mandible using free hand cortical shell technique
48116357|NCT00568854|BIOLOGICAL|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
48116358|NCT00329251|BIOLOGICAL|Hepatitis A|
48316623|NCT02522832|OTHER|Titre 2|Virus infection
48316624|NCT02522832|OTHER|Titre 3|Virus infection
48316625|NCT05764018|DIETARY_SUPPLEMENT|Caffeine|Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise
48316626|NCT05764018|OTHER|Hypoxia|Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.
48316627|NCT05764018|OTHER|Placebo|Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.
48316628|NCT05764018|OTHER|Normoxia|Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)
48316629|NCT04520022|DRUG|Human Umbilical Cord Blood-derived Mesenchymal Stem Cells|3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
48485455|NCT01007474|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
48644850|NCT00005819|DRUG|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
48644851|NCT00005819|DRUG|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
48644852|NCT00005819|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
48644853|NCT06544655|DRUG|BMS-986484|Specified dose on specified days
48644854|NCT06544655|BIOLOGICAL|Nivolumab|Specified dose on specified days
48644855|NCT06543121|OTHER|Translating the Stroke Knowledge Test into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the test and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
48116359|NCT00329251|BIOLOGICAL|Hepatitis B|
48316630|NCT05290142|OTHER|Digital Training with Coaching (DT-C)|An identical digital training course and helpline will be available for the participants in this group. In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. The focus will be on clarifying learning objectives and redirecting participants to relevant materials rather than providing new learning opportunities. Participants will also be able to send text messages to coaches with queries related to course content, progress and technical difficulties. Coaches will reply to participants' messages within one working day and send reminders about upcoming telephone sessions, as well as prompts if the participant has not logged into the course for 3 consecutive days.
48316631|NCT05290142|OTHER|Self-Guided Digital Training|Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available offline and online on a smartphone app (called 'Sangath Training') as well as a website (https://training.sangath.in/login/index.php) that can be accessed through an internet-enabled device. The training will be delivered through didactic lectures, role-play demonstrations, and recommended readings spread across 16 modules. Participants will be provided with automated feedback on their learning through self-assessment quizzes after each module. Modules will be available sequentially and unlocked after accessing all content in the preceding module, over a period of 4 weeks. Technical helpline: Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface.
48316632|NCT03508765|DIAGNOSTIC_TEST|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
48316633|NCT03508765|DIAGNOSTIC_TEST|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
48316634|NCT03508765|BEHAVIORAL|Digit Span subtest|Evaluates auditory attention and working memory
48316635|NCT03508765|BEHAVIORAL|Brief Test of Attention|Assesses selective auditory attention
48316636|NCT03508765|BEHAVIORAL|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
48316637|NCT03508765|BEHAVIORAL|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
48316638|NCT03508765|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency.
48316639|NCT03508765|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
48316640|NCT03508765|BEHAVIORAL|The Center for Epidemiological Study-Depression|assesses perceived depression
48316641|NCT03508765|BEHAVIORAL|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
48316642|NCT03508765|OTHER|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
48644856|NCT06543121|OTHER|Validity|Content validity will be calculated with the Content Validity Index, which is a result of 10 expert opinions in terms of clarity, difficulty, and suitability of the Turkish version of the Stroke Knowledge Test. For face validity, the final version of the form will be provided with opinions from 3 stroke patients.
48116360|NCT00329251|BIOLOGICAL|Influenza|
48644857|NCT06543121|OTHER|Internal consistency and Reliability|The internal consistency of the items will be tested with Cronbach alpha. Test-retest reliability will be tested with intraclass correlation coefficient.
48644858|NCT00545948|DRUG|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
48644859|NCT00545948|DRUG|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
48644860|NCT05751811|DEVICE|Virtual reality|"The immersive video simulated a magical journey through a calming starry sky on a flying carpet. The headset will play the immersive video content throughout the hysteroscopic procedure; and will stop playing the content as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
48644861|NCT05751811|PROCEDURE|Music therapy|"Relaxing and light music will play throughout the hysteroscopic procedure; and will stop playing as the procedure comes to an end. Participant can adjust the volume of the sound according to her comfort.~The duration of hysteroscopic operation will be 5 to 20 minutes."
48644862|NCT06688552|OTHER|Proprioception Measurements|Laser cursor-assisted angle repetition test was used for proprioception assessment. A coordinate plane with different movement angles was fixed on a wall and the person was positioned 1 meter from this wall. The laser pointer was fixed on the person's arm for shoulder proprioception measurement, 5 cm above the elbow to avoid being affected by other joints, 5 cm above the person's wrist for elbow joint proprioception and fixed on the person's second metatarsal bone for wrist proprioception.
48316643|NCT04762147|DRUG|paracetamol, the group P|The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
48116361|NCT00329251|BIOLOGICAL|Pneumococcal|
48116362|NCT00329251|BIOLOGICAL|Tetanus-diphteria|
48116363|NCT00329251|BIOLOGICAL|Varicella|
48116364|NCT00329251|BIOLOGICAL|Measles-Mumps-Rubella|
48116365|NCT05817097|DRUG|Dipeptidyl peptidase-4 inhibitor|The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.
48116366|NCT00516386|DRUG|RhIGF-1|35-40 mcg/k/dose twice daily SC
48116367|NCT01013246|OTHER|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
48116368|NCT03480854|OTHER|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
48116369|NCT05573334|DEVICE|BioNourish|"BioNourish is a 510k-cleared class II medical device that has been on the market for over two years. It is a vaginal moisturizing gel that is designed with pH, osmolality, and lactic acid levels that match those observed in healthy vaginas. It does not have an active ingredient, but only provides moisture in a formula that is matched for physicochemical characteristics to healthy vaginal fluid."
48116370|NCT01195883|DRUG|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
48316644|NCT04762147|DRUG|fentanyl, group-F administered as an active comparator|The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
48316645|NCT04861961|PROCEDURE|DS vs. SADI-S vs. OAGBP|Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
48316646|NCT03361319|DRUG|Vargatef|small molecule triple kinase inhibitor
48485456|NCT01007474|DEVICE|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
48485457|NCT02708888|OTHER|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
48485458|NCT02708888|OTHER|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
48485459|NCT03936049|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group
48485460|NCT03936049|DRUG|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
48485461|NCT01634282|DRUG|OPC-262|Orally administered once daily
47966133|NCT00851747|DRUG|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
47966134|NCT00851747|DRUG|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
47966135|NCT00813306|DRUG|AZD2066|13 mg oral solution, 1 single dose
47966136|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
47966137|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
47966138|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
47966139|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
47966140|NCT00838578|BIOLOGICAL|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
47966141|NCT00838578|DRUG|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
47966142|NCT05913492|BEHAVIORAL|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
47966143|NCT03902288|OTHER|Fresh pomegranate juice|Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
47966144|NCT01306942|DRUG|Dasatinib|
48316647|NCT03361319|DRUG|Abraxane|Paclitaxel formulated as albumin bound nanoparticles
48316648|NCT03361319|OTHER|placebo|Placebo in place of Ninedanib
48316649|NCT01525927|DRUG|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
48316650|NCT01525927|RADIATION|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
48316651|NCT01525927|RADIATION|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
48316652|NCT04237740|DRUG|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
48485462|NCT04070287|COMBINATION_PRODUCT|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
48316653|NCT04110418|DRUG|Methylene Blue|"Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h"
48316654|NCT03649321|DRUG|Bemcentinib|200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
48316655|NCT03649321|DRUG|Nab-paclitaxel|25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
48316656|NCT03649321|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
48116371|NCT01195883|DRUG|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
48316657|NCT03649321|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
48316658|NCT00235651|DRUG|Amphotericin B|
48316659|NCT05370313|BEHAVIORAL|Market Price Condition (control)|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Cigarette taxes increased across trials at the same magnitudes used in the tax conditions.
48485463|NCT04070287|COMBINATION_PRODUCT|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
48485464|NCT04070287|COMBINATION_PRODUCT|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
48485465|NCT04070287|COMBINATION_PRODUCT|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
48485466|NCT04070287|COMBINATION_PRODUCT|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
47966145|NCT01306942|DRUG|Trastuzumab|
48116372|NCT04843306|BEHAVIORAL|Biofeedback|Relaxation coaching will be used in this study.
48116373|NCT04843306|BEHAVIORAL|Active Breathing Control Technique|Active breathing control (ABC) requires patients to reproducibly perform multiple deep-inspiratory breath holds during treatment.
48116374|NCT04367272|PROCEDURE|First Arthroplasty|First Knee
48116375|NCT04367272|PROCEDURE|Second Arthroplasty|Second Knee
48116377|NCT00697489|PROCEDURE|correction of POP plus preventive continence procedure|
48116378|NCT00697489|PROCEDURE|POP surgery followed by eventual incontinence procedure|
48316660|NCT05370313|BEHAVIORAL|Tobacco Parity Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all tobacco products are placed in the high-tax tier while products that do not contain tobacco (e.g., herbal cigarettes and nicotine-free ENDS) are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
48316661|NCT05370313|BEHAVIORAL|Nicotine-Content Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, products with greater than 3 mg nicotine per single unit are placed in the high-tax tier, products with 0.6-3.0 mg/unit in the medium-tax tier, and those with 0.5 mg/unit or less in the no-tax tier.
48316662|NCT05370313|BEHAVIORAL|Harm-Reduction Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all combustible products with high abuse liability are placed in the high-tax tier. All non-combustible products or combustible products with low abuse liability are placed in the medium-tax tier. Nicotine Replacement Therapy products are placed in the no-tax tier.
48316663|NCT05370313|BEHAVIORAL|Modified Risk Tobacco Product (MRTP) Tax Condition|Tobacco products in the Experimental Tobacco Marketplace are placed into three tax tiers: high-, medium-, and no-tax. In this condition, all non-MRTP tobacco products are placed in the high-tax tier, MRTPs are placed in the medium-tax tier, and Nicotine Replacement Therapy products are placed in the no-tax tier.
47966146|NCT01306942|DRUG|Paclitaxel|
48316664|NCT05094921|OTHER|Aquatic Halliwick method|The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck \& Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck \& Stanat 2001b).
48316665|NCT05094921|PROCEDURE|Conventional physical therapy|Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
48316666|NCT01044680|DIETARY_SUPPLEMENT|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
48316667|NCT01044680|DIETARY_SUPPLEMENT|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
48316668|NCT04273399|OTHER|High-impact exercise intervention|"* Twelve-week high-impact exercise intervention~* Majority home based sessions, some supervised sessions~* Three exercise sessions per week~* Between 50 - 100 jumps per session~* Progressive jumping exercises to increase mechanical loading"
48644863|NCT06688552|OTHER|Fatigue Measurement|Myoton PRO® (Myoton AS, Tallinn, Estonia) muscle palpation device was used to assess fatigue, and the dynamic stiffness parameter was taken as the basis. The stiffness value is calculated as the maximum acceleration (N/m) of oscillation and deformation in the tissue sensed by the transducer (Chen et al., 2017). The increase in muscle dynamic stiffness has been associated with fatigue level (Klich et al., 2019; Shitova et al., 2020; Wang, 2017). Before the measurement, the athletes' pectoralis major, deltoideus and triceps brachii muscle reference points were determined and marked, and measurements were taken over these points. The athletes were asked to keep their muscles relaxed throughout the measurement in order not to affect the tissue stiffness and the application was performed at room temperature.
47966147|NCT04653961|DEVICE|DreaMed Advisor Pro DSS-MDI algorithm|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
48316669|NCT04273399|OTHER|Acute response to high-impact exercise|"* First session of twelve-week high-impact exercise session used to assess the acute physiological response to one session of high-impact exercise in both Crohn's disease and healthy controls~* One supervised session of high-impact exercise~* Bloods to assess acute inflammatory and bone turnover response post-exercise"
48316670|NCT03703830|DEVICE|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
48316671|NCT03703830|OTHER|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
48316672|NCT03703830|DEVICE|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
48316673|NCT03703830|DEVICE|Cerebello-spinal direct current stimulation|Cerebello-spinal transcranial direct current stimulation (csDCS) will be applied during 25 minutes at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11)
48316674|NCT03703830|DEVICE|Sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation (csDCS sham) will be applied during 30 seconds at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11). However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
48316675|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
48485467|NCT00831623|RADIATION|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
48485468|NCT00831623|RADIATION|Proton|As above
47966148|NCT00707720|DEVICE|TERIS procedure|The implantation of the restrictive implant
48316676|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
48316677|NCT04937816|DRUG|Placebo|Placebo
48485469|NCT02055443|OTHER|12-lead holter monitor application|"-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~* The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~* After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
48485470|NCT00560027|OTHER|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
48485471|NCT05189236|PROCEDURE|Control Group (Only Algorithm of Febrile Neutropenia Management)|"Common Procedure Steps~1. The child is admitted to the unit and evaluated.~2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~3. The inclusion and exclusion criteria are evaluated.~4. The group of the child to be included in the study is determined in accordance with the randomization order.~5. The first section of the patient information and follow-up form is filled out.~6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~1. Common procedure steps are followed.~2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
48644864|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 1|The study foresees the intake of 1 capsule per day during 84 days
48644865|NCT06032598|DIETARY_SUPPLEMENT|Berry extract 2|The study foresees the intake of 1 capsule per day during 84 days
48644866|NCT06032598|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 84 days
48644867|NCT04991597|OTHER|Cold Compress Pack|Palmar aspect of forearm will have a cold compress pack placed on it.
48644868|NCT04991597|OTHER|Room Temperature Compress Pack|Palmar aspect of forearm will have a room temperature compress pack placed on it.
48644869|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
48644870|NCT04991597|DRUG|Lidocaine Epinephrine|Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
48316678|NCT04937816|DRUG|Empagliflozin|Empagliflozin once daily
48644871|NCT04179656|DRUG|Pyrotinib|400 mg administered orally, once daily, continuously in 21 day cycles
48644872|NCT02810132|DRUG|Metformin|See above
48644873|NCT02810132|DRUG|Placebo|See above
48644874|NCT00003067|BIOLOGICAL|aldesleukin|
48644875|NCT00003067|BIOLOGICAL|lymphokine-activated killer cells|
48316679|NCT03925818|DRUG|Bismuth Subcitrate Potassium|Pylera capsules
47966149|NCT02779829|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number SR15-40-Z12-006.
47966150|NCT03207230|DEVICE|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
48316680|NCT03925818|DIETARY_SUPPLEMENT|Gastrus|Gastrus 1 tablet
48316681|NCT04073940|BEHAVIORAL|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
48644876|NCT05042466|DRUG|Trauma|0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.
48644877|NCT06358950|DRUG|ALKS 2680|Oral tablet of ALKS 2680 for once daily administration
48644878|NCT06358950|DRUG|Placebo|Oral tablet containing matching placebo for once daily administration
48644879|NCT03641560|DRUG|Enzalutamide|Enzalutamide will be administered orally
48644880|NCT03641560|DRUG|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
47966151|NCT03207230|DEVICE|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
47966152|NCT03207230|DEVICE|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
47966153|NCT00999232|DRUG|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
47966154|NCT00999232|DRUG|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
48644881|NCT05562856|COMBINATION_PRODUCT|surface pre-reacted glass filler coating material|the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
47966155|NCT01416272|DEVICE|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
47966156|NCT02256631|BIOLOGICAL|VRC01|Administered by subcutaneous injection in the thigh
48116379|NCT05559346|OTHER|Diaphragmatic exercises|Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
48116380|NCT05559346|OTHER|conventional physiotherapy|The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
48116381|NCT06047522|DEVICE|Casque Lumeen|Participants will take part in virtual reality sessions via headset. They will benefit from a before/after evaluation, and a 3-week intervention where they will have 1 virtual reality session per week.
48116382|NCT00016471|PROCEDURE|Audiogram|
48116383|NCT00016471|PROCEDURE|Electroretinogram|
48116384|NCT04668170|BIOLOGICAL|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
48116385|NCT04668170|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
48116386|NCT04828148|BEHAVIORAL|Survey|An online survey made by the authors was used, which is comprised of a total of 48 questions where different types of information are distinguished regarding the participant who is answering it such as age, gender, medical degree, comorbidities if during the pandemic they have been in contact with patients suspected or confirmed of COVID-19 infection if they have been infected by COVID-19 and the outcome of this infection. It also refers to whether they know doctors in the same specialty or others who have died from COVID-19 infection.
48116387|NCT00158639|BEHAVIORAL|Home BP;secure messaging;pharmaceutical care;|
48116388|NCT00592813|BEHAVIORAL|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
48116389|NCT00592813|BEHAVIORAL|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
48116390|NCT06014775|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
47966157|NCT02256631|BIOLOGICAL|VRC01LS|Administered by subcutaneous injection in the thigh
48116391|NCT05924958|DRUG|Eprolidone|This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
48116392|NCT03239899|DRUG|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
48316682|NCT00458406|DEVICE|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
48316683|NCT00458406|DEVICE|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
48316684|NCT01648543|PROCEDURE|lumbar sympathetic ganglion block|
48316685|NCT04510194|DRUG|Metformin|Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
48316686|NCT04510194|DRUG|Placebo|placebo; appearance and size are exact matching to the three study drugs.
48644882|NCT06688604|BEHAVIORAL|skin contact|Ensuring mother-infant skin-to-skin contact by the researcher within the first 5 minutes after birth
48644883|NCT06220266|DRUG|Phytoestrogen|consume 1 capsule twice a day for 2 months which one capsule composed of dry weight 50 mg of Pueraria Mirifica 1or Pueraria Mirifica 2 or Pueraria Mirifica 3
48644884|NCT06220266|DRUG|Diet control & life style modification|Diet control \& life style modification
48644885|NCT06234475|BEHAVIORAL|Mobile health support|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months"
47966158|NCT02256631|BIOLOGICAL|VRC07-523LS|Administered by subcutaneous injection in the thigh
47966159|NCT00126191|DRUG|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
47966160|NCT00126191|DRUG|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
47966161|NCT00126191|DRUG|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
47966162|NCT00126191|DRUG|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
48116393|NCT06499584|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered."
48485472|NCT05189236|PROCEDURE|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|"Procedure Steps for Experiment Group:~1. Common procedure steps are followed.~2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
48116394|NCT01352533|PROCEDURE|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
48485473|NCT02714231|DRUG|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
48485474|NCT02714231|DRUG|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
48485475|NCT00701974|BIOLOGICAL|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
48485476|NCT00701974|BIOLOGICAL|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
48485477|NCT05364996|DIAGNOSTIC_TEST|bronchial endoscopy with bronchoalveolar lavage (LBA)|Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
48485478|NCT05364996|DIAGNOSTIC_TEST|Blood sampling|collection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay
48485479|NCT02823314|DEVICE|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
48485480|NCT02823314|DEVICE|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
48485481|NCT06414239|DEVICE|Use of a VR mask|Virtual reality mask
48485482|NCT06414239|OTHER|Standard of care|Without any premedication or anesthesia
48485483|NCT05329493|DEVICE|Cooling digit device application|Cooling digit device will be applied on subject's right hand ( fifth finger).
48485484|NCT00111358|BEHAVIORAL|Lifestyle Modification|
48485485|NCT00111358|OTHER|No lifestyle modification|
48485486|NCT03359824|OTHER|Exercise|
48485487|NCT05023577|DRUG|Rabeprazole|20mg bid
48485488|NCT05023577|DRUG|Bismuth potassium citrate|0.6g bid
48485489|NCT05023577|DRUG|Metronidazole|0.4g qid
48485490|NCT05023577|DRUG|Clarithromycin|0.5g bid
48485491|NCT05023577|DRUG|Levofloxacin|0.5g qd
48485492|NCT05915793|OTHER|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
48485493|NCT05915793|OTHER|Diaphragm strengthening|Diaphragm strengthening
48644886|NCT06234475|BEHAVIORAL|Financial incentive|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
48116395|NCT01352533|PROCEDURE|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
48116396|NCT01352533|PROCEDURE|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
48116397|NCT04951492|DRUG|Olaparib|Given PO
48316687|NCT04510194|DRUG|Fluvoxamine|An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
48485494|NCT02246868|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
48485495|NCT04540055|PROCEDURE|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
48485496|NCT04540055|PROCEDURE|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
48485497|NCT00283322|OTHER|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
48485498|NCT00720226|DRUG|Losartan|Losartan 100 mg daily
48485499|NCT00720226|DRUG|Placebo|Placebo pill daily
48485500|NCT03399318|DRUG|Acetaminophen|"30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments"
48485501|NCT03399318|DRUG|Ibuprofen|10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
48485502|NCT03399318|DRUG|placebo for acetaminophen|"placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo"
48485503|NCT03399318|DRUG|placebo for ibuprofen|placebo for ibuprofen
48485504|NCT00608595|DRUG|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
48485505|NCT00608595|GENETIC|gene expression analysis|not noted
48485506|NCT00608595|GENETIC|protein expression analysis|Not noted
48485507|NCT00608595|OTHER|immunohistochemistry staining method|not noted
48485508|NCT00608595|OTHER|laboratory biomarker analysis|not noted
48485509|NCT00608595|OTHER|mass spectrometry|
48316688|NCT04510194|DRUG|Ivermectin|An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
48316689|NCT05251454|PROCEDURE|Brain Stimulation|Participants will receive brief electrical brain stimulation as they perform the study tasks. This will be linked to events occurring on screen and/or to specific changes in their brain activity. The stimulation parameters will be individualized for each participant, but will never exceed safe limits for charge density (30 µC/phase).
48316690|NCT03571256|DRUG|TEV-50717|6-, 9-, 12-, 15-, and 18 mg oral tablets
48316691|NCT03571256|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID.
48316692|NCT02875847|DIETARY_SUPPLEMENT|HMO1|
48316693|NCT02875847|DIETARY_SUPPLEMENT|HMO2|
48316694|NCT02875847|DIETARY_SUPPLEMENT|Dextropur|
48316695|NCT05971004|DEVICE|Arthrys (Collagen Peptide solution)|one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point
48485510|NCT00608595|PROCEDURE|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
48485511|NCT00608595|PROCEDURE|neoadjuvant therapy|not noted
48485512|NCT00608595|PROCEDURE|therapeutic conventional surgery|not noted
48485513|NCT05844631|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
48485514|NCT03186703|BEHAVIORAL|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
48485515|NCT06188052|DRUG|Tranexamic acid|Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
48485516|NCT00869024|BIOLOGICAL|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
48485517|NCT04146831|DRUG|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
48485518|NCT00777127|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
48644887|NCT06234475|BEHAVIORAL|Combine intervention|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months~7. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
48644888|NCT06234475|BEHAVIORAL|Control group|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months for those without abstinence at 12-month follow-up after follow-ups ending~6. Acceptance and Commitment Therapy based rear-time Chat-based support for 3 months for those without abstinence at 12-month follow-up after follow-ups ending"
48644889|NCT06688448|DEVICE|Dafodil prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
48644890|NCT06688448|DEVICE|Aortic Valve Replacement - Inspires Resilia prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
48644891|NCT04569825|DRUG|Ophtamesone|local application intranasally as drops
48316696|NCT05971004|DRUG|Depo medrol|one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
48316697|NCT02669862|DRUG|A-101 Solution 40|
48316698|NCT02669862|DRUG|A-101 Solution 45|
48316699|NCT02669862|DRUG|Vehicle Solution|
48485519|NCT00777127|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
48485520|NCT02605798|DRUG|Elbanovir|1 tablet contains 400 mg sofosbuvir
48485521|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
48485522|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
48485523|NCT04447937|OTHER|No Interventions|There are no interventions associated with the study.
48485524|NCT04224727|BEHAVIORAL|Group Commitment Contract|A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.
48485525|NCT04224727|BEHAVIORAL|Individual Monetary Rewards|Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.
48316700|NCT01919918|DRUG|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
48316701|NCT04228120|BEHAVIORAL|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
48316702|NCT04365439|BIOLOGICAL|Blood plasma|Convalescent plasma after COVID-19
48316703|NCT02191241|DRUG|Red Vine Leaf Extract|
48116398|NCT03411369|DIETARY_SUPPLEMENT|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
47966163|NCT00126191|DRUG|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
47966164|NCT00126191|DRUG|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
47966165|NCT00126191|DRUG|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
47966166|NCT00126191|DRUG|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
48116399|NCT03411369|OTHER|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
48116400|NCT05929079|DRUG|Retatrutide|Administered SC
48116401|NCT05929079|DRUG|Placebo|Administered SC
48316704|NCT00218855|DRUG|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
48116402|NCT03851549|DEVICE|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
48485526|NCT04224727|BEHAVIORAL|Individual Commitment Contract|Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.
48485527|NCT04224727|OTHER|Information|"In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates."
48644892|NCT06687499|DRUG|Bismuth-based susceptibility-guided treatment|The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori. A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
48116403|NCT06677255|DRUG|VUM02 Injection (UC-MSCs)+BAT|"The dose-escalation phase (phase I):~Single dose escalation Phase 1a study: 3 dose levels of a single IV infusion; Multiple dose escalation Phase 1b study: 3 dose levels of twice weekly for 4 consecutive week.~The dose-expansion phase (phase II):~-Two dose groups will be selected by the investigator and the sponsor based on the results of the Phase 1b study, twice a week for 4 consecutive weeks for a total of 8 doses."
48116404|NCT06677255|OTHER|The control group with Best Available Therapy (BAT)|According to BAT scheme, the drug administration is determined by PI according to the condition of the patients.
48316705|NCT00218855|DRUG|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
48316706|NCT04719065|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
48316707|NCT01000727|DRUG|Darapladib 160 mg|Lp-PLA2 inhibitor
48644893|NCT06690710|BIOLOGICAL|allogeneic engineered Gingival Fibroblasts (aeGF)|single intra-articular injection of the study drug (aeGF) in the knee joint
48644894|NCT06688019|DEVICE|conventional oxygenation (nasal cannula)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
48316708|NCT01000727|DRUG|Placebo|Placebo administered
48316709|NCT01000727|OTHER|Standard Therapy|Guideline mandated therapy for individual's condition
48485528|NCT01582919|OTHER|Neuroimaging|
48485529|NCT01583517|PROCEDURE|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
48485530|NCT01583517|PROCEDURE|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
48644895|NCT06688019|DEVICE|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
48644896|NCT03878069|BIOLOGICAL|elapegademase-lvlr|Revcovi is administered intramuscularly (i.m.). Weekly dosage is calculated in mg/kg of body weight, and can be adjusted over the course of the trial based on ADA activity and dAXP concentration as well as on clinical assessment by the treating physician.
48116405|NCT00381173|DRUG|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
48644897|NCT06613477|DRUG|PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease|Table 3: Digoxin dosing regimen based on optimized Cmin,ss Dose to be given twice daily (mcg/kg/dose) PNA\<30 days 30 days \< PNA \< 180 days eGFR≤40 1.4 1.4 40\<eGFR≤60 1.6 1.6 eGFR\>60 1.9 2.8
48644898|NCT06683898|OTHER|External Focused Pilates|Pilates training was implemented with an external focus (EF).
48644899|NCT06683898|OTHER|Internal Focused Pilates|Pilates training was implemented with an internal focus (IF).
48644900|NCT06686173|OTHER|None-placebo|This is one kind descriptive study. The different donor groups made the cohorts different: the parous female donor and young male donor
48644901|NCT06686173|OTHER|non-intervention study|This study is one kind of non intervention study
48644902|NCT06686173|OTHER|donor selection|the intervention of this study was the different donor groups: the parous female donor and young male donor. All the patients involved in this study were treated by the combination of ATG and PTCy
48116406|NCT02158091|DRUG|IPI-145|oral PI3K delta/gamma inhibitor
48116407|NCT02158091|DRUG|Fludarabine|intravenous chemotherapy
48116408|NCT02158091|DRUG|Cyclophosphamide|intravenous chemotherapy
48316710|NCT04548999|DRUG|Ocrelizumab|"The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight \<75 kg) or 1800 mg (participant's body weight \>/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.~During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)"
48644903|NCT04473833|PROCEDURE|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
48644904|NCT06686979|OTHER|No Intervention: Observational Cohort|The patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
48644905|NCT06689878|BEHAVIORAL|Mobile Cognitive Behavioral App|"A mobile cognitive behavioral therapy (CBT) app called Maya that includes modules with educational content and teaching and practice of strategies that address depression and anxiety after stroke."
47966167|NCT00126191|DRUG|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
47966168|NCT00126191|DRUG|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
47966169|NCT02927665|DEVICE|Reshape Integrated Dual Balloon|
47966170|NCT01658462|DRUG|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
47966171|NCT01658462|DRUG|Nintedanib|"200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered"
47966172|NCT01658462|DRUG|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
47966173|NCT00987675|OTHER|pharmacological study|
47966174|NCT00987675|OTHER|questionnaire administration|
47966175|NCT00987675|PROCEDURE|assessment of therapy complications|
47966176|NCT00987675|PROCEDURE|high-intensity focused ultrasound ablation|
47966177|NCT00987675|PROCEDURE|quality-of-life assessment|
47966178|NCT00247975|DRUG|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
47966179|NCT01301352|OTHER|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
47966180|NCT00042289|DRUG|atazanavir/cobicistat|atazanavir/cobicistat 300/150 mg q.d.
47966181|NCT00042289|DRUG|darunavir/ritonavir dosage #1|darunavir/ritonavir twice daily 600/100 mg b.i.d.
47966182|NCT00042289|DRUG|darunavir/ritonavir dosage #2|darunavir/ritonavir twice daily 800/100 mg b.i.d.
47966183|NCT00042289|DRUG|darunavir/ritonavir dosage #3|darunavir/ritonavir twice daily 900/100 mg b.i.d.
47966184|NCT00042289|DRUG|elvitegravir/cobicistat|elvitegravir/cobicistat 150/150 mg q.d.
47966185|NCT00042289|DRUG|dolutegravir|dolutegravir 50 mg q.d.
47966186|NCT00042289|DRUG|tenofovir alafenamide fumarate (TAF)|TAF 25 mg q.d. without cobicistat or ritonavir boosting
48116409|NCT02158091|DRUG|Rituximab|intravenous immunotherapy
48116410|NCT01399671|OTHER|vestibular stimulation|vestibular stimulation
48116411|NCT04310072|DEVICE|Neuromuscular electrical stimulation|NMES therapy induces visible rhythmic and repeated muscle contractions without volitional effort from the patient by applying electrodes to the thigh and/or calf muscles.
48116412|NCT00583817|DEVICE|Endovascular stent-graft implantation|Endovascular repair of aorta
48644906|NCT03549507|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
48644907|NCT06687785|PROCEDURE|Entire Papilla Preservation Technique|A buccal intrasulcular incision was made in the tooth with the defect and a vertical incision was made extending from the buccal center of the tooth to the mesial papillary crest and crossing the mucogingival line. Then, using a micro periosteal elevator, a full-thickness mucoperiosteal flap was lifted from the incision site to the defect under the papilla. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the vertical incision was sutured with 6/0 polypropylene suture using simple suture technique.
48644908|NCT06687785|PROCEDURE|Conventional Flap Surgery Technique|After buccal and lingual intrasulcular incisions were made to eliminate the teeth and papillae adjacent to the defect, a full-thickness mucoperiosteal flap was raised in the vestibular and lingual direction with a periosteal elevator. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the papillary incisions were sutured with 5/0 polypropylene suture using simple suture technique.
48644909|NCT05231252|PROCEDURE|Cyclophotocoagulation|Transcleral cyclophotocoagulation is used to treat glaucoma secondary to silicone oil.
48644910|NCT06686342|OTHER|No intervention|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
47966187|NCT00042289|DRUG|TAF w/cobicistat|TAF 10 mg q.d. with cobicistat
48116413|NCT03912961|OTHER|Picture of the retina with a handheld retinal camera|Patient with diabetes will have their undilated and dilated images taken, with the images being centered on the macula and on the optic disc.
48116414|NCT05187975|PROCEDURE|Acupuncture|"Acupuncture:~Scalp acupuncture includes middle line of forehead (MS1), a front line by the forehead (MS2), and middle line of vertex (MS5), these acupoints are needled for 1 inch with the direction with scalp tilted 15-30 degrees.~Body acupuncture includes Yintang (DU29), Taichong (LR3), Shenmen (HT7), Neiguan (PC6), Danzhong (RN17), Qimen (LR14), Taixi (KI3).~Traditional Chinese medicine:~Chaihushugan Power: Chaihu 12g, Chenpi 12g, Chuanxiong 9g, vinegar Xiangfu 9g, Zhike 9g, Shaoyao 9g, roasted Gancao 3g.~Repetitive transcranial magnetic stimulation:~The CCY-I magnetic field stimulator from Wuhan Irid Medical Equipment New Technology Co is used, with a frequency of 10Hz.~Standard care:~The same as the standard care group."
48116415|NCT02147535|DRUG|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
48116416|NCT01482975|OTHER|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
48116417|NCT01482975|OTHER|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
48116418|NCT01786525|BEHAVIORAL|House Calls|60-minute home based educational intervention which will be administered by a health educator
48116419|NCT01786525|BEHAVIORAL|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
48116420|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (MRI, exercise testing, clinical function) will be performed 3 hours after time of dosing.
48485531|NCT01583517|PROCEDURE|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
47966188|NCT00042289|DRUG|TAF w/cobicistat or ritonavir|TAF 25 mg q.d. with cobicistat or ritonavir boosting
47966189|NCT00042289|DRUG|efavirenz|efavirenz 600 mg q.d.
47966190|NCT00042289|DRUG|darunavir/cobicistat|darunavir/cobicistat 800/150 mg q.d.
47966191|NCT00042289|DRUG|lopinavir/ritonavir dosage #1|lopinavir/ritonavir 800/200mg b.i.d.
47966192|NCT00042289|DRUG|atazanavir/ritonavir/tenofovir dosage #1|atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
47966193|NCT00042289|DRUG|rifampicin|rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
47966194|NCT00042289|DRUG|ethambutol|ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
47966195|NCT00042289|DRUG|isoniazid|isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
47966196|NCT00042289|DRUG|pyrazinamide|pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
47966197|NCT00042289|DRUG|kanamycin|kanamycin (2nd line TB drug)
47966198|NCT00042289|DRUG|amikacin|amikacin (2nd line TB drug)
47966199|NCT00042289|DRUG|capreomycin|capreomycin (2nd line TB drug)
47966200|NCT00042289|DRUG|moxifloxacin|moxifloxacin (2nd line TB drug)
47966201|NCT00042289|DRUG|levoflaxacin|levofloxacin (2nd line TB drug)
47966202|NCT00042289|DRUG|ofloxacin|ofloxacin (2nd line TB drug)
47966203|NCT00042289|DRUG|ethionamide/prothionamide|ethionamide/prothionamide (2nd line TB drug)
47966204|NCT00042289|DRUG|terizidone/cycloserine|terizidone/cycloserine (2nd line TB drug)
47966205|NCT00042289|DRUG|para-aminosalicylic acid (PAS)|para-aminosalicylic acid (PAS) (2nd line TB drug)
47966206|NCT00042289|DRUG|high dose INH|high dose INH (2nd line TB drug)
48316711|NCT04548999|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
48316712|NCT04548999|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
48316713|NCT04548999|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
48316714|NCT06298461|DRUG|KleanLyte|Laxative for colonoscopy bowel preparation
48316715|NCT06298461|DRUG|Bi-PegLyte|Laxative for colonoscopy bowel preparation
48316716|NCT05632627|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.
48485532|NCT02616484|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
48485533|NCT02616484|OTHER|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
47966207|NCT00042289|DRUG|bedaquiline|bedaquiline (2nd line TB drug)
48116421|NCT05195775|DRUG|Tadalafil|Patient will be randomized to one dose of 0.6 mg/kg tadalafill on one of two study visits. On both visits, assessments (Doppler US, exercise testing, clinical function) will be performed 3 hours after time of dosing.
48316717|NCT05632627|DRUG|Placebo|Placebo arm
48316718|NCT04081597|DRUG|Star-101|Administered orally
48316719|NCT04081597|DRUG|Placebo|Administered orally
48316720|NCT00710034|OTHER|Oral tobacco|Snus
48316721|NCT00710034|DRUG|Nicotine Gum|4 mg Nicotine gum
47966208|NCT00042289|DRUG|clofazamine|clofazamine (2nd TB drug)
47966209|NCT00042289|DRUG|delamanid|delamanid (2nd line TB drug)
47966210|NCT00042289|DRUG|linezolid|linezolid (2nd line TB drug)
48316722|NCT04873024|DEVICE|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
47966211|NCT00042289|DRUG|pretomanid|pretomanid (2nd line TB drug)
47966212|NCT00042289|DRUG|ethinyl estradiol|oral contraceptives formulated with 30-35 μg ethinyl estradiol
47966213|NCT00042289|DRUG|etonogestrel implant|etonogestrel implant contraceptive
47966214|NCT00042289|DRUG|nevirapine|nevirapine 200 mg twice a day
47966215|NCT00042289|DRUG|amprenavir|amprenavir 1200mg twice a day
47966216|NCT00042289|DRUG|abacavir|abacavir 300mg twice a day
47966217|NCT00042289|DRUG|lopinavir/ritonavir dosage #2|lopinavir/ritonavir (Kaletra) 400/100mg twice a day
47966218|NCT00042289|DRUG|indinavir/ritonavir dosage #1|indinavir/ritonavir 800/100mg twice a day
47966219|NCT00042289|DRUG|fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg twice a day
47966220|NCT00042289|DRUG|lopinavir/ritonavir dosage #3|lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
47966221|NCT00042289|DRUG|atazanavir/ritonavir dosage #1|atazanavir/ritonavir 300/100 mg once a day
47966222|NCT00042289|DRUG|didanosine delayed release (Videx® EC)|didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
47966223|NCT00042289|DRUG|emtricitabine|emtricitabine 200 mg once a day
48316723|NCT01523119|DRUG|Ondansetron|Orally Disintegrating Tablets 8 mg
47966224|NCT00042289|DRUG|tenofovir|tenofovir 300 mg once a day
47966225|NCT00042289|DRUG|nelfinavir dosage #1|nelfinavir \[625 mg tablets\] 1250 mg twice a day
47966226|NCT00042289|DRUG|tipranavir/ritonavir|tipranavir/ritonavir 500/200 mg twice a day
47966227|NCT00042289|DRUG|lopinavir/ritonavir dosage #4|lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
47966228|NCT00042289|DRUG|raltegravir|raltegravir 400 mg twice a day
47966229|NCT00042289|DRUG|etravirine|etravirine 200 mg twice a day
48316724|NCT03014440|DRUG|Cannabidiol|
48316725|NCT01151046|DRUG|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
48316726|NCT01151046|DRUG|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
48316727|NCT01151046|DRUG|Exemestane|Exemestane (25 mg) administered orally once per day
48316728|NCT03458832|DIAGNOSTIC_TEST|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
48316729|NCT03458832|DEVICE|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
48485534|NCT02616484|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
48485535|NCT00784524|BIOLOGICAL|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
48316730|NCT00426517|DRUG|Campath 1H|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
48316731|NCT00426517|DRUG|Busulfan|Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
48316732|NCT00426517|DRUG|Horse Anti-human Thymocyte Globulin (h-ATG)|Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
48316733|NCT00426517|DRUG|Total Body Irradiation (TBI)|TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
48316734|NCT00426517|DRUG|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
48485536|NCT00784524|BIOLOGICAL|aldesleukin|Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.
48485537|NCT02459665|BIOLOGICAL|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
48485538|NCT02459665|DRUG|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
48485539|NCT02459665|BIOLOGICAL|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
48644911|NCT06686342|OTHER|No Intervention: Observational Cohort|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
48644912|NCT06358508|DEVICE|Sapphire 3 Coronary Dilatation Catheter|To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.
47966230|NCT00042289|DRUG|maraviroc|maraviroc 150 mg or 300 mg twice a day
48116422|NCT03462589|DRUG|SY-008|The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
48644913|NCT06691425|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT (5 x 8 Gy)
47966231|NCT00042289|DRUG|atazanavir/ritonavir dosage #2|atazanavir/ritonavir 400/100mg once a day
47966232|NCT00042289|DRUG|tenofovir/atazanavir/ritonavir dosage #2|tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
47966233|NCT00042289|DRUG|nelfinavir dosage #2|nelfinavir \[625 mg tablets\] 1875 mg twice a day
47966234|NCT00042289|DRUG|indinavir/ritonavir dosage #2|indinavir/ritonavir 400/100 mg twice a day
47966235|NCT00042289|DRUG|rilpivirine|rilpivirine (25 mg q.d.)
47966236|NCT00042289|DRUG|darunavir/ritonavir dosage #4|darunavir/ritonavir once daily 800/100 mg q.d.
47966237|NCT04048928|BEHAVIORAL|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
47966238|NCT02154776|DRUG|LEE011|3 weeks on and 1 week off
47966239|NCT02154776|DRUG|Buparlisib|daily
47966240|NCT02154776|DRUG|Letrozole|2.5 mg daily;
48316735|NCT00448916|DRUG|Pregabalin|Orally-administered pregabalin
48316736|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
48316737|NCT00999856|DEVICE|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
48316738|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
48316739|NCT00999856|DEVICE|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
48316740|NCT00999856|DEVICE|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
48316741|NCT06174181|DEVICE|Preservative-free ophtalmic lubricant emulsion|Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
48485540|NCT05270928|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
48485541|NCT03812991|DRUG|Miacalcin Calcitonin Salmon Nasal Spray|Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
48644914|NCT06691425|DRUG|Chemotherapy|Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel
48644915|NCT05497960|BEHAVIORAL|Vivo workout|2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
48316742|NCT06174181|OTHER|Routine treatment|Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
48316743|NCT01025817|DRUG|Everolimus and tacrolimus|"Everolimus:~* Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~* Dose: 1.5 mg per day~* Frequency: 0.75 mg twice daily~Tacrolimus:~* Dose adjusted to maintain specific blood levels"
48316744|NCT01025817|DRUG|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
48316745|NCT05755334|DRUG|Ropivacaine|Administration of Ropivacaine
48316746|NCT05804409|DIAGNOSTIC_TEST|FECAL ELASTASE|screening for pancreatic exocrine insufficiency in MAFLD patients
48316747|NCT00835887|DIETARY_SUPPLEMENT|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
48316748|NCT04761029|OTHER|RIIS|unilateral Rhomboid intercostal and subserratus block
48485542|NCT05528640|OTHER|Mental Health Literacy Program|Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
48116423|NCT05801068|DRUG|Factor Xa Inhibitor|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
47966241|NCT02318147|PROCEDURE|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
47966242|NCT02318147|DRUG|The traditional treatment|the traditional treatments according to associated guidelines
47966243|NCT04456608|DRUG|Aspirin|Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
47966244|NCT06266572|BEHAVIORAL|Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)|Web-based educational platform for clinicians and individuals with OUD that will decrease barriers to care and enhance treatment outcomes
47966245|NCT05108155|PROCEDURE|Cemented THA|THA with cement fixation
47966246|NCT05108155|PROCEDURE|Unemented THA|THA with uncemented / pressfit fixation
48316749|NCT04761029|DRUG|Tramadol|intravenous patient-controlled analgesia (tramadol)
48316750|NCT05290649|DIAGNOSTIC_TEST|clinical assessment|mini mental test, pulmonary function test, respiratory muscle strength test, trunk impairment scale, timed up and go test, barthel index
48316751|NCT00912015|DRUG|Tramadol OAD|
48485543|NCT02324673|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
47966247|NCT06145672|PROCEDURE|follicular unit extraction and implantaion|extract hair follicles as grafts from donor area and implant them in recipient area
47966248|NCT03415217|OTHER|Neighbourhood Team Development Program|The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
48116424|NCT00917865|DRUG|anti [18F]FACBC|Anti\[18F\]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
48316752|NCT00912015|DRUG|Tramadol OAD|
48316753|NCT00912015|DRUG|Tramadol OAD|
48316754|NCT00912015|DRUG|Tramadol OAD 100mg|
48316755|NCT06130852|BEHAVIORAL|Behavioral Parent Training|10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.
48485544|NCT02039752|OTHER|Treatment|
48485545|NCT01083017|DRUG|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
48485546|NCT01083017|BEHAVIORAL|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
48316756|NCT00240552|DRUG|fosamprenavir|
48316757|NCT00240552|DRUG|Telzir®|
48316758|NCT05542329|DEVICE|Monitoring by Tele-Medecine|Monitoring by Tele-Medecine
48316759|NCT01592409|DRUG|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
48316760|NCT01592409|DRUG|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
48485547|NCT01083017|DRUG|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
48485548|NCT00882206|DRUG|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~\*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
48485549|NCT00882206|DRUG|decitabine|Days 1-4, 15 mg/m\^2 intravenously (IV) over 1 hour
48485550|NCT00882206|DRUG|doxorubicin hydrochloride|Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
48485551|NCT00882206|DRUG|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age \<18 years and 400 mg orally every day for \>18 years on Days 5-33.
48316761|NCT02742350|DEVICE|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
48316762|NCT02569619|BEHAVIORAL|Activity Intervention|
48316763|NCT02569619|BEHAVIORAL|Healthy Diet Intervention|
48316764|NCT04385914|OTHER|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
48316765|NCT01897922|OTHER|An investigational infant formula containing a probiotic source|
48316766|NCT01897922|OTHER|Control: Marketed routine infant formula|
48316767|NCT02841787|BEHAVIORAL|iCBT for late life depression|
48316768|NCT02812433|DRUG|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
48316769|NCT02812433|DRUG|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
48316770|NCT03924791|DRUG|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
48316771|NCT03924791|DRUG|Methylprednisolone Acetate|In combination with lidocaine
48316772|NCT03924791|DRUG|Dexamethasone|In combination with lidocaine
48316773|NCT02300415|BIOLOGICAL|blood sample|Dosage of presepsine
48316774|NCT01070524|DRUG|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
48316775|NCT01070524|DRUG|Budesonide extrafine pMDI|Budesonide extrafine pMDI
48316776|NCT01070524|DRUG|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
48316777|NCT00283998|PROCEDURE|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
48316778|NCT01321502|DRUG|famciclovir|500 mg tablet
48316779|NCT02622724|DRUG|Interferon beta-1a|Investigational drug
48316780|NCT02622724|DRUG|Placebo|Placebo for investigational drug
48316781|NCT02825264|DEVICE|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
48316782|NCT00648193|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
48316783|NCT00648193|DRUG|Paxil® 40 mg Table|40mg, single dose fasting
48316784|NCT01093755|DRUG|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
48316785|NCT01093755|DRUG|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
48316786|NCT01111201|BEHAVIORAL|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
47966249|NCT06327035|OTHER|Gait rehabilitation|"Assessment of gait and balance abilities after stroke during neurorehabilitation from the subacute phase of stroke to 6 months after stroke.~The assessments will be carried out on entrance to the neurological center, then at 1 ,3 and 6 months and on hospital discharge."
48316787|NCT00677690|OTHER|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
48316788|NCT00677690|OTHER|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
48316789|NCT02393118|DEVICE|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
48316790|NCT05433194|BIOLOGICAL|ABO1009-DP|Vaccine
47966250|NCT02359760|PROCEDURE|Piezocision|Flapless corticotomies
48116425|NCT04358549|DRUG|Favipiravir|Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets
48116426|NCT04358549|OTHER|Standard of Care|Standard of Care for individual study site as determined by each hospital's protocol
48116427|NCT04436393|DIAGNOSTIC_TEST|Guardant360 test|tumor cfDNA testing
48316791|NCT04820543|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
48316792|NCT01113021|DEVICE|Photon stimulation by low level laser therapy|
48316793|NCT02268006|RADIATION|IMRT-SIB|
48316794|NCT02268006|DRUG|Capecitabine|
48316795|NCT02268006|PROCEDURE|Surgery|
48316796|NCT00982241|DIETARY_SUPPLEMENT|water|drinking water / normal dietary fluids for oral intake
48316797|NCT00724724|DRUG|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
48316798|NCT00724724|DRUG|Aspirin|Aspirin 100mg Qd for 1 year
48116428|NCT00761709|DRUG|AL-39256 Ophthalmic Suspension, 1%|
48316799|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
48316800|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
48316801|NCT03294408|DIAGNOSTIC_TEST|multimodal imaging|
48316802|NCT02456870|OTHER|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
48316803|NCT03625427|DIETARY_SUPPLEMENT|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
48316804|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 500 mg (Dose 1)|Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
48316805|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 1,000 mg (Dose 2)|Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
48316806|NCT02697513|BEHAVIORAL|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
48316807|NCT00793819|DRUG|silodosin|α1-adrenergic antagonist
48316808|NCT01795898|DRUG|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
48316809|NCT00002903|DRUG|docetaxel|
48316810|NCT03230344|PROCEDURE|open flap debridement|open flap debridement simultaneously with root canal treatment
48316811|NCT03230344|PROCEDURE|open flap debridement|open flap debridement and delayed root canal treatment
48316812|NCT00131040|DRUG|Aprotinin|
48316813|NCT03430817|DRUG|Citicholine|Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
48316814|NCT03430817|DRUG|Amantadine|Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
48316815|NCT02953782|DRUG|Magrolimab|Administered intravenously
48316816|NCT02953782|DRUG|Cetuximab|Administered intravenously
48316817|NCT05674838|OTHER|Leg Elevation|Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge and both of her legs elevated on an orange peanut ball. She will remain in this position for approximately 40 minutes.
48316818|NCT03348852|DEVICE|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
48316819|NCT03545698|OTHER|Avizia Telehealth Platform|Avizia will be utilized as a communication tool between home-based caregivers (family members, formal caregivers, or informal caregivers) and the House Calls care management team.
48485552|NCT00882206|DRUG|methotrexate|\*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
48485553|NCT00882206|DRUG|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
48644916|NCT06679582|DRUG|Luveltamab tazevibulin|"Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.~Other Names:~* STRO-002~* Luvelta"
48644917|NCT06690749|DEVICE|Negative pressure therapy, NPT|"We designed the experiment based on current clinical cases involving negative pressure therapy (NPT) for wounds and related animal studies. In this study, we applied three levels of negative pressure: -105 mmHg, -125 mmHg, and -145 mmHg, each for 10 minutes.~The -125 mmHg dosage was chosen based on findings from a previous study. Similar studies that utilized increments and decrements of 20 mmHg informed our research.~Moreover, to prevent any damage to new capillaries, we established a base dosage of -125 mmHg and refrained from using negative pressure levels exceeding -150 mmHg."
48644918|NCT01810172|DEVICE|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
48644919|NCT01810172|DEVICE|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
48644920|NCT06686576|BIOLOGICAL|QL1706|Phase Ib/Ⅲ： QL1706 will be administered
47966251|NCT00766311|OTHER|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
48644921|NCT06686576|DRUG|CAPEOX|Phase Ⅲ：CAPEOX will be administered
47966252|NCT00766311|OTHER|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
48116429|NCT00761709|DRUG|Latanoprost Ophthalmic Solution, 0.005%|
48316820|NCT05653297|DEVICE|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
48316821|NCT05181020|BEHAVIORAL|Maternal Voice Exposure|Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
48316822|NCT02572258|OTHER|Nutritional cookie|
48316823|NCT04758429|DEVICE|Machine-learning Algorithm|System technology/Software
48316824|NCT04912037|DEVICE|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
48316825|NCT01051986|PROCEDURE|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
48316826|NCT01051986|PROCEDURE|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
48316827|NCT01052987|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
48316828|NCT01052987|DRUG|Allopurinol|Allopurinol tablets 300 mg, QD
48316829|NCT01052987|DRUG|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
48316830|NCT01052987|DRUG|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
48485554|NCT00882206|DRUG|prednisone|40mg/m2/day divided BID (days 5 - 33)
48485555|NCT00882206|DRUG|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
48316831|NCT01052987|DRUG|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
48316832|NCT01502982|DRUG|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
48644922|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 1|A Flu mRNA vaccine composition in combination with Dose 1 of a COVID-19 component will be administered.
47966253|NCT00766311|OTHER|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
48116430|NCT00761709|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
48116431|NCT04928248|OTHER|Diabetes Dashboard integrated with Disease Manager App|The Diabetes Dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface. The Diabetes Dashboard is integrated within the diabetes module of the EHR-integrated Disease Manager App, which uses key information from the Diabetes Dashboard and provides a link to the Diabetes Dashboard.
48116432|NCT05316220|DRUG|Mesalamine|Oral Capsules
48116433|NCT05316220|DRUG|Placebo|Oral Capsule
48116434|NCT02703714|DRUG|Pembrolizumab|200 mg given intravenously (IV)
48116435|NCT02703714|DRUG|Sargramostim|250 µg given subcutaneously (SC)
48116436|NCT04363996|OTHER|New Bioactive Restorative Material|Filling material
48116437|NCT03529396|DRUG|Chloroquine|Standard chloroquine (three days)
48116438|NCT03529396|DRUG|Primaquine|Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
48116439|NCT03529396|DRUG|Primaquine|Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
48116440|NCT03529396|DRUG|Chloroquine|Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
48116441|NCT03529396|DRUG|Primaquine|Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
47966254|NCT00766311|OTHER|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
48116442|NCT06002945|OTHER|Blood sample|Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
48116443|NCT05263115|OTHER|Resistance Exercise intervention|12-week progressive resistance exercise intervention
48116444|NCT05263115|OTHER|Functional stair climbing and stepping-based exercise intervention|12-week progressive stair climbing and stepping-based exercise intervention
48116445|NCT01077934|DEVICE|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
48316833|NCT01226355|DEVICE|stent|"NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd."
48316834|NCT04157985|DRUG|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
48316835|NCT04157985|OTHER|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
48485556|NCT00882206|DRUG|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
48644923|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal /SARS-CoV-2 mRNA Dose 2|A Flu mRNA vaccine composition in combination with Dose 2 of a COVID-19 component will be administered.
48644924|NCT06680375|COMBINATION_PRODUCT|Flu Seasonal mRNA|An investigational mRNA Flu Seasonal vaccine will be administered.
47966255|NCT00766311|OTHER|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
47966256|NCT00766311|OTHER|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
47966257|NCT00766311|OTHER|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
48116446|NCT06422650|DRUG|Nigella Sativa capsule 500mg|Nigella Sativa capsule 500mg twice daily for 8 weeks
48116447|NCT06422650|DRUG|Placebo|Oral placebo identical to astaxanthin
48116448|NCT02798835|DRUG|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
48116449|NCT02798835|DRUG|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
48116450|NCT02798835|DRUG|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
48116451|NCT02798835|DRUG|Bupivacaine|Used in spinal anesthetic
48116452|NCT02798835|DRUG|Fentanyl|May or may not be used in spinal anesthetic
48116453|NCT02798835|DRUG|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
48116454|NCT02798835|DRUG|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
48316836|NCT02796391|DRUG|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
48316837|NCT02796391|BEHAVIORAL|One on One Counseling|All participants will receive One on One Counseling.
48316838|NCT04004078|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
48316839|NCT03420378|DIETARY_SUPPLEMENT|vitamin D|Vitamin D replacement
48316840|NCT03824925|DRUG|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
48316841|NCT03824925|DRUG|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
48316842|NCT00398385|DRUG|cisplatin|
48316843|NCT00398385|DRUG|gemcitabine hydrochloride|
48316844|NCT00398385|PROCEDURE|adjuvant therapy|
48316845|NCT00398385|PROCEDURE|conventional surgery|
48316846|NCT00398385|PROCEDURE|neoadjuvant therapy|
48316847|NCT02338791|DEVICE|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
48316848|NCT03338517|OTHER|Helium Neon Laser|
48316849|NCT04986449|BEHAVIORAL|nutritional and culinary intervention|"Each family will attend a total of 4 culinary-nutritional workshops between April and June 2021. Workshops 1 and 2 will be held in the kitchen located at the Science Building of the University of Navarra and will be given individually to each family.~Workshops 3 and 4 will be online (Zoom) and will be held in groups of 5 families. These workshops will be held from 5.30 pm to 7.30 pm on Fridays or from 11.30 am to 1.30 pm on Saturdays.~Finally, a meeting will be organized with all the families (parents and children) where the recipes prepared by the children for the n-CHEF challenge will be shared and prizes will be awarded."
48316850|NCT01758666|DRUG|Methotrexate,Calcium folinate|
48485557|NCT02356211|OTHER|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
48116455|NCT01803139|DEVICE|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
48316851|NCT05176431|DEVICE|ESWT (wave type: focused)|Extracorporeal Shock Wave Therapy, device: Electronica, Pagani, Italy
48316852|NCT05176431|DEVICE|ESWT (wave type: radial)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
48316853|NCT05176431|DEVICE|ESWT (wave type: sham)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
48316854|NCT04995328|OTHER|Radiation Care Gel|The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
48644925|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 1|Dose 1 of an investigational mRNA COVID-19 vaccine will be administered.
48316855|NCT04729582|BIOLOGICAL|Primary human muscle stem cells (Satori-01)|Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.
48316856|NCT04729582|OTHER|Placebo|Placebo is the injection solution without muscle stem cells.
48316857|NCT01562704|DRUG|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
48316858|NCT02352805|DEVICE|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
48316859|NCT01412658|DIETARY_SUPPLEMENT|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
48316860|NCT01412658|DIETARY_SUPPLEMENT|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
48316861|NCT03791359|OTHER|CardioPulmonary Resuscitation|Whether the victim received CPR as per standard protocol.
48316862|NCT01122628|DEVICE|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
48316863|NCT05055167|DRUG|Envafolimab|single agent, 300mg Q3W IH until disease progressed
48316864|NCT00646841|DRUG|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
48316865|NCT02568917|PROCEDURE|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
48316866|NCT02568917|PROCEDURE|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
48316867|NCT06259279|BEHAVIORAL|High intensity high impact exercise intervention|"Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes."
48316868|NCT02235116|OTHER|Survey|
48316869|NCT03085641|DEVICE|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
48316870|NCT05414305|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
48316871|NCT05019040|DRUG|PA1010|TDF as control
48316872|NCT03329040|OTHER|No Intervention.|No intervention.
48316873|NCT00256087|DRUG|Probiotic Lactobacillus|
48485558|NCT06205472|RADIATION|Adjuvant SIB radiotherapy|Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
47966258|NCT04234750|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
48644926|NCT06680375|COMBINATION_PRODUCT|SARS-CoV-2 mRNA Dose 2|Dose 2 of an investigational mRNA COVID-19 vaccine will be administered.
48644927|NCT06680375|COMBINATION_PRODUCT|Licensed Flu Seasonal|A licensed Flu Seasonal vaccine will be administered.
48316874|NCT00256087|OTHER|Lactose Powder|
48644928|NCT06680375|COMBINATION_PRODUCT|Licensed COVID-19 mRNA|A licensed mRNA COVID-19 vaccine will be administered.
47966259|NCT03476330|DRUG|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
48316875|NCT02038218|DRUG|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
48485559|NCT01606852|DRUG|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
48644929|NCT06680375|DRUG|Placebo|Placebo will be administered.
48316876|NCT02310828|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
48316877|NCT02310828|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
48316878|NCT00694954|DEVICE|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
48644930|NCT06680375|COMBINATION_PRODUCT|Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA|An Investigational Flu Seasonal/SARS-CoV-2 mRNA with a SARS-CoV-2 mRNA dose level resulting from study Phase 1 will be administered.
48644931|NCT06680375|COMBINATION_PRODUCT|Phase 2 selected SARS-CoV-2 mRNA|A selected SARS-CoV-2 mRNA dose level resulting from study Phase 1 will be administered.
48644932|NCT06629506|DEVICE|MicroMatrix® Flex|MicroMatrix® Flex is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, partial thickness burns, skin tears), draining wounds. The device is intended for one-time use.
48316879|NCT00694954|OTHER|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
48316880|NCT04116476|DRUG|MT-7117|Single Dose of MT-7117
48316881|NCT02320695|DRUG|Saline|
48316882|NCT02320695|DRUG|Isopropyl Alcohol|
48316883|NCT02320695|DRUG|Pain Relieving Cream|
48316884|NCT02320695|DRUG|Antibiotic/Pain Relieving Ointment|
48316885|NCT02320695|DRUG|Original Ointment|
48316886|NCT02320695|DRUG|Pain Relief Ointment|
48316887|NCT02939937|DRUG|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
48316888|NCT02939937|DRUG|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
48316889|NCT00000585|DRUG|penicillin|
48316890|NCT04255784|DEVICE|Active iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
48316891|NCT04255784|DEVICE|Sham iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
48316892|NCT00310570|DEVICE|Circumferential thermoplastic thimble splint|
48316893|NCT00310570|DEVICE|"dorsal aluminium foam Mexican Hat splint"|
48316894|NCT00310570|DEVICE|stack splint (control)|
48316895|NCT02521961|OTHER|Informational Intervention|Watch a Chair-robics DVD
48316896|NCT02521961|OTHER|Informational Intervention|Receive community resource booklet
48485560|NCT00825552|DRUG|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
48316897|NCT02521961|OTHER|Quality-of-Life Assessment|Ancillary studies
48316898|NCT02521961|OTHER|Questionnaire Administration|Ancillary studies
48316899|NCT02521961|PROCEDURE|Support Group Therapy|Attend support group sessions
48316900|NCT01211964|DRUG|LEO 22811|Oral administration of solution and tablet.
48316901|NCT02887833|OTHER|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
48316902|NCT05201586|OTHER|Conditional Cash Transfer|CCTs will be given to participants in the form of a pre-loaded debit card.
48644933|NCT06629506|DEVICE|MicroMatrix® UBM Particulate|MicroMatrix® UBM Particulate is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
48316903|NCT05201586|OTHER|Semi-structured interviews|Research team will conduct semi-structured interviews exploring how social determinants of health and social needs impact health. Participants will be asked to set a health goal. 6 months after the initial interview, the team will interview the patients again and evaluate whether that health goal was achieved.
48316904|NCT05008588|BIOLOGICAL|Conditioned Medium|Intranasal of 3 cc of conditioned medium each, for 3 days in a row
48316905|NCT05008588|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
48316906|NCT05008588|PROCEDURE|Neurologic and Neutrophic Drugs|Such as clopidogrel, piracetam, citicoline
48316907|NCT02607254|DRUG|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
48316908|NCT02607254|DRUG|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
48316909|NCT05025735|DRUG|Dapagliflozin 10Mg Tab|"Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib."
48316910|NCT02389673|DEVICE|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
48485561|NCT06137157|DRUG|ATR12-351|Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
48485562|NCT03163433|BEHAVIORAL|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
48316911|NCT02019394|DRUG|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
48316912|NCT00834704|DRUG|PEGPH20|PEGylated recombinant human hyaluronidase
48316913|NCT02902744|DRUG|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
48316914|NCT00128700|DRUG|temozolomide|
48316915|NCT00128700|DRUG|vatalanib|
48316916|NCT00128700|PROCEDURE|adjuvant therapy|
48316917|NCT00128700|RADIATION|radiation therapy|
48316918|NCT01747278|DRUG|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
48485563|NCT04719741|OTHER|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
48485564|NCT02691832|DEVICE|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
48485565|NCT05800574|RADIATION|Radiation therapy (5 days for 7 weeks)|Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)
48485566|NCT05800574|RADIATION|Radiation therapy (5 days for 6 weeks)|Mon-Fri (5 days for 6 weeks), total 35 fractions over 30 treatment days of RT (two doses 6 hours apart except for the last 6th Friday of the 6 weeks )
48485567|NCT05800574|DRUG|Cisplatin|Cisplatin, 40mg/m2 (weekly for 7 weeks)
48316919|NCT03288493|BIOLOGICAL|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
48316920|NCT03288493|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
48316921|NCT03379610|DIAGNOSTIC_TEST|Nasopharngeal brush|"1. Baseline nasopharngeal brush before treatment~2. Post-treatment reassessment of residual NPC"
48316922|NCT02975440|DRUG|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
48316923|NCT02975440|DRUG|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
48316924|NCT02975440|DRUG|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
48316925|NCT01405313|DEVICE|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
48316926|NCT01405313|DEVICE|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
48316927|NCT00204997|PROCEDURE|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
48316928|NCT02403830|DRUG|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
48316929|NCT02403830|OTHER|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
48485568|NCT05248984|DRUG|Ketorolac|"Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg"
47966260|NCT02590367|DRUG|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks."
47966261|NCT02590367|DRUG|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
47966262|NCT02590367|DRUG|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
47966263|NCT04566679|DIETARY_SUPPLEMENT|Dibuzin|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
48316930|NCT02403830|DRUG|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
48316931|NCT02403830|DRUG|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
48316932|NCT06128798|DIETARY_SUPPLEMENT|Oral Impact|A serving of 74 gm (containing 309 kcal ) of oral impact mixed with 250 ml of water. Each participant will receive total of 3 servings daily for 7 days pre operatively .
48316933|NCT06128798|DIETARY_SUPPLEMENT|Nutren Optimum|A serving of 66.8 gm ( containing 304 kcal ) of nutren optimum mixed with 300 ml of water.Each participant will receive total of 3 servings daily for 7 days pre operatively .
48316934|NCT05232422|BEHAVIORAL|Hatha yoga course|Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
48316935|NCT05514652|DRUG|Low opioid anesthesia|Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
48316936|NCT02045212|DRUG|RPh201|SC injection twice a week during 13/26 weeks
48316937|NCT02045212|DRUG|Placebo|SC injection twice a week during 13/26 weeks
48316938|NCT04121429|OTHER|Observation|No intervention will be performed
48316939|NCT04667806|BEHAVIORAL|Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))
48316940|NCT06244940|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGC) from subject samples|Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
48316941|NCT01428518|DRUG|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
48485569|NCT06139224|DIETARY_SUPPLEMENT|10 day prebiotic consumption|20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.
48485570|NCT00794482|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
48485571|NCT02999594|DRUG|Tramadol Hydrochloride|50mg intramuscularly
47966264|NCT04566679|DIETARY_SUPPLEMENT|placebo|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
47966265|NCT01264900|BEHAVIORAL|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
48316942|NCT02367534|PROCEDURE|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
48316943|NCT05658354|OTHER|Computerized cognitive program|BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
48316944|NCT02985502|OTHER|pancreatogenic diabetes|pancreatogenic diabetes
48316945|NCT02051894|DRUG|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
48316946|NCT05217992|OTHER|Genetic assessment (hemophilia testing)|Determination of carrier ship of hemophilia with molecular tests
48316947|NCT02679248|DIETARY_SUPPLEMENT|Neo40 Daily®|
48316948|NCT02679248|DIETARY_SUPPLEMENT|Placebo|
48316949|NCT04949178|OTHER|No intervention|This is an observational study.
48316950|NCT00209521|DRUG|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
48316951|NCT00209521|DRUG|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
48485572|NCT02999594|DRUG|Distilled Water|2ml intramuscularly
48485573|NCT00697606|DEVICE|Seprafilm®|Seprafilm® placed at time of primary cesarean
48116456|NCT05619016|DIAGNOSTIC_TEST|[68Ga]Ga-ABY-025 PET|\[68Ga\]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.
48485574|NCT00697606|OTHER|Control|no Seprafilm® used at primary cesarean
48485575|NCT01709734|DRUG|galeterone|
48485576|NCT01912638|DEVICE|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
48485577|NCT01912638|DRUG|Provisc|Provisc is an cohesive viscoelastic.
48485578|NCT05009836|DRUG|Savolitinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
48485579|NCT05009836|DRUG|Placebo|Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse
48485580|NCT01674647|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
48485581|NCT01674647|DRUG|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
48316952|NCT04161274|PROCEDURE|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
48485582|NCT06233019|OTHER|Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart|Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
48485583|NCT00143429|DRUG|Xalatan|
48485584|NCT00614822|DRUG|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
48316953|NCT04161274|PROCEDURE|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
48316954|NCT04161274|PROCEDURE|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
48316955|NCT04161274|PROCEDURE|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
48316956|NCT03377010|OTHER|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
48316957|NCT03377010|OTHER|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
48316958|NCT01266655|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
48316959|NCT01266655|DRUG|Placebo|Placebo
48316960|NCT01324622|DEVICE|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
48316961|NCT01324622|PROCEDURE|laminectomy|standard procedure
48316962|NCT02819895|OTHER|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
48316963|NCT06361264|COMBINATION_PRODUCT|Karanahan|During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days.
48485585|NCT02365259|DEVICE|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
48485586|NCT00746902|DEVICE|nCPAP|Active nCPAP
48485587|NCT03595163|DRUG|Sevoflurane|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
48485588|NCT03595163|DRUG|Propofol|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
48485589|NCT03078582|DRUG|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
48644934|NCT06629506|DEVICE|Cytal® Wound Matrix 2-Layer|Cytal® Wound Matrix is intended for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears), and draining wounds. The device is intended for one-time use.
48644935|NCT06685679|DRUG|Melatonin|oral melatonin 3 mg/kg/day divided in 3 doses , after enteral feeding, for 3 consecutive days, as combined therapy to milrinone
48644936|NCT06685679|OTHER|Placebo|Equivalent amount of distilled water will be given every hours as combined therapy to milrinone
48116457|NCT05619016|DIAGNOSTIC_TEST|Biopsy and analysis of HER2 expression|Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis \>10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
48116458|NCT04414904|OTHER|Exposure: Covid-19 infection|Previous history of COVID-19 infection.
48316964|NCT01087411|BEHAVIORAL|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
48316965|NCT01087411|BEHAVIORAL|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
48316966|NCT01087411|DIETARY_SUPPLEMENT|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
48316967|NCT01087411|DIETARY_SUPPLEMENT|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
48316968|NCT04425772|DRUG|FNC+Standard of Care|FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
48316969|NCT04425772|DRUG|FNC dummy tablet+Standard of Care|FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
48316970|NCT00213928|DRUG|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
48316971|NCT03007017|PROCEDURE|Deceased donor nephrectomy, prior to cross clamp of donor aorta|"The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study."
48316972|NCT03007017|PROCEDURE|Deceased donor nephrectomy, standard of care|The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
48316973|NCT04325594|PROCEDURE|Cardiac catheterization|Catheterization of the right and left heart cavities
48485590|NCT02678442|DEVICE|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
48485591|NCT02678442|DEVICE|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
48485592|NCT05883033|DEVICE|VAC|Vacuum Assisted Closure device
48485593|NCT03418857|DRUG|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
48485594|NCT03418857|DRUG|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
48485595|NCT04531670|BEHAVIORAL|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
48485596|NCT04531670|OTHER|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
48485597|NCT06082297|DEVICE|Chattanooga Physio, DJO, neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
48485598|NCT02692482|DEVICE|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
48485599|NCT02692482|PROCEDURE|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
48485600|NCT04911465|DEVICE|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
48644937|NCT01555424|DIETARY_SUPPLEMENT|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
48644938|NCT01555424|DIETARY_SUPPLEMENT|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
48116459|NCT02748590|DEVICE|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
48116460|NCT05888584|OTHER|Research readiness tool|Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
48116461|NCT04520659|BIOLOGICAL|RSV LID/ΔM2-2/1030s|10\^5 plaque-forming units (PFU); administered as nose drops
48316974|NCT04325594|BIOLOGICAL|Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells|After performing cardiac catheterization, selective coronary angiography will be performed abruptly to assess the condition of the coronary canal by access through the right radial or common femoral artery on the right after 70 U/kg of heparin iv. Then 20 ml of the finished suspension (1×10(7) umbilical cord-derived mesenchymal stromal cells diluted in 20 ml of heparinized saline) will be administrated into the mouth of the left coronary artery (LCA) without occlusion of the vessel with a balloon catheter and without stopping the coronary blood flow. Cell injection will be carried out using a standard 6 Fr catheter for selective coronary angiography with perfusion for 10 minutes at a volume rate of 2 ml/min, thereby introducing 1×10(6) cells per minute
48644939|NCT06349304|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of grape powder as part of daily diet
48644940|NCT06349304|DIETARY_SUPPLEMENT|Placebo grape powder|Consumption of placebo grape powder as part of daily diet
48644941|NCT04334681|PROCEDURE|Un-roofing curettage method|In this method, the roof of the pilonidal cyst is opened, and the inside is cleaned, and curettage is performed. The wound is closed with a dressing after hemostasis.
48485601|NCT04801108|PROCEDURE|Robotic or VATS lobar fissure completion|The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.
48316975|NCT05502471|DIAGNOSTIC_TEST|Zonulin|Serum zonulin level
48316976|NCT05502471|DIAGNOSTIC_TEST|Occludin|Serum occludin level
48644942|NCT04334681|PROCEDURE|Modified Limberg Flap Group|In this method, the pilonidal cyst is excised with a rhomboid incision and closed with the modified Limberg flap method.
48644943|NCT06686563|OTHER|Intervention Group: Gamma stimulation|Participants in this group be stimulated with gamma frequency (39-42 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
48644944|NCT06686563|OTHER|Control Group: Theta stimulation|Participants in this group will be stimulated with theta frequency (4-7 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
48644945|NCT05985174|DIAGNOSTIC_TEST|CD64 , HLA-DR|"CD64 is atype of integral membrane glycoprotein , when activated , it increases the neutrophils' potential for phagocytosis and bacterial killing .~HLA-DR is on the surface of monocyte\\macrophages , dendritic cells and plays a crucial role in adaptive immune response"
48316977|NCT03731364|DRUG|CA-008|5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
48316978|NCT03731364|DRUG|Placebo|Placebo
48644946|NCT06361446|DRUG|Zonisamide 50 MG|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
48644947|NCT06361446|DRUG|Propranolol|"The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months."
48644948|NCT02390999|PROCEDURE|48 hours of therapeutic hypothermia|
48316979|NCT00062699|DRUG|Zemplar (paricalcitol injection)|
48316980|NCT00062699|DRUG|Calcijex|
48644949|NCT04279769|DRUG|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
47966266|NCT05738954|OTHER|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
47966267|NCT03064984|OTHER|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
48116462|NCT04520659|BIOLOGICAL|Placebo|Administered as nose drops
48116463|NCT05583110|DRUG|Tucatinib|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
48485602|NCT04801108|DEVICE|Endobronchial valves placement|Endobronchial valves will be placed in the target lobe after the fissure completion.
48485603|NCT06083402|DIETARY_SUPPLEMENT|HyaCera™|1 Ritual HyaCera capsule once daily
48485604|NCT06083402|DIETARY_SUPPLEMENT|Placebo|1 placebo capsule once daily
48116464|NCT05583110|DRUG|Trastuzumab|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
48116465|NCT05583110|DRUG|Vinorelbine|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
48116466|NCT02667808|OTHER|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
48316981|NCT01368159|DEVICE|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
48316982|NCT00283530|PROCEDURE|Tumor biopsy|
48316983|NCT01096043|DRUG|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
48316984|NCT01096043|DRUG|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
48316985|NCT01096043|DRUG|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
48316986|NCT01096043|DRUG|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
48485605|NCT03686020|DIAGNOSTIC_TEST|Enzyme Linked Immunosorbent assay (ELISA)|measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
48485606|NCT04291807|BEHAVIORAL|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
48644950|NCT04279769|DRUG|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
48644951|NCT06687070|DRUG|APG -2449|Orally once a day(QD), every 28 days as a cycle.
48644952|NCT06687070|DRUG|PLD|Injected on the first day of each cycle, every 28 days as a cycle.
48644953|NCT03052257|BEHAVIORAL|Educational - glaucoma|Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
47966268|NCT03064984|OTHER|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
48644954|NCT03052257|BEHAVIORAL|Dose monitoring and reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
47966269|NCT02207296|DEVICE|Plethysmographic variability index|
47966270|NCT02550990|BEHAVIORAL|Cognitive training|
48485607|NCT00107042|BIOLOGICAL|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
48485608|NCT00107042|BIOLOGICAL|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
48116467|NCT02667808|OTHER|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
47966271|NCT02550990|BEHAVIORAL|Aerobic exercise training|
47966272|NCT02550990|BEHAVIORAL|Sequential combination of aerobic exercise and cognitive training|
47966273|NCT01687998|DRUG|Evacetrapib|Administered Orally
47966274|NCT01687998|DRUG|Placebo|Administered Orally
48644955|NCT03052257|BEHAVIORAL|Educational - general|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
48644956|NCT03052257|BEHAVIORAL|Dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
48116468|NCT04706078|DIAGNOSTIC_TEST|The biotype of gingival|The biotype of gingival was also determined by periodontal probe.
48116469|NCT03692013|DRUG|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
48116470|NCT03646435|DEVICE|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
48116471|NCT02043054|DRUG|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~* BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~* BMI \< 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
48116472|NCT02043054|DRUG|Sitagliptin|Sitagliptin (Januvia®, Merck \& Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
48116473|NCT00510887|DRUG|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
48116474|NCT00510887|DRUG|Rituximab|Rituximab 375 mg/m2 IV on day 1
48116475|NCT00510887|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
48116476|NCT00510887|DRUG|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
48116477|NCT00510887|DRUG|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
48116478|NCT00005137|OTHER|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
48116479|NCT05544721|DRUG|Ropivacaine|0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
48116480|NCT00212745|BEHAVIORAL|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
48644957|NCT03721458|OTHER|Sequence|Potentially identifying genetic defects that could have clinical significance
48116481|NCT05164341|DRUG|metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
48316987|NCT00541138|DRUG|carboplatin|CBDCA AUC=3
48316988|NCT00541138|DRUG|tamoxifen citrate|Tamoxifen 100mg bid
48316989|NCT00541138|DRUG|topotecan hydrochloride|Topotecan 0.75 g/m2/d
48316990|NCT00541138|OTHER|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
48316991|NCT03159377|DEVICE|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
48316992|NCT05725382|DEVICE|The NOL monitor (Pain Monitoring Device monitor-PMD200™)|NOL-guided perioperative remifentanil administration
48316993|NCT04389580|DRUG|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
48644958|NCT05660291|BEHAVIORAL|Early time-restricted eating|Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).
48644959|NCT05660291|BEHAVIORAL|Late time-restricted eating|Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).
48116482|NCT05164341|DRUG|Placebo|Placebo
48116483|NCT01296191|DRUG|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
48116484|NCT01296191|DRUG|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
48316994|NCT04389580|DRUG|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
48644960|NCT02410200|DRUG|dimethyl fumarate|
48644961|NCT02176759|OTHER|Administration of rice fortified with regular FePP|
48644962|NCT02176759|OTHER|Administration of rice fortified with regular FePP with citrate added during extrusion|
48644963|NCT02176759|OTHER|Administration of rice fortified with regular FePP and citrate added at consumption|
48644964|NCT02176759|OTHER|Administration of rice fortified with ferrous sulphate|
48644965|NCT00252148|BIOLOGICAL|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
47966275|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
47966276|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
48485609|NCT03204071|DRUG|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
48485610|NCT03204071|DRUG|Aloevera|Oral prophylaxis followed by placement of aloevera gel
48485611|NCT03204071|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
48485612|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Low-pressure pneumoperitoneum (8-9 mmHg)~2. Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~3. PONV prophylaxis in patients of risk~Postoperative care~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
48644966|NCT04672811|DEVICE|Study App and Apple Watch|Study App and Apple Watch
47966277|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
47966278|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
47966279|NCT03678129|DRUG|AZD7325_10|Single oral dose (10mg)
47966280|NCT03678129|DRUG|AZD7325_20|Single oral dose (20mg)
47966281|NCT03678129|DRUG|Placebo|Single oral dose placebo (capsule)
47966282|NCT03678129|DRUG|Clobazam|Single dose (5mg)
47966283|NCT00004983|BEHAVIORAL|diabetes self-management education|
47966284|NCT02680080|DRUG|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
47966285|NCT02680080|DIETARY_SUPPLEMENT|Grapefruit group|one liter of fresh pink-grapefruit juice
47966286|NCT00257543|PROCEDURE|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
47966287|NCT04096729|OTHER|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
47966288|NCT01741597|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
47966289|NCT01741597|OTHER|pharmacological study|Correlative studies
47966290|NCT01741597|BIOLOGICAL|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
47966291|NCT01435369|DRUG|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
47966292|NCT05989750|DEVICE|Ultrasonic scaler|Ultrasonic scaling for subgingival cleaning every 6 months for 2 years according to the manufacturer's procedures.
47966293|NCT05989750|DEVICE|Air-Flow Prophylaxis Master|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning according to the manufacturer's procedures.
47966294|NCT05478369|BEHAVIORAL|storybook|anxiety and fear during operative
47966295|NCT03978338|DIETARY_SUPPLEMENT|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
47966296|NCT03978338|OTHER|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
47966297|NCT01299740|BEHAVIORAL|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
48316995|NCT03395275|BEHAVIORAL|Quantitative Sensory Tests|"Three testing modalities will be utilized for this study:~1. Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~2. Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~3. Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results."
48316996|NCT03395275|BEHAVIORAL|surveys|surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
48644967|NCT04755231|DEVICE|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
47966298|NCT01299740|OTHER|Control Group|Treatment as usual
47966299|NCT06049862|BEHAVIORAL|MaRiTensi App|"MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat."
47966300|NCT03969446|DRUG|Decitabine|Given IV
47966301|NCT03969446|BIOLOGICAL|Pembrolizumab|Given IV
47966302|NCT03969446|DRUG|Venetoclax|Given PO
48316997|NCT04705727|DRUG|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
48316998|NCT04705727|DRUG|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
48316999|NCT05509153|DRUG|NAC|1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day
48317000|NCT05509153|DRUG|Placebo|Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day
48644968|NCT04755231|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
47966303|NCT03425877|DEVICE|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
47966304|NCT03425877|BEHAVIORAL|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, \& Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley \& Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
47966305|NCT03425877|BEHAVIORAL|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
47966306|NCT03425877|BEHAVIORAL|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
47966307|NCT03425877|BEHAVIORAL|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
47966308|NCT05626985|DIAGNOSTIC_TEST|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
47966309|NCT02920372|DRUG|EPOETIN ALFA|
47966310|NCT01965301|DRUG|BP1.5375 suspension|single oral dose
47966311|NCT01965301|DRUG|Diphenhydramine|single oral dose of Diphenhydramine 50mg
47966312|NCT01965301|DRUG|Placebo|Single oral dose
47966313|NCT01335191|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
47966314|NCT01335191|OTHER|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
47966315|NCT02756013|DRUG|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
47966316|NCT02756013|DRUG|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
47966317|NCT03140943|DRUG|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
47966318|NCT01105728|PROCEDURE|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
47966319|NCT03222336|BEHAVIORAL|Family pedigree and data collection|"1. Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~2. Collect and analyze medical history, genetic and biochemical assessment data"
47966320|NCT00701675|DRUG|sertraline 50 mg daily|50 mg daily
47966321|NCT00701675|DRUG|sertraline 100 mg daily|100 mg daily
47966322|NCT00701675|DRUG|Placebo 50 or 100 mg|50mg or 100mg matching placebo
48317001|NCT00740883|DRUG|warfarin|18 months of warfarin therapy, once daily
48317002|NCT00740883|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
48317003|NCT03285074|OTHER|No intervention|No intervention
48644969|NCT05483140|OTHER|Option 1|Partial meal replacement to achieve 900-1000 kcal/day (4 meal replacement products per day combined with 150-200 kcal from vegetable meals (recipes provided))
48644970|NCT05483140|OTHER|Option 2|Partial meal replacement to achieve 900-1000 kcal/day (2 meal replacement products per day combined with one balanced meal (recipes provided))
48644971|NCT05483140|OTHER|Option 3|A real food low energy diet to achieve 800-1000 kcal/day (recipes provided)
48644972|NCT05902858|DEVICE|Conventional intubation with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo conventional intubation with hyperangulated videolaryngoscope
48644973|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope
48116485|NCT03648346|DRUG|Cohort 1: HL217 Ophathalmic Solution BID|Two drops of 3 mg/mL of the treatment in one eye twice a day
48116486|NCT03648346|DRUG|Cohort 2: HL217 Ophathalmic Solution QID|Two drops of 3 mg/mL of the treatment in one eye 4 times a day
48116487|NCT03648346|DRUG|Placebo|Placebo eye drops
48644974|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope
48116488|NCT04339348|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg will be given 3 hours before LNG-IUD insertion plus inert placebo cream vaginally at the time of LNG-IUD insertion
48116489|NCT04339348|DRUG|Lidocaine-Prilocaine Topical cream|Lidocaine-Prilocaine cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
48116490|NCT04339348|DRUG|placebo|inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
48317004|NCT04677530|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
48317005|NCT04677530|DRUG|Matching Placebo|Matching placebo will be administered orally.
48317006|NCT01684475|DRUG|CJH1 (CLR4001)|
48317007|NCT01290133|DRUG|GW597599|Single dose IV infusion
48317008|NCT01290133|DRUG|Placebo|Single dose IV infusion
48317009|NCT04121312|BEHAVIORAL|Facilitation Intervention|"See arm description"
48644975|NCT04524429|PROCEDURE|Bariatric Surgery|Bariatric surgery includes sleeve gastrectomy and gastric bypass.
48644976|NCT02921282|GENETIC|Genotype dopamine|Laboratory investigations of nicotine reinforcement
47966323|NCT03121638|BIOLOGICAL|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
47966324|NCT03121638|BIOLOGICAL|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
47966325|NCT03121638|BIOLOGICAL|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
47966326|NCT03121638|BIOLOGICAL|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
48116491|NCT03860532|DRUG|HMPL-011 tablets|Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
48116492|NCT03860532|DRUG|HMPL-011 capsules|Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
48116493|NCT03938246|DRUG|TVB-2640|Oral dose, tablet, daily dosing
48116494|NCT03938246|OTHER|Placebo|Oral dose, tablet, daily dosing
48116495|NCT02059980|BEHAVIORAL|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
48116496|NCT02059980|BEHAVIORAL|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
48116497|NCT00131066|OTHER|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
48644977|NCT02921282|GENETIC|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
48644978|NCT01127204|DRUG|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
48644979|NCT01127204|DRUG|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
48644980|NCT05654519|DRUG|PENG/LFCN and QL Blocks|Bupivacaine 0.25% injection
48644981|NCT05818007|DRUG|Hyaluronic acid|The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
48644982|NCT05818007|DRUG|Sodium bicarbonate|sodium bicarbonate solution
48644983|NCT00131742|DRUG|telbivudine|
47966327|NCT03121638|BIOLOGICAL|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
47966328|NCT00358683|DRUG|Certolizumab pegol|
47966329|NCT04589078|DEVICE|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
47966330|NCT04736407|OTHER|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
48116498|NCT02468388|OTHER|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
48116499|NCT02468388|OTHER|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
48116500|NCT02468388|OTHER|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
48116501|NCT06554743|BEHAVIORAL|Default Veg|Received a plant-based meal as the default option on the event RSVP form that required participants to pre-select their meal choice
48116502|NCT06554743|BEHAVIORAL|Default Meat|Received a meal with meat as the default option on the event RSVP form that required participants to pre-select their meal choice
48317010|NCT03474406|OTHER|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
48317011|NCT05790473|DIAGNOSTIC_TEST|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
48644984|NCT00131742|DRUG|lamivudine|
48644985|NCT06366165|PROCEDURE|seemingly irrelevant funny videos and memes in teaching|linking funny videos and memes to special care dentistry curriculum lectures
48644986|NCT05472181|DEVICE|rTMS (Repetitive TMS)|TMS stimulation produce electromagnetic pulses that can directly changes the neural firing in the brain. The rTMS applies the magnetic pulses in a repetitive manner, and can induce either an inhibitory or excitatory effect on cortical neurons. In this study we use high frequency rTMS (10 Hz) to provide the excitatory effect.
48644987|NCT05472181|BEHAVIORAL|Speech training|The behavioural training will include reading sentences in which a syllable is spoken in time to a rhythmic beat.
48116503|NCT04641741|DRUG|Mepolizumab 100 MG|Discovery of predictive/prognostic biomarkers of response to mepolizumab using flow cytometry, transcriptomic, and proteomic technologies.
48317012|NCT05413005|COMBINATION_PRODUCT|ECP regular-intensity arm|"* Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~* Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)"
48317013|NCT05413005|COMBINATION_PRODUCT|ECP accelerated-intensity arm|"* Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Cryo-ECP bags infused once-a-week~* Weeks 17-24: Cryo-ECP bags infused every two weeks"
48485613|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Standard CO2 pressure (12-14 mmHg)~2. No additional anesthesia~Postoperative care~1. Mobilization in 4-6 h after surgery~2. Fluid intake in 6 hours~3. Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
48485614|NCT02207335|DRUG|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
48485615|NCT02207335|DRUG|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
48485616|NCT03348748|OTHER|Laboratory Biomarker Analysis|Correlative studies
48485617|NCT03348748|OTHER|Quality-of-Life Assessment|Ancillary studies
48485618|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest-dose of SBRT
48485619|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo lowest- or higher-dose of SBRT
47966331|NCT03187275|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
47966332|NCT03187275|OTHER|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
47966333|NCT00743483|DRUG|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
47966334|NCT05007392|DRUG|Dotinurad|Dotinurad oral tablets.
47966335|NCT05007392|DRUG|Febuxostat|Febuxostat oral tablets.
47966336|NCT05007392|OTHER|Dotinurad Matched Placebo|Dotinurad matched placebo oral tablets.
47966337|NCT05007392|OTHER|Febuxostat Matched Placebo|Febuxostat matched placebo oral tablets.
47966338|NCT03393130|DIAGNOSTIC_TEST|APOE genotyping|APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
47966339|NCT06263205|PROCEDURE|Non-Dressing of Surgical Wound|In this intervention, participants undergoing gastrointestinal tumor surgery will receive standard wound disinfection and initial postoperative care, which includes the application of dressings immediately after surgery. However, unlike traditional methods, the dressings will be removed 48 hours post-surgery, and the surgical wounds will then be left exposed without any further dressing. This method is intended to evaluate the effects of an exposed surgical wound on healing, pain, and healthcare costs, compared to traditional dressing methods.
47966340|NCT06263205|PROCEDURE|Regular Dressing Change of Surgical Wound|This intervention involves the standard postoperative wound care for participants with gastrointestinal tumors. After surgery, the surgical wounds will be disinfected and covered with dressings. These dressings will be changed every 48-72 hours, following traditional wound management practices. The purpose of this intervention is to serve as a comparator for assessing the effectiveness of the non-dressing approach, focusing on wound healing, pain management, and healthcare costs.
48116504|NCT04287894|DRUG|Durvalumab|The IP will be given to the patient as long as there is a clinical benefit, in invertigator's judgment. Per day, 1500 mg
48116505|NCT04287894|DRUG|Tremelimumab|Per day 75mg
48116506|NCT04287894|DRUG|Pemetrexed|500 mg/m2 on day 1 every 3 weeks for 2 cycles
48116507|NCT04287894|DRUG|Cisplatin|6 mg / m2 on day 1 every 3 weeks for 2 cycles
48485620|NCT03348748|DRUG|Stereotactic Body Radiation Therapy|Undergo highest-dose of SBRT
47966341|NCT02499783|BIOLOGICAL|adalimumab|subcutaneous injections of adalimumab
47966342|NCT02499783|OTHER|placebo|subcutaneous injections of placebo
47966343|NCT06304129|DIAGNOSTIC_TEST|Blood ponction|Blood ponction
48116508|NCT04287894|RADIATION|chemo radiotherapy|Once-daily fraction, 2 Gy per fraction. Total dose is 60 Gy.
48317014|NCT05413005|BIOLOGICAL|T1DM standard of care|"The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)"
48317015|NCT03488914|BEHAVIORAL|YMHP Intervention|
48317016|NCT03488914|BEHAVIORAL|Enhanced Treatment as Usual|
48485621|NCT03348748|PROCEDURE|Thoracic Surgical Procedure|Undergo thoracic surgery
48485622|NCT03686150|DIETARY_SUPPLEMENT|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
48485623|NCT04455178|DRUG|Spironolactone|spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
48485624|NCT04455178|DRUG|Indapamide|indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
48485625|NCT01557842|DRUG|Drug Treatment|Class I and III antiarrhythmic drug treatment.
48485626|NCT01557842|DEVICE|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
48485627|NCT03781024|COMBINATION_PRODUCT|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
48485628|NCT01559987|OTHER|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
48485629|NCT01559987|OTHER|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
48485630|NCT01559987|OTHER|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
48485631|NCT02516904|DRUG|CD101 IV|antifungal
48644988|NCT02576704|DEVICE|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
48644989|NCT04157582|OTHER|Pilates training|"1. Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~2. Pilates mat training performed in 5 different positions (30 minutes).~   1. One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~  2. Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~  3. Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~  4. Half roll back, Oblique roll up were performed in the sitting position.~  5. Swimming was performed in the kneeling position.~3. The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)"
48644990|NCT04157582|OTHER|Conventional physical therapy|"1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times)."
47966344|NCT04674930|OTHER|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
48644991|NCT05944393|DRUG|Ropivacaine 0.2% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.5% ropivacaine
48644992|NCT05944393|DRUG|Normal saline 0.9% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.9% normal saline
48644993|NCT03004495|DRUG|CHF5259 and CHF6001|b.i.d. for 14 days
47966345|NCT05878145|BEHAVIORAL|Structured rehabilitation exercise program|Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
47966346|NCT05881928|DRUG|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
47966347|NCT05881928|DRUG|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
47966348|NCT05881928|DEVICE|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
47966349|NCT01558232|DEVICE|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
47966350|NCT03651869|DRUG|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
47966351|NCT03651869|DRUG|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
47966352|NCT03651869|DRUG|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
47966353|NCT03651869|DRUG|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
47966354|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
47966355|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
47966356|NCT05975242|BEHAVIORAL|Smartphone diabetes management application|The intervention is a smartphone diabetes management application that is combined with structured blood glucose testing.
47966357|NCT00361569|DRUG|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
47966358|NCT00361569|DRUG|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
47966359|NCT00361569|OTHER|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
47966360|NCT00361569|OTHER|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
48644994|NCT03004495|DRUG|CHF5259 + placebo|b.i.d. for 14 days
48644995|NCT03004495|DRUG|CHF6001 + placebo|b.i.d. for 14 days
47966361|NCT03727529|OTHER|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
47966362|NCT03727529|OTHER|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
48116509|NCT04287894|PROCEDURE|Resection|After CIT-CRT
48485632|NCT02516904|DRUG|Placebo|normal saline
48644996|NCT03004495|OTHER|Placebo|b.i.d. for 14 days
48317017|NCT04946799|BEHAVIORAL|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
48317018|NCT04946799|BEHAVIORAL|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
48317019|NCT04946799|BEHAVIORAL|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
48644997|NCT04840186|PROCEDURE|Liver-resection or ablation|Liver-resection of colorectal liver metastasis. Ablation can be used as adjunct to surgery.
48644998|NCT04840186|DRUG|2nd line chemotherapy|2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist
48644999|NCT04881097|BEHAVIORAL|no intervention|no intervention
48645000|NCT03378635|DRUG|Dasiglucagon|Glucagon analog
48645001|NCT03378635|DRUG|GlucaGen|Native glucagon
48645002|NCT03378635|DRUG|Placebo|Placebo for dasiglucagon
48645003|NCT00555373|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
48645004|NCT02011529|OTHER|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
48317020|NCT01013909|DRUG|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
48317021|NCT01013909|DRUG|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
48317022|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
48317023|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
48317024|NCT01013909|DRUG|Lamisil Once|One application of Lamisil Once
48317025|NCT03580382|DRUG|Trametinib daily Until PD|1.0 mg daily
48317026|NCT03580382|DRUG|CDX-3379 (ERBB3 antibody)|15mg/kg IV Q3W
48645005|NCT03418363|DIETARY_SUPPLEMENT|DHEA Oral Capsule|Daily 100mg DHEA supplement
48645006|NCT03418363|OTHER|Placebo Oral Capsule|Daily oral capsule
48645007|NCT00309946|DRUG|cediranib maleate|Given orally
48645008|NCT06569966|BEHAVIORAL|preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon|The contents of the ileostomy were collected and placed in a wide mouth container, mixed with 500mL normal temperature saline, and placed in a funnel with double layer medical gauze. The filtrate of the ileal contents was collected and placed into an enema for use. The catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. The adverse reactions such as abdominal pain, abdominal distension and fever were observed. The number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded
48317027|NCT02913352|PROCEDURE|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
48317028|NCT02913352|PROCEDURE|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
48317029|NCT01463865|DRUG|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
48317030|NCT01463865|DRUG|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
48317031|NCT04575272|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
48317032|NCT02097758|DEVICE|Transcatheter device closure|"Closure of atrial septal defect with device~* choosing device size with 3D image and the formula~* we do not use sizing balloon for choosing of the device size"
47966363|NCT03962842|OTHER|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
47966364|NCT01018966|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
48317033|NCT04330755|DRUG|Saline Solution|Placebo
48317034|NCT04330755|DRUG|Levosimendan|Levosimendan
48645009|NCT04636580|BEHAVIORAL|parent accompanying the child during treatment|After the parents were divided into two groups, anxious and non-anxious, the groups were equally divided randomly and the parents accompanied their children during the treatment
48645010|NCT06002594|OTHER|group low-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 4 ml of 0.9% sodium chloride(NaCl) solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
48317035|NCT04330755|DRUG|Magnesium Sulfate|Magnesium Sulfate
48317036|NCT04817072|OTHER|Blood sample|Blood sample (20mL) for pro-inflammatory cytokines assay
48317037|NCT06191120|RADIATION|[18F]-ALF-FAPI-74 PET/CT scan|Participants will receive up to three \[18F\]-ALF-FAPI-74 PET/CT scans. \[18F\]-ALF-FAPI-74 is a PET tracer with high binding specificity and selectivity to FAP-expressing cells.
48317038|NCT04146571|DRUG|Ensartinib|Oral, ALK inhibitor
48485633|NCT01993602|PROCEDURE|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
48317039|NCT03966105|DIAGNOSTIC_TEST|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
48645011|NCT06002594|OTHER|group high-volume irrigation|Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 20 ml of 0.9% NaCl solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
48645012|NCT04157738|DRUG|Rapid-Acting Insulin|Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
48645013|NCT04157738|DRUG|Long acting insulin|Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
48645014|NCT01545310|DRUG|SLV354|One dose of ABT-354
48645015|NCT04014192|DRUG|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
48645016|NCT04014192|DRUG|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
48645017|NCT04014192|DRUG|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
47966365|NCT00388960|DRUG|Amrubicin|"Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression."
47966366|NCT00388960|DRUG|Cisplatin|"Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression."
48116510|NCT02100371|DRUG|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
48317040|NCT01732185|GENETIC|Patient|Blood and histological samples will be done at day of the inclusion.
48317041|NCT02231450|DRUG|Lu AE58054 encapsulated film-coated tablets|
48317042|NCT03052842|DRUG|C16G2 Strip|Antimicrobial Peptide
48116511|NCT01908296|DRUG|FK949E|Oral
48116512|NCT01908296|DRUG|fluvoxamine|Oral
48116513|NCT05095246|BIOLOGICAL|KB407 (Nebulization)|Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
48116514|NCT06677606|PROCEDURE|PENG block|The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle
48317043|NCT03052842|OTHER|Placebo Strip|Placebo
48645018|NCT06524648|DIAGNOSTIC_TEST|niPGT-A|"Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.~Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).~Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active."
48645019|NCT06497686|DIAGNOSTIC_TEST|mesoscale nonlinear optical gigascope|An nonlinear optical microscope with ultra-large field of view and ultra-high resolution.
48645020|NCT06497686|DIAGNOSTIC_TEST|Fluorescence microscope|An optical microscope used to examine the fluorescence signal from stained tissues.
47966367|NCT00388960|DRUG|Etoposide|Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
47966368|NCT05812885|DEVICE|TENS|Active TENS
47966369|NCT05095545|DRUG|AV5080|Hard gelatin capsules with a white body
48317044|NCT01658579|DRUG|HOE901-U300 (new formulation of insulin glargine)|
48317045|NCT01658579|DRUG|Lantus (insulin glargine)|
48317046|NCT06250894|DRUG|PD-1inhibitor|Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
48317047|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
48317048|NCT00501215|BEHAVIORAL|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
48485634|NCT05603052|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
48645021|NCT01840163|OTHER|Static version of CanSORT tool|
48645022|NCT01840163|OTHER|CanSORT Online Tool|
48645023|NCT05970939|OTHER|Development of the Telerehabilitation Usability Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
48645024|NCT01812746|DRUG|BIND-014|
48645025|NCT01807741|DRUG|Asenapine|Available in 5 and 10 mg.
48645026|NCT01807741|DRUG|Placebo|
48645027|NCT02702999|DEVICE|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
48645028|NCT02702999|DEVICE|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
48317049|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
48317050|NCT00501215|BEHAVIORAL|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
48645029|NCT02913573|DEVICE|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
47966370|NCT05095545|OTHER|Placebo|Hard gelatin capsules with a white body
47966371|NCT01393496|OTHER|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
47966372|NCT01393496|OTHER|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
48317051|NCT00244699|BEHAVIORAL|MI Alone or Plus Mindfulness-Based Skills Training|
48485635|NCT05603052|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
48485636|NCT00280176|DRUG|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
48485637|NCT00280176|DRUG|fluorouracil|225mg/m2 given weekly, up to 6 weeks
48485638|NCT00280176|RADIATION|radiation therapy|180 cGy, every 5 days, up to six weeks
48485639|NCT05906199|DRUG|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
48485640|NCT05906199|DRUG|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
48116515|NCT06677606|PROCEDURE|PAI block|LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
48116516|NCT02122445|DEVICE|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
48116517|NCT02988817|BIOLOGICAL|Enapotamab vedotin (HuMax-AXL-ADC)|Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
48116518|NCT01400776|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
48116519|NCT01400776|DRUG|Vehicle|Vehicle administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
48116520|NCT04283552|DEVICE|Dynamic PET/CT Imaging|-Will take approximately 60 minutes
48116521|NCT03996863|DEVICE|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
48116522|NCT03996863|DEVICE|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
48116523|NCT01773980|OTHER|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
48116524|NCT01773980|OTHER|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
48317052|NCT06032299|PROCEDURE|Single Distal Femur Implant|Single implant constructs will be either a retrograde intramedullary nail with interlocking screws or a single plate and screw construct.
48317053|NCT06032299|PROCEDURE|Dual Distal Femur Implant|Dual implant constructs will either be an intramedullary nail with an additional plate and screw construct or dual (two plates in any orientation) plate and screw construct.
48317054|NCT05279989|OTHER|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
48485641|NCT00650988|PROCEDURE|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
48485642|NCT02159781|PROCEDURE|periodontal treatment - scaling and root planning|
48116525|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
48116526|NCT01185769|DIETARY_SUPPLEMENT|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
48116527|NCT05590468|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)
48116528|NCT05590468|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
48116529|NCT06034886|DRUG|Troriluzole|BHV-4157 140mg, 200mg or 280mg once daily by mouth.
48116530|NCT00501618|DRUG|Fazaclo|single-arm
48116531|NCT03426033|DRUG|ISIS 681257|Xmg dose administered as a subcutaneous injection
48116532|NCT03426033|DRUG|Warfarin|25mg tablet administered orally
48116533|NCT05006092|DEVICE|ENDOMIND|CADe system for Polyp detection
48116534|NCT04149548|DIAGNOSTIC_TEST|ultrasound|Obstetric ultrasound to pregnant women
48116535|NCT00795054|OTHER|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
48116536|NCT02632305|DRUG|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
48116537|NCT05317611|DRUG|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
48317055|NCT05279989|OTHER|Health Information Videos|Participants will receive videos of health information.
48317056|NCT03534063|GENETIC|CYP2D6-guided opioid therapy|Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
48317057|NCT03806179|DRUG|10 MBq/kg Betalutin|10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
48317058|NCT03806179|DRUG|15 MBq/kg Betalutin|15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
48317059|NCT05619562|DIAGNOSTIC_TEST|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
48317060|NCT02984852|DRUG|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
48317061|NCT02984852|DRUG|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
48317062|NCT02984852|DRUG|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
48485643|NCT05842967|BIOLOGICAL|RSVpreF|120-µg
48485644|NCT05842967|OTHER|Placebo|Placebo
48485645|NCT04516408|BIOLOGICAL|Recombinant zoster vaccine|Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.
48485646|NCT04516408|BIOLOGICAL|Placebo|Sterilized water
48317063|NCT02984852|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
48317064|NCT00907582|PROCEDURE|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
48317065|NCT02294409|BEHAVIORAL|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
48485647|NCT05684146|DEVICE|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
48485648|NCT05684146|DEVICE|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
48485649|NCT05555394|OTHER|Basic Body Awareness Therapy|The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
48485650|NCT05555394|OTHER|Stretching Exercise|It consists in stretching movements of whole body
48485651|NCT03103074|DRUG|Botulinum B Toxin|Intradermal injections
48485652|NCT03103074|OTHER|Placebo Saline|Intradermal injections
48485653|NCT01953094|PROCEDURE|Screening Anal Pap Smear - No High Resolution Anoscopy|
48485654|NCT01953094|PROCEDURE|Screening Anal Pap Smear - With High Resolution Anoscopy|
48485655|NCT01846273|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
48485656|NCT01846273|DRUG|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
48485657|NCT01846273|DRUG|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
48485658|NCT03463993|DRUG|Tranexamic Acid|TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
48645030|NCT02913573|DRUG|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
48645031|NCT06688409|DIAGNOSTIC_TEST|awake ABPM|Comparison of a BP measured with the home BP devices and the average awake ABPM performed immediately after
48485659|NCT03463993|DRUG|Oxytocin|5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
48485660|NCT00010413|DRUG|cyclophosphamide|
48485661|NCT00010413|DRUG|filgrastim|
48485662|NCT01394848|DEVICE|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
48485663|NCT01394848|DEVICE|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
48485664|NCT01394848|DRUG|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
48485665|NCT01394848|DRUG|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
48645032|NCT06571968|DEVICE|fully guided stent|The guides were designed with metal sleeves for guided drilling and guided implant placement and additional guide sleeves for the stabilization of the template by fixation screws. All surgical procedures with drills were done thiough the stent.
48645033|NCT03949114|BEHAVIORAL|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
48485666|NCT02180698|OTHER|Laboratory Biomarker Analysis|Correlative studies
48485667|NCT02180698|RADIATION|Radiation Therapy|Undergo radiation therapy
48485668|NCT02180698|DRUG|TLR4 Agonist GLA-SE|Given intratumorally
48485669|NCT05266079|DRUG|Intervention Group|Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
48485670|NCT05266079|DRUG|Control Group|Er-Xian decoction
48485671|NCT03184220|PROCEDURE|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~* Suboccipital induction~* Posterior elongation of the cervical fascia in Supine position~* Assisted cervical fascia~* Myofascial induction of sternocleidomastoid"
48645034|NCT03949114|BEHAVIORAL|nursing care|Traditional post-operative nursing care
48645035|NCT03949114|BEHAVIORAL|rehabilitation|"1. Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~2. On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
48645036|NCT02273427|DRUG|BIIL 284 BS|
48645037|NCT02273427|OTHER|high fat meal|
48645038|NCT02273427|OTHER|low fat meal|
48645039|NCT02242903|DRUG|LY3079514|Administered SC
48645040|NCT02242903|DRUG|LY3079514|Administered IV
48645041|NCT02242903|DRUG|Placebo|Administered SC
48645042|NCT02242903|DRUG|Placebo|Administered IV
48116538|NCT05317611|DRUG|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
48317066|NCT02294409|BEHAVIORAL|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
48485672|NCT03184220|PROCEDURE|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
48485673|NCT06202924|BEHAVIORAL|Static balance assessment|Biodex stabilometer device will be used to evaluate the static balance of the participants.
48645043|NCT03242070|OTHER|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
48645044|NCT03594656|DRUG|Ganoderma|0.8g twice daily
48645045|NCT03594656|DRUG|Placebos|0.8g twice daily
48645046|NCT05312892|DRUG|Amlodipine|Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.
48645047|NCT05312892|DRUG|Moxonidine|Moxonidine
48645048|NCT05312892|DRUG|Placebo|Placebo
48116539|NCT05317611|DRUG|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
48116540|NCT04677322|DRUG|Adult patients diagnosed and treated for high blood pressure|Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
48317067|NCT04629612|PROCEDURE|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
48317068|NCT04502550|DRUG|Propofol|Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
48645049|NCT06110871|OTHER|inhaled lavender|They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.
48645050|NCT06110871|OTHER|Working Group 2: Focusing|During IUD application
48645051|NCT06110871|OTHER|Working Group 3 music|for a total of 30 minutes
48116541|NCT05485389|OTHER|simulation based learning|An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
48116542|NCT01066923|DRUG|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
48645052|NCT05639439|DEVICE|"Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A"|"Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
48645053|NCT05639439|DEVICE|"Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B"|"Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
48645054|NCT05639439|DEVICE|"Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C"|"Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
48645055|NCT05639439|DEVICE|"Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D"|"Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)"
48645056|NCT02585180|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
48645057|NCT02585180|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
48645058|NCT00274950|BIOLOGICAL|bleomycin sulfate|
48645059|NCT00274950|DRUG|carboplatin|
48645060|NCT00274950|DRUG|cisplatin|
48645061|NCT00274950|DRUG|etoposide|
48645062|NCT00274950|DRUG|ifosfamide|
48645063|NCT00274950|DRUG|vinblastine sulfate|
48645064|NCT00274950|PROCEDURE|adjuvant therapy|
48645065|NCT00274950|PROCEDURE|conventional surgery|
48116543|NCT01066923|OTHER|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
48116544|NCT01066923|DRUG|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
48317069|NCT04880538|PROCEDURE|Endoscopic procedure|Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
48317070|NCT04773353|DRUG|Follitropin Delta (FE 999049)|FE 999049 will be administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 will have their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. For participants with low AMH (\<15 pmol/L) the daily FE 999049 dose will be 12 μg, irrespective of body weight. For participants with high AMH (≥15 pmol/L) the daily FE 999049 dose will be on a continuous scale ranging from 0.19 to 0.10 μg/kg, i.e. dependent on actual AMH and body weight. The daily FE 999049 dose will be fixed throughout the stimulation period and maximum allowed daily dose will be 12 μg. Participants could be treated for a maximum of 20 days.
48317071|NCT04773353|DRUG|Follitropin Alfa (GONAL-F)|GONAL-F will be administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F will be 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose will be 450 IU. Participants could be treated for a maximum of 20 days.
48317072|NCT01364233|DEVICE|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
48317073|NCT05255913|DRUG|Nanosilver|preventive material for arresting caries
48317074|NCT05255913|DRUG|Silver diamine fluoride|preventive material for arresting caries
48317075|NCT05674045|DRUG|EG017 3mg|EG017 3mg/day Oral administration for 12 weeks, once daily
48317076|NCT05674045|DRUG|EG017 6mg|EG017 6mg/day Oral administration for 12 weeks, once daily
48317077|NCT00988741|DRUG|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
48317078|NCT00988741|DRUG|Placebo|The placebo is provided in a capsule form.
48317079|NCT06373172|OTHER|virtual simulation-based education program|"We used vSim® for Nursing - Nursing Medical-Surgical as the virtual simulation-based education program. Four modules were included: (a) acute myocardial infarction, (b) diabetes mellitus, (c) transfusion, and (4) asthma. Each module learning sessions was conducted based on scenarios, which consisted of five steps: Suggested reading, Pre-simulation quiz, vSim, Post-simulation quiz, and Guide reflection questions. For each module, the intervention was performed for two hours. The participants attended four module learning sessions and received eight hours of training. Debriefing using guided reflection questions were completed in the form of a team reflection, followed by an instructor-learner discussion and feedback for 20 minutes of each module."
48317080|NCT00002344|DRUG|Azithromycin|
48485674|NCT06202924|BEHAVIORAL|Dynamic balance assessment:|Individuals' dynamic balance performances were evaluated with the Y balance test. Y balance test is a test method with proven validity and reliability in athletes and healthy subjects. (Intra-class correlation 0.99-1, Inter-class correlation 0.85-0.91).
48485675|NCT06202924|BEHAVIORAL|Isokinetic strength evaluation:|Quadriceps muscle strength of the participants will be evaluated with an isokinetic dynamometer. Isokinetic dynamometers are considered the gold standard in muscle strength measurements. These devices have the ability to objectively report the amount of force produced by individuals at predetermined angular speed and joint range of motion.
48485676|NCT05506722|DEVICE|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
48485677|NCT01805726|DRUG|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
48317081|NCT04570657|BIOLOGICAL|MEDI3506|Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2
48485678|NCT01805726|DRUG|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
48485679|NCT01805726|DRUG|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
48485680|NCT03517254|DIETARY_SUPPLEMENT|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
48317082|NCT04570657|DRUG|Placebo|Participants will receive multiple doses of placebo
48485681|NCT03517254|OTHER|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
48485682|NCT03517254|OTHER|Placebo|Maltodextrin powder to mimic glutamine,
48485683|NCT03517254|OTHER|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
48645066|NCT00544726|BEHAVIORAL|Physical training|
48645067|NCT00544726|BEHAVIORAL|No training|
48645068|NCT02380157|DRUG|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
48645069|NCT02380157|DRUG|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
48116545|NCT01066923|OTHER|Passive cooling|Removing protective garments for passive cooling following exercise
48116546|NCT01066923|DRUG|Daily placebo|Placebo comparator for daily aspirin therapy
48116547|NCT01066923|DRUG|Acute placebo|Placebo comparator for acute aspirin therapy
48317083|NCT03933423|DEVICE|Home based phototherapy and referral|CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
48317084|NCT06224881|DRUG|Ascorbic acid|2 gm every 8hrs for 4 days
48317085|NCT04478149|DEVICE|SafelyYou|technology to detect and prevent falls
48317086|NCT04478149|OTHER|Control|technology present but not activated
48317087|NCT04668001|DEVICE|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
48317088|NCT04668001|DEVICE|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
48317089|NCT00042250|DRUG|Chemotherapy for hematologic malignancy|
48317090|NCT06065358|PROCEDURE|Tumor biopsy|Patients with advanced suspected HGSOC will be considered eligible (FIGO stage from III C or greater). At the time of surgery, patients' disease extension will be assessed with the Fagotti score (PIV) and the Vizzielli score (VS). Only patients who are not considered operable in the first place, will be enrolled. Samples will be taken during surgery that will take place in the operating rooms of oncological gynaecology.
48317091|NCT02055430|PROCEDURE|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
48485684|NCT04128202|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
48645070|NCT03881878|DRUG|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)"
48317092|NCT02055430|PROCEDURE|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
48317093|NCT02055430|PROCEDURE|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
48317094|NCT02413619|PROCEDURE|Vitrectomy|Vitrectomy
48317095|NCT02413619|PROCEDURE|Cataract surgery|Cataract surgery
48317096|NCT02413619|PROCEDURE|Combined surgery|Combined vitrectomy and cataract surgery at the same time
48317097|NCT04901741|DRUG|Olaptesed pegol|400 mg per week as continous infusion until progression or intolerable toxicity
48317098|NCT04901741|DRUG|Pembrolizumab|200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations
48317099|NCT01993862|OTHER|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
48317100|NCT03424889|DRUG|Xylometazoline|Nasal administration of Xylometazoline
48317101|NCT03424889|DRUG|Saline|Nasal administration of 0.9% Saline
48317102|NCT01325324|DEVICE|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
48317103|NCT01642524|BIOLOGICAL|hypertonic saline mixed Dextran|single dose administered intravenously
48317104|NCT01642524|BIOLOGICAL|Saline solution|placebo - saline solution
48645071|NCT03881878|DRUG|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
48116548|NCT01763970|RADIATION|SBRT|
48317105|NCT02311699|BEHAVIORAL|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.
48116549|NCT05353517|DEVICE|Device: focal muscle vibration and theta burst stimulation|non invasive techniques of neuromodulation for inducing plasticity in M1 and spinal cord
48116550|NCT00539292|PROCEDURE|Primary placement of a spring-loaded silo|
48116551|NCT00539292|PROCEDURE|Primary Closure|primary closure of abdomen
48317106|NCT04771052|OTHER|COVID Rehabilitation Program for the Elderly (CORE)|In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
48317107|NCT02179528|DRUG|Etoposide|
48317108|NCT01218789|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
48317109|NCT05958095|DEVICE|MamaLift Plus|MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.
48317110|NCT05958095|DEVICE|Digital Sham App|The digital sham app delivers content, tips, and suggestion for general wellbeing support.
48317111|NCT05899387|PROCEDURE|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
48317112|NCT05899387|PROCEDURE|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
48485685|NCT04128202|BEHAVIORAL|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
48485686|NCT02409394|DRUG|Hetrombopag Olamine|
48485687|NCT00433277|DRUG|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
48645072|NCT02268305|DRUG|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
48116552|NCT02962141|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
48116553|NCT02962141|DEVICE|Balloon Dilatation Catheter|Control group
48116554|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
48116555|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
48116556|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
48485688|NCT03043118|OTHER|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
48485689|NCT02328950|DRUG|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
48645073|NCT02268305|OTHER|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
48645074|NCT04356378|OTHER|Data record|Data record
48645075|NCT05339659|DEVICE|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
48645076|NCT03484195|DRUG|FOLFOXIRI|Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
48645077|NCT04081012|DRUG|N-acetyl cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
48116557|NCT01576523|BIOLOGICAL|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
48116558|NCT04410510|DRUG|P2Et (Caesalpinia spinosa extract)|P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
48116559|NCT04410510|OTHER|Placebo|Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
48116560|NCT02743078|DRUG|Bevacizumab|10 mg/kg every 2 weeks intravenously over 30 minutes.
48317113|NCT05899387|PROCEDURE|Blood sampling|Blood sampling at defined time points according to protocol
48317114|NCT01752582|DEVICE|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
48317115|NCT01752582|DEVICE|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
48317116|NCT00601796|BIOLOGICAL|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
48317117|NCT00601796|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
48317118|NCT00601796|DRUG|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
48317119|NCT06423287|DIETARY_SUPPLEMENT|Lactobacillus plantarum LP-KFY04|Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
48317120|NCT06423287|OTHER|Take placebo in addition to the limited diet.|Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks'trial.
48317121|NCT01533935|DRUG|Placebo|placebo matching tiotropium + olodaterol
48317122|NCT01533935|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
48317123|NCT01533935|DRUG|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
48317124|NCT01533935|DRUG|Tiotropium|tiotropium
48317125|NCT01533935|DRUG|Olodaterol|Olodaterol 5 mcg once daily
48116561|NCT02743078|DEVICE|TTFields Therapy|Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.
48317126|NCT01533935|DEVICE|Respimat|Respimat inhaler
48317127|NCT02917551|OTHER|7 days of adequate antibiotic treatment|
48317128|NCT02917551|OTHER|14 days of adequate antibiotic treatment|
48317129|NCT04863924|DIAGNOSTIC_TEST|Liquid Biopsy|All patients will have a liquid biopsy with ctDNA molecular profiling
48317130|NCT04128579|DRUG|Itolizumab [Bmab 600]|EQ001
48485690|NCT06231394|OTHER|multimodal pelvic floor rehabilitation|A multimodal pelvic floor rehabilitation program will be performed on all children for 10 weeks, two days a week and approximately 45 minutes. A multimodal pelvic floor rehabilitation will include education, bladder and bowel training, manual techniques, exercise training (diaphragmatic breathing exercise, pelvic floor muscle training, trunk stabilization exercises based on developmental kinesiology) and a home program. The home program will be given on other days of the week.
48317131|NCT01184404|DRUG|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
48317132|NCT03358693|DRUG|Ustekinumab|Subject receives Ustekinumab open-label as per guidelines
48317133|NCT03358693|DRUG|Infliximab|Subject receives Infliximab open-label as per guidelines
48317134|NCT03358693|DRUG|Secukinumab|Subject receives Secukinumab open-label as per guidelines
48317135|NCT03358693|DRUG|Dupilumab|Subject receives Dupilumab open-label as per guidelines
48317136|NCT03358693|DRUG|Brodalumab|Subject receives Brodalumab open-label as per guidelines
48317137|NCT03358693|DRUG|Ixekizumab|Subject receives Ixekizumab open-label as per guidelines
48317138|NCT03358693|DRUG|Baricitinib|Subject receives Baricitinib open-label as per guidelines
48317139|NCT03358693|DRUG|Abrocitinib|Subject receives Abrocitinib open-label as per guidelines
48317140|NCT03358693|DRUG|Upadacitinib|Subject receives Upadacitinib open-label as per guidelines
48317141|NCT03358693|DRUG|Tralokinumab|Subject receives Tralokinumab open-label as per guidelines
48317142|NCT01457001|DRUG|25-OH-D vitamin|
48317143|NCT04496791|DEVICE|RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
48317144|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
48317145|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
48317146|NCT02472119|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-free diet
48317147|NCT00186056|DRUG|Mifepristone|Glucocorticoid antagonist
48317148|NCT00186056|DRUG|Placebo Oral Tablet|Inactive placebo tab
48317149|NCT05349058|DRUG|Immune Checkpoint Inhibitors|Patients receive Immune Checkpoint Inhibitor as per oncology protocol
48317150|NCT00194272|DRUG|Methotrexate|Two dose methotrexate
48317151|NCT04199208|OTHER|Prehabilitation and Immunonutrition|See study synopsis
48317152|NCT04199208|OTHER|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
48116562|NCT04226703|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|"Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge root.~Indirect Laryngoscopy: Grading of laryngoscopic view (I=Visible anterior commissure and vocal cords, II= visible posterior part of vocal cords and posterior commissure, III= Visible posterior commissure and epiglottis, IV= Visible only epiglottis tip and posterior pharyngeal wall)"
48317153|NCT05601024|BEHAVIORAL|Laughter Therapy|The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
48317154|NCT00519493|PROCEDURE|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
48317155|NCT00519493|DEVICE|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
48317156|NCT04021394|DIAGNOSTIC_TEST|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
48317157|NCT04021394|DIAGNOSTIC_TEST|Parsortix CTC platform|EMT-independent platform
48317158|NCT06395428|DRUG|Haloperidol|Intramuscular injection of drug
48317159|NCT06395428|DRUG|Ketorolac Tromethamine|Intramuscular injection of drug
48317160|NCT01518426|DEVICE|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~* with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~* with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
48317161|NCT00434512|BIOLOGICAL|HIV vaccine 732461|
48317162|NCT04182698|DRUG|Simultaneous chemoradiotherapy for An Luo|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
48317163|NCT00745186|DRUG|Glucagen|0.2 mg or 1 mg Glucagen single injection
48317164|NCT00745186|DRUG|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
48317165|NCT02214316|OTHER|Hypertonic Saline|
48317166|NCT00492856|DRUG|mercaptopurine|Given orally
48317167|NCT00492856|DRUG|methotrexate|Given orally
48317168|NCT00492856|DRUG|tretinoin|Given orally
48317169|NCT02680886|DEVICE|Novosyn® Quick|Skin closure
48317170|NCT04694547|OTHER|There is no intervention, as this is a survey study|Survey
48317171|NCT05154149|OTHER|Neck Disability Pain Index|Single time collection of the data
48317172|NCT05870644|OTHER|Cycling exercise in room temperature at 25 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 25 degree Celsius.
48317173|NCT05870644|OTHER|Cycling exercise in room temperature at 34 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 34 degree Celsius.
48317174|NCT06295497|DEVICE|Lung-SIGHT|"* The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up."
48645078|NCT04081012|DRUG|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
48317175|NCT01410266|OTHER|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
48317176|NCT01409031|DRUG|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
48317177|NCT01409031|OTHER|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
48485691|NCT06273202|OTHER|Infant Massage|Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
48485692|NCT05392374|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2
48485693|NCT02358967|DIETARY_SUPPLEMENT|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
48485694|NCT02358967|DIETARY_SUPPLEMENT|Placebo|2 x 150 mg capsules
48645079|NCT05023174|PROCEDURE|Hiatal Hernia Repair with Platelet Rich Plasma|Platelet rich plasma will be injected into the crura of the diaphragm and coating the mesh placed during surgery.
48645080|NCT05023174|PROCEDURE|Hiatal Hernia Repair without Platelet Rich Plasma|Surgery will be performed without the addition of platelet rich plasma injection
48645081|NCT00002461|BIOLOGICAL|filgrastim|
48645082|NCT00002461|BIOLOGICAL|sargramostim|
48645083|NCT00002461|DRUG|carmustine|
48645084|NCT00002461|DRUG|cisplatin|
48645085|NCT00002461|DRUG|cyclophosphamide|
48645086|NCT00002461|DRUG|etoposide|
48645087|NCT00002461|PROCEDURE|autologous bone marrow transplantation|
48645088|NCT00002461|PROCEDURE|in vitro-treated bone marrow transplantation|
48317178|NCT05487716|BEHAVIORAL|High-intensity interval training (HIIT)|Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.
48317179|NCT03164226|DEVICE|Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain|To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
48317180|NCT04070352|DRUG|Fidaxomicin|patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
48317181|NCT03542045|DEVICE|Cemented ATTUNE® Knee System|This product is for total knee arthroplasty. Four implant configurations are permitted: Cruciate Retaining Fixed Bearing (CR FB), Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing (PS FB) and Posterior Stabilizing Rotating Platform (PS RP)
48317182|NCT05343806|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
48317183|NCT05343806|DRUG|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
48317184|NCT01602926|PROCEDURE|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
48317185|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
48317186|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
48317187|NCT00077610|DRUG|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
48317188|NCT00077610|DRUG|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
48485695|NCT02486913|OTHER|Enhanced Health Check|National Health Service Health Check enhanced by risk report
48485696|NCT01202877|DRUG|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
48485697|NCT01202877|DRUG|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
48485698|NCT04457453|OTHER|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
48485699|NCT04457453|OTHER|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
48485700|NCT04457453|OTHER|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
48485701|NCT05093465|BEHAVIORAL|Technology Intervention|"Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day."
48485702|NCT05093465|OTHER|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
48645089|NCT00002461|PROCEDURE|peripheral blood stem cell transplantation|
48645090|NCT00002461|RADIATION|radiation therapy|
48485703|NCT05470764|DRUG|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
48485704|NCT05470764|DRUG|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
48485705|NCT00093002|DRUG|Fulvestrant|250 mg \& 500 mg intramuscular injection
48645091|NCT04386239|DRUG|Sarilumab Prefilled Syringe|Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
48317189|NCT00077610|DRUG|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
48317190|NCT06105424|PROCEDURE|Lung Permeability Assessment|A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
48317191|NCT04448808|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
48485706|NCT05128370|OTHER|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
48485707|NCT03431974|DRUG|LD-Aminopterin oral capsule|anti-folate treatment
48485708|NCT03431974|DRUG|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
47966373|NCT02456441|OTHER|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
47966374|NCT02456441|OTHER|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
48485709|NCT04130659|COMBINATION_PRODUCT|MARIAL® + PPI (generic Omeprazole)|"MARIAL® administration: 1 stick twice daily after meals from day 1 to 28.~Omeprazole administration: 20 mg cps once daily from day 1 to day 28"
48485710|NCT04130659|DRUG|PPI alone (generic omeprazole)|Omeprazole administration: 20 mg cps once daily from day 1 to day 28
48317192|NCT04448808|DRUG|Placebo|Placebo of BX-1, oral solution
48645092|NCT01778231|DIETARY_SUPPLEMENT|Nutrof Total|Antioxidant and trace element supplement
47966375|NCT06276283|DRUG|DZD9008 plus Bevacizumab|DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
47966376|NCT02794883|BIOLOGICAL|Durvalumab|Given IV
47966377|NCT02794883|OTHER|Laboratory Biomarker Analysis|Correlative Studies
48317193|NCT05528874|DIETARY_SUPPLEMENT|Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes|Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
48317194|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 4 before recipe 5|"After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner."
48317195|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 5 before recipe 4|Same as previous group, but starting with recipe 5
48485711|NCT04130659|DEVICE|MARIAL® alone|MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.
48485712|NCT01311752|PROCEDURE|surgical management of high grade lesions|"Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.~Surgical sample will be collected to study human papillomavirus related genital pathology."
48485713|NCT00859001|DRUG|FM+R|Fludarabine-Mitoxantrone-Rituximab
48485714|NCT00859001|DRUG|Zevalin (Ibritumomab Tiuxetan)|
48485715|NCT05290324|DRUG|Midazolam|Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
48485716|NCT03858426|OTHER|no intervention|no intervention
48485717|NCT03964610|DIAGNOSTIC_TEST|color fundus photography (CFP) and OCT-A|Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
48485718|NCT03321994|DEVICE|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
48485719|NCT03321994|DEVICE|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
48485720|NCT06037278|DEVICE|MyPAO|use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
48485721|NCT05465642|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
48645093|NCT01778231|DIETARY_SUPPLEMENT|Placebo|
48645094|NCT00989443|DRUG|Cidofovir gel|topical gel applied once a week for 3 weeks
48645095|NCT02554838|OTHER|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
48645096|NCT02554838|OTHER|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
48645097|NCT02554838|BEHAVIORAL|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
48116563|NCT04631003|DIAGNOSTIC_TEST|dynamic functional testing|First, with an arthroCT of the wrist by intraarticular injection of contrast agent, a possible scaphulonary band lesion is detected. The surgeon does not yet know the findings of the possible ligament injury at this time, but he can assess the fracture in the CT. Subsequently, a dynamic functional test of the scapholunary distance is carried out intraoperatively under investigation with the modified Watson test before and after performing the osteosynthesis. For this purpose, the wrist is intraoperatively brought under pull on the thumb from a radial abduction into an ulnarabduction. In the presence of a scapholunary instability, a change in the distance of the scapholunary joint gap is shown here under illumination. Now the surgeon receives the finding of the Arthro-CT regarding an existing ligament injury. If necessary, this is treated in the same anaesthetic with a band seam and ossary transfixation.
48116564|NCT01234116|DRUG|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
48645098|NCT02767687|OTHER|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
47966378|NCT02794883|PROCEDURE|Surgical Procedure|Undergo surgical tumor resection
48317196|NCT01449552|DRUG|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
47966379|NCT02794883|BIOLOGICAL|Tremelimumab|Given IV
48317197|NCT01449552|PROCEDURE|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
48116565|NCT05625334|DRUG|ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
48116566|NCT05625334|DRUG|non-enteric-coated chewable aspirin|Orally administered
48317198|NCT01449552|OTHER|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
48317199|NCT01449552|OTHER|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
48317200|NCT01700517|OTHER|Spinal anesthesia|spinal anesthesia
48317201|NCT01700517|OTHER|Femoral nerve block|Femoral nerve block
48317202|NCT01700517|OTHER|sciatic nerves block|sciatic nerves block
48317203|NCT03503214|DIAGNOSTIC_TEST|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
48317204|NCT03503214|DIAGNOSTIC_TEST|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
48317205|NCT02929849|DIETARY_SUPPLEMENT|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
48317206|NCT02929849|DIETARY_SUPPLEMENT|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
48317207|NCT02929849|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
48485722|NCT05043064|PROCEDURE|Wet lab tasks|Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model
48485723|NCT02610764|PROCEDURE|Blood Test for CTC evaluation|
48485724|NCT04192123|DEVICE|HM242|HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
47966380|NCT00009997|BIOLOGICAL|trastuzumab|
47966381|NCT00009997|DRUG|cyclophosphamide|
47966382|NCT00009997|DRUG|doxorubicin hydrochloride|
47966383|NCT00009997|DRUG|paclitaxel|
47966384|NCT00009997|DRUG|tamoxifen citrate|
47966385|NCT00009997|PROCEDURE|conventional surgery|
47966386|NCT01516346|DRUG|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
48116567|NCT04719377|DEVICE|catheter placement|catheter placement
48116568|NCT00001992|BIOLOGICAL|rgp120/HIV-1IIIB|
48116569|NCT00160004|BEHAVIORAL|Intensive Controlled Exercise|
48645099|NCT06295471|DEVICE|DFG Laser|Laser treatment to the upper thigh
48116570|NCT06285097|DRUG|PF-07820435|immune agonist
48645100|NCT06295471|DEVICE|CO2 Laser|Laser treatment to the upper thigh
48116571|NCT06285097|BIOLOGICAL|Sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
48116572|NCT04874558|DIAGNOSTIC_TEST|Ultra-low dose chest CT|A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
48116573|NCT06547164|DRUG|Midazolam|Midazolam will be administered orally.
48116574|NCT06547164|DRUG|Camizestrant|Camizestrant will be administered orally.
48116575|NCT06547164|DRUG|Carbamazepine|Carbamazepine will be administered orally.
48116576|NCT00317902|DRUG|Epoetin alfa|
48645101|NCT06295471|DEVICE|Optical coherence tomography (OCT)|Angiographic OCT imaging at areas of interest
48645102|NCT01905085|DEVICE|No intervention|
48116577|NCT05501249|BEHAVIORAL|Aquatic Integrated Cognitive Motor Training|Aquatic exercise class with focus on cognitive and physical exercise
48317208|NCT04144452|OTHER|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
48317209|NCT04144452|OTHER|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
48317210|NCT00316381|PROCEDURE|Autologous bone marrow-derived stem cells|
48317211|NCT06153082|DIAGNOSTIC_TEST|ROTEM|In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid
48317212|NCT06153082|DIAGNOSTIC_TEST|Thromboelastography|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
48317213|NCT01848899|DRUG|Iodixanol|contrast media used during coronary angiography
48317214|NCT01848899|DRUG|Ioxaglate|contrast media used during coronary angiography
48317215|NCT01848899|DRUG|Bivalirudin|A direct thrombin inhibitor
48317216|NCT01689376|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
48317217|NCT02723604|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
48317218|NCT01838174|DRUG|ACTHAR Gel (ACTH)|15 days of daily injections
47966387|NCT01516346|DRUG|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
48116578|NCT00145743|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
48116579|NCT04581850|BEHAVIORAL|Sleep recording|Sleep is recorded at home during 7 nights in a row using a connected headband. The participant also has to fill in a sleep agenda every day.
48317219|NCT01838174|DRUG|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
48317220|NCT03571321|DRUG|Ruxolitinib|"Participants will receive one of 3 doses \[taken by mouth\] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.~Remission consolidation regimen:~* Days 1-14 and 29-43~Interim maintenance regimen:~* Days 1-14 and 29-43~Delayed Intensification regimen:~* Days 1-14 and 29-43"
48317221|NCT03571321|DRUG|Cyclophosphamide|"Remission consolidation regimen:~* 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~* 1000 mg/m2 IV on Day 29"
48317222|NCT03571321|DRUG|Cytarabine|"Remission consolidation regimen:~* 75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39~Delayed Intensification regimen:~* 75 mg/m2/day IV or SC on Days 29-32 and 36-39"
48317223|NCT03571321|DRUG|Mercaptopurine|"Taken by mouth.~Remission consolidation regimen:~* 60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~* 75 mg/m2 on Days 1-84"
48317224|NCT03571321|DRUG|Vincristine|"Remission consolidation regimen:~* 1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50~Interim maintenance regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41~Delayed Intensification regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50~Maintenance Therapy:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57"
48645103|NCT04575688|DRUG|Exparel|Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
48645104|NCT04575688|DRUG|Bupivicaine|Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
47966388|NCT01516346|DRUG|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
48116580|NCT04581850|BEHAVIORAL|Cognitive tasks|Working memory and inhibition capacity is assessed during computer-based tasks (2-back and Go/No-Go tasks) at enrollment and 1 month after enrollment.
48116581|NCT04581850|OTHER|Questionnaires|"The participant has to fill in several questionnaires at enrollment and 1 month after enrollment in order to assess:~* PTSD severity~* chronotype~* Sleep quality~* Daytime sleepiness~* Mood state~* Depression~* Mental disorders and their consequences"
48116582|NCT06395870|BIOLOGICAL|LUCAR-G39D cells product|Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
48645105|NCT06691178|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.
48645106|NCT04693377|PROCEDURE|Cryosurgery|Undergo cryoablation
48645107|NCT04693377|OTHER|Quality-of-Life Assessment|Ancillary studies
48317225|NCT03571321|DRUG|Pegaspargase|"Remission consolidation regimen:~* 2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43~Interim maintenance regimen:~* 2500 IU/m2 IM or IV on Days 2 and 22~Delayed Intensification regimen:~* 2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43."
48645108|NCT04693377|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
48645109|NCT06688123|DRUG|SHR-3167|Dose level 1.
48645110|NCT06688123|DRUG|SHR-3167|Dose level 2.
48645111|NCT06688123|DRUG|Insulin glargine|Dose level 3.
48317226|NCT03571321|DRUG|Rituximab|"For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~* 375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~* 375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~* 375 mg/m2 IV on Days 1 and 8"
48645112|NCT00968630|OTHER|Laboratory Biomarker Analysis|Correlative studies
48645113|NCT00968630|PROCEDURE|Leukapheresis|Undergo leukapheresis
48645114|NCT06682000|DRUG|DWC202404, DWC202314|- 2 tablet, Oral, Once a day
48317227|NCT03571321|DRUG|Methotrexate (Intrathecal Administration)|"Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \[IT\] administration).~Remission consolidation regimen:~* 15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~* 15 mg on Days 1 and 31~Delayed Intensification regimen:~* 15 mg on Days 1, 29, and 36~Maintenance Therapy:~* 15 mg on Day 1~* 15 mg on Day 29 (First 4 courses only)"
48645115|NCT06682000|DRUG|DWC202404, DWC202314P|- 2 tablet, Oral, Once a day
48645116|NCT01242215|DEVICE|ipragliflozin|oral
48645117|NCT01242215|DRUG|Placebo|oral
48645118|NCT01242215|DRUG|Sulfonylurea|oral
48645119|NCT06686433|OTHER|Novel infant formula|Infants are fed with the novel infant formula from the date of enrollment to the age of 6 months.
48645120|NCT06686433|OTHER|Standard infant formula|Infants are fed with the standard infant formula from the date of enrollment to the age of 6 months.
48645121|NCT06659341|DRUG|BAY3498264|Oral
48317228|NCT03571321|DRUG|Methotrexate (Intravenous Administration)|"Interim maintenance regimen:~* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41"
48645122|NCT06681194|DRUG|Silver Nitrate|"See Silver nitrate only study arm"
48645123|NCT06681194|DRUG|triamcinolone|"See Triamcinolone only study arm"
48645124|NCT06681194|DRUG|Silver nitrate + triamcinolone|"See Combination group study arm"
48645125|NCT06058455|BEHAVIORAL|IDEA3 Sexual Assault Resistance Intervention|Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS \& SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
48645126|NCT06058455|BEHAVIORAL|Consent Workshop|Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
48645127|NCT06689345|DEVICE|taVNS - transauricular vagal nerve stimulation|30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.
48645128|NCT06689345|DEVICE|rPMS - repetitive peripheric magnetic stimulation|Magnetic stimulation on the efferent portion of the vagal nerve on the neck, on the following configuration: 20Hz, 25 pulses in the trein, in every inhalation, for 20 inhalations with 50% of machine capacity (500 pulses total).
48645129|NCT06689345|DEVICE|rTMS - repetitive transcranial magnetic stimulation|rTMS intermitent theta- burst on the left DLPFC, on the following configuration: 50 Hz in treins of 5Hz, with 110% of the resting motor limiar and 600 pulses in 3 minutes.
47966389|NCT02087397|OTHER|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
47966390|NCT02087397|BIOLOGICAL|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
47966391|NCT00816530|DEVICE|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density \> 50% is confirmed by routine digital screening mammography, ABUS will be performed.
48317229|NCT03571321|DRUG|Dexamethasone|"Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~* 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~* 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61"
48317230|NCT03571321|DRUG|Doxorubicin|"Delayed Intensification regimen:~* 25 mg/m2 IV on Days 1, 8, 15"
48645130|NCT06689345|DEVICE|taVNS sham|Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute
48645131|NCT06684535|DRUG|Dexmedetomidine|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.
48645132|NCT06684535|DRUG|Saline|Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline.
48645133|NCT02596893|DRUG|GED-0301|
48645134|NCT02596893|DRUG|Placebo|
48645135|NCT05381753|DRUG|Avapritinib|Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
48317231|NCT03571321|DRUG|Thioguanine|"Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~* 60 mg/m2 on Days 29-42"
48317232|NCT03571321|DRUG|Methotrexate Oral Product|"Taken by mouth.~Maintenance Therapy:~* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\]"
48317233|NCT02431468|DRUG|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
48317234|NCT02431468|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
48317235|NCT03734367|BEHAVIORAL|Emotional abilities training program|A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
48317236|NCT04316663|BEHAVIORAL|Well-Being Intervention|The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
48317237|NCT04316663|BEHAVIORAL|Sleep Hygiene|The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
48317238|NCT00694694|DRUG|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
48317239|NCT00694694|DRUG|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
48317240|NCT02531789|OTHER|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
48317241|NCT01414712|OTHER|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
48317242|NCT00211588|DRUG|galantamine|
48317243|NCT01398033|DEVICE|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
48317244|NCT01398033|DEVICE|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
48317245|NCT00377611|BIOLOGICAL|Fluarix™|
48317246|NCT01257919|DRUG|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
48317247|NCT01257919|DRUG|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
48317248|NCT05506592|OTHER|dermatological product|cosmetic shampoo
48317249|NCT06009224|OTHER|ERAS perioperative management|"* Epidural analgesia~* Fluid balance~* Other items are the same as conventional"
48317250|NCT04350190|DRUG|Apatinib mesylate tablet|The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.
48317251|NCT04350190|DRUG|PD-1|The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
48317252|NCT04209777|DRUG|Probiotic Blend Chewable Tablet|Lactobacillus-reuteri probiotics were used as an experimental drug.
48485725|NCT00788593|DRUG|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
48485726|NCT00788593|DRUG|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
48645136|NCT05381753|DRUG|Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )|Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
48645137|NCT06681974|BEHAVIORAL|CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.|"* Establish a regular sleep schedule~* Do not stay in bed longer than our regular sleep schedule.~* Avoid naps during the day~* Do not perform exciting activities and/or activities that demand physical or mental energy in the 3 hours prior to going to bed.~* Avoid the use of mobile screens, as well as exposure to intense light in the 3 hours prior to going to bed.~* Follow a healthy bedtime routine~* Healthy lifestyle habits: avoid tobacco, alcohol and other toxic substances."
48317253|NCT04209777|DRUG|Antibiotics|Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
48317254|NCT01722487|DRUG|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
48317255|NCT01722487|DRUG|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
48116583|NCT02847702|DRUG|VM902A 200-mg Capsules|Taken orally with food twice daily
48116584|NCT02847702|DRUG|VM902A 400-mg Capsules|Taken orally with food twice daily
48317256|NCT02065310|OTHER|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
48317257|NCT00647868|DRUG|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
48317258|NCT05248087|DEVICE|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
48317259|NCT05248087|DEVICE|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
48317260|NCT06151366|OTHER|non interventional|non interventional
48317261|NCT05500924|OTHER|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
48317262|NCT03984331|DEVICE|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
48317263|NCT03984331|DEVICE|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
48485727|NCT00788593|DRUG|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
47966392|NCT05384093|DEVICE|High Intensity Stretch Device|High Intensity Stretch and Physical Therapy are used either together or alone to treat study arm.
47966393|NCT05466656|OTHER|Continuous quality improvement cycle model|The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
47966394|NCT02535117|PROCEDURE|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
48116585|NCT02847702|DRUG|Naproxen 500-mg Capsules|Taken orally with food twice daily
48317264|NCT02276235|DEVICE|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
48317265|NCT02276235|DEVICE|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
48317266|NCT05298696|DRUG|Cilostazol|Cilostazol 100 mg twice daily
48317267|NCT05298696|DRUG|Placebo|Placebo twice daily
48485728|NCT04914624|BEHAVIORAL|ACBT training|Performed 5 days before surgery and one month after surgery, twice a day.
48485729|NCT04914624|DEVICE|acpella®PEP|Continuously instruct patients to perform positive expiratory pressure training 5 days before surgery and one month after surgery, twice a day.
48485730|NCT04914624|DEVICE|EDP-type II external diaphragm pacemaker|Use external diaphragm pacemaker to stimulate patients' diaphragms.
48485734|NCT01685658|DRUG|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
48116586|NCT02847702|DRUG|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
48116587|NCT05594576|PROCEDURE|GI GENIUS™ artificial intelligence system|Device used during coloscopy for detection of colonic adenoma
48116588|NCT05594576|PROCEDURE|ENDOCUFF VISION® endoscopic cap|Device used during coloscopy for detection of colonic adenoma
48485735|NCT01685658|DRUG|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
48645138|NCT06681974|BIOLOGICAL|EXPERIMENTAL: program of exercises that will be composed of 4 blocks|the first is the work of the soft palate (retropalatine level), the second is the work of the functionality of the tongue (retroglossus level), the third is the work of the position of the hyoid bone (hypopharyngeal level), and the fourth is work on anterior head tilt and craniocervical extension (anterior head posture).
48645139|NCT05073757|DEVICE|Personalized guides and plates|Patients will be included in the study and then followed clinically according to the routine care of orthognathic surgery with personalized guides and plates. The only specific act this study is the completion of an OQLQ quality of life questionnaire by patients preoperatively and between 8 to 12 months postoperatively.
48116589|NCT05925920|DRUG|ENT-03|single dose of active drug
48116590|NCT05925920|DRUG|Placebo|single dose of placebo comparator
48317268|NCT05874453|OTHER|eye care protocol|The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
48645140|NCT05988892|BEHAVIORAL|Physical Activity|Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address.
48645141|NCT06678568|OTHER|telemedicine follow-up in 3rd week|Intervention group will be appointed with telemedicine follow-up in 3rd week after injury, instead of hospital follow-up visit.
48645142|NCT06625775|DRUG|BBO-10203|Participants will receive assigned dose of BBO-10203 orally (PO) QD
48645143|NCT06625775|DRUG|Trastuzumab|Participants will receive trastuzumab infusion (IV) or subcutaneous (SC)
48645144|NCT05626686|DEVICE|CLINY catheter|Subjects using a single use catheter for bladder management at inclusion. During the study period, subjects will use the reusable CLINY catheter for 28 test-days
48645145|NCT06685120|COMBINATION_PRODUCT|PRP + HA injection|Following autologous PRP harvesting and production, 5 mL of PRP and 40 mg/2 mL of HA will be infiltrated into the knee joint affected by gonarthrosis. The combined procedure will be performed by first infiltrating the hyaluronic acid, and next, leaving the needle inserted into the joint to avoid a second needle insertion, the PRP will be infiltrated, respecting the conditions of sterility. In this way, the two products will not be mixed in the same syringe.
48645146|NCT06685120|BIOLOGICAL|PRP injection|Following autologous PRP harvesting and production, patients randomized into control group 1 will undergo single intra-articular PRP infiltration. Five mL of PRP will be infiltrated into the knee joint affected by gonarthrosis.
48645147|NCT06685120|DEVICE|HA injection|Patients randomized into control group 2, will undergo similar blood sampling as the PRP+ HA group and the PRP group to maintain blinding. They will then undergo intra-articular infiltration of 40 mg/ 2 ml HA into the knee with gonarthrosis.
47966395|NCT02535117|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
47966396|NCT03627247|BEHAVIORAL|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar \& Kofman, 2012).
48116591|NCT05662917|BEHAVIORAL|Individual semi-structured interviews|After information and written consent, the investigator will interview the participants through a semi-structured individual interview (conducted by an interview guide). The interview is expected to last 45 minutes (variable depending on the subject). It will be recorded by dictaphone, respecting the anonymity of the participant throughout the interview. The subject's participation will end after the interview.
48317269|NCT05037097|BIOLOGICAL|ARCT-165|Dose 3
48485736|NCT04422119|PROCEDURE|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
48116592|NCT05861050|PROCEDURE|Biopsy|Undergo tumor biopsy
48116593|NCT05861050|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48116594|NCT05861050|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48116595|NCT05861050|PROCEDURE|Computed Tomography|Undergo CT scan
48116596|NCT05861050|BIOLOGICAL|Glofitamab|Given IV
48116597|NCT05861050|DRUG|Lenalidomide|Given PO
48116598|NCT05861050|BIOLOGICAL|Obinutuzumab|Given IV
48317270|NCT05037097|BIOLOGICAL|ARCT-154|Dose 2
48485737|NCT04422119|PROCEDURE|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
48485738|NCT05946902|DRUG|tolterodine|tolterodine 4 mg per day
48485739|NCT05946902|DRUG|mirabegron|mirabegron 25 mg per day
48485740|NCT05946902|DRUG|tolterodine , mirabegron|tolterodine 4 mg and mirabegron 25 mg per day
48116599|NCT05861050|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48317271|NCT05037097|BIOLOGICAL|ARCT-021|Dose 1
48317272|NCT04116450|PROCEDURE|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
48317273|NCT01115738|DRUG|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
48317274|NCT01115738|DRUG|Clopidogrel|Loading dose administered once orally.
48645148|NCT06691568|DEVICE|Air purifier|Purifiers were turned on for the active group and off for the placebo
48645149|NCT00557739|DRUG|mometasone furoate|Topical 0.1% mometasone furoate
48645150|NCT00557739|DRUG|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
48645151|NCT00557739|DRUG|Vehicle (placebo)|Topical placebo
48485741|NCT00474435|DRUG|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~* emtricitabine 200 mg~* tenofovir DF 300 mg~* efavirenz 600 mg"
48485742|NCT02229565|DEVICE|Biopsy or prostatectomy|
48645152|NCT06596135|DRUG|Setmelanotide|Open-label daily injections of setmelanotide
48645153|NCT06678828|DEVICE|ClarityDX Prostate|The ClarityDX Prostate report will be shared for participants randomized into ClarityDX Prostate arm before the healthcare team decided if an MRI and/or biopsy should be done.
48116600|NCT05861050|DRUG|Venetoclax|Given PO
48116601|NCT01128790|OTHER|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
48317275|NCT01115738|DRUG|Placebo|Loading dose administered once orally
48317276|NCT04382898|BIOLOGICAL|BNT112|Intravenous bolus injection
48317277|NCT04382898|DRUG|Cemiplimab|Intravenous infusion
48317278|NCT02316756|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
48317279|NCT02316756|DRUG|Placebo|Placebo which will be given as oral suspension
48317280|NCT01743872|PROCEDURE|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
48317281|NCT01743872|PROCEDURE|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
48317282|NCT01743872|PROCEDURE|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
48317283|NCT01743872|PROCEDURE|Heparinized Normal Saline Injection|Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
48645154|NCT06678828|DEVICE|ClarityDX Prostate, blinded|ClarityDX Prostate will be run for the control participants but the participant and healthcare provider will be blinded to the ClarityDX Prostate results and will be considered for prostate MRI and/or biopsy based on standard of care criteria. Once the care path has been decided upon, the results of the ClarityDX Prostate will be unblinded to the participant's health care team to assess whether there is a change in the decision of the participant's care path.
48645155|NCT06311331|DEVICE|Total Talus Replacement (TTR)|The restor3d patient-specific TTR Implant and Instrumentation System is designed to replace a native talus bone that has been affected by a disease state or injury. The implant is an additively manufactured Cobalt Chromium alloy (ASTM F3213) construct produced by laser powder bed fusion. The data-driven design of the implant enables the patient to salvage their joint while maintaining ankle range of motion, reducing pain and improving physical function.
48645156|NCT06593587|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine 120 mcg
48645157|NCT06593587|OTHER|Placebo|Placebo
48645158|NCT06690047|BIOLOGICAL|Ruconest|recombinant human C1-esterase inhibitor
48317284|NCT03201952|DRUG|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
48645159|NCT06683092|OTHER|RETRIAL-MH|participants will complete biweekly surveys, from 2 weeks prior to starting VTD to 6 months after, and 2 quarterly surveys (at 9mo and 12mo).
48116602|NCT01128790|OTHER|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
48116603|NCT02843217|BEHAVIORAL|Lifestyle, screening|
48116604|NCT00473902|BEHAVIORAL|Training|
48317285|NCT03201952|DRUG|Placebos|Ileostomy administration of 5cc saline placebo once
48317286|NCT02575573|OTHER|Factors influencing resuscitation decisions of patients|
48317287|NCT02575573|OTHER|Factors leading to not asking patients about resuscitation preference|
48317288|NCT06166914|DRUG|Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).
48645160|NCT06683092|OTHER|RETRIAL-Liver|participants will have a liver function test done prior to starting VTD and 28 days after.
48645161|NCT06683092|OTHER|RETRIAL-Neuro|participants will complete a neurological assessment prior to starting VTD and 28 days after.
48645162|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device + PRF|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed followed by application of PRF clots and membrane. Then, the flap will be closed and sutured.
48645163|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device alone (control)|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed. Then the flap will be closed and sutured.
48645164|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fasting)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally after at least 10 hours overnight fast
48645165|NCT06689436|DRUG|5 mg Apixaban Oral Dissolving Film (fed)|Single dose of 5 mg Apixaban Oral Dissolving Film will be administered orally at 30 minutes after the start of a standardized high-fat, high-calorie breakfast that is preceded by at least 10 hours overnight fast
48645166|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (US RS/RLD)|Single dose of 5 mg Apixaban Oral Tablet (US RS/RLD) will be administered orally after at least 10 hours overnight fast
48645167|NCT06689436|DRUG|5 mg Apixaban Oral Tablet (EU product)|Single dose of 5 mg Apixaban Oral Tablet (EU product) will be administered orally after at least 10 hours overnight fast
48645168|NCT05691361|DRUG|ADX-324|siRNA duplex oligonucleotide
48645169|NCT05691361|DRUG|Placebo|saline
48645170|NCT06689085|COMBINATION_PRODUCT|Testosterone enanthate|XYOSTED 50mg, XYOSTED 75 mg, XYOSTED 100 mg
48317289|NCT06166914|DRUG|Placebo|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
48317290|NCT04091230|DEVICE|TRUSbx|Trans Rectal UltraSound guided Prostate Biopsy
48317291|NCT05929924|DIETARY_SUPPLEMENT|Extra virgin olive oil|EVOO will be included in the participant's daily diet for 6 months
48317292|NCT04821973|DEVICE|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
48317293|NCT04821973|DEVICE|usual monitoring|usual nurse respiratory monitoring
48317294|NCT04459702|DRUG|hydroxychloroquine|Treatment with the drug hydroxychloroquine
48317295|NCT04459702|DRUG|Azithromycin|Treatment with the drug azithromycin
48317296|NCT04459702|DRUG|Ritonavir|Treatment with the drug ritonavir
48645171|NCT01084759|DRUG|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. \> 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
48317297|NCT04459702|DRUG|Lopinavir|Treatment with the drug lopinavir
48317298|NCT05120934|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
48645172|NCT01084759|DRUG|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
48645173|NCT03416387|DEVICE|3D PRINTING|A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
48645174|NCT06689176|DEVICE|Irrisept® Antimicrobial Wound Lavage|Irrisept® Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device comprised of a 450mL bottle of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United States Pharmacopeia (USP) and an applicator (labeled Irriprobe®). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle. The CHG acts as a preservative to inhibit microbial growth in the solution.
47966397|NCT02826902|DRUG|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
48116605|NCT00473902|DRUG|Creatine Monohydrate, Conjugated Linoleic Acid|
48485743|NCT02213952|DRUG|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
48317299|NCT05120934|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
48485744|NCT02213952|OTHER|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
47966398|NCT02826902|DRUG|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
47966399|NCT05315401|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
48317300|NCT05120934|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
48317301|NCT05120934|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
48317302|NCT05120934|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
48317303|NCT05120934|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
48317304|NCT05398419|OTHER|Music listening intervention|Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
48317305|NCT05398419|OTHER|Non-musical sounds listening intervention|Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
48485745|NCT03382249|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
48485746|NCT03382249|COMBINATION_PRODUCT|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
48485747|NCT00027079|DRUG|ondansetron (Zofran)|
48485748|NCT00027079|DRUG|naltrexone (ReVia)|
48485749|NCT00027079|BEHAVIORAL|Cognitive Behavioral Therapy|
48485750|NCT03664050|DRUG|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
48317306|NCT03247205|BEHAVIORAL|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
48485751|NCT03664050|PROCEDURE|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
48645175|NCT06690125|DIAGNOSTIC_TEST|Classical and computerized assessment|"Patients with right hemisphere stroke will undergo a battery of standardized paper-based tests, as part of routine clinical practice, including cognitive assessments.~Additionally, they will complete computerized tests involving the presentation of unisensory (Auditory or Visual Stimuli) and multisensory stimuli (visual and auditory stimuli)"
48645176|NCT06402565|DRUG|NOX1416 plus SOC|Topical Nitric Oxide
48485752|NCT04065776|RADIATION|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
48645177|NCT06402565|OTHER|Placebo plus SOC|Placebo plus SOC as provided in the Arm/Group description.
48645178|NCT06672939|DRUG|Orforglipron|Administered orally
48645179|NCT06672939|DRUG|Placebo|Administered orally
48645180|NCT06510621|PROCEDURE|Socket-Shield Technique|A high-speed turbine was used to cut the tooth crown 1.5-2 mm from the buccal gingival margin. The tooth was then divided along the long axis, approximately 2 mm from the buccal side(Figure 1c, 1d). The palatal roots were removed using minimally invasive elevation and extraction forceps. Next, the buccal socket-shield was trimmed to approximately 4-6 mm in height (1 mm from the buccal gingival margin)\[18\], 3-4 mm in width, and 1-1.5 mm in thickness\[19,20\]. The trimming process required with clear visualization of the shield and calibration by periodontal probe. Finally, the socket-shield was removed by minimally invasive forceps when the adjacent tooth moved proximate to the shield during the process of closing orthodontic gap.
48645181|NCT06538064|OTHER|No Intervention|This is a non-interventional study.
48645182|NCT06679452|OTHER|Emotion-Focused Therapy|This feasibility protocol is a two-arm, parallel, double-blinded, RCT aimed at informing a future trial assessing the effectiveness of EFT in resolving emotional injuries in older adults in the context of interpersonal offenses.
48645183|NCT06688942|BEHAVIORAL|Horizons App Intervention|Participants will receive access to the Horizons app intervention. The intervention pairs patient-centered information about chronic graft-versus-host disease with self-management strategies. Within each module, patients will engage in didactics and exercises that are relevant to the participant's chronic graft-versus-host disease concerns. The app contains 6 digital modules delivered via tablet over approximately 6 weeks. Each module should take up to approximately 20 minutes and are self-guided.
48645184|NCT06687005|PROCEDURE|non-surgical periodontal therapy|non-surgical periodontal therapy
48645185|NCT06051617|DRUG|Seladelpar|"* Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis."
48645186|NCT06051617|DRUG|Placebo|One capsule daily for up to 36 months.
48645187|NCT05371470|DEVICE|Ellipsis Health Voice Application|Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety
48317307|NCT05665621|OTHER|Eight-week in-school strength and balance training program|Training program consisting of two 1-hour strength and balance training sessions per week.
48317308|NCT06281782|OTHER|topical retinoids and platalet rich plasma|We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.
48317309|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
48317310|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
48485753|NCT00195013|DRUG|glutamine|10 grams three times a day (orally) for four days and then stop
48485754|NCT00195013|DRUG|Placebo|10 grams three times a day (orally) for four days and then stop
48485755|NCT01436565|DRUG|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
48485756|NCT01436565|DRUG|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
48485757|NCT03074539|DRUG|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
48485758|NCT03074539|PROCEDURE|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
48485759|NCT03074539|PROCEDURE|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
48485760|NCT00225537|DRUG|4-Methylumbelliferone (Heparvit®)|
48485761|NCT05376618|OTHER|no intervention|no intervention
48645188|NCT06682273|OTHER|Thread-embedding acupuncture|Thread-embedding acupuncture is performed every week for 4 weeks, using a single Polydioxaone thread inserted into acupoints on the body through the needle. After the thread is inserted, the needle will be immediately withdrawn.
48645189|NCT06682273|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into therapeutic points on the ear. The patches with the needle will remain in place for one week.
48645190|NCT06682273|OTHER|Sham thread-embedding acupuncture|Sham thread-embedding acupuncture is performed every week for 4 weeks, using the needle without thread inserted into acupoints on the body. After insertion, the needle will be immediately withdrawn, and no thread will be left in the body.
48317311|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
48317312|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
48317313|NCT01972009|PROCEDURE|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
48317314|NCT05178251|PROCEDURE|appendectomy|appendectomy for acute appendicitis
48317315|NCT03761043|BEHAVIORAL|Professional Behavior Change Intervention|IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
48317316|NCT02365493|DRUG|Beta-Lactam|
48116606|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
48485762|NCT00780923|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
48485763|NCT02531607|OTHER|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
48485764|NCT01426035|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
48485765|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
48485766|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
48485767|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
48116607|NCT03947086|DEVICE|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
48317317|NCT04054349|OTHER|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
48317318|NCT03034759|OTHER|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
48485768|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
48485769|NCT00952276|BIOLOGICAL|Normal saline solution|0.5 mL, Intramuscular on Day 0
48485770|NCT04925713|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
48645191|NCT06682273|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into non-therapeutic points on the ear. The patches with the needle will remain in place for one week.
48645192|NCT06687629|PROCEDURE|Concha bullosa crushing|Concha bullosa crushing
48645193|NCT06687629|PROCEDURE|Concha bullosa resection|Concha bullosa resection
48116608|NCT03947086|BEHAVIORAL|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, \& Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao \& Maurer, 2009; Dillon, Kannan, Dean, Spelke, \& Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
48317319|NCT01012505|OTHER|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
48317320|NCT00301782|BIOLOGICAL|bleomycin sulfate|
48116609|NCT04674436|BEHAVIORAL|Walking|6 minute casual walk
48317321|NCT00301782|DRUG|carboplatin|
48317322|NCT00301782|DRUG|cisplatin|
48317323|NCT00301782|DRUG|etoposide phosphate|
48317324|NCT00301782|DRUG|vincristine sulfate|
48317325|NCT03775096|DRUG|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
48317326|NCT01451034|PROCEDURE|WHYX cancer group|WHYX cancer diagnosed by pathologic report
48317327|NCT06233734|DEVICE|The Lokomat (Hocoma, Zurich, Switzerland).|The Lokomat is a device which can be used to implement robot-assisted gait training safely within disabled stroke populations. The robot-assisted gait training group will receive training via the Lokomat. Involvement in the study will not influence the duration or frequency of robot-assisted gait training sessions they receive. The amount of training they receive via the Lokomat will be determined (as per standard care) by the care team at the stroke ward.
48317328|NCT03496467|COMBINATION_PRODUCT|Nepafenac PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
48317329|NCT03496467|COMBINATION_PRODUCT|Placebo PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
48317330|NCT02155764|DEVICE|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
48485771|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions|"The Experimental will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a multisensory experience merging visual and digital auditory stimuli. The audio recording also included some ambient natural sound effects, to make the practice more immersive."
48116610|NCT04423146|OTHER|The evocation of reproducible motor evoked potential according to the different BIS levels|The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
48116611|NCT03621696|DRUG|Cisplatin|-100 mg/m\^2 intravenous push bolus (IVPB)
48116612|NCT03621696|RADIATION|Intensity modulated radiation therapy|-IMRT or IMPT can be used
48116613|NCT03621696|RADIATION|Intensity modulated proton therapy|-IMRT or IMPT can be used
48116614|NCT03621696|PROCEDURE|Surgery|-Standard of care
48485772|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions without audio guided experience|"The Control will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a monosensorial experience with video guided stimulation of naturalistic scenarios."
48485773|NCT05978908|DRUG|FC-12738|Retro enversio pentapeptide of thymopentin
48485774|NCT05978908|DRUG|Saline|placebo
48317331|NCT02155764|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
48485775|NCT02947074|BEHAVIORAL|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
48485776|NCT02058082|PROCEDURE|Intracytoplasmic sperm injection|
48317332|NCT02155764|DEVICE|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
48317333|NCT01260935|PROCEDURE|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
48317334|NCT01260935|PROCEDURE|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
48317335|NCT04108013|DRUG|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
48485777|NCT04334655|OTHER|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
48485778|NCT03690882|OTHER|systematic review of medical imaging|
47966400|NCT05315401|DIETARY_SUPPLEMENT|Placebo|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
47966401|NCT05315401|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week.
48485779|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
48485780|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
48485781|NCT02963402|DRUG|Tocilizumab|
48485782|NCT02963402|DRUG|Adalimumab|
48485783|NCT01095042|BEHAVIORAL|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
48485784|NCT00192270|BIOLOGICAL|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.
48485785|NCT03898713|DIAGNOSTIC_TEST|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
48485786|NCT00521274|BIOLOGICAL|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
47966402|NCT06465394|PROCEDURE|Exercise|Neck exercises in a cross over design that the participants will do both types of interventions with a washout period inbetween.
47966403|NCT06166667|PROCEDURE|Fecal Microbiota Transplant（FMT）|Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.
48317336|NCT04108013|DRUG|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
48317337|NCT03866252|DRUG|LSD|LSD administration per os
48317338|NCT05636371|OTHER|Written Communication|Written patient care updates provided to families of ICU patients each day
48485787|NCT00521274|DRUG|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
48485788|NCT02701413|DEVICE|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
48485789|NCT02701413|DEVICE|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
48485790|NCT03521648|PROCEDURE|PAE|Prostatic artery embolization
48485791|NCT03521648|PROCEDURE|TURP|Transurethral resection of the prostate
48485792|NCT03521648|PROCEDURE|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
48485793|NCT02046525|BIOLOGICAL|Autologous fecal microbiota therapy|
48485794|NCT02046525|OTHER|Placebo|Saline enema
48317339|NCT03535324|BEHAVIORAL|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
48317340|NCT03535324|OTHER|Control|There will be no intervention
48317341|NCT01404026|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
48317342|NCT06124547|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
48317343|NCT01288898|DRUG|ASP1941|Oral
48317344|NCT01288898|DRUG|Placebo|Oral
48317345|NCT01374776|DRUG|intravenous iron carboxymaltose|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
48317346|NCT04078672|PROCEDURE|NOTAL-OCT V3.0|AMD and DR patients
48317347|NCT04834973|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
48317348|NCT04834973|DRUG|pembrolizumab|"Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy."
48317349|NCT03808038|OTHER|None- Observational Study|None- Observational Study
48317350|NCT04729556|DEVICE|Sericin and chitosan cream|A novel film-forming cream containing sericin and chitosan
48317351|NCT02991937|DRUG|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
48317352|NCT02991937|PROCEDURE|Surgical Treatment|Appendectomy
47966404|NCT02256020|OTHER|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
47966405|NCT02256020|OTHER|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
47966406|NCT05801874|DIAGNOSTIC_TEST|Movement analysis|Qualitative and quantitative computerized and instrumental assessment of gait and posture.
47966407|NCT02059395|OTHER|Mastery based learning|Participants are allowed to follow the course content at their own speed
48317353|NCT02649543|PROCEDURE|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
48317354|NCT02649543|PROCEDURE|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
48317355|NCT02649543|PROCEDURE|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
48317356|NCT02351258|DEVICE|70% Isopropyl alcohol embedded caps|Protective cap on central lines
48317357|NCT02351258|OTHER|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care"
48317358|NCT01248910|BEHAVIORAL|Alpine Skiing|
48317359|NCT06296433|OTHER|VR rehabilitation|VR software application containing education, exergames, therapeutic exercises and relaxation sections.
48317360|NCT06296433|OTHER|VR video application|VR software application that plays 2D nature videos
48317361|NCT04536337|DRUG|ALG-000184|Single or multiple doses of ALG-000184
48317362|NCT04536337|DRUG|Placebo|Single or multiple doses of Placebo
48317363|NCT04536337|DRUG|Entecavir|multiple doses of Entecavir
48317364|NCT00364494|PROCEDURE|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht\<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht\>25% bleed or not
47966408|NCT02059395|OTHER|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
47966409|NCT03744091|DRUG|P1|10 mg or 20 mg of THC:THCa
47966410|NCT00873015|DRUG|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
48317365|NCT04371952|DRUG|Doxycycline|comparison of doxycycline 200 mg/day to placebo
48317366|NCT04371952|DRUG|Placebo|Placebo : lactose, 380 mg/gélule
48317367|NCT06317077|OTHER|PAP therapy setting|Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated
48317368|NCT06317077|OTHER|exclusive use of Löwenstein Medical full face masks|Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation
48317369|NCT02554253|DRUG|Ketamine|Ketamine used for induction
48317370|NCT02554253|DRUG|Propofol|Propofol for induction
48317371|NCT01879176|DEVICE|CytoSorb|
48317372|NCT04504032|DRUG|Rivaroxaban|Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
48317373|NCT04504032|DRUG|Placebo|Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
48317374|NCT00772382|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
48317375|NCT05097053|BIOLOGICAL|MVC-COV1901(3 Months)|MVC-COV1901 vaccine after a 3-month Interval
48317376|NCT05097053|BIOLOGICAL|MVC-COV1901(6 Months)|MVC-COV1901 vaccine after a 6-month Interval
48317377|NCT01744509|DEVICE|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
48317378|NCT00292448|DRUG|Ba 679 BR Respimat|
48317379|NCT00292448|DRUG|Tiotropium (Spiriva) inhalation capsule 18 ug|
48317380|NCT03809832|DIAGNOSTIC_TEST|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
48317381|NCT02012608|DRUG|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
48317382|NCT02012608|DRUG|Placebo|For subjects undergoing breast conserving therapy
48317383|NCT04342182|BIOLOGICAL|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
48317384|NCT01872741|PROCEDURE|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
48317385|NCT01872741|PROCEDURE|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
48645194|NCT06689280|BEHAVIORAL|Video-supervised home-based exercise training|12 weeks of patient-centered video-supervised home-based exercise training that will be kick-started during hospitalization and continued for 12 weeks after discharge, followed by 12 weeks of self-directed maintenance exercise.
47966411|NCT00873015|DRUG|Saline|14 day continuous infusion of a vehicle control infusion
48317386|NCT05272527|BEHAVIORAL|Transition to Motherhood Program|Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
48317387|NCT00132821|DRUG|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
48317388|NCT00132821|DRUG|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
48317389|NCT00132821|DRUG|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
48317390|NCT00132821|DRUG|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
48317391|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Once Daily|
48317392|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Twice Daily|
48317393|NCT02293018|DRUG|1.5% (w/w) MTC896 Gel Once Daily|
48317394|NCT06324994|DRUG|Linperlisib in combination with Obinutuzumab and Venetoclax|Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.
48317395|NCT03440437|DRUG|FS118|Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.
48485795|NCT05802108|DRUG|Evolocumab combined with statins|The experimental group was treated with evolocumab combined with statin for lipid-lowering
48485796|NCT05802108|DRUG|Statin|the control group was treated with statin only for lipid-lowering
48645195|NCT06687980|DRUG|Dupilumab|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
48645196|NCT06687980|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
48317396|NCT03440437|DRUG|Paclitaxel|Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.
48317397|NCT06283784|OTHER|Yovis Capsules|Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
48317398|NCT06283784|OTHER|Placebo|Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
48317399|NCT03365427|OTHER|APP|An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
48317400|NCT00588250|OTHER|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
48485797|NCT04526392|OTHER|Questionnaire|Pubertal course questionnaire
48485798|NCT00373191|DRUG|chemotherapy|N/A- not dictated by study
48485799|NCT00373191|DRUG|endocrine therapy|N/A- not dictated by study
47966412|NCT03777774|PROCEDURE|Passive Redon subgaleal drains|Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
48317401|NCT05900011|BEHAVIORAL|Quality of life questionnaire|Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
48317402|NCT04914832|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
48317403|NCT05838833|DRUG|INV-001|Patient will be assigned to one of three arms.
48317404|NCT02640352|DIETARY_SUPPLEMENT|Probi Defendum|
48317405|NCT02640352|DIETARY_SUPPLEMENT|Placebo|
48317406|NCT04095806|OTHER|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
48317407|NCT00153894|BEHAVIORAL|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
48485800|NCT00373191|GENETIC|DNA methylation analysis|laboratory analysis
48485801|NCT00373191|GENETIC|protein analysis|laboratory analysis
48485802|NCT00373191|OTHER|laboratory biomarker analysis|laboratory analysis
48485803|NCT00373191|OTHER|questionnaire administration|questionnaire
48485804|NCT00373191|PROCEDURE|adjuvant therapy|N/A- not dictated by study
48485805|NCT00373191|PROCEDURE|conventional surgery|N/A- not dictated by study
48485806|NCT00373191|RADIATION|radiation therapy|N/A- not dictated by study
48485807|NCT02972502|DRUG|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
48485808|NCT02972502|DRUG|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
48645197|NCT06687733|GENETIC|NGGT002|adeno-associated viral vector with human phenylalanine hydroxylase gene
48645198|NCT06679153|DRUG|VVN461 Ophthalmic Solution 1.0%|VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
47966413|NCT03777774|PROCEDURE|Vacuum Redon subgaleal drains|Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
47966414|NCT03777774|PROCEDURE|No Redon subgaleal drains|A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
48317408|NCT00153894|BEHAVIORAL|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
48317409|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
48317410|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
48317411|NCT03991364|OTHER|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
48317412|NCT03991364|OTHER|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
48317413|NCT03501745|BEHAVIORAL|WeChat|Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
48317414|NCT03169010|OTHER|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
48317415|NCT03169010|GENETIC|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
48317416|NCT05444478|PROCEDURE|Microwave ablation|only microwave ablation for tumor
48317417|NCT05444478|DRUG|Lenvatinib|lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)
48317418|NCT06186635|OTHER|Traditional yoga|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
48317419|NCT06186635|OTHER|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
48485809|NCT02972502|OTHER|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
48485810|NCT02972502|DRUG|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
48485811|NCT05234320|DRUG|CG-SpikeDown, intranasal formulation|The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
48485812|NCT05234320|DRUG|Vehicle (Placebo)|patients will receive active drug or placebo in addition to standard of care
48485813|NCT05234320|DRUG|Standard of core (type of therapy is depend of decide of the site)|patients will receive active drug or placebo in addition to standard of care
48485814|NCT01197157|DRUG|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
48485815|NCT01197157|DRUG|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
48645199|NCT06679153|DRUG|VVN461 Ophthalmic Solution 0.5%|VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
48645200|NCT06679153|DRUG|Prednisolone acetate|Prednisolone acetate, 1%, for up to 28 days
48645201|NCT04515810|OTHER|Internet-Based Intervention|Use smartphone application
48317420|NCT00948662|DRUG|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
48317421|NCT00948662|DRUG|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
48317422|NCT00948662|DRUG|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
48317423|NCT02074306|DEVICE|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
48317424|NCT02074306|DEVICE|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
48317425|NCT02852148|DEVICE|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
48317426|NCT05254314|DRUG|Semaglutide Pen Injector 2.4mg weekly|Once weekly subcutaneous injection
48317427|NCT05254314|OTHER|Placebo|Once weekly subcutaneous injection
48317428|NCT02406547|DEVICE|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
48317429|NCT02406547|DEVICE|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
48317430|NCT04759014|OTHER|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life
48317431|NCT04922515|OTHER|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
48317432|NCT04813939|DEVICE|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
48317433|NCT02117596|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
48317434|NCT01592669|PROCEDURE|passive leg raising|bilateral PLR was achieved by raising the legs of patient
48317435|NCT05397899|OTHER|Abdominal hypopressive Exercises (AHE)|Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.
48317436|NCT05397899|OTHER|General exercises|General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
48317437|NCT03683706|BEHAVIORAL|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
48317438|NCT02523664|DRUG|Hydrocortisone|effects of hydrocortisone on memory while fMRI
48317439|NCT02523664|DRUG|Placebo|
48485816|NCT04755257|DEVICE|Isokinetic test|Using IsoMed 2000 device (D. \& R. Ferstl GmbH, Hemau, Germany) we conducted the isokinetic test of concentric (CON) and eccentric (ECC) shoulder internal (IR) and external (ER) strength at the angular velocity of 60˚/s in both Method I (scapular position) and Method II (25⁰ Abd and 20⁰ ER). There were seven days between the testing sessions, and both tests were conducted at the same time of day. The same examiner with experience in performing isokinetic testing with IsoMed 2000 tested all subjects in both testing sessions.
47966415|NCT00517998|DRUG|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
47966416|NCT06556485|PROCEDURE|Catheter ablation|Preventive ablation therapy
47966417|NCT06556485|DRUG|Medical therapy|Optimal medical therapy
48317440|NCT03054948|DRUG|SMOFLipid|SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
48317441|NCT03054948|DRUG|Standard therapy|In most cases standard therapy will be IntraLipid.
48317442|NCT00664300|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
48317443|NCT00396240|DRUG|Rosuvastatin|
48317444|NCT00396240|PROCEDURE|Initiatives to improve compliance|
48317445|NCT02905942|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
48317446|NCT02905942|DRUG|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
48317447|NCT04124536|BEHAVIORAL|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
48317448|NCT06411249|DRUG|Belimumab (GSK1550188)|GSK1550188 will be administered subcutaneously.
48485817|NCT06302972|OTHER|Traditional treatment|Hot Pack will be applied at the beginning of the session for 10 minutes. Wall corner stretching exercises, neck isometric exercises and neck stretching exercises will be performed Cold pack will be applied at the end of the session for a few minutes.
48645202|NCT04515810|OTHER|Best Practice|Engage in standard care
48645203|NCT04515810|OTHER|Questionnaire Administration|Ancillary studies
48317449|NCT00885417|DRUG|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
48317450|NCT06334042|DIAGNOSTIC_TEST|Serum Chromium Level|Measuring serum chromium levels from patients who admitted in intensive care unit.
48317451|NCT04254783|DRUG|Risankizumab|Intravenous (IV) infusion
48317452|NCT04254783|DRUG|Cytochrome P450 (CYP) Substrates|Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
48317453|NCT06174363|DRUG|Maxigesic|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
48317454|NCT06174363|DRUG|0.9% saline solution|For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
48317455|NCT05679973|DEVICE|Polybutester suture|After third molar surgery this suture used for primary closure.
48317456|NCT05679973|DEVICE|Polypropylene suture|After third molar surgery this suture used for primary closure.
48485818|NCT06302972|OTHER|IASTM and CCEP|"Instrument Assisted Soft Mobilization Technique (IASTM); For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The Comprehensive Corrective Exercise Program (CCEP) will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
48645204|NCT01337505|DRUG|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
48317457|NCT06269679|DIAGNOSTIC_TEST|CBCT|Cone Beam Computed Tomography (CBCT) has a better sensitivity and sensibility to detect OIF.
48317458|NCT03198754|DEVICE|PEI Experimental Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
48317459|NCT03198754|DEVICE|Comparison Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
48317460|NCT05312424|DIETARY_SUPPLEMENT|Placebo|300 mg olive oil
48317461|NCT05312424|DIETARY_SUPPLEMENT|Low GG|150 mg GG
48317462|NCT05312424|DIETARY_SUPPLEMENT|High GG|300 mg GG
48485819|NCT01497626|DRUG|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
48645205|NCT06688786|DRUG|neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy|Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab
48645206|NCT03809962|DEVICE|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
48645207|NCT00653705|OTHER|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
48645208|NCT00653705|OTHER|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
48645209|NCT06683924|PROCEDURE|Pulsed Radiofrequency Ablation|The area where the lateral femoral cutaneous nerve is seen with US will be anesthetized with 1 ml of 1% lidocaine and a 22 Gauge, 10 cm-5 mm RF cannula will be inserted. Sensory fibers will be stimulated with 0.3-0.5 V. Then, motor fibers will be stimulated up to 1.5 V. If no motor contraction is seen, LFCN will be ablated at 42 degrees Celsius for 240 seconds. The procedure will be completed with the injection of 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone through the RF cannula.
47966418|NCT01969968|OTHER|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
48116615|NCT03621696|OTHER|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
48317463|NCT03248245|OTHER|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
48317464|NCT03248245|OTHER|TAU|Ordinary practices related to interprofessional team collaboration
48317465|NCT00734786|OTHER|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
48317466|NCT02507193|PROCEDURE|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
48645210|NCT06683924|DRUG|Steroid (dexamethasone) Injection|Where the lateral femoral cutaneous nerve is visible with US, 2 ml of 2% lidocaine and 2 ml (8 mg) dexamethasone will be injected.
48317467|NCT02507193|PROCEDURE|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
48317468|NCT04875338|DRUG|plate-rich plasma|1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
48317469|NCT04875338|DRUG|saline (0.9 NACI)|1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
48317470|NCT04875338|DRUG|betametazon|1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
48317471|NCT00652431|DRUG|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
48317472|NCT00652431|DRUG|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
48317473|NCT00652431|DRUG|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
48317474|NCT01208038|DRUG|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
48317475|NCT03072641|DIETARY_SUPPLEMENT|ProBion Clinica|
48317476|NCT05883553|DEVICE|Usability and added value of device within sexual activity|Participants and there partners will be asked to use the device over the course of 4 months, during which both will provide answers to questionnaires on quality of relation and sexual life, and detailed questions on the usability and the added value of the used device during sexual activity along with overall satisfaction with the device.
48317477|NCT01364350|OTHER|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
48317478|NCT01691352|PROCEDURE|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
48485820|NCT05917028|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
48485821|NCT03815968|OTHER|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
47966419|NCT00713323|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
48485822|NCT05748327|DEVICE|Alcasite restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), conditioning with primer, mixing alcasite capsula, place restoration, polymerizing and finishing
48485823|NCT05748327|DEVICE|Bulk fill glass hybrid restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), mixing bulk fill glass hybrid capsula, conditioning, place restoration, apply coating, polymerizing and finishing
48485824|NCT02464826|DRUG|Nailprotex|Nailprotex apply to the abnormal nail twice daily
48485825|NCT03261882|OTHER|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
48485826|NCT05518266|PROCEDURE|US-guided Parasternal block|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
48485827|NCT05518266|PROCEDURE|Surgeon-delivered parasternal block|Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
48485828|NCT06415266|OTHER|Quality of life questionnaire (QLQ)|Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
48485829|NCT06415266|OTHER|Satisfaction survey|The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
47966420|NCT02871297|DRUG|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
48317479|NCT01691352|PROCEDURE|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
48317480|NCT03136367|OTHER|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
48317481|NCT03136367|OTHER|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
48317482|NCT05445011|DRUG|Fludarabine + Cyclophosphamide + TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
48317483|NCT00554892|PROCEDURE|bowel preparation|oral laxatives, retrograde enemas
48317484|NCT00554892|PROCEDURE|no preparation bowel|no preparation bowel
47966421|NCT01446289|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
47966422|NCT01446289|BIOLOGICAL|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
48317485|NCT03180359|BIOLOGICAL|Recommended vaccine scheme according to French Vaccine Schedule 2015|"* BCG~* Measles mumps rubella (MMR)~* Varicella (chicken pox)~* Rotavirus~* Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~* Yellow Fever~* Diphteria tetanus poliomyelitis whopping cough (DTwP)~* Haemophilus influenzae type b~* Hepatitis B~* Meningococcus conjugate~* Pneumococcus~* Human papillomavirus~* Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
48317486|NCT02247674|PROCEDURE|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
48317487|NCT01755195|DRUG|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
48317488|NCT01518712|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
48317489|NCT01518712|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
48317490|NCT04143620|PROCEDURE|Procedure|Triple procedure
48485830|NCT06415266|OTHER|Assessment of patient needs in the field of oncosexology|Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
48485831|NCT04432519|PROCEDURE|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
48485832|NCT04068974|DRUG|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
48485833|NCT04068974|DRUG|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
47966423|NCT01354990|DRUG|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
47966424|NCT05142163|OTHER|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
48485834|NCT01612039|DRUG|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
47966425|NCT05142163|OTHER|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI \<10%, for values \>10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
47966426|NCT01774604|DRUG|Indomethacin|100 mg Indomethacin PR x 1
47966427|NCT01774604|DRUG|Placebo|
47966428|NCT02174250|DRUG|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
47966429|NCT02174250|DRUG|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
48485835|NCT01612039|DRUG|Placebo|Matching placebo tablets
48485836|NCT00693225|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
47966430|NCT05699031|DEVICE|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
48317491|NCT01472172|DEVICE|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
48317492|NCT00314652|DRUG|Buprenorphine transdermal delivery system|
48317493|NCT02961686|RADIATION|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
48317494|NCT03007485|OTHER|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
48317495|NCT04288479|BEHAVIORAL|Single high-intensity interval training session|10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
48317496|NCT01047761|OTHER|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
48317497|NCT02625324|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
48317498|NCT03282708|OTHER|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
48317499|NCT05268315|BEHAVIORAL|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
48317500|NCT02726932|OTHER|No intervention, merely observational|
48317501|NCT02840890|PROCEDURE|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
48485837|NCT03512951|OTHER|Digital signal processing algorithms|The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
48485838|NCT05237440|BIOLOGICAL|Biological dosage|Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
48485839|NCT00304707|DRUG|Bupropion|300 mg QD
48317502|NCT02840890|PROCEDURE|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
48317503|NCT00498238|DRUG|Levothyroxine|
48645211|NCT06690541|DRUG|Lorlatinib 100 mg|Patients received continuous daily PO dosing of lorlatinib 100mg QD from the date of first dosing (per the current protocol) or until one of the following criteria were met (whichever occurred first): disease progression; initiation of a new anticancer therapy; unacceptable toxicities; global deterioration of health-related symptoms; pregnancy; withdrawal of consent; loss to follow-up; death; investigator decision dictated by protocol non-compliance; or study termination.
48645212|NCT04560998|DRUG|Semaglutide|Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
48645213|NCT04560998|DRUG|Placebo (semaglutide)|Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
48645214|NCT06412055|DEVICE|NEURO SWING AFO (Fior& Gentz, Lüneburg In Duderstadt, Germany)|stiffness-optimized custom-made spring-hinged AFO with the NEURO SWING® system ankle joint build in
48645215|NCT06412055|DEVICE|WalkOn Reaction® (Ottobock, Duderstadt)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (2.8 Nm/degree).
48645216|NCT06412055|DEVICE|Matrix Max2® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (1.4 Nm/degree)
48317504|NCT01547910|DIETARY_SUPPLEMENT|Fish Oil|Fish oil given in supplementary dose
48317505|NCT03971084|OTHER|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
48317506|NCT03971084|OTHER|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
48317507|NCT04202653|DRUG|ETV|entecavir 0.5 mg qd
48317508|NCT04202653|DRUG|TQ-A3334|TQ-A3334 po qw
48317509|NCT04202653|DRUG|TQ-B2450|TQ-B2450 q3w iv
48645217|NCT06412055|DEVICE|Matrix® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (0.6 Nm/degree)
47966431|NCT05699031|OTHER|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
48317510|NCT05203276|DRUG|Envafolimab|300mg，SC，Q3W，d1
48317511|NCT05203276|DRUG|Endostar|210mg，CIV，Q3W，d1-3
48485840|NCT00304707|DRUG|placebo|placebo
48485841|NCT05880121|DIAGNOSTIC_TEST|MRI|brain MRI
48485842|NCT03529643|DRUG|Dexmedetomidine|Anesthesia with sevoflurane-remifentanil-dexmedetomidine
48485843|NCT03529643|OTHER|Without dexmedetomidine|Anesthesia with sevoflurane-remifentanil
48317512|NCT01971489|DRUG|Buparlisib|Given PO
48317513|NCT01971489|DRUG|Cisplatin|Given IV
48317514|NCT01971489|DRUG|Gemcitabine Hydrochloride|Given IV
48317515|NCT01971489|OTHER|Laboratory Biomarker Analysis|Correlative studies
48317516|NCT01971489|OTHER|Pharmacological Study|Correlative studies
48317517|NCT01971489|OTHER|Questionnaire Administration|Ancillary studies
48317518|NCT06080776|DRUG|SH-1028 tablets|The initial dose of SH-1028 tablets is 200 mg once daily.
48317519|NCT06080776|DRUG|Placebo SH-1028 tablets|Placebo SH-1028 tablets.
48317520|NCT01429792|DRUG|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
48317521|NCT01429792|DRUG|ribavirin [Copegus]|standard treatment, orally daily
48317522|NCT03177980|DRUG|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
48317523|NCT03177980|DRUG|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
48317524|NCT02503631|DEVICE|Stool Sample Collection Kit|Stool sample collection kit
48317525|NCT05216848|OTHER|Wijma Delivery Expectancy Questionnaire|Simple questionaire identifying the level of fear of childbirth in pregnancy
48317526|NCT05216848|OTHER|Clinical data collection|Collection of the standard clinical data during hospitalization
48317527|NCT00238303|DRUG|vorinostat|Given orally
48317528|NCT00238303|PROCEDURE|conventional surgery|Patients undergo surgery to remove tumor
48317529|NCT06380361|DEVICE|BioSpy System|One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.
48317530|NCT02848339|DRUG|aspirin|aspirin desensitization
48317531|NCT02176291|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
48485844|NCT00750126|DRUG|Fludarabine, Busulfan, Thymoglobulin|"study :~* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~* the effectiveness of the protocol on tumor response~* overall survival"
48485845|NCT05703243|DIAGNOSTIC_TEST|Comprehensive liquid molecular panel test|Lab test
48645218|NCT06690931|DEVICE|Brain-Computer Interface with FES and VR|"The intervention utilizes the recoveriX PRO system. This is a neurofeedback therapy device that combines Brain-Computer Interface based motor imagery, functional electrical stimulation (FES), and virtual reality (VR). This approach enables participants to engage in motor imagery exercises while receiving real-time feedback based on neural signals.~Participants will complete a total of 24 recoveriX sessions, scheduled at 6 sessions per week, with each session lasting 1 hour."
47966432|NCT02446483|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
47966433|NCT02446483|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
47966434|NCT02677532|DRUG|Paracetamol|1 g every 8 hours
47966435|NCT02677532|DRUG|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
47966436|NCT02677532|DRUG|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
48317532|NCT02176291|DRUG|Placebo|matched placebo
48317533|NCT00301028|BIOLOGICAL|Cetuximab|Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.
48317534|NCT00301028|DRUG|Carboplatin|AUC 2 weekly for 6 courses.
48317535|NCT00301028|DRUG|Paclitaxel|135 mg/m\^2 weekly for 6 courses.
48485846|NCT05703243|OTHER|EORTC QLQ-30|Quality of life questionnaire
48485847|NCT05904275|DRUG|caudal epidural injection|Preoperative Ultrasound guided caudal epidural injection in lumbosacral spine surgeries for postoperative analgesia.
48485848|NCT00398931|DRUG|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
48485849|NCT00398931|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
48485850|NCT00431782|DRUG|ATI-5923|
47966437|NCT02677532|DRUG|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
47966438|NCT02677532|DRUG|Morphine|Intravenous slow bolus of 10 mg morphine
47966439|NCT02677532|DEVICE|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
48317536|NCT00301028|PROCEDURE|Conventional Surgery|Following induction in second part of study.
48317537|NCT00301028|RADIATION|Radiation Therapy|Following induction in second part of study.
48317538|NCT03060083|OTHER|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
48317539|NCT03060083|OTHER|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
48317540|NCT00217867|BEHAVIORAL|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
48317541|NCT02634931|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
48317542|NCT06286436|OTHER|Dual-task training|The intervention will consist of three different tasks that participants have to carry out while performing mental calculations (counting backwards from 100 by ones, twos, and threes). The three tasks will be as follows: grouping blocks of different colours into groups according to colour; picking up beans with a spoon and carrying them to a specific place; opening and closing a bottle cap with the affected hand. The total duration of the intervention will be 12 sessions, divided into three days per week for four weeks.
48317543|NCT02643186|DRUG|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
48317544|NCT02643186|PROCEDURE|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
48317545|NCT01133431|DRUG|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
48317546|NCT01133431|DRUG|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
48317547|NCT03365804|DEVICE|3D Printed Brace|All subjects' body shape will be scanned to generate sterolithography (STL) files for 3D printing.
48317548|NCT02557360|DIETARY_SUPPLEMENT|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
48317549|NCT03030911|DRUG|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
48317550|NCT03030911|DRUG|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
48317551|NCT03030911|DRUG|Fentanyl|The drug will be administered in both groups
48317552|NCT03030911|DEVICE|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
48317553|NCT03105596|DRUG|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
48317554|NCT04427917|DRUG|PF-06835919|PF-06835919 300 mg repeated doses
47966440|NCT02677532|DEVICE|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
47966441|NCT02677532|DRUG|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
48317555|NCT04427917|DRUG|Placebo|Placebo repeated doses
48317556|NCT03448224|OTHER|Questionnaire Administration|Questionnaire
48317557|NCT03448224|OTHER|Internet-Based Intervention|Intervention
48317558|NCT02077387|BEHAVIORAL|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
48317559|NCT02077387|BEHAVIORAL|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
48317560|NCT06516939|DRUG|bFGF|Half-face randomized control
48317561|NCT06516939|DRUG|Bovine Basic Gel|Bovine Basic Gel
48317562|NCT04949555|OTHER|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
48317563|NCT04039191|BEHAVIORAL|SMS education|Patients will receive additional educational SMS messages post-operatively
48485851|NCT01192984|BIOLOGICAL|KW-0761|Intravenously 8 times at 1-week intervals
48485852|NCT05974917|DEVICE|Serious Game (SG)|"SG which was conceived as a running game, in which an Avatar runs through the forest and overcomes obstacles through the player's performance of physical exercises.~Children will play while watching an imaginary Avatar, who shows the right movements to perform in order to collect rewards. SG will be projected with a 4K projector and controlled by the child's movements, which will be tracked in markerless mode using Azure's Kinect sensor. SG will include an adaptive tool to enable the experience based on the child's specific motor skills.~The dynamics of SG will be adapted by considering real motor and physiological data acquired during each SG session via a wristband. These data are necessary to keep the child in the aerobic zone (60-80% of maximum heart rate). The movements are:~1. Side bending: Moving an obstacle to open a passage.~2. High jump: Overcoming a low, frontal obstacle.~3. Side lunge: Avoiding a side obstacle.~4. Squat: Passing under a low, frontal obstacle."
48485853|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
48485854|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
48485855|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
48485856|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
48485857|NCT01387763|DRUG|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
48645219|NCT06690931|DEVICE|Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback|"The participants will train the Motor Imagination (MI) combined with Functional Electrical Stimulation (FES) and Virtual Reality (VR) feedback. Feedback provided to the patients will not be linked to the neural signals.~The amount of stimulation delivered by the feedback devices (FES and VR) will be similar to the experimental group."
48645220|NCT06689020|PROCEDURE|Continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) therapy|During application of CPEP and CHFO, EIT is monitored.
48317564|NCT04039191|BEHAVIORAL|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
48317565|NCT06372067|DEVICE|Intramedullary screw|Intramedullary (IM) screw fixation is a minimally invasive technique that provides rigid fixation of fractures, acting as an internal splint and load-sharing device. IM screw fixation may allow for early mobilization without the operative site morbidity of open reduction and its associated complications.
48317566|NCT06372067|DEVICE|Kirschner wire|Kirschner wire (K-wire) fixation is a minimally invasive technique that provides non-rigid fixation of fractures. K-wires allow for fracture fixation with minimal soft tissue injury and preserved blood supply. However, patients require prolonged postoperative immobilization and are at risk of malunion and pin tract infection.
48116616|NCT03621696|OTHER|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
48116617|NCT03621696|OTHER|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
48116618|NCT03621696|OTHER|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
48116619|NCT03621696|OTHER|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
48317567|NCT04713566|OTHER|oral rinces|natural and commercial oral rinses were compared for efficacy
48317568|NCT02815293|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
48116620|NCT05783726|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
48317569|NCT02815293|DRUG|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
48317570|NCT06127706|DEVICE|twin vaginal delivery simulation|skill test after formal lecture and simulation in group 1 and after digital learning only
48317571|NCT04886999|BEHAVIORAL|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
48317572|NCT01648452|BIOLOGICAL|NT-501 CNTF-releasing implant|20 ng/day released into the eye
47966442|NCT02677532|DRUG|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
47966443|NCT05069532|RADIATION|MSCT chest|CORAD 4-5 MSCT chest
47966444|NCT05069532|DIAGNOSTIC_TEST|PCR|PCR positive for COVID-19
47966445|NCT01582165|DRUG|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
48317573|NCT01258530|DRUG|over-encapsulated oseltamivir|75 mg once
48317574|NCT01258530|DRUG|oseltamivir|75 mg once
48317575|NCT05208203|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
48317576|NCT01234857|DRUG|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
48485858|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique + PRF|
48485859|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique|
48485860|NCT03546803|OTHER|3M™ Cavilon™ Advanced Skin Protectant|liquid skin protectant on skin to protect from radiation dermatitis
48317577|NCT01234857|DRUG|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
48485861|NCT05618145|OTHER|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
48116621|NCT05783726|BEHAVIORAL|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
48116622|NCT05783726|BEHAVIORAL|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
48116623|NCT05783726|BEHAVIORAL|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
48116624|NCT02399943|DRUG|Trametinib|
48116625|NCT02399943|DRUG|Panitumumab|
48116626|NCT06007118|RADIATION|APBI|accelerated partial breast irradiation to the surgery bed (5 x 6,0 Gy; in 5 working days)
48317578|NCT01234857|DRUG|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
48317579|NCT01234857|DRUG|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
48317580|NCT06219434|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
48317581|NCT06219434|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
48317582|NCT06219434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48317583|NCT06219434|OTHER|Questionnaire Administration|Ancillary studies
48317584|NCT00838916|BIOLOGICAL|albiglutide|albiglutide weekly injection
48485862|NCT03998579|OTHER|The CanMoRe programme|An exercise intervention in Primary Health Care
48485863|NCT03998579|OTHER|Home exercise|An active control group
48116627|NCT06007118|RADIATION|WBI|accelerated whole breast irradiation with the boost to tumor bed (15x 2,67 Gy + 5x 2,0 Gy, every working day)
48317585|NCT00838916|DRUG|insulin glargine|insulin glargine
48317586|NCT04507620|DEVICE|cervical neck collar|devices used for cervical immobilization
48317587|NCT06468501|BEHAVIORAL|Price reduction on healthier foods|Price reduction (10%) on healthier foods based on the UK NPM
48485864|NCT03604341|DRUG|Dronabinol 5mg Cap|Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
48485865|NCT03604341|OTHER|Placebo|Subjects randomized to placebo and ibuprofen 800mg for pain
47966446|NCT01582165|DRUG|Placebo.|Placebo once daily vs rosuvastatin for 6 months
48116628|NCT03822572|OTHER|endurance exercise|defined exercise program
48116629|NCT03822572|OTHER|control|habitual physical activity before the diagnosis
48116630|NCT03707691|BEHAVIORAL|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
48116631|NCT03707691|BEHAVIORAL|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
48116632|NCT03707691|BEHAVIORAL|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
48317588|NCT06468501|BEHAVIORAL|Price increase to less healthy foods|Price increase (10%) on less healthy foods based on the UK NPM
48485866|NCT03276780|BEHAVIORAL|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
48485867|NCT03276780|DRUG|combination NRT|Both groups will receive combination NRT to help with smoking cessation
48485868|NCT03338842|DEVICE|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
48317589|NCT06468501|BEHAVIORAL|Combination of price reduction on healthier foods and price increase on less healthy foods|Combination of price reduction (10%) on healthier foods based on the UK NPM and price increase (10%) on less healthy foods based on the UK NPM
48116633|NCT03802708|DIAGNOSTIC_TEST|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
48116634|NCT05756140|OTHER|No intervention|No Control
48116635|NCT04068207|DRUG|Minocycline|Tab. Minocycline 100mg po per day for 12 months
48317590|NCT06468501|BEHAVIORAL|Control|Existing price structure
48317591|NCT00379197|DRUG|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
48317592|NCT00379197|PROCEDURE|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-\[18F\]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
48317593|NCT02277899|OTHER|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
48317594|NCT02277899|OTHER|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
48317595|NCT02277899|OTHER|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
48317596|NCT02277899|OTHER|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
48317597|NCT02277899|OTHER|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
48317598|NCT04402008|DRUG|Poziotinib Once Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
48317599|NCT04402008|DRUG|Poziotinib Twice Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
48317600|NCT04402008|DRUG|Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
48317601|NCT01934894|DRUG|cabazitaxel|
48317602|NCT01934894|DRUG|lapatinib|
48485869|NCT03444272|DRUG|Sofosbuvir and Daklatasuvir|HCV Treatment (Sofosbuvir and Daklatasuvir)
48485870|NCT05613725|OTHER|Blood sample collection|Blood sample collection
48485871|NCT04133246|BEHAVIORAL|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
48116636|NCT02071836|BEHAVIORAL|Right Turns web application|
47966447|NCT05465083|DEVICE|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
48485872|NCT04133246|BEHAVIORAL|Individual interview|Interview led by the psychologist about the patient's parenthood
48485873|NCT00653484|BEHAVIORAL|Physical Activity|
47966448|NCT02667054|DRUG|RX0041 4%|Anesthetic
48116637|NCT02071836|BEHAVIORAL|Treatment as usual|
48116638|NCT01561989|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
48116639|NCT01561989|OTHER|questionnaire administration|Ancillary studies
48116640|NCT01561989|BIOLOGICAL|trivalent influenza vaccine|Given IM
48116641|NCT04861532|DIAGNOSTIC_TEST|Imaging|MRI scanning using new protocols
48116642|NCT03381820|OTHER|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
48116643|NCT02804425|OTHER|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
48485874|NCT00653484|BEHAVIORAL|Energy Restriction|
47966449|NCT02667054|DRUG|Placebo|Placebo Comparator
47966450|NCT02667054|DRUG|RX0041 8%|Anesthetic
47966451|NCT05517915|OTHER|Inspiratory muscle training.|Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
47966452|NCT05517915|OTHER|Sham inspiratory muscle training.|Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
47966453|NCT01247909|DRUG|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
48116644|NCT04189770|DEVICE|Accelerometer|Wear accelerometer
48116645|NCT04189770|OTHER|Ecological Momentary Assessment|Complete EMA questionnaire
48116646|NCT04189770|OTHER|Questionnaire Administration|Complete questionnaire
48116647|NCT04189770|OTHER|Survey Administration|Complete survey
48116648|NCT03174171|DRUG|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
48116649|NCT02889237|DIETARY_SUPPLEMENT|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
48116650|NCT02889237|DIETARY_SUPPLEMENT|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
48116651|NCT02889237|DIETARY_SUPPLEMENT|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
48116652|NCT02229019|BEHAVIORAL|Volunteer mealtime assistance|
48116653|NCT02549170|BIOLOGICAL|HYQVIA|Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
48116654|NCT02549170|BIOLOGICAL|0.25% albumin placebo solution with rHuPH20|Participants will receive placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20.
48116655|NCT02549170|BIOLOGICAL|IGIV GAMMAGARD LIQUID/KIOVIG|Participants will receive GAMMAGARD LIQUID/KIOVIG
48317603|NCT03970395|OTHER|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
48317604|NCT03970395|OTHER|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
48116656|NCT02549170|BIOLOGICAL|IGIV GAMUNEX®-C|Participants will receive GAMUNEX®-C
48116657|NCT06677177|DIETARY_SUPPLEMENT|Nano-water, Tamsulosin Dutasteride|Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
48317605|NCT03970395|OTHER|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
48317606|NCT03157973|OTHER|Education intervention|eHealth tool and standardized nurse-led follow-up.
48317607|NCT05957497|BIOLOGICAL|Biological samples transport and analysis|Biological samples transport and analysis
48317608|NCT01098461|BIOLOGICAL|albiglutide|subcutaneous injection of albiglutide
48317609|NCT01098461|BIOLOGICAL|placebo|subcutaneous injection of placebo to match albiglutide
48317610|NCT00797069|OTHER|standard nutritional product (medical food)|once during crossover
48317611|NCT00797069|OTHER|nutritional product for diabetes (medical food)|once during crossover
48485875|NCT00653484|BEHAVIORAL|Physical Activity and Energy Restriction|
48485876|NCT06398613|DIAGNOSTIC_TEST|PSMA PET/CT|Prostate-Specific Membrane Antigen Emission Tomography/Computed Tomography (PSMA PET/CT) will done preoperatively
47966454|NCT06236672|DRUG|GLP-1 receptor agonist|GLP-1 RA initiated between January 2019 and December 2022
47966455|NCT06236672|DRUG|basal insulin|basal insulin initiated between January 2019 and December 2022
48116658|NCT06677177|DRUG|Regular water, tamsulosin, Dutasteride|Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months
48116659|NCT04280497|DRUG|Administration procedures|"Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;~9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.~Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off."
48317612|NCT00797069|OTHER|diabetes specific experimental nutritional product (medical food)|once during crossover
48317613|NCT05566652|DEVICE|Neural Pressure Support|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
48317614|NCT05566652|DRUG|Pressure Support Ventilation|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
48317615|NCT06131125|OTHER|Plyometric training exercises|This includes plyometric training exercises thrice a week for 6 weeks
48317616|NCT06131125|OTHER|Explosive strength training exercises|this includes explosive strength training exercises thrice a week for 6 weeks
48317617|NCT03408951|OTHER|Recording|The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
48317618|NCT03408652|DRUG|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
48317619|NCT05829616|DRUG|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
48317620|NCT05016869|DRUG|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
48317621|NCT04089813|DRUG|Metformin|Patients use metformin to control blood sugar
48317622|NCT05480293|DRUG|Ranibizumab|ranibizumab，0.5mg,IVT
48485877|NCT03708965|DRUG|JR-141|IV infusion (lyophilized powder)
48485878|NCT04950959|DEVICE|Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T|The system is used for trajectory planning and is intended to assist the physician in the positioning of an instrument, such as a needle, where CT imaging is used for target trajectory planning and intraoperative tracking. The XACT ACE Robotic System uses a computerized quantitative guidance system, which provides real-time, accurate needle guidance, including advancement and steering of the needle from the entry point on the subject's body to the target point within the body.
48485879|NCT02139917|BEHAVIORAL|Transitional community based palliative care|"transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* relief of signs and symptoms encountered~* home visit with spiritual support"
48317623|NCT05480293|DRUG|SCT510A|SCT510A，1.25mg,IVT
48317624|NCT03482323|BEHAVIORAL|Exercise|Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
48317625|NCT03482323|BEHAVIORAL|Tai-Chi|Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
48317626|NCT06008249|DRUG|Lithium Carbonate 400 MG|Lithium carbonate vs placebo (2:1)
48317627|NCT02389712|DRUG|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
48317628|NCT02389712|DRUG|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
47966456|NCT06237829|BEHAVIORAL|Single bump acuity|Investigators will design bumps of varying heights, spacings, diameters, and bump shapes (rounded top, flat top, angled top) which give a precise amount of mechanical stimulus to the finger. Subjects will be asked if they could notice a bump on the surface and instructed to make the judgment quickly (\<2 seconds). A psychometric curve, with a standard braille bump serving as the positive, \~100% success rate control, will be constructed
47966457|NCT06237829|BEHAVIORAL|Optimal spacing between bumps|Investigators will fabricate and characterize two bumps of varying widths (ranging from 150 μm to 3 times the bump width, based on fabrication resolution available in commercial tactile aid machines). Subjects will be asked to run their finger across the two bumps (two bumps always form a line, so investigators do not need to ask subjects to orient their fingers) quickly and asked if they felt one bump or two.
47966458|NCT06237829|BEHAVIORAL|Improving signal from a single bump with designer materials|"Investigators will coat single bumps with our designer materials (with alkyl and amino functional groups) to improve the mechanical stimuli from a single bump. Subjects will then be asked to perform a similar experiment as the single bump acuity test and the optimal spacing between bumps test. (can you notice the bump? or did you feel one or two bumps)."
47966459|NCT06504641|OTHER|Isla for Frailty|"Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password."
47966460|NCT00594659|BEHAVIORAL|Psychotherapy|Nine session treatment
47966461|NCT00594659|BEHAVIORAL|Computerized Psychotherapy|Nine session computer delivered treatment
47966462|NCT00594659|BEHAVIORAL|Motivational enhancement therapy|Two session treatment
47966463|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use
47966464|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use
47966465|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use
47966466|NCT05232396|BIOLOGICAL|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg i.v., single use
47966467|NCT04213079|DEVICE|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
48485880|NCT01314378|BEHAVIORAL|Mindfulness Training|Eight session intensive behavioral training program for smokers
48485881|NCT01314378|BEHAVIORAL|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
48116660|NCT03607708|OTHER|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
48485882|NCT04933786|BEHAVIORAL|Digital Health Nudging|Short daily text messages with information and motivation concerning physical activity.
48485883|NCT02848066|PROCEDURE|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
48485884|NCT05957419|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
48317629|NCT03691402|BEHAVIORAL|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
48317630|NCT03691402|BEHAVIORAL|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
48645221|NCT06686706|OTHER|IASTM|"Graston therapy-8 min per session~Procedure:~The patient will be lying down with their knee bent 30 degrees. After a 5-minute ultrasound treatment and static stretching exercises.Treatment will be administered using the Graston tool (using the sweep approach). Applying a moderate amount of effort from the medial side of the heel to the metatarsals and from the metatarsals to the medial side of the heel, to-and-fro stroking at a 60° angle will be done on the sole of the foot for approximately eight minutes (60-70 strokes per minute with a 5- to 10-second rest interval. A cold pack will be used for five minutes after therapy. The GT session will last approximately 30 minutes.~Conventional Therapy:~Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min Functional status and Quality of Life (QOL) will be assessed before and after treatment of 4 weeks using using tools.~Intervention will be conducted once a week for 4 weeks."
48317631|NCT03670914|DIAGNOSTIC_TEST|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
48317632|NCT03635398|DEVICE|Sipnose device|SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
48317633|NCT03635398|DEVICE|MAD (Mucosal Atomization Device)|MAD (Mucosal Atomization Device)
48317634|NCT03635398|DRUG|midazolam|oral administration of midazolam
48317635|NCT03936517|DRUG|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
48317636|NCT03936517|DRUG|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
48317637|NCT03733873|DRUG|Desmopressin|take desmopressin for 3 months
48317638|NCT03733873|DRUG|Suoquan|take Suoquan mixture for 3 months
48317639|NCT06461611|BEHAVIORAL|Health Diary Program|The health diary is constructed based on the theory of health action process approach, which is used to plan and clock for self-management behaviors of adolescent patients during fixed orthodontic treatment.
48317640|NCT06461611|BEHAVIORAL|Traditional Health Education|Traditional health education is that the nurse orally teaches the patient about fixed orthodontic knowledge, and the patient obtains a paper information.
48317641|NCT01132989|DRUG|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and \< 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
48485885|NCT01861236|DRUG|Firmagon® (degarelix)|Monthly subcutaneous injections
48317642|NCT05075148|OTHER|radiology|Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)
48317643|NCT02382341|DEVICE|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
48485886|NCT03910660|DRUG|BXCL701 plus Pembrolizumab|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle."
48317644|NCT01985633|BIOLOGICAL|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
48317645|NCT01985633|BIOLOGICAL|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
48645222|NCT06686706|OTHER|KT group|"Kinesio tapping (left there for 3 days)~Procedure:~We will use a standard 2 (5 cm) kinesiology tape. Fascia tape will be applied to the plantar fascia, and it will be left there for three days. For four weeks, it will be applied once a week. The patient will be in a prone position, lying with the ankle joints in a neutral position while applying tape. With the toes extended against the bed or ground. The tape will be marked on the Achilles tendon. It will be cut longitudinally into five slices of equal width. It will be applied to the forefoot by stretching it by 25%. The last strap will be applied with gentle compression across the bases of the five slices beneath the foot and wrapped around the rear foot.(5) Conventional Therapy Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min"
47966468|NCT04213079|DEVICE|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
47966469|NCT03310775|BEHAVIORAL|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
47966470|NCT00454883|DRUG|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
48317646|NCT05582785|DIAGNOSTIC_TEST|Hyperfine MRI|Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
48317647|NCT00726817|DRUG|Butyrate|
48485887|NCT03910660|DRUG|BXCL701 monotherapy|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day."
48116661|NCT03607708|OTHER|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
48317648|NCT00358995|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
48485888|NCT00052026|DRUG|carvedilol|low-dose carvedilol administered twice daily for 8 months
48116662|NCT06399679|DRUG|Rivastigmine|Rivastigmine 3mg by mouth once, followed by rivastigmine 1.5mg by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
48485889|NCT00052026|DRUG|placebo|administered twice daily for 8 months
48485890|NCT00052026|DRUG|carvedilol|high-dose carvedilol administered twice daily for 8 months
48485891|NCT00489281|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
48485892|NCT00489281|DRUG|Fludarabine|Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.
48485893|NCT00489281|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
48485894|NCT00489281|DRUG|Sirolimus|The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
48485895|NCT00489281|PROCEDURE|Allogeneic bone marrow transplant|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
48485896|NCT00489281|RADIATION|Total body irradiation - 200|200 centigray (cGy) in one fraction on Day -1.
48485897|NCT00489281|DRUG|Levetiracetam|Given at 500 mg PO twice daily from Day -6 to Day +365.
48485898|NCT00489281|BIOLOGICAL|Anti-thymocyte globulin|Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.
48485899|NCT00489281|RADIATION|Total body irradiation - 400|400 centigray (cGy) in one fraction on Day -1.
48485900|NCT03927924|PROCEDURE|High-intensity focused ultrasound|Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
48485901|NCT01820351|OTHER|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
48485902|NCT02333487|DRUG|Lu AF35700|5 mg tablets for oral administration
48485903|NCT02549573|DRUG|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
48485904|NCT02549573|BEHAVIORAL|Physical Therapy|All subjects will participate in a standardized PT intervention
48485905|NCT03505814|DEVICE|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
48485906|NCT03505814|DEVICE|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
48485907|NCT04013945|DIETARY_SUPPLEMENT|Superba Boost (Active)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
48485908|NCT04013945|DIETARY_SUPPLEMENT|Vegetable oil (Placebo)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
48485909|NCT02224573|DRUG|GWP42003-P|
48485910|NCT00751738|DRUG|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
48485911|NCT05080647|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
48485912|NCT02677181|DRUG|ATG|rabbit ATG（Sanofi）
48485913|NCT02677181|DRUG|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
48116663|NCT06399679|DRUG|Placebo|Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
48116664|NCT05930561|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.
48116665|NCT05930561|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator
48485914|NCT02677181|DRUG|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
48485915|NCT02677181|DRUG|Methotrexate|short-term methotrexate
48485916|NCT01509521|DRUG|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
48485917|NCT01509521|DRUG|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
48485918|NCT00280072|DEVICE|Renal Assist Device|
48645223|NCT06678997|DEVICE|Zinc-L carnosine/Polaprezinc|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
48116666|NCT05628493|BEHAVIORAL|Gut microbiota Analysis|fecal samples were collected per patient on days 1,3 and 7 after ICU admission. All eligible patients were given antibiotics therapy, actively control infection source by puncture drainage or surgery if necessary, as well as other supportive therapy to maintain organ function.
48116667|NCT04339855|OTHER|CAD with LCI for colorectal polyp detection|Polyps within fully recorded endoscopy videos with LCI mode, covering the whole spectrum of adenomatous histology, are used to evaluate the efficacy of CAD with LCI for polyp detection.
48317649|NCT00358995|BEHAVIORAL|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
48116668|NCT03670368|BEHAVIORAL|Mentoring|The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
48317650|NCT04635072|DRUG|Stabilised Whole Rice Bran|Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
48317651|NCT06316882|DIAGNOSTIC_TEST|Screening endoscopy|We perform upper endoscopy, when the patient authorizes it, during their screening colonoscopy
48317652|NCT04343313|DEVICE|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
48317653|NCT00216099|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
48485919|NCT01997021|OTHER|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
48485920|NCT01997021|OTHER|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
48645224|NCT06678997|OTHER|Thickened formula|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
48645225|NCT01992081|DEVICE|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
48645226|NCT01992081|OTHER|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
47966471|NCT01230632|DIETARY_SUPPLEMENT|high fat overfeeding|Dietary Supplement:3 days overfeeding
47966472|NCT03628820|BEHAVIORAL|Dog Therapy|5 minutes spent with therapy dog during shift
47966473|NCT03628820|BEHAVIORAL|Coloring|5 minutes spend coloring mandalas during shift
48116669|NCT03670368|BEHAVIORAL|Comparison group - written materials|Written materials from the mentoring sessions will be provided to those in the comparison group
48116670|NCT01983371|DRUG|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
48116671|NCT01983371|OTHER|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
48317654|NCT00216099|DIETARY_SUPPLEMENT|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
48116672|NCT05089097|OTHER|evaluation of delirium with CAM-ICU Score|the CAM-ICU score is an evaluation tool to verify the presence or absence of delirium in a subject
48317655|NCT00216099|DIETARY_SUPPLEMENT|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
48485921|NCT01997021|OTHER|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
48485922|NCT00742599|DRUG|NPO-11|20 ml NPO-11
48485923|NCT00742599|DRUG|Placebo|20 ml NPO-11(Placebo)
48485924|NCT01100879|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
48485925|NCT00635518|BEHAVIORAL|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
48485926|NCT00247299|DEVICE|IPL Quantum Product manufactured by Luminis Ltd.|
48317656|NCT06426199|DRUG|Chitosan-Hyaluronate Gel Mixture|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Chitosan-Hyaluronate Gel Mixture into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
48317657|NCT06426199|DRUG|Hyaluronic Acid|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Hyaluronic acid into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
48317658|NCT01160341|DRUG|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
48317659|NCT04202718|DIAGNOSTIC_TEST|VitalPatch Device|The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
48317660|NCT00335504|DRUG|oligofructose-enriched inulin|Given orally
48317661|NCT00335504|DRUG|sulindac|Given orally
48317662|NCT00335504|DRUG|placebo|Given orally
48317663|NCT00335504|DRUG|atorvastatin calcium|Given orally
48317664|NCT00335504|OTHER|laboratory biomarker analysis|Correlative studies
48317665|NCT01682499|DRUG|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
47966474|NCT04632810|OTHER|Ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks
47966475|NCT04632810|OTHER|non-ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks
48317666|NCT04905199|PROCEDURE|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
48317667|NCT02428452|BEHAVIORAL|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
47966476|NCT04053101|DEVICE|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
48317668|NCT05312931|OTHER|OSCE|Students undergo OSCE (objective structured clinical exams). It means students will perform CPR for 2 min and their success rate will be monitored.
48317669|NCT03670316|DRUG|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
47966477|NCT05534737|OTHER|MAICP + usual care of social services|The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
47966478|NCT05534737|OTHER|Control|usual care of social services
47966479|NCT02423876|DRUG|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:~* 0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~* 3 mL/hr RN bolus, to be used as needed based on pain ratings~* 3 mL/30 minutes patient bolus, which is available on patient demand."
47966480|NCT02423876|OTHER|Intraoperative Complication Management and Prevention|Undergo ERP
47966481|NCT02423876|PROCEDURE|Pain Therapy|Undergo ERP
48116673|NCT03204968|DEVICE|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
48116674|NCT02951013|OTHER|restrictive transfusion|Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
48116675|NCT02951013|OTHER|liberal transfusion|
47966482|NCT03416946|DEVICE|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
47966483|NCT03416946|OTHER|Traditional|Traditional cutting method
47966484|NCT03797014|DRUG|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
47966485|NCT01744574|OTHER|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
48116676|NCT03195426|PROCEDURE|distal nerves blocks group|"* ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~* SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~* SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
48317670|NCT03670316|OTHER|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
48317671|NCT00736580|OTHER|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
48317672|NCT00736580|OTHER|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
48317673|NCT05768841|BEHAVIORAL|mental health issues|survey on mental health issues in endurance athletes
48317674|NCT02860806|DRUG|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
48645227|NCT02694055|OTHER|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
48645228|NCT02694055|OTHER|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
47966486|NCT01744574|DRUG|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
48116677|NCT03195426|PROCEDURE|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
48116678|NCT03301025|DRUG|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
48116679|NCT03301025|DRUG|placebo|given a placebo identical capsule once one hour before anesthesia
48116680|NCT00651105|DRUG|Vildagliptin|
48116681|NCT00651105|DRUG|Placebo|
48116682|NCT04583306|OTHER|Raman analysis of saliva, characterization of the Raman database and building of the classification model|Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
48116683|NCT06674486|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France).
48317675|NCT02860806|DRUG|Placebo|Intravenous infusion of matching placebo.
48317676|NCT02296996|DRUG|Dabrafenib + Trametinib|
48317677|NCT03712501|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
48317678|NCT01202721|DRUG|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
48317679|NCT01202721|DRUG|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
48645229|NCT02694055|OTHER|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
47966487|NCT01744574|OTHER|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
48317680|NCT00403312|BEHAVIORAL|Smoking Cessation Behavioral Program|
48317681|NCT00403312|DRUG|Nicotine Patch|
48317682|NCT00403312|BEHAVIORAL|Physical Activity|
48317683|NCT06220630|OTHER|Breast cancer|Male patients who were microscopically diagnosed as primary breast cancer.
48317684|NCT00947752|DRUG|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
48317685|NCT00947752|DRUG|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
48317686|NCT01760824|DRUG|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
48645230|NCT02694055|OTHER|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
48317687|NCT01760824|DRUG|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
47966488|NCT01146418|BIOLOGICAL|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
48317688|NCT02608437|DRUG|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
48317689|NCT02608437|DRUG|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
48317690|NCT03230474|DRUG|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
48317691|NCT03230474|DRUG|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
48317692|NCT00437333|DRUG|Metformin cloridrate|
47966489|NCT01146418|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
47966490|NCT04397783|PROCEDURE|construction of an end colostomy|longitudinal incision in the construction of an end colostomy
47966491|NCT01844440|PROCEDURE|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
47966492|NCT06297161|DRUG|Bosulif|chronic myelogenous leukemia patients
47966493|NCT00901316|PROCEDURE|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
48116684|NCT06674486|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
48116685|NCT04763044|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
48317693|NCT02976376|OTHER|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
48116686|NCT04763044|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
48116687|NCT04763044|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
48116688|NCT04763044|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
48116689|NCT04763044|DRUG|1100 ppm SnF2|Each subject will be assigned to this treatment during the fifth period for this crossover study.
48116690|NCT05591703|BEHAVIORAL|Clinical Outcomes and Questionnaires|Clinical patient-reported outcomes will be administered remotely at specified timepoints. No treatment or intervention will be administered in this protocol.
48317694|NCT03359694|DRUG|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
48317695|NCT03359694|DRUG|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
48317696|NCT03359694|DRUG|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
48317697|NCT04479917|DRUG|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
48317698|NCT04479917|DRUG|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
48645231|NCT02694055|OTHER|Training of primary health centre staff|"Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management"
48116691|NCT06677307|DRUG|KRRO-110|KRRO-110 drug product, IV
48116692|NCT02634970|DRUG|Ranibizumab|0.5 mg, intravitreal injection
48116693|NCT02163876|DRUG|HuCNS-SC cells|surgery arm
48116694|NCT00513526|BIOLOGICAL|Gardasil|week 0, 8, 24, 128
48317699|NCT03611517|BEHAVIORAL|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
47966494|NCT00901316|PROCEDURE|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
48485927|NCT05151575|BEHAVIORAL|supervised group-based walking and non-supervised individual-based walking interventions|Group exercise interventions tended to be systematic and supervised by professionals. The current intervention is proposing to conduct a randomized control trial that is not only examining the nature of walking on older adults' well-being but also involving the elements of group-based and professional supervision intervention, aiming at comparing with the individual-based intervention without professional supervision. Qualified professional fitness trainers (1 male and 1 female separately for male and female groups, respectively) will be involved in the group-based intervention programs in order to provide appropriate guidance and supervision to the participants. Whereas, the non-supervised individual-based intervention will be conducted by a research assistant (males and females) to ensure the attendance and general safety, but without providing professional advice or supervision.
48485928|NCT03560687|DRUG|Sucrosomial Iron|CardioSideral 2 caps per day
47966495|NCT02508181|DEVICE|I-gel|supraglottic airway device without cuff
47966496|NCT02508181|DEVICE|LMA Supreme|supraglottic airway device with cuff
48485929|NCT03912402|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
48116695|NCT03920566|OTHER|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
48116696|NCT00899899|GENETIC|microarray analysis|
48485930|NCT03912402|BIOLOGICAL|Bevacizumab|IV infusion
48485931|NCT03912402|DRUG|Paclitaxel|IV infusion
48485932|NCT03912402|DRUG|Cisplatin (or carboplatin)|IV infusion
48485933|NCT02553902|DEVICE|Sleep position trainer|
48485934|NCT02553902|DEVICE|Mandibular advancement device|
48645232|NCT06686316|DEVICE|Device: Hypoxic Gas Mixture|The EG (Experimental Group) will undergo a 6-week intervention protocol of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
48645233|NCT06686316|OTHER|Sham Hypoxic-Hyperoxic exposure|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
48645234|NCT05795660|BIOLOGICAL|platelet rich plasma|platelet rich plasma injection
47966497|NCT01405742|DRUG|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
47966498|NCT01324908|PROCEDURE|extracorporeal photopheresis|Undergo ECP
48116697|NCT00899899|GENETIC|reverse transcriptase-polymerase chain reaction|
48116698|NCT00899899|OTHER|laboratory biomarker analysis|
48317700|NCT05425485|BEHAVIORAL|Multi-component intervention|Web-based strategy with processes, materials, and patient and doctor education formats.
48485935|NCT02553902|DEVICE|Continuous positive airway pressure|
48485936|NCT03975413|OTHER|Fecal Microbiota Transplantation (FMT)|Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
48485937|NCT02691741|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
48485938|NCT02691741|DEVICE|AT LISA® tri IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
48485939|NCT05160714|RADIATION|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
48485940|NCT03016338|DRUG|Niraparib|200 or 300 mg daily PO, for 21 day cycle
48485941|NCT03016338|DRUG|TSR-042|500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
47966499|NCT01324908|OTHER|laboratory biomarker analysis|Correlative studies
48317701|NCT03898869|DIAGNOSTIC_TEST|Intraoperative NIRS monitoring|Near infrared spectroscopy non invasively used to register changes in tissue oxygen amount during endovascular revascularization
48317702|NCT03218982|BEHAVIORAL|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
48485942|NCT02037165|DRUG|Placebo to BI 1026706|Placebo tablet
48485943|NCT02037165|DRUG|Pregabalin|Pregabalin hard capsule
48485944|NCT02037165|DRUG|BI 1026706|BI 1026706 oral solution
48645235|NCT03464552|DRUG|Celecoxib 200mg|oral capsule 3 hours before procedure
47966500|NCT03562832|DRUG|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
47966501|NCT03517098|PROCEDURE|The ERAS group|"ERAS pathway for orthopedic surgeons:~1. Shortened preoperative fasting from intake.~2. Preoperative tranexamic acid administration.~3. No indwelling catheters.~4. No tourniquet used for TKA.~5. No drainage tube.~6. Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~1. Intravenous 20 mg of dexamethasone before anesthetic induction.~2. Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~3. Laryngeal mask for airway.~4. Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~5. Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
48116699|NCT05296148|DEVICE|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
48317703|NCT00950079|DRUG|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
48317704|NCT00950079|DRUG|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
48317705|NCT01702363|DRUG|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
48317706|NCT06553950|DRUG|Botox injection|"Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle."
48317707|NCT06553950|DRUG|Mandibular stabilization splint|Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
48317708|NCT06553950|DRUG|Muscle relaxant|Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
48317709|NCT02526719|PROCEDURE|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
48317710|NCT04179968|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
48485945|NCT02037165|DRUG|Celecoxib|Celecoxib hard capsule
48485946|NCT06181747|DEVICE|a serious mobile device-based game prototype (Save the Muse Home)|The cognitive impairment corresponding to the symptoms, which we are interested in, focuses on executive inhibition, motor inhibition, sustained attention, selective attention, working memory, and planning ability. The training content will be presented in different scenarios as effective training components. The story line of the warrior breakthrough runs through the whole game, each level is adapted according to the functional damage areas of different patients, and each level involves reward and punishment mechanisms to keep the interest of the players, the difficulty gradient of each level is kept moderate, and the game includes design elements such as space, time, object attributes, actions, rules, skills, and probabilities, etc., which ultimately completes Save the Muse Home, a serious game for the treatment of ADHD.
48485947|NCT04597489|PROCEDURE|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
48485948|NCT04597489|PROCEDURE|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
48317711|NCT04179968|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
48317712|NCT05087641|DEVICE|IAB System|Bronchoscopic implantation of one or multiple IABs
48485949|NCT00192855|DRUG|Entacapone|Entacapone 600mg BID
48485950|NCT00407758|DRUG|enzastaurin hydrochloride|
48485951|NCT06201416|BIOLOGICAL|SBT777101|Experimental treatment
48485952|NCT03138902|DIETARY_SUPPLEMENT|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
48485953|NCT00791141|DRUG|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
48485954|NCT05443269|DIETARY_SUPPLEMENT|Jump Start Nutritional Program|Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
48317713|NCT03453151|DRUG|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
47966502|NCT03517098|PROCEDURE|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
48317714|NCT05380674|BEHAVIORAL|The short questionnaire of healthy habits|collects sociodemographic data, weight, height, and physical activity, self-reported.
48317715|NCT06289166|DRUG|STSP-0601 for Injection|A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
48317716|NCT05578235|PROCEDURE|stapled side-to-side anastomosis|Standard procedure for CD
48317717|NCT05578235|PROCEDURE|Handsewn anastomosis|handsewn end-to-end or Kono-s anastomosis
48317718|NCT03212664|OTHER|exercise|physical therapy exercises
48317719|NCT03777722|DEVICE|Tailored Lighting Intervention|Lighting Intervention - active or placebo
48317720|NCT06447324|DEVICE|Fender Mate matrix system|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
48317721|NCT06447324|DEVICE|T-band matrix|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
48317722|NCT05249816|BIOLOGICAL|NVX-CoV2373|A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
48317723|NCT05249816|BIOLOGICAL|BBIBP-CorV vaccine|BBIBP-CorV vaccine administered per manufacturer instructions.
48317724|NCT05178056|DEVICE|Spinal Cord Epidural Stimulation|Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.
48317725|NCT05178056|OTHER|Respiratory Training|Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.
48317726|NCT02731118|DIETARY_SUPPLEMENT|Salovum|AF-enriched egg yolk
48317727|NCT02731118|DIETARY_SUPPLEMENT|Placebo|egg yolk
48317728|NCT04092244|DIAGNOSTIC_TEST|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
48485955|NCT01713179|DRUG|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
48485956|NCT05349578|DIAGNOSTIC_TEST|swab RUT|rapid urease test using swab instead of biopsied tissue
48485957|NCT00248170|DRUG|Letrozole|2.5 mg tablets
48485958|NCT00248170|DRUG|Anastrozole|1 mg tablets
48485959|NCT00543452|OTHER|Oxygen|4 liters of oxygen a minute
48485960|NCT00543452|OTHER|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
48485961|NCT05443100|OTHER|Whole-body cryostimulation (WBC)|Multidisciplinary rehabilitation program consisting of 10 WBC sessions.
48485962|NCT05443100|OTHER|Rehabilitation program|Multidisciplinary rehabilitation program consisting of diet and physical exercise.
48485963|NCT04719104|DEVICE|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
48485964|NCT03544398|OTHER|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
48485965|NCT05695495|DRUG|N,N-Dimethyltryptamine (5mg)|Intravenous bolus application over 45 seconds
48317729|NCT04774679|PROCEDURE|Endosonographic fine needle aspiration biopsy|An endoscopic ultrasound device will be inserted to the stomach and biopsy will performed with a needle
48485966|NCT05695495|DRUG|N,N-Dimethyltryptamine (10mg)|Intravenous bolus application over 45 seconds
47966503|NCT00839891|DRUG|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
48116700|NCT00595205|OTHER|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
48317730|NCT01293032|PROCEDURE|Neoadjuvant Therapy|Undergo neoadjuvant therapy
48317731|NCT01293032|PROCEDURE|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
48317732|NCT01293032|OTHER|Laboratory Biomarker Analysis|Correlative studies
48317733|NCT01293032|GENETIC|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
48317734|NCT01293032|DRUG|Systemic Chemotherapy|Undergo chemotherapy
48485967|NCT05695495|DRUG|N,N-Dimethyltryptamine (15mg)|Intravenous bolus application over 45 seconds
48485968|NCT05695495|DRUG|N,N-Dimethyltryptamine (20mg)|Intravenous bolus application over 45 seconds
48485969|NCT05695495|DRUG|N,N-Dimethyltryptamine (25mg)|Intravenous bolus application over 45 seconds
48485970|NCT05695495|DRUG|Placebo (saline)|Intravenous bolus application over 45 seconds
48317735|NCT01293032|DRUG|Tamoxifen Citrate|Undergo hormonal therapy
48317736|NCT01293032|DRUG|Aromatase Inhibition Therapy|Undergo hormonal therapy
48317737|NCT06366828|OTHER|retrospective|follow up
48485971|NCT04821765|DRUG|PD-1 antibody|200mg, d1, q3W
48485972|NCT04821765|RADIATION|Chemoradiation|50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
48485973|NCT04821765|DRUG|Albumin-Bound Paclitaxel|150mg/m2, d1, q3W
48485974|NCT04821765|DRUG|Cisplatin|75mg/m2, d1, q3W
48317738|NCT05047159|DEVICE|rTMS|"Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex."
48317739|NCT05047159|DEVICE|light therapy|Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
48645236|NCT03464552|PROCEDURE|Colposcopic guided biopsy|Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
47966504|NCT00531323|DRUG|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
47966505|NCT00531323|DRUG|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
48317740|NCT05047159|DEVICE|ECT|The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
48317741|NCT05047159|DEVICE|MST|A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
48317742|NCT05047159|DRUG|drug therapy|There is no restriction on the choice of therapeutic drugs.
48317743|NCT06187116|OTHER|Physiotherapist consultation|The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
48317744|NCT06187116|OTHER|Orthopaedic surgeon consultation|The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
48317745|NCT01341379|DRUG|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
48485975|NCT01045421|DRUG|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
48485976|NCT01791153|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
48485977|NCT01791153|DRUG|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
48645237|NCT03464552|DRUG|Placebo oral capsule|oral capsule 3 hours before procedure
48645238|NCT06689215|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
48645239|NCT06688435|BIOLOGICAL|SYS6020 injection|The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days or 28 days according to the protocol design.
47966506|NCT00620867|DRUG|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
47966507|NCT00620867|DRUG|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
47966508|NCT00620867|OTHER|placebo|matched placebo orally for 6 weeks
47966509|NCT04123314|DRUG|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
47966510|NCT03815942|BIOLOGICAL|ChAdOx1-MVA 5T4 vaccine|ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units
47966511|NCT03815942|DRUG|Nivolumab Infusion [Opdivo]|Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
47966512|NCT01010061|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
47966513|NCT01010061|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
47966514|NCT01010061|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
47966515|NCT03131765|BIOLOGICAL|YS-0N-001|Cancer vaccine
47966516|NCT04370574|DIAGNOSTIC_TEST|Soluble Biomarkers dosage|"1. CytoLyt® fluid will be first processed for routine PDAC diagnosis. In essence, the samples are filtered, tissue fragments and cells are kept for analysis while flow-through is kept until the diagnosis is confirmed. Once this is completed, the samples will be transferred to the lab where the proteins found in the CytoLytR fluid will be precipitated and then solubilized. The protein extracts are stored at -80°C pending proteomic analysis. The remaining CytoLytR fluid supernatant is also stored at - 80°C to be used for metabolomics.~2. Blood sample will be collected from each patient that underwent diagnostic biopsy. Dry tube for serum analysis will be collected at the time of inclusion during the routine blood test. The serum samples are intended for the validation phase (WP4) and will be exclusively dedicated to this study."
48116701|NCT03147391|DEVICE|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
48317746|NCT03772561|DRUG|AZD5363+Olaparib+Durvalumab|Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
48485978|NCT01791153|DRUG|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
48485979|NCT01791153|DRUG|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
48485980|NCT01791153|DRUG|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
48485981|NCT01791153|DRUG|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
48485982|NCT01007747|OTHER|Geranium oil|Daily topical application over neuropathic pain
48485983|NCT06304649|DEVICE|Cast or brace alternative|Waterproof alternative to a cast or brace for broken bones
48485984|NCT04336839|PROCEDURE|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
48485985|NCT05793814|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri 3613|Daily for 6 month
48485986|NCT05793814|DIETARY_SUPPLEMENT|Placebo|Daily for 6 month
48645240|NCT05202171|OTHER|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
48645241|NCT05202171|OTHER|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
47966517|NCT05012332|PROCEDURE|Erector Spinae Plane Block|All volunteers receive an Erector Spinae Plane Block and an MRI.
47966518|NCT02940535|DRUG|Diphereline (Triptorelin embonate)|
47966519|NCT02940535|DRUG|Decapeptyl (Triptorelin)|
47966520|NCT02940535|DRUG|human menopausal gonadotropin|
47966521|NCT02940535|DRUG|human chorionic gonadotropin|
48485987|NCT04710537|OTHER|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
48485988|NCT04710537|OTHER|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
48485989|NCT03718741|RADIATION|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
48485990|NCT01005329|BIOLOGICAL|Bevacizumab|Given IV
48485991|NCT01005329|DRUG|Carboplatin|Given IV
48485992|NCT01005329|DRUG|Cisplatin|Given IV
48645242|NCT02601365|DRUG|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
48645243|NCT02601365|DRUG|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
48116702|NCT03282786|OTHER|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
48116703|NCT03419442|DRUG|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
48116704|NCT03419442|DRUG|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
48116705|NCT03419442|DRUG|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
48485993|NCT01005329|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48485994|NCT01005329|DRUG|Paclitaxel|Given IV
48485995|NCT00534794|DRUG|Elestat|Elestat BID for 2 days
48485996|NCT00534794|DRUG|Pataday|Pataday QD for 2 days
48485997|NCT04631887|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises."
48485998|NCT00005586|DRUG|L-leucovorin|
48485999|NCT00005586|DRUG|fluorouracil|
48486000|NCT00005586|PROCEDURE|adjuvant therapy|
48486001|NCT03220126|BIOLOGICAL|LY3074828|Administered IV
48486002|NCT03220126|BIOLOGICAL|LY900021|Administered SC
48317747|NCT02073435|BEHAVIORAL|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~* Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~* Bowel preparation (e.g. Colace or Golytely)~* Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~* Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~* I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is \> 500cc)~* I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~* NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~* Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
48317748|NCT02712372|DRUG|AZD4831|AZD4831 1-50 mg/g oral suspension
48317749|NCT02712372|DRUG|AZD4831 placebo|AZD4831 placebo oral suspension
48317750|NCT06271447|OTHER|Traditional therapy|"All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.~Since the questionnaires to be used in the study are related to fear of movement and pain, neuroscience education will be included in the treatment program of the patients. Patients will be informed about proper posture and movement regarding fear of movement and pain avoidance behaviors."
48317751|NCT06102811|OTHER|Low Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.075% (50 mL)
48317752|NCT06102811|OTHER|High Concentration Local Anesthetic Fascia Iliaca Compartment Block|Fascia iliaca block with Ropivacaine 0.25% (50 mL)
48317753|NCT01069523|DRUG|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
47966522|NCT04533581|DRUG|ME-401|In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
47966523|NCT04403477|BIOLOGICAL|Convalescent plasma|Apheretic convalescent plasma from a COVID-19 survivor
48486003|NCT00287859|DRUG|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
48486004|NCT05055648|RADIATION|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
48486005|NCT05055648|RADIATION|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
48645244|NCT02601365|DRUG|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
47966524|NCT04388202|DRUG|Sertraline|FDA approved antidepressant
47966525|NCT04388202|DRUG|Escitalopram|FDA approved antidepressant
47966526|NCT02314702|DEVICE|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
47966527|NCT00192556|BEHAVIORAL|food|
47966528|NCT04546815|DRUG|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
47966529|NCT06467474|BEHAVIORAL|PEG-D program|PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
47966530|NCT06467474|DRUG|TAU|The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\&#39;s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.
47966531|NCT01742702|DRUG|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
48317754|NCT01069523|DRUG|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
48486006|NCT03716934|DEVICE|Arctic Front Advance® balloon catheter|Cryoablation of bidirectional block of all pulmonary veins
48486007|NCT03716934|DRUG|Antiarrhythmic drug|The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
48645245|NCT02674828|BEHAVIORAL|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
48645246|NCT02674828|OTHER|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
48645247|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS|20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
48645248|NCT04698447|DIETARY_SUPPLEMENT|Placebo (without any active ingredients)|20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
48486008|NCT03716934|DEVICE|Confirm RX heart monitor® (Abbott)|Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
48486009|NCT00000674|DRUG|Pyrimethamine|
48486010|NCT00000674|DRUG|Leucovorin calcium|
48486011|NCT00000674|DRUG|Clindamycin|
48486012|NCT03648242|BEHAVIORAL|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~* One-click addition of elevated BMI to problem list~* Reminder to utilize Suggested PowerPlan~* One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~* Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~* Links to existing, evidence-based childhood obesity screening and management guidelines"
47966532|NCT01742702|DRUG|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
47966533|NCT01742702|DRUG|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
48116706|NCT06299293|OTHER|Facial Emotion Recognition Test|In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.
48116707|NCT04048135|DRUG|Pegozafermin|Subcutaneous injection
48116708|NCT04048135|OTHER|Placebo|Subcutaneous injection
48116709|NCT01431586|DRUG|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
48317755|NCT05552534|OTHER|STIR PROTOCOL|"Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months."
48317756|NCT05102149|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
48317757|NCT05102149|DRUG|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
48317758|NCT05102149|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
48317759|NCT05102149|DRUG|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
48486013|NCT00211965|BIOLOGICAL|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
48486014|NCT00211965|BIOLOGICAL|placebo|single dose IM
48486015|NCT01904006|PROCEDURE|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
48486016|NCT01904006|PROCEDURE|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
48486017|NCT04698772|DRUG|Ketamine|Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
47966534|NCT01742702|DIETARY_SUPPLEMENT|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
48317760|NCT06207422|OTHER|Moderate intensity training program|A 10-week intervention program performed at 60-70% of the heart rate reserve. Heart rate reserve will be calculated using the Karvonen formula (target heart rate = \[(predicted maximum heart rate (= 220 - age) - resting heart rate) x %intensity\] + resting heart rate). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
48317761|NCT06207422|OTHER|High intensity training program|A 10-week intervention program performed at ≥80% of the predicted maximum heart rate (target heart rate = predicted maximum heart rate (= 220 - age) x %intensity). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
48486018|NCT04698772|DRUG|Morphine|Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
47966535|NCT01742702|DIETARY_SUPPLEMENT|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
48116710|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium lactis|The probiotic will be administered orally over a period of 12 weeks.
48116711|NCT05064930|DIETARY_SUPPLEMENT|Probiotic Bacillus coagulans|The probiotic will be administered orally over a period of 12 weeks.
48116712|NCT05064930|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as a placebo will be administered orally over a period of 12 weeks. The taste and appearance of the placebo will be similar to those of the probiotic formulation.
48116713|NCT00955695|DRUG|erlotinib hydrochloride|
48116714|NCT00955695|DRUG|gefitinib|
48116715|NCT00955695|OTHER|questionnaire administration|
48116716|NCT00955695|PROCEDURE|quality-of-life assessment|
48116717|NCT00955695|RADIATION|whole-brain radiation therapy|
48116718|NCT05631210|OTHER|Privacy agreements with pictograms|The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
48317762|NCT02617732|DRUG|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
48317763|NCT02617732|DRUG|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
48486019|NCT04176588|DRUG|Etrasimod|Drug:Etrasimod Tablet other name:APD334
48486020|NCT04176588|DRUG|Placebo|Drug:placebo Tablet
48486021|NCT05481359|DEVICE|Ablamap Software|Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation.
48486022|NCT00197522|BIOLOGICAL|CD34+ derived DCs|
48486023|NCT02980250|DRUG|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
48116719|NCT02339779|PROCEDURE|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~1. First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~2. Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~3. Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
48645249|NCT04698447|DIETARY_SUPPLEMENT|Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS|20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
48645250|NCT06690450|DRUG|Venofer® 200 mg|A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes
48645251|NCT06690450|DRUG|Venofer® 100 mg|A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
48645252|NCT03847818|DRUG|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|"Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles"
48645253|NCT05952323|OTHER|Teach-back|According to the prepared educational materials for medical devices, students will be trained using the teach-back method.
48645254|NCT05952323|OTHER|Video-assisted teaching|Students will be sent educational videos related to medical devices and asked to watch them.
48645255|NCT03307824|DEVICE|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
48645256|NCT03307824|PROCEDURE|Glue-Free Suture Technique|Suture Technique
47966536|NCT01742702|DRUG|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
47966537|NCT05877352|RADIATION|Intraoperative Electron Radiotherapy (IOERT)|IOERT can be defined as the direct application of high-energy electron beam irradiation to a tumour bed during an operative procedure. This approach permits precise delivery of a single large fraction of radiation directly and specifically to high recurrence risk anatomical target areas, which the treating clinicians (surgeon and attending clinical oncologist) predict will be a close or involved margin, while simultaneously displacing and shielding dose-limiting radiosensitive structures such as the small bowel or ureter or any anastomoses, if not involved by tumour.
47966538|NCT05877352|PROCEDURE|Extended Margin Surgery|Surgery intended to remove both a tumour and any metastases
47966539|NCT05618197|OTHER|Passive heating|\~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C) sessions over a period of 6 weeks.
47966540|NCT02923960|OTHER|Standard ONS|One serving (237 ml) standard oral nutritional beverage
48317764|NCT03509337|DIAGNOSTIC_TEST|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
48317765|NCT01490749|DRUG|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
48486024|NCT02980250|DRUG|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
47966541|NCT02923960|OTHER|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
47966542|NCT02923960|OTHER|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
48317766|NCT01490749|DRUG|XELOX|Patients will receive two cycles of XELOX.
48486025|NCT02980250|DRUG|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
48486026|NCT02980250|DRUG|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
48486027|NCT00355472|DRUG|KW-0761|IV administration at 4 escalating dose levels.
48486028|NCT05500040|BEHAVIORAL|Multimodal Rehabilitation|The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
48486029|NCT00126126|OTHER|EBAR Program|Evidence Based Amputee Rehabilitation Program
48486030|NCT01713231|DIETARY_SUPPLEMENT|standard-dose vitamin D (400IU per day)|
48486031|NCT01713231|DIETARY_SUPPLEMENT|high-dose vitamin D (2000 IU per day)|
48486032|NCT05897918|DRUG|Tranexamic Acid 500 MG|Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
48645257|NCT00285714|PROCEDURE|3D stereophotogrammetric imaging|
48645258|NCT00285714|PROCEDURE|3D CT-imaging with cone-beam CT|
48317767|NCT01490749|DRUG|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
48317768|NCT01490749|RADIATION|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
48317769|NCT03953261|DRUG|Curcumin supplement|Intervention is 2 grams of curcumin supplement per day
48317770|NCT02235987|DRUG|octreotide|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
48317771|NCT02235987|DRUG|DG3173|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
48486033|NCT06260579|BEHAVIORAL|Exercise/physical activity|personalized exercise training and physical activity program
48645259|NCT00285714|PROCEDURE|Case report form|
48317772|NCT05316090|PROCEDURE|Core stability exercises program|Strengthening to the trunk muscles
48317773|NCT05316090|PROCEDURE|Traditional physical therapy program|Neurodevelopmental training excercises
48317774|NCT05126706|BEHAVIORAL|Digital lifestyle management|Digital lifestyle management for Weight Loss Control after Thyroidectomy
48317775|NCT06115434|PROCEDURE|cystectomy|cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.
48317776|NCT02654574|OTHER|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
48317777|NCT01996306|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
48317778|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
48317779|NCT01996306|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
48317780|NCT01996306|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
47966543|NCT00716534|DRUG|ABT-869|12.5 mg ABT-869
47966544|NCT00716534|DRUG|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
48116720|NCT02339779|PROCEDURE|breast implant|"Implant-based reconstruction typically will occur as follows:~1. During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~2. The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~3. When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
48116721|NCT03953222|DEVICE|Wearable real-time feedback device|The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
48116722|NCT05981547|DEVICE|Libre 3 continuous glucose monitoring sensor|Libre 3 CGM sensor applied to women prior to their Oral Glucose Tolerance test.
48317781|NCT01996306|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
48317782|NCT01996306|BIOLOGICAL|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
48116723|NCT06484504|DIETARY_SUPPLEMENT|Kombucha beverage|After 4-weeks of consuming a beige diet (i.e. low-fiber, low polyphenol diet), 20 subjects (kombucha group) will consume one bottle (two servings) of kombucha daily for 4 weeks and 10 subjects (control group) will not change their dietary habits
48317783|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
47966545|NCT00716534|DRUG|ABT-869|7.5 mg ABT-869
48116724|NCT03996278|OTHER|Grafalon|None interventional study but there are two groups
48317784|NCT01996306|DRUG|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
48486034|NCT05690074|DEVICE|Spectra Wave Writer™ Spinal Cord Stimulator System|Device: 5-6-5 Specify electrode Device: Restore Advance Pulse Generator
47966546|NCT00716534|DRUG|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
47966547|NCT00716534|DRUG|Paclitaxel|Paclitaxel (200 mg/m2)
47966548|NCT01235143|DRUG|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
47966549|NCT01235143|DRUG|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
47966550|NCT03365830|DIAGNOSTIC_TEST|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
47966551|NCT03210311|DEVICE|compression|a compression stocking is worn, a garment compression class 2, flat knitted
47966552|NCT04255108|DEVICE|Cova Patch|CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
48317785|NCT01524367|DRUG|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
48317786|NCT01524367|DRUG|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
48317787|NCT04191421|BIOLOGICAL|Siltuximab|Given IV
48317788|NCT04191421|BIOLOGICAL|Spartalizumab|Given IV
48317789|NCT02517827|DEVICE|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
48317790|NCT02517827|PROCEDURE|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
48317791|NCT00091702|BIOLOGICAL|Cold-adapted live attenuated influenza vaccine (FluMist)|
48317792|NCT00091702|BIOLOGICAL|Inactivated influenza vaccine (IAIV)|
48317793|NCT01798940|DRUG|Torrent's Pioglitazone|
48317794|NCT05902546|OTHER|High intensity interval training|Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest
48317795|NCT05902546|OTHER|moderate intensity aerobic exercise|Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
48317796|NCT05872594|DIAGNOSTIC_TEST|Online questionnaire|data will be collected remotely on the online platform Qualtrics
48317797|NCT02506296|DRUG|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
48317798|NCT02506296|DEVICE|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
48645260|NCT05385523|PROCEDURE|Rhomboid Intercostal and Sub-Serratus block technique (RISS)|The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.
48317799|NCT02836535|BEHAVIORAL|qualitative interviews|
48317800|NCT04853524|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
47966553|NCT05269498|DEVICE|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
47966554|NCT04332146|BEHAVIORAL|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
47966555|NCT04332146|BEHAVIORAL|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
48317801|NCT04853524|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|A combination of BIC, FTC and TAF will be administered orally.
48317802|NCT00002545|DRUG|carmustine|
48317803|NCT00002545|RADIATION|low-LET photon therapy|
48317804|NCT01626352|DRUG|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.
48317805|NCT01626352|DRUG|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
48317806|NCT03478319|DRUG|ACE-2494 or placebo|Recombination fusion protein
48317807|NCT01911845|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
48317808|NCT01911845|DRUG|ABT-333|Tablet
48317809|NCT01911845|DRUG|Ribavirin (RBV)|Tablet
48317810|NCT02136121|DEVICE|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
48317811|NCT05673473|RADIATION|scoliosis radiographs|Low dose fluoroscopic imaging technique for scoliosis x-rays
48317812|NCT05466266|DEVICE|ICE|All patients received ICE examination.
48317813|NCT05466266|DEVICE|TEE|All patients received TEE examination.
48317814|NCT04757727|OTHER|Decriptive study of EDB|data on EDB will be register
48317815|NCT00001165|DRUG|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
48317816|NCT02704676|OTHER|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
48317817|NCT05108220|DIETARY_SUPPLEMENT|Cannabidiol (CBD)- containing consumer products|Oils or capsules containing CBD which could be purchased commercially within the U.S.
48317818|NCT05265130|DRUG|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
48486035|NCT03347136|DEVICE|CPAP|
48486036|NCT03347136|DEVICE|NIPPV|
48486037|NCT05368441|DRUG|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
48486038|NCT05368441|DRUG|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
48486039|NCT00283413|DEVICE|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
48486040|NCT00283413|DEVICE|Bare metal stent|Any commercially available bare metal stent for coronary indication
48486041|NCT00965770|DEVICE|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
48486042|NCT04473521|DEVICE|Investigational denture adhesive cream|The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.
48486043|NCT04473521|DEVICE|Super Poligrip Free|The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
48317819|NCT05265130|DRUG|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
47966556|NCT02647814|BEHAVIORAL|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
47966557|NCT04176978|DRUG|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
48486044|NCT00836329|BEHAVIORAL|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
47966558|NCT04176978|OTHER|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
47966559|NCT06021145|DRUG|Empagliflozin|26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.
47966560|NCT06021145|DRUG|Placebo|26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
47966561|NCT00523562|OTHER|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
47966562|NCT02042183|DRUG|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
47966563|NCT02042183|DRUG|Placebo|0 mcg soft capsules of placebo for oral administration
47966564|NCT04550208|OTHER|3D analysis of different landing tasks|General as well as more sport-specific landing tasks are investigated with 3D analysis by using an opto-electronic system
47966565|NCT03648983|PROCEDURE|arm circumference measurement|Undergo arm circumference measurement
47966566|NCT03648983|DEVICE|Bioimpedance spectroscopy|bioimpedance spectroscopy
48116725|NCT02817984|BIOLOGICAL|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
48116726|NCT05658406|DRUG|Ringer's Lactate|infusion of 15 mL/kg/hour Ringer's lactate intraoperative
48116727|NCT05658406|DRUG|Ringer's Lactate|infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
48116728|NCT05658406|DRUG|Ringer's Lactate|infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
48116729|NCT05658406|DRUG|normal Saline|standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
48116730|NCT05350527|OTHER|Consultation of a Web Platform|Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
47966567|NCT04565106|DEVICE|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
47966568|NCT06050278|OTHER|Tapestry technology|The study involves the immediate freezing and preservation in liquid nitrogen of a tumor histological sample from surgical resection, obtained from the operating room, within one hour of removal. Surgery is part of the normal clinical practice of patients with lung cancer.
47966569|NCT04353518|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.
47966570|NCT04353518|OTHER|Placebo|Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
47966571|NCT04893278|OTHER|Virtual reality|Use of Virtual reality goggles during procedure
47966572|NCT01810874|PROCEDURE|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
47966573|NCT01810874|PROCEDURE|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
47966574|NCT04833010|OTHER|Cardiopulmonary Exercise Test|Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
47966575|NCT04833010|OTHER|Cognitive Performance Test|Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
48116731|NCT02444598|DEVICE|Vaccum Assisted Closure device|Negative-pressure wound therapy
47966576|NCT02259881|DRUG|Low dose of BIBT 986 CL, per i.v. infusion|
47966577|NCT02259881|DRUG|Medium dose of BIBT 986 CL, per i.v. infusion|
48116732|NCT02444598|PROCEDURE|Conventional wound dressings|Conventional wound dressings
48317820|NCT04898738|OTHER|Alcohol based hand sanitizer|Provision of ABHS to randomly selected households
47966578|NCT02259881|DRUG|High dose of BIBT 986 CL, per i.v. infusion|
47966579|NCT02259881|DRUG|Placebo|
47966580|NCT02259881|DRUG|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
48317821|NCT01371487|DRUG|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
48317822|NCT05838300|DEVICE|Warm humidified CO2|Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source
48317823|NCT05838300|DEVICE|Dry CO2|Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
48317824|NCT04889573|GENETIC|Blood sample|The blood samples will be collected from healthy volunteers : 7 tubes of 7 ml with anti-coagulant Héparine Lithium and 1 tube of 7ml with anti-coagulant EDTA
48317825|NCT02467647|DRUG|Thalidomide|
48317826|NCT02467647|DRUG|HLJDT|
48317827|NCT04127734|PROCEDURE|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
48317828|NCT00747396|OTHER|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
48317829|NCT02004912|OTHER|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
48317830|NCT06145685|PROCEDURE|Minimally invasive non-surgical periodontal therapy|Minimally invasive non-surgical periodontal therapy
48317831|NCT06145685|PROCEDURE|Conventional non-surgical periodontal therapy|Conventional non-surgical periodontal therapy
48317832|NCT03053596|DEVICE|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
48317833|NCT00696462|DEVICE|forced-air warming|forced-air warming device
48317834|NCT01095575|DRUG|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
48317835|NCT06081036|OTHER|Questionnaire|Questionnaire about children development
48317836|NCT02815241|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-046)
48317837|NCT00022971|BIOLOGICAL|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
48317838|NCT00022971|BIOLOGICAL|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
47966581|NCT03367221|DEVICE|NAVA ventilation|Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
48317839|NCT00356863|BEHAVIORAL|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
48317840|NCT00976950|DRUG|Tipranavir|
48317841|NCT00976950|DRUG|ritonavir|low-dose
48317842|NCT02289404|DRUG|NVP-1203|Oral
48317843|NCT02289404|DRUG|NVP-1203|Oral
48317844|NCT01264094|DRUG|Clevudine|clevudine 30 mg qd
48317845|NCT03990519|DRUG|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
48317846|NCT03990519|DRUG|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
48317847|NCT02173496|OTHER|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
48317848|NCT03069846|DEVICE|Spectra-Scope|"The Spectra-Scope consists of the light collection module and the spectral analysis module.~The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.~Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.~All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF."
48486045|NCT00836329|BEHAVIORAL|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
48486046|NCT01712919|RADIATION|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
48486047|NCT01712919|DRUG|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
47966582|NCT01087138|BEHAVIORAL|exercise|exercise class 3x's/week
48486048|NCT01712919|BIOLOGICAL|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
47966583|NCT01087138|BEHAVIORAL|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
48486049|NCT01570348|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
47966584|NCT00512005|DEVICE|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
48116733|NCT04151407|DRUG|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
48116734|NCT02514278|DRUG|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"* oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~* 5FU: 2400 mg/m2"
48317849|NCT04832919|BEHAVIORAL|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
48317850|NCT01583998|BEHAVIORAL|e-MBC|antidepressant treatment
48317851|NCT00022035|BIOLOGICAL|trivalent influenza vaccine|
48317852|NCT01669811|DRUG|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
48317853|NCT01669811|DRUG|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
48317854|NCT02700100|DEVICE|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~* Tetralogy of Fallot~* Truncus Arteriosus~* Pulmonary Atresia~* Transposition of Great Arteries with Ventricular Septal Defect (VSD)~* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
48317855|NCT00286390|PROCEDURE|Acupuncture|
48317856|NCT01064193|PROCEDURE|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~* Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~* Insert carefully the pipelle de Cornier® in the uterus through the cervix.~* Withdraw the piston to create a negative pression~* Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~* Withdraw the pipelle de Cornier® when filled with tissue~* Reinsert internal piston to deposit sample in cup filled with a fixative."
48317857|NCT01064193|PROCEDURE|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
48317858|NCT04302103|BIOLOGICAL|RC18 160mg|subcutaneous injection
48317859|NCT04302103|BIOLOGICAL|RC18 240 mg|subcutaneous injection
48317860|NCT05299814|BEHAVIORAL|Behavioral Parenting Intervention|8 session evidence based parenting intervention
48317861|NCT04348591|BEHAVIORAL|Cognitive Restructuring|All participants will learn how to change their thinking in order to be less upset when confronted with stressors
48317862|NCT04348591|DEVICE|neurostimulation|all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
48486050|NCT01570348|DRUG|Cyclophosphamide|Given IV
48486051|NCT01570348|DRUG|Fludarabine Phosphate|Given IV
48486052|NCT01570348|OTHER|Laboratory Biomarker Analysis|Correlative studies
48486053|NCT01570348|DRUG|Mycophenolate Mofetil|Given PO
48486054|NCT01570348|DRUG|Mycophenolic Acid|Given PO
48486055|NCT01570348|OTHER|Quality-of-Life Assessment|Ancillary studies
48116735|NCT02514278|RADIATION|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
48116736|NCT02514278|PROCEDURE|Local excision in good responders|"If local excision:~* Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~* Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
48116737|NCT02514278|PROCEDURE|Rectal excision in bad responders|
48116738|NCT02514278|DRUG|Capecitabine|1600 mg/m2 daily 5 days/7
48116739|NCT04081792|PROCEDURE|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
48116740|NCT06103630|OTHER|Oropharyngeal Exercises|Oropharyngeal Exercises
48116741|NCT06103630|OTHER|Mandibular advancement device|Mandibular advancement device
48486056|NCT01570348|DRUG|Tacrolimus|Given IV or PO
48486057|NCT01570348|RADIATION|Total-Body Irradiation|Undergo TBI
48486058|NCT01575717|DRUG|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
47966585|NCT01651377|DRUG|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
48645261|NCT05385523|PROCEDURE|General Anaesthesia|"Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization."
48116742|NCT03967704|PROCEDURE|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss \> 2 cm and/or pain.
48645262|NCT05385523|DRUG|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
48645263|NCT05385523|DRUG|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
48645264|NCT05385523|DRUG|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
48645265|NCT05428670|DRUG|Zanubrutinib+Rituximab+Lenalidomide|Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.
48645266|NCT05428670|DRUG|RCHOP/RCDOP|RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
48645267|NCT06439784|OTHER|whole body SPECT/CT|Patient will unergo a whole body SPECT/CT in treatment position
48116743|NCT04861324|BEHAVIORAL|Dietary Intervention|Increasing fruit and vegetable by two servings a day and at least 30 min a day of postprandial physical activity
48116744|NCT06106516|DEVICE|novel vital sign monitor|Devices that are to be introduced into the clinic but where data from clinical relevant conditions such as complications are lacking to assess the validity under clinical conditions
48645268|NCT00631241|PROCEDURE|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
48645269|NCT00631241|PROCEDURE|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
48116745|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
48486059|NCT01575717|DRUG|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
48116746|NCT01519752|DRUG|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
48116747|NCT01519752|DRUG|Placebo|Placebo applied to affected area once a day for 28 days
48116748|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
48116749|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
48116750|NCT02011698|PROCEDURE|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
48116751|NCT03814252|DEVICE|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
48116752|NCT02645006|BEHAVIORAL|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
48486060|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
48486061|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
48486062|NCT02519621|DEVICE|NPWT PRO without irrigation|NPWT PRO without irrigation.
48486063|NCT02519621|DEVICE|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
48486064|NCT02519621|DEVICE|KCI Ulta|KCI Ulta NPWT without irrigation
48486065|NCT05361291|DRUG|Lidocaine Hydrochloride|Inferior alveolar nerve block
48486066|NCT05372276|OTHER|Assessment 1|Mental Toughness Questionnaire in Sport
48486067|NCT05372276|OTHER|Assessment 2|Sport Imagery Questionnaire
48486068|NCT05372276|OTHER|Assessment 3|The Pittsburgh Sleep Quality Index
48486069|NCT05372276|OTHER|Assessment 4|The Perceived Stress Scale (PSS)
48486070|NCT00157859|DRUG|Chloroquine and sulphadoxine-pyrimethamine|
48486071|NCT06205433|OTHER|IHSS Basic Training|The intervention is the Center for Caregiver Advancements 30-hour IHSS Basic training course.
48486072|NCT03574311|DRUG|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
48486073|NCT03574311|OTHER|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
48645270|NCT05677360|BEHAVIORAL|HPV MISTICS -Provider Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.
48645271|NCT05677360|BEHAVIORAL|HPV MISTICS - Parent Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.
48645272|NCT05677360|BEHAVIORAL|HPV MISTICS- HPV Vaccine Champion Level|The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
48645273|NCT01044043|PROCEDURE|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
48317863|NCT05259267|BEHAVIORAL|Online Group Therapy for PTG|Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.
48645274|NCT05689736|BEHAVIORAL|Motivational Enhancement|"Motivational Enhancements (ME) will include three features:~1. Personalized change plan. Parents will describe their intervention goals, motivation for participation, steps they are willing to take to meet those goals, as well as potential barriers to engagement and strategies to try to overcome such barriers. We will display the change plan to remind parents of their personalized responses. ME will also integrate participants' change plan responses into intervention content.~2. Assessment feedback. We will provide norm-referenced feedback for each selected parenting measure after the week 1 assessment. For simplicity, feedback will graphically categorize the parent or child in 3 categories per outcome: red (≥90th %ile), yellow (70-89th %ile), and green (\<70th %ile).~3. Modified, personalized SMS text nudges. Parents will receive 2 weekly personalized SMS messages based on their change plan responses."
48486074|NCT03282968|DEVICE|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
48486075|NCT03282968|OTHER|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
48486076|NCT03354455|DEVICE|Repetitive transcranial magnetic stimulation|"Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot."
47966586|NCT01651377|DRUG|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
48486077|NCT01046552|PROCEDURE|preoperative ERCP and LC|preoperative ERCP followed by LC
48486078|NCT01046552|PROCEDURE|Intraoperative ERCP and LC|LC and intraoperative ERCP
48486079|NCT04292366|PROCEDURE|Invitation procedure|Optimised invitation procedures in an organised colorectal cancer screening programme
47966587|NCT04556162|DIAGNOSTIC_TEST|fractional sodium excretion|fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.
47966588|NCT04556162|OTHER|risk subgroups|subgroup analysis will be performed to identify the patient groups at risk for sodium depletion
47966589|NCT03546660|DEVICE|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
47966590|NCT06084663|DRUG|Apremilast 30 mg Tablets|Each film-coated tablet contains 30 mg of apremilast
47966591|NCT06084663|DRUG|Otezla 30 mg film-coated tablets|Each film-coated tablet contains 30 mg of apremilast
48486080|NCT00059787|DRUG|paclitaxel|Given IV
48486081|NCT00059787|DRUG|carboplatin|Given IV
48486082|NCT00059787|DRUG|erlotinib|Given PO
48486083|NCT03014193|DEVICE|Semiquantitative Multi-Level Pregnancy Test|
48486084|NCT01974128|PROCEDURE|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
48486085|NCT00070616|DRUG|Palifermin 6 x 60 μg/kg/day|
48486086|NCT00070616|DRUG|Palifermin 2 x 180 μg/kg/day|
48486087|NCT00070616|RADIATION|radiotherapy|
48486088|NCT00070616|DRUG|Chemotherapy|
48486089|NCT02441582|OTHER|Telemetry|
48486090|NCT02441582|OTHER|Non-telemetry|
48317864|NCT05259267|BEHAVIORAL|Online Support Group|Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
48317865|NCT06108869|OTHER|ABT Online Programme|"When the study begins, participants meet each week on Microsoft teams for a 6 week period. Each session will last approximately 1 hour. There will be a maximum of six other participants and two facilitators present at each session. Each session will consist of:~* A short ABT practice~* An educational component related to the development of our ABT practice~* A group discussion on the week's topic and how it relates to you and your diagnosis"
48317866|NCT06108869|OTHER|Delayed Control group|Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
48317867|NCT06365515|DRUG|Levodopa administration|To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.
48317868|NCT06365515|DRUG|Placebo administration|Placebo tablets will be administered as the placebo-controlled condition.
48317869|NCT05944991|OTHER|Olive oil message|Message of olive oil 2 times daily
48317870|NCT06552858|DRUG|Fluzoparib|150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.
48317871|NCT06552858|DRUG|Dalpiciclib|150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.
48317872|NCT01205555|DEVICE|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (\<8 IU\\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\\L) the insemination will be the next day."
48317873|NCT00231244|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
48317874|NCT01569425|OTHER|Dietary intervention|High Calorie breakfast and high calorie dinner
48317875|NCT05846997|DIAGNOSTIC_TEST|Liquid biopsy and imaging|Liquid biopsy and imaging
48317876|NCT02094872|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
48317877|NCT02094872|DRUG|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
48317878|NCT02094872|PROCEDURE|therapeutic procedure|
48317879|NCT02094872|OTHER|laboratory biomarker analysis|Correlative studies
48317880|NCT02094872|OTHER|quality-of-life assessment|Ancillary studies
48317881|NCT05149248|BIOLOGICAL|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
48317882|NCT05149248|BIOLOGICAL|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
48317883|NCT05149248|OTHER|Control group|HPV vaccination at 12 months
48317884|NCT05149248|BIOLOGICAL|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
48317885|NCT03496363|DIAGNOSTIC_TEST|TSH , T4|Thyroid stimulating hormone
48317886|NCT00621452|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
47966592|NCT05604352|DEVICE|DiaSole|Diabetic ulcer offloading insole
48317887|NCT00621452|DRUG|cyclophosphamide|Given IV
48317888|NCT00621452|BIOLOGICAL|aldesleukin|Given subcutaneously
48317889|NCT00621452|GENETIC|polymerase chain reaction|Correlative studies
48317890|NCT00621452|GENETIC|gene rearrangement analysis|Correlative studies
48317891|NCT00621452|PROCEDURE|lymph node biopsy|Optional correlative studies
48317892|NCT00621452|BIOLOGICAL|genetically engineered lymphocyte therapy|Receive genetically modified T cells
48317893|NCT00621452|PROCEDURE|bone marrow aspiration|Optional correlative studies
48317894|NCT00621452|OTHER|flow cytometry|Correlative studies
48317895|NCT00621452|OTHER|laboratory biomarker analysis|Correlative studies
48317896|NCT00621452|OTHER|enzyme-linked immunosorbent assay|Correlative studies
48317897|NCT06282900|OTHER|University students|A cross-sectional study (Level IV evidence) will be conducted at the university (Acibadem University, Turkey). All students at the university will be invited to respond to a self-administered online survey. The survey will be prepared via Google Forms.
48317898|NCT03259490|DRUG|Empagliflozin/linagliptin/metformin HCl|Once daily
48317899|NCT03259490|DRUG|Empagliflozin|Once daily
48317900|NCT03259490|DRUG|Linagliptin|Once daily
48317901|NCT03259490|DRUG|Metformin HCl|Once daily
47966593|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
48317902|NCT05580055|DIAGNOSTIC_TEST|Affinity|Blood Analyser
48317903|NCT01858155|DRUG|Melatonin|
48317904|NCT00354263|BIOLOGICAL|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
48645275|NCT05689736|BEHAVIORAL|Simplification|We will follow recommendations of research on improving the readability of patient-directed text (e.g., fewer, shorter, less complex words, minimizing colons, semicolons, and decimal points). We will employ the Dale-Chall Readability (DCRI) score, which was developed for health education materials and, compared to other readability metrics, has higher correlations with comprehension. The target DCR score is 7 (8th grade reading level). We will avoid lower DCR scores because moderate levels of complexity enhance, attention, absorption, satisfaction, and ultimately engagement.
48116753|NCT02645006|BEHAVIORAL|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
48645276|NCT05689736|BEHAVIORAL|Gamification|"Gamification will include four features:~1. Game-like graphical environment (e.g., avatars to represent the participant).~2. Digital rewards. Parents will receive points and badges for completing intervention activities.~3. Leaderboard. A leaderboard will be used to activate competitive motives and social referencing. The leaderboard will display the points/badges of the participant relative to 4 other actual or simulated anonymized parents who are at a similar point in the intervention; their number of points and badges will be determined by those of the participant.~4. Modified, personalized SMS text nudges. SMS text nudges will alternate between Core content (e.g., reminder to complete a module) and reminders about game features such as badges and standings."
48645277|NCT05689736|BEHAVIORAL|Low Engagement Nudges|SMS text nudges will be sent to participants who have fallen behind in completing specific intervention tasks within a given time window; e.g., failing to log-in to the next module by a predetermined date, timed to program enrollment or in a prespecified number of days since completing the previous module.
48116754|NCT05172388|OTHER|Air purifier|Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
48116755|NCT04807556|OTHER|Alusti Test|Physical and psychological functional conditions are key factors in the elderly population
48116756|NCT01872026|DRUG|ASP7991|oral
48317905|NCT00354263|BIOLOGICAL|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
48317906|NCT03148431|DRUG|LY3002815|Administered IV
48486091|NCT02438982|DRUG|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
48116757|NCT04105868|OTHER|Neurofeedback|Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
48116758|NCT01068743|DRUG|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
48317907|NCT03148431|DRUG|Placebo|Administered IV
48339976|NCT04013165|BEHAVIORAL|Village-based intervention|"1. Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~2. Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
48486092|NCT02438982|DRUG|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3, it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
48116759|NCT01068743|DRUG|metformin|Tablets, Oral, 850 mg, once daily, single dose
48116760|NCT01068743|DRUG|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
48116761|NCT06383442|OTHER|L-HIIT|the long-interval HIIT group (4 × 4 min Exercise/4 min Rest)
48116762|NCT06383442|OTHER|M-HIIT|the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest)
48486093|NCT01538836|BEHAVIORAL|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
48116763|NCT00310726|OTHER|abrupt weaning at 4 months|abrupt weaning at 4 months
48116764|NCT00310726|OTHER|Continued exclusive breastfeeding|Continued exclusive breastfeeding
48116765|NCT00003432|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
48317908|NCT05590741|BEHAVIORAL|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
48317909|NCT01676402|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
48317910|NCT01676402|BIOLOGICAL|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
48317911|NCT05120999|DEVICE|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
48317912|NCT06106633|DEVICE|TriNaV|Assess Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization Via Pressure-Enabled Drug Delivery With the TriNav Infusion System
48317913|NCT05628584|COMBINATION_PRODUCT|High FODMAP diet with metformin|Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
48317914|NCT05628584|COMBINATION_PRODUCT|Low FODMAP diet with metformin|Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
48486094|NCT01538836|BEHAVIORAL|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
48486095|NCT01299805|DRUG|Vortioxetine|Encapsulated tablet
48486096|NCT01299805|DRUG|Placebo|Vortioxetine placebo-matching capsules.
48486097|NCT05790421|OTHER|Foot Muscle Energy Technique|Starting from the preparation position, at the restriction barrier, the patient is asked to exert a small effort (no more than 20% of available strength) towards plantarflexion, against unyielding resistance, with appropriate breathing. The patient produces isometric effort contracts either gastrocnemius or soleus (depending on whether the knee is unflexed or flexed). This contraction is held for 7-10 seconds together with a held breath. The exercise was repeated until the full range of movement was obtained.
48486098|NCT05790421|OTHER|Conventional Physical Therapy Program|Graduated active resisted range of motion exercises for both UL and LL and graduated gait training
48486099|NCT03632317|DRUG|Panobinostat|30 mg/m\^2
47966594|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
47966595|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
47966596|NCT01439269|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
47966597|NCT06293001|OTHER|No intervention|No intervention
47966598|NCT03567304|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
48317915|NCT01711684|DRUG|Diphenylcyclopropenone (DPCP)|Topical application of study drug
48317916|NCT04936724|OTHER|Pictorial Warning Labels|Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.
48486100|NCT03632317|DRUG|Everolimus|3.0 mg/m\^2
47966599|NCT00441714|PROCEDURE|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
48486101|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
48486102|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
48486103|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
48486104|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
47966600|NCT00135096|DRUG|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
47966601|NCT00135096|DRUG|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
47966602|NCT03384095|DRUG|Hyaluronic Acid (HA)|Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
47966603|NCT03384095|OTHER|Placebo|Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
47966604|NCT03602144|OTHER|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
47966605|NCT03602144|OTHER|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
48317917|NCT01945333|BEHAVIORAL|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
47966606|NCT01793896|BEHAVIORAL|Control period|Analysis at recruitment and after a month without any intervention
48317918|NCT04003077|DEVICE|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm\^2; power density, 300mW/cm\^2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm\^2.
48317919|NCT00674830|BEHAVIORAL|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
48317920|NCT00674830|BEHAVIORAL|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
48317921|NCT00674830|BEHAVIORAL|placebo|usual care
48317922|NCT02034604|DRUG|Naftofidil|
48317923|NCT02034604|DRUG|Tamsulosin|
48317924|NCT05882890|OTHER|cranio sacral therapy|Manual treatment of 5 grams on the whole airwaysystem, the throat, the neck, the meninges, the craniel , nerve sleeves, the visceral cranium, the soft tissue in the mouth
48317925|NCT02176590|BEHAVIORAL|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
47966607|NCT01793896|BEHAVIORAL|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
48317926|NCT02176590|OTHER|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
48486105|NCT02918747|DRUG|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
48486106|NCT02918747|DRUG|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
47966608|NCT01793896|BEHAVIORAL|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
48486107|NCT02918747|DRUG|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
48486108|NCT02918747|DRUG|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
48317927|NCT01449201|DRUG|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
48317928|NCT02991157|DRUG|Nimodipine|
48317929|NCT01755468|DRUG|Intermittent insulin therapy|
48317930|NCT01755468|DRUG|Continuous metformin|
48317931|NCT04155710|BIOLOGICAL|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
47966609|NCT01793896|BEHAVIORAL|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
47966610|NCT03153969|DEVICE|SHOFU Beautifil II LS|Placed under manufacturer's instructions
47966611|NCT03153969|DEVICE|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
47966612|NCT00834171|DRUG|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
47966613|NCT00834171|DRUG|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
47966614|NCT05314751|BEHAVIORAL|Questionnaire and interview|An online survey and an in-depth interview.
47966615|NCT03369093|DRUG|Amoxicillin|Twice daily doses of injectable amoxicillin
47966616|NCT05392296|OTHER|Power ball|experimental group getting the power ball training with conventional treatment.
48317932|NCT04155710|DRUG|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
48317933|NCT04155710|DRUG|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
48317934|NCT04155710|DRUG|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
48317935|NCT06539247|COMBINATION_PRODUCT|Motor Relearning Program with Electrical Muscle Stimulation (MRA + EMS)|This arm will receive a 30-minute motor relearning program focused on improving foot drop and gait patterns and Electrical Muscle Stimulation (EMS) for Targeted Activation (10 minutes) with 40 mA (default) adaptive, considering both intensity and duration for safe foot lift during walking.
48317936|NCT06539247|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation Technique with Electrical Muscle Stimulation (PNF + EMS)|"This arm will receive a 30-minute intervention combining Proprioceptive Neuromuscular Facilitation (PNF) techniques and EMS. The program will consist of:~PNF Techniques for Neuromuscular Facilitation (20 minutes) and Electrical Muscle Stimulation (EMS) for Muscle Response Enhancement (10 minutes): Similar to Arm 1, EMS will be applied to the affected ankle dorsiflexors for 10 minutes with the same parameters."
48317937|NCT00509496|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.
48317938|NCT00509496|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenous
48486109|NCT02918747|DRUG|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
48317939|NCT00509496|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
48317940|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
48317941|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
48317942|NCT02498756|BIOLOGICAL|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
48317943|NCT02498756|DRUG|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
48317944|NCT04359082|DIETARY_SUPPLEMENT|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
48317945|NCT04359082|OTHER|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
48317946|NCT04949906|DRUG|Raise serum brain granules|Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
47966617|NCT05392296|OTHER|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
48317947|NCT04949906|DRUG|No nourishing serum brain granules are used|No nourishing serum brain granules are used
48486110|NCT02918747|DRUG|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
48486111|NCT02918747|DRUG|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
48486112|NCT02918747|DRUG|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
48486113|NCT02918747|RADIATION|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
48486114|NCT00821366|BEHAVIORAL|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
47966618|NCT05970562|DEVICE|Ambulatory Voice Monitoring with Biofeedback (AVM-B)|AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, \[100% frequency AVM-B\] and/or summary statistics every 2 minutes of voicing \[Summary AVM-B\].
48116766|NCT06075212|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
48317948|NCT02985268|DEVICE|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus \[degenerative MR\] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
48317949|NCT02985268|DRUG|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
48317950|NCT02985268|DEVICE|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
48317951|NCT03105206|PROCEDURE|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
48317952|NCT04284904|DIAGNOSTIC_TEST|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
48317953|NCT00856479|DEVICE|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
48486115|NCT00821366|DIETARY_SUPPLEMENT|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
47966619|NCT05970562|BEHAVIORAL|Conversation Training Therapy|CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.
48116767|NCT06269822|DIAGNOSTIC_TEST|Sympathetic skin response, heart rate variability test, quantitative EEG|Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique
48116768|NCT02700191|DEVICE|uCor|
48486116|NCT00821366|DRUG|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
48486117|NCT00454519|PROCEDURE|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
48116769|NCT01750866|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
48116770|NCT01750866|DRUG|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
48317954|NCT00856479|PROCEDURE|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
48317955|NCT01889966|DRUG|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
48317956|NCT05966532|BEHAVIORAL|Hot Cognitive Task|"1. Emotion processing:~   * Participants will be shown a series of faces that appear quickly and be asked to identify what emotion is shown.~  * Participants will be shown a face of an emotion and indicate if participant can see the emotion changing.~  * Participant will be shown a series of emotions and asked to respond to only a specific emotion.~2. Motivation reward and processing:~   * Participant will play with a simulated roulette and make a bet to evaluate their decision-making behavior.~  * Participant will be shown colored circles and choose the one more likely to win money.~3. Impulsivity:~   • Participant will be shown a series of stimuli where they will be asked to respond to the correct stimulus.~4. Social cognition:~   * Participant will be shown a series of moral situations in which a character is accidentally or intentionally harmed and be asked to rate the degree of guilt from the perspective of the victim or perpetrator."
48116771|NCT01750866|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
48317957|NCT05966532|BEHAVIORAL|Cold cognitive tasks|"* Montreal Cognitive Assessment (MoCA) - This will ask participants questions related to their cognition such as visuospatial skills, naming, memory, attention, language, and recall.~* Measurement of Everyday Cognition (ECog) - This scale will ask participants about their everyday memory, language, visuospatial ability, organization, and divided attention.~* Test of Premorbid Function (TOPF) - This test will evaluate memory performance and abilities of stud participants before onset pre-morbid status.~* California Verbal Learning Test -3rd Edition (CVLT-3) -This test will measure verbal learning and memory of study participants.~* Three tests from the Delis-Kaplan Executive Function System (D-KEFS; Verbal Fluency, Color-Word Interference, and Tower Tests). -These measures assess word finding and problem-solving ability."
48317958|NCT05966532|OTHER|Structural magnetic resonance imaging (sMRI)|This is a non-invasive procedure to assess the structure and function of participant's brain. Structural neuroanatomical data will be acquired using structural magnetic resonance. Imaging (sMRI) with the University of Texas Southwestern (UTSW) 3T (three Tesla field) MRI scanner. Prior to participation, the investigator's team will screen participant's to ensure eligibility to participate in the sMRI scan.
48317959|NCT05966532|OTHER|Magnetoencephalography imaging (MEG)|This is a non-invasive procedure to measure participant's brain activity. Participants will be sitting inside the machine in a chamber, with more space than a traditional MRI machine. A hat will be placed on top of participant's head which records their brain activity. Resting-state and task-based MEG recordings will occur in a three-layer magnetically shielded room (MSR) following our UTSW Advanced Neuroscience Imaging Research (ANSIR) established procedures. Before the scan, five coils will be secured to participant's head and a three-dimensional (3D) digitizer will be used to map the location of the coils, fiducials, and scalp surface. During recording, an electric current with a unique frequency label (i.e., 320 Hz) will be fed to each coil, which will permit real time head location tracking and subsequent offline head motion correction.
48317960|NCT02701803|DEVICE|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
48317961|NCT00432952|BEHAVIORAL|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
48317962|NCT02675153|DRUG|Rapamycin|Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
48317963|NCT02952326|PROCEDURE|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
48486118|NCT00454519|PROCEDURE|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
48116772|NCT03286244|DRUG|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
48116773|NCT06231069|DIETARY_SUPPLEMENT|Multi-nutrient supplement|12 weeks of supplement intake of milk proteins, N-3 PUFAs, creatine, and vitamin D at levels previously shown to augment muscle protein synthesis in young individuals.
47966620|NCT06497998|DEVICE|Mechanical characterization|"The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness.~The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement.~The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI.~On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure:~* global elasticity of the oocyte.~* global viscosity behaviour of the oocyte.~* local elasticity of the oocyte.~* local viscosity behaviour of the pellucid membrane."
47966621|NCT04528108|DRUG|Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine|Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
48116774|NCT06231069|OTHER|Exercise|12 weeks of short-duration mixed endurance and resistance exercise.
48116775|NCT04271410|BIOLOGICAL|CD19 CAR-T cells|CD19 CAR-T cell therapy
48116776|NCT05214924|BIOLOGICAL|Injectable platelet-rich fibrin|Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
48116777|NCT05214924|BIOLOGICAL|Platelet-rich plasma|Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
48116778|NCT03268577|OTHER|Internet-Based Intervention|Complete ASA24
48116779|NCT03268577|OTHER|Internet-Based Intervention|Complete ACT24 reporting
48116780|NCT03268577|DEVICE|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
48116781|NCT03268577|OTHER|Questionnaire Administration|Ancillary studies
48116782|NCT05173714|BEHAVIORAL|SLIMM|Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
48116783|NCT05173714|BEHAVIORAL|Standard Resistance Training|Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
48116784|NCT05173714|BEHAVIORAL|Guided Resistance Training|Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
48116785|NCT05173714|DRUG|Placebo|Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
48116786|NCT05173714|DRUG|Semaglutide|Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
48116787|NCT05716763|DRUG|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
48116788|NCT05716763|DRUG|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
48116789|NCT04075942|PROCEDURE|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
48116790|NCT03107806|DEVICE|OptiScanner®|"1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®"
48116791|NCT04516603|DRUG|Fampridine SR|Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
48116792|NCT04516603|DRUG|Placebo|no active component
48116793|NCT03783754|DRUG|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
48116794|NCT03783754|DRUG|Placebo oral capsule|matched placebo
48116795|NCT05332366|DRUG|Delgocitinib cream|Cream for topical application
48116796|NCT05332366|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
48116797|NCT01268813|OTHER|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
48317964|NCT02952326|PROCEDURE|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
48339977|NCT00396305|DRUG|Placebo|Sterile phosphate buffered saline solution.
48486119|NCT01252849|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
48486120|NCT01252849|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
48486121|NCT01252849|DEVICE|iStent|Implantation of Three iStents through a small temperal clear corneal incision
48317965|NCT04365985|DRUG|Naltrexone|Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
48317966|NCT04365985|DRUG|Ketamine|Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
48317967|NCT04365985|OTHER|Placebo|Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
48317968|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
48317969|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
48317970|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS C|High casein-protein, high-caloric control product.
48317971|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
48317972|NCT02276716|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
48317973|NCT01673503|DEVICE|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
48317974|NCT03650686|OTHER|Food weighing (gold standard)|Method which consists in weighing precisely the main dish at the beginning and then end of meal using a SOEHNLE scale (+/- 1g).
48317975|NCT03650686|OTHER|Automated photographic method (method to be evaluated)|The nursing staff will position the tray for automatic picture taking before and after the meal. Taking a photograph of the entire tray will allow the patient's identity to be identified by his meal card which will then be coded for analysis and the plate will be targeted at the time of the nutritional analysis by the software. This method will automatically provide the percentage of each main dish food consumed using an advanced image processing algorithm and an optimized artificial intelligence system that will recognize the food before and after consumption. Automatic processing and transfer will enable food intake to be collected.
48317976|NCT03650686|OTHER|Semi-quantitative method (routine method)|Staff will indicate whether 1, ¾, ½, ¼ or 0 (corresponding to 100%, 75%, 50% 25% or 0) of the food in the main course has been consumed.
48317977|NCT02547636|OTHER|Observational study|No intervention will be used in this study.
48317978|NCT04037670|PROCEDURE|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
48317979|NCT03365479|DRUG|Iloprost|Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
48317980|NCT01319643|DRUG|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
48317981|NCT05012852|DEVICE|VagiVitalAC|In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
48317982|NCT02391350|BEHAVIORAL|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
48486122|NCT03249740|DRUG|GB-102|Intravitreal injection of GB-102
48317983|NCT02391350|PROCEDURE|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
48317984|NCT05274113|DRUG|Dexamethasone 4mg|4 mg of Dexamethasone will be given before surgery
48486123|NCT03249740|DRUG|Aflibercept|Intravitreal injection of Aflibercept.
48317985|NCT05274113|DRUG|Ropivacaine|Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
48486124|NCT05920564|OTHER|Upper fibers of trapezius stretching|The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.
47966622|NCT04528108|DRUG|Gong Xue Ning capsules|Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
47966623|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
48486125|NCT05920564|OTHER|Standard care|The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
48486126|NCT00098228|DRUG|QAB149|
48486127|NCT01000610|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
48317986|NCT04866303|DIAGNOSTIC_TEST|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
48317987|NCT02701686|BEHAVIORAL|quit immediately (QI)|advise to quit immediately using the AWARD model
48317988|NCT02701686|BEHAVIORAL|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
47966624|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
48317989|NCT04511026|DRUG|Lymphoseek|Radioactive diagnostic agent
48486128|NCT01000610|DRUG|methotrexate|10-25 mg weekly (oral or parenteral)
48486129|NCT01000610|DRUG|methylprednisolone|100 mg iv prior to each rituximab infusion
48486130|NCT03606720|OTHER|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
48486131|NCT03606720|OTHER|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
48486132|NCT02919826|BEHAVIORAL|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
48486133|NCT06233578|DEVICE|RADPAD|The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
48486134|NCT00097045|DRUG|omega interferon|
48486135|NCT00097045|DRUG|Ribavirin|
47966625|NCT05613478|PROCEDURE|Postoperative TACE treatment|TACE treatment after radical surgery
47966626|NCT05613478|PROCEDURE|Radical surgery|Radical surgery
47966627|NCT05613478|PROCEDURE|Preoperative TACE treatment|TACE treatment before preoperative camrelizumab combined with apatinib mesylate
47966628|NCT04904562|DRUG|Angiotensin II|Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)
47966629|NCT04904562|DRUG|Placebo|Placebo
47966630|NCT00476697|DEVICE|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
47966631|NCT01796080|OTHER|Mueller manoeuvre|
47966632|NCT01796080|OTHER|Inspiratory threshold|
47966633|NCT01796080|OTHER|Expiratory apnoea|
48317990|NCT04511026|DEVICE|Single Photon Emission Computed Tomography (SPECT)|Imaging test
48317991|NCT04511026|DRUG|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
48486136|NCT00374075|DRUG|Valproic Acid|
48486137|NCT05382520|DIAGNOSTIC_TEST|Questionares and practice|Questionares and practice
48486138|NCT03202901|DIETARY_SUPPLEMENT|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
48486139|NCT03202901|DIETARY_SUPPLEMENT|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
47966634|NCT01796080|OTHER|Steady state normal breathing|
47966635|NCT04686071|OTHER|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
47966636|NCT04686071|OTHER|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
47966637|NCT06558032|DRUG|Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)|One tablet of the test drug was given orally under fasting condition
48317992|NCT04511026|DEVICE|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
48317993|NCT04445493|DEVICE|MindRhythm Harmony|Passive recording of the head pulse
48116798|NCT05251688|OTHER|Cryoanalgesia|"On the first day of the study, the PI met the participants and assessed their level of consciousness using the Modified Glasgow Coma Scale to ensure that they were unconscious and reviewed the medical records to collect their sociodemographic data. After that, the participants received routine care before the arterial puncture. The PI assessed their pain scores during the puncture.~In the second meeting (on the same day or the following day), the PI prepared the ice packs by crushing small pieces of ice and wrapping them in smooth gauze to avoid skin damage and moisture in the puncture area. Before the arterial puncture, the ice pack was applied over the selected puncture site (radial, brachial, or femoral artery) for 5 minutes in addition to the routine care. After removing the ice pack, the nurse palpated the artery, wiped of the residue of ice vapor present on the skin, and took the arterial blood sample. During the puncture, the PI assessed the participants' pain scores."
48116799|NCT03557008|BIOLOGICAL|Rabies Vaccine|A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
47966638|NCT06558032|DRUG|Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)|One tablet of the test drug was given orally under fasting condition
47966639|NCT00827333|OTHER|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
47966640|NCT00827333|OTHER|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
47966641|NCT00827333|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
47966642|NCT00827333|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
47966643|NCT00827333|PROCEDURE|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
47966644|NCT06352489|PROCEDURE|Posterior component separation technique.|By dividing the posterior rectus sheath, a posterior plane is reached which can be advanced by dividing the transversus abdominis muscle with reinforcement of the midline with synthetic mesh.
47966645|NCT05019352|DEVICE|CytoSorb cytokine adsorber|device for extracorporeal hemoadsorption
47966646|NCT05019352|DEVICE|CRRT|continuous renal replacement therapy
47966647|NCT03282643|DRUG|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
47966648|NCT03282643|DRUG|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
47966649|NCT03282643|DRUG|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
47966650|NCT00705198|DRUG|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
47966651|NCT00705198|DRUG|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
47966652|NCT00705198|RADIATION|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
47966653|NCT03859752|BIOLOGICAL|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
47966654|NCT03426813|OTHER|Historical control group for early mobilization|
47966655|NCT00211510|DEVICE|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
47966656|NCT00211510|DEVICE|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
47966657|NCT04353271|DRUG|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
48317994|NCT03065634|BEHAVIORAL|Return to work and living healthy after head and neck cancer|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
48317995|NCT03065634|BEHAVIORAL|socio-legal counseling|"Non-manualized socio-legal counseling~two socio-legal counseling sessions delivered by a social worker"
47966658|NCT04353271|OTHER|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
47966659|NCT01804283|PROCEDURE|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
47966660|NCT01804283|PROCEDURE|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
47966661|NCT01804283|DEVICE|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
47966662|NCT01804283|DEVICE|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
47966663|NCT00718952|DRUG|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
48317996|NCT02084836|OTHER|Functional Magnetic Resonance Imaging|
48317997|NCT00343291|BIOLOGICAL|Cetuximab|Administered intravenously
47966664|NCT00718952|DRUG|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
47966665|NCT00718952|DRUG|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
47966666|NCT06209177|DRUG|ARO-CFB|ARO-CFB for sc injection
47966667|NCT06209177|DRUG|Placebo|sterile normal saline (0.9% NaCl for sc injection)
47966668|NCT01724918|DRUG|Lacosamide|
48317998|NCT00343291|BIOLOGICAL|Bevacizumab|Administered intravenously
47966669|NCT02895230|OTHER|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
48116800|NCT03557008|DRUG|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
48317999|NCT00343291|DRUG|Paclitaxel|Administered intravenously
47966670|NCT00287885|DRUG|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day
47966671|NCT03668860|DRUG|Dexamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
48318000|NCT00343291|DRUG|Carboplatin|Administered intravenously
48318001|NCT02049749|BEHAVIORAL|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
47966672|NCT03668860|DRUG|Betamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
47966673|NCT03668860|DRUG|Celestone Soluspan 6Mg/Ml Suspension for Injection|Intramuscular. Total dose: 1 mL (6 mg)
47966674|NCT03668860|DRUG|Dexamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
47966675|NCT03668860|DRUG|Betamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
47966676|NCT02530060|DRUG|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
47966677|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
47966678|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
47966679|NCT03231605|BIOLOGICAL|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
47966680|NCT05298631|OTHER|Stabilization exercises|The activation of deep cervical muscle to reduce the activity of surface muscles is known as stabilization exercises
47966681|NCT05298631|OTHER|Dynamic exercises|The exercises in which muscle tension remains constant but muscle length changes is known as dynamic exercises
47966682|NCT00956020|BIOLOGICAL|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
47966683|NCT01003288|BIOLOGICAL|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~\* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
47966684|NCT03504657|DEVICE|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
47966685|NCT03504657|DEVICE|stenting angioplasty|Angioplasty with a stenting
47966686|NCT05686811|OTHER|Myofascial release therapy therapy|Group A was treated with myofascial release therapy and routine physical therapy. For routine physical therapy subjects will first applied TENS, hot pack and neck isometric exercises then myofascial release therapy will be given. For myofascial release therapy subjects was in the supine or possibly sitting position, the examiner was seated at the head of the table, the examiner was used his right thumb to palpate (using flat palpation) the upper trapezius muscles from medial to lateral to establish if any MTrPs are present. The entire mass of the upper trapezius muscle is lifted by the supraspinatus muscle and grasped with a pincer grasp. The muscles at this point rotate between the thumb and forefinger to detect the delicate location of the trigger point. Treatment session longs for 10 minutes of myofascial release on each side
47966687|NCT05686811|OTHER|Post isometric relaxation technique|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
48116801|NCT03557008|DRUG|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
48116802|NCT03557008|DRUG|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
48116803|NCT01568073|DRUG|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
48116804|NCT01568073|DRUG|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
48116805|NCT01568073|DRUG|Placebo|200 mg
48116806|NCT01568073|DRUG|Levodopa|
48116807|NCT01568073|DRUG|Carbidopa|DOPA decarboxylase inhibitor
48116808|NCT01568073|DRUG|Benserazide|DOPA decarboxylase inhibitor
48645278|NCT05689736|BEHAVIORAL|Essentials for Parenting Toddlers and Pre-schoolers (EFP)|"All parents will receive the Core intervention content, including text, demonstrations (videos and vignettes), and interactive activities (e.g., skill-building), and comprising five modules: Communicating with Your Child; (2) Giving Directions; (3) Creating Structure; (4) Using Discipline and Consequences; and (5) Using Time-out. The Core intervention will be augmented with more prescriptive behavioral skills practice exercises and SMS text nudges to remind participants to complete intervention modules.~All conditions will be housed on Westat servers accessible through any device that can use the Internet, including computers, tablets, and smartphones. Westat has extensive technical capacities for web programming/hosting."
47966688|NCT00118677|PROCEDURE|Treatment interruption|
47966689|NCT01135420|BEHAVIORAL|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
47966690|NCT01135420|OTHER|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
47966691|NCT01472302|DEVICE|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
47966692|NCT01472302|DEVICE|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
47966693|NCT03198572|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.
48116809|NCT00888108|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
48116810|NCT00888108|DRUG|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
48116811|NCT00081250|DIETARY_SUPPLEMENT|creatine monohydrate|Given orally
48116812|NCT00081250|OTHER|placebo|Given orally
48116813|NCT03532711|DRUG|fluorouracil|chemotherapy treated patients
48116814|NCT01839981|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
48116815|NCT03396146|OTHER|12 ml total blood tubes volume|12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
48116816|NCT03396146|OTHER|Fecal sample|Fecal sample at inclusion
48116817|NCT04492631|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5|Sachets containing Streptococcus salivarius DB-B5 will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks. The participants will consume 10 billion colony forming units (CFU) per day.
48116818|NCT04492631|OTHER|Placebo|Sachets containing a placebo (probiotic carrier) will be dissolved in water and consumed by the participants (n=30) once daily for 4 weeks.
48116819|NCT01599897|BIOLOGICAL|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
48486140|NCT05485220|OTHER|Aerobic exercise|Aerobic exercise group: Peak workload will be determined by performing an exercise test on the patients. Training will be given at 60-70% of the peak workload for 45 minutes with an arm ergometer 3 days a week for 8 weeks.
48645279|NCT06550089|DRUG|Oxytocin|Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
47966694|NCT03198572|DRUG|Placebo|placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
47966695|NCT03198572|DRUG|Berberine|Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
47966696|NCT03945578|OTHER|Pelvic Floor muscle training - PFMT|Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
48116820|NCT01599897|BIOLOGICAL|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
48116821|NCT05919446|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Each session in the ACT group will include the first hour of ACT intervention followed by 1 hour of back exercise class. The ACT group will be led by a trained ACT counsellor and a trained exercise trainer.
48645280|NCT03649087|OTHER|Vitrification|Vitrification of ovarian tissue
48645281|NCT03324412|DRUG|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
48116822|NCT05919446|BEHAVIORAL|back exercise|The control group will undergo 1 hour of back exercise class, while the control group will be led by a trained exercise trainer.
48116823|NCT06396611|BEHAVIORAL|Exercise Training as Intervention|Supervised Exercise Training as an Intervention using Resistance Training.
48116824|NCT04666506|OTHER|Virtual reality|"The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog)."
48645282|NCT03324412|DRUG|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
48645283|NCT05950997|DRUG|Acalabrutinib|100 mg capsules administered by mouth once daily (28-day cycles)
48645284|NCT05950997|DRUG|Obinutuzumab|100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
48645285|NCT06688162|OTHER|Usual Care|During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.
48645286|NCT06688162|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
48486141|NCT05485220|OTHER|High-intensity interval training|High-intensity interval training Group: Peak workload will be determined by performing an exercise test on the patients and arm ergometer HIIT will be done with a total of 45 minutes, 90-95% of the peak workload for 30 seconds, 60 seconds in between, active recovery at 40-50% workload, 3 days a week for 8 weeks.
48486142|NCT02485821|DRUG|Estradiol|
48645287|NCT06688058|BIOLOGICAL|V540D|Experimental vaccine and adjuvant administered via intramuscular (IM) injection
48645288|NCT06688058|BIOLOGICAL|GARDASIL®9|Suspension administered via IM injection
48116825|NCT02541188|GENETIC|Genetic analysis|
48116826|NCT01186198|DEVICE|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
48116827|NCT01932450|PROCEDURE|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
48116828|NCT01932450|DRUG|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
48116829|NCT00188136|DRUG|Melphalan, ATG, Fludarabine|allo Tx during aplasia
48116830|NCT00481182|DRUG|fosamprenavir + ritonavir + methadone|
48116831|NCT02165761|DEVICE|GORE® Hybrid Vascular Graft|
48116832|NCT02165761|DEVICE|Non-heparin bonded synthetic graft|
48486143|NCT02485821|DRUG|Placebo|
48486144|NCT02485821|DRUG|Misoprostol|
48645289|NCT06688045|DRUG|Nemtabrutinib|Oral administration
48486145|NCT03142516|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
48645290|NCT06688045|DRUG|Itraconazole|Oral administration
48645291|NCT05624632|OTHER|Remote cognitive testing|Remote cognitive testing
48645292|NCT06679062|DRUG|Suvorexant|Suvorexant is described chemically as: \[(7R)-4-(5-chloro-2-benzoxazolyl) hexahydro-7-methyl-1H-1,4-diazepin-1-yl\]\[5-methyl-2-(2H-1,2,3-triazol2-yl)phenyl\]methanone. SUV's empirical formula is C23H23ClN6O2 and the molecular weight is 450.92. Each film coated tablet contains 10mg or 20mg of suvorexant.
48645293|NCT06679062|OTHER|Placebo|Film coated tablet to match the active drug.
48645294|NCT04210076|BEHAVIORAL|MBAT-T|The MBAT-Team program builds on the basic 4-week, 8-hour MBAT-Soldier program. In addition to the basic program, MBAT-Team includes exercises promoting the cultivation of attention and emotion regulation in the service of effective team interactions (e.g., mindful communication and listening; monitoring and attention to the activities and emotional states of others, and additional practices to promote collective mindfulness).
48645295|NCT04210076|BEHAVIORAL|MBAT-I|The MBAT-Individual program is based on the basic 4-week, 8-hour MBAT-Soldier curriculum.
48486146|NCT03142516|DRUG|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
48486147|NCT03142516|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
48486148|NCT03142516|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
48645296|NCT06688487|OTHER|early extubation of hypoxemic patients|patient extubated after the spontaneous ventilation trial despite the presence of hypoxemia defined by SpO2 ≤ 90% either in T-piece under 6 L/min, or under FiO2 = 40% if SBT is performed in spontaneous ventilation with minimal inspiratory assistance.
48645297|NCT04883554|OTHER|Olfactory therapeutic|The sessions of the olfactory sensory therapy group take place according to the care framework at a frequency of one session of 45 minutes per week
48645298|NCT04883554|OTHER|Body therapy|very specific stages at a weekly frequency and lasts 1 hour. Kinesic time or time to set the body in motion (20 min) Kinesthetic time: time of slow movements (20 min) Talk time (20 min)
48645299|NCT05365880|DRUG|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
48645300|NCT05365880|DRUG|Placebo|The active placebo comparator will be provided to participant.
47966697|NCT03945578|OTHER|Visceral Manual Therapy - VMT|Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
48116833|NCT03626558|OTHER|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
48116834|NCT02921399|OTHER|eradication timing|patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.
48116835|NCT02368171|OTHER|measure exhaled carbon monoxide and nitric oxide|
48116836|NCT03189329|DRUG|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
48318002|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
48486149|NCT04636242|PROCEDURE|Skin Biopsy|A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
48486150|NCT04636242|DRUG|5 Aminolevulinic Acid + Phototherapy|5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
48486151|NCT01492972|RADIATION|Radiation|"Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
48486152|NCT01492972|DRUG|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
48645301|NCT05604157|OTHER|Use of Tourniquet|Application of tourniquet or not in adults undergoing a primary total knee replacement.
48645302|NCT05366660|OTHER|Interrogation/programming|As the study investigates remote programming, we will describe two locations: local (patient side) and remote (expert side). Local support is defined by a physician or a technician under the direct responsibility of a nearby physician who connect the patient to the remote programming system. Similar to a conventional check-up, an external defibrillator will be located in the near vicinity of the patient. The patient will first be connected to the programmer as during a conventional follow-up. The programmer will then be connected to a local PC which captures the programmer VGA video output and controls the programmer through a mouse emulator. This local PC will be remotely controlled by the remote PC using Cisco Webex, a communication software used worldwide to support telemedicine.
48645303|NCT00124033|PROCEDURE|Transcystic Stenting (Facilitated ERCP)|
48645304|NCT03339765|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
48645305|NCT02118415|OTHER|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
48645306|NCT00677300|DRUG|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
48645307|NCT00677300|DRUG|Darunavir|800 mg P.O. (orally) once daily
48645308|NCT00677300|DRUG|Ritonavir|100mg once daily
48645309|NCT00677300|DRUG|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
48645310|NCT00188032|PROCEDURE|Computer-Assisted diagnostic Decision Support|
48645311|NCT00188032|PROCEDURE|written diagnostic guidelines|
48645312|NCT00188032|PROCEDURE|electronic therapeutic reminders|
48645313|NCT06686849|BEHAVIORAL|Low-touch: texting|Text message: The patients' primary caregiver will be sent up to three text messages spaced one week apart, starting at one week post no-show. The message will identify the child by the first name and give information about the missed visit (date, time, clinic location) and how to reschedule (by clinic-specific phone number, and/or directing the patient to myatriumhealth.org). If a patient has a newly scheduled well-child visit on file prior to all three text messages being sent, messages will be stopped.
47966698|NCT03945578|OTHER|Manual Sham Therapy - MST|The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine
47966699|NCT03868124|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
47966700|NCT03868124|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
47966701|NCT05914805|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
47966702|NCT05914805|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
47966703|NCT02837601|DEVICE|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
48318003|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
48486153|NCT05562908|PROCEDURE|Pedicled|Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.
48486154|NCT05562908|PROCEDURE|Surgical skeletonised|Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
48486155|NCT05562908|PROCEDURE|Thunderbeat skeletonised|Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
48486156|NCT04267263|BEHAVIORAL|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
48486157|NCT00532935|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period
48486158|NCT00532935|DRUG|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
48486159|NCT01783002|RADIATION|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
48486160|NCT01783002|RADIATION|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
48486161|NCT01783002|RADIATION|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
48486162|NCT02650401|DRUG|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
48486163|NCT00336128|BEHAVIORAL|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
47966704|NCT03837197|DEVICE|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
48318004|NCT00987233|DRUG|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
48318005|NCT03216317|BEHAVIORAL|Intervention Group|Isometric handgrip training consisting of four series
48645314|NCT06686849|BEHAVIORAL|High-touch: Community health worker outreach|Community health worker (CHW) outreach: Within three business days of patient enrollment and randomization to the high-touch intervention arm, the community health worker will call the primary phone number in the patient's record. Up to three phone call attempts will be made and logged for this number, then a fourth and final attempt will be made to reach the secondary contact phone number in the patient's health record. If the caregiver is successfully reached, the CHW intervention will be limited to one phone call in which the CHW will assess reason(s) why the patient missed the appointment, will screen for social and other needs, and will assist in rescheduling the missed appointment and addressing potential barriers to attendance.
48645315|NCT01522274|BEHAVIORAL|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
48645316|NCT01522274|BEHAVIORAL|Health education|Videos
48116837|NCT03189329|DRUG|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
48318006|NCT04873284|DRUG|fosaprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV"
48318007|NCT04873284|DRUG|aprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg)."
48318008|NCT04873284|DRUG|Granisetron plus dexamethasone|Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
48318009|NCT02864940|DEVICE|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
48318010|NCT02864940|DEVICE|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
48318011|NCT05557955|OTHER|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
48318012|NCT00122356|DRUG|Alendronate sodium|70mg tablets, once weekly
48318013|NCT04347317|PROCEDURE|Low Intensity IMT|"The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
48339978|NCT00396305|BIOLOGICAL|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
48486164|NCT00336128|BEHAVIORAL|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
48486165|NCT01576302|BEHAVIORAL|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
48486166|NCT01576302|BEHAVIORAL|Muscle relaxation|Progressive passive muscle relaxation
48486167|NCT03739138|BIOLOGICAL|MK-4621|"MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data."
48486168|NCT03739138|BIOLOGICAL|Pembrolizumab|200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
48486169|NCT03870113|BIOLOGICAL|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
48486170|NCT02054013|PROCEDURE|Prostatic artery embolization|
48486171|NCT02054013|PROCEDURE|monopolar transurethral prostatectomy|
48486172|NCT02350582|DEVICE|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
48645317|NCT00004083|DRUG|cisplatin liposomal|
48645318|NCT04348058|BEHAVIORAL|Telephone recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation
48645319|NCT04348058|BEHAVIORAL|Combined methods recruitment to screening colonoscopy|Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
48645320|NCT00117442|DRUG|carboplatin|Chemotherapy
48645321|NCT00117442|DRUG|paclitaxel|chemotherapy
48645322|NCT00117442|DRUG|pegfilgrastim|Growth factor for mobilization
48318014|NCT04347317|PROCEDURE|High Intensity IMT|"The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
48318015|NCT04585217|PROCEDURE|Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)|"Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality."
48318016|NCT01734486|DRUG|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
48318017|NCT01734486|DRUG|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
48318018|NCT02537379|DRUG|SOF|SOF 400 mg tablets administered orally once daily
48318019|NCT02537379|DRUG|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
48318020|NCT03936816|OTHER|GBS vaginal double swab|The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
48318021|NCT03357146|DEVICE|Optical coherence tomography angiography|OCTA scans per built-in device protocol
48318022|NCT05062941|OTHER|Conventional physiotherapy|Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.
48318023|NCT05062941|DEVICE|High-intensity laser therapy (HILT)|"HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total."
48318024|NCT05255588|DEVICE|EarlyTect® CRC test|A highly accurate and sensitive real time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE/qMSP) for measuring SDC2 methylation in stool DNA to detect CRC.
48318025|NCT03483506|DRUG|BI 1467335|Film-coated tablet
48318026|NCT03483506|DRUG|BI 1467335 (C-14) intravenous solution|Intravenous solution
48318027|NCT05384158|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy
48318028|NCT05384158|BEHAVIORAL|valuation with instruction|repeat laboratory sessions of computerized learning game
48318029|NCT05384158|BEHAVIORAL|valuation without instruction|repeat laboratory sessions of computerized learning game
48318030|NCT03440255|DEVICE|Transcutaneous Vagus Nerve Stimulation|"TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)"
48318031|NCT00264849|DRUG|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
48486173|NCT04467359|OTHER|ERAS|Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.
48486174|NCT04467359|OTHER|Perioperative routine rehabilitation nursing|Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
48486175|NCT02459041|OTHER|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
48486176|NCT00949455|DRUG|lapatinib ditosylate|Given orally
48486177|NCT00949455|OTHER|Placebo|Given orally
48486178|NCT05982821|OTHER|Artificial Intelligent|Artificial intelligence assisted radiologists to extract ultrasound features of thyroid nodules.
48486179|NCT02860182|OTHER|measure the elastic properties of aortic wall|
48645323|NCT05802836|OTHER|no interventions|no intervention, only 3 different patients groups
48645324|NCT05346640|DEVICE|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
48645325|NCT03810495|DRUG|naltrexone implant|1.8 g implant containing 60% naltrexone
47966705|NCT03837197|DEVICE|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
47966706|NCT03670888|BIOLOGICAL|JHL1101|100 mg/10 mL solution in a single-use vial
48318032|NCT00264849|OTHER|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
48318033|NCT03874624|DIAGNOSTIC_TEST|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
48318034|NCT00434863|DRUG|botulinum toxin type A|
48318035|NCT05243394|OTHER|Gamified virtual reality treadmill gait training with tDCS|Progressive treadmill gait training in a gamified virtual reality environment with tDCS
48318036|NCT05243394|OTHER|Gamified virtual reality treadmill gait training|Progressive treadmill gait training in a gamified virtual reality environment
48318037|NCT05243394|OTHER|Treadmill gait training|Progressive treadmill gait training
48318038|NCT01219517|OTHER|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
48318039|NCT06484439|DRUG|Ketorolac|10 mg PO q 6h scheduled
48318040|NCT06484439|DRUG|Oxycodone|5 mg PO PRN
47966707|NCT03670888|BIOLOGICAL|Rituximab|100 mg/10 mL solution in a single-use vial
48318041|NCT06484439|DRUG|Acetaminophen|650 mg q 6h scheduled
48318042|NCT06484439|DRUG|Ibuprofen|600 mg PO scheduled q6h
48318043|NCT06484439|DRUG|Hydrocodone|5 mg hydrocodone PO PRN q6h
48318044|NCT06013605|BEHAVIORAL|Walking Exercise and Leg Straightening|Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
48318045|NCT06013605|BEHAVIORAL|Leg Straightening|Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
48318046|NCT03939806|DRUG|Oxytocin|To be given to Oxytocin group following the clamping of the umbilical cord
48318047|NCT03939806|DRUG|Carbetocin|To be given to Carbetocin group following the clamping of the umbilical cord
48318048|NCT02290054|PROCEDURE|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
48318049|NCT02290054|PROCEDURE|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
48486180|NCT06525922|BEHAVIORAL|Center M|Center M consists of weekly, 1-hour, telehealth, mindfulness-based Cognitive Behavioral Therapy (CBT) group sessions for four consecutive weeks. Participants joined group sessions on their personal computer, tablet, or phone. Each visit involved the introduction of a core mental well-being theme, learning skills to develop non-judgmental self-awareness and/or cognitive reappraisal skills, skills practice, and discussion of home practice materials. Home practice materials included written mindful awareness instructions, audio-guided meditations, self-compassion exercises, and practices in recognizing the interrelationships between thoughts, feelings, and behaviors.
48318050|NCT02290054|PROCEDURE|Intra-venous anesthesia|
48318051|NCT06553677|PROCEDURE|Tunneled coronal advanced flap with connective tissue graft|Tunneled coronal advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites.
48318052|NCT06553677|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites
47966708|NCT05889377|PROCEDURE|Socket preservation|Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
47966709|NCT03601975|DRUG|Gemcitabine/Cisplatin|gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
48318053|NCT05511831|DRUG|Ketotifen Fumarate|Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance
48318054|NCT05511831|DRUG|standard treatment|Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) \[19\], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
48318055|NCT04345926|DRUG|Propofol|Stepped propofol concentration after 20 min of LOS
47966710|NCT01910857|BEHAVIORAL|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
47966711|NCT00970970|OTHER|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
47966712|NCT02467868|BIOLOGICAL|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
48318056|NCT04345926|DEVICE|Electroencephalogram recording|Acquisition of EEG activity
48318057|NCT00074841|DRUG|Azithromycin/Chloroquine|
48318058|NCT00074841|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
48318059|NCT00028561|DRUG|ixabepilone|Given IV
48318060|NCT00028561|DRUG|carboplatin|Given IV
48318061|NCT00028561|OTHER|laboratory biomarker analysis|Correlative studies
48318062|NCT00028561|OTHER|pharmacological study|Correlative studies
48318063|NCT04224285|OTHER|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
48318064|NCT03611322|DRUG|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
48318065|NCT03611322|DRUG|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
48318066|NCT03611322|DRUG|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
47966713|NCT02467868|BIOLOGICAL|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
48318067|NCT03611322|DEVICE|DV3372|DV3372 device will be used for administration of semaglutide
47966714|NCT01292434|BEHAVIORAL|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
47966715|NCT00000308|DRUG|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
47966716|NCT00000308|DRUG|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
47966717|NCT00000308|DRUG|placebo|placebo
47966718|NCT02420392|DRUG|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
47966719|NCT03890601|BIOLOGICAL|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
48318068|NCT03611322|DEVICE|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
48318069|NCT04868006|PROCEDURE|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
48318070|NCT04868006|PROCEDURE|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
48318071|NCT04868006|PROCEDURE|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
48645326|NCT06686888|DIETARY_SUPPLEMENT|SCFA|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
47966720|NCT06239766|DIAGNOSTIC_TEST|Breast Cancer Risk Assessment|Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
47966721|NCT00454012|PROCEDURE|biophysical profile|
47966722|NCT02687633|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
47966723|NCT02887638|OTHER|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~* Analysis of the sitting-posture profile:~  o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~* Analysis of the dural profile before and after the provoking task:~  o Determination of the dural sensitivity by the use of the slump-test~* Analysis of the pain profile before and after the provoking task:~  * Determination of pressure pain sensitivity by the use of pressure algometry~ * Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
47966724|NCT00253227|DRUG|galantamine hydrobromide|
47966725|NCT05214885|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
47966726|NCT06506149|DEVICE|Microwave ablation(MWA) device|The device for USG-guided MWA treatment would be performed under USG guidance, aiming to ablate the entire thyroid gland, i.e. the right lobe, left lobe, isthmus and pyramidal lobe.
47966727|NCT03895385|DRUG|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
47966728|NCT03355820|PROCEDURE|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.
47966729|NCT04013204|OTHER|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
47966730|NCT00970060|BEHAVIORAL|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
47966731|NCT01502930|BEHAVIORAL|IRT|Internet-based IRT with therapist support during 6 weeks
47966732|NCT01502930|BEHAVIORAL|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
47966733|NCT06066983|BEHAVIORAL|DINOSAUR|This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.
47966734|NCT06066983|OTHER|Psychoeducation|This intervention provides psychoeducation regarding anxiety and autism.
47966735|NCT06505304|PROCEDURE|Colonoscopy|"The colonoscopy will be performed at 3 or 6 months after surgery according to FC:~* In patients with FCP \>=150µg/g at around 3 months after surgery, a colonoscopy will be immediately performed~* In patients with FCP \<150µg/g at around 3 months after surgery, the colonoscopy will be organized at 6 months after surgery~Colonoscopy will be performed using high definition white-light endoscopy (HD-WLE) followed by virtual chromoendoscopy (VCE). The neoterminal ileum, ileocolic anastomosis and right colon will be assessed.~A follow-up colonoscopy will be performed within 18 months after index colonoscopy, as standard of care."
48318072|NCT00930605|DRUG|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
48318073|NCT00930605|DRUG|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
47966736|NCT06505304|PROCEDURE|Intestinal biopsies|During index colonoscopy, at least 2 biopsies from each of the segments will be taken as standard of practice to assess inflammation in post-operative CD. Only in Irish sites, twelve biopsies - four in the area of ileocolonic anastomosis, four in the neo-terminal ileum and four in the colon just distal to the anastomosis- will be taken for research purposes, in addition to standard-of-care biopsies.
47966737|NCT06505304|PROCEDURE|Confocal laser endomicroscopy|pCLE with fluorescein injection will be performed during index colonoscopy, in centres where is available, to assess early alteration of the barrier function.
47966738|NCT06505304|PROCEDURE|Intestinal ultrasound|All patients will undergo a cross-sectional imaging test as part of their standard of care at 3 and 6 months after surgery. A follow-up IUS will be performed within 18 months after index colonoscopy, as standard of care.
48318074|NCT02489565|OTHER|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
48318075|NCT02144558|OTHER|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
48318076|NCT04646980|DIETARY_SUPPLEMENT|Biobran/MGN-3|Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
48318077|NCT04646980|OTHER|Placebo|Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
48318078|NCT00706667|DRUG|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
48318079|NCT01530438|OTHER|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
48318080|NCT06310096|OTHER|TLF fascial stretching exercise|"Relaxed lumbo-pelvic upright sitting with arms in neutral anatomical position (O'Sullivan et al., 2006). The subjects had to bend both knee flexed 90. The feet of the Participant lied flat on the ground. Trunk was in aligned position and the angle between upper body and lower body was 90. Seated position led to caudal tensioning of the pTLF via stretching of the gluteus maximus (GM)~Seated position with passive arms elevation Seated position with passive caudal stretching of TLF through thigh elevation. The subjects had to bend both hips while keeping their feet onto a stool (30 cm high) so to pull the GM and the TLF"
48486181|NCT04259138|BIOLOGICAL|Treatment Algorithm A|Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.
48486182|NCT04259138|BIOLOGICAL|Treatment Algorithm B|"Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
47966739|NCT06505304|DIAGNOSTIC_TEST|Stool|Stool samples will be collected at 3 and 6 months after surgery and used for faecal calprotectin analysis. Research stool will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for metagenomics (only in Irish sites).
47966740|NCT06505304|DIAGNOSTIC_TEST|Blood|Blood will be collected at 3 and 6 months after surgery and used as standard of care. Research blood will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for research - i.e. proteomic, genomic, cell experiments (only in Irish sites).
47966741|NCT06505304|DIAGNOSTIC_TEST|Saliva|Saliva will be collected during the visit of index colonoscopy and at 12 months after surgery for research - i.e. optical spectroscopy (only in Irish site)
47966742|NCT06505304|OTHER|Clinical follow-up|Patients will be followed-up at 6, 12 and 24 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. The following scores will be repeated: Harvey Bradshaw Index (HBI) and CD Activity Index score (CDAI). Participants will give an update on their medication use.
47966743|NCT05773482|BEHAVIORAL|Breathing and Attention Training (BAT)|BAT is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
48318081|NCT06310096|OTHER|conventional physiotherapy program.|hotpack, ultrasound ,Tens
48318082|NCT04798391|DRUG|Dexamethasone|Steroids and analgesics
48318083|NCT05779332|OTHER|survey application|Children's OHRQoL was measured by the Child Perceptions Questionnaire (CPQ8-10). Oral examination of children were conducted for presence and severity of MIH, dental caries experience and oral hygiene status.
47966744|NCT05773482|BEHAVIORAL|Breathing Control|Controlled Breathing (without mindfulness) is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
48116838|NCT02807467|DRUG|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
48318084|NCT05436899|OTHER|LapSim training|Complete 4 courses, each of 12 weeks, of virtual reality simulation on LapSim surgical simulator.
48318085|NCT05436899|OTHER|LapSim exam|Completed at the beginning and at the end of each of the 4 courses the corresponding exam task.
48318086|NCT03446430|DEVICE|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
48645327|NCT06686888|DIETARY_SUPPLEMENT|microcristalline cellulose|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
48116839|NCT02807467|DRUG|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
48116840|NCT01867216|DRUG|Placebo|Administered orally as capsules
48318087|NCT05672966|BIOLOGICAL|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
48645328|NCT05363215|DRUG|S-217622|Tablet for oral administration
48645329|NCT06056544|BEHAVIORAL|Client Centered Care Coordination|During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
48645330|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
48645331|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
48486183|NCT04259138|BIOLOGICAL|Treatment Algorithm C|"Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."
48486184|NCT05876728|GENETIC|Genotyping|Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.
48645332|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
47966745|NCT05006196|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care."
47966746|NCT05813951|DRUG|Linezolid|linezolid either continues infusion or standard intermittent dose
47966747|NCT02430311|DRUG|Olaparib|Tablet-150mg, Oral
47966748|NCT02430311|DRUG|Paclitaxel|Injection
47966749|NCT02430311|DRUG|Olaparib|Tablet-100mg, Oral
48116841|NCT01867216|DRUG|LY2922470|Administered orally as capsules
48116842|NCT00982098|PROCEDURE|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
48486185|NCT03563846|DRUG|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
48486186|NCT00549016|DEVICE|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
48486187|NCT02710513|DIETARY_SUPPLEMENT|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
48645333|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
48645334|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
48645335|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
48645336|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.2 Usage|Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.
48116843|NCT01256736|DRUG|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
48116844|NCT01256736|DRUG|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
48116845|NCT00812526|PROCEDURE|Suction cup application|
48116846|NCT00812526|PROCEDURE|Squatting|
48116847|NCT02083575|DRUG|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
48116848|NCT02083575|DRUG|deferiprone , deferesarox|iron chelator
48318088|NCT05672966|BIOLOGICAL|Placebo|0.5mL, Intramuscular
48318089|NCT02095236|BEHAVIORAL|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
48318090|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
48318091|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
48645337|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
48645338|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
48116849|NCT02242695|DRUG|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
48116850|NCT02242695|DRUG|Canesten vaginal tablets|one vaginal tablet for 7 days
48318092|NCT04892758|DRUG|Formoterol fumarate 10 mcg|Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
48116851|NCT05218733|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive bilateral ultrasound-guided ESPB by the an experienced anesthetist in US regional blocks, with each block 20 mL of bupivacaine 0.25%
48116852|NCT05218733|DRUG|Intra thecal morphine.|General anesthesia using intravenous fentanyl (1µgm/kg) and patients will receive intra thecal morphine with spinal needle 25G, 3 ml containing 300 ug preservative free morphine
48116853|NCT05218733|DRUG|General anesthesia using intravenous fentanyl (1µgm/kg)|Patients will receive general anesthesia using intravenous fentanyl (1µgm/kg)
48318093|NCT04892758|DRUG|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
48318094|NCT04218916|DRUG|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
48318095|NCT04218916|DRUG|Placebo|2 placebo capsules once, three times a day
48486188|NCT04705870|DEVICE|cerebral MRI|"MRI of routine care in the context of MS includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~* SWI EPI 0.6 iso (7 minutes)~The sequences added by the search are:~* SWI non EPI QSM 6 echo (10 minutes)~* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)~* SWI EPI to TR equivalent to SWI non EPI (6 minutes)"
47966750|NCT06534554|BEHAVIORAL|Patient Navigation|A lay patient navigator working will contact patients seen in the UAB ED via phone within \~72 hours following the ED visit. During this initial phone conversation, the navigators will: 1) conduct a baseline assessment to identify barriers to attending an outpatient visit for gout care and to adhering to gout treatment recommendations and 2) determine the level of support and assistance needed by the patient.
47966751|NCT00000489|PROCEDURE|coronary artery bypass|
47966752|NCT02787096|DEVICE|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
47966753|NCT03680105|DRUG|RJX|RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
47966754|NCT03680105|DRUG|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
47966755|NCT05955105|DRUG|ILB-2109|ILB-2109 tablets will be administered by mouth every day in 21-day cycles
48116854|NCT03047746|DEVICE|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
48318096|NCT01009788|DRUG|ABT-888|Capsules taken orally twice a day on days 1-7 of each 28 day cycle
48486189|NCT04251091|OTHER|Treadmill walking|Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets
48486190|NCT04251091|OTHER|Overground Walking|Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
48486191|NCT03380520|DRUG|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
48486192|NCT03380520|DRUG|Placebo|IV nacl 0.9%
47966756|NCT05955105|DRUG|Toripalimab|Toripalimab injection will be administered via IV every 21 days.
47966757|NCT05489744|DRUG|[14C]Afuresertib|Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
47966758|NCT02215512|DRUG|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
48116855|NCT01371968|DRUG|alfentanil|Alfentanil is administered intravenously at the end of surgery.
48116856|NCT00989937|DRUG|Oxytocin|20 IU BID or 40 IU BID
48116857|NCT00989937|DRUG|Placebo|20 IU BID or 40 IU BID
48116858|NCT04992364|OTHER|Burnout and Clinical performances questionnaires|Subjects were given questionnaires to assess burnout score and clinical performances
48116859|NCT00568659|PROCEDURE|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
48116860|NCT03038217|DRUG|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
48116861|NCT03038217|PROCEDURE|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
48116862|NCT03038217|PROCEDURE|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
48116863|NCT03038217|OTHER|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
48318097|NCT01009788|DRUG|temozolomide|capsules taken orally once a day on days 1 through 5 of a 28 day cycle
48318098|NCT05415046|PROCEDURE|Sacral ESPB|Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
48318099|NCT01968954|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
48318100|NCT01968954|OTHER|Placebo|subcutaneous injection, every 2 weeks for 12 months
48318101|NCT02119884|DRUG|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
48318102|NCT02119884|DRUG|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
48486193|NCT02214420|DRUG|Simeprevir|
48486194|NCT02214420|DRUG|Sofosbuvir|
48486195|NCT02214420|DRUG|Ribavirin|
48486196|NCT02778503|OTHER|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
48116864|NCT00094575|PROCEDURE|Endovascular Repair|Endovascular Repair
48116865|NCT00094575|PROCEDURE|Standard Open Repair|Standard Open Repair
48116866|NCT04257136|DRUG|VBI-S|VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.
48116867|NCT02886637|OTHER|None intervention|
48116868|NCT01499771|DRUG|Atorvastatin|80 Mg tablets
48116869|NCT01860820|DEVICE|Geko device|
48116870|NCT04575493|DIETARY_SUPPLEMENT|Crano-cure|Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
48116871|NCT04575493|DRUG|Ciprofloxacin 500 mg|Being a standard drug as antibiotic and will be used in Control group.
48116872|NCT02728765|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
48318103|NCT02444819|DRUG|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
48318104|NCT04673136|DEVICE|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
48318105|NCT04673136|OTHER|Colonoscopy|Standard colonoscopy
48318106|NCT02815176|OTHER|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
48318107|NCT04103398|COMBINATION_PRODUCT|TACE+sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
48318108|NCT04103398|PROCEDURE|TACE|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
48116873|NCT04512651|OTHER|Tibiotarsal Thrust Manipulation|The dancers were positioned in dorsal decubitus position with the heel outside the stretcher. The osteopath positioned in a lateral feint, inflected knees and forearms in the same plane as the participant's leg. With the internal hand slipped the pinky finger on the medial edge of the foot to the talus neck, the other fingers on the dorsum of the foot and the thumbs controlling the first metatarsus. The position of the talus in relation to the tibia was corrected, initially by placing the foot in eversion and then in dorsal flexion. The osteopath left the body weight behind, causing a traction in the joint. The thrust consisted of a impulse of high speed and low amplitude impulse in a caudal direction, closing the elbows20. The technique was performed until the obtainment (achieved) the joint noise only in the restricted foot, and only one service was performed. After one week, a reassessment of the painful sensation after the dance was performed.
48116874|NCT04512651|OTHER|Simulation Tibiotarsal Thrust Manipulation|Simulation of the technique Tibiotarsal Thrust Manipulation, with the participants and the osteopath positioned in the same way as the IG, however there was no reproduction of joint noise.
48116875|NCT03472807|OTHER|Collection of blood sample or saliva|at Inclusion
48116876|NCT03472807|OTHER|Collection of a tumor sample taken before the participation of the patient in study|at Inclusion
48318109|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at morning
48318110|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at night
48318111|NCT06362499|DEVICE|Experimental Group|After the initial assessment, all volunteers will receive a POWERbreathe® classic light resistance device (POWERbreathe®, Nsc, Brazil), to carry out the training, and will be individually guided on how to use it and how to complete the protocol. They will perform a trial session to familiarize themselves with the device that will not be considered for analysis. Every week, volunteers will receive a telephone call from researcher 2, who will not participate in the evaluation, to confirm whether the exercise with the POWERbreathe® will be performed appropriately at the recommended frequency, intensity, and duration and whether there are any questions regarding the protocol. At the end of each week, participants will receive a video call from researcher 2 to adjust the device according to G1's weekly load progression.
48318112|NCT04287101|OTHER|Post-operative PT and OT|Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
48486197|NCT02778503|OTHER|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
48486198|NCT04772391|OTHER|Exercise Sessions|Participant will complete up to 8 exercise sessions
48486199|NCT02978924|DEVICE|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
48486200|NCT05001464|DEVICE|reflectance pulse oximeter|Wearing reflectance pulse oximeter at the same time on the night of PSG examination
48116877|NCT03472807|OTHER|Collection of blood sample if tumor sample is not available|at Inclusion
48116878|NCT02863900|OTHER|cohort of BC of each subtypes|
48116879|NCT05908942|DEVICE|Nerve ablation|radiofrequency and phenol ablation of the genicular nerves will be performed
48116880|NCT02983617|DRUG|Tirabrutinib|Administered orally once daily
48116881|NCT02983617|DRUG|Entospletinib|Administered orally once daily
48116882|NCT02983617|DRUG|Obinutuzumab|Administered intravenously
48116883|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
48116884|NCT01666704|DRUG|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
48116885|NCT01666704|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
48318113|NCT00384826|DRUG|erlotinib|Erlotinib 150 mg/day (until progression)
48645339|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
47966759|NCT04079608|BEHAVIORAL|FLASH curriculum|High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.
47966760|NCT04079608|BEHAVIORAL|Sexual Health Education for Adolescents|Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
48318114|NCT00384826|DRUG|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
48318115|NCT01889654|OTHER|Venous blood sampling|
48318116|NCT04224896|DIAGNOSTIC_TEST|UPPER ENDOSCOPY|UPPER ENDOSCOPY
48318117|NCT03144323|BEHAVIORAL|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
48318118|NCT05471245|DEVICE|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
48318119|NCT00422708|PROCEDURE|Local anesthesia|
48318120|NCT04469374|OTHER|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
48318121|NCT04469374|OTHER|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
48486201|NCT05081336|DRUG|Statin|Statin +/- ezetimib +/- Alirocumab
48318122|NCT00444509|DRUG|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
48318123|NCT00444509|DRUG|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
48318124|NCT05600647|DEVICE|Electromagnetic Field therapy with an exercise program|"1. The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~2. the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
48318125|NCT05600647|OTHER|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
48318126|NCT02099942|DEVICE|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~* as stand-alone intervention~* as a bridge to transcatheter aortic valve replacement (TAVR)~* as a bridge to surgical aortic valve replacement (SAVR)~* as an intraprocedural predilatation prior to TAVR"
48318127|NCT01042613|PROCEDURE|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
48318128|NCT01042613|PROCEDURE|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
48318129|NCT00980980|DRUG|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
48486202|NCT05473819|DRUG|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe \[Tyco Healthcare, tyco.com\] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
48486203|NCT05473819|DRUG|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
48486204|NCT05112419|DRUG|Zibotentan|All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
48486205|NCT01194102|BEHAVIORAL|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
48645340|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
48645341|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
48645342|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 6|Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks.
48645343|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1 Usage|Participants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks.
48116886|NCT06408493|BEHAVIORAL|MYCardio-PEER|MYCardio-PEER participants will attend an 8-weeks intervention program delivered over the social networking application. Bite-sized videos and infographic posters on healthy diet and lifestyle for primary prevention of CVD will be delivered weekly, supplemented by interactive peer-group activities to encourage behavior change.
48318130|NCT06197932|OTHER|Routine exercise and running training|impact of a 4-week running training program on physical performance variables in a control group comprising 15 participants. The control group exclusively underwent running training, and measurements were taken for variables such as the strength of the big toe of both right and left feet using a hip and toe dynamometer (measured in kilograms). Additionally, assessments included vertical jump height and horizontal jump distance (both measured in centimeters), balance using the Y-balance test, and agility via the T-test. All measurements were conducted with standardized equipment, both before and after the training period. se physical performance indicators.
48318131|NCT06197932|OTHER|Big Toe Strengthening Exercise|impact of a 4-week intervention involving toe-strengthening exercises and concurrent running training on 15 participants. Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for three weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
48318132|NCT03521193|DEVICE|patent foramen ovale closure|Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
48318133|NCT03585322|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
48318134|NCT03360539|BEHAVIORAL|Nurse-Family Partnership|
48318135|NCT01367301|DRUG|paclitaxel|Given IV
48318136|NCT01367301|DRUG|carboplatin|Given IV
48486206|NCT01194102|OTHER|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
48486207|NCT01194102|OTHER|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
48486208|NCT04810442|OTHER|Nap|45-minute nap between scanning procedures
48486209|NCT02668822|DRUG|ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)|Medicated vaginal ring
48645344|NCT06543589|DEVICE|High-flow-nasal-cannula|Respiratory support will be provided by devices that deliver a blend of heated and humidified gas mixture of air and oxygen at gas flows exceeding 8 L/ min via binasal cannula.
48645345|NCT05194072|DRUG|SGN-B7H4V|Given into the vein (IV; intravenously)
47966761|NCT04729868|DRUG|Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)|evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
48318137|NCT01367301|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
48486210|NCT02668822|DRUG|Placebo vaginal ring|Placebo vaginal ring
48486211|NCT02668822|DRUG|Ibuprofen|Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
48486212|NCT06330519|DRUG|Dexamethasone sodium phosphate injection|Patients receive 0.8ml of dexamethazone by periodontal ligament injection 30 minutes before the inferior alveolar nerve block
48486213|NCT06330519|OTHER|1,1,1,2 tetrafluoroethane|EndoIce (1,1,1,2 tetrafluoroethane) applied on the buccal, lingual (3 s/surface), and occlusal surfaces (4 s) for a total of 10 s then standard IANB was administered
48486214|NCT06330519|OTHER|intraoral soft tissue cryotherapy|Small ice packs (wrapped in sterile gauze) placed intraorally in the mouth on the vestibular surface of the treated tooth for 5 minutes then standard IANB was administered
48486215|NCT03465436|DRUG|Lasmiditan|100 mg administered orally (PO)
47966762|NCT03132818|OTHER|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
47966763|NCT05497583|OTHER|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
48318138|NCT01367301|RADIATION|brachytherapy|Undergo HDR brachytherapy
48318139|NCT01367301|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48318140|NCT01367301|OTHER|laboratory biomarker analysis|Correlative studies
48318141|NCT05656898|DEVICE|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
48486216|NCT03465436|DRUG|Lasmiditan|400 mg administered PO
48486217|NCT03465436|DRUG|Placebo|Placebo administered for lasmiditan or moxifloxacin
48486218|NCT03465436|DRUG|Moxifloxacin|400 mg moxifloxacin administered PO
48645346|NCT05194072|DRUG|Pembrolizumab|400 mg every 6 weeks, given by IV
48318142|NCT05656898|DEVICE|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
48318143|NCT05656898|DEVICE|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
48318144|NCT02503176|DRUG|KCT-0809 ophthalmic solution|
48318145|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
48318146|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
48318147|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
48318148|NCT00808249|DRUG|Placebo|2 tablets taken twice a day for 28 days
48318149|NCT05963295|DIAGNOSTIC_TEST|toxoplasma igG|Dignosis of toxoplasma
48645347|NCT06672081|PROCEDURE|Early Catheter-Interventional Treatment|Patients will undergo a catheter-interventional treatment within 60 min. after randomization. Fibrinolytic treatment will be prepared parallel to interventional treatment preparations to avoid any delay in its administration if clinically necessary. Catheter-interventional treatment may include any certified devices for the treatment of PE including aspiration thrombectomy, local fibrinolytic therapy, local ultrasound treatment as assistance to local fibrinolysis or any combination of these.Transfemoral venous access routes will be used for any catheter-directed treatment using sheath-sizes as recommended in the IFUs by the respective manufacturers. Sheaths will be withdrawn immediately after catheter-based thrombectomy or after completion of catheter-directed local fibrinolysis, typically 5 to 10 hours after initiation.
48645348|NCT06672081|DRUG|Conventional care|reperfusion treatment
48645349|NCT06687109|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
48645350|NCT06687109|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty
48645351|NCT06689774|BEHAVIORAL|Cognitive-Motivational Feedback|Salvation Army personnel will be trained to offer adult consumers who use tobacco cognitive-motivational feedback about tobacco use via a no-cost, web-based Qualtrics survey that assesses participant knowledge, beliefs, and priorities and provides feedback to promote knowledge of the costs and risks of smoking and knowledge of the costs and benefits of tobacco use treatment options, including Wisconsin Tobacco Quit Line services. The survey is also designed to help participants weigh the importance of the pros and cons of continuing to use tobacco, and the pros and cons of trying to change their tobacco use.
47966764|NCT05497583|OTHER|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
47966765|NCT01211470|DRUG|Daptomycin|Active Comparator: Daptomycin.
47966766|NCT01211470|DRUG|PMX-30063-investigational drug|Experimental: PMX-30063
48116887|NCT01527253|OTHER|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
48318150|NCT03878524|DRUG|Abemaciclib|Given PO
48318151|NCT03878524|DRUG|Abiraterone|Given PO
48318152|NCT03878524|DRUG|Afatinib|Given PO
48116888|NCT03570957|DRUG|MT-2990|MT-2990 solution for injection in vial
48318153|NCT03878524|BIOLOGICAL|Bevacizumab|Given IV
48318154|NCT03878524|DRUG|Bicalutamide|Given PO
48318155|NCT03878524|PROCEDURE|Biospecimen Collection|Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)
48318156|NCT03878524|DRUG|Bortezomib|Given IV
48318157|NCT03878524|DRUG|Cabazitaxel|Given IV
48318158|NCT03878524|DRUG|Cabozantinib|Given PO
48318159|NCT03878524|DRUG|Capecitabine|Given PO
48318160|NCT03878524|DRUG|Carboplatin|Given IV
48318161|NCT03878524|DRUG|Celecoxib|Given PO
48318162|NCT03878524|DRUG|Cobimetinib|Given PO
48318163|NCT03878524|DRUG|Copanlisib|Given IV
48318164|NCT03878524|DRUG|Dabrafenib|Given PO
48318165|NCT03878524|DRUG|Dacomitinib|Given PO
48318166|NCT03878524|DRUG|Darolutamide|Given PO
47966767|NCT02654743|DIETARY_SUPPLEMENT|Sulforaphane|Children with ASD will receive Sulforaphane in this study
48318167|NCT03878524|DRUG|Dasatinib|Given PO
48318168|NCT03878524|DRUG|Doxorubicin|Given IV
48318169|NCT03878524|BIOLOGICAL|Durvalumab|Given IV
48318170|NCT03878524|DRUG|Enasidenib|Given PO
48318171|NCT03878524|DRUG|Entrectinib|Given PO
48318172|NCT03878524|DRUG|Enzalutamide|Given PO
48318173|NCT03878524|DRUG|Erlotinib|Given PO
48318174|NCT03878524|DRUG|Everolimus|Given PO
48318175|NCT03878524|DRUG|Fluorouracil|Given IV
48318176|NCT03878524|DRUG|Idelalisib|Given PO
48318177|NCT03878524|DRUG|Imatinib|Given PO
48318178|NCT03878524|BIOLOGICAL|Ipilimumab|Given IV
48318179|NCT03878524|DRUG|Lenvatinib|Given PO
48318180|NCT03878524|DRUG|Leucovorin|Given IV
48318181|NCT03878524|DRUG|Lorlatinib|Given PO
48318182|NCT03878524|DRUG|Losartan|Given PO
48318183|NCT03878524|DRUG|Nab-paclitaxel|Given IV
48318184|NCT03878524|DRUG|Neratinib|Given PO
48318185|NCT03878524|BIOLOGICAL|Nivolumab|Given IV
48318186|NCT03878524|DRUG|Olaparib|Given PO
48318187|NCT03878524|DRUG|Oxaliplatin|Given IV
48318188|NCT03878524|DRUG|Palbociclib|Given PO
48318189|NCT03878524|DRUG|Panobinostat|Given PO
48318190|NCT03878524|BIOLOGICAL|Pembrolizumab|Given IV
48318191|NCT03878524|BIOLOGICAL|Pertuzumab|Given IV
48318192|NCT03878524|DRUG|Ponatinib|Given PO
48318193|NCT03878524|OTHER|Quality-of-Life Assessment|Ancillary studies
48645352|NCT06689774|BEHAVIORAL|Staff Tobacco Quit Line Referral Implementation Support|Salvation Army personnel will receive training and will be engaged in efforts to plan, evaluate, adapt, and sustain tobacco treatment referral as part of the social services they provide to adult Salvation Army service consumers who use tobacco. Implementation support will take the form of ongoing engagement of an outreach specialist with a team of Salvation Army personnel and consumers who lead Quit Line referral efforts in the Salvation Army.
47966768|NCT04835532|PROCEDURE|guided bone gereration|"guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation."
47966769|NCT04942899|DRUG|letrozole|concurrent capecitabine 500 mg three times daily in combination with letrozole 2.5 mg orally once daily.
48116889|NCT03570957|DRUG|Placebo|Placebo solution for injection in vial
48318194|NCT03878524|DRUG|Regorafenib|Given PO
48318195|NCT03878524|DRUG|Ruxolitinib|Given PO
48318196|NCT03878524|DRUG|Sirolimus|Given PO
48318197|NCT03878524|DRUG|Sorafenib|Given PO
48318198|NCT03878524|DRUG|Sunitinib|Given PO
48318199|NCT03878524|DRUG|Trametinib|Given PO
48318200|NCT03878524|BIOLOGICAL|Trastuzumab Emtansine|Given IV
48318201|NCT03878524|DRUG|Tretinoin|Given PO
48318202|NCT03878524|DRUG|Vemurafenib|Given PO
48318203|NCT03878524|DRUG|Venetoclax|Given PO
48318204|NCT03878524|DRUG|Vismodegib|Given PO
48318205|NCT03878524|DRUG|Vorinostat|Given PO
48318206|NCT05824637|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
48486219|NCT01574664|DEVICE|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
47966770|NCT03220178|DRUG|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
47966771|NCT03220178|DRUG|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
47966772|NCT03220178|DRUG|Anastrozole|1mg per day
47966773|NCT03220178|DRUG|Letrozole|2,5mg/day
47966774|NCT03220178|DRUG|Exemestane|25mg/day
47966775|NCT01318993|DRUG|GSK1605786A|500 milligrams twice daily
48116890|NCT05747495|OTHER|Online training in CPR-AED|"The online training has been designed according to the Catalan Resuscitation Council (CCR) and the European Resuscitation Council (ERC) guidelines. The aim of this training is to provide theoretical and practical knowledge to respond to aid situations (from unconscious people to drowning, both adults and children), as well as the use of the AED.~The contents are available at the link \[https://register.magnore.com/registre-curs-de-reanimacio-cardiopulmonar-dea/\]."
48116891|NCT05264012|PROCEDURE|Neurosurgery|Neurosurgery
48318207|NCT05824637|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
48318208|NCT02176395|DRUG|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
48318209|NCT02176395|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
48318210|NCT02176395|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
48486220|NCT01095679|DRUG|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
48645353|NCT06689774|BEHAVIORAL|Consumer Incentives for Immediate Referral to a Tobacco Quit Line|Salvation Army personnel will offer an incentive to adult consumers who use tobacco to encourage immediate acceptance of a live call with the Wisconsin Tobacco Quit Line. The incentive will be designed by Salvation Army personnel to fit the local context and to be sustainable over time, such as extra access to existing support or resources.
48318211|NCT00014378|DRUG|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
48318212|NCT00734734|BIOLOGICAL|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
48318213|NCT00247182|BEHAVIORAL|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
48318214|NCT00247182|BEHAVIORAL|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
48318215|NCT00247182|BEHAVIORAL|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
48318216|NCT02172079|OTHER|Real mobilization-with-movement (MWM)|
48116892|NCT04996680|DEVICE|Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
48116893|NCT04996680|OTHER|Standardised low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
48116894|NCT04996680|DEVICE|Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
48645354|NCT05516407|DRUG|FEN164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
48318217|NCT02172079|OTHER|Sham mobilization-with-movement (MWM)|
48486221|NCT01095679|DRUG|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
48486222|NCT05406024|DEVICE|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
48486223|NCT00753220|BIOLOGICAL|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells"
48486224|NCT00753220|DRUG|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
48486225|NCT04429529|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
47966776|NCT02871700|BEHAVIORAL|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
47966777|NCT02871700|BEHAVIORAL|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
47966778|NCT02871700|BEHAVIORAL|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
48645355|NCT06680648|PROCEDURE|addition of oxygeninsufflation via working channel of flexible scope|addition of oxygeninsufflation via working channel of flexible scope in order to improve visibility when advancing the flexible scope
48116895|NCT05957653|DRUG|lidocaine and sufentanil|A total of 20ml of 2% lidocaine and 1μg/ml sufentanil was injected into the bladder through the catheter.
48116896|NCT05957653|DRUG|Saline|A total of 20ml normal saline was injected into the bladder through the catheter.
48116897|NCT05228054|PROCEDURE|laser procedure|In modified litothomy position patients with hemorrhoidal deasease will be treated with transcutaneous laser 1940nm 3watt in impulse regimen
48116898|NCT05228054|PROCEDURE|sclerotherapy|In modified litothomy position patients with hemorrhoidal deasease will be treated with sclerotherapy with Aethoxysklerol
48318218|NCT00234572|DRUG|Lanreotide (Autogel formulation)|
48318219|NCT00134225|DEVICE|Muscle Pattern Recognition (MPR)|
48318220|NCT05534204|PROCEDURE|Silk suture|Patients with bilateral impacted lower third molars will have operations for both sides. On one side for primarily closure after operation silk suture will be used.
48645356|NCT06680648|PROCEDURE|no-oxygen insufflation|no-oxygen insufflation added to the flexible scope while advancing it
48645357|NCT06691477|OTHER|No Interventions|No intervention required. Subjects accepted regular medical treatment
48116899|NCT00575523|DRUG|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
48116900|NCT00575523|DRUG|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
48318221|NCT05534204|PROCEDURE|Polyester suture|Patients with bilateral impacted lower third molars will have operations for both side. On one side for primarily closure after operation polyester suture will be used.
48318222|NCT00422409|PROCEDURE|Endoscopic stenting|
48318223|NCT02047630|DRUG|Generic latanoprost|
48318224|NCT02047630|DRUG|Brand-name latanoprost|
48318225|NCT03051087|DRUG|Ganirelix acetate|
48318226|NCT03587480|PROCEDURE|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
48318227|NCT03587480|PROCEDURE|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
48486226|NCT04429529|OTHER|0.9% Saline|Placebo
48486227|NCT00594620|DIETARY_SUPPLEMENT|Flav-ein capsules|Soy/isoflavone supplementation
48486228|NCT00594620|DRUG|Placebo|Placebo
48486229|NCT04576182|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
48318228|NCT04395352|DEVICE|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
48318229|NCT01363713|DRUG|DE-114 ophthalmic solution|
48486230|NCT04576182|BEHAVIORAL|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
47966779|NCT02231944|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
47966780|NCT01478477|DIETARY_SUPPLEMENT|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
47966781|NCT01478477|OTHER|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
48116901|NCT01302236|DRUG|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
48116902|NCT03430414|DIAGNOSTIC_TEST|Transcriptome Analysis|Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
48116903|NCT04804046|DIETARY_SUPPLEMENT|Synbiotic|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with three Bifidobacterium spp. (3x10\^9 CFU) plus three dietary fibers (24 g fiber) daily for six months.
48116904|NCT04804046|OTHER|Digestible Maltodextrin|Eighteen participants with Crohn's disease that are undergoing an ileocecal resection will supplement their normal diet with Maltodextrin daily for six months.
48116905|NCT00731523|DRUG|fingolimod (FTY720)|
48116906|NCT00465192|DRUG|estradiol, 10 mcg|
48116907|NCT00465192|DRUG|estradiol, 25 mcg|
48116908|NCT00465192|DRUG|placebo|
48116909|NCT04320771|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
48116910|NCT04614636|DRUG|FT538|Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
48116911|NCT04614636|DRUG|Cyclophosphamide|Lympho-conditioning Agent
48116912|NCT04614636|DRUG|Fludarabine|Lympho-conditioning Agent
48116913|NCT04614636|DRUG|Daratumumab|Monoclonal Antibody, CD38, Anti-CD38
48116914|NCT04614636|DRUG|Elotuzumab|Monoclonal Antibody
48116915|NCT01043458|DRUG|ABT-126|ABT-126 Low Dose \& ABT-126 High Dose
48116916|NCT01043458|DRUG|Placebo for ABT-126|Matching Placebo for Arms 1 \& 2
48116917|NCT02092519|DEVICE|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
48116918|NCT02092519|DEVICE|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
48116919|NCT02299375|DRUG|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
48486231|NCT00728442|DEVICE|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
48486232|NCT03914235|COMBINATION_PRODUCT|Tumescent Anesthesia|A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.
47966782|NCT01478477|OTHER|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
47966783|NCT01478477|OTHER|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
47966784|NCT01478477|PROCEDURE|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
48116920|NCT02299375|DRUG|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
48116921|NCT02299375|DRUG|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
48116922|NCT05653583|DEVICE|Wrist Device|peripheral nerve stimulation via wrist-worn device
48116923|NCT05653583|DEVICE|Ear Device|peripheral nerve stimulation via ear-worn device
48116924|NCT05653583|DEVICE|Sham Device|Wrist-worn device that does not actually deliver stimulation
48116925|NCT01184664|DRUG|Nicotine Patch|Varenicline + nicotine patch
48116926|NCT01184664|DRUG|Placebo|Varenicline + placebo patch
48116927|NCT01184664|DRUG|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
48116928|NCT04275245|DRUG|Meplazumab for Injection|humanized MAb against CD147
48318230|NCT02207595|DRUG|UCB5857|"* Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
48318231|NCT02207595|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
48318232|NCT01062568|DRUG|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
48486233|NCT03914235|DRUG|Lidocaine|Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).
48486234|NCT03914235|DEVICE|Pneumatic tourniquet|Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.
48486235|NCT03914235|PROCEDURE|Open release of the tendon|Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.
48318233|NCT01062568|DRUG|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
48116929|NCT00432588|DRUG|misoprostol|
48318234|NCT00318903|DRUG|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
48318235|NCT00318903|DRUG|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
48318236|NCT00318903|PROCEDURE|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
48318237|NCT00318903|PROCEDURE|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
48318238|NCT02312076|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
48318239|NCT02178176|BEHAVIORAL|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
47966785|NCT01478477|PROCEDURE|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
48318240|NCT02178176|BEHAVIORAL|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
48486236|NCT05461118|PROCEDURE|Experimental:Treatment group|Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
48486237|NCT00255255|DRUG|Budesonide/Formoterol|
47966786|NCT00629707|OTHER|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
47966787|NCT01346449|BEHAVIORAL|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
47966788|NCT01346449|BEHAVIORAL|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
47966789|NCT01346449|BEHAVIORAL|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
47966790|NCT01346449|BEHAVIORAL|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
47966791|NCT05090007|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
47966792|NCT05090007|OTHER|gut microbiota|gut microbiota
47966793|NCT04580069|PROCEDURE|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
47966794|NCT02957305|DRUG|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
47966795|NCT02957305|DRUG|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
47966796|NCT04578431|DIETARY_SUPPLEMENT|Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)|The intervention is found in light products ingested by millions of people on a daily basis worldwide
47966797|NCT06497621|PROCEDURE|Single step PVS impression|Single-step final impression method for complete denture fabrication using medium body PVS for border molding and wash impression in a single-step (i.e., one insertion of impression tray in mouth).
47966798|NCT06497621|PROCEDURE|Conventional two-step PVS impression|Border molding with heavy-body PVS first, followed by wash impression with light-body PVS
47966799|NCT05706532|DIAGNOSTIC_TEST|active standing|Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
47966800|NCT02590003|DRUG|Carboplatin|
47966801|NCT02590003|DRUG|Nab-paclitaxel|
47966802|NCT02235909|DRUG|Azilsartan Medoxomil Low-dose|
47966803|NCT02235909|DRUG|Losartan|
47966804|NCT02235909|DRUG|Placebo for Azilsartan Medoxomil|
47966805|NCT02235909|DRUG|Placebo for Losartan|
47966806|NCT02235909|DRUG|antihypertension medication - Add-on Therapy|add-on therapy (e.g., a calcium channel blocker, such as amlodipine, a diuretic, such as hydrochlorothiazide, or a beta-blocker such as metoprolol) per PI's clinical judgment.
47966807|NCT02235909|DRUG|Azilsartan Medoxomil Medium-dose|
47966808|NCT02235909|DRUG|Azilsartan Medoxomil High-dose|
47966809|NCT05063604|DRUG|Citalopram|20 mg tablet one or twice daily for 12 weeks
47966810|NCT05063604|BEHAVIORAL|Psychotherapy|One session weekly for 12 weeks
47966811|NCT05860478|DEVICE|Wearable device|The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .
47966812|NCT06062082|PROCEDURE|adrenalectomy|laparoscopic exeresis of the adrenal gland
47966813|NCT00586001|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
48116930|NCT00432588|DRUG|dinoprostone|
48116931|NCT01667796|DIETARY_SUPPLEMENT|Vitamin D3|
48116932|NCT03145649|OTHER|Dietary therapy or insulin injection|
48318241|NCT04158089|BEHAVIORAL|Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)|"Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.)."
48318242|NCT05606679|GENETIC|Analysis combinations of maternal KIR and HLA-C genotypes|Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
48318243|NCT02152670|DRUG|Methylphenidate|
48318244|NCT02152670|DRUG|Alpha Methyl Para Tyrosine (AMPT)|
48318245|NCT02152670|OTHER|[11C]PHNO|
48318246|NCT02152670|OTHER|[11C]raclopride|
48318247|NCT01028833|OTHER|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
48318248|NCT03558555|DRUG|Acetaminophen IV Soln|1000mg of IV acetaminophen
48318249|NCT03558555|DRUG|Oral Acetaminophen|oral acetaminophen 975mg pills
48318250|NCT03558555|DRUG|Placebo Pills|placebo match to acetaminophen
48486238|NCT03252327|OTHER|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
48486239|NCT04399876|COMBINATION_PRODUCT|Microdevice|"Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate"
48645358|NCT04822558|OTHER|Plantar pressure measurement|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
48645359|NCT04822558|OTHER|Gait analysis|Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model
48645360|NCT04822558|PROCEDURE|Ankle and hindfoot reconstruction surgery|Ankle and hindfoot reconstruction surgery
48645361|NCT01034657|DRUG|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
48645362|NCT01034657|DRUG|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
48645363|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Physical Activity|Self-Monitoring of Behavior for Physical Activity: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring the number of steps taken on the prior day relative to their baseline average number of steps.
48645364|NCT05941000|BEHAVIORAL|Action Planning for Physical Activity|Action Planning for Physical Activity: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to walk an extra 1,000 steps relative to their baseline average step count.
48645365|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Mood|Self-Monitoring of Behavior for Mood: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring their mood on the prior day.
48116933|NCT05899452|BEHAVIORAL|Bubble blowing (active)|Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)
48645366|NCT05941000|BEHAVIORAL|Action Planning for Mood|Action Planning for Mood: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to improve their mood.
47966814|NCT03725202|DRUG|Upadacitinib|It will be administered orally.
48116934|NCT05899452|BEHAVIORAL|Video distraction (passive)|Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
48116935|NCT03019614|DRUG|Hydrocortisone|Generic hydrocortisone
48116936|NCT03019614|DRUG|Chronocort|Modified formulation of hydrocortisone
48116937|NCT00484913|PROCEDURE|abdominal hot compress|
48318251|NCT03558555|DRUG|Saline|Intravenous saline
48318252|NCT05109819|RADIATION|Esophagus sparring radiotherapy treatment|A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.
48318253|NCT02341118|GENETIC|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
48318254|NCT03864718|PROCEDURE|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
48318255|NCT04051151|BEHAVIORAL|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
48318256|NCT01919905|DIETARY_SUPPLEMENT|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
48318257|NCT01132677|DEVICE|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
48318258|NCT01132677|DRUG|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
48318259|NCT04387994|OTHER|Blood samples collection|Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.
48318260|NCT04836819|DRUG|Lidocain|IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
48318261|NCT04836819|DRUG|Ketamine|IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
48486240|NCT03827564|DEVICE|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
48486241|NCT00736918|BEHAVIORAL|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
48486242|NCT00736918|OTHER|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
48486243|NCT04445220|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
48486244|NCT05424614|OTHER|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
48486245|NCT03965637|DRUG|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
48486246|NCT02480582|OTHER|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\\kg
48486247|NCT02480582|OTHER|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
48645367|NCT06687408|PROCEDURE|RATS Group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in robotic-assisted thoracic surgery (RATS) approach, which has been already applied to these patients in minimally invasive surgical techniques as part of their regular medical care recently.
47966815|NCT03725202|DRUG|Corticosteroid (CS)|It will be administered orally.
48486248|NCT04463290|OTHER|No intervention, Patients selection based on clinical symptoms and radiological imaging|No intervention
48486249|NCT04293549|DRUG|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
48486250|NCT01852734|PROCEDURE|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
48486251|NCT01852734|PROCEDURE|embolizations|comparison between the two microspheres
48645368|NCT06687408|PROCEDURE|VATS group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in video-assisted thoracic surgery (VATS) approach.
47966816|NCT03725202|OTHER|Placebo|It will be administered orally.
48486252|NCT01319786|OTHER|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
48486253|NCT01319786|OTHER|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
48486254|NCT01704430|DIETARY_SUPPLEMENT|Glutamine|Enteric L-Glutamine
48486255|NCT01704430|DIETARY_SUPPLEMENT|Maltodextrin|Enteric Maltodextrin
48486256|NCT02770105|OTHER|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
48486257|NCT02770105|OTHER|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
48486258|NCT02770105|OTHER|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
48486259|NCT02770105|OTHER|Placebo|Oral administration of 200ml of distilled water
48486260|NCT05339269|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
47966817|NCT02818400|PROCEDURE|composite tissue allotransplantation|
48116938|NCT02410018|DEVICE|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
48645369|NCT02667561|DRUG|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
48645370|NCT02667561|DRUG|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
48645371|NCT02667561|DRUG|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
47966818|NCT05160103|OTHER|Cosmetic Formulations|Topical emulsions containing anti-aging ingredients
47966819|NCT02468674|DRUG|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
48116939|NCT00444600|DRUG|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
48116940|NCT00444600|DRUG|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
47966820|NCT02468674|DRUG|Placebo|"Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
47966821|NCT02393183|DRUG|ASTED|A tablet of ASTED will be taken twice a day
47966822|NCT02393183|DIETARY_SUPPLEMENT|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
47966823|NCT02393183|OTHER|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
47966824|NCT01941667|BEHAVIORAL|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
47966825|NCT01941667|OTHER|Usual Care|Usual care as defined by by the Cardiology Department.
47966826|NCT05176730|BEHAVIORAL|Mindfulness meditation|Similar to the information included in arm/group descriptions
47966827|NCT06075862|PROCEDURE|Decompressive surgery|Decompressive lumbar spinal surgery
47966828|NCT03943147|DRUG|BMS-986165|Specified dose on specified days
47966829|NCT03943147|DRUG|Placebo|Specified dose on specified days
47966830|NCT03943147|DRUG|Mycophenolate Mofetil|Specified dose on specified days
47966831|NCT05939440|OTHER|Proactive Cost of Care (P-COC) intervention|As in Arm description
48318262|NCT04836819|DRUG|Dexmedetomidine|IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
48318263|NCT00900913|DRUG|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
48645372|NCT02667561|DRUG|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
48645373|NCT01093534|DRUG|Placebo|Matching solifenacin placebo tablet
48645374|NCT01093534|DRUG|solifenacin|Tablet for oral administration
48645375|NCT06679530|OTHER|Mindful Music Listening (MML)|Self-guided mindful music listening intervention comprised of 1-hour daily music listening during inpatient hospitalization.
47966832|NCT05939440|OTHER|Usual Care|As in Arm description
47966833|NCT03129165|OTHER|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
47966834|NCT02370745|DRUG|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
48645376|NCT06054802|DEVICE|eCAP|eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
47966835|NCT02370745|DRUG|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
47966836|NCT02370745|DIETARY_SUPPLEMENT|Oral amino acids|Oral amino acids containing 15 g of amino acids
47966837|NCT02370745|DRUG|GIP|This will be co infused with GLP-1 and intravenous amino acids
47966838|NCT02370745|DRUG|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
47966839|NCT00530244|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
48645377|NCT02529956|DRUG|UCB4940|"* Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use"
48645378|NCT02529956|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use"
48645379|NCT03407833|OTHER|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
48645380|NCT03407833|OTHER|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
47966840|NCT00530244|DIETARY_SUPPLEMENT|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
47966841|NCT05449652|OTHER|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
47966842|NCT00517816|DRUG|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
48318264|NCT05353101|DRUG|Cyclosporine 0.05% eye drops|Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
48318265|NCT05353101|DRUG|Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%|Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
48318266|NCT00864422|BEHAVIORAL|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
48318267|NCT00864422|BEHAVIORAL|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
48318268|NCT04412382|DIAGNOSTIC_TEST|NETosis markers|"NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.~Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed."
48318269|NCT01717664|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
48318270|NCT02446353|DRUG|Apetrol ES / Megace|Sequences of administered drugs
48318271|NCT05667792|DEVICE|Microsoft Kinect 360|Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
48318272|NCT05667792|OTHER|Pediatric Rehabilitation|Bobath therapy
48318273|NCT04738825|BEHAVIORAL|Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)|"Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be stepped up to receive PrEP adherence and support services (n=5)."
48318274|NCT05235217|DRUG|Test product (T) 40 mg Hard Gelatin Capsules|Hard Gelatin Capsules products containing 40 mg Esomeprazole
48486261|NCT06107478|OTHER|Self-report questionnaires (only for parents)|"Quantitative part (all investigating centers): When they come to the various timepoints (T0, T1, T2), participants will be asked to fill in self-questionnaires, either electronically or on paper. If they are unable to come to the center at T1 and/or T2, they will be offered the option of completing the self-questionnaires online. These can also be sent by e-mail or postal mail and received by the same means if necessary.~The tools:~* Quality of life: Pediatric Quality of Life Inventory~* Anxiety: Edmonton Symptom Assessment System; Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale~* Depression: Edmonton Symptom Assessment System; PROMIS depression scale~* Parent-child relationship: Ad hoc questionnaire~* Parent-caregiver relationship: Enabling Practices Scale Socio-demographic data on parents and children, data relating to supportive care will be collected at inclusion. Massage habits will be collected at T1 and T2."
48486262|NCT06107478|OTHER|Interview (only for parents)|"Qualitative part (exclusively at CLB):~Participants (parents) in the qualitative part of the study will be asked to complete a self-administered questionnaire on socio-demographic data when they come to the center at T0. Clinical data will also be collected at T0. At T1, an interview will be organized with a researcher dedicated to the study. Qualitative interviews will preferably take place face-to-face, although videoconferencing may be used in certain circumstances."
48486263|NCT06107478|OTHER|Clinical data collection (only concerning Children)|The children's medical data (patients) will be collected in a Case Report Form (CRF; e.g. type of cancer, date of diagnosis, anti-cancer treatments received, symptoms) at T0.
47966843|NCT03273114|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
48318275|NCT05235217|DRUG|Reference product (R) 40 mg Hard Gelatin Capsules|Reference product (R) 40 mg Hard Gelatin Capsules
48116941|NCT00444600|DRUG|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
48318276|NCT02239770|DRUG|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
48645381|NCT03407833|OTHER|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
47966844|NCT03273114|OTHER|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
47966845|NCT03702985|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
47966846|NCT03702985|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
47966847|NCT03702985|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
47966848|NCT03702985|DRUG|Amifostine|400mg/m2 per week
47966849|NCT01251237|DRUG|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
47966850|NCT03699605|OTHER|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
47966851|NCT03699605|OTHER|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
47966852|NCT00067665|OTHER|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
47966853|NCT04475991|DRUG|Maraviroc + Currently used therapy|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
47966854|NCT04475991|PROCEDURE|Curently used therapy for COVID-19 non-critical patients|"Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga"
47966855|NCT04475991|DRUG|Favipiravir + Currently used therapy|"Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)."
47966856|NCT04475991|DRUG|Maraviroc+Favipiravir+CT|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
47966857|NCT03256643|BEHAVIORAL|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
47966858|NCT03256643|BEHAVIORAL|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
48116942|NCT00444600|DRUG|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
48116943|NCT00490802|DRUG|Oxytocin|Intranasal Oxytocin
48116944|NCT00490802|DRUG|Placebo|Placebo Comparator
48116945|NCT01922830|DIETARY_SUPPLEMENT|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
48486264|NCT00970008|OTHER|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
48486265|NCT00970008|OTHER|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
48486266|NCT00970008|OTHER|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
48486267|NCT00970008|OTHER|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
48116946|NCT01922830|DIETARY_SUPPLEMENT|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
48116947|NCT01314352|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
48116948|NCT04970342|DRUG|Placebo (Lactose) Capsule|Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
47966859|NCT03256643|BEHAVIORAL|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
48645382|NCT03407833|OTHER|Excised Liver Tissue Sampling|Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
48645383|NCT04642079|BIOLOGICAL|20vPnC|20-valent pneumococcal conjugate vaccine
48645384|NCT00385489|DRUG|LXR-623|
47966860|NCT06434259|DEVICE|Digi-physical support system|A support system named Evira will be used to provide behavioral treatment.
47966861|NCT01602159|PROCEDURE|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
47966862|NCT01602159|PROCEDURE|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
47966863|NCT03035370|BIOLOGICAL|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
47966864|NCT03035370|BIOLOGICAL|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
47966865|NCT03035370|BIOLOGICAL|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
47966866|NCT03035370|BIOLOGICAL|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
47966867|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
48318277|NCT02239770|DRUG|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
48318278|NCT05100316|OTHER|Screening Platform|Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
48318279|NCT05644379|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
48645385|NCT02549820|DEVICE|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
48645386|NCT06676878|DEVICE|Incremental exercise|A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.
48645387|NCT05106062|DEVICE|on remote monitoring|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
47966868|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
47966869|NCT02502578|DRUG|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
47966870|NCT05817825|BEHAVIORAL|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
47966871|NCT05817825|BEHAVIORAL|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (\>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
48318280|NCT05644379|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
48645388|NCT01903733|DRUG|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
48645389|NCT05966727|DRUG|Cholestyramine Powder|Bile salt chelating resin, used as a lipid-lowering treatment.
48645390|NCT06691828|DRUG|NX-5948|NX-5948 will be given once by IV and then given once by mouth.
47966872|NCT04798664|BEHAVIORAL|Removal of Financial Barriers|Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
47966873|NCT04798664|BEHAVIORAL|Financial Incentives|Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
47966874|NCT04798664|BEHAVIORAL|Mobile Health Application|Episodic future thinking tool to overcome temporal discounting of future
47966875|NCT05902455|PROCEDURE|Punch biopsy|Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
47966876|NCT04510584|DRUG|Atezolizumab|Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
47966877|NCT04510584|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
47966878|NCT04998110|OTHER|Ambulatory Supportive Care|Ambulatory supportive care visits monthly for six months - a monthly visit with an ambulatory palliative care provider educated in kidney disease
47966879|NCT02292797|OTHER|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
47966880|NCT00039130|BIOLOGICAL|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC\>5000/ul courses II-VII
47966881|NCT00039130|BIOLOGICAL|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV \& VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
47966882|NCT00039130|DRUG|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
47966883|NCT00039130|DRUG|cytarabine|1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI
47966884|NCT00039130|DRUG|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
47966885|NCT00039130|DRUG|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
47966886|NCT00039130|DRUG|etoposide|80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI
47966887|NCT00039130|DRUG|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
47966888|NCT00039130|DRUG|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
47966889|NCT00039130|DRUG|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
48318281|NCT01503060|BEHAVIORAL|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
47966890|NCT00039130|DRUG|prednisone|60 mg/sq m PO/day Days 1-7 course I
47966891|NCT00039130|DRUG|vincristine sulfate|2 mg IV push Day 1 courses II-VII
47966892|NCT00039130|DRUG|Allopurinol|300 mg/day PO Days 1-14, course I
47966893|NCT03794297|DRUG|Dabrafenib Mesylate|Given PO
47966894|NCT03794297|OTHER|Quality-of-Life Assessment|Ancillary studies
47966895|NCT03794297|OTHER|Questionnaire Administration|Ancillary studies
47966896|NCT03794297|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
47966897|NCT06404502|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants;~PRISMA has four sessions."
47966898|NCT04081974|OTHER|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
47966899|NCT02197000|DIETARY_SUPPLEMENT|DIM-Avail 100mg|DIM 100 mg\*1 daily for 2 years
47966900|NCT02672865|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
47966901|NCT06506786|OTHER|Garden-fresh Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.
48318282|NCT01503060|BEHAVIORAL|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
47966902|NCT06506786|OTHER|Supermarket Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.
47966903|NCT04694742|OTHER|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
47966904|NCT05337228|DRUG|IN-C006 Peri inj.|IN-C006 peri inj. will be injected continuously for 3 days.
47966905|NCT05337228|DRUG|RPN301|RPN301 will be injected continuously for 3 days.
47966906|NCT04770181|DEVICE|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
47966907|NCT04770181|DEVICE|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
47966908|NCT02159417|OTHER|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~* Knowledge of the disease~* Food~* Physical Activity and care of feet~* The therapeutics"
47966909|NCT03589872|DIAGNOSTIC_TEST|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
47966910|NCT02231008|DRUG|tasimelteon|
47966911|NCT02231008|DRUG|placebo|
47966912|NCT02688478|OTHER|Phthalate|Delivered by inhalation on day 1 of the triad
47966913|NCT02688478|OTHER|Filtered Air|Delivered by inhalation on day 1 of the triad
47966914|NCT02688478|OTHER|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
48645391|NCT02616952|DIETARY_SUPPLEMENT|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
47966915|NCT05061732|DRUG|Rabeprazole|20mg bid
47966916|NCT05061732|DRUG|Bismuth potassium citrate|0.6g bid
47966917|NCT05061732|DRUG|Metronidazole|0.4g qid
47966918|NCT05061732|DRUG|Clarithromycin|0.5g bid
47966919|NCT05061732|DRUG|Levofloxacin|0.5g qd
47966920|NCT05061732|DRUG|Amoxicillin|1g tid
47966921|NCT05061732|DRUG|Metronidazole|0.4g tid
47966922|NCT05061732|DRUG|Doxycycline|0.1g bid
47966923|NCT05061732|DRUG|Tetracycline|0.5g qid
47966924|NCT00592943|DRUG|armodafinil|tablet, taken by mouth, once each study day
47966925|NCT04401085|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
47966926|NCT04401085|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
47966927|NCT01721655|DRUG|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
47966928|NCT01721655|DRUG|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
47966929|NCT03921944|DIAGNOSTIC_TEST|CT scan of the shoulders|studies of both operative and nonoperative shoulders
47966930|NCT02099175|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
47966931|NCT02099175|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
47966932|NCT02099175|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
47966933|NCT02099175|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
47966934|NCT02099175|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
47966935|NCT02099175|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
47966936|NCT02099175|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
47966937|NCT02099175|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
48318283|NCT01503060|DRUG|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
48645392|NCT02616952|BEHAVIORAL|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
48645393|NCT05444088|DRUG|Adebrelimab|intravenous infusion
48645394|NCT05444088|DRUG|Bevacizumab|intravenous infusion
48645395|NCT05444088|DRUG|SHR-8068|intravenous infusion
48645396|NCT01789502|DEVICE|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
48318284|NCT01503060|DRUG|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
48645397|NCT01789502|DEVICE|Plastic stents|Plastic stents were inserted by ERCP
48645398|NCT06190275|BIOLOGICAL|GT201 in combination with PD-1 inhibitors|GT201 in combination with a PD-1 inhibitor for advanced (HNSCC)
48645399|NCT00397046|DRUG|neratinib|HKI-272
48645400|NCT06685770|OTHER|Mini mental state assessment test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
47966938|NCT02099175|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
47966939|NCT02099175|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
47966940|NCT02407860|OTHER|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
47966941|NCT02407860|OTHER|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
48486268|NCT01334684|DRUG|Metformin|Metformin, pills, 850 mg three times a day for three months
48486269|NCT06132633|DEVICE|Neospot vitals measurement|Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
48486270|NCT03394755|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
48486271|NCT02133001|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
48645401|NCT06685770|OTHER|Mini-cog test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
48645402|NCT00272246|PROCEDURE|deep brain stimulation of the internal globus pallidus|
48645403|NCT03004677|BEHAVIORAL|Continuous skin-to-skin contact|Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
48318285|NCT01503060|DRUG|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
48318286|NCT01503060|DRUG|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
48318287|NCT02981277|DRUG|Transcricoid injection|Lignocaine delivery using Transcricoid Injection
48318288|NCT02981277|DRUG|Spray as you go|Lignocaine delivery using Spray as you go method
48486272|NCT02133001|DRUG|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
48645404|NCT03004677|OTHER|Standard Care|Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
47966942|NCT01686529|PROCEDURE|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
48486273|NCT02373670|BEHAVIORAL|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
48645405|NCT02393469|OTHER|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
48645406|NCT02393469|OTHER|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
48645407|NCT00678574|DRUG|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
48645408|NCT06514729|PROCEDURE|Adopting different ventilation modes during the operation|The ventilation side adopts different ventilation modes combined with continuous positive pressure ventilation on the surgical side.
48645409|NCT04908527|BEHAVIORAL|Walking to OR|Patients, after being prepared for the OR, walk to the operating room
48645410|NCT05295953|DEVICE|TBS|Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
48645411|NCT05295953|DEVICE|Sham TMS|Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
48645412|NCT06649110|DRUG|LTP|LTP001
48645413|NCT06649110|DRUG|Placebo|Placebo
48645414|NCT00203242|DRUG|Depacon IV and Depakote ER|
48318289|NCT01362218|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
48645415|NCT03397641|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
48645416|NCT03397641|OTHER|Placebo|Normal Saline
48645417|NCT02115243|DRUG|Ipilimumab|
48645418|NCT06500936|OTHER|SMS|The intervention included two series of SMS messages. First, women of IG received one weekly SMS messages for 2 weeks. Those women that did not register a mammography in SITAM 45 days after the 2nd message, received the second series, consisting of one weekly SMS message over two weeks.
47966943|NCT01686529|DRUG|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
47966944|NCT02560597|PROCEDURE|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
47966945|NCT04003012|DRUG|EMLA|EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
48318290|NCT01362218|DRUG|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
47966946|NCT04003012|DRUG|Lidocaine|lidocaine 1%
47966947|NCT01059084|DRUG|Valacyclovir|1000 mg tid
47966948|NCT01202292|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
48339979|NCT00565019|DRUG|Triamcinolone Acetonide|"* Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~* Doses will range from 60-120 mg depending on extent of the disease.~* Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~* PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: \>10 cm2, dosage 100-120 mg"
48339980|NCT00544804|DRUG|lapatinib ditosylate|
48486274|NCT02373670|BEHAVIORAL|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
48486275|NCT02370914|DEVICE|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
48486276|NCT02370914|BEHAVIORAL|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
48486277|NCT04316130|DEVICE|Uincare Homeplus|Interactive digital healthcare system
48486278|NCT04316130|OTHER|Brochure|Brochure
48486279|NCT00095433|DRUG|rhuFab V2 (ranibizumab)|
48486280|NCT01825135|DEVICE|Neuromuscular electrical stimulation|
48645419|NCT00787800|DEVICE|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
48645420|NCT00787800|DEVICE|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
48645421|NCT06668467|BEHAVIORAL|Mindfulness-based Stress Reduction|An 4-week Mindfulness-based stress reduction training programme
48645422|NCT05169944|DRUG|Magrolimab|Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
48645423|NCT06687395|OTHER|Skill training on different models|Skill training on different models (medium/high fidelity vs. self-made model)
48318291|NCT05005988|BEHAVIORAL|Actions for Empowered Maternal Neonatal Care|"The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting."
48318292|NCT04703322|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
48318293|NCT05779579|DRUG|HS-10517 Dose 1|HS-10517 Dose 1+Ritonavir
48318294|NCT05779579|DRUG|HS-10517 Dose 2|HS-10517 Dose 2+Ritonavir
48318295|NCT05779579|DRUG|HS-10517 Dose 3|HS-10517 Dose 3+Ritonavir
48318296|NCT05779579|DRUG|HS-10517 Dose 4|HS-10517 Dose 4+Ritonavir
48116949|NCT04970342|DRUG|0.75 mg Alprazolam Capsule|Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
48318297|NCT05779579|DRUG|Placebo|Dose level A of placebo
48318298|NCT02200471|DEVICE|VeinViewer|
48318299|NCT04872816|DEVICE|Continuous airway positive pressure|The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
48318300|NCT03766802|BEHAVIORAL|Wearable watch training group.|3 orientation session Watch notifies 3/week for exercise
48318301|NCT03766802|BEHAVIORAL|Mobile application training group.|"3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise."
48318302|NCT03766802|BEHAVIORAL|Supervised exercise training group|3/week training supervised by a physical therapist
48318303|NCT01766882|BEHAVIORAL|Lower sodium intervention|"1. Lower sodium intervention:~1. Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately \>180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~2. Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
48318304|NCT01766882|OTHER|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
48318305|NCT05685667|DEVICE|needless laser injector (Mirajet)|Mirajet injection was performed 2-3 passes until a total of 2cc of diluted PLA/HA solution was completely injected to the one half of the face.
48318306|NCT05685667|DEVICE|needle injection|For traditional method of needle injection, intradermal injection using multi-puncture/micro-papule technique was used. A series of injections at 0.5-1 cm apart was performed on one half of the face so that a total of 2cc of diluted PLA/HA solution was injected.
48318307|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (low dose)|The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.
48318308|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (high dose)|The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.
48318309|NCT06350058|BIOLOGICAL|Placebo|Aluminum hydroxide adjuvant.
48318310|NCT01142609|BEHAVIORAL|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
48116950|NCT04970342|DRUG|Cannabis (6.18% THC / <0.025% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / \<0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
48486281|NCT01825135|DEVICE|sham stimulation|sham stimulation will be applied to the quadriceps
48486282|NCT02357342|DRUG|Sirolimus|intravitreal injection
48486283|NCT02357342|DRUG|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
48318311|NCT00983840|OTHER|Family Eats|8-session web-based program on healthy eating for African American families
48318312|NCT04673617|DRUG|AB-101|NK cell therapy
48318313|NCT04673617|DRUG|Rituximab|Anti-CD20 antibody therapy
48318314|NCT04673617|DRUG|Interleukin-2|Immune cytokine
48318315|NCT04673617|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
48318316|NCT04673617|DRUG|Fludarabine|Lymphodepleting chemotherapy
48318317|NCT04673617|DRUG|Bendamustine|Chemoimmunotherapy
48318318|NCT04381429|DRUG|A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
48318319|NCT04381429|DRUG|F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
48318320|NCT00900172|BIOLOGICAL|bevacizumab|
48318321|NCT00900172|DRUG|carboplatin|
48318322|NCT00900172|DRUG|paclitaxel|
48318323|NCT00900172|GENETIC|gene expression analysis|
48318324|NCT00900172|GENETIC|polymerase chain reaction|
48318325|NCT00900172|GENETIC|polymorphism analysis|
48318326|NCT00900172|OTHER|laboratory biomarker analysis|
48318327|NCT00570752|OTHER|Placebo|
48318328|NCT00570752|DRUG|BMS-582949|
48318329|NCT00570752|DRUG|Atorvastatin|
48318330|NCT00570752|DRUG|Statin|
48318331|NCT00434122|DRUG|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
48318332|NCT00434122|DRUG|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
48318333|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
48318334|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
48318335|NCT03097796|DRUG|PUL-042|PUL-042 Inhalation Solution
48318336|NCT03373552|DIAGNOSTIC_TEST|Platelet function assay|Platelet function assay
48318337|NCT02295735|DEVICE|Mepilex® Border Sacrum and Mepilex® Border Heel|
48318338|NCT05065996|DIAGNOSTIC_TEST|Aortic MRI + 4D flow MRI|Together with routine aortic MRI specific 4D flow MRI sequence will be done.
48645424|NCT03722628|DIAGNOSTIC_TEST|MMP1 genotypes polymorphism|Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
47966949|NCT03268369|RADIATION|MRI of the brain|to eliminate a structural intra-cerebral lesion
48116951|NCT04970342|DRUG|Cannabis (0%/ THC / 0% CBD)|Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
48318339|NCT01895816|DIETARY_SUPPLEMENT|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus \& ZINGIBER OFFICINALE \& Onion \& Ocimum basilicum \& Cinnamomum zelanicum \& Citrullus lanatus \& Citrullus vulgaris \& Daucus carota
48318340|NCT01617187|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
47966950|NCT03268369|RADIATION|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq \[18F\]F-A-85380
48318341|NCT01617187|DRUG|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
48318342|NCT01617187|DRUG|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
48318343|NCT01617187|DRUG|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
47966951|NCT03268369|RADIATION|PET scan [18F]FDG|exam performed after iv injection of 200 MBq \[18F\]FDG
47966952|NCT06505590|DEVICE|Educational content|Patients will have access to educational content on the mobile app Resilience © in the format of articles, videos or podcasts on treatment related symptoms and on validated supportive care interventions. This version is currently public available in France and Belgium at www.resilience.care and is considered the control group (education only).
48318344|NCT01963208|DRUG|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
48318345|NCT01963208|DRUG|Placebo|placebo
48318347|NCT00000150|PROCEDURE|Subfoveal Choroidal Neovascularization Removal|
48318348|NCT04205578|DRUG|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
48318349|NCT04205578|DRUG|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
48318350|NCT02713191|DRUG|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
48318351|NCT02713191|DRUG|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
48318352|NCT02713191|OTHER|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
48318353|NCT02713191|DRUG|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
48318354|NCT02713191|DRUG|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
48318355|NCT03904641|RADIATION|aPDT|For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.
48318356|NCT03904641|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
48318357|NCT00870831|OTHER|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
47966953|NCT06505590|DEVICE|Educational material plus self-management program - self-administered version|Patients will have access to the same mobile app (Resilience ©) with its educational content will be powered with a self-guided fatigue self-management program based on a cognitive behavioral therapy approach.
48318358|NCT02867345|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
48318359|NCT02867345|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
48318360|NCT02867345|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
48318361|NCT03938441|OTHER|Intermittent Fasting|"The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day."
48318362|NCT00649376|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fasting
48318363|NCT00649376|DRUG|Allegra® Tablets 180 mg|180mg, single dose fasting
48318364|NCT03143868|BEHAVIORAL|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
48318365|NCT04259385|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
48318366|NCT04259385|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
48318367|NCT03677817|DRUG|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
48318368|NCT03677817|DRUG|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
48318369|NCT03472235|DEVICE|Microneedle|"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session."
48318370|NCT05194046|DRUG|JP-1366 20mg 1capsule|will be orally administered
48318371|NCT05194046|DRUG|Amoxicillin 500Mg Cap|Amoxicilin 500Mg 2 capsules will be orally administered
48318372|NCT05194046|DRUG|Clarithromycin 500Mg Tab|Amoxicilin 500Mg 1 tablet will be orally administered
48318373|NCT00698789|DRUG|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
48486284|NCT02704234|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
48486285|NCT02704234|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
48486286|NCT03383419|DRUG|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
48486287|NCT05863624|PROCEDURE|Open hernioplasty|Inguinal hernia is operated using open surgery
48486288|NCT05863624|PROCEDURE|TEP hernioplasty|Inguinal hernia is operated using laparoendoscopic technique
48486289|NCT04281394|DEVICE|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
48486290|NCT04281394|OTHER|conventional gait training|even level gait training and range of motion exercises
47966954|NCT06505590|DEVICE|Educational material plus self-management program - guided version with mental health professional|Patients will have access to the same mobile app (Resilience ©) with its educational content and the self-management program of arm 2 and weekly calls with a certified mental health professional certified in cognitive behavioural therapy for guided coaching across the self-management program.
47966955|NCT01670240|DRUG|Adalimumab|
47966956|NCT01670240|DRUG|Placebo|
48318374|NCT00698789|DRUG|INCB019602|20 mg in AM with placebo administration in PM
47966957|NCT02900196|OTHER|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
47966958|NCT02900196|OTHER|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
48318375|NCT00698789|DRUG|INCB019602|5 mg in PM with placebo administration in AM
48486291|NCT00210899|DRUG|ceftobiprole medocaril|
48486292|NCT00210899|DRUG|Vancomycin plus Ceftazidime|
48486293|NCT04638439|DRUG|P1101 + Nivolumab + Entecavir|"P1101 (Ropeginterferon alfa-2b) 450 µg subcutaneously (SC) Q2W for 6 doses (12 weeks) \*, followed by 0.3 mg/kg Nivolumab for 6 doses (12 weeks) \*\*, with a follow up of 24 weeks. All patients will also receive Entecavir 0.5 mg QD from Day 1 to Follow-up 24.~\*: HBsAg will be checked at treatment week 12 (or 16, if applicable).~\*\*: Only patients with \> 0.5 log10 decline in HBsAg at treatment week 12 or 16 will be sequentially treated with Anti-PD1."
47966959|NCT00006237|BIOLOGICAL|interleukin-2|Given IV
47966960|NCT00006237|BIOLOGICAL|filgrastim|Given subcutaneously
47966961|NCT00006237|BIOLOGICAL|interferon alfa|Given IV and subcutaneously
47966962|NCT00006237|DRUG|cisplatin|Given IV
48318376|NCT00698789|DRUG|INCB019602|20 mg in PM with placebo administration in AM
48318377|NCT00698789|DRUG|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
48318378|NCT00698789|DRUG|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
48318379|NCT00698789|DRUG|Metformin|Stable dose metformin monotherapy
48318380|NCT00668304|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
48318381|NCT05556642|OTHER|Biospecimen collection|Clinical information and biospecimens will be collected
48318382|NCT05845918|BEHAVIORAL|PRISEM CEP|Participants in PRISEM CEP will undergo assessment and goal setting during the intake process to ensure that the program meets their needs. All participants partake in lifestyle programs in individual or group-based in-person activities that address cognitive, physical, social, and functional independence, education, and well-being goals.
48318383|NCT05845918|BEHAVIORAL|PRISEM Remote|"Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another."
48318384|NCT06227338|DRUG|Indocyanine green|"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."
48318385|NCT02021448|OTHER|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
48318386|NCT02725827|OTHER|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
48318387|NCT02725827|OTHER|Control medium|The usual embryo transfer medium used in the study centres.
48318388|NCT02145923|PROCEDURE|Peripheral blood stem cell mobilisation and collection|
48318389|NCT02145923|DRUG|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
48318390|NCT02145923|DRUG|Bone marrow derived allogeneic MMSCs infusion|
48318391|NCT02145923|PROCEDURE|Autologous peripheral blood stem cells infusion|
47966963|NCT00006237|DRUG|dacarbazine|Given IV
47966964|NCT00006237|DRUG|vinblastine|Given IV
48116952|NCT03789955|PROCEDURE|Fluoroscopic-guided TEB|When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
48318392|NCT01969799|DRUG|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
48318393|NCT01969799|DRUG|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
47966965|NCT06557798|DEVICE|Any commercially available transcatheter aortic valve|Redo TAVI will be performed using any commercially available transcatheter aortic valve according to the preferences of the local team in keeping with standard clinical care.
48318394|NCT00199758|DRUG|cisplatin|
48318395|NCT00199758|DRUG|Gemcitabine|
48318396|NCT00199758|DRUG|Taxol|
48318397|NCT01922284|BIOLOGICAL|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
48318398|NCT01922284|BIOLOGICAL|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
48318399|NCT01922284|BIOLOGICAL|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
48318400|NCT01922284|BIOLOGICAL|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
48318401|NCT05415852|DEVICE|Laser|Laser
48318402|NCT01393171|DEVICE|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
48318403|NCT01393171|PROCEDURE|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
48318404|NCT01393171|PROCEDURE|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
48318405|NCT03629418|DRUG|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
48318406|NCT03629418|DRUG|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
48339981|NCT00544804|GENETIC|gene expression analysis|
48339982|NCT00544804|OTHER|diagnostic laboratory biomarker analysis|
48339983|NCT01855113|DEVICE|Invisalign|
47966966|NCT06557798|PROCEDURE|Surgical explantation and aortic valve replacement|Surgical explantation and aortic valve replacement will be performed according to the preferences of the local team in keeping with standard clinical care. Any commercially available approved surgical aortic valve may be used. Additional surgery, such as aortic root replacement, root enlargement, CABG, mitral valve repair/replacement, etc. will be performed at the discretion of the local team.
47966967|NCT06557798|OTHER|Conservative management|Conservative treatment, including optimal medical therapy +/- balloon aortic valvuloplasty
47966968|NCT04382339|DRUG|SOF/RBV/PegINFα-2|SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
47966969|NCT04071561|OTHER|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
47966970|NCT04071561|OTHER|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
47966971|NCT03513328|DRUG|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
47966972|NCT03513328|DRUG|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
47966973|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution_#2|40cc
47966974|NCT05062356|DRUG|EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge|10cc
47966975|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#2|20cc
47966976|NCT05062356|DRUG|Ketorolac|15mg
47966977|NCT05173805|DRUG|YL-15293|After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
47966978|NCT01938456|DRUG|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
47966979|NCT01938456|DRUG|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
47966980|NCT01938456|DRUG|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter\^2 or 75 mcg/body
48645425|NCT06688110|DEVICE|Gixam System|Jubaan's Gixam System is designed to predict the likelihood of colorectal adenomas or SSL by using white light in the 400 to 720 nm range to capture ultra-high-definition images of the of the tongue and analyzing the spectral signature of the oral microbiome to predict the presence of colorectal adenomas or SSL with help of artificial intelligence (AI).
47966981|NCT00941785|DRUG|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
47966982|NCT00941785|DRUG|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
47966983|NCT03886805|OTHER|Dual task with variable- and fixed-priority instructions|The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
47966984|NCT03886805|OTHER|Dual-task with variable-priority instructions|The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
47966985|NCT01486732|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
47966986|NCT01486732|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
47966987|NCT01486732|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
47966988|NCT02837328|DRUG|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
47966989|NCT02837328|DRUG|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
47966990|NCT01421004|DRUG|TKI258|
48116953|NCT03516435|DEVICE|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
47966991|NCT01600638|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
48116954|NCT03516435|DEVICE|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
48339984|NCT04097080|DRUG|NBTX-001|Active drug group will receive 6 doses of NBTX-001 given three times a week.
48645426|NCT00706537|DRUG|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
48645427|NCT00706537|DRUG|Placebo|Placebo as two tablets once daily for three weeks
48318407|NCT04370717|OTHER|telehealth consultation|"A telehealth consultation will be scheduled and conducted without modifications from the routine clinic protocol. The case report will include ICD-10 code and plan of care.~After one week, patients will receive an electronic satisfaction survey. An in-person follow-up and/or procedural visit will be subsequently scheduled. During this visit, the same physician will complete physical examination, document the diagnosis and proceed with either the same or modified plan of care. The research coordinator will enter diagnostic and procedural codes in the case report form."
48318408|NCT04754165|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
48318409|NCT01498237|DEVICE|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
47966992|NCT04963335|BEHAVIORAL|Exergame Training|The individualized exergames were designed for a pressure sensitive plate connected to a personal computer and a frontal screen. The pressure-sensitive plate allows a precise analysis of the user's movements. This concurrent motor-cognitive training aims to improve motor and cognitive functions in an ecological valid setting. The cognitive functions are triggered by specific stimuli in the game scenarios. The video games are controlled via specific (whole body) movements as steps, weight shifting, jumps, and arm movements. The training focus is mainly on multi-tasking, balance and coordination as well as executive functions and attention. Furthermore, the meaningful games (colorful and appealing visuals) were designed to motivate the players to move. As the exergame will automatically adapt (individual progression) during play time, participants are challenged at their individual motor and cognitive level.
48318410|NCT01498237|PROCEDURE|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
48318411|NCT05464862|DRUG|Popliteal Plexus Block with 10 ml|Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
48318412|NCT05464862|DRUG|Popliteal Plexus Block with 20 ml|Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
48318413|NCT05464862|DRUG|Popliteal Plexus Block with 30 ml|Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
48318414|NCT05464862|DRUG|Femoral Nerve Block|Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
48318415|NCT05464862|DRUG|Sciatic Nerve Block|Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
48318416|NCT04614116|OTHER|External cooling|water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.
48486294|NCT01576094|DRUG|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
48486295|NCT01576094|DRUG|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
48486296|NCT00674401|PROCEDURE|Radiofrequency catheter ablation|"* In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
47966993|NCT03715881|DRUG|Oral prednisolone administration 50 mg|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
48318417|NCT04614116|DIAGNOSTIC_TEST|FDG PET/CT|o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.
48318418|NCT04614116|DIAGNOSTIC_TEST|13C-Glucose injection|0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection
48318419|NCT06256783|DRUG|Baozhu Keli|Once enrolled, participants will be administrated Baozhu Keli
48318420|NCT02565771|OTHER|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
48318421|NCT00847938|DRUG|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
48318422|NCT00847938|DRUG|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
48318423|NCT00847938|DRUG|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
48318424|NCT01814683|DRUG|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
48318425|NCT01814683|DRUG|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
48318426|NCT01814683|DRUG|Placebo|14 days placebo.
48318427|NCT02159469|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
48318428|NCT01984879|OTHER|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
48318429|NCT00001940|DRUG|Voriconazole|
48318430|NCT05483621|DRUG|Beta-hCG|Treatment of spermatogenesis
48318431|NCT00669916|BIOLOGICAL|AIN457|single infusion of 3 mg/kg
48318432|NCT00669916|DRUG|Placebo|single infusion of placebo
47966994|NCT03715881|DRUG|Intravenous Erythropoietin injection|1000 units of erythropoietin every 12 hours for three days
48116955|NCT04836806|DRUG|Cetirizine and Famotidine|Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
48116956|NCT04836806|DRUG|Placebo|Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
48116957|NCT05586711|DRUG|vaginal estradiol 10 μg|Vagifem® (estradiol), vaginal tablets
48318433|NCT04305886|OTHER|Discussion Guide|Written list of prompts to facilitate discussion
48116958|NCT05586711|DRUG|vaginal DHEA 6.5 mg|Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries
48318434|NCT03425942|BEHAVIORAL|Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)|This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.
48318435|NCT03425942|BEHAVIORAL|Internet Applied Relaxation Techniques (IART-i)|This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
48318436|NCT05902819|BEHAVIORAL|Imagery|Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
48318437|NCT05902819|DRUG|Minocycline|Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
48318438|NCT05902819|DRUG|Placebo|Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
48318439|NCT05040789|BIOLOGICAL|CoVLP formulation|"The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline)."
48318440|NCT06473493|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
48318441|NCT01426399|DRUG|LC15-0444|LC15-0444 50mg qd (8 days once daily)
48318442|NCT01426399|DRUG|Metformin|Metformin 1000 mg bid (8 days twice daily)
48318443|NCT01426399|DRUG|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
48318444|NCT02260466|OTHER|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
48318445|NCT04515043|DRUG|INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.|blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
48318446|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
48318447|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
48318448|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
48318449|NCT03360136|BEHAVIORAL|Multi-professional CBT-rehabilitation|"See Detailed description"
48318450|NCT05722795|DRUG|Imatinib 400 MG Oral Tablet|One tablet daily 10 days before surgery.
48645428|NCT06689163|DRUG|HRS-1167 tablets|HRS-1167 tablets
47966995|NCT01434030|BEHAVIORAL|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
47966996|NCT03773692|BEHAVIORAL|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
47966997|NCT01316796|DRUG|Sodium Nitrite Cream|
47966998|NCT03856892|OTHER|High Dose Yoga|"Participants engage in an intensive full yoga practice of hatha breath-based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices. The high dose of yoga is an interpretation of the Translational Model of Yoga (TMY) and Yoga Process formula, both developed in this study's cultural research: a systematized psycho-physical yoga method of Hatha Zone (HZ) focus (below-navel, exhale, inner focus), incorporating key components of practice-focus-surrender (PFS) approach and repeat-engage-trust (RET) elements."
47966999|NCT03856892|OTHER|Medium Dose Yoga|"The medium dose of yoga is a regular practice of primarily body-posture training with minimal reference to the breath, but with a longer period of time duration in training prior to intervention commencement. Participants have 5 months of pre-training before initiating the intervention."
47967000|NCT05075122|BIOLOGICAL|UV1|UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
47967001|NCT05075122|DRUG|Sargramostim for Injection|75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
48116959|NCT02517450|BEHAVIORAL|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
48116960|NCT02517450|OTHER|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
48318451|NCT03926767|OTHER|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
48318452|NCT03926767|OTHER|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
48318453|NCT03926767|OTHER|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
48339985|NCT04097080|DRUG|Standard of Care|Placebo group will receive reconstituted air given three times a week.
48339986|NCT02478918|OTHER|Phone call|Automated phone call reminder
48486297|NCT03223948|DEVICE|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
48645429|NCT06689163|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
48645430|NCT06689163|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
48645431|NCT04275869|OTHER|Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
48486298|NCT01862393|DEVICE|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
48486299|NCT01862393|DEVICE|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
48486300|NCT01862393|DEVICE|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
48645432|NCT01978015|DRUG|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
48645433|NCT01978015|DRUG|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
48645434|NCT01978015|DRUG|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
48645435|NCT01978015|DRUG|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
48318454|NCT03926767|OTHER|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
48318455|NCT02619318|BEHAVIORAL|Balancing Everyday Life (BEL)|
48318456|NCT02619318|BEHAVIORAL|Care as usual (generally standard occupational therapy)|
48318457|NCT02056535|BEHAVIORAL|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
47967002|NCT05075122|DRUG|Pembrolizumab injection|200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
47967003|NCT02584816|BIOLOGICAL|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
47967004|NCT02584816|BIOLOGICAL|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
47967005|NCT02584816|BIOLOGICAL|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
47967006|NCT02584816|BIOLOGICAL|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
47967007|NCT02261155|PROCEDURE|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
47967008|NCT00113620|DRUG|Neurodex|
47967009|NCT04103658|RADIATION|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
47967010|NCT01227759|DRUG|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
47967011|NCT01227759|DRUG|Placebo|Placebo containing no active ingredient
48318458|NCT01259973|DRUG|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
48318459|NCT01259973|DRUG|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
48318460|NCT01259973|DRUG|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
48318461|NCT01313806|DEVICE|Resonator|Treatment group vs. Placebo group
48318462|NCT01313806|DEVICE|Placebo|Inactive Resonator Device
48318463|NCT02670460|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
48318464|NCT03298152|PROCEDURE|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
48318465|NCT03298152|PROCEDURE|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
48318466|NCT04284020|BEHAVIORAL|Therapeutic educational program|See arm/group descriptions
48318467|NCT04284020|OTHER|PFMT|See arm/group descriptions
48318468|NCT04284020|OTHER|TTNS|See arm/group descriptions
48318469|NCT02951390|OTHER|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
47967012|NCT05841485|DIAGNOSTIC_TEST|Assessment of coronary microvascular dysfunction using intracoronary pressure-temperature wire|The primary assessment method in this study is the measurement of coronary microvascular dysfunction using a pressure-temperature wire to determine coronary flow reserve (CFR) and index of microvascular resistance (IMR).
47967013|NCT03474770|DRUG|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
47967014|NCT05471791|DEVICE|Back2Play App|This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
47967015|NCT03228927|OTHER|comparison of twin A to twin B|Comparison of Twin A to Twin B
47967016|NCT01987297|DRUG|ATRA+Arsenic|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients."
47967017|NCT01987297|DRUG|ATRA+Chemo|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients."
47967018|NCT01986283|DRUG|Capsule|Taken once
48318470|NCT01303380|DRUG|Canakinumab|
48486301|NCT03024047|DEVICE|Pacemaker|
48116961|NCT00160914|BEHAVIORAL|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
48318471|NCT04651725|OTHER|Exercises|Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
48318472|NCT04627298|BEHAVIORAL|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
48318473|NCT01040208|DRUG|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
48318474|NCT01040208|DRUG|flibanserin 100 mg qhs|100mg qhs
48486302|NCT03297372|DEVICE|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
48486303|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
48486304|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
48486305|NCT04669717|DRUG|1/d 500 mg Azithromycine Pfizer for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
48486306|NCT02609412|OTHER|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
48486307|NCT02609412|OTHER|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
48486308|NCT02609412|DEVICE|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
48486309|NCT02645344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
48486310|NCT02645344|BEHAVIORAL|Sensory Cueing (SC)|
48486311|NCT02645344|BEHAVIORAL|Conventional Rehabilitation|
48486312|NCT00949689|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
48486313|NCT05861635|DRUG|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
48486314|NCT03392675|BEHAVIORAL|Self-monitoring of BF and intervention|"Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support."
48486315|NCT00898534|DEVICE|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
48486316|NCT04332016|OTHER|biological samples collection|collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
48486317|NCT02790034|DRUG|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
47967019|NCT01986283|DRUG|PF-00345439|40 mg capsule swallowed whole, taken once
47967020|NCT01986283|DRUG|PF-00345439|40 mg capsule chewed, taken once
48318475|NCT01040208|DRUG|placebo 2 tablets qhs|50 mg placebo
48486318|NCT02790034|DRUG|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients
48486319|NCT02790034|DRUG|Placebo|Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
48486320|NCT01475253|DRUG|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
47967021|NCT01986283|DRUG|oxycodone|40 mg solution, taken once
48116962|NCT06092697|OTHER|3D printed PEEK restorations|Indirect dental restoration
48318476|NCT00987012|DIETARY_SUPPLEMENT|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
48318477|NCT00987012|DIETARY_SUPPLEMENT|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
48318478|NCT03447613|PROCEDURE|surgery|All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
48318479|NCT06129396|OTHER|Aerobic exercise|The aerobic exercise consists of: (1) 5 min warm-up exercise, (2) 20 min aerobic exercise with HR at target zone (one research assistant will be onsite to monitor whether the HR is around the range of moderate intensity), and (3) 5 min cool-down exercise.
48318480|NCT06129396|OTHER|Video-watching|The video-watching group will be asked to watch a nature documentary for 30 mins
48318481|NCT00733382|DRUG|dexamethazone|injection form, 8 miligram, injected once
48486321|NCT01475253|OTHER|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
48486322|NCT01475253|PROCEDURE|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
48486323|NCT06490003|DRUG|Fluoro Uracil|Esophageal cancer chemotherapy（First line treatment)
48486324|NCT05405231|BEHAVIORAL|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
48486325|NCT05405231|BEHAVIORAL|Passive Implementation|The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
48645436|NCT04588558|DEVICE|Flywheel exercise|Flywheel training is a strength training modality that offers the possibility of performing exercises with eccentric overload and variable resistance as compared to conventional gravity-based resistance training. Flywheel exercise applied three days a week for 8 weeks
47967022|NCT05636059|OTHER|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
47967023|NCT05636059|OTHER|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
47967024|NCT05636059|OTHER|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
47967025|NCT01044628|DEVICE|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be \>90%
47967026|NCT01044628|DEVICE|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
47967027|NCT06505564|BEHAVIORAL|AVATAR therapy|In the initial phase of treatment, patients collaborate with therapists to visualize the source of their auditory hallucinations. Therapists adjust their voice to match the hallucinations, prompting patients to recall key statements for future sessions. Subsequent sessions involve dialogues with a computerized avatar. Using the altered voice, therapists interact in real-time through the avatar, engaging patients in role-playing. They alternate between the avatar and supportive therapist roles to empower patients with positive affirmations and discussions. Sessions last approximately 50 minutes, utilizing Oculus Rift VR headsets and noise-cancelling headphones to enhance immersion. HEKA VR software adjusts avatar proximity, and patients have the option to record dialogues for home use and sharing. Therapists receive bi-weekly supervision from HEKA VR-trained colleagues. Participants continue their regular medication prescribed by their psychiatrists alongside this experimental therapy
47967028|NCT01781143|DEVICE|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
47967029|NCT01416064|DRUG|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
47967030|NCT04112784|DEVICE|INVSENSOR00039|Noninvasive pulse oximeter sensor
48486326|NCT00065013|BEHAVIORAL|strength training|
48486327|NCT02306057|PROCEDURE|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
48486328|NCT02306057|PROCEDURE|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
48486329|NCT02306057|PROCEDURE|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
48486330|NCT02306057|PROCEDURE|TCPC|Surgical procedure Total CavoPulmonary Connection
48486331|NCT00614809|DRUG|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
48486332|NCT00962988|DRUG|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
48486333|NCT00962988|OTHER|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
48486334|NCT01368627|DEVICE|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
48645437|NCT04588558|OTHER|Home exercise|The active ROM exercise was performed via knee in extension to full-flexion, then knee in flexion to full-extension exercises, repeated 10 times. The strengthening exercises consisted of quadriceps strengthening by holding maximal isometric contractions for 10 s and performing 10 repetitions. Stretching targeted the gastrocnemius- soleus and hamstring muscle and was performed by asking the patient to stretch the muscle for 30 s and to complete three repetitions for each muscle group.
48318482|NCT05015205|OTHER|Muscle Energy Technique|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The muscle was positioned in position and patient was asked to apply 20% force isometrically and hold the isometric contractions for 7-10 seconds. Then the patient was asked to relax for about seconds. On exhalation, therapist takes muscle to new restriction barrier. Hold this position for 30 seconds at the end barrier as an end-stretch with 3 repetitions.
48318483|NCT05015205|OTHER|Postural Correction Exercises|: Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. Hip flexors and back extensors were stretched while hip extensors and abdominals were strengthened. Seated hip flexion used to stretch back extensors while lunge position used to stretch hip flexors. The abdominals were strengthened by using curl up exercises while hip extensors were strengthened by resisted contractions in prone lying.
47967031|NCT05561699|DRUG|Penpulimab Combined With CRT|"1. Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~2. Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~3. PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~4. Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 \~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions."
48318484|NCT06389188|PROCEDURE|RHB Group|The RHB-group were treated with passive manual therapy (P-MT) by soft tissue mobilization, massage and muscular stretching of the anterior and posterior cervical muscles; active therapeutic exercises (A-TE); and oculo-cervical exercises (OC-E). Patients received a total of 20 sessions of 30 minutes each during 4 weeks
48318485|NCT01671722|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
47967032|NCT05557981|BEHAVIORAL|Coaching|A novel coaching curriculum based in positive psychology with an emphasis on self-reflection, goal setting and adverse event processing.
48116963|NCT06441786|BEHAVIORAL|A metacognitive group therapy of depression and anxiety in youth with autism|"The treatment model is based on Adrian Wells' transdiagnostic A-M-C model and treatment structure described in Wells (2009) Metacognitive therapy for anxiety and depression. The group treatment is delivered in 10 weekly sessions."
48116964|NCT00393848|DRUG|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
48116965|NCT00393848|DRUG|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
48318486|NCT01869166|BIOLOGICAL|CART-EGFR|
48318487|NCT01635634|OTHER|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
48318488|NCT00352755|PROCEDURE|Surgical debulking with peritonectomy|
48318489|NCT00352755|DRUG|Intraperitoneal 5FU|
48318490|NCT00352755|DRUG|FOLFOX|
48318491|NCT01953328|DRUG|Atorvastatin|Administered orally once a day
48318492|NCT01953328|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
48318493|NCT01953328|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
48318494|NCT03348111|DEVICE|Air-polishing device|Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
48318495|NCT01930812|PROCEDURE|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
48318496|NCT01930812|PROCEDURE|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
48318497|NCT01930812|DRUG|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
48318498|NCT06473285|DRUG|Drug: Esketamine (Continuous infusion)|Continuous intravenous infusion of ketamine at a dose of 0.3mg/(kg · h). Collect resting state EEG and auditory event-related potential (ERP) before administration (baseline), 60 minutes after administration, 30 and 60 minutes after discontinuation.
48318499|NCT01691872|DRUG|Retigabine|Retigabine
48318500|NCT00127530|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
48318501|NCT00127530|DRUG|Placebo|sugar pill, twice a day (b.i.d.)
48318502|NCT01714817|BIOLOGICAL|BMS-188667|
48318503|NCT01714817|DRUG|Mycophenolate mofetil|
48486335|NCT06027541|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, GnRHa, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
48318504|NCT01714817|DRUG|Prednisone|
48318505|NCT01714817|BIOLOGICAL|Placebo matching with BMS-188667|
48318506|NCT01255891|RADIATION|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
48318507|NCT00052884|BIOLOGICAL|filgrastim|
48318508|NCT00052884|DRUG|amifostine trihydrate|
48645438|NCT04588558|DEVICE|Electrotherapy group|"The participants in the electrotherapy group received TENS (Intellect; Chattanooga Group, Hixson, TN), therapeutic ultrasound (Intellect 340 Combo) and exercise. TENS was applied via four electrodes around the knee joint: two on the medial and two on the lateral aspect on either side of the joint line for approximately 20 min. For pain relief, the devices were set to a continuous mode (110 Hz, 50 μ). Electrical pulses were asymmetric and biphasic.~Therapeutic pulsed ultrasound therapy was administered using a 1-MHz frequency, 0.8 W/cm power ultrasound device with a sound-head area of 5 cm2 and effective radiating area of 3.5-5 cm2 . Ultrasound was applied to the medial and lateral parts of the knee in circular movements for a duration of 5 min with the patient in a supine position.~All participants received the same standardized exercise program. The exercises included aerobic, active ROM, strength, and stretching exercises"
48645439|NCT04223687|OTHER|Sugar-Sweetened Beverage Warning Label|Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.
48318509|NCT00052884|DRUG|melphalan|
48318510|NCT00052884|PROCEDURE|bone marrow ablation with stem cell support|
48645440|NCT04223687|OTHER|Neutral label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
48318511|NCT00052884|PROCEDURE|peripheral blood stem cell transplantation|
48318512|NCT05124795|DRUG|IMU-935|IMU-935 capsules
48318513|NCT00074724|PROCEDURE|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
48318514|NCT00074724|DRUG|Modern medical management|Therapies with evidence-based recommendations.
48318515|NCT00074724|DEVICE|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
48318516|NCT00074724|DRUG|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
48318517|NCT00835107|DRUG|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
48318518|NCT00835107|DRUG|placebo|placebo comparator, oral capsules, BID, for one month
48318519|NCT03771612|DRUG|Naproxen|Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
48318520|NCT03771612|DRUG|Placebos|Half of the participants will be randomly assigned to receive a placebo pill twice daily
48318521|NCT00306774|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
48318522|NCT00306774|DIETARY_SUPPLEMENT|Placebo|Placebo capsule per day for 2 years
48318523|NCT06396663|OTHER|Rapid Opioid de-escalation|"Option 1: 10% - 50% decrease/day until opioids discontinued (≤ 10 days). For Fentanyl patches in decrements of 12 mcg/hr.~Option 2: Stop all opioid medication completely"
48318524|NCT06396663|OTHER|Gradual Opioid de-escalation|Option 1: 20% - 50% decrease/weekly until opioids discontinued Option 2: 10% - 20% decrease/weekly until 30 mg daily. Then reduce by 5% - 10% everyday.
48318525|NCT06396663|OTHER|Continuation of opioids|Continue on opioids and review in 1 weeks time.
48318526|NCT01999855|OTHER|Phoniatric tests|
48318527|NCT00002434|DRUG|Trimetrexate glucuronate|
48318528|NCT00002434|DRUG|Leucovorin calcium|
48318529|NCT01674244|BEHAVIORAL|Integrative Exercise|
48318530|NCT01674244|BEHAVIORAL|Monitor Only Waitlist|
48318531|NCT05397223|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
48116966|NCT00393848|DRUG|Placebo|Placebo for Ketoconazole
48318532|NCT05397223|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
48318533|NCT05397223|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
48318534|NCT05397223|BIOLOGICAL|FLUAD®|adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine
48318535|NCT05397223|BIOLOGICAL|mRNA-1647|Sterile lyophilized product
48318536|NCT05598294|PROCEDURE|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
48318537|NCT05570045|DIETARY_SUPPLEMENT|Colos Gain|"Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
48318538|NCT05166759|DEVICE|Doppler ultrasound|Pulmonary artery pressure and right heart function will be assessed using Doppler ultrasound
48645441|NCT04794478|DEVICE|Dexcom Continuous Glucose Monitoring System|Dexcom Continuous Glucose Monitoring System
48645442|NCT01028560|BIOLOGICAL|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
48318539|NCT05915234|DEVICE|Crushed ice|Each participant will receive two active devices and one sham comparator in a crossover design.The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of crushed ice. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
48645443|NCT01028560|OTHER|Standard of care|standard of care asthma and allergy treatment
48318540|NCT05915234|DEVICE|Frozen peas|Each participant will receive two active devices and one sham comparator in a crossover design. The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of frozen peas. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
48486336|NCT03218891|BEHAVIORAL|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~* 5 minutes warm up~* 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~* 10 minutes of localized exercises;~* 5 minutes of relaxation."
48486337|NCT02769884|DEVICE|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
48486338|NCT05512520|COMBINATION_PRODUCT|Intensity-modulated radiotherapy concurrent with capecitabine|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
48486339|NCT03631082|OTHER|Slump stretching|Slump stretching will be provided to this group along with standardized exercises.
48486340|NCT03631082|OTHER|Lumbar mobilization|Lumbar mobilizations will be provided to this group along with standardized exercises.
48486341|NCT06051084|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
48486342|NCT06051084|BEHAVIORAL|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
48486343|NCT04529330|PROCEDURE|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
48486344|NCT05845294|PROCEDURE|Routine Care|Routine care for patients undergoing colorectal cancer stoma
48486345|NCT05845294|PROCEDURE|Short-term structured psychological Care|Short-term structured psychological care for colorectal cancer stoma patients based on conventional care
48486346|NCT00121160|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
48645444|NCT03139253|DRUG|amoxicillin|amoxicillin 1000 mg bid. for 14 days
48645445|NCT03139253|DRUG|clarithromycin|clarithromycin 500 mg bid. for 14 days.
48645446|NCT03139253|DRUG|tinidazole|tinidazole 500 mg bid. for 14 days.
48645447|NCT03139253|DRUG|levofloxacin|levofloxacin 500 mg qd. for 14 days.
48645448|NCT03139253|DRUG|furazolidone|furazolidone 100 mg bid. for 14 days.
48645449|NCT03139253|DRUG|tetracycline|tetracycline 750 mg bid. for 14 days.
48645450|NCT03139253|DRUG|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
48645451|NCT02481141|DRUG|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
48645452|NCT02481141|DRUG|Placebo|
48116967|NCT00915239|DRUG|Pantoprazole|40 mg pantoprazole once daily for 28 days
48116968|NCT00915239|DRUG|Placebo|identical placebo once daily for 28 days
48645453|NCT06688864|BEHAVIORAL|EPIO App|Participants will receive access to the app-based cognitive-behavioral pain self-management intervention program (EPIO) for 3 months.
48116969|NCT01060514|DRUG|Pazopanib|dose escalation, administered orally, daily
48116970|NCT01060514|DRUG|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
48116971|NCT02162446|DRUG|satoreotide trizoxetan|
48116972|NCT04153058|PROCEDURE|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
48318541|NCT05915234|DEVICE|Room temperature gel|Each participant will receive two active devices and one sham comparator in a crossover design. The sham comparator device used consists of an opaque bag with an external plastic cover and an aluminum interior filled with 80 grams of ultrasound gel at room temperature. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed.
48318542|NCT02730442|DRUG|F901318|Administration of F901318 intravenously
48318543|NCT02730442|DRUG|Fluconazole|Oral administration
48318544|NCT01021852|DRUG|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
48318545|NCT01021852|DRUG|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
48645454|NCT05812144|OTHER|Remote monitoring program|Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
48645455|NCT00808756|DIETARY_SUPPLEMENT|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
48645456|NCT00808756|OTHER|Standard infant formula.|Standard infant formula.
48645457|NCT06687889|OTHER|Elastography Measurements|Elastography Measurements
48645458|NCT06687889|OTHER|Bone Mineral Density Measurement (DEXA)|Bone Mineral Density Measurement (DEXA)
48318546|NCT03326154|OTHER|No intervention, observational|Observation
48318547|NCT04727502|DRUG|Duloxetine|duloxetine
48318548|NCT04727502|DRUG|Pregablin|Pregablin
48318549|NCT00325286|DRUG|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
48645459|NCT06687889|OTHER|Berg balance scale|Berg balance scale
48645460|NCT06687889|OTHER|Functional reach test|Functional reach test
48318550|NCT05782179|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to alhydrogel as an adjuvant
48318551|NCT05782179|BIOLOGICAL|Placebo|Normal Saline 0.9 %
48318552|NCT00702156|DRUG|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
48116973|NCT04153058|PROCEDURE|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
48116974|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
48318553|NCT00702156|DRUG|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
48318554|NCT01892319|DRUG|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
48318555|NCT01892319|DRUG|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
48645461|NCT06687889|OTHER|Timed Up and Go Test|Timed Up and Go Test
48645462|NCT06687135|OTHER|KOKU|"KOKU is a digital strength and balance programme designed to prevent physical decline and frailty KOKU provides access to personalised, progressive strength and balance exercises.~More information can be found at: https://kokuhealth.com/"
48645463|NCT06687135|OTHER|FaME / OTAGO leaflet and AGE UK Stay Steady Leaflet|"A leaflet with information on a combination of strength and balance exercises and walking programs, performed on a weekly basis by older adults at home, or community settings. The exercises can be done individually or in a group setting and are aimed at reducing falls in older adults.~More information can be found at: https://fameexercise.com/ and https://www.livestronger.org.nz/assets/Uploads/acc1162-otago-exercise-manual.pdf https://www.ageuk.org.uk/information-advice/health-wellbeing/exercise/staying-steady-download-page/#:\~:text=This%20guide%20outlines%20things%20you%20can"
48645464|NCT06688695|BEHAVIORAL|Neurodevelopmental support|The Intervention for Neurodevelopmental Support in Preterm Infants using Responsive parenting and E-health (INSPIRE) aims to support the infant's neurodevelopment by supporting the parents to develop a responsive approach. The intervention will enhance the infant's social and environmental interactions, focusing on developing both the infant's and parent's strengths, seeking opportunities instead of problems in behaviour, enhancing mutually satisfying interaction and parental empowerment.
48116975|NCT02539108|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
48116976|NCT00149864|DRUG|Mycophenolate sodium (enteric coated)|
48116977|NCT03799783|DRUG|dexmedetomidine|To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
48116978|NCT03110965|BEHAVIORAL|Yoga poses|Patients are asked to perform one or two yoga poses daily for 4-10 months
48116979|NCT01294033|OTHER|Fractional inspired oxygen (FiO2) 0.21|
48318556|NCT06502444|BEHAVIORAL|Moving Forward Together Activity Intervention|The activity intervention program consists of videos and handouts to encourage participants to access these materials if they wish to increase their physical activity. The program lasts 8 weeks. Participants may access program materials for an additional four weeks after the program ends
48318557|NCT02278640|DEVICE|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
47967033|NCT05495490|PROCEDURE|Osseodensification Internal Sinus Lift|"The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing."
48318558|NCT05973006|BIOLOGICAL|NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine|Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
48318559|NCT05973006|BIOLOGICAL|Prototype/XBB.1.5 Bivalent Vaccine (5 µg)|A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
48318560|NCT02326207|DEVICE|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
48318561|NCT03677895|DRUG|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
48318562|NCT02999568|OTHER|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
48318563|NCT03103906|OTHER|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
48116980|NCT01294033|OTHER|Fractional inspired oxygen 0.28|Supplemental oxygen
48318564|NCT03103906|OTHER|Cleanser (Reference Product)|Moisturizing facial cleanser
48318565|NCT03103906|OTHER|Sunscreen (Reference Product)|SPF 50 sunscreen
48318566|NCT03721185|COMBINATION_PRODUCT|Dr.K. Treatment|Overweight and obesity treatment response
48318567|NCT05624775|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will cook and engage virtually (with video and sound on) from their home kitchens via the digital platform. Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($20 per class = $100 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions. Recipes will provide enough food for a family of four. clinic patients
47967034|NCT05495490|PROCEDURE|Osteotome Internal Sinus Lift|"The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure."
47967035|NCT06111300|DRUG|Dexmedetomidine|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
48116981|NCT00636207|DRUG|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
48116982|NCT00636207|DRUG|Placebo|Placebo dry powder inhaler
48116983|NCT01576952|DRUG|ISV-303|Bromfenac in DuraSite
48116984|NCT01576952|OTHER|DuraSite Vehicle|DuraSite Vehicle
48116985|NCT03093467|BEHAVIORAL|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
48318568|NCT03147339|OTHER|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
48318569|NCT06359743|PROCEDURE|Quadratus Lamborum versus superior hypogatric|Ultrasound Guided Quadratus Lumborum Block versus Laparoscopic Superior Hypogastric Plexus Block for Postoperative Analgesia after Laparoscopic Hysterectomy
48318570|NCT02343276|DRUG|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
48318571|NCT02343276|OTHER|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
48116986|NCT03093467|DRUG|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
48116987|NCT03093467|BEHAVIORAL|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
48116988|NCT03849495|DRUG|CKD-370|Test drug
48116989|NCT03849495|DRUG|D745|Reference drug
48116990|NCT02950948|DRUG|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
48116991|NCT02950948|DRUG|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
48645465|NCT00569998|DEVICE|NovoPen™ 4|
47967036|NCT01409330|DIETARY_SUPPLEMENT|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
47967037|NCT04339439|DEVICE|Vessel loop (FDA product code FZZ)|The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
47967038|NCT03913312|BIOLOGICAL|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC\>1.5\*107/kg;HLA 4-5/6
47967039|NCT00750997|DRUG|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
47967040|NCT05310461|PROCEDURE|Transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
47967041|NCT05310461|PROCEDURE|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention|Deferred transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
47967042|NCT04091594|DEVICE|Flexible orthotic|Participants will receive the SIAFO to wear
47967043|NCT04091594|DEVICE|Standard orthotic|Participants will received the standard AFO to wear
47967044|NCT02313792|DRUG|Palifermin|
47967045|NCT03324308|DIAGNOSTIC_TEST|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
47967046|NCT01497158|OTHER|Self-help brochure|Self help brochure given at baseline visit.
48318572|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
48486347|NCT03353623|DEVICE|Serious Game|"Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination."
48486348|NCT03353623|OTHER|Conventional Therapy|Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
48486349|NCT02225665|GENETIC|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
48486350|NCT02225665|GENETIC|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
48486351|NCT02225665|DRUG|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
48486352|NCT01269281|DRUG|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
48645466|NCT00569998|DEVICE|NovoPen® 3|
48645467|NCT05678127|PROCEDURE|Skin biopsy|"Two 3mm skin biopsies from the abdominal wall will be taken. One at the triggerpoint of the pain, the second one at the contralateral, non-affected side of the abdominal wall.~Lidocaine will be used for local anaesthesia of the skin, before the biopsies will be taken."
48645468|NCT05758142|DIETARY_SUPPLEMENT|Potassium Chloride|Oral administration of potassium chloride tablets
48645469|NCT05758142|OTHER|Placebo|Oral administration of inert placebo tablets
48645470|NCT02120248|OTHER|Telephone-based breastfeeding peer counseling|
48645471|NCT01433861|PROCEDURE|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
48645472|NCT06151665|PROCEDURE|single file rotary|Kedo-S plus file is the fifth generation of pediatric files will be used in pulpectomy of primary molars
48645473|NCT06151665|PROCEDURE|Conventional Manual K files|Stainless-steel K files is the golden standard files used in pulpectomy of primary molars
47967047|NCT01497158|OTHER|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
47967048|NCT02195583|DRUG|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
47967049|NCT02195583|DRUG|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
48318573|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
48318574|NCT00348582|DRUG|Ketorolac, Nepafenac|
48318575|NCT00469404|DRUG|Buprenorphine|
48645474|NCT02284854|DRUG|BIA 2-093|
47967050|NCT02195583|DRUG|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
47967051|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
47967052|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
48645475|NCT02284854|DRUG|Carbamazepine|
48645476|NCT02922712|DRUG|NISE|Nise 200mg Max per day in 2 divided doses
48645477|NCT00055887|DRUG|carboplatin|
48645478|NCT00055887|DRUG|cisplatin|
48645479|NCT00055887|DRUG|efaproxiral|
48645480|NCT00055887|DRUG|gemcitabine hydrochloride|
48645481|NCT00055887|DRUG|paclitaxel|
48645482|NCT00055887|DRUG|vinorelbine ditartrate|
47967053|NCT02195583|DRUG|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
47967054|NCT00509015|DRUG|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S\&25mg P/20 kg, 1 day, single dose
47967055|NCT00509015|DRUG|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
47967056|NCT00509015|DRUG|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
47967057|NCT00509015|DRUG|placebo tablets|3 days of lactose tablets (160mg) albochin
47967058|NCT05999032|BEHAVIORAL|CASE in person version (High Intensity Package)|Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
47967059|NCT05999032|BEHAVIORAL|CASE-V remote version (Low Intensity Package)|CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).
47967060|NCT05999032|BEHAVIORAL|CASE and HARP in person (High Intensity package)|"Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit."
48318576|NCT03829865|DIAGNOSTIC_TEST|High resolution esophageal manometry|High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
47967061|NCT05999032|BEHAVIORAL|CASE-V and HARP-V remote version (Low Intensity package)|"HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals."
48318577|NCT03405493|BEHAVIORAL|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
48318578|NCT03405493|BEHAVIORAL|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
48318579|NCT00101491|BEHAVIORAL|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
47967062|NCT00598988|PROCEDURE|traditional Chinese acupuncture|10 treatments over 6 weeks
47967063|NCT00598988|OTHER|standard medical care|standard care as provided by primary physician
47967064|NCT01172431|DRUG|Indapamide|Indapamide SR 1.5mg qd
47967065|NCT01172431|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
47967066|NCT04244682|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|In the rTMS procedure a small plastic coil will be placed next to the participant's head. The position of the coil will be guided by neuro-navigational software utilizing the individual's MRI scan. The coil will be placed over the relevant brain region using the Brainsight TMS-MRI co-registration system for visualizing the coil position with respect to the participant's individual MRI scan. The coil will then generate a series of repetitive magnetic pulses, and stimulation will occur, disrupting typical function of the targeted brain region.
48116992|NCT06238869|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|CCBT (Computerized Cognitive Behavioral Therapy) is a unique approach to improving mental well-being. It utilizes computer-based cognitive and behavioral techniques to induce relaxation and regulate emotional responses by targeting specific brain regions. CCBT offers interactive and personalized interventions, empowering individuals to address mental health challenges like depression and anxiety. Its convenience and accessibility through digital platforms make it a practical choice for enhancing emotional well-being.
48318580|NCT00799344|DEVICE|Catania Stent|coronary stent implantation
48645483|NCT00055887|PROCEDURE|radiation therapy|
48645484|NCT04543253|OTHER|MUSE biofeedback|biofeedback through a headband
47967067|NCT06278701|OTHER|late-evening snacks|have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
47967068|NCT04329897|BEHAVIORAL|Software Messaging|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
47967069|NCT01796561|DIETARY_SUPPLEMENT|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
47967070|NCT00000329|DRUG|Opioid-Related Disorders|
47967071|NCT01394432|PROCEDURE|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
47967072|NCT00969917|DRUG|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
47967073|NCT02094677|DEVICE|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
48645485|NCT06690021|DRUG|Dexmedetomidine|Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine
47967074|NCT02094677|DEVICE|etafilcon A|Participants were randomized to wear etafilcon A control lens.
47967075|NCT02094677|DEVICE|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
47967076|NCT06084234|DIAGNOSTIC_TEST|GALAD|GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
47967077|NCT06084234|DIAGNOSTIC_TEST|Liver Ultrasound with or without AFP|This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
47967078|NCT06504784|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|10g/day of dietary fibre mixture - a mixture of oligo-and polysaccharides
47967079|NCT06504784|OTHER|Placebo|10g/day of placebo (glucose)
47967080|NCT03478332|DRUG|Yangxinshi pill|0.6g/tablet
48645486|NCT00338611|BEHAVIORAL|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
48645487|NCT00338611|BEHAVIORAL|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
48645488|NCT00338611|BEHAVIORAL|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
48645489|NCT00338611|BEHAVIORAL|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
47967081|NCT03478332|DRUG|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
47967082|NCT03478332|DRUG|Placebos|Yangxinshi simulant
48645490|NCT05381597|DRUG|Combination cream of 5-fluorouracil and calcipotriene|Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
48645491|NCT05381597|DRUG|5-fluorouracil cream|Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
47967083|NCT06247020|DIETARY_SUPPLEMENT|Supplementation with sodium- butyrrate|Oral supplementation with sodium butyrrate capsules
47967084|NCT06247020|DIETARY_SUPPLEMENT|Placebo|Oral supplementation with placebo capsules
47967085|NCT06193057|PROCEDURE|Total ankle arthroplasty|Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
47967086|NCT03384238|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
47967087|NCT03384238|BIOLOGICAL|Panitumumab|Given IV
47967088|NCT03384238|DRUG|Panitumumab-IRDye800|Given IV
48116993|NCT06238869|BEHAVIORAL|Music Therapy|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
48645492|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
48645493|NCT02920294|DIETARY_SUPPLEMENT|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
48645494|NCT02920294|DIETARY_SUPPLEMENT|Placebo|Acidified dairy drink without ferments
48645495|NCT02496156|BEHAVIORAL|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
48645496|NCT02496156|BEHAVIORAL|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
47967089|NCT01850875|BEHAVIORAL|Eye-Movement-Desensitization-Reprocessing|
47967090|NCT00192569|DRUG|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
47967091|NCT00192569|DRUG|Ribavirin (HIV conifected patients only)|"* genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
47967092|NCT04858243|OTHER|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
47967093|NCT04858243|OTHER|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
48645497|NCT05307094|BEHAVIORAL|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
48645498|NCT06159582|BEHAVIORAL|eSTEP|eSTEP (Electronic Support to Engage with PrEP) is an mHealth intervention to promote engagement on the full PrEP care continuum and is tailored to the unique needs of GBMSM and TW. eSTEP is a mobile app (eSTEP) intervention with interactive components delivered before in-person HIV testing and PrEP initiation visit and interactive components delivered after PrEP is initiated.
47967094|NCT00251485|DRUG|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
47967095|NCT02788812|PROCEDURE|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
47967096|NCT02788812|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
47967097|NCT01714011|DRUG|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
48318581|NCT04257955|BEHAVIORAL|Interview and evaluation of Engagement|(i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
48318582|NCT00330863|DRUG|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
48645499|NCT06159582|BEHAVIORAL|Usual Care|Usual HIV testing and PrEP clinical care
47967098|NCT01714011|DRUG|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
48318583|NCT00330863|DRUG|Risperidone|Target dose is 4 mg/day.
48318584|NCT00330863|DRUG|Olanzapine|Target dose is 15 mg/day.
48318585|NCT00330863|DRUG|Quetiapine|Target dose is 600 mg/day.
47967099|NCT02232165|OTHER|Hypotension avoidance|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP \>= 65 mmHg is not inferior to induced hypertension.
47967100|NCT02232165|OTHER|Induced hypertension|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
47967101|NCT03715530|DEVICE|PAMG-1 immunoassay|The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
47967102|NCT03706079|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
47967103|NCT03706079|OTHER|Placebo|Placebo subcutaneous injection
47967104|NCT02973217|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|
48318586|NCT00330863|DRUG|Ziprasidone|Target dose is 120 mg/day.
48318587|NCT00330863|DRUG|Aripiprazole|Target dose is 20 mg/day.
48318588|NCT00330863|DRUG|Paliperidone|Target dose is 6 mg/day.
48318589|NCT04105244|BEHAVIORAL|Resourcefulness Training©|The intervention includes self-help and help-seeking skills.
47967105|NCT04976660|DRUG|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
48318590|NCT05524740|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
48318591|NCT03532672|OTHER|Acute Fasting|The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
48318592|NCT05941351|PROCEDURE|flap fixation|flap fixation using running or interrupted sutures
48318593|NCT06553430|BEHAVIORAL|aerobics exercises|Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks
48318594|NCT01575405|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
48486353|NCT02406638|OTHER|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
48486354|NCT03307564|DEVICE|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
48486355|NCT01106521|RADIATION|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
48486356|NCT02834806|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
48486357|NCT05616403|OTHER|No intervention|This is an observational study without any intervention
48318595|NCT01575405|DRUG|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
48318596|NCT01575405|DRUG|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
48318597|NCT04102735|DEVICE|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
48318598|NCT04102735|DEVICE|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
48645500|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
48645501|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
47967106|NCT00249756|BEHAVIORAL|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
47967107|NCT00249756|BEHAVIORAL|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
47967108|NCT05279183|DIETARY_SUPPLEMENT|Erythritol|Subject specific dose of erythritol dissolved in 300 mL tap water.
47967109|NCT05279183|DIETARY_SUPPLEMENT|Sucrose|30 g sucrose dissolved in 300 mL tap water.
48645502|NCT05308641|PROCEDURE|standard multimodal pain therapy|standard multimodal pain therapy
48645503|NCT06494436|DEVICE|All Microvention Class III implantable device CE marked|Endovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
48645504|NCT04983238|DRUG|BYON5667 & SYD985|Ocular administration: BYON5667, Intravenous administration: SYD985
48645505|NCT04983238|DRUG|Placebo & SYD985|Ocular administration: Placebo, Intravenous administration: SYD985
48645506|NCT01903720|DRUG|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
48645507|NCT06688591|OTHER|Intervention programme to optimise medication management and prevent MRPs|The intervention is based on a four-step patient empowerment process: 1) the patient understands their role; 2) the patient acquires sufficient knowledge to be able to engage with their healthcare professionals; 3) the patient improves their skills; and 4) there is a facilitating environment (30). Each older adult participant's plan will be unique and consider their preferences, medication literacy and treatment adherence.
48645508|NCT06162468|PROCEDURE|Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel|EUS-PCA using gemcitabine and paclitaxel
48645509|NCT05318378|DIAGNOSTIC_TEST|BIXAM|Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together
48645510|NCT00000726|DRUG|Foscarnet sodium|
48645511|NCT00641212|DRUG|Budesonide|
47967110|NCT05279183|DIETARY_SUPPLEMENT|Sucralose|Subject specific dose of sucralose dissolved in 300 mL tap water.
47967111|NCT03486548|DRUG|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
47967112|NCT03486548|DRUG|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
47967113|NCT03486548|DEVICE|Ultrasound|ultrasound
48645512|NCT00641212|DRUG|Placebo|
48645513|NCT01730573|PROCEDURE|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
48645514|NCT01730573|PROCEDURE|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
48645515|NCT06687343|DIETARY_SUPPLEMENT|EAA Supplement|Dissolved in water and ingested 4 times a day
48645516|NCT06687343|DIETARY_SUPPLEMENT|NEAA Supplement|Dissolved in water and ingested 4 times a day
48645517|NCT06687343|DIETARY_SUPPLEMENT|Maltodextrin Supplement|Dissolved in water and ingested 4 times a day
48645518|NCT06680830|DRUG|NEU-411|NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
48645519|NCT06680830|OTHER|Placebo|Orally-administered matched placebo
48645520|NCT06570109|OTHER|Frailty|defined as weigh loss (\>4.5 kg in one year), exhaustion, slow gait speed (below 20th percentile for sex and height), weakness (handgrip strength below 20th percentile for sex and BMI), and low physical activity (by the Physical Activity Scale for the Elderly). The presence of three or more out of five criteria is defined as frailty while one to two criteria is prefrailty
48645521|NCT05905198|DEVICE|Programming|programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.
47967114|NCT03548259|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma injection
47967115|NCT03548259|PROCEDURE|Platelet-poor plasma|Platelet-poor plasma injection
47967116|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
48645522|NCT06690008|PROCEDURE|Experimental group|SDF application
47967117|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.
47967118|NCT00444912|BIOLOGICAL|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
47967119|NCT05329701|OTHER|Individualized treatment duration strategy|As listed under arm description.
47967120|NCT02221947|DRUG|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
47967121|NCT02221947|DRUG|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
47967122|NCT04068870|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
47967123|NCT01758432|COMBINATION_PRODUCT|PRT064445/Apixaban|
47967124|NCT01758432|COMBINATION_PRODUCT|Placebo/Apixaban|
47967125|NCT01758432|DRUG|Placebo|
47967126|NCT04959422|OTHER|Active scheduling|Active scheduling, tracking and rescheduling, if necessary.
47967127|NCT02052531|DRUG|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
47967128|NCT02052531|OTHER|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
47967129|NCT05981898|DEVICE|OPTIVF dosage|Dosage predicted by Opt-IVf
47967130|NCT05981898|DEVICE|traditional Dosage|Dosage used traditionally by doctors
48318599|NCT03755284|OTHER|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
48645523|NCT06691295|OTHER|Questionnaires|"This study aims to explore transdiagnostic psychological processes (PP) via the administration of self-reported scales and questionnaires, in a population of newly diagnosed FND patients, prior to any therapeutic management.~The main objective is to describe the psychometric properties (scores on tools measuring psychological processes) of NFT patients (presenting the main phenotypes; sensitivo-motor; and seizures and discomfort)."
48645524|NCT05262673|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
48645525|NCT01141868|BEHAVIORAL|Internet Intervention|online treatment for insomnia
48116994|NCT06238869|BEHAVIORAL|Health education|Health education focuses on providing insights into adolescent mental health, offering practical coping strategies and behavior patterns. It emphasizes the crucial link between parental guidance and the well-being of adolescents. By fostering healthier psychological interactions, it cultivates an environment supportive of adolescent mental health, strengthens family support, and promotes comprehensive development in physical, mental, and cognitive aspects.
48116995|NCT05898074|DEVICE|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
47967131|NCT05662631|DEVICE|BioIntellisense BioSticker|"This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis."
48318600|NCT05267912|PROCEDURE|Biopsy|We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
48645526|NCT04112368|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
48645527|NCT04112368|DRUG|Oral Micronized Progesterone 200mg|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
48318601|NCT02425007|DEVICE|Incentive spirometry|
48318602|NCT05912309|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
48318603|NCT05912309|BEHAVIORAL|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
48486358|NCT04038086|DIAGNOSTIC_TEST|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
48645528|NCT04112368|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
48645529|NCT04112368|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
47967132|NCT04289675|DRUG|Interferon-Beta|Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
48645530|NCT03733535|DRUG|Benralizumab|Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
48645531|NCT03733535|DRUG|129 Xenon|1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
48645532|NCT05760612|DRUG|Trastuzumab and nelatinib|Postoperative adjuvant treatment, for about 1 year
48645533|NCT05760612|DRUG|Trastuzumab and Parstuzumab|Postoperative adjuvant treatment, for about 1 year
48645534|NCT03468127|OTHER|Soy foods|Isolated soy protein, soy protein, soybean products, soy milk
48645535|NCT02207101|DIETARY_SUPPLEMENT|E-OJ-01 (OXYJUN)|
48645536|NCT02207101|DIETARY_SUPPLEMENT|Placebo|
48645537|NCT06687759|DRUG|[14C]MK-1084|Oral administration
48318604|NCT05912309|BEHAVIORAL|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
48318605|NCT02513368|DEVICE|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
48318606|NCT02513368|PROCEDURE|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
48318607|NCT02344407|BIOLOGICAL|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
48318608|NCT02344407|BIOLOGICAL|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
48318609|NCT02344407|BIOLOGICAL|Placebo|
48318610|NCT02156492|DRUG|Evacetrapib|Administered orally.
48318611|NCT02156492|DRUG|Simvastatin|Administered orally.
48318612|NCT02156492|DRUG|Atorvastatin|Administered orally.
48318613|NCT02266082|OTHER|No intervention|There is no intervention in this study.
48318614|NCT03520816|OTHER|Burn Physiotherapy Protocol|It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
48318615|NCT05657782|BIOLOGICAL|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
48318616|NCT03768791|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
48318617|NCT03768791|OTHER|SCS is switched on|Spinal cord stimulator is on
47967133|NCT01501175|OTHER|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
47967134|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
47967135|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
48318618|NCT01534234|DEVICE|PARADYM RF SONR|SonR CRT Optimization
48486359|NCT04038086|OTHER|circadian rhythm|Blood and CSF will be collected five times throughout the day.
48486360|NCT04038086|DRUG|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
48645538|NCT03673228|BEHAVIORAL|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
47967136|NCT05587803|DEVICE|Neurowave and Sedline indices in view|3 additional electrodes are attached on the patients forehead. After electrode placement, the indices of both the SEDLINE device and the NEUROWAVE device are noted every 5 seconds for 1 minute
48318619|NCT01534234|DEVICE|PARADYM RF SONR|Echocardiography Optimization
48318620|NCT02723292|BEHAVIORAL|TOP|
48318621|NCT02723292|BEHAVIORAL|Control intervention|
48318622|NCT04026854|BEHAVIORAL|Quality of live at work|The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
48318623|NCT05454202|DEVICE|ANI|Pain measurement during care procedures in palliative care
48318624|NCT05291598|DRUG|IV meloxicam|Participants will be administered meloxicam 30 mg IV push pre-operatively.
48318625|NCT05291598|DRUG|Ketorolac|Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
48486361|NCT04515537|DIETARY_SUPPLEMENT|Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),|Patient use 2 capsules 3 time a day by oral.
48486362|NCT04515537|PROCEDURE|Infiltrtion of SVf|After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
48486363|NCT00389831|DRUG|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
48486364|NCT00389831|OTHER|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
48486365|NCT01589861|DRUG|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
48318626|NCT00003225|DRUG|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
48318627|NCT00003225|DRUG|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
48318628|NCT04208334|DIETARY_SUPPLEMENT|Curcumin|We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.
48318629|NCT04208334|OTHER|Placebo|We give a control arm to consume placebo for 60 consecutive days.
48318630|NCT01345344|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
48318631|NCT01345344|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
48318632|NCT06216938|BIOLOGICAL|Vusolimogene oderparepvec (RP1)|Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.
48318633|NCT01869751|DRUG|Prucalopride|Treatment with prucalopride for slow-transit constipation
48318634|NCT03303040|OTHER|Electrical stimulation of hemidiaphragm|Electrical impulses
48318635|NCT03420326|BEHAVIORAL|Frailty status assessment|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
48318636|NCT00239837|BEHAVIORAL|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
48318637|NCT00881855|DRUG|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
48318638|NCT00881855|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
48318639|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Coated Tablets
48318640|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Coated Tablets
48318641|NCT00032994|BEHAVIORAL|Behavior Therapy|
48318642|NCT04224428|DRUG|Fexofenadine Pill|fexofenadine tablets 60 mg once daily will be taken for six months
47967137|NCT02975336|DRUG|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
48318643|NCT04224428|DRUG|Placebo oral tablet|lactose oral tablet
48318644|NCT03830814|PROCEDURE|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
48486366|NCT01974024|DRUG|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
48486367|NCT06026852|DEVICE|Prediction of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.
48486368|NCT06026852|DIAGNOSTIC_TEST|Determination of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.
47967138|NCT02975336|DRUG|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
48486369|NCT06026852|OTHER|Daily short questionnaire|Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.
48486370|NCT02009748|DIETARY_SUPPLEMENT|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
48486371|NCT02009748|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo (vehicle) once daily
48486372|NCT02546843|DRUG|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
47967139|NCT02975336|DRUG|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
48486373|NCT02546843|DRUG|Cisatracurium|cisatracurium 0.15mg/kg intravenously
47967140|NCT02975336|DRUG|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
47967141|NCT02975336|DRUG|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
48318645|NCT00643591|OTHER|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
48318646|NCT01948141|DRUG|nintedanib|Given PO
48318647|NCT01757613|DRUG|AK 3012|cutaneous use twice a day
48318648|NCT03719326|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist for oral use
48318649|NCT03719326|DRUG|IPI-549|IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
48318650|NCT03719326|DRUG|Pegylated liposomal doxorubicin (PLD)|Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
48318651|NCT03719326|DRUG|nanoparticle albumin-bound paclitaxel (NP)|NP is a microtubule inhibitor for intravenous (IV) use
48318652|NCT04007055|DIAGNOSTIC_TEST|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
48318653|NCT04007055|DRUG|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
48318654|NCT06098196|DRUG|Aminophyllin|Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
48318655|NCT03279302|DRUG|Glepaglutide|Solution for injection
47967142|NCT01939652|PROCEDURE|Restrictive VS Standard Fluid Regime|
47967143|NCT01939652|DRUG|Drag: Crystalloids and Colloids|
47967144|NCT04052347|BEHAVIORAL|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
48645539|NCT03673228|BEHAVIORAL|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
47967145|NCT04052347|BEHAVIORAL|routine shared decision-making|control group
47967146|NCT02014025|PROCEDURE|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
48318656|NCT03095716|OTHER|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
48486374|NCT02546843|DRUG|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
48486375|NCT02546843|DRUG|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
47967147|NCT02014025|PROCEDURE|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
47967148|NCT06505902|OTHER|Exercise|Exercise by bicycle and performing diffusing capacity measurements at the same time with arterial blood gasses.
47967149|NCT02129400|DRUG|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
48645540|NCT03673228|DRUG|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
47967150|NCT02129400|DRUG|Aer medicinalis Linde 100%|
47967151|NCT00534391|DRUG|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
47967152|NCT00534391|DRUG|Artificial tear|4 times daily
48645541|NCT05928208|DIAGNOSTIC_TEST|no intervention|no intervention
48645542|NCT04121871|OTHER|No intervention|Not required
48645543|NCT06417788|DEVICE|Dental implant placement|Dental implant placement guided by Navident® (ClaroNav Inc., Toronto, Canada)
48645544|NCT06417788|PROCEDURE|Static guided implant placement|Dental implant placement guided by a stereolithographic pilot drill guide.
48645545|NCT00059280|BIOLOGICAL|Myozyme|20 mg/kg qow or 40mg/kg qow
48645546|NCT03224377|DIAGNOSTIC_TEST|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
48645547|NCT04628052|PROCEDURE|Colonoscopy|Music vs. No-Music
47967153|NCT02892578|OTHER|electrocardiogram|
47967154|NCT04394260|BEHAVIORAL|Savvy Caregiver Program via Remote Learning|The SCP program is comprised of four pre-recorded Savvy Caregiver videos (each 1 hour and 45 minutes in length). Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
47967155|NCT04394260|BEHAVIORAL|Focus group|After watching the Savvy Caregiver videos participants will take part in a focus group to discuss their experience with the SCP and how the course material applies to them as a LGBT caregiver. The semi-structured discussion will include, but not be limited to the following questions: 1) Can you tell me about your role as a caregiver? (Probes: living situation, experiences, challenges). 2) What went well with the SCP, and what could be improved? 3) How relevant to your situation as an LGBT caregiver were the course materials? 4) How well did the questionnaire reflect your experiences with discrimination due to sexual orientation and/or gender identity? (Probe about when working with your care recipient's health care providers, in-home aides/visiting nurses, adult day care staff, respite, etc? 5) What are some of the additional caregiver challenges that should be considered in these questionnaires? (Probes: mental health, physical health, and social life strain, Quality of life, stress).
47967156|NCT03047915|OTHER|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
48318657|NCT02822911|BEHAVIORAL|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
48318658|NCT02822911|PROCEDURE|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
48486376|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
48486377|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
48486378|NCT02758249|DRUG|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
48486379|NCT02758249|DRUG|propofol|patients are anesthetized by using propofol infusion
48486380|NCT05785689|DRUG|Dexmedetomidine|To reduce postoperative agitation
48486381|NCT05785689|DRUG|Placebo|Placebo bolus saline
48645548|NCT02591407|PROCEDURE|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
48645549|NCT02591407|PROCEDURE|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
48645550|NCT05633771|OTHER|Hyrimoz|There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
48318659|NCT02822911|PROCEDURE|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
48318660|NCT02822911|PROCEDURE|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
48318661|NCT00923234|DRUG|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
48318662|NCT00923234|DRUG|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
48318663|NCT01999166|RADIATION|radiography (X-ray)|
48318664|NCT01999166|GENETIC|DNA sampling|
48318665|NCT03722784|DEVICE|Invigor A (test)|silicone hydrogel lens
48318666|NCT03722784|DEVICE|Invigor B (control)|silicone hydrogel lens
48318667|NCT01170117|DRUG|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
48318668|NCT01170117|DRUG|Placebo|Control Group will receive placebo pill
48318669|NCT04407455|DIAGNOSTIC_TEST|Karaduman Chewing Performance Scale|For chewing evaluation, children will be asked to bite and chew a standardized biscuit. Each chewing evaluation will be scored according to the KCPS.
48318670|NCT05359406|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
48318671|NCT00809458|DRUG|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
48318672|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for control|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
48318673|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for patients|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. Anti-nuclear antibodies test by immunoflourescence for ITP patients.~6. Bone marrow aspiration (for diagnosis of ITP).~7. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
48318674|NCT04030780|DIETARY_SUPPLEMENT|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
48318675|NCT04030780|OTHER|Placebo|similar capsules administered twice daily
48318676|NCT05855928|DIAGNOSTIC_TEST|Mime Therapy|electrical stimulation with the MIME therapy and protocol
48318677|NCT05855928|DIAGNOSTIC_TEST|PNF Technique|electrical stimulation with the PNF technique with the routine physical therapy
48339987|NCT03037567|BEHAVIORAL|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
48486382|NCT03852459|DRUG|S-Ibuprofen|Topical Gel 5%
48486383|NCT03852459|DRUG|Vehicle|Vehicle Gel
48486384|NCT03144817|OTHER|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
48486385|NCT02786719|DRUG|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
48486386|NCT02786719|DRUG|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
48486387|NCT02786719|DRUG|Cisplatin|Cycle 3+5 (given daily x 4 days)
47967157|NCT05452031|BEHAVIORAL|Care2Sleep|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
48486388|NCT02786719|DRUG|Etoposide|Cycle 3+5 (given daily for 3 days)
48486389|NCT02786719|DRUG|Vincristine|Cycle 4+6 (given daily for 3 days)
47967158|NCT05452031|BEHAVIORAL|Sleep Education|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
48339988|NCT04516031|PROCEDURE|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
48486390|NCT02786719|DRUG|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
48486391|NCT02786719|DRUG|Doxorubicin|Cycle 4+6 (given daily for 3 days)
48486392|NCT02786719|DRUG|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
48486393|NCT03421041|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
48486394|NCT03293173|COMBINATION_PRODUCT|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
48486395|NCT03293173|COMBINATION_PRODUCT|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
48486396|NCT05397743|OTHER|Quality of Life|Questionnaire Perceived stress scale (PSS) + Questionnaire Short form 36 (SF-36) + Questionnaire Visual functioning questionnaire 25 (VFQ-25)
48486397|NCT01185028|DRUG|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
48486398|NCT05557903|BIOLOGICAL|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
48318678|NCT01794481|PROCEDURE|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
47967159|NCT06338371|BEHAVIORAL|Pelvic Floor exercise training|The level of sexual function was determined by implementing FSFI for all individuals included in the sample. The participants were divided into two groups, control and training groups, using the randomization program on the computer. Pelvic floor exercise training was given to one group. Trainings were conducted online on different days. Each training lasted 120 minutes. After training was completed, women in the training group were instructed to perform three sets of 8-12 repetitive pelvic floor muscle contractions per day and to use an exercise diary to record their practice. Women in the training group were also given a booklet and the recording of the training video was shared. the training, a brochure explaining how to perform the pelvic floor muscle exercises, which was included in the training content, was prepared and delivered to the training group on the first day of each week. After the training, FSFI was applied to both groups 3 times, in the 1st, 2nd, and 3rd months.
47967160|NCT01448486|DRUG|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
47967161|NCT04444895|DRUG|Lanadelumab|Lanadelumab SC injection
47967162|NCT00875875|DRUG|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
47967163|NCT02784275|DRUG|Cyclo-Z|
48486399|NCT01358552|OTHER|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
48486400|NCT02506608|PROCEDURE|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
47967164|NCT02784275|DRUG|Placebo|
48486401|NCT06027138|OTHER|blood flow resistance training|Muscle size and explosive power was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press ,vertical jump test and timed push ups and pull up tests .secondly treat the arm and thigh muscles to to blood flow resistance training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles.
48486402|NCT06027138|OTHER|slow motion strength training|We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
48486403|NCT02114957|DIETARY_SUPPLEMENT|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
48486404|NCT01930175|DRUG|VAY736|
48486405|NCT01930175|DRUG|Placebo|
47967165|NCT03558854|DRUG|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
48486406|NCT05839535|BEHAVIORAL|BDJ|BDJ is a mind-body intervention
48486407|NCT05839535|DEVICE|tDCS|tDCS is a brain stimulation method.
48486408|NCT05839535|DEVICE|sham tDCS|sham tDCS
48486409|NCT05839535|OTHER|exercise|exercise including stretching and other activities.
48486410|NCT00000813|BIOLOGICAL|ALVAC-HIV gp160MN (vCP125)|
48486411|NCT00000813|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
47967166|NCT03558854|DRUG|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
47967167|NCT04661839|BIOLOGICAL|COVID-HIGIV|COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.
47967168|NCT04661839|OTHER|Placebo (saline)|The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.
48318679|NCT00274157|BEHAVIORAL|Behavior|
48318680|NCT00274157|BEHAVIORAL|diet control, smoking cessation, exercize|
48486412|NCT00000813|BIOLOGICAL|rgp120/HIV-1 SF-2|
48486413|NCT02019082|DEVICE|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
48645551|NCT01539525|BEHAVIORAL|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
48645552|NCT01539525|OTHER|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
48645553|NCT06499909|OTHER|Hypnosis|The patient will receive a course of hypnosis
47967169|NCT02072018|DRUG|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
48318681|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
48318682|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
48318683|NCT00383721|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
48318684|NCT00383721|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
48318685|NCT00383721|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
48318686|NCT00607568|DRUG|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
48318687|NCT02559713|DRUG|Vedolizumab|Vedolizumab IV infusion
48318688|NCT01881971|DRUG|Placebo|suger pill manufactured to mimic crestor pills
48318689|NCT01881971|DRUG|Rouvastatin calcium|
48318690|NCT04600050|OTHER|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
48318691|NCT04600050|OTHER|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
48318692|NCT01951235|DRUG|Imeglimin|
48318693|NCT01951235|DRUG|Placebo|
48318694|NCT00615251|DRUG|DR-2011|Progesterone vaginal ring for approximately 10 weeks
48318695|NCT00615251|DRUG|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
47967170|NCT02072018|DRUG|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
48486414|NCT02019082|DEVICE|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
48486415|NCT01040884|OTHER|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
48318696|NCT00798655|DRUG|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
48318697|NCT00798655|DRUG|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
48318698|NCT00798655|RADIATION|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
48318699|NCT04922619|DEVICE|tonotopy based fitting then default fitting|Cochlear implant with default fitting then tonotopy based fitting
47967171|NCT01617200|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
47967172|NCT01617200|DRUG|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
47967173|NCT01617200|DRUG|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
47967174|NCT01617200|DRUG|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
48318700|NCT04922619|DEVICE|default fitting then tonotopy based fitting|Cochlear implant with tonotopy based fitting then default fitting
48318701|NCT05580471|DEVICE|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
48318702|NCT00126178|BIOLOGICAL|HSPPC-96|
48318703|NCT03416686|DEVICE|Radiofrequency (RF star electrode electrode_Fixed)|"The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed)."
48318704|NCT05049837|OTHER|Group Specific Aim 1|600 cases: two normal and two tumor formalin-fixed tissue samples
48318705|NCT05049837|OTHER|Group Specific Aim 2|600 cases: two normal and two tumor formalin-fixed tissue samples.
48318706|NCT05049837|OTHER|Group Specific Aim 3|600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples
48318707|NCT05049837|OTHER|Group Specific Aim 4|600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples
48318708|NCT05049837|OTHER|Group Specific Aim 5|600 cases; two normal and two tumor formalin-fixed tissue samples
48486416|NCT03393871|DIAGNOSTIC_TEST|absolute blood flow measurement|Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.
48486417|NCT05614206|BEHAVIORAL|Behavioral intervention based on Applied Behavior Analysis principles|"Intervention sessions are conducted by licensed therapists with a training in applied behavior analysis or behavior analysts. One-to-one interventions for 3 h/week are carried out over a period of 5 months.~The intervention focused on two target symptoms, imitation and joint attention, as two of the pivotal skills in early development. Behavior analytic techniques are used, including discrete trial, shaping for positive reinforcement, systematic prompting and fading procedures, and reinforcement procedures, according to the published manual.~Imitation sessions start with imitation recognition and imitation of familiar actions (gestural and object imitation) and end with the imitation of novel actions. Joint attention evolvs from initiating requests (starting with gaze shift with the child looking away from an interesting object to the adult and back) to coordination of gaze shift, vocalization and gestures through reaching, and pointing and showing behaviors."
47967175|NCT05193370|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
47967176|NCT05193370|DRUG|Vasopressin|Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
47967177|NCT01774968|DRUG|Human Regular U-500 Insulin|
47967178|NCT03673852|BEHAVIORAL|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
48318709|NCT05049837|OTHER|Group Specific Aim 6|210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.
48318710|NCT04859478|DIAGNOSTIC_TEST|Dual energy / spectral portal venous chest computed tomography|Each patient undergoes an additional dual energy / spectral chest CT in addition to standard care CTPA. The intervention is performed immediately after standard care CTPA.
48318711|NCT04347226|DRUG|BMS-986253|BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
48318712|NCT06167499|OTHER|Diabetes Therapeutic Education conducted by nurses|"Individual consultations with the therapeutic education IDE, who will help the patient to achieve the therapeutic objectives set before the medical consultation.~Once the objectives have been set, the IDE will set up individual workshops and subsequently assess the patient's learning and its impact on his or her care. These workshops can include equipment demonstrations and practical exercises, explanations of treatment adaptation protocols, and dietary or sexual advice."
48318713|NCT02601066|DEVICE|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
48318714|NCT04903184|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.
48318715|NCT04903184|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo.
48318716|NCT05214781|PROCEDURE|modified radical mastectomy|excision of the whole breast tissue including nipple and skin with axillary clearance
48318717|NCT04550221|BEHAVIORAL|Shauriana|The components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions. The four in-person health education and coaching sessions will be delivered once per week, by trained peer facilitators who identify as GBMSM. These sessions will focus on the following topics: sexual health basics (understanding how HIV and STIs are transmitted, prevented, and diagnosed/treated), relationships (types of relationships we have, characteristics of healthy relationships, communication skills), stress and coping (understanding mental health challenges, adaptive and maladaptive coping strategies), and healthy sexuality and empowerment (understanding sexual orientation and gender identity, challenging stereotypes about GBMSM, making sexual choices).
48318718|NCT05597059|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
48318719|NCT06245044|BEHAVIORAL|No MI Help|Participants will complete the medication verification task without any MI help
48486418|NCT04999033|OTHER|no intervention|This is a cross-sectional study, and no intervention will be included
47967179|NCT03673852|BEHAVIORAL|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
48486419|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
47967180|NCT02523248|PROCEDURE|tonsillectomy|Tonsillectomy with cold steel
47967181|NCT02523248|PROCEDURE|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
47967182|NCT03265769|OTHER|radial access site|radial route
47967183|NCT03265769|OTHER|femoral access site|femoral route
47967184|NCT05262608|DRUG|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
47967185|NCT01443871|OTHER|Aromatherapy|Subject will assigned inhale aromatherapy
47967186|NCT01443871|OTHER|Pure water|Subject will assigned inhale Pure water
47967187|NCT02326532|OTHER|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
47967188|NCT02326532|OTHER|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
47967189|NCT04768595|DIETARY_SUPPLEMENT|Placebo|Two, 1g capsules taken daily with food
47967190|NCT04768595|DIETARY_SUPPLEMENT|Ceto 10|Two, 1g capsules daily with food
48645554|NCT06688630|DEVICE|The laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is the application of a Reimers \& Janssen LaserPen, with a power of 150mW and a wavelength of 810nm, alternating between Nogier frequencies A and C. The dosage is 2 joules per point, with a therapy duration of 26 seconds per point, targeting bilateral acupuncture points BL2, TE23, ST2, LI4, and ST36. The LaserPen is applied without pressing the laser probe onto the body surface.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
48645555|NCT06688630|DEVICE|The sham laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is a procedure using the same device but without activating the laser, so no energy is emitted. Performed at the same points as laser acupuncture therapy.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
47967191|NCT04768595|DIETARY_SUPPLEMENT|Fish oil|Two, 1g capsules daily with food
47967192|NCT03399721|DEVICE|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
47967193|NCT03399721|DEVICE|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
47967194|NCT01278979|DEVICE|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~1. Depth of tear, from the fourchette into the greatest depth of the perineal body.~2. Length of tear, from the fourchette to the apex of the vaginal tear.~3. Length of tear, from the fourchette along perineal skin towards the anus.~4. Length of the perineal body, from the fourchette to outer margin of anus."
47967195|NCT01278979|OTHER|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
47967196|NCT02673138|DRUG|canagliflozin|basal interruption with canagliflozin
47967197|NCT02673138|OTHER|basal interruption without canagliflozin|basal interruption
47967198|NCT05074667|DEVICE|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
47967199|NCT05074667|OTHER|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
47967200|NCT05060471|DRUG|Toripalimab|Four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab.
47967201|NCT05190159|DEVICE|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
48645556|NCT06314152|PROCEDURE|Lightweight mesh fixation in 3 points or 1 point|Lightweight mesh fixation in 3 points
48645557|NCT06690138|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
47967202|NCT02574468|DRUG|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
47967203|NCT02574468|PROCEDURE|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
47967204|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation|"Position the patient on a chair with a backrest and stand behind the patient. Support the patient's arm under the crook of the elbow with the shoulder joint abducted to 90° and medially rotated. The forearm will automatically fall into pronation. Place the thumb of your other hand in the web space between the patient's thumb and index finger and fully flex the patient's wrist and pronate the forearm. Move the hand supporting the crook of the elbow on to the posterior surface of the elbow joint and, while maintaining full Wrist flexion and pronation, extend the patient's elbow until you feel that all the slack Has been taken up in the tendon. Step sideways to stand behind the patient's head, Taking Care to prevent the patient from leaning away either forwards or sideways, which would reduce the tension on the tendon.~Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
47967205|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena|"In addition to Group A mentioned protocols Pain release phenomenon (PRP) was delivered as well. The Pain Release Phenomenon Technique (PRPS) is a technique pioneered by Brian Mulligan for management of Pain. There are different types of Pain release Phenomenon as follows:~1. Stretch PRP: affected muscle is eccentrically contracted.~2. Contraction PRP: affected muscle is concentrically contracted.~3. Compression PRP: affected joint surfaces are compressed together.~4. Distraction PRP: affected joint surfaces are distracted away from each other. The types of PRP are performed along with pertained duration of hold time by the therapist. And always painful PRP technique is chosen for the treatment. In the present study stretch PRP technique was used which provoked pain stimuli and was maintained for 15-20 seconds. Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
47967206|NCT05251571|OTHER|Conventional Exercise Group with Telerehabilitation|Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
47967207|NCT05251571|OTHER|Balance Coordination Group with Telerehabilitation|Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
47967208|NCT05770687|DRUG|SGLT2 inhibitor|Patients started on SGLT2 inhibitors after PCI for AMI
47967209|NCT03483740|BEHAVIORAL|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
47967210|NCT03483740|BEHAVIORAL|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
47967211|NCT02084654|DRUG|Exenatide 5 and 10 mcg 2 times a day|
47967212|NCT02084654|DRUG|placebo|
47967213|NCT04250220|DIAGNOSTIC_TEST|e-Health based strategy: PPG-based screening using a smartphone and ECG patch|PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
47967214|NCT04587232|DIAGNOSTIC_TEST|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
47967215|NCT04587232|DIAGNOSTIC_TEST|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
47967216|NCT04587232|DIAGNOSTIC_TEST|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
47967217|NCT04587232|DIAGNOSTIC_TEST|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
47967218|NCT00486200|DRUG|ASP2151|Oral administration.
48318720|NCT06245044|BEHAVIORAL|Scenario #1|Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.
47967219|NCT00486200|DRUG|valacyclovir|Oral administration of active comparator.
47967220|NCT00486200|DRUG|Placebo|Oral administration of placebo.
47967221|NCT00993083|BIOLOGICAL|MVA-NP+M1|Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
48318721|NCT06245044|BEHAVIORAL|Scenario #2|MI help will be displayed concurrently with the filled and reference images.
48318722|NCT06552715|DEVICE|Placement of resorbable HAp-based composite|The resorbable HAp-based composite device will be immersed in a saline solution for 15 minutes, allowing it to transition from a rigid state to a flexible and deformable one (Fig. 1). Subsequently, the device will be shaped appropriately on the resin model, ensuring proper placement within the bone defect to be regenerated. Patients will receive antibiotic prophylaxis of 1 g amoxicillin, 1 hour before the procedure (or 300 mg clindamycin in case of penicillin allergy). Before the surgical procedure, patients will rinse with 2% chlorhexidine for one minute to reduce the bacterial load in the oral cavity. For the surgical procedure, under local anesthesia with Articaine and Adrenaline 1:100000, mucoperiosteal flaps will be raised. The pre-shaped resorbable device will then be adapted to the defect and fixed with osteosynthesis screws, used according to clinical practice for this type of intervention. Finally, the flaps will be sutured to ensure primary intention closure.
48318723|NCT06093217|DEVICE|Artificial Intelligence|AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist
48486420|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
47967222|NCT03090802|BEHAVIORAL|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
47967223|NCT00558558|DRUG|Haelan|4 oz orally twice daily for 8 Weeks
47967224|NCT03298165|DEVICE|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
48318724|NCT04914741|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
48318725|NCT04914741|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
48318726|NCT04914741|DRUG|Doxorubicin|Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
48318727|NCT04914741|DRUG|Vincristine|Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
48645558|NCT06690138|DRUG|Itraconazole|Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.
48116996|NCT05898074|DEVICE|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
48116997|NCT01211093|PROCEDURE|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
48318728|NCT04914741|DRUG|Prednisolone|Prednisolone 100mg orally on Days 1-5 of every 21-day cycle
48486421|NCT04352608|BIOLOGICAL|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
48645559|NCT06687603|DEVICE|EsoCheck|FDA-approved, non-endoscopic, encapsulated swallowable balloon. EsoCheck will produce a sample which will subsequently be tested with EsoGuard assay. The EsoCheck is performed and completed in approximately 5 minutes.
48645560|NCT06687603|DIAGNOSTIC_TEST|EsoGuard|Approved laboratory, methylated DNA panel that detects esophageal neoplasia. The EsoGuard assay tests the EsoCheck samples to detect BE in GERD participants.
48645561|NCT05722353|OTHER|Biocollection|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
48645562|NCT02934217|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
48645563|NCT02934217|DRUG|Placebo|One single intravenous bolus injection of Placebo
48645564|NCT02934217|PROCEDURE|Echocardiography|3 years after AMI
48645565|NCT06689306|BEHAVIORAL|7E learning model|7E learning model7E learning cycle is a teaching model that encourages students to be active, to think about the findings they obtain, to interpret their findings according to their initial plans and to predict them in new situations. This model provides students with opportunities for discussion and interaction. The model is designed based on constructivist theory. The guiding concept of constructivism is that later learning is greatly influenced by previous knowledge; therefore, learning should be based on the interaction of old and new knowledge. 7E learning cycle model consists of seven steps: Reveal, Participate, Explore, Explain, Elaborate, Evaluate and Extend. According to past studies, 7E model is more effective in developing students than traditional learning models.
48645566|NCT00045331|GENETIC|proteomic profiling|
48645567|NCT06686303|OTHER|High frequency Segmental Vibrator|Segmental vibrations of high frequency was used on each flexor and extensor interspersed with a 1 minute break.
48645568|NCT06686303|OTHER|Combined effects of high frequency segmental vibrator and neuromuscular electrical stimulation.|Segmental vibrations of high frequency with Neuromuscular Electrical Stimulation was given on each flexor and extensor.
48645569|NCT03015779|OTHER|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
48645570|NCT00107614|DRUG|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
48645571|NCT05134519|DRUG|Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)|Regimen: RC48-ADC: 2.0 mg/kg, intravenous drip, once every 2 weeks,4-6 cycles
48645572|NCT00938080|BIOLOGICAL|AG013|Mouth rinse once a day for 14 days
48645573|NCT00938080|BIOLOGICAL|AG013|Mouth rinse three times a day for 14 days
48645574|NCT00938080|BIOLOGICAL|AG013|Mouth rinse six times a day for 14 days
48645575|NCT00938080|OTHER|Placebo|Mouth rinse once a day for 14 days
48645576|NCT00938080|OTHER|Placebo|Mouth rinse three times a day for 14 days
48645577|NCT00938080|OTHER|Placebo|Mouth rinse six times a day for 14 days
48645578|NCT02174445|DRUG|Imatinib|Imatinib, 400 to 800 mg p.o., daily
48645579|NCT02174445|DRUG|Nilotinib|300mg p.o., twice-daily
48645580|NCT05118438|OTHER|Health Promotion Nursing Intervention|A one-on-one program was conducted over six sessions, with each session ranging from 60 to 120 minutes. The caring program for health promotion included the following concepts: understanding the self; sharing traumatic events and negative emotions; re-framing the meaning of traumatic events; identifying thoughts and physical and emotional responses; developing health-promoting activities; and maintaining a positive attitude during the process of change .
48645581|NCT01340534|DEVICE|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
48645582|NCT01340534|PROCEDURE|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
48645583|NCT06057025|BIOLOGICAL|"Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition"|"Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition."
48645584|NCT00461812|DRUG|Mometasone|
48645585|NCT00461812|DRUG|Advair|
48645586|NCT03186378|COMBINATION_PRODUCT|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
48645587|NCT02605967|DRUG|Spartalizumab|Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
48645588|NCT02605967|DRUG|Investigator choice of chemotherapy|Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
48645589|NCT03194529|BIOLOGICAL|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
48645590|NCT05750004|PROCEDURE|computer guided immediate implant placement|Atraumatic extraction followed by immediate implant placement using safe angle position computer guided surgical stents, followed by customized healing abutments. after 3 months, Impressions for final prosthesis will be done
48645591|NCT00495781|PROCEDURE|%-hypo (laboratory parameter, functional iron deficiency)|
48645592|NCT00495781|PROCEDURE|CHr (laboratory parameter, functional iron deficiency)|
48645593|NCT00495781|PROCEDURE|RET-HE (laboratory parameter, functional iron deficiency)|
48645594|NCT01045265|OTHER|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
48645595|NCT06684678|OTHER|individualized automatic coaching message for glycemic management and depressive symptom|For 12 weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on data from continuous glucose monitoring and bi-weekly personalized coaching messages for depression symptoms based on depression questionnaires, instead of non-face-to-face diabetes management.
48116998|NCT01211093|PROCEDURE|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
48116999|NCT01211093|PROCEDURE|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
48318729|NCT04914741|DRUG|Glofitamab|Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm
48318730|NCT04914741|DRUG|Polatuzumab vedotin|Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle
48318731|NCT04512469|DEVICE|Low molecular weight mesh|Following liver implantation, the subcostal incision will be closed using a running fascial closure with absorbable 1-0 Polydioxanone (PDS) suture and staples, with the treatment group also receiving a mesh.
48318732|NCT02473003|BEHAVIORAL|high intensity exercise|high intensity exercise 80-90%
48318733|NCT02473003|BEHAVIORAL|low/medium intensity exercise|low/medium intensity exercise 40-50%
48318734|NCT02473003|BEHAVIORAL|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
48318735|NCT02240537|DRUG|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
48318736|NCT02240537|DRUG|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
48318737|NCT02240537|DRUG|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
48318738|NCT00204334|DRUG|darbopoeitin|
48318739|NCT06259773|DIAGNOSTIC_TEST|knee stability test (DYNEELAX)|Each knee was tested under a force 120 Newtons in a posterior to anterior direction to create anterior tibial translation at 20 degrees knee flexion. Side-to-side difference of anterior/posterior tibial translation (mm) was measured from radiographs. Measurement of rotation and translation by DYNEELAX was also recorded.
48486422|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
48486423|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
48486424|NCT04352608|BIOLOGICAL|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
48645596|NCT03471286|DRUG|Epacadostat|Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
47967225|NCT03026400|PROCEDURE|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
47967226|NCT03026400|PROCEDURE|Subumbilical incision|Considered here as the ''control'' intervention.
48318740|NCT02266758|OTHER|GDM Screening Methods|
48318741|NCT06460636|OTHER|progressive muscle relaxation therapy|Participants will undergo progressive relaxation exercises, including muscle tension and release with deep breathing, held for 5 seconds each. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
48318742|NCT06460636|OTHER|aquatic therapy|participants will receive aquatic therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall.
48318743|NCT06187623|OTHER|Clinic based exercise|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
48318744|NCT06187623|OTHER|Home based exercise|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
48318745|NCT00302718|BEHAVIORAL|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
48486425|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
48486426|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
48486427|NCT04352608|BIOLOGICAL|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
48645597|NCT04392362|DRUG|Adenosine|A vial of adenosine with 6mg
48645598|NCT01907646|DEVICE|bladder training|vescical catheter
48645599|NCT01907646|PROCEDURE|No bladder training|
48645600|NCT01337310|DRUG|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
47967227|NCT05724563|DRUG|Zimberelimab|Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
47967228|NCT05724563|DRUG|Domvanalimab|Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
47967229|NCT04229784|PROCEDURE|Radiofrewuency surgery|The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
47967230|NCT04546061|BEHAVIORAL|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
48318746|NCT00302718|BEHAVIORAL|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
48318747|NCT00302718|BEHAVIORAL|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
48318748|NCT05144243|DRUG|Venetoclax|Tablet: Oral
48318749|NCT05144243|DRUG|Azacitidine|Subcutaneous Injection (SC)
48318750|NCT02612389|OTHER|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
48318751|NCT06020339|OTHER|The midwife-led continuous care model (MLCC)|"Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care."
48318752|NCT04915924|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
48318753|NCT00448760|DRUG|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
48486428|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
48486429|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
48486430|NCT04352608|BIOLOGICAL|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
48486431|NCT00513682|DRUG|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
48486432|NCT00049699|DRUG|laromustine|
48486433|NCT00952549|PROCEDURE|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
48486434|NCT02221037|DRUG|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
48486435|NCT02221037|DRUG|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
48486436|NCT05790954|OTHER|Guided imagery|Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
48486437|NCT00608192|BEHAVIORAL|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
48645601|NCT04565353|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
48645602|NCT06686394|BIOLOGICAL|Patritumab deruxtecan|Patritumab deruxtecan administered via IV infusion
48645603|NCT06686394|BIOLOGICAL|Trastuzumab|Trastuzumab deruxtecan administered via IV infusion
47967231|NCT05270343|DRUG|Cholecalciferol (Vit D3) 400Unit Cap|Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
47967232|NCT03303365|RADIATION|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
47967233|NCT04395443|OTHER|medication reconciliation|the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
47967234|NCT02848040|OTHER|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
47967235|NCT06284746|DRUG|Tirolizumab+SOX/XELOX|Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
48318754|NCT00448760|DRUG|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
48318755|NCT00448760|DRUG|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
48318756|NCT00448760|DRUG|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
47967236|NCT06284746|DRUG|SOX/XELOX|Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
47967237|NCT05329610|DIETARY_SUPPLEMENT|Beta-alanine|Slow-release beta-alanine.
48318757|NCT00448760|GENETIC|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
48318758|NCT00448760|GENETIC|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
48318759|NCT00448760|PROCEDURE|Conventional surgery|Surgical removal of tumor for correlative studies
47967238|NCT05329610|DIETARY_SUPPLEMENT|Placebo|Taste and appearance-matched placebo (tapioca starch).
47967239|NCT02337660|PROCEDURE|Liver biopsy|One ultrasound guided liver biopsy
48318760|NCT05732844|DEVICE|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
48318761|NCT05732844|OTHER|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
47967240|NCT02337660|OTHER|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
47967241|NCT00545662|DRUG|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
47967242|NCT00545662|DRUG|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
47967243|NCT00488462|DEVICE|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
47967244|NCT06091267|DRUG|IV Decitabine|The subjects will receive decitabine 20 mg/m\^2 IV daily × 5 days in 28-day cycles.
48318762|NCT01361919|PROCEDURE|Feedback During CPR Training and Testing|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool."
48318763|NCT01361919|PROCEDURE|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
48486438|NCT00608192|BEHAVIORAL|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
48645604|NCT06686394|BIOLOGICAL|Trastuzumab Biosimilar|Trastuzumab biosimilar administered via IV infusion
48645605|NCT06686394|BIOLOGICAL|Pertuzumab|Pertuzumab administered via IV infusion
47967245|NCT06091267|DRUG|Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles.
47967246|NCT06091267|DRUG|only Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.
47967247|NCT01136603|DEVICE|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
47967248|NCT04269096|OTHER|Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol
48318764|NCT01361919|PROCEDURE|Feedback during CPR Training Not Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
48117000|NCT03833648|OTHER|UControl Pain App with Education|The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
48318765|NCT02130258|DEVICE|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
48318766|NCT02130258|PROCEDURE|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
48486439|NCT03697330|DRUG|Ringer lactate|"Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood."
48486440|NCT00804141|DRUG|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
48497977|NCT05191303|DEVICE|Mobile intervention of breastfeeding counseling|The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
48645606|NCT06686394|BIOLOGICAL|Tucatinib|Tucatinib administered as oral tablets
48645607|NCT01323543|DEVICE|Elaspine™|Implantation of device
48645608|NCT02412436|DRUG|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate intramuscular injection
48645609|NCT01248468|DRUG|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
48645610|NCT01248468|DRUG|Sumatriptan|100 mg Sumatriptan
48645611|NCT01248468|DRUG|Placebo|placebo
48645612|NCT02301793|BEHAVIORAL|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
48117001|NCT05928637|DRUG|D745, D759, D150|QD, PO for 5 days
48117002|NCT00592241|DEVICE|"Adi Insulin Pump Usability"|no intervention
48117003|NCT01415349|DRUG|SSP-002358|1 mg, oral, once
48117004|NCT01415349|DRUG|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
48318767|NCT01165593|OTHER|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
48318768|NCT04134585|OTHER|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
48645613|NCT02301793|BEHAVIORAL|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
47967249|NCT04356391|PROCEDURE|Connective Tissue Graft Technique|For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
48318769|NCT06012045|BEHAVIORAL|Enhanced Cue Exposure Therapy|The E-CET will consist of six weekly sessions and will be delivered by a clinical psychology trainee in person. The first session will be used to introduce the rationale and procedures of E-CET to the participant to establish therapeutic alliance, agreement on treatment goals and tasks, and to collect information on idiosyncratic CS-US expectancies to be targeted in exposures. In this session, questions will be asked specifically to assess idiosyncratic CS-US expectancies related to the four categories: positive reinforcement, craving/drive reduction, mood regulation, and disinhibition. An exhaustive list of all idiosyncratic NEE-triggering cues and CSUS expectancies will be generated from this session. These cues and CS-US expectancies will be targeted in the following exposure sessions and in homework exposures with the goal to cover as many of them as possible during the 6-week treatment.
47967250|NCT04356391|PROCEDURE|Pinhole Surgical Technique|For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
47967251|NCT05881538|OTHER|Exercise group|Participants will perform a 16-week High Intensity Interval Training exercise program, twice a week. The intervention will be conducted telematically with real time supervision.
47967252|NCT02165215|DRUG|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
47967253|NCT02165215|DRUG|Placebo|Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
47967254|NCT01154790|DRUG|CG100649|6 subjects: study drug 2 subjects: placebo
47967255|NCT01154790|DRUG|Placebo|6 subjects: study drug 2 subjects: placebo
47967256|NCT01154790|DRUG|Naproxen|6 subjects: study drug 2 subjects: placebo
48318770|NCT06012045|BEHAVIORAL|Behavioral Lifestyle Intervention|It consists of six weekly sessions of behavioral counseling integrating behavioral strategies for making changes related to diet and exercise. These behavioral strategies will include education about healthy and balanced diets, and ways to attain the minimum level of physical activity for wellbeing (150 minutes moderate-to-vigorous exercise per week), goalsetting, problem-solving, coping, and relaxation. A manualized protocol developed by the PI's team for previous studies in the local community will be used.
48318771|NCT04908917|DEVICE|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
48318772|NCT04908917|DEVICE|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
48318773|NCT01883934|OTHER|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
48318774|NCT01883934|OTHER|Control|
48318775|NCT02664532|OTHER|Miller group|Miller blade was used for laryngoscopy
48318776|NCT02664532|OTHER|Macintosh group|Macintosh blade was used for laryngoscopy
48318777|NCT04195100|DRUG|Pilocarpine Ophthalmic Solution|"1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day"
48318778|NCT04700852|DEVICE|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
48318779|NCT05949606|DRUG|SI-B001|Administration by intravenous infusion
48318780|NCT05949606|DRUG|SI-B003|Administration by intravenous infusion
48318781|NCT04627142|DRUG|BI 1701963|Tablet
48318782|NCT04627142|DRUG|Camptosar®|Solution for infusion
48318783|NCT01734980|PROCEDURE|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
48645614|NCT06309433|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone
47967257|NCT03182478|BEHAVIORAL|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
47967258|NCT03182478|BEHAVIORAL|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
48318784|NCT03032081|OTHER|High intensity exercise|High intensity exercise, defined as an exercise intensity of \> 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
48318785|NCT03032081|OTHER|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
47967259|NCT06557005|OTHER|Facilitated Transition to Primary Care|The intervention includes default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.
48318786|NCT06025123|DEVICE|Early transnasal evaporative cooling with the RhinoChill device|Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours
48318787|NCT03963934|OTHER|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
48645615|NCT06691256|DEVICE|HiDO-ALZ|HiDO-ALZ platform, an AI-driven medication dispensing and observation system designed to improve adherence in individuals with dementia and diabetes.
48645616|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated immediately after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe
47967260|NCT03716037|OTHER|Physical Activity for Life (PAL)|The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
47967261|NCT03613844|DRUG|DHA|DHA supplementation
47967262|NCT03613844|DRUG|Placebo|Placebo for DHA
47967263|NCT05728905|OTHER|Therapeutic exercise|Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.
47967264|NCT05728905|OTHER|Orthopedic manual therapy|Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
47967265|NCT04276571|DEVICE|exergames with GRAIL virtual immersive reality environment|The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
47967266|NCT00163839|BEHAVIORAL|Dietary Therapy|
47967267|NCT00649324|DRUG|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
47967268|NCT00649324|DRUG|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
47967269|NCT03704467|DRUG|M6620|Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
47967270|NCT03704467|DRUG|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
47967271|NCT03704467|DRUG|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
47967272|NCT06388434|BEHAVIORAL|Protective Arm Balance Response Training|Participants will be trained in the reach to grasp arm balance response while being exposed to unpredictable balance perturbations
47967273|NCT01063868|DRUG|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
47967274|NCT01063868|DRUG|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
47967275|NCT04645082|DIAGNOSTIC_TEST|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
47967276|NCT00730769|DRUG|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
47967277|NCT05993130|OTHER|The patients were not intervened. This is a retrospective study|The patients were not intervened. This is a retrospective study
48117005|NCT00064714|DRUG|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
48339989|NCT04516031|PROCEDURE|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
48339990|NCT05906667|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
48645617|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated 5 minutes delayed after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
48645618|NCT06687577|BEHAVIORAL|DBT-C|Tobacco cessation treatment adapted for high risk population.
48645619|NCT06687577|BEHAVIORAL|Treatment as usual|Standard behavioral tobacco cessation treatment.
48645620|NCT02006836|DIETARY_SUPPLEMENT|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
48645621|NCT02006836|DIETARY_SUPPLEMENT|Glucose|We dissolved 50 g of glucose in 200 ml water.
47967278|NCT05132387|OTHER|ECMO assisted CPR in out-of-hospital cardiac arrest|Patients included in the registry will be transferred during LUCAS assisted CPR by the Wroclaw Emergency Medical Services to the Emergency Department of the Wroclaw University Hospital where blood gasses will be assessed. If two or more of the following: end-tidal carbon dioxide (CO2) \> 10 mm Hg, arterial partial pressure of oxygen (PaO2) \>50 mm Hg or oxygen saturation \>85%, and lactic acid \<18 mmol/L will be fulfilled patient will be further transferred to the Cardiac Catheterization Laboratory for V-A ECMO implantation followed by coronary/pulmonary artery angiography and intervention.
47967279|NCT05532761|OTHER|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
47967280|NCT01386827|BIOLOGICAL|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml \> 2 years later
48486441|NCT04178031|DEVICE|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
48486442|NCT03236948|BEHAVIORAL|Women for Women International Intervention|
48486443|NCT03866018|OTHER|Adapted physical activity|12 sessions of one hour of adapted physical activity.
48486444|NCT06204419|DRUG|XH-S002 （A）|XH-S002 powder will be administered orally as per assigned treatment regimen.
48486445|NCT06204419|OTHER|Placebo（B）|XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
48486446|NCT05636566|DRUG|Sevoflurane|inhalational anaesthesia for maintenance
48486447|NCT05636566|DRUG|Propofol infusion for maintance|propofol infusion after induction for maintenance of anaesthesia
48486448|NCT05636566|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
48645622|NCT02006836|OTHER|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
48645623|NCT02006836|DRUG|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
48645624|NCT02006836|DRUG|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
48645625|NCT06689189|OTHER|Blood fluorescence metabolite analysis|This is an observational study and does not involve intervention. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient\&#39;s blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 4 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results, which are pivotal for the timely diagnosis and intervention in septic patients.
48645626|NCT04699305|DEVICE|ActiGraft|Whole blood clot (WBC) gel
48645627|NCT06691542|DRUG|platelet-rich plasma|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
48486449|NCT02588066|PROCEDURE|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
48486450|NCT04798235|BIOLOGICAL|TSHA-101|AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
48486451|NCT04531657|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
48486452|NCT05485519|DRUG|Dexmedetomidine|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
48486453|NCT05485519|DRUG|Midazolam|(1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
48486454|NCT03516136|DEVICE|EndoFast Reliant SCP|POP repair procedure with the EndoFast Reliant SCP system
48486455|NCT01066949|BEHAVIORAL|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
47967281|NCT01386827|BIOLOGICAL|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml \> 2 years later
47967282|NCT01386827|BIOLOGICAL|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
47967283|NCT01386827|BIOLOGICAL|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
47967284|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
47967285|NCT00982137|BIOLOGICAL|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
47967286|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
47967287|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
47967288|NCT05307146|DEVICE|macro/micro electrode recording|intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
47967289|NCT04108793|OTHER|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
47967290|NCT00560456|OTHER|Chronic sleep restriction and driving simulator|"* One night of normal sleep~* Driving simulator~* Night 1: night of total sleep deprivation~* Night 2: night of sleep recovery~* Night 1 to 5: nights of sleep restriction~* Driving simulator after night 1 to 5~* Night 6: night of sleep recovery~* Driving simulator"
48318788|NCT04568317|BEHAVIORAL|Space from Depression|This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
48339991|NCT06231030|OTHER|Validity, Reliability and Adaptation|Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
47967293|NCT03258437|DIETARY_SUPPLEMENT|DA-9401|
48645628|NCT06691542|DRUG|Metformin|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
48645629|NCT06691542|OTHER|cryotherapy|platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
47967294|NCT03258437|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
47967295|NCT04092439|DIETARY_SUPPLEMENT|Watermelon Juice|100% Watermelon Juice
47967296|NCT04920019|PROCEDURE|Thoracic continuous epidural analgesia|"Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)"
47967297|NCT02862171|DRUG|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
48117006|NCT00064714|DRUG|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
48645630|NCT06687590|DEVICE|Peripheral balloon angioplasty|Serration balloon angioplasty of iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistula
48645631|NCT03734055|BEHAVIORAL|Peer Mentoring|Manualized peer mentorship program designed to provide modeling and reinforcement by peers (mentors) to other African American women with SLE (mentees) to encourage them to engage in activities that promote disease self-management.
48645632|NCT03734055|BEHAVIORAL|Social Support Group|Social support controls will participate in a lupus support group created for this project, on the same schedule as peer mentoring sessions.
48645633|NCT06691360|DRUG|AK137|IV infusion, specified dose on specified days.
48645634|NCT06685887|DRUG|HIPEC|HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.
48117007|NCT04813952|DRUG|Sevoflurane inhalant product|The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
48117008|NCT00004266|DRUG|Lisinopril|
48117009|NCT00004266|DRUG|Nifedipine|
48117010|NCT00004266|DRUG|Simvastatin|
48117011|NCT04616911|PROCEDURE|Rerouting seton|Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
48645635|NCT06685887|DRUG|SOX|Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w
48645636|NCT06685887|DRUG|Immune Checkpoint Inhibitors|Tislelizumab, 200 mg, q3w
47967298|NCT05131698|COMBINATION_PRODUCT|Tislelizumab and Lenvatinib|"TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight \< 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)"
47967299|NCT06052085|OTHER|Pain Neuroscience Education|Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.
47967300|NCT06052085|OTHER|Biomedical Pain Education|4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.
47967301|NCT06052085|OTHER|Standard Physiotherapy Program|Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
47967302|NCT06262880|DIETARY_SUPPLEMENT|plant derived phenolics|Dietary supplement containing plant derived phenolics
47967303|NCT06262880|OTHER|Microcrystaline cellulose (MCC)|Placebo treatment: Microcrystaline cellulose
48318789|NCT04568317|DEVICE|Mood Monitor watch app|"The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program."
48318790|NCT04156932|PROCEDURE|uterine artery closure|Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
48318791|NCT01188564|DRUG|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
48318792|NCT01188564|DRUG|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
48318793|NCT05900193|DIETARY_SUPPLEMENT|TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test|Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
48645637|NCT06679478|PROCEDURE|Enhanced Recovery After Surgery (ERAS) Early Mobilization Protocol|The intervention is applied from the first day after surgery until discharge. (including the day of discharge).
48645638|NCT06158438|DEVICE|BTL-754-4 Treatment|Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
47967304|NCT01119417|DRUG|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
48318794|NCT03850782|DRUG|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
48645639|NCT06687447|OTHER|Oxycotin Massage Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. At this stage, the patient will receive an oxytocin massage for 10 minutes while in a sitting position. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
48645640|NCT06687447|OTHER|Reflexology Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed women who want to participate in the study, and pre-test data will be collected. The pre-test data of the research were it will be collectedapproximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured. In practice; The foot is first relaxed and warmed up with passive movements, then the sole of the foot is scanned with the thumb walking crawling technique. The application will be applied first to the right foot for 10 minutes and then to the left foot for a total of 20 minutes. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again and uterine involution and physiological parameters will be evaluated.
48645641|NCT06687447|OTHER|Control Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. Patients in the control group will not undergo any intervention and will receive their routine care. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
48318795|NCT00832546|DRUG|Placebo|
48486456|NCT01066949|BEHAVIORAL|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
48486457|NCT01343095|DEVICE|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
48318796|NCT00832546|DRUG|Oral NGX426 (Powder in solution)|
48486458|NCT01343095|DEVICE|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
48486459|NCT05870371|BEHAVIORAL|Feldenkrais Awareness Through Movement technique|10 group sessions, 50 minutes each, over a period of five weeks, which will include the application of the Feldenkrais Awareness Through Movement technique
48486460|NCT05870371|BEHAVIORAL|Acupuncture|10 sessions, two per week, of 25 minutes acupuncture each, which will include the insertion of a sterile disposable needle into standardized local, regional, and systematic or general acupuncture points that modify pain behavior in area of Cervical Spine.
48486461|NCT05870371|BEHAVIORAL|Stretching|10 sessions, two per week, of 15 minutes stretching each, which will include lateral flexion and counterrotation of the head performed for the upper part of the trapezius and the anterior scalene, lateral flexion and corresponding rotation for the levator scapulae, and flexion for the extensors of the Cervical Spine. The following muscles will be applied: upper trapezius, levator scapulae, scalenes, extensors of the Cervical Spine (splenoid, spinous, semispinalis, longus cephalic and cervical, iliocostalis cervical, multifidus and subscapularis), and sternocleidomastoid.
47967305|NCT01119417|DRUG|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
47967306|NCT01119417|DRUG|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
47967307|NCT01119417|DRUG|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
47967308|NCT01119417|DRUG|Saline|2-3 IV saline infusions for 15 min each.
48117012|NCT04616911|PROCEDURE|LIFT|Ligation of the intersphincteric fistula tract
48117013|NCT05290168|DIAGNOSTIC_TEST|abdominal Doppler|"1. Inferior vena cava diameter and distensibility~2. Hepatic vein Doppler~3. Portal vein Doppler~4. Splenic artery and vein Doppler~5. Renal artery and vein Doppler"
48339992|NCT02021071|RADIATION|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
48486462|NCT00164541|BEHAVIORAL|Arts Based Program|
48486463|NCT00164541|BEHAVIORAL|Curriculum|
48486464|NCT01144728|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
48486465|NCT02940730|DRUG|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
47967309|NCT05473598|BEHAVIORAL|Stand Down app|Patients in this condition will receive Usual Care (UC) and be provided a unique code and password to access Stand Down. The app is based on principles of motivational enhancement and cognitive-behavioral therapies and comprises 7 modules organized around 4 goals: 7 modules organized around 4 goals: (i) Enhance awareness of drinking patterns (assessment and personalized feedback), (ii) Establish and monitor progress towards drinking goal - i.e., moderation or abstinence, (iii) Manage cravings and other problems using in-the-moment tools, and (iv) Connect users with other types of support. App usage will be tracked by the research team for the duration of the study (32 weeks).
47967310|NCT05473598|BEHAVIORAL|Peer-Supported Stand Down|Patients assigned to this condition will receive UC and access to Stand Down, plus four phone sessions from a Peer over 8 weeks. Sessions will be bi-weekly, approx. 15-30 minutes in length, and focus on enhancing patients' engagement with the app.
47967311|NCT05473598|OTHER|Usual Care|All patients, regardless of condition, will have access to usual care for hazardous drinking in primary care. In this setting, usual care entails a spectrum of alcohol-related services including annual screening for hazardous drinking, brief intervention following a positive screen (advice from a provider to reduce their drinking), and referral (as needed) to specialty AUD treatment.
47967312|NCT00993070|DRUG|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
47967313|NCT00993070|DRUG|placebo|vehicle gel, applied 4 times per day for 8 weeks
47967314|NCT05365178|DRUG|TQB3616 capsule|TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
47967315|NCT05365178|DRUG|Placebo|It is a placebo
47967316|NCT05365178|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
48486466|NCT02940730|DRUG|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
48486467|NCT04542850|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
48486468|NCT06011876|OTHER|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
48486469|NCT06011876|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
48486470|NCT06011876|OTHER|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
48486471|NCT05536037|DRUG|Metformin|Given PO
48486472|NCT05536037|PROCEDURE|Biopsy|Undergo biopsy
48486473|NCT03804398|DEVICE|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
48486474|NCT03804398|DEVICE|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
48486475|NCT01427166|OTHER|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
48486476|NCT01751542|BEHAVIORAL|Mindfulness + Residential Treatment|
48486477|NCT01751542|BEHAVIORAL|Residential treatment alone|
48486478|NCT05116488|DIAGNOSTIC_TEST|ECG(electrocardigraph)|Detection of electrocardiographic Brugada patterns using high precordial leads positioning as placing the precordial leads in the second intercostal space has been proposed to add sensitivity to the ECG diagnosis of Brugada syndrome.
48486479|NCT02317679|DRUG|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
48486480|NCT02317679|DEVICE|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
48486481|NCT00140660|DRUG|rituximab|375 mg/m2 on D1
48486482|NCT05009966|DRUG|SYSA1801 for injection|SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
48486483|NCT05495113|DEVICE|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48486484|NCT05495113|DEVICE|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48318797|NCT05525338|DRUG|Alectinib|In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
48318798|NCT04881240|BIOLOGICAL|CD19-CAR(Mem) T-cells|Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
48318799|NCT04881240|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
48318800|NCT04881240|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
48645642|NCT06691815|DIAGNOSTIC_TEST|Triptorelin (GnRH agonists)|"1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone, AMH, and Inhibin B. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg for subcutaneous administration. Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin Acetate, with the determination of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: This consists of determining LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Luteoliberin 100 μg)"
48645643|NCT06166641|PROCEDURE|Surgical procedure at operating room|A surgical procedure in an operating room is a medical intervention that involves making incisions or using minimally invasive techniques to treat a specific condition or perform a diagnostic procedure. The operating room, also known as the operating theater or surgical suite, is a sterile environment specifically designed to minimize the risk of infection and ensure the safety of both the patient and the surgical team.
48645644|NCT03203707|BEHAVIORAL|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
48645645|NCT06690970|DIAGNOSTIC_TEST|68Ga/18F-PSMA|Each subject receive a single intravenous injection of 68Ga/18F-PSMA, and undergo PET/CT imaging within the specificed time.
48645646|NCT06685965|DRUG|RE03|Buccal Dexmedetomidine
48645647|NCT06685965|DRUG|Placebo|Matching Placebo
48645648|NCT06589518|DRUG|Tenofovir Alafenamide Citrate|Tenofovir alafenamide is administered once every day with 25mg PO for 48 weeks.
48645649|NCT05706376|BEHAVIORAL|Promoting Positive Family Futures|Promoting Positive Family Futures is a group-based program that aims to help parents and their adolescent children (13-16 yrs) cope with chronic violence by developing emotional and cognitive awareness, learning constructive conflict resolution strategies, and developing family-wide emotional security and positive family relationships. Emotional Security Theory is the foundational conceptual model for the program, and as such, the PPFF focuses on promoting family-wide communication and establishing emotional security in both the family and community across multiple sessions.Firmly grounded the cultural context of Palestine, the intervention also incorporates intervention elements derived from social ecological theories of resilience, and cognitive behavioral approaches to coping. In total, the program includes 8 sessions lasting approximately 1.5 hours each.
48645650|NCT05706376|BEHAVIORAL|Treatment as Usual|Families assigned to the TAU condition will participate in a common service offered by both PCC and CRS - a weekly adolescent-only support group. Both CRS and PCC conduct extended group programs for children and adolescents (24 sessions at PCC; 25 sessions at CRS).
48318801|NCT04881240|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
48318802|NCT04881240|DEVICE|CliniMACS|A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
48318803|NCT04881240|PROCEDURE|Leukapheresis|Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
48318804|NCT05992415|OTHER|Intervention Using Patient Navigators|Consented participants referred to ophthalmology from the 9 developments randomized to the Intervention Arm will receive ongoing support from patient navigators to assist with all aspects of follow-up eye care, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
48339993|NCT02021071|RADIATION|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
48486485|NCT01843348|DRUG|Everolimus|
48486486|NCT01843348|DRUG|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
48486487|NCT01843348|DRUG|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
48486488|NCT01843348|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
48486489|NCT01843348|DRUG|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
48486490|NCT01843348|DRUG|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
48486491|NCT01843348|DRUG|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
48486492|NCT00302302|DRUG|L-arabinose|
47967317|NCT04178564|BEHAVIORAL|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
47967318|NCT03568734|OTHER|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
47967319|NCT03017495|DRUG|Midazolam|2 mg/mL oral solution
47967320|NCT03017495|DRUG|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
47967321|NCT04130620|DIAGNOSTIC_TEST|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
47967322|NCT05733780|DRUG|Prolectin-M|"Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus"
47967323|NCT06374901|DRUG|Tislelizumab|Preoperative treatment with Tislelizumab
47967324|NCT06374901|DRUG|SOX/XELOX|Preoperative treatment with SOX/XELOX
47967325|NCT04904328|DEVICE|Lumishade® Active Lens|"Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
47967326|NCT04904328|DEVICE|Lumishade® Sham Lens|"Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
48645651|NCT06691087|BEHAVIORAL|Influence of the parameters of the sound timbre on the perception of a sound|"The experiment consists of evaluating the sound level of n complex stimuli, then equalising them in loudness, in order to measure a loudness curve in function of timbre descriptors.~The stimuli will then be listened to again in pairs. The task is there to compare the stimuli using a VAS to indicate how different the two sounds are."
48645652|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test|The experiment consists in identifying the parameters of the sound timbre that most disturb the understanding of complex sound scenes, by asking the participants to identify sounds whose timbre has been modified.
48645653|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test with hearing aids|The experiment will be identical to intervention 2. This time, the modification of the stimulus timbres will focus on the most problematic dimensional modifications, i.e. those where the difference between normal-hearing and hearing-impaired listeners is greatest. We will then modify the signal processing parameters of the hearing aid simulator (for example, the size of the averaging window or the gain balance of the filters), to observe their impact on the salience of certain stimuli.
48645654|NCT06552130|OTHER|Spiroergometer test with intranasal insulin spray|Participants will undergo a 60 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.
48645655|NCT06552130|OTHER|Spiroergometer test with intranasal placebo spray|Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
48645656|NCT06686836|PROCEDURE|Sinus lift augmentation with bone substitute (Bio-Oss)|A maxillary sinus lift augmentation was performed with a lateral window approach that was filled with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®).At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically.
47967327|NCT03874637|DEVICE|Treament|Placement of the FemPulse System with therapy delivery
47967328|NCT03874637|DEVICE|Sham Control|Placement of the FemPulse System without therapy delivery
47967329|NCT05881915|DRUG|Phenylephrine|phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
47967330|NCT05881915|DRUG|Epinephrine|epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
47967331|NCT04317469|DIAGNOSTIC_TEST|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
47967332|NCT02798133|PROCEDURE|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
47967333|NCT02798133|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
47967334|NCT02098967|DRUG|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
48318805|NCT05992415|OTHER|Usual Care Without Patient Navigators|Consented participants referred from the 5 developments randomized to the Usual Care Arm 2 who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence. Arm 2 represents a realistic choice available for participants following screening over a 1-year period.
47967335|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
47967336|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
48486493|NCT05884879|BEHAVIORAL|Tinnitus simulation|The control group will perform speech perception tests and listening effort tests in the absence and presence of a simulated tinnitus percept using a bone vibrator.
48645657|NCT06686836|PROCEDURE|Open sinus lift surgery lift using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®(Geistlich AG, Wolhusen, Switzerland)) - L-PRF Block|"A maxillary sinus lift augmentation was performed with a lateral window approach that was filled using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®) (L-PRF block).~L-PRF block will be performed as described by Cortellini et al. 2018. L-PRF membranes are cut into small pieces and mixed with Bio-Oss® at a ratio of 2 membranes / 0.5 g biomaterial. Pieces of the block will be removed and compacted in the sinus cavity until it is filled.~At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically."
47967337|NCT01619696|PROCEDURE|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
47967338|NCT02171377|DEVICE|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
47967339|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
47967340|NCT02171377|DEVICE|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
47967341|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
47967342|NCT01746745|DRUG|[^14C]-LY2940680|Administered as solution by mouth
47967343|NCT03572062|BIOLOGICAL|Formulation A|RSV vaccine
47967344|NCT03572062|BIOLOGICAL|Formulation B|Adjuvanted RSV vaccine
47967345|NCT03572062|BIOLOGICAL|Formulation C|RSV vaccine
47967346|NCT03572062|BIOLOGICAL|Placebo|Placebo
47967347|NCT01619423|DRUG|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
48486494|NCT04026373|BEHAVIORAL|modified Prolonged Exposure|
48486495|NCT04026373|BEHAVIORAL|Treatment as usual|May include consult to health psychology and any follow-up deemed appropriate
47967348|NCT01619423|DRUG|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
47967349|NCT01619423|DRUG|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
47967350|NCT01619423|DRUG|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
47967351|NCT02429544|BEHAVIORAL|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
47967352|NCT02429544|BEHAVIORAL|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
47967353|NCT02429544|DEVICE|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
48339994|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
48486496|NCT04556890|DEVICE|Active rTMS/Active iTBS DFPLC/Sham Pain M1|Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
48645658|NCT06686329|BEHAVIORAL|Control (CON)|Standardized meal with insulin administered 15 minutes before eating
47967354|NCT02429544|OTHER|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
47967355|NCT02429544|BEHAVIORAL|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
47967356|NCT00596284|BEHAVIORAL|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
47967357|NCT00596284|BEHAVIORAL|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
47967358|NCT03591835|OTHER|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
47967359|NCT03591835|OTHER|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
47967360|NCT00005045|DRUG|carboxyamidotriazole|
47967361|NCT05236049|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
47967362|NCT01309594|PROCEDURE|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
47967363|NCT04540029|OTHER|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
47967364|NCT03949361|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
47967365|NCT03949361|DIAGNOSTIC_TEST|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
47967366|NCT03949361|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
48486497|NCT04556890|DEVICE|Active rTMS/Active iTBS|Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
48486498|NCT02323165|OTHER|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
48486499|NCT04624152|BEHAVIORAL|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
48486500|NCT01727687|BEHAVIORAL|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
48486501|NCT02740829|DRUG|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
48486502|NCT02740829|DRUG|Intranasal placebo|Placebo
48486503|NCT03114696|DIETARY_SUPPLEMENT|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
48486504|NCT03114696|DIETARY_SUPPLEMENT|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
48497978|NCT02694471|BEHAVIORAL|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
48645659|NCT06686329|BEHAVIORAL|Missed Dose (MISS)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM
47967367|NCT03949361|DIAGNOSTIC_TEST|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
47967368|NCT03949361|DIAGNOSTIC_TEST|FDG-PET|Dynamic PET scanning of the neck-region
47967369|NCT03949361|DIAGNOSTIC_TEST|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
47967370|NCT03949361|DIAGNOSTIC_TEST|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
47967371|NCT00379093|BEHAVIORAL|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~* A personalized risk report;~* An educational booklet titled Healthy Drinking as You Age;~* A drinking diary;~* Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
47967372|NCT00828659|DRUG|Placebo|
47967373|NCT00828659|DRUG|Active Comparator #1|
47967374|NCT00828659|DRUG|Active Comparator #2|
47967375|NCT00828659|DRUG|Active Comparator #3|
47967376|NCT00828659|DRUG|Lorcaserin Dose #1|
47967377|NCT00828659|DRUG|Lorcaserin Dose #2|
47967378|NCT00828659|DRUG|Lorcaserin Dose #3|
47967379|NCT05288920|PROCEDURE|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
47967380|NCT05288920|DRUG|Transforaminal injection of Steroids alone|Transforaminal injection of Steroids alone
47967381|NCT06099197|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
47967382|NCT06099197|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
47967383|NCT05066854|PROCEDURE|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
47967384|NCT05066854|PROCEDURE|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
47967385|NCT05004870|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
47967386|NCT05476471|BEHAVIORAL|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
47967387|NCT04002713|OTHER|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
47967388|NCT04002713|OTHER|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
47967389|NCT03925974|DRUG|KN026 10 mg/kg QW|10 mg/kg QW as safety run-in dosage
47967390|NCT03925974|DRUG|KN026 20 mg/kg Q2W|20 mg/kg Q2W as target dosage
47967391|NCT03925974|DRUG|KN026 30 mg/kg Q3W|30 mg/kg Q3W as another target dosage
47967392|NCT05111171|DEVICE|sheath|Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
48497979|NCT00655876|DRUG|cetuximab|Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m\^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m\^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.
48497980|NCT00655876|DRUG|cisplatin|Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m\^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.
47967393|NCT01218373|DEVICE|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
47967394|NCT01218373|DEVICE|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
47967395|NCT04945954|OTHER|Drug: Cyclophosphamide|"Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)"
47967396|NCT00066885|DRUG|calcitriol + docetaxel|
47967397|NCT04106115|DRUG|Durvalumab|1500 mg IV infusion every 4 weeks for up to 7 doses
47967398|NCT04106115|BIOLOGICAL|S-488210/S-488211|S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
47967399|NCT04568044|PROCEDURE|Blood sample|Peripheral blood sample will be obtained.
47967400|NCT03461913|PROCEDURE|Cesarean section|Lower segment elective Cesarean section
47967401|NCT04284670|OTHER|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
47967402|NCT01007097|DRUG|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
47967403|NCT01007097|DRUG|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
47967404|NCT01007097|DRUG|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
47967405|NCT01007097|DRUG|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
47967406|NCT01007097|DRUG|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
47967407|NCT01007097|DRUG|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
47967408|NCT01007097|DRUG|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
47967409|NCT01369095|DRUG|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C\&D)
47967410|NCT01369095|DRUG|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C\&D)
47967411|NCT01369095|DRUG|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
47967412|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
48318806|NCT06308640|DEVICE|Insertion of the device intraorally|"* The distalizer appliance will be checked for adaptation intraorally, the two bands of the maxillary first molars will be fitted in their accurate position on the teeth.~* The screw insertion will be carried out with the patient under local anesthesia.~* They will be placed inside the two eyelets of the anterior arms of the screw in the appliance"
48318807|NCT02082145|DEVICE|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
48318808|NCT00972829|DRUG|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
48318809|NCT00972829|DRUG|Ezetimibe|Ezetimibe 5 or 10 milligrams
47967413|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
47967414|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
47967415|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
47967416|NCT03544658|PROCEDURE|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
47967417|NCT03544658|PROCEDURE|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
47967418|NCT03544658|PROCEDURE|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
47967419|NCT03544658|PROCEDURE|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
47967420|NCT04706091|DRUG|Suvorexant|10-mg or 20-mg suvorexant capsules
47967421|NCT04706091|OTHER|Placebo|Matching placebo capsules
47967422|NCT00523016|PROCEDURE|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
48318810|NCT02193815|DRUG|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
48318811|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 4% solution
48318812|NCT02193815|DRUG|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
48318813|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 2% Ointment
48318814|NCT02193815|DRUG|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
48318815|NCT02193815|DRUG|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
48339995|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
48339996|NCT01171014|DIETARY_SUPPLEMENT|Placebo|Placebo, once a day for 14 days
48339997|NCT00040950|BIOLOGICAL|rituximab|
47967423|NCT00523016|PROCEDURE|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
47967424|NCT02859168|BEHAVIORAL|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
47967425|NCT02859168|DEVICE|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
47967426|NCT00404846|PROCEDURE|Hyperbaric Oxygenation Therapy|
47967427|NCT03274024|DEVICE|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
47967428|NCT03274024|PROCEDURE|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
48318816|NCT05250830|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
48318817|NCT05250830|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
48497981|NCT00655876|DRUG|paclitaxel|Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
48645660|NCT06686329|BEHAVIORAL|Missed Dose + 15min walk (MISS+EX)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM with a 15-minute walk performed immediately after insulin administration
48645661|NCT03359395|DRUG|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
48645662|NCT03359395|DRUG|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
47967429|NCT04546945|DIAGNOSTIC_TEST|CD56|detection of CD56 by flow cytometry
47967430|NCT04532944|DIAGNOSTIC_TEST|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
47967431|NCT04669132|DRUG|Olanzapine|- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
47967432|NCT04669132|DRUG|Netupitant|- Netupitanto 300 mg, once daily, on chemotherapy day;
47967433|NCT04669132|DRUG|Palonesetron|- Palonosetron 0.56 mg, once daily, on chemotherapy day;
48497982|NCT00655876|RADIATION|radiation therapy|1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
48497983|NCT00687089|OTHER|Sexual, cognitive functional tests and measurement weight|
48645663|NCT04291885|DRUG|Avelumab|Avelumab IV infusion
48645664|NCT04291885|DRUG|Placebo|Placebo IV infusion
48645665|NCT00561821|DRUG|Esmirtazapine|one tablet daily
48645666|NCT00561821|DRUG|Placebo|one tablet daily
48645667|NCT02998125|PROCEDURE|Total knee arthroplasty|prospective assessments for the functional outcome before and after the total knee arthroplasty
48645668|NCT06684821|PROCEDURE|Racz catheter|Patients will undergo epidural neuroplasty using Racz catheter during lumber fixation.
48645669|NCT06684821|PROCEDURE|Classic lumber fixation|Patients will undergo classic lumber fixation.
47967434|NCT02289417|DRUG|Apremilast|
47967435|NCT02289417|DRUG|Placebo|
47967436|NCT02733432|DRUG|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
47967437|NCT02733432|DRUG|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
47967438|NCT02733432|DRUG|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
47967439|NCT02733432|DRUG|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
47967440|NCT02733432|DRUG|Fluconazole|oral fluconazole (150mg) on Day 1
48318818|NCT06134791|OTHER|No intervention|No intervention
48318819|NCT04212286|DIAGNOSTIC_TEST|Diagnostic CEUS and EOB-MRI|Undergo Sonovue-CEUS and EOB-MRI
48318820|NCT02242227|DRUG|Salmeterol xinafoate|
48318821|NCT02242227|DRUG|Serevent® Diskus®|
48318822|NCT02242227|DRUG|Placebo (HandiHaler®)|
48318823|NCT02242227|DRUG|Placebo (Diskus®)|
48339998|NCT00040950|DRUG|agatolimod sodium|
48645670|NCT06679907|DEVICE|WaveLinQ® device|The WaveLinQ® system employs a dual catheter technique to establish communication between deep arteries and veins, typically using a ulnar or radial artery and vein. This procedure necessitates fluoroscopic guidance to position the catheters correctly, a control angiogram, and potential embolization to enhance blood flow.
48645671|NCT06679907|DEVICE|Ellipsys® device|The Ellipsys® system enables the entire AVF creation process to be conducted under ultrasound guidance without the need for fluoroscopy or contrast media. It uses a single needle to puncture the superficial vein, the perforator and the artery and potential balloon angioplasty to enhance blood flow.
47967441|NCT05433324|OTHER|MRI and PET Scans|All groups will undergo cognitive tests and brain imaging scans (MRI \& PET)
47967442|NCT00424983|DRUG|Zoledronic acid|
47967443|NCT04589806|PROCEDURE|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
47967444|NCT01352858|DRUG|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
47967445|NCT01352858|DRUG|Arthroscopy & saline irrigation alone|
47967446|NCT00192361|BIOLOGICAL|CAIV-T|
48645672|NCT06679907|DEVICE|No device|Surgical AVF creation will involve a direct approach to the proximal radial, ulnar, or brachial artery to create a 4-6 mm longitudinal arteriotomy. An oblique incision will be made at the elbow crease. The cephalic, basilic, or perforating vein may be used for the side-to-end anastomosis. If a transposition is required due to adiposity, it will be performed either during the same procedure or at a later time through tunneling or lipectomy.
47967447|NCT05211362|BIOLOGICAL|Sticky Bone and Repeated Injectable PRF (iPRF)|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
47967448|NCT05211362|BIOLOGICAL|bone substitute|The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
47967449|NCT04564937|DRUG|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
48318824|NCT04300491|OTHER|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
48645673|NCT06143423|DRUG|AP026 (TQA2226) for injection|AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
47967450|NCT00536562|BEHAVIORAL|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition \& psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
48318825|NCT05662306|DRUG|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
48486505|NCT03363399|DIAGNOSTIC_TEST|Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection. The samples will be stored at 4°C overnight.~Blood samples containing at least 105 neutrophils will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8-color flow cytometer and analyzed using Becton Dickinson (BD) Fluorescence-activated cell sorting (FACS) Diva Software version 6. Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
48318826|NCT05662306|BEHAVIORAL|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
48318827|NCT04980352|OTHER|real world treatment by doctors|real world treatment by doctors
48486506|NCT05899322|BEHAVIORAL|Primary Care Intervention for PTSD Spanish Speaking Adolescents|This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
48486507|NCT05899322|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
48486508|NCT04523402|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy with GEMOX regimen before liver resection
48486509|NCT03100734|BIOLOGICAL|Benepali|As specified in the treatment arm
48486510|NCT03100734|BIOLOGICAL|Enbrel|As specified in the treatment arm
48486511|NCT04921124|DRUG|Teriparatide|PTH(1-34) cartridge and pen device
47967451|NCT05307068|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
47967452|NCT05500157|PROCEDURE|aspiration sclerotherapy versus laparoscopic fenestration|See arm description
47967453|NCT02576002|DRUG|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
47967454|NCT01032837|DRUG|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
47967455|NCT01032837|DRUG|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
47967456|NCT01032837|DRUG|Placebo|Matching placebo provided as capsules and as a suspension.
47967457|NCT05866172|PROCEDURE|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
47967458|NCT05866172|DRUG|Zoledronic acid|Zoledronic acid 4mg iv.drip
47967459|NCT02541019|DRUG|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
47967460|NCT02541019|DRUG|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
47967461|NCT04804969|DEVICE|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
47967462|NCT04678245|BEHAVIORAL|Above the Influence-Vaping (ATI-V)|Peer-nominated 8th grade and 9th grade Peer Leaders (PL) will be trained in a half day ATI-V training. Adult Advisors (AA) will attend a half day ATI-V AA training and the PL training. The training day builds leadership skills in the PLs, develops skills for rising above pressure to vape including identification of personal reasons to rise, identification of healthy support people, teaching accurate use statistics, and sharing stories of prior success in rising above negative pressures. The ATI-V team of PLs and AAs then will run four interactive messaging campaigns to reach the rest of the student body. These four campaigns are (1) Introduction to ATI-V and My Reasons to Rise (2) Gain and Loss (3) Who's Got My Back (4) The Facts. Each campaign features a portion in which PLs model healthy norms and behaviors, and a second portion in which all the rest of the students engage in an interactive component to build and demonstrate the target skill.
47967463|NCT03713086|BIOLOGICAL|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
47967464|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202 Dose level 1|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
47967465|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202 Dose level 2|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
47967466|NCT03713086|BIOLOGICAL|Rabies mRNA vaccine CV7202 Dose level 3|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
48318828|NCT05554471|DEVICE|MYNX CONTROL™ Venous Vascular Closure Device 6F-12F|Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.
47967467|NCT01509950|PROCEDURE|Staples|Staples for closure of cesarean section skin incision
47967468|NCT01509950|PROCEDURE|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
47967469|NCT01509950|PROCEDURE|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
47967470|NCT03019575|DRUG|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
47967471|NCT03019575|DRUG|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
47967472|NCT00057278|DRUG|gabapentin|
47967473|NCT05122832|DIAGNOSTIC_TEST|Blood test|Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
47967474|NCT05122832|DIAGNOSTIC_TEST|STEPwise Approach to NCD Risk Factor Surveillance (STEPS)|The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
47967475|NCT05122832|DIAGNOSTIC_TEST|Spirometry|Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
47967476|NCT06555536|OTHER|Tele OI|A data collection and Telemedicine tool translated into an APP.
47967477|NCT05944757|DRUG|PRP plasma rich platelets|Twenty patients (20) underwent 0.5 ml 100 % intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
47967478|NCT05944757|DRUG|Autologous serum|Twenty patients (20) underwent intrastromal injection of 0.5 ml 100 %of autologous serum (second group) every 2 weeks for 1 month
47967479|NCT06193291|PROCEDURE|Feet heating|Feet placed in hot water
47967480|NCT06193291|PROCEDURE|Calf heating|Feet to calves placed in hot water
48318829|NCT01773096|DRUG|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
48318830|NCT01773096|DRUG|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
48318831|NCT04397718|DRUG|Degarelix|Degarelix is an FDA-approved drug for prostate cancer
48318832|NCT04397718|OTHER|Saline|09% Saline
47967481|NCT02403492|DEVICE|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
47967482|NCT02403492|DEVICE|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
47967483|NCT02403492|DEVICE|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
47967484|NCT05375370|OTHER|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
47967485|NCT05806281|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
47967486|NCT05823129|BEHAVIORAL|Tele-rehabilitation caregiver empowerment enhanced post- discharge rehabilitation directive|The intervention group will receive an implemented TUG test-based telerehabilitation program. The TUG test-based telerehabilitation involves patients routinely doing two TUG tests by themselves twice daily. Each patient will be provided with a unique link to the TUGstopwatch, a prerecorded video outlining instructions on how to properly conduct a TUG test, and support and guidance for patients and caregivers throughout the study period.
47967487|NCT03524898|DRUG|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
47967488|NCT03524898|DRUG|gemcitabine|1000 mg/m2
48318833|NCT02085213|DRUG|Glyceryl Trinitrate|
47967489|NCT05666609|PROCEDURE|placement of non-cutting seton (silicone)|Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
47967490|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
47967491|NCT04978727|BIOLOGICAL|SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
47967492|NCT04978727|BIOLOGICAL|SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years|500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients \< 30 kg, and 100 mcg for patients ≥ 30 kg.
48318834|NCT02085213|DRUG|Matched Placebo|Matched placebo
48318835|NCT04395534|PROCEDURE|Complete mesocolic excision|
48486512|NCT03051139|BEHAVIORAL|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
47967493|NCT01703039|DRUG|Riluzole|
47967494|NCT01703039|DRUG|Sertraline|
47967495|NCT01703039|OTHER|placebo|
47967496|NCT02955160|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
48318836|NCT03741920|DEVICE|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~* A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording.~* A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
48318837|NCT02658994|BEHAVIORAL|Thinking Healthy Program Peer Delivered Plus|
48318838|NCT02658994|OTHER|Enhanced Usual Care|
48318839|NCT03671382|BEHAVIORAL|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
48318840|NCT00002207|DRUG|Stavudine|
48318841|NCT00002207|DRUG|Didanosine|
47967497|NCT02955160|BIOLOGICAL|Tdap|Tetanus, diphtheria, and pertussis vaccine
47967498|NCT01935297|BEHAVIORAL|Exercise|endurance and resistance exercise 3x/week for 8 weeks
47967499|NCT02284984|DRUG|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
48318842|NCT00478725|DRUG|GW786034, oral|oral, 800 mg
48318843|NCT00478725|DRUG|GW786034, IV|IV, 5 mg
48318844|NCT00478725|DRUG|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
47967500|NCT01148472|DRUG|Escitalopram|20mg once daily; orally
48318845|NCT03093961|DEVICE|IASD implant|Single arm for implant
48318846|NCT05494541|OTHER|Crizanlizumab|Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
48318847|NCT03107676|OTHER|trunk extensors endurance training|endurance training
48318848|NCT04223700|PROCEDURE|Ultrasound imaging & fluoroscopic confirmation|The researchers use ultrasound to scan the left and right sides of the paravertebral sagittal imaging to identify trapezius, semispinalis, erector spinae muscle, transverse process and rhomboid muscle. The radiopaque marker is attached respectively to the skin of the inferior margin of the rhomboid muscle on the left and right thoracic spinal spines. Then, as the first step for the scheduled nerve block to the patient, thoracic vertebra level verification using C-arm is performed. At this time, left and right level of the transverse process of thoracic spine marked with the radiopaque marker are confirmed and recorded.
48645674|NCT06143423|DRUG|AP026 (TQA2226) for injection matching placebo|AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.
47967501|NCT01148472|DRUG|Duloxetine|60mg once daily; orally
48318849|NCT01829802|DRUG|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
48318850|NCT01829802|DRUG|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
48318851|NCT01829802|DRUG|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
48318852|NCT01766817|DRUG|BMS-986020|
48318853|NCT01766817|DRUG|Placebo matching with BMS-986020|
48318854|NCT04753242|OTHER|Online survey questionnaire|Self-developed questionnaire based on relevant literature, own experience and consultation with participating professional societies. The survey contains 25 questions on structural and process variables regarding psychosocial care structures that psychosocial C\&L services have established in acute hospitals in the context of the COVID-19 pandemic, the implementation and use of COVID-19-related services for patients, relatives and staff, special challenges, as well as needs and wishes for the future. Thereby the survey is aiming at the creation of a data basis for improving the structural and process quality of psychosocial care services through psychosocial C\&L services in the context of pandemics, especially the COVID-19 pandemic.
48318855|NCT03388996|DIAGNOSTIC_TEST|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
48318856|NCT05521217|DIAGNOSTIC_TEST|MyotonPRO|"Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device."
48486513|NCT06502197|PROCEDURE|Silastic Stenting|Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.
47967502|NCT01367210|DRUG|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
47967503|NCT01367210|DRUG|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
47967504|NCT03441308|BEHAVIORAL|Educational method of group treatment|
47967505|NCT03093883|DRUG|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
48117014|NCT04062760|DRUG|Standard diuretic therapy|The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
48318857|NCT00275925|DRUG|Oxcarbazepine|
48318858|NCT00041769|PROCEDURE|Therapeutic Drug Monitoring (TDM)|
48486514|NCT04085536|PROCEDURE|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
48486515|NCT03674502|DRUG|ADU-1604|anti-CTLA-4 monoclonal antibody
48486516|NCT00841360|OTHER|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
48645675|NCT04652999|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot). The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds. The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
48645676|NCT04652999|BEHAVIORAL|Neutral Guided Imagery|This placebo consists on neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, be it positive or negative, which occurred before patient has the current DFU. Then, questions are asked which allow a more detailed reconstruction of the event and the patient is asked to imagine according only to the instructions given. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered in each of the questions given.
48645677|NCT02369679|DEVICE|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
47967506|NCT03093883|DRUG|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
47967507|NCT01785693|DRUG|levobupivacaine, clonidine|
47967508|NCT06506565|DRUG|Ketamine|Infusion during wound care
47967509|NCT06506565|DRUG|0.9% NaCl|Infusion during wound care
47967510|NCT04073069|DRUG|The DR group|Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
47967511|NCT04073069|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
47967512|NCT01885403|DEVICE|non-invasive respiratory parameter measurements|
47967513|NCT05152030|DIAGNOSTIC_TEST|'TIB' Olfactory Test|A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
47967514|NCT05152030|DIAGNOSTIC_TEST|Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)|The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
48318859|NCT02163993|DRUG|Galcanezumab|Administered SQ
48318860|NCT02163993|DRUG|Placebo|Administered SQ
47967515|NCT02829632|BEHAVIORAL|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
48318861|NCT01623531|DRUG|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
48486517|NCT00841360|OTHER|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
48645678|NCT02369679|DEVICE|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
48645679|NCT04452162|DIAGNOSTIC_TEST|MRI|You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
48486518|NCT05664282|DEVICE|Damon self-ligating brackets|
48486519|NCT05664282|DEVICE|Victory self-ligating brackets|
48645680|NCT01560559|PROCEDURE|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
48645681|NCT02527265|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
48645682|NCT05410795|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
48486520|NCT00833352|DEVICE|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
48645683|NCT02192086|OTHER|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
47967516|NCT02829632|BEHAVIORAL|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
48486521|NCT04595916|DRUG|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
48486522|NCT04595916|DRUG|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
47967517|NCT02829632|BEHAVIORAL|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
47967518|NCT05572450|OTHER|Infectious Titre 1|Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
48318862|NCT02337595|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
48318863|NCT03001843|DRUG|Ketamine|Anesthesia of only Ketamine
48318864|NCT03001843|DRUG|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
48318865|NCT03001843|BEHAVIORAL|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
48318866|NCT00282789|DEVICE|bilevel positive airway pressure|
48318867|NCT00282789|DEVICE|bilevel positive airway pressure (Device)|
48318868|NCT05946759|DEVICE|Histolog Scanner|The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
48318869|NCT05004142|DRUG|FCN-437c+Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
48318870|NCT05004142|DRUG|FCN-437c+Letrozole+Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
48486523|NCT04461132|OTHER|Manual Lymphatic drainage (MLD)|MLD vith vodder technique was applied to leg
47967519|NCT05572450|OTHER|Infectious Titre 2|Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
48318871|NCT03986775|DIETARY_SUPPLEMENT|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
48318872|NCT03986775|DIETARY_SUPPLEMENT|sucrose|conventional beverage with sucrose
48318873|NCT05840419|DEVICE|Laparoscopic appendectomy|Laparoscopic appendectomy with Airseal or with standard insufflation
47967520|NCT05572450|OTHER|Infectious Titre 3|To be determined (TBD), depending on outcome of Part A
48318874|NCT01079533|BEHAVIORAL|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
48318875|NCT01079533|BEHAVIORAL|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
48318876|NCT05059951|DRUG|Immune checkpoint inhibitor|Chemotherapy follow the guild line.
48318877|NCT02591004|DRUG|Magesium sulphate|\*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
48318878|NCT02591004|DRUG|Nifedipine|\*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
48318879|NCT02591004|RADIATION|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
48318880|NCT06379802|BEHAVIORAL|Individualized physical activity and diet|Precision health
48486524|NCT04461132|OTHER|Skin Care|Wound was cleaned with salin and covered by dressing without including active products
48486525|NCT04461132|OTHER|Exercise|breathing and foot pump exercise was prescribed
48486526|NCT04461132|OTHER|Shame Manual Lymphatic drainage|manual lymphatic drainage was applied with light touch instead of real mld techniques
47967521|NCT05572450|OTHER|Infectious Titre 4|TBD, depending on outcome of Part A
47967522|NCT01560793|BIOLOGICAL|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
47967523|NCT00099008|DIETARY_SUPPLEMENT|Genistein|oral Genistein twice daily on days 1-84
47967524|NCT00099008|DIETARY_SUPPLEMENT|Placebo|oral Placebo twice daily on days 1-84
48318881|NCT03117062|OTHER|occlusal reduction|relief of occlusion following endodontic treatment
48318882|NCT04815304|DIAGNOSTIC_TEST|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
47967525|NCT03409835|DRUG|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
47967526|NCT03409835|DRUG|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
48318883|NCT04637945|DIETARY_SUPPLEMENT|ACRB|Product will be consumed once daily, preferably with breakfast.
48318884|NCT04637945|OTHER|Placebo|Product will be consumed once daily, preferably with breakfast.
48318885|NCT02035982|DRUG|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
48318886|NCT02035982|DRUG|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
48318887|NCT02130479|BEHAVIORAL|Contingency Management-Family Engagement|
48318888|NCT02130479|BEHAVIORAL|Treatment as Usual|
48318889|NCT03241563|DRUG|Sodium Deoxycholate|
48486527|NCT01047579|DRUG|Rivastigmine transdermal|
48486528|NCT03737318|BEHAVIORAL|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
48497984|NCT01315132|DEVICE|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
47967527|NCT04764903|OTHER|No intervention|There is no intervention in this study
47967528|NCT03315624|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
47967529|NCT06507813|DRUG|ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 45 mg ADC189 tablets once; patients weigh over 80 kilograms, given 90 mg ADC189 tablets once.
47967530|NCT06507813|DRUG|Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 40 mg Baloxavir marboxil tablets once. Patients weigh over 80 kilograms, given 80 mg Baloxavir marboxil tablets once.
48497985|NCT03290365|DRUG|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
48318890|NCT03241563|DRUG|Triamcinolone|Triamcinolone 40mg/ml
48318891|NCT02258867|DRUG|Placebo|Solution for subcutaneous injection
48318892|NCT02258867|DRUG|Gevokizumab|Solution for subcutaneous injection
48318893|NCT02319096|OTHER|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
48318894|NCT02260856|DEVICE|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
48318895|NCT02260856|PROCEDURE|Percutaneous Drill Epiphysiodesis|
48318896|NCT02260856|PROCEDURE|Percutaneous Screw Epiphysiodesis|
48645684|NCT02192086|OTHER|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
48645685|NCT05084378|DRUG|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
48645686|NCT05084378|DRUG|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
48645687|NCT05084378|DRUG|Topical Antibiotic|2 grams Vancomycin powder
48645688|NCT05084378|DRUG|Saline Lavage Solution|1 litre of sterile isotonic saline
47967531|NCT06507813|DRUG|Placebo of ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 1 tablet of placebo once; patients weigh over 80 kilograms, given 2 tablets of placebo once.
47967532|NCT06507813|DRUG|Placebo of Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 2 tablets of placebo once; patients weigh over 80 kilograms, given 4 tablets of placebo once.
48318897|NCT06536764|OTHER|Progressive Muscle Relaxation Exercises|Progressive muscle Relaxation exercises will be performed by this group.Advise women to sit in chair. The therapist's voice will then instruct them to contract and release different muscle groups. They will practice tensing a muscle group until they feel the slight contraction and then release it, simultaneously contracting and relaxing all other muscle groups.Practice will progress in the same manner, starting with the muscles in the feet, then the calf, thigh, gluteal muscles, abdomen, chest, hands, forearms, arms, shoulders, neck, face, and finally the forehead muscles .
48318898|NCT06536764|OTHER|Conventional Therapy(Hot pack,TENS,Patient Education)|Conventional therapy including hot pack and TENS will be applied for 10 minutes each. Meanwhile, patients will be given education to ease back pain and improve sleep.
48318899|NCT01142284|DRUG|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
48318900|NCT01029431|DEVICE|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted \& the evaluation described below will be conducted. The first LMA will then be removed \& the other device inserted \& assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment \& before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, \& inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
47967533|NCT06507813|DRUG|ADC189 granules|"For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once."
48318901|NCT00039195|BIOLOGICAL|filgrastim|
48318902|NCT00039195|BIOLOGICAL|rituximab|
48318903|NCT00039195|DRUG|carboplatin|
48318904|NCT00039195|DRUG|cyclophosphamide|
48318905|NCT00039195|DRUG|doxorubicin hydrochloride|
48318906|NCT00039195|DRUG|etoposide|
48318907|NCT00039195|DRUG|ifosfamide|
48318908|NCT00039195|DRUG|prednisone|
48318909|NCT00039195|DRUG|vincristine sulfate|
48318910|NCT00039195|PROCEDURE|peripheral blood stem cell transplantation|
48318911|NCT00039195|RADIATION|radiation therapy|
48318912|NCT02358369|DRUG|Bimatoprost|Bimatoprost sustained release Ocular Insert
48318913|NCT02358369|DRUG|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
48318914|NCT02358369|DEVICE|Placebo Ocular Insert|Placebo ocular insert OU.
48645689|NCT03203603|OTHER|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
47967534|NCT06507813|DRUG|Placebo of ADC189 granules|Placebo. Given once only.
48318915|NCT02358369|DRUG|Placebo Eye Drops|Placebo eye drops BID OU.
48318916|NCT02518308|BEHAVIORAL|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
48318917|NCT03497026|DEVICE|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
48318918|NCT05491694|DRUG|Toripalimab|Toripalimab 240mg
48318919|NCT05491694|DRUG|Epirubicin|90mg/m2，IVD，q3w
48645690|NCT06630390|DRUG|Daridorexant 50 mg|Administered consistent with labeling from the US Food and Drug Administration.
48645691|NCT06630390|OTHER|Placebo|Identical appearing to daridorexant
48645692|NCT04191135|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
48645693|NCT04191135|DRUG|Olaparib|oral tablets
48318920|NCT05491694|PROCEDURE|High Intensity Focused Ultrasoun|HIFU treatment at lesion site
48318921|NCT05491694|DRUG|Cyclophosphamide|600mg/m2，IVD，q3w
48318922|NCT05491694|DRUG|Carboplatin|AUC 5，IVD，q3w
48318923|NCT05491694|DRUG|Nab-paclitaxel|260mg/m2，IVD，q3w
48318924|NCT05122195|OTHER|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
48318925|NCT02612961|OTHER|3mL of normal saline from the pink sodium chloride bullet|
48318926|NCT02612961|OTHER|Sham Comparator of 3mL normal saline|
48318927|NCT03414008|DRUG|BI 1291583|Single dose
48318928|NCT03414008|DRUG|Matching placebo: Tartaric acid|Single dose
48318929|NCT02029352|DRUG|Sinecatechins 10%|
48318930|NCT02029352|DRUG|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
48318931|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at \<3-day and placebo supplementation at 6-wk postpartum.
48318932|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (6 wk postpartum)|Placebo supplementation at \<3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
48318933|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at \<3-day and 6-wk postpartum
48318934|NCT02043223|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation, both at \<3-day and 6-wk postpartum.
48318935|NCT06504329|PROCEDURE|MCAT + subepithelial connective tissue graft|After the tunnel is prepared using the MCAT technique, a connective tissue graft harvested from the palate will be placed into the tunnel with guiding sutures and secured in place. The flap will be advanced coronally to cover the connective tissue, ensuring primary closure.
48318936|NCT06504329|PROCEDURE|MCAT + enamel matrix derivate|Participants in the Experimental groups will receive Emdogain as part of the treatment protocol. Emdogain will be applied in gel form with a dosage of 0.15 ml. It will be administered in conjunction with the modified coronally advanced tunnel (MCAT) technique. Emdogain will be used as an enamel matrix derivative to promote periodontal tissue regeneration.
48318937|NCT06504329|PROCEDURE|MCAT + subepithelial connective tissue graft + enamel matrix derivative|As part of the treatment protocol, participants will receive Emdogain in addition to the connective tissue graft. Emdogain will be applied in gel form at a dosage of 0.15 ml. It will be used in conjunction with the Modified Coronally Advanced Tunnel (MCAT) technique. Emdogain, an enamel matrix derivative, will be used to support periodontal tissue regeneration.
48318938|NCT01885078|DRUG|Baricitinib|Administered orally
48318939|NCT01885078|DRUG|Placebo|Administered orally
48645694|NCT04191135|DRUG|Carboplatin|IV infusion
48318940|NCT06431243|DRUG|A group Purinostat Mesylate 6mg/m2|Purinostat Mesylate 6mg/m2 + EM 25mg
48318941|NCT06431243|DRUG|A group Purinostat Mesylate 8.4mg/m2|Purinostat Mesylate 8.4mg/m2 + EM 25mg
48318942|NCT06431243|DRUG|A group Purinostat Mesylate 11.2mg/m2|Purinostat Mesylate 11.2mg/m2 + EM 25mg
48497986|NCT03290365|DRUG|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
48645695|NCT04191135|DRUG|Gemcitabine|IV infusion
47967535|NCT06507813|DRUG|Placebo of Oseltamivir granules|For patients 2-4 years old. Placebo. Given 10 times (5 days, BID).
48318943|NCT06431243|DRUG|A group Purinostat Mesylate 15.0mg/m2|Purinostat Mesylate 15.0mg/m2 + EM 25mg
48318944|NCT06431243|DRUG|B group Purinostat Mesylate 6.0mg/m2|Purinostat Mesylate 6.0mg/m2 + Tislelizumab 200mg
48318945|NCT06431243|DRUG|B group Purinostat Mesylate 8.4 mg/m2|Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg
48318946|NCT06431243|DRUG|B group Purinostat Mesylate 11.2 mg/m2|Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
48497987|NCT03492827|DRUG|chlorhexidine acetate gargle|observe whether it can achieve the effect of preventing postoperative infection
48497988|NCT02069483|BEHAVIORAL|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
47967536|NCT06507813|DRUG|Oseltamivir granules|For patients 2-4 years old. Patients \<15kg, given 30mg×10 times (5 days, BID) Oseltamivir granules. 15kg \~ \<23kg, given 45mg×10 times (5 days, BID) Oseltamivir granules. 23kg \~ \<40kg, given 60mg×10 times (5 days, BID) Oseltamivir granules. ≥40kg, given 75mg×10 times (5 days, BID) Oseltamivir granules.
47967537|NCT03138278|OTHER|Telephone support on demand|Dedicated phone number for help and advice for caregivers
47967538|NCT00263601|BIOLOGICAL|Allergovit 6-grasses|Subcutaneous injections
48318947|NCT06431243|DRUG|B group Purinostat Mesylate 15.0 mg/m2|Purinostat Mesylate 15.0mg/m2 + Tislelizumab 200mg
48318948|NCT00321425|PROCEDURE|brachial plexus block|
48318949|NCT00321425|PROCEDURE|ultrasound guidance|
48318950|NCT00321425|PROCEDURE|electrical nerve stimulation|
48318951|NCT04350229|DRUG|Drug omission|Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
48318952|NCT04350229|OTHER|Control group|No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
48318953|NCT03802838|DEVICE|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
48318954|NCT03802838|DRUG|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
48318955|NCT02346500|DEVICE|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
48318956|NCT05052541|DRUG|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
48318957|NCT05052541|DRUG|THC|Oral solution containing 5mg THC per 1 ml
48318958|NCT05052541|DRUG|Placebo|Oral solution containing no active drug
48645696|NCT06689098|DIAGNOSTIC_TEST|Magnetocardiography scan|The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.
48645697|NCT05626608|DEVICE|Classical ring stimulation|Unilateral or bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
48645698|NCT05626608|DEVICE|Stimulation in directional mode|Directional stimulation of the subthalamic nucleus in the treatment of Parkinson's disease using Boston Cartesia(TM) electrodes
48645699|NCT00752362|DEVICE|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
48645700|NCT00752362|DEVICE|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
48645701|NCT00752362|DEVICE|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
48645702|NCT03615430|PROCEDURE|serratus plane block with local anesthetic|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
48645703|NCT03615430|PROCEDURE|serratus plane block with saline|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
48486529|NCT03737318|BEHAVIORAL|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
48486530|NCT03737318|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
48645704|NCT02184442|DEVICE|TAVR Implantation with SAPIEN XT|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
48645705|NCT02184442|DEVICE|TAVR Implantation with SAPIEN|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
48318959|NCT04245527|DEVICE|Joovv Infrared Light Device|Joovv is the leading manufacturer of personal, in-home red light therapy devices
48645706|NCT04950764|DRUG|Seladelpar 10 mg|Seladelpar 10 mg single oral dose
48318960|NCT05442294|BEHAVIORAL|Juego de Llaves|The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
48339999|NCT04587960|PROCEDURE|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
48486531|NCT02122718|DRUG|Allopurinol|
48486532|NCT02122718|DRUG|Placebo|
48645707|NCT04950764|DRUG|Seladelpar 10 mg or less|Seladelpar 10 mg or less, once daily for 28 days
48645708|NCT01674361|DRUG|Bitopertin|Bitopertin once daily orally.
48645709|NCT01674361|DRUG|Placebo|Placebo matched to bitopertin once daily orally.
48645710|NCT01674361|DRUG|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
48645711|NCT02430103|DRUG|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
48645712|NCT01517178|DEVICE|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
48645713|NCT01517178|DEVICE|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
48645714|NCT06480461|DRUG|VGN-R09b|This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
47967539|NCT00263601|OTHER|Placebo|Subcutaneous injections
47967540|NCT03118648|DIAGNOSTIC_TEST|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
47967541|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
47967542|NCT02197247|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
47967543|NCT02197247|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
47967544|NCT02197247|PROCEDURE|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
47967545|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
47967546|NCT01550289|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
47967547|NCT01550289|BIOLOGICAL|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
47967548|NCT01776892|DRUG|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
47967549|NCT01776892|PROCEDURE|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
47967550|NCT00426790|PROCEDURE|Positive end-expiratory pressure|
47967551|NCT04833881|OTHER||
47967552|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
47967553|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
47967554|NCT05366946|OTHER|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
47967555|NCT06411197|OTHER|Hypertonic saline injection|Injection with hypertonic saline (7%)
47967556|NCT06411197|OTHER|Isotonic saline injection|Injection with isotonic saline (0.9%)
47967557|NCT02710396|DRUG|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks."
48645715|NCT06566703|BEHAVIORAL|All Nations Snuff Out Smokeless|All Nations Snuff Out Smokeless is a culturally tailored smokeless tobacco cessation program that incorporates group-based and individual counseling.
47967558|NCT02710396|DRUG|Carboplatin|Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
47967559|NCT02710396|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
47967560|NCT02710396|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
47967561|NCT01459471|PROCEDURE|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
48318961|NCT04180800|OTHER|Lubben Social Network Scale - 6|One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
48318962|NCT00760604|PROCEDURE|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
48486533|NCT02664857|DRUG|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
48486534|NCT02664857|DRUG|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
47967562|NCT06504823|OTHER|Light level|light application
47967563|NCT02801396|DEVICE|Etafilcon A Design 1 (Test 1)|
47967564|NCT02801396|DEVICE|Etafilcon A Design 2 (Test 2)|
47967565|NCT02801396|DEVICE|Etafilcon A (Control)|
47967566|NCT02406716|OTHER|Biospecimen retention|
47967567|NCT01371175|BIOLOGICAL|DNA.HIVA|0.5mg DNA.HIVA or placebo
47967568|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^6 pfu MVA or placebo
47967569|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^7 pfu MVA or placebo
47967570|NCT01371175|BIOLOGICAL|MVA.HIVA|2.5x10\^8 pfu MVA or placebo
47967571|NCT00880009|DRUG|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
47967572|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
47967573|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
48318963|NCT05390424|DIAGNOSTIC_TEST|Blood collection using Dried Blood Spot|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
48645716|NCT06566703|BEHAVIORAL|Healthy Living|Healthy Living is an educational program that provides information about diet, exercise, stress, and general health. It uses group-based and individual discussion, along with educational materials.
48645717|NCT01335685|DRUG|Ixazomib|Ixazomib capsules
48318964|NCT03256474|OTHER|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
48318965|NCT02626572|DRUG|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
48645718|NCT01335685|DRUG|Melphalan|Melphalan tablets
48645719|NCT01335685|DRUG|Prednisone|Prednisone tablets
48645720|NCT01104870|DRUG|UT-15C|oral
48645721|NCT06691711|BEHAVIORAL|ASPIRE support package|The ASPIRE support package has a modular structure with core modules that all participating families are encouraged to complete initially, followed by optional modules which the family is supported to select from according to their strengths and needs. Core modules provide psychoeducation for the caregiver and optional modules contain information on the selected positive psychology topic together with instructions for suggested activities to be completed by the caregiver with their child to implement evidence-based positive psychology strategies. All resources can be accessed both electronically via an online portal or via the printed resource pack. Each caregiver is supported through the programme by a trained practitioner who offers regular support sessions (up to 8 in total) to provide information, advice and encouragement. Support sessions can take place face-to-face, by video call or over the phone according to participant preference.
48645722|NCT06542380|DEVICE|TAVI, pacemaker|Retrospective analysis of need for pacemaker implantation after TAVI
48645723|NCT01414647|DIETARY_SUPPLEMENT|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
48645724|NCT01414647|DIETARY_SUPPLEMENT|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
48645725|NCT01414647|OTHER|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
48645726|NCT06687239|DIAGNOSTIC_TEST|Blinded estimation of fetal weight|Blinded ultrasound-based estimation of fetal weight
48645727|NCT06687239|DIAGNOSTIC_TEST|Non blinded estimation of fetal weight|Non-blinded ultrasound-based estimation of fetal weight
48318966|NCT02626572|DRUG|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
48318967|NCT02626572|DRUG|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
48318968|NCT02626572|DRUG|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
48318969|NCT06552806|DIETARY_SUPPLEMENT|SLAB51|One dose of SLAB51 is administered after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
48486535|NCT01304758|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
48486536|NCT03144102|BEHAVIORAL|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
48486537|NCT03144102|DEVICE|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
48497989|NCT02069483|BEHAVIORAL|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
48645728|NCT06688617|OTHER|Swedish Hand Massage|Swedish technique hand massage: Effleurage-petrissage-friction-tapotement,-vibration-effleurage
48645729|NCT05272176|BEHAVIORAL|Coping Long Term with Active Suicide Program (CLASP)|Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
48645730|NCT06690619|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48645731|NCT06690619|DIETARY_SUPPLEMENT|315 mg Alpha-GPC|350 mg of 90% pure alpha-GPC (315 mg)
48645732|NCT06690619|DIETARY_SUPPLEMENT|630 mg Alpha-GPC|700 mg of 90% pure alpha-GPC (630 mg)
48645733|NCT06691490|DEVICE|Transcranial Magnetic Stimulation Sham|cTBS over SMA and cTBS over precuneus (control site)
48645734|NCT03071302|OTHER|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
48645735|NCT06688097|BEHAVIORAL|Compression of esophageal|Before the start of FMV, ultrasound is used to locate the esophagus, and pressure is applied to the esophagus at the cricoid level to collapse the esophageal lumen. Esophageal pressure is released just before tracheal intubation following 4 minutes of ventilation.
48645736|NCT05615350|OTHER|Meals served during breakfast with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
48645737|NCT05615350|OTHER|Meals served during lunch with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
48645738|NCT05196529|OTHER|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
48645739|NCT06686121|BEHAVIORAL|Home Based Exercise|This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention
48318970|NCT04039633|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
48318971|NCT04039633|PROCEDURE|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
48318972|NCT02066194|PROCEDURE|Electroacupuncture|
48318973|NCT00236119|DRUG|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
48318974|NCT00236119|DRUG|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
48318975|NCT00236119|DRUG|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
48318976|NCT00236119|DRUG|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
48318977|NCT01147575|DIETARY_SUPPLEMENT|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
48318978|NCT01147575|DIETARY_SUPPLEMENT|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
48318979|NCT04008901|DRUG|BST-104 (Lonicera Flos Extract)|175 mg of Lonicera Flos extract in 1 tablet (300 mg)
48318980|NCT04008901|DRUG|Placebo oral tablet|0 mg of Lonicera Flos extract in 1 tablet (300 mg)
48318981|NCT03579550|PROCEDURE|office hysteroscopic metroplasty intervention arm|One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
48486538|NCT03144102|BEHAVIORAL|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
48486539|NCT03144102|DEVICE|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
48486540|NCT00368095|BEHAVIORAL|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
48645740|NCT06686121|DRUG|Nitrate Rich Beetroot Juice|Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.
48318982|NCT02205606|DRUG|HGP0816 5mg|P.O.
48318983|NCT02205606|DRUG|HGP0816 10mg|P.O.
48318984|NCT02205606|DRUG|HGP0816 20mg|P.O.
48318985|NCT02205606|DRUG|HCP1306 5/10mg|P.O.
48318986|NCT02205606|DRUG|HCP1306 10/10mg|P.O.
48318987|NCT02205606|DRUG|HCP1306 20/10mg|P.O.
48486541|NCT03609281|RADIATION|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
48486542|NCT03693534|DIAGNOSTIC_TEST|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
48318988|NCT06290271|OTHER|Intracranial artery flow pattern|the cerebral blood flow patterns observed after the occluded artery has been recanalized.
48486543|NCT03827941|OTHER|1 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
48486544|NCT03827941|OTHER|20 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
48318989|NCT02932332|OTHER|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
48318990|NCT02932332|OTHER|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
48318991|NCT02932332|OTHER|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
48340000|NCT04587960|PROCEDURE|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
48340001|NCT02321072|DRUG|Oxygen|
48318992|NCT02932332|OTHER|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
48318993|NCT04399512|PROCEDURE|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
48318994|NCT06372821|DRUG|NIO752|Antisense oligonucleotide
48318995|NCT06372821|OTHER|Placebo|Saline
48318996|NCT04117178|DRUG|Donepezil|Adjustment of treatment with donepezil according to serum level.
48318997|NCT04117178|DRUG|Memantine|Adjustment of treatment with memantine according to serum level.
48318998|NCT04117178|DIAGNOSTIC_TEST|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
48318999|NCT00119730|DRUG|Fludarabine|Given on days 1-3 of each 28-day cycle
48319000|NCT00119730|DRUG|Mitoxantrone|Given on day 1 of each 28-day cycle
47967574|NCT05081973|OTHER|A model for predicting extubation success based on extubation readiness estimator and lung ultrasonography score|"Parameters to be recorded before and after extubation to create a new dual extubation model from all babies who met the extubation criteria included in the study:~1. Lung ultrasound score: Lung ultrasound will be performed prior to the extubation and after the extubation. Lung aeration will be scored based on three chest areas for each side (upper anterior, lower anterior and lateral) and a score of 0 to 3 points will be given for each area (Total score ranges from 0 to 18 points).~2. Probability of Successful Extubation: It will be calculated by extubation readiness estimator provided by the website named http://extubation.net/.~This parameter will be calculated only 1 hour prior to the scheduled extubation time."
47967575|NCT04455113|DIAGNOSTIC_TEST|Phosphorus level|infusion
47967576|NCT00920712|DRUG|Weiqi decotion|Decoction ,two times a day
47967577|NCT00004730|DRUG|magnesium sulfate|
47967578|NCT05912010|DIAGNOSTIC_TEST|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
48319001|NCT00119730|DRUG|Rituximab|Given on day 1 of each 28-day cycle
48319002|NCT00119730|DRUG|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
47967579|NCT03072147|DRUG|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
47967580|NCT03072147|DRUG|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
47967581|NCT00569608|OTHER|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
47967582|NCT02521870|DRUG|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses).
47967583|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
47967584|NCT02521870|DRUG|SD-101(2)|Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
47967585|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
47967586|NCT02521870|BIOLOGICAL|SD-101(3)|Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
47967587|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
47967588|NCT01081678|DRUG|Placebo|Administered by subcutaneous (under the skin) injection
47967589|NCT01081678|DRUG|Romosozumab|Administered by subcutaneous injection
48319003|NCT03761719|OTHER|No intervention|No intervention
48319004|NCT03570034|DEVICE|Obalon Balloon System|Obalon Balloon System with a moderate intensity Weight Loss Behavioral Modification Program
48319005|NCT02494739|OTHER|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
48319006|NCT02494739|OTHER|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
48319007|NCT01885858|BEHAVIORAL|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
48340002|NCT01878227|DRUG|Coenzyme A|Coenzyme A 400mg per day
48340003|NCT01878227|DRUG|Fenofibrate 200mg|Fenofibrate 200mg per day
48340004|NCT01402388|BEHAVIORAL|Group lifestyle programme|
48340005|NCT05387213|BEHAVIORAL|Team Huddles|Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
48319008|NCT01885858|BEHAVIORAL|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
48319009|NCT05785390|DRUG|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
48319010|NCT05785390|OTHER|Placebo|Identical placebo
48319011|NCT05833685|OTHER|no intervention|no intervention
48319012|NCT06348407|DRUG|IgE monoclonal antibody|omalizumab
48319013|NCT01892618|DRUG|Prevenar 13|13-valent pneumococcal conjugated vaccine
48319014|NCT01892618|DRUG|Pneumovax|23-valent pneumococcal polysaccharide vaccine
48319015|NCT02997384|OTHER|Information|information of women about their risk of breast cancer and the screening methods recommended for them
48319016|NCT02604927|DIETARY_SUPPLEMENT|Beta-alanine|
48319017|NCT02604927|DIETARY_SUPPLEMENT|Dextrose|
48645741|NCT06686121|BEHAVIORAL|Attention Control|"Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging age pages relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D."
47967590|NCT05959031|DEVICE|kTMP|a new non-invasive brain stimulation tool
47967591|NCT05959031|DEVICE|Sham kTMP|a new non-invasive brain stimulation tool with sham setting selected
47967592|NCT06504680|PROCEDURE|Repair of flexor tendon injury zone ll using 8- strand|Repair cut flexor zone ll using 8-strand with and without splinting the wrist
47967593|NCT00573612|BEHAVIORAL|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
48319018|NCT03095924|OTHER|News items with spin|Interpretation of news items with spin
48319019|NCT03095924|OTHER|News items without spin|Interpretation of news items without spin
48319020|NCT02727270|OTHER|No Intervention - Observational Study|No Intervention - Observational Study
48319021|NCT00396149|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
48319022|NCT00396149|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
48319023|NCT02637726|DRUG|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
48319024|NCT02637726|DRUG|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
48319025|NCT02637726|DRUG|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
48319026|NCT02637726|DEVICE|EEG Monitoring|Maintaining a bispectral index between 45 and 55
48319027|NCT02637726|DRUG|Remifentanil|Remifentanil at discretion of the anesthesiologist
48319028|NCT05852678|OTHER|cohort|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
48645742|NCT06686121|DRUG|Placebo Beetroot Juice Without Nitrate|Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.
48319029|NCT00764478|DRUG|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
48319030|NCT00764478|DRUG|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
48319031|NCT00764478|DRUG|Placebo|placebo sublingual tablet, administered BID for 21 days
48319032|NCT03861195|PROCEDURE|laparoscopic surgery|patients affected by uterine diseases that undergo treatment
48645743|NCT04187404|BIOLOGICAL|EO2401|Multiple dose of EO2401
48645744|NCT04187404|BIOLOGICAL|Nivolumab|Multiple dose of nivolumab
48645745|NCT02434809|PROCEDURE|Bronchoscopic Implantation|Calypso transponders
48645746|NCT02434809|DEVICE|Cone-Beam CT-Guided|
48645747|NCT02434809|RADIATION|stereotactic body radiation treatments|
48319033|NCT06191887|BIOLOGICAL|Autologous BAFFR-targeting CAR T Cells|Given IV
48319034|NCT06191887|DRUG|Bendamustine|Given IV
48319035|NCT06191887|PROCEDURE|Biopsy|Undergo biopsy
48319036|NCT06191887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48319037|NCT06191887|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy/aspirate
48486545|NCT01014416|DRUG|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
47967594|NCT00573612|BEHAVIORAL|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
47967595|NCT05909748|DEVICE|GEMINUS Transcatheter Aortic Valve Implantation system|Implantation of the GEMINUS Transcatheter Aortic Valve Implantation system
47967596|NCT01195558|OTHER|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
47967597|NCT06505876|BEHAVIORAL|Basic treatment|including anti-infection therapy, blood pressure and blood glucose control
48319038|NCT06191887|PROCEDURE|Computed Tomography|Undergo CT scan
48319039|NCT06191887|DRUG|Cyclophosphamide|Given IV
48319040|NCT06191887|PROCEDURE|Echocardiography|Undergo echocardiography
48319041|NCT06191887|DRUG|Fludarabine|Given IV
48319042|NCT06191887|PROCEDURE|Leukapheresis|Undergo leukapheresis
48319043|NCT06191887|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48319044|NCT06191887|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48340006|NCT03105245|OTHER|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
48319045|NCT01231360|OTHER|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
48319046|NCT01231360|OTHER|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
48319047|NCT00001735|PROCEDURE|Gene therapy|
48319048|NCT01348425|DEVICE|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
48319049|NCT01348425|DEVICE|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
48319050|NCT03924141|BEHAVIORAL|Training in de-escalation|Will receive one hour of de-escalation training
48319051|NCT02745132|OTHER|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
48319052|NCT05674500|OTHER|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
48319053|NCT05674500|OTHER|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
47967598|NCT06505876|DEVICE|Oral Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48319054|NCT03432052|PROCEDURE|centralization|Wrist centralization involves aligning the distal ulna with the middle finger metacarpal and passing a large Kirschner wire or a small Steinmann pin through the middle finger metacarpal, carpus, and ulna for temporary stability. This is followed by soft tissue balancing in order to counteract the volar and radial directed force vectors consisting of reefing the ulnocarpal wrist capsule and transferring the extensor carpi ulnaris muscle distally and flexor carpi ulnaris muscle dorsally on the wrist.
48319055|NCT01566643|DRUG|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
48319056|NCT01566643|DRUG|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
48319057|NCT01566643|DRUG|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
48319058|NCT00029991|DRUG|Gingko Biloba (Herb)|
48319059|NCT04764409|PROCEDURE|Chemoembolization|Transarterial Chemoembolization (TACE)
48645748|NCT06689228|OTHER|Rational Drug Use Training|Rational Drug Use Training and Tele-monitoring will include information on drugs and their importance, rational drug use, rational drug use in haemodialysis patients, harms of irrational drug use, benefits of rational drug use, obstacles encountered in rational drug use, ways to overcome obstacles encountered in rational drug use, and increasing self-efficacy. The first training is planned to last approximately 30-35 minutes for each patient and the second training (summary training) is planned to last approximately 15-20 minutes. With telemonitoring, reminder messages will be sent to patients' phones at intervals.
48319060|NCT04764409|PROCEDURE|Chemoinfusion|Transarterial Infusion (TAI)
48319061|NCT05640674|DRUG|Ibuprofen|Non-opioid
48319062|NCT05640674|DRUG|Hydrocodone/acetaminophen|Opioid
48319063|NCT05640674|DRUG|Acetaminophen|Non-opioid
48645749|NCT06679517|PROCEDURE|TAVI|Clinical follow-up up to 10 years of patients undergoing TAVI
48340007|NCT00430885|DRUG|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
48486546|NCT05717582|DRUG|apalutamide|Patients receive apalutamide 240mg,qd,po.
48486547|NCT05717582|DRUG|androgen deprivation therapy|Patients receive systemic ADT.
47967599|NCT06505876|DEVICE|Nasogastric Tube Feeding|The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
47967600|NCT05673889|DRUG|ARV-471|Experimental
47967601|NCT05673889|DRUG|Dabigatran etexilate|Probe substrate
47967602|NCT03486223|DRUG|GSK2256294|Drug will be taken daily by mouth for 7 days.
47967603|NCT03486223|DRUG|Placebo oral capsule|Placebo will be taken daily by mouth for 7 days.
47967604|NCT00002105|DRUG|Doxorubicin hydrochloride (liposomal)|
47967605|NCT00002105|DRUG|Bleomycin sulfate|
47967606|NCT00002105|DRUG|Vincristine sulfate|
48645750|NCT06686784|BEHAVIORAL|After School Plus|"The afterschool program as usual runs M-H and consists of a variety of clubs from which middle school students chose to enroll for a semester (\~4 months). Clubs are offered on either a M/W or T/H schedule. Students receive a snack in the cafeteria each day before attending their class.~Afterschool plus is the same as Afterschool as Usual with the addition of young adult mentors. Following snack, mentors will lead students in a short emotion regulation exercise including physical activity and breathing exercises. Mentors will prompt students to identify how they are feeling and make connections between the activities they are doing and their mood and then do activities with students in each class. On T/H, \~4 mentors will lead a new DiscoverU  club which is based on behavioral activation principles and spends more time helping students identify and do more activities that improve their mood. The class promotes physical activity as an important strategy for mental health."
47967607|NCT00944905|BIOLOGICAL|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
47967608|NCT03621397|DEVICE|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
47967609|NCT03449797|PROCEDURE|AVS performed with no intraprocedural rapid cortisol assay|AVS performed plus intraprocedural rapid cortisol assay
47967610|NCT03449797|PROCEDURE|AVS performed plus intraprocedural rapid cortisol assay|Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
47967611|NCT05021497|OTHER|Global Positional Re-education|A series of gentle active movements and postures aimed at realigning joints and stretching shortened muscles. GPR includes 8 therapeutic postures in lying, sitting and standing.
47967612|NCT05021497|OTHER|Conventional Physical Therapy Program|Axial traction will be given for 5 minutes, followed by mobilization of the muscle fascia along with static stretching of the scalene, levator scapulae, upper trapezius, sternocleidomastoid and pectoralis minor muscles.
47967613|NCT04935320|DRUG|HTL0016878.HCl Solution 10 mg|Oral solution fasted
47967614|NCT04935320|DRUG|HTL0016878.Citrate Capsule 10 mg|Oral capsule fed or fasted
47967615|NCT03060629|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
47967616|NCT03060629|BIOLOGICAL|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
47967617|NCT03060629|BIOLOGICAL|Placebo|Participants will receive matching placebo.
47967618|NCT02250378|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
47967619|NCT02250378|PROCEDURE|therapeutic conventional surgery|Undergo wedge resection
47967620|NCT02250378|OTHER|laboratory biomarker analysis|Correlative studies
47967621|NCT02250378|OTHER|quality-of-life assessment|Ancillary studies
48319064|NCT05363683|PROCEDURE|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
47967622|NCT03823001|DIAGNOSTIC_TEST|virtual biopsy (VB) monitoring protocol|"1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
47967623|NCT00483639|OTHER|Medical chart review|medical chart review
47967624|NCT00483639|OTHER|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
47967625|NCT00483639|PROCEDURE|management of therapy complications|management of therapy complications
47967626|NCT00483639|PROCEDURE|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
47967627|NCT00483639|OTHER|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
47967628|NCT01072331|DRUG|MP-513|MP-513 10 mg, once a day, for 4 weeks
47967629|NCT01072331|DRUG|MP-513|MP-513 20 mg, once a day, for 4 weeks
47967630|NCT01072331|DRUG|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
47967631|NCT04718298|DEVICE|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
48319065|NCT05363683|PROCEDURE|Standard Care|Standard care post-operative physical therapy
48319066|NCT01929655|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
47967632|NCT05501301|OTHER|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
48319067|NCT05073835|DRUG|Semaglutide 3 mg|Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
48319068|NCT05073835|DRUG|Placebo|Placebo
48319069|NCT04848454|DRUG|Camrelizumab with vinorelbine and cisplatin|Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
48319070|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
48319071|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
48319072|NCT05902429|DRUG|Cladribine 10 mg oral tablet|Cladribine tablets (Mavenclad®, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body weight distributed over 2 years as one treatment course of 1.75 mg/kg per year. Each treatment course will consist of 2 weeks of treatment, one at the beginning of the first month and one at the beginning of the second month of the respective year of treatment. Each treatment week will consist of 4 or 5 days in which the participant will receive 10 mg or 20 mg (1 or 2 tablets, respectively) as a single daily dose, depending on body weight, according to the tables available in label. Upon completion of the two treatment courses, no further courses will be required in years 3 and 4.
48319073|NCT02486952|DRUG|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
48319074|NCT02486952|DRUG|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
48319075|NCT02486952|DRUG|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
48319076|NCT02486952|DRUG|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
48319077|NCT02486952|DRUG|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
48319078|NCT03903744|PROCEDURE|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
48319079|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
48486548|NCT05717582|PROCEDURE|cytoreductive radical prostatectomy with/without pelvic lymph node dissection|Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
48486549|NCT05717582|RADIATION|metastasis-directed therapy with radiation|Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
48486550|NCT03757780|OTHER|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
48486551|NCT00359632|DRUG|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
48645751|NCT06690684|BIOLOGICAL|Hematological indicators|This project is a retrospective clinical cohort study. STEMI patients undergoing PCI were selected to explore whether hematological indicators such as PIV, SHR, and Lp(a) can improve the accuracy of predicting short-term MACE events in STEMI patients.
47967633|NCT00288054|BIOLOGICAL|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
48319080|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56
48319081|NCT03038243|OTHER|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
48319082|NCT00305253|DEVICE|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
48319083|NCT00414778|DRUG|LHT344|
48319084|NCT01783717|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
48319085|NCT03951688|OTHER|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
48319086|NCT05355727|OTHER|Clinical decision support tool recommended outcome|The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
48486552|NCT00359632|DRUG|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
48486553|NCT05536726|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
47967634|NCT00288054|DRUG|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
48645752|NCT06690684|BIOLOGICAL|Serological indicators in patients with myocardial infarction|This study selected STEMI patients who underwent PCI and collected their hematological indicators to explore the value of PIV, SHR, Lp(a) and other indicators in improving the accuracy of predicting MACE in STEMI patients in the short term.
48319087|NCT05678946|OTHER|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
48319088|NCT05678946|OTHER|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
48319089|NCT05678946|OTHER|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
48319090|NCT01418053|DRUG|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
47967635|NCT00288054|RADIATION|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
48319091|NCT01418053|DRUG|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
48319092|NCT02136199|OTHER|Active Implementation of ShareEBM Toolkit|
48319093|NCT02136199|OTHER|Passive Dissemination of Share EBM|
48319094|NCT00862316|DEVICE|Oxford Unicompartmental Knee|Knee Arthroplasty
48319095|NCT05080959|DRUG|CPL-01|Subjects will receive a single dose
48319096|NCT05080959|DRUG|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
48319097|NCT05080959|DRUG|Placebo|Subjects will receive a single dose
48645753|NCT06690684|BIOLOGICAL|Levels of biomarkers in blood of patients with acute myocardial infarction|Hemoglobin, neutrophil count, lymphocyte count, monocyte count and platelet count values, N-terminal pro-B type natriuretic peptide (NT-proBNP), peak creatine kinase isoenzymes (CK-MB), peak troponin T levels, total cholesterol (TC), fasting blood glucose (FBG), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and blood urine nitrogen, blood creatinine (Cr) and other indicators
48645754|NCT02311374|OTHER|Brain connectivity and physiology|Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
48645755|NCT02311374|OTHER|Brain Wave|ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
48645756|NCT06690229|DRUG|glass ionomer cement|A cement used for crown cementation
48319098|NCT00574119|DRUG|spironolactone|spironolactone 50 mg daily for 6 months
48319099|NCT00423085|DRUG|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
48486554|NCT05536726|DRUG|608 Q4W|608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
48645757|NCT06690229|DRUG|self-adhesive resin cement|A cement used for crown cementation
48645758|NCT06690229|DRUG|resin modified glass ionomer cement|A cement used for crown cementation
48645759|NCT03521609|BEHAVIORAL|Emotional intelligence intervention|Brief group intervention based on emotional intelligence
48645760|NCT06678854|OTHER|Training about Aphasia|Training will include direct teaching, aphasia simulations, scenario-based training and a panel with persons with aphasia with the goal of increasing confidence for law enforcement officers and first responders providing services to and communicating with persons with aphasia.
48486555|NCT05536726|DRUG|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
48319100|NCT00423085|DRUG|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
48319101|NCT01056341|DRUG|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
48319102|NCT01056341|DRUG|Placebo|Treatment with placebo for 6 months
48319103|NCT00642746|DRUG|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
48319104|NCT00642746|DRUG|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
48319105|NCT00642746|DRUG|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
48319106|NCT00642746|DRUG|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
48319107|NCT00642746|DRUG|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
48319108|NCT04271475|DRUG|Macitentan|Participants will receive Macitentan film-coated tablets orally od.
48319109|NCT04271475|DRUG|Placebo|Participant will receive matching placebo tablets orally od.
48319110|NCT04872335|OTHER|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
48117015|NCT04062760|DRUG|Early sequential nephron blockade|"After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value"
48117016|NCT04446598|DEVICE|non-ablative SMOOTH mode Erbium YAG laser|Erbium:YAG (Er:YAG) laser with non-ablative SMOOTH™ mode
48319111|NCT04872335|OTHER|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
48319112|NCT01222572|RADIATION|Stereotactic boost|
48319113|NCT01222572|RADIATION|Conventional RT|
48319114|NCT01222572|DRUG|Etoposide|
48319115|NCT01222572|DRUG|Cisplatin|
48319116|NCT02385877|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
48645761|NCT06688968|BEHAVIORAL|neuropsychologist interview|"It will take place either at the hospital or at the participant's home.~This interview will consist of :~* socio-demographic data collection~* neuropsychological tests:~  * MMSE test (Mini Mental State Examination) cognitive function~ * RL-RI-16 test (16-item free recall/indexed recall test)~ * BECS test (Semantic knowledge assessment battery )~ * WCST test (Wisconsin Card Sorting Test )~ * Musical Cognition Test~ * Help from the participant's relative to answer certain questions, in particular the MuseEQ-24 questionnaire"
48319117|NCT02385877|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
48319118|NCT00852189|DRUG|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
48319119|NCT00852189|DRUG|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
48319120|NCT00852189|DRUG|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
48645762|NCT06688968|BEHAVIORAL|questionnaire|"The participant answers questionnaires:~* Questionnaire MusEQ-24 self reported (Music Engagement Questionnaire)~* Questionnaire BMRQ (Barcelona Reward Music Questionnaire)~* Questionnaire SHAPS (Snaith-Hamilton Pleasure Scale)~* Questionnaire LARS (Lille's Apathy Rating Scale)~* Questionnaire PHQ-9 (Patient Health Questionnaire 9 items)"
48645763|NCT06368193|DEVICE|Neuralert Monitor|Device to identify upper extremity asymmetry in patients who are high risk for stroke.
48117017|NCT04446598|DRUG|Tadalafil 5mg|oral tadalafil 5 mg was administered daily over a period of two months
48117018|NCT01109745|OTHER|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
48319121|NCT01941524|DRUG|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
48319122|NCT01941524|DRUG|Beractant instillation|aEEG and NRs monitoring during beractant instillation
48319123|NCT02843646|DEVICE|Walk Aide training|
48319124|NCT06073652|OTHER|Control 1st age starter infant formula|A standard bovine milk-based term infant formula.
48319125|NCT06073652|OTHER|Experimental 1st age starter infant formula|Same content as Control formula plus supplemented with a HMO blend and a probiotic
48319126|NCT00494871|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
48319127|NCT00494871|DRUG|Warfarin|Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)
48319128|NCT00494871|DRUG|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
48319129|NCT00494871|DRUG|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
48319130|NCT03097224|BEHAVIORAL|Prehabilitation|Four weeks of tele-supervised prehabilitation
48319131|NCT00006604|DRUG|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
48319132|NCT00006604|DRUG|Ritonavir|Administered as 100 mg capsules or oral solution.
48319133|NCT06048406|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
48319134|NCT06552338|OTHER|Observational|No intervention. Study is observational
48319135|NCT00000875|DRUG|Indinavir sulfate|
48319136|NCT00000875|DRUG|Diphenhydramine hydrochloride|
48319137|NCT00000875|DRUG|Lymphocytes, Activated|
48645764|NCT06687356|PROCEDURE|Surgery with Intraoperative Optical Coherence Tomography application|Surgery with the application of intraoperative optical coherence tomography technique. Intraoperative optical coherence tomography technique can provide intraocular images and show changes in intraocular structures, assisting in analyzing the correlation between preoperative, intraoperative anterior segment structural changes and postoperative surgical effects in patients with lens diseases.
47967636|NCT00867724|DEVICE|Aer-O-Scope Colonoscopy|Screening Colonoscopy
48319138|NCT00000875|DRUG|Lamivudine|
48319139|NCT00000875|DRUG|Zidovudine|
48319140|NCT00000875|DRUG|Acetaminophen|
48486556|NCT00983918|DRUG|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
48486557|NCT00983918|DRUG|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
47967637|NCT02065115|OTHER|Cryotherapy (ice pack)|
47967638|NCT05349916|OTHER|Control|300 g rice porridge + 150 ml drinking water
47967639|NCT05349916|OTHER|Isomaltodextrin Low Dose|300 g rice porridge + (5 g IMD in 150 ml drinking water)
47967640|NCT05349916|OTHER|Isomaltodextrin High Dose|300 g rice porridge + (10 g IMD in 150 ml drinking water)
48486558|NCT00983918|DRUG|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
47967641|NCT05349916|OTHER|GPC partially digestible maltodextrin|300 g rice porridge + (15 g GPC fiber in 150 ml drinking water)
47967642|NCT05349916|OTHER|Resistant Starch Type 4|300 g rice porridge + (15 g RS4 starch in 150 ml drinking water)
47967643|NCT02393170|OTHER|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
48319141|NCT00000875|DRUG|Aldesleukin|
48319142|NCT06288958|OTHER|Quality of Life and social participation in Italian children with CP|CP-QOL and PEM-CY questionnaires are fulfilled by families of children.
48319143|NCT04944888|DRUG|Eliglustat|Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
48319144|NCT04944888|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
48319145|NCT02771652|BEHAVIORAL|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
48319146|NCT02771652|OTHER|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
48319147|NCT03449316|BEHAVIORAL|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
48319148|NCT06320938|OTHER|Neuroscience-Based Pain Education Combined with Home Exercise Program|Neuroscience-Based Pain Education and Home Exercises will be applied.
48486559|NCT00983918|DRUG|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
48486560|NCT03627234|BEHAVIORAL|Same Day Discharge|Patients will be randomized to same day discharge
48486561|NCT03627234|BEHAVIORAL|Overnight Stay|Patients will be randomized to stay overnight
48486562|NCT03050918|BEHAVIORAL|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
48486563|NCT03221348|BIOLOGICAL|CHO-H01|Glyco-engineered anti-CD20 antibody
48497990|NCT01159197|BEHAVIORAL|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
48645765|NCT06687356|PROCEDURE|Conventional surgery|Conventional lens surgery, without the application of intraoperative optical coherence tomography technique.
48319149|NCT06320938|OTHER|Myofascial Induction Techniques Combined with Home Exercise Program|Myofascial Induction Techniques and Home Exercises will be applied.
48319150|NCT06320938|OTHER|Home Exercises Group|Home Exercises wiil be applied
48319151|NCT01804322|OTHER|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug"
47967644|NCT02393170|OTHER|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
48319152|NCT01804322|OTHER|usual care|usual care according to the participating Epilepsy Centers
48319153|NCT02417467|OTHER|Nicotine E-Cigarette|
48319154|NCT02417467|OTHER|Non-Nicotine E-Cigarette|
48319155|NCT02417467|BEHAVIORAL|Counseling|
48319156|NCT01575197|BIOLOGICAL|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.
48319157|NCT05439694|DRUG|Tranexamic acid|have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
48319158|NCT06490419|DEVICE|Electrolipolysis|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, with physiological nutrient content: carbohydrates-50%, proteins-20%, fats-30% and fiber daily consumption of 30 - 40 g in dry form (grain and vegetables). Calorie distribution: breakfast-40%, lunch-40%, dinner-20%. Behavioral therapy to correct eating disorders: diary of food and lifestyle, motivational phone calls every week~Electrolipolysis:~the participants will receive electrolipolysis applied to abdomen, thigh and gluteal regions, 3 sessions/week, for 3 months, 60 minutes/session; 30 minutes on the abdomen and thigh and 30 minutes on gluteal region. the device will be set to cause a contraction for 4 seconds followed by a relaxation for 4 seconds with a pulse width of 400 microseconds and a frequency of 20 pulses per minute."
48319159|NCT06490419|DEVICE|ultrasound cavitation|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, as in the electrolipolysis group.~ultrasound cavitation (UC): The participants will be treated by UC on the abdomen for 30 minutes, two sessions per week for 3 months. From standing position, the abdominal area of each patient will be divided transversally into 3 parts; part I: from the xiphoid process to 3 cm above the umbilicus, part II: from 3cm above the umbilicus to 2 cm below the umbilicus and part III: from 2 cm below the umbilicus to the pubic bone. Vertically, each part will be divided into right and left segments in relation to the linea alba, forming a total of 6 abdominal segments.~The program of cavitation; frequency (40 kHz) will be chosen, the time will be adjusted at 30 minutes. The cavitational head will be, then, moved very slowly on each abdominal segment in a small circular movement for 5 minutes."
48319160|NCT00592553|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the respective arms.
48319161|NCT00592553|DRUG|Placebo|Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
48645766|NCT06689371|OTHER|Group A (Dry Needling)|The patient will receive dry needling on suboccipital, upper trapezius and SCM muscles with conventional therapy 3 sessions per week for 4 weeks.
47967645|NCT02795832|DRUG|ZPL-5212372 1% w/w Ointment BID|
47967646|NCT02795832|DRUG|Placebo Ointment BID|
48117019|NCT01109745|OTHER|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
48117020|NCT03009136|DRUG|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
48319162|NCT01797965|DRUG|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
48486564|NCT01435447|DRUG|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
48645767|NCT06689371|OTHER|Group B (Dry cupping)|Patients will receive dry cupping on suboccipital, upper trapezius and SCM muscles weeks with conventional therapy 3 sessions per week for 4 weeks.
48645768|NCT06689371|OTHER|Group C (control)|will receive standard exercise three sessions per week for four weeks. This standard regimen consists of the same exercises as group A and B.
48645769|NCT05652205|DRUG|Linaclotide|Capsule; oral
48645770|NCT05652205|DRUG|Placebo for Linaclotide|Capsule; oral
47967647|NCT01764672|DRUG|Methylphenidate|Oral dose 40mg (2 x 20mg)
47967648|NCT01764672|OTHER|Placebo|Oral intake of 2 placebo tablets
47967649|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
47967650|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
47967651|NCT05477056|OTHER|PrecivityAD blood test|Clinician Survey post receipt of PrecivityAD blood test result
47967652|NCT04546438|DEVICE|miraDry®|"MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions)."
48117021|NCT03009136|DRUG|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
48319163|NCT02709473|DRUG|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
48319164|NCT02709473|DRUG|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
48645771|NCT06688396|DEVICE|Mobile 6L AI-EKG Screening|"Participants with dilated cardiomyopathy (probands) will invite their first-degree relatives to undergo DCM screening procedures.~Probands and first-degree relatives will complete a mobile 6L AI-EKG which will be transmitted to a mobile app and interpreted by the AI-ECG algorithm. Results will be shared electronically or verbally to the participant.~If available, the probands clinical 12L EKGs will be obtained if recorded within 30 days of their Kardia 6L recording.~All participating FDR's will be encouraged to pursue cardiac screening per ACC/AHA recommendations. Study staff will obtain echocardiogram results up to 6 months of participant enrollment."
48645772|NCT06686485|DEVICE|FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems|"The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath.~The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium."
48645773|NCT02438397|DRUG|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
48645774|NCT02438397|DRUG|metformin|500 mg tid by Merck
48645775|NCT02438397|DRUG|Acarbose|100mg tid by Bayer
48645776|NCT03680131|DRUG|EB01 Cream Placebo|Vehicle Cream containing 0% EB w/w applied BID
48645777|NCT03680131|DRUG|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
48645778|NCT03680131|DRUG|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
48645779|NCT03680131|DRUG|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
48645780|NCT02365064|DEVICE|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
48645781|NCT01627106|DRUG|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
48645782|NCT01627106|DRUG|Amiodarone|Administered IV as per product label
48645783|NCT05143515|BEHAVIORAL|PACE label|There were 34 food and drinks choices available for consumption in the pop up café. The labels were displayed next to the food/drink item in the pop up café. The food items were kept in the same position for each participant kitchen to simulate the café environment. Then researchers changed the labels on the display according to the randomisation allocation of each participant. After randomsation participants were informed that they have £10 to spend in the pop-up café and that they could eat the food they selected in a private social eating room.
48645784|NCT05681585|OTHER|Implementation support program|"The intervention consists of:~I Implementation strategies:~1.1 Ensuring leadership commitment 1.2 Responsive evaluation 1.3 Whole ward approach 1.4 Train the trainer model 1.5 Sustainability after the study~II Implementation interventions 2.1 Implementation team 2.2 ACP coordinator 2.3 Training and supervision: Kick-off, training of resource persons and health care personnel including practical exercises, network conferences 2.4 Toolkit and shared resources: ACP guideline, teaching material, information leaflets, documentation templates etc. 2.5 Structured fidelity measurements of the implementation level of a) the implementation interventions and b) the clinical intervention, with tailored feedback and supervision~III Clinical intervention: Advance Care Planning 3.1 Routine information and invitation to Advance Care Planning to all eligible patients 3.2 Written information to patients and relatives 3.3 Documentation and collaboration with other health care levels"
48645785|NCT02013908|PROCEDURE|Acupuncture plus standard ED management|
48486565|NCT06406439|DEVICE|Smart Insulin Pen|The subject allocated to the intervention or control group through randomization will visit hospital maximun 5 times during the 12-week application period, including the baseline visit, in the following process.
48486566|NCT04083586|OTHER|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
48486567|NCT01878721|RADIATION|PET/CT|positron emission tomography/computed tomography
48645786|NCT02013908|PROCEDURE|Standard ED management alone|
47967653|NCT06255106|OTHER|cast treatment|Surgical intervention vs cast treatment
47967654|NCT05388331|OTHER|No intervention|No intervention
47967655|NCT00864331|RADIATION|radiation|39 Gy in 13 daily fractions of 3 Gy
47967656|NCT00864331|OTHER|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
47967657|NCT00864331|DRUG|Chemotherapy|Chemotherapy given alone
48117022|NCT03379935|PROCEDURE|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
48319165|NCT02709473|DRUG|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
48319166|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
48319167|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
48319168|NCT01159626|DRUG|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
48319169|NCT01159626|DRUG|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
48319170|NCT01159626|DRUG|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
48319171|NCT01159626|DRUG|Placebo|Oral single dose as matching placebo
48319172|NCT01159626|DRUG|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
48319173|NCT01159626|DRUG|Placebo|Oral multiple doses as matching placebo for 7 days
48319174|NCT00121511|DRUG|Efudex (5-fluorouracil)|
47967658|NCT00864331|OTHER|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
47967659|NCT01427686|DRUG|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
47967660|NCT01427686|DRUG|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
47967661|NCT05658120|DRUG|noradrenaline/adrenaline|norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
47967662|NCT00958750|DRUG|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
47967663|NCT00804674|DRUG|bupivacain|
47967664|NCT00804674|DRUG|placebo|
47967665|NCT04105101|DEVICE|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
48117023|NCT05652933|DIAGNOSTIC_TEST|Software for identifying vessel occlusion, infarct volume and penumbra|Assessment of the AI tool software
48319175|NCT01595165|PROCEDURE|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
48319176|NCT01595165|PROCEDURE|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
48319177|NCT01265420|BIOLOGICAL|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
48319178|NCT04939025|PROCEDURE|Multi-interventional program|"1. Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~2. Routine and tailored lengthening measures of the mesentery~3. Intraoperative control of pouch vascularization using ICG~4. Early diagnosis and active assessment of the integrity of the anastomosis.~   1. Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~  2. Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~5. Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~6. MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
48319179|NCT04307836|DEVICE|Renal Denervation|Renal Denervation: DENEX system
47967666|NCT05154591|GENETIC|Adipose-derived stromal vascular fraction cells|Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
48319180|NCT01479959|DEVICE|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
47967667|NCT01631981|DRUG|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
48117024|NCT01449422|DEVICE|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
48319181|NCT00992784|BIOLOGICAL|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
48319182|NCT00992784|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
48319183|NCT03001154|BEHAVIORAL|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
48319184|NCT03001154|BEHAVIORAL|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
48319185|NCT03001154|OTHER|Waiting-list|Weekly assessments of public speaking
48319186|NCT06215222|OTHER|Microbiota Sampling|We will sample the Saliva, Feces, and intestinal microbiome for genetic microbiome analysis and bacterial isolation
48319187|NCT02307071|DEVICE|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
48486568|NCT04439773|DRUG|placebo|the control group will be given the same volume of saline.
48319188|NCT03739476|DRUG|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
48319189|NCT03739476|DRUG|Placebo oral capsule|Compare the incidence of postoperative delirium.
48319190|NCT02476357|DEVICE|Harmonic scalpel|
48486569|NCT04439773|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
47967668|NCT01631981|DRUG|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
48319191|NCT05990036|OTHER|Sports vision enhancement training curriculum|A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
47967669|NCT02211040|BEHAVIORAL|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
47967670|NCT04119921|DRUG|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
48319192|NCT00449111|DRUG|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
48486570|NCT05335213|DIAGNOSTIC_TEST|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
48486571|NCT00204022|DRUG|Mycophenolate mofetil|Mycophenolate mofetil
48486572|NCT00204022|DRUG|Azathioprine|Azathioprine
48117025|NCT01449422|DEVICE|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
48486573|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
48117026|NCT01215344|DRUG|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
48117027|NCT01215344|DRUG|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
48117028|NCT01215344|DRUG|Dexamethasone|20 mg the day before and the day after receiving VELCADE
48117029|NCT01215344|DRUG|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
48486574|NCT02898103|DEVICE|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
48486575|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
48486576|NCT03333499|DRUG|YanXinShi placebo pills|participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
48486577|NCT03333499|DRUG|YanXinShi pills|participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
48486578|NCT03333499|DRUG|Trimetazidine pills|participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
48486579|NCT03333499|DRUG|YanXinShi and Trimetazidine pills|participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
48486580|NCT00375492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
48486581|NCT00375492|DRUG|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
48486582|NCT05223491|PROCEDURE|En Bloc resection|Tumour is resected and removed from the bladder in one piece, if possible.
48486583|NCT05223491|PROCEDURE|Conventional TURB|Tumour is resected piecemeal.
48319193|NCT00011479|DRUG|Abacavir sulfate|
48319194|NCT00970957|DRUG|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
48319195|NCT00970957|DRUG|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
48319196|NCT04897282|DIAGNOSTIC_TEST|UCRI|Biomarker panel and algorithm
48319197|NCT02723110|OTHER|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
48319198|NCT02723110|OTHER|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
48319199|NCT03013205|PROCEDURE|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
48319200|NCT03013205|PROCEDURE|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
48319201|NCT03013205|PROCEDURE|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
48319202|NCT03013205|PROCEDURE|Physiotherapy|
48319203|NCT04096352|BEHAVIORAL|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
48319204|NCT04096352|BEHAVIORAL|Indirect Method|Information on voice function and voice hygiene.
48319205|NCT00004363|DRUG|chlorpropamide|
48319206|NCT00004363|DRUG|desmopressin|
48319207|NCT00001251|DRUG|Mafosfamide|
48319208|NCT01907984|DRUG|Diclofenac|
48486584|NCT04214717|COMBINATION_PRODUCT|DC-CIK combined with Chemotherapy|Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.
48486585|NCT04214717|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
48486586|NCT05666947|OTHER|Home-based exercise|Eight weeks of home-based exercise programs
48117030|NCT01215344|DRUG|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
48319209|NCT01907984|DRUG|Midazolam|
48319210|NCT02399592|DRUG|Bevacizumab|10 mg/kg q3w
48319211|NCT02399592|DRUG|Tocotrinol|300 mg tid
48319212|NCT03464123|OTHER|Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device
48319213|NCT03298191|DRUG|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
48319214|NCT03298191|DRUG|Ritodrine|Those women will be given Ritodrine for tocolysis
48319215|NCT03298191|DRUG|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
48319216|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 2% Twice a day|nasal spray
48319217|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 3% Twice a day|nasal spray
48319218|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 4% Twice a day|nasal spray
48319219|NCT01277341|DRUG|Placebo Nasal Spray|nasal spray
48319220|NCT06079775|DRUG|Xeruborbactam Oral Prodrug|Experimental
48319221|NCT06079775|DRUG|Ceftibuten|Experimental
48319222|NCT06079775|DRUG|Xeruborbactam Oral Prodrug Placebo|Placebo Comparator
48319223|NCT06079775|DRUG|Ceftibuten Placebo|Placebo Comparator
48319224|NCT04573127|OTHER|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
48319225|NCT05834907|BEHAVIORAL|Circle of Security Parenting|"COS-P is an attachment-based, home visiting intervention intended to supporting parents in serving as a secure base from which their children can explore the world, and to which their children can return in times of distress (Bowlby, 1988). Such secure base parenting increases the likelihood of children's secure attachment. COS-P also targets parental responses to children's expression of their needs (e.g., crying), and is designed to help parents understand the ways in which their own (parental) dysregulated emotional, physiological, and behavioral responses to children's emotions and behaviors can limit their responsiveness to their children's attachment needs."
48319226|NCT05834907|BEHAVIORAL|Little Talks|Little Talks is an early literacy home visiting intervention developed for low-income, racial and ethnic minority infants and toddlers, and has been tested in Early Head Start contexts (Manz et al., 2016; Manz et al. 2017). Little Talks uses book sharing to promote early literacy and has been adapted in both English and Spanish. The intervention utilizes modular treatments during home visits, teaching parents how to facilitate language interactions with their children through book sharing. Age appropriate books are given to parents to share with their children during the intervention.
48319227|NCT05189158|DIAGNOSTIC_TEST|Hypercapnic hyperoxic ventilatory response|"The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear."
48486587|NCT00652756|DEVICE|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
48486588|NCT00652756|OTHER|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
48486589|NCT02274207|DEVICE|NPWT application|NPWT mode is cyclic mode : -125\~-50 mmHg
48486590|NCT03466541|BEHAVIORAL|Riskbruk|The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.
48117031|NCT01215344|DRUG|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
48319228|NCT05189158|DIAGNOSTIC_TEST|Hypoxic eucapnic ventilatory response|The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
48486591|NCT03466541|BEHAVIORAL|Balance|Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
48486592|NCT00109759|BIOLOGICAL|RagweedMATAMPL|
48486593|NCT00109759|DRUG|Placebo|
48486594|NCT05302570|RADIATION|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
48486595|NCT01709994|DRUG|Aspirin|100 mg/day of aspirin
48486596|NCT04375839|DEVICE|Zirconia implant|Following standard surgical protocol, Zirconia implant will be placed in horizontally deficient ridge.
48486597|NCT04375839|DEVICE|Titanium implant|Following standard surgical protocol, Titanium implant will be placed in horizontally deficient ridge.
48486598|NCT04263428|BEHAVIORAL|Irregular sleep|Experimental-induced sleep variability
48486599|NCT01456091|BEHAVIORAL|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
48486600|NCT03339505|DIETARY_SUPPLEMENT|Salovum|Dietary supplement with high concentration of anti-secretory factor
48486601|NCT03339505|DIETARY_SUPPLEMENT|Placebo|Placebo for Salovum
48486602|NCT02377635|DIETARY_SUPPLEMENT|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
48486603|NCT02377635|DIETARY_SUPPLEMENT|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
48117032|NCT01215344|DRUG|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
48117033|NCT03995446|DEVICE|low-level laser|low level laser emission on specific acupuncture points
48117034|NCT03995446|DEVICE|Sham laser|Sham laser
48319229|NCT05071560|OTHER|Combined exercise training|"Before the intervention, these women will undergo an evaluation of cardiorespiratory fitness, functional fitness, psychological status and a physiatry assessment. A consent form is signed before the start.~The physical exercise intervention was planned based on the recommendations of the American College of Sports Medicine for cancer survivors (ACSM 2019), with two supervised combined training sessions (mobility, aerobic training, strength and flexibility training) planned, and one unsupervised aerobic training session per week, interspersed with at least one rest day in between, for 8 weeks. The intensity will be individualized and defined based on the initial assessment. The structure of the training plan was based on the FITT-VP principles (frequency, intensity, time, type, volume and progression) recommended by the ACSM (2019)."
48486604|NCT02011919|DEVICE|Echopulse|HIFU Under ultrasound guidance
48486605|NCT02269644|DRUG|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
48486606|NCT02269644|DRUG|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
48486607|NCT02269644|DRUG|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
48486608|NCT02269644|DRUG|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
48486609|NCT02066337|PROCEDURE|scaling and root planing|
48486610|NCT02066337|DRUG|placebo gel|
48486611|NCT02066337|DRUG|Ozonated olive oil gel|
48486612|NCT06411340|OTHER|Observation|Observation
48486613|NCT04731311|DEVICE|Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease|4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
48486614|NCT02854059|BIOLOGICAL|IdeS (0.25 mg/kg)|Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
48486615|NCT02854059|BIOLOGICAL|IdeS (0.50 mg/kg)|Single i.v. infusion of IdeS (0.50 mg/kg).
48486616|NCT04792359|DEVICE|Equinometer|Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
48486617|NCT00514969|DRUG|Imatinib (STI571)|
48486618|NCT02826291|DEVICE|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
48486619|NCT01088919|DRUG|ASP1941|oral tablet
48486620|NCT01088919|DRUG|pioglitazone hydrochloride|oral tablet
48486621|NCT03173170|DRUG|TAK-954|TAK-954 Infusion
48486622|NCT03173170|DRUG|Itraconazole|Itraconazole Capsule
48486623|NCT02100319|DRUG|Azilsartan|Azilsartan tablets
48645787|NCT06686095|PROCEDURE|Group Adductor canal block|Adductor canal block procedure: The patient will be informed about the technique and consent will be obtained. The patient's hip will be slightly externally rotated, and an ultrasonography linear probe will be placed on the medial thigh, at the midpoint of the patella and vastus medialis. After locating the femoral artery at approximately 3-4 cm depth, if not visible, the artery can be traced distally from the inguinal region using Doppler mode. Once the vastus medialis and sartorius muscles are identified, the superficial femoral artery is centered at the midpoint of the sartorius muscle. The adductor canal roof, along with the saphenous and vastus medialis nerves, appears as hyperechoic structures. A needle is inserted in-plane, advancing toward the anterolateral femoral artery aspect, and 5-20 mL of LA is injected.
48645788|NCT06686095|PROCEDURE|Group Genicular Nerve Block|Genicular Nerve Block: The patient is informed and consent is obtained. With a pillow in the popliteal fossa, the knee is slightly flexed. For the superior lateral genicular nerve, a linear USG probe is positioned on the lateral femoral epicondyle, moving proximally to visualize the bone metaphysis. The superolateral artery is seen between the vastus lateralis fascia and the femur. Using in-plane or out-of-plane technique, the needle is guided to the bone, and 4-5 mL of LA is injected. For the superior medial nerve, the probe is placed on the medial epicondyle and moved proximally to visualize the bone near the adductor tubercle. The artery lies between the femur and vastus medialis fascia. For the inferomedial artery, the probe is placed on the tibial medial condyle, moving distally. A negative aspiration test is conducted before each LA injection.
47967671|NCT04119921|DRUG|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
48645789|NCT06686095|PROCEDURE|Group IPACK Block|IPACK Block: Before the procedure, the patient is informed about the technique and written consent is obtained from the patient. The patient lies in the prone position. The linear USG probe is placed approximately 2-3 cm above the popliteal fossa and scanned distally to identify the femoral shaft and popliteal artery. If the femoral condyles are initially visualized, the probe is moved until the condyles disappear and the femoral shaft is identified as a straight line and hyperechoic. Color doppler can be used to identify the popliteal vessels. The peripheral block needle is advanced between the femoral shaft and the popliteal artery. After negative aspiration control, 15-20 mL of LA medication is injected here.
48645790|NCT06688071|DIAGNOSTIC_TEST|Single Group Assignment|68Ga-DOTA/NOTA-FAPI-04 Each subject receive a single intravenous injection of 68Ga/18F-FAPI, and undergo PET/CT imaging within the specificed time.
48645791|NCT06613984|BIOLOGICAL|Bretovameran|Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.
48645792|NCT04837196|DRUG|ASP7517|Intravenous (IV)
48645793|NCT04837196|DRUG|Pembrolizumab|Intravenous (IV)
48645794|NCT00216658|DRUG|fentanyl|
47967672|NCT04119921|DRUG|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
47967673|NCT04119921|DRUG|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
47967674|NCT03566147|BIOLOGICAL|Human primary Retinal Pigment Epithelial (HuRPE) cells|HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
48645795|NCT05513170|PROCEDURE|Use of Densah Burs in closed sinus lift|Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
48645796|NCT05513170|PROCEDURE|Closed sinus lift using osteotomes|Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
48645797|NCT01171937|DRUG|Risperidone|children get randomized to either placebo or active risperidone
48645798|NCT01171937|DRUG|Placebo|Children get randomized to either placebo or risperidone
48645799|NCT02448173|BIOLOGICAL|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
48645800|NCT02448173|PROCEDURE|Surgery|Surgical resection of Stage II colon cancer
47967675|NCT02789202|OTHER|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
47967676|NCT02789202|OTHER|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
47967677|NCT04923191|OTHER|Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care|percutaneous coronary intervention
47967678|NCT04874298|OTHER|Ginger|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Ginger and Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
47967679|NCT04874298|OTHER|Peppermint|Peppermint
47967680|NCT04051073|DEVICE|Continuous non-invasive blood pressure monitoring|Continuous non-invasive blood pressure monitoring using CNAP
48645801|NCT00926900|DRUG|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
48645802|NCT00926900|DRUG|Placebo|Placebo
48645803|NCT02071654|DEVICE|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
48645804|NCT02336555|DRUG|MK-8291|MK-8291 oral tablets
48645805|NCT02336555|DRUG|Placebo|Placebo oral tablets
48645806|NCT05844319|OTHER|tele-education|The treatment of the patients will be carried out by tele-education method.
48645807|NCT00000472|DRUG|tissue plasminogen activator|
47967681|NCT00332007|DRUG|Tonabersat|two tablets once daily
47967682|NCT00332007|DRUG|Placebo|two tablets once daily
47967683|NCT02303366|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
47967684|NCT02303366|DRUG|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
47967685|NCT01346228|BEHAVIORAL|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
47967686|NCT04802291|BEHAVIORAL|HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood|Comparison of 2 educational interventions
48319230|NCT03524105|BEHAVIORAL|Program for Parents (Parenting Program)|Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of \~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
48319231|NCT03524105|BEHAVIORAL|Thrive Professional Learning|Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
48319232|NCT03403894|BEHAVIORAL|Asking caregivers in their practice|A questionary is given to caregivers
48319233|NCT02499341|DRUG|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
48319234|NCT02499341|DRUG|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
47967687|NCT02825056|DRUG|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
47967688|NCT02825056|DRUG|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
47967689|NCT00756756|DRUG|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
47967690|NCT00756756|DRUG|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
48319235|NCT03714282|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
48319236|NCT03714282|DEVICE|Conventional gait training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
48319237|NCT03714282|OTHER|Healthy control group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
47967691|NCT00316849|OTHER|pharmacological study|
47967692|NCT00316849|PROCEDURE|adjuvant therapy|
47967693|NCT00316849|RADIATION|3-dimensional conformal radiation therapy|
48319238|NCT01980706|DRUG|Baclofen|Baclofen is a GABA-B agonist
48319239|NCT01980706|DRUG|Placebo|Pill containing no pharmacologically active substance.
48319240|NCT00212303|BEHAVIORAL|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
48645808|NCT00000472|DRUG|heparin|
47967694|NCT00316849|RADIATION|intensity-modulated radiation therapy|
47967695|NCT00316849|DRUG|temsirolimus|Given IV
47967696|NCT00316849|DRUG|temozolomide|Given orally
47967697|NCT05175053|OTHER|Renal replacement therapy|Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)
47967698|NCT05175053|OTHER|Best medical management|The best medical management continues until the patient meets absolute indication of renal replacement therapy
47967699|NCT00386178|DRUG|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
47967700|NCT04997434|BEHAVIORAL|Art-therapy in the emergency department|"The intervention will begin with a 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. Since the art-therapeutic intervention that will be proposed seeks to generate pleasant feelings, it will be important to rely on the patient's tastes. At the end of the interview, modern art therapy will be presented to the patient and several artistic activities will be proposed (origami, drawing, creative writing).~Once the activity has been chosen, the patient will have 15 to 20 minutes to carry it out, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the 15 to 20 minutes of the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session."
47967701|NCT06147804|PROCEDURE|Surgical managment of Urinary bladder trauma after gynaecological and obstetric operation|How to manage Urinary bladder trauma after gynaecological and obstetric operations by the best method to prevent the occurrnce of vesicouterine fistula
47967702|NCT01292746|DEVICE|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
47967703|NCT04329533|OTHER|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
48319241|NCT04696874|PROCEDURE||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
48319242|NCT03137121|DRUG|Olanzapine|Olanzapine is used as an anti-emetic.
48319243|NCT03137121|OTHER|Placebo|The placebo is a non-anti-emetic.
48486624|NCT01369602|DRUG|PF-04991532|single dose 300-mg
47967704|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening with tension.|A Foley balloon will be placed for cervical ripening with tension.
47967705|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening without tension.|A Foley balloon will be placed for cervical ripening without tension.
48645809|NCT03109392|DRUG|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
48645810|NCT03109392|DRUG|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
48645811|NCT03109392|DRUG|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
48645812|NCT02534623|PROCEDURE|Spinal anesthesia|
47967706|NCT00502645|DEVICE|CS-1 DECISION SUPPORT SYSTEM|
47967707|NCT05984966|BEHAVIORAL|Supported Employment|PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Worker to facilitate distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated (Aim 1). In addition, in Aim 2 they will distribute the rapid test kits in places of residence such as tents, shelters, apartments, trailers, or houses or locations where other PWID frequently engage with services such as syringe exchange. The kit is the BinaxNOW COVID-19 Antigen Self Test, which is approved to be used as a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. PWID community members will be offered a free test kit, and the Peer Health Worker will record whether the community member elected to take the test (yes/no), and they will also collect administrative demographic data on the PWID.
47967708|NCT04022993|DRUG|Lantus Solostar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
47967709|NCT04022993|DRUG|Insulin RinGlar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
47967710|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
47967711|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
47967712|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
47967713|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
47967714|NCT03261973|DEVICE|DV8|DV8 esophageal deviation tool
47967715|NCT00779701|DRUG|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
47967716|NCT01425281|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
48319244|NCT02237157|DRUG|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
48486625|NCT01369602|DRUG|PF-04991532|single dose 300-mg
47967717|NCT01425281|DEVICE|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
47967718|NCT03311724|DRUG|Tirzepatide|Administered SC
47967719|NCT03311724|DRUG|Placebo|Administered SC
47967720|NCT01361152|DEVICE|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
47967721|NCT01361152|DEVICE|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
47967722|NCT02981121|BEHAVIORAL|Exercise and Diet remedies|
47967723|NCT02981121|DRUG|Metformin|
47967724|NCT03868020|PROCEDURE|Computed Tomography|Undergo PET/CT
47967725|NCT03868020|RADIATION|Fluciclovine F18|Given IV
47967726|NCT03868020|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
47967727|NCT04800354|BEHAVIORAL|Nurse-led Mindfulness Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time they experience intense pain or take pain medication before and after surgery.
47967728|NCT04800354|BEHAVIORAL|Nurse-led Pain Psychoeducation|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
47967729|NCT02080949|RADIATION|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
48340008|NCT05381675|OTHER|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
48340009|NCT05381675|OTHER|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
48486626|NCT01369602|DRUG|PF-04991532|single dose 300-mg
48645813|NCT02534623|PROCEDURE|General anesthesia|
48645814|NCT02534623|DRUG|bupivacaine|
48645815|NCT02534623|DRUG|fentanyl|
48645816|NCT02534623|DRUG|propofol|
48645817|NCT02534623|DRUG|sevoflurane|
48645818|NCT03167658|BEHAVIORAL|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
48319245|NCT05760820|BEHAVIORAL|SES Children (SES Mini & SES Nxt)|"SES Children (SES Mini \& SES Nxt) is a digital intervention aiming to develop children's self-efficacy and ability to overcome the challenges that come with a divorce and major life crises, thereby reducing the negative impacts of these on children's overall mental health and wellbeing. The intervention formatted to specific age groups between the ages of 3 and 17, and is relevant to all children whose parents have split up, regardless of whether they experience a higher or lower degree of conflict between the parents, a or higher or lower degree of strain from the judicial divorce.~The intervention covers a variety of topics, including when my parents fight, a bonus family, packing the overnight bag, to live in two places, and children's rights."
48319246|NCT03236428|DRUG|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
48319247|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
48319248|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
48319249|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
48319250|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
48319251|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
47967730|NCT04987346|OTHER|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
47967731|NCT04987346|OTHER|Walking on an instrumented treadmill while dual-tasking|Participants aged between 6 and 17 years will be asked to walk at comfortable walking speed while playing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) game.
47967732|NCT03323710|DRUG|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
47967733|NCT03323710|DRUG|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
47967734|NCT03719885|DEVICE|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
47967735|NCT05325671|PROCEDURE|transarticular multimodal drug infiltration|as described previously
47967736|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
47967737|NCT00621153|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
47967738|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
48319252|NCT00254293|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
48319253|NCT02471001|BIOLOGICAL|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
48319254|NCT04903964|OTHER|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
48645819|NCT05947422|DIAGNOSTIC_TEST|High resolution CT Chest|"CT chest in our institution will be done with standard high resolution protocol . No I.V contrast will be given. Scans will be obtained during full inspiration in supine position from the thoracic inlet to the level of the diaphragm.~Patients with CT chest performed outside our institution will be reviewed in DICOM format and assessed for its compatibility to be integrated into the computer-based analysis software."
48645820|NCT05947422|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed using standard techniques according to ATS-ERS criteria 2019 . Spirometry device (Zan 300, NSPIRE HEALTH GMBH Co.) will be used. Percentage predicted values (%pred) will be calculated based on reference values for healthy adults. All patients will be required to undergo spirometry in a reproducible way, and the best values will be reported. Spirometry should meet international acceptability and repeatability standards
47967739|NCT06063824|OTHER|Single-Session Method of Levels Intervention|This is a single session of method of levels psychotherapy delivered to patients of GP surgeries in primary care.
47967740|NCT04946188|DEVICE|Opuz NICGM|A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
48319255|NCT00575094|DRUG|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
48319256|NCT02033772|PROCEDURE|Thoracoscopic surgery|
48319257|NCT02432040|DRUG|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
48319258|NCT02432040|DRUG|Placebo|Placebo tablets, made to look like the interventional drug
48319259|NCT05338957|DRUG|MRG002+HX008|Administrated intravenously
48340010|NCT02661945|DEVICE|Near focus with narrow band imaging|
48319260|NCT05041452|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameters
48319261|NCT06553846|DRUG|Lutetium [177Lu]-FAP-75|Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
48319262|NCT06364865|DEVICE|laparoscopic procedure|Not applicable, subject requiring procedure will have a laparoscopic procedure performed according to the institutions standard of care procedures. There are no clinical procedures performed on the subject as part of this registry study. Surgeon will answer questionnaires regarding use of the device upon completion of the laparoscopic procedure.
48319263|NCT01089582|OTHER|No intervention|
48319264|NCT03079349|OTHER|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
48319265|NCT03079349|OTHER|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
48319266|NCT03615469|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
48319267|NCT03615469|DEVICE|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
48319268|NCT01023412|DIETARY_SUPPLEMENT|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
48319269|NCT05830513|DEVICE|Virtual Reality|Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects.
47967741|NCT01101503|DRUG|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
48117035|NCT02849535|BEHAVIORAL|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
48117036|NCT01006824|OTHER|Capsule endoscopy|Capsule endoscopy
48319270|NCT05838651|DEVICE|MinerOss® X Plug|A xenograft composed of 80% bovine cancellous particulate and 20% bovine Type I collagen.
48319271|NCT05838651|DEVICE|Striate+ Membrane|A non-crosslinked collagen covering used to keep bacteria out and hold the bone graft in place.
48319272|NCT00424333|DRUG|Inhaled human insulin|
48319273|NCT02276521|BIOLOGICAL|Cervarix®|All groups will received one dose of Cervarix® vaccine
48319274|NCT06402812|OTHER|Interview|A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
48319275|NCT05562024|BIOLOGICAL|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
48319276|NCT03783052|DEVICE|SmartPill in fasted state|SmartPill administration in fasted state
48319277|NCT03783052|DEVICE|SmartPill in fed state|SmartPill administration in fed state
48319278|NCT03783052|OTHER|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
48319279|NCT03783052|OTHER|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
48319280|NCT02695706|DEVICE|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
48486627|NCT01369602|DRUG|PF-04991532|single dose 300-mg
48319281|NCT00230529|DRUG|infliximab|
48486628|NCT01588236|DRUG|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
48486629|NCT01588236|DRUG|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
48486630|NCT01588236|DRUG|Placebo|3 capsules of placebo tid (morning, midday, and evening)
48486631|NCT05874440|DRUG|Tenofovir Disoproxil Fumarate and Entcavir|Regular registration of side effects of the drugs, cause of non-compliance to treatment
48486632|NCT01675024|DRUG|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
48319282|NCT01357915|PROCEDURE|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
48319283|NCT01357915|BIOLOGICAL|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
48319284|NCT05248971|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is an evidence-based treatment method for children and adolescents who have been exposed to trauma and experience posttraumatic stress symptoms. The treatment model has a family and caregiver focus, and non-offending caregivers are included in the treatment. TF-CBT is normally provided through 8-12 treatment sessions.
48319285|NCT05926258|DRUG|Chloroprocaine 3% eye gel|ocular surface anesthesia
48319286|NCT05926258|DRUG|Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops|ocular surface anesthesia
48319287|NCT03657667|PROCEDURE|Ureteroscopy|Endoscopic removal of kidney stones
48319288|NCT01354353|DRUG|LY2140023|Administered orally
47967742|NCT01101503|DRUG|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
47967743|NCT03955744|OTHER|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
48319289|NCT01354353|DRUG|Aripiprazole|Administered orally
48319290|NCT03368131|DRUG|Trastuzumab|intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
48645821|NCT02672605|OTHER|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
48117037|NCT01006824|OTHER|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
48117038|NCT01422616|DRUG|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus \[maximum bolus dose of 9mg\] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
48117039|NCT01422616|DRUG|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
48319291|NCT03368131|DRUG|Capecitabine|825\~1000mg/m2 bid d1-14
48319292|NCT03368131|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
48319293|NCT03368131|RADIATION|Radiotherapy|45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
48319294|NCT02681055|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
48319295|NCT00204425|DIETARY_SUPPLEMENT|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
48319296|NCT00598195|DRUG|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
48319297|NCT05242445|DRUG|Cetrelimab|Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
48319298|NCT05242445|DRUG|Placebo|Placebo will be administered via SC injection or as an IV infusion.
48319299|NCT02808312|DRUG|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
48319300|NCT05545579|OTHER|circuit trainng|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
48117040|NCT01422616|OTHER|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
48117041|NCT01422616|OTHER|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
48319301|NCT05545579|OTHER|trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
48645822|NCT06256484|DRUG|ATA3219|ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.
48645823|NCT05373680|DRUG|Metformin|Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
47967744|NCT06050395|BEHAVIORAL|Quality fo Life Questionnaire (FHSI)|Participants will take a survey at baseline and visit 2 (weeks 6-8), and visit 3 (week 10-14). The Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index-8 (FHSI) questionnaire uses a 5-point Likert-type scale, 0=not at all and 4=Very much. A lower total score indicates better quality of life.
47967745|NCT06050395|BEHAVIORAL|Vioscreen Food Frequency Questionnaire (FFQ)|Participants will receive a web-based link and information to complete VioScreen, a web-based food frequency questionnaire, which allows participants to choose the average frequency of consumption of food items over a given time frame (1 month, 3 month, 1 year, etc.) on a Likert scale with choices ranging by individual questions. Total energy and nutrient intake is estimated by summing intakes from each food based on the selected portion size, reported frequency of consumption, and nutrient content of each food item. Anti-inflammatory and pro-inflammatory dietary patterns are calculated using the energy-adjusted dietary inflammatory index (DII) score to represent the inflammatory potential of an individual's overall diet, using data from FFQ responses. Higher DII scores represent more pro-inflammatory diets while lower (i.e., more negative) DII scores represent more anti-inflammatory diet.
48319302|NCT02694094|DIETARY_SUPPLEMENT|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
48319303|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
48117042|NCT04581317|OTHER|meals|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
48319304|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
48117043|NCT04581317|OTHER|AES 8 basic usage|For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
48319305|NCT02753829|OTHER|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
48319306|NCT05138549|DRUG|Astaxanthin|12 mg oral astaxanthin supplement
48319307|NCT05138549|OTHER|Placebo|Oral placebo identical to astaxanthin supplement
48319308|NCT05138783|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
48319309|NCT05138783|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
48319310|NCT03746964|PROCEDURE|Cardiac MRI|Preoperative cardiac MRI
48319311|NCT03746964|OTHER|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
48319312|NCT00654784|DRUG|idebenone|idebenone 450 mg/day (150 mg three times a day)
48319313|NCT00654784|DRUG|placebo|
48319314|NCT03296865|DEVICE|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
48319315|NCT02723591|DRUG|Tacrolimus|Oral Capsule
48319316|NCT02723591|DRUG|Tacrolimus immediate release|Oral Capsule
48319317|NCT04901533|PROCEDURE|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
48319318|NCT04901533|PROCEDURE|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
48319319|NCT01728883|DEVICE|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
47967746|NCT06050395|BEHAVIORAL|Educational Handouts|Participants will receive educational handouts on diet.
47967747|NCT06050395|BEHAVIORAL|NutritionCoaching|Participants will receive bi-weekly nutrition coaching on anti-inflammatory dietary patterns and foods.
48319320|NCT01441115|PROCEDURE|Radiation Therapy|
48319321|NCT01441115|DRUG|ECI301|
48319322|NCT05825209|DRUG|Food-Grown Magnesium|1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
48319323|NCT05825209|DRUG|Microcrystalline cellulose|1 daily dose of 2 capsules containing microcrystalline cellulose
48319324|NCT02697084|OTHER|anal cancer|Anal cancer patients with TEP TDM
48319325|NCT04501198|DEVICE|moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35\~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
47967748|NCT06050395|BEHAVIORAL|Follow-Up Survey|Participants will complete a custom exit/follow up survey regarding relevance, acceptability, intervention length and timing, an barriers/facilitators. This survey contains 38 questions scored from 1 -Strongly agree to 5-Strongly disagree. A lower score indicates patient satisfaction with the program and the skills and knowledge gained in the program.
47967749|NCT06050395|BEHAVIORAL|Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire|The FAACT questionnaire uses a 5 point Likert-type scale, 0=Not at all, 4=Very much. A higher score indicates better appetite and quality of life.
48319326|NCT04501198|DEVICE|Moxibustion combined with lifestyle intervention.|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
48319327|NCT04501198|DEVICE|lifestyle intervention|All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
48319328|NCT05691634|PROCEDURE|MRI|Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).
48319329|NCT05691634|OTHER|Likert scale questionnaire|The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)
48319330|NCT06554028|DRUG|chemotherapy TP regimen combined with Tislelizumab|"Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.~•Response rate of primary tumor or lymph nodes is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If the primary lesion reaches CR/PR and the lymph nodes reach CR, chemoradiotherapy based on cisplatin is conducted. If the primary lesion reaches CR/PR and lymph node PR/PD, cervical lymph node dissection will be performed, followed by radiotherapy/concurrent chemoradiotherapy. If the primary lesion is SD/PD, regardless of the condition of the lymph nodes, primary lesion resection and lymph node dissection should be performed, followed by adjuvant radiation/chemoradiation.~Other Names:~Docetaxel Cisplatin Paclitaxel"
48319331|NCT03314220|BEHAVIORAL|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
48319332|NCT05125536|OTHER|Music therapy|rutin
48319333|NCT01238315|BIOLOGICAL|HuCNS-SC|Surgery to implant human CNS stem cells
48319334|NCT00513097|BEHAVIORAL|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
48319335|NCT00513097|BEHAVIORAL|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
48319336|NCT00513097|BEHAVIORAL|Survey|On-line evaluations and questionnaires
48319337|NCT00004879|BIOLOGICAL|panitumumab|
48319338|NCT02892565|OTHER|Blood sample|
48319339|NCT02482441|DRUG|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
48319340|NCT02482441|DRUG|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
48319341|NCT00651404|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
48319342|NCT00651404|DRUG|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
48319343|NCT04669041|DRUG|Rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
48319344|NCT04669041|DRUG|SPC ezetimibe/rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
48319345|NCT04669041|DRUG|Rosuvastatin active capsule|Pharmaceutical form:Capsule Route of administration: Oral
48319346|NCT04669041|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
48319347|NCT04669041|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
47967750|NCT06050395|BEHAVIORAL|Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire|Participants will complete the PROMIS-Cog form which measures self-reported cognitive deficits. The questionnaire uses a 5 point Likert-type scale, 1=Very often and 5=Never. A higher score indicates higher cognitive function.
47967751|NCT05448183|DRUG|Toripalimab, Gemcitabine,Oxaliplatin|Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), combined withTACE (Gemcitabine 1000mg/m2 , Oxaliplatin 135mg/m2) in a cycle of 3 weeks(q3w).
47967752|NCT01044771|DRUG|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
48319348|NCT00180141|DRUG|Elidel-Creme|
48319349|NCT03598738|DRUG|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
48319350|NCT02628249|DIETARY_SUPPLEMENT|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
48319351|NCT02628249|DIETARY_SUPPLEMENT|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
48319352|NCT02628249|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
48319353|NCT02628249|DIETARY_SUPPLEMENT|Essential amino acids|Essential amino acids modeled after egg protein.
48319354|NCT02628249|DIETARY_SUPPLEMENT|Non essential amino acids|Non essential amino acids modeled after egg protein.
48319355|NCT04044092|OTHER|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
48319356|NCT04044092|OTHER|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
48319357|NCT05068193|DRUG|BR2008-1 (R)|After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
48319358|NCT05068193|DRUG|BR2008 (T)|After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
48319359|NCT01665521|OTHER|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
48319360|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
48645824|NCT05373680|DRUG|Empagliflozin|Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
48645825|NCT05373680|OTHER|Control|Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
48645826|NCT02549300|OTHER|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
47967753|NCT01178957|OTHER|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
47967754|NCT00525330|DRUG|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
47967755|NCT00525330|DRUG|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
48319361|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
48319362|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
48645827|NCT00978185|OTHER|medical chart review|
48645828|NCT00978185|OTHER|questionnaire administration|
47967756|NCT00525330|DRUG|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
48319363|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
48645829|NCT00978185|PROCEDURE|acupressure therapy|
47967757|NCT01862874|BIOLOGICAL|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
47967758|NCT01862874|BIOLOGICAL|Placebo|Formulated with AAHS adjuvant
48319364|NCT01336179|PROCEDURE|Salvadora persica|twice daily use, two minutes interval
48319365|NCT01336179|PROCEDURE|Toothbrush|Twice daily use two minutes interval
48319366|NCT04995471|BEHAVIORAL|In presence RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
48319367|NCT04995471|BEHAVIORAL|In presence RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
48645830|NCT00978185|PROCEDURE|quality-of-life assessment|
48645831|NCT00978185|PROCEDURE|sham intervention|
48645832|NCT00978185|PROCEDURE|standard follow-up care|
48645833|NCT02062255|DRUG|Aspirin|
48645834|NCT02062255|DIETARY_SUPPLEMENT|Omega 3 FFA|
48645835|NCT02569008|DRUG|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
48645836|NCT02868879|OTHER|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
47967759|NCT04357132|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora Application
47967760|NCT04357132|OTHER|VR-Distraction|Participants will be instructed to use one of four applications
48117044|NCT04581317|OTHER|AES 8 advanced usage|In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
48319368|NCT04995471|BEHAVIORAL|Tele-RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
48319369|NCT04995471|BEHAVIORAL|Tele-RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
48319370|NCT06342102|PROCEDURE|PENG + LFCN block|The PENG block was performed under ultrasound guidance. After skin disinfection, the needle was advanced between the psoas tendon and pubic ramus where 20 mL of 0.5% ropivacaine were injected. The LFCN block was performed following the PENG block.10 ml of 0.5% ropivacaine were injected near the nerve into the fat-filled flat tunnel (FFFT) located at the level of the superior anterior iliac spine and lateral to the sartorius muscle.
48319371|NCT06342102|PROCEDURE|FIC block|FICB was performed under ultrasound guidance. The needle was advanced above the fascia iliaca and 20 mL of 0.5% ropivacaine were injected
48319372|NCT03713931|DIAGNOSTIC_TEST|PUMA Score questionnaire|"Every patient who meet the criteria for active search (older than 40 years, smokers or ex-smokers of more than 10 pack-years who attend the usual care in the first level of care) will be scored with the PUMA´s questionnaire in an application and electronic database (RedCap) specially designed for the active search of cases.~Patients with PUMA´s score ≥ 5, and without exclusion criteria for spirometry will be referred to perform spirometry at the institution"
48319373|NCT04910763|BEHAVIORAL|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
48319374|NCT00844649|DRUG|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m\^2 administered by intravenous infusion
48319375|NCT00844649|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
48319376|NCT01337063|OTHER|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
48319377|NCT03509272|DEVICE|remote monitoring|"Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day"
48319378|NCT06553183|PROCEDURE|immersive virtual reality|Exercise based on virtual reality video games. Immersive type will be used.
48319379|NCT06553183|PROCEDURE|traditional physicaltherapy|pneumatic compression, exercise and skin care
47967761|NCT03918122|OTHER|Self-Assessment via pre and post survey|Master Preceptor Fellows will assess and evaluation professional development, knowledge, clinical practices and master preceptor knowledge before the Master Preceptor Fellowship and After completion of the Master Preceptor Fellowship
47967762|NCT01927874|PROCEDURE|Infiltration|injection of local anesthetic, associated with general anesthesia
47967763|NCT01927874|PROCEDURE|Spinal block|injection of anesthetic
48117045|NCT02817334|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
48117046|NCT02747381|DIETARY_SUPPLEMENT|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
48117047|NCT05018325|PROCEDURE|Colonoscopy with 6 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
48117048|NCT05018325|PROCEDURE|Colonoscopy 9 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
48117049|NCT05018325|PROCEDURE|Colonoscopy 12 minute withdrawal|Withdrawal time will be determined using a digital stopwatch by the nursing staff.
48319380|NCT01887587|DRUG|MLN9708|
48319381|NCT01887587|DRUG|Vincristine|
48319382|NCT01887587|DRUG|Doxorubicin|
47967764|NCT01927874|DRUG|Bupivacaine|10ml 0.5% bupivacaine.
48117050|NCT04065802|RADIATION|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
47967765|NCT01927874|DRUG|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
48319383|NCT01887587|DRUG|Dexamethasone|
48319384|NCT00004929|BIOLOGICAL|MUC-2-KLH vaccine|
48319385|NCT00004929|BIOLOGICAL|QS21|
48319386|NCT03215654|OTHER|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
48319387|NCT02679209|BIOLOGICAL|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
48319388|NCT02679209|BIOLOGICAL|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
48117051|NCT06371196|DRUG|Babaodan Capsule|Babao Dan Capsule (State Drug License: Z10940006) is produced by Xiamen Traditional Chinese Medicine Factory Co., Ltd; Packing specification: 0.3g/capsule, 6 capsules/board×2 boards/small box; Ingredients are in vitro cultivated cowhide, snake gallbladder, antelope horn, pearl, panax ginseng, artificial musk, and so on. Intervention measures are really the original UDCA treatment program based on the addition of eight treasure Dan capsule, 2 capsules / times, tid, oral. Course of treatment: 3 months (based on 30 days/month).
48117052|NCT00084045|PROCEDURE|Intrapartum HIV counseling/testing|
48319389|NCT05675891|OTHER|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
48319390|NCT04811248|OTHER|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
48319391|NCT04755465|DEVICE|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics."
48319392|NCT04755465|OTHER|Structured Exercise|Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
48319393|NCT00972127|DRUG|Neramexane|25 mg or 2x25mg tablets
48117053|NCT00084045|PROCEDURE|Postpartum HIV counseling/testing|
48319394|NCT04809389|BIOLOGICAL|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
48319395|NCT04809389|BIOLOGICAL|Matching placebo|0.9% NaCl solution
48319396|NCT04674618|DEVICE|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
48486633|NCT01675024|DRUG|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
48486634|NCT04984421|BEHAVIORAL|Healthy School Start|The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
48486635|NCT00864617|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
48486636|NCT00864617|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
48486637|NCT04882917|DRUG|M4076|M4076 will be administered orally, in Part 1A and Part 1B.
48117054|NCT00459758|DEVICE|Hans unit|
48117055|NCT06364839|OTHER||
48117056|NCT00930098|DRUG|clofarabine|
48117057|NCT03339024|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
48117058|NCT03339024|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
48117059|NCT05625282|PROCEDURE|Weil osteotomy|Open, oblique, distal osteotomy of the metatarsal bone, with screw fixation.
48117060|NCT05625282|PROCEDURE|Plantar plate repair|Plantar plate reconstruction at metatarsophalangeal area, using sutures.
48117061|NCT01846936|PROCEDURE|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
47967766|NCT01646723|BEHAVIORAL|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
47967767|NCT00764647|BEHAVIORAL|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
47967768|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
47967769|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
47967770|NCT03012165|DRUG|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
47967771|NCT01626391|DRUG|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
47967772|NCT01626391|DRUG|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
47967773|NCT00306215|DRUG|CCX282-B|CCX282-B or placebo capsules
47967774|NCT02362061|RADIATION|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
47967775|NCT02847832|OTHER|Standardized transvaginal ultrasound examination|
47967776|NCT03990454|DRUG|SLC-391|SLC-391 is an AXL inhibitor
47967777|NCT01604174|OTHER|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
47967778|NCT01604174|OTHER|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
47967779|NCT05188911|DRUG|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
47967780|NCT05188911|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
47967781|NCT05188911|DRUG|Androgen deprivation therapy|Patients would get medical or surgical castration.
47967782|NCT01587820|DRUG|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
47967783|NCT01587820|DRUG|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
47967784|NCT05032560|DRUG|ABX464|Drug: ABX464 ABX464 is a new anti-inflammatory drug
48486638|NCT05132569|DRUG|Tolebrutininb|Pharmaceutical form: Film-coated tablet Route of administration: Oral
47967785|NCT05032560|DRUG|Placebo|Drug: Matching Placebo placebo matching with ABX464
47967786|NCT06093815|DEVICE|Injection|A pre specified amount will be injected in tissue at selected timepoints
47967787|NCT06260085|OTHER|Relatives vioce record|In the study, it was emphasized that the messages to be played to the patient should be 3-5 minutes and simple terms should be used in a way that can be understood by individuals with low education level. Written informed consent was obtained from the patient and the patient's relatives before the application. In the message recorded by a patient's relative decided by the patient's family members, the patient's relative said what he/she wanted to say to the patient and recorded it using a voice recorder. The researcher had a preliminary interview with the patient's relative before the voice recording was taken about the use of the voice recorder and the content of the message (Table 1) in order to prevent the messages from negatively affecting the patient. The voice recording created by the patient's relative was played to the patient by the researcher using a music pillow. After the patient listened to the audio recording, it was erased under the witness of the patient's relative.
47967788|NCT02035930|DRUG|dexmedetomidine|
47967789|NCT03839901|OTHER|Home exercise program|Home exercise programme with participants followed up at week 1, 4, 6 and 8.
47967790|NCT03627143|OTHER|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~1. Selection of one or more local physician champions from both the ED as well as the cardiology group;~2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~4. Development of local action plan addressing local barriers to implementation;~5. Provision of the free Smartphone App to be developed for the guidelines;~6. Regular reminders provided by the local research staff;~7. Audit and feedback charts of site compliance"
48117062|NCT01846936|PROCEDURE|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
48486639|NCT05132569|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral
48486640|NCT05852808|DRUG|Intra-articular steroid injections|"The patient will be placed in prone position and the facet joints will be imaged by pa-radiation path with attention to radiation protection. 20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints. The patient is monitored after the intervention for another 30 minutes before leaving the hospital. In order to track the pain level, the patient will be instructed to keep a pain diary. The patient will be contacted via telephone 72h after the intervention and asked about the pain level.~The intervention is finished after one consultation."
47967791|NCT05622084|DEVICE|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
47967792|NCT05806411|DIAGNOSTIC_TEST|Analysis of calcific aortic valves|Microbiologic analysis of calcofic aortic valves
47967793|NCT04950998|BEHAVIORAL|Moving Up - A|Moving Up - A is a physical activity smartphone app for persons with mild cognitive impairment or mild forms of dementia. The app includes a personally tailored set of messages, tips, strategies, and tasks designed to increase physical activity levels and disrupt extended periods of sedentary time. Users also have the ability to track their steps and and sedentary behavior time as well as their progress towards activity goals.
47967794|NCT03557099|DRUG|Hetrombopag Olamine|once daily
47967795|NCT05135117|OTHER|NeuroRescue Cooling Collar|Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
47967796|NCT05135117|OTHER|Ice Towel|Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
48319397|NCT03544268|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
47967797|NCT01965587|PROCEDURE|novasure mirena IUS combined|novasure mirena IUS combined
48319398|NCT03544268|DRUG|Definity|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
48319399|NCT04650958|PROCEDURE|Deep brain stimulation|Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
48319400|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
48319401|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
48319402|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
48319403|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
48319404|NCT00183950|DRUG|Noscapine|
48319405|NCT02858154|OTHER|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
47967798|NCT05011565|OTHER|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
47967799|NCT03184831|PROCEDURE|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
47967800|NCT03184831|PROCEDURE|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
47967801|NCT00858130|DEVICE|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
47967802|NCT02251184|DRUG|Aggrenox|
47967803|NCT02251184|DRUG|Dipyridamole|
47967804|NCT02251184|DRUG|Aspirin|
47967805|NCT02251184|DRUG|Lansoprazole|
47967806|NCT05357313|DEVICE|Bright light therapy|Exposure to 10,000lux bright light for 30minutes a day for six weeks
47967807|NCT05357313|DEVICE|Inactive negative ion generator|Exposure to an inactive negative ion generator for 30 minutes a day for six weeks
47967808|NCT00318630|DRUG|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
47967809|NCT00318630|DRUG|Placebo|Subjects will also receive placebo oral tablet.
47967810|NCT06110780|OTHER|acupuncture|"The insertion of the needles will be applied to a depth of 1-2 cm according to the thickness of the local tissues according to the standards of Traditional Chinese Medicine. The EA parameter will be set to a frequency of 2 HZ/100 HZ at a current that the patients' tolerance is best between 0.5 mA and 1.2 mA.~The patient will be electrically stimulated for 30 minutes until the patient feels Teh Chi - heaviness, numbness and swelling."
47967811|NCT01958333|PROCEDURE|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
47967812|NCT01958333|PROCEDURE|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
47967813|NCT01958333|PROCEDURE|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
48319406|NCT02858154|OTHER|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
47967814|NCT00900965|DEVICE|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
48319407|NCT06243341|DIETARY_SUPPLEMENT|Lepidium meyenii (MACA)|The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
48319408|NCT00553137|DRUG|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
48319409|NCT00553137|DRUG|fluconazole|150 mg fluconazole tablets once daily for 14 days
48319410|NCT02787642|DRUG|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
48319411|NCT02787642|RADIATION|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
48319412|NCT02106455|DRUG|Sodium risedronate|Sodium risedronate tablets
48319413|NCT02365584|DRUG|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
48319414|NCT00383422|DRUG|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
48319415|NCT00383422|DRUG|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
48319416|NCT00792233|OTHER|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
48319417|NCT00490763|BEHAVIORAL|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
48319418|NCT04810234|DEVICE|transcutaneous vagal nerve stimulation (tVNS)|Cervical and auricular transcutaneous stimulation of the vagus nerve
48319419|NCT02476591|BEHAVIORAL|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
48319420|NCT01160952|DRUG|itraconazole|the two groups are defined by different treatment duration
47967815|NCT00900965|DEVICE|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
47967816|NCT03821155|OTHER|Vestibular rehabilitation|Specialized physical therapy aimed at restoring balance
47967817|NCT03821155|DRUG|Corticosteroid|Prednisolone
48117063|NCT01846936|PROCEDURE|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
48319421|NCT03238586|BEHAVIORAL|WELL Program|
48319422|NCT01397552|DRUG|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
48319423|NCT01397552|DRUG|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
48319424|NCT00789958|DRUG|capecitabine|"Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
48319425|NCT00789958|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, IV, Days 1 \& 8 of each cycle
48319426|NCT00789958|RADIATION|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
48319427|NCT00789958|RADIATION|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
48319428|NCT04556617|DRUG|PLX2853|PLX2853 tablets
48319429|NCT04556617|DRUG|Olaparib|Olaparib tablets
48319430|NCT04556617|DRUG|Abiraterone acetate|Abiraterone acetate tablets
48319431|NCT04556617|DRUG|Prednisone|Prednisone (or equivalent) tablets
48319432|NCT03819764|BEHAVIORAL|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
48319433|NCT03819764|BEHAVIORAL|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
48319434|NCT03548038|OTHER|taste test|All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
48319435|NCT04248192|BIOLOGICAL|DD HST-NEETs|HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
48319436|NCT05671601|DIAGNOSTIC_TEST|Automatic picture recognition|A machine that processes photographs automatically taken
48319437|NCT05671601|DIAGNOSTIC_TEST|Manual Assessment Group|Manual recognition of pictures
48319438|NCT01546389|BIOLOGICAL|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
48319439|NCT01546389|DRUG|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
48319440|NCT02010437|DRUG|Sodium Tetradecyl Sulphate (STS)|
48319441|NCT01797510|BEHAVIORAL|Web Based Health Coaching|
48319442|NCT05463042|BEHAVIORAL|Intermittent Hypoxia|During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
48645837|NCT03047044|OTHER|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
48645838|NCT03047044|OTHER|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
48645839|NCT04602598|DRUG|Zanubrutinib 80 MG|Zanubrutinib 80 MG for 24 weeks
48645840|NCT05530915|OTHER|Gel capsule|Single capsule per dose
48645841|NCT03024411|OTHER|iPod (Music/video games)|Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
47967818|NCT02123121|DRUG|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
47967819|NCT02123121|DRUG|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
48117064|NCT06261996|DRUG|Fospropofol|Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.
48645842|NCT01066299|DRUG|Syntocinon®|single dose of OXT (24 IU)
47967820|NCT02123121|OTHER|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
47967821|NCT02123121|OTHER|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
48319443|NCT05463042|BEHAVIORAL|Normoxia (sham)|During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
48319444|NCT00348842|PROCEDURE|Newcastle Virus|
48319445|NCT02850991|RADIATION|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
48319446|NCT02850991|RADIATION|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
48319447|NCT01680978|DRUG|aleglitazar|150 mcg orally daily, 6 weeks
48319448|NCT01680978|DRUG|placebo|orally daily, 6 weeks
48319449|NCT02760017|DRUG|B. forficata|
48319450|NCT02760017|DRUG|Placebo|
48319451|NCT01605344|DRUG|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
48319452|NCT01605344|DRUG|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
48645843|NCT01066299|DRUG|inactive nasal spray|single dose (24 IU)
48645844|NCT06144658|DEVICE|Augmented Reality Headset / Hololens 2 or Varjo XR3|Augmented Reality Headset
48645845|NCT06058793|DRUG|Brigimadlin|Brigimadlin
47967822|NCT04841460|DIETARY_SUPPLEMENT|Low-fat ground beef|5% fat ground beef
47967823|NCT04841460|DIETARY_SUPPLEMENT|High-fat ground beef|25% fat ground beef
47967824|NCT00772291|DRUG|pregabalin|pregabalin 150-600mg/day during 8 weeks
47967825|NCT00772291|DRUG|placebo|placebo drug during 8 weeks
48117065|NCT04234776|DRUG|Ketamine|(0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole
47967826|NCT06392620|OTHER|Study Group|n individually planned exercise program including stretching, strengthening, respiratory, aerobic and posture exercises will be applied via video conference method
47967827|NCT01332955|DRUG|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
48645846|NCT04518943|BEHAVIORAL|Walking|Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
48645847|NCT05289453|PROCEDURE|lens extraction by phacoemulsification|lens extraction by phacoemulsification
48645848|NCT03027050|PROCEDURE|T-PRF|Applied for treatment of periodontal bone loss.
47967828|NCT01332955|BIOLOGICAL|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
47967829|NCT01332955|DRUG|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
47967830|NCT00653055|DRUG|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
48645849|NCT03027050|PROCEDURE|Open Flap Debridement alone|
47967831|NCT00653055|DRUG|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
48319453|NCT00205296|BEHAVIORAL|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
48645850|NCT01796470|DRUG|Entospletinib|Entospletinib tablets administered orally twice daily
48645851|NCT01796470|DRUG|Idelalisib|Idelalisib tablets administered orally twice daily
48319454|NCT06068322|OTHER|Exercise training on a stationary bicycle|"Training is performed two to three times per week for a total of 30 sessions using a group format.~Both regimens start with a five-minute warm-up and ends with a five-minute cool-down, performed at an intensity corresponding to 30% of the maximal work rate achieved during a CPET (i.e., max aerobic power \[MAP\]) with a self-selected pedalling cadence of 50-70 revolutions per minute (RPM).~All exercise sessions will be held and supervised by an experienced health care professional, i.e. physiotherapists or other health professional.~The different types of exercise training is described under the specific arm.~Following the first 12-week training period, participants with COPD will enter a 21-month maintenance phase. They will continue to exercise using the same training modality (HIIT or MICT) as during the first 12-weeks but can select between three different settings to continue their training: Home, Outpatient, or Mix setting."
48486641|NCT05852808|RADIATION|Low-dose radiation therapy|The treatment consists of an informing consultation, a planning CT scan and a series of 10 radiation sessions delivered over 3.5 weeks ( = 12 visits in total). The clinical target volume (CTV) will be defined based on the MRI and SPECT/CT. Planning target volume (PTV) will be expanded in all directions by 0.5 cm beyond the CTV. Patients will be treated in a supine position with minimum 6 MV photons and a 3D-technique or volumetric modulated arc therapy (VMAT)-technique. A kilovolt (kV) and in exception a cone-beam CT will be performed before each treatment for positioning accuracy. A dose of 0.5 Gy x 10 fractions (3 times per week) will be delivered over 3.5 weeks. Each radiotherapy treatment session takes approximately 15 minutes. If a second radiotherapy series will be done (NRS 4-10 at visit 4), the radiotherapy dose und fractionation will be the same as the first series.
48645852|NCT04402073|DRUG|Sonidegib|Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
47967832|NCT05226715|OTHER|chiropractic manual therapy|high velocity low amplitude thrust into a human joint
47967833|NCT02864498|DRUG|DS107|
47967834|NCT02864498|DRUG|Placebo|
47967835|NCT03711812|PROCEDURE|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
47967836|NCT03711812|PROCEDURE|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
47967837|NCT00224042|DRUG|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
47967838|NCT00224042|DRUG|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
47967839|NCT03723941|DRUG|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
47967840|NCT03723941|OTHER|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
47967841|NCT03500354|DIETARY_SUPPLEMENT|Nutrient drink|High calorie drink with therapeutic supplements
47967842|NCT04592250|OTHER|Survey Administration|Complete survey
47967843|NCT05649397|OTHER|cervical manipulation|provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
47967844|NCT05649397|OTHER|conventional therapy|15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
47967845|NCT00635596|BIOLOGICAL|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
47967846|NCT02804932|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 8 weeks
47967847|NCT02804932|OTHER|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 8 weeks
47967848|NCT03155568|PROCEDURE|sciatic nerve block|sciatic nerve block at popliteal fossa
47967849|NCT03155568|PROCEDURE|ankle block|block of major nerves supplying the foot at the level of the ankle
47967850|NCT03155568|DRUG|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
47967851|NCT03989271|DRUG|Quercetin|Placebo
47967852|NCT01748669|DIETARY_SUPPLEMENT|Garlic oil|Oral administration
48117066|NCT04234776|DIAGNOSTIC_TEST|Cognition|Composite tools
47967853|NCT00837642|DIAGNOSTIC_TEST|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
47967854|NCT01581814|DRUG|Metformin|500 mg of Metformin per 3/die
48319455|NCT05614713|PROCEDURE|Selected physical therapy program|Gait training and balance training
48486642|NCT00444821|DEVICE|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
48645853|NCT04402073|DRUG|Cisplatin|Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
48645854|NCT04402073|DRUG|Lomustine|Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
48645855|NCT04402073|DRUG|Vincristine|Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
47967855|NCT01581814|DRUG|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
47967856|NCT01581814|DRUG|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
47967857|NCT00755092|BEHAVIORAL|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
48319456|NCT05614713|PROCEDURE|Modified physical therapy program to increase sensory input|Gait training and balance training using sensory stimulating matts
48319457|NCT02851433|DRUG|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
48319458|NCT02851433|DRUG|total intravenous anaesthesia with Propofol.|
48645856|NCT04402073|RADIATION|radiotherapy|Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
48319459|NCT04903119|DRUG|Nilotinib 100mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
48319460|NCT04903119|DRUG|Nilotinib 200mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
48319461|NCT04903119|DRUG|Nilotinib 300mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
48319462|NCT04903119|DRUG|Nilotinib 400mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
48645857|NCT02853214|GENETIC|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
48645858|NCT03612414|DIETARY_SUPPLEMENT|Aqualief|Three tablets/day
48645859|NCT03612414|DIETARY_SUPPLEMENT|Placebo|Three tablets/day
47967858|NCT00755092|BEHAVIORAL|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
47967859|NCT00738595|DRUG|EVT 302|EVT 302 5 mg once daily
47967860|NCT00738595|DRUG|Placebo|Placebo to match EVT 302, 5 mg
47967861|NCT00738595|DRUG|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
47967862|NCT00738595|DRUG|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
47967863|NCT05096897|OTHER|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
47967864|NCT05553249|BEHAVIORAL|Written Exposure Therapy|Virtual, group-based Written Exposure Therapy
47967865|NCT06241534|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
48117067|NCT04234776|OTHER|Suicide risk|MADRS (10) and HAM-D (3)
48117068|NCT04234776|OTHER|Depression thoughts|EPD
48117069|NCT04234776|OTHER|Quality of life and disability|Quality of life and disability
48117070|NCT04234776|OTHER|Clinical and epidemiological factors|Variables and categories
48117071|NCT04234776|DEVICE|Safety of ketamine IM|Vital signs
48117072|NCT04234776|OTHER|Tolerability of ketamine IM|UKU-SERS, YOUNG, CADSS and BPRS-12.
48319463|NCT04903119|DRUG|Dabrafenib|All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.
47967866|NCT06241534|BEHAVIORAL|Relaxation-therapeutic recordings|"8 sessions of relaxation-therapeutic recordings in the non-sleep deep rest concept.~The content of the recording is based on the 'body scanning technique', which constitutes the core of the therapy. This approach aims to quiet the overactive sympathetic part of the autonomic nervous system. During therapy, the patients take a 'journey' through their own body from feet to head. Following the voice of the narrator, the patient focuses on specific body parts, tries to feel this place and then relaxes tense muscles. Relaxation of individual body parts (muscle groups) is combined with breathing exercises. Conscious and mindful breathing deepens the state of relaxation. Additionally, the recording includes therapeutic suggestions related to making a choice between: overload and relief, holding on and letting go, acting and sensing. Furthermore, suggestions focus the patient on inner wisdom that allows them to make the best decisions."
47967867|NCT06241534|DEVICE|Virtual reality therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
47967868|NCT06241534|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
47967869|NCT04765956|DEVICE|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
47967870|NCT02048605|BEHAVIORAL|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
47967871|NCT02048605|BEHAVIORAL|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
47967872|NCT03234933|OTHER|Mobility Tracker|Tracking Patient's movements and calories
47967873|NCT00506662|DRUG|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
47967874|NCT00506662|DRUG|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
47967875|NCT01351922|OTHER|No treatment given|Patients will fill out a questionaire by interview.
47967876|NCT01991691|DEVICE|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
47967877|NCT02787668|OTHER|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO \<10%; fat \>65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
48319464|NCT04903119|DRUG|Trametinib|All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
48319465|NCT01679093|DRUG|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
48319466|NCT01679093|DRUG|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
48319467|NCT01679093|DRUG|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
48645860|NCT04241432|DEVICE|vibrating platform|Use of two different types of vibrating platform
48645861|NCT01821846|DRUG|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
48645862|NCT03445442|PROCEDURE|SCP|Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
47967878|NCT02787668|OTHER|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
47967879|NCT03606499|DRUG|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
47967880|NCT04737083|GENETIC|CGH array|a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
48319468|NCT04717193|DRUG|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
48319469|NCT04717193|PROCEDURE|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
48319470|NCT03309267|PROCEDURE|Intercostal block|Intercostal block +patient controlled analgesia
48319471|NCT03309267|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
48319472|NCT04675359|PROCEDURE|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
47967881|NCT03677362|BEHAVIORAL|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (\~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (\~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
47967882|NCT00256191|DRUG|TPI 287 Injection|
47967883|NCT02321800|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
47967884|NCT02321800|DRUG|Imipenem/cilastatin|1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
47967885|NCT04433377|PROCEDURE|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
47967886|NCT04433377|PROCEDURE|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
47967887|NCT01594281|DRUG|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
47967888|NCT01594281|PROCEDURE|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
47967889|NCT05979870|PROCEDURE|Valvuloplasty,|Choice of type of intervention decided on a multidisciplinary conference
47967890|NCT03915821|DEVICE|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
47967891|NCT00500669|DRUG|Betadine|Topically
48319473|NCT01819311|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
48319474|NCT01819311|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
48645863|NCT03445442|PROCEDURE|NTR|Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
48645864|NCT03445442|PROCEDURE|VMR|Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
48645865|NCT03584386|DEVICE|V-CAMS (aka Jaspr)|V-CAMS is an integrated software system for use on any device by suicidal patients.
47967892|NCT06268002|DIETARY_SUPPLEMENT|Vernonia cinerea|Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
48319475|NCT00330525|DRUG|sibutramine|
48319476|NCT03121833|DRUG|Endostar|Recombinant Human Endostatin Injection
48319477|NCT03121833|DRUG|Placebo|500ml 0.9% sodium chloride
48319478|NCT03121833|DRUG|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
48340011|NCT03620604|DEVICE|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
48340012|NCT00742040|DRUG|Captopril|A rapid 3-day up-titration protocol
48645866|NCT03690999|DIETARY_SUPPLEMENT|Placebo|Placebo product
48645867|NCT03690999|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic supplement
48645868|NCT04589624|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
48645869|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48645870|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo hpMRI
48645871|NCT00233168|BEHAVIORAL|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
48645872|NCT00233168|BEHAVIORAL|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
48645873|NCT05591287|PROCEDURE|Contrast enhanced harmonic Endoscopic Ultrasound|Solid pancreatic masses suspected for PDAC detected by cross-sectional imaging and confirmed at EUS will be enrolled. The
48645874|NCT04195672|DEVICE|NIPE (MDoloris®) and CBS values|"During different procedures of care with the bed-side nurse, NIPE ware recorded. Monitoring started 15 minutes before care and continuously recorded until 10 minutes after the procedure. Pain assessment was evaluated by the CBS under 3 periods for each patient: 1- before any procedure (T1) representing the baseline, 2- during the procedure of care (T2), and 3- after the procedure (T3). Investigator who performed the CBS was blind to NIPE during the procedure recording.~This study did not change the procedure of care before or after and had no impact on care"
48319479|NCT02042339|DRUG|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
48319480|NCT04123717|DRUG|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
48319481|NCT04496440|OTHER|Contracture Correction Therapy|Non-drug and non-surgical treatment of contracted knee capsules
47967893|NCT06268002|DIETARY_SUPPLEMENT|Placebo|Sweetener
47967894|NCT04067544|DEVICE|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
47967895|NCT03622944|PROCEDURE|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
47967896|NCT03622944|PROCEDURE|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
47967897|NCT03622944|PROCEDURE|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
47967898|NCT06011044|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block test is a medical intervention that involves the administration of a local anesthetic to the intercostal nerves, which are located between the ribs. The intervention involves injecting a small amount of anesthetic solution near the targeted intercostal nerves, which temporarily numbs the area and provides potential pain relief. The intercostal nerve block test is considered a diagnostic tool to help guide further treatment decisions for conditions such as intercostal neuralgia, rib fractures, or postoperative pain. It is generally a safe and well-tolerated procedure, often performed under local anesthesia or with the assistance of image guidance to ensure accurate needle placement. Following the test, the patient's response is evaluated, and if pain relief is achieved, it may indicate that intercostal nerve block injections could be an appropriate treatment option.
47967899|NCT00454896|DRUG|VESIcare®|Oral
48645875|NCT01934231|DRUG|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
48645876|NCT02532907|PROCEDURE|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
48645877|NCT01570907|DRUG|Quetiapine Fumarate|25 mg tablet
48645878|NCT06256432|DRUG|Ambrisentan|Endothelin receptor antagonist
48645879|NCT06256432|DRUG|Terlipressin|Terlipressin
48645880|NCT06014723|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
48645881|NCT06634160|DIAGNOSTIC_TEST|Fibroscan|Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).
48645882|NCT06634160|OTHER|Sample collection|20 mL whole blood sample
47967900|NCT00454896|DRUG|placebo|Oral
48645883|NCT06671899|OTHER|Constraint-induced movement therapy (CIMT)|Clinically implemented modified CIMT. Including the three main components; intensive and repetitive task-oriented training of the affected limb, constraint of the non-affected limb and behavioural strategies known as the Transfer Package. In this model the training is supervised by therapist from several professions and some training sessions is performed in group settings with other inpatients and outpatients undergoing primary rehabilitation at the clinic.
47967901|NCT04334070|DRUG|Lamprene®/Clofazimine|All participants will receive Lamprene/clofazimine 50 mg capsules. The recommended dose of clofazimine for this program is 100 mg once daily, administered orally, preferably with meals. Duration of treatment will be decided by the treating physician. When considering clofazimine for the treatment of NTM infection, clofazimine is to be administered as part of a multi-drug regimen.
47967902|NCT04154735|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
47967903|NCT04154735|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
47967904|NCT04154735|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
47967905|NCT04154735|DRUG|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
47967906|NCT04154735|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
47967907|NCT04154735|DRUG|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
47967908|NCT04154735|DRUG|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
47967909|NCT00418015|PROCEDURE|Blood Draw|Blood for OPRM1 analysis
47967910|NCT03201835|DRUG|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
47967911|NCT03201835|DRUG|Sativex|spray X 4 actuations
47967912|NCT03201835|DRUG|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
47967913|NCT03201835|DRUG|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
47967914|NCT03201835|DRUG|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
47967915|NCT04828252|DEVICE|Low level laser treatment|The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
48117073|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
48645884|NCT00010907|DRUG|NPI-028|
48645885|NCT01830465|DRUG|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
48645886|NCT01830465|DRUG|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
48645887|NCT01830101|DRUG|TMZ plus concurrent re-irradiation|
48645888|NCT01830101|DRUG|Temozolomide|low-dose temozolomide daily for one year
48645889|NCT06296030|BEHAVIORAL|POOF ACT program|The goal of this study is to test this culturally tailored intervention (POOF) against classic ACT, to discover if POOF does better at decreasing race-based trauma in African Americans.Guided by the cultural humility framework and social determinants of health model, we examine POOF, a culturally-tailored ACT model for use with anxious African Americans. The POOF approach builds on research on ACT for the general population, an evidence-based intervention, by tailoring the language of ACT while retaining the fidelity of the ACT model. Our hypotheses examine acceptability and attitudes toward treatment, treatment outcomes for psychological symptoms (i.e., anxiety) and an ACT-related outcome (i.e., psychological flexibility), and a possible underlying mechanism of change (i.e., race-based stress).
48645890|NCT06296030|BEHAVIORAL|Classic ACT program|This protocol is for a classic, non-adapted ACT intervention.
48117074|NCT04271449|BEHAVIORAL|Virtual reality device|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be the cerebellum.~Prismatic googles will also be used in the same way in all groups during prism exposure."
48319482|NCT04118114|DRUG|PRL3-zumab|IV administration every 2 weeks
48319483|NCT02859493|DEVICE|Saccharomyces cerevisiae|
48319484|NCT02859493|DEVICE|Placebo|
48340013|NCT00742040|DRUG|Captopril|A slower 9-day up-titration protocol
47967916|NCT06300372|PROCEDURE|M-TAPA plane block|As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied bilaterally (60 ml in total).
48645891|NCT02513641|DEVICE|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of \~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
48645892|NCT00181545|PROCEDURE|escalation of dose (radiotherapy treatment)|
47967917|NCT06300372|PROCEDURE|Postoperative pain management|For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
47967918|NCT01961193|DEVICE|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
47967919|NCT01961193|DEVICE|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
47967920|NCT05395715|PROCEDURE|Electrical stimulation|Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery
47967921|NCT06485167|DEVICE|HIFEM- chair|The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
47967922|NCT03262909|DEVICE|GelrinC|Patients will undergo GelrinC implantation.
47967923|NCT03262909|OTHER|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
47967924|NCT06340373|DEVICE|DCB Angioplasty|Drug-coated balloons (DCB) are designed to deliver drugs (antiproliferative drugs: Paclitaxel, Sirolimus etc.) to the target lesion/vessel wall without leaving nothing behind unlike stent strut or drug delivery system. Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function
47967925|NCT05638568|DIAGNOSTIC_TEST|LS test|If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)
47967926|NCT03736447|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
47967927|NCT03736447|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
47967928|NCT00306618|DRUG|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
48319485|NCT00376987|DIETARY_SUPPLEMENT|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
48645893|NCT03844412|DRUG|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
48645894|NCT03844412|DRUG|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
48645895|NCT03844412|DRUG|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
48645896|NCT03844412|DRUG|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
48319486|NCT03015922|DRUG|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
48319487|NCT03015922|BIOLOGICAL|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
47967929|NCT04821947|OTHER|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
47967930|NCT00779714|DRUG|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
47967931|NCT00779714|DRUG|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
47967932|NCT00779714|DRUG|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
47967933|NCT04238702|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG 7 days intervention period
48319488|NCT05902013|DEVICE|laryngoscopy|laryngoscopy for nasotracheal intubation
48319489|NCT02915952|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
48319490|NCT02915952|OTHER|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
48319491|NCT02572128|OTHER|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
48319492|NCT04966884|DRUG|JAK Inhibitor|"1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. Tofacitinib 5 mg twice daily for 12 months."
48319493|NCT01287533|DRUG|Ibandronate|monthly dosage of ibandronate 150mg
48319494|NCT01287533|DRUG|Placebo|monthly dosage of placebo
48319495|NCT04741334|DRUG|direct anticoagulant|exposure to direct anticoagulant
48319496|NCT04741334|DRUG|antiplatelet drugs|exposure to antiplatelet drugs
47967934|NCT04238702|DRUG|Losartan 50Mg Tab|Losartan 50 MG 7 days intervention period
47967935|NCT04238702|OTHER|Placebo|Placebo 7 days intervention period
48319497|NCT04741334|DRUG|Dicumarols|exposure to dicumarols
48486643|NCT04303650|DEVICE|Ultrasound measurement of quadriceps muscle layer thickness|With patient in supine position ultrasound will be performed using a 12MHZ Transducer connected to Sonosite M Turbo machine. The probe will be placed perpendicular to the long axis of the thigh on its anterior surface at the two thirds of the length between the anterior superior iliac spine and the upper border of the patella. After identifying the muscle tissue, the thickness of the quadriceps muscle will be obtained by measuring the distance between the cortex of femur and the most superficial muscular fascia. Measurements will be performed by applying maximal compression on the probe without inflicting pain to prevent underestimation of muscle wasting linked to subcutaneous edema. measurements will be made on both sides repeatedly on ICU days 1, 3, 7, and 10. Every time three ultrasound measurements will be taken per site and the average of three measurements for each site will be used and combined to provide total muscle depth
48486644|NCT02623049|OTHER|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
48486645|NCT03097588|DRUG|Netupitant|300 mg, Given PO, QD
47967936|NCT00656383|OTHER|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
47967937|NCT00656383|OTHER|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
48486646|NCT03097588|DRUG|Palonosetron Hydrochloride|0.5 mg, Given PO, QD
48486647|NCT03097588|OTHER|Questionnaire Administration|Ancillary studies
47967938|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
47967939|NCT01087645|DRUG|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
47967940|NCT01087645|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
47967941|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
47967942|NCT01087645|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo
47967943|NCT00019097|DRUG|autologous tumor cell vaccine|
47967944|NCT00019097|DRUG|keyhole limpet hemocyanin|
47967945|NCT00019097|DRUG|melphalan|
47967946|NCT00019097|DRUG|sargramostim|
48319498|NCT00999219|DRUG|FK199B|oral
48319499|NCT00999219|DRUG|Zolpidem|oral
48319500|NCT02139995|BEHAVIORAL|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
48319501|NCT02987348|DRUG|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
48319502|NCT02987348|DRUG|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
48319503|NCT02987348|DRUG|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
48486648|NCT03637335|COMBINATION_PRODUCT|irradiation + carboplatin|30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
48486649|NCT03637335|COMBINATION_PRODUCT|irradiation + placebo|30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
47967947|NCT06499311|OTHER|Foot Reflexology|Foot Reflexology is an alternative medical practice involving the application of pressure to specific points on the feet. It has been reported as a non-invasive complementary therapy that was addressed as an effective technique that is reported to reduce premenstrual symptoms.
47967948|NCT06499311|OTHER|Acupressure|Acupressure is a sort of massage therapy, was addressed as an effective technique that is reported to reduce premenstrual symptoms. Acupressure is a well-known form of Traditional Chinese Medicine that is a component of alternative treatments.
47967949|NCT02971397|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
47967950|NCT02971397|DRUG|Cytarabine|Given IV
47967951|NCT02971397|DRUG|Daunorubicin Hydrochloride|Given IV
47967952|NCT02971397|OTHER|Laboratory Biomarker Analysis|Correlative studies
47967953|NCT04640285|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
47967954|NCT04640285|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
48319505|NCT03882346|COMBINATION_PRODUCT|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
48319506|NCT06119724|PROCEDURE|Bipolar enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using bipolar
48340014|NCT04153929|DRUG|BI 456906|Solution for Injection
48486650|NCT01780779|OTHER|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
47967955|NCT04640285|OTHER|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
47967956|NCT04640285|OTHER|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
47967957|NCT04433403|OTHER|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
47967958|NCT00052689|DRUG|bortezomib|Given IV
47967959|NCT00052689|DRUG|gemcitabine hydrochloride|Given IV
47967960|NCT01243892|DEVICE|NuSpin|Device for administration of doses of somatropin.
47967961|NCT01243892|DRUG|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
47967962|NCT02713347|BEHAVIORAL|ADAPT Intervention|"The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
47967963|NCT05479071|DIAGNOSTIC_TEST|Blood test|Screening of antibodies against LDL
47967964|NCT04483271|DIETARY_SUPPLEMENT|300 mg of omega3-FA|"The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured."
47967965|NCT01785069|DEVICE|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
47967966|NCT04736836|DRUG|Rifaximin|locally absorbed antibiotic
48486651|NCT00411398|DRUG|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
47967967|NCT04399317|DEVICE|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
47967968|NCT04004715|DIETARY_SUPPLEMENT|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
47967969|NCT04004715|DIETARY_SUPPLEMENT|Whey Protein|commercially available whey protein isolate
47967970|NCT04004715|DIETARY_SUPPLEMENT|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
47967971|NCT00866385|DRUG|AZD8566|Single 6 mg oral solution dose
48645897|NCT06685900|DEVICE|digital therapeutics|Early intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the third week of participation. From the fourth week onward, for a duration of 12 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
48645898|NCT06685900|DEVICE|digital therapeutics|Late intervention group will undergo app usage training, disease education, blood pressure measurements, orthostatic blood pressure measurements, and postprandial blood pressure measurements up to the ninth week of participation. From the tenth week onward, for a duration of 6 weeks, non-pharmacological treatment education will be provided through a digital therapeutic, and blood pressure will be measured according to a specified schedule.
48645899|NCT05835596|DEVICE|Access to MumCare app|Education, push warning to book cardiovascular health follow-up at own general practitioner , registration of BP and lipids, HbAc
48645900|NCT06085638|DRUG|Azacitidine|Given by SC (under the skin) or IV (vein)
48645901|NCT06085638|DRUG|Tamibarotene|Given by PO
48645902|NCT06085638|DRUG|Venetoclax|"Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax"
48645903|NCT03470883|OTHER|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (\> 12 months)
48645904|NCT01668199|DRUG|TZP-101|
48645905|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.02%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
48645906|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.04%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
47967972|NCT00866385|DRUG|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
47967973|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
47967974|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
47967975|NCT02781597|DRUG|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
47967976|NCT02781597|DRUG|Placebo|Patients will receive 0.9% normal saline
47967977|NCT05015244|PROCEDURE|3T (Tesla) Magnetic Resonance Imaging (MRI)|Neurological evaluation using MRI and neuropsychological tests
47967978|NCT02204878|DRUG|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
47967979|NCT01926236|OTHER|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
47967980|NCT01926236|DRUG|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
47967981|NCT01926236|DRUG|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
47967982|NCT01926236|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
47967983|NCT00289991|DRUG|Itraconazole|Prophylaxis
47967984|NCT00289991|DRUG|Vfend - voriconazole|Prophylaxis
47967985|NCT01297712|DEVICE|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
47967986|NCT02095574|DRUG|[14C]ABT-199 (GDC-0199)|\[14C\]ABT-199 will be administered as a single oral administration
48319507|NCT06119724|PROCEDURE|Thulium laser enbloc resection of bladder tumor|Enbloc retrival of bladder tumor entoto using cystoscopy using thulium laser
48319508|NCT02222454|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
47967987|NCT03067961|OTHER|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
48319509|NCT03886142|PROCEDURE|radiofrequency|radiofrequency of the genicular nerves
48645907|NCT05451329|DRUG|VVN539 Ophthalmic Solution Vehicle|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
48319510|NCT03886142|PROCEDURE|platelet rich plasma injection|intra articular injection of platelet rich plasma
47967988|NCT01443260|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
47967989|NCT04176666|DEVICE|NettOpp|NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
47967990|NCT01805154|DEVICE|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
48319511|NCT05357326|DRUG|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
48319512|NCT05357326|DEVICE|Orthokeratology|wear orthokeratology at night while sleeping
48319513|NCT05357326|DRUG|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
48319514|NCT00091143|BIOLOGICAL|gp100 antigen|
48319515|NCT00091143|BIOLOGICAL|incomplete Freund's adjuvant|
48319516|NCT00091143|BIOLOGICAL|keyhole limpet hemocyanin|
48319517|NCT00091143|DRUG|fludarabine phosphate|
48319518|NCT00091143|PROCEDURE|peripheral blood stem cell transplantation|
48340015|NCT04153929|DRUG|Placebo|Solution for Injection
48340016|NCT04153929|DRUG|Semaglutide|Solution for Injection
48340017|NCT04989660|DRUG|6% aqueous phenol|1.5 mL of 6% aqueous phenol will be injected at each target genicular nerve under ultrasound guidance.
48340018|NCT04989660|DRUG|Isotonic saline|1.5 mL of isotonic saline will be injected at each target genicular nerve under ultrasound guidance.
48645908|NCT04795453|OTHER|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
47967991|NCT04753645|BEHAVIORAL|Handwashing stations at the public places and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
47967992|NCT04753645|BEHAVIORAL|No activities of the HBCC project and also no soap (Pure Control)|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
47967993|NCT04753645|BEHAVIORAL|Soap distributed but no activities of the HBCC project|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
47967994|NCT04753645|BEHAVIORAL|HBCC project and Soap|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
47967995|NCT04047745|DRUG|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
47967996|NCT04047745|DRUG|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
47967997|NCT00370032|DRUG|alosetron|
47967998|NCT04551755|DRUG|Ivermectin and Doxycycline|"1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
47967999|NCT04551755|OTHER|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
47968000|NCT06060782|DRUG|Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen|"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"
47968001|NCT01116583|DRUG|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
47968002|NCT01116583|DRUG|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4"
47968003|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
47968004|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
47968005|NCT03859505|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
47968006|NCT03859505|DEVICE|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
47968007|NCT05574790|OTHER|annual follow up|Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
48340019|NCT04815538|BEHAVIORAL|the subscale of Health-Promoting Lifestyle Profile II|"Nutritional health behavior included the following nine items: choose a low-fat diet; limit the use of sugars; eat servings of bread, cereal, and rice; eat servings of fruit; eat servings of vegetables; eat servings of meat, poultry, fish, dietary guidelines"
48486652|NCT03780946|PROCEDURE|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
48645909|NCT04795453|OTHER|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
48645910|NCT03357497|OTHER|Very early mobilization|The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
48645911|NCT03599726|DRUG|Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
48645912|NCT03599726|DRUG|Placebo|Placebo 5 mg per day for week 1-2 or 5-6
48645913|NCT02893436|PROCEDURE|Surgery with tracheal intubation curarisation|
48645914|NCT05751226|DRUG|BI 1820237|BI 1820237
48645915|NCT05751226|DRUG|semaglutide|semaglutide
48645916|NCT05751226|DRUG|Placebo|Placebo
48645917|NCT05751226|DRUG|BI 456906|BI 456906
48645918|NCT05861401|GENETIC|Janus Kinase 1 and 2|Under complete sterile precautions, 3mL of blood will be withdrawn by venipuncture and put in EDTA tube; DNA extraction will be done after centrifugation and used for genotyping assay of (JAK 1 and JAK2) gene with the polymerase chain reaction(PCR).
48319519|NCT04942938|DEVICE|Neubie|The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
48319520|NCT00118729|DRUG|GW685698X Aqueous Nasal Spray|
48319521|NCT00484536|DRUG|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
48319522|NCT00484536|DRUG|placebo|capsules, once daily
48319523|NCT00484536|DRUG|CDP323|250 mg Capsules, 500 mg, once daily
48319524|NCT04379219|DRUG|Methotrexate|giving methotrexate at least 1 w week before surgery
47968008|NCT04286243|OTHER|Community-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the community
48319525|NCT01493986|DRUG|Ropivacaine|Dosage. Onset time
47968009|NCT04286243|OTHER|Clinic-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the clinic
48319526|NCT06200740|DEVICE|Sonara|web application facilitating asynchronous observation of methadone dosing
48319527|NCT02586987|DRUG|Selumetinib|Selumetinib oral
48319528|NCT02586987|DRUG|MEDI4736|MEDI4736 IV
48117075|NCT04271449|DEVICE|tDCS (transcranial direct current stimulation)|"Non invasive functional brain stimulation that allows to modulate the excitability of a targeted area (inhibitory or excitatory) thanks to a small current that goes beyond two electrodes. For this arm, the targeted are will be either the cerebellum or the primary motor cortex, but the stimulation will be turned off after 15 seconds to insure a sham condition.~Prismatic googles will also be used in the same way in all groups during prism exposure."
48117076|NCT02202824|OTHER|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
48319529|NCT02586987|DRUG|Tremelimumab|Tremelimumab, IV
48319530|NCT05626517|DIAGNOSTIC_TEST|Ocular Imaging|The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.
48486653|NCT03780946|PROCEDURE|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
47968010|NCT02646137|DRUG|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
48117077|NCT06553365|DRUG|FCN-159|FCN-159 8mg qd po
48319531|NCT05626517|OTHER|Questionnaires|3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
48319532|NCT04752098|DIAGNOSTIC_TEST|Vibro-acoustic analysis (VAA), based on ultrasound radiation force|The study will develop and validate a new ultrasonic method for assessment of infant bone by evaluating structural and mechanical characteristics of the infant tibia. This project will utilize a novel, non-invasive method, vibro-acoustic analysis (VAA), to evaluate infant bone properties in a wide frequency range while reducing the artifacts from soft tissue.
48319533|NCT03653403|DRUG|IDP-126 Gel|Component A
48319534|NCT03653403|DRUG|Control Gel|gel
48319535|NCT05528224|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate\<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention."
48486654|NCT04300413|OTHER|High-Intensity Rehabilitation plus Mobility (HeRo)|Progressive, high-intensity strengthening and functional intervention coupled with structured mobility based in principals of behavioral economics.
48486655|NCT04529226|DRUG|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
48486656|NCT04529226|DRUG|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
47968011|NCT02646137|PROCEDURE|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
48319536|NCT05528224|OTHER|Cognitive Behavioral Group Therapy (CBGT)|OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
47968012|NCT02646137|PROCEDURE|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
48319537|NCT05528224|DRUG|conventional medical treatment (TAU)|"In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual."
48319538|NCT02673892|OTHER|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
48319539|NCT01876394|OTHER|Coconut Oil|Shake with 50 g Coconut oil
48319540|NCT01876394|OTHER|Canola Oil|Shake with 50 g Canola oil
48319541|NCT01876394|OTHER|Grapeseed Oil|Shake with 50 g Grapeseed oil
48319542|NCT01876394|OTHER|Chia Oil|Shake with 50 g Chia oil
48319543|NCT01876394|OTHER|Butter|Shake with 50 g Butter
48319544|NCT02345824|DRUG|Ribociclib|CDK4/6 INHIBITOR
48319545|NCT03134508|OTHER|treated by antiTNFα|pregnant IBD women treated by antiTNFα
48319546|NCT03134508|OTHER|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
48319547|NCT00748553|DRUG|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
48319548|NCT00748553|DRUG|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
48319549|NCT02942316|DEVICE|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~* after induction, before opioid administration~* after opioid administration, steady state~* surgical incision~* end of procedure"
47968013|NCT04524390|DRUG|Maralixibat|A small molecule inhibitor of the ileal bile acid transporter (IBAT)
47968014|NCT04524390|OTHER|Placebo|Identical to maralixibat except for the active drug substance
48319550|NCT03386656|DRUG|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
48319551|NCT03386656|OTHER|Saline Solution|Placebo
47968015|NCT03608098|DEVICE|Short Pulse Duration|The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)
47968016|NCT03608098|DEVICE|Long Pulse Duration|The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
47968017|NCT06440096|DIAGNOSTIC_TEST|hemogram|hemogram
47968018|NCT06270667|BEHAVIORAL|Aerobic Exercise|Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
48319552|NCT04317352|PROCEDURE|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
48319553|NCT02499003|DRUG|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
48319554|NCT00000567|PROCEDURE|high-frequency ventilation|
48319555|NCT01268423|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
48319556|NCT01268423|PROCEDURE|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
48319557|NCT00923819|PROCEDURE|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
48319558|NCT00923819|BEHAVIORAL|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
48319559|NCT04695106|DRUG|Ticagrelor|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
48340020|NCT03437291|PROCEDURE|Cesarean section|Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
47968019|NCT06270667|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
47968020|NCT05482724|BEHAVIORAL|Super Skills for Life|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández.~The intervention was administered by a trained clinical psychologist in SSL. Sessions were held after school hours once a week for eight weeks, with each session lasting approximately one hour. The contents of the program were covered through playful activities in groups of 4 to 6 children"
47968021|NCT03008603|DEVICE|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
47968022|NCT05705414|DRUG|Valine|A medical food intended for use under medical supervision
47968023|NCT05705414|DRUG|EEA|A medical food intended for use under medical supervision
47968024|NCT01615185|DRUG|full-dose amisulpride|amisulpride 800mg/d
47968025|NCT04944069|DRUG|Almonertinib|110 mg oral once daily
47968026|NCT04944069|DRUG|Bevacizumab|15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
47968027|NCT04779060|DRUG|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
47968028|NCT04779060|DRUG|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
47968029|NCT04779060|DRUG|saline|normal saline will be mixed with bupivacaine intrathecally
47968030|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
47968031|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
47968032|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
47968033|NCT00680017|DRUG|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
47968034|NCT00680017|DRUG|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
47968035|NCT05045014|OTHER|Balance assessment|Romberg test and one-leg standing test will be used.
47968036|NCT05045014|OTHER|Unterberger test|During 50 steps, he will count in place with 45 degrees of hip flexion, and after 50 steps, the angle of rotation between the first position and the final position of the right foot will be measured with the help of a goniometer and the displacement distance.
47968037|NCT05045014|OTHER|Corsi Block Tapping (mobıl app)|Spatial memory will be evaluated.
47968038|NCT05045014|OTHER|Navigation performance|Two triangles (one equilateral, one oblique triangle, at 30°, 60° and 90° angles respectively) with route segment lengths between 150 and 300 cm will be marked on the floor and the participants will be asked to complete the task with their eyes closed. The final deviation amount will be recorded.
47968039|NCT05045014|OTHER|Cobb angle measurement|It will be evaluated with the help of X-ray.
47968040|NCT05045014|OTHER|Scolio Detector (mobıl app)|The degree of rotation will be measured with the mobile application called Scolio Detector.
48486657|NCT01264549|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
47968041|NCT05228132|DEVICE|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
47968042|NCT02880059|DEVICE|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
48486658|NCT03351231|DRUG|BMS-986242|Specified dose on specified days
48486659|NCT03351231|BIOLOGICAL|Nivolumab|Specified dose on specified days
48486660|NCT00857259|DRUG|Everolimus|5 mg oral tablet
48486661|NCT00857259|DRUG|Ranibizumab|0.5 mg administered by intravitreal injection
47968043|NCT00814970|DEVICE|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
47968044|NCT02878746|DEVICE|Robotic mirror therapy|2-dimensional
47968045|NCT02878746|DEVICE|Conventional mirror therapy|2- and 3-dimensional
47968046|NCT02944968|DEVICE|THERMOCOOL SMARTTOUCH® SF-5D catheter|
47968047|NCT04040114|DEVICE|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
48340021|NCT03437291|DEVICE|Transabdominal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
48340022|NCT03437291|DEVICE|Transvaginal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
47968048|NCT05904197|OTHER|Gamified Cards about Nephrotic Syndrome|"* The study intervention Spin to Win - Nephro Cards will include the following items with simple Arabic language and graphic designation appropriate to children's developmental levels including; nephrotic syndrome, hygiene practices, weight control, fluids, blood pressure control, diet, medication...etc.~* A spin wheel with numbers and images similar to the educational gamified cards will be designed. Children will request to spin the wheel. After the spin, the educational gamified Nephro Cards will reveal and discuss with the child."
47968049|NCT02416921|BEHAVIORAL|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
47968050|NCT02416921|BEHAVIORAL|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
47968051|NCT02818569|DRUG|Dexmedetomidine|Oral form
47968052|NCT02818569|OTHER|Saline Placebo|Saline Placebo
47968053|NCT04670198|BEHAVIORAL|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
47968054|NCT04670198|BEHAVIORAL|Waiting-list control|Usual care for 6 months, followed by the YES programme.
47968055|NCT03435484|OTHER|Arm A|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
47968056|NCT03435484|OTHER|Arm B|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
47968057|NCT06457880|PROCEDURE|PENG BLOCK|Preoperative ultrasound guided PENG block (ropivacaine 0.5 % 20 mL)
47968058|NCT06457880|PROCEDURE|Femoral Nerve Block|Preoperative ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL)
47968059|NCT06457880|PROCEDURE|Obturator Nerve Block|Preoperative ultrasound guided obturator nerve block (ropivacaine 0.5 % 5 mL)
47968060|NCT03599999|DRUG|Adverse events detection|type of adverse events detected during treatment with Temocillin and imputed to Temocillin
47968061|NCT06037447|PROCEDURE|3-steps standardized repair-oriented strategy|3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
47968062|NCT06309732|DRUG|Pegfilgrastim|6mg at each cycle
47968063|NCT06309732|DRUG|Dactinomycin|1mg/m2
47968064|NCT06309732|DRUG|Methotrexate|Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
47968065|NCT06309732|DRUG|Etoposide|90mg/m2 injection for infusion
47968066|NCT06309732|DRUG|Cisplatin|50mg/m2
47968067|NCT06309732|DRUG|Epirubicin|37.5mg/m2
47968068|NCT06163729|DRUG|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
47968069|NCT06455644|OTHER|CT group|After completing the AF ablation, select the appropriate LAA occluder based on preoperative CT measurements for implantation.
47968070|NCT06455644|OTHER|DSA group|After completing the AF ablation, select the appropriate LAA occluder based on intraoperative DSA measurements for implantation.
47968071|NCT02221791|DIETARY_SUPPLEMENT|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
47968072|NCT02221791|DIETARY_SUPPLEMENT|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
47968073|NCT02221791|DIETARY_SUPPLEMENT|Placebo|Participants will consume 70g white chocolate + placebo capsules
47968074|NCT03217331|DRUG|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
47968075|NCT02975505|OTHER|Strict blood pressure control|Systolic Blood Pressure Target \< 120 mm Hg (measured at home)
48340023|NCT01553721|DRUG|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
48340024|NCT01553721|DRUG|placebo|Phase IIa - placebo Phase IIb - placebo
48319560|NCT04695106|DRUG|Dabigatran Etexilate|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
47968076|NCT01666574|OTHER|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
47968077|NCT01666574|OTHER|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
47968078|NCT00315172|PROCEDURE|Non-Exercise Activity Thermogenesis (NEAT)|
47968079|NCT03748758|COMBINATION_PRODUCT|Drug: OP0201|Drug OP0201
47968080|NCT03748758|COMBINATION_PRODUCT|Drug: Placebo|Placebo
47968081|NCT01056653|BEHAVIORAL|Standard Dose|Two intevention home visits
48645919|NCT01121029|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
48645920|NCT04297774|BEHAVIORAL|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
48645921|NCT04297774|BEHAVIORAL|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
47968082|NCT01056653|BEHAVIORAL|High Dose|Four intervention home visits
47968083|NCT01056653|BEHAVIORAL|Comparison Group|One home visit, information only
47968084|NCT00582166|DRUG|Ibritumomab Tiuxetan (Zevalin) + Rituximab|Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
47968085|NCT04194398|DEVICE|OCS Lung System|Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
47968086|NCT04008576|BEHAVIORAL|Group Blended Transdiagnostic treatment|The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
47968087|NCT05014789|DEVICE|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
47968088|NCT04678661|DEVICE|Smartphone application and web portal|"My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders."
48340025|NCT02608372|OTHER|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
48486662|NCT00911807|DRUG|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
47968089|NCT04678661|BEHAVIORAL|Standard Insulin Therapy Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
48319561|NCT04695106|DRUG|Aspirin|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
48319562|NCT04695106|DRUG|Clopidogrel|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
47968090|NCT05697315|PROCEDURE|Control|No block was performed
47968091|NCT05697315|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
47968092|NCT04166175|PROCEDURE|botox injection in intersphincteric space|injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
47968093|NCT04166175|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy under GA in lithotomy position
47968094|NCT05878860|BIOLOGICAL|ATSN-201|AAV.SPR-hGRK1-hRS1syn
47968095|NCT02447042|PROCEDURE|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
47968096|NCT02447042|DEVICE|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
48645922|NCT04297774|BEHAVIORAL|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
48645923|NCT03060707|DRUG|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
48645924|NCT05839821|BEHAVIORAL|noF-noRAS|resting state, that is, without finger-tapping and without listening to RAS
47968097|NCT05363644|BIOLOGICAL|BioDFence G3|Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
47968098|NCT01941121|BEHAVIORAL|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
47968099|NCT06505434|PROCEDURE|Cataract surgery|Phaco + IOL Implantation
47968100|NCT00569881|DRUG|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
48486663|NCT00911807|DRUG|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
48645925|NCT05839821|BEHAVIORAL|F-noRAS|finger-tapping without listening to RAS
47968101|NCT02412605|PROCEDURE|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
48645926|NCT05839821|BEHAVIORAL|noF-100RAS|listening to RAS with the 100% of the baseline tempo and without finger-tapping
48645927|NCT05839821|BEHAVIORAL|F-100RAS|finger-tapping and listening to RAS with 100 % of baseline tempo
47968102|NCT03678298|OTHER|Epidemiological/treatment profiles|All consecutively hospitalized adult patients (older than 18 years of age) undergoing surgery, interventional drainage or conservative treatment, with diagnosis of cIAIs (defined as abdominal infections originating in an organ cavity, extending into the peritoneal space, and forming an abscess or peritonitis, will be included in the study.
47968103|NCT04602988|DEVICE|EEG|EEG monitoring of brain rhythms
47968104|NCT00745836|DRUG|statin|
47968105|NCT04991909|DRUG|HRS4800|HRS4800
47968106|NCT04991909|DRUG|Placebo|Placebo
47968107|NCT00380952|DEVICE|Dune Device|
48319563|NCT05098158|OTHER|Non-pharmacological pain treatment|Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.
48319564|NCT01062620|DRUG|AXL1717|Phase I study with increasing dosage and treatment duration
48645928|NCT05839821|BEHAVIORAL|F-105RAS|finger-tapping and listening to RAS with 105 % of baseline tempo
48645929|NCT05839821|BEHAVIORAL|F-110RAS|finger-tapping and listening to RAS with 110 % of baseline tempo
48645930|NCT03890107|DEVICE|OtoSight Middle Ear Scope|OtoSight imaging using a near-infrared laser
48645931|NCT00952562|DIETARY_SUPPLEMENT|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
47968108|NCT03982407|DRUG|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
47968109|NCT05884905|PROCEDURE|short hydration|NSS infusion prior to and following cisplatin administration within 6 hours
47968110|NCT05884905|PROCEDURE|conventional hydration|NSS infusion prior to and following cisplatin administration over 24 hours
47968111|NCT00598832|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
47968112|NCT00598832|DRUG|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
47968113|NCT02853604|DRUG|ADXS11-001|
47968114|NCT02853604|DRUG|Placebo|
47968115|NCT00279305|DRUG|Anti-CD20 (rituximab)|
47968116|NCT00279305|DRUG|Placebo Comparator|Placebo intravenous infusion
47968117|NCT02535988|RADIATION|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
47968118|NCT02535988|DRUG|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
47968119|NCT00217620|DRUG|sorafenib|800 mg per day, daily until progression
47968120|NCT01807975|OTHER|Forced oscillation|
47968121|NCT06096753|DEVICE|Bruxoff gnathological function analysis|The recordings will be carried out for 3 randomly selected nights within 3 weeks, with at least 4 hours of sleep per night.
47968122|NCT04430218|DEVICE|iSens|The study involves a surgical implant of cuff electrodes on the nerves in the amputated limb, and muscle recording electrodes the remaining muscles. These will be connected to an implanted stimulator. The stimulator will connect wirelessly to an advanced prosthesis. This may allow a user to move the prosthetic hand intuitively and feel what your prosthesis is touching.
47968123|NCT00456560|DRUG|AV650|
47968124|NCT00456560|DRUG|Fluvoxamine|
47968125|NCT00456560|DRUG|Paroxetine|
48319565|NCT05171582|PROCEDURE|Surgery 1 (Test group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
48645932|NCT00952562|DIETARY_SUPPLEMENT|placebo|Empty capsules, 3 capsules per day for 16 weeks
48645933|NCT03408808|PROCEDURE|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
48645934|NCT03408808|PROCEDURE|Aspiration alone|Aspiration of the ganglion
48645935|NCT04491708|OTHER|Pilates exercises|The participants attended two half-hour Pilates exercise classes twice a week, for one month, to familiarize themselves with the exercises and to learn the 5 Pilates' principles. After the learning period, two experimental sessions were performed: a Mat Pilates session and a Reformer apparatus Pilates session. The order of each session was randomized and drawn beforehand. Each experimental session lasted about one and a half hours and the interval between the sessions was 48 hours. Participants were asked to not perform any exercise and to refrain from food or fluids except water eight hours prior to each experimental session. Prior to the start of the experimental sessions, participants received a standard breakfast of 321 kcal that was 76% (61 g) carbohydrate, 8% (6,7 g) protein, 16% (5,9) fat, provided by the study researchers. All sessions were conducted at the same time in the morning, and the room temperature (22°C) and humidity (40-50%) were controlled during the whole session.
48645936|NCT00470808|DRUG|POMx|
47968126|NCT02770560|DEVICE|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
47968127|NCT02578316|DRUG|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
47968128|NCT00025493|DRUG|docetaxel|
47968129|NCT02861300|DRUG|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
47968130|NCT02861300|DRUG|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
47968131|NCT01324843|DRUG|EMLA Cream|
47968132|NCT01324843|DRUG|Aveeno Daily Moist|
48340026|NCT02608372|OTHER|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
47968133|NCT01324843|DEVICE|Derma Vax|
47968134|NCT01324843|PROCEDURE|Intradermal Electroporation|
47968135|NCT01324843|PROCEDURE|Visual Analogue Scale|
47968136|NCT01324843|PROCEDURE|Present Pain Intensity|
47968137|NCT01324843|PROCEDURE|McGill Pain Questionnaire|
47968138|NCT01324843|PROCEDURE|Skin Assessment|
47968139|NCT02809404|DRUG|Everolimus|
47968140|NCT05527340|DRUG|Iberdomide|Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)
47968141|NCT05527340|DRUG|Dexamethasone|Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.
47968142|NCT05527340|DRUG|Daratumumab|Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
48340027|NCT02608372|OTHER|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
47968143|NCT05457764|DEVICE|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
47968144|NCT01920321|PROCEDURE|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
47968145|NCT05544604|DEVICE|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
47968146|NCT01023932|DEVICE|Cochlear Implants|
47968147|NCT06506266|OTHER|HFA-152a|HFA-152a is administered via oral inhalation
47968148|NCT06506266|OTHER|HFA-134a|HFA-134a is administered via oral inhalation
47968149|NCT06506266|OTHER|Radiolabeled saline solution|Radiolabeled saline solution is administered via oral inhalation
47968150|NCT04170816|DEVICE|Dry needling|DN and KT therapy will be applied 3 sessions in 1-week intervals
47968151|NCT04995991|BEHAVIORAL|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
48645937|NCT04491110|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
48645938|NCT04491110|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
48645939|NCT02011542|DRUG|VSL#3|This is a probiotic mixture
48645940|NCT02011542|DRUG|Placebo|This is a pill with inactive ingredients.
48645941|NCT02197065|DRUG|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
48645942|NCT02197065|DRUG|Placebo|
47968152|NCT04995991|BEHAVIORAL|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
47968153|NCT05453604|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
47968154|NCT00052481|PROCEDURE|quality-of-life assessment|
47968155|NCT02495298|PROCEDURE|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
47968156|NCT02495298|PROCEDURE|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
47968157|NCT03220360|PROCEDURE|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
47968158|NCT03220360|PROCEDURE|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
47968159|NCT03220360|PROCEDURE|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
47968160|NCT00187577|DRUG|Latanoprost (Xalatan)|
47968161|NCT00187577|DRUG|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
48340029|NCT00568607|DRUG|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
48645943|NCT03173378|OTHER|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
48645944|NCT04402814|DIAGNOSTIC_TEST|Clungene rapid test cassette|Blood will be tested for the presence of IgG and IgM antibodies using the Clungene rapid test cassette.
48645945|NCT02815254|OTHER|High intensity functional exercise|
48645946|NCT02815254|OTHER|Low intensity functional exercise|
48645947|NCT04729426|OTHER|Peanut Ball Position|The group of healthy pregnant women who meet the inclusion criteria will be determined by randomization according to the order of application to the delivery room. A group (intervention group) will be given positions using the peanut ball tool in active phase and transition phase and the positions will be changed every 30 minutes.
48645948|NCT02980458|DRUG|Deferiprone 500Mg Tablet|
48645949|NCT02980458|DRUG|Deferiprone 500 MG Oral Tablet [Ferriprox]|
47968162|NCT00187577|DRUG|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
47968163|NCT02430012|BEHAVIORAL|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
47968164|NCT03304548|OTHER|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
47968165|NCT04637230|DIAGNOSTIC_TEST|Electrocardiogram analysis by Artificial Intelligence|1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
48319566|NCT05171582|PROCEDURE|Surgery 2 (Control group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
48319567|NCT03752606|BIOLOGICAL|TACHOSIL GROUP|
48319568|NCT03187912|DRUG|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
48319569|NCT04587453|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
48319570|NCT04587453|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
47968166|NCT03821883|DRUG|Aspirin Tablet|Aspirin 100mg qd
47968167|NCT03821883|DRUG|Placebo|Placebo qd
47968168|NCT06461364|PROCEDURE|Assessment of cuspal deflection of bulk-fill restorations|To assess the performance of bulk-fill restorations on premolar teeth in class II cavities using some selected FDI criteria, a total sample size of 30 (10 for each group test) will be sufficient to detect: an effect size of 1.22 at a power (1-β error) of 0.8 and using a two-sided hypothesis test and a significance level (α error) 0.05 for data. Two teeth will be added to each group to compensate drop out samples.
47968169|NCT05125757|OTHER|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
47968170|NCT05125757|OTHER|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
47968171|NCT00745823|DRUG|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
47968172|NCT00745823|DRUG|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
47968173|NCT00745823|DRUG|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
47968174|NCT03105895|PROCEDURE|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
47968175|NCT02505204|OTHER|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
47968176|NCT02505204|OTHER|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
47968177|NCT02794038|DEVICE|Soberlink Cellular Device|BAC breath analyzer
47968178|NCT02794038|DEVICE|BACtrack S80 Pro|BAC breath analyzer
47968179|NCT06184932|BEHAVIORAL|HAHE|Participants will self-initiate rehabilitative activities through the HAHE program.
47968180|NCT06184932|BEHAVIORAL|Exergame|Participants will self-initiate rehabilitative activities through the Exergame program.
47968181|NCT02805101|DRUG|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
48319571|NCT04587453|OTHER|Topical corticosteroids (TCS)|TCS administered as needed.
48319572|NCT02288624|DIETARY_SUPPLEMENT|Processed orange juice|3 different formulation of edible orange drinks
48645950|NCT06446323|DRUG|0.2 ml dose of sucrose|Both interventions aim to provide pain relief to neonates following minor procedures by administering sucrose solution orally. The study evaluates the efficacy of each dose (0.2 ml vs. 0.5 ml) in reducing post-procedural pain intensity, as measured by the Premature Infant Pain Profile (PIPP). Additionally, any adverse events associated with the administration of sucrose solution are documented and analyzed as part of the study.
48486664|NCT00911807|DRUG|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
48486665|NCT00280878|DRUG|gemcitabine|
48645951|NCT03733782|DIETARY_SUPPLEMENT|Modular enteral protein - Prosource|Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
48645952|NCT05552365|BEHAVIORAL|Adapted Cognitive Behavioural|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder. Intervention includes psychoeducative, bodily relaxation, graded exposure, cognitive restructuring and brainstorming. Adaptations include increasing the number of visual supports, use of physical objects to illustrate concepts in addition to language.
48645953|NCT05552365|OTHER|Treatment as Usual|Participants given a mental health brochure with contact information, where they can access services provided by mental health support service providers.
48645954|NCT03207087|DEVICE|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
48645955|NCT02695771|DRUG|Mitomycin C|Cancer chemotherapeutic agent
48645956|NCT02695771|DRUG|Gemcitabine|Cancer chemotherapeutic agent
48645957|NCT02505074|PROCEDURE|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
48645958|NCT01832194|DRUG|Botox|
48645959|NCT06500598|DRUG|Evinacumab|
48645960|NCT03376412|DEVICE|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
48319573|NCT00353496|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
48486666|NCT00280878|DRUG|vinorelbine|
48486667|NCT00280878|DRUG|ifosfamide|
48486668|NCT00280878|DRUG|rituximab|
48486669|NCT00305552|DRUG|THALIDOMIDE|THALIDOMIDE
48645961|NCT04308993|PROCEDURE|percutaneous transhepatic choledochoscopy|percutaneous transhepatic choledochoscopy
48645962|NCT06011824|OTHER|Blood draw|10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)
48645963|NCT05145816|DRUG|Belantamab mafodotin 2.5 mg/kg (8 weeks)|2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
48645964|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (8 weeks)|1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
48645965|NCT05145816|DRUG|Belantamab mafodotin 1.4 mg/kg (12 weeks)|1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
48645966|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (12 weeks)|1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
48645967|NCT05145816|DRUG|Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages|Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
48645968|NCT05145816|DRUG|Belantamab mafodotin 1.0 mg/kg (12 weeks)|1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
48645969|NCT06310694|COMBINATION_PRODUCT|intervention group (Elastane circular dressing on sterile transparent dressing)|A circular dressing made of elastane material was placed on the patients in the intervention group on a sterile transparent dressing to provide additional fixation on the peripheral intravenous catheter.
48645970|NCT00292903|BEHAVIORAL|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
48645971|NCT00292903|BEHAVIORAL|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
48319574|NCT00353496|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
48319575|NCT03277300|DIETARY_SUPPLEMENT|dietary supplement|good dietary supplement for critically ill patients
47968182|NCT02805101|DRUG|MTA|MTA is going to be used as the sealing agent for the perforation.
47968183|NCT05430932|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
48319576|NCT04937582|DIAGNOSTIC_TEST|Cognitive assessment|Complete cognitive and psychological assessment
48486670|NCT03353298|DRUG|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
48486671|NCT03353298|DRUG|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
48486672|NCT03044236|PROCEDURE|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
47968184|NCT02872207|DRUG|BAY 987516 (Y65-122)|5 µL in one eye
48319577|NCT04937582|DIAGNOSTIC_TEST|Imaging|"Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)"
48319578|NCT04937582|DIAGNOSTIC_TEST|Routine care|"Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture"
48319579|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary
48319580|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary (before the end of their participation in the study)
48319581|NCT06067412|DRUG|Levetiracetam|Efficacy in fits
48319582|NCT06067412|DRUG|Phenytoin|Efficacy in fits
48319583|NCT04243356|BEHAVIORAL|Nurse Encounter Group|Nurses in this group will meet with former ICU patients in a post ICU clinic visit. This will be a structured meeting for approximately 15 minutes with the nurse and former patient. The encounter will be observed by a member of the research team. Surveys will be completed before and after the visits. Additionally, nurses will be interviewed 4-7 days after meeting with their former patients.
48319584|NCT04243356|OTHER|Nurse control group|This group will complete surveys.
48645972|NCT05477641|PROCEDURE|Pericapsular Nerve Group Block with Lateral Femoral Cutaneous Nerve Block|Local anesthetic will be deposited along the lower pelvis to block 3 nerves that innervate the anterior hip capsule
48645973|NCT05477641|PROCEDURE|Fascia Iliaca Compartment Block|Local anesthetic is deposited between the fascia iliaca and the internal oblique muscle in an attempt to block 3 nerves that innervate the hip.
47968185|NCT02872207|DRUG|BAY 987516 (Y65-118)|5 µL in one eye
47968186|NCT02872207|DRUG|Control|5 uL in other eye
47968187|NCT03910374|PROCEDURE|Dural closure|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
47968188|NCT02097004|BIOLOGICAL|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
47968189|NCT02097004|BIOLOGICAL|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
48319585|NCT00093860|DRUG|Propranolol|
47968190|NCT02097004|DRUG|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
48319586|NCT06013995|DRUG|BMS-986326|Specified dose on specified days
48319587|NCT06013995|OTHER|Placebo for BMS-986326|Specified dose on specified days
48319588|NCT04311177|DRUG|Losartan|Losartan; 25 mg daily; oral administration
48319589|NCT04311177|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
48319590|NCT01955850|BEHAVIORAL|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
48319591|NCT00607438|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
48486673|NCT05002413|DIAGNOSTIC_TEST|Resistell AST|The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the Resistell Phenotech device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli and Klebsiella pneumoniae to ceftriaxone and ciprofloxacin.
48486674|NCT01368926|DRUG|RO4917523|single oral doses
48486675|NCT01368926|DRUG|RO4917523|multiple oral doses
48486676|NCT01368926|DRUG|placebo|oral doses
48486677|NCT01479257|BEHAVIORAL|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
48486678|NCT01479257|DEVICE|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
48486679|NCT01479257|DEVICE|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
47968191|NCT02836730|PROCEDURE|Low back pain surgery|
47968192|NCT02790203|DRUG|Celecoxib|NSAIDS
47968193|NCT02790203|DRUG|Placebo|Placebo
47968194|NCT00953901|DRUG|Fresh Frozen Plasma Transfusion|
47968195|NCT02587260|DRUG|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
47968196|NCT02587260|DRUG|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
47968197|NCT02587260|DRUG|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
48117078|NCT01653834|PROCEDURE|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
48319592|NCT00607438|DRUG|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
48319593|NCT01013896|BEHAVIORAL|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
48319594|NCT01013896|OTHER|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
48319595|NCT03756740|OTHER|telerehabilitation and physical therapy|subject will receive the LBP exercises as a video to his/her mobile or e-mail
48319596|NCT03756740|OTHER|control|subjects will receive the LBP exercises as printed pictures on paper
48319597|NCT02602938|DRUG|Aspirin|Take aspirin (100mg) orally once a day for 2 months
48486680|NCT01810094|DEVICE|Fracture Fixation|Thoracolumbar Fracture Fixation
48486681|NCT00064584|DRUG|CT53518|
48645974|NCT02133677|DRUG|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
48319598|NCT01709136|DRUG|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
47968198|NCT04859361|DRUG|Aldara 5% Topical Cream|5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
47968199|NCT04859361|PROCEDURE|LLETZ|LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
48319599|NCT04361643|DRUG|Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
48319600|NCT04361643|DRUG|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
48319601|NCT04547894|DRUG|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
48319602|NCT01933165|DEVICE|LipiView|
48319603|NCT01091987|BEHAVIORAL|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
47968200|NCT06354595|DEVICE|Multidimensional Rehabilitation in the Metaverse|Using the multidimensional rehabilitation space in the metaverse, evaluate the platform after use.
47968201|NCT01061177|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
47968202|NCT03676010|OTHER|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
47968203|NCT03676010|OTHER|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
47968204|NCT03676010|OTHER|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
47968205|NCT03676010|OTHER|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
47968206|NCT03676010|OTHER|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
47968207|NCT03676010|OTHER|Solid tumours undergoing image-guided tumor ablation|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
47968208|NCT02217267|DRUG|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
47968209|NCT02217267|DRUG|Placebo|
47968210|NCT05378204|OTHER|Main study:|"For each included patient, tumor biopsy specimen and blood samples will be collected at baseline visit (before the first dose of PARPi treatment).~During the treatment period: blood samples will be scheduled every 8 weeks (i.e. 2 cycles).~At the time of progression: tumor biopsy and blood samples will be collected."
48319604|NCT04136613|DEVICE|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
48319605|NCT04881578|OTHER|continuous cardiac monitoring before and after transcatheter PFO closure|Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF
47968211|NCT05378204|OTHER|Sub-study:|For each included patient, tumor biopsy specimen and blood samples will be collected as soon as possible after progression (before initiation of the post PARPi anti-tumoral treatment).
47968212|NCT01099605|DEVICE|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
48319606|NCT00193219|DRUG|Bevacizumab|5 mg/kg IV
48319607|NCT00193219|DRUG|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
48319608|NCT00193219|DRUG|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
48319609|NCT00193219|DRUG|Leucovorin|350 mg IV
48319610|NCT00193219|DRUG|Oxaliplatin|85 mg/m2 IV
48319611|NCT06441136|OTHER|PhoRTE Program|Speech therapy program guided by a speech language pathologist. This program includes in person or virtual visits and at home exercises.
48319612|NCT06441136|OTHER|University of California Los Angeles (UCLA) Loneliness Scale|A questionnaire measuring levels of loneliness.
48319613|NCT06441136|OTHER|Social Disconnectedness Scale|A questionnaire that asks about social network size and the frequency of social activities attended.
48319614|NCT06441136|OTHER|Patient Health Questionnaire 9|A questionnaire measuring levels of depression.
48486682|NCT01189526|DRUG|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
48645975|NCT05151419|PROCEDURE|bronchoscpe|bronchoscopic biopsy from lung mass using cryobiopsy and forceps
48645976|NCT00276003|DRUG|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
48319615|NCT06441136|OTHER|Aging Voice Index|A questionnaire of patient-reported voice outcome measures designed to capture the quality of life impact of dysphonia in older adults.
48319616|NCT06441136|OTHER|The Edmonton Frail Scale|A questionnaire that measures frailty levels.
48319617|NCT06441136|OTHER|Vocal Effort Scale|A picture based questionnaire scale that asks the subject to rate their perceived effort when using their voice.
48319618|NCT06441136|OTHER|Montreal Cognitive Assessment|A screening tool used to test for cognitive impairment.
48486683|NCT01189526|PROCEDURE|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
48486684|NCT02537873|DRUG|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
48486685|NCT02537873|DRUG|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
48486686|NCT02537873|DRUG|Placebo comparator|Dextrose in gelatin capsule
48486687|NCT02170948|DRUG|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
48486688|NCT02378441|DRUG|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
48486689|NCT02378441|DRUG|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
48486690|NCT04417582|PROCEDURE|bariatric surgey|patients undergone bariatric surgery or prescribed antiobesity drugs
48486691|NCT01731717|BEHAVIORAL|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
48486692|NCT01731717|BEHAVIORAL|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
48486693|NCT01731717|BEHAVIORAL|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
48486694|NCT01731717|BEHAVIORAL|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
48645977|NCT03247673|DRUG|CT-P16|CT-P16 is a biosimilar product for Avastin
48645978|NCT03247673|DRUG|EU-approved Avastin|EU-approved Avastin
48645979|NCT03247673|DRUG|US-licensed Avastin|US-licensed Avastin
48319619|NCT06441136|OTHER|Voice Handicap Index-10|A questionnaire used to measure quality of life impact of dysphonia.
48645980|NCT05095441|BIOLOGICAL|C5252|A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
48319620|NCT06441136|OTHER|Voice Problem Impact Scales|A 4 question survey that captures impact of voice on four domains - work/daily activities, social life, home, and overall quality of life.
48319621|NCT06441136|OTHER|Cough Severity Index|A 10 question survey asking to rate severity of cough.
48319622|NCT06441136|PROCEDURE|Laryngoscopy|Nose is anesthetized and a flexible endoscope is passed to visualize the larynx at rest and during sustained vowel production (/i/) for 3-5 seconds. This will be used to measure bowing index and normalized glottal gap of the vocal folds.
48319623|NCT06441136|OTHER|Acoustic, perceptual, and aerodynamic assessments|Participants will complete voice recording tasks including sustained vowel production, six standard sentences, and 20 seconds of natural conversational speech. This will be used to measure CAPE-V rating, Cepstral peak prominence, fundamental frequency, signal-to-noise ratio, voice type components, mean flow rate, subglottal pressure, and vocal efficiency.
48319624|NCT06289400|DEVICE|Magnetic field application|The applicator (Size: 15x15 cm) has placed 1-3 cm above the skin surface at the painful area. During the treatment, treatment has applied with ready-made protocols included in the device.
48319625|NCT06289400|OTHER|Conventional treatment|Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
48319626|NCT02299141|DRUG|Nintedanib|
48319627|NCT01665248|OTHER|18-F Sodium Fluoride Uptake in Positron emission tomography|
48319628|NCT05098548|PROCEDURE|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
48486695|NCT01731717|PROCEDURE|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
48486696|NCT01731717|BEHAVIORAL|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
48645981|NCT04987450|DRUG|Methylprednisolone, prednisone|The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
48645982|NCT05531201|PROCEDURE|collaboration general practitioner and physiotherapist|training general practitioner and physiotherapist
48645983|NCT02006615|DEVICE|Functional near infrared spectroscopy|Using high-sensitivity infrared to detect the active brain areas
48645984|NCT02006615|DEVICE|rTMS|To modulate brain cortex
48645985|NCT03150641|PROCEDURE|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
48319629|NCT01861938|BIOLOGICAL|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
48486697|NCT01731717|OTHER|Control group: treatment as usual|treatment as usual
47968213|NCT01099605|DEVICE|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
47968214|NCT03660540|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
47968215|NCT05115903|DRUG|Tapered doses of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified
47968216|NCT05115903|DRUG|Standard dose of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
47968217|NCT00796198|DRUG|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
47968218|NCT00796198|DRUG|Xalatan|Xalatan ophthalmic solution one drop at 10pm
47968219|NCT04654117|OTHER|Consultee-centered administrative consultation|The consultee-centered administrative consultation model expressly focuses on supporting providers to increase EBP implementation within their specific setting.
47968220|NCT05199662|DRUG|Intravenous tenecteplase|Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
47968221|NCT05199662|DRUG|Placebo|Placebo matching IV TNK
47968222|NCT01996852|BEHAVIORAL|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
47968223|NCT01996852|DRUG|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
47968224|NCT01996852|DEVICE|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
47968225|NCT00078442|DRUG|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
47968226|NCT04784065|DEVICE|Hand orthosis|An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
47968227|NCT04394286|GENETIC|SHP648|Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
47968228|NCT05089942|DRUG|Recombinant Human Insulin Patch ZJSRM2021|health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
48117079|NCT02794194|OTHER|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
48117080|NCT02794194|OTHER|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
48340030|NCT05057325|OTHER|Pulpectomy using single file system ( One Shape file)|Rotary file instrument for pulpectomy of primary molars ( One shape file)
48486698|NCT03340987|PROCEDURE|vestibular incision subperiosteal tunnel access|vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
47968229|NCT05089942|DRUG|Placebo|health subjects receive placebo patch
47968230|NCT01595932|DIETARY_SUPPLEMENT|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
47968231|NCT01595932|DIETARY_SUPPLEMENT|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
47968232|NCT05081141|DIAGNOSTIC_TEST|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
48117081|NCT05993026|BEHAVIORAL|Mental health course|The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
48117082|NCT02607670|DRUG|TAT4 Gel|
48117083|NCT02607670|DRUG|Matching placebo|
48117084|NCT03238391|PROCEDURE|Ischemic preconditioning|It is mentioned before in arm/group descriptions
48340031|NCT05057325|OTHER|Pulpectomy using single file system ( WaveOne Gold file)|Rotary file instrument for pulpectomy of primary molars ( WaveOne Gold file)
48319630|NCT03195855|OTHER|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
48319631|NCT05499702|BEHAVIORAL|Caloric Restriction|"Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake"
47968233|NCT04992676|DIAGNOSTIC_TEST|Polysomnograpy|Home polysomnography will be conducted using the scalable, modular Embletta system. Trained staff will instrument the participants in the evening and perform biocalibration to ensure optimal data quality
48319632|NCT05499702|DRUG|Hyperglycemic clamp|Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
48319633|NCT04136080|OTHER|vasopressors|control the mean arterial pressure with vasopressors
48319634|NCT03053427|DRUG|Placebo|Oral administration
48319635|NCT03053427|DRUG|Gabapentin enacarbil|Oral administration
47968234|NCT04992676|DIAGNOSTIC_TEST|actigraphy|A water resistant accelerometer with light sensor and event marker will be worn on the nondominant wrist for approximately 7 days. Activity counts from the device will be analyzed by proprietary software algorithms for determination of the following: sleep onset, sleep offset, total sleep time, total wake time, and sleep efficiency.16 Daytime sleep periods will be also scored to determine frequency and duration of naps. Daily data will be averaged across the 7-day period, as well as separately for weekdays and weekend, to compute measures of habitual sleep patterns.
47968235|NCT04959916|BEHAVIORAL|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
47968236|NCT03435445|BEHAVIORAL|Online platform group|The online platform has social network, gamification and short-text sessions.
47968237|NCT03435445|BEHAVIORAL|Online dietitian coaching|Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
47968238|NCT03435445|BEHAVIORAL|Control group|Minimal intervention with four videos with diet, physical activity and behavior change recommendations
47968239|NCT06491940|DRUG|Losartan|Patients will receives Losartan (LS) 50 mg per day.
47968240|NCT06491940|DRUG|Losartan + Hydrochlorothiazide|Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
47968241|NCT06259721|DRUG|Anti-PD1 antibody, nimotuzumab and capecitabine|"Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment."
48319636|NCT04190953|OTHER|Twin block then Hyrax|Patients will undergo mandibular advancement prior to maxillary expansion
48319637|NCT04190953|OTHER|Hyrax then Twin block|Patients will undergo maxillary expansion prior to mandibular advancement
47968242|NCT01090271|DEVICE|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
47968243|NCT01031355|DRUG|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
47968244|NCT01031355|DRUG|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
48319638|NCT02998424|DRUG|Propofol|Continuous infusion
48319639|NCT02998424|DEVICE|Pupillary diameter measurement|Instantaneous measure
48319640|NCT02172521|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
48319641|NCT01892098|DIETARY_SUPPLEMENT|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
48319642|NCT01892098|DIETARY_SUPPLEMENT|Placebo|Cellulose pill given as placebo
48319643|NCT01015482|DRUG|Remifentanil|Remifentanil Infusion
48319644|NCT01015482|DRUG|Midazolam|Midazolam Infusion
48319645|NCT04922749|BEHAVIORAL|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
48319646|NCT02648724|DRUG|Sym015|Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
47968245|NCT01031355|DRUG|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
47968246|NCT00268593|DRUG|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
47968247|NCT00268593|DRUG|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
48117085|NCT04591067|OTHER|Testing of physical capacity|"This cross-sectional study will involve evaluation of physical capacity by assessment of:~1. Gait function~2. Muscle activity during walking~3. Endurance during walking~4. Hip muscle strength~5. Hip range of motion~6. Hip and muscle-tendon-related groin pain~7. Hip and groin related patient-reported outcome measures (PROMs)"
48117086|NCT02667743|DRUG|Paclitaxel Micelles for Injection|
48319647|NCT05018117|DRUG|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
48319648|NCT05018117|OTHER|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
48319649|NCT00751114|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
48319650|NCT00751114|DRUG|Sitagliptin|Oral administration. 100 mg film-coated tablets.
47968248|NCT00268593|DRUG|prednisone|5 mg twice a day orally
47968249|NCT05530421|DRUG|Selinexor|Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
47968250|NCT05530421|DRUG|Venetoclax|Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
48117087|NCT02667743|DRUG|Paclitaxel Injection|
48117088|NCT02667743|DRUG|Cisplatin|
48117089|NCT05972915|DIAGNOSTIC_TEST|Separation sign|The separation sign was recorded as positive if separation of the myometrium from the placenta was observed in all areas of the placenta. The sign was recorded as negative if the myometrium and placenta moved as one structure and no clear zone could be seen over any part of the placenta after release, even if separation was noted at the margins of the placenta.
48117090|NCT02220816|BEHAVIORAL|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
48117091|NCT02220816|BEHAVIORAL|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
48319651|NCT00751114|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
48319652|NCT00731263|DRUG|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
48319653|NCT06211530|DEVICE|SpO2 Sensor Testing|Participants participating in this study will be connected to eight (8) Portrait Mobile P-SA01PL/P-SP01PL prototype sensors provided by GEHC and two reference monitors, Nellcor N-600X V 1.6.0.0 and a forehead sensor, used as standard operating procedures at the site. Data will be collected using the Portrait Hub patient monitor. The participants are exposed to a desaturation protocol that sequentially decreases the SpO2 in a stepwise fashion. The goal is to achieve six stable oxygenation plateaus between 100 and 70% SpO2, while recording simultaneous SpO2 readings from the prototype and reference devices. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
47968251|NCT05530421|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
47968252|NCT00598104|DRUG|QAX576|
47968253|NCT00598104|DRUG|Placebo|
47968254|NCT02614586|DRUG|TAK-058|TAK-058 oral solution.
47968255|NCT02614586|DRUG|Ondansetron|Ondansetron capsule.
47968256|NCT02614586|DRUG|TAK-058 Placebo|TAK-058 placebo-matching, solution.
47968257|NCT02614586|DRUG|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
47968258|NCT01372137|DRUG|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
47968259|NCT01372137|OTHER|Glucose 5%|Placebo
47968260|NCT05228171|BEHAVIORAL|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
48117092|NCT06376383|PROCEDURE|Tonsillectomy|Standard tonsillectomy
48117093|NCT06376383|PROCEDURE|Tonsillotomy|Tonsillotomy
48117094|NCT00394615|PROCEDURE|Metabolic Imaging|
48117095|NCT02566707|DRUG|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
48117096|NCT02566707|DRUG|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
48117097|NCT02566707|DRUG|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
48319654|NCT03718052|PROCEDURE|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
48486699|NCT03340987|PROCEDURE|Coronally advanced flap|Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
48486700|NCT05895734|DEVICE|NDS-Powerball®,|Rehabilitation using the Powerball system
48486701|NCT05895734|OTHER|Conventional treatment|Rehabilitation by conventional treatment
48486702|NCT00016276|DRUG|dexrazoxane hydrochloride|Given IV
48486703|NCT00016276|DRUG|doxorubicin hydrochloride|Given IV
47968261|NCT00215332|DEVICE|CHARITE|Lumbar Total Disc Replacement
47968262|NCT01267760|DEVICE|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
48117098|NCT05475405|OTHER|scapulothoracic mobilization|Patient in prone lying position. The left hand of the physical therapist lifts the scapula to distract from the thoracic wall while the right hand mobilizes and stretches the inferior muscle groups attached to the scapula.
48117099|NCT05475405|OTHER|IASTM|"Restrictions and myofascial adhesions should be assessed prior to treatment along both sides using IASTM tool and a lubricant.~Once restrictions are assessed, fanning strokes at 45 degree angles to skin should be applied using the tool. This technique should be performed for 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers for each muscle group in scapulothoracic region. Total time for IASTM application is 10 mints. Upon completing all this patient should be given a home plan consisting of 2 different self-stretches targeting levator scapulae and upper trapezius"
48117100|NCT02235272|DRUG|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
48117101|NCT02235272|DRUG|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
48117102|NCT04960709|DRUG|Durvalumab|Anti- PD-L1 Antibody
48117103|NCT04960709|DRUG|Tremelimumab|Human IgG2 mAb
48117104|NCT04960709|DRUG|Enfortumab Vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate
48117105|NCT04960709|PROCEDURE|Radical Cystectomy|For cisplatin-ineligible or cisplatin-refusal patients
48117106|NCT03600051|DEVICE|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
48117107|NCT05702515|OTHER|Digital ECG Data Collection|synchronized digital data collected from the G4 and ECG machines during the PICC insertion procedure
48319655|NCT03718052|PROCEDURE|Conventional Care|Conventional care according to the 2015 European guidelines.
48319656|NCT05371990|OTHER|Determination of Eating habits|Questionnaire
48319657|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
48319658|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
48319659|NCT05394584|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
48319660|NCT03800862|DEVICE|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
48319661|NCT02430428|DEVICE|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
48486704|NCT00016276|DRUG|cyclophosphamide|Given IV
48486705|NCT00016276|DRUG|paclitaxel|Given IV
48486706|NCT00016276|BIOLOGICAL|trastuzumab|Given IV
48486707|NCT00016276|PROCEDURE|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
47968263|NCT04688957|PROCEDURE|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
47968264|NCT04688957|PROCEDURE|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
48117108|NCT04308330|DRUG|Vorinostat|This is a phase I study of the combination of four drugs: vorinostat, vincristine, irinotecan, and temozolomide. This is called a Phase I study because the goal is to find the highest dose of vorinostat that investigators can give safely when it is used together with the chemotherapy drugs vincristine, irinotecan and temozolomide. Investigators are using vorinostat because it seems to work against cancer in test tubes and animals. It may be most effective when it is given with chemotherapy. The combination of these three agents together has never been given to children. Vincristine, irinotecan, and temozolomide are approved and used for the treatment of other types of cancer in adults and children. Vorinostat is approved and used to treat cancer in adults. The combination of these four drugs together is experimental. Investigators do not know if this combination of medicines will work in people. There is a lot that investigators do not yet know about this combination of medicines.
48117109|NCT00726544|DRUG|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
48486708|NCT00016276|RADIATION|radiation therapy|Undergo radiation therapy
48486709|NCT00016276|DRUG|tamoxifen citrate|Given orally
48486710|NCT00016276|OTHER|laboratory biomarker analysis|Correlative studies
48486711|NCT00363402|PROCEDURE|PET-CT|
48645986|NCT00363363|BEHAVIORAL|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
48319662|NCT05408312|BIOLOGICAL|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
48645987|NCT00363363|BEHAVIORAL|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
48645988|NCT02749461|PROCEDURE|heel stick|Consecutive routine blood sampling heel sticks
48645989|NCT01269320|DRUG|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
48645990|NCT03220256|DRUG|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
47968265|NCT00810030|DRUG|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
47968266|NCT00810030|DRUG|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
47968267|NCT04148053|DIAGNOSTIC_TEST|TB-antigen responsive T cell markers|A blood test including a series of T cell markers which are responsive to TB antigens
47968268|NCT03889444|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
47968269|NCT04193098|BIOLOGICAL|CTL|CTL injection
47968270|NCT04193098|BIOLOGICAL|Toripalimab|Toripalimab injection
47968271|NCT00838396|DRUG|XP19986 CR|
47968272|NCT00838396|DRUG|Placebo for XP19986 CR|
47968273|NCT01896102|GENETIC|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
47968274|NCT01192854|DRUG|Clevudine|Clevudine flexible dosages of 30 mg/day
47968275|NCT01192854|DRUG|Adefovir|Adefovir flexible dosages of 10 mg/day
48117110|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
48117111|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
48117112|NCT00726544|DRUG|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
48319663|NCT05408312|BIOLOGICAL|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
48319664|NCT05408312|BIOLOGICAL|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
48319665|NCT05408312|BIOLOGICAL|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
48319666|NCT04301921|OTHER|Traditional punkcture site and No anticoagulation|Traditional punkcture site and No anticoagulation
48319667|NCT04301921|OTHER|Traditional punkcture site and ACT-guided anticoagulation|Traditional punkcture site and ACT-guided anticoagulation
48340032|NCT05862298|DIAGNOSTIC_TEST|venous excess ultrasound score|Venous congestion is classified into 4 grades. If the Inferior vena cava is not plethoric, there is deemed to be no congestion (grade 0), and further Doppler examination is not performed. When the IVC is plethoric but there are no severely abnormal waveforms (defined as S-wave reversal on hepatic, \>50% pulsatility on portal, and a monophasic pattern on intrarenal Doppler), congestion is considered to be mild (grade 1). Plethoric IVC with at least 1 severely abnormal pattern is considered to be moderate congestion (grade 2), while 2 or more abnormal Doppler patterns constitute severe congestion (grade 3)
47968276|NCT00319553|BIOLOGICAL|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
47968277|NCT00319553|BIOLOGICAL|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
47968278|NCT00307411|DRUG|Growth hormone|
47968279|NCT00313157|DRUG|Metoprolol|
47968280|NCT00313157|DRUG|Diltiazem|
47968281|NCT00313157|DRUG|Verapamil|
47968282|NCT00313157|DRUG|Carvedilol|
47968283|NCT01947582|DEVICE|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
47968284|NCT04552847|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
47968285|NCT04552847|DEVICE|PET/CT|Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
47968286|NCT04552847|DEVICE|PET/MR|Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
48645991|NCT00079781|PROCEDURE|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
47968287|NCT02295384|OTHER|Retrospective Audit|Retrospective Audit
47968288|NCT01482000|OTHER|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
47968289|NCT01482000|OTHER|usual care|The control group will get the usual care with some additional tests for the study.
47968290|NCT05091047|DEVICE|Erchonia EVRL|42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.
47968291|NCT05478785|DRUG|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
47968292|NCT04946006|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
47968293|NCT01445262|DRUG|Levocetirizine|
47968294|NCT00942253|OTHER|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
47968295|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
47968296|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|
47968297|NCT01644565|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|
47968298|NCT05644353|DRUG|Mirikizumab|Administered SC.
47968299|NCT04254497|DIAGNOSTIC_TEST|EGFR mutation detection kit|A microsieve membrane filter device to effectively isolate circulating tumor cells from whole blood sample has been developed by the Institute of Bioengineering and Nanotechnology. The device exploits the size difference between cancer cells and blood cells to achieve the cancer cell capture on a microsieve filter with \> 85% recovery rate from 4.5-ml whole blood within 10 min, demonstrated with cancer cells spiked into whole blood samples. The device contains a densely packed pore array (\> 8000 pores/mm\^2) with an optimized pore diameter of 10 µm. Fluid regulation and cell counting are achieved by a simple vacuum pumping and laboratory fluorescence microscope. The captured cells are stained with anti-EpCAM-PE for CTCs, anti-CD45-FITC for white blood cells, and 4',6-diamidino-2-phenylindole (DAPI) for cell nuclei. The CTCs are identified with anti-EpCAM positive, anti-CD45 negative and DAPI positive, characterized using a fluorescence microscope.
47968300|NCT05862480|OTHER|Spray with Hypochlorous Acid Group|For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
47968301|NCT05862480|OTHER|Spray with Placebo Group|For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
47968302|NCT06280170|OTHER|Artificial Intelligence platform for case managers|Providers will have access to the Eleos Health mobile AI platform to document their case management encounters.
47968303|NCT00566371|DRUG|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
47968304|NCT00566371|DRUG|placebo|placebo
47968305|NCT04195698|DRUG|Upadacitinib|Upadacitinib will be administered oral as tablet
47968306|NCT02321878|DRUG|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."
47968307|NCT06272760|OTHER|Home-based hand-arm bimanual intensive training (Tele-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training. HABIT has been adapted into a home-based format by ZOOM, referred to as Home-Based HABIT (H-HABIT).
48117113|NCT03039361|BEHAVIORAL|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
48117114|NCT01471145|DRUG|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
48340033|NCT02001688|DRUG|Kamada-AAT for Inhalation, 80mg|
48319668|NCT06020027|BEHAVIORAL|Water is K'é|Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
48319669|NCT00062114|BIOLOGICAL|rituximab|
48319670|NCT00062114|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48319671|NCT03529383|DEVICE|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
48340034|NCT02001688|DRUG|Placebo|
48340035|NCT02001688|DRUG|Kamada-AAT for Inhalation, 160mg|
48340036|NCT02251171|DRUG|Tipranavir|
48340037|NCT02251171|DRUG|Ritonavir|
48340038|NCT02251171|DRUG|Rifabutin|
48340039|NCT05008146|RADIATION|Baseline [C-11]NOP-1A PET Scan|Radiotracer
48486712|NCT04780932|DRUG|Macitentan 10mg|Macitentan 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
47968308|NCT06272760|OTHER|Hand-arm bimanual intensive training (In-clinic-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training.
48117115|NCT05544643|DEVICE|Medtronic Extended Mio 30 Infusion Set|Safety and Efficacy of Medtronic Extended Mio 30 Infusion Set
48117116|NCT06553261|PROCEDURE|suturing of leak, lavage, drainage|Operative suturing of the leak, lavage, drainage within a revision surgery.
48117117|NCT06553261|PROCEDURE|Formation of a new anasthomosis|Operative resection of the old leaking anastomosis and formation of a new one.
48117118|NCT06553261|PROCEDURE|Fecal diversion|Formation of a deviating stoma.
48117119|NCT00471627|PROCEDURE|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
48117120|NCT00064012|DRUG|bortezomib|
48117121|NCT00064012|DRUG|docetaxel|
48117122|NCT02768571|DRUG|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation
48117123|NCT02768571|DRUG|Placebo|Placebo- saline 100 ml/day \* 21 days with rehabilitation
48117124|NCT00319306|DRUG|Budesonide/formoterol|
48117125|NCT00319306|DEVICE|Symbicort® Turbohaler®|
48117126|NCT00470899|PROCEDURE|drainage of placenta of fetal blood|
48117127|NCT01525446|RADIATION|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of \> 3 cm)
48117128|NCT04042129|OTHER|gynecologic operations with urological complications|
48117129|NCT04193410|BEHAVIORAL|Various health-promoting initiatives|No intervention is allocated in this study other than activities planned by childcare centres in accordance with wishes and needs of childcare centre staff and parents.
48117130|NCT00668863|DRUG|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48117131|NCT00668863|DRUG|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
48117132|NCT03751891|DEVICE|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
48117133|NCT03751891|DEVICE|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer_A which will be fitted to the participants individual Hearing loss.
48117134|NCT03751891|DEVICE|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer_B which will be fitted to the participants individual Hearing loss.
48117135|NCT00529659|DRUG|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
48117136|NCT00529659|DRUG|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
48117137|NCT04187664|BEHAVIORAL|Postoperative Monitoring|Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.
48117138|NCT04187664|DIAGNOSTIC_TEST|High-sensitivity cardiac troponin testing|High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
48117139|NCT03712930|DRUG|Pamiparib|60 mg orally twice daily (BID)
48117140|NCT05208554|BEHAVIORAL|Integrated health counseling and step prescription|8 weekly dyad-based sessions with a health counselor to train couples in the use of communal coping strategies to support one another in achieving physical activity goals plus individualized step prescription based on remotely-monitored Fitbit-derived step counts the week prior
48340040|NCT05008146|DRUG|Hydrocortisone|Intravenous, 1mg/Kg
48340041|NCT05008146|RADIATION|Post-hydrocortisone [C-11]NOP-1A PET Scan|Radiotracer
47968309|NCT02649998|DRUG|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
47968310|NCT02649998|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
47968311|NCT02872194|DRUG|BAY987516, Y55-170|10 uL in one eye
47968312|NCT02872194|DRUG|BAY987516, X72-151|10 uL in one eye
47968313|NCT02872194|DRUG|BAY987516, Y49-034|10 uL in one eye
47968314|NCT02872194|DRUG|Standard shampoo mixture (control)|10 uL in one eye
47968315|NCT01156870|DRUG|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
47968316|NCT02725710|DRUG|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
48319672|NCT03529383|BEHAVIORAL|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached."
48486713|NCT04780932|DRUG|Placebo|Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
48645992|NCT00079781|DEVICE|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
48645993|NCT02842242|DRUG|MYK-461|
48645994|NCT01082458|DRUG|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
48645995|NCT01423084|BIOLOGICAL|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
48645996|NCT06276075|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery|66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
48645997|NCT04409769|OTHER|Description of use of ceftaroline and ceftobiprole|Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
48117141|NCT03746665|BIOLOGICAL|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
48645998|NCT01623427|PROCEDURE|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
48645999|NCT01623427|PROCEDURE|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
48646000|NCT06690632|OTHER|water preparation|ingestion of 1.5L of water 30min prior MRE acquisition
48646001|NCT06690632|OTHER|polyethylene glycol preparation|ingestion of 1.5L of water diluted PEG 45 min prior MRE acquisition (standard protocol)
47968317|NCT02725710|DRUG|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
47968318|NCT02139631|OTHER|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
47968319|NCT01929343|DRUG|lidocaine following cue-induced craving|as described in Arm Description
47968320|NCT01929343|DRUG|lidocaine following neutral stimulus|as described in Arm Description
47968321|NCT01929343|DRUG|saline|as described in Arm Description
47968322|NCT02650674|OTHER|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
48319673|NCT01665755|DEVICE|Upstroke Compression Defibrillation|
47968323|NCT02650674|OTHER|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
47968324|NCT02650674|OTHER|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
47968325|NCT02650674|OTHER|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
47968326|NCT02650674|OTHER|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
47968327|NCT02650674|OTHER|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
48117142|NCT03332992|BEHAVIORAL|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
48117143|NCT03332992|BEHAVIORAL|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
47968328|NCT01311479|PROCEDURE|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
47968329|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
47968330|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
47968331|NCT02316106|DRUG|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
47968332|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20. If, as per investigator discretion, there is a positive benefit/risk ratio, absence of Grade greater than or equal to (\>=) 3 treatment related toxicity, and at least stable disease has been achieved, treatment can be extended and given every 8 weeks after Cycle 20. For participants participating in treatment extension, the duration of infusion may be shortened to a 90-minute infusion or can switch to daratumumab 1800mg subcutaneous (Q8w).
47968333|NCT02316106|DRUG|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
47968334|NCT03478202|DIETARY_SUPPLEMENT|GOLO RELEASE|GOLO RELEASE plus Diet
47968335|NCT01795209|DRUG|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
47968336|NCT01795209|DEVICE|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
47968337|NCT01795209|PROCEDURE|Rescue laser|"In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3"
47968338|NCT05139238|DRUG|Labetalol|Intravenous labetalol, a short acting ant-hypertensive
47968339|NCT05139238|DRUG|Nifedipine|Oral nifedipine, a short acting ant-hypertensive
47968340|NCT00439478|DRUG|Radioiodine|
48319674|NCT01665755|DEVICE|Precompression Defibrillation|
47968341|NCT00273832|PROCEDURE|coronary artery computed tomography angiogram|
47968342|NCT00273832|PROCEDURE|single photon emission computed tomography|
47968343|NCT03039283|DEVICE|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
48319675|NCT03046628|DEVICE|TcPO2|
48319676|NCT03046628|DEVICE|Green laser (at 532nm) and a fast camera|
48646002|NCT06686615|DRUG|Bempedoic acid|No drug was administered in this observational study.
48646003|NCT06686615|DRUG|Ezetimibe|No drug was administered in this observational study.
48646004|NCT06686615|DRUG|Rosuvastatin|No drug was administered in this observational study.
47968344|NCT06064643|OTHER|Online Survey|All participants will be asked to complete an online survey
47968345|NCT06064643|OTHER|Qualitative Interview|30 survey participants will take part in a single one-hour qualitative interview.
47968346|NCT06064643|OTHER|Bleed Diary|50 participants will complete a 30 day bleed diary
47968347|NCT03810560|DEVICE|laser device Er,Cr:YSGG laser|laser device with open flap debridement
48319677|NCT01634321|DRUG|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
48319678|NCT04621669|DRUG|SHR3680|240 mg
48319679|NCT04621669|DRUG|digoxin|0.25 mg
48486714|NCT06166784|DEVICE|Mectascrew B|reconstruction of ACL or PCL rupture
48486715|NCT03046498|BEHAVIORAL|Evidence-Based Program|DSMP and DPP
48486716|NCT06030349|DEVICE|Non-invasive ventilation|Non-invasive ventilation
48486717|NCT00109837|BIOLOGICAL|filgrastim|As needed per physician discretion
47968348|NCT01340885|DRUG|Strattera|10-30 mg b.i.d. for 6 weeks
47968349|NCT01340885|DRUG|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
47968350|NCT01340885|OTHER|Placebo|2-6 pills for 6 weeks
47968351|NCT00020904|DRUG|ixabepilone|
47968352|NCT03951571|DRUG|Anlotinib Hydrochloride|Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
48319680|NCT04621669|DRUG|Rosuvastatin calcium|10 mg
48319681|NCT04621669|DRUG|metformin hydrochloride|500 mg
48319682|NCT03870126|OTHER|Flavored beverage|Consume one beverage at the beginning of each visit of the cross-over sequence
48319683|NCT05140954|DRUG|co-formulated 25mg TAF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
48646005|NCT06686615|DRUG|Atorvastatin|No drug was administered in this observational study.
48319684|NCT00240188|PROCEDURE|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
48319685|NCT00240188|PROCEDURE|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
48319686|NCT01968720|DRUG|CAT-2003|
48319687|NCT01968720|DRUG|Placebo|
48319688|NCT03061370|PROCEDURE|Esophagectomy or Gastrectomy|Surgical resection
48319689|NCT05522673|DRUG|11(R)-rolipram|Injected IV followed by PET scanning
48319690|NCT04613102|DRUG|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
48319691|NCT04253041|BEHAVIORAL|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
48319692|NCT03503682|RADIATION|standard treatment|3000 cGy in 10 daily fractions
48319693|NCT03503682|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
48319694|NCT03305094|PROCEDURE|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
48319695|NCT04640207|DEVICE|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
48319696|NCT03075176|DEVICE|Wavefront optimized LASIK|Wavefront optimized laser vision correction
48319697|NCT03075176|DEVICE|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
48319698|NCT03075176|DEVICE|Topography-guided LASIK|Topography-guided laser vision correction
48319699|NCT03075176|DEVICE|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
48319700|NCT00310388|DRUG|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
48319701|NCT00702585|DRUG|Org 36286|Org 36286 single-dose subcutaneous injection
48319702|NCT00702585|DRUG|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
48319703|NCT05038748|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
48319704|NCT05038748|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
48319705|NCT00592852|DRUG|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
48319706|NCT01237106|OTHER|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
48319707|NCT06082648|DEVICE|Transcranial magnetic stimulation|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.
48319708|NCT06082648|DEVICE|Sham Transcranial magnetic stimulationt|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
48319709|NCT04147832|OTHER|Alert to provider|Provider will receive an alert of sub-optimal patient attendance using 4 rules.
48319710|NCT00786136|DRUG|rosuvastatin|rosuvastatin
48319711|NCT05152472|DRUG|Atezolizumab 1200 mg|(Intravenous administration)
48319712|NCT05152472|DRUG|Imatinib 400 MG|(Per os)
48319713|NCT03021291|DEVICE|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
48319714|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
48319715|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
48319716|NCT00516633|BEHAVIORAL|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
48319717|NCT03419052|BEHAVIORAL|Speed of processing training|Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.
48319718|NCT03419052|BEHAVIORAL|MIND foods|"The MIND diet (created by the Rush Aging \& Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery."
48319719|NCT03419052|BEHAVIORAL|Cognitive training control|Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.
48319720|NCT03419052|BEHAVIORAL|Control foods|Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
48319721|NCT04494633|OTHER|Clinical Encounters Medical School 3D Simulation|A 3D simulation related to coping with the stresses of medical school and burnout.
48319722|NCT02612441|DEVICE|real Acupuncture Needles|Acupuncture needles
48319723|NCT02612441|DEVICE|sham Acupuncture Needles|sham Acupuncture Needles
48319724|NCT03664622|DRUG|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
48319725|NCT03664622|DRUG|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
48319726|NCT01021605|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
48319727|NCT01019486|DRUG|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
48319728|NCT01019486|DRUG|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
48319729|NCT01597037|BEHAVIORAL|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
48319730|NCT06196957|COMBINATION_PRODUCT|pursed lip breathing|pursed lip breathing
48319731|NCT00912899|DRUG|Noscapine HCl|Escalating doses given twice per day
48319732|NCT04869904|PROCEDURE|dental and plaque sampling|sampling of dental plaque and saliva during the treatment
48319733|NCT02909998|OTHER|Blood sample|Conservation at the end of the blood sample
48319734|NCT03277144|DEVICE|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
48319735|NCT03277144|OTHER|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
48319736|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
48319737|NCT00313950|BIOLOGICAL|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
48319738|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
48319739|NCT02587624|PROCEDURE|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
48319740|NCT05801809|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
48319741|NCT01293149|DRUG|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
48117144|NCT03332992|BEHAVIORAL|General intentions|Question language asking about general interest in getting influenza vaccination
48117145|NCT03332992|BEHAVIORAL|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
48319742|NCT01293149|DRUG|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
48319743|NCT01757782|DRUG|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be \<10% of previous value and SpO2 was not increasing \>5 of previous value) and blood pressure remained stable
48319744|NCT01757782|DRUG|Placebo (distilled water)|Distill water oral
48319745|NCT03720730|OTHER|EMA|"The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2)."
48319746|NCT00154141|DRUG|Fibrin sealant (FS2)|
48319747|NCT03444818|DRUG|[14C]-E6007|Oral administration
48319748|NCT00361127|DRUG|isotonic saline infusion|
48319749|NCT00138424|DRUG|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
48319750|NCT00138424|DRUG|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
48319751|NCT02551198|DRUG|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]"
48319752|NCT02551198|DRUG|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]
48319753|NCT05910541|BEHAVIORAL|Mindful breathing|30 minutes of mindful breathing session for 4 consecutive days, guided by investigators in addition to standard care.
48319754|NCT05910541|OTHER|Standard care (control)|Standard care such as pain control, oxygen supplement.
48319755|NCT05278650|OTHER|Senior PharmAssist^TM Program Implementation|"Representatives from three diverse communities will participate in co-design workshops to refine the Senior PharmAssistTM (SPA) implementation toolkit, which will then be delivered to agency staff from these partnering communities through a series of learning collaborative sessions to facilitate implementation of SPA core components in each community.~Community champions will be trained to deliver a community-based program to deliver the core components of SPA:~1. Medication Therapy Management (MTM);~2. Medication co-payment assistance;~3. Tailored community referrals; and~4. Medicare insurance counseling"
48319756|NCT00815906|DRUG|SBI-087|IV, Single dose
48319757|NCT00815906|DRUG|SBI-087|IV, Single dose
48319758|NCT00815906|DRUG|SBI-087|SC, Single dose
48319759|NCT00815906|DRUG|SBI-087|SC, Single dose
48319760|NCT05266794|DRUG|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
48319761|NCT05266794|DRUG|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
48319762|NCT05145478|DEVICE|Shockwave Intravascular Lithotripsy (IVL)|Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.
48319763|NCT04802980|DRUG|HB002.1T|HB002.1T is a vascular endothelial growth factor receptor decoy
48319764|NCT04802980|DRUG|Oxaliplatin|Oxaliplatin is an anti-tumor drug
48486718|NCT00109837|DRUG|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
47968353|NCT03951571|DRUG|Placebo Oral Tablet|Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
48319765|NCT04802980|DRUG|Capecitabine|Capecitabine is an anti-tumor drug
48319766|NCT04802980|DRUG|Paclitaxel|Paclitaxel is an anti-tumor drug
48319767|NCT04802980|DRUG|Gemcitabine|Gemcitabine is an anti-tumor drug
48319768|NCT04802980|DRUG|Cisplatin|Cisplatin is an anti-tumor drug
48319769|NCT04802980|DRUG|Carboplatin|Carboplatin is an anti-tumor drug
48319770|NCT01642836|BEHAVIORAL|MMM|"1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions."
48319771|NCT01642836|BEHAVIORAL|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
48319772|NCT00135837|DRUG|Verteporfin for injection|
48319773|NCT06186752|BEHAVIORAL|MyIBD|MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
48319774|NCT04649073|BIOLOGICAL|OPC-415|OPC-415 (up to 1×10\^7cells/kg) On 2 days
48486719|NCT00109837|DRUG|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
47968354|NCT02366052|BEHAVIORAL|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
47968355|NCT02366052|DIETARY_SUPPLEMENT|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
48319775|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
48319776|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
48319777|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
48319778|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
48319779|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
48486720|NCT00109837|DRUG|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
48486721|NCT00109837|DRUG|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
48319780|NCT01769079|DRUG|Nitrate|Two arms: placebo and nitrate
48319781|NCT01769079|DRUG|Placebo|
48319782|NCT02230878|DRUG|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
48319783|NCT02230878|DRUG|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
48486722|NCT00109837|DRUG|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
48486723|NCT00109837|DRUG|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC \< 3,000
48319784|NCT02230878|DRUG|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
48486724|NCT00109837|DRUG|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
48486725|NCT00109837|DRUG|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
48486726|NCT00109837|DRUG|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
47968356|NCT02366052|OTHER|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
47968357|NCT03940040|OTHER|Usual care|Usual Care
47968358|NCT03940040|OTHER|High flow nasal oxygen|High flow nasal oxygen
48117146|NCT03332992|BEHAVIORAL|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
48117147|NCT00194974|DRUG|methyldopa|
48117148|NCT00194974|DRUG|labetalol|
48117149|NCT00194974|DRUG|nifedipine|
48117150|NCT00194974|DRUG|clonidine|
48117151|NCT00904852|DRUG|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
48117152|NCT02700958|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
48117153|NCT02700958|PROCEDURE|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
48117154|NCT02858882|OTHER|Screening|Screening of elite swimmers
48117155|NCT00970359|BIOLOGICAL|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
48117156|NCT04856982|DRUG|Tofersen|Administered as specified in the treatment arm
48117157|NCT04856982|DRUG|Placebo|Administered as specified in the treatment arm
48117158|NCT01996917|DEVICE|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
48117159|NCT04303156|DRUG|Islatravir|Single oral dose of 60 mg Islatravir administered in capsule form
48117160|NCT03093298|OTHER|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
48117161|NCT04191954|DRUG|Fasudil eye drops (concentration 0.5 percent)|receive Fasudil eye drops (concentration 0.5 percent) twice daily
48117162|NCT04191954|DRUG|receive artificial tears drop|receive artificial tears drop with the same frequency
48117163|NCT01231568|DRUG|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
48117164|NCT01231568|DRUG|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
48117165|NCT01231568|DRUG|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
48117166|NCT01231568|DRUG|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
48117167|NCT00459446|DRUG|MS-325 Injection (Gadofosveset Trisodium)|
48319785|NCT02230878|DRUG|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
48319786|NCT02230878|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
48319787|NCT04465396|DRUG|Teduglutide|Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
48117168|NCT00043654|DRUG|Mifepristone|
48117169|NCT03057639|OTHER|Quality-of-Life Assessment|Ancillary studies
48117170|NCT03057639|OTHER|Questionnaire Administration|Ancillary studies
48117171|NCT04944407|PROCEDURE|LHP|A skin microincision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe (1.85 mm of diameter) was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions), 8 watt per 3 seconds each, of approximately 24 Joule using a 1470-nm diode laser generator (LEONARDO® DUAL 45 Biolitec® Jena, Germany) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
48319788|NCT04465396|DEVICE|Syringe Injection|Teduglutide was administered using syringe.
48319789|NCT04465396|DEVICE|Pen injector|Teduglutide was administered using pen injector.
48319790|NCT00579501|DRUG|Trabectedin|Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
48319791|NCT00579501|DRUG|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
48319792|NCT05836363|PROCEDURE|Ascending aorta replacement|The aneurysmatic ascending aorta tract is replaced with a tubular dacron prosthesis
48319793|NCT06399731|DEVICE|High-frequency (10Hz) rTMS|High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.
48319794|NCT06399731|DEVICE|Anodal tDCS|Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.
48319795|NCT01694420|DRUG|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
48319796|NCT01692353|OTHER|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
48319797|NCT06553508|PROCEDURE|Trochanteric bursa repaired|As a routine procedure in our centre, the trochanteric bursa is left unrepaired after a hip arthroplasty.
48319798|NCT06553508|PROCEDURE|Trochanteric bursa unrepaired|For the experimental arm, the trochanteric bursa is repaired after a hip arthroplasty. The conventional joint closure is performed after reduction and then the bursa is retrieved and repaired.
48319799|NCT04489485|BEHAVIORAL|Teen Depression Module used for care|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
48319800|NCT02357641|OTHER|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
48319801|NCT06460142|DIAGNOSTIC_TEST|Aortic/ cardiac magnetic resonance imaging|MRI scans will be performed to detect systemic vascular involvement in GCA patients, aiming to provide detailed images of affected tissues.
48117172|NCT04944407|PROCEDURE|MM|The hemorrhoidectomy was performed by radiofrequency (LigaSure TM Small Jaw® Covidien®, Colorado, USA) or ultrasound (Focus® Ultracision® harmonic scalpel; Ethicon Endo-Surgery®, Inc., Cincinnati, Ohio). The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
48117173|NCT05308381|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
48486727|NCT00109837|DRUG|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
48117174|NCT05308381|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
48117175|NCT05308381|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
48117176|NCT02800434|PROCEDURE|hand allograft|
48117177|NCT04674449|DIAGNOSTIC_TEST|Disclosure of IDP results|The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
48117178|NCT04674449|OTHER|IDP performed but results not disclosed|The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
48117179|NCT01947790|DRUG|pioglitazone group|
48117180|NCT01947790|DRUG|Metformin group|
48117181|NCT00005027|DRUG|becatecarin|
48319802|NCT06460142|DIAGNOSTIC_TEST|Vascular ultrasound|Vascular ultrasound will be employed to examine the temporal and axillary arteries in GCA patients, searching for signs indicative of active inflammation.
48319803|NCT06460142|DIAGNOSTIC_TEST|Transorbital Ultrasound|Transorbital ultrasound will be employed to assess the ophthalmic artery and its branches in GCA patients to detect intracranial inflammatory processes that could lead to severe neuro-ophthalmological complications.
48319804|NCT06460142|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Contrast-Enhanced Ultrasound (CEUS) is utilized to evaluate aortic involvement in GCA patients as an alternative, bed-side, realtime, radiation-free diagnostic tool.
48319805|NCT06460142|DIAGNOSTIC_TEST|Optical coherence tomography angiography|OCTA will be used to assess vascular changes in the retina of GCA patients, providing detailed imaging that can help detect early signs of ocular involvement and identify risk factors of anterior ischemic optic neuropathy.
48340042|NCT04061941|BEHAVIORAL|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
48117182|NCT04412018|DRUG|Icosapent ethyl|Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
48117183|NCT05530499|OTHER|Almond supplementation|Daily consumption of 57g of whole almonds
48117184|NCT05530499|OTHER|Cookie supplementation|Daily consumption of cookie snack calorically equivalent to 57 grams of whole almonds.
47968359|NCT01369758|DEVICE|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
48319806|NCT06460142|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography will be performed to evaluate blood circulation and highlight any blockages in the blood vessels of the retina in patients with GCA to detect vascular abnormalities that may lead to severe vision complications.
48319807|NCT06460142|DIAGNOSTIC_TEST|Fundus autofluorescence|This imaging technique will be used to observe the health of the retina and detect any changes in GCA patients that could suggest disease activity, particularly useful for assessing the integrity of the retinal pigment epithelium.
48319808|NCT06460142|DIAGNOSTIC_TEST|Color Fundus Photography|Color fundus photography will be used to document the appearance of the optic disc and retinal vasculature in GCA patients, aiding in the long-term monitoring of ocular changes and the effects of therapeutic interventions.
47968360|NCT05148598|DEVICE|ADRCs|Adipose Derived Regenerative Cells (ADRCs) processed with Celution System
47968361|NCT05148598|OTHER|Standard Care|Standard care
47968362|NCT05148598|OTHER|Placebo|Placebo visually indistinguishable from ADRCs
47968363|NCT04805424|PROCEDURE|Lipo-abdominoplasty|Abdominoplasty plus liposuction
47968364|NCT04805424|PROCEDURE|Abdominoplasty|Abdominoplasty
47968365|NCT04162639|BIOLOGICAL|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
47968366|NCT05575531|OTHER|MEWSS and Nursing Guide Application|MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
48319809|NCT06460142|DIAGNOSTIC_TEST|Cell-based ex-vivo assay with high-content analysis|This assay predicts individual patient responses to different DMARDs by analyzing patient-derived PBMCs for specific immune responses to therapeutic agents.
48319810|NCT06460142|DIAGNOSTIC_TEST|3'mRNA sequencing|3'mRNA sequencing analyzes gene expression profiles related to the immune response in PMR/GCA patients, aiding in understanding the genetic underpinnings of inflammation and vascular remodeling.
47968367|NCT01306396|BEHAVIORAL|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
48319811|NCT06460142|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Used to measure cytokine levels in the serum and plasma of PMR/GCA patients, ELISA aids in profiling inflammatory markers that are indicative of disease activity and response to treatment.
48319812|NCT06460142|DIAGNOSTIC_TEST|Flow cytometry|Employed to analyze immune cell phenotypes in patients with PMR and/or GCA, this test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and guiding therapy.
48319813|NCT06460142|DIAGNOSTIC_TEST|Laboratory assessment:|Serum Chemistry (nt-proBNP, troponin T, CRP, ESR, blood count)
48486728|NCT00109837|DRUG|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
48486729|NCT00109837|DRUG|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
48486730|NCT00109837|DRUG|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
47968368|NCT04717791|DEVICE|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
47968369|NCT06218693|BEHAVIORAL|VIA Family|A family-based, multi-component, individual-tailored intervention based on case-management.
47968370|NCT06218693|BEHAVIORAL|Treatment As Usual (TAU)|care as usual
47968371|NCT05185193|DEVICE|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
47968372|NCT05185193|DEVICE|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
47968373|NCT01024452|DEVICE|DAWN AC|computerized dosing management system for anticoagulation clinics
47968374|NCT01024452|DEVICE|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
47968375|NCT02172768|OTHER|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
48319814|NCT06460142|DIAGNOSTIC_TEST|Immunohistochemistry of Temporal Artery Biopsies|Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.
48486731|NCT00109837|RADIATION|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
47968376|NCT02172768|OTHER|daily dosing|micafungin daily for 8 days
47968377|NCT02172768|DRUG|micafungin|
48486732|NCT00109837|DRUG|allopurinol|300 mg/d PO Days 1-7
48486733|NCT00109837|DRUG|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
47968378|NCT00415831|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
47968379|NCT03937011|DEVICE|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"1. Robotic Bariatric Sleeve gastrectomy~2. Robotic Hysterectomy with or without oophorectomy;"
48319815|NCT06460142|DIAGNOSTIC_TEST|Functional assessment questionnaires|The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.
48319816|NCT04237402|OTHER|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
48319817|NCT06140069|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
48319818|NCT04765137|DRUG|Atorvastatin Oral Tablet|Atorvastatin pill 40 mg to be taken every night
48319819|NCT03443843|DRUG|loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
48319820|NCT03443843|DRUG|Placebo tablet|Placebo tablet orally
48319821|NCT03443843|DRUG|Fluticasone Propionate|Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
48319822|NCT03443843|DRUG|Placebo spray|Placebo Nasal Spray, 2 sprays per nostril
48319823|NCT01419704|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
48319824|NCT03367065|RADIATION|Dynamic contrast enhanced computerised tomography|
48319825|NCT05479409|RADIATION|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
48319826|NCT01284270|OTHER|Cardiac MRI|Cardiac MRI
48319827|NCT04296526|BEHAVIORAL|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
48319828|NCT04296526|BEHAVIORAL|Exercise Education|To organize sessions for how to proper exercise.
48319829|NCT04296526|BEHAVIORAL|Social Support|Supports such as peer influence or reminder phone messages
48319830|NCT03169023|BEHAVIORAL|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
48319831|NCT03169023|BEHAVIORAL|Enhanced Usual Care Packets|-From the American Cancer Society Website
48319832|NCT03169023|OTHER|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
48319833|NCT03169023|OTHER|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
48319834|NCT03169023|OTHER|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
48319835|NCT03169023|OTHER|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
48319836|NCT03169023|OTHER|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
48319837|NCT03169023|BEHAVIORAL|iOTA|-Washington University based intervention
48319838|NCT06027931|PROCEDURE|Conservative Access Opening, Traditional Access Opening|Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.
48319839|NCT03661489|DRUG|Remimazolam|For induction and maintenance of general anesthesia
48319840|NCT03661489|DRUG|Propofol|For induction and maintenance of general anesthesia
48319841|NCT01006720|DRUG|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
48319842|NCT01006720|DRUG|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
48319843|NCT01006720|DRUG|Saline|Saline 0.9% (Saline)
48319844|NCT00442013|DRUG|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
48319845|NCT00442013|DRUG|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
48319846|NCT02622100|DEVICE|Bioresorbable Vascular Scaffold|
48319847|NCT02437058|OTHER|preidictive model|
48319848|NCT05938777|BEHAVIORAL|Non-Stage-Matched Intervention|The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
48319849|NCT01727050|DEVICE|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
48319850|NCT01727050|DEVICE|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
48319851|NCT03916471|DEVICE|Solyx™ SIS System|Single-incision sling system
48319852|NCT03916471|DEVICE|Obtryx™ II System (Halo)|Transobturator Mid-urethral Sling System
48319853|NCT04252612|DRUG|Pramlintide|SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
48319854|NCT03136952|DEVICE|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
48319855|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 1|
48319856|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 2|
48319857|NCT02317536|OTHER|Placebo|Placebo
48319858|NCT04004559|OTHER|No interventions|As this is a patient registry, there are no interventions.
48319859|NCT02336412|OTHER|SMS reminder|Daily SMS medication reminder
48319860|NCT01965236|DIETARY_SUPPLEMENT|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
48319861|NCT01965236|DIETARY_SUPPLEMENT|Placebo|
48319862|NCT02757781|BEHAVIORAL|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
48319863|NCT02486887|DEVICE|telemonitoring of weight, pulse and blood pressure|
48319864|NCT01161082|DRUG|REGN727(SAR236553)|subcutaneous
48319865|NCT00053261|PROCEDURE|management of therapy complications|
48319866|NCT00289562|DRUG|forodesine hydrochloride (BCX-1777)|
48319867|NCT05402436|OTHER|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
48319868|NCT02675894|DEVICE|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
48319869|NCT02675894|DEVICE|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
48319870|NCT05175937|DEVICE|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
48319871|NCT05175937|DEVICE|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
48319872|NCT01086150|PROCEDURE|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
48319873|NCT01086150|DRUG|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
48319874|NCT06146335|PROCEDURE|Kono-S anastomosis (KSa)|antimesenteric functional end-to-end handsewn anastomosis connecting small intestine and colon after surgery
48319875|NCT06146335|PROCEDURE|Side-to-side anastomosis (SSa)|side-to-side anastomosis connecting small intestine and colon after surgery
48319876|NCT03170479|DIETARY_SUPPLEMENT|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
48319877|NCT03170479|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
48319878|NCT03901261|PROCEDURE|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
48319879|NCT03166865|BIOLOGICAL|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10\~7 diluted on 5 mL of Platelet Rich Plasma
48319880|NCT03166865|OTHER|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
48319881|NCT05876858|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
48319882|NCT05876858|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
48319883|NCT04825236|OTHER|MyVoice:CF|"Participants will be given access to MyVoice:CF, a web-based decision aid (DA). This tool includes information about fertility, genetics, parenting, pregnancy, and breastfeeding within the context of cystic fibrosis (CF). The tool includes interactive elements designed to give users the ability to assess and reflect on their own reproductive goals and experiences and promote self-efficacy to engage in shared decision-making with their CF and women's health providers.~Upon completion of use of the decision aid, a summary sheet is generated based on the user's interaction with the tool. This summary is supplied to the provider prior to the next appointment."
48319884|NCT02059213|DRUG|Ibrance|
48319885|NCT02059213|DRUG|Bicalutamide|
48319886|NCT02059213|DRUG|Zoladex|
48319887|NCT02059213|DRUG|Lupron Depot|
48319888|NCT01568424|DEVICE|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
48319889|NCT05896618|DEVICE|TPA|1. Group I (TPA group).In which patients will receive Transpalatal arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
48319890|NCT05896618|DEVICE|Nance appliance|2. Group II (Nance group).In which patients will receive Nance holding arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
48319891|NCT03267992|BEHAVIORAL|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
48319892|NCT06250517|DEVICE|EVLP|The right lung will be perfused for 3h with EVLP
48319893|NCT06250517|DEVICE|Cold preservation|The left lung will be cold preserved as usual protocol
48319894|NCT01238133|DRUG|Carboplatin|Given IV
48319895|NCT01238133|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
48319896|NCT01238133|OTHER|Laboratory Biomarker Analysis|Correlative studies
48319897|NCT01238133|DRUG|Paclitaxel|Given IV
48319898|NCT01238133|OTHER|Pharmacological Study|Ancillary studies
48319899|NCT01238133|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48319900|NCT05997017|DRUG|nab-sirolimus|Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
48319901|NCT01261806|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
48319902|NCT01261806|BEHAVIORAL|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
48319903|NCT03096002|BEHAVIORAL|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
48319904|NCT06406686|PROCEDURE|Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter|Durable block across the cavotricuspid isthmus by radiofrequency ablation.
48319905|NCT01523314|DRUG|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
47968380|NCT01410201|DRUG|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
48319906|NCT01523314|OTHER|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
48486734|NCT01534637|DRUG|aprepitant|Given PO
48319907|NCT03824548|OTHER|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
48319908|NCT00393913|DEVICE|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
48319909|NCT04482868|PROCEDURE|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
48319910|NCT06483490|OTHER|This is a cross-sectional, non pharmacological study|Measurement of immune checkpoint levels, mitochondrial dysfunction, pollutant concentrations and G-quadruplex levels and their correlation in all enrolled subjects.
48319911|NCT02497157|DRUG|Oxaliplatin (L-OHP)|
48319912|NCT02497157|DRUG|Irinotecan hydrochloride hydrate (CPT-11)|
48319913|NCT02497157|DRUG|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
48319914|NCT02497157|DRUG|Levofolinate calcium (l-LV)|
48486735|NCT01534637|DRUG|gemcitabine hydrochloride|Given IV
48319915|NCT02497157|DRUG|Bevacizumab (Bmab)|
48319916|NCT03038659|DEVICE|Penile Duplex|Measuring intima media thickness
48319917|NCT02856685|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
47968381|NCT04466020|OTHER|Qualitative research interviews to be conducted|None. Qualitative research interviews to be conducted
47968382|NCT03072992|DRUG|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
47968383|NCT03072992|DRUG|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
47968384|NCT03072992|DRUG|Placebo|Placebo i.v. solution, once weekly for 12 weeks
47968385|NCT04971408|OTHER|passive heat stress|as above
48319918|NCT04104906|OTHER|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
48319919|NCT04104906|OTHER|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
48319920|NCT00670397|DRUG|HPPH|IV
48319921|NCT00913133|DRUG|Desirudin|Desirudin SC 15mg q12h
48319922|NCT04972487|DRUG|Tofersen|Administered as intrathecal bolus injection
48319923|NCT00929734|DRUG|Rosuvastatin|10mg tablets, once daily in three months
48319924|NCT00929734|DRUG|Placebo|1 tablet, once daily in three months
48486736|NCT01534637|DRUG|capecitabine|Given PO
48486737|NCT01534637|DRUG|fluorouracil|Given IV
48486738|NCT01534637|PROCEDURE|radiation therapy|Undergo radiation therapy
48486739|NCT01534637|OTHER|questionnaire administration|Ancillary studies
48486740|NCT01534637|PROCEDURE|quality-of-life assessment|Ancillary studies
48486741|NCT01534637|PROCEDURE|nausea and vomiting therapy|Receive aprepitant
48319925|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
48319926|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
48319927|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with less ≤ 3mm from each other.|Implant Placement of 2 contiguous dental implants with less ≤ 3mm from each other.
48319928|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with > 3mm from each other.|Implant Placement of 2 contiguous dental implants with \> 3mm from each other.
48319929|NCT04606654|OTHER|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
48319930|NCT04606654|OTHER|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
48319931|NCT00555048|BIOLOGICAL|alemtuzumab|
48319932|NCT00555048|DRUG|busulfan|
48319933|NCT00555048|DRUG|cyclophosphamide|
48319934|NCT00555048|DRUG|methotrexate|
48319935|NCT00555048|DRUG|tacrolimus|
48319936|NCT00555048|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48319937|NCT00555048|PROCEDURE|peripheral blood stem cell transplantation|
48319938|NCT00075244|DRUG|Replagal|
48646006|NCT02712216|PROCEDURE|Laparoscopy|Determine best port sites to insert bariatric trocars
48646007|NCT06543862|OTHER|CADx (AI) system|The CADx system will be used to predict the histopathology of the polyp detected.
48646008|NCT00178659|OTHER|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
48646009|NCT06689241|DRUG|Enoxaparin|40mg
48646010|NCT06689241|DRUG|rivaroxaban|10mg
47968386|NCT04971408|OTHER|control|participant engage in activity as usual
47968387|NCT05045248|DRUG|Apraclonidine Hcl 0.5% Oph Soln|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
47968388|NCT02462460|DEVICE|MRI|
47968389|NCT02462460|BEHAVIORAL|Optional Screening Questionnaire|
48319939|NCT00743600|OTHER|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
48319940|NCT00743600|OTHER|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
48319941|NCT02541474|OTHER|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
48319942|NCT00311181|DEVICE|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
48319943|NCT05378516|OTHER|no intervention|no intervention
48319944|NCT03179280|DRUG|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
48319945|NCT01647659|DRUG|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
48319946|NCT01647659|DRUG|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
48319947|NCT05844956|DRUG|DZD8586|Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
48319948|NCT00123916|DRUG|Benznidazole|Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
48319949|NCT00123916|DRUG|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
48319950|NCT03714035|OTHER|no intervention|no intervention
48646011|NCT06504966|DRUG|MAB-22|Single subcutaneous dose of 60 mg
48646012|NCT06504966|DRUG|Prolia®|Single subcutaneous dose of 60 mg
48646013|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
48646014|NCT01019174|DRUG|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
48646015|NCT03818880|DEVICE|Novel spectacle lens design|Spectacle lens to control progression of myopia
48646016|NCT00069953|BIOLOGICAL|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients \>70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
48646017|NCT00069953|BIOLOGICAL|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
48646018|NCT00069953|DRUG|cisplatin|During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
47968390|NCT01782222|DRUG|Rotigotine|"Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
47968391|NCT01782222|OTHER|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
48319951|NCT06286358|DIAGNOSTIC_TEST|Kinocardiography|Technology Measuring Cardiac Mechanical Activity Via Accelerometers and Gyroscopes
47968392|NCT05789810|OTHER|Manuel pressure|10-second manual pressure was applied on the insulin injection area.
47968393|NCT05789810|OTHER|ShotBlocker|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
47968394|NCT05789810|OTHER|Control|No intervention was performed to reduce pain and fear.
47968395|NCT01749397|DRUG|Floxuridine|Given IP
47968396|NCT01749397|OTHER|Laboratory Biomarker Analysis|Correlative studies
47968397|NCT01749397|OTHER|Pharmacological Study|Correlative studies
47968398|NCT01749397|DRUG|Veliparib|Given IV
47968399|NCT00583609|DRUG|PEG3350|PEG3350
47968400|NCT05166824|DEVICE|TempSure|Radiofrequency platform
47968401|NCT05166824|DEVICE|Scalpel|Cold knife
47968402|NCT05166824|DEVICE|Bovie|Electrosurgery and electrocautery platform
48117185|NCT03114267|OTHER|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
48117186|NCT04275193|DRUG|Zishenqing|Zishenqing Granule
48319952|NCT04850716|OTHER|non-intervention|non-intervention
47968403|NCT05166824|DEVICE|Pelleve|Radiofrequency platform
47968404|NCT01694472|BIOLOGICAL|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10\^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10\^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
47968405|NCT00527501|DRUG|Travoprost/brinzolamide|
47968406|NCT05191524|OTHER|Constrained induced movement|Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.
47968407|NCT05191524|OTHER|Proprioceptive Neuromuscular facilitation|Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
47968408|NCT00634374|DEVICE|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
47968409|NCT03431428|PROCEDURE|transanal surgery|Transanal surgery could Preserve anus to reduce trauma and improve the quality of life
47968410|NCT03431428|PROCEDURE|Miles surgery|Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.
47968411|NCT03431428|DRUG|Preoperative chemoradiotherapy|After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
47968412|NCT00739791|BEHAVIORAL|exercise intervention|
47968413|NCT00739791|GENETIC|gene expression analysis|
47968414|NCT00739791|GENETIC|polymerase chain reaction|
47968415|NCT00739791|GENETIC|proteomic profiling|
48117187|NCT04275193|DRUG|Placebo|Granule manufactured to mimic Zishenqing(containing 10% composition)
48117188|NCT05452759|DEVICE|high-flow oxygen therapy device for Severe pneumonia patients with artificial airway|Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.
48319953|NCT01973452|DRUG|Dexmedetomidine|
48319954|NCT01973452|DRUG|Placebo|
48319955|NCT01199250|OTHER|Laboratory Biomarker Analysis|Correlative studies
48319956|NCT01782794|OTHER|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
48319957|NCT01608724|DRUG|Saxagliptin|oral, 5 mg once a day (Q.D.)
48319958|NCT01173796|PROCEDURE|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
48319959|NCT01173796|PROCEDURE|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
48319960|NCT05392894|PROCEDURE|Haploidentical stem cell transplantation|Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.
48319961|NCT05392894|OTHER|Standard medical care|Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.
48319962|NCT03270150|DEVICE|BTL-899|BTL-899
48319963|NCT02491502|DEVICE|Echopulse|HIFU Under ultrasound guidance
48319964|NCT06240299|PROCEDURE|Neurofeedback|A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen
48319968|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
48319969|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
48319970|NCT02860845|DEVICE|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
48319971|NCT02860845|DRUG|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
48646019|NCT00069953|DRUG|fluorouracil|During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
47968416|NCT00739791|GENETIC|reverse transcriptase-polymerase chain reaction|
47968417|NCT00739791|OTHER|laboratory biomarker analysis|
47968418|NCT00739791|OTHER|medical chart review|
47968419|NCT00739791|OTHER|questionnaire administration|
47968420|NCT00739791|PROCEDURE|psychosocial assessment and care|
48319972|NCT02860845|DRUG|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
48319973|NCT02571751|DEVICE|UNIGEL Silicone Gel-Filled Breast Implant|
48319974|NCT02182141|DRUG|BIBF 1120 ES|
48319975|NCT04486963|DRUG|Sanhuangjingshimingwan|Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
48319976|NCT04486963|DRUG|Sanhuangjingshimingwan Placebo|Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
48319977|NCT00775502|DRUG|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
48319978|NCT05682586|BIOLOGICAL|umbilical cord mesenchymal stem cells|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
48319979|NCT05682586|DRUG|paxlovid|Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
47968421|NCT00739791|PROCEDURE|quality-of-life assessment|
47968422|NCT00739791|PROCEDURE|support group therapy|
47968423|NCT00739791|PROCEDURE|therapeutic dietary intervention|
47968424|NCT01157260|DRUG|Kremezin|AST-120 2g three times a day
47968425|NCT03119831|DRUG|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
47968426|NCT03119831|DRUG|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
47968427|NCT03119831|DRUG|C31G|Rinsing with 15ml for one minute twice daily for 14 days
47968428|NCT01155271|OTHER|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP"
48319980|NCT06015802|OTHER|diagnosed and treated reasonably according to the clinical guidelines and clinical pathways|The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
48319981|NCT01487096|DRUG|Teriflunomide|"film-coated tablet~oral administration"
48319982|NCT01487096|DRUG|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
48319983|NCT02855450|DRUG|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
48319984|NCT02855450|DRUG|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
48319985|NCT04574063|BEHAVIORAL|Lifestyle intervention to reduce breast cancer risk|Women will be educated about lifestyle factors which increase breast cancer risk. They will also be guided through an online goal setting process.
48319986|NCT04895605|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
48319987|NCT04895605|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
48319988|NCT01417065|DRUG|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
48319989|NCT00173693|BEHAVIORAL|exercise for strength, balance, health education|
48646020|NCT00069953|DRUG|paclitaxel|During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
48646021|NCT00069953|PROCEDURE|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
48646022|NCT00069953|RADIATION|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (\> 6 MV) will be used to deliver multiple (\> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
48646023|NCT00288561|DRUG|ranibizumab|
47968429|NCT01142349|BEHAVIORAL|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
47968430|NCT01142349|BEHAVIORAL|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
47968431|NCT01142349|BEHAVIORAL|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
47968432|NCT04672993|DEVICE|Urine collection device for men|Use of urine collection device for men
48319990|NCT05811767|OTHER|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
48319991|NCT01552824|PROCEDURE|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
48319992|NCT01552824|PROCEDURE|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
48340043|NCT00425945|DRUG|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
48486742|NCT01534637|PROCEDURE|management of therapy complications|Receive aprepitant
47968433|NCT05438394|DRUG|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
47968434|NCT03196102|BEHAVIORAL|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
47968435|NCT03196102|BEHAVIORAL|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
48486743|NCT06213467|DEVICE|diode laser 940nm|Exposure for the two implants was done at the same visit, with one implant being exposed using diode laser and the other implant using traditional method
48486744|NCT00303875|BEHAVIORAL|behavioral dietary and exercise intervention|
48486745|NCT04551820|PROCEDURE|Regular Hours|The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.
48486746|NCT04551820|PROCEDURE|After Hours|The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.
48486747|NCT04551820|DEVICE|Robotic-assisted Cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
48486748|NCT00554320|PROCEDURE|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
47968436|NCT03196102|BEHAVIORAL|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
47968437|NCT04100265|DEVICE|Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
48319993|NCT06303947|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48319994|NCT06303947|DEVICE|Nasogastric tube|The group is given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48319995|NCT06303947|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48319996|NCT00483275|DRUG|Alfacalcidol|
48319997|NCT00483275|BEHAVIORAL|Balance, gait and strength training|
48319998|NCT00483275|BEHAVIORAL|Patient education|
48319999|NCT05197478|OTHER|Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey|"To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire"
48320000|NCT05320692|DRUG|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
48320001|NCT05320692|PROCEDURE|TACE|TACE Alone.
48486749|NCT00554320|PROCEDURE|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
48646024|NCT00295503|DRUG|bevacizumab|15 mg/kg IV every 3 weeks
47968438|NCT04100265|DEVICE|Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
47968439|NCT01120002|DRUG|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
47968440|NCT01120002|DRUG|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
47968441|NCT00873574|BIOLOGICAL|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
48320002|NCT01583452|OTHER|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
48320003|NCT03665428|DRUG|PAMB treatment (modified quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
48646025|NCT00295503|DRUG|cisplatin|75 mg/m2 IV every 3 weeks
48646026|NCT00295503|DRUG|pemetrexed|500 mg/m2 every 3 weeks
48646027|NCT01901757|DRUG|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
48646028|NCT01901757|DRUG|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
48646029|NCT05378425|DRUG|NTX-1088|IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
48646030|NCT05378425|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
47968442|NCT02249585|DEVICE|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
47968443|NCT02249585|DEVICE|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
47968444|NCT02249585|DRUG|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
47968445|NCT02249585|DRUG|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
48320004|NCT03665428|DRUG|PBMT treatment (bismuth-containing quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
48320005|NCT06017583|DRUG|Tislelizumab|Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
48320006|NCT06017583|DRUG|Capecitabine|Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
48320007|NCT06017583|DRUG|Oxaliplatin|Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
48320008|NCT06017583|RADIATION|SIB-IMRT|The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
48320009|NCT06017583|RADIATION|IMRT|The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
48320010|NCT04900480|OTHER|Direct access to publicly subsidized physiotherapy|This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
47968446|NCT00612040|DRUG|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
48320011|NCT01760993|DRUG|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
48320012|NCT03720821|BEHAVIORAL|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
48320013|NCT04204655|DIAGNOSTIC_TEST|BIA|Bioelectrical Impedance Analysis
48320014|NCT00539253|DRUG|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
48320015|NCT05515822|DRUG|Oxycodone Hydrochloride|The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
48486750|NCT06446141|OTHER|Osteopathic technique|Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.
48646031|NCT02928900|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
48646032|NCT03138382|DEVICE|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
48646033|NCT03138382|DEVICE|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
48646034|NCT03261375|DEVICE|Renal Artery Radiofrequency Ablation System (Generator and Catheter )|A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
48320016|NCT05515822|DRUG|Dezocine|Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
48320017|NCT05515822|DRUG|Esketamine and Oxycodone|Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
48320018|NCT04982159|OTHER|There is no intervention. This is an observational study.|There is no intervention. This is an observational study.
48486751|NCT01638650|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
48486752|NCT01638650|DRUG|ritonavir|100 mg bid orally, Days 1-14
48486753|NCT01638650|DRUG|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
48646035|NCT03261375|DRUG|Antihypertensive Agents|Calcium channel blocker, Diuretic
48646036|NCT03261375|DEVICE|Sham Procedure|Catheterization without renal denervation
48646037|NCT06004583|DIAGNOSTIC_TEST|Biochemical blood analysis|Serum CRP and albumin levels
48646038|NCT05579522|PROCEDURE|Fat graft injection|Fat graft injection in the interdental papilla.
48646039|NCT05579522|PROCEDURE|Hyaluronic acid injection|Hyaluronic acid injection in the interdental papilla
47968447|NCT00612040|DRUG|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
47968448|NCT00612040|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
47968449|NCT00612040|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
47968450|NCT06279091|BEHAVIORAL|Diaphragmatic Breathing|apply breathing exercises to evaluate the effectiveness on anxiety reduction
47968451|NCT06279091|BEHAVIORAL|Bubble Blower Breathing|apply breathing exercises by using bubble blower to evaluate the effectiveness on anxiety reduction
48320019|NCT05328856|DEVICE|Hansgrohe prototype|Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out with a mixing function for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
48320020|NCT01916993|DRUG|NBI-98854 50 mg capsule|
48320021|NCT06155760|DRUG|Prednisolone|10mg of prednisolone plus standard medical therapy for 60 days
48320022|NCT06155760|OTHER|Standard Medical therapy|IV Albumin, Diuretics, Multi vitamins as per clinicians decision
48320023|NCT06155760|DRUG|Placebo|Placebo
48320024|NCT02128282|DRUG|CX-4945|API powder-in-capsule in 200 mg strength.
48320025|NCT02128282|DRUG|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
48320026|NCT02128282|DRUG|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
48320027|NCT04703348|DIAGNOSTIC_TEST|Motor imagery Questionnaire - Revised Second (MIQ-RS)|"Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities."
48320028|NCT01453309|PROCEDURE|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
48320029|NCT01453309|PROCEDURE|No Cell Saver|Cell Saver will not be available during surgery
48320030|NCT06110299|DIAGNOSTIC_TEST|air injection|delination of the ureter and pelvis by injecting air under C-ARM
48646040|NCT06536504|OTHER|Steinway Spirio M recording/player piano|Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via sealed envelopes with the randomization list generated by the study statistician. Each participating provider will be enrolled into the corresponding music intervention arm following patient randomization.
48646041|NCT06410131|DRUG|FTL008.16|IV infusion every 2 weeks
48646042|NCT04298333|DRUG|BP-C1|"BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days."
48646043|NCT04957927|DRUG|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age|Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
48320031|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
48320032|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
47968452|NCT06279091|BEHAVIORAL|Tell Show Do|apply basic behavioral management technique as control group
47968453|NCT03641430|OTHER|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
47968454|NCT04173988|GENETIC|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells."
48320033|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
48320034|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
48320035|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
48320036|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
48320037|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
48320038|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
48320039|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
48320040|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
48320041|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
48320042|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
48320043|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
48320044|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
48320045|NCT01759498|DIETARY_SUPPLEMENT|HYDRO|
47968455|NCT04173988|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
48320046|NCT01759498|DIETARY_SUPPLEMENT|ACTIVE|
48320047|NCT01759498|DIETARY_SUPPLEMENT|HYDRO 2|
48320048|NCT03656120|DRUG|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
48320049|NCT03656120|DRUG|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
48320050|NCT03656120|DRUG|placebo control group|Participants only take placebos for 12 weeks during the research.
48320051|NCT03624517|DRUG|Octreotide|Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
48646044|NCT06137092|DRUG|Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)|rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
48320052|NCT00679718|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
47968456|NCT04173988|DRUG|Fludarabine|Chemotherapy for lymphodepletion
47968457|NCT03267706|OTHER|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
47968458|NCT00329238|DRUG|Dabigatran|Dabigatran 150 mg BID (twice daily)
47968459|NCT00329238|DRUG|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
48320053|NCT06007339|DEVICE|PerQseal ELITE|"The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
48320054|NCT06278558|OTHER|Interviews with a psychologist/psychiatrist|All patients with a high score (≥11) on the HADS anxiety and/or depressive symptoms scale and who are not already receiving known psychological treatment or treatment mentioned in the file will be contacted by telephone by the investigator or a qualified person designated by him/her in order to conduct a telephone interview with the patient and refer him/her to a psychologist or psychiatrist if necessary. The number and percentage of consultations with a psychologist or psychiatrist following this telephone interview will be calculated in order to highlight the benefits of such a practice (HADS assessment + telephone interview with +/- referral) for earlier and easier referral. Depending on the number of patients contacted, consideration may be given to testing the effect of this approach on post-traumatic development.
48320055|NCT03544554|BEHAVIORAL|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
48486754|NCT06096714|DRUG|Nicotine|Nicotine will be infused using a pump.
48646045|NCT02511743|OTHER|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
48646046|NCT06690957|DIAGNOSTIC_TEST|68Ga/18F-TATE/JR11/LM3|Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time.
48646047|NCT06063720|DEVICE|Endoscreen QC|Artificial intelligence monitoring of effective withdrawal time
48646048|NCT03822715|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
48320056|NCT05270850|PROCEDURE|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
48320057|NCT05270850|PROCEDURE|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
48320058|NCT04636008|DRUG|Sintilimab|Sintilimab+Hypofractionated radiotherapy
48320059|NCT04636008|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
48320060|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv low dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6
48320061|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv middle dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6
48320062|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells - iv high dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6
48320063|NCT05405036|OTHER|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
48320064|NCT01273389|DRUG|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
48320065|NCT01273389|DRUG|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
48320066|NCT01426607|DEVICE|AMO|
48320067|NCT04507477|BIOLOGICAL|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
48320068|NCT02854904|DRUG|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
48320069|NCT02854904|DRUG|Placebo|Placebo controlled
48320070|NCT05425875|PROCEDURE|Bronchoalveolar lavage using wall mount suction|BAL will be performed using wall mount suction with a pressure \<100 mmHg
48320071|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction|A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope
48320072|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction with rubber tubing|A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
48320073|NCT00642655|DRUG|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
48320074|NCT01252342|DRUG|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
47968460|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
48486755|NCT06096714|OTHER|Saline|Saline with be used to compare Nicotine, Saline will be infused using a pump
48320075|NCT01252342|DRUG|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
48486756|NCT03653494|PROCEDURE|phrenic block|phrenic block by 1% ropivacaine 5ml
48486757|NCT03653494|PROCEDURE|no phrenic block|no phrenic block
48486758|NCT01546324|PROCEDURE|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
48486759|NCT04429334|DRUG|nangibotide|nangibotide 1.0 mg/kg/h
48486760|NCT04429334|DRUG|placebo|matching placebo
48320076|NCT05963048|DRUG|Rituximab|IV infusion 1000 mg
48320077|NCT05963048|DRUG|IL6 inhibitor|6 mg/kg I V infusion monthly
48320078|NCT01153191|PROCEDURE|Normal saline pressurized irrigation|same
48486761|NCT04711967|BIOLOGICAL|Fecal Microbiota Transplantation|fecal microbiota transplantation
48486762|NCT04711967|DRUG|drug|drug
48486763|NCT03290287|DRUG|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
48486764|NCT03290287|DRUG|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
48486765|NCT05855616|DEVICE|"Group chlorhexidine dressing"|Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
48486766|NCT05855616|OTHER|"Group solution"|Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
48486767|NCT00384007|PROCEDURE|Hydrodiscectomy with Spinejet|
48320079|NCT01153191|DRUG|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
48320080|NCT03670394|DIAGNOSTIC_TEST|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
48320081|NCT02671942|DRUG|Roflumilast|
48320082|NCT02671942|DRUG|Placebo|
48320083|NCT02961712|BIOLOGICAL|NK cells|single intravenous injection of NK cells (0.9\~1\*10\^9)
48320084|NCT02961712|BIOLOGICAL|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
48320085|NCT01982773|BEHAVIORAL|Virtual Hope Box Smartphone App|Smartphone app
48320086|NCT01982773|BEHAVIORAL|Enhanced Treatment as Usual|Printed materials
48320087|NCT00532961|DRUG|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
48486768|NCT04127955|OTHER|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
48486769|NCT02113176|DRUG|Minocycline|
48486770|NCT03982576|OTHER|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
48486771|NCT03982576|BEHAVIORAL|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
48646049|NCT03822715|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
48646050|NCT00551993|PROCEDURE|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
48646051|NCT00551993|PROCEDURE|Laparoscopic Sacral Colpopexy|Standard laparoscopy
48646052|NCT02034266|DIETARY_SUPPLEMENT|Omega-3 supplementation|5 mL twice daily, administered under the tongue
48646053|NCT06673238|DRUG|ABBV-722|Oral Capsule
48320088|NCT00532961|DRUG|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
48320089|NCT01078701|BIOLOGICAL|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
48320090|NCT01078701|BIOLOGICAL|Placebo|SPGN buffer
48320091|NCT02656758|BEHAVIORAL|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
48320092|NCT04955002|OTHER|No intervention|No intervention
48320093|NCT02979730|OTHER|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
48646054|NCT06673238|DRUG|Placebo|Oral Capsule
48646055|NCT04591587|PROCEDURE|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
48646056|NCT06238856|DRUG|SLIT™ Amikacin|Amikacin administered via the Pari LC STAR™ nebulizer.
48320094|NCT02979730|OTHER|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
48320095|NCT05678075|BEHAVIORAL|Whole-food plant-based nutrition education|Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
48340044|NCT02421146|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
48646057|NCT06238856|DRUG|Placebo|Nebulized saline.
48646058|NCT01341990|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
48646059|NCT01341990|DEVICE|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
48646060|NCT01341990|DEVICE|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
48320096|NCT04753814|DIAGNOSTIC_TEST|Diagostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
48320097|NCT00092066|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
48320098|NCT04281342|DRUG|Aprocitentan 25 mg|Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
48320099|NCT04281342|DRUG|Aprocitentan 100 mg|Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
48320100|NCT04281342|DRUG|Matching placebo|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.
48320101|NCT04281342|OTHER|Moxifloxacin control to establish assay sensitivity|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
48320102|NCT00239486|DRUG|Pramipexole|
48320103|NCT05942157|OTHER|Therapeutic Drug Monitoring (TDM)|Upon randomization and before the bacterial culture results are known, blood sampling will be obtained from the patient during the morning round of initial empiric antibiotic administration. PK/PD target analysis based on the clinical susceptibility breakpoints of Enterobacterales (the most prevalent organism family of DT-GNB infections in our setting) will be performed and a dosage recommendation will be communicated to the primary ID clinician. Antibiotic dosing adjustments (if any) will be made within 8 - 24 hours of the blood sampling by the Primary / Infectious Diseases clinician. In case of inappropriate dosing, where the PK/PD target is not achieved or exceeded with antibiotic side effects observed, the dosage will be increased or decreased, respectively.
48320104|NCT05833321|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|"measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire"
48320105|NCT03294928|OTHER|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
48320106|NCT01165151|BEHAVIORAL|behavioral weight loss program|weekly, group-based lifestyle weight loss program
48320107|NCT04357119|PROCEDURE|One-anastomosis gastric bypass|"Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision."
48320108|NCT01585935|DRUG|SMOFLIPID|target dose: 3g/kg/d
48320109|NCT01585935|DRUG|INTRALIPID|target dose: 3g/kg/d
48320110|NCT00893048|DRUG|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
48320111|NCT00893048|DRUG|Placebo Oral Tablet|Placebo
48320112|NCT01483898|BIOLOGICAL|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
48320113|NCT01483898|OTHER|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
48320114|NCT01044238|DRUG|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
48320115|NCT01044238|DRUG|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
48320116|NCT02990897|BEHAVIORAL|clinical decision support message|The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
48320117|NCT04321252|DRUG|KAE609|"* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)"
48320118|NCT04321252|DRUG|Placebo|matching placeo for iv administration
48320119|NCT04558788|DIAGNOSTIC_TEST|Immunohistochemistry on intestinal biopsies|Immunohistochemistry will be performed on human intestinal biopsies
48320120|NCT04597255|DEVICE|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
48320121|NCT01787643|OTHER|Height-Adjustable Desk Intallation in Office|
48486772|NCT03982576|BEHAVIORAL|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
48486773|NCT03982576|BEHAVIORAL|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
48646061|NCT01002729|OTHER|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI \< 30 given Oseltamivir
48320122|NCT04719676|OTHER|Core strength training using unstable surface|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on unstable surface"
48320123|NCT04719676|OTHER|The stable surface would be gym floor.|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on stable gym Floor"
48320124|NCT06357260|DRUG|Pregabalin and Carbamazepine|Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need
48320125|NCT06357260|DRUG|Carbamazepine|Carbamazepine with dose of Carbazmaepine being titrated as per patients's need
48320126|NCT04523064|DRUG|Empagliflozin 25 MG|Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
48320127|NCT04415216|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
48320128|NCT02635152|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
48320129|NCT02635152|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
48320130|NCT02141802|BEHAVIORAL|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
48320131|NCT02141802|BEHAVIORAL|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
47968461|NCT01507597|DRUG|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
48320132|NCT04054843|DIAGNOSTIC_TEST|Afamin|Plasma maternal afamin levels
48320133|NCT05869539|DRUG|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
48320134|NCT04507867|DIETARY_SUPPLEMENT|Nutritional support system (NSS)|"1. Combination of three B vitamins (B1, B6 and B12) Neurobion 10 mg solution for IM injection, One every 24 hours for the first 5 days.~2. Probiotics Saccharomyces boulardii CNCM I-745 Floratil. One morning and one evening 250 mg capsule during the first 6 days~3. One envelope of NSS-1 in the morning and one envelope in the afternoon mixed with 400 ml of water each, contain nutritional support system."
48320135|NCT04507867|OTHER|Conventional nutritional support designed by hospital nutritionists|Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
48320136|NCT05948410|BEHAVIORAL|The State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.
48320137|NCT05948410|BEHAVIORAL|Perceived Stress Scale|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale
48320138|NCT05948410|BEHAVIORAL|Visual Analog Scale|The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end points.
48320139|NCT00115765|DRUG|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
48320140|NCT00115765|DRUG|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
48320141|NCT00115765|DRUG|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
48320142|NCT00115765|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
48486774|NCT03982576|BEHAVIORAL|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
48486775|NCT01953822|OTHER|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
48486776|NCT01888341|DRUG|Isotretinoin|Isotretinoin Capsules,20 mg
48646062|NCT01002729|OTHER|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI \> 40 given Oseltamivir
48646063|NCT01757496|DEVICE|Cough Assist|
48646064|NCT05463471|DRUG|Compound sodium acetate ringer injection|Quickly infuse 500ml of compound sodium acetate ringer injection for volume expansion within 20-30 minutes
48646065|NCT05463471|DRUG|Albumin|Quickly infuse 500ml of albumin for volume expansion within 20-30 minutes
48320143|NCT06175962|BEHAVIORAL|TRAINING AND EXERCISE|"Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp."
48320144|NCT02782871|DEVICE|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
48320145|NCT01760941|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
48320146|NCT01760941|OTHER|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
48320147|NCT01760941|OTHER|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
48320148|NCT01860534|BEHAVIORAL|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
48320149|NCT00219232|DRUG|Rivastigmine Transdermal Patch|
48320150|NCT00190983|DRUG|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
48320151|NCT02143193|BEHAVIORAL|Skin-to-Skin Contact|
48320152|NCT05508672|OTHER|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
48320153|NCT05508672|OTHER|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
48320154|NCT04653818|DRUG|Velpatasvir/Sofosbuvir|sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
48320155|NCT02299063|DRUG|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
48320156|NCT02299063|DRUG|0.9% NaCl|
48320157|NCT04958616|DIAGNOSTIC_TEST|Skin prick test.|Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
48320158|NCT00960934|DRUG|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
48320159|NCT00960934|DRUG|Placebo|Dose-matched oral placebo to MK-5442
48320160|NCT00960934|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
48320161|NCT00960934|DIETARY_SUPPLEMENT|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
48320162|NCT06400316|DIETARY_SUPPLEMENT|Amino Acid Supplement|The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.
48320163|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
48320164|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
48320165|NCT02594397|OTHER|acupoints combination 1|
48320166|NCT02594397|OTHER|acupoints combination 2|
48320167|NCT02594397|OTHER|sham acupoints combination|
48320168|NCT04693442|OTHER|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling \& scar assessment questionnaires
48320169|NCT03214692|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
48320170|NCT05855317|OTHER|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
48320171|NCT00370695|DEVICE|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
48320172|NCT02481336|OTHER|Questionnaires|EORTC CIPN20 and EQ-5D-3L
48320173|NCT02481336|PROCEDURE|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
48320174|NCT02481336|GENETIC|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
48320175|NCT01370057|DEVICE|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
48646066|NCT04722679|DRUG|Non-VKA Oral Anticoagulants (NOAC)|Follow clinical practice.
48320176|NCT01670409|RADIATION|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
48320177|NCT01670409|DRUG|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
48320178|NCT06017947|PROCEDURE|Music care|20 min music listening during transportation to hospital
48320179|NCT03374384|OTHER|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
48320180|NCT03209635|DIETARY_SUPPLEMENT|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
48320181|NCT03209635|DIETARY_SUPPLEMENT|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
48320182|NCT03191669|OTHER|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
48320183|NCT06310577|DEVICE|Leak-free bronchoscope adapter|Bronchoscopy using both a standard adapter and a leak-free adapter will be performed.
48320184|NCT00994656|DEVICE|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
48320185|NCT05766839|DRUG|Patiromer|Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split
48320186|NCT01434381|BIOLOGICAL|Pfs25-EPA/Alhydrogel|
48320187|NCT02054143|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
48320188|NCT02054143|DRUG|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
48320189|NCT02941913|DRUG|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
48320190|NCT02765633|DRUG|Cangrelor|
48320191|NCT01884857|DRUG|Metoprolol Succinate ER Tablets 50 mg|1\* 50 mg tablet once a day
48320192|NCT01884857|DRUG|'TOPROL-XL®' ER Tablets 50 mg|1 \* 50 mg tablet per day
48320193|NCT04791683|OTHER|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
48320194|NCT01461512|DRUG|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
48320195|NCT01461512|DRUG|Placebo administration|NaCl isotonic
48320196|NCT06466928|PROCEDURE|Total pancreatectomy|Surgical removal of the entire pancreas
48320197|NCT02236949|BEHAVIORAL|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
48320198|NCT00100412|DRUG|Graded dobutamine infusions|
48320199|NCT00100412|DRUG|Graded phenylephrine injections|
47968462|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
48320200|NCT00100412|BEHAVIORAL|Psychosocial challenge involving socioevaluative public speaking|
48320201|NCT02156960|DRUG|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
48320202|NCT02156960|DRUG|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
48320203|NCT02156960|DRUG|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
48320204|NCT02303951|DRUG|Vemurafenib|Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
48320205|NCT02303951|DRUG|Cobimetinib|Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
48320206|NCT02303951|DRUG|Atezolizumab|Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
48320207|NCT03017482|DEVICE|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~* Questionnaires about the utility and impact of the device~* Use of the device in children younger than the current FDA approval range"
48320208|NCT00278772|DRUG|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
48320209|NCT00278772|OTHER|Placebo|oral dose, placebo
48320210|NCT02547116|DRUG|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
48320211|NCT03816410|PROCEDURE|LAA amputation|complete surgical amputation of the left atrial appendage
48320212|NCT00473837|DRUG|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
48320213|NCT00473837|DRUG|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
48320214|NCT01945424|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
48320215|NCT05388591|OTHER|Musicotherapy|Music listening with the application Music Care (style of music chosen by the patient) during wound suturing
47968463|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
48320216|NCT01814488|PROCEDURE|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if \<40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
48320217|NCT04912570|PROCEDURE|Manual Thrombus Aspiration|Manual thrombus aspiration using one of the FDA approved aspirators will be done.
48320218|NCT04912570|PROCEDURE|Standard PCI|Standard PCI according to the most recent guidelines
48320219|NCT01274741|BEHAVIORAL|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
48320220|NCT01274741|BEHAVIORAL|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
48320221|NCT02979301|DRUG|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
48320222|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using ND:YAG laser|A free running, pulsed, 1064 nm wavelength-specific ND:YAG laser will be used. A thin 300 μm laser fiber optic will be placed parallel to the root surface, allows easy access into deep periodontal pockets. The initial pass with the laser is known as Laser Troughing, and it is done with a micro-short duration pulse, with a 4.0 watt power, 150 μs duration in pulsed mode and 20Hz frequency. Ultrasonic scaler will be then used to remove calculus. The second pass is carried out with 650 μs pulse duration, 10-30 seconds for each tooth, 4.0 watt power and 20HZ frequency, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed. Relieving the occlusion is the last step of the LANAP protocol.
48320223|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using diode laser|"Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm attached with a power average set at 0.5-1.5 watt will be used.~The first pass laser troughing is done using a thin flexible fiber-optic cable 300 μm placed parallel to the root surface, attached with a power average set at 0.5-1 watt, in continuous mode. Ultrasonic scaler will be then used to remove calculus which present on the root surface. The second pass is carried out with 1-1.5 watt power in continuous mode, 10-30 seconds for each tooth, and, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed in order to enhance the healing"
48320224|NCT06358937|PROCEDURE|Scaling and Root Planing using ultrasonic and curettes|Scaling and root planing (SRP) using ultrasonic device at a moderate setting and with the appropriate tips and curettes will be also used where indicated and time spent in SRP on each tooth will not be restricted.
48320225|NCT02918409|DRUG|Colistin|
48320226|NCT02918409|DRUG|Tobramycin|
48320227|NCT06512623|DEVICE|Hemoadsoprtion|The hemoadsorption treatment will be performed during the entire duration of the CPB. Blood flow within the cartridge will be measured.
48320228|NCT05798689|COMBINATION_PRODUCT|Probiotic administration and gluten|Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
48486777|NCT03074396|DEVICE|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
48486778|NCT03074396|DEVICE|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
48486779|NCT05826132|OTHER|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
47968464|NCT01455259|BIOLOGICAL|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
47968465|NCT02454998|OTHER|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
48486780|NCT05826132|OTHER|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
48486781|NCT01920542|DRUG|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
48486782|NCT01920542|DRUG|no dexmedetomidine|no administration of dexmedetomidine on control group
47968466|NCT04240769|DEVICE|Total or Partial Knee Arthroplasty|Reconstruction of part or all of the native articulation at the knee joint via implant.
47968467|NCT04976751|DRUG|Percutaneous electrical nerve stimulation treatment|Using the percutaneous electrical nerve stimulation instrument to different points of the body
47968468|NCT04826991|DEVICE|Active UV Device|Active water treatment system
47968469|NCT04826991|DEVICE|Inactive UV Device|Inactive water treatment system
47968470|NCT00222794|DRUG|Atomoxetine (Strattera)|
47968471|NCT03056885|OTHER|Conventional One-Lung Ventilation|Vt 10 ml/kg
47968472|NCT03056885|OTHER|Protective One-lung ventilation|Vt 5 ml/kg
48320229|NCT05798689|COMBINATION_PRODUCT|Placebo administration and gluten|The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
48320230|NCT03205826|OTHER|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
48320231|NCT01890070|DIETARY_SUPPLEMENT|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
48320232|NCT01890070|DIETARY_SUPPLEMENT|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
48320233|NCT01890070|DIETARY_SUPPLEMENT|Red wine|Italian Organic Red Wine
48320234|NCT01890070|DIETARY_SUPPLEMENT|Olive Oil|Italian Organic Olive Oil
48320235|NCT01890070|DIETARY_SUPPLEMENT|Wild mixed greens|Italian organic wild mixed greens
48320236|NCT01890070|DIETARY_SUPPLEMENT|Chestnut|Italian Organic Chestnut
48320237|NCT01890070|OTHER|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
48320238|NCT05506553|DEVICE|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
48320239|NCT05506553|DEVICE|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
48320240|NCT05164406|PROCEDURE|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
48320241|NCT01841957|PROCEDURE|ISBCS|same-day cataract surgery
48320242|NCT01841957|PROCEDURE|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
48320243|NCT01134757|BIOLOGICAL|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
48320244|NCT05646446|BEHAVIORAL|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
48320245|NCT03550131|BEHAVIORAL|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
48320246|NCT03550131|BEHAVIORAL|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
48320247|NCT05127070|DEVICE|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
48320248|NCT06126874|OTHER|Patient Education|Individuals in both study groups will be provided with patient education through verbal and visual presentations. In the content of patient education; information about the importance of the research topic and the content of the study through anatomical models and short animations, lifestyle recommendations for urinary incontinence symptoms (avoiding bladder irritants such as alcohol, caffeine, tea, spicy foods, acidic foods and chocolate, regulating water / fluid consumption, recommendations for attention to bowel regularity and increasing physical activity levels) and recommendations for sexual functioning (coitus positions that facilitate erection, recommendations for reshaping the sexual schema, recommendations for the physical dimension of sexual health) will be given.
47968473|NCT02809937|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
48320249|NCT06126874|OTHER|Pelvic Floor Muscle Training|In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program. In the first 2 weeks of PFMT, individuals will perform 3 sessions of exercise per day. In each 2-week control, the number of sessions will be increased by 1 session and PFMT application will be completed with 5 sessions per day in the study.
48320250|NCT06126874|OTHER|Aerobic Exercise Training|Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).The intensity of aerobic exercise training will be planned according to the Maximal Heart Rate (MHR) method and Modified Borg Scale (MBS). In the first 2 weeks in the clinic, training will be started with 50 min (+10 min warm-up and cool-down) at 60% of the MHR, the exercise intensity will be increased by 5% every 2 weeks, and the program will be terminated by providing exercise training at 85% of the MHR in the 10th-12th week. Patients will be asked to adjust the intensity of aerobic exercise outside the clinic to correspond to the 12-14 (slightly difficult) degree of perceived fatigue according to the MBS.
48340045|NCT02421146|DEVICE|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
47968474|NCT02809937|DRUG|placebo|normal saline infusion
48320251|NCT06126874|OTHER|Resistance Exercise Training|Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training. These exercises are leg press, leg extension, leg curl, squat, seated row, lateral pull down, biceps curl, triceps extension, dumble fly, lateral raises, bench press and abdominal crunch. Exercises will be performed with free weights (dumbbells), resistance bands (therabands) or body weight.
48320252|NCT05512208|DRUG|Avutometinib (VS-6766) + defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle."
48320253|NCT06011330|DRUG|Fruquintinib combined with anti-PD-1 antibodies|Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
48320254|NCT04263948|DEVICE|Picado system internet platform and connected objects|The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
48320255|NCT00057460|DRUG|Talampanel|
48320256|NCT03939351|DIAGNOSTIC_TEST|OCT-angiography and SD-OCT|Performing an OCT-angiography and SD-OCT examination
48320257|NCT02781454|DRUG|Mexiletine|
48320258|NCT02781454|DRUG|Placebo|
48320259|NCT04045236|OTHER|Registry|Data collection
48320260|NCT05160558|DRUG|BIIB132|Administered as specified in the treatment arm
48320261|NCT05160558|DRUG|BIIB132-Matching Placebo|Administered as specified in the treatment arm
47968475|NCT00159120|OTHER|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
48320262|NCT03488251|DRUG|MT-3724|MT-3724 will be administered.
48320263|NCT03488251|DRUG|Gemcitabine|Gemcitabine will be administered.
48320264|NCT03488251|DRUG|Oxaliplatin|Oxaliplatin will be administered.
48320265|NCT04314596|OTHER|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
48320266|NCT04314596|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
47968476|NCT02223832|DRUG|ACT-128800|
47968477|NCT02952781|DEVICE|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
47968478|NCT01897454|DRUG|Fluorouracil|Given IV
47968479|NCT01897454|DRUG|Gemcitabine Hydrochloride|Given IV
47968480|NCT01897454|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48320267|NCT04807036|DEVICE|Hypotension Prediction Index|HemoSphere Clinical Platform with Acumen Hypotension Prediction Index Feature
48320268|NCT00446485|DRUG|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
48320269|NCT00446485|DRUG|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
48320270|NCT00446485|DRUG|placebo|placebo during 6 months
48320271|NCT01831206|PROCEDURE|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
48320272|NCT03106506|PROCEDURE|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
48320273|NCT01305213|BIOLOGICAL|Bevacizumab|Given IV
48320274|NCT01305213|DRUG|Fosbretabulin Tromethamine|Given IV
48320275|NCT01305213|OTHER|Laboratory Biomarker Analysis|Correlative studies
48320276|NCT00656734|BIOLOGICAL|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
48320277|NCT04373239|PROCEDURE|Assisted Reproductive Technology|Assisted reproductive technology includes IVF and IVF+ICSI.
48320278|NCT02685891|OTHER|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
48320279|NCT02685891|OTHER|sham condition|in the sham condition, no tones will be played
48320280|NCT05617404|DIAGNOSTIC_TEST|CT scan|Polytrauma patients with thoracic CT-scan
48320281|NCT00165841|DRUG|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
48320282|NCT00901147|DRUG|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
48320283|NCT03338114|DRUG|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
48320284|NCT03312712|RADIATION|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
48320285|NCT03312712|OTHER|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
48320286|NCT03312712|OTHER|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
48320287|NCT03312712|DIAGNOSTIC_TEST|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
48320288|NCT04619264|DRUG|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
48320289|NCT04619264|PROCEDURE|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
48320290|NCT03786237|DRUG|Rigosertib Oral Capsules / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
48320291|NCT02207478|PROCEDURE|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
48320292|NCT02207478|PROCEDURE|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
48320293|NCT00503490|DRUG|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
48320294|NCT00503490|DRUG|placebo|BID
48320295|NCT03085355|PROCEDURE|Exercises and PNE|Exercise for stretching and strength for neck muscles and pain neuroscience education
48320296|NCT03085355|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
48320297|NCT05212155|BEHAVIORAL|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
48340046|NCT05359445|BIOLOGICAL|IMA401 (Phase Ia)|Intravenous infusions in escalating dose levels
48340047|NCT05359445|BIOLOGICAL|IMA401 (Phase Ib)|Treatment at recommended dose for extension (RDE)
48340048|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #1)|Single dose administered intranasally on Day 1
48486783|NCT01272115|BEHAVIORAL|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
48486784|NCT02988869|DRUG|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
48486785|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
48486786|NCT02988869|DRUG|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
48486787|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
48320298|NCT04981574|OTHER|Massage and stretching on neck area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
48320299|NCT04981574|OTHER|Massage and stretching on low back area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
48320300|NCT02749877|BEHAVIORAL|Working Memory Training|(Training Details already described above)
48320301|NCT02749877|BEHAVIORAL|Physical Training|(Training Details already described above)
48320302|NCT00848250|DRUG|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
48320303|NCT00848250|OTHER|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
48320304|NCT05693090|DRUG|Tipifarnib|Oral administration
48320305|NCT05693090|DRUG|Osimertinib|Oral administration
48320306|NCT04751903|BEHAVIORAL|oral motor stimulation|Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions.It took 15 minutes to apply the OMS by lightly touching their cheeks, lips, gums, and tongue with fingertips for the first 12 minutes, followed by letting the infant suck on a pacifier for the remaining 3 minutes. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants.
48320307|NCT05294211|DEVICE|M•care™ System|The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
48320308|NCT05294211|DEVICE|Cardiotocography (CTG)|A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
48320309|NCT00707655|DRUG|Zalutumumab|Eight weekly infusions
48320310|NCT04093817|DEVICE|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
48486788|NCT01208428|BEHAVIORAL|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
47968481|NCT01897454|DRUG|Irinotecan Hydrochloride|Given IV
48646067|NCT03859856|OTHER|hormone panel and ultrasonography|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
48320311|NCT02695524|OTHER|Scapula-focused exercises|
48320312|NCT02695524|OTHER|Motor control exercises|
48320313|NCT00778986|DEVICE|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
48320314|NCT04528797|DRUG|Levothyroxine|
48320315|NCT04528797|DRUG|Methylprednisolone|
48320316|NCT05372341|OTHER|descriptive|posotcovid patients will be elective surgery postoperative outcomes
48320317|NCT05539105|PROCEDURE|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
47968482|NCT01897454|DRUG|Leucovorin Calcium|Given IV
47968483|NCT01897454|DRUG|Oxaliplatin|Given IV
47968484|NCT02114216|PROCEDURE|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
48646068|NCT01485367|DRUG|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
48646069|NCT00395447|PROCEDURE|Straight-forward Device Replacement|
48646070|NCT00395447|PROCEDURE|Device Replacement with Upgrade|
48646071|NCT01091883|DEVICE|Exablate treatment|MR Guided Focused Ultrasound
48646072|NCT01091883|RADIATION|Radiation|External Beam Radiation
48646073|NCT01345942|DRUG|RO5428029|Single oral dose
48646074|NCT03485885|DIETARY_SUPPLEMENT|Standardized maqui berry extract enriched in anthocyanins|Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
48646075|NCT05101161|BEHAVIORAL|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
48646076|NCT02430714|DRUG|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
48646077|NCT03399747|DRUG|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
48646078|NCT01189721|DRUG|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
48646079|NCT01704989|PROCEDURE|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
48646080|NCT01704989|DRUG|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
48646081|NCT00601185|PROCEDURE|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
48646082|NCT02451007|DRUG|lurbinectedin (PM01183)|
48646083|NCT05506631|PROCEDURE|Outpatient Foley balloon placement|Cervical ripening with balloon placement in the outpatient setting
48646084|NCT05506631|PROCEDURE|Inpatient Foley Balloon placement|Cervical ripening with balloon placement in the inpatient setting
48320318|NCT05539105|PROCEDURE|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
48486789|NCT01208428|BEHAVIORAL|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
48486790|NCT03865537|PROCEDURE|Cold snare EMR|Participants will have their large polyp removed without electrocautery
48646085|NCT00002431|DRUG|Chlorhexidine gluconate|
48646086|NCT02570425|DEVICE|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
48646087|NCT02570425|DEVICE|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
48646088|NCT00866775|DRUG|Eslicarbazepine acetate|1600 mg QD
48646089|NCT00866775|DRUG|Eslicarbazepine acetate|1200 mg QD
48646090|NCT03258229|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
48646091|NCT03258229|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 weeks
48646092|NCT04482621|DRUG|Decitabine|"Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.~Decitabine will be administered via Intravenous Administration 10/mg/m\^2/day Dosage: 10mg/m\^2/day IV day x 5 days (1 cycle only)"
48486791|NCT03865537|PROCEDURE|Hot snare EMR|Participants will have their large polyp removed with electrocautery
48486792|NCT03865537|PROCEDURE|Eleview injection|Participants will have their polyp submucosally injected with Eleview
48486793|NCT03865537|PROCEDURE|Placebo injection|Participants will have their polyp submucosally injected with placebo
48486794|NCT01059721|PROCEDURE|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
48486795|NCT03589248|DIAGNOSTIC_TEST|GIF score|assessment by GIF score
48486796|NCT03589248|DIAGNOSTIC_TEST|US score|assessment by ultrasonography score
48646093|NCT04482621|OTHER|Placebo Saline|Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m\^2/day IV day x 5 days (1 cycle only)
48646094|NCT00692237|DRUG|Sildenafil|100 mg daily (3 capsules/day)
48646095|NCT00692237|DRUG|Placebo|Placebo 100 mg (3 capsules/day)
48486797|NCT02239198|OTHER|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
48486798|NCT00214331|DRUG|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
48486799|NCT00214331|DRUG|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
48486800|NCT00214331|DRUG|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
48486801|NCT00006108|BIOLOGICAL|trastuzumab|
48486802|NCT00006108|DRUG|capecitabine|
48486803|NCT00006108|DRUG|paclitaxel|
48486804|NCT01020799|DRUG|AZD7268|15 mg, oral, twice daily (BID)
48486805|NCT01020799|DRUG|Escitalopram|20 mg, oral, once daily (QD)
48486806|NCT01020799|DRUG|Placebo capsules|Placebo capsules to match AZD7268
48486807|NCT01020799|DRUG|Placebo tablets|Placebo tablets to match encapsulated escitalopram
48486808|NCT06237387|OTHER|Periodontal examination|Determining the patient's oral hygiene status and the severity of gingivitis. For this purpose, the non-invasive Löe-Silness plaque and gingival index system will be used.
48486809|NCT03996551|BEHAVIORAL|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
48486810|NCT05540821|DIAGNOSTIC_TEST|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
48486811|NCT01838928|DRUG|Bupivacaine|
48486812|NCT06533462|DIETARY_SUPPLEMENT|Multiallergen powder|OIT multiallergen powder.
48486813|NCT00049842|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
48486814|NCT02947724|DRUG|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
48486815|NCT05336110|OTHER|Postponing surgery|Postponing surgery for patients with Sars-cov-2 infection
48486816|NCT05271136|OTHER|Anti-aging Serum|Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
48486817|NCT05271136|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after serum
48486818|NCT05271136|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants
48486819|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
48486820|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
48646096|NCT06105645|DEVICE|DIXI Medical Microdeep® Micro- Macro Depth electrodes|It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.
48646097|NCT06105645|DEVICE|Standard electrodes|Standard electrodes used usually during the SEEG
48646098|NCT01046669|DEVICE|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
48646099|NCT01046669|OTHER|Standard medical care for septic shock|Standard medical care for septic shock
48646100|NCT02105480|DEVICE|Computer aided auscultation (CAA)|
48646101|NCT00417287|DRUG|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
48486821|NCT00513552|DRUG|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
48486822|NCT03064321|BEHAVIORAL|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
48486823|NCT03064321|OTHER|Information Control|Information on websites that are general health promoting
48486824|NCT02447159|BEHAVIORAL|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
48486825|NCT05028231|PROCEDURE|Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
48486826|NCT01784354|OTHER|Acupressure|
48486827|NCT01784354|OTHER|Acupressure dilatation|
48486828|NCT01784354|BEHAVIORAL|education|
48486829|NCT04714151|DRUG|K-877 ER 0.2 mg/day (once daily)|K-877 ER 0.2 mg tablet
48486830|NCT04714151|DRUG|K-877 ER 0.4 mg/day (once daily)|K-877 ER 0.4 mg tablet
48486831|NCT04714151|DRUG|K-877 IR 0.2 mg/day (twice daily)|K-877 IR 0.1 mg tablet
48320319|NCT05539105|PROCEDURE|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
48320320|NCT01763021|DRUG|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
48320321|NCT01763021|DRUG|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
48320322|NCT00104078|DRUG|MYO-029|
48320323|NCT03337139|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
48320324|NCT03337139|BEHAVIORAL|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
48320325|NCT03337139|BEHAVIORAL|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
48320326|NCT02570529|DRUG|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
48320327|NCT02570529|DRUG|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
48320328|NCT00831441|DRUG|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
48320329|NCT00831441|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
48320330|NCT02366754|DEVICE|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
48320331|NCT02366754|DEVICE|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
48320332|NCT04627116|DRUG|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
48320333|NCT02694627|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
48320334|NCT04148599|DRUG|dexmedetomidine infusion|a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
48320335|NCT04148599|DRUG|lidocaine infusion|a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
48320336|NCT04148599|DRUG|Placebos|50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
48320337|NCT00804739|OTHER|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
48320338|NCT02049801|DRUG|MEK inhibitor MEK162|Given PO
48320339|NCT02049801|DRUG|idarubicin|Given IV
48320340|NCT02049801|DRUG|cytarabine|Given IV
48320341|NCT02049801|OTHER|pharmacological study|Correlative studies
48320342|NCT02049801|OTHER|laboratory biomarker analysis|Correlative studies
48486832|NCT04008693|DIETARY_SUPPLEMENT|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
48486833|NCT04008693|OTHER|Placebo|800 mg of maltodextrin (four capsules)
48486834|NCT03859128|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 )|Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
48486835|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
48486836|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
48646102|NCT01292265|BIOLOGICAL|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
48320343|NCT01477372|BEHAVIORAL|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
48320344|NCT00438399|DRUG|C. propionate - Corticosteroid 1|Twice daily application
48320345|NCT00438399|DRUG|C. propionate- Corticosteroid 2|Twice daily application
48320346|NCT00438399|DRUG|C. propionate -Corticosteroid 3|Twice daily application
48320347|NCT00438399|DRUG|Corticosteroid 1- C. propionate|Twice daily application
48320348|NCT00438399|DRUG|Corticosteroid 2 - C. propionate|Twice daily application
48320349|NCT00438399|DRUG|Corticosteroid 3 - C. propionate|Twice daily application
48320350|NCT04881201|PROCEDURE|blood sample|blood sample
48320351|NCT02323321|DEVICE|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
48320352|NCT02512744|PROCEDURE|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
48320353|NCT02512744|DEVICE|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
47968485|NCT03845985|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
48320354|NCT01536002|DRUG|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
48320355|NCT04214730|COMBINATION_PRODUCT|NK combined with Chemotherapy|Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months
48320356|NCT04214730|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
48320357|NCT01870219|DRUG|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
48320358|NCT01870219|DRUG|Ketamine|ketamine was given to 1mg/kg ıv bolus
48320359|NCT05246176|DEVICE|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
48320360|NCT06179615|OTHER|surface hardness test for denture teeth|surface hardness test of denture teeth at insertion then after 6 months of use
48320361|NCT06179615|OTHER|wear resistance of denture teeth measurement|2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
48320362|NCT00364325|OTHER|Acute Decompensated Heart Failure|Standard of Care
48320363|NCT00675103|DRUG|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
48486837|NCT00906373|DRUG|Sorafenib|400 milligrams (mg) twice per day orally
48486838|NCT04108559|PROCEDURE|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
48646103|NCT04831619|DRUG|PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)|A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
48646104|NCT03087149|DIETARY_SUPPLEMENT|monitored vit D supplementation|The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born \<30 GA, at 8 week of age for infants born \<26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
48320364|NCT05877651|BIOLOGICAL|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
48320365|NCT01467648|DRUG|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
48320366|NCT01467648|DRUG|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
48320367|NCT03225716|DRUG|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
48320368|NCT03225716|DRUG|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
48320369|NCT00755846|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
48320370|NCT00755846|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
48320371|NCT00755846|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
48320372|NCT00755846|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
47968486|NCT03963037|OTHER|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
47968487|NCT02160574|DRUG|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
47968488|NCT02160574|DRUG|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
47968489|NCT02160574|DRUG|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
47968490|NCT02160574|OTHER|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
47968491|NCT04700761|PROCEDURE|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
47968492|NCT04700761|PROCEDURE|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
47968493|NCT03799081|PROCEDURE|Fetoscopy|Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
47968494|NCT02335866|PROCEDURE|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
47968495|NCT02335866|PROCEDURE|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
47968496|NCT05304273|DRUG|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
47968497|NCT05304273|DRUG|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
47968498|NCT02781831|PROCEDURE|Standard rehab|Standard hospital based rehabilitation for patients with stroke
48320373|NCT00755846|DRUG|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
48646105|NCT03087149|DIETARY_SUPPLEMENT|standard vit D supplementation|The vitamin D supplementation dose is 500IU from 7th day of age.
48646106|NCT06517511|DRUG|Selinexor Oral Tablet [Xpovio]|Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.
48646107|NCT06517511|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
48646108|NCT01744366|DRUG|Degarelix|
48646109|NCT01744366|DRUG|Goserelin|
48646110|NCT06199830|DIAGNOSTIC_TEST|positive bronchial provocation test|Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.
47968499|NCT02781831|DEVICE|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
47968500|NCT04260152|DEVICE|Geistlich Fibro-Gide|Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
47968501|NCT04260152|PROCEDURE|Connective Tissue Graft (CTG|Surgical recession root coverage with coronally advanced flap in combination with CTG
47968502|NCT01755078|DRUG|Sevelamer HCl|Non-metal phosphate binder
47968503|NCT01755078|DRUG|Calcium-based phosphate binder|
47968504|NCT02664844|BEHAVIORAL|Physical activity|
47968505|NCT05827510|DEVICE|BTL-585F|BTL-585F device with BTL-585-4 applicator
47968506|NCT06486376|BEHAVIORAL|Water, Sanitation and Hygiene Education Against Diarrhoea, Undernutrition and Pneumonia|Intervention components include teacher training, stepdown training of teachers to children and distribution of IEC materials.
47968507|NCT06497413|DEVICE|Transcranial Photobiomodulation|The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.
47968508|NCT06497413|DEVICE|Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered|In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.
47968509|NCT02774525|BEHAVIORAL|Reinforcement for drug & alcohol abstinence|
47968510|NCT02774525|BEHAVIORAL|Parenting intervention|
47968511|NCT02774525|BEHAVIORAL|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug \& alcohol screening plus support for personal goal setting
47968512|NCT03919799|DRUG|Belumosudil (KD025)|ROCK-2 Inhibitor
47968513|NCT03919799|DRUG|Placebo|Inactive substance
47968514|NCT02901314|OTHER|on-demand audio messages of heart failure education themes|
47968515|NCT02716454|PROCEDURE|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
47968516|NCT05317182|OTHER|Occlusal Splints Analogic-Analogic|Take a conventional impression to the patient and conventional fabrication of the splint.
47968517|NCT05317182|OTHER|Occlusal Splints Analogic-Digital|Take a conventional impression to the patient and digital fabrication of the splint.
48320374|NCT00755846|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
48320375|NCT05024877|DRUG|Hetrombopag|Hetrombopag would be given started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
48320376|NCT05024877|DRUG|Stanozolol Tablets|Stanozolol would be given 2mg tid.
48320377|NCT01070602|PROCEDURE|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
48320378|NCT04109235|OTHER|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
48320379|NCT04109235|OTHER|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
48486839|NCT04108559|PROCEDURE|Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
48646111|NCT06164600|DIETARY_SUPPLEMENT|Bovine colostrum|A powdered form of the first 6 hours bovine colostrum \[65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M\]
48646112|NCT06164600|DRUG|Placebo|Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
47968518|NCT05317182|OTHER|Occlusal Splints Digital-Digital|Take a digital impression to the patient and digital fabrication of the splint.
48646113|NCT01272219|DRUG|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
48646114|NCT01272219|DRUG|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
48646115|NCT01272219|DRUG|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
48646116|NCT01272219|DRUG|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
47968519|NCT03903068|DEVICE|NEXALIN ADI AC stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
48320380|NCT02024191|DIETARY_SUPPLEMENT|Glutamine|
48320381|NCT04561245|DRUG|ALT-801|Injected subcutaneously (SC)
48320382|NCT04561245|OTHER|Placebo|Injected subcutaneously (SC)
48320383|NCT01032993|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
48320384|NCT01032993|OTHER|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
48320385|NCT02193256|DRUG|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
48486840|NCT04108559|OTHER|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
48486841|NCT05196360|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
48486842|NCT03656874|OTHER|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
48486843|NCT02594371|DRUG|Oraxol|
48486844|NCT02594371|DRUG|IV paclitaxel|
48486845|NCT03881345|DRUG|Anticoagulants|anticoagulation according to the main diagnosis
48486846|NCT03881345|PROCEDURE|Open surgery|removal of blood clots with open surgery
48646117|NCT04768478|DRUG|CBD|25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
48646118|NCT04768478|DRUG|Placebo|Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
48646119|NCT02224079|DRUG|BIIB 722 CL|
48646120|NCT02224079|DRUG|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
48320386|NCT02193256|DRUG|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
48320387|NCT02193256|DRUG|Placebo|
48646121|NCT05327543|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga focuses on the correct alignment of the body while practicing the physical exercises of yoga. Props are used to support the body in finding the right alignment. Relaxation is also part of this intervention. Participiants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
48320388|NCT00797797|DRUG|No Treatment Added|No added treatment
47968520|NCT03903068|DEVICE|Pseudo-stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
47968521|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
47968522|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
48320389|NCT00797797|DRUG|Milnacipran Added|Milnacipran 100 mg/d added
48320390|NCT00946881|DRUG|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
48320391|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
48320392|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
48320393|NCT06179030|DIAGNOSTIC_TEST|serum samples|The serum samples were taken from the patients at the 3rd month (switch point)
47968523|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
47968524|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
48320394|NCT06179030|DRUG|dexamethasone implant versus ranibizumab|dexamethasone implant versus ranibizumab will be studied as a secondary outcome
47968525|NCT02478632|DRUG|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
47968526|NCT04175483|OTHER|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
47968527|NCT01749137|DRUG|Setmelanotide|Daily subcutaneous infusion
47968528|NCT01749137|DRUG|Placebo|Daily subcutaneous infusion
47968529|NCT05468827|PROCEDURE|lymphatic mapping with indocyanine green|subserosal injection of indocyanine green near the primary tumour with subsequent assessment of the dye spread along lymphatics
47968530|NCT03613545|PROCEDURE|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
47968531|NCT03613545|PROCEDURE|Infusion of sham|Infusion of sham
47968532|NCT03613545|DRUG|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
47968533|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
48320395|NCT01192750|OTHER|immunohistochemistry staining method|
48320396|NCT01192750|OTHER|laboratory biomarker analysis|
47968534|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
48320397|NCT01192750|OTHER|medical chart review|
48320398|NCT04504370|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
48320399|NCT04504370|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
48320400|NCT04831515|DEVICE|Lens A|daily disposable soft contact lens - test lens
48320401|NCT04831515|DEVICE|Lens B|daily disposable soft contact lens - control lens
48486847|NCT03881345|PROCEDURE|Thrombolysis|removal of blood clots with thrombolysis
47968535|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
48320402|NCT01905150|DRUG|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
48320403|NCT01905150|DRUG|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
48320404|NCT01905150|DIETARY_SUPPLEMENT|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
48320405|NCT04436874|DEVICE|endoscopy|transplant infusion of feces from healthy donors into affected subjects
48320406|NCT03116373|OTHER|mandible fixation|Intubation device will be fixed on mandible
48320407|NCT03116373|OTHER|Maxilla fixation|Intubation device will be fixed on maxilla
48320408|NCT02542917|DEVICE|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
48320409|NCT04215523|DRUG|Dapagliflozin|Dapagliflozin dispensing claim for any dose is exposure
48320410|NCT04215523|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim for any dose is reference
48320411|NCT02418533|DRUG|menotropin|Menopur is used for controlled ovarian stimulation (COH)
48486848|NCT03881345|PROCEDURE|Venous stenting|elimination of vein obstruction by stenting
48320412|NCT02418533|DRUG|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
47968536|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
47968537|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
48117189|NCT05452759|DEVICE|AIRVOTM2 device for Severe pneumonia patients with artificial airway|Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
48320413|NCT05116514|OTHER|Case management|"Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months"
48320414|NCT01935362|DIETARY_SUPPLEMENT|Citrus supplement|
48320415|NCT01935362|DIETARY_SUPPLEMENT|Placebo|
48646122|NCT05327543|BEHAVIORAL|Meditative Yoga|Meditative Yoga in the context of this study means practicing the physical exercises of yoga as well as meditation. Additionally, each week one of the yamas/niyamas, which are ethical principles to live by in the Yoga philosophy, will be presented at the beginning of each class and will form the theme of the class. Participants receive 1x90 min guided yoga class per week for 8 weeks and are encouraged to continue their practice at home daily for at least 30 minutes.
48320416|NCT03162497|DRUG|Azithromycin|Azithromycin 15mg/g eyedrops
48320417|NCT03162497|DRUG|Doxycycline|Doxycycline 100 mg per os
48320418|NCT04417504|OTHER|MobFood breakfast kit|Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood_PPS4.
48320419|NCT04417504|OTHER|Control isocaloric breakfast|White bread, butter and milk.
48320420|NCT00285103|DRUG|SPC2996|
48320421|NCT02017236|DRUG|Volitinib|600mg Volitinib ,single dose,oral
48320422|NCT02225444|OTHER|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
48646123|NCT05846919|PROCEDURE|face-mask preoxygenation|face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
48320423|NCT01908517|BEHAVIORAL|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
48486849|NCT03347760|DRUG|DOTATOC-68Ga PET initial|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
48646124|NCT05846919|PROCEDURE|HFNOC preoxygenation|HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
48320424|NCT03630484|OTHER|Expiratory Rib Cage Compression|Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
48320425|NCT03630484|OTHER|Compression + Ventilator Hyperinflation|Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
48320426|NCT03811171|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
48486850|NCT03347760|DRUG|DOTATOC-68Ga PET at 6 months|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
48486851|NCT03347760|BIOLOGICAL|blood sample|blood tests will be carried out during the control visit to ensure that biological parameters are normalized
48646125|NCT05846919|PROCEDURE|HFNOC + face-mask preoxygenation|HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
48340049|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #2)|Single dose administered intranasally on Day 1
48340050|NCT03696446|BEHAVIORAL|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
48340051|NCT03696446|BEHAVIORAL|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
48340052|NCT01855425|RADIATION|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
48486852|NCT02356991|DRUG|Famitinib|
48486853|NCT02356991|DRUG|Placebo|
48486854|NCT05369078|DRUG|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
48486855|NCT05369078|DRUG|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
48486856|NCT06161142|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(2-4 weeks after the 1st measurement)
48646126|NCT00072995|BEHAVIORAL|Four Diets Differing in Macronutrient Composition|
48340053|NCT05490498|OTHER|Collection of breast milk|Collection of breast milk through a sterilized breastfeeding device. Once the collection is completed, the milk will be transferred to a sterile jar provided in a dedicated survey package for transport to the laboratory.
47968538|NCT04843293|BEHAVIORAL|Olfactory stimulation|Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
47968539|NCT01953263|OTHER|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
47968540|NCT06298383|DRUG|Trypsin, Bromelain and Rutoside|Flamogen is a combination of trypsin 48 mgs, bromelain 90mg and rutoside 100 mg in one tablet that provides an anti inflammatory, anti edematous activity. each patient will receive a single dose of 2 tablets one hour before treatment.
47968541|NCT06298383|DRUG|Diclofenac Potassium|Non-steroidal anti inflammatory drug. cataflam is known for its potent anti inflammatory and analgesic properties. each patient will receive one tablet of cataflam 50 mg 1 hour before treatment.
47968542|NCT06298383|DRUG|Prednisolone Oral Tablet|Steroids are potent anti inflammatory drugs, patients are going to receive one tablet of 30 mg solupred one hour before treatment
47968543|NCT06298383|OTHER|Placebo|A tablet of Compacted powdered milk
47968544|NCT04379024|DRUG|DUAVEE 0.45Mg-20Mg Tablet|One capsule daily for 6 months (+/- 1 month)
47968545|NCT00394368|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|
47968546|NCT00394368|DRUG|fluticasone propionate plus salmeterol xinafoate combination|
47968547|NCT06485765|OTHER|Diet planning|Healthy eating planning
47968548|NCT03167411|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
47968549|NCT03167411|DRUG|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
47968550|NCT01756898|DRUG|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
47968551|NCT01756898|DRUG|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
47968552|NCT01756898|DRUG|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
48486857|NCT06161142|DIAGNOSTIC_TEST|Extended laboratory diagnostics|Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
48486858|NCT06161142|DIAGNOSTIC_TEST|Symptom and clinical findings checklist for hypophosphatasia|Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
47968553|NCT01756898|DRUG|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
47968554|NCT06045884|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
48486859|NCT06161142|DIAGNOSTIC_TEST|SF-36|Quality of life questionnaire
47968555|NCT06045884|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
47968556|NCT06045884|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
47968557|NCT00986557|BIOLOGICAL|adoptive immunotherapy|
47968558|NCT00986557|BIOLOGICAL|alemtuzumab|
47968559|NCT00986557|BIOLOGICAL|in vitro-treated peripheral blood lymphocyte therapy|
47968560|NCT00986557|DRUG|foscarnet sodium|
47968561|NCT00986557|DRUG|ganciclovir|
47968562|NCT00986557|GENETIC|polymerase chain reaction|
47968563|NCT00986557|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
47968564|NCT00986557|PROCEDURE|infection prophylaxis and management|
47968565|NCT00986557|PROCEDURE|peripheral blood stem cell transplantation|
47968566|NCT00986557|PROCEDURE|standard follow-up care|
47968567|NCT00986557|RADIATION|radiation therapy|
47968568|NCT00119106|DRUG|Tenofovir disoproxil|Antiretroviral
47968569|NCT00119106|DRUG|Placebo|Placebo
47968570|NCT03556072|OTHER|Routine ERCP|
47968571|NCT05012683|DEVICE|Point Partial|Patient is fit with Point Partial partial finger prosthetic system
47968572|NCT00519831|BIOLOGICAL|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
47968573|NCT00519831|DRUG|vinflunine|Vinflunine 320 mg/m² every 21 days
47968574|NCT05832385|RADIATION|IMRT|anal cancer: chemoradiotherapy, radiation dose\>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
48117190|NCT00936507|OTHER|Energy Density/Portion Size|
48117191|NCT03106142|PROCEDURE|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
48117192|NCT04147910|DRUG|KW-6356|Single oral dose of KW-6356
48340054|NCT06231641|DRUG|Lemborexant 5 MG [Dayvigo]|Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
48646127|NCT00072995|BEHAVIORAL|Diets Low in Saturated Fat|
48646128|NCT03239054|BEHAVIORAL|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
48486860|NCT06161142|DIAGNOSTIC_TEST|Short physical performance battery (SPPB) score|The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
48646129|NCT03239054|BEHAVIORAL|Control group|Information will be given as part of standard care
48486861|NCT06161142|DIAGNOSTIC_TEST|Physical examination|A full rheumatological examination will be performed.
48486862|NCT06161142|DIAGNOSTIC_TEST|Recording of vital signs|(including body temperature, blood pressure, heart rate)
47968575|NCT04035798|DRUG|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
47968576|NCT02621060|DRUG|Placebo|Placebo: 1200 mg per day for three months
48340055|NCT06231641|OTHER|Matching Placebo|Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
48486863|NCT06161142|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|A body composition measurement by BIA (Bioelectrical Impedance Analysis \[proportional mass of muscle, water and fat in kg\]) will be performed.
48486864|NCT06161142|DIAGNOSTIC_TEST|Genetic testing of the alkaline phosphatase gene|Investigation of mutations regarding the alkaline phosphatase gene
48486865|NCT00209586|DRUG|fospropofol disodium|
48486866|NCT03088618|PROCEDURE|Nasal septoplasty|Type of surgery
48486867|NCT04880720|OTHER|Blood sampling|Blood sampling - 10mL
48646130|NCT03308773|OTHER|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
47968577|NCT02621060|DRUG|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
47968578|NCT04031391|OTHER|Physical activity|"The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels"
48646131|NCT04265118|DEVICE|Sidewards Tilting Bed|Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
48646132|NCT03102528|OTHER|No intervention|No intervention
48646133|NCT05609058|DEVICE|dedicated treatment board with no degree|the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
48646134|NCT01065805|BIOLOGICAL|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
47968579|NCT02275468|DRUG|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
48340056|NCT00003519|DRUG|cyclophosphamide|
48340057|NCT00003519|DRUG|docetaxel|
48340058|NCT00003519|DRUG|doxorubicin hydrochloride|
48340059|NCT00778310|DRUG|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
48646135|NCT00005775|DRUG|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
48646136|NCT00005775|DRUG|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
48486868|NCT01434576|BIOLOGICAL|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
48486869|NCT01434576|BIOLOGICAL|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
48486870|NCT01434576|DRUG|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
48486871|NCT06264791|OTHER|Stress|To manipulate stress, we follow the personalized imagery script procedure developed by Sinha and colleagues. Participants randomly assigned to the stress condition will be interviewed about one week prior to the lab session. They will share a detailed description of a stressful event from their life (last 12 months) with the interviewer. Based on this interview, the experimenter will write a script (\~500 words), that will then be audiotaped. Participants will listen to this personalized audiotape during the experiment, and will be asked to imagine this event as vividly as possible. Participants randomly assigned to the no stress condition will listen to a generic audiotape that describes a non-stressful event (\~500 words). They will not be interviewed. During the lab session, participants will first complete a 3-min color counting task. The participant will then listen to the audiotape (personalized stressful audiotape in stress condition, generic non-stressful audiotape in no stress c
48646137|NCT01991886|DEVICE|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
48646138|NCT04343833|PROCEDURE|Immediate dental implants|At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
47968580|NCT01320904|PROCEDURE|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
47968581|NCT01320904|PROCEDURE|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
48646139|NCT04990310|DRUG|[14C]-CORT113176|\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.
47968582|NCT00848874|BEHAVIORAL|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
47968583|NCT01606007|DRUG|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
47968584|NCT01606007|DRUG|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
47968585|NCT01606007|DRUG|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
47968586|NCT01606007|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
48320427|NCT01303809|OTHER|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:~1. Pre-op carbohydrate loading~2. No pre-op GIK while NBM~3. Pre-medication~4. Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~5. Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~6. Fluid restriction~7. Standardised method of anaesthesia~8. Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~9. 10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~1. Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~2. Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~3. Post operative oxygenation~4. Incentive spirometry~5. Drains (e.g. IDC) removed in recovery~6. Full mobilisation 4-8 hours post op)~7. Early Follow up"
48320428|NCT04309669|DRUG|TOT'HEMA|three ampoules per day during 12 weeks
48486872|NCT06264791|OTHER|Alcohol|Intoxication: Participants randomly assigned to the alcohol condition will be administered 100-proof Vodka mixed with orange juice (1:3 ratio) to induce a BAC of .06% (based on Widmark's formula). They will be breathalyzed every 5 minutes until they reach peak BAC, at which point they will continue with the experiment. Participants randomly assigned to the no alcohol condition will be administered water mixed with orange juice (1:3 ratio). Each participant in the no alcohol condition will be yoked to a participant in the alcohol condition and will complete the same number of breath tests. Once participants in the alcohol condition reach peak BAC and participants in the no alcohol condition performed the same number of breath tests as the participant they are yoked to, participants will continue to the stress induction.
48486873|NCT04954378|DIAGNOSTIC_TEST|radiomics|
48486874|NCT00027742|BIOLOGICAL|pegylated interferon alfa|
48486875|NCT00027742|DRUG|temozolomide|
48486876|NCT03987347|OTHER|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
48486877|NCT03494114|DRUG|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
48486878|NCT03829358|DRUG|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
48486879|NCT03829358|DRUG|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
48486880|NCT06335459|OTHER|epidemiology|Analysis of 2000 AP WB radiographs of Foot in Upper Egypt For Random People and determind cases of Hallux valgus and calculate the prevalence
48486881|NCT00925301|DRUG|migalastat hydrochloride|Oral capsule QOD
48486882|NCT00925301|DRUG|Placebo|Oral capsule QOD
48486883|NCT01946074|DRUG|paclitaxel|Paclitaxel will be administered by intravenous infusion.
48646140|NCT00100750|DRUG|Gemcitabine Hydrochloride|Given IV
48646141|NCT00100750|DRUG|Tipifarnib|Given PO
48486884|NCT01946074|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
48646142|NCT00100750|OTHER|Laboratory Biomarker Analysis|Correlative studies
48646143|NCT02661815|DRUG|Paclitaxel|Please see arm/group description.
48646144|NCT02661815|DRUG|Ricolinostat|Please see arm/group description.
48646145|NCT02661815|DRUG|Bevacizumab|Please see arm/group description.
48646146|NCT05639803|DRUG|PEGIFNα1b|100μg/vial
48646147|NCT05639803|DRUG|Placebo|0.5ml/vial
48646148|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet once daily
48646149|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet once daily
48646150|NCT00504556|DRUG|Edoxaban (DU-176b)|30mg tablet two times a day
48646151|NCT00504556|DRUG|Edoxaban (DU-176b)|60mg tablet two times a day
48646152|NCT00504556|DRUG|warfarin|warfarin tablets
48646153|NCT05701631|DIAGNOSTIC_TEST|Radiomic model|Radiomic model for PCP diagnosis
48646154|NCT00178828|DRUG|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
48646155|NCT00178828|DRUG|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
48320429|NCT03695393|BEHAVIORAL|ACT Therapy|The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
47968587|NCT01606007|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
48320430|NCT06159166|DRUG|Mirdametinib|This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
48486885|NCT01946074|DRUG|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
48486886|NCT01946074|DRUG|ABBV-181|ABBV-181 will be administered by intravenous infusion.
48486887|NCT00894114|BIOLOGICAL|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
48486888|NCT00894114|BIOLOGICAL|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
48486889|NCT03896984|DRUG|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
48486890|NCT03896984|DRUG|Abiraterone|Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
48486891|NCT03896984|DRUG|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
48486892|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose level 1 or 2|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
48486893|NCT03736928|OTHER|placebo|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
48486894|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 3|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
48486895|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 4|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
48646156|NCT02844712|OTHER|Evaluation of reexposure to a negatively tested betalactam|
48646157|NCT02729012|DRUG|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
48646158|NCT02729012|OTHER|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
48486896|NCT04695756|OTHER|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
48486897|NCT02619448|DRUG|Carboplatin|chemotherapy
48486898|NCT02619448|DRUG|Paclitaxel|chemotherapy
48486899|NCT02619448|RADIATION|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
48486900|NCT03078452|DEVICE|Power drill|Undergo bone marrow biopsy using power drill
48486901|NCT03078452|DEVICE|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
48486902|NCT06440187|DRUG|Gemcitabine+ nivolumab|Gemcitabine+ nivolumab q 2wks
48486903|NCT02823730|OTHER|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
48486904|NCT05320848|BEHAVIORAL|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
48486905|NCT03993249|BIOLOGICAL|Nivolumab|standard of care chemoradiotherapy + Nivolumab
48486906|NCT03993249|OTHER|chemoradiotherapy|standard of care chemoradiotherapy
48486907|NCT02135406|BIOLOGICAL|CART-19 T cells|
48486908|NCT00347113|DRUG|Albendazole and praziquantel|
48486909|NCT03827928|BEHAVIORAL|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
48486910|NCT06159309|OTHER|Hyperbaric oxygen therapy|HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician
48486911|NCT06133803|DRUG|Lovenox|A low-molecular-weight heparin, 40mg daily injection.
48486912|NCT06133803|DRUG|Aspirin|Aspirin 81mg daily tablet.
48486913|NCT06133803|PROCEDURE|Embryo transfer|Embryo transfer
48486914|NCT02265341|OTHER|Laboratory Biomarker Analysis|Correlative studies
48486915|NCT02265341|DRUG|Ponatinib Hydrochloride|Given PO
48486916|NCT02265341|OTHER|Quality-of-Life Assessment|Ancillary studies
48486917|NCT01819324|BEHAVIORAL|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
48486918|NCT01819324|BEHAVIORAL|Standardized Lifestyle Management|SLM material (every other week for 4 months)
48646159|NCT00760305|BEHAVIORAL|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
48646160|NCT04632342|DRUG|HL301 tablet 300mg|"* Experimental group 1 : 2 tablets at once, twice a day~* Experimental group 2 : 2 tablets at once, three times a day"
47968588|NCT03456050|BEHAVIORAL|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
48320431|NCT01321840|PROCEDURE|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
48320432|NCT01750632|PROCEDURE|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
48320433|NCT05875558|PROCEDURE|M-TACE|Lipiodol combined with microspheres
48320434|NCT04366752|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
48320435|NCT04366752|OTHER|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
48320436|NCT04895098|DRUG|statin and ezetimibe combination therapy|Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
48320437|NCT04895098|DRUG|statin monotherapy|Receiving statins (atorvastatin/rosuvastatin or others) as monotherapy in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
48320438|NCT06412419|DIAGNOSTIC_TEST|Magnifying Endoscopy and Endoscopic Ultrasonography|The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.
48320439|NCT03090373|DEVICE|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
48320440|NCT00391417|DRUG|estradiol gel|
48320441|NCT04260919|PROCEDURE|Chest physiotherapy|
48320442|NCT05078073|DEVICE|Hyperbaric oxygen therapy|Patients with aGVHD treated with HBOT every two days
48320443|NCT04699071|DRUG|pembrolizumab and lenvatinib|"All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent."
48320444|NCT03004469|DRUG|P-3074|
48320445|NCT03004469|DRUG|Finasteride|
48320446|NCT03004469|DRUG|P-3074 Vehicle|
48320447|NCT03004469|DRUG|Finasteride Placebo|
48320448|NCT04151355|DRUG|Atorvastatin 20mg|atorvastatin (20 mg once daily)
48486919|NCT03093272|DRUG|Leuprolide Acetate|a GnRH agonist
48486920|NCT03093272|DRUG|Prednisone|Prednisone is a corticosteroid
48486921|NCT03093272|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
48320449|NCT03308981|DEVICE|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
48320450|NCT03308981|OTHER|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
48320451|NCT02568124|DRUG|Tranexamic Acid|
48320452|NCT02568124|DRUG|Placebo|
48320453|NCT06082752|PROCEDURE|Massage session|Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).
48340060|NCT00778310|DRUG|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
48646161|NCT04632342|DRUG|Placebo of HL301 tablet|2 tablets at once, three times a day
48646162|NCT05125172|OTHER|Focus of Attention|Focus of attention instruction and feedback. Focus of attention refers to what people are thinking about during motor tasks. An external focus refers to thinking about an outside outcome or target. An internal focus of attention refers to thinking about how someone is moving their body.
47968589|NCT03456050|BEHAVIORAL|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
47968590|NCT02891161|DRUG|durvalumab|1500 mg Q4 weekly
47968591|NCT02891161|RADIATION|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
47968592|NCT00216632|DRUG|risperidone|
47968593|NCT05742594|DRUG|Lazertinib|Lazertinib will be administered orally.
47968594|NCT02968771|OTHER|Non intervention|
47968595|NCT04696315|DIAGNOSTIC_TEST|Multiple features extraction|"In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD."
47968596|NCT05117437|OTHER|Physiological test|This test was conducted to determine the endurance levels of the participants.
47968597|NCT05117437|OTHER|Physical test|Height, weight, and BMI were determined
47968598|NCT05117437|OTHER|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
47968599|NCT05708183|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
48486922|NCT03093272|DRUG|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
48486923|NCT01200940|OTHER|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
47968600|NCT05708183|DIETARY_SUPPLEMENT|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
47968601|NCT05676112|DRUG|nintedanib|nintedanib
47968602|NCT05676112|DRUG|pirfenidone|pirfenidone
48486924|NCT01200940|OTHER|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
48646163|NCT05875610|DRUG|Venlafaxine 75 MG|Venlafaxine 75 mg extended release capsules for a 7-days duration
48646164|NCT05875610|DRUG|Gabapentin 400 mg|Gabapentin 400 mg capsules
48646165|NCT05612750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.
48486925|NCT01200940|OTHER|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
48486926|NCT01200940|OTHER|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
48486927|NCT03264820|DEVICE|Laser Doppler|- Laser measurements at the level of each finger at 47 °C and at ambient temperature
48486928|NCT03264820|DEVICE|Laser speckle|- Laser measurements at the forearm
48486929|NCT03264820|BEHAVIORAL|pain evaluation|Visual scale assesment pain
48486930|NCT03264820|OTHER|Blood pressure and heart rate|Measurement of blood pressure and heart rate
48486931|NCT00017394|BIOLOGICAL|bevacizumab|Given IV
48486932|NCT00017394|DRUG|vinorelbine tartrate|Given IV
48486933|NCT00017394|OTHER|laboratory biomarker analysis|Correlative studies
48486934|NCT02651142|PROCEDURE|Patients receive SLNB|Patients receive sentinel lymph node biopsy
48486935|NCT00826579|PROCEDURE|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
48486936|NCT00826579|PROCEDURE|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
48486937|NCT00916136|PROCEDURE|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
48320454|NCT04186468|OTHER|ICU follow-up clinic|The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
48320455|NCT00877669|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
48320456|NCT00877669|PROCEDURE|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
48320457|NCT05955209|DRUG|Disitamab Vedotin（RC48-ADC）|Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
48320458|NCT03532984|DIAGNOSTIC_TEST|Beam test to predict falls|Dynamic balance will be determined in all participants during beam walking. The beams are 4m long, 2cm high, and 4, 8, and 12cm wide. After a practice trial, participants will perform three trials on each width with and without a calculation task. Trials will be block-randomized based on beam width then on task. Instructions: 'Traverse the entire length of the beam safely at your preferred speed without stepping off, facing forward, with your arms folded in front of your chest. Trials end when you step off, walk sideways, or unfold the arms.' Outcomes are the sum of length traversed, average velocity, number of steps, and average step length determined from video recordings made at 90° relative to the walking direction with full beam length in view using off-the-shelf video cameras.
48320459|NCT01195363|DRUG|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
48320460|NCT01195363|DRUG|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
48320461|NCT01376726|BIOLOGICAL|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
48320462|NCT01376726|BIOLOGICAL|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
48320463|NCT05831618|OTHER|Interactive Visuo-Vestibular training|Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.
48320464|NCT05831618|OTHER|Vestibular rehabilitation training|Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
48320465|NCT05909605|DEVICE|sphygmomanometer|Comparison to the ultrasound sensor
48320466|NCT05909605|DEVICE|Arterial Line|Comparison to the ultrasound sensor
48320467|NCT03889600|OTHER|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
48320468|NCT03440853|BEHAVIORAL|TASCCI|TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
48320469|NCT03440853|OTHER|Technology Delivered Health Education Intervention|The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
48320470|NCT05431049|PROCEDURE|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
48320471|NCT04569916|RADIATION|radiotherapy|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
48320472|NCT04569916|DRUG|irinotecan liposome|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
48320473|NCT04569916|DRUG|apatinib|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
48646166|NCT05612750|BEHAVIORAL|Empowered Relief|A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.
48646167|NCT00127478|DRUG|Atrasentan|
48320474|NCT04569916|DRUG|PD-1 antibody|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
48646168|NCT04767646|PROCEDURE|Intensive rehabilitation program with CPNB|"The patient will have an intensive rehabilitation program (two 30-minute kinesitherapy sessions every day and 30-minute occupational therapy sessions 5 days a week) with the CPNB.~The patient will have follow-up consultation at 1 month, 3 month, 6 month and 1 year after the beggining of the intensive rehabilitation program"
48646169|NCT02544763|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
48320475|NCT05950347|DEVICE|Active Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
48320476|NCT05950347|DEVICE|Sham Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
48320477|NCT00484965|PROCEDURE|Coronary stenting|
48320478|NCT00574431|OTHER|Data Collection|Collection of patient data before implementation of a nutritional management protocol
48320479|NCT00574431|OTHER|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
48320480|NCT00389103|BIOLOGICAL|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
48320481|NCT00874679|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
48320482|NCT02072772|BEHAVIORAL|Positively Smoke Free group treatment|See Arm Description
48320483|NCT02072772|BEHAVIORAL|Standard Care|See Arm Description
48320484|NCT02853006|BIOLOGICAL|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
48320485|NCT02853006|PROCEDURE|Biopsy|
48320486|NCT02853006|PROCEDURE|Excised tissues|
48320487|NCT05830188|BEHAVIORAL|Coping and Resilience Intervention for Adolescents|It is a school-based resilience enhancement program to help adolescents build skills of positive coping and social support to minimize negative coping and distress by sharing, identifying, and discussing their feelings, thoughts, and actions regarding problems and stressful events.
48320488|NCT05830188|OTHER|Printing materials of Coping and Resilience Intervention for Adolescents|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group.
48320489|NCT01500018|DRUG|TC-5214|Single oral dose of 2 mg
48320490|NCT01500018|DRUG|TC-5214 Placebo|Single oral dose
48486938|NCT00644384|DRUG|acitretin|
48646170|NCT02544763|DRUG|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
48320491|NCT01500018|DRUG|Ketamine|Single oral dose of 100 mg
48320492|NCT01500018|DRUG|Phentermine|Single oral dose of 45 mg
48320493|NCT01500018|DRUG|TC-5214|Single oral dose of 8 mg
48320494|NCT01500018|DRUG|TC-5214|Single oral dose of 16 mg
48320495|NCT01500018|DRUG|Phentermine|Single oral dose of 90 mg
48320496|NCT01767519|BIOLOGICAL|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
48320497|NCT01767519|DRUG|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
48320498|NCT01767519|DRUG|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
48320499|NCT01767519|DRUG|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
48320500|NCT04913415|OTHER|Low Suction Strategy of Chest Tube Management|A digital chest tube will be set to a low pressure mode (-8mmHg) during recovery after minimally invasive lung resection.
48320501|NCT04913415|OTHER|Standard Suction Strategy of Chest Tube Management|A digital chest tube will be to the standard suction mode (-20mmHg) during recovery after minimally invasive lung resection.
48320502|NCT03998917|DIAGNOSTIC_TEST|Discrimination of neuromuscular alterations protocol|Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
48486939|NCT00644384|GENETIC|gene expression analysis|
48486940|NCT00644384|GENETIC|northern blotting|
48320503|NCT04005950|DEVICE|Scalpel Bougie technique|ScalpelCric Set
48486941|NCT00644384|GENETIC|polymerase chain reaction|
48486942|NCT00644384|GENETIC|protein expression analysis|
48486943|NCT00644384|OTHER|laboratory biomarker analysis|
48646171|NCT01407614|PROCEDURE|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
48646172|NCT00752219|DRUG|ceftazidime/NXL104 + metronidazole|IV TID
48646173|NCT00752219|DRUG|meropenem|IV TID
48646174|NCT01357746|PROCEDURE|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
48646175|NCT02241031|BIOLOGICAL|MPs|MPs are generated from cord blood using a combination of cytokines.
48646176|NCT02241031|DRUG|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
48646177|NCT00940511|BEHAVIORAL|Coordinated care|
48486944|NCT05228496|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
47968603|NCT06506708|OTHER|Hydrotherapy + massage|The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once every two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
47968604|NCT01314573|BEHAVIORAL|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
47968605|NCT01314573|BEHAVIORAL|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
47968606|NCT04614064|OTHER|Exposure to London Underground ambient particulate matter|Exposure to particulate matter on the London Underground
47968607|NCT04614064|OTHER|Exposure to London air ambient particulate matter|Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)
47968608|NCT01202812|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
48320504|NCT04005950|DEVICE|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
48320505|NCT04408118|DRUG|Atezolizumab|"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
47968609|NCT01202812|OTHER|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
48320506|NCT04408118|DRUG|Paclitaxel|Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
47968610|NCT06505668|DRUG|Atenolol 25 mg|Patients will be receiving Atenolol 25mg OD for 2 months.
47968611|NCT06505668|DRUG|Ivabradine 10mg|Patients will be receiving Ivabradine 5mg BD for 2 months.
47968612|NCT03569033|DRUG|Gefapixant|Gefapixant 45 mg will be administered orally.
47968613|NCT03569033|DRUG|Placebo|Placebo tablet matching gefapixant will be administered orally.
47968614|NCT02444520|BEHAVIORAL|Integrated GP Care|"The overall aims of the intervention are to help the patient:~1. develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~2. understand factors that may be maintaining the problem;~3. learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~4. adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
47968615|NCT00687323|DRUG|temozolomide|
47968616|NCT00228384|DEVICE|GORE VIABAHN Endoprosthesis|Implantation
48320507|NCT04408118|DRUG|Bevacizumab|Will be administered intravenously over 30-90 minutes on Days 1 and 15.
48320508|NCT04779671|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 30 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
48320509|NCT04779671|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
48320510|NCT05394740|DRUG|Regorafenib|"90 mg administered orally, once daily for 21 consecutive days followed by 7 days off~\*Repeat every 4 weeks as Regorafenib therapy"
48320511|NCT05394740|DRUG|Nivolumab|CohotA:360 mg administered intravenously, every 3 weeks \*Administered on the same day as CapeOX therapy Cohort B: 240 mg administered intravenously, every 2 weeks \*Administered on the same day as FOLFOX therapy
48320512|NCT05394740|DRUG|CapeOX|"For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy"
48646178|NCT05192031|BEHAVIORAL|Smoking cessation support|Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
47968617|NCT00228384|DEVICE|Bare Nitinol Stent|Implantation
47968618|NCT06197750|OTHER|Vestibular stimulation|Vestibular stimulation by swing
47968619|NCT06197750|OTHER|General strengthening exercises|General strengthening exercises
47968620|NCT02994212|DIETARY_SUPPLEMENT|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
47968621|NCT04077268|OTHER|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
47968622|NCT03162991|OTHER|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for \~30-55 minutes per exercise session.
47968623|NCT04195087|DEVICE|Masimo Radical-7® Pulse CO-Oximeter®|The perfusion index and Pleth variability index will be recorded from the device monitor.
47968624|NCT00904644|DRUG|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
47968625|NCT00440713|DRUG|Aripiprazole|
47968626|NCT00440713|BEHAVIORAL|Interpersonal Therapy|
48320513|NCT05394740|DRUG|FOLFOX regimen|"For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy"
48320514|NCT00931476|DRUG|somatropin|
48320515|NCT00931476|DRUG|placebo|
48320516|NCT03497260|DIETARY_SUPPLEMENT|Fructose|Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
48320517|NCT03497260|OTHER|Plain water|Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
48320518|NCT05073965|DIETARY_SUPPLEMENT|Vitamin D|Subjects were assigned to receive a 1000IU vitamin D supplement dose
48320519|NCT05073965|OTHER|Placebo|Subject were assigned to receive a placebo
48320520|NCT04876599|BEHAVIORAL|IN FOCUS|Adapted Resiliency Group Intervention
48320521|NCT04876599|BEHAVIORAL|Usual Care|Referral to Virtual Group Support
48320522|NCT05699772|BEHAVIORAL|Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)|The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.
48320523|NCT05699772|BEHAVIORAL|Brain Health Group (BHG)|The BHG was developed by researchers and clinicians at Baylor Scott \& White Institute for Rehabilitation.
48320524|NCT00084812|DRUG|cisplatin|
48320525|NCT00084812|DRUG|safingol|
48320526|NCT03117166|DRUG|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
48320527|NCT03117166|DRUG|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
48320528|NCT02595047|PROCEDURE|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
48320529|NCT03141372|DEVICE|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
48320530|NCT01413841|DRUG|Nasal oxygen|3 l oxygen
48320531|NCT01413841|DRUG|Regular nasal air|3 l nasal air
48320532|NCT00282269|PROCEDURE|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
48320533|NCT01486784|DRUG|Birinapant|IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
48320534|NCT05412472|DRUG|GC4419|45 mg IV infusion of GC4419 over 60 minutes.
47968627|NCT00528788|DRUG|doxercalciferol|
47968628|NCT03699098|DIAGNOSTIC_TEST|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
47968629|NCT00005794|DRUG|perifosine|
48320535|NCT01144234|BEHAVIORAL|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
48320536|NCT01144234|BEHAVIORAL|Information letter|In this arm the pregnant women got an information letter
48320537|NCT02930616|DEVICE|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
48320538|NCT02930616|DEVICE|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
48320539|NCT00002212|DRUG|Bexarotene|
48320540|NCT02588027|DRUG|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
48320541|NCT02588027|DRUG|Placebo|Pharmacy formulated placebo
48320547|NCT04686019|OTHER|Inspiratory muscle training (IMT)|"IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks."
48320548|NCT04638712|OTHER|Microbiopsy sample|before and after chemotherapy
48646179|NCT02976688|OTHER|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
48646180|NCT06269666|DEVICE|P200TxE|SLO and OCT imaging
48646181|NCT00506311|DRUG|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
48646182|NCT01908699|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
48646183|NCT01908699|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
47968630|NCT03013738|BEHAVIORAL|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
47968631|NCT03013738|OTHER|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
48320549|NCT04638712|OTHER|Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level|before and after chemotherapy
48646184|NCT06304896|DRUG|Carvedilol|Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.
48646185|NCT06304896|DRUG|Ramipril|Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.
48646186|NCT06304896|DRUG|Rosuvastatin|Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
47968632|NCT01186510|PROCEDURE|lung perfusion|see literature of proceeding
47968633|NCT01186510|PROCEDURE|no lung perfusion|see literature of proceeding
47968634|NCT01180946|DIETARY_SUPPLEMENT|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
48320550|NCT00641524|PROCEDURE|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
47968635|NCT01180946|OTHER|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
48320551|NCT03314181|DRUG|Dexamethasone|Infusion; Intravenous (IV), or Tablet; Oral
48646187|NCT06304896|DRUG|Colchicine|Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.
47968636|NCT04124276|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
47968637|NCT04124276|DIETARY_SUPPLEMENT|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks.
48320552|NCT03314181|DRUG|Daratumumab|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
48320553|NCT03314181|DRUG|Venetoclax|Tablet; Oral
48320554|NCT03314181|DRUG|Bortezomib|Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
48320555|NCT05762874|DRUG|Ruxolitinib|JAK inhibitor
48320556|NCT01213368|DRUG|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets~Route of administration: oral"
48320557|NCT01213368|DRUG|placebo|"Pharmaceutical form: tablets~Route of administration: oral"
48320558|NCT00692510|DRUG|AZD3480|Capsule, oral, dose once daily, 7 days
48646188|NCT06304896|DRUG|Placebo|Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
48646189|NCT03401879|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
48646190|NCT03401879|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
48320559|NCT00692510|DRUG|Placebo|Capsule, oral, dose once daily, 7 days
48320560|NCT00692510|DRUG|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
48646191|NCT03401879|DEVICE|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
47968638|NCT01955096|PROCEDURE|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
47968639|NCT01955096|PROCEDURE|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
47968640|NCT04445311|DRUG|Ivermectin|3 successive days ttt of ivermectin started within 48 hours of symptoms
47968641|NCT01257087|DRUG|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
47968642|NCT03808545|BEHAVIORAL|Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.
48320561|NCT03303092|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
48320562|NCT03303092|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
48320563|NCT03303092|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
48320564|NCT02129335|OTHER|stress|stress level and survival
48320565|NCT05657704|DRUG|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
48320566|NCT03311399|OTHER|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
48320567|NCT03311399|OTHER|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
48320568|NCT01824264|DRUG|LIK066|Experimental treatment doses
48320569|NCT01824264|DRUG|Sitagliptin|Active comparator treatment dose
48320570|NCT01824264|DRUG|Placebo|Placebo comparator dose
48320571|NCT06089161|OTHER|Standard of Care|Participants in this group will receive standard of care treatment for sleep apnea.
47968643|NCT03808545|BEHAVIORAL|BIPAMS + Diet|For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
47968644|NCT05675397|DIETARY_SUPPLEMENT|donor human milk|Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
48320572|NCT06089161|BEHAVIORAL|Personalized OSA Treatment|Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
48320573|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -IV|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
48320574|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
48646192|NCT03401879|DEVICE|Optical coherence tomography angiography (OCTA)|Retinal microvasculature will be assessed using OCTA.
48646193|NCT04487821|OTHER|Cawthorne Cooksey Exercises|"Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing"
48646194|NCT03621215|DIETARY_SUPPLEMENT|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
48646195|NCT03621215|OTHER|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
48646196|NCT05301972|DRUG|BET Inhibitor|Bromodomain and Extra-Terminal Inhibitor
48646197|NCT00204581|DRUG|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
48646198|NCT01026428|DRUG|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
48646199|NCT01026428|OTHER|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
48320575|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -Intratumoral Injections|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
48320576|NCT00718289|OTHER|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
48320577|NCT00718289|OTHER|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
47968645|NCT06204445|DIETARY_SUPPLEMENT|Green coffee|Each cup of coffee provides approximately 400 mg of hydroxycinnamic acids.
47968646|NCT06204445|DIETARY_SUPPLEMENT|Roasted coffee|Each cup of coffee provides approximately 150 mg of hydroxycinnamic acids.
47968647|NCT01816204|BEHAVIORAL|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
48320578|NCT06432556|GENETIC|scRNAseq|A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)
48320579|NCT06432556|PROCEDURE|two Skin biopsies|2 skin biopsies from a lesional area
47968648|NCT01816204|BEHAVIORAL|face-to-face individual therapy|weekly individual counseling as usual.
48320580|NCT06432556|PROCEDURE|one Skin biopsies|1 skin biopsies from a lesional area
48320581|NCT03029481|DRUG|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
48320582|NCT00139425|BEHAVIORAL|Disease Management Assessment|
48320583|NCT06390631|DEVICE|Continuous Positive Airway Pressure|Patients with COPD were recruited to breath under the atmosphere pressure and different levels of CPAP (4, 6, 8 and 10 cm H2O).
48320584|NCT00530530|DRUG|ASP8825|oral
48320585|NCT00530530|DRUG|Placebo|oral
48320586|NCT03434704|DRUG|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine"|Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age \> 65 years.
48320587|NCT03434704|PROCEDURE|PBSC graft|(target 4-8 × 106 CD34+ cells/kg patient body weight)
48646200|NCT01952262|OTHER|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
48646201|NCT00983801|DRUG|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
48646202|NCT01048359|BEHAVIORAL|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
48646203|NCT01048359|BEHAVIORAL|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
48646204|NCT01048359|BEHAVIORAL|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
48646205|NCT06501339|PROCEDURE|maintenance ECT|Frequency of weekly sessions for 1 month, then fortnightly for 5 months
48646206|NCT06501339|DRUG|Aripiprazole tablet|Aripiprazole 10 mg in the morning throughout the study period
48646207|NCT05100992|PROCEDURE|Percutaneous Coronary Interbention|Percutaneous Coronary Interbention
48646208|NCT02811419|DEVICE|i-scan|examination will be performed with i-scan digital enhancement
47968649|NCT06242158|PROCEDURE|arthroscopic assisted mini-open 5 step repair|"First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair"
47968650|NCT03336671|PROCEDURE|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
47968651|NCT03336671|PROCEDURE|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
47968652|NCT00702611|DEVICE|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
48646209|NCT02811419|DEVICE|standard high-definition white light|examination will be performed with high-definition white light
47968653|NCT00943059|DRUG|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
47968654|NCT00943059|DRUG|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
47968655|NCT02765295|DEVICE|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
48320588|NCT03434704|DRUG|GvHD prophylaxis|"Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: \>80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5."
48320589|NCT03434704|DRUG|Primary antifungal prophylaxis|Posaconazole delayed-release tablet \[available in 100 mg tablets\]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
48320590|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
48320591|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
48340061|NCT04708769|BEHAVIORAL|Smartphone App Participants (APP)|Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
48646210|NCT01877278|DEVICE|Wearable pulsed electromagnetic fields|
48646211|NCT06002698|PROCEDURE|Root canal treatment (Control)|Root canal treatment - Removal of the inflamed pulp tissues from the whole root canals of the tooth.
48646212|NCT06002698|PROCEDURE|Full pulpotomy (Experimental)|Full pulpotomy - Removal of the inflamed coronal pulp tissues from the crown of the tooth.
48646213|NCT03169374|DEVICE|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
48646214|NCT05122143|DEVICE|Treatment A|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril"
48646215|NCT05122143|DEVICE|Treatment B|"Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)"
48646216|NCT05122143|OTHER|Treatment C|No treatment
48646217|NCT06334718|BEHAVIORAL|Interviews and simulation|Work package 1: interview study Work package 2: simulated cardiac arrest study with AED delivered by drone following a simulated emergency (999) call.
48646218|NCT02842385|OTHER|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
48646219|NCT03063164|DEVICE|Intralase IFS150|Intralase flap creation
48646220|NCT03063164|DEVICE|Visumax|Visumax flap creation
48646221|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
48646222|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
48646223|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 24 weeks
48646224|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 48 weeks
48646225|NCT01482403|DRUG|boceprevir|800 mg three times a day for 24 weeks
47968656|NCT02765295|DEVICE|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
48646226|NCT01482403|DRUG|boceprevir|800 mg three times a day for 48 weeks
48646227|NCT01482403|DRUG|mericitabine|1000 mg twice daily for 24 weeks
48646228|NCT01482403|DRUG|mericitabine placebo|mericitabine placebo
48646229|NCT01482403|DRUG|boceprevir placebo|boceprevir placebo
47968657|NCT03918083|BEHAVIORAL|Wellness|Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
47968658|NCT01826604|DEVICE|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
48646230|NCT01482403|DRUG|boceprevir|800 mg three times a day for 44 weeks
47968659|NCT01826604|OTHER|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
48117193|NCT04962282|OTHER|Follow-up by telephone|Studies have shown that the compliance of patients at 8-12 weeks reaches a peak, so this time node is the most suitable time node to investigate compliance. Telephone follow-up is irreplaceable convenience, so the telephone follow-up survey of patient compliance with exercise prescriptions is The most feasible method The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.The purpose of the telephone follow-up is to 1. Investigate the compliance of the patients; 2. Make the patients fill out a self-made research compliance scale influencing factors through the telephone.
48646231|NCT00674063|DRUG|alefacept|IV
48646232|NCT00635466|PROCEDURE|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
48646233|NCT02557919|OTHER|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
48646234|NCT02557919|OTHER|Usual Best Practice|.5 day training on tobacco control and emerging products.
48117194|NCT02147678|DRUG|Etomidate|
48117195|NCT02147678|DRUG|Propofol|
48117196|NCT02147678|DRUG|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
48646235|NCT06686290|OTHER|Post-Isometric Relaxation Technique|Post isometric relaxation will be performed with the frequency of 5 times, such that it includes 30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold.
48646236|NCT06686290|OTHER|Static Stretching|Static Stretching
48646237|NCT04231565|DRUG|Tenofovir alafenamide Fumarate|Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
48117197|NCT02147678|DRUG|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
48646238|NCT04717479|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
48646239|NCT01204385|PROCEDURE|Sample collection|Middle ear fluid and urine
48646240|NCT05476731|DIAGNOSTIC_TEST|culture and antifungal sensitivity and molecular detection|"Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine"
48646241|NCT06685016|DIAGNOSTIC_TEST|Evaluation of Dentin hypersensitivity with VAS scale|Dentin hypersensitivity and periodontal indices evaluation are performed after and before IPR, at 1 week, 1 month and 3 months
48646242|NCT06686771|RADIATION|SBRT|Please refer to the current NCCN NSCLC guidelines for possible treatment options
48646243|NCT06686771|OTHER|Second-line standard of care therapy|Please refer to the current NCCN NSCLC guidelines for possible treatment options.
48646244|NCT06677554|DRUG|Addition of ultrasound with contrast injection (SonoVue®)|Addition of contrast evaluation with SonoVue® injection (5 min including 1 min of acquisition) within the diagnostic strategy
48117198|NCT04181255|DRUG|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
48117199|NCT04181255|DRUG|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
48117200|NCT04141865|DEVICE|Xen|Xen microstent implantation
48117201|NCT04141865|DEVICE|Aqueous shunt|Aqueous shunt implantation
48646245|NCT06677554|OTHER|Standard Care (in control arm)|No addition of ultrasound with contrast
48646246|NCT03578263|DRUG|Carbetocin|Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.
48646247|NCT03578263|DRUG|oxytocin|Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
48646248|NCT03578263|DRUG|ergometrine|intramuscular ergometrine 0.2 mg.
48646249|NCT06686914|DRUG|Cannabidiol (CBD) Oil 300mg|Cannabidiol (CBD) Oil 300mg, 1 dose
47968660|NCT06312345|DRUG|Drug: ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
47968661|NCT02932670|OTHER|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
47968662|NCT04662125|DRUG|caffeine, paracetamol tablet|oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
48117202|NCT00177086|OTHER|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
48117203|NCT05834842|BEHAVIORAL|Unisalud|"The UNISALUD intervention will be made up of 42 videos, made using the visual collage technique, where illustration, video fragments and visual interactions are mixed and in some there will be a presenter to achieve captivating visual material. to the participant. Likewise, it will be accompanied by digital infographics that will help reinforce the information proposed by the intervention."
48320592|NCT04992039|OTHER|WHO HEARTS technical package|"Components of WHO HEARTS technical package are~1. Universal BP screening via A\&D arm-in BP device.~2. Training of Medical Officers and Nurses on BP measurement using standard techniques.~3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~4. Use of a drug and dose specific hypertension treatment protocol.~5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~6. Training and support for team-based model of hypertension care delivery.~7. Access to the Simple data dashboard for program monitoring.~8. Standardized procedure for patient follow-up.~9. Community-based prescription refilling."
48320593|NCT02231294|DRUG|Sifrol®|
48486945|NCT05228496|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
48486946|NCT02240563|PROCEDURE|Low-level laser therapy|
48486947|NCT02240563|PROCEDURE|Non laser ordinary red light|
48486948|NCT03017118|DIETARY_SUPPLEMENT|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
48486949|NCT03017118|OTHER|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
48486950|NCT00496535|DRUG|TNFerade biologic|
48486951|NCT05372874|DRUG|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
48486952|NCT02596321|DRUG|Mitizax|Allergen extract
48486953|NCT02596321|DRUG|Placebo|Placebo tablet
48646250|NCT06686914|DRUG|Cannabidiol (CBD) Oil 150mg|Cannabidiol (CBD) Oil 150mg, 1 dose
48486954|NCT03621319|DEVICE|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
48486955|NCT03621319|DEVICE|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
48486956|NCT02164734|DEVICE|Endotracheal intubation|
48486957|NCT02164734|DEVICE|Laryngeal mask airway|
48486958|NCT02164734|DRUG|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
48486959|NCT05695092|BEHAVIORAL|Progressive muscle relaxation|Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
48486960|NCT05695092|OTHER|control|control group will not receive any intervention
48486961|NCT03957187|DIAGNOSTIC_TEST|Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement|"Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.~The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement."
48486962|NCT03477019|DRUG|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
47968663|NCT04662125|DRUG|Oral prednisolone|patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
47968664|NCT04662125|DRUG|oral pregabalin|patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
47968665|NCT03290872|DEVICE|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
48117204|NCT02167906|OTHER|arterial stiffness measurement|
48320594|NCT00700531|DEVICE|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
48486963|NCT03477019|PROCEDURE|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
47968666|NCT03290872|DEVICE|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
48320595|NCT00700531|PROCEDURE|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
48320596|NCT05602610|OTHER|No intervention|No intervention
48486964|NCT05449509|DIAGNOSTIC_TEST|Abdominal aortic Duplex ultrasound|All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.
48486965|NCT00996931|DRUG|lenalidomide|2.5 mgs per day orally for 12 weeks
48646251|NCT06686914|DRUG|Placebo Oil|Placebo Oil, 1 dose
48646252|NCT06687850|BEHAVIORAL|animal assisted therapy|The canine was included in therapy sessions to determine the effect of the canine on prosocial behavior and emotional regulation in autistic children with varying verbality.
47968667|NCT01994447|OTHER|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
47968668|NCT05516394|PROCEDURE|Laparoscopic liver resection|Liver tumors are resected with minimally invasive approach, laparoscopically.
47968669|NCT05422196|PROCEDURE|Platelet-rich fibrin|Addition of platelet-rich fibrin into the cleft site.
47968670|NCT02517983|OTHER|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
47968671|NCT00257101|BEHAVIORAL|self-medication monitoring|
47968672|NCT05801276|DIAGNOSTIC_TEST|Methylation assay|Methylation assay of CDO1 and HOXA9 genes in plasma circulating tumor DNA
47968673|NCT04771039|OTHER|reason for consultation|search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD
47968674|NCT03249883|DEVICE|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
47968675|NCT05393258|RADIATION|temporally-modulated pulsed radiotherapy (TMPRT)|Intensity modulated RT (IMRT) using single or two arc therapy will be used for RT delivery.
47968676|NCT03374397|DRUG|Surgiguard|Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
47968677|NCT03586180|BEHAVIORAL|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
47968678|NCT01182675|DRUG|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
47968679|NCT01182675|DRUG|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
47968680|NCT04605445|PROCEDURE|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
47968681|NCT04605445|PROCEDURE|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
47968682|NCT02761278|PROCEDURE|Endometrial biopsy|
47968683|NCT05255159|DIAGNOSTIC_TEST|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
48486966|NCT01227655|DRUG|BIA 9-1067|Capsules will be used.
47968684|NCT03921671|COMBINATION_PRODUCT|Ramucirumab|Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
47968685|NCT00356473|DRUG|Atorvastatin|
47968686|NCT00075959|DRUG|NXY-059|
47968687|NCT01827605|OTHER|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
48320597|NCT05641948|OTHER|MRI scan|Participants will undergo brain MRI scan at 3 intervals
48320598|NCT04944329|PROCEDURE|Hip fracture surgery|Hip fracture surgery
48320599|NCT02392494|DRUG|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
48320600|NCT05386654|DEVICE|imPulse™ Tor System|Self-directed blood pressure data capture
48320601|NCT00178048|DRUG|paroxetine|
48486967|NCT01227655|DRUG|Placebo|comparator
48486968|NCT01227655|DRUG|Levodopa|
48486969|NCT01227655|DRUG|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
47968688|NCT01827605|DRUG|BEAM|"BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc"
47968689|NCT03968770|DIETARY_SUPPLEMENT|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
47968690|NCT03968770|DIETARY_SUPPLEMENT|Control group|Placebo of Probiotic once daily taken by 6 weeks.
47968691|NCT03968770|OTHER|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
47968692|NCT03971214|DRUG|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
47968693|NCT04546230|PROCEDURE|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle \& a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later \& continued throughout the procedure."
47968694|NCT04546230|PROCEDURE|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen \& infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
47968695|NCT00961233|DRUG|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
47968696|NCT00961233|DRUG|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
47968697|NCT04659161|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
47968698|NCT04659161|DRUG|Placebo|Placebo Capsules twice a day (BID)
47968699|NCT00016887|BIOLOGICAL|filgrastim|
47968700|NCT00016887|BIOLOGICAL|recombinant interferon alfa|
47968701|NCT00016887|DRUG|carmustine|
48486970|NCT01227655|DRUG|Benserazide|DOPA decarboxylase inhibitor
48320602|NCT01511107|DRUG|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
48320603|NCT01511107|DRUG|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10"
48320604|NCT00135486|BIOLOGICAL|MenC-TT|
48320605|NCT00135486|BIOLOGICAL|Hib-MenC-TT|
48320606|NCT04046406|DEVICE|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
48320607|NCT01750944|PROCEDURE|Ankle first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPA-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPT-LR are re-measured."
47968702|NCT00016887|DRUG|cyclophosphamide|
48320608|NCT01750944|PROCEDURE|Toe first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPT-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPA-LR are re-measured."
48646253|NCT05954494|BIOLOGICAL|BPAN Patients|Patients, children or adults with a neurological impairment (epilepsy, dystonia, cognitive impairment...) related to a pathogenic variant of the WDR45 gene
47968703|NCT00016887|DRUG|cytarabine|
47968704|NCT00016887|DRUG|dexamethasone|
47968705|NCT00016887|DRUG|etoposide|
48320609|NCT06443476|PROCEDURE|Tenting abutment technique|To evaluate a novel method using a designed tenting abutment to reduce number of surgeries and the edentulous healing period is shortened. In addition, to prevent vertical and horizontal collapse of the bone graft and minimizes resorption of the bone graft during the healing the atrophic posterior mandible.
48320610|NCT06443476|PROCEDURE|Tent pole technique|using the Tent pole technique to gain bone vertical and horizontal loss
48320611|NCT05630170|DEVICE|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
48320612|NCT02701192|OTHER|Coccygectomy|Patient receiving coccygectomy surgery.
48320613|NCT00747617|DRUG|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
48646254|NCT02101853|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
47968706|NCT00016887|DRUG|melphalan|
48320614|NCT03107455|DEVICE|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
48320615|NCT05658185|BEHAVIORAL|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~* Adjustment to the disease:~* Self-esteem/self-concept:~* Coping with fear:~* Emotional self-regulation:~* Social area and enjoyment:~* Decision making and problem solving:~* Communication and listening skills:"
48486971|NCT03642522|DEVICE|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
48486972|NCT00352235|DRUG|KRN7000|
48486973|NCT03786133|DIAGNOSTIC_TEST|Analysis of microbiological tests|Collection and comparison of microbiological data
48320616|NCT03512977|PROCEDURE|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
48486974|NCT03716076|DRUG|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
48486975|NCT01304693|BIOLOGICAL|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
48486976|NCT01304693|BIOLOGICAL|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
48486977|NCT05797584|DRUG|Dobutamine|Dobutamine 5.0 - 10.0 mcg/Kg/min ev
48486978|NCT05797584|OTHER|Passive leg raising|Passive leg raising for acute volume load
48486979|NCT05743231|PROCEDURE|interpectoral area block + serratus anterior area block group|The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
48646255|NCT02101853|DRUG|Asparaginase|Given IM or IV
48320617|NCT03512977|DRUG|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
48320618|NCT06214351|OTHER|Use of mobile midwifery application|Pregnant women in the experimental group will have a mobile midwifery application installed on their smartphones. The pregnant woman will be able to reach the research midwife 24/7. With the informative content and algorithm mechanism in the application, she will be able to provide individual care and detect early signs of danger, enabling her to seek medical attention.
48320619|NCT02495740|BEHAVIORAL|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
48320620|NCT00844064|DRUG|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
48320621|NCT04311619|DRUG|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
48320622|NCT04311619|DEVICE|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
48320623|NCT05668312|OTHER|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
48486980|NCT05278572|BEHAVIORAL|Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)|Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
48486981|NCT04209335|OTHER|isometric core muscle endurance testing|holding previously described isometric positions until fatigue
48646256|NCT02101853|BIOLOGICAL|Blinatumomab|Given IV
47968707|NCT00016887|PROCEDURE|bone marrow ablation with stem cell support|
48486982|NCT05517161|BEHAVIORAL|INSIGHT|See Keegan et al., 2020
48646257|NCT02101853|DRUG|Cyclophosphamide|Given IV
48646258|NCT02101853|DRUG|Cytarabine|Given IT and IV or SC
48646259|NCT02101853|DRUG|Dexamethasone|Given PO or IV
48646260|NCT02101853|DRUG|Etoposide|Given IV
48646261|NCT02101853|DRUG|Leucovorin Calcium|Given IV or PO
48646262|NCT02101853|DRUG|Mercaptopurine|Given PO
48646263|NCT02101853|DRUG|Methotrexate|Given IT, IV, and PO
48646264|NCT02101853|DRUG|Mitoxantrone|Given IV
48646265|NCT02101853|DRUG|Mitoxantrone Hydrochloride|Given IV
48646266|NCT02101853|DRUG|Pegaspargase|Given IV
48646267|NCT02101853|OTHER|Pharmacological Study|Correlative studies
48646268|NCT02101853|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
47968708|NCT00016887|PROCEDURE|peripheral blood stem cell transplantation|
47968709|NCT00016887|RADIATION|radiation therapy|
47968710|NCT03535610|DEVICE|Uterine Embolization|Uterine Embolization with PVA Microspheres
47968711|NCT00700661|DRUG|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
47968712|NCT00700661|DRUG|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
47968713|NCT00190697|DRUG|arzoxifene|
48646269|NCT02101853|DRUG|Therapeutic Hydrocortisone|Given IT
48646270|NCT02101853|DRUG|Thioguanine|Given PO
48646271|NCT02101853|DRUG|Vincristine|Given IV
48646272|NCT02101853|DRUG|Vincristine Sulfate|Given IV
48646273|NCT04606849|OTHER|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
47968714|NCT01616667|PROCEDURE|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
47968715|NCT01312272|DRUG|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
47968716|NCT01312272|DRUG|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
47968717|NCT01565512|DRUG|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
47968718|NCT01565512|DRUG|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
47968719|NCT02389361|DRUG|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
47968720|NCT02389361|DRUG|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
47968721|NCT01389817|DEVICE|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
47968722|NCT02873000|BEHAVIORAL|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
48117205|NCT04878198|BEHAVIORAL|Jogging program|This intervention consists of 50 sessions of morning jogging sessions at moderate intensity level. Each intervention session will be administered by a trained research assistant assisted by student helpers. All the research staff (i.e. student helpers and research assistant) will be required to attend a workshop (see educational plan) to standardize the procedure on implementing the intervention, as well as handling and motivating their ASD partners. Motivation techniques in previous protocol will be used to enhance the compliance rate.
48320624|NCT05668312|OTHER|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
48486983|NCT02121561|BEHAVIORAL|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
48486984|NCT01057381|DRUG|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
48486985|NCT01057381|DRUG|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
48486986|NCT01057381|DRUG|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
48486987|NCT01057381|DRUG|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
48486988|NCT01857960|BEHAVIORAL|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
48486989|NCT00603291|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
48486990|NCT00603291|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
48646274|NCT04606849|DEVICE|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
48646275|NCT05476848|DIAGNOSTIC_TEST|ELISA test for Cytokines|ELISA tests specific for cytokines (IL-1, IL-6, IL-10) and immunoglobulins (IgA, IgG, IgM) will be performed by a biochemistry lab, both for blood samples and oral swap samples.
48646276|NCT00337597|OTHER|Glucose 5%|
48486991|NCT00603291|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
48320625|NCT03736954|BEHAVIORAL|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
48486992|NCT04273919|DEVICE|HTC Vive with Karuna Virtual Reality Program|HTC Vive head-mounted display and an HTC Vive body tracker adhered to a belt on the patient's low back, which will be placed 2 inches below the waist
48486993|NCT04273919|DEVICE|HTC Vive with Lumen Program|HTC Vive head-mounted display with Lumen program
48646277|NCT00337597|OTHER|NaCl 0.9%|
47968723|NCT04199910|OTHER|There is no intervention, only research blood samples are collected|Research blood samples collected
47968724|NCT00041990|DRUG|decitabine (5-aza-2'deoxycytidine)|
48486994|NCT03987594|PROCEDURE|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
47968725|NCT04952493|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
48117206|NCT04878198|DRUG|Melatonin supplement intervention|This intervention is a 10-week melatonin supplement intervention where melatonin supplement will be provided 30 minutes before bedtime.
47968726|NCT04952493|DRUG|Sodium Iodide I 131|RAI treatment may shrink the tumor
47968727|NCT04952493|DRUG|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
47968728|NCT03585257|BIOLOGICAL|25% IV albumin|"Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
47968729|NCT03585257|OTHER|Placebo|"Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
48117207|NCT06530056|OTHER|Costovertebral Mobilization+Conventional Therapy|"Patient would receive costovertebral mobilization in side lying position for left 10th to 6th, in sitting position for right 10th to 2nd rib and in supine lying position for 1st rib.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises Frequency; 4 times/week for 3 weeks"
48486995|NCT03987594|PROCEDURE|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
48646278|NCT02192476|OTHER|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
48646279|NCT02192476|OTHER|California tri-pull taping (CTPT)|"Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape."
48646280|NCT01832298|DRUG|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
47968730|NCT02454491|DRUG|Heparin|intraradial administration of heparin 5000 ui
47968731|NCT02454491|DRUG|Verapamil|intraradial administration of verapamil 5 mg
47968732|NCT04101461|DRUG|Iron|PharaFerro27; Devart Lab Company, Egypt
47968733|NCT04101461|DIAGNOSTIC_TEST|Complete blood count|to assess the anemia
47968734|NCT04101461|DIAGNOSTIC_TEST|Serum ferritin|to assess the anemia
47968735|NCT04101461|DIAGNOSTIC_TEST|Serum hepcidin|to assess the iron abosrption
47968736|NCT04101461|DIAGNOSTIC_TEST|Serum Iron|to assess the anemia
47968737|NCT04101461|DIAGNOSTIC_TEST|Serum total iron binding capacity|to assess the anemia
47968738|NCT02704117|DEVICE|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
47968739|NCT00136799|DRUG|Fluvastatin|
47968740|NCT03333447|OTHER|MRI|
47968741|NCT02320383|BIOLOGICAL|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
47968742|NCT02320383|DRUG|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
47968743|NCT01499056|BIOLOGICAL|stem cell injection|intra articular inection of mesenchymal stem cell
47968744|NCT01845493|DIETARY_SUPPLEMENT|Alpha Sprout Homogenate|Alpha Sprout Homogenate
47968745|NCT01845493|DIETARY_SUPPLEMENT|Sulforaphane Homogenate|Active
47968746|NCT02066805|DRUG|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
48117208|NCT06530056|OTHER|Conventional Therapy|"Electrotherapy:~• Hot Pack 10 minutes~Posture Corrective Exercises:~* Thoracic Rotation 10 rep/session~* Thoracic extension 10 rep/session~* Scapular retraction 5 rep/session~* Deep neck flexor Isometric 5 rep/session~Deep Breathing Exercises:~• Pursed lip breathing 10 repetition in one session"
48486996|NCT02792959|DEVICE|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
48486997|NCT02792959|DEVICE|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
48646281|NCT06613685|DRUG|GS-1720|Tablets administered orally without regard to food
48646282|NCT06613685|DRUG|GS-4182|Tablets administered orally without regard to food
47968747|NCT04380116|DEVICE|Soberlink|Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
47968748|NCT02079220|DRUG|Arm A|"* Capecitabine~* Oxaliplatin~* Ziv-aflibercept"
48117209|NCT05500378|OTHER|Head extension and rotation movement|Active exercise of the head
48486998|NCT06128694|DIETARY_SUPPLEMENT|NUTRICAN|Per serving/sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1 g L-Valine, 1.1 g L-Isoleucine, 2.1 g L-Leucine, 75 mg sodium, 12 vitamins and 9 minerals.
48486999|NCT04603911|DRUG|Liposomal bupivacaine|The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
48487000|NCT04603911|DRUG|Bupivacaine, epinephrine, dexamethasone, and clonidine|The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
48487001|NCT00000824|DRUG|Lymphocytes, Activated|
48487002|NCT05329298|DRUG|BPI-361175|Subjects will receive BPI-361175 until disease progression
48487003|NCT01855048|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
48487004|NCT01855048|OTHER|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
48487005|NCT01072266|DRUG|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
48646283|NCT06613685|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
48646284|NCT06613685|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
48646285|NCT06613685|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
47968749|NCT02079220|DRUG|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
48117210|NCT01472146|DRUG|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
48320626|NCT03011580|DIETARY_SUPPLEMENT|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
48320627|NCT03011580|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
48320628|NCT01308723|DRUG|RO5323441|escalating doses iv
48487006|NCT03153618|OTHER|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
47968750|NCT04638933|OTHER|No intervention|No intervention
47968751|NCT01152697|DRUG|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
47968752|NCT01152697|DRUG|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
48117211|NCT01742481|BEHAVIORAL|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
48320629|NCT01308723|DRUG|RO5323441|iv every 2 weeks
48320630|NCT01308723|DRUG|sorafenib|400 mg orally twice daily to once every other day
48487007|NCT02247219|BEHAVIORAL|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
48487008|NCT05574894|DRUG|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
48487009|NCT05574894|DRUG|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
48487010|NCT03016221|OTHER|Axanova hot gel|Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
48487011|NCT03016221|OTHER|Axanova activ gel|Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
48487012|NCT03016221|OTHER|Perskindol Dolo Gel|Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
48646286|NCT06613685|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
48646287|NCT05856461|PROCEDURE|Pulmonary vein isolation|Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
48646288|NCT05856461|PROCEDURE|Sham pulmonary artery denervation|Sham pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries with creation of the false ablation points. No true ablation lesions will be performed in the pulmonary artery
48646289|NCT05856461|PROCEDURE|Pulmonary artery denervation|Pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries and 3 circles of ablation lesions (bifurcation of the main pulmonary artery, left and right pulmonary arteries)
48646290|NCT05588843|DRUG|SAR443122|oral capsule
48646291|NCT05588843|DRUG|Placebo|oral capsule
48646292|NCT05865886|DRUG|BI 1291583|BI 1291583
47968753|NCT01152697|BEHAVIORAL|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
47968754|NCT00169598|PROCEDURE|positron emission tomography|
47968755|NCT04390178|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
47968756|NCT06184100|OTHER|Virtual Self-Management Program (SMP)|Four sessions, 60-90 minutes each, will be conducted over eight weeks with a group size of 4-6 participants via videoconferencing platforms such as Zoom or Microsoft Teams. Each session will include Power Point delivered presentations, interactive activities, and group discussions. This is a multifaceted program that includes JIA disease education, self-management strategies, and peer support.
47968757|NCT06184100|OTHER|No Intervention|No intervention. Participant only receives standard of care.
48646293|NCT05865886|DRUG|Placebo|Placebo matching BI 1291583
47968758|NCT01649661|BEHAVIORAL|questionnaire|
47968759|NCT03085381|BIOLOGICAL|HPV vaccine|
47968760|NCT03085381|BIOLOGICAL|Placebo|
47968761|NCT03218904|DIETARY_SUPPLEMENT|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
47968762|NCT03218904|DIETARY_SUPPLEMENT|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2- single oral dose of Glycosade®
47968763|NCT00089154|BIOLOGICAL|apolizumab|Given IV
47968764|NCT00089154|OTHER|laboratory biomarker analysis|Correlative studies
47968765|NCT00089154|OTHER|pharmacological study|Correlative studies
47968766|NCT00571545|BEHAVIORAL|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
47968767|NCT00571545|BEHAVIORAL|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
47968768|NCT04189081|DEVICE|dry mouth rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
47968769|NCT04189081|OTHER|Water Control|negative control
47968770|NCT05202652|DIETARY_SUPPLEMENT|HealthSpan|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the oral capsule containing the active ingredients, for three consecutive months.
47968771|NCT05202652|DIETARY_SUPPLEMENT|Placebo|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the placebo, for three consecutive months.
47968772|NCT02408315|DRUG|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
47968773|NCT04993248|OTHER|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
47968774|NCT02744690|DRUG|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
47968775|NCT05394961|PROCEDURE|Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19|As above
48487013|NCT03016221|OTHER|Perskindol Classic Gel|Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
48487014|NCT03016221|OTHER|Perskindol Cool Kühl-Gel|Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
47968776|NCT02400632|DEVICE|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
47968777|NCT01481727|DEVICE|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (\>18mmHg) for at least six hours, nocturnal ventilation.
47968778|NCT01481727|DEVICE|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
48646294|NCT02716246|BIOLOGICAL|ABO-102|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
48646295|NCT02716246|DRUG|Adjuvant Immunosuppression (IS) Therapy|The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IS therapy. Not all participants may receive IS therapy.
48646296|NCT02958072|OTHER|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
47968779|NCT06557837|DIAGNOSTIC_TEST|Questionnaires and pain assessment|Participants complete two questionnaires: the Oswestry Disability Index (ODI) and the EQ-5D-5L. They also rate their low back pain using the Visual Analogue Score (VAS) scale and respond to two additional questions about their posture and gait.
47968780|NCT06557837|DIAGNOSTIC_TEST|Standing sagittal whole spine X-ray|Participants undergo standard preoperative X-ray imaging of the entire spine to capture the upright posture. This imaging is conducted before and after 6-minute of continuous walking to compare changes in spino-pelvic and sagittal balance parameters.
48117212|NCT04236973|DEVICE|Molbio Truenat™ HCV assay (the investigational product)|The Molbio Truenat™ HCV assay (the investigational product) is a quantitative chip-based Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) tests for the detection of HCV genomic RNA from human whole blood, EDTA plasma and serum. The Truenat™ HCV assay runs on the Truelab™ Uno, Truelab™ Duo or Truelab™ Quadro Dx. Results of testing by Truenat™ HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
48117213|NCT04236973|OTHER|Abbott RealTime HCV assay|Plasma specimens will be also tested on Abbott RealTime HCV assay that is approved for HCV diagnostics use by countries' authorities. Only the results of Abbott RealTime HCV assay may be used to make clinical decisions.
47968781|NCT06557837|DIAGNOSTIC_TEST|Dynamic test|With the dynamic test, we analyze body movements of participants during gait using 49 reflective markers placed on their bodies according to the Qualisys PAF package: Instituti Ortopedici Rizzoli (IOR) and 10 EMG electrodes on specific leg and back muscles. Participants walk for 6 minutes between two cones set 7 meters apart, while a 12-camera Qualisys Motion Capture System tracks marker movements for comprehensive kinematic analysis. Data are recorded at five key moments: standing before and after the test, and during three phases of gait (at the beginning, middle, and end). Participants are barefoot and dressed in underwear for accurate measurement. Static recordings before and after walking involve stepping on a tensiometric force plate to measure the center of gravity. Before the test, participants perform stretching exercises to ensure consistent preparation.
47968782|NCT06557837|DIAGNOSTIC_TEST|Muscle strength and body composition measurement|Participants have their body composition analyzed and the maximum isometric strength of their paraspinal and abdominal muscles measured using the Dr. Wolff BackCheck device.
47968783|NCT00027261|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
47968784|NCT03440268|DRUG|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
47968785|NCT03440268|DRUG|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
47968786|NCT02312102|DRUG|Lenalidomide|Chemotherapy
48646297|NCT00558480|DRUG|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
48646298|NCT00558480|DRUG|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
48646299|NCT01722643|BEHAVIORAL|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
48646300|NCT01722643|BEHAVIORAL|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
48646301|NCT06681012|DEVICE|Gelsectan®|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
48646302|NCT06681012|DRUG|Placebo|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
48646303|NCT06688656|DRUG|Pemetrexed 500 mg/m2|1. Pemetrexed: 500mg/m² on Day 1, Q3W, administered via intravenous infusion for a total of 3 cycles.
47968787|NCT02312102|DRUG|Velcade|Chemotherapy
48487015|NCT03016221|OTHER|Dolor-X Hot Gel|Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
48646304|NCT06688656|DRUG|carboplatin|AUC=5 on Day 1, Q3W，administered via intravenous infusion for a total of 3 cycles.
48487016|NCT03016221|OTHER|Dolor-X Classic Gel|Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
48646305|NCT06688656|DRUG|Sintilimab|Sintilimab, 200mg, administered via intravenous infusion on the 3rd day of each cycle, Q3W, for a total of 3 cycles.
48646306|NCT06689358|DRUG|0.4 ml/kg of 0.5% bupivacaine|0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space
48646307|NCT06689514|DRUG|alpha receptor antagonist|Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)
47968788|NCT00130598|DRUG|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
47968789|NCT01747044|DRUG|Milnacipran|100mg/day
47968790|NCT01747044|DRUG|Placebo|
47968791|NCT04144244|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IUI treatment
47968792|NCT04144244|OTHER|Gradient-Density Centrifugation|sperm selection of IUI treatment
48117214|NCT04628715|DEVICE|RSA biofeedback|Biofeedback intervention based on breathing at resonance frequency
48487017|NCT03016221|OTHER|Dolor-X Cool Gel|Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
48487018|NCT00196131|DRUG|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
48487019|NCT05778955|GENETIC|detection and monitoring of cirulating tumor DNA|detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma
48487020|NCT03767855|DRUG|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
48487021|NCT03767855|DRUG|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
48487022|NCT03767855|DRUG|CK-3773274 - Tablets|CK-3773274 formulated as tablets
47968793|NCT02272062|OTHER|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
47968794|NCT05824793|COMBINATION_PRODUCT|A-PRF+|A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
47968795|NCT03600545|OTHER|Brain Fitness App|Brain exercises using an iPAD
47968796|NCT02937883|OTHER|Empowerment intervention|Empowerment intervention for persons with young onset dementia
47968797|NCT05564429|DRUG|18F-SF12051|Injected intravenously followed by PET scanning
47968798|NCT05758298|OTHER|Non-medicated gum|Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
47968799|NCT05758298|DRUG|NICOTINE 2MG GUM|Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
47968800|NCT05758298|DRUG|NICOTINE 4MG GUM|Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
47968801|NCT03645798|BEHAVIORAL|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
47968802|NCT03645798|BEHAVIORAL|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
47968803|NCT05650905|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
47968804|NCT05650905|DEVICE|Fourier domain optical coherence tomography (FDOCT)|Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
47968805|NCT05650905|DEVICE|Optical coherence tomography (OCT)|Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
47968806|NCT05650905|DEVICE|Laser Speckle Flowgraphy (LSFG)|Normalized blur and Relative flow volume will be assessed using the LSFG
48646308|NCT06689514|DRUG|Low dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID
47968807|NCT05650905|DIAGNOSTIC_TEST|Proteomics and Metabolites in Plasma, tear fluid and finger sweat|Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
47968808|NCT06364098|DRUG|Misoprostol|400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
48646309|NCT06689514|DRUG|High dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID
47968809|NCT00131118|DRUG|Zoledronic Acid|
48320631|NCT03596658|DRUG|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
48320632|NCT05868096|OTHER|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
48320633|NCT05868096|OTHER|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
48320634|NCT05766865|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
48320635|NCT05766865|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
48320636|NCT06463548|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
48646310|NCT05757167|DIAGNOSTIC_TEST|Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT)|"Detection of Plasmodium falciparum HRP-II antigen1~Method: Lateral Flow; Time to Result: 20 minutes; Sample Type: Fingerstick Whole Blood; Sample Volume: 5µl; Storage Conditions: 1-30°C; Shelf Life: 12 months; Sensitivity/Specificity: 99.0%/98.6%"
48646311|NCT05757167|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|oral tablets: 6 doses of 80/480 mg over 3 days
48320637|NCT06463548|DRUG|Capecitabine|Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
48320638|NCT06463548|DRUG|Lenvatinib|Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
48320639|NCT00206895|PROCEDURE|Photodynamic therapy|
48320640|NCT05727085|OTHER|All pregnant women with a twin pregnancy and the offspring|No intervention
48646312|NCT05175378|OTHER|Lifestyle intervention|We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
48646313|NCT04867629|DIETARY_SUPPLEMENT|Rapeseed oil|20mL of rapeseed oil to be consumed daily in replacement to habitual oil
48646314|NCT04867629|DIETARY_SUPPLEMENT|Sunflower oil|20mL of sunflower oil to be consumed daily in replacement to habitual oil
48646315|NCT06691789|OTHER|Social support|This intervention includes a social support given to the students during COVID-19 pandemic
48646316|NCT04693715|DRUG|RNS60|RNS60 injection solution
48646317|NCT04693715|DRUG|Placebo|Placebo injection solution
48646318|NCT06688253|DRUG|IV efgartigimod|IV efgartigimod
47968810|NCT06431087|OTHER|Mindfulness course|Online or in presence Information on Mindfulness, healthy diet and exercise.
47968811|NCT06083662|DRUG|Neratinib Maleate|"* neratinib 240mg po daily~* herzuma 8mg/kg (loading) --\> 6mg/kg q3w"
48646319|NCT06081244|DRUG|Sacituzumab govitecan|10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
47968812|NCT01794884|DRUG|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
48320641|NCT01105221|DEVICE|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20\*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
48320642|NCT01105221|DRUG|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
48320643|NCT01393756|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
48320644|NCT04822857|DIAGNOSTIC_TEST|AMH|The group was divided according to the level of Anti-Müllerian Hormone
48320645|NCT01123577|OTHER|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
48320646|NCT05668468|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis IVS-1 capsule|Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
48320647|NCT05668468|OTHER|Placebo cellulose capsule|Daily cellulose capsule
48320648|NCT00935519|DEVICE|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
48320649|NCT03746223|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
48646320|NCT06081244|DRUG|Pembrolizumab|200 mg every 3 weeks (q3w)
47968813|NCT01794884|DRUG|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
47968814|NCT01898806|DRUG|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
47968815|NCT01898806|DRUG|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
47968816|NCT01898806|DRUG|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
47968817|NCT01898806|DRUG|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
47968818|NCT05214456|OTHER|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
48320650|NCT03746223|DRUG|Rituximab|Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
48320651|NCT03746223|DRUG|Lenalidomide|25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
48320652|NCT03773926|DEVICE|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
48320653|NCT03258346|OTHER|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
48320654|NCT03258346|DIETARY_SUPPLEMENT|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
48320655|NCT03258346|DIETARY_SUPPLEMENT|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
48320656|NCT02561299|DEVICE|Peripheral Orbital Atherectomy System|Orbital Atherectomy
48646321|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule during 16 days. Participants will receive a total dose of 20 capsules of MBK-01.
48646322|NCT06687382|BIOLOGICAL|MBK-01|Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule for 16 days and a maintenance dose 3 months after the ending of the initial dose. The maintenance dose is administered the same as the initial dose: 4 capsules of MBK-01 orally the first day, followed by a single daily capsule for 16 days. Participants will receive a total dose of 40 capsules of MBK-01.
48320657|NCT02561299|DEVICE|014 Drug Coated Balloon|Drug Coated Balloon
48320658|NCT02209311|PROCEDURE|Oral mucosa biopsy|
48320659|NCT02209311|PROCEDURE|Sinus lift with implantation of tissue engineered construction|
47968819|NCT05214456|OTHER|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
47968820|NCT06072846|BEHAVIORAL|Reiki Energy Therapy|Reiki Therapy will be applied to the intervention group
47968821|NCT05120128|DEVICE|Acuvue® Oasys 1-Day|TEST Lens
47968822|NCT00836485|DRUG|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
47968823|NCT00836485|DRUG|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
48646323|NCT06689748|OTHER|Delphi procedure|The study involves generating consensus statements by experts on the training requirements for physicians involved with airway management in critically ill patients using a Delphi process.
48487023|NCT00530686|DRUG|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
48646324|NCT04037397|DRUG|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
48320660|NCT02209311|DEVICE|Dental implant|
48646325|NCT04037397|PROCEDURE|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
48646326|NCT06690645|OTHER|Exposure: psychological stress status|The assessment of depressive, anxiety or perceived Stress was conducted using PHQ-9, GAD-7 or PSS scale. Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 or a PSS score ≥ 20 were categorized as the stressed group.
48646327|NCT06687369|DRUG|MB12 (Proposed Pembrolizumab Biosimilar)|200mg IV, every 3 weeks on Day 1
47968824|NCT00836485|DRUG|Olopatadine 0.2%|1 gtt/eye on two separate occasions
47968825|NCT00836485|DRUG|Artificial tears|1 gtt/eye on two separate occasions
48646328|NCT06687369|DRUG|EU-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
48117215|NCT03966508|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
48117216|NCT06131385|DRUG|intravenous thrombolysis|Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
48117217|NCT02420613|RADIATION|Radiation Therapy|Undergo radiation therapy
48117218|NCT02420613|DRUG|Temsirolimus|Given IV
48646329|NCT06687369|DRUG|US-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
48646330|NCT06687369|DRUG|Pemetrexed|500 mg/m2 IV, every 3 weeks on Day 1
48646331|NCT06687369|DRUG|Carboplatin|Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.
48646332|NCT06687369|DRUG|Cisplatin|75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
48646333|NCT06690255|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
48646334|NCT06596356|DRUG|[14C] TS-172|Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
48646335|NCT06687993|DRUG|Donepezil 2.5 mg|2.5 mg daily oral intake for 90 days
48646336|NCT06687993|DRUG|Donepezil 5 mg|5 mg daily oral intake for 90 days
48320661|NCT01562366|DEVICE|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
48320662|NCT01562366|PROCEDURE|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
48646337|NCT06687993|DRUG|Placebo Comparator|daily oral intake for 90 days
48646338|NCT02477033|DIETARY_SUPPLEMENT|Butyricicoccus pullicaecorum 25-3T|
48646339|NCT02477033|OTHER|Maltodextrin|
48646340|NCT06686108|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle
48320663|NCT04346264|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
48487024|NCT01693627|DEVICE|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
48646341|NCT06686108|DRUG|Decitabine (DAC)|decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.
48646342|NCT06686108|DRUG|Venetoclax|venetoclax, 400mg/d, days 1-7 of each 28-day cycle
48117219|NCT02420613|DRUG|Vorinostat|Given PO
48487025|NCT01693627|DEVICE|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
48487026|NCT01693627|DEVICE|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
48487027|NCT01693627|DEVICE|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
48487028|NCT03695848|DEVICE|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
48487029|NCT00847106|DRUG|Daclizumab|
48487030|NCT00847106|BIOLOGICAL|Dendritic cells|
48487031|NCT01023295|DRUG|fosbretabulin|single dose, intravenous infusion
48487032|NCT01023295|DRUG|Saline|single dose, intravenous infusion
48487033|NCT03977831|PROCEDURE|Radical Cystectomy|Participants are randomly and blinded assigned
48487034|NCT02943967|PROCEDURE|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
48487035|NCT02943967|PROCEDURE|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
48487036|NCT04259255|DRUG|Edaravone (Radicava®/Radicava ORS®)|"Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles."
48487037|NCT04799652|OTHER|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
48487038|NCT04700280|DRUG|GLPG3970|GLPG3970 film-coated tablet.
48487039|NCT04700280|DRUG|Placebo|Placebo film-coated tablet.
47968826|NCT04180228|OTHER|self-administred questionnaire|On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
47968827|NCT02657291|DRUG|Ropivacaine|Local anesthetic
47968828|NCT02657291|DEVICE|Ultrasound|Ultrasound guided block
47968829|NCT00016185|DRUG|alvocidib|
47968830|NCT00016185|DRUG|docetaxel|
47968831|NCT03168854|BIOLOGICAL|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
47968832|NCT03168854|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
48117220|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, single dose
48117221|NCT00734240|DRUG|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
48117222|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, single dose
48117223|NCT00734240|DRUG|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
48487040|NCT01635062|DRUG|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
48487041|NCT01635062|DRUG|Placebo|Subjects will receive placebo for 3 weeks.
48487042|NCT03112980|DEVICE|Transcatheter aortic valve implantation|(TAVI)
48487043|NCT03112980|PROCEDURE|Surgical aortic valve replacement|(SAVR)
47968833|NCT04332562|OTHER|dietary restriction (salt restriction)|salt restriction for one week after being diagnosed with hypertension
48117224|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
48117225|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, single dose
48117226|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, single dose
48117227|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, single dose
48117228|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, single-dose
48487044|NCT02783430|DRUG|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
48487045|NCT02783430|DRUG|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
48487046|NCT02783430|DRUG|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
48487047|NCT03364166|PROCEDURE|surgical excision|"* Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~* A neck dissection will be done in all cases of negative or positive neck lymph node.~* Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
48487048|NCT04670666|DRUG|MADALENA ASSOCIATION|Madalena association coated tablet.
47968834|NCT05279443|OTHER|yoga-based exercises therapy|Accompanied by a certified yoga instructor, and under the supervision of an PMR specialist and a Sports Medicine specialist, YBEs were administered to our patients included in the study for 8 weeks, 2 sessions a week, and with sessions of 60 minutes, using personal mats and equipment in a 2475 m3 (18mx25mx5.5m) gym area that belonged to our hospital, in the form of group therapy for 5 (five) people and in accordance with the social distancing rules. The exercises program was applied as a exercise program consisting of physical postures (asana) to improve the body's muscle strength and flexibility, breathing exercises (pranayama) to increase respiratory function, and relaxation and meditation (dhyana) techniques.
47968835|NCT00848471|DEVICE|Quark RMR|Quark RMR calorimeter (Cosmed)
47968836|NCT00848471|DEVICE|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
47968837|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
47968838|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)|Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
47968839|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)|Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
47968840|NCT04370405|DRUG|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
47968841|NCT04317131|DIAGNOSTIC_TEST|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
47968842|NCT04317131|DEVICE|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
47968843|NCT04317131|DEVICE|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
47968844|NCT04317131|DEVICE|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
47968845|NCT04317131|DEVICE|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
47968846|NCT05533684|DRUG|Gabapentin|single preoperative dose of 600 mg gabapentin
47968847|NCT02026739|PROCEDURE|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
47968848|NCT02026739|PROCEDURE|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
48117229|NCT00734240|DRUG|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
48487049|NCT04670666|DRUG|METFORMIN|Metformin 1000 mg extended-release tablet.
48487050|NCT04670666|DRUG|EMPAGLIFLOZIN + LINAGLIPTIN|Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
48117230|NCT00734240|DRUG|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
48117231|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
48117232|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
48117233|NCT00734240|DRUG|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
48487051|NCT04670666|OTHER|MADALENA ASSOCIATION PLACEBO|Madalena association placebo tablet.
48487052|NCT04670666|OTHER|METFORMIN PLACEBO|Metformin placebo tablet.
48117234|NCT00734240|DRUG|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
48117235|NCT00734240|DRUG|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
48117236|NCT01271517|DRUG|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
48117237|NCT01271517|DRUG|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
48117238|NCT01271517|DRUG|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
48487053|NCT04670666|OTHER|EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO|Empagliflozin + linagliptin placebo tablet.
48487054|NCT01120652|BEHAVIORAL|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
48487055|NCT01120652|BEHAVIORAL|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
48487056|NCT03722355|RADIATION|Conventional RT|Radiation therapy
47968849|NCT06436365|PROCEDURE|Locking expert intramedullary nail fixation|"the fracture was reduced to enable the insertion of the guide wire to restore the rotation, length, and angulation. Poller screws were used as control deformity by narrowing the medullary canal and were inserted on the deformity concave side between the nail and bone cortex. A ball-ended guidewire was placed through the entry point to the tibial canal and then to the tibial fracture site under the guidance of fluoroscopy. The guide wire should be inserted centrally within the distal segment on both lateral and anteroposterior views and be far about 1 to 0.5 centimeters from the ankle joint. Reamers with deep fluted and small diameters were used slowly to increase the diameter to reach 0.5 mm till the cortical chatter.~The nail was inserted by attachment of insertion device and locking of the proximal screw to the nail by directing its apex posteriorly. The nail insertion was done by flexing the knee to prevent any patellar impingement."
48320664|NCT02474524|BEHAVIORAL|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
47968850|NCT06436365|PROCEDURE|Distal locked plate|Cobb dissector was used in creation extra-periosteal subcutaneous tunnel for gentle introduction of a proper plate which was determined by choosing appropriate size and level guided by imaging which helped in prevention of any periosteal damage. Manual closed reduction was performed using the percutaneous clamps. Distal screws were positioned as the following, one was inserted above the medial malleolus, another one was inserted right and below the fracture, and the other screws were inserted to help in anatomical plate positioning. By reduction preservation, proximal screws were inserted by small incisions which was followed by insertion of the remained distal screws.
47968851|NCT06364943|OTHER|with/without dry eye syndrome|compare tear ferning structure between dry eye and non-dry eye patients
47968852|NCT03676257|OTHER|Endocrine therapies|No intervention
47968853|NCT03677505|DEVICE|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
47968854|NCT03677505|DEVICE|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
47968855|NCT03980002|DRUG|FCR and Ibrutinib|"Induction treatment:~Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~1. FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~2. Ibrutinib:420mg/d"
47968856|NCT03980002|DRUG|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
47968857|NCT03980002|DRUG|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
47968858|NCT01217814|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
47968859|NCT01217814|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
47968860|NCT01217814|DRUG|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
47968861|NCT01217814|DRUG|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
48487057|NCT03722355|RADIATION|Hyperfractionated RT|Radiation therapy
48487058|NCT03722355|DRUG|Carmustine|Chemotherapy
48487059|NCT01487382|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
48487060|NCT05916521|DRUG|0.454% stannous fluoride|Brush two times daily
48487061|NCT05916521|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
47968862|NCT01217814|DRUG|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
47968863|NCT00000445|DRUG|naltrexone (Revia)|
48117239|NCT03923946|BEHAVIORAL|Compassion focused therapy|Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
48487062|NCT05916521|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
48487063|NCT04376528|DRUG|Cyclosporin A|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)
48487064|NCT04376528|DRUG|Mycophenolate Mofetil|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )
48487065|NCT04957420|DRUG|Neupro|Rotigotine Patches
48487066|NCT02865395|DRUG|Belladonna and Opium Suppository|
48487067|NCT02865395|PROCEDURE|Rectal Exam|
48487068|NCT00216645|DRUG|doxorubicin hydrochloride|
48117240|NCT01574807|DRUG|mepivacaine + lidocaine followed by lidocaine +lidocaine|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
48487069|NCT01374139|DRUG|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
48487070|NCT01374139|DRUG|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
48487071|NCT03885882|DRUG|E0302 SR1|E0302 SR1, oral tablet.
48487072|NCT03885882|DRUG|E0302 SR3|E0302 SR3, oral tablet.
48646343|NCT02999997|BEHAVIORAL|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
48646344|NCT03370835|DRUG|Metoprolol succinate ER|Cardioselective beta-blocker
48646345|NCT03370835|DRUG|Carvedilol|Non-cardioselective beta-blocker
48646346|NCT00480025|BIOLOGICAL|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
48646347|NCT00480025|BIOLOGICAL|Placebo Control|Intramuscular administration, 13 doses
47968864|NCT03292562|DEVICE|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
47968865|NCT03292562|DEVICE|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
47968866|NCT05055362|OTHER|Honey Spice Group|Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
47968867|NCT01650844|OTHER|School-Based Telemedicine Enhanced Asthma Management|
47968868|NCT01650844|OTHER|Enhanced Usual Care|
48117241|NCT01574807|DRUG|lidocaine + lidocaine followed by mepivacaine + lidocaine|1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
48487073|NCT03885882|DRUG|E0302 SR2|E0302 SR2, oral tablet.
48646348|NCT06688318|BIOLOGICAL|Intra-articular secretome injection therapy|Intra-articular secretome injection therapy from hypoxic umbilical cord mesenchymal stem cell conditioned media
47968869|NCT03305575|DRUG|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
48117242|NCT03450096|OTHER|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
48487074|NCT03885882|DRUG|E0302 IR|E0302 IR, oral tablet.
48487075|NCT01089621|DRUG|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
48487076|NCT00597116|DRUG|Vinorelbine|
48487077|NCT00597116|DRUG|Vandetanib|once daily oral dose
48487078|NCT00234182|DRUG|Interferon alpha-2b|
48487079|NCT06415617|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving . The participants will be engaged in psychoeducation through group discussion, individualised goal setting and reflective exercises."
48487080|NCT06415617|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
48487081|NCT03785535|DEVICE|Vibrotactile stimulation|The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
48117243|NCT04985136|DRUG|camrelizumab；Rivoceranib|Camrelizumab at 200 mg via intravenous administration (IV), once every 2 weeks (Q2W), in combination with 250 mg of rivoceranib mesylate, oral administration, once a day (QD)
48117244|NCT04985136|DRUG|Rivoceranib|Rivoceranib mesylate (750 mg, QD, po)
47968870|NCT03305575|DRUG|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
48117245|NCT04985136|DRUG|Sorafenib|Sorafenib tosylate (400 mg, twice a day (BID), po)
48117246|NCT04985136|DRUG|Regorafenib|Regorafenib (160 mg, administer for 21 days then stop for 7 days, po)
48117247|NCT06551909|RADIATION|Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost|Patients with Glioblastoma will receive neoadjuvant stereotactic radiotherapy to Planning Target Volume (PTV) to 30 Gy in 5 fractions, and a Simultaneous Integrated Boost delivering 35-50 GY to GTV. Patients will be divided into groups of 5 and will receive (in the absence of 2 G4 toxicities per group), the following dose levels: 35-40-42.5-45-47.5 and 50 Gy. Standard Temozolomide chemotherapy will be prescribed after surgery.
48117248|NCT00224601|PROCEDURE|Colonoscopy with chromoscopy|
48487082|NCT04102631|DIAGNOSTIC_TEST|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
48117249|NCT05377151|OTHER|Mobile application|"Nutrition intervention using either mHealth interventions or conventional methods will be carried out among pregnant women).~Subjects will be allocated into three groups, namely, two interventions group which are:~Group 1: mHealth intervention group (98 subjects)~Group 2: mHealth intervention group + dietitian consultation (98 subjects)~Group 3: control group (98 subjects)"
47968871|NCT01435200|DRUG|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
47968872|NCT06321783|OTHER|Assessment|Evaluation of cervical proprioception, hand-eye coordination, postural control and endurance of cervical muscles
47968873|NCT00585247|DRUG|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
48117250|NCT03399916|BEHAVIORAL|Prompt sent|
48117251|NCT00946582|BEHAVIORAL|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
48487083|NCT04102631|DIAGNOSTIC_TEST|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
48117252|NCT04756245|BEHAVIORAL|Virtual Reality|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
48320665|NCT02474524|BEHAVIORAL|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
48487084|NCT03166553|DRUG|Elemene|
48487085|NCT06226701|DEVICE|Cryolipolysis device|"-Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months."
48487086|NCT01170910|PROCEDURE|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
48646349|NCT06689670|DEVICE|Needle based delivery of INT001 into liver tumors under real-time image guidance|Using ultrasound or CT imaging, the liver tumor is located. Under local anesthesia or, if necessary, intravenous sedation, the needle is inserted through the skin and the needle tip is brought to the center of the liver tumor using image guidance. 1-2 ml of the INT-001 is injected. The needle is removed and a bandaid is applied to the skin entry site. Right after, or as soon as MRI becomes available, MRI is performed to show that the entire tumor has been treated.
48646350|NCT06686862|DRUG|ibuprofen|Ibuprofen tapering schedule during 3 weeks. First week: Ibuprofen 600 mg every 8 hours. Second week: Ibuprofen 600 mg every 12 hours. Third week: Ibuprofen 600 mg every 24 hours.
48646351|NCT03570515|BEHAVIORAL|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
48646352|NCT03570515|BEHAVIORAL|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
48646353|NCT06691737|OTHER|Whole Body Vibration|"Whole body vibration consists of 3-minute vibrations with a 30-second break. Participants were asked to step onto the platform barefoot and position their feet 3 from the center of the platform, with feet pointing forward, knees slightly bent, and upper limbs along the body. The training was divided into two parts: week 1 with a frequency of 20 Hz, and a constant amplitude of 3 mm."
48646354|NCT02965456|DRUG|IDP 121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
48646355|NCT02965456|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
48117253|NCT04756245|BEHAVIORAL|Video Conference|Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
47968874|NCT00585247|OTHER|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
48646356|NCT06689267|DIAGNOSTIC_TEST|computed tomography myocardial perfusion|The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients.
48646357|NCT06689267|PROCEDURE|Invasive Coronary Angiography|Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed.
48117254|NCT03899324|DRUG|Bumetanide white, oblong, scored tablet|Bumetanide with a titration period
48117255|NCT03899324|DRUG|Placebo white, oblong, scored tablet|placebo intake identically to group 1
48117256|NCT02986269|PROCEDURE|general anesthesia across LMA|general anesthesia across LMA
48117257|NCT02986269|PROCEDURE|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
48320666|NCT05385497|OTHER|Aerobic Exercise|Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper
48320667|NCT05385497|DEVICE|Virtual Reality|Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
48646358|NCT06687421|OTHER|High-risk treatment SOC|radiotherapy (RT) + ADT (3 years) + Abiraterone acetate (2 years), with radical prostatectomy being an option if contraindication for RT exists)
48646359|NCT06687421|OTHER|Active monitoring|Followed with PSA measurements
48646360|NCT06687421|PROCEDURE|Radical prostatectomy|Radical prostatectomy
48646361|NCT06687421|RADIATION|Radiotherapy|Radiotherapy
48646362|NCT06687421|DRUG|Androgen deprivation therapy|GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel
47968875|NCT03689348|DIETARY_SUPPLEMENT|Avena sativa|A supplement derived from wild green oat
48320668|NCT05692648|BEHAVIORAL|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
48487087|NCT01170910|PROCEDURE|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
48487088|NCT04439084|OTHER|Prospective Chart Review|Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
48487089|NCT03642782|DEVICE|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
48117258|NCT02986269|PROCEDURE|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
48117259|NCT06012331|PROCEDURE|concentrated growth factors in open apex|"Dry canals with paper points. A 10 ml of venous blood will be collected and transferred to sterile tubes without anticoagulant solutions by a trained nurse. The tubes will be centrifuged machine using a one-step centrifugation protocol at variable rpm, after centrifugation, four layers will be obtained: the first layer at the top is serum, second layer is the fibrin buffy coat, the third layer is the liquid phase containing growth factors, The concentrated growth factor was separated from the red blood cells and serum using sterile scissors.~CGF will be packed into canal to the full working length using sterile pluggers.~The coronal level of the CGF gel is near the cervical area above cementoenamel junction and white MTA placed as capping material after CGF, then GIC and composite restoration"
48487090|NCT01069952|DEVICE|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
48487091|NCT00228241|DEVICE|AAI vs. DDD vs. BIV pacing in different patients groups|
48487092|NCT00350649|BEHAVIORAL|Standard CBT|Manualized delivery of CBT by trained clinicians
48487093|NCT00350649|BEHAVIORAL|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
48487094|NCT00350649|BEHAVIORAL|CM/abstinence|Contingency Management
47968876|NCT03689348|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48487095|NCT00350649|BEHAVIORAL|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
47968877|NCT04999176|DRUG|Rivaroxaban|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
48117260|NCT06012331|PROCEDURE|Blood Clot (BC)|"1. Create bleeding into the canal by over-instrumenting (induce by rotating a pre-curved K-file at 2 mm past the apical foramen with the goal of having the entire canal filled with blood to CEJ level)~2. Stop bleeding at a level that allows for 3-4 mm of restorative material.~3. Then white MTA as a coronal plug material be followed by GIC, then composite restoration."
48117261|NCT03811574|DRUG|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
48487096|NCT03036774|PROCEDURE|Ultrasonic measurement of antral area|"Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures."
48487097|NCT00887328|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
48487098|NCT00887328|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
48487099|NCT00892788|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
48646363|NCT06690463|DIAGNOSTIC_TEST|sacroiliac joint injection|"The procedure involves the administration of a 2.5 cc injection of 2% lidocaine to the sacroiliac joint, targeting the articular or periarticular areas. The injection is performed under real-time ultrasound guidance to ensure accurate placement of the needle.~The 2% lidocaine solution is injected into both the joint space (articular area) and the surrounding soft tissues (periarticular area), which may include ligaments, capsules, and adjacent muscles. The goal is to temporarily anesthetize the joint and surrounding structures to assess the contribution of the sacroiliac joint in the patient's pain, as well as to provide therapeutic pain relief. The use of ultrasound ensures minimal risk of injury to surrounding structures and enhances the accuracy of the injection.~This intervention is commonly used in both diagnostic and therapeutic settings, helping to confirm the role of the sacroiliac joint in a patient's symptoms and providing relief in cases of sacroiliac joint dysfunction."
48646364|NCT06682572|DRUG|Avutometinib (VS-6766) + Defactinib (VS-6063)|combination therapy
48646365|NCT06684379|DRUG|Placebo comparator|A single dose of saline solution 0.9% for infusion
48646366|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose A) for infusion
48646367|NCT06684379|DRUG|PRS CK STORM|A single dose of PRS CK STORM (dose B) for infusion.
48646368|NCT04100603|OTHER|No Intervention|There is no intervention for this study
47968878|NCT04999176|DRUG|Enoxaparin|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
48487100|NCT00892788|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
48487101|NCT02188082|DRUG|IvabRadine hemisulfate Sustained-release Tablets|
48646369|NCT06689384|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 4 different intraoral scanners (IOS) (Trios 3, 3Shape; Primescan, Dentsply; Element 5D, iTero; Lumina, iTero) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
48646370|NCT06689384|PROCEDURE|Clamp placement on canine and 2nd molar teeth and rubberdam rubber band insertion|"The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth.~A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology."
47968879|NCT02746744|DRUG|Rituximab|Infusion of Mabthera/Rituximab every 6 months
47968880|NCT02746744|DRUG|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
48117262|NCT03811574|DRUG|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
48117263|NCT00767013|OTHER|DSCT, TTE|One assessment each
48117264|NCT00551980|BEHAVIORAL|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
48117265|NCT06188377|DEVICE|measured by a impedance analyzer|the healthy chinese neonates will be measured by a impedance analyzer, and will be compared with that of other ethnicity whose data have been reported by literatures.
48487102|NCT02188082|DRUG|placebo|
48487103|NCT02196740|DRUG|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
48487104|NCT02196740|DRUG|creosote|Pulp removal,Root canal irrigation and disinfection
48487105|NCT02631018|BEHAVIORAL|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
48320669|NCT05692648|BEHAVIORAL|Hourly position change group|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
48320670|NCT05692648|BEHAVIORAL|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation. Phototherapy was started with neonates in supine position. In the second period, the neonate was placed in the prone position after routine feeding was performed.
48320671|NCT02864966|DEVICE|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
48320672|NCT00979446|BEHAVIORAL|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
48320673|NCT00979446|BEHAVIORAL|Self-directed|Received study materials but no phone coaching
48320674|NCT03911336|DRUG|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
48320675|NCT03911336|DRUG|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
48487106|NCT02631018|BEHAVIORAL|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
48487107|NCT03507348|DRUG|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
48487108|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
48646371|NCT05544344|BEHAVIORAL|Healthy ReStart|In addition to receiving mental health services as usual, subjects receive services from health coaches over a four-month period to assist them in creating a Restart plan and attaining related life goals.
47968881|NCT02746744|DRUG|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
47968882|NCT03003390|DRUG|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given \<24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
48320676|NCT03911336|DRUG|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
48487109|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
48487110|NCT03507348|OTHER|Transplant Day-0|TRANSPLANTATION
48487111|NCT00446199|DRUG|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
48487112|NCT00446199|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
48487113|NCT00446199|DRUG|Estradiol (E2 0.3mg)|One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
48487114|NCT00446199|DRUG|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
48320677|NCT05738902|OTHER|Assessment of compliance to ERAS.|Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
48487115|NCT04136418|DEVICE|COPDPredict mobile App|An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
48487116|NCT04136418|OTHER|Usual care|Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
48487117|NCT00986570|BIOLOGICAL|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
48646372|NCT05544344|OTHER|Services as Usual|Subjects receive mental health services as usual.
48646373|NCT06687187|DRUG|Neostigmine|two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
48646374|NCT06689254|DRUG|Mifepristone 1200 mg daily|Oral tablets
48487118|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 1|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
48487119|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 2|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
48487120|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 3.|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
48487121|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 4|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
48646375|NCT06689254|DRUG|Placebo|Oral tablet
48487122|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 5|2 doses of study intervention are administered to participants intramuscularly. If selected as dose level 1 or dose level 2 in Phase 2 Part B, 1 dose is administered to participants.
48487123|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 6|1 dose of study intervention is administered to participants intramuscularly.
48487124|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 7|1 dose of study intervention is administered to participants intramuscularly.
48117266|NCT01909167|BEHAVIORAL|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
48320678|NCT04597281|OTHER|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
48320679|NCT02247284|DEVICE|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
48320680|NCT00679731|DRUG|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
48320681|NCT00679731|DRUG|Methotrexate|5.0 to 25 mg weekly
48340062|NCT04708769|BEHAVIORAL|Diabetes Prevention Program Participants (DPP)|In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist. They will also be provided with a wireless bluetooth scale and portable blood pressure machine.
48487125|NCT06382311|DRUG|Placebo|2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.
48487126|NCT01389934|DRUG|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
48487127|NCT01389934|DRUG|Placebo|Women of this group be infused saline 2 ml / h for 48h.
48487128|NCT05101226|BEHAVIORAL|Yoga attended in person|One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
48487129|NCT05101226|BEHAVIORAL|Yoga attended online|One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
48646376|NCT06691555|DEVICE|Suprachoroidal silicone tube (SST) shunt|This intervention involves implanting a modified suprachoroidal silicone tube (SST) shunt, derived from the Aurolab Aqueous Drainage Device (AADI), to lower intraocular pressure in patients with primary open-angle and pseudoexfoliative glaucoma. The SST shunt, measuring 13.0-15.0 mm with a 0.3 mm inner and 0.6 mm outer diameter, is designed to reach the posterior suprachoroidal space. Six slits near the distal end aid aqueous outflow. Implantation involves creating a scleral flap, accessing the SCS, and placing the distal end in the SCS and proximal end in the anterior chamber (AC). The shunt is secured with sutures, and viscoelastic is injected into the AC to prevent hypotony. No antimetabolites or cautery are used.
47968883|NCT04869644|BEHAVIORAL|Goal setting|Goal setting: set or agree on a goal defined in terms of behavior to be achieved.
48646377|NCT06688890|OTHER|Surgical hand rub with the reference product; n-propanol 60%.|Propanol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
48646378|NCT06688890|OTHER|Surgical hand rub with the product P1; Sorbectol for 1 min.|Sorbectol hand rub for 1 min. The applied volume of product is sufficient to keep the hand moist for a total time of 1 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
48646379|NCT06688890|OTHER|Surgical hand rub with the product P2; Sorbectol for 3 min.|Sorbectol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
48646380|NCT06688890|OTHER|Surgical hand rub with the product P3; Sorbectol for 5 min.|Sorbectol hand rub for 5 min. The applied volume of product is sufficient to keep the hand moist for a total time of 5 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
47968884|NCT04869644|BEHAVIORAL|Action Planning|Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity.
47968885|NCT04869644|BEHAVIORAL|Self-monitoring of behavior|Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit.
47968886|NCT04869644|BEHAVIORAL|Behavioral Practice/Rehearsal|Behavioral rehearsal: prompt practice or rehearsal of walking one or more times in a context when the performance may not be necessary, in order to increase habit and skill.
48340063|NCT03382262|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
48117267|NCT01909167|OTHER|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
48117268|NCT04792905|DEVICE|Cardiologs|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
48487130|NCT04877171|OTHER|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
48487131|NCT04877171|OTHER|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
48117269|NCT00393484|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
48487132|NCT00361114|DRUG|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
48487133|NCT00361114|DRUG|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
48117270|NCT00393484|DRUG|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
48117271|NCT00393484|DRUG|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
48487134|NCT00361114|DRUG|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
48117272|NCT00393484|DRUG|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
48117273|NCT04306718|PROCEDURE|membrane peeling|ERM and ILM are peeled routinely during surgery
48117274|NCT05382104|DRUG|Maribavir|Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
48117275|NCT02807493|DEVICE|Occlusal Support Device|Bite plate
48487135|NCT05212064|DEVICE|high-flow oxygen nasal cannula therapy|Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.
48487136|NCT05212064|OTHER|nasal cannula oxygen therapy|Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
48487137|NCT04870723|BEHAVIORAL|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
48487138|NCT06331858|DEVICE|hip device-assisted concentric abductor strengthening (HDACAS)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
48487139|NCT06331858|DEVICE|knee device-assisted concentric flexor-extensor strengthening (KDACFES)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
48487140|NCT00886041|PROCEDURE|laparoscopy|subjected to laparoscopy
48117276|NCT02807493|OTHER|Control|Control group
48117277|NCT00861029|DRUG|Pazopanib|Subjects treated with pazopanib
48117278|NCT00861029|OTHER|Placebo for pazopanib|Control for comparison with pazopanib
48117279|NCT00861029|DRUG|Moxifloxacin|Comparator for pazopanib
48117280|NCT00861029|OTHER|Placebo for moxifloxacin|Placebo for moxifloxacin
48117281|NCT00296361|DRUG|Tacrolimus|immunosuppression
48117282|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-DP plus MTZ to assess whether DP is superior to SP in preventing adverse birth outcomes. This intervention arm will also be compared to the IPTp-SP plus MTZ placebo arm to assess whether the combination of MTZ with IPTp-SP is superior to IPTp-SP alone in reducing adverse pregnancy outcomes.
48340064|NCT03382262|DRUG|TAcs 40 mg|Immediate-release 40mg TAcs IA injection
48340065|NCT02829775|DRUG|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
48340066|NCT02829775|DRUG|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
48487141|NCT00886041|OTHER|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
48487142|NCT01778153|BEHAVIORAL|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
48487143|NCT00567736|DRUG|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
48487144|NCT00567736|DRUG|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
48487145|NCT02796131|DRUG|RDX5791|
48487146|NCT02796131|DRUG|Placebo|Placebo
48117283|NCT04189744|DRUG|IPTp-dihydroartemisinin-piperaquine plus metronidazole|Metronidazole (MTZ) is indicated for the treatment of BV and TV and is also safe to administer in the second and third trimesters of pregnancy, and its use with SP or DP may result in better birth outcomes than SP alone. Malaria parasites have developed resistance against SP and the treatment is sub-optimal at clearing malaria infection compared to dihydroartemisinin-piperaquine (DP), therapy that has a suitable profile for use in IPTp. This intervention arm can be compared to the intervention arm IPTp-SP plus MTZ to assess whether DP is superior to SP in in reducing adverse pregnancy outcomes.
48320682|NCT02834234|GENETIC|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
48117284|NCT04189744|DRUG|IPTp-sulphadoxine-pyrimethamine|The World Health Organization (WHO) recommends providing intermittent preventive treatment (IPTp) using sulphadoxine-pyrimethamine (SP) to pregnant women during the second and third trimesters of pregnancy to clear placental infection.
48117285|NCT01537419|BEHAVIORAL|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
48320683|NCT02608034|DRUG|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
48320684|NCT02608034|DRUG|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
48320685|NCT02608034|DRUG|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
48320686|NCT00163072|DRUG|transdermal Megace|oral vs transdermal levels
48320687|NCT02456181|BEHAVIORAL|JumpMath|
48320688|NCT00184782|PROCEDURE|FDG-PET|
48320689|NCT01794247|DRUG|Magnesium sulfate|
48487147|NCT02701231|DEVICE|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
48320690|NCT01794247|DRUG|Fentanyl|
48320691|NCT01794247|DRUG|Lidocaine|
48320692|NCT01594138|OTHER|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
48320693|NCT01693133|OTHER|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
48487148|NCT02701231|DRUG|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
48487149|NCT02701231|DEVICE|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
48487150|NCT00891371|DRUG|lanreotide (Autogel formulation)|Autogel 120mg
48320694|NCT01693133|OTHER|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
48320695|NCT06483165|OTHER|BE FAST Educational video|A 1-minute educational video format using BE FAST. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
48320696|NCT06483165|OTHER|F.A.S.T. Educational Video|A 1-minute educational video format using F.A.S.T. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
48320697|NCT06082557|DRUG|T60c injection|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."
47968887|NCT04869644|BEHAVIORAL|Habit Formation|Prompt rehearsal \& repetition of walking 2,000 steps or more in the same context repeatedly so that the context elicits the behavior.
48117286|NCT01537419|BEHAVIORAL|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
48117287|NCT03086161|BEHAVIORAL|Interpersonal Psychotherapy|Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy
48320698|NCT04696458|DIETARY_SUPPLEMENT|Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483)|Probiotic Capsules in blister packets of capsules containing the probiotic intervention contain a combination of three strains of lactic acid bacteria: two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483).
48320699|NCT04696458|OTHER|Placebo Comparator: Placebo|Placebo Capsules in blister packets of capsules containing the inert (controlled) non-interventional treatment.
48320700|NCT00057395|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
48320701|NCT06170801|BEHAVIORAL|Kiesler Circle Training (KCT)|Kiesler Circle Training is a transdiagnostic modular group treatment, which comprises a baseline module and four additional independent modules (nonverbal communication, verbal communication, conflict training and empathy and corrective interpersonal experiences). KCT is based on a heuristic model to explain and anticipate interactions developed by Donald Kiesler and other representatives of the interpersonal theory. The circumplex model arranges the variety of interpersonal behaviors in terms of a circular continuum allocated on two orthogonal axes: The vertical axis addresses interpersonal control (agency), the horizontal axis addresses interpersonal communion. The model further allows illustrating complementary action tendencies to anticipate other's reactions and to guide own behavior to achieve interpersonal goals. KCT is designed for increasing the awareness of such interpersonal action tendencies and for improving interpersonal behavioral flexibility.
48487151|NCT04918303|DEVICE|SKNA recording|"The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6"
48487152|NCT03903458|DRUG|Tinostamustine|First-in-human administration of the combination of Tinostamustine and Nivolumab.
48487153|NCT03196414|BIOLOGICAL|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
48487154|NCT04766541|OTHER|no intervention|There is no intervention.
48487155|NCT05895721|OTHER|Virtual Reality|Virtual Reality as adjunct treatment
48487156|NCT00344214|BEHAVIORAL|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
47968888|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 1|Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
47968889|NCT04579757|DRUG|Surufatinib and Tislelizumab _ Part 2|Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
47968890|NCT04847362|BEHAVIORAL|Experimental|education group
48117288|NCT03086161|BEHAVIORAL|Treatment-as-usual|Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
48117289|NCT03359889|DRUG|PraxbindTM|Drug
48117290|NCT00492271|DRUG|Friulimicin B|Intravenous, once daily, single dose
48117291|NCT05780788|DEVICE|Monitoring Tooth Movement|Monitoring Canine Retraction
48117292|NCT06148727|DEVICE|Dental implant placement|Procedure/ surgery: Surgical placement of dental implants, four interforaminal dental implants were placed
48487157|NCT00344214|BEHAVIORAL|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
48487158|NCT05253274|DEVICE|Virtual Reality Glasses|In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
48646381|NCT06689072|OTHER|rTMS|To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder
48117293|NCT06148727|DEVICE|Bar attachment|Device: attachment, implants were connected to each others by 3 implant assembly in a trapezoidal design implants were loaded after 3 months of osseo-integration Control Group: patients received coventionally constructed heat cured overdenture Study Group: patients received 3d printed overdenture
48117294|NCT03050814|DRUG|Avelumab|10 mg/kg intravenous (IV) over 30-60 min on Day 1
48117295|NCT03050814|BIOLOGICAL|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
48117296|NCT03050814|DRUG|Bevacizumab|5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
47968891|NCT02256189|DRUG|Sitagliptin|Sitagliptin 100 mg daily
48117297|NCT03050814|DRUG|5-Fluorouracil (FU)|400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.
47968892|NCT02256189|DRUG|Placebo|Placebo one tablet daily
47968893|NCT04387032|OTHER|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
47968894|NCT04387032|OTHER|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
47968895|NCT03570021|PROCEDURE|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection \[Hartl DM, Ann Surg 2012\], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons \[Hartl DM, World J Surg 2012\]."
47968896|NCT03570021|PROCEDURE|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
47968897|NCT05932485|PROCEDURE|Stellate nerve block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
47968898|NCT05119452|OTHER|Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)|The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
47968899|NCT02126020|DRUG|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
47968900|NCT04012983|DIAGNOSTIC_TEST|gingival crevicular fluid level|gingival crevicular fluid collection
47968901|NCT00603616|DRUG|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
47968902|NCT00603616|DRUG|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
47968903|NCT06446011|PROCEDURE|root canal treatment in Ckd patients|root canal treatment in teeth with apical periodontitis to observe periapical healing , and change in eGFR ,blood urea and creatinine and HSCRP
47968904|NCT06446011|PROCEDURE|root canal treatment in healthy patients|root canal treatment in teeth with apical periodontitis to observe periapical healing and change in HSCRP
47968905|NCT05027100|DRUG|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
47968906|NCT00217295|DRUG|Avonex and Topamax|
47968907|NCT05469828|DRUG|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
47968908|NCT05469828|OTHER|control|Standard of care
47968909|NCT01051323|DRUG|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
47968910|NCT03355040|OTHER|induction of labour|induction of labour
47968911|NCT04309539|PROCEDURE|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
47968912|NCT04309539|PROCEDURE|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
48117298|NCT03050814|DRUG|Leucovorin|400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
48646382|NCT06689072|BEHAVIORAL|Psychotherapy|Using psychotherapy in opioid use disorder.
48646383|NCT06689540|BIOLOGICAL|MTS105|"MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg."
48646384|NCT04845555|OTHER|Observation of the association between clotting factor level and risk of bleeding whilst physical activity|"The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit."
48646385|NCT06680232|BIOLOGICAL|PBGENE-HBV|PBGENE-HBV is an in vivo gene editing intervention based on a novel proprietary ARCUS® platform designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.
48117299|NCT03050814|DRUG|Oxaliplatin|85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
48117300|NCT03050814|DRUG|Capecitabine|625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
48117301|NCT03050814|DRUG|5-Fluorouracil (FU)|2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
48117302|NCT05896319|DEVICE|Hyaluronic acid gel|"Post-operative application of Hyaluronic acid gel 3 times per day (8 hours distance between each application) for 7 days after oral hygiene and without swallowing, eating or drinking for one hour after the application, as follows: wash your hands thoroughly before each application, apply a layer of gel on the injured mucosa, massage with a finger in order to facilitate spreading of the product over the treated area."
48117303|NCT02988037|BEHAVIORAL|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
48117304|NCT03837431|DIAGNOSTIC_TEST|Skin slit|Skin slit microscopy, RDT and PCR
48117305|NCT03837431|DIAGNOSTIC_TEST|Dental broach|Dental broach RDT and PCR
48117306|NCT03837431|DIAGNOSTIC_TEST|Tape disc|Tape disc PCR
48117307|NCT05448846|PROCEDURE|Enhanced Recovery After Surgery|ERAS protocol includes preoperative counselling, optimization of nutrition, standardized analgesic and anesthetic regimens and early mobilization.
48646386|NCT06682598|OTHER|Multicomponent physical exercise training|The subjects will perform one session per day of multicomponent physical exercise training, consisting of strength, power, balance, and walking exercises. The program will have progressive intensity and volume, adapted to the frailty level of the patient. The frailty level will be screened by the Short Physical Performance Battery. Each session will consist of two strength exercises for the upper limbs and one to three for the lower limbs. Also, one exercise for balance, and walking. Participants will be instructed to perform the concentric phase of the movement as fast as possible, since a good quality of movement is maintained, and the eccentric phase in two seconds. An expert researcher will supervise the entire session.
48646387|NCT06686056|COMBINATION_PRODUCT|AIM-CHD Mobile Health Intervention|The AIM-CHD platform synchronizes data from hospitalization records, questionnaires, AI-powered voice follow-ups, and wearable devices to perform risk stratification and manage uncontrolled risk factors. It provides individualized follow-up plans, medication reminders, and lifestyle education, with real-time assessments of vital health metrics to prompt necessary in-person consultations. The app offers online consultation access and emergency services through Fuwai Hospital. Additionally, it delivers personalized patient education, aligning with the latest clinical guidelines.
48646388|NCT06686056|COMBINATION_PRODUCT|Usual post-discharge care|Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.
48646389|NCT06687460|OTHER|Brief electrical stimulation|During the nerve micro-reconstruction surgery, electrical stimulation is given to the distal end of the damaged nerve for 30 minutes.
48646390|NCT06679504|PROCEDURE|Fibrin glue fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Fibrin Glue fixation
47968913|NCT03123718|DRUG|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
48117308|NCT05448846|BEHAVIORAL|Home-based multicomponent exercise program (EXE)|"Home-based multicomponent exercise program:~A) Strength and balance (20 to 40 minutes, 2 days/week):~* Chair sit to stand exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 in the Rated of Perceived Exertion, 0-10 scale (RPE).~* Seated curl to press exercise \| 1 to 3 sets completing repetitions until rating 5 to 8 RPE.~* Monopodal balance \| 1 to 3 sets with progressive time targets up to 60-second for each leg.~B) Gait (at least 30 minutes at an intensity that allows for comfortable conversation, 2 days/week on separate days from strength and balance exercise)~C) Inspiratory Muscle Training: 30 inspirations at 40% of maximal inspiratory pressure through a Power Breathe device, 2 times per day)"
48117309|NCT00910767|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
48117310|NCT00910767|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
48646391|NCT06679504|PROCEDURE|Tack fixation|Laparoscopic Totally Extraperitoneal Inguinal Hernia Repair With Tack Mesh Fixation
48117311|NCT01061203|DRUG|Grazax|Treatment with 75.000 SQ-T once daily
48117312|NCT01061203|DRUG|Placebo|Tablet with no active grass component.
48117313|NCT05162755|DRUG|S095029|S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.
48117314|NCT05162755|DRUG|S95029 and Sym021|Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
48117315|NCT05162755|DRUG|S095029 and Sym021 and anti-HER2 therapy|Patients will be administered with S095029, Sym021 and anti-HER2 therapy.
48646392|NCT02180867|DRUG|Doxorubicin|Given IV
48646393|NCT02180867|DRUG|Doxorubicin Hydrochloride|Given IV
48646394|NCT02180867|DRUG|Ifosfamide|Given IV
48117316|NCT05162755|DRUG|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|Patients will be administered with S095029, Sym021 and futuximab/modotuximab.
48117317|NCT04152694|OTHER|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
48117318|NCT01016522|DIETARY_SUPPLEMENT|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
48646395|NCT02180867|DRUG|Pazopanib|Given PO
48646396|NCT02180867|DRUG|Pazopanib Hydrochloride|Given PO
48646397|NCT02180867|RADIATION|Radiation Therapy|Undergo radiation therapy
48117319|NCT03210129|BEHAVIORAL|Motivational interviewing|"the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.~Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle."
48646398|NCT02180867|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48646399|NCT04147884|DEVICE|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
48646400|NCT01251861|DRUG|Akt Inhibitor MK2206|Given PO
48646401|NCT01251861|DRUG|Bicalutamide|Given PO
47968914|NCT03123718|DRUG|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years."
48117320|NCT05822063|DRUG|Lidocaine topical|lidocaine spray
48117321|NCT05822063|OTHER|cold packs|ice packs
48117322|NCT05822063|DEVICE|flash lights|flash lights by camera
48117323|NCT01124734|DRUG|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
48646402|NCT01251861|OTHER|Clinical Observation|Undergo clinical observation
48646403|NCT01251861|OTHER|Laboratory Biomarker Analysis|Correlative studies
48646404|NCT06686407|PROCEDURE|Open lumbar decompression ± fusion|"Open lumbar decompression by laminectomy and transpedicular screw fixation using screws and rods ± interbody cage device"
48646405|NCT06686407|PROCEDURE|"Minimally invasive lumbar foraminal decompression using unilateral biportal endoscopy device"|A new endoscopic technique that uses a Unilater Biportal Endoscopy for lumbar foraminal decompression
48646406|NCT05472987|PROCEDURE|Ventral Hernia Repair|Patients will undergo retromuscular ventral hernia repair
48646407|NCT06602258|DRUG|E2814|E2814 IV infusion.
48646408|NCT06602258|DRUG|Lecanemab|Lecanemab SC injection.
48646409|NCT06602258|DRUG|Placebo|Placebo IV infusion.
48646410|NCT06690736|DIAGNOSTIC_TEST|CXCR4 PET/CT Imaging|Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
48646411|NCT02579551|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical excision
48646412|NCT01265147|DRUG|Cisplatin|40mg/m2/w
48646413|NCT01265147|DRUG|Nedaplatin|40mg/m2/w
48646414|NCT06688734|PROCEDURE|Inital water seal|After chest tube placement, the chest tube will be placed to 20cm H2O of suction for 1 minute to evacuate all pneumothorax. After this, the chest tube will be placed to water seal, defined as the water seal chamber on the chest tube drainage system being filled up to the 2cm line and not on suction. All other management decisions related to the chest tube will be left to the providers.
48646415|NCT06688734|PROCEDURE|Initial suction|After chest tube placement, the suction group will have their chest tube placed to 20cm H2O of suction delivered by the chest tube drainage suction. All other management decisions related to the chest tube will be left to the providers.
48646416|NCT06686992|BEHAVIORAL|Vaccination|The researcher will fill in the questionnaire and scales 5 minutes before the vaccination. During the procedure, the child will be played with roll-and-draw. The scales will be filled in again 5 minutes after the procedure. It will take an average of 5-10 minutes to fill out the forms.
48646417|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB).|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
48117324|NCT01124734|DRUG|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
48320702|NCT06170801|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is based on the interrelationships of thoughts, actions and feelings. Presumably, individual CBT will address intrapersonal therapeutic foci such as behavioral activation, identification of dysfunctional thoughts, overcoming fears by exposure, etc. Individual CBT may also include interpersonal functioning as therapeutic foci. Disorder-specific treatment manuals are available for all diagnoses included in the study. Of note, state-of-the-art CBT does not necessarily mean, that individual CBT-sessions strictly adhere to a manual. However, because both study sites are CBT training institutes, which guarantee supervision at least every four hours, it can be estimated that state-of-the-art CBT is realized.
48320703|NCT01057069|DRUG|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
48320704|NCT01057069|DRUG|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
48487159|NCT00252174|DRUG|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
48487160|NCT00252174|DRUG|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
48646418|NCT06689202|OTHER|The Hiroshima University - Dental Behavioral Inventory (HU-DBI) by Kawamura will be used as a validated instrument to assess oral health-related knowledge, attitudes, and behaviors (KAB)|The assessment will include 20 HU-DBI items, which employ a dichotomous response format (agree/disagree). However, only 12 items will be used to calculate the overall KAB score, which will range from 0 to 12, with higher scores indicating better oral health KAB.
48646419|NCT06688357|DEVICE|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
48646420|NCT06688357|DEVICE|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
47968915|NCT06120998|PROCEDURE|Arthroscopic rotator cuff repair|All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
48320705|NCT01057069|DRUG|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
48320706|NCT03115476|DRUG|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
48487161|NCT00252174|BEHAVIORAL|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
48487162|NCT00252174|DRUG|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
48117325|NCT05287282|OTHER|TECAR application|Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
48117326|NCT05459259|OTHER|Interviews and Delphi Survey|no intervention delivered
48117327|NCT04324333|BEHAVIORAL|Digital wearable system|Owlytics Healthcare's system is dedicated to improving the lives of all seniors by using the predictive power of data analytics.
48117328|NCT04853706|DIAGNOSTIC_TEST|3d cam|The 3D-CAM is a short interview that uses verbal responses and allows completion of the Confusion Assessment Method (CAM) diagnostic algorithm
48117329|NCT04853706|DIAGNOSTIC_TEST|DSM 5|The DSM-5 is the gold standard for diagnosing delirium. But proper use requires professional psychiatric background and training.
48117330|NCT04122937|PROCEDURE|Cytoreductive surgery|Partial removal of peritoneal tissue involved by neoplastic invasion
48117331|NCT04395378|DEVICE|Continuous Glucose monitoring DEXCOM G6|Continuous glucose monitoring during flight and normal living life
48117332|NCT05533515|DIAGNOSTIC_TEST|CTC Blood Test|We will draw blood to measure the level of Circulating Tumour Cells
48646421|NCT06686238|DEVICE|Hypoxic Gas Mixture|The EG (Experimental Group) will undergo a single session of IHHE (Intermittent Hypoxia-Hyperoxia Exposure) session using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). They will breathe air with an oxygen concentration (FiO2) ranging from 10-14% for 5 minutes, followed by 3 minutes of rest in hyperoxia (FiO2 30-40%), for a total of 6 cycles. During the hypoxic phase, oxygen saturation will be maintained between 85-92%, while during the hyperoxic phase, it will be kept above 95%. This process is regulated by the device's AI. Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the intervention
48646422|NCT06686238|DEVICE|Sham|The Sham Group (SG) will follow a single session protocol of 5 cycles of 6 minutes per session with an FiO2 of 21% using the MITOVIT® Hypoxic Training System (COMMIT GmbH, Salzgitter, Germany). Participants will be asked to sit and breath normally in each exposure. An attendance checklist will be used to monitor compliance with the placebo intervention.
48646423|NCT06671496|DRUG|Zasocitinib|Zasocitinib tablets.
48646424|NCT06671496|DRUG|Placebo|Zasocitinib matching placebo.
48646425|NCT06027398|DIAGNOSTIC_TEST|SARS-CoV-2 RNA detection|SARS-CoV-2 RNA detection in used mask filters
47968916|NCT02352402|DRUG|Ticagrelor|
47968917|NCT02352402|DRUG|Placebo|
47968918|NCT04942444|OTHER|Dry needling|One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
48117333|NCT05700630|BIOLOGICAL|FT538|FT538 is an investigational off-the-shelf cryopreserved NK cell product derived from an iPSC that contains three functional modifications: 1) a novel high affinity, non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface and remains fully functional after NK cell activation, thus augmenting ADCC; 2) an IL-15 receptor fusion that promotes NK cell activity and enhances cell persistence; and 3) the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.
48117334|NCT05700630|DRUG|Vorinostat|Vorinostat is a histone deacetylase inhibitor (HDACi) that is FDA approved for the treatment of cutaneous T-cell lymphoma and, under investigation in HIV as disruptor of HIV latency.
48320707|NCT03115476|DRUG|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
47968919|NCT00043914|DRUG|lamotrigine|
47968920|NCT03491371|DRUG|Methylsulfonic apatinib|Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
47968921|NCT01734863|RADIATION|External Beam Radiotherapy|
47968922|NCT00547482|DEVICE|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
48646426|NCT06689995|OTHER|Bio-immune Capsule|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg
47968923|NCT00764738|DEVICE|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
48646427|NCT06689995|OTHER|Placebo|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days
48320708|NCT03115476|OTHER|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
48320709|NCT03925961|OTHER|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
48320710|NCT04377061|DIAGNOSTIC_TEST|Evaluation of anemia|Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.
48646428|NCT06687902|DIAGNOSTIC_TEST|Digital breast tomosynthesis|In digital breast tomosynthesis (DBT), images are acquired using a specialized X-ray tube that moves in an arc around the breast. This technique captures multiple low-dose images from various angles, typically within a 15° to 60° range. These images are then reconstructed into 1-mm slices to create a 3D representation of the breast, allowing for detailed layer-by-layer evaluation. The number of images acquired varies depending on the size of the breast and the specifications of the equipment but generally ranges from 10 to 25 projections, captured within a few seconds.
48646429|NCT00004061|BIOLOGICAL|filgrastim|
48646430|NCT00004061|BIOLOGICAL|palifermin|
48646431|NCT00004061|DRUG|cyclophosphamide|
48646432|NCT00004061|DRUG|etoposide|
48646433|NCT00004061|DRUG|ifosfamide|
48646434|NCT00004061|PROCEDURE|peripheral blood stem cell transplantation|
48646435|NCT00004061|PROCEDURE|quality-of-life assessment|
48646436|NCT00004061|RADIATION|radiation therapy|
48646437|NCT00538278|OTHER|Database|database
48646438|NCT06691113|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
48646439|NCT06691113|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
48646440|NCT06691113|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Subcutaneous
48646441|NCT04704700|DEVICE|repair of a cuff tear|Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
48646442|NCT04704700|DEVICE|repair of a cuff tear|Group (Control): standard Arthroscopic repair of the cuff rotator
48646443|NCT06688773|BEHAVIORAL|Progressive relaxation exercise|In this study, the relaxation exercises CD, which is a material created by the Turkish Psychological Association, was used. This CD consists of three parts. The first part consists of 10 minutes and this part explains the definition and purpose of deep relaxation exercise and the points to be considered during the exercise. The second part of the CD consists of 30 minutes of verbal explanation of the items of relaxation exercises accompanied by the sound of a stream. The third part consists of 30 minutes and includes only relaxation music.
48646444|NCT06688773|OTHER|Control group: Standart nursing care group|Routine postoperative patient care in the clinic was applied.
48646445|NCT05747937|DIAGNOSTIC_TEST|Skin biopsy|A punch skin biopsy of 3mm will be used to analyze cutaneous innervation
48646446|NCT05747937|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
48320711|NCT05360420|DIAGNOSTIC_TEST|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
48320712|NCT01721031|PROCEDURE|DPNB|Patients receive DPNB 30min before extubation at the end of operation
48320713|NCT01721031|DRUG|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
48646447|NCT05747937|DIAGNOSTIC_TEST|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire
48646448|NCT05747937|DIAGNOSTIC_TEST|Dinamic Sweat Test|Test for the functional assessment of postganglionic sudomotor pathway
48646449|NCT06691464|DIAGNOSTIC_TEST|PET|FAPI - PET/CT
48646450|NCT06690177|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
48646451|NCT06690177|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
48646452|NCT06687668|OTHER|Short Leg Walking Plaster Cast|A short leg walking plaster cast that extends from the head of the metatarsal to the mid-calf. This cast provides stability to the fracture site while allowing limited weight-bearing, and is designed to restrict inversion and eversion movements, thereby reducing the risk of fracture displacement. Applied for six weeks.
48646453|NCT06687668|OTHER|Walking Foot Plaster Cast|A walking foot plaster cast that covers the foot from the metatarsal heads but leaves the toes exposed. This cast allows weight-bearing while restricting side-to-side movement, providing support to the fracture area without immobilizing the ankle. It will be used for six weeks.
48646454|NCT06687213|BEHAVIORAL|Smoking cessation counselling group|Case group will be counseled to cessate smoking and will be followed up with HbA1c
48646455|NCT01523431|DRUG|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
48646456|NCT01523431|DRUG|5-fluorouracil|The 5-FU dosage will remain the standard.
48646457|NCT01523431|DRUG|Leucovorin|The LV dosage will remain the standard.
48117335|NCT04625257|OTHER|Saliva based assay: crude RNA extraction|Crude RNA extraction to inactivate the virus and stabilize the RNA for transport at room temperature. Validation of the crude RNA extraction from saliva in combination with NGS diagnostics and LAMP assays and point of care test (POCT) for rapid detection of viral antigens on patients' samples.
48320714|NCT06341179|BEHAVIORAL|Sleep extension|Children and their parents will receive a behavioral intervention consisting of two in-person sessions and four virtual sessions. The two in-person sessions will take place at the beginning of the study (during weeks 1 and 2) and will focus on effective behavioral strategies to enhance sleep time, including goal setting (e.g., bedtimes and wake-up times), self-monitoring (via actigraphy), problem-solving and preplanning, stimulus control (i.e., sleep hygiene recommendations), and positive reinforcement. The four virtual sessions will take place at frequent intervals during the 12-week intervention (at weeks 4, 6, 8, and 10) and will act as reminders/refreshers to reinforce strategies to enhance changes in sleep time. Parents will receive advice in relation to altering only their children's sleeping routine (bedtime), and they will be instructed not to directly modify their children's food consumption or physical and sedentary activities during daytime.
48646458|NCT06690697|DRUG|JS004|200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
48646459|NCT06690697|DRUG|Toripalimab|240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
48646460|NCT06690697|DRUG|Axitinib|5 mg, po, bid, each 21 days as a treatment cycle
47968924|NCT00764738|DRUG|Ranibizumab Ophthalmic|0.5 mg ranibizumab vs 2.0 mg ranibizumab
47968925|NCT05830721|DEVICE|MY01 + Standard of Care|In addition to standard of care, the MY01 device will be inserted by an orthopedic surgeon into the leg on the same side as the ECMO tubing. This will occur within 6 hours of the start of ECMO. Insertion of the device involves a needle, which is removed once the device is inserted. Monitoring of the device will occur as described by the device manufacturer, which includes a mobile application. If at any time the compartment pressures suggest that there may be ACS, an orthopedic surgeon will be called to perform a physical exam. If the physical exam supports the diagnosis of ACS, then an additional pressure measurement with a needle may be also taken to confirm the measurement. If the diagnosis of ACS is made, the decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team. Monitoring of with the device will be done for 24 hours. The device will be removed after 24 hours or if the diagnosis of ACS is made.
47968926|NCT05830721|DEVICE|14-Gauge Slit Catheter + Standard of Care|For the 14-gauge slit catheter group, the exact same protocol will be followed as the MY01 group. The 14-gauge slit catheter consists of tubing that is 14-gauge in size, which is inserted into the leg with a needle. The needle will be removed once the tubing is inserted. The tubing is then connected to a monitor, which will display the pressure in the leg. Just like the MY01 group, the leg will be numbed and cleaned before the tube is inserted in the leg. Instead of the data being recorded on a mobile device, a nurse or nurse technician will document pressure readings every 4 hours for a total of 24 hours. Once monitoring is finished, the 14-gauge slit catheter will be removed from the leg.
47968927|NCT05830721|OTHER|Standard of Care|If assigned to standard of care, the participant will undergo monitoring within 1 hour of the start of ECMO. For standard of care group, this will involve monitoring the leg with the ECMO tubing with physical exam every 4 hours for the first 24 hours. This will be performed by a trained nurse. If at any time there is suspicion for ACS, the physical exam will be verified by an orthopedic surgeon. The orthopedic surgeon will decide if pressure measurements will be necessary. If so, then a single pressure measurement from each compartment will be taken with a needle device. If the ACS diagnosis is made, any further monitoring of that leg is stopped. The decision to proceed with surgery, or fasciotomy, will be a joint decision made by entire team, which includes surgeons and medical doctors. This is currently the standard of care at the Johns Hopkins Hospital.
47968928|NCT02417597|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
47968929|NCT00791960|DRUG|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
47968930|NCT00791960|OTHER|Placebo|single dose, 10 mL normal saline, IV
48117336|NCT04625257|OTHER|Validation of the NGS method|Compare the results obtained with the next-generation sequencing (NGS) method to the nasopharyngeal swabs analysed in a FAMH certified lab.
48646461|NCT06690697|DRUG|Sorafenib|0.4 g, po, bid, each 21 days as a treatment cycle
48646462|NCT06569433|PROCEDURE|THERAPEUTIC EXERCISE AND MOBILISATION OF THE FEMORAL NERVE|"the control group that will perform only therapeutic exercise will perform a specific exercise programme for knee tendinitis under the supervision of a physiotherapist, while the intervention group that will perform therapeutic exercise plus femoral nerve mobilisation will receive therapeutic exercise sessions and femoral nerve mobilisations performed by a trained physiotherapist.~The intervention will last for 6 weeks, during which 60-minute sessions will be held at the centre, measurements will be taken during the six weeks, using standardised questionnaires to evaluate the variables (set out below) and always measuring the range of movement and femoral nerve mobility with the Slump Test on the same day of the week and at the same time of treatment."
48646463|NCT06691698|OTHER|The Cognitive Orientation to Daily Occupational Performance Approach|CO-OP is a client-centred, performance-based, problem-solving focused, occupation-focused and occupation-based intervention. In CO-OP the person is guided to use a meta-cognitive strategy to find his or her own strategies for specific activities. The main purpose is to enable meta-cognitive thinking in every day activities, leading to enhanced self-efficacy, occupational performance and independency.
48117337|NCT04625257|OTHER|Validation of the LAMP assays|The RNA will be analyzed onsite using the loop mediated amplification (LAMP) assay.
47968931|NCT01872377|RADIATION|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
48117338|NCT04625257|OTHER|Validation of the POCT Antigen and Antibody tests|Rapid point of care tests (POCT) detecting viral protein antigens (Ag) and antibodies (Ab) on patients' samples. POCT are often employed in low income countries, but for COVID-19 they are not yet characterized. Their performance is to be characterized that they can be used as a safe guard if the lab diagnostics fail.
48117339|NCT04434677|RADIATION|Hypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 40.05 Gray (2.67 Gy/ fx) over 15 fractions with or without boost over 3 weeks
48117340|NCT04434677|RADIATION|ultraHypofractionation|3D conformal Radiotherapy whole breast irradiation +- Supraclavicular fossa using Linear Machine (6-15 MV energy) 26 Gray (5.2 Gy/fx) over 5 fractions over 1.5 weeks
48117341|NCT04901312|BEHAVIORAL|Adolescent Community Reinforcement Approach|The Adolescent Community Reinforcement Approach (A-CRA) is a developmentally-appropriate behavioral treatment for youth and young adults ages 12 to 24 years old with substance use disorders. A-CRA seeks to increase the family, social, and educational/vocational reinforces to support recovery. This intervention has been implemented in outpatient, intensive outpatient, and residential treatment settings. A-CRA includes guidelines for three types of sessions: individuals alone, parents/caregivers alone, and individuals and parents/caregivers together. According to the individual's needs and self-assessment of happiness in multiple life areas, clinicians choose from a variety of A-CRA procedures that address, for example, problem-solving skills to cope with day-to-day stressors, communication skills, and active participation in positive social and recreational activities with the goal of improving life satisfaction and eliminating alcohol and substance use problems.
48487163|NCT01211704|DRUG|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
48487164|NCT01211704|DRUG|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
48646464|NCT03984188|DRUG|Theophylline ER|200 mg extended release (ER) low-dose theophylline taken orally daily
48646465|NCT03984188|DRUG|Placebo oral tablet|Manufactured methylcellulose placebo tablet taken orally daily
48646466|NCT03984188|OTHER|Standard of Care Treatment|Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment
48646467|NCT05524792|OTHER|no interventional study|no interventional study
48117342|NCT04901312|BEHAVIORAL|Assertive Continuing Care|Assertive Continuing Care (ACC) uses Community Reinforcement Approach (CRA) procedures, home visits, and case management for individuals following an initial substance use treatment episode. It stresses rapid initiation of services after discharge from residential, intensive outpatient, or regular outpatient treatment in order to promote recovery and prevent relapse.
48117343|NCT04901312|BEHAVIORAL|Trauma Affect Regulation Guide for Education and Therapy|Trauma Affect Regulation: Guide for Education and Therapy is a psychosocial intervention for traumatized adolescents, adults, and families, and for workforce and organizational responses to secondary/vicarious traumatization. T4, the 4-session version, provides education about the impact of complex traumatic stress on the brain's stress response system, and strengths-based practical skills for re-setting the trauma-related alarm/survival reactions that occur in complex PTSD.
47968932|NCT04506372|DRUG|Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers|Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
48117344|NCT04901312|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.
48117345|NCT04901312|OTHER|Opioid Education Workbook|A digital workbook designed to be completed on a computer in about 2 hours. Topics include opioid use, opioid use disorder, and prevention and treatment of opioid overdose.
48117346|NCT01563354|DRUG|Pasireotide LAR|60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
48117347|NCT01563354|DRUG|Everolimus|10 mg tables administered orally once a day
48487165|NCT04810520|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
48487166|NCT04810520|OTHER|Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
48117348|NCT01563354|DRUG|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
48117349|NCT00813449|DRUG|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
48117350|NCT00813449|DRUG|dacarbazine plus placebo (control group)|dacarbazine plus placebo
48117351|NCT00153569|BIOLOGICAL|Tyrosinase, MAGE-3, GnTV|
48646468|NCT06690723|DRUG|Dapagliflozin (Forxiga)|Dapagliflozin plus lifestyle modification
48646469|NCT06690723|DRUG|Vitamin D3 ( Colecalciferol)|Vitamin D3 plus lifestyle modification
48117352|NCT04488783|DIETARY_SUPPLEMENT|zinc and ascorbate|oral zinc and ascorbate
48117353|NCT06290297|DEVICE|Telerehabilitation VRRS|Telerehabilitation programs delivered at home, aiming to improve cognitive, motor and/or speech-language skills, through VRRS - Khymeia or Niurion devices. Such technologies are equipped with a wide library of activities to be performed also with the use of peripheral sensors. A one-shot assessment is also proposed to children admitted to institutes adhering to the project in order to understand the feasibility of the use of such devices. Ad hoc feasibility questionnaire are administered at the end of the one shot session and after the home training to the main stakeholders (children, families, clinicians)
48117354|NCT00478478|PROCEDURE|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
48646470|NCT06690723|DRUG|Vitamin D3 plus Dapagliflozin|Vitamin D3 plus Dapagliflozin plus lifestyle modification
48646471|NCT06690723|BEHAVIORAL|Lifestyle modification|Lifestyle modification alone
48646472|NCT03098927|BEHAVIORAL|Motor imagery training|Motor imagery training
48646473|NCT04740346|DIAGNOSTIC_TEST|Computed tomography, Chest X-ray, and blood test|CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
48646474|NCT02944045|DRUG|Methylprednisolone|"Methylprednisolone intra veinous~* Day 1 to 5 : 30mg twice per day~* Day 6 to 10 : 30mg per day~* Day 11 to 21 : 20mg per day"
48646475|NCT02944045|DRUG|Placebo|saline serum
48646476|NCT05164172|DRUG|Eptinezumab|Concentrate for solution for infusion
48646477|NCT06691152|BIOLOGICAL|CD19 Universal CAR-T cells|Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
48646478|NCT04619849|DIAGNOSTIC_TEST|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
48646479|NCT04619849|DIAGNOSTIC_TEST|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
48646480|NCT05775718|DRUG|Zoster Vaccine Recombinant|Injection
48646481|NCT06687096|OTHER|A recipe booklet|A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
48320715|NCT05465031|DRUG|Sacubitril-valsartan|Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
48320716|NCT02570763|DEVICE|Active tDCS stimulation|
48487167|NCT01421342|DRUG|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
48487168|NCT01421342|DRUG|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
48646482|NCT06687096|OTHER|standart diet list|patients prepared with a routine colonoscopy preparation scheme
48646483|NCT06689410|OTHER|blood or saliva sample|Collection of blood or saliva
47968933|NCT04506372|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
48320717|NCT02570763|DEVICE|Sham tDCS stimulation|
48320718|NCT02525419|BEHAVIORAL|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
48320719|NCT02525419|BEHAVIORAL|HP-IF|High Protein, Intermittent Fast
48320720|NCT02525419|BEHAVIORAL|HH|Heart Healthy
48320721|NCT00996021|DRUG|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
48320722|NCT00996021|DRUG|Placebo Suspension|Placebo is a liquid with no drug in it.
48320723|NCT00996021|DRUG|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
48320724|NCT05725421|PROCEDURE|Donor Radical and Partial Nephrectomy|Donor participants will undergo laparoscopic radical nephrectomy (RN) . Donor kidney then will undergo cold perfusion and ex-vivo partial nephrectomy (PN) with cold ischemia. During PN, careful inspection of tumor will be performed to ensure it is well-encapsulated. If any infiltrative features (versus well encapsulated tumor) are noted intraoperatively then transplant will not be performed. Multiple surgical margins will be sent (either frozen section or standard with priority). If final margins are positive or concerning, then transplant will not be performed. Biopsies of the tumor will be performed and sent to pathology (either frozen section or standard with priority).
48320725|NCT05725421|PROCEDURE|Kidney Transplantation|The donor kidney will remain on ice while pathologic analysis is performed, and transplant recipient surgery is initiated (if pathologic analysis satisfactory). Cold ischemia with delay for pathology will have minimal functional impact in this setting based on extensive prior experience with renal transplantation where kidneys are routinely kept hypothermic for several hours prior to transplantation.
48320726|NCT05725421|PROCEDURE|Laparoscopic Radical Nephrectomy|Radical nephrectomy consists of the removal of the kidney together with the perirenal fat and regional lymph nodes. The transperitoneal approach allows early control of the renal vessels.
48320727|NCT06069011|OTHER|Interdisciplinary management|assessment and treatment in an interdisciplinary model
48320728|NCT06069011|OTHER|usual care|assessment and treatment in usual care model
48320729|NCT04543955|DRUG|Telotristat (Low-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
48320730|NCT04543955|DRUG|Telotristat (High-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
48320731|NCT00332800|DRUG|Nutritional Supplementation|
48320732|NCT06019936|DRUG|MT2004 Capsule|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
48320733|NCT06019936|DRUG|MT2004 Capsule Placebo|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
48320734|NCT01354041|BEHAVIORAL|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
48487169|NCT01421342|DRUG|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
48487170|NCT01826461|DRUG|PDI-192|
48487171|NCT01826461|DRUG|Vehicle|
48646484|NCT00421408|DIETARY_SUPPLEMENT|Whey protein supplement|40-g whey protein supplement daily for 18 months
48646485|NCT00421408|DIETARY_SUPPLEMENT|Placebo|Placebo supplement daily for 18 months
48320735|NCT00455130|DRUG|Inhaled mannitol|
48320736|NCT05759845|DRUG|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
48320737|NCT05759845|DRUG|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
48320738|NCT05759845|DRUG|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
48320739|NCT05307445|DEVICE|Photobiomodulation with Bioptron Hyperlight Therapy|The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
48320740|NCT06011291|DRUG|SYH2051 tablets|Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
48320741|NCT06011291|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Radical or adjuvant radiotherapy
48320742|NCT01991405|DEVICE|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
48320743|NCT02208024|RADIATION|Stereotactic Body Radiation Therapy|
48320744|NCT01588353|DRUG|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
48320745|NCT02723266|BEHAVIORAL|STOPPING-GDM|Educational counseling and skills building Intervention
48320746|NCT04780958|OTHER|Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.|Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
48487172|NCT00065455|DRUG|Vitamin A|
48487173|NCT02860442|BEHAVIORAL|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
48487174|NCT02860442|OTHER|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
48487175|NCT02434224|PROCEDURE|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
48487176|NCT05403736|OTHER|Cardiac Aggressive Risk MitigAtion Plan|Cardio-oncology consultation along with long-term collaborative cancer care visits during standard of care radiation therapy that will occur weekly for up to 6 weeks followed by 6-week and 3-month follow-up visits. Health will be monitored with biosensor monitoring devices.
48487177|NCT05535439|PROCEDURE|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
48487178|NCT03911921|DRUG|RSYRT decoction|Compound granules of traditional Chinese medicine
48487179|NCT03911921|DRUG|Astragalus membranaceus|One herb
48487180|NCT02493920|OTHER|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm).
48487181|NCT02493920|DEVICE|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
48646486|NCT06690476|DRUG|Dose escalation(IPM514 monotherapy)|Drug：IPM514 Intramuscular Injection A total of 7 administrations, including 2 cycles of vaccination with each cycle at QW × 3 doses; there is a 2-weeks interval between the two cycles, then followed by a boost dose 3 weeks after the 2'nd cycle.
48646487|NCT06690476|DRUG|Dose expansion (IPM514 combined with tislelizumab)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration The usage and dosage of the tislelizumab will be based on the drug instructions. IPM514 administration is planned to be concomitant with PD-1 antibody and to be stopped after 9 doses of treatment, while the PD-1 antibody will be continuously administered for a maximum of 1 year.
48487182|NCT05477160|DRUG|STAR-0215 (SC)|STAR-0215 will be administered as an SC bolus injection.
48487183|NCT05477160|DRUG|Placebo (SC)|Placebo will be administered as an SC bolus injection.
48487184|NCT05477160|DRUG|STAR-0215 (IV)|STAR-0215 will be administered as an IV bolus injection.
48646488|NCT06690476|DRUG|Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
48646489|NCT06688188|DRUG|68Ga-JH12|The dose will be 148-222 MBq given intravenously.
48487185|NCT05477160|DRUG|Placebo (IV)|Placebo will be administered as an IV bolus injection.
48487186|NCT05500716|OTHER|Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD|"In this application, vagus nerve stimulation is applied to the patients in addition to the traditional rehabilitation program. In our research, vagal nerve stimulation will be applied with the Vagustim Device and all applications will be applied at a frequency of 10 Hz, a pulse amplitude of 300 microseconds and for 20 minutes."
48487187|NCT05500716|OTHER|Traditional Rehabilitation Program|This intervention includes: Deep Friction Massage, Myofascial Trigger Point Compression Therapy, Temporomandibular Joint Mobilization, Rocabado Exercises, Muscle-Energy Techniques.
48487188|NCT00767338|BEHAVIORAL|Timed intercourse|Timed intercourse
48487189|NCT00767338|PROCEDURE|Microsurgical varicocelectomy|Microsurgical varicocelectomy
48487190|NCT00767338|PROCEDURE|Intrauterine insemination|Intrauterine insemination
48487191|NCT05749679|OTHER|training and audit|"An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~1. Hygienic and dietary measures~2. Physical activity~3. Smoking cessation~4. Avoidance of nephrotoxic substances~5. Treatment of hypertension~6. Proteinuria reduction~7. Oral antidiabetics; choice~8. Optimal HBA1c~9. Statin~10. Compliance"
48487192|NCT05749679|OTHER|Routine care|"Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual."
48487193|NCT03010982|DRUG|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
48487194|NCT04209673|OTHER|Multimodal Pain management including TENS unit|Patient receiving multimodal pain management strategies which includes the use of TENS.
48487195|NCT04209673|OTHER|Multimodal Pain management not including TENS unit|Patient receiving multimodal pain management strategies which does not includes the use of TENS.
48487196|NCT05748119|DRUG|MEB-1170|Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
48487197|NCT05748119|DRUG|Placebo|Equivalent number and size of capsules containing placebo
48487198|NCT05417360|DIETARY_SUPPLEMENT|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
48487199|NCT05417360|DIETARY_SUPPLEMENT|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
47968934|NCT04506372|BEHAVIORAL|Diary to register drug adherence|To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
47968935|NCT04506372|BEHAVIORAL|Quality of life questionnaire|Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
48646490|NCT06686264|OTHER|core stability group A|Abdominal hollowing in supine (10 reps \& 2 sets) Single leg bridge (10 reps \& 2 sets), 3 session per week for 6 weeks Prone Single leg raise(10 reps \& 2 sets) Double leg bridge (10 reps \& 2 sets) Abdominal hallowing in 4 point kneeling(10 reps \& 2 sets), Complete Back stretch Pelvic rotations Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
48646491|NCT06686264|OTHER|traditional exercises group B|Complete Back stretch Pelvic rotations, 3 sessions per week for 6 week Posterior Pelvic tilt Knee to chest Piriformis stretch Maitland mobilization ( based on assessment) 10 reps 10 sec hold 2 session per day
48320747|NCT04803968|OTHER|bicycle ergometer and arm ergometer exercise|"After the bicycle ergometer training is completed, there will be a 15-minute break for blood pressure measurement of the patients.~Then the combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.~For this, the patient will sit upright in front of the height-adjustable arm ergometer stand (Lode Angio Arm Ergometer with Automat) with the fulcrum of the handle at shoulder height.~The arm endurance training group will work for a total of 20 minutes, at 60% of the peak workload and at 50 rpm."
48117355|NCT04293705|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
48487200|NCT04842500|BEHAVIORAL|Demand Informed Moderator Analysis|This analysis is designed to determine the degree to which relative price, and the timing of extinction, interact to increase or abate responding during extinction (thereby highlighting mechanisms of control).
48487201|NCT06451393|DRUG|Neoadjuvant chemotherapy with radical tumor resection surgery|All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
48117356|NCT03635151|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
48487202|NCT00390702|DEVICE|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
48487203|NCT03212521|DRUG|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
48487204|NCT05714566|DIAGNOSTIC_TEST|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
48487205|NCT00273741|DRUG|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
48117357|NCT03635151|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
48487206|NCT00273741|DRUG|placebo comparator|placebo capsules
48487207|NCT00507546|DRUG|Ramelteon|8 mg nightly
48487208|NCT00507546|DRUG|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
48487209|NCT00055133|DRUG|Micellar Paclitaxel for Injection|
48646492|NCT06687304|DEVICE|Light enhancement|Light recipe that mimics the varying daylight of the day
48646493|NCT02505672|RADIATION|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
48117358|NCT05863481|PROCEDURE|Laparoscopic cerclage placement|The surgical method of the laparoscopic cerclage procedure at Aarhus University Hospital previous described in a paper by Riiskjaer et al (DOI: 10.1111/aogs.12001)
48487210|NCT01939041|DEVICE|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
48487211|NCT01939041|DEVICE|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
48487212|NCT01939041|BEHAVIORAL|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
48487213|NCT01859806|PROCEDURE|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
48487214|NCT01859806|PROCEDURE|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
48487215|NCT03564301|DRUG|Placebo oral capsule|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
48487216|NCT03564301|DRUG|Metronidazole 250 MG|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
47968936|NCT04506372|BEHAVIORAL|WHODAS questionnaire|Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
47968937|NCT00221585|BEHAVIORAL|Psychosocial treatment/Psychodynamic treatment|
47968938|NCT06141187|PROCEDURE|Vertebroplasty|PVP
47968939|NCT06141187|PROCEDURE|Sham Vertebroplasty|Sham PVP
47968940|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
47968941|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
47968942|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
47968943|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
48487217|NCT02599259|DEVICE|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
48487218|NCT03951584|OTHER|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
47968944|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
47968945|NCT00631995|DIETARY_SUPPLEMENT|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
47968946|NCT01542125|DRUG|Liposomal Lidocaine|4% Liposomal Lidocaine
47968947|NCT01542125|DRUG|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
47968948|NCT06214338|DIETARY_SUPPLEMENT|Low dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.
47968949|NCT06214338|DIETARY_SUPPLEMENT|High dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.
47968950|NCT01207791|BEHAVIORAL|screening|Brief screening to assess eligibility and collect minimal baseline data
47968951|NCT01207791|BEHAVIORAL|assessment|comprehensive substance use assessment
47968952|NCT01207791|BEHAVIORAL|referral|referral to treatment if indicated or requested
47968953|NCT01207791|BEHAVIORAL|Brief intervention|30-minute brief intervention session in ED
47968954|NCT01207791|BEHAVIORAL|booster sessions|two 15-minute booster counseling sessions conducted by telephone
47968955|NCT06295289|DEVICE|Hybrid Closed-loop Insulin Delivery System|The Hybrid Closed-loop Insulin Delivery System system consisted of a Medtronic pump, a continuous glucose monitoring system（SIBIONICS®）and an open-source algorithm integrated into the phone. Insulin pump therapy group consisted of a Medtronic pump, and a continuous glucose monitoring system（SIBIONICS®). The difference between the two groups is that the artificial pancreas system automatically regulates the basal rate to maintain blood glucose in a target range.
47968956|NCT06295289|DEVICE|Insulin pump|Participants used conventional insulin pumps to control blood glucose, At the same time, a continuous glucose monitoring system was used to monitor glucose changes. Health care providers adjust the insulin dose of patients according to their blood glucose level.
48646494|NCT05478213|DEVICE|Monophasic Action Potential (MAP) Catheter|The EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
47968957|NCT02301000|BIOLOGICAL|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
47968958|NCT02301000|DRUG|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
48487219|NCT01193738|PROCEDURE|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
48487220|NCT03438227|DRUG|Iron dextran|Single intravenous infusion of iron dextran 1000mg.
48487221|NCT03438227|DRUG|Ferrous sulfate 325mg|Oral iron supplementation with ferrous sulfate 325mg one to three times daily
48487222|NCT05123677|DIAGNOSTIC_TEST|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
48487223|NCT05123677|DIAGNOSTIC_TEST|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
48487224|NCT01612884|DRUG|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
48487225|NCT01612884|DRUG|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
48487226|NCT06063759|DEVICE|VitalDetect|measurement of microcirculating blood flow, SpO2 (mmHg or %), heart rate (beats/min)
48487227|NCT03132194|DRUG|DPSG 7.5%|topical gel
48646495|NCT06690671|DRUG|Golidocitinib in combination with anti-PD-1|Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.
48646496|NCT06689423|DEVICE|Credo POCT Device|Testing Credo's POCT device for respiratory viruses detection.
47968959|NCT03523897|PROCEDURE|Robot Assisted Total Knee Replacement|A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
47968960|NCT03523897|PROCEDURE|Traditional Total Knee Replacement|A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
47968961|NCT06147739|OTHER|Temporary Anchorage Devices|intrusion
47968962|NCT03809052|DRUG|GB1211|Hard capsules for oral use
47968963|NCT03809052|DRUG|Placebo|Hard capsules for oral use
47968964|NCT05559138|OTHER|no intervention|no intervention
47968965|NCT05705596|OTHER|Sucrose|10% sucrose corresponding to a regular soft drink
47968966|NCT05705596|DRUG|Hesperetin|increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
47968967|NCT02057679|DRUG|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
47968968|NCT02057679|DRUG|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
47968969|NCT00185939|DRUG|Augmentin|
47968970|NCT03588039|DRUG|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
47968971|NCT03588039|BIOLOGICAL|Pembrolizumab|Intravenously administered
48487228|NCT03132194|DRUG|Aczone|topical gel
48487229|NCT03132194|DRUG|Placebo|topical gel
48487230|NCT03748355|GENETIC|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
48646497|NCT04718441|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
48646498|NCT06611813|DRUG|Neoadjuvant Chemotherapy in Combination with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
48646499|NCT06611813|DRUG|HR+ HER2 breast cancer|During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.
48646500|NCT03719300|DRUG|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
48646501|NCT06690567|DEVICE|Impella implantation|To implante Impella
47968972|NCT00793091|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
47968973|NCT00793091|DRUG|Placebo|4 drops applied daily for 120 days
47968974|NCT06071130|BEHAVIORAL|Fit and Strong|Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F\&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F\&S! cycles at each center (totaling 8 F\&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F\&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F\&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F\&S! for 3 sessions a week for 8 weeks.
47968975|NCT00000793|DRUG|Mexiletine hydrochloride|
47968976|NCT00000793|DRUG|Benztropine mesylate|
47968977|NCT00000793|DRUG|Amitriptyline hydrochloride|
47968978|NCT05832398|DRUG|FOLFOX , FOLFIRI or FOLFOXIRI regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
47968979|NCT05832398|DRUG|FOLFOX or CapeOX regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
47968980|NCT02036294|OTHER|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
48117359|NCT06373549|PROCEDURE|Patients with coronary artery bypass surgery routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
48646502|NCT05378763|DRUG|Poziotinib|Poziotinib tablets
48646503|NCT05378763|DRUG|Docetaxel|Docetaxel IV infusion
48320748|NCT04803968|OTHER|bicycle ergometer exercise|All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training (Lode Corival Cpet Ergoline type: 960900 serial number: 20160094, Netherlands). The exercise protocol for the lower extremities will consist of a total of 40 minutes, including an 8-minute warm-up phase and an 8-minute cool-down phase. Exercise intensity, on the other hand, will be arranged as recommended in the European Society of Cardiology (ESC) 2020 guideline for chronic heart failure patients, at a workload corresponding to 70-80% of peak oxygen consumption (VO2peak), with a turnover rate of 60 cycles / min.
47968981|NCT02036294|OTHER|Usual Care|Standard Healthcare Services
48320749|NCT01490762|DRUG|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
48487231|NCT03819621|DEVICE|IRISS Medical Technologies mediGrid app|IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
48487232|NCT02199678|DRUG|Placebo|placebo
48487233|NCT02199678|DRUG|ketamine 25 mg|ketamine
48487234|NCT02199678|DRUG|ketamine 35 mg|ketamine
48646504|NCT06688201|OTHER|Other neurosurgical techniques|Those include open craniotomy, small skull window microsurgery, and endoscopic surgery. The attending clinician is required to consider which type of craniotomy or other procedure according to the expertise and availability at the hospital.
48320750|NCT01490762|DRUG|Regular Human Insulin|Subcutaneous injection
48320751|NCT04325776|DRUG|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
48320752|NCT04325776|DRUG|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
48487235|NCT02199678|DRUG|ketamine 50 mg|ketamine
48487236|NCT03113448|DRUG|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
47968982|NCT02082275|OTHER|OB Nest|"* Reduction in the number of clinic office visits~* Assignment to a specific nursing care team~* Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~* Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~* Augmentation of in-person visits between care providers and patients with video conversations.~* Maternal outcomes will be monitored through surveys and questionnaires."
47968983|NCT01193868|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
47968984|NCT01193868|OTHER|laboratory biomarker analysis|Correlative studies
48487237|NCT03113448|DRUG|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
48487238|NCT04614493|DEVICE|SonoCloud-9 (SC9) device|"daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months) with 6 concomitant Blood Brain Barrier opening sessions by ultrasound~+ 9 Blood Brain Barrier opening sessions by ultrasound without any associated drug"
48487239|NCT04614493|DRUG|Temozolomide according Stupp protocol|daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months)
47968985|NCT01193868|OTHER|pharmacological study|Correlative studies
47968986|NCT02158403|OTHER|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
47968988|NCT00393393|DRUG|intra-articular injection of Hylan G-F 20|
47968989|NCT01484847|DRUG|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
47968990|NCT00064337|BIOLOGICAL|filgrastim|
48487240|NCT00004748|DRUG|colchicine|
48487241|NCT00004748|DRUG|methotrexate|
47968991|NCT00064337|DRUG|cyclophosphamide|
47968992|NCT00064337|DRUG|dexamethasone|
47968993|NCT00064337|DRUG|melphalan|
47968994|NCT00064337|DRUG|thalidomide|
47968995|NCT00064337|PROCEDURE|peripheral blood stem cell transplantation|
47968996|NCT02298920|DRUG|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
47968997|NCT01634724|DRUG|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
47968998|NCT01818232|DRUG|[14C]-LX4211|
48320753|NCT06092853|OTHER|Gingival crevicular fluid (GCF) and serum samples|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
48320754|NCT04212858|GENETIC|zinc-finger protein 217 gene|search for zinc-finger protein 217 gene in myeloma patients
48320755|NCT03901807|DEVICE|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
48487242|NCT00004748|DRUG|ursodiol|
48487243|NCT03415984|DIAGNOSTIC_TEST|Color retinography|Color retinography
48487244|NCT03415984|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography
48487245|NCT03415984|DIAGNOSTIC_TEST|Fundus autofluorescence imaging|Fundus autofluorescence imaging
48487246|NCT02614313|PROCEDURE|Open breath test with fructose|Open randomised fructose 35g during breath test
48487247|NCT02614313|PROCEDURE|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
48487248|NCT02614313|PROCEDURE|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
48487249|NCT02614313|PROCEDURE|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
48320756|NCT05936034|OTHER|Patients suffering from chemotherapy-induced ototoxicity|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Control group: standard support; Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
48320757|NCT05936034|OTHER|Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Experimental group: standard treatment with hearing aids (wearing a hearing aid).~Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
48320758|NCT00016393|DRUG|ixabepilone|
48320759|NCT00213252|DRUG|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
48320760|NCT00213252|DRUG|Prednisolone|Six daily doses of oral prednisolone
48320761|NCT04206527|BEHAVIORAL|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
48320762|NCT04206527|BEHAVIORAL|Enhanced FP training|Participation in an enhanced FP training including PCC
48320763|NCT03991559|DRUG|Manganese Chloride|Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
48320764|NCT03991559|DRUG|Anti-PD-1 antibody|Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
48320765|NCT03991559|COMBINATION_PRODUCT|Systemic therapy|Whether and which should be given depends on the treatment regimen before enrollment.
48320766|NCT03811717|OTHER|FAST+EX|Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
48320767|NCT03811717|OTHER|FAST|Participants will complete an 8-hour fast.
47968999|NCT04246450|DEVICE|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
47969000|NCT03465306|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
48320768|NCT05522894|DRUG|AK104|10mg/kg IV every 3 weeks (Q3W)
48320769|NCT05522894|DRUG|Cisplatin|75mg/m2 IV every 3 weeks (Q3W)
48320770|NCT05522894|DRUG|Paclitaxel|175mg/m2 IV every 3 weeks (Q3W)
48320771|NCT06241287|BEHAVIORAL|Better Living with Non-memory led Dementia programme|an 8-week duration 6-module educational programme covering the following topics: 1) Welcome to the programme and what to expect from it; 2) Understanding the disease; 3) How to provide better support for the person with dementia; 4) How to look after the caregiver's own mental health; 5) Where to find additional sources of support, and 6) An introduction to the value of support groups. At the end of modules 2, 3, and 4, participants will be asked to complete a real-life task to put in practice skills learned in the specific module (e.g., approaching a friend and explaining the disease in lay terms). The first session (onboarding) will be facilitated via Zoom by one of the members of the research team. Up to 3 total interactions between facilitators and participants will be offered to support participants' engagement with the programme. All course modules will be printable using the pdf download button on the programme's page.
48487250|NCT03867799|DRUG|Nivolumab|Immunotherapy
47969001|NCT03465306|DEVICE|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
47969002|NCT03782792|DRUG|Spesolimab|Solution for infusion
47969003|NCT03782792|DRUG|Placebo|Solution for infusion
47969004|NCT04386252|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
47969005|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab|Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
47969006|NCT04997382|DRUG|Chemotherapy alone or Chemotherapy with or without Bevacizumab|Bevacizumab, 15mg/kg，every 21 day
47969007|NCT03819101|DRUG|Acetylsalicylic acid|100mg
47969008|NCT03819101|DRUG|Atorvastatin|80 mg
48320772|NCT06241287|OTHER|Waiting list|Signposting individuals to the publicly available Rare Dementia Support website. The control group will further receive access to the Better Living with Non-memory led Dementia programme after completing the collection of measures at 6 months.
48320773|NCT00817401|DEVICE|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
48320774|NCT01518244|DRUG|Brinzolamide/timolol maleate fixed combination|
48320775|NCT03689413|DRUG|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
48320776|NCT04019652|DRUG|CS-3150|Single, oral administration; 10-mg or 40-mg dose
48320777|NCT04019652|DRUG|Moxifloxacin|Single, oral administration; 400 mg-tablet
48320778|NCT04019652|DRUG|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
48320779|NCT04019652|DRUG|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
48320780|NCT01079429|GENETIC|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
48320781|NCT02580994|DRUG|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
48320782|NCT02580994|DRUG|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
48320784|NCT02035150|DIETARY_SUPPLEMENT|Oatmeal|A breakfast consisting of oatmeal
48320785|NCT02035150|DIETARY_SUPPLEMENT|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
47969009|NCT06498492|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.
47969010|NCT05223244|DRUG|bupivacaine, triamcinolone, and heparin (BTH)|30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
47969011|NCT05223244|DRUG|dimethyl sulfoxide (DMSO)|50mL of DMSO and 1mL of triamcinolone (10mg/mL)
47969012|NCT01486667|DRUG|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
48320786|NCT02035150|DIETARY_SUPPLEMENT|No Breakfast|A breakfast consisting of plain water
48320787|NCT06085261|BEHAVIORAL|home-based telerehabilitation group|Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
48320788|NCT06085261|BEHAVIORAL|center-based traditional rehabilitation group|"Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.~The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group."
48320789|NCT00789269|DRUG|rhubarb|14 days of rhubarb
48320790|NCT00789269|DRUG|placebo|14 days of placebo
48320791|NCT04768335|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
48320792|NCT02063919|OTHER|the mucosal microbiome in the biopsy specimen was analysed|
48320793|NCT00972842|DRUG|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
47969013|NCT01486667|DRUG|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
47969014|NCT05036824|DRUG|tinzaparin|Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
48320794|NCT03695640|DRUG|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
48320795|NCT03695640|PROCEDURE|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
48320796|NCT01962519|DIETARY_SUPPLEMENT|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
48320797|NCT01999946|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
48320798|NCT01492283|OTHER|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
48320799|NCT01492283|OTHER|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
48320800|NCT00773565|DIETARY_SUPPLEMENT|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
48320801|NCT05577091|GENETIC|Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.|"Intratumoral or intraventricular administration via Ommaya reservoir.~Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients.~Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells.~In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly.~Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study."
48320802|NCT01536119|BEHAVIORAL|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
48320803|NCT05102396|DRUG|Topical oxybutynin spray|Participants will receive topical oxybutynin spray (10%).
48320804|NCT05102396|DRUG|Topical placebo spray|Participants will receive topical placebo spray.
48320805|NCT05102396|DRUG|Oral oxybutynin|Participants will receive oxybutynin (tablets).
47969015|NCT03192111|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
48320806|NCT01970930|PROCEDURE|Blood specimen|4 green top tube 40 cc of blood draw
48320807|NCT05391568|OTHER|Real Dry Needling|"Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
48320808|NCT05391568|OTHER|Sham Dry Needling|"Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
48320809|NCT01235286|PROCEDURE|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
48320810|NCT03484351|OTHER|Fall Monty Activity Programme (FallMAP)|The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing \& falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
48320811|NCT01825655|DRUG|Cetirizine|
47969016|NCT01408485|DEVICE|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~* Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~* IBI 1500T9 V1.43 RF Generator"
48646505|NCT06688201|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
48117360|NCT06373549|PROCEDURE|Patients who underwent heart valve surgery without coronary artery disease routine procedural administration of cardioplegia solutions|To investigate the effectiveness of myocardial protection methods, blood samples were collected from the coronary sinus before the aortic cross-clamping and at 4 minutes after aortic cross-clamping, through a coronary sinus cannula with a yellow-capped gel tube. The collected blood samples were kept in an upright position for 20 minutes to allow separation into serum fraction, then centrifuged at 3000 g for 10 minutes (Beckman Coulter, Microfuge 16, USA). The obtained serums were aliquoted into 250 μl portions in Eppendorf tubes, separately for each patient.
48117361|NCT01197807|PROCEDURE|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
48117362|NCT01197807|PROCEDURE|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
48117363|NCT02708069|OTHER|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
48117364|NCT02708069|OTHER|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
48117365|NCT02689180|DRUG|Placebo|Replacement of furosemide by placebo
48117366|NCT02689180|DRUG|Furosemide|Maintenance of furosemide on usual doses
48117367|NCT05920746|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 10-20 Hz, type of impulse: bipolar, rectangular pulse
48117368|NCT00742300|PROCEDURE|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
48117369|NCT05579106|DEVICE|Nociception Level Monitor (NOL) by Medasense Biometrics Ltd., Israel|"The NOL monitor measures various parameters via a sensor in a finger probe that is attached to the patient.~These parameters are:~* Temperature~* Galvanic skin response~* Accelerometer~* Photoplethysmograph (pulse rate, pulse rate variability, photoplethysmograph amplitude)~All this data is combined in an algorithm which produces a number between 0-100. Between 10-25 indicates adequate analgesia, below 10 too much analgesia, above 25 too little analgesia. No actions are taken based on this measurement."
48117370|NCT05579106|DEVICE|Bispectral index (BIS)|The BIS processes EEG information to provide a direct measurement of the patient's level of consciousness and insight into the effects of anesthesia on the brain.
48117371|NCT05579106|OTHER|Questionnaire perception of the nurse on pain patient|The investigators developed a questionnaire with 7-questions regarding the perception of the responsible nurse on the pain of the patient. When the investigators measured for 8 hours with the BIS and the NOL they will ask the nurse what his or her perception was of the pain of the patient. Eventually the investigators will compare the answers of this questionnaire with the NOL and BIS values that they observed, whether the information corresponds or not.
48117372|NCT02889718|DEVICE|CONCERT-CL® station|"During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~* Port B = open loop: Analgesic~* Port A = closed loop: Hypnotic~* Port C = closed loop: Curare"
48117373|NCT02889718|OTHER|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
48117374|NCT01331824|DRUG|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
48117375|NCT02074488|OTHER|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
48117376|NCT02074488|OTHER|Informational Brochure|Informational Brochure on falls prevention
48117377|NCT00773708|DRUG|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
48117378|NCT00368186|BIOLOGICAL|Pneumo 23|
48320812|NCT01825655|DRUG|Placebo or sugar pill|
48320813|NCT04365998|DEVICE|BUBOLight® Device|1 session of phototherapy with BUBOLight® device during 4 hours.
48320814|NCT02115113|DRUG|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
48320815|NCT02115113|DRUG|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
48320816|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
48320817|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
47969017|NCT05048784|DRUG|Sotorasib|Oral tablet
48117379|NCT01626612|PROCEDURE|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
48117380|NCT01626612|PROCEDURE|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
48117381|NCT03751943|DEVICE|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
48117382|NCT05475041|PROCEDURE|Major liver resection|Major liver resection (3 or more contiguous segments)
48117383|NCT05475041|PROCEDURE|Technically major liver resection|Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
48320818|NCT03522272|OTHER|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
48320819|NCT06350565|DRUG|Dexamethasone|This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
48320820|NCT02758223|BIOLOGICAL|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
48320821|NCT00581906|RADIATION|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.
48320822|NCT01204255|DRUG|lorazepam|Given topically
48320823|NCT01204255|DRUG|diphenhydramine hydrochloride|Given topically
48320824|NCT01204255|DRUG|haloperidol|Given topically
48320825|NCT01204255|OTHER|questionnaire administration|Ancillary studies
48320826|NCT01204255|OTHER|laboratory biomarker analysis|Correlative studies
48320827|NCT01427283|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
48320828|NCT01427283|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
48320829|NCT01427283|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
48320830|NCT04113382|DRUG|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
48320831|NCT04113382|DRUG|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).
48320832|NCT02517151|DRUG|Ferric carboxymaltose|
48320833|NCT02517151|DRUG|Placebo|
48320834|NCT02556593|RADIATION|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
48320835|NCT02556593|RADIATION|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
48320836|NCT02556593|DRUG|erlotinib|erlotinib 150mg daily
47969018|NCT00114946|DRUG|Avastin|
47969019|NCT03009981|DRUG|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
48117384|NCT04219930|DIAGNOSTIC_TEST|Expression of nucleotide protein -3|Expression of nucleotide protein -3 will be measured in serum by ELISA
48117385|NCT02981888|RADIATION|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
48117386|NCT03156595|BEHAVIORAL|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
48117387|NCT03156595|BEHAVIORAL|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
48117388|NCT00002972|DRUG|paclitaxel|
48117389|NCT03383146|DRUG|Placebo|Placebo injected subcutaneously twice daily.
48117390|NCT03383146|DRUG|Relamorelin|Relamorelin 10 μg injected subcutaneously twice daily.
48117391|NCT06203197|OTHER|Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)|intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
48117392|NCT01663584|PROCEDURE|Blood draw|
48320837|NCT01476384|DIETARY_SUPPLEMENT|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
48320838|NCT01476384|DIETARY_SUPPLEMENT|Placebo|250 ml water
48320839|NCT01653158|DRUG|CP-751,871|"CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
48320840|NCT01653158|DRUG|Docetaxel|Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.
48320841|NCT06433518|DRUG|recombinant hCG|"Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups."
48320842|NCT05125107|DEVICE|Quantitative Flow Ratio derived PPG and dQFR/ds|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)"
48320843|NCT01621724|GENETIC|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
48646506|NCT06691646|BEHAVIORAL|Gaze-control training game|An eyetracker-controlled computer game designed to improve attentional control by training inhibitory control over direction of gaze. It includes six mini-games, each designed to train different aspects of oculomotor control, including selective attention, motor inhibition, motor timing, and spatial working memory.
48117393|NCT01180088|PROCEDURE|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
48320844|NCT06322524|DEVICE|Gamma sensory flicker|participants were exposed to flicker stimulation through a light and sound device, the flicker was 40 Hz.
48320845|NCT04597619|OTHER|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
48320846|NCT03095521|DRUG|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
48320847|NCT03095521|DRUG|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
48117394|NCT00488657|DEVICE|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
48117395|NCT03573284|DIAGNOSTIC_TEST|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
48320848|NCT04540302|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
48646507|NCT06690164|DRUG|Atorvastatin 40mg Tablet|once a day for 30 days
48646508|NCT06690164|DRUG|Omeprazole 20mg Capsule|once a day for 30 days
48646509|NCT06688266|OTHER|Nerve Gliding Exercises|"This group will receive 25-minute session of nerve gliding exercises per session five days a week for six weeks. It will include: Warm-Up (5 minutes)~Neural Gliding of the upper quadrant:~Median nerve glide (5 minutes) Ulnar nerve glide (5 minutes) Radial nerve glide (5 minutes) Cool Down (5 minutes)"
48117396|NCT03573284|DIAGNOSTIC_TEST|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
48117397|NCT01982890|OTHER|Control|No intervention as this group is simply followed prospectively.
48117398|NCT01443845|DRUG|Roflumilast|Roflumilast 500 µg, oral administration, once per day
48117399|NCT01443845|DRUG|Placebo|Dose-matched placebo, oral administration, once per day.
48117400|NCT00477776|DRUG|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
48117401|NCT00477776|DRUG|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
48320849|NCT04540302|DEVICE|PTA|Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
48320850|NCT05136378|DRUG|Low Dose Selenious Yeast Tablets|Low dose of Selenious Yeast Tablets
48320851|NCT05136378|DRUG|High Dose Selenious Yeast Tablets|High Dose Selenious Yeast Tablets
48320852|NCT03565848|PROCEDURE|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
48646510|NCT06688266|OTHER|Hand Grip Strength Exercises|"This group's participants will also receive a 25 -minute session five days per week (for six weeks). Warm-Up (5 minutes) Conventional Grip Strength Exercises (15 Minutes)~* Tendon gliding sequence of exercises for hand~* Squeezing a rubber ball or stress ball~* Dead Hang Cool Down (5 Minutes)"
48646511|NCT06677996|DRUG|varegacestat|Experimental intervention
48320853|NCT02344420|PROCEDURE|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
48320854|NCT02344420|BEHAVIORAL|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
48320855|NCT02344420|PROCEDURE|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
48320856|NCT02344420|BEHAVIORAL|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
48320857|NCT00325650|DRUG|Rimonabant|Tablet, oral administration
48320858|NCT00325650|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
48320859|NCT00684125|DEVICE|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
48320860|NCT00684125|DEVICE|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
48320861|NCT00483158|DRUG|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
48320862|NCT01717703|DIETARY_SUPPLEMENT|Water|
48320863|NCT01717703|DIETARY_SUPPLEMENT|Fruit drink|
48320864|NCT01717703|DIETARY_SUPPLEMENT|Cola|
48320865|NCT01717703|DIETARY_SUPPLEMENT|1% chocolate milk|
48320866|NCT00240539|PROCEDURE|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
48320867|NCT03077763|DRUG|Sodium Nitrite|
48320868|NCT00360919|BEHAVIORAL|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
48320869|NCT01881841|BEHAVIORAL|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
48320870|NCT01924052|DRUG|CGRP|Calcitonin-gene-related-peptide (CGRP)
48320871|NCT04914377|DRUG|TQ Formula/Tab|TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
48646512|NCT06677996|DRUG|Itraconazole (200 mg)|Intervention to evaluate DDI with experimental intervention
48646513|NCT06684652|PROCEDURE|3TB+6SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained sextant six-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
48646514|NCT06684652|PROCEDURE|3TB+12SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained fore-zone 12-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
48320872|NCT02397694|DRUG|BIC|75 mg tablet administered orally once daily
48320873|NCT02397694|DRUG|F/TAF|200/25 mg FDC tablet administered orally once daily
48320874|NCT02397694|DRUG|DTG|50 mg tablet administered orally once daily
48320875|NCT02397694|DRUG|BIC Placebo|Tablet administered orally once daily
48320876|NCT02397694|DRUG|DTG Placebo|Tablet administered orally once daily
48320877|NCT02397694|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily
48320878|NCT05129995|OTHER|Passive heat treatment|Participants will be subjected to an 8-week (3 x pw) passive heat treatment, by means of infrared sauna bathing, intervention.
48320879|NCT02488096|DEVICE|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
48117402|NCT04689061|DEVICE|Arthrex FastThread Interference Screw|The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
48646515|NCT00410436|BEHAVIORAL|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
48646516|NCT03795870|DIETARY_SUPPLEMENT|Polymeric Tube Feeds|Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
48646517|NCT03795870|DIETARY_SUPPLEMENT|Blenderized Tube Feeds|Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
48646518|NCT06054061|BEHAVIORAL|Experimental: experimental wellbeing promotion group (Think and Cope Positively)|"Session 1: Welcome. 2: Identifying and amplifying positive emotions. 3: Experiencing positive emotions. 4: Identifying my negative trap thoughts. 5: Transforming my automatic thoughts into positive ones. Session 6: Experiencing my positive thoughts I. 7: Experiencing my positive thoughts II. 8: Learning to be kinder to myself. 9: Identifying a life project (Individual appointment).10: Identifying coping strategies I. 11: Identifying coping strategies II. 12: Identifying adaptive coping strategies linked to well-being. 13: Building my life purpose with my environment. 14: Helping me to build my life purpose? 15: Multi-family session, farewell and closing."
47969020|NCT03009981|DRUG|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
48117403|NCT06176924|DEVICE|tDCS|tDCS (2mA, 20 min anode placed on DLFPC of left side and cathode on supraorbital cortex of right side) along with relaxation technique.
48117404|NCT06176924|OTHER|Relaxation technique|Relaxation technique
48646519|NCT06054061|BEHAVIORAL|TAU|The usual treatment in the intervention of people affected by severe mental disorder in the network of public and subsidized centers in Spain consists of improving psychosocial functioning. To this end, and depending on the characteristics of the user, work is done in groups and individually on social skills, psychoeducation about the disease, adherence to pharmacological treatment, improvement of daily living activities, promotion of independent leisure, support to families in the process of relapse prevention, and training for labor market insertion.
48646520|NCT03629002|BIOLOGICAL|Study of the gene expression profile|qPCR analysis
48646521|NCT03564067|DEVICE|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
48117405|NCT04797416|DEVICE|FGM infiltration 1 hour group|The sensor is activated immediately after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
48117406|NCT04797416|DEVICE|FGM infiltration 6-hour group|Reactivate the sensor 5 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
48646522|NCT03564067|BEHAVIORAL|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
48646523|NCT03611361|DEVICE|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
48646524|NCT00183612|DRUG|Olanzapine|
48646525|NCT02898675|DEVICE|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
48646526|NCT02898675|DEVICE|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
48646527|NCT00323245|BEHAVIORAL|Physiotherapy for urinary incontinence|See Detailed Description.
48117407|NCT04797416|DEVICE|FGM infiltration 12-hour group|Reactivate the sensor 11 hours after wearing (including the time between the sensor activation and the first blood glucose value stored，about 1 hour).
48117408|NCT00687011|DRUG|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
48117409|NCT00704184|DRUG|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
48646528|NCT06569784|DRUG|[14C]HSK31858|A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
48646529|NCT01866735|OTHER|Standardized Rehabilitation Therapy|
48646530|NCT03956082|DEVICE|Ultravision™ Visual Field Clearing System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
48646531|NCT03956082|DEVICE|Ultravision Ionwand™|The Ionwand™ is introduced into the abdomen through either the Ultravision™ 5mm Trocar or a 2.5 mm percutaneous catheter. The Ionwand™ provides the source of electrons that create the negative ions that transiently charge the surgical smoke particles and accelerate their sedimentation.
48646532|NCT06291727|DRUG|Mepivacaine|Patients will be administered a standard dose of mepivacaine 1.5% (4.5ml, 67.5mg) for total knee arthroplasty prior to surgery
48646533|NCT06291727|DRUG|Bupivacaine|Patients will be administered a standard dose of 0.75% hyperbaric bupivacaine (1.4ml, 10.5mg) for total knee arthroplasty prior to surgery
48646534|NCT01071785|DIETARY_SUPPLEMENT|guar gum|guar gum 10g/day for six weeks
48646535|NCT02339675|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
48646536|NCT02423954|DRUG|Temsirolimus|
48646537|NCT02423954|DRUG|Irinotecan|
47969021|NCT03009981|DRUG|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
47969022|NCT03009981|DRUG|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
47969023|NCT00160628|DRUG|Levetiracetam|
48117410|NCT00704184|DRUG|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
48117411|NCT00704184|DRUG|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
48487251|NCT06426173|OTHER|Resistance Training Program|The resistance training program will be individualized and divided into four stages of increasing complexity. It will be conducted for approximately 40 minutes per day, three times a week, for 12 weeks, under supervision. Each patient will begin the program at the stage corresponding to their functional capacity. The resistance load will be set at 50% of the maximum resistance (1RM) obtained in the initial assessment. Throughout all stages of the exercise program, the target intensity will range from light (≤ 12) to moderate (≤ 15) on the Borg scale.
48646538|NCT02423954|DRUG|Irinotecan + capecitabine|
48646539|NCT02423954|DRUG|nivolumab|
47969024|NCT03442205|PROCEDURE|LC + LCBDE + ENBD + primary closure of CBD|LC + LCBDE + ENBD + primary closure of CBD
47969025|NCT03442205|PROCEDURE|ERCP technique + LC|ERCP technique + LC
47969026|NCT03442205|PROCEDURE|LC + LCBDE + primary closure of CBD|LC + LCBDE + primary closure of CBD
47969027|NCT02967744|DRUG|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
47969028|NCT04243681|COMBINATION_PRODUCT|CD 34 and MSC infusion|Combination of stem cells
47969029|NCT04243681|DRUG|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
47969030|NCT01833013|OTHER|live birth date and quality of life assessment|
47969031|NCT05004025|DEVICE|Novocure Optune|Novacure Optune with Opdivo and Yervoy
47969032|NCT05004025|DRUG|Opdivo|Novacure Optune with Opdivo and Yervoy
47969033|NCT05004025|DRUG|Yervoy|Novacure Optune with Opdivo and Yervoy
48117412|NCT00704184|DRUG|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
48117413|NCT06554756|OTHER|Saliva, serum and GCF sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant. Gingival crevicular fluid (GCF) samples were taken from the vestibular, mesial, and distal surfaces of a single-rooted tooth with standard paper strips (Periopaper, Oraflow Inc., Plainview, NY, USA). Saliva, GCF and serum were then stored at -80 °C until analysis.
48117414|NCT03547791|DRUG|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
48117415|NCT03547791|DRUG|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
48117416|NCT02751138|PROCEDURE|Surgery|Tumor resection
48117417|NCT03973892|DIAGNOSTIC_TEST|Cere|Magnetic Rseonance imaging for brain tumour follow-up
48117418|NCT02725762|DEVICE|LT-300 Active (PBM)|
48117419|NCT02725762|DEVICE|LT-300 Inactive (Sham)|
48646540|NCT06289283|OTHER|Urine samples and tissue samples: Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigera|"Samples for microbiome analysis:~Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigerator until be analyzed at the microbiology laboratory of TBRI.~Urine samples (50 ml) for microbiome analysis will be collected during cystoscopy examination. Samples will be stored at -80 °C until processing.~Tissue and urine samples from patients with bladder cancer: Under standard procedure of diagnostic cystoscopy urine sample will be collected under complete aseptic conditions, patients who has bladder tumor will undergo transurethral resection of bladder tumor, a tissue sample 0.5x0.5 cm will be investigated for microbiome analysis. Samples will be stored at -80 °C until processing. Histopathological diagnosis with Hematoxylin and eosin stain will be done by an expert pathologist for tumor grade and stage according to WHO 22, and EAU guidelines 2023. This procedure will be applied for"
48646541|NCT00663195|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
48646542|NCT04833907|DRUG|rAAV-Olig001-ASPA|Intracerebroventricular administration of a single dose
48487252|NCT06426173|OTHER|Standard Treatment Group|Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
48487253|NCT04221607|OTHER|Sensate Focus exercise|Structured exercise to enhance intimacy
48487254|NCT05964790|DRUG|HS-10380|Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
48646543|NCT04833907|DRUG|Levetiracetam|Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
48646544|NCT04833907|DRUG|Prednisone|Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
48646545|NCT05809830|DRUG|LB-100 plus Doxorrubicin|In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin
48646546|NCT05809830|DRUG|Doxorubicin|The control arm in Phase II will be Doxorrubicin alone
48646547|NCT00919360|PROCEDURE|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
47969034|NCT01918774|BEHAVIORAL|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
48117420|NCT02351648|OTHER|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
48117421|NCT02351648|OTHER|Control|Patients receive usual standard of care from the internal medicine team
48487255|NCT05964790|DRUG|Placebo|Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
48646548|NCT00919360|PROCEDURE|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
48646549|NCT00919360|PROCEDURE|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
48646550|NCT00919360|PROCEDURE|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
48646551|NCT05952375|DRUG|Chimeric antigen receptor T cell preparation targeting Claudin18.2|Chimeric antigen receptor T cell preparation targeting Claudin18.2
48646552|NCT05127200|DEVICE|Starstim (Neuroelectrics)|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
48646553|NCT03830398|DRUG|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
48646554|NCT03830398|DRUG|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
48646555|NCT03830398|DRUG|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
48646556|NCT00071994|DRUG|gefitinib|Given orally
48646557|NCT00071994|OTHER|laboratory biomarker analysis|Correlative studies
48646558|NCT04065841|DRUG|Tropifexor|100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day
48646559|NCT04065841|DRUG|Licogliflozin|30mg tablet of licoglifozin taken orally every day
48646560|NCT04065841|OTHER|Placebo|licogliflozin placebo + tropifexor placebo
48646561|NCT05535855|DRUG|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
48646562|NCT04016428|BEHAVIORAL|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
48646563|NCT04016428|BEHAVIORAL|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
48646564|NCT03871504|OTHER|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
47969035|NCT01382212|DRUG|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
48320880|NCT02488096|DEVICE|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy \~ 1 week after the MRI."
48487256|NCT03143478|DEVICE|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
48487257|NCT00366041|DRUG|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
48487258|NCT00366041|DEVICE|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
47969036|NCT04606030|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
48117422|NCT02671344|OTHER|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
48117423|NCT02399865|OTHER|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
48117424|NCT05552443|DRUG|Hydromorphone 2.5 mcg/kg|2.5 mcg/kg intrathecal
48117425|NCT05552443|DRUG|Hydromorphone 2.75 mcg/kg|2.75 mcg/kg intrathecal
48320881|NCT01504386|PROCEDURE|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
48320882|NCT01504386|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
48320883|NCT00423735|DRUG|Dasatinib|Given PO
48320884|NCT00423735|OTHER|Pharmacological Study|Correlative studies
48487259|NCT06490575|OTHER|Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults|Participants in the intervention group attended four face-to-face workshops (one session per week). Each session took about 30 minutes and consisted of lectures with PowerPoint presentations, discussion, questions and answers, and the distribution of educational pamphlets and booklets.
48487260|NCT04323020|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
48487261|NCT02973321|DRUG|SAR425899|Self-administered by SC injection using a solution for injection in cartridge.
48487262|NCT02973321|DRUG|Placebo|Self-administered by SC injection using a solution for injection in cartridge.
47969037|NCT04606030|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
48117426|NCT05552443|DRUG|Hydromorphone 3 mcg/kg|3 mcg/kg intrathecal
48117427|NCT05552443|DRUG|Hydromorphone 3.25 mcg/kg|3.25 mcg/kg intrathecal
48487263|NCT02973321|DRUG|Liraglutide|Self-administered by SC injection using a pre-filled pen.
48487264|NCT02973321|DRUG|Metformin|Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.
48487265|NCT02743143|BEHAVIORAL|Exercise therapy|
48487266|NCT02743143|OTHER|Follow-up care as usual|
48117428|NCT05552443|DRUG|Hydromorphone 3.5 mcg/kg|3.5 mcg/kg intrathecal
48117429|NCT05552443|DRUG|Hydromorphone 4 mcg/kg|4 mcg/kg intrathecal
48117430|NCT05552443|DRUG|Hydromorphone 4.5 mcg/kg|4.5 mcg/kg intrathecal
48117431|NCT05552443|DRUG|Hydromorphone 5 mcg/kg|5 mcg/kg intrathecal
48117432|NCT00835770|DRUG|dimethyl fumarate|BG00012 capsules
48117433|NCT00835770|DRUG|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
48117434|NCT02658370|DEVICE|animated home-based exercises (Wii-fit)|
48117435|NCT02658370|PROCEDURE|conventional home-based exercise program|
48117436|NCT03104387|OTHER|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
48646565|NCT06055699|OTHER|Fecal sampling|"Stool samples are a collection of products derived from the human body that is not invasive in any way and samples not taken as part of usual care.~Stool samples will be collected at home within 7 days of the visit M0, M3 and M6 and within 14 days of the visit M12 in an ethanol tube and in DNA/RNA shield, and transported at room temperature to Saint-Antoine Hospital (CRB SAT, AP-HP, Pr. SIMON ), samples will be aliquoted (3 aliquots per tubes) and stored at -80°C for a period of 5 years (renewable) At the end of the research, stool samples will be analysed using metagenomics sequencing.~DNA extraction will be performed following the standards of the The International Human Microbiome Standards . DNA will be stored at -80°C."
48646566|NCT06055699|OTHER|Blood sampling|"Blood samples (serum, 15 ml) are an additional and minimal collection performed following a sample taken as part of usual care.~Blood samples (serum) will be collected during the visit at M0, M3 (± 7 days), M6 (± 7 days) and M12 (± 7 days).~In the hours following collection, the samples must be aliquoted and stored at -80°C in a secure place in the participating centre."
48646567|NCT00338000|DRUG|Epoetin alfa|
48646568|NCT00000603|PROCEDURE|stem cell transplantation|
48646569|NCT02595437|DRUG|Triferic|
48646570|NCT02594579|DRUG|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
48646571|NCT02594579|DRUG|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
48646572|NCT05918146|DRUG|Dextrose|Dextrose injection plus physical therapy
48646573|NCT05918146|DRUG|Normal saline|Normal saline injection plus physical therapy
48646574|NCT00666978|BEHAVIORAL|smoking cessation intervention|
48646575|NCT00666978|DRUG|bupropion hydrochloride|
48646576|NCT00666978|GENETIC|gene expression analysis|
48646577|NCT00666978|GENETIC|polymerase chain reaction|
48646578|NCT00666978|OTHER|counseling intervention|
47969038|NCT05830968|DEVICE|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is \~6 months, depending on subject recruitment rate.
48117437|NCT03104387|OTHER|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
48117438|NCT01354795|PROCEDURE|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
48117439|NCT01354795|PROCEDURE|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
48117440|NCT03806348|PROCEDURE|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
48117441|NCT05425199|OTHER|Habituation exercises + vestibular treatment|"Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes"
48117442|NCT05425199|OTHER|proprioceptive training + vestibular therapy|Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets
48117443|NCT05425199|OTHER|conventional vestibular treatment|Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
48320885|NCT01523561|BEHAVIORAL|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
48117444|NCT03963336|DRUG|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
48117445|NCT03963336|DRUG|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
48320886|NCT06411223|BEHAVIORAL|Collaborative drug therapy management model|CDTM+ is an interdisciplinary approach to patient care in which clinicians collaborate with pharmacists to provide and manage patient drug therapy.
48487267|NCT01829919|DRUG|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
48646579|NCT00666978|OTHER|educational intervention|
48646580|NCT00666978|PROCEDURE|psychosocial assessment and care|
48646581|NCT04572269|OTHER|No Intervention|This protocol does not involve an intervention of drug/device, diet, exercise or PAP compliance.
48117446|NCT04957069|PROCEDURE|fixation|double row fixation with 3-4 wire anchors
48646582|NCT02252510|OTHER|HALOSPERM|
48646583|NCT01724814|DRUG|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
48646584|NCT01724814|DRUG|Placebo|Singe dose SC administration of Placebo
48646585|NCT03902210|BEHAVIORAL|Online Yoga|60 minutes per week of online yoga through Udaya.com
48646586|NCT03902210|BEHAVIORAL|Podcast|60 minutes per week of podcasts
48117447|NCT04957069|PROCEDURE|primary repair|end-to-end repair
48117448|NCT01580293|BIOLOGICAL|BAY94-9027|Intravenous infusion of BAY94-9027
48117449|NCT06609057|OTHER|Nutritional Intervention|Receive Cooking for Your Health in Southern New Mexico intervention
48117450|NCT06609057|OTHER|Questionnaire Administration|Ancillary studies
48117451|NCT06609057|OTHER|Survey Administration|Ancillary studies
48646587|NCT01713829|OTHER|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
48646588|NCT01713829|OTHER|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
48646589|NCT04613089|OTHER|Natural History|Natural History and Clinical Follow Up.
48320887|NCT06411223|DRUG|Cabotegravir/Rilpivirine|Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
48320888|NCT06098937|DEVICE|Kalifilcon Toric Lens|Kalifilcon A Daily Disposable Toric for Ametropia
48320889|NCT06098937|DEVICE|Total1 for Astigmatism|Total1 for Astigmatism
48487268|NCT02439203|DRUG|JM-010|
48646590|NCT04502186|BEHAVIORAL|Raising Our Spirits Together|Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
48646591|NCT04502186|OTHER|Enhanced Control Condition|The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
48117452|NCT06609057|OTHER|Discussion|Ancillary studies
48117453|NCT00536341|DRUG|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
48117454|NCT00536341|DRUG|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6
48117455|NCT00536341|DRUG|Fludarabine|25 mg/m2 on Days 1, 2, and 3
48117456|NCT04178239|DIAGNOSTIC_TEST|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
48117457|NCT03692117|DEVICE|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
48117458|NCT00780299|DEVICE|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
48117459|NCT00780299|PROCEDURE|CVVH|hemofiltration intermittent dialysis
48117460|NCT05530577|DRUG|Semaglutide|Semaglutide (subcutaneous)
48487269|NCT02439203|DRUG|Placebo|
48487270|NCT06051383|OTHER|Self management|"patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~* Introduction to the concept of self-management.~* Education/reassurance~* Managing fluid intake.~* Caffeine abstinence~* Alcohol advice~Session 2 :~* Adjusting medications~* Constipation advice.~* Strategies for dribbling. pelvic floor exercise.~* Double-voiding.~* Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months"
48487271|NCT04395651|DEVICE|PET/CT|It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.
48320890|NCT06098937|DEVICE|Precision1 for Astigmatism|Precision1 for Astigmatism
48320891|NCT06098937|DEVICE|MyDay Toric|MyDay Toric
48320892|NCT02732340|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
48320893|NCT03932682|BIOLOGICAL|QIVc|QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
48320894|NCT03932682|BIOLOGICAL|Comparator|Meningococcal Group C Polysaccharide Conjugate Vaccine (MenC vaccine, Neisvac-C)
48320895|NCT00165646|DRUG|E3810|E3810 5mg: once daily orally for 4 weeks
48487272|NCT05060432|DRUG|EOS-448|Anti-TIGIT monoclonal antibody
47969039|NCT03112395|DEVICE|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
47969040|NCT00000297|DRUG|Labetalol|
47969041|NCT01606475|BIOLOGICAL|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
47969042|NCT02496585|DRUG|Nintedanib|
47969043|NCT02496585|DRUG|Prednisone|
48117461|NCT05530577|DRUG|Sham/placebo|Sham subcutaneous injection
48487273|NCT05060432|DRUG|pembrolizumab|Anti-PD-1 monoclonal antibody
48117462|NCT00566527|BIOLOGICAL|ProQuad® manufactured with recombinant Human Albumin (rHA)|A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
48117463|NCT00006446|PROCEDURE|Training in parenting skills and communication|
48320896|NCT00165646|DRUG|E3810|E3810 10mg: once daily orally for 4 weeks
48320897|NCT00165646|DRUG|Placebo|Placebo: once daily orally for 4 weeks
48320898|NCT05685576|DEVICE|Piezotomed ridge splitting and osseodensification|Ridge expansion using piezotomed ridge splitting and osseodensification
48320899|NCT01983410|BEHAVIORAL|The risk assessment questionnaire|
48487274|NCT05060432|DRUG|inupadenant|A2A receptor antagonist
48487275|NCT05060432|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
48487276|NCT05060432|DRUG|SOC chemotherapies|SOC chemotherapies in 1L mNSCLC
48117464|NCT06213324|DRUG|Ketamine|0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
48117465|NCT06213324|DRUG|Placebo|Normal saline delivered intravenously
48320900|NCT01983410|OTHER|Blood specimens|
48320901|NCT01983410|OTHER|tumor tissue samples will be requested|
48320902|NCT01724983|DRUG|ketamine|
48320903|NCT01724983|DRUG|fentanyl|
48320904|NCT06525545|PROCEDURE|early mobilizzation of the ankle|perform flexion-extension exercises of the operated ankle
48320905|NCT03896789|OTHER|PEGASUS Program for Care|This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
48320906|NCT05430711|DRUG|Dinoprostone|After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
48320907|NCT01714752|PROCEDURE|measure of left ventricular and diastolic pressure at exercise|
48320908|NCT00374855|DRUG|PPAR alpha|
48320909|NCT00374855|DRUG|Hydrochlorothiazide|
48320910|NCT00374855|DRUG|Placebo|
48320911|NCT06409091|DEVICE|Medium weight or Heavy weight mesh|Patients received a hernia repair with one of the two groups
48320912|NCT06022978|PROCEDURE|Submucosal Saline Injection|Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
48320913|NCT06022978|PROCEDURE|Blue laser Imaging and Magnifying Endoscopy|It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
48320914|NCT00235690|PROCEDURE|Blood draws|PK samples obtained around a clinical dosing of colistin
48320915|NCT00235690|OTHER|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
48320916|NCT01289626|DRUG|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
48320917|NCT01289626|DRUG|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
48320918|NCT02137759|RADIATION|Standard Radiation Therapy|Radiation therapy to 60 Gy
48487277|NCT01633502|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
48487278|NCT01633502|DEVICE|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
48487279|NCT01888575|DRUG|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
48320919|NCT02137759|DRUG|Standard Temozolomide|Temozolomide given orally
48320920|NCT02137759|DRUG|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
47969044|NCT02496585|OTHER|Placebo|
48320921|NCT03284008|OTHER|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
48320922|NCT03284008|OTHER|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
48320923|NCT04894812|OTHER|Neurodevelopmental technique|"1. st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~2. nd month: balance and corrective reactions; using CP ball and tilt board.~3. rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars)."
48320924|NCT00228969|DRUG|RWJ-333369|
48320925|NCT04020146|OTHER|Gingival biopsies|Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
48320926|NCT04689594|COMBINATION_PRODUCT|CLS2702C/CLS2702D|"CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months \[24 weeks\]); follow-up period, 6 months \[24 weeks\]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device"
48320927|NCT00261326|DRUG|simvastatin|80 mg once daily
48487280|NCT06209801|BEHAVIORAL|Mirror therapy|60 seconds of intervention
48487281|NCT06209801|DEVICE|Neuromuscular electrical stimulation|60 seconds of intervention
48487282|NCT06209801|BEHAVIORAL|Motor imagery|60 seconds of intervention
48487283|NCT02053129|OTHER|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
48487284|NCT02053129|OTHER|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
47969045|NCT06041867|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
48320928|NCT00261326|DRUG|placebo|calcium tablets once daily
48320929|NCT03751592|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
48320930|NCT00296725|DRUG|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
48320931|NCT00296725|DRUG|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
48320932|NCT00328965|DRUG|Lacidipine|Lacidipine 2, 4, 6mg
48487285|NCT05053347|DIETARY_SUPPLEMENT|Flaxseed oil capsule|The participants were asked to take flaxseed oil capsule 5d/day(ALA 2.5g/d). The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
48646592|NCT02375711|BIOLOGICAL|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
48646593|NCT03814629|DRUG|Weifuchun|The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
47969046|NCT06041867|DIETARY_SUPPLEMENT|Agaricus bisporus capsules|Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily
48646594|NCT00236197|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
48646595|NCT00236197|DRUG|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
48646596|NCT03165695|DRUG|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
47969047|NCT06041867|DIETARY_SUPPLEMENT|Control capsules|Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily
47969048|NCT03547583|DRUG|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
47969049|NCT03547583|DRUG|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
47969050|NCT04478539|DEVICE|Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter|"Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF)."
47969051|NCT00885846|OTHER|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
47969052|NCT00885846|OTHER|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
47969053|NCT00459628|RADIATION|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
47969054|NCT00459628|RADIATION|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
47969055|NCT02661893|DRUG|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
48320933|NCT04178252|OTHER|mask|investigators will add eye mask to standard treatment
48320934|NCT04178252|OTHER|headset|investigators will add headset to standard treatment
48320935|NCT04178252|OTHER|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
48320936|NCT06056349|DRUG|Midazolam oral solution|Buccal administration
48487286|NCT05053347|DIETARY_SUPPLEMENT|Corn oil capsule|The participants were asked to take corn oil capsule 5d/day. The intervention period is about 6 months separated by a one-month washout period. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
48487287|NCT00680186|DRUG|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
48487288|NCT00680186|DRUG|Dabigatran etexilate|150mg bid
48487289|NCT05672693|OTHER|Several Calculation Formulas of Intraocular Lens|Comparison of the accuracy of several intraocular lens calculation formulas
48487290|NCT02794259|DEVICE|tDCS|
48487291|NCT02794259|DEVICE|sham-tDCS|
48487292|NCT00988689|OTHER|Dietary Intervention|soup with or without starch
48646597|NCT03165695|DRUG|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
47969056|NCT02661893|DRUG|Rifampin|Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
47969057|NCT04786145|PROCEDURE|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
47969058|NCT04786145|PROCEDURE|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
47969059|NCT04786145|PROCEDURE|Placebo|No active treatment is given.
48320937|NCT06056349|DRUG|ClonazePAM Oral Product|Orodispersable
48320938|NCT06056349|OTHER|Usual medication/ traditional|Medication that is usually used in the emergency department
48646598|NCT04392570|DIAGNOSTIC_TEST|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
48646599|NCT01045239|DEVICE|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
48646600|NCT01045239|DEVICE|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
48646601|NCT00885898|PROCEDURE|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
48646602|NCT00885898|PROCEDURE|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
48646603|NCT03357172|BIOLOGICAL|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
48646604|NCT03357172|BIOLOGICAL|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
47969060|NCT04945005|PROCEDURE|Transesophageal guidance of lead implantation|In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
47969061|NCT05367401|DRUG|Sabatolimab|Solution for intravenous infusion
47969062|NCT05367401|DRUG|Magrolimab|Solution for intravenous infusion
47969063|NCT05367401|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
48320939|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
48320940|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
48320941|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
48320942|NCT02927873|DRUG|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
48320943|NCT00257491|DRUG|Telmisartan|
48487293|NCT01490320|BEHAVIORAL|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
48487294|NCT01490320|BEHAVIORAL|Play Nicely Program|Multimedia program available at www.playnicely.org.
48487295|NCT01490320|OTHER|Control Group|Standard care in primary care clinic.
48487296|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator flaps|closure of myelomeningocele defect by perforator island flap after complete incision of the flap all around based on perforator vessel .
48117466|NCT06555653|OTHER|Video based multimedia information|The intervention group was shown a 5 minute informational video before amniocentesis including definition of amniocentesis, its indications, the setup of amniocentesis room, the purpose and steps of the procedure, potential complications and how to manage them
48487297|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator-plus flaps|closure of myelomeningocele defect by perforator-plus island flap harvesting leaving skin bridge connecting to the flap and dissection of the perforator vessel
48117467|NCT03829813|OTHER|Music therapy|20 to 40 minute music therapy treatment session with a qualified music therapist.
48487298|NCT03142035|DRUG|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
48487299|NCT03142035|DRUG|gonapeptyl|gonadotropic releasing hormone agonist
48487300|NCT03142035|PROCEDURE|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
47969064|NCT01538043|OTHER|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
48117468|NCT04233632|DEVICE|FC2 Condom|FC2: FC2 is composed of a synthetic nitrile rubber latex and 170mm in length. It has a flexible inner ring as the internal retention mechanism and a circular ring as the outer retention mechanism at the open end of the condom. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is available in clear and other colors/scents. It is manufactured by Female Health Company, USA and has USFDA, World Health Organisation (WHO)/United Nations Populations Fund (UNFPA) and South African Bureau of Standards (SABS) approval
48117469|NCT04233632|DEVICE|Cupid Condom|Cupid is composed of a Natural rubber latex and is 155mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in clear and red color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union (EU) and SABS approval
48320944|NCT00257491|DRUG|Telmisartan/HCTZ|
48320945|NCT03813745|OTHER|early denudation|COCs will be denudated in 30 min after oocyte retrieval
48320946|NCT03813745|OTHER|late denudation|COCs will be denudated 2 hr after oocyte retrieval
48320947|NCT03337152|DRUG|primaquine|Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
48487301|NCT02893995|DRUG|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
48487302|NCT02893995|DRUG|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
48487303|NCT05742698|DRUG|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
48646605|NCT03357172|BIOLOGICAL|Blood sample|Before donation
48646606|NCT03357172|BIOLOGICAL|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
48646607|NCT04682691|DRUG|Erythromycin (400mg)|oral Erythromycin (400mg)
48646608|NCT04682691|DRUG|metoclopramide (10mg)|oral metoclopramide (10mg)
48646609|NCT04682691|DIETARY_SUPPLEMENT|naturally flavored water|naturally flavored water
47969065|NCT03118115|DEVICE|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
47969066|NCT00810238|BIOLOGICAL|C-Cure|Intraventricular injection
47969067|NCT01559597|BIOLOGICAL|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
48646610|NCT02504775|DRUG|Mejoral® 500 Tablets|500 mg tablet of paracetamol
48117470|NCT04233632|DEVICE|Cupid 2 Condom|Cupid2 is composed of a Natural rubber latex and is 125mm in length. It has a Medical grade sponge as the internal retention mechanism and an octagonal outer frame as the outer retention mechanism. It is pre-lubricated with silicone oil. It has a shelf-life of 3 years and is available in Clear and purple color, vanilla scented variety. It is manufactured by Cupid Ltd, India and has WHO)/UNFPA, India Drug Control Authority, CE Mark of the EU and SABS approval
48320948|NCT03337152|DRUG|chloroquine + primaquine|Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
48646611|NCT02504775|DRUG|Tylenol® Caplets|500 mg tablet of paracetamol
48646612|NCT01018771|PROCEDURE|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
48117471|NCT02678572|COMBINATION_PRODUCT|Melphalan/HDS|Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
48117472|NCT03686891|OTHER|Skin prick tests with four native legumes|Skin prick tests with four native legumes
48117473|NCT03883529|OTHER|Writing about and reviewing birth experience|Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
48117474|NCT03083197|DRUG|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
48117475|NCT03083197|DRUG|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
48117476|NCT03083197|DRUG|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
48117477|NCT03671213|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
48646613|NCT01018771|PROCEDURE|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
48117478|NCT05570435|BIOLOGICAL|Blood collection|Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
48117479|NCT03881488|DRUG|CTX-471|IV infusion every 2 weeks
48117480|NCT03881488|DRUG|Pembrolizumab (KEYTRUDA®)|IV infusion every 6 weeks
48117481|NCT02615210|DEVICE|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
48117482|NCT05944003|PROCEDURE|Resuscitative thoracotomies|Resuscitative thoracotomies is an effective life saving measure in appropriate populations \[1-8\]. Unfortunately, when used outside of these populations the mortality rate is typically more than 90% \[1-8\]. Western Trauma Association and Eastern Association for the Surgery of Trauma have provided guidelines for which trauma patients are a candidate for RT \[1-
48117483|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
48117484|NCT00642980|DRUG|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
48117485|NCT00642980|DRUG|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
48117486|NCT05955391|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
48320949|NCT02566252|DRUG|PUL-042 Inhalation Solution|PUL-042
48320950|NCT02566252|DRUG|Cromolyn Sodium|Pre-treatment
48320951|NCT02566252|DRUG|Albuterol sulfate|Pre-treatment
48646614|NCT01825863|DRUG|Ropivacaine|
48646615|NCT01825863|DRUG|Saline 9%|
48646616|NCT04495998|DIAGNOSTIC_TEST|Brief Motor Scale_portuguese version (BMS_pt)|translate, adapt and validate Brief Motor Scale for portuguese population with schizophrenia
48646617|NCT03995472|DRUG|SHR-1501|Administered subcutaneously
48646618|NCT03995472|DRUG|SHR-1316|Administered intravenously
48320952|NCT05228106|DIAGNOSTIC_TEST|[68Ga]-PSMA-617|The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.
48320953|NCT00523341|BIOLOGICAL|Denosumab|Administered by subcutaneous injection once every 6 months.
48320954|NCT03326830|DEVICE|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher\&Paykel, New-Zealand).
48320955|NCT03326830|DEVICE|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
48320956|NCT01956240|PROCEDURE|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
48320957|NCT01956240|PROCEDURE|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
48320958|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
48320959|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
48320960|NCT04533815|BEHAVIORAL|LOCK sleep intervention|Nursing home staff are trained to use a collaborative problem-solving approach to sleep quality improvement using front-line huddling
48320961|NCT02497872|PROCEDURE|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
48320962|NCT00699101|DEVICE|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
48320963|NCT00667251|BIOLOGICAL|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
48320964|NCT00667251|DRUG|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
48320965|NCT00667251|DRUG|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
48320966|NCT00667251|DRUG|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
48320967|NCT02381496|DRUG|ACT-453859 1 mg|Capsule
48320968|NCT02381496|DRUG|ACT-453859 3 mg|Capsule
48487304|NCT05742698|DRUG|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
48487305|NCT03036839|DRUG|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
48320969|NCT02381496|DRUG|ACT-453859 10 mg|Capsule
48487306|NCT03603938|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
48320970|NCT02381496|DRUG|ACT-453859 30mg|Capsule
48320971|NCT02381496|DRUG|ACT-453859 100 mg|Capsule
48320972|NCT02381496|DRUG|ACT-453859 300 mg|Capsule
48320973|NCT02381496|DRUG|ACT-453859 800 mg|Capsule
48320974|NCT02381496|OTHER|Placebo|Matching ACT-453859 placebo capsule
48320975|NCT02381496|DRUG|Setipiprant 500 mg|Capsule
48320976|NCT02381496|DRUG|Setipiprant 1000 mg|Capsule
48320977|NCT00000524|DRUG|cyclosporine|
48487307|NCT02350634|DRUG|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie \[mCi\]) of 18F-AV-1451.
48487308|NCT03274622|BEHAVIORAL|Impact Parent Training|
48487309|NCT03274622|BEHAVIORAL|No Impact|
48320978|NCT00000524|DRUG|prednisone|
48320979|NCT03263936|DRUG|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5
48320980|NCT03263936|DRUG|Vorinostat|Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
48320981|NCT03263936|DRUG|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (\>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
48320982|NCT03263936|DRUG|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
48320983|NCT03263936|DRUG|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
48320984|NCT03309592|DRUG|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
48320985|NCT03309592|DRUG|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
48320986|NCT03331094|PROCEDURE|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
48320987|NCT03331094|PROCEDURE|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
48320988|NCT01471704|DRUG|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
48320989|NCT01471704|DRUG|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
48487310|NCT03878888|DRUG|Exparel 266 MG Per 20 ML Injection|patients receive Exparel in bilateral TAP blocks for open abdomen surgery
48487311|NCT02446834|BEHAVIORAL|intensive lifestyle intervention|3 months low GI diet and exercise
48487312|NCT02446834|DRUG|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
48487313|NCT02446834|DRUG|Metformin|Use metformin 3 months to treat PCOS
48320990|NCT01471704|DRUG|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
47969068|NCT05041205|DIETARY_SUPPLEMENT|Beauty drink powder|Beauty drink powder is designed as a oral beauty product to provide benefits to skin
47969069|NCT05041205|DEVICE|Cosmetic apparatus|This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
47969070|NCT06383221|COMBINATION_PRODUCT|"Mental Fitness Boot Camp - Advanced Counseling Step-by-Step Care"|Simple and scientific advice
47969071|NCT00884871|PROCEDURE|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
48320991|NCT00199134|DRUG|Letrozole|Size of the tumor is followed
48320992|NCT00472355|DRUG|apomorphine|
48320993|NCT04380974|PROCEDURE|OCTA plus OCT guided 3+PRN regimen|"For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
48320994|NCT04380974|PROCEDURE|OCT guided 3+PRN regimen|"For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
48117487|NCT03166449|DIETARY_SUPPLEMENT|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
48117488|NCT03166449|DIETARY_SUPPLEMENT|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
47969072|NCT00241215|DRUG|Botulinum toxin serotype A|
48117489|NCT01841437|DEVICE|iStent|
48117490|NCT03209037|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
48320995|NCT04380974|DRUG|Anti-VEGF drug|Conbercept or other anti-VEGF drugs
47969073|NCT03939260|OTHER|Extracorporeal CO2 Removal|Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume \< 6 ml/kg and Pplat \<20-25 cmH2O).
47969074|NCT02745444|DIETARY_SUPPLEMENT|low-calorie formula diet|
47969075|NCT02745444|DIETARY_SUPPLEMENT|protein-restricted diet|
48320996|NCT00490659|DRUG|gemcitabine|
48320997|NCT00490659|DRUG|cisplatin|
48320998|NCT00490659|PROCEDURE|radical surgery|
48487314|NCT02446834|DRUG|Acarbose|Use acarbose 3 months to treat PCOS
47969076|NCT00483730|DRUG|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
47969077|NCT00003105|BIOLOGICAL|filgrastim|
47969078|NCT00003105|DRUG|cisplatin|
47969079|NCT00003105|DRUG|doxorubicin hydrochloride|
47969080|NCT00003105|DRUG|gemcitabine hydrochloride|
47969081|NCT00003105|DRUG|ifosfamide|
47969082|NCT00003105|DRUG|paclitaxel|
47969083|NCT01815593|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
47969084|NCT00277498|DRUG|Xalacom|
47969085|NCT00277498|DRUG|Xalatan|
48117491|NCT04057196|BEHAVIORAL|Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)|The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
48117492|NCT01496521|DRUG|Aspirin|100mg qd for 6 months.
47969086|NCT00277498|DRUG|Timolol|
48117493|NCT01496521|DIETARY_SUPPLEMENT|Tea Polyphenols|300mg bid for 6 months.
48117494|NCT05434624|DRUG|Midazolam|Before the procedure, all patients were given i.v. 0:02 - 0:04 mg / kg midazolam (zolamide 15 mg / 3 mL, and medications, Turkey) will be administered.
48117495|NCT05434624|DRUG|Propofol|Propofol 0.5 mg/kg bolus dose will be administered to Group II. Maintenance will be provided with 60 mcg/kg/min propofol infusion, and the propofol infusion dose will be increased by 10 mcg/kg/min by titration until the BIS value is 40-60 during the procedure.
48320999|NCT00490659|PROCEDURE|chemoradiotherapy|
48321000|NCT05851339|OTHER|SF- 36 Questionnaire|applicants will fill health related quality of life SF-36 Questionnaire after PCNL or RIRS
48321001|NCT00280241|DRUG|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
48321002|NCT00280241|DRUG|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
48321003|NCT00280241|DRUG|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
48321004|NCT02211976|DRUG|Bisacodyl|
48321005|NCT02211976|DRUG|Simeticone|
48321006|NCT05138406|OTHER|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
48321007|NCT05138406|OTHER|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
48117496|NCT01968226|DRUG|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis \>50% who are undergoing planned carotid endarterectomy will be imaged under PET with \[F-18\] RDG-K5
48117497|NCT05958654|BEHAVIORAL|Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool|DETECT-RPC is an elder mistreatment (EM) screening tool designed for medics who respond to older adults' homes and will be adapted for home-based primary care (HBPC). The DETECT-RPC tool is designed to (1) be brief, (2) be based on the clinician's direct observations of the older adult and the older adult's physical and social environment, (3) provide reporting guidance, and (4) be integrated into their existing procedures and medical charting software.
48117498|NCT04989387|DRUG|INCA00186|INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
48117499|NCT04989387|DRUG|Retifanlimab|Retifanlimab will be administered every 4 weeks as per protocol
48321011|NCT01948388|DRUG|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
48321012|NCT02871193|DRUG|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
48321013|NCT02871193|DRUG|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
48321014|NCT02871193|OTHER|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
48321015|NCT03518814|OTHER|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
48321016|NCT02389140|OTHER|Trigger point release|Trigger point therapy
48321017|NCT02389140|OTHER|Ultrasound|sham ultrasound
48321018|NCT01954472|BEHAVIORAL|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
48321019|NCT01954472|BEHAVIORAL|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.~Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
48321020|NCT01278017|DRUG|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
48321021|NCT03700788|DRUG|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
48321022|NCT03700788|DRUG|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
48321023|NCT02266615|GENETIC|Biobanking of biomaterial for future genetic research.|
48321024|NCT01363557|OTHER|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
47969087|NCT05180084|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory, self-determination theory and self-compassion therapy for low self-esteem among young adults.
48117500|NCT04989387|DRUG|INCB106385|INCB106385 will be administered orally once or twice a day.
48117501|NCT00710515|DRUG|AZD6244|75mg
48117502|NCT01517347|DRUG|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
48321025|NCT01363557|DRUG|Gefitinib (IRESSA)|250 mg/day
48321026|NCT03589885|DRUG|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
48487315|NCT00941057|DRUG|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
47969088|NCT00653575|BEHAVIORAL|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
47969089|NCT00653575|BEHAVIORAL|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
47969090|NCT05948397|DIAGNOSTIC_TEST|Combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and quality of life scale|A combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and quality of life scale would be given to all patients. The sum of the responses for the third, fourth and fifth questions and quality of life scale scores will be recorded.
47969091|NCT05948397|DIAGNOSTIC_TEST|Bladder diary|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance
48117503|NCT02379299|DEVICE|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
48117504|NCT02379299|DEVICE|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
48117505|NCT05657730|DIETARY_SUPPLEMENT|Water Kefir beverage|Participants will consume the water kefir beverage for two weeks.
48117506|NCT02244060|OTHER|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
48117507|NCT05499039|DEVICE|High flow nasal cannula (HFNC)|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%"
48117508|NCT05499039|DEVICE|Non-Invasive Mechanical Ventilation (NIV)|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation"
48487316|NCT00941057|DRUG|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
48487317|NCT00941057|DRUG|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
48487318|NCT04960306|BIOLOGICAL|Fecal filtrate transplantation|"Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
48487319|NCT04960306|BIOLOGICAL|Conventional fecal microbiota transplantation|"Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
48487320|NCT04918641|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
48487321|NCT04544020|DIETARY_SUPPLEMENT|NG feeding|NG feeding
48487322|NCT00287313|DRUG|Vitamin K|
48487323|NCT01125020|DRUG|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
48487324|NCT01125020|DRUG|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
48487325|NCT04904159|PROCEDURE|Thyroidectomy|total thyroidectomy
48487326|NCT04904159|PROCEDURE|Lobectomy|Lobectomy
48487327|NCT00905788|PROCEDURE|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
48487328|NCT01032772|BEHAVIORAL|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
48487329|NCT01032772|BEHAVIORAL|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
48487330|NCT01147978|BEHAVIORAL|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
48487331|NCT00000476|DRUG|digitalis|
48487332|NCT00289003|DRUG|Soluble beta-1,3/1,6-glucan|
48487333|NCT00313443|PROCEDURE|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
48321027|NCT03589885|DRUG|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
48321028|NCT03589885|DRUG|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
48487334|NCT00594646|DRUG|TRUVADA + Raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
47969092|NCT05948397|DIAGNOSTIC_TEST|Pad test|"One-hour pad test.~* the test is started by putting one pre-weighted pad without patient voiding, -patient drinks 500 ml of sodium-free liquid in \<15 min- then sits or rests,~* patient walks for 30 min, including climbing one flight of stairs (up and down),~* patient performs the following activities: standing up from sitting (10 ), coughing vigorously (10 ), running on the spot for 1 min, bending to pick up an object from the floor (5 ), and washing hands in running water for 1 min (this activity program may be modified according to the patient's physical fitness),~* the total amount of urine leaked is determined by weighing the pad. In the analysis of 1-hr pad test, an increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and \>50 g severe incontinence. The values for 24-hr pad test are classified as follows: Mild (4-20 g/ 24 hr), moderate (21-74 g/24 hr), and severe (\>75 g/24 hr) incontinence"
47969093|NCT02555683|DRUG|QAW039|QAW039 150 mg once daily
47969094|NCT02555683|DRUG|QAW039|QAW039 450 mg once daily
47969095|NCT02555683|DRUG|Placebo|Placebo once daily
47969096|NCT03799770|DIAGNOSTIC_TEST|Optic nerve sheath diameter by ultrasound at 5 minutes post-reperfucion|"Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the ﬁnal ONSD value was calculated by average 4 measured values.~We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion."
47969097|NCT02145780|DIETARY_SUPPLEMENT|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
47969098|NCT02145780|DIETARY_SUPPLEMENT|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
47969099|NCT03060538|DRUG|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
47969100|NCT03060538|OTHER|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
47969101|NCT00194597|DRUG|Viagra (sildenafil citrate)|
47969102|NCT01666782|BIOLOGICAL|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
47969103|NCT01666782|BIOLOGICAL|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
47969104|NCT01760460|DRUG|Anacetrapib|
47969105|NCT01760460|DRUG|Placebo for anacetrapib|
47969106|NCT04660669|OTHER|ESDM intervention|Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.
47969107|NCT04660669|OTHER|MOOC|Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
47969108|NCT01095731|DRUG|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
48321029|NCT03589885|DRUG|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
47969109|NCT01095731|DRUG|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
47969110|NCT03924453|DIAGNOSTIC_TEST|Pearl Powered by Proov|Participants self test in their homes and report back data via uploading onto an app and taking surveys.
48321030|NCT00734344|DRUG|Raltegravir|Raltegravir 400 mg. BID
48321031|NCT00734344|DRUG|Efavirenz|600 mg once daily
48321032|NCT00734344|DRUG|Emtricitibine|200mg once daily
48321033|NCT00734344|DRUG|Tenofovir disoproxil once daily|300mg once daily
48321034|NCT00734344|DRUG|Tenofovir disoproxil twice daily|300mg twice daily
47969111|NCT02613975|DEVICE|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
47969112|NCT03641443|DEVICE|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
47969113|NCT00640601|DRUG|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
47969114|NCT00680706|DRUG|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
48321035|NCT01063816|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
48321036|NCT01063816|DRUG|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
48321037|NCT01063816|DRUG|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
48321038|NCT01643759|DRUG|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
48321039|NCT00082758|BIOLOGICAL|hu14.18-Interleukin-2 fusion protein|Given IV
48321040|NCT04260828|DRUG|Aspirin 100mg|Daily active drug administered orally for 3 months.
48321041|NCT04260828|OTHER|Placebo|Sugar pill administered orally for 3 months.
48321042|NCT00955292|DRUG|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
48321043|NCT00064350|DRUG|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
48321044|NCT00064350|DRUG|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
48487335|NCT05507762|BIOLOGICAL|UC-MSCs|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection Duration: 5 injections per trial group for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively"
48487336|NCT05507762|BIOLOGICAL|Saline solution|Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection Duration: 5 injections per person for the entire duration of the course, at 1st treatment, 2-week, 4-week, 16-week, and 24-week respectively
48321045|NCT04533958|DEVICE|HYPNO VR® device|"The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each Docetaxel infusion, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the chemotherapy program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff."
48321046|NCT05006521|DRUG|KN-002|KN-002 dry powder inhaler
47969115|NCT00680706|DRUG|Placebo|D5W (50 ml)
48321047|NCT04260659|DRUG|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
48321048|NCT04260659|DRUG|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
48321049|NCT04260659|DRUG|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
48321050|NCT04260659|DRUG|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
48321051|NCT04260659|DRUG|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
48487337|NCT01435031|DEVICE|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation"
48487338|NCT02608970|DRUG|BMS-986177|
48487339|NCT02608970|OTHER|Placebo|
48117509|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501|"CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
48117510|NCT00700336|DRUG|pemetrexed and cisplatin|"Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
48321052|NCT04260659|DRUG|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension \> 140/90 mmHg or tachycardia \> 120min occurs. If necessary rescue dosis may be repeated.
48646619|NCT05391958|BEHAVIORAL|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC \> 2.
48646620|NCT05391958|BEHAVIORAL|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC \> 2.
48646621|NCT05391958|GENETIC|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
48646622|NCT05391958|GENETIC|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
48646623|NCT02571881|PROCEDURE|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
48646624|NCT02571881|DRUG|Oxycodone|
48646625|NCT02571881|DRUG|oxycodone-naloxone|
48646626|NCT00235625|DRUG|Curcuminoids C3 Complex®|
48646627|NCT05814614|OTHER|pelvic physical therapy|Pelvic floor muscle exercises, biofeedback, bladder training
48646628|NCT00262613|DRUG|sodium pyruvate in 0.9% sodium chloride solution|
48646629|NCT03391791|GENETIC|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
48646630|NCT04060355|BEHAVIORAL|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
48646631|NCT04060355|BEHAVIORAL|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
48646632|NCT01664715|BEHAVIORAL|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
48646633|NCT01664715|BEHAVIORAL|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
48646634|NCT01664715|BEHAVIORAL|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
48646635|NCT04365881|OTHER|Cross-sectional observational study|Survey
48646636|NCT03230565|DRUG|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
48321053|NCT04144855|DRUG|TQB3474 injection|This is a kind of heat shock protein (HSP90) inhibitor.
48487340|NCT00037102|DRUG|interferon beta 1a|
48487341|NCT00037102|DRUG|methotrexate|
48646637|NCT03230565|DRUG|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
48646638|NCT02822690|OTHER|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
48646639|NCT04941573|COMBINATION_PRODUCT|Hyperpolarized 129-Xenon (MagniXene) MRI of the lung|Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
48487343|NCT00186043|DRUG|Quetiapine/Seroquel|Quetiapine/Seroquel
48487344|NCT00186043|DRUG|Placebo|Placebo
48487345|NCT04750135|DRUG|metformin 500 mg TID Oral Tablet|biguanides derivatives
48487346|NCT04750135|DRUG|Placebo|Placebo
48487347|NCT02165618|OTHER|Medication review, based on but not limited to the RASP list|"Systematic approach:~1. Medication reconciliation~2. Applying the RASP list~3. Expert review (not based on the RASP list)~4. Multidisciplinary discussion"
48487348|NCT01000493|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
48487349|NCT01000493|OTHER|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
48646640|NCT00318136|DRUG|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
48646641|NCT00318136|DRUG|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
48321054|NCT05411640|OTHER|Aerobic exercise with Blood flow restriction|Experimental group will be given aerobic exercises with blood flow restriction training. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. . Arterial occlusion of 60% will be achieved by Blood Flow Restriction apparatus. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
48321055|NCT05411640|OTHER|Aerobic exercise without Blood flow restriction|Active Comparator group will be given aerobic exercises. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
48487350|NCT00975962|DRUG|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
48487351|NCT00975962|PROCEDURE|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
48487352|NCT05451732|PROCEDURE|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
48487353|NCT01166555|DRUG|PF-04236921|single subcutaneous dose
48487354|NCT02314572|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
48487355|NCT03418506|BEHAVIORAL|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
48487356|NCT04199884|BEHAVIORAL|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
48487357|NCT04199884|BEHAVIORAL|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
48487358|NCT04163978|DRUG|Nitric Oxide|in situ 240mL nitric oxide releasing sinus irrigation solution
48487359|NCT04163978|DRUG|Budesonide|Saline based sinus irrigation 1mg Budesinide solution
48487360|NCT02003911|DRUG|Azithromycin|Azithromycin suspension (200mg/5mL)
48487361|NCT02003911|DRUG|Placebo|
48487362|NCT05678231|DEVICE|Zero Degree Knee Positioner|The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
48487363|NCT06048289|OTHER|Blood samples, tumor biopsy specimens will be collected|Blood samples, tumor biopsy specimens at baseline will be collected
48487364|NCT00046449|DRUG|Investigational Seasonal Affective Disorder (SAD) Drug|
48646642|NCT00318136|DRUG|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
48646643|NCT06570707|OTHER|Brighter Bites|Families will receive a distribution of fresh fruits and vegetables (FV) (\~20lbs., 50 servings/family/distribution) for \~16 weeks during the school year using primarily donated produce from local food banks. Nutrition education will be implemented for children using the evidence-based Coordinated Approach to Child Health (CATCH) program and for parents using bilingual nutrition handbooks and fun food experiences such as healthy FV recipe tastings for families during produce pick-up time will be conducted.
48646644|NCT02904265|DRUG|Diazepam|
48646645|NCT02904265|DRUG|Acetazolamide|
48646646|NCT03537729|BEHAVIORAL|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
48646647|NCT03537729|BEHAVIORAL|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
48646648|NCT04806945|DRUG|HLX10|IV infusion.
48646649|NCT04806945|DRUG|Paclitaxel|IV infusion
48646650|NCT04806945|DRUG|Cisplatin|IV infusion
48646651|NCT04806945|DRUG|Carboplatin|IV infusion
48321056|NCT05411640|OTHER|Patient Education and dietary modification|Participants will individually instruct to reduce total energy intake and increase physical activity, aiming at a 5% reduction in body weight. The participants will be given pamphlets providing general information on pre diabetes and dietary modifications. Total intervention protocol for the group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
48321057|NCT00315705|DRUG|clofarabine|Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
48321058|NCT00315705|DRUG|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
48321059|NCT00315705|DRUG|Cyclophosphamide|Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
48321060|NCT04429685|DRUG|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
48321061|NCT04429685|DRUG|Saline (placebo)|Saline (placebo)
48487365|NCT06482671|DRUG|Rikkunshi-to|Kampo medicine (Herbal). ikkunshito is composed of the following eight herbal medicines: extracts of Atractylodes lancea Rhizome, Ginseng, Pinellia tuber, Poria sclerotium, Jujube, Citrus unshiu Peel, Glycyrrhiza, and Ginger. Among these, the extracts of the Atractylodes lancea Rhizome, Ginseng, Poria sclerotium, Pinellia tuber, Citrus unshiu Peel, and Glycyrrhiza
48487366|NCT06482671|OTHER|Placebo|inactive drug, The matching placebo contains Corn Starch (vehicle), Lactose Hydrate (vehicle), Dextrin (vehicle), Magnesium Stearate (lubricant), FD\&C Blue No.1 Aluminum Lake (coloring agent), FD\&C Yellow No.5 Aluminum Lake (coloring agent), and Red Ferric Oxide (coloring agent).
48487367|NCT05333237|DIETARY_SUPPLEMENT|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
48646652|NCT04806945|DRUG|Placebo to HLX10|IV infusion
48646653|NCT05816161|DIAGNOSTIC_TEST|Integrated Neuromuscular Inhibition Technique|Exercises
48646654|NCT05816161|DIAGNOSTIC_TEST|Myofascial Release|Exercises
48646655|NCT01269437|DRUG|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
48646656|NCT05855993|OTHER|Nerve Glide Exercise with Ultra Sound|A brief demonstration will be given to perform the nerve glides exercises to both group. The duration of exercise programmed is 15 minutes every 3 to 5 times per day for 4 weeks. Group A will perform exercise with ultrasound
48646657|NCT05855993|OTHER|Nerve Glide Exercise without Ultra Sound|Group B will perform exercise for 10 minutes every 3 to 5 times per day without ultrasound.
48646658|NCT06418269|OTHER|Therapeutic Play|"Children will be asked to fill in the Child Patient Identification Form, State Anxiety Scale in Children and Child Fear Scale 30 minutes before insulin treatment. Before the insulin treatment, the children in the experimental group will have their blood glucose measured and insulin administered on a doll using the therapeutic play method. The child will be told that the doll is hospitalized with a diagnosis of Type 1 diabetes and will be expected to assume the role of a nurse to administer insulin to the doll. Then, the steps of blood glucose measurement and insulin treatment (subcutaneous) will be explained to the child and the child will be asked to administer insulin to the baby. Within 10 minutes after subcutaneous insulin treatment, the child will be asked to fill out the State Anxiety Scale in Children and Child Fear Scale."
48646659|NCT04194697|BEHAVIORAL|Exercise|Exercise program
48646660|NCT04194697|BEHAVIORAL|No exercise|No exercise program
48646661|NCT05077111|PROCEDURE|Thoracic Epidural Anesthesia|Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
48646662|NCT05077111|PROCEDURE|General Anesthesia with One Lung Ventilation|Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
48321062|NCT05432674|COMBINATION_PRODUCT|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
48321063|NCT00077519|DRUG|tipifarnib|
48321064|NCT00077519|RADIATION|radiation therapy|
48321065|NCT01758965|OTHER|PPI|monotherapy of PPI
48321066|NCT01758965|OTHER|H2RA and surgicel|combination therapy of H2RA and surgicel
48321067|NCT06188559|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
48321068|NCT03991884|DRUG|Etoposide|Given IV
48321069|NCT03991884|DRUG|Doxorubicin|Given IV
48321070|NCT03991884|DRUG|Vincristine|Given IV
48321071|NCT03991884|DRUG|Prednisone|Given PO or IV
48321072|NCT03991884|DRUG|Cyclophosphamide|Given IV
48321073|NCT03991884|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
48321074|NCT05429177|DRUG|QY101 ointment or vehicle|QY101 ointment or vehicl topical applied to skin
48321075|NCT04377334|BIOLOGICAL|MSC|infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells
48321076|NCT00432094|DRUG|carboplatin|Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
48117511|NCT00700336|DRUG|pemetrexed, cisplatin and CBP501, dose finding|"Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
48321077|NCT00432094|DRUG|etoposide|600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
48321078|NCT00432094|DRUG|ifosfamide|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
48487368|NCT05333237|DIETARY_SUPPLEMENT|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
48117512|NCT00639002|DRUG|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
48117513|NCT00639002|DRUG|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
48321079|NCT00432094|DRUG|paclitaxel|225 mg/m\^2 intravenous over 3 hours on Day -7.
48646663|NCT02498795|OTHER|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
48646664|NCT02498795|OTHER|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
48646665|NCT02498795|OTHER|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
48646666|NCT02621853|DEVICE|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
48321080|NCT00432094|DRUG|thiotepa|150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
48321081|NCT00432094|PROCEDURE|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)
48321082|NCT00432094|DRUG|Mesna|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
48321083|NCT00432094|BIOLOGICAL|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
48321084|NCT04494555|DEVICE|Static socket|For the static socket configuration, both the microprocessor control and user control are disabled, and the panels are positioned in their flush configuration to create the user's as-prescribed socket shape.
48321085|NCT04494555|DEVICE|User adjusted socket|Sockets are configured for user control by disabling automated control and enabling push buttons on the side of the socket to adjust socket size. Each button push effects a socket size change of approximately 0.3% volume. An upper button effects a socket size increase, and a lower button a socket size decrease. The buttons are countersunk so reduce risk of accidental pushes, and they do not function unless the user is stationary. An additional button push will not be executed until motor motion from the prior push has been completed. If a button is continuously held then the motor will continue moving until the button is released. Limits are set on cable length to ensure that sockets sizes threatening to the user's residual limb (too tight) are avoided. The push buttons effect inner-loop control that operates completely within the mechanism, achieving high-resolution adjustment of cable length with minimal error.
48321086|NCT04494555|DEVICE|Microprocessor-adjusting sockets|"A strategy for automatically controlling the size of the socket during walking to compensate for unknown changes in limb volume will be used. The controller is essentially a regulator that continuously measures socket fit, and adjusts the socket to maintain a prescribed reference set point. Because the fit is automatically sustained, the prosthesis user is unaware of its operation."
48321087|NCT05986032|DIAGNOSTIC_TEST|Respiratory Oscillometry|Measurement of respiratory system reactance by respiratory oscillometry
48321088|NCT06019910|OTHER|Snus with or without tobacco|At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
48487369|NCT05333237|DIETARY_SUPPLEMENT|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
48487370|NCT05480826|GENETIC|study of the transmission of genetic variants|the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
48487371|NCT01816815|DRUG|BAY1002670|
48646667|NCT06571903|OTHER|Teaching from videos|Teaching from videos for independent study
48321089|NCT01225471|BIOLOGICAL|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
48321090|NCT00489840|DRUG|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
48487372|NCT01816815|DRUG|Placebo|
48487373|NCT03095573|DEVICE|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
48487374|NCT03095573|DEVICE|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
48646668|NCT05335967|BEHAVIORAL|Self-management program|The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
48321091|NCT00489840|DRUG|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
48321092|NCT02289482|DRUG|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
48646669|NCT05335967|OTHER|Information package|The patients in this group will receive an information package on a healthy diet.
48321093|NCT02289482|DRUG|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
48321094|NCT02289482|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
48321095|NCT02289482|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
48321096|NCT05059548|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
48321097|NCT03056976|DEVICE|Single-implant mandibular overdenture|Complete mandibular denture retained by a single midline implant
48487375|NCT05338021|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
48487376|NCT00765011|DRUG|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
48321098|NCT03056976|DEVICE|Two-implant mandibular overdenture|Complete mandibular denture retained by two implants in the canine region
48487377|NCT00765011|PROCEDURE|H&N surgery|Rescue surgery
48646670|NCT05318443|DRUG|SIBP04|SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
48646671|NCT05318443|DRUG|Avastin|Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
48646672|NCT05318443|DRUG|Paclitaxel|Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
48646673|NCT05318443|DRUG|Carboplatin|Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
48646674|NCT04634136|DIAGNOSTIC_TEST|Lab tests|CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
48646675|NCT04634136|DIAGNOSTIC_TEST|ECG|Electrocardiogram
48321099|NCT03056976|DEVICE|Fixed mandibular denture|A fixed mandibular denture retained by four implants
48321100|NCT02225574|DRUG|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
48321101|NCT02225574|DRUG|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
48321102|NCT02225574|BEHAVIORAL|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
48321103|NCT01452555|BEHAVIORAL|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
48321104|NCT00375635|PROCEDURE|mFPSA treatment|
48117514|NCT02113072|DRUG|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
48321105|NCT06084338|RADIATION|stereotactic ablative radiotherapy|Metastasis directed
48321106|NCT06084338|DRUG|Pluvicto|PSMA targeted radiopharmaceutical therapy
48321107|NCT06084338|DRUG|topical testosterone|Topical testosterone 1.62% gel
47969116|NCT03792191|RADIATION|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
48117515|NCT02113072|DRUG|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
48321108|NCT05611840|PROCEDURE|Robotic surgery|one-stage robotic common bile duct exploration and cholecystectomy
48321109|NCT05611840|PROCEDURE|Endo-laparoscopic surgery|Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
48321110|NCT01309438|DRUG|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
48321111|NCT01309438|DRUG|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
48321112|NCT01309438|DRUG|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
48487378|NCT00906113|DRUG|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
48646676|NCT04634136|DIAGNOSTIC_TEST|Cannabinoid Levels|Determination of levels of cannabidiol (CBD) and delta-9-tetrahydrocannbinol (THC) for determination of levels at following time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
48321113|NCT01309438|DRUG|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
48321114|NCT06033950|DRUG|Finerenone|Oral finerenone.
48646677|NCT04634136|DRUG|Full-spectrum Medical Canabis Product (HemPhar)|Active substance
48646678|NCT04634136|DRUG|Placebo|Placebo
48646679|NCT04634136|DIAGNOSTIC_TEST|Spasticity level according to modified Ashworth scale (Bohannon)|"A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.~Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):~0 No increase in muscle tone~1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )~2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved~3. Considerable increase in muscle tone, passive movement difficult~4. Affected part(s) rigid in flexion or extension~Best score is 0 (no spasticity), worst score is 4 (severe spasticity)."
48646680|NCT04634136|DIAGNOSTIC_TEST|Gross Motor Function Measure|"A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy~The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.~Reference curves exist for GMFM-88 for each age group.~Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75."
48646681|NCT04634136|DIAGNOSTIC_TEST|Borg rating of perceived exertion scale|Borg rating of perceived exertion scale
48117516|NCT02113072|DRUG|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
48321115|NCT06033950|DRUG|Placebo|Matching oral placebo.
48321116|NCT03110146|DEVICE|EnSite Precision|Ablation procedure
48321117|NCT05237180|OTHER|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
48321118|NCT02752568|PROCEDURE|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
48321119|NCT02752568|PROCEDURE|assisted hatching|using Octax laser 20120644-laser 5452
48321120|NCT02752568|PROCEDURE|controlled ovarian hyperstimulation|using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol
48321121|NCT03825094|DEVICE|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
48321122|NCT01322646|DEVICE|CarChipPro|On board driving monitor
47969117|NCT03792191|RADIATION|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
48117517|NCT02561039|DRUG|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
48117518|NCT02589340|DRUG|Buspirone|
48117519|NCT02589340|DRUG|Placebo|Sugar Pill
48117520|NCT00643071|DRUG|Tacrolimus|Oral
48321123|NCT01322646|BEHAVIORAL|Driver's Education|10 Session License to Learn Program.
48321124|NCT01322646|BEHAVIORAL|STEER Program|8-session behavioral parent training and teen social skills/communication training program
48321125|NCT01322646|OTHER|Driving Simulator Practice|Practice Driving on a driving simulator
48487379|NCT00906113|DRUG|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
48487380|NCT05587335|BEHAVIORAL|PREP|Relationship intervention to improve communication and conflict resolution for couples
48321126|NCT03522350|DEVICE|EmbryoScope|Standard of care arm
48321127|NCT03522350|DEVICE|EmbryoScope+|Experimental arm
48321128|NCT00262080|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
48321129|NCT00262080|DRUG|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
48321130|NCT03873402|BIOLOGICAL|Nivolumab|Specified dose on specified days
48321131|NCT03873402|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48321132|NCT03873402|OTHER|Ipilimumab placebo|Specified dose on specified days
48321133|NCT03201146|DRUG|Apatinib|Doses to be determined following the completion of Phase I of the study.
48321134|NCT03201146|DRUG|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
48321135|NCT03201146|DRUG|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
48321136|NCT03201146|DRUG|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
48321137|NCT03201146|DRUG|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
48487381|NCT05587335|BEHAVIORAL|OurRelationship|Relationship intervention to improve communication and conflict resolution for couples
48487382|NCT02919813|BEHAVIORAL|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
48646682|NCT04634136|DIAGNOSTIC_TEST|Edmonton symptom assessment system|Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
48321138|NCT05508438|DEVICE|Transfemoral mitral-valve repair|Transfemoral mitral-valve repair
48321139|NCT04853043|DRUG|Cetuximab|Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
48321140|NCT00109304|BIOLOGICAL|VEE 3526|
48321141|NCT02370017|BIOLOGICAL|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
48321142|NCT00530556|DRUG|zolpidem|
48321143|NCT01124201|OTHER|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
48321144|NCT04538911|DRUG|BCG-PPD|BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
48321145|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin)|"Participants will receive one of the following Gemcitabine-based systemic therapy alone:~Gemcitabine 1000mg/m2 and Cisplatin 25 mg/m2, each administered on Days 1 and 8 every 3 weeks (q3w)~Duration: 3 months (in addition to 3 months previously received)"
48321146|NCT06214572|RADIATION|RT|"Participants will receive radiation therapy in addition to systemic therapy Hypofractionated external image guided radiation to a dose of 40-55Gy in 10 sessions (up to 60Gy in 15 sessions) over 2-3 weeks.~This is followed by systemic therapy as in the Systemic therapy alone arm."
48321147|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus oxaliplatin)|"Gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 IV infusion on days 1 and 8 q2w.~Duration: 3 months"
48321148|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab)|"Durvalumab 1500 mg via intravenous (IV) infusion q4w, starting on Cycle 1 in combination with cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 each administered on Days 1 and 8, q3w.~Duration 3 months Durvalumab (12 months)"
48321149|NCT06214572|DRUG|Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)|Gemcitabine 800 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel 100 mg/m2, on days 1 and 8, q3w Duration: 3 months
48321150|NCT00607958|DRUG|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
48321151|NCT04427436|OTHER|No Intervention|No Intervention
48321152|NCT05931744|DRUG|Budesonide|after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
48321153|NCT05931744|DRUG|Prednisone|patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
48321154|NCT05931744|DRUG|Saline|saline intrapolyp injection
48487383|NCT02919813|BEHAVIORAL|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
48487384|NCT01827124|DRUG|Carbetocin|
48487385|NCT01827124|DRUG|oxytocin|
48487386|NCT05362721|DIAGNOSTIC_TEST|Pressure-volume loop catheter|The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
48646683|NCT05800626|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|ERCP performed for clinical practice
48646684|NCT04156100|DRUG|AGEN1223|AGEN1223 is a bispecific antibody.
48487387|NCT04039386|DEVICE|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
48646685|NCT04156100|DRUG|AGEN1223 and balstilimab|AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
48646686|NCT00339365|BEHAVIORAL|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
48646687|NCT00339365|BEHAVIORAL|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
48487388|NCT04039386|OTHER|Control|Subjects in the control group will receive standard care.
47969118|NCT03792191|PROCEDURE|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
48321155|NCT05851586|PROCEDURE|Supervised exercise + home exercise program|The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.
48321156|NCT05851586|PROCEDURE|Home exercise program only|The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
48321157|NCT06279312|DIETARY_SUPPLEMENT|Placebo drink|consume 1 drink per day for 4 weeks
48321158|NCT06279312|DIETARY_SUPPLEMENT|Adaptogen Elixir drink|consume 1 drink per day for 4 weeks
48321159|NCT01318772|DEVICE|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.~The system includes a new digital camera and a new image processor."
48321160|NCT03769935|DRUG|cis Platinum, etoposide, S1|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
48321161|NCT03280433|OTHER|Aortic valve replacement|
48321162|NCT00005060|DRUG|Taxotere-Cisplatin-5FU|Preoperatively
48321163|NCT00005060|DRUG|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
48321164|NCT00286130|DRUG|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
48321165|NCT00286130|DRUG|FOLFOX 6|"FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
48321166|NCT00286130|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
48321167|NCT01573507|OTHER|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
48321168|NCT06521957|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
48321169|NCT04709302|BIOLOGICAL|COVID-19|Patients diagnosed with a COVID-19 infection
48321170|NCT04709302|BIOLOGICAL|HIV|Patients diagnosed HIV-positive
48321171|NCT04709302|DRUG|ART|Patients on ART
48321172|NCT03241472|DRUG|Letrozole|oral tablets 5 mg
48487389|NCT04407078|DRUG|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
48487390|NCT04407078|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
48646688|NCT01594814|PROCEDURE|RFA|radiofrequency ablation of slow pathway or accesory pathway
48646689|NCT05206045|OTHER|Standard of care|Standard of care for patients with Sezary Syndrome
48321173|NCT03241472|DRUG|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
48321174|NCT00004278|DRUG|ganciclovir|
48321175|NCT05912920|PROCEDURE|gastric band|gastric band
48321176|NCT02938052|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
48321177|NCT04859335|RADIATION|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
48321178|NCT01938963|BEHAVIORAL|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
48487391|NCT03659461|DRUG|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
48487392|NCT01631513|DRUG|Nucynta ER|100 to 250 mg every 12 hours
47969119|NCT03792191|PROCEDURE|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
48321179|NCT01666691|DRUG|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
48321180|NCT01666691|DRUG|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
48321181|NCT02750904|BEHAVIORAL|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study."
48321182|NCT02750904|BEHAVIORAL|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
48321183|NCT05611359|PROCEDURE|Thermal Ablation|Thermal hepatic ablation Combined with Chemotherapy
48321184|NCT05611359|DRUG|Chemotherapy|Chemotherapy
48321185|NCT03408548|PROCEDURE|Scaling root planning|Periodontal treatment
48321186|NCT03408548|DIETARY_SUPPLEMENT|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
48487393|NCT03295695|DIAGNOSTIC_TEST|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-\[18F\]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
48646690|NCT02665650|BIOLOGICAL|AFM13|
48646691|NCT02665650|BIOLOGICAL|Pembrolizumab|
48646692|NCT00921544|OTHER|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
48646693|NCT00921544|OTHER|Sterile water|Sterile water administered 2 mins prior to eye exam
48321187|NCT03408548|OTHER|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
48321188|NCT00539916|BEHAVIORAL|Regular orange juice consumption|600 mL /day.
48321189|NCT04061252|DRUG|KHK4827|brodalumab 210mg Q2W, SC
48321190|NCT04061252|DRUG|Placebo|Q2W, SC
48321191|NCT01695850|DRUG|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
48321192|NCT01695850|DRUG|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
48321193|NCT01695850|DRUG|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
48321194|NCT02417909|OTHER|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
48321195|NCT04777721|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
48321196|NCT04812418|DIETARY_SUPPLEMENT|Noctesia|3 tablets every day at bedtime with a large glass of water
48321197|NCT04812418|DIETARY_SUPPLEMENT|Placebo|3 tablets every day at bedtime with a large glass of water
48321198|NCT02170649|DRUG|BIA 2-093|
48487394|NCT03295695|BIOLOGICAL|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-\[18F\]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
48487395|NCT03295695|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
47969120|NCT03792191|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
47969121|NCT03792191|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
48117521|NCT03403998|OTHER|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
48117522|NCT03403998|OTHER|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
48117523|NCT05384210|DRUG|Milnacipran|Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.
48321199|NCT02471911|DRUG|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
48321200|NCT02471911|DRUG|Rituximab|IV Rituximab 375 mg/m2 on D1
48321201|NCT02471911|DRUG|Etoposide|IV Etoposide 100 mg/m2 on D1-3
48321202|NCT02471911|DRUG|Carboplatin|IV Carboplatin AUC 5 on D2
48321203|NCT02471911|DRUG|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
48487396|NCT05723679|OTHER|HeO2 gas mixture|Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
48487397|NCT05723679|OTHER|Room air gas mixture|Normal room air
48487398|NCT01782482|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
48487399|NCT01782482|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
48487400|NCT01674413|DRUG|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
47969122|NCT00684346|OTHER|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
47969123|NCT00495183|DRUG|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
48117524|NCT05384210|DRUG|Gabapentin|Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months
48321204|NCT02471911|DRUG|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
48321205|NCT00103467|BIOLOGICAL|rPA102 Vaccine|
48321206|NCT03638661|DIETARY_SUPPLEMENT|vegetable (canola, flaxseed) derived n-3 fatty acid|vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.
48321207|NCT03638661|DIETARY_SUPPLEMENT|soybean oil|soybean oil used formula
48321208|NCT02106988|RADIATION|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
47969124|NCT00495183|DRUG|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
47969125|NCT00495183|DRUG|Placebo|Placebo
47969126|NCT03200860|DRUG|Empagliflozin 10 MG|10 mg daily, oral, 30 days
48321209|NCT02106988|DRUG|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
48321210|NCT02106988|DRUG|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
48321211|NCT02106988|DRUG|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
48321212|NCT02106988|DRUG|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
48321213|NCT02106988|DRUG|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
48321214|NCT03796182|DRUG|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
48321215|NCT03796182|DRUG|PF-04965842|PF 04965842 100 mg tablets
48321216|NCT04799236|DRUG|Group 1: Miltefosine|Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days
48321217|NCT04799236|DRUG|Group 2: Pentavalent Antimony|will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes
48646694|NCT01954511|OTHER|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
47969127|NCT03200860|DRUG|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
48321218|NCT04799236|DRUG|Group 3: Liposomal amphotericin B|3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
48646695|NCT01954511|OTHER|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
48646696|NCT01954511|DEVICE|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
48646697|NCT04898309|DRUG|GNR-038, 50 МЕ/ kg|A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
48646698|NCT04898309|DRUG|GNR-038, 100 МЕ/ kg|A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
48646699|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
48646700|NCT04898309|DRUG|Placebo|A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
47969128|NCT02478996|OTHER|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
48321219|NCT00066664|GENETIC|proteomic profiling|
48321220|NCT01977079|OTHER|procalcitonin|
48321221|NCT00819585|DRUG|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
48321222|NCT00819585|DRUG|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
48646701|NCT04898309|DRUG|GNR-038. The dose will be selected according to results of stage 1 clinical trial.|A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
48646702|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
47969129|NCT01832649|BEHAVIORAL|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
47969130|NCT01832649|BEHAVIORAL|Health education|Supervised groups 2 times per week during 8 weeks.
47969131|NCT00541931|DRUG|Dietary Supplement: LifePak Nano|Daily use
47969132|NCT05820178|DEVICE|tDCS|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
47969133|NCT05820178|DEVICE|rTMS|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
47969134|NCT02194244|DRUG|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
48117525|NCT05384210|DRUG|Combined gabapentin/milnacipran|Patients will receive combined gabapentin as group B and MLN as group A
48646703|NCT05686720|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 5.0×10\^7 and 2.0×10\^8 cells. The infusion is given every 2 weeks.
48646704|NCT00104403|DRUG|GW679769|
48646705|NCT00104403|DRUG|Dexamethasone|
48646706|NCT00104403|DRUG|Ondansetron Hydrochloride|
48646707|NCT02241772|DRUG|TA-8995|
48646708|NCT02241772|DRUG|Placebo|
48646709|NCT04961515|DRUG|Orelabrutinib|Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined regimen, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) and dose level 3 (250mg) with rules for escalation and de-escalation. If the DLT is not found, the dose of 250mg qd will be used for phase II trial.
48646710|NCT04961515|DRUG|Orelabrutinib|Orelabrutinib: orally maximum tolerated dose from phase 1b daily (150 mg or 200 mg or 250mg)
48646711|NCT04961515|DRUG|Sintilimab|The dose of sintilimab is fixed dose. 200 mg intravenously every 3 weeks
47969135|NCT02194244|DRUG|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
48321223|NCT00819585|DRUG|Allopurinol|100-300 mg orally once daily for 24 weeks.
48321224|NCT00819585|DRUG|Placebo Matching Canakinumab|Subcutaneous injection.
48321225|NCT00819585|DRUG|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
48321226|NCT04417725|OTHER|Not applicable - this is a non-interventional, observational study.|Not applicable - this is a non-interventional, observational study.
48321227|NCT05353166|DRUG|REGN5381|Single dose administered via IV infusion
48487401|NCT01674413|DRUG|Adalimumab PRN|"160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool."
48487402|NCT01674413|DRUG|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
48487403|NCT05968534|BEHAVIORAL|MOSAIC Plus|"This is a single-arm study. Participants will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
48321228|NCT05353166|DRUG|Matching Placebo|Single dose administered via IV infusion
48321229|NCT03741296|PROCEDURE|Single stage revision|One-stage exchange hip joint replacement surgery
48321230|NCT03741296|PROCEDURE|Two-stage revision|Two-stage exchange hip joint replacement surgery
48321231|NCT05739877|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
48321232|NCT05739877|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
48646712|NCT04118426|RADIATION|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
48117526|NCT00994097|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
48321233|NCT03468699|COMBINATION_PRODUCT|Autologous BMMC transplantation|Stem cell transplantation
48321234|NCT04585295|DIETARY_SUPPLEMENT|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
48321235|NCT04585295|DIETARY_SUPPLEMENT|BCAA Big 6|1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
48321236|NCT04585295|DIETARY_SUPPLEMENT|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
48646713|NCT04942327|BEHAVIORAL|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
47969136|NCT02883270|DEVICE|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
47969137|NCT02883270|OTHER|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
47969138|NCT01815216|PROCEDURE|Bariatric surgery|Gastric bypass surgery
47969139|NCT01815216|BEHAVIORAL|Brain activity in resting state|Measure of activity in brain networks during resting state
47969140|NCT01815216|BEHAVIORAL|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
48321237|NCT03832920|OTHER|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
48117527|NCT00994097|DRUG|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
48117528|NCT00994097|DRUG|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
48117529|NCT00994097|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
48117530|NCT05619861|BIOLOGICAL|CAR-T|Patients will receive CAR-T treatment
48117531|NCT00838253|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
48321238|NCT00679068|DRUG|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
48321239|NCT00729313|DRUG|Lanreotide microparticles|
48321240|NCT00729313|DRUG|Placebo|
48321241|NCT03306485|OTHER|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
48321242|NCT01557218|OTHER|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
48321243|NCT01557218|OTHER|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
48646714|NCT00085020|BIOLOGICAL|trastuzumab|
48646715|NCT00085020|DRUG|lapatinib ditosylate|
47969141|NCT01925105|OTHER|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
48117532|NCT00838253|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
48321244|NCT01557218|OTHER|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
48321245|NCT01557218|OTHER|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
48321246|NCT01557218|OTHER|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
48321247|NCT01557218|OTHER|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
48117533|NCT00838253|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
48321248|NCT01557218|OTHER|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
48321249|NCT01557218|OTHER|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
48321250|NCT05784337|DEVICE|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter Mitral Valve Replacement
48321251|NCT05869552|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management. The intervention will consist of an initial session with the youth focusing on accessing mental health care plus case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to three months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
48321252|NCT05869552|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 3 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training and support on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 3 months.
48321253|NCT03497429|DRUG|Niraparib|Niraparib capsule
48321254|NCT03586245|DIETARY_SUPPLEMENT|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
48321255|NCT03586245|DIETARY_SUPPLEMENT|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
48321256|NCT03586245|DIETARY_SUPPLEMENT|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
48646716|NCT04021368|DRUG|RVU120(SEL120)|RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
48646717|NCT00265005|DRUG|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
47969142|NCT02954731|BEHAVIORAL|UP-CBT|"Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy"
47969143|NCT02954731|BEHAVIORAL|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
47969144|NCT01130142|DRUG|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
47969145|NCT01130142|DRUG|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
47969146|NCT02213367|DRUG|Bilastine|20mg (8 weeks)
48117534|NCT00838253|DRUG|Placebo|Placebo continuous i.v. infusion for 24 hours
48321257|NCT00757926|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
48321258|NCT00757926|OTHER|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
48321259|NCT04876703|DEVICE|Multichannel Functional electrical stimulation|The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.
48321260|NCT04876703|OTHER|Standard motor training|Standard motor training is the conventional rehabilitation treatment
48487404|NCT03407430|DRUG|Pregabalin|During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
48646718|NCT03098706|PROCEDURE|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
48117535|NCT00067353|DRUG|Fluoride varnish|
48117536|NCT06555770|BEHAVIORAL|müzik müdahalesi|One group of patients will be listening to music for 15 minutes during the surgery, while the other group will be applied a stress ball.
48117537|NCT06367816|PROCEDURE|INTELLiVENT|Closed-loop mode of ventilation
47969147|NCT02213367|DRUG|Bilastine|40mg
47969148|NCT02213367|DRUG|Bilastin|80mg
48117538|NCT06367816|PROCEDURE|Conventional ventilation|Mode of ventilation
48117539|NCT00523146|DRUG|Kanion Capsule|
48117540|NCT00827346|DRUG|Clopidogrel|600 mg now
48117541|NCT00827346|DRUG|Clopidogrel|600 mg now and 600 mg in 3 hours
48117542|NCT00827346|DRUG|Clopidogrel|900 mg now
48117543|NCT00827346|DRUG|Clopidogrel|600 mg now and 300 mg in 3 hours
48117544|NCT00486005|DRUG|Olanzapine Hydrochloride|
48117545|NCT00486005|DRUG|Nizatidine|
48117546|NCT00486005|DRUG|Placebo|
48117547|NCT01475123|DRUG|Nicorandil|15mg per day
48646719|NCT03098706|PROCEDURE|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
48117548|NCT00149279|PROCEDURE|Surgery: D2 dissection|
48321261|NCT01157052|OTHER|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1 (Arm A) or cycle 2 (Arm B)"
48321262|NCT01864798|DRUG|Denosumab|
48646720|NCT05168124|BEHAVIORAL|Acceptance Commitment Therapy for chronic fatigue|ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
48646721|NCT05168124|BEHAVIORAL|Micro breaks in everyday life for chronic fatigue|"In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being."
48646722|NCT00108563|DRUG|Citalopram or Placebo|
48646723|NCT05500131|BEHAVIORAL|Observation|"Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe."
48646724|NCT05218161|DRUG|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
47969149|NCT03001531|DEVICE|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
48117549|NCT00149279|PROCEDURE|Surgery: D2+paraaortic dissection|
48321263|NCT00878631|DRUG|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
48321264|NCT00878631|DRUG|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
47969150|NCT03001531|DEVICE|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
47969151|NCT04333797|OTHER|Risk and Protective Factors Assessment|First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
47969152|NCT02955602|DRUG|MBX-8025 2 mg Capsule|"Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
48117550|NCT02675088|RADIATION|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
48117551|NCT02675088|RADIATION|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
48117552|NCT06502353|DEVICE|BLOOM43|Heat preconditioning
48117553|NCT00851669|BEHAVIORAL|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
48117554|NCT00851669|BEHAVIORAL|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
48321265|NCT05446025|DIAGNOSTIC_TEST|Blood sample|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
48321266|NCT06516185|DEVICE|direct-printed aligner|Patients will be treated with direct-printed aligners until dental alignment is achieved.
48321267|NCT06516185|DEVICE|thermoformed aligner|Patients will be treated with thermoformed aligners until dental alignment is achieved.
48321268|NCT04253834|DEVICE|Incentive spirometer|The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.
48321269|NCT04253834|DEVICE|GO2 Mouthpiece|The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
48646725|NCT01407887|DRUG|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
48646726|NCT02368873|PROCEDURE|Application of IPOM mesh|
48646727|NCT04604366|DRUG|misoprostol|it stimulates uterine contractions
48646728|NCT04970589|OTHER|Mango|400g of mango/day
48646729|NCT04970589|DIETARY_SUPPLEMENT|Probiotics|1 probiotics capsule/day
48646730|NCT04970589|OTHER|Placebo|1 Placebo capsule/day
48646731|NCT03090542|DIETARY_SUPPLEMENT|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
48646732|NCT04544631|OTHER|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
48646733|NCT03965117|DRUG|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
48646734|NCT06530303|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
48646735|NCT06530303|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
48646736|NCT06530303|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
48646737|NCT06530303|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
47969153|NCT02955602|DRUG|MBX-8025 5 mg Capsule|"Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
48487405|NCT03407430|DRUG|Placebo|During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
48487406|NCT04989777|DEVICE|IABP (Intra-aortic balloon pump ) implantation|Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
48487407|NCT04211142|PROCEDURE|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)|Laparoscopic inguinal hernia repair
48487408|NCT04211142|PROCEDURE|Open Inguinal Hernia Repair (Lichtenstein repair)|Open Inguinal Hernia Repair
48487409|NCT00772135|DRUG|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
48487410|NCT05773157|BEHAVIORAL|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
48487411|NCT00337441|DRUG|Epoetin Alfa (drug)|
48487412|NCT02218112|PROCEDURE|bariatric surgery (gastric bypass)|
48487413|NCT03712241|DRUG|K-285|Topical
48487414|NCT03712241|DRUG|Indomethacin|Capsule
48487415|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
48487416|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
48487417|NCT01414049|PROCEDURE|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
48487418|NCT01414049|PROCEDURE|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
48487419|NCT01565265|DRUG|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
48487420|NCT01565265|DRUG|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
48487421|NCT02801084|BEHAVIORAL|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 \& 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
48487422|NCT06071819|DIAGNOSTIC_TEST|Structured Clinical Interview for DSM-5|A structured interview will be administered to confirm the diagnosis reported in clinical charts
48487423|NCT06091228|OTHER|tongue scraper|tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
48487424|NCT05058534|DEVICE|Multiline Neo®|Multiperfusion neonatal system
48487425|NCT06236568|DEVICE|D-HOPE machine perfusion|use of the device
48487426|NCT06236568|PROCEDURE|Liver transplantation|Liver transplantation for HCC within Milan criteria
48487427|NCT02286219|DRUG|FS102|Experimental
48646738|NCT06530303|DRUG|Pembrolizumab|Intravenous (IV) infusion
48646739|NCT04019704|DRUG|AXS-05|Oral AXS-05 tablets, taken daily for 6 weeks.
48646740|NCT04019704|DRUG|Placebo|Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
48646741|NCT01724385|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
48646742|NCT01569763|DEVICE|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
48646743|NCT01569763|DEVICE|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
48646744|NCT03948620|DRUG|Macrolides|Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
47969154|NCT02955602|DRUG|MBX-8025 10 mg Capsule|"Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
48646745|NCT03948620|DRUG|Penicillins|The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
48646746|NCT06045286|RADIATION|Radiation: High- and Low-dose radiotherapy|High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.
48646747|NCT06045286|DRUG|PD-1 Inhibitors|Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
48646748|NCT02122185|DRUG|metformin hydrochloride|Given PO
48646749|NCT02122185|DRUG|placebo|Given PO
48646750|NCT02122185|DRUG|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
48646751|NCT02397369|OTHER|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
48646752|NCT02397369|BEHAVIORAL|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
48646753|NCT02397369|BEHAVIORAL|Tobacco users:Behavioural therapy Only|"1. Focus Group discussion:~   This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~2. Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
48646754|NCT02397369|OTHER|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
48646755|NCT05520866|BEHAVIORAL|PrehabPal|Web based application
48646756|NCT03599297|PROCEDURE|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
48487428|NCT02070302|DRUG|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
48487429|NCT02070302|DRUG|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
48646757|NCT05983900|PROCEDURE|BRIX3000|chemo-mechanical caries removal agent
48646758|NCT05983900|PROCEDURE|papacarie|chemo-mechanical caries removal agent
48646759|NCT05983900|PROCEDURE|hand excavation|mechanical caries removal
47969155|NCT00708968|BEHAVIORAL|FOCUS Program|Supportive, educative sessions with patients and spouses.
47969156|NCT03626883|PROCEDURE|single-bundle, single-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with single hamstring tendon
47969157|NCT03626883|PROCEDURE|single-bundle, double-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with 2 hamstring tendons
48646760|NCT00323986|DRUG|azithromycin (drug)|
48646761|NCT06500689|DRUG|Allisartan Isoproxil/Sustained-Release Indapamide|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
48646762|NCT06500689|DRUG|Allisartan Isoproxil|"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."
48646763|NCT00514397|DRUG|motexafin gadolinium|
48646764|NCT00514397|DRUG|temozolomide|
47969158|NCT03439553|BEHAVIORAL|Ads display with target websites|Ads are shown, but users are referred to control websites.
47969159|NCT03439553|BEHAVIORAL|Ads display with control websites|Ads are shown, but users are referred to control websites.
48487430|NCT02672202|DRUG|Duloxetine|"* 60 mg/d - twice before surgery and once a day for post operative days 3-7~* 30 mg/d - once a day for post operative days 1-2"
48487431|NCT02672202|DRUG|Pregabalin|"* 75 mg/d - twice a day for post operative days 1-2~* 150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
48646765|NCT00514397|PROCEDURE|adjuvant therapy|
48646766|NCT00514397|PROCEDURE|quality-of-life assessment|
48646767|NCT00514397|RADIATION|radiation therapy|
48646768|NCT01793571|PROCEDURE|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
48646769|NCT04493203|DRUG|Nivolumab|Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1. It is a type of Immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
48321270|NCT03916172|BEHAVIORAL|The Open Door Approach to Parenting Teenagers (APT)|APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
48646770|NCT04493203|DRUG|Axitinib|Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1-3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours)
48646771|NCT02985775|BIOLOGICAL|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
48646772|NCT01314248|DEVICE|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
48646773|NCT03191734|DEVICE|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
48646774|NCT00124657|DRUG|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
48646775|NCT00600704|PROCEDURE|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
48646776|NCT00600704|PROCEDURE|Free fluid infusion|Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
48646777|NCT00594308|DRUG|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
47969160|NCT05988099|DIETARY_SUPPLEMENT|Complex product|400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
47969161|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in liposomal formulation|400 mg of chokeberry extract in liposomal formulation
47969162|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in traditional formulation|400 mg of chokeberry extract in traditional formulation
47969163|NCT05988099|OTHER|Placebo|Placebo
47969164|NCT06266078|DEVICE|Innovative PPE|The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall
48117555|NCT04831190|BEHAVIORAL|Tailored Exercise Intervention|The exercise program to be implemented for neuro-oncology patients will combine aerobic, resistance, balance, and flexibility exercises delivered in one-to-one setting (i.e., personal training) twice per week, for 12 weeks. Based on needs and preferences, participants will have the option to join a circuit-type group class once per week in place of one of their personal training sessions. During COVID-19, all sessions will be delivered remotely. If facilities are open and deemed safe for cancer patients, participants will have the option to attend an in-person session, integrated in the community. Whether delivered in-class or remotely, the intervention will follow exercise progression principles (i.e., frequency, intensity, time, type, overload, and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs, with aims of promoting wellness and physical function. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
48117556|NCT00177216|DRUG|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or \>). The dose was decreased to 5 mg if side effects occurred.
48117557|NCT00177216|DRUG|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
48117558|NCT00177216|DRUG|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
48117559|NCT03876210|COMBINATION_PRODUCT|PK101|PK101-001 + PK101-002 (combination)
48117560|NCT03876210|DRUG|PK101-001, PK101-002|coadministration
48117561|NCT06137365|DRUG|Cannabis|Cannabis gummy product will be prepared using cannabis flower extract.
48117562|NCT06137365|DRUG|Placebo|Placebo gummy product will be prepared using the same ingredients as the cannabis gummy but will not contain active cannabinoids.
48117563|NCT03293056|OTHER|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
48321271|NCT03284255|DEVICE|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
48321272|NCT03284255|DEVICE|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
48646778|NCT00594308|DRUG|Fludarabine|25mg/m2/day for 5 consecutive days
48646779|NCT00594308|DRUG|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
48646780|NCT00594308|DRUG|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
48646781|NCT00594308|DRUG|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
48646782|NCT05647252|DRUG|Whole Body and nasal decolonization with octenidin (Octenisan Set)|"Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period"
48646783|NCT05647252|BEHAVIORAL|Questionnaire for study participants immediately after the decolonization|"A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators."
48117564|NCT03293056|OTHER|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
48117565|NCT03069313|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
48117566|NCT05300061|BEHAVIORAL|Personal Values Intervention|A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
48646784|NCT03939494|BEHAVIORAL|Telehealth Encounter|Contact will be made with participants via Face Time or Skype.
48646785|NCT03232892|DRUG|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
48646786|NCT05996445|BIOLOGICAL|XmAb662|Intravenous (IV) administration
48646787|NCT05996445|BIOLOGICAL|Keytruda® (pembrolizumab)|Intravenous (IV) administration
48646788|NCT03731000|DEVICE|PHIL® device|Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
48646789|NCT00595075|DRUG|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
48646790|NCT00595075|DRUG|placebo|placebo identical in appearance to active experimental drug x 1 dose
48646791|NCT03715829|DRUG|PF-06651600|Induction dose 1. Oral tablet taken QD
48646792|NCT03715829|DRUG|PF-06651600|Induction dose 2. Oral tablet taken QD
48646793|NCT03715829|DRUG|PF-06651600|Maintenance dose A. Oral tablet taken QD
47969165|NCT06266078|DEVICE|Traditional PPE|The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
48117567|NCT05300061|BEHAVIORAL|Prosocial Values Intervention|A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
48117568|NCT02403596|DRUG|Exacyl®|
48117569|NCT02403596|OTHER|Placebo of Exacyl®|
48117570|NCT00622531|DEVICE|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
48117571|NCT00622531|OTHER|hidden BNP value|no intervention
48117572|NCT04128358|DIAGNOSTIC_TEST|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
48117573|NCT04128358|DIAGNOSTIC_TEST|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
48117574|NCT06400394|DEVICE|Hydrocyn Aqua®|The study solution comes in a liquid form containing hypochlorous acid (HOCl) in a concentration of 0.003%. It is used as a topical agent for wound and peritoneal lavage before wound closure
48117575|NCT06400394|DEVICE|Normal Saline|aqueous solution of electrolytes and other hydrophilic molecules
48117576|NCT03460067|RADIATION|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
48117577|NCT04110223|GENETIC|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
48117578|NCT01888848|DIETARY_SUPPLEMENT|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
48117579|NCT01888848|DIETARY_SUPPLEMENT|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
48117580|NCT00786006|DRUG|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
48117581|NCT00786006|DRUG|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
48117582|NCT02058017|DRUG|OPB-51602|
48117583|NCT06335654|DIAGNOSTIC_TEST|artificial intelligence system|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. After endocytoscopic observation, the artificial intelligence system will be open and display the predictive result. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue. After endocytoscopic observation, the artificial intelligence system will be open again and display the predictive result.
48321273|NCT00507416|DRUG|Bortezomib|Bortezomib bolus intravenous (IV) injection
48646794|NCT03715829|DRUG|PF-06651600|Maintenance Dose B. Oral tablet taken QD
48646795|NCT03715829|DRUG|PF-06651600|Maintenance Dose C. Oral tablet taken QD
48646796|NCT03715829|DRUG|placebo|placebo
48646797|NCT03715829|DRUG|PF06700841|Oral tablet taken QD
48321274|NCT00507416|DRUG|Dexamethasone|Dexamethasone for oral administration
48321275|NCT00507416|DRUG|Melphalan|Melphalan for oral administration
48321276|NCT00507416|DRUG|Prednisone|Prednisone for oral administration
48646798|NCT03715829|DEVICE|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
48646799|NCT01515254|BEHAVIORAL|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
48646800|NCT01994005|BEHAVIORAL|Facebook|Facebook page with contraception information used for counseling
48646801|NCT01994005|BEHAVIORAL|Pamphlet|Contraceptive knowledge pamphlets
48646802|NCT03049397|OTHER|Communication Intervention|Complete Enhancing Connections program
48646803|NCT03049397|OTHER|Questionnaire Administration|Ancillary studies
48646804|NCT01713322|BEHAVIORAL|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
48646805|NCT01713322|BEHAVIORAL|No pain management education|Control - parents receive general information about childhood immunization.
48646806|NCT00667043|DRUG|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
48646807|NCT00667043|DRUG|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
47969166|NCT05364125|OTHER|Olfactory Training|Four aromatic substances will be used (Citrus limon, Eucalyptus radiata, Pelargonium graveolens, Juniperus virginiana)
47969167|NCT05364125|OTHER|Control|Normal Saline will be used
48321277|NCT00507416|DRUG|Thalidomide|Thalidomide for oral administration
48646808|NCT02098473|DRUG|RPC4046|
48646809|NCT02098473|DRUG|Placebo|
48646810|NCT03318393|DRUG|Bivalirudin|Continuous infusion
48646811|NCT03318393|DRUG|Unfractionated heparin|Continuous infusion
48646812|NCT06478615|PROCEDURE|Coring out Fistulectomy with Closure of Internal Sphincter Opening|The patient was laid in the lithotomy position. Skin preparation and draping were done. Normal saline irrigation was performed. The anal canal was sufficiently dilated to permit the introduction of a self-retaining retractor. With H2O2 injection into the fistula tract, the internal opening and tract of the fistula will be identified. The incision was made around the external opening, and the tract was all cored out along the tract from the external opening to the internal sphincter. Meticulous hemostasis will be performed, stay suture by PDS 4/0 around fistiolous opening at the internal sphincter, excision of fistulous tract above stay suture, then closure of internal sphincter defect by PDS 3/0. Anal packing with 4 × 4 epinephrine gauze and sterile protective dressing was performed. After the operation, a stool softener and pain controller were prescribed, and patients were discharged.
48646813|NCT06478615|PROCEDURE|Lay Open Fistulotomy and Primary Sphincter Repair|Patients were put in a lithotomy position and the skin was then draped. After identification of the external fistula orifice probing of the fistula tract with identification of the fistulous tract and internal orifice with H2O2 injection into the fistula tract. The fistula was laid open and fistulectomy was then conducted and dissected with diathermy cautery help. Then Primary repair of the sphincter with PDS 3/0 with proper hemostasis using coagulation diathermy.
48646814|NCT02940223|DRUG|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
48646815|NCT02940223|BEHAVIORAL|Exercise Intervention|Complete resistance exercises and undergo walking program
48646816|NCT02940223|BEHAVIORAL|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
48646817|NCT02940223|OTHER|Laboratory Biomarker Analysis|Correlative studies
48646818|NCT02940223|OTHER|Placebo|Given PO
48646819|NCT02940223|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
47969168|NCT00908713|DRUG|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
48321278|NCT01434641|OTHER|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
48321279|NCT04621006|DIAGNOSTIC_TEST|Continuously assessment of disease activity|Continuous measures of disease activity and activity in the contact activation system.
48321280|NCT00057590|BEHAVIORAL|Care manager outreach and monitoring|
48321281|NCT00637715|DRUG|Alfuzosin|
48321282|NCT03132168|BEHAVIORAL|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
48321283|NCT03132168|PROCEDURE|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
48321284|NCT03132168|OTHER|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
48321285|NCT03946826|DRUG|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
48321286|NCT03946826|DRUG|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
48321287|NCT03946826|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
48487432|NCT02672202|DRUG|Placebo|"* non-active - twice before surgery~* non-active - twice a day for post operative days 1-7"
48487433|NCT05210452|BIOLOGICAL|Follicular stem cells|Cultured autologous follicular stem cells
47969169|NCT00908713|DRUG|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
47969170|NCT02949869|OTHER|Spinal Sonography|As described previously
47969171|NCT00662805|DRUG|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
48487434|NCT05210452|OTHER|Standard treatment according to the clinical protocols|Standard treatment of alopecia according to the clinical protocols
48487435|NCT05927831|DRUG|Grape Seed Extract|Grape seed extract will be applied in the form of a gel on the tooth surface
48487436|NCT05927831|DEVICE|Low-level laser therapy|The device will be set at a wavelength of 810 nm, with a power output of 0.5 watts tip of diameter 300 μ in non-contact mode
48487437|NCT01706874|OTHER|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
48487438|NCT04645979|OTHER|Online survey|Participants will be invited to complete an online questionnaire about their experience of product use.
48487439|NCT01300923|DRUG|Acamprosate|
48487440|NCT00449982|DRUG|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
48487441|NCT05937321|BEHAVIORAL|Share plus intervention|"Participants will receive the Share plus intervention:~* Set up Follow app~* Start Share plus intervention~* Communication and problem-solving strategies~* Detailed action plan including glucose targets~* Review communication and problems~* New communication content~* Revise action plan as needed for communication and problem-solving hypo- and hyperglycemia,~* Dyadic glucose pattern management training using Clarity, set automatic Clarity downloads~* Dyad set goals for regular times to discuss glucose trends and problem-solving~* Dyadic review of glucose targets after an in-depth analysis of CGM data and dyadic treatment strategies to improve glucose TIR"
48487442|NCT05937321|BEHAVIORAL|Control group|Diabetes self-management education materials
48487443|NCT02384252|OTHER|functional tissu atrial analysis|
47969172|NCT02018185|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
48117584|NCT00622219|OTHER|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
48117585|NCT01458210|DRUG|Ortho-Cyclen|Administered orally
48117586|NCT01458210|BIOLOGICAL|Dulaglutide|Administered subcutaneously
48117587|NCT03281382|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
48117588|NCT04779892|DRUG|Infliximab|100mg/vial
48117589|NCT03293498|BIOLOGICAL|NanoFlu|Vaccine
48117590|NCT03293498|BIOLOGICAL|Fluzone HD - Day 0|Vaccine
48117591|NCT03293498|BIOLOGICAL|Fluzone HD - Day 21|Vaccine
48117592|NCT03293498|OTHER|Saline - Day 21|Placebo
48117593|NCT03320434|DRUG|PRT-2761 0.5%|Six drops in each eye over a 17 day period.
48117594|NCT03320434|DRUG|PRT-2761 1%|Six drops in each eye over a 17 day period.
48487444|NCT03130114|DRUG|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
48487445|NCT03130114|OTHER|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
48487446|NCT01644136|PROCEDURE|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
48487447|NCT01644136|PROCEDURE|regional lymph node dissection|Undergo pelvic lymph node dissection
48487448|NCT01644136|DEVICE|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
48487449|NCT00488670|DRUG|Escitalopram|See Detailed Description.
48117595|NCT03320434|DRUG|Patanol|Six drops in each eye over a 17 day period.
48117596|NCT03320434|DRUG|Pred-forte|Four drops in each eye over a 3 day period.
48117597|NCT03320434|DRUG|PRT-2761 0%|Six drops in each eye over a 17 day period.
48117598|NCT02728349|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
48117599|NCT00482729|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
48117600|NCT00482729|DRUG|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
48117601|NCT05289349|DRUG|Propofol|Propofol (2 mg/kg) for induction of anesthesia , and ( 6 mg/kg/h) for maintenance of anesthesia
48117602|NCT05289349|DRUG|Sevoflurane|Sevoflurane 1.0-1.5 minimum alveolar concentration (MAC)
48117603|NCT00919685|BIOLOGICAL|blood sample|from rest of blood sample collected for other measurements
48117604|NCT03370796|OTHER|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
48117605|NCT04616963|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
48487450|NCT04808830|OTHER|Evaluation of musculoskeletal pain prevalence|Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.
48487451|NCT04808830|OTHER|Evaluation of quality of life|Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.
48646820|NCT02940223|OTHER|Questionnaire Administration|Ancillary studies
48321288|NCT04550611|OTHER|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
48321289|NCT04550611|OTHER|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
48321290|NCT00000639|DRUG|Itraconazole|
48321291|NCT00000639|DRUG|Flucytosine|
48321292|NCT00000639|DRUG|Fluconazole|
48321293|NCT00000639|DRUG|Amphotericin B|
48117606|NCT04616963|DRUG|Emtricitabine Tenofovir Alafenamide 200/25 mg|Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
48117607|NCT05143658|PROCEDURE|LLS versus LP|Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
48321294|NCT04158986|BEHAVIORAL|Nurse-driven post-discharge intervention|"Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~* Filling in the Chronic Liver Disease Questionnaire.~* Therapeutic conversations including drawing and review of genogram and eco-map.~* Information about- and help to initiate contact to relevant municipal offers.~* Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge"
48321295|NCT01519063|DRUG|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
48321296|NCT01519063|DRUG|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
48321297|NCT05518175|DEVICE|Traditional laparoscopy|Utilizes three or four 5 mm ports for access and retrieval.
48487452|NCT04808830|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity will be evaluated using 6-min walk test.
48487453|NCT04808830|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form
48487454|NCT01138111|DRUG|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
48646821|NCT01259531|DRUG|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
48321298|NCT05518175|DEVICE|Single site laparoscopy|One port is placed via a 2 to 3 cm umbilical/fascia incision to accommodate the Gelpoint device, where several laparoscopic instruments are used. With this technique, there is a single incision, hidden in the umbilicus a
48321299|NCT05518175|DEVICE|V-Notes surgery|One port placed trans-vaginally via a 2-3 cm vaginal incision with no abdominal scars
48321300|NCT06251219|DIAGNOSTIC_TEST|PCR|PCR test for EV71, CA16, CA10, or CA6
48321301|NCT05933252|OTHER|Augmented reality (AR)|an app on an iPad every 15 minutes
48321302|NCT02089620|DRUG|Yasmin|will be used every 21 days for three months by the patient
48321303|NCT02089620|DIETARY_SUPPLEMENT|Calver|Calver will be given daily for 3 months
48487455|NCT03271606|COMBINATION_PRODUCT|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
48646822|NCT02327780|OTHER|FODMAP diet|
48646823|NCT04775758|BEHAVIORAL|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
48321304|NCT02089620|DRUG|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
48321305|NCT02089620|DRUG|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
48321306|NCT03571841|BEHAVIORAL|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
48321307|NCT03571841|BEHAVIORAL|Telephone Booster|One month following the group session, women will receive a telephone booster session (\<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
48321308|NCT00467025|DRUG|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
48321309|NCT00467025|DRUG|Sorafenib|400 mg PO BID
48321310|NCT00467025|DRUG|AMG 386 placebo IV|AMG 386 placebo IV
48321311|NCT03835000|PROCEDURE|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
48321312|NCT04265170|DEVICE|BlastX with negative pressure therapy|Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
48321313|NCT03583372|DRUG|Vibegron|single daily dose 75 mg
48487456|NCT03271606|COMBINATION_PRODUCT|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
48487457|NCT06206083|GENETIC|Descriptive and analytical|Patients with EC endometroid
48321314|NCT03583372|DRUG|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
48321315|NCT03583372|DRUG|Tolterodine Tartrate ER|single daily dose of 4 mg
48321316|NCT06051981|DRUG|5% sodium fluoride|a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
48321317|NCT06051981|DRUG|Intensive 5% sodium fluoride|Intensive FV will be applied three times a week for a week (every two days).
48321318|NCT06051981|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate|for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
48321319|NCT06051981|DRUG|Resin infiltration|resin infiltration will be applied as specified by the manufacturer.
48321320|NCT00638924|OTHER|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
48321321|NCT01667393|DEVICE|IDEV SUPERA Stent|
48321322|NCT01667393|DEVICE|Percutaneous Transluminal Angioplasty|
47969173|NCT02018185|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
47969174|NCT05687383|DEVICE|Safe breastfeeding pillow|A randomized controlled trial
48321323|NCT05819736|OTHER|Monitoring|Monitoring
48321324|NCT00253318|DRUG|Docetaxel|40 mg/m\^2 IV over 1 hour on Day 1.
48321325|NCT00253318|DRUG|RAD001|30 mg orally on Days 1 and 8.
48321326|NCT00253318|DRUG|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
48321327|NCT05984797|OTHER|Integrated Short-term Palliative Rehabilitation|"Participants will be offered up to 3 manualised sessions (face to face and/or remotely, via telephone or video-conference) delivered by an expert rehabilitation practitioner (physiotherapist, occupational therapist,).~Core components focus on (i) self-management of symptoms, (ii) physical activities and fitness, and (iii) social participation. Delivery of rehabilitation intervention components will include explicit use of behaviour change techniques including goal setting and action planning to focus on outcomes that are meaningful for the person, their family, and clinicians."
48321328|NCT06382337|OTHER|Group A : ice cream cone technique|collagen membrane and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
48321329|NCT06382337|OTHER|Group B : the vestibular socket therapy|cortical lamina fixed by bone tacks and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
48321330|NCT01632735|BEHAVIORAL|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
48321331|NCT01561560|DEVICE|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
48321332|NCT01561560|DEVICE|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
48321333|NCT05342467|DRUG|Gemeprost 1 Mg Vaginal Pessary|Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
48321334|NCT05342467|DRUG|Dinoprostone 3 mg|Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
48321335|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
48321336|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
48321337|NCT03799926|DRUG|placebo|Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
48321338|NCT03799926|DRUG|placebo|Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
48321339|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
48321340|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
48321341|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
48321342|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
48321343|NCT02581111|DRUG|Naloxone|Naloxone 8-mg IV bolus
48321344|NCT02581111|DRUG|Normal saline|
48321345|NCT03543306|DRUG|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
48321346|NCT05400473|OTHER|Therapeutic exercise|This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.
48321347|NCT05400473|OTHER|Photobiomodulation|Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
48117608|NCT04854863|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
47969175|NCT01977794|DRUG|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
47969176|NCT01977794|DRUG|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
47969177|NCT01095783|PROCEDURE|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
47969178|NCT01095783|PROCEDURE|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
48117609|NCT05591040|DEVICE|Biofeedback|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, two surface electrodes will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
48117610|NCT05591040|OTHER|Conventional|Each participant will attend 5 sessions per week for a total duration of 4 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, specific task for timing and coordination, Masako maneuver. The control group will perform this training for 45 minutes, with a verbal feedback from the speech and language therapist in relation to the efficacy of the performance.
48117611|NCT00432523|BIOLOGICAL|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
48117612|NCT05844449|DRUG|VNZ/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
48117613|NCT01395758|DRUG|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
48117614|NCT01395758|DRUG|Pemetrexed, docetaxel or gemcitabine|Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
47969179|NCT04915430|OTHER|Training|
47969180|NCT03213522|PROCEDURE|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
47969181|NCT03213522|PROCEDURE|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
47969182|NCT04956367|PROCEDURE|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
47969183|NCT04956367|DEVICE|CO2 laser with PRP|CO2 laser with PRP
47969184|NCT04956367|DEVICE|CO2 laser with placebo|CO2 laser with placebo
47969185|NCT06237998|DEVICE|Telemedicine|Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
47969186|NCT05262127|BEHAVIORAL|Flash Version of EMDR|EMDR and the inclusion of a positive engaging focus generated autonomously by participant
47969187|NCT00380822|DRUG|miglitol|
47969188|NCT02398175|OTHER|reanimation/intubation|
47969189|NCT01496807|DRUG|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
47969190|NCT01496807|DRUG|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
47969191|NCT01372462|DEVICE|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
47969192|NCT01372462|DEVICE|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
47969193|NCT01372462|DEVICE|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
47969194|NCT05425134|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
47969195|NCT02753868|BEHAVIORAL|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
48321348|NCT04163640|OTHER|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
48321349|NCT00501046|DRUG|Placebo|9g /day (3 times a day)
48646824|NCT04775758|BEHAVIORAL|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
48321350|NCT00501046|DRUG|AST-120|9g /day (3 times a day)
48321351|NCT02699242|DEVICE|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
48321352|NCT03355794|DRUG|ribociclib|Oral capsule or liquid formula
48321353|NCT03355794|DRUG|Everolimus|Oral tablets or dispersible tablets
48321354|NCT03915236|DEVICE|MON4STRAT Strategy|Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
48321355|NCT03915236|OTHER|Control group|Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
48321356|NCT02165033|DRUG|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
48321357|NCT03767296|DRUG|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, .....(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)"
48321358|NCT03767296|DRUG|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,...(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)"
48321359|NCT02472691|DRUG|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
48321360|NCT02472691|DRUG|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
48321361|NCT02472691|BIOLOGICAL|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10\^6 CD3/kg (1st DLI), 1-5x10\^6 CD3/kg (2nd DLI) and 5-15x10\^6 CD3/kg (3rd DLI).
48646825|NCT03351959|RADIATION|neo-adjuvant treatment|long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
47969196|NCT02753868|PROCEDURE|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
47969197|NCT02549937|DRUG|surufatinib|orally once daily (QD) in patients with advanced solid tumor.
48321362|NCT02836860|OTHER|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
48321363|NCT00777231|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
47969198|NCT04336085|PROCEDURE|caudal block|Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
48321364|NCT03296293|OTHER|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
48321365|NCT03296293|OTHER|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
48321366|NCT03296293|OTHER|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
48321367|NCT03630978|PROCEDURE|Liver resection|Major or minor, open or laparoscopic liver resection
48321368|NCT00917306|DRUG|PEP005 Gel|0.05% two day treatment
48321369|NCT00150670|DRUG|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
48321370|NCT00150670|DRUG|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
48321371|NCT01595659|BEHAVIORAL|Passenger|Driving with risk accepting or risk averse passenger
48321372|NCT00214968|DRUG|Modafinil|maximum dosage 400 mg/day (4 tablets)
48487458|NCT02349620|BIOLOGICAL|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
48487459|NCT01908413|DRUG|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
48646826|NCT00003192|DRUG|aminocamptothecin|
48646827|NCT06501183|BIOLOGICAL|Anti-CDH17 CAR-T cells|Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
48646828|NCT00335426|PROCEDURE|Spinal manipulative therapy|
48646829|NCT04202094|DIAGNOSTIC_TEST|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
48646830|NCT04202094|DIAGNOSTIC_TEST|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
48646831|NCT04202094|DIAGNOSTIC_TEST|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
48646832|NCT04202094|DIAGNOSTIC_TEST|Semen analysis|A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
48117615|NCT06100458|OTHER|Skin and leakage protocol|The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
48487460|NCT00695435|DRUG|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
48487461|NCT00695435|DRUG|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
48646833|NCT06566300|PROCEDURE|injection of autologous nanofat grafting|Injection of nanfat graft
47969199|NCT04336085|PROCEDURE|pericapsular nerve group block|In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
47969200|NCT03167190|PROCEDURE|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
47969201|NCT03167190|PROCEDURE|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
48117616|NCT04962477|OTHER|Nasal brush sampling|Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.
48117617|NCT04562844|OTHER|sociale cognition|several social cognition test
48117618|NCT04618614|DEVICE|HD-tDCS 1 mA to S1|Anodal high definition transcranial direct current stimulation of the right primary somatosensory cortex with an intensity of 1 mA
47969202|NCT02824952|DRUG|Tagrisso|taking orally everyday for 6 or 12 weeks.
47969203|NCT02632981|OTHER|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
47969204|NCT02632981|OTHER|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
48117619|NCT04618614|DEVICE|HD-tDCS 1 mA to M1|Anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1 mA
48117620|NCT04618614|DEVICE|Sham control|Sham stimulation of the right primary somatosensory cortex
48117621|NCT06155071|OTHER|Plyometric Training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
48117622|NCT06155071|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
48117623|NCT05362110|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
48117624|NCT05362110|DRUG|RLD2002|Take it once daily for 8 weeks orally.
48117625|NCT05362110|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
48117626|NCT05362110|DRUG|HPP2004|Placebo drug. Take it once daily for 8 weeks orally.
48487462|NCT00695435|DRUG|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
47969205|NCT00002014|DRUG|Zidovudine|
47969206|NCT00002014|DRUG|Didanosine|
47969207|NCT04873804|OTHER|Transcranial Direct Current Stimulation|The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
47969208|NCT00777608|DRUG|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
47969209|NCT00777608|DRUG|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
48487463|NCT05333484|OTHER|Programed Pilates|The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of \> 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
48487464|NCT03352141|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
48487465|NCT03168321|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
48487466|NCT03168321|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
48487467|NCT00788502|BEHAVIORAL|Healing Touch|
48487468|NCT00788502|BEHAVIORAL|Desensitization Therapy|
48646834|NCT06566300|PROCEDURE|microneedling with autologus nanofat graft|delivery of nanofat graft with microneedling
48646835|NCT06651060|BEHAVIORAL|Menu label|Participants will view a sample of items from a restaurant menu, displayed with labels
48646836|NCT03622515|COMBINATION_PRODUCT|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
48646837|NCT03008473|DEVICE|video laryngoscope and chest CT iminge|
48646838|NCT03008473|DEVICE|Conventional intubation of uniblocker|
48646839|NCT04840771|PROCEDURE|Endoscopic Endonasal Pituitary Surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter.
48646840|NCT00720083|DRUG|cisplatin|Given IV
48646841|NCT00720083|DRUG|vandetanib|Given orally
48646842|NCT00720083|RADIATION|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
48646843|NCT06673485|PROCEDURE|Patients received vitamin D and calcium supplementation during the healing period|"The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill, maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paralling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement.~During the healing period, the patients recieved Vitamin D and Calcium Supplements."
48646844|NCT06673485|PROCEDURE|Patients have not received any nutritional supplementation during the healing period.|The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill while maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paraling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement. During the healing period, the patients did not receive vitamin or calcium supplements.
48646845|NCT02172651|DRUG|Vitamin D3|Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
48646846|NCT02172651|DRUG|Placebo|Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
48646847|NCT00214526|PROCEDURE|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
48646848|NCT00214526|DRUG|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
48321373|NCT02572895|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
48487469|NCT00306163|DRUG|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
48487470|NCT00306163|DRUG|Fluticasone|inhaled Fluticasone 100 µg, twice daily
48487471|NCT02467608|DRUG|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
48487472|NCT02467608|DRUG|HRZE|the same as experimental group,without the excipient of HUEXC030 only
48646849|NCT00698412|DEVICE|Cane|This group use the cane every day since the baseline
48487473|NCT01824134|OTHER|Klean & Klear The Dandy Day Corp|
48646850|NCT02376855|OTHER|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
48487474|NCT01824134|OTHER|The Skin Gel Herbal Answers, Inc|
48487475|NCT03304028|DEVICE|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
48646851|NCT04859231|OTHER|Control|Cow's milk-based formula
48646852|NCT04859231|OTHER|Investigational|Cow's milk-based formula with added source of enriched whey protein
48646853|NCT05961631|OTHER|Bio-electrical Impedance Analysis|Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)
48646854|NCT04331951|DIAGNOSTIC_TEST|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
48321374|NCT05010525|DRUG|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
48321375|NCT02763072|DEVICE|Enlighten Laser|
48321376|NCT02763072|DEVICE|Excel V Laser|
48321377|NCT01423773|DEVICE|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
48321378|NCT01423773|DEVICE|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
48646855|NCT05226195|OTHER|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
48321379|NCT01423773|DEVICE|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
48321380|NCT02124707|DRUG|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
48321381|NCT02124707|DRUG|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
48321382|NCT02124707|DRUG|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
48321383|NCT03415763|DRUG|Capecitabine|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
48321384|NCT03415763|DRUG|mFOLFOX6 or CAPOX|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
48321385|NCT04251689|DRUG|Mannitol|Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
48321386|NCT04251689|DRUG|Placebo|0.9% normal saline 100 ml
48321387|NCT03154151|BEHAVIORAL|Online Cognitive-Behavioral Therapy|Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
48321388|NCT03154151|BEHAVIORAL|Online Supportive Therapy|Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
48321389|NCT04786548|DRUG|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
48321390|NCT05072665|DEVICE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
48321391|NCT01544803|BEHAVIORAL|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
48646856|NCT00004856|BIOLOGICAL|trastuzumab|Given IV
48321392|NCT01544803|BEHAVIORAL|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
48321393|NCT00987922|DEVICE|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
48321394|NCT02489006|DRUG|Olaparib|
48646857|NCT05885750|BEHAVIORAL|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
48321395|NCT02489006|DRUG|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
48321396|NCT05071352|DRUG|Nefopam|Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
48321397|NCT05071352|DRUG|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.|In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
48321398|NCT04144075|BEHAVIORAL|Mindful Self-Compassion Program|It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
48321399|NCT04144075|BEHAVIORAL|Cognitive Behaviour Therapy Group|It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
48321400|NCT04144075|OTHER|Treatment as usual|It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
48321401|NCT05014048|DIETARY_SUPPLEMENT|Vitamin D3|20 mikrog vitamin D3 daily
48321402|NCT05014048|DIETARY_SUPPLEMENT|Placebo|Placebo
48321403|NCT02780765|DEVICE|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
48321404|NCT02780765|DEVICE|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
48321405|NCT02808741|DRUG|F901318 SDD|Pharmacokinetics area under curve
48321406|NCT02808741|DRUG|F901318 IR|Pharmacokinetics area under curve
48321407|NCT02808741|DRUG|F901318 IR Fasting|Pharmacokinetics area under curve
48487476|NCT03304028|BEHAVIORAL|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
48487477|NCT03304028|DEVICE|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
48487478|NCT03304028|OTHER|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team...etc.
48646858|NCT05885750|BEHAVIORAL|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
48646859|NCT05885750|BEHAVIORAL|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
48646860|NCT06268730|OTHER|SinuSonic|The SinuSonic is a commercially available, over-the-counter, self-applied nasal device designed to enhance physical well-being by reducing nasal congestion via simultaneous administration of acoustic vibration and gentle oscillating expiratory pressure.
48646861|NCT04390009|DIAGNOSTIC_TEST|Entire-body PET-CT scans|Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
48646862|NCT04390009|DRUG|Amyvid radiopharmaceutical|Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
48487479|NCT03304028|BEHAVIORAL|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
47969210|NCT00777608|DRUG|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
48487480|NCT03438539|BEHAVIORAL|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
48487481|NCT03438539|BEHAVIORAL|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
47969211|NCT00777608|DRUG|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
47969212|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
48321408|NCT02808741|DRUG|F901318 IR Fed|Pharmacokinetics area under curve
48321409|NCT02598466|DRUG|Abatacept|
48321410|NCT05084794|PROCEDURE|Internal fixation|Fixation of posterior malleolus with either plate or screws.
48321411|NCT04813536|OTHER|the Standard Shiftwork Index questionnaire|"1. Biographical information: This includes personal data (e.g., age, sex, marital status, and domestic situations), shift details (e.g., shift start and end times), organization of shiftwork, and general job satisfaction~2. Sleep and fatigue: Measures the effect of shiftwork on perceived sleep quality and quantity and fatigue"
48321412|NCT04813536|OTHER|complete blood picture|5ml blood to estimate changes of total leucocytic count, Hemoglobin, eosinophilic, monocyte
48321413|NCT04813536|OTHER|lipid profile|5ml blood to estimate changes of plasma triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and HDL-C
48646863|NCT02973152|PROCEDURE|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
48321414|NCT04498819|BEHAVIORAL|Wearable Activity Trackers, Exercise Prescription and Virtual Care|"The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime."
48321415|NCT01108497|PROCEDURE|Bone Marrow Aspiration|
48321416|NCT00523406|PROCEDURE|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
48321417|NCT02305654|PROCEDURE|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
48321418|NCT02305654|DRUG|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
48321419|NCT02305654|DRUG|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
48321420|NCT02305654|DRUG|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
48321421|NCT02305654|RADIATION|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
48321422|NCT02305654|PROCEDURE|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
48321423|NCT01018719|DEVICE|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
48487482|NCT03438539|BEHAVIORAL|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
48487483|NCT03353454|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
48487484|NCT03353454|DRUG|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
48487485|NCT06309277|DRUG|GM-1020|N-methyl-D-aspartate (NMDA) receptor antagonist
48487486|NCT01144364|DRUG|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
48321424|NCT02232087|DRUG|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
48321425|NCT02232087|DRUG|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
48321426|NCT02453009|DRUG|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
48487487|NCT02071953|DEVICE|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
48487488|NCT02071953|DEVICE|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
48487489|NCT03937128|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
48487490|NCT03937128|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
48487491|NCT04332848|DRUG|ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
48487492|NCT04332848|DRUG|SGT|Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
48487493|NCT06231719|OTHER|Cold Spray|Using cold spray for injection site before the Anti-D immunglobulin injection. 2 sprays of cold spray are applied from a distance of 25 cm.
48487494|NCT06231719|OTHER|Manuel Pressure|Using manuel pressure ( about 10 second ) before the Anti-D immunglobulin injection.
48487495|NCT06231719|OTHER|Standard Injection Procedure|Using any special method for injection
47969213|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
48321427|NCT02453009|DRUG|Prednisone|Pharmaceutical form:tablet Route of administration: oral
48321428|NCT02453009|DRUG|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
48321429|NCT01961843|DRUG|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
48321430|NCT01961843|DRUG|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
48321431|NCT04678011|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
48487496|NCT05959434|BEHAVIORAL|Cognitive Processing Therapy + Relapse Prevention|Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol use disorder
48487497|NCT05959434|BEHAVIORAL|Relapse Prevention|Cognitive-Behavioral Therapy that targets alcohol use, specifically
48487498|NCT01665924|DRUG|GLPG0634 100mg capsule once a day for 10 days|
48321432|NCT05899712|OTHER|Removable Partial Denture Construction|Construction of class I Removable partial denture by digital workflow
48321433|NCT02490917|DEVICE|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
48321434|NCT02490917|DEVICE|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
48321435|NCT02043405|BEHAVIORAL|Weight loss and exercise training intervention|Combined weight loss and exercise training intervention
48321436|NCT02043405|BEHAVIORAL|Weight loss Only Intervention|Weight loss Only Intervention
48321437|NCT06390254|OTHER|Resilience-Enhancing Nursing Suppor|The resilience-building nursing intervention in this study is a multifaceted approach aimed at enhancing the psychological well-being and coping abilities of community-dwelling older adults. Unlike standard care, which typically focuses on symptom management, this intervention emphasizes proactive strategies to promote resilience and improve overall quality of life.
48321438|NCT02157506|DRUG|CXL-1427|
48321439|NCT02157506|DRUG|Placebo|
48321440|NCT06090344|OTHER|Traditional video format|6 x 3 minute videos designed in the same format as traditionally found on the internet
48321441|NCT06090344|OTHER|Evidence-informed video format|6 x 3 minute videos designed in the format recommended by advice in the literature
48321442|NCT02477293|DRUG|Hyeonggaeyeongyo-tang|
48321443|NCT06345755|DRUG|VX-407|Solution or Suspension for oral administration.
48321444|NCT06345755|DRUG|Placebo|Solution or Suspension for oral administration.
48321445|NCT06345755|DRUG|Midazolam|Syrup for oral administration.
48646864|NCT02973152|PROCEDURE|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
48646865|NCT01489826|DRUG|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
48646866|NCT01489826|OTHER|Cremophor|Drug vehicle.
48646867|NCT03737890|OTHER|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
48646868|NCT03737890|OTHER|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
48646869|NCT02969226|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
48321446|NCT02094053|DRUG|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
48321447|NCT02094053|DRUG|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
48321448|NCT02094053|DRUG|Placebo|placebo (oral) once daily, for 24 weeks
48321449|NCT01940510|DRUG|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
48321450|NCT01940510|DRUG|rifampin|Multiple doses Days 8-16 and Days 17-20
48321451|NCT02363270|PROCEDURE|Ketamine|IV Push or or IV Drip
48321452|NCT03353753|DRUG|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
48321453|NCT03353753|DRUG|Placebo Oral Tablet|Placebo
48321454|NCT02568345|DRUG|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
48321455|NCT01458314|OTHER|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
48321456|NCT01458314|OTHER|Rehabilitation without NIV|Training in patients without NIV adoption
48321457|NCT01935336|DRUG|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
48321458|NCT05078606|DEVICE|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
48321459|NCT05078606|DEVICE|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
48321460|NCT05078606|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
48321461|NCT00698061|BIOLOGICAL|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
48646870|NCT02969226|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
48321462|NCT00698061|BIOLOGICAL|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
48321463|NCT05478330|DRUG|Flutamide 1% gel|Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
48321464|NCT05478330|DRUG|topical gel without flutamide|Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
48321465|NCT02662985|DRUG|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections."
48321466|NCT02662985|DRUG|Placebo|Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
48321467|NCT05738694|DRUG|Axitinib plus Toripalimab|Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
48321468|NCT05738694|PROCEDURE|nephrectomy|nephrectomy
48321469|NCT00887146|DRUG|concomitant temozolomide (TMZ)|75 mg/m\^2, orally daily
48321470|NCT00887146|RADIATION|radiotherapy|
48321471|NCT00887146|DRUG|procarbazine|Days 8-21: 60 mg/m\^2 orally
48321472|NCT00887146|DRUG|adjuvant temozolomide (TMZ)|150 or 200 mg/m\^2 orally
48321473|NCT00887146|DRUG|CCNU|Day 1: 110 mg/m\^2 orally
48321474|NCT00887146|DRUG|vincristine|Days 8 and 29: 1.4 mg/m\^2 IV
48321475|NCT01129180|DRUG|azacitidine|Given SC
48321476|NCT01129180|DRUG|bortezomib|Given IV
48321477|NCT01129180|PROCEDURE|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
48321478|NCT05294822|PROCEDURE|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
48321479|NCT02072720|DRUG|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
48321480|NCT06102642|BIOLOGICAL|Combining free gingival graft with frenotomy procedure|The aim of the study is to evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
48646871|NCT02969226|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS \>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O
48321481|NCT01114373|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
48321482|NCT01114373|DRUG|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
48321483|NCT04574921|OTHER|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
48321484|NCT04574921|OTHER|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
48321485|NCT05133193|DRUG|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
48321486|NCT01310816|DRUG|IPI-926|Oral
48321487|NCT01310816|DRUG|Placebo Arm|oral placebo
48321488|NCT06167642|DRUG|Ofatumumab|Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
48646872|NCT02969226|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
48646873|NCT05860868|DRUG|2 cycles induction chemotherapy|"Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
48646874|NCT05860868|DRUG|3 cycles induction chemotherapy|"Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week)."
48646875|NCT06075537|DRUG|tividenofusp alfa|Intravenous repeating dose
48321489|NCT02927340|DRUG|Lorlatinib|
48321490|NCT04721041|PROCEDURE|Washed Microbiota Transplantation (WMT)|Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5u, three times.
48321491|NCT05263128|OTHER|Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome|To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
48321492|NCT04973215|OTHER|no intervention|this is not an intervention study
48321493|NCT05562284|PROCEDURE|intra-arterial thrombolysis|IAT introduces rt-PA directly into the ophthalmic circulation by super-selective microcatheterization.
48321494|NCT05562284|OTHER|conservative treatments|conservative treatments
48321495|NCT00946569|DRUG|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
48321496|NCT00946569|DRUG|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
48321497|NCT02821455|PROCEDURE|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
48321498|NCT00516425|BIOLOGICAL|pegfilgrastim|
48321499|NCT00516425|DRUG|cyclophosphamide|
48321500|NCT00516425|DRUG|doxorubicin hydrochloride|
48321501|NCT00516425|DRUG|epirubicin hydrochloride|
48321502|NCT00516425|GENETIC|proteomic profiling|
48321503|NCT00516425|OTHER|diagnostic laboratory biomarker analysis|
48321504|NCT00516425|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
48321505|NCT00516425|OTHER|pharmacological study|
48321506|NCT00516425|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
48321507|NCT00516425|PROCEDURE|adjuvant therapy|
48321508|NCT06409702|DRUG|Carfilzomib|"Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued"
48321509|NCT06409702|DRUG|Daratumumab|"28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued"
48321510|NCT06409702|DRUG|Lenalidomide|"28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression"
48321511|NCT06409702|DRUG|Dexamethasone|"28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8"
48321512|NCT06409702|DRUG|VRD for first-cycle induction therapy|"Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。"
48321513|NCT03508141|DRUG|Fibrinogen Concentrate|Experimental
48321514|NCT03508141|DRUG|Cryoprecipitate|Comparator
48321515|NCT03398122|PROCEDURE|TACE|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
48321516|NCT03398122|DRUG|Apatinib|a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
48321517|NCT05847491|DIAGNOSTIC_TEST|IGRA/Tuberculin skin test|"All patients will receive:~* Clinical evaluation;~* Chest x-ray.~* IGRA (or tuberculin skin test if immunocompromised)~* Therapeutic proposal if eligible"
48321518|NCT05650931|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
48321519|NCT05650931|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
48321520|NCT05650931|PROCEDURE|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
48646876|NCT02534155|DEVICE|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
48321521|NCT03119844|OTHER|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
48646877|NCT02534155|PROCEDURE|Mitral valve Surgery|Repair or replace mitral valve
48321522|NCT03119844|OTHER|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
48646878|NCT03179709|BEHAVIORAL|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
48646879|NCT02594852|DEVICE|+ laser|Use of laser in the treatment
48646880|NCT04309500|BEHAVIORAL|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
48646881|NCT05375266|OTHER|Sampling|This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
48646882|NCT03854435|OTHER|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
48646883|NCT03854435|OTHER|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
48646884|NCT06510075|BEHAVIORAL|Digital Health intervention|Health care information delivered via a link in a text message that is then opened in a secure browser.
48321523|NCT03119844|OTHER|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
48321524|NCT03075748|DEVICE|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
48321525|NCT03000387|DRUG|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
48321526|NCT03000387|DRUG|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
48321527|NCT00738374|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
48321528|NCT00738374|DRUG|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
48321529|NCT03357913|OTHER|Lung transplantation|To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
48321530|NCT03268694|BEHAVIORAL|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
48321531|NCT03268694|BEHAVIORAL|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
48321532|NCT03268694|BEHAVIORAL|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
48321533|NCT00418964|PROCEDURE|Single bundle hamstring|Single bundle hamstring
48321534|NCT00418964|PROCEDURE|Double bundle hamstring|Double bundle hamstring
48321535|NCT00418964|PROCEDURE|Bone patellar tendon bone|Bone patellar tendon bone
48321536|NCT00441441|DRUG|fluticasone propionate|fluticasone propionate 100mcg HFA
48321537|NCT00441441|DRUG|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
48321538|NCT05985434|PROCEDURE|Surgical treatment|decompression with or without stabilization; stabilization only; debulking; en bloc resection
48321539|NCT05107349|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
48646885|NCT06510075|BEHAVIORAL|Community Health Worker|Health care information delivered via CHW.
48646886|NCT06510075|BEHAVIORAL|Digital Health Intervention plus Community Health Worker|Health care information delivered via DHI plus CHW
48646887|NCT06111235|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
47969214|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
47969215|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
47969216|NCT04007978|GENETIC|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
47969217|NCT05937542|BEHAVIORAL|Qualitative Investigation of Participant Experiences|There is no intervention. This is a retrospective qualitative study.
47969218|NCT04620356|DEVICE|DryNites Pyjama Pants|DryNites Pyjama Pants are disposable, absorbent youth pants designed to help children manage bed wetting by absorbing involuntary urine loss and protecting the child's garments and bedding. DryNites Pyjama Pants are underwear-like alternatives that can be discreetly worn beneath pyjamas or nightwear during the bedwetting phase.
47969219|NCT00571948|OTHER|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
48646888|NCT06111235|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
48646889|NCT01830387|DEVICE|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
48646890|NCT01830387|OTHER|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
48646891|NCT03928015|DRUG|Adjunctive dronabinol|5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
47969220|NCT00571948|OTHER|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
47969221|NCT01340612|DEVICE|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
48321540|NCT05217953|DEVICE|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
48321541|NCT01319110|DRUG|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
48321542|NCT01319110|DIETARY_SUPPLEMENT|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
48321543|NCT01398072|DRUG|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
48321544|NCT01398072|DRUG|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
48321545|NCT01398072|DRUG|Doxycycline|An oral dose of 100 mg once daily.
48321546|NCT01398072|DRUG|Placebo|Oral dose of one table once daily.
48321547|NCT05711199|DRUG|Glyceroltrinitrat|transdermal patch
48321548|NCT05350566|DIETARY_SUPPLEMENT|Olive leaf extract|A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water before exercise.
48321549|NCT05350566|DIETARY_SUPPLEMENT|Placebo|A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water before exercise.
48321550|NCT00939224|DEVICE|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
48321551|NCT04000555|DRUG|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
48321552|NCT04000555|OTHER|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
48321553|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
48646892|NCT03928015|DRUG|Systemic analgesics|multimodal analgesia including opioid and non-opioid analgesics
48646893|NCT06286072|OTHER|Education and message|COPD general education content and fatigue-specific coping strategies. Messages sent to phones
48646894|NCT06674434|OTHER|Mobilization with Movement|Mobilization with Movement (MWM) is a manual therapy technique that combines active, patient-directed movements with passive joint mobilization to treat tennis elbow. To find joint restrictions or dysfunctions, a comprehensive patient assessment is the first step in the process. While the patient was in a supine position with the elbow fully extended and the forearm pronated, the therapist applied a sustained lateral glide of the forearm and stabilized the distal portion of the arm. While the patient asked to make a fist, the therapist kept up the lateral glide. Each session included three sets of movement-based mobilizations, each with ten repetitions. The entire course of treatment consists of twelve sessions.
48646895|NCT06674434|OTHER|Sustained Stretch|The basic concept of stretching involves lengthening the tendon during a state of relaxation. To stretch the Extensor Carpi Radialis Brevis tendon, the following position should be adopted: the elbow should be extended, the forearm in a pronated position, the wrist flexed, and the wrist should also be ulnar deviated, based on the patient's comfort level. This position should be maintained for 30 to 45 seconds and repeated three times before and after exercises in each treatment session, with a 30-second rest period in between.
48646896|NCT05541666|BEHAVIORAL|The Emotional Freedom Technique|The Emotional Freedom Technique (EFT) is a method that uses cognitive functions and physical components (tapping acupuncture points) to bring about psychological changes. The Emotional Freedom Technique is a non-invasive procedure that uses acupuncture meridians. We stimulate these energy points by touching the 14 basic meridian points ın this technique. We make suggestions to our subconscious by repeating the setup sentence for the problem we want to solve. Thus, we try to solve the blockages in the meridians that prevent the flow of energy. Energy blockages disrupt the balance of the mind/body/energy system. This situation causes negative emotions such as stress, panic, fear, and sadness in the person. And with the effect of emotions, disturbances may occur in our physical body. When the energy blockage is removed, the person can feel positive emotions such as happiness, personal power, feeling good, understanding, and loving behavior.
48646897|NCT00489476|DRUG|Staccato Loxapine|
48646898|NCT00489476|DRUG|Staccato Placebo|Placebo aerosol inhalation (0mg)
48646899|NCT06571825|DRUG|Venetoclax|The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.
48321554|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
48321555|NCT01350960|DRUG|SPC5001|3 weekly SC injections
48321556|NCT01350960|DRUG|Saline 0.9%|3 weekly SC injections
48321557|NCT01350960|DRUG|SPC5001|3 weekly SC injections
48321558|NCT01350960|DRUG|SPC5001|3 weekly SC injections
48321559|NCT01350960|DRUG|SPC5001|3 weekly SC injections
48321560|NCT01350960|DRUG|SPC5001|3 weekly SC injections
48321561|NCT04567446|OTHER|Stool|collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
48646900|NCT06571825|DRUG|Allogeneic transplant|"The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity."
48646901|NCT03743142|PROCEDURE|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
48646902|NCT03933631|DRUG|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
48646903|NCT03933631|DRUG|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
48646904|NCT03933631|DRUG|Ofloxacin|Ofloxacin Drops
48646905|NCT06395766|DIAGNOSTIC_TEST|BREF,MSPSS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL )~2. the Zimet Multidimensional Scale of Perceived Social Support -. The original version on the MSPSS"
48646906|NCT05513105|DIAGNOSTIC_TEST|Iron study of neonates|Blood sambles
48646907|NCT00690352|BEHAVIORAL|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
48646908|NCT06196320|DRUG|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion
48646909|NCT06196320|DRUG|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
48646910|NCT06500871|DRUG|Diclofenac Potassium|NSAID
48321562|NCT04567446|OTHER|Blood sample|20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
48646911|NCT02040012|DRUG|AZP-531|
48646912|NCT02040012|DRUG|Placebo|
48646913|NCT01258699|DRUG|Thiocacid HR Tab 600mg|600mg for 1 day
48646914|NCT01258699|DRUG|BK-C-0701 320mg|320mg for 1 day
48646915|NCT01258699|DRUG|BK-C-0701 480mg|480mg for 1 day
48646916|NCT03717454|OTHER|Surgery|The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
48646917|NCT03717454|DRUG|Drug treatment|The medication will continue if DA causes tumors to shrink.
48646918|NCT06220253|PROCEDURE|vaginal hysterectomy by bipolar vessels sealing|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be coagulated and cut by a bipolar vessel sealing instrument
48646919|NCT06220253|PROCEDURE|vaginal hysterectomy by traditional technique|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be sutured by absorbable threads
48646920|NCT00606099|DRUG|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
48646921|NCT00606099|DRUG|adefovir dipivoxil|Active Comparator
48646922|NCT06498531|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
48646923|NCT06498531|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
48646924|NCT04802109|DEVICE|wearing level D personal protective equipment|rubber gloves + surgical face mask + general isolation clothing
48646925|NCT04802109|DEVICE|wearing Level C personal protective equipment with N-95|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing"
48646926|NCT04802109|DEVICE|wearing Level C personal protective equipment with Powered Air-Purifying Respiratory|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory"
48646927|NCT04238182|OTHER|wet cupping|This smoker group will receive single wet cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm . Cupping of BL 17 will be done bilaterally.
48646928|NCT04238182|OTHER|dry cupping|The smoker group will receive single dry cupping session. The first site is between the two scapulae (interscapular), opposite the T1-T3 scapular spine. This area is called Al-Kahil in Arabic. The second site is located on the spinous process of seventh cervical vertebra and it is called GV14 in Chinese medicine. The third site is BL-17 (Ge Shu Diaphragm Shu) is located 1.5 cun lateral to the lower border of the spinous process of the seventh thoracic vertebra (T7). BL 17 can directly act on the septum transversum of diaphragm. Cupping of BL 17 will be done bilaterally.
48646929|NCT04338620|DRUG|camrelizumab、albumin-bound paclitaxel and platinum|Experimental Group：camrelizumab、albumin-bound paclitaxel and platinum. Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg on day1 of each cycle. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle. Platinum included Cisplatin/carboplatin/Nedaplatin
48646930|NCT04338620|DRUG|albumin-bound paclitaxel and platinum|"Control group：albumin-bound paclitaxel and platinum. Albumin-bound paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 130 mg/m2 on day1 and day8 of each cycle.~Platinum included Cisplatin/carboplatin/Nedaplatin"
48646931|NCT01950598|PROCEDURE|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
48646932|NCT01950598|PROCEDURE|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
48646933|NCT01890538|DRUG|Administration of 100 mg dimenhydrinate intravenous|
48646934|NCT01890538|DRUG|2 g piracetam intravenous|
48117627|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair applying tissue glue for mesh fixation|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving applying tissue glue for mesh fixation. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
48321563|NCT01951690|DRUG|defactinib (VS-6063)|
48646935|NCT00160368|BEHAVIORAL|Potassium supplementation|
48646936|NCT00742157|DRUG|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
47969222|NCT01340612|DEVICE|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
47969223|NCT02019329|OTHER|Placebo|Oral daily administration from Days 1-12
47969224|NCT02019329|DRUG|RO5545965|Oral daily administration from Days 1-12
48321564|NCT02640144|DRUG|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
48321565|NCT02640144|DRUG|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
48321566|NCT06534814|DIAGNOSTIC_TEST|AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)|The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.
48321567|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|DDD+/-R pacing
48321568|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|ODO pacing
48321569|NCT01481168|DEVICE|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
48646937|NCT04321031|DRUG|Placebo|Tablet
48646938|NCT04321031|DRUG|PF-06865571|Tablet
48646939|NCT04321031|DRUG|PF-05221304|Tablet
48646940|NCT00537797|OTHER|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
48646941|NCT03992482|DRUG|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
48646942|NCT03992482|DRUG|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
48646943|NCT05768347|BIOLOGICAL|Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)|Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.
48646944|NCT06549920|RADIATION|Internal mammary node irradiation|Irradiation of the internal mammary nodes in intercostal space 1-4.
48646945|NCT05396612|OTHER|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
48646946|NCT04619745|OTHER|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
48646947|NCT01848457|DRUG|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)
48646948|NCT01848457|DRUG|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
48646949|NCT00655356|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
48646950|NCT00655356|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
48646951|NCT02462629|DRUG|BLZ-100|
48646952|NCT00310843|DRUG|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
48646953|NCT06067893|DRUG|Dexmedetomidine|Patient receives dexmedetomidine for 48 hours post-operatively
48646954|NCT06067893|DRUG|Normal Saline|Patient receives normal saline for 48 hours post-operatively
48646955|NCT01140932|DRUG|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
48646956|NCT01140932|BEHAVIORAL|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
47969225|NCT02019329|DRUG|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
47969226|NCT00188669|DRUG|pentoxifylline|
48646957|NCT02925143|OTHER|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
48321570|NCT05108519|OTHER|Electronic Health Record Review|Medical records are reviewed
48321571|NCT05166746|DRUG|Clindamycin|Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
48646958|NCT04882605|GENETIC|MHC typing|Allelic genotyping resolution of MHC genes (HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -DPA1, -DPB1 and -DRB3/4/5) using Illumina technology.
48646959|NCT04882605|GENETIC|KIR typing|Allelic genotyping resolution of all 13 KIR genes (KIR2DL1, KIR2DL2/2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS3/2DS5, KIR2DS4, KIR3DL1/3DS1, KIR3DL2, KIR3DL3), 2 KIR pseudogenes (KIR2DP1 and -3DP1) using Illumina technology.
48646960|NCT04882605|GENETIC|Assessment of KIR-based prediction scores|Compiling donor/recipient MHC and KIR typings into 28 major KIR-based prediction scores
48646961|NCT06402474|PROCEDURE|sunbed position|30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
48646962|NCT00376558|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
48646963|NCT02680496|DEVICE|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
48646964|NCT02680496|OTHER|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
48646965|NCT02680496|OTHER|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
48646966|NCT00694928|DRUG|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
48646967|NCT00694928|DRUG|butoconazole nitrate|semi-solid, single dose
48646968|NCT04205916|DRUG|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
48646969|NCT04205916|OTHER|Standard of care surgery|Standard method used for surgery and the use of post operative drops
48646970|NCT06433245|PROCEDURE|effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
47969227|NCT00188669|DRUG|alpha-Tocopherol|
48321572|NCT05166746|OTHER|Placebo|"The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium.~The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate"
48321573|NCT04982510|DEVICE|complete denture|3D printed complete denture
48321574|NCT04742426|OTHER|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
48646971|NCT03818971|OTHER|electroretinogram (flash, pattern and multifocal)|we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
48646972|NCT06429085|DEVICE|Rex robotic assisted balance exercises|Individual is supported by a Rex robotic exoskeleton which enables assisted and supervised practise of balance exercises. This intervention took place as a supported and supervised series of 5 sessions over 5 weeks as an Out-patient.
48646973|NCT03146793|DRUG|Sodium Thiosulfate|25g intravenously 3 times per week
48646974|NCT05522400|BEHAVIORAL|Virtual Reality (VR) and human computer interaction system|The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
48646975|NCT04300790|DRUG|Alpelisib|Alpelisib (BYL719): starting dose at 300 mg/QD.; 2 tablets once a day, oral administration, continuously during 28-day cycles until disease progression or unacceptable toxicity.
47969228|NCT02325960|DRUG|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
47969229|NCT02325960|DRUG|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
47969230|NCT01830478|DRUG|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
48321575|NCT04742426|OTHER|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
48321576|NCT05010629|DRUG|9-ING-41|Intravenous infusion
48321577|NCT05010629|DRUG|Carboplatin|Intravenous infusion
48321578|NCT00413335|DRUG|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
48646976|NCT04300790|DRUG|Metformin|500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days
48646977|NCT04300790|DRUG|Fulvestrant|"fulvestrant (500 mg IM injections; loading dose 500mg every two weeks for the first month; then every 4 weeks as per standard of care \[SoC\].~Patients should be started on metformin and fulvestrant within 7 to 14 days prior to start on alpelisib (D1C1)"
48646978|NCT04300790|DRUG|Letrozole|Letrozole 2.5 mg tablets, once daily, orally
48646979|NCT04300790|DRUG|Exemestane|Exemestane 25 mg tablets, once daily, orally
48646980|NCT04300790|DRUG|Vildagliptin|Vildagliptin 50 mg tablets, twice daily, orally with breakfast and dinner
48646981|NCT04300790|DRUG|Tamoxifen|Tamoxifen 20 mg tablets, once daily, orally
47969231|NCT01830478|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
48321579|NCT00413335|DRUG|Placebo|Subject receives placebo.
48321580|NCT04124692|DEVICE|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
48321581|NCT01604057|DRUG|ZT-034 Low Dose Nasal Spray|Nasal Spray
48321582|NCT01604057|DRUG|ZT-034 Mid Dose Nasal Spray|Nasal Spray
48646982|NCT04801901|PROCEDURE|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
48321583|NCT01604057|DRUG|ZT-034 High Dose Nasal Spray|Nasal Spray
48321584|NCT01604057|DRUG|Teriparatide|20 mcg subcutaneous daily
48321585|NCT01604057|DRUG|Placebo|Nasal Spray
48321586|NCT05364983|DEVICE|Juvene IOL|Cataract extraction and implantation of a posterior chamber IOL
48321587|NCT05364983|DEVICE|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)|Cataract extraction and implantation of a posterior chamber IOL
48321588|NCT06248905|OTHER|Rehabilitation program based on the strengthening of gluteal muscles|Physiotherapy program (8 weeks)
48646983|NCT04801901|PROCEDURE|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
48646984|NCT02084186|OTHER|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
48321589|NCT06248905|OTHER|Extracorporeal shock wave therapy|Focused shock wave therapy (3 weeks)
48321590|NCT04580823|DIETARY_SUPPLEMENT|Fasting with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.
48321591|NCT04580823|DIETARY_SUPPLEMENT|Post-Prandial with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
48321592|NCT03978182|DEVICE|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
48487499|NCT00655850|DRUG|Paclitaxel|"* Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~* Dexamethasone 20mg, intravenously (IV)~* Diphenhydramine 50 mg IV~* Ranitidine 50 mg IV~* Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~* The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~* Dose Level 1 ________80 mg/m2/weekly~* Dose Level -1 ________70 mg/m2/weekly"
48646985|NCT02084186|OTHER|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
48646986|NCT05634070|DEVICE|PCL Pectus scaffold implantation and autologous fat grafting|A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
48646987|NCT03410771|DRUG|Monitor antibiotic exposure (PK profile)|several plasma samples to measure drug exposure
48646988|NCT03410771|DEVICE|Bioelectrical impedance analysis to measure body composition|non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
48646989|NCT02303483|DIETARY_SUPPLEMENT|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
48646990|NCT02303483|DIETARY_SUPPLEMENT|Placebo|
48646991|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
48321593|NCT01380444|PROCEDURE|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
48321594|NCT01380444|PROCEDURE|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
48646992|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
48646993|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
48646994|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
48646995|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
48646996|NCT00337454|DRUG|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
47969232|NCT03414814|DRUG|Osimertinib 80 MG [Tagrisso]|Osimertinib 80mg once daily until disease progression
47969233|NCT01979445|DRUG|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
47969234|NCT01979445|DRUG|Clopidogrel|Clopidogrel 600 mg single oral dose
47969235|NCT01979445|DRUG|Prasugrel|Prasugrel 60 mg single oral dose
48321595|NCT05225220|DEVICE|Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)|Electrode clip will be placed on the left ear.
48321596|NCT00059215|DRUG|Prasugrel (CS-747)|Administered orally
48321597|NCT00059215|DRUG|Clopidogrel|Administered orally
48321598|NCT00232440|DEVICE|BodyFIX|
48321599|NCT00511342|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
48646997|NCT04304196|OTHER|TEMPO|TEMPO is designed as a 7- to 10-week, web-based intervention containing 5 modules to pace patient-caregiver dyads' learning, avoid information overload, and allow sufficient practice time in-between modules . Each module is organized along six key components: needs assessment, tailored information and skills training, goal setting and action planning, motivational and social support, monitoring, automated feedback, and addressing time demands. Overall, modules aim to a) increase dyads' confidence in using strategies to address key psychosocial issues in the acute survivorship phase (e.g., dealing with stress and worry, communicating with partner and family, uncertainty management) and b) assist dyads in developing the self-regulatory skills necessary to meet the physical activity guidelines. Each module specifies a series of online (i.e. didactic material and interactive worksheets) and offline activities (i.e. practicing the proposed skills).
48646998|NCT04304196|OTHER|Usual care|Patients will receive usual care throughout the study. Dyads in this group will not receive any information resources from the research team, but will have access to all of those available at their participating center (sites will be asked to provide a description of usual care practices). Participants will be given access to the TEMPO website after having completed their final questionnaire, as thanks for participating.
48646999|NCT01093573|DRUG|midostaurin|Given orally
48647000|NCT01093573|DRUG|azacitidine|Given IV
48647001|NCT01093573|OTHER|bone marrow aspiration|Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
48647002|NCT01093573|OTHER|mutation analysis|Correlative study
48647003|NCT01093573|OTHER|Pharmacokinetic study|Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
48647004|NCT05128929|DRUG|Hymecromone (H01)|800 mg oral H01 two times a day (total dose: 1600 mg/day).
48647005|NCT05128929|DRUG|Placebo|Oral tablet placebo (inactive ingredients) two times a day.
48647006|NCT03039751|DRUG|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
48647007|NCT03039751|DRUG|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
48647008|NCT05205720|PROCEDURE|Celiac plexus block|The surgeon is instructed to perform a single celiac plexus block under direct vision. 10ml 0.5% ropivacaine is injected into the nerve in both sides.
48647009|NCT05205720|DRUG|Ropivacaine|Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
48647010|NCT03373669|BIOLOGICAL|Oral Cholera Vaccine|Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
48647011|NCT03373669|BIOLOGICAL|Adjusted Dose Oral Cholera Vaccine|The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
48647012|NCT04503421|OTHER|Blood Flow Restriction Therapy|Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
48647013|NCT00290628|DRUG|anti-thymocyte globulin|
48647014|NCT00290628|DRUG|busulfan|
48647015|NCT00290628|DRUG|cyclophosphamide|
48647016|NCT00290628|DRUG|cyclosporine|
48647017|NCT00290628|DRUG|filgrastim|
48647018|NCT00290628|DRUG|melphalan|
48647019|NCT00290628|DRUG|methylprednisolone|
48647020|NCT00290628|DRUG|mycophenolate mofetil|
48647021|NCT00290628|PROCEDURE|radiation therapy|
48647022|NCT00290628|PROCEDURE|umbilical cord blood transplantation|
48647023|NCT00619398|DRUG|Prograf|Oral
47969236|NCT03089866|DRUG|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
47969237|NCT03808532|OTHER|Cura+ Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
48321600|NCT00511342|DRUG|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
48321601|NCT01446601|DEVICE|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
48321602|NCT02958397|BIOLOGICAL|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
48647024|NCT00619398|DRUG|FK506MR capsule|Oral
48487500|NCT00655850|DRUG|Gemcitabine|"Premedication~* Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~* Prior to receiving paclitaxel chemotherapy~* Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~* The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~* Dose Level 2 ________300 mg/m2/weekly~* Dose Level 1 ________200 mg/m2/weekly~* Dose Level -1 ________150 mg/m2/weekly"
47969238|NCT00376727|BIOLOGICAL|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
48321603|NCT02935114|DRUG|37% Carbamide Peroxide|"* no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
48321604|NCT02935114|DRUG|35% hydrogen Peroxide|"* Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
48321605|NCT04222933|DEVICE|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
48487501|NCT00655850|BIOLOGICAL|Avastin|"* The dose of Avastin is 10 mg/kg IV every 2 weeks~* It will be administered following the administration of chemotherapy~* The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~* It should not be administered or mixed with dextrose solutions."
48487502|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part A)|20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
48487503|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part B)|250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
48487504|NCT05576623|OTHER|Placebo (Part B)|50 participants will receive placebo via intramuscular injection in the deltoid muscle
48487505|NCT03721731|DEVICE|Obesity treatment with a Plication device|Plicating the stomach to treat obesity
48487506|NCT00206492|DRUG|Iressa|Iressa
48487507|NCT00206492|DRUG|Tamoxifen|Tamoxifen
48487508|NCT00586482|DRUG|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
48487509|NCT00586482|DRUG|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
48487510|NCT00586482|BEHAVIORAL|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
48487511|NCT05571267|DRUG|Zimura|Zimura 2 mg, administered by intravitreal injection
48487512|NCT05571267|DRUG|Avastin|Avastin 1.25 mg, administered by intravitreal injection
48487513|NCT05571267|DRUG|Lucentis|Lucentis 0.5 mg, administered by intravitreal injection
48487514|NCT05571267|DRUG|Eylea|Eylea 2 mg, administered by intravitreal injection
48487515|NCT02099604|DRUG|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
48487516|NCT04704141|DRUG|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
48487517|NCT04965389|DRUG|BMS-986177 Oral Solution|Specified dose on specified days
48487518|NCT04965389|DRUG|[14C]BMS-986177 Solution for Infusion|Specified dose on specified days
48487519|NCT04965389|DRUG|BMS-986177 Spray-dried Dispersion Capsules|Specified dose on specified days
47969239|NCT00376727|GENETIC|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
48321606|NCT04222933|DEVICE|Classical cryotherapy|application of an ice bag
48321607|NCT00854178|DRUG|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
48321608|NCT04839354|DRUG|Arginine Hydrochloride|One-time L-arginine loading dose (200 mg/kg IV) + standard dose (100 mg/kg IV TID)
48487520|NCT04690036|DRUG|toripalimab injection|when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
47969240|NCT00376727|OTHER|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
48321609|NCT04839354|OTHER|Normal saline|Placebo (normal saline) loading dose (2ml/kg IV) + 1ml/kg IV TID
48321610|NCT03539861|DEVICE|Hemodialysis|Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
48487521|NCT04647383|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
48487522|NCT04647383|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
48487523|NCT04647383|DRUG|Placebo|COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
48487524|NCT04647383|DRUG|Lemborexant 10 mg|COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
48487525|NCT02813421|DEVICE|CGM Informed|
48487526|NCT02110017|OTHER|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
47969241|NCT00376727|OTHER|laboratory biomarker analysis|Cetuximab Pharmacodynamics
48647025|NCT05982379|OTHER|Technology Based Motivation Program|"A 10-week Technology Based Motivation Program was given to the intervention group. The website and four training modules were used with the children in the intervention group. Nine coaching interviews with each child (once a week) were conducted over WhatsApp. The children were encouraged to do progressive relaxation and breathing exercises at least twice a week, and eight therapeutic stories (once a week) were sent to the child's phone in the form of animation.~Three training modules were used with the primary caregivers, and coaching interviews were conducted on WhatsApp twice during the program. Primary caregivers practiced progressive relaxation and breathing exercises at least twice a week. In addition, eight motivation messages were sent to the child and primary caregiver, and 24/7 consultancy was provided."
48647026|NCT04126174|DEVICE|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
47969242|NCT03267758|DIETARY_SUPPLEMENT|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
47969243|NCT03267758|DIETARY_SUPPLEMENT|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
47969244|NCT03152071|PROCEDURE|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
47969245|NCT03152071|PROCEDURE|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
47969246|NCT05318170|PROCEDURE|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
47969247|NCT05812196|DIAGNOSTIC_TEST|Lung function test|Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.
47969248|NCT05812196|BIOLOGICAL|COVID infection|Verified COVID-19 infection.
48321611|NCT06527456|OTHER|participation of the general practitioner|participation of the general practitioner in encouraging cervical cancer screening
47969249|NCT05476198|PROCEDURE|Brachial plexus block|The effect of brachial plexus block method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
47969250|NCT05476198|PROCEDURE|General anesthesia|The effect of general anesthesia method on preoperative anxiety levels in patients who will undergo orthopedic upper extremity surgery.
47969251|NCT04447300|PROCEDURE|high power application|Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
47969252|NCT04447300|PROCEDURE|Standard power application|Standard power application
48487527|NCT05606588|BEHAVIORAL|Playful sensorimotor training|"For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue."
47969253|NCT00594438|DEVICE|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
48321612|NCT05641038|OTHER|Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.
47969254|NCT00594438|DEVICE|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
47969255|NCT00074152|DRUG|chemotherapy|Given within 10 weeks after surgery.
47969256|NCT00074152|RADIATION|radiation therapy|Given within 6 months after surgery
47969257|NCT01991769|BEHAVIORAL|47 min moderate intensity training|
47969258|NCT01991769|BEHAVIORAL|exercise healthy volunteers|
47969259|NCT01991769|BEHAVIORAL|control; no exercise training|
48321613|NCT05641038|OTHER|Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
48321614|NCT02031822|PROCEDURE|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
48321615|NCT04711876|BIOLOGICAL|Cytokine level in blood and CSF|Measure of cytokine level
48321616|NCT00421603|DRUG|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
48321617|NCT00421603|DRUG|Placebo|Placebo
48487528|NCT04551911|DRUG|Rayaldee|30 mcg calcifediol Extended-Release (ER) Capsule
48647027|NCT04126174|OTHER|Manual LRI|Manual LRI
48647028|NCT05102461|DIETARY_SUPPLEMENT|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
47969260|NCT01233531|BEHAVIORAL|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
47969261|NCT01233531|BEHAVIORAL|B--No cash transfers|No monthly cash transfers
47969262|NCT01591759|DRUG|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
47969263|NCT01591759|DRUG|Placebo|Placebo arm of single-blind study
48321618|NCT06099691|BEHAVIORAL|Qualitative Interviews|Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
48321619|NCT00269737|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
48321620|NCT02919124|DEVICE|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
48321621|NCT05585892|OTHER|Elaboration and individual mailed feedback|see above
48321622|NCT01987388|OTHER|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
48321623|NCT01987388|OTHER|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
48487529|NCT04551911|DRUG|Placebo|0 mcg calcifediol Extended-Release (ER) Capsule
48487530|NCT06028503|BEHAVIORAL|Acceptance and Commitment Therapy|"Approximately 3 hours of ACT will be administered based on Gregg et al.;s (2007) protocol:~1. What is ACT?~2. Coping and Stress Management~3. Acceptance and Action"
48487531|NCT06028503|DEVICE|Abbott FreeStyle® Libre® 3|The Abbott FreeStyle® Libre® 3 (FDA approved) consists of a single use disposable electrochemical sensing unit which is placed on the upper arm and an App for smart phones where the participant can view their glucose data, including their current glucose reading, their 'trend arrow' so participants can see how glucose is changing, and their glucose history. The FreeStyle system does not require user calibration. A sensor log will be maintained for accountability of all sensors received as well as used sensors (including the lot/serial number, expiration date, and the date). Sensors will be stored at manufacturers recommendations.
48647029|NCT05102461|DIETARY_SUPPLEMENT|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
48647030|NCT02446288|DEVICE|TMJ Next Generation|
48647031|NCT02446288|DEVICE|DSG Relaxer|
48647032|NCT00359398|PROCEDURE|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
48647033|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
48647034|NCT02465814|DRUG|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
48647035|NCT02465814|DRUG|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
48647036|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
47969264|NCT01740947|DRUG|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
47969265|NCT06558565|PROCEDURE|stromal vascular fraction or platelet rich plasma|stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half
48647037|NCT02465814|DRUG|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
48647038|NCT02465814|DRUG|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
47969266|NCT02211937|DRUG|BI 44847 solution, low dose|
47969267|NCT02211937|DRUG|BI 44847 suspension, high dose|
47969268|NCT02211937|DRUG|BI 44847 tablet, low dose|
47969269|NCT02211937|DRUG|BI 44847 tablet, high dose|
47969270|NCT02211937|OTHER|high fat breakfast|
48321624|NCT01987388|OTHER|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
48321625|NCT01987388|OTHER|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
48647039|NCT02465814|DRUG|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
48647040|NCT03796221|BEHAVIORAL|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
47969271|NCT05757453|DEVICE|MHealth|Mobile application
47969272|NCT05570500|BEHAVIORAL|Oral health education|oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
48321626|NCT03628417|PROCEDURE|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
48321627|NCT03628417|PROCEDURE|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
48321628|NCT02678663|PROCEDURE|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
48321629|NCT02678663|PROCEDURE|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
48321630|NCT04389398|DEVICE|pocket compression fixation belt|Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
48321631|NCT02753036|DRUG|Chemotherapy|standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
48321632|NCT01390961|DRUG|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
48321633|NCT00743457|DEVICE|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
48321634|NCT02494388|PROCEDURE|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
48321635|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
47969273|NCT03641274|OTHER|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
48487532|NCT06028503|OTHER|Generic Education|Participants will be given information about how lifestyle choices, including daily dietary choices, affect blood sugar for people with T2D, and best practices related to checking blood sugar and carbohydrate counting if participants are on insulin therapy. These sessions will also include education on diabetes nutrition guidelines and improving self-management through better food and lifestyle choices.
48487533|NCT03673319|PROCEDURE|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
48487534|NCT03673319|PROCEDURE|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
48487535|NCT03806842|DEVICE|Easytech group|total shoulder replacement
48647041|NCT03796221|BEHAVIORAL|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
48487536|NCT04184661|OTHER|blood sample|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
48487537|NCT03023514|DIETARY_SUPPLEMENT|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
48647042|NCT00121966|DRUG|Insulin Aspart|
48647043|NCT00121966|DRUG|Insulin NPH|
48647044|NCT00121966|DRUG|Metformin|
47969274|NCT05384574|DIETARY_SUPPLEMENT|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
47969275|NCT06158373|OTHER|infant massage practice|infant massage practice
47969276|NCT06158373|OTHER|Safe Swaddling|Safe Swaddling
47969277|NCT06158373|OTHER|Control|Control
47969278|NCT05317832|BEHAVIORAL|WI program|This 14-week web-based physical activity intervention (WI) program was developed by the National Center on Health, Physical Activity and Disability. The WI program was developed with guidance from literature and practice in health behavior change and internet-based health promotion programming. The content and features of the WI program include motivational resource, updated weekly resources, and customizable features.
48321636|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
48321637|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
47969279|NCT05317832|BEHAVIORAL|WI Program Reminder|Participants will be provided with reminders to use the WI program
47969280|NCT05317832|BEHAVIORAL|JITAI Goal Setting|Participants will be provided with standard, tailored, or no goal for the day. The goal will focus on recommending minutes of moderate-intensity (or higher) physical activity and a reminder to perform strength exercises.
48117628|NCT06412445|PROCEDURE|Laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair using self-fixating mesh|The operation will be performed using 3 trocars, with 10 mm trocar above the umbilicus and 5 mm and 12 mm trocars at the level of the umbilicus in the left and right midclavicular lines. Pneumoperitoneum will be established and a 30° optic will be used. After accessing the inguinal region, dissection of the parietal peritoneum will be performed in the direction from the anterior superior iliac spine up to the medial umbilical ligament. During dissection, gonadal vessels, vas deferens, Cooper's ligament and the posterior fascia of the rectus abdominis muscle will be visualized and prepared. Then, the prepared implant sized 15×15 cm will be introduced, spread out in the abdominal cavity and placed in the groin in order to cover the hernia opening by 2-3 cm in all directions. Fixation will be based on a mechanical effect involving the adherence of grips to tissue using self-fixating mesh. Reconstruction of the parietal peritoneum will be followed, with continuous absorbable sutures.
48117629|NCT05692778|OTHER|Patients being foot examined by using an eHealth tool|Patients being foot examined by using an eHealth tool that has been developed, will be tested with the intention to implement the eHealth tool
48117630|NCT05692778|OTHER|Patients being foot examined in traditional manner|Patient are being foot examined in the way as health care professionals usually make the foot examination in patients with diabetes
48117631|NCT02658240|DRUG|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
48117632|NCT02658240|DRUG|Epinephrine|0.5 mg epinephrine
48321638|NCT04726293|DIETARY_SUPPLEMENT|Mango|Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks
48321639|NCT04726293|DIETARY_SUPPLEMENT|Control|control beverage 1 cup, twice a day for 4 weeks
48321640|NCT05415150|DRUG|Thrombolytic Agent|Subjects may receive one or more of the treatment options
48647045|NCT00121966|DRUG|Rosiglitazone|
47969281|NCT05317832|BEHAVIORAL|JITAI physical activity message|Participants will be provided with minutes of moderate-intensity (or higher) physical activity achieved, minutes of physical activity remaining, or no message.
47969282|NCT05317832|OTHER|Notification EMA|Participants will be inquired through an ecological momentary assessment (EMA) if they received a JITAI physical activity message.
48647046|NCT01267136|DRUG|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
47969283|NCT05317832|OTHER|End of day EMA|Participants will be inquired, through an ecological momentary assessment (EMA), if they performed aerobic and/or strength exercises for the day.
47969284|NCT05317832|OTHER|Wake up time EMA|Participants will be inquired, through an ecological momentary assessment (EMA), about the time they plan to wake up next day. This information will be used to provide a goal setting message for next day.
47969285|NCT05317832|OTHER|Weekly PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
47969286|NCT05317832|OTHER|Daily PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the day.
48117633|NCT04490252|DIETARY_SUPPLEMENT|Fasting mimetic diet|Fasting mimetic diet for 5 days, another cycle after 25 days
48117634|NCT02621632|DEVICE|(Socknleg)To done of a novel compression system|To done a novel compression system.
48117635|NCT05157724|PROCEDURE|PLASMA|"The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged."
48321641|NCT03206242|OTHER|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
48321642|NCT04237324|PROCEDURE|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
48321643|NCT04237324|PROCEDURE|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
48321644|NCT05293652|OTHER|Iontophoresis|Hydrocortisone iontophoresis
48321645|NCT05293652|OTHER|Phonophoresis|Hydrocortisone Phonophoresis
48647047|NCT01267136|DRUG|Tramadol suspension|Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
48647048|NCT01118637|BEHAVIORAL|StopPulling.com|subsidized access to an interactive self-help website for TTM
48647049|NCT06497946|BEHAVIORAL|SlimTrack Plataform|SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
48647050|NCT06497946|BEHAVIORAL|Diet prescription|Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
48117636|NCT03071185|PROCEDURE|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
48117637|NCT03977935|DEVICE|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
48117638|NCT03087578|OTHER|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
48117639|NCT03087578|DRUG|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
48117640|NCT04487431|DRUG|BAY1817080|Oral single dose
48117641|NCT04487431|DRUG|[14C]BAY1817080|Oral single dose
48117642|NCT01372761|DRUG|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
48117643|NCT01372761|DRUG|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
48117644|NCT00573482|BEHAVIORAL|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~* Four group education sessions to introduce the REDE principles of eating;~* Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~* Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~* Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
48117645|NCT00573482|BEHAVIORAL|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
48117646|NCT04682483|DRUG|Vasopressor|The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
48117647|NCT04682483|DRUG|Inotrope|Inotropes include dobutamine and milrinone.
48117648|NCT04682483|DEVICE|Acute Mechanical Circulatory Support Devices|Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
48117649|NCT02986412|OTHER|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
48117650|NCT01069471|BIOLOGICAL|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
48117651|NCT05554614|BEHAVIORAL|BTW app with reward-based feedback|Teen drivers will be notified of their weekly driving performance via a driving safety score with information on the types of high-risk driving behaviors committed as well as progress on maintaining and/or improving weekly safe driving behaviors. Educational materials on different driving situations and scenarios associated with the high-risk driving behaviors (e.g. 90-second videos) will be provided for the driver to review at any point and time. Information on these driving behaviors and the education material will be provided via push notifications from the BTW app. Weekly leader boards will show the driver's driving safety score in comparison to other drivers of the same age. Consistently high driver safety scores in certain driving skill areas (e.g., cornering) and a total overall score above 70% of other users on that skill or total score will unlock gamification-based rewards (e.g., driving safety badges, driving safety score leader board, group challenges with winners).
48117652|NCT05554614|BEHAVIORAL|BTW app with situational supervised driving practice|Teen drivers will be provided bi-weekly push-notifications from the BTW app notifying them of situational supervised driving practice activities that are to be completed during the assigned week. There are 12 situational supervised driving activities and six skill-building driving activities (Table 1). Skill-building sessions are assigned for off weeks during the first half of the six months (weeks 2-12), allowing for skills to be further developed when the situations are encountered for a second time (weeks 15-23). Parents will be prompted to directly log situational supervised and skill-building driving activities in the app after the session within the BTW app to obtain the module completion date and duration time.
48321646|NCT05293652|OTHER|traditional PT program|Ultrasound and deep friction massage
48647051|NCT05428007|DRUG|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
48117653|NCT05554614|BEHAVIORAL|Sham BTW app|Teens will be provided links to passive education materials and information on car maintenance every week. They will not be given feedback on their driving performances.
48117654|NCT06455241|OTHER|HABIT (Hand Activities Behavior Intervention)|A Novel Occupational Therapy Intervention for Enhancing Daily Hand-Use of the affected upper extremity Among Individuals post Stroke.
47969287|NCT04396678|BEHAVIORAL|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
47969288|NCT04107610|DEVICE|I-PAS|I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.
48117655|NCT02035969|BEHAVIORAL|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
48117656|NCT06178978|DEVICE|KalEYEdoscope|"KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session."
48117657|NCT01470040|DRUG|discontinuation of aspirin therapy|discontinuation of aspirin therapy
48117658|NCT01470040|DRUG|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
48117659|NCT03690596|OTHER|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
48117660|NCT03690596|OTHER|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
48117661|NCT03690596|OTHER|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
48117662|NCT05335798|DEVICE|Bodyweight augment system|Motorized cables will be providing downward force on the participant's pelvis
48117663|NCT05335798|DEVICE|Smart insole|Insole provided auditory feedback when heel strike or toe-off events happen
48117664|NCT03535558|DRUG|Fluoroquinolone (FQ)|Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
48117665|NCT03535558|DRUG|Azithromycin (AZ)|Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
48117666|NCT03535558|DRUG|Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination|Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
48117667|NCT04014114|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
48117668|NCT02092077|DRUG|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
48117669|NCT02092077|DRUG|somatropin|Dose may be adjusted as required
48117670|NCT02390986|DRUG|LON002|Extension study to provide continuing access to LON002 medication.
48117671|NCT00716859|DRUG|Timolol|Timolol 0.5% dosed twice-daily
48487538|NCT03023514|DRUG|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
48487539|NCT02698865|DEVICE|MONOVISC|Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
48487540|NCT02698865|DEVICE|Saline|Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
48117672|NCT00716859|DRUG|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
48117673|NCT05948956|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Juvenescence Cognitive Switch ™ and electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise.
48117674|NCT05948956|DIETARY_SUPPLEMENT|Electrolyte Beverage|Participants will consume an electrolyte solution diluted in water, before each of 5 1-hour sessions of aerobic exercise.
48117675|NCT05948956|BEHAVIORAL|Cycling Intervention|"Five 1-hour sessions of cycling on the ergometer over a 2-week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down."
48117676|NCT02622672|DIETARY_SUPPLEMENT|water-soluble ubiquinol|100 mg/d
48487541|NCT03237533|DRUG|Dexamethasone|Dexamethasone will be applied locally on the lesion
48487542|NCT01580657|BEHAVIORAL|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
48117677|NCT02622672|DIETARY_SUPPLEMENT|Placebo|glycerin.soy-lecithin, and water
48117678|NCT05684094|BEHAVIORAL|Sleep extension and advance|"Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives."
48117679|NCT05684094|BEHAVIORAL|Regular sleep duration and timing|Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
48117680|NCT00835952|DRUG|ATX-101|ATX-101 single doses
48117681|NCT02009813|PROCEDURE|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
48117682|NCT03062332|GENETIC|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
48117683|NCT01600729|DRUG|No Intervention|No intervention.
48117684|NCT00150176|DRUG|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
48117685|NCT00150176|DRUG|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
48117686|NCT00150176|DRUG|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
48117687|NCT02797717|RADIATION|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
48117688|NCT02797717|DRUG|Vincristine|ARM A and ARM B
48117689|NCT02797717|DRUG|Etoposide|ARM B , 100mg/m2/day
48117690|NCT02797717|DRUG|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
48117691|NCT02797717|DRUG|Doxorubicin|ARM B , 25mg/m2
48117692|NCT02797717|DRUG|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
48117693|NCT02797717|DRUG|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
48117694|NCT06484855|DRUG|IBI355|IBI355 IV. Q4W
48117695|NCT06484855|DRUG|IBI355 placebo|IBI355 placebo IV. Q4W
48117696|NCT00001730|DRUG|Thyrogen|
48117697|NCT00979992|OTHER|Laboratory Biomarker Analysis|Correlative studies
48117698|NCT00979992|DRUG|Sunitinib Malate|Given PO
48321647|NCT05890118|DRUG|Stelara|A commercial formulation of ustekinumab for SC control (0.5mg)
48321648|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.5mg)|RaniPill capsule containing ustekinumab with a dose of 0.5mg
48321649|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.75mg)|RaniPill capsule containing ustekinumab with a dose of 0.75mg
48321650|NCT01600768|DRUG|Beta-Lactams|infusion time: 30 mins or 1 hr
48321651|NCT01600768|DRUG|Beta-Lactams|infusion time 4 hrs
48321652|NCT02168894|PROCEDURE|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
48647052|NCT05428007|DRUG|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
47969289|NCT00967668|BEHAVIORAL|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
48321653|NCT02168894|PROCEDURE|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
48487543|NCT01580657|BEHAVIORAL|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
48487544|NCT01580657|BEHAVIORAL|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
48487545|NCT01580657|BEHAVIORAL|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
48487546|NCT01580657|BEHAVIORAL|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
48487547|NCT01580657|BEHAVIORAL|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
48321654|NCT02168894|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
48321655|NCT01850862|OTHER|Collective group exercise program in patients with KOA|
48321656|NCT01850862|OTHER|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
48321657|NCT05594108|DIAGNOSTIC_TEST|ultrasonography|transabdominal ultrasonography
48321658|NCT00229164|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|
48321659|NCT00084929|PROCEDURE|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
48117699|NCT05420090|BEHAVIORAL|Banana arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied.Food consumption frequency and food-based follow-up will be carried out.Participants will consume 1 portion of banana (gross 80-85 g) given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
48321660|NCT00608439|DRUG|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
48321661|NCT00608439|OTHER|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
48487548|NCT00269542|DRUG|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
48487549|NCT00269542|DRUG|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
48647053|NCT05428007|DRUG|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
48487550|NCT03053336|BEHAVIORAL|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
48487551|NCT04715997|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
48647054|NCT04008069|DRUG|Sarilumab|Sarilumab 200 mg administered subcutaneously
48647055|NCT04008069|DRUG|Placebo|Placebo administered subcutaneously
48647056|NCT06215157|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
48647057|NCT06215157|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
48647058|NCT04859686|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.
48647059|NCT04859686|PROCEDURE|Acupuncture Treatment|"Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation."
48647060|NCT06569888|DEVICE|LIPUS stimulation|Low Intensity Pulsed Ultrasound stimulation of the gut at the pre-clinically optimized conditions and energy dosage
48487552|NCT04715997|DRUG|Placebo|Normal saline
48117700|NCT05420090|BEHAVIORAL|Milk arm|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. Food consumption frequency and food-based follow-up will be carried out. Participants will consume 200 ml of whole milk given to them for 6 weeks, approximately 45 minutes-1 hour before bedtime. The frequency of food consumption will be taken from the participants each week.
48487553|NCT01478737|DRUG|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
48487554|NCT01478737|PROCEDURE|Vitrectomy|Vitrectomy only
48647061|NCT01293955|DRUG|JOINS 200mg|1 tablet at each time, 3 times a day
48647062|NCT01293955|DRUG|Placebo|placebo of Joins 200mg
48647063|NCT01827306|DRUG|Biofreeze|
48647064|NCT00379379|DEVICE|electroacupuncture|
48647065|NCT02513251|OTHER|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
48647066|NCT02292355|OTHER|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
48321662|NCT06076200|DRUG|Piperacillin Sodium and Tazobactam Sodium for Injection|Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
48321663|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] with preservative|solution for intramuscular injection, 0.5 ml
48321664|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] without preservative|solution for intramuscular injection, 0.5 ml
48321665|NCT05152017|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
48487555|NCT05680870|DRUG|Omeprazole|Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
48321666|NCT00088569|DRUG|0-15 Water|
48321667|NCT05510778|DIETARY_SUPPLEMENT|Charcocaps|250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine
48321668|NCT05510778|OTHER|Placebo|capsules containing \~250 mg cellulose
48321669|NCT02957149|OTHER|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
48321670|NCT02957149|DEVICE|Angel Concentrated Platelet Rich Plasma System|
48321671|NCT01899859|DRUG|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
48321672|NCT01899859|DRUG|Placebo|GR-MD-02 Placebo
48321673|NCT03839017|DEVICE|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
48487556|NCT02511899|DIETARY_SUPPLEMENT|Mango fruit powder|Dietary supplement; Mango fruit powder
48647067|NCT01635530|DRUG|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
48647068|NCT01635530|DRUG|Ceftriaxone|2 g intravenous once a day, three weeks
48647069|NCT04376008|PROCEDURE|Standard prostate biopsy|Transperineal TRUS guided standard prostate biopsy (SB).
48321674|NCT03294668|BEHAVIORAL|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
48647070|NCT04376008|PROCEDURE|Targeted and standard prostate biopsy|Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
48321675|NCT03294668|OTHER|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
48321676|NCT04677621|OTHER|Nurse Telehealth|Subjects will receive nurse telehealth Mobile Decision Support System (MAP) DBS care
48321677|NCT04677621|OTHER|STANDARD DBS|Subjects will receive standard in-person clinic-based DBS care administered without the use of Mobile Decision Support System (MAP) DBS
48321678|NCT04195659|PROCEDURE|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
48647071|NCT02812537|OTHER|patients with conduct disorders|interview with a specialist
48647072|NCT05904379|DRUG|AK112|Subjects receive AK112 intravenously.
48647073|NCT05904379|DRUG|AK104|Subjects receive AK104 intravenously.
48647074|NCT05904379|DRUG|Carboplatin|Subjects receive carboplatin intravenously.
48647075|NCT05904379|DRUG|paclitaxel|Subjects receive paclitaxel intravenously.
48647076|NCT05904379|DRUG|pemetrexed|Subjects receive pemetrexed intravenously.
48647077|NCT05904379|DRUG|Docetaxel|Subjects receive docetaxel intravenously.
48647078|NCT06381960|DRUG|Fuzheng Quxie Recipe|Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
48647079|NCT06381960|DRUG|Fuzhengquye Fang Recipe simulant|Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
48647080|NCT06537401|BEHAVIORAL|Hypercaloric, High Fat Diet|Participants will select meals from a list of sample breakfast, lunch, and dinner options from grocery stores. Typical intake will be estimated as 160-170% of resting metabolic rate, which will then be multiplied by 1.65 as the target calorie intake for the HFD. Target fat intake will be 65% of the HFD calorie target. To ensure participants will achieve the desired calorie and fat intake, they will also be provided with pre-made nutrient shakes and half-and-half. Participants will supplement their food intake with one to three shakes per day for each of the three days, depending on the fat and calorie content of the foods they select. They will be asked to add half-and-half equally between across the shakes.
48647081|NCT02715856|OTHER|Monitoring Device|Undergo surgical wound and physical activity monitoring
48647082|NCT02715856|OTHER|Physical Activity Measurement|Undergo physical activity measurement
48647083|NCT02715856|OTHER|Quality-of-Life Assessment|Ancillary studies
48647084|NCT02715856|OTHER|Questionnaire Administration|Ancillary studies
48647085|NCT02715856|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
48321679|NCT06169930|OTHER|This was an observational study without any intervention|This was an observational study without any intervention
48647086|NCT02715856|OTHER|Survey Administration|Ancillary studies
48647087|NCT02090894|DEVICE|UV Light (Laser Genesis)|
48321680|NCT03569865|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
48321681|NCT01422590|DRUG|Sitagliptin|Single oral administration of sitagliptin 100 mg
48321682|NCT01422590|DRUG|Mitiglinide|Single oral administration of mitiglinide 10 mg
48321683|NCT01422590|DRUG|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
48321684|NCT02068131|DRUG|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
48321685|NCT02068131|DRUG|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
48487557|NCT05051202|OTHER|Sugars from Fiber|Proprietary blend of Sugars from Fiber baked into 50 g flapjack
48487558|NCT05051202|OTHER|Resistant Maltodextrin|Resistant Maltodextrin baked into 50 g flapjack
48487559|NCT04774341|DRUG|anticoagulation treatment|Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
48487560|NCT06453512|DEVICE|Doublebase Once|Emollient
48487561|NCT04803188|DIAGNOSTIC_TEST|Magnetic Resonance|"Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy."
48647088|NCT02915601|DRUG|Sodium bicarbonate|
48647089|NCT02915601|DRUG|Placebo|
48647090|NCT02349477|DRUG|Gabapentin|gaba potentiating medication
48647091|NCT02349477|DRUG|Placebo|a pill that looks exactly like the active medication but does not contain medication
48647092|NCT03810365|BEHAVIORAL|Brief behavioral treatment for insomnia|Brief Behavioral Treatment for Insomnia includes content on sleep restriction, stimulus control, and sleep hygiene content with 1 month for primary outcome followed by 3 month 12 month follow-up visits.
48117701|NCT05420090|BEHAVIORAL|No intervention|Venous blood samples will be taken from the participants in 3 groups before starting the study. Pittsburgh Sleep Quality Index will be applied. The frequency of food consumption will be taken from the participants each week.Participants are expected not to make any changes in their diet. As in other groups, the frequency of food consumption will be taken from the participants every week in this group. In order to observe the possible changes in the experimental arms, the individuals in the control arm will be asked not to consume bananas and whole milk after 16:00 and they will be informed about this.
48117702|NCT03378141|BEHAVIORAL|Maternal Nutrition Behavior change|Counseling and community mobilization
48647093|NCT03810365|BEHAVIORAL|Healthy Eating Control|Healthy eating control involves healthy eating content with 1 month for primary outcome followed by 3 month and 12 month follow-up visits.
47969290|NCT00967668|BEHAVIORAL|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
47969291|NCT01115101|DRUG|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
47969292|NCT01115101|DRUG|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
48117703|NCT01047852|PROCEDURE|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
48117704|NCT01767714|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
48117705|NCT01767714|DRUG|Plerixafor|0.24 mg/kg/day subcutaneous injection
48487562|NCT04180176|OTHER|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
48487563|NCT05624827|DIAGNOSTIC_TEST|Testing DNA methylation test for predicting prognosis of untreated CIN 2|After being diagnosed with CIN 2, patients will first be contacted by telephone and invited to participate in the study. If patients agree to participate in the research, they will sign a consent to participate in the research. After that, we will perform a colposcopy and take a cervical swab for analysis with the QIAsure Methylation Test Kit (Qiagen, Gaithersburg, USA), which will determine the methylation of tumor suppressor genes FAM19A4 and has-mir-124. Patients will complete a questionnaire. The total duration of tracking in both groups will be two years. The QIAsure Methylation Test will be performed to analyze methylation. It is a methylation-specific PCR test that detects hypermethylation of the tumor promoter suppressor genes FAM19A4 and has-mir-124. The samples on which we will use this test are bisulfite-converted DNA obtained by triage test for high-risk HPV - Hybrid Capture 2 HPV DNA Test (hc2, Qiagen, Gaithersburg, USA).
48487564|NCT04356118|DRUG|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
48487565|NCT04356118|DRUG|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
48487566|NCT04356118|DRUG|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
48487567|NCT05260164|DEVICE|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
48487568|NCT05130138|OTHER|Pharmaceutical intervention|Patients with pharmacokinetic and/or pharmacodynamics interactions will be proposed to participate to educational sessions to discuss about treatments taken and modifications possibilities.
48487569|NCT05070702|DRUG|CT-1500|Hard Capsule
48487570|NCT05070702|DRUG|Placebo|Hard Capsule
48487571|NCT02214368|OTHER|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
48487572|NCT02214368|DEVICE|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
48487573|NCT02214368|DRUG|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
48647094|NCT06370663|RADIATION|Radiotherapy|Radiotherapy + Hepatic Arterial Infusion Chemotherapy (Gesitabine) + Chemotherapy (GEMOX)
48647095|NCT06370663|DRUG|HAIC (GEMOX)|Hepatic Arterial Infusion Chemotherapy (GEMOX)
48647096|NCT06370663|DRUG|Chemotherapy|Chemotherapy (Gesitabine)
48647097|NCT02533128|DRUG|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg
48647098|NCT02533128|DRUG|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
48647099|NCT02115672|DRUG|BL-8040|BL-8040 will be added to imatinib to improve CML response.
48647100|NCT02262221|OTHER|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
48647101|NCT02167685|DRUG|CMX001|
48117706|NCT01767714|DRUG|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
48117707|NCT03641703|BIOLOGICAL|FLT180a|FLT180a is a replication-incompetent adeno-associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
48321686|NCT02297542|BIOLOGICAL|Flu Vaccine|
48321687|NCT02300896|OTHER|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
48321688|NCT02338492|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
48321689|NCT03448978|BIOLOGICAL|Descartes-08|autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
48321690|NCT03448978|DRUG|Fludarabine|intravenous fludarabine
48321691|NCT03448978|DRUG|Cyclophosphamide|intravenous cyclophosphamide
48647102|NCT01974479|BIOLOGICAL|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
48647103|NCT00718731|DRUG|GSI-136|
48647104|NCT00718731|OTHER|Placebo|
48647105|NCT06486441|DRUG|Sacituzumab govitecan-hziy|Administered intravenously
48647106|NCT06486441|DRUG|Doxorubicin|Administered intravenously
48647107|NCT06486441|DRUG|Paclitaxel|Administered intravenously
48321692|NCT05783193|DRUG|TGIR (Traditional Gastrointestinal Remedy)|TGIR botanical formulation
48647108|NCT06570239|PROCEDURE|intervention group|"Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks."
48647109|NCT05030389|BEHAVIORAL|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
48647110|NCT05030389|BEHAVIORAL|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
48321693|NCT05783193|DRUG|Placebo|Placebo capsules
48321694|NCT00061126|DRUG|ABX-EGF|
48321695|NCT00954317|PROCEDURE|epidural placed low|epidural placed low
48321696|NCT00954317|PROCEDURE|high epidural|high epidural
48321697|NCT05344625|DRUG|Ketamine 100 MG/ML|Ketamine Assisted Psychotherapy
48321698|NCT05643157|DEVICE|Adaptive Optics - Optical Coherence Tomography (AO-OCT) retinal imaging|AO-OCT used in this study is an investigational OCT imaging system. . In this instrument, ocular aberration sensing and correction is achieved with a Shack-Hartmann wavefront sensor (SHWS) and deformable mirror, respectively. A pupil camera and fixation target are used to position the participant's head and eye for scanning a particular retinal region within 15 degrees of the fovea. Data collected generally includes AO-OCT volume videos and SHWS measurements of ocular aberrations.
48321699|NCT01349686|PROCEDURE|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
48321700|NCT01349686|PROCEDURE|Fasting|No intake of fluids during labour.
48321701|NCT05078099|DEVICE|CureSight|Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
48321702|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted low dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
48321703|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
48321704|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
48321705|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
48321706|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
48321707|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
48321708|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted high dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
48321709|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
48321710|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
48321711|NCT03814590|DRUG|Placebo (Saline solution)|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
48321712|NCT03089216|PROCEDURE|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
48321713|NCT03089216|PROCEDURE|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
48321714|NCT03089216|PROCEDURE|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
48321715|NCT03089216|PROCEDURE|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
48321716|NCT03089216|DRUG|8% arginine and calcium carbonate|using during all the treatment.
48321717|NCT00873769|DRUG|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
48321718|NCT01333696|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
48321719|NCT03092349|DEVICE|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
48321720|NCT00423618|RADIATION|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
48321721|NCT06195826|PROCEDURE|Gravity infusion|hysteroscopic myomectomy with the gravity infusion method
48321722|NCT06195826|PROCEDURE|Pump infusion|hysteroscopic myomectomy with the pump infusion method
48321723|NCT00946530|DEVICE|Bright light|Participants uses bright light
48321724|NCT00946530|DEVICE|Control|Participants uses dim light
48321725|NCT04810299|OTHER|Aromatherapy|Aromatherapy; It is one of the complementary therapy methods defined as the therapeutic use of essential oils obtained from parts of plants such as root, seed, leaf, flower, shell with appropriate methods.
48321726|NCT04810299|OTHER|Classical foot massage|Classical foot massage; It is defined as a massage technique based on the principle of systematic relaxation
48321727|NCT03252314|DEVICE|Second-generation hydrogel coils|Hydrogel coils 90% by length
48321728|NCT03145194|DRUG|Ticagrelor|2 x 90mg Ticagrelor tablets
48321729|NCT03145194|OTHER|Placebo|2 x matching placebo tablets
48647111|NCT05030389|BEHAVIORAL|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
48647112|NCT05030389|BEHAVIORAL|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
48647113|NCT00002011|DRUG|Methoxsalen|
48647114|NCT04611009|BEHAVIORAL|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
48321730|NCT00160576|DRUG|Levetiracetam|
48321731|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
48321732|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
48321733|NCT05439460|DRUG|Phenylephrine|5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
48321734|NCT05439460|DRUG|Epinephrine|5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
48487574|NCT02214368|OTHER|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate\>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2\> 0.5 or breathing at least 10 L/min oxygen.
48647115|NCT04611009|BEHAVIORAL|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
48321735|NCT05439460|DRUG|Arginine Vasopressin|5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
48321736|NCT00754728|DEVICE|JACTAX DES|Drug Eluting Stent
48321737|NCT05807386|BEHAVIORAL|Home-based exercise programme|A 12 week, online delivered, home-based exercise programme.
48321738|NCT04793763|OTHER|traditional therapeutic exercises|group A will receive traditional exercises
48321739|NCT04793763|OTHER|traditional therapeutic exercises and McKenize technique|Group B will receive traditional therapeutic exercises and McKenize technique
48321740|NCT04793763|OTHER|traditional therapeutic exercises and deep neck flexor exercises|Group C receive traditional therapeutic exercises and deep neck flexor exercises
48647116|NCT06467656|OTHER|Individualized, periodized endurance training for ultra-endurance triathlon.|Endurance exercise consisting of swimming, cycling and running training for a minimum of 3 hours /week up to a maximum of 20 hours/week with regular rest days and intensities being fluctuated throughout the program to optimize training stimulus and adaptation. Strengthening exercises to complement the aerobic training, enhance conditioning and prevent injury will also be performed 1-2 hours/week for the first 9-months of the program.
47969293|NCT04678271|BEHAVIORAL|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
48321741|NCT01578057|DRUG|tasimelteon|20mg, once
48321742|NCT01578057|DRUG|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
48321743|NCT01578057|OTHER|Placebo tasimelteon|once
48321744|NCT01578057|DRUG|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
48321745|NCT01353937|DRUG|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
48321746|NCT04793386|DIAGNOSTIC_TEST|carotid ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
48321747|NCT00012012|DRUG|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
48321748|NCT00012012|DRUG|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
48321749|NCT00012012|RADIATION|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
48321750|NCT00012012|RADIATION|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
48321751|NCT05321485|OTHER|MedicijnWijs|"The mobile phone app MedicijnWijs will guide the participants with their azathioprine therapy during 6 weeks. Information about azathioprine is given as well as general information about IBD, specified to disease modality (Crohn's Disease and Ulcerative Colitis). Contact details of the patient's pharmacy are listed, questions about the patient's symptoms are asked, and push notifications are added to remind the patients to take their medication.~At the beginning of the 6-weeks guidance, two validated questionnaires that are translated and validated in Dutch will have to be filled in: the MARS-5 and the IBD-KID2. After 6 weeks, the participants have to fill out the same questionnaires again to assess potential changes in the scores compared to baseline. Also, a number of questions will be asked to assess the ease of use of MedicijnWijs."
48321752|NCT00514202|DRUG|Placebo|matched placebo
48321753|NCT00514202|DRUG|Dextroamphetamine SR|60 mg/day
48321754|NCT00980343|DRUG|vismodegib|Given orally
48321755|NCT00980343|PROCEDURE|therapeutic conventional surgery|undergo surgery
48321756|NCT00980343|OTHER|laboratory biomarker analysis|correlative studies
48647117|NCT06467656|OTHER|Time-Aligned Control|Participants will receive no specific intervention and will continue to live their lives as if they were not in a study.
48647118|NCT04564014|BEHAVIORAL|ISSS|The ISSS aims to help participants acquire problem-solving (e.g., interpersonal problems) and time management based on the treatment manual of the therapy. Video introductions for each session and example teacher characters who depict the targeted problems and demonstrate implementation of coping/management techniques in a variety of situations. ISSS will use metaphors, daily examples, and lively narrative stories to enhance motivation for participation and understanding of the intervention contents. Session 2-5 will assign exercise and homework. Within 48 hours, participants will receive personalized written feedback (e.g., suggestions) from an e-Coach on the exercises they have completed. Participants can contact e-Coaches via the online system if they have any questions regarding the contents. Questions that beyond the contents will be referred to the health psychologist (PI) by e-Coaches.
48321757|NCT00980343|OTHER|pharmacological study|correlative studies
48321758|NCT03363412|DEVICE|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
48321759|NCT04989504|OTHER|Best Practice|Receive standard of care
48321760|NCT04989504|DEVICE|Wound Dressing Material|Apply Mepitel Film
48321761|NCT04989504|OTHER|Quality-of-Life Assessment|Ancillary studies
48321762|NCT04989504|OTHER|Questionnaire Administration|Ancillary studies
48321763|NCT05720442|DRUG|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
48321764|NCT05720442|DRUG|Mosapride Citrate|The mosapride citrate tablets will be administrated.
48321765|NCT03627858|DRUG|beclomethasone / formoterol / glycopyrronium|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
48321766|NCT06006312|DIAGNOSTIC_TEST|fecal elastase-1 test|Personal information of the enrolled subjects will be collected and a fecal collection device will be distributed. Fecal elastase-1 levels will be measured after the fecal sample is collected.
48321767|NCT06006312|DIAGNOSTIC_TEST|72-hour fecal fat quantification|Enrolled subjects will eat a standard meal (100g of fat) daily for five consecutive days and collect stool samples for the last 72h. The fat content in the sample will be quantitatively detected and the fat absorption coefficient will be calculated.
48321768|NCT06006312|DIAGNOSTIC_TEST|blood sample test|The enrolled subjects will undergo oral glucose tolerance test and will be collected blood samples for measurement of plasma glucose, insulin level, C-peptide level, glycosylated hemoglobin and vitamin.
48321769|NCT05689138|OTHER|Oral and Fecal Sample Collection|No interventions
48321770|NCT04119817|DIETARY_SUPPLEMENT|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
48321771|NCT04119817|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
48321772|NCT03323918|OTHER|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
48321773|NCT03323918|OTHER|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
48321774|NCT00139685|DRUG|Depo-Provera Contraceptive Injection - DP150CI|
48321775|NCT01429077|DRUG|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
48321776|NCT01429077|DRUG|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
48321777|NCT02621879|PROCEDURE|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
48321778|NCT00747838|PROCEDURE|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
48321779|NCT06081673|DRUG|Penpulimab injection|Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
48321780|NCT06081673|DRUG|cisplatin|Cisplatin :75mg/m2, D1, IV(21 days/cycle)
48647119|NCT04564014|OTHER|Education Materials|Participants will recieve education materials addressing the following issues: (1) introduction to mental health and mental illness; (2) signs and symptoms of depression; (3) treatment of depression and available community resources; (4) signs and symptoms of anxiety; (3) treatment of anxiety and available community resources. The education materials will be carefully developed by the health psychologists and clinical psychologist of the research team who are very experienced in education intervention for mental and emotional health.
48321781|NCT06081673|DRUG|albumin-paclitaxel|albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
48487575|NCT04587102|OTHER|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
48647120|NCT05092776|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
48647121|NCT05092776|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
48647122|NCT02162173|PROCEDURE|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
48647123|NCT03344705|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
48321782|NCT02152592|DRUG|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
48321783|NCT02152592|DRUG|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
48321784|NCT01221688|PROCEDURE|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
48321785|NCT01221688|PROCEDURE|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
48321786|NCT03737422|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
48321787|NCT03737422|OTHER|control|no supplementation
48321788|NCT02252692|DRUG|Enalapril|oral administration
48321789|NCT04315610|OTHER|Access to mobile phone application|Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
48487576|NCT04587102|OTHER|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
48647124|NCT03344705|DRUG|Fludarabine|Two days before cell infusion,all patients will be treated with fludarabine for 3 days
48647125|NCT03344705|DRUG|Cyclophosphamide|Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
48487577|NCT00358293|DRUG|Tizanidine (sublingual or oral)|
48647126|NCT02502383|BEHAVIORAL|ACTION PAC|School-based health center providers will use motivational interviewing to assist students with adopting strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI and other health results discussion with clinical providers. Adolescents with overweight/obesity will meet with providers for 16 sessions over 2 years.
48487578|NCT04917718|DRUG|Conversion from IR Tacrolimus to XR Tacrolimus|All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus
48487579|NCT04757181|OTHER|The IBD-AID|Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
48487580|NCT00215449|DRUG|Formoterol Fumarate|
48487581|NCT03580564|DRUG|KL-A167|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
48487582|NCT02823483|OTHER|Sunscreen Lotion (BAY987521)|50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
48487583|NCT02823483|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
48647127|NCT02502383|BEHAVIORAL|Communication with parents|A letter containing BMI and other health results and obesity prevention recommendations will be sent to parent/guardians.
48647128|NCT05293262|PROCEDURE|Endourological surgery|Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
47969294|NCT04165785|DEVICE|OPT IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
48117708|NCT01426295|DEVICE|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC\> 500/mm3), and / or mucositis grade 0."
48117709|NCT01426295|DRUG|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC\> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
48117710|NCT05188430|DEVICE|Medical Device (Kaptufat®)|"140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals"
48117711|NCT05188430|OTHER|Placebo|Oral administration: 3 tablets twice a day before the main meals
48117712|NCT04377698|BIOLOGICAL|Platelet Rich Fibrin|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
48117713|NCT04377698|BIOLOGICAL|FDBA|regeneration, restoration or reconstitution of the lost periapical tissues of the tooth by using regenerative therapies that utilize growth factors and barrier membranes.
48117714|NCT03009305|OTHER|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
48117715|NCT03009305|DEVICE|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
48487584|NCT01843686|DEVICE|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
48487585|NCT01843686|OTHER|Placebo Saline Gel and Usual and Customary Standard of Care|
48487586|NCT00024648|DRUG|LErafAON|
48647129|NCT01878474|DRUG|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
48647130|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
48647131|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
48647132|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
48117716|NCT03009305|DEVICE|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
48117717|NCT03704727|DIETARY_SUPPLEMENT|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10\^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10\^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10\^10 CFU/g Streptococcus thermophilus
48321790|NCT04315610|OTHER|Treatment as usual|Active comparator group, based on traditional information and follow-up.
48321791|NCT05150834|OTHER|This is observational study|We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
48321792|NCT00905723|DRUG|estradiol|1 mg daily for 6 months
48647133|NCT01878474|DRUG|Placebo|Single ascending dose in Caucasian men
48647134|NCT01878474|DRUG|Placebo|Age-effect in Caucasian men
48647135|NCT01878474|DRUG|Placebo|Gender-effect in Caucasian women
48647136|NCT01878474|DRUG|Placebo|Single ascending dose in Japanese men
48647137|NCT03402581|DEVICE|c-mac laryngoscope|type of laryngoscopes
48647138|NCT01941342|PROCEDURE|Pancreatoduodenectomy|
48647139|NCT01941342|PROCEDURE|ENBD and Pancreatoduodenectomy|
48647140|NCT01941342|PROCEDURE|EBD and Pancreatoduodenectomy|
48647141|NCT01941342|PROCEDURE|PTCD and Pancreatoduodenectomy|
47969295|NCT04165785|DEVICE|Sham OPT IPL|Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
48117718|NCT00520546|OTHER|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq \[18F\]Fluoroethylcholine chloride (FEC; Eckert \& Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
48117719|NCT00520546|OTHER|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
48487587|NCT02692729|PROCEDURE|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
48117720|NCT06436144|DRUG|Osimertinib|Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles.
48117721|NCT03786991|OTHER|No intervention|No intervention
48117722|NCT01972763|DRUG|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
48117723|NCT04476472|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
48117724|NCT06006806|RADIATION|Pencil Beam Scanning Proton Therapy|"Part of the normal proton therapy process is to have a CT scan (called a CT simulation) performed that is used to create a proton treatment plan. A proton treatment plan is a computer model of the proton beam that is used to calculate where the protons will go inside the body. During the treatment planning process, the clinical team works to find the best possible placement of the protons. This study uses a process called Spot Delete to keep protons from stopping in the skin, which is believed to be related to skin reddening. Spot Delete is a software application that was developed at the Thompson Proton Center and is used in the treatment planning process."
48117725|NCT02906735|PROCEDURE|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
48117726|NCT05919017|DRUG|Naltrexone implant|Naltrexone implant
48321793|NCT00905723|DRUG|isoflavone|150 mg isoflavone daily for 6 months
48117727|NCT05919017|DRUG|Placebo|Placebo
48117728|NCT04583514|BEHAVIORAL|Control|Weight-stable Control group
48117729|NCT04583514|BEHAVIORAL|Overfeeding|30% Overfeeding group
48117730|NCT04731948|DIETARY_SUPPLEMENT|Folic Acid|400µg Folic Acid per day for 16 weeks
48117731|NCT04731948|DIETARY_SUPPLEMENT|2 µg Vitamin B12|2 µg Vitamin B12 per day for 16 weeks
48321794|NCT00905723|DRUG|Placebo|sugar pill daily for six months
48321795|NCT03721393|DEVICE|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
48321796|NCT04015414|DRUG|Varenicline|191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
48117732|NCT04731948|DIETARY_SUPPLEMENT|10 µg Vitamin B12|10 µg Vitamin B12 per day for 16 weeks
48117733|NCT04731948|DIETARY_SUPPLEMENT|50 µg Vitamin B12|50 µg Vitamin B12 per day for 16 weeks
48321797|NCT04015414|DRUG|Cytisine|185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
48321798|NCT01005511|DEVICE|Grindcare|Active treatment
48321799|NCT01005511|DEVICE|Grindcare - inactive|Placebo treatment
48321800|NCT05836519|OTHER|Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale|Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
48321801|NCT02767453|PROCEDURE|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
48321802|NCT02767453|PROCEDURE|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
48321803|NCT03337594|DRUG|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
48321804|NCT03337594|DRUG|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
48321805|NCT03337594|PROCEDURE|Surgery|Cardiac surgery
48321806|NCT00424528|DRUG|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
48321807|NCT00424528|DRUG|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
48647142|NCT05791630|OTHER|the labour care guide (LCG)|The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour
48117734|NCT01542593|DEVICE|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
48117735|NCT00115713|BEHAVIORAL|Aerobic Exercise Training|
48117736|NCT00115713|BEHAVIORAL|Resistance Exercise Training|
48321808|NCT00424528|DRUG|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
48321809|NCT00424528|DRUG|Placebo|Placebo inhalation solution and placebo inhalation powder
48321810|NCT04979949|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
48321811|NCT04979949|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
48321812|NCT01442532|DRUG|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
48647143|NCT06289062|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
48321813|NCT01442532|DRUG|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
48321814|NCT01442532|DRUG|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
48647144|NCT06289062|DRUG|Cisplatin|75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
47969296|NCT04165785|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
48321815|NCT01442532|DRUG|Placebo|Form=tablet, route=oral use, for 14 days
48321816|NCT01442532|DRUG|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
48321817|NCT03608904|OTHER|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
48321818|NCT03608904|OTHER|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
48321819|NCT03026335|BEHAVIORAL|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
48321820|NCT03026335|BEHAVIORAL|Control|Business as usual with students in non-itervened schools
48321821|NCT00258388|DRUG|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
48321822|NCT00258388|DRUG|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
48487588|NCT02692729|PROCEDURE|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
48487589|NCT03897647|DEVICE|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
47969297|NCT04397107|DRUG|IL-2|Patients were received low dose recombinant human Interleukin-2
47969298|NCT01628575|PROCEDURE|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
47969299|NCT01540240|DRUG|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
47969300|NCT01540240|DRUG|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
48321823|NCT00258388|DRUG|prednisone|5mg PO BID
48321824|NCT00680290|PROCEDURE|Exercise|Exercise x 8 weeks
48321825|NCT05893069|DRUG|Oxandrolone|oral oxandrolone for 12 weeks
48321826|NCT05893069|DRUG|Placebo|oral placebo for 12 weeks
48321827|NCT04658472|DRUG|SAR445088 (IV)|Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)
48321828|NCT04658472|DRUG|SAR445088 (SC)|Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)
48321829|NCT02874183|BEHAVIORAL|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
48321830|NCT03309787|BEHAVIORAL|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
48647145|NCT06289062|DRUG|Nab paclitaxel|260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
48647146|NCT06289062|PROCEDURE|biopsy|cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
48647147|NCT01294930|OTHER|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
48647148|NCT01558505|DEVICE|PEB|paclitaxel-eluting balloon angioplasty
48647149|NCT01558505|DEVICE|POBA|conventional balloon angioplasty
48647150|NCT01655446|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
48487590|NCT01302613|DRUG|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
48117737|NCT03769571|BEHAVIORAL|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
48487591|NCT01302613|DRUG|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
48487592|NCT01302613|DRUG|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
48647151|NCT01655446|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
48647152|NCT01655446|BEHAVIORAL|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
48647153|NCT01655446|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
47969301|NCT03570073|OTHER|Manual vitrification|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
47969302|NCT03570073|OTHER|Vitrification with GaviTM system|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
47969303|NCT02080234|DRUG|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
47969304|NCT02080234|RADIATION|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
47969305|NCT05661799|BEHAVIORAL|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
47969306|NCT05661799|BEHAVIORAL|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
48117738|NCT05181592|DRUG|Luspatercept|Once 1.75 mg/kg on Day 1 of each 21-day cycle for 24 weeks (9 cycles)
48117739|NCT05515900|DIETARY_SUPPLEMENT|Sodium|Daily sodium supplementation of 2000 mg.
48117740|NCT05515900|DIETARY_SUPPLEMENT|HMB|Daily HMB supplementation of 3 g.
48117741|NCT05515900|OTHER|Placebo|Placebo pills that will be identical to sodium or HMB supplementations
48117742|NCT03475524|DRUG|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
48117743|NCT03475524|DRUG|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
48117744|NCT03475524|DRUG|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
48117745|NCT03475524|DRUG|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
48117746|NCT03348371|OTHER|Ethanol|The intervention is two different administrationforms of ethanol, orally and i.v.
48117747|NCT03381781|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
48487593|NCT01302613|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
48487594|NCT01302613|RADIATION|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
48487595|NCT01302613|PROCEDURE|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
48647154|NCT01655446|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
48117748|NCT03381781|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
48117749|NCT03381781|DRUG|Cytarabine|15mg/m\^2,hypodermic injection,q12h,d1-7
48117750|NCT03262623|OTHER|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
48117751|NCT03262623|OTHER|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
48647155|NCT05196503|BIOLOGICAL|Treatment|"Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF."
48647156|NCT02912611|PROCEDURE|Education and Protocol based management|
48647157|NCT06675708|DIETARY_SUPPLEMENT|Creatine|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. One experimental group will receive creatine supplementation, and the other group will receive a placebo through dextrose administration. In both cases, the doses will be administered in the same manner to both groups
48117752|NCT05598580|DRUG|Lenalidomide|Lenalidomide capsules (25 mg) were administered orally on days 1-21 of a 28-day cycle for 24 weeks with continuous antiretroviral therapy.
47969307|NCT00393029|BIOLOGICAL|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
48321831|NCT05270642|PROCEDURE|Microwave Thermal guided by Plan for Microwave Thermal Field system|When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
48321832|NCT02705508|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
47969308|NCT00393029|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
47969309|NCT00393029|BIOLOGICAL|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.
47969310|NCT00393029|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
47969311|NCT00393029|DRUG|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
47969312|NCT05712759|OTHER|Influenza-like illness group|"Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.~ILI is defined by fever \> 37,8°C or/and cough or sore throat."
47969313|NCT06185283|DIAGNOSTIC_TEST|panoramic x-ray|Long cone paralleling technique and a film holder designed specifically for implant imaging were used for intraoral radiograph. To maintain the same film- implant distance and cone implant distance, a modification were carried out for the film holder. This modification is a hole drilled exactly above the implant fixture so the distance were maintained during subsequent film exposures. Through this modification, standardized radiographs were achieved.
47969314|NCT04174755|DRUG|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
47969315|NCT04174755|BEHAVIORAL|Standard of care|Diet and exercise advice for 40 weeks
47969316|NCT04959903|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT
48117753|NCT05598580|DRUG|Adenosylmethionine|Adenosylmethionine capsules (1000 mg, twice a day) were administered orally for 24 weeks with continuous antiretroviral therapy.
48321833|NCT02705508|DRUG|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
48321834|NCT02705508|DRUG|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
48321835|NCT02705508|RADIATION|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
48321836|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with investigational device
48321837|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with reference device
48321838|NCT03785795|DEVICE|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
48321839|NCT04101487|OTHER|Cash Transfer|Monthly cash transfers
47969317|NCT00030121|DRUG|recombinant human atrial natriuretic polypeptide|
47969318|NCT02088281|DRUG|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
47969319|NCT02036697|DRUG|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
48117754|NCT05384496|DRUG|Nivolumab and/or Ipilimumab|Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.
48117755|NCT05384496|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT upon local or oligometastatic progression. The prescribed dose of SBRT will be 30 Gy in 5 fractions.
48487596|NCT03412812|RADIATION|Dose Escalated Five Fraction Stereotactic Radiosurgery|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
48487597|NCT05820867|PROCEDURE|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
48487598|NCT05820867|PROCEDURE|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
48117756|NCT05384496|DRUG|axitinib|5mg twice daily
48321840|NCT04101487|OTHER|Cash Transfers and Nutrition Education|Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
48647158|NCT06675708|DIETARY_SUPPLEMENT|Dextrose|From the total sample obtained after recruitment, randomization will be performed using the SPSS statistical program, creating two groups. Dextrose group will be administered in the same manner as creatine to the experimental group. The doses will be prepared in the same way for both groups.
48321841|NCT06419517|DEVICE|EMG-triggered ES|The ES treatment protocol consisted of daily endovaginal electrostimulation sessions for four weeks. We used a portable unit EVOSTIM ®, which allowed us to use different frequencies and length of impulse and a probe Perisphera ® The average current intensity was adjusted according to the sensation of discomfort in each patient.
48321842|NCT06419517|OTHER|Pelvic Floor Muscle Training|Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
48647159|NCT04949087|PROCEDURE|Glenohumeral Injection|Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
48321843|NCT03292952|DRUG|KP415 oral capsule|Daily dose
48321844|NCT03292952|DRUG|Placebo oral capsule|Daily dose
48647160|NCT04499001|OTHER|Pharmacist's consultation|Information about bDMARDs management.
48647161|NCT01885338|DRUG|N-acetylcysteine (NAC)|
48647162|NCT01885338|DRUG|Inactive placebo capsule|
48647163|NCT03003065|DRUG|Temoporfin|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
48647164|NCT04343768|DRUG|Hydroxychloroquine|This Drug will be used in all arms.
48647165|NCT04343768|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms.
48647166|NCT04343768|DRUG|Interferon Beta-1A|This drug will be only used in Arm 1.
48117757|NCT00957411|BIOLOGICAL|cetuximab|Given IV
48321845|NCT00390416|DRUG|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
48321846|NCT04705441|BEHAVIORAL|SMART 2|Participants receiving the SMART intervention will participate in 8 group-format 45-60 minute sessions (up to 10 participants per group), which will be collaboratively delivered over Zoom by a Nurse Educator and a Peer Educator with epilepsy. Telephone call-in and supplemental printed materials will be available for those who do not have internet access. The initial group session portion of SMART will be completed over 10-12 weeks. Educational components address the challenges imposed by epilepsy and comorbidity, as well as problem-identification and goal-setting, while Peer Educators and the group format address adherence, social support/social isolation, and self-efficacy. Following group sessions, participants will have 3 brief (no more than 15 minutes) monthly web-based or telephone maintenance sessions conducted by the Nurse Educator. Telephone sessions will address on-going issues of epilepsy self-management, including treatment adherence.
48321847|NCT02262234|OTHER|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
48487599|NCT03776292|OTHER|monitoring|Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
48487600|NCT02470793|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
48487601|NCT02470793|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
48487602|NCT03001219|DRUG|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
48647167|NCT04343768|DRUG|Interferon Beta-1B|This drug will be only used in Arm 2.
48647168|NCT06572150|PROCEDURE|Deep Brain Stimulation - Minimal Electrophysiology|Participants will undergo standard work-up and follow-up for DBS, but with minimal intraoperative electrophysiological testing.
48647169|NCT06572150|PROCEDURE|Deep Brain Stimulation - Standard|Participants underwent DBS surgery with standard intraoperative electrophysiological testing.
48647170|NCT00713193|DRUG|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
48647171|NCT00713193|DRUG|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
48647172|NCT05557591|DRUG|BNT116|BNT116 is administered by IV injection.
48647173|NCT05557591|DRUG|Cemiplimab|Cemiplimab is administered Q3W by IV infusion
48117758|NCT00957411|DRUG|cisplatin|Given IV
48117759|NCT05984836|BEHAVIORAL|Implement health education|"Implement health education class for the rural mothers in the for of one session will take about 30 minutes and it will include the following:~First aid (fracture, burn, bleeding, injuries and food poising). Critique malpractice for injuries management behavior at home.~About 10 mothers will be included in the session. Each session will take 30 minutes (in the family health center), to cover all theoretical contents.~The researcher will use different teaching methods as demonstration and discussion, learning aids as handout, video and pictures."
48487603|NCT03001219|DRUG|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
48647174|NCT02976844|PROCEDURE|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
48647175|NCT05917964|DRUG|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
48647176|NCT05240976|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.
48117760|NCT02506257|DRUG|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
48647177|NCT05240976|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
48647178|NCT03997500|DRUG|normal saline|a bolus of normal saline was given followed by normal saline infusion
48647179|NCT03997500|DRUG|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
48647180|NCT02741193|DEVICE|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
47969320|NCT02036697|DRUG|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
47969321|NCT02036697|DRUG|Morphine|morphine 150 mcg.
47969322|NCT02036697|DRUG|Fentanyl|15 mcg
47969323|NCT03329573|DRUG|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
47969324|NCT03329573|DRUG|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
47969325|NCT01317160|DEVICE|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
47969326|NCT01930266|DIETARY_SUPPLEMENT|Experimental|
48321848|NCT02262234|OTHER|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
48321849|NCT04201977|OTHER|Foam Roller Recovery|Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
48321850|NCT04201977|OTHER|Active recovery|Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
47969327|NCT01930266|BEHAVIORAL|Active comparator|
47969328|NCT01699204|DIETARY_SUPPLEMENT|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
47969329|NCT01699204|OTHER|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
48117761|NCT02506257|DRUG|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
48117762|NCT02506257|DRUG|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
48117763|NCT02506257|DRUG|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
48321851|NCT04201977|OTHER|Immersion in cold water|Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
48321852|NCT04201977|OTHER|Passive recovery|Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
48487604|NCT03001219|DRUG|Placebo|Participants will receive intravenous infusion of placebo.
48487605|NCT03001219|DRUG|RO7123520|Participants will receive intravenous infusion of RO7123520.
48487606|NCT05715554|OTHER|Homeopathy|Individualized homoeopathic medicines on impregnated lactose pellets was prescribed based on totality of physical, emotional, and mental symptoms.
48487607|NCT00376974|BEHAVIORAL|American Academy of Ophthalmology Glaucoma Educational Tape|
47969330|NCT01699204|OTHER|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
47969331|NCT06139029|DRUG|3% normal saline|nebulization
47969332|NCT06139029|DRUG|steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline|nebulization
48117764|NCT02380209|OTHER|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
48117765|NCT06490991|DRUG|HRS-5965 tablets；HRS-5965 capsules|Medication regimen: 1 Drug: HRS-5965 tablets Medication regimen: 2 Drug: HRS-5965 capsules
48117766|NCT00044863|BIOLOGICAL|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
48117767|NCT00567333|OTHER|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
48117768|NCT00567333|OTHER|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
48117769|NCT06672718|DRUG|SPY002-091|Experimental
48117770|NCT06672718|OTHER|Placebo|Placebo
48117771|NCT02810080|DEVICE|Closed Loop Control Ventilation|Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software
48117772|NCT02810080|DEVICE|Manual Control Ventilation|Manual control ventilation using ZOLL 731 ventilator
48117773|NCT02146716|OTHER|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
48117774|NCT01533870|DRUG|NKTR-118|Oral 25 mg
48117775|NCT01533870|DRUG|Rifampin|Oral 600 mg
48117776|NCT01090544|DEVICE|Nasal Insufflation|Breathing therapy
48117777|NCT00743444|DRUG|AZD3355|65 mg capsules, oral, 3 single doses
48117778|NCT00743444|DRUG|Placebo|capsules, oral, 3 single doses
48487608|NCT04691180|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given intravenously
48487609|NCT04691180|DRUG|Placebo|Placebo given intravenously
48117779|NCT00596609|DRUG|Intrathecal Morphine|"* In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~* In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
48117780|NCT05992701|DEVICE|Directional deep brain stimualtion|Directional deep brain stimualtion in the treatment of Parkinson's disease using L305/L306 leads and G107R/G107 implanted pulse generators (Beijing Pins Medical Co.).
48117781|NCT01816958|OTHER|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
48321853|NCT00709358|OTHER|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
48487610|NCT02917226|OTHER|Clinical decision support and monitoring system|
48647181|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
48647182|NCT05109559|BIOLOGICAL|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
48117782|NCT04291729|DRUG|Ganovo+ritonavir+/-Interferon nebulization|Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
48117783|NCT03049969|DEVICE|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
48117784|NCT02729701|DRUG|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
48117785|NCT05702775|PROCEDURE|Endoscopic treatment group (EUS-GBD group|The placement of a endoscopic drain performed using a linear echoendoscope that allows the gallbladder to be punctured from the gastric antrum or the duodenal bulb to generate a cholecystogastrostomy or a cholecystoduodenostomy, respectively. Transmural gallbladder drainage will be performed by placing a metal apposition stent (LAMS) with the 15x15mm Hot AXIOS device (Boston Scientific) in the case of cholecystogastrostomy or 15x10 or 10x10mm in the case of cholecystoduodenostomy. Subsequently, the interior of the gallbladder will be irrigated with saline solution until the vesicular content comes out.
48117786|NCT00085436|BIOLOGICAL|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
48321854|NCT00709358|OTHER|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
48321855|NCT00225290|DRUG|Thalidomide(Thado)|
48321856|NCT04130828|DRUG|Ferrous Fumarate|Ferrous fumarate 200 mg PO PC
48487611|NCT02795637|DRUG|dasotraline|dasotraline 8mg capsule/day
48487612|NCT00117403|DRUG|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
48487613|NCT00117403|DRUG|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
48487614|NCT00117403|DRUG|Placebo capsules|one placebo capsule three times per day with meals
48487615|NCT00117403|DRUG|Placebo wafers|two placebo wafers three times per day with meals
48487616|NCT05622136|DRUG|Regorafenib Oral Product|Dose escalation strategy
48647183|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
48647184|NCT00666614|OTHER|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
48647185|NCT00666614|OTHER|Normal Hospital Environment|Normal Hospital Environment
48117787|NCT00085436|BIOLOGICAL|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
47969333|NCT04557878|DRUG|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
47969334|NCT04557878|BIOLOGICAL|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
48117788|NCT00085436|BIOLOGICAL|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
48117789|NCT00003516|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
48117790|NCT06107894|BIOLOGICAL|Tumor-infiltrating lymphocytes|After NMA Lymphodepletion, autologous TILs will be intravenous infused into patients.
48117791|NCT06107894|DRUG|IL-2|IL-2 will be subcutaneous administrated for 14 days following TILs infusion.
48647186|NCT00526851|OTHER|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
47969335|NCT05173662|PROCEDURE|Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process|Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
47969336|NCT00520936|DRUG|pemetrexed|1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
47969337|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
47969338|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
47969339|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
47969340|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
48117792|NCT05531032|OTHER|Phone Interview|Phone interview questionnaire
48117793|NCT00430872|BEHAVIORAL|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
48117794|NCT02903615|OTHER|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
48117795|NCT02903615|OTHER|Standard diet|Standard diabetes diet recommendations
48117796|NCT00002270|DRUG|Interferon alfa-2b|
48117797|NCT00002270|DRUG|Zidovudine|
48117798|NCT04753580|GENETIC|Stool collection|"The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g."
48117799|NCT04426461|BEHAVIORAL|Behavioral Activation|Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
48117800|NCT04426461|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
48117801|NCT04426461|BEHAVIORAL|Supportive therapy|Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
48647187|NCT04122690|BEHAVIORAL|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
48647188|NCT04122690|BEHAVIORAL|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
47969341|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
47969342|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
47969343|NCT04525378|OTHER|Mesenchymal stromal cell-based therapy|Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
48117802|NCT02047981|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
48117803|NCT02047981|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
48117804|NCT02709304|DRUG|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
48117805|NCT02709304|DRUG|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
48117806|NCT01227876|DRUG|Ster|prednisolone 1% ophthalmic suspension
48117807|NCT01227876|DRUG|Pred Fort|prednisolone 1% ophthalmic suspension
48117808|NCT01925339|DEVICE|Test (immediate restoration)|Test (immediate restoration)
48117809|NCT01925339|DEVICE|Control: delayed restoration|Control: delayed restoration
47969344|NCT05884996|OTHER|PNF training|Resistance training with elastic bands in diagonals of PNF
47969345|NCT01798511|PROCEDURE|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
47969346|NCT01798511|OTHER|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
47969347|NCT05000463|DRUG|Ozone|The participants will lay flat and the area of injection will be prepared with antiseptic. Maintenance of ultrasonography probe sterility was also guaranteed using a sterile barrier. Under sonographic guidance, superficial peroneal nerve, deep peroneal, sural , asphenous, and tibila nerves will be injected An ozone/oxygen mixture ( 25μg/ml) will be injected in each nerev
47969348|NCT05000463|DRUG|Convtrol group|The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
47969349|NCT02740881|OTHER|Counselor Training Methods|
47969350|NCT01966159|DEVICE|SYNERGY Investigational Device|percutaneous coronary intervention
47969351|NCT01966159|DEVICE|PE Plus Investigational Device|percutaneous coronary intervention
48117810|NCT01257555|DEVICE|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
48117811|NCT03842488|DRUG|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
48117812|NCT03842488|DRUG|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
48117813|NCT03146065|BIOLOGICAL|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
48117814|NCT03146065|DRUG|Placebo|Comparison of Placebo to different doses of PF-06730512
48117815|NCT01202955|DRUG|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
48647189|NCT06481072|OTHER|Digital patient education|This educative intervention includes both medical and psychological explanations, as well as basic strategies to manage pediatric FAPD. The medical information spans the topics of pain, functional abdominal pain and general advice in terms of child health, and the psychological information is based on cognitive-behavioural and pain management theoretical approaches. The intervention consists of six short, animated films with a total run-time of approximately 30 minutes. The films each cover one of the following topics; Why and how do we feel pain? What is functional abdominal pain? How to help: general advice, Thoughts, feelings and behaviour, Goals and strategies. The films are accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform that is recognised by the care provider as meeting current safety criteria and standards.
48117816|NCT01202955|DRUG|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
48117817|NCT04218266|DRUG|BAY2433334|Tablet, taken orally once a day.
48117818|NCT04218266|DRUG|Apixaban|Capsule, taken orally twice a day.
48117819|NCT04218266|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
48321857|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
48487617|NCT04277871|BEHAVIORAL|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
48487618|NCT05315622|OTHER|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
48487619|NCT05315622|OTHER|Placebo|"Manual tension without reaching the manipulation thrust"
48487620|NCT03458637|BEHAVIORAL|LITE Program and Usual Care|Family based lifestyle Intervention
48487621|NCT03458637|BEHAVIORAL|Usual Care|Usual care consisting of 3 visits to weight management clinic
48487622|NCT05192759|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
48487623|NCT06422338|OTHER|IMCI-enhanced by sTREM-1 levels (SoC + sTREM-1 POC)|IMCI-guidelines (standard of care) + Point-Of-Care Rapid Triage Test (POC-RTT) based on sTREM-1 quantification
48487624|NCT03801421|PROCEDURE|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
48487625|NCT03801421|PROCEDURE|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
48117820|NCT04218266|OTHER|Apixaban matching placebo|Capsule, taken orally twice a day.
48117821|NCT03634280|OTHER|Kinesio taping|In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
48321858|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
48487626|NCT01277718|DRUG|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
48117822|NCT05471635|BIOLOGICAL|COVID-19 Vaccine|All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
48117823|NCT01599117|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
48117824|NCT01599117|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
48117825|NCT02529995|DRUG|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
48321859|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
48321860|NCT00518921|DRUG|Placebo|Placebo, double dummy
48321861|NCT01147081|BIOLOGICAL|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
48321862|NCT03335618|OTHER|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
48321863|NCT03335618|OTHER|Passive Activity Monitoring|Passive step tracking without check-ins
48321864|NCT01017809|DRUG|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
48321865|NCT00514436|BEHAVIORAL|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
48321866|NCT05605041|DEVICE|Headspace|Headspace is an app that allows users to practice mindfulness through guided meditation
48321867|NCT01469806|DEVICE|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
48487627|NCT01277718|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
48487628|NCT06124274|BEHAVIORAL|Protein tracer drink|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13 Carbon(13C)\]-leucine.
48487629|NCT03801941|DEVICE|wearing ATLAS device during evaluation at 4th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
48487630|NCT03801941|OTHER|wearing ATLAS device during evaluation at 5th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
48117826|NCT02529995|DRUG|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
48117827|NCT04975945|DRUG|Ceftriaxone Sodium|Intravenous vs local action
48117828|NCT00687167|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
48117829|NCT00687167|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
48117830|NCT00247208|DEVICE|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
48117831|NCT00247208|DEVICE|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
48117832|NCT03639350|BEHAVIORAL|IER+MED group|Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.
48117833|NCT03639350|BEHAVIORAL|DASH group|Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
48117834|NCT05834946|OTHER|Megagen implant placement|Megagen implant with sand-blasted, large-grit, acid-etched (SLA) and nano-calcium ions incorporated surface
48117835|NCT05834946|OTHER|Biomate-Swiss implant|Biomate-Swiss implant with precision dimension laser (PDL) surface
48117836|NCT03429998|DRUG|evolocumab|evolocumab 140 mg/biweekly
48117837|NCT03429998|DRUG|evolocumab and LDL apheresis|evolocumab 140 mg/biweekly LDL-apheresis monthly
48117838|NCT03429998|PROCEDURE|LDL apheresis|LDL apheresis biweekly
48647190|NCT06481072|OTHER|Digital patient education and iCBT|This includes the educative intervention and a fully digital, four session version of the Aim to Decrease Anxiety and Pain Treatment (ADAPT), a CBT treatment program for FAPD. The treatment focuses on pain-management through the following core elements; The Pain-Gate Theory, breathing and relaxation strategies, calming statements, activity pacing, problem solving and behavior activation. This intervention is also accessed by the patient via 1177.se and maintained on the SoB (Stöd- och behandling) platform.
48117839|NCT01595061|DRUG|Cisplatin|Given IV
48117840|NCT01595061|DRUG|Gemcitabine Hydrochloride|Given IV
48117841|NCT01595061|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48117842|NCT01595061|PROCEDURE|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
48117843|NCT00151424|DRUG|asenapine|Asenapine 5-10mgBID
48117844|NCT00151424|DRUG|Placebo|Matched against asenapine and olanzapine
48647191|NCT05208957|OTHER|No intervention|No intervention
48647192|NCT03374332|DRUG|Gemtuzumab Ozogamicin (GO)|Patients will be given gemtuzumab ozogamicin on days 1,4, and 7. Capped at 4.5mg individual doses. Total doses capped at 13.5mg.
48647193|NCT03374332|OTHER|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of CD3+ cells and maximum of CD3+ cells/kg irrespective of the number of CD34+ cells.
48647194|NCT05282394|PROCEDURE|Abdominal massage|abdominal massage
47969352|NCT02077244|BEHAVIORAL|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
47969353|NCT01525810|DRUG|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
48117845|NCT00151424|DRUG|Olanzapine|10-20 mg QD
48117846|NCT05997966|OTHER|Progresive Resistance Exercises|At the beginning of the study, there will be a home visit (week 0) where the exercises will be taught. Exercise brochures explaining the exercises in written and visual form will also be given to each participant during the first and subsequent home visits. After the first home visit, individuals will be asked to keep an exercise diary prepared by the physiotherapist in order to control the exercises, the occurrence of side effects and dependence on the treatment, and information will be obtained from the individuals by phone calls every week. Two more home visits will take place in weeks 5 and 9 to further the IDE program. Apart from these visits and phone calls, the participant will be allowed to call the physiotherapist if needed. In the exercise group, the 12-week home-based IDE program will be applied 2 sets/day for 3 days/week (on non-consecutive days).
48647195|NCT05282394|OTHER|Reading|guidance given to parents about reading with baby
48647196|NCT00103701|DRUG|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
48647197|NCT03405753|DIETARY_SUPPLEMENT|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
48117847|NCT05997966|OTHER|No intervation|After a general education about osteoarthritis in the control group, 30 minutes of walking will be requested twice a week, and no other intervention will be made.
48117848|NCT01434862|DRUG|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
48117849|NCT01434862|DEVICE|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
48117850|NCT01434862|DRUG|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
48117851|NCT05447975|OTHER|Tai Chi training|"As for Tai Chi training, standardized Tai Chi was taught by professional Tai Chi coaches from Sino Taiji of Fuxing International in classes: Qishi (Starting Posture), Shangsanbu (Twist Step), Yema Fenzong(Part the Wild Horse's Mane on Both Side), Jingang Daozhui (Buddha's warrior attendant pounds mortar), Shoushi (Closing Posture). Patients participated in this class were trained, twice a week, 60 min per time. PD patients whose attendance rate less than 75% were excluded."
48321868|NCT01747785|OTHER|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
48321869|NCT01747785|OTHER|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
48647198|NCT03405753|DIETARY_SUPPLEMENT|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
48647199|NCT00846482|DRUG|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
48647200|NCT02853084|DRUG|HL2351|The dose will be adjusted based on disease activities
48647201|NCT05704699|BEHAVIORAL|eTRE|eating between 0800h and 1600h daily
48647202|NCT05704699|BEHAVIORAL|eTRE with BISC|eating between 0800h and 1600h daily and completing 3 sessions of BISC per week of study duration
48647203|NCT01201044|DRUG|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
48647204|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
48647205|NCT01201044|RADIATION|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
48647206|NCT01201044|DRUG|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
48647207|NCT04938531|OTHER|Exercise|Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
48647208|NCT03154567|DRUG|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
47969354|NCT01780818|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
47969355|NCT01780818|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
47969356|NCT01780818|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
48117852|NCT01198275|DRUG|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
48117853|NCT01198275|DRUG|Placebo|1.0 g of olive oil,one capsule twice a day
48647209|NCT05692557|DEVICE|Virtual reality|"The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there."
48321870|NCT01747785|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
48321871|NCT00250991|DRUG|activase|
48321872|NCT00250991|DRUG|integrilin|
48321873|NCT04782193|BIOLOGICAL|CD19 and CD22 targeted prime CAR- T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
48321874|NCT04883658|DRUG|CKD-348(2)|QD, PO
48321875|NCT04883658|DRUG|CKD-828, D097, D337|QD, PO
48647210|NCT05692557|PROCEDURE|Progressive muscle relaxation|The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
48321876|NCT03377244|BEHAVIORAL|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
48321877|NCT03377244|BEHAVIORAL|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
48321878|NCT03377244|BEHAVIORAL|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
48321879|NCT05240638|DEVICE|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
48321880|NCT02299765|DRUG|Gefitinib|patients in arm A will be given gefitinib as target therapy
48321881|NCT02299765|DRUG|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
48117854|NCT01198275|DRUG|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
48321882|NCT02299765|DRUG|carboplatin|patients in arm A will be given carboplatin chemotherapy
48117855|NCT01198275|DRUG|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
48117856|NCT03123198|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
48321883|NCT02126943|DRUG|Opsumit (macitentan)|10 mg tablets
48321884|NCT00050791|DRUG|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
48321885|NCT00050791|BEHAVIORAL|Very Low Calorie Diet|placebo injections
48321886|NCT03136133|DIETARY_SUPPLEMENT|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
48321887|NCT03600948|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
48321888|NCT06330285|OTHER|e-learning|"CPET (Cardiopulmonary exercise test) e-learning application The content, planning and design of 4 lessons are as follows:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
48321889|NCT06330285|OTHER|face to face learning|"CPET (Cardiopulmonary exercise test) face to face education. The content, planning and design of 4 lessons are as follows:~Contents:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
48321890|NCT05557734|PROCEDURE|caudal block|injection of local anesthestic through the scral hiatus into the sacral canal to reach caudal epidural space
48321891|NCT05557734|PROCEDURE|perianal block|local anesthestic infiltration in the perianal area to block terminal branches of the nerves supplying the anal canal
48117857|NCT03924882|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
48117858|NCT03101410|BEHAVIORAL|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
48321892|NCT01025011|DEVICE|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
48321893|NCT04566822|BEHAVIORAL|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
48321894|NCT04566822|BEHAVIORAL|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
47969357|NCT01511198|DRUG|liraglutide|Injected subcutaneously once daily
48117859|NCT03101410|BEHAVIORAL|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
48117860|NCT01038648|DRUG|Sitagliptin|100mg/day
48117861|NCT01038648|OTHER|life style modification at base line|Advice on physical activity, diet and drug adherence.
48117862|NCT00933400|DIAGNOSTIC_TEST|CT Coronary Angiography (CTCA)|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
48321895|NCT04566822|BEHAVIORAL|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
48647211|NCT04873193|DEVICE|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
48647212|NCT04858997|DRUG|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
48647213|NCT04858997|DRUG|AI|AI, orally once daily (continuously)
48117863|NCT00933400|PROCEDURE|Traditional Strategy|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
48117864|NCT05389436|PROCEDURE|Ambulatory care|The surgery is performed in ambulatory setting
48117865|NCT05389436|PROCEDURE|Inpatient care|The surgery is performed during inpatient care
48117866|NCT06335446|OTHER|Novel mapping algorithm|Signals will be collected during the catheter ablation. These signals STAR maps will be created post procedure and these will be compared to the conventional maps used during the atrial tachycardia ablation. This will be used to validate the STAR maps created.
48117867|NCT06193005|OTHER|no intervention|no intervention
48647214|NCT03364257|DIAGNOSTIC_TEST|iDTECT Blood|Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
47969358|NCT01511198|DRUG|metformin|1000 mg twice daily, administered orally
48117868|NCT00807144|DRUG|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
48117869|NCT00807144|DRUG|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
47969359|NCT01022229|DIETARY_SUPPLEMENT|Compound Natural Health Product|"* 15-35 mg zinc citrate~* 150-350 mg magnesium lactate~* 30-70 mg pyridoxine hydrochloride~* 150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
47969360|NCT01022229|DIETARY_SUPPLEMENT|Placebo|Placebo
48117870|NCT05317910|OTHER|MUSIC CARE|"Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique \[1, 2\] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed."
48117871|NCT04210505|DRUG|Povidone-Iodine Topical Ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
48321896|NCT04566822|BEHAVIORAL|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
48321897|NCT03892746|DEVICE|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.
48647215|NCT05518981|DEVICE|Respiratory Remote Patient Monitor (Spire Health Tag)|"The RPM service, tailored to chronic respiratory disease patients, utilizes a system that includes three components: undergarment-adhered cardiorespiratory sensors, in-home data transmission hub, and web-based clinical dashboard. The sensors are a set of six proprietary, skin-safe devices that include sensors for intermittent photoplethysmography, continuous respiratory force, and tri-axis accelerometers for activity. Clinical liaisons monitor deviations from patient-specific baselines and contact subjects for a risk assessment call, including questions about symptoms. If a subject fails the risk assessment, they are escalated to the site to be seen, and potentially treated, by their pulmonologist."
48647216|NCT01919476|OTHER|Bagel|
48647217|NCT01919476|OTHER|Cream Cheese|
48647218|NCT01919476|OTHER|Almond Butter|
48647219|NCT05168592|BEHAVIORAL|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
47969361|NCT02528929|DIETARY_SUPPLEMENT|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
47969362|NCT03185767|OTHER|blood sampling|blood sampling
47969363|NCT05249374|DRUG|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
47969364|NCT05249374|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
47969365|NCT05050539|BEHAVIORAL|Low Intensity|5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.
47969366|NCT05050539|BEHAVIORAL|High Intensity|Low intensity implementation strategies with the addition of holistic individualized facilitation and tailored educational materials.
47969367|NCT05180279|BEHAVIORAL|7-day sleep lab|Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
48321898|NCT03892746|DEVICE|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
48321899|NCT03162055|DRUG|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
47969368|NCT05862415|OTHER|therapeutic Exercise|"The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed. The step loading periodization principle was taken into account in both resistance training and aerobic exercises.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc.~For the aerobic training: Intensity was established between 50-65% and 80-85% of HRmax for both groups (SAG and ASG). Aerobic training includes walking and running periods and was carried out on a 400 m outdoor track. In periodization, especially 1st-4th."
47969369|NCT04905485|BEHAVIORAL|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
47969370|NCT02517567|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
48321900|NCT03162055|DRUG|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
48321901|NCT00661349|DRUG|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
48321902|NCT00661349|DRUG|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
48647220|NCT05168592|BEHAVIORAL|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
48321903|NCT05669300|PROCEDURE|Yilmaz Suturation|uterine closure with Yilmaz Technique and single layer continue locked suturation
48647221|NCT05106374|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
48647222|NCT05106374|PROCEDURE|Cognitive Assessment|Complete thinking test
48647223|NCT05106374|OTHER|Physical Performance Testing|Complete walking test
48647224|NCT05106374|OTHER|Quality-of-Life Assessment|Ancillary studies
48647225|NCT05106374|OTHER|Questionnaire Administration|Complete questionnaire
48647226|NCT04872647|BEHAVIORAL|Phone-Based Health Coaching Utilizing Lifestyle Action Plans|Culturally sensitive health coaches trained in motivational interviewing provide 10-20 minutes of weekly phone-based health coaching. They not only guide the patient in creating a SMART goal, but assess and build off of the previous weeks' goal and problem-solve with the patient. During the week, the coach and patient text regarding daily blood glucose monitoring with real-time feedback and coaching about the implementation of the patients' goal.
48117872|NCT04210505|OTHER|Standard Care|Control group will receive standard care as provided by the dialysis center
48117873|NCT05031390|PROCEDURE|Physiotherapist-led training|Patients will undergo a 12-week physiotherapist-led training program consisting of 8 supervised sessions and home-based training in between
47969371|NCT02517567|DEVICE|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
48117874|NCT01764464|DRUG|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
48117875|NCT01764464|DRUG|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
48117876|NCT00857545|OTHER|Laboratory Biomarker Analysis|Correlative studies
48117877|NCT00857545|BIOLOGICAL|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
48117878|NCT00857545|BIOLOGICAL|Saponin-based Immunoadjuvant OBI-821|Given SC
48117879|NCT03389191|DRUG|Acyclovir|
48117880|NCT03385681|OTHER|Tailored Educational Intervention|The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
48117881|NCT06111040|OTHER|Measurement|The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
48117882|NCT00886951|DRUG|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
48117883|NCT06555159|BEHAVIORAL|Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling)|Aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate. (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload
48117884|NCT06555159|BEHAVIORAL|Control group: Continuous aerobic physical exercise|Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax, keeping this intensity for the 8 week intervention period.
48117885|NCT00712335|DRUG|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
48117886|NCT00712335|DRUG|Montelukast|PO 10 mg QHS for 3 weeks
48117887|NCT00712335|DRUG|Salmeterol|DPI 50mg BID for 3 weeks
48117888|NCT02296424|DRUG|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
47969372|NCT02517567|DEVICE|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
47969373|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
47969374|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
47969375|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
47969376|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
47969377|NCT03253276|DRUG|Obeticholic acid|Placebo-controlled
47969378|NCT03253276|DRUG|Placebos|
47969379|NCT05009121|DIAGNOSTIC_TEST|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
47969380|NCT02849678|DRUG|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
47969381|NCT02849678|DRUG|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
47969382|NCT01348503|DRUG|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
47969383|NCT01348503|DRUG|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
47969384|NCT01411202|DRUG|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
47969385|NCT01411202|OTHER|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
48647227|NCT04957082|BEHAVIORAL|Culturally Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.
48647228|NCT04957082|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
48647229|NCT04082273|DEVICE|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
47969386|NCT01417442|GENETIC|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
47969387|NCT03046004|OTHER|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
47969388|NCT03046004|OTHER|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
47969389|NCT03778762|PROCEDURE|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
47969390|NCT03778762|PROCEDURE|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
47969391|NCT03346278|BEHAVIORAL|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
47969392|NCT01765088|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
47969393|NCT01765088|DRUG|α-IFN|3mIU (3million) D1，3，5
47969394|NCT04007081|PROCEDURE|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
47969395|NCT04007081|DIAGNOSTIC_TEST|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
47969396|NCT04007081|OTHER|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
47969397|NCT04007081|OTHER|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
47969398|NCT00996645|OTHER|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
47969399|NCT03598530|PROCEDURE|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
47969400|NCT01966900|BIOLOGICAL|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
47969401|NCT02495168|DRUG|Generic Budesonide/Formoterol Fumarate Dihydrate|Oral inhalation, generic formulation of the brand-name product.
47969402|NCT02495168|DRUG|Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)|Oral inhalation, brand-name product.
47969403|NCT02495168|DRUG|Placebo|Oral inhalation, no active ingredient.
47969404|NCT00257478|DRUG|YM155|
47969405|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils|4 months consumption
47969406|NCT01611649|DIETARY_SUPPLEMENT|Formula containing plant oils|4 months consumption
48321904|NCT04312438|DIAGNOSTIC_TEST|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
48321905|NCT02723136|DEVICE|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
48647230|NCT04082273|OTHER|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
48321906|NCT04667234|DRUG|AMG 510|Administered as an oral tablet.
48321907|NCT01728753|DRUG|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
48321908|NCT01728753|DRUG|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
48321909|NCT01728753|DRUG|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
48321910|NCT01728753|DRUG|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
47969407|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
47969408|NCT01191333|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
47969409|NCT01191333|DEVICE|Sham Device|Placebo Device that simulates active rTMS treatment
47969410|NCT00139698|DRUG|olmesartan alone or in combination with hydrochlorothiazide|
48321911|NCT02292316|BEHAVIORAL|gait and cognitive assessments|several tests are given in each domain
48321912|NCT02292316|BIOLOGICAL|blood sample|routine analyses in rheumatology such blood count and 25OH-D
48321913|NCT02292316|OTHER|osteodensitometry|Looking for osteoporosis
48647231|NCT06034431|OTHER|Ride Share|"The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes"
48647232|NCT06366919|DIAGNOSTIC_TEST|Alexander Technique (AT)|The AT arm of study will involve participants receiving indivisual sessions. These sessions will typically focus on non specific neck pain management improving posture , movement coordination and body awareness through gentle hands on guidance
48321914|NCT00037635|DRUG|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
48321915|NCT00037635|DRUG|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
48647233|NCT06366919|DIAGNOSTIC_TEST|Feldenkrais Technique (FT)|The FT arm of study will involve participants recieving individual sessions. These sessions will typically focus on pain improvement, maintaining alignment, reducing muscle tension and promoting ease of movement.
48647234|NCT00002656|DRUG|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
47969417|NCT00011076|DRUG|Pirfenidone|
47969418|NCT01412515|DRUG|everolimus|everolimus per os 10mg per day
47969419|NCT05475132|OTHER|Exergaming|exercise games will be done for a total of 8 weeks ,100min of exergaming/week (5 days × 20 min).
47969420|NCT05475132|OTHER|Conventional Dexterity Exercises|Exercises traditionally used for dexterity will be done for 8 weeks, 100min of exercises/week (5days × 20 min)
47969421|NCT01523990|DRUG|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
47969422|NCT01523990|DRUG|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
47969423|NCT01998529|DRUG|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
48321916|NCT03716986|DIAGNOSTIC_TEST|MRI Oxygen Saturation Map|Calculation of the oxygen saturation map of gliomas cases
48647235|NCT03094377|OTHER|Multisensory therapy|Sensory stimulation, motor training and ADL training
48647236|NCT03094377|OTHER|Conventional training|Motor training and ADL training
48647237|NCT04677361|COMBINATION_PRODUCT|MILs™ in Combination with Pembrolizumab|Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
48647238|NCT02769481|DRUG|Bexagliflozin|20 mg, tablet
47969424|NCT01998529|DRUG|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
47969425|NCT03954145|PROCEDURE|Enamel pumicing before bonding the lingual retainer.|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors."
47969426|NCT03954145|PROCEDURE|Enamel sandblasting before bonding the lingual retainer.|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
47969427|NCT06177327|OTHER|Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.|Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
47969428|NCT00002098|DRUG|Lentinan|
47969429|NCT00002098|DRUG|Didanosine|
47969430|NCT00603668|BIOLOGICAL|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
48321917|NCT00466583|DRUG|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
48321918|NCT01405118|DRUG|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
48321919|NCT00347763|PROCEDURE|10% permethrin in water applied as low volume spray|
48321920|NCT00061919|DRUG|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
48647239|NCT02769481|DRUG|Placebo for Bexagliflozin|inactive tablet to match active comparator bexagliflozin
48647240|NCT02769481|DRUG|Glimepiride|2, 4 or 6 mg, capsule
48647241|NCT02769481|DRUG|Placebo for Glimepiride|inactive capsules to match active comparator glimepiride
48647242|NCT00394225|DRUG|Oxygen|
48647243|NCT00394225|DRUG|Helium|
48647244|NCT03829683|DRUG|Vitamin C|200mg/kg/24hours
48647245|NCT03829683|DRUG|Dextrose 5% in water|50mL intravenously every 6 hours
48647246|NCT03320083|BEHAVIORAL|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
48647247|NCT03419624|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg tablet once daily
48647248|NCT03419624|DRUG|Exenatide 2 mg [Bydureon]|Exenatide 2 mg injection once weekly
48647249|NCT03419624|DRUG|Placebo Oral Tablet|Placebo oral tablet once daily
48647250|NCT03419624|DRUG|Placebo injection|Placebo injection once weekly
48647251|NCT03419624|DRUG|Insulin|daily Insulin injections
48647252|NCT03419624|DRUG|Metformin, if taken before|If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
48647253|NCT02636335|DEVICE|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
48647254|NCT04130425|DEVICE|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
48647255|NCT04130425|DEVICE|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
48647256|NCT04130425|DEVICE|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
48647257|NCT05227014|PROCEDURE|Colorectal resection|All patients undergoing elective colorectal surgery with anastomosis will be included in a prospective database after written informed consent.
48647258|NCT04469946|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
48647259|NCT00534586|DRUG|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
48647260|NCT00534586|DRUG|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
48647261|NCT00534586|DRUG|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
48647262|NCT00534586|DRUG|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
48647263|NCT06563713|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 0 following protocol requirements
48647264|NCT06563713|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements
48647265|NCT02796482|DIETARY_SUPPLEMENT|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
48321921|NCT00061919|DRUG|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
48321922|NCT05273840|DIETARY_SUPPLEMENT|Ivital Control|Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.
48647266|NCT04551053|DRUG|parsaclisib|parsaclisib will be administered QD orally
48647267|NCT04551053|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
48647268|NCT04551053|DRUG|placebo|placebo will be administered QD orally
48647269|NCT06019728|DRUG|AGALSIDASE BETA (GZ419828)|Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
48647270|NCT06019728|DRUG|Acetaminophen|Tablet or solution; Oral
47969431|NCT02496611|DRUG|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
47969432|NCT02496611|DRUG|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
48321923|NCT05273840|BEHAVIORAL|lifestyle intervention|Patients will receive lifestyle interventions.
48321924|NCT03102359|DRUG|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
48647271|NCT06019728|DRUG|Diphenhydramine|Tablet or solution; Oral
48647272|NCT06019728|DRUG|Dexamethasone|Tablet or solution; Oral
48647273|NCT06019728|DRUG|Montelukast|Tablet or chewable tablet or oral granules; Oral
48647274|NCT01690325|DRUG|Docetaxel|
48647275|NCT01690325|DRUG|Trastuzumab|
48647276|NCT01690325|DRUG|Bevacizumab|
48647277|NCT01690325|DRUG|Epirubicin|
48321925|NCT03102359|DEVICE|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
48321926|NCT04556370|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
48647278|NCT01690325|DRUG|Cyclophosphamid|
48647279|NCT06569329|DEVICE|GentleWave System Root Canal Therapy|This device has 510k market approval for its intended use within this study.
48647280|NCT06569329|DEVICE|EdgePro Laser Root Canal Therapy|This device has 510k market approval for its intended use within this study.
48647281|NCT06569329|DEVICE|The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy|This device has 510k market approval for its intended use within this study.
48647282|NCT00684554|DRUG|Buprenorphine|Dose is determined according to the participants' individual need.
48117889|NCT04206098|OTHER|Factors associated with Hospital admission for an Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD)|Develop a descriptive predictive model fo factors that influence clinical characteristic of patients that require hospital admission
48321927|NCT04556370|DRUG|Norepinephrine|Different infusion dose of norepinephrine simultaneous with subarachnoid block
48487631|NCT03297528|DRUG|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
48487632|NCT00110695|DRUG|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. \[or if given with trastuzumab 75 mg/m2 IV over 15 min.\]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
47969433|NCT00176228|DRUG|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
47969434|NCT03612505|BEHAVIORAL|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~* Introduction (10 minutes)~* Lesson on \*Early Childhood Development\* topic (20 minutes)~* Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~* Observe caretakers one-on-one in play role with the child (25 minutes)~* Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
47969435|NCT05063487|OTHER|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
47969436|NCT05063487|OTHER|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
47969437|NCT05119205|DIAGNOSTIC_TEST|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
47969438|NCT05310890|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
47969439|NCT05310890|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
47969440|NCT00164775|DRUG|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
47969441|NCT00164775|DRUG|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
47969442|NCT00721500|DEVICE|etafilcon A|contact lens
48321928|NCT03230162|DRUG|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
48321929|NCT03230162|DRUG|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
48321930|NCT02070406|DRUG|cyclophosphamide|Given IV
48321931|NCT02070406|DRUG|fludarabine phosphate|Given IV
48321932|NCT02070406|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
47969443|NCT00721500|DEVICE|narafilcon A|contact lens
47969444|NCT00674245|DRUG|Pantoprazole|40 mg once daily for 4 weeks
47969445|NCT00674245|DRUG|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
47969446|NCT00674245|DRUG|placebo|40 mg once daily for 4 weeks
47969447|NCT01308554|DRUG|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
48117890|NCT03264443|BEHAVIORAL|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
48117891|NCT03264443|BEHAVIORAL|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
48321933|NCT02070406|BIOLOGICAL|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
48321934|NCT02070406|BIOLOGICAL|aldesleukin|Given SC
48321935|NCT02070406|RADIATION|fludeoxyglucose F 18|Correlative studies
48321936|NCT02070406|PROCEDURE|positron emission tomography|Correlative studies
48487633|NCT02017730|DRUG|BMS-986020|
48487634|NCT02017730|DRUG|[11C]BMT-136088|
48117892|NCT01071408|OTHER|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
48117893|NCT04992156|DRUG|Palbociclib|Palbociclib 125mg/d
48321937|NCT02070406|OTHER|laboratory biomarker analysis|Correlative studies
48321938|NCT02737735|DRUG|standard chemotherapy medicine combined with Chinese herbs|
48117894|NCT03929770|PROCEDURE|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
48487635|NCT05483582|DEVICE|4-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
48487636|NCT05483582|DEVICE|2-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
48487637|NCT01991665|OTHER|Digital examination|
48487638|NCT01991665|OTHER|Sonography evaluation|
48647283|NCT01470820|OTHER|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
48647284|NCT00636337|BEHAVIORAL|Attention Training|Computer program training for attention difficulties.
48647285|NCT00636337|BEHAVIORAL|Placebo|Comparison computer program
47969448|NCT01308554|DRUG|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
47969449|NCT01819831|RADIATION|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
47969450|NCT01819831|PROCEDURE|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
47969451|NCT03200405|DEVICE|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
47969452|NCT03200405|DEVICE|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
47969453|NCT01881360|OTHER|Gluten-free diet|A diet that is free of the gluten component
47969454|NCT01881360|OTHER|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
47969455|NCT05731778|DRUG|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
47969456|NCT05731778|DRUG|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
47969457|NCT05867745|OTHER|Interview|As previously specified
47969458|NCT05867745|OTHER|Survey|As previously specified
47969459|NCT05867745|OTHER|Letter to a friend (autoethnography)|As previously specified
47969460|NCT00465374|PROCEDURE|Change ventilatory parameters with stress index monitoring|
47969461|NCT03604380|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
48117895|NCT03929770|PROCEDURE|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
48117896|NCT00939978|DRUG|rhEPO|recombinant human erythropoietin(rhEPO)
48117897|NCT04287114|BEHAVIORAL|Acute exercise|Acute exercise with different exercise intensities
48117898|NCT05094050|DRUG|ABBV-951|Continuous Subcutaneous Infusion (CSCI)
48321939|NCT02737735|DRUG|standard chemotherapy medicine|
48321940|NCT03190226|PROCEDURE|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
48487639|NCT01332578|DRUG|Paracetamol|Present in both test and active comparator
48487640|NCT01332578|DRUG|Phenylephrine|Test product
48487641|NCT01332578|DRUG|Ascorbic Acid|Test product
48487642|NCT00094081|DRUG|tirapazamine (SR259075)|
48487643|NCT00094081|DRUG|cisplatin|
48487644|NCT00094081|PROCEDURE|Radiation Therapy|
48487645|NCT06070987|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 100 units. The dose range of each target muscle is as below:100 units in rectus femoris.
48647286|NCT03785847|DIAGNOSTIC_TEST|Ventica|Impedance pneumography measurement
48647287|NCT02191995|BEHAVIORAL|yoga|
48647288|NCT01608308|DRUG|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
48117899|NCT01535144|DEVICE|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
48321941|NCT03190226|PROCEDURE|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
48321942|NCT01415856|DEVICE|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
48321943|NCT01415856|DEVICE|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
48321944|NCT01478399|DRUG|PB1023 Injection|90 mg Dose
48321945|NCT04877314|OTHER|Intermittent fasting|30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
48321946|NCT06191965|DRUG|MitoQ|"MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ."
48321947|NCT06191965|DRUG|Placebo|Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
48321948|NCT03337555|DEVICE|McGrath|McGrath videolaryngoscope
48321949|NCT03337555|DEVICE|Pentax|Pentax videolaryngoscope
48647289|NCT01608308|DRUG|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
47969462|NCT03604380|OTHER|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
47969463|NCT03851705|DRUG|Inclisiran Sodium for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
47969464|NCT03851705|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection)
47969465|NCT03851705|DRUG|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
47969466|NCT02846311|DEVICE|Flu Test|
47969467|NCT04053114|OTHER|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
47969468|NCT01131754|OTHER|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
47969469|NCT03803397|BIOLOGICAL|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
47969470|NCT03275454|DRUG|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
47969471|NCT03275454|DRUG|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
47969472|NCT03619954|BIOLOGICAL|NK cells infusion|"Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10\^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10\^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times"
48117900|NCT01535144|DEVICE|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
48117901|NCT01551407|DRUG|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
48117902|NCT01082809|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
48117903|NCT05997836|OTHER|Implementation Facilitation|Implementation Facilitation involves and External Facilitator (from outside of the participating medical center) and an Internal Facilitator (from inside the participating medical center) working together to help BHIP teams within the site adopt care practices that are more consistent with the CCM
48117904|NCT05997836|OTHER|Centralized Technical Assistance|Centralized Technical Assistance involves having external experts available for ad hoc consultation related to collaborative BHIP care practices.
48117905|NCT06034665|OTHER|Exercise|All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.
48321950|NCT03337555|DEVICE|Macintosh|Macintosh direct laryngoscope
48321951|NCT02812446|OTHER|IAI infection|
48321952|NCT02812446|OTHER|Staphylococcus aureus nasal carriage infection|
48321953|NCT01547468|PROCEDURE|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
48647290|NCT00854737|DIETARY_SUPPLEMENT|cytidine|cytidine (2g po daily for 4 months)
48647291|NCT00854737|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
48117906|NCT03767907|BEHAVIORAL|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
48647292|NCT00854737|DRUG|placebo|sugar pill
48647293|NCT03199651|OTHER|Best Practice|Receive usual care
48117907|NCT03767907|BEHAVIORAL|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
48117908|NCT02540746|BEHAVIORAL|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
48117909|NCT02540746|BEHAVIORAL|Motivational Enhancement|Three week Motivational Enhancement group
48117910|NCT02540746|BEHAVIORAL|Family Skills Training|12-week group-based family skills training using Family Connections model
48117911|NCT01118377|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
48117912|NCT01118377|RADIATION|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
48117913|NCT03950778|DRUG|Human albumin|Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
48117914|NCT04567355|BEHAVIORAL|Migraine Manager|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
48117915|NCT00187941|DRUG|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
48321954|NCT01547468|PROCEDURE|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
48321955|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121 without MF59®
48321956|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241 without MF59®
48321957|NCT05664334|BIOLOGICAL|Placebo|Diluent
48321958|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, without MF59®
48321959|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, without MF59®
48321960|NCT05664334|BIOLOGICAL|IVX-241|225 mcg of IVX-241, without MF59®
48321961|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, with MF59®
48321962|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241, with MF59®
48321963|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, with MF59®
48321964|NCT05664334|OTHER|MF59®|MF59® as an adjuvant
48487646|NCT06070987|OTHER|BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot after BoNT-A injected in the affected rectus femoris, then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
47969473|NCT04954703|OTHER|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
48647294|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
48647295|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
47969474|NCT04954703|OTHER|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
47969475|NCT05438056|OTHER|education with mobile application|providing training to mothers of premature babies with a mobile application
47969476|NCT01806298|DRUG|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
47969477|NCT01145443|OTHER|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
48117916|NCT02154217|DRUG|Bimatoprost|
48117917|NCT02154217|DRUG|Latanoprost/Timolol|
48117918|NCT03816228|DRUG|F 18 T807 Flortaucipir|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
48117919|NCT04711213|DRUG|Dexamethasone Dose 1|Dexamethasone ophthalmic suspension dose 1
48117920|NCT04711213|DRUG|Dexamethasone Dose 2|Dexamethasone ophthalmic suspension dose 2
48117921|NCT04711213|DRUG|Placebo Dose 1|Placebo suspension dose 1
48117922|NCT04711213|DRUG|Placebo Dose 2|Placebo suspension dose 2
48321965|NCT01094730|DEVICE|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
48321966|NCT01094730|DEVICE|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
48321967|NCT03297437|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
48647296|NCT03199651|OTHER|Laboratory Biomarker Analysis|Correlative studies
48647297|NCT03199651|OTHER|Medical Chart Review|Undergo medical record abstraction
48647298|NCT03199651|OTHER|Quality-of-Life Assessment|Ancillary studies
48321968|NCT04527276|OTHER|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
48487647|NCT06070987|OTHER|None BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot (do not inject BoNT-A in the affected rectus femoris), then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
48487648|NCT02015689|BEHAVIORAL|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
48487649|NCT02015689|BEHAVIORAL|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
47969478|NCT01908374|DIETARY_SUPPLEMENT|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
47969479|NCT01365910|DRUG|linifanib|Given PO
48487650|NCT02015689|BEHAVIORAL|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
48487651|NCT02015689|BEHAVIORAL|CDC VIS|CDC Vaccine Information Statement (VIS)
48487652|NCT03176459|DRUG|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
48487653|NCT03176459|DRUG|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
48487654|NCT01936519|DRUG|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
48487655|NCT01936519|DRUG|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
48647299|NCT03199651|OTHER|Questionnaire Administration|Ancillary studies
47969480|NCT01594762|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
48647300|NCT03199651|BEHAVIORAL|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
48647301|NCT03434899|BEHAVIORAL|Physical exercise and online support|Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
48647302|NCT03434899|BEHAVIORAL|Physical exercise|Person-centered design of health care plan individually adjusted physical exercise.
48647303|NCT05274698|BEHAVIORAL|muscle energy technique|It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
47969481|NCT01594762|DRUG|Topical placebo cream|14 days of treatment
47969482|NCT01594762|OTHER|Standard wound care|14 days of treatment
47969483|NCT05169047|OTHER|Best Medical Treatment|For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.
48321969|NCT02025491|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
48321970|NCT00750555|DRUG|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
47969484|NCT05169047|OTHER|Subthreshold Spinal Cord Stimulation|SCS will be programmed at subthreshold stimulation.
47969485|NCT01738321|OTHER|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
47969486|NCT01911078|PROCEDURE|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
47969487|NCT01911078|DEVICE|EnligHTN™ Renal Denervation System.|
48647304|NCT05274698|BEHAVIORAL|conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.|"Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel"
48647305|NCT00903344|DRUG|Vitamin D3|4000IU vitamin D3 tablet taken daily
48647306|NCT00903344|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
48647307|NCT04787341|DRUG|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
47969488|NCT03700775|OTHER|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal \<130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
47969489|NCT01310101|DRUG|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
47969490|NCT00601458|DRUG|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
47969491|NCT00601458|DRUG|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
47969492|NCT00601458|DRUG|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
47969493|NCT02560571|DEVICE|ultrasound|
47969494|NCT02560571|OTHER|blood test|
47969495|NCT00681005|DRUG|rabeprazole|20 mg bid for 14 days
47969496|NCT00681005|DRUG|pantoprazole|pantoprazole 40 mg bid
47969497|NCT04988178|OTHER|Data extraction from medical files|Data extraction from medical files
47969498|NCT00453297|DRUG|MF101|
47969499|NCT00786149|OTHER|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
47969500|NCT00786149|OTHER|Varenicline without counseling|Brief advice, one time during initial session
47969501|NCT03295812|OTHER|standard therapy|standard therapy,non-interventional study
47969502|NCT00280098|DRUG|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
47969503|NCT01008592|DRUG|levocetirizine or placebo|oral administration, single tablet, 5 mg.
47969504|NCT04991415|OTHER|Manual Therapy|
47969505|NCT00036829|PROCEDURE|pain therapy|
47969506|NCT06504849|BEHAVIORAL|Receiving LSM messages.|"* LSM messages via instant messaging applications~* Chat-type support messages via instant messaging applications"
47969507|NCT06504849|BEHAVIORAL|Receiving brief pre-HTN messages.|"* A flyer with brief pre-HTN information which is distributed during the recruitment phase~* Brief pre-HTN messages via instant messaging applications"
47969508|NCT00385983|DEVICE|Harmonic Scalpel|
47969509|NCT01701557|OTHER|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
47969510|NCT01701557|OTHER|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
47969511|NCT00378820|BEHAVIORAL|Whey without milk minerals|
47969512|NCT00378820|BEHAVIORAL|Whey with milk minerals|
47969513|NCT00378820|BEHAVIORAL|Casein without milk minerals|
47969514|NCT00378820|BEHAVIORAL|Casein with milk minerals|
47969515|NCT00971594|BEHAVIORAL|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk
47969516|NCT00971594|BEHAVIORAL|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
47969517|NCT03940404|DRUG|Anlotinib Hydrochloride|Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
47969518|NCT00438984|DRUG|cyclophosphamide|Given IV
47969519|NCT00438984|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
47969520|NCT00438984|BIOLOGICAL|aldesleukin|Given IV or SC
47969521|NCT00438984|OTHER|immunohistochemistry staining method|Correlative studies
48321971|NCT05138874|BEHAVIORAL|Trending Feedback|Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.
48321972|NCT05138874|BEHAVIORAL|Benchmark Peer Comparison Feedback|Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.
48321973|NCT05138874|BEHAVIORAL|Private Commitment|Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.
48321974|NCT05138874|BEHAVIORAL|Public Commitment|Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.
48321975|NCT04994444|DRUG|Nicoderm CQ 21Mg/24Hr Transdermal System|Nicoderm CQ patch started 3 weeks prior to quit date. Starting on quit date, patch/gum or patch/lozenge will be used for 8 weeks. Patch will be tapered over the 8 week period.
48321976|NCT04839991|DRUG|CB307|Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
48321977|NCT04858880|RADIATION|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
48321978|NCT05216068|DIAGNOSTIC_TEST|NGS|Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
48321979|NCT02461836|DRUG|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
48321980|NCT02461836|RADIATION|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
48647308|NCT04787341|DRUG|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
48321981|NCT03051724|OTHER|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
48321982|NCT01167582|BIOLOGICAL|Red blood cell transfusion|Liberal versus restrictive transfusion
48321983|NCT03553602|RADIATION|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen\[until end of radiotherapy\])"
48321984|NCT04090905|OTHER|Standard clinical monitoring|Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
48117923|NCT01094613|DRUG|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
48117924|NCT01094613|DRUG|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
48647309|NCT02901561|DRUG|misoprostol 200|
48647310|NCT02901561|DRUG|misoprostol 400|
48647311|NCT04791020|DRUG|Lidocain topical + paracervical blockade|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
48647312|NCT04791020|DRUG|Lidocaine topical|5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
48647313|NCT01400152|DEVICE|Additional active warming|Chemical heat pad applied to the upper torso
48647314|NCT03635879|OTHER|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
47969522|NCT00438984|PROCEDURE|biopsy|Optional correlative studies
47969523|NCT00438984|OTHER|laboratory biomarker analysis|Correlative studies
47969524|NCT00438984|OTHER|immunologic technique|Correlative studies
48117925|NCT00000493|DRUG|propranolol|
48117926|NCT00000493|DRUG|hyaluronidase|
48117927|NCT04894565|PROCEDURE|rehabilitation|physical therapy 24 hrs after surgery
48321985|NCT04090905|DIAGNOSTIC_TEST|Holter monitoring|Cardiac rhythm monitoring before, during, and until hospital discharge (preferably ≥72 hours after abdominal surgery)
48321986|NCT03827590|DRUG|Test|three times a day for five days
48321987|NCT03827590|DRUG|Active Comparator Control 1|three times a day for five days
48647315|NCT03635879|OTHER|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
48647316|NCT03635879|OTHER|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
47969525|NCT00438984|GENETIC|polymerase chain reaction|Correlative studies
48117928|NCT06397963|BIOLOGICAL|GT307 injection|GT307 injection to treat solid tumours
48117929|NCT03696862|PROCEDURE|free gingival graft|Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
48321988|NCT03827590|DRUG|Active Comparator Control 2|three times a day for five days
48321989|NCT03827590|DRUG|Placebo|three times a day for five days
48321990|NCT00598169|BIOLOGICAL|rituximab|375mg/m2 on Day 1
48647317|NCT03635879|OTHER|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
47969526|NCT00427843|BEHAVIORAL|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
47969527|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
48117930|NCT01323777|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
48117931|NCT00477035|DRUG|CIK cells|2x10e8 cells/kg
48117932|NCT00477035|DRUG|etoposide|60 mg/kg
48117933|NCT00477035|DRUG|bcnu|15 mg/kg
48117934|NCT00477035|DRUG|cyclophosphamide|100 mg/kg
48117935|NCT00477035|DRUG|gemcitabine|1250 mg/m2
48117936|NCT00477035|DRUG|vinorelbine|30 mg/m2
48117937|NCT00477035|DRUG|melphalan|200 mg/m2
48117938|NCT01563380|BIOLOGICAL|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
48117939|NCT00006505|DRUG|Islet Transplantation|Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
48117940|NCT04434586|DEVICE|femoropopliteal revascularization for TASC C or TASC D lesion|Femoropopliteal revascularization: ATL or ATL/stenting for TASC C/D lesions. Control group: only angiography 2D final control. Experimental group: angiography + OCT control
48117941|NCT03553212|RADIATION|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
48117942|NCT01460563|DRUG|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
48117943|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
48117944|NCT01460563|DRUG|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
48117945|NCT04778124|PROCEDURE|Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)|All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
48117946|NCT04778124|PROCEDURE|Excision of thrombosed hemorrhoid / Hemorrhoidectomy /|One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
48117947|NCT02464293|OTHER|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
48117948|NCT03718598|BEHAVIORAL|Tendon and Nerve Gliding Exercises|Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
48117949|NCT00616733|DRUG|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
48321991|NCT00598169|DRUG|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
48487656|NCT05288036|OTHER|Proprioceptive Neuromuscular Rehabilitation group|The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
48647318|NCT03635879|OTHER|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
47969528|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
47969529|NCT03434275|DRUG|N1539|Once Daily
48117950|NCT00616733|DRUG|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
48117951|NCT00616733|DRUG|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
48117952|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
48647319|NCT03635879|DRUG|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
48647320|NCT03066518|DRUG|Melatonin 5 mg|
48647321|NCT03066518|OTHER|Placebo|
48321992|NCT00598169|DRUG|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
48321993|NCT00598169|DRUG|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
48321994|NCT00598169|DRUG|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
48647322|NCT03223805|OTHER|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
48117953|NCT05789771|DRUG|Abemaciclib|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
48321995|NCT00598169|DRUG|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
48321996|NCT00598169|GENETIC|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
48321997|NCT00598169|GENETIC|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
48117954|NCT05789771|DRUG|Abemaciclib|Abemaciclib 200 mg orally every 12 hours
48117955|NCT05815797|DRUG|SDD formula|SDD formula consists of 23 herbal medicines
48321998|NCT00505232|DRUG|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~1. Patients younger than 60 years who will receive 8 chemotherapy cycles~2. Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) \[0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets \< 100,000/µl\] will be administered 8 to 12 weeks after last chemotherapy."
48321999|NCT05796505|BEHAVIORAL|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
48322000|NCT02849314|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
48647323|NCT03976726|DEVICE|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
48647324|NCT05066139|OTHER|EPODIG-G program (coordination of supportive care)|EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
47969530|NCT03434275|DRUG|Placebo|Once Daily
47969531|NCT02079545|DRUG|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
47969532|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
47969533|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
48117956|NCT05815797|DRUG|Placebo|Placebo
48117957|NCT03375151|DEVICE|EEG based feedback|Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
48117958|NCT03375151|BEHAVIORAL|Standard practice based feedback|Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
48117959|NCT03375151|BEHAVIORAL|No feedback|Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
48117960|NCT04558424|DIETARY_SUPPLEMENT|zinc gluconate and ascorbic acid|This group will consist of 50 patients who will receive 220 mg zinc and 1gm ascorbic acid for 10 days in addition to their standard treatment.
48647325|NCT02554474|BEHAVIORAL|Education, Fitbit/FitViz, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
47969534|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
47969535|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
47969536|NCT05577442|DRUG|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
48322001|NCT02849314|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
48322002|NCT03792451|DRUG|Pegvaliase|Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
48647326|NCT02554474|BEHAVIORAL|Same intervention with a 9-week delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 9-week delay.
48647327|NCT01217047|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
48117961|NCT05528146|DIETARY_SUPPLEMENT|Psyllium huks|psyllium in 250ml of water
48117962|NCT03891927|DIETARY_SUPPLEMENT|extra virgin olive oil|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
48117963|NCT06238752|DRUG|Apatinib Combined With Tislelizumab and Chemotherapy|apatinib (250 mg, qd, d1-14), tislelizumab(200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks
48117964|NCT01285635|DRUG|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
48117965|NCT01285635|DRUG|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
48117966|NCT02735291|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
48117967|NCT03610815|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment|Screening, Brief Intervention, Referral to Treatment
48117968|NCT00739141|DRUG|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
47969537|NCT05368571|OTHER|CHOICES-TEEN|This is a four-session hybrid in-person and Telehealth counseling intervention that is designed to reduce the risk of HIV/STI and alcohol- and marijuana-exposed pregnancy for young women who are involved in the juvenile justice system between the ages of 14-19.
48322003|NCT04717141|OTHER|Selective nerve block|"D0 :~* Information, collection of consent, inclusion,~* Clinical and instrumental evaluation,~* Realization of the selective nerve block,~* Post-selective nerve block clinical and instrumental re-evaluation,~* Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~- Clinical and instrumental post-botulinum toxin injection evaluation."
48322004|NCT04777214|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
48322005|NCT04777214|DEVICE|Sham TMS|Sham TMS will be administered
48322006|NCT00456729|DRUG|Metronidazole|
48497991|NCT06276049|OTHER|custom GPT supported self-directed learning|"The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience."
48647328|NCT01217047|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
48647329|NCT01217047|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
47969538|NCT05368571|OTHER|Health and Life Skills Education|This is a four-session psychoeducational intervention that is designed to provide information on time management, sleep, nutrition and exercise, and financial management.
48117969|NCT06124066|DRUG|Mirabegron 50 MG|The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.
48117970|NCT02892903|DEVICE|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow \<3 will not be examined but will be 'awarded' an FFR value of 0.5
48117971|NCT00214591|DRUG|GALIDA|
48117972|NCT05060614|PROCEDURE|Hip fracture surgery|Hip fracture surgery
48117973|NCT02706717|DRUG|Visbiome Extra Strength|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
48117974|NCT02706717|DRUG|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
48322007|NCT00456729|PROCEDURE|Blood tests|
48322008|NCT06188195|DRUG|Dexamethasone|ACS intervention were used in the experimental group
48322009|NCT00246948|PROCEDURE|Active conservative treatment of sciatica|
48322010|NCT01928485|OTHER|active surveillance|Undergo active surveillance
48322011|NCT01928485|DRUG|Sunphenon|Given PO
48322012|NCT01928485|OTHER|laboratory biomarker analysis|Correlative studies
47969539|NCT03961581|BEHAVIORAL|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
48322013|NCT01928485|OTHER|Questionnaire Administration|Ancillary studies
47969540|NCT06036212|DEVICE|Robotic System|Robotic assisted Unicompartmental Knee replacement (UKA)
48647330|NCT01217047|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
48117975|NCT02761239|DEVICE|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
48117976|NCT01681381|DEVICE|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
48117977|NCT01681381|DEVICE|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
48117978|NCT00634621|DRUG|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
48117979|NCT02944188|PROCEDURE|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
48117980|NCT02944188|PROCEDURE|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
48117981|NCT01277614|BEHAVIORAL|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
48117982|NCT05126121|DRUG|three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol|Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
48322014|NCT02822534|DRUG|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
48322015|NCT05638763|DRUG|Dasatinib Pill|Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year
47969541|NCT06036212|DEVICE|Conventional|Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
48322016|NCT05638763|DRUG|Ketoconazole Pill|Patients will receive ketoconazole 200mg two times a day, orally, for one year.
48322017|NCT05140395|DIAGNOSTIC_TEST|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
48322018|NCT01396902|BEHAVIORAL|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
48322019|NCT01396902|BEHAVIORAL|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
48487657|NCT05288036|OTHER|Progressive Resistance Exercise Group|"Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation."
48487658|NCT05288036|OTHER|Control Group|The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
48487659|NCT03331237|PROCEDURE|scalene block|scalene block using 5ml of ropivacaine
48487660|NCT03331237|PROCEDURE|ISO block|ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
48487661|NCT05962450|BIOLOGICAL|iNKT Cells|the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108\~109cells/m2.
48487662|NCT05962450|DRUG|PD-1|Intravenous infusion, according to the drug instructions.
48487663|NCT05962450|DRUG|Regorafenib|Oral administration, according to the drug instructions.
48487664|NCT04787952|OTHER|cold expossure|subjects were exposed for the cold, to activate and diagnose potential brown tissue activity
48487665|NCT01797484|DRUG|Ranolazine|Improvement of myocardial microcirculation
48647331|NCT03654326|DRUG|Gefapixant|Gefapixant tablet 45 mg taken orally
47969542|NCT04298801|PROCEDURE|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing|"A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours."
47969543|NCT04298801|OTHER|Physician-directed diagnostic testing|Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
47969544|NCT04400591|BIOLOGICAL|Nonconforming Lisocabtagene Maraleucel|Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
47969545|NCT03917914|DRUG|Bisoprolol|As in arm description
47969546|NCT03917914|DRUG|Placebo Oral Tablet|As in arm description
47969547|NCT06370650|PROCEDURE|platelet rich plasma, narrow band UVB|Role of PRP in treating stable vitiligo
47969548|NCT04584645|OTHER|Targeted digital intervention|Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
47969549|NCT01927237|OTHER|HLR|
47969550|NCT01927237|OTHER|EHR|
47969551|NCT04494074|OTHER|External Cooling|External Cooling
47969552|NCT02845505|OTHER|Intravascular Ultrasound, coronary computed tomography angiography|
47969553|NCT06501833|OTHER|FIFA 11+ KIDS PROGRAM|The experimental group will perform eight weeks of FIFA 11+ kids program (3/week).
47969554|NCT06501833|OTHER|REGULAR TRAINING|The control group will be continuing their regular training
47969555|NCT01296620|DRUG|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
47969556|NCT01296620|DRUG|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
47969557|NCT01296620|DRUG|5% dextrose in water|Placebo
47969558|NCT01984177|DRUG|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
47969559|NCT05083572|DRUG|Colonic lavage with polyethylene glycol|The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
47969560|NCT05083572|DIETARY_SUPPLEMENT|Probiotic|The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
47969561|NCT05083572|DRUG|Antibiotic|"The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course."
47969562|NCT02102906|PROCEDURE|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
47969563|NCT00542555|DRUG|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
48647332|NCT03654326|DRUG|Placebo|Placebo matching gefapixant tablet taken orally
48647333|NCT03654326|DRUG|Naproxen|Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
47969564|NCT00542555|DRUG|Naproxcinod 375 mg|
47969565|NCT00542555|DRUG|Naproxen|
47969566|NCT00542555|DRUG|Naproxcinod 750 mg|
47969567|NCT02868775|PROCEDURE|cystoscopy, bladder hydrodistention and bladder biopsy|
47969568|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
47969569|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
47969570|NCT02034214|BEHAVIORAL|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
48117983|NCT05344924|DRUG|TACE+penpulimab+anlotinib vs. penpulimab+anlotinib|Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
48117984|NCT04724018|DRUG|Sacituzumab Govitecan (SG)|Intravenous infusion
48647334|NCT00423865|DRUG|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
48117985|NCT04724018|DRUG|Enfortumab vedotin-ejfv (EV)|Intravenous infusion
48117986|NCT02525796|DRUG|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
48117987|NCT02525796|DRUG|amiloride|amiloride, titrated up to a maximum of 10mg BID
48117988|NCT02525796|DRUG|Placebo|
48117989|NCT02525796|DRUG|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
48647335|NCT00423865|DRUG|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
48117990|NCT04960072|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
48322020|NCT00207259|BEHAVIORAL|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
48322021|NCT02090192|PROCEDURE|WBV training|
48322022|NCT02090192|PROCEDURE|PRT training|
48117991|NCT05677061|DEVICE|Dynamic Hip Screw with HA-coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with hydroxyapatite coating on the screw thread was used to fix the fracture
48117992|NCT05677061|DEVICE|Dynamic Hip Screw without coating (Hiploc)|During surgery for pertrochanteric hip fracture a lag screw with no coating on the screw thread was used to fix the fracture
48117993|NCT04734132|DIETARY_SUPPLEMENT|Moringa|Leaves of Moringa oleifera from an organic Iberian peninsula cultivar. A single lot was prepared from the same crop. Leaves were dried and ground and encapsulated as a organic dietary supplement. No other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
48117994|NCT04734132|DIETARY_SUPPLEMENT|Placebo|Placebo capsules were indistinguishable from the experimental capsules in material and color (opaque white). Same number of capsules were consumed as in the experimental arm and no other changes in diet or physical activity were included although a general healthy lifestyle pattern was recommended.
48117995|NCT01875744|DRUG|Polyethylene glycol 4000|
48117996|NCT03222323|DRUG|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
48117997|NCT03222323|DRUG|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
48117998|NCT03222323|DRUG|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
48117999|NCT03222323|DRUG|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
48118000|NCT03222323|DRUG|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
48118001|NCT01139398|DIETARY_SUPPLEMENT|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
48322023|NCT04109872|DRUG|Lenalidomide|Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
48322024|NCT05582161|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
48647336|NCT00423865|GENETIC|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
48647337|NCT00423865|OTHER|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
48118002|NCT01368016|DRUG|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
48118003|NCT01368016|DRUG|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
48118004|NCT05090930|DEVICE|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection|HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated
48118005|NCT05090930|DEVICE|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber|CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
48647338|NCT00423865|OTHER|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
48647339|NCT00423865|OTHER|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
48322025|NCT05674201|COMBINATION_PRODUCT|Propofol-Dexmedetomidine|Propofol-Dexmedetomidine AND Propofol-Remifentanil
48322026|NCT02702011|DRUG|empagliflozin medium dose|
48322027|NCT02702011|DRUG|empagliflozin low dose|
48322028|NCT02702011|DRUG|empagliflozin high dose|
48322029|NCT02702011|DRUG|placebo|
48322030|NCT00542724|DRUG|VIAject™|Dosage as individually required
48322031|NCT00542724|DRUG|Regular Human Insulin|Dosage as individually required
48322032|NCT04985331|DEVICE|W-GenZD|"W-GenZD is a program that delivers evidence based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent."
48322033|NCT02357797|DRUG|Vortioxetine|
48322034|NCT02357797|OTHER|Placebo|
48322035|NCT00003810|DRUG|docetaxel|
48322036|NCT00003810|DRUG|gemcitabine hydrochloride|
48322037|NCT00835419|DRUG|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
48322038|NCT03222076|BIOLOGICAL|Ipilimumab|Given IV
48322039|NCT03222076|BIOLOGICAL|Nivolumab|Given IV
48118006|NCT04937842|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
48118007|NCT00068198|BIOLOGICAL|Dryvax|
48118008|NCT04808778|DRUG|Hydroxyurea therapy per standard care|Moderate-dose of 20mg/kg/day
48118009|NCT04760834|OTHER|Questionnaire|Complete a questionnaire to look for signs of concussion in the past. The questions also seek to collect data on participants' knowledge, concussion management and potential confounding factors
48118010|NCT05793723|DIAGNOSTIC_TEST|Pulmonary function testing device|Patients will undergo pulmonary function tests with the Exhalyzer D (Ecomedics, Switzerland) device. This device consists of 1) an ultrasonic flow measuring system for measuring flow, volume and molecular mass, 2) a nitrogen washout system to measure functional residual capacity (FRC) and other indices, 3) a carbon dioxide infrared measurement device for monitoring the level of carbon dioxide in exhaled breath.
48118011|NCT00366171|DRUG|Bifeprunox|
48118012|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 3)|
48118013|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5)|
48118014|NCT02290067|DEVICE|Blood glucose monitoring system (Omnitest 5D)|
48118015|NCT04825028|DEVICE|Angiography-drived Index of Microcirculatory Resistance|"From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation."
48118016|NCT00983593|BEHAVIORAL|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
48118017|NCT05133375|PROCEDURE|Tracheal Intubation|Before reporting to Operation theatre, a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3 minutes after intubation.
48118018|NCT04583046|DRUG|normal saline inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).
48118019|NCT04583046|DRUG|iloprost inhalation|When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
48118020|NCT05076799|DRUG|100 ml lactulose combined with 1 L PEG|the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
48118021|NCT05076799|DRUG|100 ml lactulose combined with 2 L PEG|the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
48118022|NCT05076799|DRUG|200 ml lactulose|the participants were instructed to consume 200 ml lactulose alone
48118023|NCT05076799|DRUG|3 L Polyethylene glycol solution|the participants were instructed to consume 3000 mL of PEG solution
48118024|NCT02709655|DRUG|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
48118025|NCT02709655|DRUG|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
48118026|NCT02709655|DRUG|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
48118027|NCT02709655|OTHER|Placebo|Encapsulated tablet, orally
48118028|NCT06307223|DRUG|30% supramolecular salicylic acid|The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
48118029|NCT06307223|DRUG|supramolecular active zinc|The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
48322040|NCT04273126|BEHAVIORAL|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
48647340|NCT00423865|PROCEDURE|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
48647341|NCT01872182|DRUG|ALS-L1023|daily twice for 12 weeks
48118030|NCT05344326|OTHER|Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)|CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
48647342|NCT01872182|DRUG|placebo|daily twice for 12 weeks
48322041|NCT06159829|BEHAVIORAL|experimental|intervention group used VR with a natural landscape and relaxing musical accompaniment during the upper endoscopy procedure.
48322042|NCT00033033|DRUG|Reserpine|
48322043|NCT04482699|BIOLOGICAL|RAPA-501-Allo off-the-shelf Therapy of COVID-19|Allogeneic off-the-shelf RAPA-501 cells
48647343|NCT03607669|OTHER|Mangafodipir trisodium|Manganese-based MRI contrast agent
48647344|NCT04642209|DEVICE|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
48118031|NCT03586817|DRUG|Palonosetron|75 mcg during the anesthesia
48647345|NCT05388968|BIOLOGICAL|Metatranscriptomic|Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
48118032|NCT03586817|DRUG|Fosaprepitant|150 mg during the anesthesia
48118033|NCT05468398|DEVICE|Soothe VR|The Soothe VR system is manufactured by Applied VR. It is a HIPAA-compliant platform and has been validated by randomized control trials. It has not yet been reviewed by the FDA.
48118034|NCT04164056|DEVICE|deep brain stimulation|deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
48118035|NCT04528472|OTHER|Acupuncture Treatment|stimulate acupoints to accelerate recovery
48118036|NCT04528472|OTHER|Regular Treatment|Oral Medicine and Rehabilitation Treatment
48118037|NCT06117332|DEVICE|Visual prosthesis|"In response to the stimulation/image on the monitor, subjects will be asked to either make a perceptual judgment or perform a simple behavioral task. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, or walking to a target location. Both patient response and reaction time will be recorded.~In some cases, the investigators will also collect data measuring subjects' eye position. This is a noninvasive procedure that will be carried out using standard eye-tracking equipment via an infra-red camera that tracks the position of the subjects' pupil. Only measurements like eye position or eye blinks will be recorded, so these data do not contain identifiable information."
48118038|NCT00018785|PROCEDURE|donor bone marrow infusion|
48322044|NCT04482699|OTHER|Placebo|RAPA-501-Allo cell placebo
47969571|NCT02034214|OTHER|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
47969572|NCT02034214|BEHAVIORAL|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
47969573|NCT01633853|DRUG|Vitamin D2|Treatment with Vit D2.
47969574|NCT01633853|DRUG|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
48118039|NCT00656721|DEVICE|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
48647346|NCT05388968|DIAGNOSTIC_TEST|Specific microbiologic diagnosis|If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
48647347|NCT00345280|PROCEDURE|impression cytology, obtain the tear fluid|Vitamin A
48647348|NCT02980900|DIETARY_SUPPLEMENT|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
47969575|NCT01877265|DRUG|LY2605541|
47969576|NCT04009343|DRUG|Artemether-lumefantrine|Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
47969577|NCT04009343|DRUG|Dihydroartemisinin-piperaquine|Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
47969578|NCT03663816|DEVICE|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
47969579|NCT02280304|BEHAVIORAL|Inner Resources for Veterans (IRV)|Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation
47969580|NCT02280304|BEHAVIORAL|Essential Skills therapy|This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
48322045|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 20J|120W Lumenis Holmium:YAG laser 20J
47969581|NCT01271062|PROCEDURE|gastric bypass surgery|
48322046|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 40 J|120W Lumenis Holmium:YAG laser 40J
48322047|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 60 J|120W Lumenis Holmium:YAG laser 60J
48322048|NCT00261170|DRUG|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
48118040|NCT05067621|DRUG|Semaglutide Pen Injector|Semaglutide (Wegovy) pen is a subcutaneous injection that contains 2.4mg/0.75mL of active ingredient. The injection pen can deliver doses of 0.24mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
48118041|NCT05067621|DRUG|Placebo|Injection pen contains excipients.
47969582|NCT01271062|PROCEDURE|abdominal surgery|
47969583|NCT01271062|BEHAVIORAL|very low caloric diet|
47969584|NCT00802139|DRUG|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
47969585|NCT00802139|DRUG|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
48118042|NCT00120367|DRUG|Enfuvirtide|
48118043|NCT00120367|DRUG|Tenofovir-Emtricitabine|
48118044|NCT01828775|OTHER|palliative care|Receive early PCI
48322049|NCT00261170|OTHER|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
48322050|NCT06440850|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47969586|NCT01175252|OTHER|Database analysis|Review and collect data from database
47969587|NCT04335461|PROCEDURE|Cephalomedullary nailing of extracapsular hip fracture|All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
48647349|NCT02980900|DIETARY_SUPPLEMENT|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
48322051|NCT06440850|DRUG|Cobimetinib|Given PO
48322052|NCT06440850|PROCEDURE|Computed Tomography|Undergo CT scan
48322053|NCT06440850|PROCEDURE|Diagnostic Imaging|Undergo I-123 diagnostic scan
48322054|NCT06440850|PROCEDURE|I-131 Uptake Test|Undergo I-131 whole body scan
48322055|NCT06440850|RADIATION|Iodine I-131|Given PO
48322056|NCT06440850|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48322057|NCT06440850|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48647350|NCT02980900|DIETARY_SUPPLEMENT|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
48647351|NCT02980900|DIETARY_SUPPLEMENT|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
47969588|NCT04335461|DEVICE|cephalomedullary nail|Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
47969589|NCT04335461|DRUG|Regional Anesthetics|Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
47969590|NCT03506282|OTHER|Running while listening to a traffic audio track|While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
48118045|NCT01828775|OTHER|palliative care|Receive delayed PCI
48118046|NCT01828775|PROCEDURE|quality-of-life assessment|Ancillary studies
48118047|NCT01828775|OTHER|survey administration|Ancillary studies
48118048|NCT04929587|OTHER|This is a observational research, there is no intervention|This is a observational research, there is no intervention
48118049|NCT02537483|DRUG|IDP-120 Gel|Investigational Product: IDP-120 Gel
48118050|NCT02537483|DRUG|IDP-120 Component A|Comparator Product: IDP-120 Component A
48118051|NCT02537483|DRUG|IDP-120 Component B|Comparator Product: IDP-120 Component B
48118052|NCT02537483|DRUG|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
48118053|NCT06150287|OTHER|Florajen Digestion|Florajen Digestion is a probiotics. One probiotics capsule contains 15 billion Colony Forming Unit (CFU) of live microorganisms. No live microorganisms are present in the placebo capsules.
47969591|NCT03506282|OTHER|Running with music at moderate volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB)."
48118054|NCT01691326|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
48118055|NCT01691326|BIOLOGICAL|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
48322058|NCT06440850|BIOLOGICAL|Recombinant Thyrotropin Alfa|Given IM
48322059|NCT06440850|PROCEDURE|Ultrasound Imaging|Undergo neck ultrasound
48322060|NCT06440850|DRUG|Vemurafenib|Given PO
48322061|NCT03639012|DIETARY_SUPPLEMENT|Carbohydrate drink|Children randomised to this group will receive a preoperative carbohydrate drink 90-120mins prior to surgery
48322062|NCT05487313|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopic device after ultrasound guidance
48322063|NCT01780909|DRUG|Paromomycin Sulfate Fasted State|
48322064|NCT01780909|DRUG|Paromomycin Sulfate Fed State|
48322065|NCT01780909|DRUG|Paromomycin Sulfate w/ domperidone|
48322066|NCT01780909|DRUG|Paromomycin Sulfate w/ loperamide HCl|
48322067|NCT00676936|DRUG|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
48322068|NCT00676936|DRUG|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
48322069|NCT01904734|DRUG|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
48322070|NCT04752124|OTHER|Exercise Therapy|High intensity speed based interval treadmill training
48322071|NCT04752124|OTHER|conventional therapy|conventional physical therapy
48322072|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
48322073|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
48322074|NCT05263817|BIOLOGICAL|CD19/BCMA CAR T-cells|Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
48647352|NCT05814549|DIAGNOSTIC_TEST|NavDx|"Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints~o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase."
48647353|NCT03825666|OTHER|ProvideXtra® Fresenius Kabi|Improving wellbeeing
48647354|NCT05179005|DEVICE|RibFix Advantage|Intrathoracic rib fracture stabilization
48647355|NCT06231472|PROCEDURE|peroperative inferior vena cava measurement|peroperative inferior vena cava measurement
48647356|NCT06306976|PROCEDURE|Elective Midline Laparotomy|"Patients with midline ventral incisional hernia with a range of hernia morphology who plan to undergo open retromuscular VHR.~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral MFR (TAR or EOR at the discretion of the operating surgeon). All repairs beginning with retrorectus dissection to the level of the linea semilunaris.~All patients will have permanent mesh reinforcement of the abdominal wall (large-pore, midweight polypropylene). Fascia will be closed over the mesh with 0 or 2-0 polydioxanone slowly absorbable suture using a small-bite technique and a 4:1 suture length:wound length ratio."
48647357|NCT06306976|PROCEDURE|Imaging: Ultrasound|"Ultrasound procedure will involve the following steps:~1. For control group 1 and group 2 patients, Images will be taken at two points along the bilateral RA; at the level of the umbilicus and midway between the umbilicus and xiphoid process. Bilateral external oblique (EO), internal oblique (IO), and transversus abdominis (TA) images will be performed at the level of the anterior axillary line midway between the costal margin and iliac crest."
48647358|NCT06306976|OTHER|Tensiometry|"For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure. The tensiometer is attached to a clamp attached to the fascia at the midpoint of the hernia defect. Tension required for medialization to the midline will be performed after adhesiolysis (baseline), retrorectus dissetion, incision of the PLIO (if performed), and after completion of TAR or EOR (if performed).~Control group 2 patients will be undergoing first time laparotomy and will have tensiometry performed."
47969592|NCT03506282|OTHER|Running with music at moderate-to-high volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB)."
47969593|NCT05541952|BIOLOGICAL|BCG|Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
47969594|NCT03428360|DRUG|Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category|The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
47969595|NCT04753983|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|Diagnostic imaging measuring the metabolic changes that occur within the brain used for measuring and mapping brain activity
47969596|NCT05633823|OTHER|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~* A user account will be created after the application is downloaded to the mobile phone/tablet.~* After logging into the application, the map of the game will be displayed.~* The game will start with the first level of the game consisting of 5 levels.~* At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~* After watching the videos, interactive games will be played.~* Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~* After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
47969597|NCT00870792|BEHAVIORAL|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
47969598|NCT01709513|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets.
47969599|NCT01709513|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet.
47969600|NCT01709513|DRUG|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
47969601|NCT01709513|DRUG|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
47969602|NCT02299830|PROCEDURE|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
47969603|NCT02299830|PROCEDURE|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
47969604|NCT02299830|PROCEDURE|stent placement|use stent placement to open the airway compressed by out neoplasm
48647359|NCT03731455|DEVICE|WISE Cortical Strip|The WISE Cortical Strip is a medical device composed by a strip and by a cable.
48647360|NCT06007157|BEHAVIORAL|Hypersodic/Hyposodic diet|Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).
48647361|NCT01951729|DRUG|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
48647362|NCT01951729|DRUG|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
47969605|NCT02299830|PROCEDURE|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
47969606|NCT02252783|DRUG|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
48322075|NCT05856825|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted radical cystectomy
48322076|NCT03986008|DRUG|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
48322077|NCT03986008|DRUG|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
47969607|NCT01731990|DRUG|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
47969608|NCT01731990|DRUG|Placebo|Matching placebo of Canakinumab
47969609|NCT00730132|DRUG|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
47969610|NCT00730132|DRUG|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
48647363|NCT01951729|DRUG|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
48647364|NCT01951729|DRUG|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
48647365|NCT01951729|DRUG|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
48647366|NCT01951729|DRUG|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
48647367|NCT01951729|DRUG|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
48647368|NCT01951729|DRUG|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
47969611|NCT00006097|DRUG|CC-1088|
47969612|NCT06373107|BEHAVIORAL|High intensity gait training|Participants will practice walking that is vigorous enough to keep their heart rate over a certain level during their physical therapy sessions. During the sessions, participants will walk and step vigorously enough to keep the heart rate between 60-80% of their maximum heart rate. Maintaining this heart rate during exercise helps to improve heart health and walking, which can affect people after a stroke.
47969613|NCT05840991|DEVICE|elastic bandage|3M™ Coban™ elastic bandage
47969614|NCT05840991|DEVICE|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
47969615|NCT04316065|DRUG|YHP1906|YHP1906 Tab. 5 mg
48487666|NCT00627471|DRUG|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
47969616|NCT04316065|DRUG|YHR1902|Comparator. YHR1902 Tab. 5 mg
47969617|NCT03206528|DEVICE|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
47969618|NCT01238471|DRUG|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
47969619|NCT01238471|DRUG|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
47969620|NCT02742610|BEHAVIORAL|Mindfulness with Contingency Management|
47969621|NCT02742610|BEHAVIORAL|Active Control|
47969622|NCT02997020|OTHER|EDSPD|The equipment \& conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
48118056|NCT02439827|BEHAVIORAL|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
48647369|NCT06368674|OTHER|Intervention group Case Manager (CM)|The CM will be informed about the discharge plan from the nurse at the geriatric ward, as will the municipality for those with need of home help care. An outline of the intervention has been created with managers from primary care and rehabilitation within primary care and municipality care. Core components in the intervention will be active follow-up of the discharge, rehabilitation and care plans. If there are plans that have not been executed or unmet needs, the CM will take adequate contacts to ensure that actions are made to meet the needs. These contacts can be, e.g. the GP for medical needs, the rehabilitation unit in primary or municipality care for unmet rehabilitation needs, and the home help service for unmet care needs. The CM will have a network of contact persons in hospital, primary and community care, as well as in rehabilitation in primary and community care, in order to facilitate for prompt actions to meet the needs.
48322078|NCT04816149|BEHAVIORAL|VA Standard Suicide Intervention|Our active control condition is standardized and contains the elements of standard practice suicide-specific intervention delivered at the VA, which include: 1) suicide risk assessment using the CSSR-S, 2) VA Safety Planning Intervention, 3) timely referral to VA mental health outpatient care, including couples intervention (engagement will be tracked), and 4) Suicide Prevention Coordinator (SPC) follow-up contacts (which have been found to significantly reduce suicidal behavior).
48647370|NCT06368674|OTHER|Control Group|The participants in the control group with a planned follow-up by a primary health care centre within the catchment area of the Sahlgrenska University Hospital that does not have CMs designated for active follow up of discharged frail older people. Thus, the participants in the control group will not actively be followed-up after discharge.
48647371|NCT04621279|PROCEDURE|Normothermia|Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).
48647372|NCT04621279|PROCEDURE|Whole body therapeutic hypothermia|Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.
47969623|NCT01722084|BEHAVIORAL|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
47969624|NCT00855569|DEVICE|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
47969625|NCT03799731|DRUG|GM102|GM102 7 mg/kg weekly
47969626|NCT03799731|DRUG|Trifluridine/Tipiracil|Lonsurf 35 mg/m² twice daily during 10 days per cycle
47969627|NCT03799731|DRUG|GM102 expansion|GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
47969628|NCT02780310|DRUG|Lenvatinib|
48497992|NCT02589483|PROCEDURE|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
47969629|NCT05541770|OTHER|Survey|Healthcare workers/Physicians involved in cancer diagnosis \& management in the Arab countries should respond to a survey
47969630|NCT05201703|DRUG|Fycompa|Fycompa 4 mg daily
48647373|NCT06537466|DIETARY_SUPPLEMENT|Mediterranean diet|This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
48647374|NCT06537466|DIETARY_SUPPLEMENT|Very Low Ketogenic Diet|The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
48647375|NCT01943084|DRUG|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
48118057|NCT05132478|OTHER|Emotionally Supportive Video|The video is approximately 6 1/2 minutes in length and portrays an emotionally supportive conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy with the addition of emotionally supportive statements and gestures.
48647376|NCT01943084|DRUG|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
48647377|NCT02018809|BEHAVIORAL|Medication Adherence Partner|
48647378|NCT02018809|DEVICE|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
48647379|NCT02800746|DRUG|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
48118058|NCT05132478|OTHER|Standard Video|The video is approximately 5 minutes in length and portrays a standard conversation between a patient and surgeon during which the surgeon discusses: the diagnosis, prognosis, available treatment options, benefits and harms of the options, and need for decision making. The surgeon speaks for the majority of the simulated visit and discusses total and hemi-thyroidectomy.
48118059|NCT05076058|DIETARY_SUPPLEMENT|Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza|"Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g"
48647380|NCT02800746|DRUG|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
47969631|NCT05201703|DRUG|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
47969632|NCT05876598|DRUG|antibiotic treatments|The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
48118060|NCT05076058|OTHER|Placebo tablet|"Brand names: BY-HEALTH；~Main contents : starch"
48118061|NCT01501188|OTHER|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
48118062|NCT01501188|OTHER|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
48118063|NCT05919368|DIETARY_SUPPLEMENT|Yam pill|It consists of sweet potato, white art and ginseng
48118064|NCT01860612|DEVICE|Artificial Iris (CustomFlex)|
48118065|NCT05263336|DRUG|Verdye Green|intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
47969633|NCT01558271|DRUG|LY2189265|
47969634|NCT01558271|DRUG|Placebo|
47969635|NCT01558271|DRUG|Liraglutide|
47969636|NCT02364739|OTHER|Written information|Brochure
47969637|NCT02364739|OTHER|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
47969638|NCT00939497|DRUG|Risperidone|
48497993|NCT02589483|DEVICE|Hemopatch|The rectal anastomosis reinforced with Hemopatch
48647381|NCT04054882|BIOLOGICAL|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
48647382|NCT04054882|BIOLOGICAL|Sabin-IPV|administration of Sabin-IPV only
48647383|NCT04054882|BIOLOGICAL|DTaP|administration of DTaP only
48647384|NCT02531386|DEVICE|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
48647385|NCT04420182|OTHER|Virtual Care at Home|Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
48647386|NCT02634697|BEHAVIORAL|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
48647387|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 1|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
48647388|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 2|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
48647389|NCT03851666|OTHER|12 weeks daily administration Placebo|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation."
47969639|NCT05956496|OTHER|Allograft Material ADM-S|A piece of the allograft material (ADM-D) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
47969640|NCT05956496|OTHER|Allograft Material ADM-D|A piece of the allograft material (ADM-S) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
47969641|NCT05315128|DRUG|Methotrexate|A randomized comparative effectiveness clinical trial
47969642|NCT02433730|DRUG|Testosterone|intramuscular injection
47969643|NCT02433730|DRUG|placebo|intramuscular injection
47969644|NCT00660309|DRUG|Aliskiren|Aliskiren 300 mg tablets
47969645|NCT00660309|DRUG|Irbesartan|Irbesartan 300 mg tablets
47969646|NCT00660309|DRUG|Captopril|Captopril 25 mg tablet
47969647|NCT04168528|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
47969648|NCT03443375|OTHER|Physical exercise|The interventions proposed in the present trial were based on a safe and well-established exercise training program
47969649|NCT03558698|OTHER|Good ventilation|Good ventilation with a low concentration of CO2
48322079|NCT04816149|BEHAVIORAL|Treatment for Relationships and Safety Together (TR&ST)|TR\&ST consists of eleven 90-minute sessions delivered in three phases. During phase one, couples receive a tailored cognitive-behavioral conceptualization of suicide and relationship distress based on clinical interview, as well as psychoeducation about their bidirectional influences. They also engage in behavioral activation focused on positive couple activities, emotion regulation, distress tolerance, and conflict management strategies. In phase two, couples learn communication skills and discuss suicidal thoughts and behaviors, as well as their relationship challenges that interact with suicidal thoughts and behavior. Phase three is focused on conjoint thought challenging to shift dysfunctional cognitions related to suicide and relationship problems.
48487667|NCT00627471|DRUG|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
48487668|NCT02622113|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
48487669|NCT02622113|DRUG|Insulin|
48497994|NCT06387485|DEVICE|3D Printed Anatomic Model|Patient-specific 3D printed anatomic model for pre-surgical planning
48647390|NCT00205634|DRUG|Biaxin ( clarithromycin)|
47969650|NCT03558698|OTHER|Ventilation CO2|CO2 High and Good ventilation
48647391|NCT05648747|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
47969651|NCT03558698|OTHER|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
47969652|NCT02161731|DRUG|Evacetrapib|Oral administration
47969653|NCT02161731|DRUG|Warfarin|Oral administration
47969654|NCT01893164|PROCEDURE|simple decompression|decompression of the ulnar nerve
47969655|NCT01893164|PROCEDURE|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
47969656|NCT01893164|PROCEDURE|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
47969657|NCT05680896|BIOLOGICAL|inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV|the protection of COVID-19 vaccines on breakthrough infection
47969658|NCT03098953|DRUG|Loteprednol Etabonate|one drop per eye for each eye
47969659|NCT01530061|OTHER|Egg Breakfast|Egg, Toast and Jelly
47969660|NCT01530061|OTHER|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
47969661|NCT06425666|PROCEDURE|Intervention group /arm 1 (Cataract surgery alone)|Cataract surgery (experimental intervention / arm 1) is performed using a small incision technique. The main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. A thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag.
48322080|NCT03803592|BEHAVIORAL|Dyadic MCS program|"In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period."
48322081|NCT06262893|PROCEDURE|Shoulder arthroscopy blocks|Effect of dexamethasone adjuvant in combined supraclavicular block and suprascapular block versus Interscalene block in patients undergoing shoulder arthroscopy.
48322082|NCT02558556|DEVICE|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
48322083|NCT02558556|OTHER|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
48322084|NCT03019744|DEVICE|MeCFES-assisted task-oriented upper limb rehabilitation|
48322085|NCT03019744|OTHER|Usual Care task-oriented upper limb rehabilitation|
48647392|NCT04315961|DRUG|Blinded drug dose conditions|Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
48647393|NCT04413708|BEHAVIORAL|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
48647394|NCT04526457|OTHER|Standard of Care|Randomized to standard of care with lipid testing only.
48647395|NCT04526457|OTHER|Genetic Testing|Randomized to genetic testing.
47969662|NCT06425666|PROCEDURE|Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)|After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
47969663|NCT05251090|DRUG|ADVATE|50 international units (IU)/kg, a single dose.
47969664|NCT05251090|DRUG|FRSW107|50 IU/kg, a single dose.
47969665|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter
48322086|NCT02056834|DEVICE|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
48322087|NCT02217228|DEVICE|Sebacia microparticles and laser|
48322088|NCT02217228|DEVICE|Vehicle suspension and laser|
48322089|NCT02217228|DEVICE|Sebacia microparticles without laser|
48322090|NCT05202769|OTHER|Video filming|Video clips taken using RGB and thermal imaging cameras under varying conditions of lighting, movement and procedures taking place.
48647396|NCT06475495|DRUG|KYV101|an autologous fully-human anti-CD19 CAR T-cell immunotherapy
47969666|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter
48647397|NCT06475495|DRUG|Rituximab (active comparator)|anti CD20 monoclonal antibody
48647398|NCT05405257|DRUG|Oxytocin|IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
48647399|NCT05405257|OTHER|Placebo|IV, 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
47969667|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
47969668|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
47969669|NCT01809483|DEVICE|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
47969670|NCT01809483|DEVICE|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
47969671|NCT05199012|DIETARY_SUPPLEMENT|Black pepper extract|Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
48322091|NCT02992158|BEHAVIORAL|behavioral activation|
48322092|NCT02992158|BEHAVIORAL|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
48322093|NCT03280342|DRUG|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
48118066|NCT04415528|OTHER|Emotion-Focused Mindfulness Therapy|"EFMT is a group intervention of 8weekly meetings of 2.5 hours with 10 - 12 participants per group. Participants are provided instruction that encourages noting and experiencing bodily sensations and emotions during meditations. Meditations are conducted in silence for between 20 and 35 minutes. Participants are asked to journal their recollection of the meditation and experiences that arise for them as they journal. Each participant then describes their experience in meditation, with the facilitator offering empathic exploration to support transforming negative emotions into adaptive emotions.~The study will be conducted in an online PHIPPA protected platform and has been modified to accommodate electronic delivery. Maximum number of participants per group will be six, and each session will be 1.5 hours. Data will be collected at three points by a research assistant to evaluate the feasibility of EFMT for older adults and determine whether anxiety is influenced by the intervention."
48118067|NCT03200626|PROCEDURE|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
48118068|NCT02338245|DRUG|ASLAN001|ASLAN001 400mg BID
48487670|NCT04048941|PROCEDURE|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
47969672|NCT04664166|OTHER|Alpena Otago Telehealth Program|"A physical therapist will use video visits to evaluate the participants and provide exercise instructions from Week 1 to Week 4. Each participant will use the Blue Marble Health in Motion app from a mobile tablet to complete the exercise guided by an avatar at their own pace after receiving the exercise instructions from the physical therapist. Participants are encouraged to exercise three days a week and 30 minutes each day using the app for 6 months. The exercise protocol based on the evidence-based Otago program includes warm up, strengthening, and balance exercise.~3.5. Research Study Design and Data Analyses:"
47969673|NCT02067338|DRUG|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
47969674|NCT02067338|DRUG|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
47969675|NCT05808972|DRUG|Sodium chloride 0.9% (SC)|This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
47969676|NCT05808972|DRUG|Ringer lactate (RL)|The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
47969677|NCT00317356|DRUG|OPC-6535(Tetomilast)|
47969678|NCT03167840|BEHAVIORAL|Physical and Cognitive Training|Physical Exercise and Cognitive Training
47969679|NCT03167840|BEHAVIORAL|Physical Training|Physical training alone
47969680|NCT03167840|BEHAVIORAL|Cognitive training|Cognitive training alone
47969681|NCT03931538|DIAGNOSTIC_TEST|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
47969682|NCT03931538|DIAGNOSTIC_TEST|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
47969683|NCT00920283|DEVICE|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
48118069|NCT02338245|DRUG|Lapatinib|Lapatinib 1250mg QD
48118070|NCT02338245|DRUG|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
48118071|NCT01655888|DRUG|Tremelimumab|Tremelimumab is administered as endovenous infusion
48322094|NCT03280342|DRUG|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
48322095|NCT03466021|DRUG|Liraglutide|Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
48322096|NCT03466021|DRUG|Placebo|Matching injection
47969684|NCT00920283|DEVICE|Driver Cobalt Alloy Coronary Stent|
48487671|NCT04048941|PROCEDURE|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
47969685|NCT03772691|PROCEDURE|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
47969686|NCT03772691|PROCEDURE|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
47969687|NCT01929460|DRUG|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
48118072|NCT02006017|OTHER|Evidence summary alone plus a recommendation|
48118073|NCT02006017|OTHER|Evidence summary alone|
48118074|NCT05836285|OTHER|ARRC|Eligible for ARRC and managed in ARRC unit
48487672|NCT04048941|PROCEDURE|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
48487673|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
48487674|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
48487675|NCT00958126|BIOLOGICAL|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
48487676|NCT04337619|BEHAVIORAL|Behavioral Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
48487677|NCT04337619|BEHAVIORAL|Mindful Acceptance|Integration of acceptance and willingness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
48118075|NCT05836285|OTHER|Usual Care|Eligible for ARRC but managed elsewhere as no ARRC bed available
48322097|NCT03885089|DRUG|Infliximab [infliximab biosimilar 3]|\<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
48647400|NCT03241160|OTHER|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
48647401|NCT03767387|OTHER|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
48647402|NCT05377814|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing physical activity
48647403|NCT06098352|BEHAVIORAL|PEBL Continuous Performance Task|A PEBL version of the Conners Continuous Performance Task
48647404|NCT01963832|DRUG|Fluoxetine|
48647405|NCT01963832|DRUG|Placebo|
48647406|NCT01963832|PROCEDURE|eCMIT|
48647407|NCT01963832|PROCEDURE|Usual Care|
48647408|NCT01080547|PROCEDURE|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
48647409|NCT01080547|DRUG|XELOX Chemotherapy|XELOX chemotherapy
47969688|NCT01929460|OTHER|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
47969689|NCT01270776|DRUG|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
47969690|NCT01270776|DRUG|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
47969691|NCT01752127|PROCEDURE|percutaneous coronary intervention using drug eluting stent|"1. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
47969692|NCT02587715|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
47969693|NCT02587715|OTHER|Liberation therapy|
47969694|NCT02380781|BEHAVIORAL|Information in the form of a video|see intervention description
47969695|NCT06505655|DIAGNOSTIC_TEST|trehalase levels|We think that in surgical patients requiring hypotensive anesthesia, acute kidney injury, which may occur due to intraoperative renal hypoperfusion, can be diagnosed early by evaluating the urine trehalase value using the ELISA method
48118076|NCT02731885|DRUG|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
48118077|NCT02731885|DRUG|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
48118078|NCT01662336|DRUG|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
48118079|NCT01662336|BEHAVIORAL|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
48487678|NCT04337619|BEHAVIORAL|Values|Integration of values clarification and awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
48647410|NCT01080547|DRUG|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
48647411|NCT01080547|OTHER|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
48647412|NCT01080547|OTHER|Conventional Perioperative Treatment|Conventional treatment during perioperation period
48647413|NCT01080547|PROCEDURE|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
48647414|NCT01543230|DEVICE|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
48647415|NCT03151603|DRUG|Arctuvan|application of a herbal drug
48647416|NCT03151603|DRUG|Fosfomycin|application of an antibiotic drug
48647417|NCT03151603|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan
48647418|NCT03151603|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin
48647419|NCT00001789|DRUG|BG9588|
48647420|NCT05546372|DEVICE|Endobiliary radiofrequency ablation (eRFA)|Intraductal radiofrequency ablation of tumor prior to stent placement
48647421|NCT05546372|DEVICE|uncovered self-expanding metal stent (uSEMS)|Intraductal placement of uncovered metal stent
48647422|NCT01916226|DRUG|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
48647423|NCT01916226|DRUG|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
47969696|NCT04925362|OTHER|Biological specimens|"Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~* added for the research : blood, urine, stools~* collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)"
48322098|NCT03550638|DEVICE|Coil system(Ton-bridgeMT)|1. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
48322099|NCT03550638|DEVICE|Axium Detachable Coil(Medtronic)|2. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
48322100|NCT05654766|DIAGNOSTIC_TEST|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
48322101|NCT05654766|DIAGNOSTIC_TEST|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
48487679|NCT04337619|BEHAVIORAL|Mindful Awareness|Integration of mindfulness and present-moment awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
48647424|NCT01916226|DRUG|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
48647425|NCT01916226|DRUG|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
47969697|NCT04925362|OTHER|Additional visit|Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
47969698|NCT04690998|OTHER|Blood Samples|Genetic, proteomic, neurofilament analysis
47969699|NCT04690998|OTHER|MRI|Spinal and muscular MRI
47969700|NCT06320002|BEHAVIORAL|Communication Intervention for fecal ostomy surgery|This is a educational video-based supportive intervention to address practical skills and adaptation to life with a fecal ostomy
47969701|NCT00496821|DRUG|ALN-RSV01|
47969702|NCT02941198|DEVICE|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
47969703|NCT02941198|DEVICE|Cu T380 A|Cu T380 A will be inserted into the uterus
47969704|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
48487680|NCT04004117|DRUG|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
48322102|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
47969705|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
47969706|NCT05636683|PROCEDURE|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
47969707|NCT05113420|DRUG|Detralex|Diosmin+ Hesperidin
48322103|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
48322104|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
47969708|NCT05113420|DRUG|Troxevasin|Troxerutin
47969709|NCT01685281|DRUG|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
47969710|NCT01685281|DRUG|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
48118080|NCT04769765|OTHER|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
48118081|NCT05032638|BEHAVIORAL|Therapist guided training|Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
48487681|NCT04004117|DRUG|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
48487682|NCT04785508|DEVICE|neuromuscolar tape|neuromuscalar tape application in decompression technique (hand and arm)
48487683|NCT04785508|BEHAVIORAL|antigravity arm position|antigravity arm position
48487684|NCT02080832|DRUG|Citalopram|20 mg or 40 mg daily for 8 weeks
48487685|NCT02080832|DRUG|Placebo|Placebo daily for 8 weeks
48497995|NCT06387485|DIAGNOSTIC_TEST|CT/MRI|Standard imaging type for bony tumors
48497996|NCT04465773|PROCEDURE|general anesthesia for scheduled gynecological surgery|
48497997|NCT04465773|DRUG|Propofol|continuous infusion, target concentration adjusted to maintain bispectral index between 45 and 55
48647426|NCT00832026|DEVICE|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
48647427|NCT02003898|DEVICE|Medtronic MiniMed 530G Insulin Pump|
48322105|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|control biscuit on a daily basis for 8 months
47969711|NCT03833245|BEHAVIORAL|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
48322106|NCT05344027|DRUG|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
48322107|NCT01791699|DRUG|Moxonidine|
48322108|NCT01791699|DRUG|Placebo|
48322109|NCT02178293|DRUG|Benzidamine hydrochloride|
48322110|NCT02178293|DRUG|Ketoprofen lysine salt|
48322111|NCT03120481|OTHER|no intervation|no intervention
48322112|NCT04246593|OTHER|Mobile Market program implementation|"Mobile Market program implementation includes utilizing a Veggie Van model which sells reduced cost locally-grown produce in communities with barriers to accessing fresh F\&Vs because of availability, cost, or lack of produce preparation skills.The Veggie Van visits sites that already serve the target market (e.g., lower-income housing communities, community health centers, community colleges). While Mobile Market programs vary in their model and operation, we believe that the three components of Veggie Van's success are it's share model, price reductions (incentives), and educational component"
47969712|NCT04397224|DIAGNOSTIC_TEST|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
48322113|NCT03213977|DRUG|R-DA-EPOCH|R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
48322114|NCT03213977|DRUG|R-CEOP90|R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
48322115|NCT00899210|OTHER|laboratory biomarker analysis|
48322116|NCT00899210|PROCEDURE|cryosurgery|
48487686|NCT01528020|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
48487687|NCT01528020|BEHAVIORAL|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
48487688|NCT02418117|OTHER|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
48487689|NCT03967587|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
48322117|NCT00899210|PROCEDURE|radiofrequency ablation|
48322118|NCT00899210|PROCEDURE|therapeutic conventional surgery|
48322119|NCT06319001|OTHER|Low-volume high intensity exercise|This intervention will consist of 10 x 10-second interval sprints on a stationary bicycle interspersed with 50-second breaks between repetitions. The cycle resistance will be adjusted to the level equaling the highest power output, which will be determined during warm-up sprints.
48322120|NCT06319001|OTHER|Combined intermittent sauna and cold water bath (sauna+cold bath).|This intervention will consist of 3x10 min bouts in the dry sauna interspersed with 2x 60 seconds of cold water immersion up to the neck.
48322121|NCT00839878|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
48322122|NCT04721067|DEVICE|SHUTi|SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.
48487690|NCT04975321|DEVICE|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
48487691|NCT04975321|DEVICE|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
48487692|NCT04975321|DEVICE|Composite strip crown|Placement of an anterior primary crown restoration
48487693|NCT04718194|BEHAVIORAL|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
47969713|NCT00580684|BIOLOGICAL|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
47969714|NCT06440057|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
47969715|NCT02052583|PROCEDURE|therapeutic hypothermia at 32 ° C|
48322123|NCT04721067|BEHAVIORAL|Sleep Education/Hygiene|A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
48322124|NCT05338281|DEVICE|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
48322125|NCT02119234|DRUG|Beclometasone/formoterol/glycopyrrolate|
48322126|NCT02119234|DRUG|Placebo|
48322127|NCT02932189|DEVICE|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
48322128|NCT02995330|PROCEDURE|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
48487694|NCT04718194|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
48487695|NCT02867657|BEHAVIORAL|Mindfulness|Five days MBSR curriculum with meditation and yoga
48487696|NCT03037034|DEVICE|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
48487697|NCT01322126|DEVICE|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
48487698|NCT05824117|OTHER|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
48487699|NCT02477774|DEVICE|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
48487700|NCT01183325|DEVICE|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
48487701|NCT01280617|DRUG|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
48647428|NCT06114641|DRUG|Enoxaparin sodium injection|Originator Enoxaparin with a trade name is Lovenox.
48647429|NCT00088881|BIOLOGICAL|rituximab|Given IV
47969716|NCT02052583|PROCEDURE|therapeutic hypothermia at 34 ° C|
48487702|NCT01280617|DRUG|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
48487703|NCT00922558|OTHER|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
48487704|NCT02712801|DRUG|Zidovudine|Dose will be adjusted according to the child's weight.
48487705|NCT02712801|DRUG|Nevirapine|Dose will be adjusted according to the child's weight.
47969717|NCT04829396|OTHER|placebo|Powder consisting of 13 g of digestible carbohydrates with similar appearance as the investigational fibre mixture.
47969718|NCT04829396|DIETARY_SUPPLEMENT|Fibre mixture|The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day.
47969719|NCT03673033|PROCEDURE|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
47969720|NCT00735410|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
47969721|NCT00695487|DRUG|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
48647430|NCT00088881|DRUG|prednisone|Given orally
47969722|NCT01352910|DEVICE|rTMS|120 pulses 0.2 Hz
47969723|NCT01352910|DEVICE|Sham rTMS|120 pulses 0.2 Hz
47969724|NCT04849598|OTHER|Oxygen therapy|Oxygen therapy during ESWTs and Stair Walking Test: one test using the prescribed constant oxygen flow and one using an automatic oxygen titration system. SpO2 target range: 90 - 94%
47969725|NCT00382252|PROCEDURE|computed tomography|
47969726|NCT00382252|PROCEDURE|positron emission tomography|
47969727|NCT00382252|PROCEDURE|radiofrequency ablation|
47969728|NCT02176499|DRUG|Telmisartan, low dose|
47969729|NCT02176499|DRUG|Telmisartan, high dose|
47969730|NCT02176499|DRUG|Placebo|
48322129|NCT02995330|DRUG|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
48322130|NCT02995330|DRUG|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
48322131|NCT06243822|DRUG|Ketamine|ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.
48487706|NCT02712801|DRUG|Lamivudine|Dose will be adjusted according to the child's weight.
48487707|NCT02712801|DRUG|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
48487708|NCT00752674|OTHER|Neuromuscular balance|
48487709|NCT02818387|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
48487710|NCT02818387|DRUG|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
48647431|NCT00088881|DRUG|cyclophosphamide|Given IV
48647432|NCT00088881|DRUG|doxorubicin|Given IV
48647433|NCT00088881|DRUG|vincristine|Given IV
48647434|NCT00088881|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
48647435|NCT00088881|RADIATION|radiation therapy|Undergo radiotherapy
47969731|NCT00567294|BEHAVIORAL|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
48118082|NCT05032638|BEHAVIORAL|Upper extremity (UE) Training|The 4-week UE training is completed in the participants home on their own and communication with study staff is virtual. Participants will receive daily communication through the Expiwell app to answer survey questions related to adherence, and safety/adverse events. Participants will also complete weekly check-ins with their research therapist over Zoom to answer questions about difficulties related to UE training activities, refinement of training goals, and to receive feedback on their training performance. Each weekly check-in will be approximately 45 minutes.
48118083|NCT04444258|OTHER|Application of computer aided virtual reality glasses|Experimental I Group: After the Fetal Development Assessment Information Form (FEGBF), a computer-aided and guided virtual reality application prepared by the researchers including the phases of the fetus week by week will be watched and then FEGBF will be applied again by changing the locations of the questions.
48118084|NCT04444258|OTHER|Teaching fetal development theoretically|Control Group: FEGBF will be applied after 4 hours of theory training. Virtual pregnancy application will not be watched.
48118085|NCT06267131|DEVICE|Brain Pulse Oximeter|Sensor is placed on the right and/or left forehead and maintained with an elasticized headband. The duration of monitoring will last for approximately 60 minutes per monitoring session to obtain sufficient data. Serial monitoring will occur on three consecutive days.
48322132|NCT06243822|DRUG|Propofol|Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
48322133|NCT03178812|PROCEDURE|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
48322134|NCT03178812|DIAGNOSTIC_TEST|Laboratory Blood test|Laboratory Blood Test
48322135|NCT01295580|DEVICE|ARTZ|Hyaluronic acid (five 2.5 mL injections)
48322136|NCT01295580|DEVICE|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
48487711|NCT02818387|DRUG|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
48487712|NCT02880748|OTHER|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
48487713|NCT02880748|OTHER|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
48487714|NCT03666481|BEHAVIORAL|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
48487715|NCT02804555|OTHER|Oxygen|Oxygen administration
48487716|NCT00677079|DRUG|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
48487717|NCT02801552|DEVICE|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
48487718|NCT01763918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
47969732|NCT00567294|BEHAVIORAL|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
48322137|NCT04095754|PROCEDURE|Head-Up Position|Anti-Trendelenburg Position
48487719|NCT01763918|DRUG|Placebo|Administered by subcutaneous injection
48487720|NCT04203121|RADIATION|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
48647436|NCT00088881|PROCEDURE|positron emission tomography|Undergo PET scans
48118086|NCT02209415|BEHAVIORAL|standard follow-up|Outpatient clinic visits
48118087|NCT02209415|PROCEDURE|PET/CT and EUS|PET/CT and EUS
48118088|NCT02186197|OTHER|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
48118089|NCT02359370|DRUG|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
48322138|NCT04095754|DRUG|Dexmedetomidine|Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
48322139|NCT04095754|DRUG|Induction and maintenance of anaesthesia|"Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim."
48322140|NCT00005847|BIOLOGICAL|recombinant interferon alfa|
48322141|NCT00005847|DRUG|estramustine phosphate sodium|
48322142|NCT00005847|DRUG|isotretinoin|
48322143|NCT00005847|DRUG|mitoxantrone hydrochloride|
48322144|NCT00005847|DRUG|paclitaxel|
48487721|NCT03322384|DRUG|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
48497998|NCT04465773|DRUG|Remifentanil, Ultiva®|continuous infusion, target concentration 1 ng/ml
48647437|NCT00467467|DRUG|Alfuzosin Hydrochloride|
48647438|NCT00283985|DRUG|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
48647439|NCT00283985|DRUG|Methotrexate|3 gr/m2 at J1
48647440|NCT00283985|DRUG|Dexamethasone|40 mg/ per os at J1, J2 and J4.
48322145|NCT00005847|DRUG|vinorelbine ditartrate|
48322146|NCT01471860|DEVICE|BAROSTIM NEO System|
48322147|NCT01471860|DRUG|Medical Management|
48322148|NCT02359695|DRUG|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
48322149|NCT05911815|RADIATION|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
48118090|NCT02359370|DRUG|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
48322150|NCT00261248|BIOLOGICAL|Immunization with inactivated bacteria|
48322151|NCT00255086|DRUG|Memantine|10mg Memantine
48322152|NCT00255086|DRUG|Placebo pill|10mg placebo pill
48322153|NCT02943018|OTHER|anovaginal distance variation|Kappa calculation
48322154|NCT03431701|OTHER|Chlorhexidine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
48322155|NCT03431701|OTHER|Iodine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
48322156|NCT03431701|OTHER|Antibiotics|All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
48322157|NCT03000374|DRUG|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
48322158|NCT03000374|DRUG|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
48322159|NCT03000374|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
48322160|NCT03000374|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
48647441|NCT00283985|DRUG|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
48322161|NCT04612153|OTHER|Epidemiologic|Epidemiologic study. Observational, transverse study
48322162|NCT01635010|PROCEDURE|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
48322163|NCT03655717|DRUG|Dronabinol|Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
48322164|NCT03655717|DRUG|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
48487722|NCT03322384|DRUG|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
48487723|NCT03322384|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
48322165|NCT03655717|DRUG|Placebo dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
48322166|NCT03655717|DRUG|Placebo ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
48322167|NCT01996748|DRUG|DF277|Two administrations daily for 7 days
48487724|NCT04171713|BEHAVIORAL|Mindfulness-Based Health Promotion + Treatment as usual|Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
48487725|NCT04171713|BEHAVIORAL|Attachment-based compassion therapy + Treatment as usual|It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
48647442|NCT00272805|DRUG|carvedilol|
48118091|NCT05088629|DIAGNOSTIC_TEST|Clinical Tests|Clinical Tests
48118092|NCT04597658|BEHAVIORAL|Bodyweight supported treadmill training (BWSTT)|In the BWSTT group, walking training will be given by asking the patients to walk on the treadmill as fast as they can, without exceeding the medium intensity according to the Borg scale. Bodyweight support will be gradually reduced according to the patient's tolerance.
48322168|NCT01996748|DRUG|Placebo|Two administrations daily for 7 days
48322169|NCT05154266|BEHAVIORAL|Taking it Further|This programme is offered to individuals who have already completed a Mindfulness-Based Cognitive Therapy (MBCT) or Mindfulness-Based Stress Reduction Programme (MBSR). In this programme, participants explore weekly themes (i.e. 'Responding not reacting' and 'Taking care of ourselves, taking care of others'). These themes reinforce the learning from the eight-week MBCT/MBSR courses whilst also providing new learning opportunities. The programme makes some of the dimensions that are implicit in MBCT/MBSR more explicit; for example, the cultivation of attitudes of mindfulness (such as equanimity, joy, and kindness). These attitudes of mindfulness require a foundational mindfulness practice and thus this is an additive learning theme from traditional MBCT/MBSR programmes.
48322170|NCT05415345|BIOLOGICAL|Cecolin|Bivalent HPV Vaccine
48322171|NCT05415345|BIOLOGICAL|Hecolin|Hepatitis E vaccine
48322172|NCT02745236|OTHER|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
48322173|NCT02745236|OTHER|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
48647443|NCT00382473|BEHAVIORAL|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
48647444|NCT06570135|DIAGNOSTIC_TEST|Detecting Brain Activity with Functional Near Infrared Spectroscopy|Use a functional near-infrared spectroscopy to detect brain activity in the two groups of subjects during resting state and task state.
48118093|NCT04597658|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program includes posture and breathing exercises, lower extremity stretching, active-assistive range of motion and strengthening, balance-coordination exercises, and walking with a physiotherapist on a smooth surface.
48322174|NCT04639401|OTHER|motor entrainment to auditory cues and music during walking on quality of movement|The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
48322175|NCT06509711|OTHER|PLYOMETRICS jump training with HIIT (4 weeks,3 sessions per week)|First set of drills 6 x 40-cm hurdle jumps +5-s sprint\* at 130% of aerobic maximum speed. Second set of drills 6 x 30-cm hurdle jumps with extended legs + 5-s sprint at 130% of aerobic maximum speed. Third set of drills 6 x horizontal jumps + 5-s sprint at 130% of aerobic maximum speed. Fourth set of drills 3 right-leg and 3left-leg hops +5-s sprint at 130% of aerobic maximum speed. Each drills set was performed 2 times in a row. Afterwards, 10 seconds of rest were allowed. Thereafter, this sequence of effort-rest was repeated 8 times. After then, a 3-5 min recovery period was allowed before commencing the next drills set;
48322176|NCT06509711|OTHER|PLYOMETRICS JUMP TRAINING WITHOUT HIIT (4weeks, 3sessions Per week)|Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
48487726|NCT04171713|BEHAVIORAL|Treatment as usual|participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
48647445|NCT02364895|OTHER|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
48647446|NCT02364895|OTHER|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
47969733|NCT00567294|BEHAVIORAL|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
47969734|NCT05238402|DRUG|Statin|Statin on COVID 19 patienst
48118094|NCT03164408|PROCEDURE|Orthopaedic Implant Removal|
48118095|NCT03424499|PROCEDURE|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
48322177|NCT04149639|DIETARY_SUPPLEMENT|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
48487727|NCT02277704|DRUG|TNX-102 SL|
48487728|NCT02277704|DRUG|Placebo|
48487729|NCT05990582|DIAGNOSTIC_TEST|CBCL|A questionnaire on behaviour
48487730|NCT05990582|DIAGNOSTIC_TEST|SDQ|A questionnaire on behaviour
48487731|NCT05990582|DIAGNOSTIC_TEST|CCC-2-NL|A questionnaire on communcational skills
48647447|NCT02364895|OTHER|Males Group 2: New letter with neutral gender content|Unisex letter
48647448|NCT02364895|OTHER|Males Group 3: New letter with male-specific content|New letter tailored for men
48647449|NCT02364895|OTHER|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
48647450|NCT02364895|OTHER|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
48647451|NCT02364895|OTHER|Females Group 2: New letter with neutral gender content|Unisex letter
48647452|NCT01487785|DRUG|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
48322178|NCT03948308|BIOLOGICAL|blood sample|blood sample before, during and after infection treatment
48322179|NCT03899532|DEVICE|Remote Ischemic Conditioning|Standard manual blood pressure cuff
47969735|NCT06009705|DRUG|toripalimab|JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
48118096|NCT03424499|PROCEDURE|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
48118097|NCT03424499|DIAGNOSTIC_TEST|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
48118098|NCT04065113|PROCEDURE|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
48118099|NCT04065113|PROCEDURE|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
48118100|NCT05458817|OTHER|digital platform|Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.
47969736|NCT04644081|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
47969737|NCT04644081|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
47969738|NCT04644081|DRUG|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
47969739|NCT03753529|OTHER|Deep friction massage|Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
48118101|NCT00194714|BIOLOGICAL|HER-2/neu Peptide Vaccine|Given ID
48118102|NCT00194714|OTHER|Laboratory Biomarker Analysis|Correlative studies
48118103|NCT00703950|PROCEDURE|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
48118104|NCT00703950|PROCEDURE|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
48118105|NCT05102409|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed once
48118106|NCT05102409|DRUG|Xiidra® (5% lifitegrast ophthalmic solution)|Xiidra® (5% lifitegrast ophthalmic solution) dosed once
48118107|NCT02803801|BEHAVIORAL|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
48322180|NCT03899532|OTHER|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
48322181|NCT00192439|BEHAVIORAL|High Risk Respiratory Disease|
48322182|NCT06157047|PROCEDURE|Crestal Bone Expansion obtained with the Magnetic Mallet®|A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
48322183|NCT00868452|DRUG|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
48487732|NCT05990582|DIAGNOSTIC_TEST|MCH Feeding scale|A questionnaire on feeding problems
48118108|NCT01210820|DEVICE|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
48322184|NCT00868452|DRUG|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
48487733|NCT05990582|DIAGNOSTIC_TEST|TRF|A questionnaire on behaviour
48487734|NCT05990582|DIAGNOSTIC_TEST|WISC-5-NL|An IQ test for children
48487735|NCT05990582|DIAGNOSTIC_TEST|Movement ABC|A test to assess motor function
48118109|NCT00682708|DIETARY_SUPPLEMENT|PlumpyNut|
48118110|NCT00682708|DIETARY_SUPPLEMENT|PlumpyDoz|
48118111|NCT06250413|OTHER|FMT|Capsulated oral auto fecal microbiota transplant
48118112|NCT06250413|OTHER|Placebo|Capsulated hot chocolate powder
48118113|NCT06250413|DRUG|Amox Clav|5 day course of Amoxicillin Clavulanic acid given to all participants
48322185|NCT06390917|DEVICE|PVA recognition function|Ventilator with the function of identify and judge PVAs
48487736|NCT05990582|DIAGNOSTIC_TEST|CELF-5-NL|A test to assess language development
48487737|NCT05990582|DIAGNOSTIC_TEST|Emma Toolbox|Test of executive functions
48487738|NCT03244423|DRUG|Normal saline at induction|0.5 ml/kg
48487739|NCT03244423|DRUG|Normal saline infusion|1ml/kg/hr. during surgery for six hours
48487740|NCT03244423|DRUG|Intravenous tranexamic acid|50 mg/kg
48118114|NCT05878158|DRUG|Simvastatin|pulpotomy of immature permanent teeth
48118115|NCT04854395|DRUG|Marcain 5 mg/ml|Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
48118116|NCT00396513|DRUG|Simvastatin|
48118117|NCT00396513|DRUG|Simvastatin and Metformin|
48118118|NCT00396513|DRUG|Metformin|
48118119|NCT00455494|DRUG|AQ-13|
48118120|NCT06430346|BEHAVIORAL|Exercise|Physical activity and resistance training
48118121|NCT05030077|DRUG|Anlotinib|Anlotinib(12mg) oral daily for days 1-14, 21 days per cycle
48118122|NCT05030077|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
48487741|NCT03244423|DRUG|infusion tranexamic acid|1mg/kg/hr infusionfor 6 hours
48487742|NCT03244423|DRUG|topical tranexamic acid|50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
48487743|NCT03244423|DRUG|topical normal saline|2 ml/kg into the pericardial cavity before sternal closure
48487744|NCT00588640|DRUG|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
48487745|NCT00588640|DRUG|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
48487746|NCT00588640|DRUG|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
48487747|NCT03874494|DRUG|Brexpiprazole|Brexpiprazole 2-4 mg/day
48487748|NCT03874494|DRUG|Aripiprazole|Aripiprazole 10-20 mg/day
47969740|NCT03753529|OTHER|Pressure release|First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
47969741|NCT03753529|OTHER|control group|Stretching and transcutaneous electrical nerve stimulation
47969742|NCT04554979|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
47969743|NCT02641808|OTHER|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
47969744|NCT02641808|OTHER|no follicular flushing|
47969745|NCT06233981|RADIATION|Moderate-dose Hypofractionated Intensity-modulated Radiotherapy|All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
48118123|NCT05030077|DRUG|Carboplatin|If the patients can't tolerate cisplatin, they will be treated with carboplatin (AUC 4.5mg/mL·min) IV day 1
48118124|NCT05030077|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
48118125|NCT05709899|OTHER|nerve blocks|Comparison of ultrasound-guided erector spinae plane block and transmuscular quadratus lumborum block for postoperative analgesia in abdominal cancer surgeries.
48118126|NCT00162292|DRUG|BMS-582949 and Methotrexate|
48118127|NCT05033314|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg PO daily as thromboprophylaxis
48118128|NCT05033314|DRUG|Placebo|matching placebo daily
48118129|NCT02569866|DRUG|Cephalexin|Capsules containing cephalexin/500mg
48118130|NCT02569866|DRUG|Placebo|Capsules containing placebo/500mg
48118131|NCT05932082|PROCEDURE|myomectomy or not|The study group receive myomectomy, while the control group don't receive myomectomy.
48487749|NCT01681966|DRUG|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
48487750|NCT00485030|DEVICE|Cypher|sirolimus-eluting stent
48118132|NCT00566514|DIETARY_SUPPLEMENT|D-ribose|5 grams administered orally TID
48118133|NCT00566514|OTHER|dextrose|5 grams orally TID
48487751|NCT00485030|DEVICE|Xience-V|everolimus-eluting stent
48487752|NCT02087124|OTHER|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
48497999|NCT04465773|PROCEDURE|tetanic stimulations|10-20-30-40-50-60 milliamps, 5 seconds, 100 Hertz 2 minutes between stimulations delivered via the standard neuromuscular blocking agents monitor
48322186|NCT03591055|OTHER|CGA, medication review, exercise and cognitive stimulation|Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
48322187|NCT00051545|DRUG|Seocalcitol|
48322188|NCT01378936|BEHAVIORAL|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
48322189|NCT01378936|BEHAVIORAL|Motivational Interview only|45 minute Motivational Interview session
48322190|NCT00003466|DRUG|temozolomide|
48322191|NCT00510224|DRUG|Sandostatin|Sandostatin 30mg intramuscular every 28 days
48322192|NCT00171314|DRUG|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
48322193|NCT00171314|DRUG|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
48322194|NCT01228942|DEVICE|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
48487753|NCT03346070|DRUG|Sugammadex 2 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by ABW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
48487754|NCT03346070|DRUG|Sugammadex 2 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by IBW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
48487755|NCT03346070|DRUG|Sugammadex 4 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex (4 mg/kg by ABW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
48487756|NCT03346070|DRUG|Sugammadex 4 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants will receive a single i.v. bolus of Sugammadex (4 mg/kg by IBW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
48647453|NCT06243250|DIAGNOSTIC_TEST|Hyperpolarized 13C-MRI|Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.
48647454|NCT01740518|DRUG|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
48647455|NCT01156467|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
48322195|NCT06066203|DRUG|GNC-035|GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
48322196|NCT01593163|DRUG|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
48322197|NCT01593163|DRUG|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
48322198|NCT05124340|BIOLOGICAL|BCG vial vaccine|Intradermal injection
48322199|NCT05124340|BIOLOGICAL|BCG ampoule vaccine|Intradermal injection
48322200|NCT05097248|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
48322201|NCT05097248|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
48322202|NCT05097248|DRUG|Losartan|Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
48322203|NCT00903747|DRUG|prucalopride|2-10 mg prucalopride
48322204|NCT00903747|DRUG|moxifloxacin|400 mg moxifloxacin (Group 2a)
48322205|NCT00903747|DRUG|placebo|placebo (Group 2b)
48322206|NCT01206452|DRUG|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
48322207|NCT01206452|OTHER|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
48322208|NCT01206452|PROCEDURE|Ablation Procedure|Atrial Fibrillation (AF) ablation
48647456|NCT01156467|DEVICE|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
48647457|NCT06571071|OTHER|De-Stress and Chill Gummies-U001|Two gummies in sequence daily after meal for 60 days
48647458|NCT06571071|OTHER|De-Stress and Chill Gummies-I001|Two gummies in sequence daily after meal for 60 days
48118134|NCT06326632|OTHER|Constant-load Aerobic Exercise|The CL-AE group received a 12-week aerobic training, three times in addition to the respiratory re-training. the program included a moderate-intensity aerobic training program, with an intensity set at 65% of the maximum age-predicted heart rate for 45 minutes. The training intensity and duration were maintained at the same level throughout the program. The CL-AE program included a warm-up for 5 minutes and a cool-down for 5 minutes
48118135|NCT06326632|OTHER|Graded Aerobic exercise|The G-AE group received a 12-week intensity- and duration-graded aerobic training, three times in addition to the respiratory re-training. The G-AE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The G-AE program also included a warm-up for 5 minutes and a cool-down for 5 minutes.
48322209|NCT01733901|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
48322210|NCT01733901|PROCEDURE|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
48322211|NCT02559206|DRUG|Linaclotide|Oral, once daily
48322212|NCT02559206|DRUG|Matching Placebo|Oral, once daily
48322213|NCT02589795|BIOLOGICAL|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
47969746|NCT06233981|DRUG|Tislelizumab|One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
47969747|NCT00297830|DRUG|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
47969748|NCT00297830|DRUG|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
47969749|NCT00297830|OTHER|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
47969750|NCT00297830|OTHER|Placebo Alendronate|Placebo alendronate 70 mg once weekly
47969751|NCT05450952|DIETARY_SUPPLEMENT|Theanine Formulation|Theanine Formulation Tablet
47969752|NCT05450952|DIETARY_SUPPLEMENT|Placebo|Placebo Tablet
47969753|NCT01651247|PROCEDURE|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
47969754|NCT04113005|DRUG|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
47969755|NCT06103123|DIAGNOSTIC_TEST|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives
47969756|NCT06103123|OTHER|Baseline Quality of Life questionnaire|Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study
47969757|NCT03899571|DRUG|Oseltamivir Oral Capsule for 5 days post-exposure|Patients will receive oseltamivir for 5 days after last influenza exposure.
47969758|NCT03899571|DRUG|Oseltamivir Oral Capsule for 10 days post-exposure|Patients will receive oseltamivir for 10 days after last influenza exposure.
48322214|NCT02589795|BIOLOGICAL|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
47969759|NCT01377883|OTHER|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
47969760|NCT01377883|BEHAVIORAL|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
47969761|NCT02032121|PROCEDURE|Blood specimen|
48118136|NCT06326632|OTHER|Respiratory Re-training|The respiratory re-training lasted for 30 minutes per session and was repeated three times a week for 12 consecutive weeks. The program consisted of diaphragmatic breathing exercises, breath-hold, and breathing control exercises, pursed lip breathing, respiratory muscle strengthening, postural correction exercises, and relaxation techniques.
48118137|NCT04115683|OTHER|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
48322215|NCT02589795|DEVICE|Trigrid Delivery System - Intramuscular|Electroporation
48322216|NCT02589795|DEVICE|Trigrid Delivery System - Intradermal|Electroporation
48322217|NCT01146249|OTHER|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
48647459|NCT06571071|OTHER|Placebo Gummies-001|Two gummies in sequence daily after meal for 60 days
47969762|NCT02032121|PROCEDURE|Echocardiography|
47969763|NCT01830270|DRUG|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
48322218|NCT04012944|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)."
48322219|NCT00426114|DRUG|Administration of an IV glucose-injection|
47969764|NCT01830270|DRUG|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
47969765|NCT01830270|DRUG|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
47969766|NCT01830270|PROCEDURE|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
47969767|NCT02968901|DRUG|macitentan|used in open label
47969768|NCT02968901|DRUG|tadalafil|used in open label
48322220|NCT05846295|OTHER|ESTIMATE|An online educational module consisting of a video tutorial and feedback during a questionnaire
47969769|NCT03325283|DEVICE|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
47969770|NCT05282758|OTHER|Free Movement Dance|Free Movement Dance as a physiotherapy intervention
48322222|NCT00671814|DRUG|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
48322223|NCT00671814|DRUG|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
48322224|NCT00671814|DRUG|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
48322225|NCT00188266|DRUG|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
48322226|NCT06043141|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
48647460|NCT04911751|DRUG|KBL697|1 capsule BID of KBL697 or Placebo
48647461|NCT04911751|DRUG|KBL697|5 capsules BID of KBL697 or Placebo
48647462|NCT04917939|OTHER|RNA sequencing|Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.
47969771|NCT05282758|OTHER|Modified person-centred progressive resistance exercise|Modified person-centered progressive resistance exercise as a physiotherapy intervention
47969772|NCT05664971|BIOLOGICAL|Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
47969773|NCT05664971|BIOLOGICAL|Toripalimab|240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
47969774|NCT05664971|DRUG|Docetaxel|60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
48647463|NCT06391333|DEVICE|laryngeal mask airway and endotracheal tube|The two most commonly used devices for mechanical ventilation.
48118138|NCT04115683|OTHER|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
48647464|NCT03906955|BEHAVIORAL|Efficacy for Lifestyle PA|The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
48647465|NCT03906955|BEHAVIORAL|Efficacy for Work-life Balance|The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
48322227|NCT06043141|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
48322228|NCT06043141|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold (PPT) is used to measure deep muscular tissue pain sensitivity.
48322229|NCT00002717|DRUG|cisplatin|
48322230|NCT00002717|DRUG|paclitaxel|
48322231|NCT03210779|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
48322232|NCT03210779|DIETARY_SUPPLEMENT|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
48322233|NCT04674839|DRUG|MS-20|fermented soymilk product
48322234|NCT04674839|OTHER|Placebo|No active ingredient
48498000|NCT04465773|DEVICE|VideoAlgesiGraph|non invasive infrared camera placed in front of the left eye of the patients during the study period, connected to a laptop. No part of the device touches the eye.
47969775|NCT05664971|DRUG|Pemetrexed|500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
48118139|NCT03265886|DRUG|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
47969776|NCT05664971|DRUG|Cisplatin|75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
48118140|NCT03265886|DRUG|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
48118141|NCT04666857|OTHER|early motor intervention|infants with CHD after open heart surgery will receive early intervention
48118142|NCT03152344|PROCEDURE|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value \>12 seconds).
48322235|NCT03179007|BIOLOGICAL|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
48322236|NCT02545842|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48322237|NCT06483763|OTHER|SmokerFace App from the Education Against Tobacco (EAT) program|The SmokerFace App utilizes photo-aging technology that requires users to take a selfie. This selfie is processed by the software to generate four images depicting the consequences of smoking (or not smoking) one pack a day over both a one-year and 15 years. The app provides explanations of these smoking beauty-reducing visual outcomes and educates users about the aesthetic impacts of smoking, along with potential health consequences.
48322238|NCT06483763|OTHER|The use of standardized school-based educational module|This module is designed to promote a tobacco- and nicotine-free environment and is validated by at least three experts in related fields (27). The intervention will be customized to fit the Omani sociocultural context and will be administered in the classrooms of respective schools by the same team of trained medical students
48647466|NCT05757349|BEHAVIORAL|Face-down position time 1-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
48647467|NCT05757349|BEHAVIORAL|Face-down position time 3-day|Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
48118143|NCT02634541|DRUG|Adalimumab|Biologic drug
48118144|NCT02634541|OTHER|PET/CT imaging|PET/CT imaging
48118145|NCT02152813|BEHAVIORAL|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
48118146|NCT01343290|DRUG|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
48118147|NCT02645149|DRUG|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
48118148|NCT02645149|DRUG|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
48487757|NCT03346070|DRUG|Neostigmine + Glycopyrrolate|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 µg/kg; 5 mg maximum) and Glycopyrrolate (10 µg/kg; 1 mg maximum), dosed according to participant ABW for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
48647468|NCT06127901|PROCEDURE|Any surgery under any type of anaesthesia.|Any surgery under any type of anaesthesia.
47969777|NCT05664971|DRUG|Carboplatin|AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
47969778|NCT05664971|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
47969779|NCT05664971|DRUG|Etoposide|100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
47969780|NCT05165901|DEVICE|Scrambler Therapy|LG Medipain is a type of non-invasive neuromodulation.
47969781|NCT01858298|OTHER|Conservative treatment: pulpectomy and composite resin crown|
48647469|NCT04519138|DEVICE|Endodrill Model X|The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract
47969782|NCT01858298|OTHER|Non-conservative treatment: Tooth extraction|
47969783|NCT06051227|DRUG|Fentanyl Citrate|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
48647470|NCT04519138|DEVICE|Fine-needle aspiration/biopsy|The standard method is used for biopsy sampling in the upper gastrointestinal tract
47969784|NCT06051227|DRUG|Esketamine|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
47969785|NCT05916014|DIAGNOSTIC_TEST|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
47969786|NCT00975650|DRUG|Nasobol®|Intra-nasal Testosterone (2 syringes), b.i.d.
48118149|NCT02645149|DRUG|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
48322239|NCT06461546|DRUG|Imlifidase|"* Imlifidase (POD0, pre-transplantation), imlifidase, 0.25 mg/kg over a period of 15 minutes, prior to transplantation.~* Dose Adjustment Criteria~FC-XM screening and single antigen will be performed after 6 hours of imlifidase infusion, It will take 3 hours to obtain the results, respectively:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - 2nd Imlifidase infusion will be required (imlifidase dose: 0.25mg/Kg).~FC-XM screening and single antigen will be performed after 2 hours of the 2nd Imlifidase infusion:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - The scheduled kidney transplant will be canceled."
48322240|NCT00078559|DRUG|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
48322241|NCT00078559|DRUG|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
48322242|NCT00078559|DRUG|Tacrolimus|2mg orally twice daily, on days 1-60
48322243|NCT00078559|PROCEDURE|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
48322244|NCT00078559|DRUG|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
48322245|NCT00078559|DRUG|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
47969787|NCT00975650|DRUG|Androderm® (Positive Control)|QD administration
48322246|NCT00078559|DRUG|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
47969788|NCT02626546|PROCEDURE|Major surgical procedure|observation of postoperative outcomes
47969789|NCT00878423|DRUG|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
47969790|NCT00878423|DRUG|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
47969791|NCT06342414|DIAGNOSTIC_TEST|ELUCIDATE|ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)
47969792|NCT06124560|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
47969793|NCT00134238|DRUG|torcetrapib/atorvastatin|
47969794|NCT00134238|DRUG|atorvastatin|
47969795|NCT06281990|BEHAVIORAL|Education|"1. Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.~2. When the patient was hospitalized, anxiety level with the Trait Anxiety scale and pain level with VAS were determined one day before surgery.~3. Postoperatively, the patient's pain level before analgesics every 4-6hours for 2days, the patient's anxiety level with the State Anxiety Scale one day after surgery, the development of complications in the postoperative period, vital signs were evaluated, and the duration of hospitalization was recorded."
47969796|NCT06368544|OTHER|lower-body positive-pressure|By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
47969797|NCT05850546|DRUG|Rituximab|Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
47969798|NCT05850546|DRUG|Corticosteroid|guideline-recommended corticosteroid therapy
47969799|NCT04873505|DIETARY_SUPPLEMENT|troches|Take one troche after each meal.
47969800|NCT02417831|DRUG|tamsulosin capsules|
47969801|NCT02417831|DRUG|tamsulosin HCl|
47969802|NCT04774328|DRUG|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
47969803|NCT04774328|DRUG|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
48322247|NCT00078559|DRUG|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
48322248|NCT00078559|DRUG|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
48322249|NCT00078559|DRUG|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
48322250|NCT00078559|DRUG|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
48322251|NCT00078559|DRUG|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
48322252|NCT00078559|DRUG|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
48322253|NCT04093258|DEVICE|Dailies Total 1® Multifocal Contact Lenses|TEST
48322254|NCT04093258|DEVICE|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
48487758|NCT03346070|DRUG|Rocuronium or Vecuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide or Vecuronium Bromide administered via i.v. infusion and dosed according to participant ABW. NMBAs were concomitant medications used per label as adjunct to general anesthesia.
48487759|NCT06434922|DEVICE|Prevention Strategies|Data collection sessions lasted approximately 1 to 1.50 hours, with education and foot care provided once a month. Subsequently, patients underwent monthly follow-ups for three months, during which they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management.
48487760|NCT06434922|DEVICE|Standard Strategiies|Group were educated about DM management, medication adherence, dietary practices, physical exercise routines, and foot care through pamphlets
48487761|NCT02494050|BEHAVIORAL|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
48487762|NCT02494050|BEHAVIORAL|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
48647471|NCT03893916|PROCEDURE|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
48647472|NCT05356429|OTHER|Small molecule LCDM|The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
47969804|NCT01776112|OTHER|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
47969805|NCT01776112|OTHER|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
47969806|NCT03992001|BIOLOGICAL|Blood component A|PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
47969807|NCT03992001|BIOLOGICAL|Blood component B|PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
47969808|NCT04418453|OTHER|Integration of telemedicine for MOUD in primary care|Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
47969809|NCT04460638|BIOLOGICAL|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
47969810|NCT04460638|OTHER|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
48322255|NCT05027516|DRUG|Rocephin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
48322256|NCT05027516|DRUG|Azithromycin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
48487763|NCT02494050|BEHAVIORAL|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
48647473|NCT03958097|COMBINATION_PRODUCT|NK cell and PD-1 antibody|Each patient enrolled the study will received both NK cell and PD-1 antibody.
47969811|NCT04507737|OTHER|Rapid Response Team Composition_ ICU Nurse|In case of deterioration a Rapid Response Team may be activated. We will be examining the composition of the teams alternating between a MET or a CCOT.
47969812|NCT05013684|OTHER|Particle Repositioning Maneuver|treatment with Particle Repositioning Maneuver
48322257|NCT02791971|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~* Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~* Printed materials for recipients to keep and/or share with friends.~* Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~* Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
47969813|NCT01294631|DRUG|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
48322258|NCT02791971|BEHAVIORAL|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
48322259|NCT04766138|DEVICE|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
48322260|NCT00589979|DRUG|Lidoderm (Lidocaine 5% Patch)|Topical Patch
48322261|NCT00589979|DRUG|Placebo Patch|Topical Patch
48322262|NCT04625894|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
48322263|NCT04625894|DRUG|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
48322264|NCT03160664|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
48322265|NCT03160664|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
48322266|NCT03160664|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
48322267|NCT00258206|BIOLOGICAL|rituximab|
48322268|NCT00258206|DRUG|cyclophosphamide|
48322269|NCT01136668|PROCEDURE|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
48322270|NCT01136668|PROCEDURE|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
48322271|NCT05764278|OTHER|exercise|exercise group: first bed exercise after 0\~24hr onset ; sit at bed after 24\~48hr onset control group: first bed exercise after 24\~48hr onset ; sit at bed after 48\~72hr onset
47969814|NCT04711044|OTHER|Papain|Papain will be applied using cowhage spicules inactivated by heat
48322272|NCT03617003|DRUG|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
48322273|NCT03617003|PROCEDURE|Endoscopy|Endoscopy of the bladder
48487764|NCT01543555|DRUG|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
47969815|NCT04711044|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
48487765|NCT01543555|DRUG|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
47969816|NCT04711044|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
47969817|NCT04711044|OTHER|L-menthol|A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
48647474|NCT04486677|BEHAVIORAL|Caring Cards Group|Group of Veteran card-makers.
48322274|NCT04846166|DIAGNOSTIC_TEST|Periodontally healthy group|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
48322275|NCT04846166|DIAGNOSTIC_TEST|Periodontitis|: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
48322276|NCT03863067|PROCEDURE|Epiduroscopy|Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
48322277|NCT01949727|OTHER|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
48322278|NCT02841319|OTHER|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
48322279|NCT00091923|DEVICE|Eye patch|
48322280|NCT00091923|DEVICE|Spectacles|
48322281|NCT00243100|DRUG|vorinostat|Given orally
48322282|NCT00243100|DRUG|gemcitabine hydrochloride|Given IV
48322283|NCT00583440|BEHAVIORAL|12-step facilitation|12 weekly individual 12-step facilitation sessions
48322284|NCT00583440|BEHAVIORAL|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
48322285|NCT06441851|PROCEDURE|Videolaparoscopic Partial Nephrectomy|Videolaparoscopic partial nephrectomy
48322286|NCT06441851|PROCEDURE|Robot-assisted Partial Nephrectomy|Robot-assisted partial nephrectomy
48322287|NCT02665364|BIOLOGICAL|IFNα-Kinoid|
48322288|NCT02665364|OTHER|Placebo|
48322289|NCT02665364|OTHER|ISA 51 VG|
48322290|NCT02387372|DRUG|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
48322291|NCT02387372|DRUG|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
48322292|NCT01240655|DRUG|LCL161|
48322293|NCT01240655|DRUG|Paclitaxel|
48322294|NCT03517917|OTHER|Tumour tissue collection|Collection of tumour tissue and blood
48322295|NCT05450458|DRUG|KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA|KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
48322296|NCT06258135|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|Single 7g dose daily for 28 days
48322297|NCT06258135|DIETARY_SUPPLEMENT|Maltodextrin|Single 7g dose daily for 28 days
48322298|NCT05528770|DEVICE|FCL+BPS|The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances
48322299|NCT05528770|DEVICE|FCL|The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.
48322300|NCT01413542|DRUG|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
48322301|NCT01413542|DRUG|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
48322302|NCT01413542|DRUG|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
48322303|NCT01413542|DRUG|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
48322304|NCT01413542|DRUG|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
48322305|NCT01413542|DRUG|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
48647475|NCT04486677|BEHAVIORAL|Caring Cards Recipients|Group of Veteran card-recipients.
48322306|NCT01478152|OTHER|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
48322307|NCT03498287|DEVICE|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
48322308|NCT03498287|DEVICE|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). \*Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
48322309|NCT04785391|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
48322310|NCT04662216|PROCEDURE|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
48647476|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
48118150|NCT02645149|DRUG|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
48118151|NCT02645149|DRUG|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
48647477|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
48647478|NCT02735642|BEHAVIORAL|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
48322311|NCT04662216|PROCEDURE|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
48498001|NCT02430779|PROCEDURE|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
48647479|NCT02735642|BEHAVIORAL|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
48647480|NCT02735642|BEHAVIORAL|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
48647481|NCT02735642|OTHER|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
48647482|NCT02739880|DEVICE|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
48647483|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
48647484|NCT01103115|DIETARY_SUPPLEMENT|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
48647485|NCT01103115|DIETARY_SUPPLEMENT|Placebo|placebo tablets
48647486|NCT05073731|OTHER|Telerehabilitation-based Upper Extremity Training|"Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training."
48498002|NCT02430779|DEVICE|NanoKnife|
48498003|NCT00123474|DRUG|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
48647487|NCT00101400|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
47969818|NCT05157230|BEHAVIORAL|exercise|volunteers in the exercise arm instructed to do three basic deltoid muscle exercises 3 times daily at least 20 repetitions for each exercise for five days. exercises were side lateral shoulder raises, front shoulder raises with hyperextension and mid range arm circles.
47969819|NCT05174377|DIAGNOSTIC_TEST|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
47969820|NCT02204397|DRUG|INGAP Peptide, Ustekinumab|
47969821|NCT06446700|OTHER|neck disability index and visual functional questionnaire|participants complete the 2 questionnaire by an online form and paper
48118152|NCT02202395|DRUG|LTS 0.25mg|use LTS 0.25mg/d
48118153|NCT02202395|DRUG|LTS 0.5mg|use LTS 0.5mg/d
48118154|NCT02202395|DRUG|LTS 1.0mg|use LTS 1.0mg/d
48118155|NCT02202395|DRUG|Placebo|use placebo once daily
48498004|NCT00123474|DRUG|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
48498005|NCT00123474|DRUG|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
48322312|NCT04020094|COMBINATION_PRODUCT|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
48322313|NCT01906866|DRUG|Circadin 2/5/10 mg|Circadin 2/5/10 mg. Active arm
48322314|NCT01906866|DRUG|Placebo|Control arm
48322315|NCT01841918|BIOLOGICAL|Avian Flu Vaccine|
48647488|NCT03582397|DEVICE|Virtual Reality Mirror Therapy|Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
48647489|NCT02174770|OTHER|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
48322316|NCT04727606|DRUG|Ure-Na|"* Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~* Treatment will continue for approximately 1 month."
48322317|NCT04413643|DEVICE|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 \>45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
48322318|NCT04888234|DRUG|Ru-Yi-Jin-Huang Powder|Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
48322319|NCT01362946|BEHAVIORAL|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
48647490|NCT02174770|OTHER|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
48322320|NCT01362946|BEHAVIORAL|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
48322325|NCT04050501|DEVICE|non-invasive Vagus Nerve Stimulator|Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
48647491|NCT00912509|DRUG|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
48322326|NCT04622969|BEHAVIORAL|Healthy Child Development Program|The Healthy Child Development Program is a family-based intervention focused on strengthening positive behaviors in children, managing misbehavior, and addressing healthy lifestyle choices.
48498006|NCT00123474|DRUG|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
48498007|NCT05710939|OTHER|exercises|
48498008|NCT03907384|BEHAVIORAL|Mat Pilates training|This group completed 12-weeks of training
48647492|NCT00912509|DEVICE|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
48647493|NCT04228003|DIETARY_SUPPLEMENT|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
48118156|NCT01514344|DRUG|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
48118157|NCT01514344|BIOLOGICAL|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
48322327|NCT05108480|OTHER|Experimental group|This study followed the protocol designed for patients with hemophilic knee arthropathy. For its implementation, a 30-cm long15-cm diameter foam roller was used, and a ball 22 cm in length and 8 cm in diameter. The total duration of the intervention was 15 minutes, with 7 sessions per week over a period of 8 weeks. The physiotherapist who supervised the intervention followed up on all patients by telephone on a weekly basis to check for the absence of haemarthrosis during the intervention and to detect the possible need for protocol adaptations depending on the clinical situation of each patient. Each patient was individually provided with instructions as to how perform the exercises during the pretreatment evaluation, customizing the program if necessary. All patients had access to a mobile application, designed ad hoc for the research study (He-Foam®), where they could learn about the exercises through demonstration videos.
48322328|NCT02769806|PROCEDURE|MRI|
48322329|NCT03482141|DEVICE|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
48322330|NCT04414696|BEHAVIORAL|Exercise intervention|eHealth exercise intervention for postpartum women at increased risk of depression
48322331|NCT04042675|DIAGNOSTIC_TEST|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
48322332|NCT03386578|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
48322333|NCT03386578|BEHAVIORAL|Behavioral HIV risk reduction package|HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
48322334|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone
48322335|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
48322336|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with nivolumab combination
48322337|NCT05085431|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
48322338|NCT04706429|DRUG|Trientine|Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
48322339|NCT04706429|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
48487766|NCT06032455|BEHAVIORAL|Multisystemic therapy|Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.
48487767|NCT06032455|BEHAVIORAL|Multisystemic therapy - intellectual disabilities|Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
48487768|NCT06138470|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
48487769|NCT06138470|DIETARY_SUPPLEMENT|Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
48322340|NCT05543460|PROCEDURE|MARPE with Corticopunctures|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency aided with corticopunctures made along the mid-palatal suture
48322341|NCT05543460|DEVICE|MARPE|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency
48322342|NCT03054987|PROCEDURE|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
48487770|NCT06138470|DIETARY_SUPPLEMENT|Saffron and Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
48487771|NCT06138470|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Food supplements are taken during 6 weeks by healthy volunteers
48487772|NCT03131622|BEHAVIORAL|Digital Therapeutics|
48322343|NCT03054987|PROCEDURE|ERCP|During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
48322344|NCT06164145|OTHER|Usual care|The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.
48322345|NCT06101524|PROCEDURE|Free gingival unit, free gingival greft|The free gingival graft and the free gingival unit taken from the upper jaw palatal mucosa were sutured to the lower jaw anterior region.
48647494|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 14 days before surgery|
48322346|NCT02251444|PROCEDURE|outpatient rehabilitation program|
48322347|NCT02251444|PROCEDURE|physical therapy|
48322348|NCT03810209|DRUG|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
48322349|NCT03810209|DRUG|Normal saline|adding normal saline to local anaesthetic in SAP block
48322350|NCT05389059|PROCEDURE|CAF+CM|Periodontal surgery including CAF+CM application
48322351|NCT05389059|PROCEDURE|I-PRF|Periodontal surgery including CAF+CM application with i-PRF
48322352|NCT02763293|OTHER|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
48322353|NCT00470652|DEVICE|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was \>4/10. After a 10-day test period, the post-intervention data collection started.
48322354|NCT00004418|DRUG|glyceryl trierucate/glyceryl trioleate|Administration of glyceryl trierucate/glyceryl trioleate
48322355|NCT03904524|BEHAVIORAL|SET-to-Meet|The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
48322356|NCT01611129|BEHAVIORAL|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
48322357|NCT01006863|DRUG|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
48487773|NCT04231734|OTHER|Ketogenic Diet|Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)
48498009|NCT02348723|DRUG|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
48647495|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 72 hours before surgery|
48647496|NCT04304287|PROCEDURE|Without preoperative blood donation|
48647497|NCT04194619|OTHER|Questionnaire|Interview of women with a rare vascular disease through a phone questionnaire about severe and specific obstetrical complications during and after pregnancy.
48647498|NCT02096926|DRUG|Placebo|
48647499|NCT02096926|DRUG|Ibuprofen|400 mg PO
48647500|NCT03127163|DEVICE|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
48647501|NCT04125758|BEHAVIORAL|Mindfulness training|Brief audio recordings discussing mindfulness or guided mindfulness practices.
48498010|NCT02348723|DRUG|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
48647502|NCT04125758|BEHAVIORAL|Tracking time spent on mobile device|Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
48647503|NCT05900349|OTHER|Carbohydrate mouth rinsing|the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
48647504|NCT05900349|OTHER|200 mg caffeine gum|Chewing caffeinated gum for 20 minutes
48647505|NCT02685852|DRUG|Exenatide|Exenatide at a dose of 5 mcg
48647506|NCT02685852|DRUG|Acarbose|Acarbose at a dose of 25 mg
48647507|NCT02685852|DRUG|Exenatide Placebo|Placebo for Exenatide
48322358|NCT01006863|DRUG|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
48322359|NCT01006863|DRUG|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine \[group 5 (n=30)\] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
48322360|NCT05469477|BEHAVIORAL|Persuasive education|The research team will use psychology and communications research to present information about seat belts and distracted driving in a way that builds intrinsic motivation to change. Because positively framed messages are more effective at promoting seat belt wearing, the team's messaging will employ this framing. Education will address common reasons that survey participants give for not consistently buckling up or for phone use while driving.
48322361|NCT05469477|BEHAVIORAL|WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)|Participants will receive an intervention on improving driving behavior with a specific goal in mind and how to reach that goal. Participants will do this by thinking through 4 parts: a wish, an outcome, an obstacle and a plan. This has been shown to build motivation, and help achieve the desired change.
48322362|NCT05469477|BEHAVIORAL|Customized Habit Tips|Participants will receive weekly text-message tips, informed by findings from survey responses, plus reminders to address stated obstacles.
48322363|NCT05469477|BEHAVIORAL|Raffle Financial Incentive|Each week, participants who adhere to seat belt use or abstain from phone use while driving get a chance at prize money. One winner will be randomly chosen for each target behavior and earn prize money; the rest will not receive compensation.
48322364|NCT05469477|BEHAVIORAL|Shared Pot Financial Incentive|This will be identical to the raffle incentive, except that each week participants who adhere to seat belt use or abstain from phone use while driving will be guaranteed an equal share of prize money.
48322365|NCT05469477|BEHAVIORAL|Weekly SMS Support text|Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
48322366|NCT05469477|BEHAVIORAL|Weekly SMS Encouragement|Those who have a perfect streak going midway through each week will receive an additional encouraging message cheering them on.
48322367|NCT03988608|DRUG|Eltrombopag 25 mg|film-coated tablets containing 25 mg of eltrombopag free acid in each tablet
48322368|NCT04985318|DRUG|Cablivi®|Intervention with Cablivi® take place outside of the study
48322369|NCT04703127|DRUG|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
48322370|NCT04703127|DRUG|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
48322371|NCT04198324|PROCEDURE|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
48322372|NCT04198324|PROCEDURE|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
48322373|NCT00750165|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
48322374|NCT02943512|OTHER|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
48322375|NCT01833104|BEHAVIORAL|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills \& interoceptive body awareness. 2 exercises: Breathing Meditation \& Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, \& other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation \& Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
48487774|NCT06367036|OTHER|Topical hypericum perforatum oil intervention|The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.
48487775|NCT06223217|OTHER|Surveys and Questionnaires|The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
48487776|NCT00732420|DRUG|topotecan|Topoisomerase I inhibition.
48487777|NCT00732420|DRUG|pazopanib|Tyrosine kinase inhibitor
48498011|NCT02013479|DIETARY_SUPPLEMENT|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
48647508|NCT02685852|DRUG|Acarbose Placebo|Placebo for Acarbose
48647509|NCT03493893|DEVICE|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
48647510|NCT05438771|COMBINATION_PRODUCT|Ankaferd Blood Stopper|mouth wash
48647511|NCT05438771|OTHER|Bicarbonate|mouth wash
48647512|NCT01627912|OTHER|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink \[white wine or red wine or 12.5% ethanol or water\]/kg of individual, parallel with a standardized meal.
48647513|NCT04389463|OTHER|No intervention|No description
48322376|NCT01833104|BEHAVIORAL|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
48322377|NCT01833104|BEHAVIORAL|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
48322378|NCT03956225|DEVICE|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
48322379|NCT03956225|DEVICE|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
48118158|NCT03565796|BEHAVIORAL|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
48118159|NCT03565796|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
48322380|NCT06347341|DIETARY_SUPPLEMENT|Clinical study comparing a gluten-containing diet to a gluten-free diet|The study includes a basal period of 2 weeks, 2 test periods of a maximum duration of 1 week and a wash-out period of 2 to 3 weeks.
48322381|NCT01379495|BEHAVIORAL|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
48322382|NCT00608452|OTHER|Symptom Assessment Scale|"* Memorial Symptom Assessment Scale~* History and neurologic examination"
48322383|NCT06379867|DRUG|HSK3486|0.4 mg/kg, IV bolus administration
48322384|NCT06379867|DRUG|Placebo|IV bolus administration
48322385|NCT06379867|DRUG|Moxifloxacin|0.4 g, Oral administration with 240 mL
48322386|NCT03300752|BEHAVIORAL|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
48322387|NCT03300752|BEHAVIORAL|Control Intervention|PCP will provide discussion of healthy lifestyles.
48322388|NCT02898519|OTHER|cohort|Blood sampling
48322389|NCT04184115|DRUG|DPI-386 Nasal Gel|1.5 mg reservoir of scopolamine to be delivered over a 72-hour period
48322390|NCT04184115|DRUG|Placebos|Placebo Nasal Gel and placebo patch
48487778|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques
48647514|NCT00801255|DRUG|RO5024048|500mg po bid/100mg po q8h for 7 days
48647515|NCT00801255|DRUG|danoprevir|500mg po bid/100mg po q8h for 14 days
48647516|NCT00801255|DRUG|danoprevir|1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days
48118160|NCT03565796|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
48118161|NCT03565796|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
48118162|NCT03565796|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
48118163|NCT03234088|BEHAVIORAL|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
48118164|NCT00360698|DRUG|Insulin Glargine|One daily injection at bedtime
48118165|NCT00360698|DRUG|Glimepiride|At same dosage as during the run-in period
48322391|NCT00176241|DRUG|gemcitabine|2000-3000mg/m2 IV on days 1 \& 15
48322392|NCT00176241|DRUG|paclitaxel|150 mg/m2 IV on days 1 \& 15
48322393|NCT00176241|RADIATION|radiation|50-80 cGy on days 1,2,15,16
48322394|NCT02284685|BEHAVIORAL|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
48322395|NCT00853489|DEVICE|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
48322396|NCT00853489|PROCEDURE|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
48322397|NCT05797454|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the lesion
48322398|NCT05797454|PROCEDURE|Wire-guided localization|Positioning guide wire in the center of the lesion
48322399|NCT01174953|DRUG|finasteride|"Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)"
48322400|NCT05412537|OTHER|MI|How to motivate people
48322401|NCT05412537|OTHER|CAU|consult as usual
48487779|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia and additive bb-glasses|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, bb-glasses worn from 3 hrs before bedtime.
48487780|NCT04463498|OTHER|8-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
48647517|NCT00801255|DRUG|danoprevir|1000mg po bid/200mg po q8h for 14 days
48322402|NCT02683694|DEVICE|iOCT|the number of subjects that can be peeled without dye are assessed
48322403|NCT03364335|DRUG|Leu Sil 1.0mg|Leu 1100 mg + 1mg Sil BID
48322404|NCT03364335|DRUG|Leu Sil 4.0mg|Leu 1100 mg + 4mg Sil BID
48322405|NCT03364335|DRUG|Leu Met Sil 1.0mg|Leu 1100 mg + Met 500mg + 1mg Sil BID
48322406|NCT03364335|DRUG|Leu Met Sil 4.0mg|Leu 1100 mg + Met 500mg + 4mg Sil BID
48322407|NCT03364335|DRUG|Placebo|Placebo
48322408|NCT05841264|BEHAVIORAL|good feeding, cleaning|taking healthy food which contain minerals, vitamins essential for normal growth
48322409|NCT02513784|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
48322410|NCT01196650|DRUG|IN 10 003 formulation A|
48322411|NCT01196650|DRUG|IN 10 003 formulation B|
48322412|NCT01196650|DRUG|Placebo capsules|
48322413|NCT03364673|OTHER|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
48322414|NCT03364673|OTHER|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
48322415|NCT03734952|RADIATION|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
48322416|NCT03734952|DRUG|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
48322417|NCT03734952|PROCEDURE|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
48322418|NCT03734952|RADIATION|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
48487781|NCT03459352|OTHER|ePRO|"Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction."
48487782|NCT02429934|BIOLOGICAL|abatacept also known as Orencia also known as CTLA4-Ig|125mg injected subcutaneously weekly for 16 weeks
48118166|NCT00360698|DRUG|Insulin Glulisine|One bolus given before the main meal
48118167|NCT00360698|DRUG|Metformin|At same dosage as during the run-in period
48118168|NCT01580319|OTHER|physical exercise|150 minutes per week
48322419|NCT06061042|BEHAVIORAL|Early time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
48322420|NCT06061042|BEHAVIORAL|Late time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
48322421|NCT02300428|DIETARY_SUPPLEMENT|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
48322422|NCT00479024|DRUG|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
48322423|NCT05786014|BEHAVIORAL|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
48322424|NCT05786014|BEHAVIORAL|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
48322425|NCT06270355|PROCEDURE|Risk based screening|Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
48487783|NCT02429934|DRUG|Placebo|
48487784|NCT01221246|DRUG|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
48498012|NCT02013479|DIETARY_SUPPLEMENT|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
48498013|NCT00253695|DEVICE|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
48647518|NCT00801255|DRUG|danoprevir|1000mg/600mg po twice daily for 14 days
48647519|NCT00801255|DRUG|danoprevir|1000mg/900mg po twice daily for 14 days
48647520|NCT01292993|DRUG|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
48322426|NCT00000255|DRUG|Nitrous oxide|
48322427|NCT03905395|BEHAVIORAL|Meditation and mindfulness|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
48322428|NCT01784952|DIETARY_SUPPLEMENT|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
48322429|NCT01240148|DRUG|AZD3161|Single dose, intradermal injection
48322430|NCT01240148|DRUG|Lidocaine|Single dose, intradermal injection
48322431|NCT01240148|DRUG|AZD3161 Placebo|
48322432|NCT03832153|PROCEDURE|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
48322433|NCT01495338|DRUG|AC-170 0.17%|1 drop in one eye at one timepoint
48322434|NCT01495338|DRUG|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
48322435|NCT01495338|DRUG|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
48322436|NCT01495338|DRUG|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
48322437|NCT05890313|DIAGNOSTIC_TEST|Mini Mental State Examination|MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.
48322438|NCT05890313|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.
48322439|NCT05890313|DEVICE|Brain on Track (version BOT.0.0.0 03.03.2023)|Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
48322440|NCT06171672|OTHER|Semi-structured interview|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
48322441|NCT00965783|OTHER|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
48322442|NCT00965783|OTHER|Extension|Bedtime is extended by 2 hours per night for 4 nights
48487785|NCT01221246|DRUG|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
48118169|NCT05887063|OTHER|Dementia Awareness Course UK|An online course delivered to a small group of informal caregivers in between 3 and 4 hours. The course is made up of three modules: what is dementia, positive engagement and caring for someone with dementia. The course is delivered by one facilitator and includes teaching, discussions and activities.
48322443|NCT02806466|PROCEDURE|Fiberoptic bronchoscopy|
48487786|NCT02547766|DRUG|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
48647521|NCT01292993|DRUG|1000 mg metformin|1000 mg metformin given as a solid oral dose form
48647522|NCT06419907|BEHAVIORAL|Type 2 Live Well (structured diabetes self management education programme)|Structured diabetes self management education programme designed to support those with type 2 diabetes self care and prevent long term associated complications.
48118170|NCT04640259|OTHER|Online Survey|Epidemiological Survey (approx 200 questions)
48118171|NCT02600520|DRUG|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
48118172|NCT02600520|DRUG|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
48118173|NCT02600520|DRUG|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
48118174|NCT01903798|DRUG|Mycophenolate mofetil|Immunosuppressive agent
48118175|NCT01903798|DRUG|Prednisolone|Corticosteroid
48118176|NCT01903798|DRUG|Rilonacept|
48322444|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 1)|Single dose of AZD3152 300 mg IM on Visit 2 Day 1
48322445|NCT05932641|BIOLOGICAL|Placebo (Cohort 1)|Single dose of Placebo IM on Visit 2 Day 1
48322446|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 2)|Single dose of AZD3152 600 mg IM on Visit 2 Day 1
48322447|NCT05932641|BIOLOGICAL|Placebo (Cohort 2)|Single dose of Placebo IM on Visit 2 Day 1
48322448|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 3)|Single dose of AZD3152 1200 mg IV on Visit 2 Day 1
48322449|NCT05932641|BIOLOGICAL|Placebo (Cohort 3)|Single dose of Placebo IM on Visit 2 Day 1
48322450|NCT02190747|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
48322451|NCT02190747|DRUG|Placebo|
48322452|NCT03529136|BIOLOGICAL|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
48322453|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 1.8%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
48322454|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 1.8% 5% 5%|"At lab visit 1 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
48322455|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 1.8%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 1.8% electronic cigarette pod nicotine concentration for 6 weeks of home use."
48322456|NCT05887947|OTHER|Electronic Cigarette Nicotine Concentration Order 5% 1.8% 5%|"At lab visit 1 participants receive 5% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 48 hours, at lab visit 2 participants receive 1.8% electronic cigarette pod nicotine concentration during the 10-puff standardized puff bout and 60-minute ad libitum session.~After a washout period of at least 7 days, during phase two, participants received 5% electronic cigarette pod nicotine concentration for 6 weeks of home use."
48322457|NCT01785810|DRUG|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
48322458|NCT06348810|BEHAVIORAL|Dual-task training|The dual-task training is a combination of cognitive tasks and motor tasks which is done simultaneously or at the same time.
48322459|NCT06348810|BEHAVIORAL|Cognitive training|Participants only receive cognitive tasks
48322460|NCT06348810|BEHAVIORAL|Motor training|Participants only receive motor tasks
48322461|NCT06348810|OTHER|Usual care|assist participants with activities of daily living, medication management, and social activities (such as singing, watching television).
48322462|NCT05960461|BEHAVIORAL|FMF (Families Moving Forward) Connect Pro|"FMF Connect Pro is a program supported by mental health providers to increase access to care for children (ages 3 to 12) with fetal alcohol spectrum disorders (FASD) and their families. FMF Connect Pro teaches and supports providers in 3 main activities:~1. Routine screening of prenatal alcohol exposure (PAE)~2. Apply DSM-5 diagnostic criteria for Neurodevelopmental Disorder Associated with Prenatal Alcohol Exposure (ND-PAE)~3. Support caregivers using the FMF Connect app~FMF Connect Pro involves a Provider Dashboard with several main sections:~* Learning - includes content and additional resources to support providers in learning how to screen PAE, diagnose ND-PAE, and support families using the FMF Connect app.~* Tools and Resources - includes: screening, diagnostic, and documentation templates; app tip sheets; workbooks; supporting articles, websites, and other resources~* Clients - providers can track clients' progress using the FMF Connect app"
48322463|NCT05960461|BEHAVIORAL|ECHO (Extension of Community Healthcare Outcomes) implementation.|Mental health providers participate in a 13-session tele-mentoring training program using the ECHO (Extension of Community Healthcare Outcomes) approach. Each session involves a brief didactic presentation and case-based learning using de-identified cases shared by participants. The curriculum teaches providers how to do FMF Connect Pro.
48322464|NCT05960461|BEHAVIORAL|Self-Directed Learning implementation.|Mental health providers complete 13 learning modules asynchronously on the FMF Connect Pro Dashboard. These modules include pre-recorded didactic content, brief exercises to assess learning, and additional resources. The curriculum teaches providers how to do FMF Connect Pro.
48322465|NCT02557854|DRUG|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
48322466|NCT02557854|DEVICE|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
48487787|NCT05355038|BEHAVIORAL|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
48487788|NCT05355038|BEHAVIORAL|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
48498014|NCT03893435|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
48498015|NCT04359576|DIAGNOSTIC_TEST|Primary and secondary hemostasis|Focus on platelet aggregation, primary and secondary hemostasis parameters
48322467|NCT01740388|DRUG|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
48322468|NCT01740388|DRUG|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
48322469|NCT03832439|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
48322470|NCT03832439|DIETARY_SUPPLEMENT|microcrystalline cellulose|Placebo
48322471|NCT02445599|DRUG|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
48322472|NCT02445599|DRUG|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
48322473|NCT02445599|DRUG|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
48322474|NCT02445599|DRUG|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
48322475|NCT02445599|DRUG|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
48322476|NCT02445599|DRUG|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
48322477|NCT02445599|DRUG|Metamizole-sodium|Additional rescue analgetic 2g intravenously
48322478|NCT02445599|DRUG|Tramadol|Additional rescue analgetic 100mg intravenously
48322479|NCT03740412|BEHAVIORAL|Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls|The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
48322480|NCT00668200|DRUG|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
48322481|NCT00668200|DIETARY_SUPPLEMENT|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
48322482|NCT00668200|DIETARY_SUPPLEMENT|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
48487789|NCT05355038|BEHAVIORAL|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
48322483|NCT05553678|DRUG|Midazolam|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
48322484|NCT05553678|DRUG|Normal saline|Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
48322485|NCT02062463|DRUG|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)
48322486|NCT02062463|DRUG|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)
48322487|NCT00000113|OTHER|Progressive Addition Lenses|Varilux comfort with +2.00 addition
48322488|NCT00000113|OTHER|single vision lenses|
48322489|NCT01107405|DRUG|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
48322490|NCT01107405|DRUG|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
48322491|NCT01107405|DRUG|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
48322492|NCT01107405|DRUG|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
48322493|NCT01107405|DRUG|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
48322494|NCT02638896|DRUG|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
48322495|NCT02638896|DRUG|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
48487790|NCT02839486|OTHER|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
48322496|NCT02638896|DRUG|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
48322497|NCT02638896|DRUG|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
48322498|NCT05231174|OTHER|A self-evlaution tool based on Large Language Model|"Following the baseline assessment, participants will be guided to use a self-evaluation tool independently to assess their risk of diabetic retinopathy (DR). This tool is a fusion of a conversational AI system based on LLM and an existing logistic diagnostic model.~The AI system is designed to collect clinical variables, including age, duration of diabetes, Body Mass Index (BMI), and insulin usage. Additionally, clinical test data such as mean arterial pressure, HbA1c, serum creatinine, and microalbuminuria will be extracted from a local dataset using the patient's name and ID. Once collected, these data will be transmitted to a server-based diagnostic model for further analysis to determine the presence of DR."
48322499|NCT03709524|DEVICE|Airtraq + fiberoptic|video laryngoscope with a monitor
48322500|NCT03709524|DEVICE|Airtraq|video laryngoscope with a monitor
48322501|NCT03709524|DEVICE|Nasotracheal Airtraq + styletted tube|video laryngoscope with a monitor
48322502|NCT02907320|DRUG|CYCLO 3 ® FORT|
48322503|NCT02907320|DRUG|MPFF|
47969822|NCT04189159|BEHAVIORAL|PROMPT|PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
47969823|NCT05529303|BEHAVIORAL|Such as art therapy, play therapy, breathing techniques|The Cognitive Behavioral Therapy (CBT) model suggests that the individual's dysfunctional thoughts about self, the world, and/or others are based on irrational or illogical assumptions. An individual's self and his/her view of the world are central to the determination of his/her feelings and behaviors and thus can be changed through changing the individual's thoughts, feelings, and behaviors. CBT techniques are in line with the use of expressive art techniques. The common goal in both CBT and expressive arts is to achieve behavior change in the individual. An intervention program has been prepared by the researcher in line with this literature information.
47969824|NCT00346112|PROCEDURE|psycho-educational|
48322504|NCT02907320|DRUG|placebo CYCLO 3 ® FORT|
48322505|NCT02907320|DRUG|placebo MPFF|
48322506|NCT03585192|OTHER|Skin Group|"1. If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~2. A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
48322507|NCT03585192|OTHER|Warmer Group|"1. Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~2. If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
48322508|NCT04169061|DRUG|Acthar|Acthar gel for subcutaneous injection
48118177|NCT05816486|DIAGNOSTIC_TEST|Immunobiogram|This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.
48322509|NCT05260892|DEVICE|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
48322510|NCT04028999|DEVICE|Evaluate the effects of the EO31 shoulder sling in adults post-stoke|Investigator want to evaluate the efficient of the EO31 shoulder sling in adults post-stroke. The EO31 shoulder sling is made-to-measure shoulder pads for upper limb after cerebrovascular accident
48322511|NCT00003817|DRUG|dolasetron mesylate|
48322512|NCT00003817|DRUG|granisetron hydrochloride|
48322513|NCT00003817|DRUG|ondansetron|
48322514|NCT00003817|DRUG|tropisetron|
48322515|NCT00003817|PROCEDURE|quality-of-life assessment|
47969825|NCT00913497|DRUG|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
47969826|NCT00913497|DRUG|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
48118178|NCT00326144|DRUG|Quetiapine fumarate|
48118179|NCT01595334|DRUG|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (\>4.5 mIU/ml) in the study arm
48118180|NCT01595334|DRUG|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
48322516|NCT02168933|DEVICE|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
48322517|NCT02168933|DEVICE|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
48322518|NCT03102216|DIAGNOSTIC_TEST|iSTAT|iSTAT troponin, INR, CG4+ and Chem8
48322519|NCT03102216|DIAGNOSTIC_TEST|CBC|Complete Blood Count
48322520|NCT03102216|DIAGNOSTIC_TEST|ECG|ElectroCardioGram
48322521|NCT03102216|DIAGNOSTIC_TEST|Lodox|Low dose x-ray
48487791|NCT02839486|OTHER|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
47969827|NCT02567916|DRUG|Fresofol|
47969828|NCT02567916|DRUG|Propofol|
48118181|NCT04900636|DEVICE|Telemedicine Arm|Patients with DM1 ≥ 18 years of age, users of closed loop hybrid systems, assigned to a follow-up program using a telemedicine platform combined with face-to-face visits according to protocol.
48118182|NCT00731185|DRUG|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
48118183|NCT00731185|DRUG|Placebo|
48118184|NCT01998711|BEHAVIORAL|Memory group|Five 1-1.5 hour weekly session of memory training
48322522|NCT05071729|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant on Day 1.
48322523|NCT03051841|DRUG|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
48322524|NCT02581865|DRUG|NBI-98854|
48322525|NCT02581865|DRUG|Placebo|
48322526|NCT04113447|OTHER|observational|observational
48322527|NCT05123612|BEHAVIORAL|Fiber|Additional 20 grams of fiber/day.
48322528|NCT05123612|BEHAVIORAL|Fermented Foods|6 servings of fermented foods/day
48322529|NCT00218426|DRUG|naltrexone implant|naltrexone implant is 1000 mg naltrexone
48322530|NCT00218426|DRUG|oral naltrexone|oral naltrexone 50 mg/day
48322531|NCT00218426|DRUG|oral placebo naltrexone|oral placebo naltrexone resembles active medication
48322532|NCT00218426|DRUG|placebo implant|placebo implant resembles active medication
48322533|NCT01021813|DRUG|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
48322534|NCT01021813|DRUG|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
48487792|NCT02049021|DEVICE|MECTA SPECTRUM 5000Q ECT|
48487793|NCT02049021|PROCEDURE|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
48322535|NCT03350178|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
48322536|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 48 weeks
48322537|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 24 weeks
48322538|NCT03827668|DRUG|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
48322539|NCT03827668|DRUG|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
48322540|NCT03827668|DRUG|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
48322541|NCT05585086|OTHER|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
48647523|NCT04377256|PROCEDURE|Ridge preservation: Tooth extration and immediat bone grafting in the socket|Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
48647524|NCT02688335|DEVICE|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
48647525|NCT02839928|DRUG|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
48647526|NCT02839928|DEVICE|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
48647527|NCT02839928|DRUG|EMLA|
48647528|NCT02943499|BEHAVIORAL|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
48647529|NCT02943499|BEHAVIORAL|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
48118185|NCT03318484|DRUG|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
48322542|NCT00966303|OTHER|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
48322543|NCT05393921|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
48322544|NCT04419324|DEVICE|transoral flexible endoscope with magnifying narrow band imaging|To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
48322545|NCT03497234|DIAGNOSTIC_TEST|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
48322546|NCT03604510|PROCEDURE|Electroencephalographic recordings|24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
48322547|NCT02596152|OTHER|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
48322548|NCT02596152|OTHER|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
48322549|NCT01913808|DRUG|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
48322550|NCT01913808|DRUG|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
48322551|NCT00423241|DEVICE|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
48647530|NCT02943499|DEVICE|Smartphone|
48647531|NCT01955265|BEHAVIORAL|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
48647532|NCT01955265|BEHAVIORAL|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
48322552|NCT00423241|DEVICE|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
48322553|NCT00731848|DIETARY_SUPPLEMENT|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
48322554|NCT02541006|DRUG|Tiotropium 18 mcg|tiotropium 18 mcg once a day
48487794|NCT02307643|DRUG|MT-1303 Low dose|
47969829|NCT01612481|PROCEDURE|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
48322555|NCT04333121|OTHER|weight|we can monitoring the growth of the infants by weight gain degree
48322556|NCT05795010|OTHER|MRD test|ctDNA detection based on tumor whole exon sequencing
48322557|NCT02863939|DEVICE|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
48322558|NCT02863939|OTHER|exercise|
48322559|NCT01254513|DRUG|Docetaxel every 3 weeks + Prednisone|"* Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously"
48487795|NCT02307643|DRUG|MT-1303 High dose|
48487796|NCT04535752|DRUG|ANX009|Single or multiple ascending dose
48487797|NCT04535752|DRUG|Placebo|Single or multiple ascending dose
48487798|NCT00106938|DEVICE|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
48647533|NCT00529815|DEVICE|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
47969830|NCT01612481|PROCEDURE|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
48118186|NCT03318484|COMBINATION_PRODUCT|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
48118187|NCT05929105|PROCEDURE|artificial intelligence (AI)-assisted three-dimensional preoperative planning technology|In the AI planning group, AI was used to assist in the 3D planning to complete the preoperative design. Preoperative planning was performed by two experienced surgeons and without the chief physician to ensure that the results of the preoperative planning did not affect the selection of intraoperative procedures and prosthesis size.
48487799|NCT00106938|PROCEDURE|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
48487800|NCT02182128|DRUG|BIBF 1120|
48487801|NCT03970265|DIAGNOSTIC_TEST|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
48647534|NCT00529815|DEVICE|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
48647535|NCT01421459|DRUG|LY2963016|Administered subcutaneously
48647536|NCT01421459|DRUG|Lantus|Administered subcutaneously
48647537|NCT01421459|DRUG|OAMs|Administered orally
47969831|NCT05169385|BEHAVIORAL|Parent SMART|Parent SMART experimental intervention
47969832|NCT05169385|BEHAVIORAL|Treatment as Usual|Residential treatment as usual
47969833|NCT02034669|DEVICE|Laminectomy|surgical laminectomy with glial scar resection
47969834|NCT02034669|DEVICE|Intradural space|ADSCs injection into Intradural space at damage site
47969835|NCT02034669|DEVICE|Intrathecal|ADSCs Intrathecal into lumbar puncture
48647538|NCT01079390|DEVICE|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
48647539|NCT02120261|DRUG|Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
48647540|NCT02120261|DRUG|Lidocaine Hydrochloride|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
47969836|NCT02034669|DEVICE|Intravenous|ADSCs intravenous
47969837|NCT01970046|DRUG|Placebo/Metformin|"* Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
47969838|NCT01970046|DRUG|SP2086 50 mg b.i.d/Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
47969839|NCT01970046|DRUG|SP2086 50 mg q.d./Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
47969840|NCT03521934|DRUG|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
47969841|NCT03521934|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
48118188|NCT05929105|OTHER|X-ray film template for 2D planning|A traditional X-ray film template was used to complete the preoperative design in the traditional planning group. The position and size of the prosthesis, the level of femoral neck osteotomy, the length of the LLs and the restoration of eccentricity were estimated by X-ray. A plastic template provided by the manufacturer was used to take the line of the lower edge of the teardrop on both sides as the horizontal reference line, and the acetabular template was placed at 40 abduction on the inner edge of the teardrop so that the lower edge of the acetabular cup was adjacent to the teardrop. An appropriate type of acetabular component was selected to fill the acetabulum and maintain coverage, and the femoral component that best matched the femoral medullary cavity was chosen. The height of the osteotomy was determined, and the planning model was recorded after the surgeons were happy with the placement and outcome.
48487802|NCT01757574|DRUG|Alemtuzumab infusion|
48487803|NCT05450328|DRUG|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
48487804|NCT05450328|DRUG|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
48487805|NCT01385306|DEVICE|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
48322560|NCT01254513|DRUG|Docetaxel weekly+ Prednisone|"* Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously"
48322561|NCT02746523|OTHER|Sensory Organization Test|Balance and proprioception test
48322562|NCT02746523|GENETIC|Biomarkers|Blood, urine, and saliva biomarkers
48322563|NCT02746523|OTHER|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
48322564|NCT02746523|OTHER|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
48322565|NCT02746523|OTHER|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
48322566|NCT04679259|DIAGNOSTIC_TEST|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
48322567|NCT04679259|DIAGNOSTIC_TEST|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
48322568|NCT04679259|DIAGNOSTIC_TEST|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
48322569|NCT05800106|DRUG|Sunitinib malate capsules generic product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
48322570|NCT05800106|DRUG|Sunitinib malate capsules reference product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
48322571|NCT02407041|DRUG|GR-MD-02|IV infusion
48322572|NCT03828149|COMBINATION_PRODUCT|Drug:OP0201|Drug: OP0201
48322573|NCT03828149|COMBINATION_PRODUCT|Drug: Placebo|Drug: Placebo
48322574|NCT04121520|OTHER|Questionnaire|"1. Comprehensive perioperative assessment~2. Questionnaire administration"
48322575|NCT06160869|BEHAVIORAL|Acceptance and commitment therapy|"The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients."
48322576|NCT06160869|COMBINATION_PRODUCT|Treatment as usual|The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
48322577|NCT03269890|PROCEDURE|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
48322578|NCT03269890|PROCEDURE|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
48118189|NCT00506298|DRUG|bezafibrate + diflunisal|bezafibrate + diflunisal
48118190|NCT00506298|DRUG|bezafibrate + placebo|bezafibrate + placebo
48118191|NCT00716924|DRUG|Clopidogrel|300 mg
48118192|NCT00716924|DRUG|Clopidogrel|600 mg
48118193|NCT02384577|DRUG|Budesonide, Formoterol Fumarate Dihydrate|
48118194|NCT00142558|DRUG|MK0663; etoricoxib / Duration of Treatment: 5 Days|
48118195|NCT00142558|DRUG|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
48118196|NCT02894242|DEVICE|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
48322579|NCT00934427|DRUG|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
48322580|NCT00934427|DRUG|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
48322581|NCT01194804|DRUG|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
48322582|NCT00192036|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
48322583|NCT00192036|DRUG|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
48322584|NCT00192036|RADIATION|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
48322585|NCT04822272|DEVICE|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
48322586|NCT02029495|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
48322587|NCT02029495|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
48322588|NCT02029495|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
48322589|NCT03985748|DEVICE|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
48322590|NCT03985748|DEVICE|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
48322591|NCT05398393|DRUG|oral Tenofovir Amibufenamide 25mg each day|patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
48322592|NCT05398393|DRUG|lipid lowering drugs (e.g. Atorvastatin and amlodipine.)|lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
48322593|NCT03217773|PROCEDURE|ESD|Refer to arm description
48322594|NCT03217773|PROCEDURE|TAMIS|Refer to arm description
48322595|NCT03215082|OTHER|Vestibular-Visual Intervention|vestibular-visual exercises
48322596|NCT03215082|BEHAVIORAL|standard care|standard care
48322597|NCT03983928|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48322598|NCT03983928|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
48322599|NCT02287701|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
47969842|NCT03379168|DEVICE|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
48322600|NCT04306055|OTHER|Questionnaire with precaution information|Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
47969843|NCT03379168|DRUG|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
47969844|NCT03379168|DRUG|Saline|Sterile saline injection will act as a placebo group.
48322601|NCT04306055|OTHER|Experimental: Questionnaire without precaution information|Ever blood donors in this group would receive a questionnaire which dose not include the information above.
48322602|NCT05329779|DRUG|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
48322603|NCT05329779|DRUG|placebo|The placebo is a 0.45% sodium chloride infusion.
48322604|NCT02466568|DRUG|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
48322605|NCT02466568|BIOLOGICAL|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
48487806|NCT05086718|OTHER|Endoscopic ear surgery|Endoscopic approach without posterior meatal flap elevation will be employed in the ear with dry chronic suppurative otitis media. Tympanoplasty utilizing composite cartilage-fascia graft will be performed. After three months of time period successful outcome will be taken as closure of air bone gap on pure tone audiometry.
48487807|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
48487808|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
48487809|NCT00262041|BIOLOGICAL|MenACWY polysaccharide vaccine|
48487810|NCT06125496|OTHER|Pain management|Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
48487811|NCT03510182|DEVICE|transcranial direct current stimulation|
48487812|NCT02129647|DRUG|Axitinib|
48487813|NCT04746599|PROCEDURE|Autologous Fat Grafting|The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
48487814|NCT02883517|GENETIC|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
48487815|NCT00292188|DRUG|pregabalin|pregabalin
48487816|NCT00292188|DRUG|Placebo|placebo
48487817|NCT05057026|OTHER|Training Program Adult Mental Health Practice Support Program|"The Adult Mental Health Practice Support Program (PSP) was designed in 2009 by the General Practice Services Committee (GPSC) to address needs expressed by the province's family physicians to improve patient care in British Colombia. Its content and delivery model has been designed using evidence-based key ingredients and implication factors understood to be important for effective stigma reduction. These include the following:~* the use of contact-based education,~* skills-building to increase confidence and provide another management option with or without drugs particularly if access to mental health support services is difficult or absent~* tools - using the principles of cognitive behavioural theory~The training will be delivered virtually over a total of 4 sessions two weeks apart, covering an 8-week period. A two hour virtually delivered booster session will be provided to students approximately one year after the delivery of the initial training."
48487818|NCT03823235|OTHER|Human embryo culture|humidifed or dry incubator
48498016|NCT03814616|DRUG|Pyronaridine tetraphosphate 180mg:artesunate 60mg|ACT
47969845|NCT05466877|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
47969846|NCT05466877|DRUG|Placebo|MG-K10 Humanized Monoclonal Antibody Injection
47969847|NCT02338141|DEVICE|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
47969848|NCT02338141|DEVICE|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
48322606|NCT00000196|DRUG|Naltrexone|
48322607|NCT03046940|OTHER|Patient-centered style of communication|Different doctor-patient communication
48322608|NCT03046940|OTHER|Doctor-centered style of communication|Different doctor-patient communication
48322609|NCT02895256|DRUG|Any treatment for cluster headache|
48322610|NCT00609219|BIOLOGICAL|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2"
48322611|NCT06091189|BEHAVIORAL|Relevant Trier Social Stressor Test (TSST)|The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.
48322612|NCT06091189|DRUG|Ethanol|The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.
48322613|NCT06091189|BEHAVIORAL|Placebo Trier Social Stressor Test (TSST)|The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.
48322614|NCT06091189|BEHAVIORAL|Placebo Beverage|Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.
48322615|NCT06091189|BEHAVIORAL|Irrelevant Trier Social Stressor Test (TSST)|The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.
48322616|NCT01911013|PROCEDURE|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
48322617|NCT01911013|DEVICE|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
48322618|NCT01911013|DEVICE|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
48322619|NCT04426838|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference|The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
48322620|NCT04000087|OTHER|AI-enabled ECG-based Screening Tool|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
48322621|NCT03937193|DIAGNOSTIC_TEST|computerized tomography|abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
48322622|NCT00126399|DRUG|doxycycline|
48322623|NCT04785079|PROCEDURE|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
48322624|NCT00460447|DRUG|Gemtuzumab Ozogamicin|
48322625|NCT05167461|OTHER|Collection of imaging by ultrasonography|The investigators will collect burn image data to be processed through the software combined with the deep machine learning to find automated diagnostic burn assessment with accuracy of \>95% compared to human assessment
48322626|NCT04899713|OTHER|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
48322627|NCT05277688|DRUG|adjuvant concurrent chemoradiotherapy|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
48322628|NCT05277688|RADIATION|radiotherapy|Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
48322629|NCT05014295|OTHER|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
48322630|NCT04353336|DRUG|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
48322631|NCT04156828|DRUG|Copanlisib|Given IV
48322632|NCT04156828|DRUG|Gemcitabine|Given IV
48322633|NCT04156828|DRUG|Carboplatin|Given IV
48322634|NCT04156828|DRUG|Dexamethasone|Given PO
48322635|NCT04156828|BIOLOGICAL|Rituximab|Given IV
48322636|NCT04156828|BIOLOGICAL|Pegfilgrastim|Given SC
48487819|NCT04943159|DRUG|Afamelanotide|Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
48487820|NCT01969474|DRUG|Cannabis|Cannabis capsules given once daily for a month
48487821|NCT01969474|DRUG|Placebo|Placebo
48487822|NCT01184248|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
48487823|NCT04969861|DRUG|Bempegaldesleukin|Specified dose on specified days
47969849|NCT00607971|DRUG|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
47969850|NCT05928169|DRUG|Topical and systemic drugs|Recruitment and follow-up will be independent on the type of treatment
47969851|NCT00335868|DRUG|danusertib|
48487824|NCT04969861|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
48487825|NCT00773942|BEHAVIORAL|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
47969852|NCT00335868|OTHER|laboratory biomarker analysis|
47969853|NCT00335868|OTHER|pharmacological study|
47969854|NCT04449900|OTHER|This is observational study with the examination of OCTA|This is observational study with the examination of OCTA
48322637|NCT02237976|BEHAVIORAL|Self-hypnosis|
48322638|NCT02237976|BEHAVIORAL|Routine practice|
48322639|NCT03170583|DEVICE|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
48322640|NCT00019721|BIOLOGICAL|MART-1 antigen|
48322641|NCT00019721|BIOLOGICAL|aldesleukin|
48322642|NCT00019721|BIOLOGICAL|gp100 antigen|
48322643|NCT00019721|BIOLOGICAL|incomplete Freund's adjuvant|
48322644|NCT04905875|PROCEDURE|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
48322645|NCT00580944|PROCEDURE|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
48322646|NCT03666975|DEVICE|LIV 30 Hz|LivMD LIV platform
48322647|NCT03325556|DRUG|Placebo|Placebo, tablets, once daily by mouth
48487826|NCT00773942|BEHAVIORAL|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
48647541|NCT02120261|DRUG|Triamcinolone acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
48647542|NCT01629888|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
48647543|NCT01629888|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
47969855|NCT00880828|OTHER|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
48118197|NCT05220215|OTHER|Nordic Hamstring Exercise|To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.
48118198|NCT05220215|OTHER|Hamstring Curl with Resistance band|"Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation"
48118199|NCT00156741|DEVICE|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
48118200|NCT00156741|PROCEDURE|Required pacemaker setting|
48118201|NCT02531152|DRUG|Latanoprost|
48118202|NCT02531152|DRUG|SAR366234|
48118203|NCT03221777|DIAGNOSTIC_TEST|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.\[87\]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
48118204|NCT01611831|BEHAVIORAL|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
48118205|NCT01611831|BEHAVIORAL|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
48118206|NCT00237770|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
48118207|NCT00237770|PROCEDURE|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
48118208|NCT06383117|DIETARY_SUPPLEMENT|Calcium carbonate|2 capsules containing 600 mg of calcium carbonate each
48118209|NCT06383117|DIETARY_SUPPLEMENT|Placebo Control|2 capsules containing methylcellulose
48647544|NCT06103799|BEHAVIORAL|IMB model-based continuity of care|The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.
48647545|NCT05497245|OTHER|mobile app-based breastfeeding education|"The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab."
47969856|NCT00880828|OTHER|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
47969857|NCT00880828|DRUG|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
48118210|NCT02163252|BEHAVIORAL|Standard|
48118211|NCT02163252|BEHAVIORAL|Early Intervention|
48118212|NCT06492512|DRUG|daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
48118213|NCT06492512|DRUG|alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
47969858|NCT02634320|DRUG|Aripiprazole Lauroxil|Monthly IM injection
47969859|NCT02792972|OTHER|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
47969860|NCT02792972|OTHER|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
47969861|NCT04374721|DIAGNOSTIC_TEST|circadian gene expression evaluation|patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
48322648|NCT03325556|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth
48322649|NCT03325556|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg total daily dose, tablets, once daily by mouth
48322650|NCT01892397|DEVICE|Optune (NovoTTF-100A)|
48322651|NCT06446206|DRUG|Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib|Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
48322652|NCT01844830|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
48322653|NCT01844830|DRUG|Placebo|Inactive ingredients supplied in identical nasal sprayer
48322654|NCT01230736|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
48322655|NCT02618343|DRUG|IPA|IPA Aromatherapy for the experimental arm
48322656|NCT02618343|DRUG|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
48118214|NCT02841150|DRUG|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.
48118215|NCT02841150|DRUG|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1\*560 mg, tablet.
48118216|NCT00009217|DRUG|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
48118217|NCT00009217|DRUG|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
48322657|NCT01396993|PROCEDURE|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
48322658|NCT01396993|PROCEDURE|Breast Surgery|Breast conserving therapy without defect correction
48322659|NCT00889993|DIETARY_SUPPLEMENT|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
48322660|NCT00488592|BIOLOGICAL|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
48647546|NCT01084135|DRUG|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
47969862|NCT03694821|DRUG|Ketorolac Tromethamine Injection|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
48118218|NCT01528306|BIOLOGICAL|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
48118219|NCT01528306|OTHER|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(\>12 cm2 and ≤ 24 cm2) 2 sprays each; (\>24 cm2 and ≤ 36 cm2) 3 sprays each; (\>36 cm2 and ≤ 48 cm2) 4 sprays each"
48118220|NCT02284555|DRUG|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
48118221|NCT00004423|DRUG|-aminosalicylic acid|
48118222|NCT06255795|DRUG|chidamide, anti-PD1 antibody, and pegaspargase|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
48118223|NCT06255795|DRUG|DDGP|6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
48118224|NCT01982136|PROCEDURE|end-to-end urethroplasty|
48118225|NCT01982136|PROCEDURE|substitution urethroplasty (buccal mucosa)|
48118226|NCT01982136|PROCEDURE|substitution urethroplasty (pedicled skin flap)|
48322661|NCT00488592|BIOLOGICAL|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
48322662|NCT00488592|DRUG|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
48647547|NCT01084135|OTHER|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
48647548|NCT02118831|BIOLOGICAL|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
48118227|NCT04830501|DRUG|TT-00434|Once daily \[QD\], 28 days/cycle.
48118228|NCT00239083|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
48322663|NCT00488592|BIOLOGICAL|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
48322664|NCT01948895|DRUG|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
48322665|NCT05765695|PROCEDURE|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
48322666|NCT06377345|DEVICE|AeviceMD device|The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management
48322667|NCT06377345|BEHAVIORAL|Standard care|All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.
48322668|NCT00006454|DRUG|carboplatin|
48322669|NCT00006454|DRUG|paclitaxel|
48322670|NCT00006454|DRUG|topotecan hydrochloride|
48322671|NCT01693055|DEVICE|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
48322672|NCT06313177|PROCEDURE|syndesmosis fixation with screws|syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture
48322673|NCT01478438|DEVICE|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
48322674|NCT03910647|DRUG|pantoprazole|effect of this drug on renal function
48322675|NCT03385382|DRUG|Dexamethasone intravitreal implant 0.7 mg|Intravitreal Implant of dexamethasone
48647549|NCT02118831|DRUG|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
48322676|NCT03385382|DRUG|Ranibizumab Injection|Injection of ranibizumab
48322677|NCT03712345|DRUG|IFX-1 low dose|Single IV infusions of IFX-1
48322678|NCT03712345|DRUG|IFX-1 high dose|Single IV infusions of IFX-1
48647550|NCT02118831|DRUG|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
48647551|NCT02118831|DRUG|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
48322679|NCT03712345|DRUG|Placebo|Placebo
48322680|NCT04697433|DEVICE|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
48322681|NCT04047758|DRUG|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment \[3 weeks on (days 1-21) and 1 week off (days 22-28)\], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
48647552|NCT04868071|BEHAVIORAL|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
48647553|NCT01242384|DEVICE|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
48647554|NCT06465641|DRUG|Methylphenidate Hydrochloride|Methylphenidate hydrochloride in capsules
48647555|NCT06465641|DRUG|Placebo|Microcrystalline cellulose in capsules
48647556|NCT03615274|DEVICE|Executive function training|Home-based executive function training with adaptive difficulty, through Cogmed and Cognifit systems over 6 weeks (30-45 minuts/day, 5 days per week). Cognitive training will consist on working memory training (Cogmed, www.cogmed.com) and executive/inhibitory function training (Cognifit, www.cognifit.com).
48322682|NCT04047758|DRUG|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
48487827|NCT00750022|BEHAVIORAL|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
48487828|NCT00750022|BEHAVIORAL|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
48487829|NCT05715814|DRUG|Empagliflozin 25 MG|PO once daily
48487830|NCT04254835|DRUG|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
48487831|NCT04254835|DRUG|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
48487832|NCT02429141|PROCEDURE|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
48487833|NCT02429141|PROCEDURE|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
48487834|NCT03175289|OTHER|Best Practice|Undergo therapy session conducted by a speech pathologist
48487835|NCT03175289|OTHER|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
48487836|NCT03175289|OTHER|Exercise Intervention|Perform prescribed home exercises
48487837|NCT03175289|OTHER|Expiratory Muscle Strength Training|Participate in EMST
48487838|NCT03175289|OTHER|Quality-of-Life Assessment|Ancillary studies
48487839|NCT03175289|OTHER|Questionnaire Administration|Ancillary studies
48487840|NCT01397708|BIOLOGICAL|INXN-2001|"* approximately 1.0 x 1012 viral particles (vp) per injection~* one intratumoral injection of INXN-2001 per study cycle~* maximum of 6 study cycles"
48487841|NCT01397708|DRUG|INXN-1001|"* 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
48487842|NCT04916340|BEHAVIORAL|Muscular Strength Training Group|"Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM"
48487843|NCT04916340|BEHAVIORAL|Muscular Fitness Training Group|"Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM"
48487844|NCT04595266|DRUG|FOLFOX regimen|"Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1"
48487845|NCT04595266|BIOLOGICAL|Anti-EGFR or Bevacizumab|"In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.~Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications."
48487846|NCT04595266|DRUG|LIVERPEARLS-Irinotecan|Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
48487847|NCT02221908|DEVICE|Mespere Venus 1000 CVP System|
48487848|NCT01973023|OTHER|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
48487849|NCT05828121|BEHAVIORAL|POINT1|Receiving treatment
48118229|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
48118230|NCT00551577|PROCEDURE|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
48118231|NCT00371085|BEHAVIORAL|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
48118232|NCT03460756|DRUG|Ganaxolone|Oral
48118233|NCT03460756|DRUG|Placebo|Oral
48118234|NCT03785834|PROCEDURE|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
48118235|NCT00003005|DRUG|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
48118236|NCT00003005|DRUG|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
48322683|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
48487850|NCT05723718|OTHER|Observational Survey|Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
48322684|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
47969863|NCT03694821|DRUG|Methylprednisolone Acetate Injection|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
48322685|NCT04497298|BIOLOGICAL|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
48322686|NCT04497298|OTHER|Placebo|Physiological saline solution (0.9% NaCl)
48322687|NCT03587818|OTHER|person-centred communication|The intervention aimed to actively make use of a person-centred approach to support patients undergoing CRC surgery to be prepared for surgery, discharge and recovery in relation to CRC. This was accomplished through person-centred communication, which was based on a standardized dialogue tool with tailored written information material (component I), in combination with an approach for professionals to facilitate person-centred communication (component II) in consultations.
48322688|NCT03363217|DRUG|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
48322689|NCT00780052|DRUG|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
48322690|NCT03182465|DIAGNOSTIC_TEST|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
48322691|NCT01864824|DRUG|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
48322692|NCT01864824|DRUG|Placebo|Placebo
48322693|NCT02486211|DRUG|Amantadine|100mg twice per day for 7 days at 0600 and 1200
48322694|NCT02486211|DRUG|Placebo|Placebo comparator
48322695|NCT03110419|OTHER|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
48322696|NCT02713763|DRUG|Sunitinib|Sunitinib 37.5 mg/day
48322697|NCT03490357|PROCEDURE|Control - Transversus Abdominus Plane Block|Abdominal fascial plane block - regional anesthesia
48322698|NCT03490357|PROCEDURE|Quadratus Lumborum Block|Abdominal fascial plane block - regional anesthesia
48322699|NCT01875367|DRUG|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
48487851|NCT05736536|BEHAVIORAL|Chance2Act|A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
48487852|NCT02896777|OTHER|Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.
48322700|NCT01875367|DRUG|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
48487853|NCT02896777|OTHER|Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.
48487854|NCT02896777|OTHER|Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
47969864|NCT03694821|DRUG|Hylan G-F 20|One knee injection of Hylan G-F 20 (Synvisc-One)
48118237|NCT03506880|BEHAVIORAL|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
48322701|NCT01875367|DRUG|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
48322702|NCT03754062|DRUG|Placebo - Cap|Administration of Placebo by pill.
48487855|NCT01570816|DEVICE|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
48487856|NCT03269799|DRUG|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
48487857|NCT03269799|OTHER|placebo|non surgical periodontal treatment+placebo for 2 months
48487858|NCT06278038|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
47969865|NCT02006719|BIOLOGICAL|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
47969866|NCT02006719|OTHER|Placebo|Placebo injection
47969867|NCT00714649|DRUG|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
47969868|NCT00394147|DRUG|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
47969869|NCT00394147|DRUG|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
47969870|NCT03987529|OTHER|sevoflurane|volatile anesthetic
47969871|NCT03987529|OTHER|propofol|intravenous anesthetic
47969872|NCT04964375|DRUG|ABSK043 oral capsule|ABSK043 is a novel, oral small molecule inhibitor of PD-L1
48118238|NCT03506880|BEHAVIORAL|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
48322703|NCT03754062|DRUG|L-dopa|Administration of L-dopa by pill.
48322704|NCT03754062|DRUG|Haloperidol|Administration of Haloperidol by pill.
48322705|NCT03648307|DIAGNOSTIC_TEST|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
48322706|NCT00280319|BEHAVIORAL|interpersonal psychotherapy for groups|psychotherapy
48487859|NCT06278038|DRUG|Venlafaxine hydrochloride sustained-release tablets|75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks
48647557|NCT03615274|OTHER|Psychoeducation|Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.
48322707|NCT00280319|BEHAVIORAL|creative play therapy|consisted of play activities
48322708|NCT01401465|DRUG|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
48322709|NCT01401465|DRUG|mometasone|200 mcg mometasone aqueous nasal spray once daily
48322710|NCT02172092|DRUG|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
48322711|NCT02912598|DEVICE|Mallinckrodt™ Endobronchial Tube|
48322712|NCT02912598|DEVICE|Fuji Uniblocker™|
48322713|NCT02912598|DEVICE|ETView VivaSight™-SL+EB|
48322714|NCT02912598|DEVICE|COOK© Arndt Endobronchial Blocker|
48322715|NCT06388330|OTHER|low FODMAP diet|strict low FODMAP diet followed by reintroduction of different FODMAPs and glucose (control)
48322716|NCT04157868|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
48322717|NCT04157868|DRUG|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
48322718|NCT04629898|BEHAVIORAL|multi-task in the real world and virtual reality video sport games|This was a 2-staged intervention study. The 1st stage intervention uses multitasks in the real world including stepping exercise, ball-kicking activity and bean-bag tossing activity. The 2nd stage intervention used video sport games conveyed by Xbox Kinect. Tennis and golf games were selected.
48322719|NCT01172834|BEHAVIORAL|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
48322720|NCT02615795|DEVICE|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
48322721|NCT05053997|BEHAVIORAL|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
48118239|NCT00676234|DRUG|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
48647558|NCT03615274|DEVICE|Placebo non-adaptive training|Executive function training with non-adaptive difficulty through Cognifit system over 6 weeks (30-45 minuts/day, 5 days per week). Exercices will be the same as the ones in the experimental group but minimizing the executive/working memory component and without incresing difficulty.
48322722|NCT05133245|OTHER|Diagnostic study only|Diagnostic study only
48322723|NCT00954837|PROCEDURE|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
48322724|NCT01830296|DRUG|Remifentanil+morphine|Morphine, Remifentanil+Morphine
48322725|NCT04959552|DEVICE|FreeStyle Libre 2|The FreeStyle Libre 2 Flash Glucose Monitoring
48498017|NCT00085423|BIOLOGICAL|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
48647559|NCT04369612|PROCEDURE|Standard follow-up|Standard post-transplant follow-up
48647560|NCT04369612|PROCEDURE|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
48647561|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
48322726|NCT03744130|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|"1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station"
48322727|NCT05584930|OTHER|Collection of blood sample|"* Visit 1 : At inclusion (day 1 of chemotherapy treatment)~* Visit 2 : Onset of aplasia~* Visit 3a : day 1 of the 1st febrile aplasia~* Visit 3b : day 3 of the 1st febrile episode~* Visit 3c : day 8 of the 1st febrile episode~* Visit 4a : second febrile episode (after 7 days)~* Visit 4b : day 3 of the second febrile episode (after 7 days)"
47969873|NCT06498999|BEHAVIORAL|4-STEP-Training Program for Social Media Addiction (4-STEP-TPS)|"4 Modules with 1 Module being delivered in 1 weekly session of approximately 90 minutes. The details of each module/step is described as follows:~Step 1 (Module 1): S = Screening, Assessment and Psychoeducation: Involves screening and assessment of the problem, interpretation of the results, feedback and psychoeducation, identifying and breaking the resistance, motivation, and conceptualization.~Step 2 (Module 2): T = Treatment Conceptualization and Planning: Involves pattern identification, distortion identification, as well as pattern and distortions modifications.~Step 3 (Module 3): E = Effective Management Strategies: Involves management strategies to treat the earlier identified patterns as well as the implementation and confirmation of activities via a Pattern Schedule Chart.~Step 4 (Module 4): P = Prevention (Lapse-Relapse): Involves self-reflection and support building, monitoring and dependency check and slip plans and support additions"
48322728|NCT04658381|GENETIC|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
48322729|NCT04658381|PROCEDURE|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
47969874|NCT06385600|DRUG|Labetalol|Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
47969875|NCT06385600|DRUG|Phentolamine|Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
47969876|NCT03384212|DRUG|Cladribine|
47969877|NCT03384212|DRUG|Fludarabine|
47969878|NCT03384212|DRUG|Busulfan|
47969879|NCT03384212|DRUG|Cytarabine|
47969880|NCT02552771|PROCEDURE|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
47969881|NCT02552771|PROCEDURE|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
47969882|NCT03766581|DRUG|BMS-986177|Oral administration
47969883|NCT03766581|OTHER|Placebo|Oral Administration
47969884|NCT03766581|DRUG|Clopidogrel|Oral administration
47969885|NCT03766581|DRUG|Aspirin|Oral administration
47969886|NCT01572558|PROCEDURE|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
47969887|NCT01572558|DRUG|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
47969888|NCT02164825|DRUG|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
47969889|NCT02164825|DRUG|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
47969890|NCT00497718|PROCEDURE|Chiropractic Manipulation|
48118240|NCT04034745|DRUG|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
48118241|NCT03782350|DRUG|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
47969891|NCT05450731|OTHER|12-week supervised exercise based cardiac rehabilitation program|12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (AF) in patients at six- and twelve-months post-ablation procedure.
47969892|NCT06238583|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The recommended dose of copanlisib is 60 mg administered as a 1 hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off), OR at a lower dose if dose reduction has occurred on prior treatment. Patients currently included on study protocols may continue their treatment regimen at the discretion of their healthcare provider.
47969893|NCT00580021|OTHER|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
48118242|NCT03782350|DRUG|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
48118243|NCT05908799|DRUG|Pembrolizumab + Pemetrexed-Platinum|Medication records in EHR database used to define exposure group
48322730|NCT00964158|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
48322731|NCT06329999|DRUG|CMGV|"Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses."
48322732|NCT01956266|BEHAVIORAL|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
48322733|NCT03017365|OTHER|Stable Resistance Training|traditional machine-based resistance training
48322734|NCT03017365|OTHER|Unstable Resistance Training|free weight resistance training using unstable devices
48322735|NCT03017365|OTHER|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
48322736|NCT00691262|DRUG|tacrolimus ointment|transdermal
48322737|NCT04113148|OTHER|Physiological measurements from heel|Measurements of blood flow, tissue oxygen saturation, temperature, pressure
48322738|NCT04433624|OTHER|Group (B)|Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae
48118244|NCT05908799|DRUG|Pemetrexed-Platinum|Medication records in EHR database used to define comparator group
48322739|NCT04806516|DEVICE|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~* Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~* Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~* DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~* Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~* Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~* Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~* Research Lab Programmer (RLP), Model 4NR010: 1 unit~* Research Software Development Kit (RDK), Model 4NR013: 2 units~* Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
48322740|NCT04806516|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
48322741|NCT06071299|BEHAVIORAL|FCC|Children evaluated for abusive injuries. Caregiver offered meeting with IPV advocate during visit (survivor-centered care, immediate access to services; continued engagement with advocate for ongoing needs). Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
48322742|NCT06071299|BEHAVIORAL|CCC|Children evaluated for abusive injuries. Medical provider offers IPV resources to caregiver. Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.
48322743|NCT02779673|OTHER|Yoghurt drink containing plant stanol as esters|
48322744|NCT02779673|OTHER|Yoghurt drink without plant stanol as esters|
48487860|NCT01370213|DRUG|Preparative Regimen|"Preparative Regimen:~1) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
48487861|NCT01370213|BIOLOGICAL|NK Cells|CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
48118245|NCT04199728|DRUG|Liraglutide Pen Injector|Liraglutide will be provided using an injection pen provided by the manufacturer
48118246|NCT04199728|DRUG|Placebo|Placebo injection pen
48487862|NCT01370213|DRUG|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
48487863|NCT01370213|BIOLOGICAL|CD34 Graft/Anti-thymocyte globulin|Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10\^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.
48487864|NCT01370213|BIOLOGICAL|Donor TCR α/β-depleted Graft/ATG|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10\^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
47969894|NCT04819074|PROCEDURE|Microsurgery|Microsurgery for unruptured intracranial aneurysm
48118247|NCT04450199|DRUG|Vitamin D2|Vitamin D tablets
48118248|NCT04450199|OTHER|Placebo|Over encapsulated sugar pills
48118249|NCT02748486|BEHAVIORAL|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
48118250|NCT02748486|BEHAVIORAL|Group discussion|Group discussion of current events
48322745|NCT04485091|COMBINATION_PRODUCT|20% TCM and PBM|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.
48322746|NCT04485091|OTHER|20% TCM and PBM placebo|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
48322747|NCT05625854|BEHAVIORAL|Blow a fan to the face combine aromatherapy|Blow a fan with aromatherapy to the face
48322748|NCT05625854|BEHAVIORAL|Blow a fan to the face|Blow a fan to the face
48647562|NCT01379937|BIOLOGICAL|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
47969895|NCT04893044|BEHAVIORAL|Video|"The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all."
47969896|NCT00226707|DRUG|Pimecrolimus Cream 1%|
47969897|NCT04034485|DRUG|lerodalcibep|PCSK9 inhibitor
47969898|NCT04034485|DRUG|evolocumab|PCSK9 inhibitor
47969899|NCT06265012|BIOLOGICAL|PHV01|Marburg virus vaccine
47969900|NCT06265012|BIOLOGICAL|Placebo|Lactated Ringer's Solution
47969901|NCT02007694|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
47969902|NCT05677581|OTHER|iodine nutrition status|iodine nutrition status
48118251|NCT02748486|BEHAVIORAL|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
48118252|NCT02271789|OTHER|problematic tooth|problematic tooth
48118253|NCT01708499|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48118254|NCT03900442|DRUG|PTX-100|Doses of 500 to 2000 mg/m2 will be administered.
48322749|NCT05625854|BEHAVIORAL|Blow a fan to the feet|Blow a fan to the feet
48322750|NCT05708937|BEHAVIORAL|Mindfulness based phone app|"Creating mindfulness-based suggestions for infertile women:~Mindfulness-based content was created by taking the opinions of experts in the fields of women's health nursing, psychology and linguistics. It consists of 6 different parts. The content of meditation that the patient will apply according to the treatment stage is different. Infertility mindfulness departments; Breath Awareness, Body \& Uterus Awareness, Needle Therapy and Ovarian Awareness, Pre-Egg Collection (OPU) Diaphragm Breathing, Pre-embryo Transfer Uterine Awareness, Embryo and Uterine Awareness (Post transfer).~Audio recordings of mindfulness-themed meditation content:~After the meditation contents are planned; the sound recording was taken with a professional recorder (Sony ICD-PX470). The audio recordings taken were professionally edited by the expert. Mp3 recordings were created by adding background music to sound recordings in computer environment. Audio recordings of mindfulness-themed meditation content"
47969903|NCT05052762|OTHER|Group A: Elastic resisted training for Gluteus Maximus strength|"Subjects attended physical therapy two times per week for a total of 10 visits. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) are added. Each exercise was performed for 10 repetitions. Elastic resistance was Added to the fire hydrant, hip extension in prone and deadlift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
47969904|NCT05052762|OTHER|Group B: Weight resisted training for Gluteus Maximus strength|Subjects attended p two times per week for a total of 10 visits. The participants performed PHEKF in 90° knee flexion with 30° hip abduction and 10° hip extension to increase the muscle activity of the gluteus maximus. In the prone position, the participant performed 10° hip extension until the posterior knee reached the horizontal bar. The participants maintained 90° knee flexion with 30° hip abduction and 10° hip extension in the prone position against the resistance. Sandbags (3 kg) will be used to provide resistance on the ankle through a rope and pulley. Each subject performed three sets with three repetitions of five seconds each. 1-minute break is allowed between each set.
47969905|NCT00795860|BEHAVIORAL|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
48118255|NCT03476746|DRUG|LEO 90100 foam|A foam formulation of the active comparator Dovobet® ointment
48118256|NCT03476746|DRUG|Dovobet® ointment|Ointment formulation containing same active ingredients as LEO 90100 foam
48118257|NCT03385824|BEHAVIORAL|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
48118258|NCT01060137|DRUG|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
48118259|NCT00030238|DRUG|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
48118260|NCT00030238|DRUG|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
48322751|NCT05326217|OTHER|Aerobic exercise|The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).
48322752|NCT05326217|OTHER|Resistant exercise|The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
48322753|NCT04092816|BEHAVIORAL|FAMILY Intervention|The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
48322754|NCT04733846|OTHER|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
48322755|NCT03059719|BIOLOGICAL|Exenatide injection(Byetta)|
48322756|NCT03059719|BIOLOGICAL|PB-119 injection|
48322757|NCT03258047|COMBINATION_PRODUCT|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
48322758|NCT03287752|DEVICE|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
48322759|NCT03287752|DEVICE|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
48322760|NCT02421744|BEHAVIORAL|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
48322761|NCT02421744|BEHAVIORAL|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
48322762|NCT05684653|DRUG|Orelabrutinib Tablets|50 mg, single oral dose
48322763|NCT00878215|DEVICE|Explorer Liver Image Guided System|
48322764|NCT00878215|DEVICE|Explorer Liver Passive Tracking|
48322765|NCT00878215|PROCEDURE|Liver surgery|-Standard of care
48322766|NCT00878215|PROCEDURE|Liver abalation|-Standard of care
48322767|NCT02066753|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
48322768|NCT00796094|OTHER|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
48322769|NCT03034408|DRUG|Nalmefene|
48322770|NCT03034408|DRUG|Baclofen|
48322771|NCT03034408|DRUG|Placebo Oral Capsule|
48322772|NCT00701155|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
48322773|NCT06114394|PROCEDURE|UPV/EHU technique (Aguirre-Zorzano et al 2017)|"The UPV/EHU technique (Aguirre-Zorzano et al., 2017) begins with the elevation of the full thickness flap (FTF) in the palate and an intrasulcular incision performed with a number 12 blade, preserving the papillae in the interproximal spaces. Then, the FTF is dissected with a 15c blade, holding the flap with tissue forceps, leaving the epithelium and a thin layer of the connective tissue in the flap, so that the underlying connective tissue can be harvested. After that the flap is sutured."
48322774|NCT06114394|PROCEDURE|Single incision technique (Huerzeler & Weng 1999)|The CTG is harvested with the single incsion technique described by Huerzeler \& Weng in 1999.
48322775|NCT02935686|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.
48322776|NCT02935686|BIOLOGICAL|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
48322777|NCT02935686|BIOLOGICAL|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
48322778|NCT02935686|OTHER|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
48322779|NCT02935686|BIOLOGICAL|gp140 HIV Bivalent Vaccine|gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
48322780|NCT02863367|DRUG|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
48322781|NCT02863367|DRUG|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
48322782|NCT00497016|DRUG|atorvastatin 80 mg|
48322783|NCT00611221|PROCEDURE|Massage|Massage therapy by an RMT during labour
48322784|NCT00611221|PROCEDURE|Massage|Massage by anyone else, eg. husband, nurse, doula
48487865|NCT04966364|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
48487866|NCT04966364|DEVICE|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
48322785|NCT04641819|DRUG|Yangzheng Compound Mixture|"At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions."
48322786|NCT04641819|OTHER|Conventional Treatment|Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
48322787|NCT02999880|PROCEDURE|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
48322788|NCT04172909|OTHER|LEGO Bricks MRI|LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
48322789|NCT04172909|OTHER|Mock MRI tube|Mock MRI tube will be used by the child life specialist to prepare the child for MRI
48322790|NCT00002511|RADIATION|low-LET photon therapy|
48322791|NCT02766790|DIETARY_SUPPLEMENT|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
48322792|NCT02766790|OTHER|Placebo|Placebo, an inactive formulation
48322793|NCT04935047|OTHER|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
48322794|NCT00395837|BEHAVIORAL|Aerobic exercise|
48322795|NCT01286948|DRUG|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
48322796|NCT01266434|DRUG|Simvastatin|10 mg once daily for 8 weeks
48322797|NCT01266434|DRUG|B1-6-12|1 tablet once daily for 8 weeks
48322798|NCT00736866|DRUG|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
48322799|NCT00736866|DRUG|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
48322800|NCT04325282|DEVICE|Active rTMS|1Hz rTMS delivered for 15-20 minutes
48322801|NCT04325282|DEVICE|Sham rTMS|sham rTMS delivered for 15-20 minutes
48322802|NCT04197544|PROCEDURE|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
48322803|NCT04940442|BEHAVIORAL|Outreach|Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened
48322804|NCT01397448|DRUG|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
48322805|NCT01397448|DRUG|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
48322806|NCT01397448|DRUG|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
48322807|NCT01527227|OTHER|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
48322808|NCT04962503|DRUG|Afamelanotide|Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
48322809|NCT01965912|DRUG|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
48322810|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
48322811|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
48322812|NCT00723411|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
48487867|NCT03188718|DEVICE|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
48487868|NCT00551382|DRUG|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
48487869|NCT00551382|DRUG|Placebo|Look alike tablets or granules 1 per day for 12 weeks
48487870|NCT02604472|OTHER|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
48322813|NCT02947022|DRUG|Calcium DTPA|"On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
48322814|NCT02947022|DRUG|Zinc DTPA|"On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
48118261|NCT03508310|OTHER|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
48322815|NCT05044585|OTHER|Remote Automated Monitoring System|The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.
48322816|NCT02140203|OTHER|Yoga Training|one-year experimental training (three times per week and one hour per session)
48322817|NCT05945901|DRUG|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
48322818|NCT05945901|DRUG|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
48322819|NCT03522701|BEHAVIORAL|CBTI|Refer to the arm description
48322820|NCT04410198|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
48322821|NCT02670330|DRUG|SD-101-6.0 cream|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
48322822|NCT03074994|DRUG|Peri-articular TXA (15 mg/kg)|combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
48322823|NCT03074994|DRUG|Intraarticular TXA 2 g (40 mL)|inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
48322824|NCT03074994|PROCEDURE|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area|(Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
48118262|NCT04910555|OTHER|strong desire to void - cognitive task|Strong desire to void - cognitive task (verbal fluency)
48118263|NCT03925558|DIETARY_SUPPLEMENT|Probiotics|
48322825|NCT03074994|PROCEDURE|TXA 40 mL inject into intraaricular knee capsule|after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
48322826|NCT04466501|DEVICE|ACR LAB|"The ACR \| LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm."
48647563|NCT01379937|BIOLOGICAL|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
48647564|NCT01379937|BIOLOGICAL|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
48647565|NCT03303066|DRUG|FG-4592|Oral
48118264|NCT03925558|DIETARY_SUPPLEMENT|Placebo|
48118265|NCT05971563|DIETARY_SUPPLEMENT|Casein|Natural protein
48118266|NCT05971563|DIETARY_SUPPLEMENT|L-amino acids|Synthetic amino acids based protein substitute for Phenylketonuria
48118267|NCT05971563|DIETARY_SUPPLEMENT|CGMP-AA|Glycomacropeptide based protein substitute for Phenylketonuria
48118268|NCT00588302|DRUG|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
48322827|NCT05775744|OTHER|Tight postpartum blood pressure control|The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
48322828|NCT03155295|OTHER|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
48118269|NCT01598636|PROCEDURE|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
48118270|NCT02515838|DRUG|Sevuparin|The Drug Product sevuparin solution for IV infusion
48118271|NCT02515838|OTHER|Placebo|Placebo for IV infusion
48322829|NCT03155295|OTHER|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
48322830|NCT05101460|DEVICE|XVIVO Perfusion System (XPS™) with STEEN Solution™|XVIVO Perfusion System (XPS™) with STEEN Solution™
48322831|NCT03101059|PROCEDURE|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
48322832|NCT02311309|OTHER|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration \>8 g/dL.
48322833|NCT02311309|OTHER|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration \< 8 g/dL.
48322834|NCT04628728|OTHER|Survey based on questionnaire (self-designed)|Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.
48322835|NCT02496481|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
48322836|NCT02496481|BEHAVIORAL|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
48322837|NCT02542436|OTHER|No intervention|No intervention administered in this study
48322838|NCT05429229|DRUG|VisuXL®|It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.
48322839|NCT05429229|DRUG|Lagricel PF®|It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
48487871|NCT02604472|OTHER|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
48487872|NCT03026972|BIOLOGICAL|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
48487873|NCT03026972|BIOLOGICAL|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
48487874|NCT03026972|BIOLOGICAL|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
48487875|NCT03026972|BIOLOGICAL|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
48487876|NCT03026972|BIOLOGICAL|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
48498018|NCT00085423|BIOLOGICAL|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
48647566|NCT03303066|DRUG|Placebo|Oral
47969906|NCT00795860|BEHAVIORAL|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
48118272|NCT04674371|OTHER|central venous catheter insertion|Every operator should perform the CVC Insertion Procedure according to his common clinical practice.
48118273|NCT02685488|DEVICE|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
47969907|NCT02728609|DEVICE|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
48118274|NCT02685488|DEVICE|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
48322840|NCT05429229|DRUG|Humylub PF®|It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
48322841|NCT02692170|BIOLOGICAL|CVI-HBV-001|Investigational Product
48322842|NCT02692170|BIOLOGICAL|Conventional Hepatitis B vaccine (20 μg)|Investigational Product
48322843|NCT03220711|DEVICE|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
48322844|NCT03220711|DRUG|Fluorescein|Fluorescent dye used for imaging contrast only.
48322845|NCT01011452|DRUG|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
48322846|NCT01011452|DRUG|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
48322847|NCT03546790|DRUG|Marijuana|Marijuana smoked via blunts with different cigar wrappers
48322848|NCT05015166|BEHAVIORAL|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
48322849|NCT05015166|BEHAVIORAL|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
48322850|NCT04315480|DRUG|Tocilizumab|single intravenous administration 8mg/Kg
48322851|NCT05261880|OTHER|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
48322852|NCT05261880|OTHER|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
48322853|NCT04790266|DIAGNOSTIC_TEST|Cardiac MRI|cCardiac MRI, ecocardiography and cardiotoxicity blood tests will be repeated as previously scheduled
48322854|NCT02327221|DRUG|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
48322855|NCT02327221|DRUG|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
48487877|NCT00208117|DRUG|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
48487878|NCT00208117|DRUG|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
48487879|NCT03257150|PROCEDURE|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.
48487880|NCT03257150|DEVICE|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
48487881|NCT06360068|DRUG|Sulfasalazine Tablets|All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.
48487882|NCT04420338|BIOLOGICAL|Blood sample|rapid serological tests carried out
48118275|NCT04168801|DIETARY_SUPPLEMENT|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
48118276|NCT02990234|PROCEDURE|Capsular Repair|
48487883|NCT04420338|BIOLOGICAL|Serum tube collection|SARS-COV2 seroconversion assay
48487884|NCT03116321|DRUG|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
47969908|NCT02728609|DEVICE|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
48118277|NCT02990234|PROCEDURE|No Capsular Repair|
48322856|NCT00394238|PROCEDURE|Ultrasonographic imaging|
48322857|NCT05753098|DRUG|estrogen therapy|oral estradiol valerate
48322858|NCT05753098|DRUG|Sildenafil|PDE5 inhibitor
48322859|NCT05753098|DRUG|Clomiphene Citrate 50mg|used for ovulation induction
48322860|NCT02590523|DRUG|Vancomycin|Intracameral vancomycin injection during cataract surgery
48322861|NCT02590523|DRUG|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
48322862|NCT02590523|DRUG|Placebo|Intracameral placebo injection with BSS during cataract surgery
48322863|NCT00403819|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
48487885|NCT00542763|DRUG|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
48487886|NCT04133649|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
48487887|NCT03393455|OTHER|not accurate|not accurate
48487888|NCT01355354|DRUG|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
48322864|NCT06113497|DRUG|Cocktail injection|Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml
48487889|NCT01355354|DRUG|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
48487890|NCT00571194|DRUG|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
48118278|NCT04201041|PROCEDURE|pudendal nerve pulsed radiofrequency|received pudendal nerve pulsed radiofrequency through trans-vaginal approach or trans-gluteal approach
48322865|NCT01981278|DRUG|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
48322866|NCT01981278|DRUG|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
48322867|NCT03604237|DIAGNOSTIC_TEST|Targeted group|Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
48322868|NCT05591794|OTHER|Aerobic and resistance exercises|Participants in the study group will be given an aerobic exercise program on the treadmill for 8 weeks, 2 days a week, 20 minutes at a rate of 60-80% of the target heart rate. Participants will work on the treadmill for 20 minutes at 60-70% of the target heart rate for the first four weeks, and at 70-80% of the target heart rate for the last four weeks. Resistance exercises will consist of exercises that will work large muscle groups with rubber bands. According to Borg, the resistance exercises to be applied will be three sets of 10 repetitions for each movement at an RPE of 11-12 during the first four weeks, and 3 sets of 15 repetitions at the same RPE for the last four weeks, 2 times a week for 20 minutes.
48322869|NCT05591794|DIETARY_SUPPLEMENT|Diet program|Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.
48322870|NCT05591794|OTHER|Regular walking program|Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.
48322871|NCT01991938|DRUG|VS-5584|
47969909|NCT03438669|OTHER|no intervention|no intervention
47969910|NCT00044278|DRUG|lamotrigine|
47969911|NCT03841669|BEHAVIORAL|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
47969912|NCT03841669|BEHAVIORAL|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
47969913|NCT02131194|DIETARY_SUPPLEMENT|Lenstatin|Dietary Supplement Lenstatin
47969914|NCT02131194|DRUG|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
47969915|NCT00952575|DRUG|polyclonal anti-D immunoglobulin|single injection of 300 µg
47969916|NCT00952575|DRUG|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
47969917|NCT06505421|BEHAVIORAL|Resistance training|Eccentric resistance training and tradional resistance training
47969918|NCT04059783|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
47969919|NCT01013376|DRUG|MC-1101|MC-1101 1.0%
47969920|NCT01013376|DRUG|Vehicle|Vehicle
47969921|NCT03504475|DRUG|Paroxetine Hydrochloride Tablet 20 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
47969922|NCT03504475|DRUG|Paxil® 20 mg|Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
47969923|NCT02973698|OTHER|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
47969924|NCT02973698|OTHER|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
47969925|NCT02973698|OTHER|Control|No intervention will do
47969926|NCT04254705|PROCEDURE|Rectal Biopsy|Suction biopsy or forceps biopsy
47969927|NCT00065689|DEVICE|high-intensity light therapy|
47969928|NCT04856371|DRUG|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
48118279|NCT06193850|OTHER|Observation during time|Evaluation through clinical investigation and questionnaires useful for evaluating the patient's psycho-physical conditions
48118280|NCT01895023|DRUG|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
48118281|NCT01895023|DRUG|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
48118282|NCT01895023|DRUG|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
48322872|NCT03637907|OTHER|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
48322873|NCT03608891|DEVICE|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
48322874|NCT03608891|DEVICE|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
48322875|NCT02910544|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
48322876|NCT03085147|DRUG|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
48322877|NCT03314714|PROCEDURE|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
48322878|NCT00377910|DRUG|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
48322879|NCT01206478|DRUG|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
48322880|NCT01206478|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
48118283|NCT02290470|DRUG|Olanzapine|"* Drug: Olanzapine 10 mg oral~* Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~* Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
48322881|NCT01206478|DRUG|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
48322882|NCT02916095|DRUG|Kanitinib|Oral administration of Kanitinib tablets.
48322883|NCT02858687|OTHER|Nasopharyngeal swab|
48322884|NCT05279664|OTHER|Remote ischemic conditioning (RIC) + Standard of Care for NEC|RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
48322885|NCT05279664|OTHER|Standard of Care for NEC|Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.
48322886|NCT01756066|BEHAVIORAL|Different levels of cost sharing|
48322887|NCT04348656|BIOLOGICAL|Convalescent plasma|Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
48322888|NCT04586244|DRUG|retifanlimab|retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
48322889|NCT04586244|DRUG|epacadostat|epacadostat will be administered daily twice daily orally up to and including day of surgery.
48322890|NCT04586244|DRUG|INCAGN02385|INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
48118284|NCT02290470|DRUG|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
48118285|NCT04460313|OTHER|nasopharyngeal sample|Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
48118286|NCT04460313|OTHER|Stools collection or anorectal swab samples|For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
48322891|NCT04586244|DRUG|INCAGN02390|INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
48322892|NCT01545609|OTHER|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
48322893|NCT00000993|DRUG|Zidovudine|
48322894|NCT03810417|DRUG|Digoxin Antibodies Fab Fragments|Digoxin antibodies
48322895|NCT03810417|OTHER|Placebo|Saline
48322896|NCT00118508|DRUG|risedronate (including placebo)|risedronate 35mg weekly
48322897|NCT00567541|DEVICE|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
48322898|NCT04234126|PROCEDURE|ERCP|Routine ERCP for CBD stone with the gallbladder in situ, the chronic gallbladder status was defined as gallbladder wall thickness≥4mm, chronic cholecystitis, polyps,crudely or calculus .
48118287|NCT04916145|DEVICE|SAT-008|SAT-008 is a digital device containing several types of activities related to the immune function of adults.
48322899|NCT01895452|DRUG|ALKS 9072, Low Dose|Intramuscular injection, given monthly
48322900|NCT01895452|DRUG|ALKS 9072, High Dose|Intramuscular injection, given monthly
48322901|NCT05154513|OTHER|Cohort 1|No intervention provided in this study
48322902|NCT00111475|DRUG|Romiplostim|Administered by subcutaneous injection
48322903|NCT00111475|DRUG|Placebo|Administered by subcutaneous injection
47969929|NCT04856371|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
48118288|NCT05543057|RADIATION|3DCRT|Three-dimensional conformal radiotherapy (3DCRT)
48647567|NCT04198337|PROCEDURE|Endoscopic Full Thickness Resection|Endoscopic full thickness resection achieved by resecting the submucosal tumor using retraction techniques and submucosal dissection, followed by closure
47969930|NCT04856371|DRUG|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
47969931|NCT04856371|DRUG|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
47969932|NCT00933972|DRUG|RO4998452|20mg po single dose
48118289|NCT05806255|DEVICE|The RELIEF App|"RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit."
48118290|NCT02990546|DRUG|midodrine|Midodrine will be given to treatment arm as enteral medication
48118291|NCT02990546|OTHER|Standard of Care|Patients in the control arm will receive standard of care for septic shock
48118292|NCT00214266|DRUG|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
48118293|NCT03264742|OTHER|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
48118294|NCT02711839|DIETARY_SUPPLEMENT|Commercial diabetic formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
48118295|NCT02711839|DIETARY_SUPPLEMENT|White sweet potato formula|The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
48118296|NCT01713946|DRUG|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
48322904|NCT06472388|DRUG|Everolimus 5 MG|oral everolimus 5 mg/daily
48487891|NCT03384017|OTHER|Transcutaneous Spinal Cord Stimulation and Gait Training|"TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session."
48647568|NCT05533372|DRUG|IA-14069|IA-14069 for oral administration.
48647569|NCT05533372|DRUG|Placebo|Placebo for oral administration.
48647570|NCT05533372|DRUG|Methotrexate|Methotrexate for oral administration.
48647571|NCT03109769|BEHAVIORAL|Mobile phone application|
47969933|NCT02023567|DRUG|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
48118297|NCT01713946|DRUG|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
48322905|NCT05576155|DRUG|Compound 21|Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M
48322906|NCT05576155|DRUG|Compound 21 + losartan|Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M.
48647572|NCT03109769|BEHAVIORAL|Verbal oral hygiene instructions|
48647573|NCT03940157|BEHAVIORAL|Oh Happy Day Class - Still I Rise|one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
47969934|NCT02681562|DRUG|olaparib|
47969935|NCT05127668|DEVICE|Airglove (TM)|A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.
47969936|NCT05127668|DEVICE|Warm-water Immersion|The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
47969937|NCT02319993|DRUG|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
48322907|NCT00259740|DRUG|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
48322908|NCT03711994|OTHER|Alkantis|cold therapy pack placed on the wound post operatively
48322909|NCT00895193|OTHER|Apple pectin|Apple pectin 2000mg
48322910|NCT00895193|DRUG|Aspirin 325 mg|Aspirin 325 mg
48322911|NCT00895193|OTHER|Placebo|Placebo
48322912|NCT01795586|DRUG|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m\^2; Level 2: 1.1 mg/m\^2; Level 3: 1.4 mg/m\^2"
48322913|NCT01795586|DRUG|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
48322914|NCT04255836|DRUG|Durvalumab|Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
48322915|NCT04255836|DRUG|the first line chemotherapy for metastatic NSCLC|paclitaxel+carboplatin or pemetrexed+cisplatin
48322916|NCT04255836|RADIATION|stereotactic body radiotherapy (SBRT)|SBRT total doses of 50-60Gy/≤10F
48322917|NCT01182337|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
48322918|NCT01182337|DRUG|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
48322919|NCT02598518|BEHAVIORAL|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
48322920|NCT02598518|BEHAVIORAL|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
48322921|NCT00020566|BIOLOGICAL|dactinomycin|Given IV
48322922|NCT00020566|DRUG|busulfan|Given orally and IV
48322923|NCT00020566|DRUG|doxorubicin hydrochloride|Given IV
47969938|NCT02319993|DRUG|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
48322924|NCT00020566|DRUG|etoposide|Given IV
48322925|NCT00020566|DRUG|ifosfamide|Given IV
48322926|NCT00020566|DRUG|melphalan|Given orally and IV
48322927|NCT00020566|DRUG|vincristine sulfate|Given IV
48322928|NCT00020566|PROCEDURE|autologous hematopoietic stem cell transplantation|Given IV
47969939|NCT02319993|DRUG|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
47969940|NCT00923338|DEVICE|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
47969941|NCT01363674|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
48322929|NCT00020566|PROCEDURE|conventional surgery|Given to patients deemed to require it
48322930|NCT00020566|RADIATION|radiation therapy|Given to patients deemed to require it
48322931|NCT04973410|DIAGNOSTIC_TEST|Coronary Physiology|Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)
48322932|NCT04973410|DIAGNOSTIC_TEST|15O-H2O-PET scan|Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
48322933|NCT02990455|DRUG|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
48322934|NCT02189590|DEVICE|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
48322935|NCT02189590|DEVICE|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
47969942|NCT02575495|DRUG|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
48322936|NCT05678192|DRUG|oral menopausal hormone therapy|Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
48322937|NCT05678192|DRUG|transdermal menopausal hormone therapy|Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
48322938|NCT04888351|OTHER|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
48322939|NCT04888351|OTHER|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
48322940|NCT02011867|DEVICE|Cork Electrode|
48322941|NCT01938690|DEVICE|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
48322942|NCT05519618|PROCEDURE|Epidural veins pressure and flow measurement|"The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine."
48322943|NCT03451500|DRUG|carbidopa-levodopa|See previous
48322944|NCT04171648|OTHER|Roasted Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.
48322945|NCT04171648|OTHER|Boiled Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.
48322946|NCT02379754|DRUG|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
48322947|NCT01933750|DEVICE|PresVIEW Device Implantation|
48322948|NCT01148316|DRUG|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
48322949|NCT01148316|BEHAVIORAL|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
48322950|NCT04363437|DRUG|Colchicine|People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
48322951|NCT04363437|DRUG|Usual Care|COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
48322952|NCT01044420|DRUG|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
48322953|NCT03363334|DRUG|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
48322954|NCT03363334|DRUG|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
48322955|NCT01464463|BEHAVIORAL|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
48487892|NCT03858218|OTHER|questionnaires set|questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
48487893|NCT04462471|DIAGNOSTIC_TEST|I-124 PET/CT lesion dosimetry|I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
48487894|NCT04462471|DRUG|Vemurafenib|Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
48487895|NCT04462471|DRUG|Copanlisib|Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
48487896|NCT05613517|OTHER|Eye examination|"* orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~* ocular biometry~* corneal topography~* monocular photographs in photopic condition"
48487897|NCT05862194|DRUG|Lazertinib|Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
48487898|NCT05862194|DRUG|Platinum-based Chemotherapy|Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
48647574|NCT05500846|DEVICE|The Visual Ice Cryoablation System|Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
48322956|NCT01464463|BEHAVIORAL|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
48487899|NCT00441350|DRUG|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
48322957|NCT01464463|BEHAVIORAL|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
48322958|NCT00005848|DRUG|chemotherapy|
48322959|NCT00005848|DRUG|tipifarnib|
48118298|NCT01713946|DRUG|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
47969943|NCT02575495|DRUG|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
48118299|NCT01713946|DRUG|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
48118300|NCT02383472|DEVICE|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
48118301|NCT02383472|DEVICE|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
48322960|NCT04044209|DRUG|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
48322961|NCT04044209|DRUG|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
48322962|NCT03900754|DRUG|Oxytocin|Intranasal administration of oxytocin
48322963|NCT03900754|DRUG|Placebo|Placebo
48322964|NCT03307954|DEVICE|Ekso Therapy (Exoskeleton Suit)|
48322965|NCT03307954|OTHER|Usual Physiotherapy|
48487900|NCT00441350|DRUG|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
48647575|NCT02214628|DRUG|Fovista® (anti-PDGF BB) plus anti-VEGF|
47969944|NCT05725967|PROCEDURE|Primary Obesity Endoscopic Procedures|Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
47969945|NCT05725967|PROCEDURE|Endoscopic Revision of Bariatric Surgical Procedures|Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
48647576|NCT02439463|PROCEDURE|Below-knee amputation|Patients with traumatic below-knee amputation.
47969946|NCT05725967|PROCEDURE|Bariatric Surgery Procedures|Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
47969947|NCT05725967|DEVICE|Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction|Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
47969948|NCT05725967|DEVICE|Intragastric Balloon|An endoscopic bariatric procedure involving the placement of an intragastric balloon.
47969949|NCT05725967|DEVICE|Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal|Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
47969950|NCT05725967|DEVICE|Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy|Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
47969951|NCT05725967|DEVICE|Aspiration Therapy|Placement of an aspiration therapy device for the treatment of obesity.
48322966|NCT00503880|BIOLOGICAL|filgrastim|subcutaneously one day prior to treatment
48322967|NCT00503880|DRUG|clofarabine|single IV dose over 1 hour daily for 5 days
48322968|NCT00503880|DRUG|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
48322969|NCT00503880|GENETIC|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
48322970|NCT00503880|PROCEDURE|biopsy|bone marrow biopsy
48118302|NCT01241916|DEVICE|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
48322971|NCT00413062|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
48322972|NCT00413062|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
48322973|NCT05683652|DEVICE|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
48322974|NCT05837052|PROCEDURE|serplulimab plus chemotherapy as conversion treatment|Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.
48322975|NCT06394518|DRUG|TNP-2092 for injection|The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
48322976|NCT06394518|DRUG|placebo|The placebo for TNP-2092 active drug
48322977|NCT02058758|DEVICE|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
48487901|NCT03892213|DRUG|Benznidazole|Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.
48487902|NCT03892213|DRUG|E1224|"E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly."
48487903|NCT04546893|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
48487904|NCT04019184|DRUG|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
48487905|NCT04019184|DRUG|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
48647577|NCT04080531|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
48647578|NCT04080531|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
47969952|NCT03663998|BIOLOGICAL|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
47969953|NCT03663998|BIOLOGICAL|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
47969954|NCT03773991|DIAGNOSTIC_TEST|Lung MRI|Proton Lung Magnetic Resonance Imaging
47969955|NCT03773991|DIAGNOSTIC_TEST|Sodium MRI|Sodium Soft Tissue Magnetic Resonance Imaging
47969956|NCT03773991|DIAGNOSTIC_TEST|Chest CT|High-resolution Quantitative Chest CT
47969957|NCT03773991|DIAGNOSTIC_TEST|Echocardiography|Transthoracic 2D Speckle-Tracking Echocardiography
47969958|NCT03773991|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide|Fractional Exhaled Nitric Oxide testing
47969959|NCT03773991|DIAGNOSTIC_TEST|Pulmonary Function Tests|Spirometry and Plethysmography
47969960|NCT03773991|DIAGNOSTIC_TEST|Blood Sampling|Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
48118303|NCT01241916|DEVICE|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
48118304|NCT03132922|GENETIC|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
48118305|NCT03132922|RADIATION|Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation|Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
48322978|NCT02539355|OTHER|Diet A|12-week diet
48322979|NCT02539355|OTHER|Diet B|12-week Diet
48322980|NCT02692456|DEVICE|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
48487906|NCT05987917|DEVICE|BTL-785-2|Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation
48487907|NCT05987917|OTHER|No Treatment|The subject who will serve as control will not be treated with the study device.
48647579|NCT02315976|DRUG|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
48647580|NCT03355092|DEVICE|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
47969961|NCT03773991|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test
47969962|NCT03773991|DIAGNOSTIC_TEST|Dyspnea Questionnaires|Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
47969963|NCT05059600|DRUG|ZULRESSO®|Intravenous infusion of ZULRESSO®.
47969964|NCT04476069|DRUG|IBUPROFEN|given to children 30 minutes before extraction / orally for one time only
47969965|NCT03148132|DRUG|Bevacizumab Injection|0.5mg/0.02 mL
48647581|NCT01414790|PROCEDURE|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
48647582|NCT05973045|PROCEDURE|Operative Hysteroscopy 24 Centigrade Degree|Operative hysteroscopy will be performed at room temperature distention medium.
48322981|NCT02692456|DEVICE|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
48322982|NCT02221271|DRUG|NPB-01|
48322983|NCT04045717|RADIATION|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
48322984|NCT04392206|DRUG|Adipose Derived Mesenchymal Stem Cells|The dose will be specifically tailored to each subject's vascular anatomy determined by the surgeon through ultrasound measurements. Approximately 3-5 million cells in 5ml Ringer Lactate (RL) Solution
48322985|NCT03786198|BEHAVIORAL|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
48322986|NCT03786198|BEHAVIORAL|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
48322987|NCT01769261|OTHER|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
48322988|NCT01769261|OTHER|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
48322989|NCT01769261|OTHER|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
48322990|NCT06386809|DEVICE|TAVNS|TAVNS is a recently introduced treatment involving transcutaneous electrical stimulation of the auricular branch of the vagus nerve with VAGUSTIM device.
48322991|NCT06386809|OTHER|Exercise program|Rocabado 6x6 exercises will be applied in our study. Rocabado exercise, which is the most commonly used exercise method in the literature, is a set of exercises for the craniocervical and craniomandibular system.
48322992|NCT00150059|DRUG|Pimecrolimus Cream 1%|
48322993|NCT00674518|BEHAVIORAL|One on one counseling|Motivational Interviewing
48322994|NCT00674518|BEHAVIORAL|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
48322995|NCT00674518|BEHAVIORAL|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
48322996|NCT03379506|DRUG|EBR/GZR FDC Tablet|Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
48647583|NCT05973045|PROCEDURE|Operative Hysteroscopy 37 Centigrade Degree|Operative hysteroscopy will be performed using a heated distention medium.
47969966|NCT03148132|DRUG|Ranibizumab Ophthalmic|0.25mg/0.025 mL
48322997|NCT03379506|DRUG|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
48322998|NCT03379506|DRUG|Grazoprevir Oral Granules|Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
48322999|NCT03379506|DRUG|Elbasvir Oral Granules|Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
48323000|NCT03677310|DRUG|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
48323001|NCT03677310|DRUG|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
48323002|NCT03493867|DEVICE|Vitaliti|Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
48323003|NCT00156299|DRUG|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
48323004|NCT00156299|DRUG|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
48323005|NCT01621672|DRUG|Revlimid|10 mg/day in the morning same time each day
48323006|NCT02791087|OTHER|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
48323007|NCT02791087|OTHER|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
48487908|NCT02448849|BIOLOGICAL|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
48647584|NCT04967001|DIAGNOSTIC_TEST|PSMA PET|68Ga-PSMA PET
48647585|NCT02365688|PROCEDURE|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
48323008|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
48118306|NCT03697655|DRUG|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
48118307|NCT00373529|DRUG|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day as a 1-hour intravenous infusion for 5 consecutive days."
48323009|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
48323010|NCT01811901|OTHER|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
48323011|NCT06402669|OTHER|Packed Red Blood Cell Administration|Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.
48118308|NCT00947453|DRUG|montelukast|montelukast 10 mg once daily for 8 weeks
48323012|NCT05356741|DRUG|AMX-818|Administered as IV infusion
48323013|NCT05356741|DRUG|pembrolizumab|Administered as IV infusion
48323014|NCT01930526|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
48323015|NCT01690169|DRUG|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
48323016|NCT01690169|DRUG|placebo|A single dose of oral placebo administered.
48323017|NCT06087042|DIAGNOSTIC_TEST|serum and unstimulated salivary samples|"Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC"
48323018|NCT06101082|BIOLOGICAL|Intravenous infusion anti-HER2-CAR-T cell|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
48323019|NCT01532713|PROCEDURE|oxygen administration|nasal O2 5L/min via nasal cannula
48323020|NCT00145249|DRUG|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
47969967|NCT05329974|OTHER|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
47969968|NCT00277147|DRUG|BB IND 6989|
48323021|NCT00145249|DRUG|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
48323022|NCT05444010|BEHAVIORAL|mandala painting|nurse painted mandala for relaksing
48323023|NCT06136312|DEVICE|Multi4|TURBT procedure performed with the Multi4 instrument in local anesthesia
48323024|NCT04841720|DRUG|HSK16149|HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
48323025|NCT04841720|DRUG|Metformin Hydrochloride tablet|Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);
47969969|NCT01606436|DRUG|LY2140023|Administered orally.
47969970|NCT01606436|DRUG|Placebo|Administered orally.
48118309|NCT05000216|BIOLOGICAL|Moderna mRNA-1273|Administration: One dose administered intramuscularly.
48118310|NCT05000216|BIOLOGICAL|BNT162b2|Administration: One dose administered intramuscularly.
48118311|NCT05000216|BIOLOGICAL|Ad26.COV2.S|Administration: One dose administered intramuscularly.
48118312|NCT05000216|DRUG|Continue IS (MMF or MPA)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
48323026|NCT04841720|DRUG|HSK16149+Metformin（phase 3）|Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.
48647586|NCT06286475|DRUG|VRG50635|Specified dose on specified days
47969971|NCT01606436|DRUG|Moxifloxacin|Administered orally.
48647587|NCT06286475|DRUG|Placebo|Specified dose on specified days
48647588|NCT06379620|DEVICE|Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)|Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days
48647589|NCT00707304|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
48323027|NCT05741086|DRUG|Evolocumab|evolocumab (140 mg every 2 weeks)
48647590|NCT00707304|DRUG|Placebo|Oral, twice per day
47969972|NCT04830774|DEVICE|ILR, PMK, ICD|"* Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.~* Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions"
47969973|NCT03098550|BIOLOGICAL|Nivolumab|Specified dose on specified days
48118313|NCT05000216|DRUG|Continue IS (MTX)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
48118314|NCT05000216|BIOLOGICAL|Continue IS (B cell depletion therapy)|Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.
48118315|NCT05000216|BIOLOGICAL|Monovalent [B.1.351] CoV2 preS dTM-AS03|One dose administered intramuscularly
48118316|NCT05000216|DRUG|Withhold IS (MMF or MPA)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
48323028|NCT05741086|DRUG|Atorvastatin|Atorvastatin 20-40mg
48323029|NCT03891394|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
48323030|NCT05590767|PROCEDURE|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
48323031|NCT01872091|OTHER|cryotherapy by immersion|
48323032|NCT01872091|OTHER|Control group|
48323033|NCT00762372|DRUG|desflurane|volatile liquid for inhalation
48323034|NCT00762372|DRUG|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
48647591|NCT06674200|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery is shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Separate the mesentery around the stoma and shape it into a sturdy support structure.~Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
48647592|NCT06674200|PROCEDURE|Regular|"The stoma surgery is performed using conventional non-molding suturing techniques. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Perform routine suturing around the stoma without additional mesentery shaping. Form the stoma, ensuring a tight fit of the surrounding tissues."
48647593|NCT03487458|PROCEDURE|Rib Fixation Surgery|Rib Fixation Surgery
47969974|NCT03098550|BIOLOGICAL|Daratumumab|Specified dose on specified days
47969975|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg）|
47969976|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg）|
47969977|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg）|
47969978|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg） and vaccine|
48118317|NCT05000216|DRUG|Withhold IS (MTX)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
48118318|NCT05000216|DRUG|Withhold IS (B cell depletion therapy)|Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.
48118319|NCT05000216|BIOLOGICAL|Moderna mRNA-1273, Bivalent|Administration: One dose administered intramuscularly.
47969979|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg） and vaccine|
47969980|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg） and vaccine|
47969981|NCT02559921|BIOLOGICAL|placebo and vaccine|
47969982|NCT04876924|DRUG|BBP-711|BBP-711, oral suspension
47969983|NCT04876924|DRUG|Placebo|Placebo matching BBP-711
48323035|NCT00762372|DRUG|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
48323036|NCT05334680|DEVICE|ANNE Sensor|The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
48323037|NCT02451436|BEHAVIORAL|Sleep and Media Use Intervention|
48323038|NCT02451436|BEHAVIORAL|Study Skills Control Group|
48323039|NCT03400137|DIAGNOSTIC_TEST|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
48487909|NCT02448849|OTHER|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
48487910|NCT06015477|DRUG|Ticagrelor monotherapy|starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.
48487911|NCT06015477|DRUG|Dual Antiplatelet Therapy|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
48487912|NCT02239107|DRUG|N-Acetyl cysteine|
48487913|NCT02239107|PROCEDURE|laparoscopic ovarian drilling|
48323040|NCT06402968|DRUG|Clevidipine Injection|Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
48323041|NCT06402968|DRUG|Alternate IV Antihypertensive Regimen|"The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour."
48323042|NCT05369026|OTHER|Single leg immobilization|2 weeks of single-leg immobilization
48323043|NCT04654091|PROCEDURE|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
48323044|NCT04654091|PROCEDURE|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
48323045|NCT02065596|DRUG|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
48487914|NCT05667636|RADIATION|salvage SBRT|steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
48487915|NCT03064438|DRUG|ACCU-D1|ACCU-D1
48487916|NCT03064438|DRUG|Vehicle|Placebo Comparator
48487917|NCT05253924|DIAGNOSTIC_TEST|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1, Piezo1, Piezo2, TRPV1 andTRPM8) will be investigated. Saliva sample will be collected for PT and FT. Genomic DNA will be extracted from aliquots of 0. 4 ml of each saliva sample with the Oragene OG575 (DNA Genotek) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
48487918|NCT05253924|DIAGNOSTIC_TEST|EEG acquisition|Both PT and FT infants will have their EEG signal recorded during mother-baby interaction according to a modified version of the Still Face paradigm; the EEG signal will be recorded by means of the medical system eego mylab (AntNeuro), using special headphones equipped with 32 electrodes and suitable to acquire the EEG signal since early childhood. After spectral analysis of the EEG signal, the difference in signal strength in the alpha band recorded by two homologous electrodes (or electrode clusters) (i.e. right alpha - left alpha) will be calculated to obtain the FAA index. Because the alpha frequency band is associated with cortical inhibitory activity, a lower asymmetry reflects less left hemisphere activation than right hemisphere activation. The analysis of EEG data will be performed in MatLab environment using the eeglab software and algorithms developed ad hoc.
48487919|NCT03715998|DRUG|Ramipril|1 or 2 capsules administered orally, twice daily
48487920|NCT03715998|DRUG|Firibastat|1 or 2 capsules administered orally, twice daily
48487921|NCT04781036|DRUG|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 2 weeks
48487922|NCT00578071|DRUG|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
48118320|NCT05000216|BIOLOGICAL|BNT162b2, Bivalent|Administration: One dose administered intramuscularly.
48118321|NCT06242041|DRUG|sodium zirconium cyclic silicate|On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.
48487923|NCT00578071|DRUG|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
47969984|NCT00018200|DRUG|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
48118322|NCT06014216|OTHER|Flavoured ice lollies (popsicles)|Blackcurrant flavoured ice popsicles, 105ml volume.
48118323|NCT06014216|OTHER|Water|Water from tap, one cup given by recovery nurses.
48118324|NCT00118768|DRUG|valopicitabine|
48118325|NCT00118768|DRUG|Pegylated Interferon Alfa|
48323046|NCT02065596|PROCEDURE|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
48323047|NCT05271396|OTHER|Clinical Assessment|The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
48323048|NCT04111172|BIOLOGICAL|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Given as intramuscular injection
48323049|NCT00000240|DRUG|Buprenorphine|
48323050|NCT02909569|DRUG|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
48323051|NCT04350736|DRUG|TD-0903|Study drug to be administered by inhalation
48323052|NCT04350736|DRUG|Placebo|Placebo to be administered by inhalation
48323053|NCT01806376|DRUG|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
48323054|NCT02831842|DRUG|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
48323055|NCT02831842|DRUG|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
48323056|NCT02831842|DRUG|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
48323057|NCT02435641|OTHER|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
48323058|NCT01843400|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
48323059|NCT00650091|DRUG|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
48323060|NCT00650091|DRUG|Placebo|Participants will receive placebo each day.
48323061|NCT05405595|DRUG|ADG126|ADG126 and Pembrolizumab (KEYTRUDA®) combination treatment both will be dosed until progressive disease (PD), intolerable toxicities, withdrawals of consent, or up to 35 cycles.
48323062|NCT05371067|OTHER|Fructose respiratory test|Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
48323063|NCT01353144|DRUG|aspirin|aspirin, 100 mg, qd x 8 weeks
48323064|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
48323065|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
48323066|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
48323067|NCT01336166|BIOLOGICAL|Placebo control|120 adults were assigned to receive 1 dose of placebo.
48487924|NCT00578071|DRUG|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
48323068|NCT02704494|DRUG|Resveratrol|Resveratrol 500mg daily
48323069|NCT02704494|DRUG|Placebo|Placebo 1 capsule daily
48323070|NCT02704494|DRUG|Losartan|Losartan 12.5mg daily
48323071|NCT00027456|DRUG|Leptin A-100|
48323072|NCT00070980|PROCEDURE|Massage therapy|
48323073|NCT02899117|OTHER|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
48323074|NCT00110318|PROCEDURE|Manual therapy and therapeutic exercise|
48323075|NCT00110318|PROCEDURE|Corticosteroid injections|
48323076|NCT02626845|DRUG|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
48323077|NCT02626845|OTHER|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
48323078|NCT04065373|DEVICE|ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
48323079|NCT00440895|DRUG|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
48323080|NCT05913141|OTHER|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
48323081|NCT01023438|OTHER|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
48323082|NCT01023438|OTHER|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
48487925|NCT00578071|RADIATION|Radiation Therapy (RT)|Daily for 6 weeks
48487926|NCT01393730|DRUG|Abiraterone acetate|
48487927|NCT01393730|DRUG|Dutasteride|
48487928|NCT01393730|DRUG|Prednisone|
48487929|NCT02291471|DRUG|T0001，10mg|
48487930|NCT02291471|DRUG|T0001，20mg|
48487931|NCT02291471|DRUG|T0001，35mg|
48487932|NCT02291471|DRUG|T0001，50mg|
48487933|NCT02291471|DRUG|T0001，65mg|
48487934|NCT02291471|DRUG|T0001，75mg|
47969985|NCT00018200|DRUG|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
47969986|NCT00018200|DRUG|Benztropine|Daily dose 0.125 to 0.5mg
48323083|NCT06118567|DRUG|Nitrous oxide|Nitrous oxide gas.
48323084|NCT06118567|DRUG|Room Air|Room Air
48323085|NCT02496117|PROCEDURE|Electrical mapping, nerve stimulation checked renal denervation procedure|
48323086|NCT02496117|PROCEDURE|Electrial mapping, nerve stimulation guided renal denervation procedure|
48323087|NCT00220766|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
48323088|NCT00220766|DRUG|Dextrose, 5% in Water|
48323089|NCT03670524|OTHER|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
48323090|NCT02946541|DRUG|evogliptin 5mg|evogliptin 5mg, QD
48323091|NCT02946541|DRUG|Placebo|Placebo, QD
48323092|NCT00695240|DEVICE|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
48323093|NCT02843581|DEVICE|Cryosurgery|Argon-helium cryosurgical system
48323094|NCT02843581|BIOLOGICAL|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
48323095|NCT03265743|OTHER|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
48323096|NCT04284943|PROCEDURE|Long limb Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
48323097|NCT04284943|PROCEDURE|Conventional Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
48323098|NCT04284943|PROCEDURE|Billroth II reconstruction after subtotal gastrectomy|The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
48323099|NCT03974113|DRUG|Fitusiran|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
48323100|NCT01317615|DRUG|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
48498019|NCT00085423|DRUG|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
48118326|NCT00637936|DRUG|Oxygen|Inspiratory fraction during anaesthesia
48118327|NCT06232044|DRUG|Iberdomide|Receive PO
48118328|NCT06232044|BIOLOGICAL|Belantamab Mafodotin|Receive IV
48118329|NCT06232044|DRUG|Dexamethasone|Receive PO
48323101|NCT01317615|DRUG|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
48323102|NCT01317615|DRUG|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
48323103|NCT02298478|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
48118330|NCT06232044|PROCEDURE|Echocardiography|Undergo ECHO
48118331|NCT06232044|PROCEDURE|Computed Tomography|Undergo CT
48118332|NCT06232044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48323104|NCT01628094|DRUG|RO5024048|
48323105|NCT01628094|DRUG|RO5190591|
48323106|NCT01628094|DRUG|RO5466731|
48323107|NCT01628094|DRUG|ribavirin [Copegus]|
48323108|NCT01628094|DRUG|ritonavir|
48323109|NCT02709928|DRUG|TD-0714|
48323110|NCT02709928|DRUG|Placebo|
48323111|NCT01689402|DEVICE|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
48323112|NCT04375241|OTHER|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
48323113|NCT00114270|DRUG|letrozole|
48323114|NCT00114270|DRUG|zoledronic acid|
48323115|NCT02793323|OTHER|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
48323116|NCT02793323|OTHER|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
48323117|NCT02793323|OTHER|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
48323118|NCT02793323|OTHER|IV placebo|100 ml IV saline
48323119|NCT02793323|OTHER|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
48118333|NCT06232044|PROCEDURE|Positron Emission Tomography|Undergo PET
48118334|NCT06232044|PROCEDURE|Bone Marrow Biopsy|Undergo Bone Marrow Biopsy
48118335|NCT06232044|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspirate
48118336|NCT06232044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48118337|NCT02389777|BIOLOGICAL|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
48118338|NCT02389777|BIOLOGICAL|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
48118339|NCT02147054|DRUG|Rocuronium|
48118340|NCT02147054|DRUG|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
48118341|NCT05215925|DRUG|HLX07+carboplatin+pemetrexed|HLX07 1500mg q3w+carboplatin+pemetrexed
48118342|NCT05215925|DRUG|HLX07+docetaxel|HLX07 1500mg q3w+docetaxel
48118343|NCT05215925|DRUG|HLX07|HLX07 1500mg q3w
48118344|NCT00648349|DRUG|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
48118345|NCT00648349|DRUG|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
48118346|NCT01361945|DRUG|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
48118347|NCT06148298|OTHER|Non-Human Subject Research study.|This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
48118348|NCT04094532|DRUG|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
48118349|NCT04094532|DRUG|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
48323120|NCT05739812|DEVICE|telesurgery by domestic surgical robot|telesurgery of urological diseases by domestic surgical robot
48323121|NCT02351843|DEVICE|MECTA Spectrum 5000Q|
48118350|NCT01939171|DRUG|Thymoglobulin|
48118351|NCT03230786|DRUG|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
48118352|NCT06522295|DEVICE|ultrasonography|Ultrasonographic Measurement of Optic Nerve Sheath Diameter
48118353|NCT04391101|DRUG|Convalescent plasma|400-500ml convalescent plasma
48118354|NCT02726828|DRUG|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
48118355|NCT02726828|DRUG|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
48118356|NCT02726828|DRUG|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
48118357|NCT00137371|DRUG|PVC (daily for 21 days, 7 days off)|
48118358|NCT00137371|DRUG|PVC (twice weekly)|
48118359|NCT02202772|DRUG|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
48118360|NCT02202772|DRUG|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
48118361|NCT02202772|DRUG|Cisplatin|Intravesical installation of Cisplatin for 2hours
48118362|NCT05210257|OTHER|Conventional physiotherapy|Group 1 was given conventinal physiotherapy Physiotherapy agents; 5 min ultrasound 1.5 watts/cm2 20 min conventional TENS 20 min heat agent application (hot pack) Exercise program; Stretching and relaxation exercises, Neck strengthening exercises that include concentric and isometric contractions Posture exercises 3 sets per day, 1 in the hospital with 10 repetitions
48118363|NCT05210257|OTHER|Neuroscience education|"Conventional physiotherapy program and The neuroscience education trainings will be conducted in the form of face-to-face interviews and 45-50 minute one-to-one sessions.~In sessions ; neurons and nerve conduction in the session, the formation process of pain, peripheral neuropathic pain, pain spread during the session, neuroplasticity, peripheral and central sensitization, hyperalgesia and allodynia, acute-chronic pain, The effects of stress, fear, anxiety, false thoughts and beliefs about pain and other psychosocial factors on the pain process and determining possible psychosocial factors in the patient during the session, Strategies for controlling the pain process and coping with psychosocial factors in the session will be completed by explaining the effect mechanisms of exercise on pain."
48118364|NCT04326192|DEVICE|Research electrode|A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.
48118365|NCT04319874|DRUG|Ganoderma lucidum|Participants take ganoderma lucidum spore powder once a day, 1000mg
48323122|NCT00479557|BIOLOGICAL|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
48323123|NCT00479557|BIOLOGICAL|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
48323124|NCT00479557|BIOLOGICAL|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
48323125|NCT00479557|DRUG|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
48323126|NCT05874687|DRUG|hypotension + treat|Heart Rate and Mean Arterial Pressure (MAP) will be recorded throughout the procedure (every 2 minutes for the first 15 minutes). Ephedrine (in 6 mg increments) will be used as well as the isotonic balanced crystalloid solution to treat hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg (250 mL bolus). The Ephedrine dose will be recorded. Bradycardia, which is defined as a heart rate less than 50 beats per minute, will be treated with intravenous Atropine (0.5 mg).
48323127|NCT05704439|DRUG|Neurologist Initiated Treatment|Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
48323128|NCT05704439|OTHER|Placebo|Usual care
48323129|NCT05331430|OTHER|Dry needling on cervical trigger point|One experimental group will receive dry needling treatment on the upper trapezius fibres using the Hong technique and the other experimental group will receive passive muscle stretching treatment on the upper trapezius fibres.
48323130|NCT04776811|DEVICE|Continuous glucose monitoring system|Medtronic Guardian Connect with Guardian Sensor 3
48323131|NCT01480557|PROCEDURE|liquefaction|Cataract extraction surgery type
48323132|NCT01480557|PROCEDURE|Torsional ip|A type cataract surgery using torsional ip technology
48323133|NCT02705118|DEVICE|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
48323134|NCT02705118|DEVICE|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
48323135|NCT00370240|DRUG|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
48323136|NCT00370240|OTHER|placebo|The PCB group received saline solution in equal volume.
48323137|NCT02439944|DRUG|Nicotine patch|
48323138|NCT02439944|DRUG|Nicotine mouthspray|
48323139|NCT03805581|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
48323140|NCT03227965|BIOLOGICAL|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
48323141|NCT03998020|OTHER|scale of severity|assessment of the severity of the sleep disorders by scale
48487935|NCT06001723|BEHAVIORAL|Forest Therapy|Forest healing activities are guided by professionals, allowing participants to engage in a two-hour sensory experience within the forest environment. This includes activities such as stacking leaves and stones, closing their eyes to listen to sounds, engaging in physical stretches, blindfolded tree identification, connecting with tree companions, creating earth mandalas, and partaking in tea ceremonies and sharing insights.
48487936|NCT05302921|PROCEDURE|Cryoablation Therapy|"Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only."
48498020|NCT00085423|DRUG|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
48498021|NCT01706237|DEVICE|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
48323142|NCT03998020|GENETIC|blood sample|Genetical study, serum and sample
48323143|NCT03822871|DRUG|CTT1403|Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
48323144|NCT03822871|DRUG|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
48323145|NCT03822871|DRUG|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
48323146|NCT06097767|DRUG|Caffeine citrate|It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
48323147|NCT06097767|DRUG|Amikacin|it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
48323148|NCT03519672|OTHER|No intervention|This is a non-interventional study.
48323149|NCT01030458|DRUG|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
48323150|NCT01030458|DRUG|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
48118366|NCT04319874|DRUG|Chemotherapy|Subjects are treated with conventional chemotherapy
48118367|NCT04319874|DRUG|Placebos|Subjects are treated with conventional chemotherapy and Placebos once a day, 1000mg
48118368|NCT05369169|BEHAVIORAL|Resonance breathing|Participants will synchronize their breathing with a visual pacer (E-Z Air, Thought Technology, Ltd., Plattsburgh, NY) that moves up (inhale) and down (exhale) at the rate of 0.1 Hz (6 breaths per min)
48323151|NCT02652507|DRUG|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
48323152|NCT02652507|DRUG|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
48323153|NCT05085028|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
48323154|NCT04561921|DRUG|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
48118369|NCT05369169|BEHAVIORAL|Low demand cognitive task|Different colored rectangles are presented for 10 sec each, and participants are instructed to silently count the number of blue rectangles
48118370|NCT03310112|BEHAVIORAL|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
48118371|NCT03310112|BEHAVIORAL|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
48323155|NCT04561921|DRUG|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
48118372|NCT04112069|DEVICE|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
48118373|NCT04112069|OTHER|Usual Care|Usual care
48118374|NCT00502424|DEVICE|Splint|
48118375|NCT03133117|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
48118376|NCT02640781|PROCEDURE|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
48118377|NCT02640781|PROCEDURE|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
48118378|NCT00439569|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
48487937|NCT05302921|DRUG|Nivolumab|"Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
48647594|NCT05952310|OTHER|Natural Killer (NK) cells (a new immunotherapy)|"It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells."
48647595|NCT04989218|DRUG|Novel combination of chemotherapy and immunotherapy|This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
48647596|NCT01346917|DRUG|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
48647597|NCT01346917|DRUG|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
48647598|NCT05708690|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
48118379|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
48118380|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
48118381|NCT01924676|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
48118382|NCT06552260|DRUG|Troriluzole|Tripeptide prodrug of Riluzole, 100 mg capsule, taken orally per protocol.
48118383|NCT04750044|OTHER|early refeeding|In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
48118384|NCT04750044|OTHER|delayed refeeding|In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
48118385|NCT01485653|DRUG|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
48118386|NCT04297306|BEHAVIORAL|Exercise Prescription|Standardised Exercise Prescription.
48118387|NCT04297306|DEVICE|Exercise Prescription and Virtual Reality Exercise Gaming support|Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
48647599|NCT05708690|DRUG|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
48118388|NCT02541565|DRUG|Cyclophosphamide|Given IV
48118389|NCT02541565|DRUG|Doxorubicin Hydrochloride|Given IV
48118390|NCT02541565|OTHER|Laboratory Biomarker Analysis|Correlative studies
48118391|NCT02541565|BIOLOGICAL|Pembrolizumab|Given IV
48323156|NCT04411212|DRUG|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
48323157|NCT04411212|OTHER|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
48323158|NCT01969669|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
48323159|NCT01969669|DRUG|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
48323160|NCT03435263|OTHER|home management|pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
48323161|NCT02051725|OTHER|Active life-style intervention|
48323162|NCT00847756|OTHER|questionnaire|Identification of risk factors
48323163|NCT00847756|PROCEDURE|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
48323164|NCT00847756|PROCEDURE|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
48323165|NCT00847756|PROCEDURE|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
48323166|NCT06498752|DRUG|PD-1 monoclonal antibody consolidation therapy|PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
48323167|NCT03935165|DRUG|Indocyanine Green|"0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~- Indocyanine Green is administered Intravenously"
48323168|NCT02058485|DRUG|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
48323169|NCT02058485|DRUG|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
48323170|NCT00233818|DEVICE|Sirolimus-coated Bx VELOCITY Stent|
48323171|NCT06293664|OTHER|α-MSH infusion|Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
48647600|NCT05827237|DIAGNOSTIC_TEST|Clinical decision rule|Clinical decision rule for acute chest pain, consisting of the Marburg Heart Score (5 questions) combined with a high-sensitive troponin I point of care test
48118392|NCT02541565|DRUG|Prednisone|Given PO
48118393|NCT02541565|BIOLOGICAL|Rituximab|Given IV
48118394|NCT02541565|DRUG|Vincristine Sulfate|Given IV
48118395|NCT05383859|BEHAVIORAL|Intervention|"1. Dietary and/ or physical activity: face to face plus written material (at baseline)~2. 3 months later: motivational phone call."
48323172|NCT06293664|OTHER|Placebo solutions|Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
48323173|NCT03831802|DEVICE|Embrace with Alert and Mate apps|Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
48323174|NCT03831802|DEVICE|Embrace with Mate app only|Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
48647601|NCT00000501|BEHAVIORAL|diet, sodium-restricted|
48647602|NCT00000501|BEHAVIORAL|diet, reducing|
48323175|NCT02693795|OTHER|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
48487938|NCT05302921|DRUG|Ipilimumab|"Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease."
48647603|NCT00000501|DRUG|potassium|
48647604|NCT02017834|PROCEDURE|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
47969987|NCT03798483|OTHER|Individualised exercise|The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
47969988|NCT03498027|DEVICE|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
47969989|NCT01716767|OTHER|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
47969990|NCT01716767|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
47969991|NCT03565744|BEHAVIORAL|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
47969992|NCT03310021|BIOLOGICAL|Andexanet alfa|fXa inhibitor antidote
47969993|NCT03310021|DRUG|Apixaban|factor Xa inhibitor
48647605|NCT05333965|DEVICE|Lens A (lehfilcon A lens)|Daily wear for 1 month.
48118396|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in plasma after DNAse digestion.|Plasma will be tested after DNAse digestion for quantification of virion-associated HCMV DNA (defined as true breakthrough HCMV productive infection).
48487939|NCT03274713|DEVICE|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
48647606|NCT05333965|DEVICE|Lens B (comfilcon A lens)|Daily wear for 1 month.
48647607|NCT01871922|DRUG|Placebo|Saline
48647608|NCT01871922|DRUG|Atropine|Atropine
47969994|NCT03310021|DRUG|Rivaroxaban|factor Xa inhibitor
47969995|NCT03310021|DRUG|Edoxaban|factor Xa inhibitor
47969996|NCT03310021|DRUG|Placebo|Placebo
47969997|NCT05544916|DRUG|XC221|200 mg/day, for 5 days
47969998|NCT05544916|DRUG|Placebo|2 tablets/day, for 5 days
48118397|NCT06339892|DIAGNOSTIC_TEST|Determination of HCMV DNA in blood or plasma.|HCMV DNA will be determined in blood or plasma without DNAse digestion, as per current clinical practice.
48118398|NCT05505071|DEVICE|DANTE SPACE sequence|investigational MRI sequence less than 15 minutes
48323176|NCT02693795|OTHER|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
48118399|NCT04834219|PROCEDURE|On-Pump CABG|Patients who have undergone on-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
48647609|NCT04478734|DRUG|Moderate doses of Thiamine y Biotin|Thiamine 600 mg every day + Biotin 150mg every day
48647610|NCT04478734|DRUG|High doses of Thiamine y Biotin|Thiamine 1200 mg every day + Biotin 300mg every day
48647611|NCT02458027|DIETARY_SUPPLEMENT|Hemp Shake|Hemp Protein
48647612|NCT02458027|DIETARY_SUPPLEMENT|Hemp|Hemp Protein Shake
48647613|NCT02458027|DIETARY_SUPPLEMENT|Soybean Shake|Soybean Protein
48647614|NCT02458027|DIETARY_SUPPLEMENT|Soybean|Soybean Protein Shake
48647615|NCT02458027|DIETARY_SUPPLEMENT|Control|Non-Protein Shake
48647616|NCT02317042|DEVICE|Juno|Juno device set to ST mode with participant's current therapy settings.
48647617|NCT02317042|DEVICE|Juno|Juno device set to AutoEPAP iVAPS mode.
48647618|NCT02317042|DEVICE|Juno|Juno device set to Fixed EPAP iVAPS mode.
48323177|NCT02581566|DRUG|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
48323178|NCT02581566|DRUG|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
48323179|NCT02581566|DRUG|Bupivacaine|Intrathecal Bupivacaine
47969999|NCT02684916|PROCEDURE|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation."
48118400|NCT04834219|PROCEDURE|Off-Pump CABG|Patients who have undergone off-pump Coronary artery bypass grafting (CABG) surgery are planned by the Department of Cardiovascular Surgery.
48323180|NCT06362460|DRUG|[14C] RAY1216|400 mg suspension containing 100μCi of \[14C\]RAY1216
48323181|NCT05579912|PROCEDURE|Esophageal and gastric resections requiring an anastomosis|Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
48323182|NCT06198075|OTHER|Control Group|Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks
48323183|NCT06198075|DEVICE|Experimental Group|Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted.
48323184|NCT04010890|BEHAVIORAL|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
48323185|NCT00066118|DEVICE|Dental amalgam restorations|
48323186|NCT05299242|DRUG|Adalimumab Injection|40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd
48323187|NCT05299242|DRUG|Placebo|Saline \[0.9% NaCl\]
48323188|NCT05136846|DRUG|Carboplatin|Given IV
48323189|NCT05136846|BIOLOGICAL|Durvalumab|Given IV
48323190|NCT05136846|DRUG|Paclitaxel|Given IV
48323191|NCT05136846|DRUG|Papaverine|Given IV or SC
48487940|NCT03274713|DEVICE|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
48487941|NCT03511274|BEHAVIORAL|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
48487942|NCT03504280|DRUG|Cholecalciferol|
48487943|NCT04274023|DRUG|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
48487944|NCT05077436|DRUG|Vamifeport Formulation 1|Vamifeport Formulation 1 is available as 60 mg oral capsules
48487945|NCT05077436|DRUG|Vamifeport Formulation 2|Vamifeport Formulation 2 is available as 60 mg oral capsules
48487946|NCT05881902|BEHAVIORAL|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
48487947|NCT05881902|BEHAVIORAL|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
48323192|NCT05136846|RADIATION|Radiation Therapy|Undergo RT
48323193|NCT05136846|DRUG|Pemetrexed|Given IV
48323194|NCT02275767|DEVICE|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
48323195|NCT02275767|DEVICE|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
48323196|NCT02275767|DEVICE|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
48323197|NCT00126789|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
48323198|NCT05089344|DRUG|Growth Hormone|growth hormone
48323199|NCT05089344|DRUG|Clomiphene citrate daily and recombinant FSH (Gonal-F®)|Clomiphene citrate daily and recombinant FSH (Gonal-F®)
48323200|NCT01383967|DRUG|LY2979165|Administered orally
48323201|NCT01383967|DRUG|placebo|Administered orally
48323202|NCT02118857|OTHER|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
48323203|NCT02986685|DRUG|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
48323204|NCT02986685|DRUG|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
48323205|NCT01582971|OTHER|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
48323206|NCT05436886|DRUG|Neurogabin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
48323207|NCT05436886|DRUG|Parketin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
48323208|NCT00155454|PROCEDURE|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
48323209|NCT05311293|DIAGNOSTIC_TEST|Endoscopy|Observe the extent of colonic lesions and obtain intestinal mucosal samples
48323210|NCT00883220|BEHAVIORAL|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
48323211|NCT04959253|COMBINATION_PRODUCT|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
48487948|NCT03250299|DRUG|Microtubule-Targeted Agent BAL101553|Given PO
48487949|NCT03250299|RADIATION|Radiation Therapy|Undergo radiation therapy
48118401|NCT05709431|OTHER|Questionnaire CIQoL-35|The Cochlear Implant - Quality of Life (CIQoL) PROM is a quality-of-life assessment questionnaire for adults with cochlear implants (1-7). The CIQoL responds to an important need for a questionnaire that captures the benefits of cochlear implantation as perceived by patients and that can be used in clinical practice. The CIQoL is available in two lengths: 35 questions (CIQoL-35) and 10 questions (CIQoL-10). The CIQoL-35 has interesting measurement properties including good construct validity, convergent validity, and test-retest reliability.
48118402|NCT04826445|OTHER|Data collection|Imaging collection
48118403|NCT03592069|DRUG|10 day concomitant regimen|10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
48118404|NCT03592069|DRUG|14 day hybrid regimen|14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
48118405|NCT00447733|BEHAVIORAL|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
48118406|NCT00447733|BEHAVIORAL|Treatment as usual|Non-standardized psychiatric outpatient treatment
48487950|NCT05334355|OTHER|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
48487951|NCT04793035|DEVICE|Omega-Cuff|An omega-shaped nitinol device to be placed and secured on the Lower Esophageal Sphincter area
48118407|NCT05346978|DIETARY_SUPPLEMENT|Nasturtium (Tropaeolum majus)|Freeze dried nasturtium (Edible flower)
48118408|NCT05346978|DIETARY_SUPPLEMENT|Placebo|collagen colored with green pigment used in the food industry
48118409|NCT02594735|DRUG|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight \< 50 KG).
48118410|NCT01814033|OTHER|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
48118411|NCT01814033|OTHER|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
48118412|NCT04745663|DRUG|Povidone-Iodine 0.3%|Low concentration iodine
48323212|NCT04959253|COMBINATION_PRODUCT|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
48323213|NCT04958421|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
48323214|NCT04922697|OTHER|Educational Intervention|Watch educational videos and use wearable air pollution sensor
48487952|NCT00658931|DRUG|Drug treatment with Cymbalta|Drug treatment with Cymbalta
48487953|NCT00787579|DEVICE|Bifocal spectacles|+1.50D bifocal spectacles
48487954|NCT00787579|DEVICE|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
48487955|NCT04037930|BEHAVIORAL|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
48487956|NCT02527018|DEVICE|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
48487957|NCT02495181|DRUG|Intravitreal Aflibercept|
48487958|NCT03907800|DRUG|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
48487959|NCT03907800|DRUG|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
48487960|NCT03907800|DRUG|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
47970000|NCT02684916|PROCEDURE|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
47970001|NCT01206660|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
47970002|NCT01206660|DRUG|placebo|Placebo administered to affected area twice a day for 28 days
48323215|NCT04922697|OTHER|Questionnaire Administration|Complete questionnaires
48323216|NCT04331990|OTHER|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
47970003|NCT04890769|DEVICE|Moisture sensor wound dressing|Clinical procedure for change of wound dressing
47970004|NCT02004210|PROCEDURE|transarterial radioembolization (TARE)|transarterial radioembolization
47970005|NCT02004210|PROCEDURE|transarterial chemoembolization (TACE)|transarterial chemoembolization
47970006|NCT01619982|DRUG|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is \> 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is \> 8 hours in duration.
47970007|NCT01619982|DRUG|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
47970008|NCT04997161|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
47970009|NCT04997161|OTHER|Enhanced dietary advice|Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
47970010|NCT04997161|OTHER|Standard dietary advice including K+ restriction.|Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
47970011|NCT05475795|OTHER|Metapex|obturation of root canals of primary molars with Metapex
47970012|NCT05475795|OTHER|Endoflas|obturation of root canals of primary molars with Endoflas
47970013|NCT02785432|DEVICE|Sham low level laser|Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
47970014|NCT02785432|DEVICE|Active low level laser|Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
47970015|NCT06238050|PROCEDURE|introduction of oxygen therapy or not|During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
48323217|NCT04331990|OTHER|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
48487961|NCT02907541|OTHER|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
48487962|NCT02907541|OTHER|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
48487963|NCT02907541|OTHER|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
48487964|NCT04435106|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
48487965|NCT04435106|DRUG|Standard of Care|Study participants received Standard of Care
48487966|NCT03946020|PROCEDURE|Guided bone regeneration with or without autologous bone|Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
48487967|NCT04471402|DRUG|Precedex|Intranasal Precedex 3mcg/kg
47970016|NCT03648541|DRUG|Spesolimab|Solution
47970017|NCT01088997|DRUG|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
48118413|NCT04745663|DRUG|Povidone-Iodine 5%|Standard concentration iodine
48118414|NCT02961010|BEHAVIORAL|Keeping Safe|A whole school Preventative Education programme
48118415|NCT03074331|DRUG|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
48118416|NCT06006052|COMBINATION_PRODUCT|regeneration technique|clinical procedure of regenerative endodontic as AAE mentioned using different material in each group
48118417|NCT03407131|PROCEDURE|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
48118418|NCT03407131|PROCEDURE|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
48118419|NCT00357097|DRUG|Ropinirole|
48118420|NCT02962791|PROCEDURE|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
48323218|NCT04331990|OTHER|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
48323219|NCT04096326|DRUG|AGN-151586|AGN-151586 solution for injection.
48323220|NCT04096326|DRUG|Placebo|Placebo solution for injection.
48323221|NCT00884052|DRUG|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
48323222|NCT00884052|DRUG|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
48323223|NCT06156514|DRUG|Gemcitabine|Weekly application of gemcitanibe at 300 mg/m2 intravenously in a 30-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
48118421|NCT02962791|DEVICE|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
48118422|NCT02962791|DEVICE|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
48118423|NCT02962791|DEVICE|Echocardiography|Standard Echocardiography will de bone for patient
48118424|NCT01760109|DRUG|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
48118425|NCT02108210|DRUG|Anakinra|
48118426|NCT02108210|DRUG|Placebo|
48118427|NCT03882554|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
48487968|NCT02006368|OTHER|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
48118428|NCT02633267|BEHAVIORAL|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
48118429|NCT02633267|BEHAVIORAL|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
48118430|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
48323224|NCT06156514|DRUG|Cisplatin|Weekly application of Cisplatin at 40 mg/m2 intravenously in a 60-minute infusion, concomitantly with radiotherapy for a total of 5-6 weeks followed by bachytherapy, in patients diagnosed with locally advanced cervical cancer
48323225|NCT01703611|OTHER|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
48323226|NCT01703611|OTHER|Usual Nutrition Care|Usual nutrition care in India
48323227|NCT00169117|BEHAVIORAL|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
48323228|NCT01587573|OTHER|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
48323229|NCT06269289|OTHER|web based education|Training presentations will be prepared in 5 modules by taking expert opinions in line with the literature. Training will be aimed at empowering patients to control asthma. It will include topics such as medication use, device use, exercise and disease management. Each week, an intervention group will be invited online to a module and the training will be given by the researcher.
48323230|NCT06269289|OTHER|Standard education brochure|The control group will not be given web-based training, but will be given the standard asthma education brochure of the Ministry of Health.
48323231|NCT02702518|DRUG|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
48323232|NCT02702518|DRUG|Vehicle|Drug vehicle 4 times a day for 8 weeks
48323233|NCT02387619|DRUG|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
48323234|NCT02387619|DRUG|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
48323235|NCT02387619|DRUG|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
48323236|NCT03674203|BIOLOGICAL|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
48323237|NCT02765178|OTHER|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
48323238|NCT02765178|OTHER|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
48323239|NCT02765178|OTHER|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
48323240|NCT02765178|OTHER|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
48487969|NCT03138447|DEVICE|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
48487970|NCT03236142|PROCEDURE|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
48487971|NCT03236142|PROCEDURE|Standard Duodenal Switch Operation|
48487972|NCT00648024|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
48487973|NCT00648024|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fasting
48487974|NCT03763760|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
48487975|NCT04197128|DEVICE|Resorbable Collagen membrane with bone graft for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)"
48498022|NCT00525447|DRUG|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
48498023|NCT00525447|DRUG|lenalidomide|Up to 25 mg daily of a 21-day cycle.
48323241|NCT02765178|OTHER|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
48323242|NCT02027168|OTHER|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
48323243|NCT03296787|DRUG|TAK-954|TAK-954 intravenous infusion.
48323244|NCT00257023|DRUG|paliperidone|
48323245|NCT03754803|OTHER|HIV Symptom Distress Module Questionnaire|The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
48323246|NCT03754803|OTHER|HIV treatment satisfaction questionnaire|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
48323247|NCT04436029|BIOLOGICAL|Descartes 11|Car T-cells
48323248|NCT04248790|BEHAVIORAL|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
48498024|NCT00525447|DRUG|dexamethasone|40 mg administered weekly.
48323249|NCT05275621|DEVICE|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
47970018|NCT05170841|DRUG|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 MG|Administered as one single tablet to be taken every 8 hours
48323250|NCT05275621|PROCEDURE|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
48323251|NCT00078988|BIOLOGICAL|filgrastim|Given IV
48323252|NCT00078988|DRUG|carboplatin|Given IV
48323253|NCT00078988|DRUG|etoposide|Given IV
48323254|NCT00078988|DRUG|isotretinoin|Given IV
48323255|NCT00078988|DRUG|thiotepa|Given IV
48323256|NCT00078988|PROCEDURE|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
48323257|NCT00078988|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
48323258|NCT00186654|PROCEDURE|Acupuncture|
47970019|NCT05170841|DRUG|Tramadol Hydrochloride 100 MG|Administered as two capsules with 50 mg each to be taken every 8 hours
47970020|NCT05170841|DRUG|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 MG or two capsules if matching Tramadol Hydrochloride 100 MG
47970021|NCT04943497|OTHER|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
48323259|NCT00186654|PROCEDURE|Perinatal massage|
48323260|NCT02101840|DRUG|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
48323261|NCT02101840|DRUG|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
47970022|NCT04943497|OTHER|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
47970023|NCT04943497|OTHER|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
47970024|NCT04943497|OTHER|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
47970025|NCT03293589|PROCEDURE|open revascularization|surgical revascularization (i.e. Bypass surgery)
47970026|NCT03293589|PROCEDURE|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
47970027|NCT04511169|BEHAVIORAL|digital self-help|The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
47970028|NCT00521014|BIOLOGICAL|filgrastim|
48323262|NCT02101840|DRUG|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
48323263|NCT01978158|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
48323264|NCT03036449|BEHAVIORAL|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation.....~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists..."
48323265|NCT02977013|DIAGNOSTIC_TEST|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
48323266|NCT05913479|DEVICE|Mucogyne Gel|At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
48323267|NCT05207306|PROCEDURE|Type of interfascial plane block|"In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way."
48323268|NCT02716194|BIOLOGICAL|BAX 826|
48323269|NCT02716194|BIOLOGICAL|Octocog alfa|
48323270|NCT04529421|BEHAVIORAL|Online instruction|For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
48323271|NCT04529421|BEHAVIORAL|In-person instruction|For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
48323272|NCT02500602|DRUG|doxazosin|active medication
48323273|NCT02500602|DRUG|placebo|placebo pill
48323274|NCT03001583|BEHAVIORAL|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
47970029|NCT00521014|BIOLOGICAL|rituximab|
47970030|NCT00521014|BIOLOGICAL|sargramostim|
47970031|NCT00521014|DRUG|carmustine|
47970032|NCT00521014|DRUG|cytarabine|
47970033|NCT00521014|DRUG|etoposide|
48323275|NCT03001583|BEHAVIORAL|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
48323276|NCT02982538|BEHAVIORAL|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
48323277|NCT02982538|BEHAVIORAL|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
48323278|NCT04793854|OTHER|Measure of the Life habits (MHAVIE)|"Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,...)."
48323279|NCT00671580|DRUG|PZ-601|750 mg
48323280|NCT00671580|DRUG|PZ-601|1000 mg
48487976|NCT04197128|DEVICE|Ribose cross linked collagen matrix for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)."
48323281|NCT00671580|DRUG|Standard of Care|as directed
48487977|NCT03982563|BEHAVIORAL|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
48487978|NCT03982563|BEHAVIORAL|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
48487979|NCT03982563|BEHAVIORAL|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
48487980|NCT03982563|BEHAVIORAL|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
47970034|NCT00521014|DRUG|melphalan|
47970035|NCT00521014|PROCEDURE|autologous hematopoietic stem cell transplantation|
47970036|NCT02129998|OTHER|IVF/ICSI treatment|
47970037|NCT03689478|OTHER|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
48323282|NCT02974387|DRUG|Fluorometholone(FML)|
48323283|NCT02974387|DRUG|Loteprednol (Lotemax)|
48323284|NCT00001906|BIOLOGICAL|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
47970038|NCT02660502|DRUG|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
47970039|NCT02660502|DRUG|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
47970040|NCT02660502|DRUG|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
47970041|NCT02660502|DRUG|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
47970042|NCT03466008|BEHAVIORAL|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
48323285|NCT04381663|PROCEDURE|conservative treatment|conservative treatment for patients with cervical spine stenosis without myelopathy
48323286|NCT04381663|PROCEDURE|surgical treatment|surgical decompress the spinal canal in patients with moderate to severe degenerative cervical spine myelopathy
47970043|NCT06275698|DIETARY_SUPPLEMENT|Manuka honey MGO 1000|Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.
47970044|NCT06275698|DIETARY_SUPPLEMENT|Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
47970045|NCT00407797|DRUG|Pregabalin|150 to 600 mg/day during 21 weeks
47970046|NCT06446167|OTHER|Exercises|All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.
48323287|NCT05603507|OTHER|inspiratory muscle training|training done with a pressure threshold-loading device
48323288|NCT05603507|OTHER|pulmonary rehabilitation|Circuit training of aerobic and resistive exercise
48323289|NCT04238884|DRUG|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
48323290|NCT04238884|DRUG|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
48323291|NCT01236742|DEVICE|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
48323292|NCT01236742|DEVICE|single-vision glasses|daily wear of spectacle glasses to correct vision
48323293|NCT00574496|DRUG|cyclophosphamide|
48323294|NCT00574496|DRUG|cyclosporine|
48323295|NCT00574496|DRUG|fludarabine phosphate|
48323296|NCT00574496|DRUG|gemcitabine hydrochloride|
48323297|NCT00574496|DRUG|ifosfamide|
48323298|NCT00574496|DRUG|mechlorethamine hydrochloride|
48323299|NCT00574496|DRUG|melphalan|
48487981|NCT02581878|DRUG|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
48323300|NCT00574496|DRUG|methotrexate|
48323301|NCT00574496|DRUG|mycophenolate mofetil|
48647619|NCT04674319|BEHAVIORAL|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
48487982|NCT02527499|BEHAVIORAL|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
48647620|NCT00772200|PROCEDURE|Cognitive Assessment|Complete COG Standard Neuropsychological and Behavioral Battery
48647621|NCT00772200|OTHER|Quality-of-Life Assessment|Ancillary studies
48487983|NCT02527499|BEHAVIORAL|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
48487984|NCT02527499|BEHAVIORAL|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
47970047|NCT06446167|OTHER|MLS Laser Treatment|The MLS Laser applied to the treatment group was administered using an ASA brand Mphi model device. Patients in the Laser group were positioned in a prone position. Treatment was applied continuously for 7 minutes along the plantar fascia, sole of the foot, heel area, and Achilles tendon in accordance with the plantar fasciitis treatment program on the device, at a dose of 1.73 J/cm2 and a frequency of 700 Hz. A treatment program was established with 3 sessions per week, totaling 10 sessions
48323302|NCT00574496|DRUG|prednisone|
48323303|NCT00574496|DRUG|procarbazine hydrochloride|
48323304|NCT00574496|DRUG|vincristine sulfate|
48323305|NCT00574496|DRUG|vinorelbine tartrate|
48323306|NCT00574496|PROCEDURE|allogeneic bone marrow transplantation|
48323307|NCT00574496|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48323308|NCT00574496|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
48323309|NCT00574496|PROCEDURE|peripheral blood stem cell transplantation|
48118431|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
48323310|NCT00574496|PROCEDURE|umbilical cord blood transplantation|
48323311|NCT00574496|RADIATION|total-body irradiation|
48323312|NCT03849976|BEHAVIORAL|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
48323313|NCT00781599|DRUG|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
48323314|NCT00781599|BEHAVIORAL|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
48323315|NCT00781599|BEHAVIORAL|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
48323316|NCT04994652|DEVICE|Videolaryngoscopy|Indirect laryngoscopy using the C-MAC videolaryngoscope
48323317|NCT04994652|DEVICE|Direct laryngoscopy|Direct laryngoscopy with a standard laryngoscope
48323318|NCT03170557|OTHER|Traditional chinese acupuncture|Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
48323319|NCT03170557|OTHER|Aspecific needle skin stimulation|Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
48323320|NCT01766570|OTHER|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
47970048|NCT06446167|OTHER|ESWT treatment|The treatment group was administered with the Swiss DolorClast Master ESWT device, which produces radial shock waves. Patients in the ESWT group were positioned in a prone position. The most painful point in the heel area was identified through palpation. Gel was applied to this area, followed by the surrounding soft tissues, towards the plantar fascia and the attachment area of the Achilles tendon at the dorsal aspect of the heel. Radial ESWT treatment was applied at a frequency of 10 Hz, pressure of 2.5 bars, and 2000 impulses per session, once a week for a total of 4 sessions
48647622|NCT03882372|DEVICE|Nasal high flow|See arm description.
48647623|NCT02333474|BIOLOGICAL|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
48647624|NCT02333474|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
48647625|NCT01378273|DRUG|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
48647626|NCT01378273|OTHER|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
48647627|NCT03907202|DRUG|Daily injection of KBP/placebo for up to 28 days|Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
48647628|NCT01687595|DRUG|HerpV and QS-21|HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
48647629|NCT01687595|DRUG|Placebo|phosphate buffered saline
48323321|NCT01766570|OTHER|Placebo|
48647630|NCT06124313|DIETARY_SUPPLEMENT|Vaginal Probiotic|"This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei"
48647631|NCT05314075|PROCEDURE|Upper Body Forced Air Warming device|Patients will have the Bair Hugger placed over the body
48323322|NCT00879606|DRUG|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
47970049|NCT02279537|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
48118432|NCT01390818|DRUG|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
48323323|NCT00879606|DRUG|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
48647632|NCT05314075|PROCEDURE|Under Body Forced Air Warming device|Patients will have the Bair Hugger placed under the body
48647633|NCT02799043|PROCEDURE|Standard PVI|Standard PVI procedure without FIRMap.
48647634|NCT02799043|PROCEDURE|FIRM-Guided Procedure and PVI|
47970050|NCT03308734|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
47970051|NCT05432232|DEVICE|HistoSonics Investigational System|The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
47970052|NCT05423145|BEHAVIORAL|self-administered acupressure|The acupressure intervention is self-administered. The intervention group receives an app that instructs them on how to perform a stimulating acupressure protocol, consisting of six acupoints with four of the acupoints performed on both the left and the right sides of the body for a total of ten points. Each of the ten acupoints is to be stimulated for 3 minutes per point for a total treatment time of 30 minutes daily for 6 weeks.
47970053|NCT06119945|DRUG|DWJ1568|One tablet of DWJ1568
48118433|NCT01390818|DRUG|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
47970054|NCT06119945|DRUG|DWC202215|One tablet of DWC202215
47970055|NCT00179114|DRUG|Botulinum Toxin Type A|
48647635|NCT03841474|DRUG|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
48647636|NCT03841474|DRUG|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
47970056|NCT00179114|DRUG|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
48118434|NCT01733095|DRUG|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
48647637|NCT02529488|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
47970057|NCT03118258|BEHAVIORAL|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
48118435|NCT00468702|DEVICE|CoaguChek S|
48118436|NCT00812877|DRUG|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
48118437|NCT00812877|DRUG|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
48118438|NCT03619616|DRUG|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
48118439|NCT03619616|DRUG|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
48118440|NCT03619616|DRUG|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
48118441|NCT03619616|DRUG|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
48118442|NCT03619616|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
48118443|NCT03619616|DRUG|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
48647638|NCT05235828|BEHAVIORAL|Sudarshan Kriya Yoga (SKY)|This is the experimental arm of the study, where participants will be trained in a form of breathing based meditation that incorporates different breathing techniques centred around controlling arousal and attention. Participants will be encouraged to learn all of the techniques that are covered during these sessions and also utilize the techniques that are most appropriate for their personal needs. After some initial training sessions, participants will be encouraged to practice their new SKY techniques in environments and situations that they have been avoiding. They would begin with situations that are less triggering, and progress to more difficult situations. At each group session, participants will describe their experiences and discuss ways to continue to incorporate the SKY techniques into their daily lives, until it reaches a point of being natural to use these skills throughout the day, both in practice, and in application.
48647639|NCT00661154|DRUG|Bevacizumab|2-12microCi IV injection
48647640|NCT03424980|COMBINATION_PRODUCT|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
48647641|NCT04523519|BEHAVIORAL|Video directly observed therapy with contingency management|PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
47970058|NCT03118258|BEHAVIORAL|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
47970059|NCT03771677|DRUG|Nucleotide Analog|such as Entecavir,entecavir 0.5mg per day
47970060|NCT03771677|DRUG|Interferon Alfa-2A|Peginterferon alfa-2a 180ug per week
47970061|NCT03558178|PROCEDURE|Doin with acupuncture|Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
47970062|NCT03558178|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
47970063|NCT04032860|DRUG|Tenofovir Disoproxil|patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
48118444|NCT03619616|DRUG|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
48118445|NCT06327685|DRUG|Avapritinib|Avapritinib is an oral tyrosine kinase inhibitor.
48118446|NCT06327685|DRUG|Decitabine|Decitabine is a nucleoside metabolic inhibitor given intravenously.
48118447|NCT06327685|COMBINATION_PRODUCT|Decitabine/Cedazuridine|Decitabine/Cedazuridine is a combination medicine given orally.
48118448|NCT05663151|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
48118449|NCT03357289|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
48647642|NCT04523519|BEHAVIORAL|Integrated Next-Step Counseling|Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
48647643|NCT04192838|PROCEDURE|Laparoscopic incisional ventral hernia repair|Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.
48647644|NCT04192838|PROCEDURE|Open incisional ventral hernia repair|Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
47970064|NCT04032860|DRUG|Entecavir|patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
47970065|NCT03732157|PROCEDURE|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
47970066|NCT03732157|PROCEDURE|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
47970067|NCT03645369|DEVICE|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
47970068|NCT03645369|DEVICE|Ice pack|Ice pack containing gel
47970069|NCT00000208|DRUG|Buprenorphine|
47970070|NCT00637338|BIOLOGICAL|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
48647645|NCT06239753|BEHAVIORAL|Dynamic Neuromuscular Stabilization|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).
48647646|NCT06239753|BEHAVIORAL|Standard Prenatal Education Program Implementation|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
47970071|NCT00637338|BIOLOGICAL|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
47970072|NCT03539081|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
47970073|NCT03539081|OTHER|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
47970074|NCT03539081|OTHER|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
47970075|NCT03539081|OTHER|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
47970076|NCT03539081|OTHER|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
47970077|NCT03539081|OTHER|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
47970078|NCT03539081|OTHER|Anthropometric Measurements|Height and weight will be obtained.
47970079|NCT03539081|BEHAVIORAL|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
47970080|NCT03539081|BEHAVIORAL|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
47970081|NCT02947503|DRUG|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
47970082|NCT03706456|BIOLOGICAL|Darvadstrocel|Darvadstrocel cell suspension for intralesional injection.
47970083|NCT03824613|DIAGNOSTIC_TEST|Urinary miRNA|MiRNA detection in urine
47970084|NCT04206501|DEVICE|Medtronic ICD with Opti Vol-Monitor|Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
47970085|NCT04433221|BIOLOGICAL|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection
47970086|NCT02936830|DRUG|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
47970087|NCT02936830|DRUG|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
47970088|NCT02936830|DRUG|Glycerol|Glycerol with water in a 1: 1 ratio
47970089|NCT00041483|DRUG|Anecortave Acetate 15 mg sterile suspension|
47970090|NCT00041483|OTHER|Photodynamic Therapy (PDT)|
47970091|NCT02649465|DRUG|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
47970092|NCT02649465|DRUG|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
47970093|NCT01561170|DEVICE|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
48118450|NCT03423277|DEVICE|Easy Stretch Toolkit|Study the use of novel intraoral tools for management of facial burns and other facial disorders
48487985|NCT04078438|DEVICE|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
47970094|NCT01561170|DEVICE|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
47970095|NCT01397084|DRUG|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
47970096|NCT01488929|DRUG|TC-5619|
47970097|NCT01488929|DRUG|Placebo|
48487986|NCT04078438|DRUG|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
48118451|NCT00073684|BEHAVIORAL|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
47970098|NCT05200091|OTHER|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~* Forward tilt of base of support;~* Backward tilt of base of support;~* Translation forward;~* Translation backward;~* Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
47970099|NCT00388778|DRUG|Doxycycline|
48647647|NCT04544605|OTHER|Individualized-Chinese herbal medicine|"I. Lung and spleen qi deficiency syndrome Clinical manifestations: shortness of breath, fatigue, fatigue, anorexia, nausea, fullness, weak stool, and uneasiness. The tongue is pale and greasy. Recommended prescription: French Pinellia 9g, Chenpi 10g, Codonopsis 15g, Sunburn Astragalus 30g, Stir-fried Atractylodes 10g, Poria 15g, Huoxiang 10g, Amomum villosum 6g (later), and Licorice 6g~II. Qi and Yin deficiency syndrome Clinical manifestations: fatigue, shortness of breath, dry mouth, thirst, palpitations, sweating, poor appetite, low or no lever, dry cough and little sputum; dry tongue, fine or weak pulses. Recommended prescription: North and south radix salviae 10g, 15g ophiopogonis, 6g American ginseng, 6g schisandra, 6g gypsum l5g, 10g light bamboo leaves, 10g mulberry leaves, 15g reed root, 15g salviae miltiorrhiza, 6g raw liquorice."
48647648|NCT01772251|DRUG|Oshadi Icp|
48647649|NCT06048497|DEVICE|Corrected carotid flow time measurement guided fluid preload|Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was \> 327 ms.
48647650|NCT02322931|PROCEDURE|Intra-operative C-arm CT imaging|"1. Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~2. Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~3. One Cine loop C-arm scan in the sagittal plane while retracting the probe.~4. One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
48647651|NCT05757726|DEVICE|Velocity pAVF system|A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
47970100|NCT01377532|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions. A radiation safety officer will instruct the patient, family, and caretakers about specific UCSF radiation safety guidelines for both hospitalization and discharge.
48323324|NCT02880397|DRUG|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
48323325|NCT02880397|DRUG|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
48323326|NCT01226212|DIETARY_SUPPLEMENT|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
48323327|NCT01226212|DIETARY_SUPPLEMENT|Placebo|maltodextrose
48323328|NCT02294318|BEHAVIORAL|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
48323329|NCT02294318|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
48323330|NCT03285763|DRUG|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
48647652|NCT01893099|DRUG|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
48647653|NCT01893099|DEVICE|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
48647654|NCT00707369|DRUG|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
48647655|NCT00707369|DRUG|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
48647656|NCT05995561|OTHER|no intervention is planned.|no intervention is planned.
48647657|NCT03111108|DRUG|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
48647658|NCT03307590|DRUG|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
48647659|NCT03307590|DRUG|Bupivacaine|Caudal block by bupivavaine alone
48323331|NCT01224587|DRUG|D1000078|Oral, one single dose
48647660|NCT05420337|PROCEDURE|Group ıntramuscular|Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
48647661|NCT05420337|PROCEDURE|Group TAP|Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
48647662|NCT02051387|DRUG|Cannabidiol CR|
48647663|NCT02051387|DRUG|Cannabidiol|
48647664|NCT02051387|DRUG|Amisulpride|
48647665|NCT02051387|DRUG|Olanzapine|
48647666|NCT02051387|DRUG|Quetiapine|
48647667|NCT02051387|DRUG|Risperidone|
48647668|NCT02051387|DRUG|Placebo|
48647669|NCT01386645|OTHER|low glycemic index (LGI) diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab
48647670|NCT01386645|OTHER|high glycemic index (HGI) diet plus placebo (PLAC)|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
48647671|NCT01386645|DRUG|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
48647672|NCT01347086|DRUG|Matching placebo (low dose)|single dose of matching placebo
48647673|NCT01347086|DRUG|BI 207127 NA (medium dose)|Single does of BI 207127 NA
48647674|NCT01347086|DRUG|BI 207127 NA (low dose)|single dose of BI 207127 NA
47970101|NCT01974804|PROCEDURE|MRI|
48647675|NCT01347086|DRUG|Matching placebo (medium dose)|Single dose of matching placebo
48647676|NCT01347086|DRUG|BI 207127 NA (high dose)|Single dose of BI 207127 NA
48647677|NCT01347086|DRUG|Matching placebo (high dose)|Single dose of matching placebo
48647678|NCT04172688|DIETARY_SUPPLEMENT|Prebiotic oligofructose-enriched inulin|Synergy1
48647679|NCT04172688|DIETARY_SUPPLEMENT|Placebo maltodextrin|Equicaloric dose of maltodextrin
48647680|NCT00980629|DRUG|M516102|Twice a day
47970102|NCT06410612|DRUG|regional anesthesia and PAI|this is the block portion of the study
47970103|NCT06410612|DRUG|PAI|this is the no block portion of the study
47970104|NCT02228460|DRUG|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
48323332|NCT01224587|DRUG|D1000082|Oral, one single dose
48323333|NCT01224587|DRUG|D1000083|Oral, one single dose
48323334|NCT01224587|DRUG|D1000085|Oral, one single dose
48323335|NCT06518200|BEHAVIORAL|Individualised health recommentations|Individualised recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application based on patients reported status.
48647681|NCT00980629|DRUG|placebo|Twice a day
48647682|NCT02553473|DRUG|Doxycycline|
48647683|NCT02553473|DRUG|Placebo|
48647684|NCT01897896|DRUG|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
48647685|NCT05196061|OTHER|Questionnaire|"Subjects will be asked to complete a questionnaire. The questionnaire will garner demographic data, medical history, medication and supplement history, gut-specific, skin-specific questions; etc. The complete questionnaire is provided with this submission for review. Demographic data includes:~1. Age~2. Sex~3. Race~4. Ethnicity"
48647686|NCT05196061|OTHER|Stool sample|Stool samples will be collected using a specific kit consisting of a ready-to-use package, including a user guide. When stool samples are collected, they will be immediately placed in previously prepared Fast prep tubes (MP, Cat# 5076-200-34340) containing 500 μL glass beads (Sigma-Aldrich G8772-100g) and 1 mL ASL™ lysis buffer (Qiagen DNA Extraction Kit) and transported to the laboratory where assays will be conducted. Samples will be kept in a - 20 degree Celsius freezer until they are analyzed.
48647687|NCT05196061|OTHER|Skin swab|Skin swabbing is a safe, non-invasive method to sample microbiota on human skin. Areas to be swabbed: Right upper back, Non-dominant ventral forearm or Most representative lesion
48647688|NCT05196061|OTHER|Oral rinse|Briefly, 20-25 ml saline will be provided in separately labelled blue capped 50-mL Falcon™ centrifuge tubes (Fisher Scientifics Co.). Each subject will be asked to swish and gargled the saline from the tube into their mouth for 2 minutes and expectorate the rinse into the tube. The tubes will be closed tightly and stored in -80 C until sequencing can be completed. Prior to use, all the tubes with oral wash samples will be completely thawed on ice, then centrifuged at 4000 rpm for 15 minutes and 20-25 ml supernatant transferred into fresh 50-mL centrifuge tubes. The pellet left in each tube will be used to extract DNA for microbiome studies
48647689|NCT04423211|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
48647690|NCT04423211|DRUG|Apalutamide|Given PO
48647691|NCT04423211|PROCEDURE|Computed Tomography|Undergo PET/CT
48487987|NCT04078438|OTHER|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
48487988|NCT00607152|DRUG|Rasburicase|0.20mg/kg per day IV
48487989|NCT00607152|DRUG|Allopurinol|100mg tablets
48487990|NCT00073021|DRUG|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
48487991|NCT00073021|DRUG|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
48487992|NCT05513586|DRUG|TAK-771|Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
48487993|NCT01725919|BEHAVIORAL|CI therapy|constraint induced movement therapy
48487994|NCT04790123|PROCEDURE|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
48487995|NCT04790123|PROCEDURE|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
48487996|NCT06358287|PROCEDURE|cryogenic auriculotherapy|Compressed nitrogen is used to create a 'cryonic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point.
47970105|NCT04762784|DRUG|Tocilizumab|Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
48323336|NCT06518200|BEHAVIORAL|General health recommendations|Recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application.
48323337|NCT06518200|BEHAVIORAL|Individualised physical exercise program|Follow-up of an individualised exercise program adjusted by daily monitoring of the level of physical, physiological and psychological condition.
48323338|NCT01248494|DRUG|BEZ235|"* Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID"
48323339|NCT01248494|DRUG|BKM 120|"* Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily"
48323340|NCT01248494|DRUG|Letrozole|All levels: 2.5mg/day PO
48323341|NCT01248494|DRUG|BKM120|"* Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~* Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~* Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
48323342|NCT04972734|BIOLOGICAL|premature newborns developing a NEC|weekly Blood sample and daily Stools sample during 12 weeks + Blood and stool sample during NEC
48323343|NCT04972734|BIOLOGICAL|premature newborns without NEC|weekly Blood sample and daily Stools sample during 12 weeks
48323344|NCT02227108|DRUG|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
48323345|NCT04448093|PROCEDURE|dental treatment|Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
48323346|NCT04910074|DEVICE|Low-level laser therapy|The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
48323347|NCT04910074|DEVICE|Dummy LLLT|The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
48487997|NCT06288022|OTHER|total tubeless mini-PCNL|When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
48487998|NCT06288022|OTHER|tubeless mini-PCNL|When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
48487999|NCT04298645|OTHER|Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.|Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
48488000|NCT05518630|BEHAVIORAL|Nomothetic Versus Idiographic Assessment in Chronic Pain|Participants with either endometriosis, vulvodynia, and/or fibromyalgia will answer a twice-daily diary for 42 days and a short weekly diary six times in total. In addition, they will answer two longer surveys at the start and at the end of the 42 days. These questionnaires ask about psychological flexibility, depression, catastrophizing, and pain interference. The data collected is only observational and does not include any intervention.
48647692|NCT04423211|DRUG|Degarelix|Given SC
48647693|NCT04423211|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48647694|NCT04423211|OTHER|Fluciclovine F18|Given IV
47970106|NCT04762784|DRUG|Glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
47970107|NCT05608798|DEVICE|ODI-Tech medical device|"The device captures and stores frames of the movement of blood in capillaries and spectra containing information on oxygen saturation. Proprietary software is used to analyse the obtained frames and spectra to calculate microvascular parameters such as functional capillary density and microvascular oxygen saturation.~ODI-Tech can be brought to the patient's bedside and operates non-invasively. The device parts are in contact with the patient for less than 5 minutes."
47970108|NCT05701527|DRUG|EBC-129|EBC-129 will be administered on Day 1 of each 21-Day cycle via a 30-120-minute intravenous (IV) fusion.
47970109|NCT05701527|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
48647695|NCT04423211|DRUG|Goserelin Acetate|Given SC
48647696|NCT04423211|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
48323348|NCT04488224|DEVICE|Nano-X Patient Rotation System|"The Nano-X prototype is a horizontal patient rotation system that immobilises participants while being rotated on the horizontal axis.~This device will be used to rotate patients horizontally while cone-beam Computed Tomography (CBCT) projections are acquired."
48323349|NCT04488224|RADIATION|Conventional CBCT scan|A conventional cone-beam Computed Tomography (CBCT) scan is acquired on standard radiotherapy machinery.
48323350|NCT04488224|OTHER|Psychometrically validated questionnaires|The Claustrophobia Questionnaire (CLQ), Short Form State/Trait Anxiety inventory (STAI) and Fast Motion Sickness (FMS) questionnaires administered. CLQ only once before the first session, STAI and FMS both before and after each Nano-X CBCT session.
48323351|NCT03334396|DRUG|Baricitinib|Administered orally.
48323352|NCT03334396|DRUG|Placebo|Administered orally.
48323353|NCT03664232|DRUG|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
48323354|NCT03664232|DRUG|Placebo|Participants will receive a matching placebo orally twice daily for 12 weeks.
48323355|NCT04377490|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
48323356|NCT04377490|BIOLOGICAL|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
48323357|NCT04762407|DRUG|HGP1910|Take it once per period.
48323358|NCT04762407|DRUG|HGP1909|Take it once per period.
48323359|NCT04762407|DRUG|HCP1903|Take it once per period.
48323360|NCT00618449|DRUG|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
48323361|NCT00618449|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
48323362|NCT05805670|OTHER|Yoga and Mindfulness|"Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery"
48323363|NCT01937052|OTHER|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
48323364|NCT01937052|BEHAVIORAL|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
48323365|NCT01650818|OTHER|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
48323366|NCT01650818|OTHER|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
48323367|NCT01180114|BEHAVIORAL|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
48323368|NCT01180114|OTHER|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
48118452|NCT00073684|BEHAVIORAL|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
48323369|NCT04965376|PROCEDURE|Glenohumeral joint steroid injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
48323370|NCT04965376|PROCEDURE|Suprascapular nerve block steroid injection|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
48323371|NCT00425568|DRUG|AndroGel (Transdermal Testosterone Gel)|
48323372|NCT00073814|DRUG|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
48323373|NCT00073814|DRUG|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
48323374|NCT00073814|DRUG|Placebo|Placebo MDI QID
48323375|NCT02395497|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
48323376|NCT02395497|DRUG|Tacrolimus|
48323377|NCT02395497|PROCEDURE|Penile Allotransplantation|
48323378|NCT00307424|DEVICE|AutoCPAP|
48323379|NCT00307424|DEVICE|FixCPAP|
48323380|NCT06209814|DEVICE|Conventional denture|Patients in this group received conventional maxillary and mandibular complete dentures. The patients used these dentures for 45 days. Then, the conventional maxillary denture was replaced by open faced denture with soft acryl resin wing.
48488001|NCT06053762|BEHAVIORAL|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
48647697|NCT04423211|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48118453|NCT00073684|BEHAVIORAL|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
48647698|NCT04423211|DRUG|Leuprolide Acetate|Given IM
48647699|NCT04423211|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
48118454|NCT00073684|BEHAVIORAL|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
48118455|NCT00073684|BEHAVIORAL|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
48323381|NCT06209814|DEVICE|Maxillary open-faced denture|Patients in this group received a maxillary open faced denture with soft acryl resin wing and a conventional mandibular complete denture. The patients used these dentures for 45 days. Afterward, the maxillary open-faced denture was replaced by one with a conventional construction.
48323382|NCT01330563|DRUG|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
48323383|NCT03839914|DRUG|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
48323384|NCT06410079|PROCEDURE|total hip replacement|Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene
48323385|NCT00599261|PROCEDURE|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
48323386|NCT06512948|PROCEDURE|High tibial osteotomy|Surgical treatment for patients with osteoarthritis and indications for high tibial osteotomy
48323387|NCT03852914|DEVICE|Sodium hyaluronate 2%|Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
47970110|NCT03564314|OTHER|SUPPORT AKI Clinical Decision Support|Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
47970111|NCT04302298|DEVICE|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
47970112|NCT04653545|DIAGNOSTIC_TEST|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
47970113|NCT02392143|OTHER|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test \[18\]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
48118456|NCT06354140|DRUG|Tegafur|Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
48323388|NCT01541527|BIOLOGICAL|blood test|One blood test entering in the usual follow-up of the patient
48488002|NCT06053762|BEHAVIORAL|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
48118457|NCT00239434|DRUG|tiotropium inhalation powder capsule|
48118458|NCT00239434|DRUG|ipratropium bromide Metered Dose Inhaler|
48118459|NCT00436072|DRUG|ZD6474|Orally on a daily basis
48118460|NCT00436072|DRUG|Cetuximab|Infusion once weekly
48488003|NCT03335579|COMBINATION_PRODUCT|inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil|Different combination of opioids and anesthetics
48118461|NCT00436072|DRUG|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
48118462|NCT00465816|BIOLOGICAL|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
48118463|NCT00465816|BIOLOGICAL|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
48323389|NCT02626741|DIETARY_SUPPLEMENT|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
48488004|NCT01207999|PROCEDURE|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
48488005|NCT01207999|OTHER|Data collection|Questionnaire completion
48488006|NCT04320979|RADIATION|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
48488007|NCT04320979|RADIATION|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
48488008|NCT03601546|OTHER|Clinical examination|Blood test and patient interview as for standard patient care
48647700|NCT04423211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
48323390|NCT02626741|BEHAVIORAL|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
48323391|NCT00928356|PROCEDURE|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
48323392|NCT00928356|PROCEDURE|Off Pump CABG|Standard of Care Off Pump CABG
48323393|NCT04147871|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
48488009|NCT03119974|DRUG|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
48118464|NCT01012453|BEHAVIORAL|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
48118465|NCT00738023|DRUG|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
48118466|NCT00738023|DRUG|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
48118467|NCT00738023|DRUG|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
48118468|NCT05682183|BEHAVIORAL|Multi-domain Psychoeducation Self-management Programme|The MPSP is a 5-weeks psychoeducation programme aimed at improving the biopsychosocial health of people with MDD (PMDD). It will be conducted on every Saturday in the morning, afternoon and evening. Specific time of each session will be further discussed with the centre. Each session will last for approximately 45 minutes to 60 minutes and will be capped at 10 participants. The mode of session will be face-to-face (F2F) session conducted at MindCare.
48118469|NCT05682183|OTHER|Treatment as usual|Care management from assigned care manager
48118470|NCT06328023|OTHER|SCOAT 6 to find association|we will use SCOAT 6 to find the association between concussion , sleep and physical performance
48118471|NCT00191412|DRUG|Pemetrexed|
48118472|NCT01063140|BIOLOGICAL|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
48118473|NCT01063140|BIOLOGICAL|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
48118474|NCT02769468|OTHER|The Back|
48118475|NCT02769468|OTHER|Chest|
48118476|NCT02769468|OTHER|Left Axilla|
48118477|NCT05325853|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
48323394|NCT04147871|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
48323395|NCT05529290|DRUG|Dexketoprofen Trometamol + Thiocolchicoside|Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
48488010|NCT04317599|OTHER|Non Interventional study|Non Interventional study
48118478|NCT05325853|DRUG|Proparacaine Ophthalmic|0.5% Proparacaine Hydrochloride
48118479|NCT03339258|DRUG|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
48118480|NCT03339258|DRUG|Placebo|Placebo, or inactive pill.
48118481|NCT03988023|BIOLOGICAL|Ampion|4 mL injection of Ampion
48118482|NCT03988023|DRUG|Saline|Saline solution, 4 mL, single intra-articular injection
48118483|NCT03956004|OTHER|OM1 Dell Shared Decision Making Tool|Decision aid meant to improve shared decision making among patients and providers.
48118484|NCT03956004|OTHER|Education material from OM1 Dell Shared Decision Making Tool|Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
48118485|NCT04491032|PROCEDURE|Caudal anesthesia|Caudal epidural injection will be performed after induction of general anesthesia.
48118486|NCT03926884|DIETARY_SUPPLEMENT|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
48118487|NCT03926884|DIETARY_SUPPLEMENT|Control|warm water with negligible amount of the three-seeds mixture
48118488|NCT01351493|DRUG|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
48118489|NCT01351493|DRUG|placebo|placebo Gel, once or twice per day, 12weeks
48118490|NCT06190522|DIAGNOSTIC_TEST|Emergency physician clinical ultrasound|Clinical ultrasound by emergency doctor consisting in obtaining frontal sections of the 2 kidneys and a transverse section of the bladder
48323396|NCT05529290|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
48323397|NCT05529290|DRUG|Dexketoprofen Trometamol (25mg)|Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
48323398|NCT05529290|DRUG|Paracetamol|Paracetamol (500 mg) is a mild analgesic and antipyretic. It was given to the patients to take only if needed as max. dose 2000mg.
48118491|NCT00483093|DRUG|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
47970114|NCT02392143|OTHER|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
48118492|NCT00483093|DRUG|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
48323399|NCT01884168|BIOLOGICAL|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
48323400|NCT04295200|OTHER|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
48118493|NCT04828642|DIETARY_SUPPLEMENT|Vitamin C and vitamin E|1000 mg 235 mg
48118494|NCT04828642|DIETARY_SUPPLEMENT|Placebo|Placebo
48323401|NCT04003337|OTHER|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
48323402|NCT00921882|PROCEDURE|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
48323403|NCT03579524|PROCEDURE|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
48488011|NCT05649735|DEVICE|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
48647701|NCT04423211|OTHER|Quality-of-Life Assessment|Ancillary studies
48647702|NCT04423211|OTHER|Questionnaire Administration|Ancillary studies
48647703|NCT04423211|DRUG|Relugolix|Given PO
48647704|NCT04423211|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48118495|NCT03276871|PROCEDURE|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
48118496|NCT03276871|DEVICE|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
48118497|NCT02617069|BIOLOGICAL|botulinum toxin injection|
48118498|NCT02617069|BIOLOGICAL|0.9% normal saline injection|
48118499|NCT02617069|DEVICE|Implantable loop recorder|
48118500|NCT00222326|BEHAVIORAL|Pelvic floor muscle training and lifestyle modification|
48323404|NCT03579524|PROCEDURE|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
48647705|NCT04423211|DRUG|Triptorelin|Given IM
48647706|NCT04423211|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
48647707|NCT02826681|DRUG|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
48118501|NCT00751075|DRUG|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
48118502|NCT00751075|DRUG|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
48118503|NCT00751075|DRUG|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
48118504|NCT00751075|DRUG|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
48118505|NCT01408849|DRUG|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
48118506|NCT01408849|DRUG|Omeprazole|Standard therapy
48118507|NCT02301442|BEHAVIORAL|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
48118508|NCT02301442|BEHAVIORAL|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic \& strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers \& exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
48118509|NCT01686906|PROCEDURE|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
48323405|NCT02263495|DRUG|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
48323406|NCT02263495|DRUG|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
48323407|NCT02263495|DRUG|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
48323408|NCT01656317|OTHER|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
48323409|NCT05835245|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
48323410|NCT05835245|DRUG|Sintilimab|a PD-1 immune check inhibitor
47970115|NCT02392143|OTHER|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
47970116|NCT01294267|DEVICE|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
47970117|NCT01587001|DIETARY_SUPPLEMENT|N-acetyl-cysteine|900mg three times daily for 8 weeks
48323411|NCT05835245|DRUG|Lenvatinib|Lenvatinib capsules
48323412|NCT02383680|BIOLOGICAL|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
48323413|NCT02786940|DEVICE|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
48323414|NCT04066530|DRUG|AD-203|AD-203 administered two times daily for two weeks
48323415|NCT04066530|DRUG|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
48323416|NCT04101760|DRUG|Long-acting granulocyte colony stimulating factor|Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
48323417|NCT04101760|DRUG|Short-acting granulocyte colony stimulating factor|Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
48323418|NCT03730194|DIETARY_SUPPLEMENT|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
48647708|NCT02826681|DRUG|Placebo (Normal Saline)|Normal Saline Solution
48647709|NCT03160573|DRUG|ClōSYS® Unflavored Rinse|
48118510|NCT05957900|BEHAVIORAL|Multisensory stimulation module|"* Tactile Stimulation; Gentle stroking massage with moderate pressure, with warm palms for 3 min in a sequence of chest, upper limbs, and lower limbs in supine position.~* Visual Stimulation; Black and white visual stimulation card hung at 8-10 in. from the neonate for 3 min.~* Vestibular Stimulation; neonates placed in a hammock for 3 min.~* Kinesthetic stimulation: It consist of passive exercises (flexion and extension) of upper and lower limbs; one of the hands support the stimulated limb, whereas the other hand will perform the movements for 3 min. in supine position.~* Oral stimulation: the perioral structures will stroke by gently tapping the cheeks, lips and jaw by the index and middle finger for 2 min and stroking the intraoral structures by rubbing the gum and applying downward pressure of the tongue for 2 min. Non-nutritive sucking for 8 minutes.~* Olfactory Stimulation for 3 min. using mother's milk.~* Auditory Stimulation listening to mother's heart beats for 3 min."
48488012|NCT05649735|DEVICE|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
48647710|NCT03160573|DRUG|ClōSYS® Flavored Rinse|
48647711|NCT03160573|OTHER|Placebo-Flavored Oral Rinse|Flavor-matched placebo rinse
48647712|NCT03160573|OTHER|Placebo-Unflavored Oral Rinse|Unflavored-matched placebo rinse
48647713|NCT01456403|OTHER|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
48647714|NCT02239042|PROCEDURE|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
48647715|NCT04031950|DEVICE|Novel wearable paediatric device|The patient will wear the novel wearable paediatric device at the same time as polysmnography
48647716|NCT06375564|DRUG|177Lu-AB-3PRGD2 radioligand therapy|Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
48118511|NCT00051272|DRUG|Extended-release Bupropion Hydrochloride|
48118512|NCT04107402|OTHER|Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay|Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
48118513|NCT02794480|DEVICE|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
48488013|NCT05649735|OTHER|Placebo|Sterile saline solution
47970118|NCT01587001|DRUG|Placebo|Matching placebo three times daily for 8 weeks.
47970119|NCT00415662|DEVICE|Pulsed Signal Therapy (PST)|
48118514|NCT02794480|DEVICE|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
48118515|NCT02794480|DEVICE|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
48647717|NCT02486770|BIOLOGICAL|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
48647718|NCT02486770|BIOLOGICAL|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
48647719|NCT02486770|BIOLOGICAL|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
48647720|NCT03907579|BEHAVIORAL|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
48118516|NCT05883475|OTHER|Disabilities of the Arm, Shoulder, and Hand Questionnaire|Upper limb function was assessed with the Turkish version of the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH). The questionnaire DASH is a self-report instrument with 30 items. The total score ranges from 0 to 100, with higher scores indicating a worse upper limb function.
48323419|NCT03730194|BEHAVIORAL|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
48118517|NCT05883475|OTHER|Arm Motor Ability Test|The test assesses hemiparetic upper extremity functional tasks.The increase in the scores of both subparameters of the scale, which is composed of the parameters of functional ability and quality of movement, indicates an improvement in the motor functions of the upper limbs.
48118518|NCT05883475|OTHER|Nine Hole Peg Test|Fine motor skills of the upper extremities were assessed.The patient was asked to insert the nine sticks in the box on the table into the holes in the other box as quickly as possible and then remove them immediately. As time increases, fine motor skills of the upper extremities decrease
48118519|NCT05883475|OTHER|Pittsburg Sleep Quality Index|"Sleep quality was assessed using the this test.This scale, which provides a quantitative measure of sleep quality, is a 19-item self-report scale. The total score greater than 5 indicates poor sleep quality."
48118520|NCT05883475|OTHER|Functional Independence Measure|This test assessed functional capacity in activities of daily living.The higher a person's score, the higher the level of independence.
48118521|NCT02367924|DRUG|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
48118522|NCT01821612|DRUG|oxaliplatin|IV
48323420|NCT05663736|DRUG|Gemigliptin|DPP-4 inhibitor
48323421|NCT05663736|DRUG|Glimepiride|Glimepiride
48647721|NCT02431520|PROCEDURE|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
48118523|NCT01821612|DRUG|irinotecan|IV
48118524|NCT01821612|DRUG|leucovorin|IV
48118525|NCT01821612|DRUG|5-fluorouracil|IV
48118526|NCT01821612|DRUG|capecitabine|PO
48323422|NCT05866393|BEHAVIORAL|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
48118527|NCT01821612|RADIATION|radiation|
48323423|NCT00274872|DRUG|fluorouracil|
48323424|NCT00274872|DRUG|leucovorin calcium|
48323425|NCT00274872|DRUG|oxaliplatin|
48323426|NCT04450056|OTHER|No intervention|No intervention
48118528|NCT01821612|PROCEDURE|surgery|
48118529|NCT01821612|DRUG|gemcitabine|IV
48118530|NCT04584099|DEVICE|Radiofrequency device treatment|TempSure firm
48118531|NCT04610671|DRUG|CG0070|CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with 5% DDM and normal saline.
48323427|NCT02130154|OTHER|18-FDG PET CT scan and 123I-MIBG SPECT scan|
48323428|NCT03266666|BEHAVIORAL|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
48323429|NCT03266666|OTHER|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
48323430|NCT00142012|BEHAVIORAL|Nutrition Intervention|
48323431|NCT01789853|BEHAVIORAL|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
48323432|NCT01789853|BEHAVIORAL|Conventional Physical Therapy|Regular physical therapy for 8 weeks
48118532|NCT04610671|DRUG|Nivolumab|Two neoadjuvant doses of nivolumab 480 mg Q4W (every 4 weeks) for 2 doses (week 2 and 6)
48323433|NCT01925638|DRUG|BAY86-9766|
48323434|NCT01925638|DRUG|Ketoconazole|
48323435|NCT04165941|BIOLOGICAL|DRI cell therapy|Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
48323436|NCT03128385|OTHER|Intensive CIT Model Program|"Day Camp Model:~1. The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
48323437|NCT03128385|OTHER|Distributed CIT Model Program|"Home-Based Model:~1. The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
48118533|NCT01495663|DRUG|I-131-CLR1404|"Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
48118534|NCT02496975|DRUG|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
48118535|NCT02496975|OTHER|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
48118536|NCT02738840|PROCEDURE|MRI scan|MRI scan
48488014|NCT04403217|OTHER|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
48488015|NCT02407171|DRUG|MK-3475|200 mg every 2 weeks by IV infusion
48488016|NCT02407171|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
48647722|NCT02431520|PROCEDURE|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
48647723|NCT06267014|BEHAVIORAL|Virtual Reality sessions|One session during 10-15 minutes per week for 6 weeks.
48647724|NCT00626665|DRUG|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
48323438|NCT04874467|PROCEDURE|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
48118537|NCT01465516|DRUG|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
48323439|NCT05476185|BEHAVIORAL|READY4Life Programming - classroom instruction|The intervention group receives 16 hours of classroom instruction.
48323440|NCT01064076|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
48323441|NCT00362791|BEHAVIORAL|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
48323442|NCT00362791|BEHAVIORAL|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
48323443|NCT00362791|BEHAVIORAL|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
48323444|NCT04413721|PROCEDURE|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
48323445|NCT01120379|DEVICE|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
48323446|NCT03273517|PROCEDURE|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
48323447|NCT05426629|DEVICE|Venus Glow|"The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore."
48488017|NCT04056975|BIOLOGICAL|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
48488018|NCT04656730|DRUG|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
48488019|NCT00287300|DRUG|Sulfadoxine-Pyrimethamine|
48488020|NCT00287300|DRUG|Azithromycin|
47970120|NCT05780658|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
47970121|NCT05778097|DRUG|Apalutamide 60mg Tab|Apalutamide 60Mg Tab (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
47970122|NCT05778097|DRUG|Androgen deprivation therapy(ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
47970123|NCT02863952|OTHER|Single photon emission computed tomography myocardial perfusion imaging|
47970124|NCT02863952|DEVICE|novel cadmium-zinc-telluride (CZT) SPECT cameras|
47970125|NCT02601469|DRUG|DSXS|twice daily for 28 days
47970126|NCT01010490|PROCEDURE|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
47970127|NCT01010490|PROCEDURE|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
47970128|NCT01010490|PROCEDURE|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
47970129|NCT05184218|DRUG|IGM-6268|Active Comparator
47970130|NCT05184218|DRUG|Placebo|Placebo Comparator
47970131|NCT03391180|DRUG|ICON Remineralization|A material used for the Remineralization of white spot lesions.
47970132|NCT03391180|DRUG|CPP-ACPF|Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
47970133|NCT02505867|DEVICE|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
47970134|NCT06066944|OTHER|Self-Thai Foot Massage|It is a specific technique and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Self-Thai foot massage is often based on traditional Thai massage techniques but adapted for self-application.
48323448|NCT02483104|DRUG|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
48323449|NCT02483104|DRUG|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
48323450|NCT02483104|DRUG|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
48488021|NCT00287300|DRUG|Artesunate|
48488022|NCT05343052|OTHER|Patient Reported Outcomes Surveys|"* Oslo Sports Trauma Research Center Hamstring Injury Screening Questionnaire (HaOS) at baseline~* Functional Assessment Scale for Acute Hamstring Injuries (FASH) within 7 days of injury and within 7 days of return to sport (RTS)"
48118538|NCT06335472|PROCEDURE|3 nerves pulsed radiofrequency with hydrodissection|"Patient will be in a sitting position, targeting the SSN, needle will be pushed towards floor of the suprascapular fossa, SSN is just adjacent to the suprascapular artery.~The axillary nerve, between the deltoid muscle posteriorly, triceps muscle caudally and humerus anteriorly, axillary nerve appears as hyperechoic round in relation to posterior circumflex humeral artery.~Lateral pectoral nerve, middle of coracoid process should be targeted, lie within hyperechoic fascial plane between pectoralis major and pectoralis minor muscle.~hydrodissection, US transducer will be positioned inferior to scapular line , landmarks are contours of glenoid rim and humeral head, needle will be advanced until enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by infusion of up to 40 mL of normal saline, until capsule is adequately distended and resistance felt"
48647725|NCT04650256|OTHER|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
47970135|NCT01802931|DRUG|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
47970136|NCT01802931|DRUG|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
48118539|NCT06335472|PROCEDURE|suprascapular nerve pulsed radiofrequency with hydrodissection|"The patient will be positioned in a sitting position, PRF needle will be pushed forward towards the floor of the suprascapular fossa the SSN will be visualized just adjacent to the suprascapular artery.~hydrodissection will be done under all aseptic measures ,the US transducer will be positioned just inferior to the scapular line , landmarks are contours of posterior glenoid rim and humeral head, needle will be advanced until the needle tip will enter the GHJ capsule.~A solution composed of 3 mL of lidocaine 1%, 3 mL of bupivacaine 0.25%, and 1 mL of dexamethasone 40 mg, followed by an infusion of up to 40 mL of normal saline , until the capsule is adequately distended and resistance will be felt."
48118540|NCT05640154|BEHAVIORAL|educational program|The nursing educational program will be implemented in small groups from (5-7) in outpatient clinics. It includes nutrition, exercise, control hypertension , engage in weight control measures, smoking cessation, stress management, breathing exercise, appropriate treatment of diseases, control of diabetes, control of cholesterol in blood and routine follow up).
48118541|NCT02468297|DEVICE|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
48118542|NCT02468297|DRUG|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
48118543|NCT00857649|DRUG|Memantine|20 mg Oral Tablets Once Daily
48118544|NCT00857649|DRUG|Placebo|Oral Tablets Once Daily
48118545|NCT02784132|OTHER|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
48118546|NCT06394271|DEVICE|EVAR|Catheter based insertion of aortic endograft via iliac or femoral arteries
48118547|NCT05561881|OTHER|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
48118548|NCT05561881|OTHER|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
48118549|NCT00012454|DRUG|E-Selectin nasal spray|
48118550|NCT04775654|DIETARY_SUPPLEMENT|Blackcurrant|Two capsules containing 455mg of CurrantCraft 11% black currant extract.
48118551|NCT04775654|OTHER|Placebo|Two capsules containing an inert material.
48118552|NCT04145492|DRUG|Vitamin K2|Patients will take 90 ug of vitamin K2
48118553|NCT04145492|DRUG|Cholecalciferol (inactive vitamin D)|Patients will take 10 ug of vitamin inactive vitamin D
48118554|NCT04145492|DRUG|Vitamin K2 and Cholecalciferol|Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
48488023|NCT05343052|OTHER|Clinical Assessments|"* Injury History at baseline, within 7 days of injury, within 7 days of RTS~* Pain and Function Assessments within 7 days of injury, within 7 days of RTS"
48488024|NCT05343052|OTHER|Biomechanical and Neuromuscular Assessments|"* Eccentric Strength measure at baseline and within 7 days of RTS~* Sprinting Biomechanics at baseline and within 7 days of RTS"
48488025|NCT05343052|DEVICE|Conventional MRI|at baseline, within 7 days of injury, and within 7 days of RTS
48488026|NCT05834530|OTHER|3D Printed Complete Dentures|Denture bases printed from a pre-polymerized block via additive technique, using photon S desktop 3D printer\* that relies on SLA technology and post cured by post curing unit.
48647726|NCT02787174|OTHER|Asthma Medication Adherence Education|
47970137|NCT05130320|OTHER|Not Interventional their treatments are their routine NHS care|Not Interventional their treatments are their routine NHS care
47970138|NCT02137174|OTHER|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
47970139|NCT03460860|DIETARY_SUPPLEMENT|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
47970140|NCT03460860|DIETARY_SUPPLEMENT|Placebo|The intervention is to be taken once daily, for 12 weeks.
48118555|NCT03522454|DIETARY_SUPPLEMENT|Protein-rich oral nutritional supplement|Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
48118556|NCT03522454|BEHAVIORAL|Home-based supervised exercise program|WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
48118557|NCT03560934|DRUG|Dronabinol|Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
48118558|NCT04294329|PROCEDURE|US-guided Quadratus lumborum block.|Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
48118559|NCT04294329|DRUG|Bupivacaine|Bupivacaine
48118560|NCT04294329|DRUG|Saline|normal saline
48118561|NCT03675581|DRUG|Microgynon|fixed sequence trial
48118562|NCT03675581|DRUG|Nintedanib|fixed sequence trial
48118563|NCT06079931|DRUG|Babaodan Capsule|The patient received 66-66Gy/30-33F radiation therapy. During radiation therapy, concurrent chemotherapy includes receiving 45mg/m2 paclitaxel and carboplatin (AUC 2) once a week; From the start of radiation therapy to 2 months after the completion of CCRT, the patient takes 2 capsules of Babaodan orally every day, tid (1.8 g/day), and systemic corticosteroids can be used for acute radiation pneumonia patients with G ≥ 2.
48647727|NCT04332770|OTHER|levothyroxine withdrawal|All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
48647728|NCT06521593|PROCEDURE|Applying a tourniquet for either a short or long time during total knee replacement|All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation while in group two who underwent short duration application of a tourniquet, the tourniquet was only applied just before cementation, was inflated also to 150 mmHg above the systolic blood pressure of the patients, and was deflated after bone cementation.
48647729|NCT00383565|DRUG|romidepsin|Given IV
48118564|NCT03427034|DEVICE|BladderLight®|Using a cell collection device to look for the presence of bladder cancer cells
48323451|NCT03701217|DRUG|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
48647730|NCT01554358|BEHAVIORAL|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~--------------------------------------------------------------------------------"
48647731|NCT01514422|DRUG|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
48647732|NCT05513573|DRUG|HLX07|1500 mg, D1，Q3W
48647733|NCT05513573|DRUG|HLX10|300 mg, D1, up to 2 years,Q3W
48118565|NCT06105333|PROCEDURE|standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline|CrSO2 (Cerebral regional oxygen saturation) monitoring was visible to the clinical team with the same SpO2 target as in the control group. If SpO2 (oxygen saturation) remained between the 10th and 90th centiles and within local limits, and crSO2 was \<10th centile according to published reference ranges, FiO2 (fraction of inspired oxygen) was increased by 10-20% every 60 seconds or respiratory support was started or increased. If crSO2 remained \>10th centile for \>60 seconds or if rSO2 was \>90th centile,FiO2 was reduced by 10-20% or respiratory support was adjusted accordingly. If there was a history of blood loss or clinical signs of blood loss, intravenous fluids (10 mL/kg) were considered.
48118566|NCT01493310|DRUG|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
48647734|NCT05513573|DRUG|placebo|1500 mg, D1，Q3W
48118567|NCT01493310|DRUG|placebo|Given orally
48118568|NCT01493310|DRUG|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
48118569|NCT05881317|DEVICE|ArtiAid® Plus Intra-articular Injection|Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks
48323452|NCT00304317|DRUG|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
48323453|NCT00304317|OTHER|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
48323454|NCT03615911|BIOLOGICAL|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
48488027|NCT06443788|DIAGNOSTIC_TEST|transperineal ultrasound|"The following measurement will be recorded:~1. Amniotic fluid pooling assessment will be performed in sagittal and transverse planes. ,~   * Images will be evaluated for appearance of accumulated hypoechogenic fluid around cervix. Whenever collection is spotted, three largest dimensions of fluid will be measured (length, width, depth).~  * Fluid accumulations around the cervix that are clearly demarcated from surrounding tissues will be considered positive.~2. Cervical length: it will be measured between the internal os point to the external os point below. Cervical dilatation will be measured in a transverse plane from inner to inner.~3. Presence of fetal part prolapse and/or cord prolapse"
48647735|NCT05513573|DRUG|chemotherapy|gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
48647736|NCT00057798|DRUG|gemcitabine hydrochloride|
48647737|NCT00057798|DRUG|vinorelbine ditartrate|
48647738|NCT00057798|GENETIC|cytogenetic analysis|
48647739|NCT00057798|GENETIC|loss of heterozygosity analysis|
48647740|NCT00057798|GENETIC|microarray analysis|
48647741|NCT00057798|PROCEDURE|conventional surgery|
48647742|NCT00057798|PROCEDURE|neoadjuvant therapy|
48647743|NCT02777190|DRUG|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
48118570|NCT04251013|DEVICE|Biliary brushing with the RX Cytology brush, Boston Scientific|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
48118571|NCT04251013|DEVICE|Biliary brushing with the Infinity® brush, US Endoscopy|"Biliary brushing during ERCP:~* Performing a dozen back and forth movements in the stenosis~* Bile aspiration if possible, by the catheter of the brush for cytological analysis~* The contents of the brush will be spread over 3 blades (numbered) then sectioned and placed in cytolit with the contents of the tubing of the brush flushed with a few cc of cytolit. Each brush in a numbered pot. Blades 1,2 and 3 +/- bile 1 joined to pot n ° 1; blades 4,5 and 6 +/- bile 2 joined to pot 2~  * In the event of technical failure (impossibility of accessing the stenosis with the first or second brush, impossibility of removing the brush), the patient will be considered to have failed for this brush (absence of pathological material brought back)"
48118572|NCT00096967|DRUG|Avastin (bevacizumab)|
48118573|NCT00010738|PROCEDURE|Meditation|
48118574|NCT00002018|DRUG|Interferon alfa-n3|
48118575|NCT05261997|PROCEDURE|extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct|In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.
48118576|NCT05261997|DRUG|pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)|Patients will receive drugs to control pancreatic insufficiency
48118577|NCT05744258|DEVICE|Bio-electrical impedance analysis|"Bio-electrical Impedance Analysis will be performed by trained personnel. BIA will be performed after fasting for at least 6 hours. Subjects should refrain from intensive physical activity the day be-fore the measurement. For women, measurements will be performed outside menstruating periods. Subjects will lay down on an examination couch with bare feet. Any jewelry will be removed.~Reactance and resistance will be obtained. Phase angle will be calculated according to the formula:~PhA (°) = (reactance/ resistance° x (180°/π). Body composition, including muscle mass and percentage body fat will be calculated."
48118578|NCT01240330|DEVICE|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
48118579|NCT02694835|DEVICE|Delefilcon A contact lenses with UV Absorber|
48647744|NCT02510742|DEVICE|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
48647745|NCT02510742|DEVICE|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
48647746|NCT03301415|DRUG|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
48118580|NCT02694835|DEVICE|Delefilcon A contact lenses|
48118581|NCT05303415|OTHER|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
48118582|NCT01954407|BEHAVIORAL|Smoking-Related Messages|
48118583|NCT05910918|BEHAVIORAL|Intensive Care Nurses' Training Package|For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
48647747|NCT05333588|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|The autologous TILs will be intravenous infused into patients.
48647748|NCT01647880|DRUG|Verum arm receiving Gilenya®|
48647749|NCT01647880|DRUG|Active Comparator receiving Extavia®|
48647750|NCT06571006|OTHER|music|"The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB"
48488028|NCT02327507|BEHAVIORAL|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
48488029|NCT03795831|DEVICE|ClearSight feasibility testing|A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
47970141|NCT03949504|PROCEDURE|New Find-risk questionnaire software|FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
47970142|NCT04985864|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
47970143|NCT04985864|DEVICE|Treadmill gait training|Lokomat robot training was applied to stroke patients.
47970144|NCT00787852|DRUG|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*"
47970145|NCT00787852|DRUG|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*"
47970146|NCT00923247|DRUG|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
47970147|NCT00923247|DRUG|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
47970148|NCT03387332|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
47970149|NCT04235985|COMBINATION_PRODUCT|Chlorhexidine Gluconate with HUBS|4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
47970150|NCT04010487|GENETIC|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
47970151|NCT04264091|OTHER|Observational|Observational
47970152|NCT00401453|BEHAVIORAL|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
47970153|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
47970154|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
47970155|NCT05830591|OTHER|Characterization of the microbiome in oral and fecal samples|The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
47970156|NCT01578460|DEVICE|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
47970157|NCT01578460|DEVICE|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
47970158|NCT01625702|DEVICE|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
47970159|NCT04211623|OTHER|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~* 10 degrees active wrist extension on the affected hand,~* 10 degrees active thumb abduction,~* 10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~* using fork or a spoon,~* combing hair~* brushing teeth~* writing~* dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
48118584|NCT02014129|DRUG|LY2835219|Administered orally
48118585|NCT00666068|OTHER|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
48118586|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
48118587|NCT00666068|OTHER|Placebo|injected at 2200, 2300, 0000, and 0100
48488030|NCT01173913|DRUG|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
48118588|NCT04838496|DRUG|FOLFOXIRI Protocol|"FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age."
48118589|NCT02568644|DIETARY_SUPPLEMENT|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols).
48118590|NCT02568644|OTHER|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
48118591|NCT02568644|DRUG|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
48647751|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)_Low Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -Low Dose :~   7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
47970160|NCT04211623|OTHER|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~* carrying a tray,~* cutting a fruit with a knife,~* holding and cutting the paper with scissor,~* buttoning and~* Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
47970161|NCT02879305|DRUG|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
48118592|NCT06379711|DEVICE|Transcutaneous Spinal Cord Stimulation (tSCS)|Transcutaneous spinal cord stimulation (tSCS) will be delivered via a non-invasive central nervous system stimulator TESCoN or SCONE (SpineX Inc., CA - experimental type II medical devices) through self-adhesive electrode(s) placed on the skin between spinous processes over the midline of the vertebral column as the cathode(s) and two rectangular electrodes placed symmetrically on the skin over the iliac crests as anodes. Stimulation will be applied at various waveforms and frequencies (ranging between 1Hz and 90Hz) with and without a carrier frequency. Current amplitude will start at 10mA and proceed incrementally until tolerable or responses plateau. If spasticity occurs or is uncomfortable, the current will be decreased. Specific areas for electrode placement will be examined and prepared to reduce skin impedance. tSCS will be delivered under the supervision of a physician (Dr. Krassioukov/Dr. Berger) by trained doctoral/post-doctoral trainees.
48118593|NCT04479865|DRUG|Aricept 5mg Tablet|1 tablet once daily
48118594|NCT04479865|DRUG|Aricept 10mg Tablet|1 tablet once daily
48118595|NCT04479865|DRUG|DA-5207 150mg|1 patch once weekly
48118596|NCT04479865|DRUG|DA-5207 170mg|1 patch once weekly
48118597|NCT04882072|DRUG|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
47970162|NCT02879305|DRUG|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
47970163|NCT02879305|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
47970164|NCT02879305|DRUG|Iron therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
48118598|NCT04882072|OTHER|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
48118599|NCT04882072|DRUG|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
47970165|NCT01812174|DEVICE|17mm aortic valve (On-X )|Heart aortic valve replacement surgery: 17mm Aortic
47970166|NCT01812174|DEVICE|23mm mitral valve (On-X)|Heart mitral valve replacement surgery: 23mm Mitral
47970167|NCT02810197|BEHAVIORAL|Psychopathological assessment|
47970168|NCT02810197|BEHAVIORAL|Neuropsychological assessment|
47970169|NCT02810197|DEVICE|Functional magnetic resonance imaging (fMRI)|
47970170|NCT04847947|DRUG|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
47970171|NCT04847947|DRUG|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
47970172|NCT04614740|DRUG|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
48118600|NCT00542789|DRUG|Esomeprazole|20mg once daily oral
48118601|NCT00542789|DRUG|Placebo|once daily oral
48118602|NCT03348917|DRUG|7.5% Povidone-Iodine [PVP-I]|Betadine® 7.5% skin cleanser (PVP-I 7.5%)
48118603|NCT03348917|DRUG|4% chlorhexidine skin cleanser|Unity antiseptic hand wash (no alcohol)
48118604|NCT03348917|DRUG|Plain non antibacterial soap|Guardian gel hand wash (not medicated),
48118605|NCT02976116|DRUG|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
48118606|NCT02976116|DRUG|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
48118607|NCT03260010|DRUG|Fosfomycin|Infectofos 5 g
48118608|NCT05099575|DRUG|Syntocinon, papal, misotac|Using different drugs to prevent atonic PPH during CD in high risk group
47970173|NCT03802669|OTHER|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
47970174|NCT00198939|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
47970175|NCT00198939|OTHER|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
47970176|NCT01184300|GENETIC|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
47970177|NCT05680597|OTHER|Balance Tele-Rehabilitation Agility Boot Camp (ABC)|The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
47970178|NCT06460220|BEHAVIORAL|Safe Alternatives for Teens and Youth - Parent (SAFETY-P)|The parent component of SAFETY focuses on enhancing parents' skills in supporting youth safety and managing parental distress during a suicidal crisis, ideal content to adapt for web-based delivery for parents. Specifically, parent information includes psychoeducation about suicide risk and protective factors, lethal means restriction, development of a parent distress tolerance plan (i.e., Parent Safety Plan), parent self-care and sources of support, strengthening the youth/parent relationship, and focus on care linkage for the youth. The SAFETY-P asynchronous parent intervention module will include text, interactive handouts, vignettes, and short video examples. The SAFETY-P module will allow for parents to access information and skills training on their own time, with the opportunity and encouragement to ask informed questions of their child's clinician; this will provide clinicians the opportunity to utilize their check-ins with parents more effectively to address youth safety.
47970179|NCT06460220|BEHAVIORAL|Treatment As Usual (TAU)|TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
47970180|NCT03042624|DIETARY_SUPPLEMENT|Fermented rice|7 g of powder obtained from Lactobacillus paracasei CBA L74
47970181|NCT03042624|DIETARY_SUPPLEMENT|Maltodextrins|7 g of maltodextrins powder
47970182|NCT04785976|PROCEDURE|Surgical clipping and endovascular coiling|Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
47970183|NCT05104229|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
47970184|NCT05104229|DRUG|Standard of Care|Standard of Care VTE prophylaxis
47970185|NCT04443270|DRUG|Chloroquine phosphate|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
47970186|NCT06312605|PROCEDURE|Injectable applied vitamin C|Surgical gingival depigmentation is done for all participants, after then they receive injectable vitamin C
47970187|NCT06312605|PROCEDURE|Topical applied Vitamin C|Surgical gingival depigmentation is done for all participants, after then they are instructed to apply topical vitamin C
47970188|NCT06312605|PROCEDURE|Surgical depigmentation only|Surgical gingival depigmentation only without any drug
47970189|NCT01419678|OTHER|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
47970190|NCT02115893|DIETARY_SUPPLEMENT|Sodium Nitrate|
47970191|NCT02115893|DIETARY_SUPPLEMENT|Sodium Chloride|
47970192|NCT05512572|DEVICE|IPL|intense pulsed light
48488031|NCT01173913|DRUG|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
48488032|NCT01173913|DRUG|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
48488033|NCT04099979|OTHER|No Intervention|There is no intervention for this study
48647752|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) High Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)_High Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -High Dose :~   1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
48647753|NCT03008980|OTHER|Diagnostic Test|
47970193|NCT05512572|PROCEDURE|Conservative treatment or excision with curettage|conservative treatment or excision with curettage but without IPL-MGX treatment as a control
47970194|NCT06379412|OTHER|observational study, no intervention|observational study, no intervention
48647754|NCT06549322|OTHER|The exercise in morning|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: AM 11:00-11:30"
48647755|NCT06549322|OTHER|The exercise in evening|"Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: PM 05:00-05:30"
48647756|NCT05299957|DIAGNOSTIC_TEST|PETMRI|PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
48647757|NCT01908387|DRUG|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
48647758|NCT04841798|OTHER|[11C]SL25.1188 PET radiotracer|Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using \[11C\]SL25.1188 PET
48647759|NCT04769778|DRUG|Valsartan 80Mg Oral Tablet|treatment with 80mg /day of valsartan
48647760|NCT06538350|OTHER|Telemedicine Consultation|Telemedicine intervention will be delivered via Zoom and Video WhatsApp platforms via a secure internet connection.
48647761|NCT06538350|OTHER|Face-to-Face Consultation|Face-to-Face consultation according to the standard of care.
48647762|NCT05600257|DEVICE|DBT|Image with digital breast tomosynthesis
48647763|NCT05600257|DEVICE|DM|Image with digital mammography
48118609|NCT01612169|BEHAVIORAL|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
48647764|NCT02658188|DRUG|ASP8825|Oral
48647765|NCT00005995|DRUG|shark cartilage extract AE-941|
48647766|NCT02124005|DRUG|Bupivacaine|
48647767|NCT03236805|DRUG|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
48647768|NCT03236805|DRUG|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
48647769|NCT04816903|DIAGNOSTIC_TEST|Gyni|Vaginal discharge collection
48647770|NCT05851365|DRUG|Hyperpolarized Bicarbonate (13C)|Given IV
48118610|NCT01612169|BEHAVIORAL|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
48488034|NCT06441461|OTHER|Primary informal caregiver at work.|Employees becoming a primary informal caregiver for a child or an adolescent with mental health problems in the period from 2000 to 2018.
48488035|NCT00657228|DRUG|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
48488036|NCT00657228|DRUG|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
48647771|NCT05851365|PROCEDURE|Magnetic Resonance imaging|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
48647772|NCT01266200|PROCEDURE|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
48647773|NCT01266200|PROCEDURE|XIA|Treatment of the fracture with Xia and conventional operation technique
48647774|NCT02772120|DRUG|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
48647775|NCT02772120|DRUG|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
48647776|NCT01235117|DRUG|azacitidine|
48647777|NCT01235117|OTHER|laboratory biomarker analysis|
48647778|NCT05732870|PROCEDURE|Relevant orthopaedic surgery|Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
48647779|NCT00935207|OTHER|Pediatric Pain Diary|Pain diary designed for pediatric patients
48647780|NCT01050218|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
48647781|NCT01903863|BIOLOGICAL|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
48118611|NCT03400254|DRUG|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
48118612|NCT03400254|DRUG|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC \>1.0 x 109/L and platelet count \> 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped."
48118613|NCT02994173|DRUG|Oxycodone|Current clinical practice, used as a control in this study
48118614|NCT02994173|DRUG|S-Ketamine 0.25|dosage
48118615|NCT02994173|DRUG|S-Ketamine 0.5|dosage
48647782|NCT04525469|BEHAVIORAL|Narrative Exposure Therapy|"NET involves: 1) diagnostic interview and psychoeducation, 2) laying out the Lifeline, 3) NET therapy sessions (constructing the trauma narrative in context of the life course), 4) final session rituals. Laying out the Lifeline (using rope or string) allows participants to take a bird's eye view of the events of their life using simple items such as flowers to represent positive events and stones to represent traumatic events. The focus of NET sessions is to encourage participants to describe the details of traumas and integrating the cold memories (i.e., facts) with the hot memories (e.g., cognitions, emotions, physiological feelings, and sensory information). The therapist makes notes after each session narrating the details of the traumas (stones) and reads this at the beginning of each subsequent session. Final session rituals involve re-reading the trauma narrative, hopes for the future, and laying out the final Lifeline placing flowers for hopes and wishes for the future."
48118616|NCT02994173|DRUG|S-Ketamine 0.75|dosage
48118617|NCT03876249|OTHER|exposure to RSV|No intervention will be given, children naturally exposed to RSV in their early life
48647783|NCT05148663|DIAGNOSTIC_TEST|CCM Hemorrhagic Panel|Biomarker
48647784|NCT04845542|BEHAVIORAL|ReStoreD|ReStoreD is a remotely-administered behavioral intervention in which couples coping with stroke learn and practice goal-setting, communication strategies, and positive psychology activities, such as expressing gratitude, finding meaning, and fostering connections. Participants are provided with 8 weekly modules, each featuring two components: 1) psychoeducational materials, such as an informational video and resources/links about a general topic related to resilience, coping, and/or overall well-being of the individual and couple, and 2) examples of positive psychology activities that relate to the week's theme or topic. Participants are asked to complete at least two positive psychology activities alone and two together each week.
48647785|NCT01681875|OTHER|very low nicotine content cigarettes|
48647786|NCT04203771|DIETARY_SUPPLEMENT|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum \[now Lactoplantibacillus plantarum\] KABP051 (CECT7481) and Lactobacillus brevis \[now Levilactobacillus brevis\] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10\^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
47970195|NCT00536198|DRUG|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
47970196|NCT00536198|DRUG|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
47970197|NCT02600572|OTHER|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
47970198|NCT02600572|OTHER|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
47970199|NCT01006096|DRUG|erlotinib|100mg tablet, once daily for 16 weeks
47970200|NCT01006096|OTHER|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
48118618|NCT04411849|OTHER|Best Practice|Receive usual care
48118619|NCT04411849|PROCEDURE|HPV Self-Collection|Receive HPV self-testing intervention
48118620|NCT04411849|OTHER|Informational Intervention|Receive information about cervical cancer
48118621|NCT04411849|BEHAVIORAL|Patient Navigation Program|Receive telephone-based patient navigation
47970201|NCT02314416|BIOLOGICAL|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
48118622|NCT06038799|BEHAVIORAL|Caregiver Skills Training (CST)|The investigators are comparing the relative efficacy of CST between a CST group led by clinicians trained and supervised remotely versus a group led by clinicians trained an supervised face-to-face.
48118623|NCT00223587|OTHER|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
48118624|NCT03067116|DIAGNOSTIC_TEST|Posturography Evaluation|Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
48118625|NCT03067116|DIAGNOSTIC_TEST|Anthropometrics|measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
48118626|NCT03067116|DIAGNOSTIC_TEST|Vitals|measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
48118627|NCT03067116|OTHER|Health and daily activity questionnaires|one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
48118628|NCT00493649|DRUG|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
48118629|NCT00493649|DRUG|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
48118630|NCT00493649|DRUG|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
48118631|NCT06041373|DEVICE|Verily Watch Cardio|The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.
48118632|NCT06041373|DEVICE|iRhythm Zio monitor|The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.
48488037|NCT05415020|BEHAVIORAL|Lifestyle Behavior Protocol|Virtual training on building a skillset to improve lifestyle behavior that reduces migraine attacks
48488038|NCT05415020|BEHAVIORAL|Sham Behavior Protocol|Virtual training on the disease of migraine and how migraine can progress to chronic migraine.
48488039|NCT04387682|DIETARY_SUPPLEMENT|β-glucan|β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
48488040|NCT00770692|DRUG|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
48488041|NCT00770692|DRUG|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
48488042|NCT00770692|DRUG|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
48488043|NCT00770692|DRUG|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
48488044|NCT03664895|DRUG|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
48488045|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
48647787|NCT04203771|OTHER|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
48647788|NCT04203771|PROCEDURE|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
48488046|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
48488047|NCT03777904|DIAGNOSTIC_TEST|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
48488048|NCT03777904|DIAGNOSTIC_TEST|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
48488049|NCT01348984|DRUG|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
48488050|NCT01348984|DRUG|placebo patch|group 2 = placebo patch
48488051|NCT04339920|DIAGNOSTIC_TEST|Spermine Measuring Device|The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
48488052|NCT01940328|DEVICE|Transchoracic ultrasound Doppler|
48647789|NCT04203771|DRUG|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
48647790|NCT00002046|DRUG|Zidovudine|
48323455|NCT05239559|DEVICE|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit:~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
48488053|NCT03896282|OTHER|Mobilization at a dedicated daycare facility|"All THA's are performed using a standard posterolateral approach with simple posterior soft-tissue repair. No infiltration anesthesia (LIA) is used in THA's. All TKA's are performed with a standard medial parapatellar approach without the use of tourniquet. Physiotherapy is started as soon as possible after surgery in the dedicated day care facility. Time till first mobilization is recorded as is total time mobilized supervised by a physiotherapist before discharge.~Patients are discharged if fulfilling the discharge criteria before 8 pm. Number of hours spent in hospital in total is recorded."
48488054|NCT03333954|DEVICE|PRIMA|"The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration.~The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors"
48488055|NCT05608681|DRUG|EP-104IAR|Long-acting fluticasone propionate for injection
48488056|NCT05526859|OTHER|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
48647791|NCT06019494|PROCEDURE|Oocyte retrieval with low aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.42 ml/sec.
47970202|NCT04356950|OTHER|Thrombin generation test assay|lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: \[ETP (%)(TM+) / ETP (%)(TM-)\].
47970203|NCT04356950|OTHER|Fibrin generation markers assays|D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)
48488057|NCT05526859|OTHER|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
48488058|NCT00937651|DRUG|Placebo|Placebo
48488059|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
48488060|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
48488061|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
48488062|NCT05160753|PROCEDURE|Laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area|A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method., and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed.
48488063|NCT06004778|BEHAVIORAL|Motivational Support Program|In studies conducted on adolescents with poor sleep quality, no study using motivational interviewing technique was found.
48488064|NCT06004778|BEHAVIORAL|Educational support|educational support
48488065|NCT04689100|DRUG|JMT101|Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
48488066|NCT04689100|DRUG|JMT101|IV infusion Q2W (28-day cycles)
48488067|NCT03433365|OTHER|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
48488068|NCT00000374|DRUG|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
48647792|NCT06019494|PROCEDURE|Oocyte retrieval with high aspiration flow rate|High aspiration flow rate All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.62 ml/sec.
48647793|NCT01432431|PROCEDURE|spiritual therapy|Undergo palliative spiritual care
47970204|NCT01134276|PROCEDURE|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
47970205|NCT05010421|DRUG|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
47970206|NCT05010421|DEVICE|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
47970207|NCT02164500|DRUG|Ruxolitinib|
48118633|NCT06041373|DEVICE|Schiller CARDIOVIT FT-1|The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.
48118634|NCT01830738|PROCEDURE|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
48647794|NCT01432431|OTHER|questionnaire administration|Ancillary studies
48647795|NCT01432431|OTHER|survey administration|Ancillary studies
48647796|NCT01432431|OTHER|counseling intervention|Undergo palliative spiritual care
48647797|NCT01432431|OTHER|psychosocial support for caregiver|Undergo palliative spiritual care
48647798|NCT01432431|PROCEDURE|psychosocial assessment and care|Undergo palliative spiritual care
48323456|NCT04084132|PROCEDURE|Pulmonary valve replacement|Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
48323457|NCT01650792|DRUG|Aspirin|
48647799|NCT06548295|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|"Restraint the involved extremity by using a mitten. Repetitive task practice i.e filling a glass, drinking a glass of water, and eating with a spoon , stacking cones and stacking blocks, grasping and releasing of an object, reaching forward and sideways, lifting and dropping of an object from the one end of table to the other end.~The shaping exercises included cube stacking, card turning, throwing balls into a box, grasping/holding and placing objects of different sizes, and drawing and painting exercises. Intervention: 5 sessions per week for 50 minutes for 6 weeks"
48647800|NCT06548295|COMBINATION_PRODUCT|conservative treatment|"The conservative rehabilitation program consisted of upper-limb range of motion exercises, positioning, stretching, and strengthening exercises, Passive mobilization of the shoulder ,elbow , wrist and small joints of hand Stretching of the affected arm including biceps, triceps and muscles of forearm and hand.~Strengthening exercises of upper arm and forearm muscles involved. Intervention: 5 sessions per week for six weeks and 50 mintues"
48647801|NCT02416544|OTHER|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
48647802|NCT06005831|OTHER|sandbag|The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
48647803|NCT03607500|BEHAVIORAL|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
48647804|NCT04923997|BEHAVIORAL|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
47970208|NCT06504095|OTHER|intervention group (Flipped Teaching Method Group)|"Patient safety training will be provided to students using the flipped classroom teaching method, consisting of both out-of-class and in-class activities.~Out-of-Class Activity: For the Flipped Teaching method, a Learning Management System-Web-Based Distance Education System will be established. Lecture videos for each lesson will be uploaded to the system 7 days before the class day. Students will have the flexibility to watch the instructional videos as many times as they wish until the class day.~In-Class Activity: The researcher will come prepared for in-class activities such as question-answer sessions, discussions, brainstorming. No lecturing will be done by the researcher. The researcher will solely guide the students."
47970209|NCT01824641|DEVICE|Eliminate aspiration catheter|Eliminate aspiration catheter
47970210|NCT01824641|PROCEDURE|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
47970211|NCT01201018|DRUG|Oshadi D, Oshadi R|Oral administration
47970212|NCT02427893|DRUG|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
47970213|NCT02427893|DRUG|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
47970214|NCT04743739|DRUG|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
47970215|NCT04743739|DRUG|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
47970216|NCT01050712|DRUG|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
47970217|NCT01050712|DRUG|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
47970218|NCT04489680|OTHER|Educational|Teaching session
47970219|NCT01402414|RADIATION|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
47970220|NCT01402414|RADIATION|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
47970221|NCT01402414|RADIATION|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
47970222|NCT05805904|DRUG|BMS-986278|Specified dose on specified days.
47970223|NCT05805904|DRUG|Placebo|Specified dose on specified days
47970224|NCT00757887|BIOLOGICAL|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
47970225|NCT01201382|BEHAVIORAL|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
47970226|NCT01201382|BEHAVIORAL|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
47970227|NCT03727347|DEVICE|InSeca Stylus|Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
48323458|NCT00228150|DRUG|SR57667B|
48647805|NCT03912753|BEHAVIORAL|Comunică|Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
47970228|NCT05221528|DIAGNOSTIC_TEST|Measurement of lipid profiles|Measured: total cholesterol, high-density lipoprotein cholesterol, and triglyceride Calculated: low-density lipoprotein
48647806|NCT03912753|OTHER|Education Attention Control|The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
48118635|NCT01830738|PROCEDURE|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
48118636|NCT04958798|BEHAVIORAL|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
48118637|NCT01547546|DRUG|GDC-0084|Multiple doses
48118638|NCT04004819|DRUG|Rituximab|A lower dosage of rituximab for HTLV-1-associated myelopathy
48118639|NCT02780440|BEHAVIORAL|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
48118640|NCT02780440|BEHAVIORAL|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
48118641|NCT02780440|BEHAVIORAL|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
48118642|NCT01305252|DRUG|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
48118643|NCT01305252|DRUG|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
48118644|NCT00947635|DIETARY_SUPPLEMENT|Dietary intervention - supplements|Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
48118645|NCT04381273|OTHER|No intervention|questionnaire-based assessment
48323459|NCT01549743|DRUG|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
48323460|NCT01549743|DRUG|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
48647807|NCT01027754|DRUG|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
48647808|NCT01027754|DRUG|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
48118646|NCT04433078|DRUG|Doxycycline|100 MG Tablet
48118647|NCT04433078|DRUG|Placebo|Placebo Tablet
48118648|NCT00508924|DRUG|Argatroban|
48118649|NCT00508924|DRUG|Argatroban|
48118650|NCT00508924|DRUG|Argatroban|
48118651|NCT00508924|DRUG|Heparin|
48118652|NCT00538122|DEVICE|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
48118653|NCT00855400|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
48323461|NCT01549743|DRUG|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
47970229|NCT03728790|DEVICE|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
48118654|NCT00855400|PROCEDURE|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
48118655|NCT00457275|DRUG|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
48323462|NCT03390712|DRUG|Paliperidone Palmitate|Monthly injections
48323463|NCT03390712|DRUG|Risperidal Consta|Bi-weekly injection
48118656|NCT04958343|PROCEDURE|pelvic reconstruction|After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.
48118657|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera with Crocus (saffron)|Dietary Supplement:Aloe Vera with Crocus (saffron) with 1L of Aloe Vera with Crocus (saffron) 1 glass bottle per 15 days
48118658|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Aloe Vera (simple)|Dietary Supplement:Aloe Vera (simple)with 1L of Aloe Vera 1 glass bottle per 15 days
48118659|NCT04436614|DIETARY_SUPPLEMENT|Dietary Supplement:Mediterranean Diet|Dietary Supplement:Mediterranean dietary protocol Intervention:mediterranean diet
48118660|NCT01606124|DRUG|defined green tea catechin extract|Given PO
48118661|NCT01606124|OTHER|placebo|Given PO
48118662|NCT01606124|OTHER|questionnaire administration|Ancillary studies
48118663|NCT01606124|OTHER|laboratory biomarker analysis|Correlative studies
48323464|NCT03390712|DRUG|Antipsychotic|Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
48323465|NCT00419913|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA 25 mg tid
47970230|NCT05405205|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water
48323466|NCT00095368|DRUG|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
48488069|NCT00000374|DRUG|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
48647809|NCT03615768|COMBINATION_PRODUCT|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
47970231|NCT05405205|DIETARY_SUPPLEMENT|probiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water
48488070|NCT00043758|DRUG|Tolvaptan|
48488071|NCT01090375|OTHER|Exercise|
48488072|NCT01090375|OTHER|Non Exercise|
48488073|NCT01516866|PROCEDURE|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
48488074|NCT04555304|DRUG|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
48488075|NCT04555304|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
48488076|NCT05940623|DEVICE|Standard care and home IOP telemonitoring with smart phone-based intervention|We expect that (1) GAT measurements over 30 months of follow-up for patients randomized to Management Paradigm I to be smaller compared with those randomized to Management Paradigm II; and that (2) the rates of RNFL/GCIPL thinning would be slower for those randomized to Management Paradigm I compared with those randomized to Management Paradigm II
48488077|NCT02980302|PROCEDURE|Cutaneous biopsy|Under local anesthesia
48488078|NCT03605251|DRUG|TAS5315 low dose|Oral administration for 12 or 36 weeks
48488079|NCT03605251|DRUG|TAS5315 high dose|Oral administration for 12 or 36 weeks
48488080|NCT03605251|DRUG|Placebos|Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
48488081|NCT05603455|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis|Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months
47970232|NCT05405205|DIETARY_SUPPLEMENT|placebo|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
47970233|NCT00889460|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
48323467|NCT01106625|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
48488082|NCT05603455|DIETARY_SUPPLEMENT|Placebo|Placebo
48488083|NCT01021241|BIOLOGICAL|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
48488084|NCT01112813|DRUG|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
48488085|NCT05946174|OTHER|Intervention Set A|exercise sessions and meals over approximately 12 weeks
48488086|NCT05946174|OTHER|Intervention Set B|exercise sessions and meals over approximately 3 weeks
48488087|NCT05946174|OTHER|Intervention Set C|meals over approximately 3 weeks
48647810|NCT03615768|DRUG|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
47970234|NCT00889460|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
48323468|NCT01106625|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
48323469|NCT01106625|DRUG|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
48323470|NCT01106625|DRUG|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
48488088|NCT04948229|OTHER|Blood serum samples|Blood serum samples will be taken.
48488089|NCT00971984|OTHER|Medical records summary|Summary of Medical files and laboratory results.
48488090|NCT05590156|PROCEDURE|Conventional Rehabilitation|Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.
48488091|NCT05590156|DEVICE|Robotic Rehabilitation (ExoRehab X)|Robotic Rehabilitation
48488092|NCT05590156|PROCEDURE|Action Observation Therapy (AOT)|Action Observation Therapy (AOT)
48488093|NCT01421121|BIOLOGICAL|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
48488094|NCT01421121|BIOLOGICAL|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
48647811|NCT03615768|DRUG|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
48647812|NCT04231019|OTHER|self-administered questionnaire|"Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered."
48118664|NCT04129619|DRUG|ORP-101|Oral tablet
48118665|NCT04129619|DRUG|Placebo|Oral tablet
48118666|NCT02860286|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
47970235|NCT03618498|PROCEDURE|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
48118667|NCT03688360|BEHAVIORAL|Cognitive Behavioral Therapy|. Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
48118668|NCT03340857|OTHER|Intelligent electric bicycle (VELIS) sessions|Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
48118669|NCT04428736|BEHAVIORAL|Disclosure Toolkit|"Participants will receive a Disclosure Toolkit consisting of a family letter, gene information chatbot, and informational website to aid in communicating their genetic test results with at-risk relatives."
48118670|NCT04327167|BEHAVIORAL|Video and questionnaire|Potential donors would be shown a video and asked to complete a questionnaire to capture change in attitude towards donation.
48118671|NCT00813059|DRUG|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
48118672|NCT05309733|GENETIC|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
48118673|NCT05640869|BEHAVIORAL|Modified Diabetes Prevention Program Curriculum|The modified DPP curriculum will be an exact copy of the current DPP curriculum except that references to the prevention of diabetes will be modified to prevention of health outcomes associated with overweight/obesity and/or management of overweight/obesity.
48118674|NCT00713063|BEHAVIORAL|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
48647813|NCT02473302|OTHER|ham|160g per day during 4 days
48647814|NCT02473302|OTHER|ham + pomegranate extract|160g per day during 4 days
47970236|NCT05338593|OTHER|Outcome|Mortality rate of prolonged therapy.
47970237|NCT02937909|OTHER|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
47970238|NCT03125317|OTHER|Music|a kind of music which the participant likes will be listened using speakers
47970239|NCT03125317|OTHER|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
47970240|NCT03125317|OTHER|control|No intervention
47970241|NCT00130936|DRUG|Epirubicin|
47970242|NCT00130936|DRUG|Carboplatin|
47970243|NCT00130936|DRUG|Capecitabine|
47970244|NCT02119481|BEHAVIORAL|Mindfulness-based stress reduction|
47970245|NCT02119481|BEHAVIORAL|Expressive writing condition|
47970246|NCT05511909|DRUG|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
47970247|NCT05511909|DRUG|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
47970248|NCT05511909|DRUG|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
47970249|NCT01101984|DRUG|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
47970250|NCT01101984|DRUG|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
47970251|NCT06230887|BEHAVIORAL|Building Spiritual Strength|Spiritually Integrated group intervention for moral injury
47970252|NCT06230887|BEHAVIORAL|Present Centered Group Therapy|Active control, manualized evidence-based coping skills intervention for PTSD
47970253|NCT00415805|DRUG|Multihance|0.5 Molar, single injection at 0.2 mL/kg
47970254|NCT00415805|DRUG|vasovist|0.25 molar single injection 0.03 ml/kg
47970255|NCT02491203|OTHER|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
47970256|NCT05061771|DRUG|nomacopan (rVA576)|Nomacopan an inhibitor of complement C5 and LTB4
47970257|NCT05061771|OTHER|Placebo|Placebo
47970258|NCT01595997|DRUG|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
47970259|NCT03395743|BIOLOGICAL|AB-PA01|AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections
47970260|NCT00120835|DRUG|valopicitabine|
47970261|NCT00120835|DRUG|pegylated interferon|
47970262|NCT00284583|DRUG|Injection of Steroid into Foot|
47970263|NCT00284583|DRUG|Injection of Alcohol into Foot|
47970264|NCT00284583|DRUG|Injection of Lidocaine into Foot|
47970265|NCT01393691|BEHAVIORAL|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
47970266|NCT01393691|BEHAVIORAL|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
47970267|NCT00209469|DRUG|alendronate sodium|
47970268|NCT00054145|DRUG|perifosine|
47970269|NCT01239004|DRUG|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
47970270|NCT01239004|DRUG|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
47970271|NCT00096070|RADIATION|radiation therapy|Undergo radiation therapy
47970272|NCT00096070|DRUG|oxaliplatin|Given IV
47970273|NCT00096070|DRUG|fluorouracil|Given IV
47970274|NCT00096070|DRUG|gemcitabine hydrochloride|Given IV
47970275|NCT06201702|DIETARY_SUPPLEMENT|pomegranate extract|Drink 2 mL of pomegranate extract three times a day for 10 days during the 3 menstrual cycles (from 7 days before to 3 days after the estimated onset of menstruation).
47970276|NCT02069717|OTHER|Not applicable-observational study|
48118675|NCT00713063|BEHAVIORAL|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
48118676|NCT00610649|DRUG|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
48118677|NCT00610649|DRUG|Placebo|Orally administered matching placebo capsules.
48118678|NCT05074836|DIETARY_SUPPLEMENT|Formula milk|"Brand name: Yili (QQ star formula milk);~Type: SCI-PRO NUTRI 5+6TM formula milk designed for young children aged over 3 years;~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
48488095|NCT01421121|BIOLOGICAL|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
48488096|NCT01421121|BIOLOGICAL|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
48488097|NCT01421121|BIOLOGICAL|Placebo|0.5ml placebo, two doses, 28 days interval
48488098|NCT00217269|DEVICE|Coronary Artery Stenting|Endeavor Drug eluting stent
48488099|NCT00217269|DEVICE|Coronary Artery Stenting|Taxus Drug Eluting Stent
48488100|NCT02041091|DRUG|Tabalumab Auto-Injector|Administered SC
48488101|NCT02041091|DRUG|Tabalumab Prefilled Syringe|Administered SC
48488102|NCT06436352|PROCEDURE|Capsulotomy and fixation|"Firstly, Guide wire insertion passing anterior to the GT and the neck is done. then passing a pointed Schanze 5 or 6 ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.~Then we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
48488103|NCT06436352|PROCEDURE|Fixation only|"we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
48488104|NCT00125411|DRUG|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
48647815|NCT02473302|OTHER|ham + tocopherol|160g per day during 4 days
48647816|NCT02473302|OTHER|rare sirloin steak|110g per day during 4 days
48647817|NCT02473302|OTHER|marinated rare sirloin steak|110g per day during 4 days
48647818|NCT02473302|OTHER|marinated cooked sirloin steak|110g per day during 4 days
48647819|NCT05691569|OTHER|doll therapy|empathy dolls
47970277|NCT04391127|DRUG|Hydroxychloroquine|Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
47970278|NCT04391127|DRUG|Ivermectin|Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
47970279|NCT04391127|DRUG|Placebo|Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
47970280|NCT06341842|DRUG|Dapagliflozin 10mg Tab|Dapaglifloziin 10 mg 1 tab daily
47970281|NCT05477810|DRUG|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
48118679|NCT05074836|DIETARY_SUPPLEMENT|Regular milk|"Brand name: Yili；~Type: regular milk (pure milk);~Dosage: 195ml\*2/d;~Intervention duration: 12 months"
48118680|NCT05074836|OTHER|Control foods|"Brand: N/A;~Food type: grain foods (e.g., bread);~Dosage: 20-40g \* 2/d grain foods~Intervention duration: 12 months"
48118681|NCT02234739|DRUG|Voriconazole|2-week long intravenous instillation of voriconazole
48323471|NCT02271867|PROCEDURE|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
48323472|NCT00229203|DRUG|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
48323473|NCT00086944|BIOLOGICAL|oblimersen sodium|Given IV
48323474|NCT00086944|BIOLOGICAL|rituximab|Given IV
48647820|NCT05284071|DEVICE|Device: Actiste 1.0 and the Companion app with TBL Backend|Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes and may improve the patients' adherence to treatment plans. Actiste automatically logs and shares real-life data on blood glucose values and actual injected insulin doses. With Actiste's built-in sensor, the exact injected dose is displayed and saved in the device memory together with a time stamp, which makes it easy for the user to know how much and when the insulin was injected, and spot missed doses. This simplifies the daily diabetes care for the user and thus may improve the quality of life for people with diabetes.
48647821|NCT02369939|RADIATION|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
48647822|NCT02369939|DRUG|Mitomycin C|MMC w1, w5
48118682|NCT04373590|BEHAVIORAL|Decision aid|The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
48323475|NCT00086944|DRUG|ifosfamide|Given IV
48323476|NCT00086944|DRUG|carboplatin|Given IV
48323477|NCT00086944|DRUG|etoposide|Given IV
48488105|NCT05513716|OTHER|Retrospective tissue sample analysis|Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
48647823|NCT02369939|DRUG|5-Fluorouracil|5-FU w1, w5
48647824|NCT02369939|PROCEDURE|Hyperthermia|6x deep regional hyperthermia
48647825|NCT01177358|DRUG|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
47970282|NCT05477810|DRUG|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
47970283|NCT02611219|OTHER|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"* 38 question questionnaire~* Answers range from 1=all of the time to 5=none of the time"
47970284|NCT02611219|OTHER|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"* 38 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
47970285|NCT02611219|OTHER|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
48118683|NCT04431297|OTHER|Mindfulness Rounds|Virtually delivered mindfulness education sessions of 15-30 minutes, two times/week, for four weeks
48323478|NCT00086944|BIOLOGICAL|filgrastim|Given SC
48323479|NCT00086944|BIOLOGICAL|pegfilgrastim|Given SC
48323480|NCT00086944|OTHER|laboratory biomarker analysis|Correlative studies
48323481|NCT00918086|DIETARY_SUPPLEMENT|Vitamin D pill|Oral tablet taken for 16 weeks
48323482|NCT00918086|DIETARY_SUPPLEMENT|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
48323483|NCT00966810|PROCEDURE|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect \> 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
48323484|NCT04290481|OTHER|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
48323485|NCT00817206|DRUG|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
48323486|NCT00817206|DRUG|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
48323487|NCT01519284|DRUG|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
48323488|NCT01519284|DRUG|Entacapone|Entacapone 200 mg
48323489|NCT01519284|DRUG|Placebo|placebo (four times a day)
48488106|NCT04085471|DIAGNOSTIC_TEST|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
48488107|NCT00102830|DRUG|AMG 386|
48488108|NCT06346002|BEHAVIORAL|Mindfulness-based intervention|The MBI program implemented comprised ten weekly sessions. Please refer to the arm/group descriptions for further details.
48488109|NCT03896464|PROCEDURE|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
48488110|NCT03896464|PROCEDURE|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
47970286|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
47970287|NCT02611219|OTHER|General Health Module-Baseline Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
47970288|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
48118684|NCT01039948|BIOLOGICAL|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
48118685|NCT01039948|DRUG|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
48118686|NCT06519253|OTHER|Virtual reality (VR) music intervention|The VR music intervention consists of musical performance which were already recorded. This is accessible classic music. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.
48118687|NCT06519253|OTHER|Music only control|The control group consists of the same musical performances, with the audio only
48118688|NCT04993898|OTHER|Plyometric training with warm up and cool down|These Include Squat to Squat Jump, Lunge to Plyo Lunge, Step Jack to Star Jumps, Plank to Plyo Spider Lunge, Plank to Frogger Frequency = 2 days per week for 2 weeks and then 4 days per week after 2nd week to 4th week Intensity =500 jumps Time = 30 min
48118689|NCT04993898|OTHER|Conventional training with warm up & cool down|These include Squats, Single leg squat, Cork hip lift, Press ups, Normal warm-up time 15 min before game.
48323490|NCT01519284|DRUG|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
48647826|NCT01177358|DRUG|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
48647827|NCT06673953|OTHER|Respiratory Muscle Training by (The Breather)|Patients are instructed to inhale deeply and forcefully (at non fatigable resistance) for 2-3 seconds, slight pause, and then exhale forcefully for 2-3 seconds for 10 repetitions with 2 sets.
48647828|NCT06673953|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of: (TENS / Low-intensity continuous ultrasonic / Infrared radiation application / Cervical Stabilization exercise )
47970289|NCT02611219|OTHER|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
47970290|NCT02611219|OTHER|SCT Daily Activity Log|"* Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
47970291|NCT02611219|OTHER|The Functional Independence Measure for Children|"* 18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~* Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
47970292|NCT02611219|OTHER|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
47970293|NCT02611219|OTHER|3-Minute Step Test|"* Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~* Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
47970294|NCT02611219|OTHER|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"* 7 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
47970295|NCT02611219|OTHER|HSCT Module-Follow Child-Self Report (5-12 years)|"* 10 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
47970296|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
47970297|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
47970298|NCT06259747|OTHER|Acutaping|Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application
47970299|NCT06259747|DRUG|Doxylamine and Pyridoxine|traditional medical treatment for nausea and vomiting during pregnancy
47970300|NCT00977899|BIOLOGICAL|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
47970301|NCT01845831|DRUG|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
48323491|NCT01519284|DRUG|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
48323492|NCT01519284|DRUG|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
47970302|NCT01845831|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
48118690|NCT01958866|DRUG|Tinospora Crispa-extract Product|
48118691|NCT01958866|DRUG|Acetaminophen|
48118692|NCT01958866|OTHER|Placebo|
48118693|NCT03675256|BIOLOGICAL|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
48118694|NCT03675256|BIOLOGICAL|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
48118695|NCT03675256|BIOLOGICAL|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
48323493|NCT00623467|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
48323494|NCT04591795|DRUG|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
48323495|NCT04591795|DRUG|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
47970303|NCT01845831|DRUG|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
48323496|NCT03617367|BIOLOGICAL|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
48323497|NCT04622085|DEVICE|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
48323498|NCT04622085|DEVICE|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
48647829|NCT02096380|DRUG|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
47970304|NCT01845831|DRUG|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
47970305|NCT01845831|DRUG|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
47970306|NCT01845831|DRUG|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
48323499|NCT03638882|BEHAVIORAL|Duolingo|Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.
48323500|NCT03638882|BEHAVIORAL|BrainHQ|Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.
48488111|NCT03195036|BEHAVIORAL|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
48647830|NCT02096380|DRUG|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
48647831|NCT05874804|DEVICE|Carry Life UF|A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.
48647832|NCT05874804|DRUG|2.27% glucose peritoneal dialysis dwell|A 5-hour CAPD dwell with a 2.27% glucose PD fluid.
48323501|NCT03638882|BEHAVIORAL|Passive Control|No Intervention.
48323502|NCT01391819|OTHER|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
48647833|NCT05077605|OTHER|Functional residual capacity measure by electrical impedance tomography|Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.
48647834|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
48323503|NCT01391819|PROCEDURE|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
48323504|NCT01806636|DEVICE|PneumRx Coil System|
48488112|NCT04117737|OTHER|Virtual reality combined with anti-gravity treadmill|"The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life."
48647835|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
48647836|NCT00392288|DRUG|Placebo|Placebo MDI over twelve weeks
48647837|NCT03017911|PROCEDURE|Piccline|
47970307|NCT01462097|BEHAVIORAL|Aerobic exercise training|12 months of aerobic exercise
47970308|NCT01462097|BEHAVIORAL|Health Education|12 months of health education sessions
48323505|NCT02810652|OTHER|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
48323506|NCT02810652|OTHER|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
48323507|NCT04584658|DIAGNOSTIC_TEST|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
48323508|NCT04584658|DIAGNOSTIC_TEST|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
48323509|NCT04584658|OTHER|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
48323510|NCT04584658|OTHER|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
48323511|NCT01640990|DRUG|Saline|30mins run-in period
48323512|NCT01640990|DRUG|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
48323513|NCT01640990|DRUG|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
48323514|NCT01140854|PROCEDURE|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
48323515|NCT01140854|OTHER|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
48323516|NCT01887392|OTHER|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
48323517|NCT03747744|OTHER|CD1c (BDCA-1)+ myDC|Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
48323518|NCT05045469|DRUG|dian dao san|dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
48323519|NCT02500394|PROCEDURE|Ionosteril|biomarker guided volume substitution with Ionosteril
48323520|NCT04191291|BEHAVIORAL|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
48323521|NCT06036134|BEHAVIORAL|Baseline surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, gender, income, education level, relationship to the child), parental COVID-19 vaccine hesitancy, intentions to vaccinate child against COVID-19, and parents' attitudes, perceived norms, and perceived behavioral control about vaccinating their child against COVID-19,
48323522|NCT06036134|BEHAVIORAL|Digital Storytelling Intervention|In Aim 1, the investigators are creating intervention materials for Study Aim 2. These intervention materials include ten digital stories (each 2-3 minutes long) with a diverse sample of Hispanic parents and legal guardians who transformed from being COVID-19 vaccine-hesitant to vaccine-accepting. Each story uses individuals' own brief first-person visual narratives/stories that use digital images, audio recordings, music, and text to document personal experiences.
48323523|NCT06036134|BEHAVIORAL|Information Control Intervention|The control group participants will receive a CDC COVID-19 vaccine information sheet appropriate for their child's age.
47970309|NCT03296358|DRUG|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
48323524|NCT02322268|DIETARY_SUPPLEMENT|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
48323525|NCT00353964|DRUG|rEV131|
48323526|NCT00353964|DRUG|Prenisolone sodium phosphate 1.0%|
48323527|NCT00353964|DRUG|rEV131 vehicle|
48323528|NCT03687138|OTHER|24h urin sample|The samples will analyzed by proteomic techniques
48323529|NCT04815551|DRUG|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
48323530|NCT04815551|DRUG|Placebo|Placebo is sterile liquid for IV infusion.
48323531|NCT02462941|DRUG|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
48323532|NCT02462941|PROCEDURE|Cardiac catheterization|(non-experimental) standard procedure
48323533|NCT02086721|DRUG|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
48323534|NCT04900038|DRUG|GSK3640254|GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
48323535|NCT04900038|DRUG|Dolutegravir|DTG was available as 50 mg tablets administered orally.
48323536|NCT04900038|DRUG|Lamivudine capsules|3TC was available as 300 mg capsules administered orally as a blinded treatment.
48323537|NCT04900038|DRUG|Lamivudine tablets|3TC was available as 300 mg tablets administered orally as an unblinded treatment.
48323538|NCT03441893|DIAGNOSTIC_TEST|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
48118696|NCT05283447|OTHER|Osteopathic Medicine|The clinical protocol subject to analysis for the intervention group consists of manual approach techniques for the myofascial and viscerofascial structures of the anterior face of the neck, maneuvers for the mediastinal region, techniques for normalizing the tone of the thoracic diaphragm and its pillars, on the peritoneal ligaments, and caudal traction of the stomach for manual correction of hiatal hernia.
48118697|NCT05283447|OTHER|Control|The physiotherapeutic treatment on the control group consists of an approach to the lumbopelvic joint restrictions and a massage on the inframesocolic abdominal region with minimal pressure, which does not affect the activity and position of the stomach.
48118698|NCT04092231|BEHAVIORAL|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
48118699|NCT00006330|DRUG|Digoxin|
48118700|NCT00006330|DRUG|Hawthorn|
48323539|NCT03441893|DRUG|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
48323540|NCT03441893|DRUG|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
48647838|NCT03721367|OTHER|Diagnostic Ultrasound|All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
48647839|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies!|Fruits and Vegetables
47970310|NCT03296358|DRUG|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
47970311|NCT01102959|DEVICE|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
47970312|NCT01337739|DRUG|Placebo Comparator|Placebo administration (.9 normal saline sterile)
47970313|NCT01337739|DRUG|Active Comparator|Administration of Dexmedetomidine
47970314|NCT02912910|OTHER|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
47970315|NCT02912910|OTHER|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
47970316|NCT01114425|DRUG|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
47970317|NCT01114425|DRUG|Truvada®|
47970318|NCT03930797|BEHAVIORAL|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
47970319|NCT03930797|BEHAVIORAL|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
47970320|NCT02709733|BEHAVIORAL|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
47970321|NCT03214965|BEHAVIORAL|Facebook group|A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
47970322|NCT04010149|DEVICE|Active tDCS|For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
47970323|NCT04010149|DEVICE|SHAM tDCS|For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
48118701|NCT04732338|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy (OMT) is a non-pharmacological, noninvasive form of manual medicine. Osteopathic practitioners use a wide variety of therapeutic manual techniques to improve physiological function and help restore homeostasis in the body. There is a structural assessment is to identify possible abnormalities of tissue texture. Areas of asymmetry and misalignment of bony landmarks are also evaluated, along with the quality of motion, balance, and organization. These asymmetries, also known as somatic dysfunctions, are then treated by a variety of manual treatments, administered by osteopaths.
48118702|NCT01257932|DEVICE|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
48118703|NCT00060684|DRUG|Pixantrone (BBR 2778)|
48118704|NCT00060684|DRUG|fludarabine|
48323541|NCT03441893|DRUG|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
48323542|NCT03441893|DRUG|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
47970324|NCT04985097|PROCEDURE|Implantation of trifocal diffractive intraocular lenses|Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training
48118705|NCT00060684|DRUG|dexamethasone|
48118706|NCT00060684|DRUG|rituximab|
48323543|NCT01244347|DRUG|folic acid|
48323544|NCT01244347|DRUG|folic acid|
48488113|NCT02620215|DEVICE|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
48647840|NCT01918020|BEHAVIORAL|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
48118707|NCT02153541|DRUG|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
48118708|NCT02153541|OTHER|Glycerin with Oxyquinoline Sulfate|50% of participants will receive the glycerin with oxyquinoline sulfate. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
48118709|NCT05907473|OTHER|Virtual Reality Therapy|Patients in this group will play balance-based games with the Virtual Reality System.
48118710|NCT05907473|OTHER|Conventional Rehabilitation|In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.
48118711|NCT03364595|PROCEDURE|plate fixation|ORIF of the radial head fracture
48323545|NCT02000713|OTHER|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
48323546|NCT02000713|OTHER|Clinical Exam|Brief neurological exam will be performed.
48323547|NCT01705197|DRUG|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
48323548|NCT00456794|DRUG|Istradefylline (KW-6002)|
48488114|NCT02620215|DRUG|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
48488115|NCT00350402|BEHAVIORAL|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
48488116|NCT02494817|BEHAVIORAL|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
48488117|NCT02827890|DRUG|Januvia Tab. 100mg|Januvia Tab. 100mg\*1T/day for 5days, QD, PO
48488118|NCT02827890|DRUG|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
48488119|NCT01856036|PROCEDURE|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
48488120|NCT03866915|DIAGNOSTIC_TEST|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
48488121|NCT03866915|DIAGNOSTIC_TEST|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
48488122|NCT05147038|DEVICE|Tele-coaching|"The participants are instructed to use a Fitbit fitness tracker to record the number of steps. This device is compatible with the m-PAC App, which was developed for this specific group of participants (individuals suffering from a chronic lung disease). The participants receive a feedback via the m-PAC App every day and they also receive a week report to be albe to adjust their step goal. They are asked to increase or keep their week goal every Sunday after reviewing a weekly report. The participants also receive tips for their PA improvement and they are asked for medication change specification (every Wednesday)."
48488123|NCT05265819|DEVICE|X-BOX kinetic360|1) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.
48647841|NCT02683798|DIETARY_SUPPLEMENT|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
48647842|NCT02683798|DIETARY_SUPPLEMENT|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
48647843|NCT04938843|DIETARY_SUPPLEMENT|F. prausnitzii and D. piger|Dietary supplementation with capsules containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
48323549|NCT02785952|BIOLOGICAL|Ipilimumab|Given IV
48323550|NCT02785952|OTHER|Laboratory Biomarker Analysis|Correlative studies
48118712|NCT03364595|PROCEDURE|replacement|replacement of the radial head fracture
48323551|NCT02785952|BIOLOGICAL|Nivolumab|Given IV
48647844|NCT04938843|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo capsules identical to those containing F. prausnitzii and D. piger once daily for 12 consecutive weeks
48647845|NCT05992740|DEVICE|bronchoscope|bronchoscpe with broncial brush and biopsy or bronchial wash and biopsy
48647846|NCT06255626|DRUG|CD40.RBDv vaccin (SARS-Cov2 Vaccin)|1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
47970325|NCT01804465|DRUG|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
47970326|NCT01804465|DRUG|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
47970327|NCT01500694|DRUG|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
48118713|NCT00595790|BIOLOGICAL|IC51|
48118714|NCT02180763|BIOLOGICAL|Gammanorm|Sub-Q IgG
48118715|NCT00002542|DRUG|CMF regimen|
48118716|NCT00002542|DRUG|cyclophosphamide|
48323552|NCT02785952|OTHER|Quality-of-Life Assessment|Ancillary studies
48488124|NCT05265819|DIETARY_SUPPLEMENT|mediterranean diet|Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
47970328|NCT03801291|PROCEDURE|Transvaginal repair|Vaginal incision through which plication of the rectovaginal septum is done
48118717|NCT00002542|DRUG|doxorubicin hydrochloride|
48118718|NCT00002542|DRUG|epirubicin hydrochloride|
48118719|NCT00002542|DRUG|fluorouracil|
48118720|NCT00002542|DRUG|methotrexate|
48118721|NCT00002542|DRUG|tamoxifen citrate|
48118722|NCT00002542|RADIATION|radiation therapy|
48323553|NCT02785952|OTHER|Questionnaire Administration|Ancillary studies
48323554|NCT04693689|OTHER|RNA vaccine|We elicit subjects' willingness to receive RNA COVID-19 vaccine
48323555|NCT04693689|OTHER|20% adoption rate|We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
48323556|NCT04693689|OTHER|40% adoption rate|We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
48323557|NCT04693689|OTHER|60% adoption rate|We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
48323558|NCT04693689|OTHER|80% adoption rate|We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
48323559|NCT04693689|OTHER|Conventional vaccine|We elicit subjects' willingness to receive conventional COVID-19 vaccine
48488125|NCT05265819|DRUG|thyroid hormone replacement therapy|thyroid hormone replacement therapy
48488126|NCT03425279|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
48488127|NCT03425279|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
48488128|NCT01091272|DRUG|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
48488129|NCT01091272|DRUG|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
48488130|NCT01091272|DRUG|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
48488131|NCT01091272|DRUG|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
48488132|NCT01835704|OTHER|Radio-frequency dennervation of facet joint|
48647847|NCT06569654|DEVICE|Saebo splint|"The SaeboFlex orthosis was fitted individually for each participant in the intervention group. The orthosis was adjusted to ensure proper alignment and comfort.~Participants were instructed on how to don and doff the orthosis correctly and safely.~The orthosis positions the wrist and fingers in extension in preparation for grasp and release activities, enabling participants to perform functional tasks despite limited voluntary movement.~Task-Oriented Repetitive Training:~The intervention consisted of 45-minute sessions, conducted twice a week, over a period of 12 weeks.~Each session focused on repetitive, task-oriented exercises designed to improve motor function and enhance neuroplasticity.~Training Activities:~* Moving the Ball~* Bringing the Ball to the Mouth~* Reaching Towards a Target~* Manipulating the Ball Around a Target~* Placing the Ball into Tubes~* Throwing the Ball~* Catching a Rolling Ball"
48647848|NCT03656614|DRUG|Sugammadex|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)"
48647849|NCT03656614|DRUG|Neostigmine|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow."
48647850|NCT03656614|DRUG|Saline 0.9%|At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
48647851|NCT05062707|PROCEDURE|Blood sampling|Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
48647852|NCT04377776|OTHER|Practice details|Questionnaire
48647853|NCT01813227|DRUG|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
48118723|NCT01066026|PROCEDURE|hyaluronic acid with metallic cannula or standard needle.|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
48647854|NCT01813227|DRUG|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
48647855|NCT01813227|DRUG|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
47970329|NCT03801291|PROCEDURE|Transperineal repair|Perineal incision through which plication of the rectovaginal septum is done
47970330|NCT00664872|OTHER|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
48118724|NCT01066026|DRUG|Hyaluronic acid injected with the new tool.|hyaluronic acid with metallic cannula.
48118725|NCT03557411|DRUG|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
48118726|NCT02972944|PROCEDURE|Laparoscopic cholecystectomy|
47970331|NCT00664872|BEHAVIORAL|case management|
47970332|NCT01130012|BEHAVIORAL|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
48118727|NCT02972944|PROCEDURE|Non-operative treatment|
48323560|NCT04693689|OTHER|0% adoption rate|We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
48323561|NCT03707964|OTHER|Crisis Resource Management Skill Training|Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.
48323562|NCT03707964|OTHER|Standard ACLS Training|Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
48323563|NCT05109130|PROCEDURE|Surgical approach|Different surgical methods for rectal cancer resection
48647856|NCT05459779|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.
47970333|NCT01130012|BEHAVIORAL|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
48118728|NCT05904925|OTHER|Pilates exercises|Sessions will last 60 minutes: five minutes for warming up, 50 minutes for the practice of Pilates exercises, and five minutes for relaxing with the Swiss ball. The exercise protocol will be divided into three gestational phases, covering the entire gestational period, with different and specific objectives for each phase. In all phases, the exercises will be classified into three levels of difficulty: basic, intermediate, and advanced, according to the evolution of each pregnant woman throughout the practice of Pilates. Modifications will be allowed to facilitate or hinder the execution of the movement. The exercises will be performed in one or two sets of seven to 10 repetitions. The number of series, repetitions and exercises and interval time between them, as well as the level of difficulty of the exercises, will be gradually adjusted. The intensity of the exercises will vary between light and moderate and will be controlled by the Borg scale.
48118729|NCT01689090|OTHER|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
48118730|NCT01689090|OTHER|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
48488133|NCT01835704|OTHER|Diagnostic nerve-blocks performed under direct x-ray vision|
48488134|NCT05339646|DRUG|SSD8432 dose 1~7 and Ritonavir|"Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date."
47970334|NCT03181334|BEHAVIORAL|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
47970335|NCT03181334|BEHAVIORAL|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
47970336|NCT03181334|BEHAVIORAL|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
47970337|NCT03181334|BEHAVIORAL|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
47970338|NCT03181334|BEHAVIORAL|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
48488135|NCT05339646|DRUG|SSD8432 dose 8~9|Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
48647857|NCT05459779|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
48647858|NCT02395328|BEHAVIORAL|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
48647859|NCT00003158|DRUG|carboplatin|
48647860|NCT00003158|DRUG|etoposide|
48647861|NCT00003158|DRUG|paclitaxel|
48647862|NCT00003158|RADIATION|radiation therapy|
47970339|NCT03143439|BEHAVIORAL|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
48118731|NCT01689090|OTHER|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
48118732|NCT00252278|DRUG|atomoxetine|
48118733|NCT03366636|BEHAVIORAL|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~* 1. Thinking about the future~* 2. Present actions to achieve future success~* 3. Safeguarding one's future~* 4. Creating a Healthy Life Plan~* 5. Navigating service systems"
48323564|NCT06324279|DEVICE|Transvaginal ultrasound|Transvaginal ultrasound will be used to see the presence of cervical sliding sign
48323565|NCT06324279|DRUG|Misoprostol 200mcg Tab|Induction of labor by misoprostol
48488136|NCT05339646|DRUG|SSD8432 dose 10~12 and ritonavir|Cohort 6: SSD8432 dose 10 or placebo, on day 1 \~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 \~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 \~day6 Cohort 9: to be decided
47970340|NCT00948701|BEHAVIORAL|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
47970341|NCT01747798|DRUG|auranofin|Given PO
47970342|NCT01747798|OTHER|laboratory biomarker analysis|Correlative studies
47970343|NCT03644212|DRUG|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
47970344|NCT00319865|DRUG|Velcade|
47970345|NCT00319865|DRUG|Thalidomide|
47970346|NCT00319865|DRUG|Adriamycin|
47970347|NCT00319865|DRUG|Dexamethasone|
47970348|NCT06081205|OTHER|Admission in the Cardiac Intensive Care Unit (CICU)|all patients admitted in the CICU will be enrolled in the study provided they give their informed consent.
47970349|NCT05013073|OTHER|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
47970350|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
47970351|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
47970352|NCT02340975|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion.
47970353|NCT02340975|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion.
47970354|NCT02340975|BIOLOGICAL|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
47970355|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
47970356|NCT03164252|RADIATION|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
47970357|NCT03164252|RADIATION|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
47970358|NCT03164252|RADIATION|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
47970359|NCT03712072|DEVICE|Magnetoencephalography (MEG)|The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
47970360|NCT03712072|DEVICE|Electroencephalography (EEG)|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp.
47970361|NCT03712072|DEVICE|Transcranial Magnetic Stimulation (TMS)|The device will be used for motor mapping. Motor threshold is operationally defined as minimum machine output necessary to elicit a response from the abductor pollicis brevis right (APB), contralateral to the stimulated hemisphere, of 50 microvolts, on \>50% of trials. Upper limb motor mapping is conducted at 110% abductor pollicis brevis motor threshold in each hemisphere, or at 100% machine output (MO). Lower limb motor mapping is conducted at a fixed machine output corresponding to the magnitude sufficient to elicit reliable tibialis anterior (TA) motor evoked potentials (MEPs). Single pulse TMS is performed while motor evoked potentials are recorded bilaterally from the APB, deltoid, and TA using surface electromyography (EMG).
47970362|NCT02288897|DRUG|PV-10 (10% rose bengal disodium)|
47970363|NCT02288897|DRUG|Dacarbazine, temozolomide or talimogene laherparepvec|
47970364|NCT00245115|BIOLOGICAL|filgrastim|
47970365|NCT00245115|DRUG|busulfan|
47970366|NCT00245115|DRUG|cyclophosphamide|
47970367|NCT00245115|PROCEDURE|in vitro-treated bone marrow transplantation|
47970368|NCT00245115|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
47970369|NCT02379871|OTHER|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
47970370|NCT02379871|OTHER|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
48323566|NCT02530671|DEVICE|Toothbrushing with manual toothbrush|
48323567|NCT02530671|DEVICE|Toothbrushing with power toothbrush|
48323568|NCT05847244|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
48323569|NCT01895491|BIOLOGICAL|VM206DNA|
48488137|NCT05339646|DRUG|SSD8432 dose 13 and Ritonavir|"Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date"
48647863|NCT06167746|OTHER|Digital Health Information (DHI)|Digital health information websites.
48647864|NCT06167746|BEHAVIORAL|Virtual Health Coach for You|Study participants in the intervention group will receive 10-session virtual health coaching intervention session delivered over 6 months with the goal of improving caregiver self-care and coping, decreasing stress, and improving the hospital-to-home experience The 10 sessions are on average 60 minutes and cover the following topics: care transitions, caregiving demand, self-care, and coping.
48647865|NCT00192478|BIOLOGICAL|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
48647866|NCT03366259|DRUG|Misoprostol 200Mcg Tab|administration of 200 Mcg of misoprotol rectal
48647867|NCT03366259|PROCEDURE|elective cesarean section|elective cesarean section for full term patients
48647868|NCT04512625|BIOLOGICAL|Desensitizers|The main aims and objectives of the present study were to evaluate and compare the effectiveness of three commercially available desensitizing agents: Gluma (Hareus Kulzer), Sheildforce Plus (Tokuyama), and Telio CS (Ivoclar Vivadent) desensitizer in reducing the pre- and post-cementation sensitivity for full coverage restorations.
48647869|NCT05398692|OTHER|Virtual vs On Site Pulmonary Rehabilitation|As part of the on site or virtual visits, the subject will receive standard pulmonary rehabilitation educational instruction on balance and strength training, stretching, nutrition, hydration, pacing, proper breathing, small or mini-lectures, and information on relaxation techniques. If post exertional malaise is present, the patient will only receive the educational sessions, no aerobic training.
48118734|NCT03195608|DEVICE|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
48118735|NCT03195608|BEHAVIORAL|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
48118736|NCT06177106|OTHER|Solar Simulated Light|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
48118737|NCT00392054|PROCEDURE|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
48488138|NCT05339646|DRUG|SSD8432 dose 14 and Ritonavir|Cohort 11: to be decided
48118738|NCT00392054|DRUG|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
48323570|NCT01895491|BIOLOGICAL|VM206Ad|
48323571|NCT04276129|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
48323572|NCT04276129|OTHER|post-surgical CHX mouth-rinses indication|CHX mouth-rinses (0.12%) will be indicated 2 times/day after the surgical procedure
48323573|NCT03247413|DRUG|Dexamethasone 4 mg/ml|dexamethasone 4 milligram given post-ablation at each lesion site
48323574|NCT03247413|DRUG|Normal saline|Placebo, normal saline administered post-ablation at each lesion site
48488139|NCT05262192|OTHER|nutrition education|Nutrition education will be given to the patients in the experimental group.
48488140|NCT03992417|DRUG|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
48488141|NCT01469702|DRUG|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
48323575|NCT02178501|DIETARY_SUPPLEMENT|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
48647870|NCT05530538|BEHAVIORAL|BrainWeighve App|46 total adolescents (14-18 years old) with %BMIp95 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll two successive groups of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually).
48647871|NCT02698787|DEVICE|Experimental sound coding strategy (FAST)|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
47970371|NCT01380275|DRUG|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
48118739|NCT04149002|BEHAVIORAL|Intervention Arm Weekly IP3 text messages|Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.
48118740|NCT04149002|OTHER|Active Control Arm General pregnancy text messages|Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
48118741|NCT02459782|PROCEDURE|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
48118742|NCT05742126|DRUG|HSK36273|Multiple continuous IV infusion ascending doses for 5 days
48118743|NCT05742126|DRUG|Placebo|Matching placebo
48118744|NCT05742126|DRUG|Heparin sodium injection|Matching positive control
48647872|NCT02698787|DEVICE|Commercially available ACE sound coding strategy|Commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with FAST sound coding strategy using crossover design in newly implanted subjects. Both groups will receive the experimental and control strategy
48118745|NCT01763086|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
48647873|NCT00044733|DRUG|Mylotarg (gemtuzumab ozogamicin) Injection|
48647874|NCT00311831|BEHAVIORAL|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
48647875|NCT00311831|BEHAVIORAL|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
48647876|NCT06265441|PROCEDURE|Group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance in which the adductor canal is identified and 20 ml of 0.25% bupivacaine will be injected|The patients in group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance (SonoSite™, Inc., Bothell, WA 98021, USA) in which the patients are placed in the supine position with the arms resting comfortably across the chest and the affected lower extremity is externally rotated. Adductor canal was identified beneath the sartorius muscle and 22-gauge 90-mm spinal needle is inserted from anterolateral to posteromedial direction at a point approximately at the junction between the middle and distal third of the thigh on the anteromedial femur, this location is called mid adductor canal, then 20 ml of 0.25% bupivacaine is injected in the canal
48118746|NCT01912131|BEHAVIORAL|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
48118747|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
48118748|NCT01912131|BEHAVIORAL|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry \& Behavioral Sciences,
48323576|NCT00289185|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
48323577|NCT00289185|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
48323578|NCT00289185|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
48323579|NCT03623282|DRUG|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
48323580|NCT06018610|OTHER|Rehabilitation|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.
48323581|NCT06018610|OTHER|Control|Conventional rehabilitation will be applied to the control group.
48323582|NCT02303171|DRUG|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
48323583|NCT02303171|DRUG|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
48323584|NCT04084626|DRUG|PD1 antibody|2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years).
48323585|NCT04084626|DRUG|lenalidomide|5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14.
48323586|NCT05402098|PROCEDURE|Endodontic treatment using traditional access|Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access
48323587|NCT05402098|PROCEDURE|Endodontic treatment using conservative access|Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
48323588|NCT05966844|BEHAVIORAL|Mindfluness and Virtual Reality|They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
48647877|NCT06265441|PROCEDURE|Group B will receive adductor canal block under ultrasound guide 20 ml bupivacaine 0.25% and IPACK block under direct visualization of ultrasound of 20 ml bupivacaine 0.25%|The patients in Group B will receive adductor canal block as described in group A then IPACK block, in which the patients are placed in a supine position and knee is placed in position of 90° flexion. A low-frequency ultrasound probe is positioned in the popliteal crease 1 finger breadth above the patella, and a spinal needle is inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle is placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.25% bupivacaine is injected while the needle is being withdrawn after negative aspiration.
47970372|NCT01380275|DRUG|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
47970373|NCT02418364|OTHER|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
48118749|NCT01912131|BEHAVIORAL|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
48118750|NCT01912131|BEHAVIORAL|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
48323589|NCT04406051|PROCEDURE|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 5 mL/kg of colloid infusion prior to the initiation of spinal anesthesia
48488142|NCT01469702|DRUG|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
48488143|NCT01469702|DRUG|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
48488144|NCT02957266|RADIATION|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
48488145|NCT02957266|RADIATION|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
48488146|NCT02957266|DRUG|Cisplatin|Weekly Cisplatin
48488147|NCT02957266|DRUG|Gemcitabine|Weekly Gemcitabine
48647878|NCT06570928|OTHER|Cannabis|0,2 ml of CBD:THC (50 mg:5 mg)
48647879|NCT06570928|OTHER|Placebo|Product vehicle, medium chain triglycerides (MCT)
48647880|NCT00911157|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
48647881|NCT00911157|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
48323590|NCT04406051|PROCEDURE|norepinephrine infusion and crystalloid co-loading (NOR-CRYST)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 10 mL/kg of crystalloid infusion simultaneously with the initiation of spinal anesthesia
48323591|NCT01053117|OTHER|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
48488148|NCT02957266|GENETIC|PIK3CA|PIK3CA mutations rate
48488149|NCT02957266|GENETIC|KRAS|KRAS mutations rate
48488150|NCT02957266|GENETIC|BRAF|BRAF mutations rate
48488151|NCT02957266|GENETIC|RRM1|RRM1 mutations rate
48488152|NCT04368611|PROCEDURE|start with fundus|fundus first dissection then complete cholecystectomy as usual
48488153|NCT04368611|PROCEDURE|calot first dissection|start dissection by calot approach
48488154|NCT05638841|OTHER|After radiofrequency ablation of atrial fibrillation|This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
48488155|NCT04683757|OTHER|Establishment of a Survival Prediction Model|a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer
48488156|NCT02206620|DRUG|Donepezil|
48488157|NCT02431819|DEVICE|contention socks|Patients wear contention socks during 15 days.
48488158|NCT01264042|DIETARY_SUPPLEMENT|Ferrous Sulfate|60 mg with 200 mL water, single administration
48488159|NCT05818748|DEVICE|virtual reality|virtual reality distraction
48488160|NCT03376542|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
48488161|NCT02149121|BIOLOGICAL|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
48488162|NCT02149121|DRUG|Rituxan|US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
48488163|NCT02149121|DRUG|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
48118751|NCT06187246|BEHAVIORAL|Avatar-based intervention|"Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life."
48118752|NCT06187246|OTHER|Individual informative talks|Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
48118753|NCT01823133|DRUG|gemigliptin only|gemigliptin 50mg qd on day 1\~7
48647882|NCT03338920|DRUG|sumatriptan nasal powder|nasal powder administered via nosepiece
47970374|NCT02418364|OTHER|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
48118754|NCT01823133|DRUG|rosuvastatin only|rosuvastatin 20mg qd on day 1\~7
48118755|NCT01823133|DRUG|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7
48118756|NCT03939195|OTHER|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
48118757|NCT05027607|PROCEDURE|Bascom's pit-pick|Pit-pick procedure of simple pilonidal sinus disease in the natal cleft in a day-surgery setting.
47970375|NCT01008488|DRUG|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
48118758|NCT06277037|OTHER|Non-interventional|This is a rollover study
48118759|NCT04968366|BIOLOGICAL|Autologous dendritic cells pulsed with multiple neoantigen peptides.|Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
47970376|NCT01367002|DRUG|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
48118760|NCT04968366|DRUG|Temozolomide adjuvant chemotherapy|Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
48118761|NCT04035668|DRUG|Remibrutinib|Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
48118762|NCT04035668|DRUG|Placebo|Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
48118763|NCT01736891|DRUG|Rasagiline|Tablets, qd
48647883|NCT03338920|DRUG|Placebo|lactose monohydrate powder administered via nosepiece
48647884|NCT04026958|DRUG|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
48118764|NCT01736891|DRUG|Placebo|Tablets, qd
48118765|NCT04382404|DRUG|Sofosbuvir-Velpatasvir Drug Combination|One pill once a day for 12 weeks
48118766|NCT04746131|DRUG|IMM0306|IMM0306 is an bi-specific antibody
48118767|NCT03014947|DRUG|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
48488164|NCT05758220|DEVICE|MRI|Structural MRI volumetry, resting functional MRI \& MR spectroscopy
48488165|NCT03501836|DEVICE|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
48118768|NCT03014947|DRUG|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
48488166|NCT03914768|BIOLOGICAL|Immunomodulatory DC vaccine to target DIPG and GBM|This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
48488167|NCT01597479|DRUG|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
48488168|NCT05492370|DIETARY_SUPPLEMENT|EpiCor|2 gummies daily
48488169|NCT05492370|DIETARY_SUPPLEMENT|Placebo|2 gummies daily
48647885|NCT04026958|DRUG|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
48647886|NCT06501248|DRUG|Triticum Aestivum|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
48323592|NCT03489681|DEVICE|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
48323593|NCT04023942|BEHAVIORAL|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
48323594|NCT03299855|OTHER|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
48323595|NCT03659370|OTHER|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
48647887|NCT06501248|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
48647888|NCT06290037|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
48647889|NCT06290037|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
48647890|NCT06290037|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
48647891|NCT06290037|OTHER|Short Physical Performance Battery|Evaluation of functional capability and provide a measure of the biological age of an older individual by measuring lower extremity physical performance status(standing balance, walking speed, and chair stand tests).
48323596|NCT03659370|OTHER|Acupuncture|Acupuncture
48323597|NCT04357990|DEVICE|Viruxal Oral and Nasal Spray|Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
48647892|NCT06290037|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
47970377|NCT01367002|DRUG|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
48323598|NCT04357990|OTHER|Placebo|The placebo will be a similar spray containing saline only.
48323599|NCT06087952|OTHER|Randomised treatment advice (discontinue vs continue after 3 months)|Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score
48323600|NCT06087952|DIAGNOSTIC_TEST|VTE-BLEED score|Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score
48323601|NCT06087952|DIAGNOSTIC_TEST|L-TRRiP score|Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score
47970378|NCT04517812|OTHER|Exercise-based games via the VirtualRehab platform|A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
47970379|NCT02495285|DRUG|Gelofusine 4%|
48647893|NCT06536855|BIOLOGICAL|Gardasil 9|"GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.~GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11."
48647894|NCT02914483|BEHAVIORAL|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
47970380|NCT02495285|DRUG|Gelaspan 4%|
48118769|NCT03014947|DRUG|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
48118770|NCT01678872|DRUG|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
48118771|NCT06196177|DRUG|Levosimontane injection|Levosimendan injection was given once intravenously with a micro-pump: 12.5mg levosimendan injection was diluted with 5% glucose injection to 50ml at the initial pump speed of 2ml/h for 24h.
48118772|NCT01198028|DRUG|Erlotinib|Given PO
48118773|NCT05081999|OTHER|Medical Assessment|medical hx, events inquiry, adherence to treatment arm periodically over 4 years
48118774|NCT05081999|OTHER|Quality of Life Assessment|online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
47970381|NCT04362982|OTHER|ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.|Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
47970382|NCT02034201|DRUG|Lisdexamfetamine|
47970383|NCT02034201|DRUG|Placebo|
47970384|NCT06117657|DRUG|Low dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.
47970385|NCT06117657|DRUG|Middle dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.
47970386|NCT06117657|DRUG|High dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.
47970387|NCT01023620|DRUG|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
47970388|NCT01023620|OTHER|Observation|Participants will be observed for 16 weeks but will not receive drug
47970389|NCT04404296|DEVICE|25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy|Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
47970390|NCT04115839|DRUG|Filgotinib|Tablets will be administered orally once daily with or without food.
47970391|NCT04115839|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
47970392|NCT04234178|DRUG|Epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
48323602|NCT06087952|OTHER|Advise to continue anticoagulant treatment after 3 months|Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
48488170|NCT01405131|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
48647895|NCT02914483|BEHAVIORAL|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
47970393|NCT04234178|DRUG|Intrathecal+Epidural|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
48647896|NCT02914483|DIAGNOSTIC_TEST|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
48647897|NCT04098783|OTHER|Home visit, health education|
47970394|NCT02551978|OTHER|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
47970395|NCT02481232|BIOLOGICAL|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
48118775|NCT00809497|DRUG|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
48118776|NCT04837976|OTHER|Semi-structured interviews and a consensus workshops using nominal group techniques.|Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.
48118777|NCT01457612|DIETARY_SUPPLEMENT|Strawberry|20g twice per day (BID) in beverage
48118778|NCT01457612|DIETARY_SUPPLEMENT|Placebo1|Placebo Beverage 1 without fiber
48118779|NCT01457612|DIETARY_SUPPLEMENT|Placebo2|Placebo Beverage 2 with Fiber
48118780|NCT00328835|PROCEDURE|Brief Elevation of IOP|
48118781|NCT05238480|DEVICE|XC mouthguard|Use of a Xtreme Conventional custom-made mouthguard while playing rugby
48323603|NCT06087952|OTHER|Advise to discontinue anticoagulant treatment after 3 months|Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
48323604|NCT00720421|DRUG|AZD7325|AZD7325 10 mg oral 2 capsules
48323605|NCT00720421|DRUG|AZD7325|AZD7325 1 mg oral 2 capsules
48323606|NCT00720421|DRUG|AZD7325|AZD7325 Placebo oral 2 capsules
48647898|NCT00370955|PROCEDURE|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
48647899|NCT02522221|DRUG|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
48647900|NCT02522221|DRUG|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
48323607|NCT00720421|DRUG|Lorazepam|Lorazepam 1 mg oral 2 tablets
48323608|NCT00720421|DRUG|Lorazepam|Lorazepam Placebo oral 2 tablets
48323609|NCT06082869|DRUG|Protegera™ toothpaste (NaF)|Plaque Reduction
48323610|NCT06082869|DRUG|Crest™ Cavity Protection toothpaste (NaF)|Plaque Reduction
48323611|NCT00546039|DRUG|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
48323612|NCT00546039|DRUG|Placebo|Capsule
48488171|NCT01405131|DRUG|methylprednisolone|tablets 32 mg single dose
48488172|NCT00988936|DRUG|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
48488173|NCT05893381|DRUG|[177Lu]Lu-PSMA I&T|The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
48323613|NCT04005196|DIAGNOSTIC_TEST|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
48323614|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
48323615|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
48323616|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
48323617|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
48323618|NCT03102320|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
48323619|NCT03102320|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
48323620|NCT03102320|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
48323621|NCT00368498|DRUG|teicoplanin|
48323622|NCT05208723|BEHAVIORAL|Stress and emotion management|The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
48323623|NCT00205699|DRUG|risperidone|randomized to begin 12 week trial of risperidone
48323624|NCT00205699|DRUG|olanzapine|randomized to begin 12 week trial of olanzapine
48323625|NCT00205699|DRUG|aripiprazole|randomized to 12 week trial of aripiprazole
48647901|NCT04702607|PROCEDURE|contrast enhanced 4DCT|Functional Lung Imaging with DECT and 4DCT
48647902|NCT00170365|BEHAVIORAL|Restorative Yoga|
47970396|NCT05416398|OTHER|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
47970397|NCT02551965|OTHER|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
47970398|NCT05071469|OTHER|Kinesiotaping|KT was applied.
47970399|NCT05071469|OTHER|Mulligan Mobilization Technique|MMT was applied
47970400|NCT03033394|DRUG|Beta-lactam antibiotic|Routine clinical dosing
47970401|NCT01102504|DRUG|Placebo|Placebo
47970402|NCT01102504|DIETARY_SUPPLEMENT|Ateronon|Tomato extract containing 28 mg lycopene/ day
47970403|NCT05863832|DRUG|Ciprodiazole|Ciprofolxacin 500 mg / Metronidazole 500 mg
47970404|NCT05863832|DRUG|Ciprofloxacin Tablets & Metronidazole tablets|Ciprofolxacin 500 mg + Metronidazole 500 mg
47970405|NCT05657444|DRUG|Tenecteplase|intra-arterial tenecteplase during endovascular treatment
48118782|NCT05238480|DEVICE|XP mouthguard|Use of a Xtreme Pro custom-made mouthguard while playing rugby
48118783|NCT02301208|DRUG|Nedaplatin|Nedaplatin combine with IMRT
48118784|NCT02301208|DRUG|Cisplatin|Cisplatin combine with IMRT
48118785|NCT01566916|PROCEDURE|Total Hip Arthroplasty|
48118786|NCT01404182|BIOLOGICAL|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
48323626|NCT03177265|BEHAVIORAL|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
48323627|NCT03177265|BEHAVIORAL|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
48323628|NCT03177265|BEHAVIORAL|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
48323629|NCT03177265|BEHAVIORAL|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
48323630|NCT04615702|DIAGNOSTIC_TEST|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~1. Clinically (abdominal pain consistent with acute pancreatitis),~2. Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~3. Imaging criteria of acute pancreatitis"
48323631|NCT04615702|DEVICE|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
48323632|NCT04615702|DEVICE|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
48647903|NCT04802005|OTHER|Aerobic Interval Training|The aerobic interval training group
48647904|NCT05613179|PROCEDURE|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
48323633|NCT04615702|DIAGNOSTIC_TEST|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
48323634|NCT04615702|DEVICE|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
48647905|NCT05613179|PROCEDURE|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
48647906|NCT04050436|DRUG|Cemiplimab|Cemiplimab administered intravenously
48647907|NCT04050436|BIOLOGICAL|RP1|RP1 administered intratumorally
48647908|NCT00736151|DRUG|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
48323635|NCT04615702|DRUG|Ringer lactate|"The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
48488174|NCT05893381|RADIATION|Stereotactic Radiotherapy|Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
48488175|NCT02979093|DRUG|Oxytocin|All women will receive a nasal spray containing oxytocin.
48118787|NCT03947684|DEVICE|Transcranial Magnetic Stimulation Device|The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
48118788|NCT03958136|PROCEDURE|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis
48323636|NCT04615702|COMBINATION_PRODUCT|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
48323637|NCT04615702|COMBINATION_PRODUCT|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"* Mild attack: no antibiotic prophylaxis administered.~* Severe attack:~* Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~* Duration: Not more than 2 weeks~* Antibiotics given:~  * Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~ * Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~    b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~ * In case of pancreatic infection, Carbapenems ± metronidazole were given."
48323638|NCT04615702|DIETARY_SUPPLEMENT|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~* Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~* Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~* The nutrition started with small amount and increased gradually over 16hrs~* Infusion rate ꞊ Total caloric requirements / 16hrs"
48323639|NCT04615702|DEVICE|nasogastric tube|in case of ileus or vomiting
48323640|NCT04615702|PROCEDURE|retroperitoneal necrosectomy|"* General anesthesia , Supine position with 30 degree tilt towards the right side~* A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~* Then, aspiration is done from the possible collection.~* After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~* At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~* After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
48323641|NCT04615702|PROCEDURE|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
48323642|NCT04615702|PROCEDURE|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
48323643|NCT04615702|PROCEDURE|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
48488176|NCT02979093|DRUG|Placebos|All women will receive a nasal spray containing a placebo solution.
48488177|NCT02979093|PROCEDURE|Functional MRI scanning|Study participants undergo two functional MRI scans.
48118789|NCT03958136|BIOLOGICAL|Biomarkers blood, urine and microbiota samples|Biomarkers blood, urine and microbiota samples for multi-omic analysis
48118790|NCT03958136|BEHAVIORAL|Patient Reported Outcome (PRO)|Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
48118791|NCT02479906|DEVICE|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
48118792|NCT02479906|DEVICE|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
48323644|NCT04615702|PROCEDURE|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~* The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~* After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~* The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
48647909|NCT04052126|OTHER|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
48323645|NCT04615702|PROCEDURE|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
48323646|NCT05123898|PROCEDURE|Soft tissue augmentation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
48323647|NCT03090464|OTHER|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
48323648|NCT03368625|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
48323649|NCT03271788|OTHER|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
48323650|NCT05937217|OTHER|myofascial induction and direct scar release techniques|Manual therapy techniques used to reduce chronic lower transverse abdominal scars pain and improve quality of life of the affected women
48323651|NCT05937217|DEVICE|therapeutic ultrasound|Ultrasound petron (model SM 500) specifications: output frequency:1Mhz, output power:5W/cm², power intensity:5 degree (0.8-1.2-1.6-2.0-2.5), time intensity:5-30(step by 5 min) . It will be applied for both groups for 10 minutes
48323652|NCT02614287|DRUG|Galcanezumab|Administered SC
48488178|NCT02030314|DRUG|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
48488179|NCT03126357|OTHER|Product A|Usual Brand Cigarette
48488180|NCT03126357|OTHER|Product B|FT21039 an electronic tobacco vapor product
48488181|NCT03126357|OTHER|Product C|FT21092 an electronic tobacco vapor product
48488182|NCT03126357|OTHER|Product D|FT21018 an electronic tobacco vapor product
48488183|NCT03126357|OTHER|Product E|4mg nicotine gum
48488184|NCT00166153|DRUG|Mycophenolate Mofetil|
48488185|NCT05102136|DRUG|REGN9933|Administered intravenously (IV) or subcutaneous (SC) per the protocol
48488186|NCT05102136|DRUG|Placebo|Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol
48488187|NCT03216694|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
48488188|NCT01834430|DIETARY_SUPPLEMENT|enteral nutrition|
48488189|NCT04906317|DRUG|midazolam and dezocine|Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level
48488190|NCT04906317|DRUG|Propofol|standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
48488191|NCT05841290|PROCEDURE|Primary local anesthesia|Tooth will be anaesthetized using Local anesthesia containing Articaine with epinephrine 1:100,000.
48488192|NCT05841290|PROCEDURE|Supplemental local anesthesia|if needed
48488193|NCT05841290|PROCEDURE|Removal Of Caries and Access Cavity|• Access cavity will be performed using a carbide round steel bur and tapered diamond stone until complete deroofing.
48488194|NCT05841290|PROCEDURE|Rubber dam isolation of tooth|Rubber dam isolation of tooth using certain clamps .
48488195|NCT05841290|PROCEDURE|Bleeding control|bleeding is controlled by using excavator for the removing the pulp tissue . using a piece of cotton soaked with Sodium hypochlorite. using local anesthesia with vasoconstrictor if needed and if suitable for the patient.
48488196|NCT05841290|PROCEDURE|Canal negotiation|Coronal patency of the coronal and the Middle part of the canal using file #10 Apical patency of the apical part of the canal using #10
48488197|NCT05841290|PROCEDURE|Coronal flaring|Coronal flaring using Orifice opener of a certain Rotary system in and out motion first then brushing motion touching all the canal walls
48488198|NCT05841290|PROCEDURE|Working Length Determination (W.L)|Working length determination (W.L) using #10 K File , working length is recorded using apex locator and confirmatory radiograph.
48488199|NCT05841290|PROCEDURE|Glide path|Glide path of the canal Using #10 ,15 ,20 ,25 K files till becoming Super-Loose Inside the Canal at the recorded w.l to create a path for the rotary file .
48488200|NCT05841290|PROCEDURE|Irrigation|Irrigation using 5.25% sodium hypochlorite introduced using side vented needle
48488201|NCT05841290|PROCEDURE|Cleaning and shaping using rotary system|Cleaning and shaping using rotary system plus irrigation and apical patency between every rotary file .
48488202|NCT05841290|PROCEDURE|Second w.l determination|Second w.l determination using electronic apex locator before using final finishing rotary file .
48647910|NCT01006486|OTHER|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
48647911|NCT01006486|OTHER|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
48498025|NCT06088056|DRUG|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
48647912|NCT01942460|DRUG|Ferumoxytol|
48647913|NCT00000437|DRUG|Naltrexone Tablet and Nicotine Patch|
48647914|NCT00000437|DRUG|Naltrexone Tablet and Placebo Patch|
48647915|NCT00000437|DRUG|Placebo Tablet and Nicotine Patch|
48647916|NCT00000437|DRUG|Placebo Tablet and Placebo Patch|
48647917|NCT04717739|DEVICE|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
48647918|NCT02956863|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
48647919|NCT02956863|PROCEDURE|Exercises|Exercise for stretching and strength for neck muscles
48647920|NCT03263390|PROCEDURE|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
48647921|NCT03263390|DRUG|Anti Obesity Drugs|Response to FDA approved anti obesity medications
48647922|NCT04245605|PROCEDURE|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
48647923|NCT01670149|DRUG|Rifaximin|Tablets
48647924|NCT01670149|DRUG|Placebo|Tablets
48647925|NCT03778697|PROCEDURE|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
48647926|NCT04119024|PROCEDURE|Biopsy|Undergo biopsy
48647927|NCT04119024|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48647928|NCT04119024|PROCEDURE|Computed Tomography|Undergo CT scan
48647929|NCT04119024|DRUG|Cyclophosphamide|Given IV
48647930|NCT04119024|DRUG|Fludarabine Phosphate|Given IV
48647931|NCT04119024|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
48647932|NCT04119024|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
48647933|NCT04119024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48647934|NCT04119024|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48647935|NCT04290676|DRUG|DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
48647936|NCT02402907|DEVICE|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
48647937|NCT02402907|DEVICE|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
48647938|NCT00498407|DRUG|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
48647939|NCT03008213|DRUG|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
48647940|NCT06468943|DRUG|Polatuzumab Vedotin|1.8mg/kg/21d（d0） Intravenous infusion
48647941|NCT06468943|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
48647942|NCT06468943|DRUG|Rituximab|375mg/㎡/21d（d0） Intravenous infusion
48647943|NCT06468943|DRUG|Cyclophosphamide|750mg/㎡/21d（d1） Intravenous infusion
48647944|NCT06468943|DRUG|Doxorubicin|50mg/㎡/21d（d1） Intravenous infusion
48647945|NCT06468943|DRUG|Prednisone|100mg PO （d1-d5）/21d
48647946|NCT02524899|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
48647947|NCT02524899|DRUG|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
48647948|NCT02524899|DRUG|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
48647949|NCT01348906|PROCEDURE|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
48647950|NCT00831155|DRUG|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
48647951|NCT00002101|DRUG|Ethambutol hydrochloride|
48647952|NCT00002101|DRUG|Clarithromycin|
48647953|NCT00002101|DRUG|Rifabutin|
48647954|NCT02808611|DRUG|propranolol|Reduction of the ANS response
48647955|NCT02808611|DRUG|Placebo|
48647956|NCT00966446|DRUG|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
48647957|NCT00966446|DRUG|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
48647958|NCT06456684|DIAGNOSTIC_TEST|Fluoro[18F]promethazine|It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease
48647959|NCT04945369|OTHER|clinical and biological measurements and questionnaires|"Blood and urinary samples collection for evaluation of insulin resistance and of renal function analysis.~Assessment of body composition by BOP-POD and by impedancemetry. Assessment of pulse wave by popmetre. Assessment of physical activity by accelerometer and by questionnaire Questionnaires for analysis of eating behaviour"
48647960|NCT03773562|DRUG|Erenumab|Erenumab will be used per label instructions.
48647961|NCT06625086|OTHER|Convensional exercises|Exercises will be provided to individuals in the Self-Guided Exercise group through a brochure.
48647962|NCT06625086|OTHER|Supervised exercises|Exercises will be administered to individuals with PFPS under the supervision of a physiotherapist.
48647963|NCT06625086|OTHER|Web based exercises|The exercises will be administered to participants through a web-based application.
47970406|NCT06014268|OTHER|electronic clinical decision support system|"eCDSS will alert clinicians if patients with documented atrial fibrillation are admitted to the hospital under their care.~The eCDSS will consist of prompts appearing on patients' electronic health records asking clinicians to clinically assess the risk of stroke (using CHAD2AD2-VASc tool) and the risk of bleeding (using the ORBIT tool) and record the scores on ePJS. Recommendations include reviewing the stroke and bleeding scores in specific cases, referral to an anticoagulation clinic to reduce AF related stroke risk (a referral template and emails/ telephone of the OAC clinics will be provided) and managing modifiable bleeding risk factors."
47970407|NCT04487392|DRUG|Estrogen vaginal cream group (group A)|The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
47970408|NCT04487392|RADIATION|Photobiomodutation group (group B)|The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
47970409|NCT01949558|BEHAVIORAL|Dietary Intervention|
47970410|NCT02418702|DRUG|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
48647964|NCT05806528|OTHER|Ultrasound|Use ultrasound to make placental invasion index
47970411|NCT02418702|OTHER|placebo|20 patients will randomly be assigned a placebo
47970412|NCT06120387|PROCEDURE|Radical surgery|Radical nephroureterectomy
47970413|NCT06120387|RADIATION|Kidney sparing surgery+Postoperative radiotheray|Kidney sparing surgery+Postoperative radiotheray
48118793|NCT04981158|PROCEDURE|(Epidural /GA using tolerable endotracheal tube (TET) group, group II|patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.
48118794|NCT04981158|PROCEDURE|standard general anesthetic technique, control group, group I|patients will undergo standard general anesthesia with classic endotracheal tube
48118795|NCT04425551|PROCEDURE|laser light|laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
48118796|NCT02309034|BEHAVIORAL|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
48118797|NCT02309034|BEHAVIORAL|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
48118798|NCT02309034|OTHER|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
48647965|NCT05197374|DRUG|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
48323653|NCT00624728|RADIATION|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (\>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (\> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
48323654|NCT03714906|PROCEDURE|Stellate ganglion block|Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
48323655|NCT02719236|PROCEDURE|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed."
48647966|NCT01723839|DRUG|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
48647967|NCT00001311|DEVICE|heparin-surface modified intraocular lens|
48647968|NCT05315778|BIOLOGICAL|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
47970414|NCT05888766|DRUG|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
48647969|NCT06548620|DRUG|RD06-04 cell infusion|CAR T Cells
48647970|NCT04850963|DEVICE|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
47970415|NCT01839851|DRUG|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
47970416|NCT01839851|DRUG|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
47970417|NCT01308775|BEHAVIORAL|SIS.NET, Routine Follow-up|"* SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~* Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
47970418|NCT00950105|DRUG|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
48323656|NCT02719236|PROCEDURE|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
48647971|NCT04850963|DEVICE|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
48647972|NCT04850963|DEVICE|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
48647973|NCT01176500|DRUG|(18)Fluciclatide|
48647974|NCT05169593|DRUG|Biological Drug|Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
48647975|NCT03618069|DIAGNOSTIC_TEST|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
48647976|NCT01744626|DRUG|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
48647977|NCT01744626|DRUG|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
48647978|NCT06036264|OTHER|Collected of Datas|age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
48647979|NCT06036264|OTHER|semi-structured interview|Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
48647980|NCT01873508|DRUG|RO4917523|Fast release MR capsule, single dose
48118799|NCT04404686|DRUG|Indomethacin|Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
48118800|NCT04404686|DRUG|Nifedipine|Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
48647981|NCT01873508|DRUG|RO4917523|Target release MR capsule, single dose
48647982|NCT01873508|DRUG|RO4917523|Slow release MR capsule, single dose
48647983|NCT01873508|DRUG|RO4917523|\[13C\]-labeled tracer dose i.v.
48647984|NCT06184087|OTHER|Educational/Instructional|ICAP constructive-interactive engagement mode
48647985|NCT03275831|DEVICE|PluroGel|Surfactant based gel
48647986|NCT03275831|DEVICE|Intrasite gel|Hydrogel
48647987|NCT04514276|OTHER|consecutive fetoneonatal healthcare pathway|(1) early perceiving of pregnant women with higher risks for early fetal growth restrictions via color Doppler sonography, fetal biometry, haemogram check (currently additional screenings) (2) structured care of the high risk women who are pregnant (3) concerted neonatal health care (4) adapted paediatric aftercare, certain dates and responsible persons are scheduled.
48647988|NCT02056145|PROCEDURE|LFCNB|LFCNB - Normal Saline solution 10 cc
48647989|NCT02056145|PROCEDURE|FNB|FNB - Normal saline solution 10 cc
47970419|NCT02469753|DRUG|NSAIDs|continuous daily
48118801|NCT02917343|BEHAVIORAL|mirror therapy and repetitive task training|
47970420|NCT02469753|DRUG|NSAIDs|on demand
48118802|NCT00547469|DRUG|DDP733|
48118803|NCT02945098|OTHER|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
48118804|NCT02945098|OTHER|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
47970421|NCT02469753|DRUG|anti-TNF|
47970422|NCT01468012|DRUG|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
48118805|NCT03923101|DIAGNOSTIC_TEST|Topographic, tomographic and biomechanical analysis.|"The study is based upon data obtained during routine medical follow-ups using~1. the Pentacam high resolution (Oculus, Wetzlar, Germany)~2. the Corvis ST (Oculus, Wetzlar, Germany)~3. the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~4. the Ocular Response Analyzer (Reichert Technologies, New York, USA)."
48118806|NCT02979808|DEVICE|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
48323657|NCT02531464|OTHER|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
47970423|NCT01468012|DRUG|Placebo|matched placebo for LCE condition dosed twice daily
47970424|NCT01015898|RADIATION|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
47970425|NCT04176757|DRUG|ZN-c5|ZN-c5 study drug to be administered orally daily
47970426|NCT00496808|DRUG|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
47970427|NCT04218825|DRUG|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
47970428|NCT02131207|DEVICE|magnetic resonance imaging|Undergo pelvic MRI
47970429|NCT02131207|PROCEDURE|prostate biopsy|Undergo prostate biopsy
48323658|NCT05879627|DRUG|BAT8007 for injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
48118807|NCT04478851|BEHAVIORAL|Group Exercise Classes|The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
48647990|NCT02056145|PROCEDURE|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
47970430|NCT05965154|DRUG|Carrilizumab, bevacizumab,capecitabine|"1. Carrilizumab: 200mg/ cycle, three weeks as a treatment cycle, the first day of each cycle, intravenous drip;~2. Bevacizumab: 7.5mg/kg, intravenous infusion on the first day of each cycle, every 3 weeks for 1 cycle (Q3W);~3. Capecitabine: 1250mg/m2, three weeks as a treatment cycle, oral twice a day (once in the morning and once in the evening; Stop the drug for 1 week after 2 weeks of treatment."
47970431|NCT02627105|BEHAVIORAL|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
48323659|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg QD|4-mg Leuprolide oral tablet once daily for 28 consecutive days.
48323660|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg BID|4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
48323661|NCT02807363|DRUG|Leuprolide Depot|3.75 mg intramuscular depot injection
48323662|NCT02807363|DRUG|Leuprolide Oral Tablet 10-mg BID|10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
48323663|NCT00131820|BIOLOGICAL|Typhoid Vi vaccine|
48323664|NCT00131820|BIOLOGICAL|Hepatitis A (control)|
48323665|NCT01736254|DRUG|Evacetrapib|
48323666|NCT01736254|DRUG|Gemfibrozil|
48323667|NCT03016026|PROCEDURE|ERAS|Undergo an ERAS program
48323668|NCT05319080|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
48323669|NCT00693680|DIETARY_SUPPLEMENT|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
48323670|NCT00693680|DIETARY_SUPPLEMENT|Placebo|placebo + imipramine (100-200mg/day)
48647991|NCT02056145|PROCEDURE|FNB|FNB - Chirocaine 0.25%, 20 cc
48323671|NCT00004095|DRUG|gemcitabine hydrochloride|
48323672|NCT00004095|DRUG|irinotecan hydrochloride|
48647992|NCT02957903|DRUG|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
48647993|NCT02957903|DRUG|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
48647994|NCT04314973|DEVICE|Active Pelvis Orthosis|Walking with the robotic device providing the assistive protocol.
47970432|NCT02627105|BEHAVIORAL|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
48323673|NCT00545987|DEVICE|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
47970433|NCT01523353|BEHAVIORAL|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
47970434|NCT01230905|RADIATION|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
47970435|NCT02073760|OTHER|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
48323674|NCT00545987|DEVICE|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
48323675|NCT03548974|BEHAVIORAL|Treatment group 1|The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
48323676|NCT03548974|BEHAVIORAL|Treatment group 2|The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
48323677|NCT05698745|PROCEDURE|bioespecimen samples|Blood, serum, plasma, urine, stools, small/large bowel tissue.
48498026|NCT06026774|BIOLOGICAL|iNeo-Vac-R01 in combination with standard adjuvant therapy|Personalized mRNA vaccine encoding neoantigen, IH injection
48498027|NCT03728855|BEHAVIORAL|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
48498028|NCT04051112|DRUG|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
48647995|NCT04314973|OTHER|Walking exercises|Walking exercises without wearing the robotic device.
48647996|NCT03434886|OTHER|CFView|Registry patient portal
48647997|NCT03434886|OTHER|CF educational videos|CF educational videos
48323678|NCT06148012|OTHER|dental implant|"Digital panoramic radiographs taken during the patients' treatment periods (T0, T1) were used in the study. Measurements of marginal bone levels on radiographs were performed using the Image J software. The distance between the most coronal part of the implant neck and the most apical part of the defect caused by marginal bone loss was measured.~Fractal analysis (FA) was conducted on panoramic radiographs (OPG) with a size of 2952x1435 pixels and a depth of 32 bits. FA on these radiographs at T0 and T1 times was performed using the box counting method determined by White and Rudolp with the ImageJ program(23)."
47970436|NCT05012488|OTHER|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
47970437|NCT02978430|DEVICE|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
47970438|NCT02978430|OTHER|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
47970439|NCT00959231|DRUG|cyclophosphamide|
47970440|NCT00959231|DRUG|cyclosporine|
47970441|NCT00959231|DRUG|fludarabine phosphate|
47970442|NCT00959231|DRUG|mycophenolate mofetil|
47970443|NCT00959231|OTHER|laboratory biomarker analysis|
47970444|NCT00959231|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
47970445|NCT00959231|PROCEDURE|umbilical cord blood transplantation|
47970446|NCT00959231|RADIATION|total-body irradiation|
47970447|NCT02414997|PROCEDURE|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
47970448|NCT02414997|PROCEDURE|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
48323679|NCT03134313|DEVICE|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
48323680|NCT03662633|DIAGNOSTIC_TEST|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
48323681|NCT03662633|DIAGNOSTIC_TEST|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
48323682|NCT04083898|BIOLOGICAL|Isatuximab|Isatuximab will be administered on a 28-day cycle
48323683|NCT04083898|DRUG|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
48323684|NCT04083898|DRUG|Prednisone|Prednisone will be administered on a 28-day cycle as follows
48323685|NCT01155596|BEHAVIORAL|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
48323686|NCT01836211|OTHER|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
48323687|NCT01836211|OTHER|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
48323688|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
48323689|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
48323690|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
48323691|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
48323692|NCT03943953|BEHAVIORAL|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~1. Facial palsy: Coping with the early stages.~2. Facial palsy: Coping with comments, questions and staring.~3. Facial palsy: Communicating with confidence.~4. Facial palsy: Managing anxiety.~5. Facial palsy: Managing your mood.~6. Facial palsy: Building your self-esteem.~7. Facial palsy: Advice for friends, family and partners."
48647998|NCT01607008|OTHER|MRI imaging|"3 total MRI imaging studies:~1. pre standard radiation treatment~2. during standard radiation treatment~3. post standard radiation treatment"
48647999|NCT06183593|OTHER|Radiofrequency application|Radiofrequency stimuli will be applied at pain threshold intensity. Arm and leg will be stimulated.
48648000|NCT06183593|OTHER|Pinprick stimuli|Pinprick stimuli will be administered at varying speeds and forces using an automated device
48648001|NCT02862262|DEVICE|ARIES Bordetella Assay|
48648002|NCT00931541|DRUG|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
48648003|NCT00931541|DRUG|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
48648004|NCT04369326|OTHER|Community-Based TPT Initiation|Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy
48488203|NCT05841290|PROCEDURE|Apical gauging|"Establish the depth of apical constriction - this is the zero reading on your apex locator. your working length will be 0.5mm - 1mm short of this.~After cleaning and preparing the canal system to your working length, passively insert 02 taper hand files, starting from #15. If the file goes past the apical constriction (your working length + 0.5-1mm), then choose the next largest file and repeat.~When a file passively binds short of the apical constriction, that will be the upper limit of the apical constriction diameter. The smaller file before that would be the lower limit.~Apical gauging helps with:~Choosing the best master cone that closely matches canal length and taper Achieving true tug back - as opposed to false tug back! Minimising gutta percha extrusions during obturation"
48488204|NCT05841290|PROCEDURE|Activation of the irrigant|Activation of the irrigant using Manual Dynamic Agitation and Ultra x or eddy tips for activation
48323693|NCT06482580|OTHER|PNF exercise|Ankle and foot exercises practiced for 6 weeks.
48323694|NCT06482580|OTHER|Clam exercise|Hip exercise practiced for 6 weeks.
48323695|NCT06482580|OTHER|Short-foot exercise|Foot exercise practiced together for 6 weeks.
48488205|NCT05841290|PROCEDURE|Master cone check|Master cone check Clinically and confirmatory radiograph
47970449|NCT03088982|OTHER|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
47970450|NCT00187369|PROCEDURE|Method of Delivery|CS or VB
47970451|NCT03798405|BEHAVIORAL|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
48323696|NCT01832012|OTHER|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
48323697|NCT01832012|OTHER|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
48323698|NCT03111550|DEVICE|Investigational Intraocular Lens Device #1: TECNIS Model ZHR00|Intraocular lens replaces the natural lens removed during cataract surgery.
48323699|NCT03111550|DEVICE|Investigational Intraocular Lens Device #2: TECNIS Model ZQR00|Intraocular lens replaces the natural lens removed during cataract surgery.
48323700|NCT03111550|DEVICE|TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00|Intraocular lens replaces the natural lens removed during cataract surgery.
48488206|NCT05841290|DRUG|application of resin based sealer inside the canal in the resin based sealer group|application done by inserting inside the canal by spreader or master cone
48648005|NCT02829918|DRUG|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
48648006|NCT03765983|DRUG|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
48648007|NCT03765983|DRUG|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
48648008|NCT00764426|DRUG|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
48648009|NCT00764426|DRUG|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
48648010|NCT06606275|DRUG|Apixaban|Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, playing a crucial role in preventing blood clot formation. It is commonly prescribed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and for treating and preventing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
47970452|NCT04629352|DEVICE|Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)|In verum transcranial direct current stimulation (tDCS), patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
48118808|NCT05989035|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|"Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory."
48118809|NCT05074069|PROCEDURE|Gynaecological reconstruction|Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
48488207|NCT05841290|DIAGNOSTIC_TEST|application of the sillicon based sealer inside the canal in the sillicon based group|application done by injection inside the canal
48488208|NCT05841290|PROCEDURE|Obturation|done by lateral condensation technique
48648011|NCT06606275|DRUG|Warfarin|Warfarin is a vitamin K antagonist widely used as an anticoagulant to prevent thromboembolic events, particularly in conditions like atrial fibrillation, venous thromboembolism, and in patients with mechanical heart valves. It inhibits the enzyme vitamin K epoxide reductase, thereby reducing the activation of vitamin K-dependent clotting factors (II, VII, IX, X) and regulatory proteins C and S. Due to its narrow therapeutic index, warfarin requires regular monitoring of the International Normalized Ratio (INR) to optimize anticoagulation while minimizing the risk of bleeding. Warfarin's pharmacokinetics and pharmacodynamics can be influenced by genetic polymorphisms, diet, and drug interactions, necessitating individualized dosing strategies.
47970453|NCT04629352|DEVICE|Sham Accelerated Transcranial Direct Current Stimulation (acctDCS)|In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
47970454|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Metallic)|Calcaneus Displacement Osteotomy using two metallic screws
47970455|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Bio-integrative)|Calcaneus Displacement Osteotomy using two bio-integrative screws
48488209|NCT05841290|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"Pain is evaluated using visual analogue scale (VAS) which is a pain rating scale. Scores are based on measures that are self-reported of symptoms that are recorded through a single handwritten mark placed at one point along the length of a 10-cm line representing a continuum between the two ends of the scale; on the left end of the scale (0 cm) means no pain and the on the right end of the scale (10 cm) worst pain"
47970456|NCT05965505|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
48648012|NCT00833729|DRUG|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
48648013|NCT02518698|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
47970457|NCT00635167|DRUG|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
47970458|NCT00673803|PROCEDURE|cataract surgery|cataract surgery with implantation of an IOL
47970459|NCT04993521|PROCEDURE|Block type|Regular block type
47970460|NCT02207244|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
47970461|NCT02207244|DRUG|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
47970462|NCT02207244|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
47970463|NCT02207244|DRUG|Placebo for adalimumab|Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
47970464|NCT05069649|DRUG|Ergoferon|Tablet for oral use.
47970465|NCT05069649|DRUG|Placebo|Tablet for oral use.
48118810|NCT03084549|DRUG|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
48118811|NCT03084549|DRUG|Administration of placebo|Administration of placebo in the margins of the episiotomy
48118812|NCT04088123|DRUG|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
48118813|NCT03496103|BIOLOGICAL|ragweed pollen|three hours ragweed pollen in a allergen exposure chamber
48118814|NCT05493254|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
48648014|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
48648015|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
48648016|NCT00460915|DRUG|Lacidipine & Amlodipine|
48118815|NCT05493254|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
48118816|NCT03419013|OTHER|New adhesive strip|This strip is made of a newly developed adhesive
48648017|NCT01342042|BIOLOGICAL|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
48648018|NCT03382171|OTHER|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
48648019|NCT00484328|DRUG|Ribavirin|different dosing regimes of Ribavirin
48648020|NCT03015948|DRUG|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
47970466|NCT03293290|DRUG|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
47970467|NCT02244606|DRUG|SCY-078|
47970468|NCT02244606|DRUG|Fluconazole|
47970469|NCT02244606|DRUG|Micafungin|
47970470|NCT04352504|OTHER|Almond|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
47970471|NCT04352504|OTHER|Pretzel|Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
48118817|NCT01032798|DRUG|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
48118818|NCT00646035|DRUG|paricalcitol capsules|baseline iPTH/60
48648021|NCT03015948|DRUG|Placebo|a single dose of placebo (n=2) for each dose cohort .
48648022|NCT05313958|DRUG|Cladribine|5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
48648023|NCT05313958|DRUG|G-CSF|5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
47970472|NCT06411678|DRUG|68GA-DOTA-dPNE|Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection
47970473|NCT05489510|COMBINATION_PRODUCT|Pulsed or continuous lighting|The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).
47970474|NCT03609632|OTHER|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
47970475|NCT04070430|OTHER|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
48118819|NCT03410446|DRUG|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
48118820|NCT00025324|BIOLOGICAL|filgrastim|
48118821|NCT00025324|DRUG|carboplatin|
48648024|NCT05313958|DRUG|Cytarabine|2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
48648025|NCT05313958|DRUG|Idarubicin|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
48118822|NCT00025324|DRUG|cyclophosphamide|
48323701|NCT04599049|OTHER|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
48323702|NCT05360355|PROCEDURE|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
48323703|NCT00411736|DRUG|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
48648026|NCT05313958|DRUG|Mitoxantrone|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
47970476|NCT04070430|OTHER|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
47970477|NCT03009578|DRUG|Iron Sucrose Injection|iron Intramuscular injections
48118823|NCT00025324|DRUG|etoposide|
48118824|NCT00025324|DRUG|thiotepa|
48118825|NCT00025324|PROCEDURE|autologous bone marrow transplantation|
48118826|NCT00025324|PROCEDURE|bone marrow ablation with stem cell support|
48118827|NCT00025324|PROCEDURE|conventional surgery|
48118828|NCT00025324|PROCEDURE|peripheral blood stem cell transplantation|
48118829|NCT00025324|RADIATION|radiation therapy|
48118830|NCT06518538|DRUG|CPI-613, modified Folfirinox|"* CPI-613, devimistat~* mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan"
48118831|NCT03595852|DRUG|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
48118832|NCT03595852|DRUG|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
48118833|NCT02995655|DRUG|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
48118834|NCT02995655|DRUG|Azacitidine|Azacitidine at a dose of 75mg/m\^2 on Days 1-7 of each 28-day cycle.
48118835|NCT02995655|PROCEDURE|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
48118836|NCT02995655|PROCEDURE|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
48118837|NCT00744224|DRUG|Placebo|Single dose of placebo with saline infusion
48118838|NCT00744224|DRUG|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
48118839|NCT00744224|DRUG|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
48118840|NCT05184361|BEHAVIORAL|Intermittent energy restriction (IER)|"Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.~Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.~In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.~The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks."
48323704|NCT00411736|DRUG|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
48323705|NCT01757756|DRUG|Pf-05175157|200-mg administered twice daily for 14 days
48323706|NCT01757756|DRUG|placebo|placebo administered twice daily for 14 days
48323707|NCT01757756|DRUG|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
48323708|NCT06364631|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.
48488210|NCT05500573|PROCEDURE|Sperm Sorting|Selection of gender specific spermatozoa using a multilayer density gradient solution
48648027|NCT05313958|DRUG|Sorafenib|200mg/m2/day was taken orally until molecular biology remission for 2 years
47970478|NCT03009578|DRUG|Ferrous Bisglycinate|oral iron tablets
47970479|NCT02662296|DRUG|Ibrutinib|Given PO
47970480|NCT02662296|DRUG|Idelalisib|Given PO
47970481|NCT01950741|DRUG|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
47970482|NCT05449795|DEVICE|Device: Contour Next and Contour Plus Elite BGMS testing of arterial blood|The purpose of the study is to extend the intended use of two BGMSs to include testing of arterial blood by Health Care Professionals (HCP) in a clinical setting.
47970483|NCT06296966|DRUG|VSJ-110|ophthalmic solution
48118841|NCT05184361|BEHAVIORAL|Continuous energy restriction (CER)|A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
48323709|NCT06364631|DRUG|Ipilimumab|"The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion.~When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle."
48323710|NCT06364631|DRUG|Pembrolizumab|Pembrolizumab is to be administered as an approximately 30-minute IV infusion.
48323711|NCT06364631|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
47970484|NCT06296966|DRUG|Placebo|ophthalmic solution
47970485|NCT00171392|DRUG|Enteric-coated mycophenolate sodium|
48118842|NCT03366701|OTHER|Rehabilitation|The intervention (routine care) correspond to five weeks rehabilitation program
48323712|NCT06364631|DRUG|Axitinib|Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.
48323713|NCT06364631|DRUG|Lenvatinib|Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.
48323714|NCT00002386|DRUG|Indinavir sulfate|
47970486|NCT04635462|OTHER|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
48118843|NCT02698228|DRUG|Bupivacaine (femoral nerve block)|0.5% bupivacaine
48118844|NCT02698228|DRUG|Morphine|Intravenous injection of 0.1mg/kg of morphine
48118845|NCT02698228|DEVICE|Ultrasound|
48118846|NCT01877343|DEVICE|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
48118847|NCT05350475|RADIATION|Proton therapy|Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
48118848|NCT05350475|RADIATION|Photon therapy|Patients in the photon arm will receive standard treatment with photon therapy.
48118849|NCT00117702|DRUG|Tacrolimus|day 0-100, then taper
48118850|NCT00117702|DRUG|Everolimus|day 0-56
48118851|NCT01852071|GENETIC|Infusion of autologous EFS-ADA LV CD34+ (OTL-101)|autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
48118852|NCT01852071|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
48118853|NCT01852071|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
48118854|NCT01227278|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
48118855|NCT01227278|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
48323715|NCT00002386|DRUG|Lamivudine|
48323716|NCT00002386|DRUG|Stavudine|
48323717|NCT00002386|DRUG|Zidovudine|
48323718|NCT00002386|DRUG|Zalcitabine|
48323719|NCT00002386|DRUG|Didanosine|
48498029|NCT00002353|BIOLOGICAL|P3C541b Lipopeptide|
48498030|NCT00239044|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
48498031|NCT04701112|DEVICE|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
48498032|NCT03449927|OTHER|Specialized menu|-Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
48498033|NCT03449927|OTHER|Standard of care menu|-Standard registered dietitian support
48498034|NCT03449927|OTHER|Self report dietary intake worksheet|-Self report nausea and diarrhea
48498035|NCT03449927|OTHER|Post study questionnaire|-Completed upon count recovery and prior to discharge
48498036|NCT00476983|DRUG|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
48498037|NCT01490983|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
48498038|NCT01490983|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
48498039|NCT00057083|OTHER|Telemedicine Care|
48498040|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
48498041|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
48323720|NCT02229630|RADIATION|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
48323721|NCT03537352|PROCEDURE|Any appropriate surgical treatment|Any appropriate surgical treatment for the management of patient's current disorder
48323722|NCT03537352|DRUG|Any appropriate drug or non-drug treatment excluding surgery|Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
48323723|NCT02456376|PROCEDURE|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
48118856|NCT00834951|RADIATION|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
48323724|NCT02456376|PROCEDURE|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
48323725|NCT05197673|BEHAVIORAL|Theory of planned behaviours (TPB) based intervention|Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
48323726|NCT03694041|DRUG|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
48648028|NCT03139266|BEHAVIORAL|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
48648029|NCT03139266|BEHAVIORAL|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
48648030|NCT02579759|DRUG|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
48323727|NCT03694041|DRUG|SAD: Placebo|Drug: Placebo Placebo for 1day
48648031|NCT02579759|DRUG|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
47970487|NCT04635462|OTHER|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
47970488|NCT00717132|BEHAVIORAL|Individual Behavior Modification|Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
47970489|NCT00717132|BEHAVIORAL|Family-based behavior modification|Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
47970490|NCT04056910|DRUG|ivosidenib and nivolumab|"Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days."
48648032|NCT02579759|DRUG|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
48648033|NCT06221046|OTHER|Cream D|"Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 2 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 2 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment"
47970491|NCT02639143|DRUG|ticagrelor|
47970492|NCT02639143|DRUG|Clopidogrel|
47970493|NCT03576989|DIETARY_SUPPLEMENT|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
47970494|NCT03576989|OTHER|placebo|placebo contains mineral oil
48323728|NCT03694041|DRUG|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
48323729|NCT03694041|DRUG|MAD: Placebo|Matching study drug will be repeatedly administered.
48323730|NCT03694041|OTHER|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
48323731|NCT03694041|OTHER|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
48323732|NCT00111150|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily|
48323733|NCT06182813|OTHER|Beta auditory beats (Group A)|Beta auditory beats for 25 min and then perform alternate wall toss test.
48323734|NCT06182813|OTHER|white noise (Group B)|Involves participants receiving White noise for 25 min and then perform alternate wall toss test.
48648034|NCT06221046|OTHER|Control|"Prevention~1. Daily cleansing /moisturizing protection using 3-in-1 perineal wipes after each incontinence episode~2. Avoid rubbing/scrubbing~3. Reduce exposure to moisture as much as possible~4. Reassess frequently~Management - no clinical signs of infection~MILD/MODERATE~1. Continue with prevention methods, apply CREAM ARM 1 as a barrier product after every fecal incontinence event~2. Discontinue CREAM ARM 1 use after skin has healed~3. If no improvement after 3 days, consult a physician / NP~Management - with clinical signs of infection~FUNGAL: Continue with prevention methods, adding Clotrimazole 1% cream twice daily.~1. Prescribe order required for Clotrimazole 1% and must be reordered every 7 days unless prescribed for a longer duration~2. Discontinue use after the skin has healed~3. If no improvement after 3 days, consult a physician / NP~BACTERIAL: requires physician assessment"
48648035|NCT06404047|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
48648036|NCT06404047|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
48648037|NCT06404047|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
48648038|NCT06404047|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
48648039|NCT00964522|OTHER|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
47970495|NCT01929096|DRUG|Compound Edaravone Injection|
48118857|NCT02186769|DRUG|Risperdal® Consta®|
48118858|NCT02186769|DRUG|LY03004|
48323735|NCT06441110|DRUG|Tislelizumab in Combination with Bacillus Calmette-Guérin|Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.
48323736|NCT03351569|DRUG|Intravenous immunoglobulin|Intravenous drip.
48323737|NCT02860754|OTHER|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
48323738|NCT06342323|RADIATION|SBRT|the fiducial marker was implanted with 3D template assistance under CT guidance
48488211|NCT00666848|DRUG|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
48118859|NCT06499714|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 days at an altitude of 3600 m.
48118860|NCT04470401|DRUG|AbobotulinumtoxinA|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
48118861|NCT04470401|DRUG|Saline|application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
48118862|NCT03372473|DRUG|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg, one dose per day
47970496|NCT01929096|DRUG|Edaravone Injection|
48118863|NCT03372473|DRUG|Montelukast|Montelukast 5mg
48118864|NCT01801514|DEVICE|Computed Tomography scan|Routine Computed Tomography scan
48323739|NCT03317249|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram
48323740|NCT03317249|DIAGNOSTIC_TEST|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
48323741|NCT03317249|DIAGNOSTIC_TEST|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
48488212|NCT00666848|DRUG|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
48488213|NCT00666848|DRUG|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
47970497|NCT01691781|DRUG|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
47970498|NCT02367183|DRUG|GED-0301|
48118865|NCT02361918|PROCEDURE|Colon surgery|
48488214|NCT00666848|DRUG|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
48488215|NCT00188227|DRUG|Midazolam (sedative)|
48488216|NCT00188227|DRUG|Piritramid (analgetic)|
48488217|NCT00188227|BEHAVIORAL|Cognitive exercises|
48488218|NCT00308126|DRUG|Hydroxyethyl Starch 130/0.4 (Voluven)|
48498042|NCT01980966|DRUG|MHAA549A|IV dose
48118866|NCT03565055|BEHAVIORAL|IPCST|"Integrative Psychosocial \& Community Skills Training (IPCST) programme~The IPCST programme includes:~1. psychoeducation, internalized stigma reduction, \& strength and coping enhancement~2. motivational interviewing skills~3. Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~4. augmented supported employment with social skills training (Tsang, Fung, Li, Leung \& Cheung, 2010) and~5. family and patient involvement in care"
48118867|NCT03565055|BEHAVIORAL|E.A.S.Y|"The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~1. Extensive public education~2. Early referral and assessment~3. Ongoing treatment services"
48118868|NCT01941758|BIOLOGICAL|trivalent influenza vaccine|
48118869|NCT01941758|OTHER|laboratory biomarker analysis|Correlative studies
48118870|NCT04652583|DEVICE|Earstim - Active Stimulation|Intramuscular stimulation
48118871|NCT04652583|DEVICE|Earstim - Sham Stimulation|Sham stimulation
48118872|NCT03238313|BEHAVIORAL|Plan A|
48118873|NCT03238313|BEHAVIORAL|Toxic Life Cycle of a Cigarette|Video
48118874|NCT00757133|PROCEDURE|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
48118875|NCT00757133|PROCEDURE|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
48118876|NCT03703336|BIOLOGICAL|ROTAVIN (liquid formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 plaque forming units (PFU) of strain G1P\[8\] per dose of 2 mL.
48118877|NCT03703336|BIOLOGICAL|ROTAVIN-M1 (frozen formulation)|Live attenuated human rotavirus vaccine containing ≥ 2x10\^6 PFU of strain G1P\[8\] per dose of 2 mL.
48118878|NCT02301559|BEHAVIORAL|Pilates exercises|Pilates exercises with emphasis on pelvic region
48118879|NCT03149991|DRUG|Brexpiprazole|Administration of up to 3mg brexpiprazole
48118880|NCT03149991|DRUG|Ketamine|administration 6 times over two weeks of inhaled ketamine
48118881|NCT03149991|DRUG|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
48118882|NCT01075113|DRUG|sorafenib tosylate|Given orally
48118883|NCT01075113|DRUG|vorinostat|Given orally
48118884|NCT01726842|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
48118885|NCT05467319|DRUG|Ferric Derisomaltose Injection|1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
48118886|NCT05467319|DRUG|Normal saline|100 mL of 0.9% normal saline (w/v) by intravenous infusion
48118887|NCT00391846|DRUG|Captopril|
48118888|NCT00391846|DRUG|Enalapril|
48118889|NCT00391846|DRUG|Lisinopril|
48118890|NCT00391846|DRUG|Ramipril|
48118891|NCT00391846|DRUG|Trandolapril|
48118892|NCT00391846|DRUG|Bisoprolol|
48118893|NCT00391846|DRUG|Carvedilol|
48118894|NCT00391846|DRUG|Metoprolol succinate|
48118895|NCT00391846|DRUG|Candesartan|
48118896|NCT00391846|DRUG|Valsartan|
48118897|NCT00391846|DRUG|Eplerenone|
48118898|NCT00391846|DRUG|Spironolactone|
48118899|NCT00391846|DRUG|Diuretics|
48118900|NCT00391846|DRUG|HF treatment according to Swedish guidelines|
48118901|NCT00391846|PROCEDURE|Blood samples|
48118902|NCT00391846|PROCEDURE|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
48118903|NCT05563168|DRUG|DILTIAZEM TEVA 60 mg or placebo|DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
48118904|NCT05146375|BIOLOGICAL|TGFBR2|"TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis."
48118905|NCT01759771|DRUG|Vitamin D3|4,000 IU of VD3 for at least one year
48118906|NCT01759771|DRUG|Placebo|Placebo for at least one year
48118907|NCT04421469|DRUG|Triprilimab(JS001)|"1. JS001 240mg d1, gemcitabine(1g/m²),d1,8 + nedaplatin (80-100mg/m²),d2,q3w,6cycles.The curative effect was evaluated every 2 cycles.If the therapeutic evaluation was SD,the chemotherapy scheme was changed;~2. Local treatment of active lesions(including radiotherapy and/or radiofrequency ablation);~3. JS001 maintenance treatment."
48118908|NCT04077164|OTHER|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
48118909|NCT04459169|PROCEDURE|diagnostic algorithm|Cardiac amyloidosis diagnosed according to Gillmore's algorithm
48118910|NCT00405535|DRUG|glycine|
48118911|NCT00405535|OTHER|placebo|
48118912|NCT04718688|OTHER|CO-OP rehabilitation|"The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them."
48118913|NCT03135184|DEVICE|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
48118914|NCT02847780|DEVICE|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
48488219|NCT00033904|DRUG|autologous human tumor-derived HSPPC-96|
48118915|NCT02847780|DEVICE|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
47970499|NCT02367183|DRUG|Placebo|
48118916|NCT03551535|BEHAVIORAL|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
48118917|NCT01102231|DRUG|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
48118918|NCT01102231|DRUG|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
48118919|NCT01102231|RADIATION|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
48118920|NCT01070069|DEVICE|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
48118921|NCT01070069|DEVICE|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
47970500|NCT05540353|DEVICE|Transvaginal photobiomodulation|Low light laser therapy applied transvaginally using a small vaginal wand with sterile disposable wand covers. The intervention last 3-5 minutes based on a surface area calculation performed at the beginning of the intervention, and involves a gentle in and out motion of the wand to deliver light energy to the muscles of the pelvic floor.
48118922|NCT01070069|DEVICE|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
48118923|NCT01620034|RADIATION|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
48118924|NCT05724420|BEHAVIORAL|STRIVE course delivery|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session..
48118925|NCT02003469|DEVICE|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
48323742|NCT03317249|DIAGNOSTIC_TEST|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
48488220|NCT00998972|DRUG|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
47970501|NCT05540353|DEVICE|Sham therapy|Use of the same vaginal wand as active arm, but without activation of the machine. The intervention last 3-5 minutes, and involves a gentle in and out motion of the wand to massage the muscles of the pelvic floor, without delivery of light therapy.
47970502|NCT01332500|DRUG|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
48118926|NCT05142202|RADIATION|Breast Irradiation after Breast-Conserving Surgery|All recruited participants will be treated with adjuvant to breast-conserving surgery accelerated partial breast irradiation with multicatheter interstitial brachytherapy technique and prescribed five times 5,4 Gy delivered in 3 consecutive days (6 hours minimum gap between the fractions). Treatment starts not later than 12 weeks after surgery (optimally 4-8 weeks), after wound healing, and obtaining the final pathological report with full immunohistochemistry and proper risk group assignment.
48118927|NCT00592410|DRUG|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
48323743|NCT03317249|OTHER|Echocardiogram|optional (for non-IST participants only)
48488221|NCT05963191|DEVICE|Colorectal cancer screening with CAD EYE colonoscopy|"The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis."
48648040|NCT04442750|PROCEDURE|Erector spinae plane block Technique|The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.
47970503|NCT01332500|DRUG|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
47970504|NCT03149198|OTHER|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
48498043|NCT01980966|DRUG|Placebo|IV dose
48323744|NCT06490198|DRUG|OBI-833/OBI-821|"OBI-833 is a glycoconjugate that consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as the carrier protein.~OBI-821 is a saponin-based adjuvant derived from the bark of the Quillaja saponaria Molina tree. It is a purified saponin adjuvant structurally similar to adjuvant QS-21. The OBI-833/OBI-821 combination represents a carbohydrate-conjugate vaccine combined with an immune adjuvant, intended to serve as an active cancer immunotherapy."
48323745|NCT03064958|OTHER|Herbs and spices|Mix of commonly used herbs and spices
48323746|NCT03064958|OTHER|High fat meal|Meal containing 1000kcal and 45g fat
48648041|NCT04442750|PROCEDURE|General anesthesia|"Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\\kg will be provided every 30 minutes.~Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels.~At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes."
48648042|NCT04442750|DRUG|Bupivacaine 0.5%|The patient will receive 30ml bupivacain 0.5% in erector spinae block
48118928|NCT04802369|DIAGNOSTIC_TEST|Diagnostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of arterial hypertension, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, non-invasive assessment for central arterial pressure waveform analysis and body mass analysis.
48118929|NCT00242359|DRUG|omalizumab|
48118930|NCT00106080|BEHAVIORAL|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
48118931|NCT02685189|OTHER|Previous exposure to stannsoporfin|No intervention in this protocol
48323747|NCT00067314|DRUG|Edotecarin|
48323748|NCT05072717|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
48323749|NCT01807195|OTHER|contrast medium usage|
48488222|NCT05520593|DIETARY_SUPPLEMENT|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
48488223|NCT04275726|DEVICE|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
48498044|NCT01980966|DRUG|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
48498045|NCT02384135|OTHER|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
48648043|NCT04442750|DRUG|Bupivacaine 0.375%|The patient will receive 30ml bupivacain 0.375% in erector spinae block
48648044|NCT04442750|DRUG|Bupivacaine 0.25%|The patient will receive 30ml bupivacain 0.25% in erector spinae block
48648045|NCT05547854|BEHAVIORAL|Behavior Therapy Training Institute|In-person therapist training will follow the Tourette Association of America's established Behavior Therapy Training Institute procedures and will consist of 12 hours of in-person training conducted over the course of 2 days. Day 1 will involve standardized didactic lectures on tic disorders and video demonstrations of therapeutic techniques. Day 2 will involve break-out groups and role-play practice of CBIT techniques. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a training instructor while providing CBIT to a study-enrolled patient.
48648046|NCT05547854|BEHAVIORAL|CBIT-Trainer|In the online therapist training condition participants will be provided with access to the CBIT-Trainer program and asked to complete the training over the course of 4 weeks. CBIT-Trainer is designed for the average user to complete in approximately 12 hours. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a CBIT expert while providing CBIT to a study-enrolled patient.
48648047|NCT04256018|DRUG|Mogamulizumab|Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
48648048|NCT04256018|RADIATION|LD TSEBT|Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
47970505|NCT03149198|OTHER|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
48323750|NCT04462757|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
48323751|NCT00845546|DRUG|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
48323752|NCT03335956|DRUG|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
48323753|NCT03335956|DRUG|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
48323754|NCT03335956|DRUG|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
48323755|NCT03335956|DRUG|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
48648049|NCT02898610|DRUG|Colchicine|
48648050|NCT05452005|DRUG|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
48648051|NCT02193347|BIOLOGICAL|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
47970506|NCT02256852|BIOLOGICAL|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
47970507|NCT05769439|OTHER|No intervention in an observational study|This study is an observational study only.
47970508|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
47970509|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
47970510|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
47970511|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
47970512|NCT01385566|BIOLOGICAL|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
47970513|NCT01385566|BIOLOGICAL|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
47970514|NCT04026997|DRUG|CIN-102 Dose 1|CIN-102 Dose 1
47970515|NCT04026997|DRUG|CIN-102 Dose 2|CIN-102 Dose 2
47970516|NCT04026997|DRUG|CIN-102 Dose 3|CIN-102 Dose 3
47970517|NCT04026997|DRUG|Placebo|Placebo
47970518|NCT03087669|DEVICE|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
47970519|NCT03087669|DRUG|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
47970520|NCT03870698|PROCEDURE|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
47970521|NCT03695250|DRUG|IDO1 Inhibitor BMS-986205|Given PO
47970522|NCT03695250|BIOLOGICAL|Nivolumab|Given IV
47970523|NCT05771376|OTHER|Qigong exercise program|"The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks."
47970524|NCT05771376|OTHER|Home exercise program|"The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks."
47970525|NCT00960778|DRUG|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
47970526|NCT00960778|OTHER|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
47970527|NCT06169696|DEVICE|Intervention/Treatment|Non-invasive EEG headband device
47970528|NCT01308671|DRUG|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
47970529|NCT01308671|BEHAVIORAL|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
47970530|NCT04773860|OTHER|Muscle Energy Techniques|A 4 week intervention will be carried out consisting of Muscle Energy Techniques on the accessory muscle of respiration. That is, Pectoralis Minor, Sternocleidomastoid, Upper trapezius, Scalene muscles and Latissimus Dorsi
48323756|NCT03335956|DRUG|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
48648052|NCT02193347|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
48648053|NCT02193347|DRUG|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
48648054|NCT03931811|DEVICE|Short wave diathermy|SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
48648055|NCT03931811|OTHER|Prolotherapy|Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
48648056|NCT00803049|DRUG|Teriflunomide (HMR1726)|Tablet, oral administration QD.
48648057|NCT06570642|BEHAVIORAL|Physical Activity Goals mHealth Intervention|On days participants plan to exercise, they engage in two daily goal sessions (morning and evening). Morning sessions provide an activity goal for the day and ask the participant to create a plan, anticipate barriers, and brainstorm solutions for achieving this goal. The affect-based goal condition asks participants to engage in either (1) a type (50% of daily goals) or (2) a context (50% of daily goals) of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity (1) in a place; (2) in a social situation; or (3) while listening to something that makes them feel good. The intensity-based goal condition asks participants to maintain a certain target heart rate range during physical activity. Starting heart rate reflects the approximate age-adjusted heart rate max, with goals progressively increasing from 55% to 70% heart rate max.
48648058|NCT06570642|BEHAVIORAL|TYPE/CONTEXT enhancement|TYPE/CONTEXT augments intervention effects by providing tailored recommendations for activity types and contexts that satisfy personally-important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk will be used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm will then recommend the corresponding activity type or context while accounting for reported constraints (e.g., ability, access). These details will be incorporated into a tailored recommendation provided to participants each Sunday as they make activity plans for the upcoming week. Specifically, the program will randomly select either type or context (i.e., location, audio, social) recommendations and will rotate every two weeks. For TYPE, participants' top 3 activity types are recommended; for CONTEXT, participants' top 3 activity contexts are recommended.
48648059|NCT06570642|BEHAVIORAL|SAVOR enhancement|SAVOR implements a brief savoring exercise on the smartphone that takes place either after the planned physical activity session or during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer three open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty. Savoring prompts will rotate daily and have a day lag built in every week (i.e., Week 1 Monday Savoring Prompts are Week 2 Tuesday Savoring Prompts).
48648060|NCT00002171|DRUG|Nelfinavir mesylate|
48648061|NCT03016702|OTHER|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
48323757|NCT03335956|DRUG|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
47970531|NCT01952405|BEHAVIORAL|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
47970532|NCT00025272|DRUG|carboplatin|
48323758|NCT03335956|DRUG|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
47970533|NCT00025272|DRUG|etoposide|
47970534|NCT00025272|DRUG|topotecan hydrochloride|
47970535|NCT00025272|RADIATION|radiation therapy|
47970536|NCT02893943|DIETARY_SUPPLEMENT|Probiotics|
47970537|NCT02893943|DIETARY_SUPPLEMENT|Placebo|
47970538|NCT00522197|DIETARY_SUPPLEMENT|multi-herbal agent ACAPHA|
47970539|NCT00522197|DIETARY_SUPPLEMENT|Sugar Pill|
47970540|NCT01895569|DRUG|Metformin|Metformin will be added to therapy for the first threre months.
47970541|NCT01895569|DRUG|Pioglitazone|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin, pioglitazone will be added.
48323759|NCT03335956|DRUG|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
48323760|NCT03335956|DRUG|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
48323761|NCT03335956|DRUG|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
47970542|NCT01895569|DRUG|Sitagliptin|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
47970543|NCT05199129|DRUG|HCP1904-3|Take once daily for 8 weeks orally
47970544|NCT05199129|DRUG|RLD2001-1|Take once daily for 8 weeks orally
47970545|NCT03103568|DRUG|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
48323762|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
48323763|NCT03335956|DRUG|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
48323764|NCT03335956|DRUG|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
48323765|NCT03335956|DRUG|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
48323766|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
48323767|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
48648062|NCT03016702|OTHER|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
48648063|NCT00128492|DRUG|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
48648064|NCT03211858|DRUG|Insulin aspart|SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 millimoles/liter \[mmol/L\] \[\<180 milligram/deciliter {mg/dL}\]) while avoiding hypoglycemia.
48648065|NCT03211858|DRUG|NovoLog/NovoRapid|NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
48648066|NCT03211858|DRUG|Insulin glargine (HOE901)|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
48323768|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
48648067|NCT03614832|DRUG|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
48648068|NCT03614832|DRUG|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
48648069|NCT05594875|DRUG|SHR-1921|Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
48648070|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from fillet|Intact cod protein from fillet 8 g protein daily for 8 weeks
48648071|NCT03538821|DIETARY_SUPPLEMENT|Intact cod protein from residual material|Intact cod protein from residual material, 8 g protein daily for 8 weeks
48648072|NCT03538821|DIETARY_SUPPLEMENT|Control|Control group receive tablet containing fillers
48648073|NCT06232993|OTHER|Kinesio taping|Kinesio taping is a technique that involves the application of a special elastic tape to the skin to provide support to muscles and joints without restricting the body's range of motion. This method is designed to facilitate the body's natural healing process and improve muscle function while providing support and stability to muscles and joints. Kinesio tape is believed to help reduce pain, support muscles during movement, and aid in rehabilitation. It is commonly used in sports medicine and physical therapy to address a variety of musculoskeletal conditions and injuries.
48648074|NCT06232993|OTHER|Occlusal Splinting|Occlusal splinting, also known as a bite guard or night guard, is a removable dental appliance typically made of plastic that is custom-fitted to a patient's upper or lower teeth. It is primarily used to address issues related to teeth grinding (bruxism) or temporomandibular joint (TMJ) disorders. The splint is designed to fit over the teeth, creating a barrier between the upper and lower teeth to prevent grinding and clenching during sleep. Occlusal splints aim to reduce the impact of bruxism on the teeth and jaw, alleviate associated pain, protect the teeth from wear, and promote relaxation of the jaw muscles.
48648075|NCT06232993|OTHER|Exercises|For patients with bruxism, exercises can be beneficial in managing symptoms and promoting relaxation of the jaw muscles. These exercises aim to reduce the frequency and intensity of bruxism, alleviate associated pain, and improve overall jaw function and comfort. It's important for patients to consult with healthcare professionals to determine the most appropriate exercises for their individual needs.
48648076|NCT03014505|BIOLOGICAL|FMT|Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
48648077|NCT03014505|OTHER|traditional treatments|traditional treatments for Decompensated Cirrhosis in part 2
48648078|NCT00007943|DRUG|gemcitabine hydrochloride|
48648079|NCT01813357|DRUG|Rosuvastatin|encapsulated tablet 20mg daily
48648080|NCT01813357|OTHER|Placebo|Placebo arm included to maintain blinding
48648081|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
47970546|NCT03103568|DRUG|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
47970547|NCT03103568|DRUG|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
47970548|NCT03103568|DRUG|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
47970549|NCT03103568|DRUG|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
48648082|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
48648083|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
48648084|NCT00215657|DRUG|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
47970550|NCT03103568|DRUG|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
48323769|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
48323770|NCT03333330|DRUG|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
48498046|NCT00002752|RADIATION|iodine I 131 monoclonal antibody 81C6|
48498047|NCT00097903|DRUG|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
48323771|NCT00643487|PROCEDURE|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
48323772|NCT01836744|DEVICE|Survival rate dental implant (OsseoSpeed™)|
48323773|NCT03281447|OTHER|Nurse navigation|
48323774|NCT03281447|OTHER|Current care coordination|
48323775|NCT05766228|OTHER|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
48323776|NCT05665244|PROCEDURE|Laryngeal cryotherapy|Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.
48323777|NCT05665244|DEVICE|Cryoprobe|Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
48323778|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - maximum|"Breathing assistance from the breathing assist machine using a method in which doctors try to find the pressures that expands the lungs the best. This is based on measurements of one's respiratory pressures and volumes. This is done by adjusting the pressure settings. This allows one's lungs to expand with the least amount of change in pressure during breathing.~PEEP (positive end-expiratory pressure) will be set at the maximum static respiratory system compliance (Crs) during a descending PEEP titration curve."
48323779|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - standard|"Breathing assistance from the breathing assist machine using the pressure settings typical for your disease.~Standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol: PEEP will be set following a routinely used PEEP table according to patients' blood oxygenation status."
48323780|NCT05254613|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
48323781|NCT05254613|DRUG|Placebo|Placebo will be administered as SC infusion(s).
48323782|NCT00249977|DRUG|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
48323783|NCT02611063|DRUG|fostamatinib|100mg qd, 150mg qd, or 100mg bid
48323784|NCT00469846|PROCEDURE|L-arginine supplementation in a medical food|
48648085|NCT00215657|DRUG|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
48648086|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
48648087|NCT00215657|DRUG|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
48323785|NCT00469846|PROCEDURE|Vitamin C and E supplementation in a medical food|
48323786|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
48323787|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
48323788|NCT01327872|DRUG|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
48323789|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
48488224|NCT04275726|DEVICE|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
48488225|NCT00345020|PROCEDURE|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
48498048|NCT03321838|BEHAVIORAL|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
48498049|NCT00723723|DRUG|Statin|Statin
48498050|NCT02468752|DRUG|Oxygen|
48498051|NCT02468752|OTHER|Air|
48323790|NCT02199613|DRUG|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
48323791|NCT03719482|DRUG|[18F]MNI-1054|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-1054 injection and PET scan.
48648088|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
48648089|NCT00215657|DRUG|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
48648090|NCT00215657|DRUG|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
48648091|NCT05081271|BIOLOGICAL|Homologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
48648092|NCT05081271|BIOLOGICAL|Heterologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
48648093|NCT01917032|DIETARY_SUPPLEMENT|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
48648094|NCT01917032|DIETARY_SUPPLEMENT|placebo|
48648095|NCT05227365|DEVICE|Lenire|The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.
48648096|NCT05601063|BEHAVIORAL|Winterlight Speech Assessment|Digital assessment of speech and language abilities
48648097|NCT04178863|DEVICE|CATS Tonometer|latanoprost vs. timolol
48118932|NCT02504086|BEHAVIORAL|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
48323792|NCT06079957|PROCEDURE|Ergonomic training|"1. Individuals will be given a copy of ergonomic guidelines to follow which includes:~* Organize workstation according to the primary , secondary and tertiary zones.~* Place frequently used items within the reach of an arm.~* Don't move head while reading documents instead raise or lower the eyes to read.~* Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~* Keep reference material upright at desk.~* Avoid slouched postural habits, sit upright.~* Adjust chair height in such a way that it shouldn't compress the thigh.~* Arm rest should be at elbow flexion of 90 degrees.~* Phone must be cradled between neck and shoulder to avoid forward head posture."
48488226|NCT05495984|BEHAVIORAL|ERPs with electroencephalography (EEG)|E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.
48488227|NCT05495984|BEHAVIORAL|MIO|A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.
48488228|NCT04731402|OTHER|Acupressure, laughter yoga and mindfulness stress reduction program|Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
48488229|NCT03338348|DRUG|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
48488230|NCT03338348|DRUG|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
48488231|NCT01955655|DRUG|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
48488232|NCT01955655|OTHER|Placebo|
48488233|NCT00356980|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
48488234|NCT00356980|OTHER|pharmacological study|
48498052|NCT04636060|DIETARY_SUPPLEMENT|Eisen|Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
48498053|NCT04955535|PROCEDURE|Arthroscopic synovectomy|Arthroscopic synovectomy
48648098|NCT04178863|DRUG|Latanoprost|latanoprost IOP reduction
48648099|NCT02989025|DRUG|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
48648100|NCT04719312|PROCEDURE|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
48648101|NCT04384497|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
48323793|NCT06079957|PROCEDURE|Neck Exercises|"Neck Exercises Strengthening exercises of Deep cervical flexors,rhomboids,lower Trapezius, Middle Trapezius, serratus anterior.~Neck Stretching of Suboccipitals,Sternocleidomastoid ,Scalenes,Upper trapezius, Levator scapulae,Pectoralis major and minor."
48648102|NCT02327143|DRUG|LY2835219|Administered orally
48648103|NCT02327143|DRUG|¹³C₈-LY2835219|Administered IV
48648104|NCT05281458|PROCEDURE|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
48648105|NCT01016041|DEVICE|everolimus stent|stenting
48648106|NCT01016041|DEVICE|paclitaxel stent|stenting
47970551|NCT01292616|DRUG|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
47970552|NCT01484197|DRUG|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
47970553|NCT01484197|DRUG|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
47970554|NCT01484197|DRUG|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
47970555|NCT01484197|DRUG|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
48648107|NCT03345082|BIOLOGICAL|OPT-302|Intravitreal injection
47970556|NCT01484197|DRUG|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
47970557|NCT04072497|BIOLOGICAL|One shot of the zoster vaccine|One shot of the zoster vaccine (with live virus \>=4.3 LgPFU per dose)
47970558|NCT04072497|BIOLOGICAL|One shot of the varicella vaccine|One shot of the varicella vaccine (with live virus \>=3.3 LgPFU per dose)
47970559|NCT04072497|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
47970560|NCT00000688|DRUG|Ganciclovir|
47970561|NCT04692571|DEVICE|PSICON Measurement Apparatus|Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist \[hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)\]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
47970562|NCT03326102|DRUG|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
47970563|NCT03326102|DRUG|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
48118933|NCT02685969|PROCEDURE|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
48323794|NCT04704895|DIETARY_SUPPLEMENT|Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
48323795|NCT04704895|DIETARY_SUPPLEMENT|Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
48323796|NCT02807064|DRUG|Bifidobacteria|0.5 ml per os all days for 2 months
48323797|NCT02807064|DRUG|placebo|0,5 ml per os all days for 2 months
48648108|NCT03345082|BIOLOGICAL|ranibizumab|Intravitreal injection
48648109|NCT03345082|OTHER|sham intravitreal injection|Sham (mock) intravitreal injection
48648110|NCT05968937|DRUG|20 mg baclofen vaginal suppository daily per vagina|20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy
48648111|NCT05968937|DRUG|Placebo|Vaginal suppository composed of Supposibase F daily per vagina
48648112|NCT05819866|DRUG|Leriglitazone|Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
48648113|NCT05819866|DRUG|Placebo|Placebo will match the study drug visually and by taste
48323798|NCT02867449|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
48323799|NCT02867449|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
48323800|NCT02000518|RADIATION|external beam radiotherapy|
48648114|NCT02261610|PROCEDURE|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
48648115|NCT03829514|DRUG|Fenofibrate|40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
48648116|NCT00313521|DRUG|thiotepa|
48648117|NCT00313521|PROCEDURE|adjuvant therapy|
48648118|NCT00313521|RADIATION|radiation therapy|
48323801|NCT01315847|DRUG|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
48323802|NCT01315847|DRUG|[11C]MK-4232|Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
48323803|NCT03977350|DEVICE|EEG monitoring|EEG monitoring under general anesthesia
48323804|NCT04392336|OTHER|Trust/Respect feedback|This feedback includes information on the level of trust/respect that a consumer has for their clinician in addition to symptom feedback.
48323805|NCT05467462|DRUG|I.V carbetocin administration|Group I: carbetocin was intravenously administered immediately after birth of the baby.
48323806|NCT05467462|DRUG|I.V Oxytocin administration|Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
48323807|NCT05467462|DRUG|I.V carbetocin and tranexamic acid administration|Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
48323808|NCT05467462|DRUG|I.V Oxytocin and tranexamic acid administration|Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
48323809|NCT03616327|DEVICE|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
48323810|NCT01866761|PROCEDURE|Periodontal treatment|
48323811|NCT01927419|DRUG|Nivolumab|
48323812|NCT01927419|DRUG|Ipilimumab|
48323813|NCT01927419|DRUG|Placebo|Matching nivolumab
48323814|NCT04334915|DRUG|Cenicriviroc Mesylate (CVC)|Administered orally
48323815|NCT04334915|DRUG|Placebo|Administered orally
48323816|NCT03632252|DEVICE|Powered ankle prosthesis|This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
48323817|NCT04706169|DEVICE|Surface Electromyography|SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
48323818|NCT05767710|BEHAVIORAL|AI telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
48323819|NCT05767710|BEHAVIORAL|general telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
48323820|NCT05767710|BEHAVIORAL|traditional rehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
48323821|NCT05767710|BEHAVIORAL|AI telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
48498054|NCT04106167|GENETIC|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
48498055|NCT02403453|DEVICE|Rhine Cervical Disc|RHINE Cervical Disc
48648119|NCT03605550|DRUG|PTC596|Oral tablets
48323822|NCT05767710|BEHAVIORAL|general telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
48648120|NCT03605550|RADIATION|Radiotherapy|Cycle1
48648121|NCT03199534|DRUG|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
48648122|NCT03199534|DRUG|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
47970564|NCT00589251|OTHER|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
47970565|NCT01161862|DEVICE|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
47970566|NCT00574132|DRUG|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
48323823|NCT05767710|BEHAVIORAL|traditional rehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
48323824|NCT05767710|BEHAVIORAL|AI telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
48323825|NCT05767710|BEHAVIORAL|general telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
48323826|NCT05767710|BEHAVIORAL|traditional rehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
48323827|NCT01022567|PROCEDURE|Appendicectomy|Standard appendicectomy
48323828|NCT01022567|DRUG|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
48323829|NCT00000450|DRUG|Naltrexone Tablet|
48323830|NCT00000450|DRUG|Matched Placebo Tablet|
48323831|NCT03543358|DRUG|rovalpituzumab tesirine|Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
48648123|NCT03199534|DRUG|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
48648124|NCT05534490|OTHER|therapatic Foot massaje (sweden technic)|Everything is explained to the individuals on the day of surgery. After the surgery, when the individuals regains consciousness in the service, the Swedish massage technique is applied bilaterally for 10 minutes. In addition to the demographic data of the patient before the application and in the preoperative period; pain, mental level, delirium status, mobility, kinesiophobia, balance, and functional independence level measurement evaluations are made. Massage is continued for a total of 20 minutes, 10 minutes for each foot, once a day until the patient is discharged. The measurements are repeated on the day the individual will be discharged.
47970567|NCT00574132|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
47970568|NCT00574132|DRUG|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
48488235|NCT02772094|BIOLOGICAL|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
48488236|NCT05882916|DEVICE|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
48488237|NCT05882916|BEHAVIORAL|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
48488238|NCT02191475|DRUG|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
48323832|NCT03543358|DRUG|rovalpituzumab tesirine|Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
48488239|NCT02191475|DRUG|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
48488240|NCT01034787|DRUG|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
48488241|NCT01648504|OTHER|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
48488242|NCT01882920|DRUG|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.
48488243|NCT01882920|DRUG|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
48488244|NCT04867421|OTHER|No intervention|No intervention
48488245|NCT04328519|OTHER|observation|observation
48488246|NCT03486054|DEVICE|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
48323833|NCT03555188|DRUG|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
48323834|NCT01566058|DEVICE|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
48323835|NCT01566058|OTHER|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
48323836|NCT03863236|DIETARY_SUPPLEMENT|regular diet|The control group (group 1) will continue their regular diet.
48323837|NCT03863236|DIETARY_SUPPLEMENT|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
48323838|NCT01500928|DEVICE|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
48323839|NCT04436809|PROCEDURE|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
48323840|NCT04436809|PROCEDURE|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
47970569|NCT03216889|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
47970570|NCT03216889|BEHAVIORAL|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
47970571|NCT00899054|DRUG|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
48323841|NCT03506022|OTHER|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram \[chin\], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
48323842|NCT05511675|DEVICE|cold application|ISO-BALL
48323843|NCT05283863|DEVICE|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
48118934|NCT03472755|OTHER|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
48118935|NCT03472755|OTHER|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
48488247|NCT03486054|DEVICE|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
48118936|NCT05938166|DEVICE|oral care augmented reality (AR)|Augmented reality (AR) is an extension of perceptible reality, whereby additional information, such as texts or virtual objects, can be displayed in the user's field of vision.The oral care augmented reality (AR) simulation training can train foreign care workers by switching languages (Indonesian) and therefore reduce language-related learning barriers.
48488248|NCT03941353|OTHER|Usual care|Benchmark study with retrospective patient analysis evaluating the actual care patients with a fragile hip fracture receive
48488249|NCT04413136|BEHAVIORAL|Web-ORLA|
48118937|NCT02933944|BIOLOGICAL|TG02-treatment|
48118938|NCT02933944|DRUG|Pembrolizumab|
48118939|NCT04380155|OTHER|Exercise|Moderate intensity cycling trials of different duration (30, 60 and 120 min)
48118940|NCT04562259|RADIATION|Verification of Kimmerle's anomaly by x-ray methods of research|In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.
48118941|NCT00411034|DRUG|OROS Hydromorphone HCI|
48118942|NCT04790604|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
48118943|NCT01901081|DEVICE|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
48118944|NCT00621569|BEHAVIORAL|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
48323844|NCT05283863|DEVICE|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
48323845|NCT01995279|DEVICE|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
48323846|NCT01995279|OTHER|Sham Ultrasound|Ultrasound turned off.
48118945|NCT00621569|BEHAVIORAL|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
48118946|NCT00584246|DRUG|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
48118947|NCT00584246|DRUG|Placebo|50 - 150 mg po qhs for 2 months
48118948|NCT06449170|OTHER|Mango Ataulfo|In this intervention, subjects consumed 150g of mango Ataulfo plus 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage has the purpose of providing energy intake and limiting the noise that the control beverage may contribute to the metabolomic profile in urine and serum.
48118949|NCT06449170|OTHER|Avocado Hass|In this intervention, subjects consumed 120g of avocado hass plus 150 ml of a control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolomic profile in urine and serum.
48323847|NCT02764983|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
48323848|NCT02764983|BEHAVIORAL|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
48323849|NCT02764983|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
48488250|NCT04413136|BEHAVIORAL|Control|
48488251|NCT06126666|DRUG|ABL103|ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
48488252|NCT02619136|PROCEDURE|Transfusion|Red Blood Cell Transfusion
48488253|NCT05011630|OTHER|Pancreaticoduodenectomy|The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
48488254|NCT00838708|DRUG|SRD174 Cream|topical SRD174 Cream
48488255|NCT00838708|OTHER|vehicle cream|topical vehicle cream
48488256|NCT05628779|DEVICE|TriClip TTVr system (Abbott Vascular)|Edge-to-edge leaflet approximation for the tricuspid valve
48648125|NCT06385834|OTHER|Morning aerobic exercise|Patients were randomly assigned to morning aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
48648126|NCT06385834|OTHER|Evening aerobic exercise|Patients were randomly assigned to evening aerobic exercise training for a 12-week outpatient training program that included a combination of warm-up, aerobic, and relaxation exercises three times a week. Each class consists of 10 minutes of warm-up training, 40 minutes of aerobic training and 10 minutes of relaxation training. The intensity of aerobic exercise training will be personalized. According to the guidance of relevant guidelines, the exercise intensity of patients will be determined according to the results of their first cardiopulmonary exercise experiment, and the exercise load will be gradually increased according to the exercise program until the predetermined goal is reached. Patient fatigue levels will be monitored throughout the exercise using the borg scale.
48648127|NCT05230654|DRUG|Fosaprepitant|Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
48648128|NCT05230654|DRUG|Placebo(normal saline)|Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
48648129|NCT02219100|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
48118950|NCT06449170|OTHER|Nopal|In this intervention, subjects consumed 300g of cooked nopal and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
48648130|NCT03689088|DEVICE|Goldfish|Goldfish will be placed in the eye for 24h monitoring
48648131|NCT03689088|DEVICE|Tonometry|Fellow eye will be measured by tonometry
48118951|NCT06449170|OTHER|3 corn tortilla|In this intervention, subjects consumed 3 corn tortillas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
48118952|NCT06449170|OTHER|Guava|In this intervention, subjects consumed 3 guavas and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
48488257|NCT05628779|DEVICE|PASCAL TTVr system (Edwards Lifesciences)|Edge-to-edge leaflet approximation for the tricuspid valve
48488258|NCT02536235|OTHER|heat|activated heating pad to lower abdomen
48488259|NCT01554826|BIOLOGICAL|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
48488260|NCT01554826|BIOLOGICAL|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
48488261|NCT00190242|DRUG|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
48488262|NCT00190242|DRUG|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
48648132|NCT00236795|DRUG|norelgestromin + ethinyl estradiol; triphasil.|
48648133|NCT02459600|OTHER|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
48118953|NCT06449170|OTHER|Amaranth|In this intervention, subjects consumed 1/2 cup of amaranth and 150 ml of control beverage (Supportan® Drink Cappuccino). The addition of the control beverage provides energy intake and limits the noise that the beverage may contribute to the metabolic profile in urine and serum.
48118954|NCT06449170|DIETARY_SUPPLEMENT|Control Beverage (Supportan Drink ® Capuccino)|In this intervention, subjects consumed 290ml of Supportan Drink ® Capuccino to act as a control for the metabolomic profiling in urine and serum.
48118955|NCT05551065|DEVICE|Point-of-care ultrasound (POCUS)|Point-of-care ultrasound (POCUS) using a hand-held ultrasound (Vscan, GE Healthcare)
48323850|NCT02764983|BEHAVIORAL|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
48323851|NCT02764983|BEHAVIORAL|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
48323852|NCT02764983|BEHAVIORAL|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
48488263|NCT01045915|BIOLOGICAL|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
48488264|NCT05466175|DRUG|Olverembatinib|Given PO
48648134|NCT00005931|DRUG|SU5416|
48488265|NCT05466175|DRUG|Prednisone|Given Intravenous
48488266|NCT05466175|DRUG|Vincristine|Given Intravenous
48488267|NCT03913897|OTHER|distraction methods|The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
48488268|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
48118956|NCT04517136|BEHAVIORAL|Assessment of work-related stress|Assessment of burnout, mindfulness, interoceptive awareness, anxiety, post-traumatic stress disorder, coping flexibility and sleep through questionnaires.
48118957|NCT04517136|BIOLOGICAL|Saliva sample collection|Saliva sample is collected before and after emotional stimulation in order to measure resting-state allostatic load biomarkers: Dehydroepiandrosterone (DHEA), cortisol and chromogranin A levels
48118958|NCT04517136|DEVICE|Cardiac and electrodermal recordings|Electrocardiogram and electrodermal activity (tonic and phasic) is collected at rest and after emotional stimulation.
48323853|NCT02764983|PROCEDURE|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
48488269|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Current Adhesive|single application
47970572|NCT00899054|RADIATION|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
47970573|NCT05209958|DIAGNOSTIC_TEST|Neutrophil Lynphosite ratio|The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
48118959|NCT04517136|BEHAVIORAL|Assessment of behavioral response to emotional stimulation|"Emotional stimulation involves asking the participants to remember a recent event related to the COVID-19 crisis that has been emotionally difficult for them.~Perceived stress, situational awareness and emotions is assessed after emotional stimulation through questionnaires."
48118960|NCT03908671|BIOLOGICAL|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine
48323854|NCT02764983|OTHER|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
48323855|NCT06010355|PROCEDURE|Discussion|Participate in focus groups
48323856|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
48323857|NCT06010355|OTHER|Interview|Undergo interview
48323858|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
48323859|NCT06010355|OTHER|Test|Complete test
48323860|NCT01840228|DRUG|Micronized progesterone suppository|
48323861|NCT01480492|DRUG|Telbivudine|600mg,1/d,one year
48323862|NCT04765436|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
48323863|NCT04765436|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48323864|NCT03919968|BEHAVIORAL|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
48323865|NCT03919968|BEHAVIORAL|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
48323866|NCT01431729|OTHER|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
48323867|NCT05318105|DEVICE|Aquadex Smartflow® System|ultrafiltration
48648135|NCT05388825|DRUG|TPN171H 2.5mg|TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
48648136|NCT05388825|DRUG|TPN171H 5mg|TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
47970574|NCT02577510|DRUG|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
48323868|NCT05318105|DRUG|IV Loop Diuretics|diuretics
48323869|NCT03664284|PROCEDURE|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
48323870|NCT04082468|DIAGNOSTIC_TEST|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T \& B lymphocyte panel at above time points
48648137|NCT05388825|DRUG|TPN171H 10mg|TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
48118961|NCT06145984|BEHAVIORAL|Mindfulness|Participants receive a two-hour professional training to get familiar with the basic techniques of mindfulness. The training is given by a mindfulness professional and consists of psycho-education, instructions for mindfulness and guided practice. It focuses mainly on attending to stimuli such as breathing, external sounds or bodily sensations and becoming aware of where one's attention is. After the professional training, participants receive instructions about the audio application with which participants continue performing short exercises using the learned technique every day guided by an application on their smartphone customized for this research. Specifically, participants perform one short exercise (10 min) per day for in total six days. The exercises that are being performed are: attention to breathing part 1, attention to breathing part 2, attention to sounds, attention to bodily sensations, attention to thoughts, attention to emotions and feelings.
48648138|NCT05388825|DRUG|Placebo 5mg|Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
48648139|NCT05388825|DRUG|Placebo 10mg|Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
48648140|NCT05355298|DRUG|AMP945 ascending doses|Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
48648141|NCT05355298|DRUG|AMP945 RP2D|Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.
48648142|NCT02548819|OTHER|MRI|MR imaging of patients with implanted cardiac devices
48648143|NCT02540902|DEVICE|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
48323871|NCT04724733|BEHAVIORAL|Smoke Sense|Smoke Sense is a smartphone application (app). Smoke Sense participants will be asked to establish a profile which includes demographics, baseline health information and current beliefs about smoke and air pollution. In the Symptoms \& Smoke Observations tab, participants are asked to report their weekly observations of smoke, health symptoms, and exposure reduction behaviors. In the Fire \& Smoke Near Me tab, participants review the most recent AQ data measured at an AQ monitoring sites. Participants are asked to complete the AQ 101 module which test knowledge of AQ facts and provides correct answers. Badges are awarded for accomplishments within the app to promote certain desired behaviors: completing a user profile, launching the app weekly to check local AQ, reporting smoke and symptom observations, expanding AQ knowledge with AQ lessons, and exploring the map. Finally, participants can engage with other users by viewing cumulative statistics of symptoms and smoke observations.
48323872|NCT04724733|BEHAVIORAL|Smoke Sense Plus|Participants randomized to the Smoke Sense Plus intervention will be asked to do everything that the Smoke Sense intervention group does on a weekly basis, as well as: 1) Receive weekly push notifications that remind them to, for example, review their asthma action plan, refill any expired medications, take their daily controller medication, identify a clean air space in their home and community, 2) Monitor their lung function weekly via mobile spirometry, and 3) Subscribe to a social network to share strategies to minimize exposure.
48323873|NCT04534036|DIETARY_SUPPLEMENT|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
48323874|NCT04534036|OTHER|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
48323875|NCT03018912|OTHER|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~1. How many days a week are you satisfied with your sleep?~2. How many days a week is sleepiness a problem?"
48323876|NCT06070116|DRUG|Ivermectin w/ Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)
48323877|NCT06070116|DRUG|Ivermectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
48323878|NCT06070116|DRUG|Moxidectin + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)
48323879|NCT06070116|DRUG|Moxidectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
48488293|NCT03083821|DRUG|Baraclude|Specified dose on specified day
48488294|NCT00317642|DRUG|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m\^2 / day up to 3 cycles
48488295|NCT00317642|DRUG|placebo|placebo (sodium Chloride) 1-hour IV infusion
48488296|NCT00317642|DRUG|cytarabine|cytarabine IV infusion 1g/m\^2/day for up to 3 cycles
48648144|NCT04003142|DRUG|Fezolinetant|Oral tablet
48648145|NCT04003142|DRUG|placebo|Oral Tablet
48648146|NCT05109195|OTHER|Standard of Care (SOC)|Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
48648147|NCT05406531|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
48648148|NCT05406531|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
48648149|NCT05406531|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
48648150|NCT01555580|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
48648151|NCT01773889|DRUG|Denileukin Diftitox/SC Pegylated IFNα-2a|
48323880|NCT05982223|PROCEDURE|Acupuncture|The frequency of acupuncture will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
48323881|NCT05982223|PROCEDURE|Mind-body therapy|The frequency of mind-body therapy (hypnosis, guided imagery) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
48323882|NCT05982223|PROCEDURE|Touch therapy|The frequency of touch therapy (shiatsu, reflexology) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
48323883|NCT05982223|PROCEDURE|Movement therapy|The frequency of movement therapy (Tai-Chi, Qi-Qong) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
48323884|NCT05982223|DIETARY_SUPPLEMENT|Herbal supplements|The choice of herbal supplement will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
48323885|NCT05982223|BEHAVIORAL|Emotional treatment|The frequency of emotional treatments (counseling, spiritual guidance) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
48323886|NCT01464242|DRUG|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
48323887|NCT01464242|DRUG|Placebo|Placebo 400mg orally 3 times a day for 20 days
48323888|NCT01464242|DRUG|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
48488297|NCT03401450|DRUG|ACB within true AC with bupivacaine 0.5% 20cc|The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
48488298|NCT03401450|DRUG|ACB proximal to true AC with bupivacaine 0.5% 20cc|Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
48488299|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
48488300|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
48488301|NCT02555020|DIETARY_SUPPLEMENT|Allocated to MN NPO group,|Patients received NPO from MN.
48488302|NCT05652959|DEVICE|Cerviron®|Cerviron® is a medical device manufactured by PFC Pharma Manufacturing SL formulated following the provisions of the European Regulation 2017/745 on Medical Devices. Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21. Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
48488303|NCT04629261|BEHAVIORAL|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
48488304|NCT02504346|DRUG|AZD9291|
48488305|NCT01621191|DRUG|Duloxetine|Administered Orally
48488306|NCT03832699|DRUG|Dydrogesterone 10 MG|Oral progesterone 10 mg TID
48488307|NCT03832699|DRUG|Endometrin 100Mg Vaginal Insert|Vaginal Endometrin 100 mg twice daily
48488308|NCT02310646|DRUG|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
48488309|NCT02310646|DRUG|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
48488310|NCT03077321|BEHAVIORAL|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
48323889|NCT01512147|OTHER|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
48648152|NCT05457205|OTHER|Electrical neuromodulation|Electrical neuromodulation intervention using transcutaneous spinal stimulation: two self-adhesive semicircle electrodes (forming a 5cm round electrode) will be centered midline over the T11-12 spinal processes, and two 8×13 cm electrodes will be placed paraumbilical and interconnected to serve as a counter electrode. A current-controlled stimulator will deliver symmetric biphasic pulses (500-μs/phase). Electrical stimulation will be applied according to the description in each study arm.
48648153|NCT02674256|DRUG|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
48648154|NCT02674256|OTHER|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
48648155|NCT00747201|BEHAVIORAL|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
48648156|NCT00747201|BEHAVIORAL|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
48648157|NCT02452593|OTHER|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
48488311|NCT03077321|BEHAVIORAL|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
48648158|NCT04488887|DIAGNOSTIC_TEST|Optical coherence tomography angiography|patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
48488312|NCT02894866|DEVICE|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
48488313|NCT05402982|DEVICE|Electrical Cardiometry (EC) ICON|Electrical Cardiometry (EC) ICON (Osypka Medical, Berlin, Germany) is an FDA approved device used for non-invasive measurement of some hemodynamic parameters as cardiac output,cardiac index, stroke volume,stroke volume variation, systemic vascular resistance, thoracic fluid content, ICON (index of contractility), variation of ICON,corrected flow time and systolic time ratio.The set data of EC are the height, weight,hemoglobin, Oxygen saturation(SPO2),age, gender ,blood pressure and heart rate(HR) of the patient
48488314|NCT05402982|OTHER|Rohrich formula|Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2
48488315|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
48488316|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
48488317|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
48648159|NCT03999073|OTHER|Ultrasound measurement|Ultrasound measurement
48648160|NCT00332566|BIOLOGICAL|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
48648161|NCT00332566|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
48648162|NCT02442531|DRUG|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
48648163|NCT03923998|DRUG|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
48648164|NCT03923998|RADIATION|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
48648165|NCT03923998|PROCEDURE|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
48118962|NCT06145984|BEHAVIORAL|Positive Fantasizing|"In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total."
48118963|NCT01484353|BEHAVIORAL|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
48488318|NCT00311311|DRUG|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
48488319|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
48488320|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
48488321|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
48488322|NCT03024736|OTHER|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
48488323|NCT01490866|DRUG|Axitinib|5-mg tablets PO BID
48488324|NCT01490866|DRUG|Bevacizumab|5 mg/kg Days 1 and 15; IV
48488325|NCT01490866|DRUG|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
48488326|NCT01490866|DRUG|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
48488327|NCT01490866|DRUG|Leucovorin|400 mg/m2 Days 1 and 15; IV
48488328|NCT01490866|DRUG|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
48488329|NCT00004734|DRUG|pyridoxine|
48488330|NCT00004734|DRUG|cyanocobalamin|
48488331|NCT00004734|DRUG|folic acid multivitamin|
48488332|NCT02621034|PROCEDURE|Control|K-file hand instrumentation
48488333|NCT02621034|PROCEDURE|Reciproc|reciprocating rotary instrument
48488334|NCT02621034|PROCEDURE|One shape|full rotation protocol
48488335|NCT00562770|DRUG|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
48488336|NCT00562770|DRUG|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
48488337|NCT01064531|DEVICE|MIS Femoral Neck Stem implant|
48488338|NCT00932230|OTHER|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
48488339|NCT05670106|DRUG|[177Lu]Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
48488340|NCT05670106|OTHER|Best supportive/best standard of care (BS/BSOC)|Best supportive/best standard of care as defined by the local investigator
48488341|NCT05670106|DRUG|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
48488342|NCT04799678|OTHER|Recording voice samples|A maximum of 9 voice sample recording session will be carried out on their phones and take less than 2 minutes each
48488343|NCT06437418|DIAGNOSTIC_TEST|abdominal ultrasonography.|Evaluate the gallbladder ejection fraction (EF)
48648166|NCT02244957|DEVICE|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations \<88% while on stable bi-level settings.
48648167|NCT02244957|DRUG|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
48488344|NCT03167593|DIETARY_SUPPLEMENT|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
48488345|NCT03167593|OTHER|Control placebo|Maltodextrin
48118964|NCT05319457|OTHER|The radon app|Participants will be asked to use the radon app.
48323890|NCT06046716|BEHAVIORAL|Mindful compassion based on behavioural change taxonomy experimental group|Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
48323891|NCT00295217|DEVICE|ExAblate 2000|
48323892|NCT02335580|DRUG|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
48323893|NCT02335580|PROCEDURE|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
48323894|NCT01827930|DRUG|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
48323895|NCT01827930|DRUG|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
48323896|NCT01827930|DRUG|Imatinib Mesylate|Imatinib Mesylate for CP CML
48323897|NCT00790179|PROCEDURE|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
48323898|NCT00664755|DRUG|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study."
48323899|NCT00664755|DEVICE|transdermal nicotine patch|"Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study."
48323900|NCT02483403|OTHER|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
48323901|NCT02483403|DEVICE|MRI|
48323902|NCT03418051|OTHER|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
48323903|NCT03418051|OTHER|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
48323904|NCT05550818|OTHER|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
48323905|NCT05550818|OTHER|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
48323906|NCT05165979|OTHER|Hospitalization due to COVID-19|Hospitalization due to COVID-19
48323907|NCT02632500|OTHER|Quality of chest compressions|
48323908|NCT05126745|DEVICE|color flow Doppler ultrasonography|Doppler ultrasonography
48323909|NCT01430572|DRUG|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
48323910|NCT01430572|DRUG|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
48648168|NCT06570031|DRUG|ONO-4578|Specified dose on specified days
48323911|NCT04799184|DRUG|Levobupivacaine 0.25% with epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
48323912|NCT04799184|DRUG|Levobupivacaine 0.25% without epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
48648169|NCT06570031|DRUG|letrozole|Specified dose on specified days
48648170|NCT06570031|DRUG|Palbociclib|Specified dose on specified days
48648171|NCT06570031|DRUG|abemaciclib|Specified dose on specified days
48648172|NCT03539640|OTHER|PEEP: 5 cmH2O|During second part of the study (MRI)
48648173|NCT03539640|OTHER|PEEP: 10 cmH2O|During second part of the study (MRI)
48648174|NCT03539640|OTHER|PEEP: 15 cmH2O|During second part of the study (MRI)
48118965|NCT05319457|OTHER|Print brochure|Participants will receive print brochures.
48648175|NCT01530516|DEVICE|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
48118966|NCT04738058|DRUG|Bovine Lactoferrin Supplement|Bovine lactoferrin or placebo will be given to both arms with each feed for 30 days or till discharge from NICU the Lactoferrin dose 100mg/day Then determin is effect by serum zonulin level
48648176|NCT01530516|DEVICE|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
48118967|NCT04738058|DRUG|placebo|placebo
48118968|NCT02759913|PROCEDURE|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
48118969|NCT05193786|PROCEDURE|Different level of PEEP|Different level of PEEP (low versus high) was applied in noninvasive ventilation.
48118970|NCT04987021|DEVICE|Cochlear Implant (CI)-CI500 series, CI600 series or Freedom series cochlear implants|The Remote Assist (RA) System is intended to support clinicians to conduct a remote programming session with their CI recipients.
48118971|NCT02024685|BEHAVIORAL|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
48118972|NCT02024685|BEHAVIORAL|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
48488346|NCT04390321|OTHER|LLMcare|Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
48488347|NCT00679913|PROCEDURE|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
48488348|NCT00679913|PROCEDURE|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
48488349|NCT01832675|DRUG|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
48488350|NCT01832675|DRUG|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
48488351|NCT02370225|OTHER|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
48488352|NCT04793074|COMBINATION_PRODUCT|Transforming nanoparticle dressing|Transforming nanoparticle dressing
48488353|NCT04793074|COMBINATION_PRODUCT|Conventional compression dressing|Conventional compression dressing
48488354|NCT02265172|PROCEDURE|Physiotherapy screening|Physiotherapy screening.
48488355|NCT02265172|PROCEDURE|Standard practice|Orthopaedic surgeon assessment
48648177|NCT04214444|BIOLOGICAL|Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma|The investigators aim to describe efficiency and tolerability of prime-boost vaccination against pneumococcus in patients with Diffuse large B-cell Lymphoma. The investigators search to evaluate immunogenicity of prime-boost depending on the time of prevenar administration (before or after immunochemotherapy) and on the dose (single or double dose).
48648178|NCT05664711|DRUG|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
48648179|NCT00945542|OTHER|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
48648180|NCT00945542|OTHER|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR\>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
48648181|NCT01550965|BIOLOGICAL|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
48648182|NCT06541080|DIAGNOSTIC_TEST|Shallow Whole Genome Sequencing (sWGS)-GIPXplore|GIPXplore will be used to mine shallow whole genome sequencing cell free DNA data for identification of signatures.
47970575|NCT02577510|DRUG|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
47970576|NCT05230550|DRUG|Somapacitan|Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
47970577|NCT03217175|DEVICE|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
47970578|NCT03217175|DEVICE|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
48118973|NCT06031012|DRUG|glutamine combined with thalidomide|Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
48118974|NCT06031012|DRUG|glutamine alone|Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.
48118975|NCT00215397|DRUG|Formoterol Fumarate|
48323913|NCT05101395|OTHER|Giemsa stain|Giemsa special stain was employed for detection of H. Pylori microorganisms.
48118976|NCT04399148|DRUG|Desloratadine 5 mg|Desloratadine (H1-antihistamine): oral tablet (1 x 5 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
48118977|NCT04399148|DRUG|Aprepitant 125 mg|Aprepitant (NK1-antagonist): hard capsule (1 x 125 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
48648183|NCT06541080|DIAGNOSTIC_TEST|methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay|Aberrant methylation in ccfDNA will be analyzed using the novel, highly sensitive MSRE-smMIP-seq technology.
48118978|NCT04399148|DRUG|Ketotifen 1 MG|Ketotifen (H1-antihistamine and mast cell stabilizer): capsule (1 x 1 mg), taken with 240 ml water, 4 hours prior to the histamine skin prick
48118979|NCT03379051|DRUG|Venetoclax|BCL-2 Inhibitor
48323914|NCT03689062|PROCEDURE|induction of labor|oxytocin intravenous drip
48323915|NCT03689062|PROCEDURE|follow up|hospitalization and antibiotics
48648184|NCT02811614|PROCEDURE|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
48648185|NCT02811614|PROCEDURE|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
48648186|NCT02811614|PROCEDURE|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
48323916|NCT05649644|PROCEDURE|Selective Trunk Block (SeTB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. After local anesthetic (LA) infiltration (1-2 ml lidocaine 1%), the nerve block needle will be inserted and placed within the interscalene groove. Then, a 7 ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. After that, the tip will be redirected lateral to the middle trunk. A further 8 ml of the LA mixture will be injected after which the nerve block needle will be completely withdrawn. The transducer will then be manipulated to a sub-omohyoid position. After LA infiltration, the nerve block needle is inserted in-plane until the needle tip is positioned close to and lateral to (9-12 o'clock position) the inferior trunk. A 10 ml of the LA mixture is injected in small aliquots and the needle will be removed after the injection.
48488356|NCT01176643|OTHER|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
48488357|NCT01521065|DEVICE|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
48488358|NCT04300829|DRUG|cicaderma + simple hygiene rules|Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
48648187|NCT03248661|BEHAVIORAL|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
47970579|NCT03217175|DRUG|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
47970580|NCT03217175|DRUG|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
47970581|NCT04384211|OTHER|Computer Assisted Detection Software For Vertebral Fractures|A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
47970582|NCT01804075|DRUG|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
48118980|NCT03379051|DRUG|Umbralisib|PI3K-Delta Inhibitor
48118981|NCT03379051|BIOLOGICAL|Ublituximab|Glycoengineered Anti-CD20 mAb
48118982|NCT03379051|DRUG|Lenalidomide|Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties
48118983|NCT03495713|DRUG|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
47970583|NCT01804075|DRUG|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
48118984|NCT00459745|DRUG|Pravafen|
48118985|NCT00459745|DRUG|Pravastatin|
48118986|NCT00459745|DRUG|Fenofibrate|
48118987|NCT02861846|BIOLOGICAL|profile of CSF biomarkers of AD|dosage of biomarker of AD
48118988|NCT04223297|PROCEDURE|lung ultrasound|"The lung ultrasound will be performed by following the  Blue protocol "
48118989|NCT05603013|DRUG|Vinorelbine|Vinorelbine Tartrate Oral
48118990|NCT05603013|RADIATION|Radiotherapy|hypofractionated radiotherapy
47970584|NCT01002027|BEHAVIORAL|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
48323917|NCT05649644|PROCEDURE|Supraclavicular Brachial Plexus Block (SC BPB)|Patient will lie supine on the examination couch with the ipsilateral arm in the neutral position (adducted), neck slightly extended and the head turned slightly to the contralateral side. Patient will receive a subcutaneous infiltration with 1-2 ml of 0.9% normal saline (NS) at the superior and middle trunk level after which the needle will be completely withdrawn. Then, a local anesthetic (LA) infiltration (1-2 ml lidocaine 1%) will then be performed at the supraclavicular fossa and the nerve block will be inserted in-plane to place the needle tip at the corner pocket. After that, 15-ml of a 1:1 mixture of lidocaine 2% with 1:200,000 epinephrine and levobupivacaine 0.5% will be slowly injected in aliquots. Once completed, the needle tip is gently withdrawn and redirected into the cluster formed by the divisions of brachial plexus. Then, the remaining 10-ml of the same LA mixture will be injected in small aliquots and the needle will be removed after the injection.
48323918|NCT00046176|DRUG|abacavir/lamivudine|
48323919|NCT00046176|DRUG|abacavir|
48323920|NCT00046176|DRUG|lamivudine|
48323921|NCT04447703|OTHER|Interview|Attend Interview
48323922|NCT04447703|OTHER|Internet Based Intervention|Use web-based genetic education tool online
48323923|NCT04447703|OTHER|Survey Administration|Ancillary Studies
48323924|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
48488359|NCT04300829|OTHER|Simple hygiene rules and a maximum of one topical treatment|Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
48488360|NCT05223257|OTHER|AOT|Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
48488361|NCT02227654|PROCEDURE|Abnormal Ovarian Ultrasound|Ultrasound
48488362|NCT02164630|BEHAVIORAL|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
48488363|NCT02164630|OTHER|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
48488364|NCT03891017|OTHER|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
48488365|NCT03891017|OTHER|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
48648188|NCT01620047|DRUG|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
48648189|NCT01620047|DRUG|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
48648190|NCT01620047|DRUG|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
48648191|NCT00001784|DRUG|Mexiletine|
48648192|NCT03709030|DIAGNOSTIC_TEST|magnetic resonance cholangiopancreatography (MRCP)|magnetic resonance imaging of liver, gall bladder, pancreas
48323925|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
48118991|NCT05603013|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
48118992|NCT05603013|DRUG|GM-CSF|GM-CSF subcutaneous injection
48323926|NCT04447703|OTHER|Survey Administration|Ancillary Studies
48118993|NCT05603013|DRUG|IL-2|IL-2 subcutaneous injection
48118994|NCT01503749|DRUG|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
48323927|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
48323928|NCT04447703|OTHER|Internet-Based Intervention|Use web-based genetic education tool online
48323929|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
48323930|NCT04447703|OTHER|Survey Administration|Ancillary Studies
48323931|NCT04419818|BEHAVIORAL|Virtual Reality|Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
48323932|NCT03304470|DRUG|ATx201 2% Cream|Anhydrous Cream
48118995|NCT01503749|OTHER|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
48118996|NCT05740657|DRUG|Fentanyl|The drugs were administered in the course of a surgery or for pain management.
48118997|NCT06169735|DRUG|Indocyanine green|ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
48118998|NCT06169735|DEVICE|SPY Portable Handheld Imaging|Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
48323933|NCT03304470|DRUG|ATx201 Cream Vehicle|Anhydrous Cream
48323934|NCT01220986|PROCEDURE|Liver biopsy|0, 30, 60, 90 min post inflow-division
48323935|NCT05184309|OTHER|ConventioanalExercises|Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
48323936|NCT05184309|OTHER|Serious games|A Serious game program will be applied to the individuals twice a week for 6 weeks in this group. Armrotate, Uball, Balance Surf and Balance Adventure games will be developed by Becure company for shoulder rehabilitation. These games developed for shoulder rehabilitation will be applied to individuals under the supervision of a physiotherapist. Each game will be played for 10 minutes, for a total of 40 minutes.
48323937|NCT04729062|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
48118999|NCT06109220|BEHAVIORAL|Stromal vascular fraction,SVF|SVF was injected into the knee cavity
48323938|NCT05227482|RADIATION|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
48323939|NCT05227482|RADIATION|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
48323940|NCT00988260|DRUG|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
48648193|NCT03720808|OTHER|Balloon Blowing|The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
48648194|NCT03720808|OTHER|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
48119000|NCT04435236|PROCEDURE|Cervical ESP block|Cervical ESP block will be performed as described by Elsharkawy at al. (7). ISB block will be performed in transverse orientation of the ultrasound probe to visualize the trunks of the brachial plexus between the anterior and middle scalene muscles
48119001|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
48119002|NCT01616459|BIOLOGICAL|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
48119003|NCT01616459|BIOLOGICAL|Synflorix™|Intramuscular injection
48119004|NCT01616459|BIOLOGICAL|Prevnar 13™|Intramuscular injection
48119005|NCT01616459|BIOLOGICAL|Infanrix hexa™|Intramuscular injection
48323941|NCT00988260|DRUG|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
48323942|NCT00988260|DRUG|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
48119006|NCT04296227|DEVICE|The Vital Detect blood pressure monitor|The end goal is to provide Non-invasive Blood Pressure (NIBP) accuracy data to support validation of the Vital Detect blood pressure monitor.
48119007|NCT01366677|BEHAVIORAL|Yoga Intervention|Three yoga classes per week for 8 weeks.
48119008|NCT02359188|DEVICE|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
48119009|NCT00480077|DEVICE|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
48119010|NCT01610297|DRUG|ICL670|Oral dose of ICL670 at 10 mg/kg daily
48323943|NCT00862121|DRUG|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
48323944|NCT00862121|DRUG|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
48323945|NCT00698035|DRUG|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
48323946|NCT00698035|DRUG|Estring|2mg ring inserted vaginally once every 12 weeks
48323947|NCT02756975|DEVICE|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
48119011|NCT04901936|DRUG|Pegcetacoplan|Complement (C3) inhibitor
48119012|NCT06554418|BEHAVIORAL|Communities Care|Communities Care is a violence prevention program targeting social norms and behavioral change
48119013|NCT05933551|OTHER|Z Technique Training|Training on Z technique will be given on the planned day, time and place. The education is planned to be given at Tarsus University. The training content will be presented to the participants as a powerpoint presentation (30 min), laboratory practice (15 min) and question-answer (15 min).
48119014|NCT00262730|DRUG|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
48119015|NCT00262730|DRUG|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
48323948|NCT02756975|DEVICE|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
48323949|NCT02922192|DRUG|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
48323950|NCT03354702|OTHER|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
48323951|NCT03354702|OTHER|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
48323952|NCT00406991|DRUG|aspirin|
48323953|NCT00406991|DRUG|clopidogrel|
48323954|NCT04209257|DEVICE|Functional Electrical Stimulation.|Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
48323955|NCT04468334|DEVICE|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
48323956|NCT01188096|DRUG|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
48488366|NCT00161382|BEHAVIORAL|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
48648195|NCT03720808|OTHER|Coughing|The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
48648196|NCT03720808|OTHER|Control|No intervention was performed to reduce pain and fear in the control group.
48648197|NCT05182476|DRUG|Placebo|Oral tablets
48648198|NCT05182476|DRUG|Luvadaxistat|Oral tablets
48648199|NCT05632601|DIAGNOSTIC_TEST|PET scan|PET scan
48119016|NCT00262730|RADIATION|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
48323957|NCT00143975|DRUG|Cytarabine|3 g/m2 bid. i.v day 1-3
48323958|NCT00143975|DRUG|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
48323959|NCT00143975|DRUG|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
48323960|NCT00143975|DRUG|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
48323961|NCT02849249|BIOLOGICAL|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
48323962|NCT03051828|PROCEDURE|fencing|No intervention: practice fencing
48323963|NCT04532918|DRUG|Verinurad|The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
48323964|NCT04532918|DRUG|Allopurinol|The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
48323965|NCT04532918|DRUG|Cyclosporine|The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
48323966|NCT04532918|DRUG|Rifampicin|The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
48323967|NCT01839201|OTHER|control|No psychological intervention
48323968|NCT01839201|OTHER|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
48323969|NCT01839201|OTHER|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
48323970|NCT04091334|DEVICE|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
48648200|NCT03889015|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
48323971|NCT04091334|OTHER|Standard care|Standard care and evaluation and monitoring
48323972|NCT00084942|DRUG|capecitabine|
48323973|NCT00084942|DRUG|gemcitabine hydrochloride|
47970585|NCT05651997|PROCEDURE|MACT|"* A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~* The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~* The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~* The membrane is implanted and sutured onto the injured site."
48119017|NCT06196099|DEVICE|Blood Flow Restriction|The study participants were instructed to rest quietly in a seated position for 10 minutes. During the last 3 minutes of the resting period, upper arm blood pressure was measured twice using an automatic blood pressure monitor (BP170, InBody, Korea). The blood flow restriction cuffs (BFR Therapy Cuff, BFR Therapy Co., USA) - measuring 5cm in width and 60cm in length - were applied to the upper third of the thigh on both legs. To maintain consistency in measurements, the distance from the proximal part of the kneecap to the distal edge of the cuff was measured. A Capillary Reaction Time (CRT) test was used to assess the appropriateness of the cuff pressure; this involved applying thumb pressure to the quadriceps muscle after cuff application and timing how long it took for the skin color to return to normal.
48119018|NCT06196099|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation (NMES) was applied five times a week for one week using a four-channel stimulator (Compex Physio, Chattanooga, Switzerland). The stimulation protocol was set to a frequency of 35Hz, with electrodes attached to the vastus lateralis and vastus medialis muscles. The therapist adjusted the intensity and alternating output of the electrodes selectively to facilitate the squat exercises required during the intervention. During the stimulation period, participants were engaged in a squat exercise program, with the total duration of stimulation being 10 minutes.
48119019|NCT06196099|BEHAVIORAL|Squat exercise|In this study, the squat exercise was performed in four sets. Participants were instructed to position their feet shoulder-width apart and educated to squat in such a way that their knees did not extend beyond their toes. To ensure consistency in performing the squat at the same angle, a mark was made on the wall at the pelvic height during a 90° squat. This allowed participants to perform squats at the same height. The exercise was conducted under the guidance of a physical therapist with five years of clinical experience.
48119020|NCT03100513|DRUG|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
48119021|NCT03100513|DRUG|Polyethylene Glycol|PEG as single dose of (3sachets if patient \<75Kg over 3 hours or 4 sachets if patient \>75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
48323974|NCT05454722|DEVICE|ADEX Gel|Emollient Gel with added anti-inflammatory
48323975|NCT02556424|DRUG|Dexamethasone|Intravitreal implant at D0
48323976|NCT02556424|DRUG|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
48488367|NCT00161382|BEHAVIORAL|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
48488368|NCT04487743|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
48648201|NCT03889015|DIETARY_SUPPLEMENT|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
48648202|NCT03463460|OTHER|Laboratory Biomarker Analysis|Correlative studies
48648203|NCT03463460|BIOLOGICAL|Pembrolizumab|Given IV
48648204|NCT03463460|DRUG|Sunitinib Malate|Given PO
48648205|NCT00389480|DRUG|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
48648206|NCT02044146|DRUG|Ticagrelor, Prasugrel, Clopidogrel|
48648207|NCT06472024|PROCEDURE|Verum Acupuncture|Acupuncture therapy uses filiform needles at a perpendicular angle at acupuncture points to produce a therapeutic effect.
47970586|NCT05651997|PROCEDURE|AMT|This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
47970587|NCT04970797|DRUG|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
47970588|NCT00228683|PROCEDURE|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
47970589|NCT03251300|DRUG|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
47970590|NCT03251300|DRUG|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
47970591|NCT00822783|DRUG|Omalizumab|
47970592|NCT00822783|DRUG|Placebo|
48323977|NCT03428802|OTHER|Laboratory Biomarker Analysis|Correlative studies
48488369|NCT04487743|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
48488370|NCT02573753|BEHAVIORAL|Sleep restriction|
48488371|NCT02573753|DIETARY_SUPPLEMENT|Weight gain|
48488372|NCT02296684|BIOLOGICAL|MK-3475 (neoadjuvant)|
48488373|NCT02296684|PROCEDURE|Surgery|Standard of care
48488374|NCT02296684|RADIATION|Intensity modulated radiation therapy|Recommended, standard of care
48488375|NCT02296684|RADIATION|Image-guided radiation therapy|Recommended, standard of care
48488376|NCT02296684|DRUG|Cisplatin|Standard of care
48488377|NCT02296684|BIOLOGICAL|MK-3475 (adjuvant)|
48488378|NCT02296684|PROCEDURE|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
48323978|NCT03428802|BIOLOGICAL|Pembrolizumab|Given IV
48323979|NCT05091892|OTHER|Hydrotherapy programm|Treatment
48323980|NCT02800473|DEVICE|Strorz (commercial)|
48323981|NCT02800473|DEVICE|CyPaM2 (experimental)|
48323982|NCT01392053|OTHER|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
48119022|NCT00727922|DRUG|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
48323983|NCT02578823|DEVICE|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
48323984|NCT02578823|DEVICE|Arcticgel™|
48323985|NCT02578823|PROCEDURE|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
48323986|NCT01230749|DRUG|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
48323987|NCT01230749|DRUG|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
48323988|NCT01230749|DRUG|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
48323989|NCT01989182|DEVICE|Spiration Valve System|
48323990|NCT01989182|OTHER|Medical Management|
48323991|NCT01868776|DRUG|buffered lidocaine|
48323992|NCT01868776|DRUG|nonbuffered lidocaine|
48323993|NCT01434264|PROCEDURE|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
48323994|NCT04613505|BEHAVIORAL|Semi-structured interview|Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.
48323995|NCT04613505|BEHAVIORAL|Same day consent questionnaire|A questionnaire (yet to be developed) will be administered to participants.
48488379|NCT04686838|BEHAVIORAL|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
48488380|NCT04686838|BEHAVIORAL|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
48323996|NCT03922035|OTHER|Best Practice|Receive standard peri-/post-transplant supportive care
48488381|NCT05671172|DRUG|Hyaluronidase|hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS
48488382|NCT05671172|DRUG|Bupivacaine Injection|20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
47970593|NCT04220320|DIAGNOSTIC_TEST|Vaginal examination.|Cervical properties as evaluated by a vaginal examination.
47970594|NCT04220320|DIAGNOSTIC_TEST|Transvaginal sonography.|Cervical length as evaluated by a transvaginal sonography.
48323997|NCT03922035|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
48323998|NCT01033487|DRUG|placebo|oral inhaled formulation, single dose
48323999|NCT01033487|DRUG|active comparator|oral inhaled formulation, single dose
48324000|NCT01033487|DRUG|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
48324001|NCT01033487|DRUG|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
48324002|NCT01033487|DRUG|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
48324003|NCT03517306|OTHER|No Interventions|No Interventions
48324004|NCT04473144|DRUG|Ulinastatin|In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
48324005|NCT01754207|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
48324006|NCT01754207|DEVICE|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
48324007|NCT04243252|BEHAVIORAL|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
48324008|NCT04243252|OTHER|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
48324009|NCT05838209|DRUG|test|Ozone oil used as an adjunctive of scaling and root planing and control,
48488383|NCT02939014|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
48498056|NCT01470911|DRUG|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
48648208|NCT06472024|PROCEDURE|Sham Acupuncture|Sham Acupuncture therapy uses filiform needles but is only attached with tape to acupuncture points
48119023|NCT04630535|PROCEDURE|aorto-bifemoral bypass surgery|aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)
48648209|NCT06209450|PROCEDURE|Ventral hernia repair with mesh fixation|Sutured versus suturless mesh fixation
48648210|NCT02346812|OTHER|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
48648211|NCT02346812|OTHER|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
48648212|NCT02674763|DRUG|IMGN779|
48119024|NCT05968859|BEHAVIORAL|Aerobic Training|Aerobic training will be conducted at 30 minutes 3 times a week using brisk walking with target heart rates goals based on percentage of peak HR reserve (HRR= peak-rest HR) during baseline exercise right heart catheterization (RHC). The target HR will progress over the study period from 50% to 70% of peak HR reserve added to resting HR using the standard Karvonen formula (Goal HR = rest HR + target % of HRR). HR will be monitored using Fitbits to guide training intensity with raw data analyzed using the Fitabase platform to monitor compliance
48119025|NCT05968859|BEHAVIORAL|Leg Training|Leg training will be performed using assigned ankle weights to perform knee extension while seated. Initial weight assignment will be guided by a protocol driven in-person exercise tolerance test using varying weights to identify the optimal initial and target training weight for each patient based on the 10 repetition maximum weight identified during this test. Leg training weight will begin at 40% of the baseline 10-repetition maximum weight for weeks 1-4 during which time patients will be required to complete 3 sets of 10 repetitions (30 repetitions total) on 3 days per week. For weeks 4-8, 55% of the initial 10-repetition maximum weight will be used for 4 sets of 10 repetitions (40 repetitions total). For weeks 8-12, 70% of the initial 10-repetition maximum weight will be used for 5 sets of 10 repetitions (50 repetitions total).
48119026|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy lifestyles
48119027|NCT03199209|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about healthy homes
48119028|NCT03199209|BEHAVIORAL|Patient Visit|Attend study visit with research staff
48119029|NCT03199209|OTHER|Questionnaire Administration|Ancillary studies
48119030|NCT03199209|OTHER|Text Message|Receive information about healthy lifestyles
48119031|NCT03199209|OTHER|Text Message|Receive texts about healthy homes
48648213|NCT03093246|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
48119032|NCT00686504|DRUG|AZD2066|single dose of oral dose, 3 times per subject
48119033|NCT00686504|DRUG|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
48119034|NCT00139672|DRUG|PD-217,014|
48119035|NCT01150383|OTHER|Physical exercise training with supplemental oxygen|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above)."
48648214|NCT03093246|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
48324010|NCT05838209|DRUG|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
48324011|NCT00327548|BEHAVIORAL|guided imagery|
48324012|NCT05397483|BEHAVIORAL|Legal Education plus Trauma-informed Therapy (LETiT)|Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
48324013|NCT05397483|BEHAVIORAL|Intervention As Usual (IAU)|Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
48324014|NCT04229472|DIAGNOSTIC_TEST|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
48324015|NCT04229472|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
48324016|NCT05435742|BIOLOGICAL|SON-080|Recombinant human interleukin-6 (rhIL-6)
48324017|NCT02159261|DRUG|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
48324018|NCT02601443|DEVICE|Cervical Pessary|
48324019|NCT03099980|BIOLOGICAL|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
48324020|NCT05663242|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
48324021|NCT05663242|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
48324022|NCT00748085|DEVICE|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
48648215|NCT03093246|OTHER|Placebo|Placebo pills over a period of 180 days
48648216|NCT03093246|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
48648217|NCT02350998|DRUG|OTO-201|
48648218|NCT01767857|DRUG|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
48324023|NCT04851002|PROCEDURE|Application of concentrated growth factor with dental implants|Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
48324024|NCT04851002|PROCEDURE|Application of advanced platelet rich fibrin with dental implants|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant
48324025|NCT04851002|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied
48324026|NCT04851002|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied
48324027|NCT00795353|DRUG|Amevive exposure|Commercial alefacept prescribed by Physician
48324028|NCT01911299|DIETARY_SUPPLEMENT|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
48324029|NCT01911299|DIETARY_SUPPLEMENT|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
48324030|NCT03258697|DRUG|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
48324031|NCT00546286|DRUG|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
48324032|NCT00546286|DRUG|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
48324033|NCT00044486|DRUG|Posaconazole oral suspension|
48324034|NCT05713578|DRUG|apantamide+docetaxel+ADT|Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
48324035|NCT05713578|DRUG|apantamide+ADT treatment|apantamide+ADT treatment
48324036|NCT04197986|DRUG|Infigratinib|Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
48324037|NCT04197986|DRUG|Placebo|Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
48324038|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg lorlatinib
48324039|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
48324040|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg QD lorlatinib
48324041|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
48324042|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
48324043|NCT01431144|PROCEDURE|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
48324044|NCT01431144|PROCEDURE|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
48324045|NCT03427541|PROCEDURE|Surgeries|Surgeries
48324046|NCT05796882|BEHAVIORAL|Whole Food Plant-Based Diet Ad Libitum|"Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed"
48324047|NCT05796882|BEHAVIORAL|Nutritional Standard Care|Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
48324048|NCT01369212|DRUG|Tenofovir|300 mg daily for 192 weeks (4 years)
48324049|NCT01369212|DRUG|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
48324050|NCT04682353|DRUG|TV-46046|SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
48324051|NCT04682353|DRUG|Depo-subQ Provera|SC injection of 104 mg/0.65 mL
48324052|NCT04296006|DRUG|Sustained Release d-amphetamine|Twice daily administration of active or placebo d-amphetamine
48324053|NCT04296006|BEHAVIORAL|Money|Three money values offered as alternatives to cocaine
48324054|NCT04339270|DRUG|Azithropycin according to symptoms|"Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
48648219|NCT01767857|DRUG|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
48648220|NCT05541328|OTHER|Tisagenlecleucel|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
48324055|NCT04339270|DRUG|Azithromycin according to rheology or symptoms|"Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
48324056|NCT01673191|DRUG|Dexamethasone intravitreal implant|
48324057|NCT01673191|DRUG|Steroid plus NSAID eye drop combination therapy|
48324058|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
48488384|NCT01916746|PROCEDURE|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
48488385|NCT00450983|BIOLOGICAL|muromonab-CD3|
48488386|NCT00450983|BIOLOGICAL|natural killer cell therapy|
48488387|NCT00450983|DRUG|fludarabine phosphate|
48648221|NCT06569641|DEVICE|Neoneur Feeding System|The Neoneur Feeding System is placed between a nipple and a bottle, and used to measure feeding skill patterns.
48119036|NCT01150383|OTHER|"Physical exercise training with room air supplementation"|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above)."
48119037|NCT02759016|DRUG|BI 836826|
48488388|NCT00450983|DRUG|methotrexate|
48488389|NCT00450983|DRUG|thiotepa|
48488390|NCT00450983|GENETIC|gene expression analysis|
48488391|NCT00450983|OTHER|flow cytometry|
48488392|NCT00450983|OTHER|immunologic technique|
48488393|NCT00450983|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48648222|NCT01764932|PROCEDURE|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
48488394|NCT00450983|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48488395|NCT00450983|RADIATION|total-body irradiation|
48488396|NCT00290394|DRUG|rosiglitazone(drug), blood pressure lowering effect|
48488397|NCT05434858|OTHER|Dual-energy CT (DECT) and ultrasound|DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
48488398|NCT03994549|DRUG|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
48488399|NCT03913260|DRUG|LY3375880|Administered SC
48488400|NCT03913260|DRUG|Buffer Matrix (No LY3375880)|Administered SC
48488401|NCT03913260|DEVICE|Autoinjector (AI)|AI used to administer LY3375880 or Buffer Matrix
48488402|NCT03913260|DEVICE|Manual Syringe|Manual syringe used to inject LY3375880
48488403|NCT02919241|BEHAVIORAL|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
48488404|NCT02919241|BEHAVIORAL|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
48488405|NCT03082170|DEVICE|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
48648223|NCT03133377|BEHAVIORAL|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
47970595|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(High dose 2g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins \& vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
48119038|NCT02759016|DRUG|Ibrutinib|Standard of Care
48648224|NCT01716637|BIOLOGICAL|Etanercept|
48648225|NCT01716637|DIETARY_SUPPLEMENT|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
48119039|NCT04212195|GENETIC|Next generation sequencing|Saliva samples
48119040|NCT04212195|DIAGNOSTIC_TEST|Imaging and fluid biomarkers|Magnetic resonance imaging of the brain and urine, blood and cerebrospinal fluid sampling
48119041|NCT00970658|DRUG|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
48119042|NCT00970658|DRUG|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
48324059|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
48324060|NCT01175213|BIOLOGICAL|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
48324061|NCT00379262|DRUG|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
48324062|NCT00379262|DRUG|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
48488406|NCT03082170|DIAGNOSTIC_TEST|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
48488407|NCT03082170|BEHAVIORAL|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
48488408|NCT04887233|OTHER|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
48324063|NCT00379262|DRUG|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
48324064|NCT00965406|DRUG|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
48488409|NCT04887233|OTHER|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
48488410|NCT04235699|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
48488411|NCT01764243|DRUG|MT-4666|low dose, high dose
48488412|NCT01764243|DRUG|Placebo|
48488413|NCT00735917|DRUG|saracatinib|Given PO
48488414|NCT00735917|OTHER|pharmacogenomic studies|Optional correlative studies
48488415|NCT00735917|OTHER|pharmacological study|Optional correlative studies
48119043|NCT02015520|DRUG|Clazakizumab|
48324065|NCT06504485|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
48324066|NCT00974051|DRUG|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
48488416|NCT00735917|PROCEDURE|positron emission tomography|Optional correlative studies
48324067|NCT00974051|OTHER|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
48324068|NCT00974051|OTHER|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
48488417|NCT00735917|RADIATION|fludeoxyglucose F 18|Optional correlative studies
48488418|NCT00735917|OTHER|laboratory biomarker analysis|Optional correlative studies
48119044|NCT02015520|DRUG|Placebo (Matching with Clazakizumab)|
48119045|NCT02831712|DIETARY_SUPPLEMENT|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
48324069|NCT00373490|DRUG|Vorinostat|600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
48488419|NCT03676166|DRUG|Cannabis|Inhaled cannabis
48488420|NCT04158960|BEHAVIORAL|Equine-assisted activities|Participants performed riding-related activities on and off of a horse once per week for 8 weeks
48488421|NCT04158960|BEHAVIORAL|GaitWay program|Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
48488422|NCT03396666|OTHER|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
48324070|NCT00373490|DRUG|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
48324071|NCT06027073|BIOLOGICAL|omalizumab|adding omalizumab to anti asthmatic therapy
48324072|NCT00709033|BIOLOGICAL|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
48324073|NCT02415764|BEHAVIORAL|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
48119046|NCT05910749|DEVICE|QEEG-Guided sLoreta Neurofeedback Training|The team will produce a neurofeedback (NFB) protocol based on QEEG sLORETA Brodmann Voxel evaluation of brain deviated/dysregulated areas. Subsequent 12 to15 sessions of individualized NFB protocol will be conducted using BrainAvatar software to normalize these regions. The NFB session will display the cortical surface and subsurface networks being trained in a live fashion. Patients will be seated on a comfortable chair in a dimly lit room and, wearing a 19-channel EEG-cap connected to an EEG amplifier, they will receive auditory and visual feedback when they meet Brodmann Voxels Z-Scores inside of +/-1.5 standard deviations (SD) on each electrode training site. Thresholds for the feedback will be first set a +/-2 SD and brought down to +/-1.5 SD throughout the sessions (subject performance dependent). Patients are encouraged to relax, hear the sounds, and watch a feedback game.
48119047|NCT06147167|DEVICE|individualized intermittent theta burst sitmulation (iTBS)|Participants undergo daily sessions of individualized intermittent theta-burst stimulation (iTBS) administered with the MagStim stimulator (Rapid2, MagStim, Whiteland, United States). The intervention spans five days a week and extends over a three-week period. In this group, participants receive a personalized iTBS protocol comprising three pulses of stimulation delivered at 50 Hz, repeated every 200 ms. The stimulation frequency is tailored based on the electroencephalogram (EEG) results and is administered every 10 seconds, with a total duration of 190 seconds. The treatment is administered once a day for five days a week and continues for three weeks, with an immediate cessation in case of any discomfort. This study design ensures a meticulous and tailored approach to iTBS administration.
48119048|NCT06147167|DEVICE|standard iTBS|The MagStim stimulator (Rapid2, MagStim, Whiteland, United States) was employed in the current study. The intermittent theta-burst stimulation (iTBS) protocol utilized three pulses of stimulation delivered at a frequency of 50 Hz, with a repetition rate of every 200 ms. These pulses were organized into 2-second trains, repeated every 10 seconds, resulting in a cumulative duration of 190 seconds (equivalent to a total of 600 pulses). Notably, the administration of the treatment ceased promptly in the event of any participant discomfort.
48119049|NCT06147167|DEVICE|sham stimulation|The device and protocol are identical to the standard iTBS, with the only difference being the orientation of the coil, which is perpendicular to the scalp.
48119050|NCT06331611|DEVICE|TOF monitoring|Reversal with Sugammadex will be based on TOF monitoring
48119051|NCT03032224|PROCEDURE|Resection of the esophagus and the gastroesophageal junction|
48119052|NCT04498663|BEHAVIORAL|Emotion- and Relationship-Focused Therapeutic Interview|In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
48119053|NCT00367159|PROCEDURE|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
48119054|NCT06338618|PROCEDURE|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
48324074|NCT02787330|BEHAVIORAL|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
48119055|NCT05579899|DRUG|EVO101|Topical Cream
48119056|NCT00293358|DRUG|carboplatin|
48324075|NCT02787330|BEHAVIORAL|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
48324076|NCT04439370|DIAGNOSTIC_TEST|Microneurography to measure muscle sympathetic nerve activity (MSNA)|Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
48324077|NCT04439370|DIAGNOSTIC_TEST|Baroreflex sensitivity testing|Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
48324078|NCT04439370|DIAGNOSTIC_TEST|Sympathoexcitatory Maneuvers|Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
48324079|NCT04439370|DIAGNOSTIC_TEST|Blood tests|Serum FSH, estrogen, progesterone, and testosterone will be measured
48324080|NCT03184857|PROCEDURE|open maxillary sinus lifting|biopsy of the region 6 months later
48324081|NCT00410449|DRUG|Alpha tocopherol|
48119057|NCT00293358|DRUG|cisplatin|
48119058|NCT00293358|DRUG|etoposide phosphate|
48119059|NCT00293358|DRUG|ifosfamide|
48119060|NCT00293358|PROCEDURE|adjuvant therapy|
48119061|NCT00293358|PROCEDURE|conventional surgery|
48119062|NCT00293358|PROCEDURE|neoadjuvant therapy|
48119063|NCT00293358|RADIATION|radiation therapy|
48324082|NCT04653142|DRUG|BI 765063|BI 765063
48324083|NCT04653142|DRUG|BI 754091|BI 754091
48324084|NCT01000779|DRUG|Propranolol|upto 320mg/day maximum
48324085|NCT01000779|DEVICE|multi band ligator for esophageal varices|to obliterate esophageal varices
48324086|NCT02862548|DRUG|TAF|Tablet administered orally
48324087|NCT02862548|DRUG|TDF|Tablet administered orally
48324088|NCT02862548|DRUG|Other approved antivirals|Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
48324089|NCT00565656|DRUG|BEVACIZUMAB|Administration of Bevacizumab
48324090|NCT02941289|PROCEDURE|visual search performance of everyday objects in realistic scenes|
48324091|NCT05854251|DRUG|Anakinra|Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
48324092|NCT05854251|DRUG|Placebo|0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
48488423|NCT01684436|DEVICE|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
48324093|NCT01974986|OTHER|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
48488424|NCT05656079|DRUG|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
48488425|NCT05656079|DRUG|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
48488426|NCT05656079|DRUG|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
48488427|NCT05656079|DRUG|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
48488428|NCT05656079|DRUG|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
48488429|NCT05656079|DRUG|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
48488430|NCT01698775|DRUG|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
48488431|NCT01698775|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
48488432|NCT01698775|DRUG|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
48488433|NCT01698775|DRUG|Placebo to glipizide|Matching placebo to glipizide daily
48488434|NCT01698775|BIOLOGICAL|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
48488435|NCT01432574|BIOLOGICAL|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
48488436|NCT00177502|BEHAVIORAL|behavioral exercise intervention|
48488437|NCT01846117|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
48488438|NCT03653052|DRUG|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
48488439|NCT01301508|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
48488440|NCT01301508|DRUG|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
48488441|NCT01301508|DRUG|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
48488442|NCT01301508|DRUG|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
48488443|NCT05468788|BEHAVIORAL|Intervention: Integrative Community Therapy-based Psychodrama|Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
48488444|NCT05468788|BEHAVIORAL|Control: Improvisational Theatre|Participants play improvisational theatre games.
48488445|NCT01769274|DRUG|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
48488446|NCT01769274|DRUG|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
48488447|NCT00957619|DRUG|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
48324094|NCT01974986|OTHER|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
48324095|NCT01974986|OTHER|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
48488448|NCT00957619|DRUG|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
48488449|NCT02646449|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
48488450|NCT02646449|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
48488451|NCT02756247|DRUG|Buparlisib|
48488452|NCT02756247|DRUG|Ibrutinib|
48488453|NCT00876018|OTHER|Nutritional supplement|Fortified nutritional powder
48488454|NCT00876018|OTHER|Placebo|Un-fortified nutritional powder
48488455|NCT00809159|BIOLOGICAL|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
48488456|NCT00809159|DRUG|Placebo|Placebo to AIN457
48488457|NCT02630836|DRUG|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
48488458|NCT02630836|PROCEDURE|Surgical treatment|Isolated endomedullary nailing
48324096|NCT01995136|DRUG|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
48324097|NCT06098209|DRUG|Dexmedetomidine|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
48324098|NCT06098209|DRUG|Propofol|Patient will receive propofol 0.3-4 mg/kg/h.
48488459|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
48488460|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
48488461|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
48488462|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
48648226|NCT06214325|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, a minimum of 24 hours apart, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
48488463|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
48648227|NCT00979615|DRUG|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
48648228|NCT00979615|DRUG|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
48648229|NCT06548113|DEVICE|TMS|transcranial magnetic brain stimulation
48648230|NCT00004228|DRUG|asparaginase|Given IV
48648231|NCT00004228|DRUG|cyclophosphamide|Given IV
48648232|NCT00004228|DRUG|cytarabine|Given IV
48648233|NCT00004228|DRUG|daunorubicin hydrochloride|Given IV
48648234|NCT00004228|DRUG|dexamethasone|Given IV
48648235|NCT00004228|DRUG|doxorubicin hydrochloride|Given IV
48119064|NCT05547607|DIAGNOSTIC_TEST|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
48119065|NCT03957213|DEVICE|Acute Intermittent Hypoxia|Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
48119066|NCT03957213|BEHAVIORAL|Computerized Cognitive Training|60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
48488464|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
48488465|NCT05575635|DRUG|fruquintinib + concurrent radiotherapy + chemotherapy|"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0\~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"
48488466|NCT01079832|RADIATION|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
48648236|NCT00004228|DRUG|leucovorin calcium|Given IV
48119067|NCT03654235|OTHER|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
48119068|NCT03654235|OTHER|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
48488467|NCT01079832|PROCEDURE|quality-of-life assessment|Ancillary studies
48648237|NCT00004228|DRUG|mercaptopurine|Given IV
48648238|NCT00004228|DRUG|methotrexate|Given IV
48648239|NCT00004228|DRUG|prednisone|Given IV
48648240|NCT00004228|DRUG|thioguanine|Given PO
48648241|NCT00004228|DRUG|vincristine sulfate|Given IV
48648242|NCT00004228|RADIATION|radiation therapy|
48488468|NCT05402462|DIAGNOSTIC_TEST|upper endoscopy|detect esphageal motility disorder by upper endoscopy and esophageal manometry
48488469|NCT02914236|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
48488470|NCT01938404|BIOLOGICAL|Octaplas|Octoplas infusion solution for IV administration
48488471|NCT01938404|DRUG|Standard Plasma|Plasma given as replacement fluid
48488472|NCT00072020|DRUG|zoledronic acid|
48488473|NCT00072020|PROCEDURE|adjuvant therapy|
48488474|NCT00072020|PROCEDURE|neoadjuvant therapy|
48648243|NCT05684198|DEVICE|subcutaneous NPWT|Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
48648244|NCT02496312|BEHAVIORAL|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
48648245|NCT02012777|DRUG|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
48648246|NCT00836901|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
48648247|NCT00836901|DRUG|Augmentin®|400 mg-57 mg chewable tablet
48648248|NCT01678365|DRUG|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
48648249|NCT02202265|DIETARY_SUPPLEMENT|Olive oil|30ml a day of olive oil
48648250|NCT02202265|DIETARY_SUPPLEMENT|Nuts|30g a day of nuts
48648251|NCT02202265|DIETARY_SUPPLEMENT|Control diet|Diet based on standard guidelines
48648252|NCT01928537|DRUG|rigosertib sodium|
48648253|NCT06672822|DRUG|Sodium Thiosulfate (STS)|Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg/ml) will be used for injection under ultrasound guidance.
48648254|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
48119069|NCT03654235|OTHER|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
48119070|NCT01591239|BEHAVIORAL|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
48119071|NCT01591239|BEHAVIORAL|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
48119072|NCT06516861|DRUG|Magnesium Sulfate 20 MG/ML|Administered intravenously with a dose of 30 mg/kg
48119073|NCT06516861|DRUG|Lidocaine IV|Administered intravenously with a dose of 1.5mg/Kg
48119074|NCT06516861|DRUG|saline solution|Administered intravenously with 20 ml
48324099|NCT02321618|BEHAVIORAL|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
48488475|NCT05335993|BIOLOGICAL|Oregovomab|2 mg, added to 50 mL of Sodium Chloride infused over 20 ± 5 minutes.
48488476|NCT05335993|DRUG|Niraparib|300mg administered orally once daily starting at the first day of treatment (Day 1 Week 1) to the end of Week 12. Subjects whose baseline weight is \<77 kg or platelet count is \<150,000 μL, the daily dosing will be 200mg.
48648255|NCT01284738|OTHER|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
48648256|NCT00875407|OTHER|Scintigraphy in 123I-IBZM|
48648257|NCT02203279|OTHER|Rebase II Fast|It is going to be used a direct relining material
48648258|NCT02203279|OTHER|Flexacryl|This is going to be used as a second direct relining material
48648259|NCT02203279|OTHER|Vertex|This is going to be used as an indirect relining material
48119075|NCT02190643|BEHAVIORAL|Cessation counseling with adherence focus|
48648260|NCT05512819|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
48648261|NCT05512819|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
48119076|NCT02190643|BEHAVIORAL|Cessation counseling without adherence focus|
48119077|NCT03160599|OTHER|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.
48119078|NCT05486897|OTHER|None, pure observational study|None, pure observational study
48119079|NCT04056611|DRUG|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
48119080|NCT04056611|DRUG|Placebo|Matching placebo will be administered orally.
48119081|NCT04056611|DRUG|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
48324100|NCT02321618|BEHAVIORAL|BP educational materials|Exposure to hypertension educational materials
48488477|NCT05143151|BIOLOGICAL|CD276 CAR-T cells|CD276 CAR-T cells infusion
48488478|NCT04375852|DIAGNOSTIC_TEST|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
48648262|NCT06216262|OTHER|Control group|Brushing teeth twice a day for 8 weeks
48648263|NCT06216262|OTHER|Arginine|Brushing teeth twice a day for 8 weeks
48648264|NCT06216262|OTHER|Novamin|Brushing teeth twice a day for 8 weeks
48648265|NCT06216262|OTHER|Propolis|Brushing teeth twice a day for 8 weeks
48648266|NCT06216262|OTHER|Casein Phosphopeptide Amorphous Calcium Phosphate|Following the procedure in the control group, it is applied to the tooth surface once a day for 3 minutes before going to bed at night for 8 weeks
48648267|NCT06216262|OTHER|Potassium Nitrate|Following the procedure in the control group, mouthwash twice a day in the morning and evening for 8 weeks
48119082|NCT03664401|DEVICE|Kerecis Oral™|
48119083|NCT03664401|OTHER|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
48324101|NCT01042951|BIOLOGICAL|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
48324102|NCT01042951|OTHER|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
48648268|NCT03253627|BEHAVIORAL|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
48324103|NCT00789191|DRUG|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
48648269|NCT03253627|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
48648270|NCT06080204|DRUG|Octreotide LAR|Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
48648271|NCT04210102|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
48648272|NCT04210102|DIAGNOSTIC_TEST|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
48648273|NCT04071535|DEVICE|sudoscan、nerve conduction tests|To evaluate sudomotor nerve and macrofibropathy.
48648274|NCT01657331|DRUG|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
48648275|NCT01657331|DRUG|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
48648276|NCT01657331|DRUG|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
48648277|NCT03694730|OTHER|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
48648278|NCT03694730|OTHER|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
48648279|NCT02837952|DRUG|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
48648280|NCT02837952|DRUG|Placebo|Placebo
48648281|NCT00324545|BEHAVIORAL|Medium-intensity Minimally-directive Counseling|
48648282|NCT05855278|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
48648283|NCT05736913|BIOLOGICAL|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
48648284|NCT05736913|BIOLOGICAL|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
48648285|NCT01258985|BEHAVIORAL|Tai Chi|12 weeks of Tai Chi
48648286|NCT01258985|BEHAVIORAL|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
48648287|NCT06430411|PROCEDURE|Radical prostatectomy|Removal of the prostate and seminal vesicles.
48648288|NCT06430411|RADIATION|Prostate irradiation|Radiation therapy of the prostate.
48648289|NCT06430411|PROCEDURE|Surgical metastasectomy|Surgical removal of metastases.
48648290|NCT06430411|RADIATION|Irradiation of metastases|Radiation therapy of metastases.
48648291|NCT06430411|DRUG|Abiraterone acetate|Administered as part of multimodal treatment for oligometastatic prostate cancer
48324104|NCT00789191|DRUG|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
48324105|NCT00789191|DRUG|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
48324106|NCT00789191|DRUG|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
48324107|NCT03520725|OTHER|No Intervention|This gruop did not have an intervention
48324108|NCT03520725|DIETARY_SUPPLEMENT|Pineapple snack bar|30 g daily of pineapple snack bar
48324109|NCT03520725|DIETARY_SUPPLEMENT|Mango snack bar|30 g daily of mango snack bar
48324110|NCT03172858|DEVICE|Intracervical balloon catheter|cervical ripening balloon
48324111|NCT03172858|DRUG|Oxytocin|medication used to induce contractions
48324112|NCT05723315|DRUG|recombinant human B-type natriuretic peptide|The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
48324113|NCT02603185|DRUG|Hemay007|
48324114|NCT02603185|DRUG|placebo|
48324115|NCT00050986|DRUG|Temozolomide|Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
48648292|NCT06430411|DRUG|Enzalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
48648293|NCT06430411|DRUG|Darolutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
48324116|NCT00050986|DRUG|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
48648294|NCT06430411|DRUG|Apalutamide|Administered as part of multimodal treatment for oligometastatic prostate cancer
48648295|NCT06430411|DRUG|Docetaxel|Administered as part of multimodal treatment for oligometastatic prostate cancer
48648296|NCT06430411|DRUG|Lutetium-PSMA|Administered as part of multimodal treatment for oligometastatic prostate cancer
48648297|NCT06430411|DRUG|Androgen deprivation treatment|Administered as part of multimodal treatment for oligometastatic prostate cancer
48648298|NCT01628770|DRUG|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
48648299|NCT01628770|DRUG|Ferrous sulphate|200mg twice daily
48648300|NCT03702595|OTHER|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
48648301|NCT02542280|PROCEDURE|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
48648302|NCT02542280|PROCEDURE|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
48648303|NCT02542280|DRUG|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
48324117|NCT04595396|PROCEDURE|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
48324118|NCT01818388|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
48324119|NCT01700985|DRUG|122-0551|Applied twice daily for two weeks
48324120|NCT01700985|DRUG|Vehicle|Applied twice daily for two weeks
48488479|NCT02422914|BEHAVIORAL|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
48488480|NCT02422914|BEHAVIORAL|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
48488481|NCT02422914|BEHAVIORAL|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
48488482|NCT01933464|DRUG|Cromolyn Sodium|
48488483|NCT01933464|DRUG|Normal Saline|
48488484|NCT01252875|PROCEDURE|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
48488485|NCT01252875|PROCEDURE|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
48488486|NCT00266526|BIOLOGICAL|Recombinant birch pollen|
48488487|NCT02044549|DRUG|carbetocin|Oxycontin analogue
48488488|NCT02044549|DRUG|Syntometrine|Uterotonins
48488489|NCT04906252|DIAGNOSTIC_TEST|Echocardiography|Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution
48488490|NCT04906252|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
48488491|NCT04026685|DRUG|Phenylephrine infusion|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
48488492|NCT04026685|DRUG|Phenylephrine infusion and Ringer-Acetate bolus|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
48488493|NCT04322149|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
48488494|NCT04131049|OTHER|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
48488495|NCT04131049|OTHER|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
48648304|NCT03208179|DRUG|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
48648305|NCT03208179|DRUG|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
48648306|NCT03208179|DRUG|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
48324121|NCT03101514|DRUG|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
48324122|NCT03101514|DRUG|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
48324123|NCT03148626|OTHER|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
48324124|NCT03148626|OTHER|Control|Usual Education
48324125|NCT00644254|PROCEDURE|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
47970596|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
47970597|NCT06074367|DRUG|placebo capsules|A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
47970598|NCT02609269|OTHER|Decipher Cancer Classifier|The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA
47970599|NCT02100085|BIOLOGICAL|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
48324126|NCT00796042|OTHER|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
48324127|NCT00796042|OTHER|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
48324128|NCT06322706|DRUG|ABSK021|ABSK021 oral
48324129|NCT06322706|DRUG|Omeprazole|Omeprazole oral
48488496|NCT04131049|OTHER|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
48488497|NCT04131049|OTHER|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
48488498|NCT01915719|PROCEDURE|Early non invasive ventilation|
48488499|NCT01915719|PROCEDURE|Oxygen therapy only|
48488500|NCT03507478|DEVICE|BPI1000013|Foam insole
48488501|NCT04146363|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
48488502|NCT04146363|OTHER|Placebo|Subcutaneous Injection
48488503|NCT03356886|PROCEDURE|Spinal Manipulative Technique|1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
48488504|NCT03356886|BEHAVIORAL|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
48488505|NCT03500497|DIAGNOSTIC_TEST|RetHe measurement (Sysmex)|RetHe measurement is done from blood samples gained during standard patient care perioperatively
48324130|NCT03971500|DRUG|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
48324131|NCT03971500|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
48488506|NCT04882566|OTHER|Paleolithic Diet|Advice to follow Paleolithic Diet for Inflammatory bowel disease Patients
48488507|NCT05441995|OTHER|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
47970600|NCT01388764|DRUG|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
47970601|NCT05950958|OTHER|Multimodal therapy for prevention of delirium|Multimodal therapy for prevention of delirium
48119084|NCT06197217|DRUG|WPV01|Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
48324132|NCT01763463|DRUG|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
48488508|NCT05099484|DRUG|The MedMilk study|This observational, pragmatic PK study will enroll lactating women who are taking medications that were prescribed by their treating medical provider or as an over-the-counter medication.
47970602|NCT03146013|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
47970603|NCT05251974|DIAGNOSTIC_TEST|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
48119085|NCT06197217|DRUG|Placebo|Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
48324133|NCT01763463|DRUG|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
48488509|NCT02071849|DEVICE|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
48488510|NCT01068379|PROCEDURE|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
48488511|NCT01068379|PROCEDURE|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
47970604|NCT01996293|DRUG|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
48119086|NCT05234853|DRUG|PUR001|Monoclonal antibody
48324134|NCT04196205|BIOLOGICAL|Anti-CD19 CAR-T|1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh
48324135|NCT00383214|DRUG|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
48488512|NCT01698437|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
48488513|NCT05729919|PROCEDURE|Free gingival graft technique|"A horizontal partial thickness incision will be trace at the MGJ to dissect the alveolar mucosa from the keratinized tissue. The alveolar mucosa will be dissected from the underlying periosteum to create an envelope of 4-5 mm apical to the bone dehiscence associated with the gingival recessions. The keratinized tissue coronal to the first incision and neighboring the recession will be de-epithelialized to expose the connective tissue and create a trapezoidal recipient bed having a large apical base at the MGJ and a narrower coronal base just coronal to the CEJ of the experimental units. The grafts will be taken from the palate.The grafts will be positionned with the coronal edge of the CEJ.~Interrupted sutures (6-0 polypropylene, prolene) will be positionned to stabilize the graft. Sling crossed sutures anchored to the periosteum apical to the graft and placed to ensure a tight adaptation of the graft to the root surface"
48488514|NCT00223353|OTHER|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
48488515|NCT01473121|OTHER|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
48488516|NCT05033912|DRUG|CST-2032, matching placebo for CST-2032, CST-107|CST-2032 and matching placebo oral liquid; CST-107 white capsules
48119087|NCT01599104|DRUG|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
48324136|NCT00383214|OTHER|Placebo|Intravenous
48324137|NCT01590862|DEVICE|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
48324138|NCT04493957|BEHAVIORAL|ACCOMPAGNE Education Program|"The following workshops will be organised :~* Presentation workshop~* Cognitive skills workshop~* Perception and Environment workshop~* Responsibilities workshop~* Representation workshop -~* Caregivers workshop,~* Solutions workshop"
48324139|NCT04493957|BEHAVIORAL|Usuals recommandations|Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
48119088|NCT01599104|DRUG|Olmesartan|Olmesartan 20 mg capsule one daily
48119089|NCT01599104|DRUG|Placebo|Placebo to LCZ696 or Olmesartan
48119090|NCT00002964|DRUG|porfimer sodium|
48119091|NCT00002964|OTHER|fluorophotometry|
48324140|NCT06512194|DRUG|Psilocybin|The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of synthetic psilocybin.
48324141|NCT06512194|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For both the active and sham taVNS procedure, participants will be provided with, and trained on, use of a taVNS device that applies gentle stimulation to the left ear.
48488517|NCT04841330|DEVICE|Securis™ Stabilization Device|A trained clinician will apply and remove, and participants will wear the Securis™ Stabilization Device for up to one week (7 days) on their forearm. A shortened catheter will be placed (not inserted) over the Securis™ device in accordance with the product Information for Use (IFU), and an extension set attached to the catheter and secured in place, to simulate clinical use.
48488518|NCT00845975|DEVICE|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
47970605|NCT00864383|DRUG|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
48488519|NCT00845975|DEVICE|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
47970606|NCT06086470|DEVICE|Qidni/D Hemodialysis System|Qidni/D is a hemodialysis device for patients with end-stage renal disease.
47970607|NCT06133205|OTHER|Catgut Embedding at acupoints|Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
48488520|NCT01474902|DRUG|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
48488521|NCT06248268|OTHER|(Neuro-)psychological assessment|The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.
48488522|NCT06105320|OTHER|LCHF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%"
48488523|NCT06105320|OTHER|HCLF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%"
48488524|NCT03527251|DRUG|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
48488525|NCT03527251|DRUG|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
48488526|NCT01289444|BEHAVIORAL|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
48488527|NCT01289444|BEHAVIORAL|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
48488528|NCT06392204|PROCEDURE|CAD/CAM patient specfifc fracture reduction/plate guide and customized 3D grid plate|Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate
48488529|NCT06392204|PROCEDURE|Champy's techqniue|Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
48488530|NCT00545207|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
48488531|NCT00545207|DRUG|Placebo|po monthly for 2 years
48488532|NCT02610387|DEVICE|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
48648307|NCT05460169|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
48648308|NCT00648713|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
48648309|NCT00648713|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fed
48648310|NCT05447663|DRUG|Siremadlin|30-40 mg QD siremadlin capsules, orally (1-5 days of 28 or 42 days cycle)
47970608|NCT02473432|PROCEDURE|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
47970609|NCT02473432|PROCEDURE|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
47970610|NCT02473432|PROCEDURE|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
47970611|NCT05654337|OTHER|Expert health counseling|Expert advice on dietary education, lifestyle change, and physical exercise schedule
47970612|NCT03129100|DRUG|Ixekizumab|Administered SC
47970613|NCT03129100|DRUG|Placebo|Administered SC
48324142|NCT06512194|DEVICE|Sham taVNS|For both the active and sham taVNS procedure, participants will be provided with, and trained on, use of a taVNS device that applies gentle stimulation to the left ear.
48324143|NCT06512194|OTHER|Treatment as Usual|Treatment as usual consists of an integration 1-day, 1-week, and 2-weeks post-psilocybin dosing.
48324144|NCT05096013|OTHER|individual nutritional therapy|Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
48324145|NCT00141700|DRUG|Rituximab|
48324146|NCT00897325|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48488533|NCT02610387|DEVICE|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
48488534|NCT00560937|DRUG|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
48488535|NCT00560937|DRUG|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
48488536|NCT05306171|BEHAVIORAL|Online training for healthcare professionals|"The online training (4 modules) will use the technique of hybrid learning, combining meetings that will require the presence of participants and mediator at the same time and platform (live) with recorded meetings (interviews with experts) that will be watched by the participants at any time (from a distance).~Module 1: Self Care; Module 2: Stress and anxiety management; Module 3: Relationships; Module 4: Communication."
48488537|NCT06073535|PROCEDURE|Extraction of mandibular third molar|"After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary."
48488538|NCT06073535|DEVICE|i-PRF|20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
48488539|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane|Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation
48488540|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)|Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method
48488541|NCT06331741|PROCEDURE|Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity|Arthroplasty with consequent collagen membrane implantation
48488542|NCT02013375|PROCEDURE|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
48488543|NCT02013375|DRUG|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
48488544|NCT02013375|RADIATION|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
48488545|NCT02013375|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
48488546|NCT02013375|DRUG|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
48324147|NCT00897325|OTHER|Laboratory Biomarker Analysis|Correlative studies
48324148|NCT06499727|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
48488547|NCT01312311|DRUG|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
48324149|NCT06499727|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
48324150|NCT06041295|BEHAVIORAL|on-the-job training of lung expansion therapy|on-the-job training of lung expansion therapy
47970614|NCT03853408|PROCEDURE|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
47970615|NCT02223897|DRUG|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
48324151|NCT02302885|OTHER|Blood collection|Blood Collection
48324152|NCT00054249|DRUG|T900607|
48324153|NCT02555657|BIOLOGICAL|pembrolizumab|
48324154|NCT02555657|DRUG|capecitabine|
48324155|NCT02555657|DRUG|eribulin|
48324156|NCT02555657|DRUG|gemcitabine|
48324157|NCT02555657|DRUG|vinorelbine|
48119092|NCT05572060|DRUG|Metformin|Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.
48119093|NCT05572060|OTHER|standardized protocol|standardized protocol
48119094|NCT05395546|OTHER|dCBT-I|"1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group~2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor~3. Scale assessment needs to be completed at the end of treatment~4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation"
48119095|NCT00435578|DRUG|Glufosfamide|
48119096|NCT05925140|DRUG|Lopinavir / Ritonavir|"Kaletra is a medication that is produced by AbbVie, a pharmaceutical company based in the United States. It is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients. Kaletra contains two active ingredients, lopinavir, and ritonavir, which work together to inhibit the replication of the HIV virus.~Administration dose and duration of treatment: Patients will receive a loading dose (800/200, daily) of lopinavir 400 mg plus ritonavir 100 mg orally every 12 h for 10 days or until discharge, if sooner."
48119097|NCT05925140|DRUG|Remdesivir (RDV)|"Remdesivir is provided by the United States as an FDA-approved drug, an antiviral medication developed by Gilead Sciences, and has been authorized for emergency use and approved for the treatment of COVID-19 in certain countries, including the United States.~Administration dose and duration of treatment: intravenously as a 200-mg loading dose on day 1, followed by a 100-mg once daily on days 2-10 or until hospital discharge or death. Duration is generally 5 days or until hospital discharge, whichever is first, but may extend to up to 10 days based on clinical response: For inpatients not requiring IMV and/or ECMO: 5 days; if clinical improvement is not demonstrated, treatment may be extended up to 10 days total. For inpatients requiring IMV and/or ECMO: 10 days."
48119098|NCT05925140|DRUG|Tocilizumab|"Actemra is an FDA-approved brand name for Tocilizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, an immunosuppressive drug produced by Roche. It belongs to a class of medications known as IL-6 receptor antagonists and is designed to suppress the activity of the immune system. By blocking IL-6 receptor signaling, Actemra helps reduce inflammation and is used in the treatment of various autoimmune conditions and cytokine release syndrome.~Administration dose and duration of treatment: TCZ was administered 8 mg/kg intravenously (800 mg per infusion) as a single 60-minute intravenous infusion for 4 Weeks initially. The second infusion (400 mg) after 24 h may be administered based on clinical response in case of respiratory worsening, or 8 mg/kg at T0 followed by 8 mg/kg after 12 h."
48119099|NCT05925140|OTHER|Corticosteroid Therapy-enhanced Standard Care (CTSC)|(1) Methylprednisone (120mg/24h/IV) followed by 80mg/day (7days), and if necessary, continued with 40mg/day; or a pulse therapy (patient in critical state (360mg/day/IV) for 3 serial days, followed by 80mg/day (7days), and if necessary, continued with a dose of 40mg/day. (2) Standard Care: Normal Saline 0.9% (500cc/24h); vitamins \[D (Oravil, 100.000IU/2ml PO STAT), C (10g/250cc in normal saline, 60drops/min/day), B (BECOZYME, 6 ampoules IV STAT)\]; Omeprazole (RISEK, 40 mg/day IV); Paracetamol (PREFALGAN, 1g IV each 8h 3 times per day), Ketoprofen (PROFENID, 100mg/12h); Ceftriaxone (ROCEPHIN, 2g/day for 3 consecutive days), Doxycycline (VIBRAMYCIN, 100mg/12h PO for 8 days), Ivermectin (12mg/day for a period of 5 days); TOPLEXIL (Syrup, 10cc/each 8h) or SINECOD (Syrup, 15cc/each 8h); ATORVASTATIN (20mg/day); LOVENOX (40mg/12h if \<80kg, or 60mg/12h if \>80kg). Tranquillizers: NORMOCALM (400mg/night), XANAX (10mg/day), SEROQUEL (25mg/night), DEPIA (2mg/day), to be administered orally
48119100|NCT04207294|OTHER|Pork arm|The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
48119101|NCT04207294|OTHER|Chicken arm|The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
48119102|NCT06081049|DRUG|Colchicine|0.5 mg once daily
48119103|NCT06081049|DRUG|Placebo|Once daily
48119104|NCT05263609|DRUG|Axitinib|If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).
48488548|NCT02615171|BEHAVIORAL|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
48488549|NCT02615171|BEHAVIORAL|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
48488550|NCT04109313|DRUG|LOU064|Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
48119105|NCT05263609|DRUG|Pembrolizumab|If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
47970616|NCT02223897|DRUG|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
47970617|NCT06478485|DIAGNOSTIC_TEST|No Intervention: MCSM|No Intervention: MCSM
47970618|NCT00729651|DRUG|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
47970619|NCT00729651|DRUG|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
47970620|NCT00729651|DIETARY_SUPPLEMENT|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
47970621|NCT02349087|DEVICE|Acute EEG with fast applicable EEG electrode|
47970622|NCT03800329|DEVICE|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
47970623|NCT03800329|OTHER|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
48119106|NCT02178111|OTHER|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
48119107|NCT02178111|PROCEDURE|episiotomy|
48119108|NCT04410458|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
48119109|NCT00943358|BIOLOGICAL|MF59 H1N1 vaccine|3.75-7.5ug dose
48119110|NCT00943358|BIOLOGICAL|Plain H1N1 vaccine|7.5-15ug
48119111|NCT00121329|DRUG|Intrauterine lidocaine infusion 4%|
48119112|NCT00134446|DEVICE|transcranial magnetic stimulation|
48119113|NCT02662894|DRUG|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
48119114|NCT02662894|DRUG|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
48119115|NCT02662894|DRUG|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
48119116|NCT02662894|DRUG|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
48119117|NCT00529516|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
48119118|NCT00529516|BIOLOGICAL|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
48119119|NCT04377815|OTHER|General Public cohort|No intervention is being tested
48119120|NCT05706480|DIAGNOSTIC_TEST|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
48119121|NCT05706480|DIAGNOSTIC_TEST|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
48119122|NCT05706480|DIAGNOSTIC_TEST|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
48119123|NCT05498818|DIETARY_SUPPLEMENT|Synaquell|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
48119124|NCT05498818|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
48119125|NCT00035828|DRUG|ABX-IL8|
48119126|NCT00505791|DRUG|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure \> 100 mmHg.
48119127|NCT01234363|DEVICE|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
48119128|NCT04380467|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|(aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
48119129|NCT04125810|BIOLOGICAL|Probiotic|Probiotic
48119130|NCT04125810|OTHER|Placebo|Placebo
47970624|NCT01560364|OTHER|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
48488551|NCT04788160|OTHER|Cervical SNAGs along with conventional therapy|"cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~* Conventional therapy will include:~* Hot pack over the cervical region for 10 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be done 10 times in sitting position."
48488552|NCT04788160|OTHER|Conventional Therapy|"* Patients in this group will undergo only conventional therapy which will include:~* Hot pack for 15 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position."
48648311|NCT05091450|BEHAVIORAL|Couple-based I-BMS intervention for infertility|It is based on the previous I-BMS intervention for women undergoing IVF treatment, and aims to improve fertility quality of life and couple flourishing by (1) increasing awareness of the interconnectedness between physical and psychosocial well-being, (2) practicing body-mind-spirit techniques, (3) facilitating personal growth and partner empathy and compassion, and (3) creating the shared meaning of life, family, children. As a strength-focused and meaning-oriented approach, it utilizes experiential and self-reflective exercises to help participants reconstruct the meaning behind their ordeal and rediscover the strengths that keep them going.
48648312|NCT03009461|PROCEDURE|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
48648313|NCT03009461|DRUG|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
48648314|NCT02098486|DRUG|Moxifloxacin|
48119131|NCT01611246|DEVICE|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
48119132|NCT02200770|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg.
48119133|NCT02200770|OTHER|Placebo|Participants will receive IV placebo matched to inebilizumab.
48119134|NCT02755181|BEHAVIORAL|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
48119135|NCT04066725|DRUG|Aspirin 81 mg|Participants will be given ASA 81 mg orally once daily for a total of 60 days
48119136|NCT04066725|DRUG|Aspirin 325mg|Participants will be given ASA 325 mg orally once daily for a total of 60 days
48119137|NCT04066725|DRUG|Placebo oral tablet|Participants will be given placebo orally once daily for a total of 60 days
48488553|NCT01334710|DRUG|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
48488554|NCT05783648|DRUG|Use of tranexamic acid|Percentage of correct use according to POISE-3 criteria of tranexamic acid
48488555|NCT03481413|DEVICE|Ablation|Ablation therapy for cardiac arrhythmias
48488556|NCT02676713|DRUG|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
48488557|NCT02676713|DRUG|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
48488558|NCT02676713|DRUG|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
48488559|NCT02676713|DRUG|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
48488560|NCT04997655|DIAGNOSTIC_TEST|Ultrasound measurement|In the patient group who will undergo elective laparoscopic cholecystectomy, the diaphragmatic thickness values measured and recorded routinely at the pre-operative, post-extubation and post-operative 30th minute, at the end of inspiration and expiration, and the inspiratory amplitude in m-mode in the ultrasound measured from the right anterior axillary line subcostal area were observed as observational data. will be saved in our file.
48488561|NCT04107155|DIETARY_SUPPLEMENT|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
48488562|NCT04107155|DIETARY_SUPPLEMENT|Placebo|Placebo
48488563|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
48488564|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
48648315|NCT02098486|DRUG|ceftriaxone|
48648316|NCT06415383|DRUG|Vitamin B6 100 MG|Vitamin B6 in for the form of pyridoxal phosphate (PLP)
48648317|NCT06415383|OTHER|Placebo|Placebo tablet containing microcrystalline cellulose
48648318|NCT05630365|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
48119138|NCT03658460|OTHER|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
48119139|NCT01123408|DRUG|Clozapine|500 mg/day
48119140|NCT01123408|DRUG|Olanzapine|20 mg/day
48119141|NCT01123408|DRUG|Haloperidol|20 mg/day
48119142|NCT05103423|DRUG|BDB-001 Injection|Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
48648319|NCT00090064|DRUG|Midomafetamine HCl|125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl
48648320|NCT00090064|DRUG|Lactose placebo pill|125 mg followed by a supplemental half-dose of 62.5 mg
48648321|NCT00090064|BEHAVIORAL|Therapy|Non-directive therapy provided by a team of two co-therapists
48648322|NCT03147885|DRUG|Selinexor|Given PO
48119143|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
48648323|NCT00100893|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
48648324|NCT00049946|DRUG|talnetant|
47970625|NCT04007718|BEHAVIORAL|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
47970626|NCT01745133|DRUG|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
48119144|NCT05103423|DRUG|Placebo|Multiple IV infusions of Placebo Injection diluted in sodium chloride
48119145|NCT02967458|DRUG|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
47970627|NCT01745133|DRUG|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
47970628|NCT01745133|DRUG|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
47970629|NCT03208244|DRUG|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
47970630|NCT01031927|DRUG|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
48119146|NCT01216722|OTHER|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
47970631|NCT02646072|DRUG|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
48119147|NCT05340114|DEVICE|CEREBO®|Near-infrared based point-of-care portable intracranial hematoma detector
48119148|NCT06235294|DIETARY_SUPPLEMENT|Resveratrol|Daily capsule of 200 mg Polygonum cuspidatum (Solgar®, Dietimport, Lisboa, Portugal) yielding 100 mg/day resveratrol (trans-3,5,4'-trihydroxystilbene), by morning, every day during the 3 months preceding in vitro fertilization treatment.
48488565|NCT05166954|PROCEDURE|LSG|Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
47970632|NCT01785927|OTHER|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
48488566|NCT05166954|PROCEDURE|RYGB|Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia.
48119149|NCT06235294|DIETARY_SUPPLEMENT|Folic acid|Daily capsule of 400 mcg folic acid (Solgar®, Dietimport, Lisboa, Portugal), by morning, every day during the 3 months preceding in vitro fertilization treatment.
48119150|NCT03452189|DRUG|Vancomycin|Oral vancomycin 250mg capsules
48119151|NCT03452189|OTHER|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
48488567|NCT02307214|OTHER|BaroReflex Sensitivity, endothelial function measurement|no other
48488568|NCT00463320|DRUG|Pazopanib eye drops and Allergen Refresh Plus eye drops|
48488569|NCT00605865|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
48488570|NCT05943119|RADIATION|Radiotherapy in painting dose on histoscannographic mapping|"The target volumes to be delineated are as follows:~* High-risk CTV (Clinical Target Volume), corresponding to all initially invaded areas, as identified by comparison between the operative report and the anatomo-pathological report (ideally with histo-surgical mapping).~* Low-risk CTV, corresponding to naso-sinusal structures not initially invaded but at risk of recurrence, and located close to the high-risk target volume, including at least 5 mm around the high-risk volume and excluding non-risk areas (muscle, bone)."
48488571|NCT05943119|RADIATION|Standard pan-sinusal Radiotherapy|"The target volumes to be delineated are as follows:~* High-risk CTV, including the entire post-operative cavity,~* Low-risk CTV, adapted from the recommendations described by Lapeyre (Cancer/Radiotherapy 2005), and including at least 5 mm around the high-risk volume, excluding non-risk areas (muscle, bone)."
48488572|NCT03380559|DRUG|Injection, botulinum toxin + corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
48648325|NCT00049946|DRUG|risperidone|
48648326|NCT04101331|DRUG|AFM13|weekly intravenous infusions of 200mg
48648327|NCT02231580|DRUG|BN82451B|BN82451B capsule
48119152|NCT01369498|DRUG|Simtuzumab|Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks
48119153|NCT01369498|DRUG|Ruxolitinib|In Stage 2, participants will be on a stable dose of ruxolitinib
48119154|NCT00766298|BEHAVIORAL|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
48119155|NCT00766298|BEHAVIORAL|Weight Loss|The reduction of kcal/day through implementation of low fat diet
48648328|NCT02231580|DRUG|Placebo|Placebo capsule
48648329|NCT02644057|DRUG|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
48324158|NCT00861679|PROCEDURE|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~1. Number of Cells:~   * Number of nucleated cells infused exceed 2,5x10\*7/kg recipient BW or~  * Number of nucleated cells collected exceed 3x10\*7/kg BW~  * Number of CD34+ cells infused exceed 2x10\*5/kg Recipient BW~2. GVHD-prophylaxis:~   • MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~   • UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~3. HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~4. If many choices available ABO- major incompatibility should be avoided."
48324159|NCT02510170|OTHER|no intervention|
48324160|NCT03937258|DRUG|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
48324161|NCT03937258|DRUG|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
48648330|NCT02644057|DRUG|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
48648331|NCT06168968|BEHAVIORAL|Life and Medication Recommendations|Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
48648332|NCT03747263|PROCEDURE|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
47970633|NCT02344277|DEVICE|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
47970634|NCT03303924|DRUG|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
47970635|NCT00069056|PROCEDURE|Laser Treatment|
48324162|NCT05310513|OTHER|Whether the patient needs to be admitted to the ICU|According to ICU admission or not, patients were grouped into ICU group and NOT-ICU group.
48324163|NCT00744016|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
48324164|NCT00744016|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
48324165|NCT05685888|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
48488573|NCT03380559|DRUG|Injection, placebo of toxin + corticoid|"* Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
47970636|NCT04096963|DEVICE|The WATCHMAN FLX Delivery System|WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
47970637|NCT02215187|BEHAVIORAL|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
48488574|NCT03380559|DRUG|Injection, botulinum toxin + placebo corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
48488575|NCT06138119|BEHAVIORAL|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/ she belongs. Stereotype threat manipulation will be performed on the male and female participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare fiberoptic intubation performance between male and female anesthesiologists. Additionally, we are investigating whether the high inclination of males towards computer games has any impact on their fiberoptic intubation success. The other participants (Control Group) will not be given any prior information."
48488576|NCT00105573|BEHAVIORAL|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
48648333|NCT05524935|DRUG|Pembrolizumab|Pembrolizumab Day 1 of each 21 day (3 week) cycle
48648334|NCT05524935|DRUG|Olaparib|Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
48119156|NCT00766298|BEHAVIORAL|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
48119157|NCT04504786|OTHER|Vitality acupunch (VA) exercise program|The VA had three phases and took 40 minutes to complete.
48119158|NCT04504786|OTHER|Control|Participants maintained their daily activities.
48119159|NCT01993160|DRUG|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
48119160|NCT01993160|RADIATION|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
48119161|NCT01993160|RADIATION|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
48324166|NCT00866268|DEVICE|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
48648335|NCT05856747|DRUG|TBP-PI-HBr|TBP-PI-HBr tablets.
47970638|NCT02215187|BEHAVIORAL|Attention Control|Social contact control (health education/no skill training)
47970639|NCT04734015|BEHAVIORAL|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
47970640|NCT04344392|DIAGNOSTIC_TEST|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
47970641|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
47970642|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
47970643|NCT02325375|PROCEDURE|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
47970644|NCT04866225|DRUG|Oral [14C]PF-06865571|Oral radiolabeled PF-06865571
47970645|NCT04866225|DRUG|Oral PF-06865571|Oral PF-06865571
47970646|NCT04866225|DRUG|IV [14C]PF-06865571|IV radiolabeled PF-06865571
47970647|NCT05239247|OTHER|Mckenzie extension exercise|"Hot pack applied on lumbar region for (ten minute). Mckenzie extension exercise performed 02 sets of 05 repetitions with 45 second hold and 15 sec rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
47970648|NCT05239247|OTHER|Eldoa stretch technique|"Hot pack applied on lumbar region for (ten minute). Eldoa stretch performed 02 sets of 05 repetitions with 45 second hold and 15 second rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
47970649|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
48324167|NCT00866268|DEVICE|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
48488577|NCT00105573|BEHAVIORAL|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
48648336|NCT05879718|DRUG|Placebo|Placebo (intravenous infusion)
48648337|NCT05879718|DRUG|PF-06823859|PF-06823859 (intravenous infusion)
48648338|NCT04153162|DEVICE|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
48648339|NCT01505985|DIETARY_SUPPLEMENT|Oral nutritional Supplement|Specialized nutritional supplement for seniors
48648340|NCT01505985|DIETARY_SUPPLEMENT|Placebo|placebo product with no specific nutrients
47970650|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
47970651|NCT05460845|BEHAVIORAL|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
48648341|NCT02105012|DRUG|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
48648342|NCT02105012|DRUG|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
48119162|NCT01376089|DRUG|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
48119163|NCT01376089|DRUG|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
48119164|NCT03013452|DEVICE|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
48324168|NCT06398106|DRUG|Proactive TDM-based dosing of secukinumab|"Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
48648343|NCT02105012|DRUG|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
47970652|NCT05534945|DRUG|Programmed intermittent epidural bolus 5 ml|patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
48324169|NCT06398106|DRUG|Proactive TDM-based dosing of ixekizumab|"Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
48324170|NCT06398106|DRUG|Proactive TDM-based dosing of guselkumab|"Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week"
48324171|NCT00004799|BIOLOGICAL|whole-cell pertussis vaccine|
48324172|NCT00004799|BIOLOGICAL|diphtheria-tetanus vaccine|
48324173|NCT04511780|OTHER|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
48324174|NCT05432102|DIAGNOSTIC_TEST|Pulse oxymetry|Diagnostic intervention to diagnose OSA.
48324175|NCT05432102|DIAGNOSTIC_TEST|Respiratory polygraphy|Diagnostic intervention to diagnose OSA.
48488578|NCT00105573|BEHAVIORAL|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
47970653|NCT05534945|DRUG|Programmed intermittent epidural bolus 6 ml|patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
47970654|NCT05534945|DRUG|Programmed intermittent epidural bolus 7 ml|patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
47970655|NCT05534945|DRUG|Programmed intermittent epidural bolus 8 ml|patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
47970656|NCT05534945|DRUG|Programmed intermittent epidural bolus 9 ml|patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
47970657|NCT05534945|DRUG|Programmed intermittent epidural bolus 10 ml|patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
47970658|NCT02206048|DRUG|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
47970659|NCT02206048|PROCEDURE|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
47970660|NCT04481867|PROCEDURE|densah bur|osseodensification densah bur
47970661|NCT02685085|DRUG|Misoprostol ( Prostaglandin E2)|
47970662|NCT02685085|DEVICE|Foley's catheter|
48324176|NCT03989752|DEVICE|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
47970663|NCT06261203|DRUG|Aspirin|To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
47970664|NCT06153329|DRUG|THDB0206 injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
48324177|NCT05265143|OTHER|bolus/intermittant feeding|sequential randomization
48324178|NCT03067129|DRUG|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
48324179|NCT03067129|DRUG|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
48324180|NCT02733406|OTHER|Target Controlled Infusion|
48324181|NCT02733406|OTHER|Velocity Controlled Infusion|
48324182|NCT02193828|BIOLOGICAL|Collagenase clostridium histolyticum|Single injection into nodule
48324183|NCT02193828|BIOLOGICAL|Placebo|Single injection into nodule
48488579|NCT04090970|DEVICE|Briagen|Natural complex carbohydrate wound dressing for skin wounds
48488580|NCT04944134|BIOLOGICAL|COVID-19 Vaccination|Receipt of full COVID-19 vaccination
48488581|NCT02836834|BIOLOGICAL|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
48488582|NCT00145639|DRUG|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
48648344|NCT02105012|DRUG|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
48648345|NCT02105012|DRUG|Placebo MDI|Placebo MDI administered as 2 inhalations BID
48648346|NCT03474601|OTHER|Dynamic hormone study and Magnetic resonance imaging|"1. Medical history~2. Imaging examination including brain magnetic resonance imaging~3. Blood (Basal hormone study and follow-up study) and pituitary tumor tissue"
48648347|NCT06527872|OTHER|None (Observational study)|Not Applicable since Observational Study
48648348|NCT04463927|OTHER|non-nutritive sucking|intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
48488583|NCT00145639|PROCEDURE|Limb Sparing|See Detailed Description for treatment plan.
48648349|NCT01579877|DIETARY_SUPPLEMENT|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
48648350|NCT01579877|DIETARY_SUPPLEMENT|Placebo herbal extract granule|The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
48648351|NCT05347797|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
48648352|NCT05565560|DRUG|Apremilast|Oral tablets
48648353|NCT02580006|DRUG|EPORON|single dose administration subcutaneously
48648354|NCT02580006|DRUG|EPREX|single dose administration subcutaneously
48648355|NCT06457503|DRUG|Toripalimab|Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
48648356|NCT06457503|DRUG|Cisplatin|Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
48648357|NCT06457503|DRUG|Gemcitabine|Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
48648358|NCT06457503|DRUG|Carboplatin|In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
48648359|NCT06554899|OTHER|Clinician-led intervention to address fear of cancer recurrence (CIFeR)|The intervention includes five components informed by theoretical models and existing interventions for FCR: 1) FCR normalization: reassurance that FCR is a common and normal phenomenon after treatment for cancer, 2) Providing prognostic information: asking patients whether they would like information about their risk of recurrence and, if yes,providing this information, 3) Providing education and take-home information on red-flag recurrence symptoms, 4) Brief advice on managing worry: distraction, meditation, mindfulness, reassurance, and links to online resources to manage FCR, and 5) referral to a psychologist if FCR is high (FCRI-SF \>= 22), or if deemed helpful by the patient or clinician. Access will be provided to ConquerFear-Group delivered online by trained psychologists.
48648360|NCT06451614|DEVICE|SpaceIT Hydrogel System|"SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use.~SpaceIT has an iodinated PEG powder making it radiopaque."
48648361|NCT06451614|DEVICE|Commercially available Boston Scientific Spacer|Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
48648362|NCT02039206|DEVICE|Deep TMS|1Hz Stimulation
48648363|NCT05211960|BEHAVIORAL|Mindfulness-based meditation|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness.
48648364|NCT00725231|BIOLOGICAL|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
48648365|NCT00725231|DRUG|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
48648366|NCT01103518|DRUG|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
48119165|NCT03013452|BEHAVIORAL|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
48119166|NCT01997944|BIOLOGICAL|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
48324184|NCT04173052|DEVICE|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
48488584|NCT02719106|DEVICE|Ultimaster stent|
48119167|NCT01997944|BIOLOGICAL|Pegasys|180 mcg dosing every week
48119168|NCT04237155|OTHER|Questionnaire|Subjects will complete a verbal material scoring questionnaire
48119169|NCT04237155|OTHER|Cognitive tests|Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference
48119170|NCT02178098|DRUG|ETC-1002|ETC-1002 capsules taken once daily
48324185|NCT00215436|DRUG|Formoterol Fumarate|
48324186|NCT01475864|PROCEDURE|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
48488585|NCT06133075|DRUG|Mirabegron 50 MG|10 patients will receive drug for 8 weeks
48488586|NCT06133075|DRUG|Mirabegron 25 MG|10 patients will receive drug for 8 weeks
48488587|NCT04135521|DRUG|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
48488588|NCT01800526|DRUG|N-Acetylcysteine|Oral and Intravenous administration of NAC
48488589|NCT02726893|OTHER|no intervention|
48119171|NCT02178098|DRUG|Placebo|Placebo capsules taken once daily
48119172|NCT02502708|DRUG|Indoximod|Indoximod will be administered orally twice daily.
48119173|NCT02502708|DRUG|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
48648367|NCT06468930|DEVICE|Low-level light therapy (LLLT)|LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.
48119174|NCT02502708|RADIATION|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
48119175|NCT02502708|DRUG|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
48119176|NCT02502708|DRUG|Etoposide|Etoposide will be administered orally daily.
48119177|NCT01703923|DRUG|FP01|
48119178|NCT01703923|DRUG|placebo|
48119179|NCT04723394|DRUG|AZD7442|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
48119180|NCT04723394|DRUG|Placebo|Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
48119181|NCT00557024|PROCEDURE|RFA|radiofrequency ablation
48119182|NCT00557024|PROCEDURE|radiotherapy after RFA|radiotherapy after RFA
48488590|NCT05174676|DEVICE|Dextreme|"A unique robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the movement.~The setting of stroke patients in a simulated environment enhances patient motivation and participation. The completion of games (tasks) is a great indicator for the patients that they are progressing in the treatment and are on their way to recovery."
48488591|NCT02514161|OTHER|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
48488592|NCT02514161|OTHER|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
48488593|NCT06371144|DRUG|Paracetamol|Analgestic
48488594|NCT04568031|DRUG|AZD1222|For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
48488595|NCT04568031|DRUG|0.9% (w/v) saline|For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
48119183|NCT03926442|OTHER|Italian Herb meal|Italian Herb in active breakfast meal
48119184|NCT03926442|OTHER|Cinnamon Meal|Cinnamon in active breakfast meal
48119185|NCT03926442|OTHER|Pumpkin Spice meal|Pumpkin Spice Mix in active breakfast meal
48119186|NCT03926442|OTHER|Placebo meal|Placebo in breakfast meal
48119187|NCT03861364|DRUG|Propofol|2,4 mg/kg
48119188|NCT03861364|DRUG|Propofol|1,4 mg/kg
48119189|NCT00433199|DRUG|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
48119190|NCT00433199|DRUG|Placebo|Placebo Control
48119191|NCT01542229|BEHAVIORAL|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
48488596|NCT03043560|DRUG|Ezogabine|daily for 5 weeks
48488597|NCT03043560|DRUG|Placebos|placebo pill daily for 5 weeks
48488598|NCT01077882|BEHAVIORAL|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
48488599|NCT01077882|BEHAVIORAL|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
48488600|NCT01077882|BEHAVIORAL|Lifestyle factors and psycho-education|by dietician and psychiatrist
48488601|NCT01077882|OTHER|no educational program|standard care without educational program
48488602|NCT01869478|DRUG|Intravenous Thrombolysis|
48488603|NCT01869478|DEVICE|Endovascular Arterial Reperfusion|
48488604|NCT05775822|DIAGNOSTIC_TEST|CT scan and blood sample collection|"Each enrolled patient performs:~* preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~* a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~* CT scan"
48488605|NCT02744131|DRUG|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
48488606|NCT02744131|DRUG|Metformin 1500mgs per day|
48488607|NCT03274882|DRUG|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
48488608|NCT01046799|DRUG|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
48488609|NCT01705236|DRUG|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
48488610|NCT04158349|DRUG|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
48488611|NCT04158349|DRUG|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
48648368|NCT06468930|DEVICE|Intense pulsed light (IPL)|The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
48119192|NCT01542229|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
48488612|NCT04798118|PROCEDURE|toilet bronchoscope|Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
48648369|NCT04919473|BIOLOGICAL|Gene Therapy product:vMCO-I|The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
48648370|NCT01460615|DRUG|Hydrocortisone|
48648371|NCT05339425|OTHER|No additional intervention will be administered.|No additional intervention will be administered.
48648372|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
48648373|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
48648374|NCT04823052|DRUG|Placebo|Placebo Capsule
48648375|NCT04823052|DRUG|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
48648376|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
48648377|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
48648378|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
48648379|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
48648380|NCT06057103|DRUG|Oseltamivir|Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
48648381|NCT06057103|DRUG|ZX-7101A and Oseltamivir|ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
48119193|NCT03926936|DRUG|Fulvestrant|intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
48119194|NCT04425629|DRUG|casirivimab+imdevimab combination therapy|Administered intravenously (IV) single dose
48488613|NCT01408563|DRUG|Fludarabine|30 mg/m2/day IV x 6 days
48488614|NCT01408563|DRUG|Melphalan|100 mg/m2/day IV x 1 day
48488615|NCT01408563|RADIATION|Total Body Radiation|200 cGy on Day 0
48488616|NCT01408563|BIOLOGICAL|Cord Blood|2 cord blood units IV
48488617|NCT06489938|BEHAVIORAL|Mirror therapy|In mirror therapy, a wooden mirror (41×50×33 cm3) will be positioned in the participant's sagittal midplane, blocking the participant's view of the affected arm performance. We will also provide a foldable bed tray table to ensure that the participants focus on the mirror reflection of the less affected arm. The mirror therapy will consist of movement and functional practices.
48648382|NCT06057103|DRUG|ZX-7101A|ZX-7101A Tablets single dose tablet, 80 mg, Oral
48648383|NCT00273663|DEVICE|TCES|
48648384|NCT06673875|PROCEDURE|conservative treatment of stress urinary incontinence - pelvic floor muscle training|evaluation of pelvic floor muscle rehabilitation to change the clinical severity of urinary incontinence
48648385|NCT06673875|DEVICE|vaginal device Aniball INCO|"the firt group - the pelvic floor muscle training with vaginal device Aniball INCO according manual after education by the urogynecologist, who is educated in pelvic floor dysfunction.~the second group - the pelvic floor muscle training without vaginal device, the education was performed by certified physiotherapist trained in pelvic floor disorder."
48648386|NCT04148755|PROCEDURE|Endoscopic ultrasound guided fine needle aspirate|All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
48648387|NCT06399484|OTHER|Manual mobilizations of the median nerve|"Slippage of the median nerve in the wrist: the subject's starting position (P0) will be recumbent supine with the cervical spine in a neutral position, the shoulder girdle in neutral position, 30º of glenohumeral abduction in neutral rotation, 90º of elbow flexion, prone-supination of the neutral forearm, wrist and fingers in neutral position. From this position the movements will be 1) Glenohumeral abduction up to 90º; 2) Glenohumeral external rotation to the frontal plane; 3) Supination of the forearm; 4) Extension of the wrist and fingers; 5) Elbow extension. This position is will combine with an ipsilateral cervical inclination (distal sliding). The proximal slide is carried out bringing the fingers of the hand towards the flexion while performing a contralateral cervical tilt.~Median nerve tension: the starting position and movements are the same described above but this time it will be done with contralateral cervical tilt."
48648388|NCT06399484|OTHER|Wrist movements|Movements of the wrist joint will be performed as a placebo treatment
48119195|NCT03540381|OTHER|neoatherosclerosis|
48119196|NCT04114786|DEVICE|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
48119197|NCT04114786|DEVICE|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
48119198|NCT04593251|BIOLOGICAL|CALY-002|1-hour intravenous infusion
48119199|NCT04593251|BIOLOGICAL|Placebo|1-hour intravenous infusion
48119200|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
48119201|NCT02269280|DRUG|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
48648389|NCT06638541|RADIATION|Prostate radical radiotherapy|Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
48648390|NCT06675201|BIOLOGICAL|neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)|"Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause."
48648391|NCT02156505|PROCEDURE|placement of double bare stent|
48648392|NCT02156505|DEVICE|DoubleBare stent|
48648393|NCT01755754|COMBINATION_PRODUCT|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
48648394|NCT01755754|DEVICE|Female Condom|Female condom
48648395|NCT05786547|DRUG|Varenicline|Per package dosing, tablet taken orally
48648396|NCT05786547|BEHAVIORAL|Positively Smoke Free Mobile (PSF-M)|Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
48648397|NCT05786547|BEHAVIORAL|Standard Care|Brief cessation advice plus referral to local tobacco quitline
48648398|NCT00385112|PROCEDURE|Echocardiogram|2D echocardiogram with Doppler flow
48648399|NCT05240924|BEHAVIORAL|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
48648400|NCT05240924|OTHER|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
48119202|NCT02269280|OTHER|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
48324187|NCT01764256|BIOLOGICAL|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
48648401|NCT01498380|DRUG|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease \< 20% or blood pressure decrease/increase \< 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease \>/= 20% or SBP/DBP/MAP decrease or increase \>/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
48119203|NCT02269280|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
48119204|NCT00779636|DRUG|Desloratadine|Desloratadine 10 mg daily x 28 days
48119205|NCT00779636|DRUG|Placebo|Placebo daily x 28 days
48119206|NCT03639558|DRUG|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
48119207|NCT03639558|DRUG|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
48324188|NCT01764256|OTHER|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
48119208|NCT04508348|OTHER|Human Milk|Exclusive Human Milk diet
48119209|NCT04508348|OTHER|Standard of Care|This diet will include mother's milk and/or formula
48119210|NCT00334594|DRUG|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
48119211|NCT00334594|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
48119212|NCT00334594|PROCEDURE|Therapeutic conventional surgery|Extrapleural pneumonectomy
48119213|NCT00334594|RADIATION|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
48119214|NCT01120418|DRUG|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
48119215|NCT02161783|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
48119216|NCT02161783|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
48119217|NCT02161783|RADIATION|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
48119218|NCT02161783|BIOLOGICAL|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
48119219|NCT04531917|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.
48119220|NCT04531917|OTHER|Behavioural Graded Activity|"Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain."
48119221|NCT04531917|OTHER|Usual care|The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
48119222|NCT04111328|DRUG|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
48119223|NCT04111328|DRUG|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
48119224|NCT04111328|DRUG|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
48119225|NCT04111328|DRUG|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
48119226|NCT04111328|DRUG|intravenous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .
48119227|NCT04111328|DRUG|subcutaneous sufentanil and dexmedetomidine|The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.
48119228|NCT04111328|DRUG|intravenous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.
48119229|NCT04111328|DRUG|subcutaneous hydromorphone and dexmedetomidine|The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
48119230|NCT04144595|DIAGNOSTIC_TEST|2 hour 75 g Oral glucose tolerance test|In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
48119231|NCT03733522|PROCEDURE|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
48119232|NCT03733522|PROCEDURE|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
48119233|NCT00251576|DRUG|A-Phase: tirofiban; Z-Phase simvastatin|
48324189|NCT00920036|DEVICE|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
48324190|NCT05293574|DRUG|norethisterone acetate|Norethindrone, a progesterone agonist
48324191|NCT04258046|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
48488618|NCT06489938|BEHAVIORAL|Task-oriented approach|The task-oriented approach will provide both bimanual common-goal and dual-goal tasks for the participants.
48488619|NCT06489938|BEHAVIORAL|Impairment-oriented approach|The impairment-oriented approach will focus on the movement components. Arm BASIS or Arm Ability training will be provided based on the severity of the participant's impairment.
48488620|NCT06493903|BEHAVIORAL|Positive Minds, Strong Joints|In this10-week physical and mental health intervention, participants will receive recommended exercise intervention and evidence-based mental health intervention for pain, depression and anxiety.
48488621|NCT01825122|DRUG|Nadolol|
48488622|NCT01825122|DRUG|Placebo|
48488623|NCT00136318|DRUG|Escitalopram|
48648402|NCT04327817|DEVICE|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
48488624|NCT00136318|DRUG|Placebo|
48119234|NCT00251576|DRUG|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
48119235|NCT00251576|DRUG|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
48119236|NCT00251576|DRUG|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
48324192|NCT02368080|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
48324193|NCT03921138|OTHER|Histopathologic tube anomalies|Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
48324194|NCT01539785|PROCEDURE|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
48488625|NCT00136318|DRUG|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
48488626|NCT00136318|DRUG|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
48488627|NCT03045237|OTHER|physical exercises classes|3 physical exercises classes, one of them in the pool.
48119237|NCT00251576|DRUG|Duration of Treatment: Z-Phase, 2 years.|
48119238|NCT03197090|DEVICE|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
48119239|NCT05253612|DIAGNOSTIC_TEST|Analog testing conducted by a trained test leader using, ISPOCD test battery|Cognitive function will be measured by using the International Study Group of Postoperative Cognitive Dysfunction (ISPOCD) analog test battery v
48488628|NCT01598519|BEHAVIORAL|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
48119240|NCT05253612|DIAGNOSTIC_TEST|self-administered Mindmore digital cognitive screening battery|Cognitive function will be measured by using the Mindmores digital test battery
48324195|NCT01539785|PROCEDURE|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
48324196|NCT04362449|COMBINATION_PRODUCT|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
48324197|NCT04362449|COMBINATION_PRODUCT|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
48488629|NCT03438396|DRUG|tisotumab vedotin|All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
48488630|NCT04597398|DEVICE|Evaluation of blood flow with indocyanine green|
48648403|NCT06467058|DEVICE|DABQ questionnaire versus Actigraph as reference method|"In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package."
48324198|NCT06106646|DIETARY_SUPPLEMENT|No active intervention in this protocol (previously randomized to Vitamin C)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
48324199|NCT06106646|OTHER|No active intervention in this protocol (previously randomized to Placebo)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
48340067|NCT01608529|DEVICE|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
48648404|NCT05776004|DRUG|CAL02|CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.
48648405|NCT05776004|DRUG|Placebo|Physiological 0.9% sodium chloride solution for iv administration
48648406|NCT02714842|DRUG|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
48648407|NCT02714842|DRUG|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
48648408|NCT02714842|DRUG|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
48648409|NCT02714842|DRUG|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
48119241|NCT03524534|OTHER|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
48119242|NCT03524534|OTHER|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
48119243|NCT02528188|DRUG|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
48119244|NCT02528188|BIOLOGICAL|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
48119245|NCT02528188|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
48119246|NCT00190008|DRUG|piracetam|
48119247|NCT00171184|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
48324200|NCT03475576|OTHER|Keuzewijzer|"The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values."
48324201|NCT06190405|DIAGNOSTIC_TEST|Hemoglobin A1c|Patients with a HbA1c \<5.7% will be considered a normal test, and they will continue their routine prenatal care, including GDM screening at 24-28 weeks. Patients with a HbA1c ≥5.7% and ≤6.4% will be diagnosed with early GDM. Patients with a HbA1c ≥6.5% will be diagnosed with pregestational diabetes. Patient diagnosed with early GDM or pregestational diabetes will be treated as per usual clinical protocol for gestational/pregestational diabetes.
48324202|NCT06190405|DIAGNOSTIC_TEST|Risk-based screening by ACOG with two-step GTT|Patients will be assessed for risk factors for GDM as per ACOG. Patients with a negative screen will continue routine care, including GDM screening at 24-28 weeks. Patients with a positive screen will undergo a two-step GTT screening. Patients with a 1-h GTT \<135 mg/dL will continue with routine care, including GDM screening at 24-28 weeks. Patients with a 1-h GTT ≥185 mg/dL and \<200 mg/dL will be diagnosed with early GDM. Patients with a 1-h GTT ≥200 mg/dL will be diagnosed with pregestational DM. Patients with a 1-h GTT ≥135 mg/dL and \<185 mg/dL will undergo a fasting 3-h GTT. Patient will be diagnosed with early GDM by Carpenter and Coustan criteria. Patients will be diagnosed with pregestational DM if their fasting glucose value is ≥126 mg/dL. If patients pass the 3-h GTT, they will continue routine care, including GDM screen at 24-28 weeks with a 3-h GTT. Patient diagnosed with early GDM/pregestational DM will be treated as per usual clinical protocol for GDM/pregestational DM.
48324203|NCT01403701|BEHAVIORAL|Physical therapy|pelvic floor physical therapy
48324204|NCT03894774|BEHAVIORAL|Intensive in-patient psychotherapy treatment|Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
48324205|NCT03894774|OTHER|Treatment as usual|Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
48324206|NCT05576480|RADIATION|Short-course radiotherapy|5×5Gy in Week 1
48324207|NCT05576480|DRUG|Penpulimab|Apply once in the first week, then every 3 weeks from the third week for four cycles
48324208|NCT05576480|DRUG|CAPEOX|Apply every 3 weeks from week 3 for 4 cycles
48324209|NCT05576480|PROCEDURE|TME surgery|Patient will receive radical rectal cancer surgery
48324210|NCT04143763|OTHER|Ecological Momentary Intervention (EMI)|Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
48324211|NCT01892449|OTHER|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
48324212|NCT01892449|OTHER|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
48324213|NCT06051136|BEHAVIORAL|Pulmonary rehabilitation|"The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation."
48324214|NCT01900678|DEVICE|VytronUS Ablation System|Pulmonary vein isolation.
48488631|NCT00556023|DRUG|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
48488632|NCT06264245|OTHER|Audiological profile|Video otoscopy Tympanometry High-frequency tonal audiometry
48488633|NCT06264245|OTHER|Hearing self-assessments|Hearing skills questionnaire Subjective assessment of tinnitus using a visual analogue scale Self-questionnaire on the impact of tinnitus Hyperacusis self-questionnaire
48488634|NCT06264245|OTHER|Objective and subjective audiological tests|Acoustic Omission Measurement of the stapedial reflex by tympanometry High-frequency tonal audiometry - exposed ear only Speech audiometry in noise Tinnitus and subjective discomfort thresholds Psychoacoustic intensity perception test
48488635|NCT06264245|OTHER|Self-assessment of exposure sound quality|A self-assessment of the sound quality of the manipulated sounds heard during the exhibition will be carried out during the second follow-up visit. The elements on which the participant will be asked to make a qualitative judgement will relate to intelligibility difficulties or not; background noise (these two items in the form of a mark between 0 and 10); the clear, muffled or shrill nature of the sounds, their resonant or saturated side.
48488636|NCT02487381|DRUG|delta-9-tetrahydrocannabinol|
48648410|NCT04781842|OTHER|Boxing exercise program|Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
48648411|NCT00883311|DEVICE|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
48648412|NCT00626951|DEVICE|LMA Supreme|Extraglottic airway devices
48648413|NCT00626951|DEVICE|LMA ProSeal|
48648414|NCT02251470|OTHER|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
48648415|NCT02251470|OTHER|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
48648416|NCT03188380|DIAGNOSTIC_TEST|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
48648417|NCT03188380|DIAGNOSTIC_TEST|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
48488637|NCT02487381|DRUG|Cannabidiol|
48488638|NCT02487381|DRUG|Placebo|
48488639|NCT05981248|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
48648418|NCT04083599|BIOLOGICAL|GEN1042|Intravenous
48648419|NCT04083599|DRUG|Pembrolizumab|Intravenous
48648420|NCT04083599|DRUG|Cisplatin|Intravenous
48488640|NCT00453778|DRUG|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
48648421|NCT04083599|DRUG|Carboplatin|Intravenous
48648422|NCT04083599|DRUG|5-FU|Intravenous
48648423|NCT04083599|DRUG|Gemcitabine|Intravenous
48648424|NCT04083599|DRUG|Nab paclitaxel|Intravenous
48119248|NCT00171184|DRUG|Placebo|Placebo tablet once daily with sham titration
48488641|NCT05777759|DEVICE|Restylane Lyft with Lidocaine|hyaluronic acid
48488642|NCT05777759|DEVICE|Juvederm Voluma XC|hyaluronic acid
48488643|NCT01543659|DRUG|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
48488644|NCT03660241|DRUG|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
48648425|NCT04083599|DRUG|Pemetrexed|Intravenous
48648426|NCT04083599|DRUG|Paclitaxel|Intravenous
48648427|NCT06207851|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
48648428|NCT03637816|DRUG|Anamorelin Hydrochloride|Given PO
48648429|NCT03637816|OTHER|Placebo|Given PO
48648430|NCT03637816|OTHER|Questionnaire Administration|Ancillary studies
48119249|NCT05712993|PROCEDURE|V2 thermal radio frequency|V2 targeted thermal radio frequency safely without sustained V3 stimulation
48119250|NCT00226772|DRUG|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
48119251|NCT00226772|DRUG|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
48119252|NCT02217904|DRUG|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
48119253|NCT02217904|DRUG|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
48119254|NCT02217904|DRUG|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
48119255|NCT02217904|DRUG|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
48488645|NCT00209989|DRUG|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
48488646|NCT00209989|PROCEDURE|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
48488647|NCT02957188|OTHER|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
48488648|NCT00683982|DRUG|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
48488649|NCT00683982|DRUG|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
48488650|NCT00683982|OTHER|Oral hydration solutions|Oral hydration solutions as needed
48488651|NCT03938129|OTHER|Blood sample|1st trimester blood sample for bio-bank
48488652|NCT03938129|OTHER|Urine sample|1st trimester urine sample for bio-bank
48488653|NCT03938129|OTHER|Pregnancy, maternal health, and fetal health data|Pregnancy, maternal health, and fetal health data
48119256|NCT02217904|DRUG|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
48119257|NCT02217904|DRUG|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
48119258|NCT03656406|BEHAVIORAL|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
48119259|NCT03656406|DEVICE|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
48119260|NCT04134078|DRUG|inhaled nitric oxide|Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
48488654|NCT00832221|DRUG|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
48488655|NCT00832221|DRUG|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
48488656|NCT00832221|DRUG|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
48488657|NCT02494934|BEHAVIORAL|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
48488658|NCT02494934|BEHAVIORAL|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
48488659|NCT05366465|OTHER|SMA adult patients|An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
48488660|NCT00027859|DRUG|docetaxel|
48119261|NCT02059044|OTHER|ISTOP-ADE|Interactive Voice Response System + Pharmacist
48119262|NCT06196788|DRUG|Gemcitabine|1000 mg per square meter
48119263|NCT06196788|DRUG|Nab paclitaxel|120 mg per square meter of body-surface area
48119264|NCT02296463|BIOLOGICAL|RSV F Vaccine with adjuvant (0.5mL injection)|
48119265|NCT02296463|BIOLOGICAL|RSV F Vaccine (0.5mL injection)|
48119266|NCT02296463|BIOLOGICAL|Hepatitis A Vaccine (0.5mL injection)|
48119267|NCT02296463|BIOLOGICAL|Placebo (0.5mL injection)|
48488661|NCT00027859|DRUG|estramustine phosphate sodium|
48488662|NCT00027859|DRUG|ketoconazole|
48488663|NCT00027859|DRUG|therapeutic hydrocortisone|
48488664|NCT02050425|DEVICE|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
48488665|NCT02050425|DEVICE|CPAP|Patients continue therapeutic CPAP therapy
48488666|NCT00003517|DRUG|antineoplaston A10|
48488667|NCT00003517|DRUG|antineoplaston AS2-1|
48488668|NCT00003517|DRUG|bicalutamide|
48648431|NCT01248819|DRUG|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
47970665|NCT06153329|DRUG|Humalog®|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
47970666|NCT06153329|DRUG|BC222insulin lispro injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
47970667|NCT01305902|BEHAVIORAL|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
47970668|NCT00001006|DRUG|AS-101|
47970669|NCT04483141|DIAGNOSTIC_TEST|Abbey Pain Scale|Hetero-assessment of pain
47970670|NCT00258401|DIETARY_SUPPLEMENT|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
47970671|NCT00258401|PROCEDURE|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
47970672|NCT00258401|PROCEDURE|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
48119268|NCT05942768|DRUG|regorafenib plus anti-PD-1 antibodies|The patients were treated orally with regorafenib (80 mg once daily for 21 days on/7 days off, over a 28-day cycle), combined with 1 of the 5 anti-PD-1 antibodies (i.e., nivolumab, pembrolizumab, camrelizumab, sintilimab, or toripalimab). The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks
48119269|NCT02210806|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
48119270|NCT02210806|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
48488669|NCT00003517|DRUG|flutamide|
48119271|NCT02210806|OTHER|Placebo DPI|Placebo, 1 inhalation
48119272|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
48119273|NCT02210806|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
48119274|NCT02882698|BEHAVIORAL|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
48119275|NCT02882698|BEHAVIORAL|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
48119276|NCT02882698|BEHAVIORAL|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
48119277|NCT02882698|BEHAVIORAL|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
48488670|NCT00003517|DRUG|leuprolide acetate|
48488671|NCT00003517|PROCEDURE|alternative product therapy|
48488672|NCT00003517|PROCEDURE|antiandrogen therapy|
48488673|NCT00003517|PROCEDURE|biological therapy|
48488674|NCT00003517|PROCEDURE|biologically based therapies|
48488675|NCT00003517|PROCEDURE|cancer prevention intervention|
48488676|NCT00003517|PROCEDURE|complementary and alternative therapy|
48340068|NCT02835898|OTHER|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
48488677|NCT00003517|PROCEDURE|differentiation therapy|
48340069|NCT04800094|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
48340070|NCT04500067|DRUG|IVIG|Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
48340071|NCT04499638|DEVICE|Peripheral vascular catheters|Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
48340072|NCT02955368|DRUG|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
48340073|NCT02955368|DRUG|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
48340074|NCT02955368|DRUG|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
48340075|NCT01855945|BIOLOGICAL|Swine Influenza|Comparison of different dosages of vaccines
48340076|NCT00000361|DRUG|Corticosteroids|
48340077|NCT00000361|DRUG|Methotrexate|
48340078|NCT04399824|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
48340079|NCT04399824|OTHER|Quality-of-Life Assessment|Ancillary studies
48340080|NCT04399824|OTHER|Questionnaire Administration|Ancillary studies
48340081|NCT04399824|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48340082|NCT02949713|BEHAVIORAL|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
47970673|NCT03137290|DRUG|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
47970674|NCT03137290|DRUG|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
47970675|NCT00147446|BEHAVIORAL|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
47970676|NCT00147446|OTHER|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
48119278|NCT01130467|DRUG|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
48119279|NCT01130467|DRUG|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
48119280|NCT01130467|BEHAVIORAL|behavioral modification|Parenting and teaching skill education
48119281|NCT04014634|DRUG|Methylprednisolone|Single GON injection with methylprednisolone
48119282|NCT04014634|OTHER|Placebo|Single GON-injection with NaCl
48119283|NCT04301635|PROCEDURE|Maxillo-mandibular Advancement + Counterclockwise rotation|Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
48119284|NCT02618486|PROCEDURE|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
48488678|NCT00003517|PROCEDURE|endocrine therapy|
48488679|NCT00003517|PROCEDURE|hormone therapy|
48488680|NCT00749502|DRUG|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
47970677|NCT01375556|DRUG|Ethanol|
47970678|NCT00404937|DRUG|Tobradex (Antibiotic steroid combination)|
48119285|NCT06446726|DRUG|Tislelizumab|Patients will undergo two cycles of immunotherapy, each cycle lasting 21 days. Day 3 and Day 24: Tislelizumab, fixed dose of 200 mg
48119286|NCT06446726|RADIATION|Low-dose radiotherapy|Patients will undergo two cycles of low-dose radiotherapy. Day 1/2 and Day 22/23: Low-dose radiotherapy (8 Gy/4f)
48119287|NCT06446726|DRUG|Nab-paclitaxel|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Nab-paclitaxel 260 mg/m2
48119288|NCT06446726|DRUG|Cisplatin|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Cisplatin 75 mg/m2.
48119289|NCT00111709|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
48488681|NCT04919941|OTHER|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
48488682|NCT04647669|DRUG|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
48119290|NCT00111709|DRUG|Comparator: placebo / Duration of Treatment - 1 day|
48119291|NCT03759743|DIETARY_SUPPLEMENT|LMT1-48|capsules containing Probiotics
48119292|NCT03759743|DIETARY_SUPPLEMENT|Placebo|capsules that did not contain any probiotics
48119293|NCT02486835|DEVICE|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
48119294|NCT02486835|DEVICE|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
48119295|NCT05826379|BEHAVIORAL|Adaptive Daily Goal Setting|Daily step goals displayed by the study application
48119296|NCT05826379|BEHAVIORAL|Interim Goal Prompt|Short-term step goals
48340083|NCT03350971|OTHER|Virtual reality training|training with Wii games, ergometer exercise, ambulation, standing exercises
48488683|NCT04647669|DRUG|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
48488684|NCT04647669|DRUG|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
48488685|NCT04647669|OTHER|Standard of Care|Treatment according to local hospital protocol
48488686|NCT05637437|BEHAVIORAL|Peer supported diabetes self-care intervention|"Participants in the intervention group will attend a multi-faceted 8 weeks peer supported diabetes self-care intervention through digital communication.~* Weekly group video telephony meeting facilitated by trained peer supporters.~* Support and assistance through instant messaging services between peer supporters and participants."
48488687|NCT05637437|OTHER|Usual care|Participants in the control group will receive the usual care of the hospital.
48488688|NCT05559112|OTHER|Vitamin D-enriched mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
48488689|NCT05559112|OTHER|Study Powder|Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
48119297|NCT03446482|OTHER|observation of differents tasks|Evaluation by an external observer (nurse student in research stage or clinical research technician) of the distribution of medical time for the performance of the different tasks of anesthesiologist (in minutes)
48119298|NCT02434744|DRUG|KD026|Dosed in combination
48488690|NCT03648034|PROCEDURE|ropivacaine|To perform scalp nerve blocks with ropivacaine
48324215|NCT03454412|PROCEDURE|Intensive Neurophysiological Rehabilitation|Intensive Neurophysiological Rehabilitation System (INRS) is a combination of different treatment modalities that complement and reinforce each other. It includes spinal manipulative therapy, physical therapy, occupational therapy, joints mobilization techniques, special massage therapy, mechanotherapy, computer games therapy and other treatments with daily duration up to 4 hours.
48488691|NCT03648034|PROCEDURE|saline|To perform scalp nerve blocks with saline
48488692|NCT04572282|DEVICE|Mentora app|Remote monitoring mobile app
48488693|NCT06394674|DRUG|Furmonertinib|Drug: Furmonertinib
48488694|NCT02964819|OTHER|exercise|
48488695|NCT02964819|DEVICE|Interferential current therapy|
48488696|NCT02964819|DEVICE|Therapeutic Ultrasound|
48488697|NCT06468293|OTHER|Psychological support|Psychological support intervention
48488698|NCT03542084|OTHER|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
48488699|NCT05007184|BEHAVIORAL|Chilean Warning Labels|These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
48488700|NCT05007184|BEHAVIORAL|Nutri-Score Labels|These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
48488701|NCT02582918|BEHAVIORAL|Outreach with patient education and patient navigation services|"* Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
48488702|NCT04764955|DIETARY_SUPPLEMENT|Placebo|This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
48488703|NCT04764955|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
47970679|NCT04770662|OTHER|Questionnaires|"Administered Questionnaires:~* Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~* Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~* General Questionnaire: demografic , scholar and social information and child psychiatric history~* Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~* Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)"
48119299|NCT02434744|DRUG|Placebo|Dosed in combination
48119300|NCT02434744|DRUG|Metformin|Drug prescribed by each subject's prescribing physician
48324216|NCT04094766|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
48340084|NCT03350971|OTHER|Control|chest physical therapy exercises
48340085|NCT02079519|DRUG|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
48119301|NCT06217874|OTHER|Non-Interventional Study|Non-interventional study
48119302|NCT01166152|BEHAVIORAL|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
48119303|NCT04982445|DRUG|CABENUVA|CABENUVA will be administered IM at infusion centers/ASAs
48119304|NCT02490254|OTHER|Surveillance card|
48119305|NCT00189813|DRUG|YM060|
48119306|NCT00186186|DRUG|Depakote ER|Depakote ER
48119307|NCT02779062|OTHER|Interview|Interview
48119308|NCT05833906|DRUG|CKR-051 Dose 1|Subjects will be administered 5 g of CKR-051.
48119309|NCT05833906|DRUG|CKR-051 Dose 2|Subjects will be administered 10 g of CKR-051.
48119310|NCT05833906|DRUG|CKR-051 Dose 3|Subjects will be administered 10 g of CKR-051.
48324217|NCT02793895|DEVICE|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
48324218|NCT02793895|OTHER|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
48324219|NCT02793895|DEVICE|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
48324220|NCT01894464|BEHAVIORAL|Teacher led intervention|
48324221|NCT02310906|DRUG|Placebo|SRP-4053 placebo-matching solution for IV infusion.
48324222|NCT02310906|DRUG|SRP-4053|SRP-4053 (golodirsen) solution for IV infusion.
48324223|NCT03411850|BIOLOGICAL|Orencia|FDA approved biologic
48324224|NCT03411850|OTHER|Placebo|
48324225|NCT02802878|DEVICE|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
48648432|NCT01248819|DRUG|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
48648433|NCT03706066|DEVICE|Acrysof IQ PanOptix IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
48648434|NCT03706066|PROCEDURE|Cataract surgery|Per investigator's standard of care
48648435|NCT00242892|PROCEDURE|Intra coronary measures of pressure|Intra coronary measures of pressure
48648436|NCT03510533|OTHER|Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation|blood samples (12ml) and stool samples (30g) collections
47970680|NCT06083285|OTHER|Implement the CRRT specialist nursing group management program on the basis of routine care|Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
48324226|NCT02802878|DEVICE|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
48324227|NCT00040014|DRUG|exemestane|
48324228|NCT00349752|BIOLOGICAL|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
48324229|NCT00349752|OTHER|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
48324230|NCT05690334|DRUG|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48488704|NCT02844517|DEVICE|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
48488705|NCT02439671|BEHAVIORAL|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~* Social communication (e.g. listening, perspective taking)~* Self-determination (e.g. problem-solving, self-advocacy)~* Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
48648437|NCT00168285|BEHAVIORAL|Pulmonary Rehabilitation|
48648438|NCT05019963|BEHAVIORAL|NexJ Connected Wellness|NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
48648439|NCT05019963|OTHER|Usual Care|Participants will receive a treatment plan as decided on with their clinician(s).
48648440|NCT01903590|PROCEDURE|TVT surgery TOT surgery|
48648441|NCT06572033|BEHAVIORAL|Simulation|Observational study with simulations.
48648442|NCT04226105|DRUG|GP40081|1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
48648443|NCT04226105|DRUG|NovoMix 30|1 ml of the NovoMix 30 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
48648444|NCT06304012|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
48648445|NCT06304012|DEVICE|Intermittent Oro-esophageal Tube Feeding|The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
48648446|NCT06304012|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
48324231|NCT05690334|DRUG|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48324232|NCT05690334|DRUG|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48324233|NCT01661868|DRUG|Olaparib|Tablet formulation will be used.
48324234|NCT05551598|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 12 weeks (Q12W)
48324235|NCT02262884|DEVICE|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
48324236|NCT02262884|DEVICE|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
48324237|NCT04393350|DRUG|Lenvatinib|Given PO
48648447|NCT06590428|OTHER|Therapeutic Drug Monitoring for Linezolid|TDM with dose adjustment for trough concentration \>2.5 mg/L LZD
48648448|NCT06673836|DEVICE|DYNAMIC CYCLING|"Balance Training: Exercises focused on improving coordination and balance, such as standing on one leg, walking on uneven surfaces, or using balance boards.~Core Strengthening: Strengthening core muscles helps children maintain stability during dynamic movements, such as walking or running.~Proprioceptive Training: Exercises that improve awareness of the body's position in space, such as obstacle courses or activities that challenge movement coordination."
48648449|NCT06673836|DEVICE|INCLINED TREAD MILL|Dynamic Cycling: Refers to the fluctuating nature of movement patterns, often used in therapies like stationary biking or recumbe.nt cycling, where the intensity and resistance vary. Dynamic cycling can also refer to training that involves alternating between high and low-intensity phases or cycling between different positions (sitting, standing) or speeds during the activity
48648450|NCT02118246|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
47970681|NCT03817788|DRUG|polyethylene glycol|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
47970682|NCT03817788|DRUG|sodium phosphate|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
47970683|NCT03101683|RADIATION|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
47970684|NCT04531943|DRUG|Estrogen|Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.
47970685|NCT04531943|DRUG|Estrogen plus Progesterone|Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
47970686|NCT04015336|BIOLOGICAL|E7 T-Cell Receptor (TCR)|The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10\^10 TCR+ T cells (unless fewer cells are generated) administered once.
47970687|NCT04456660|DIAGNOSTIC_TEST|Markers of ultrasound|CRL, HR, and other ultrasound measurements.
47970688|NCT04456660|DIAGNOSTIC_TEST|Immunologic factors|Measurement of NK cells subpopulations types in the maternal serum
48119311|NCT05833906|DRUG|CKR-051 Dose 4|Subjects will be administered 10 g of CKR-051.
48324238|NCT04393350|DRUG|Lenvatinib Mesylate|Given PO
48324239|NCT04393350|BIOLOGICAL|Pembrolizumab|Given IV
48324240|NCT04393350|OTHER|Quality-of-Life Assessment|Ancillary studies
48324241|NCT04393350|OTHER|Questionnaire Administration|Ancillary studies
48488706|NCT06425770|PROCEDURE|indirect digital impression and 3D printed cast|the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration
48488707|NCT06425770|PROCEDURE|direct digital impression|the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration
48488708|NCT06425770|PROCEDURE|conventional impresion and cast|conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
48648451|NCT02118246|DEVICE|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
48648452|NCT03538808|DRUG|Varenicline|Participants will be provided varenicline medication
47970689|NCT04456660|DIAGNOSTIC_TEST|Serum factors|Measuring the maternal serum concentration of sFlt-1, PLGF, glycodelin-A, and other substances.
47970690|NCT03500952|OTHER|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
47970691|NCT03500952|OTHER|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
47970692|NCT06077318|OTHER|Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
47970693|NCT06077318|OTHER|Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
47970694|NCT00630396|DRUG|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
47970695|NCT05006911|DRUG|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
47970696|NCT05362097|OTHER|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
47970697|NCT02859454|DRUG|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
47970698|NCT06218641|DEVICE|CP - conventional protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
47970699|NCT06218641|DEVICE|DP - delayed protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
48119312|NCT05833906|DRUG|Placebo|Placebo comparator.
48119313|NCT01970891|DEVICE|neuromuscular stimulation device|Effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait amelioration.
48119314|NCT03833661|DRUG|M7824|Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
48119315|NCT05016830|DEVICE|Bilateral transcranial direct current stimulation|A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
48119316|NCT02021006|DRUG|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
48119317|NCT02021006|OTHER|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
48324242|NCT05861804|PROCEDURE|Rhomboid Intercostal Nerve Block|Before the induction of general anesthesia, under aseptic conditions, rhomboid intercostal nerve block will be performed with a single dose of 20 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
48648453|NCT03538808|OTHER|Placebo|Participants will be provided placebo medication
48324243|NCT04179435|BEHAVIORAL|Behavioral testing on cognitive computerized tasks|Testing on cognitive computerized tasks
48324244|NCT04179435|OTHER|brain MRI|Brain MRI scans
47970700|NCT01666496|BEHAVIORAL|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
47970701|NCT01666496|BEHAVIORAL|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
47970702|NCT04603456|DRUG|Lacteol fort|Lacteol fort is a drug containing lactobacilli
47970703|NCT04603456|DRUG|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
48119318|NCT02021006|DRUG|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
48324245|NCT04179435|OTHER|TMS|Measure of the cortical inhibitory capacity using TMS measures
47970704|NCT04603456|DRUG|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
47970705|NCT04730284|OTHER|Health supplements|tailor-made Synbiotics, 4g per day for 28 days
47970706|NCT05038436|DEVICE|Polyglucosamine L112|Two tablets once daily per os
47970707|NCT05630209|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
47970708|NCT05630209|DRUG|Doxorubicin|Doxorubicin infusion
47970709|NCT00492908|DEVICE|Helistent Titan2 (Titanium coated stent)|Titan2
47970710|NCT00492908|DEVICE|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
47970711|NCT02452489|DEVICE|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
47970712|NCT02452489|DEVICE|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
48324246|NCT05958758|DRUG|Psilocybin-assisted therapy within a community of practice model (group administered)|The community of practice is 10 weeks long, meeting virtually for 2 hours each week, in a structured process, run through the Roots to Thrive treatment program. The psilocybin-assited therapy sessions occur midway through the 10-week program.
48488709|NCT03392493|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
47970713|NCT02452489|DEVICE|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
47970714|NCT04019574|DRUG|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
47970715|NCT04019574|DRUG|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
47970716|NCT04019574|DRUG|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
47970717|NCT04019574|OTHER|Placebo|IV Placebo as a bolus injection
47970718|NCT00353262|DRUG|Avastin|7.5mg/kg iv (cycle 3 only)
47970719|NCT00353262|DRUG|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
47970720|NCT00353262|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
47970721|NCT05742100|DRUG|Darvadstrocel|expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
47970722|NCT02530593|BEHAVIORAL|There is no intervention, only observation|
47970723|NCT00289445|DRUG|Mitomycin C|
47970724|NCT00289445|DRUG|5-FU|
47970725|NCT00289445|DRUG|Folinic acid|
47970726|NCT02092493|DEVICE|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
47970727|NCT05410691|DEVICE|Handheld US device|Handheld US-guided AVF/AVG cannulation
47970728|NCT04146233|OTHER|Point of care gastric ultrasound|Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
47970729|NCT04774315|DRUG|Omalizumab|omalizumab 300mg SQ every 4 weeks as part of standard of care
47970730|NCT04080401|DEVICE|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
47970731|NCT04080401|OTHER|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
47970732|NCT04360252|OTHER|Gracie Diet|"The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest."
48324247|NCT02071264|BEHAVIORAL|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
48324248|NCT03866148|DEVICE|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
48324249|NCT04409652|PROCEDURE|Head on bed|During emergence, head is kept on bed without pillow.
48324250|NCT04409652|PROCEDURE|Head on pillow|During emergence, head is kept on pillow.
48324251|NCT05738499|OTHER|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
48324252|NCT05738499|OTHER|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
48488710|NCT03392493|BEHAVIORAL|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
48488711|NCT01893645|DEVICE|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
48488712|NCT00393471|DRUG|Etanercept|
48488713|NCT05768659|BEHAVIORAL|Fear Conditioning|"It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered."
48488714|NCT03145831|DRUG|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
48488715|NCT05579483|DIETARY_SUPPLEMENT|Prebiotics|The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
48488716|NCT05579483|DIETARY_SUPPLEMENT|Placebo|The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
48488717|NCT00725530|DEVICE|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
48488718|NCT00725530|DEVICE|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
48488719|NCT04154150|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
48488720|NCT04154150|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
48488721|NCT04154150|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
48488722|NCT02410356|DRUG|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
48488723|NCT02410356|DRUG|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
48488724|NCT01956695|DRUG|Lenalidomide|
48488725|NCT01956695|DRUG|Rituximab|
48488726|NCT02758522|DRUG|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
48488727|NCT02758522|DRUG|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
47970733|NCT04271969|DEVICE|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
48488728|NCT02758522|DRUG|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
48648454|NCT06362889|COMBINATION_PRODUCT|Microneedling with CBD|Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device
48648455|NCT05424705|DIAGNOSTIC_TEST|OCT, NIRS|
47970734|NCT02154243|DRUG|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
47970735|NCT02154243|OTHER|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
48324253|NCT03285906|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
47970736|NCT03967652|DIAGNOSTIC_TEST|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
47970737|NCT00844714|DRUG|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
47970738|NCT03174834|OTHER|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
48324254|NCT03457103|DEVICE|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
48324255|NCT03457103|DEVICE|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
48324256|NCT02813759|OTHER|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
48324257|NCT02813759|OTHER|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
48324258|NCT01644942|OTHER|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
48324259|NCT01594294|DEVICE|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
48324260|NCT01594294|DEVICE|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
48324261|NCT01594294|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
48324262|NCT01594294|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
48324263|NCT01594294|DEVICE|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
48324264|NCT03448861|DEVICE|Polso Wearebale watch|The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
48324265|NCT01156207|DRUG|Aliskiren|300mg Aliskiren qd for 6 month
48488729|NCT04555681|DIAGNOSTIC_TEST|Collection of subgingival dental plaque|Identification and quantification using q-PCR of the 21 bacteria most frequently found in the dental plaque (including the periopathogenic bacteria) and Candida albicans.
48488730|NCT02736682|DRUG|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
48648456|NCT03897270|PROCEDURE|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
48648457|NCT06433921|DRUG|Salbutamol HFA-152a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
48324266|NCT03897868|DRUG|HCP1803|HCP1803
48324267|NCT03897868|DRUG|Amlodipine|Amlodipine
48324268|NCT03897868|DRUG|Losartan|Losartan
48324269|NCT03897868|DRUG|Placebo|Placebo
48488731|NCT02736682|DRUG|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
48648458|NCT06433921|DRUG|Salbutamol HFA-134a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
48648459|NCT06433921|DRUG|Placebo|A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
48648460|NCT04193176|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
48648461|NCT04193176|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
48648462|NCT06639308|PROCEDURE|Endoscopic Flexor Hallucis longus tendon transfer to tendon achilles|The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. A tunnel was created into calcenous the tendon is introduced into the tunnel and the tendon is secured with an interference screw of same size than the tunnel
47970739|NCT06110611|DEVICE|Astra Tech Osseospeed EV® dental implant|Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.
48488732|NCT03185403|OTHER|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
48488733|NCT03185403|OTHER|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
48488734|NCT03185403|DRUG|ropivacaine|
48648463|NCT06639308|PROCEDURE|Open Flexor Hallucis longus transfer to tendon achilles|The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
48324270|NCT01996891|OTHER|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
48324271|NCT05539469|DEVICE|Ortodontika app|parents will download and use Ortodontika smartphone application for all the duration of the study. It will be an aid during orthopedic treatment. During the activations, a notification will be set to remind the daily activation of RME. After the end of the activation protocol, parents will receive a notification every 2 weeks to instruct their children to proper oral hygiene maneuvers. Parents will have to show their children the videos for oral hygiene maintenance every 2 weeks until the end of the study.
48488735|NCT03185403|DRUG|Sufentanil|
48648464|NCT03062436|OTHER|Stopping the standard drug therpy|Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
48648465|NCT03062436|DIAGNOSTIC_TEST|Quantitative bcrabl recording every month for first 6 months|Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
48648466|NCT04656275|DRUG|BI 1323495|BI 1323495
48648467|NCT04656275|DRUG|Placebo|Placebo
48648468|NCT05800665|DRUG|RO7656594|RO7656594 will be administered orally at specified dose on specified days.
48324272|NCT05539469|OTHER|Verbal instructions|verbal instructions will be given chairside to patients and parents regarding RME activation and its cleaning, together with instructions for daily oral hygiene manoeuvres.
48324273|NCT05310994|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
48324274|NCT05310994|DIETARY_SUPPLEMENT|Wasabi Leaf Extract Drink|consume 1 bottle per day
48324275|NCT00457470|DRUG|AG-014699|
48324276|NCT06509724|RADIATION|Conventional Fractionated IMRT|"* Dose: 1.8-2.0 Gy per session, total 25-28 sessions (40-50.4Gy)~* Chemotherapy: Weekly, total 5-6 sessions"
48488736|NCT03325985|BEHAVIORAL|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
48324277|NCT06509724|RADIATION|Hypofractionated IMRT|"* Dose: 2.5 Gy per session, total 16 sessions (40Gy)~* Chemotherapy: Weekly, total 3 sessions"
48488737|NCT03325985|BEHAVIORAL|Facilitated,outpatient specialty palliative care|In-person or telehealth palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
48488738|NCT04529447|OTHER|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
48324278|NCT03831308|DIAGNOSTIC_TEST|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
48488739|NCT00069186|DRUG|Creatine Monohydrate|
48488740|NCT03314818|DEVICE|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
48488741|NCT04971213|DEVICE|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
48488742|NCT04971213|DEVICE|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
48488743|NCT05529472|DEVICE|Peripheral Orbital Atherectomy System (OAS)|Treatment with Orbital Atherectomy System (OAS) followed by Percutaneous Old Balloon Angioplasty (POBA), pre-dilation and Drug Coated Balloon (DCB) - Medtronic IN.PACT™ Admiral™
48488744|NCT06094452|OTHER|Computerized Cognitive Training|Participants in intervention group will receive a multidomain, adaptive computerized cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Multidomain coverage paradigms include working memory, calculation, processing speed, attention, executive function, and short-term and long-term memory.
48488745|NCT06094452|OTHER|Treatment As Usual|Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet .
48488746|NCT04860596|BEHAVIORAL|collaborative health management model|nursing education program
48648469|NCT06532565|DRUG|GS-2121|Tablet administered orally
48648470|NCT06532565|DRUG|Zimberelimab|Administered intravenously
48648471|NCT02954562|OTHER|fMRI|Participants will undergo two to three fMRI scans
48648472|NCT02993666|DEVICE|Bair Hugger|forced air warming with Bair Hugger air warmer
48324279|NCT06035588|OTHER|Daily whitening|Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
48324280|NCT06035588|OTHER|Alternate whitening|Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
48324281|NCT04274660|BEHAVIORAL|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
48488747|NCT00590278|DRUG|Tomudex|
48488748|NCT00590278|PROCEDURE|Radiotherapy|
48488749|NCT00590278|PROCEDURE|Haematology|
48488750|NCT00590278|PROCEDURE|Biochemistry|
48648473|NCT05513456|BEHAVIORAL|Randomization to a different factors in the case descriptions|The case descriptions will include factors like age, co-morbid status and acute physiological parameters; but the factor of sex/gender will be randomized. Moreover, randomization to case description of typical vs non-typical national name will be done.
48648474|NCT01321580|DEVICE|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
48324282|NCT04114500|DIAGNOSTIC_TEST|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
48324283|NCT03798249|OTHER|Gluten|Tereos
48324284|NCT03798249|OTHER|Placebo|Nestlé Health Science
48324285|NCT03188432|DRUG|Carboplatin|Given IV and IP
48324286|NCT03188432|OTHER|Quality-of-Life Assessment|Ancillary studies
48648475|NCT05254418|DRUG|dulaglutide injection|All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
48648476|NCT00814736|DRUG|UK369,003|oral tablet, once a day
48648477|NCT00814736|DRUG|sildenafil|single oral dose on day 14 or day 17
48648478|NCT00814736|DRUG|sildenafil matching placebo|single oral dose on day 14 or day 17
48648479|NCT06174779|DRUG|HM11260C|Test drug
48648480|NCT06174779|DRUG|Placebo|Placebo drug
48648481|NCT02475863|DEVICE|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
48648482|NCT02475863|OTHER|Standard Practice|Warfarin dose adjustments according to standard unit protocol
48648483|NCT04003402|DRUG|ASP8062|oral
48648484|NCT04003402|DRUG|Alcohol|oral
48324287|NCT03188432|OTHER|Questionnaire Administration|Ancillary studies
48324288|NCT03188432|PROCEDURE|Cytoreductive Surgery|Undergo CRS
48324289|NCT06003257|OTHER|stainless steel crown|stainless steel full coverage crown for deciduous teeth
48324290|NCT06003257|OTHER|zirconia crown|zirconia full coverage crown for deciduous teeth
48324291|NCT06003257|OTHER|fiberglass crown|fiberglass full coverage crown for deciduous teeth
48324292|NCT04580251|PROCEDURE|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
48324293|NCT05776914|BIOLOGICAL|Donor Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
48324294|NCT05776914|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
48324295|NCT00216177|DRUG|Infliximab|Remicade
48324296|NCT00216177|DRUG|Adalimumab|Humira
48324297|NCT01963754|DEVICE|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
48324298|NCT01963754|DRUG|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
48324299|NCT01963754|DRUG|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
48324300|NCT06391957|DIETARY_SUPPLEMENT|Spirulina supplement|Participants consume a 3g spirulina supplement 3 times daily for 5 consecutive days.
48324301|NCT06391957|PROCEDURE|Eccentric exercise|On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.
48324302|NCT06391957|DIETARY_SUPPLEMENT|Placebo supplement|Participants consume a macronutrient matched placebo supplement 3 times daily for 5 consecutive days.
48324303|NCT03011450|DRUG|K-877|
48324304|NCT03011450|DRUG|Fenofibrate|
48324305|NCT03011450|DRUG|Placebo (for K-877)|
48648485|NCT04003402|DRUG|ASP8062 Placebo|oral
48648486|NCT04003402|DRUG|Alcohol Placebo|oral
48648487|NCT05808764|DRUG|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
48648488|NCT01380132|PROCEDURE|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
48648489|NCT04206787|DRUG|Afatinib|drug
48648490|NCT00004665|DRUG|dehydroepiandrosterone|
48648491|NCT04921306|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
48648492|NCT04921306|DRUG|Placebo|Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
48648493|NCT00078195|BIOLOGICAL|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
48648494|NCT00078195|BIOLOGICAL|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
48648495|NCT00078195|BIOLOGICAL|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
48648496|NCT00078195|BIOLOGICAL|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
48648497|NCT00078195|BIOLOGICAL|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
48648498|NCT00078195|BIOLOGICAL|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
48648499|NCT06536972|OTHER|knowledge|"Develop an instrument to evaluate knowledge about humidification systems among different health professionals in intensive care units (ICU).~Describe the knowledge about humidification systems among different health professionals in intensive care units (ICU)."
48648500|NCT05134883|OTHER|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
47970740|NCT01129817|OTHER|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
48119319|NCT02021006|DRUG|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
48119320|NCT02021006|DRUG|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~* nitrofurantoin 1.5-2 mg/kg per day~* amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~* cefixime 2 mg/kg per day~* trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
48119321|NCT01677936|OTHER|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
48119322|NCT01677936|OTHER|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
48119323|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
48119324|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
48119325|NCT04218110|DRUG|Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic|Application of antiseptic drug to the inguinal area of the subjects
48119326|NCT04218110|DRUG|Prevantics 3.15 % / 70 % Swabstick|Application of antiseptic drug to the inguinal area of the subjects
48324306|NCT01357304|BEHAVIORAL|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
48324307|NCT01208701|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
48324308|NCT01208701|DRUG|Unikalk|1 tablet Unikalk pr day for 5 days
48324309|NCT04437173|DEVICE|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
48324310|NCT00657124|DIETARY_SUPPLEMENT|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
48324311|NCT00657124|DIETARY_SUPPLEMENT|Placebo|placebo
48324312|NCT06050967|COMBINATION_PRODUCT|Enzyme replacement therapy for Gaucher disease in combination with altus care application|In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
48324313|NCT02833220|DEVICE|Single-Pulse Transcranial Magnetic Stimulation|Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
48324314|NCT02201381|DRUG|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
48324315|NCT03675438|OTHER|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
48324316|NCT03176173|RADIATION|Image-guided Radiation Therapy|"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."
48324317|NCT03176173|DRUG|Immunotherapy (physician's choice for standard of care immunotherapy)|Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
48488751|NCT02341833|DRUG|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
48488752|NCT01099059|DRUG|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for \>30 Kg)
48488753|NCT01099059|DRUG|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)
48119327|NCT06335576|OTHER|This study is a single-arm and observational study with no intervention.|This study is a single-arm and observational study with no intervention.
48119328|NCT06345586|DRUG|Drospirenone|4 mg tablet once daily
48119329|NCT05089526|DRUG|ketamine-lidocaine-dexmedetomidine|"In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
48119330|NCT05089526|DRUG|fentanyl|In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
48648501|NCT05134883|OTHER|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
48119331|NCT03022123|DRUG|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
48119332|NCT01598259|DRUG|Melatonin|po 1 hour before bedtime
48119333|NCT01598259|OTHER|placebo|po, 1 hour before bed
48119334|NCT02265276|DRUG|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
48119335|NCT02265276|DRUG|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
48119336|NCT04479969|BEHAVIORAL|Video Chat|Video chat with health coach using a computer tablet.
48119337|NCT02868268|OTHER|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
48119338|NCT02781766|OTHER|Thrombin generation measurement.|
48119339|NCT05608018|OTHER|Intervention Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.
48119340|NCT05608018|OTHER|Intervention non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with all features turned on.
48119341|NCT05608018|OTHER|Control Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.
48119342|NCT05608018|OTHER|Control non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with some features turned off.
48648502|NCT06475820|DRUG|Baricitinib|"GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day."
48648503|NCT00474357|BEHAVIORAL|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
48648504|NCT05852470|DEVICE|Clareon Vivity/Vivity Toric Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
48648505|NCT05852470|DEVICE|Clareon Monofocal/Clareon Toric IOL|Single vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
48648506|NCT02998320|DRUG|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
48648507|NCT03377322|DRUG|Probiotic Capsule|Probiotic - one capsule a day for four weeks
47970741|NCT01129817|OTHER|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
48119343|NCT01546753|DRUG|Walnut Protein Powder|Blinded study product dosing begins with a 1-day oral desensitization protocol to walnut for subjects in the active arm. Starting at 0.1 mg protein and increasing to a maximum of 6 mg or until allergic symptoms develop. Subjects continue daily dosing of blinded OIT (walnut) with build-up every 2 weeks to a maximum daily dose of 1500mg at week 34, followed by 4 weeks of daily maintenance dosing. OFC to walnut and second tree nut occurs at week 38 then treatment is unblinded and open-label maintenance dosing occurs.
48119344|NCT01546753|DRUG|Oat Powder (placebo)|Blinded study product dosing begins with a one-day oral desensitization protocol with placebo (oat) powder. Subjects in the placebo group will undergo the same protocol as those in the active group with placebo OIT dosing. Unblinding to treatment assignment will occur after the 38 week oral food challenge. Placebo subjects will cross-over to active, open-label treatment with walnut powder after the 38 week oral food challenge. beginning with initial escalation day, through build-up and maintenance dosing per the same protocol sequence as noted for active, walnut powder. Subjects will complete an oral food challenge to walnut and the second tree nut at week 38 then will continue on long-term, open-label maintenance dosing until the end of study using same protocol design.
48488754|NCT02031016|DRUG|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
48648508|NCT03377322|DRUG|Placebo Capsule|Placebo - one capsule a day for four weeks
48648509|NCT06675786|DEVICE|I.V. House UltraDressing|I.V. House UltraDressing (I.V. House, Inc., St. Louis, MO, USA) will be applied according to the manufacturer's instructions and secured with an anti-slip tape without the need for further taping. It is intended to prevent complications such as catheter-related displacement, phlebitis, infiltration, extravasation, catheter occlusion, and folding of PVCs.
48648510|NCT06673576|DIAGNOSTIC_TEST|Complete crown technique for superimposition|the complete crown technique, the crown of the tooth corresponding to the gingival margin under evaluation will be selected using the paint method and circular selection tool. The same selection process will be applied to the moving model.
47970742|NCT00134095|DRUG|irinotecan hydrochloride|
47970743|NCT00134095|DRUG|tegafur-gimeracil-oteracil potassium|
47970744|NCT00134095|PROCEDURE|adjuvant therapy|
47970745|NCT00134095|PROCEDURE|conventional surgery|
47970746|NCT00134095|PROCEDURE|neoadjuvant therapy|
47970747|NCT02697825|PROCEDURE|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
48648511|NCT06673576|DIAGNOSTIC_TEST|Gold standard technique for superimposition|the gold standard technique, adjacent intact teeth and a portion of the palatal gingiva will be selected. Superimpositions will be executed utilizing the software's iterative closest point algorithm (ICP).
48648512|NCT06329622|COMBINATION_PRODUCT|low-protein diet + Ketosteril|low-protein diet (0.6-0.8g protein/kg body weight/day) and Ketosteril 0.12 g/kg body weight/day will be prescribed with the target energy intake of 25-30kcal/kg body weight/day.
48324318|NCT00436319|PROCEDURE|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2\<80 pg/ml and progesterone \<1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
48119345|NCT01546753|DRUG|Open-label Walnut Protein Powder|Open-label treatment phase begins after the 38 week oral food challenge with unblinding of treatment assignment. For those on active treatment, daily maintenance dosing occurs for up to a total of 298 weeks. For those on placebo treatment, cross-over to active, open-label treatment occurs using the same active treatment protocol. Placebo-crossover subjects will complete an oral food challenge to walnut and the second tree nut at week 38 of active therapy then continue on long-term, open-label maintenance dosing until the end of study using same protocol design. All subjects may reach a qualifying IgE to walnut/second tree nut early and will undergo an OFCs on and 4 weeks off OIT. All subjects will have OFCs on and 4 weeks off OIT at week 142 and at week 298, unless both walnut/second tree nut OFCs are passed at previous OFC prompting addition of these foods into the diet.
48324319|NCT00823524|BIOLOGICAL|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
48648513|NCT06329622|DIETARY_SUPPLEMENT|low-protein diet|low-protein diet (0.6-0.8g protein/kg body weight/day) with the target energy intake of 25-30kcal/kg body weight/day.
48648514|NCT01906320|BEHAVIORAL|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
48648515|NCT03163329|PROCEDURE|TAVR|Transcatheter Aortic Valve Replacement
48648516|NCT03163329|PROCEDURE|SAVR|Surgical Aortic Valve Replacement
48648517|NCT04059822|OTHER|Slow and deep breathing|Please see arm description
48324320|NCT01959399|DRUG|ASP015K|oral tablet
48324321|NCT01959399|DRUG|Rosuvastatin|oral tablet
48324322|NCT01738737|DEVICE|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
48324323|NCT01738737|OTHER|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
47970748|NCT02531204|DRUG|ASP1585|oral
47970749|NCT00428311|DRUG|Metformin|
48648518|NCT04783428|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as part of this DMP
48648519|NCT03453515|BEHAVIORAL|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
48648520|NCT03453515|BEHAVIORAL|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
48324324|NCT01738737|DEVICE|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
48324325|NCT04846894|DIAGNOSTIC_TEST|Ga-68 PSMA-11 PET/CT imaging|Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
48324326|NCT02905903|DRUG|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
48324327|NCT04237818|DIETARY_SUPPLEMENT|Placebo drink|consume 2 bottle (30 mL) per day for 56 days
48648521|NCT06640608|BEHAVIORAL|ICBT - Internet Based Cognitive Behavioral Therapy|The study (intervention) group received 6 consecutive sessions utilizing ICBT techniques to overcome Fear of childbirth
48324328|NCT04237818|DIETARY_SUPPLEMENT|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|consume 2 bottle (30 mL) per day for 56 days
48648522|NCT05438576|OTHER|Artificial Intelligence enabled electrocardiogram (AI-ECG)|An artificial intelligence algorithm which analyses ECG data and generates prediction probabilities for a diagnosis of cardiomyopathy.
48648523|NCT01518179|DEVICE|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
48648524|NCT01518179|OTHER|Routine follow up and treatment|Control
48648525|NCT06655714|OTHER|No intervention|No intervention
48648526|NCT06466655|OTHER|MitoTempol|Two intradermal microdialysis probes will be inserted into the dermal layer of the ventral forearm and perfused with either lactated Ringer's solution (control) or MitoTempol (0.5 mM) to scavenge mitochondrial-derived superoxide.
48648527|NCT06511830|DIAGNOSTIC_TEST|Dental Monitoring images|Dental Monitoring is a series of intraoral photos that will be taken and assessed to determine the subject's dental plaque levels
48648528|NCT06673758|OTHER|tai chi exercises|tai chi exercises of three basic levels will be given with sessions of two weeks five time a day and follow efftects of tai chi exercises by 6minute walk test and time up and go test and check the results before and after exercises
48648529|NCT06673758|OTHER|Art and crafts activity|Art and crafts activity will be given to control group and check cardiorespiratory fitness before and after arts and crafts activity
48648530|NCT06484543|OTHER|Maslinic Acid|Consumption of Maslinic Acid for 12 weeks
48648531|NCT06484543|OTHER|Placebo|Consumption of Placebo for 12 weeks
48648532|NCT05434598|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
48648533|NCT04362254|DRUG|Spesolimab|Spesolimab
48648534|NCT05650827|BEHAVIORAL|Resistance training|10 weeks of resistance training 3 times pr. week.
48648535|NCT05650827|DIETARY_SUPPLEMENT|Protein supplement|A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
48648536|NCT05740826|DEVICE|Algometer|The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
47970750|NCT00428311|DRUG|Ethynyl-estradiol plus cyproterone acetate|
47970751|NCT03756844|BEHAVIORAL|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
47970752|NCT04982809|DRUG|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
47970753|NCT02031354|DIETARY_SUPPLEMENT|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
48324329|NCT03235817|OTHER|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
48648537|NCT02977871|PROCEDURE|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
48648538|NCT06570811|DRUG|Placebo|Placebo tablets is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
48648539|NCT06570811|DRUG|Coenzyme Q10 200mg twice daily|400 mg daily (200mg twice daily) of Coenzyme Q10 (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) is supplied to breast cancer patients who receive 80 mg/ m2 paclitaxel (taxol®) chemotherapy.
48648540|NCT05140109|OTHER|Arm 1: Cognitive-dissonance based program|The first four sessions focus on body image and the last four sessions on eating behavior.
48648541|NCT05140109|OTHER|Arm 2: Mindfulness-based program|The sessions focus on different contents as body image, eating behavior and emotion regulation.
48648542|NCT05140109|OTHER|Arm 3: Person-centered program|The sessions are not structured. Participants can bring any subject they need to talk.
48648543|NCT05310357|DIAGNOSTIC_TEST|Testing for chromosomal instability (CIN)|The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment.
47970754|NCT00824239|PROCEDURE|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
47970755|NCT00824239|PROCEDURE|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
47970756|NCT05566912|OTHER|filling out a survey|This research is a descriptive study
47970757|NCT06341868|DEVICE|KneeStim|Participant will be randomized to either be in control or experimental group
47970758|NCT01850771|PROCEDURE|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
47970759|NCT01850771|PROCEDURE|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
47970760|NCT01564381|DIETARY_SUPPLEMENT|ResA|90mg of resveratrol conjugated with arginine.
47970761|NCT01564381|DIETARY_SUPPLEMENT|Resveratrol|90mg of resveratrol.
48119346|NCT05033938|PROCEDURE|Early Mobilization Protocol|Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
48648544|NCT06669208|BIOLOGICAL|HydroVax-005 CHIKV|HydroVax-005 CHIKV vaccine
48648545|NCT06669208|OTHER|Placebo|NaCl 0.9%, Normal Saline
48648546|NCT04774562|BEHAVIORAL|Video-Assisted Discharge Education (VADE)|Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.
48648547|NCT04774562|BEHAVIORAL|Physiotherapy (PT) Program|Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
48648548|NCT02755883|BEHAVIORAL|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
48648549|NCT02755883|BEHAVIORAL|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
48648550|NCT06675474|OTHER|Clinical periodontal measurements|Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.
48648551|NCT06675474|OTHER|Saliva sampling|The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.
48648552|NCT06675474|OTHER|Serum Sampling|5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.
48648553|NCT06675474|OTHER|GCF sampling|GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.
48648554|NCT06675474|OTHER|Subgingival plaque sampling|Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.
48648555|NCT05554731|DEVICE|a New Balloon Catheter for Intraairway Hemostasis|In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
47970762|NCT01564381|DIETARY_SUPPLEMENT|Placebo|Made up of cellulose.
47970763|NCT01391559|DRUG|arformoterol|15 mcg administered via nebulizer
47970764|NCT01391559|DRUG|salmeterol|50 mcg delivered vis Diskus
47970765|NCT03205332|BEHAVIORAL|Concreteness Training|
48119347|NCT05033938|PROCEDURE|Late Mobilization Protocol|Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
48119348|NCT00099086|DRUG|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
47970766|NCT01889004|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
47970767|NCT01889004|DRUG|Propofol|Escalating concentrations until loss of responsiveness
47970768|NCT00189982|DRUG|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
48119349|NCT00099086|DRUG|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
48324330|NCT03235817|DEVICE|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
48324331|NCT03235817|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
48324332|NCT02469792|PROCEDURE|Liposuction|
48324333|NCT02469792|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
48324334|NCT02469792|PROCEDURE|Arthroscopic surgery|
48324335|NCT02469792|OTHER|Intraarticular administration of autologous ADRC|
48324336|NCT03082989|DEVICE|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
48324337|NCT03082989|OTHER|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
48324338|NCT03083509|OTHER|Resistance exercise weight training session|A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
48324339|NCT03083509|OTHER|High-Intensity stochastic cycling session|A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
48324340|NCT03083509|OTHER|Simulated Team sport protocol|A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
48324341|NCT01697267|BIOLOGICAL|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
48324342|NCT01697267|DRUG|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
47970769|NCT02800681|OTHER|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
48324343|NCT04154696|PROCEDURE|Liver transplantation of a graft after assessment by normothermic perfusion|Liver transplantation of a graft after assessment by normothermic perfusion
48324344|NCT04632537|DRUG|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
48119350|NCT00099086|DRUG|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
48119351|NCT00099086|RADIATION|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
48324345|NCT04632537|DRUG|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
48324346|NCT04857749|OTHER|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
48488755|NCT02031016|DRUG|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
48324347|NCT04857749|OTHER|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
48324348|NCT01240512|DRUG|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
48324349|NCT06295432|DRUG|DZD9008+AZD4205|Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
48648556|NCT05554731|DEVICE|Traditional Therapy|A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
48324350|NCT06454851|BEHAVIORAL|Prosocial VR intervention|A four-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include four weekly sessions, each lasting between 15 to 20 minutes. Each session will depict a different daily life scenario-campus, lecture hall, canteen, and library, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
48324351|NCT06454851|OTHER|No intervention|The waitlist control group will not receive the intervention during the study.
48324352|NCT03696706|RADIATION|LED photobiomodulation|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
48324353|NCT03696706|RADIATION|Placebo LED photobiomodulation|In this group, the same procedures as the LED group will be made, but the device will be turned off.
48324354|NCT01507844|DEVICE|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
48324355|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
48324356|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg|
48324357|NCT03536598|DRUG|Valsartan 160 mg + Rosuvastatin 20 mg|
48324358|NCT05041322|DRUG|Buspirone|Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
48324359|NCT05041322|DRUG|Placebo|Subjects take placebo pills (twice a day) for 14 Days.
47970770|NCT02800681|OTHER|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
48324360|NCT04687605|PROCEDURE|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
48324361|NCT03930641|DRUG|RTH258|6 mg in prefilled syringe
48324362|NCT05297656|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe
48324363|NCT05297656|OTHER|Sham Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe
48648557|NCT06455800|DIAGNOSTIC_TEST|lung function measurements|Patients will once a year be monitored with different lung function methods
48648558|NCT00165308|DRUG|Tamoxifen|Given orally, daily for one year.
48648559|NCT05075473|OTHER|Segmental stabilization|Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.
48648560|NCT05075473|OTHER|Generalized Lumber stabilization exercsies|It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
48648561|NCT00532415|DRUG|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
48648562|NCT00773461|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
47970771|NCT02800681|OTHER|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
47970772|NCT02800681|OTHER|Other general interviewer ratings|1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
47970773|NCT01297660|OTHER|Video-urodynamic examination|
47970774|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
48324364|NCT05297656|OTHER|Home exercises programe|Only Home exercises programe
48324365|NCT05419271|PROCEDURE|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
48324366|NCT00231855|DRUG|Topotecan and Taxotere|
48648563|NCT00773461|DRUG|Placebo|iv every 4 weeks for 24 weeks
48648564|NCT00900042|GENETIC|DNA ploidy analysis|
48648565|NCT00900042|GENETIC|DNA stability analysis|
48648566|NCT00900042|GENETIC|chromosomal translocation analysis|
48648567|NCT00900042|GENETIC|cytogenetic analysis|
48648568|NCT00900042|OTHER|flow cytometry|
48648569|NCT00900042|OTHER|laboratory biomarker analysis|
48648570|NCT01013870|DRUG|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
48488756|NCT02031016|DRUG|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
48488757|NCT04642859|BEHAVIORAL|Computerized Cognitive abilities training battery for reading (CATB-R)|Specially designed Arabic computerized training program for dyslexia
48488758|NCT01828944|DIETARY_SUPPLEMENT|olive oil|
48488759|NCT02350374|OTHER|carbohydrate counting|"patients must fill their logbook with the following data:~* cho amount at breakfast, lunch, snack and dinner~* insulin amount at breakfast, lunch, snack and dinner"
48119352|NCT05767294|OTHER|Observation|clinical manifestation (body temperature, fever days before admission, cough, red throat/sore throat, runny nose, shortness of breath, wheezing, vomiting), physical signs (auscultation of lungs, X-ray results), length of stay, therapeutic measures (oxygen therapy, ICU admission, antibiotic therapy, etc.)
48119353|NCT05732649|BEHAVIORAL|Auditory neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound.
48119354|NCT05732649|BEHAVIORAL|Tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of tactile stimulation (i.e., electrical or vibrotactile stimulators applied on both hands and feet).
48119355|NCT05732649|BEHAVIORAL|Auditory and tactile neurofeedback|Network interaction measured with EEG at visual areas will be coupled with the intensity of a sound and tactile stimulation.
48119356|NCT05732649|BEHAVIORAL|Neurofeedback|Participants train to decrease the intensity of a sensory stimulation (defined in Experiment 1) that is coupled with the network interaction at a specific brain region.
48119357|NCT01551953|BEHAVIORAL|Tai chi|12 week tai chi class
48119358|NCT01551953|BEHAVIORAL|Mind-body breathing|12 week breathing class
48119359|NCT01551953|BEHAVIORAL|Education|12 week education class
48119360|NCT04425668|BEHAVIORAL|Academic detailing (AD)|In addition to continuing educational (CE) videos this group will receive up to two personalized, one-on-one, education sessions from an academic detailer. The sessions will last between 15-30 minutes. Each AD visit will consist of: an introduction, a brief needs assessment, key educational messages, a discussion of challenges the provider faces, and giving the provider leave-behind educational materials. The AD visit key educational messages are specific recommendations for opioid-prescribing practice change. When appropriate the detailer will suggest a phone call with Dr. Romesh Nalliah to discuss specific dentistry questions. There may also be a second AD visit if agreed upon by the dentist.
48119361|NCT04425668|OTHER|Continuing educational|"Dentists enrolled in the CE program will serve as the control group. They will have access to the 3 hours of CE content online similar to the AD group; however, they will not receive academic detailing or the opportunity to connect via phone with Dr. Nalliah.~In this group, if the dentists have content-specific questions after participating in the CE program, they may contact MichiganOPENdental@umich.edu for responses appropriately directed to Dr. Nalliah."
48119362|NCT06322797|DEVICE|rTMS|"Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. First, the resting motor threshold was measured for each patient. At the lowest stimulus output, a stimulus was applied to the M1 cortex of the uninjured hemisphere aiming at the site that caused the largest visible twitch in the participant's thumb. The resting motor threshold was defined as the intensity required to generate a motor-induced potential of \> 50 uV in the contralateral abductor pollicis brevis muscle at least 5 out of 10 times with 30 s of inter-stimulus time interval.~Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min."
48324367|NCT04250012|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.
47970775|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
48324368|NCT04250012|BEHAVIORAL|Psychoeducation|The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
48324369|NCT00868166|DRUG|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
48488760|NCT05993715|DIETARY_SUPPLEMENT|Nitrate supplementation|Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (\~12.8 mmol/day nitrate) or nitrate-depleted (\~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
48488761|NCT05993715|DIETARY_SUPPLEMENT|Placebo supplementtaion|2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
48488762|NCT00942695|OTHER|1.5PD|average American diet plus 1.5 oz per day pistachios
48488763|NCT00942695|OTHER|3.0PD|average American diet plus 3.0 oz per day pistachios
48488764|NCT00942695|OTHER|control|average American diet without pistachios
48488765|NCT01660334|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
48488766|NCT04511052|DIETARY_SUPPLEMENT|Probiotic|Daily intake of 10 x 10\^9 CFU of a proprietary strain for a total duration of 10 weeks
48488767|NCT04511052|OTHER|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
48488768|NCT04511052|DIETARY_SUPPLEMENT|Carotenoid supplement|1 capsule daily containing \~20 mg of total carotenoids for a total duration of 10 weeks
48488769|NCT00134173|DRUG|torcetrapib/atorvastatin|
48488770|NCT00134173|DRUG|atorvastatin|
48488771|NCT05954182|BEHAVIORAL|Cognitive Intervention|This is a virtual, group cognitive intervention. 12 live, weekly sessions will occur during the first 3 months of the study. Groups will be made up of 5-10 participants and will be led by a neuropsychologist. These sessions will include education on the brain and cognitive function as it relates to epilepsy, as well as compensatory strategies for use in daily life. After the 12 sessions, participants will be asked to continue to practice what they learned for the next nine months until their participation ends.
48324370|NCT00868166|DRUG|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
48324371|NCT00868166|DRUG|Riluzole|Riluzole given as add-on therapy 50mg bid
48324372|NCT01608490|DEVICE|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
48324373|NCT00945074|OTHER|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
48488772|NCT02882672|OTHER|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
48488773|NCT02882672|OTHER|Control|They did not do ant exercise training during 8 weeks.
48324374|NCT00945074|OTHER|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
48324375|NCT00945074|OTHER|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
48324376|NCT01848639|DRUG|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
48324377|NCT01848639|DRUG|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
48324378|NCT05174130|DEVICE|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
48324379|NCT00234416|DRUG|Gefitinib|
48324380|NCT00234416|DRUG|Gemcitabine|
48488774|NCT03252418|DRUG|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
48648571|NCT01013870|DRUG|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
48648572|NCT02594943|DEVICE|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
48648573|NCT02594943|DEVICE|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
48648574|NCT05822245|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
48648575|NCT05822245|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
48648576|NCT05822245|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
48648577|NCT06675682|DIETARY_SUPPLEMENT|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.
48648578|NCT05996653|DIAGNOSTIC_TEST|Saturation Transfer (ST)-MRI|"Non-contrast magnetic resonance imaging Saturation Transfer scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)"
48648579|NCT01729429|BEHAVIORAL|HPV brochure, recall, reminders|"* HPV-vaccine specific brochure mailed before clinic visit~* Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~* Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
47970776|NCT00640991|DRUG|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
47970777|NCT00003211|BIOLOGICAL|filgrastim|
48324381|NCT04972916|OTHER|Patient navigation-based tobacco harm reduction intervention|At the first intervention interview, the patient navigators will educate participants about the benefits of quitting, introduce smoking cessation resources, motivate participants to link with treatment, help participants attend smoking cessation treatments, and assess barriers that prevented them from being able to consider smoking cessation. The cessation treatment resources will be discussed include PennState Health Smoking Cessation Clinic, Pennsylvania Quitline, or visiting their primary care provider (PCP) to discuss cessation, prescription medications, and/or nicotine replacement therapy. A follow-up call will be made 1 month later to further assist and motivate to use tobacco treatment services, and assess interim tobacco treatment engagement outcome.
48324382|NCT02726113|DRUG|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
48648580|NCT01729429|BEHAVIORAL|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
48648581|NCT05484557|DRUG|Apixaban|treatment for 6 to 12 weeks
48648582|NCT05484557|DRUG|Enoxaparin Sodium|treatment for 6 to 12 weeks
48648583|NCT01791179|BEHAVIORAL|Comprehensive substance abuse services|
48648584|NCT01894646|RADIATION|Positron Emission Tomography (PET) Imaging|
48648585|NCT05087446|BEHAVIORAL|Early assessment team|Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.
48648586|NCT05087446|BEHAVIORAL|Admission to General psychiatric outpatient clinic|Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
48648587|NCT01993680|DRUG|Pyridostigmine bromide|"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
48648588|NCT01993680|DRUG|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
48648589|NCT00077285|BIOLOGICAL|filgrastim|
48648590|NCT00077285|DRUG|carboplatin|
47970778|NCT00003211|DRUG|amifostine trihydrate|
47970779|NCT00003211|DRUG|cisplatin|
47970780|NCT00003211|DRUG|cyclophosphamide|
47970781|NCT00003211|DRUG|vincristine sulfate|
47970782|NCT00003211|PROCEDURE|peripheral blood stem cell transplantation|
47970783|NCT00003211|RADIATION|radiation therapy|
48324383|NCT02726113|OTHER|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
48324384|NCT00111917|DRUG|Infliximab|anti-TNF
48324385|NCT00111917|OTHER|Placebo|Placebo infusion
48648591|NCT00077285|DRUG|cyclophosphamide|
48648592|NCT00077285|DRUG|dexrazoxane hydrochloride|
48648593|NCT00077285|DRUG|doxorubicin hydrochloride|
48648594|NCT00077285|DRUG|etoposide|
48648595|NCT00077285|DRUG|ifosfamide|
48648596|NCT00077285|DRUG|irinotecan hydrochloride|
48648597|NCT00077285|DRUG|vincristine sulfate|
48648598|NCT00077285|PROCEDURE|conventional surgery|
48648599|NCT00077285|RADIATION|radiation therapy|
48324386|NCT06118346|BEHAVIORAL|Female-Specific Cognitive Behavioral Therapy (FS-CBT)|FS-CBT is a unique 12-session weekly group CBT treatment designed for women Veterans with AUD and/or risky drinking, and provides (1) AUD interventions, (2) general female-specific content, (3) female-Veteran content, (4) wellness and self-care, and (5) a novel 24/7 social support for abstinence discussion mobile app.
48324387|NCT06118346|BEHAVIORAL|Usual Care|Usual care means that participants will receive brief alcohol counseling and have access to available treatments for AUD at the VA.
48324388|NCT02452801|DRUG|ALKS 5461|Single dose, given orally
48324389|NCT05484180|OTHER|training and counseling supported guided imagery application|After the preparation process, as a nursing attempt to the individuals in the experimental group; Training and consultancy supported guided imagery based on the health promotion model will be implemented. This initiative; It will take a total of 12 weeks, including 6 weeks of training program and 6 weeks of counseling program and guided imagery.
48324390|NCT02075749|DRUG|Triamcinolone Acetonide|
48324391|NCT02075749|DRUG|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
48324392|NCT06485986|OTHER|DBS on/off|DBS will be turned on and off for experimental periods to compare the effect of DBS on behaviour.
48324393|NCT00101621|DRUG|M40403|
48324394|NCT01506050|DRUG|Desloratadine|Desloratadine ODT 5 mg
48324395|NCT03013244|BEHAVIORAL|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
48324396|NCT05003063|DRUG|Donepzil|Test
48648600|NCT03684785|DRUG|Cavrotolimod|Intratumorally dosed cavrotolimod.
48648601|NCT03684785|BIOLOGICAL|Pembrolizumab|Pembrolizumab dosing as per the US prescribing information.
48648602|NCT03684785|BIOLOGICAL|Cemiplimab|Cemiplimab dosing as per the US prescribing information.
48119363|NCT06322797|DEVICE|rTMS|Stimulation was performed using a biphasic stimulator (ALTMS® Remed, Republic of Korea) and a 70-mm figure-eight coil. The routine stimulation procedure is described as follows. After identifying the brain site that is activated during finger tapping during fMI, Stimulation was given at 100% of the resting motor threshold stimulator output: 20 Hz, 5-s train duration, 55-s inter-train interval, and a total number of stimulations of 2000 pulses per session for 20 min. the resting motor threshold was measured for each patient at target brain site.
48119364|NCT06322797|DEVICE|Sham|In Sound Mode, no actual stimulation is applied, and 20 minutes of treatment is performed like other experimental groups.
48119365|NCT03740009|DRUG|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
48324397|NCT05003063|DRUG|Placebo oral tablet|Test
48324398|NCT04385615|OTHER|Fasting Mimicking Diet|Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
48324399|NCT04077736|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
48324400|NCT00059618|DRUG|PS-341 (Bortezomib)|Starting dose 0.8 mg/m\^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
48119366|NCT03824262|DEVICE|HICO-VARIOTHERM 550|Warming during perioperative period.
48119367|NCT03824262|DEVICE|Mistral-Air Plus forced air warming device|Warming during perioperative period.
48119368|NCT03407846|PROCEDURE|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
48324401|NCT00059618|DRUG|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
48324402|NCT06141655|DRUG|Influenza vaccine|Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
48488775|NCT03252418|DEVICE|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
48648603|NCT03684785|DRUG|Cavrotolimod|Subcutaneously dosed cavrotolimod
48648604|NCT06675175|DRUG|AZD4144|Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.
48648605|NCT06675175|OTHER|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
48648606|NCT05560880|BEHAVIORAL|High Intensity Interval Gait training|Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
48648607|NCT05560880|BEHAVIORAL|Moderate Intensity Interval gait training|subjects will walk for 20 minutes at theri best comfortable pace
48119369|NCT02070666|BEHAVIORAL|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~* Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure \< 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~* Fraction of inspired oxygen inspired oxygen fraction (FiO2) \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cmH2O"
48119370|NCT02070666|BEHAVIORAL|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~* Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~  · FiO2 \> 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cm H2O."
48648608|NCT05894083|PROCEDURE|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
48324403|NCT01589055|DRUG|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
48324404|NCT05866653|DRUG|lidocaine transdermal patch|The topical pain-relieving treatment 5% lidocaine transdermal patch has been registered in the USA since 1999
48648609|NCT05894083|COMBINATION_PRODUCT|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV_High and PTV_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV_High in 2 Gy per fraction.
48648610|NCT05894083|OTHER|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
48648611|NCT05894083|RADIATION|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
48648612|NCT01861275|DEVICE|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
47970784|NCT03633695|DEVICE|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
47970785|NCT03633695|DEVICE|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
48324405|NCT06303492|PROCEDURE|GUS|Aspiration risk assessment by GUS
48324406|NCT01669941|DRUG|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
48324407|NCT01669941|DRUG|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
48648613|NCT05118529|OTHER|Routine care|Mobilization to chair
47970786|NCT01378949|DRUG|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
47970787|NCT01378949|DRUG|Morphine|Morphine 1 mg/cc
48648614|NCT06499961|BEHAVIORAL|Digital version of Holistic Healthy Life Education|Participants need to attend a two-day workshop related to (1) health risk appraisal and self-care; (2) exercise, fitness and self-acupressure; (3) emotion and stress management; (4) the whole food plant-based (WFPB) diet; and (5) meditation and mindfulness practices, led by a multi-disciplinary team. Before the intervention commences, they will take pre-blood test and further receive the e2HLE with Hera Leto for three months. During the intervention, participants will attend (1) nine weekly workshops pertaining to WFPB diet, exercise, fitness and self-acupressure, and meditation and mindfulness and followed by weekly tele-counselling sessions; (2) three process evaluation practice sharing sessions in the format of focus group, making up a total of twelve sessions. The process evaluation practice sharing sessions will be audio-recorded; (3) mutual support networking platform will be held between case managers and participants within Hera Leto system.
48648615|NCT06499961|OTHER|Waitlist control|usual care first, then switch to receive the intervention
48648616|NCT06088277|BEHAVIORAL|TM HIV|Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
48648617|NCT06088277|BEHAVIORAL|TM HL|Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
48119371|NCT02070666|OTHER|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
48324408|NCT01669941|DRUG|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
48324409|NCT04825119|DRUG|Nusinersen|Patients with SMA who will be treated with nusinersen will be included.
48648618|NCT05880784|OTHER|Reinforcement of Peer coaching and clinical audit|The goal of the proposed research study is to test the effectiveness and feasibility of an intervention to enhance peer coaching and clinic audit activities to facilitate the implementation of the Package of Essential Non- Communicable Diseases (PEN) in Nepal.
48648619|NCT05880784|OTHER|Continuation of usual practice without intervention|No intervention will be carried out, instead usual practice will be evaluated at the start and the end of the study period.
48324410|NCT05291416|DIAGNOSTIC_TEST|densitometry/ handgrip dynamometer|all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
48488776|NCT06310928|OTHER|Thermal Blanket|Thermal blankets, a passive heating blanket, have a silver surface to prevent heat loss through radiation. Thermal insulation is achieved thanks to the fact that they are covered with a reflective surface to reflect light radiation, i.e. thermal radiation. It is a cost-effective, easy-to-clean, flexible material that takes the desired shape. Thermal blankets generate heat by providing thermal insulation with infrared radiation and can provide thermal vasodilation or thermotherapy. In 2013, Lima et al. used infrared thermal blankets to provide thermal vasodilation and as a result, it was found to reduce vascular resistance. Therefore, FORCLAZ brand blanket, also known as emergency blanket, used in natural disaster management, peripheral vascular resistance studies and hypothermia prevention studies was used in this study.
48488777|NCT00576641|BIOLOGICAL|autologous dendritic cells|
48488778|NCT00809965|DRUG|Rivaroxaban 2.5 mg|One tablet twice daily
48488779|NCT00809965|DRUG|Rivaroxaban 5 mg|One tablet twice daily
48488780|NCT00809965|DRUG|Placebo|One placebo tablet twice daily
48648620|NCT01629563|DRUG|PGL4001 5 mg|PGL4001 5 mg daily administration
48648621|NCT01629563|DRUG|PGL4001 10 mg|PGL4001 10mg daily administration
48648622|NCT03386058|DEVICE|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
48648623|NCT05032222|OTHER|Uroflowmetry|Diagnostic test
48648624|NCT05848843|DRUG|Durvalumab|Given by vein (IV)
48648625|NCT05848843|DRUG|Adagrasib|Given by PO
48648626|NCT04359329|DRUG|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
48648627|NCT00949065|BIOLOGICAL|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
48324411|NCT01404442|DRUG|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
48488781|NCT00809965|DRUG|Standard of care|
48488782|NCT05955495|OTHER|Food|Post-operative feeding includes water, liquid diet, soft diet.
48488783|NCT00000651|DRUG|Zidovudine|
48488784|NCT00000651|DRUG|Zalcitabine|
48488785|NCT00908921|DRUG|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
48488786|NCT02138942|DEVICE|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
48488787|NCT01157897|BIOLOGICAL|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
48488788|NCT01157897|OTHER|P. vivax sporozoite challenge|P. vivax sporozoite challenge
48488789|NCT02709486|DRUG|Tanezumab|2.5 mg
48488790|NCT02709486|DRUG|Tanezumab|5 mg
48648628|NCT06543537|BEHAVIORAL|Collaborative Agenda-Setting Intervention|A collaborative agenda-setting intervention (CASI) to promote patient-centered communication, set agendas for discussion at in-clinic visits, increase discussion of psychosocial concerns, and reduce clinician burden. The intervention is integrated into the patient portal and electronic health record. Prior to a clinic visit, the intervention elicits patients' and caregivers' preferences and concerns, then communicates this information to clinicians. Patients, caregivers, and clinicians receive communication resources, while patients and caregivers receive tailored educational materials and navigation to supportive care services.
48119372|NCT03474822|BIOLOGICAL|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
48119373|NCT02190578|DEVICE|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
48119374|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
48119375|NCT05264870|DRUG|Norepinephrine|treatment of postspinal hypotension
48119376|NCT01373398|DRUG|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
48324412|NCT01404442|DRUG|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
48324413|NCT01404442|DRUG|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
48324414|NCT02279121|DEVICE|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
48324415|NCT02279121|DRUG|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
48324416|NCT00048399|DRUG|Fludarabine|
48324417|NCT00048399|DRUG|CAMPATH 1H|
48324418|NCT00048399|DRUG|FK506|
48324419|NCT00048399|PROCEDURE|Stem Cell Transplantation|
48324420|NCT04324918|DRUG|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
48324421|NCT04324918|DRUG|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
48324422|NCT00003893|DRUG|CMF regimen|
48324423|NCT00003893|DRUG|cyclophosphamide|
48324424|NCT00003893|DRUG|doxorubicin hydrochloride|
48324425|NCT00003893|DRUG|epirubicin hydrochloride|
48324426|NCT00003893|DRUG|fluorouracil|
48324427|NCT00003893|DRUG|methotrexate|
48324428|NCT00003893|DRUG|mitomycin C|
48324429|NCT00003893|DRUG|mitoxantrone hydrochloride|
48324430|NCT00003893|PROCEDURE|adjuvant therapy|
48324431|NCT00003893|RADIATION|radiation therapy|
48488791|NCT02709486|DRUG|Placebo|Placebo
48488792|NCT02442271|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
48488793|NCT02442271|DRUG|ribavirin|Tablet
48488794|NCT05960474|OTHER|Outcomes for Patients with CMD|Our objective is to perform a retrospective/prospective descriptive study on the short term to longterm (up to 5 years of follow-up) outcomes of patients with coronary microvascular disease diagnosis invasively
48488795|NCT01478282|DRUG|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
48488796|NCT01478282|DRUG|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
48488797|NCT00061217|DEVICE|Unrectified prosthetic socket|
48488798|NCT00061217|DEVICE|Rectified prosthetic socket|
48488799|NCT04204759|DEVICE|Transcranial direct current stimulation|Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).
48488800|NCT04204759|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
48488801|NCT01047930|BEHAVIORAL|Exercise|"Each 3-day experimental period will include one of the following conditions:~1. Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~2. Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~3. No exercise - subject will watch television or read and they will be required to remain sedentary."
48488802|NCT02867475|OTHER|Physical activity motivation|Physical activity motivation
48488803|NCT06077331|DRUG|HS-10374 tablets 1mg|Administered orally QD for 12 weeks
48488804|NCT06077331|DRUG|HS-10374 tablets 5mg|Administered orally QD for 12 weeks
48488805|NCT06077331|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
48488806|NCT01347658|DIETARY_SUPPLEMENT|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
48488807|NCT04325152|DEVICE|FCSEMS plus Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
48488808|NCT04325152|DEVICE|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
48488809|NCT01453413|OTHER|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
48119377|NCT05183490|DRUG|Rapidly generated virus specific T (R-MVST) cells|"The R-MVST products will be manufactured individually for each patient from a selected donor; it is an anti-viral prophylaxis and treatment of viral reactivation.~SCT dose escalation:~Cohort / R-MVST dose~* (-1A) 0.25x10\^6 R-MVST TNC/kg~* (1A) 0.5x10\^6 R-MVST TNC/kg~* (2A) 1x10\^6 R-MVST TNC/kg~SOT dose escalation:~Cohort / R-MVST dose~* (-1B) 1x10\^6 R-MVST TNC/kg~* (1B) 2x10\^6 R-MVST TNC/kg~* (2B) 4x10\^6 R-MVST TNC/kg"
48648629|NCT05411120|OTHER|Western Diet|Western Diet is by high intakes of pre-packaged foods, refined grains, red meat, processed meat, high-sugar drinks, candy and sweets, fried foods, conventionally-raised animal products, butter and other high-fat dairy products, and low intakes of fruits, vegetables, whole grains.
48648630|NCT05411120|OTHER|CLEAN-MED|Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.
48119378|NCT02947958|OTHER|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
48119379|NCT02947958|OTHER|Hospital (control)|The patient will keep his usual care at the tertiary care.
48119380|NCT06492070|OTHER|Best Practice|Undergo standard of care
48324432|NCT05780346|OTHER|TGNB-CARE (Connecting and Reflecting Experience)|12 session 60-minute mentalizing-focused parenting group with approximately 6 caregivers, facilitated by a mental health clinician
48648631|NCT01149460|DRUG|Valacyclovir|Test 1000 mg Tablet
48648632|NCT01149460|DRUG|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
48324433|NCT02853032|DEVICE|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
48324434|NCT02853032|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
48324435|NCT02853032|DEVICE|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
48324436|NCT03699449|DRUG|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
48324437|NCT03699449|DRUG|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
48648633|NCT06265818|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
48488810|NCT00107549|BIOLOGICAL|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
48488811|NCT00107549|BIOLOGICAL|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
48488812|NCT05415774|DEVICE|1 : S-C1-C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
48488813|NCT05415774|DEVICE|2 : S-C2-C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
48488814|NCT05415774|DEVICE|3 : C1 - S - C2|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
48488815|NCT05415774|DEVICE|4 : C1 -C2 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
48488816|NCT05415774|DEVICE|5 : C2 - S - C1|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
48119381|NCT06492070|DRUG|Cilostazol|Given PO
48119382|NCT06492070|DEVICE|Cryocompression Therapy|Undergo cryocompression therapy
48119383|NCT06492070|DRUG|Paclitaxel|Given by infusion
48119384|NCT06492070|OTHER|Quality-of-Life Assessment|Ancillary studies
48324438|NCT03699449|DRUG|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
47970788|NCT01983813|OTHER|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~1. Contact via email, phone or text every 2-4 weeks~2. Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~3. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
47970789|NCT01983813|OTHER|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
48324439|NCT03699449|DRUG|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
48324440|NCT03699449|DRUG|durvalumab + tremelimumab + paclitaxel treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)"
48324441|NCT03699449|DRUG|durvalumab +chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
48324442|NCT03779893|COMBINATION_PRODUCT|BioCoat® by Premier®.|Bioactive pits and fissure sealant
47970790|NCT04742010|DRUG|Zoledronic Acid|"* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes"
48324443|NCT03779893|COMBINATION_PRODUCT|3M™ Clinpro™ Sealant.|conventional pits and fissure sealant
48324444|NCT02816125|DIETARY_SUPPLEMENT|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
48324445|NCT02462733|BEHAVIORAL|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
48488817|NCT05415774|DEVICE|6 : C2 - C1 - S|"Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) :~* Standard stimulation~* 125Hz at both STN and SNr for C1,~* 125Hz for STN and 60 for SNr for C2"
48488818|NCT00325832|DEVICE|BpTRU|
48488819|NCT00325832|DEVICE|Conventional mercury sphygmomanometry|
48488820|NCT01108666|DRUG|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
48488821|NCT01641133|BIOLOGICAL|Synflorix (3-Dose)|3 doses administered intramuscularly
48488822|NCT01641133|BIOLOGICAL|Synflorix (2-Dose)|2 doses administered intramuscularly
48488823|NCT01641133|BIOLOGICAL|Synflorix (Single Dose)|1 dose administered intramuscularly
48488824|NCT01641133|BIOLOGICAL|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
48488825|NCT01641133|BIOLOGICAL|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
48648634|NCT06265818|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
48648635|NCT03288857|DEVICE|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
48648636|NCT06497829|DIETARY_SUPPLEMENT|geranylgeraniol|GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily
47970791|NCT04742010|DRUG|Placebo|as above
47970792|NCT02277756|DEVICE|thermode|thermal stimulation with test thermode
47970793|NCT05647655|DEVICE|Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.
48488826|NCT02983136|BEHAVIORAL|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~* Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~* The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
48488827|NCT00358748|DRUG|Hydrocortisone|See detailed description above.
48488828|NCT05897268|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
48488829|NCT05897268|DRUG|Tislelizumab|a PD-1 immune check inhibitor
48488830|NCT05897268|DRUG|Lenvatinib|Lenvatinib capsules
48648637|NCT04353661|DRUG|Azithromycin|Azithromycin will be administered orally.
48648638|NCT04353661|OTHER|HP xenon (¹²⁹XE)|HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
47970794|NCT00291577|DRUG|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
47970795|NCT00291577|DRUG|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
47970796|NCT05968391|RADIATION|PET scan metabolic day|11C-Acetate and 11C-Acetoacetate PET scans
47970797|NCT05382624|PROCEDURE|Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.|The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
48324446|NCT02462733|BEHAVIORAL|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
48324447|NCT03992209|OTHER|Standard care|Usual operating room practice
48324448|NCT03992209|OTHER|Protocolized care|Hand washing per protocol
48324449|NCT05688501|OTHER|descriptiv group|no intervention
48488831|NCT04471038|BIOLOGICAL|SAB-176|Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
48488832|NCT04471038|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
48488833|NCT02053675|DRUG|Vasopressin infusion|
48488834|NCT01785121|BEHAVIORAL|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
48488835|NCT01785121|BEHAVIORAL|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
48488836|NCT02263235|BIOLOGICAL|administration of stable isotope-labelled leucine-|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
48488837|NCT02263235|OTHER|collection of CSF, blood, urine, saliva|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
48488838|NCT04534218|DRUG|Regorafenib|"* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
48488839|NCT04534218|DRUG|Cyclophosphamide|50 mg per os, daily, for 6 months
48488840|NCT04534218|DRUG|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
48488841|NCT04534218|DRUG|Aspirin|75 mg orally and daily until progression
48488842|NCT00653965|DRUG|Rosuvastatin|
48488843|NCT00653965|DRUG|Atorvastatin|
48488844|NCT01941355|BEHAVIORAL|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
48488845|NCT01941355|BEHAVIORAL|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
48488846|NCT03477552|DEVICE|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
47970798|NCT05289791|OTHER|ultrasonic activation of bioceramic sealer|activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
47970799|NCT03987217|DIETARY_SUPPLEMENT|Creatine Monohydrate|Given orally
47970800|NCT03987217|BEHAVIORAL|Exercise Intervention|Complete POWER resistance training program
47970801|NCT03987217|OTHER|Questionnaire Administration|Ancillary studies
47970802|NCT01702805|PROCEDURE|Liberal Cell Transfusion|
47970803|NCT01702805|PROCEDURE|Restricted red cell transfusion|
47970804|NCT05609006|DIETARY_SUPPLEMENT|High-Energy, Low-Volume ONS|2 bottles/day of a High-Energy, Low-Volume ONS
48324450|NCT01509872|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
48324451|NCT01509872|BEHAVIORAL|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
48324452|NCT03833375|OTHER|Decision Aid|Shared-decision making tool
48488847|NCT03477552|OTHER|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
48488848|NCT01124357|DEVICE|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
48488849|NCT01124357|DEVICE|thermachoice|ThermachoiceTM III thermal balloon ablation
48488850|NCT05225974|DRUG|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
48488851|NCT05225974|DRUG|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
48488852|NCT03932123|DRUG|Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime|Efficacy and safety of antibiotics
48648639|NCT01532219|BEHAVIORAL|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
48119385|NCT02502396|OTHER|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
48648640|NCT01532219|BEHAVIORAL|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
48648641|NCT04546243|PROCEDURE|resection group|patients received VATS
48119386|NCT02355197|DRUG|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C .....) per day from the time of diagnosis until the time of delivery
48119387|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
48119388|NCT01517815|DRUG|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
48119389|NCT01839526|DRUG|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
48119390|NCT05454228|BEHAVIORAL|postoperative delirium|Postoperative delirium (POD) occurs within 1 week after surgery in patients, with obvious time characteristics, mainly occurring within 1-3 days after surgery. Postoperative delirium has adverse effects on the short and long term prognosis of patients. Patients with delirium have an increased risk of postoperative complications, perioperative death, longer hospital stay and increased medical costs during hospitalization.
48119391|NCT02125695|PROCEDURE|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
48119392|NCT02125695|PROCEDURE|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
48119393|NCT02125695|PROCEDURE|Skin Biopsy|As described in the treatment arm
48324453|NCT02103452|PROCEDURE|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
48324454|NCT06375980|OTHER|Intraoperative Mechanical Ventilation Strategies|The intervention involves the management of mechanical ventilation during major abdominal surgery. This includes the adjustment of ventilation parameters such as tidal volume, respiratory rate, peak pressure, positive end-expiratory pressure (PEEP), and inspiratory flow rate. The aim is to optimize ventilation strategies to reduce the risk of postoperative pulmonary complications
48488853|NCT05545761|OTHER|music therapy|Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
48648642|NCT04546243|RADIATION|radiotherapy group|patients received radiotherapy
48648643|NCT00089583|DRUG|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
48648644|NCT00089583|DRUG|Ritonavir|Ritonavir solution bid
48648645|NCT04439357|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
47970805|NCT05609006|DIETARY_SUPPLEMENT|High-Energy Standard ONS|2 bottles/day of a High-Energy Standard ONS
48324455|NCT03371342|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
48324456|NCT03371342|DRUG|Botox|Botox(Botulinum toxin type A)
48324457|NCT05157399|DEVICE|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
48324458|NCT05157399|DEVICE|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
48648646|NCT02038647|DRUG|Alisertib|Alisertib tablets
48648647|NCT02038647|DRUG|Placebo|Placebo matching tablets
48324459|NCT00980421|DIETARY_SUPPLEMENT|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
47970806|NCT00724360|DRUG|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
48324460|NCT04659434|DRUG|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~* Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~* R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
48324461|NCT04404010|OTHER|Immersive Virtual Reality|Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
48488854|NCT06367595|DRUG|Magnesium sulfate|IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
48648648|NCT02038647|DRUG|Paclitaxel|Paclitaxel intravenous injection
48648649|NCT01455090|DRUG|BMS-650032|
48648650|NCT01455090|DRUG|BMS-790052|
48648651|NCT01455090|DRUG|BMS-791325|
48648652|NCT01455090|DRUG|Ribavirin|
48648653|NCT04680208|PROCEDURE|Surgical procedure under anesthesia|Different varieties of surgical procedures done under anesthesia
48648654|NCT06257875|DRUG|Lutikizumab Matching Placebo|SC Injection
48648655|NCT06257875|DRUG|Lutikizumab Matching Placebo|IV Infusion
47970807|NCT02248103|PROCEDURE|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
47970808|NCT02248103|BIOLOGICAL|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
47970809|NCT05096767|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed
48324462|NCT04404010|OTHER|Surgical Technical Instructional Video|Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
48488855|NCT05212883|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionnaires
48488856|NCT01467206|BEHAVIORAL|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
48488857|NCT01467206|BEHAVIORAL|Standard care|Standard care as it is given to all stoke patients after stroke
48488858|NCT05372783|DRUG|STI-9199|STI-9199 is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
48488859|NCT05372783|DRUG|Placebo|Diluent solution
48488860|NCT04175743|DRUG|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
48488861|NCT03898674|DRUG|Intra venous fluid|Volume of intra venous fluid administered during GDT protocol
48488862|NCT02025751|DRUG|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
48648656|NCT06257875|DRUG|Adalimumab Matching Placebo|SC Injection
47970810|NCT05277324|OTHER|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
47970811|NCT02294591|DRUG|N-acetylcysteine|Add-on treatment of NAC
47970812|NCT02294591|DRUG|Placebo|Add-on treatment of placebo
47970813|NCT04462445|DRUG|Pazopanib|
47970814|NCT05367648|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
47970815|NCT05367648|OTHER|Placebo|Placebo comparator
47970816|NCT03207854|PROCEDURE|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
48648657|NCT06257875|DRUG|Lutikizumab|Subcutaneous (SC) Injection
48648658|NCT06257875|DRUG|Lutikizumab|Intravenous (IV) Infusion
48648659|NCT06257875|DRUG|Adalimumab|SC Injection
48648660|NCT06303752|DRUG|ADRC injection|Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
47970817|NCT03207854|OTHER|Laboratory Biomarker Analysis|Correlative studies
47970818|NCT03207854|OTHER|Questionnaire Administration|Ancillary studies
47970819|NCT03031314|DEVICE|barbed suture|
47970820|NCT03031314|DEVICE|standard suture|
47970821|NCT01251601|OTHER|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
48648661|NCT06303752|DRUG|ADRC001 injection|Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
48648662|NCT06571669|DEVICE|Neuromodulation|Neuromodulation
48648663|NCT04245579|OTHER|Multifactorial Memory Training Program (UMAM method)|
48648664|NCT06673940|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS is applied on the acupuncture points Intervention arm
48648665|NCT06673940|OTHER|Physical Therapy program|Physical therapy methods
48488863|NCT02025751|DRUG|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
47970822|NCT01811654|DEVICE|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
48119394|NCT04426500|DRUG|Bupivacain|Direct injection of 0.25% bupivacaine into surgical wounds
48119395|NCT04426500|DRUG|Ultrasound-guided transversus abdominus plane block|bilateral TAP using ultrasound guidance in prostatectomies
48488864|NCT06052488|BEHAVIORAL|Strength After Breast Cancer|Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
47970823|NCT02289339|DEVICE|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
48119396|NCT04426500|DRUG|Laparoscopic-guided transversus abdominus plane block|bilateral TAP using laparoscopic guidance in prostatectomies
48119397|NCT02107339|DRUG|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
48119398|NCT02107339|DRUG|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
48488865|NCT02439749|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
48488866|NCT02439749|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
48119399|NCT03868397|DIAGNOSTIC_TEST|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
48119400|NCT02861066|BEHAVIORAL|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
48488867|NCT02441244|DRUG|Visbiome|Visbiome probiotic
48488868|NCT02441244|OTHER|Placebo|Placebo
48648666|NCT06482515|BEHAVIORAL|Time-restricted eating|Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.
48648667|NCT06482515|BEHAVIORAL|Nutrition counseling|Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.
48648668|NCT00324857|BEHAVIORAL|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
48648669|NCT00324857|BEHAVIORAL|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
48648670|NCT00324857|BEHAVIORAL|MI plus Decision aid|Patient viewed the video and then underwent MI.
48648671|NCT00324857|OTHER|Attention control|patients received a booklet.
48648672|NCT04645030|DIAGNOSTIC_TEST|Ultra low-dose computer thermography|The ULD-CT scan will be executed according to a standardized predeveloped technical protocol. The technical protocol will differentiate between patients with BMI \<25 and \>25 to insure optimal ULD-CT image quality.
48648673|NCT04645030|DIAGNOSTIC_TEST|lung ultrasound|"LUS will be performed by trained researchers. Before inclusion researchers preforming LUS scans, will undergo a training program and will complete 25 supervised LUS scans to be certified in LUS. At the end of the training program, researchers will be tested to insure proficiency in LUS.~LUS will be performed according to LUS protocol with seven scanning's zones on each side; 2 anterior, 2 lateral and 3 posterior."
48648674|NCT06131840|DRUG|PF-08046050|Given into the vein (IV; intravenous)
48648675|NCT06673641|DRUG|Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
48648676|NCT06673641|DRUG|CABTREO Topical Gel|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
48324463|NCT03111264|BEHAVIORAL|CHAMP|"The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
48324464|NCT03111264|BEHAVIORAL|CHAMP+|The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
48324465|NCT03450915|BIOLOGICAL|M-001|A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
48324466|NCT03450915|BIOLOGICAL|Saline|0.9% sodium chloride (NaCl)
48324467|NCT03006471|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
48488869|NCT03504995|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
48324468|NCT03006471|DRUG|Placebo - Cap|one per day before breakfast during 12 weeks.
48324469|NCT00945802|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
48324470|NCT00945802|DRUG|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
48324471|NCT02516150|DRUG|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
48324472|NCT02516150|DRUG|Glucagon|injection of 50 micrograms of glucagon
48488870|NCT02642536|BEHAVIORAL|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
47970824|NCT05948020|BIOLOGICAL|CBT102-A capsule|"Orally CBT102-A will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with 1.25×10\^11 live cell. The shelf life is 6 months.~Subjects receive oral dose of 1 capsule CBT102-A (1.25 x 10\^11 live cell) before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule CBT102-A (2.5 x 10\^11 live cell) before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule CBT102-A (5 x 10\^11 live cell) before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule CBT102-A (1 x 10\^12 live cell) before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
48119401|NCT04010006|PROCEDURE|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
48324473|NCT00438789|DRUG|eculizumab|600mg IV every week and 900mg IV every 2 weeks
48324474|NCT01187784|BEHAVIORAL|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
48324475|NCT00630812|DRUG|inhaled mannitol|400 mg BD for 26 + 26 weeks
48324476|NCT00630812|DRUG|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
48324477|NCT05175209|DIAGNOSTIC_TEST|EMG|Electromyelography
48324478|NCT02557412|DEVICE|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
48324479|NCT02557412|BEHAVIORAL|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
48324480|NCT02557412|OTHER|Conventional treatment|Hygiene and diet recommendations on sleep
48119402|NCT04010006|PROCEDURE|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
48119403|NCT02743195|DIETARY_SUPPLEMENT|Polyphenol/prebiotic blend|
48119404|NCT01231802|DRUG|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
48119405|NCT01231802|DRUG|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
48119406|NCT01231802|DRUG|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
48119407|NCT01231802|DRUG|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
48119408|NCT01318382|DEVICE|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
48119409|NCT01115959|DRUG|valproic acid|treatment of 1 month dosage of 400 mg BID
48324481|NCT03016546|BEHAVIORAL|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
47970825|NCT05948020|OTHER|Placebo capsule|"Orally placebo will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with Lactose powder filler. The shelf life is 6 months. The color, condition, smell and other appearances are exactly the same as CBT102-A.~Subjects receive oral dose of 1 capsule placebo before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule placebo before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule placebo before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule placebo before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
48119410|NCT01115959|DRUG|placebo bid|
48119411|NCT04867902|BEHAVIORAL|Positive Psychology-Motivational Interviewing Intervention|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
48648677|NCT06673641|DRUG|Placebo Control|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
48648678|NCT06599320|OTHER|Oral rehabilitation with dental implants|Patients rehabilitated with implant-supported fixed partial dental prostheses
48648679|NCT05596409|DRUG|Elacestrant|Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
48648680|NCT02577575|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
48648681|NCT02577575|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
48648682|NCT00892450|DRUG|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
48648683|NCT03105765|DRUG|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
48648684|NCT03105765|DRUG|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
48648685|NCT02510274|DRUG|ASP3325|oral
48648686|NCT03636230|DEVICE|Remote Monitoring|Remote Monitoring only
48648687|NCT03636230|OTHER|Standard of care|In-Clinic visits only
48648688|NCT01586897|DEVICE|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
47970826|NCT04521153|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
47970827|NCT04521153|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
47970828|NCT04521153|PROCEDURE|TACE treatment|TACE treatment
47970829|NCT04521153|PROCEDURE|Radical surgery|Radical surgery
47970830|NCT03673332|DRUG|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
47970831|NCT00484874|DRUG|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
48119412|NCT01278394|DRUG|AN2690 Solution, 5.0%|Once daily application for 360 days
48119413|NCT00166283|BEHAVIORAL|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
48648689|NCT01586897|OTHER|Usual Care|
48648690|NCT06645600|DIAGNOSTIC_TEST|Fracture risk|To calculate fracture risk, the percentages for major and hip fracture risks will be calculated using the Fracture Risk Assessment Tool (FRAX®). The one-leg stance test, used to assess static posture and balance, and the 30-second sit-to-stand test, used to evaluate endurance and lower extremity strength, will be applied to the patients.
48648691|NCT02439411|DRUG|Trametinib|
48648692|NCT02019836|OTHER|Determining maternal and neonatal vitamin D levels|
48648693|NCT00569075|OTHER|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
48648694|NCT00423462|BEHAVIORAL|Brief dynamic psychotherapy|
48648695|NCT05281575|BEHAVIORAL|Baby Friendly Spaces (BFS)|Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).
48648696|NCT05823441|DRUG|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
48648697|NCT05823441|DRUG|Placebo|Volunteers inhale 24 units of placebo spray
48648698|NCT05823441|BEHAVIORAL|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
48648699|NCT05823441|BEHAVIORAL|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
48488871|NCT02642536|BEHAVIORAL|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
48488872|NCT06395376|OTHER|Bikram Hot Yoga Intervention|"Active participants engage in a yoga intervention which entails participating in a minimum of 60-minutes of hot yoga (Bikram sequence), 3x per week in a heated room at 40 degrees C. The intervention will be 6-weeks of active intervention when they are participating in yoga, followed by an 6-week washout period where they will be asked to not practice yoga. Participants will be asked to give blood at 9 timepoints throughout the 12-week study, including baseline, week one, midpoint, end of Hot Yoga Intervention (Week 6) and after Washout (Week 12)"
47970832|NCT04805541|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
47970833|NCT04805541|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
48488873|NCT06395376|OTHER|Hot Yoga Washout|"The Washout period consists of 6-weeks occurring immediately after the Hot Yoga Intervention during which the participants do not perform any hot yoga."
48488874|NCT03828136|DEVICE|Novum Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
48488875|NCT03828136|DEVICE|Allograft Ring or Block|Standard of Care
48488876|NCT02208232|PROCEDURE|cataract surgery|cataract surgery with implantation of intraocular lens
48488877|NCT05173246|DRUG|JS001|JS001 240mg, ivdrip, d1, Q3w
48488878|NCT05173246|DRUG|nab-paclitaxel|nab-paclitaxel 220 mg/m2,ivdrip, d1,d8,Q3w
48488879|NCT05173246|DRUG|Cisplatin|Cisplatin 75mg/m2, ivdrip,d1,Q3w
48488880|NCT05173246|DRUG|Carboplatin|Carboplatin AUC 5,d1,Q3w
48488881|NCT05329506|OTHER|patient population|questionnaires, standard of care
48488882|NCT00618202|DRUG|Balsalazide|
48488883|NCT04677855|DRUG|PCUR-101|50 mg capsules
48488884|NCT04677855|DRUG|Dutasteride 0.5 mg|0.5 mg capsules
48488885|NCT04677855|DRUG|Abiraterone and Prednisone|500 mg tablets Abiraterone with 5 mg Prednisone Tablets
48488886|NCT04048343|DRUG|Biological: Experimental: Tezepelumab|Tezepelumab subcutaneous injection every 4 weeks
48488887|NCT01842126|BIOLOGICAL|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
48488888|NCT01842126|BIOLOGICAL|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
48488889|NCT01842126|DRUG|Placebo IV|Ascending Doses intravenous (IV) of Placebo
48488890|NCT01842126|DRUG|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
48119414|NCT00166283|BEHAVIORAL|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
48488891|NCT01651546|BEHAVIORAL|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
48488892|NCT02524587|DEVICE|standard polyethylene acetabular irradiated at 3 Mrad|
48488893|NCT02524587|OTHER|radio stereometric analysis (RSA) of the acetabular|
48488894|NCT02524587|DEVICE|acetabular polyethylene vitamys®|
48488895|NCT00953472|DRUG|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
48488896|NCT00953472|OTHER|no-added salt diet|instruction to reduce salt for one week prior to study
48488897|NCT00161798|BIOLOGICAL|Tick-borne encephalitis vaccine|
48488898|NCT04997395|DRUG|MediCabilis Cannabis sativa 50|Already described
48488899|NCT00976794|DRUG|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
48488900|NCT00976794|DRUG|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
48488901|NCT05032313|DIAGNOSTIC_TEST|IUO CLPD Limited Panel|This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
47970834|NCT04805541|DEVICE|EyeCheckup - AI Based DR Screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
47970835|NCT00317005|DRUG|folate treatment|
48488902|NCT02132754|BIOLOGICAL|MK-4166|
48119415|NCT05177601|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of mood disorders.
48119416|NCT05177601|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
48648700|NCT03784729|OTHER|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
48119417|NCT05177601|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during TMS treatments (20 days).
47970836|NCT06451601|DEVICE|Intermittent hypoxia-hyperoxia therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, occupation, environment, body mass index, nutritional status, abdominal circumference, hip circumference, smoking, alcohol. Also, the patients performed a 6-minute walking test.~Other Names:~* Hydrokinetotherapy~* Hydrothermotherapy~* Electrotherapy~* Massage therapy~* Kinetotherapy"
48119418|NCT05177601|DRUG|Placebo oral capsule|Daily oral placebo during the TMS treatments (20 days).
48119419|NCT00879463|PROCEDURE|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
48119420|NCT00879463|PROCEDURE|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
48488903|NCT02132754|BIOLOGICAL|Pembrolizumab|
48488904|NCT02794857|DRUG|NP001|
48648701|NCT03784729|OTHER|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
48648702|NCT01674062|DRUG|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
48648703|NCT01674062|DRUG|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
48648704|NCT00189878|DRUG|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
47970837|NCT01445561|DRUG|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
47970838|NCT04938232|DRUG|Nivolumab|Intravenous infusion
47970839|NCT04938232|DRUG|Ipilimumab|Intravenous infusion
47970840|NCT00365729|BEHAVIORAL|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
48119421|NCT04426890|BIOLOGICAL|CT-P39|Prefilled syringe (PFS) of 1 mL solution
48119422|NCT04426890|BIOLOGICAL|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
48119423|NCT01244113|DRUG|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
48119424|NCT02267967|DRUG|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
48119425|NCT04597203|DEVICE|755-nm picosecond alexandrite laser with topical 2% hydroquinone|treatment one side of the face with 755-nm picosecond alexandrite laser with topical 2% hydroquinone
48119426|NCT04597203|DRUG|topical 2% hydroquinone|treatment one side of the face with topical 2% hydroquinone
48119427|NCT06417346|PROCEDURE|Laparoscopic TEP Repair|Laparoscopic TEP Repair performed
48119428|NCT06417346|PROCEDURE|Open Technique (Lichtenstein)|Open Technique (Lichtenstein) performed
48119429|NCT03462823|DEVICE|Osteoconductive scaffold-hamstring tendon composite repair|The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
48119430|NCT03462823|DEVICE|Hamstring tendon-only repair|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
48119431|NCT00074646|DRUG|CC-8490|
48488905|NCT02794857|DRUG|Placebo|
48488906|NCT05695755|DIAGNOSTIC_TEST|ECHO, Serum electrolytes|echocardiography, serum electrolytes and cortisol level for all patients
48324482|NCT03016546|BEHAVIORAL|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
48324483|NCT03486210|BEHAVIORAL|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
48324484|NCT03486210|OTHER|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
48324485|NCT03633565|DRUG|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
48324486|NCT03633565|DRUG|Prednisolone (Steroids)|tablet 20 mg
48324487|NCT03633565|PROCEDURE|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
48324488|NCT06047899|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
48324489|NCT06047899|OTHER|Placebo|mannitol formulated for oral administration (capsules)
48324490|NCT00672360|DIETARY_SUPPLEMENT|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
48324491|NCT00672360|DIETARY_SUPPLEMENT|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
48324492|NCT05462613|OTHER|quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire- Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D3L questionnaire (EuroQol-5 Dimensions, 3 levels)
48324493|NCT05462613|PROCEDURE|Blood sample|Blood sample for plasma collection Blood sample for ctDNA (circulating tumoral DNA) collection
48488907|NCT05163197|PROCEDURE|Transperineal Laser Ablation of Prostate Cancer|Minimal invasive transperineal laser ablation treatment for prostate cancer
48648705|NCT00189878|DRUG|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
48488908|NCT01124708|DRUG|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
48488909|NCT01124708|DRUG|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
48648706|NCT03556384|DRUG|Temozolomide|"Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters"
47970841|NCT03346915|BEHAVIORAL|WoW and BNI|The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
47970842|NCT02012075|DRUG|Extended-Release Carvedilol Sulfate|
47970843|NCT02012075|DRUG|Sustained-release Metoprolol Succinate|
47970844|NCT03888456|OTHER|osteopathic treatment|the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified
48488910|NCT00974948|PROCEDURE|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
48488911|NCT03235661|DEVICE|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
48488912|NCT03235661|DEVICE|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
48488913|NCT06406660|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
48648707|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by intravenous (IV) infusion
48648708|NCT02290951|DRUG|Odronextamab multiple dose levels|Administered by subcutaneous (SC) injection
48324494|NCT05462613|DRUG|Regorafenib|"- Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
48324495|NCT05462613|DRUG|Metronomic chemotherapies|"* Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~* Cyclophosphamide: 50 mg per os, daily, for two months"
48324496|NCT05462613|DRUG|Aspirin|75 mg orally and daily during two months
48324497|NCT05462613|DRUG|Bevacizumab|5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity
48648709|NCT06549907|OTHER|Multi-omics testing|Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.
48324498|NCT05462613|DRUG|FOLFIRI or FOLFOX|every 2 weeks according to investigator practice
48324499|NCT00174785|DRUG|dronedarone (SR33589)|oral administration (tablets)
48324500|NCT00174785|DRUG|placebo|oral administration (tablets)
48324501|NCT02180217|DRUG|osilodrostat|Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
48324502|NCT02180217|DRUG|LCI699 matching placebo|Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
48324503|NCT02527122|DIAGNOSTIC_TEST|Allergen extracts|
48324504|NCT04000347|DRUG|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
48648710|NCT06549907|OTHER|MRI|MRI will be conducted to investigate image characteristics during treatment
48648711|NCT02981160|OTHER|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
48648712|NCT06542341|DEVICE|decoLITE (TN2037)|Red/Near infra red light therapy
48324505|NCT04000347|DRUG|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
47970845|NCT03888456|OTHER|sham|the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
47970846|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
47970847|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
47970848|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
48324506|NCT05597917|DRUG|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
48488914|NCT03679052|DRUG|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
48488915|NCT03679052|DRUG|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
47970849|NCT04603443|DIETARY_SUPPLEMENT|Protein Control|Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
48324507|NCT05597917|BIOLOGICAL|tTF-NGR|Patients will receive standard trabectedin according to arm 1 plus the safe dose according to safety run-in part of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following days, q d 22 x until disease progression or contraindications against further application.
47970850|NCT01927224|DRUG|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
47970851|NCT01927224|DRUG|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
47970852|NCT01927224|DRUG|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
47970853|NCT05458843|PROCEDURE|Fluid replacement|Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.
47970854|NCT05458843|PROCEDURE|No fluid replacement|Participants will not be permitted to drink.
47970855|NCT04968301|DEVICE|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
48119432|NCT04974450|DIETARY_SUPPLEMENT|Trigona honey|composition : vitamin C 0.15%, Protein 1.32%, lipid 0.23%, carbohydrate 64.12%, beta carotene 10.61 ppm, Calcium 273,23, magnesium 338.94, zinc 12.49 ppm, and acidity 5.76. Total polyphenol 133.52 ppm, total flavonoid 159.62 ppm. This liquid has a sour profile
48119433|NCT04974450|DIETARY_SUPPLEMENT|control|Artificial honey with fructose, Glucose, pure honey (2,271%), citric acid, and lime extract (0,076%).
48119434|NCT00854191|DEVICE|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
48324508|NCT05048706|DEVICE|Laser lithotripsy (SP TLF)|Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)
48324509|NCT05048706|DEVICE|Laser lithotripsy (Ho:YAG)|Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
48324510|NCT04684914|BIOLOGICAL|HepTcell|Intramuscular injection
48488916|NCT03679052|DRUG|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
48488917|NCT00969319|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
48648713|NCT03796286|OTHER|Medium-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
48648714|NCT03796286|OTHER|High-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
48488918|NCT05884242|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
48648715|NCT03796286|OTHER|Control bar (0 g fiber)|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
47970856|NCT05292443|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
47970857|NCT06204146|BEHAVIORAL|massage|stressn level and preterm growth
47970858|NCT00681083|DEVICE|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
47970859|NCT00681083|DEVICE|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
47970860|NCT05280782|DRUG|Ga-68 Galmydar|Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
47970861|NCT02161081|PROCEDURE|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
47970862|NCT06499597|OTHER|Observation|All individuals included in the study will be included in this group and evaluations will be made.
47970863|NCT06011057|DIAGNOSTIC_TEST|Serum C reactive protein (CRP) level|An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.
48119435|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
47970864|NCT06011057|DIAGNOSTIC_TEST|Ultrasound|All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
47970865|NCT04077827|DRUG|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
47970866|NCT06083272|DEVICE|Vitalthings Guardian M10 fixed and M10 mobile|VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
47970867|NCT02091934|PROCEDURE|Wavefront-guided PRK|Wavefront-guided PRK
47970868|NCT02091934|PROCEDURE|Wavefront-optimized PRK|Wavefront-optimized PRK
47970869|NCT06172322|DRUG|NTQ1062 with Fulvestrant|"Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle."
48119436|NCT00807937|DRUG|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
48119437|NCT00807937|DRUG|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
48119438|NCT00807937|DRUG|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
47970870|NCT03066804|DRUG|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
47970871|NCT03066804|DRUG|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
47970872|NCT03066804|DRUG|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
47970873|NCT03066804|DRUG|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
48119439|NCT03051165|DEVICE|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
48119440|NCT06327386|DIAGNOSTIC_TEST|18F-FAPI#18F-FDG|FAPI and FDG combined with PET/MR imaging in patients with gastric cancer after neoadjuvant therapy
48324511|NCT04684914|DRUG|Placebo|Intramuscular injection
48324512|NCT02303873|DRUG|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).
48324513|NCT00280150|BIOLOGICAL|bevacizumab|Given IV
48324514|NCT00280150|DRUG|carboplatin|Given IV
48324515|NCT00280150|DRUG|erlotinib hydrochloride|Given orally
48324516|NCT00280150|DRUG|paclitaxel|Given IV
48648716|NCT05810649|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.
48648717|NCT06223880|DRUG|AXS-05|"Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period"
48648718|NCT06223880|DRUG|Bupropion|Up to 26 weeks in double-blind period
48648719|NCT00406731|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
48648720|NCT00406731|DRUG|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
48324517|NCT00280150|RADIATION|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
48324518|NCT00859989|BEHAVIORAL|behavioral dietary intervention|
48648721|NCT00406731|DRUG|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
47970874|NCT03066804|DRUG|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
47970875|NCT03066804|DRUG|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
47970876|NCT03176498|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
47970877|NCT03176498|DRUG|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
47970878|NCT03958851|DIAGNOSTIC_TEST|Doppler ultrasonography of renal arteries|"Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken."
48119441|NCT04266912|DRUG|Avelumab|Given IV
48119442|NCT04266912|DRUG|Berzosertib|Given IV
48119443|NCT02769858|DEVICE|Light therapy|Light therapy glasses
48119444|NCT03175861|OTHER|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
48119445|NCT06143371|BIOLOGICAL|CAN10|Single dose intravenous or Multiple doses subcutaneously
48119446|NCT06143371|BIOLOGICAL|CAN10 - Placebo|Single dose intravenous or Multiple doses subcutaneously
48488919|NCT05884242|DRUG|Lipopolysaccharide (LPS)|LPS will be administered intravenously.
48488920|NCT02033330|DIETARY_SUPPLEMENT|phenolics form orange peel|
48648722|NCT00406731|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
48119447|NCT01403168|OTHER|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
48119448|NCT01403168|OTHER|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
48119449|NCT04058626|DIAGNOSTIC_TEST|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
48324519|NCT00859989|BEHAVIORAL|exercise intervention|
48324520|NCT00859989|BEHAVIORAL|telephone-based intervention|
48324521|NCT00859989|OTHER|counseling intervention|
48324522|NCT00859989|OTHER|educational intervention|
48324523|NCT00859989|OTHER|immunoenzyme technique|
48324524|NCT00859989|OTHER|laboratory biomarker analysis|
48324525|NCT00859989|OTHER|questionnaire administration|
48324526|NCT00859989|OTHER|study of socioeconomic and demographic variables|
48324527|NCT00859989|PROCEDURE|evaluation of cancer risk factors|
48324528|NCT00859989|PROCEDURE|support group therapy|
48324529|NCT06072859|OTHER|Humidified Forest Oils|60mls Limonene in 200mls water humidified with a diffuser.
48648723|NCT00406731|DEVICE|Goldmann applanation tonometer|Intraocular pressure measurements
48648724|NCT00406731|DEVICE|HP-CMS patient monitor|blood pressure and pulse rate measurements
48648725|NCT00406731|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
48324530|NCT06072859|OTHER|Virtual Reality using Surface Pro and headphones|Surface Pro has a looped visual that can be manipulated by the participant to simulate walking on a forest path or through a forest visual. This is paired with headphones to experience ambient forest sounds.
48324531|NCT03870256|DRUG|misoprostol|Patient receive 600mic gm sublingual misoprostol
48324532|NCT03870256|DRUG|Carbetocin|Patient receive 100 mic gm carbetocin IV
48648726|NCT03292029|DIAGNOSTIC_TEST|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
48648727|NCT04078516|DIAGNOSTIC_TEST|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
48648728|NCT04078516|DIAGNOSTIC_TEST|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
48648729|NCT04078516|DIAGNOSTIC_TEST|Heart rate variability|4 measurements of heart rate.
48648730|NCT04078516|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
48648731|NCT04078516|DIAGNOSTIC_TEST|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
48648732|NCT04078516|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
48648733|NCT04078516|DIAGNOSTIC_TEST|Questionnaires|Questionnaires for detecting painful neuropathy
48648734|NCT04078516|DIAGNOSTIC_TEST|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
47970879|NCT03958851|DIAGNOSTIC_TEST|Renal biopsy|Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
48648735|NCT04105257|DIAGNOSTIC_TEST|All patients|Comparison of the results of the CTP with MRI
48648736|NCT06498791|OTHER|Venipuncture|Blood drawing
48648737|NCT06498791|OTHER|Questionnaire|Completion of the questionnaire
48648738|NCT05181085|DRUG|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
47970880|NCT03958851|DIAGNOSTIC_TEST|kidney function tests|blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
48119450|NCT04058626|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
48648739|NCT05181085|DRUG|Placebo|inactive analogue
48648740|NCT06570837|DIETARY_SUPPLEMENT|Iron|observation effect of iron dificincy
48648741|NCT01933516|DRUG|GP2013|GP2013
48648742|NCT02290574|RADIATION|Hyperthermia with concurrent chemo-radiation therapy|
48648743|NCT00993473|DRUG|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~* Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~* Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~* Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~* HbA1c \<7.5%."
48648744|NCT00993473|DRUG|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
48648745|NCT00993473|DRUG|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
48648746|NCT00223379|PROCEDURE|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
48648747|NCT05498220|DRUG|Polatuzumab vedotin (PV)|1.8 mg/kg, intravenous, at day 1, in every 21 days
48648748|NCT05498220|DRUG|Rituximab|375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
48648749|NCT05498220|DRUG|Hyaluronidase|1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
48648750|NCT05498220|DRUG|Gemcitabine|1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
48119451|NCT04058626|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
48324533|NCT03870256|DRUG|TA|The patient receives 1gm oral tranexamic acid
48324534|NCT06089668|OTHER|Observational Study|None, this is a non-interventional trial
48324535|NCT00208494|DEVICE|Total Hip Replacement|Total hip replacement
48648751|NCT05498220|DRUG|Cisplatin|75 mg/m2, intravenous, at day 1, in every 21 days
48648752|NCT05498220|DRUG|Dexamethasone|40 mg intravenous at day 1, Per oral days at days 2-4
48324536|NCT00208494|DEVICE|Total hip replacement|Total hip replacement
48324537|NCT03558191|DRUG|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
48324538|NCT00144755|DRUG|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
48324539|NCT02646267|DRUG|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
48324540|NCT02646267|DRUG|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
48324541|NCT02646267|DRUG|dabigatran etexilate|110mg, twice a day, oral
48324542|NCT00737685|DRUG|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
48324543|NCT04991883|OTHER|case series review of clinical and histological data|We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.
48324544|NCT03136770|DIETARY_SUPPLEMENT|CK-30|Compound K 600 mg
48324545|NCT03136770|DIETARY_SUPPLEMENT|Red ginseng extracts|Red ginseng extracts 2.94 g
48324546|NCT01889628|DIETARY_SUPPLEMENT|Liquid-based Nutritional Formulae and liquid glucose|
48324547|NCT01609179|DRUG|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
48324548|NCT03329417|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
48324549|NCT00937794|BEHAVIORAL|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
48324550|NCT00937794|OTHER|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
48324551|NCT04406935|DEVICE|treatment with the study device (NuEra)|"Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz"
48324552|NCT04314479|BEHAVIORAL|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
48324553|NCT03345433|BEHAVIORAL|interactive group drumming sessions|interactive group drumming sessions
48324554|NCT03711006|OTHER|Fecal Microbiota Transplantation Capsules|25 daily multi-donor FMT Capsules for 50 days
48324555|NCT01681576|DRUG|Valsartan|Valsartan 320mg tablet once daily
48324556|NCT01681576|DRUG|LCZ696|LCZ696 400mg tablet once daily
48324557|NCT02769351|DEVICE|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
48648753|NCT05498220|DRUG|GCSF|granulocyte-colony stimulating factor (GCSF )
48648754|NCT05254860|PROCEDURE|LPS Ventral Rectopexy|Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
48648755|NCT06194799|DRUG|ACP-204|ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
48648756|NCT02257021|DRUG|BILR 355 BS|
48324558|NCT02396342|GENETIC|AAV5-hFIX|AAV5hFIX gene therapy
48324559|NCT01923233|BIOLOGICAL|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
48324560|NCT02160886|BEHAVIORAL|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
48648757|NCT02257021|DRUG|Tipranavir|
48648758|NCT02257021|DRUG|Low dose of ritonavir|
48648759|NCT02257021|DRUG|High dose of ritonavir|
48119452|NCT04058626|DIAGNOSTIC_TEST|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
48119453|NCT04058626|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
47970881|NCT03958851|DIAGNOSTIC_TEST|The 24-hour urine protein test|The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
47970882|NCT03958851|DIAGNOSTIC_TEST|complete blood counting (CBC)|A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
47970883|NCT02531906|DRUG|Gabapentin|Given PO
48324561|NCT02160886|BEHAVIORAL|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
48324562|NCT02429258|DRUG|Farxiga|Farxiga 10mg/day
48324563|NCT02429258|DRUG|Placebo|Placebo
48324564|NCT02429258|DRUG|Metformin|Metformin background therapy \>/= 1500mg/day
48324565|NCT02429258|DRUG|Insulin|Insulin \>/= 30 units
48324566|NCT00151749|DRUG|Colesevelam hydrochloride|
48324567|NCT00369395|DRUG|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
48488921|NCT06357663|OTHER|Mindfulness practice with Calligraphy|The unique style of Art Meditation where mindfulness (heightened awareness) is achieved by combination of movement and focus on Chinese Tao Calligraphy while chanting a mantra. The practitioners repeatedly trace the lines of Tao calligraphy with fingers and chant the mantra. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age.
47970884|NCT02531906|DRUG|Methadone Hydrochloride|Given PO
47970885|NCT02531906|DRUG|Oxycodone Hydrochloride|Given PO
47970886|NCT02531906|OTHER|Quality-of-Life Assessment|Ancillary studies
47970887|NCT02531906|OTHER|Questionnaire Administration|Ancillary studies
47970888|NCT00877253|DRUG|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
47970889|NCT00877253|DRUG|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
47970890|NCT00877253|DRUG|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
47970891|NCT04391647|OTHER|First-void urine collection|"* One time collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.~* IF HPV positive and the woman gave consent to be contacted again: Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) each day during 14 days (n = 14)"
47970892|NCT04391647|OTHER|Blood draw|- One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
47970893|NCT00596375|PROCEDURE|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
47970894|NCT00596375|DRUG|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
47970895|NCT01932112|DRUG|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
48324568|NCT01555905|DEVICE|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
48324569|NCT02210104|DRUG|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
48488922|NCT02881060|DIETARY_SUPPLEMENT|Alcohol|
47970896|NCT01808989|OTHER|Exercise oxymetry|
48119454|NCT04771780|DRUG|KHK7791|oral administration
48324570|NCT02210104|DRUG|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
48324571|NCT02210104|BIOLOGICAL|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.
48324572|NCT05010993|DIAGNOSTIC_TEST|Nine Hole Peg Test|Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)
48324573|NCT05010993|DIAGNOSTIC_TEST|Purdue Pegboard Test|Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)
48324574|NCT05010993|DIAGNOSTIC_TEST|Box and Block Test|Each person will be tested by the Box and Block Test (3 attempts per subtest)
48488923|NCT02881060|DIETARY_SUPPLEMENT|Placebo|
48488924|NCT02343757|DEVICE|PET/MRI|
48488925|NCT04315870|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
48648760|NCT02098603|BEHAVIORAL|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
48648761|NCT04884074|PROCEDURE|Standard Sleeve Gastrectomy plus Anterior Crural Repair|The procedure is performed in a similar fashion as standard sleeve gastrectomy. After gastric mobilization is completed as standard sleeve gastrectomy, the anterior phrenoesophageal ligament is divided and distal 3cm esophagus is mobilized. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist and the hiatus opening is closed with 2/0 non-absorbable suture over the bougie anterior to the esophagus. The hiatus repair was sized by comfortably placement a dissection forceps adjacent to the esophagus without tension. Sleeve gastrectomy is then performed as the standard technique.
48648762|NCT04884074|PROCEDURE|Standard sleeve gastrectomy (SSG, the control group)|"The procedure is performed in French position with a standard 5-port approach and a pneumoperitoneum not exceeding 15mmHg.~The greater omentum is then completely detached from the greater curvature of stomach using either ultrasonic or bipolar shear device. All adhesion between posterior gastric wall and pancreatic capsule is freed and the cardia is completely free with left crura completely exposed. A Mid-Sleeve tube (40Fr) is inserted per-orally by the anesthetist with its balloon tip reaching the gastric antrum and insufflated with 50cc of air. Sleeve gastrectomy is then performed using laparoscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up cardia at about 1cm lateral to the angle of His, along the Mid-sleeve tube which is lying against the lesser curve of stomach. The staple line is reinforced with absorbable sutures. Distal stomach is anchored at retroperitoneum with non-absorbable stitch."
48648763|NCT05704634|DRUG|Cemiplimab|Given by Injection under the skin every 2 weeks
48648764|NCT05704634|DRUG|Kevzara (Sarilumab)|Given by IV (vein) over about 30 minutes every 3 weeks.
48648765|NCT03073070|DRUG|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
48648766|NCT04843839|DRUG|Nepafenac 0.1% Oph Susp|Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
48324575|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
47970897|NCT02716571|OTHER|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
47970898|NCT01354977|DRUG|Resveratrol|1,000mg twice daily for 28 days
48324576|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
48324577|NCT05751486|BIOLOGICAL|Toripalimab /JS001|JS001 IV (if applicable) .
48488926|NCT00324311|DRUG|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
48488927|NCT02882685|PROCEDURE|Roux-en-y gastric bypass|
48648767|NCT04843839|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
48648768|NCT00434941|DRUG|Capecitabine|
48648769|NCT00434941|RADIATION|Radiotherapy|
48324578|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
48324579|NCT06163560|DEVICE|"Smartphone app Happy Baby HK"|"Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers."
48488928|NCT02882685|PROCEDURE|Single anastomosis gastric bypass|
48488929|NCT02733081|PROCEDURE|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
48488930|NCT02632513|DEVICE|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
48488931|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
48488932|NCT04714229|BIOLOGICAL|Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine|0.5mL single intramuscular dose on Day 0
48488933|NCT01592136|DRUG|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
48498057|NCT01470911|DRUG|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
48324580|NCT06163560|DEVICE|Family Health Service parenting booklet|The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
48324581|NCT02326467|DRUG|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
48324582|NCT03589820|OTHER|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
48324583|NCT03658993|DRUG|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
48324584|NCT00055536|DRUG|natalizumab|
48488934|NCT05195866|DIAGNOSTIC_TEST|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
48488935|NCT05240131|DRUG|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
48488936|NCT05240131|DRUG|Placebo|Placebo is administered orally twice a day.
47970899|NCT01182987|BEHAVIORAL|Dementia Care Management|"The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution."
47970900|NCT04481932|DRUG|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
47970901|NCT03922503|PROCEDURE|Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
48324585|NCT04824417|DRUG|Itraconazole 200 mg|Control
48488937|NCT05240131|DRUG|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
48324586|NCT04824417|DRUG|Voriconazole 200mg|Comparator
48324587|NCT02405585|DRUG|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
48324588|NCT02405585|BIOLOGICAL|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
48324589|NCT02405585|RADIATION|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
48324590|NCT02405585|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection."
48324591|NCT01091909|PROCEDURE|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
48498058|NCT06160505|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
48648770|NCT02767973|OTHER|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
48648771|NCT06570265|DEVICE|GBR membrane|GBR procedure is a technique often used in conjunction with dental implants to enhance the success and stability of the implant. This technique involves using barrier membranes to protect the bone graft or defect site from the rapid proliferation of surrounding soft tissues. In this clinical investigation resorbable, collagen membrane will be used.
48648772|NCT04989517|DRUG|AT193|Topical
48648773|NCT05773352|DEVICE|Tornier Perform® Humeral System - Fracture|"A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains."
48648774|NCT04670315|DIAGNOSTIC_TEST|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
48648775|NCT00364195|DRUG|Tesmilifene (YMB1002)|
48648776|NCT00827307|DRUG|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
48648777|NCT00827307|DRUG|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
48648778|NCT02262663|DRUG|Vilaprisan (BAY1002670)|
48648779|NCT03788044|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
48648780|NCT02094885|BIOLOGICAL|Bioseal Fibrin Sealant|
48488938|NCT03627741|DRUG|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
48488939|NCT00017537|BIOLOGICAL|MVF-HER-2(628-647)-CRL 1005 vaccine|
48488940|NCT03245957|OTHER|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
48488941|NCT03245957|OTHER|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
48648781|NCT02094885|OTHER|Manual Compression|
48648782|NCT04799717|BEHAVIORAL|Gaming session|Participants will be provided the option to play an online game with the clinician for the first half of the session through an online platform.
48648783|NCT06395220|OTHER|Detection of donor-specific anti-HLA antibody (DSA)|"Detection methods~1. . Morphology: using microscope to observe the morphology of bone marrow.~2. . Immunophenotyping: using multi-color flow cytometry (MFC) to detect immunophenotype of leukemia cells and leukemia-associated immunophenotype of bone marrow samples.~3. . Cytogenetics analysis: G-band and/or fluorescence in situ hybridization (FISH) analysis are used in this study~4. . Molecular detection: Real-time quantitative RT-PCR (RQ-PCR) and/or next generation sequencing techniques are used to detect the molecular marker, such as: PML/RARA, AML-ETO, BCR/ABL, and WT1.~5. . HLA-Typing: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined according to the literatures published by our group \[Huo MR, et al. Bone Marrow Transplant. 2018;53(5):600-608\]..~6. . Other analyses: Detection of minimal residual diseases were performed using MFC and RQ-PCR according to the methods reported by our group \[Li SQ, et al. Blood,2022;140(5):516-520\]."
48648784|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
48648785|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
48648786|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
48648787|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
48648788|NCT00188435|PROCEDURE|Minimum Dose CT|
48648789|NCT06380907|DRUG|ZL-1102 1% w/w gel BID for 16 weeks|"ZL-1102~1% w/w gel BID for 16 weeks"
48648790|NCT06380907|DRUG|ZL-1102 3% w/w gel BID for 16 weeks|ZL-1102 3% w/w gel BID for 16 weeks
48648791|NCT06380907|DRUG|ZL-1102 3% w/w gel QD for 16 weeks|ZL-1102 3% w/w gel QD for 16 weeks
48648792|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel BID for 16 weeks|Vehicle 0% w/w gel BID for 16 weeks
48648793|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel QD for 16 weeks|Vehicle 0% w/w gel QD for 16 weeks
48648794|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
48648795|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|Placebo shockwave therapy directed at subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
48648796|NCT00771147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
48648797|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 0.5 mg/kg Q2W
48648798|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 2 mg/kg Q2W
48648799|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 5 mg/kg Q2W
48648800|NCT04450901|DRUG|YBL-006|Route of Administration: IV infusion; 10 mg/kg Q2W
48648801|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200 mg Q2W
48648802|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q3W
48648803|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 300 mg Q2W
48648804|NCT04450901|DRUG|YBL-006|Route of administration : IV infusion, 200mg Q2W
48648805|NCT04131894|BIOLOGICAL|autogenous dentin graft|
48648806|NCT04131894|BIOLOGICAL|platelet rich fibrin (PRF)|
48324592|NCT02521688|PROCEDURE|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
48324593|NCT05511519|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
48324594|NCT05511519|DRUG|Placebo Oral Tablet|Placebo tablet manufactured to match ATI-450 in appearance
48324595|NCT06481657|OTHER|train with oxygen and without oxygen enrichment (placebo).|The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).
48324596|NCT05365386|DEVICE|Tixel C|This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.
48324597|NCT05602012|BEHAVIORAL|Mindfulness based cognitive counseling group|Intervention: The sessions were conducted by the researchers who received training in the field of Mindfulness Based Cognitive Therapy. Sessions are structured as follows; 'Awareness and autopilot, living in our minds, tidying up the dispersed mind, recognizing the unpleasant/version, allowing, ways to take care of oneself, turning to face difficulties, being stuck in the past, living in the present?'
48324598|NCT04485117|DEVICE|Bispectral Index Monitor|Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.
48324599|NCT04485117|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
48324600|NCT04485117|DRUG|Sevoflurane|Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.
48324601|NCT04485117|DRUG|Propofol|Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
48324602|NCT05496322|DEVICE|Continuous Non Invasive Blood Pressure Monitoring|Continuous non-invasive arterial pressure monitoring
48324603|NCT05496322|DEVICE|Intermittent Non Invasive Blood Pressure Monitoring|Intermittent non-invasive arterial pressure monitoring
48324604|NCT01025258|BEHAVIORAL|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
48648807|NCT01641666|DRUG|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
48648808|NCT01641666|DRUG|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
48648809|NCT01641666|DRUG|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
48648810|NCT03389100|DRUG|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
48648811|NCT04925089|OTHER|Blood and Tissue collection|Blood and tissue will be collected and analyzed for detection of ctDNA and genetic change
48648812|NCT00930800|OTHER|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
48648813|NCT05889741|DRUG|Ropivacaine injection|6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
48648814|NCT05889741|DRUG|Normal saline|6.5cc of Normal Saline one time into the stellate ganglion.
48648815|NCT04462419|RADIATION|Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|Undergo PET-MRI imaging
48648816|NCT04462419|OTHER|Fluciclovine F18|Given IV
48648817|NCT01837953|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
48119455|NCT06219642|BEHAVIORAL|Mindfulness using virtual reality|"In each session, participants will be led through the following mindfulness script while using the VR device here is an abbreviated version with excerpts:~Look around. Try to bring yourself to the moment you are in. Notice the presence of the scene around you. How does the air feel against your skin? How do your feet feel against the ground? Where are you? What do you see? Do you hear anything? What do you smell? What do you taste? While you stay seated, imagine you are walking. What body sensations are you experiencing? What thoughts are you having? What emotions are you feeling? At the end of the intervention, participants are asked questions like, What did you notice about your thoughts and mood before, during, and after the VR session? Did you notice a change in how your body felt or your emotions? Was there anything difficult or uncomfortable about the experience that you feel comfortable sharing?"
48119456|NCT06131892|OTHER|Defibrillation|Defibrillation
48119457|NCT02178423|PROCEDURE|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
48324605|NCT01025258|BEHAVIORAL|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
48324606|NCT05923450|PROCEDURE|Colorectal Resection|Radical resection of colorectal cancer
48488942|NCT02823860|OTHER|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
48119458|NCT02326987|DRUG|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
48324607|NCT02325947|DEVICE|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
48324608|NCT02325947|DEVICE|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
48488943|NCT03480438|DRUG|Blinatumomab|Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
48488944|NCT06390202|OTHER|no intervention|there is no intervention in this study
48488945|NCT02268266|DEVICE|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
48488946|NCT04754126|BEHAVIORAL|Amazing Me|The Amazing Me Program is an evidence-based program designed to help children between the ages of 9 and 11 build self-esteem, body confidence, and eliminate weight-based bullying and teasing. This school-based curriculum satisfies national educational health requirements and provides tools for teachers to implement in 4th and 5th grade classrooms.
48119459|NCT02326987|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
48119460|NCT03632811|OTHER|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
48648818|NCT01837953|BEHAVIORAL|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
48648819|NCT05474716|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
48648820|NCT06236139|BIOLOGICAL|Anti-STEAP1 CAR T-cells|Given IV
48648821|NCT06236139|PROCEDURE|Biopsy|Undergo tumor biopsy
48648822|NCT06236139|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48648823|NCT06236139|PROCEDURE|Bone Scan|Undergo NM bone scan
48648824|NCT06236139|PROCEDURE|Computed Tomography|Undergo CT scan
48648825|NCT06236139|DRUG|Cyclophosphamide|Given IV
47970902|NCT03922503|PROCEDURE|Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
47970903|NCT05421624|DEVICE|Digital music therapeutic|The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
48324609|NCT05424549|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
48488947|NCT00563680|DRUG|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
48648826|NCT06236139|PROCEDURE|Echocardiography|Undergo ECHO
48648827|NCT06236139|DRUG|Enzalutamide|Given PO
48648828|NCT06236139|DRUG|Fludarabine|Given IV
48648829|NCT06236139|PROCEDURE|Leukapheresis|Undergo leukapheresis
48648830|NCT06236139|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48648831|NCT06236139|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48648832|NCT06236139|PROCEDURE|Positron Emission Tomography|Undergo PET scan
47970904|NCT05421624|BEHAVIORAL|Active-Control|The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
47970905|NCT01654536|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
48324610|NCT05424549|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed six times over two consecutive days
48324611|NCT01288508|DIETARY_SUPPLEMENT|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
48648833|NCT00266032|DRUG|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
48648834|NCT00266032|DRUG|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
48648835|NCT00266032|DRUG|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
47970906|NCT01654536|DRUG|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
47970907|NCT01831050|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
47970908|NCT01831050|BIOLOGICAL|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
48324612|NCT01288508|DIETARY_SUPPLEMENT|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
48648836|NCT01309100|DEVICE|Investigational Lens|Bausch \& Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
48648837|NCT01309100|DEVICE|Acuvue Oasys Lens|Johnson \& Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
47970909|NCT01831050|BIOLOGICAL|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
47970910|NCT01831050|BIOLOGICAL|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
47970911|NCT01831050|BIOLOGICAL|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
47970912|NCT01831050|BIOLOGICAL|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India \[SII\]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
48324613|NCT05956587|DRUG|BL-B01D1|Administration by intravenous infusion
48324614|NCT05956587|DRUG|SI-B003|Administration by intravenous infusion
48324615|NCT03948126|OTHER|Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)|
48324616|NCT03201887|BEHAVIORAL|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
48324617|NCT03201887|BEHAVIORAL|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
48324618|NCT01151540|DRUG|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
48648838|NCT01309100|DEVICE|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
48648839|NCT00842465|BIOLOGICAL|blood collection for hormonal status analysis|for hormonal status analysis
48648840|NCT00842465|PROCEDURE|breast Biopsy or surgery|breast Biopsy or surgery
48648841|NCT00842465|GENETIC|blood collection|blood collection for prlR gene sequencing
48648842|NCT00842465|OTHER|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
47970913|NCT04803370|OTHER|Convalescent Plasma with antibody against SARS-CoV-2.|"Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient."
47970914|NCT04803370|OTHER|Standard treatment for COVID-19|The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-Interleukin-6 monoclonal antibody, oxygen therapy, etc..)
48119461|NCT03482804|OTHER|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
48119462|NCT03010813|PROCEDURE|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
48119463|NCT03611972|DIETARY_SUPPLEMENT|Sugar-sweetened beverage|Sugar-sweetened koolaid-flavored water.
48648843|NCT02489045|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
48119464|NCT06515301|BEHAVIORAL|Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.|Information already available
47970915|NCT06464068|DRUG|Durvalumab|"All drugs will be administered intravenously. Induction treatment will be administered on a 21-day cycle for four cycles and will consist of:~* etoposide 80-100 mg/m² (administered on days 1-3 of each 21-day cycle);~* investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m² (administered on day 1 of each cycle);~* durvalumab 1500 mg every 3 weeks in combination with chemotherapy (induction phase) followed by maintenance phase with durvalumab 1500 mg every 4 weeks. Patients will continue treatment until disease progression per investigator assessment, unacceptable toxicity, or other discontinuation criteria were met for a maximum of 24 months. Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months."
48648844|NCT04560530|RADIATION|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
48119465|NCT02613546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~1. evaluation session;~2. sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
48648845|NCT04437823|BIOLOGICAL|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
48119466|NCT02613546|BEHAVIORAL|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
47970916|NCT00963937|DRUG|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
47970917|NCT00963937|DRUG|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
47970918|NCT00963937|DRUG|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
48119467|NCT00818454|DRUG|Combivent CFC MDI|
48119468|NCT00818454|DRUG|Albuterol HFA MDI|
48119469|NCT00818454|DRUG|Respimat Combivent|
48119470|NCT04484935|DRUG|Nirsevimab|Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
48119471|NCT02781623|PROCEDURE|MRI|
48119472|NCT05951309|DRUG|inofolic combi|The patients in this group were given inofolic combi once a day for 12-16 weeks
48119473|NCT05951309|DRUG|Glucophage 500Mg Tablet|The patients in this group were given glucophage three times a day for 12-16 weeks
47970919|NCT02468232|DRUG|LCZ696|The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
47970920|NCT02468232|DRUG|Enalapril|The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
47970921|NCT02468232|DRUG|Placebo to LCZ696|LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
47970922|NCT02468232|DRUG|Placebo to Enalapril|Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
48119474|NCT02313363|DEVICE|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
48119475|NCT01837875|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
48119476|NCT01837875|BEHAVIORAL|Mail-delivered arthritis kit|"The Arthritis Self-Management Tool Kit contains 1) a Self Test to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets."
48648846|NCT06658236|OTHER|Proprioceptive Neuromuscular Facilitation|Group A will follow a PNF-based training protocol to enhance strength, flexibility, and coordination. The exercises include two main movement patterns: flexion-abduction-external rotation with the elbow extended and extension-adduction-internal rotation with the elbow extended. These patterns target the muscles around the shoulder and upper chest. A yellow Thera-Band adds light resistance, increasing muscle engagement. The protocol also employs the reversal of antagonists technique, alternating between opposing muscle groups for balanced development and improved coordination. Participants will complete three sets of ten repetitions per session, with a 60-second rest between sets. The program spans 12 weeks, with three weekly sessions, allowing for consistent progress and muscle recovery. This structured approach aims to improve functional mobility and the performance of activities involving similar movements, offering a comprehensive training strategy through PNF and resistance.
47970923|NCT01635946|DRUG|Isavuconazole|oral
47970924|NCT01635946|DRUG|atorvastatin|oral
48324619|NCT03886025|OTHER|Anodal transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
47970925|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
47970926|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
47970927|NCT00381485|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
47970928|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
47970929|NCT01878838|PROCEDURE|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
47970930|NCT04440202|BEHAVIORAL|Conventional sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
47970931|NCT04440202|BEHAVIORAL|Enriched sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
47970932|NCT03328312|DRUG|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR \>0.9
48324620|NCT03886025|BEHAVIORAL|Cognitive training|Iowa Gambling Task will be used for cognitive training
48498059|NCT00128830|DRUG|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
48498060|NCT00128830|DRUG|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
47970933|NCT03328312|DRUG|neostigmine+atropine|Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation
47970934|NCT03328312|DRUG|neostigmine+atropine+sugammadex|4. Time of extubation
47970935|NCT05174260|DEVICE|perfusion index, pleth variable index|a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
48324621|NCT03886025|OTHER|Sham transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
48324622|NCT00067470|DRUG|Placebo|
48324623|NCT00067470|DRUG|N-acetylgalactosamine 4-sulfatase|
48324624|NCT03810001|BEHAVIORAL|Mechanical Stimulation|micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
48324625|NCT04218799|DRUG|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
48119477|NCT01837875|BEHAVIORAL|Support group|"Interested participants will be referred to the Lupus: Listening and Learning Group, a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved."
48119478|NCT01837875|BEHAVIORAL|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
48119479|NCT00479635|DRUG|TPI 287|160 mg/m2 every three weeks for six cycles
47970936|NCT03547180|BEHAVIORAL|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
47970937|NCT03547180|BEHAVIORAL|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
47970938|NCT03547180|BEHAVIORAL|In-vivo exposure|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
47970939|NCT05641324|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
47970940|NCT05641324|DRUG|Lenalidomide with low-dose dexamethasone|Lenalidomide and dexamethasone administered orally
47970941|NCT05641324|DRUG|Daratumumab|Daratumumab administered by subcutaneous injection
47970942|NCT05142943|OTHER|Visual illusion|the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes.
47970943|NCT05142943|OTHER|Physical exercise|"* General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~* Gross mobility and coordination: ball games.~* Fine mobility and coordination: writing tasks, puzzles, abacus ...~* Strength exercises: shoulder, elbow, wrist, fingers.~* Stretching."
47970944|NCT05142943|OTHER|Sham Visual illusion|only the placebo visual illusion
47970945|NCT00732017|DEVICE|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
47970946|NCT00732017|DEVICE|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
47970947|NCT00732017|OTHER|standard physical therapy treatment|"* Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~* Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~* Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
47970948|NCT00946699|BIOLOGICAL|MEDI-551|0.1 mg/kg
47970949|NCT00946699|BIOLOGICAL|Placebo|0.3 mg/kg
47970950|NCT00946699|BIOLOGICAL|MEDI-551|1.0 mg/kg
47970951|NCT00946699|BIOLOGICAL|MEDI-551|3.0 mg/kg
47970952|NCT00946699|BIOLOGICAL|MEDI-551|10.0 mg/kg
47970953|NCT00946699|OTHER|Placebo|Placebo
47970954|NCT02512588|DRUG|BTD-001|
48119480|NCT00479635|DRUG|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
48119481|NCT01875250|BIOLOGICAL|PROSTVAC-F (Fowlpox)/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
48119482|NCT01875250|BIOLOGICAL|PROSTVAC-V (Vaccinia)/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
47970955|NCT02512588|DRUG|Placebo|
47970956|NCT05685966|OTHER|no intervention|no intervention
47970957|NCT05704361|DRUG|RO7121932 IV - SAD|Part 1: Participants will receive a single dose of RO7121932 administered as IV infusion.
48119483|NCT01875250|DRUG|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
48119484|NCT03068078|DIETARY_SUPPLEMENT|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
48119485|NCT00903539|DEVICE|SecurAcath Securement System|Subcutaneous catheter securement system
48119486|NCT00226538|DRUG|Phenytoin|
48119487|NCT00226538|DRUG|Rifampicin|
48119488|NCT00226538|DRUG|Diclophenac|
48119489|NCT00226538|DRUG|Fluconazole|
48648847|NCT06658236|OTHER|Chest Expansion Exercises|Group B participants followed a breathing-coordinated exercise protocol using a yellow Thera-Band to improve upper extremity function. The protocol began with subjects breathing generally at rest. They were then instructed to synchronize their movements with their breathing: performing upper extremity flexion, abduction, and external rotation during inhalation, followed by extension, adduction, and internal rotation during exhalation. This coordination between breathing and movement aimed to enhance muscle activation and control. Each session included three trials of ten repetitions for each exercise, with a 1-minute rest between trials. The protocol was conducted three times per week over 12 weeks. This approach was designed to promote strength, flexibility, and coordination in the upper body while integrating breath control, which may also support relaxation and better movement efficiency. The structured schedule ensures consistent practice and gradual improvement over the 12 weeks
48119490|NCT03796936|BEHAVIORAL|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
48119491|NCT06460688|OTHER|Mother Rehabilitative Aid Education Program|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.
48119492|NCT06460688|OTHER|Neuro physical Therapy|Routine neuro physical therapy will be given which includes Stretching, truck control and independent transition, train standing and activation of base, gain walking with minimal assistance, Gain ground clearance with stair climbing. for 45 minutes, 5 days a week for 8 weeks. Participants in group B will not be educated about treatment plan. Routine home plan was given in this group once in a week, for 8 weeks.
48119493|NCT05781347|PROCEDURE|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under general anesthesia which uses radiofrequency (RF) energy delivered to the lower esophageal sphincter and cardia.
48119494|NCT05781347|DEVICE|Stretta|Stretta is a FDA approved device for the management of GERD.
48119495|NCT02703701|BEHAVIORAL|Physician at triage|A physician embedded at triage
48119496|NCT02703701|OTHER|Usual Care|No physician at triage
48119497|NCT03247023|DEVICE|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
48488948|NCT04390802|DRUG|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
48498061|NCT00128830|DRUG|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
48119498|NCT01673555|DRUG|GSK1278863|GSK1278863
48119499|NCT01673555|DRUG|Placebo|Placebo
48119500|NCT02840422|DEVICE|ARTHRUM H 2%|ARTHRUM H 2%
48324626|NCT00788697|DRUG|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
48324627|NCT00788697|OTHER|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
48324628|NCT02816372|OTHER|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
48324629|NCT04583111|DRUG|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
47970958|NCT05704361|DRUG|RO7121932 SC - SAD|Part 2: Participants will receive a single dose of RO7121932 administered as SC injection.
48648848|NCT04545892|DRUG|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
48648849|NCT06191744|DRUG|Epcoritamab|Subcutaneous (SC) Injection
48648850|NCT06191744|DRUG|Prednisone|Oral Tablet
48648851|NCT06191744|DRUG|Rituximab|Intravenous (IV) Infusion
48648852|NCT06191744|DRUG|Lenalidomide|Oral Capsule
48648853|NCT06191744|DRUG|Doxorubicin|IV Injection
48648854|NCT06191744|DRUG|Vincristine|IV Injection
48648855|NCT06191744|DRUG|Cyclophosphamide|IV Injection
48648856|NCT06191744|DRUG|Obinutuzumab|IV Infusion
48648857|NCT06191744|DRUG|Bendamustine|IV Infusion
48648858|NCT01546987|DRUG|GnRH agonist|LHRH agonists are administered with a variety of techniques. The manufacturer's instructions should be followed. Begins within 6 weeks after registration (if not started prior) at same time as anti-androgen and TAK-700 (if applicable).
48648859|NCT01546987|DRUG|Anti-androgen|Starts at same time as GnRH agonist, ends at end of radiation therapy. Either flutamide (orally 250 mg three times a day) or bicalutamide (orally 50 mg once a day).
48648860|NCT01546987|DRUG|TAK-700|300 mg twice daily (BID) (600 mg per day) orally, continuously for 2 years starting with ADT.
48324630|NCT04583111|DRUG|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
48324631|NCT01396239|DRUG|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
48498062|NCT00128830|DRUG|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
48648861|NCT01546987|RADIATION|Radiation therapy|Starts 8-10 weeks after initiation of ADT. Initially 45 Gy (1.8 Gy / fraction) to prostate and pelvic lymph nodes delivered with 3DCRT/IMRT, then a boost using intensity-modulated radiation therapy (IMRT), low dose rate (LDR) brachytherapy, or high dose rate (HDR) brachytherapy.
48648862|NCT06674954|PROCEDURE|Regional Anesthesia|"After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block, superficial cervical block, and supraclavicular brachial plexus block will be applied to these patients under ultrasound guidance. Total of 40 ml of local anesthetic solution (20 ml %0.5 bupivacaine + 10 ml %2 lidocaine + 10 ml physiological saline) will be prepared; 15 ml will be used for interscalene brachial plexus block, 10 ml will be used for superficial cervical block, and 15 ml will be used for supraclavicular brachial plexus block.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
48648863|NCT06674954|PROCEDURE|General Anesthesia|"Anesthesia induction will be performed with 2.5 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl. Maintenance will be achieved with sevoflurane (MAC: 0.9-1.0) and remifentanil (0.05-0.2 mcg/kg/min). Remifentanil titration will be done according to basal heart rate and blood pressure.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
48648864|NCT02217982|DRUG|Simethicone|
48648865|NCT02217982|DRUG|Loperamide|
48648866|NCT02217982|OTHER|Peanut Butter|
47970959|NCT05704361|DRUG|RO7121932 - MAD|Part 3: Participants will receive multiple doses of RO7121932 administered as SC injections.
47970960|NCT02139228|BIOLOGICAL|Hib-CRM197|No vaccine administered in V37_07E2 study
47970961|NCT02139228|BIOLOGICAL|Hib-TT|No vaccine administered in V37_07E2 study
47970962|NCT00709930|DEVICE|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
47970963|NCT00709930|DEVICE|Placebo magnetic field generator|Placebo device with no magnetic fields
48648867|NCT02018679|PROCEDURE|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
48648868|NCT02018679|PROCEDURE|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
48324632|NCT01396239|OTHER|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
48324633|NCT02527655|BEHAVIORAL|Choice-Based Physical Activity and Active Transportation|
48324634|NCT04356417|OTHER|- Synthetic anti-malarial drugs|Prevalent users will be those with at least one dispensing of AMD or ARBs/ACEi's from 01/01/2019 to 01/01/2020. Exposed users will be those among prevalent users who still received AMD or ARBs/ACEi's on 31/12/2019. The inclusion period will be from 01/01/2019 to 01/01/2020. The study end date will be 30/06/2020. For each treatment AMD or ARB/ACRi's, the persistence of treatment will be defined as the length of time from initiation to discontinuation. Initiation will be the date of the first reimbursement of AMD or ARB/ACRi's during the inclusion period. We will define the discontinuation of treatment as a period of more than 90 days without fulfilment of a prescription for the same treatment after the period covered by the previous prescription i.e 30 days. Exposure to a combination of drugs will be defined as a period shorter than 30 days between the prescription of two different systemic drugs and the fulfilment of another prescription for both drugs in the following 90 days.
48324635|NCT01241019|DRUG|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
48324636|NCT04075526|DRUG|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
48324637|NCT04075526|DRUG|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
48324638|NCT04075526|OTHER|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
48324639|NCT02645383|DEVICE|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
48488949|NCT03344978|OTHER|Cardboard Cot Care|Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
48498063|NCT03050710|DEVICE|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
48648869|NCT00226044|DRUG|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
47970964|NCT01288105|DEVICE|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom \>95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with \<95% stent strut coverage will receive perioperative bridging.
48119501|NCT04954196|DRUG|Amlodipine 5mg|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive,HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative,HRT will be stopped gradually~Amlodipine administration: On the day of the first monitoring Dm (corresponding to D13 D16 of the cycle), a single per os dose of amlodipine 5 mg is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.The treatment will be maintained until the pregnancy test is performed then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
48119502|NCT04954196|DRUG|Placebo|"HRT administration: On Day 1 of the cycle, HRT is planned in accordance with the department's standard practice.~* The frozen embryo transfer will be performed 6 days after progesterone initiation.~* The HRT will be maintained until the pregnancy test is performed: If the test is positive, HRT will be continued for up to 12 weeks of amenorrhea at the same doses and then gradually stopped. If the test is negative, HRT will be stopped gradually~Placebo administration:On the day of the first monitoring Dm (corresponding to D13-D16 of the cycle), a single per os dose of placebo (Microcrystalline cellulose) is taken at night, neither the patient nor the investigator knows what drug is the patient getting. Monitoring is systematically performed the next morning.. The treatment will be maintained until the pregnancy test is performed, then if the test is positive, the treatment will be maintained for a total duration of 7 weeks."
47970965|NCT04177160|BEHAVIORAL|Music|Subjects sit still and listen to preferred music for 5 minutes.
48119503|NCT05882617|OTHER|implants supported overdentures|implant supported and retained with different number of implants retained by ball attachments
48119504|NCT04263519|DRUG|Tacrolimus|Oral Immunosuppressant
48119505|NCT02725086|DRUG|Leucostim®|
48119506|NCT02725086|DRUG|Neupogen®|
48119507|NCT04011631|PROCEDURE|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
48119508|NCT06437600|PROCEDURE|Immediate angioplasty|See arm/group descriptions.
48119509|NCT02317965|OTHER|Maternal Blood Draw|Maternal Blood Draw
48119510|NCT04469855|DRUG|semaglutide|Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.
48119511|NCT00006431|BIOLOGICAL|DC RCC-RNA|
48119512|NCT02778828|DRUG|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T\> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
48119513|NCT03803605|BIOLOGICAL|VRC07-523LS|VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
48119514|NCT03803605|DRUG|Vorinostat (VOR)|Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
48119515|NCT03873337|BEHAVIORAL|Persistence Targeted Smoking Cessation in SMI (PTSC-S)|All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth
48119516|NCT03873337|DRUG|Nicotine patch|All participants will receive 10 weeks of nicotine patch
48119517|NCT06001190|DIETARY_SUPPLEMENT|probiotic:Lactobacillus crispatus|We seek to observe that probiotic supplement(arm A) can improve vagina microbiome distribution by comapred to placebo group(arm B) in our study.
48119518|NCT06320912|DEVICE|The intraparenchymal portal vein covered stent|The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.
48119519|NCT06320912|DEVICE|TIPS Covered Stent System GORE|The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.
48119520|NCT02234778|DEVICE|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
48119521|NCT03335748|OTHER|Cognitive training Cogmed program|Cognitive training Cogmed program
48648870|NCT05579288|DRUG|Nitrous oxide (N2O/O2)|Nitrous oxide (N2O/O2) for pain alleviation
48648871|NCT05579288|DRUG|Oxygen (O2)|Oxygen (O2) as placebo for control group
47970966|NCT04177160|BEHAVIORAL|White noise|Subjects sit still and listen to white noise for 5 minutes.
47970967|NCT00079898|PROCEDURE|Acupuncture|
47970968|NCT03539536|DRUG|Telisotuzumab vedotin|Intravenous (IV) infusion
47970969|NCT01980394|PROCEDURE|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
47970970|NCT01678911|DRUG|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
47970971|NCT01209260|DEVICE|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
48488950|NCT03344978|OTHER|Incubator Care|Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
48648872|NCT03422887|DRUG|Nalbuphine|Nalbuphine administration during surgery
48324640|NCT02645383|DEVICE|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
48324641|NCT00209833|DRUG|Cytarabine|
47970972|NCT01209260|DEVICE|Mechanical Needle|Mechanical needle for transseptal access
48324642|NCT00209833|DRUG|Idarubicin|
48324643|NCT00209833|DRUG|Etoposide|
47970973|NCT00865696|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
48119522|NCT05162586|DRUG|Enpatoran low dose|Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
47970974|NCT00865696|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
47970975|NCT06332235|DRUG|Silodosin 8 mg|Dosing schedule: Oral, once daily
47970976|NCT05415839|DEVICE|Laser|Laser
47970977|NCT02628652|DIETARY_SUPPLEMENT|GOS|
47970978|NCT02628652|DIETARY_SUPPLEMENT|GLOS|
47970979|NCT02628652|DIETARY_SUPPLEMENT|FOS|
47970980|NCT00036452|DRUG|lopinavir/ritonavir|
47970981|NCT00036452|DRUG|emtricitabine|
47970982|NCT00036452|DRUG|stavudine|
47970983|NCT00036452|DRUG|tenofovir DF|
47970984|NCT00506480|PROCEDURE|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
47970985|NCT02966262|DEVICE|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
47970986|NCT01004705|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
48119523|NCT05162586|DRUG|Enpatoran medium dose|Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
48324644|NCT00209833|DRUG|Fludarabine|
48488951|NCT00522340|BEHAVIORAL|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
48488952|NCT00001662|DRUG|CX516 (Ampalex)|
48488953|NCT01112943|OTHER|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
48488954|NCT01112943|OTHER|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
47970987|NCT01004705|DRUG|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
47970988|NCT00300391|DRUG|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
47970989|NCT00300391|OTHER|Saline placebo|control arem
47970990|NCT00669227|OTHER|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
47970991|NCT00669227|OTHER|placebo suspension|intracoronary administration at the same day as cell aspiration
48488955|NCT01112943|OTHER|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
48488956|NCT02216019|OTHER|Whole blood|preoparatoire whole blood and postoperative whole blood
47970992|NCT01906502|DEVICE|Sensimed Triggerfish|
48119524|NCT05162586|DRUG|Enpatoran high dose|Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
48119525|NCT05162586|DRUG|Placebo|Participants will receive placebo matched to Enpatoran up to 24 weeks.
48324645|NCT00209833|DRUG|G-CSF|
48324646|NCT00209833|DRUG|Daunorubicine|
48324647|NCT01794013|BEHAVIORAL|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
48324648|NCT01794013|BEHAVIORAL|Routine care|routine care
48488957|NCT04121650|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
48488958|NCT02759770|OTHER|no intervention|This is a clinical observational study, no intervention was included.
48488959|NCT00003179|DRUG|medroxyprogesterone|
48648873|NCT03422887|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
48648874|NCT03422887|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
48119526|NCT02657200|OTHER|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
48119527|NCT02299752|PROCEDURE|single-gloving system|single-gloving system was used during Catheterization
47970993|NCT03304743|DIAGNOSTIC_TEST|Dental panoramic radiograph|"If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
47970994|NCT00686933|DRUG|ABT-089|Subjects will take up to 80 mg daily for 24 months
48324649|NCT02103036|PROCEDURE|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
48324650|NCT02103036|PROCEDURE|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
48324651|NCT02103036|DEVICE|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
48119528|NCT02299752|PROCEDURE|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
48324652|NCT02103036|DEVICE|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
48324653|NCT01191905|DRUG|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
48324654|NCT01191905|DRUG|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
48324655|NCT05257135|BIOLOGICAL|Biological collection|- Blood samples collected at different times: at inclusion and during treatment ( every 6 month)
48324656|NCT04758858|OTHER|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
48488960|NCT05018520|DRUG|Six Courses of R-CHOP Plus Two Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)
48488961|NCT05018520|DRUG|Four Courses of R-CHOP Plus Four Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)
47970995|NCT04955197|DIAGNOSTIC_TEST|exfoliated cytology|Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
48488962|NCT06414278|OTHER|Non-Interventional Study|Non-interventional study
48488963|NCT05020249|DRUG|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
48488964|NCT05020249|OTHER|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
48488965|NCT03150823|PROCEDURE|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
48488966|NCT03150823|PROCEDURE|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
48648875|NCT04665895|DRUG|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals|twice daily inhalation throughout the study
48648876|NCT04665895|DRUG|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK|twice daily inhalation throughout the study
48648877|NCT04665895|DRUG|Placebo|twice daily inhalation throughout the study
47970996|NCT01412359|DRUG|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
48119529|NCT05007665|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
48119530|NCT06218303|BIOLOGICAL|MUC1 Peptide Vaccine|MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.
48324657|NCT04758858|DEVICE|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
48324658|NCT04758858|OTHER|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
48488967|NCT03150823|PROCEDURE|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
48648878|NCT03678857|DIETARY_SUPPLEMENT|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
48488968|NCT00033813|DRUG|Oxatomide (tinset)|
48488969|NCT06032273|BEHAVIORAL|Investigator-designed lung transplant education website|Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.
48488970|NCT06000735|DEVICE|7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2|All participants will go through the same intervention described above
48648879|NCT00002256|DRUG|Zalcitabine|
48648880|NCT03720275|GENETIC|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
48119531|NCT06218303|DRUG|Hiltonol®|A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
48119532|NCT06218303|DRUG|Aromatase Inhibitor|A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
48488971|NCT03755479|DEVICE|Hybrid Closed Loop Insulin Pump Minimed 670G|Five Day Group Education on Minimed 670G
47970997|NCT00963547|DRUG|MK-2206|\[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
47970998|NCT00963547|BIOLOGICAL|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
48119533|NCT02834598|DEVICE|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
48324659|NCT04758858|OTHER|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
48324660|NCT04758858|OTHER|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
48324661|NCT04758858|OTHER|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
48488972|NCT00599898|DRUG|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
48648881|NCT06305234|DRUG|Pegvaliase|Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation
48324662|NCT04758858|OTHER|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
48324663|NCT04758858|OTHER|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
48324664|NCT04758858|OTHER|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
48324665|NCT04758858|DEVICE|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
48324666|NCT04758858|OTHER|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
48324667|NCT04758858|OTHER|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
48324668|NCT04758858|OTHER|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
48324669|NCT04758858|OTHER|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
48324670|NCT04758858|OTHER|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
48324671|NCT04758858|OTHER|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
48324672|NCT04758858|OTHER|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
48324673|NCT04758858|OTHER|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
48324674|NCT03195504|DEVICE|HFNC|High flow nasal oxygen (60 l) under GA
48324675|NCT03195504|DEVICE|CON (control)|Standard oxygen (10-15 l) under GA
48324676|NCT02006264|DRUG|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
48324677|NCT02006264|DRUG|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
48324678|NCT02404883|OTHER|Online Decision-Aid Tool|
48119534|NCT03418805|DRUG|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
48324679|NCT04875403|OTHER|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
48498064|NCT05671016|PROCEDURE|MRI scans and questionnaires|Extra baseline MRI scan performed and questionnaires (EORTC validated questionnaires involving EORTC QLQ C-30, EORTC BN20 and EORTC ELD14) to assess quality of life at baseline, 4 weeks and 8 weeks after treatment
48498065|NCT02289235|DRUG|Ginger|Ginger powder capsule 1000 mg twice daily for 3 months
48648882|NCT00855166|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
47970999|NCT00963547|DRUG|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
47971000|NCT03473977|BIOLOGICAL|Benralizumab|Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
48119535|NCT03418805|DRUG|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
48119536|NCT03418805|DRUG|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
48324680|NCT04875403|OTHER|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
48648883|NCT00855166|DRUG|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
48648884|NCT00855166|DRUG|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
48648885|NCT00855166|DRUG|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
48119537|NCT05628792|DIAGNOSTIC_TEST|CT|Ultra High Resolution CT scan
47971001|NCT03473977|BIOLOGICAL|Placebo|Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
47971002|NCT02421432|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
47971003|NCT01473836|DRUG|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
48119538|NCT00199966|DRUG|Divalproex sodium extended release|
47971004|NCT01473836|DRUG|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
48119539|NCT03882502|OTHER|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
48498066|NCT02289235|DRUG|Placebo|Placebo powder 2 capsules twice daily for 3 months
48648886|NCT02887352|OTHER|assessment of problem-solving ability|
48648887|NCT04507269|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
47971005|NCT04906291|OTHER|Toothpaste use|Brushing three times a day
47971006|NCT01331915|BIOLOGICAL|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
47971007|NCT03334903|DRUG|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
47971008|NCT00270868|PROCEDURE|Double guide wire technique|
47971009|NCT00270868|PROCEDURE|Standard bile duct cannulation|
47971010|NCT00065403|DEVICE|Acupuncture|
48119540|NCT01359592|BIOLOGICAL|rituximab|
48119541|NCT01359592|DRUG|cyclophosphamide|
48119542|NCT01359592|DRUG|doxorubicin hydrochloride|
48119543|NCT01359592|DRUG|prednisone|
48119544|NCT01359592|DRUG|vincristine sulfate|
48119545|NCT01359592|OTHER|R-CHOP regimen|
48324681|NCT04744701|DIAGNOSTIC_TEST|Hemochron Signature Elite Whole Blood Microcoagulation System|Bedside test of Activated Partial Thromboplastin Time
47971011|NCT06505317|DIAGNOSTIC_TEST|AI-based PAD screening intervention|"Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis."
47971012|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 0 to 7 days
47971013|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 8 to 14 days.
47971014|NCT00373152|PROCEDURE|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
47971015|NCT00373152|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
47971016|NCT00373152|PROCEDURE|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
48119546|NCT01359592|OTHER|laboratory biomarker analysis|
48119547|NCT01359592|RADIATION|fludeoxyglucose F 18|
48119548|NCT01359592|RADIATION|selective external radiation therapy|
48119549|NCT01359592|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48119550|NCT03806907|RADIATION|Computed tomography lung subtraction iodine mapping|Subtraction of the non-contrast CT from the contrast-enhance CTPA produces the CT-LSIM
48119551|NCT00906529|DRUG|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
48119552|NCT05632471|BEHAVIORAL|"web-based I know digital games training for intervation grup"|"I know digital games training consisting of 10 web-based videos"
48119553|NCT05632471|OTHER|The control group was not trained|The control group was not trained
48119554|NCT04385056|BIOLOGICAL|MSCTC-0010|MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
48119555|NCT05390749|DRUG|Orelabrutinib|Orelabrutinib will be given as 150mg orally d1-d21 for 6 cycles,every 21 days for 1 cycle.
48119556|NCT05390749|DRUG|Pomalidomide|Pomalidomide will be given as 4mg d1-d14 for 4 cycles,every 21 days for 1 cycle.
48119557|NCT05390749|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
48119558|NCT05390749|DRUG|Methotrexate|methotrexate 3.5g/m2 civ d1/cycle5-6
48119559|NCT02628678|DIETARY_SUPPLEMENT|FOS|
48119560|NCT03990649|DRUG|Soticlestat|Soticlestat tablets
48119561|NCT03990649|DRUG|Placebo|Soticlestat matching placebo tablets
48324682|NCT01990755|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
48324683|NCT01990755|OTHER|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
48324684|NCT01990755|DRUG|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
48324685|NCT01990755|DIETARY_SUPPLEMENT|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
48324686|NCT01990755|DRUG|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
48648888|NCT04507269|DRUG|Placebo|Saline given by subcutaneous injection
48648889|NCT00289978|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
48119562|NCT06263673|DRUG|Sitagliptin|100 mg once daily, oral
48324687|NCT00195767|DRUG|divalproex sodium|
48324688|NCT03431324|BEHAVIORAL|Episodic Future Thinking about Mating Opportunities|"Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events."
48119563|NCT06263673|DRUG|Dapagliflozin|10 mg once daily, oral
48488973|NCT00599898|DRUG|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
48488974|NCT05651555|BEHAVIORAL|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact \& Pad for caregivers with a parent in an institution
48488975|NCT04920916|BIOLOGICAL|Dupilumab|Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
48488976|NCT04920916|DRUG|Placebo|Normal Saline.
48488977|NCT04486755|RADIATION|Hypofractionated Radiation Therapy|All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
48488978|NCT00852566|DRUG|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
48119564|NCT06263673|DRUG|Placebo|Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
48119565|NCT04225949|OTHER|survey 1|survey with one version of depiction
48119566|NCT04225949|OTHER|survey 2|survey with one version of depiction
48488979|NCT00852566|DRUG|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
48488980|NCT06104241|BIOLOGICAL|BGT007 Injection|BGT007 injection (d0) were infused intravenously once, and the dose group was 5.0× 10\^7 cells,1.0 ×10\^8 cells, 3.0× 10\^8 cells,1.0 × 10\^9 cells,3.0 ×10\^9 cells.
48488981|NCT06321003|DEVICE|OCT (Optical Coherence Tomography)|OCT diagnosis in oral carcinogenesis
48488982|NCT00979381|BIOLOGICAL|influenza vaccine|influenza vaccination
48488983|NCT03704402|OTHER|Alcohol policy|Introduction of new mutual alcohol policy
48488984|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
48648890|NCT00289978|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
48119567|NCT06162858|OTHER|IMU (Inertial Measurement Devices)|Functional placing and reaching of objects of different weights on different heights
48119568|NCT05580380|OTHER|Limited Relationship|In this group, participants will share information regarding their low back pain history to a clinician who is not providing eye-contact, has farther physical distance, and is not directly facing the participant. The clinician will not provide verbal affirmations or ask clarifying questions about the patient's low back pain history. Instead, more time will be spent on completion of documentation.
48119569|NCT05580380|OTHER|Enhanced Relationship|A condition in which the clinician is providing enhanced relatedness with consistent eye contact, closer physical distance, facing the patient, and providing non-verbal affirmations (i.e. nodding, smiling), as the participant shares their low back pain history. The clinician will provide empathic verbal affirmations and will ask clarifying questions about the patient's low back pain history.
48488985|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
48488986|NCT04508036|DIAGNOSTIC_TEST|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
48488987|NCT01784666|DRUG|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
48488988|NCT01784666|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
47971017|NCT00373152|RADIATION|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
48119570|NCT00049790|DRUG|recombinant human Angiostatin protein|
48119571|NCT00049790|DRUG|paclitaxel|
48119572|NCT00049790|DRUG|carboplatin|
48119573|NCT05119010|DIETARY_SUPPLEMENT|Continuous ketogenic diet|ARM A : continuous ketogenic diet
48119574|NCT05119010|DIETARY_SUPPLEMENT|Discontinuous ketogenic diet|ARM B : discontinuous ketogenic diet
48119575|NCT05119010|DIETARY_SUPPLEMENT|beta-hydroxybutyrate (BHB) supplementation|ARM C : BHB supplementation
48488989|NCT05422430|BEHAVIORAL|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
48648891|NCT00289978|DRUG|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
48648892|NCT02970812|DEVICE|Electrical Muscle Stimulation|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
48119576|NCT06168149|DIAGNOSTIC_TEST|fetal lung elastography measurement|"Elastography measurements are planned to be performed as in the studies Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study and Feasibility of 2-D ultrasound shear wave elastography of fetal lungs in case of threatened preterm labour: a study protocol in the literature examples section of the file."
48488990|NCT05422430|BEHAVIORAL|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
48488991|NCT00906984|DEVICE|TheraSphere|Given IV
48488992|NCT01131572|DRUG|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
48488993|NCT03799991|BEHAVIORAL|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
48488994|NCT03799991|BEHAVIORAL|Active control|Strength and flexibility exercises that do not involve head movements.
48648893|NCT02970812|DEVICE|Transcutaneous Electrical Nerve Stimulation|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
48648894|NCT04248673|OTHER|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
47971018|NCT06318182|OTHER|Education|Young men who are included in the research sample and agree to participate in the study will be given training within the scope of the health belief model.
47971019|NCT03947320|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
47971020|NCT00299910|DRUG|Montelukast|
47971021|NCT01480050|DRUG|temozolomide|standard of care drug
47971022|NCT01480050|OTHER|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
47971023|NCT01480050|OTHER|pharmacological study|
47971024|NCT01480050|DRUG|Mibefradil|
47971025|NCT05973500|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet for 42 Days
47971026|NCT04664062|BEHAVIORAL|Medication Assisted Treatment|All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
47971027|NCT01738373|DRUG|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
47971028|NCT00769470|BIOLOGICAL|trastuzumab|Given IV
47971029|NCT00769470|DRUG|carboplatin|Given IV
48119577|NCT00376363|DEVICE|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
48119578|NCT00376363|DEVICE|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
48119579|NCT06077110|OTHER|P-OMICs-flow services|The Service Intervention is the P-OMICs-flow clinic being delivered at The Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.
48119580|NCT00648726|DRUG|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
48119581|NCT00648726|DRUG|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
48119582|NCT00648726|DRUG|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
48119583|NCT01876602|BEHAVIORAL|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
48488995|NCT06222541|BEHAVIORAL|"Nudges in Web-Based Supermarket"|"While shopping in the web-based supermarket, participants assigned to the nudge arm will see retail nudges to discourage sugary drink purchases and promote healthier substitutes."
48488996|NCT04072276|BIOLOGICAL|EV71 vaccine|EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
48488997|NCT03824990|BEHAVIORAL|Quality improvement of management of neonatal jaundice|During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
48488998|NCT02103270|DRUG|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
47971030|NCT00769470|DRUG|docetaxel|Given IV
48648895|NCT04248673|OTHER|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
48648896|NCT02456883|DRUG|gilteritinib|oral
48648897|NCT02456883|DRUG|14C-labeled gilteritinib|oral
48648898|NCT00047580|DRUG|tizanidine hydrochloride capsule|
48648899|NCT02144246|OTHER|Non-hormonal period|
48648900|NCT02144246|DRUG|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
47971031|NCT00769470|DRUG|lapatinib ditosylate|Given orally
47971032|NCT00285805|DRUG|Rosiglitazone versus placebo|
47971033|NCT00285805|DRUG|response (sodium excretion) to amiloride infusion|
47971034|NCT00285805|DRUG|response (sodium excretion) to furosemide infusion|
47971035|NCT02716428|DRUG|Faldaprevir|
47971036|NCT02716428|DRUG|TD-6450|
47971037|NCT02716428|DRUG|Ribavirin|
48119584|NCT06315777|GENETIC|cumulus cell oocytes complex (COC) among women with poor ovarian reserve|level of expression of Gremlin-1 (GREM1), Hyaluronic acid synthetase-2 (HAS2), and Prostaglandin-endoperoxide synthase-2 (PTGS2) in cumulus cell oocytes complex (COC) among women with poor ovarian reserve were analyzed
48324689|NCT03431324|BEHAVIORAL|Targeted Mating-EFT Intervention|"This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate."
48324690|NCT04623463|BEHAVIORAL|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
48324691|NCT05164679|BEHAVIORAL|multimodal training (MMT)|Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
48324692|NCT01009983|BIOLOGICAL|panitumumab|Given IV
48119585|NCT03446859|OTHER|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
48119586|NCT03982303|DRUG|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
48119587|NCT06426823|OTHER|Saline / placebo|NaCl (9 mg/ml)
48119588|NCT06426823|OTHER|GIPR antagonist / study tool|GIP(3-30)NH2
48488999|NCT02103270|DRUG|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
48489000|NCT02103270|DRUG|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
48489001|NCT00085774|DRUG|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
48489002|NCT00085774|DRUG|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
48489003|NCT00085774|DRUG|placebo aerosol by HFA|placebo HFA
48489004|NCT05373121|BEHAVIORAL|Online Peer Support|Signposting to online peer support groups and forums
47971038|NCT04284410|BEHAVIORAL|CLASP-PE arm|Participants will complete 8-16 weekly or twice weekly individual therapy sessions (with total session number determined by clinical need, as is typical in clinical trials of PE for PTSD), 1 therapy session (session 3) with a supportive significant other (SO), consistent with the CLASP protocol, and 11 brief (30 minute) phone calls as possible, with calls occurring every week in between therapy sessions and on a less frequent basis following treatment termination up to 3 months after the final in-person therapy session. In addition, the supportive SOs will complete 11 brief (30 minute) phone calls with the therapist at the same frequency as participants. Participants will sign a release of information prior to involving the supportive significant other in treatment.
47971039|NCT03000140|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
47971040|NCT03000140|BEHAVIORAL|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
47971041|NCT04819568|DRUG|Terlipressin|Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid
47971042|NCT04819568|OTHER|Standard of Care|Standard of Care
48489005|NCT05344651|DEVICE|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
48489006|NCT03285789|OTHER|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
47971043|NCT04404361|DRUG|Pacritinib|100 mg capsules
47971044|NCT04404361|DRUG|Placebo|Placebo capsules matching pacritinib 100 mg capsules
47971045|NCT02877381|PROCEDURE|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
48119589|NCT01281163|DRUG|Akt Inhibitor MK2206|Given PO
48119590|NCT01281163|OTHER|Laboratory Biomarker Analysis|Correlative studies
48119591|NCT01281163|DRUG|Lapatinib Ditosylate|Given PO
48119592|NCT01281163|OTHER|Pharmacogenomic Study|Correlative studies
48324693|NCT01009983|DRUG|paclitaxel|Given IV
48324694|NCT01009983|DRUG|carboplatin|Given IV
48324695|NCT01009983|PROCEDURE|laboratory biomarker analysis|Correlative study
48324696|NCT01009983|PROCEDURE|immunohistochemistry staining method|Correlative study
47971046|NCT02877381|PROCEDURE|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
47971047|NCT00390468|DRUG|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
47971048|NCT02285803|DEVICE|transcranial direct current stimulation (tDCS)|
47971049|NCT02581514|OTHER|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
47971050|NCT04753060|PROCEDURE|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
47971051|NCT00869453|OTHER|test meal|Mixed meal containing bread, butter, beef
47971052|NCT00869453|OTHER|glucose|administration of a glucose meal
47971053|NCT00869453|OTHER|fat|administration of a lipid meal
47971054|NCT00869453|OTHER|protein|administration of a protein meal
47971055|NCT00869453|OTHER|control|no meal
47971056|NCT03064451|PROCEDURE|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
47971057|NCT02466178|DEVICE|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
47971058|NCT04031937|OTHER|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
47971059|NCT04229563|DEVICE|AURYON™ System|"The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system."
47971060|NCT03912155|OTHER|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
47971061|NCT01246401|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
47971062|NCT02073552|DRUG|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
47971063|NCT02073552|DRUG|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
47971064|NCT02264197|DRUG|BIBX 245 CL - fed|
48119593|NCT01281163|OTHER|Pharmacological Study|Correlative studies
48324697|NCT05931055|DIAGNOSTIC_TEST|Fragmentomics|The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.
48324698|NCT04446026|DRUG|teneligliptin|teneligliptin 20mg PO qd for 24weeks
47971065|NCT02264197|DRUG|BIBX 245 CL- fasted|
48119594|NCT00502229|DRUG|Clomiphene citrate, metformin, highly purified urinary FSH|
48119595|NCT00200213|BEHAVIORAL|portion or unportioned food|
48119596|NCT05692635|DIAGNOSTIC_TEST|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
48119597|NCT05692635|OTHER|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
48119598|NCT05692635|OTHER|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
48119599|NCT05692635|DRUG|Gadolinium|Given intravenously
48119600|NCT01189331|DEVICE|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
48119601|NCT03365895|PROCEDURE|Diffusion Tensor Imaging|Undergo non-enhanced MRI using MRN and DTI
48119602|NCT03365895|OTHER|Laboratory Biomarker Analysis|Correlative studies
48119603|NCT03365895|PROCEDURE|Magnetic Resonance Imaging|Undergo non-enhanced MRI using MRN and DTI
48119604|NCT03365895|OTHER|Questionnaire Administration|Ancillary studies
48119605|NCT05407571|BEHAVIORAL|Significance of Echogenic Amniotic Fluid on Perinatal Outcome|To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
48119606|NCT04496830|DEVICE|SOMAscan|Analysis of previously donated cerebrospinal fluid using a SOMAscan assay
48119607|NCT04954638|OTHER|endodontic desinfection|"* outcome assessment of the retreatment of endodontically treated teeth presenting chronic apical periodontitis~* effectiveness of hyperpure chlorine dioxide compared with sodium hypochloride~* using microbiological methods~* outcome assessed by radiological method and clinical evaluation"
48119608|NCT05150067|OTHER|A Blended Learning Programme|A blended learning programme with face-to-face training and an online module on handover practice
48119609|NCT05150067|OTHER|Waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed
48119610|NCT06453798|OTHER|cervical spine exercises|Cervical spine exercise training is a method to improve the neck function through the patient's self-exercise.
48119611|NCT06453798|OTHER|Neuromobilization|Neuromobilization is a technical technique for rehabilitation therapists to loosen the trapped nerves of patients with professional methods.
48119612|NCT04794959|DIAGNOSTIC_TEST|Dual-energy CT|CMI patients planned for endovascular stent placement will be contacted and informed about this study prior to their procedure. If they wish to take part in the study, then a date for a pre-operative DECT scan will be arranged. Before scanning the patient will be given a standardized calorie dense drink (Nutridrink). This will take place one week prior to their surgical procedure. Following the surgical procedure, the patient will undergo another DECT scan before discharge.
48119613|NCT00306397|DRUG|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
48119614|NCT03906435|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
48324699|NCT04446026|DRUG|Placebo|teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
48324700|NCT00985556|DRUG|capecitabine|Given orally
48324701|NCT00985556|DRUG|oxaliplatin|Given IV
48489007|NCT03285789|OTHER|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
48489008|NCT06141161|DRUG|corticosteroids|inhailed or oral corticosteroids
48119615|NCT01904071|PROCEDURE|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
48119616|NCT01904071|PROCEDURE|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
48119617|NCT01904071|DRUG|IVMS (IV Morphine)|Intravenous Morphine
48119618|NCT03968354|BIOLOGICAL|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"* Preservation of liver tissue obtain by liver biopsy, constitution of a collection~* Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
48119619|NCT00431704|DRUG|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
48119620|NCT00431704|DRUG|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
48324702|NCT00985556|DRUG|tegafur-gimeracil-oteracil potassium|Given orally
48324703|NCT00213161|DRUG|iron supplement, iron drops|
48324704|NCT03978624|DRUG|Pembrolizumab|200 mg IV on day 1 and day 22
48324705|NCT03978624|DRUG|Entinostat|5 mg given orally on day 1, day 8 and day 15
48324706|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|patient with sponiloarthritis who comes to the clinic Hospital for clinical evaluation of disease. Assessment instrumental evaluation of the axial involvment t, with x-ray of the spine and pelvis every 5 years, and MRI of the spine and pelvis every 2 years.
48324707|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|peripheral involvement, with joint ultrasound at baseline, at 3 months from the start of a new therapy, and therefore in the event of reactivation of the disease
48119621|NCT00431704|DRUG|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
48324708|NCT05578482|DRUG|Dicloxacillin Oral Capsule|Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
48324709|NCT05578482|DRUG|Elocon 0.1 % Topical Cream|Both groups are treated with elocon for five days.
48324710|NCT03160105|DRUG|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
47971066|NCT03975608|BEHAVIORAL|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~1. Symptom management and communication with healthcare providers~2. Changes in self and relations with each others~3. Spirituality, sense of meaning, and purpose~4. Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
47971067|NCT06125028|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PTF i.v. injection
47971068|NCT06125028|DRUG|[18F]Fluorodeoxyglucose|\[18F\]FDG i.v. injection.
48119622|NCT00108823|DRUG|Roflumilast|
48119623|NCT04065334|BEHAVIORAL|High dose training|4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
48324711|NCT03160105|OTHER|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
48324712|NCT04335604|DRUG|JPI-547|The dose levels will be escalated following a 3+3 dose escalation scheme.
48324713|NCT00795509|DRUG|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
48324714|NCT01702662|DEVICE|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
48324715|NCT06134713|DRUG|cryotherapy with sterile saline at 2.5ºC|In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
48324716|NCT06134713|DRUG|control with sterile saline at room temperature|In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
48324717|NCT01374763|DRUG|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
48324718|NCT01374763|DRUG|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
48324719|NCT00645294|DRUG|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
48324720|NCT00645294|DRUG|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
48324721|NCT00645294|DRUG|Adefovir Dipivoxil|ADV 10 mg on Day 1
48324722|NCT01185249|PROCEDURE|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
48324723|NCT00335998|DRUG|triapine|Given IV
48324724|NCT00335998|OTHER|laboratory biomarker analysis|Correlative studies
48324725|NCT00335998|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
48324726|NCT00335998|RADIATION|brachytherapy|Undergo intracavitary or interstitial brachytherapy
48119624|NCT04065334|BEHAVIORAL|low dose training|1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
48324727|NCT00335998|DRUG|cisplatin|Given IV
48324728|NCT00335998|OTHER|pharmacological study|Correlative studies
48324729|NCT06386172|OTHER|Clinical decision support trigger|Investigation of CDS-triggers effect on primary care physicians detection and management of chronic kidney disease
48324730|NCT00602719|DRUG|Zolpidem|
48324731|NCT03837353|DRUG|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
48324732|NCT03837353|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
48119625|NCT01304342|DRUG|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
48324733|NCT00824928|PROCEDURE|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
48119626|NCT01304342|DRUG|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
48324734|NCT01954069|DEVICE|Semi-quantitative pregnancy test|
48324735|NCT06459622|DIAGNOSTIC_TEST|Serum IL_25 and eosinophils in nasal polyp tisuee|Serum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids
48324736|NCT00634114|DRUG|Esomeprazole|10mg once daily oral administration
48324737|NCT00634114|DRUG|Esomeprazole|20mg once daily oral administration
48324738|NCT00634114|DRUG|Omeprazole|10mg once daily oral administration
48324739|NCT06429423|BEHAVIORAL|Acute exercise low intensity|"A 15-minute exercise on low intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
48324740|NCT06429423|BEHAVIORAL|Acute exercise moderate intensity|"A 15-minute exercise on moderate intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
48648901|NCT00645138|PROCEDURE|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
48648902|NCT00645138|PROCEDURE|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
48324741|NCT02240745|OTHER|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
48648903|NCT04835597|BEHAVIORAL|Behavioral Assessment|Complete movement assessment
48648904|NCT04835597|OTHER|Electronic Health Record Review|SAE data is collected
48648905|NCT06675266|DIAGNOSTIC_TEST|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester screening scan|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester of pregnancy
47971069|NCT03378232|DIETARY_SUPPLEMENT|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
48119627|NCT01304342|DRUG|Normal saline|Normal saline intravenously and intranasally
48119628|NCT02639910|BIOLOGICAL|Tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
48119629|NCT02639910|DRUG|Idelalisib|idelalisib dose: 150 mg twice daily orally
48119630|NCT02639910|DRUG|Venetoclax|venetoclax dose: 400 mg once daily orally
48119631|NCT02952209|DEVICE|Xenograft|
48119632|NCT06217692|OTHER|nutrition education|nutrition education
48119633|NCT04581733|DRUG|MT1621|All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.
48648906|NCT01893814|DIETARY_SUPPLEMENT|Probiotics|
48648907|NCT01893814|DIETARY_SUPPLEMENT|Control|
48648908|NCT04917510|PROCEDURE|Erector spinae block|See experimental arm group description
48648909|NCT04917510|PROCEDURE|Local block|See control and study arm group descriptions for the local block
48648910|NCT01111552|DRUG|Escitalopram|Escitalopram oral capsules.
48648911|NCT01111552|DRUG|Aripiprazole|Aripiprazole oral capsules.
48648912|NCT01111552|DRUG|Placebo|Study drug matching placebo capsule.
48324742|NCT02005224|OTHER|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
48324743|NCT00475540|DEVICE|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
48489009|NCT03325400|OTHER|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
48489010|NCT02017860|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
48489011|NCT05143931|BEHAVIORAL|Home food environment and grocery delivery (AVOID)|Participants (Arms 2 \& 4) will receive 6 months of coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices
48489012|NCT05143931|BEHAVIORAL|Inhibitory control training (RESIST)|Participants assigned to RESIST (Arms 3 \& 4) will receive 6 months of coaching (Zoom and/or email/text) and gamified inhibitory control training.
48489013|NCT05143931|BEHAVIORAL|WW|Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
48489014|NCT02363608|OTHER|standard post surgery care|
48489015|NCT02363608|BEHAVIORAL|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
48489016|NCT02363608|BEHAVIORAL|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
48489017|NCT00004402|DRUG|calcitriol|
48489018|NCT00004402|DRUG|interferon gamma|
48324744|NCT04826458|DEVICE|TreC-Onco|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
48324745|NCT04826458|OTHER|Paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
48324746|NCT02776956|DRUG|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
48324747|NCT02776956|DRUG|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
48324748|NCT00823940|DRUG|GSK1362885|5 - 100mg of GSK1362885 or placebo
48324749|NCT00823940|DRUG|GSK1362885|100 - 600mg or placebo
48324750|NCT00823940|DRUG|Glucagon|0.5mg IV bolus
48324751|NCT00823940|DRUG|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
48324752|NCT06239506|OTHER|no intervention|no intervention
48324753|NCT01974726|OTHER|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
48324754|NCT01974726|OTHER|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
48324755|NCT01974726|OTHER|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
48324756|NCT01974726|OTHER|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
48489019|NCT00198653|BEHAVIORAL|Newborn Thermal Care Practice|
48489020|NCT04150198|DEVICE|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
48489021|NCT04669470|PROCEDURE|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
48489022|NCT04341376|BEHAVIORAL|Enhanced First Connections|Enhanced First Connections is a short-term home visiting program that includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation.
48489023|NCT01363804|DRUG|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
48489024|NCT05799027|DIAGNOSTIC_TEST|Raman spectrum|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
48489025|NCT06221267|DRUG|Rimegepant|No intervention. The study will record the usage, timing, frequency, and dosage of rimegepant in a real-world clinical setting.
48489026|NCT04729465|DRUG|Propofol|Propofol
48489027|NCT04729465|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor
48489028|NCT02562482|BIOLOGICAL|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
48489029|NCT02562482|OTHER|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
48489030|NCT06322394|DRUG|high-dose BXOS110|3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.
48119634|NCT00184041|DRUG|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
48119635|NCT00337545|DRUG|RAD001|
48119636|NCT04598321|DRUG|Talazoparib Oral Capsule|An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
47971070|NCT03378232|DIETARY_SUPPLEMENT|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
47971071|NCT03378232|DIETARY_SUPPLEMENT|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
48119637|NCT04981015|DIAGNOSTIC_TEST|Three-day bladder diary|A three-day bladder diary for recording voiding-flow pattern of a women
48119638|NCT05323266|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.
48119639|NCT05323266|DEVICE|High-Flow Nasal Cannula (HFNC)|The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.
48119640|NCT01151839|PROCEDURE|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
48119641|NCT01151839|PROCEDURE|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
48489031|NCT06322394|DRUG|low-dose BXOS110|2.0 mg/kg, maximum dose not exceeding 200 mg，Participants received one administration by intravenous infusion.
47971072|NCT02563405|DRUG|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
47971073|NCT02563405|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
48119642|NCT00291824|BEHAVIORAL|Cardiovascular risk factors and willingness to change|
48119643|NCT03107117|BEHAVIORAL|Computer Counseling|two computer counseling online programs for a teen and a parent
48119644|NCT03107117|BEHAVIORAL|Standard Care|A referral for substance use counseling
48119645|NCT03532243|PROCEDURE|incremental inspiratory load|inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
48119646|NCT04167020|DEVICE|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
48489032|NCT06322394|DRUG|Placebo|Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.
48489033|NCT04816630|DEVICE|CBC-Diff Monocyte Volume Width Distribution|MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
47971074|NCT00895167|DIETARY_SUPPLEMENT|curcumin|one oral dose of 12 caplets = 12 g curcumin
48489034|NCT04219735|DRUG|Minocycline|Minocycline 100mg BID
48489035|NCT04219735|DRUG|Placebos|Placebo
48489036|NCT02870400|DRUG|REGN2477|Participants will receive ascending doses of REGN2477
47971075|NCT03952104|OTHER|Strength training|Strength training
47971076|NCT04023604|OTHER|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
47971077|NCT04023604|OTHER|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
47971078|NCT03502980|DEVICE|Bard PowerPICC|PICC Insertion
47971079|NCT03502980|DEVICE|Bard PowerMidline catheter|Midline Insertion
48119647|NCT05689125|DEVICE|Railroaded bougie|Residents expose the glottis by a video laryngoscope and place the tip of bougie through the vocal cords. Then, an assistant loads an endotracheal tube on the free end of the bougie. Residents advance the endotracheal tube over the bougie and withdraw the bougie.
48119648|NCT05689125|DEVICE|Preloaded bougie|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation using a bougie with a preloaded endotracheal tube while an assistant secures the free end of the bougie. Residents withdraw the bougie when the endotracheal tube reaches an appropriate depth.
48119649|NCT05689125|DEVICE|Stylet|Residents expose the glottis by a video laryngoscope and perform the endotracheal intubation with the assistance of a stylet. An assistant withdraws the stylet when the tip of the endotracheal tube passes through the vocal cords. Then residents place the endotracheal tube to an appropriate depth.
48119650|NCT01407198|DRUG|Nilotinib|Orally, daily 200 - 400 mg BID
48119651|NCT01407198|RADIATION|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
48489037|NCT02870400|DRUG|Placebo|Participants will receive matching placebo
48324757|NCT01974726|OTHER|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
48324758|NCT01974726|OTHER|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
48324759|NCT01974726|OTHER|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
48324760|NCT01974726|OTHER|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
48324761|NCT01974726|OTHER|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
48324762|NCT00604435|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
48489038|NCT03544879|BEHAVIORAL|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
48489039|NCT03544879|BEHAVIORAL|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works \& What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
48489040|NCT05391334|DEVICE|Qumea|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
48119652|NCT04732260|DRUG|Letermovir|"Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg."
48489041|NCT05467046|DEVICE|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
48489042|NCT00944268|DRUG|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
48489043|NCT00999180|PROCEDURE|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
48489044|NCT00999180|PROCEDURE|Saline and Kinesiotherapy|Saline and Kinesiotherapy
48489045|NCT01274806|OTHER|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
48489046|NCT00325208|DEVICE|partial-vacuum milk bottle|
48489047|NCT00325208|DEVICE|anti-vacuum milk bottle|
48489048|NCT01027741|BEHAVIORAL|Phone Referral|Participants receive phone referral to cancer control and prevention services.
48489049|NCT01027741|BEHAVIORAL|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
48489050|NCT01027741|BEHAVIORAL|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
48119653|NCT03098368|DRUG|Rotigotine|
48119654|NCT03098368|DRUG|Placebo|Placebo of rotigotine patch
48119655|NCT01865253|DEVICE|Renal Denervation|Renal Denervation
48324763|NCT00604435|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
48324764|NCT04230798|OTHER|Injury prevention program|The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
48648913|NCT05746273|DRUG|Transdermal Nicotine Patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
48324765|NCT05533255|OTHER|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
48489051|NCT04107142|BIOLOGICAL|Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell|Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
48489052|NCT03376620|DRUG|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
48489053|NCT03376620|DRUG|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
48489054|NCT06337214|BEHAVIORAL|Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy|Comparing cancer patients who have participated in the program with those who have not, this study will examine differences in two types of quality of life questionnaires and constitution between the two groups.
48489055|NCT05307887|DEVICE|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
48489056|NCT02595008|DRUG|DSXS|Active treatment
48489057|NCT01687582|DRUG|GLP-1 analog|GLP-1 analog treatment
48489058|NCT02482493|DEVICE|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
48489059|NCT04073628|DEVICE|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
48489060|NCT03181321|BEHAVIORAL|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
48489061|NCT01251978|DRUG|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
48489062|NCT01251978|DRUG|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
48489063|NCT00926016|DRUG|Pioglitazone (Actos)|pioglitazone 45 mg a day
48489064|NCT02416011|BEHAVIORAL|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
48489065|NCT02416011|BEHAVIORAL|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
48489066|NCT00775541|DIETARY_SUPPLEMENT|Vitamin C|One IV infusion of 2 gm vitamin C
48489067|NCT03821363|BIOLOGICAL|SCT-I10A|Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
48489068|NCT05106543|DEVICE|Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients|Kinesiological Taping
48648914|NCT05746273|DRUG|Transdermal Placebo Patch|Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
48648915|NCT05898334|DEVICE|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
48119656|NCT01179334|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
48324766|NCT05533255|OTHER|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
48119657|NCT01179334|DRUG|Placebo|Placebo for 12 weeks
48324767|NCT02862223|DIETARY_SUPPLEMENT|Neoprinol|
48324768|NCT03483766|DEVICE|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
48489069|NCT02612220|PROCEDURE|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
48489070|NCT02612220|OTHER|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
48489071|NCT02219971|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
48324769|NCT01016548|BIOLOGICAL|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
48648916|NCT05898334|DEVICE|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
48324770|NCT03908710|OTHER|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
48648917|NCT05806190|DEVICE|Continuous Glucose Monitoring|Continuous Glucose Monitoring using a Dexcom G6 Continuous Glucose Monitoring Device
48119658|NCT01179334|DRUG|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
48324771|NCT04504435|DRUG|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
48324772|NCT04504435|DRUG|Placebo|Matching placebo capsules will be provided
48324773|NCT06103448|DEVICE|Ankle-brachial index - system 100|Measurement of ankle brachial index on all four limbs, drawing three blood drops for point of care (POC) cholesterol meter and one drop of blood for POC glucometer
48324774|NCT03428997|DEVICE|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
48324775|NCT03428997|OTHER|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
48324776|NCT05387252|DIETARY_SUPPLEMENT|Mulberry juice|Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.
48324777|NCT02147496|OTHER|Dietary Intervention|
48324778|NCT00981318|DRUG|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
48324779|NCT01333852|DRUG|metformin up to 2500mg/d|metformin up to 2500mg/d
48324780|NCT01333852|DRUG|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
48489072|NCT03867955|OTHER|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
48489073|NCT03634345|DRUG|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
48489074|NCT03634345|DRUG|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
48648918|NCT00154245|DRUG|Enteric-Coated Mycophenolate sodium (EC-MPS)|
48648919|NCT05528445|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
48648920|NCT01171079|DEVICE|application of oxidized regenerated cellulose|
48648921|NCT05875831|BEHAVIORAL|Active Cycle of Breathing|Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients
48648922|NCT05875831|DIAGNOSTIC_TEST|Coughing|Coughing to Improve Pulmonary Functions in Post-Surgical Patients
48648923|NCT04594603|OTHER|Phacoemulsification for cataract|Phacoemulsification for removal of cataract
48648924|NCT02189967|RADIATION|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
48324781|NCT01333852|DRUG|placebo|placebo
48340086|NCT02685124|DIETARY_SUPPLEMENT|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
48489075|NCT03634345|DRUG|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
48489076|NCT04365179|DRUG|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
48489077|NCT03667014|DRUG|Dupilumab|Dupilumab treatment
48648925|NCT02189967|RADIATION|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
48648926|NCT02624479|DRUG|Sodium thiosulfate|oral administration of thiosulfate
48648927|NCT01137565|DRUG|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
48648928|NCT01137565|DRUG|Placebo|Placebo to AMG 853
48648929|NCT05879159|BEHAVIORAL|Questionnaires|Survey
48648930|NCT04883775|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent.
48119659|NCT01803555|DRUG|Budesonide/Formoterol SPIROMAX®|BF Spiromax will be administered per dose and schedule specified in the arm.
48324782|NCT05782166|BEHAVIORAL|Betel Quid Educational Booklet|"Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
48324783|NCT05782166|BEHAVIORAL|Betel Quid Cessation Intervention Module|"All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
48324784|NCT00664209|DRUG|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
48324785|NCT00664209|DRUG|placebo|placebo therapy
48324786|NCT03276013|DRUG|Pembrolizumab|pembrolizumab in combination with doxorubicin
48324787|NCT01867814|PROCEDURE|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
48324788|NCT04275050|DRUG|TQB3303|TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
48324789|NCT02388841|RADIATION|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
48324790|NCT00123149|DRUG|Epoetin alfa|
48324791|NCT05437393|DEVICE|Deep brain stimulation|Deep brain stimulation of the centromedian nucleus (bilateral)
48324792|NCT03783728|DRUG|Rifapentine 600 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
48324793|NCT03783728|DRUG|Isoniazid 900 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
48648931|NCT04883775|DRUG|MVT-5873|MVT-5873 will be administered intravenously over at least 60 minutes.
48648932|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
48648933|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
48648934|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
48648935|NCT01235637|DRUG|Alfentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
48119660|NCT01803555|DRUG|SYMBICORT® TURBOHALER®|Symbicort Turbohaler will be administered per dose and schedule specified in the arm.
48648936|NCT01235637|DRUG|Sufentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
48119661|NCT01803555|DRUG|SYMBICORT placebo|SYMBICORT placebo multi-dose dry powder inhaler (DPI) identical in appearance to SYMBICORT TURBOHALER will be administered per dose and schedule specified in the arm.
48119662|NCT01803555|DRUG|SPIROMAX Placebo|SPIROMAX Placebo multi-dose dry powder inhaler (DPI) identical in appearance to BF SPIROMAX will be administered per dose and schedule specified in the arm.
48119663|NCT03643939|DEVICE|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
48119664|NCT03643939|DEVICE|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
48119665|NCT02577835|DEVICE|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
48324794|NCT03783728|DRUG|Pyridoxine 50 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
48324795|NCT05314881|GENETIC|TNFS4, NCF gene|study the gene polymorphisms from the blood sample of the included SLE patients
48340087|NCT06349382|DIETARY_SUPPLEMENT|carbohydrate-rich beverage|Patients in the OCHL group will drink a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL in the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL two hours before the induction of anesthesia.
48340088|NCT02563925|RADIATION|Brain radiotherapy or Stereotactic Radiosurgery|
48340089|NCT02563925|DRUG|Tremelimumab|
48340090|NCT02563925|DRUG|HER2 directed therapy|
48340091|NCT02563925|DRUG|Durvalumab|
48340092|NCT01105936|DRUG|Paracetamol|665 mg sustained release paracetamol caplets
48340093|NCT01105936|DRUG|Placebo|Placebo caplets
48119666|NCT04297371|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
48489078|NCT03992794|DIAGNOSTIC_TEST|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
48489079|NCT04324593|DEVICE|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
48489080|NCT05907330|DRUG|CU104|CU104 will administer the study drug once a day after a meal
48648937|NCT02067598|OTHER|scapular exercise|
48648938|NCT04431284|OTHER|Questionnaires|The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
48648939|NCT00562198|DRUG|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
48648940|NCT00562198|DRUG|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
48648941|NCT01961180|DRUG|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
48648942|NCT01961180|DRUG|Placebo|Placebo
48648943|NCT01880775|DRUG|Prilocaine|experimental
48489081|NCT05907330|DRUG|Placebo|Placebo will administer the study drug once a day after a meal
48489082|NCT06000917|DRUG|pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel|"Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration"
48119667|NCT04244214|OTHER|More Stamina|More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
48119668|NCT01388881|OTHER|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
48119669|NCT06167213|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
48119670|NCT05876013|PROCEDURE|ACL reconstruction|Randomized between hamstring and patellar tendon graft
48489083|NCT04400760|DRUG|DAPA Tx|The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
48648944|NCT01880775|DRUG|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
48648945|NCT06673771|OTHER|Vestibular Rehabiliation Therapy|"Moving the eye horizontally between two stationary target while keeping the head still Moving the eye vertically between two stationary target while keeping the head still Moving the target horizontally and tracking it with the eye while keeping the head still Moving the target vertically and tracking it with the eye while keeping the head still Moving the head horizontally while a keeping a look on stationary target Moving the head vertically while a keeping a look on stationary target Moving the head and target in opposite direction horizontally while tracking the target with eyes Moving the head and target in opposite direction vertically while tracking the target with eyes.~Sit down and stand up, sit down and stand up with eye open and eye close Stand up, but turn to the right while standing Stand up, but turn to the left while standing Place an object on the floor. Take it and bring it above your head and place it on the floor again"
48340094|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose|3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).
48489084|NCT00788229|DRUG|AT01|eye drop for 12 weeks
48489085|NCT00788229|DRUG|AT02|eye drop for 12 weeks
48489086|NCT00788229|DRUG|AT03|eye drop for 12 weeks
48489087|NCT00788229|DRUG|AT04|eye drop for 12 weeks
48489088|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 75 mg/capsule|Take 2 capsules per day at any time.
48489089|NCT05683327|DIETARY_SUPPLEMENT|UltraHA® 40 mg/capsule|Take 2 capsules per day at any time.
48489090|NCT05683327|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
48489091|NCT03966859|DRUG|Atorvastatin 20mg|oral dose, once daily for 7 days
48489092|NCT03966859|OTHER|Lactose placebo|oral dose, once daily for 7 days
48489093|NCT01701037|DRUG|dabrafenib|150 mg given PO
48648946|NCT06673771|OTHER|Conventional treatment|Standing balance training, weight shifting training, walking training, muscle strength training, step-up-and-down training.
48648947|NCT04559139|DRUG|Cisplatin|Given IV
48648948|NCT04559139|DRUG|Gemcitabine Hydrochloride|Given IV
48648949|NCT04559139|PROCEDURE|Lymphadenectomy|Undergo portal lymphadenectomy
48340095|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose|3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
48340096|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) low dose|3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).
48489094|NCT01701037|DRUG|trametinib|2 mg given PO
48489095|NCT01701037|OTHER|laboratory biomarker analysis|Correlative studies
48489096|NCT05532579|OTHER|Invasive Physiotherapy Group|The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.
48489097|NCT05532579|OTHER|Sham Group|Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
48489098|NCT00431158|OTHER|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol"
48489099|NCT04892797|OTHER|Covid-19+ observational|This is observational--there is no intervention
48489100|NCT06242561|BEHAVIORAL|Data collection from sepsis management|observational study
48489101|NCT03521063|DRUG|Budesonide|Drug: Budesonide inhalation suspension
48489102|NCT03521063|DRUG|Poractant Alfa|Drug: Poractant alfa intratracheal suspension
48489103|NCT03521063|DRUG|Saline|Sodium chloride injection 0.9%
48489104|NCT02182791|DRUG|Nevirapine|
48489105|NCT02182791|DRUG|EE/NET|
48489106|NCT01817465|DRUG|Motilitone ®|
48489107|NCT01817465|DRUG|Pantoline®|
48489108|NCT01817465|DRUG|Motilitone® and Pantoline®|
48489109|NCT04236583|OTHER|Telehealth|Post-discharge virtual visit
48489110|NCT05541991|DIETARY_SUPPLEMENT|single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a single dose of standardised rhubarb extract
48489111|NCT05541991|DIETARY_SUPPLEMENT|placebo coated tablet|coated tablet without active principle
48489112|NCT05541991|DIETARY_SUPPLEMENT|double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract|coated tablet with a double dose of standardised rhubarb extract
48489113|NCT00703508|DRUG|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
48648950|NCT04559139|PROCEDURE|Partial Hepatectomy|Undergo partial hepatectomy
48648951|NCT00299715|DRUG|Paliperidone extended-release|
48648952|NCT04484428|DRUG|K-285|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
48648953|NCT04484428|DRUG|Menthol|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
48648954|NCT05804084|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
48648955|NCT05804084|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
48489114|NCT02340845|BIOLOGICAL|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
48648956|NCT05518162|DEVICE|InBloom|The Rose Program (RPv2) application will be built for iOS and Android devices (including tablets) and will feature a video-based Learning Management System (LMS) which provides resources for people with postpartum depression to improve their wellbeing. Each InBloom session will contain 4-5 video modules with specific themes contained in each ROSE session which are 3-5 minutes each.
48648957|NCT05518162|BEHAVIORAL|ROSE|"ROSE will be offered as a psychoeducational course on adjusting to parenthood by a health professional embedded in the obstetric clinics. There are five 90-minute group sessions which provide interpersonal rationale for the program, a review of the course outline, ground rules for the group, and the signs and symptoms of baby blues and postpartum depression, stress management skills. managing role transitions with an emphasis on transition to motherhood and the development of a support system, identifying types of interpersonal conflicts common around childbirth and techniques for resolving them, skills for resolving interpersonal conflicts and an opportunity to review and reinforce the content of the previous sessions."
48119671|NCT04026594|OTHER|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
48324796|NCT05865873|BEHAVIORAL|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
48324797|NCT00671216|DRUG|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
47971080|NCT05238090|OTHER|Passive and active analytical stretching exercises|"For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process."
48119672|NCT04026594|OTHER|Relaxation group|control group
48324798|NCT00671216|DRUG|GW642444|Subjects will receive 50 mcg once daily as a single dose
48324799|NCT00671216|DRUG|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
48324800|NCT00671216|DRUG|Placebo|Placebo matching study medication will be inhaled by subjects
48324801|NCT02451202|PROCEDURE|Deep Neuromuscular Blockade|"* During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~* At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
48324802|NCT02451202|PROCEDURE|Moderate Neuromuscular Blockade|- During maintenance phase, if recovery at the presence of \<10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
48324803|NCT02451202|DRUG|Sugammadex|
48324804|NCT02451202|DRUG|Rocuronium|
48324805|NCT02616016|DEVICE|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
47971081|NCT05238090|OTHER|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
48119673|NCT00173524|BEHAVIORAL|PharmacoEconomic Assessment|Collecting PE data.
48119674|NCT00332241|DRUG|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
48119675|NCT00332241|DRUG|Placebo|Tablets, Oral, once daily, 8 weeks
48119676|NCT05042024|PROCEDURE|Scaling and root planing|Conventional periodontal therapy, non-surgical periodontal therapy
48324806|NCT02275598|DRUG|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
48324807|NCT02275598|DRUG|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
48324808|NCT02523820|DRUG|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
48324809|NCT02523820|DRUG|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
48324810|NCT02674672|DEVICE|VenaTech® (VenaTech Retrievable Filter)|
48324811|NCT05883007|RADIATION|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
48324812|NCT02331524|BEHAVIORAL|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
48324813|NCT02331524|OTHER|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
48119677|NCT05042024|DRUG|Oral L-arginine aspartate administration|The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
48324814|NCT03489135|DEVICE|ReVene Thrombectomy Catheter|Endovascular treatment of an acute iliofemoral DVT
48324815|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
48324816|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
48324817|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
48324818|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
47971082|NCT04160195|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|Dose-escalation trial starting dose: 0.66 x10\^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10\^6 CAR+ T cells/kg based on cohort) infuse on day 0
48324819|NCT06215456|DEVICE|Virtual reality therapy|VR therapy will be applied using a head mounted display, the PICO G2 4K headset (Barcelona, Spain). For VRD de application'SyncVR Relax \& Distract' (SyncVR Medical, Utrecht, The Netherlands) will be used. This application contains a wide range of relaxation games, relaxing 360 videos, and relaxation exercises each with a duration of 5-20 minutes. Patients can choose videos, games, or exercises according to their own preferences. For VRH sessions, the application HypnoVR (Strasbourg, France) will be used. This app contains several hypnotic narratives integrating sequences of controlled breathing, cardiac coherence, and hypnotic suggestions. Each VRH sessions can be personalized through selecting different environments and musical compositions.The first VRH session will be set to last 20 minutes and the second VRH session will be set to the continuous setting.
48324820|NCT02229110|OTHER|Signal|Automatic signal in the electronic medical record
48324821|NCT01899677|OTHER|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
48324822|NCT01899677|DRUG|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
48324823|NCT03522493|DEVICE|"Yaalom Katom"|Full face Gas mask
48324824|NCT00961922|OTHER|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
48119678|NCT05042024|DRUG|Oral L-ornithine aspartate administration|The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
48119679|NCT04337307|BIOLOGICAL|Skin sampling of the hands of the healthcare workers involved in the decontamination of incubators|"Each incubator will be sampled in 5 points before and after decontamination. The healthcare worker that will be involved in the decontamination will also be sampled (skin sample of the hand) before and after decontamination of the incubator.~All the samples will be analyzed for the presence of pathogenic bacteria, using an inoculation on selective agar then an identification of each bacterial colony."
48119680|NCT05158153|OTHER|ORKID Bundled Intervention|During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure \> 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure \< 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.
48324825|NCT00961922|OTHER|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
48324826|NCT04470492|COMBINATION_PRODUCT|Doctormate®+Medical Management|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
48324827|NCT04470492|DRUG|Medical Management|Patients will be treated with conventional medication for 3 months.
48324828|NCT01690689|DEVICE|Implant surgery|surgery
47971083|NCT04160195|DRUG|Cyclophosphamide|500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
47971084|NCT04160195|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
47971085|NCT04670848|DEVICE|Sleepiz One+ vs. polysomnography|Simultaneous sleep recording with polysomnography and Sleepiz One+ device
47971086|NCT03170401|DIETARY_SUPPLEMENT|Protein supplementation|enteral protein supplementation
48119681|NCT05158153|DRUG|Furosemide|160 mg oral furosemide twice daily to be taken every day at home
48119682|NCT00731497|DEVICE|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
48119683|NCT03677349|PROCEDURE|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
47971087|NCT03170401|OTHER|Standard enteral nutrition|Standard enteral nutrition.
48324829|NCT04578106|BIOLOGICAL|Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination|After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
48324830|NCT02133742|DRUG|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
48324831|NCT02133742|DRUG|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
48324832|NCT01965418|DRUG|Fufang Biejia Ruangan Tablet|
48324833|NCT01965418|DRUG|Placebo|
48324834|NCT03123055|DRUG|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
48324835|NCT03123055|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
48648958|NCT03801109|OTHER|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
48648959|NCT03801109|OTHER|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
48119684|NCT06502275|BEHAVIORAL|Mobile Health Management Frailty Care Program|"Through the LINE communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise."
48119685|NCT03960398|DRUG|Iatrogenic disease impact on emergency consultations|Determination of the proportion of emergency consultations linked to iatrogenic diseases
48119686|NCT03914859|BIOLOGICAL|IN VITRO FERTILIZATION|Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.
48648960|NCT03801109|OTHER|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
48648961|NCT03801109|OTHER|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
48648962|NCT00001476|DRUG|Gene Therapy Method for CGD|
48648963|NCT00001476|DEVICE|Isolex 300i Magnetic Cell Selector|
47971088|NCT04698460|PROCEDURE|Hybrid coronary revascularization|A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
47971089|NCT04698460|PROCEDURE|Coronary artery bypass grafting|A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
47971090|NCT02442518|PROCEDURE|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
48119687|NCT05684354|OTHER|Patient Reported Outcomes (PROs)|"The day before or the morning before surgery, the patient filled the first QoR-15 scale alone or could be helped by one of the investigators in case of questions or difficulties.~The second QoR-15 scale was distributed the day before or the day of discharge from the hospital"
48119688|NCT05218044|PROCEDURE|Cryoablation|The cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
48119689|NCT04117789|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
48648964|NCT06673784|DIAGNOSTIC_TEST|ophthalmic saline eye drops|for optical examination
48648965|NCT06673784|DRUG|Saline|Most one natural and not effects on study
48648966|NCT05853952|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
48648967|NCT05853952|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
48648968|NCT01548885|DEVICE|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48648969|NCT01548885|DEVICE|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
47971091|NCT04658498|OTHER|Procedure: Usual Care (UC)|Intermittent spontaneous breathing periods
47971092|NCT04658498|OTHER|Procedure: UC + HI-IMT|UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.
47971093|NCT04658498|OTHER|Procedure: UC + LI-IMT (sham IMT)|UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
48119690|NCT04117789|BEHAVIORAL|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
48119691|NCT04117789|OTHER|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
48648970|NCT01548885|DEVICE|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48648971|NCT01548885|DEVICE|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48648972|NCT01548885|DEVICE|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48648973|NCT04450212|GENETIC|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
48648974|NCT04450212|DIETARY_SUPPLEMENT|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (\~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
48648975|NCT01881932|DEVICE|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
48648976|NCT01881932|DEVICE|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
48324836|NCT04496947|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~* Elicitation of the Relaxation Response (RR) through mind-body techniques;~* Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and~* Coping strategies and adaptive perspective-taking to promote positive well-being."
48648977|NCT05681949|OTHER|ADBoard|Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
48648978|NCT00619242|DRUG|sorafenib|2 tablets with water by mouth twice a day for two weeks.
47971094|NCT01983436|OTHER|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
48324837|NCT00288834|BEHAVIORAL|dysphagia rehabilitation|
47971095|NCT02418598|GENETIC|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.
48324838|NCT01204333|DRUG|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
48324839|NCT01204333|DRUG|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
47971096|NCT02418598|GENETIC|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.
48324840|NCT00139139|BIOLOGICAL|Hepatitis A vaccine|
48324841|NCT05093998|DRUG|AV5080|oral hard gelatin capsules
48324842|NCT05093998|OTHER|Placebo|Hard gelatin capsules with a white body
48648979|NCT03019263|DIETARY_SUPPLEMENT|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
48324843|NCT04875949|PROCEDURE|Immunoabsorption/plasmapheresis procedure|
48648980|NCT03019263|OTHER|Control|Nutritional counseling
48648981|NCT02957019|DRUG|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
48648982|NCT02957019|DRUG|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
48648983|NCT02957019|DRUG|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
48648984|NCT01834378|BEHAVIORAL|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
48648985|NCT01834378|BEHAVIORAL|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
48648986|NCT05802537|BEHAVIORAL|Home-based exergame program|The home-based exergame program was conducted using the Nintendo Switch and Ring Fit Adventure program at participants' homes. The program included a 10-minute warm-up, 30 minutes of main exercise, and a 10-minute cool-down, lasting a total of 50 minutes per session. Sessions were held three times per week for eight weeks. The exercises targeted lower extremity strength, balance, and flexibility and included yoga, leg exercises (e.g., squats, knee lifts), and other activities performed in a gamified virtual environment. Participants received guidance on using the console, and family members were involved to support proper execution of the exercises.
48648987|NCT05802537|BEHAVIORAL|Online education on fall prevention and musculoskeletal health management|The online education intervention consisted of weekly sessions conducted for 50 minutes over an eight-week period, focusing on fall prevention and musculoskeletal health management. Participants joined the sessions via a video-conference platform. The content covered education on aging, musculoskeletal disorders, fall prevention strategies, and understanding falls and fractures. These sessions aimed to enhance participants' awareness and knowledge, thereby helping them adopt preventive behaviors.
48648988|NCT06570057|BEHAVIORAL|Participatory, learning and Action (PLA) Based intervention|An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
47971097|NCT03542474|BEHAVIORAL|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
48648989|NCT06662513|OTHER|No Intervention: Observational Cohort|No intervention - retrospective observational study
48119692|NCT00388661|DRUG|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
48324844|NCT04480242|DRUG|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
48324845|NCT04480242|DRUG|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
48324846|NCT04480242|DRUG|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
48324847|NCT04480242|DRUG|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
48324848|NCT04480242|BEHAVIORAL|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
48324849|NCT03513250|DRUG|hyoscine-n-butylbromide|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
48119693|NCT00388661|DRUG|Placebo comparator|Placebo comparator
47971098|NCT03996252|DRUG|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
48119694|NCT00554736|BIOLOGICAL|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
48119695|NCT02308319|DRUG|Tenofovir disoproxil fumarate|300mg q.d. per oral
48119696|NCT02576613|OTHER|MPP-S|\> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
48119697|NCT02576613|OTHER|TAU|standard medical treatment without structured psychotherapeutic intervention
48119698|NCT00823225|PROCEDURE|standard therapy|wound debridement, moist wound dressing
48119699|NCT00823225|DRUG|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~\> 2,5g/l 1 000 000 IU, \< 2,5g/l 500 000 IU"
48119700|NCT02773303|DEVICE|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
48119701|NCT02773303|DEVICE|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
48324850|NCT03513250|DRUG|control group|an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
48648990|NCT01313325|OTHER|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
48648991|NCT06673706|OTHER|Front-of-package label|Participants will see packaged food-and-beverage items displayed with labels as specified by their assigned group
48648992|NCT04668599|OTHER|Cardiopulmonary rehabilitation|Patients will undergo standardized cardio-pulmonary rehabilitation program.
48648993|NCT02062346|DRUG|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
48648994|NCT02062346|DRUG|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
48648995|NCT02062346|DRUG|Placebo|Intravenous infusion of saline
48119702|NCT05001529|BIOLOGICAL|anti IL5 receptor antibodies|Subjects with severe uncontrolled asthma will be assigned to treatment with Omalizumab (anti Ig E antibodies) or Mepolizumab (anti IL-5 antibodies) according to medical advice and standardized protocols for asthma treatment.
48119703|NCT04816799|BEHAVIORAL|Startle Adjuvant Rehabilitation Therapy (START)|Exposure to loud acoustic stimulus during training of motor task (in this case speech).
48119704|NCT03731377|DRUG|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
48648996|NCT01946646|DRUG|S-1-CCRT|
48648997|NCT04164186|OTHER|Automatic detection and segmentation of NSCLC tumors|an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.
47971099|NCT03996252|DRUG|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
47971100|NCT01452828|DRUG|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
48119705|NCT05757388|DRUG|Parecoxib + paracetamol|Administers after induction of anesthesia.
48119706|NCT05757388|DRUG|Normal saline|Administers after induction of anesthesia.
48324851|NCT00505895|DRUG|Melphalan|Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
48324852|NCT00505895|DRUG|Fludarabine|30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
48324853|NCT00505895|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
48324854|NCT00505895|DRUG|Rituximab|375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
48324855|NCT02892838|DEVICE|mobile bearing knee system for total knee arthroplasty|
48648998|NCT02411851|DRUG|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
48648999|NCT02411851|OTHER|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
48649000|NCT02769416|OTHER|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
47971101|NCT01452828|DRUG|TR-701 FA|Two separate infusions of 200 mg
48649001|NCT04013854|DRUG|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
48649002|NCT04013854|DRUG|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
47971102|NCT01452828|DRUG|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
48324856|NCT02892838|DEVICE|fixed bearing total knee prosthesis|
48324857|NCT04740736|PROCEDURE|Saline Infusion|Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
48324858|NCT04520828|OTHER|postural repositioning|The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
48324859|NCT03031548|DEVICE|Point-of-care ultrasound exam|No intervention
48324860|NCT03031548|RADIATION|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
48649003|NCT06670677|OTHER|Lifestyle survey completion|For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
48649004|NCT06670677|OTHER|Unlimited on-demand blood pressure measurements with G2C|For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated
48649005|NCT06670677|OTHER|Continual blood pressure measurements with G1|For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.
48649006|NCT05802849|DRUG|Acetazolamide|Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
48649007|NCT06674044|GENETIC|Atorvastatin|Atorvastatin 10mg once a day for 1 month
48649008|NCT05633056|BEHAVIORAL|Adherence support intevention|Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.
47971103|NCT01331447|DRUG|exemestane|25 mg tablet
48649009|NCT04007731|DIETARY_SUPPLEMENT|DrRip - high protein, high fibre and creatine load|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
48649010|NCT04007731|DIETARY_SUPPLEMENT|Voltage energy bar|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
47971104|NCT06204744|OTHER|Home-based GRASP program|The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
48649011|NCT02196974|PROCEDURE|cryobiopsy|
48649012|NCT02117271|DEVICE|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
48649013|NCT02117271|OTHER|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
48649014|NCT05277935|DEVICE|Use of the WeCancer app combined with the smartwatch.|To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
47971105|NCT06204744|OTHER|Conventional occupational therapy home program|The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
48324861|NCT05368129|PROCEDURE|Balloon dilation|Balloon dilation was performed after DES implantation.
48324862|NCT03922633|DRUG|E3112|Intravenous infusion.
48324863|NCT03922633|OTHER|Placebo|Intravenous infusion.
48324864|NCT02131012|DRUG|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
48324865|NCT02483689|DRUG|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
48324866|NCT02483689|OTHER|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
48324867|NCT02483689|DRUG|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
48119707|NCT05289258|BEHAVIORAL|Neuropsychological treatment|combination of the programs tested by (Von Ah et al. 2012). These programs are, on the one hand, a cognitive training adapted from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) (Jobe et al., 2001) and, on the other, a processing speed training using the Insight program (from Posit Science) (Mahncke et al., 2006). The first consists of teaching patients memorization techniques, and the second consists of a series of exercises on information processing of varying difficulty. These exercises automatically adjust your difficulty to maintain an 85% rate of return. Treatment is carried out in groups of 10 cancer survivors. It consists of 10 weekly sessions of 2 hours each (the first hour for memory training and the second for processing speed exercises). In order to improve the adherence to treatment of the participants, emails and telephone text messages will be sent with reminders of appointments and tasks to be performed.
48489115|NCT03639974|OTHER|PEP in a blow-bottle device|A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.
48489116|NCT03639974|OTHER|EPAP|The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.
48489117|NCT03639974|OTHER|conventional physiotherapy|Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
48489118|NCT04560465|DRUG|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
48489119|NCT00546572|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
48489120|NCT00546572|BIOLOGICAL|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
48649015|NCT00592280|DRUG|Two-Layer Method pancreas preservation system drug|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
48649016|NCT00592280|DEVICE|Two-Layer Method pancreas preservation system device|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
48649017|NCT06671548|DRUG|Relugolix|"* Relugolix (40 mg) tablet administered orally once daily；~* megestrol acetate (1 mg) administered orally once daily；~* medroxyprogesterone acetate (2 mg) administered orally once daily"
48649018|NCT06671548|DRUG|Relugolix placebo|"Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor."
48649019|NCT06160778|DRUG|Ketorolac Tromethamine|Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
48649020|NCT06160778|DRUG|Morphine Sulfate|Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
48649021|NCT06160778|DRUG|normal saline|Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
48649022|NCT06160778|DRUG|Normal saline|Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
48649023|NCT01507103|BIOLOGICAL|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
48649024|NCT01507103|DRUG|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
48649025|NCT01507103|OTHER|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
48324868|NCT02483689|OTHER|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
48324869|NCT04417114|DRUG|Rosuvastatin|Statin
48324870|NCT02878629|DEVICE|Mandibular Advancement Devices|
48324871|NCT03489993|DIAGNOSTIC_TEST|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
48324872|NCT03489993|DIAGNOSTIC_TEST|FGF23 and klotho|Measured using ELISA's.
48324873|NCT00776399|DEVICE|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
48324874|NCT02219087|DRUG|Liposomal bupivacaine|
48324875|NCT02219087|DRUG|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
48324876|NCT00223691|DRUG|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
48324877|NCT00223691|DRUG|Acarbose|25-100 mg, PO. Single dose.
48324878|NCT00223691|DRUG|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
48324879|NCT00223691|DRUG|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
48324880|NCT00223691|DRUG|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
48324881|NCT00223691|DRUG|placebo|PO.Single dose.
48324882|NCT00223691|DRUG|Modafinil|50-400 mg PO. Single dose
48324883|NCT00223691|DRUG|Octreotide|5-50 µg, S.C. Single dose.
48324884|NCT00223691|OTHER|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
48324885|NCT00223691|DRUG|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
48324886|NCT00223691|DRUG|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
48324887|NCT00223691|DRUG|Tranylcypromine|5 - 40 mg PO. Single dose
48324888|NCT00223691|DRUG|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
48324889|NCT00223691|DRUG|Celecoxib|50-200 mg PO. Single dose
48649026|NCT02389738|DRUG|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
48649027|NCT02389738|DRUG|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
48324890|NCT00223691|DRUG|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
48649028|NCT02389738|DEVICE|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
48324891|NCT00223691|DRUG|Methylphenidate|5 or 10 mg PO. Single dose.
48649029|NCT01485198|PROCEDURE|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
48649030|NCT01485198|DRUG|Acetaminophen|Acetaminophen (750mg orally TID) administration
48649031|NCT05642975|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
48324892|NCT00223691|DRUG|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
48324893|NCT00223691|DRUG|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
48324894|NCT00223691|DRUG|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
48324895|NCT00223691|DIETARY_SUPPLEMENT|Bovril|6-10 g, PO. Single dose.
48324896|NCT00223691|DRUG|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
48324897|NCT00223691|DRUG|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
48324898|NCT00223691|DRUG|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
48324899|NCT00223691|DEVICE|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
48324900|NCT00223691|DEVICE|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
48324901|NCT03620812|DIETARY_SUPPLEMENT|rapeseed or soy protein or no protein|25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
48324902|NCT04082702|BEHAVIORAL|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (\~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
48324903|NCT04082702|BEHAVIORAL|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
48489121|NCT04928534|DIAGNOSTIC_TEST|Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination|"1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination"
47971106|NCT03078660|BEHAVIORAL|Smartphone Application|The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
48489122|NCT00004135|BIOLOGICAL|filgrastim|
47971107|NCT03078660|BEHAVIORAL|Traditional Nutritional Counseling|Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
47971108|NCT05948696|BEHAVIORAL|Horticultural group therapy.|Estimated 10 persons with schizophrenia who attend to a 12-week horticultural group therapy will be assessed for their experience about the program.
47971109|NCT03059602|OTHER|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
47971110|NCT03223597|DRUG|Radium-223 dichloride|Registry of patients who receive Radium-223.
47971111|NCT01103648|DRUG|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
47971112|NCT01103648|DRUG|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
47971113|NCT01103648|DRUG|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study."
47971114|NCT06281106|DRUG|Deucravacitinib|Daily drug intake for 4 weeks.
47971115|NCT04664712|DIETARY_SUPPLEMENT|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) \[17, 18\], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
48489123|NCT00004135|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48489124|NCT00004135|DRUG|cyclophosphamide|
48489125|NCT00004135|DRUG|fludarabine phosphate|
48489126|NCT00004135|PROCEDURE|peripheral blood stem cell transplantation|
48489127|NCT02213913|DRUG|lenalidomide|Given PO
48489128|NCT02213913|DRUG|etoposide|Given IV
48489129|NCT02213913|DRUG|prednisone|Given PO
48489130|NCT02213913|DRUG|vincristine sulfate|Given IV
48489131|NCT02213913|DRUG|doxorubicin hydrochloride|Given IV
48489132|NCT02213913|DRUG|cyclophosphamide|Given IV
47971116|NCT04664712|DEVICE|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
47971117|NCT05464069|DEVICE|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
47971118|NCT00844831|DRUG|Lubiprostone|24 mcg bid for 28 days
47971119|NCT04649060|DRUG|Melflufen|Powder for solution for i.v. infusion
47971120|NCT04649060|DRUG|Dexamethasone|Oral tablets
48324904|NCT04465123|DRUG|Spironolactone or hydrochlorothiazide|"Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours."
48324905|NCT04465123|DRUG|Placebo|"Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours."
48324906|NCT03750071|BIOLOGICAL|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
48649032|NCT06426927|OTHER|Colorectal Cancer Educational Videos in Spanish|Enrolled participants will watch three educational videos on Colorectal Cancer (CRC) in Spanish. Knowledge on CRC symptoms, risk factors, facts, screening and treatment will be assessed before and immediately after the educational video and at 30 +/- 7 days. In addition, the association between increase in CRC knowledge and willingness to participate in Cancer Clinical Trials (CCT) will be explored.
48649033|NCT01520103|DRUG|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
48649034|NCT01520103|DRUG|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
48649035|NCT06675136|PROCEDURE|Biopsy|Undergo tumor biopsy
47971121|NCT04649060|DRUG|Daratumumab|Solution for s.c. injection
48324907|NCT03750071|BIOLOGICAL|Avelumab|Monoclonal anti-PD-L1 Antibody
48324908|NCT03348241|DRUG|Gum Arabic|Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
48324909|NCT03348241|DRUG|Chemotherapy|Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
48324910|NCT03348241|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
48649036|NCT06675136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47971122|NCT00465205|DRUG|Valacyclovir|500mg oral twice daily
47971123|NCT00465205|DRUG|Matching Placebo|500 mg oral twice daily
48324911|NCT01479374|DRUG|AL-4943A ophthalmic solution|
48324912|NCT01479374|DRUG|AL-4943A vehicle|Inactive ingredients used as placebo
48324913|NCT01479374|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
48324914|NCT03528889|PROCEDURE|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
48324915|NCT03052439|OTHER|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
48324916|NCT03314558|OTHER|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
48324917|NCT00629525|DRUG|RAD001|RAD001 at a dose of 10 mg PO daily
48340097|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose|3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 Group in Stage 2 (Africa).
48489133|NCT02213913|BIOLOGICAL|rituximab|Given IV
48489134|NCT02213913|OTHER|quality-of-life assessment|Ancillary studies
48489135|NCT02213913|OTHER|laboratory biomarker analysis|Correlative studies
48649037|NCT06675136|PROCEDURE|Computed Tomography|Undergo CT
48649038|NCT06675136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48649039|NCT06675136|OTHER|Medical Device Usage and Evaluation|Given PIPAC
47971124|NCT05173883|DRUG|injection ，CU-20401|Subcutaneous injection，cohort A 6 sites
47971125|NCT05173883|DRUG|injection ，placebo|Subcutaneous injection，just one site
47971126|NCT02762357|DEVICE|Novosyn® Quick|Episiotomy closure
47971127|NCT01535547|DRUG|isavuconazole|oral
47971128|NCT01535547|DRUG|tacrolimus|oral
47971129|NCT03594721|OTHER|Marvel AM|Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
48649040|NCT06675136|DRUG|Nab-paclitaxel|Given IP
48649041|NCT06675136|DRUG|Paclitaxel|Given IV
48649042|NCT06675136|OTHER|Questionnaire Administration|Ancillary studies
48649043|NCT06675136|BIOLOGICAL|Ramucirumab|Given IV
48649044|NCT00458705|DRUG|bortezomib|
48649045|NCT00458705|DRUG|dexamethasone|
48649046|NCT00458705|DRUG|pegylated liposomal doxorubicin hydrochloride|
48649047|NCT00458705|DRUG|thalidomide|
48649048|NCT06661421|DEVICE|Dry Needling|This intervention combines Dry Needling Therapy (DNT) with routine physical therapy for children with spastic cerebral palsy. The experimental group will receive DNT alongside physical therapy, while the control group will undergo only physical therapy. Routine Physical Therapy includes a warm-up, stretching, and strengthening exercises like hamstring stretches and squats, adjusted over a month with increasing intensity. Dry Needling targets the gastrocnemius muscle using a fast-in, fast-out technique with sterile needles, applied weekly for 10 weeks. This combined approach aims to reduce spasticity, improve mobility, and enhance range of motion, distinguishing it from standard therapies.
48649049|NCT06661421|OTHER|Cerebral Palsy conventional Treatment|Sessions will include a 5-minute warm-up, stretching, and strengthening exercises. Hamstring stretches will be done with the child supine, one leg flat, and the opposite hip flexed to 90°. Active knee extension will be held for 5 seconds, followed by a 40-second assisted stretch, repeated five times. If a short psoas is detected, a prone psoas stretch will involve assisted hip extension for 5 seconds, followed by a 40-second hold, repeated five times. Strengthening exercises like squats, heel rises, and step-ups with a loaded backpack will target the lower extremities. The program will last one month, with three sessions per week, focusing on hamstring stretches and progressive resistance exercises.
47971130|NCT01190774|BEHAVIORAL|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
48324918|NCT03554070|PROCEDURE|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
48324919|NCT03554070|DEVICE|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
47971131|NCT01190774|BEHAVIORAL|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
47971132|NCT06342466|DRUG|Bortezomib|Bortezomib 1.3mg/m2 sc weekly
47971133|NCT06342466|DRUG|Pomalidomide|4mg per day taken orally on 1-21 of repeated 28-day cycles
47971134|NCT06342466|DRUG|Dexamethasone|Dexamethasone 20mg-40mg weekly
47971135|NCT04425915|BIOLOGICAL|Convalescent Plasma|Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients
47971136|NCT04425915|OTHER|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
47971137|NCT00023504|BIOLOGICAL|Pneumovax|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
47971138|NCT00023504|BIOLOGICAL|Rabavert|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
47971139|NCT00023504|BIOLOGICAL|Prevnar|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
47971140|NCT00023504|BIOLOGICAL|Tetanus diphtheria toxoid|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
47971141|NCT03849196|DRUG|2L PEG-Asc|PEG-Asc powder
48324920|NCT02781350|OTHER|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
48489136|NCT01179126|PROCEDURE|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
48649050|NCT04839926|DRUG|0.5mg CY150112|single oral CY150112 while fasting on day 1.
48649051|NCT04839926|DRUG|1.5mg CY150112|single oral CY150112 while fasting on day 1.
48649052|NCT04839926|DRUG|4.5mg CY150112|single oral CY150112 while fasting on day 1.
47971142|NCT03849196|DRUG|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
47971143|NCT03849196|DRUG|1L PEG-Asc|PEG-Asc powder
47971144|NCT02031068|BEHAVIORAL|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~1. Sub-maximal aerobic training for up to 15 minutes~2. Light coordination and sport-specific exercises for up to 10 minutes~3. Visualization and imagery techniques~4. Home program~A physiotherapist will supervise the rehabilitation."
47971145|NCT02031068|BEHAVIORAL|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
47971146|NCT00002136|DRUG|Tecogalan sodium|
47971147|NCT02949037|OTHER|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
47971148|NCT02216591|DEVICE|Active Cognitive Training (ACT)|
48649053|NCT04839926|DRUG|10mg CY150112|single oral CY150112 while fasting on day 1.
47971149|NCT02216591|DEVICE|Control (CON)|
47971150|NCT00071474|PROCEDURE|shamanic healing|
47971151|NCT05243836|DEVICE|S.T.O.P® F2|Ocufilcon D, 55% water
47971152|NCT05243836|DEVICE|S.T.O.P® DT|Ocufilcon D, 55% water
47971153|NCT05243836|DEVICE|MiSight®|Omafilcon A (60% water)
47971154|NCT00064116|BIOLOGICAL|rituximab|Rituximab 375 mg/m² i.v. day 1
47971155|NCT00064116|DRUG|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
47971156|NCT04101877|DRUG|Bevacizumab Injection|25 mg/ml
47971157|NCT04101877|DRUG|Aflibercept Injection|40 mg/ml
48649054|NCT04839926|DRUG|18mg CY150112|single oral CY150112 while fasting on day 1.
47971158|NCT05574699|OTHER|Social Risk Score and CDS Tool|A social risk score, which helps to identify patients with high social needs based on the risk score in the CDS tool and a closed loop referral, which helps to refer the patients to CBOs, if needed.
47971159|NCT05574699|OTHER|Standard of Care|Currently available process for screening, assessment, and addressing social needs in the clinic setting, which may include providing a sheet of various educational resources, or a list of organizations that can address the identified social need.
47971160|NCT00492037|DRUG|YM087 oral|
47971161|NCT00655044|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
47971162|NCT01414010|DIETARY_SUPPLEMENT|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
47971163|NCT01414010|DIETARY_SUPPLEMENT|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
47971164|NCT01414010|DRUG|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
48649055|NCT04839926|DRUG|24mg CY150112|single oral CY150112 while fasting on day 1.
47971165|NCT02260700|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
47971166|NCT02260700|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
47971167|NCT02260700|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
47971168|NCT05642208|DRUG|Dupilumab step-down|step down dupilumab injections
48324921|NCT02781350|DIETARY_SUPPLEMENT|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
48324922|NCT01476748|DEVICE|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
48649056|NCT03288259|PROCEDURE|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
48649057|NCT03288259|DRUG|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
48649058|NCT03115515|DRUG|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
48649059|NCT06154850|OTHER|Immersive virtual reality|Oculus Quest 2 will be used with NatureTrek application for 10 minutes.
48649060|NCT06154850|OTHER|Non-immersive virtual reality|Patients will watch a video including scenes from NatureTrek application on a screen.
48649061|NCT06501105|DEVICE|WOUNDCHEK Bacterial Status|Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.
48649062|NCT05653011|OTHER|Endoscopic biopsy|"When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.~In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions."
48649063|NCT06134999|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
48649064|NCT06134999|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
48649065|NCT03768050|OTHER|Advanced care for frail elderly|"Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning\&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network."
48649066|NCT00050011|DRUG|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
48649067|NCT00050011|DRUG|Letrozole|Participants received Letrozole 2.5 mg daily.
48324923|NCT03046342|DIAGNOSTIC_TEST|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
48324924|NCT01958125|DEVICE|gammaCore|Vagal stimulation
48340098|NCT05480800|BIOLOGICAL|Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose|3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
48649068|NCT06174272|BEHAVIORAL|Transitional Care Program|Intensive monitoring post discharge for cirrhosis and fluid overload
48649069|NCT06482853|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
48649070|NCT06482853|DRUG|Saline|Saline will be used as the placebo comparator.
48324925|NCT00556192|DRUG|rituximab|"1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
48324926|NCT00599027|DRUG|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
48324927|NCT00599027|DRUG|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
48649071|NCT05360602|DIETARY_SUPPLEMENT|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
48649072|NCT05360602|DRUG|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
48649073|NCT06672133|DRUG|Adebrelimab|Given：IV
48649074|NCT06672133|RADIATION|Radiation Therapy|Undergo radiation therapy
48649075|NCT06377592|OTHER|Sample collection without intervention|No Intervention
48649076|NCT04361331|DRUG|Lenvatinib combined with gemox|Arm2: Lenvatinib + gemox
48649077|NCT04361331|DRUG|Toripalimab combined with lenvatinib|Toripalimab combined with lenvatinib
48649078|NCT04351672|BEHAVIORAL|Early Time-Restricted Feeding|Eat between 8 am and 4 pm for two weeks
48649079|NCT04351672|BEHAVIORAL|Late Time-Restricted Feeding|Eat between 1 pm and 9 pm for two weeks
48649080|NCT00003907|DRUG|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
48649081|NCT00003907|DRUG|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
48649082|NCT00003907|DRUG|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
48324928|NCT03541655|DRUG|Bupivacaine HCl|0.25% Bupivacaine HCl
47971169|NCT06141109|DRUG|Sintilimab 200mg+MB07133 600mg|"1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects，the administration method is as 1."
47971170|NCT03550898|DIAGNOSTIC_TEST|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
47971171|NCT03779724|OTHER|exercises|
48324929|NCT03541655|DRUG|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
47971172|NCT01299792|OTHER|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
47971173|NCT04258384|OTHER|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
48324930|NCT05508685|OTHER|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
48324931|NCT05508685|OTHER|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
48324932|NCT05508685|OTHER|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
48489137|NCT01179126|PROCEDURE|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
48489138|NCT04412148|DRUG|Triamcinolone Acetonide|intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions
48489139|NCT04412148|OTHER|saline|intralesional injection of saline
48489140|NCT00570882|DRUG|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
48489141|NCT00570882|DRUG|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
48489142|NCT04284514|DRUG|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
48489143|NCT04284514|DRUG|Placebo Ophthalmic Solution|Matched vehicle-control
48489144|NCT03805308|PROCEDURE|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
48489145|NCT00416026|BEHAVIORAL|Educational/Counseling/Training|
48489146|NCT03265067|DEVICE|autoRIC|Application of the autoRIC device
48489147|NCT00438477|DRUG|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
48489148|NCT00438477|PROCEDURE|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
48489149|NCT00438477|RADIATION|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
48324933|NCT05508685|OTHER|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
48324934|NCT02731807|DIETARY_SUPPLEMENT|Dose A: TA-65 24mg, powder|
48324935|NCT02731807|DIETARY_SUPPLEMENT|Dose B: TA-65, 8mg, powder|
48649083|NCT00003907|PROCEDURE|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
48649084|NCT05702489|DRUG|ZX-7101A|a drug to treatment influenza in Chinese adults
48649085|NCT05112926|DEVICE|Embosphere Microspheres|Embosphere Microspheres are 100-300μm small, compressible, hydrophilic, biocompatible spheres made of acrylic polymer and porcine-derived gelatin used for embolization of geniculate artery.
48649086|NCT05308719|DEVICE|High Flow Nasal Therapy|High Flow Nasal Oxygen (Airvo2 Device)
48119708|NCT05289258|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (PU).|This intervention focuses on a deficit in emotional regulation common in all emotional disorders (ED). Therefore, it focuses on the adaptive value of emotions and promotes tolerance to intense emotions as well as the identification and modification of dysfunctional emotional regulation strategies. Patients receive 10 group therapy sessions (3-5 cancer survivors per group) with all PU modules (Barlow et al., 2011). The Spanish version of the therapist's guide and the patient's workbook are used (Barlow et al., 2015). All patients receive the workbook to help them read the contents of each session, do the recommended exercises between sessions, and to help them once the treatment is finished. The treatment lasts 10 weeks (one session a week). As in the previous intervention group, emails and telephone text messages will be used with reminders of appointments and tasks to be carried out.
48324936|NCT02731807|DIETARY_SUPPLEMENT|Dose C: TA-65 3.2mg, capsule|
48324937|NCT02731807|DIETARY_SUPPLEMENT|Dose D: TA-65 8mg, capsule|
48324938|NCT02731807|DIETARY_SUPPLEMENT|Dose E: TA-65 32mg, capsule|
48324939|NCT00736788|DRUG|AZD1704|single dose oral suspension, 4 different dose levels
48489150|NCT01944787|OTHER|Routine|IV Hydration at 125 cc hour
48649087|NCT02483910|BEHAVIORAL|Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
48649088|NCT02483910|BEHAVIORAL|Standard of care delivered via telehealth (e.g., Zoom or WebEx)|Usual care including speech therapy in school, community or both
47971174|NCT02024815|RADIATION|External Beam radiotherapy|External Beam radiotherapy
48119709|NCT05289258|BEHAVIORAL|Waitlist group|The control group will receive the Adapted Mnesic Cognitive Training (ACTIVE) (Jobe, et al., 2001), as well as the Insight (Posit Science) program (Mahncke et al., 2006) once the interventions in groups 1 and 2 have been completed.
48119710|NCT03366870|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
47971175|NCT02364752|PROCEDURE|Blood Draw|
48324940|NCT00736788|DRUG|Placebo|single dose oral suspension
48324941|NCT06197542|OTHER|Active Release Technique|active TrP was identified, and sustained and constant pressure was applied .for stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.
48324942|NCT06197542|OTHER|Instrument Assisted Soft Tissue Mobilization|The therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin. .
48324943|NCT04180501|COMBINATION_PRODUCT|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
48324944|NCT05467930|OTHER|Survey|Survey completion by the participant to collect information about health and social experience
48324945|NCT05467930|OTHER|Medical History Review|Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
47971176|NCT02364752|PROCEDURE|Loop Diuretic Withdrawal/Salt Load|
47971177|NCT05823961|DEVICE|Cross-linked hyaluronic acid eye drops|Cross-linked hyaluronic acid (CLHA)-based eyedrops
47971178|NCT04277416|DEVICE|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
47971179|NCT00940225|DRUG|Cabozantinib|
47971180|NCT00940225|DRUG|Placebo|
48324946|NCT05467930|OTHER|Sample Collection|Collection of nasal and blood samples
48324947|NCT04573205|DRUG|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
48489151|NCT01944787|OTHER|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
48489152|NCT03174106|DEVICE|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
48649089|NCT05609786|BEHAVIORAL|Personalized safety planning tool|The myPlan Kenya app is a web-based safety planning tool that is secure, private, free and personalized to the user. The app includes multiple, evidence-based modules: Strategies (safety strategies tailored to the user's needs and violence experience); Resources (referrals to local health, safety and justice resources and services); About You (questionnaires that help the user assess their relationship safety and tailor their Strategies, including My Relationship, Red Flags, My Safety, My Priorities); Understanding (knowledge sections that share information on relationships and violence, including Healthy Relationships, Harmful Beliefs About Abuse, About Violence).
48324948|NCT05575284|PROCEDURE|Robot-assisted urological surgery|Patient with programmed robot-assisted urological surgery
48324949|NCT04683107|OTHER|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
47971181|NCT01336764|BEHAVIORAL|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
48324950|NCT04683107|OTHER|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
48324951|NCT04536649|RADIATION|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
48324952|NCT03264794|DRUG|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
48324953|NCT03264794|DRUG|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
48324954|NCT03264794|DRUG|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
48324955|NCT03297216|DRUG|17P|Synthetic progestin
48324956|NCT03297216|OTHER|Placebo|Non-active placebo comparator
48489153|NCT05410366|OTHER|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
48489154|NCT00517959|RADIATION|Stereotactic Conformal radiotherapy|SCRT
48489155|NCT00517959|RADIATION|Conventional radiotherapy|
47971182|NCT01336764|BEHAVIORAL|Control|Unguided listening to radio/music.
47971183|NCT01622504|DRUG|MVP005|2 mg single dose administered intranasally
48324957|NCT01594333|DRUG|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
48489156|NCT00375570|DRUG|ME-609|Topical treatment 5 times daily for 5 days
48489157|NCT02276768|DRUG|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
48489158|NCT02276768|DRUG|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
47971184|NCT01622504|DRUG|MVP005|4 mg single dose administered intranasally
47971185|NCT01622504|DRUG|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
47971186|NCT01216306|BEHAVIORAL|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
47971187|NCT01250275|OTHER|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
48324958|NCT01594333|DRUG|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
48489159|NCT02276768|DRUG|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
47971188|NCT01250275|OTHER|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
47971189|NCT01250275|OTHER|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
48324959|NCT01835613|OTHER|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
48324960|NCT05298644|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
48324961|NCT05298644|DRUG|Active Comparator|Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
48324962|NCT00570531|DRUG|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
48324963|NCT00570531|DRUG|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
48489160|NCT02276768|DRUG|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
48489161|NCT02276768|OTHER|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
48489162|NCT04798365|BEHAVIORAL|Intervention group|medical education and distribution of educations materials
48649090|NCT00140920|DRUG|MK0966; rofecoxib|
48324964|NCT00570531|DRUG|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
48324965|NCT00570531|DRUG|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
47971190|NCT01250275|OTHER|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
48119711|NCT03366870|BEHAVIORAL|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
48324966|NCT00570531|RADIATION|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
48324967|NCT00570531|PROCEDURE|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
48324968|NCT04818528|OTHER|Constraint Induced Movement Therapy and Routine Physical Therapy|"Intensive, graded practice of the paretic upper limb to enhance task-specific use of the affected limb. Constraint or forced use therapy, with the non-paretic upper limb contained in a mitt to promote the use of the impaired limb during 90% of the total hours awake. Adherence enhancing behavioral methods designed to transfer the gains obtained in the clinical setting or the laboratory to patients' real-world environment (ie, a transfer package).~As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization."
48324969|NCT04818528|OTHER|Routine Physical Therapy|As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
48324970|NCT00642018|DRUG|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
48324971|NCT00642018|DRUG|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
48324972|NCT00642018|DRUG|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
48119712|NCT03196310|DRUG|Platelet Concentrate|Platelet Rich plasma
48324973|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Plasma
48324974|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Serum
48324975|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Urine
48324976|NCT04368455|BEHAVIORAL|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
48324977|NCT04368455|BEHAVIORAL|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
48324978|NCT03286712|DRUG|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
48324979|NCT00433446|BIOLOGICAL|CNTO 328|
48324980|NCT03215524|BIOLOGICAL|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
48324981|NCT03215524|BIOLOGICAL|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
48324982|NCT00234728|DEVICE|Occlusive dressing|
48324983|NCT00507598|OTHER|No intervention|Correlative study collecting serum and tissue samples
48324984|NCT03749798|PROCEDURE|Cataract surgery|Intraoperative wavefront measurements will be carried out during cataract surgery
48649091|NCT00140920|DRUG|Comparator: diclofenac 2x 75 mg|
47971191|NCT01250275|OTHER|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
47971192|NCT01250275|OTHER|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
47971193|NCT01250275|OTHER|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
48324985|NCT03743233|DEVICE|Hand file|A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
48324986|NCT03743233|DEVICE|Reciprocating|Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
48324987|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
48324988|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
48489163|NCT05314894|BEHAVIORAL|Education|Giving training to the students in the initiative group to quit smoking in three sessions, sending messages via whatsapp program and telephone counseling
47971194|NCT05503615|OTHER|Observational|No application will be made to the control group.
47971195|NCT05503615|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
47971196|NCT01661621|DRUG|Detrusitol 4 mg QD|Group 1
47971197|NCT01661621|DRUG|Doxazosin 4 mg QD|Group 2
48119713|NCT03196310|DRUG|Corticosteroid injection|Kenalog
48324989|NCT00063583|DRUG|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
48489164|NCT03150355|PROCEDURE|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
48324990|NCT00251875|DEVICE|online health information journal|
48324991|NCT04716153|OTHER|Multifactorial sensory rehabilitation workshops|A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.
48489165|NCT00103038|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
48489166|NCT00103038|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
48489167|NCT00103038|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
48489168|NCT00103038|DRUG|Ferumoxytol|Given IV
48489169|NCT00103038|DRUG|Gadolinium|Given IV
48489170|NCT00103038|PROCEDURE|MRI-Based Angiogram|Undergo MRA
48489171|NCT03255512|DRUG|Vericiguat (BAY1021189)|2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
48489172|NCT03255512|DRUG|Placebo|Matching placebo
48489173|NCT03255512|DRUG|Isosorbide mononitrate (ISMN)|30 mg/tablet or 60 mg/tablet
48489174|NCT04481178|OTHER|Laser (QS, Picosecond laser)|QS-Nd Yag Laser, Picosecond laser
48489175|NCT03022474|BEHAVIORAL|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
48489176|NCT02624726|DRUG|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
48489177|NCT02624726|DRUG|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
48119714|NCT03196310|OTHER|Normal Saline|Control Group - Placebo
48489178|NCT02624726|DRUG|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
48489179|NCT02624726|DRUG|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
48489180|NCT03326674|DRUG|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
48489181|NCT03326674|DRUG|Capecitabine|Capecitabine alone at approved dose
47971198|NCT05710536|OTHER|Formulation X|This formulation containing stem cell secretome and liquorice root extract
47971199|NCT02771054|DRUG|TAF/FTC|Change of nucleoside backbone
47971200|NCT06173921|PROCEDURE|robotic system|Implant placement will be navigated by robotic system based on a digital plan
47971201|NCT06173921|PROCEDURE|Static navigation system|Implant placement will be navigated by static navigation system based on a digital plan
47971202|NCT04804878|PROCEDURE|Collection of blood, tissue, and other biological samples.|Behavioral health assessments, including quality of life.
47971203|NCT04804878|OTHER|Medical Chart Review|Health data abstracted directly from patient's health records
47971204|NCT05086406|OTHER|Combination of Video and Virtual Pre-operative Counseling|Intervention will be a pre-operative counseling video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications.
47971205|NCT03026010|PROCEDURE|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
47971206|NCT03733002|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
47971207|NCT03733002|DRUG|Placebo of AngongNiuhuang pill|This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
47971208|NCT03733002|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke.
47971209|NCT04814134|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
47971210|NCT04814134|OTHER|Standard of care|Available standard treatment
47971211|NCT01302093|DRUG|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
47971212|NCT01302093|DRUG|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
48489182|NCT00302120|PROCEDURE|Contrast-enhanced MR mammography|
48489183|NCT01366092|DRUG|Interleukin-2|Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus
47971213|NCT04547569|BEHAVIORAL|Speech adaptation|Sensorimotor adaptation in speech
47971214|NCT04547569|BEHAVIORAL|Vibrotactile Discrimination|Vibrotactile Discrimination
47971215|NCT04547569|OTHER|fMRI|fMRI measurement of brain activity
47971216|NCT04547569|BEHAVIORAL|Speech production|Speech production task
47971217|NCT04984720|BEHAVIORAL|Smartphone based digital application|Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
48340099|NCT05480800|BIOLOGICAL|Typhoid conjugate vaccine (TCV) full dose|3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses_2 Group in Stage 2 (Africa).
47971218|NCT01177917|OTHER|Infant Formula|
47971219|NCT02495805|PROCEDURE|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
47971220|NCT02495805|PROCEDURE|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
47971221|NCT02254486|DRUG|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
47971222|NCT02254486|DRUG|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
48489184|NCT01949948|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
48489185|NCT01949948|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
48489186|NCT02592109|BEHAVIORAL|Enhanced Counseling using CFR based on Linear Programming|
48489187|NCT01362465|PROCEDURE|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
48489188|NCT01875471|DEVICE|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
48489189|NCT01875471|DEVICE|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
48489190|NCT03499002|OTHER|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
48649092|NCT00498966|DRUG|Perifosine|"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."
48649093|NCT02704000|BEHAVIORAL|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
48649094|NCT00945880|DRUG|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
48119715|NCT05948644|DRUG|TPN171H|TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
48649095|NCT01509404|DRUG|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
48649096|NCT01509404|BIOLOGICAL|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
48119716|NCT01336946|BEHAVIORAL|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
47971223|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
48119717|NCT01336946|BEHAVIORAL|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
48324992|NCT04716153|OTHER|Usual care|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
48489191|NCT03915665|DRUG|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
48489192|NCT03915665|DEVICE|Air-powder|Erythritol powder using air-powder device
48489193|NCT03974750|DEVICE|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
48489194|NCT03149458|OTHER|dance|dance program
48489195|NCT03149458|OTHER|control|upper limb rehabilitation
47971224|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
48489196|NCT01685541|OTHER|Maximum After Visit Summary Content|
48489197|NCT01685541|OTHER|Intermediate After Visit Summary Content|
48649097|NCT01509404|DRUG|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
48649098|NCT04837222|OTHER|No Intervention|This is a non-interventional study.
47971225|NCT04229394|DRUG|2ccPA|"Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1"
47971226|NCT04229394|DRUG|placebo|"A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1"
48489198|NCT01685541|OTHER|Minimum After Visit Summary Content|
47971227|NCT03660267|OTHER|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
48649099|NCT01983670|OTHER|Temporal electrical stimulation|
48649100|NCT05652218|DEVICE|LB-CRT|LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1)
48119718|NCT03244046|BEHAVIORAL|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
48119719|NCT03244046|BEHAVIORAL|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
48119720|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
48489199|NCT01685541|OTHER|Usual AVS|
48649101|NCT05652218|DEVICE|BIV-CRT|BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).
47971228|NCT03660267|OTHER|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
47971229|NCT03660267|OTHER|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
47971230|NCT00217594|DRUG|Alemtuzumab (Campath)|
47971231|NCT00140595|DRUG|rituximab|
47971232|NCT00140595|DRUG|doxorubicin|
47971233|NCT00140595|DRUG|cyclophosphamide|
47971234|NCT02860013|DEVICE|Telemedicine|
47971235|NCT06229990|DRUG|Furosemide Injection|After taking furosemide at 1.5 mg/kg intravenously, if the urine output exceeds 200 mL within 2 hours, the patients are going to withhold CRRT. But if there is no response, the titration of furosemide to 2.5 mg/kg and 3.5 mg/kg every 6 hours is scheduled according to the urine output \>200 mL in 2 hours (not exceeding 250 mg).
47971236|NCT04083053|PROCEDURE|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
48324993|NCT04716153|OTHER|Tests and Questionnaire|fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
48489200|NCT00573157|DRUG|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
48489201|NCT00573157|DRUG|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
48489202|NCT00573157|DRUG|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
48489203|NCT00573157|DRUG|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
48489204|NCT01591889|DRUG|Tinidazole|500 mg tablet
48489205|NCT01591889|DRUG|Tinidazole|500 mg tablet
48489206|NCT04063488|DRUG|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
48489207|NCT02140866|OTHER|Hand Exercise|
48489208|NCT02140866|OTHER|Compensatory Intervention Program (CIP)|
48324994|NCT06414538|OTHER|Digital Mind Map Technique|"Students determined as a result of randomization will be given a pre-test before entering the Family Planning course planned according to the academic calendar. The determined topics will be explained to the students using the digital mind map technique. A post-test will be administered to the students 1 week after the end of the subject and a satisfaction survey of the digital mind map technique will be administered. Permanence test will be applied 35 days after the last test application."
48489209|NCT03046134|BIOLOGICAL|PCV13|Conjugated pneumococcal vaccine
47971237|NCT04083053|PROCEDURE|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
48489210|NCT04431882|PROCEDURE|optic nerve sheath fenestration|A standard medial transconjunctival orbitotomy was performed in all cases under general anesthesia. The medial rectus muscle was disinserted and reflected nasally with 6-0 synthetic polyester suture in typical fashion for eye muscle surgery. A traction suture was then placed through the insertion stump of the medial rectus in a baseball stitch fashion to facilitate abduction of the globe. The pupil was monitored at all times. A custom- made cupped orbital retractor was inserted along the medial scleral wall and used to retract the orbital fat and allow visualization of the optic nerve sheath. Retraction and globe abduction were relaxed if any changes in pupil size were noted. When adequate visualization was achieved, multiple dural sheath fenestrations approximately 3 mm in length. Expulsion of cerebrospinal fluid was invariably observed with the initial incision into the dural sheath.
47971238|NCT02516345|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
48489211|NCT03022708|DEVICE|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
47971239|NCT02516345|BEHAVIORAL|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
47971240|NCT05611398|PROCEDURE|Orthopedic Surgery|A complete retrospective chart review was performed for all the patients' records and included all patients aged 18 years or higher who presented to Arrowhead Regional Medical Center with long bone fractures with Injury Severity Score \<16 and their repair and lactate levels at the time of surgery
47971241|NCT04254471|DRUG|AL3810|5mgQD, 7.5mgQD, 10mgQD
48489212|NCT00762931|DEVICE|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
47971242|NCT04254471|DRUG|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
47971243|NCT04254471|DRUG|Placebo|Placebo
48489213|NCT04147988|OTHER|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
48489214|NCT03035552|BEHAVIORAL|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
48489215|NCT05886439|DRUG|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
47971244|NCT05667545|DRUG|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
47971245|NCT05380804|DIAGNOSTIC_TEST|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
47971246|NCT00719420|DRUG|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
48119721|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
48119722|NCT01042197|RADIATION|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
48119723|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
48119724|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
48119725|NCT01042197|RADIATION|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
48119726|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
48324995|NCT06414538|OTHER|Classic Method Group|After the students in the control group are determined, a pre-test will be conducted before the subject is given training. The same knowledge test will be repeated as a final test after students have received classical course training and completed the subject. Students will be given a retention exam 35 days after the last exam. After the retention test application, the mind map method will be explained to the students in the control group and the determined topics of the course will be explained with the prepared digital mind map technique. In this way, all students participating in the study will also have access to the additional educational materials used.
48324996|NCT03372668|OTHER|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
48324997|NCT05271422|DEVICE|Real Pulse Electrical Stimulation (NuEyne 01)|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
48324998|NCT05271422|DEVICE|Sham Pulse Electrical Stimulation|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
48324999|NCT05474911|DEVICE|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
48340100|NCT05480800|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
48119727|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
48119728|NCT01042197|RADIATION|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
48119729|NCT00362778|DRUG|Insulin|intravenous continuous insulin infusion for 48 hours
48119730|NCT03647969|DRUG|Nivolumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks"
48119731|NCT03647969|DRUG|Ipilimumab|1mg/kg i.v. d1 over 30 minutes every 6 weeks
48119732|NCT03647969|DRUG|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
48119733|NCT03647969|DRUG|FLOT|"Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin\* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~\* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline."
48119734|NCT06554327|DEVICE|Multiplex PCR|In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.
48119735|NCT00738699|DRUG|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
48119736|NCT00738699|DRUG|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
48119737|NCT00738699|DRUG|Paclitaxel|
48119738|NCT01721434|DRUG|Levosimendan|
48119739|NCT01721434|DRUG|Placebo|Similar coloured placebo
48119740|NCT02238483|DRUG|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
48119741|NCT02238483|DRUG|Placebo|Inhaled placebo solution
48325000|NCT05474911|OTHER|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
48325001|NCT05118542|DRUG|Propylthiouracil|PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
48325002|NCT05118542|DRUG|Methimazole|methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
48325003|NCT05128682|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
47971247|NCT00719420|DRUG|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
47971248|NCT02893514|OTHER|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
47971249|NCT02893514|OTHER|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
47971250|NCT01788332|DRUG|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
47971251|NCT01788332|OTHER|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
47971252|NCT01410786|PROCEDURE|Conventional Instrumentation|Standard Oxford surgical instruments
47971253|NCT01410786|PROCEDURE|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
47971254|NCT00739674|DRUG|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB"
47971255|NCT00739674|BEHAVIORAL|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension \[DASH\]) including:~* Healthy diet~* Reduction in sodium intake to less than 2300 mmol/day~* Low alcohol consumption (less than 2 standard drinks/day)"
47971256|NCT00871702|GENETIC|CD34-TK75 transduced donor lymphocytes|
47971257|NCT00871702|RADIATION|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
47971258|NCT01264497|DRUG|TH9507|1 and 2 mg, sc daily for 12 weeks
47971259|NCT03290898|BEHAVIORAL|High Intensity Interval Training|Training (HIIT)
47971260|NCT01680705|OTHER|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
47971261|NCT00795106|DRUG|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
47971262|NCT00795106|DRUG|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
47971263|NCT01004627|PROCEDURE|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
48325004|NCT05541484|DRUG|SGLT2 inhibitor|See above.
48325005|NCT05541484|DEVICE|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
47971264|NCT03801486|OTHER|Experimental: Sprouted Chickpea Flour|255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
47971265|NCT03801486|OTHER|Control: Semolina Flour|255g of pasta with 100% semolina flour (SEM100) with butter.
48119742|NCT04559555|DRUG|Nilotinib|The compassionate use dose of nilotinib is 400 mg orally twice daily and should not be taken with food
48325006|NCT01692912|OTHER|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
48119743|NCT00721565|BEHAVIORAL|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
48119744|NCT02622984|BEHAVIORAL|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
48325007|NCT05269550|RADIATION|High Intermediate Risk Patients|Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)
48325008|NCT05269550|RADIATION|High Risk or Very High-Risk Patients|Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the start of radiotherapy (concurrent plus adjuvant)
48325009|NCT02887859|BIOLOGICAL|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
48325010|NCT02072382|DRUG|Metformin|metformin 850mg twice a day for eight weeks
48325011|NCT02072382|DRUG|Placebo|
48489216|NCT05886439|DRUG|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
48489217|NCT05886439|DRUG|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
48649102|NCT04097665|DEVICE|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1\*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
48649103|NCT01260311|DRUG|Fesoterodine|Any dose of Fesoterodine
48325012|NCT03172481|DRUG|PRC-063 oral capsules|Daily dose
48325013|NCT03172481|DRUG|Placebo oral capsules|Daily dose
48649104|NCT04691115|DRUG|AM1476|AM1476 Capsules
48325014|NCT05218057|PROCEDURE|Ureteroscopic lithotripsy|Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
48489218|NCT02262793|DRUG|telmisartan|
48489219|NCT02262793|DRUG|ASA/ER-DP|
48649105|NCT04691115|DRUG|Placebo|Placebo Capsules
48649106|NCT00151073|DRUG|Zoledronic acid|
48119745|NCT02622984|BEHAVIORAL|SBIRT|"Face to face standard intervention considered treatment as usual."
48119746|NCT01684150|DRUG|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
48119747|NCT01377428|DRUG|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
48119748|NCT01377428|DRUG|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
48119749|NCT01170962|DRUG|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
48119750|NCT01170962|DRUG|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
48119751|NCT01170962|DRUG|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
48119752|NCT01170962|DRUG|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
48119753|NCT01170962|DRUG|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
48649107|NCT00151073|DRUG|Estramustine|
48649108|NCT00151073|DRUG|Docetaxel|
48649109|NCT06066099|DRUG|AP31969|Oral tablets
48649110|NCT06066099|DRUG|Placebo|Oral tablets
48325015|NCT01274455|GENETIC|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
48325016|NCT04248400|OTHER|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
48325017|NCT04248400|OTHER|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
48325018|NCT04518982|DRUG|Sintilimab and lenalidomide|Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
48325019|NCT04518982|DRUG|Sintilimab placebo and lenalidomide placebo|Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
48325020|NCT03428841|PROCEDURE|Audiometry|
48325021|NCT01047748|DRUG|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
48325022|NCT01047748|DRUG|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
48325023|NCT02680587|RADIATION|SBRT|SBRT (1-5 fractions) will be administered.
48325024|NCT02590887|DIETARY_SUPPLEMENT|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
48325025|NCT05424887|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
48325026|NCT05424887|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
48325027|NCT05267197|OTHER|3D Telemedicine|3D Telemedicine system
48489220|NCT01669473|OTHER|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~1. Medication Review: a consolidated list of the medications a patient is currently taking.~2. Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~3. Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
48325028|NCT05267197|OTHER|2D Telemedicine|2D Telemedicine system
48325029|NCT05568056|BEHAVIORAL|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
48325030|NCT03844503|DIETARY_SUPPLEMENT|Cereal Bar no fiber|Cereal Bar no fiber
48325031|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
48325032|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
48489221|NCT01415219|OTHER|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
48649111|NCT01392066|BEHAVIORAL|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
48649112|NCT06673914|BEHAVIORAL|Control Group: Diet Group|"Patient in Diet Group and Oleuropein and Diet Group will be given a personalized diet and be followed up by a dietician."
48649113|NCT06673914|DIETARY_SUPPLEMENT|Oleuropein and Diet Group|"Dietary Supplement: Oleuropein (Olive Leaf Extract) Patients in Oleuropein and Diet Group will receive 200 mg/day oleuropein supplement and personalized diet followed up by a dietician."
48325033|NCT06070740|DRUG|Durvalumab and Chemotherapy(oxaliplatin and capecitabine)|"Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators."
48325034|NCT00002247|DRUG|Ganciclovir|
48325035|NCT02397603|DRUG|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
48325036|NCT02397603|DRUG|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
48325037|NCT02116816|DIETARY_SUPPLEMENT|Polyphenol|Polyphenol
48325038|NCT06018935|OTHER|No intervention|No intervention
48325039|NCT01833325|RADIATION|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
48325040|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Imatinib|
48325041|NCT01771458|PROCEDURE|Tumor biopsy|
48325042|NCT01771458|DRUG|Standard Chemotherapy|
48325043|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Everolimus|
48325044|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Vemurafenib|
48489222|NCT02254018|DRUG|bivatuzumab mertansine|
48489223|NCT05337774|DRUG|[18F]PI-2620|The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
48119754|NCT05727241|DIAGNOSTIC_TEST|Ultrasound|The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.
48119755|NCT01137708|DRUG|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
47971266|NCT00828347|DRUG|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
47971267|NCT00828347|DRUG|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
47971268|NCT00002581|DRUG|cyclophosphamide|
47971269|NCT00002581|DRUG|fluorouracil|
47971270|NCT00002581|DRUG|methotrexate|
47971271|NCT00002581|DRUG|tamoxifen citrate|
47971272|NCT00002581|PROCEDURE|conventional surgery|
47971273|NCT00002581|RADIATION|radiation therapy|
47971274|NCT06501066|BIOLOGICAL|umbilical cord mesenchymal stem cells|Patients assigned to UC-MSC administration groups will receive one administrations
48119756|NCT01137708|DRUG|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
48325045|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Sorafenib|
48325046|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Erlotinib|
48325047|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
48325048|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Dasatinib|
48325049|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
48325050|NCT01771458|DRUG|Targeted therapy based on molecular profiling : Abiraterone|
48325051|NCT02941341|DRUG|r-hFSH|As per standard practice
48325052|NCT04623502|OTHER|13C-Glucose|Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
48325053|NCT04623502|OTHER|13C-Acetate|Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
48325054|NCT04623502|OTHER|13C-Lactate|Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
48325055|NCT04623502|OTHER|13C-Glutamine|Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
48325056|NCT04623502|OTHER|13C-Fructose|Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
48325057|NCT04014270|DEVICE|Self-modulated functional electrical stimulation (SM-FES)|"The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks."
48325058|NCT04014270|OTHER|Standard Care|"The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks."
48325059|NCT05871970|BIOLOGICAL|TARA-002|All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
48325060|NCT03409029|DIAGNOSTIC_TEST|MRI Scan|Additional imaging using MRI scan
48325061|NCT02745301|OTHER|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
48325062|NCT03379012|DRUG|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
48325063|NCT01898364|DRUG|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
48325064|NCT04080869|DRUG|retinyl palmitate|topical retinyl palmitate loaded ethosomes
48325065|NCT04080869|DRUG|Tretinoin|topical tretinoin
48325066|NCT01925651|RADIATION|No Bolus|no bolus use
48119757|NCT06285786|OTHER|Ergonomic Training on Patient Handling Techniques|"Each participant will receive an ergonomic training on proper patient handling technique, adhering to the appropriate program to use with the SAMS bed and the Vendlet between session 1 \& 2.~In small groups of 6-10 participants, a healthcare ergonomist (M. Leger) will be responsible to demonstrate, instruct and evaluate each participant on all 4 techniques on the SAMS bed. Each participant will have multiple opportunities to demonstrate their skills.~In the same session, each participant will also receive proper training from a specialized occupational therapist on how to use the Vendlet. Each participant will have multiple opportunities to demonstrate their skills.~After completing the intervention, each participant will be prepared to participate in the post-intervention data collection session in the laboratory."
48119758|NCT03270124|BEHAVIORAL|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
48119759|NCT03270124|BEHAVIORAL|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
48119760|NCT03270124|BEHAVIORAL|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
48325067|NCT01925651|RADIATION|Alternate Bolus|0.5cm bolus use in alternate days
47971275|NCT02927431|DRUG|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
47971276|NCT02927431|DRUG|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
47971277|NCT02927431|DRUG|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
47971278|NCT02927431|DRUG|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
47971279|NCT05273918|OTHER|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
47971280|NCT05273918|OTHER|body mediation|15 workshops once a week during 90 minutes
47971281|NCT02793934|OTHER|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
47971282|NCT02793934|OTHER|New model of rehabilitation|
47971283|NCT02793934|OTHER|Old model of rehabilitation|
47971284|NCT02793934|OTHER|ICF reader|
47971285|NCT03330730|OTHER|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
47971286|NCT00056316|BEHAVIORAL|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
47971287|NCT00056316|BEHAVIORAL|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
47971288|NCT05938972|BIOLOGICAL|Mepolizumab|Monoclonal antibodies
47971289|NCT03937297|BEHAVIORAL|Six Arts|"The Six Arts intervention is a 24 session, twice a week intervention protocol. There will be four sessions per Art, with specific sequence designed to enhance group dynamic and create harmony. Each session starts with a 15 minutes warm-up exercise, followed by the Six Art theme activity. The program design emphasizes on integrated cognitive, physical, and social activities covering all domains of Six Arts."
47971290|NCT03937297|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|The CST to be used involve 24 sessions of theme activities, twice a weekly intervention protocol. It is modified into CST-Hong Kong for activities that are not applicable in Hong Kong Chinese culture (e.g. word games involving alphabets)
47971291|NCT03937297|BEHAVIORAL|Usual Care|usual dementia care provided by participating center
48119761|NCT05028959|OTHER|Multidisciplinary monitoring of healthy women|Multidisciplinary monitoring
48119762|NCT00000924|DRUG|Ritonavir|
48119763|NCT00000924|DRUG|Nelfinavir mesylate|
48119764|NCT00000924|DRUG|Nevirapine|
48119765|NCT00000924|DRUG|Stavudine|
48119766|NCT00000924|DRUG|Didanosine|
48325068|NCT01925651|RADIATION|Continuous Bolus|0.5 cm bolus use in continuous days
48325069|NCT03224481|OTHER|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
48325070|NCT00211718|DRUG|intra-articular botulinum toxin type a|
48119767|NCT04564196|PROCEDURE|Breath Sample|breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
48489224|NCT04166513|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the targeted region.
48649114|NCT05891782|BEHAVIORAL|HAPA-based Multidomain Fall Risk Management|"According to the HAPA and the conceptual model of IC, this intervention consists of 3 stages.~Stage 1: The main format will be group lectures and scenario simulation, each intervention will have a duration of 30 to 45 minutes. Intervention content will utilize BCT \[5.1, 5.3, 5.5, 5.6, 9.3, 15.1\] .~Stage 2: This stage will utilize mostly group lectures or one-to-one interviews, to provide an action and coping plan to participants for fall risk management. This will apply BCT \[1.1-1.4, 4.1\] at week 4.Firstly, individualized targets will be established. Secondly, professionals and participants will collaborate to develop an implementation plan.~Stage 3:Recovery self-efficacy will be implemented as group discussions, with each intervention lasting 15-30 minutes. Maintenance will be implemented in one-to-one interviews, with each intervention lasting 15-30 minutes.Finally, the consolidation and outlook will provide the foundation for the habit formation of healthy behaviors."
48489225|NCT04166513|DEVICE|Active Control Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.
48489226|NCT04166513|BEHAVIORAL|Phonologic-Focused Speech Therapy|Participants are asked to generate or choose from a list phonologic information about a target picture.
48489227|NCT04166513|BEHAVIORAL|Semantic-Focused Speech Therapy|Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
48489228|NCT06139393|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
48489229|NCT06139393|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
48649115|NCT05891782|BEHAVIORAL|Regular health education lectures|Weeks 1-4 will be provided with fall-related regular health education lectures. Weeks 5-16 will have regular activities according to the daily arrangement of the nursing home. Meanwhile, telephone, WeChat, or face-to-face interviews will be conducted fortnightly, to understand the needs of the participants. During the process, staff will provide usual care such as vital signs monitoring, disease treatment, medication prescription, and health record maintenance.
48119768|NCT00382681|DEVICE|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
48119769|NCT00382681|DEVICE|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
48119770|NCT03226899|DRUG|Lesinurad|200 mg oral tablet
48119771|NCT03226899|DRUG|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
48119772|NCT03226899|DRUG|Placebo|matching placebo oral tablet
48119773|NCT03226899|DRUG|colchicine|Gout flare prophylaxis: commercially available colchicine is provided through the Month 6 study visit. Actual colchicine dose (0.5 or 0.6 mg qd) and frequency were adjusted based on the local label, subject medical history, and clinical judgement.
48119774|NCT03226899|DRUG|corticosteroids|Gout flare prophylaxis: Participants unable to take colchicine are permitted to take a short course of low-dose oral corticosteroids up to the Month 3 study visit
48119775|NCT06399029|DRUG|Ruxolitinib Topical Cream|Ruxolitinib cream will be applied topically twice daily on up to 20% of the body surface over 12 weeks in patients with lichenoid skin toxicity under anti PD1 treatment.
48119776|NCT06459063|DRUG|Allocetra - Safety run-in phase|Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.
48119777|NCT06459063|OTHER|Placebo|Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.
48119778|NCT06459063|DRUG|Allocetra - Randomization phase|Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
48119779|NCT03040596|DRUG|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
48119780|NCT03040596|BEHAVIORAL|Standard voice therapy|Standard voice therapy sessions
48119781|NCT05918614|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
48489230|NCT03735134|DRUG|Colchicine Loading Dose|Two milligrams of colchicine will be administrated in addition to the standard of care treatment
48489231|NCT03735134|DRUG|Standard of care treatment prior to elective PCI|All medications normally given to patients prior to elective PCI
47971292|NCT03671460|BIOLOGICAL|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
48649116|NCT02093273|BIOLOGICAL|tOPV pilot batch|the tOPV vaccine is given orally
48649117|NCT02093273|BIOLOGICAL|tOPV commercial batch|tOPV vaccine is given orally
47971293|NCT04047940|DRUG|LY900020|Administered orally
47971294|NCT04047940|DRUG|Metformin XR|Administered orally
47971295|NCT04047940|DRUG|Atorvastatin|Administered orally
47971296|NCT04047940|DRUG|Valsartan|Administered orally
47971297|NCT05144321|OTHER|Impact of environment upon obstetrical|Impact of environment upon obstetrical
47971298|NCT05144321|OTHER|neonatal and maternal adverse outcome|neonatal and maternal adverse outcome
47971299|NCT02658929|BIOLOGICAL|bb2121|bb2121
48119782|NCT05918614|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
48119783|NCT00540748|DRUG|oxytocin|5 U i.v. during surgical abortion
48119784|NCT03565523|OTHER|Beetroot|Containing 385 mg nitrate
48325071|NCT03900806|BEHAVIORAL|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
48325072|NCT01745991|DEVICE|CoSeal spray|
48489232|NCT02523196|DRUG|HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
47971300|NCT03714867|DRUG|Pregabalin 150mg|150 mg concealed pregabalin capsule
47971301|NCT03714867|OTHER|Placebo|Concealed placebo capsule
47971302|NCT01479517|DRUG|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
47971303|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
47971304|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
47971305|NCT01260636|DRUG|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
47971306|NCT01260636|DRUG|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
47971307|NCT01761890|BEHAVIORAL|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
47971308|NCT04522960|DIAGNOSTIC_TEST|MEG+hdEEG+MRI|"We will perform several tests:~* Neuropsychological testing to evaluate evolution of cognition during our study.~* Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~* MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
47971309|NCT05517044|OTHER|Nitrogen tent preacclimatization to high altitude|The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
48119785|NCT03565523|OTHER|Placebo beverage|\<0.1 mmol nitrate in sucrose solution with beet coloring
48119786|NCT01869543|OTHER|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
48489233|NCT02523196|DEVICE|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
48649118|NCT03670433|OTHER|Cost analysis of medication reconciliation|"1. The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~2. The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
48649119|NCT03903341|OTHER|fMRI|bold signal in visual pathway
48119787|NCT01869543|OTHER|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
48119788|NCT01827345|DIETARY_SUPPLEMENT|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
48119789|NCT00089544|DRUG|Dacarbazine|Given IV
48119790|NCT00089544|DRUG|Doxorubicin Hydrochloride|Given IV
48119791|NCT00089544|BIOLOGICAL|Filgrastim|Given subcutaneously
48119792|NCT00089544|DRUG|Ifosfamide|Given IV
48119793|NCT00089544|OTHER|Laboratory Biomarker Analysis|Correlative studies
48119794|NCT00089544|RADIATION|Radiation Therapy|Undergo radiotherapy
48119795|NCT00089544|DRUG|Thalidomide|Given orally
48119796|NCT00089544|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48325073|NCT00565058|BIOLOGICAL|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
48489234|NCT04223999|PROCEDURE|Skullremodeling surgery|"Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor."
47971310|NCT05237531|BEHAVIORAL|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
47971311|NCT05237531|BEHAVIORAL|Standard of care|Education per provider preference (no standardization, current standard of care)
47971312|NCT05237531|BEHAVIORAL|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
47971313|NCT00138203|DRUG|vorinostat|Given PO
48119797|NCT02708108|BEHAVIORAL|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
48119798|NCT02708108|BEHAVIORAL|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
47971314|NCT00138203|OTHER|laboratory biomarker analysis|Correlative studies
47971315|NCT00813735|DRUG|Eszopiclone|Eszopiclone 2mg daily at bedtime
47971316|NCT00813735|DRUG|Placebo|Placebo daily at bedtime
47971317|NCT00813735|DRUG|Escitalopram|Escitalopram 10mg or 20mg
47971318|NCT00618072|DRUG|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
47971319|NCT05777577|DIETARY_SUPPLEMENT|probiotic therapy|probiotic including bifidobacterium
47971320|NCT01421108|BEHAVIORAL|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
47971321|NCT01421108|BEHAVIORAL|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
48119799|NCT02365766|DRUG|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
48119800|NCT02365766|DRUG|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
48119801|NCT02365766|DRUG|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
48119802|NCT02365766|PROCEDURE|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
47971322|NCT02650362|OTHER|fMRI|
47971323|NCT04221009|BEHAVIORAL|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
47971324|NCT02771002|DEVICE|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
48119803|NCT06210334|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d3, q3w
48119804|NCT06210334|DRUG|Lenvatinib|Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd
48119805|NCT00000152|DRUG|Aspirin|
48119806|NCT00000152|DRUG|Beta-Carotene|
48119807|NCT03616535|OTHER|Cognitive training|The investigators will provide participants with tablets to play brain games.
48119808|NCT03616535|OTHER|Exercise training|The investigators will provide participants with foot peddlers.
48119809|NCT03616535|OTHER|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
48325074|NCT00511953|DRUG|Gabapentin Extended Release tablets|1800mg
48325075|NCT00511953|DRUG|Gabapentin|1800mg
48325076|NCT01088438|BEHAVIORAL|Contextualization workshop|A four-hour course on contextualization.
48325077|NCT04369755|OTHER|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
48119810|NCT03303651|PROCEDURE|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
48119811|NCT03303651|PROCEDURE|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
48119812|NCT02802995|DRUG|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
48119813|NCT00174382|DRUG|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
48119814|NCT00220272|DRUG|SR57667B|
48119815|NCT05463432|DRUG|HR19024|Intravenous infusion
48119816|NCT05692024|DRUG|Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.|Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.
48119817|NCT05692024|DRUG|Placebo|Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
48119818|NCT01854229|DEVICE|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
48119819|NCT00432718|PROCEDURE|Saline Instillation before Tracheal Suctioning|
48119820|NCT06522880|DIAGNOSTIC_TEST|CMV PCR on saliva|Observational study to measure prevalence of CMV shedding by saliva PCR
48119821|NCT00964730|DRUG|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
48119822|NCT00964730|DRUG|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
48119823|NCT00964730|DRUG|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
48119824|NCT04496050|DRUG|Prostaglandin E1|The same drug will be used. In this study the same patients will be evaluated after the same dose of medication.
48119825|NCT05111483|OTHER|Tupler technique|"The subjects with DRA will receive Tupler's technique treatment plan for 18 weeks in which four steps will be followed.~1. Repositioning with diastasis rehab splint :~2. Protect the connective tissue~3. Tupler's technique exercises (elevators, contractions, standing pelvic tilt, head lifts, leg slides, low back stretch) with 10 repetitions for each exercise.~4. Diastasis safe exercises program to maintain the gains"
48119826|NCT05111483|OTHER|conventional therapy|"The subjects with DRA will receive conventional physical therapy treatment for 16 weeks in which researcher will follow these steps:~1. Tie a scarf around abdomen while performing exercises~2. Exercise program for diastasis recti abdominal muscles; sit ups, reverse sit ups, reverse trunk twist and U-seat exercises. (10 repetitions for each exercise)~3. Respiratory rehabilitation manoeuvre"
48119827|NCT00131638|DRUG|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
48119828|NCT00131638|DRUG|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
48325078|NCT02729948|OTHER|Survey Administration|Ancillary studies
48325079|NCT02729948|DEVICE|Tethered Capsule Endoscope|Undergo TCE
48325080|NCT00371111|DRUG|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
48325081|NCT00371111|DRUG|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
48325082|NCT04923919|DRUG|Anti-CLL1 CART cells|In this study, patients with acute myeloid leukemia were treated with autologous anti-CLL1 CAR T cells by a single, intravenous infusion.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the efficacy of CAR T cells.
48325083|NCT05677191|DEVICE|Proximal Femoral Nail|open reduction
48325084|NCT05677191|COMBINATION_PRODUCT|Dual Mobility Arthroplasty|Hip Arthroplasty Surgery
48489235|NCT04223999|OTHER|Control|Tumor treating fields combined with best medical treatment.
48489236|NCT01957228|PROCEDURE|bone biopsies|
48325085|NCT01578785|DRUG|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
48489237|NCT05183295|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food
48489238|NCT05291832|OTHER|Brain.fm Music|Experimental arm
48325086|NCT01578785|DRUG|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
48325087|NCT03766724|DRUG|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
48325088|NCT03766724|DRUG|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin|Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
48325089|NCT03766724|DRUG|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
48325090|NCT03766724|DRUG|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin|Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
48325091|NCT03125876|DRUG|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
48325092|NCT01026389|DRUG|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
48325093|NCT01026389|DRUG|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
48325094|NCT04070170|DEVICE|Low-level Laser Therapy|Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons
48325095|NCT04070170|PROCEDURE|Orthodontic force|Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
48325096|NCT03140995|BEHAVIORAL|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
48325097|NCT03771456|PROCEDURE|Colorectal resections|Colorectal resections
48325098|NCT03987334|OTHER|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
48325099|NCT03987334|OTHER|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
48325100|NCT04430946|DIAGNOSTIC_TEST|Standardized test meal|A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
48489239|NCT05291832|OTHER|Spectrally-matched Noise|Active control arm
48489240|NCT04322578|DRUG|Crizotinib|Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
48489241|NCT04322578|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt erery 21day.
47971325|NCT01384760|BEHAVIORAL|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
47971326|NCT01384760|BEHAVIORAL|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
48325101|NCT04626193|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
48325102|NCT04626193|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
48325103|NCT04865250|DRUG|Atezolizumab 1200 mg abs day 1 q22 (iv)|Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
48325104|NCT05092880|DEVICE|radioembolization|holmium-166 microspheres
48325105|NCT05092880|DRUG|Standard of care first-line systemic therapy|Capecitabine plus anti-VEGF antibody
48325106|NCT02488616|OTHER|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
48489242|NCT04519034|OTHER|no intervention|There will be no intervention
48489243|NCT05255926|DRUG|68Ga-pentixafor|All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
48489244|NCT05255926|DEVICE|PET/CT|PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
48649120|NCT02573896|DRUG|Dinutuximab|17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
48325107|NCT02488616|OTHER|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
48325108|NCT02488616|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
48325109|NCT02488616|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
48325110|NCT02488616|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
48325111|NCT04338516|DEVICE|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
48119829|NCT05231408|OTHER|High-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
48325112|NCT04338516|DEVICE|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
48325113|NCT05429554|DRUG|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
48325114|NCT05247619|DRUG|Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin|Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.
48325115|NCT05619679|OTHER|Kidney Transplantation|Kidney transplantation
48325116|NCT00110578|PROCEDURE|Adoptive transfer of HIV-specific CD8+ T cells|
48325117|NCT00110578|DRUG|Aldesleukin|
48489245|NCT04694326|DIAGNOSTIC_TEST|HbA1c|The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
48649121|NCT02573896|BIOLOGICAL|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
48119830|NCT05231408|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
48119831|NCT02012569|DRUG|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
48119832|NCT02012569|DRUG|Placebo|
48119833|NCT01000480|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
48119834|NCT01000480|DRUG|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
48119835|NCT01000480|RADIATION|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
48119836|NCT01396837|DEVICE|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
48325118|NCT04493294|RADIATION|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
48325119|NCT01236313|PROCEDURE|TEE report|Information will be collected during cardiac surgery.
48325120|NCT03153020|OTHER|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
48325121|NCT02680405|PROCEDURE|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
48325122|NCT02680405|PROCEDURE|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
48489246|NCT02922101|BEHAVIORAL|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
48489247|NCT02922101|BEHAVIORAL|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
48649122|NCT02573896|DRUG|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
48649123|NCT02691494|DRUG|Elagolix|Film-coated tablets
48119837|NCT01326039|DRUG|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
48119838|NCT01326039|DRUG|saline|perineural isotonic saline 20 ml
48119839|NCT00332917|DRUG|Pardoprunox|12-42 mg
48325123|NCT02680405|PROCEDURE|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
48325124|NCT04388098|OTHER|Diagnosis of caries experience and periodontal health|
48325125|NCT02469532|DEVICE|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
48649124|NCT02691494|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
48649125|NCT02691494|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
48649126|NCT02691494|DRUG|Placebo for Elagolix|Film-coated placebo tablets
48325126|NCT02469532|DEVICE|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
48325127|NCT04556656|DRUG|Pridopidine|Pridopidine hard gelatin capsule
48325128|NCT04556656|DRUG|Placebo|Pridopidine-matching placebo hard gelatin capsule
48325129|NCT03941236|DRUG|dasiglucagon|Glucagon analog
48325130|NCT03084289|BIOLOGICAL|ChAd63-METRAP|The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
48325131|NCT03084289|BIOLOGICAL|MVA ME-TRAP|The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
48325132|NCT03386331|BEHAVIORAL|diet and exercise|Diet and lifestyle intervention
48325133|NCT03256734|OTHER|Policy intervention|Incentive payment for physicians
48325134|NCT03771599|OTHER|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
48325135|NCT03771599|OTHER|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
48325136|NCT04511819|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
48489248|NCT06471530|DRUG|TE-8105 SAD Cohort 1|Each participant will receive one dose of TE-8105 0.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
48489249|NCT06471530|DRUG|TE-8105 SAD Cohort 2|Each participant will receive one dose of TE-8105 0.75 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
48489250|NCT06471530|DRUG|TE-8105 SAD Cohort 3|Each participant will receive one dose of TE-8105 1.5 mg or less than or equal to 2.5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
47971327|NCT05339737|DEVICE|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values \>25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
48325137|NCT04511819|DRUG|Placebo oral tablet|Placebo will be administered with food when possible.
48489251|NCT06471530|DRUG|TE-8105 SAD Cohort 4|Each participant will receive one dose of TE-8105 3 mg or less than or equal to 5 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
48489252|NCT06471530|DRUG|TE-8105 SAD Cohort 5 (Adaptive cohort)|Each participant will receive one dose of TE-8105 less than or equal to 6 mg injection via subcutaneous (SC) injection into the abdomen administered on Day 1.
48489253|NCT06471530|DRUG|TE-8105 MAD Cohort 1|Each participant will receive 5 doses of TE-8105 0.5 mg or less than or equal to 1.5 mg injection via SC injection into the abdomen on Day 1 and then Q2W for 5 doses.
48489254|NCT06471530|DRUG|TE-8105 MAD Cohort 2|Each participant will receive 5 doses of TE-8105 1 mg or less than or equal to 3 mg injection via SC injection into the abdomen on Day 1 and then Q2W for 5 doses.
47971328|NCT00413127|DRUG|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
47971329|NCT00413127|DRUG|NaCl 0,9%|Administration of placebo i.v.
48325138|NCT00740922|DRUG|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
48325139|NCT00194025|DRUG|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
48325140|NCT00003450|BIOLOGICAL|Ad5CMV-p53 gene|
48325141|NCT01232751|DIETARY_SUPPLEMENT|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
48325142|NCT04224818|DRUG|Dual trigger|Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
48325143|NCT04224818|DRUG|hCG (standard)|human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
48325144|NCT01825980|DRUG|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
48325145|NCT01825980|DRUG|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
48325146|NCT01825980|DRUG|Placebo|Placebo
48498067|NCT00998478|OTHER|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
48119840|NCT01116635|DRUG|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
48119841|NCT05597280|DRUG|BE-PEP Bedaquiline|bedaquiline
48119842|NCT05597280|DRUG|SDR-PEP Rifampicin|SDR-PEP: rifampicin
48119843|NCT05597280|DRUG|BE-PEP Rifampicin|BE-PEP rifampicin
48119844|NCT05967533|DRUG|Fermented Wheat Germ Extract|Given PO
48119845|NCT05624112|DRUG|Dupilumab|Dupilumab solution in a pre-filled syringe for Subcutaneous injection
48119846|NCT03915340|DRUG|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
48119847|NCT03915340|DRUG|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
48119848|NCT00761605|DRUG|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
48119849|NCT05975749|DRUG|Serplulimab|Serplulimab: 4.5mg/Kg on day 1
48119850|NCT05975749|DRUG|Trastuzuma|Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
48119851|NCT05975749|DRUG|Chemotherapy|Chemotherapy: Capecitabine or S-1 and Oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² or S-1 40 mg/m2 twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
48119852|NCT04225403|BEHAVIORAL|Telephone-based motivational interviewing for smoking cessation|"The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~* Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~* Risks. Help identify what negative consequences tobacco use has.~* Rewards. Help identify potential benefits of quitting smoking.~* Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~* Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change."
48119853|NCT03931265|DIAGNOSTIC_TEST|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
48119854|NCT06011109|DRUG|APG-157|The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.
48119855|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
48119856|NCT01128075|DEVICE|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
48325147|NCT05136651|BEHAVIORAL|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
48325148|NCT05250193|DEVICE|DK ScoreTM Coronary Scoring Balloon|After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
47971330|NCT05087212|DRUG|plerixafor + G-CSF|subcutaneous (SC) injection
48119857|NCT05303753|OTHER|fermented dairy protein with prebiotic fiber|During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
48119858|NCT02275377|OTHER|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
48119859|NCT02275377|OTHER|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
48119860|NCT01214824|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
48119861|NCT04982536|DEVICE|VMCore Biopsy System|Prostate Examine
48119862|NCT04982536|DEVICE|Standard of Care Biopsy Needle|Prostate Examine
48325149|NCT05250193|DEVICE|Non-Slip Element Coronary Dilatation Catheter|After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
48325150|NCT05246007|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 0.02 ml/kg/h (0.025 μg/kg/h) during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
48325151|NCT05246007|DRUG|Normal Saline|Placebo (normal saline) will be infused at a rate of 0.02 ml/kg/h during the night before surgery, the night of surgery, and the first 2 nights after surgery (from 9:00 pm-6:00 am).
48325152|NCT04633057|DRUG|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
48325153|NCT04633057|DRUG|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
48649127|NCT04770545|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
48649128|NCT00178139|BEHAVIORAL|Music Therapy|Music Therapy
48649129|NCT03977298|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
48649130|NCT03977298|PROCEDURE|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
48649131|NCT05756556|COMBINATION_PRODUCT|T3011 + Cobimetinib|1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)
48649132|NCT06355141|OTHER|oral assessment|observational oral assessment
48649133|NCT05438160|DEVICE|Digital therapeutics app CT-155|Patients to be treated with digital therapeutics app CT-155 downloadable into personal smartphones
48649134|NCT02866331|DRUG|G-CSF (Leucostim)|
48649135|NCT02866331|BIOLOGICAL|CB (autologous cord blood)|
48649136|NCT02866331|DRUG|Placebo (Normal saline)|
48649137|NCT06501573|DRUG|SGB-9768|SGB-9768 for sc injection
48649138|NCT06501573|OTHER|Placebo|sterile normal saline (0.9% NaCl) for sc injection
48649139|NCT02941029|OTHER|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
48649140|NCT04391608|DRUG|Switching to Tenofovir Alafenamide|Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
48649141|NCT01666366|PROCEDURE|Coronary artery bypass grafting|
48649142|NCT04074837|DRUG|NNI-362|NNI-362 small molecule in liquid suspension.
48649143|NCT04074837|DRUG|Placebo|Placebo liquid suspension
48489255|NCT06055036|BEHAVIORAL|Black Impact Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
48489256|NCT00056745|BIOLOGICAL|TBC-3B|
48649144|NCT00468546|DRUG|MabThera/Rituxan|1
48649145|NCT00468546|DRUG|Methotrexate|2
47971331|NCT04429139|DRUG|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
48119863|NCT01815008|DRUG|Clopidogrel|Clopidogrel 75 mg daily
48119864|NCT01815008|DRUG|Aspirin|Aspirin 81 mg daily
48119865|NCT02511613|DRUG|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
48119866|NCT02511613|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
48489257|NCT03762499|DIAGNOSTIC_TEST|Echocardiography scan|Non-invasive ultrasound imaging of the heart.
48489258|NCT02469779|BEHAVIORAL|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
48498068|NCT02715544|OTHER|Healthy lifestyle|The families will receive a designed for these purposes intervention
48649146|NCT00468546|OTHER|Placebo|3
48649147|NCT02762890|DRUG|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
48649148|NCT02762890|DRUG|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
48649149|NCT04010838|PROCEDURE|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
48649150|NCT00005626|DRUG|Irinotecan|Irinotecan as outlined in treatment arm
48649151|NCT00195611|DRUG|Prevenar|
48649152|NCT01793454|OTHER|Fraction of inspired oxygen 40%|
48119867|NCT02511613|DRUG|ranibizumab|ranibizumab intravitreal injection
48119868|NCT05729672|BEHAVIORAL|Received the Nightingale in Gen-sEx course|The experimental group (n=75) will participate in the SPOC- based education program, consisting of five online teaching and learning modules over the span of 3 months and two hours of offline classroom.
48649153|NCT01793454|OTHER|Fraction of inspired oxygen 80%|
48649154|NCT05007860|BIOLOGICAL|PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.|Vaccines administered per standard of care
48649155|NCT03919019|OTHER|Macuprev Group|oral supplementation (Macuprev) 2 capsules per day for 6 months
48649156|NCT03919019|OTHER|Placebo Group|oral placebo 2 capsules per day for 6 months
47971332|NCT05315154|PROCEDURE|No axillary surgery|In the study arm will be omitted surgery in axilla
48119869|NCT05052450|OTHER|Observational|Patients data were collected throughout the following time
48325154|NCT02215408|BEHAVIORAL|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
48325155|NCT04907591|DEVICE|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
48325156|NCT01464788|DRUG|Low Dose Argatroban|100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
48489259|NCT02469779|BEHAVIORAL|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
48489260|NCT02469779|BEHAVIORAL|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
48489261|NCT02469779|BEHAVIORAL|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
48489262|NCT05177172|OTHER|High beta glucans|higher dose betaglucans
48489263|NCT05177172|OTHER|Low beta glucans|lower dose beta glucans
48489264|NCT05177172|OTHER|Low beta glucans + low polar lipids|low dose betaglucans in a combination with low dose of polar lipids
48489265|NCT05177172|OTHER|Polar lipids|low dose polar lipids
48489266|NCT05177172|OTHER|Control|No beta glucans or polar lipids
48489267|NCT00371306|DRUG|Insulin versus glucovance (glyburide/metformin)|
48489268|NCT04859842|OTHER|Pulse Electromagnetic Field|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
48489269|NCT04859842|OTHER|Interferential Current|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
48489270|NCT04859842|OTHER|Sham|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
48489271|NCT01744119|DEVICE|Vascutek Anaconda™ Stent Graft System|
48489272|NCT05393505|DRUG|Meropenem Injection|Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours
48489273|NCT05393505|DRUG|Levofloxacin|Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.
48489274|NCT05393505|DRUG|Amoxicillin Clavulanate|Given if patient has no known allergies at 1.2 g IV bolus within 1 hour of ED registration, then every 8 hours. If the patient can tolerate oral drugs, 1 g twice daily after the first IV bolus.
48119870|NCT04366908|DRUG|BAT + Calcifediol|"The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule"
48325157|NCT01464788|DRUG|High Dose Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
48489275|NCT05393505|DRUG|Antibiotic|"Any antibiotic for empirical therapy of common infections as recommended by the fifth version of Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) guideline, with reference to previous bacterial sensitivity pattern"
48489276|NCT02512536|DRUG|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
48489277|NCT04171024|DEVICE|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
48489278|NCT04171024|DEVICE|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
48489279|NCT01940497|DRUG|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
48489280|NCT01940497|DRUG|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
47971333|NCT05315154|PROCEDURE|SLNB|in the control arm will be realized SLNB
47971334|NCT01357733|OTHER|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
47971335|NCT04690491|OTHER|follicular cyclus|Days of cyclus 6-12
48325158|NCT01464788|DRUG|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
48325159|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
48489281|NCT01940497|DRUG|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
48325160|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
48325161|NCT03146221|OTHER|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
48325162|NCT02581358|OTHER|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
48325163|NCT01824173|OTHER|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
48325164|NCT01824173|OTHER|Aerobic exercise|Moderate intensity for 45 minutes
48489282|NCT01940497|DRUG|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
48489283|NCT01443936|BIOLOGICAL|Ad4-H5-VTN vaccination-tonsillar route|
48489284|NCT01443936|BIOLOGICAL|Ad4-H5-vaccination-oral route|
48489285|NCT01045993|DEVICE|Heat Device|8-Hour Heatwrap
47971336|NCT04690491|OTHER|luteal cyclus|Days of cyclus 20-24
47971337|NCT00285454|PROCEDURE|Retrograde coronary venous delivery of cells.|
47971338|NCT05908513|DRUG|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
48119871|NCT04366908|DRUG|BAT|The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
48119872|NCT04353102|DRUG|YH002|YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
48119873|NCT01368198|OTHER|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
48119874|NCT01368198|OTHER|OPTIVE™|One instillation of the eye drop in each eye
48325165|NCT01398267|DRUG|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
48325166|NCT01398267|DRUG|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
48325167|NCT01398267|DRUG|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
48325168|NCT05630430|PROCEDURE|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
48325169|NCT02452177|DRUG|Vitamin D|
48325170|NCT04564430|DRUG|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
48325171|NCT04564430|OTHER|Saline|controlgroup receiving saline
48489286|NCT01045993|DEVICE|Sham Device|Inactive wrap worn for 8 hours
48489287|NCT01045993|DRUG|marketed analgesic|2 x 200 mg ibuprofen tablets
48489288|NCT01045993|DRUG|Placebo|2 x placebo tablets
48489289|NCT02974036|OTHER|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
48489290|NCT01237353|DIETARY_SUPPLEMENT|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
48489291|NCT01237353|DRUG|Rabeprazole|rabeprazole po daily x 5 days
48489292|NCT02072824|DRUG|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
48489293|NCT02072824|DRUG|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
48489294|NCT02072824|DRUG|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
48489295|NCT02109536|DEVICE|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
48325172|NCT03943979|OTHER|Cognitive Training|Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
48325173|NCT03943979|DEVICE|transcranial Direct-Current Stimulation (tDCS)|tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
48325174|NCT02661841|OTHER|LI-Guided Therapy|Preemptive treatment according to LI monitoring
48325175|NCT02661841|OTHER|Heart Failure Guidelines|Treatment according to clinical signs
47971339|NCT05908513|DRUG|Placebo|Similar chemical structure of NAC but without function
48325176|NCT04694105|DRUG|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
48325177|NCT04694105|DRUG|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
47971340|NCT03762421|BEHAVIORAL|Psycho-social skills development workshops based on PM plus|5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.
48325178|NCT04694105|DRUG|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
47971341|NCT03762421|BEHAVIORAL|Routine training induction sessions|The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
48325179|NCT05425719|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
48325180|NCT05425719|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.
47971342|NCT01853761|DEVICE|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
47971343|NCT01853761|DEVICE|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
47971344|NCT01853761|DEVICE|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
47971345|NCT01853761|DEVICE|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
47971346|NCT01853761|DEVICE|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
47971347|NCT01853761|DEVICE|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
47971348|NCT06408051|PROCEDURE|Injection of onabotulinumtoxinA into the bladder wall|BTX was injected into the detrusor muscles at 20 sites
48325181|NCT06112002|OTHER|Educational Intervention|Attend an educational session
47971349|NCT02980601|DEVICE|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
47971350|NCT02980601|PROCEDURE|STSG|0.012mm STSG
47971351|NCT01115725|DRUG|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
47971352|NCT04972695|DIAGNOSTIC_TEST|Fundus Photographs (retinographies)|Fundus photographs under mydriasis
48325182|NCT06112002|BEHAVIORAL|Health Education|Receive educational materials
48325183|NCT06112002|OTHER|Survey Administration|Ancillary studies
48325184|NCT02940717|OTHER|Vita suprinity|New glass ceramic material
48325185|NCT02940717|OTHER|Emax CAD|standard etchable glass ceramic used for laminate venneers
48325186|NCT02829866|DEVICE|AMIStem-H|
48325187|NCT01556802|DRUG|Minocicline|Minocicline 100mg oral twice a day for 5 days
48325188|NCT01556802|DRUG|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
47971353|NCT04441606|RADIATION|68Ga-FAPI-04 PET/CT|"* Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~* Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~* Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression."
47971354|NCT03849898|PROCEDURE|Surgery|Surgical fracture treatment
47971355|NCT03849898|OTHER|Non-Surgical fracture treatment|Non-Surgical fracture treatment
47971356|NCT00963196|DIETARY_SUPPLEMENT|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
47971357|NCT00963196|DRUG|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
47971358|NCT00622245|DRUG|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
47971359|NCT00622245|DRUG|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
48119875|NCT05622396|PROCEDURE|Mindfulness Based Stress Reduction|Inspired by the standard Mindfulness Based Stress Reductio program, the study MAdaPARK is a 8 week program with weekly sessions of 2h30 and a full day of practice designed from the analysis of the post-program interviews carried out as part of the M-PARK study,as well as the reflections of the working group specially set up for this purpose. Several areas of adaptation have been identified: shorter mediations, a break time during the sessions, more times for exchanges, a more developed practice in movement, and finally, more important work based on self-esteem and self-compassion.
47971360|NCT00622245|DRUG|Placebo|per oral doses, twice daily as capsules during 13 weeks
47971361|NCT03748147|DRUG|Misoprostol|prostaglandin e1
47971362|NCT00000752|DRUG|Pseudoephedrine hydrochloride|
47971363|NCT00000752|DRUG|Guaifenesin|
47971364|NCT00000752|DRUG|Cefuroxime axetil|
47971365|NCT00000752|DRUG|Beclomethasone dipropionate|
47971366|NCT03268902|DRUG|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
47971367|NCT03268902|DRUG|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
48119876|NCT04575740|DEVICE|PAP|Positive airway pressure to treat sleep apnea
48119877|NCT05234983|BEHAVIORAL|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
48119878|NCT01601041|OTHER|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
48498069|NCT02715544|OTHER|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
47971368|NCT03268902|DIETARY_SUPPLEMENT|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
47971369|NCT03268902|DRUG|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
47971370|NCT00469183|DRUG|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
48119879|NCT00322920|DRUG|Topotecan|
48119880|NCT00322920|DRUG|Cisplatin|
48119881|NCT04747743|OTHER|a self structured questionnaire|A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
48325189|NCT03270553|DRUG|plazomicin|single intravenous dose
47971371|NCT00595530|DRUG|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~* Patients begin the ketamine infusion at 0.05 mg/kg/hr.~* 4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~  1. patient's pain has not improved to an acceptable level~ 2. side effects remain acceptable~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~* Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
47971372|NCT02170298|DRUG|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
47971373|NCT00572702|PROCEDURE|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
47971374|NCT00572702|PROCEDURE|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
47971375|NCT02195440|DRUG|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
48119882|NCT02550067|DRUG|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
48325190|NCT03270553|DRUG|metformin|single oral dose
48325191|NCT02961517|OTHER|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
48325192|NCT02000453|DRUG|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
48325193|NCT05314712|BEHAVIORAL|Sleep intervention|Participants will receive a 9-week sleep intervention through text and Facebook that include traditional Blackfoot cultural components combined with scientifically validated strategies for sleep.
48119883|NCT02550067|DRUG|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
48325194|NCT03180827|PROCEDURE|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
47971376|NCT04232384|PROCEDURE|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
48119884|NCT02550067|DRUG|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
47971377|NCT04232384|PROCEDURE|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
47971378|NCT03296241|DEVICE|laser|
47971379|NCT03296241|DEVICE|sham control|
48119885|NCT02089217|PROCEDURE|Carotid endarterectomy (CEA)|Carotid endarterectomy
48119886|NCT02089217|DEVICE|Carotid Stenting (CAS)|Carotid stenting
48119887|NCT02089217|OTHER|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
48119888|NCT02089217|OTHER|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
48325195|NCT05165992|DRUG|Nebulized Fentanyl|Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
48325196|NCT00680160|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
48325197|NCT00794014|PROCEDURE|Conservative strategy|"* Main vessel stenting was performed.~* Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow \<3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) \>75% in LM subgroup.~* Side branch stenting was performed if TIMI flow \<3 in the Side branch after ballooning in non-LM subgroup, and DS \>50% or dissection in the Side branch after ballooning in LM subgroup."
48325198|NCT00794014|PROCEDURE|Aggressive strategy|"* Main vessel was performed.~* Side branch ballooning and kissing ballooning were done if DS \>75% in the side branch after main vessel stenting in non-LM subgroup, and DS \>50% in LM subgroup.~* Side branch stenting was performed if DS \>50% in the side branch after ballooning in non-LM subgroup, and DS \>30% or dissection in the side branch after ballooning in LM subgroup."
48325199|NCT00243113|DRUG|docetaxel|
48325200|NCT00243113|RADIATION|radiation therapy|
48325201|NCT02567617|DIETARY_SUPPLEMENT|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
48325202|NCT02567617|DIETARY_SUPPLEMENT|Placebo controlled|Starch capsules
48119889|NCT06555588|BEHAVIORAL|ENGAGE|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is based on an integration of Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches for managing symptoms of pain, fatigue, and distress. Participants are trained in behavioral symptom management skills (e.g., activity pacing, mindfulness) with an emphasis on engaging in highly valued activities.
48119890|NCT06555588|BEHAVIORAL|Supportive Care|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is designed to provide participants with education, support, and resources for a range of issues relevant to those with advanced cancer (e.g., education on symptoms, body image concerns, and financial concerns).
48325203|NCT04282057|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
48325204|NCT04282057|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
48325205|NCT04282057|DEVICE|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
47971380|NCT05261256|DIAGNOSTIC_TEST|Exercise stress echocardiography|Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.
47971381|NCT05770791|DIETARY_SUPPLEMENT|Black Seed ( Nigella Sativa)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
47971382|NCT05770791|DIETARY_SUPPLEMENT|Cumin Seed (Cuminum Cyminum)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
47971383|NCT05238441|BIOLOGICAL|SCTV01E|D0; intramuscular injection
48119891|NCT05871450|BEHAVIORAL|Inclusive events|Inclusive events such as inclusive sport festivals, citizen festivals or working groups at school are organized
48119892|NCT04906161|DIAGNOSTIC_TEST|Vitamin D and calcium levels|Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
48119893|NCT06045845|DIETARY_SUPPLEMENT|Beet Juice|70 milliliter (70mL) standard Beet Juice (Beet It Sport Shot) consumed 2.5 hours before exercise test
48119894|NCT06045845|DIETARY_SUPPLEMENT|Placebo|70mL placebo Beet Juice (Beet It Sport Shot with nitrate removed) consumed 2.5 hours before exercise test
48119895|NCT04781881|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
48119896|NCT03559348|DRUG|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
48325206|NCT02222389|BEHAVIORAL|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
48325207|NCT02222389|BEHAVIORAL|CM for drugs|"Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
48325208|NCT02222389|BEHAVIORAL|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
48325209|NCT02222389|BEHAVIORAL|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
47971384|NCT05238441|BIOLOGICAL|Comirnaty|D0; intramuscular injection
47971385|NCT05238441|BIOLOGICAL|SCTV01E|D180; intramuscular injection
47971386|NCT05238441|BIOLOGICAL|Comirnaty|D180; intramuscular injection
47971387|NCT01104506|PROCEDURE|fMRI|
47971388|NCT01104506|PROCEDURE|mTMS|
48119897|NCT00616668|DEVICE|Air- Limb|
48119898|NCT02825368|BIOLOGICAL|MMR|0.5 mL, subcutaneous
48119899|NCT02825368|BIOLOGICAL|Tdap|0.5 mL, intramuscular
48119900|NCT02825368|OTHER|Diphtherinum®|
48119901|NCT02825368|OTHER|Pertussinum®|
48119902|NCT02825368|OTHER|Tetanotxicum®|
48119903|NCT02825368|OTHER|Morbilinum®|
48119904|NCT02825368|OTHER|Ourlianum®|
48325210|NCT00386490|DRUG|larazotide acetate|capsule for oral administration
48325211|NCT04474119|DRUG|KN046|In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
48325212|NCT04474119|DRUG|KN046 placebo|"In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks."
48325213|NCT04238676|DRUG|PP353|active administered by intradiscal injection
48119905|NCT02825368|OTHER|Sterile saline|0.5 mL, intramuscular
48119906|NCT02825368|OTHER|Sugar pellets|
48119907|NCT02115139|DRUG|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
48119908|NCT02444416|PROCEDURE|blood sample|
48119909|NCT00003017|BIOLOGICAL|recombinant interleukin-12|
48119910|NCT00946842|DRUG|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
48325214|NCT04238676|OTHER|Placebo|Sham injection
48325215|NCT03729934|DIETARY_SUPPLEMENT|Ketone Ester|This arm receives 25 g ketone ester.
48325216|NCT03729934|DIETARY_SUPPLEMENT|Ketone Salt|This arm receives 25 g ketone salt.
48325217|NCT02842112|OTHER|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
48325218|NCT05843110|OTHER|Decision-making process|Retrospective evaluation using scales, questionnaires and a semi-structured interview
48325219|NCT03943888|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
48325220|NCT03943888|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
48325221|NCT03943888|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
47971389|NCT05755048|BIOLOGICAL|Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
47971390|NCT05755048|BIOLOGICAL|Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
47971391|NCT00088517|DRUG|[11C]NNC-112|
47971392|NCT04882540|DRUG|brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use"
47971393|NCT00607009|BEHAVIORAL|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
47971394|NCT02338440|DRUG|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
47971395|NCT05801250|BEHAVIORAL|AI Platform|AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
47971396|NCT03767530|DEVICE|Mibo Thermoflo|Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
47971397|NCT03767530|OTHER|Warm compresses and eyelid massage|Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
47971398|NCT02505997|DRUG|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
48119911|NCT00946842|DRUG|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
48325222|NCT03943888|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
48325223|NCT04007601|DEVICE|Active tDCS|Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
48325224|NCT04007601|DEVICE|Sham tDCS|Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
48325225|NCT01549223|DRUG|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
48325226|NCT01549223|DRUG|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
48325227|NCT04986020|DIAGNOSTIC_TEST|MRI|Identification of novel biomarkers from MRI
48119912|NCT00946842|DRUG|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
48119913|NCT00946842|DRUG|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
48119914|NCT00946842|DRUG|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
48119915|NCT00946842|DRUG|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
48119916|NCT00390793|DRUG|Cyclophosphamide|Given IV
48119917|NCT00390793|DRUG|Cytarabine|Given IV or IT
48119918|NCT00390793|DRUG|Dasatinib|Given PO
48119919|NCT00390793|DRUG|Dexamethasone|Given IV or PO
48649157|NCT05336357|DEVICE|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
48649158|NCT02281864|BEHAVIORAL|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
48649159|NCT02281864|OTHER|Control Group: Quitline|Referral to the Quitline
48649160|NCT01772693|DEVICE|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
48119920|NCT00390793|DRUG|Doxorubicin|Given IV
48119921|NCT00390793|DRUG|Methotrexate|Given IV or IT
48119922|NCT00390793|DRUG|Prednisone|Given PO
47971399|NCT02505997|DRUG|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
47971400|NCT01695265|OTHER|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
48119923|NCT00390793|DRUG|Vincristine|Given IV
48119924|NCT05623553|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
48119925|NCT02306577|DRUG|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
48649161|NCT01772693|DEVICE|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
48649162|NCT03622905|DEVICE|DBS-f On|Deep Brain Stimulation of the fornix
48649163|NCT03622905|DEVICE|DBS Off|Deep Brain Stimulation of the fornix turned off
48649164|NCT03139721|DEVICE|Mosaic model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
48649165|NCT03070067|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
48649166|NCT04229017|PROCEDURE|Anterior Cervical Discectomy and Fusion|Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
48649167|NCT04229017|DEVICE|Posterior Cervical Stabilization System (PCSS)|Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
48649168|NCT03747237|OTHER|Edema measurement methods|A correlation between the results of the first and second methods will be examined.
48649169|NCT04504669|DRUG|AZD8701|FOXP3 antisense oligonucleotide
48649170|NCT04504669|BIOLOGICAL|Durvalumab|anti PDL-1 monoclonal antibody
48649171|NCT00092742|DRUG|MK0663, etoricoxib|
48649172|NCT00092742|DRUG|Comparator: Diclofenac sodium|
47971401|NCT01695265|DEVICE|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
48119926|NCT01426269|DRUG|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
48119927|NCT01426269|DRUG|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
48119928|NCT01426269|DRUG|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
48119929|NCT00534183|DRUG|Olanzapine|Olanzapine in dose range of 10-20mg
48119930|NCT00534183|DRUG|Risperidone|Risperidone 1-6mg
48119931|NCT00534183|DRUG|Haloperidol|Haloperidol 10-20mg
48119932|NCT06464198|PROCEDURE|simultaneous postoperative radiochemotherapy|The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated.
48119933|NCT00632424|DRUG|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
48119934|NCT04260906|DEVICE|Vagus nerve stimulator|Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.
48325228|NCT01310218|OTHER|extended postoperative dressing|2 weeks of bulky dressing
48325229|NCT01310218|OTHER|short postoperative dressing|2 days bulky dressing followed by bandaid
48325230|NCT00700895|DRUG|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
48649173|NCT03115463|OTHER|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
47971402|NCT03926169|DRUG|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
48325231|NCT04163107|DRUG|Hydroxychloroquine|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
48489296|NCT02662231|PROCEDURE|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
48489297|NCT03251274|OTHER|machine bathing|machine bathing 20-min duration at evening
48489298|NCT03251274|OTHER|traditional bathing|traditional bathing
47971403|NCT03926169|DRUG|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
48325232|NCT04163107|DRUG|Carfilzomib Injection|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
48325233|NCT04163107|DRUG|Dexamethasone|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
48325234|NCT01345097|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty
48489299|NCT00709436|DRUG|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
47971404|NCT04426968|DRUG|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
47971405|NCT04426968|DRUG|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
47971406|NCT04426968|DRUG|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
47971407|NCT04426968|DRUG|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
47971408|NCT04426968|DRUG|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
48325235|NCT05017714|DRUG|Recombinant cytokine gene derived protein injection|"Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care."
48325236|NCT02491697|BIOLOGICAL|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
48325237|NCT02491697|DRUG|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
48340101|NCT05480800|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
48489300|NCT00709436|DRUG|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
48489301|NCT02283164|BEHAVIORAL|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
48489302|NCT03091660|BIOLOGICAL|BCG Solution|Given intravesically
48489303|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Solution|Given intravesically
48489304|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Vaccine|Given ID
48489305|NCT03091660|OTHER|Laboratory Biomarker Analysis|Correlative studies
48489306|NCT03182582|DEVICE|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
48325238|NCT01967524|DRUG|botulinum toxin A + ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
48325239|NCT01967524|DRUG|Ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
48649174|NCT05682677|DEVICE|iTBS|iTBS over the left dorsolateral prefrontal cortex
48649175|NCT05682677|DEVICE|sham iTBS|sham iTBS over the left dorsolateral prefrontal cortex
48649176|NCT05682677|BEHAVIORAL|Personalized, Augmented Cognitive Training (PACT)|6 sessions of PACT
47971409|NCT04426968|DRUG|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
47971410|NCT04426968|DRUG|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
47971411|NCT04080414|BEHAVIORAL|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
47971412|NCT04080414|BEHAVIORAL|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
47971413|NCT00897104|DRUG|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
47971414|NCT00897104|DRUG|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
48119935|NCT04260906|OTHER|exercise|The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
48119936|NCT04157426|OTHER|Percutaneous electrolysis|Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
48119937|NCT04157426|OTHER|Dry needling|Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
48119938|NCT04178226|OTHER|Manual Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
48325240|NCT02246023|DEVICE|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
48325241|NCT02246023|DEVICE|Oxygen saturation|Continuous measurement of oxygen saturation;
48325242|NCT02246023|DEVICE|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
48489307|NCT03182582|PROCEDURE|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
48649177|NCT06546592|DEVICE|AI assisted contouring|Initial are generated automatically using software powered by artificial intelligence
47971415|NCT00897104|DRUG|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
47971416|NCT05601284|BEHAVIORAL|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
48119939|NCT04178226|DEVICE|Laser Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
48119940|NCT04177459|BEHAVIORAL|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
48119941|NCT04177459|OTHER|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
48119942|NCT01551056|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
48119943|NCT01551056|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
48649178|NCT00594997|BEHAVIORAL|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
48649179|NCT00594997|BEHAVIORAL|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
48649180|NCT03633058|DRUG|Ketamine|oral ketamine dosed twice daily for 5 days
48649181|NCT05571696|BEHAVIORAL|Immune Strength|Immune Strength is a 12 week online program that provides content, strategies, and guidance on how to improve your immune system and increase your mental wellbeing, with a focus on stress, sleep, nutrition, and exercise. In addition to the online program, each participant will be paired with a Cleveland Clinic Coach who will communicate with the participant via email. The Coach will help guide the participant throughout the program and provide encouragement and guidance for making behavior changes for making a more resilient immune system.
48325243|NCT02246023|DEVICE|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
48119944|NCT04561219|DRUG|Nitazoxanide|Nitazoxanide 500mg three times a day for 5 days
48119945|NCT04561219|DRUG|Placebo|Placebo three times a day for 5 days
48119946|NCT02407834|OTHER|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
48119947|NCT02407834|OTHER|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
48119948|NCT02407834|OTHER|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
48119949|NCT02407834|OTHER|S4|Immersion in Saline solution for 20 minutes, during 7 days.
48649182|NCT06010563|DEVICE|Transcatheter pulmonary valve implantation (TPVI)|A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
48119950|NCT00348322|DRUG|Systane Free Lubricant Eye Drops|
48119951|NCT03432403|DEVICE|Ambu LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
48119952|NCT03432403|DEVICE|Gastro LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
48325244|NCT02246023|DEVICE|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
48325245|NCT01768468|DRUG|LAYLA tablet|1 tablet twice a day
48325246|NCT01768468|DRUG|JOINS tablet|1 tablet at each time, 3 times a day
48325247|NCT04810585|DRUG|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~* aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~* Folinic acid: 400 mg/m2 IV infusion for over 2 hours~* Irinotecan: 150 mg/m2 IV infusion for over 1 hours~* 5-FU: 400 mg/m2 IV bolus injection for over 5 minute~* 5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
48325248|NCT01586806|DRUG|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
48325249|NCT01586806|DRUG|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
48119953|NCT02647268|DRUG|Oxytocin|Oxytocin, 10-5M solution
48119954|NCT02647268|DRUG|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
48119955|NCT00701896|DRUG|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
48119956|NCT00701896|DRUG|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
48119957|NCT00701896|OTHER|Biological Control|No treatment intervention only information and procedures.
48119958|NCT00701896|BEHAVIORAL|Motivational Interview|60 minute one-on-one Interview
48119959|NCT02720965|OTHER|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
48119960|NCT02568683|DRUG|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
48119961|NCT02568683|DRUG|Vincristine|VCR administered intravenously
48119962|NCT01129232|DRUG|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
48119963|NCT01129232|OTHER|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
48119964|NCT05426317|OTHER|Blood sample|This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
48119965|NCT05084612|DEVICE|standard LMA insertion|"Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete~the laryngeal mask will be inserted with using the standard method described by Brain; after lubrication of the posterior aspect of the partially deflated mask, the patient's head will be positioned with head extended at the atlanto-axial joint and flexed at the neck with non-dominant hand. The LMA will be held like a pen and index finger will be placed at the junction of LMA tube and cuff. Index finger will be used to press the LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of the hypopharynx. LMA will then be held with non-dominant hand and index finger will be removed."
48119966|NCT05084612|DEVICE|New technique LMA insertion|Following pre-oxygenation, anaesthesia will be induced with atropine 0.1mg/kg, Fentanyl 2 µg /kg, Propofol 2 mg/kg and atracurium 0.5 mg/kg. When neuromuscular blockade will be complete LMA will be inserted by a two Person Insertion with lateral rotation Technique; after lubrication of the posterior aspect of the partially deflated mask, the assistant will achieve jaw thrust and mouth opening then LMA will be inserted by the anaesthiologist. LMA will be inserted by holding the mask by index, middle finger and thumb; after insertion of the entire cuff inside the mouth, the LMA will be rotated anticlockwise through 90° (the inner surface of LMA will be directed medially towards the mouth cavity) and advanced through the side of the tongue until resistance felt, then turned back in the hypopharynx.
48119967|NCT04369495|OTHER|BAFF serum levels|BAFF levels in serum in visit 0,1,2 during induction therapy
48325250|NCT01586806|DRUG|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
48325251|NCT04980313|DEVICE|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
47971417|NCT05601284|BEHAVIORAL|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
48325252|NCT04980313|DEVICE|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
48325253|NCT04740099|OTHER|SOONER Video & Kit|A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
48325254|NCT04740099|OTHER|Standard of Care|A handout including a map and list of locations offering this service.
48325255|NCT02853955|DEVICE|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
48325256|NCT00131664|DRUG|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
48325257|NCT00131664|DRUG|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
48325258|NCT00131664|DRUG|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
48325259|NCT02540096|OTHER|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
48325260|NCT02540096|OTHER|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
48325261|NCT03263156|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
48325262|NCT00234208|PROCEDURE|Medical thoracoscopy|
48325263|NCT00234208|PROCEDURE|Simple chest tube drainage|
48325264|NCT03886831|DRUG|PRT543|PRT543 will be administered orally
48325265|NCT03641547|DRUG|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
48489308|NCT03647046|DEVICE|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
48489309|NCT00772720|DRUG|raltegravir|raltegravir 400 mg BID for 7 days
48325266|NCT03641547|DRUG|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 \& B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
48325267|NCT03641547|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
48325268|NCT03641547|RADIATION|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
48325269|NCT00506948|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
48489310|NCT00772720|DRUG|Placebo|Placebo BID for 7 days
48489311|NCT04958382|DRUG|ciprofol|intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
48489312|NCT04958382|DRUG|medium/long chain fat emulsion injection (C8-24Ve)|at the infusion rate of 25-30 mL/h
48489313|NCT00632086|DRUG|PA32540|
48489314|NCT00632086|DRUG|aspirin component of PA32540|The 325 mg aspirin component of PA32540
48489315|NCT00632086|DRUG|Ecotrin|325 mg Ecotrin
47971418|NCT03665805|OTHER|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
47971419|NCT04212650|DRUG|Losartan|Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
47971420|NCT04212650|OTHER|Placebo|Appearance-matched microcrystalline cellulose placebo
48489316|NCT03122340|DRUG|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
48489317|NCT03122340|OTHER|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
48489318|NCT00378716|DRUG|5-fluorouracil|
48489319|NCT00378716|DRUG|leucovorin calcium|
48489320|NCT00378716|DRUG|tegafur|
48325270|NCT00506948|DRUG|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
48325271|NCT00506948|DRUG|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
48325272|NCT00506948|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
48325273|NCT04552431|DRUG|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
48325274|NCT04552431|DRUG|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
48325275|NCT04552431|DRUG|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
47971421|NCT02943278|BEHAVIORAL|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
47971422|NCT02943278|BEHAVIORAL|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
47971423|NCT00035516|DRUG|Epothilone|
47971424|NCT01804621|BEHAVIORAL|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
47971425|NCT00597181|PROCEDURE|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
47971426|NCT00597181|PROCEDURE|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
47971427|NCT03662490|DEVICE|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
47971428|NCT03930199|OTHER|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
47971429|NCT03405129|BEHAVIORAL|Phoenix|Phoenix cessation app
47971430|NCT03405129|BEHAVIORAL|NRT order button|Ability to order NRT through smartphone app
47971431|NCT03405129|BEHAVIORAL|Factoid|Factoid app
47971432|NCT02038023|DRUG|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
47971433|NCT04278638|RADIATION|IORT|IORT in surgery of laryngocarcinoma
47971434|NCT04278638|PROCEDURE|surgery|total laryngectomy or hemilaryngectomy
47971435|NCT04278638|RADIATION|External radiotherapy|External radiotherapy
47971436|NCT00691418|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
47971437|NCT00691418|DIETARY_SUPPLEMENT|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
47971438|NCT05013593|DIETARY_SUPPLEMENT|Red Clover Extract (RCE)|Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)
47971439|NCT05013593|OTHER|Placebo (PL)|Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
47971440|NCT02254252|DRUG|Nicorandil|nicorandil (10mg tablets, two times a day)
47971441|NCT02254252|DRUG|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
48325276|NCT04552431|DRUG|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
48325277|NCT04227184|DRUG|Trospium|Drug to treat overactive bladder
48325278|NCT04227184|DRUG|Placebo oral tablet|Placebo tablet containing no active drug
48325279|NCT00914043|GENETIC|gene expression analysis|
48325280|NCT00914043|GENETIC|microarray analysis|
48325281|NCT00914043|GENETIC|polymerase chain reaction|
48325282|NCT00914043|GENETIC|polymorphism analysis|
48325283|NCT00914043|GENETIC|reverse transcriptase-polymerase chain reaction|
48325284|NCT00914043|OTHER|biologic sample preservation procedure|
48325285|NCT00914043|OTHER|enzyme-linked immunosorbent assay|
48325286|NCT00914043|OTHER|laboratory biomarker analysis|
48325287|NCT00914043|PROCEDURE|fatigue assessment and management|
48325288|NCT00977015|DRUG|Treatment A|Inhaled, 750/150, single dose
48325289|NCT00977015|DRUG|Treatment B|Inhaled, 750/150, single dose
48325290|NCT02602171|OTHER|Oldenburger sentence test, localization test|
48325291|NCT06289842|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
48325292|NCT05948852|PROCEDURE|metabolic surgery (SADIS and OAGB)|TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
48325293|NCT00587769|DRUG|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
48325294|NCT04925518|DEVICE|Closed Loop Mechanical Ventilation|Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
48325295|NCT04925518|DEVICE|Conventional Mechanical Ventilation|Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
48489321|NCT00378716|DRUG|uracil|
48325296|NCT01995812|BEHAVIORAL|Hula and heart health education|
48325297|NCT03129204|BEHAVIORAL|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
48325298|NCT03372629|DRUG|ID-085|Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
48325299|NCT03372629|DRUG|Placebo oral capsule|Placebo capsules matching ID-085 capsules
48325300|NCT02884830|DEVICE|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
48325301|NCT04209894|DIAGNOSTIC_TEST|Ultrasound|Evaluation consisted of the detection of grey scale (GS) enthesitis and Power Doppler signal in enthesis areas of participants. The Madrid Sonography Enthesitis Index (MASEI) scoring system was used to quantify the extent of sonographic entheseal abnormalities
48325302|NCT01381718|DRUG|modafinil|Given PO
48325303|NCT01381718|OTHER|placebo|Given PO
48325304|NCT03111355|DIETARY_SUPPLEMENT|Brazil nut|one nut a day for 2 months, no intervention for 2 months
48489322|NCT06127368|DRUG|GB-5001A|Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.
48489323|NCT06127368|DRUG|GB-5001D|Depending on the cohort, volume will be varied to administer.
48489324|NCT06127368|DRUG|Oral cohort|Single dose of Aricept tablet.
48489325|NCT04135196|OTHER|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
48489326|NCT03421366|DRUG|Posaconazole|A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
48489327|NCT04209205|DRUG|AIN457 6 mg/kg i.v.|AIN457 6 mg/kg delivered by i.v. infusion
48489328|NCT04209205|DRUG|Placebo|Matching placebo to AIN457 i.v. infusion
48489329|NCT04209205|DRUG|AIN457 3 mg/kg|AIN457 3 mg/kg delivered by i.v. infusion
48489330|NCT04004143|OTHER|No intervention|No intervention.
48489331|NCT03450395|OTHER|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
48489332|NCT00506818|OTHER|Multifactorial vascular-risk-factor-intervention|
47971442|NCT03795987|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
48325305|NCT01450956|DRUG|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
48325306|NCT01450956|OTHER|Control|Patients will receive only oxygen and air through oxygenator
48325307|NCT03280069|DEVICE|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
48340102|NCT05480800|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control_Stage 2 Group in Stage 2 (Africa).
48340103|NCT05480800|DRUG|Placebo|3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo_Step 1 and Placebo_Step 2 in Stage 1 (Europe).
48340104|NCT05480800|OTHER|Saline|3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo_Step 1, iNTS-TCV full dose_1, Placebo_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose_2 and Control_Stage 2 groups in Stage 2 (Africa).
48489333|NCT05732974|OTHER|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
48489334|NCT00034983|DRUG|aprepitant|
48489335|NCT00034983|DRUG|Comparator: paroxetine HCL|
48489336|NCT03639519|DRUG|Ascorbic Acid 500Mg Chew Tab|Ascorbic acid will be administered at the night before surgery and will be continued for five days
48489337|NCT03639519|OTHER|Carbonated orange beverage|The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
48489338|NCT06265207|OTHER|Virtual reality|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
48489339|NCT06265207|OTHER|routine maintenance|routine maintenance
48489340|NCT01159782|OTHER|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
48119968|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
48119969|NCT00591500|BEHAVIORAL|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
48489341|NCT01684163|DRUG|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
48649183|NCT06010563|DEVICE|VenusP-ValveTM System|"VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."
48489342|NCT01684163|DRUG|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
48489343|NCT01684163|DRUG|Placebo|Intravenous administration of normal saline into arm.
48489344|NCT05865977|DEVICE|diaphragmatic tissue Doppler imaging，dTDI|dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.
48489345|NCT01847820|DEVICE|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
48489346|NCT03091413|DIAGNOSTIC_TEST|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient."
47971443|NCT04026308|OTHER|Safety Net App|The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
47971444|NCT04821921|OTHER|No intervention|Care as usual
47971445|NCT04869332|DEVICE|three cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
47971446|NCT04869332|DEVICE|four cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
47971447|NCT00533195|DRUG|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
47971448|NCT00533195|DEVICE|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
47971449|NCT02331914|PROCEDURE|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
47971450|NCT02331914|PROCEDURE|Tumor biopsy|Tumor biopsy after disease progression
48119970|NCT02665988|DEVICE|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
48489347|NCT02998450|DRUG|IMR-687|1 of 6 possible single doses administered orally following overnight fast
48649184|NCT06083571|DRUG|Ketorolac|Non-inferiority
48649185|NCT06083571|DRUG|Prochlorperazine|Adjunct
48649186|NCT06083571|DRUG|Diphenhydramine|Adjunct
48649187|NCT01514279|BEHAVIORAL|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
47971451|NCT03468153|BIOLOGICAL|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
48119971|NCT02665988|DEVICE|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
48119972|NCT01061671|DRUG|simvastatin|40 mgms of simvastatin daily
47971452|NCT02554487|DEVICE|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI \> 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI \< 5) following stroke serve as a control group
47971453|NCT02319889|RADIATION|Stereotactic Body Radiotherapy|Undergo SBRT
47971454|NCT02319889|DRUG|Carboplatin|Given IV
47971455|NCT02319889|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
48119973|NCT01061671|DRUG|Placebo|Matched placebo pill daily
48119974|NCT05868161|DEVICE|Pounce Thrombectomy System|Non-surgical removal of thrombi and emboli from the peripheral arterial vasculature with the Pounce Thrombectomy System.
47971456|NCT04047394|DRUG|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
47971457|NCT03761277|DEVICE|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
48119975|NCT03402633|OTHER|Examination of leukotrichia in vitiligo patients|Examination of leukotrichia will be enhanced by wood's light and dermoscopy for better enhancing of the lesions and good magnification
48325308|NCT03560635|BEHAVIORAL|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
48325309|NCT02325817|DEVICE|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
47971458|NCT03761277|DRUG|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
48119976|NCT02206269|DEVICE|Alair System|The Alair system is used for doing bronchial thermoplasty.
48119977|NCT01697059|DRUG|Piperacillin + Amoxicillin|
48119978|NCT05344014|PROCEDURE|Photobiomodulation|In experimental groups, before topical anesthesia, PBMT was applied by utilizing a diode laser (EpiX; Biolase technology, inc., USA) with a continuous wavelength of 940 nm on a 400-μm fiber with only biostimulation properties. In accordance with the recommendations of the device's manufacturer, it was applied using circular motions in a manner as slowly as possible (an average of 33-36 circular movements in 60 s)
48325310|NCT02325817|DEVICE|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
48325311|NCT03181477|DEVICE|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
48489348|NCT02998450|DRUG|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
47971459|NCT00116467|BIOLOGICAL|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
48119979|NCT05344014|PROCEDURE|Placebo|In the control group (placebo), the laser probe was directed to the mucosa for (buccal and palatal area), but not activated, and the sound of the laser device previously recorded on the mobile telephone was played for the same time of experimental group in order to provide similar conditions
48119980|NCT02372253|DRUG|Verapamil|
48119981|NCT02372253|DRUG|Placebo|
48119982|NCT01346982|DRUG|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
48649188|NCT01514279|BEHAVIORAL|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
48119983|NCT03294499|OTHER|Questionnaire|Patients will be asked to complete one off questionnaire.
48325312|NCT05151679|DRUG|Chelated Iron|"Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules )."
48325313|NCT05151679|DRUG|Iron sucrose|to group 2 where they will receive chelated oral iron, they will be given iron chelated amino acid containing 15 mg of elemental iron once daily for 6 weeks. the women will be advised to take 1 tab of iron chelated amino acid containing 15mg of elemental iron once daily with meals for 6 weeks from the day of recruitment.
48325314|NCT04782804|DRUG|Capecitabine|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
48325315|NCT04782804|DRUG|PD-1 Antibody（Tislelizumab）|PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
48325316|NCT01213069|OTHER|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
48325317|NCT06531226|OTHER|Fill in personality questionnaires|For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.
48325318|NCT02683018|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
48325319|NCT02683018|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
48325320|NCT00318565|DEVICE|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
48325321|NCT03248947|DRUG|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
48325322|NCT03248947|OTHER|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
48325323|NCT02919683|DRUG|Nivolumab|
48325324|NCT02919683|DRUG|Ipilimumab|
48325325|NCT02919683|PROCEDURE|Standard of Care Surgery|
48325326|NCT02333591|DRUG|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
48325327|NCT02333591|DRUG|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
48325328|NCT02333591|DRUG|Saline|Infused intravenously for 2,5 hours.
48325329|NCT06145464|BEHAVIORAL|Adhesion to the use of collective shadow|Quantitative evaluation of the use of shadow provided by one or two collective fabric devices, with 6 per 3 metres of size, containing 100% UV blocking filters, that will be installed in the sand on Foz do Lizandro beach, according to the recommendations provided in all groups of the study.
48325330|NCT06145464|BEHAVIORAL|Adhesion to the use of sun protector|Quantitative evaluation of the use of sun protector according to the recommendations provided in all groups of the study.
48325331|NCT06145464|BEHAVIORAL|Adhesion to the use of the information disposed in the infographic|Quantitative evaluation of the use of the information disposed in the infographic and provided in all groups of the study.
48325332|NCT06145464|BEHAVIORAL|Adhesion to the health literacy sessions in the interventional groups|Provision of health literacy sessions about skin cancer prevention by two different types of providers in the two interventional groups, 15 days before the use of sun protective interventions implemented at the beach
48325333|NCT04327518|DEVICE|TECNIS® Toric II|Toric Intraocular Lens
48325334|NCT06194981|DRUG|Oxaliplatin and capecitabine/ S-1 and capecitabine|Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
48325335|NCT04432506|BIOLOGICAL|Anakinra|Given SC
48325336|NCT04432506|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
48325337|NCT04432506|DRUG|Cyclophosphamide|Given IV
48325338|NCT04432506|DRUG|Fludarabine|Given IV
48649189|NCT00190528|DRUG|neoadjuvant chemotherapy + radical hysterectomy|
48649190|NCT00190528|PROCEDURE|radical hysterectomy|
48649191|NCT00090675|DRUG|ZD1839|
48649192|NCT01346592|BIOLOGICAL|Trivalent split influenza vaccine (TIV)|
48649193|NCT01346592|BIOLOGICAL|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
48649194|NCT01346592|BIOLOGICAL|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
48649195|NCT00638391|DRUG|Anastrozole|
48119984|NCT01444417|DRUG|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10\^9/L and ≤ 200 x 10\^9/L.
48119985|NCT01444417|DRUG|Placebo|Matching placebo administered by subcutaneous injection
48325339|NCT02350933|PROCEDURE|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
48325340|NCT00211250|DRUG|Valproic Acid and Depakote ER|
48325341|NCT02930369|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
48649196|NCT00890656|DRUG|Cyclophosphamide (CTX)|300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
48649197|NCT00890656|DRUG|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
48649198|NCT00890656|DRUG|Doxorubicin|50 mg/m\^2 by vein (IV) over 24 hours
48649199|NCT00890656|DRUG|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
48649200|NCT00890656|DRUG|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
48649201|NCT00890656|DRUG|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
48119986|NCT04064424|OTHER|Prevention video advertisement|Skin Cancer Prevention videos
48119987|NCT04064424|OTHER|Prevention images for advertisement|Skin Cancer Prevention images
48119988|NCT04064424|OTHER|No Advertisement|No skin cancer prevention videos or images were advertised.
48325342|NCT04929756|BEHAVIORAL|Visual Feedback|Gaze-contingent visual feedback
48325343|NCT00171106|DRUG|valsartan|
48325344|NCT04126031|DRUG|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
48325345|NCT04126031|DRUG|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
48489349|NCT00775684|DRUG|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
48649202|NCT00890656|DRUG|Ara-C|3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
48649203|NCT00890656|DRUG|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
48649204|NCT02592655|DEVICE|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
48649205|NCT02592655|DEVICE|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
48649206|NCT02592655|DEVICE|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
48649207|NCT02592655|DEVICE|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
48649208|NCT02592655|DEVICE|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
48649209|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
48649210|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
48119989|NCT02965846|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
48119990|NCT02965846|DRUG|Vehicle|1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
48489350|NCT00775684|DRUG|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
48489351|NCT00775684|DRUG|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose \< 110mg/dl
48649211|NCT03194932|DRUG|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
48649212|NCT03194932|DRUG|Cytarabine|Given intravenously (IV) or intrathecally (IT).
48649213|NCT03194932|DRUG|Idarubicin|Given IV.
48649214|NCT03194932|DRUG|Intrathecal Triple Therapy|Given IT.
48649215|NCT03194932|DRUG|Azacitidine|Given IV.
48649216|NCT05772156|DRUG|Methylergonovine|Methylergonovine 200mcg Intramuscular (IM)
48649217|NCT05772156|DRUG|Placebo|Matching saline placebo
47971460|NCT03274505|OTHER|Questionnaires|"* Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) \> 10)"
47971461|NCT03142087|OTHER|exercises|exercise
47971462|NCT06376279|GENETIC|IEM-EP|Data from IEM-inborn error of metabolism cohort of individuals
47971463|NCT02840097|DRUG|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
47971464|NCT02840097|DRUG|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
48489352|NCT04476628|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
48489353|NCT04476628|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
48649218|NCT03361631|DRUG|Autologous Bone Marrow derived Mesenchymal Stem Cells|Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
48649219|NCT04412239|BEHAVIORAL|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
47971465|NCT02737098|OTHER|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
48119991|NCT05284136|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet (CDED)|16-week course of CDED+Partial Enteral Nutrition. During the first 6 weeks (phase 1 of CDED), patients will be prescribed the CDED and oral Modulen 1 liter (1000kcal) daily. Between week 6 and 16 (phase 2 of CDED), patients will be prescribed CDED and oral Modulen (500 mL).
48119992|NCT05284136|DRUG|Oral prednisolone|oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
48119993|NCT00620997|DRUG|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
48119994|NCT00620997|DRUG|saline drops|saline drops continuously PRN for up to 7 days
48119995|NCT01112670|DRUG|Sitagliptin|sitagliptin 100 mg x 1 dose
48119996|NCT01112670|DRUG|atorvastatin|atorvastatin 40 mg x 5 doses
48489354|NCT04476628|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
48489355|NCT00896324|BEHAVIORAL|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
48649220|NCT03692026|PROCEDURE|Immediate implant placement|implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
48649221|NCT03692026|DRUG|Hyaluronic acid and Melatonin Mixture|a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
48649222|NCT06496100|DRUG|Triticum Aestivum|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
48649223|NCT06496100|DRUG|Placebo (calcined magnesia)|The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
48649224|NCT01977976|PROCEDURE|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
48119997|NCT00832325|BEHAVIORAL|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
48649225|NCT04325607|PROCEDURE|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
48119998|NCT00832325|BEHAVIORAL|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
48119999|NCT00832325|BEHAVIORAL|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
48649226|NCT04325607|PROCEDURE|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
48649227|NCT02682251|OTHER|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
48489356|NCT00896324|BEHAVIORAL|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
48649228|NCT05305703|OTHER|cervical stretching|Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each
47971466|NCT02737098|OTHER|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
47971467|NCT04648631|DEVICE|antibiofilm surfactant wound gel (ABWG)|ABWG is a hydro-gel applied topically using a tongue depressor
47971468|NCT02596308|BIOLOGICAL|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
48120000|NCT00955825|DRUG|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
48120001|NCT00955825|DRUG|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
48120002|NCT02214160|DRUG|UX007|Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
48325346|NCT03140423|DRUG|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
48120003|NCT01130727|OTHER|green tea extract|1.21g of green tea extract (965 mg of flavonols)
48649229|NCT05305703|OTHER|soft tissue mobilization|Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
48649230|NCT00987935|DRUG|Sorafenib|400 mg twice daily
48649231|NCT00987935|DRUG|BIBF 1120|Twice daily
48649232|NCT03221335|DEVICE|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
47971469|NCT05650216|DRUG|Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)|"1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity."
47971470|NCT00267384|DRUG|Oral N-Acetylcysteine|
48649233|NCT06498180|OTHER|Periodontal initial treatment under local anesthesia|Removal of plaque retention factors, supragingival scaling and subgingival scraping under local anesthesia with articaine (combined with manual and ultrasound methods), and polishing
48649234|NCT06498180|DRUG|Glucocorticoid Therapy|Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
47971471|NCT06135350|DRUG|Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day|"Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~* 2400 mg/day (4 tablets twice a day) for the first 2 days and;~* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
48120004|NCT01130727|OTHER|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
48120005|NCT01130727|OTHER|placebo|placebo
48120006|NCT01130727|OTHER|low polyphenol cocoa extract|placebo
48120007|NCT01042639|BEHAVIORAL|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
48489357|NCT00896324|BEHAVIORAL|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
48120008|NCT03649113|PROCEDURE|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
48120009|NCT00477308|PROCEDURE|salvage therapy|
48120010|NCT04277715|BEHAVIORAL|Parent training|Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
48120011|NCT01576107|OTHER|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
48120012|NCT01576107|OTHER|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
48325347|NCT03140423|DRUG|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
48489358|NCT05120102|DEVICE|Diode laser|K2 diode laser of 980nm wavelength
48489359|NCT03966391|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
48489360|NCT01940094|DRUG|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
48649235|NCT06498180|BEHAVIORAL|oral hygiene instruction|Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes
48649236|NCT04355832|DRUG|Glucagon-like peptide-1|Infusion of Glucagon-like peptide-1
48649237|NCT04355832|DRUG|Placebos|Infusion of normal saline solution that will mimic Glucagon-like peptide-1
48649238|NCT06029166|DEVICE|Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)|Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
48649239|NCT01985282|BEHAVIORAL|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
48649240|NCT00165607|DRUG|MENATETRANONE|
48325348|NCT05651516|DRUG|18F-PI-2620 PET/CT|PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
48325349|NCT00426556|DRUG|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
48489361|NCT01940094|DRUG|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
47971472|NCT06135350|OTHER|Placebo|"Placebo arm patients will receive placebo:~* 4 tablets twice a day for the first 2 days and;~* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
47971473|NCT02948972|PROCEDURE|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
47971474|NCT02948972|PROCEDURE|In vitro fertilization without surgery|IVF without endometriosis surgery
47971475|NCT02088047|DEVICE|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
47971476|NCT01997632|BIOLOGICAL|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
47971477|NCT01997632|BIOLOGICAL|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
47971478|NCT03624894|OTHER|impression|common polyvinylsiloxane oral impression
47971479|NCT01939743|DRUG|Diclofenac suppository plus lidocaine gel|
47971480|NCT01939743|DRUG|Lidocaine gel only|
47971481|NCT01775085|BEHAVIORAL|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts \& Sources of Meaning; 2) Identity, Cancer Survivorship, \& Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present \& Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity \& Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, \& Humor; and 8) Transitions: Reflections \& Hopes for the Future.
47971482|NCT01775085|BEHAVIORAL|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
47971483|NCT05081154|OTHER|Product A|P1012915, a nicotine pouch with 8 mg nicotine
48120013|NCT03400488|DRUG|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
48120014|NCT03400488|OTHER|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
48120015|NCT03484065|OTHER|Questionnaire quality of life|
48489362|NCT00973765|DRUG|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
48489363|NCT00973765|DRUG|placebo|placebo 2 pills po BID x 7 days
48649241|NCT04295928|BEHAVIORAL|PPP|Personalized Pharmaceutical Plan on therapeutic adherence to immunosuppressive treatments after the transplantation
48120016|NCT04213053|PROCEDURE|strabismus surgery|Lees screen before and after concomitant strabismus surgery
48489364|NCT05377593|DEVICE|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
48489365|NCT00077584|DRUG|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
48489366|NCT00077584|DRUG|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
48649242|NCT05586321|BIOLOGICAL|GEN1056|GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
48649243|NCT03403127|DIAGNOSTIC_TEST|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
48489367|NCT00077584|DRUG|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
48649244|NCT06549868|BEHAVIORAL|Yoga-based bedtime routine|"Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period."
48649245|NCT05957094|DRUG|Pharmacological agent: Citalopram|Participants will be given 40 mg in capsule form, which is a normal clinical dose.
48649246|NCT05957094|OTHER|Placebo|Participants will ingest a placebo (sugar pill) that is identical in appearance to the drug condition.
48120017|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email (iCBT-E)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails, therapists will serve to provide encouragement and support as the parent works through the program independently."
48120018|NCT05284435|BEHAVIORAL|Cognitive Behavioral Therapy-Email and Videoconferencing (iCBT-EV)|"Participating families will receive an access to the website that contains treatment materials for both parent and child.~During each of the weekly emails and six videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently. Therapists will also assist the parent with any problem-solving as needed."
48120019|NCT01028118|OTHER|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
48120020|NCT01267383|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
48120021|NCT02940951|OTHER|QPSS|Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
48120022|NCT02940951|OTHER|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
48120023|NCT01900834|OTHER|No treatment given|The participants will not receive any treatment
48120024|NCT05876143|DEVICE|Unicompartmental knee arthroplasty|"Knee joint could be subject to natural or pathological wear or shocks (primary or secondary evolutive or traumatic osteoarthritis) which cause pain and reduced mobility of the knee.~When only one lateral or medial compartment of the femoro-tibial knee joint is affected, the treatment of unicompartmental femoro-tibial osteoarthritis of the knee is generally carried out by the implantation of a so-called unicondylar knee prosthesis (UKP), in order to reduce pain and improve joint mobility of the knee compared to the preoperative state."
48120025|NCT04048993|OTHER|Biobank development and integrative physiological analysis|Collection of biological samples (blood, urine, interstitial fluid, adipose tissue and muscle) from subjects enrolled in the Section registry, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
48120026|NCT04232371|PROCEDURE|New Ablation Technique|Patient will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.
48120027|NCT04232371|PROCEDURE|Standard Ablation Technique|Ablation performed using the traditional anatomical / electrogram guided ablation approach.
48649247|NCT05752838|OTHER|No intervention|This is a survey study, and there were no intervention
48120028|NCT00821184|DRUG|Vesicare (solifenacin)|5mg po qd
48120029|NCT00821184|BEHAVIORAL|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
48120030|NCT05032794|OTHER|Unrestricted diet before colonoscopy|Free diet, without restrictions
48120031|NCT05032794|OTHER|1-day low residue diet|To follow a diet low in residues / fiber. the day before the colonoscopy.
48120032|NCT05032794|DRUG|Bisacodyl 5 MG|If the participant is at risk of inadequate bowel cleansing, defined by a score of Dik et al ≥ 2 it will be given Bisacodyl 5 milgrams bid for 3 days.
48120033|NCT03663504|OTHER|No Preparation|No preparation before surgery
48489368|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Starting Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
48120034|NCT03663504|DRUG|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
48120035|NCT03248271|DRUG|Insulin Lispro|Insulin
48120036|NCT05291104|DIETARY_SUPPLEMENT|Folic acid, choline chloride|In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
48120037|NCT02544152|DRUG|Lubiprostone|8 mcg administered orally twice daily (BID)
48120038|NCT02544152|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
48120039|NCT05140434|DIAGNOSTIC_TEST|Exercise test|exercise test on an exercise bike with increasing load
48120040|NCT05140434|DIAGNOSTIC_TEST|Cardiac CT|cardiac CT scan
48120041|NCT02155010|DRUG|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
48120042|NCT02155010|DRUG|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
48120043|NCT04593914|DEVICE|Cavilon Advanced Skin Protectant|"3M™ Cavilon™ Advanced Skin Protectant is a polymeric-cyanoacrylate solution intended for the protection of intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier. It is elastomeric, adhering to the contours of the skin and providing a uniform film. The film is transparent and possesses good oxygen and moisture vapor permeability.~The polymer-cyanoacrylate is dispersed in a non-stinging solvent. The film is colorless, non-cytotoxic and has a low dermatitis potential. The film adheres to dry, moist or wet skin surfaces and remains intact during conditions of continuous or repeated exposure to moisture or caustic irritants. It will wear off the skin and does not require removal."
48649248|NCT06674668|OTHER|Vibrotactile stimulation|The intervention includes traditional physiotherapy and 20 minutes of vibrotactile device use. As traditional physiotherapy, 30 seconds of 8 repetitions of passive wrist stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Afterwards, the Intellinetix Elbow Wearable Vibration Device providing vibration will be worn on the affected tissue. The patient will remain in a comfortable position on the treatment table with the affected extremity for 20 minutes (10 minutes × 2).
48649249|NCT06674668|OTHER|Traditional physiotherapy|For traditional physiotherapy, passive stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Stretching exercises will be performed on the wrist flexor and extensor muscles for 30 seconds and 8 repetitions. Mill's manipulation, described by James Cyriax, will be applied once for radial head mobilization. The treatment will be completed with a 5-minute deep friction massage, affecting the wrist extensor muscle tendons and their ending points.
48649250|NCT00625105|BEHAVIORAL|Biofeedback|
47971484|NCT05081154|OTHER|Product B|P1013018, a nicotine pouch with 10 mg nicotine
47971485|NCT05081154|OTHER|Product C|P1013015, a nicotine pouch with 8 mg nicotine
48120044|NCT03339115|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
48120045|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
47971486|NCT05081154|OTHER|Product D|P1012815, a nicotine pouch with 8 mg nicotine
47971487|NCT05081154|OTHER|Product E|P1013315, a nicotine pouch with 8 mg nicotine
47971488|NCT05081154|OTHER|Product F|P1013115, a nicotine pouch with 8 mg nicotine
47971489|NCT05081154|OTHER|Product G|P1013215, a nicotine pouch with 8 mg nicotine
48325350|NCT00426556|DRUG|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel \& Trastuzumab
48325351|NCT00426556|DRUG|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
48325352|NCT04882709|DEVICE|Receiver-in-canal hearing aid 1 default|A receiver-in-canal hearing aid developed by the Study Sponsor used with the default settings as specified in the Study Sponsor's fitting software.
48325353|NCT04882709|DEVICE|Receiver-in-canal hearing aid 2|A receiver-in-canal hearing aid developed by another hearing aid manufacturer used with the default settings as specified in the manufacturer's fitting software.
48649251|NCT00003670|DRUG|arzoxifene hydrochloride|
48649252|NCT02323620|PROCEDURE|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
48649253|NCT02708368|OTHER|blood withdrawal|3 times
48649254|NCT03124602|DEVICE|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
47971490|NCT03570645|DRUG|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
47971491|NCT03570645|DRUG|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
47971492|NCT03570645|DRUG|control group|block with only ropivacaine
47971493|NCT02817100|DRUG|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
47971494|NCT02817100|DRUG|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
47971495|NCT02817100|DRUG|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
47971496|NCT06170723|DRUG|BMS-986368|Specified dose on specified days
47971497|NCT06170723|DRUG|Itraconazole|Specified dose on specified days
47971498|NCT06170723|DRUG|Famotidine|Specified dose on specified days
47971499|NCT05779995|DRUG|XW001|Inhalation solution
47971500|NCT05779995|DRUG|Placebo|Inhalation solution with matched volume
48120046|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
48120047|NCT02422784|DIETARY_SUPPLEMENT|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
48120048|NCT02020252|BEHAVIORAL|Testing an interactive technology in a diverse health literary population|Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. We tested an interactive technology designed for patients with diverse health literacy skills aimed at improving patient receptiveness, willingness, knowledge, self-efficacy and positive attitudes regarding clinical trials.
48120049|NCT05025995|BEHAVIORAL|Serious health game|Serious health game
48120050|NCT04593810|PROCEDURE|INTELLiVENT-ASV|INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.
48120051|NCT04593810|PROCEDURE|CONVENTIONAL VENTILATION|Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.
47971501|NCT06451094|DEVICE|US therapy|3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
48120052|NCT02869022|DRUG|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
47971502|NCT06451094|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
48120053|NCT02869022|DRUG|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
48325354|NCT04882709|DEVICE|Receiver-in-canal hearing aid 1 strategy 1|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
47971503|NCT01725178|BEHAVIORAL|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
47971504|NCT06293495|DEVICE|Gamma 3 Nail (Stryker)|Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)
47971505|NCT06293495|DEVICE|Chimaera Nail (Orthofix)|Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)
47971506|NCT05753423|DIAGNOSTIC_TEST|Interview-based questionnaires & Clinical examination|Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
48120054|NCT02869022|PROCEDURE|organ perfusion for heart transplantation|
48325355|NCT04882709|DEVICE|Receiver-in-canal hearing aid 1 strategy 2|A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
48325356|NCT03825263|DEVICE|Intermittent Pressure Compression|The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
48325357|NCT04350905|OTHER|Mosquito Feeding|Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
48120055|NCT05293548|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
48120056|NCT05293548|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
48325358|NCT01046383|DIETARY_SUPPLEMENT|IMN1207|20 grams of IMN1207 per day for 40 weeks.
48325359|NCT01046383|DIETARY_SUPPLEMENT|Casein|20 grams of Casein per day for 40 weeks
48325360|NCT01896908|OTHER|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
47971507|NCT05145530|PROCEDURE|selective anterior cervical discectomy and fusion (ACDF)|selective anterior cervical discectomy and fusion (ACDF)
47971508|NCT05145530|PROCEDURE|SNRB+ selective anterior cervical discectomy and fusion (ACDF)|US-guided selective nerve root block (SNRB) + selective anterior cervical discectomy and fusion (ACDF)
47971509|NCT00869154|BEHAVIORAL|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
47971510|NCT00869154|BEHAVIORAL|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
48120057|NCT03084744|BEHAVIORAL|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
48120058|NCT03084744|BEHAVIORAL|Active monitoring|Active tele-monitoring by clinical psychologists.
48120059|NCT04805996|BEHAVIORAL|Diabetes remission using total diet replacement and eHealth contact with the healthcare provider|Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
48120060|NCT02064959|DEVICE|Temperature management Zoll Intravascular Temperature Management device|
48120061|NCT02708927|OTHER|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
48120062|NCT02708927|OTHER|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
48120063|NCT01134237|DRUG|urokinase|intrapleural urokinase injection
48120064|NCT01134237|DRUG|placebo|Normal saline as a placebo for control arm
48120065|NCT00816751|PROCEDURE|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
48120066|NCT00816751|PROCEDURE|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
48120067|NCT00816751|DRUG|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
47971511|NCT04606914|DRUG|mirvetuximab soravtansine (MIRV; IMGN853)|Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
47971512|NCT06081257|DIETARY_SUPPLEMENT|"KB-120 small molecular nutrient and vitamin E"|"The experimental group was given oral KB-120 small molecular nutrients, once a day, once a bag (30ml), and vitamin E100mg orally twice a day for a total of 3 menstrual cycles"
47971513|NCT06081257|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
48120068|NCT00643929|DRUG|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
48120069|NCT01706354|PROCEDURE|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
48120070|NCT01706354|PROCEDURE|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
48120071|NCT01394510|DRUG|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
48120072|NCT04249713|DRUG|Brodalumab|Interleukin 17 Receptor A Antagonist
48325361|NCT00355849|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
48325362|NCT00355849|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
48120073|NCT02756377|DRUG|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
48120074|NCT02756377|DRUG|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
48120075|NCT05685030|DIETARY_SUPPLEMENT|Placebo|product vehicle (sunflower oil)
48325363|NCT00742807|DRUG|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
48120076|NCT05685030|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri CCT 7862|Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
48120077|NCT05685030|DIETARY_SUPPLEMENT|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863|Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day
48325364|NCT00742807|DRUG|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
48325365|NCT03110198|DRUG|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
48325366|NCT03110198|DRUG|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
48325367|NCT03110198|DRUG|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
48325368|NCT03670069|DRUG|Itacitinib|Given PO
48325369|NCT03670069|OTHER|Laboratory Biomarker Analysis|Correlative studies
48325370|NCT05306548|PROCEDURE|Surgical carpal tunnel release|Open surgical division of the flexor retinaculum of the palm/wrist to release pressure on the median nerve
48120078|NCT06020963|PROCEDURE|Low Intensity Shockwave Therapy (LiSWT)|Low Intensity Shockwave Therapy (LiSWT) has been used for many years. Its mechanism is to use shock wave energy to promote angiogenesis to achieve the functions of tissue repair and cell regeneration.
48120079|NCT06020963|DRUG|Tamsulosin|Tamsulosin is a selective alpha-1 blocker, its main function is to relax the smooth muscles of the base of the prostate, urethra, and bladder, and improve lower urinary tract symptoms.
48120080|NCT06459024|OTHER|Registration into the STREAM platform|All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
48120081|NCT05973578|RADIATION|Stereotactic radiotherapy|Single-session high dose stereotactic radiotherapy
48120082|NCT03674814|DRUG|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
48120083|NCT03674814|DRUG|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
48120084|NCT02788604|OTHER|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
48325371|NCT05306548|DRUG|Injection, Triamcinolone Hexacetonide, Per 5 Mg|Ultrasound-guided injection of 20 mg of triamcinolone hexacetonide (or -acetonide) into the carpal tunnel space close to the median nerve
48649255|NCT06466837|BEHAVIORAL|Just-in-time intervention|The intervention group participants will receive just-in-time intervention from a developed app for healthy behavior reminder
48649256|NCT06466837|BEHAVIORAL|Active control|The control group participants will receive six nursing consultations during the 3-month program period.
48649257|NCT04928287|BIOLOGICAL|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
48649258|NCT04928287|OTHER|Placebo|Placebo will be administered intravenously to study participants who qualify.
48649259|NCT04028167|DRUG|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
48649260|NCT00214669|BEHAVIORAL|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
48649261|NCT00214669|BEHAVIORAL|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
48649262|NCT00214669|BEHAVIORAL|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
48649263|NCT06675240|BEHAVIORAL|MediNF|Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
48120085|NCT02788604|OTHER|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
48120086|NCT04217512|DRUG|Pantoprazole low dose|Pantoprazole 0.6 mg/kg
48120087|NCT04217512|DRUG|Pantoprazole high dose|Pantoprazole 1.6 mg\\kg
48120088|NCT04217512|OTHER|Standard hydration|Standard hydration alone
48120089|NCT04217512|DRUG|Cisplatin|Cisplatin
48120090|NCT06451185|OTHER|A haemostatic mineral powder product.|The intervention is the addition of an approved and commercially available haemostatic powder product which is indicated for the temporary external control of bleeding. Recommended application is at central venous catheter insertion, prior to the site being covered with a transparent dressing. Comprising a hydrophilic polymer and potassium ferrate, once in contact with protein-rich body fluids, the mechanism of action of the powder is to dehydrate and to absorb exudate. This simultaneously forms a low pH seal barrier which is hostile to microbial penetration while also purporting to help maintain clean and dry environment beneath transparent site dressings.
48325372|NCT00213980|DRUG|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
48325373|NCT06139861|BEHAVIORAL|TranS-C|Transdiagnostic Sleep and Circadian Intervention (TranS-C) is an evidence based cognitive-behavioral sleep therapy.
48649264|NCT04076657|BEHAVIORAL|Brock String Therapy|Oculomotor exercise to improve binocular vision function
48649265|NCT04076657|BEHAVIORAL|Standard of Care|patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
48649266|NCT00449787|DRUG|Sumatriptan 100 mg|Sumatriptan 100mg tablet
48649267|NCT00449787|DRUG|Naproxen|Naproxen 500mg tablet
48649268|NCT01348581|DEVICE|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
48649269|NCT02005926|PROCEDURE|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
48649270|NCT00307580|DRUG|Cathflo Activase (Alteplase)|
48649271|NCT05720091|DRUG|ZX-7101A 80mg|a drug to treatment influenza in Chinese adults
48649272|NCT05715723|DRUG|Reamberin|Reamberin® in the average daily dose of 10 ml/kg daily
48649273|NCT06245655|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS 7000 digital TENS unit, a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
48649274|NCT01366274|OTHER|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
48649275|NCT01366274|OTHER|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
47971514|NCT04383795|DRUG|Antithyroid Drug|Administration of antithyroid Drug for 6 months
47971515|NCT06506383|OTHER|No Intervention as this is an ecological study|No Intervention as this is an ecological study
47971516|NCT01250405|DRUG|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
47971517|NCT01250405|DRUG|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
47971518|NCT03972332|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
47971519|NCT00812578|DRUG|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
47971520|NCT06076616|BEHAVIORAL|Prehabilitation and rehabilitation|A personalized lifestyle counseling programme.
47971521|NCT02537197|DRUG|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
47971522|NCT04388189|DRUG|Duloxetine|FDA approved antidepressant
47971523|NCT04388189|DRUG|Bupropion|FDA approved antidepressant
47971524|NCT04813198|BEHAVIORAL|TIPSTART|TIPSTART is a multimodal, cognitive behavior-based therapy integrating peer-sharing, technology, aerobic and resistance training.
47971525|NCT05502601|PROCEDURE|Non-surgical periodontal treatment|"SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
47971526|NCT00357968|DRUG|Prasugrel|Administered orally
47971527|NCT00357968|DRUG|Clopidogrel|Administered orally
47971528|NCT00357968|DRUG|Placebo for Prasugrel|Administered orally
48649276|NCT00027300|DRUG|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
48649277|NCT00027300|DRUG|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
48489369|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Low Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
48489370|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 Middle Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
48489371|NCT04669535|BIOLOGICAL|AXO-AAV-GM2 High Dose|1:1 ratio of AAVrh8-HEXA and AAVrh8-HEXB, administered via bilateral thalamic (BiTh) and dual intracisterna magna (ICM)/intrathecal (IT) administration into the cerebrospinal fluid (CSF).
47971529|NCT00357968|DRUG|Placebo for Clopidogrel|Administered orally
47971530|NCT00439244|DRUG|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
48120091|NCT05036408|OTHER|Behavioral, Psychological or Informational Intervention|Participate in group psychological intervention
48120092|NCT05036408|OTHER|Educational Intervention|Attend educational session
48120093|NCT05036408|PROCEDURE|Manipulative and Body-Based Intervention Procedure|Undergo osteopathic manual treatments
48325374|NCT06139861|BEHAVIORAL|Psychoeducation|The overarching principle is to provide information about how sleep, stress, diet, health, exercise, accidents and mood are inter-related and have reciprocal effects.
48325375|NCT04861519|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
48489372|NCT00818129|DRUG|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
48489373|NCT00818129|DRUG|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
48489374|NCT00468078|PROCEDURE|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
48489375|NCT00468078|DRUG|F-18 FPCIT|5mCi, intravenous injection
48649278|NCT05991687|OTHER|In-home drug disposal pouch|Will receive a drug disposal pouch to inactivate leftover prescription opioids for disposal after surgery.
48649279|NCT05991687|OTHER|Mail-in prepaid envelope|Will receive a prepaid envelope to mail leftover prescription opioids for disposal after surgery
48120094|NCT05036408|BEHAVIORAL|Occupational Therapy|Participate in occupational therapy
48325376|NCT05001061|DRUG|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
48325377|NCT03519516|DRUG|PRO-174|"Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
48325378|NCT03519516|DRUG|Sophixín Ofteno®|"* Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
48325379|NCT01752439|DEVICE|Anodal transcranial direct current stimulation|
48489376|NCT03257475|RADIATION|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
48489377|NCT01739296|OTHER|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
48489378|NCT01739296|OTHER|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
48120095|NCT05036408|OTHER|Physical Activity|Participate in physical activity
48489379|NCT06192836|PROCEDURE|Manual Removal 1|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
48489380|NCT06192836|PROCEDURE|Manual Removal 2|"1. Placenta will be removed manually~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
48489381|NCT06192836|PROCEDURE|Controlled Cord Traction 1|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed"
48489382|NCT06192836|PROCEDURE|Controlled Cord Traction 2|"1. Placenta will be delivered via controlled cord traction~2. Uterine incision will be repaired as double layered~3. Uterine massage will be performed for one minute duration, after uterine incision is closed"
48120096|NCT05036408|PROCEDURE|Physical Therapy|Participate in physical therapy
48120097|NCT05036408|OTHER|Questionnaire Administration|Ancillary studies
48325380|NCT01752439|DEVICE|Sham transcranial direct current stimulation|
48325381|NCT00927264|BEHAVIORAL|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits \& 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
48325382|NCT00927264|BEHAVIORAL|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
48489383|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 1|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. No uterine massage will be performed after placental delivery"
48489384|NCT06192836|PROCEDURE|Controlled Cord Traction+Uterine Massage 2|"1. Placenta will be delivered via controlled cord traction plus uterine massage~2. Uterine incision will be repaired as double layered~3. Additional uterine massage for one minute duration will be performed after uterine incision is closed"
48325383|NCT00906867|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
48325384|NCT00906867|PROCEDURE|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
48325385|NCT05058898|OTHER|blood samples|5 mL
48120098|NCT00945607|OTHER|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
48120099|NCT06215092|OTHER|Psychological assessment|Psychological assessment of cognitive and social-emotional functioning.
48120100|NCT04806178|BIOLOGICAL|Bacillus Calmette Guerin|0.1 ml of lyophilized, live, and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.
48120101|NCT04806178|OTHER|PLACEBO|0.1 ml 0.9% saline in the same volume as the BCG vaccine in a single dose.
48120102|NCT03279861|DRUG|Entresto|First line therapy in Entresto arm
48120103|NCT03279861|DRUG|Valsartan|"First line therapy in usual meds arm"
48120104|NCT04956575|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
48120105|NCT04956575|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
48325386|NCT05058898|OTHER|Scabs and pus samples|if available
48325387|NCT01205451|DRUG|Botulinum toxin type A|Botulinum toxin type A
48325388|NCT00453843|DEVICE|rehabilitation robotics|sequence of intervention
48325389|NCT00453843|PROCEDURE|Movement therapy|sequence of intervention
48489385|NCT01016093|DRUG|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
48489386|NCT01016093|DRUG|Placebo|Placebo
48649280|NCT05795712|OTHER|Therapy Change from Baseline|The patient will be followed up from the point of view of therapy according to symptoms and flare-ups irrespective of systemic or peripheral eosinophil assessment
48649281|NCT06225037|DEVICE|Sedline EEG monitoring|Propofol titrated according to the raw EEG and spectrogram, aiming to maintain sedation (alpha oscillations +/- slow oscillations) and preventing burst suppression, keeping the PSI greater than 25 where possible.
48649282|NCT06225037|DEVICE|Sedline EEG with output concealed|Clinician will be blinded to the sedline output but data will be collected for analysis (Sedline output will only be analysed at data analysis)
47971531|NCT00439244|DRUG|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
48120106|NCT04956575|BIOLOGICAL|Active Comparator|0.5 milliliter (mL) intramuscular (IM) injection
48120107|NCT04426916|OTHER|Spondylolisthesis|Spondylolisthesis at a single level
48120108|NCT05861193|PROCEDURE|Treatment of the abfraction with BOPT technique|"The steps to follow for the treatment of abfraction using composite resin and the B.O.P.T. technique will consist of:~* Selection of the color of the composite, placement of the retraction cord and chamfering of the coronal margin of the lesion;~* Application of 37% phosphoric acid etching and adhesive in 3 steps; placement of the composite by layers, following the conventional obturation technique.~* Execution of an overfilling with the composite at the level of the cervical emergence profile of the tooth, with the aim of emphasizing said anatomical particularity.~* Removal of the retraction cord.~* Diamond milling with red rim flame diamond bur and contra-angle, positioned from the most apical point of the restoration at an angle of 45º without touching the restored dental portion, with the aim of performing a level rotary gingival curettage from the margin of the restoration.~* Polishing with a fine-grain flame bur, and polishing discs of decreasing granulometry."
48120109|NCT02531113|DRUG|RPC1063|
48120110|NCT04676334|DRUG|Rucaparib|Rucaparib will be administered daily.
48120111|NCT05875883|PROCEDURE|Neck ultrasound|The investigators will scan patients' necks with an ultrasound and look for anatomical landmarks to identify the phrenic nerve
48325390|NCT00565214|DIETARY_SUPPLEMENT|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
48325391|NCT00565214|DIETARY_SUPPLEMENT|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
48325392|NCT02067416|DRUG|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
48325393|NCT02067416|DRUG|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
48325394|NCT01110772|DEVICE|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
48649283|NCT06114472|DRUG|aromatherapy blend containing Lavender|hree drops of aromatherapy blend containing Lavender essence 10% were poured on cotton in cast containers, and the patient was asked to inhale it for 5 minutes from a distance of 10 cm
48649284|NCT06570499|OTHER|Implant impression|definitive impressions on implants
48649285|NCT02704377|OTHER|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
48649286|NCT02704377|PROCEDURE|Dual X-ray Absorptiometry|Undergo iDXA
47971532|NCT00439244|DRUG|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
47971533|NCT03878628|DRUG|Adipose tissue-derived mesenchymal stem cells|CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
47971534|NCT01080534|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
47971535|NCT03036696|OTHER|Pregnant Mothers Interview|"Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.~Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
48120112|NCT00824135|DRUG|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
48325395|NCT01110772|DEVICE|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
48325396|NCT02488525|DRUG|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
48489387|NCT06198036|OTHER|Hold-Relax Technique|Participants in this group will be treated with hold-relax PNF Technique
48649287|NCT02704377|OTHER|Laboratory Biomarker Analysis|Correlative studies
48649288|NCT02704377|OTHER|Quality-of-Life Assessment|Ancillary studies
48649289|NCT02704377|OTHER|Questionnaire Administration|Ancillary studies
47971536|NCT03036696|OTHER|Breastfeeding Mothers Interview|"Breastfeeding mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.~Data collection for breastfeeding mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
48120113|NCT00824135|PROCEDURE|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
47971537|NCT03018821|DRUG|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
48120114|NCT00824135|OTHER|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
48489388|NCT06198036|OTHER|Muscle Energy Technique|Participants in this group will be treated with Muscle Energy Technique via Reciprocal Inhibition Mechanism
48649290|NCT06292507|OTHER|MYOFASCIAL STRETCH|Group A 10 participants will receive Myofascial Stretching
47971538|NCT03018821|DRUG|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
47971539|NCT03018821|DRUG|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
48120115|NCT00824135|DRUG|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
48120116|NCT00824135|DRUG|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
48120117|NCT00824135|DRUG|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
48120118|NCT00824135|DRUG|Rituximab|375 mg/m2 intravenous for 1 dose total
48120119|NCT00824135|OTHER|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
48120120|NCT01109524|DRUG|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
48120121|NCT01109524|DRUG|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
48120122|NCT01109524|DRUG|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
48120123|NCT05989542|DRUG|PLB1001|200mg BID Oral
48120124|NCT01366898|DRUG|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
48120125|NCT01574339|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative."
48120126|NCT03697538|PROCEDURE|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
48489389|NCT00226421|DRUG|Oxymorphone Extended Release|
48489390|NCT04715360|COMBINATION_PRODUCT|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
48120127|NCT05051449|DRUG|Ketamine Hydrochloride|Ketamine will be administered by a nurse in a 2-week treatment phase, during which participants will receive six IV infusions of 0.5 mg/kg (over 40-50 minutes) ketamine three times per week. Infusion days for patients will be on Mondays, Wednesdays, and Fridays, +/- 1 day. Ketamine infusions will take place at the UMB General Clinical Research Center (GCRC). The GCRC nurse will deliver ketamine within a private exam room. The infusions will last 40-50 min, and the participant will be observed by the GCRC clinical staff for 2 hours post-infusion. Vital signs will be monitored throughout the treatment; specifically, blood pressure, pulse ox and heart rate will be checked prior to treatment, q20 minutes during infusion, and q30-60 minutes after infusion for up to three hours.
48120128|NCT01634893|DRUG|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
48120129|NCT01000831|BIOLOGICAL|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
48120130|NCT04565418|BEHAVIORAL|High-intensity interval training|3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions
48489391|NCT04715360|DRUG|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
48489392|NCT06453239|DIAGNOSTIC_TEST|Pro-Neurotensin level as a Serum Biomarker|Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.
48489393|NCT03692143|DRUG|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
48649291|NCT06292507|OTHER|CONTRACT-RELAX TECHNIQUE|group B 10 participants will receive Control-Relax Stretching Technique.
48649292|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread mixed with fermented brown seaweed|5-day intake period
48649293|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread|5-day intake period
48649294|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single dose of AT-527 and digoxin will be co-administered."
48649295|NCT05137626|DRUG|AT-527 + digoxin|"* Day 1: A single dose of digoxin will be administered.~* Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later)."
48649296|NCT05250180|OTHER|Animal Assisted Therapy|Patients enrolled in the study will be randomly scheduled to have a dog be a part of their PT and OT sessions on two days (one in the first week and one in the second week) during their stay. On these days, the therapist will lead the therapy session and integrate the dog at whatever level is appropriate based on the patient's level of functioning and therapy goals.
48120131|NCT01668940|OTHER|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
48120132|NCT01668940|OTHER|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
48120133|NCT01668940|OTHER|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
48120134|NCT05552924|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
48120135|NCT02875938|BEHAVIORAL|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
48120136|NCT02875938|BEHAVIORAL|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
48120137|NCT02875938|BEHAVIORAL|Control|control condition using reading materials without music.
48120138|NCT03281616|BEHAVIORAL|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
48120139|NCT01301716|DRUG|GDC-0980|Oral escalating dose
48120140|NCT01301716|DRUG|bevacizumab|Intravenous repeating dose
48120141|NCT01301716|DRUG|carboplatin|Intravenous repeating dose
48120142|NCT01301716|DRUG|cisplatin|intravenous repeating dose
48120143|NCT01301716|DRUG|paclitaxel|Intravenous repeating dose
48120144|NCT01301716|DRUG|pemetrexed|intravenous repeating dose
48120145|NCT05670834|GENETIC|genotyping assay by real-time PCR|genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
48120146|NCT05670834|DIAGNOSTIC_TEST|ELISA|. IL-6 level in serum will be analyzed by ELISA assay kit.
48120147|NCT05868772|DEVICE|Active Sentry Handpiece|With low IOP settings
48120148|NCT05868772|DEVICE|Ozil Handpiece|With high IOP settings.
48120149|NCT01248936|DRUG|RO5185426|
48120150|NCT02270645|DEVICE|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
48649297|NCT05250180|OTHER|Control|treatment as usual as dictated by their treatment team
47971540|NCT03018821|DRUG|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
47971541|NCT03018821|DRUG|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
47971542|NCT03018821|DRUG|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
48649298|NCT04913090|DRUG|XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
47971543|NCT03018821|DRUG|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
47971544|NCT03018821|DRUG|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
47971545|NCT03018821|DRUG|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
48120151|NCT01393067|DEVICE|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
48120152|NCT01393067|DEVICE|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
48120153|NCT04995718|OTHER|Intelligent Physical Exercise Training (IPET)|Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
48120154|NCT05372588|DRUG|NVX-CoV2515|Intramuscular (deltoid) injection of co-formulated Omicron BA.1 SARS-CoV-2 rS vaccine with Matrix-M adjuvant (0.5 mL).
48120155|NCT05372588|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
48120156|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2515|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
48120157|NCT05372588|DRUG|NVX-CoV2540|Intramuscular (deltoid) injection of co-formulated prototype SARS-CoV-2 rS vaccine with Matrix-M adjuvant(0.5 mL).
48120158|NCT05372588|DRUG|NVX-CoV2373 + NVX-CoV2540|Intramuscular (deltoid) injection of 5 µg total (2.5 µg NVX-CoV2373 + 2.5 µg NVX-CoV2515) with 50 µg Matrix-M adjuvant.
47971546|NCT03018821|DRUG|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
48120159|NCT06407024|PROCEDURE|laparoscopic transabdominal adrenalectomy|Adrenalectomy performed by laparoscopic approach
48489394|NCT03692143|PROCEDURE|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
48649299|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
48649300|NCT04913090|DRUG|XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
47971547|NCT03018821|DRUG|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
47971548|NCT03018821|DRUG|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
47971549|NCT03018821|DRUG|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
47971550|NCT03489824|PROCEDURE|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
47971551|NCT00528658|DRUG|Paracetamol|1g qid
47971552|NCT00528658|DRUG|Ibuprofen|400mg tid
47971553|NCT00528658|DRUG|Paracetamol Placebo|equivalent to 1g qid
47971554|NCT00528658|DRUG|Ibuprofen placebo|Equivalent to 400mg tid
47971555|NCT00787891|DRUG|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
47971556|NCT00787891|DRUG|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
47971557|NCT03641924|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
47971558|NCT00461162|BEHAVIORAL|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
47971559|NCT00461162|BEHAVIORAL|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
47971560|NCT00461162|BEHAVIORAL|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
47971561|NCT00028405|DRUG|LS 11(Taporfin Sodium)|
47971562|NCT00028405|DEVICE|Lumaflex Light Delivery Catheter|
47971563|NCT00959764|DRUG|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
47971564|NCT00959764|DRUG|Intranasal Calcitonin|Intranasal Calcitonin Spray
47971565|NCT00959764|DRUG|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
47971566|NCT03598985|DIAGNOSTIC_TEST|"Smartphone MyAnkle balance application"|"Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between."
48120160|NCT06407024|PROCEDURE|robotic transabdominal adrenalectomy|Adrenalectomy performed by robotic approach
48120161|NCT00328731|PROCEDURE|Procedure|
48120162|NCT01884441|DRUG|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
48649301|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
47971567|NCT05786391|OTHER|Flat position|Flat patient position during the cystoscopy
47971568|NCT05786391|OTHER|Trendelenburg position|Trendelenburg position (head down) during the cystoscopy
47971569|NCT05786391|DEVICE|Insufflation|Insufflation to 15 mm Hg
48120163|NCT01884441|DRUG|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
48649302|NCT04913090|DRUG|"XZP-5610 Tablet （for Part C1）"|Tablet(s) administered fasted orally once daily for 1 Day
47971570|NCT02503735|DRUG|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
47971571|NCT00003499|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
47971572|NCT04299490|BEHAVIORAL|Sleep Fragmentation|Subjects are provided an 8-hour sleep opportunity. Two speakers are placed 12 inches from the head of the bed and four remote-activated mechanical vibrators are placed underneath the mattress. EEG microarousals (\>3 s), as defined according to standard criteria, are elicited at a frequency of 30 or more events per hour.
48120164|NCT01884441|DRUG|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
48489395|NCT03692143|DRUG|Alendronate|Alendronate Sodium, oral, 70mg, once a week
48649303|NCT04913090|DRUG|"XZP-5610 Tablet for Part C2"|Tablet(s) administered after a high-fat meal orally once daily for 1 Day
48649304|NCT02137278|DRUG|Vasoactive drug therapies|Continue current vasoactive therapy
48649305|NCT02137278|OTHER|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
48649306|NCT01448304|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
48120165|NCT06328985|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
48120166|NCT06328985|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
48120167|NCT06328985|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
48120168|NCT00018603|DRUG|guanfacine|
48120169|NCT05461417|DEVICE|D-SAD|Patients equipped with Panthera D-SAD® orthosis will be recruited.
48120170|NCT01332058|BEHAVIORAL|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
48120171|NCT06478992|PROCEDURE|A:hysteroscopic suture fixation of Mirena|A(the thickness of the thickest uterine myometrium ≥30mm ):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
48120172|NCT06478992|PROCEDURE|A: simple Mirena placement under hysteroscopy|A(the thickness of the thickest uterine myometrium ≥30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
48120173|NCT06478992|PROCEDURE|B: hysteroscopic suture fixation of Mirena|B(the thickness of the thickest uterine myometrium\<30mm):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
48120174|NCT06478992|PROCEDURE|B：simple Mirena placement under hysteroscopy|B(the thickness of the thickest uterine myometrium\<30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
48120175|NCT02620813|DRUG|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
48120176|NCT02620813|DRUG|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
48120177|NCT04528706|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
48120178|NCT00519389|BIOLOGICAL|H5N1 VLP Vaccine|Two doses - Day 0 \& Day 28
48120179|NCT00519389|BIOLOGICAL|Placebo|Two doses - Day 0 \& Day 28
48120180|NCT02759588|BIOLOGICAL|GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab|GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
48120181|NCT02615769|BEHAVIORAL|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
48120182|NCT02615769|BEHAVIORAL|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
48120183|NCT06294275|BIOLOGICAL|LP-001 Dose 1 (Single)|A single dose of LP-001 (Dose 1) was administered subcutaneously.
48120184|NCT06294275|BIOLOGICAL|LP-001 Dose 2 (Single)|A single dose of LP-001 (Dose 2) was administered subcutaneously.
48120185|NCT06294275|BIOLOGICAL|LP-001 Dose 3 (Single)|A single dose of LP-001 (Dose 3) was administered subcutaneously.
48120186|NCT06294275|BIOLOGICAL|LP-001 Dose 4 (Single)|A single dose of LP-001 (Dose 4) was administered subcutaneously.
48120187|NCT06294275|BIOLOGICAL|LP-001 Dose 5 (Single)|A single dose of LP-001 (Dose 5) was administered subcutaneously.
48120188|NCT06294275|BIOLOGICAL|LP-001 Dose 6 (Single)|A single dose of LP-001 (Dose 6) was administered subcutaneously.
48120189|NCT06294275|BIOLOGICAL|Placebo (Single)|A single dose of placebo was administered subcutaneously.
48120190|NCT06294275|BIOLOGICAL|LP-001 Dose 7 (Multiple)|LP-001 (Dose 7) was administered multiple times subcutaneously.
48120191|NCT06294275|BIOLOGICAL|LP-001 Dose 8 (Multiple)|LP-001 (Dose 8) was administered multiple times subcutaneously.
48489396|NCT02666352|DRUG|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
48489397|NCT02666352|DRUG|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
48649307|NCT04494737|BEHAVIORAL|Active Comparator: Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
48649308|NCT04494737|BEHAVIORAL|Active Comparator: Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
48649309|NCT00135876|DRUG|dalteparin|
48649310|NCT00779610|PROCEDURE|Vibration with flexion|Vibration with forearm flexion (active contraction)
48649311|NCT00779610|PROCEDURE|Vibration without flexion|Vibration without forearm flexion (passive)
48649312|NCT03514693|PROCEDURE|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
48325397|NCT03819478|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
48325398|NCT03819478|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
48649313|NCT03514693|PROCEDURE|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
48649314|NCT06515106|BEHAVIORAL|Remote cognitive rehabilitation program|Behavioral: Remote cognitive rehabilitation program Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
48649315|NCT01837550|BEHAVIORAL|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
48325399|NCT03819478|DIETARY_SUPPLEMENT|NutraBio™ CarboMax Supplement|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, \~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
48325400|NCT03819478|DIETARY_SUPPLEMENT|6-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
48325401|NCT03819478|DIETARY_SUPPLEMENT|18-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
48325402|NCT03715959|PROCEDURE|Aspiration of Breast|Undergo NAF
48649316|NCT01837550|BEHAVIORAL|Control group|The control group only had access to reading material.
48649317|NCT05181696|DIAGNOSTIC_TEST|Chest X-ray|Retrospective analysis of chest x-rays of patients with COVID-19
48649318|NCT06548516|PROCEDURE|Control group (conventional scalpel surgery)|The patients in the control group will undergo frenectomy using conventional scalpel surgery.
48649319|NCT06548516|PROCEDURE|Diode laser group|The patients in the laser group will undergo frenectomy using a diode laser.
48649320|NCT06675617|DEVICE|Allay Aortic Stent|Endovascular treatment of an aortic dissection
47971573|NCT04299490|DRUG|Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)|On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
48649321|NCT06142305|PROCEDURE|DDH surgery and casting|DDH surgery and casting
47971574|NCT04299490|BEHAVIORAL|Sleep Continuity Disruption|An 8-hour sleep opportunity period starting from lights out is divided into eight, one-hour intervals. One of the intervals is randomly determined to be a 60 minute forced awakening, during which no sleep is permitted. Each of the remaining seven, 60-minute intervals are subdivided into tertiles (20 min. blocks). A 20-min forced awakening (FA) is randomly scheduled to occur in either the 1st, 2nd, or 3rd tertile of each hour. During FAs, staff keep subjects awake, either by voice or gentle shaking.
47971575|NCT04299490|BEHAVIORAL|Undisturbed Sleep|Subjects sleep normally for an 8 hour period.
48325403|NCT03715959|PROCEDURE|Biospecimen Collection|Undergo NAF
48325404|NCT04227392|DEVICE|vaginal radiofrequency|2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
48649322|NCT06405347|BEHAVIORAL|Inpatient Whole Health Bundle|Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle, which is comprised of a variety of offerings aimed at improving the wellbeing of the patient. They can choose to use any or none of the bundle elements.
47971576|NCT00160485|DRUG|Glyburide|dosage required to obtain adequate glucose control
48120192|NCT06294275|BIOLOGICAL|Placebo (Multiple)|Placebo was administered multiple times subcutaneously.
48120193|NCT01291446|DIETARY_SUPPLEMENT|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
48120194|NCT00893425|DRUG|ramipril|
48325405|NCT03522883|DIETARY_SUPPLEMENT|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
48325406|NCT01492296|PROCEDURE|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
48325407|NCT01492296|PROCEDURE|conventional fasting|patients were evaluated after fasting for 8 hours
48325408|NCT03769324|DIAGNOSTIC_TEST|Osmolarity Test|Osmolarity Test
48325409|NCT00685529|DRUG|Racemic formoterol|12 µg of racemic formoterol fumarate BID
48649323|NCT02743312|DEVICE|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
48120195|NCT05184036|DIAGNOSTIC_TEST|Low Vision|"* The application of a questionnaire evaluating the functionality and quality of life and records several of the daily life of Greek LV patients.~* The evaluation of the basic parameters of visual function included in the LIFE4LV platform in order to evaluate the effectiveness of this platform in correlation with the routine ophthalmologic exams.~* The evaluation of existing digital supportive tools for LV and record of the patient's feedback"
48325410|NCT00685529|DRUG|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
48649324|NCT02743312|DEVICE|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
47971577|NCT00160485|DRUG|Insulin|variable dosage to obtain glucose control
48325411|NCT00685529|DRUG|Racemic formoterol|24 µg of racemic formoterol fumarate BID
48325412|NCT02602717|OTHER|lymph nodes cyto-punction|
48325413|NCT06168500|PROCEDURE|Test group|3.0mm diameter implant
48649325|NCT02743312|DEVICE|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
48649326|NCT02372357|DRUG|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
47971578|NCT03932110|DIAGNOSTIC_TEST|omentin, visfatin|diagnostic blood test
47971579|NCT03103737|BEHAVIORAL|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
47971580|NCT05886829|COMBINATION_PRODUCT|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
47971581|NCT05886829|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
47971582|NCT01343498|DRUG|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
47971583|NCT06365398|DRUG|Heparin|As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
47971584|NCT06365398|DRUG|Heparin Sodium Injection|In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
47971585|NCT06365398|OTHER|No heparinization|No additional heparin was administered via the sheath or arterial route in the no heparinization group.
48325414|NCT06168500|PROCEDURE|Control group|4.0 diameter implant + guided bone regeneration
48649327|NCT02372357|PROCEDURE|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
47971586|NCT02300688|DRUG|Treatment A|administration of 1 time administration of the test drug (Treatment A)
47971587|NCT02300688|DRUG|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
48120196|NCT04855903|DEVICE|Covirtua Cognition software|Cognitive training with Covirtua Cognition software
48325415|NCT01074658|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
48325416|NCT02960698|OTHER|IRM and comportemental tasks|
48649328|NCT05158699|DRUG|Bromfenac|Bromfenac topical eye drops (Yellox)
48325417|NCT00032838|DRUG|Yohimbine|
48489398|NCT02825329|DEVICE|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
48649329|NCT05158699|DRUG|Dexamethasone|Dexamethasone topical eye drops
48649330|NCT05158699|DRUG|Triamcinolone Acetonide|0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
48649331|NCT05158699|DRUG|Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution|Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
48649332|NCT05805150|DEVICE|Control Lens (stenfilcon A)|One week wear
48649333|NCT05805150|DEVICE|Test Lens (senofilcon A)|One week wear
48649334|NCT06673459|BIOLOGICAL|TBICy|The TBI-Cy group was administered 250 mg/m2/d oral Me-CCNU on day -8. A total of 12 Gy TBI was for each patient and fractionated dose was 2 Gy twice daily or 4Gy once daily on days -8 to -6. Occluding of the lung fields during TBI, the corresponding irradiation dose reduced to a total of 8 Gy. On day -5, the schedule was intravenous 2 g/m2 Ara-C every 12 hours. Then intravenous 1.8 g/m2 CTX once per day from days -4 to -3.
48649335|NCT06673459|BIOLOGICAL|BuCy|The BuCy group received oral Me-CCNU 250 mg/m2/d twice daily on day -8, intravenous cytosine arabinoside (Ara-C) 2 g/m2 twice daily on day -7, intravenous Bu 3.2 mg/kg/d from days -6 to -4, and intravenous cyclophosphamide (CTX) 1.8 g/m2/d from days -3 to -2. There were no patients accepted oral Bu.
48649336|NCT02172261|DRUG|BI 10773|
48649337|NCT02172261|DRUG|Glimepiride|
48649338|NCT02584647|DRUG|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
48649339|NCT02584647|DRUG|Sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
48649340|NCT00967486|PROCEDURE|Carotid endarterectomy with routine shount|
48649341|NCT00967486|PROCEDURE|Carotid endarterectomy with selective shunt|
47971588|NCT03755297|OTHER|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
48649342|NCT01933152|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
48649343|NCT03491176|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48649344|NCT03491176|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
48649345|NCT03491176|OTHER|Quality-of-Life Assessment|Ancillary studies
48649346|NCT03491176|OTHER|Questionnaire Administration|Ancillary studies
47971589|NCT02085317|DRUG|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
47971590|NCT02085317|DRUG|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
47971591|NCT01720121|OTHER|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
48120197|NCT06059560|DIETARY_SUPPLEMENT|Nutritional therapy|Intensive nutritional therapy based on real world therapy
48649347|NCT04622267|DEVICE|Barbed suture|to close a C-section incision
48649348|NCT04622267|PROCEDURE|Standard antimicrobial suture|to close a C-section incision
48649349|NCT04699877|DRUG|Gilteritinib|Oral
48649350|NCT06190990|OTHER|Otago Exercise + Exer gaming|In this group the participant will receive otago exercises and exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 week
48649351|NCT06190990|OTHER|exer gaming based programme|In this group the participant will receive exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 weeks and then after 4 weeks.
48649352|NCT04248452|DRUG|Capecitabine|Given PO
48649353|NCT04248452|DRUG|Fluorouracil|Given IV
48649354|NCT04248452|DRUG|Leucovorin|Given IV
48649355|NCT04248452|DRUG|Leucovorin Calcium|Given IV
48649356|NCT04248452|DRUG|Oxaliplatin|Given IV
48649357|NCT04248452|RADIATION|Radiation Therapy|Undergo radiation therapy
48120198|NCT00226018|DEVICE|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
47971592|NCT05221515|BEHAVIORAL|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
48120199|NCT00226018|DEVICE|Placebo|placebo
48120200|NCT05678023|OTHER|Effect on contrast media depending on the time of its administratsion|CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered
48120201|NCT00924807|DRUG|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
48120202|NCT03403413|DEVICE|muscle vibration during walking|Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group. Gait assessment both with and without muscle vibration were collected at follow-up after 12 sessions of gait training with muscle vibration.
48120203|NCT02228356|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
48325418|NCT01225978|DEVICE|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
48325419|NCT02823678|PROCEDURE|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
48325420|NCT00997321|DRUG|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
48489399|NCT05334264|PROCEDURE|Cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
48489400|NCT01610453|PROCEDURE|ultrasound examination|transabdominal and transperineal ultrasound examinations
48489401|NCT02479542|OTHER|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
48489402|NCT02479542|DEVICE|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
48489403|NCT05649449|BEHAVIORAL|Self-Directed Care|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
48489404|NCT05649449|BEHAVIORAL|Services as usual|Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
48489405|NCT04476966|DRUG|Bladogra|1 tablet contains 25 mg Mirabegron
48489406|NCT04476966|DRUG|Myrbetriq (first dosing)|1 tablet contains 25 mg Mirabegron
48489407|NCT04476966|DRUG|Myrbetriq (second dosing)|1 tablet contains 25 mg Mirabegron
47971593|NCT05221515|BEHAVIORAL|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
47971594|NCT06177587|OTHER|Assesment of biomarkers in acute coronary syndromes|Collection of 20ml of blood from peripheral vein.
47971595|NCT04525417|DIAGNOSTIC_TEST|AAZ Covid-19 rapid test|To assess the immune status
48325421|NCT00997321|DRUG|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
48325422|NCT00096590|OTHER|coagulation study|
48325423|NCT00096590|OTHER|immunoenzyme technique|
48325424|NCT00096590|OTHER|laboratory biomarker analysis|
48325425|NCT00096590|OTHER|physiologic testing|
48325426|NCT00096590|PROCEDURE|study of high risk factors|
48325427|NCT02983058|RADIATION|PET/SPECT Scan|PET scan will be performed on a mCT scanner
48325428|NCT02983058|DEVICE|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
47971596|NCT04763304|OTHER|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
48325429|NCT00450047|DEVICE|Speed-feedback therapy system with a bicycle ergometer|
48325430|NCT00450047|DEVICE|Ergometer at conventional settings|
48325431|NCT00986310|DRUG|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
48325432|NCT00986310|DRUG|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
48325433|NCT04494464|OTHER|No intervention|
47971597|NCT04763304|OTHER|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
48325434|NCT03529123|DRUG|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
48649358|NCT02510248|DRUG|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
48325435|NCT03529123|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
48489408|NCT02575612|PROCEDURE|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (\> 50 ultrasound guided minimal invasive biopsies per year, \> 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
48649359|NCT02510248|DRUG|Placebo|Placebo to match AL-704
48489409|NCT01298713|DRUG|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
48489410|NCT01298713|DRUG|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
48489411|NCT04327713|DIETARY_SUPPLEMENT|fish oil supplement|daily fish oil supplement vs. placebo
48489412|NCT04910659|OTHER|acupuncture|P6, LI4 and LI 11 stimulation
48649360|NCT01110512|DRUG|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day."
48649361|NCT01110512|DRUG|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day"
48649362|NCT00002985|DRUG|daunorubicin hydrochloride|
48325436|NCT03529123|DRUG|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
48325437|NCT03529123|DRUG|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
48325438|NCT01852695|BEHAVIORAL|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
48325439|NCT04150562|DRUG|rhIL-15|Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
48325440|NCT04150562|BIOLOGICAL|Avelumab|avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
48325441|NCT01603030|DRUG|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
48325442|NCT01603030|DRUG|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
48325443|NCT02214485|BEHAVIORAL|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
48489413|NCT04226235|BEHAVIORAL|Yoga session|a 1-hour yoga session was completed by all participants following a DVD.
48489414|NCT03286478|BEHAVIORAL|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
48489415|NCT03286478|BEHAVIORAL|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
48489416|NCT03286478|BEHAVIORAL|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
48489417|NCT04487002|PROCEDURE|surgical resection|
48649363|NCT00002985|DRUG|pegylated liposomal doxorubicin hydrochloride|
48649364|NCT04433572|DRUG|Temsirolimus|0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
48649365|NCT04433572|DRUG|Saline placebo|Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
47971598|NCT00000350|PROCEDURE|radioactive substance|
47971599|NCT05015465|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
47971600|NCT04597788|OTHER|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
47971601|NCT04597788|OTHER|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
47971602|NCT00627120|DRUG|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
48325444|NCT02214485|BEHAVIORAL|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
48325445|NCT04037917|DEVICE|CorNeat EverPatch|Covering Ophthalmic Implants
48325446|NCT01828918|GENETIC|microRNAs|
48325447|NCT00503178|PROCEDURE|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
48325448|NCT03700632|OTHER|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
48325449|NCT03046043|PROCEDURE|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
48325450|NCT03046043|PROCEDURE|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
48325451|NCT05181904|OTHER|Gastric ultrasound|Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
48489418|NCT01901874|DEVICE|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
48489419|NCT02399098|BEHAVIORAL|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
48489420|NCT00974974|DRUG|IPX066|extended-release carbidopa-levodopa capsules
48489421|NCT00974974|DRUG|IR CD-LD|immediate-release carbidopa-levodopa tablets
48489422|NCT05303376|BIOLOGICAL|IBIO123|5 or 10 mg
48649366|NCT06113198|BIOLOGICAL|rMenB+OMV NZ|3 doses of rMenB+OMV NZ vaccine administered intramuscularly on Day 1, Day 61, and any day between Day 241 - Day 391.
48325452|NCT02748941|DEVICE|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~* Ulceration \>2 mm~* Plaque thickness~* GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~* CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~* Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~* Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification"
48325453|NCT00718666|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
48325454|NCT00312299|DEVICE|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
48325455|NCT00312299|DEVICE|Round edge PMMA IOL|Round edge PMMA IOL
48325456|NCT00312299|DEVICE|Acrysof IOL|Acrysof IOL
48325457|NCT00312299|DEVICE|square Edge PMMA IOL|Square edge PMMA intra ocular lens
48325458|NCT00312299|DEVICE|Square Edge PMMA IOL|Square Edge PMMA IOL lens
48325459|NCT01789346|DEVICE|532nm KTP|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
48325460|NCT01789346|DEVICE|595nm PDL|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
48489423|NCT05303376|OTHER|Placebo|matching placebo
48489424|NCT01949753|BEHAVIORAL|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
48489425|NCT01949753|BEHAVIORAL|Exposure therapy|Exposure with response prevention without pharmacological facilitation
48489426|NCT00304720|DRUG|Tacrolimus and MMF|
48489427|NCT03659474|OTHER|compression|compression by Game Ready
47971603|NCT03607162|DIAGNOSTIC_TEST|DIAFEVER algorithm|PCT rapid test-based predictive algorithm
48325461|NCT05447598|OTHER|Nurse-led remote monitoring program|Symptoms of disease progression, clinical parameters, medication adherence and follow-up needs will be reported by patients or with support from relatives or homecare nurses 2-4 times/months over a three months period using a digital platform. Telephone monitoring is planned for patients who are not able to comply with the digital platform. In addition, an individualized self-treatment plan for diuretics and lifestyle advice will be prepared, preferably together with relatives at the outpatient clinic. Participants will also have access to a website with written information and videos about HF and self-management. Finally, a pillbox will be delivered to facilitate drug adherence.
48325462|NCT05447598|OTHER|Usual care treatment|Usual care treatment and follow-up care at the outpatient clinic and in primary care
48325463|NCT00765128|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
48325464|NCT00765128|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
48325465|NCT05137730|DRUG|rhPTH(1-84)|Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
48325466|NCT04000919|DRUG|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
48325467|NCT04000919|DRUG|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
48325468|NCT04000919|DRUG|Placebo oral tablet|Placebo
48325469|NCT04000919|DRUG|Carbidopa|Carbidopa (50mg)
48325470|NCT01529385|DEVICE|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
48325471|NCT01529385|DEVICE|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
48325472|NCT00367198|DIETARY_SUPPLEMENT|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
48325473|NCT02649530|DRUG|WNT974|
48325474|NCT00796133|DRUG|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
48325475|NCT01408667|DRUG|TRC150094|50 mg Tablets once a day
48649367|NCT06639477|OTHER|Treatment As Usual|In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.
48649368|NCT06639477|BEHAVIORAL|Active Condition|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
47971604|NCT04593225|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL SFCAMINA|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
47971605|NCT04593225|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
47971606|NCT05798091|BEHAVIORAL|Supportive-expressive group therapy|The intervention is based on the evidence-based supportive-expressive (SEGT) approach and was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. The SEGT approach fosters mutual support, promotes openness and emotional expression. It has been shown to yield improvements in anxiety, psychosocial functioning, health literacy, and social support in breast cancer survivors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
48325476|NCT01408667|OTHER|Placebo|Tablets once daily
48325477|NCT06420596|OTHER|Conventional Physiotherapy|Conventional physiotherapy is one prescription of 9 in person physiotherapy sessions (according to FMH Switzerland guidelines). The frequency of the physiotherapy sessions are at the discretion of the treating clinician, but the recommendation is 1 to 2 sessions per week.
48325478|NCT06420596|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports therapeutic exercises in people with musculoskeletal disorders. It is the first app-supported physiotherapy solution available in Switzerland.
48325479|NCT04526119|DRUG|Acotiamide hydrochloride hydrate|A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
48325480|NCT04526119|DRUG|Placebo|A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
48325481|NCT02019524|BIOLOGICAL|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
48489428|NCT03659474|OTHER|ice pack|cryotherapy for ice pack
48489429|NCT03659474|OTHER|immersion|immersion therapy
48489430|NCT03477955|PROCEDURE|PEEK interspinous spacer|To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
48649369|NCT06639477|BEHAVIORAL|Active Comparator|Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
48649370|NCT05887336|DEVICE|Walther System|Walther System providing INMEST treatment
48649371|NCT05887336|DEVICE|Sham Walther System|Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
48649372|NCT05887336|DRUG|Non preserved ocular lubricants|"* Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)"
48649373|NCT05887336|PROCEDURE|Eye lid procedure|Lid hygiene, warm eye bag, lid massage and Omega 3
48649374|NCT04195256|DRUG|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
48649375|NCT04195256|DRUG|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
48649376|NCT04195256|DRUG|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
48649377|NCT04195256|DRUG|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
48649378|NCT05352919|DRUG|Litifilimab|Administered as specified in the treatment arm.
47971607|NCT05798091|OTHER|Treatment as usual|All patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed. The types of psycho-social supports provided to patients in the TAU condition will be documented (e.g., referral to psychiatrist, social worker, etc.).
47971608|NCT03032705|DEVICE|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
47971609|NCT03032705|DEVICE|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
47971610|NCT02550106|DRUG|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
48489431|NCT03197558|COMBINATION_PRODUCT|Tymbion Iontophoresis and Tube Delivery System (TDS)|Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
48649379|NCT05352919|DRUG|Litifilimab-matching placebo|Administered as specified in the treatment arm.
48649380|NCT05035628|OTHER|Cardiopulmonary exercise training|"Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions."
47971611|NCT01513161|DRUG|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
47971612|NCT01513161|DRUG|Placebo|
48489432|NCT05600205|BEHAVIORAL|GOAL!|GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
48649381|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3-15mg/day; administered orally
48649382|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
48649383|NCT01592747|DRUG|Placebo capsules|Once daily, oral administration.
48649384|NCT06568432|DEVICE|CRP+SAA POCT|CRP+SAA POCT will be provided in 20 village clinics in the intervention group
48325482|NCT02019524|BIOLOGICAL|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
47971613|NCT06007885|OTHER|Pathways and Resources to Engagement and Participation (PREP)|Participants engage in an 8-week community-based activity of their choice (Goal#1). To engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home/community and use the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will work with the youth to search for the programs, identify and remove potential environmental barriers for participation (e.g., accessibility, equipment) and educate instructors regarding the youth's specific needs. This process, which includes up to 9 hours of OT support, will set the stage for enrolment of the youth in a community activity for a period of 8 weeks. The intervention will be repeated for a new goal (Goal#2). However, for Goal#2, youth will have the opportunity to select and pursue their new goal (#2) for 8 weeks without OT support first. Then, the OT will provide the PREP intervention for up to 6 weeks to achieve Goal #2.
47971614|NCT01415284|DRUG|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
48325483|NCT02019524|BIOLOGICAL|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
48325484|NCT01261546|DRUG|Dexamethasone|"* Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
48325485|NCT01261546|DRUG|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
48325486|NCT01195831|DRUG|Xamiol® gel|Once daily application
48325487|NCT01195831|DRUG|Calcipotriol scalp solution|Twice daily application
47971615|NCT04370938|BEHAVIORAL|Coping strategies video|No additional description
47971616|NCT03669172|BIOLOGICAL|Donor IL-15 stimulated NK cells infusion|DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
47971617|NCT02798575|DEVICE|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
47971618|NCT03971058|BIOLOGICAL|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
47971619|NCT01163175|OTHER|Ruminant trans fats|"Consumption of the 4 experimental diets:~1. a diet rich in ruminant TFA (8 g/day);~2. a diet moderately rich in ruminant TFA (4 g/day);~3. a diet rich in industrial TFA (8 g/d);~4. a control diet (minimal dietary TFA of industrial and ruminant sources)."
47971620|NCT00706823|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
47971621|NCT00706823|DEVICE|Laryngeal Mask Airway-Unique|supra-glottic airway device
47971622|NCT00736684|DEVICE|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
47971623|NCT00736684|DEVICE|Gamma Nail 3TM (Gamma3)|intramedullary nailing
47971624|NCT03695120|OTHER|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
47971625|NCT00670683|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
47971626|NCT03416530|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
47971627|NCT01055171|DRUG|Propranolol|40 mg; Single Administration.
47971628|NCT01055171|DRUG|Placebo|40 mg; Single Dose.
47971629|NCT06508632|BEHAVIORAL|Mandala group|Individual mandala activity will be carried out in all sample groups after admission to the clinic where they come to receive outpatient chemotherapy and when they start taking medication. Children will color (paint).
47971630|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
48325488|NCT04880850|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
48325489|NCT04880850|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 26 weeks
48325490|NCT04880850|DRUG|Insulin aspart|Participants will receive subcutaneous (s.c.) injections of insulin aspart 2-4 times daily for 26 weeks
48325491|NCT03058822|DRUG|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
48325492|NCT02830035|PROCEDURE|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
48325493|NCT02830035|PROCEDURE|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
48325494|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
48325495|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
48325496|NCT02682030|DEVICE|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
48325497|NCT02682030|DEVICE|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
48325498|NCT03077113|DIAGNOSTIC_TEST|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
48325499|NCT03077113|DIAGNOSTIC_TEST|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
48325500|NCT01344252|DRUG|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
48325501|NCT02028585|DIETARY_SUPPLEMENT|Low-fat milk group|
48489433|NCT02642796|DEVICE|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
48325502|NCT02935699|DRUG|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
48325503|NCT02935699|DRUG|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
48325504|NCT05781763|BEHAVIORAL|High intensity interval training (HIIT)|"2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist"
48325505|NCT05781763|OTHER|Control group|Continuing with exercise as usual during 12 months
48325506|NCT04631458|OTHER|standard of care.|Observational trial.
48325507|NCT00164736|DRUG|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
48489434|NCT05456711|DIAGNOSTIC_TEST|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
48489435|NCT05655247|PROCEDURE|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|A split-thickness non-advanced tunnel will be performed according to Zabalegui et al. (1999).
48489436|NCT05655247|PROCEDURE|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|A full-thickness coronally-advanced tunnel (Modified Coronally Advanced Tunnel - MCAT) will be performed according to Aroca et al. (2010).
48325508|NCT00164736|DRUG|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
48489437|NCT01242930|DRUG|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
48325509|NCT00164736|DIETARY_SUPPLEMENT|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
48325510|NCT05239377|OTHER|IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator|Digital decision support
48325511|NCT00405821|DRUG|Acyclovir|400mg twice daily for 24 months
48325512|NCT00405821|DRUG|Placebo|Placebo tablet twice daily for 24 months
48325513|NCT00625898|DRUG|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
48325514|NCT00625898|DRUG|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
48325515|NCT00625898|DRUG|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
48489438|NCT01242930|DRUG|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
48489439|NCT01242930|DRUG|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
48489440|NCT02768038|OTHER|Observational|Blood, stool ja biopsy specimens
48489441|NCT04244201|DEVICE|Vaporous Hyperoxia Therapy|1 hour of treatment, 4 times per week
48120204|NCT01029587|DRUG|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
48120205|NCT00002842|DRUG|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
48120206|NCT00002842|DRUG|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
48120207|NCT00002842|DRUG|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
48120208|NCT00002842|PROCEDURE|adjuvant therapy|Chemotherapy given after hepatic resection
48325516|NCT00625898|DRUG|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
48325517|NCT00625898|DRUG|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
48325518|NCT00625898|DRUG|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
48325519|NCT00625898|DRUG|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
48325520|NCT00484549|PROCEDURE|Blood sample|Ischemic stroke hospitalized
48325521|NCT04043403|DEVICE|Open Loop DBS|Standard DBS therapy at a constant frequency and voltage
48325522|NCT04043403|DEVICE|Adaptive (Closed Loop) DBS|DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
47971631|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
47971632|NCT02619552|DRUG|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
47971633|NCT03631472|DEVICE|RheOx|RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
47971634|NCT06239454|DEVICE|interleaving stimulation|ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).
47971635|NCT06239454|DEVICE|empirical stimulation|Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60\~90µs pulse width, 130\~185Hz frequency and varied voltage) during the follow-up.
48120209|NCT00002842|PROCEDURE|conventional surgery|Hepatic resection
48120210|NCT04238429|DRUG|Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate|Use the toothpaste to brush teeth twice a day for 8 weeks
48325523|NCT04043403|DEVICE|Intermittent Open Loop DBS|Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
48325524|NCT02463136|BEHAVIORAL|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
48325525|NCT02463136|DEVICE|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
48489442|NCT00755404|DRUG|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
48120211|NCT04238429|DRUG|Control toothpaste|Use the toothpaste to brush teeth twice a day for 8 weeks
48120212|NCT03701386|PROCEDURE|cesarean hysterectomy|Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
48120213|NCT03701386|PROCEDURE|N&H sandwich technique|In the N\&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
48120214|NCT00265200|DRUG|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
48120215|NCT04759482|DIAGNOSTIC_TEST|polysomnography|Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
48120216|NCT05505916|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
48120217|NCT03381053|DRUG|Imatinib 400mg|The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
48120218|NCT01866969|OTHER|questionnaire administration|Ancillary studies
48120219|NCT01866969|PROCEDURE|quality-of-life assessment|Ancillary studies
47971636|NCT05923437|OTHER|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk mothers express between 06:00-17:59 in the daytime breast milk storage bag and the milk mothers express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
48120220|NCT01837472|DRUG|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
48120221|NCT01837472|DRUG|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
48120222|NCT02549313|PROCEDURE|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
48120223|NCT04333355|BIOLOGICAL|Convalescent Plasma|Along with the administration of convalescent plasma, patients will continue to receive supportive standard care.
48120224|NCT01765543|DRUG|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
48120225|NCT01765543|DRUG|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
48489443|NCT00755404|DRUG|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
48489444|NCT04440319|BEHAVIORAL|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
47971637|NCT00101595|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
48120226|NCT04688866|OTHER|Sequencing|This is an observational study, since the assignment of the medical intervention (e.g. cerclage or pessary) is not at the discretion of the investigator. However, cervical samples collected from both groups are subjected to amplicon sequencing for taxonomic classification of microorganisms.
48489445|NCT05752682|DIAGNOSTIC_TEST|Diagnostic pathway|Each included patient will undergo to the faint and fall protocol, to assess the effectiveness of a patients' flow pathways developed in accordance with the most recent guidelines on syncope of the European Society of cardiology and of guidelines on falls of the American and British Geriatrics Societies.
48120227|NCT00629850|DEVICE|Powerlung Performer|Inspiratory/Expiratory muscle trainer
48120228|NCT02095171|DRUG|PRX002|
48120229|NCT02095171|OTHER|Placebo|
48120230|NCT03843021|OTHER|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
48120231|NCT00295724|DRUG|Bicifadine|
48120232|NCT05800041|DRUG|WTX221|Drug: WTX221 WTX221 infusion once every 30 days for two doses in total Drug: CTX Co-administration of CTX and WTX221 at the initial infusion
48120233|NCT05673252|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts
48489446|NCT00003138|BIOLOGICAL|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
48120234|NCT05673252|PROCEDURE|biopsy|histopathology findings
48120235|NCT00217841|DRUG|Aurograb|
48120236|NCT02285413|BIOLOGICAL|DC vaccination|DC vaccination without cisplatinum
48120237|NCT02285413|BIOLOGICAL|DC vaccination with cisplatinum|DC vaccination with cisplatinum
48120238|NCT03700294|DRUG|ADCT-601|Intravenous (IV)
48120239|NCT04716855|OTHER|Quality of life and daily living activities assessment tests|
48120240|NCT02570568|DEVICE|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
48120241|NCT02570568|DEVICE|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
48120242|NCT02570568|PROCEDURE|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
48120243|NCT02282085|DRUG|Aripiprazole Once-Monthly|
48120244|NCT02282085|DRUG|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
48120245|NCT03019913|OTHER|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
48649385|NCT02416479|BEHAVIORAL|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
48649386|NCT02416479|BEHAVIORAL|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
48649387|NCT03218475|OTHER|MR Guided Focused Ultrasound|Two treatments of focused ultrasound under MRI guidance
48649388|NCT06675032|BIOLOGICAL|PCV24 formulation 1|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
47971638|NCT01772108|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
47971639|NCT04604223|DRUG|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
47971640|NCT05868200|DRUG|Capitano zenzero toothpaste|"Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months ."
47971641|NCT05868200|DRUG|Colgate total toothpaste|Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
47971642|NCT05386069|DRUG|NOMO Protocol|Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
47971643|NCT03797599|BEHAVIORAL|20 minutes of mindfulness practice|A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
47971644|NCT03797599|BEHAVIORAL|5 minutes of mindfulness practice|A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
47971645|NCT03797599|OTHER|5 minute audio book|5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
47971646|NCT03797599|OTHER|20 minute audio book|20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
47971647|NCT03797599|OTHER|25 minute audio book|25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
48325526|NCT01262612|DRUG|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
48325527|NCT01262612|DRUG|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
48325528|NCT00152074|BEHAVIORAL|Reduce salt intake|
48325529|NCT04873076|DEVICE|Audiovisual distraction using 2d video glasses from HappyMed GmbH|Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
47971648|NCT00488176|DRUG|montelukast|montelukast sodium
47971649|NCT00488176|DRUG|cetirizine|cetirizine
47971650|NCT00488176|DRUG|montelukast and cetirizine|montelukast and cetirizine
47971651|NCT00488176|DRUG|placebo|placebo
48649389|NCT06675032|BIOLOGICAL|PCV24 formulation 2|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
48120246|NCT03680703|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
47971652|NCT03090178|OTHER|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
47971653|NCT04413396|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
47971654|NCT01738360|DRUG|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
47971655|NCT00713050|BEHAVIORAL|Imitate Therapy|Imitation-based computer therapy
47971656|NCT03935204|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
47971657|NCT03935204|BIOLOGICAL|Placebo|Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48120247|NCT02287441|OTHER|Tomato|Tomato Products (tomato)
48120248|NCT02287441|OTHER|Raw|Vegetables Prepared Raw (raw).
48120249|NCT01867632|DEVICE|Acellular Dermal Matrix|
48120250|NCT01820780|OTHER|Natriuretic peptides levels to J7 and J14|
48325530|NCT01522625|DRUG|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
48325531|NCT01522625|DRUG|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
48649390|NCT06675032|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|"13-Valent Pneumococcal Polysaccharide Conjugate Vaccine:Dosage form: Injection Specification:0.5 mL/strip Dosage: The preferred site for infants is the anterolateral thigh (lateral femoral muscle), and for toddlers and children, the deltoid muscle of the upper arm.~Dosing schedule:6 weeks months: 4 doses, one dose each of basic immunization at 2, 4, and 6 months of age, and one dose of booster immunization at 12-15 months of age, with the earliest of the first dose being given at 6 weeks of age. The first dose should be given at 6 weeks of age at the earliest."
48649391|NCT06675032|BIOLOGICAL|Sodium Chloride Injection|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
48649392|NCT02576197|DIETARY_SUPPLEMENT|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
48649393|NCT02576197|DIETARY_SUPPLEMENT|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
48649394|NCT02155972|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotic supplement
48649395|NCT02155972|OTHER|Placebo|Placebo capsules
48649396|NCT01277185|DIETARY_SUPPLEMENT|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
48649397|NCT01277185|DIETARY_SUPPLEMENT|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
48649398|NCT05607303|OTHER|Clinical estrogen therapy|No research interventions will be used as a part of the study since the research is observational. Estrogen treatment will be prescribed and followed by participant's clinical physician.
48649399|NCT00974597|DEVICE|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
48649400|NCT04637620|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of MDD
48649401|NCT04637620|DRUG|Sertraline|Use of SSRI as an active comparator
48325532|NCT01737658|OTHER|Exercise Program|Exercise Program for Obese Adolescents
48340105|NCT04984460|DIAGNOSTIC_TEST|Fluorescence morphological detection of liquid-based thin-layer film-making fungi|"Samples from outpatient or inpatient clinics to be tested for fungal vaginitis. A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd.~Samples are human vaginal secretions. Each sample should be the amount on one swab.~The sample is not in menstrual period. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days."
48340106|NCT00138229|BIOLOGICAL|aldesleukin|
48649402|NCT04637620|DRUG|Placebo Cap|Use of placebo as a comparator
48649403|NCT04701710|DRUG|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
48340107|NCT00138229|BIOLOGICAL|filgrastim|
48120251|NCT01820780|OTHER|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
48325533|NCT03905629|OTHER|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay \>15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~* Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~* Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~* Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
48325534|NCT00779324|DRUG|Amantadine Hydrochloride|100 mg every morning and noon
48325535|NCT00779324|DRUG|Placebo|one placebo tablet every morning and 12 Noon
48325536|NCT03728504|DRUG|ASN002|Daily dose of ASN002 for 32 weeks
48325537|NCT03728504|DRUG|Placebo Oral Tablet|Daily dose of Placebo Oral Tablet for 16 weeks
48489447|NCT00003138|BIOLOGICAL|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
48649404|NCT06473103|DEVICE|Two photon fluorescence microscopy imaging|Excised tissues will be imaged with two photon fluorescence microscopy prior to submission for histological processing.
48649405|NCT01883375|BEHAVIORAL|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
48649406|NCT01883375|BEHAVIORAL|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
48649407|NCT02392728|BEHAVIORAL|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
48649408|NCT02392728|BEHAVIORAL|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
47971658|NCT03923712|BEHAVIORAL|Supervised Exercise Programme|The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
47971659|NCT00304993|DRUG|fenofibrate|
48120252|NCT01820780|OTHER|Phone calls in 6 months and 12 months|
48120253|NCT01820780|OTHER|Natriuretic peptides levels at 6 months|
48120254|NCT01820780|OTHER|Consultation with the general doctor or the cardiologist to J30 with blood results|
48120255|NCT04374916|DEVICE|Premaquick®|Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.
48120256|NCT04374916|DEVICE|PARTOSURE®|An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
48325538|NCT03076866|OTHER|observational follow-up:clinical, radiological et biological|
48325539|NCT01217190|DRUG|Ondansetron (ODFS)|Test Article
48325540|NCT01217190|DRUG|Zofran (ODT)|Comparator
48325541|NCT00460681|DRUG|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
48325542|NCT05991674|DIAGNOSTIC_TEST|patch test for diagnosing allergic contact dermatitis|European Baseline Series (EBS) System of allergens
48325543|NCT06382363|PROCEDURE|POC-cHbA1c testing|The point-of-care HbA1c instrument employed in this study will be the Cobas b 101 (Roche Diagnostics, Switzerland) diagnostic test system. A capillary blood sample will be obtained by dermal puncture of a fingertip using a disposable lancet and resorbed in the specially marked area of the Cobas b 101 test disc. The disc will be inserted in the autoanalyzer. Test results displayed in both % and mmol/l will be available within 10 minutes.
48325544|NCT03823092|DIAGNOSTIC_TEST|polarization sensitivity|test of polarization vision as described in Study Description
48340108|NCT00138229|BIOLOGICAL|therapeutic autologous lymphocytes|
48489448|NCT00003138|PROCEDURE|Transfusion|Red cell and platelet transfusions
48489449|NCT05222542|OTHER|Sampling of plasma and cerebrospinal fluid at specified time points|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
48489450|NCT04132336|DRUG|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
48489451|NCT04132336|DRUG|Naproxen sodium (Aleve)|Tablet, oral, single dose
47971660|NCT00304993|DRUG|niacin|
47971661|NCT00304993|DRUG|rosiglitazone|
47971662|NCT01204853|DRUG|Sitaxentan|sitaxentan sodium 100 mg
48120257|NCT04169698|DRUG|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
48120258|NCT04169698|DRUG|Alendronate 70Mg Tab|Bisphosphonates
48120259|NCT03284905|DIETARY_SUPPLEMENT|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
48120260|NCT03284905|DIETARY_SUPPLEMENT|Placebo supplement|Capsule containing maize starch
48325545|NCT00995670|DRUG|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
48325546|NCT00995670|DRUG|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
48325547|NCT00995670|DRUG|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
48325548|NCT00995670|DRUG|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
48325549|NCT00845494|BEHAVIORAL|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
48325550|NCT06190743|OTHER|Prevention events organized by participating centers|Cardiovascular disease primary prevention events organized by centers participating in the study where capillary sampling will be performed on subjects to quantify plasma levels of cardiovascular risk factors and validated questionnaires will be administered
48325551|NCT05374148|BEHAVIORAL|health education|health education to prevent respiratory diseases among workers
47971663|NCT05065632|DIAGNOSTIC_TEST|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
47971664|NCT00003746|DRUG|2-chlorodeoxyadenosine (CDA) daily|Daily administration
47971665|NCT00003746|DRUG|2-chlorodeoxyadenosine weekly|Weekly administration
47971666|NCT01183156|BEHAVIORAL|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
47971667|NCT01183156|BEHAVIORAL|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
47971668|NCT03775811|OTHER|AUTOMATED POLYP CLASSIFICATION|COLONIC POLYP HISTOLOGY PREDICTION IN WHITE LIGHT IMAGES COMBINING ARTIFICIAL INTELLIGENCE AND CLINICAL INFORMATION
47971669|NCT03464305|DRUG|acetylsalicylic acid|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
47971670|NCT03464305|DRUG|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
47971671|NCT00125294|DRUG|Methadone|
48489452|NCT04132336|DRUG|Caffeine|Tablet, oral, single dose
48489453|NCT04132336|DRUG|Placebo|Tablet, oral, single dose
47971672|NCT03750604|DIAGNOSTIC_TEST|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
47971673|NCT02820753|BEHAVIORAL|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
47971674|NCT03506178|DRUG|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
48120261|NCT01549756|BEHAVIORAL|bulletin board and teleophone depth interview|qualitative based research
48120262|NCT02948114|OTHER|Control: Cow milk-based infant formula|
48120263|NCT02948114|OTHER|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
48120264|NCT02948114|OTHER|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
48325552|NCT02691221|BEHAVIORAL|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
48325553|NCT03302208|DRUG|Pregabalin|Pregabalin capsule 150 mg oral
48325554|NCT03302208|DRUG|Placebo|Placebo
48340109|NCT00138229|DRUG|cyclophosphamide|
48489454|NCT04281979|DRUG|Study Agent|The study agent will be administered via beverages and/or a capsule. The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used. The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
48120265|NCT02948114|OTHER|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
48489455|NCT04281979|DRUG|Placebo|In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
48649409|NCT04147169|BEHAVIORAL|Focused end-of-life conversations to promote connections among patients, family members and clinicians.|All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.
48120266|NCT04006717|DEVICE|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
48120267|NCT04006717|PROCEDURE|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
48120268|NCT00580112|DRUG|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
48120269|NCT00580112|DRUG|Trabectedin|Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
48120270|NCT03684044|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.
48120271|NCT03684044|OTHER|Placebo|Participants will receive matching placebo on Days 1, 4 and 7.
48120272|NCT05348096|DRUG|Low-dose ibrutinib|Daily ibrutinib (140mg QD) and itraconazole (100mg BID) for six months.
48120273|NCT05341869|PROCEDURE|Para-cervical block|Block of inferior hypogastric plexus with local anesthetic
48120274|NCT06414850|BEHAVIORAL|Animal Assisted Therapy (AAT)|A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
48120275|NCT05103358|DRUG|nab-sirolimus|Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
48120276|NCT00095667|DRUG|lapatinib ditosylate|Given orally
48120277|NCT00095667|OTHER|laboratory biomarker analysis|Correlative studies
48120278|NCT02036307|DIETARY_SUPPLEMENT|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
48120279|NCT02036307|DIETARY_SUPPLEMENT|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
48120280|NCT03584659|DEVICE|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
48120281|NCT03045354|OTHER|Mashed potatoes|Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
48120282|NCT03045354|OTHER|Traditional breakfast|Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
48120283|NCT03045354|OTHER|Breakfast skipping|No breakfast
48120284|NCT03045354|OTHER|French fries|Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
48120285|NCT03045354|OTHER|Beans|Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
48120286|NCT03819816|OTHER|DEA-App|"The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~1. Information module~   The information module consists of general information on the disease and the care of people suffering from dementia.~2. Activity module~   The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~3. Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility."
48120287|NCT03819816|OTHER|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
48120288|NCT01373697|DRUG|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
48120289|NCT01373697|DRUG|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
48120290|NCT02278627|OTHER|manual lymphatic drainage|
48120291|NCT05255224|OTHER|Not applicable as observational study|Not applicable as observational study
48120292|NCT01833923|DRUG|anlotinib|oral medicine.
48489456|NCT04712149|DEVICE|Weekly digital follow up|weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
48489457|NCT06337825|BEHAVIORAL|Activity Tracker (Fitbit)|Wearable, activity tracker
48489458|NCT06337825|DIAGNOSTIC_TEST|HbA1C|Average blood glucose (sugar) levels reported as a percentage
48325555|NCT04441879|BEHAVIORAL|Be a Mom Coping with Depression|Be a Mom Coping with Depression is a blended cognitive-behavioral intervention for the treatment of postpartum depression. It consists of 13 weeks of face-to-face and online sessions, each session targeting a specific thematic content, and providing participants with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content.
48649410|NCT03696186|DRUG|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
48649411|NCT03696186|DRUG|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
48120293|NCT06235424|DRUG|Del Nido Cardioplegia Solution|The route of cardioplegia delivery differed according to surgeons' preferences. The total dosage of cardioplegia depends on the type of cardioplegia. The standard dose of del Nido cardioplegia in our institution is 1000 ml as an initial dose and is delivered with a system pressure of 90-150 mmHg. The solution is prepared by our hospital's pharmacy. At 60. minute of cross-clamp (XC) if XC time was expected to exceed 90 minutes another dose of solution would be delivered. The volume of an additional dose was 500 ml. The temperature of the delivered del Nido cardioplegia was 4\*C.
48120294|NCT06235424|DRUG|HTK solution|The route of cardioplegia delivery differed according to surgeons' preferences. The dose of the HTK cardioplegia is calculated with an application of 20 mL/kg rule. It is delivered with a system pressure of 90-150 mmHg. If the XC time exceeds 120 minutes additional dose is given (10 mL/kg rule). The temperature of the delivered crystalloid cardioplegia is 4\*C
47971675|NCT03506178|DRUG|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
48120295|NCT00223535|BEHAVIORAL|Cognitive Remediation|
48120296|NCT00223535|BEHAVIORAL|Social Skills Training|
48120297|NCT00925886|PROCEDURE|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
48120298|NCT02722070|DEVICE|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
48120299|NCT03666403|PROCEDURE|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
48120300|NCT03666403|PROCEDURE|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
48120301|NCT03666403|PROCEDURE|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
48120302|NCT00317577|DRUG|brimonidine, timolol|
48120303|NCT05298020|DRUG|Envafolimab|400mg,sc,d1,Q4W
48120304|NCT05298020|DRUG|Endostar|210mg，CIV72h，d1-3，Q4W
48120305|NCT05298020|DRUG|Nab paclitaxel|125mg/m2,iv,d1,d8,Q4W
48120306|NCT05298020|DRUG|Gemcitabine|1000mg/m2, iv,d1,d8，Q4W
48120307|NCT04815616|RADIATION|Radiotherapy|Capecitabine with adjuvant radiotherapy in treatment of Early Stages Breast Cancer
48120308|NCT01711905|DIETARY_SUPPLEMENT|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
48649412|NCT03696186|DRUG|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
47971676|NCT03506178|DRUG|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
47971677|NCT03506178|DEVICE|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
48120309|NCT01698125|PROCEDURE|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
48120310|NCT00933426|DRUG|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
48120311|NCT00933426|DRUG|Paclitaxel|50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
48120312|NCT04290572|DRUG|Isotretinoin capsules|Jelly capsules of isotretinoin
48340110|NCT00138229|DRUG|fludarabine phosphate|
48340111|NCT05793112|DRUG|INF108F probiotic|Oral suspension
48649413|NCT03696186|DRUG|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
48120313|NCT01263002|DRUG|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd~1. Assess the complete virological response(HBV DNA \< 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd~2. Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd~3. During medication of Clevudine, virological breakthrough : add adefovir 10mg qd~4. During treatment period, composite virological response : stop the medication and F/U for 2 years~5. Recurrence after stopping treatment(HBV DNA \> 2,000IU/ml) retreat medication at composite virological response.~   * complete virological response: HBV DNA \< 60 IU/ml~  * virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
48325556|NCT04441879|BEHAVIORAL|Be a Mom|Be a Mom is an online intervention consisting of 6 modules, each one targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Women will receive biweekly phone calls from a psychologist between completion of each module to provide support.
48325557|NCT00264446|DRUG|ADH300004|
48120314|NCT04247074|BIOLOGICAL|botulinum toxin neuromodulator|QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
48325558|NCT03647436|OTHER|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
48120315|NCT04247074|BIOLOGICAL|Placebo|Placebo will be injected into either the LCL, GL, or both the LCL and GL
48489459|NCT06337825|BEHAVIORAL|The PROMPT Questionnaire|The PROMPT Questionnaire which is a 30-question previously validated assessment for non-specific symptoms in PHPT, will be administered to patients preoperatively and at 2-weeks and 6-months postoperatively
48649414|NCT03696186|DRUG|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
48649415|NCT03696186|DRUG|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
47971678|NCT00818818|DRUG|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
47971679|NCT03978520|DRUG|Elsubrutinib|Capsule; Oral
47971680|NCT03978520|DRUG|Placebo for elsubrutinib|Capsule; Oral
48120316|NCT06244615|DEVICE|Verum (WO 6607)|Mouth and throat rinse and gargle solution
48120317|NCT06244615|DEVICE|Placebo (WO 6608)|Mouth and throat rinse and gargle solution
48489460|NCT04751084|DRUG|Buscopan 20 milligrams/ML Injectable Solution|cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer
48489461|NCT02689063|DRUG|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
48120318|NCT00801658|DEVICE|selective Laser Trabeculoplasty (SLT)|
48489462|NCT02689063|DRUG|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
48489463|NCT02689063|DRUG|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
48489464|NCT02689063|DRUG|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
48649416|NCT02831335|OTHER|MRI|Perform MRI studies
48649417|NCT02831335|OTHER|MRI|Perform MRI studies
48649418|NCT02831335|OTHER|MRI|Perform MRI studies
48649419|NCT02831335|OTHER|Group 4|Perform MRI studies
47971681|NCT03978520|DRUG|Upadacitinib|Film-coated tablet; Oral
47971682|NCT03978520|DRUG|Placebo for upadacitinib|Film-coated tablet; Oral
47971683|NCT01282892|PROCEDURE|excess of visceral fat|excess of visceral fat
48325559|NCT01921946|DRUG|Fimasartan|
47971684|NCT01282892|PROCEDURE|patients with NAFLD|patients with NAFLD
47971685|NCT04981769|DIAGNOSTIC_TEST|Covid-19 test|PCR Covid-19 test
48120319|NCT05377567|BEHAVIORAL|TAU + FIBRO-On|Group treatment protocol of 12 weekly 60 minute sessions (virtual intervention)
48120320|NCT05377567|BEHAVIORAL|TAU + FIBRO-Out|Group treatment protocol of 12 weekly 120 minute sessions (outdoor intervention)
48120321|NCT05377567|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
48325560|NCT01921946|DRUG|Rosuvastatin|
48325561|NCT05628025|OTHER|Organ phantom of prostate|Participants will operate on a 3D printed model of the prostate.
48489465|NCT04703582|DIAGNOSTIC_TEST|Activated clotting time|Relationship between elongated baseline activated clotting time and comorbidity
48649420|NCT06487559|DRUG|Livmoniplimab|Intravenous infusion
48649421|NCT06487559|DRUG|Budigalimab|Intravenous infusion
48649422|NCT06470867|BEHAVIORAL|VA S.A.V.E.|The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.
48649423|NCT06470867|BEHAVIORAL|Control training|"An attention control informational video containing information relevant to veterans' mental health but not including elements thought to be active ingredients in the intervention."
48649424|NCT01582555|DRUG|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
48649425|NCT01582555|DRUG|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
48649426|NCT06673693|DRUG|Tislelizumab|SBRT
48649427|NCT06435858|DRUG|Empagliflozin|Empagliflozin 10mg
47971686|NCT04933994|DEVICE|computed Tomography|All cases were detected with computed Tomography
47971687|NCT02414984|BIOLOGICAL|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
48489466|NCT02302521|DEVICE|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
48120322|NCT03995992|BEHAVIORAL|sport|10 days of sport (diving or multisport), once training per day
48120323|NCT02309996|BEHAVIORAL|Supervisor Training Program|
48120324|NCT06369701|DEVICE|Compressive tissue floss band|Compressive tissue flossing (CTF) is a compressive technique that uses a latex elastic band to compress the tissues and restrict the circulation of fluids in the targeted area for a short time. CTF acts on the mechanoreceptors in the underlying fascial layers, causing blood reperfusion of the compressed tissue, and/or causing fascial shearing and the sliding potential of the fascia to be restored (Starrett \& Cordoza, 2015). Proposed benefits from references include improving joint mobility in the joints of the limbs (Starrett \& Cordoza, 2015), improving muscular power, and decreasing pain with motion (Angelopoulos et al., 2021) (Cage et al., 2022) (Jianhong et al., 2021).
48120325|NCT04246307|DIAGNOSTIC_TEST|TEG® and ClotPro® parameters|"Systemic sampling is performed six times:~* before the surgery (S1)~* during the hepatectomy, 10 minutes before the anhepatic phase (S2)~* in the anhepatic phase, before starting portal vein anastomosis: (S3)~* in the neohepatic phase, 15 minutes after releasing portal vein clamping: (S4)~* in the neohepatic phase, at the end of the surgery: (S5)~Regional sampling from the portal vein representing afferent flow to the liver is performed once:~• in the anhepatic phase, before starting portal vein anastomosis: (R)~Simultaneously with haemostasis and blood gas analyses, the following investigations will be performed (the following tests are also routinely performed at the given time points, independently of this study):~* haemodynamic measurements by PiCCO~* arterial blood gas analysis from radial artery catheter~* central venous blood gas analysis from subclavian vein catheter~* blood temperature measurement in the femoral artery by PiCCO catheter~* hourly urinary output"
48120326|NCT03921580|OTHER|Control Canned Tuna|210 g/day
48120327|NCT03921580|OTHER|Enriched Canned Tuna Variety 1|210 g/day
48120328|NCT03921580|OTHER|Enriched Canned Tuna Variety 2|210 g/day
48120329|NCT04457752|BIOLOGICAL|Dual Layer Amniotic Membrane (DLAM). Artacent®|"Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."
48489467|NCT05925504|DRUG|Luspatercept|The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
48649428|NCT06435858|DRUG|Placebo|Placebo capsule
48649429|NCT06018376|DRUG|Systemic oncological treatment|Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
47971688|NCT03340532|OTHER|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
47971689|NCT03340532|OTHER|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
47971690|NCT03340532|OTHER|Sleep hygiene video|Contain information on better sleep hygiene
47971691|NCT02720471|DRUG|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
47971692|NCT02720471|DRUG|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
47971693|NCT01816282|DRUG|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
47971694|NCT03950115|DEVICE|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
47971695|NCT04936256|DEVICE|Clareon|Clareon monofocal intraocular lens (IOL)
48120330|NCT06012071|DEVICE|Zirconia dental implants|Dental implants produced from zirconia material, either wit tissue-level or bone-level platform.
48120331|NCT03772652|OTHER|Observation|Soft tissue implant measurements
48120332|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
48120333|NCT00825084|DRUG|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
48120334|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
47971696|NCT05217147|OTHER|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
47971697|NCT00887978|DRUG|UT-15C SR|treprostinil diolamine sustained release tablets
47971698|NCT00887978|DRUG|Placebo|
47971699|NCT00394732|DEVICE|Total Disc Prosthesis|
48120335|NCT00825084|DRUG|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
48120336|NCT01365598|DRUG|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
48489468|NCT04912882|DIAGNOSTIC_TEST|Circulating tumor cell|detecting circulating tumor cell pre- and post operatively
48489469|NCT00474474|PROCEDURE|Virtual patient is NOT introduced|
48489470|NCT00114621|DRUG|Anthrax Vaccine|
47971700|NCT00394732|BEHAVIORAL|Multidisciplinary rehabilitation program|
47971701|NCT03128554|OTHER|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
47971702|NCT06113744|BIOLOGICAL|Placebo|saline
48325562|NCT06152419|DEVICE|Questionnaire|Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information.
48649430|NCT03757117|DRUG|Feminizing hormone therapy|"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
48649431|NCT03757117|BEHAVIORAL|Peer navigation|Transgender women community peer navigation
48649432|NCT05447858|OTHER|SWEA|Managers with one or several l staff experiencing WRNP will be educated in the Prehab guide. The manager should read and listen to all modules and a 1-h lecture recorded by the research team before participating in two workshops (4 h each), together with other managers and an experienced expert in work environmental health and rehabilitation. In the workshops, different themes will be discussed, such as physical, psychological, and organisational work-related health, prevention, and rehabilitation, how to lead problem-solving dialogue, how work-related adaptations can be performed related to WRNP, and questions about the Prehab guide. The Prehab guide will be used to deliver managerial support in the work with the Swedish Work Environment Authority's regulations regarding SWEA and the prevention of ill health, sick leave, and accidents, work adaptations, and workplace-oriented rehabilitation.
48649433|NCT05447858|OTHER|Neck-specific exercise|NSEs will be performed based on a well-structured framework of evidence-based exercises for facilitation of deep neck muscles, improved interaction between the different muscle layers of the neck, increased neck muscle endurance, and improved postural control .
48649434|NCT04505787|DRUG|Esflurbiprofen hydrogel patch 165 mg (EFHP)|patch application with PK blood sampling
48649435|NCT04505787|DRUG|Froben 100 mg comprimidos revestidos|tablet administration with PK blood sampling
48649436|NCT05024214|DRUG|Lenvatinib + Envafolimab|"Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle."
48649437|NCT05024214|DRUG|Sunitinib|Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
48649438|NCT06569615|OTHER|shock wave therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Radial shockwave therapy, (Storz Medical Shock Master MP200 device) for 10 minutes/session, one session/week, for 8 weeks."
48649439|NCT06569615|OTHER|LASER Therapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given LASER, (LEVELASER EZ1 EASYONE) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
48649440|NCT06569615|OTHER|Cryotherapy|"All the participants in first week will receive the ice pack for 15 minutes 3 times a day at the lumbosacral area to reduce inflammation in the area, along with rest to reduce irritation at the lumbosacral area for the first week.~From the 2nd week:~Participants will be given Cryotherapy, (Gymna UniphyCryoflow 1000 IR Shock Master ICE-CT device) over the lumbosacral area for 10 minutes/Session, three session/week, for 8 weeks."
48649441|NCT06569615|OTHER|Exercises|The assigned exercises for all participants will include 1. Bilateral bridging, 2. Knee to chest, 3. Back extension within a pain-free range, 4. Plank, 5. Baby pose stretch, 6. Cat and camel, 7. Bilateral adductor ball squeezes and 8. Stretching exercise (Gluteal /Piriformis stretch, Quads /Hams stretch. The treatment plan involved performing three sets of exercises, with each set comprising 8 to 10 repetitions. 20-30 minutes of exercise session will be conducted three times per week over a span of 8 weeks.
48649442|NCT05592379|DRUG|Psilocybin|The IV formulation of psilocybin will be prepared using bulk psilocybin that will satisfy Good Manufacturing Practice (GMP) criteria. The IV psilocybin solution will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center (PRC).
48649443|NCT05592379|DRUG|Clonidine|Clonidine will be administered orally in a 0.2mg dose
47971703|NCT06113744|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
47971704|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg|Low-dose
48120337|NCT04272645|DRUG|Abemaciclib 200 MG|200 MG orally BID Days 1-21
48325563|NCT03374553|DEVICE|MINI DO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
48325564|NCT03374553|DEVICE|MINI SO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
48325565|NCT04830228|DEVICE|Ballon expandable stent and PTA|Endovascular treatment for the peripheral artery disease of the Iliac artery
47971705|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg|Mid-dose
47971706|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg|High-dose
48120338|NCT04272645|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg IV on Day 1 of 21-day cycle
48120339|NCT04272645|DRUG|Abemaciclib 150 MG|150 MG orally BID Days 1-21
48120340|NCT00338624|DRUG|oxybutynin chloride extended release|
48120341|NCT01340417|OTHER|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
48649444|NCT05592379|OTHER|Saline|The IV placebo (saline) will be prepared under sterile conditions by the University of Wisconsin Pharmaceutical Research Center.
48325566|NCT03224585|DRUG|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
48325567|NCT03224585|DRUG|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
48325568|NCT00598715|DEVICE|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
48325569|NCT00598715|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
48649445|NCT02134808|DRUG|Creatine|Creatine is a nutritional supplement.
48649446|NCT02134808|DRUG|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
48649447|NCT04964752|DEVICE|continuous glucose-monitoring|Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
48649448|NCT06372041|DEVICE|transcranial Alternating Current Stimulation|tACS will be performed by using a Conformite Europeenne (CE) marked stimulator device (Starstim ®, Neuroelectrics, Barcelona, Spain). By applying alternating current at the gamma frequency band (range 30-80), known to be associated to motor performance, tACS can entrain or synchronize neural oscillations in the targeted brain regions. By modulating cortical excitability of the cerebellum, a region strongly involved in motor learning and coordination, tACS is expected to influence the strength and coordination of motor responses elicited during the training. tACS will be delivered through two saline-soaked surface sponge electrodes (dimension: 25cm2 each), one placed over F3 (left frontal region) and the other over the right cerebellar hemisphere. The intensity will be set to 1mA, and this value will be gradually reached with a ramping-up phase of 30 secs. The frequency of the stimulation will match the IGF identified during the EEG recording performed at rest.
48649449|NCT04582812|OTHER|Bilateral and simultaneous diaphragm ultrasonography reeducation plus inspiratory training|Bilateral and simultaneous diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
48649450|NCT04582812|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
47971707|NCT03748888|BEHAVIORAL|Exercise group|"An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min."
48649451|NCT04508530|BIOLOGICAL|Panzyga|Panzyga 10% IVIG
47971708|NCT02771912|DRUG|Propofol|Propofol and excipients
47971709|NCT02771912|DRUG|Placebo|Qualitative composition of Propofol lipuro 2% excipients
47971710|NCT05070299|BEHAVIORAL|Psychosexual Educational Partner Program (PEPP)|A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.
47971711|NCT00003594|DRUG|irinotecan|
47971712|NCT00003594|DRUG|fluorouracil|
47971713|NCT00003594|DRUG|leucovorin calcium|
47971714|NCT00003594|DRUG|oxaliplatin|
47971715|NCT03129698|DRUG|Apatinib|Apatinib 250mg daily
47971716|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
47971717|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 4D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
47971718|NCT06062511|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
47971719|NCT02771093|DRUG|Trelagliptin|Trelagliptin 100 mg tablet
47971720|NCT02771093|DRUG|Alogliptin|Alogliptin 25 mg tablet
47971721|NCT02058667|RADIATION|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
47971722|NCT02866552|DRUG|Stromal Vascular fraction|
47971723|NCT02866552|DRUG|Ringer lactate|
47971724|NCT06313229|PROCEDURE|implant placement 6 months after ridge augmentation|the deficient ridge was grafted first followed by implant placement after 6-monthes
47971725|NCT06313229|PROCEDURE|implant placement Simultaneously with ridge augmentation|the deficient ridge was grafted and followed by implant placement simultaneously
47971726|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
47971727|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
48325570|NCT03968614|OTHER|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
48649452|NCT04508530|OTHER|Placebo|Placebo
48649453|NCT01959919|DEVICE|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
48489471|NCT00114621|PROCEDURE|Blood Chemistry|
48489472|NCT00114621|PROCEDURE|Hematology|
48120342|NCT03618524|OTHER|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
48120343|NCT02789215|BEHAVIORAL|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
48649454|NCT06553157|DRUG|Statin|Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.
48325571|NCT03968614|OTHER|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
48325572|NCT01654523|DEVICE|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
48325573|NCT03446651|DRUG|Lysine Chloride|Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
48325574|NCT03446651|OTHER|Placebo|Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
48325575|NCT02097433|DRUG|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
48325576|NCT01152736|DRUG|Nicotine|2 mg Single-dose
48325577|NCT03601208|DIAGNOSTIC_TEST|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
48325578|NCT05915494|OTHER|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
48325579|NCT05915494|OTHER|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
48325580|NCT06275243|DIAGNOSTIC_TEST|Kit Buccal swab collection & stabilization de Canvax®|Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
48489473|NCT00114621|PROCEDURE|Urinalysis|
48489474|NCT00054041|BIOLOGICAL|HspE7|Given subcutaneously
48489475|NCT00054041|PROCEDURE|therapeutic conventional surgery|Undergo large loop excision
48489476|NCT00054041|OTHER|laboratory biomarker analysis|Correlative studies
48489477|NCT02688426|DEVICE|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
48489478|NCT02688426|DEVICE|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
48489479|NCT04198636|DRUG|LY01011|LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
48489480|NCT04198636|DRUG|Xgeva 120 MG in 1.7 ML Injection|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
48489481|NCT06219486|DIAGNOSTIC_TEST|D-dimer|The investigators will measure a D-dimer test on participants and randomize on informing the physician on the value.
48649455|NCT06553157|OTHER|placebo|placebo
47971728|NCT02268344|DEVICE|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
47971729|NCT04691505|DRUG|Methotrexate|Methotrexate is used as the reference group.
47971730|NCT04691505|DRUG|Hydroxychloroquine|Hydroxychloroquine is used as the exposure group.
48120344|NCT00111813|DRUG|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
48489482|NCT03075319|PROCEDURE|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
48649456|NCT05597124|BEHAVIORAL|Cardio-Dance Fitness|This is an aerobic cardio-dance fitness exercise class in a social context with aerobic intensity assessed by heart rate monitoring throughout the class. Participants will meet three times a week for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
48489483|NCT03075319|PROCEDURE|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
48489484|NCT05389982|OTHER|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
48489485|NCT05389982|OTHER|Standard Care|Office based pathway
48489486|NCT00792727|DRUG|ketoprofen Patch|2 topical patches applied once daily for 28 days
48489487|NCT00792727|OTHER|Placebo Patch|2 topical placebo patches applied once daily for 28 days
47971731|NCT00840450|DRUG|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
47971732|NCT04838613|DRUG|[18F]CTT1057|Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
47971733|NCT04838613|DRUG|[68Ga]Ga-PSMA-11|Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
47971734|NCT00740831|DRUG|PGL4001|tablets
47971735|NCT00740831|DRUG|leuprorelin|solution for injection
47971736|NCT04293120|OTHER|Training with weighted ball|Participants will stop or catch a weighted ball
47971737|NCT03995121|RADIATION|[11C]APP311|It has been shown that \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
47971738|NCT03765905|DIAGNOSTIC_TEST|study|Scube-1 scube-2 scube-3
48325581|NCT06275243|OTHER|Cholesterol levels according to ApoE Genotype|Enhancing the quality of life of study participants by investigating cholesterol levels based on their ApoE genotype.
48325582|NCT06275243|OTHER|Assessing cardiovascular risk factors in all participants|Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
48325583|NCT05750134|OTHER|OBPLUS Clinical Database : data analysis|The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
48325584|NCT05750134|OTHER|"Biological collection Liver, bile ducts and pancreas: sample analysis"|"The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection Liver, bile ducts and pancreas. These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication."
48325585|NCT00004696|DRUG|morphine|
48325586|NCT01409993|DRUG|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
48325587|NCT01409993|DRUG|Placebo|Matching placebo three times a day for three months
48325588|NCT01409993|DIAGNOSTIC_TEST|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
48325589|NCT01409993|DIAGNOSTIC_TEST|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
48325590|NCT01193140|DRUG|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
48325591|NCT01193140|DRUG|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
48325592|NCT04024059|BEHAVIORAL|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
48325593|NCT04024059|BEHAVIORAL|Contingency Management for abstinence|Incentives contingent on opiate abstinence
48325594|NCT00790101|DRUG|Risedronate|
48489488|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
48489489|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
48489490|NCT04029987|PROCEDURE|Control|Conventional analgesia
48489491|NCT02027870|DEVICE|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
48489492|NCT00652028|DRUG|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
48489493|NCT04593017|DIETARY_SUPPLEMENT|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
48489494|NCT04593017|OTHER|Placebo Probiotic|Placebo
48325595|NCT00790101|DRUG|Raloxifene|
47971739|NCT01257997|BIOLOGICAL|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
47971740|NCT06231160|PROCEDURE|Systematic Therapy Combined With Microwave Ablation|Patients with unresectable pancreatic cancer were included for laboratory examination, and quality of life and pain scores were recorded. The experimental group underwent microwave ablation first, followed by chemotherapy according to the guidelines; The control group received the same chemotherapy. Record the use of chemotherapy drugs and the occurrence of adverse events. Follow up will be conducted at 30 days, 90 days, and 180 days after chemotherapy to evaluate pancreatic function and quality of life.
47971741|NCT04720898|DEVICE|LUNA-EMG|The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot provides optimized range of motion's movements and a visual feedback on the patient's performance. In addition, it may enhance neuroplasticity due to the increased number of movements repetitions which could influence motor learning.
47971742|NCT04688853|BIOLOGICAL|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
48649457|NCT05597124|BEHAVIORAL|Strength, Flexibility & Balance|This intervention will serve as a stringent, structurally equivalent, active comparator to the CDF intervention, identical in duration, frequency, and social contact except for the content of this non-aerobic intervention. SFB will involve non-aerobic activity with strength, flexibility, and balance training.
47971743|NCT05444192|DEVICE|CAD/CAM insoles|computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
47971744|NCT06387095|PROCEDURE|1. no block|After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
47971745|NCT06387095|PROCEDURE|2. superficial parasternal block|After induction, the patient will undergo an ultrasound-guided superficial parasternal plan block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
47971746|NCT06387095|PROCEDURE|3. deep parasternal block|After induction, the patient will undergo an ultrasound-guided deep parasternal plane block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
47971747|NCT06293404|DRUG|Bupivacain|7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)
47971748|NCT03047694|OTHER|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
48325596|NCT00790101|OTHER|Placebo|
48325597|NCT00707343|RADIATION|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
48325598|NCT00080886|BIOLOGICAL|rituximab|
48325599|NCT00080886|DRUG|carmustine|
48325600|NCT00080886|DRUG|cytarabine|
48649458|NCT05101148|DRUG|Selumetinib|The dosing regimen for selumetinib (25 mg/m2 bid) will be based on BSA, during T1 and T2 the dose will be 25mg/m2, consistent with the approved prescribing information in the US. If T3 is required, appropriate dose of selumetinib will be defined by Data Review Committee for T3.
47971749|NCT03047694|OTHER|usual care|speech therapy
47971750|NCT03203304|DRUG|Nivolumab|240mg every two weeks by IV infusion
47971751|NCT03203304|DRUG|Ipilimumab|1mg/kg every six weeks by IV infusion
47971752|NCT02790528|DRUG|Atorvastatin|20mg QD
47971753|NCT02790528|DRUG|Placebo|Placebo drug will be administered.
47971754|NCT05914298|DIAGNOSTIC_TEST|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
48325601|NCT00080886|DRUG|etoposide|
48325602|NCT00080886|DRUG|melphalan|
48325603|NCT00080886|PROCEDURE|autologous bone marrow transplantation|
48325604|NCT00080886|PROCEDURE|peripheral blood stem cell transplantation|
48325605|NCT01241396|OTHER|Any MMY treatment|Any line of treatment for MMY
48325606|NCT00699842|DRUG|Lenalidomide|"Dose Level Lenalidomide Schedule~1. 15mg/day for d1-21 out of 28 days~2. 20mg/day for d1-21 out of 28 days~3. 25mg/day for d1-21 out of 28 days"
48325607|NCT00139620|DRUG|Tarceva, erlotinib, OSI-774|
48325608|NCT02755610|OTHER|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
48325609|NCT04460417|BEHAVIORAL|Enhanced Care|The session began with the therapist reviewing the participants' personal feedback sheet within the context of clear messaging that there is no safe level of smoking and of how smoking affects the participant individually and the Black community collectively. The participant was encouraged to quit smoking, else to reduce smoking if abstinence was not desired, and to use NRT within the next week to help foster behavior change and alleviate withdrawal symptoms. This portion of the counseling was presented within a culturally-targeted framework such that myths regarding NRT common among persons with low health literacy were discussed and debunked and historical mistrust of the medical community and concerns about exploitation were also addressed. Each participant in EC was offered a starter kit of NRT with a one week supply of patches or lozenges.
48325610|NCT04460417|BEHAVIORAL|TAU|"Participants met with a research assistant for 3-5 minutes and received the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information. They did not receive counseling or specialized care and were advised to refer to the resources should they be interested in quitting smoking."
48325611|NCT04151095|OTHER|BFR Exercise Training|Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
48325612|NCT04151095|OTHER|CTL Exercise Training|Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
48325613|NCT03018457|DEVICE|ISQ|Measured by Osstell.
48325614|NCT01701219|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
48325615|NCT04278508|DRUG|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
48325616|NCT00941889|DRUG|Saline|0.5 ml
48340112|NCT05793112|DRUG|Placebo|Oral suspension
47971755|NCT05914298|DIAGNOSTIC_TEST|PUL|measurement of ulnar length with anthropometer and patient's height
47971756|NCT05914298|DIAGNOSTIC_TEST|Range of motion|measurement of range of motion of elbow, forearm and wrist
48340113|NCT02349204|BEHAVIORAL|Music - Mozart's sonata for 2 pianos in D-440|
48325617|NCT00941889|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
48649459|NCT03290677|PROCEDURE|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
48325618|NCT00627835|DRUG|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
48325619|NCT00627835|DRUG|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
48325620|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
48325621|NCT00627835|DRUG|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
48325622|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
48325623|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients|"For each patient, a blood sample will be taken at D0 before the CAR-T cells are injected then at D3, D7, D10, D30 after the injection. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis by effector immune cells (T lymphocytes, NK cells, CAR-T cells) and to define the phenotypic signature of trogocytosis."
48489495|NCT02686203|DEVICE|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
48489496|NCT02426047|DIETARY_SUPPLEMENT|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
48489497|NCT05019820|OTHER|Knee strengthening exercises with isokinetic dynamometer|18 sessions of strengthening exercises around the knee with an isokinetic dynamometer 3 days a week
48489498|NCT05019820|OTHER|Strengthening around the knees with home exercise programe|18 sessions of strengthening exercises for the muscles around the knee at home, 3 days a week
48489499|NCT04075019|BEHAVIORAL|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
48325624|NCT06352242|OTHER|Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers|For each healthy volunteer, a single blood sample will be taken at enrollment. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis of normal lymphocytes and NK cells.
48325625|NCT00697658|DRUG|Paliperidone ER|6 mg tablet once daily, variable treatment length.
48489500|NCT00003034|DRUG|doxorubicin hydrochloride|Given IV
48489501|NCT00003034|DRUG|ranpirnase|Given IV
48489502|NCT04901013|OTHER|Affinity|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).
48489503|NCT05787470|BEHAVIORAL|Quantative sensory testing|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
48489504|NCT05787470|DIAGNOSTIC_TEST|Blood Draw|Sample of blood will be taken.
47971757|NCT00447460|PROCEDURE|Mesenchymal stem cell (MSC)|
48325626|NCT00369967|DRUG|NuvaRing|Initiation of NuvaRing for contraception
48325627|NCT04745286|DRUG|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
48325628|NCT04745286|DRUG|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
48325629|NCT04031053|OTHER|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
48325630|NCT02877355|DRUG|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
48489505|NCT04128475|OTHER|N/A - observational study.|N/A - observational study.
48489506|NCT01796158|BEHAVIORAL|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
48489507|NCT01796158|BEHAVIORAL|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
48489508|NCT03254602|DEVICE|Intense Therapeutic Ultrasound Treatment|
48649460|NCT03290677|PROCEDURE|Biopsy|Removing a small piece of the affected area to confirm cancer
48649461|NCT06391489|BEHAVIORAL|HOBSCOTCH-PACS|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
48325631|NCT00477555|DEVICE|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
47971758|NCT04603690|DIETARY_SUPPLEMENT|Complementary therapy|A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
48120345|NCT00111813|DRUG|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
48120346|NCT06552728|OTHER|Energy Healing|EH derives from the theory that by using the body's biological energy, there can be a therapeutic effect that guides the patient towards a homeostatic state. Preliminary data in chronic pain patients, suggests that EH, delivered by an experienced practitioner, is able to reduce self-reported pain symptoms within minutes. Effects lasting for weeks to months have also been anecdotally reported. For patients with pain, this can result in a reduction of symptoms. Participants will also be presented with sham EH as a control.
48120347|NCT02575560|OTHER|history data|history data of PFS after 1st line or second line theray
48120348|NCT03118323|OTHER|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
48120349|NCT04456725|BEHAVIORAL|Intensive management|The intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them intensively, with the support of the study team.
48325632|NCT04325945|DEVICE|Low level laser therapy|808nm low level laser therapy on acupuncture points
48649462|NCT04951544|OTHER|LetSync v1.0|Study B will entail a pilot randomized, controlled trial (RCT) of an mHealth behavioral intervention, LetSync, with 80 couples (N=160) to assess its acceptability, feasibility, and preliminary impact on retention in care and ART adherence as measured by antiretroviral concentrations in hair. Participants in the intervention arm will use LetSync v1.0 for 6 months and provide acceptability and feasibility data. Participants will then continue to use LetSync v1.0 while the Waitlist-Control group begins to use LetSync v2.0.
48649463|NCT04951544|OTHER|LetSync v2.0|LetSync v2.0 will be developed by taking feedback from participants regarding LetSync v1.0. Participants in the waitlist-control group will be given LetSync v2.0 to use during the last 6 months of the trial.
48649464|NCT06068192|OTHER|no intervention|no intervention
48649465|NCT04968600|PROCEDURE|total knee arthroplasty|Posterior-cruciate-ligament is retained in one arm and sacrificed in another arm during total knee arthroplasty
48649466|NCT05179915|OTHER|Therapeutic Touch focused on sacral region|In the latent phase of labor, the field energy of the sacral region will be cleared for an average of 15 minutes.
48120350|NCT04456725|BEHAVIORAL|Control|Usual care
48325633|NCT00363051|DRUG|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
48325634|NCT00363051|DRUG|Octreotide Depot|
48325635|NCT00502320|DRUG|Ramelteon|one 8 mg tablet at bed for up to 4 months
48325636|NCT00502320|DRUG|Placebo|one tablet at bedtime for up to 4 months
48325637|NCT05684952|DRUG|Shenlingcao Oral Liquid|Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
48325638|NCT00781248|DEVICE|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
48325639|NCT05124977|DRUG|Antimicrobial Stewardship|Antimicrobial stewardship based on daily clinical assessment of clinical cure. Discontinuation of appropriate antibiotic therapy antibiotics if criteria of clinical cure of confirmed pneumonia are met. Intensivists will perform clinical assessment daily in order to decide on the pursuit or discontinuation of antibiotic therapy.
48325640|NCT05124977|DRUG|Standard management|Standard management: duration of appropriate antibiotic for confirmed pneumonia fixed for 7 days according to guidelines. In the control group, intensivists will perform clinical assessment daily, but the antibiotic will not be discontinued until 7 days whatever the clinical cure.
48325641|NCT06079866|DEVICE|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
48120351|NCT02764645|DEVICE|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
48120352|NCT02764645|DEVICE|22Fr curved Cannula|arterial cannula for use in cardiac surgery
48120353|NCT02498717|DEVICE|GameReady|Cryotherapy and compression
48120354|NCT02498717|OTHER|RICE|SOC ice and elevation
48120355|NCT06162897|BEHAVIORAL|Dyadic Case Management|Subjects enrolled in the intervention arm will be offered focused case management centered around goal setting and future orientation. Subjects will be assigned two case managers to support their goals.
48120356|NCT02317874|DRUG|Carboplatin|Given IV
48325642|NCT06079866|DEVICE|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
48325643|NCT05435144|DIETARY_SUPPLEMENT|Elderberry|European black elderberry extract
48325644|NCT05435144|OTHER|Placebo|Inactive placebo
48325646|NCT03452891|OTHER|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
48325647|NCT03452891|DRUG|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
48489509|NCT06097793|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
48120357|NCT02317874|DRUG|Paclitaxel|Given IV
48489510|NCT03146182|BEHAVIORAL|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
48489511|NCT03146182|BEHAVIORAL|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
48649467|NCT05504746|DRUG|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
48649468|NCT05504746|DRUG|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
48120358|NCT02317874|DRUG|Talazoparib|Given PO
48120359|NCT03295747|DRUG|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
48489512|NCT06148064|OTHER|Collaplug with low level laser|Immediate implant placement with applying a collaplug material in the jumping gap followed by low level laser application using Siro laser (660 nm, avg. power density: 0.5-WATT) circular spot diameter and area: 0.71 cm/0.4cm2) applied in six points in contact mode with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before bone perforation and after suturing.
48489513|NCT06148064|OTHER|Collaplug|Implant of suitable diameter and height was placed in the fresh extracted socket immediately after extraction and the jumping gap was augmented by the collaplug followed by healing abutment placement.
48120360|NCT00593866|RADIATION|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
48325648|NCT02158702|DRUG|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
48325649|NCT05101486|BIOLOGICAL|Ad26.RSV.PreF-based Vaccine|Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
48325650|NCT03308565|BIOLOGICAL|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
48325651|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
48325652|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
48325653|NCT05239468|DRUG|Bezafibrate 100 mg|One tablet of bezafibrate 100 mg IR once daily
48325654|NCT05239468|DRUG|Bezafibrate 200 mg|Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
48325655|NCT05239468|DRUG|Obeticholic Acid 5 mg|One tablet of obeticholic acid 5 mg tablet once daily.
48325656|NCT05239468|DRUG|Obeticholic Acid placebo|One tablet of obeticholic acid placebo tablet once daily
48489514|NCT06456437|DEVICE|Post-conditioning Balloon dilation and contraction|The balloon was filled at a pressure of no more than 4 atm at the original occlusion of the vessel to block blood flow for 2 minutes (confirmed by angiography), and then contracted to reperfuse the blood flow for 2 minutes, and the above steps were repeated 4 times to complete the in situ ischaemic post-acclimatisation intervention.
48649469|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
48649470|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
48649471|NCT03209765|OTHER|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
48649472|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection low dose administered by subcutaneous injection
48649473|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection medium dose administered by subcutaneous injection
48325657|NCT05239468|DRUG|Bezafibrate Placebo|One tablet of bezafibrate placebo tablet once daily
48325658|NCT06005298|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment (SBIRT)|"SBIRT has been defined by SAMHSA as a comprehensive, integrated, public health approach to the delivery of early intervention for individuals with risky alcohol and drug use and the timely referral to more intensive substance abuse treatment for those who have substance abuse disorders. There is consensus that a comprehensive SBIRT model includes screening, brief intervention/brief treatment, and referral to treatment. In addition there are following characteristics:~* It is brief (e.g., typically about 5-10 minutes for brief interventions; about 5 to 12 sessions for brief treatments)~* The screening is universal.~* One or more specific behaviors related to risky alcohol and drug use are targeted.~* The services occur in a public health non-substance abuse treatment setting.~* It is comprehensive (comprised of screening, brief intervention/treatment, and referral to treatment).~* Strong research or experiential evidence supports the model's effectiveness."
48325659|NCT00098020|DRUG|Isotretinoin|
48325660|NCT05883085|DRUG|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
48325661|NCT01160653|DEVICE|FES-IM|implantable Functional Electrical Stimulation
48649474|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection high dose administered by subcutaneous injection
48649475|NCT06425341|DRUG|HRS-5635 Injection|HRS-5635 Injection lowest dose administered by subcutaneous injection
48649476|NCT03630510|OTHER|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
48325662|NCT01160653|OTHER|Cognitive training|training of impaired cognitive processes
48325663|NCT02195934|OTHER|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
48325664|NCT02195934|OTHER|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
48325665|NCT04145869|PROCEDURE|Cholangiography|All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
48325666|NCT05314361|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD (written by the NPA).
48325667|NCT00039468|DRUG|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
48649477|NCT02025218|DRUG|Gefitinib standard dose|
48649478|NCT05464030|DRUG|M9140|M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.
48325668|NCT00039468|DRUG|thalidomide|400mg/day oral
48649479|NCT05464030|DRUG|M9140|M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.
48325669|NCT05181540|BIOLOGICAL|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
48120361|NCT00593866|DRUG|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
48325670|NCT05181540|OTHER|Placebo|Placebo
48325671|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
48325672|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
48325673|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
48489515|NCT05211999|BEHAVIORAL|Precede-Proceed Model Based Simulation Experience|The program was created on the basis of the PRECEDE-PROCEED Model.The program consists of eight phases. It will be carried out with theoretical training and simulation experience in the experimental group. In the control group, theoretical training will be given. Results will be followed.
48325674|NCT06041646|DRUG|Sublingual film containing Igalmi|Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
48325675|NCT01499901|PROCEDURE|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
48489516|NCT05211999|BEHAVIORAL|Control Group|No intervention in control group just theoretical education was done for them.
48489517|NCT05434377|OTHER|ergocalciferol supplementation|Participants in both groups will recieve ergocalciferol with different supplementation regimens for 6 months.
48489518|NCT05434377|OTHER|dialysis techniques|Both groups will have participants treated with maintenance hemodialysis and peritoneal dialysis.
48489519|NCT05434377|OTHER|sunlight exposure time|Both groups will be advised to receive similar hours of daily sunlight exposure time.
48325676|NCT01499901|PROCEDURE|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
48489520|NCT06010030|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.
48489521|NCT06010030|BEHAVIORAL|Speech Therapy|Participants will receive either semantic or phonological focused speech therapy
48489522|NCT03581071|DRUG|TS-143|
48120362|NCT01279798|BIOLOGICAL|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
48120363|NCT04162444|DIAGNOSTIC_TEST|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
48325677|NCT01611350|OTHER|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
48325678|NCT01611350|OTHER|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
48489523|NCT01101204|DRUG|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
48489524|NCT04745715|PROCEDURE|craniectomy|craniectomy outcomes and survival
48489525|NCT02916693|DRUG|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
48489526|NCT03456960|DRUG|TAK-438ASA|TAK-438ASA tablet.
48325679|NCT01611350|OTHER|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
48325680|NCT00354497|OTHER|physiologic testing|
48325681|NCT00354497|OTHER|study of socioeconomic and demographic variables|
48325682|NCT00354497|PROCEDURE|evaluation of cancer risk factors|
48325683|NCT00354497|PROCEDURE|mutation carrier screening|
48325684|NCT00354497|PROCEDURE|study of high risk factors|
48325685|NCT01943318|PROCEDURE|Liver biopsy|Histologic evaluation
48325686|NCT01943318|DEVICE|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
48325687|NCT03550287|DIETARY_SUPPLEMENT|Experimental product|10 g/day
48325688|NCT03550287|DIETARY_SUPPLEMENT|Placebo product|10 g/day
48489527|NCT03456960|DRUG|TAK-438|TAK-438 tablet.
48489528|NCT03456960|DRUG|Aspirin|Aspirin enteric-coated tablet.
48489529|NCT03453671|BEHAVIORAL|Mindfulness|Participants will use mindfulness techniques while exercising
48489530|NCT03453671|BEHAVIORAL|Distraction|Participants will distract themselves while exercising
48120364|NCT04162444|DIAGNOSTIC_TEST|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
48325689|NCT03882255|DRUG|Ponesimod dose range (2 - 20 mg)|Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
48489531|NCT03453671|BEHAVIORAL|Self-monitoring|Participants will use associative attentional focus while exercising
48489532|NCT00615654|OTHER|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
48120365|NCT04162444|DIAGNOSTIC_TEST|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
48325690|NCT03882255|DRUG|Placebo Propranolol|Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
47971759|NCT04603690|DRUG|Standard of care|This arm will receive standard of care as per the hospital guidelines
47971760|NCT02947997|DEVICE|OFDI capsule|Imaging of esophagus using OFDI capsule and system
47971761|NCT01693653|DRUG|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
47971762|NCT01506128|OTHER|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
47971763|NCT03761524|PROCEDURE|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
48325691|NCT03882255|DRUG|Propranolol 80 mg|Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
48325692|NCT01313520|DRUG|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
48325693|NCT01313520|DRUG|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
48325694|NCT01164865|DEVICE|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
48325695|NCT01164865|DEVICE|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
48325696|NCT01164865|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
47971764|NCT03761524|PROCEDURE|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
47971765|NCT00107471|BIOLOGICAL|filgrastim|Given PO
47971766|NCT00107471|DRUG|topotecan hydrochloride|Given IV
47971767|NCT00107471|RADIATION|radiation therapy|
47971768|NCT04187014|DRUG|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
47971769|NCT04187014|DRUG|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
47971770|NCT06295250|BEHAVIORAL|Manualized Group Based Psychotherapy|Manualized Group Based Psychotherapy. Adapted from the World Health Organization (WHO) Problem Management Plus (PM+) intervention, this intervention includes behavioral activation, enhancing social support, and problem management.
47971771|NCT06295250|OTHER|Poverty Alleviation|This intervention includes Asset transfer, skill transfer, financial literacy education, stipend, savings accounts, veterinary support, feed, and agricultural training
48120366|NCT04162444|OTHER|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~* Antiplatelet agents~* Loop diuretics~* Potassium-sparing diuretics~* Angiotensin-converting enzyme inhibitors"
48120367|NCT04162444|DIAGNOSTIC_TEST|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~* Perimeter of the aortic valve~* Diameter of the aortic valve at sinuses level~* Height of the aortic sinuses~* Morphology of the aortic valve"
48325697|NCT04260061|DEVICE|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
48489533|NCT02014077|PROCEDURE|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy( VATS )for retained haemothorax
48489534|NCT02014077|PROCEDURE|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
48489535|NCT02405663|PROCEDURE|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
47971772|NCT04091854|DRUG|HMS5552|To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
47971773|NCT06341400|DRUG|DisitamabVedotinForIicction Toripalimab|Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
48120368|NCT04162444|DIAGNOSTIC_TEST|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
48120369|NCT04162444|DIAGNOSTIC_TEST|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~* Heart rate~* Sinus rhythm (yes/no)~* Positive R wave in leads V5-6~* Angle α less than 0~* Presence/absence of abnormal Q wave~* Presence/absence of ST-segment depression in precordial leads"
48120370|NCT00802464|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
48120371|NCT00802464|BIOLOGICAL|Placebo|2 vaccinations at Months 0 and 2 with placebo
48120372|NCT04241354|BIOLOGICAL|Leukocyte-poor platelet rich plasma|Platelet rich plasma was prepared using PurePRP Supra Physiologic Protocol A preparation \[EmCyte Corp. Fort Myers FL\].
48120373|NCT02621086|DIETARY_SUPPLEMENT|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
48120374|NCT04728568|DRUG|Sintilimab|Sintilimab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
48325698|NCT00828685|PROCEDURE|CRPP|Closed reduction, percutaneous pinning
48325699|NCT00828685|PROCEDURE|ORIF|Open reduction, internal fixation
48325700|NCT00839423|DRUG|Placebo|capsules, daily, orally
48325701|NCT00839423|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
48325702|NCT00839423|DRUG|Venlafaxine XL|capsules, daily, orally
48325703|NCT05632224|DRUG|Aprepitant|The drug is given 1 hour before the start of the surgery
48325704|NCT05632224|DRUG|Granisetron|The drug is given 10 minutes before the patients's extubation
48325705|NCT02204826|DRUG|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
48325706|NCT02204826|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
48489536|NCT02405663|PROCEDURE|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
47971774|NCT03706105|BEHAVIORAL|Cardiac Rehabilitation|3 x week \~1 hour of exercise + education
48649480|NCT05464030|DRUG|Bevacizumab|Bevacizumab will be administered intravenously as per standard of care.
48649481|NCT05464030|DRUG|Capecitabine|Capecitabine will be administered orally as per standard of care.
47971775|NCT04464889|DRUG|MDG1021 dose 1|3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
47971776|NCT04464889|DRUG|MDG1021 dose 2|3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
48120375|NCT05048914|DRUG|Ibuprofen|treatment of acute migraine attack
48120376|NCT04481074|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
48120377|NCT01324453|PROCEDURE|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
48325707|NCT02604862|OTHER|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
48325708|NCT02604862|OTHER|AZD1236|AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
48489537|NCT04515082|DIAGNOSTIC_TEST|Stool-based SDC2 and SFRP2 DNA methylation test|A diagnostic device measuring syndecan 2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) methylation status in stool DNA to detect colorectal cancer
48489538|NCT04515082|DIAGNOSTIC_TEST|FIT|Fecal immunochemical test
48489539|NCT05702879|DRUG|Ozanimod|Start of standard therapy
48489540|NCT05702879|DRUG|TNF Inhibitor|Start of standard therapy
48489541|NCT05702879|DRUG|Steroids|Start of standard therapy
48489542|NCT05702879|DRUG|Vedolizumab|Start of standard therapy
48489543|NCT05702879|DRUG|Ustekinumab|Start of standard therapy
48649482|NCT05464030|DRUG|5-fluorouracil (5-FU)|5-FU will be administered intravenously as per standard of care.
48649483|NCT05464030|DRUG|Folinic acid|Folinic acid will be administered intravenously as per standard of care.
48649484|NCT04310657|DIAGNOSTIC_TEST|mNGS|Metagenomics second generation sequencing technology
48649485|NCT06674681|DIAGNOSTIC_TEST|HPV Self-Collection|HPV self-collection program for in-clinic and mailed cervical cancer screening.
48649486|NCT04043247|DEVICE|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
48649487|NCT04043247|DEVICE|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
48649488|NCT00009542|DRUG|kava (Piper methysticum)|
48325709|NCT04916535|OTHER|diagnostic flow|exams to estimate the risk of adverse events in patients with MAD
48325710|NCT00861861|DRUG|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
48325711|NCT00861861|DRUG|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
48325712|NCT00004992|BEHAVIORAL|Intensive lifestyle|
48325713|NCT00004992|DRUG|Metformin|
48489544|NCT01244061|DRUG|Varenicline|Varenicline 1mg twice daily
48489545|NCT01244061|DRUG|Placebo|Matched placebo twice daily
48489546|NCT04905849|BEHAVIORAL|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=\> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=\> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=\> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
47971777|NCT04464889|DRUG|MDG1021 dose 3|3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
47971778|NCT04464889|DRUG|MDG1021 optimal dose|20 patients to receive the selected optimal dose
47971779|NCT04799431|DRUG|Neoantigen Vaccine with Poly-ICLC adjuvant|"Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
47971780|NCT04799431|DRUG|Retifanlimab|500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
47971781|NCT04010708|DIAGNOSTIC_TEST|Urinary Iodine Concentration Measurement|UIC
47971782|NCT00118001|BEHAVIORAL|Worry exposure|
47971783|NCT00118001|BEHAVIORAL|Applied relaxation|
47971784|NCT01925677|DEVICE|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
47971785|NCT02387398|PROCEDURE|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
47971786|NCT03578861|OTHER|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
48120378|NCT01324453|PROCEDURE|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
48120379|NCT05832190|OTHER|Standard of care|Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
48120380|NCT05832190|DIETARY_SUPPLEMENT|Biotin supplement|1 capsule per day of Biotin 450µg during 3 months before the surgery.
48325714|NCT00004992|DRUG|Placebo|
48325715|NCT00200018|DEVICE|Enterra Therapy System (H9900014)|
48325716|NCT01731613|DIETARY_SUPPLEMENT|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
48325717|NCT00857753|DRUG|Fentanyl patch 25 ug/nr Sandoz|
48325718|NCT00857753|DRUG|Duragesic|
48325719|NCT01682070|BIOLOGICAL|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
48325720|NCT01682070|BIOLOGICAL|Placebo|
48325721|NCT03328624|DEVICE|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
48489547|NCT04905849|BEHAVIORAL|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
48489548|NCT01799317|DRUG|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
48489549|NCT01957072|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails."
48498070|NCT02299024|BEHAVIORAL|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
48325722|NCT03954444|DRUG|Oxymetazoline Hydrochloride|Test Comparator
48325723|NCT03954444|DRUG|Rhofade Cream, 1%|Reference Comparator
48325724|NCT03954444|DRUG|Placebo|Placebo Comparator
48325725|NCT01016691|DRUG|High Dose Drug Device|device inserted for 4 days
48325726|NCT01016691|DRUG|Low Dose Drug Device|device inserted for 4 days
48325727|NCT01016691|DRUG|Placebo Device|device inserted for 4 days
48325728|NCT01016691|DRUG|bimatoprost 0.03%|one drop in each eye on one day only
48325729|NCT05596903|OTHER|EMDR 2.0 group protocol|EMDR 2.0 group protocol
48325730|NCT05596903|OTHER|Mhgap stress module|Mhgap stress module
48340114|NCT02294669|DEVICE|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
48340115|NCT00028639|DRUG|bortezomib|
48325731|NCT02264899|OTHER|in Memento-VASCOD|"* Pulse wave velocity assessment~* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~* Neuropsychological testing and behaviorial and mood scales~* Urinary albumin excretion measurement"
48325732|NCT03480958|DEVICE|Intravenous morphine patient controlled device|24 hour morphine consumption will be recorded
48325733|NCT03480958|OTHER|Erector Spinae Plane Block|erector spinae plane block will be administered before the surgery
48325734|NCT03480958|OTHER|Thoracic Paravertebral Block|thoracic paravertebral block will be administered before the surgery
48325735|NCT05304000|BEHAVIORAL|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
48325736|NCT05304000|BEHAVIORAL|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
48325737|NCT05304000|BEHAVIORAL|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: \<20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
48120381|NCT05832190|DIETARY_SUPPLEMENT|Fiber supplement|3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
48120382|NCT01845259|DRUG|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
48120383|NCT01845259|DRUG|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
48120384|NCT06550245|OTHER|Infants observing familiar and unfamiliar racial groups|All infants will see videos of people from familiar and unfamiliar racial backgrounds. Depending on the caregiver's race, infants will be assigned to see people who are from the same racial background as their caregiver (i.e., familiar) and people who are not.
48120385|NCT02544880|DRUG|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
48340116|NCT03532724|DEVICE|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
48498071|NCT04332965|PROCEDURE|Non-Surgical Periodontal Treatment|Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
48649489|NCT00842803|DRUG|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
48649490|NCT03333200|OTHER|Palliative Care|Collecting information about the natural progression of these diseases
48120386|NCT02544880|BIOLOGICAL|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
48120387|NCT02544880|BIOLOGICAL|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
48649491|NCT03333200|BIOLOGICAL|Hematopoetic Stem Cell Transplantation|Following patients who have received HSCT as part of their clinical care.
48120388|NCT02544880|OTHER|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
48649492|NCT06509984|DRUG|Apremilast treatment|treatment of apremilast
48120389|NCT02544880|OTHER|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
48120390|NCT02544880|OTHER|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
48120391|NCT02544880|OTHER|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
48120392|NCT04565119|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Bio-BOOST study.
47971787|NCT03116971|DRUG|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
48120393|NCT00686855|DRUG|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
48120394|NCT00686855|DRUG|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
48120395|NCT02147717|DEVICE|Laser stimulation|"Infants will be divided in 2 groups:~* Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~* Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
48120396|NCT02147717|DEVICE|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
48325738|NCT05304000|BEHAVIORAL|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
48489550|NCT06490237|PROCEDURE|near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode|"During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression, vestibular neurotomy, meningioma or schwannoma removal), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests in noise and in silence. During the operation, stimuli are delivered in silence and in noise, under the same conditions as during the preoperative auditory exploration."
48120397|NCT00269789|DRUG|Ritalin|
48120398|NCT00269789|DRUG|OROS Methylphenidate HCl|
48120399|NCT00269789|DRUG|Placebo|
48120400|NCT05186714|BEHAVIORAL|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
48120401|NCT00609336|DRUG|gemcitabine hydrochloride|Given IV
48325739|NCT02252575|DEVICE|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
48325740|NCT04426370|OTHER|Observational|Physical examination and questionnaires
48120402|NCT00609336|DRUG|docetaxel|Given IV
48325741|NCT05191355|BIOLOGICAL|blood test|Blood spot collection for sampling
48325742|NCT04438252|DIAGNOSTIC_TEST|ICDAS II|Index for caries detection
48325743|NCT04438252|DEVICE|CariScan Pro|Device for early caries detection
48489551|NCT01615042|DRUG|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
48489552|NCT00841906|DEVICE|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
48498072|NCT02938754|BEHAVIORAL|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
48649493|NCT01909453|DRUG|LGX818|LGX818- Orally 100 mg and 50 mg capsules
48120403|NCT00609336|DRUG|capecitabine|Given PO
48120404|NCT00609336|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48120405|NCT00609336|DRUG|oxaliplatin|Given IV
48120406|NCT00609336|PROCEDURE|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
48120407|NCT00609336|PROCEDURE|therapeutic conventional surgery|Undergo therapeutic conventional surgery
48120408|NCT00609336|OTHER|laboratory biomarker analysis|Correlative studies
48325744|NCT04438252|RADIATION|Digital Radiograpgy|Device for digital x-ray imaging
48325745|NCT05907993|DRUG|Ibuprofen 800 mg|Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
48325746|NCT05262582|PROCEDURE|Sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
48325747|NCT05262582|PROCEDURE|Two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
48325748|NCT04902534|DRUG|Naoqingzhiming Tablets (contains echinacoside 180mg)|Single dose escalation and multiple dose escalation
48325749|NCT04902534|DRUG|placebo of Naoqingzhiming Tablets (without echinacoside)|Single dose escalation and multiple dose escalation
48325750|NCT03987919|DRUG|Tirzepatide|Administered SC
48325751|NCT03987919|DRUG|Semaglutide|Administered SC
48325752|NCT00003026|DRUG|bicalutamide|
48325753|NCT00003026|DRUG|flutamide|
48325754|NCT00003026|DRUG|triptorelin|
48325755|NCT00003026|RADIATION|radiation therapy|
48340117|NCT02409147|PROCEDURE|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
48120409|NCT06215053|OTHER|erector spine plane block|After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (MARCAİNE), 10 ml will consist of lidocaine 2% (Aritmal), and 10 ml will consist of physiological saline.
48120410|NCT03875963|OTHER|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler \[calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin\].
48120411|NCT04802148|PROCEDURE|membrane guided regeneration|after tooth extraction, the socket was filled with membrane and graft (FDBA)
48120412|NCT04802148|PROCEDURE|collagen plug|after tooth extraction, the socket was filled with collagen plug
48120413|NCT04441008|DEVICE|Accelerated Intermittent Theta Burst (aiTBS)|High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
48120414|NCT04441008|DEVICE|Electroconvulsive therapy (ECT)|ECT as per standard clinical care and management.
48120415|NCT05178225|DIETARY_SUPPLEMENT|ubiquinol (reduced coenzyme Q10)|supplementation with ubiquinol (reduced coenzyme Q10), in a daily dose of 2x100 mg. one morning after breakfast, and second dose after dinner.
48120416|NCT05178225|OTHER|mountain spa rehabilitation|special spa rehabilitation in the mountain High Tatras; Functional capacity of the lungs (6MWT) at before and after 16-18 days of rehabilitation, Borg scale for dyspnea and oxygen saturation SpO2 (%) were monitored.
48120417|NCT05178225|DIAGNOSTIC_TEST|2x14 ml of peripheral blood collected in a tube with anticoagulant|2x14 ml of peripheral blood collected in a tube with anticoagulant
48120418|NCT06081075|OTHER|Genetic testing|Rapid whole genome sequencing
48120419|NCT01116596|DRUG|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
48120420|NCT02556138|DEVICE|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
48120421|NCT00255359|DRUG|XTL-2125|
48325756|NCT05510206|DEVICE|Leveling and alignment|"Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires"
48325757|NCT06281145|BEHAVIORAL|Heart-rate variability biofeedback intervention|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
48325758|NCT02721251|BEHAVIORAL|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
48325759|NCT02721251|BEHAVIORAL|Weight Loss|16 week. the goal is 10% weight loss.
48325760|NCT02721251|BEHAVIORAL|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
48325761|NCT02535832|DRUG|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
48325762|NCT02535832|DRUG|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
48325763|NCT00003219|DRUG|perillyl alcohol|
48325764|NCT01560221|BEHAVIORAL|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
48325765|NCT01560221|DRUG|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
48120422|NCT01723631|DEVICE|Trap Myelin Test|
48325766|NCT01560221|DRUG|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
48325767|NCT00593840|RADIATION|Intensity modulated radiation therapy|
48340118|NCT00223912|DEVICE|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
48340119|NCT02989480|RADIATION|PET CT|PET CT scans
48489553|NCT00841906|DEVICE|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
48325768|NCT05735509|DEVICE|Rubber dam|Intraoral impressions can be taken with rubber dam in place. The care provider will take two impressions, one with the rubber dam in place and one without. The investigator will randomly chose one of the two impressions for crown manufacturing, and the crown will be delivered by the care provider blindly
48325769|NCT04223024|DRUG|CCRT+Nimotuzumab|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
48325770|NCT04223024|DRUG|CCRT alone|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
48489554|NCT05701644|DRUG|C1K 150mg|Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
48649494|NCT01909453|DRUG|MEK162|MEK162- Orally 15 mg tablets
47971788|NCT03116971|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.
48325771|NCT00443235|DRUG|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
48325772|NCT00443235|DRUG|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
48325773|NCT04968340|PROCEDURE|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
48325774|NCT04968340|PROCEDURE|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
48325775|NCT00844285|DRUG|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
48325776|NCT04358198|DIAGNOSTIC_TEST|Artificial intelligence|The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa. Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
48325777|NCT06108349|DRUG|Cannabidiol|Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
48325778|NCT02072512|DRUG|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
48325779|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
48325780|NCT02072512|DRUG|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
48325781|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
48489555|NCT05701644|DRUG|C1K 300mg|Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
48489556|NCT05701644|DRUG|Placebo with the same volume of C1K 300mg|Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
48489557|NCT05701644|DRUG|C1K 600mg|Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
48489558|NCT05701644|DRUG|Placebo with the same volume of C1K 600mg|Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
48489559|NCT05701644|DRUG|C1K 900mg|Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
48489560|NCT05701644|DRUG|Placebo with the same volume of C1K 900mg|Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
48489561|NCT05701644|DRUG|C1K 1200mg|Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
47971789|NCT03116971|DRUG|Etoposide|Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
48120423|NCT01402479|DRUG|Ramipril|ramipril 2.5mg twice a day
48325782|NCT00453232|BIOLOGICAL|bleomycin sulfate|
48325783|NCT00453232|BIOLOGICAL|pegfilgrastim|
48325784|NCT00453232|DRUG|cisplatin|
48325785|NCT00453232|DRUG|etoposide|
48340120|NCT02989480|OTHER|Cardiac MRI|Cardiac MRI
48340121|NCT00801346|OTHER|laboratory biomarker analysis|
48340122|NCT00801346|OTHER|metabolic assessment|
48340123|NCT00801346|OTHER|questionnaire administration|
48340124|NCT00801346|PROCEDURE|assessment of therapy complications|
48340125|NCT00801346|PROCEDURE|fatigue assessment and management|
48489562|NCT05701644|DRUG|Placebo with the same volume of C1K 1200mg|Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
48489563|NCT01722565|PROCEDURE|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
48489564|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
48489565|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
48489566|NCT02249676|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
48649495|NCT01909453|DRUG|vemurafenib|Tablets in bottles or blisters 240 mg
48649496|NCT02163356|DRUG|Fenretinide/LXS Oral Powder|Oral Powder
48649497|NCT02163356|DRUG|Ketoconazole|Oral Tablet
48649498|NCT02163356|DRUG|Vincristine|IV
48649499|NCT04403685|DRUG|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
48120424|NCT05664477|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
48120425|NCT05664477|DRUG|Placebo|Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
48120426|NCT01926678|OTHER|Swedish massage therapy|
48120427|NCT01926678|OTHER|Light touch therapy|
48120428|NCT02000349|OTHER|PGD|PGD using Next generation sequencing
48120429|NCT02396602|BEHAVIORAL|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
48120430|NCT00180505|DEVICE|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
48120431|NCT02259543|OTHER|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
48120432|NCT01947634|OTHER|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
48120433|NCT03278769|PROCEDURE|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
48120434|NCT04933890|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
48120435|NCT01897155|OTHER|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
48120436|NCT01897155|OTHER|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
48120437|NCT00003868|DRUG|cyclophosphamide|
48120438|NCT00003868|DRUG|methotrexate|
48120439|NCT00003868|PROCEDURE|allogeneic bone marrow transplantation|
48489567|NCT06219993|PROCEDURE|robot-assisted modified Kasai portoenterostomy|"1. A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~2. dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot."
48489568|NCT06219993|PROCEDURE|traditional open Kasai portoenterostomy|Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
48489569|NCT04627480|DEVICE|Fisher Wallace Neurostimulation Device|a Cranial Electrotherapy Stimulator Device (CES).
48489570|NCT05404074|DRUG|Cobitolimod 500mg|Rectal administration
48120440|NCT00003868|PROCEDURE|peripheral blood stem cell transplantation|
48120441|NCT00003868|RADIATION|iodine I 131 monoclonal antibody BC8|
48120442|NCT00003868|RADIATION|radiation therapy|
48120443|NCT02886286|DRUG|Bupivacaine|Patient-activated intrathecal bolus for incident pain
48120444|NCT02886286|DRUG|Opioid|Patient-activated intrathecal bolus for incident pain
48120445|NCT04143204|OTHER|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
48120446|NCT02382328|DRUG|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
48120447|NCT02382328|DRUG|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
48120448|NCT03983681|BEHAVIORAL|Strategy-Based Training to Enhance Memory (STEM)|Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).
48120449|NCT03983681|BEHAVIORAL|Placebo control exercises|Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
48120450|NCT03737591|DIAGNOSTIC_TEST|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
48120451|NCT03667911|OTHER|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
48120452|NCT02415140|OTHER|Rate of depression|
48120453|NCT01875848|DRUG|buprenorphine/naloxone|partial opioid agonist
48120454|NCT01875848|DRUG|opioid dose escalation|up to 25% increase in patient's current opioid dose
48120455|NCT01318655|DRUG|NKTR-118|Tablet, Oral, Once daily
48120456|NCT01318655|DRUG|Placebo|Tablet, Oral, Once daily
48340126|NCT00801346|PROCEDURE|quality-of-life assessment|
48340127|NCT01033604|PROCEDURE|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
48120457|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 1Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
48325786|NCT04198103|DEVICE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
48325787|NCT04032626|DRUG|Lenalidomide 10 mg|Lenalid
48325788|NCT04032626|DRUG|Placebo|Placebo
48325789|NCT05765487|DRUG|Sildenafil|Sildenafil Cream, 3.6%
48325790|NCT05765487|DRUG|Vehicle|No Active or experimental ingredients
48325791|NCT05765487|DRUG|Placebo|Cream with only L-arginine
48325792|NCT03007121|DRUG|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
48325793|NCT03007121|DRUG|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
48325794|NCT03007121|DRUG|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
48325795|NCT00004207|DRUG|liposomal daunorubicin citrate|
48325796|NCT01861054|DRUG|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
48325797|NCT02357953|OTHER|Measurement of cardiac index|
48325798|NCT05605483|OTHER|Salad bar|Schools where the school district has installed salad bars
48489571|NCT01613950|DRUG|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
48489572|NCT01613950|DRUG|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
48489573|NCT03869203|OTHER|Enhanced recovery after surgery (ERAS)|The patients in the ERAS group were given a pre-treatment drug \[300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)\] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
48489574|NCT03866720|OTHER|Carbohydrate rich breakfast|A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
48489575|NCT03866720|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
47971790|NCT04964310|GENETIC|genetic polymorphism|Observe the genetic polymorphism frequency difference between case and control groups
47971791|NCT00080808|DRUG|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
48325799|NCT05605483|OTHER|Waitlisted control|Schools where the school district has not yet installed salad bars
47971792|NCT00080808|DRUG|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
47971793|NCT00080808|DRUG|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
47971794|NCT00080808|DRUG|Sildenafil citrate|Oral sildenafil as needed
47971795|NCT00080808|PROCEDURE|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
48325800|NCT05605483|OTHER|Salad bar post-COVID|Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
48325801|NCT06194175|PROCEDURE|Bariatric surgery|"Participants whose application for bariatric surgery was accepted, regardless of the type of surgical intervention (e.g., sleeve gastrectomy, Roux-en-Y Gastric Bypass).~This longitudinal study includes five measurement times: before surgery and then, 6 months, one year, one and a half years and two years after surgery. At each measurement time, participants are asked to respond to a set of online questionnaires. Responses are anonymous."
48325802|NCT00729326|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
48325803|NCT00729326|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
48325804|NCT00729326|DRUG|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
48325805|NCT00729326|DRUG|placebo|oral administration (100mg), once a day in the morning
48325806|NCT02709083|DRUG|Dasatinib|Given orally
48325807|NCT02709083|DRUG|Imatinib Mesylate|Given orally
48325808|NCT02709083|DRUG|Nilotinib|Given orally
48325809|NCT01178736|PROCEDURE|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
48325810|NCT01178736|PROCEDURE|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
48325811|NCT01178736|PROCEDURE|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
48325812|NCT01178736|PROCEDURE|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
48325813|NCT03198780|OTHER|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
48325814|NCT06372886|PROCEDURE|portal/superior vein resection|portal/superior vein resection
48325815|NCT04584853|DRUG|Abemaciclib|Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
48489576|NCT05544565|DRUG|IV Antibacterial Agents|Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
48489577|NCT05544565|DRUG|Orally antibacterial agents|Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
47971796|NCT06358365|DEVICE|The AquaPass System|The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
47971797|NCT02640014|DIETARY_SUPPLEMENT|Milk|Milk Oral immunotherapy
48489578|NCT05544565|PROCEDURE|Fecal/Rectal Swab|Collected by the nurse or the physician (D0,D3,D14) (and parents for D45), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
48489579|NCT05544565|PROCEDURE|PCT assay|Dosage of procalcitonin (if not performed in standard care) at D0
48489580|NCT05544565|PROCEDURE|Renal scintigraphy|A DMSA scintigraphy (99mTc-DMSA) will be performed at 6 months (± 15 days) for evaluation of the kidney growth and renal scars
48649500|NCT02232932|PROCEDURE|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
48649501|NCT02232932|PROCEDURE|RESECTION|Intent-to-treat R0 liver resection
48649502|NCT06145763|PROCEDURE|Biospecimen Collection|Ancillary studies
48649503|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use iCanQuit smartphone app
48649504|NCT06145763|BEHAVIORAL|Smoking Cessation Intervention|Use NCI QuitGuide smartphone app
48649505|NCT06145763|OTHER|Survey Administration|Ancillary studies
47971798|NCT03490097|DRUG|Simvastatin 10mg|tablets
48649506|NCT06396325|OTHER|Tales from the Magic Keep™|Exergame targeting upper limb and trunk movement designed for use on the Microsoft Azure Kinect Dose: At least 3 times a week for 20 minutes over 8 weeks (8 hours total) Continue with regularly accessed physical activities and rehabilitation services
47971799|NCT03490097|DRUG|sofosbuvir plus daclatasvir|sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
47971800|NCT01057342|DRUG|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
47971801|NCT01057342|DRUG|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
47971802|NCT01057342|DRUG|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
47971803|NCT05954806|DRUG|Antivenom Snakes|No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
47971804|NCT00153075|DEVICE|Berodual Respimat|
48325816|NCT04584853|DRUG|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)|Standard of care endocrine therapy for a minimum of 5 years from randomisation
48325817|NCT03179436|BIOLOGICAL|Quavonlimab|Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
48325818|NCT03179436|BIOLOGICAL|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
48489581|NCT01457261|DRUG|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
48489582|NCT00773695|DRUG|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
48649507|NCT06396325|OTHER|Usual Care|•Continue with regularly accessed physical activities and rehabilitation services
47971805|NCT00153075|DEVICE|Berodual HFA-MDI|
47971806|NCT06155604|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
47971807|NCT06155604|DRUG|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
48325819|NCT03179436|DRUG|Pembrolizumab/Quavonlimab|Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
48325820|NCT02698618|PROCEDURE|Diagnostic|"Pre-PCI and treatment:~1. At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~2. At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
48340128|NCT01033604|PROCEDURE|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
47971808|NCT01009632|BEHAVIORAL|Resonant voice|4-hr of resonant voice exercise
48120458|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 10Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
48120459|NCT05273788|DEVICE|Sham Stimulations|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
48120460|NCT01758328|DRUG|busulfan|
48120461|NCT01758328|DRUG|melphalan|
48120462|NCT01758328|DRUG|fludarabine|
48120463|NCT01758328|BIOLOGICAL|anti-thymocyte globulin (ATG)|
48120464|NCT01758328|PROCEDURE|a T cell depleted stem cell transplant|
48120465|NCT02273986|DRUG|Digoxin|
48120466|NCT02273986|DRUG|K-877|
48120467|NCT05520294|OTHER|High-performance liquid chromatography-tandem mass spectrometry assays|Paraffin blocks will be requested for slide creation, and at least 12 mL of whole blood will be collected in 2 green top tubes, centrifuged, and plasma transferred for storage at -80 C until further processing
48120468|NCT03648762|BEHAVIORAL|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
48120469|NCT03648762|BEHAVIORAL|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
48120470|NCT03648762|BEHAVIORAL|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
48120471|NCT03638440|DRUG|Naloxegol|Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone
48325821|NCT02698618|DRUG|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence \[Body Mass Index (BMI) ≥30 kg/m2\] with the implementation of a dedicated randomization list.
48325822|NCT02698618|PROCEDURE|PCI|"1. Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~2. PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~3. Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
48325823|NCT00822484|BIOLOGICAL|ILV-095|
47971809|NCT01009632|BEHAVIORAL|Voice rest|4-hr of complete refrain from any voice use
47971810|NCT01009632|BEHAVIORAL|Spontaneous speech|
47971811|NCT00279591|DEVICE|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
48120472|NCT06093243|OTHER|data collection|data collection
48120473|NCT04530747|DRUG|Metformin + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing metformin extended release (XR). Metformin XR dosing will be 500 mg (1 x 500 mg) every evening (qPM) during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
48120474|NCT04530747|DRUG|Placebo oral capsule + PAP|"Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea."
48120475|NCT04454151|DRUG|Azithromycin Tablets|given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
48120476|NCT05848531|DRUG|Clonidine|Comparing Clonidine with Morphine PCIA for the treatment of Vaso-Occlusive crisis in Sickle Cell disease patient
48325824|NCT00822484|OTHER|Placebo|
48325825|NCT05651893|BEHAVIORAL|re-examination|During colonoscopy, the left colon was examined a second time in the forward view.
48325826|NCT05651893|BEHAVIORAL|extended withdraw time|During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
48325827|NCT01763866|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
47971812|NCT00279591|DEVICE|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
47971813|NCT04314336|DRUG|Public procurement|Cost minimisation study through public procurement
48120477|NCT01740531|BIOLOGICAL|S-303 Treated Red Blood Cells (RBCs)|
48120478|NCT01740531|BIOLOGICAL|Conventional, untreated Red Blood Cells|
48325828|NCT01763866|DRUG|Ezetimibe|Administered orally once a day
48325829|NCT01763866|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
48325830|NCT01763866|DRUG|Placebo to Ezetimibe|Administered orally once a day
48325831|NCT01763866|DRUG|Atorvastatin|Administered orally once a day
48325832|NCT01763866|DRUG|Rosuvastatin|Administered orally once a day
48325833|NCT01763866|DRUG|Simvastatin|Administered orally once a day
48325834|NCT02573376|BEHAVIORAL|Directly Observed Therapy|
48325835|NCT02573376|BEHAVIORAL|Wirelessly Observed Therapy|
48325836|NCT06033846|DRUG|Minocycline|treatment with minocycline combined with first/second-line drugs for autoimmune encephalitis
48325837|NCT03514069|DRUG|ruxolitinib|Starting dose ruxolitinib 10 mg twice daily
48325838|NCT03514069|RADIATION|radiation|60gy for 6 weeks
48325839|NCT03514069|DRUG|temozolomide|75mg/m2
48325840|NCT00890071|OTHER|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
48325841|NCT03896113|DRUG|Celecoxib 200mg capsule|Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
48325842|NCT01252641|BIOLOGICAL|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
48325843|NCT06168370|RADIATION|CT guided strategy|"1. With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~2. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~3. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT."
48325844|NCT02209649|DRUG|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
48489583|NCT00773695|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
48325845|NCT02209649|DRUG|Lacidipine|
48325846|NCT02209649|DRUG|Telmisartan|
48325847|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
48489584|NCT00773695|DRUG|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
48489585|NCT00773695|DRUG|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
48489586|NCT00773695|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
48489587|NCT00773695|DRUG|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
48489588|NCT00773695|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
48325848|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
48325849|NCT05009030|DRUG|COVID-19 vaccine|Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
48325850|NCT03780036|DEVICE|Megaprosthetic Implants the Next Generation (MING)|Use of either porous of porous+hydroxyapathite collars.
48325851|NCT03441568|DEVICE|Modified Diprobase formulation (BAY987534)|The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
48325852|NCT00992732|DRUG|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
48325853|NCT00992732|DRUG|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
48325854|NCT01926847|DRUG|Riociguat (Adempas, BAY63-2521)|
48325855|NCT01926847|DRUG|Placebo|
48325856|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
48325857|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol Placebo solution|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
48325858|NCT02570282|DRUG|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
48325859|NCT02570282|DRUG|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
48325860|NCT02273557|DRUG|Asasantin ER (new formulation I - low)|
48325861|NCT02273557|DRUG|Asasantin ER (new formulation III - medium)|
48120479|NCT05393804|BIOLOGICAL|Ide-cel (bb2121)|Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
48325862|NCT02273557|DRUG|Asasantin ER (new formulation II - high)|
48325863|NCT02273557|DRUG|Asasantin ER (present commercial formulation)|
48325864|NCT06095752|OTHER|blood viscosity , albumin / fibrinogen ratio and red cell distribution|In multiple myeloma patients ,we get blood viscosity , albumin / fibrinogen ratio and red cell distribution directly after confirmed diagnosis to determine the prognosis of the disease in association with these tests results
48325865|NCT01755312|DEVICE|Medication reminder|Medication reminder
48120480|NCT02271854|DRUG|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
48120481|NCT02271854|DRUG|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
48120482|NCT06166225|BEHAVIORAL|Internet-based weight loss program|12-month, automated and behaviorally-based, Internet-delivered weight loss and weight loss maintenance program
48325866|NCT05108610|OTHER|Shi-style manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
48325867|NCT05108610|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
48325868|NCT01671956|BIOLOGICAL|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
48325869|NCT01671956|BIOLOGICAL|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
48325870|NCT06264349|OTHER|Lifestyle Educational Intervention|The Lifestyle Educational Intervention (LEI) consists of promoting a healthy lifestyle during pregnancy and breastfeeding. In particular, the contents concern: i). macro- and micronutrient requirements during pregnancy/breastfeeding; ii). definition of the concept of the food pyramid and healthy plate also considering aspects of food sustainability; iii). definition of the principles of food safety during pregnancy; iv). importance of maternal and infant sleep quality; v). importance of maternal physical activity during pregnancy and lactation; vi). psychological aspects regarding the mother-child dyad.
48325871|NCT00694629|DRUG|rifampin|tablet, 10 mg/kg, daily, 8 weeks
48120483|NCT06166225|BEHAVIORAL|Yoga|9-month Iyengar yoga program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12, and self-guided yoga practice recommendations.
48325872|NCT00694629|DRUG|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
48325873|NCT00694629|DRUG|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
48498073|NCT02938754|BEHAVIORAL|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
48120484|NCT06166225|BEHAVIORAL|Health and Wellness|9-month health and wellness program consisting of live (Zoom) yoga classes delivered 1-2 times per week during months 4-12.
48120485|NCT02539225|DRUG|Ramucirumab|Administered IV
48120486|NCT02539225|DRUG|Placebo|Administered IV
48120487|NCT02539225|DRUG|S-1|Administered PO
48120488|NCT02539225|DRUG|Oxaliplatin|Administered IV
48120489|NCT02539225|DRUG|Paclitaxel|Administered IV
48120490|NCT02191319|DRUG|Viramune®|
48120491|NCT03436277|DRUG|L-Carnitine|L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
48325874|NCT00694629|DRUG|rifapentine|20 mg/kg, daily, 8 weeks
48325875|NCT05997186|PROCEDURE|Surgical reconstruction|Surgical reconstruction with a free reinnervated profunda artery perforator flap
48325876|NCT03700736|BEHAVIORAL|Healthy Moms|The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
48325877|NCT03383978|BIOLOGICAL|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
48325878|NCT03383978|DRUG|Ezabenlimab|Intravenous infusion of Ezabenlimab 240mg q 3 weeks
48325879|NCT01921634|OTHER|Modified Pathologic Analysis|
48325880|NCT05258708|BIOLOGICAL|mRNA-1273 COVID-19 vaccine|two doses of mRNA-1273 vaccine at 28-day intervals
48325881|NCT04176445|DEVICE|Orthostatic board posture|Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
48325882|NCT04176445|OTHER|Bedside sitting posture|Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
48325883|NCT02484612|BEHAVIORAL|acute exercise|
48120492|NCT03436277|DIETARY_SUPPLEMENT|Sucralose|Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
48120493|NCT04773327|OTHER|Mecapegfilgrastim Injection|24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle
48325884|NCT03126331|DRUG|Nivolumab|"Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more."
48325885|NCT03126331|DRUG|Ipilimumab|Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
48325886|NCT02411526|DRUG|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
48120494|NCT01896349|OTHER|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
48120495|NCT01896349|DRUG|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
48120496|NCT01896349|DRUG|sertraline|
48120497|NCT01896349|DRUG|paroxetine|
48120498|NCT01896349|DRUG|Citalopram|
48120499|NCT01896349|DRUG|escitalopram|
48120500|NCT01896349|DRUG|fluvoxamine|
48120501|NCT01896349|DRUG|Venlafaxine|
48325887|NCT02411526|DRUG|Risperdal Consta|Risperdal Consta administered as a IM injection
48325888|NCT02411526|DRUG|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
48325889|NCT06180759|DRUG|Intravenous infusion of DMT|A dose rate of 1.2 mg/min will be administered
48325890|NCT06180759|DRUG|Intravenous infusion of ketamine|A dose rate of 1.0 mg/min will be administered
48120502|NCT01896349|DRUG|Duloxetine|
48120503|NCT01896349|DRUG|Bupropion|
48120504|NCT01896349|DRUG|Lithium|
48325891|NCT06180759|DRUG|Intravenous infusion of placebo|A Placebo (saline infusion) will be administered.
48325892|NCT05729425|DEVICE|Ultrasound Microvessel Imaging|Undergo microvessel ultrasound imaging
48325893|NCT01235169|DEVICE|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
48325894|NCT06419647|BEHAVIORAL|Intervention|Daily mood tracking tasks
48489589|NCT05387174|BEHAVIORAL|: Nursing intervention in two risk factors of the Metabolic Syndrome, abdominal obesity and arterial hypertension and quality of life in the climacteric period.|Nursing intervention with technological support (Metamorphosis) in two risk factors of Metabolic Syndrome, abdominal obesity and hypertension and quality of life in the climacteric period, developed in 3 months, in the experimental group that includes individual nursing counseling, group education virtually and physical activity sessions for 12 weeks virtually.
48489590|NCT00395174|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
48120505|NCT01896349|DRUG|Risperidone|
48120506|NCT01896349|DRUG|tranylcypromine|
48120507|NCT01896349|DRUG|Imipramine|
48120508|NCT01896349|DRUG|amitriptyline|
48120509|NCT01896349|DRUG|Clomipramine|
48120510|NCT01896349|DRUG|nortriptyline|
48120511|NCT01896349|DRUG|trazodone|
48120512|NCT01896349|DRUG|Mirtazapine|
48120513|NCT01896349|DRUG|sulpiride|
48120514|NCT05100589|DIETARY_SUPPLEMENT|PeakATP|Powder - 400mg Peak ATP, maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
48120515|NCT05100589|DIETARY_SUPPLEMENT|Placebo|Powder - maltodextrin, silica-colloidal anhydrous, citric acid anhydrous, sucralose, guar gum
48120516|NCT03743506|DIAGNOSTIC_TEST|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
48489591|NCT01660191|DRUG|Pitavastin 4mg|
48489592|NCT01660191|DRUG|Atorvastatin 20mg|
48489593|NCT01660191|DRUG|Rosuvastatin 5mg|
48489594|NCT01802749|DRUG|Bevacizumab|
48120517|NCT03743506|DIAGNOSTIC_TEST|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
48120518|NCT06155877|BEHAVIORAL|Activité Vaccins et Vaccination - LAMAP|Two activities created by the La Main a la Pate foundation
48120519|NCT06155877|BEHAVIORAL|Kidivax Chatbot|A chatbot created by our team to answer the most common questions about vaccination, based on a literature review and on focus groups.
48120520|NCT05073562|DIETARY_SUPPLEMENT|Iron and folic acid (IFA) supplementation|Weekly IFA supplementation for duration of the study.
48120521|NCT05073562|BEHAVIORAL|Targeted nutrition education|Structured nutrition education package delivered at household level by trained Community Health Assistants (CHAs)
48120522|NCT05073562|DRUG|Mebendazole Pill|One-time deworming treatment with mebendazole.
48120523|NCT05073562|OTHER|Standard nutrition services|Basic nutrition services currently provided at the health facility and at community level in Liberia
48120524|NCT06152939|OTHER|Primary percutaneous coronary intervention or thrombolytic therapy|Primary percutaneous coronary intervention or thrombolytic therapy
48120525|NCT02881203|DEVICE|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
48120526|NCT02881203|DEVICE|RPM|Varian Real-time Position Management (RPM) system
48120527|NCT04275908|DEVICE|MHSAFE app|App to detect presence of mental state
48325895|NCT02293356|DRUG|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
48325896|NCT04779944|OTHER|other|questionnaire
48325897|NCT03798184|PROCEDURE|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
48325898|NCT02717065|OTHER|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
48325899|NCT02717065|OTHER|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
48489595|NCT01802749|DRUG|Paclitaxel|
48489596|NCT01802749|DRUG|Carboplatin|
48325900|NCT04786132|OTHER|Cognitive-motor training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
48325901|NCT04786132|OTHER|Motor training|A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.
48325902|NCT04840017|OTHER|rehabilitation exercise|Rehabilitation exercise of intrinsic foot muscles
48325903|NCT04416126|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
48325904|NCT04416126|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
48325905|NCT00943982|DRUG|Interferon Gamma 1-b|
48325906|NCT04624035|PROCEDURE|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
48489597|NCT01802749|DRUG|pegylated liposomal doxorubicin|
47971814|NCT04314336|DRUG|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
47971815|NCT03370601|DRUG|Infliximab|Infliximab 10mg/kg every 8 weeks
47971816|NCT03370601|DRUG|Mercaptopurine|6-mercaptopurine 1 à 1,5 mg/kg
47971817|NCT03370601|DRUG|Azathioprine|Azathioprine 2 à 2.5mg/kg/j
47971818|NCT03370601|DRUG|Infliximab|Infliximab 5mg/kg every 8 weeks
47971819|NCT05911516|DIETARY_SUPPLEMENT|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
47971820|NCT05911516|DIETARY_SUPPLEMENT|Placebo|Placebo
48325907|NCT04624035|PROCEDURE|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
48340129|NCT05912036|BEHAVIORAL|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
48340130|NCT03352128|DIETARY_SUPPLEMENT|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
48489598|NCT01802749|DRUG|Gemcitabine|
47971821|NCT02837783|DRUG|Linaclotide|Oral, once daily
47971822|NCT02837783|DRUG|Placebo|Oral, one daily
47971823|NCT06279962|OTHER|Survey questionnaire|The intervention is being assigned to one of the 8 different versions of the survey vignette.
47971824|NCT04134468|DRUG|Pegvorhyaluronidase alfa|IV infusion
47971825|NCT04134468|DRUG|Abraxane|IV infusion
47971826|NCT04134468|DRUG|Gemcitabine|IV infusion
47971827|NCT01664533|DRUG|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
47971828|NCT04669600|DRUG|SAR445088 (BIVV020)|Pharmaceutical form:solution for injection
48325908|NCT04003753|OTHER|VR App|Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
48325909|NCT05249985|DEVICE|NMES|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.
48325910|NCT05249985|DIETARY_SUPPLEMENT|Protein|Participants will consume a daily protein supplement
48325911|NCT01844622|OTHER|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
48325912|NCT00943488|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
48325913|NCT04695548|OTHER|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
48325914|NCT04695548|OTHER|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
48325915|NCT04695548|OTHER|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
48325916|NCT04695548|OTHER|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
48325917|NCT04540081|OTHER|Epic Healthy Planet Population Health Module|Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
48325918|NCT03255993|DRUG|SPH3127 50mg|SPH3127 50mg
48325919|NCT03255993|DRUG|SPH3127 100mg|SPH3127 100mg
48325920|NCT03255993|DRUG|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
48325921|NCT03255993|DRUG|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
48325922|NCT03308162|BEHAVIORAL|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
48325923|NCT02534194|OTHER|Image acquisition|Images of baby's face (including ear) and feet
48325924|NCT00218920|BEHAVIORAL|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
48325925|NCT00218920|BEHAVIORAL|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
48325926|NCT00218920|BEHAVIORAL|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax \[maximal HR (heart rate)\], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
48325927|NCT02795546|DRUG|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
48489599|NCT06224166|DIAGNOSTIC_TEST|Collection and use of tissue samples, blood and saliva|"For tissue collection, tumor and surrounding tissues will be used healthy specimens taken during surgical removal, according to clinical practice. Blood and saliva sampling will be carried out at different times:~i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the follow-up (FU)"
48120528|NCT05521061|DIETARY_SUPPLEMENT|2-fucosyllactose|Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
48325928|NCT02795546|BIOLOGICAL|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
48325929|NCT02679443|DIETARY_SUPPLEMENT|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
48325930|NCT03428685|DRUG|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
48325931|NCT03428685|DRUG|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
48325932|NCT03741725|OTHER|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
48325933|NCT03741725|OTHER|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
48325934|NCT04508725|DIAGNOSTIC_TEST|Doppler Ultrasound|Power doppler measurements will be made
48325935|NCT04508725|DEVICE|SIEMENS S3000 and Verasonics Vantage 256|Vantage 256 used for power doppler ultrasound, manufactured by Verasonics
48325936|NCT04508725|DRUG|Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor plus immune checkpoint inhibitor|Participants will receive less than 4 weeks of TKI treatment during the first 12 weeks. Plus immune checkpoint inhibitor (arm 1) or non-immune checkpoint inhibitor (arm 2)
48325937|NCT04545788|DRUG|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
48325938|NCT01705548|RADIATION|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
48325939|NCT03698188|PROCEDURE|Injectable platelet-rich fibrin|A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
48325940|NCT03698188|PROCEDURE|Platelet-rich plasma|A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
48325941|NCT05551338|OTHER|Serious games|The training protocol will entail using a tablet-based program that includes 6 serious games. Patients will be asked to use the program twice a week for 3 months. The serious games that will be used in this study were developed to challenge short-term memory and selective attention in six different games. Each of the six games comprise 20 different stages of varying difficulty, where stage 1 is the easiest and stage 20 is the most difficult.
48325942|NCT04782986|DIAGNOSTIC_TEST|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
48325943|NCT03532581|OTHER|Indocyanine Green Solution|Given Subcutaneous injection
47971829|NCT05930977|PROCEDURE|total thyroidectomy followed by thyroid auto transplantation|"All studied cases received general endotracheal anaesthesia, and all underwent total thyroidectomy.~Frozen section will be done intraoperative to exclude malignancy and obtain piece of healthy tissue part .~Most healthy-looking part of gland was selected after complete excision. Thyroid tissue to be transplanted weighed between two and five grammes. This section was finely split into ten-fifteen fragments with scalpel. Small pocket was created in sternomastoid muscle, into which these minor fragments were implanted, and this pocket was closed with absorbable sutures to prevent displacement of implanted fragments and was marked with metallic stables, as well as good hemostasis of thyroid bed and skin was closed with subcuticular sutures using absorbable three-zero Vicryl sutures."
48325944|NCT03532581|PROCEDURE|Lymphangiography|Undergo lymphangiography
48325945|NCT03701646|DEVICE|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
48325946|NCT00756886|DRUG|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
48325947|NCT00756886|DRUG|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
47971830|NCT02010775|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
48325948|NCT01811355|DRUG|Mexiletine|Sodium channel blocker
48325949|NCT01811355|DRUG|Placebo|Placebo
48325950|NCT03341923|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
48325951|NCT03341923|DEVICE|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
48325952|NCT01113554|OTHER|questionnaire administration|
48325953|NCT01113554|BEHAVIORAL|exercise intervention|
48325954|NCT01113554|PROCEDURE|quality-of-life assessment|
48325955|NCT01113554|OTHER|survey administration|
48325956|NCT01113554|PROCEDURE|management of therapy complications|
48325957|NCT01113554|PROCEDURE|psychosocial assessment and care|
48325958|NCT00987623|DEVICE|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
48325959|NCT00987623|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
48325960|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
48325961|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
48325962|NCT03944070|DRUG|Ranibizumab|Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
48325963|NCT02952703|BEHAVIORAL|brief pre-delivery smoking cessation counseling|
48325964|NCT02952703|BEHAVIORAL|additional pre-delivery smoking cessation counseling|
48325965|NCT02952703|BEHAVIORAL|post- delivery smoking cessation counseling|
48325966|NCT02952703|BEHAVIORAL|incentives|
48325967|NCT05812469|BEHAVIORAL|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
48325968|NCT05812469|BEHAVIORAL|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
48325969|NCT04840706|DEVICE|HFNC Airvo|HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
48325970|NCT04840706|OTHER|Standard care|No HFNC treatment
48325971|NCT01054976|DRUG|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
48325972|NCT03864809|BEHAVIORAL|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
48325973|NCT00002392|DRUG|Thalidomide|
48325974|NCT01922778|PROCEDURE|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
48325975|NCT01527019|DRUG|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
48325976|NCT01527019|DRUG|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
48325977|NCT01527019|DRUG|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
48325978|NCT04744636|DRUG|Other|"Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
48325979|NCT04744636|DRUG|Other|"Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0).~The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP):~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
48489600|NCT04566705|OTHER|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
47971831|NCT02010775|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
47971832|NCT00159406|OTHER|Registry and Database|Data Collection
48120529|NCT03878199|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
48325980|NCT03763903|OTHER|3D training|Skills (FLS tasks) training using 3D visualization
48325981|NCT03763903|OTHER|2D training|Skills (FLS tasks) training using 2D visualization
48325982|NCT05751057|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|All NSTEMI patients will undergo to CMR before invasive coronary intervention.
48325983|NCT03143972|DRUG|Dexmedetomidine|Single drug administration
48489601|NCT04340817|DIAGNOSTIC_TEST|Proteomics|Mass-spectometry proteomics
48489602|NCT04340817|DIAGNOSTIC_TEST|Transcriptomics|Next generation sequencing
48489603|NCT04340817|GENETIC|Genomics|Targeted genetics
48489604|NCT02409602|OTHER|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
48489605|NCT03828266|OTHER|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
48120530|NCT03878199|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48120531|NCT03878199|DRUG|Ruxolitinib|Given PO
48120532|NCT00969137|DRUG|saline|intravenous saline
48325984|NCT03143972|DRUG|Remifentanil|Single drug administration
48325985|NCT03312868|RADIATION|SBRT|Stereotactic Body Radiotherapy
48325986|NCT00765440|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|Given orally
48325987|NCT00765440|OTHER|placebo|Given orally
48489606|NCT04722159|DEVICE|Renal denervation|Catheter-based inhibition of renal sympathetic nerve traffic.
48489607|NCT05218382|DEVICE|Virtual reality|immersive virtual reality technology
48489608|NCT05218382|DEVICE|No virtual reality|Virtual reality with blank screen
48120533|NCT00969137|DRUG|Nicotine|Intravenous nicotine
48120534|NCT04966416|DIETARY_SUPPLEMENT|Pyrophosphate|50 mg/kg bwt once daily in gelatine capsules.
48120535|NCT04966416|DIETARY_SUPPLEMENT|Placebo|Glucose in gelatine capsules.
48120536|NCT00003375|DRUG|lomustine|
48120537|NCT00003375|DRUG|procarbazine hydrochloride|
48120538|NCT00003375|DRUG|vincristine sulfate|
48120539|NCT00003375|RADIATION|radiation therapy|
48325988|NCT02092441|OTHER|Alcohol prep pad group|Subjects inhale scent of alcohol pad
48325989|NCT02092441|OTHER|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
48120540|NCT00566124|DRUG|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
48325990|NCT01207817|OTHER|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
48325991|NCT01290445|DRUG|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
48325992|NCT01290445|BEHAVIORAL|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
48325993|NCT01290445|OTHER|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
48325994|NCT02546427|RADIATION|Helical TomoTherapy (HT)|
48325995|NCT02546427|RADIATION|CyberKnife SBRT|
48325996|NCT02546427|RADIATION|Permanent Prostate Implant (PPI)|
48325997|NCT02546427|RADIATION|HDR brachytherapy|
48325998|NCT00012896|BEHAVIORAL|Telephone Care + Educational (AV Materials)|
48325999|NCT03209440|BEHAVIORAL|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
48326000|NCT03209440|BEHAVIORAL|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
48326001|NCT03209440|BEHAVIORAL|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
48326002|NCT06019923|OTHER|No intervention|No intervention
48120541|NCT00566124|DRUG|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
48120542|NCT00566124|DRUG|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
48120543|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with parallel lesioning|"Intervention type: RF nerve lesioning at 80-85 degree Celsius for 90 seconds Intervention name: Straight sharp conventional (SIS's technique)~Intervention description:~Technique as described in the SIS Practice Guidelines for parallel lesioning cannulae placement"
48489609|NCT01700426|DRUG|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
48489610|NCT01700426|OTHER|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
48489611|NCT00181220|DRUG|valproic acid|
48489612|NCT02697773|OTHER|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
48489613|NCT02697773|BIOLOGICAL|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
48489614|NCT02697773|BIOLOGICAL|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
48489615|NCT05115526|OTHER|PEEP setting|PEEP setting according to various methods
48649508|NCT05035173|OTHER|Survivorship Clinic Assessments|"Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit."
48649509|NCT05035173|OTHER|Survivorship Clinic Nurse Resource|"Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes."
47971833|NCT03204903|PROCEDURE|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
48326003|NCT03230747|DEVICE|Edwards SAPIEN M3 System|SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
48326004|NCT03094832|DRUG|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
48326005|NCT02503774|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arms' description.
48326006|NCT02503774|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arms' description.
48326007|NCT02026206|DEVICE|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
48649510|NCT05035173|OTHER|Survivorship Clinic Dietitian Resource|"Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise."
48649511|NCT05703126|DIAGNOSTIC_TEST|History taking|Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.
47971834|NCT03204903|PROCEDURE|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
47971835|NCT00855920|DRUG|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
47971836|NCT00855920|DRUG|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
47971837|NCT00855920|OTHER|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
47971838|NCT00855920|OTHER|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
47971839|NCT04061213|DIAGNOSTIC_TEST|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
47971840|NCT05979701|OTHER|Simulation training|The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
47971841|NCT05502757|OTHER|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
47971842|NCT03229278|DRUG|Enzyme Inhibitor Therapy|Given trigriluzole PO
47971843|NCT03229278|OTHER|Laboratory Biomarker Analysis|Correlative studies
48326008|NCT02026206|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
48326009|NCT01546844|OTHER|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
48326010|NCT00042484|PROCEDURE|Community-level intervention & policy change|
47971844|NCT03229278|BIOLOGICAL|Nivolumab|Given IV
47971845|NCT03229278|BIOLOGICAL|Pembrolizumab|Given IV
48326011|NCT04945824|DRUG|Dexamethasone Ophthalmic|Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
48326012|NCT04945824|DEVICE|Dilator|Intracanalicular Dilator Device
48326013|NCT03691753|DEVICE|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
47971846|NCT04249583|BIOLOGICAL|botulinum toxin|neuromodulator to be injected in the GL region
47971847|NCT04249583|BIOLOGICAL|Placebo|Placebo to be injected in the GL area
47971848|NCT05864872|PROCEDURE|axillary brachial plexus block|conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
47971849|NCT02638545|DRUG|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
48326014|NCT03691753|DEVICE|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
48326015|NCT00681538|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
48120544|NCT05818774|PROCEDURE|Radiofrequency neurotomy (RFN) of Cervical Medial Branch Nerves (CMBNn) with end-on lesioning with multitined trident cannulae|"Intervention type: RF nerve lesioning lesioning at 80-850 Celsius for 90 seconds Intervention name: End-on placement of the multitined trident cannulae~Intervention description:~Patient in lateral position, targeting joint position between the inferior C2 and superior C3 facets, the middle of the facet pillars for the third to fifth cervical levels, and the superior part of the sixth and seventh cervical facets."
48120545|NCT05082935|BEHAVIORAL|Phase II Promotores de Salud|Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.
48120546|NCT05082935|BEHAVIORAL|Phase I Promotores de Salud Outreach|Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
48120547|NCT00181740|DRUG|atomoxetine (Strattera)|
48120548|NCT02455297|DRUG|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
48120549|NCT06521801|OTHER|Observation|Observation
48489616|NCT04248348|DRUG|Low Molecular Weight Heparin|Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
48489617|NCT05174117|COMBINATION_PRODUCT|single irradiation|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
48489618|NCT05174117|COMBINATION_PRODUCT|Double irradiation|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
48120550|NCT05382936|DRUG|SL-901|Patients will take study medication daily, with dosage based on their assigned cohort and regimen.
48120551|NCT00111085|DRUG|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
48120552|NCT00111085|DRUG|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
48120553|NCT00111085|DRUG|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
48120554|NCT00111085|DRUG|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
48649512|NCT05703126|DIAGNOSTIC_TEST|Anthropometry|Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.
47971850|NCT05320120|DRUG|56mg esketamine (2x Spravato® 28 mg nasal spray)|56mg esketamine (2x Spravato® 28 mg nasal spray)
47971851|NCT05320120|DRUG|0.9% saline solution nasal spray|0.9% saline solution nasal spray
47971852|NCT02397278|DRUG|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
47971853|NCT05776589|DEVICE|The mechanical ventilation mode|Changing the mechanical ventilation mode
47971854|NCT00970567|BEHAVIORAL|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
47971855|NCT05621785|DEVICE|Lung Ultrasonografi|All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG
47971856|NCT02817256|DIETARY_SUPPLEMENT|Vitamins and Minerals|Multivitamins and Minerals supplementation
47971857|NCT02742480|DRUG|Dabigatran|
48120555|NCT01236001|DRUG|Lacosamide|
48120556|NCT03757572|OTHER|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
48120557|NCT03757572|OTHER|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
48489619|NCT03564041|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
48489620|NCT03564041|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
48489621|NCT01440439|DRUG|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
48326016|NCT00681538|DRUG|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
48326017|NCT01216449|DRUG|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
48326018|NCT01216449|DRUG|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
48326019|NCT01951248|DEVICE|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
48326020|NCT03927638|BEHAVIORAL|sit/stand|Subjects will be asked to both sit and stand during a single trial.
48326021|NCT03516734|DIETARY_SUPPLEMENT|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
48326022|NCT03516734|OTHER|Non Iron-fortified lentils|Non-fortified lentils will be provided
48326023|NCT03516734|OTHER|Usual Intake|No lentils will be provided.
48489622|NCT01440439|DRUG|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
48489623|NCT03413137|PROCEDURE|Transperineal mpMRI-US Fusion prostate biopsy|mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
48489624|NCT03413137|PROCEDURE|Transrectal mpMRI-US Fusion prostate biopsy|using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
48489625|NCT05791682|DRUG|Sealant, Fissure|FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
48489626|NCT00003638|BIOLOGICAL|Detox-B adjuvant|
48649513|NCT05703126|DIAGNOSTIC_TEST|Complete blood count|Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
48649514|NCT05703126|DIAGNOSTIC_TEST|Biochemical blood test|Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.
48649515|NCT05703126|DIAGNOSTIC_TEST|Coagulogram|Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).
48649516|NCT05703126|DIAGNOSTIC_TEST|Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine|Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.
48489627|NCT00003638|BIOLOGICAL|THERATOPE STn-KLH vaccine|
48649517|NCT05703126|DIAGNOSTIC_TEST|Stress echocardiography with the definition of global longitudinal deformation of the myocardium|Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.
48649518|NCT05703126|DIAGNOSTIC_TEST|Triplex scanning of neck vessels|Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.
48649519|NCT05703126|DIAGNOSTIC_TEST|Electrocardiography|Before and after each course of chemotherapy: Electrocardiography.
48649520|NCT05703126|DIAGNOSTIC_TEST|Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes|Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.
47971858|NCT02742480|DRUG|Acenocoumarol|
48120558|NCT04738903|PROCEDURE|Femtosecond laser assisted LASIK eye surgery|FS-LASIK eye surgery includes corneal flap creation with femtosecond laser using the Femtosecond laser WaveLight FS200 followed by excimer laser vision correction of the patient's refractive error using excimer laser WaveLight EX500.
48120559|NCT05971680|DRUG|VITAMIN B1 500mg|VITAMIN B1 (High Potency) 500mg tab every day for 3 months
48120560|NCT05971680|DEVICE|intra-uterine contraceptive device|intra-uterine contraceptive device
48120561|NCT04978051|DRUG|Firazyr|Icatibant 10 MG/ML Prefilled Syringe
48326024|NCT03726619|BEHAVIORAL|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
48326025|NCT03726619|BEHAVIORAL|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
48489628|NCT00003638|BIOLOGICAL|keyhole limpet hemocyanin|
48340131|NCT03352128|DIETARY_SUPPLEMENT|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
48489629|NCT00003638|DRUG|cyclophosphamide|
48489630|NCT03731221|DRUG|Bupi HCI and lipo bupi|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
48649521|NCT05703126|DIAGNOSTIC_TEST|Cytogenetic examination of the bone marrow to determine genetic abnormalities.|Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
48649522|NCT05703126|DIAGNOSTIC_TEST|Cytological examination of bone marrow cells with cytochemical examination|Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.
48649523|NCT05703126|DIAGNOSTIC_TEST|Immunophenotypic examination of the bone marrow by flow cytometry|Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.
48649524|NCT05703126|DIAGNOSTIC_TEST|Determination of the presence of a FLT3 mutation using the PCR Method|Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.
48326026|NCT05978856|OTHER|Accuracy of computer software in predicting soft tissue profile changes|"Separate analyses will be performed on the initial and final cephalograms.~* All of the cephalometric analyses will be done via computer software,the linear and angular measurements will be done via the software.~* Through the use of software, the initial cephalogram and the initial photograph will be linked.~* Then, the final values of some angles will be tracted from the post-treatment cephalogram.~* These values will be inserted in the treatment simulationsection of the software.~* A post-treatment projected image of the patient will be simulated by the software.~* Then the actual post-treatment photograph will be placed on the simulated image in transparent form.~* From the pupil , real horizontal and vertical reference lines will be drawn.~* Then certain measurements will be taken from referance lines to fixed points on the soft tissue to determine the discrepancies between the real and simulated images."
47971859|NCT01111097|DRUG|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
47971860|NCT00605111|DRUG|biphasic insulin aspart|
47971861|NCT06318195|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
48326027|NCT01842841|DRUG|velaglucerase alfa|15-60 U/kg, EOW
48326028|NCT03975374|DRUG|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
47971862|NCT04191720|OTHER|Weighted blanket|Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
47971863|NCT00094744|DEVICE|Eye patch|adhesive eye patch used to cover the sound eye
48326029|NCT03975374|DRUG|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
48326030|NCT05731843|DRUG|Cohort 1 BEM + Ruzasvir|Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
48326031|NCT05731843|DRUG|Cohort 2 Ruzasvir + BEM|Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
48326032|NCT02234934|BIOLOGICAL|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve \> 0.3 integrated copies per cell."
48326033|NCT02483702|OTHER|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
48326034|NCT02483702|OTHER|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
48340132|NCT01496989|BIOLOGICAL|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
48489631|NCT03731221|DRUG|Bupi HCI|The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
48489632|NCT00362921|DRUG|Gliadel wafers in combination with O6-benzylguanine|
48489633|NCT03676517|RADIATION|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
48489634|NCT02192749|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
48649525|NCT05703126|DIAGNOSTIC_TEST|laser Doppler flowmetry|Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.
48649526|NCT02608086|BEHAVIORAL|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
47971864|NCT04294576|DRUG|BJ-001|BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
47971865|NCT04294576|DRUG|Pembrolizumab|"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."
47971866|NCT05832359|RADIATION|Panoramic rad.|In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
48340133|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
48489635|NCT02537847|DRUG|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
48489636|NCT02537847|DRUG|Ertapenem|Control group will be given ertapenem only for 10 days.
48649527|NCT02608086|BEHAVIORAL|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
48649528|NCT06060444|OTHER|Telemedicine Consult|Neurological consultation completed remotely
48649529|NCT06060444|OTHER|In-person Consult|Neurological consultation completed in-person
48326035|NCT03655574|BEHAVIORAL|Motivational + Family Check-up (MET+FCU)|In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
48326036|NCT03655574|OTHER|Psychoeducation|Psychoeducation about substances is provided to teens and parents.
48326037|NCT01933256|DRUG|HIP2B|
48326038|NCT01933256|DRUG|Placebo|
48326039|NCT03782636|DRUG|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
48326040|NCT03782636|OTHER|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
48326041|NCT02943265|OTHER|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
48326042|NCT04588831|DEVICE|Mouthguard|Protective device for orofacial complex for patients playing contact sports
48326043|NCT02381548|DRUG|Adavosertib|Given PO
48326044|NCT02381548|DRUG|Belinostat|Given IV
48326045|NCT02381548|OTHER|Laboratory Biomarker Analysis|Correlative studies
48489637|NCT02826941|OTHER|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
48489638|NCT02826941|OTHER|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
48649530|NCT05696522|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
48649531|NCT02262325|RADIATION|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
48649532|NCT02262325|DRUG|cisplatin|Given IV
48649533|NCT02262325|DRUG|etoposide|Given IV
48326046|NCT02381548|OTHER|Pharmacological Study|Correlative studies
48326047|NCT03411265|OTHER|self-administered, e-health application|"RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
48326048|NCT03047850|DIAGNOSTIC_TEST|Comparison of Delta Down and Delta Pulse Pressure|Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
48326049|NCT04164329|DRUG|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
48326050|NCT01641757|PROCEDURE|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
48326051|NCT04711499|BEHAVIORAL|Fatigue|The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
48326052|NCT01557764|DRUG|lapatinib ditosylate|Given PO
48326053|NCT01557764|BIOLOGICAL|trastuzumab|Given IV
48326054|NCT05233982|DRUG|Olaparib Oral Product|Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
48326055|NCT04185441|DRUG|Tanzânia association|Tanzânia association capsule
48326056|NCT04185441|DRUG|Omnic Ocas|Tamsulosin 0,4 mg
48326057|NCT04185441|OTHER|Omnic Ocas placebo|Tamsulosin placebo
48326058|NCT04185441|OTHER|Tanzânia association placebo|EMS association placebo
48326059|NCT01178346|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
48326060|NCT01178346|BIOLOGICAL|Placebo|Placebo vaccine given 6 times over 6 months
48326061|NCT01818986|DRUG|Sipuleucel-T|
48326062|NCT01818986|RADIATION|Stereotactic Ablative Body Radiation|
48489639|NCT01862315|DRUG|Floxuridine (FUDR)|
48489640|NCT01862315|DRUG|dexamethasone|
48489641|NCT01862315|DRUG|Gemcitabine|
48489642|NCT01862315|DRUG|Oxaliplatin|
48489643|NCT01862315|OTHER|MRI|
48489644|NCT01862315|OTHER|Research blood draws|These are optional
48489645|NCT03828448|DRUG|Ublituximab|- anti-CD 20 monoclonal antibody administered via IV infusion
48489646|NCT03828448|DRUG|Umbralisib|- PI3K Delta Inhibitor oral daily dose
48489647|NCT03273491|BEHAVIORAL|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
48489648|NCT03273491|BEHAVIORAL|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
48489649|NCT03834844|BEHAVIORAL|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
48489650|NCT03834844|OTHER|AF Education|6 weekly education modules on topics related to AF
48649534|NCT02262325|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
48649535|NCT02262325|OTHER|laboratory biomarker analysis|Correlative studies
48649536|NCT00607477|DRUG|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
48649537|NCT00607477|DRUG|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
48649538|NCT05321745|OTHER|Standardized FMT|Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
48649539|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement with a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink with cooling sensation flavour
47971867|NCT05770856|DIAGNOSTIC_TEST|Metagenomic sequencing|Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.
48120562|NCT04978051|OTHER|SoC|The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
48326063|NCT05508399|OTHER|DNA panel and RNA Sequencing|"Interventions include collecting samples, DNA panel test and full transcriptome sequencing.~Before collecting samples, obtaining written informed consent from patient in advance.~1. Blood cell samples;~2. Paraffin sample of residual tumor tissue of biopsy;~3. Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy."
48326064|NCT04249505|DEVICE|"2WIN Photoscreener"|"non-cycloplegia refraction by Adaptica 2WIN"
48326065|NCT04249505|DEVICE|"Plusoptix A12"|"non-cycloplegic refraction by Plusoptix A12 photoscreener"
48326066|NCT04249505|DEVICE|"Retinomax"|"non-cycloplegic refraction by Retinomax K+ auto refractor"
48326067|NCT04637971|OTHER|Coaching|Participants will receive 4 sessions of group coaching intervention within 6 weeks. Each session is in a group of 3-4 women and lasts for approximately 1.5 hours. The sessions will be conducted by experienced social workers.
48326068|NCT04637971|OTHER|Self-help tips plus telephone support|Participants will receive 4 self-help tips sent via SMS and 4 phone call from a social worker in 6-week of time. During the telephone call, the social worker will advise the client to make use of the tips we sent to her.
48326069|NCT00493974|DRUG|Zileuton|Zyflo tablets, 600 mg, 4 times a day
48326070|NCT00493974|DRUG|Placebo|Placebo 4 x daily
48326071|NCT03941691|DEVICE|Fully Absorbable VSD Occlusion System|Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system
48326072|NCT03941691|DEVICE|VSD Occluder|Under echocardiography guided treatment of VSD with commercially available occluder.
48326073|NCT02405806|DIETARY_SUPPLEMENT|low carbohydrate food|low carbohydrate food
48326074|NCT02405806|DIETARY_SUPPLEMENT|standard food|standard food
48489651|NCT03834844|OTHER|Phone Calls|Weekly phone call to discuss patient concerns or questions
48326075|NCT00111579|BIOLOGICAL|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
48326076|NCT00111579|OTHER|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
48326077|NCT00013481|PROCEDURE|Stroke Rehabilitation|
48649540|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement without a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink without cooling sensation flavour
48326078|NCT01810549|DRUG|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
48326079|NCT01810549|DRUG|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
48326080|NCT00216541|DRUG|epoetin alfa|
48326081|NCT05757089|DIETARY_SUPPLEMENT|ALCOFILTRUM|ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
48649541|NCT05023057|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
48649542|NCT04216550|DRUG|Apatinib|Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death
48326082|NCT01338883|DRUG|Cenicriviroc 100 mg|100 mg CVC plus Truvada
48649543|NCT00745667|PROCEDURE|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
48326083|NCT01338883|DRUG|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
48326084|NCT01338883|DRUG|Sustiva + Truvada|Sustiva plus Truvada
48326085|NCT00735670|DRUG|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
48326086|NCT00735670|OTHER|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
48326087|NCT05497895|BIOLOGICAL|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
48326088|NCT05497895|BIOLOGICAL|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
48326089|NCT05497895|PROCEDURE|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
48326090|NCT02325687|PROCEDURE|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
48326091|NCT00830570|OTHER|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
48489652|NCT02546362|DEVICE|Cefaly|
48489653|NCT03983174|PROCEDURE|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
48489654|NCT03983174|PROCEDURE|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
48489655|NCT04254939|DRUG|CS3007 (BLU-285)|"A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days."
48326092|NCT04799951|OTHER|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
48489656|NCT05562193|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.
48489657|NCT05562193|OTHER|Standard post-cancer directed treatment care control|CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
48489658|NCT03977974|DRUG|LY3526318|Administered orally
48649544|NCT00745667|PROCEDURE|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
48649545|NCT00945087|OTHER|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
48649546|NCT01968278|OTHER|Baked milk|
48649547|NCT06127810|DEVICE|CE MRI on 0.064T Scanner|Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI
48489659|NCT03977974|DRUG|Placebo|Administered orally
48489660|NCT01385982|OTHER|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
48326093|NCT00828334|DEVICE|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
48489661|NCT00865618|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
48489662|NCT00865618|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
48489663|NCT05311917|OTHER|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
48489664|NCT05311917|OTHER|base in prism prescription|base in prism prescription according to sheards criterion
48489665|NCT05311917|OTHER|conventional placebo|using near glasses with aimless eye training
48489666|NCT03566264|OTHER|Non-Interventional|Non-Interventional
48489667|NCT02006537|DRUG|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
48326094|NCT04713579|OTHER|No intervention - observational study|There is no intervention in this study as it is purely observational.
48489668|NCT00620659|DRUG|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
48489669|NCT00620659|DRUG|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
48489670|NCT00620659|DRUG|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
48489671|NCT01211782|DRUG|caprylic triglyceride|oral, 20 gm, daily x 6 months
47971868|NCT04851314|DEVICE|ICU certified ventilator|Examine anesthetic consumption rates
48489672|NCT01211782|DRUG|long-chain triglyceride|oral, 14 gm, daily x 6 months
48489673|NCT02406430|PROCEDURE|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
48326095|NCT04180995|DRUG|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
48326096|NCT02521623|DEVICE|SurgiMend® Acellular Dermal Matrix|See arm description.
48489674|NCT01884428|DRUG|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
48489675|NCT01884428|DRUG|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
48489676|NCT01884428|DRUG|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
48489677|NCT01884428|DRUG|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
48489678|NCT01884428|DRUG|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
48489679|NCT00391079|DRUG|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
48489680|NCT00391079|DRUG|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
48489681|NCT03585465|DRUG|Vinblastine|"* Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~* Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C"
48489682|NCT03585465|DRUG|Cyclophosphamide|"* Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~* Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
48489683|NCT03585465|DRUG|Capecitabine|"* Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~* Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~* Metronomic or Metronomic+Nivolumab Arm (second stage): see C"
48489684|NCT03585465|DRUG|Nivolumab|"* Arm A, B or C (First stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle~* Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 \& D15 per cycle, 28 days cycle"
48489685|NCT00711841|DRUG|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
48489686|NCT00711841|DRUG|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
48489687|NCT00711841|DRUG|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
48326097|NCT02521623|DEVICE|Strattice™ Acellular Dermal Matrix|See arm description.
47971869|NCT04851314|DEVICE|Non-ICU certified ventilator|Examine anesthetic consumption rates
47971870|NCT01516437|PROCEDURE|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
47971871|NCT01516437|PROCEDURE|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
47971872|NCT01516437|PROCEDURE|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
47971873|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing=no|
47971874|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing = yes|
47971875|NCT00127660|BEHAVIORAL|Menu: calories=no, value pricing = no|
47971876|NCT01422317|DRUG|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
48340134|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
48340135|NCT01496989|BIOLOGICAL|Ad35-GRIN/ENV|(2x10\^10vp) Delivered intramuscularly by standard needle injection
48489688|NCT04666519|DIAGNOSTIC_TEST|Zonulin Biomarker|During revision hip and knee surgery, discarded fluid/blood will be tested for the presence of zonulin biomarkers
48489689|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
48489690|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
48489691|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
48489692|NCT01748331|OTHER|Fluid restriction|Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day
48489693|NCT05243186|DEVICE|Treadmill workstation|walking on a treadmill workstation next to desk with computer and screen
48489694|NCT05243186|DRUG|Methylphenidate|Using prescription drug
48489695|NCT02413931|OTHER|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
48489696|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
48489697|NCT02451098|DRUG|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
48489698|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
48489699|NCT02451098|DRUG|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
48489700|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
48489701|NCT02451098|DRUG|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
47971877|NCT01422317|DRUG|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
48120563|NCT06103149|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
48120564|NCT00147485|DRUG|AG-024322|
48120565|NCT05106075|PROCEDURE|blood sample or joint fluid or gingival exudate|blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips
48120566|NCT03999671|OTHER|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
48120567|NCT03999671|OTHER|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
48649548|NCT06127810|DRUG|Gadopiclenol|Subjects will receive Gadopiclenol instead of standard of care contrast
47971878|NCT06091631|PROCEDURE|Magnesium sulfate vaporization|pre-opeative magnesium sulfate vaporization
47971879|NCT05658146|DRUG|Mavacamten Capsule 1|Specified dose on specified days
47971880|NCT05658146|DRUG|Mavacamten Capsule 2|Specified dose on specified days
47971881|NCT05658146|DRUG|Mavacamten Capsule 3|Specified dose on specified days
47971882|NCT02672878|DEVICE|Bioresorbable vascular scaffold|
47971883|NCT04448574|OTHER|Chest Wall Deformities Questionaire|Questionaire about epidemiological data was sent to Patients and families
48326098|NCT04257084|DIAGNOSTIC_TEST|chromoendoscopy with target biopsy; NBI with target biopsy|"Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia."
47971884|NCT00795314|DRUG|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
47971885|NCT00795314|DRUG|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
47971886|NCT06194565|DRUG|99mTc-ABH2|Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.
47971887|NCT00144053|DRUG|Cisplatin+Vindesine+MMC/ concurrent radiation|
47971888|NCT00144053|DRUG|Irinotecan+Carboplatin/concurrent radiation|
48120568|NCT02403024|BEHAVIORAL|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
48326099|NCT03812588|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
48489702|NCT05720975|DEVICE|iNstroke|Patients to undergo thromboaspiration with iNstroke.
48489703|NCT03979820|DRUG|BI 1467335|Film-coated tablet
48649549|NCT03576651|BIOLOGICAL|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
48649550|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
47971889|NCT00144053|DRUG|Paclitaxel+Carboplatin/concurrent radiation|
47971890|NCT04974385|DRUG|Liposomal bupivacaine|Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.
47971891|NCT04974385|DRUG|Bupivacaine|Active comparator as standard of care.
48489704|NCT03979820|DRUG|Placebo|Film-coated tablet
48649551|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
47971892|NCT04922437|PROCEDURE|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
47971893|NCT04922437|PROCEDURE|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
47971894|NCT04482881|DRUG|Isosorbide Mononitrate 40 MG|giving women isosorbide mononitrate 40 MG
47971895|NCT04482881|DRUG|Isosorbide Mononitrate 60 MG|giving women isosorbide mononitrate 60MG
47971896|NCT04482881|DRUG|Misoprostol|Giving women misoprostol
47971897|NCT01815515|DRUG|18F-DCFBC|"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push."
47971898|NCT02380677|DRUG|CRLX301|
47971899|NCT06217198|BEHAVIORAL|Deprexis|Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
47971900|NCT03620240|BEHAVIORAL|Sleep Education|Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
48120569|NCT02403024|BEHAVIORAL|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
48120570|NCT04951362|DRUG|intranasal spray ivermectin|intranasal spray of saline
48326100|NCT03812588|DRUG|Placebo|A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
48326101|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
48326102|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
48326103|NCT00002391|DRUG|Abacavir sulfate|
48326104|NCT00002391|DRUG|Lamivudine|
48326105|NCT00002391|DRUG|Zidovudine|
48326106|NCT00870818|DIAGNOSTIC_TEST|Blood samples for safety|serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
47971901|NCT02624908|DRUG|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
48326107|NCT00870818|BEHAVIORAL|Patient reported outcome questionnaires|EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
48326108|NCT00870818|DIAGNOSTIC_TEST|Analysis of T-cell subsets|CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
48326109|NCT06044519|BIOLOGICAL|different types of dressings|different types of dressings were compared ti see the effectiveness for for STSG donor site wound
48649552|NCT06674057|PROCEDURE|KinesioTaping|"The experimental group will receive the following treatment for week 1-3 (3 days on alternate days):~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Kinesio tape 3 times per week. (Anchor opposed to effected compartment to provide facilitation and sustained stretch).~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of mediu"
48326110|NCT01916707|DRUG|Dosing of enoxaparin for VTE prophylaxis|
48326111|NCT00380211|BIOLOGICAL|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
47971902|NCT02624908|DRUG|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
47971903|NCT05686850|PROCEDURE|High-Flow Oxygen|Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
47971904|NCT05686850|PROCEDURE|Non invasive ventilation|NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
47971905|NCT05114798|BEHAVIORAL|Time restricted eating|daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
47971906|NCT05114798|BEHAVIORAL|Calorie Restriction|daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
48326112|NCT00380211|BIOLOGICAL|Fluarix|
48326113|NCT06100484|DIAGNOSTIC_TEST|Echocardiography|Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS
48326114|NCT03171311|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
47971907|NCT03642405|DIAGNOSTIC_TEST|Electrocardiogram examination|12-lead ECG monitored by Holter
47971908|NCT03642405|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
47971909|NCT03642405|PROCEDURE|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
47971910|NCT03642405|BEHAVIORAL|Questionnaire|Questionnaire regarding patients quality of life
48120571|NCT00761189|DRUG|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
48326115|NCT03171311|PROCEDURE|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
48326116|NCT02020460|DEVICE|Subdural trial lead|
48326117|NCT02020460|DEVICE|Epidural trial lead|
48326118|NCT03859492|DEVICE|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
48489705|NCT03979820|DRUG|Phenelzine sulfate|Film-coated tablet
48489706|NCT03979820|DRUG|Tyramine|Capsules
48120572|NCT00925587|DRUG|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
48120573|NCT05639777|DRUG|Dexmedetomidine group|That will receive intranasal dexmedetomidine (1.5mcg/kg)
48120574|NCT05639777|OTHER|control group|That will receive the same volume of 2 ml of intranasal normal saline
48489707|NCT05814003|DRUG|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
48489708|NCT05814003|OTHER|Placebo|Dough inert material without any therapeutic action
48489709|NCT00110006|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
48120575|NCT00891436|DRUG|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
48120576|NCT00891436|DRUG|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
48120577|NCT06322316|PROCEDURE|The Ultrasound-guided Retrolaminar Block Group|"The ultrasound probe was placed on the back in a transverse orientation on the lateral side of the posterior median line to identify the lamina of the 5th vertebra, ESM, and transversospinalis muscles of the target segment.~A 38-mm 22-gauge regional block needle was advanced using an in-plane technique. When the puncture needle touched the lamina, 20 mL of 0.25% levobupivacaine was administered between the transversospinalis muscle and lamina. The LA diffusion between the lamina and the ESM indicated a successful puncture."
48120578|NCT06322316|PROCEDURE|The Ultrasound-guided Erector Spinae Plane Block Group|"The ultrasound probe was placed on the back in a transverse orientation to identify the tip of the T5 transverse process as flat, squared-off acoustic shadows with a faint image of the pleura visible. When the tip of the transverse process was centered on the ultrasound screen, the probe was rotated to a longitudinal orientation. In the parasagittal view, the following layers were visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, ESM, and T5 transverse process.~The block needle was inserted in-plane in a cranial-to-caudal direction until contact was made with the T5 transverse process. The correct location of the needle tip in the fascial plane deep to the ESM was confirmed by injecting 0.5-1.0 ml of normal saline and seeing the fluid lifting the ESM off the transverse process without distending the muscle. Then 20 ml levobupivacaine 0.25% was injected."
48120579|NCT05748015|DIAGNOSTIC_TEST|quantification of sensory and autonomic small nerve fibers by punch skin biopsy|We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.
48489710|NCT00110006|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
48489711|NCT00110006|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
48326119|NCT04747522|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
48326120|NCT01623141|PROCEDURE|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
48326121|NCT01084109|OTHER|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
48489712|NCT00110006|DRUG|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
48120580|NCT05748015|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
48120581|NCT05748015|OTHER|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score
48120582|NCT00978172|DRUG|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
48120583|NCT00919594|BEHAVIORAL|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
48120584|NCT00919594|BEHAVIORAL|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
48120585|NCT06521723|OTHER|Daily acute intermittent hypoxia|Each participant will be exposed to 16 sessions of daily acute intermittent hypoxia via air generators over the span of four weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
48120586|NCT06521723|DEVICE|Walking + tSTIM|Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.
48489713|NCT00110006|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
48120587|NCT00332813|BEHAVIORAL|HIV Risk Behavior Intervention|
48120588|NCT06411834|BEHAVIORAL|Decision navigation tool|An electronic, interactive form that guides patients through the major factors that influence their decision-making in thyroid cancer
48326122|NCT01084109|OTHER|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
48489714|NCT00110006|PROCEDURE|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat \^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
48489715|NCT00110006|RADIATION|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV.
48489716|NCT01250483|OTHER|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
48489717|NCT04805918|BEHAVIORAL|VIPP-SD|Parenting program
48489718|NCT04102241|DRUG|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
48489719|NCT04102241|DRUG|Placebos|Placebos are the same as drugs, but contain no Hemay005.
48326123|NCT05680194|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
48326124|NCT05680194|DRUG|Bisphosphonate|Bisphosphonate
48326125|NCT03407508|DIETARY_SUPPLEMENT|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
47971911|NCT04502589|DRUG|Perampanel Tablet|Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
47971912|NCT04502589|DRUG|Disulfiram|Disulfiram will be kept at 250mg daily
48326126|NCT01905670|DEVICE|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
48326127|NCT00418379|DRUG|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
48326128|NCT00418379|DRUG|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
48489720|NCT00061243|BIOLOGICAL|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
48489721|NCT01692314|OTHER|Resistance training|
48489722|NCT05253365|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
48489723|NCT02483832|BEHAVIORAL|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
48498074|NCT02191631|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
48498075|NCT05060354|OTHER|Blood draw|Approximately 120 mL whole blood will be collected from each subject at each timepoint
48326129|NCT00418379|DRUG|Placebo|Placebo tablet
48326130|NCT02140619|BEHAVIORAL|multiple health education interventions|
48326131|NCT02623595|RADIATION|Stereotactic body radiotherapy|A type of radiation therapy
48326132|NCT02623595|DRUG|rhGM-CSF|Immune modulating agents
47971913|NCT04495348|DRUG|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
47971914|NCT04402931|PROCEDURE|Transcatheter Valve-in-Valve Intervention|Transcatheter mitral valve-in-valve implantation with SAPIEN 3
47971915|NCT04402931|PROCEDURE|Redo Mitral valve surgery|Transcatheter Valve-in-Valve Intervention
47971916|NCT00273871|DRUG|Cyclosporin or tacrolimus|
48326133|NCT05057143|DEVICE|Implants|3D printed implants
48489724|NCT01617694|DRUG|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
48489725|NCT01617694|DRUG|Normal Saline|
48489726|NCT04154306|DIETARY_SUPPLEMENT|Red clover|2 weeks of Red clover
48489727|NCT04154306|DIETARY_SUPPLEMENT|Placebo|2 weeks of Placebo
48489728|NCT01720199|OTHER|Diario della Salute (DDS)|"DDS is composed by~1. tools for children and their parents on health and social and emotional well-being issues:~   1. a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~  2. a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~2. five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
48489729|NCT05726760|BEHAVIORAL|Seeking informed consent for participation in the study.|The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.
48489730|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
48489731|NCT05726760|DEVICE|Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.
48489732|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
48489733|NCT02244918|DRUG|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
48489734|NCT02244918|BEHAVIORAL|Smoking Cessation Counseling|
48489735|NCT03642353|DRUG|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
47971917|NCT04535700|DRUG|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
47971918|NCT04535700|OTHER|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
48326134|NCT05057143|DEVICE|Plates|Titanium plates
48326135|NCT04311801|DIAGNOSTIC_TEST|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
48326136|NCT00397709|DRUG|I ( isoniazid), II (isoniazid + rifampin )|
48326137|NCT03033251|DEVICE|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
48489736|NCT03642353|DRUG|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
48326138|NCT03033251|DEVICE|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
48326139|NCT03033251|DEVICE|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
47971919|NCT05767645|DEVICE|Mistral Procedure|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
47971920|NCT01609374|DEVICE|M6-C Artificial Cervical Disc|Total disc replacement
47971921|NCT01609374|DEVICE|Anterior plate system with corticocancellous allograft bone|Cervical fusion
47971922|NCT03462264|DEVICE|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
48326140|NCT01815580|DRUG|Atripla or Stribild|Antiretroviral therapy
48326141|NCT00000417|PROCEDURE|Counseling intervention|
48326142|NCT00000417|DEVICE|Informational film|
48326143|NCT05708768|OTHER|Receiving physician manned rapid response car services|All patients receiving services from the physician manned rapid response car will be included
48326144|NCT05027919|DRUG|Morphine|30mg subcutaneous injections of morphine 4 times daily on days 1 through 5.
48649553|NCT06674057|PROCEDURE|Control|"The control group will receive the following treatment for week 1-3 on alternate days:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of medium resistance)."
48649554|NCT00874016|DEVICE|Airtraq|Intubation using Airtraq
48326145|NCT05027919|DRUG|Naloxone + lofexidine pretreatment|0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
48326146|NCT05027919|DRUG|Naloxone + placebo pretreatment|0.4mg naloxone injection during the Naloxone challenge
48326147|NCT05027919|DRUG|Lofexidine|Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
48326148|NCT04198233|DRUG|Diazepam|Diazepam 10 mg compounded suppository
48326149|NCT04198233|DRUG|Placebos|Placebo suppository
48326150|NCT05147974|BEHAVIORAL|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
48326151|NCT01086046|DRUG|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
48489737|NCT04126421|DEVICE|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
48489738|NCT04126421|DEVICE|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
48489739|NCT00013494|PROCEDURE|Stroke Rehabilitation|
48489740|NCT03651466|DRUG|Gx-G6|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
48489741|NCT03651466|DRUG|Placebo|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
48489742|NCT02575274|PROCEDURE|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
48489743|NCT01659736|DEVICE|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
48489744|NCT05258331|GENETIC|CT303|"1. Cohort 1 : Single-dose administration, intravenous injection~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg~2. Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4)~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg"
48489745|NCT02662166|DEVICE|MR imaging|3 T MRI of the urinary bladder
48489746|NCT04912336|DIAGNOSTIC_TEST|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
48649555|NCT00874016|DEVICE|Direct Laryngoscopy|Intubation using direct laryngoscopy
48649556|NCT03989479|BEHAVIORAL|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
48649557|NCT03989479|BEHAVIORAL|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
48649558|NCT01558258|BEHAVIORAL|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
48649559|NCT05972785|DRUG|Calcium channel blocker|Drugs with ATC code C08 will be categorised as calcium channel blockers.
48326152|NCT00091936|DRUG|Didanosine|
48326153|NCT00091936|DRUG|Efavirenz|
48489747|NCT04912336|DIAGNOSTIC_TEST|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
48489748|NCT04912336|OTHER|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
48489749|NCT06333223|DIETARY_SUPPLEMENT|Mixture of (Poly)phenols and a probiotic supplement|Mixture of (Poly)phenols and a probiotic supplement
48489750|NCT06333223|DIETARY_SUPPLEMENT|Placebo comparator|Mixture of (Poly)phenols and a placebo maltodextrin comparator
48489751|NCT04934150|DEVICE|navigated repetitive Transcranial Stimulation|High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
48489752|NCT05801653|DIETARY_SUPPLEMENT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
48489753|NCT00896155|DRUG|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
48489754|NCT00896155|RADIATION|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
48498076|NCT01612026|PROCEDURE|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
48649560|NCT05972785|DRUG|Beta blocker|Drugs with ATC code C07 will be categorised as beta-blockers.
47971923|NCT03462264|OTHER|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
47971924|NCT01652612|OTHER|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
48326154|NCT00091936|DRUG|Lamivudine|
48326155|NCT00091936|DRUG|Standard TB treatment|
48326156|NCT01403467|DEVICE|Continuous positive airway pressure|CPAP 8 cmH2O
48326157|NCT01769469|DRUG|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
48326158|NCT04326023|DRUG|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
48326159|NCT01309841|DRUG|NKTR-118|12.5 mg oral tablet once daily
48649561|NCT05972785|DRUG|Diuretic|Drugs with ATC code C03 will be categorised as diuretics.
48649562|NCT05972785|DRUG|RAS|Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
48649563|NCT05972785|DRUG|Other AHT|Drugs with ATC code C02 will be categorised as other antihypertensives.
48649564|NCT05972785|DRUG|None AHT|None AHT
47971925|NCT03848117|OTHER|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
47971926|NCT03848117|OTHER|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
47971927|NCT06243263|DRUG|Bupivacain|At the end of the surgery, after wound closure, an inferior alveolar nerve block with 2ml bupivacaine 0,5 % will be realized.
48120589|NCT05105126|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC).~The cathode electrode will be placed on the right dorsolateral prefrontal cortex.~40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA."
48326160|NCT01309841|DRUG|NKTR-118|25 mg oral tablet once daily
48326161|NCT01309841|DRUG|Placebo|Oral tablet once daily
48326162|NCT00388323|OTHER|blood and biopsies|blood and biopsies
48326163|NCT05075967|OTHER|Health Equity|This community-level structural component will use a standardized, nationally replicable community coalition model (Black Treatment Advocates Networks \[BTAN\]) to implement an enhanced program model geared to 1) facilitate the effects of the other HPTN 096 interventions by minimizing barriers to HIV testing, PrEP use and viral suppression through sensitizing a local network of service providers (e.g., social, legal, economic sectors) to the needs of Black MSM and maintaining an online platform for exchanging information about the local network that can be used to link Black MSM to resources and services, and 2) amplify the effects of other HPTN 096 components by increasing Black MSM's receptivity to those activities through the integration and promotion of HPTN 096 into the activities of the community coalition model.
48326164|NCT05075967|BEHAVIORAL|Social Media Influencers|"In this community-level component, social media influencers (SMI) will be defined for the purposes of this study as users on social media who have established credibility, trust and access to a large audience of Black MSM, and who can persuade them by virtue of their authenticity and reach. SMI will provide tailored messaging for Black MSM in intervention communities on the topics of:~* HIV/sexually transmitted infections (STI) testing promotion~* PrEP (and general HIV prevention) awareness and promotion~* Definition and benefits of viral suppression.~Messages may include direction towards health care facilities (HCFs) involved in the intersectional stigma reduction component and information about the virtual peer support platform or BTAN+ events."
48326165|NCT05075967|BEHAVIORAL|Intersectional Stigma Reduction|This organizational-level component will take place in HCFs and is designed to improve cultural responsiveness in the provision of HIV prevention and health care services to Black MSM. It is expected to contribute to a reduction in HIV incidence by creating an affirming and autonomy-supportive healthcare environment that supports Black MSM engagement in HIV-related care and services and that promotes increased HIV/STI testing, PrEP uptake and viral suppression rates.
48649565|NCT03635996|DRUG|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.
48649566|NCT03635996|DEVICE|Aptar Pharma Nasal Spray Bidose System|Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
48120590|NCT05105126|DEVICE|Sham tDCS|Sham tDCS
48340136|NCT05425524|PROCEDURE|Care Bundle|Treatment step by step we have 5 steps STEP 1: Leptospirosis suspected case STEP 2: Investigations STEP 3: Antibiotics within 1 hour after Hemocultures were taken STEP 4: Intravenous Fluid STEP 5: Stage-Base Management of AKI (KDIGO)
48340137|NCT04266249|DRUG|Docetaxel|Given IV
48649567|NCT02272985|OTHER|[15O]H2O PET-CT scan|All participants will undergo 3 \[15O\]H2O PET-CT scans during the hemodialysis study session
48649568|NCT02272985|OTHER|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
48649569|NCT05044039|DRUG|Duvelisib|Patients should take duvelisib at approximately the same time every day, with or without food.
48649570|NCT06332339|BIOLOGICAL|16055 NFL delta Gly4 trimer|200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)
48649571|NCT06332339|BIOLOGICAL|Trimer 4571|100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)
48649572|NCT06332339|BIOLOGICAL|Ad4-Env145NFL, 5 x 108 viral particles (vp)|to be administered intranasally (IN) (0.07 mL into 1 nostril)
48489755|NCT01427842|DRUG|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
48489756|NCT05144347|DRUG|XL114|Tablets of XL114
47971928|NCT05168527|DRUG|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
47971929|NCT02385513|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|
47971930|NCT04592601|PROCEDURE|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
48120591|NCT03631550|DEVICE|Relivion active|1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
48120592|NCT03631550|DEVICE|Relivion Sham|1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation
48120593|NCT05862610|DRUG|Trilaciclib plus chemotherapy|Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
48326166|NCT05075967|BEHAVIORAL|Peer Support|"Peer support workers will be trained and compensated to provide emotional and practical support services. These peer support workers will have shared lived experiences with those whom they are supporting, be self-reflective of those experiences, and know when to share those experiences with others in an appropriate and supportive manner. Once trained, the peer-support workers will have demonstrated competencies in the following domains:~* HIV, PrEP, nPEP, other HIV prevention options and ART education~* Adherence to PrEP, ART and medical care~* HIV/STI testing~* New HIV diagnosis~* Addressing intersectional stigma (anti-Black racism, sexual stigmas, HIV-related stigma)~* Self-care~* Information about national and local resources and assistance programs, Black MSM-centered health services, and the cost and insurance coverage of medications and medical care~* Multicultural competency (as it relates to the HIV epidemic for Black MSM in the southern US)"
48326167|NCT05075967|OTHER|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
48326168|NCT05833971|DRUG|cadonilimab+chemotherapy|cadonilimab plus cisplatin and Nab-PTX, Q3W
48326169|NCT02800486|DRUG|Intra-arterial Cetuximab|
48326170|NCT02800486|DRUG|Intra-arterial Mannitol|
48326171|NCT02800486|RADIATION|Hypofractionated re-irradiation|
48326172|NCT00461578|DRUG|Chlorproguanil-dapsone + artesunate|
48326173|NCT04141553|DRUG|Diltiazem Injection|Randomization to one of to active comparator groups
48326174|NCT00522574|DRUG|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
48326175|NCT05557669|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
48326176|NCT02069236|OTHER|G6PD Test|All subjects are tested by multiple G6PD tests
48326177|NCT03600714|DRUG|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.
48326178|NCT03600714|DRUG|Lonafarnib|Oral prenylation inhibitor
48326179|NCT03600714|DRUG|Ritonavir|Booster of lonafarnib action
48326180|NCT05231993|PROCEDURE|Conization|A cone biopsy to remove abnormal tissue.
48326181|NCT05231993|PROCEDURE|Colposcopy|"1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
48326182|NCT02675738|OTHER|good clinical practice|
48489757|NCT02278419|DRUG|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
48489758|NCT02278419|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
48120594|NCT05862610|DRUG|Chemotherapy|epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
48120595|NCT02990949|OTHER|Timing of trigger|
48326183|NCT00436293|DRUG|Docetaxel|75 mg/m²
48326184|NCT00436293|DRUG|Cisplatin|75 mg/m²
48326185|NCT05572827|BEHAVIORAL|Breathing exercises|Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
48326186|NCT04072172|DEVICE|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
48326187|NCT03001336|OTHER|no intervention|This is a cross-sectional study
48326188|NCT00141557|DRUG|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
48326189|NCT00141557|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
48326190|NCT04904003|OTHER|Rehabilitation Intervention|Strength, flexibility, endurance, balance, mobility, (self-efficacy)
48326191|NCT00801853|DRUG|Aerovant|Aerovant 1mg bid (dry powder)
48326192|NCT00801853|DRUG|Aerovant|Aerovant 3mg bid (dry powder)
48326193|NCT00801853|DRUG|Aerovant|Aerovant 10mg bid (dry powder)
48326194|NCT00801853|OTHER|placebo|placebo control (dry powder)
48326195|NCT05700955|DRUG|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
48489759|NCT02341950|BEHAVIORAL|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
48489760|NCT03003273|OTHER|stoppage of antibiotics|antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
48326196|NCT00891163|DRUG|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
48326197|NCT00891163|DRUG|Placebo Patch|placebo
48326198|NCT01313208|DRUG|etanercept|Administered by subcutaneous injection once weekly.
48326199|NCT01313208|DRUG|Placebo|Placebo subcutaneous injection
48326200|NCT01313208|DRUG|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
48326201|NCT00124241|DRUG|telbivudine|
48649573|NCT03987685|DRUG|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
48649574|NCT05216380|BEHAVIORAL|ActivityLink|"ActivityLink is an implementation program using:~1. Didactic and experiential training sessions for clinic staff to conduct referrals~2. Secure electronic referral webform to refer patients using their email address and phone number~3. Messaging sent to the patient and provider that they have been referred to a program~4. Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~5. Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot"
48649575|NCT00216931|DRUG|iloprost|
48649576|NCT00958425|DEVICE|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
48120596|NCT03817476|DRUG|BI 425809 (Treatment T1)|Intended commercial formulation tablet from batch 1 (iCF1)
48649577|NCT00958425|DEVICE|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
48649578|NCT05463887|BEHAVIORAL|Individualized preventive care recommendations (decision tool)|Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
48649579|NCT04407247|BIOLOGICAL|Infliximab|Given IV
48649580|NCT04407247|BIOLOGICAL|Vedolizumab|Given IV
47971931|NCT00552721|OTHER|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
48326202|NCT00124241|DRUG|lamivudine|
48489761|NCT03003273|OTHER|amoxycillin/clavulanic acid|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
48489762|NCT03003273|OTHER|levofloxacin|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
48489763|NCT01338987|PROCEDURE|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
48489764|NCT01338987|DRUG|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
48498077|NCT00586352|OTHER|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
48649581|NCT04987489|DRUG|Etavopivat tablets|Etavopivat 400 mg once daily
48649582|NCT02826785|BEHAVIORAL|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
48649583|NCT00298701|BIOLOGICAL|ALK Grass tablet|
48649584|NCT05197270|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept
48649585|NCT05197270|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator Other Name: Eylea
47971932|NCT00552721|OTHER|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
47971933|NCT03041597|PROCEDURE|placement of implants|surgical procedure and placement of implants
47971934|NCT03041597|PROCEDURE|immediate loading|cone-anchored implant supported removable dental prostheses placement
48120597|NCT03817476|DRUG|BI 425809 (Treatment T2)|Intended commercial formulation tablet from batch 2 (iCF2)
48120598|NCT03817476|DRUG|BI 425809 (Treatment R)|Trial formulation 2 tablet (TF2)
48120599|NCT01675258|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
48120600|NCT06206824|DRUG|Leucettinib-21|See arm's description.
48326203|NCT04123418|BIOLOGICAL|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
48326204|NCT04123418|DRUG|WHG626|WHG626 will be administered orally in a dose escalation schedule
48326205|NCT02741219|DRUG|Normal saline|Control Group receives normal saline bolus after delivery
48326206|NCT02741219|DRUG|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
48326207|NCT02741219|DRUG|Sufentanil|sufentanil PCA after surgery
48326208|NCT02741219|DRUG|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
48326209|NCT04717076|BEHAVIORAL|App-based nutritional concept and fitness tracking|The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.
48326210|NCT04717076|BEHAVIORAL|Nutritional concept with individual nutritional counselling|Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)
48326211|NCT04717076|BEHAVIORAL|Nutritional concept without individual nutritional counselling|Nutritional concept based on personalized menu plans
48326212|NCT00836277|DRUG|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
48326213|NCT00836277|DRUG|Irinotecan|125mg/m2 IV Day 1 and Day 8
48326214|NCT05143762|DRUG|paracetamol|patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
48649586|NCT06556173|DRUG|VTX3232|Dose A
48649587|NCT01345903|PROCEDURE|therapeutic conventional surgery|Undergo robotic-assisted surgery
48649588|NCT05552339|DRUG|Finerenone (Kerendia, BAY94-8862)|Following the physicians' decision.
48649589|NCT05552339|DRUG|Type 2 DM drugs|Following the physicians' decision
48649590|NCT05180474|BIOLOGICAL|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
48649591|NCT06674382|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|This study is an observational research in which all patients will undergo haploidentical hematopoietic stem cell transplantation for the treatment of myelofibrosis. We will evaluate the efficacy of this treatment method, including survival and recurrence rates.
48649592|NCT06490666|DEVICE|femoral artery doppler|femoral artery pulse wave doppler to measure both pulsatility and resistive indices
48649593|NCT00968045|DRUG|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
48326215|NCT05143762|DRUG|Dexamethasone|patients will receive dexamethasone 0.5mg/kg IV.
48326216|NCT05143762|DRUG|normal Saline|patients will receive placebo 10 ml normal saline IV.
48326217|NCT01125878|DIETARY_SUPPLEMENT|Placebo|placebo
48326218|NCT01125878|DIETARY_SUPPLEMENT|Starch composite B|fiber mixture
48326219|NCT01125878|DIETARY_SUPPLEMENT|Starch composite C|fiber mixture
48326220|NCT01125878|DIETARY_SUPPLEMENT|Starch composite D|fiber mixture
48326221|NCT02312583|BEHAVIORAL|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
48326222|NCT02312583|BEHAVIORAL|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
48326223|NCT02827279|OTHER|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
48326224|NCT05701488|DRUG|Durvalumab|Intravenous infusion
48326225|NCT05701488|DRUG|Tremelimumab|Intravenous infusion
48326226|NCT05701488|DEVICE|SIRT|SIR (Selective Internal Radiation) Sphere resin microspheres, radioactive particles delivered via injection into an artery.
48326227|NCT02188719|BIOLOGICAL|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is \<50/mm\^3 or when the maximal dose of 4.5/mg/kg has been given.
48326228|NCT02188719|BIOLOGICAL|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
48489765|NCT01338987|DRUG|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
48489766|NCT01338987|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
48489767|NCT01338987|DRUG|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
48489768|NCT01338987|DRUG|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
48489769|NCT01338987|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
48649594|NCT05187988|PROCEDURE|supraclavicular brachial plexus block|group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
48649595|NCT05187988|PROCEDURE|Retroclavicular brachial plexus block|group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
48326229|NCT02188719|DRUG|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
48326230|NCT02188719|DRUG|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
48326231|NCT02188719|DRUG|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
48326232|NCT02188719|DRUG|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
48326233|NCT02188719|DRUG|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
48326234|NCT02188719|DRUG|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
48326235|NCT02188719|DRUG|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
48340138|NCT04266249|PROCEDURE|Lumpectomy|Undergo lumpectomy
48340139|NCT04266249|PROCEDURE|Mastectomy|Undergo mastectomy
48340140|NCT04266249|DRUG|Nab-paclitaxel|Given IV
48340141|NCT04266249|DRUG|Paclitaxel|Given IV
48340142|NCT04266249|BIOLOGICAL|Pertuzumab|Given IV
48340143|NCT04266249|RADIATION|Radiation Therapy|Undergo radiation therapy
48340144|NCT04266249|BIOLOGICAL|Trastuzumab|Given IV
48649596|NCT03755401|OTHER|TFPP|Trauma-Focused Psychodynamic Psychotherapy
48326236|NCT02188719|PROCEDURE|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level \>/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level \</=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
48326237|NCT02188719|PROCEDURE|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
48326238|NCT02188719|PROCEDURE|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
48326239|NCT02188719|PROCEDURE|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
48326240|NCT03008733|OTHER|Ultrasound UHF peripheral nerves|Ultrasound UHF peripheral nerves
48326241|NCT03008733|OTHER|Electro myography surface nerves|Electro myography surface nerves
48326242|NCT04914117|DRUG|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
48326243|NCT03288324|DRUG|Tofacitinib|Tofacitinib 5 mg twice daily
48326244|NCT04441736|DEVICE|High flow nasal cannula|Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
48326245|NCT02205398|DRUG|INC280|
48326246|NCT02205398|DRUG|cetuximab|
48326247|NCT01796262|DIETARY_SUPPLEMENT|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
48326248|NCT01796262|DIETARY_SUPPLEMENT|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
48326249|NCT06371339|DEVICE|"Additional acquisitions with the investigational gamma-camera  MoTI ."|"The gamma-camera MoTI will be used for the study to carry out 3 or 4 additional acquisitions (depending on the therapeutic indication) compared with those provided for in standard practice with a conventional gamma camera (Syngula).~Patients will receive their treatment as usual in two stages:~* 1/ Pre-therapy phase:~  1. Administration of a tracer dose of 131I (Day 0).~ 2. Assessment of 131I uptake/fixation rate at Day 0, Day 1, Day 5.~ 3. Determination of the therapeutic dose of 131I to be administered to the patient after collegial discussion.~* 2/ Therapy phase:~  1. Administration of the therapeutic dose (Day 0).~ 2. Thyroid scintigraphy and measurement of the 131I uptake rate within 4 hours of treatment.~For the study, measurements of 131I uptake/fixation rates will be carried out using both the standard gamma camera Syngula and the gamma camera MoTI."
48649597|NCT03755401|OTHER|TAU|treatment as usual at the VA for PTSD
48649598|NCT03602495|DRUG|Donafenib|Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
48649599|NCT03602495|DRUG|Placebo|Matching placebo Bid orally, continuously.
48326250|NCT00202397|DRUG|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
48326251|NCT00202397|OTHER|placebo|capsule-shaped tablet bid for 8 weeks
48326252|NCT01766479|RADIATION|CT colonography|
48326253|NCT03345732|DIAGNOSTIC_TEST|ICG and SPY system for wound complications|
48326254|NCT04715412|OTHER|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
48326255|NCT05027256|DEVICE|Entia Liberty|Home Monitoring solution
48326256|NCT05259930|OTHER|Amino MP9|Name used by Nualtra for their product of BCAA
48326257|NCT03623334|RADIATION|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
48326258|NCT03935607|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
48340145|NCT04266249|BIOLOGICAL|Trastuzumab Emtansine|Given IV
48489770|NCT01338987|DRUG|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
48489771|NCT01338987|DRUG|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
48649600|NCT02858778|OTHER|Early order of palliative care consultation|
48649601|NCT05475002|OTHER|care empowerment program|dementia care e-books, dementia virtual reality activity and family support group
48649602|NCT05475002|OTHER|dementia education|dementia education manual and family support group
48649603|NCT05283629|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~* Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~* Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
48649604|NCT05283629|BEHAVIORAL|Education Control Condition|The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
48326259|NCT05696262|BEHAVIORAL|6-walking program|Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner
48489772|NCT01338987|PROCEDURE|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
48489773|NCT03185234|DEVICE|anodal tDCS|2 mA, 10 min, 5 sessions
48489774|NCT03185234|DEVICE|sham tDCS|sham stimulation, 10 min, 5 sessions
47971935|NCT03041597|PROCEDURE|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
47971936|NCT03041597|DEVICE|Ankylos implant|
47971937|NCT00232232|DRUG|Fish oil|
48489775|NCT02782494|OTHER|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
47971938|NCT02173327|DEVICE|Continuously helm CPAP|6 hours
47971939|NCT02173327|DEVICE|Intermittent Mask CPAP|10min every 2 hour for 18 hours
47971940|NCT01310621|DRUG|Bovine surfactant|"* Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)"
48489776|NCT00842478|PROCEDURE|Toothbrushing|
48489777|NCT03113513|PROCEDURE|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
48489778|NCT02047175|DRUG|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
48489779|NCT02047175|DRUG|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
48489780|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
48489781|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
48489782|NCT02238626|DRUG|Placebo (for MN-166)|
48489783|NCT02238626|DRUG|MN-166|
48489784|NCT02238626|DRUG|riluzole|Patient is given 50 mg riluzole twice daily.
48489785|NCT04527328|DEVICE|AKST1210|AKST1210
48489786|NCT04527328|OTHER|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
48489787|NCT04527328|PROCEDURE|Hemodialysis|Hemodialysis
48489788|NCT04775420|DIAGNOSTIC_TEST|Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)|MPV and NLR are easily accessible and inexpensive tests
48489789|NCT02575976|BEHAVIORAL|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
48489790|NCT02575976|OTHER|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
48489791|NCT02575976|OTHER|wait list control|No cardiac rehabilitation.
48489792|NCT01700166|BIOLOGICAL|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
48489793|NCT06300788|OTHER|PPI and T50 dosing|Sampling for PPI determination and T50 in blood and urine.
48489794|NCT02387593|DEVICE|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
48489795|NCT03947736|DIAGNOSTIC_TEST|cfDNA was detected by dPCR|Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
48489796|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
47971941|NCT00772343|BIOLOGICAL|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
47971942|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
48489797|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
48489798|NCT02563717|DEVICE|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
48489799|NCT02563717|DEVICE|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
48489800|NCT03143608|DEVICE|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
48649605|NCT04900792|DRUG|Ferumoxytol injection|Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
48649606|NCT04900792|DRUG|Pharmacological ascorbate|Intravenous ascorbate
47971943|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
47971944|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
48326260|NCT03801356|DRUG|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
48340146|NCT03348566|OTHER|fish|fish intkae
48489801|NCT02545855|DEVICE|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
48326261|NCT06521866|DRUG|Toripalimab|240 mg IV on Day 1, every 3 weeks
48326262|NCT06521866|DRUG|Chemotherapy|"Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
48326263|NCT06521866|RADIATION|SABR|SABR: 25-60 Gy/5 Fx
48326264|NCT06521866|DRUG|Targeted therapy|Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly Bevacizumab: 5 mg/kg IV on Day 1
48326265|NCT01718626|DRUG|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
48326266|NCT01718626|DRUG|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
48489802|NCT02545855|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
48649607|NCT04900792|RADIATION|External beam radiation therapy|Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.
48649608|NCT04900792|DRUG|Temozolomide|Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
48120601|NCT01504659|DRUG|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
48120602|NCT01504659|DRUG|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
48326267|NCT03811886|DRUG|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
48326268|NCT00262977|BEHAVIORAL|Electronic prompt plus patient-directed intervention|
48326269|NCT00262977|BEHAVIORAL|Electronic prompt to clinician to prescribe aspirin|
48326270|NCT05552118|PROCEDURE|Cochlear™ Remote care|"Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit."
48326271|NCT05552118|PROCEDURE|Standard of care|Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
48326272|NCT05552118|DEVICE|Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)|CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)
48326273|NCT05248555|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
48489803|NCT03873636|OTHER|Stimulation via noninvasive brain stimulation systems|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, \& Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
48649609|NCT02795962|OTHER|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
48649610|NCT00833274|BEHAVIORAL|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
48649611|NCT06673667|DRUG|KT-621|Oral drug
48649612|NCT06673667|DRUG|Placebo|Oral drug
48326274|NCT05035823|DEVICE|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
48489804|NCT03421782|BEHAVIORAL|Cognitive Behavior Therapy|Undergo PROSPECT internet-based CBT
48489805|NCT03421782|BEHAVIORAL|Exercise Intervention|Undergo POWER exercise intervention
48489806|NCT06354491|DEVICE|Magnetic Resonance Imaging (MRI)|MRI procedures will include a 20-25 exam with periodic breath holds. The imaging series will be conducted twice to assess repeatability.
48326275|NCT01081821|DRUG|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
48326276|NCT01081821|DRUG|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
48326277|NCT04923620|DRUG|cetuximab+mFOLFOX6|cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
48326278|NCT04923620|RADIATION|short-course radiotherapy|25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6
48326279|NCT00293423|BIOLOGICAL|HSPPC-96|25 mcg
48326280|NCT00293423|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
48326281|NCT06213129|DEVICE|Na and ultrafiltration profiling|Sodium and ultrafiltration profiling are method of dialysis in which dialysate sodium concentration and ultrafiltration rate are altered during the course of the dialysis session
48326282|NCT03116308|DRUG|Opicapone (OPC)|50 mg OPC capsules; oral route
48326283|NCT05239364|PROCEDURE|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
48326284|NCT05064332|DRUG|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
48326285|NCT05064332|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
47971945|NCT04748120|PROCEDURE|Operative management|Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
47971946|NCT04748120|PROCEDURE|Non-operative management|"Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~* piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~* amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~* ertapenem 1g IV every 24 hours for 3 days~* ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis."
47971947|NCT05551039|OTHER|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
47971948|NCT04901468|OTHER|No Intervention|This is an observational study
47971949|NCT02101060|OTHER|exercise|16-week progressive aerobic and resistance exercise training
47971950|NCT02559193|OTHER|Observational study, data collection only trial.|Data collection only trial design.
47971951|NCT01032005|OTHER|double fortified salt|Refined salt of particle size \< 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
48326286|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
47971952|NCT02381288|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
47971953|NCT02381288|DRUG|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
48326287|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
48326288|NCT04611178|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
48326289|NCT05452876|OTHER|ABCp|Intervention is a care pathway that helps primary care physicians categorize back pain patients with each category having preferred interventions.
48326290|NCT05452876|OTHER|Usual Care|Standard of care treatment
48326291|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
48326292|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
48326293|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
48326294|NCT01707368|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
48326295|NCT03196193|PROCEDURE|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
48326296|NCT03196193|DEVICE|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
48326297|NCT03196193|DEVICE|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
48326298|NCT05396313|DEVICE|CRT/ICD|The patients received implantation of CRT/ICD.
48326299|NCT05069285|OTHER|self-help book|information and advice given in the self-help book
48326300|NCT05069285|OTHER|sleep hygiene advice|information and advice given on the sheet of paper with sleep hygiene
48326301|NCT02662413|OTHER|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
48326302|NCT00434499|DRUG|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
48326303|NCT00979017|DRUG|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
48120603|NCT06393595|DIAGNOSTIC_TEST|surface enhanced Raman Spectroscopy|"Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation."
48120604|NCT06523868|OTHER|GRAIL Galleri|A multi-cancer early detection (MCED) blood test.
48120605|NCT05012241|DIAGNOSTIC_TEST|Nine Hole Peg Test|At first, each patient will be asked to fill in the questionnaire. Then he/she will be tested by the Nine Hole Peg Test according to the new Czech version of extended manual for this test. Audio recording of verbal instructions will be used.
48120606|NCT05865145|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be adjusted for High or Low interval intensity training.
48120607|NCT01084707|DRUG|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
48120608|NCT01084707|DRUG|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
48120609|NCT01084707|DRUG|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
48120610|NCT03762668|DEVICE|Modified delefilcon A contact lenses|Spherical soft daily disposable contact lens
48120611|NCT03762668|DEVICE|Delefilcon A contact lenses|Spherical soft daily disposable contact lens
48120612|NCT04971447|DRUG|gender affirming hormonal treatment in transgender men|testosterone enanthate
48120613|NCT04971447|DRUG|gender affirming hormonal treatment in transgender women|GnRH agonists + estrogen
48120614|NCT04329364|COMBINATION_PRODUCT|Laser Haemorrhoidoplasty (LAH)|Using a laser diode to cause coagulative necrosis to the haemorrhoidal cushion
48120615|NCT04329364|PROCEDURE|Open milligan-morgan conventional haemorrhoidectomy|conventional excisional haemorrhoidectomy
48120616|NCT04329793|DEVICE|Assisted gait training with Walkbot System|The experimental group will receive at least 3 treatment sessions per week consisting of 40 minutes in robot-assisted gait training with Walkbot System in addition to their usual Physical therapy sessions. In total, the number of Walkbot sessions will be 20, in uninterrupted weeks.
48120617|NCT04329793|OTHER|Physical Therapy|The control group will receive their usual Physical therapy sessions during 6 weeks.
48120618|NCT05669170|BEHAVIORAL|Psychosocial intervention|"The counseling session, in which a trained study clinician will counsel the primary caregiver, will take place at each study visit and after the randomization visit. It will last approximately 20-30 minutes. Each counseling session will consist of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and the opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem-solving of specific issues that the caregiver brings to the sessions~* Answers to questions regarding the educational materials The educational materials will consist of a copy of the book The 36-Hour Day by Nancy L. Mace and Peter V. Rabins. The caregiver also will be provided with 24-hour phone access to the study nurse or physician for assistance with crises that may arise after hours."
48120619|NCT05669170|DRUG|Methylphenidate|norepinephrine and dopamine reuptake inhibitor
48120620|NCT04257409|OTHER|Physical intervention by exercise|12 week lasting exercise intervention
48120621|NCT01873326|DRUG|Paclitaxel|
48120622|NCT01873326|DRUG|Ifosfamide|
48120623|NCT01873326|DRUG|Cisplatin|
48120624|NCT01873326|DRUG|Mesna|
48120625|NCT01873326|DRUG|Bleomycin|
48120626|NCT01873326|DRUG|Etoposide|
48120627|NCT06300424|DRUG|almonertinib|110mg qd
48120628|NCT06300424|DRUG|Carboplatin|AUC 5, d1 every 3 weeks
48120629|NCT06300424|DRUG|Nab paclitaxel|135 mg/m2, d1,d8 every 3 weeks
48120630|NCT03872362|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
48120631|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 14 days
48120632|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
48120633|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered once daily for 28 days
48120634|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
48120635|NCT02034773|DRUG|Placebo|Placebo will be administered once daily for up to 28 days
48120636|NCT02034773|DRUG|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
48120637|NCT02034773|DRUG|CC-220|CC-220 1mg (once every 7 days for 28 days)
48120638|NCT02034773|DRUG|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
48120639|NCT05241041|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
48120640|NCT05241041|DEVICE|auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously.
48120641|NCT05241041|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
48120642|NCT05780528|OTHER|mulligan mobilization|The patients will receive mobilization with movement technique of lateral glide. the patients will be in supine subject and pronate forearm, during the application of the lateral glide by the physiotherapist, each patient was asked to perform the closure of the fist (provocative but painless gesture in the execution of the technique) for 3 sets of 10 repetitions.
48326304|NCT00979017|DRUG|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
48340147|NCT03175874|PROCEDURE|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
48326305|NCT00979017|DRUG|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
48326306|NCT04395963|DEVICE|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
48326307|NCT02565615|OTHER|No intervention|Because this is a non-interventional study, there is no intervention here.
48326308|NCT04134741|OTHER|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
48326309|NCT05177822|DRUG|Anakinra|Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;
48326310|NCT05177822|OTHER|Placebo|0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
48326311|NCT04034043|DEVICE|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
48326312|NCT05631548|DEVICE|iTBS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.
48326313|NCT05631548|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
48326314|NCT00957255|DEVICE|OrthoADAPT|soft tissue augmentation device
48326315|NCT00957255|PROCEDURE|Standard of care|Standard of care rotator cuff repair
48326316|NCT02293902|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48326317|NCT02293902|OTHER|Placebo (for sarilumab)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48326318|NCT02293902|DRUG|Methotrexate|Dispensed according to local practice.
48326319|NCT02293902|DRUG|Folic acid|Dispensed according to local practice.
48326320|NCT03490435|DIAGNOSTIC_TEST|Tests for diagnosis of intestinal parasitic diseases|"Feces testing:~1. fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~2. A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)"
48326321|NCT02292992|DEVICE|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
48326322|NCT03444194|PROCEDURE|liver biopsy|Liver biopsy of neoplastic tissue and normal liver tissue.
48326323|NCT06435182|DRUG|OT202 conc 0.5%|Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
48326324|NCT06435182|DRUG|OT202 conc 0.1%|Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
48489807|NCT06354491|DEVICE|Ultrasound (US)|In each ultrasound exam, each participant will be scanned by two sonographers to evaluate inter-operator variability. Each exam will take approximately 60 minutes to complete. The imaging series will be conducted twice to assess repeatability.
48326325|NCT06435182|DRUG|Placebo|Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
48326326|NCT03404518|DRUG|Norco|Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
48489808|NCT00345735|DRUG|Fentanyl|
48326327|NCT03404518|DRUG|Ibuprofen|Ibuprofen as first line therapy every 6 hours as needed for pain control
48489809|NCT04859036|DIAGNOSTIC_TEST|24 hours ambulatory Holter monitoring|
48489810|NCT05796063|DIAGNOSTIC_TEST|gastric point of care ultrasound|Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
48326328|NCT06048926|DRUG|Carrelizumab|200 mg/time, iv, Q3W
48326329|NCT06048926|DRUG|Paclitaxel injection|50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
48326330|NCT06048926|DRUG|Cisplatin|25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
48326331|NCT06048926|RADIATION|Concurrent chemoradiotherapy|Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
48326332|NCT05518799|DRUG|Midazolam|Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
48326333|NCT01089829|OTHER|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
48340148|NCT03354572|DRUG|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
48340149|NCT03354572|DRUG|Placebos|saline 0.9% prior to surgery
48326334|NCT04485234|DIAGNOSTIC_TEST|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance|Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
48326335|NCT05121909|OTHER|Colgate (R) Cavity Protection Toothpaste|Participants will use Colgate (R) Cavity Protection Toothpaste for brushing teeth twice daily.
48326336|NCT05121909|DEVICE|Colgate (R) Cello Toothbrush|Participants will use Colgate (R) Cello Toothbrush for brushing teeth twice daily.
47971954|NCT05512845|PROCEDURE|Double Factor technique|"The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery."
48120643|NCT05780528|OTHER|instrumented assisted soft tissue mobilization|the participant will receive instrumented assisted soft tissue mobilization. The participant's elbow will rest on a table. A lubricant (Vaseline) will be applied to the skin around the elbow prior to treatment and the blade will be cleaned with an alcohol pad. First, the blade will be used to find the exact areas of restriction in the common extensor origin. Then the M2T blade will be used in the treatment planes 1, 2, and 3, to apply slow strokes along the muscle, without causing any discomfort or pain, from the muscle origin to its insertion (sweeping technique)
48120644|NCT05780528|OTHER|conventional treatment|the patients will receive conventional treatment in the form of Ultrasound therapy, conventional transcutaneous electrical nerve stimulation (TENS) - hot pack - stretching and strengthening exercises and wrist rest splints
48120645|NCT06473090|OTHER|Video group|"Participants will watch a 15-minute educational video at the beginning of the session before their involvement in the 2 high-fidelity simulation scenarios.~The educational video used was developed by experts (in Human Factors and Obstetric Anesthesia) and validated by SFAR and CARO. It depicts poor use of NTS (including CLC) during a maternal cardiac arrest anesthesia scenario and then proper use of NTS during the same scenario."
48120646|NCT06473090|OTHER|Text group|"Participants will read a text-type educational support for 15 minutes at the beginning of the session before their involvement in 2 high-fidelity crisis simulation scenarios.~The text-type educational support, written in French by the same team of experts, covers all the NTS mentioned in the video and has already been used in a previous study"
48120647|NCT02238210|DRUG|Atrovent®|
48326337|NCT05121909|OTHER|Prototype 1 Mouthwash|Participants will use 20 mL of Prototype 1 Mouthwash for 30 seconds after brushing twice daily.
48326338|NCT05121909|OTHER|Prototype 2 Mouthwash|Participants will use 20 mL of Prototype 2 Mouthwash for 30 seconds after brushing twice daily.
48326339|NCT05121909|OTHER|Prototype 3 Mouthwash|Participants will use 20 mL of Prototype 3 Mouthwash for 30 seconds after brushing twice daily.
48326340|NCT05121909|OTHER|Listerine (R) Cool Mint (R) Antiseptic Mouthwash|Participants will use 20 mL of Listerine (R) Cool Mint (R) Antiseptic Mouthwash for 30 seconds after brushing twice daily.
48326341|NCT05121909|OTHER|5% Hydroalcohol Mouthwash|Participants will use 20 mL of 5% Hydroalcohol Mouthwash for 30 seconds after brushing twice daily.
48326342|NCT05549648|OTHER|Home oral excrise|The current study aimed to evaluate the efficacy and user experience of mobile phone APP, a mobile application with AI component in facial movement tracking, in improving oral functions of elderly people
48326343|NCT05821153|DRUG|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
48489811|NCT05312242|DIETARY_SUPPLEMENT|United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS|Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation
48649613|NCT04236947|BEHAVIORAL|SCPP-YA|SCPP-YA includes two modules. In the first module of ten sessions, students will learn to employ a 6-step social information processing framework for solving a wide range of real-life problems. The six-step process consists of 1) stop, clam down, and think before you act; 2) say the problem and how you feel; 3) set a positive goal; 4) think of many solutions; 5) think ahead to the consequences and 6) go ahead and try the best plan. The second module offers 1) current and accurate information about the health, social, and legal consequences of substance use, 2) correct mistaken beliefs that students have about substance use, 3) enhances awareness of social and media influences; and 4) teachers assertiveness and critical thinking skills to resist peer pressure.
48649614|NCT06042608|PROCEDURE|intercostobrachial nerve block|injection of local anesthetic to target the intercostobrachial nerve in the axilla
47971955|NCT03254836|OTHER|Standard of care|Elective radical surgery for adenocarcinoma.
47971956|NCT05038189|DIAGNOSTIC_TEST|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
47971957|NCT05038189|DIAGNOSTIC_TEST|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
47971958|NCT05038189|DIAGNOSTIC_TEST|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
48326344|NCT04906993|DRUG|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
48326345|NCT04906993|DRUG|platinum-based chemotherapy|Physician's choice chemotherapy
48326346|NCT02107430|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
48326347|NCT02107430|RADIATION|Standard radiotherapy|radiotherapy
48326348|NCT04464785|DEVICE|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
48340150|NCT06445010|OTHER|Creating Musical Playlist|Personal music playlist for therapeutic listening and sharing with other individuals in bereavement
48120648|NCT05710575|BIOLOGICAL|probiotic|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
48489812|NCT05312242|DIETARY_SUPPLEMENT|Iron Folic Acid Supplement|Standard of Care Intervention
48489813|NCT03407521|DRUG|Misoprostol|induction of abortion using misoprostol
48489814|NCT03407521|DRUG|isosorbide mononitrate|isosorbide mononitrate
48489815|NCT03407521|DRUG|Placebo|Placebo
48649615|NCT05882565|BEHAVIORAL|A brief (14-day) online mindfulness intervention|The content of the online mindfulness intervention is based on studies by Cavanagh et al. (2013, 2018). There is an approximately 10-minute audio tutorial that participants will listen to daily for 14 days. In the first week, participants will be instructed to apply their learned mindfulness skills to their daily activities. In the second week, they will continue practicing by learning to walk in a mindful manner.
48120649|NCT05710575|OTHER|placebo|Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
48120650|NCT06362278|OTHER|multi-omics studies|15cc peripheral venous blood will be collected for multi-omics studies, including whole-exome study, transcriptomics \& metabolomics studies.
48120651|NCT02058875|DRUG|Myfortic®|
48120652|NCT02058875|DRUG|Neoral®|
48120653|NCT02058875|DRUG|Cellcept®|
48120654|NCT02058875|DRUG|Prednisone|
48120655|NCT00975039|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
48120656|NCT02398617|OTHER|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
48120657|NCT00296036|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Given orally
48120658|NCT00296036|DRUG|urea/lactic acid-based topical cream|Applied topically
48120659|NCT00296036|OTHER|placebo|Given orally or applied topically
48120660|NCT06233500|PROCEDURE|pars plana vitrectomy|"All eyes in this study will be subjected to pars plana vitrectomy procedure with these main steps:~* 23 G trocar system will be used~* Posterior vitreous detachment will be induced with the aid of triamcinolone acetate injection, and core vitrectomy will be done~* Brilliant blue stain will be injected, and ILM forceps will be used for ILM peeling~Patients will be divided then into two groups:~Group A: Only wide ILM peeling up to the arcades well be done Group B: ILM peeling with flap well be done~* Shaving of the vitreous base, and then fluid air exchange~* SF 6 gas tamponade will be used"
48120661|NCT02429570|DRUG|Meclofenamate|
48649616|NCT05882565|BEHAVIORAL|Psychoeducation online|"The online psychoeducation was modified from the study by Harrer et al (2019, 2021).~This intervention consists of 14 audio tutorials about stress for 14 days, each lasting approximately 10 minutes. Additionally, there is a text version of each audio tutorial, which can be accessed by participants after listening to the audio."
48340151|NCT04716010|OTHER|Control|Participants will complete a shopping task in the online grocery store, and the products that contain red meat will not have warning labels or a 30% increase in price.
47971959|NCT05798832|OTHER|Virtually reality training group|BLS Training with VR
47971960|NCT05798832|OTHER|Traditional training group|BLS Training with Traditional
48489816|NCT05565339|DEVICE|PMEIs|"To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated."
48489817|NCT04063982|OTHER|none, only assessment at different time points|assessment at different time points
48489818|NCT00618930|DRUG|Moviprep®|use of Moviprep®
48489819|NCT00618930|DRUG|Fleet|Use of Fleet
48489820|NCT03602963|DEVICE|Dexcom G5 Mobile CGM system|The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
48489821|NCT03575871|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
48489822|NCT03575871|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
48489823|NCT03575871|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
48489824|NCT04252222|DEVICE|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
48489825|NCT03015727|DRUG|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
48489826|NCT03015727|DRUG|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
48649617|NCT03052608|DRUG|Lorlatinib|ALK-positive NSCL treatment
48489827|NCT03015727|RADIATION|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
47971961|NCT03719521|OTHER|Community-based package of integrated HIV, SRH and general health services|HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
47971962|NCT04344925|DEVICE|Aerosol-reducing Mask|Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
47971963|NCT04344925|DEVICE|Standard Mask|Patient will be put on BIPAP using the standard mask
47971964|NCT03470441|DRUG|FDY-5301|FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
47971965|NCT03470441|OTHER|Placebo|Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
47971966|NCT01512277|BIOLOGICAL|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
48489828|NCT03015727|DRUG|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
48649618|NCT03052608|DRUG|Crizotinib|ALK-positive NSCL treatment
48649619|NCT02565459|BIOLOGICAL|Mesenchymal Stromal Cells|
48649620|NCT03912428|DIAGNOSTIC_TEST|11C-MC1|PET radioligand for COX-2
48649621|NCT03912428|DRUG|Celecoxib|COX-2 inhibitor
48649622|NCT04137757|OTHER|Lower Body Negative Pressure|Lower body negative pressure will be applied.
47971967|NCT01126853|BIOLOGICAL|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
47971968|NCT02122250|BEHAVIORAL|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
47971969|NCT02122250|BEHAVIORAL|Static web-based materials|Static web-based materials
47971970|NCT01245660|DRUG|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
47971971|NCT03454776|DEVICE|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
48489829|NCT01829113|DRUG|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
48649623|NCT04137757|OTHER|Sham Pressure|Noise will be turned on but no pressure will be applied.
48649624|NCT06220318|DRUG|C019199|The C019199 will be taken orally, once a day
48649625|NCT06220318|DRUG|Sintilimab|Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
48489830|NCT01829113|DRUG|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
48489831|NCT05056883|DRUG|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
48649626|NCT03186183|BEHAVIORAL|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
48649627|NCT04592562|DEVICE|the Terumo Hydropearl® microspheres device|"Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch."
48649628|NCT02904096|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
48649629|NCT04139902|DRUG|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
48649630|NCT04139902|DRUG|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 300mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks for 6 doses (Cycles 5-10) for approximately 48 weeks."
48649631|NCT05846893|DEVICE|SeQuent® Please NEO drug-coated balloon catheter|Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
48649632|NCT05846893|DEVICE|Current-generation drug-eluting stent|Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
48649633|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Bolus)|IM in the deltoid
48649634|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
48489832|NCT05056883|DRUG|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
47971972|NCT03454776|DEVICE|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
48120662|NCT03858868|BEHAVIORAL|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
48120663|NCT03858868|BEHAVIORAL|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
48120664|NCT00224510|DRUG|lamotrigine|
48120665|NCT01761552|DRUG|Sugammadex Reversal|
48120666|NCT01761552|DRUG|Atropine/Neostigmine|
48326349|NCT04328233|BEHAVIORAL|Time-Restricted Eating|Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
48326350|NCT04700436|DRUG|Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)|"IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)"
48326351|NCT00442676|DRUG|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
48326352|NCT00442676|DRUG|Placebo|Gelatin capsules of lactose
48326353|NCT02443571|RADIATION|Fluciclovine (18F)|Not applicable. This is an observational study.
48326354|NCT00380276|DRUG|MPC-7869|800 mg BID Oral dosing
48120667|NCT04477330|OTHER|Transcranial direct current stimulation (tDCS)|1 mA tDCS
48120668|NCT04477330|OTHER|Ankle motor training|Visuomotor target tracking task
48120669|NCT04477330|BEHAVIORAL|High intensity interval speed based treadmill training (HIISTT)|Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
48120670|NCT01024881|PROCEDURE|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
48120671|NCT01024881|PROCEDURE|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
48120672|NCT05233007|PROCEDURE|Minor endoscopic biopsy|As per standard of care
48120673|NCT00563446|DRUG|Darbepoetin alfa|
48326355|NCT02652312|DRUG|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
48326356|NCT02652312|DRUG|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
48326357|NCT02652312|PROCEDURE|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
48326358|NCT02652312|PROCEDURE|fentanyl|1.5 μg/kg intraoperative
48326359|NCT02652312|PROCEDURE|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
48326360|NCT02652312|PROCEDURE|Atracurium|0.5 mg/kg IV for endotracheal intubation
48326361|NCT02652312|PROCEDURE|diclofenac sodium|1 mg/kg for postoperative analgesia
48326362|NCT02652312|PROCEDURE|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
48120674|NCT03797924|DRUG|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
48120675|NCT03797924|BEHAVIORAL|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
48120676|NCT03421678|DIAGNOSTIC_TEST|Urine Sample|One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
48120677|NCT00539734|DRUG|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
47971973|NCT04239144|PROCEDURE|Bilateral sympathectomy|Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
47971974|NCT04239144|PROCEDURE|Catheter ablation|Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
48120678|NCT02497716|DRUG|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
48120679|NCT01832467|DRUG|cetuximab-containing chemotherapy|
48120680|NCT03995498|OTHER|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
48120681|NCT03995498|OTHER|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
48120682|NCT03995498|OTHER|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
48326363|NCT01762306|DRUG|Diclofenac Potassium|
48326364|NCT01762306|DRUG|Folic Acid|
48326365|NCT03615118|OTHER|IVR/SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale; An automated phone system for monitoring and improving self-care and health outcomes
48326366|NCT03615118|OTHER|SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale
48326367|NCT01530282|OTHER|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
48120683|NCT04279548|DEVICE|Deep Brain Stimulation|Patients will have a stimulation electrode inserted neurosurgically by neuronavigation to the PSI, on the target used for drTMS, on the insula contralateral to the pain side. After surgery will be randomized to be in in either the ON or OFF DBS
48120684|NCT05204394|DRUG|VM-1500A-LAI|Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
48120685|NCT05204394|OTHER|Standard of Care|Any oral 1st line approved HIV treatment regimen
48120686|NCT04902378|DEVICE|Tandem t:slim X2 insulin pump with Control IQ technology|The intervention group will be fitted with the Tandem t:slim X2 insulin pump with Control IQ technology during pregnancy.
48120687|NCT05763524|PROCEDURE|Adrenalectomy with or without lymphadenectomy|Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
48120688|NCT01820182|DEVICE|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
48120689|NCT00194896|DRUG|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
48120690|NCT00194896|DRUG|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
48120691|NCT03212079|BEHAVIORAL|Mycoach Smart Text|Personalized text messages to you cellphone to help you become more active
48120692|NCT03212079|BEHAVIORAL|MyCoach on Amazon Alexa|This is an intelligent voice that you can communicate with via Amazon echo speaker
48120693|NCT03811587|OTHER|Fasting Mimicking diet|The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
48120694|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
48120695|NCT03425552|DRUG|Paliperidone|Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
48326368|NCT01530282|OTHER|Non invasive method|Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
48326369|NCT03173482|OTHER|questionnaire|asking about details of indication of cesarean section
48326370|NCT00165061|PROCEDURE|Esophagectomy|
48120696|NCT01850511|PROCEDURE|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
48120697|NCT01850511|DRUG|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
48120698|NCT04049435|DEVICE|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
48120699|NCT00006368|RADIATION|yttrium Y 90-edotreotide|
48120700|NCT06223048|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
48120701|NCT05199142|DRUG|SDI-118|SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
47971975|NCT03761160|OTHER|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
47971976|NCT03761160|OTHER|Usual care|Usual care per hospital guidelines
47971977|NCT04645875|OTHER|Sit regimen|See Sit regimen arm description
47971978|NCT04645875|OTHER|SitLess regimen|See SitLess regimen arm description
47971979|NCT05505682|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
47971980|NCT01728064|DRUG|Placebo|Placebo capsules
47971981|NCT01728064|DRUG|EPI-743 400 mg|
47971982|NCT01728064|DRUG|EPI-743 200 mg|
47971983|NCT03130257|DIAGNOSTIC_TEST|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
47971984|NCT03130257|DIAGNOSTIC_TEST|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
47971985|NCT03130257|DIAGNOSTIC_TEST|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
47971986|NCT03130257|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
48326371|NCT00165061|PROCEDURE|Chemoradiation|
47971987|NCT02967835|BEHAVIORAL|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
47971988|NCT01948947|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
47971989|NCT01948947|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
47971990|NCT05925660|DIAGNOSTIC_TEST|Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)|Mucorales PCR screening twice weekly during hospitalisation
47971991|NCT05780385|DEVICE|nasotracheal intubation|patients requiring tracheal intubation receive nasotracheal intubation
47971992|NCT05780385|DEVICE|orotracheal intubation|patients requiring tracheal intubation receive orotracheal intubation
47971993|NCT05926102|GENETIC|Precision screening intervention|The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
47971994|NCT05926102|OTHER|Usual care|Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
48120702|NCT05199142|DRUG|Placebo|The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
48120703|NCT00035971|DRUG|raloxifene HCI and alendronate Na|
48120704|NCT04544904|DEVICE|PAARx|Prescription Physical Activity Programming Application
48120705|NCT04544904|DEVICE|JM|Joint Management (JM) web-based joint management resource.
48120706|NCT01524952|DEVICE|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
48120707|NCT00158769|DRUG|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
48120708|NCT03036813|DRUG|voxelotor|
48120709|NCT03036813|OTHER|Placebo|
48120710|NCT04243980|DEVICE|Short anatomical femoral stem in THR|Patients with osteoarthritis after total hip arthroplasty
48120711|NCT02810184|RADIATION|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
48120712|NCT04358939|OTHER|Prone decubitus|According to the tolerance, the objective is to spend as much time as possible, up to 16 hours and beyond in prone position every 24 hours. At least two sessions of at least 30 minutes each must be performed daily.
48120713|NCT04231721|DEVICE|High Resolution Colonic Manometry and 3D-Transit system|Measurement of colonic pressure changes and passage patterns in healthy.
48120714|NCT00240149|DRUG|Regular Insulin via Insulin-Glucose Algorithm|
48120715|NCT06307301|DRUG|Abatacept Injection [Orencia] and Proleukin (aldesleukin)|Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
48120716|NCT03922061|BIOLOGICAL|dmLT|double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
48120717|NCT03922061|BIOLOGICAL|fIPV|fractional-dose inactived polio vaccine
48120718|NCT00143949|DRUG|enalapril|
48326372|NCT02950012|DIETARY_SUPPLEMENT|OPTI-BIOME™ Bacillus subtilis MB40|
48120719|NCT00143949|DRUG|losartan|
48120720|NCT01771731|DRUG|Cannabis|
48649635|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Bolus)|SC in the upper arm
47971995|NCT06498154|RADIATION|Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy|Neoadjuvant radiotherapy: whole-breast irradiation ( 50 Gy in 25 fractions) plus a mandatory boost (14 Gy in seven fractions, which began on the day following completion of whole-breast irradiation) TCb (HP) \* : Triple negative patients will receive TCb regimens with or without immunotherapy and HER2 positive patients will receive TCb(HP) regimens.
48326373|NCT02950012|OTHER|Placebo|
48326374|NCT04402346|PROCEDURE|Radiofrequency-assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
48326375|NCT04402346|PROCEDURE|Stapler assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
48326376|NCT02603354|DRUG|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
48649636|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
48120721|NCT02002052|DRUG|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
48120722|NCT02002052|RADIATION|Standard Radiotherapy, 60 Gy in 30 fractions.|
48120723|NCT02002052|RADIATION|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
48120724|NCT05773313|BEHAVIORAL|The Open Table|An organization that connects community volunteers to individuals in need to help overcome life's challenges.
48120725|NCT03793361|DRUG|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
48120726|NCT03793361|DRUG|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
48649637|NCT06033209|BIOLOGICAL|SMNP (IM, Bolus)|IM in the deltoid
48649638|NCT06033209|BIOLOGICAL|SMNP (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
48649639|NCT06033209|BIOLOGICAL|SMNP (SC, Bolus)|SC in the upper arm
48649640|NCT06033209|BIOLOGICAL|SMNP (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
48649641|NCT00251654|PROCEDURE|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
48649642|NCT01713244|PROCEDURE|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
48649643|NCT01713244|PROCEDURE|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
48120727|NCT00589667|DRUG|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
48649644|NCT01019057|PROCEDURE|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
48649645|NCT06295588|DIETARY_SUPPLEMENT|Fucoidan extracted from F. Vesiculosus|4 g daily
48649646|NCT06295588|DIETARY_SUPPLEMENT|Fucoidan extracted from U. Pinnatifida|4 g daily
48489833|NCT06168435|OTHER|eIMPAQc|e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
48649647|NCT05051436|DRUG|Mirabegron 50 MG|Mirabegron 50 mg/day will be administered for 14 weeks.
48649648|NCT05051436|DRUG|Tadalafil 10 MG|Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
48649649|NCT05051436|DRUG|Placebo|Placebo will be administered for 14 weeks after baseline procedures.
48649650|NCT03325855|OTHER|None - Observational|None - Observational
48649651|NCT01800110|DIETARY_SUPPLEMENT|pomegranate juice|
48120728|NCT01122901|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
48120729|NCT01122901|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48120730|NCT01122901|OTHER|pharmacological study|Correlative studies
48120731|NCT01122901|OTHER|laboratory biomarker analysis|Correlative studies
48120732|NCT03674034|OTHER|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
48120733|NCT01747486|BIOLOGICAL|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
48489834|NCT01921621|BEHAVIORAL|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
48489835|NCT01921621|BEHAVIORAL|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
48649652|NCT03141970|DRUG|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
48649653|NCT06675409|OTHER|Education|The effectiveness of two different training methods with virtual patients for improving the critical decision-making skills of paramedic students will be compared between two groups: one receiving expert-guided training and the other following a self-directed approach
48649654|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) food introduction-1st|1 serving size of food proven to induce histologic and clinical symptoms in EoE
48649655|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (E0E) food introduction-2nd|Either 1 serving size of different food (not food in arm 1) to induce histologic and clinical symptoms in EoE or Increase the food in arm 1 to 2 serving size a day
48649656|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) Food introduction-3rd dose|Either 1 serving size of different food (not food in arm 1 or 2) to induce histologic and clinical symptoms in EoE or Increase the food in arm 2 to 2 serving size a day or unlimited amounts of food arm 1
48649657|NCT05247866|DRUG|Dupilumab|"All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W"
48649658|NCT00812539|OTHER|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
48120734|NCT05623163|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (up to 5 sutures) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
48120735|NCT00155415|BEHAVIORAL|Different timing of taking polyethylene glycol(PEG)|
48120736|NCT01424670|DRUG|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
48120737|NCT01424670|DRUG|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
48649659|NCT00812539|OTHER|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
48120738|NCT04821219|OTHER|Treatment prediction PDT platform|PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
48120739|NCT03674047|DRUG|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
48489836|NCT06312514|BEHAVIORAL|LAFIYA|The Lafiya intervention is a comprehensive program designed to address the intersectional stigma and discrimination challenges faced by marginalized communities, particularly among Gay, Bisexual, and other Men who have Sex with Men (GBMSM). It aims to enhance HIV prevention, care, and treatment outcomes, with a focus on increasing HIV self-testing (HIVST) uptake among these key populations in Ghanaian urban slum settings.
48649660|NCT00730600|PROCEDURE|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
48649661|NCT03107299|OTHER|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
48649662|NCT01988558|DRUG|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
47971996|NCT04305262|DEVICE|Wireless continuous vital parameter monitoring|The patients included in this study will have continuous, wireless monitoring of vital parameters during the first four days of acute admission
47971997|NCT03623815|OTHER|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
47971998|NCT02130570|OTHER|Multi-Model Intensive Discharge Intervention|"1. Inpatient medication safety interventions~2. Inpatient discharge advocate~3. Structured visiting nurse (VNA) appointments~4. Post-discharge phone call by primary care personnel within 2 business days of discharge~5. Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~6. Improved communication between inpatient and primary care teams~7. High-risk patients will receive additional interventions as needed:~   1. Home pharmacist visit~  2. Enrollment in the Partners integrated Care Management Program (iCMP)~  3. Enrollment in telemedicine programs for patients with CHF~  4. Palliative care consultation regarding goals of care~8. Novel health information technology to facilitate communication and transfer of clinical information"
47971999|NCT04436120|PROCEDURE|De novo tumor tissue biopsy|De novo tissue biopsy performed following disease progression
47972000|NCT04436120|PROCEDURE|Research blood draws|Blood biospecimens collected following disease progression
47972001|NCT02974517|DEVICE|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
47972002|NCT03602183|DEVICE|Macintosh laryngoscope|intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
47972003|NCT03602183|DEVICE|Miller laryngoscope|intubation will be performed using Miller laryngoscope
47972004|NCT03602183|DEVICE|McGrath MAC EMS|intubation will be performed using McGrath MAC EMS video - laryngoscope
47972005|NCT03602183|DEVICE|GlideScope|intubation will be performed using GlideScope video - laryngoscope
47972006|NCT04234191|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
47972007|NCT04234191|DRUG|Hydromorphone|Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
48489837|NCT02660528|DRUG|Tocilizumab|Subcutaneous tocilizumab
48489838|NCT03725865|BIOLOGICAL|Induction of neural stem cells|Brain injection iNSC
48489839|NCT01762826|DIETARY_SUPPLEMENT|Myo-inositol|Dietary control plus Myo-inositol
48489840|NCT01762826|DIETARY_SUPPLEMENT|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
48489841|NCT01762826|DIETARY_SUPPLEMENT|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
48489842|NCT01762826|DIETARY_SUPPLEMENT|Placebo|Dietary control plus folic acid 400 mcg daily
48489843|NCT05982730|BEHAVIORAL|Sensory-Augmented Postural Training|To examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control and to assess the effectiveness of postural training using Segway
48489844|NCT02876926|BEHAVIORAL|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
48649663|NCT01988558|DIETARY_SUPPLEMENT|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
48649664|NCT03638180|DRUG|BLU-5937|BLU-5937 oral tablet
48649665|NCT03638180|DRUG|Placebo|Matching placebo to BLU-5937
48649666|NCT04228731|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
48649667|NCT04228731|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
48649668|NCT02890160|DEVICE|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
48649669|NCT02890160|DEVICE|XIENCE|Everolimus Eluting Coronary Stent System
48649670|NCT00608790|DRUG|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
48649671|NCT00608790|DRUG|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
48649672|NCT04225117|DRUG|enfortumab vedotin|intravenous (IV) infusion
47972008|NCT03657511|BEHAVIORAL|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
48649673|NCT04225117|DRUG|pembrolizumab|IV infusion
48649674|NCT06332755|DRUG|LB-LR1109|intravenous administration
48649675|NCT02113280|PROCEDURE|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
47972009|NCT01083368|DRUG|temsirolimus|Given IV
47972010|NCT01083368|BIOLOGICAL|bevacizumab|Given IV
47972011|NCT01083368|GENETIC|polymorphism analysis|Correlative studies
47972012|NCT01083368|OTHER|laboratory biomarker analysis|Correlative studies
47972013|NCT03471130|DRUG|MT-8554 Low dose|Oral, 7 days
47972014|NCT03471130|DRUG|MT-8554 High dose|Oral, 7 days
47972015|NCT03471130|DRUG|Placebo|Oral, 7 days
47972016|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (high)|High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
47972017|NCT03956732|DIETARY_SUPPLEMENT|Vitamin D|One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
47972018|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (medium)|Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
47972019|NCT05731895|DRUG|BI 425809 (iclepertin)|BI 425809 (iclepertin)
47972020|NCT00965042|DRUG|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
48489845|NCT02876926|BEHAVIORAL|Home-based testing only|A standard home-based HIV test kit.
48489846|NCT02876926|BEHAVIORAL|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
48489847|NCT01463436|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
48489848|NCT01463436|DIETARY_SUPPLEMENT|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
48649676|NCT02113280|PROCEDURE|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
48649677|NCT06563752|OTHER|Participants will use 3D glasses to view VR educational information|"Participants will use 3D glasses to view VR educational information, which includes:~1. Understanding of psychiatric symptoms, including symptoms, disease course, treatment, and prognosis.~2. Knowledge about medications, their relationship with symptom stabilization, and handling of side effects.~3. Schizophrenia as a chronic illness, with analogies to other chronic diseases.~4. Signs of disease relapse.~5. How to manage ongoing psychiatric symptoms of schizophrenia, including delusions, hallucinations, paranoia, and negative symptoms.~6. Strategies for interacting and communicating with patients.~7. Stress management and adjustment, as well as suicide prevention.~8. Available resources."
48649678|NCT06563752|OTHER|routine care|Before discharge, provide routine discharge preparation instructions and offer a disease education booklet with relevant health information. Follow up with two phone calls after discharge, on the 7th and 30th days.
48649679|NCT05960435|OTHER|Proprioceptive Neuromuscular Facilitation|PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
48489849|NCT03476343|DEVICE|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
47972021|NCT05831020|OTHER|VAC and bolster dressing|"Bolster dressing- Moist bulky cotton gauze dressing and wrapped with cotton bandage.~Vacuum assisted closure (VAC) dressing- A fenestrated tube placed between two sheets of sterilized foam secured to the surrounding skin using adhesive dressing (OPSITE)."
48120740|NCT02045459|BEHAVIORAL|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
48120741|NCT04348617|OTHER|Moderate exercise|50 minutes of moderate exercise on treadmill
48489850|NCT04719234|DEVICE|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
47972022|NCT03274128|RADIATION|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
47972023|NCT03274128|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
47972024|NCT04767932|BEHAVIORAL|vibration machine|Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
47972025|NCT01307397|DRUG|Vemurafenib|Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
47972026|NCT01730469|DRUG|AT1001 150 mg|AT1001 150mg is available as a capsule
47972027|NCT02777801|DRUG|Entecavir|anti-HBV
47972028|NCT03630952|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
47972029|NCT03630952|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
47972030|NCT03630952|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
47972031|NCT01280175|PROCEDURE|charcoal block|
47972032|NCT01280175|DEVICE|Aerochamber Plus spacer|
48120742|NCT04348617|OTHER|Rest|50 minutes of rest or sedentary activity
48120743|NCT00441636|DEVICE|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
47972033|NCT01280175|DRUG|pMDI standard actuator|
48120744|NCT01232712|BIOLOGICAL|ImMucin, hGM-CSF|"* Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~* After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~* In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
48120745|NCT05731999|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
48120746|NCT05911581|OTHER|intra-arterial flushing|"The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air"
48120747|NCT05911581|OTHER|intra-arterial flushing|Intra-arterial flushing with heparinized fluid at patient body temperature
48120748|NCT04968756|DEVICE|Selective retina therapy SPECTRALIS CENTAURUS device|Microsecond laser microsurgery by using the SPECTRALIS CENTAURUS device
48120749|NCT04574349|PROCEDURE|Decompressive craniectomy|Removing part of the skull (bone flap) to lower intracranial pressure
48340152|NCT04716010|OTHER|Warning Labels|While completing the shopping task in the online grocery store, the health and environmental warning labels will appear next to the image of every product that contains red meat.
48340153|NCT04716010|OTHER|Tax|While completing the shopping task in the online grocery store, all products containing red meat will have a 30% increase in price.
48489851|NCT06299852|DRUG|Trastuzumab emtansine|SRT for metastatic foci
48649680|NCT05960435|OTHER|Control Group Exercise|The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
48649681|NCT04667962|OTHER|Online questionnaire|Participants will have to complete 3 online self-questionnaires: the first one at enrollment, the second one 1 month after enrollment (M1) and the third one 3 months after enrollment (M3). Each questionnaire will take an estimated 20 minutes to complete.
48489852|NCT04583020|DRUG|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
48489853|NCT04583020|RADIATION|radiation|60Gy/30
47972034|NCT05139589|OTHER|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
48120750|NCT05203861|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
48120751|NCT05203861|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
48649682|NCT01436890|DRUG|Revamilast|Tablet. Low dose, Once daily for 12 weeks
48649683|NCT01436890|DRUG|Revamilast|Medium dose, Once daily for 12 weeks
48649684|NCT01436890|DRUG|Revamilast|High dose, Once daily for 12 weeks
47972035|NCT03119584|DRUG|linaclotide or placebo|
47972036|NCT04822454|OTHER|Night shift shadowing program|Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
47972037|NCT03240302|DEVICE|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
47972038|NCT03240302|DEVICE|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
47972039|NCT00768157|DRUG|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
47972040|NCT00768157|PROCEDURE|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
47972041|NCT01942330|PROCEDURE|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
47972042|NCT03871712|BEHAVIORAL|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
47972043|NCT03871712|BEHAVIORAL|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
47972044|NCT03947372|PROCEDURE|Appendectomy|removal of acutely inflamed appendix
48649685|NCT01436890|DRUG|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
47972045|NCT05961085|PROCEDURE|Adductor Canal Catheter|Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
47972046|NCT00885430|DRUG|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
47972047|NCT02071914|DRUG|CT-P27|Influenza A treatment drug.
47972048|NCT02071914|DRUG|Placebo|Placebo.
47972049|NCT02155062|OTHER|Whole grain rye|
47972050|NCT02155062|OTHER|Whole grain wheat|
47972051|NCT02155062|OTHER|Refined cereal|
47972052|NCT05264935|PROCEDURE|Ultrasound-Guided Puncture and Lavage (UGPL)|After local anaesthesia with rapidocain the calcific deposit of the rotator cuff will be punctured and washed out with saline solution.
48120752|NCT02906891|DEVICE|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
48120753|NCT04307199|PROCEDURE|Amniotic membrane sweep|Amniotic membrane sweeping is defined as the manual detachment of the inferior pole of the amniotic membranes from the lower uterine segment. This is performed with consent by a clinician digitally through a circular motion during a vaginal examination. If the cervical os is closed massage of the cervix will be accepted.
48120754|NCT03930121|OTHER|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
48489854|NCT04583020|DRUG|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
48649686|NCT02487329|OTHER|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
48649687|NCT02487329|OTHER|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
48649688|NCT02487329|OTHER|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
48649689|NCT02487329|OTHER|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
48326377|NCT05613842|DRUG|Copper-64 labelled SAR-Bombesin|radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
48326378|NCT05426369|BIOLOGICAL|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)
47972053|NCT02302820|OTHER|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
47972054|NCT05677724|DIAGNOSTIC_TEST|HBV DNA Sequencing|"Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed."
48120755|NCT05843708|DRUG|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
48120756|NCT05843708|DRUG|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
48120757|NCT05843708|DRUG|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
48120758|NCT00253110|DRUG|risperidone|
48120759|NCT00253110|DRUG|haloperidol|
48120760|NCT04771793|BEHAVIORAL|new physical restraint protocols|new physical restraint protocols
48120761|NCT05342818|DRUG|Neostigmine|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
48326379|NCT04489927|DEVICE|Tcore|Temperature Measurement of standard care versus the Tcore measurement
48340154|NCT04716010|OTHER|Combined Warning Labels and Tax|While completing the shopping task in the online grocery store, all products containing red meat will have the health and environmental warning labels appear next to the product image and a 30% increase in price.
48489855|NCT06127914|BEHAVIORAL|Learning Early Infant Feeding Cues|"The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods."
47972055|NCT06177730|OTHER|Pre-Hospital ECPR|Implementation of pre-Hospital ECPr in OHCA
47972056|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
47972057|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
47972058|NCT02272595|OTHER|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
47972059|NCT02272595|OTHER|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
47972060|NCT02835924|DRUG|Regorafenib|
48120762|NCT05342818|DRUG|Ondansetron 8mg|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
48120763|NCT05342818|DRUG|Metoclopramide Injection|will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs
48120764|NCT05342818|OTHER|Enteral feeding nutrition|The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position
48120765|NCT05342818|OTHER|Sequential Organ Failure Assessment (SOFA) score|SOFA score will be performed on all patients before the beginning of the study
48120766|NCT03817060|PROCEDURE|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
48340155|NCT02668952|DRUG|0.9% Normal Saline (0.9% Sodium Chloride) injection|
48340156|NCT02668952|DRUG|Isolyte S injection|
48489856|NCT00121147|DRUG|Travatan|
48489857|NCT00121147|DRUG|Azopt|
48120767|NCT03817060|PROCEDURE|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
48120768|NCT01062087|DRUG|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
48120769|NCT05511428|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
48120770|NCT05511428|OTHER|Questionnaire Administration|Ancillary studies
48120771|NCT05511428|OTHER|Quality-of-Life Assessment|Ancillary studies
48120772|NCT05511428|OTHER|Interview|Ancillary studies
48120773|NCT02806934|PROCEDURE|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
48489858|NCT00121147|DRUG|Alphagan P|
48649690|NCT06211218|DIAGNOSTIC_TEST|Cornea diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose cornea diseases from slit-lamp images.
48120774|NCT04329130|DRUG|Chidamide, Lenalidomide|All patients enrolled in the study will accept Chidamide combination with lenalidomide regimen.
48120775|NCT00125645|DRUG|Irbesartan Oral Tablet|
48120776|NCT05496777|PROCEDURE|Home-based prehabilitation program|The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
48120777|NCT06108778|DEVICE|MRI|Investigations as CT,MRI.serum ammonia and lactate
48120778|NCT02297061|BIOLOGICAL|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
48120779|NCT00944372|DRUG|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
48120780|NCT06154746|DIAGNOSTIC_TEST|slit lamb & OCT|"1. The Slit lamb is a biomicroscope. It emits a beam of light that can be varied in height and width. It allows visualization of the anterior segment of the eye. With auxiliary lenses, the examiner can also view the posterior segment. These lenses are simple, affordable, and portable. Although high-end devices like fundus cameras and optical coherence tomography have revolutionized how practitioners detect eye diseases, they can never replace these handheld lenses.~2. OCT is a noninvasive method that yields a cross-section image of the retina by exposing the eye to near-infrared light. Specifically, an emitted light beam is scattered and reflected back by the retinal surface as well as its different layers."
48120781|NCT06397144|DRUG|Paxlovid|Reference 1
48120782|NCT06397144|DRUG|Paxlovid|Reference 2
48120783|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 1
48120784|NCT06397144|DRUG|Nirmatrelvir/ritonavir|Test 2
48120785|NCT06514027|DRUG|BEBT-109 Capsules|BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.
48120786|NCT06514027|DRUG|Pemetrexed Disodium for Injection|Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.
48120787|NCT06514027|DRUG|Carboplatin Injection|Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
48120788|NCT06514027|DRUG|Cisplatin Injection|Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
48120789|NCT01587053|OTHER|therapeutic education program|
48120790|NCT06314763|DRUG|Rivaroxaban 20mg|Single dose on day 1 and day 16
48120791|NCT06314763|DRUG|Sotorasib 960mg|Daily dose from day 3 till day 16
48326380|NCT06202209|PROCEDURE|Circumferential Pulmonary Vein Isolation|Circumferential pulmonary vein isolation (CPVI) is a type of cardiac ablation procedure. Cardiac ablation procedures involve creating small scars in the heart using thermal or cold energy to block irregular electrical signals and restore normal heart rhythm. CPVI specifically creates small scars in the area where the four pulmonary veins connect to the left atrium of the heart. The pulmonary veins carry oxygen-rich blood from the lungs to the heart.
48120792|NCT04618757|BEHAVIORAL|Hedonic Reward|A reimbursement credit for hedonic expenses worth up to $50 will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
48120793|NCT04618757|BEHAVIORAL|Cash Reward|A reimbursement credit for $50 in cash will be awarded to each participant if they log at least 10,000 daily steps on at least 25 days during the first 28 days of each calendar month on Fitbit activity trackers provided by the study.
48120794|NCT04618757|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
48120795|NCT01760564|DRUG|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
48120796|NCT01641198|DEVICE|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
48326381|NCT00735085|DRUG|SLV334|1000mg SLV334 as a single dose
48326382|NCT00735085|DRUG|SLV334|1000mg SLV334 b.i.d. for one day
48326383|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for one day
48489859|NCT03580291|OTHER|Mesenchymal stem cells|The group receive pulse infusion of MSCs once of 2 x 10\^6/kg body weight
48489860|NCT03580291|DRUG|Mycophenolate Mofetil|This group receive oral MMF of 2.0 g / d.
48489861|NCT03580291|OTHER|Placebo of Mesenchymal stem cells|The group receive placebo of Mesenchymal stem cells.
48120797|NCT01641198|DEVICE|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
48120798|NCT01641198|DEVICE|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
48120799|NCT02655458|DRUG|Elotuzumab|"The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
48120800|NCT02655458|DRUG|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
48489862|NCT03580291|DRUG|Placebo of Mycophenolate Mofetil|The group receive placebo of oral mycophenolate mofetil.
48649691|NCT06003647|OTHER|Educational Intervention|Educational module and video
48649692|NCT06257420|DRUG|Rapamycin|Once weekly oral rapamycin
48649693|NCT04369105|OTHER|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
48120801|NCT02655458|OTHER|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
48120802|NCT02655458|OTHER|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
48120803|NCT05511766|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
48120804|NCT05511766|DRUG|Atorvastatin 20mg|is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties
48120805|NCT05511766|DRUG|Placebo|not containing drugs
48489863|NCT04850248|OTHER|no intervention, this is an observational study|no intervention, this is an observational study
48489864|NCT06072495|OTHER|real time MRI|ubjects will be scanned in the supine position using ACHIEVA 3T TX DStream Philips® and a 33 channels head and neck coil. An elastic strap will be fixed to the forehead to limits movement during scan. Headset will be used to cancel the loud MRI noise and to communicate with the subjects
47972061|NCT00751270|BIOLOGICAL|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
47972062|NCT00751270|DRUG|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
47972063|NCT02067871|OTHER|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
47972064|NCT02067871|OTHER|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
47972065|NCT01362205|DRUG|Dexmedetomidine|
47972066|NCT01362205|DRUG|Placebos|Inactive placebo (normal saline)
47972067|NCT06077591|OTHER|Patient-Derived Tumor Organoids|Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
47972068|NCT03844646|DEVICE|CGM|Intermittent use of a continuous glucose monitor (CGM)
47972069|NCT03844646|OTHER|Dietitian|Monthly meetings with a dietitian
47972070|NCT02139111|DRUG|Placebo|Oral placebo capsule
47972071|NCT02139111|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
47972072|NCT02139111|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
47972073|NCT02139111|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
47972074|NCT02139111|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
47972075|NCT04144205|OTHER|Change of the fraction of inspired oxygen|"After the stabilization of cardiopulmonary bypass, in the first half of patients, fraction of inspired oxygen would be set at 0.5 and maintained for 5 minutes (T0), then it would be changed to 1.0 and maintained for 5 minutes (T1). Again, fraction of inspired oxygen would be resumed to be 0.5 and maintained for 5 minutes (T2).~In the other half of patients, the direction of change in fraction of inspired oxygen will be reversed as follows. It will be set at 1.0 and maintained for 5 minutes (T0), then changed to 0.5 and maintained for 5 minutes (T1), and finally to 1.0 and maintained for 5 minutes (T2)."
47972076|NCT03775655|DRUG|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
47972077|NCT05803005|OTHER|inflammatory marker in autism spectrum disorder|Evaluate some Inflammatory markers \[IL-6, IL-8, TNF_alpha\] in children with autism spectrum disorder
47972078|NCT02373852|DEVICE|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
47972079|NCT00461045|DRUG|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
47972080|NCT02268604|DRUG|BIIB 722 CL|
47972081|NCT02268604|DRUG|Placebo|
48120806|NCT00413257|DRUG|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
47972082|NCT03637114|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
47972083|NCT03637114|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
47972084|NCT00436683|DRUG|Fermagate|Film coated tablet 500mg
47972085|NCT00436683|DRUG|Sevelamer HCl|tablet 800mg
47972086|NCT02888886|OTHER|Questionnaires about food habits and tobacco|
47972087|NCT02888886|OTHER|Spirometry|
47972088|NCT02888886|OTHER|Carotid echography|
47972089|NCT02888886|OTHER|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
48120807|NCT00413257|DRUG|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
48120808|NCT00413257|DRUG|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
48326384|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for three days
48326385|NCT00735085|DRUG|Placebo|SLV334 Placebo arm
48326386|NCT04665414|DIAGNOSTIC_TEST|MRI|preoperative MRI
48326387|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound|preoperative transvaginal ultrasound
48326388|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
48326389|NCT01279304|RADIATION|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
48340157|NCT04770298|OTHER|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
47972090|NCT06012825|BEHAVIORAL|Physical Activity|"The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min)."
48120809|NCT05083702|PROCEDURE|Fluoroscopy-guided superior hypogastric plexus block transdiscal approach|Patient lies prone, L5-S1 interspace identified under fluoroscopy, the skin is prepared and sterile drapes are placed after local anesthetic infiltration of the skin the subcutaneous tissue with 2% lidocaine a 20 guage, 15 cm needle with short bevel is inserted at the center of L5- S1 interlaminar space under anteroposterior fluoroscopic vision. The needle is then advanced toward the intervertebral disc. After confirmation, the needle is advanced through the intervertebral disc until it exists at its anterior surface confirmed by administration of 4 ml of soluble contrast media in both lateral and anteroposterior fluoroscopic view. Neurolysis is performed with 8 ml 8 % phenol solution. After neurolysis, 0.5 ml of saline is given to avoid the deposition of phenol within the intervertebral disc material. While withdrawing, the needle cephazoline 50 mg in 1 ml is injected into the disc.
48120810|NCT05083702|PROCEDURE|ultrasound-guided superior hypogastric plexus block|Patients are placed in the supine position and after sterilization, the low-frequency curved probe is used in the longitudinal axis to visualize the aortic bifurcation and is identified using a longitudinal Ultra-Sound (Phillips Healthcare, Andover, Massachusetts, US). Next, the probe is placed deeply transverse till aorta end and bifurcation seen of iliac vessels once seen we enter out of plane and inject.as it lies in front the vertebral body of the L5 vertebra. Local infiltration with 1% lidocaine is obtained at port of entry 1-1.5 inches below the umbilicus. A 15-cm, 22-G Chiba needle is inserted (out-of-plane) and advanced by avoiding vascular structures until contact with the L5-body. The needle will be withdrawan the 1-2 mm and inject 8 ml 8% phenol in saline. Finally, 0.5 ml of lidocaine is injected during Chiba needle removal
48120811|NCT04928703|DRUG|Ketamine|Ketamine IV administration
48120812|NCT01844492|BEHAVIORAL|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
48120813|NCT01844492|OTHER|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
48120814|NCT04887675|DIAGNOSTIC_TEST|MRI|Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
48120815|NCT00210691|DRUG|Risperidone|
48120816|NCT01275105|DRUG|Vehicle|one drop in each eye at designated visits
48120817|NCT01275105|DRUG|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
48120818|NCT01275105|DRUG|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
48120819|NCT01275105|DRUG|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
48120820|NCT01566968|OTHER|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
48326390|NCT01279304|RADIATION|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
48326391|NCT01279304|RADIATION|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
48326392|NCT02677220|DEVICE|CI532 cochlear implant|
47972091|NCT00790023|DRUG|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
47972092|NCT00790023|DRUG|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
47972093|NCT00790023|DRUG|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
47972094|NCT06178939|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
48326393|NCT00592670|DRUG|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
48326394|NCT00592670|DRUG|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
48326395|NCT01678716|BEHAVIORAL|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
48489865|NCT00301847|DRUG|sorafenib tosylate|
48120821|NCT01566968|OTHER|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
48120822|NCT01566968|OTHER|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
48326396|NCT01678716|DIETARY_SUPPLEMENT|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
48340158|NCT04916756|DRUG|Baricitinib 2 MG|baricitinib 2mg per day for 24 weeks
48326397|NCT01678716|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
48489866|NCT01240213|DIETARY_SUPPLEMENT|Vitamin D|2000 IU per day of Vitamin D
48489867|NCT01240213|DIETARY_SUPPLEMENT|Placebo|1 Placebo per day
47972095|NCT06178939|PROCEDURE|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
47972096|NCT04469036|OTHER|Virtual Pediatric Trauma Center|Telehealth
47972097|NCT05772832|DRUG|Dexmedetomidine|Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery
47972098|NCT05772832|DRUG|Remifentanyl|Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery
47972099|NCT00294437|DRUG|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
47972100|NCT01224860|DRUG|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
47972101|NCT01224860|DRUG|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
47972102|NCT00499577|BIOLOGICAL|CMV pp65 peptide|Given intramuscularly
47972103|NCT00499577|BIOLOGICAL|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
47972104|NCT00499577|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
47972105|NCT00499577|BIOLOGICAL|survivin Sur1M2 peptide vaccine|Given subcutaneously
47972106|NCT01152710|DRUG|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
47972107|NCT02449655|DRUG|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
47972108|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
47972109|NCT02449655|DRUG|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
47972110|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
47972111|NCT04932278|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment (OMT) is hands-on care provided by an osteopathic physician (D.O.). During osteopathic manipulative treatment, an osteopathic physician may move participants' muscles and joints using osteopathic techniques including stretching, gentle pressure and resistance, as well as thrust techniques that apply a quick, therapeutic force of brief duration that travels a short distance.
47972112|NCT04932278|PROCEDURE|Usual care|Routine concussion management with healthcare professionals.
47972113|NCT05090059|DEVICE|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
47972114|NCT05528354|DRUG|VEN and DEC based conditioning regimen|"Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days."
47972115|NCT05528354|DRUG|DEC|"In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)\>95%.~If the MRD turns positive, DLI can be performed."
48326398|NCT02181010|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
48489868|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|2000 IU per day
47972116|NCT04548570|PROCEDURE|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
47972117|NCT02744014|BEHAVIORAL|Add-on Therapy for Axial Spondyloarthritis|
47972118|NCT05812456|OTHER|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
48489869|NCT00141986|DIETARY_SUPPLEMENT|vitamin D3|400 IU per os once daily
48489870|NCT04729647|PROCEDURE|Mastectomy|Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)
48489871|NCT05396131|DEVICE|Lung Sealant|The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.
48489872|NCT05396131|DEVICE|Endobronchial Valve (EBV)|The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
48649694|NCT05938816|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR consists of weekly two-hour sessions for eight weeks, and a 7.5 hour retreat between weeks 6 and 7. The MBSR intervention will be facilitated by an experienced and certified MBSR teacher. MBSR curriculum strongly encourages completion of home practice assignments (\~30 minutes daily) to help integration of concepts into daily life. Participants will receive audio CDs and a DVD to help guide home practice.
47972119|NCT04173468|OTHER|Moblization with Movement|patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
47972120|NCT04173468|OTHER|Mulligan knee taping|patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
47972121|NCT02534870|DRUG|ABT-450/r/ABT-267|Tablet
47972122|NCT02534870|DRUG|ABT-333|Tablet
48326399|NCT02770313|BEHAVIORAL|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
47972123|NCT03385902|OTHER|optimal start time|patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
47972124|NCT03385902|OTHER|late start time|patients will start hemodialysis when their DIFE less than 30
47972125|NCT01206608|DRUG|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
47972126|NCT01206608|DRUG|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
47972127|NCT00121745|GENETIC|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
48326400|NCT05321940|BIOLOGICAL|STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells|Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe.
48489873|NCT00578981|BEHAVIORAL|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
48649695|NCT05938816|BEHAVIORAL|Health and Wellness Education (HWE)|HWE is a didactic-based group intervention designed as an active comparator for randomized-controlled trials of MBSR. HWE provides instruction to participants regarding improving their emotional and physical health. In contrast to MBSR, there are no attempts to train participants' breathing, movement, or meditation habits or practices. HWE is administered in 8 weekly 2.5-hour classes with home practice to be completed between sessions (matched to MBSR for amount and effort). HWE also features one extended 7.5-hour retreat, similar to MBSR.84 Dr. Autumn Gallegos (consultant) has conducted trials of MBSR among veterans with PTSD using a HWE control group, and will provide mentorship to the PI in administering the HWE intervention. Dr. Kaplan and a trained RA will facilitate HWE.
47972128|NCT00121745|GENETIC|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
48326401|NCT05321940|BIOLOGICAL|Dendritic Cell Vaccine|15-20 Million mature dendritic cells per dose administered via intravenous injection.
48326402|NCT04768699|DRUG|TQG203|TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
48326403|NCT04768699|DRUG|TQG203/NovoSeven®|In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
48489874|NCT05291455|DRUG|Lacosamide|lacosamide will be given
47972129|NCT00121745|GENETIC|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
47972130|NCT00121745|GENETIC|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
47972131|NCT03244215|DIAGNOSTIC_TEST|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
47972132|NCT03244215|DIAGNOSTIC_TEST|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
47972133|NCT03244215|OTHER|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
47972134|NCT04112056|DIETARY_SUPPLEMENT|Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)|It is same as that stated in arm description.
47972135|NCT00496054|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 \& P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
47972136|NCT02906059|DRUG|AZD1775|
47972137|NCT02906059|DRUG|Irinotecan|
47972138|NCT02563223|OTHER|Parabolic flight|
47972139|NCT02563223|DEVICE|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
47972140|NCT00000534|DRUG|calcium|
47972141|NCT00000534|BEHAVIORAL|dietary supplements|
47972142|NCT01379040|OTHER|Cystic Fibrosis patients|
48489875|NCT05291455|DRUG|Phenobarbital|phenobarbital will be given
48489876|NCT01349101|RADIATION|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
48489877|NCT01349101|DRUG|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
48326404|NCT04768699|DRUG|TQG203|TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
48326405|NCT02976727|DRUG|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
48326406|NCT02976727|DRUG|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
48326407|NCT02976727|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
48326408|NCT02976727|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
48326409|NCT02976727|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
48326410|NCT02976727|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
48489878|NCT01349101|DRUG|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
48489879|NCT01349101|DRUG|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
48489880|NCT01349101|DRUG|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
48489881|NCT01349101|DRUG|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
48489882|NCT01349101|GENETIC|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
47972143|NCT03971097|BEHAVIORAL|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
48326411|NCT02976727|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
48326412|NCT05070728|DRUG|Sham Injector|Sham injection
48326413|NCT05070728|DRUG|FAI Insert|FAI insert
48326414|NCT01188525|DRUG|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
48326415|NCT05362331|OTHER|Web Application|Internet based application
48326416|NCT03453021|DRUG|Mepolizumab|
48326417|NCT04172753|RADIATION|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
48326418|NCT04172753|DIAGNOSTIC_TEST|Imaging on the MR Linac|Only imaging performed on the MR Linac
48326419|NCT00895648|DRUG|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
48326420|NCT00895648|DRUG|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
48326421|NCT03882398|OTHER|Balance|"Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)"
48489883|NCT00001713|DRUG|Recombinant Tissue Plasminogen Activator|
48489884|NCT00001713|DRUG|Heparin|
48489885|NCT00001713|DRUG|Warfarin|
48489886|NCT02516423|DRUG|ixazomib|oral
48489887|NCT02516423|DRUG|lenalidomide|oral
48489888|NCT02516423|DRUG|dexamethasone|oral
48489889|NCT02516423|DRUG|zoledronic acid|IV
48489890|NCT01458106|DRUG|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
48489891|NCT01458106|DRUG|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
48489892|NCT05262036|DIETARY_SUPPLEMENT|Anti-aging Supplement|Mixture of different vitamins and nutrients
48489893|NCT05262036|DIETARY_SUPPLEMENT|Placebo|Excipient powder
48489894|NCT03604107|GENETIC|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
48649696|NCT06647888|DRUG|Envlo Tablet|Envlo Tab. 0.3mg
48649697|NCT06647888|DRUG|Envlomet SR Tablet|Envlomet SR Tablet 0.3/ Metformin1,000mg
48326422|NCT03882398|OTHER|Endurance|"Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part\* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(\*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)"
47972144|NCT03971097|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
48326423|NCT00870285|RADIATION|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
48326424|NCT00398957|DRUG|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
47972145|NCT06244732|PROCEDURE|Postoperative pain control|Postoperative analgesia after OR-AAA
47972146|NCT03497208|PROCEDURE|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
47972147|NCT03497208|PROCEDURE|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
47972148|NCT03497208|RADIATION|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
47972149|NCT03598556|DIETARY_SUPPLEMENT|Vitamin D3|180,000IU Vitamin D3 oral emulsion
48120823|NCT03775785|DIETARY_SUPPLEMENT|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
48326425|NCT05511818|DIETARY_SUPPLEMENT|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
48326426|NCT01661920|OTHER|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
47972150|NCT03598556|OTHER|Placebo|Placebo
48120824|NCT03561064|BEHAVIORAL|CBT-I|Eligible participants will receive CBT-I by a licensed clinical psychologist.
48326427|NCT01661920|OTHER|Control group|Those antibiotic duration treatments which are not modified by their doctors.
48326428|NCT04081376|DRUG|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
48326429|NCT03179579|PROCEDURE|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
48326430|NCT03179579|PROCEDURE|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
48326431|NCT05978687|DRUG|OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G|"In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
48340159|NCT05834699|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-low ABC
48340160|NCT03809247|OTHER||have no any intervention
48498078|NCT05571735|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
48120825|NCT05421364|BIOLOGICAL|Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)|Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
48120826|NCT06232577|DRUG|Hydrocodone|Given by PO
48120827|NCT06232577|DRUG|Tramadol|Given by PO
48120828|NCT06232577|DRUG|Oxycodone|Given by PO
48120829|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
48120830|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
48120831|NCT01541631|DRUG|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
48120832|NCT00661869|OTHER|Wellness Program|36 weeks of educational and supportive interventions
48120833|NCT04418999|DRUG|dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use|Experimental
48120834|NCT04418999|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Active Comparator
48120835|NCT04536519|OTHER|osteoarthritis management|"The conventional physical therapy will be consisted of an array of protocols being deployed in parallel. This will consist of~* Patient education regarding deforming forces, strategies of prevention and home exercise program~* Decreasing stiffness by controlled active range of motion and mobilization techniques involving join play.~* Mechanical stresses will be controlled in form of support provided by foot wear modification~* Range of motion will be increased muscle stretches and manual mobilization techniques~* Muscle performance and neuromuscular control will be addressed by gentle exercises of low intensity and repetitive exercises.~* Balance improvement by employing balance training activities as part of treatment~* Physical conditioning low impact or non-impact aerobics This conventional exercise will be given as baseline treatment to both of groups."
48120836|NCT03482011|DRUG|Mirikizumab|Administered SC
48120837|NCT03482011|DRUG|Placebo|Administered SC
48120838|NCT04804930|PROCEDURE|picture|We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns
48120839|NCT00785512|DRUG|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
48120840|NCT00785512|DRUG|Placebo|Matching placebo tablets, oral administration
48120841|NCT05956613|PROCEDURE|Partial pulpotomy|Use of newly introduced bioceramic putty in partial pulpotomy
48120842|NCT02079844|DRUG|Roflumilast|Roflumilast tablets
48120843|NCT02079844|DRUG|Placebo|Roflumilast placebo-matching tablets
48120844|NCT02079844|DRUG|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
48120845|NCT02060955|BIOLOGICAL|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
48120846|NCT02060955|DRUG|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
48120847|NCT03993704|DRUG|LHF-535|Oral suspension administered once daily for 14 days
48489895|NCT05992376|BEHAVIORAL|Food system and demand generation|The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
47972151|NCT00027898|DRUG|bortezomib|Given IV
47972152|NCT00027898|DRUG|carboplatin|Given IV
48120848|NCT04605016|DEVICE|Hydrophilic surface implants|A dental implant with hydrophilic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
47972153|NCT00027898|DRUG|etoposide|Given IV
47972154|NCT00027898|OTHER|laboratory biomarker analysis|Correlative studies
47972155|NCT00027898|OTHER|pharmacological study|Correlative studies
47972156|NCT02637284|DRUG|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
47972157|NCT02637284|DRUG|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
47972158|NCT02925494|DRUG|Estradiol/Norethindrone Acetate|capsules
47972159|NCT02925494|DRUG|Elagolix|film-coated tablets
47972160|NCT00490360|DRUG|Gemcitabine / Cisplatin|
47972161|NCT01165437|DEVICE|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
48120849|NCT04605016|DEVICE|Hydrophobic surface implants|A dental implant with hydrophobic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
48120850|NCT02234128|DEVICE|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
48120851|NCT03206684|DRUG|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight \<45kg were given 3mg once per chemotherapy cycle.
48120852|NCT03206684|DRUG|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight\<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10\^9/L.
48120853|NCT04882553|PROCEDURE|Diaphragmatic echography|Echography of the diaphragm at the zone of apposition. End-inspiratory and/or end-expiratory thickness of the diaphragm will be measured in M-mode.
48120854|NCT04882553|PROCEDURE|Measurement of esophageal pressure|Pressure will be measured in the lower third of the esophagus using an esophageal balloon and pressure transducer.
48120855|NCT04882553|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
48120856|NCT00899015|OTHER|pharmacological study|
48649698|NCT06671119|DEVICE|Gastric Mucosal Ablation (GMA)|Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy
48649699|NCT02914873|PROCEDURE|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
48649700|NCT01518036|DRUG|somatropin|2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
48120857|NCT03658408|DRUG|4-aminopyridine|Oral tablet of 2.5 mg given 4 times a day
48326432|NCT05978687|DRUG|Xylocaine with Epinephrine|"In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
48326433|NCT04242238|DRUG|DCC-3014|DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.
48489896|NCT05046665|DRUG|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
48489897|NCT05834166|OTHER|Upper back strengthening and Postural correction|The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
48489898|NCT03606421|RADIATION|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
48649701|NCT01518036|DRUG|somatropin|4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
48120858|NCT03658408|DRUG|placebo|2.5 mg sugar pill given orally 4 times a day
48120859|NCT06461871|OTHER|BALANCE TRAINING WITH MODERATE INTESITY AEROBIC VERSUS RESISTED TRAINING (RT)|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP A: Baseline treatment + Moderate intensity aerobic exercises in combination with balance training
48120860|NCT06461871|OTHER|Moderate intensity resistance exercises in combination with balance training|The duration of study is 6 months. Three to five sessions of both aerobic and resistance exercise training in combination with balance training are taken out per week . Each session lasting 15 minutes. GROUP B: Baseline treatment + Moderate intensity resistance exercises in combination with balance training
48649702|NCT04162158|BIOLOGICAL|allogeneic NK cells therapy|PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
48649703|NCT06020937|DIAGNOSTIC_TEST|TDI|Sniffin' Sticks Threshold and Identification Test
48649704|NCT06020937|DIAGNOSTIC_TEST|Trigeminal Test|Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
48649705|NCT06020937|DIAGNOSTIC_TEST|Cognitive Evaluation by Montreal Cognitive Assessment|Montreal Cognitive assessment
48326434|NCT04242238|DRUG|Avelumab|Start Day 1 on first cycle with further infusions of avelumab every 14 days
48326435|NCT01767870|PROCEDURE|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
48489899|NCT03606421|RADIATION|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
48120861|NCT05053568|DEVICE|CARTBox|CARTBox performs analysis of cardiac MRI scans. The result is a treatment file that displays optimal targets for left ventricular lead implantation in CRT. This file will be used as an overlay with live fluoroscopy during the implantation procedure in the intervention group.
48120862|NCT02082548|OTHER|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
48120863|NCT00002380|DRUG|Nelfinavir mesylate|
48120864|NCT00002380|DRUG|Saquinavir|
48120865|NCT05369507|BEHAVIORAL|Virtual Care Coordination|Participants randomly assigned to the virtual care coordination group will use a mobile app to assist in HCV treatment care coordination.
48120866|NCT02512341|DEVICE|Computer Aided Auscultation (CAA)|
48120867|NCT03482635|DRUG|Spesolimab|Solution for infusion
48120868|NCT03482635|DRUG|Placebo|Solution for infusion
48120869|NCT05845177|PROCEDURE|Primary Total Hip Arthroplasty|All patients surveyed have undergone primary total hip arthroplasty approximately 1 year prior to survey distribution
48120870|NCT04706052|OTHER|Superficial Parotidectomy|Classical procedure for pleomorphic adenoma of the parotid gland is superficial parotidectomy around the world. This study only observed the outcome with reference to facial nerve morbidity
48120871|NCT00262301|DRUG|recombinant human C1 inhibitor|IV
48120872|NCT00262301|DRUG|Placebo|IV
48120873|NCT05088954|PROCEDURE|transforaminal epidural steroid injection|In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
48326436|NCT01767870|PROCEDURE|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
48326437|NCT02697630|DRUG|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
48326438|NCT02697630|DRUG|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
48326439|NCT05716594|COMBINATION_PRODUCT|Plant enteral-extended anti-reflux stents|Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts
48326440|NCT05716594|COMBINATION_PRODUCT|Plant traditional stents|Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts
48326441|NCT01726413|DRUG|GRC 17356|
48489900|NCT01602471|DRUG|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
48489901|NCT02933762|DRUG|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
48120874|NCT06552819|OTHER|No intervention|No intervention
48120875|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
48120876|NCT01041612|DEVICE|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
48120877|NCT04064086|OTHER|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
48120878|NCT04064086|OTHER|Provision of the freely available resources for Kidney Disease Education|freely available resources
48120879|NCT00001277|DRUG|68Ga-Dotatate|68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
48120880|NCT00001277|DRUG|18F-DOPA|18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
48120881|NCT03273777|PROCEDURE|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
48120882|NCT04403789|OTHER|Exercise Time|Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
48120883|NCT04403789|BEHAVIORAL|Supervised Group Exercise|The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
48326442|NCT01726413|DRUG|Matching Placebo|
48326443|NCT00451750|DRUG|Cortisol|20 mg for 3 times
48326444|NCT02659605|PROCEDURE|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
48326445|NCT02659605|PROCEDURE|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
48326446|NCT04970394|BEHAVIORAL|Cervical Screening Reminder|Verbal reminder and if seen face-to-face, a written appointment booking slip.
48326447|NCT04448262|OTHER|data collection|collection of data about bronchial and systemic inflammation, quality of life, lung function
48489902|NCT02933762|DRUG|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
48489903|NCT04795908|DEVICE|Transcranial Magnetic Stimulation|rTMS will be delivered using a MagStim Super Rapid2 TMS therapy system.
48489904|NCT04795908|BEHAVIORAL|Comprehensive behavioral intervention|Patients will receive CBIT with a therapist trained in CBIT. Each session will last about an hour and will be delivered remotely via telemedicine. Sessions will be tailed to the patient's individual needs.
48326448|NCT05912712|OTHER|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
48120884|NCT03849352|BEHAVIORAL|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
48120885|NCT06020885|RADIATION|Split-course hypo-CCRT|"Split-course hypo-CCRT is administered at the following three dose levels:~* Level 1: DT 3000cGy/10 daily fractions/300cGy in the first course, DT 2000cGy/10 daily fractions/200cGy in the second course;~* Level 2: DT 2800cGy/7 daily fractions/400cGy in the first course, DT 2200cGy/10 daily fractions/220cGy in the second course;~* Level 3: DT 2500cGy/5 daily fractions/500cGy in the first course, DT 2500cGy10 daily fractions/250cGy in the second course."
48120886|NCT06020885|DRUG|Induction chemo-immunotherapy|All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
48120887|NCT06020885|DRUG|Concurrent chemotherapy|Concurrent capecitabine was administered orally at 1000mg/m2 twice daily within half an hour after meals concurrently with radiotherapy.
48120888|NCT04527822|OTHER|Nurse led discharge planning program|a discharge planning program. It is a modified discharge planning program depends basically on the Re-Engineered Discharge program which is a program developed by Boston Medical Center in collaboration with AHRQ , 2013. The intervention consists of several components. The program components include making appointments for follow-up care (e.g., medical appointments and post discharge tests/labs). Plan for the follow-up of results from tests or labs that are pending at discharge. Identify the correct medicines and a plan for the patient to obtain them. Teach a written discharge plan the patient can understand. Educate the patient about his or her diagnosis and medicines. Review with the patient what to do if a problem arises. Assess the degree of the patient's understanding of the discharge plan and provide a telephone reinforcement of the discharge plan
48120889|NCT00694447|PROCEDURE|Acupuncture|
48120890|NCT02548221|DEVICE|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
48120891|NCT01879189|BEHAVIORAL|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
48120892|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral PIF block.|"PIF block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
48120893|NCT04791592|PROCEDURE|Single-injection, ultrasound-guided bilateral TTMP block.|"TTMP block bilaterally (20 ml, 0.25% bupivacaine + 1:400.000 adrenaline). In addition, LA infiltration (10 ml, 0.25% bupivacaine) will be performed by the surgeon around the chest tube in all patients.~Intraoperative analgesia: At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV.~Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20µg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose).~In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day).~For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation in the intensive care unit."
48120894|NCT03005925|DEVICE|Smartphone|Smartphone application coupled with a hand dynamometer
48120895|NCT03005925|OTHER|physical follow up|regular visits with the specialist
48120896|NCT05447507|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\~1.0 mg/kg/h continuous infusion
48120897|NCT05447507|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
48489905|NCT05210244|DIETARY_SUPPLEMENT|Beetroot Juice (BJ) acute supplementation|One serving of 70 mL of BJ (6.4 mmol of NO3) 3h before initiating the testing session
47972162|NCT06040060|DRUG|Ketamine|The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
47972163|NCT06040060|OTHER|Placebo|While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
47972164|NCT01164982|DEVICE|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
47972165|NCT01163045|PROCEDURE|thyroidectomy|total thyroidectomy and lobectomy
48120898|NCT05993351|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (\<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.
48120899|NCT05993351|DIAGNOSTIC_TEST|Urine and saliva samples|At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.
48120900|NCT05993351|BEHAVIORAL|Questionnaires|The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
48120901|NCT06261606|OTHER|Hybrid strategy|"A hybrid strategy inclusive of:~1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131"
48649706|NCT06020937|DIAGNOSTIC_TEST|Anxiety and Depression questionnaire|Specific test to evaluate patient's mood
48120902|NCT00068601|DRUG|cyclophosphamide|Part of planned chemotherapy regimen
48120903|NCT00068601|DRUG|goserelin acetate|Given subcutaneously
48120904|NCT06495944|DRUG|Dazucorilant|75 mg soft gelatin capsules formulation for oral administration
48120905|NCT06495944|DRUG|Itraconazole|100 mg capsules for oral administration
48120906|NCT05004597|OTHER|three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)|A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
48326449|NCT05912712|OTHER|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
48326450|NCT05912712|DRUG|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
48326451|NCT05912712|BIOLOGICAL|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
48649707|NCT06020937|DIAGNOSTIC_TEST|Visual Analogue Scale Ratings|"* Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)"
48649708|NCT06020937|DIAGNOSTIC_TEST|Quality of smell Questionnaire|Patients will answer to a validated questionnaire
48649709|NCT06570083|BEHAVIORAL|Mobile Exercise Support|Participants receive three months of personalized support via WeChat, including tailored exercise recommendations, motivational messages, and educational content.
48649710|NCT06570083|BEHAVIORAL|Self-help physical activity booklet|Participants receive a self-help booklet to promote physical activity among the elderly. The booklet will include guidelines for safe and effective exercises, tips for staying motivated, and information on the health benefits of regular physical activity.
48649711|NCT00349986|DRUG|Insuline glargine|
48649712|NCT04161482|DRUG|Furosemide 80 mg (8 mg/mL)|Furoscix will be administered as a subcutaneous infusion.
48649713|NCT03794544|DRUG|Durvalumab|Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
48649714|NCT03794544|COMBINATION_PRODUCT|Oleclumab|Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
48649715|NCT03794544|COMBINATION_PRODUCT|Monalizumab|Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
48326452|NCT05740579|PROCEDURE|laparoscopic cryopreservation of one ovary|Laparoscopic removal of one ovary as child. In adulthood cortical tissue is replaced in the abdomen in order to improve fertility and pregnancy rates in Turner syndrome women.
48649716|NCT03794544|COMBINATION_PRODUCT|Danvatirsen|Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
48649717|NCT06662695|DIETARY_SUPPLEMENT|Ginger-based supplement|Ginger-based supplement in a dosage of 1500 mg
48649718|NCT06662695|DIETARY_SUPPLEMENT|Placebo|Capsules containing corn flour
48649719|NCT05323734|DRUG|Ganaxalone|GNX will be administered
48649720|NCT05323734|DRUG|Placebo|Placebo will be administered
48649721|NCT06674226|DRUG|Ciprofol|0.25mg/kg for anesthesia induction ＋0.25\~1.5 mg/kg/h for maintenance
48649722|NCT06674226|DRUG|Propofol|1.0mg/kg for induction ＋1 \~ 6mg/kg/h for maintenace
48649723|NCT02236897|OTHER|PET Scanning|
47972166|NCT06352801|BEHAVIORAL|Self-Compassion Intervention|Children participants are expected to learn the concepts of self-compassion and strategies of applying self-compassion to their daily lives.
47972167|NCT05452070|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or deep dermal injection
48120907|NCT06105125|DEVICE|Rigenera + bone substitute|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. A small punch of connective tissue will be harvested from the palate in the premolar region. Then the graft will be mechanically dissociated using the Rigenera Machine System rotating speed to 80 rpm, in 1.0 ml sterile physiologic solution. After dissociation, the cellular suspension will be passed through a disposable grid with 100 hexagonal blades filtering cells and components of extracellular matrix with a cut-off of 50 um in an average time of 90 s. Finally, part of the suspension containing AMGs will be seeded on the scaffold material and subsequently compacted within the defect. Flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
48120908|NCT06105125|DEVICE|Bone substitute alone|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. The defect will be filled with the same bone substitute employed in the test group. Finally, flaps will be positioned at the pre-surgical level or slightly coronal without any tension.
48120909|NCT01277250|BEHAVIORAL|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
48120910|NCT01837940|DIETARY_SUPPLEMENT|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
48120911|NCT01837940|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
48120912|NCT02236793|DRUG|BioChaperone PDGF-BB|
48120913|NCT02236793|OTHER|Standard of Care|
48649724|NCT06285357|DIETARY_SUPPLEMENT|EGCG + folic acid + B12|EGCG + folic acid + B12
48649725|NCT00909688|DRUG|BLI-489|
48649726|NCT00909688|DRUG|placebo|
48649727|NCT01013337|PROCEDURE|acupuncture therapy|
48649728|NCT01013337|PROCEDURE|sham intervention|Placebo acupuncture
48649729|NCT06307366|OTHER|No intervention will be used|This is a qualitative study, no intervention will be used
48649730|NCT06219174|DRUG|Pembrolizumab|200 mg IV Q3 weeks
48649731|NCT06219174|DRUG|Difluoromethylornithine|Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily
48649732|NCT03792737|DEVICE|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
48649733|NCT03792737|DEVICE|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
48649734|NCT03792737|DEVICE|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
47972168|NCT02984709|BEHAVIORAL|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
47972169|NCT02984709|BEHAVIORAL|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit
48120914|NCT03844152|DIETARY_SUPPLEMENT|Fermented whey concentrate|The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
48120915|NCT01691690|DRUG|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
48120916|NCT01691690|DRUG|Normal Saline Flush|Saline placebo will be infused intraoperatively.
48120917|NCT01691690|DRUG|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
48120918|NCT01691690|DRUG|Sevoflurane|Sevoflurane for anesthesia induction.
48120919|NCT01691690|DRUG|Nitrous Oxide/Oxygen|Combination of NO2 \& O2 for anesthesia induction.
48120920|NCT01691690|DRUG|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
48120921|NCT01691690|DRUG|Morphine|Morphine 0.1 mg/kg given prior to intubation.
48120922|NCT01691690|DRUG|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
48120923|NCT01691690|DRUG|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
48489906|NCT05210244|DIETARY_SUPPLEMENT|Placebo Juice (PLA) acute supplementation|One serving of 70 mL of juice (0.005 mmol of NO3) 3h before initiating the testing session
48120924|NCT03242148|DEVICE|Toffee Nasal Pillows Mask|Participants will be placed on this intervention for a total 14 ± 5 days from Visit 2. Participants will be using the Toffee nasal pillows mask during this treatment arm.
48120925|NCT00476346|DIETARY_SUPPLEMENT|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
48120926|NCT03205436|OTHER|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
48120927|NCT05454410|DRUG|MIJ821 Subcutaneous Injection - low dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
48120928|NCT05454410|DRUG|MIJ821 Subcutaneous Injection - medium dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
48120929|NCT05454410|DRUG|MIJ821 Subcutaneous Injection - high dose|MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
48120930|NCT05454410|DRUG|Placebo Subcutaneous Injection|0.9% sodium chloride solution to be administered as a single subcutaneous injection on Day 1
48120931|NCT03844269|DEVICE|AKL-T01|"AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level."
48120932|NCT04050969|PROCEDURE|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
48120933|NCT04050969|PROCEDURE|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
48120934|NCT00826280|DRUG|regadenoson|IV
48120935|NCT00826280|DRUG|overencapsulated caffeine|oral
48120936|NCT00826280|RADIATION|technetium|IV
48326453|NCT04546464|BEHAVIORAL|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
48326454|NCT02441855|DEVICE|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
48326455|NCT00843843|DEVICE|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
47972170|NCT06175910|PROCEDURE|percutaneous nephrolithotomy|"A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps."
48326456|NCT04990661|BEHAVIORAL|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
48326457|NCT02379390|DRUG|Cabazitaxel XRP6258|
48326458|NCT02379390|DRUG|Ezalutamide|
48489907|NCT00564226|DRUG|SSR240600C|oral administration
48120937|NCT00826280|DRUG|placebo|oral
48120938|NCT02600052|OTHER|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
48120939|NCT02600052|DEVICE|treadmill|AEROBIC TRAINING
48120940|NCT03761472|BIOLOGICAL|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
48120941|NCT03761472|BIOLOGICAL|Platelet-rich plasma injection|Platelet-rich plasma injection 5ml
48120942|NCT04452539|PROCEDURE|Paediatric cardiac surgery|All patients undergoing paediatric cardiac surgery
48120943|NCT02272816|DRUG|Carboplatin AUC-10|Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
48120944|NCT04459897|OTHER|Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.|: Retrospective histopathology review done by an expert of histopathology analysis (DAPI cell labeling). Analysis of the percentage of epithelioid cells and the percentage of gigantocellular granulomas in hepatic parenchyma of patient diagnosed for Hepatitis Granulomatous
48489908|NCT00564226|DRUG|tolterodine|oral administration
48326459|NCT02379390|DRUG|Abiraterone acetate|
48326460|NCT02379390|DRUG|Prednisone|
48326461|NCT02077985|BEHAVIORAL|Sensory Adapted Dental Environment|See study arm description.
48489909|NCT00564226|DRUG|placebo|oral administration
48489910|NCT03520868|DIAGNOSTIC_TEST|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
48649735|NCT03792737|DEVICE|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
48120945|NCT05708144|DIAGNOSTIC_TEST|ICG-SG incubation solution|The fresh excision breast cancer tissues were completely soaked in the incubation solution and performed fluorescence imaging.
48120946|NCT02692469|PROCEDURE|Duodenal Switch|Bariatric procedure
48120947|NCT02692469|PROCEDURE|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
48120948|NCT00840229|DRUG|Triamcinolone hexacetonide|20 mg
48120949|NCT00840229|DRUG|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
48489911|NCT06224621|PROCEDURE|Percutaneous Endocardial Septal Radiofrequency Ablation|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
48649736|NCT03792737|DEVICE|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
48649737|NCT03213951|OTHER|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
47972171|NCT06175910|PROCEDURE|retrograde intrarenal surgery|"urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied."
47972172|NCT01841983|OTHER|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~1. Motivate individual staff members to engage in targeted health and safety behavior changes;~2. build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~3. facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~4. promote co-worker and supervisor support for targeted health and safety behaviors."
48120950|NCT05032534|DEVICE|Cone Small, Qufora A/S|Newly developed cone in a softer material and a design matching the use for transanal irrigation.
48120951|NCT05032534|DEVICE|Colotip, Coloplast A/S|Cone currently used for transanal irrigation at the Pediatric Ward, Aarhus University Hospital.
48120952|NCT01714960|DRUG|MRZ-99030 eye drops 5mg/mL|
48120953|NCT01714960|DRUG|MRZ-99030 eye drops 20mg/mL|
48120954|NCT01714960|DRUG|Placebo to MRZ-99030 eye drops|
48120955|NCT04439747|OTHER|Ultrasound, DXA, hormonal tests|Diagnostic tests in selected groups with investigation of revealed hormonal disorders
48120956|NCT01352611|DRUG|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
48120957|NCT01628419|BEHAVIORAL|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
48326462|NCT03380624|DRUG|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
48326463|NCT03380624|DRUG|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
48489912|NCT02290275|DIETARY_SUPPLEMENT|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
48489913|NCT02290275|OTHER|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
48489914|NCT02290275|DIETARY_SUPPLEMENT|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
48489915|NCT06359860|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
48649738|NCT03213951|DIAGNOSTIC_TEST|PSMA-PET|PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
48649739|NCT01272258|DRUG|PRO 140|SC injection
48649740|NCT01272258|DRUG|Placebo|SC injection
47972173|NCT02591069|DEVICE|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
48120958|NCT03086863|DEVICE|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
47972174|NCT06052605|BEHAVIORAL|Healthy Aging in People with Epilepsy Program|This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
47972175|NCT04068714|PROCEDURE|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
47972176|NCT03986502|OTHER|Media Intervention|Watch web-based financial literacy video
47972177|NCT03986502|OTHER|Informational Intervention|Receive information on financial counseling and medical cost assistance
47972178|NCT03986502|OTHER|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
47972179|NCT03986502|OTHER|Questionnaire Administration|Ancillary studies
47972180|NCT03986502|OTHER|Quality-of-Life Assessment|Ancillary studies
47972181|NCT02634671|OTHER|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
47972182|NCT02634671|OTHER|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
47972183|NCT02634671|OTHER|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
47972184|NCT04013334|DRUG|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
47972185|NCT04013334|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
47972186|NCT04851834|DRUG|NTX-301|Oral hypomethylating agent
47972187|NCT04851834|DRUG|Platinum-based Chemotherapy|Standard of care for ovarian and bladder cancer
47972188|NCT04851834|DRUG|Temozolomide|Standard of care for high-grade glioma
47972189|NCT01356108|DEVICE|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
47972190|NCT03636932|DRUG|N-acetylcysteine (NAC)|Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.
47972191|NCT03636932|DRUG|Placebo|Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
47972192|NCT03636932|BIOLOGICAL|Blood sample|Circulating tissue factor assay
47972193|NCT03636932|BIOLOGICAL|Blood sample|The test of pro-coagulant activity of the tissue factor
48120959|NCT03086863|DEVICE|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
48489916|NCT03721536|DIAGNOSTIC_TEST|hemodynamic parameters|vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide
48120960|NCT02057939|DRUG|enzalutamide|160 mg orally once daily for six months
48120961|NCT02057939|DRUG|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
48489917|NCT03721536|DIAGNOSTIC_TEST|arterial blood gase|Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
48120962|NCT02057939|RADIATION|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
48326464|NCT04105569|PROCEDURE|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
47972194|NCT06402110|OTHER|Femoral Triangle Block|Patients will receive femoral triangle block (FTB) at the end of surgery. The probe will be positioned at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle, a block needle advanced in an in-plane technique into femoral triangle. After negative aspiration, 2ml of saline will be injected to confirm the needle tip position close to the femoral artery then injection of 15ml of bupivacaine 0.25% will be performed.
48120963|NCT03169894|DRUG|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
48326465|NCT05496894|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 3 months (Q3M)
48120964|NCT00623987|DRUG|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
48326466|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter≥2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)
48326467|NCT04953117|DEVICE|Restore DEB|subjects receiving Restore DEB
48326468|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter<2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)
48326469|NCT03737292|DRUG|Exparel|The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
48326470|NCT03737292|DRUG|Bupivacaine|The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
48489918|NCT05077371|BEHAVIORAL|Peer support program|The intervention will consist of 8 face-to-face peer social support sessions conducted by volunteers diagnosed with breast cancer who have finished their medical treatment (chemotherapy, radiotherapy, surgery) or who have been in a stable phase for at least two years and who are motivated to participate in this type of intervention.
48489919|NCT00442000|PROCEDURE|Prostatectomy|Patients undergoing prostatectomy.
48489920|NCT03250949|PROCEDURE|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter"
48489921|NCT03200691|RADIATION|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
48649741|NCT05566236|BEHAVIORAL|board game|A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
48120965|NCT05486052|OTHER|Evaluation of reliability, repeatability and validity of devices among healthy subjects|"Evaluation of reliability, reproducibility and validity of devices among healthy subjects Prior to the study among individuals with neurological disorders, an evaluation of the reliability, repeatability and credibility of the devices to be included in the biofeedback rehabilitation and optical oximetry measurements will be carried out.~The evaluation of the devices will be carried out by two independent researchers twice"
48326471|NCT03411772|PROCEDURE|TAP block|Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
48326472|NCT03411772|PROCEDURE|Bariatric surgery|Bariatric surgery will be conducted
48326473|NCT04818541|DEVICE|PPCI|Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.
48326474|NCT04818541|DEVICE|Cardiogenic shock|Closure of the femoral access site with PerQseal device after removal of the Impella pump.
48489922|NCT03200691|DRUG|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
47972195|NCT06402110|OTHER|Adductor Canal Block|Patients will receive adductor canal block (ACB) at the end of surgery. The probe will be positioned at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the Sartorius muscle and a block needle advanced in an in-plane technique toward the target nerve after negative aspiration, 2ml of saline will be injected into adductor canal to confirm the block needle tip within it, the block needle will be advanced with the guidance of ultrasound in an in-plane technique and 15ml bupivacaine 0.25% will be injected.
47972196|NCT02590614|DIETARY_SUPPLEMENT|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
48326475|NCT01790711|PROCEDURE|FMT through mid-gut|
48326476|NCT04557254|DEVICE|graft|evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
48326477|NCT01812486|RADIATION|dose de escalation|
48326478|NCT01812486|RADIATION|standard dose|
48489923|NCT00534014|DIETARY_SUPPLEMENT|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
48489924|NCT06331000|DRUG|elexacaftor-tezacaftor-ivacaftor treatment|Effect of one year elexacaftor-tezacaftor-ivacaftor treatment on glucose tolerance abnormalities in adult patients with cystic fibrosis
48489925|NCT05476120|BEHAVIORAL|BATHE|The BATHE interview technique was applied 3 times, once every 3 months, for 6 months.
48489926|NCT01376193|DRUG|Naratriptan|Collection of safety data
48120966|NCT05486052|OTHER|Biofeedback method and Health-resort based rehabilitation Health-resort based treatments supplemented with biofeedback training|"The rehabilitation programme will run for 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massages, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy.~Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, peat wraps, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy."
48120967|NCT05486052|OTHER|Health-resort based rehabilitation Control group - health-resort based treatments, without biofeedback training.|Health-resort based rehabilitation The rehabilitation programme will last 3 weeks from Monday to Friday. Patients will receive: group and individual exercises (active and assisted exercises, manipulative exercises, PNF-based exercises, balance and breathing exercises), manual massage, physical treatments such as laser, whirlpool, mud packs, carbonic acid therapy , TENS therapy, BIO-V lamp, local cryotherapy
48120968|NCT00746343|BEHAVIORAL|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
48120969|NCT00746343|BEHAVIORAL|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
48120970|NCT03544515|DEVICE|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
48489927|NCT03124862|DEVICE|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
48489928|NCT05015920|GENETIC|BD211 Drug Product|Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
47972197|NCT02590614|DIETARY_SUPPLEMENT|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
47972198|NCT02706691|DRUG|BGJ398|Given by mouth (oral)
47972199|NCT03143894|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
47972200|NCT03143894|OTHER|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
47972201|NCT01603004|OTHER|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
47972202|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
47972203|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
47972204|NCT00766337|DRUG|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
47972205|NCT04200664|DIAGNOSTIC_TEST|Hearing assessment|All study participants will undergo hearing tests, including hearing-specific questionnaires
47972206|NCT04200664|DIAGNOSTIC_TEST|Vestibular/balance assessment|Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
47972207|NCT04200664|OTHER|Quality of life assessment|All study participants will be asked to complete a set of quality of life questionnaires
47972208|NCT04200664|DIAGNOSTIC_TEST|Olfactory (smell) function testing|Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
47972209|NCT04200664|GENETIC|DNA bio-banking|Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
47972210|NCT04030611|DIAGNOSTIC_TEST|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
47972211|NCT00667069|DRUG|triptorelin|
47972212|NCT00667069|PROCEDURE|adjuvant therapy|
47972213|NCT00667069|RADIATION|3-dimensional conformal radiation therapy|
47972214|NCT05416502|PROCEDURE|Ultrasound|Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.
47972215|NCT00003993|BIOLOGICAL|aldesleukin|
47972216|NCT00003993|DRUG|bryostatin 1|
47972217|NCT04186520|BIOLOGICAL|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
47972218|NCT04186520|BIOLOGICAL|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
47972219|NCT04186520|BIOLOGICAL|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
47972220|NCT04613960|DRUG|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
47972221|NCT04613960|DRUG|normal saline|Placebo treatment
47972222|NCT02426437|OTHER|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
47972223|NCT02426437|OTHER|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
47972224|NCT04051008|BEHAVIORAL|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
48489929|NCT04963595|DRUG|Pyrotinib|400 mg once daily
48120971|NCT03544515|PROCEDURE|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
48326479|NCT04372342|DRUG|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
47972225|NCT04051008|BEHAVIORAL|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
47972226|NCT05787457|OTHER|Clinical examination|
48120972|NCT03544515|DEVICE|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
48120973|NCT03285386|BEHAVIORAL|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
48326480|NCT04372342|DRUG|remifentanil|remifentanil
48326481|NCT02913742|PROCEDURE|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
48326482|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex|TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern
48326483|NCT05931913|BEHAVIORAL|Exposure with Response Prevention|ERP will be delivered daily, immediately following TMS
48489930|NCT04963595|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
48489931|NCT04963595|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
48489932|NCT03287973|BEHAVIORAL|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
47972227|NCT05787457|OTHER|Blood testing|
47972228|NCT05787457|OTHER|MRI|
47972229|NCT03962010|DRUG|GX-G6|long acting anti-diabetic drug
47972230|NCT03962010|DRUG|Control|Control
47972231|NCT05935293|DRUG|Dexmedetomidine|iv administration dexmedetomidine
47972232|NCT00867568|DRUG|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
47972233|NCT02643381|DRUG|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
48489933|NCT03287973|DEVICE|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
48489934|NCT05378919|RADIATION|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
48489935|NCT05378919|DRUG|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
47972234|NCT02643381|DRUG|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
48120974|NCT03285386|BEHAVIORAL|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
48120975|NCT03930225|BEHAVIORAL|Stigma Directed Psycho-educational Intervention program|psycho-educational intervention with emphasis on Stigma
48489936|NCT05378919|DRUG|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
47972235|NCT02643381|PROCEDURE|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
47972236|NCT02643381|DEVICE|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
47972237|NCT04849143|OTHER|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
47972238|NCT04849143|OTHER|Gel dressing|Smith-Nephew's Intrasite gel
47972239|NCT00980382|DRUG|S-1, Docetaxel|"* Phase I study~  * S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~* Phase II study~  * S-1 (80mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (35 mg/m2) iv : Days 1, 8"
48120976|NCT03435770|DEVICE|EUSRA RFA needle|A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
48120977|NCT01881386|DEVICE|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
48120978|NCT04701879|OTHER|Spine decompression with core stability exercises|"* 50 minutes per session~* Decompression with core stability on alternate days for 8 visits."
48120979|NCT04701879|OTHER|Spine decompression|"40 minutes per session~-Decompression therapy on alternate days for 8 visits."
48120980|NCT06516315|PROCEDURE|Preoperative ultrasound examination.|Preoperative ultrasound examination performed the day before or the day of surgery.
48120981|NCT06516315|PROCEDURE|Peroperatoire angiography procedure and QFR analysis|Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
48120982|NCT04252586|DRUG|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
48120983|NCT02653508|BEHAVIORAL|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
48120984|NCT02653508|BEHAVIORAL|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
48120985|NCT02872675|DIETARY_SUPPLEMENT|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
48120986|NCT02872675|DIETARY_SUPPLEMENT|Maltodextrin|Placebo Comparator: Maltodextrin.
48120987|NCT03396900|DRUG|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
48120988|NCT03396900|OTHER|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
48120989|NCT02701257|DEVICE|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
48489937|NCT05378919|RADIATION|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
48489938|NCT02218619|DRUG|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
48489939|NCT02218619|DRUG|Sugar Pill (placebo)|Placebo
48489940|NCT01653613|GENETIC|DNA analysis|
47972240|NCT02457260|DRUG|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
47972241|NCT00660023|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
47972242|NCT06131567|PROCEDURE|Implantoplasty|Implantoplasty as surface decontamination method
48120990|NCT02701257|DEVICE|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
48120991|NCT02701257|DRUG|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
48120992|NCT02701257|DRUG|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
48489941|NCT01653613|GENETIC|fluorescence in situ hybridization|
48489942|NCT01653613|GENETIC|gene expression analysis|
48489943|NCT01653613|GENETIC|microarray analysis|
48489944|NCT01653613|GENETIC|mutation analysis|
48489945|NCT01653613|GENETIC|polymorphism analysis|
48489946|NCT01653613|GENETIC|reverse transcriptase-polymerase chain reaction|
47972243|NCT00790985|DIETARY_SUPPLEMENT|flavocoxid|medical food
47972244|NCT00790985|DRUG|Naproxen|antiinflammatory drug
48649742|NCT05872516|DEVICE|Chang Gung Atrial Fibrillation Detecting Software|This software is expected to be used in clinical testing to interpret the static 12-lead ECG of adults who are over 20 years old and suspected of having atrial fibrillation, detect whether there is a signal of atrial fibrillation, and output the results for clinicians Near-instant auxiliary diagnostic use.
48649743|NCT05597605|DEVICE|The SHINE SYSTEM|The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
48649744|NCT06571318|OTHER|Destress and Perform Capsule-U001|Two Capsules in sequence daily after meal for 60 days.
48649745|NCT06571318|OTHER|Destress and Perform Capsule-I001|Two Capsules in sequence daily after meal for 60 days.
48649746|NCT06571318|OTHER|Placebo capsules 002|Two Capsules in sequence daily after meal for 60 days
47972245|NCT03487068|DEVICE|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
47972246|NCT06389123|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
47972247|NCT01101087|DEVICE|Taurolock|
47972248|NCT01101087|OTHER|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
48120993|NCT02701257|DEVICE|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
48120994|NCT02701257|DEVICE|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
47972249|NCT02539121|DEVICE|Acupuncture|Acupuncture needles
47972250|NCT00105469|DRUG|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
48120995|NCT00067691|PROCEDURE|Acupuncture|
48120996|NCT02793154|DRUG|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate \>=6 hours apart)
48120997|NCT02793154|DRUG|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
47972251|NCT00105469|DRUG|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
47972252|NCT03281577|DRUG|TAK-954|TAK-954 IV infusion.
48649747|NCT00974532|DIETARY_SUPPLEMENT|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
47972253|NCT03281577|DRUG|Placebo|TAK-954 placebo-matching IV infusion.
47972254|NCT05009615|DIETARY_SUPPLEMENT|Green coffee extract|150 mg polyphenols from green coffee, twice daily
47972255|NCT05009615|DIETARY_SUPPLEMENT|Beta glucan|2.5 g BG twice daily
48120998|NCT01086163|DRUG|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
48120999|NCT03110549|DRUG|TMB-607|
48121000|NCT03110549|DRUG|Placebo|
48489947|NCT01653613|OTHER|laboratory biomarker analysis|
48489948|NCT03293381|DEVICE|additional biopsies|additional biopsies
48649748|NCT00974532|DIETARY_SUPPLEMENT|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
48649749|NCT01663363|DEVICE|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
48649750|NCT05620719|BEHAVIORAL|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
48489949|NCT04111848|DRUG|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
48649751|NCT05620719|OTHER|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
48649752|NCT05620719|OTHER|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
47972256|NCT05009615|DIETARY_SUPPLEMENT|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
47972257|NCT02519036|DRUG|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
47972258|NCT02519036|DRUG|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
47972259|NCT02519036|DRUG|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
47972260|NCT02519036|DRUG|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
47972261|NCT02519036|DRUG|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
47972262|NCT02519036|OTHER|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
47972263|NCT05682898|PROCEDURE|Timing of colorectal cancer surgery|The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.
47972264|NCT03528772|DRUG|Minoxidil|application of minoxidil forte 5% gel three time per day on the anus for four weeks
47972265|NCT03528772|DRUG|Glyceryl trinitrate|application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
47972266|NCT04460404|BEHAVIORAL|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~1. Basic information~2. Digestive tract symptoms:~   A constipation-related symptoms B abnormal symptoms~3. Fecal traits~4. Lifestyle habits~5. Others"
47972267|NCT02732119|DRUG|Ribociclib|supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
47972268|NCT02732119|DRUG|Everolimus|supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
47972269|NCT02732119|DRUG|Exemestane|supplied in 25 mg tablets taken orally, daily for 28 day cycle
47972270|NCT01179568|DRUG|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
47972271|NCT01179568|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
47972272|NCT01179568|OTHER|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
47972273|NCT05060302|OTHER|transthoracic echocardiography (TTE)|the included patients have a TTE preoperatively in order to evaluate the RV systolic function. TTE will also be done at day 2 and day-15 during the follow-up surgical consultation.
48121001|NCT01574794|OTHER|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
48121002|NCT01574794|OTHER|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
48121003|NCT00238836|BEHAVIORAL|Self-management of chronic illness|
47972274|NCT02309502|DEVICE|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
47972275|NCT02309502|DEVICE|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
47972276|NCT04451239|DRUG|topical steroids and cyclosporin-A|All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
47972277|NCT01144286|DRUG|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
47972278|NCT01144286|DRUG|placebo|placebo, single dose
47972279|NCT03798496|PROCEDURE|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
48489950|NCT04111848|DRUG|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
48121004|NCT00718848|PROCEDURE|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
48121005|NCT00718848|PROCEDURE|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
48121006|NCT05915546|DRUG|Emraclidine|Tablets
48326484|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: Sham|Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex
48326485|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area|TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
48489951|NCT04375930|OTHER|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
48489952|NCT04375930|OTHER|Control|It consists of only skills and discharge education
48489953|NCT03516084|DRUG|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
47972280|NCT05619263|BEHAVIORAL|Disaster PrepWise-Caregiver|The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
47972281|NCT05782491|PROCEDURE|Interscalene Block|It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
47972282|NCT05782491|PROCEDURE|PECS II Block|PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
47972283|NCT05782491|PROCEDURE|Superficial Cervical Plexus Block|This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
47972284|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
47972285|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
47972286|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
47972287|NCT00403234|DRUG|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
47972288|NCT03825315|BIOLOGICAL|DAXI 80 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
47972289|NCT03825315|BIOLOGICAL|DAXI 120 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
47972290|NCT03825315|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
47972291|NCT01959074|DRUG|Naftopidil|Naftopidil 75mg 1T qd hs
47972292|NCT01959074|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
48489954|NCT03516084|DRUG|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
48489955|NCT04180553|DIAGNOSTIC_TEST|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP \<90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
47972293|NCT01959074|DRUG|Standard treatment|aceclofenac 100mg on demand
48121007|NCT03848910|DEVICE|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
48121008|NCT03429972|DEVICE|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
48121009|NCT03429972|DRUG|Paclitaxel|80mg/m\^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
48121010|NCT06275035|DRUG|Memantine Oral Tablet|Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
48121011|NCT03792204|DIAGNOSTIC_TEST|Wearing-off 9 questionnaire|The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
48121012|NCT00529100|DRUG|Pemetrexed Phase 1|300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
48121013|NCT00529100|DRUG|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles."
48121014|NCT00529100|PROCEDURE|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
48121015|NCT00529100|DRUG|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
48121016|NCT00529100|DRUG|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
48121017|NCT05264519|OTHER|foot bath intervention|Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
48121018|NCT06268990|PROCEDURE|Fecal microbiota transplantation|FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
48121019|NCT04134611|DEVICE|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
48121020|NCT04134611|DEVICE|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
48121021|NCT05762159|OTHER|data collected|"data collected:~* Morphological data of the patients~* Data of the erector block realization~* Pupillometric data :the variation of the pupil size on stimulation (in percentage of the base diameter)"
48121022|NCT01675999|OTHER|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
48121023|NCT01675999|OTHER|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
48326486|NCT04198896|OTHER|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
48326487|NCT02915107|DEVICE|BioFreedom|PCI with BioFreedom
48326488|NCT02915107|DEVICE|Orsiro|PCI with BioFreedom
48326489|NCT01244191|DRUG|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
48121024|NCT01675999|OTHER|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
48326490|NCT01244191|DRUG|Placebo|Tivantinib Placebo tablets given twice a day
48489956|NCT04180553|OTHER|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
48326491|NCT01244191|DRUG|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
48326492|NCT02480179|DEVICE|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
48340161|NCT02846857|OTHER|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
48489957|NCT03022669|BEHAVIORAL|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
48489958|NCT03022669|BEHAVIORAL|Mobile Application|
48489959|NCT03022669|OTHER|Website|American Heart Association patient education website
48121025|NCT04586309|BEHAVIORAL|Transcendental meditation|"Instruction in the TM technique is taught over five sessions.~1. Introductory session-Review of previous scientific research on the TM program and a vision of possible benefits; Preparation- discussion of the mechanics and origin of the TM technique After the introductory session, a Personal Interview is conducted telephonically-with a teacher of the TM program.~2. Personal Instruction-individual one-on-one instruction in the TM technique. The student learns the mechanics of the TM technique. At the conclusion of this class the student is able to meditate properly.~3. First Day of Verification of Correct Practice and Further Instruction.~4. Second Day of Verification of Correct Practice-understanding the mechanics of the TM technique from personal experiences.~5. Third Day of Verification of Correct Practice-understanding the mechanics of the development of higher human potential and wellness."
48121026|NCT02282267|DRUG|Gefitinib|Iressa 250mg oral daily
48326493|NCT04577183|DEVICE|RD1 System|The RD1 is created by drawing the patient's blood with the use of citrate anticoagulant. The anticoagulant allows the clot to form later in a controlled fashion-citrate is a widely used anticoagulant. The blood is then placed in the clotting tray (within few minutes) and the coagulation is facilitated by adding calcium and kaolin (insoluble aluminum silicate). The forming clot assumes the shape of the tray containing it, and can then be applied to the wound, and then covered with primary and secondary dressings.
48121027|NCT01519037|DRUG|Cinacalcet 60 MG|one dose of oral cinacalcet, 60mg
48121028|NCT01519037|DRUG|Placebo oral tablet|one tablet of placebo
48121029|NCT04891835|OTHER|Data extraction from medical files|Data extraction from medical files
48121030|NCT02346526|PROCEDURE|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
48121031|NCT02346526|PROCEDURE|CT scan|Standard CT scans will be carried out prior to treatment, week 9, and week 25.
48121032|NCT02346526|PROCEDURE|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
48121033|NCT02346526|DRUG|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
48121034|NCT02346526|PROCEDURE|bone scan|Standard bone scans will be carried out prior to treatment, week 9, and week 25.
48121035|NCT00044057|DRUG|YM872 (zonampanel), t-PA (alteplase)|
48121036|NCT01724242|DRUG|Vaginal DHEA|
48121037|NCT01724242|DRUG|Placebo|
48326494|NCT06335823|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit turned on and half will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
48489960|NCT04689763|BEHAVIORAL|Training|The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. We plan to assess the participants before and after the intervention programs. We expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
48489961|NCT05228821|DRUG|Voxelotor Oral Tablet|During the Treatment Period, participants will receive 1500 mg of voxelotor once daily (administered as tablets) for 24 weeks in addition to ongoing current standard of care (SOC) treatment
48489962|NCT03349528|BIOLOGICAL|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
48489963|NCT03349528|BIOLOGICAL|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
48489964|NCT02776514|DRUG|Triamcort|Fluoroscopic guided injection in the knee joint
48489965|NCT02776514|DRUG|Platelet-rich-plasma|
48489966|NCT02776514|DRUG|Suplasyn1|
48489967|NCT02776514|DRUG|Placebo|
48489968|NCT02310282|DEVICE|Telemedicine|In-hospital telemedicine
48489969|NCT00687310|BEHAVIORAL|Educational intervention|Tailored asthma education based on needs assessment
48489970|NCT00004175|DRUG|cyclophosphamide|
48489971|NCT00004175|DRUG|docetaxel|
48121038|NCT01898741|RADIATION|24 Gy in 3 fractions|
48121039|NCT01149395|DRUG|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
48121040|NCT03780686|DRUG|Norepinephrine, dopamine|drugs to decrease bleeding
48121041|NCT03133039|PROCEDURE|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
48121042|NCT05212675|OTHER|Short daily dialysis|7 days 2hours dialysis
48121043|NCT05032261|DRUG|Circulatory shock with norepinephrine in ICU|Circulatory shock with norepinephrine in ICU
48121044|NCT04238793|DRUG|KLS-2031|KLS-2031 administered by transforaminal epidural injection
48121045|NCT04238793|OTHER|Placebo|Normal Saline (0.9%) administered by transforaminal epidural injection
48121046|NCT01902784|BEHAVIORAL|Storytelling Interview|
48121047|NCT02093312|DIETARY_SUPPLEMENT|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
48121048|NCT04159493|DRUG|Estriol|Vaginal Application
48121049|NCT04159493|DRUG|Placebo|Vaginal Application
48121050|NCT01544855|DIETARY_SUPPLEMENT|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
48121051|NCT03107546|DEVICE|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
48489972|NCT00004175|DRUG|doxorubicin hydrochloride|
48489973|NCT00004175|PROCEDURE|conventional surgery|
48489974|NCT04133766|BEHAVIORAL|Community Based Nutrition Package (CNBP)|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
48489975|NCT03173053|DRUG|Doxycycline|tablet
48326495|NCT06335823|DEVICE|Placebo Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit will not be turned on.
48121052|NCT03107546|OTHER|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
48121053|NCT03376152|BEHAVIORAL|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
48121054|NCT01647438|BEHAVIORAL|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
48121055|NCT01647438|OTHER|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
48121056|NCT03202199|DEVICE|PET/MRI|2 PET/MRI examinations
48121057|NCT05575622|DEVICE|CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection|Collect peripheral blood sample of 200 HCC patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 by microfluidic chip.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
48121058|NCT04146324|DRUG|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
48121059|NCT04743310|DRUG|tozuleristide|tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery
48121060|NCT04743310|DEVICE|Canvas imaging system|imaging device attached to surgical microscope
48326496|NCT00126581|DRUG|Carboplatin|Given IV
48326497|NCT00126581|DRUG|Erlotinib|Given PO
47972294|NCT03294902|DEVICE|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
47972295|NCT00662012|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
47972296|NCT00495339|DRUG|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
47972297|NCT02075710|OTHER|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
47972298|NCT02075710|OTHER|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
47972299|NCT02075710|OTHER|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
47972300|NCT02075710|OTHER|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
47972301|NCT02075710|OTHER|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
48121061|NCT04743310|PROCEDURE|Surgical resection of tumor|Standard of care surgical resection of tumor
48326498|NCT00126581|DRUG|Erlotinib Hydrochloride|Given PO
48326499|NCT00126581|DRUG|Paclitaxel|Given IV
48326500|NCT06512025|BEHAVIORAL|WWWT psychoeducative intervention|"What Were We Thinking (WWWT) is a highly structured, interactive, gender-informed, couples-based, psycho-educational program for parents and a first newborn to promote confident parental caretaking, optimize functioning in the intimate partner relationship and improve infant care manageability.~The adaptation of the WWWT programme (Catalan and Spanish version) comprises 2 sessions, each lasting 2 hours, that will be designed for groups of 5-7 families - within the first 6 weeks postpartum -, each consisting of mother, partner (or other caregiver) and their infant(s)."
48326501|NCT00387270|DRUG|Dimebon|Dimebon 10 or 20 mg TID x 7 days
48326502|NCT04771988|RADIATION|yttrium-90 radioembolization|selective/superselective treatment using resin microspheres labeled with Yttrium-90
48326503|NCT02260648|DRUG|Evacetrapib|Administered orally
48326504|NCT02260648|DRUG|Ezetimibe|Administered orally
48326505|NCT02260648|DRUG|Atorvastatin|Administered orally
48326506|NCT02260648|DRUG|Placebo|Administered orally
47972302|NCT02075710|OTHER|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
48326507|NCT00003476|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
48326508|NCT02401243|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
48326509|NCT06348953|OTHER|selective caries removal and conventional non-bioactive restorative system|conventional dental restorative adhesive and resin based composite
48326510|NCT06348953|OTHER|selective caries removal and bioactive restorative system|bioactive dental restorative resin based system
48489976|NCT03173053|DRUG|Trimethoprim|tablet
48489977|NCT03173053|DRUG|Sulfamethoxazole/trimethoprim|tablet
48489978|NCT03173053|DRUG|Clindamycin|tablet
48489979|NCT03173053|DRUG|Clarithromycin|tablet
48121062|NCT03562884|DRUG|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
48121063|NCT03562884|DRUG|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
48121064|NCT01014273|PROCEDURE|Percutaneous Coronary Intervention|
48121065|NCT03565315|BIOLOGICAL|VRC-HIVMAB095-00-AB (10E8VLS)|10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
48121066|NCT03565315|BIOLOGICAL|VRC-HIVMAB075-00-AB (VRC07-523LS)|VRC07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
48121067|NCT02949375|DRUG|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
48121068|NCT02949375|DRUG|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
48121069|NCT02949375|DRUG|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
48121070|NCT00937183|BIOLOGICAL|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
48326511|NCT00333619|BEHAVIORAL|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
48326512|NCT00333619|BEHAVIORAL|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
48326513|NCT02306239|DRUG|Terlipressin|
48326514|NCT02306239|DRUG|Norepinephrine|
48326515|NCT05815680|DRUG|metformin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
48121071|NCT00937183|BIOLOGICAL|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
48121072|NCT00937183|BIOLOGICAL|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
48121073|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; low temperature)|
48121074|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; low temperature)|
48326516|NCT05815680|DRUG|digoxin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
48326517|NCT05815680|DRUG|IBI362|Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
48121075|NCT03036644|DEVICE|e-cigarette (PG+VG without nicotine; high temperature)|
48121076|NCT03036644|DEVICE|e-cigarette (PG+VG with nicotine; high temperature)|
48121077|NCT03036644|OTHER|tobacco cigarette|
48121078|NCT02382744|DEVICE|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
48326518|NCT05815680|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
48326519|NCT05815680|DRUG|atorvastatin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
48326520|NCT02203669|OTHER|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
48326521|NCT02203669|OTHER|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
48326522|NCT04631068|PROCEDURE|Cataract surgery|Small incision cataract surgery with implantation of an intraocular lens
48489980|NCT03173053|DRUG|Ciprofloxacin|tablet
48489981|NCT03173053|DRUG|Fusidic Acid|tablet or ointment
48489982|NCT03173053|DRUG|Rifampin|tablet
48489983|NCT03173053|DRUG|Chlorhexidine|Mouthwash or bodywash
48326523|NCT03777202|PROCEDURE|High-flow nasal oxygen|High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
48326524|NCT03777202|PROCEDURE|Low-flow nasal oxygen|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
47972303|NCT02881437|DRUG|IgHy10|Sub Cutaneous IgHy10 administration
47972304|NCT03053960|DEVICE|Computed Tomography|Undergo helical CT scan
48326525|NCT02667379|OTHER|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
48326526|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
48326527|NCT04948463|DRUG|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
48489984|NCT03173053|DRUG|Mupirocin|Nasal ointment
48489985|NCT03173053|DRUG|Betadine|Shampoo
48489986|NCT02548312|OTHER|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
48649753|NCT03161262|BEHAVIORAL|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
48649754|NCT00295412|DRUG|quetiapine (drug)|
48649755|NCT02130037|BEHAVIORAL|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
48649756|NCT02130037|OTHER|psychotherapy|standard psychotherapy for eating disorders
48649757|NCT05835154|BEHAVIORAL|Assessment|Complete checklist
48649758|NCT05835154|OTHER|Questionnaire Administration|Complete questionnaires
48649759|NCT05835154|OTHER|Interview|Undergo semi-structured feedback interview
47972305|NCT03053960|DEVICE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
48649760|NCT05835154|OTHER|Electronic Health Record Review|Review of medical records
47972306|NCT03053960|DEVICE|Cone-Beam Computed Tomography|Undergo CBCT scan
47972307|NCT03053960|DEVICE|Magnetic Resonance Imaging|Undergo MRI scan
48326528|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
47972308|NCT03053960|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection of tumor
47972309|NCT03053960|PROCEDURE|Histopathologic Examination|Correlative studies
47972310|NCT06058676|PROCEDURE|carotid artery stenting|The procedures will be performed for patients with general or local anesthesia. Implantation of stents at the site of carotid artery stenosis for the treatment of carotid severe stenosis. A suitable balloon will be selected based on the internal carotid arterial（ICA）diameter, as shown on the digital subtraction angiography（DSA）image. The use of a balloon for predilatation or postdilatation depends on the degree of stenosis. The type of stent will be selected according to several factors, such as the length and configuration of the lesion, vascular morphology, vessel diameter, plaque characteristics, stent characteristics, and surgeon experience.
47972311|NCT05374434|OTHER|Conventional irrigation|The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
48326529|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
48326530|NCT04948463|DRUG|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
48326531|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
48326532|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
48326533|NCT04948463|DRUG|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
48326534|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
48326535|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
48489987|NCT02242318|DRUG|Telmisartan|
48489988|NCT02242318|DRUG|Valsartan|
48649761|NCT06189612|OTHER|Clinical reasoning based physiotherapy + cervical movement control training|An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
48489989|NCT02242318|DRUG|Placebo|
48489990|NCT00325377|PROCEDURE|MME Procedure|
48489991|NCT01708629|DRUG|210 mg brodalumab|210 mg brodalumab administered SC
48489992|NCT01708629|DRUG|140 mg brodalumab|140 mg brodalumab administered SC
48489993|NCT01708629|DRUG|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
48489994|NCT01708629|DRUG|placebo|placebo administered SC
48498079|NCT05571735|BIOLOGICAL|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
48489995|NCT01742559|PROCEDURE|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman \& Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
48121079|NCT02382744|DEVICE|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
48121080|NCT00865436|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
48121081|NCT00865436|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
48326536|NCT04948463|DRUG|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
48326537|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
48489996|NCT01742559|PROCEDURE|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
48489997|NCT06277141|BEHAVIORAL|Standard message|Participants will receive standard messaging based on the Cancer Association of South Africa (CANSA) recommendation on breast cancer screening and a reminder to screen for breast cancer.
47972312|NCT05374434|DEVICE|Inertial cavitation|The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
47972313|NCT03499704|DRUG|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
47972314|NCT03499704|DRUG|Alogliptin|Alogliptin tablets.
47972315|NCT03499704|DRUG|Metformin|Metformin tablets.
47972316|NCT03499704|DRUG|Dapagliflozin|Dapagliflozin tablets.
47972317|NCT02071121|DRUG|BIIB061|BIIB061 capsules for oral administration
47972318|NCT02071121|DRUG|Placebo|BIIB061 matching placebo capsules
47972319|NCT02071121|DRUG|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
47972320|NCT00038220|DRUG|Lopinavir/ritonavir|
47972321|NCT00038220|DRUG|Efavirenz|
47972322|NCT00038220|DRUG|Lamivudine|
47972323|NCT00038220|DRUG|Tenofovir DF|
47972324|NCT03890081|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
47972325|NCT03425747|DRUG|Calcium Carbonate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
47972326|NCT03425747|DRUG|Calcium Citrate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
47972327|NCT02737293|OTHER|Control Diet|4-week intake of Control Diet 5 day rotating menu
47972328|NCT02737293|OTHER|Med Diet|4-week intake of Med Diet 5 day rotating menu
47972329|NCT02737293|OTHER|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
47972330|NCT01437072|OTHER|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
47972331|NCT02025621|DRUG|Levosimendan|
47972332|NCT02025621|DRUG|Placebo|matching placebo
47972333|NCT04717609|PROCEDURE|Saphenous Nerve Block|Preoperative Saphenous Nerve Block for partial Meniscectomy
47972334|NCT04717609|DRUG|Ropivacaine injection|preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
47972335|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-carb)|Receive dietary guidelines and recipes and consume a low-carbohydrate diet
47972336|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-fat)|Receive dietary guidelines and recipes and consume a low-fat diet
47972337|NCT03785808|BEHAVIORAL|Special Diet Therapy (USDA control)|Receive dietary guidelines and recipes and consume USDA control diet
48121082|NCT00772044|DEVICE|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
48121083|NCT00772044|DEVICE|Sham Device|Sham device will be applied
48121084|NCT05816902|OTHER|The location of the patient's treatment|The location of the patient's treatment
48121085|NCT03332758|PROCEDURE|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
48121086|NCT03332758|PROCEDURE|External drainage|Standard of care treatment for retinal detachment.
48121087|NCT03380234|OTHER|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
48326538|NCT05640856|PROCEDURE|intubation|Endotracheal tube placement
48326539|NCT05352906|DIAGNOSTIC_TEST|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
48121088|NCT03380234|OTHER|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change \[15\]. They can then forward selected messages to other members of their household, especially smokers.
48121089|NCT03380234|OTHER|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
47972338|NCT05467280|OTHER|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
47972339|NCT00712127|OTHER|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
47972340|NCT00712127|OTHER|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
47972341|NCT03973385|DEVICE|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
47972342|NCT00158158|DRUG|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
47972343|NCT00158158|OTHER|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
47972344|NCT06056037|BEHAVIORAL|Experimental: Making ART Work|A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.
47972345|NCT06056037|BEHAVIORAL|Standard of Care|Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
47972346|NCT00002169|DRUG|Nelfinavir mesylate|
47972347|NCT00929799|DRUG|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
47972348|NCT02144012|DRUG|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
47972349|NCT02144012|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
47972350|NCT02144012|DRUG|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
47972351|NCT05741632|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
47972352|NCT05741632|DRUG|Levofloxacin Ophthalmic|Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
47972353|NCT06044428|DEVICE|Steadytemp®|Steadytemp® is a clinical thermometer intended to continuously measure axillary temperature and to display relative changes in axillary temperature to the user. The system consists of a sensor patch and a smartphone application, the body temperature measured by the sensor is transmitted via Near-Field-Communication (NFC) and subsequently displayed in the App.
47972354|NCT05892471|DRUG|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
47972355|NCT05892471|DRUG|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
47972356|NCT02612727|DEVICE|Filtered-sunlight phototherapy|Infants will receive \>= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
48121090|NCT03380234|OTHER|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
48121091|NCT02578589|PROCEDURE|Plica resection vs conservative treatment|Plica resection vs conservative treatment
48121092|NCT00895531|DRUG|Depodur|7.5 mg Depodur via the epidural catheter
47972357|NCT02612727|DEVICE|Intensive phototherapy|Infants will receive \>= four hours per day of intensive phototherapy for 1 to 10 days.
48121093|NCT00895531|PROCEDURE|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
48489998|NCT06277141|BEHAVIORAL|Radiology booking site link.|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site.
48489999|NCT06277141|BEHAVIORAL|Radiology practice telephone numbers|Participants will receive a reminder to screen for breast cancer together with a list and telephone numbers of radiology practices
48649762|NCT06189612|OTHER|Clinical reasoning based physiotherapy + orofacial movement control training|An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
48121094|NCT02971943|PROCEDURE|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
48649763|NCT06189612|OTHER|Clinical reasoning based physiotherapy + standard exercises|A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
48649764|NCT04859075|OTHER|Bifidobacterium longum 35624|1 capsule daily
47972358|NCT02714582|BEHAVIORAL|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson \& Mangino 2006).
48121095|NCT06255262|DRUG|Surufatinib|"(1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT\> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity."
48121096|NCT06255262|DRUG|Durvalumab|1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
48490000|NCT06277141|BEHAVIORAL|Radiology site link and telephone numbers|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site and a list and telephone numbers of radiology practices
47972359|NCT00830362|DRUG|Propranolol|40 mg administered once
47972360|NCT00830362|DRUG|Placebo|administered once
47972361|NCT02885012|DRUG|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
48326540|NCT03121118|OTHER|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
47972362|NCT06385639|DIETARY_SUPPLEMENT|Probiotic|This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
47972363|NCT01603355|DRUG|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
47972364|NCT05902780|DRUG|Caudal Bupivacaine injection|- Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
47972365|NCT05902780|DRUG|Caudal Dexmedetomidine Injection|- Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
47972366|NCT01844518|BIOLOGICAL|Abatacept|
47972367|NCT01140243|DIETARY_SUPPLEMENT|LCPUFA|premature infant formula supplemented with LCPUFA
47972368|NCT03025477|DRUG|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
47972369|NCT03025477|DRUG|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
47972370|NCT03025477|DRUG|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"* carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
47972371|NCT03025477|DRUG|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"* Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
47972372|NCT02792725|DRUG|Abemaciclib|Administered orally
47972373|NCT04449575|OTHER|eSwabs|from skin
47972374|NCT01288066|PROCEDURE|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
48121097|NCT00543816|DRUG|MK0767|
48121098|NCT00781378|DRUG|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
48121099|NCT00781378|DRUG|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
48121100|NCT00141349|DRUG|UK-369,003|
48490001|NCT01829087|DRUG|Botox|
48490002|NCT01829087|DRUG|placebo|
48490003|NCT02799030|DRUG|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
48490004|NCT02799030|DRUG|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
48490005|NCT02799030|DRUG|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
48649765|NCT05830097|DRUG|CBP-1019|Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
48649766|NCT06199752|DIETARY_SUPPLEMENT|probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA|probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),
47972375|NCT01288066|PROCEDURE|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
47972376|NCT02063620|DRUG|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
47972377|NCT03394326|BEHAVIORAL|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
48490006|NCT02780427|DRUG|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
48121101|NCT01480505|PROCEDURE|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
47972378|NCT00456014|DRUG|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
47972379|NCT00456014|DRUG|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
47972380|NCT01308060|DRUG|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
47972381|NCT01308060|OTHER|Placebo|
47972382|NCT01350414|DEVICE|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
47972383|NCT03459547|DEVICE|dental implant|Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
47972384|NCT04962204|BEHAVIORAL|Virtual meeting between patients/physicians and caregiver|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
47972385|NCT00471328|DRUG|Nilotinib|Nilotinib 400 mg twice daily (bid)
47972386|NCT00471328|OTHER|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
47972387|NCT06304376|PROCEDURE|Alveolar ridge grafting|Alveolar ridge grafting was carried out using anterior iliac crest bone graft. Khoury shell technique was the method of ridge reconstruction via a cortical bone shell was fixed away from alveolar ridge using two micro-screws and the gap created was filled by cancellous bone
47972388|NCT03537105|PROCEDURE|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
47972389|NCT03202498|DEVICE|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
47972390|NCT03202498|OTHER|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
47972391|NCT03202498|DEVICE|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
48121102|NCT01985542|DRUG|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
48121103|NCT03338816|DRUG|Givosiran|Givosiran by SC
48121104|NCT03338816|DRUG|Placebo|Matching placebo (normal saline \[0.9% NaCl\]) by SC
48121105|NCT01284075|BEHAVIORAL|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
48490007|NCT06240715|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
48490008|NCT01742780|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
48490009|NCT04813315|OTHER|Kendall exercise|consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor
48490010|NCT04813315|OTHER|Gong's mobilization|it is combination of glide along the facet joint and concurrent movement of cervical spine
48490011|NCT05632341|DIETARY_SUPPLEMENT|Lactococcus lactis|1 capsule once a day
48490012|NCT05632341|OTHER|maltodextrin|1 capsule once a day
48490013|NCT04691310|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
48121106|NCT01284075|BEHAVIORAL|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
48326541|NCT01807260|PROCEDURE|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
48326542|NCT04871685|DIAGNOSTIC_TEST|lung ultrasound|the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
48649767|NCT03791424|DRUG|Midazolam|Administering premedication with sedative drug to relieve anxiety
48326543|NCT00151125|DRUG|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
48326544|NCT00151125|DRUG|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
48326545|NCT00151125|DRUG|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
48326546|NCT05479305|DEVICE|The Valiant Captivia Stent Graft|Aortic arch/Descending aorta Repair
48326547|NCT06437145|OTHER|Type of Exercise|The high-intensity interval training session consists of 5-min warm-up and 5-min cool-down periods. The main part has 7 cycles. Each cycle consists of 1.5 min of 80-90% of HRpeak and 3 min of 65-70% of HRpeak. The moderate-intensity continuous training session consists of 5 min warm-up and 3-min cool down period. The main part consists of 32 min of 75% of HRpeak.
48326548|NCT04488848|OTHER|bolus glucose|bolus Glucose
48649768|NCT05384548|BEHAVIORAL|Problematic smart phone use course|A 6 session, online, group-based, psychological course targetting problematic smart phone use.
48490014|NCT03380533|DRUG|Buprenorphine|Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
48490015|NCT03380533|DRUG|Placebo Patch|Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
48649769|NCT04858347|DEVICE|Total knee replacement|Implantation of the GEMINI SL Fixed Bearing PS knee prosthesis. The operation technique of the GEMINI SL Fixed Bearing PS knee prosthesis will be followed.
48649770|NCT05596591|DEVICE|Focused extracorporeal shockwave therapy|High energy level shockwaves (between 0.28-0.60 mJ/mm\^2) will be focused over the subchondral bone with the bone marrow lesion, previously localized on MRI.
48121107|NCT01284075|OTHER|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
48121108|NCT03191981|DRUG|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
48490016|NCT03380533|DRUG|Multimodal Oral Scheme|Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
48649771|NCT05252702|DEVICE|Aveir DR Leadless Pacemaker System|Patients will undergo a dual chamber leadless pacemaker system implant wherein a leadless pacemaker will be implanted in the right ventricle and right atrium
48649772|NCT05007925|DEVICE|Intravascular Lithotripsy|Localized peripheral intravascular lithotripsy
48649773|NCT03104920|PROCEDURE|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
48649774|NCT03104920|PROCEDURE|Traditional treatment|A traditional perioperative management for HCC.
47972392|NCT03202498|OTHER|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
48490017|NCT03380533|DRUG|Tramadol|Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
48649775|NCT03492294|DIAGNOSTIC_TEST|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
48649776|NCT06539104|PROCEDURE|arteficial inteligence evaluation of oocyte and embryo development|apply AI to find out the complex oocyte quality, embryo development, embryo ploidy and pregnancy success probability from the sequence of the data starting from the recording of the meiotic spindle in polarized light, through paternal factors up to the time lapse record of early embryo development.
48649777|NCT06439927|DEVICE|Polycaprolactone nasal mesh|a 3-dimensional fabricated Polycaprolactone nasal mesh
47972393|NCT03187106|DRUG|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
47972394|NCT03187106|DRUG|Placebo|Placebo representing standard of care
48121109|NCT03191981|DRUG|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
48121110|NCT03191981|DRUG|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
48326549|NCT04488848|OTHER|continuous clucose|continuous clucose
48121111|NCT02206763|DRUG|Momelotinib (MMB)|Tablet(s) administered orally once or twice daily
48121112|NCT02206763|DRUG|Erlotinib|Tablet(s) administered orally once daily.
48121113|NCT06191666|BEHAVIORAL|Group-based education and discussion|Group-based education and discussion (60 minutes each per week, virtual and in-person) based upon guidelines for nutrition for cancer survivorship (e.g., follow a plant-based diet with a variety of vegetables, fruits, whole grains, and legumes; limit alcohol intake; reduce consumption of highly processed foods and foods high in salt; achieve a weekly calorie deficit of approximately 3500 kcal for weight loss)
48121114|NCT06191666|BEHAVIORAL|Individual 1:1 counseling|Individual 1:1 counseling sessions (30 minutes each per month, virtual) with an RD to review progress and address barriers
48121115|NCT06191666|BEHAVIORAL|Group based behavioral skills development and cooking demonstrations|Group-based behavioral skills development sessions and cooking demonstrations (60-90 minutes each per month, in-person) to focus on behavior change techniques (e.g., self-monitoring, goal setting) and nutrition skills (e.g., recipe development, label reading).
48121116|NCT06191666|BEHAVIORAL|BfitBwell|This program consists of a supervised exercise program developed by a cancer exercise specialist and based upon the NCCN guidelines for physical activity during cancer survivorship and other recommendations.
48121117|NCT02414412|DIETARY_SUPPLEMENT|Ulmus macrocarpa water extract|
48121118|NCT06117579|OTHER|Inspiratory muscle training|"Description of a typical session:~Session duration: between 12 and 20 minutes 3 cycles of 30 repetitions with 1 minute of break between each cycle. The patient should inhale as hard as possible against an inspiratory resistance generated by a valve device."
48649778|NCT06570408|BEHAVIORAL|Western Ontario and McMaster University Osteoarthritis Index (WOMAC)|1. WOMAC is widely used in the evaluation of Hip and Knee Osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales
48121119|NCT05425992|OTHER|Interview|Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
47972395|NCT03187106|DRUG|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
48649779|NCT06570408|BEHAVIORAL|Visual Analogue Scale (VAS)|2. VAS is one of the pain rating scales used in epidemiologic and clinical research to measure the intensity or frequency of various symptoms.
48649780|NCT06570408|DIAGNOSTIC_TEST|Kellgren Lawrence Grading Scale (KL score)|3. KL score is the most widely used clinical tool for the radiographic diagnosis of OA.Each radiograph was assigned a grade from 0 to 4,
47972396|NCT05106283|PROCEDURE|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
47972397|NCT01194180|BIOLOGICAL|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
47972398|NCT01194180|BIOLOGICAL|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
47972399|NCT02706340|OTHER|No intervention - observational study only|
47972400|NCT03598283|DEVICE|Ultrasound/transient elastography|The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
47972401|NCT03894553|DEVICE|ExAblate Neuro|Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
47972402|NCT03429686|OTHER|DRT Intervention|The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
47972403|NCT04425694|DEVICE|e-EWS system|The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
47972404|NCT01929798|DEVICE|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
47972405|NCT00871260|DRUG|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
47972406|NCT02704871|OTHER|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
47972407|NCT00682162|DEVICE|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
48649781|NCT06570408|BEHAVIORAL|Quality of Life Questionnaires and Assessments:|4. Quality of Life Questionnaires and Assessments: include quality of life, intestinal tract, conscious assessment of pain relief.etc.
48326550|NCT06451263|BEHAVIORAL|Nudge|Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
48326551|NCT04354155|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
48326552|NCT04643223|OTHER|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
48649782|NCT00680914|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
48649783|NCT00680914|BIOLOGICAL|Prevenar|3 doses administered intramuscularly.
47972408|NCT00682162|DEVICE|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
48121120|NCT01824485|DRUG|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
48121121|NCT01824485|DRUG|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
48490018|NCT03380533|DRUG|Placebo Tablet|Placebo tablet that the patient consumes every 8 hours during the first five days
48121122|NCT03277534|OTHER|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
48649784|NCT00680914|BIOLOGICAL|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
48490019|NCT06236932|DIETARY_SUPPLEMENT|Mediterranean diet|Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).
48649785|NCT00091897|DRUG|Rituximab|
48121123|NCT03277534|OTHER|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
48649786|NCT00091897|DRUG|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
48649787|NCT02719574|DRUG|FT-2102 (olutasidenib)|FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
48649788|NCT02719574|DRUG|Azacitidine|azacitidine will be administered per site's standard of care
47972409|NCT00929318|PROCEDURE|blood sampling|
47972410|NCT00929318|PROCEDURE|blood sampling|
47972411|NCT02205632|DEVICE|MPS II|
47972412|NCT02364479|DRUG|50mg Yisaipu|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
47972413|NCT02364479|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
47972414|NCT02364479|DRUG|Placebo|The injection method and frequency of placebo is the same as the other arms.
47972415|NCT04039698|OTHER|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
47972416|NCT04039698|DRUG|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
47972417|NCT01200602|DRUG|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
47972418|NCT01200602|OTHER|clinical observation|No treatment is given.
48121124|NCT03847259|DIAGNOSTIC_TEST|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
48649789|NCT02719574|DRUG|Cytarabine|low-dose cytarabine will be administered per site's standard of care
48649790|NCT04551586|DRUG|ACH-0145228: Immediate Release|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
48649791|NCT04551586|DRUG|ACH-0145228: Powder-in-capsule|ACH-0145228 (240 milligrams) will be administered orally on Day 1.
48649792|NCT04479852|DRUG|SP-624|Oral capsule
48649793|NCT04479852|DRUG|Placebo|Oral capsule
48649794|NCT06468865|DEVICE|Continuous glucose monitor (Dexcom® G7)|Continuous glucose monitors measures glucose levels in the interstitial fluid every 5 minutes
48649795|NCT06570915|DRUG|Daratumumab Injection|Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
48649796|NCT06571578|DEVICE|Threshold Inspiratory muscle trainer|threshold inspiratory muscle trainer device Each subject will breathe through a separate mouthpiece through attach the mouthpiece firmly While putting a nose clip and inhale deeply through the mouthpiece to generate an inspiratory pressure greater than the indicated presetting threshold pressure to compress the spring and open the valve. Using High - intensity interval training technique
48649797|NCT06571578|OTHER|posture correction exercises|"conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles"
48649798|NCT06675565|DRUG|ALN-AGT01 RVR|ALN-AGT01 RVR will be administered subcutaneously (SC)
48649799|NCT06675565|DRUG|Placebo|Placebo will be administered SC
48649800|NCT04054362|DRUG|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
48649801|NCT04054362|DRUG|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
48649802|NCT04054362|DRUG|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
48649803|NCT04054362|DRUG|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
48121125|NCT05429034|BEHAVIORAL|MIST paradigm|Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
48121126|NCT05429034|BEHAVIORAL|Sham paradigm|Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
48649804|NCT04286776|DEVICE|Direct electrical stimulation|Stimulation will not exceed 0.75 mA and will be approved prior by study investigators. Each subject will have a safety threshold testing at the beginning of each session and if 'afterdischarges' occur the subject's stimulation threshold will be lowered.
48649805|NCT04665843|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
48121127|NCT05961462|BEHAVIORAL|Exercise training|Patients randomized to the exercise group will be offered aerobic exercise plan containing 12 sessions over 4 weeks (3 times per week).
48326553|NCT04643223|OTHER|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
47972419|NCT04615481|OTHER|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
48121128|NCT02553161|DRUG|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
48649806|NCT04665843|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
48649807|NCT04665843|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
48649808|NCT05547867|PROCEDURE|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
47972420|NCT04615481|OTHER|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
48121129|NCT02553161|BEHAVIORAL|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
48121130|NCT02092116|DRUG|Romidepsin|Latency reversing agent
48121131|NCT02092116|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
48121132|NCT02092116|BIOLOGICAL|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
48121133|NCT03778645|PROCEDURE|Adrenal Venous Sampling|Adrenal Venous Sampling via an Antecubital Approach
48121134|NCT04421261|DEVICE|Air-Q Self Pressurized Airway Device with Blocker|used in low risk adult females undergoing elective surgeries
48121135|NCT04421261|DEVICE|Proseal Laryngeal Mask Airway|used in low risk adult female patients undergoing elective surgeries
48490020|NCT06236932|DIETARY_SUPPLEMENT|Melatonin supplementation|Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
48490021|NCT05780021|BEHAVIORAL|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
48649809|NCT00657683|BIOLOGICAL|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
47972421|NCT01874132|BEHAVIORAL|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
47972422|NCT06106178|OTHER|Simulator for Basic Ultrasound Skills|Basic course of a traditional ultrasound simulator focusing on hand-eye coordination
48490022|NCT02676362|OTHER|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
48490023|NCT06526455|DRUG|Vonoprazan|oral drug 3-56 days after ESD.
48490024|NCT06526455|DRUG|Esomeprazole|oral drug 3-56 days after ESD.
48490025|NCT02658513|OTHER|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
48490026|NCT02658513|OTHER|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
48490027|NCT02328742|BIOLOGICAL|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
48490028|NCT02328742|OTHER|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
48649810|NCT00657683|BIOLOGICAL|Placebo|1 dose of placebo
48649811|NCT04003389|DRUG|fezolinetant|administered orally
48121136|NCT01370343|DRUG|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
48121137|NCT01370343|DRUG|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
48121138|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
48121139|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
48121140|NCT00531596|DRUG|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
48121141|NCT03484988|DIETARY_SUPPLEMENT|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
48121142|NCT03484988|DIETARY_SUPPLEMENT|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
48121143|NCT03484988|DIETARY_SUPPLEMENT|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
48121144|NCT03695536|BEHAVIORAL|ultrasound use during resuscitation|ultrasound use during resuscitation
48121145|NCT01604161|DRUG|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
48121146|NCT06498544|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 nights at an altitude of 3600 m.
48121147|NCT06114602|BEHAVIORAL|E-Mail Reminder|Patients who have an appointment (either face-to-face or teleconsultation) scheduled with a doctor at the Hospital receive an e-mail at the time of their request as well as 14 days and 48 hours prior to the appointment, reminding them of the appointment time and the place where they have to go. In addition, a button has been added to the e-mail so that the patient can click on it and cancel it directly in a simple way.
48649812|NCT04003389|DRUG|placebo|administered orally
48649813|NCT05856942|OTHER|Health service - home-based PrEP monitoring|Home-based PrEP care
48649814|NCT00658073|PROCEDURE|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
48326554|NCT03532880|DRUG|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
48326555|NCT03532880|DRUG|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
48326556|NCT03532880|DRUG|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
48326557|NCT03532880|DRUG|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
48490029|NCT02328742|BIOLOGICAL|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
47972423|NCT06106178|OTHER|Serious Video Game|"The serious video game Underwater uses a 3D-printed ultrasound probe for maneuvering. During gameplay, coins must be collected in an underwater world using the aforementioned simulated ultrasound probe. The main focus of this game is to improve hand-eye coordination while using an ultrasound probe."
47972424|NCT02172924|BIOLOGICAL|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
47972425|NCT02172924|BIOLOGICAL|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
47972426|NCT00897260|DRUG|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
48121148|NCT04480918|DEVICE|Electroconvulsive Therapy (ECT)|ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
48121149|NCT04480918|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS for the treatment of treatment-resistant depression in an active major depressive episode
47972427|NCT00897260|RADIATION|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
47972428|NCT00897260|PROCEDURE|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
47972429|NCT00563381|DRUG|Tiotropium bromide|18 mcg/daily
47972430|NCT00563381|DRUG|Salmeterol|100 mcg/daily
48121150|NCT04480918|DRUG|Ketamine|Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
48121151|NCT04480918|DRUG|Esketamine|Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
47972431|NCT00563381|DRUG|Placebo Salmeterol|Placebo identical to Salmeterol device
47972432|NCT00563381|DRUG|Placebo Tiotropium|Placebo identical to Tiotropium device
47972433|NCT04971122|OTHER|Trendeleburg -5 degree,-10 degree,-15 degree|Use a -5 or -10 or -15 degree trendelenburg position
48326558|NCT03532880|DRUG|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
48490030|NCT02328742|BIOLOGICAL|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
48490031|NCT01576874|DRUG|Oxytocin|40 IUs of oxytocin administered intranasally one time
48649815|NCT00658073|PROCEDURE|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
48649816|NCT04464980|DRUG|SL-BUP|Daily dosing of sublingual buprenorphine-naloxone
47972434|NCT04884477|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
47972435|NCT04388618|OTHER|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
47972436|NCT03951402|DRUG|100 mg CG5503 (tapentadol hydrochloride) PR tablet|100 mg CG5503 (tapentadol hydrochloride) PR tablet.
48121152|NCT04480918|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|TMS for the treatment of OCD
48121153|NCT01105117|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
47972437|NCT03951402|DRUG|Placebo matching CG5503 PR tablet|Matching placebo tablet to CG5503 PR tablet.
47972438|NCT03951402|DRUG|Placebo matching moxifloxacin capsule|Matching placebo capsule to moxifloxacin capsule.
48121154|NCT01105117|DRUG|Flolan®|per Prescribing Information
48490032|NCT01576874|DRUG|placebo|placebo administered intranasally one time
48490033|NCT00669071|DRUG|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
48490034|NCT00669071|DRUG|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
48649817|NCT04464980|DRUG|XR-BUP|Weekly/monthly dosing of extended-release injectable buprenorphine
48649818|NCT04464980|DRUG|XR-NTX|Monthly dosing of extended-release injectable naltrexone
48649819|NCT04464980|BEHAVIORAL|MM|MM consists of standard Medical Management and the usual counseling at the treatment program.
48649820|NCT04464980|BEHAVIORAL|MMR|MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
48649821|NCT04464980|BEHAVIORAL|MMD|MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
48649822|NCT01444924|DRUG|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
48121155|NCT03454646|DRUG|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
48121156|NCT04875624|DIAGNOSTIC_TEST|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)|Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) will be administered by one of the 2 blinded examiners who are unaware of neonatal glycemia status. Bayley-4 examines Cognitive, Language, Motor, Social-Emotional and Adaptive Behavior domains of development and may require up to 120 minutes to complete.
48121157|NCT02250235|OTHER|Health risk information|
48649823|NCT01444924|DRUG|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
48649824|NCT02214212|DEVICE|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
48649825|NCT02214212|DEVICE|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
48649826|NCT00220792|BEHAVIORAL|Brief supportive-expressive group therapy|
47972439|NCT03951402|DRUG|400 mg Moxifloxacin tablet (overencapsulated)|Overencapsulated 400 mg Moxifloxacin tablet.
47972440|NCT04313218|DRUG|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
48490035|NCT01197417|DRUG|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
47972441|NCT00883805|BIOLOGICAL|Blood draw|Subjects will give blood for analysis of metal ion concentrations
47972442|NCT00883805|RADIATION|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
47972443|NCT03748797|OTHER|Moderate intensity exercise training under supervision|Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
48121158|NCT03710057|DRUG|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
48121159|NCT03066115|DRUG|L-NMMA|See arm description.
48121160|NCT03066115|DRUG|Ketorolac|See arm description.
48490036|NCT01197417|DRUG|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
47972444|NCT05628532|DEVICE|Use of the DBLG1 system|During the treatment period, the patient will use the DBLG1 system (consisting of a DBLG1 handset with an embedded software named loop mode, a TERUMO MEDISAFE WITH patch pump and a Dexcom continuous glucose monitoring (CGM) G6). The main function of DBLG1 System is to adjust the insulin delivery at the correct time in order to maintain the patient's blood glucose in the target range and thus minimize both hypoglycaemic events and long-term complications associated with elevated average glycemia.
47972445|NCT02407353|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
47972446|NCT02407353|DRUG|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
47972447|NCT03736616|DRUG|Carboplatin|Chemotherapy
47972448|NCT03736616|DRUG|Ifosfamide|Chemotherapy
47972449|NCT03736616|DRUG|Etoposide|Chemotherapy
47972450|NCT03736616|BIOLOGICAL|Rituximab|Anti-CD20 mAb
47972451|NCT03736616|DRUG|Carmustine|Chemotherapy
47972452|NCT03736616|DRUG|Cytarabine|Chemotherapy
47972453|NCT03736616|DRUG|Melphalan|Chemotherapy
48121161|NCT03066115|DRUG|Ascorbic Acid|See arm description.
48121162|NCT03066115|PROCEDURE|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
48490037|NCT01462318|DRUG|Midazolam|5 mg
48490038|NCT01462318|OTHER|Caffeine|200 mg
48490039|NCT01462318|DRUG|S-warfarin|10 mg
48490040|NCT01462318|OTHER|Vitamin K|10 mg
48490041|NCT01462318|DRUG|Omeprazole|40 mg
48490042|NCT01462318|DRUG|Dextromethorphan|30 mg
47972454|NCT03736616|OTHER|Autologous HSCT|Cellular Therapy
47972455|NCT03736616|DRUG|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
47972456|NCT05496062|DEVICE|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F\&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
47972457|NCT00453622|DEVICE|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
47972458|NCT06229340|DRUG|Leflunomide|100 mg daily for 3 days at the loading dose, then 20 mg daily at the standard dose.
48490043|NCT01462318|BIOLOGICAL|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
48649827|NCT04824287|OTHER|pelvic floor muscle exercise|pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
48326559|NCT03532880|DRUG|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
48649828|NCT03523663|OTHER|no intervention. measure eye movement data|
48121163|NCT03066115|PROCEDURE|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
48121164|NCT01136876|DRUG|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
48121165|NCT01136876|DRUG|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
48121166|NCT01897272|BEHAVIORAL|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
48121167|NCT01251224|OTHER|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
48326560|NCT03532880|RADIATION|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
48326561|NCT01365377|OTHER|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
48326562|NCT03889327|BEHAVIORAL|Neuropsychological Feedback & Psychoeducation (Cognition)|The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
48649829|NCT04928131|OTHER|No intervention - retrospective observational cohort study|
48649830|NCT01965951|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
48649831|NCT01965951|OTHER|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
48649832|NCT02685436|DRUG|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
48649833|NCT01443312|GENETIC|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
48649834|NCT04985110|DRUG|Cotrimoxazole|The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
48649835|NCT04985110|DRUG|Placebo|The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
48649836|NCT02003157|PROCEDURE|hypnosis during embryo transfer or usual transfer procedure|
48649837|NCT04743063|DRUG|sacubitril/valsartan|Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
48649838|NCT04743063|DRUG|Angiotensin II Receptor Blockers|Initiation of ARBs, identified using prescription fill in pharmacy claims
48649839|NCT00908908|DRUG|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m\^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
48649840|NCT05055427|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|"Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day"
48649841|NCT04629950|DRUG|Rimegepant|Active Agent
47972459|NCT06229340|DRUG|The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab|"Use of one of the possible MEK-inhibitor options:~Trametinib 2 mg once daily orally; Cobimetinib 60 mg on days 1-21, break 7 days, cycle 28 days orally; Binimetinib 45 mg 2 times a day daily orally. + Hydroxychloroquine 600 mg 2 times a day daily orally.~± Bevacizumab 7.5 mg/m² every 3 weeks intravenously."
48649842|NCT04629950|DRUG|Placebo|Placebo Comparator
48649843|NCT02157727|DEVICE|Infants hospitalized in health facilities performing Tele-expertise|
48649844|NCT03063645|DRUG|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
48649845|NCT03063645|DRUG|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
48649846|NCT03063645|DRUG|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
48649847|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks
48649848|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Syrup Orofer (5 ml = 50 mg)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral iron 25 mg from Emcure Pharmaceuticals Ltd. to be administered once daily for 24 weeks
48121168|NCT01251224|OTHER|Education|This group will receive education about mouse IPM.
48121169|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
48121170|NCT00522951|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
48121171|NCT00522951|DRUG|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
48121172|NCT00241241|DRUG|pegylated interferon-alfa 2a|
48121173|NCT04364451|OTHER|Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Leukaemia During Therapy With L - Asparaginase|Children that meet all the inclusion criteria for this study will be examined and undergo treatment with asparaginase (Experimental group) and will be compared to the corresponding teams of healthy children and children that have ailed and are off chemotherapy for at least 6 months (Control group).
48121174|NCT02253537|DEVICE|CST001|
48121175|NCT02959229|DRUG|Lactoferrin|
48121176|NCT02959229|DRUG|Placebo (for Lactoferrin)|placebo in form of distilled water
48121177|NCT06075472|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) is a therapeutic technique which involves specific training of respiratory muscles to yield improvements in inspiratory muscle strength and respiratory function.
48121178|NCT06075472|OTHER|Balance Exercises|Balance exercises involve functional movements at the individual's maximum level of independence.
48121179|NCT01831700|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
48490044|NCT03680287|DRUG|Within-Subject test of blinded study medication|On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
48490045|NCT06056011|DEVICE|Connex CSVM with Timmy3 module|Connex Vital Signs Monitor with the Timmy3 Investigational module
48490046|NCT03424512|BEHAVIORAL|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
48121180|NCT01831700|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
48490047|NCT02147249|DRUG|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
48121181|NCT00739739|DRUG|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
48121182|NCT00739739|DRUG|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
48121183|NCT00739739|DRUG|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
48490048|NCT05732896|DEVICE|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
48490049|NCT05023382|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
48490050|NCT01918826|DEVICE|TENS|
48121184|NCT04038814|PROCEDURE|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) \< 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
48490051|NCT00309764|BEHAVIORAL|Telemedicine|
48490052|NCT04024293|DEVICE|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
48121185|NCT04038814|PROCEDURE|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~* Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~* Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~* Automatic continuous subglottic secretion drainage"
48326563|NCT03889327|BEHAVIORAL|Psychoeducation (Health)|Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
48649849|NCT06443593|DIETARY_SUPPLEMENT|Tablet VitaBliss vitamin B12 (2.2 mcg) and Tablet Tayo (60000 IU)|Oral vitamin B12 supplement 2.2 mcg from BLISS WELNESS, Bliss Lifesciences, LLP to be administered once daily for 24 weeks and oral vitamin D3 (60000 IU) from Eris Lifesciences Ltd to be administered once in 3 months for 24 weeks
47972460|NCT04813445|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
47972461|NCT05508581|PROCEDURE|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
47972462|NCT01888237|DRUG|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
47972463|NCT01888237|DRUG|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
47972464|NCT03435861|DRUG|VX-745|active drug capsules
48121186|NCT02699385|OTHER|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
48326564|NCT01182389|PROCEDURE|Robotic VT Ablation|Robotic VT Ablation
48326565|NCT01182389|OTHER|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
48326566|NCT03419221|PROCEDURE|PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions|"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."
48326567|NCT03419221|OTHER|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
48490053|NCT03248453|OTHER|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
48490054|NCT01423136|DEVICE|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
48490055|NCT03334721|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
48490056|NCT03334721|DRUG|Placebo Oral Capsule|5 day trial of matched placebo
48490057|NCT04420221|BIOLOGICAL|Sa-5Ag half dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.
48490058|NCT04420221|BIOLOGICAL|Sa-5Ag full dose non-adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.
48490059|NCT04420221|BIOLOGICAL|Sa-5Ag half dose adjuvanted|1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.
48490060|NCT04420221|BIOLOGICAL|Sa-5Ag full dose adjuvanted|A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.
48490061|NCT04420221|BIOLOGICAL|Placebo|One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.
48649850|NCT06209372|PROCEDURE|Group PENG|Pericapsular Nerve Group Block (PENG)
48649851|NCT06209372|DRUG|Group C|Tramadol infusion
48326568|NCT01213095|DRUG|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
48326569|NCT03226132|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
48490062|NCT02556372|DRUG|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.
48649852|NCT03968406|OTHER|Quality-of-Life Assessment|Ancillary studies
48649853|NCT03968406|RADIATION|Radiation Therapy|Undergo radiation therapy
48649854|NCT03968406|DRUG|Talazoparib|Given PO
47972465|NCT03435861|DRUG|placebo|placebo capsules
47972466|NCT02171520|DRUG|Dabigatran etexilate generation I|
47972467|NCT02171520|DRUG|Dabigatran etexilate generation II|
48649855|NCT05663554|BEHAVIORAL|WW Intervention|The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.
47972468|NCT05845151|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET|Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.
48121187|NCT02699385|DRUG|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
48121188|NCT02699385|DRUG|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
48121189|NCT04691635|OTHER|evaluation of movements with sensors|evaluation of movements with sensors
48121190|NCT04018924|DEVICE|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
48121191|NCT00846326|DRUG|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
48121192|NCT00846326|DRUG|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
48121193|NCT00304135|DRUG|cisplatin|
48121194|NCT00304135|DRUG|gemcitabine hydrochloride|
48121195|NCT00304135|DRUG|oxaliplatin|
48490063|NCT01917864|BEHAVIORAL|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
48121196|NCT01873313|DRUG|Ropivacaine|
48121197|NCT01323231|BEHAVIORAL|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
48121198|NCT00535145|DRUG|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
48121199|NCT03473340|DRUG|Pirfenidone Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
48121200|NCT03473340|DRUG|Placebo Capsule|"Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
48326570|NCT03226132|BEHAVIORAL|Repeated Contact|Repeated Contact
48326571|NCT01013168|PROCEDURE|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
48326572|NCT01382199|DRUG|Lactoferrin|
48326573|NCT05534035|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
48121201|NCT00708188|DEVICE|Multidetector raw CT|Multidetector raw CT
48121202|NCT05646329|BEHAVIORAL|Motivational Interview|The motivational interview to be held with the experimental group was planned as 4 sessions together with the follow-up session.
48121203|NCT04196504|DEVICE|Echocardiograghy, ECG|transthoracic echocariography, 12 lead ECG
48121204|NCT04925336|OTHER|Nociceptive stimulation|"These investigations in healthy volunteers will study the association between cerebral and neurovegetative (sympathetic and parasympathetic) electrophysiological responses in response to a controlled and tolerable pain stimulus, determined for each individual. The pain stimulus will be delivered using an electrically conductive glove used in clinical practice for transcutaneous therapeutic stimulation.~The thresholds of nociception and tolerance will be determined in each healthy volunteer."
48326574|NCT05534035|BIOLOGICAL|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
48326575|NCT04998357|OTHER|Endovascular autologous mitochondrial transplantation|During standard-of-care endovascular reperfusion procedure, subjects will have autologous mitochondria infused via microcatheter into ischemic brain.
48326576|NCT04579796|OTHER|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
48326577|NCT04579796|PROCEDURE|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
47972469|NCT04348773|PROCEDURE|Dehydration|Dehydration of the natural tooth by tooth isolation
47972470|NCT04348773|PROCEDURE|Rehydration|Rehydration
47972471|NCT05174897|BEHAVIORAL|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
47972472|NCT02665520|PROCEDURE|liposuction for retrieval of own stem cells from fat cells|
48121205|NCT01976312|OTHER|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
47972473|NCT05538702|DEVICE|IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
48121206|NCT01976312|DRUG|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
48649856|NCT05663554|OTHER|Usual Care|The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
48649857|NCT03308331|OTHER|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
48121207|NCT01845844|DRUG|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
48121208|NCT02051491|DEVICE|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
47972474|NCT05538702|DEVICE|IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
47972475|NCT05538702|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
47972476|NCT05538702|DEVICE|IQOS 3.0 DUO turned off with a bland taste unit|Placebo device
47972477|NCT03273595|DRUG|Lapatinib|
48121209|NCT02051491|DEVICE|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
48649858|NCT02324907|DEVICE|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
48649859|NCT05646173|DEVICE|vagus stimülation device|Vagustim is a wearable medical technology device that focuses on non-invasive bilateral auricular vagus nerve stimulation (VNS). VNS is a clinically approved, safe and effective neuromodulation method.
48649860|NCT05646173|DEVICE|Electrophysical agents|Electrophysical agents (EPAs) are those modalities that administer thermal, mechanical, electrical or light energy to the patient to provide physiological effects and therapeutic benefits.
48649861|NCT05646173|OTHER|home exercise program|The home exercise program will be explained to the patients by the physiotherapist and will also be given to the patient in the form of a brochure. Patients will be instructed to do the exercises regularly, three times a day for ten repetitions each day. The content of the exercises is updated weekly.
48649862|NCT05407766|BIOLOGICAL|OSSM-001|Single injection of OSSM-001 at dose of 100M or 300M cells
48649863|NCT05407766|OTHER|Placebo|Single injection of placebo (saline)
48649864|NCT04317742|DEVICE|Sleep Healthy Using the Internet (SHUTi) Intervention Group|"SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time."
47972478|NCT03273595|BIOLOGICAL|Trastuzumab|
48121210|NCT00137995|DRUG|Rituximab|375 mg/m² D-2/D1
48121211|NCT00137995|DRUG|Etoposide|100 mg/m² D1-D2-D3
48121212|NCT00137995|DRUG|Carboplatine|max 800mg D2
48121213|NCT00137995|DRUG|Ifosfamide + Mesna|5 g/m² from D2 to D13
48121214|NCT00137995|DRUG|Cisplatine|100 mg/m² from D1 to D13
47972479|NCT03273595|DRUG|Paclitaxel|
47972480|NCT03273595|DRUG|Epirubicin|
47972481|NCT03273595|DRUG|Cyclophosphamide|
47972482|NCT00309114|PROCEDURE|bacterial interference|
47972483|NCT03122769|RADIATION|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
47972484|NCT03910062|PROCEDURE|Lower limb angiography via the reperfusion cannula and NIRS monitoring|Data collection only (lower limb angiography, lower limbs NIRS values).
47972485|NCT05614830|OTHER|Dry needling ,|The intervention group will receive sessions of dry needling to relief myofacial pain on trapezius
47972486|NCT05614830|OTHER|usual physical therapy program|Therapeutic exercise
47972487|NCT01876160|OTHER|Transcutaneous electrical nerve stimulation|
47972488|NCT05933395|DRUG|Fulvestrant|Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
48121215|NCT00137995|DRUG|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
48121216|NCT00137995|DRUG|Dexamethasone|40 mg From D1 to D4
48121217|NCT00137995|PROCEDURE|Autologous Stem Cell Transplantation|
48121218|NCT00137995|DRUG|BCNU|300mg/m² on D-6
48121219|NCT00137995|DRUG|Etoposide|200 mg/m² from D-6 to D-3
48121220|NCT00137995|DRUG|Cytarabine|100 mg/m² from D-6 to D-3
48121221|NCT00137995|DRUG|Melphalan|140 mg/m² on D-2
48121222|NCT01058499|BEHAVIORAL|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
48121223|NCT05725135|DRUG|Propofol|Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
47972489|NCT05933395|DRUG|Neratinib|Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
47972490|NCT05933395|DRUG|Alpelisib|Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
47972491|NCT05933395|DRUG|Everolimus|Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
47972492|NCT05933395|DRUG|Abemaciclib|Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
47972493|NCT01660698|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin powder
48121224|NCT03489187|DEVICE|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
48121225|NCT03311737|COMBINATION_PRODUCT|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
48121226|NCT03311737|COMBINATION_PRODUCT|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
48121227|NCT03203538|DEVICE|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
48121228|NCT03203538|DEVICE|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
48121229|NCT03203538|DEVICE|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
48121230|NCT03203538|DEVICE|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
48326578|NCT01480479|DRUG|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
48326579|NCT01480479|DRUG|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
48326580|NCT01480479|DRUG|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
48326581|NCT02056717|DRUG|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
48326582|NCT02056717|DRUG|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
48121231|NCT03203538|DEVICE|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
47972494|NCT01660698|DIETARY_SUPPLEMENT|Probiotic|probiotic blended in maltodextrin powder
48121232|NCT03203538|DEVICE|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
48121233|NCT06009094|DRUG|VC005|VC005 group with Local topical application
48326583|NCT04008108|OTHER|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
48326584|NCT06333392|PROCEDURE|Total underwater colonoscopy|one grooup will be randomized to receive a total underwater colonoscopy
48326585|NCT06333392|PROCEDURE|Conventional colonoscopy|one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
48326586|NCT04084249|DIAGNOSTIC_TEST|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
48326587|NCT04084249|OTHER|Intensified Follow-up Schedule|PET/CT-scans every 3. month
48326588|NCT01352065|DRUG|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
48649865|NCT04317742|DEVICE|Online Patient Education (PE) Control Group|The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
47972495|NCT00160693|BIOLOGICAL|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
47972496|NCT03752632|DEVICE|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
47972497|NCT03752632|DEVICE|Tourniquet|A tourniquet alone will be used.
48121234|NCT06009094|DRUG|VC005 Placebo|VC005 Placebo group with Local topical application
48121235|NCT03836378|PROCEDURE|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
48121236|NCT04204993|DEVICE|Lumee Oxygen Platform|Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
48326589|NCT01352065|DRUG|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
48326590|NCT01352065|DRUG|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
48326591|NCT05451472|DIAGNOSTIC_TEST|thyroid function tests|Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
48326592|NCT05451472|DIAGNOSTIC_TEST|complete blood count|complete blood count
48326593|NCT05451472|DIAGNOSTIC_TEST|serum creatinine|serum creatinine
48326594|NCT05451472|DIAGNOSTIC_TEST|blood urea|blood urea
48326595|NCT05451472|DIAGNOSTIC_TEST|serum electrolyte|serum electrolyte
48326596|NCT05451472|DIAGNOSTIC_TEST|serum calcium|serum calcium
48326597|NCT05451472|DIAGNOSTIC_TEST|serum phosphorus|serum phosphorus
48326598|NCT05451472|DIAGNOSTIC_TEST|parathyroid hormone level|parathyroid hormone level
48326599|NCT05451472|DIAGNOSTIC_TEST|liver function test|ALT_AST_Total biliruin_total protein _serum albumin
48326600|NCT05451472|DIAGNOSTIC_TEST|arterial blood gases|PH_PCO2_PO2_HCO3_base deficit
48326601|NCT05451472|DIAGNOSTIC_TEST|complete urine analysis|complete urine analysis
48326602|NCT00594204|DRUG|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
48326603|NCT00594204|DRUG|Placebo|matching placebo 1 tablet twice a day for 12 weeks
48121237|NCT02258815|DRUG|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
48121238|NCT00941655|DRUG|Oxaliplatin|"Oxaliplatin 460 mg/m\^2 diluted in 2.0 L/m\^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m\^2 over 120 minutes,"
48326604|NCT05202223|BEHAVIORAL|Harmony at HOME (H@H)|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
48326605|NCT03427450|DIAGNOSTIC_TEST|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
48326606|NCT05007717|BEHAVIORAL|Data-informed Stepped Care (DiSC)|"The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving"
48326607|NCT02797639|OTHER|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
48326608|NCT02797639|OTHER|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
48326609|NCT06145152|PROCEDURE|Adaptive exercise training|The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
48326610|NCT06145152|PROCEDURE|Static exercise training|The training recommendation for the day will not be adjusted based on the readiness level.
48326611|NCT05611099|DEVICE|Dreem 3 System vs WatchPAT One|Dreem 3 System and WatchPAT One will be worn simultaneously during 3 nights by each study participant, in order to compare the TST automatically outputted by both devices.
48326612|NCT05611099|OTHER|Usability Questionnaire|After having undergone the 3 nights of measurement, an end of Study Questionnaire will be performed on a separate day to obtain Usability feedback from participants who have undergone simultaneous recordings with the Dreem 3 + WatchPAT devices.
47972498|NCT04073654|PROCEDURE|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
48490064|NCT04153019|OTHER|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
48649866|NCT00005839|DRUG|capecitabine|
47972499|NCT00653744|DRUG|Rosuvastatin|
47972500|NCT00653744|DRUG|Atorvastatin|
47972501|NCT02936570|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
47972502|NCT05871645|PROCEDURE|Jakarta Surgical Uterine Conservation (JSICA) Technique|a. Identifying the placenta accrete site; b. Meticulous dissection to create a bladder flap; c. Incision 1 cm above the placenta accrete; d. Fetal delivery; e. Bottom incision to resect the placenta; f. Placental delivery; g. Uterus without placenta; h. The resection area is approximated using interrupted horizontal mattress suture; i. The continuous suture used to close all incision areas; j. Evaluation of uterine contraction
47972503|NCT05871645|PROCEDURE|Standard Hysterectomy|The main types of hysterectomy are abdominal, vaginal, and laparoscopic hysterectomy
47972504|NCT01126476|OTHER|Proton Radiotherapy|
48121239|NCT00941655|DRUG|Irinotecan|Irinotecan 165 mg/m\^2 IV over 90 minutes
48649867|NCT00005839|DRUG|oxaliplatin|
47972505|NCT02926365|BEHAVIORAL|ICBT|
48121240|NCT00941655|DRUG|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m\^2 continuous intravenous over 48 hours."
48121241|NCT00941655|DRUG|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m\^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m\^2 intravenous over 120 minutes."
47972506|NCT05858710|DRUG|DPPG2-TSL-DOX|DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
47972507|NCT02848651|DRUG|Atezolizumab|Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
47972508|NCT03740945|DRUG|Placebo|Daily administration of one placebo vaginal ovule at bedtime
47972509|NCT03740945|DRUG|Prasterone (DHEA)|Daily administration of one prasterone vaginal ovule at bedtime
48326613|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared calcium hydroxide in to the root canals|Calcium hydroxide (Merck, Darmstadt, Germany): prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.
48326614|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared double antibiotic paste in to the root canals|Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in airtight containers. The same amount of each drug powder (1:1) was mixed and the mixed samples were combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.
48326615|NCT05581706|DIAGNOSTIC_TEST|Taking standart periapical radiography with film holder|"Post-operative periapical radiographs were obtained with Digora Optime SPP system (Soredex Corp., Tuusula, Finland) using intraoral film holders to keep the plates parallel to the long axis of the teeth. A size #2 SPP was used for all exposures. SPPs were exposed with a Gendex Oralix DC dental x-ray unit (Gendex Dental Systems, Milan, Italy) operating at 60 kVp, 7 mA, 0.25 sec. and the plates were scanned immediately after exposure. The clinical and radiographical follow up was performed on 12th months.~Image-J program (version 1.47, National Institutes of Health, Bethesda, MD) with TurboReg plug-in (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) was used to determine the increase in root length, root width, and radiographic root area at 12th month follow up."
47972510|NCT05033860|OTHER|Read leaflets containing knowledge of COVID-19 and vaccination.|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
47972511|NCT00957775|BEHAVIORAL|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
47972512|NCT00957775|BEHAVIORAL|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
47972513|NCT00576927|DRUG|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
47972514|NCT00576927|DRUG|Placebo|
48326616|NCT05581706|OTHER|Sample collection for immunofluorometric assay|Periapical exudate samples were collected at the beginning of the RET and at 14th day. MMP-8 levels were measured by immunofluorometric assay (IFMA). Briefly, two monoclonal MMP-8-specific antibodies, 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as catching antibody and tracer antibody, respectively. Samples were diluted in enzyme buffer (50 mM Tris-HCl, pH 7.5; 0.2 mM NaCl, 1 mM CaCl2). Twenty microlitres of samples and 80 μl of assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylenetriaminepentaacetic acid with 2 μg/ml normal mouse serum) were pipetted into the wells. The tracer antibody was labelled using europium chelate. After adding the enhancement solution, fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
48490065|NCT01594450|BIOLOGICAL|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
47972515|NCT03164902|DEVICE|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
47972516|NCT06361485|BIOLOGICAL|Lumbar Injections with 10cc's of Wharton's Jelly Allograft|Low Back Injections with Minimal Manipulation Umbilical Cord Tissue
47972517|NCT00292266|DRUG|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
47972518|NCT00292266|DRUG|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
47972519|NCT01221571|DRUG|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
48490066|NCT01594450|PROCEDURE|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
48490067|NCT05625087|DRUG|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
48490068|NCT05625087|DRUG|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
48490069|NCT00166270|DEVICE|ExAblate 2000|
48490070|NCT03218163|DRUG|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
48490071|NCT02185313|OTHER|visual stimulus to follow|
48490072|NCT03336957|PROCEDURE|periodontal treatment|non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
48490073|NCT02780167|DRUG|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
48490074|NCT02780167|DRUG|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
48490075|NCT02780167|DRUG|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
48490076|NCT02780167|DRUG|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
48490077|NCT02780167|DRUG|Placebo|Placebo QD for 12 weeks
48490078|NCT04999930|DEVICE|Aerochamber|efficacy and patients satisfaction
48490079|NCT03720769|BEHAVIORAL|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
48121242|NCT00941655|PROCEDURE|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
48121243|NCT04834648|BEHAVIORAL|Structured Counseling|"Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility."
48326617|NCT02437487|DRUG|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
47972520|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
48326618|NCT02437487|DRUG|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
48326619|NCT04090437|PROCEDURE|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
48326620|NCT02521740|OTHER|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
48326621|NCT03169049|DEVICE|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
47972521|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
47972522|NCT04194034|BIOLOGICAL|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
47972523|NCT04194034|DRUG|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
47972524|NCT05613595|BEHAVIORAL|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
47972525|NCT05613595|BEHAVIORAL|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
48121244|NCT00847834|DRUG|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
48121245|NCT00847834|DRUG|Irbesartan 150mg|Once a day
48121246|NCT04580771|DRUG|Cisplatin|Given IV
48121247|NCT04580771|BIOLOGICAL|Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|Given SC
48121248|NCT04580771|RADIATION|Radiation Therapy|Undergo radiation therapy
48121249|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours|Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
48121250|NCT06514222|DRUG|Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours|Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
48326622|NCT03169049|DEVICE|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
48326623|NCT01406652|PROCEDURE|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
48326624|NCT04199793|DEVICE|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
48326625|NCT04199793|DEVICE|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
48326626|NCT02290964|PROCEDURE|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
48649868|NCT06570681|DIAGNOSTIC_TEST|Video call assisted assessment of acute stroke|If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards, the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via via the video-call and triages the patient.
47972526|NCT02033616|BIOLOGICAL|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
47972527|NCT02033616|BIOLOGICAL|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
47972528|NCT00036738|DRUG|Cyclosporine|Given IV or PO
47972529|NCT00036738|DRUG|Dasatinib|Given PO
47972530|NCT00036738|DRUG|Fludarabine Phosphate|Given IV
47972531|NCT00036738|DRUG|Imatinib Mesylate|Given PO
47972532|NCT00036738|DRUG|Mycophenolate Mofetil|Given PO
48121251|NCT05464316|DEVICE|Adjustable Transobturator Male System|The ATOMS sling was developed in 2008 by Agency for Medical Innovations GmbH in Austria. It is a self-anchoring adjustable system which supports the bulbar urethra dorsally and uses the trans obturator approach. This device gained its fame in the male sling scene by being adjustable, which theoretically makes it more efficacious than its competitors.
48121252|NCT05464316|DEVICE|Artificial Urinary Sphincter|"The AMS800™, which is by far the most frequently implanted AUS, was first marketed in 1983 and was developed by America Medical Holdings in Minnesota. Today, the AUS has been given the title gold standard for surgical treatment for PPI. This device is an inflatable cuff which wraps around the urethra to supply circumferential pressure. It has a control pump, which is found in the scrotum and is operated by the patient. The patient can void simply by squeezing the pump, which brings the fluid from the cuff to a reservoir and release the pressure around the urethra. The cuff is then automatically refilled with fluid within a couple of minutes to close back the sphincter."
48326627|NCT00617656|DRUG|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
48326628|NCT00617656|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
48326629|NCT00617656|DRUG|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
48326630|NCT00617656|DRUG|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
48490080|NCT03720769|BEHAVIORAL|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
48121253|NCT02318134|PROCEDURE|Fecal Microbiota Transplantation|FMT via a nasoduodenal tube with fresh bacteria from healthy donor
48121254|NCT02318134|DRUG|normal saline|Normal saline via a nasoduodenal tube.
48490081|NCT00554307|DEVICE|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
48490082|NCT05726175|DRUG|Disitamab Vedotin|Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
48490083|NCT05726175|DRUG|Penpulimab|Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
47972533|NCT00036738|DRUG|Nilotinib|Given PO
47972534|NCT00036738|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
47972535|NCT00036738|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
47972536|NCT00036738|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
47972537|NCT00036738|RADIATION|Total-Body Irradiation|Undergo TBI
47972538|NCT01822431|RADIATION|metaiodobenzylguanidine scintigraphy|
47972539|NCT02151591|DRUG|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
47972540|NCT03529851|OTHER|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
47972541|NCT01029626|PROCEDURE|Endoscopy|Realization of an upper GI endoscopy
48490084|NCT04706923|DRUG|BCV|Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
48490085|NCT02540317|BEHAVIORAL|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
48490086|NCT01362127|DRUG|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
48490087|NCT01362127|RADIATION|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
48490088|NCT05630092|DIAGNOSTIC_TEST|Maximal 6-minute Walk Test (Max_6MWT)|Instructions given to perform the walk test following the international guidelines using the phrase 'as far as you can'.
47972542|NCT00612690|BEHAVIORAL|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
48490089|NCT05630092|DIAGNOSTIC_TEST|Normal speed 6-minute Walk Test (Nor_6MWT)|Instructions given to perform the walk test following the international guidelines except using the phrase 'at a speed you would normally walk'.
48326631|NCT05991557|PROCEDURE|peroneus longus autograft|Peroneus longus tendon graft will be harvested with a longitudinal skin incision at 2 to 3 cm (2 finger-breadths) above and 1 cm (1 finger-breadth) behind the lateral malleolus, followed by superficial fascia incision in line with skin incision followed by incision of the tendon sheath proximal to the retinaculum. The peroneus longus and peroneus brevis tendons will be then identified. The tendon division location marked at 2 to 3 cm above the level of the lateral malleolus.The peroneus longus tendon will be exposed on its posterolateral surface through the incision after carefully incising the fascia
48326632|NCT05615766|DEVICE|Experimental: Device Intervention|The robotic rehabilitation programme using the MARK from Myomo (myomo.com) for the intervention group will last for 12 weeks with up to four sessions of rehabilitation per week, i.e. total of 48 sessions. Spinal cord injured inpatients in the study will have this intervention on their dominant arm in addition to the traditional rehabilitation programme assigned and standard care.
48326633|NCT02585999|DEVICE|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
48326634|NCT04256304|BEHAVIORAL|PHEinAction-Personalized Patient Engagement Plan|The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
48490090|NCT03238976|OTHER|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
48490091|NCT04445779|DIETARY_SUPPLEMENT|Coenzyme Q10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
48121255|NCT03961906|BEHAVIORAL|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
48326635|NCT04403854|DIAGNOSTIC_TEST|MRI|If possible with spectroscopy
47972543|NCT00612690|BEHAVIORAL|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
47972544|NCT06280937|OTHER|Wearing a tie|Individuals in the study group will be asked to wear a tie during one office working day.
47972545|NCT00696722|DRUG|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
47972546|NCT00696722|DRUG|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
47972547|NCT02198274|DRUG|BIBH 1|100 mg/week
47972548|NCT06131177|DIETARY_SUPPLEMENT|Nutritional supplement|Protein supplement
47972549|NCT01897402|BIOLOGICAL|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
47972550|NCT01897402|BIOLOGICAL|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
47972551|NCT02421523|PROCEDURE|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of \~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
47972552|NCT02421523|PROCEDURE|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of \~30% of the subject's MVC. Subjects will be asked to perform \~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (\~50% MVC). Similarly, if no damage has occurred at \~50% MVC, four more subjects exercise at \~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
47972553|NCT02421523|PROCEDURE|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
47972554|NCT05295511|OTHER|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
47972555|NCT04359654|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Nebulised Dornase alfa 2.5mg bd for 7 days
48121256|NCT03788590|DEVICE|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
48121257|NCT05756504|DRUG|Ketorolac|Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.
48121258|NCT05756504|DRUG|Tramadol|Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
48121259|NCT03712306|OTHER|Dietary advice|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
48326636|NCT04403854|PROCEDURE|Spinal Tap|together with CSF pressure estimate
48326637|NCT05544227|DRUG|SV-102|SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
48326638|NCT05256082|DIAGNOSTIC_TEST|six-minutes-walking test|Patients conducting a six-minutes-walking test
48326639|NCT02823041|BEHAVIORAL|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
48490092|NCT05513287|OTHER|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
48326640|NCT02823041|BEHAVIORAL|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
47972556|NCT04817865|DIAGNOSTIC_TEST|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
47972557|NCT04817865|DIAGNOSTIC_TEST|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
48326641|NCT02823041|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
48326642|NCT02823041|BEHAVIORAL|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
48649869|NCT06520098|DRUG|Venetoclax|VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
48326643|NCT01630759|DEVICE|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
48649870|NCT06520098|DRUG|Ibrutinib, Acalabrutinib, Zanubrutinib|IMBRUVICA is a kinase inhibitor Acalabrutinib is a selective, irreversible small molecule inhibitor of BTK. Zanubrutinib is BTK inhibitors
48649871|NCT01442571|DEVICE|Hyaluronic Acid Injection|
48649872|NCT01442571|DRUG|Saline Injection|
48649873|NCT03211845|OTHER|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
48649874|NCT04466033|DEVICE|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
47972558|NCT05581420|DRUG|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
47972559|NCT05581420|DRUG|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
47972560|NCT02008201|DIETARY_SUPPLEMENT|vitamin D|
47972561|NCT06313814|DIETARY_SUPPLEMENT|Swanson ginger capsule|"Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties.~Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond."
47972562|NCT02134795|DEVICE|TNM (trade name), a form of brainstem Stimulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation acts on the brainstem.
47972563|NCT01563302|DRUG|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
47972564|NCT02513953|PROCEDURE|Laparoscopic|Four Port Laparoscopic cystectomy
47972565|NCT01803373|DRUG|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
48121260|NCT03712306|OTHER|Dietary advice and advice on timing|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
48326644|NCT01630759|OTHER|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
48326645|NCT00218790|PROCEDURE|Cool Dialysate|Decreased temperature of the dialysis bath
48326646|NCT02374034|OTHER|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
48326647|NCT01031485|DIETARY_SUPPLEMENT|Milk peptides and plant sterols|
48326648|NCT01031485|OTHER|Placebo|
48326649|NCT04374279|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily for 7 days
48326650|NCT00772694|DRUG|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
48326651|NCT02505542|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
48326652|NCT02505542|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
48649875|NCT06675760|DEVICE|The intervention group|The intervention group received training through a mobile augmented reality application in the laboratory.
48649876|NCT04787016|OTHER|Pilate training|Pilates is an exercise training program used to build core strength and flexibility.
48121261|NCT01224015|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
48326653|NCT03151252|DIAGNOSTIC_TEST|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
48326654|NCT02633839|DRUG|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
48326655|NCT02633839|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
48649877|NCT03116178|OTHER|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi\<4 fluid rate is 50-60ml/hr and pvi\>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
48649878|NCT03116178|OTHER|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
48649879|NCT02842346|OTHER|ultrasonography|
48649880|NCT04115254|RADIATION|MR-guided Linac|Radiation will be delivered on an MR-guided Linear Accelerator
48649881|NCT04245098|PROCEDURE|Carpal tunnel syndrome surgery|Biopsy
48649882|NCT06457997|DRUG|PHN-010|PHN-010 is an ADC
48649883|NCT00326014|DEVICE|iStent|Glaucoma Surgery
48649884|NCT05288751|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
47972566|NCT01803373|DRUG|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
47972567|NCT01803373|DRUG|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
47972568|NCT00578812|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
47972569|NCT00578812|DEVICE|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
47972570|NCT03781596|DIAGNOSTIC_TEST|Retrospective evaluation of endoscopy prior to study drug|Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
48121262|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
48121263|NCT01224015|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
48326656|NCT00238225|DIETARY_SUPPLEMENT|calcitriol|
48326657|NCT00238225|DRUG|dexamethasone|
48649885|NCT00181246|DRUG|Transdermal Fentanyl|
48649886|NCT04248153|DRUG|BR55|BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
48649887|NCT03110510|DRUG|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
47972571|NCT03781596|OTHER|Symptom Survey|Patient will complete symptom survey prior to starting the study drugs.
47972572|NCT03781596|OTHER|Medication Compliance Phone Call|The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
48326658|NCT00238225|DRUG|ketoconazole|
48326659|NCT01606293|BEHAVIORAL|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
48326660|NCT04613999|DRUG|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
48649888|NCT03110510|DRUG|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
48649889|NCT03110510|DRUG|leucovorin calcium|Leucovorin 200 mg/m2
48649890|NCT06121921|OTHER|Perioperative multi-component intervention|"Physical Component~Self-directed daily non-ambulatory exercise programme, comprising:~* Rubber ball squeezes (3 sets of 12 reps, per hand)~* Bicep curls (3 sets of 12 reps)~* Leg extensions (3 sets of 12 reps)~* Chair rises (3 sets of 12 reps)~* Arm stretches (3 sets of 3 reps) Additional encouragement to mobilise~Cognitive Component:~Delirium prevention strategies including orientation, hydration, bowel/bladder function, infection control, analgesia, polypharmacy and cognitive stimulation~Nutritional Component:~* Formal dietician review if MUST score ≥ 2~* IV ferritin if LVEF \<45% and serum ferritin \<100ng/mL or ferritin 100-299ng/mL with TSAT \<20%"
48649891|NCT06379607|DEVICE|"High Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use higher flow rates.
48649892|NCT06379607|DEVICE|"Low Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use lower flow rates.
48649893|NCT06074497|DRUG|KGX101- Cohort -1|Single dose of 0.1, 0.3, 1μg/kg of KGX101 every 3 weeks
48649894|NCT06074497|DRUG|KGX101- Cohort 1|Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
48649895|NCT06074497|DRUG|KGX101- Cohort 2|Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks
48649896|NCT06074497|DRUG|KGX101- Cohort 3|Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
48649897|NCT06074497|DRUG|KGX101- Cohort 4|Single dose of 1,3,12μg/kg of KGX101 every 3 weeks
48649898|NCT06074497|DRUG|KGX101- Cohort 5|Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
48649899|NCT06074497|DRUG|KGX101 and Envafolimab|Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
48649900|NCT00196612|DRUG|emtricitabine, FTC (drug)|
48121264|NCT01618643|PROCEDURE|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
47972573|NCT03781596|DIAGNOSTIC_TEST|Endoscopy while on study drug|Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
47972574|NCT03781596|OTHER|Symptom Survey|The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
48326661|NCT04352595|DRUG|Hemay808|Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
47972575|NCT03781596|DRUG|Fluticasone|Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
47972576|NCT03781596|DRUG|Omeprazole|The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.
48649901|NCT00196612|DRUG|didanosine, ddI (drug)|
48649902|NCT00196612|DRUG|efavirenz (drug)|
48649903|NCT02295579|OTHER|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
48649904|NCT06571292|DEVICE|Intensive training with robotic exoskeleton for upper limbs|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
48649905|NCT06571292|DEVICE|Task specific training|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
47972577|NCT03781596|DRUG|Placebo oral capsule|The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
47972578|NCT01854710|DRUG|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
47972579|NCT01854710|DRUG|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
47972580|NCT01854710|DRUG|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
47972581|NCT01854710|DRUG|Oral placebo|Oral capsule identical in appearance to moxifloxacin
47972582|NCT00050518|BIOLOGICAL|Aventis Pasteur Smallpox Vaccine|
47972583|NCT00886899|DEVICE|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
47972584|NCT00743340|DRUG|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
47972585|NCT04472195|OTHER|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
47972586|NCT00491075|DRUG|Pemetrexed|500 mg/m\^2 IV Over 10 Minutes on Day 1.
47972587|NCT00491075|DRUG|Gemcitabine|1500 mg/m\^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
47972588|NCT04809688|DIETARY_SUPPLEMENT|Saskatoon berry|Freeze dried Saskatoon berry (30 g) will be orally administrated daily for 10 weeks.
47972589|NCT02427022|OTHER|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
47972590|NCT01233440|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
47972591|NCT01233440|BIOLOGICAL|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
47972592|NCT02547649|BIOLOGICAL|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
47972593|NCT02547649|BIOLOGICAL|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
48121265|NCT04133298|PROCEDURE|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
48326662|NCT00949910|DRUG|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
48326663|NCT03332472|OTHER|Telemedicine group|
48326664|NCT03332472|OTHER|Conventional group|
48490093|NCT04946565|DIAGNOSTIC_TEST|Semen analysis|Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
48649906|NCT05886244|DRUG|Eculizumab|Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
48326665|NCT05121038|DRUG|CEND-1|The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
47972594|NCT02547649|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
48121266|NCT04133298|PROCEDURE|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
48121267|NCT05481463|DRUG|Surufatinib|surufatinib,250mg, qd, po, 28 days for a cycle
48121268|NCT05481463|DRUG|TAS-102|TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
48326666|NCT05121038|DRUG|Panitumumab|"Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX."
48649907|NCT05868655|OTHER|Exercise with Video-Based|A program of stability and balance exercises will be provided
48326667|NCT05121038|DRUG|Folfirinox|"FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home."
48326668|NCT05344976|BIOLOGICAL|MSLN STAR-T cells|Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
48490094|NCT06196021|OTHER|Intra-articular hyaluronic acid injection|"Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid."
48490095|NCT02302859|DRUG|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
48490096|NCT02302859|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
48490097|NCT02302859|OTHER|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
48490098|NCT02302859|BEHAVIORAL|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
48649908|NCT05868655|OTHER|Standart exercise-Home-Based|Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
48649909|NCT05317247|DIAGNOSTIC_TEST|Cough sounds|The investigators will discover a cough audio signature and then validate it.
48649910|NCT04824677|OTHER|Hospital treatment of COVID disease|Hospital treatment of COVID disease
48649911|NCT05012813|OTHER|Aromatherapy with Essential Oils|Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
48649912|NCT06674343|DRUG|Furmonertinib|Furmonertinib 160mg, once daily, orally. Other Names: AST2818
48649913|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
47972595|NCT00679315|DRUG|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
47972596|NCT00679315|DRUG|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
47972597|NCT05765604|BIOLOGICAL|Recombinant COVID-19 variant vaccine(Sf9 cell)|IM
47972598|NCT05765604|BIOLOGICAL|Recombinant COVID-19 vaccine(CHO cell)|IM
47972599|NCT04235114|DRUG|50 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
48326669|NCT05061797|DIETARY_SUPPLEMENT|Thermogenic Energy Drink - Active Study Product Formula|The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
48326670|NCT05061797|DIETARY_SUPPLEMENT|Placebo|A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
48326671|NCT03716518|DRUG|Tonifying Spleen and Kidney Sequential Regimen|TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
48326672|NCT03716518|DRUG|Placebo of 'Tonifying Spleen and Kidney Sequential Regimen|Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
48326673|NCT05521100|PROCEDURE|Vascular closure device|Suture of lower extremity veins using the Proglide Vascular Closure Device
48326674|NCT05521100|PROCEDURE|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
48326675|NCT02431130|OTHER|low-fidelity instructor driven simulation training|
48326676|NCT04879654|PROCEDURE|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
48326677|NCT06253013|DEVICE|Hyfe Smartwatch|Passive recording of audio with detection of explosive sounds. When explosive sounds are detected, a 0.5-1 seconds audio clip is recorded, and run through an algorithm to determine whether or not it is a cough.
48490099|NCT02302859|OTHER|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
47972600|NCT04235114|DRUG|1 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
47972601|NCT04694417|OTHER|Compression stocking|Please see the description of the intervention in another section
47972602|NCT04694417|DIETARY_SUPPLEMENT|Magnesium tablet|Please see the description of the intervention in another section
47972603|NCT04694417|OTHER|Placebo tablet|Please see the description of the intervention in another section
47972604|NCT03287661|BEHAVIORAL|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
47972605|NCT06378476|BEHAVIORAL|IMPaCT Community Health Worker Program|The IMPaCT intervention consists of three stages: goal-setting, tailored support, and connection with long-term support. CHWs first seek to understand the patient's individual circumstances, life histories, and priorities by using a semi-structured interview guide inquiring about social and behavioral determinants of health. CHWs will then partner with patients to create customized action plans based on patient needs.
47972606|NCT06378476|OTHER|Trauma-Informed Care Training|Primary care providers and staff at two General Internal Medicine clinics will receive training in providing supportive care to patients who have experienced trauma. The trainings are all action focused and include a review of racism in medicine, understanding intergenerational trauma and its impact on care, naming and mitigating barriers to health equity, and the basics of motivational interviewing
47972607|NCT01572220|OTHER|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
47972608|NCT05391698|BEHAVIORAL|Behavioral Parent Training (BPT)|The parent training consists of 8 weekly group sessions where parents are trained on behavior modification techniques, optimal parental practices as well as techniques for the enhancement of their children's cognitive deficits.
47972609|NCT05391698|COMBINATION_PRODUCT|Child Training (iVR + CBT)|The child training program is comprised of 16 individualized weekly sessions. It utilizes the potentials of immersive virtual reality (iVR) technology for the training of focused and sustained attention and combines practices based on cognitive-behavioral approach for children's training on behavioral and emotional self-regulation skills.
47980488|NCT02226055|DEVICE|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
47980489|NCT06420479|PROCEDURE|Bariatric surgery|A well-known intervention known to induce substantial weight loss
47980490|NCT05891262|DRUG|BMS-986196|Specified dose on specified days
47980491|NCT05891262|DRUG|Loestrin|Specified dose on specified days
47980492|NCT02055690|DRUG|Pazopanib|Tyrosine Kinase Inhibitor
48121269|NCT03596853|OTHER|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
48121270|NCT03596853|OTHER|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
48121271|NCT00203372|DRUG|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
48121272|NCT00203372|DRUG|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
48121273|NCT00203372|DRUG|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
48121274|NCT00203372|DRUG|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
48121275|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose|Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
48121276|NCT00117936|COMBINATION_PRODUCT|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose|Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
48121277|NCT00117936|COMBINATION_PRODUCT|Placebo|Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
48121278|NCT04643340|OTHER|real-time fMRI|Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).
48121279|NCT04692909|DEVICE|dTMS with mPFC stimulation|dTMS with Brainsway's H7 device, stimulating the mPFC.
48121280|NCT02378597|BEHAVIORAL|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
48121281|NCT01683149|DRUG|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
48490100|NCT02302859|DEVICE|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
48649914|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
48121282|NCT01683149|DRUG|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
48121283|NCT04261465|DRUG|Olaparib|PARP INHIBITOR
48121284|NCT04261465|DRUG|Paclitaxel|Chemotherapy
48121285|NCT04261465|DRUG|Carboplatin|Chemotherapy
48121286|NCT00566072|BEHAVIORAL|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
48121287|NCT03430258|DEVICE|high-flow nasal cannula|high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
48121288|NCT03430258|DEVICE|Conventional oxygen therapy|Conventional oxygen therapy
48326678|NCT06253013|DEVICE|FitBit Versa 2|Commercial watch with the capability to monitor vital signs including oxygen saturation, respiratory rate and heart rate. Patients will be able to view their data in the FitBit app.
48326679|NCT06253013|DEVICE|Home Spirometer|Patients will be able to perform spirometry testing at home. They will be able to view their data, and it will be uploaded to a dashboard for clinicians.
48326680|NCT06253013|BEHAVIORAL|Audio recording|Patients will be asked to record several sentences which will be analyzed to detect speech patterns that may indicate changes in respiratory conditions.
48326681|NCT02912728|BEHAVIORAL|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
48326682|NCT02912728|DEVICE|Standard CGM|use of CGM alone to assess CGM adherence
48326683|NCT01204697|DRUG|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
48326684|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
48326685|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally as monotherapy
48326686|NCT02937532|BEHAVIORAL|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
48326687|NCT02937532|BEHAVIORAL|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
48326688|NCT04345302|BEHAVIORAL|Brief motivational treatment|"The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist."
48649915|NCT00663260|DRUG|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
47980493|NCT02055690|DRUG|Fosbretabulin|Vascular Disrupting Agent
48121289|NCT01565148|DRUG|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
48649916|NCT05222945|OTHER|Biopsies and bloood samplings|blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
48649917|NCT06673680|DEVICE|Do colposcopy and cervical punch biopsy then compare between findings|The aim of this study is to correlate colposcopy and histopathological findings in early screening of suspicious cervix and cervical cancer. And to do a colposcopic evaluation of all cervical lesions and the early detection of all cervical precancer and invasive lesions of the cervix in symptomatic women.
48121290|NCT01565148|DRUG|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
47972610|NCT00959309|BEHAVIORAL|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
48326689|NCT04345302|BEHAVIORAL|Enhanced Usual Care|During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
47972611|NCT00959309|BEHAVIORAL|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
47972612|NCT02528071|OTHER|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
48326690|NCT05520749|DRUG|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
48490101|NCT04802707|COMBINATION_PRODUCT|deoxycytidine and deoxythymidine|The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over 3 taking/day for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 730. Doses was chosen according to the safety and efficacy doses used in the literature.
47972613|NCT05410561|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
47972614|NCT05410561|BEHAVIORAL|TeleTx intervention|TeleTx will consist of an initial session and then 8 \~counseling sessions.
47972615|NCT04967443|DRUG|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
47972616|NCT04967443|DRUG|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
47972617|NCT04967443|DRUG|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
48121291|NCT01565148|DRUG|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
48121292|NCT01565148|DRUG|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
48326691|NCT05684601|DEVICE|Third molar surgery|It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
48326692|NCT02080286|BEHAVIORAL|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
48498080|NCT05571735|BIOLOGICAL|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
48498081|NCT04197427|DEVICE|Experimental Oral Rinse|Experimental Oral Rinse is a proprietary formulation of GRAS ingredients
48649918|NCT06197802|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
48649919|NCT06197802|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
48649920|NCT01613586|DRUG|ASP3652|Oral
48649921|NCT01613586|DRUG|Placebo|Oral
48649922|NCT05074303|BIOLOGICAL|Influenza Vaccine|All subjects will receive the influenza vaccine.
48649923|NCT05074303|DIETARY_SUPPLEMENT|Beta-glucan|2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast
47972618|NCT04922008|DRUG|capecitabine and trastuzumab|In IRIS-C cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
47980494|NCT00507962|DRUG|Cisplatin|100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks
48121293|NCT05356689|OTHER|mechanical traction|Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
48121294|NCT03724578|DRUG|Grape Seed Extract mouth wash|participants will use grape seeds extract mouth wash in addition to standard preventive measures
48121295|NCT03724578|DRUG|standard preventive measures|twice daily brushing with fluoride tooth pate and daily flossing
48121296|NCT03724578|DRUG|antimicrobial and fluoride mouth wash|using chlorhexidine and fluoride containing mouth wash
48121297|NCT03419572|OTHER|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
48649924|NCT05074303|DIETARY_SUPPLEMENT|Placebo|2 - 250 mg capsules/day of cellulose
48649925|NCT06206408|DRUG|Fezolinetant|oral
48649926|NCT06206408|DRUG|Placebo|oral
48649927|NCT05406726|DIETARY_SUPPLEMENT|palmitoylethanolamide|palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
48121298|NCT00253734|BIOLOGICAL|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
48121299|NCT00253734|BIOLOGICAL|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
48498082|NCT04197427|DEVICE|Placebo|Placebo formulation without the active ingredients
48649928|NCT05406726|DIETARY_SUPPLEMENT|Placebo|a capsule filled only with maltodextrin will be used as a placebo
48649929|NCT05757219|DRUG|Itacitinib|Participants start itacitinib 200 mg PO once daily within 1-4 days after apheresis while awaiting CAR-T-cell manufacturing, which is expected to take approximately from week -4 until day -7. Patients will remain on itacitinib 200 mg PO once daily from initiation until 30 days post-CAR-T-cell therapy (Day 30) including throughout lymphodepleting chemotherapy period (Days -5, -4, -3) and axi-cel infusion (Day 0) for a total of approximately 58 doses.
48121300|NCT02753192|OTHER|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
48490102|NCT05035342|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) capsules|Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
48490103|NCT05035342|BIOLOGICAL|Placebo capsules|"The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules."
48490104|NCT01754116|DRUG|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
48490105|NCT01754116|DRUG|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
48490106|NCT01754116|DRUG|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
48490107|NCT01754116|DRUG|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
48649930|NCT05757219|BIOLOGICAL|Chimeric antigen receptor (CAR) T-cell therapy|Yescarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help the T cells recognize cancer cells. The reengineered T cells are infused back into the patient to attack the cancer.
48649931|NCT01688791|DRUG|Vintafolide|
48121301|NCT05161429|DRUG|DPP4|Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
47972619|NCT04922008|DRUG|vinorelbine and trastuzumab|In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
47972620|NCT04008615|OTHER|2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).|"For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe."
48490108|NCT01754116|DRUG|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
48490109|NCT01622686|BEHAVIORAL|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
48490110|NCT03841890|DEVICE|the Clarus Video System as a video stylet|video-guided intubation
48649932|NCT01688791|DRUG|Carboplatin|
48649933|NCT01688791|DRUG|Paclitaxel|
48649934|NCT05935033|DRUG|Emraclidine|Tablet
48649935|NCT06675643|OTHER|Non-Interventional Study|Non-Interventional study
48649936|NCT04875533|BIOLOGICAL|20vPnC|20vPnC
48649937|NCT04875533|OTHER|Saline|Saline
48649938|NCT04875533|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
48649939|NCT04875533|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
48649940|NCT01044719|DRUG|Ceftazidime|Ceftazidime 2g TDS IV
48490111|NCT03841890|DEVICE|the Clarus Video System as a lightwand|The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
48649941|NCT01044719|DRUG|Tobramycin|Tobramycin 7mg/kg/day OD IV
48490112|NCT03841890|DEVICE|direct laryngoscope|Macintosh laryngoscope size 3
48121302|NCT05161429|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
48490113|NCT00500175|DEVICE|TempTouchRM|
48490114|NCT00500175|DEVICE|Offloading|
48649942|NCT01044719|DRUG|Meropenem|Meropenem 2g TDS IV
48649943|NCT03079999|DRUG|Aspirin|Twice daily aspirin
48649944|NCT03079999|DRUG|Placebo|Twice daily placebo
48649945|NCT02931227|PROCEDURE|temperature obtained by the non-invasive method of zero-heat flux|
47972621|NCT00850668|BIOLOGICAL|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
48121303|NCT05161429|DRUG|Basal Insulin|degludec, detemir, glargine and NPH
48121304|NCT05161429|DRUG|SLGT2|Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
48121305|NCT05161429|DRUG|SU|Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
48121306|NCT01493778|DRUG|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
48121307|NCT03830086|DRUG|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
48490115|NCT00423995|DRUG|Loratadine/montelukast combination|
48490116|NCT00038337|PROCEDURE|Health Literacy|
48490117|NCT05094752|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
48490118|NCT05094752|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
48490119|NCT04612517|DRUG|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
48490120|NCT04612517|DRUG|Placebo|Placebo; corresponding volume
48490121|NCT02725775|DIETARY_SUPPLEMENT|100% Florida OJ|
48490122|NCT02725775|DIETARY_SUPPLEMENT|Placebo Equicaloric Orange Drink|
48490123|NCT00492765|DRUG|Interferon-beta-1a|dosage and frequency as per label
48490124|NCT00492765|DRUG|Simvastatin|dosage and frequency as per Biogen Idec protocol
48490125|NCT00492765|DRUG|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
48490126|NCT05200962|DEVICE|transcranial direct current stimulation|In tDCS, direct electrical currents are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
48649946|NCT02931227|PROCEDURE|esophageal temperature|
48649947|NCT02931227|PROCEDURE|intracerebral temperature|
48649948|NCT02931227|PROCEDURE|arterial temperature|
48649949|NCT05625867|OTHER|Psychological and quality of life questionnaires|At 4/5 months and at 9 months
48649950|NCT05625867|OTHER|Interdisciplinary consultation at 4/5 months|About ten days after the questionnaires were administered
48649951|NCT04589468|OTHER|Exercise|Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
48649952|NCT05978128|BEHAVIORAL|Health Education|Access electronic patient portal with educational material
48649953|NCT05978128|OTHER|Health Promotion and Education|Receive materials on breast/lung cancer screening
48649954|NCT05978128|BEHAVIORAL|Patient Navigation|Interact with a patient navigator
48649955|NCT05978128|OTHER|Survey Administration|Ancillary studies
48649956|NCT06023069|OTHER|Number of steps recorded by mobile phone as a proxy for physical activity|This cohort is likely to have patients with many steps/day (high activity) and few steps/day (low activity)
48649957|NCT03092193|DRUG|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
48649958|NCT03092193|DRUG|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
48649959|NCT00928720|DEVICE|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
48121308|NCT03830086|DRUG|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
48490127|NCT01174082|BIOLOGICAL|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
48490128|NCT01174082|BIOLOGICAL|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
48490129|NCT01174082|DRUG|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
48649960|NCT00928720|DEVICE|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
48649961|NCT04250207|DRUG|K-321 Solution|K-321 solution drops
48121309|NCT03830086|DRUG|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
48121310|NCT03830086|DRUG|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
48490130|NCT01174082|PROCEDURE|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
48490131|NCT01174082|PROCEDURE|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
48490132|NCT05847439|DRUG|[14C]BMS-986419|Specified dose on specified days
48490133|NCT02192008|BIOLOGICAL|Salmonella Typhi|
48649962|NCT04250207|DRUG|Placebo Solution|Placebo solution drops for K-321
48649963|NCT06640764|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty with SMS Femoral Stem (Medacta)
48649964|NCT04985682|BIOLOGICAL|ADVATE|Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
48649965|NCT05593770|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
48121311|NCT03830086|DRUG|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
48121312|NCT03830086|DRUG|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
48121313|NCT05386953|DRUG|Normal saline|Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
48121314|NCT05386953|DRUG|Balanced crystalloid solution|Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
48490134|NCT02192008|BIOLOGICAL|Salmonella Paratyphi|
48490135|NCT01487070|DRUG|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
48649966|NCT05593770|DRUG|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
48649967|NCT06674824|DEVICE|massimo|measure plethysmography variability index in patients on spontaneous trial planning for extubation and evaluate its sensitivity in relation to transthoracic echocardiographic velocity time integral in early detecting weaning induced pulmonary edema
48649968|NCT06207435|BEHAVIORAL|Transportation|Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
48649969|NCT06230146|DRUG|Insulin group|"Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution).~Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas."
48649970|NCT06230146|DRUG|Botulinum toxin group|Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
47972622|NCT00479076|DRUG|aflibercept (AVE0005)|intravenous infusion
47972623|NCT00479076|DRUG|S-1|oral administration
48649971|NCT06230146|DRUG|Triamcinolone acetonide group|Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
48121315|NCT00925210|PROCEDURE|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
48121316|NCT00418496|DRUG|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
48121317|NCT00418496|DRUG|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
48490136|NCT03065595|DIETARY_SUPPLEMENT|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
48490137|NCT03065595|OTHER|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
48649972|NCT01188993|COMBINATION_PRODUCT|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
48649973|NCT01882829|DRUG|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
48649974|NCT03376282|OTHER|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
48649975|NCT04380740|DRUG|Placebo|During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.
48649976|NCT04380740|DRUG|Abatacept|Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
48649977|NCT04954989|BIOLOGICAL|Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
48649978|NCT04954989|BIOLOGICAL|Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
48649979|NCT03268278|DRUG|Buprenorphine|Buprenorphine plus local anesthetic
48490138|NCT02289859|PROCEDURE|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
48490139|NCT02289859|PROCEDURE|Wound Closure without Undermining|One side of the wound will remain un-undermined.
48490140|NCT04683419|DEVICE|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
48490141|NCT01844999|BEHAVIORAL|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
48649980|NCT03268278|DRUG|Sterile saline|Placebo 1,8 ml
48649981|NCT03268278|DRUG|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
48649982|NCT00109668|DRUG|beclomethasone dipropionate (QVAR)|
48649983|NCT04901715|DRUG|Albuterol|Albuterol HFA Metered Dose Inhaler (90mcg/puff). Subjects to use 4 puffs one time.
48649984|NCT04901715|DIAGNOSTIC_TEST|Technetium99m - Sulfur Colloid (Tc99m-SC)|Aerosolized radiolabeled Tc99m-sulfur colloid will be delivered using a modified Pari-LC Star nebulizer. The activity of Tc99m-SC loaded in the nebulizer will be adjusted to provide an estimated 40 uCi deposited in the lung for the MCC/CC scan. Patients between the age 12-18 years old will receive ¾ of the adult dose to account for the smaller lung volume.
48649985|NCT02985138|PROCEDURE|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
48649986|NCT02985138|PROCEDURE|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
48649987|NCT02985138|DEVICE|Pedicle screw and cage|Pedicle screw and cage
48649988|NCT01254539|PROCEDURE|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
48649989|NCT01254539|PROCEDURE|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
48121318|NCT06435637|DIETARY_SUPPLEMENT|Collagen protein|Ingestion of 40, 20, 20 and 20 gram of collagen protein right after and every 2 hours after a bout of exercise
47972624|NCT01658891|DRUG|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
47972625|NCT01658891|DRUG|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
47972626|NCT02480114|OTHER|Educational Intervention|Undergo oral care and pain management education session
48121319|NCT06435637|BEHAVIORAL|Resistance exercise|A single resistance exercise session of the leg press and leg extension exercise
48121320|NCT00224445|DRUG|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
48121321|NCT00224445|DRUG|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
48121322|NCT00224445|DRUG|Ritonavir|Ritonavir 100 mg capsule administered orally QD
48121323|NCT01047241|DRUG|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
48121324|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
48121325|NCT02534064|DIETARY_SUPPLEMENT|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
48121326|NCT00507338|PROCEDURE|PCI|early PCI for NSTEMI; primary PCI for STEMI
48121327|NCT04600440|BIOLOGICAL|Convalescent plasma|Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
48121328|NCT02197975|DRUG|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
48121329|NCT02197975|DRUG|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
48490142|NCT01844999|BEHAVIORAL|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
48490143|NCT04079127|DEVICE|Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.|Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
48490144|NCT00326560|PROCEDURE|Pterygium excision and conjunctival autograft|
48490145|NCT06178159|DRUG|Disitamab Vedotin Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
48490146|NCT06178159|DRUG|Pertuzumab Injection|Initial dose 840mg, after 2nd dose 420mg intravenous infusion， every 3 weeks
48490147|NCT06178159|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
47972627|NCT02480114|DRUG|Gabapentin|Given PO
47972628|NCT02480114|OTHER|Pain Therapy|Receive usual oral health care
47972629|NCT02480114|OTHER|Quality-of-Life Assessment|Ancillary studies
47972630|NCT02480114|OTHER|Questionnaire Administration|Ancillary studies
47972631|NCT02480114|DRUG|Oxycodone/Acetaminophen|Analgesia
47972632|NCT02480114|DRUG|Hydrocodone/Acetaminophen|Analgesia
47972633|NCT02480114|DRUG|Fentanyl|Transdermal Analgesia
47972634|NCT02480114|DRUG|Ibuprofen|NSAID Analgesia
47972635|NCT02480114|DRUG|Magic Mouthwash|Oral Solution to treat mucositis
47980495|NCT00507962|DRUG|Liposomal Doxorubicin|Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
47980496|NCT01588808|BEHAVIORAL|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
47980497|NCT01585194|BIOLOGICAL|Ipilimumab|Given IV
47980498|NCT01585194|OTHER|Laboratory Biomarker Analysis|Correlative studies
48121330|NCT02197975|DRUG|Placebo MDI|Placebo MDI. Administered as 2 inhalations
48121331|NCT06009536|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
48121332|NCT03230942|OTHER|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
48121333|NCT03230942|OTHER|Pos-operative rehabilitation|Physical therapy treatment
48121334|NCT05403567|OTHER|Bootle Blast Home Intervention|Children will play BB at home for 8 continuous weeks. Participants will be asked to stop playing at the end of week 8 and the game will be programmatically locked to prevent further play until the post-intervention interviews and assessments are complete.
48121335|NCT01652417|DRUG|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
48121336|NCT04082611|BEHAVIORAL|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
48490148|NCT05752565|DEVICE|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
48490149|NCT03642626|DRUG|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
48490150|NCT03642626|DRUG|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
48326693|NCT02080286|DEVICE|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
48326694|NCT02080286|DEVICE|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
48326695|NCT01492699|DRUG|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
48326696|NCT01902862|DRUG|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
48326697|NCT01902862|DRUG|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
48326698|NCT03212846|OTHER|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
48326699|NCT02567214|DRUG|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
48326700|NCT02567214|DRUG|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
48326701|NCT04370964|OTHER|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
48326702|NCT04370964|OTHER|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
48326703|NCT04428359|DRUG|Measles-Mumps-Rubella Vaccine|Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
48490151|NCT03642626|DRUG|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
48490152|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
48490153|NCT03642626|DRUG|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
48490154|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
48490155|NCT03642626|DRUG|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
48649990|NCT01254539|PROCEDURE|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
48649991|NCT05845892|OTHER|stress ball|The use of the stress ball by the experimental group patients will be reminded by a hemodialysis nurse who was not involved in the study.
47980499|NCT01585194|BIOLOGICAL|Nivolumab|Given IV
47980500|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
48326704|NCT04428359|DRUG|Vit D|Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
48326705|NCT05739760|BEHAVIORAL|Poem book about relational health|Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
48490156|NCT03642626|DRUG|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
48490157|NCT03642626|DRUG|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
48649992|NCT02399566|DRUG|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
48649993|NCT04511468|DIETARY_SUPPLEMENT|Zinc, Chromium, Vitamin C, and Copper Supplementation|Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
48649994|NCT04511468|BEHAVIORAL|Standard healthy lifestyle intervention|Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
48649995|NCT04511468|OTHER|Placebo|Placebo with inactive ingredients
47980501|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
47980502|NCT04086147|DRUG|Low dose tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
48326706|NCT05739760|BEHAVIORAL|Poem book about physical health and safety|Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
48326707|NCT04975542|OTHER|Osteopathic Manipulative Medicine|Manipulative therapies based on Osteopathic principles.
48326708|NCT04975542|OTHER|Sham|Light touch techniques to mimic to osteopathic treatment.
48326709|NCT00400712|BEHAVIORAL|physical rehabilitation|two weeks intensive physical rehabilitation
48326710|NCT01010711|DIETARY_SUPPLEMENT|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
48326711|NCT03795818|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
48326712|NCT00505102|DRUG|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
48326713|NCT02687750|DEVICE|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
48326714|NCT03445754|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
48326715|NCT03445754|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
48326716|NCT06269900|DRUG|Dexamethasone|Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.
48326717|NCT06269900|DRUG|Placebo|Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
48490158|NCT03642626|DRUG|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
47972636|NCT01423058|DRUG|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
47980503|NCT04086147|DRUG|High dose tenecteplase|Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
48121337|NCT04082611|BEHAVIORAL|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
48121338|NCT00617331|BIOLOGICAL|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
48490159|NCT03642626|DRUG|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
48121339|NCT03388281|OTHER|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
48490160|NCT03642626|DRUG|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
48326718|NCT03106948|DRUG|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
48326719|NCT03106948|DRUG|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
48326720|NCT03106948|DRUG|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
48326721|NCT03411057|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
48490161|NCT05037786|BEHAVIORAL|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
48490162|NCT05037786|BEHAVIORAL|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
48490163|NCT02799238|BIOLOGICAL|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
48490164|NCT02799238|RADIATION|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
48490165|NCT02799238|DRUG|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
48649996|NCT01950039|DRUG|Betaine|Betaine or placebo administered orally in divided doses over 12 weeks
48649997|NCT01950039|DRUG|Placebo|Placebo administered orally in divided doses over 3 months
48649998|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
48649999|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
48121340|NCT02817282|OTHER|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
48121341|NCT01736215|DRUG|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
48121342|NCT02903199|DIETARY_SUPPLEMENT|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
48121343|NCT02903199|DIETARY_SUPPLEMENT|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
48121344|NCT02903199|DIETARY_SUPPLEMENT|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
48490166|NCT03524183|BEHAVIORAL|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
48490167|NCT02880657|DIETARY_SUPPLEMENT|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
48490168|NCT02880657|DIETARY_SUPPLEMENT|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
48650000|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56"
48650001|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
48121345|NCT00404573|DRUG|RGH-188|
48121346|NCT00521755|DEVICE|Seraffix LTB|laser soldering for soft tissue wounds
48121347|NCT05104294|DIAGNOSTIC_TEST|Optical Coherence Tomography- Angiography|Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
48121348|NCT05104294|DIAGNOSTIC_TEST|Photopic negative response|Both the implicit time and amplitude of PhNR were recorded.
48121349|NCT04456322|DRUG|RT plus Nimotuzumab|Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
48121350|NCT04456322|DRUG|RT plus Cisplatin|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
48121351|NCT01387906|DRUG|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
48650002|NCT06005636|DIAGNOSTIC_TEST|Test delirium state|use scale to test whether ischemic stroke patients have post-stroke delirium
48650003|NCT01283945|DRUG|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
48121352|NCT01499199|DRUG|Dolutegravir|50mg Once Daily
48121353|NCT03113630|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
48650004|NCT02579057|DRUG|Furosemide Injection Solution (SCP-101)|
48650005|NCT02579057|DRUG|Furosemide Injection Solution, USP|
48650006|NCT01418105|PROCEDURE|Videofluroscopic swallow study (VFSS)|Barium, radiation
48650007|NCT01418105|PROCEDURE|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
48650008|NCT01418105|PROCEDURE|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
48650009|NCT03109067|OTHER|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
48121354|NCT03113630|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
48326722|NCT03411057|OTHER|Control|Standard of care including an educational video.
48490169|NCT04707976|DEVICE|Navina Smart|CE-marked NavinaTM Smart including Navina Smart App.
48490170|NCT04707976|OTHER|Standard Bowel Care|Bowel care will be scheduled at least every 2nd day according to a defined study specific standard bowel care protocol. Diet, fluids, abdominal massage, regular physical activity and medications will be used if non-interventional treatment is insufficient.
48490171|NCT01405287|DEVICE|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
48490172|NCT02881164|OTHER|Low glycemic index|Subjects intake a low glycemic index breakfast
48121355|NCT03113630|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
48121356|NCT03113630|DEVICE|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
48121357|NCT03113630|DEVICE|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
48121358|NCT03113630|DEVICE|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
48121359|NCT04356430|DRUG|Abiraterone Acetate|1000 mg orally daily for 24 weeks before robotic assisted radical prostatectomy
48121360|NCT04356430|DRUG|Prednisone|5 mg oral low dose prednisone, once daily
48121361|NCT04356430|DRUG|Goserelin 10.8 mg|10.8 mg goserelin hypodermic once per 12 weeks
48121362|NCT00124878|PROCEDURE|Male circumcision|Sleeve circumcision
48121363|NCT02120222|DRUG|selinexor|Given PO
48326723|NCT00606814|DRUG|IPI-504, docetaxel|"1. IPI-504 administered IV at a dose of 300mg/m2~2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
48490173|NCT02881164|OTHER|High glycemic index|Subjects intake a high glycemic index breakfast
48650010|NCT02362763|PROCEDURE|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
48650011|NCT06673498|DRUG|Lusutrombopag combined with recombinant human thrombopoietin|After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days
48650012|NCT04204902|DRUG|Tepotinib 100 mg|Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.
48650013|NCT04204902|DRUG|Tepotinib 250 mg|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.
48650014|NCT05206357|DRUG|Epcoritamab|Subcutaneous Injection (SC)
48326724|NCT03398746|PROCEDURE|LOOP Technique|Placement of subcutaneous loop drain
48326725|NCT03398746|PROCEDURE|Standard incision and drainage|Incise and drain with placement of packing
48326726|NCT03972826|OTHER|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
48326727|NCT03895112|DRUG|AVID200|dose cohorts of 21-day cycles
48326728|NCT05743751|DEVICE|Normothermic machine perfusion|XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.
48326729|NCT05743751|DEVICE|Hypothermic machine perfusion|LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
48326730|NCT03043729|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)
48490174|NCT01044654|GENETIC|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
48490175|NCT04658836|DRUG|Triamcinolone Acetonide 40mg/mL|Intratympanic application of triamcinolone acetonide
48490176|NCT05499013|DRUG|SLN124|SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
48490177|NCT05499013|DRUG|Placebo|sodium chloride, solution for injection
48490178|NCT04516512|BIOLOGICAL|Blood draw|For each participants to the research a peripherical blood draw will be performed
48490179|NCT00040248|DRUG|Daclizumab|
48490180|NCT00429520|DRUG|Hyaluronic acid filler/IMD1 basic|
48121364|NCT02120222|OTHER|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
48121365|NCT03298724|BEHAVIORAL|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
48121366|NCT02273544|DRUG|Asasantin ER (new formulation - low)|
48121367|NCT02273544|DRUG|Asasantin ER (new formulation - medium)|
48121368|NCT02273544|DRUG|Asasantin ER (new formulation - high)|
48121369|NCT02273544|DRUG|Asasantin ER - commercial formulation|
48121370|NCT00825630|DRUG|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
48121371|NCT00825630|DRUG|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
48650015|NCT06652490|PROCEDURE|Short-axis/out-of-plane approach versus oblique- axis approach for ultrasound-guided internal jugular venous catheter.|"In the group A, The US probe will be placed perpendicular to the venous anatomy in the SAX approach.~In the group B, The US probe will be aligned at 45° angulation with the venous anatomy, and combined with an in plane needle insertion technique. The needle will be advanced from lateral to medial."
48650016|NCT04070846|DRUG|[14C] LC350189|Carbon-14 labelded LC350189
47972637|NCT04318795|PROCEDURE|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
47972638|NCT04318795|PROCEDURE|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
48650017|NCT02363283|DRUG|Glembatumumab Vedotin|Given IV
47972639|NCT06311201|OTHER|Abdominal belt|This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.
47972640|NCT06311201|OTHER|Pilates exercises|"The Pilates exercise program for the study group (B) consisted of a 10-minute warm-up with low-intensity exercises, followed by a 40-minute central part with floor exercises like leg circles, kicks, and stretches. It included the classic hundred exercise, performed with proper form. Each exercise had two sets of 10 repetitions. The session ended with a 10-minute cool-down of stretching exercises, supervised by a physical therapist. The program was conducted three times per week, one hour per session, for eight weeks, starting from the 7th day after delivery."
47972641|NCT02554448|OTHER|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
47972642|NCT05260788|PROCEDURE|Cystoscopy|Standard of care cystoscopy procedure
47972643|NCT03769454|DRUG|PP-001|PP-001 eye drops
47972644|NCT03769454|OTHER|Placebo|Placebo eye drops
47972645|NCT01700777|OTHER|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
47972646|NCT00253045|BEHAVIORAL|Motivational groups|Motivational interviewing in group format
47972647|NCT03269383|DRUG|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
47972648|NCT03269383|OTHER|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
48650018|NCT02363283|OTHER|Laboratory Biomarker Analysis|Correlative studies
48650019|NCT02363283|OTHER|Pharmacological Study|Correlative studies
48650020|NCT06674512|BEHAVIORAL|Clinical Pharmacist-led Pharmaceutical Services|Pharmacists developed an intervention plan to reduce DRPs and improve patients' quality of life by assessing patients' medication knowledge, drug-related problems, and adherence problems in the intervention group in the order of urgency, importance, and priority to be addressed. The plan included a list of patients' medication or lifestyle-related problems, a list of programs based on the assessed problems, and other information.
47972649|NCT02786797|BEHAVIORAL|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
47972650|NCT02786797|BEHAVIORAL|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
47972651|NCT04767373|BIOLOGICAL|Clesrovimab|Clesrovimab solution
48326731|NCT03043729|DRUG|5-FU|5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)
48326732|NCT03043729|DRUG|Leucovorin|Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
48326733|NCT03043729|BIOLOGICAL|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
48650021|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
48650022|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
47972652|NCT04767373|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCL\]) solution
47980504|NCT00617773|BIOLOGICAL|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
47980505|NCT03858088|PROCEDURE|Liver transplantation|Liver transplantation from deceased donors
48121372|NCT00825630|DRUG|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
48121373|NCT00825630|DRUG|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
48121374|NCT05167656|OTHER|Intraoral manual therapy|Six intraoral manual therapy sessions based on ischemic compression and pain pressure release of the temporomandibular region muscles, applied bilateral.
48326734|NCT00555906|DRUG|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
48650023|NCT06085872|BEHAVIORAL|REThink Life Game|REThink Life Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of four levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change and positive bias.
47972653|NCT03867292|OTHER|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
48326735|NCT00555906|DRUG|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
48326736|NCT00555906|DRUG|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
48326737|NCT00304915|BEHAVIORAL|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
48326738|NCT05862558|DEVICE|Shockwave Balloon|Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue
47972654|NCT03867292|OTHER|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
47972655|NCT01717261|RADIATION|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
48326739|NCT03668535|PROCEDURE|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
48326740|NCT03668535|PROCEDURE|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
47972656|NCT04219943|PROCEDURE|Surgical Treatment for Impacted Femoral Neck Fracture|Surgical Treatment for Impacted Femoral Neck Fracture
48326741|NCT01539811|PROCEDURE|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
48326742|NCT01539811|DRUG|Short course antibiotics|Short course (\<2 weeks) of antibiotics will be prescribed
48326743|NCT01539811|DRUG|Long course antibiotics|Long course (\>2 weeks) of antibiotics will be prescribed
48326744|NCT04457128|BEHAVIORAL|Just-in-Time Adaptive Intervention|Randomized factorial design
48326745|NCT01214941|DRUG|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
48326746|NCT01214941|DRUG|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
48326747|NCT01214941|DRUG|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
48326748|NCT02766322|OTHER|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
48326749|NCT02766322|OTHER|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
48326750|NCT02766322|OTHER|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
48650024|NCT06085872|BEHAVIORAL|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress. The efficacy of the app adjunct to other therapeutic tools within the platform in our projects will be tested."
47972657|NCT01846416|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
47972658|NCT00426907|PROCEDURE|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
47972659|NCT05333146|PROCEDURE|Cardiac Surgery|Cardiac surgery (e.g. coronary bypass surgery, cardiac valve surgery, ascending aortic surgery)
48326751|NCT02766322|OTHER|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
48121375|NCT05167656|OTHER|Extraoral manual therapy|Six extraoral manual therapy sessions based on ischemic compression, pain pressure release and pressure sliding of the temporomandibular region muscles, applied bilateral.
48121376|NCT05167656|OTHER|Exercise and counselling|"Information about etiology, contributing and related factors, natural history and prognostic of the pathology of temporomandibular disorders.~Counselling based on: diet, habits like tabacism, stress and anxiety control, physical activity and awareness of dental clenching.~Exercise daily program based on active and passive mobility of the temporomandibular joint, stretching exercises and self massage."
48121377|NCT04638322|OTHER|HIFT Group|An experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the HIFT method, for 12 weeks with 2 weekly sessions (Tuesday and Thursday), with a duration of 45 min per session. Once the intervention is finished, you will undergo a final evaluation to see if there is a difference or not with the results obtained at the beginning.
48121378|NCT04622722|OTHER|Nutren Diabetes|Nutren Diabetes provides energy at 360 kcal per 360 ml
48121379|NCT04622722|OTHER|Isocaloric|Isocaloric diet One carton of soy milk (250 ml) and bologna sandwiches (two slices of bread) with mayonnaise
48121380|NCT02545036|OTHER|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
48121381|NCT05320666|BEHAVIORAL|Yes You Can…Make Smart Choices! (YYC…MSC!) program|The YYC...MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
48490181|NCT05515393|DRUG|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
48650025|NCT06085872|BEHAVIORAL|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
48121382|NCT02722473|BIOLOGICAL|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
48121383|NCT02722473|BIOLOGICAL|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
48121384|NCT00879060|DRUG|Spironolactone|spironolactone 50mg daily
48121385|NCT00879060|DRUG|Placebo|inactive placebo pill daily
48121386|NCT03943277|OTHER|No intervention, observational study|No intervention observational study
48650026|NCT06674902|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
48650027|NCT06642766|DIETARY_SUPPLEMENT|Fiber supplement|"Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.~* The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary.~* Secondary endpoints, reduction in bloating or gas, or any adverse events will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary."
48650028|NCT04760236|BIOLOGICAL|Oral Cholera Vaccine Simplified (OCV-S)|"* Manufacturer: EuBiologics Co., Ltd.~* Oral administration"
48121387|NCT01499992|PROCEDURE|Standard physical therapy program PLUS aquatic physical therapy|2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
48490182|NCT05515393|DRUG|XY03-EA Placebo|XY03-EA Placebo
48650029|NCT04760236|BIOLOGICAL|Shanchol™|"* Manufacturer: Shantha Biotechnics~* Oral administration"
48650030|NCT06674915|DRUG|HRS-5965 capsules|Oral 50 mg.
48650031|NCT00549211|DRUG|GSK557296|
47972660|NCT03331003|DEVICE|low level light therapy|iRestore low-level light therapy on androgenetic alopecia
47972661|NCT03331003|DEVICE|non-LLLT wavelength group|A LED light device is non-curative for the patients.
47972662|NCT06259266|OTHER|Anti-reflux valve for dialysis catheter|
48490183|NCT03314662|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
47972663|NCT00763672|OTHER|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
47980506|NCT06215040|PROCEDURE|Endoscopic retrograde cholangiopancratography|common bile duct stone removal
47972664|NCT00763672|OTHER|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
48650032|NCT06127771|OTHER|Programming DBS using Percept PC neurostimulator's full potential|This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
48650033|NCT03629717|PROCEDURE|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
48650034|NCT03629717|DRUG|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
48650035|NCT03629717|PROCEDURE|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
48650036|NCT03629717|DRUG|Calcium|1200mg daily
47972665|NCT04271137|COMBINATION_PRODUCT|3D printed PEEK onlay|3d computer-designed Orbital onlay
47972666|NCT04271137|COMBINATION_PRODUCT|Pre-bent orbital mesh|Pre-bent orbital mesh on 3d printed template
47972667|NCT01784978|DRUG|Sunitinib|50 mg pd
48121388|NCT01499992|OTHER|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
48490184|NCT03314662|BIOLOGICAL|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
48490185|NCT03314662|BIOLOGICAL|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
48650037|NCT03629717|DRUG|Vitamin D|800 IU daily
48650038|NCT02798003|OTHER|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
48650039|NCT03789370|DRUG|Propofol|Maintanance of general anaesthesia with propofol
48650040|NCT03789370|DRUG|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
47972668|NCT01784978|DRUG|Everolimus|10 mg pd
48121389|NCT00925899|DRUG|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
48121390|NCT00925899|DRUG|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
48121391|NCT03417869|DEVICE|QuickVue Influenza A+B|Rapid diagnostic test with IVD, QuickVue Influenza A+B
48121392|NCT01381471|DRUG|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
48326752|NCT04961099|DRUG|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
48498083|NCT04948164|DRUG|sumatriptan 85mg and naproxen sodium 500mg|Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
48650041|NCT01139970|OTHER|Laboratory Biomarker Analysis|Correlative studies
48650042|NCT01139970|OTHER|Pharmacological Study|Correlative studies
47972669|NCT04579705|OTHER|Using a brush|Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
47972670|NCT05348070|PROCEDURE|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
47972671|NCT06418100|PROCEDURE|The recto intercostal fascial plane block|After ensuring aseptic conditions, the high-frequency linear ultrasound probe was used to detect the rectus abdominis muscle and the 6-7th costal cartilage as described by Tulgar et al. After rotating and shifting the transducer, 6-7th costal cartilages, the rectus abdominis muscle, and intercostal muscles between the cartilages were confirmed. The primary investigator (B.C.) directed the needle tip caudad in the cephalic direction in-plainly, and 20 ml 0,25% bupivacaine was injected bilaterally into the plane between the costal cartilage and the rectus abdominis muscle following negative aspiration.
47972672|NCT05760833|PROCEDURE|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
47972673|NCT02704715|PROCEDURE|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
48650043|NCT01139970|DRUG|Temozolomide|Given PO
48650044|NCT01139970|DRUG|Veliparib|Given PO
48650045|NCT05320952|DEVICE|WellO2|The WellO2 breathing training device performs back-pressure steam breathing training during the inhalation and exhalation phases.
48650046|NCT02046876|OTHER|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
48650047|NCT04669197|DRUG|Paclitaxel protein bound|combination therapy
48650048|NCT04669197|DRUG|Gemcitabine|combination therapy
48650049|NCT04669197|DRUG|Cisplatin|combination therapy
48650050|NCT04669197|DRUG|Hydroxychloroquine|combination therapy
48650051|NCT03913286|DEVICE|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
48650052|NCT05369000|BIOLOGICAL|LAVA-1207|"In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion."
48650053|NCT05369000|BIOLOGICAL|LAVA-1207 plus Pembrolizumab|Pembrolizumab will be administered via intravenous infusion
48650054|NCT03574389|BIOLOGICAL|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
48121393|NCT01367483|DRUG|IV methylnaltrexone (MNTX)|
48121394|NCT02487927|BEHAVIORAL|weaning|T piece
48121395|NCT02974634|OTHER|Ostomy self management training|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
48121396|NCT03990285|DRUG|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
48121397|NCT02240446|DEVICE|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
48121398|NCT02240446|DEVICE|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
48121399|NCT03113266|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
48326753|NCT04176744|OTHER|Uni- and bilateral magnetic phrenic nerve stimulation|Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
48326754|NCT01925859|DRUG|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
48121400|NCT03573063|OTHER|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
48121401|NCT01551355|BEHAVIORAL|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
48121402|NCT02968225|BEHAVIORAL|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
48121403|NCT04960644|DRUG|MTX|MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
48121404|NCT04960644|DRUG|Corticosteroid|corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
48121405|NCT01871675|DRUG|IPI-145|
48121406|NCT01871675|DRUG|Rituximab|
48650055|NCT03574389|BIOLOGICAL|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
47972674|NCT03040102|OTHER|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
47972675|NCT03040102|OTHER|Standard of Care|Standard of Care practice is used
47972676|NCT05239923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
47972677|NCT03928574|PROCEDURE|Ultrasound-Guided Plane Block|Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
47972678|NCT03928574|PROCEDURE|Conventional Block|Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
48121407|NCT01871675|DRUG|Bendamustine|
48121408|NCT02073578|PROCEDURE|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
48121409|NCT03428958|DRUG|NUC-3373 + leucovorin|NUC-3373 + leucovorin
48121410|NCT03428958|DRUG|NUC-3373|NUC-3373
48121411|NCT03428958|DRUG|NUFOX|NUC-3373 + oxaliplatin
48121412|NCT03428958|DRUG|NUFOX + VEGF pathway inhibitor|NUC-3373 + oxaliplatin + bevacizumab
48121413|NCT03428958|DRUG|NUFOX + EGFR inhibitor|NUC-3373 + oxaliplatin + cetuximab/panitumumab
48121414|NCT03428958|DRUG|NUFIRI|NUC-3373 + irinotecan
48121415|NCT03428958|DRUG|NUFIRI + VEGF pathway inhibitor|NUC-3373 + irinotecan + bevacizumab
48326755|NCT05747755|BEHAVIORAL|ADEPT Program|Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
48650056|NCT06661915|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
48650057|NCT06661915|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
48650058|NCT06661915|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
48650059|NCT06661915|DRUG|Decitabine and Cedazuridine|Given PO
48650060|NCT06661915|DRUG|Iadademstat|Given PO
48650061|NCT05490056|OTHER|no intervention|the study will not apply on intervention
48650062|NCT06674876|BEHAVIORAL|Blog writing|Participants were asked to write 2blogs online for four weeks and attend a 4hours wellness workshop
48650063|NCT05069740|DRUG|Salsalate Pill|Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
48650064|NCT05069740|DRUG|Placebo|Placebo for the salsalate intervention
48650065|NCT06639022|PROCEDURE|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
48650066|NCT06639022|PROCEDURE|Erector spinae plane block|"Erector spinae plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
48650067|NCT06639022|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
48650068|NCT03864705|DIAGNOSTIC_TEST|Measurement of plasma metformin levels|Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
48650069|NCT06094738|DRUG|Relacorilant under fasted conditions|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
47972679|NCT06229197|PROCEDURE|Billroth II reconstruction|Billroth II reconstruction, in which a loop of jejunum is mobilized and anastomosed to the gastric remnant
48121416|NCT03428958|DRUG|NUFIRI + EGFR inhibitor|NUC-3373 + irinotecan + cetuximab/panitumumab
48121417|NCT03428958|DRUG|NUC-3373 + bevacizumab|NUC-3373 + bevacizumab
47972680|NCT06229197|PROCEDURE|Braun Anastomosis|This is an additional surgical connection (anastomosis) created between two parts of the small intestine, specifically between the afferent (incoming) and efferent (outgoing) limbs of the jejunum near the gastrojejunostomy (the new connection between the stomach and small intestine created during a Billroth II procedure).
47980507|NCT05060055|PROCEDURE|Immediate dental implant placement|Immediate dental implant placement
47980508|NCT00230997|DRUG|Galantamine|
48490186|NCT01453894|BEHAVIORAL|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
48490187|NCT00488930|OTHER|Observational|data collection ONLY
48490188|NCT02016261|DRUG|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
48490189|NCT00312676|PROCEDURE|Rapid versus slow conversion|
48490190|NCT04860765|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
48490191|NCT02668848|DIETARY_SUPPLEMENT|water|If USG\>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
48490192|NCT00002473|PROCEDURE|conventional surgery|
48490193|NCT02890836|DRUG|Antihypertensiva, mainly Metyldopa|
48650070|NCT06094738|DRUG|Relacorilant after a high-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
48650071|NCT06094738|DRUG|Relacorilant after a low-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
48650072|NCT06564051|OTHER|Non-Interventional Study|Non-interventional study
48121418|NCT02118675|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
48650073|NCT06640361|DRUG|Olverembatinib|Oral administration with meal, QOD, every 28 days for a cycle.
48650074|NCT04804436|GENETIC|Genetic analysis|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
48650075|NCT06639451|DEVICE|RANGER™ Paclitaxel Coated Balloon Catheter|A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon coated with paclitaxel at the end of it. When the tube is in place, it inflates to open the blood vessel, so that normal blood flow is restored. The tube is then removed.
48650076|NCT02793050|DRUG|Trabectedin|Collection of data on the clinical use of Trabectedin
47980509|NCT04016753|DRUG|BMS-986256|30 mg(6ml)
47980510|NCT04016753|DRUG|Loestrin|1.5 mg Norethindrone and 30ug ethinyl estradiol
48121419|NCT02118675|OTHER|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
48326756|NCT03579992|BEHAVIORAL|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
48490194|NCT04878614|DRUG|Levothyroxine Tablet|Standard clinical management
48490195|NCT04878614|DRUG|Levothyroxine Sodium|Liquid levothyroxine through enteral feeding tube
48490196|NCT03926481|BEHAVIORAL|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
48490197|NCT03794518|DRUG|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
48490198|NCT03794518|DRUG|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
48490199|NCT03508414|BEHAVIORAL|ketogenic diet|Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
48326757|NCT03579992|BEHAVIORAL|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
48326758|NCT03579992|BEHAVIORAL|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
47972681|NCT05473702|DEVICE|Nanowear SimpleSense Wearable monitoring device|The Nanowear SimpleSense is a non-invasive, wearable and portable medical device for evaluation and monitoring of cardiopulmonary condition. It utilizes physiologic and biometric sensors, SAU, and software system with a suite of algorithms to monitor patient. The parameters include: two vectors of ECG, two vectors of impedance cardiography, thoracic impedance, respiration, heart sounds, and actigraphy and postures. The device is comprised of a wearable device made of an elastomeric harness comprising of active and passive Nanosensors, heart sound sensor, connector to electrically connect the sensors to SAU, it comprises of Inertial Measurement Unit, analog front end, processing unit, storage unit, power supply, and a wireless module, and a software system equipped with the suite of algorithms to monitor heart. The signals are recorded by SAU, transferred to the iPhone over Bluetooth, which later transfers the data to a secure website over an internet connection Wi-fi or mobile network.
48121420|NCT02118675|OTHER|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
48121421|NCT02118675|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
48121422|NCT02118675|OTHER|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
48121423|NCT02118675|OTHER|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
48121424|NCT02118675|OTHER|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
48326759|NCT01559064|DEVICE|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
48326760|NCT00609011|DRUG|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
48326761|NCT02420223|DRUG|Propranolol|
48326762|NCT01108562|DRUG|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
48326763|NCT01108562|OTHER|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
48326764|NCT03176836|DIAGNOSTIC_TEST|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
48326765|NCT03176836|DIAGNOSTIC_TEST|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
48326766|NCT03176836|DIAGNOSTIC_TEST|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
48326767|NCT02335112|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
48326768|NCT02335112|DEVICE|NanoKnife|
48326769|NCT04569695|DRUG|JNJ-70033093|JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
48326770|NCT02440295|PROCEDURE|Lower Extremity Amputation|
47972682|NCT03905603|DRUG|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
48326771|NCT02440295|DEVICE|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
48326772|NCT02440295|DRUG|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
48326773|NCT03716453|PROCEDURE|Standard protocol|Give narcotic according to vital signs
48490200|NCT03508414|BEHAVIORAL|Intermittent therapeutical fasting|Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
47972683|NCT03905603|DRUG|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
48326774|NCT03716453|PROCEDURE|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score \> 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score \< 50 indicates inadequate narcotic and narcotic should be given."
48326775|NCT06161155|COMBINATION_PRODUCT|Protein digestibility|"Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation."
47972684|NCT02601690|OTHER|Blood Sampling|
47972685|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
47972686|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
47972687|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
47972688|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
47972689|NCT05715034|BEHAVIORAL|Compassionate Care|Single-session web-based program
48490201|NCT03508414|BEHAVIORAL|Active comparator|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
48490202|NCT04212533|DIETARY_SUPPLEMENT|Vitamin D|comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation
48650077|NCT05815199|OTHER|E-cigarette (EC)|Fixed dose. Participants are to use the EC as replacement for smoking combustible cigarettes. Participants will vape the EC.
48490203|NCT04212533|DIETARY_SUPPLEMENT|rice starch tablets|rice starch tablets as placebo
48490204|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 1)|
48490205|NCT02127775|DRUG|Lesinurad 400 mg (manufactured at Site 2)|
48490206|NCT05369468|DRUG|dexmedetomidine as adjuvant with bupivacaine|to assess efficacy of adding dexmedetomidine as adjuvant with bupivacaine in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
48498084|NCT04948164|DRUG|Placebo|"subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg)."
48650078|NCT05815199|OTHER|Nicotine Replacement Therapy (NRT)|Includes nicotine patches and lozenges. NRT use recommendations will follow the guidelines of the product, e.g. one patch per day.
48650079|NCT05815199|BEHAVIORAL|Harm-Reduction Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Up to five additional sessions will be delivered, 15\~20 minutes each.
48650080|NCT05815199|BEHAVIORAL|Ecological Momentary Intervention (EMI) Text Messaging|EMI can be defined as delivering tailored interventions via electronic messages (i.e., regular text messages) that include personalized feedback based on real-time assessment responses and other contextual factors. EMI will take place throughout the intervention period.
48650081|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
48650082|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
48650083|NCT00803374|DRUG|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
48650084|NCT00803374|DRUG|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
47972690|NCT05715034|BEHAVIORAL|Relaxing with Nature|Single-session web-based program
47972691|NCT00004915|DRUG|raloxifene|
48650085|NCT00803374|DRUG|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
48650086|NCT00803374|DRUG|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
47972692|NCT05627960|DRUG|AG-01 Compound|"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."
47972693|NCT00313378|DRUG|Hypothetica|
47972694|NCT03312270|BEHAVIORAL|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
47972695|NCT00663169|BIOLOGICAL|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
47972696|NCT00663169|DRUG|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
47972697|NCT00663169|OTHER|placebo matching canakinumab|5% glucose in water intravenous infusion.
47972698|NCT00663169|OTHER|placebo matching dexamethasone|Placebo intravenous infusion.
47972699|NCT05453656|BEHAVIORAL|exercise|physical activity promotion and engagement following kidney transplantation
47972700|NCT01095445|DRUG|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
48121425|NCT05346523|DEVICE|Isabel Pro - The DDx generator (CDDS)|Isabel Pro - the DDx generator is a software developped for health professionals with the intention to support them in broadening their differential diagnoses. After the first patient examination, the resident is asked to enter patient symptoms into Isabel Pro, which returns a list of possible diagnoses from its underlying database that matches the entered data. The diagnosing resident physicians will be asked to consult Isabel Pro at least once within the first hour after the first patient assessement. After entering patient symptoms into the software, Isabel Pro will itself return a list with possible diagnoses derived from their underlying database. It is then free to the physician to decide whether one or more of the suggested DDx should be considered for further diagnostic or treatment procedure based on clinical judgement.
47972701|NCT04921371|OTHER|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
47972702|NCT04921371|OTHER|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
47972703|NCT04921371|OTHER|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
47972704|NCT04921371|OTHER|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
48121426|NCT06451913|DRUG|Amoxicillin + Saccharomyces boulardii CNCM I-745|At inclusion visit (V1), the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + Saccharomyces boulardii 250 mg x 2 twice a day for 21 days
48121427|NCT06451913|DRUG|Amoxicillin + Placebo|At inclusion visit (V1),the Investigator will dispense and ask the subject to take Amoxicillin 1000 mg bid for 14 days + a matching placebo bid for 21 days
47972705|NCT04921371|OTHER|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
47972706|NCT04921371|OTHER|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
48121428|NCT06451913|OTHER|Stool samples|"The subject will be asked to collect thanks to four OMNIgene® •GUT OMR-200 kits :~* an initial stool collection when returning home at D1 (in any case before any intake of amoxicillin and of the investigational medication and up to 1 day after D1).~* a stool collection at home after the phone call 1, Day 7 (stool collection up to Day 7 + 1 day)~* a stool collection at home after the phone call 2, Day 14 (stool collection up to Day 14 + 1 day)~* at home the day of the Visit 2, Day 21 (stool collection up to Day 21 + 1 day)"
48121429|NCT06451913|OTHER|BSFS : Bristol Stool Form Scale|All included subjects will have to complete a stool diary BSFS (Bristol Stool Form Scale) daily and at each bowel movement, from Day 1 until the end of study treatment (Day 21). The patient will fill the form with the date, the time, and the stool texture.
48121430|NCT06451913|OTHER|GSRS : Gastrointestinal Symptom Rating Scale|All included subjects will have to complete a GSRS (Gastrointestinal Symptom Response Score) questionnaire weekly from Day 1 until the end of the study treatment (Day 21).
47972707|NCT03379805|DIAGNOSTIC_TEST|Near Infrared Fluorescence Imaging|The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
47972708|NCT03379805|DIAGNOSTIC_TEST|Non-contrast MRI|The anatomy is described using non-contrast MRI.
47972709|NCT03379805|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|The capillary filtration rate is measured using plethysmography
48121431|NCT02550691|PROCEDURE|blood sampling|A blood sample will be taken on subject carrying specific genotype
48121432|NCT01448317|DRUG|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48121433|NCT01448317|DRUG|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
47972710|NCT00806390|DRUG|Metoprolol|Metroprolol tartrate titrated up
47972711|NCT01694030|OTHER|Attachment security priming|
47972712|NCT05746871|DEVICE|Agilik|The Agilik is a powered orthosis system that can assist or resist motion independently in each gait phase. It is used as a pair of knee-ankle-foot orthosis (KAFO), one for each leg. The device applies up to 12 Nm across the knee in the direction of either flexion or extension. The system consists of an orthosis for each leg integrated with an electro-mechanical actuator, a battery, a carry pack, cabling and application software running on a computer. A foot pressure sensor is embedded in the footbed of the KAFO and connected to the actuator. The foot sensor and angular velocity are used to detect the gait phase of the patient and communicate with the motor controller to provide a unique torque for each gait phase. The torque ramp and intensity can be modified through the Agilik App to cater towards individual patients by assisting or resisting motion during their gait. This allows for the clinician working with the patient to adjust the settings of the device for the patient's needs.
47972713|NCT05746871|OTHER|standard care|Subjects will continue with their standard care for 5 weeks
47972714|NCT01118702|DRUG|Ritalin-SR|3-20mg tablets, once
47972715|NCT01118702|DRUG|Concerta|one 54mg tablet, once
47972716|NCT01118702|DRUG|Novo-Methylphenidate ER-C|one 54mg tablet, once
47972717|NCT04109794|PROCEDURE|E-CTG|Envelope connective tissue graft
47972718|NCT03555591|DRUG|Trelagliptin|Trelagliptin tablets
47972719|NCT01574131|DRUG|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
47972720|NCT01574131|DRUG|Sugar Pill|pill every day for 6 months
48121434|NCT01448317|DRUG|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48121435|NCT01448317|DRUG|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
48121436|NCT03117023|DRUG|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
48121437|NCT05652244|DEVICE|Mini-implants|En masse retraction of upper anterior teeth will be applied where mini-implants will be used as an anchor unit. Anterior teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
48121438|NCT05652244|DEVICE|Transpalatal arche (TPA)|Two-step retraction of upper anterior teeth will be applied where transpalatal arches (TPAs) will be used as an anchor unit. Teeth retraction will be initiated after completion of the leveling and alignment phase via closed nickel-titanium coil springs applying 150 g of force per side.
48121439|NCT01254006|DRUG|forskolin, rutin and vitamins B1 and B2|
48121440|NCT02897882|OTHER|Lung transplant|Pain evaluation
48121441|NCT03059212|DEVICE|rTMS|High frequency rTMS for 3 to 10 min to increase the excitability of cortex.
48121442|NCT03059212|BEHAVIORAL|Cognitive training program|A rehabilitation protocol that facilitates attention, memory, execution.
48121443|NCT00003612|BIOLOGICAL|trastuzumab|
48121444|NCT00003612|DRUG|carboplatin|
48121445|NCT00003612|DRUG|paclitaxel|
48121446|NCT04788641|DRUG|Tacrolimus|Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
48121447|NCT04788641|DRUG|Cyclosporin|Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
47972721|NCT00621985|DRUG|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
47972722|NCT00621985|DRUG|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
48121448|NCT04788641|DRUG|Sodium Zirconium Cyclosilicate|Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.
48121449|NCT02242487|DRUG|CVT-301|
48121450|NCT00382850|PROCEDURE|Nissen fundoplication|
48121451|NCT00819325|DRUG|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
47972723|NCT02279381|DRUG|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
48121452|NCT00819325|DRUG|oral hypoglycemic agents|sulfonylurea or metformin
48121453|NCT04304924|OTHER|The personalized telephone based intervention|"The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises."
48121454|NCT01264679|DRUG|Ferumoxytol|IV Ferumoxytol
48121455|NCT05107024|DEVICE|RFR-guided step by step balloon dilation|The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.
48121456|NCT05107024|DEVICE|Traditional balloon dilation|The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria
48121457|NCT03009994|PROCEDURE|Repair of uterine incision|
47972724|NCT02279381|OTHER|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
47972725|NCT02279381|OTHER|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
48121458|NCT03009994|PROCEDURE|Exteriorization of the uterus|
48121459|NCT03009994|PROCEDURE|Non exteriorization of the uterus|
48326776|NCT05910814|BEHAVIORAL|Sleep Deprivation (SD)|Participants in the sleep deprivation group will spend a night awake, under the supervision of an investigator, at Croix-Rousse Hospital. The investigator will provide a list of activities to maintain the participant awake.
48326777|NCT05910814|BEHAVIORAL|Normal Night (Night)|Participants in the normal night group will spend one night sleeping in their own home.
48326778|NCT05910814|BEHAVIORAL|Physical Exercise (HIIE)|"Participants in the physical exercise group (i.e. IM+HIIE, PP+HIIE, SD+PP+HIIE) will start with a 2-minute warm-up on an ergometer cycle.~After the warm-up, they will perform 3 minutes of exercise at a workload customized to their maximal aerobic power (MAP) corresponding to 80 % their MAP and then rest actively for 2 minutes at 40 % of MAP. This cycle of 5 minutes will be repeated 3 times in row, resulting in a total of 17 minutes of physical exercise including the warm-up."
48326779|NCT05910814|BEHAVIORAL|Rest control|Participants will watch a documentary during an equivalent time as the physical exercise (i.e. 17 minutes).
48650087|NCT06674239|BEHAVIORAL|Patient Follow-up and Evaluation Form, Patient Information Form Healthy Lifestyle Behaviors Scale Education Booklet|"In the experimental phase of the study, an informed consent form, patient information form, healthy lifestyle behaviors scale, patient follow-up and evaluation form and education booklet were used.~Patient Information Form: This form was developed by the researchers. Healthy Lifestyle Behaviors Scale: The scale, which measures the health-promoting behaviors associated with the individual's healthy lifestyle, consists of a total of 52 items.~Patient Follow-up and Evaluation Form: Metabolic value tests are routinely requested in the institution.~Education Booklet: An education booklet was created based on the literature and the opinions of three experts.~Data collection method: Individualized education was given to the experimental group. Then, the Patient Information Form and the Healthy Lifestyle Behaviors Scale were applied as pre-test and post-test. The laboratory values of the patients were examined and recorded in the Patient Follow-up and Evaluation Form."
48650088|NCT01877057|DIETARY_SUPPLEMENT|Saturn|
48650089|NCT00536705|DRUG|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
48650090|NCT04361487|DEVICE|NOVOSTITCH PRO Meniscal Repair System|Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
48650091|NCT04818229|DRUG|CBP-307|CBP-307 capsules oral administration.
47972726|NCT06505616|DEVICE|Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it|The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.
48326780|NCT05910814|BEHAVIORAL|Motor imagery|On the bimanual finger tapping task composed of 8 elements, the participant will be required to repeat the motor sequence mentally using MI (mental rehearsal of movement) during twelve blocks of 30 seconds. Participant will imagine performing the sequence as fast and accurately as possible without overt movement.
48326781|NCT05910814|BEHAVIORAL|Physical Practice (PP)|Participants will practice a bimanual sequential finger tapping task composed of 8 movements. Participant will be required to perform the sequence as fast and as accurately as possible during blocs of 30 s (i.e. twelve blocs during training).
48326782|NCT01714297|DRUG|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
48650092|NCT04818229|DRUG|Placebo-matched CBP-307|Placebo-matched CBP-307 capsules oral administration.
48650093|NCT04818229|DRUG|Moxifloxacin (Avelox)|Moxifloxacin tablets oral administration。
47972727|NCT02459353|DRUG|Dapagliflozin|
47972728|NCT02459353|DRUG|Placebo|
47972729|NCT00119626|DRUG|NXY-059|
47972730|NCT06472063|OTHER|pre- or perioperative treatment and D2 gastrectomy|pre- or perioperative treatment and D2 gastrectomy
47972731|NCT03385005|DEVICE|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
47972732|NCT00543556|DRUG|MK0767|
48326783|NCT05930990|BEHAVIORAL|Mamas in Harmony|Mothers attend 8x 1 hour weekly classes with their infant. Classes take place in a community venue. Mothers sit with their infant on the floor in circle formation on cushioned mats. Group singing facilitated for 40 minutes by the intervention facilitator, a professional musician/choir leader. A mix of songs are introduced that are easy to learn without the need for lyric sheets. Mothers will be encouraged to sing along. Mothers will be encouraged to interact with their infant through various sensory stimuli involving touch, sound and visual. The end of each singing session involves a short period of quiet time, soothing sounds are provided by the intervention facilitator using voice and instruments. 20 minutes of facilitated social support will follow and mothers will be provided with refreshments. Mothers will be encouraged to interact with other mothers to promote social connection.
48326784|NCT04475822|BEHAVIORAL|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
48650094|NCT04818229|DRUG|Placebo-matched Moxifloxacin|Placebo-matched Moxifloxacin tablets oral administration.
48490207|NCT05369468|DRUG|Bupivacain only|to assess efficacy of bupivacain alone in ultrasound-guided erector spinae plane block in patient undergoing laporoscopic cholecystectomy. primary outcome was the total amount of morphine consumption in the first 24-hour postoperative, and the secondary outcomes were the time of first rescue analgesia ,pain score, and safety.
48490208|NCT02334111|BEHAVIORAL|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
47972733|NCT05043506|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
47972734|NCT05043506|DRUG|Aromatase inhibitor|Aromatase inhibitor monotherapy
47972735|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
47972736|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
47972737|NCT06145061|DEVICE|all patients and healthy people will receive at least 3 infrared thermal imaging examinations of acupoints and pain threshold examinations of acupoints.|Infrared thermal imaging detection scheme of acupoints:Detection equipment NEC R550 infrared thermal imager.Records the corresponding acupoints coordinates,and starts to collect the infrared thermal image.and 6 images will be taken continuously for each detected part.The infrared thermograms were stored and extract the temperature values of the corresponding coordinates of the acupoints.The average temperature values of the acupoints in the six infrared thermograms were calculated as their temperatures.Pain threshold detection scheme of acupoints:The instrument and equipment use the FDX25 hand-held pain threshold test instrument to explore the acupoints.Place the probe of the pain measuring instrument vertically on the pain measuring acupoint, slowly and steadily press downward at a constant speed, and stop pressing immediately when the subject begins to feel pain. At this point, the reading on the display is the subject's pain threshold. All acupoints shall be measured once in total.
48490209|NCT02760264|DRUG|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
48490210|NCT02760264|DRUG|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
48490211|NCT02760264|DRUG|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
48490212|NCT02760264|DRUG|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
48121460|NCT02764242|OTHER|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
47972738|NCT01177592|DEVICE|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19\*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
48326785|NCT04475822|BEHAVIORAL|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
48326786|NCT04475822|BEHAVIORAL|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
48326787|NCT03497442|DRUG|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
48490213|NCT03014336|DEVICE|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
48490214|NCT00663832|DRUG|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
48490215|NCT03394911|BIOLOGICAL|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
48490216|NCT01320748|BEHAVIORAL|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
48490217|NCT01320748|BEHAVIORAL|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
48490218|NCT05042934|PROCEDURE|Fine-Needle Aspiration|Undergo fine-needle aspiration
48490219|NCT05042934|DRUG|Irinotecan|Given IV
48490220|NCT05042934|DRUG|Irinotecan Hydrochloride|Given IV
48490221|NCT05042934|DRUG|Lurbinectedin|Given IV
48490222|NCT00149188|DRUG|Lanreotide (Autogel formulation)|
48490223|NCT02726919|DRUG|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
48490224|NCT04010019|BEHAVIORAL|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
48650095|NCT01887197|OTHER|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
48650096|NCT01887197|DRUG|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
48650097|NCT01887197|DRUG|mannitol inhalation powder|mannitol inhalation powder
48650098|NCT01310751|DRUG|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
48650099|NCT01310751|DRUG|distilled water|2 ml per session
47972739|NCT04216771|DRUG|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
47972740|NCT04216771|DRUG|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
47972741|NCT00480298|DRUG|Administration of oral methylprednisolone|
47972742|NCT05333978|DEVICE|MSOT Device|The MSOT Device will be used to take images of the areas of inflammation in patients with inflammatory diseases such as GVHD, Colitis, and IBD, prior to, and after 4 weeks of treatment.
47972743|NCT05333978|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after each instance of MSOT imaging.
47972744|NCT00177398|DRUG|Glargine insulin vs regular insulin|
47980511|NCT06335914|DIAGNOSTIC_TEST|Ga 68 PSMA-11 PET|Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
47980512|NCT06335914|DIAGNOSTIC_TEST|18F-DCFPyL PET|Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
48121461|NCT02764242|OTHER|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
48121462|NCT02904642|BEHAVIORAL|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
48121463|NCT02904642|BEHAVIORAL|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
48121464|NCT00667056|DRUG|tacrolimus ointment|topical
48121465|NCT00667056|DRUG|placebo ointment|topical
48326788|NCT03497442|DRUG|Placebo Vehicle Gel|Vehicle Gel
48326789|NCT04142515|OTHER|no intervention|no intervention
48326790|NCT04009213|DEVICE|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
48650100|NCT04438512|DRUG|Midomafetamine|Administration of 80 or 120 mg midomafetamine HCl in combination with manualized therapy and a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively
48650101|NCT04438512|BEHAVIORAL|Psychotherapy|Manualized therapy performed by therapist team
48326791|NCT04009213|DEVICE|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2.
48490225|NCT04010019|BEHAVIORAL|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
48650102|NCT02235688|DRUG|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
48650103|NCT02235688|DRUG|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
48650104|NCT02235688|DRUG|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
48650105|NCT02235688|DRUG|gemcitabine|
48650106|NCT00563316|DRUG|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
48650107|NCT00563316|DRUG|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
48650108|NCT06639490|DEVICE|RUS GA|he RUS GA (Endoscopic Imaging Treatment Planning Software, E04010.01(2)) is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the actual intra-abdominal surgical environment, allowing for the visualization of vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS GA utilizes preoperative CT images of the patient to segment organs and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention with the patient, the surgeon uses RUS GA as a surgical navigation tool to simulate the surgery before performing the actual procedure.
48650109|NCT06639490|PROCEDURE|standard treatment|Only standard treatment is performed.(Robot-assisted gastrectomy will be performed using without software RUS GA.)
48650110|NCT00055185|DRUG|CD4-IgG2 (PRO 542)|
48650111|NCT02095457|BEHAVIORAL|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
48490226|NCT04032158|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
48490227|NCT04032158|DRUG|Avonex®|Participants received avonex® IM injection once a week.
48650112|NCT06041880|DEVICE|Passive calf muscle stretching device|Modified night splints will be used to passive stretch the calf muscle.
48650113|NCT06382207|DEVICE|Eko Duo electronic stethoscope|A digital stethoscope with 1-lead electrocardiogram (ECG), the DUO, which pairs with a mobile application that allows the clinician to further engage with the device during and after a clinical visit. The application enables the clinician to visualize the sounds and electrical signals coming from the device in real time.
48650114|NCT06382207|DEVICE|CORE 500 electronic stethoscope|The CORE 500 has 3 electrodes that produce a 3 lead ECG, which can be viewed through the Eko app. The CORE 500 also has a user interface screen which provides a number of functions including confirming when all three electrodes have good skin contact, showing a single lead ECG wave, providing heart rate, allowing the user to switch between audio modes, allowing the user to take recordings, and providing AI analysis results for recordings.
48650115|NCT00517114|DRUG|Rabeprazole 20mg twice daily|
48650116|NCT04013971|OTHER|AGRF Biofeedback Game|During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
48650117|NCT04013971|OTHER|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
48650118|NCT04013971|OTHER|Control Condition|Participants will complete a control walk with out feedback.
48326792|NCT01399749|OTHER|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
48490228|NCT04032158|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to Avonex® once a week.
48490229|NCT04032158|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
48490230|NCT00005823|DRUG|cytarabine|
48490231|NCT00005823|DRUG|daunorubicin hydrochloride|
48490232|NCT00005823|DRUG|etoposide|
48490233|NCT00005823|DRUG|hydroxyurea|
48490234|NCT00005823|DRUG|idarubicin|
48490235|NCT00005823|DRUG|mitoxantrone hydrochloride|
48490236|NCT00005823|DRUG|thioguanine|
48490237|NCT00005823|DRUG|tretinoin|
48490238|NCT00005823|DRUG|valspodar|
48490239|NCT01703936|OTHER|Agricultural and life skills training program|
48490240|NCT00541164|DRUG|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
48490241|NCT00541164|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
48326793|NCT04624828|PROCEDURE|Radiotherapy|"RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints."
48326794|NCT04624828|DRUG|androgen deprivation therapy (ADT)|"ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression"
48650119|NCT04013971|OTHER|Optional Game with VR|During the optional AGRF biofeedback game with virtual reality (VR) participants will walk on a split-belt treadmill with a head-mounted VR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with VR for 4 minutes.
48326795|NCT04624828|BIOLOGICAL|immune evaluation|We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.
48326796|NCT01148563|DEVICE|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
48326797|NCT00378755|DRUG|velcade|
48490242|NCT03344926|BEHAVIORAL|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~1. education about pain behaviors, exposure and acceptance and commitment therapy~2. education about pain physiology~3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~4. value based exposure in the participant's daily life"
48650120|NCT05984862|DEVICE|Bandage|To determine if using bandage versus no-bandage, plays a role in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure
47972745|NCT03006497|OTHER|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
47972746|NCT04119882|DIAGNOSTIC_TEST|Blood collection|New biomarker test
47972747|NCT06373627|OTHER|Hypnosis|"A hypnosis session takes place in 3 stages:~* An induction stage, where we move from an ordinary state of consciousness to a modified state of consciousness through dissociation.~* A work phase to deepen the hypnotic trance. This phase is fueled by the construction of suggestions and metaphors, analogous to those of the patient in pain.~* Finally, a return to the ordinary state of consciousness through re-association with the patient."
47972748|NCT06373627|DRUG|Conventional medications used for sedation-analgesia|MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
47972749|NCT06373627|DRUG|Medications used in addition to hypnosis|MEOPA + intravenous ketamine (0.3 mg/kg)
48121466|NCT02878772|DRUG|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
48121467|NCT02878772|DRUG|Aspirin|100mg, once daily, oral medication
48490243|NCT06457737|DEVICE|IPS Empress Direct|Resin composite will be heated and used to lute a ceramic partial coverage restoration.
48490244|NCT06457737|DEVICE|Bisco Duo-Link Universal|Dual cure adhesive resin cement will be used to lute a ceramic partial coverage restoration.
48650121|NCT05045417|DIAGNOSTIC_TEST|Serum level of IL-17|"Measurement of serum level of IL-17 :~1. To explore the role of IL-17 in systemic lupus erythematosus~2. To determine the relation between IL-17 and lupus disease activity~3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
48650122|NCT04939103|DEVICE|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
47972750|NCT05699499|OTHER|KeryFlex|KeryFlex is a painless, in-office cosmetic application of artificial nails which improves the appearance of nails damaged by various nail disorders. The composite resin creates a flexible, nonporous nail that allows the remaining natural nail to grow. KeryFlex is a three-step procedure that takes 10 to 15 minutes for a typical nail. At least 15% of the existing nail must be present for the resin application. The material used in KeryFlex is approved as a cosmetic by the FDA.
47972751|NCT03716089|PROCEDURE|Laparoscopic resection|Laparoscopic surgery under general anesthesia
47980513|NCT06335914|DIAGNOSTIC_TEST|FDG PET|Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
48121468|NCT01356069|OTHER|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
48650123|NCT05292703|OTHER|Participatory activity based on art and olfactory stimulation|practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
48650124|NCT05292703|OTHER|practicing art virtually in conjunction with olfactory identification|"For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks."
48326798|NCT03345940|DRUG|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
48121469|NCT01356069|OTHER|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
48121470|NCT01456715|BIOLOGICAL|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
48121471|NCT01456715|BIOLOGICAL|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
48121472|NCT02727296|DRUG|sevoflurane|General anesthesia with sevoflurane
48121473|NCT02727296|DRUG|propofol|General anesthesia with propofol
48121474|NCT02349503|DRUG|NBI-77860|
48326799|NCT03345940|DRUG|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
48490245|NCT06414460|DRUG|ISM3412|ISM3412 will be administered orally once daily.
48490246|NCT02138136|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration
48490247|NCT06033365|BEHAVIORAL|care navigation|Dedicated care navigation throughout study enrollment and follow-up period. Care navigation consists of addressing social support needs (e.g. transportation, communication, housing).
48650125|NCT06539260|DRUG|Vitamin D|Take 400 units of vitamin D3, twice daily, for a duration of 3 months.
48650126|NCT06539260|DRUG|Placebo|Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.
48650127|NCT04655976|BIOLOGICAL|Cobolimab|Cobolimab will be administered.
48650128|NCT04655976|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
47972752|NCT01025791|DRUG|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
48650129|NCT04655976|DRUG|Docetaxel|Docetaxel will be administered.
48650130|NCT02355509|DRUG|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
48650131|NCT02355509|DRUG|Placebo|Placebo pills are given instead of acarbose in this group
47972753|NCT01025791|DRUG|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
47972754|NCT01025791|DRUG|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
47972755|NCT00811798|BIOLOGICAL|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48326800|NCT00531245|DRUG|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
48326801|NCT03712332|BEHAVIORAL|Distress Tolerance Group|The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
48490248|NCT02635217|DEVICE|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
48490249|NCT02635217|DEVICE|room air insufflation|using standard care room air will be infused on demand
48490250|NCT02635217|PROCEDURE|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
47972756|NCT06505369|DRUG|Daratumumab|Daratumumab will be administered by SC injection
47972757|NCT06505369|DRUG|Bortezomib|Bortezomib will be administered by SC injection
48121475|NCT02349503|DRUG|NBI-77860|
48121476|NCT02349503|DRUG|NBI-77860|
48121477|NCT05506436|DEVICE|Evident 3|It consists of brief 5-minute counselling on general physical activity recommendations and explaining the plate method for a balanced diet. Also, it includes the Evident 3 application, which is a daily dietary log that provides information on calories and diet composition and shows a reminder of the 10000 steps/day.
48490251|NCT02635217|PROCEDURE|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
48490252|NCT04156620|DRUG|Secukinumab|The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
48650132|NCT00662038|DRUG|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
48326802|NCT02637024|RADIATION|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
48326803|NCT02637024|RADIATION|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
48326804|NCT05941858|OTHER|Best Practice|Receive standard cessation treatments
48326805|NCT05941858|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
48326806|NCT05941858|OTHER|Internet-Based Intervention|Receive access to WaQi program
48490253|NCT04156620|DRUG|Placebo|The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
48490254|NCT01530763|DRUG|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children \< 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
48490255|NCT01530763|DRUG|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
48490256|NCT01530763|DRUG|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
48650133|NCT05454007|BEHAVIORAL|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
48650134|NCT04869384|OTHER|Reminders and feedback to improve adherence|Subjects will receive reminders and feedback to improve their adherence.
48650135|NCT04869384|OTHER|No reminders and feedback to improve adherence|Subjects will not receive reminders and feedback to improve their adherence.
48650136|NCT01697501|OTHER|Interleukin 28B testing|Blood sampling for IL28B genotyping
48650137|NCT06361537|DRUG|OCTA-C1-INH|OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
48650138|NCT06361537|OTHER|Placebo|0.1 mL/kg BW 0.9% sodium chloride injection
48650139|NCT00879619|DRUG|sunitinib malate|Given PO
48650140|NCT00879619|DRUG|docetaxel|Given IV
48650141|NCT00879619|DRUG|prednisone|Given PO
48650142|NCT06262607|DRUG|CLE-400|Topical CLE400 gel 0.28% administered once daily
48326807|NCT05941858|DRUG|Nicotine Replacement|Receive referral for NRT
48326808|NCT05941858|OTHER|Survey Administration|Ancillary studies
48326809|NCT05941858|OTHER|Tai Chi|Practice Tai Chi
48326810|NCT03444870|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
48326811|NCT03444870|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
48326812|NCT02219633|DRUG|LEO 39652 cream|Applied for 21 days
48326813|NCT01670656|DRUG|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
48326814|NCT01670656|DRUG|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
48490257|NCT00608517|BIOLOGICAL|anti-thymocyte globulin|Given IV
48490258|NCT00608517|DRUG|cyclophosphamide|Given IV
48326815|NCT01670656|DRUG|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
48326816|NCT01670656|DRUG|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
48326817|NCT01610076|OTHER|Code Status Video|"10 minute video about Code Status"
48490259|NCT00608517|DRUG|fludarabine phosphate|Given IV
48490260|NCT00608517|DRUG|methylprednisolone|Given IV
48490261|NCT00608517|RADIATION|total-body irradiation|Given daily for 1-4 days
48490262|NCT00299845|DRUG|Lansoprazole|
48490263|NCT03374241|BIOLOGICAL|HM15211 or Placebo|Long-acting tri-agonist
48490264|NCT02581163|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
48490265|NCT02581163|DRUG|Dasabuvir|Tablet
48490266|NCT02581163|DRUG|Ribavirin|Tablet
48650143|NCT06262607|DRUG|Vehicle|Topical vehicle gel administered once daily
48650144|NCT01906138|DEVICE|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
48650145|NCT06399692|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.
48650146|NCT06399692|PROCEDURE|Percutaneous coronary intervention (PCI)|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
48650147|NCT02659371|DIETARY_SUPPLEMENT|Low energy diet|
48650148|NCT04662320|DEVICE|Checkpoint BEST System|"Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System"
48650149|NCT00548691|DRUG|Ferric Carboxymaltose|
48650150|NCT00548691|DRUG|Standard Medical Care (SMC)|
48650151|NCT03428347|BIOLOGICAL|GamEMab|drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
48650152|NCT05160441|BIOLOGICAL|Platelet Rich Plasma Injection|"Minimum 2cc Leukocyte Poor Platelet Rich Plasma~The PRP will be prepared by drawing 60cc blood from the participant through venipuncture, spinning the blood sample in a centrifuge and then injecting the platelet rich plasma (approximately 2-5cc or max collected) into the study shoulder using ultrasound guidance. This sample will be prepared by the study provider (physician assistant or physician). Any leftover blood will be safely discarded per standard protocols."
48650153|NCT05160441|BIOLOGICAL|Corticosteroid Injection|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
48121478|NCT05506436|OTHER|Implementation strategy|"Four sessions have been designed to obtain the implementation strategy:~First session: Presentation of the Evident 3 application and its results in clinical trials. Training in the use of the application and identification of possible areas for improvement.~Second session: Presentation of evidence-based practices on the management of obesity in Primary Care. Consensus selection of those related to health promotion and mHealth. Sharing of possible lines of improvement of the care offered in the practice.~Third session (optional): Intervention on those components (coherence, cognitive participation, collective action and reflective follow-up) of the NOMAD questionnaire, if very low scores are obtained.~Fourth session: Brainstorming on possible strategies for the implementation of the Evident 3 intervention. Analysis and evaluation of these strategies and determination of a common strategy for their implementation."
48650154|NCT05160441|BIOLOGICAL|Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure|Participants randomized to the corticosteroid injection (CSI) group who report no improvement in their pain level at the 6 week post-CSI visit will be unblinded to their study injection (CSI) and will be offered the option to stay in the study and receive Platelet Rich Plasma injection.
48650155|NCT05499819|OTHER|Canned black beans, drained and rinsed|Canned black beans, drained and rinsed and consumed in a tortilla wrap
48650156|NCT05499819|OTHER|Canned red kidney beans, drained and rinsed|Canned red kidney beans, drained and rinsed, drained and rinsed and consumed in a tortilla wrap
48650157|NCT05499819|OTHER|Extra-lean ground beef|Extra-lean ground beef, pan-fried and consumed in a tortilla wrap
48121479|NCT04381975|BEHAVIORAL|Move in Mind Program|Each of the six Move in Mind sessions will take place once a week for approximately 1.5 hours, with 12-17 individuals participating per class. The material and exercises taught will include physical floor exercises, breathing exercises, as well as awareness training.
48121480|NCT04381975|BEHAVIORAL|6 Week Waitlist Control|The waitlist control group will receive the Move in Mind program after 6 weeks.
48121481|NCT05075083|BIOLOGICAL|Inactivated COVID-19 vaccine|receive two doses inactivated COVID-19 vaccine with the interval of 21 days
48121482|NCT02873312|DEVICE|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~* An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~* An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~* A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
48121483|NCT01001936|DRUG|SKI-606|
48326818|NCT04387318|DEVICE|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
48490267|NCT03532113|BEHAVIORAL|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
48490268|NCT03532113|BEHAVIORAL|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
48490269|NCT03532113|BEHAVIORAL|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
48650158|NCT04264845|OTHER|Provider Focus|The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
47972758|NCT06505369|DRUG|Lenalidomide|Lenalidomide will be administered by oral route
47972759|NCT06505369|DRUG|Dexamethasone|Dexamethasone will be administered by oral route
47972760|NCT06505369|DRUG|Talquetamab|Talquetamab will be administered by SC injection
47972761|NCT06505369|DRUG|Teclistamab|Teclistamab will be administered by SC injection
47972762|NCT04757870|OTHER|frequency|Macro-scale risk factors for the frequency of and mortality of infection
47972763|NCT03102372|DIETARY_SUPPLEMENT|Whey protein supplementation|
47972764|NCT03102372|OTHER|walking program|
47972765|NCT03102372|OTHER|Very Low Calorie Diet|
47972766|NCT01828281|DEVICE|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
47972767|NCT03012438|DEVICE|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
48121484|NCT06444958|DIAGNOSTIC_TEST|observational study without any intervention component.|"extracting and analyzing the following data:~Outpatient department records: Diagnoses, treatments, patient demographics Inpatient admission records: Admission diagnoses, treatments, patient outcomes (discharged, transferred, died) Mortality records: Causes of death for pediatric patients"
48326819|NCT04387318|DEVICE|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
48326820|NCT04387318|DEVICE|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
48326821|NCT04387318|DEVICE|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
48326822|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
48326823|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
48326824|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
48326825|NCT01112423|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
48490270|NCT02428686|DRUG|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
48490271|NCT00136578|DRUG|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
48490272|NCT00136578|DRUG|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
48490273|NCT05255965|DIAGNOSTIC_TEST|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
48490274|NCT06362382|BEHAVIORAL|tele-rehabilitation training|"During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training.~After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily （a total of 3 months）training sessions and intensive supervision and management by the online community at least once a week. All patients' routines were monitored by telemetry and data, photographs and video recordings were collected by a specialized agency.~The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved."
48121485|NCT06480942|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
48121486|NCT02077426|OTHER|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
48326826|NCT01887782|DEVICE|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
48326827|NCT01887782|DEVICE|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
48326828|NCT04609995|BEHAVIORAL|Incentives|No financial incentive
48490275|NCT06362382|BEHAVIORAL|health propaganda and education|"During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times).~After discharge from the hospital, the control group followed their daily routine."
48490276|NCT03262506|OTHER|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
48490277|NCT01806038|OTHER|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
48490278|NCT01806038|OTHER|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
48490279|NCT02322619|DRUG|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
48490280|NCT03082664|DEVICE|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
48326829|NCT03173586|OTHER|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
48326830|NCT04965129|DRUG|Placebo|Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
48326831|NCT04965129|DRUG|Fish oil|All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
48121487|NCT05906940|DEVICE|Transcutaneous Vagus Nerve Stimulation|As a vagus stimulation protocol, bilateral auricular stimulation and stimulation frequency of 10 Hz, pulse width of 300 µs, biphasic application for 20 minutes, each participant will be stimulated twice, with at least 48 hours between them.
48121488|NCT02150967|DRUG|BGJ398 (infigratinib)|Capsule for oral use
48121489|NCT03593733|OTHER|Photobiomodulation Therapy|Photobiomodulation Therapy
48121490|NCT03593733|OTHER|Cold Water Immersion|Cold Water Immersion
48121491|NCT00024063|DRUG|orantinib|
48490281|NCT01649466|DRUG|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
48490282|NCT01649466|DRUG|Protaphane|Protaphane will be used as commercially available injection pens
48121492|NCT03778242|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
48121493|NCT03778242|DRUG|normal saline|2 placebo ampoules to TA in 100 ml saline by slow infusion
48121494|NCT02652689|RADIATION|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
48121495|NCT06134258|OTHER|mixed meal test|mixed meal test after fasting
48121496|NCT01608347|DRUG|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
48490283|NCT00539357|DEVICE|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
48650159|NCT04264845|OTHER|Patient Interview|A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
48326832|NCT05475574|OTHER|Discontinuation of contact precautions for ESBLE|Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
48326833|NCT01770691|DEVICE|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
48121497|NCT01608347|DRUG|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
48121498|NCT01450228|DRUG|KI1001|Prolonged release melatonin 2mg
48121499|NCT01450228|DRUG|Placebo KI1001|Placebo KI1001 tablets
48121500|NCT03434652|DEVICE|Percutaneous neurostimulation|Auricular percutaneous neurostimulation
48121501|NCT00586222|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
48121502|NCT00586222|OTHER|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
48326834|NCT00041691|DRUG|hMN14 (labetuzumab)|
48326835|NCT05943067|BIOLOGICAL|CD45RA depleted donor lymphocyte infusion (DLI)|CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT
48326836|NCT05366270|DEVICE|WBH|Hyperthermia exposure using Heckel Hyperthermia Device
48326837|NCT05366270|DEVICE|Sham|Sham (mild heating) using Heckel Hyperthermia Device
48490284|NCT00754013|DRUG|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
48490285|NCT00754013|DRUG|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
48490286|NCT00930254|PROCEDURE|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
47972768|NCT01413529|BEHAVIORAL|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
48121503|NCT03454529|OTHER|Laboratory Biomarker Analysis|Correlative studies
48121504|NCT03454529|DRUG|Simvastatin|Given PO
48121505|NCT06024824|RADIATION|Dose-Painted Intensity Modulated Radiotherapy|"Fifteen fractions of external beam radiation therapy (EBRT) delivered via IMRT/ VMAT.~Cohort 1 (n = 3-6) Single PTV 40.05 Gy/15#, homogenous dose. Cohort 2 (n = 3-6) High Risk PTV 45 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions.~Cohort 3 (n = 3-6) High risk PTV 48 Gy/15# SIB to PTV tumour, Elective PTV 40.05 Gy/15# to nodal regions."
48121506|NCT01363492|BIOLOGICAL|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
48121507|NCT03107767|PROCEDURE|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
48121508|NCT02086097|DRUG|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
48121509|NCT02086097|DRUG|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
48121510|NCT02086097|DRUG|PLACEBO|INACTIVE SUGAR PILLS
48121511|NCT02106182|DRUG|Silodosin|
48326838|NCT03141268|DIAGNOSTIC_TEST|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
48326839|NCT05553626|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
48121512|NCT02106182|OTHER|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
48121513|NCT02106182|OTHER|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
48121514|NCT02106182|OTHER|12 weeks|
48121515|NCT05286710|DEVICE|pharmacomechanical thrombectomy (PMT)|After randomization patients will be allocated to pharmacomechanical thrombectomy (PMT) via ipsilateral popliteal venous approach or to PMT via distal calf venous approach, bail-out contralateral femoral access can be used if puncture was failed in calf vein. After PMT treatment, residual thrombus was reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) was conducted if there was residual thrombus. Stenosis of iliac vein was assessed by multiangle venography and intravascular ultrasound (IVUS) was used if necessary. Percutaneous balloon angioplasty (PTA) was conducted if there was \>50% stenosis of the diameter of the iliac vein. A stent was placed if the residual stenosis was \>50% after PTA treatment.
47972769|NCT01413529|BEHAVIORAL|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
47972770|NCT04036344|BEHAVIORAL|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
48121516|NCT01337635|DRUG|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
48121517|NCT00041548|DRUG|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
47972771|NCT03423381|OTHER|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
48121518|NCT00041548|DRUG|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
48121519|NCT04526834|DRUG|CD30.CAR-T|"Bendamustine and Fludarabine (3 days)~Dose level 1: 2 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 2: 4 x 108 cell/m2 CD30.CAR-T (Day 0)~Dose level 3: 6 x 108 cell/m2 CD30.CAR-T (Day 0)"
48326840|NCT05553626|DEVICE|Bi-ventricular pacing|Bi-ventricular pacing by a CRT/CRTD device
48326841|NCT02156232|PROCEDURE|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
48490287|NCT02806258|RADIATION|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
48490288|NCT02806258|DRUG|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
47972772|NCT03423381|OTHER|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
48490289|NCT00384176|DRUG|Cediranib|oral tablet once daily
48490290|NCT00384176|DRUG|Bevacizumab|intravenous infusion
48490291|NCT00384176|DRUG|5-fluorouracil ( in FOLFOX)|intravenous infusion
48650160|NCT04264845|OTHER|PROs/Clinical Data Integration|A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
48490292|NCT00384176|DRUG|Leucovorin (in FOLFOX)|intravenous infusion
48490293|NCT00384176|DRUG|Oxaliplatin (in FOLFOX)|intravenous infusion
48490294|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire at inclusion in registry
47972773|NCT03423381|OTHER|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
47972774|NCT03423381|OTHER|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
47972775|NCT03423381|OTHER|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
47972776|NCT03423381|OTHER|Control product|A cereal based product with low concentrations of df
47972777|NCT04564729|OTHER|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
48121520|NCT01943916|DEVICE|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
48121521|NCT01943916|DEVICE|Imagio gray scale ultrasound|gray scale ultrasound alone
48121522|NCT05335642|PROCEDURE|EVAR|Endovascular repair of abdominal aortic aneurysms
48121523|NCT02847689|BEHAVIORAL|Language Treatment|Recording of a mother's voice reading a children's storybook.
48121524|NCT02847689|BEHAVIORAL|Control Treatment|Standard of Care
48121525|NCT00541333|DRUG|Copaxone Injection|
48121526|NCT05765253|DEVICE|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
48121527|NCT05765253|DEVICE|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
48121528|NCT05765253|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
48490295|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
48490296|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
48490297|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
48326842|NCT02156232|PROCEDURE|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
48121529|NCT02711059|PROCEDURE|parathyroidectomy|surgical treatment of hyperparathyroidism
48326843|NCT06006884|PROCEDURE|Bronchoscopies and Bronchoalveolar Lavages (BALs)|Bronchoscopies use a thin, lighted tube, which enters through the mouth or nose and moves down the throat to the airways to look at the lungs. BALs are done during bronchoscopies to collect samples from the lungs for testing. During this procedure, a saline solution is put through the tube to wash the airways and collect a fluid sample.
48326844|NCT06006884|DIAGNOSTIC_TEST|Chest Tomography (CT)|X-ray to create images of the bones and internal organs of the body
48326845|NCT06006884|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Measures the electrical activity of the heart by using sticky pads that are placed on your chest and limbs.
48326846|NCT06006884|DIAGNOSTIC_TEST|Pulmonary function tests (PFTs)|Testing to measure how well lungs are working
48121530|NCT00338572|BEHAVIORAL|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
48121531|NCT00338572|BEHAVIORAL|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
48326847|NCT06006884|DIAGNOSTIC_TEST|6 minute walk test (6MWT)|Walking test to see how well the lungs function with exercise over 6 minutes
48326848|NCT00178464|DRUG|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
48326849|NCT04090047|DRUG|PF-06700841|PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
48326850|NCT04090047|DRUG|Itraconazole|200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
48326851|NCT00576251|DRUG|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
48326852|NCT00576251|DRUG|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
48326853|NCT04345497|OTHER|Diabetes-Specific Formula|Diabetes-Specific Formula and Standard of Care
47972778|NCT00902915|DRUG|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
47972779|NCT01460888|DRUG|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
48326854|NCT04345497|OTHER|Standard Of Care|Standard of Care
48326855|NCT00804375|DRUG|2PX|cutaneous solution to be applied twice daily for 84 days
48326856|NCT00804375|DRUG|Placebo|cutaneous solution to be applied twice daily for 84 days
48326857|NCT01954251|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
48326858|NCT01954251|BIOLOGICAL|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
48326859|NCT01488942|OTHER|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
47972780|NCT01460888|RADIATION|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
47972781|NCT03925883|BEHAVIORAL|Patient navigation|Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
47972782|NCT05079529|DRUG|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
47972783|NCT05079529|DRUG|Placebo Group|Takes placebo capsule 3 times daily for 90 days
48326860|NCT00673894|DRUG|Sitagliptin|Glutamine 30g +sitagliptin 100mg
48326861|NCT00673894|DRUG|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
48326862|NCT03039933|BEHAVIORAL|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
48121532|NCT00203216|DRUG|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
48121533|NCT00203216|PROCEDURE|Transcranial Magnetic Stimulation|
48121534|NCT00000217|DRUG|Carbamazepine|
48121535|NCT02935998|DRUG|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score\>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
48121536|NCT04313205|DRUG|JKB-122 in capsule or tablet form|JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
47972784|NCT04826432|DRUG|Pasireotide 0.9 MG/ML|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
48121537|NCT05906875|OTHER|Lateral Stepping Exercise 1|1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.
48121538|NCT05906875|OTHER|Active Control Group Exercise 1|1. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
48121539|NCT05906875|OTHER|Active Control Group Exercise 2|2. Knee extension Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
48121540|NCT05906875|OTHER|Active Control Group Exercise 3|3. Hip flexion Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
48121541|NCT05906875|OTHER|Active Control Group Exercise 4|4. Hip abduction Three sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
48121542|NCT05906875|OTHER|Lateral Stepping Exercise 2|2. Lateral stepping: Performed without and with resistance bands. The participant will perform a series of steps to the side. If using a resistance band, the band will be placed around both ankles in a 'loop' and the participant will perform the lateral stepping. Three sets of 8-12 repetitions will be performed per side per subject.
48121543|NCT05906875|OTHER|Lateral Stepping Exercise 3|3. Single leg stance: The participant will stand on one leg with support as needed. The contralateral knee will be held at 45 degrees throughout the exercise. The instructor will observe to ensure the bent leg does not contact the ground. Three repetitions of static stance per side will be performed with a goal of 30 seconds, and a maximum time of 60 seconds, per repetition.
48121544|NCT05906875|OTHER|Lateral Stepping Exercise 4|4. Staggered stance mini-squat: Participants will stand with the feet hip-width apart and one leg placed a short step forward. The participant will squat straight down keeping the trunk upright and return to an upright position.
48121545|NCT05906875|OTHER|Lateral Stepping Exercise 5|5. Lateral Reactive Postural Control: The participant will lean into the researcher's hand to shift their center of mass outside of their base of support. Hand placement will be at the glenohumeral joint and the pelvis. The researcher will withdraw support and guard the participant as the participant regains their balance. This is item 6 on the Mini-BESTest assessment that will be incorporated as an intervention. To be performed 3x per side.
48121546|NCT03678558|OTHER|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
48121547|NCT05316246|DRUG|Brentuximab Vedotin in Combination with Tislelizumab|Brentuximab vedotin will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a dose of 1.8 mg/kg. Tislelizumab will be administered after diluted with 100 ml normal saline as an IV infusion over approximately 30 minutes on Day 1 of each 21-day cycle at a fixed dose of 200 mg. The rationale of fixed dose of Tislelizumab is according to the drug description, which is based on previous I/II phase clinical trial results of Tislelizumab. The time interval between administration of tislelizumab and brentuximab vedotin should be not less than 2 hours, and thereafter, the dosing cycle of tislelizumab is synchronized with that of brentuximab vedotin.
48121548|NCT06281054|PROCEDURE|Revascularization|Performing PCI or CABG
48490298|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
48490299|NCT04498741|DRUG|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
47972785|NCT04826432|OTHER|Saline water|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
47972786|NCT00784498|DRUG|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
47972787|NCT00784498|DRUG|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
47972788|NCT01866696|DEVICE|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~* Clinical examination~* Radiological examination~* Guided oral implants insertion~* Immediate Prosthetic loading~* Follow-up"
48121549|NCT06355492|DEVICE|Virtual reality goggles (VR )|Patients will take buccal infiltration anaethesia using (Virtual reality goggles) that properly adjusted around the patient's head and in front of his/her eyes.
48121550|NCT06355492|DEVICE|regular screen|Patients will take buccal infiltration anaethesia using (regular screen ).
47972789|NCT01830972|DRUG|SA-ER 500 mg|oral tablets
47972790|NCT01830972|DRUG|SA-IR 500 mg|oral capsules
48326863|NCT03039933|OTHER|Treatment As Usual|Treatment As Usual
48326864|NCT04870827|DRUG|13N Amonia|Administered during PET/CT scans
48326865|NCT04319419|DIETARY_SUPPLEMENT|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
48326866|NCT04319419|OTHER|Nutrition education|Group received nutrition education program during 6 months
48326867|NCT02322411|DEVICE|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
48326868|NCT02322411|BEHAVIORAL|Compensatory approaches|
48326869|NCT06314529|OTHER|Assessments|Safety and efficacy assessments
48326870|NCT03231215|DRUG|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
48326871|NCT02492685|DEVICE|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
48326872|NCT01303432|DIETARY_SUPPLEMENT|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
48326873|NCT01303432|DIETARY_SUPPLEMENT|Yogurt|One yogurt (125mL) per day
48326874|NCT01005446|DEVICE|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
47972791|NCT02139332|BEHAVIORAL|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
47972792|NCT02139332|BEHAVIORAL|Resource & Referral Group|The Resource \& Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc...), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
47972793|NCT04383405|OTHER|Aquatic Training|Aquatic Training training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises follow a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e. catching a ball thrown by the therapist). Subjects performed three sessions a week for four weeks and each session lasting 45 minutes. The training was carried out by a physiotherapist who had at least 5 years of experience in aquatic neurorehabilitation.
47972794|NCT04383405|OTHER|Conventional Training|Conventional land-based therapy consists of customized exercises focused on static and dynamic postural stability improvement. The exercises included the active-assisted mobilization, the muscle stretching the postural transition, the balance and the gait training. The control approach was carried out three times a week for four weeks and each session lasted 45 minutes.
48121551|NCT03504423|DRUG|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
48121552|NCT03504423|DRUG|Folfirinox|Folfirinox
48121553|NCT00263952|BIOLOGICAL|bee venom|
48121554|NCT02218060|PROCEDURE|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
48121555|NCT02218060|PROCEDURE|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
48121556|NCT01416558|DRUG|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
48326875|NCT05339386|DRUG|Hyperpolarized Xe129|Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
48326876|NCT01154179|OTHER|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
48326877|NCT04966195|RADIATION|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
48326878|NCT06141941|DEVICE|CGM|Continuous glucose monitoring
48326879|NCT01830816|DRUG|Ixazomib|Ixazomib capsules
48326880|NCT04394455|BEHAVIORAL|Brief cognitive behavioral therapy|9 structured psychotherapy sessions, weekly, 60-90 minutes duration. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
48326881|NCT04394455|BEHAVIORAL|Crisis intervention therapy|3 structured sessions of crisis intervention. One session each week for three weeks. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
48650161|NCT01627197|PROCEDURE|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
47972795|NCT02555072|BIOLOGICAL|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
47972796|NCT02637739|DEVICE|hysteroscope|Women of PUL with β-hCG \> 1000 IU/L or abnormal β-hCG trend (increase \< 66% or decrease \< 15%) were offered HSC.
47972797|NCT04488068|PROCEDURE|Sham Magnetic stimulation|Sham Magnetic stimulation for comparison.
48121557|NCT01044303|DRUG|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
48121558|NCT03954301|DIAGNOSTIC_TEST|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
47972798|NCT04011267|OTHER|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
47972799|NCT01856413|DRUG|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
48121559|NCT00102258|DRUG|Growth Hormone Therapy|
47972800|NCT03751111|DRUG|Naloxone|Naloxone at an sublingual dose of 40 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
47972801|NCT03751111|DRUG|Placebo|Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
48121560|NCT00411216|OTHER|Control exercises|saccadic eye movements against a plain background; no head movements
48121561|NCT00411216|OTHER|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
48121562|NCT04446078|DEVICE|PEEK- acrylic resin prosthesis supported by 4 dental implants|Patients rehabilitated for edentulism of one or both arches through an implant supported fixed prosthesis
48121563|NCT00929760|BEHAVIORAL|specialised renal care|"* Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
48121564|NCT05855655|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"This work aims to develop an internet-delivered MBI to address minority stress and its negative HIV-related health consequences experienced by young men who have sex with men (YMSM). This aim will examine the feasibility and acceptability of the internet-delivered mindfulness-based intervention (iMBI), called Mindfulness-based Queer Resilience (MBQR), for HIV prevention. The study will enroll and randomize a sample of 60 distressed, high-risk YMSM into one of two groups: MBQR intervention (n=30) or active control condition (n=30)."
48121565|NCT00522782|DRUG|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
48121566|NCT00522782|DEVICE|Nitric Oxide Analyzer|Niox NO analyzer
48326882|NCT04574388|OTHER|open label placebo|open label placebo pill
48650162|NCT05657171|DRUG|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
48121567|NCT00126646|DRUG|BL22 immunotoxin|
48121568|NCT00126646|PROCEDURE|antibody-drug conjugate therapy|
48121569|NCT00126646|PROCEDURE|immunotoxin therapy|
48121570|NCT04578392|PROCEDURE|high ligation of ileocolic artery|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
48121571|NCT04578392|PROCEDURE|mesenteric sparing|Patients will be randomized according to post-operative recurrence risk to surgery to high ligation or mesenteric sparing
48121572|NCT01950780|DRUG|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
48121573|NCT01058785|BIOLOGICAL|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
47972802|NCT04673162|DRUG|Methylprednisolone, Placebo|iv administration
48121574|NCT02833506|OTHER|Laboratory Biomarker Analysis|Correlative studies
48121575|NCT02833506|BIOLOGICAL|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
48121576|NCT02833506|DRUG|Sirolimus|Given PO
48326883|NCT00089453|DRUG|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
48121577|NCT02849054|DEVICE|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
48121578|NCT02849054|DEVICE|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
48121579|NCT02849054|DEVICE|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
48650163|NCT06675838|BEHAVIORAL|Time Management and Procrastination Behavior Management Training|"Intervention Content~Training Program Name: Time Management and Procrastination Behavior Management Training Duration: 3 sessions of 1 hour each, 5-day program Target Audience: Intern Nurses~Training Content:~Fundamentals of Time Management:~Definition and importance of time management. Key principles for effective use of time (prioritization, time blocking, planning).~Understanding Procrastination Behavior:~Definition and reasons for procrastination behavior. Effects of procrastination on student success.~Time Management Strategies:~Task Prioritization: Differentiating between urgent and important tasks. Time Blocking: Completing specific tasks in designated time slots. Daily Planning: Organizing daily tasks and activities.~Managing Procrastination Behavior:~Identification and analysis of procrastination habits. Coping strategies for procrastination (e.g., goal setting, increasing motivation, self-rewarding).~Effective Teaching Techniques:~Presentations and Information Sharing"
48121580|NCT02849054|DEVICE|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
48121581|NCT05629182|OTHER|No intervention applied - Observational study only|Observational study only. Video footage is used to review all 64 matches in the football tournament.
48121582|NCT01098344|DRUG|Notch signaling pathway inhibitor MK0752|
48326884|NCT00089453|DRUG|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
48490300|NCT04498741|DRUG|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
47972803|NCT01461603|DIETARY_SUPPLEMENT|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
47972804|NCT01461603|DIETARY_SUPPLEMENT|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
47972805|NCT01583491|PROCEDURE|autologous platlet rich fibrin|one dose immediate after surgery
47972806|NCT01583491|PROCEDURE|one side in control group|control group insert any things after surgery
47972807|NCT01943890|DEVICE|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
47972808|NCT01943890|PROCEDURE|Physiotherapy|
47972809|NCT02599129|DRUG|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
47972810|NCT02599129|DRUG|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
47972811|NCT01673867|BIOLOGICAL|Nivolumab|
47972812|NCT01673867|DRUG|Docetaxel|
47972813|NCT02533739|BEHAVIORAL|Cognitive and neuropsychological assesment|
47972814|NCT04648553|BEHAVIORAL|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
48121583|NCT01098344|DRUG|gemcitabine hydrochloride|
48121584|NCT01098344|OTHER|imaging biomarker analysis|
48121585|NCT01098344|OTHER|laboratory biomarker analysis|
48121586|NCT01098344|OTHER|pharmacological study|
48121587|NCT02840006|PROCEDURE|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
48121588|NCT02840006|PROCEDURE|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
48121589|NCT05961020|DEVICE|Total body vibration|Whole-body vibration (WBV) training has been established as a useful method to improve physical fitness in obese individuals. Vibration stimulus during half squatting might suggest a long-term effect of WBV on the endocrine system
48121590|NCT05961020|OTHER|moderate restricted diet|moderate restricted diet
48121591|NCT01845428|DRUG|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
48121592|NCT00002072|DRUG|Epoetin alfa|
48490301|NCT04498741|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
48490302|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
48490303|NCT04498741|DRUG|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
48121593|NCT03950622|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
48121594|NCT03950622|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
48121595|NCT03966846|DIETARY_SUPPLEMENT|Kefir|
48121596|NCT03966846|DIETARY_SUPPLEMENT|Milk|
48121597|NCT03245580|DIAGNOSTIC_TEST|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
48121598|NCT02990754|BEHAVIORAL|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
48490304|NCT01117337|PROCEDURE|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
48121599|NCT05592925|DIAGNOSTIC_TEST|coagulation-related factors|We retrospectively evaluated the relationship between lymph node metastasis and coagulation-related factors in 516 patients with T4a stage gastric cancer.
48121600|NCT02719600|BEHAVIORAL|Virtual reality|Evaluation of observational motor learning using virtual reality
48326885|NCT00089453|DRUG|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period \<or= 20 minutes on day -1.
48326886|NCT00089453|DRUG|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
48326887|NCT00089453|DRUG|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
47972815|NCT04648553|BEHAVIORAL|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
47972816|NCT03808493|DRUG|TAK-438 OD|TAK-438 OD tablet
47972817|NCT03808493|DRUG|TAK-438|TAK-438 tablet
47972818|NCT05227404|DIAGNOSTIC_TEST|LumiraDX|Point-of-care test for SARS-CoV-2
47972819|NCT05227404|DIAGNOSTIC_TEST|RightSign|Point-of-care test for SARS-CoV-2
47972820|NCT05227404|DIAGNOSTIC_TEST|Case Control|Genscript assay performed on the plasma sample
48326888|NCT00089453|PROCEDURE|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
48326889|NCT00089453|DRUG|Interleukin|2 at 3x10x6 IU on days +1 to 13.
47972821|NCT03004027|OTHER|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
47972822|NCT06159530|PROCEDURE|dental implants|4 dental implants placed in the mandible according to all-on 4 concept
47972823|NCT06159530|PROCEDURE|peek framework|peek framework screwed to multi-unit abutments of 4-implants
47972824|NCT06159530|PROCEDURE|visio-lign nano composite|peek framework veneered with nano composite (visio-lign) as an occlusal material
47972825|NCT06159530|PROCEDURE|zirconia crowns|peek framework covered with zirconia crowns as an occlusal material
47972826|NCT01797653|OTHER|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
48121601|NCT02976532|OTHER|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
48121602|NCT06175000|PROCEDURE|Cognitive Assessment|Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry.
48326890|NCT00089453|PROCEDURE|Infusion #1|Infusion of donor NK Cells #1 on day 0
48326891|NCT00089453|PROCEDURE|Leukapheresis #2|on day +2
48326892|NCT00089453|PROCEDURE|Infusion #2|on day +2
48490305|NCT03347422|DRUG|sutimlimab (BIVV009)|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
48490306|NCT03347422|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
47972827|NCT01797653|PROCEDURE|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
47972828|NCT03636061|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
47972829|NCT03636061|DRUG|Placebo (vehicle) nasal spray|Placebo
47972830|NCT05489198|PROCEDURE|cataract surgery with Centurion phacoemulsification system|Cataract surgery performed with the Centurion phacoemulsification system
47972831|NCT05489198|PROCEDURE|cataract surgery with Quatera 700 phacoemulsification system|Cataract surgery performed with the Quatera 700 phacoemulsification system
47972832|NCT03715010|DIETARY_SUPPLEMENT|BCAA|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
48121603|NCT06175000|BIOLOGICAL|Obinutuzumab|Given IV
48121604|NCT06175000|OTHER|Quality of Life Assessment|Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry.
48121605|NCT06517875|DRUG|Momelotinib|Momelotinib will be administered orally.
48121606|NCT06517875|DRUG|Luspatercept|Luspatercept will be administered subcutaneously.
48121607|NCT06118827|DRUG|HS-10518|QD, orally for 7 days
48326893|NCT00089453|PROCEDURE|Auto Graft|on day +14
48326894|NCT02270684|DEVICE|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
48326895|NCT01541267|DRUG|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
48326896|NCT00234819|DRUG|Bazedoxifene/Conjugated Estrogen|
48326897|NCT03108209|OTHER|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
48326898|NCT03108209|OTHER|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
48326899|NCT00799500|OTHER|Screening|Weekly vaginal pH
48326900|NCT06067282|OTHER|Microteaching|"This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching ."
48326901|NCT01372371|BIOLOGICAL|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
48498085|NCT02203422|DRUG|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
48326902|NCT01372371|BIOLOGICAL|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
48490307|NCT04082728|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
48121608|NCT06118827|DRUG|Placebo|QD, orally for 7 days
48121609|NCT00189969|BIOLOGICAL|Elstree-BN|
47972833|NCT06171763|OTHER|Telemedicine|The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
47972834|NCT02323113|DRUG|TAK-659|TAK-659 tablets.
47972835|NCT06162936|DIAGNOSTIC_TEST|Phagoburst|The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.
47972836|NCT06162936|DIAGNOSTIC_TEST|Lymphocytes subsets|To determine lymphocytes subsets in patients with suspicion of IEI
47972837|NCT06162936|DIAGNOSTIC_TEST|Genetic testing|Perform targeted genetic testing in those with reduced to absent oxidative activity in search of PIDs and susceptibility variants
47972838|NCT01234298|DRUG|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
47972839|NCT01234298|DRUG|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
47972840|NCT01234298|DRUG|Placebo|Placebo capsule taken once-daily for up to 26 weeks
48326903|NCT01372371|BIOLOGICAL|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
48326904|NCT01461408|BEHAVIORAL|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
48326905|NCT02308176|BEHAVIORAL|APP + health advice|health advice and reinforcement to it
47972841|NCT04450368|DEVICE|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
47972842|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
48121610|NCT04764994|DEVICE|Armeo®Spring ((Task-oriented upper extremity rehabilitation system)|Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.
48121611|NCT04764994|OTHER|Conventional Physical Therapy Program|This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.
48121612|NCT00309907|BIOLOGICAL|etanercept|Given IV and subcutaneously
48490308|NCT04082728|DRUG|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
48490309|NCT04310956|DEVICE|Y-Knot all-suture anchor|Y-knot all-suture anchor will be implanted to participants
48121613|NCT00309907|DRUG|methylprednisolone|Given IV and orally
48121614|NCT04928508|DRUG|OK-1|"OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg"
48490310|NCT04310956|DEVICE|Biocomposite suture anchor|Biocomposite suture anchor will be implanted to participants
48490311|NCT05747521|DRUG|Anrotinib hydrochloride combined with adriamycin|To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
48490312|NCT02932020|DRUG|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
47972843|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
47972844|NCT00724022|DRUG|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
48121615|NCT04713735|DIETARY_SUPPLEMENT|Control: Placebo|Placebo
48121616|NCT04713735|DIETARY_SUPPLEMENT|bovine lactoferrin supplement|600 mg
48121617|NCT03792620|COMBINATION_PRODUCT|Cyclo Thal Dex Daratumumab|Cyclo Thal Dex Daratumumab
48121618|NCT02219724|DRUG|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
48121619|NCT05638308|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before the standard of care biopsy for case group
48121620|NCT03435666|DRUG|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
48326906|NCT02308176|BEHAVIORAL|health advice|health advice
48326907|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water.
48326908|NCT05507970|DRUG|Placebo|Single dose dispersed in sterile water.
48326909|NCT00425477|BIOLOGICAL|sargramostim|
47972845|NCT02904330|DRUG|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
48326910|NCT00425477|DRUG|bexarotene|
48326911|NCT00425477|GENETIC|cytogenetic analysis|
48326912|NCT00425477|GENETIC|fluorescence in situ hybridization|
48326913|NCT00425477|OTHER|flow cytometry|
47972846|NCT04167644|DIAGNOSTIC_TEST|Modified Rankin Scale (mRS)|Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
47972847|NCT00412659|PROCEDURE|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
48326914|NCT00425477|OTHER|laboratory biomarker analysis|
48326915|NCT00425477|PROCEDURE|biopsy|
47972848|NCT00412659|PROCEDURE|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
48326916|NCT04226963|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
48326917|NCT04024072|DRUG|Brinzolamide 1% ophthalmic suspension|Test product
48326918|NCT04024072|DRUG|Azopt 1% Ophthalmic Suspension|Reference product
48326919|NCT00776555|DRUG|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
48326920|NCT00776555|DRUG|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
48326921|NCT03634904|DRUG|Drug bood sampling|"Total: 6 per patient~* after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~* after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~* after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~* after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session"
48326922|NCT01613547|DRUG|Amoxicillin|80 mg/kg/day for 7 days
48650164|NCT02395627|DRUG|Tamoxifen|
48650165|NCT02395627|DRUG|Vorinostat|
48650166|NCT02395627|DRUG|Pembrolizumab|
47972849|NCT00002876|DRUG|cisplatin|
47972850|NCT00002876|DRUG|etoposide|
48121621|NCT03435666|DRUG|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
48121622|NCT01855334|DRUG|Spironolactone|
48121623|NCT01855334|DIETARY_SUPPLEMENT|L-arginine|
48121624|NCT01855334|DRUG|Placebo|
48326923|NCT01613547|DRUG|Placebo|7 days
48326924|NCT02853981|DEVICE|Harmonic scalpel|a method for liver parenchymal transection
48326925|NCT02853981|DEVICE|Kelly clamp crush technique|a method for liver parenchymal transection
48326926|NCT02207556|DRUG|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use."
48326927|NCT03323996|OTHER|Semi-Structured interviews|individual semi-structured interviews
48326928|NCT01722812|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
48326929|NCT01722812|DRUG|Placebo|Twice daily topical treatment for 14 days
48326930|NCT03453190|COMBINATION_PRODUCT|Apremilast and Clobetasol|Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
48326931|NCT02878512|PROCEDURE|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
48326932|NCT02878512|PROCEDURE|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
48326933|NCT01030380|DEVICE|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
48326934|NCT04006080|BIOLOGICAL|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
48326935|NCT03017846|DRUG|Cantharidin|Application of topical cantharidin
48326936|NCT00546793|BIOLOGICAL|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
48490313|NCT02932020|DRUG|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
48490314|NCT02932020|DEVICE|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
48650167|NCT04445909|DEVICE|VA-ECMO|Deployment of extracorporeal membrane oxygenation cardiac assist device.
48650168|NCT03844035|DIAGNOSTIC_TEST|Periimplant crevicular fluid (PICF) collection|Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
47972851|NCT04043260|DEVICE|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
48121625|NCT02646358|DRUG|Vepoloxamer|
48121626|NCT04806529|DRUG|Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)|Biological/Vaccine: Investigational adjuvanted SARS-CoV-2 Subunit vaccine
48121627|NCT04806529|DRUG|Comparator|Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
48121628|NCT00042848|DRUG|modafinil|
48121629|NCT00493350|PROCEDURE|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
47972852|NCT04812145|RADIATION|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
47972853|NCT00232024|DRUG|Tegaserod|
48326937|NCT03143556|DEVICE|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
48490315|NCT02932020|DRUG|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
48490316|NCT04691050|PROCEDURE|OrthoMTA (BioMTA)|Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
47972854|NCT05490641|BEHAVIORAL|Glucose-based biofeedback|Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period. During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.
47972855|NCT05490641|BEHAVIORAL|Standard feedback|Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.
47972856|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy with proctoring|Implementation standardised laparoscopic right hemicolectomy with proctoring
47972857|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy without proctoring|Implementation standardised laparoscopic right hemicolectomy without proctoring
47972858|NCT04084665|DRUG|Guselkumab|Guselkumab
47972859|NCT01985867|DIETARY_SUPPLEMENT|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10\^8 CFU, twice daily, orally for 4 weeks)
47972860|NCT01985867|DIETARY_SUPPLEMENT|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
47972861|NCT02339272|OTHER|non interventional|
48121630|NCT00016250|DRUG|MKC-1|
48121631|NCT04548024|DEVICE|Short term monitoring|By using the Biobeat monitoring device, we will monitor CHF patients during an outpatient visit and during treatment with diuretics.
48650169|NCT05931718|BIOLOGICAL|cytokine essays|evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples
48121632|NCT02060669|DRUG|Xeloda|Xeloda
48121633|NCT06067035|OTHER|Imaging|Imaging data from patients with small-vessel liver tumours will be compared with histological data.
48121634|NCT05541341|OTHER|tisagenlecleucel|Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
48121635|NCT01739907|OTHER|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
48490317|NCT00320567|DRUG|norgestimate/ethinyl estradiol|
48490318|NCT01408095|DRUG|LY2608204|Administered orally
47972862|NCT04432896|OTHER|Dietary protocol|Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
48490319|NCT01408095|DRUG|Glimepiride|Administered orally
48490320|NCT02399735|BIOLOGICAL|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
48490321|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
48490322|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
47972863|NCT05985577|OTHER|Without any intervention|There were no special interventions for the two groups.
47972864|NCT06301685|BEHAVIORAL|Routine therapy|The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
47972865|NCT06301685|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48121636|NCT06015399|PROCEDURE|Implementation of closed insufflation technique during segmentectomy|After the identification the targeted segmental bronchus during the operation,ligating the proximal end of the targeted bronchus. Put the vessel separation forceps in the distal bronchial space to avoid the accidental damage of the vessels. Use a 50ml syringe to inject air into the distal bronchus (about 100ml is expected) until the intersegmental plane is satisfactory. Divide the target bronchus using the cutting and closing device.
48121637|NCT06015399|PROCEDURE|Implementation of dilatation and collapse technique during segmentectomy|Divide the target bronchus using the cutting and closing device. Ask the anesthesiologist to inflate the lung completely from pure oxygen to the affected side and then change to single lung ventilation. Wait for the intersegmental plane to appear(usually about 15 minutes).
48121638|NCT05662449|DEVICE|Syndesmosis fixation using Activascrew|as described prior
48326938|NCT03562754|PROCEDURE|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
48326939|NCT03562754|PROCEDURE|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
48326940|NCT04861948|DRUG|IBI188|intravenous
48326941|NCT04861948|DRUG|GM-CSF|subcutaneous injection
48326942|NCT04861948|DRUG|Cisplatin/Carboplatin|intravenous
48326943|NCT04861948|DRUG|Bevacizumab|intravenous
48650170|NCT05931718|BIOLOGICAL|NGS|evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples
48650171|NCT05931718|BIOLOGICAL|Fecal microbiome|evaluation of fecal microbiome on fecal samples
48650172|NCT05931718|DRUG|Erythropoietin|evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
48326944|NCT04861948|DRUG|Sintilimab|intravenous
48326945|NCT04861948|DRUG|Pemetrexed|intravenous
48326946|NCT05972044|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
48326947|NCT05972044|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
48326948|NCT05972044|DRUG|Placebo|Placebo tablets, taken once daily
48326949|NCT06197048|BEHAVIORAL|Nutritional counseling|"The intervention group will recieve 30 x 2 minutes with nutritonal counseling seperatet by a 15 minutes break. The participants will receive individually tailored guidance based on the information recieved at baseline measurments.~The couseling will be based on the Norwegian goverments dietary advices and the recommendation from the Directorate of Health for the prevention of cardiovascular diseases."
48326950|NCT05698121|DEVICE|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
48326951|NCT05113719|OTHER|Exercise|Both groups will perform bridge exercise
48326952|NCT05755997|DRUG|Cerebrolysin|40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
48326953|NCT05755997|DRUG|0.9 % NaCl|100 ml 0.9% NaCl per day for 4 days every month for 1 year
48326954|NCT04387929|DIAGNOSTIC_TEST|Detection of anti-COVID-19 antibody level|Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
48326955|NCT00503360|DRUG|SAD448|
48326956|NCT05517330|BIOLOGICAL|Tislelizumab|200mg IV Q3W
48326957|NCT05517330|DRUG|Afatinib|30mg PO QD
48326958|NCT03463096|OTHER|High G acceleration on a long-arm human centrifuge|Gx (chest-to-back) and Gz (head-to-toe)
48326959|NCT01481090|PROCEDURE|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
48326960|NCT06335420|DIETARY_SUPPLEMENT|Carrot juice from Yellowstone carrots cultivars|Consumption of 100 ml of carrot juice daily for 1 year
48650173|NCT05931718|DRUG|Luspatercept|evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice
48326961|NCT06335420|DIETARY_SUPPLEMENT|Placebo juice|Consumption of 100 ml of placebo juice daily for 1 year
48121639|NCT06048172|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
48121640|NCT00069901|DRUG|CT-2103 (poly(L)glutamate-paclitaxel)|
48121641|NCT00069901|DRUG|carboplatin|
48121642|NCT01937507|DRUG|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
48121643|NCT02586597|DEVICE|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
48121644|NCT04960098|PROCEDURE|arthroplasty|patient with hip and knee osteoarthritis underwent hip and knee arthroplasty
48121645|NCT02336386|DRUG|CDD|Chemotherapy
48121646|NCT02336386|DRUG|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
48121647|NCT05119764|PROCEDURE|Manual Lymphatic Drainage|"Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery."
48121648|NCT02630823|DRUG|MK-3475|
48121649|NCT02630823|PROCEDURE|Surgical resection (standard of care)|
48121650|NCT02630823|DRUG|Paclitaxel (standard of care)|
48121651|NCT02630823|DRUG|Carboplatin (standard of care)|
48121652|NCT02630823|RADIATION|Radiation (standard of care)|
48121653|NCT02630823|PROCEDURE|Endometrial biopsy|
48121654|NCT02630823|PROCEDURE|Peripheral blood draw|
48121655|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis|Standard laboratory biochemical methods will be used to determine sepsis diagnosis accord-ing to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
48121656|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine the presence of sepsis and acute kidney injury|Standard laboratory biochemical methods will be used to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to Guidelines Kidney Disease Improving Global Outcomes (KDIGO) 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
48121657|NCT06498336|DIAGNOSTIC_TEST|Laboratory examination to determine miRNA and biochemical parameters|Laboratory examination will be performed to determine miRNA and biochemical parameters.
48326962|NCT00282568|DRUG|Tacrolimus Modified Release (MR)|Oral
48326963|NCT00282568|DRUG|tacrolimus|Oral
48650174|NCT05931718|DRUG|Thrombopoietin Receptor Agonist|evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice
48326964|NCT00935337|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
48121658|NCT05384691|DRUG|Luspatercept Injection|"All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months."
48121659|NCT06033118|DRUG|gemcitabine ,oxaliplatin,anlotinib,Sintilimab|Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
48121660|NCT01336543|DRUG|Chemotherapy following concurrent Chemoradiotherapy|"1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
48650175|NCT05931718|DRUG|G-CSF|evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
48650176|NCT06387394|DRUG|BOTOX|Intramuscular Injections
48650177|NCT06387394|DRUG|Placebo|Intramuscular Injections
48650178|NCT03975946|PROCEDURE|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
48650179|NCT03975946|BIOLOGICAL|Blood Sample|Biological analysis
48121661|NCT05583253|PROCEDURE|Vitrectomy|Small gauge pars-plana vitrectomy for management of retinal detachment.
48121662|NCT03386539|DRUG|Everolimus|Everolimus tablet
48121663|NCT03386539|DRUG|Tacrolimus|Tacrolimus capsule or liquid suspension
48121664|NCT03386539|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
48326965|NCT00935337|BEHAVIORAL|Sleep Hygiene|treatment as usual
48326966|NCT05273658|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
48326967|NCT05273658|DRUG|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
48326968|NCT03115112|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
48326969|NCT03115112|DRUG|Sitagliptin|tablets containing 100 mg sitagliptin
48326970|NCT03115112|DRUG|Placebo for sitagliptin|inactive tablets to match the appearance of sitagliptin tablets
48650180|NCT03975946|PROCEDURE|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
48650181|NCT03509480|PROCEDURE|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
48650182|NCT06570876|PROCEDURE|Surgery|The decision between RS and CS depended on the patient's performance status; on the cyst's main characteristics and contact with liver structures; and on intraoperative findings.
48650183|NCT03570385|DEVICE|MRI|MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
48650184|NCT06036524|DIAGNOSTIC_TEST|Multi-modal, multi-parametric, multiscale imaging of the myofascial unit|Study Participants will undergo four study procedures at one visit, including magnetic resonance imaging (MRI), surface electromyography (sEMG), fiber-optic imaging and sensing, and questionnaires.
48650185|NCT00661687|DEVICE|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
48650186|NCT00661687|DEVICE|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
48650187|NCT01396876|BEHAVIORAL|clown|a distraction technique is performed by a clown during venipuncture
48650188|NCT04053426|OTHER|Implementation of agitation care algorithm|Following the agitation care algorithm care professional adapt their behavior regarding agitation
48650189|NCT03042975|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
48650190|NCT03042975|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
48650191|NCT06349837|DRUG|Tislelizumab|Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.
48650192|NCT06349837|RADIATION|Low Dose Radiotherapy|LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.
48650193|NCT06349837|RADIATION|Stereotactic Ablative Radiotherapy|Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.
48326971|NCT03115112|DRUG|Placebo for bexagliflozin|inactive tablets to match the appearance of bexagliflozin tablets
48650194|NCT03150888|DRUG|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
48650195|NCT03150888|OTHER|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
48650196|NCT00963885|DRUG|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
48650197|NCT00963885|DRUG|Pegasys|180micrograms sc weekly for 24 or 48 weeks
48650198|NCT00963885|DRUG|Placebo|po for 12 weeks
48121665|NCT03169244|DRUG|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
48326972|NCT05186909|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
48326973|NCT05186909|OTHER|Placebo|Placebo
48326974|NCT04819802|OTHER|Measurement of sublingual microcirculation|Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.
48121666|NCT03169244|DRUG|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
48121667|NCT01086826|DRUG|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
48326975|NCT04819802|OTHER|Plasma sampling|Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.
48326976|NCT04270487|OTHER|IBS Diet|Patients will be randomized to a diet or a mediation treatment
48326977|NCT04270487|DRUG|Otilonium Bromide|Patients will be randomized to a diet or a mediation treatment
48326978|NCT03272217|DRUG|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
48326979|NCT03272217|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
48326980|NCT03347812|PROCEDURE|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
48326981|NCT03347812|PROCEDURE|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
48650199|NCT00963885|DRUG|Placebo|po for 24 weeks
48650200|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
48650201|NCT00963885|DRUG|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
48650202|NCT00963885|DRUG|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
48650203|NCT00963885|DRUG|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
48650204|NCT03975179|PROCEDURE|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
48650205|NCT03975179|PROCEDURE|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
48650206|NCT06655727|DIAGNOSTIC_TEST|Ultrasound evaluation|No intervention
48650207|NCT05064618|DRUG|Am80|medicine taken internally
48650208|NCT05064618|DRUG|Gemcitabine|Administered intravenously at a dose of 1000mg/m2
48650209|NCT05064618|DRUG|nab-Paclitaxel|Administered intravenously at a dose of 125mg/m2
48650210|NCT05942326|BEHAVIORAL|Sleep GOALS|Web-based interventions
48650211|NCT05942326|BEHAVIORAL|Education|Brochures from the American Academy of Sleep Medicine (e.g., sleep hygiene, sleep in women) and SNAP education connection (e.g., family-friendly activities, meal planning)
48326982|NCT04422106|DIAGNOSTIC_TEST|Predictors of intestinal anastomosis leakage, application of new predictors and new scores|Early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.
48326983|NCT04209530|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
48326984|NCT05043246|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
48326985|NCT03225937|DRUG|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
48326986|NCT03225937|DRUG|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
48326987|NCT00120289|DRUG|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
48326988|NCT00120289|DRUG|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
48326989|NCT05082298|BEHAVIORAL|Dental FearLess app|Dental FearLess, is a self-administered psychoeducational intervention that will be accessed by participants via their personal smart device (In other words, this is an online application in which investigators present information about dental procedures. The user selects the procedure on which they would like information and then views a brief video on the selected procedure. It uses evidence-based tools to help participants manage their thoughts, feelings, and behavior related to dental fear to reduce fear during encounters with dental professionals.
48326990|NCT05082298|BEHAVIORAL|In-Chair Treatment Protocol|This session is a 1-hour-in-person Cognitive Behavioral Therapy (CBT) dental fear session by study staff at the dental office. Participants will practice managing their thoughts, behaviors, and/or feelings when exposed to stimuli that they report still fearing. After each practice situation, the mental health provider and participant discuss the disconfirmatory evidence generated by the situation.
48326991|NCT05940597|DEVICE|Pulse field ablation|ablation of paroxysmal atrial fibrillation by Pulse field ablation
48326992|NCT05940597|DEVICE|Cryoballoon pulmonary vein isolation|ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
48326993|NCT06377722|DRUG|Cabozantinib|This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
48326994|NCT05816967|PROCEDURE|Medication review and discharge counseling|Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
48326995|NCT03978104|DIETARY_SUPPLEMENT|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
48326996|NCT03978104|DIETARY_SUPPLEMENT|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
47972866|NCT06301685|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
47972867|NCT03322878|DRUG|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
48121668|NCT01086826|DRUG|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
48326997|NCT03978104|DIETARY_SUPPLEMENT|Control biscuits|Consumption of control biscuits together with habitual diet.
48326998|NCT00074802|DRUG|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
48326999|NCT00074802|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
48327000|NCT01918787|DEVICE|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
48327001|NCT01270100|BEHAVIORAL|Recovery management|
48490323|NCT02963311|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
48327002|NCT02402712|DRUG|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
48327003|NCT02402712|DRUG|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
48327004|NCT02402712|DRUG|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
48327005|NCT03661450|DIAGNOSTIC_TEST|Clinical Decision-Support System|Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
48327006|NCT01226706|DRUG|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
48327007|NCT01226706|DRUG|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
48327008|NCT04291976|PROCEDURE|Back-to-back high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
48327009|NCT04291976|PROCEDURE|single-pass high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
48650212|NCT06407401|DRUG|Duloxetine 60 MG|"Patients randomized to the duloxetine arm will take duloxetine orally daily, with or without food, on a continuous dosing schedule.~Initial dose is 30 mg daily for 1 week, followed by 60 mg daily for a total of 6 months of treatment, followed by a taper off the medication of 30 mg daily for 1 additional week."
48650213|NCT06407401|DRUG|Furosemide 40 mg|Patients randomized to the furosemide arm will take furosemide 40 mg orally daily, on an empty stomach with plenty of liquid, on a continuous dosing schedule.
48327010|NCT04291976|PROCEDURE|chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.
48327011|NCT01787799|DEVICE|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
48327012|NCT05289076|DRUG|Chemotherapy drug|Different combinations of chemotherapies will be tested in combination with monoclonal antibodies in zebrafish embryos against inplanted patients livermetastatic tissues.
48650214|NCT06407401|BEHAVIORAL|Booklet for healthy behaviors|All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
48650215|NCT05692323|OTHER|PREHAB|6-week supervised PREHAB program. Each week of the program consists of 3 x 1 hour supervised training sessions made up of moderate intensity aerobic training and resistance training. In addition to the supervised sessions, patients will be instructed to accumulate a total of 150 minutes per week of moderate aerobic training at home which is measured by a wrist worn FitBit device.
48650216|NCT02114944|DEVICE|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
48650217|NCT02114944|DEVICE|CPAP|Patient treated, as per attending physician's decision, with CPAP
48650218|NCT02114944|DEVICE|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
48650219|NCT02114944|DEVICE|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
47972868|NCT02923934|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
47972869|NCT02923934|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
48121669|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
48327013|NCT06138327|DRUG|BMN 255|Oral Capsule
48327014|NCT06138327|DRUG|Placebo|Oral Capsule
48490324|NCT02963311|DRUG|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
48490325|NCT05101369|DRUG|INCB086550|INCB086550 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radio labeled INCB086550.
48650220|NCT03842280|DEVICE|Diaphragm ultrasound assessment & Esophageal pressure measurement|Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
48650221|NCT05259605|OTHER|Observational|The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
48650222|NCT04739215|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg / day oral
48650223|NCT04739215|DRUG|Placebo|One Placebo capsule daily oral
48121670|NCT01086826|DRUG|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
48327015|NCT03621423|PROCEDURE|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
48650224|NCT03344887|OTHER|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
48650225|NCT03344887|OTHER|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
48650226|NCT04902482|DEVICE|iCycle Mark 3|The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
47972870|NCT01082991|OTHER|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
47972871|NCT06281600|DIETARY_SUPPLEMENT|Human milk oligosaccharide|5g daily dose of HMOs.
47972872|NCT06281600|DIETARY_SUPPLEMENT|Maltodextrin placebo|5g daily dose of maltodextrin.
47972873|NCT04951999|OTHER|Blood sampling|For 10 visits (out of the 12 of the protocol), \~40 ml of blood is sampled for research purposes in addition to care sampling.
47972874|NCT06258356|DRUG|Remimazolam|novel ultra-short-acting benzodiazepine-like anesthetic.
47972875|NCT06258356|DRUG|placebo|normal saline (compared to Remimazolam)
47972876|NCT02460302|DRUG|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
47972877|NCT02460302|DRUG|Placebo|Placebo suppository inserted vaginally
47972878|NCT02116296|BEHAVIORAL|ToyBox-intervention|
47972879|NCT05798169|OTHER|Resistance training|Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
47972880|NCT01695902|DRUG|Levosert-20|
47972881|NCT01695902|DRUG|Mirena|
47972882|NCT04605484|BIOLOGICAL|Posoleucel (formerly known as ALVR105) cells|Infusion
47972883|NCT04605484|BIOLOGICAL|Placebo (visually identical to Posoleucel)|Infusion
48121671|NCT02205853|OTHER|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
48121672|NCT02205853|OTHER|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
48327016|NCT02923752|DEVICE|MRI|Contrast-enhanced MRI
48327017|NCT06205394|OTHER|Non-Interventional Study|Non-interventional study
48327018|NCT06064903|BIOLOGICAL|CD7-CART01|A single IV infusion of CD7-CART01 on Day 0
48327019|NCT03165942|OTHER|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
48650227|NCT02918630|DRUG|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
48650228|NCT02918630|DRUG|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
48650229|NCT06074406|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO
48650230|NCT02891954|DRUG|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
47972884|NCT00387023|DRUG|Rituximab|250 mg/m\^2 IV over 4-6 hours for 2 weeks.
47972885|NCT00387023|DRUG|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
47972886|NCT05564936|DEVICE|ME&MG mobile application|ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
47980514|NCT05397756|OTHER|observer tool|The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
47980515|NCT06381050|DRUG|SHR-7631|The total dosage of SHR-7631 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
47980516|NCT03406104|GENETIC|GS010|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
47980517|NCT03406104|OTHER|Sham Intravitreal Injection|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
48327020|NCT03165942|OTHER|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
47972887|NCT05834660|BEHAVIORAL|Safe Alternatives for Teens and Youth-Acute for Schools (SAFETY-A for Schools)|SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts by phone at 1, 2, and 4 weeks after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
48650231|NCT05848089|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
48650232|NCT05848089|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
48121673|NCT05563740|OTHER|Psychosocial|Daily telephone calls with two sessions of Brief Interventions for alcohol
48121674|NCT01275287|DRUG|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients \> than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up to 1 gm/m\^2 depending on the 2 week white blood count (WBC) nadir \> 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
47972888|NCT05351125|PROCEDURE|cardiac catheterization|catheterization in critical congenital heart disease requiring atrial septostomy or balloon valvuloplastyor PDA stenting
47972889|NCT04949048|DEVICE|Magneto PE Kit|All enrolled patients will be treated with Magneto PE Kit
47972890|NCT03177694|DEVICE|Wireless bed sensor|Remote data collection
47972891|NCT04658277|DRUG|Clarithromycin|Patients in the intervention arm will take Clarithromycin 250mg daily.
47972892|NCT04658277|OTHER|Usual care|Patients will receive usual medical care
48121675|NCT01275287|DRUG|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
48121676|NCT02059382|BEHAVIORAL|ChiRunning training|
48327021|NCT03165942|DRUG|Ethanol|
47980518|NCT03764189|PROCEDURE|microosteoperforation|small holes made using large round bur
47980519|NCT04247360|DEVICE|cuff pressure|maintaining cuff pressure according the groups
48121677|NCT02059382|BEHAVIORAL|unblinded accelerometer|
48121678|NCT02059382|BEHAVIORAL|participation in online social network|
48121679|NCT02059382|BEHAVIORAL|participation in study website|
48121680|NCT02059382|BEHAVIORAL|Technology support for behavior change|
48121681|NCT02962817|OTHER|Educational intervention|
48121682|NCT02962817|OTHER|Video explaining the clinical practice guidelines on low back pain|
48121683|NCT03787966|OTHER|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
48121684|NCT03787966|OTHER|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
48327022|NCT04861558|DRUG|5Fluorouracil|Injection of 250-850 mg/m2.
48327023|NCT04861558|DRUG|Irinotecan|Injection of 360 mg/m2
48327024|NCT04861558|DRUG|Oxaliplatin|Injection of 460 mg/m2
48498086|NCT02203422|DRUG|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
48327025|NCT05565976|DRUG|Dapagliflozin 10mg Tab|10mg PO q24h for 12 months
48327026|NCT05565976|DRUG|Statins (Cardiovascular Agents)|Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
48650233|NCT05848089|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
48650234|NCT00248235|BEHAVIORAL|Exercise|
48650235|NCT02102802|DRUG|Midomafetamine|125, 75, or 30 mg midomafetamine HCl followed 1.5 to 2 hours later by a supplemental dose of midomafetamine HCl half the initial dose
48650236|NCT02102802|BEHAVIORAL|Therapy|Manualized therapy
48121685|NCT05097417|COMBINATION_PRODUCT|traditional Chinese medicine and ablation in the primary tumor sites|Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
48121686|NCT05097417|PROCEDURE|ablation|Patients will be treated with ablation in the primary tumor sites
48121687|NCT02088424|OTHER|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
48121688|NCT01507038|DRUG|YH14617|1mg once weekly
48650237|NCT04600414|OTHER|Collaborative Care for Mental Health Disorders|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
48650238|NCT04600414|OTHER|Collaborative Care for Opioid Use Disorder|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
48650239|NCT06397625|OTHER|Percutaneous electrical neurostimulation (Placebo)|"Group I (Control), will be operated with the same procedure but without electric current, and using placebo needles of the same size (Streitberger Placebo-Needle ® , Asiamed, Pullach, Germany)"
48121689|NCT01507038|DRUG|YH14617|1.6mg once weekly
48121690|NCT01507038|DRUG|YH14617|2mg once biweekly
47972893|NCT05299281|DEVICE|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
47972894|NCT02275871|OTHER|MRI|High risk screening MRI will be performed as part of the patient's routine care.
47972895|NCT02275871|OTHER|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
48121691|NCT01507038|DRUG|Placebo|Once weekly
48121692|NCT05661994|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18) to evaluate the effects of omega-3 FA supplementation on biochemical parameters, especially serum fetuin-A, anthropometric measurements, and nutritional status. 1.560 mg/day omega-3 FA supplementation was applied for 8 weeks to 16 participants with CAD included in the omega-3 group."
48121693|NCT04085094|DIETARY_SUPPLEMENT|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
48327027|NCT05565976|DRUG|Platelet Antiaggregant|Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
48327028|NCT05565976|DRUG|Antidiabetic|Previously established medical treatment for type 2 diabetes will be maintained.
48327029|NCT05317013|DRUG|CBD|CBD
48327030|NCT05317013|OTHER|Placebo|Placebo
48327031|NCT04457193|DEVICE|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
48327032|NCT02892825|OTHER|Music|headphones with music
48327033|NCT02892825|OTHER|No Music|headphones without music
47972896|NCT02546804|PROCEDURE|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
48327034|NCT05424991|BEHAVIORAL|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
48327035|NCT01804036|DRUG|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
48327036|NCT01804036|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
48327037|NCT05296837|DRUG|Doxycycline 40 MG ( 20mg twice daily)|Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily
48650240|NCT06397625|OTHER|Percutaneous electrical neurostimulation|The Group II and III electrostimulation procedure is called peripheral nerve stimulation and is known as an echo-guided peripheral nerve stimulation technique using a blunt, dry needle (active electrode). The intervention will be performed on the pudendal nerve, in an area where there is no risk of perforating any vascular-nerve bundle. The invasive technique will be performed by a physiotherapist expert in musculoskeletal and peripheral nervous system ultrasound and specialized in invasive techniques, with two years of experience in the sector. The needle will be introduced through the anterior (perineum).
48650241|NCT04098913|BEHAVIORAL|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
48650242|NCT05682443|DRUG|ONC-392|ONC-392 will be given as IV infusion, Q6W, for up to 9 doses.
47972897|NCT02546804|PROCEDURE|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
47972898|NCT02546804|PROCEDURE|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
47972899|NCT01562418|BEHAVIORAL|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
47972900|NCT01562418|BEHAVIORAL|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
47972901|NCT01562418|BEHAVIORAL|control group|general instructions no intervention
47972902|NCT00333814|DRUG|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
47972903|NCT00333814|DRUG|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
47972904|NCT00333814|DRUG|Sham injection|Sham injection at Day 0
48327038|NCT05296837|DRUG|Doxycycline 200 MG ( 100 mg twice daily)|200 mg dose doxycycline to be administered as 100mg twice daily
48327039|NCT05296837|DRUG|Placebo|Placebo to be administered in tablet form twice daily
48327040|NCT05810844|DIAGNOSTIC_TEST|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
48327041|NCT05810844|DIAGNOSTIC_TEST|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
48327042|NCT06299813|DRUG|Bentelan|The experimental treatment group will be administered betamethasone 0.1 mg per kg.
48327043|NCT06299813|DRUG|Placebo|The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
48327044|NCT00960713|DRUG|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
48327045|NCT04865185|DIAGNOSTIC_TEST|Xylocaine spray 100mg/ml|Topical application
48327046|NCT04865185|DIAGNOSTIC_TEST|Ethanol|Topical application
48498087|NCT04016220|DRUG|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
47972905|NCT05554094|DRUG|Psilocybin|Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
47972906|NCT03634462|OTHER|CDT with graded negative pressure|Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
47972907|NCT03182088|DRUG|norepinephrine infusion (0.025 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
47972908|NCT03182088|DRUG|norepinephrine infusion (0.050 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
47972909|NCT03182088|DRUG|norepinephrine infusion (0.075 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
47972910|NCT03182088|DRUG|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
47972911|NCT05459675|OTHER|Very low-calorie diet|Meal replacement (800 kcal/day, protein 90 g/day)
47972912|NCT05459675|PROCEDURE|Bariatric surgery|Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
47972913|NCT00453882|DEVICE|flostat (TM) System|
48121694|NCT04085094|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
48121695|NCT04085094|DIAGNOSTIC_TEST|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
48327047|NCT03956329|OTHER|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
48650243|NCT05682443|DRUG|lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses.|lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
47972914|NCT03858114|OTHER|Mild-to-moderate physical activity|"According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~2. Active phase (45 minutes), from \>40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~3. cool down (10 minutes), \< 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length."
48121696|NCT04085094|OTHER|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
48650244|NCT05007639|OTHER|Public Health intervention programme|The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
48340162|NCT02846857|OTHER|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
48498088|NCT04016220|DRUG|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
48498089|NCT00117325|DRUG|GW685698X|Aqueous Nasal Spray 100mcg
47972915|NCT03858114|OTHER|Cultural group program|A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
47972916|NCT00211809|BEHAVIORAL|Cognitive Behavioral Therapy|standard psychiatric evaluation
47972917|NCT00211809|DRUG|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
48121697|NCT05202912|DRUG|IDX-1197(After a meal)|randomized, open-label, single-dose, 2-period, 2-sequence crossover study in healthy male Korean and Caucasian volunteers
48121698|NCT05202912|DRUG|IDX-1197(fasting)|open-label, single-dose study in Chinese male volunteers
48121699|NCT05976295|DRUG|Jianpi Qushi Huatan Decoction|The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.
48121700|NCT05976295|DRUG|Placebo|The control group will receive a placebo treatment.
48650245|NCT05007639|OTHER|No public Health intervention programme|
48650246|NCT04721106|DRUG|Vizimpro|treatment group
48650247|NCT06674564|DIETARY_SUPPLEMENT|Zinc Acetate 50 Mg Oral Capsule|zinc suppose to improve immunity and wound healing after laryngectomy
48650248|NCT06674564|DIETARY_SUPPLEMENT|Probiotic|probiotics lowering infections rates and improving outcomes after surgery
48650249|NCT04753567|DEVICE|nCap pain relief patch|Each participant will be randomly assigned to sham or actual patch. Patches will be worn for 3 weeks. Pain and quality of life will be assessed and compared between groups
48650250|NCT04753567|DEVICE|Sham Patch|Sham patch will be worn for 3 weeks exactly like actual pain patch
48650251|NCT02946411|PROCEDURE|Cardiac surgery|Glucose level will be measured after cardiac surgery.
48650252|NCT04290897|DRUG|Anhydrous Enol-oxaloacetate|Given PO
48650253|NCT04290897|OTHER|Questionnaire Administration|Ancillary studies
48650254|NCT04487080|DRUG|Amivantamab|Participants will receive amivantamab intravenously.
48121701|NCT00018668|DRUG|Risperidone|
48121702|NCT00018668|DRUG|Olanzapine|
48121703|NCT00018668|DRUG|Quetiapine|
48121704|NCT01674699|DEVICE|EXCOR Pediatric|Ventricular Assist Device
48650255|NCT04487080|DRUG|Osimertinib|Participants will receive osimertinib capsules orally.
48650256|NCT04487080|DRUG|Lazertinib|Participants will receive lazertinib tablets orally.
48650257|NCT04487080|DRUG|Placebo|Participants will receive matching placebo orally.
48650258|NCT00803855|DRUG|AZD1446|oral, single dose
48650259|NCT05051059|OTHER|Functional outcome|3D-motion analysis and strength assessment
48121705|NCT04787653|DEVICE|Otoband|Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
48498090|NCT06157203|DEVICE|Uterine electromyography|electromyographic and fetal electrocardiographic recordings will be obtained during threatened labor
48650260|NCT05051059|OTHER|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
47972918|NCT04997811|DRUG|Sodium Valproate, Bezafibrate, Medroxyprogesterone|Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
47972919|NCT04997811|DRUG|Danazol|Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
47972920|NCT04953780|DRUG|Calaspargase pegol-mknl|Calaspargase pegol-mknl
47972921|NCT04321525|BEHAVIORAL|Cognitive-behavioral therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
47972922|NCT04321525|BEHAVIORAL|Personal Construct Therapy|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
47972923|NCT04321525|BEHAVIORAL|Personal Construct Therapy with virtual reality|10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session
48498091|NCT05736627|OTHER|Online|Online research course delivered live digitally at a distance.
48650261|NCT06290323|PROCEDURE|Quadratus lumborum block|Posterior quadratus lumborum block
48650262|NCT06290323|PROCEDURE|Placebo|Patients in the first group are the control group and after spinal anesthesia, the sensory block is formed, the lithotomy position will be taken for the surgical procedure.
48650263|NCT05967065|DIAGNOSTIC_TEST|vibration induced nystagmus test|Vibration induced nystagmus test by bone transducer B250.
47972924|NCT04165447|BEHAVIORAL|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
47972925|NCT02329353|DRUG|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
47972926|NCT02148198|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
47972927|NCT02148198|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
47972928|NCT05930912|DIAGNOSTIC_TEST|Psychoanalysis|Case-specific psychoanalysis is performed, including the participant's background during birth.
47972929|NCT05930912|DRUG|sertraline 50mg|After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
47972930|NCT05930912|DRUG|Duloxetine 20 MG|Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
48327048|NCT03956329|OTHER|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
48327049|NCT02235402|DRUG|Lacidipine|
48327050|NCT02235402|DRUG|Bendrofluazide|
48327051|NCT02235402|DRUG|Placebo|
48490326|NCT03946254|OTHER|Effect of strength training on executive functions in elderly people with mild cognitive impairment.|Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
48490327|NCT06229821|DEVICE|Intrapulmonary Percussive Ventilation|IPV applied at increasing intervals, starting every 6 hours, and ending at every 24 hours, for a total of 7 days.
48490328|NCT00626314|BIOLOGICAL|myoblast|autologous myoblast
48490329|NCT00626314|BIOLOGICAL|sham|sham injection procedure
48490330|NCT00649818|DRUG|Lorazepam Tablets 2 mg|2mg, single dose fasting
48650264|NCT02475993|OTHER|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
48650265|NCT02776176|PROCEDURE|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
48650266|NCT02776176|PROCEDURE|Traditional Program|traditional standard protocol
48650267|NCT02096887|BEHAVIORAL|Patient Education|"Patient Education using the following two instruments:~1. Framingham Risk Score calculator:~2. Know your numbers patient booklet"
48650268|NCT04422834|OTHER|Questionnaire|A group of students who studying at the Faculty of Health Sciences will be asked to fill the Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.
48650269|NCT02500966|DEVICE|DUDA device|Insertion DUDA device
48650270|NCT02500966|PROCEDURE|LEEP|Loop Electrosurgical Excision Procedure
48650271|NCT06550128|DRUG|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
47972931|NCT05930912|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is tailored to the participant's current activities and life decisions.
47972932|NCT05136768|DRUG|Sintilimab|Sintilimab: 200mg, administered by intravenous infusion on the first day of each cycle, one cycle every 3 weeks (Q3W), with the maximum cycle of 17. Suspension of Sintilimab administration: patients's request, disease progression, researcher-evaluated SAE
48650272|NCT06550128|DRUG|Placebo|Placebo will be administered subcutaneously.
48650273|NCT06444815|DRUG|VET3-TGI|Oncolytic vaccinia virus engineered with immunomodulatory transgenes
48650274|NCT06444815|DRUG|Pembrolizumab|anti-pd1 antibody
48650275|NCT06629740|DEVICE|Measurements with a eHealth system|The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.
48650276|NCT04083079|DRUG|PEG-rhG-CSF|Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
48650277|NCT04083079|DRUG|rhG-CSF|Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
48327052|NCT04078334|OTHER|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
48121706|NCT04787653|DEVICE|Placebo|Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
48121707|NCT01348217|RADIATION|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
48121708|NCT01348217|RADIATION|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
48121709|NCT01348217|RADIATION|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
48121710|NCT01348217|DRUG|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
48121711|NCT01350024|PROCEDURE|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
48121712|NCT01350024|PROCEDURE|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
48121713|NCT00197613|DRUG|(A) zidovudine, lamivudine and nevirapine|
48121714|NCT00197613|DRUG|(B) zidovudine, lamivudine and efavirenz|
48121715|NCT00197613|DRUG|(C) zidovudine, didanosine, and nevirapine|
48121716|NCT00197613|DRUG|(D) zidovudine, didanosine, and efavirenz|
48121717|NCT00197613|DRUG|(E) stavudine, lamivudine, and nevirapine|
48121718|NCT00197613|DRUG|(F) stavudine, lamivudine and efavirenz|
48121719|NCT00197613|PROCEDURE|Adherence Strategy Standard of Care (SOC)|
48121720|NCT00197613|PROCEDURE|Adherence Strategy Community-Based DOT|
48121721|NCT02764944|PROCEDURE|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
48121722|NCT05877469|OTHER|Mat pilates Training|In this group 22 patients will perform mat pilates training. Patients will be asked to stay comfortable while performing mat pilates exercies that involve different types of movements of whole body like leg lifts, toe taps, Single leg stretch, one leg circle, side bend preparation, side kicks, side leg lifts, roll down and crisscross to improve the core strength. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
48121723|NCT05877469|OTHER|Functional Training|In this group 22 patients will perform functional training. Patients will be instructed to perform their daily living movements like squatting, reaching, or even carrying a heavy object. These exercises typically use the whole body and emphasize core strength and stability. Functional training typically uses weight-bearing activities that work the core muscles in the torso. the functional movements include involve glute bridge, squats, pushups, lateral lunge, step up to shoulder press, goblet and squats. Treatments will be provided in 30 mins, three sessions per week for 8 consecutive weeks.
48121724|NCT00238797|DRUG|Gefitinib|
48121725|NCT05412199|DEVICE|Percussion Massage Therapy|Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
48121726|NCT05412199|DEVICE|Graston|Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
48121727|NCT05412199|OTHER|Dynamic Stretching|Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
48121728|NCT02738320|OTHER|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
48121729|NCT03887650|DRUG|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
48121730|NCT03887650|DRUG|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
48121731|NCT02612844|DRUG|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
48121732|NCT02612844|DRUG|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
48121733|NCT01218698|DRUG|Losartan Potassium Tablets|
48121734|NCT04620902|OTHER|Tear sampling|Tear sampling using Schirmer's strips
48327053|NCT04078334|OTHER|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
48121735|NCT03681054|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
47972933|NCT05136768|RADIATION|SBRT|"At least one metastatic lesion is suitable for SBRT. If applicable, all metastatic lesions were allowed to be irradiated.~Recommended dose: BED ≥ 80Gy. Dose fractionation is determined as per physician's discretion, generally depending on the location of irradiated lesion and the distance to surrounding OARs.~Timing of SBRT: After completing at least 2 platinum-containing chemotherapy plus sintilimab treatments, SBRT can be started after assessing that there is no AE ≥ G2."
48121736|NCT03681054|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
48121737|NCT05101941|PROCEDURE|Immediate dental implants|Implants will be immediately placed in sockets associated with chronic periapical granuloma Extraction of non-restorable Teeth with periapical granuloma and socket debridement will be done then implants will be placed
48121738|NCT00741546|PROCEDURE|Cardiac Surgery|Cardiac Surgery
48121739|NCT03059394|DEVICE|Non intervention study|Test - Retest of measurements
48121740|NCT02034903|OTHER|Feedings warmed with commercial warmer|
48121741|NCT05701397|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin cardiac amyloidsis
48121742|NCT00335049|DEVICE|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
47972934|NCT05136768|DRUG|Platinum based chemotherapy|Platinum based single or doublet chemotherapy, one cycle every 3 weeks (Q3W), 4-6 cycles.
47972935|NCT02589756|OTHER|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
48121743|NCT00335049|DEVICE|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
48121744|NCT02538107|DRUG|Methoxy-polyethyleneglycol epoetin beta|
48121745|NCT00314860|DRUG|ropinirole Extended Release (XR)|
48121746|NCT03037892|DRUG|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
48121747|NCT03037892|DRUG|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
48121748|NCT03037892|DRUG|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
48121749|NCT00773370|BEHAVIORAL|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
48121750|NCT00773370|BEHAVIORAL|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
48121751|NCT01149369|DRUG|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
48121752|NCT01149369|DRUG|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
48121753|NCT05035303|PROCEDURE|Nor-Epinephrine injection versus saline during PCNL|The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
48327054|NCT04078334|OTHER|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
48327055|NCT06014385|DRUG|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
48490331|NCT00649818|DRUG|Ativan Tablets 2 mg|2mg, single dose fasting
48490332|NCT05166681|PROCEDURE|surgical wound suturing|single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
48490333|NCT02931045|DRUG|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
48327056|NCT06014385|RADIATION|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
48327057|NCT03200093|DRUG|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
48490334|NCT02931045|DRUG|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
48650278|NCT06488833|BEHAVIORAL|Komtü Programme (Komtü)|"Mainly, 4 actions will take place:~* Training with reflective practice exercises. This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~* Healing spaces to generate a collective restorative experience, offering tools that facilitate emotional management~* Individual support for teachers to offer them resources, tools, and intervention strategies to help improve educational practice and the emotional and relational well-being of the school community~* Coaching for the school management team to help them establish some objectives together and offer them the necessary resources and tools so that they can achieve them successfully."
48650279|NCT06488833|BEHAVIORAL|Komtü Training and Reflective Practice|"This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~No other actions will take place in this group."
47972936|NCT02589756|OTHER|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
47972937|NCT02589756|OTHER|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
47972938|NCT02183194|DEVICE|Lutonix Paclitaxel Drug Coated Balloon|
47972939|NCT02891759|OTHER|Alloderm RTU|-Most commonly used acellular dermal matrices
47972940|NCT02891759|OTHER|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
47972941|NCT02891759|PROCEDURE|Skin or nipple-sparing mastectomy|-Standard of care
47972942|NCT02891759|OTHER|Breast Q|"* 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
47972943|NCT02891759|PROCEDURE|Surgery|"* To address the tissue expander~* Standard of care"
47972944|NCT00205582|DEVICE|Positron Emission Tomography|
47972945|NCT00783003|DRUG|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
48490335|NCT00781521|DRUG|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
48490336|NCT05054322|DRUG|Fluticasone Propionate|Fluticasone propionate added to usual care, total dose 1000 mcg per day for 14 days
48490337|NCT04698148|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
48490338|NCT04698148|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
48490339|NCT04698148|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
48490340|NCT03265366|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
48490341|NCT03265366|DEVICE|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
48490342|NCT05763706|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
48490343|NCT05068375|DIAGNOSTIC_TEST|Thrombophilia screening|Genetic thrombophilia and acquired thrombophilia screening
47972946|NCT00783003|DRUG|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
47972947|NCT00783003|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
47972948|NCT00783003|DRUG|Placebo|Matching placebo.
47972949|NCT01414283|DRUG|PSMA ADC|PSMA ADC administered IV
48121754|NCT03114410|BEHAVIORAL|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and young parent educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of young parent educators delivered the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth received roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
48121755|NCT05457049|DIAGNOSTIC_TEST|Molecular residual disease test|OncoMRD Lung
48121756|NCT01154985|DRUG|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
48121757|NCT01154985|DRUG|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
48327058|NCT03200093|DRUG|Placebo|Ora-Sweet 5mL taken by mouth once daily.
48327059|NCT00992602|DRUG|methotrexate|Given IV
48327060|NCT00992602|DRUG|liposomal cytarabine|Given IT or via LP
48327061|NCT00992602|OTHER|quality-of-life assessment|Ancillary studies
48327062|NCT00992602|OTHER|laboratory biomarker analysis|Correlative studies
48327063|NCT01575899|DRUG|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
48327064|NCT01575899|DRUG|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
48327065|NCT05750420|OTHER|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
48490344|NCT00313456|DRUG|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
48490345|NCT04857463|OTHER|Nutritional supplement drink|At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.
48490346|NCT04857463|OTHER|Nutritional education|At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
48490347|NCT00862017|DIETARY_SUPPLEMENT|MSg supplementation|
48490348|NCT00862017|DIETARY_SUPPLEMENT|NaCl supplementation|
48490349|NCT04053413|OTHER|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
48650280|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed|"Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
47972950|NCT01725334|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
47972951|NCT05443789|BEHAVIORAL|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
47972952|NCT05443789|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
47980520|NCT03994965|DRUG|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
47980521|NCT05450341|DEVICE|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
48121758|NCT01154985|DRUG|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
48121759|NCT06181695|DRUG|Sufentanil|Administration of intranasal sufentanil
48121760|NCT03244813|OTHER|Personalized activity program|Targeted physical activity
48121761|NCT00295464|DRUG|Betamethasone sodium phos (drug)|
48327066|NCT00566449|DRUG|Placebo|one dose daily for 4 weeks
48327067|NCT00566449|DRUG|JNJ-31001074|10 mg daily for 4 weeks
48327068|NCT00566449|DRUG|JNJ-31001074|30 mg daily for 4 weeks
48327069|NCT01106742|DIETARY_SUPPLEMENT|AndoSan|AndoSan, 20mlx3, 12 days
48327070|NCT02592395|DRUG|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
48327071|NCT02592395|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
48327072|NCT01187836|DRUG|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
48490350|NCT05709483|DRUG|Aspirin|Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
48650281|NCT05849246|DRUG|Sintilimab+Carboplatin or Cisplatin+Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
48327073|NCT01187836|DRUG|Placebo|Placebo administered for 14 hours.
48327074|NCT03509987|DEVICE|HemaCue|comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
48327075|NCT05535101|DEVICE|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
48327076|NCT05535101|DEVICE|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
48327077|NCT05381558|DRUG|Triamcinolone Injection|local injection in sinus tarsi
48327078|NCT02375204|DRUG|paclitaxel|IV
48327079|NCT02375204|DRUG|ifosfamide|IV
48327080|NCT02375204|DRUG|cisplatin|IV
48327081|NCT02375204|DRUG|pegylated G-CSF|IV
48327082|NCT02375204|DRUG|G-CSF|IV
48490351|NCT06180317|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
48490352|NCT01254474|DEVICE|Cardiac chambers mapping with MAP 4|
48490353|NCT02311920|BIOLOGICAL|Ipilimumab|Given IV
48490354|NCT02311920|OTHER|Laboratory Biomarker Analysis|Correlative studies
48490355|NCT02311920|BIOLOGICAL|Nivolumab|Given IV
48490356|NCT02311920|DRUG|Temozolomide|Given PO
48490357|NCT00312819|DRUG|chemotherapy +/- disulfiram|
48490358|NCT03452774|OTHER|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
48490359|NCT05445726|DEVICE|CPM Device|CPM device used in tangent with reference ECG for validation
47972953|NCT04250870|DIAGNOSTIC_TEST|Senior Fitness Test|"Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair."
47972954|NCT01414855|DRUG|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
47972955|NCT01414855|DRUG|cyclophosphamide|750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
47972956|NCT01414855|DRUG|doxorubicin|50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
47972957|NCT01414855|DRUG|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
47972958|NCT01414855|DRUG|vincristine|1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
48327083|NCT02375204|DRUG|carboplatin|IV
48327084|NCT02375204|DRUG|etoposide phosphate|IV
48327085|NCT02375204|PROCEDURE|stem cell reinfusion|surgical procedure
48327086|NCT02461394|DEVICE|Blood glucose monitoring systems for self-testing|
48327087|NCT03686696|DRUG|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
48327088|NCT03686696|DRUG|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
48327089|NCT03686696|DRUG|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
48327090|NCT02098694|OTHER|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
48490360|NCT00173537|PROCEDURE|for BMPR II study|
48490361|NCT00173537|GENETIC|BMPRII|
48490362|NCT06158074|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 60 minutes targeted the pudendal nerve, thrice weekly for a total of 4 weeks.
48650282|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab|"Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
48650283|NCT05605899|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
47972959|NCT06049940|BIOLOGICAL|Investigational tetanus vaccine, adsorbed|The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
47972960|NCT06049940|BIOLOGICAL|Control tetanus vaccine, adsorbed|The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
47972961|NCT01996501|DRUG|Olanzapine Orally Disintegrating 5mg Tablets|
47972962|NCT04316923|DIAGNOSTIC_TEST|ECG|ECG will be performed during each visit in the study group.
47972963|NCT04316923|DIAGNOSTIC_TEST|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
47972964|NCT04316923|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
47972965|NCT04316923|DIAGNOSTIC_TEST|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
48121762|NCT03425734|DRUG|Dexmedetomidine|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
48121763|NCT01969461|BEHAVIORAL|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
48121764|NCT02598596|BIOLOGICAL|Pegloticase|Pegloticase, IV
48121765|NCT02598596|DRUG|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
48121766|NCT04310358|OTHER|4 short PLMs group 1|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 1 (pre-test), Test 2 (immediate post-test), Test 1 (remote post-test)
48121767|NCT04310358|OTHER|4 short PLMs group 2|Participants will take the 4 short PLMs on the visual estimation of LVEF. They will also take a pretest, an immediate post-test and a remote post-test at 1 month. Test 2 (pre-test), Test 1 (immediate post-test), Test 2 (remote post-test)
48121768|NCT00925977|DRUG|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
48121769|NCT00925977|DRUG|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
48490363|NCT06158074|PROCEDURE|sacral neuromodulation|In the prone position, patients undergo sacral nerve root localization through MRI and CT fusion analysis. A 3D-printed sacral foramen puncture template is crafted for precision. Using local anesthesia, a 20G needle at a 60° angle enters the S3 sacral foramen along the template. A temporary stimulator, delivering square waves (14-35 Hz, 210-360 μs), tests motor and sensory responses to confirm accuracy. Self-fixating electrodes are then implanted, validated, and tunneled subcutaneously. External connection to a temporary stimulator provides a 4-week therapeutic experiential stimulation.
48490364|NCT00031122|OTHER|No Intervention|There is no intervention in this study
48121770|NCT00087880|DRUG|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
48121771|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
48121772|NCT00424086|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
48490365|NCT02041936|DEVICE|NanoKnife IRE System|
48121773|NCT03427632|DRUG|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
48121774|NCT02336438|DIETARY_SUPPLEMENT|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
48121775|NCT00098553|DRUG|everolimus|
48490366|NCT04975074|DRUG|Iron|One of each type of iron was taken orally according to the instructions and followed every two weeks
48490367|NCT01268605|PROCEDURE|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
48490368|NCT01268605|PROCEDURE|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
48490369|NCT04306237|DRUG|IMB-1018972|IMB-1018972 200 mg tablet for oral administration
48490370|NCT04306237|DRUG|Placebo oral tablet|Matched placebo tablet for oral administration
48490371|NCT03632967|DEVICE|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
47972966|NCT01154764|DRUG|CG100649|I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
47972967|NCT01154764|DRUG|Ketoconazole|I period: ketoconazole + CG100649 II period: CG 100649
47972968|NCT00569478|OTHER|rehabilitation|Nursing consultations and physical training
47980522|NCT05450341|DEVICE|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
48490372|NCT01520974|OTHER|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
48490373|NCT01520974|OTHER|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
48490374|NCT01746264|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
48121776|NCT04537403|DRUG|Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
48121777|NCT04537403|DRUG|Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
48121778|NCT00788853|OTHER|No treatment given|No treatment is given
48121779|NCT03720236|PROCEDURE|Implant bed preparation protocol|This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
48121780|NCT03720236|PROCEDURE|Implant loading|This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
48121781|NCT06220149|DIAGNOSTIC_TEST|FIT (fecal immunochemical test)|A FIT (fecal immunochemical test) will be done daily for the 14 days following polypectomy.
48121782|NCT06411743|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
48121783|NCT06411743|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
48121784|NCT02324010|DRUG|Sitagliptin|100mg mane for 2 days
48121785|NCT02324010|DRUG|Placebo|Inactive drug (Placebo)
48121786|NCT02928224|DRUG|Encorafenib|Orally, once daily.
48121787|NCT02928224|DRUG|Binimetinib|Orally, twice daily.
48121788|NCT02928224|DRUG|Cetuximab|Standard of care.
48121789|NCT02928224|DRUG|Irinotecan|Standard of care.
48121790|NCT02928224|DRUG|Folinic Acid|Standard of care.
48121791|NCT02928224|DRUG|5-Fluorouracil|Standard of care.
48121792|NCT06176482|DEVICE|Magnetic markers implantation|Surgical implantation of magnetic markers in the upper limb stump to allow the management of an external hand prosthesis
48121793|NCT03241017|DRUG|Durvalumab|Immunotherapy with Durvalumab after ASCT
48121794|NCT04877652|OTHER|Standard of care|Standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
48650284|NCT05605899|DRUG|Cyclophosphamide|Administered intravenously
47972969|NCT00187486|DRUG|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
48121795|NCT03292120|OTHER|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
48121796|NCT03173105|DEVICE|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
48121797|NCT03173105|DEVICE|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
47972970|NCT00187486|DRUG|Temodar|Temodar 200 mg/m\^2/day x 5 days every 28 days
47980523|NCT04168385|DRUG|Maralixibat|"Maralixibat chloride oral solution orally twice daily (up to 1200\* mcg/kg/day), and according to indication.~\*equivalent to 1140 mcg/kg/day maralixibat"
48121798|NCT03173105|OTHER|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
48121799|NCT03173105|OTHER|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
48121800|NCT00598377|DRUG|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
48121801|NCT05327049|OTHER|no intervention|treatment of deep carious lesions
48121802|NCT05327049|DEVICE|diode laser|laser light for cavity disinfection
48327091|NCT01560442|DRUG|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
48650285|NCT05605899|DRUG|Fludarabine|Administered intravenously
48650286|NCT05605899|DRUG|Etoposide|Administered intravenously
48121803|NCT05327049|DIETARY_SUPPLEMENT|Aloe Vera|herbal dietary supplement for treatment of deep carious lesions
48121804|NCT01725464|DEVICE|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
48121805|NCT00900211|GENETIC|microarray analysis|
48121806|NCT00900211|GENETIC|molecular diagnostic method|
48121807|NCT00900211|OTHER|biologic sample preservation procedure|
48327092|NCT00148850|DRUG|Pioglitazone|
48327093|NCT00002017|DRUG|Interleukin-2, Polyethylene Glycolated|
48650287|NCT05605899|DRUG|Rituximab|Administered intravenously
48650288|NCT05605899|DRUG|Doxorubicin|Administered intravenously
48650289|NCT05605899|DRUG|Vincristine|Administered intravenously
48650290|NCT05605899|DRUG|Prednisone|Administered orally
48650291|NCT06674863|OTHER|Educational Intervention|Receive a low literacy educational supplement
48650292|NCT06674863|OTHER|Interview|Undergo a structured interview
48327094|NCT00830960|DRUG|Prasugrel|Oral, daily, 90 days
48327095|NCT00830960|DRUG|Clopidogrel|Oral, daily, 90 days
47972971|NCT00187486|PROCEDURE|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
47972972|NCT01025752|BEHAVIORAL|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
47972973|NCT01025752|BEHAVIORAL|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
48327096|NCT02766595|OTHER|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
48327097|NCT00347035|DRUG|brimonidine|
48327098|NCT03860883|PROCEDURE|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
48327099|NCT03860883|PROCEDURE|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
48327100|NCT05646654|PROCEDURE|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
48327101|NCT05646654|PROCEDURE|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
47972974|NCT05813015|DRUG|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
47972975|NCT05813015|DRUG|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
47972976|NCT04103853|DRUG|Proxalutamide|Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
47972977|NCT01191801|DRUG|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
47972978|NCT01191801|DRUG|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
48121808|NCT01206504|BIOLOGICAL|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
48327102|NCT04657653|PROCEDURE|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
48327103|NCT04766151|DRUG|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
48490375|NCT00673933|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
48490376|NCT03613116|DIETARY_SUPPLEMENT|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
48490377|NCT00209846|DRUG|Gaboxadol|
47972979|NCT01837615|DEVICE|Photopill treatment|
47972980|NCT04166916|OTHER|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
47972981|NCT04166916|OTHER|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
47972982|NCT03192254|BEHAVIORAL|self-monitoring|recording fruit and vegetable consumption
47972983|NCT03192254|BEHAVIORAL|daily monetary incentives|daily payments for consuming fruits and vegetables
47972984|NCT03192254|BEHAVIORAL|delayed lump sum monetary incentives|lump sum payments for consuming fruits and vegetables
47972985|NCT05954013|BEHAVIORAL|PD_Pal intervention|The PD_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD_Pal intervention, i.e. the PD_Pal nurse. In the PD_Pal intervention, the patient, family caregiver and PD_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD_Pal nurse.
47972986|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
47972987|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
47972988|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
47972989|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
47972990|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
47972991|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
47972992|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
47972993|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
47972994|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
48121809|NCT00826657|DIETARY_SUPPLEMENT|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
48121810|NCT00826657|DIETARY_SUPPLEMENT|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
48121811|NCT03097770|BIOLOGICAL|anti-CD19/20-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
48327104|NCT04766151|DRUG|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
48327105|NCT03585673|DRUG|Docetaxel-PM|Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
48327106|NCT03585673|DRUG|Oxaliplatin|Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
48327107|NCT05903937|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion (HAI)
48327108|NCT05903937|DRUG|Melphalan|Administered via isolated hepatic perfusion
48327109|NCT05903937|DRUG|Interleukin-2|low-dose, administered s.c.
48327110|NCT03965793|DEVICE|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
47972995|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
47972996|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
47972997|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
48327111|NCT04668794|PROCEDURE|Osteosynthesis|Reduction and fixation of the carpometacarpal fracture dislocation of the hand with osteosynthesis (Kirschners wires, plate and screws)
48327112|NCT02085057|PROCEDURE|Functional Magnetic Resonance Imaging|
48650293|NCT06674863|OTHER|Questionnaire Administration|Ancillary studies
48327113|NCT00546429|DEVICE|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
48121812|NCT01636687|DRUG|Placebo|2 injections of placebo to secukinumab 150mg per dose
48327114|NCT00041353|OTHER|cytology specimen collection procedure|
47972998|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
47972999|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
47973000|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
47973001|NCT04388800|OTHER|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
47973002|NCT01375647|BIOLOGICAL|IPV|Administered per protocol
47973003|NCT01375647|BIOLOGICAL|Rotarix|Administered per protocol
47973004|NCT02396485|OTHER|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
47973005|NCT05503394|BEHAVIORAL|Peer support WeChat platform intervention|Primary caregivers of children with biliary atresia are selected as the study population and divided into intervention and control groups in chronological order at a children's hospital in Shanghai. Primary caregivers who visit the hospital between August 2022 and October 2022 are assigned to the control group and primary caregivers who visit the hospital between January 2023 and March 2023 are assigned to the intervention group. The intervention group will receive a peer support WeChat platform intervention from the day of surgery to one month postoperatively. The level of negative emotions and caregiver burden will be compared between the two groups after the intervention. The intervention group receives the same routine care as the control group.
47973006|NCT05503394|BEHAVIORAL|Routine nursing care group|Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.
48490378|NCT04936828|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
47973007|NCT02490332|DEVICE|Ventilation tube treatment|Tympanostomy
47973008|NCT00673569|DRUG|erlotinib hydrochloride|
47973009|NCT00673569|GENETIC|gene expression analysis|
47973010|NCT00673569|GENETIC|protein expression analysis|
47973011|NCT00673569|OTHER|immunoenzyme technique|
48121813|NCT01636687|DRUG|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
48327115|NCT00041353|PROCEDURE|comparison of screening methods|
48327116|NCT00041353|PROCEDURE|study of high risk factors|
48327117|NCT04907318|DEVICE|Cataract surgery|
47973012|NCT00673569|OTHER|immunologic technique|
47973013|NCT00673569|OTHER|laboratory biomarker analysis|
47973014|NCT00673569|PROCEDURE|needle biopsy|
47973015|NCT05230771|COMBINATION_PRODUCT|Palliative surgery after translational therapy|"A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location."
47973016|NCT05230771|DRUG|Chemotheraoy along|Patients receive only the prescribed chemotherapy.
48490379|NCT06363786|OTHER|Test patches|Patches (incontinence product cut outs) with a low pH formula or control patches without formula.
47973017|NCT05833854|OTHER|Virtual reality glasses group|It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.
48121814|NCT01636687|DRUG|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
48121815|NCT05208242|DRUG|hyperoncotic human albumin solution|20% human albumin solution (presented in 100ml glass bottles)
48121816|NCT05208242|DRUG|Buffered crystalloid solutions|Buffered crystalloids solutions for all intravenous fluid therapy
48327118|NCT00852306|PROCEDURE|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
48327119|NCT04011748|COMBINATION_PRODUCT|Stem Cell Educator therapy|AA subjects will be recruited and followed by the treatment with SCE therapy.
48327120|NCT03283618|BEHAVIORAL|Video Conferencing Group|
48327121|NCT02098460|DRUG|Atorvastatin, Probucol, Cilostazol|
48650294|NCT06674863|OTHER|Supportive Care|Receive standard SCP
48121817|NCT06198114|OTHER|Multi Sensory Therapy|This group will be treated with activity based training by place different( nuts, screws, bullets, coins, paper clips, coloring ,scissor cutting with different shapes , Simulated feeding (by collecting beans with a spoon and transferring them into a container),transfer light and heavy weight objects into empty box. 5 days in a week
48121818|NCT06198114|OTHER|Conventional Therapy|This group will be treated with traditional therapy in which Place toys/objects inside and encourage the student to reach in and pull them out as well as put them back in. Give the student objects that can be put together and pulled apart. Encourage the students to use two hands in an organized manner to manipulate objects (e.g., grasp/release, twist/turn, rotate and examine, open/close, stack, nest).5 days a week for an hour/daily.
48650295|NCT06674863|OTHER|Supportive Care|Receive a tailored SCP
48121819|NCT02795754|DRUG|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
48121820|NCT02795754|DRUG|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
48121821|NCT02795754|DRUG|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
48121822|NCT02795754|DRUG|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
48121823|NCT02795754|DRUG|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
48121824|NCT05266066|OTHER|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care plus antibiotic if new organ dysfunction or new infections other than VAT.
48121825|NCT05266066|OTHER|7 day antibiotic course for VAT|Patients will receive standard care plus 7 day course of antibiotic.
48327122|NCT05962918|OTHER|Perinal massage|"Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum."
48327123|NCT00316342|DEVICE|Back supports|
48490380|NCT00770536|DRUG|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
48650296|NCT04582487|OTHER|bone marrow and/or peripheral blood samples withdrawal|bone marrow and/or peripheral blood samples evaluation
48650297|NCT06125301|DEVICE|MS Sherpa|MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
47973018|NCT05833854|OTHER|Manual pressure group|In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
47973019|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
47973020|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
47973021|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
47973022|NCT00892762|DRUG|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
48121826|NCT02660970|OTHER|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
48121827|NCT02660970|OTHER|Placebo-band|Children will have to wear a 'placebo-wristband'
48121828|NCT02660970|DRUG|Iberogast|Children will have to take Iberogast drops
48121829|NCT02660970|OTHER|Placebo-drops|Children will have to take placebo-drops
48121830|NCT03809312|DRUG|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
48121831|NCT03809312|DRUG|Placebos|Placebos BID x 10 days
48121832|NCT05559281|OTHER|Botulinum|injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
48650298|NCT00281437|BEHAVIORAL|choice of exercise program|
48121833|NCT05559281|PROCEDURE|Fisher technique|The cleft lip will be treated surgically using the Fisher technique only.
48121834|NCT01153880|DRUG|Retapamulin|Prescription sales claim of retapamulin
48121835|NCT01153880|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
48121836|NCT03032913|PROCEDURE|Blood samples|Blood samples for both group
48121837|NCT03032913|PROCEDURE|Portal vein blood sample|Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
48121838|NCT04153110|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
48121839|NCT04153110|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
48121840|NCT02601170|BIOLOGICAL|Platelet-Rich Plasma Intra-Articular Injection|
48121841|NCT02601170|DRUG|Hyaluronic Acid Viscosupplementation|
48327124|NCT05823168|DRUG|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
48327125|NCT01165099|PROCEDURE|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
48327126|NCT02435550|GENETIC|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
48490381|NCT00770536|DRUG|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
48490382|NCT00770536|DRUG|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
48490383|NCT00770536|DRUG|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
48490384|NCT05772806|DEVICE|Electrocardiogram|"The electrocardiogram will help to diagnose atrial fibrillation and the electronic devices (App Fibricheck and Smart bracelet/watch) will help to detect an arrhythmic rhythm.~The echocardiography will be used for detecting criteria of atrial cardiomyopathy.~MRI may help to detect silent strokes."
48490385|NCT04831372|PROCEDURE|Off Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table
48490386|NCT04831372|PROCEDURE|On Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
48490387|NCT02156141|OTHER|Supervised high intensity training|8 weeks of supervised training
48121842|NCT02176772|OTHER|Stable iron isotopes, non-drug intervention|
48121843|NCT04920812|GENETIC|diagnosis of mitochondrial myopathy|• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
48327127|NCT01146041|DRUG|Rivastigmine|Rivastigmine 1.5 mg Capsules
48327128|NCT01601808|DRUG|Placebo|Orally once a day, continuously throughout the study
48327129|NCT01601808|DRUG|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
48327130|NCT06293677|DRUG|Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 40 mg/kg q6 h eGFR 150-199 : 30 mg/kg q4h eGFR 200-299 : 40 mg/kg q4h eGFR \&amp;gt;/= 300 : 40 mg/kg q4h~Piperacillin-tazobatam dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 150 mg/kg q6 h eGFR 150-199 : 120 mg/kg q4h eGFR 200-299 : 150 mg/kg q4h eGFR \&amp;gt;/= 300 : 180 mg/kg q4h~The maximum doses for the antibiotic prescription before the first drug monitoring will be 2gr of MER every 4 hours and 4gr of PIP every 4 hours.~The duration of infusion will be set to 2 h."
48490388|NCT02156141|OTHER|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
48490389|NCT02156141|OTHER|Control period|8 weeks with no training.
48490390|NCT02156141|OTHER|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
48490391|NCT04783974|DEVICE|Dental implants|Treatment of total or partial edentulism through the placement of osseointegrated dental implants
48490392|NCT00635115|DEVICE|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
48490393|NCT00635115|DEVICE|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
47973023|NCT00892762|DRUG|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
48121844|NCT04722588|OTHER|Introducing clinical pharmacists to the interdisciplinary ED team.|There will be two shifts, one shift from 08.00 - 15.00 and one from 12.00 - 19.00. Consequently, the hours of the day when the majority of patients arrives, are covered and the pharmacist capacity is doubled during the busiest time of the day. Early mornings are normally relatively slowed paced and the pharmacist may use this time to follow up on patients admitted during the night (from 19.00 - 08.00), in particularly those who have been admitted to wards without an assigned pharmacist.
48121845|NCT06513117|BEHAVIORAL|Behaviour change|healthy conversations to support behaviour change
48121846|NCT06513117|BEHAVIORAL|Dietary support|Guidance on healthy eating
48121847|NCT06513117|BEHAVIORAL|Breathing pattern retraining|guidance on breathing pattern in exercise
48327131|NCT06293677|DRUG|Standard dosages of piperacillin-tazobactam or meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR\> 50 : 40mg/kg q8h eGFR 25-49 : 40mg/kg q12h eGFR 15-24 : 20mg/kg q12h~Piperacillin-tazobactam :~eGFR \>50 : 100mg/kg q6h eGFR 20-49 : 50mg/kg q6h eGFR 15-29 : 50 mg/kg q8h"
48327132|NCT00019227|DRUG|pentetic acid calcium|
48327133|NCT00019227|RADIATION|yttrium Y 90 daclizumab|
48490394|NCT02707861|DRUG|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
47973024|NCT03667924|BEHAVIORAL|PorchLight Project|Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
47973025|NCT03948698|OTHER|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
47973026|NCT04528381|PROCEDURE|Laparoscopy|Laparoscopic orchiopexy
47973027|NCT00078637|DRUG|E7820|
47973028|NCT06433869|DRUG|serplulimab|Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.
47973029|NCT06433869|DRUG|Bevacizumab|Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.
47973030|NCT06433869|DRUG|rmhTNF-NC|Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
47973031|NCT05872841|DRUG|Recombinant human adenovirus type 5 + TACE|"1. Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose:~   ① The sum of the maximum diameters of the lesions was ≤10cm, and the total dose was 1. 0×1012vp (2 injections);~   ② The sum of the maximum diameters of the lesions was \>10cm, and the total dose was 1. 5×1012vp (3 injections);~2. TACE：The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply.~Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles."
47973032|NCT04700709|DRUG|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.
47973033|NCT04700709|DRUG|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
47973034|NCT01829373|BIOLOGICAL|vaccine 1650-G|
47973035|NCT04800705|OTHER|ultrasound assessment|Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
47973036|NCT01676844|DRUG|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
48121848|NCT06513117|BEHAVIORAL|Exercise training|Exercise intervention prescribed to participant fitness level
48121849|NCT05146440|DRUG|PM14|"Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial."
48121850|NCT03489915|DEVICE|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
48121851|NCT03278587|OTHER|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
48121852|NCT03278587|OTHER|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
48327134|NCT01270230|BEHAVIORAL|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
48490395|NCT02707861|DRUG|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
48490396|NCT02254369|DRUG|GC021109|
48650299|NCT01130428|DEVICE|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (\~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading \[38\]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
48490397|NCT02254369|OTHER|Placebo|
48490398|NCT03483207|DRUG|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
48490399|NCT03483207|PROCEDURE|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
48650300|NCT04103931|BEHAVIORAL|"Treatment Choices for Aortic Stenosis Decision Aid"|"A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis."
48650301|NCT05797168|DRUG|AZD5335|IV Antibody-drug conjugate
48650302|NCT05797168|DRUG|Saruparib (AZD5305)|Oral PARP inhibitor
48650303|NCT05797168|DRUG|Bevacizumab|IV Monoclonal antibody
48650304|NCT05797168|DRUG|Carboplatin|IV Alkylating agent
48650305|NCT04975165|PROCEDURE|Total knee arthroplasty|Bilateral surgery in one arm and staged surgery in another arm during total knee arthroplasty
48650306|NCT05855096|OTHER|Google Form Questionnaire|Google form questionnaire is performed by responders.
48650307|NCT02868931|BEHAVIORAL|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
48650308|NCT04527744|PROCEDURE|the injection of onabotulinumtoxinA at different point|For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
48650309|NCT01122680|DRUG|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
48650310|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
48650311|NCT01122680|DRUG|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
48650312|NCT01122680|DRUG|Placebo|placebo inhalation solution
48650313|NCT00913835|BIOLOGICAL|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
48650314|NCT00913835|DRUG|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
48650315|NCT05041699|COMBINATION_PRODUCT|IPM Ring-105|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
48650316|NCT05041699|COMBINATION_PRODUCT|IPM Ring-106|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
48327135|NCT01270230|BEHAVIORAL|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
48327136|NCT04009746|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
48327137|NCT01324687|OTHER|Telemedicine care|Availability of telemedicine
48327138|NCT03789890|DRUG|BAY1902607|BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
48327139|NCT03789890|DRUG|Itraconazole|Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
48490400|NCT03483207|DRUG|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
48490401|NCT05160467|DIAGNOSTIC_TEST|Segmental multi-frequency bio electrical impedance analysis|"A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5.~Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis."
48490402|NCT04335175|OTHER|None - observational study|None - observational study
48490403|NCT06303713|DRUG|Carboplatin|Platinum coordination compound, premixed aqueous solution of 10mg/ML, via intravenous (into the vein) infusion per protocol.
48490404|NCT06303713|DRUG|177Lu-PSMA-617|Radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
48490405|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule
47980524|NCT03584711|COMBINATION_PRODUCT|FOLFOX + panitumumab|"FOLFOX + panitumumab according to a stop and go strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment"
48327140|NCT05514106|DRUG|meta-iodobenzylguanidine (MIBG) (123I)|1 administration of 123I-MIBG for a single SPECT scan
48327141|NCT05514106|DIAGNOSTIC_TEST|123I-MIBG scintigraphy|SPECT scan involving 123I-MIBG as the ligand
48327142|NCT04776421|PROCEDURE|Diverting ileostomy|Diverting ileostomy
48490406|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable \& fruit \& placebo capsule
48490407|NCT00952536|DIETARY_SUPPLEMENT|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
48650317|NCT04415151|DRUG|Tofacitinib 10 mg|Tofacitinib will be administered in a dose of 10 mg twice daily by mouth (PO BID) until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
48650318|NCT04415151|DRUG|Placebo|Matching placebo tablets will be administered.
48327143|NCT02451033|DRUG|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
48327144|NCT02451033|DRUG|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
48327145|NCT02451033|DRUG|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
48327146|NCT04111107|DRUG|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
48327147|NCT04111107|OTHER|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
48490408|NCT02970435|BEHAVIORAL|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
48490409|NCT02970435|BEHAVIORAL|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
48490410|NCT02970435|BEHAVIORAL|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
48327148|NCT04111107|DIAGNOSTIC_TEST|Next Gen Sequencing Report|1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
48327149|NCT04261452|DIAGNOSTIC_TEST|isokinetic dynamometer|"Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values."
48327150|NCT04261452|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|"All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population."
48327151|NCT04261452|DIAGNOSTIC_TEST|Functional Capacity Tests|"The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test."
48327152|NCT04261452|DIAGNOSTIC_TEST|Lung Function Test|"Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery."
48327153|NCT04261452|DIAGNOSTIC_TEST|Doppler Echocardiography|The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
48327154|NCT04261452|DIAGNOSTIC_TEST|Anthropometry and Body Composition|"Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM)."
48327155|NCT01626989|DEVICE|BiPAP auto Advanced|Auto Servo Ventilation Device
48327156|NCT01626989|DEVICE|BiPAP auto SV4|Auto Servo Ventilation Device
48327157|NCT02475850|OTHER|Evidence-based tailored fall prevention|
48490411|NCT02427295|DRUG|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection."
48490412|NCT05973682|OTHER|Post-isometric relaxation and Conventional treatment|"The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.~+ hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30 second hold. static stretching exercises two sessions per week for 3 weeks were given to each patient"
48490413|NCT05973682|OTHER|Conventional Physical Therapy|Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
47973037|NCT01676844|DRUG|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
47973038|NCT00299975|DRUG|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
48490414|NCT03602040|BEHAVIORAL|PISICC|"PISICC consists of:~1. Standard disease-specific information leaflet~2. Personalised lifestyle consideration form~3. 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
47973039|NCT00299975|DRUG|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
48327158|NCT02475850|OTHER|Usual care|
48327159|NCT03870685|PROCEDURE|TAP Block|Transversus Plane block
48327160|NCT03870685|PROCEDURE|Surgical Site Infiltration|Surgical Site Infiltration
48327161|NCT03870685|DRUG|Exparel|liposomal bupivacaine
48327162|NCT00595257|DEVICE|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
48327163|NCT03117530|DRUG|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
48327164|NCT02576015|PROCEDURE|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
48327165|NCT02576015|PROCEDURE|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
48327166|NCT02576015|DRUG|lidocaine|
48327167|NCT02576015|DEVICE|ultrasound|
48327168|NCT02576015|DEVICE|insulated needle (Contiplex B Braun, Melsungen, Germany)|
48327169|NCT02576015|DRUG|ropivacaine|
48327170|NCT02576015|DRUG|saline|
48327171|NCT04457570|OTHER|mortality|To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
48327172|NCT05698043|DRUG|CKD-386(5)|Test
48327173|NCT05698043|DRUG|D013, D326, D337|Reference
48327174|NCT01128335|DRUG|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
48327175|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
48327176|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
48327177|NCT01128335|DRUG|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
48327178|NCT03485092|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg tablets for oral self administration once a day
48327179|NCT03485092|DRUG|Placebo Oral Tablet|placebo tablets for oral self administration once a day
48327180|NCT04876989|PROCEDURE|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
48327181|NCT04876989|PROCEDURE|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
48327182|NCT00871377|DRUG|Placebo|corn oil (n-6 fatty acids)
48327183|NCT00871377|DRUG|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
48327184|NCT00871377|DRUG|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
48327185|NCT04239547|PROCEDURE|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
48327186|NCT04239547|PROCEDURE|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
48327187|NCT02447120|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
48327188|NCT05904184|DRUG|Epoxy resin-based sealers (ERS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.
48327189|NCT05904184|DRUG|Calcium silicate-based sealers (CSS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
48327190|NCT05699317|OTHER|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
48327191|NCT03794752|DEVICE|Head-Mounted Visual Enhancement Device|Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black \& white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
48327192|NCT01360762|DRUG|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
48327193|NCT02819505|DIETARY_SUPPLEMENT|beta-alanine|
48327194|NCT02819505|DIETARY_SUPPLEMENT|Placebo|
48327195|NCT04159012|DEVICE|Transcranial direct current stimulation|"A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4)."
48327196|NCT05393076|DRUG|Linerixibat|Linerixibat dose and administration as per study intervention.
48327197|NCT02450734|PROCEDURE|Ultrasound-guided intermediate cervical plexus block|
48327198|NCT01371448|DRUG|Paroxetine|
48327199|NCT03344848|DEVICE|Orion Visual Cortical Prosthesis System|The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.
48327200|NCT04046341|BEHAVIORAL|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
48490415|NCT04076670|OTHER|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
48490416|NCT03814941|OTHER|paper-based anesthesia record|to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
48490417|NCT03814941|OTHER|electronic documents|to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
47973040|NCT00299975|DRUG|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
47973041|NCT03836937|DRUG|Obeticholic acid|Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
47973042|NCT00275769|DEVICE|Pacemaker|
47980525|NCT02323477|BIOLOGICAL|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
48327201|NCT00716638|BEHAVIORAL|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
48327202|NCT00716638|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
48490418|NCT01801683|OTHER|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
48490419|NCT02860065|DRUG|CPC-201|solifenacin and donepezil
48490420|NCT02860065|OTHER|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
48498092|NCT01476735|OTHER|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
48650319|NCT06428188|BIOLOGICAL|BCMA/CD19 CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/CD19 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/CD19 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/CD19 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
48650320|NCT04547387|DEVICE|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
48650321|NCT00471393|DRUG|1.5% diclofenac in 45.5% DMSO (topical treatment)|
48650322|NCT00471393|DRUG|45.5% DMSO (topical placebo)|
48650323|NCT06673797|OTHER|Effects of Swiss Ball exercises|"Effects of Swiss ball exercises along with stretching as baseline treatment.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times.~2. Swiss ball exercises. a.Sitting on the Swiss ball with the trunk straight, arms by the sides, and eyes opened progressed towards eyes closed for 10 seconds, then rest. b.Sitting on the Swiss ball with trunk straight and arm by the sides. The therapist would assist the patient to engage the patient in shifting the body's weight to one side and the other side sideways as well as anterior and posterior and up and down alternatively. Start with 10 repetitions. c. Standing with gym ball in front. The therapist would stand behind the patient to provide support and ask the patient to lean forward on the gym ball with both hands via outstretched arms. Start with 10 repetitions d. One leg weight bearing on a gym ball with the therapist behind the patient, gripping the patient's pelvis to provide support. Start with 10 repetitions"
48650324|NCT06673797|OTHER|EFFECTS OF FRENKEL EXERCISES ON STATIC AND DYNAMIC BALANCE IN ATAXIC CHILDREN WITH CEREBRAL PALSY|"Frenkel Exercises along with stretching as baseline treatment. The second intervention group would participate in Frenkel Exercises along with stretching as baseline treatment. The exercises would be performed 3 times per week for four weeks.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times. (11)~   a. Calf stretching. b. Hamstring stretches. c. Quads stretching~2. Frenkel\&#39;s lower limb exercises are the exercises listed below. The time of each session was set to be 10 minutes in the first week and then raised by 5 minutes every week. The patients were given 5 minutes to relax after 10 minutes of practice. (12)~   1. Supine lying~  2. While sitting~  3. Stride standing"
48650325|NCT03818074|DEVICE|Boston Wavewriter 1000Hz Spinal cord Stimulation|High frequency spinal cord stimulation.
48650326|NCT02478749|PROCEDURE|arm retraction|gently pulling through the ipsilateral arm to the knee
48327203|NCT04765748|DEVICE|Cytosorb|Cytokine filter, which can be used intraoperatively while using a heart lung machine
48327204|NCT03717363|PROCEDURE|Training programme|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
48327205|NCT03717363|BEHAVIORAL|Educational talk|An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
48498093|NCT02760524|BEHAVIORAL|NET Intervention|Neuro-emotional Technique
48327206|NCT02616185|BIOLOGICAL|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
48327207|NCT02616185|BIOLOGICAL|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
48327208|NCT02616185|DEVICE|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
48327209|NCT02616185|BIOLOGICAL|Tremelimumab|PF-06753388 will be administered every 28 days.
48327210|NCT02616185|BIOLOGICAL|PF-06801591|PF-06801591 will be administered every 28 days.
48327211|NCT02616185|BIOLOGICAL|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
48327212|NCT00043212|DRUG|Dendritic cell immunotherapy|
48327213|NCT01811381|DRUG|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
48327214|NCT01811381|BEHAVIORAL|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
48327215|NCT01811381|BEHAVIORAL|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
48327216|NCT01811381|DIETARY_SUPPLEMENT|Placebo|Subjects will take 4 capsules x BID of placebo
48327217|NCT05875129|DEVICE|VAVA prototype|Cognitive behavioral therapy for insomnia
48327218|NCT01853436|DEVICE|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
48327219|NCT02834091|PROCEDURE|Hypnoanalgesia|
48327220|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
48327221|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
48327222|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
48327223|NCT01663844|BEHAVIORAL|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
48327224|NCT01497535|DRUG|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
48327225|NCT01497535|DRUG|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
48327226|NCT05884359|DIAGNOSTIC_TEST|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
48327227|NCT03121066|DEVICE|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
48327228|NCT03121066|DEVICE|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
48327229|NCT04564326|PROCEDURE|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
48327230|NCT04564326|PROCEDURE|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
48327231|NCT04564326|DRUG|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
48327232|NCT04498572|OTHER|dry needling|dry needling for Gluteus Medius muscle in combination with exercises
48327233|NCT04498572|OTHER|sham dry needling|sham dry needling for Gluteus Medius muscle in combination with exercises
48498094|NCT04401865|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
48327234|NCT02993055|DRUG|Ulimorelin|
48327235|NCT02993055|OTHER|Placebo|
48327236|NCT01829217|DRUG|Sunitinib|
48327237|NCT04280406|DRUG|Azithromycin|azithromycin 500mg one hour before implant placement
48327238|NCT04280406|DRUG|Placebo oral tablet|identical placebo one hour before implant placement
48327239|NCT01705964|DRUG|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
48327240|NCT01705964|OTHER|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
48327241|NCT03860350|DIETARY_SUPPLEMENT|Aged Garlic Extract|
48327242|NCT03860350|DIETARY_SUPPLEMENT|Placebo|
48327243|NCT05457348|PROCEDURE|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
48327244|NCT03587571|PROCEDURE|Surgical intervention|Open reduction and plate osteosynthesis.
48327245|NCT01314976|DRUG|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
48327246|NCT01314976|DRUG|Placebo|"Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
48327247|NCT06416397|DIAGNOSTIC_TEST|Proteomic profile|"Proteomic analysis of bile samples will be performed every 5 bile samples. Bile samples will be taken during endoscopy with retrograde papillary catheterization or radiological procedures in selected patients. In clinical practice, bile samples are taken for bacteriological purposes. An average of 10 mL is taken.~Five mL are required for bacteriological analysis. The remaining millilitres, which are usually discarded, will be kept for storage and to form the bile bank at the Biological Resources Centre before to be analyzed in proteomics."
48327248|NCT06210958|OTHER|Intertransverse process block|The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block
48327249|NCT00889395|BEHAVIORAL|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
48327250|NCT00370890|DRUG|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
48327251|NCT02690207|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
48327252|NCT02227849|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
48327253|NCT02227849|DRUG|GLP-1 analogue|
48327254|NCT05994586|DIETARY_SUPPLEMENT|AP029 mix|Polyphenol-rich plant extracts Twice a day
48327255|NCT05994586|OTHER|Placebo|Twice a day
48327256|NCT02204514|PROCEDURE|Surgery for external snapping hip|
48490421|NCT03045471|DRUG|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
48327257|NCT01029015|PROCEDURE|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
48327258|NCT01029015|PROCEDURE|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
48327259|NCT00399594|PROCEDURE|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
48327260|NCT00399594|PROCEDURE|B|LV lead placement in standard (lateral / posterolateral) position.
48327261|NCT01883869|DRUG|ticagrelor|
48327262|NCT01883869|DRUG|placebo|placebo
48327263|NCT00255099|DRUG|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
48327264|NCT00255099|DRUG|Placebo|2 tablets b.i.d. / 96 weeks
48327265|NCT06197022|DEVICE|Mozec™ SEB Sirolimus Eluting Rx PTCA Balloon Dilatation Catheter|Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
48327266|NCT03040765|DRUG|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
48327267|NCT03040765|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
48327268|NCT04191603|DEVICE|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
48327269|NCT04191603|DEVICE|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
48327270|NCT05161637|DRUG|TLC590|TLC590 490mg or 588mg
48327271|NCT05161637|DRUG|Bupivacain|Bupivacaine 75mg
48327272|NCT05161637|DRUG|Ropivacaine|Ropivacaine 150mg
48327273|NCT05161637|DRUG|Normal saline|Normal saline 20mL or 24mL
48327274|NCT00709917|DRUG|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
48327275|NCT04828785|OTHER|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
48327276|NCT04828785|OTHER|Food Subsidy|$40/month food subsidy
48327277|NCT04928495|DRUG|Vitamin C|Vitamin C 500 mg / day for ten days
48327278|NCT04928495|DRUG|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
48327279|NCT04928495|DRUG|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
48327280|NCT00338468|DRUG|epoetin alfa|
48327281|NCT00249639|BEHAVIORAL|Contingency management|Rewards valued $1-$100
48490422|NCT03045471|DRUG|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
48490423|NCT01507974|DRUG|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
48490424|NCT01507974|DRUG|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
48650327|NCT06569225|DRUG|Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig|: Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
48650328|NCT05103111|OTHER|No intervention|no intervention
48650329|NCT02312128|OTHER|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
48650330|NCT02312128|RADIATION|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
48650331|NCT02312128|OTHER|Grip Strength|Grip strength measurement
48327282|NCT00643604|DRUG|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
48327283|NCT00525408|BIOLOGICAL|Mycobacterium w.|Immunomodulator
48327284|NCT00525408|DRUG|Docetaxel|Chemotherapeutic agent
48327285|NCT01992848|OTHER|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
48327286|NCT01992848|OTHER|4-day food diary|
48650332|NCT02312128|OTHER|VAS Score|Measurement pain according to the visual analogue scale (VAS)
48327287|NCT01992848|OTHER|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
48327288|NCT01992848|RADIATION|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
48327289|NCT05138237|PROCEDURE|endoscopy or surgery|"we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant"
48327290|NCT06123910|DIETARY_SUPPLEMENT|Colostrum bovine|Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
48327291|NCT06123910|OTHER|Placebo|Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
48327292|NCT01862432|OTHER|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
48650333|NCT02312128|OTHER|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
48650334|NCT05700422|DRUG|Varenicline Nasal Spray|OC-01 (varenicline solution) 0.03 mg nasal spray
48650335|NCT01930708|DRUG|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
48650336|NCT02363426|DEVICE|INVOcell Culture Device|INVOcell is a vaginal culture device
48650337|NCT02363426|DEVICE|IVF Incubation|IVF Incubator
48650338|NCT02202577|DRUG|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
48650339|NCT02202577|DRUG|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
48327293|NCT04886518|DRUG|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
48327294|NCT04886518|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
48327295|NCT02120157|DRUG|Cyclophosphamide|Chemotherapy administration
48327296|NCT02120157|RADIATION|TBI|Radiation Therapy
48327297|NCT02120157|DRUG|Busulfan|Chemotherapy Administered
48490425|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
48490426|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
48490427|NCT01507974|DRUG|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
48490428|NCT01507974|DRUG|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
48490429|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
48490430|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
48490431|NCT05036395|OTHER|The routine assessment protocol and AI-assisted cEEG Diagnostic tool|The AI-assisted cEEG diagnostic tool is an automated seizure reporting system, including a quantitively EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The tool can report electrographic seizures in real time during cEEG monitoring. The neonatologists will evaluate the neonates by AI-assisted cEEG diagnostic tool, clinical conditions, real-time cEEG and amplitude-integrated EEG traces. The investigators will make a decision after review the neonates clinical conditions, AI-assisted cEEG diagnostic report, the cEEG and amplitude-integrated EEG.
48490432|NCT05036395|OTHER|The routine assessment protocol|The routine assessment protocol is that the neonatologists will evaluate the neonates by clinical conditions, real-time cEEG and amplitude-integrated EEG traces.
48490433|NCT02677649|OTHER|cranberry|the effect of cranberry on the gut microbiota
48490434|NCT02677649|OTHER|placebo|the effect of placebo on the gut microbiota
48490435|NCT05226559|PROCEDURE|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
48650340|NCT05731544|DRUG|BMF-219|Investigational Product
48650341|NCT02727699|DRUG|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
48650342|NCT02727699|DRUG|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
48650343|NCT00521352|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
48327298|NCT02120157|OTHER|Unmanipulated Bone Marrow|Bone Marrow Transplant
48327299|NCT02120157|DRUG|Tacrolimus|Immunosuppressive Drug Administered
48327300|NCT02120157|DRUG|Mycophenolate mofetil|Immunosuppressive Drug Administered
48490436|NCT05226559|DRUG|Usual care|Standard pharmacological treatment alone.
48498095|NCT03336177|OTHER|Semi-structured face to face interviews.|Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.
48650344|NCT00521352|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
48650345|NCT02496754|DRUG|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
48650346|NCT02496754|DRUG|GnRH-a|In control group, patients use short term GnRH-a. Patients' serum or follicle fluid will be collected if needed.
48650347|NCT02275533|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48650348|NCT02275533|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48650349|NCT02275533|OTHER|Clinical Observation|Undergo standard of care clinical observation
48650350|NCT02275533|PROCEDURE|Echocardiography|Undergo ECHO
48327301|NCT00818285|DEVICE|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
48327302|NCT04105413|DIAGNOSTIC_TEST|Blood culturs|CBC, Blood culture and CRP
48327303|NCT02236741|DRUG|Mirapexin® (Sifrol®)|
48327304|NCT05485259|DIETARY_SUPPLEMENT|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
48327305|NCT05485259|OTHER|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
48327306|NCT01019772|BIOLOGICAL|LBVH0101 (Hib vaccine)|
48327307|NCT01019772|BIOLOGICAL|Hiberix™ Vaccine|
48327308|NCT04565600|DRUG|Etoricoxib|Etoricoxib 60 Mg Oral Tablet
48327309|NCT02196987|OTHER|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
48650351|NCT02275533|BIOLOGICAL|Nivolumab|Given IV
48650352|NCT06675864|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
48650353|NCT00245154|DRUG|carboplatin|Given IV
48650354|NCT00245154|DRUG|cediranib maleate|Given orally
48650355|NCT00245154|DRUG|paclitaxel|Given IV
48650356|NCT00245154|OTHER|placebo|Given orally
48650357|NCT06416982|OTHER|Perineal massage|2 minutes of perineal massage as described in arm/group descriptions.
48650358|NCT06675006|COMBINATION_PRODUCT|Medical Massage|This intervention refers to the application of therapeutic massage techniques aimed at alleviating pain and enhancing muscle relaxation in patients with nonspecific low back pain. The treatment focuses on manipulating soft tissues, including muscles, tendons, and fascia, to improve circulation, reduce muscle tension, and promote overall wellness. Medical massage is tailored to each patient's specific needs and can incorporate various techniques, including Swedish massage, Bowen Therapy, a gentle and non-invasive manual therapy, utilizes precise movements on specific points of the body to promote healing and restore balance. The therapist applies light pressure with the fingers, allowing the body to respond and relax. This technique aims to stimulate the body's innate healing mechanisms, encouraging improvements in pain levels and functional capacity. Sessions are typically structured to allow for periods of rest, giving the body time to process the treatment and enhancing its effects.
48650359|NCT02770365|DRUG|estrace cream (Perrigo)|
48121853|NCT03278587|OTHER|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
48490437|NCT02777515|BEHAVIORAL|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~1. A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~2. measurement of blood pressure~3. An electrocardiogram~4. A Holter-ECG 10 minutes~5. A transthoracic echocardiogram"
48490438|NCT05905263|OTHER|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
48650360|NCT02770365|DRUG|estrace cream (Reference)|
48650361|NCT02770365|DRUG|Placebo cream|
48650362|NCT06522386|DRUG|Pirtobrutinib|Given by mouth
48650363|NCT06522386|DRUG|Rituximab|Given by vein (IV)
48650364|NCT06522386|DRUG|Venetoclax|Given by mouth
48650365|NCT06675448|DEVICE|MitraClip|Participants will undergo the Mitraclip procedure according to current standards of practice
48650366|NCT06675448|OTHER|Moderate MR|Patients who present with moderate MR (Mitral regurgitation) will serve also as an internal control against which the outcomes of Mitraclip treated patients)
48650367|NCT01408108|PROCEDURE|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
48121854|NCT03116620|OTHER|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
48121855|NCT00417950|DRUG|Acarbose|
48327310|NCT02196987|OTHER|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
48327311|NCT03856528|OTHER|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
48650368|NCT01408108|PROCEDURE|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
48650369|NCT06016725|OTHER|Exercise Intervention|Participate in online resistance training sessions
48650370|NCT06016725|OTHER|Informational Intervention|Given educational materials
48650371|NCT06016725|OTHER|Nutritional Assessment|Participate in online nutritional counseling
48327312|NCT04929613|BEHAVIORAL|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
48327313|NCT01158729|DRUG|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
48327314|NCT01158729|OTHER|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
48327315|NCT02017613|DRUG|RP6530|Escalating doses starting at 25 mg BID
48327316|NCT02700295|DEVICE|Orthokeratology lens|
48327317|NCT00889681|DEVICE|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
48327318|NCT04075773|BEHAVIORAL|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
48327319|NCT00645918|DRUG|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
48121856|NCT03479034|OTHER|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
48121857|NCT06335719|PROCEDURE|BES|Nerve biopsies during surgery + brief electrical stimulation therapy
48327320|NCT00645918|DRUG|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
48650372|NCT06016725|OTHER|Physical Performance Testing|Ancillary studies
48650373|NCT06016725|OTHER|Quality-of-Life Assessment|Ancillary studies
48650374|NCT06016725|OTHER|Questionnaire Administration|Ancillary studies
48121858|NCT06335719|PROCEDURE|Standard of Care surgery|Nerve biopsies during surgery - no brief electrical stimulation therapy
48327321|NCT00645918|DRUG|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
48327322|NCT03277768|DEVICE|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
48327323|NCT05360823|OTHER|Birth ball|Exercises for childbirth
48327324|NCT05360823|OTHER|Squatting|Exercises for childbirth
48327325|NCT04282681|OTHER|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
48327326|NCT05717959|BEHAVIORAL|Oropharyngeal Exercises|Oropharyngeal Exercises
48327327|NCT02797691|OTHER|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
48327328|NCT02797691|OTHER|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
48327329|NCT04557163|DRUG|TS-142|TS-142 will be given as 1 mg per capsule administered orally with water.
48327330|NCT04557163|DRUG|Itraconazole|Itraconazole will given as 50 mg per capsule administered orally with water.
48327331|NCT02438215|DRUG|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
48327332|NCT04324138|DRUG|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
48327333|NCT04324138|DRUG|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
48327334|NCT03723005|DEVICE|Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
48650375|NCT04952519|DRUG|Amantadine|Patients are treated with high doses of amantadine.
48650376|NCT05117242|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV)
48650377|NCT05117242|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV
48121859|NCT01186549|DRUG|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
48121860|NCT01186549|DRUG|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
48121861|NCT01186549|DRUG|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
48121862|NCT01186549|DRUG|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
48490439|NCT00112346|DRUG|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
48490440|NCT00112346|DRUG|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
48121863|NCT01186549|DRUG|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
48327335|NCT03723005|DEVICE|Standard-of-Care|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
48327336|NCT03453918|DIETARY_SUPPLEMENT|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
48490441|NCT00004153|GENETIC|reverse transcriptase-polymerase chain reaction|
48490442|NCT00004153|PROCEDURE|sentinel lymph node biopsy|
48121864|NCT02722551|DEVICE|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
48121865|NCT02364349|DRUG|Bee Venom (BV)|Raw Bee Venom
48121866|NCT02364349|DRUG|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
48121867|NCT06205251|DEVICE|POWERbreathe Plus IMT|"Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks."
48490443|NCT02478320|DRUG|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
48490444|NCT03257904|PROCEDURE|intracranial pressure monitoring|measurement of intracranial pressure
48490445|NCT00679536|DRUG|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
48490446|NCT00679536|DRUG|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m\^2/day.
48490447|NCT00679536|DRUG|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
48490448|NCT00679536|RADIATION|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
48490449|NCT00609466|DRUG|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
48490450|NCT00609466|DRUG|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
48490451|NCT00609466|DRUG|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
48490452|NCT01030341|DEVICE|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
48490453|NCT03880760|OTHER|L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
47973043|NCT05740397|OTHER|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
48327337|NCT03453918|OTHER|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
48327338|NCT01753388|DEVICE|Liberty Stent|
48327339|NCT03120637|DRUG|Methylene Blue|
48327340|NCT01313364|DEVICE|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
48650378|NCT06113367|OTHER|Evaluation of anti-PD-(L)1 immunotherapy efficacy|Non Applicable, research on data
48650379|NCT05665751|DRUG|TLC-3595 Dose 1|Tablets administered orally
48650380|NCT05665751|DRUG|TLC-3595 Dose 2|Tablets administered orally
48650381|NCT05665751|DRUG|Placebo|Tablets administered orally
48650382|NCT03816137|BIOLOGICAL|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 20 mcg or 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
48650383|NCT03816137|BIOLOGICAL|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC ConM SOSIP. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
47973044|NCT05328193|BEHAVIORAL|Healthier Families, COVID Edition|Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.
48327341|NCT03299738|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
48327342|NCT05379894|PROCEDURE|Percutaneous nephrolithotripsy|Extraction of kidney stones through skin using nephroscope
48327343|NCT05894044|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
48327344|NCT05894044|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
48327345|NCT05894044|OTHER|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
48327346|NCT05894044|OTHER|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
48327347|NCT03472274|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
48327348|NCT03472274|DRUG|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
48327349|NCT03472274|DRUG|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1"
48327350|NCT00353327|PROCEDURE|Plasma infusion|
48327351|NCT04243616|DRUG|Cemiplimab|350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)
48650384|NCT03816137|BIOLOGICAL|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 50 mcg or 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
48650385|NCT03816137|BIOLOGICAL|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
48650386|NCT03816137|BIOLOGICAL|Mosaic SOSIPs|Mosaic gp140 Env trimers (Mos3.1, Mos3.2, Mos3.3) designed to overcome the immunodominance of hypervariable regions of Env. The immunogen will be used at the dosage of 100 mcg (100mcg or 2 x 50 mcg or 3 x 33 mcg) or at 40 mcg (2 x 20mcg) and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
47973045|NCT05328193|BEHAVIORAL|Teaching Kitchen Outreach|Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
48327352|NCT04243616|DRUG|Paclitaxel|80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)
48327353|NCT04243616|DRUG|Carboplatin (not mandatory)|Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)
48327354|NCT04243616|DRUG|Doxorubicin|60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
48327355|NCT04243616|DRUG|Cyclophosphamide|600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
48327356|NCT02021825|DRUG|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
48650387|NCT03816137|BIOLOGICAL|763 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
48327357|NCT03351439|DRUG|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
48327358|NCT03351439|DRUG|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
48490454|NCT03880760|OTHER|Placebo|Taking 1 placebo capsule twice a day before meals for six months.
48327359|NCT03351439|DRUG|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
48327360|NCT03351439|DRUG|Percocet|Standard of Care
48327361|NCT03351439|DRUG|Naprosyn|Standard of Care
48327362|NCT01462448|PROCEDURE|Blood Draw|Single blood draw of 30 ml
48327363|NCT01159509|BEHAVIORAL|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
48490455|NCT04887246|BIOLOGICAL|COVID-19 vaccines|COVID-19 vaccines available at Colombia
48490456|NCT00922987|DRUG|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
48490457|NCT02828059|DRUG|Ropivacaine|Surgical wound Infiltration over 48 hours
48327364|NCT06259864|OTHER|EXOPULSE Mollii Suit method|EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities.
48490458|NCT05816369|OTHER|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
48490459|NCT02372071|DEVICE|BiliCare|Two measurements with the BiliCare device
48327365|NCT02789449|OTHER|assessment of DLNO and DLCO|
48327366|NCT01116687|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
48327367|NCT01116687|OTHER|laboratory biomarker analysis|Correlative studies
48327368|NCT03865459|OTHER|Video group|Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
48327369|NCT01797991|DRUG|Dexamethasone per os|
48490460|NCT05665920|RADIATION|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
48490461|NCT05665920|RADIATION|Standard Radiation|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
48490462|NCT02593513|DEVICE|Daifert|
48490463|NCT02593513|PROCEDURE|Control Group|Control - Morphological Assessment
48490464|NCT00002922|DRUG|paclitaxel|
48490465|NCT00511992|DRUG|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
48490466|NCT00511992|DRUG|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
48490467|NCT00511992|DRUG|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
48490468|NCT04160013|BEHAVIORAL|Discipline education|Discipline education using the Play Nicely program.
48327370|NCT01797991|DRUG|Matching placebo for dexamethasone IV|
48327371|NCT01797991|DRUG|Dexamethasone IV|
48327372|NCT01797991|DRUG|Matching placebo for dexamethasone per os|
48327373|NCT05960110|DRUG|Fluoride varnish|Fluoride varnish 26200 ppm
48327374|NCT05960110|DRUG|Fluoride toothpaste|Fluoride toothpaste 1450 ppm
48121868|NCT03608202|BEHAVIORAL|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
48121869|NCT03608202|OTHER|Control group|Routine protocol of the treating team is followed
48327375|NCT00438893|DIETARY_SUPPLEMENT|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
48327376|NCT06017648|DEVICE|Non Invasive Ultrasound (FUBA5200)|the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
48327377|NCT06017648|DEVICE|Non Invasive Ultrasound (Contour I V3)|the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
48327378|NCT01469572|DRUG|Pasireotide|Pasireotide is given as an injection.
48327379|NCT01469572|PROCEDURE|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
48327380|NCT01469572|DRUG|Everolimus|Given orally every day for the duration of the study
48650388|NCT03816137|BIOLOGICAL|AMC011 SOSIP|HIV-1 envelope sequence, identified from two HIV infected individuals that displayed HIV neutralisation breadth early in infection (less than 12 months). The immunogen will be used at the dosage of 20 mcg or 50mcg or 100mcg and will be admixed with 500 mcg MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
48121870|NCT00803387|DRUG|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
48121871|NCT04739527|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
48121872|NCT04421924|PROCEDURE|thrombelastogram|Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm
48121873|NCT04421924|PROCEDURE|standard of care|2) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
48121874|NCT04140331|DEVICE|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
48327381|NCT02104999|DEVICE|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
48327382|NCT06138028|DRUG|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
48327383|NCT00467714|PROCEDURE|rhinoplasty|COLUMELLA STRUT PLACEMENT
48327384|NCT06159348|DIAGNOSTIC_TEST|Anemia Diagnostic Assistant (ADA)|The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.
48327385|NCT06159348|DIAGNOSTIC_TEST|Serum hemoglobin|Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
48327386|NCT05052528|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19 CAR T cells IV
48327387|NCT05052528|DRUG|Cyclophosphamide|Given IV
48490469|NCT04160013|BEHAVIORAL|Cavity Prevention|Cavity prevention using a 2 page handout.
48490470|NCT01195272|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
48650389|NCT02180672|DRUG|Nasal Fluticasone|One spray per nostril, per day.
48650390|NCT02180672|DRUG|Placebo|One spray per nostril, per day.
48327388|NCT05052528|DRUG|Fludarabine Phosphate|Given IV
48327389|NCT05052528|BIOLOGICAL|Rituximab|Given IV
48327390|NCT06511440|DEVICE|Vision-700|OCT machines used for diagnostic purposes
48327391|NCT00780702|DRUG|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
48327392|NCT00780702|DRUG|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
48327393|NCT00518232|DRUG|OROS-methylphenidate|
48327394|NCT01853098|BEHAVIORAL|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
48327395|NCT00170742|DRUG|Octreotide, 30 mg i.m. LAR formulation|
48490471|NCT01908790|DEVICE|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
48650391|NCT05821894|OTHER|Observational study|
48650392|NCT04464733|DRUG|HRS9950|HRS9950
48327396|NCT03287245|DRUG|Idasanutlin|All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
48327397|NCT00997178|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
48327398|NCT00997178|OTHER|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
48327399|NCT03213483|PROCEDURE|Coronally advanced flap and subepithelial connective tissue graft|The connective tissue graft is obtained by a single line incision from the palate.
48327400|NCT03213483|PROCEDURE|Coronally advanced flap and deepithelialized free gingival graft|The connective tissue graft is obtained by deepithelialization of a free gingival graft.
48327401|NCT03838445|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
48327402|NCT02925663|BEHAVIORAL|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
48327403|NCT05378022|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
48327404|NCT05378022|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
48327405|NCT00108953|DRUG|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
48327406|NCT00108953|DRUG|Doxorubicin/Placebo|Chemotherapy plus Placebo
48327407|NCT01543139|DRUG|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
48327408|NCT01543139|DRUG|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
48327409|NCT01543139|DRUG|Valproate|Valproate: Week0-8: 300mg/day
48327410|NCT05100433|PROCEDURE|Ultrasonic irrigation|Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
48327411|NCT04262401|BEHAVIORAL|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
48327412|NCT04262401|BEHAVIORAL|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
48327413|NCT06430710|DEVICE|Intrusion|2 different methods for incisor intrusion
48327414|NCT00001449|DRUG|gemcitabine|
48490472|NCT01908790|DEVICE|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
48650393|NCT04464733|DRUG|Placebo|Placebo
48650394|NCT06136299|OTHER|Neuromuscular Training|This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
48327415|NCT00001449|DRUG|fluorodeoxyuridine|
48650395|NCT05770180|BIOLOGICAL|Recombinant COVID-19 variant vaccine (Sf9 cell)|WSK-V102
48650396|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (CHO cell)|control 1
48327416|NCT00001449|DRUG|leucovorin|
48327417|NCT00168064|DRUG|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
48327418|NCT04178135|DRUG|rLH|rLH supplement from day 1 of stimulation
48327419|NCT04178135|DRUG|rLH|rLH supplement from day 6 of stimulation
48327420|NCT00903253|DRUG|LNK-754|
48490473|NCT04896827|OTHER|Conditioned pain modulation test|Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
48490474|NCT05056766|BEHAVIORAL|questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.|"Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy.~Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction).~Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)"
48650397|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|control 2
48327421|NCT01819506|BEHAVIORAL|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
48327422|NCT04004377|OTHER|Scale of quality life|"The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life."
48327423|NCT05363709|DRUG|Balstilimab|Given by Vein (IV)
48650398|NCT02576431|DRUG|BAY2757556 (Larotrectinib, Vitrakvi)|Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
48650399|NCT01257243|DRUG|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
48327424|NCT06256029|PROCEDURE|Recruitment maneuver|The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
48327425|NCT01326117|DRUG|tadalafil|7 days of Cialis for Daily Use (5mg)
48327426|NCT00325338|BIOLOGICAL|Ragweed MATAMPL|
48327427|NCT05341570|DRUG|BPI-21668|Subjects will receive BPI-21668 until disease progression
48327428|NCT03038802|BIOLOGICAL|Therapeutic hepatitis B vaccine|HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
48327429|NCT03038802|BIOLOGICAL|Commercial Hepatitis B vaccine|Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
48327430|NCT01546285|DEVICE|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
48327431|NCT03982238|DRUG|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
48490475|NCT03667079|OTHER|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
48490476|NCT03667079|OTHER|Mass deworming only|Delivery of mass deworming to people only
48490477|NCT03667079|OTHER|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
48490478|NCT03985787|BEHAVIORAL|Resistance Training|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
48490479|NCT04243408|OTHER|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
48490480|NCT04243408|OTHER|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
48490481|NCT04262661|DRUG|NNC0472-0147|Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
48490482|NCT04262661|DRUG|insulin glargine|Part 2: A fixed dose level of 0.5 U/kg insulin glargine will be used in all cohorts.
48490483|NCT04262661|DRUG|Placebo (NNC0472-0147)|Part 1: A single dose of placebo, dose increased in each cohort.
48490484|NCT03036553|OTHER|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
48490485|NCT05696795|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of sarcoidosis.
48490486|NCT01130636|DRUG|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
48490487|NCT03343613|DRUG|LY3381916|IDO-1 inhibitor administered orally
48490488|NCT03343613|DRUG|LY3300054|PD-L1 inhibitor administered IV
48498096|NCT04832516|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
48498097|NCT04832516|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
48650400|NCT01257243|DRUG|Syrup of guaifenesin|5ml each 4 hours
48650401|NCT00048308|DRUG|pexelizumab|
48650402|NCT06451458|BEHAVIORAL|ECHO program for DMMC|For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.
48327432|NCT03982238|DRUG|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
48327433|NCT03982238|DRUG|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
48327434|NCT03534726|DEVICE|7 T CMR|7 tesla MRI device
48327435|NCT04503928|DRUG|Euphorbia kansui Pill|1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
48490489|NCT02442583|OTHER|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
48490490|NCT00851643|BIOLOGICAL|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
48490491|NCT00851643|BIOLOGICAL|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
48490492|NCT00851643|BIOLOGICAL|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
48490493|NCT00851643|BIOLOGICAL|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
48327436|NCT02658201|DEVICE|MRI|Ultrafast MRI to assess constipation
48327437|NCT05895227|PROCEDURE|Oocyte retrieval|
48490494|NCT00851643|BIOLOGICAL|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
48490495|NCT01651143|DRUG|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
48490496|NCT01651143|DRUG|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
48490497|NCT01224028|DRUG|Tacrolimus|oral
48490498|NCT01224028|DRUG|Placebo|oral
48490499|NCT01088282|PROCEDURE|Cataract surgery|Implantation of multifocal or monofocal IOL
48327438|NCT04141592|PROCEDURE|Bariatric Surgery|Already clinically indicated surgical procedures
48327439|NCT04065191|OTHER|High-intensity interval training|Heart rate based high-intensity interval training
48327440|NCT04591041|DEVICE|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
48327441|NCT04591041|OTHER|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
48490500|NCT04190069|BEHAVIORAL|Behavioral interventions/modifications|UPMC Prescription for Wellness is an innovative physician/provider prescribed coaching and feedback program that improves patient engagement and outcomes in healthy behaviors; self-care of chronic disease and condition management; and shared decision-making. The resources available through this program are offered via a telephonic health coach, online or through a digital intervention based on the participant's convenience.
48490501|NCT00276952|DRUG|Gonyautoxin|
48490502|NCT03436914|DRUG|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
48490503|NCT06011629|DEVICE|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
48490504|NCT03822364|DRUG|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
48490505|NCT03822364|DRUG|active comparator|commercially available apomorphine injector
48490506|NCT03822364|DRUG|009-0|Inhaled placebo via Staccato device
48490507|NCT03822364|DRUG|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
48327442|NCT00003828|DRUG|vinorelbine|
48490508|NCT03822364|DRUG|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
48490509|NCT03822364|DRUG|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
48490510|NCT03822364|DRUG|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
48121875|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)|Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
48121876|NCT04917224|RADIATION|Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)|Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
48121877|NCT05157022|DEVICE|ESWT|Extracorporeal Shock-wave Therapy
48327443|NCT00517283|DRUG|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
48327444|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
48327445|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
48327446|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
48327447|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
48327448|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
48327449|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
47973046|NCT01594879|DEVICE|MIrena(LNG-IUS), oral MPA|"1. General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~2. General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
47973047|NCT02966028|DRUG|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
47973048|NCT02966028|DRUG|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
47973049|NCT00095901|DRUG|Capecitabine|
47973050|NCT03052725|DRUG|reslizumab|Reslizumab was provided in a pre-filled syringe.
47973051|NCT06347835|DIETARY_SUPPLEMENT|symbiotic|The intervention is made up of multiple probiotics and prebiotics (20g/d) and dietary pattern modification.
47973052|NCT06347835|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (20g/d) and dietary pattern modification.
47973053|NCT06347835|DIETARY_SUPPLEMENT|symbiotic placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
47973054|NCT06347835|DIETARY_SUPPLEMENT|whey protein placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
47973055|NCT02114814|BEHAVIORAL|Diabetes self-management program for Hispanics and their families|The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish
47973056|NCT02114814|BEHAVIORAL|General health educational program for Hispanics and their families|The attention control group received 8-weekly education program on general health information
47973057|NCT03469375|DRUG|modified-FOLFIRINOX|LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
47980526|NCT02406482|BEHAVIORAL|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
48327450|NCT03685487|PROCEDURE|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
48327451|NCT03685487|OTHER|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
48490511|NCT05060133|PROCEDURE|Orthognathic Surgery|Surgical corrections of dentofacial deformities and malocclusions.
48490512|NCT01393457|DRUG|levodopa/carbidopa|800/200 mg/d
48490513|NCT01393457|DRUG|Ropinirole 2 mg/d|2 mg/d
48490514|NCT01393457|DRUG|Placebo|sugar pill
48121878|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
48121879|NCT00944333|DRUG|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
48121880|NCT04811716|DRUG|Pozelimab|Administered Sub-cutaneous (SC) per protocol
48121881|NCT04811716|DRUG|Cemdisiran|Administered SC per protocol
48121882|NCT04210180|DRUG|Varenicline|0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
48121883|NCT04210180|OTHER|e-cigarette|Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
48327452|NCT02943005|PROCEDURE|Rotator cuff repair|
48490515|NCT01393457|DRUG|Ropinirole 4 mg/d|4 mg/d
48327453|NCT05514145|DEVICE|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
48327454|NCT05514145|DEVICE|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
48327455|NCT02293096|DRUG|metoprolol succinate|
48327456|NCT02293096|GENETIC|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
48327457|NCT02293096|PROCEDURE|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
48327458|NCT02307656|DRUG|Atazanavir|
48327459|NCT02307656|DRUG|Cobicistat|
48327460|NCT02307656|DRUG|Active Pharmaceutical Ingredient|
48327461|NCT00321269|BEHAVIORAL|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
48327462|NCT00321269|BEHAVIORAL|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
48490516|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
48490517|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
48490518|NCT00845234|BEHAVIORAL|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
48490519|NCT03130218|OTHER|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
48490520|NCT06225557|OTHER|ERAS community recommendation|Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
48490521|NCT06225557|OTHER|Traditional postoperative care|Usual anesthesia and analgesia in elective cesarean section.
48650403|NCT06451458|BEHAVIORAL|Usual care|The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.
48650404|NCT03044899|PROCEDURE|All surgeries in adult patients|All surgeries in adult patients
47980527|NCT02406482|BEHAVIORAL|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
48327463|NCT01608282|BEHAVIORAL|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
48327464|NCT00377429|DRUG|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
48327465|NCT05708924|DRUG|FT538|FT538 IP at assigned dose level on Day 1, Day 8, and Day 15.
48490522|NCT02978820|OTHER|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
48490523|NCT02978820|OTHER|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
48490524|NCT06467773|RADIATION|Radiation: PET-MRI with [18F]-DPA-714|Radiation: PET-MRI with \[18F\]-DPA-714
48490525|NCT00940836|DRUG|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
48327466|NCT05708924|BIOLOGICAL|Enoblituzumab|Enoblituzumab 15 mg/kg IV begin on Day -6 and continuing once every 3 weeks beginning on Day 22 until disease progression or unacceptable toxicity - refer to Section 7.2.1 for timing of the enoblituzumab dose on Day 22 if steroid pre-meds are needed due to an infusion reaction with the 1st enoblituzumab dose as there is a 14 day ban on corticosteroid use after the last dose of FT538
48327467|NCT02992834|BIOLOGICAL|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
48327468|NCT02992834|BIOLOGICAL|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
48327469|NCT03173612|DRUG|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
48327470|NCT02858973|DRUG|Q203|
48327471|NCT02858973|DRUG|Placebo|
48121884|NCT05512858|BEHAVIORAL|sensory room|the room has dimmed lighting, sensing games, essential oils, picture books and cookbooks, two heavy blankets (weighing 9 kg and 11 kg), a rocking chair, and a vestibular plate. The occupational therapist will accompany the first entry into the room to create a sensory profile, adjust and instruct on the means, and write a treatment card. The treatment card will record the patient's choices and instructions for arranging the room, and it will be used by the staff members who will admit the patient as needed. Each patient will be able to stay in the room for self-treatment according to the individual treatment card prepared at the first sensory room treatment, up to half an hour.
48121885|NCT03437850|OTHER|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
48121886|NCT05948592|BIOLOGICAL|TP-102|Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (\>1x108 PFU/mL and \<1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
48121887|NCT05948592|OTHER|Placebo|Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
48121888|NCT02102841|PROCEDURE|Skin biopsy|
48121889|NCT02102841|PROCEDURE|Skin suction blister|
48121890|NCT02102841|BIOLOGICAL|Mantoux test|
48121891|NCT03409913|RADIATION|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
48121892|NCT00753480|DRUG|D4064A|
48121893|NCT03508518|OTHER|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
48121894|NCT03508518|OTHER|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
48121895|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental|Combination of pre-probiotic
48121896|NCT06013072|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Inert compound
48121897|NCT02328963|DRUG|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
48121898|NCT02328963|DRUG|mycophenolic acid|"Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
48327472|NCT06066957|DRUG|Letermovir 480 MG [Prevymis]|"Letermovir for CMV prophylaxis in thoracic organ transplant recipients.~Letermovir will be administered by oral administration, as per study protocol. The intended duration of therapy will be up to 365 days, depending on organ transplanted and donor and recipient CMV status. However, treatment may discontinued as discussed in Section 7.~Letermovir is dosed at 480mg daily for patients with CrCl \>10. Dose adjustment, as per package insert, is recommended in setting of co-administration of cyclosporine, with dose reduction of letermovir to 240mg daily. Missed doses of letermovir will not be made up."
48327473|NCT02201355|RADIATION|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
48327474|NCT01238406|DEVICE|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
48490526|NCT00940836|DRUG|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
48490527|NCT00940836|DRUG|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
48327475|NCT01238406|DEVICE|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
48490528|NCT00016718|DRUG|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily
47980528|NCT02988531|OTHER|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
47980529|NCT04101357|DRUG|BNT411|intravenous
47980530|NCT04101357|DRUG|Atezolizumab|intravenous
48121899|NCT02396316|DRUG|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
48490529|NCT00016718|DRUG|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
48490530|NCT00016718|DRUG|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
48490531|NCT05006872|DEVICE|DIABE-TEXT|Participants will receive 170 text messages in their mobile phones during twelve months.
48490532|NCT02581007|DRUG|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
48490533|NCT02581007|DRUG|Melphalan|
48650405|NCT04491175|DEVICE|DuoTherm|New multi-modal device comprising a sculpted low back plate with multiple sensory modalities held in place with a neoprene belt capable of being tightened with patient control of variations in sensory modalities.
48650406|NCT04491175|DEVICE|TENS|LG SMART TENS stimulator is a portable electrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
47980531|NCT04101357|DRUG|Carboplatin|intravenous
47980532|NCT04101357|DRUG|Etoposide|intravenous
48121900|NCT02396316|DRUG|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
48327476|NCT00102557|DRUG|Hydroxychloroquine|
48327477|NCT05535309|DRUG|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
48327478|NCT00680953|DRUG|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
48327479|NCT00680953|DRUG|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
48327480|NCT00680953|DRUG|Alendronate sodium hydrate|Oral tablet once a week for 24 months
48327481|NCT01102218|DRUG|Erythropoietin|Standard of Care
48327482|NCT01102218|DRUG|Erythropoietin|Standard of Care
48327483|NCT01102218|DRUG|Pentoxifylline|400 mg qd po for 6 months
48327484|NCT02183623|DRUG|Simvastatin|
48327485|NCT02183623|DRUG|10 mg BI 1356 BS|
48327486|NCT04904965|DRUG|Propofol Group 1|Propofol 2.0 mg/kg/hr per 10 min
48327487|NCT04904965|DRUG|Propofol Group 2|Propofol 4.0 mg/kg/hr per 10 min
48327488|NCT04904965|DRUG|Propofol Group 3|Propofol 6.0 mg/kg/hr per 10 min
48327489|NCT04904965|DRUG|Propofol Group 4|Propofol 8.0 mg/kg/hr per 10 min
48327490|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
48327491|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
48327492|NCT03162458|DRUG|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
48327493|NCT03162458|DRUG|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
48327494|NCT03697486|BEHAVIORAL|diet with different composition|"Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
48327495|NCT03159806|DEVICE|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
48327496|NCT02855320|OTHER|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
48327497|NCT02585726|DEVICE|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
48340163|NCT02846857|OTHER|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
48340164|NCT02846857|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
48121901|NCT04597684|PROCEDURE|Cementless Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cementless knees
48121902|NCT04597684|PROCEDURE|Cemented Total Knee Arthroplasty|Total Knee Arthroplasty (TKA) with cemented knees
48121903|NCT01319617|DEVICE|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
48121904|NCT00495885|DRUG|volinanserin (M100907)|oral, one tablet taken around bedtime
48121905|NCT00495885|DRUG|Placebo|oral, one tablet taken around bedtime
48121906|NCT01398124|BIOLOGICAL|Cyclin B1 Peptide|vaccine
48121907|NCT05328271|DIETARY_SUPPLEMENT|Beta-Aminoisobutyric Acid|All supplements provided to all research participants containing BAIBA, L-Valine or placebo will be procured and prepared in a similar manner. Briefly, beta-amino isobutyric acid (BAIBA), L-Valine (an amino acid), and a resistant starch commonly consumed in various foods will be used as test agents for this study protcol. All supplements (both BAIBA and Valine) as well as placebo are produced and provided by NNB Nutrition. A certificate of analysis is provided in the attachments for the BAIBA. All supplements (BAIBA, L-Valine, and placebo) will be administered in gelatin capsules and consumed with a specified amount of cold tap water. The same number of capsules will be administered each time. All doses will be capsulated by manufacturer prior to use in the study protocol.
48121908|NCT00168519|DRUG|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
48121909|NCT03299322|DRUG|Jia Wei Yang He granule|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
48121910|NCT03299322|DRUG|Jia Wei Yang He granule Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
48121911|NCT05830942|BEHAVIORAL|Walking Exercise|aerobic walking exercise using complex (cognitively engaging) walking tasks
48121912|NCT05830942|DEVICE|Prefrontal Active tDCS|20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
48121913|NCT05830942|DEVICE|Prefrontal Sham tDCS|30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session
48121914|NCT01362153|DRUG|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
48121915|NCT01362153|DRUG|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
48121916|NCT04153747|OTHER|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
48327498|NCT02007954|DEVICE|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
48327499|NCT04055987|BEHAVIORAL|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
48490534|NCT02581007|DRUG|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
48490535|NCT02581007|PROCEDURE|peripheral blood stem cell transplant|
48490536|NCT02788149|DEVICE|Ultrasound Exam|Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
48121917|NCT04153747|OTHER|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
48121918|NCT04153747|OTHER|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
48121919|NCT04153747|DIAGNOSTIC_TEST|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
48121920|NCT01957124|PROCEDURE|PRF (Platelet-Rich Fibrin)|
48121921|NCT05193695|OTHER|Treadmill exercise|the patients walked on a treadmill for 20 minutes after dry needling, with an inclination of 5 degrees and at a speed at which the perceived exertion was 5 according to the Borg CR10 scale (Chen et al., 2002)
48121922|NCT01945125|OTHER|rhTSH Group|Patients receiving rhTSH for RIT stimulation
48121923|NCT04525651|DEVICE|Digital Acupuncture Manipulation Therapeutic Instrument|The device is based on the characteristics of traditional acupuncture manipulation of Shanghai School of Traditional Chinese Medicine, and absorbs the information of the techniques of famous experts, modulates the stimulation waveform of the electroacupuncture device by modulating the signal, and realizes the digitization of acupuncture technique information.
48121924|NCT04525651|OTHER|Manual Acupuncture|Manual acupuncture to acheive de qi.
48121925|NCT04525651|OTHER|Sham Acupuncture|Sham acupuncture to avoid de qi.
48121926|NCT03437369|DRUG|Ivabradine Oral Tablet|The target dose is 10 to 15 mg / day, administered orally in two doses
48121927|NCT03437369|OTHER|Standard of Care treatment|The study drug will be compared with the standard of Care treatment
48121928|NCT00011986|DRUG|Paclitaxel|Given IV
48327500|NCT04385147|OTHER|Endoscopic management according to standard of care|Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
48327501|NCT02271009|DRUG|AllerT|Ultrafast immunotherapy
48490537|NCT02788149|DEVICE|Polysomnography|"Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as \>50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr."
48490538|NCT05857826|OTHER|soft tissue release|Patient will be asked to lie in hook lying position using a clean glove will apply some water based lubricant gently sweep vaginal muscle from superficial to deep until find a trigger point press it and release it using circle motion for 1 to 2 minute until the trigger point is completely released.
48490539|NCT05857826|OTHER|vaginal dilators|Vaginal dilators will be used according to the patient's condition starting from small sizes to the wider ones.
48490540|NCT05626699|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
48490541|NCT03567382|DRUG|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
48490542|NCT03567382|BIOLOGICAL|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
48490543|NCT00732433|PROCEDURE|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
48490544|NCT04614623|DEVICE|AHCL pump|Advanced Hybrid Closed Loop (AHCL) pump automatically adjusts insulin infusion rate of pump customized to patient's needs to reduce occurrence of hypo and hyperglycemia
48490545|NCT04614623|OTHER|Video conferencing Application|Video conferencing application will be used to enhance communication between participant and parent with the study certified diabetes educator (CDE) nurse coordinator. These individualized sessions will be designed to help the family with solving diabetes management problems to enhance glycemic control
48490546|NCT00377507|DIETARY_SUPPLEMENT|catechin extracts|catechin extracts solution
47973058|NCT01548651|DRUG|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
47973059|NCT01548651|DRUG|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
47973060|NCT01786798|DEVICE|Transvaginal sonography|"Transvaginal sonography will be performed to:~* measure the endometrial thickness~* detect the endometrial pattern"
47973061|NCT00949520|OTHER|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
47973062|NCT00949520|OTHER|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
47973063|NCT02563444|DEVICE|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
47973064|NCT05870540|DRUG|BPL-003|A single dose administered intranasally
48121929|NCT00011986|DRUG|Carboplatin|Given IV
48121930|NCT00011986|DRUG|Gemcitabine Hydrochloride|Given IV
48327502|NCT02271009|DRUG|Placebo|placebo control
48327503|NCT04585451|DIAGNOSTIC_TEST|ALGOS System|A Quantitative Electroencephalography (QEEG) based pain biomarker assessment that scales with patient reported Numeric Rating Scale (NRS)
48327504|NCT05268705|OTHER|7-day diet|The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
48327505|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
48327506|NCT05268705|OTHER|7-day diet|The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
48121931|NCT00011986|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|
48121932|NCT00011986|DRUG|Topotecan Hydrochloride|Given IV
48121933|NCT00011986|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48121934|NCT05531708|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: Anti-mesothelin CAR-T cells are autologous genetically modified T cells. Cells will be infused intravenously.
48121935|NCT05531708|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
48121936|NCT05531708|DRUG|Cyclophosphamide|D-7 and D-6: Cyclophosphamide (60 mg/kg/day) will be administered intravenously for 2 days.
48121937|NCT02436213|OTHER|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
48121938|NCT02436213|PROCEDURE|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
48121939|NCT00373373|DRUG|Sorafenib|2 x 400 mg/d
48121940|NCT00373373|DRUG|Placebo|Chemotherapy + Placebo
48121941|NCT05765019|OTHER|Spinal mobilization|Spinal mobilization and core stabilization exercise
48121942|NCT05765019|OTHER|Core stabilization exercise|Stabilization exercises for the spine
48121943|NCT03163212|DIETARY_SUPPLEMENT|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
48327507|NCT03874754|OTHER|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate \[HR\], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
48490547|NCT00197392|DEVICE|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
48490548|NCT00197392|DEVICE|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
48490549|NCT01366378|DRUG|methylnaltrexone|
48121944|NCT04521530|OTHER|immediate functional implant loading|Patients will undergo implant placement and a minimum of 35 Ncm reading with the graded torque wrench. Temporary crowns in functional occlusion were cemented.
48121945|NCT04521530|OTHER|immediate non functional implant loading|implant will be placed into the site following the manufacturer's protocol making sure to have a minimum of 35 Newton centimeter reading with the degraded torque wrench. Non-functional temporary crowns were cemented.
48121946|NCT01896310|DEVICE|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
48121947|NCT02709850|DRUG|IONIS ANGPTL3-LRx|
48121948|NCT02709850|DRUG|Placebo|0.9%NaCl, water, riboflavin
48121949|NCT03020979|DRUG|Apatinib|Patients will take 500mg apatinib daily orally.
48121950|NCT00233038|PROCEDURE|Ethanol injection into a cyst|
48121951|NCT02200523|DEVICE|SARA electrode|
48121952|NCT02200523|DEVICE|Gold cup|
48121953|NCT00901901|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily
48121954|NCT00901901|DRUG|Erlotinib (Tarceva)|Erlotinib 150 mg once daily
48121955|NCT00901901|DRUG|Placebo|Matching erlotinib placebo 150 mg once daily
48121956|NCT00168649|DRUG|Vitamin A|
48121957|NCT03022812|OTHER|Neck-specific exercise|Neck-specific exercise
48121958|NCT02496377|DRUG|ferrous glycine sulfate Tardyferon|
48121959|NCT02496377|DRUG|Epoetin Alfa|
48121960|NCT02496377|DRUG|ferric carboxymaltose Ferinject|
48121961|NCT03072914|PROCEDURE|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
48121962|NCT03665779|DRUG|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
48121963|NCT03665779|DRUG|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
48121964|NCT03969524|DEVICE|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
48121965|NCT01211405|DRUG|Low dose MDMA|30 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg MDMA 1.5 to 2 hours later
48650407|NCT06241014|OTHER|Mulligan Mobilization and Sling Exercises|Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
48650408|NCT06241014|OTHER|Mulligan Mobilization|Mulligan Mobilization
48121966|NCT01211405|DRUG|Medium dose MDMA|75 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg MDMA 1.5 to 2 hours later
48121967|NCT01211405|DRUG|Full dose MDMA|125 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 62.5 mg MDMA 1.5 to 2 hours later
48121968|NCT01211405|BEHAVIORAL|Therapy|Non-directive therapy during each session
48327508|NCT02173392|DRUG|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
48327509|NCT02879916|DRUG|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
48327510|NCT02879916|DRUG|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
48327511|NCT05365009|DIAGNOSTIC_TEST|Multidisciplinary aproach|regular tests
48490550|NCT02505490|OTHER|Television|The purpose is to determine whether television impacts liking of food.
48490551|NCT02505490|OTHER|No Television|The purpose is to determine whether the lack of television impacts liking of food.
48490552|NCT04219683|PROCEDURE|Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap|Using Free Fibula Flap for reconstruction of mandibular segemental defect
48490553|NCT05757882|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
48490554|NCT05757882|OTHER|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
48121969|NCT04072653|PROCEDURE|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
48121970|NCT02330926|OTHER|standard care|
48121971|NCT02330926|OTHER|nutritional supplements and advice|
48121972|NCT02330926|OTHER|home-based self-assisted exercise program|
48121973|NCT02330926|DRUG|Ibuprofen|
48327512|NCT02667548|PROCEDURE|PCI|percutaneous coronary intervention
48327513|NCT03624218|BEHAVIORAL|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
48327514|NCT05896046|DRUG|SHR2554+ SHR1701|SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
48327515|NCT05896046|DRUG|SHR-1701|Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
48327516|NCT00154167|DRUG|NV-101 (phentolamine mesylate solution)|
48327517|NCT04961918|PROCEDURE|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
48327518|NCT02138396|DRUG|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
48327519|NCT02138396|DRUG|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
48327520|NCT02138396|DRUG|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
48327521|NCT00003077|DIETARY_SUPPLEMENT|omega-3 fatty acid|
48327522|NCT04949724|OTHER|translation and adaptation study|translation and adaptation study
48327523|NCT02882815|DEVICE|IrisFIT PFO Occluder|
48327524|NCT04529434|OTHER|Star Homes|110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight \& durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
48327525|NCT04529434|OTHER|Traditional African houses|A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
48490555|NCT05224284|OTHER|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
48490556|NCT03733210|DRUG|Panitumumab-IRDye800|30 mg administered intravenously (IV)
48490557|NCT03733210|DRUG|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
48490558|NCT03733210|DEVICE|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
48490559|NCT03733210|DEVICE|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
48490560|NCT03733210|DEVICE|Explorer Air camera|Fluorescence camera manufactured by SurgVision
48490561|NCT03733210|DEVICE|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
48490562|NCT03733210|DEVICE|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
48490563|NCT03733210|DEVICE|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
48650409|NCT06673901|DEVICE|Measurments|Each angle was measured three times, and the mean was calculated to represent the data used for statistical analysis. The assessment position for all measurements was relaxed, comfortable standing position and wearing loose clothing, bare feet, and one foot apart between two feet on a level floor in the same room of the same building, at the same time of day. There was a fixed point in the wall, and the woman was instructed to look at it during the assessment; this point adjusts at the level of her eyes. No specific instructions were provided to the females regarding posture so that measurements during a normal standing position. Data was recorded in a data-collecting sheet.
48327526|NCT04718324|OTHER|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
48327527|NCT04718324|OTHER|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
48327528|NCT05543642|BIOLOGICAL|Hepatitis A vaccine|Vaccination series administered to prevent hepA infection.
48327529|NCT05543642|BIOLOGICAL|Diphtheria, pertussis, and tetanus booster vaccine|Vaccination booster administered to prevent diphtheria, pertussis, and tetanus
48327530|NCT01374217|DRUG|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
48327531|NCT01374217|DRUG|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
48327532|NCT01374217|DRUG|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
48327533|NCT01374217|DRUG|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
48327534|NCT06339333|BEHAVIORAL|ACT Now GAIN Later|ACT Now GAIN Later is a Psychologist Guided Self Help Parenting Programme. This has been developed by HSE Senior psychologist,. Dr. Michelle Howard to help parents manage challenging behaviors in their children. Parents of children who are referred to HSE Psychology Services with behavioural difficulties are invited to participate in this 7 week programme.
48327535|NCT06339333|OTHER|Control Group|Waitlist Group
48490564|NCT03733210|DEVICE|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
48490565|NCT03733210|DEVICE|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
48327536|NCT04046445|DRUG|ATP128|5-6 SC injections
48327537|NCT04046445|DRUG|BI 754091|≥ 7 IV infusions
48327538|NCT04046445|DRUG|VSV-GP128|1 single IV injection
48327539|NCT02600741|OTHER|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
48327540|NCT02600741|OTHER|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
48327541|NCT02600741|DRUG|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
48327542|NCT02600741|DRUG|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327543|NCT02600741|DRUG|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327544|NCT02600741|DRUG|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327545|NCT02600741|DRUG|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48490566|NCT03733210|DEVICE|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
48490567|NCT03733210|DEVICE|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
48490568|NCT03733210|DEVICE|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
48490569|NCT00555802|OTHER|exercise|exercise
48490570|NCT00148330|DRUG|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\]) was injected into the vitreous under sterile conditions in a minor procedures area.
48327546|NCT02600741|DRUG|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327547|NCT02600741|DRUG|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327548|NCT02600741|DRUG|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327549|NCT02600741|DRUG|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327550|NCT02600741|DRUG|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327551|NCT02600741|DRUG|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327552|NCT02600741|DRUG|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327553|NCT02600741|DRUG|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48340165|NCT02846857|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
48327554|NCT02600741|DRUG|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48121974|NCT06075069|DEVICE|Feeding appliance|A preliminary alginate impression was made using wax stock tray to get a preliminary cast and construct a self-cure acrylic custom-made tray. A Medium viscosity rubber base impression material was used for making final impression which in turn will be poured to obtain a master cast. On this master cast, a feeding appliance will be constructed. Readymade facebow with two straight side length of hard, rounded, of 2mm diameter, 15cm length Nickel-Chrome wire with omega loops (at the end of the wire) was used to form extra-oral wings to be used as a retentive aid to maintain the prosthesis in situ. The appliance was fabricated in clear acrylic resin then finished and polished. A small piece of cold cure acrylic resin was added and adapted to the omega loops and manipulated to follow the checks contour.
48121975|NCT00921154|DRUG|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
48121976|NCT05965388|DRUG|nucleoside analogues or interferon|ETV、TDF、TAF、TAF、IFN-a-2b
48121977|NCT00206986|DRUG|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
48121978|NCT00206986|DRUG|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
48121979|NCT05085067|OTHER|auto-crossed-linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
48121980|NCT00840177|DRUG|cytarabine|1.5 g/m2/day given by continuous IV on days 4-7
48121981|NCT00840177|DRUG|idarubicin|12 mg/m2/day given intravenously over 10-15 minutes on days 4-6
48327555|NCT02600741|DRUG|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327556|NCT02600741|DRUG|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327557|NCT02600741|DRUG|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327558|NCT02600741|DRUG|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327559|NCT02600741|DRUG|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327560|NCT02600741|DRUG|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327561|NCT02600741|DRUG|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
48327562|NCT03516409|DIETARY_SUPPLEMENT|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~* Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~* DHA + EPA: \>1mg per sachet~* Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
48327563|NCT03516409|DIETARY_SUPPLEMENT|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
48121982|NCT00840177|DRUG|pravastatin sodium|1,280 mg/day given orally on days 1-8
48121983|NCT03751449|OTHER|Educational Intervention|Receive nutrition education
48121984|NCT03751449|BEHAVIORAL|Exercise Intervention|Complete home-based aerobic and resistance exercise program
48121985|NCT03751449|OTHER|Quality-of-Life Assessment|Ancillary studies
48121986|NCT03751449|OTHER|Questionnaire Administration|Ancillary studies
48121987|NCT00859794|OTHER|fMRI|Subjects will perform cognitive tasks during MRI scanning sessions to gather data about cognitive functions.
48121988|NCT00859794|OTHER|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsychological evaluations for analysis.
48121989|NCT00859794|OTHER|Additional electrode implantation|Subjects will typically have between 100-300 electrodes implanted as part of their surgery. Additional electrodes will be implanted that are able to record from smaller, more specific parts of the brain. This will allow for better understanding of how the brain is wired.
48121990|NCT00859794|OTHER|Electrical brain stimulation|Intracranial or extracranial electrodes will be used to deliver electrical brain stimulation (amplitude 0.5-8.0mA) or sham stimulation of between 0.4 and 3000 milliseconds during cognitive task periods.
48340166|NCT02846857|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
48490571|NCT00249691|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
48327564|NCT05224154|BEHAVIORAL|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).
48327565|NCT05224154|BEHAVIORAL|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
48327566|NCT04686318|DIAGNOSTIC_TEST|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~* Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~* Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~* Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
48327567|NCT01077388|BEHAVIORAL|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
48490572|NCT00249691|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
48490573|NCT05000970|DEVICE|blood pressure cuff PLUS tablet|all arms
48490574|NCT05000970|OTHER|Telehealth Consult|Telehealth consult with an RN
48327568|NCT04934306|OTHER|Nasometry|Repetition of several stimuli (syllables, sentences ) in the microphones of the Nasometer
48327569|NCT03591094|DRUG|PTI-428|Active
48327570|NCT03591094|DRUG|Placebo|Placebo
48327571|NCT01368666|DEVICE|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
48490575|NCT00569621|DRUG|Moxaverine|intravenous administration
48490576|NCT00569621|DRUG|physiological saline|intravenous administration
48490577|NCT01297374|BEHAVIORAL|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
48490578|NCT03722095|DEVICE|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
48490579|NCT03722095|DEVICE|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
47973065|NCT01259908|PROCEDURE|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
47973066|NCT00844389|DEVICE|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
48490580|NCT03722095|DEVICE|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
48490581|NCT03697265|DRUG|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
48490582|NCT03697265|DRUG|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
48490583|NCT03697265|DRUG|Placebo|Subcutaneous (SC) adminstration
48490584|NCT02932228|OTHER|ImPACT|"The ImPACT team offers the following services:~* An intensive intake process, including a home visit if deemed appropriate~* Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~* After-hours access to on-call team member in order to avoid unnecessary emergency care~* Optimization of chronic condition management using evidence-based protocols~* Navigation of transitions between hospital and home~* Coordination of specialty care, including contact with specialists when indicated~* Rapid response to signs of health status deterioration or other stressful events~* Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
48490585|NCT00234455|DEVICE|drug eluting-stent|PCI
48490586|NCT00234455|DEVICE|drug-eluting stent|PCI
48490587|NCT03026855|BIOLOGICAL|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
47973067|NCT00844389|DEVICE|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
47973068|NCT03100032|BIOLOGICAL|NVD-001|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
47973069|NCT03100032|PROCEDURE|Standard of Care|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
47973070|NCT06325020|OTHER|The assessment of patients with possible angina using the ORACLE pathway|"Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events."
48650410|NCT05894655|BEHAVIORAL|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
48121991|NCT04064866|DEVICE|High yield pure PRP|"The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample."
48121992|NCT04064866|OTHER|Placebo|Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
48327572|NCT04702048|DRUG|Aflibercept Injection|Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
48327573|NCT04702048|DRUG|Sham injection|Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
48327574|NCT06195501|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing (FEES) ; Transesophageal Ecocardiography (TEE)|"Flexible Endoscopic Evaluation of Swallowing (FEES):~FEES is performed for analysis of swallowing ability according to the same methodology as in the initial trial: one day before a TEE and max. 4 hours after TEE. Before the FEES anticongestive nose drops are applied and the nostrils are anaesthetized by applying a lidocaine gel via cotton sticks. During the FEES examination the participants sit upright and are asked to swallow various consistencies: FEES is aborted in case of aspiration of any of the consistencies during the examination.~Transesophageal Ecocardiography (TEE):~For the TEE anesthesia is applied via intravenous injection of propofol or a combined anesthesia, through intravenous application of propofol and local anesthesia, using lidocaine spray. All patients undergoing a TEE are sober before and at least two to four hours after TEE."
48327575|NCT04509804|OTHER|non-interventional|non-interventional
48327576|NCT00412906|DRUG|Escherichia Coli Endotoxin|
48327577|NCT03385174|OTHER|Carbon monoxide|Carbon monoxide inhalation
48327578|NCT04791267|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
48121993|NCT04064866|DEVICE|ProPlaz PPC|Trademarked name of an FDA-cleared product
48121994|NCT05537675|OTHER|To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax|Measure SUVmean (Standard Uptake Value) and SUVmax on PET exams
48121995|NCT02566902|DEVICE|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
48121996|NCT02566902|DEVICE|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
48121997|NCT02566902|DRUG|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
48121998|NCT02566902|PROCEDURE|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
48121999|NCT02566902|PROCEDURE|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
48122000|NCT01615393|DRUG|ribavirin [Copegus]|Single oral dose of 400 mg tablets
48327579|NCT01615796|DRUG|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
48327580|NCT01615796|DRUG|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
48327581|NCT00992004|DIETARY_SUPPLEMENT|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
48327582|NCT00040547|DRUG|Farnesyl Protein Transferase Inhibitor|
48327583|NCT00390247|DRUG|thalidomide|
48327584|NCT00272636|PROCEDURE|Radiofrequency catheter ablation|
48327585|NCT00272636|DRUG|Amiodarone and cardioversion|
48327586|NCT04041908|OTHER|Experimental Product|2 sachets per day
48122001|NCT01615393|DRUG|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
48340167|NCT02846857|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
48122002|NCT00142285|DRUG|Zinc sulphate (20 mg)|
48327587|NCT04775472|PROCEDURE|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
48327588|NCT04775472|PROCEDURE|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
48327589|NCT03605199|DRUG|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
48327590|NCT01283997|OTHER|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
48327591|NCT01283997|DRUG|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
48327592|NCT02329002|DEVICE|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
48327593|NCT01445106|DRUG|Nelfinavir|
48327594|NCT01445106|DRUG|Nelfinavir Mesylate|
48327595|NCT03933514|OTHER|Plaque control|Children were instructed about the hygiene procedures
48327596|NCT00237445|DRUG|telithromycin|
48327597|NCT00237445|DRUG|azithromycin|
48327598|NCT04799353|DRUG|Budigalimab|Subcutaneous (SC)
48327599|NCT04799353|DRUG|Placebo|Subcutaneous (SC)
48327600|NCT04799353|DRUG|Budigalimab|Intravenous (IV)
48650411|NCT05894655|BEHAVIORAL|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
48327601|NCT04799353|DRUG|Placebo|Intravenous (IV)
48327602|NCT01802554|BEHAVIORAL|Pleasant Events Program (PEP)|Behavioral Activation Therapy
48327603|NCT01802554|BEHAVIORAL|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
48327604|NCT05942729|OTHER|Determine the etiology of hypokinetic and hypertrophic heart disease on transthoracic echocardiography data alone|The origin of the pathology will have been previously diagnosed for each patient thanks to complementary examinations performed as part of routine care (e.g. cardiac CT, cardiac MRI, coronary angiography, thorough biology, nuclear medicine). This information will be used (i) to guide the learning of the AI method developed during the project from a sub-population (80% of the collected database will be used to train the algorithms); (ii) to serve as an evaluation criterion from a test sub-population (remaining 20% of the collected database)
48327605|NCT04387526|DRUG|(SOF and DCV)|
48327606|NCT04387526|DRUG|(SOF, DCV, and RBV)|
48327607|NCT06184737|BEHAVIORAL|iSIPsmarter|iSIPsmarter is a technology-based behavioral and health literacy intervention. It is comprised of six Internet-delivered Cores, an integrated short message service (SMS) strategy to engage users in tracking SSB behaviors, and the incorporation of a cellular enabled scale for in-home weight tracking. Participants will be prompted (via email or text) to self-monitor their sugar-sweetened beverage intake. iSIPsmarter is a highly interactive, structured, and self-guided program that uses strategies previously proven to promote behavior change. iSIPsmarter also incorporates a stepped care approach to re-engage users who struggle to complete components.
48327608|NCT06184737|BEHAVIORAL|Patient Education (PE)|The PE website will include scientifically accurate information that is typical of nutrition education websites and will include information about SSB recommendations, types of SSB and portion size, SSB-related health risks, energy balance information, identifying personal motivators and barriers to reducing SSB intake, interpreting SSB nutrition labels, and recognizing media influences and misclaims in SSB advertisements, as well as printable forms to track SSB and weight. Unlike iSIPsmarter, the content will not be tailored and will be presented all at once.
48327609|NCT03467295|PROCEDURE|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
48327610|NCT03467295|PROCEDURE|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
48327611|NCT06467123|OTHER|Tissue Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
48340168|NCT04314492|PROCEDURE|Tonsillectomy|Intracapsular removal of tonsillar tissue (\>90%) with coblation
48340169|NCT02451254|PROCEDURE|circumferential ablation|circumferential ablation of the pulmonary veins
48650412|NCT05894655|BEHAVIORAL|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
48327612|NCT06467123|OTHER|Biopsychosocial Intervention|Participants will attend eight sessions. During each session, participants will receive education on pain neuroscience education, stress management, and maintaining physical activity. Participants will complete shoulder stretching and strengthening exercises according to a graded exercise protocol.
48327613|NCT03255265|OTHER|no interventions|no interventions
48122003|NCT04414995|DRUG|Paracetamol injection and Ibuprofen injection|Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
48327614|NCT05514509|DRUG|APRETUDE|Available as intramuscular injection.
48327615|NCT05514509|DRUG|Cabotegravir tablet|Available as marketed orally administered tablets.
48490588|NCT05582252|OTHER|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
48490589|NCT03592342|DRUG|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
48490590|NCT03110601|DEVICE|Control - Conventional SCS|Conventional SCS Parameters
48490591|NCT03110601|DEVICE|Test - Stimgenics SCS|Stimgenics SCS Parameters
48490592|NCT05727917|DRUG|Hetrombopag|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response.The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
48490593|NCT05727917|OTHER|placebo|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days
48327616|NCT03805555|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
48327617|NCT03805555|PROCEDURE|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
48490594|NCT04124666|BIOLOGICAL|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
48490595|NCT04208074|OTHER|Exercise Intervention|Participants will exercise under the supervision of expert personal trainers and follow an optimized exercise program tailored to the strength and fitness level of each participant. Participants will exercise for 16 weeks; 2 days a week at the gym for an hour and 2 days of the week at home for 45 minutes.
48490596|NCT05079386|DEVICE|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
48490597|NCT06339320|PROCEDURE|Endoscopic Sleeve Gastroplasty (ESG)|The ESG procedure uses the Apollo OverStitch endoscopic suturing device, which has received FDA authorization as a minimally invasive procedure to facilitate weight loss for adults with who have been unable to lose weight or maintain weight loss through more conservative measures such as diet and exercise. This procedure involves endoscopic suturing to reduce the volume of the stomach endoscopically by approximately 70% to 80% its original size. Using the Apollo OverStitch or APOLLO ESG and ESG SX Systems, the ESG procedure is performed be folding the stomach in on itself (endoscopically) and placing full-thickness sutures through the wall of the stomach to maintain this narrow, smaller size. Following the procedure, the new stomach appears similar to the surgical sleeve stomach, although the procedure is considered less invasive with fewer complications compared to a surgical sleeve gastrectomy.
48490598|NCT06339320|DEVICE|Apollo OverStitch endoscopic suturing device|Apollo ESG is the first and only device to be authorized by the FDA to perform the ESG procedure to facilitate weight loss in patients with obesity (BMI 30 to 50 kg/m2). The FDA identifies this generic type of device as an Endoscopic suturing device for altering gastric anatomy for weight loss.
48490599|NCT05474274|OTHER|Machine learning algorithms|Machine learning techniques to rank order physiologic variables obtained via the wearable and handheld devices as well as remove low-importance and redundant variables to accurately determine postoperative pain intensity in outpatients
48490600|NCT02106650|DRUG|Folotyn and Leucovorin|
48490601|NCT02106650|DRUG|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
48327618|NCT02881710|OTHER|contrast product used to assess biomarkers variations|
48122004|NCT04414995|DRUG|Paracetamol injection and normal saline|Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
48122005|NCT04414995|DRUG|Ibuprofen Injection and normal saline|Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
48122009|NCT04861233|OTHER|No Intervention|This is a non-interventional study.
48327619|NCT03604068|DEVICE|RecoveryRx|A pulsed shortwave therapy medical device
48327620|NCT03604068|DEVICE|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
48327621|NCT06299579|DRUG|GD-11 for injection test group|The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
48327622|NCT06299579|DRUG|Placebo control group|The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
48327623|NCT02362542|DEVICE|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
48327624|NCT02289274|DRUG|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
48122010|NCT00034528|DRUG|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
48122011|NCT00034528|DRUG|Fludarabine|30 mg/m\^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
48122012|NCT00034528|DRUG|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
48327625|NCT02289274|DRUG|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
48327626|NCT01989754|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
48327627|NCT01989754|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
48327628|NCT01989754|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
48327629|NCT00892957|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
48327630|NCT00892957|OTHER|Surgical gauze pads|Manual compression with surgical gauze pads
48327631|NCT00661102|DRUG|Corticosteroids|As prescribed
48327632|NCT00661102|DRUG|Placebo|As prescribed
48327633|NCT00661102|DRUG|capecitabine [Xeloda]|As prescribed
48327634|NCT00661102|DRUG|dexpantenol [Bepantol]|As prescribed
48327635|NCT03549858|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
48327636|NCT05880407|PROCEDURE|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
48327637|NCT05880407|PROCEDURE|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
48327638|NCT00771173|DRUG|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
48122013|NCT00034528|DRUG|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
48327639|NCT00771173|OTHER|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
48327640|NCT00517335|PROCEDURE|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
47973071|NCT00075010|DRUG|Decitabine|15 mg/m\^2 by vein over 1 hour times 10 days
47973072|NCT00075010|DRUG|Valproic acid|20 mg/kg given orally daily for 10 days
48122014|NCT06186492|DRUG|WVE-006|RNA editing oligonucleotide
48122015|NCT04455633|DRUG|LX9211 low dose|11-week assessment period
48122016|NCT04455633|DRUG|LX9211 high dose|11-week assessment period
48327641|NCT03260972|DRUG|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
48327642|NCT03260972|DRUG|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
48327643|NCT03930420|BEHAVIORAL|Connect to Wellness|The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.
47973073|NCT05229380|DRUG|Saccharin test|Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
48490602|NCT02106650|DRUG|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
47973074|NCT03793738|PROCEDURE|Anterior component separation|
47973075|NCT03793738|PROCEDURE|Posterior component separation|
48122017|NCT04455633|DRUG|LX9211 Placebo|11-week assessment period
48122018|NCT03657030|DRUG|CVN424|SAD / MAD
48122019|NCT03657030|DRUG|Placebo|Placebo
48122020|NCT03113617|PROCEDURE|Computed Tomography|Undergo PET/CT
48122021|NCT03113617|DRUG|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
48122022|NCT03113617|OTHER|Laboratory Biomarker Analysis|Correlative studies
48122023|NCT03113617|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48122024|NCT02446145|DRUG|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
48327644|NCT06259357|OTHER|Protocolized protective mechanical ventilation in prone position|Prone Position: Study subjects randomized to the intervention group will be placed and maintained in prone position for at least 16 hours/day until the time of organ procurement or decline (typically 24-48 hours after donation consent) or the time that the lungs are declined for transplant.
48340170|NCT02451254|DEVICE|SVT ablation|SVT ablation
48122025|NCT02446145|DRUG|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
48650413|NCT06586827|OTHER|VCU-RRTC Online Course|"Approved by ACRE as its accrediting body and has been offered virtually through the VCU RRTC for over 15 years. The course currently entails:~i. Six modules ii. Six online discussion boards iii. Assignments in each module iv. One quiz per module v. Final assignment"
48122026|NCT06497959|DRUG|SonoVue|Placental contrast ultrasound using SonoVue by maternal intravenous injection
48327645|NCT03737045|OTHER|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
48327646|NCT06026007|OTHER|advices|each pregnant woman was advices how to elevate her legs and daily positions to elevate edema
48327647|NCT06026007|OTHER|Traditional physical therapy|each pregnant woman was advised about daily routine in addition to circulatory exercise
48650414|NCT06586827|OTHER|Zoom Technical Assistance Sessions (6 total)|Technical Assistance sessions will be provided to small groups of participants of 5-7 via Zoom technology. There will be one virtual TA session for each of the six modules that will last for 1 hour. The TA sessions will be provided by a trained SE expert/ mentor. The TA sessions will have instructional plans so that they are delivered consistently and will align with the associated module's content and will entail application and discussion that facilitates implementation and reflection of the material.
48650415|NCT06096857|DRUG|Roseomonas mucosa (RSM2015) and Cardamom seeds|Freeze dried packet to be reconstituted in water
47973076|NCT05101005|DEVICE|Drug-Coated Balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions.
47973077|NCT05101005|DEVICE|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
47973078|NCT01872988|DRUG|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
48327648|NCT06026007|OTHER|Acupressure|each pregnant woman was advised about daily routine in addition to acupressure therapy
48650416|NCT06096857|DRUG|Placebo (sucrose)|Freeze dried packet to be reconstituted in water
48650417|NCT01440751|DEVICE|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
48327649|NCT05566821|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
48327650|NCT03848611|DRUG|CM082 plus JS001|CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
48650418|NCT01440751|DRUG|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
47973079|NCT01872988|DRUG|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
47973080|NCT04766398|DRUG|KHK7791|oral administration
47973081|NCT04766398|DRUG|Placebo|oral administration
47973082|NCT02893878|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
48122027|NCT04728724|DRUG|Sintilimab|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
47973083|NCT04490538|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional transthoracic echocardiographic examination at the intensive care unit.
47973084|NCT04943315|PROCEDURE|Monolithic zirconia|posterior crowns
47973085|NCT04943315|PROCEDURE|Metal-ceramic|posterior crowns
47973086|NCT01038050|DRUG|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
47973087|NCT00003325|PROCEDURE|Sentinel lymph node mapping|Sentinel lymph node mapping
47973088|NCT00002096|DRUG|Zidovudine|
47973089|NCT00002096|DRUG|Didanosine|
48122028|NCT04728724|DRUG|Chemotherapy|"Neoadjuvant treatment stage: Sintilimab 200mg, q3w, i.v., 2-4 cycles; platinum-based chemotherapy (Non-squamus: Carboplatin AUC 5 + Pemetrexed 500mg/m2; Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2) q3w, i.v., 2-4 cycles, then receive chest CT evaluation.~Surgery stage: the patients will receive radical surgery after the neoadjuvant treatment.~Adjuvant treatment stage: according to the NCCN guidelines."
48122029|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
48122030|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed drink|Drink containing flaxseed mucilage
48122031|NCT01238744|DIETARY_SUPPLEMENT|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
48327651|NCT01064219|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
48340171|NCT00156013|DRUG|CLOFARABINE|4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles
48340172|NCT00550992|BIOLOGICAL|anti-thymocyte globulin|
48340173|NCT00550992|DRUG|asparaginase|
48340174|NCT00550992|DRUG|busulfan|
48340175|NCT00550992|DRUG|cyclophosphamide|
48122032|NCT01238744|DIETARY_SUPPLEMENT|Control drink|Control drink
48122033|NCT05042375|DRUG|camrelizumab + famitinib|Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
48122034|NCT05042375|DRUG|pembrolizumab|pembrolizumab 200 mg.
48122035|NCT05042375|DRUG|camrelizumab|Camrelizumab for injection, 200 mg.
48122036|NCT02402569|DEVICE|32 channels Deep Brain Stimulator|
48122037|NCT03953001|DEVICE|Adminstration Technique using Buzzy external distractor|External application of Buzzy distractor during administration of dental anesthetic
48122038|NCT03953001|DRUG|2% Lidocaine with 1:50,000 epinephrine|Local Dental anesthetic infiltration
48327652|NCT03846219|DRUG|IMU-838 (30 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
48340176|NCT00550992|DRUG|cyclosporine|
48340177|NCT00550992|DRUG|cytarabine|
48340178|NCT00550992|DRUG|daunorubicin hydrochloride|
48122039|NCT03953001|DRUG|Topical Anesthetic|20% Benzocaine gel was applied on the area of infiltration
48490603|NCT05675241|DIAGNOSTIC_TEST|Clinical examination of a dental implant|Clinical examination includes bleeding on probing, pocket depth, gingival biotype, suppuration, gingival index
48650419|NCT06313866|DIETARY_SUPPLEMENT|control|Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.
48122040|NCT00354653|DRUG|LAMIVUDINE|
48122041|NCT02932579|OTHER|Pharmacogenomic Testing|Saliva collection (5mL)
48122042|NCT02932579|DRUG|Ibuprofen|400 mg
48122043|NCT02932579|DRUG|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
48122044|NCT02932579|DRUG|acetominophen|650 mg
48650420|NCT06313866|OTHER|Electronuchal acupuncture group treatment|Electronuchal acupuncture
48650421|NCT06313866|OTHER|Smell therapy group treatment|nasal suction intervention with volatile oil of Acorus calamus
48650422|NCT06313866|OTHER|Electronuchal acupuncture combined with smell and inhalation therapy group treatment|On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.
48650423|NCT06313866|OTHER|Sham stimulation|In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.
48650424|NCT06675721|OTHER|Study Questionnaire|A survey questionnaire to assess factors related to vaccination adherence, including factors such as vaccine novelty, cost, and prior knowledge among vulnerable populations.
48490604|NCT05675241|DIAGNOSTIC_TEST|Radiological Examination|A standardized periapical radiograph in parallax technique will be taken.
48122045|NCT02932579|DRUG|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
48122046|NCT01571596|DRUG|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
48122047|NCT02094807|DRUG|NSAID|Will be used if other drugs are not tolerated.
48122048|NCT02094807|PROCEDURE|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
48122049|NCT02094807|DRUG|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
48122050|NCT02094807|DRUG|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
48122051|NCT02094807|PROCEDURE|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
48122052|NCT01424397|DRUG|SB-705498|12mg intranasal
48122053|NCT01424397|DRUG|FP|200ug intranasal
48122054|NCT01424397|DRUG|placebo|placebo intranasal
48122055|NCT04818931|DRUG|Cefazolin Injection|cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
47973090|NCT00002096|DRUG|Ganciclovir|
48122056|NCT04257071|BEHAVIORAL|Usual Care|The usual care for MS involves standard patient neurology visits and encounters with pharmacists, financial counselors and social workers if patients need any financial assistance with medication or other expenses.
48122057|NCT04257071|BEHAVIORAL|OOP Cost Communication and Optimization|OOP Cost Communication and Optimization includes personalized discussion of OOP cost estimates for treatment plan obtained through an online price transparency tool, personalized analysis of patients' expenses by financial counselor, and patient enrollment in any cost optimization opportunities for which patient is eligible using a comprehensive financial navigation program.
48122058|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms at the first medical examination|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
48122059|NCT03572075|PROCEDURE|pelvic floor physiotherapy|six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
48327653|NCT03846219|DRUG|IMU-838 (45 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
48327654|NCT03846219|DRUG|Placebo|"* Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
48327655|NCT03846219|DRUG|IMU-838 (10 mg/day)|"* Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
48122060|NCT03572075|PROCEDURE|standard care protocol|the treatment is the same as usual in our center
48327656|NCT04284280|DIETARY_SUPPLEMENT|Routine vs Selective use of Human Milk Donor Fortifier|Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
48327657|NCT01504048|PROCEDURE|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
48327658|NCT05783453|OTHER|Cosmetic study|"LIPIKAR BAUME LIGHT AP+M~* Formula: 2039055 06~* Aspect: Emulsion~* Batch nº: RAUO0063~* Expiry date: 10/2022~* Application area: Face and Body~* Application mode: Apply to face and body twice a day.~* Quantity of product to be applied: About 1 flask (400g) per month"
48327659|NCT05022745|OTHER|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
48327660|NCT03334474|OTHER||no intervention
48327661|NCT00311558|BIOLOGICAL|recombinant interferon alfa-2b|SSG x 5 week
48327662|NCT00311558|DRUG|sodium stibogluconate|SSG \& IFN
48327663|NCT00311558|DRUG|SSG & interferon|1 arm study with SSG \& interferon
48327664|NCT05929885|DRUG|Low Dose OXIRI (LD-OXIRI)|"The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status."
48327665|NCT00030615|DRUG|decitabine|Given IV
48327666|NCT00030615|OTHER|pharmacological study|Correlative studies
48327667|NCT00030615|OTHER|laboratory biomarker analysis|Correlative studies
48327668|NCT03071003|DRUG|SENS-401|Oral Administration
48327669|NCT03071003|DRUG|Placebo|Oral Administration
48327670|NCT01900756|BEHAVIORAL|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
48327671|NCT02967094|DRUG|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
48327672|NCT02967094|DRUG|Administration of water before upper endoscopy|
48490605|NCT05675241|DIAGNOSTIC_TEST|Peri-implant crevicular fluid sample collection|A sample of the peri-implant crevicular fluid will be collected using paper strip for 60 seconds. The sample of the fluid will be a resultant of inserting six different strips at the same time in six sites of the implant including mesiobuccal, midbuccal, distobuccal, distopalatal/distolingual, midpalatal/midlingual, mesiopalatal/mesiolingual sites of the implant.
48650425|NCT06370208|DIETARY_SUPPLEMENT|Probiotic Bactoblis® EVOL (Streptococcus salivarius eK12)|Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12
47973091|NCT00831168|BEHAVIORAL|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
47973092|NCT06334783|BIOLOGICAL|Autologous tumor-infiltrating lymphocyte cells|On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.
47973093|NCT04261348|OTHER|No intervention|There is no intervention
47980533|NCT01002703|DRUG|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
48122061|NCT03572075|DIAGNOSTIC_TEST|assessment of symptoms after four months|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
48122062|NCT00547352|DRUG|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
48122063|NCT00547352|DRUG|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
48122064|NCT03714815|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
48122065|NCT00704769|DRUG|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
48122066|NCT05660941|DRUG|Lispro|Ultra rapid Lispro
48122067|NCT05660941|DRUG|Lispro|Conventional Lispro
48122068|NCT05728008|DRUG|Ustekinumab|a human monoclonal antibody to interleukin IL 12/23 p40. It is indicated in the treatment of adult patients with moderately to severely active UC. The induction phase consists of approximately 6 mg/kg intravenous dose administration. After the induction, the maintenance phase consists of a 90mg subcutaneous dose every 8 weeks.
48122069|NCT05728008|DRUG|Tofacitinib|Jak inhibitor. It is indicated in the treatment of adult patients with moderately to severely active UC who have experienced inadequate response or have lost the response or who are intolerant to conventional therapy or to a biological agent. The induction phase consists of 10mg twice daily for 8 to 16 weeks. After the induction, the maintenance phase consists of 5mg x twice daily.
48122070|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\>FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)"
48122071|NCT00593697|DRUG|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
48122072|NCT02721134|OTHER|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
48122073|NCT05361733|DRUG|XFB-19|XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
48122074|NCT05361733|DRUG|Placebo|No active ingredient drug use to blind participants and investigators
48122075|NCT03866967|BIOLOGICAL|AK105|intravenous (IV) infusion
48122076|NCT05875714|DRUG|Apremilast|Apremilast (Otezla), oral medication Day 1: 10 mg in the morning. Day 2: 10 mg in the morning and 10 mg in the evening. Day 3: 10 mg in the morning and 20 mg in the evening. Day 4: 20 mg in the morning and 20 mg in the evening. Day 5: 20 mg in the morning and 30 mg in the evening Day 6: 30 mg twice daily Maintenance dosing: 30 mg twice daily
48122077|NCT00083902|DRUG|Thalidomide|
48122078|NCT00083902|DRUG|Dexamethasone|
48122079|NCT04295993|DRUG|Methylene Blue|The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.
47973094|NCT05784350|DRUG|fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone|"group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia."
47973095|NCT05205044|DIAGNOSTIC_TEST|Apelin-13, Apelin-36|Serum levels of Apelin-13 and Apelin-36
48122080|NCT04295993|DRUG|Norepinephrine infusion|The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
48122081|NCT05834270|DRUG|Single dose tamsulosin 0.4mg|Single dose tamsulosin 0.4mg
48122082|NCT05834270|DRUG|Double dose tamsulosin 0.4mg|Double dose tamsulosin 0.4mg
48122083|NCT01985334|DRUG|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
48122084|NCT01985334|DRUG|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
48122085|NCT01985334|DRUG|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
48122086|NCT01985334|DRUG|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
48122087|NCT01985334|DRUG|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
48327673|NCT00600028|DRUG|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
48327674|NCT00600028|DRUG|Placebo|Placebo 50-100 mg by mouth per day
48327675|NCT01277497|DRUG|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
48327676|NCT01277497|DRUG|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
48327677|NCT03909932|OTHER|Observational study : no intervention|Observational study : only exporting data
48340179|NCT00550992|DRUG|etoposide|
48340180|NCT00550992|DRUG|leucovorin calcium|
48340181|NCT00550992|DRUG|melphalan|
48340182|NCT00550992|DRUG|mercaptopurine|
48340183|NCT00550992|DRUG|methotrexate|
48340184|NCT00550992|DRUG|mitoxantrone hydrochloride|
48340185|NCT00550992|DRUG|pegaspargase|
48327678|NCT05891691|BEHAVIORAL|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
48327679|NCT02245451|DRUG|Tipranavir|
48327680|NCT02245451|DRUG|Ritonavir|
48327681|NCT02245451|DRUG|Methadone|
48327682|NCT01608399|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
48327683|NCT03833817|BEHAVIORAL|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
48327684|NCT01011036|DRUG|clobazam|test substance
48327685|NCT01011036|DRUG|clonazepam|positive control
48327686|NCT01011036|DRUG|tolterodine|active placebo
48327687|NCT05828732|OTHER|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
48327688|NCT05380349|DRUG|combinations of up to 3 FDA approved drugs from a panel of compounds|personalized drug combinations
48327689|NCT05367219|DEVICE|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
48327690|NCT06226688|PROCEDURE|Biofeedback device and other group control group|Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
48327691|NCT06226688|PROCEDURE|Control group|Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
48327692|NCT03721237|OTHER|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~1. volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~2. pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~3. PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
48327693|NCT04344262|DRUG|Atracurium Besylate regular dose|"Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2"
48650426|NCT06580938|BIOLOGICAL|PF-07921585|IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously
48327694|NCT04344262|DRUG|Atracurium Besylate minial dose|atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
48327695|NCT04480931|BEHAVIORAL|mHealth Intervention Group|Access to the mobile health application with exercise plans and education
48327696|NCT04480931|BEHAVIORAL|Educational Brochure|An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
48327697|NCT02395653|DRUG|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
48327698|NCT03569306|DEVICE|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
48327699|NCT03569306|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
48650427|NCT06580938|BIOLOGICAL|Sasanlimab|Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously
48490606|NCT04758663|BEHAVIORAL|Nap/wake conditions on memory|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
48327700|NCT01071096|DRUG|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
48327701|NCT01071096|DRUG|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
48327702|NCT03603834|DRUG|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
47980534|NCT01806545|BIOLOGICAL|SRM003|One time implant (2 SRM003 pieces) on surgery day.
48327703|NCT05872295|DRUG|IKS014|IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent.
48327704|NCT03809221|DRUG|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
48340186|NCT00550992|DRUG|prednisolone|
48340187|NCT00550992|DRUG|prednisone|
48340188|NCT00550992|DRUG|therapeutic hydrocortisone|
48490607|NCT04758663|BEHAVIORAL|Nap/wake conditions on overnight physiology|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
48490608|NCT00825136|BEHAVIORAL|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
48490609|NCT00825136|BEHAVIORAL|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
48490610|NCT01431352|DRUG|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
48122088|NCT01985334|DRUG|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
47973096|NCT02474459|DEVICE|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
47973097|NCT02474459|OTHER|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
48122089|NCT01985334|DRUG|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
48122090|NCT05035966|OTHER|Plasma β-amyloid 40 and 42 concentration|Plasma β-amyloid 40 and 42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).
48122091|NCT00062907|BIOLOGICAL|Recombinant DNA- pVAX/L523S|
48122092|NCT00062907|BIOLOGICAL|Recombinant adenovirus- Ad/L523S|
48122093|NCT00928824|DIETARY_SUPPLEMENT|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
48122094|NCT03426878|OTHER|Modified genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
48122095|NCT03426878|OTHER|Traditional genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
48122096|NCT00873405|PROCEDURE|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
48122097|NCT00873405|PROCEDURE|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
48122098|NCT06153810|DEVICE|Biofeedback stimulation|Delivery of the vibratory biofeedback stimulus
48327705|NCT05092295|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
48327706|NCT05092295|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
48327707|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
48327708|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
48327709|NCT03722914|DRUG|Benzonatate 200 mg|200 mg/pellet, 1pellet/time, 3times/day
48327710|NCT03722914|DRUG|blank control 0mg|0 mg/pellet, 1pellet/time, 3times/day
48327711|NCT00950976|OTHER|citrulline|TID for 5 days
47973098|NCT06229353|BIOLOGICAL|Gardasil 9|Prevent HPV-associated diseases and cancers
48327712|NCT00950976|OTHER|Lemonade|TID for 5 days
48327713|NCT02410096|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
48327714|NCT02410096|OTHER|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
48327715|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
48327716|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
48327717|NCT04016896|BEHAVIORAL|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
48327718|NCT04016896|OTHER|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
48327719|NCT03623425|DRUG|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
48327720|NCT03623425|DRUG|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
48340189|NCT00550992|DRUG|thioguanine|
48340190|NCT00550992|DRUG|vincristine sulfate|
48490611|NCT01431352|DRUG|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
48490612|NCT04016337|DIETARY_SUPPLEMENT|Beverages|The beverages were all made with lemon and maqui extracts, and different sweeteners
48490613|NCT02793570|OTHER|observational|
48490614|NCT01747720|DIETARY_SUPPLEMENT|Vitamin D3|Given orally
48490615|NCT01747720|DIETARY_SUPPLEMENT|Placebo|
48490616|NCT05991128|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
48490617|NCT05991128|DRUG|Placebo|n the placebo group, patients will receive the equivalent number of normal saline injections.
48490618|NCT05906420|DIAGNOSTIC_TEST|ASTRAL prognostic score|ASTRAL prognostic score
47973099|NCT06304220|DRUG|Cerazet|Comparation of the utilization of two distinct progestogens for pituitary suppression
47973100|NCT00823368|DRUG|STX209|
48327721|NCT03679429|DEVICE|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
48490619|NCT03324321|OTHER|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
48490620|NCT04717102|DRUG|0.5 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
48490621|NCT04717102|DRUG|0.75 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
48490622|NCT04717102|DRUG|1.0 MAC desflurane|On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
48490623|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
48490624|NCT01929031|DRUG|ibuprofen|tablet.
48490625|NCT01929031|DRUG|ibuprofen|tablet
48327722|NCT02296437|OTHER|Transcranial direct current stimulation combined with cognitive training|
48327723|NCT05875376|BEHAVIORAL|Couple group therapy|"1. Introduction of I statements~2. Focus of each conversation~3. Emotion acknowledgement~4. Self-assurance and positive feedback~5. teamwork and cooperation~6. Reflection"
48327724|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~* Whole Venous Blood"
48327725|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Whole Venous Blood~* Fingerstick Capillary Sample"
48327726|NCT01199055|DRUG|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
48490626|NCT01929031|DRUG|caffeine|tablet
48490627|NCT01929031|DRUG|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
48490628|NCT01929031|DRUG|placebo|tablet
48490629|NCT01929031|DRUG|placebo|tablet
48490630|NCT01929031|DRUG|caffeine|tablet
48490631|NCT01929031|DRUG|ibuprofen|tablet
48490632|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
48490633|NCT00106236|BEHAVIORAL|exercise|
48490634|NCT01036490|OTHER|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
48490635|NCT01758055|BIOLOGICAL|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
48490636|NCT05173038|BEHAVIORAL|second ejaculate|group patients received IUI for pregnancy assistance 1 hour after the first sperm extraction. The two semen were mixed and treated.
48650428|NCT04832152|OTHER|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
48650429|NCT03508440|PROCEDURE|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
48650430|NCT03508440|DRUG|Prednisone|Oral Steroid
48650431|NCT02274675|DEVICE|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
48650432|NCT02274675|OTHER|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
48490637|NCT02480218|OTHER|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
48490638|NCT04599127|OTHER|Mobilization with movement|The physical therapist will adjust the active movement of the shoulder joint during the arm elevation or abduction and shoulder external rotation
48490639|NCT04599127|OTHER|Conventional physical therapy|The exercise is tailor-made and each participant will be performing some of the exercises based on the list that physical therapist prescription
48490640|NCT02681146|OTHER|Multimodal intervention|Educational advice + physiotherapist treatment
48490641|NCT01475084|DEVICE|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
48650433|NCT04629521|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
48650434|NCT04629521|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
47973101|NCT02091544|OTHER|Lifestyle intervention|
48490642|NCT05981820|DIETARY_SUPPLEMENT|Creatine|To observe the effects of creatine in the study, 10 g of creatine supplementation was taken only on training days during the study period. Participants used 10 g of creatine monohydrate by dissolved in 200 ml of water. Creatine supplementation was taken in two doses of five grams, 30 minutes before and after training.
48327727|NCT01199055|DRUG|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
48327728|NCT01199055|DRUG|Paclitaxel|Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
48327729|NCT04632407|DIETARY_SUPPLEMENT|"Flax milk"|See above
48490643|NCT05981820|OTHER|HIIT training|"In the first three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 4 sets of 12x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets~In the last three weeks:~Warm-up: Warm-up at 70 rpm for 4 minutes, including 2-3 seconds of maximal sprint at 1.30 and 2.30 minutes Wingate-based HIIT: HIIT 5 sets of 20x15 seconds of maximal repetitions with 15 seconds of passive rest between reps in each set Cool-down: 4 minutes of passive rest between sets"
48490644|NCT00273481|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
48490645|NCT00273481|DRUG|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
48490646|NCT00273481|DRUG|timolol maleate 0.5%|
48490647|NCT00273481|DRUG|placebo|
48490648|NCT01713426|DRUG|Qutenza|Cutaneous patch
48490649|NCT01713426|DRUG|Pregabalin|Oral capsule
48490650|NCT06531369|DRUG|Flumazenil Injection（F1 group）|Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
48490651|NCT06531369|DRUG|Flumazenil Injection（F2 group）|Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.
48490652|NCT06531369|DRUG|Saline（C group）|Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
48490653|NCT04929938|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
48490654|NCT05007847|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
48490655|NCT03867617|OTHER|Regulatory T cells|Single infusion of expanded regulatory T cells.
48490656|NCT03867617|DRUG|Tocilizumab|Treatment during first month post-transplant.
48490657|NCT03867617|OTHER|Bone marrow|Infusion of donor bone marrow cells.
48490658|NCT03867617|PROCEDURE|Kidney transplant|Living donor kidney transplantation.
48490659|NCT03867617|OTHER|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
48327730|NCT04632407|DIETARY_SUPPLEMENT|"Oat fibre milk"|See above
48327731|NCT02861755|BEHAVIORAL|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
48327732|NCT02861755|BEHAVIORAL|5-week Emotion Reporting|
48327733|NCT03744182|DRUG|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
48327734|NCT03744182|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
48327735|NCT00160394|DRUG|Duac® Gel / Differin® Gel|
48327736|NCT01606735|DRUG|IBI-10090|dexamethasone
48327737|NCT01669642|DRUG|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
48327738|NCT03799328|OTHER|multi-OIT|low dose OIT to multiple foods
48490660|NCT01649271|DRUG|Herceptin|3-weekly
48650435|NCT05052892|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
48650436|NCT02193191|DRUG|Plerixafor|
48650437|NCT06674551|PROCEDURE|Suprascapular nerve block and Axillary nerve block|A linear ultrasound probe will be placed in a sagittal plane at the superior medial border of the scapula. The probe will be moved laterally and then placed parallel to the scapular spine. when the needle tip contacts the bone just medial to the spinoglenoid notch and after confirmation of absence of vascular structure by color Doppler, 10 ml of 0.5% bupivacaine will be injected with aspiration every 3 ml to avoid intravascular injection and the spread of the local anaesthetic
48650438|NCT06674551|PROCEDURE|Interscalene Nerve Block|The ultrasound probe will be placed in the supraclavicular fossa in a transverse orientation, aimed caudad into the thoracic cavity, to visualize the brachial plexus near the subclavian artery. Once identified, the plexus will be followed cephalad where it is found within the brachial plexus fascial sheath in the interscalene groove.
48650439|NCT05866523|BEHAVIORAL|Team Based Inpatient ARTAS|Infectious Disease Team will provide inpatient consultation. Social Work Team will provide 1 session of case management inpatient and up to 5 case management sessions within 90 days post discharge or until the client is linked to medical care as evidenced by visit with HIV specialist within 90 days post discharge.
48650440|NCT05866523|BEHAVIORAL|Standard of Care|Subject admitted and seen by routine inpatient medical service.
48327739|NCT02297737|BEHAVIORAL|Tai Chi|
48327740|NCT02297737|OTHER|Health Education|
48327741|NCT06356948|DRUG|Tranexamic Acid (TXA)|Study drug administration
48327742|NCT00728312|DRUG|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
48327743|NCT00728312|DRUG|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
48327744|NCT04761172|PROCEDURE|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
48327745|NCT00855257|DRUG|Acid Nicotinique|
48327746|NCT00855257|DRUG|Placebo|
48327747|NCT03019224|PROCEDURE|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
48327748|NCT03019224|PROCEDURE|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
48327749|NCT03019224|PROCEDURE|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
48327750|NCT03019224|PROCEDURE|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
48327751|NCT03019224|PROCEDURE|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
48327752|NCT03019224|DRUG|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
48327753|NCT03019224|PROCEDURE|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
48327754|NCT05663840|BEHAVIORAL|Progressive resistance exercise|Patients with predominant symptoms of cervical dystonia will receive exercise training. Patients will receive progressive resistance exercise focused cervical and shoulder training (PERFECT) plus standard-of-care (SOC) therapy. Resistance training will consist of mainly muscle-strengthening exercises for the neck, shoulder and arms and a few upper trunk muscles. Resistance training will be guided by physical therapists at twice a week schedule for 6 months. These participants will also receive SOC therapy.
48327755|NCT05663840|BEHAVIORAL|Standard of care|Subjects will receive SOC therapy only
48327756|NCT02247401|DRUG|2 DAA|ABT-450/r/ABT-267 tablets
48327757|NCT02247401|DRUG|RBV|Ribavirin tablets
48327758|NCT01271387|DRUG|tasimelteon|20 mg tasimelteon capsules, PO single dose
48340191|NCT00550992|PROCEDURE|allogeneic bone marrow transplantation|
48340192|NCT00550992|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48490661|NCT01649271|DRUG|afatinib|at MTD level
47973102|NCT00272467|DRUG|Rebamipide|"1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals"
47973103|NCT00272467|DRUG|Omeprazole|"1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea."
48122099|NCT02298452|DEVICE|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
48122100|NCT03809416|DEVICE|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
48490662|NCT01649271|DRUG|trastuzumab|3-weekly
48490663|NCT01649271|DRUG|Herceptin|weekly
48490664|NCT01649271|DRUG|afatinib|at MTD level
48122101|NCT03809416|OTHER|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
48490665|NCT01649271|DRUG|afatinib|escalating dose
48490666|NCT06417138|OTHER|biological and targeted synthetic disease modifying anti rheumatic drugs (bDMARDs) and (tsDMARDs)|This is a registry-based study. It is an observational, retrospective trial. There is/are no interventional drug(s).
48122102|NCT03809416|COMBINATION_PRODUCT|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
48490667|NCT00289757|BIOLOGICAL|Havrix™|2 doses at 6 months interval
48490668|NCT01917448|DRUG|Morphine|spinal morphine 0.15 mg
48490669|NCT01917448|OTHER|control|Patient receive only local infiltration without spinal analgesia
48122103|NCT01675895|DRUG|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
48122104|NCT01675895|DRUG|levobupivacaine Spinal anesthesia|spinal anesthesia
48122105|NCT04505358|DRUG|PU-AD|active vs placebo
48122106|NCT04505358|DRUG|Placebo|active vs placebo
48327759|NCT02411383|DEVICE|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
48122107|NCT05574452|DEVICE|ACL reconstruction using the SONAR Femoral Aimer PSI|ACL reconstruction using the SONAR Femoral Aimer PSI
48122108|NCT03544736|DRUG|Nivolumab|Experimental: Nivolumab
48122109|NCT03544736|RADIATION|Radiotherapy|Radiotherapy
48327760|NCT05366530|OTHER|Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
48327761|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
48327762|NCT00441103|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
48327763|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
48327764|NCT03242005|DEVICE|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
48327765|NCT03242005|DEVICE|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
48327766|NCT03587870|OTHER|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
48327767|NCT04722484|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
48490670|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
48122110|NCT03544736|DRUG|Chemotherapy|Chemotherapy
48122111|NCT03544736|PROCEDURE|Surgery|Surgery
48122112|NCT05993507|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, scalable intervention that is developed by World Health Organization for communities exposed to adversity. PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session 5. Facilitators will receive weekly supervisions by PM+ supervisors.
48122113|NCT05425862|DRUG|Pidnarulex|Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.
48340193|NCT00550992|PROCEDURE|umbilical cord blood transplantation|
48490671|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
48490672|NCT01828710|DIETARY_SUPPLEMENT|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
48490673|NCT02199054|OTHER|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
48490674|NCT02199054|OTHER|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
48490675|NCT02199054|OTHER|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
48490676|NCT06002087|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The current researchers adapted the Unified Protocol (UP) treatment and used the adapted version in this study. UP outlines two complimentary modules for goal setting and psychoeducation followed by five core treatment modules: mindful emotion awareness, cognitive flexibility, countering emotional behaviors, awareness and tolerance of physical sensations, and emotion exposures, and an optional relapse prevention module to help people maintain their gains after treatment.
48490677|NCT04094948|DRUG|Clenbuterol|20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
48490678|NCT04094948|DRUG|Placebos|dextrose-filled capsules
48490679|NCT03831763|DEVICE|ColdZyme|"ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap."
48490680|NCT03766490|DRUG|Anlotinib Hydrochloride|Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
48490681|NCT03766490|DRUG|Gefitinib|Tablet, P.O. 250mg qd
48490682|NCT03766490|DRUG|Icotinib|Tablet, P.O. 125mg tid
48490683|NCT05084664|DEVICE|electrical stimulation|premodulated current+ exercises
48490684|NCT05084664|DEVICE|electrical stimulation|diadynamic current+ exercises
48490685|NCT00212576|BEHAVIORAL|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
48327768|NCT05486936|RADIATION|hypofractionated radiation|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
48490686|NCT00212576|BEHAVIORAL|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
48490687|NCT06534528|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
48490688|NCT04882423|OTHER|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
48490689|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
48490690|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
47973104|NCT04943094|OTHER|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
47973105|NCT06056713|BEHAVIORAL|Hand Massage|The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
47973106|NCT02699645|DRUG|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 pill taken orally once daily for average of 72 months
48490691|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
48490692|NCT02823652|OTHER|standard genetic education|Undergo usual care
47973107|NCT02699645|DRUG|Placebo|1 pill taken orally once daily for average of 72 months
47973108|NCT02733939|DEVICE|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~* leaves the home without notice, since this might occur in a moment of disorientation;~* leaves a water tap open;~* forgets something on the stove;~* gets out of bed during the night and doesn't come back within a certain time interval;~* never goes to the bathroom in 24 hours;~* never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~* automatically turn on a light to help avoid a fall during the night;~* alert the caregiver when the temperature in the house falls or rises excessively;~* act as burglar alarm in some areas of the home."
47973109|NCT02014597|DEVICE|HOCD|feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
47973110|NCT02480439|DRUG|TAK-648 Tablet|Tak-648 tablet
48327769|NCT04133805|DIETARY_SUPPLEMENT|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
48490693|NCT02823652|OTHER|Genetic Counseling|Complete remote counseling
47973111|NCT02480439|DRUG|TAK-648 Oral Solution|TAK-648 oral solution
47973112|NCT02536196|DEVICE|Embolic Protection Device|Embolic protection
47973113|NCT02536196|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
47973114|NCT03169556|DEVICE|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
48490694|NCT02823652|OTHER|Genetic Testing|Undergo germline testing
48490695|NCT02823652|OTHER|Internet-Based Intervention|Complete on-line genetic education
48490696|NCT02823652|OTHER|Survey Administration|Ancillary studies
48490697|NCT03916523|PROCEDURE|Sustained lung inflation|"Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~1. On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~2. On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~3. On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~4. On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours."
48327770|NCT05388019|OTHER|Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)|Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.
47973115|NCT03169556|DEVICE|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
47973116|NCT04654130|OTHER|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
48490698|NCT03916523|PROCEDURE|Continuous positive airway pressure (CPAP)|Preterm infants will receive CPAP for respiratory support.
48490699|NCT03916523|PROCEDURE|Mechanical ventilation|Preterm infants in this group will receive mechanical ventilation for respiratory support
48490700|NCT02816866|OTHER|empowered primary care model|mode of survivorship care
48490701|NCT02816866|OTHER|specialty survivor clinic|mode of survivorship care
47973117|NCT01327105|DEVICE|TVU|Use of transvaginal ultrasound to determine location of micro-insert
47973118|NCT05743270|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
47973119|NCT05743270|OTHER|CCRT(concurrent chemoradiation therapy)|CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
47973120|NCT05743270|OTHER|carboplatin and paclitaxel|chemotherapeutic agents
47973121|NCT05743270|BIOLOGICAL|nivolumab|anti-PD1 monoclonal antibody
47973122|NCT02568800|DRUG|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
47973123|NCT02568800|DRUG|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
47973124|NCT00657527|DRUG|Rosuvastatin|
47973125|NCT00657527|BEHAVIORAL|Cholesterol lowering diet|
47973126|NCT04388709|DRUG|Peginterferon Lambda-1A|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
47973127|NCT05360381|DRUG|HLX35|A Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody, HLX35 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
47973128|NCT02469922|DEVICE|Positron emission tomography|
47973129|NCT02469922|RADIATION|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
47973130|NCT05211882|OTHER|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
47973131|NCT05211882|OTHER|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
47973132|NCT05576870|OTHER|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
47973133|NCT05576870|DIETARY_SUPPLEMENT|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
48490702|NCT05442671|BEHAVIORAL|Exercise intervention|16-week home exercise intervention, enriched by mobile health technology
47973134|NCT05412745|DEVICE|Kaloidon Plus|topical application; twice daily
48327771|NCT05388019|BEHAVIORAL|Caregiver Self-Assessment|Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
48327772|NCT00574457|OTHER|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
48490703|NCT02513836|OTHER|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
48490704|NCT02513836|OTHER|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
47973135|NCT05412745|DEVICE|silicone gel|topical application; twice daily
47973136|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions Only|The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
47980535|NCT01806545|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
48327773|NCT04823767|OTHER|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
48650441|NCT06455631|PROCEDURE|Facilitated Tucking, Oral Breast Milk , Kangaroo Care|Before data collection, the researcher will inform families of newborns meeting the sample criteria about the study and obtain written consent from participating parents. Newborn and parent information will be recorded. Procedures will occur between 08:00 and 16:00, with one researcher, two nurses, and a preterm newborn present during tape removal. Tape removal will be done by the same nurse. Physiological and behavioral responses will be recorded before, during, and after tape removal. Breast milk will be orally administered during tape removal, with the amount adjusted based on gestational age. Measurements will be taken at specified time points, including heart rate, respiratory rate, oxygen saturation, and PIPP-R score. These procedures will also apply to the control group. PIPP-R scores will be recorded by two evaluators based on video recordings.
48327774|NCT04203563|BEHAVIORAL|Strong People Strength Training|A community-based progressive strength training program
48327775|NCT02022072|DEVICE|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
48327776|NCT00225147|DRUG|Recombinant Human C1 Inhibitor|IV
48327777|NCT00225147|DRUG|placebo|saline solution
48327778|NCT03300258|DEVICE|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
48327779|NCT03300258|DEVICE|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
48327780|NCT04268095|OTHER|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
48327781|NCT00201981|DRUG|Rebamipide|"1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
48327782|NCT05657509|OTHER|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 60 to 95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-2 minute rest between sets.
48327783|NCT05657509|OTHER|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
48327784|NCT04605536|OTHER|animation videos|watch animation videos about capsule endoscopy
48327785|NCT04605536|OTHER|explanation about endoscopy endoscopy|Give general explanations about endoscopy endoscopy
48327786|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48327787|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48650442|NCT03988439|DRUG|IDP-118 Lotion|Topical
48122114|NCT05425862|DRUG|Talazoparib|Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
47973137|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions & Teach Back|This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
48327788|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
48327789|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48327790|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48327791|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
48122115|NCT04698655|OTHER|Information on treatment options|"Asked to read two A4 pages of information on treatment options (osteoarthritis treatment options)"
48122116|NCT04698655|OTHER|Recommendation from general practitioner|Receive a hypothetical general practitioner recommendation for exercise
48122117|NCT04698655|OTHER|Information on osteoarthritis|Asked to read 1 A4 page of brief information on osteoarthritis
48327792|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48327793|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48122118|NCT00977158|PROCEDURE|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
48327794|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
48327795|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48122119|NCT03067142|OTHER|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
48327796|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48327797|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
48327798|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48327799|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
48327800|NCT00353184|DRUG|Montelukast 5-mg orally added to standard therapy|
48650443|NCT01586910|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
48122120|NCT00014040|DRUG|Nitric Oxide and INOpulse Delivery System|
48122121|NCT00516321|DRUG|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
48122122|NCT00516321|DRUG|placebo|matched placebo taken once daily orally
48122123|NCT00364117|BEHAVIORAL|Timely Discharge (Remote Presence Technology)|
48122124|NCT05508243|OTHER|Hyaluronic Nasal Spray|Health care product - nasal application
48327801|NCT02825433|OTHER|No intervention, only ventilation monitoring|
48122125|NCT05820269|BEHAVIORAL|parents-child psychotherapy|filling out questionnaires during psychotherapy consultations
48327802|NCT06364683|OTHER|Survey study|The data collection tools to be used in the study will be filled. It does not include any invasive or non-invasive intervention.
48327803|NCT00871091|PROCEDURE|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
48327804|NCT00871091|PROCEDURE|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
48327805|NCT00871091|PROCEDURE|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
48490705|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
48490706|NCT02191007|DRUG|Calcipotriol Betamethasone ointment|
48490707|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Urea Cream|
48327806|NCT00247260|DEVICE|32P BioSilicon|
48327807|NCT00862654|DRUG|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
48327808|NCT00862654|DRUG|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
48122126|NCT05278494|DRUG|Dextromethorphan Hydrobromide|PO
48122127|NCT05278494|DRUG|Placebo|PO
48122128|NCT02284412|DRUG|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
48122129|NCT02284412|DRUG|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
48122130|NCT02284412|DRUG|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
48122131|NCT02500264|DEVICE|TENS|
48122132|NCT04769596|DEVICE|NEUROMARK™ System|The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
48327809|NCT00862654|DRUG|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
48327810|NCT00862654|DRUG|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
48327811|NCT00898404|OTHER|laboratory biomarker analysis|Correlative studies
48327812|NCT04492878|DRUG|IKERVIS®1mg/mL|One drop of study medication once daily in each eye at bedtime during 90 days.
48327813|NCT05627700|DEVICE|AVL200 IOL|The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.
48327814|NCT03902782|PROCEDURE|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
48327815|NCT03902782|PROCEDURE|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
48490708|NCT03340870|DRUG|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
48490709|NCT00444093|DRUG|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
48650444|NCT01586910|PROCEDURE|Surgical Aortic Valve Replacement (SAVR)|
48650445|NCT01586910|DEVICE|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
48650446|NCT05319015|DRUG|Neoadjuvant Lenvatinib|20 mg PO daily for 12 weeks prior to surgery
48650447|NCT05319015|DRUG|Neoadjuvant Pembrolizumab|200 mg IV every 3 weeks for 4 doses prior to surgery
48650448|NCT05319015|PROCEDURE|Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|Resection of locally advanced RCC with IVC tumor thrombus
48650449|NCT05319015|DRUG|Adjuvant Pembrolizumab|200 mg IV every 3 weeks for up to 13 doses after surgery
48650450|NCT01922895|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
48650451|NCT01922895|DRUG|Placebo for Probiotic|Capsule manufactured without active ingredients.
48650452|NCT04283279|OTHER|Virtual reality exercise|"Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments."
48327816|NCT03902782|PROCEDURE|Sham ESP block|As described earlier
48327817|NCT03902782|PROCEDURE|Sham Intercostal block|As described earlier
48327818|NCT03902782|DRUG|Bupivacaine-epinephrine|As described earlier
48327819|NCT03902782|DRUG|Dexamethasone injection|As described earlier
48327820|NCT03902782|DRUG|Normal saline|As described earlier
48327821|NCT01928992|DEVICE|3D|subjects that underwent 3D mammography
48327822|NCT01928992|DEVICE|2D|those subjects that underwent 2D mammography
48327823|NCT01233700|BEHAVIORAL|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
48327824|NCT01233700|BEHAVIORAL|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
48327825|NCT02119026|DRUG|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
48327826|NCT02119026|DRUG|Capecitabine|1000mg/m2 bid d1-14,
48327827|NCT02119026|DRUG|Bevacizumab|7,5 mg/kg given on d1 q3w
48650453|NCT04283279|OTHER|Vestibular rehabilitation exercise|Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
48650454|NCT04283279|OTHER|Control|Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
48650455|NCT01390519|OTHER|everolimis|
48650456|NCT05425355|DRUG|Intravenous (IV) acetaminophen + oral placebo|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
48650457|NCT05425355|DRUG|Intravenous (IV) placebo plus oral acetaminophen|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
48650458|NCT02364271|OTHER|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
48650459|NCT02364271|BIOLOGICAL|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
48327828|NCT02119026|DRUG|Oxaliplatin|130mg/m2 iv. d 1 q3w
48327829|NCT02119026|DRUG|Irinotecan|200mg/m2 iv. d 1 q3w .
48327830|NCT01593579|BEHAVIORAL|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine \& standing heart rate \& blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
48327831|NCT01593579|OTHER|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
48327832|NCT06460597|OTHER|Papworth Technique|The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
48327833|NCT06460597|OTHER|Pranayama|Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
48327834|NCT05421221|DEVICE|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
48327835|NCT05034458|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
48327836|NCT04995900|OTHER|Community education|Heart Matters coordinators will deliver heart health education to the community using HM materials and Partner resources.
48327837|NCT02608229|DRUG|BVD-523|
48327838|NCT02608229|DRUG|Nab-paclitaxel|
48327839|NCT02608229|DRUG|Gemcitabine|
48327840|NCT02608229|PROCEDURE|Tumor biopsy|
48327841|NCT03315728|OTHER|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
48327842|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
48327843|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
48327844|NCT03114566|OTHER|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
48327845|NCT04868747|DRUG|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
48327846|NCT04868747|DRUG|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
48122133|NCT04769596|DEVICE|Sham Device|A Sham device will be used in the nasal cavity
48327847|NCT05820620|PROCEDURE|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
48327848|NCT05820620|PROCEDURE|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
48327849|NCT05820620|OTHER|Control Group|Control Group + Patient Control Analgesia (PCA)
48327850|NCT00917085|BEHAVIORAL|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
48327851|NCT06406881|OTHER|physical therapy|"Ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise.~3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. each exercise consist of 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
48122134|NCT00244959|DRUG|anastrozole|1 mg orally daily for 12 months
48327852|NCT06406881|OTHER|myofascial release therapy|"Experimental group given MFR along with neck isometric and ocular muscle exercise.~myofascial release technique on sternocleidomastoid muscle and upper trapezius muscles. Patients will be treated 3 seconds to 2 minutes, three days in a week.~Ocular muscle exercise will perform 3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. This exercise will performed 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
48327853|NCT01954888|PROCEDURE|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
48490710|NCT00444093|DRUG|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
48650460|NCT02364271|OTHER|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
48650461|NCT06675149|DEVICE|Diacutaneus fibrolysis|Material : Stainless steel large angle and small long angle: length 22cm x height 6cm x width 2cm. Weight: 70 grams
48650462|NCT06675149|DEVICE|Transcutaneus electrical nerve stimulation|physical therapy electrical modality
48650463|NCT06675149|PROCEDURE|Massage|manual therapy intervention
48650464|NCT04160598|DRUG|IV infusion|Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
48122135|NCT00244959|PROCEDURE|adjuvant therapy|treatment received after breast cancer surgery
48650465|NCT04160598|DRUG|intrathecal fentanyl|10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
48650466|NCT02784496|OTHER|Long-term Follow-up|Undergo follow-up assessment
48122136|NCT06521411|BEHAVIORAL|CSA model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided in subsidized weekly boxes for 20 weeks to community members at Brooklyn Grange Farm in Sunset Park at a fee of $5, which was determined to be acceptable by community members. Participants that receive SNAP benefits can use their EBT card to cover their $5. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
48650467|NCT02784496|OTHER|Quality-of-Life Assessment|Ancillary studies
48122137|NCT02546999|DRUG|botox|The agent will be given only once at point zero in the time scheme for the project.
48122138|NCT02546999|DRUG|placebo|The agent will be given only once at point zero in the time scheme for the project.
48122139|NCT03631953|DRUG|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
48122140|NCT03631953|DRUG|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
48122141|NCT03631953|BIOLOGICAL|Blood sample|Therapeutic biomarkers
48122142|NCT03631953|DEVICE|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
48122143|NCT03390296|BIOLOGICAL|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
48122144|NCT03390296|DRUG|Avelumab|Given IV
48122145|NCT03390296|DRUG|Azacitidine|Given IV or SC
48650468|NCT02784496|DRUG|Ruxolitinib|Given PO
48327854|NCT01954888|PROCEDURE|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
48327855|NCT06524596|DRUG|tartaric acid butorphanol|The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
48490711|NCT02205502|DRUG|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
48490712|NCT02205502|DRUG|Normal saline|
48490713|NCT04132895|OTHER|observational only, no interventions are prescribed in protocol.|"* Treatment will be given as per usual standard of care.~* No treatments are specified by this protocol."
48490714|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
48327856|NCT06524596|DRUG|normal saline|The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
48327857|NCT06524596|DRUG|propofol and remifentanil|Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
48327858|NCT02466412|OTHER|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
48327859|NCT02466412|OTHER|mCC|Single use of subject's own menthol conventional cigarette (mCC)
48327860|NCT05536193|DRUG|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
48327861|NCT05536193|DIAGNOSTIC_TEST|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
48327862|NCT01536106|OTHER|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
48327863|NCT01536106|OTHER|Placebo control|Intracoronary infusion of autologous peripheral blood.
48327864|NCT01571648|DRUG|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
48327865|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
48327866|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
48327867|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
48327868|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
48327869|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
48327870|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
48327871|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
48327872|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
48490715|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
48650469|NCT03348462|DRUG|ethosomal preparation of anthralin|once daily with short contact topical application
48650470|NCT03348462|DRUG|liposomal preparation of anthralin|once daily with short contact topical application
48122146|NCT03390296|DRUG|Gemtuzumab Ozogamicin|Given IV
48122147|NCT03390296|DRUG|Glasdegib|Given PO
48122148|NCT03390296|DRUG|Glasdegib Maleate|Given PO
48122149|NCT03390296|DRUG|Venetoclax|Given PO
48122150|NCT03390296|DRUG|Azacitidine|Given IV or SC
48327873|NCT02712177|BIOLOGICAL|4CMenb|
48327874|NCT02712177|BIOLOGICAL|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
48327875|NCT02712177|BIOLOGICAL|conjugated pneumococcal vaccine|
48122151|NCT05279157|PROCEDURE|Implantation|Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient
48327876|NCT02712177|BIOLOGICAL|MMRV|
48327877|NCT01292044|OTHER|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
48327878|NCT02001675|DEVICE|magnetic resonance imaging (MRI)|
48327879|NCT02001675|DEVICE|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
48490716|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
48490717|NCT00003972|BIOLOGICAL|filgrastim|
48490718|NCT00003972|BIOLOGICAL|sargramostim|
48122152|NCT05279157|PROCEDURE|Lipoaspiration|"Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient"
48122153|NCT05481242|OTHER|retrospective observational study|retrospective observational study
48122154|NCT00632203|DRUG|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m\^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
48122155|NCT04533061|DRUG|Influenza vaccine|"influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season contains: A/New Caledonia/20/99 (H1N1)-like, A/Fujian/411/2002 (H3N2-like), and B/Shanghai/361/2002-like antigens~2005-2006 season contains: A/New Caledonia/20/99 (H1N1)-like, A/California/7/2004 (H3N2), and B/Shanghai/361/2002-like antigens"
48122156|NCT02574455|DRUG|Sacituzumab govitecan|10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
48122157|NCT02574455|DRUG|Eribulin|Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).
48122158|NCT02574455|DRUG|Capecitabine|1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
48122159|NCT02574455|DRUG|Gemcitabine|800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
48122160|NCT02574455|DRUG|Vinorelbine|25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
48122161|NCT04592575|OTHER|Vestibular Evaluation|Each patient will have a full vestibular evaluation by a physical therapist
48122162|NCT04114422|OTHER|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
48122163|NCT05589441|DRUG|salbutamol|10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.
48122164|NCT05589441|DRUG|Insulin|Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
48122165|NCT01154439|DRUG|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
48122166|NCT01154439|DRUG|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
48122167|NCT01154439|DRUG|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
48122168|NCT01154439|DRUG|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
48122169|NCT01154439|DRUG|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
48122170|NCT01548170|DRUG|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
48490719|NCT00003972|DRUG|busulfan|
48122171|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
48122172|NCT01548170|DRUG|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
48122173|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
48122174|NCT01548170|DRUG|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
48490720|NCT00003972|DRUG|carboplatin|
48122175|NCT02190981|DEVICE|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
48122176|NCT00864552|DRUG|Kogenate (BAY14-2222)|Patients with severe haemophilia A (\<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
48122177|NCT03185650|DEVICE|tPAD Device|A novel, transnasal aerosol generator
48122178|NCT03185650|DEVICE|PARI LC Star Nebulizer|Standard oral nebulizer
48122179|NCT04664270|BEHAVIORAL|e-CBT|e-CBT + Mindfulness + Problem Solving
48490721|NCT00003972|DRUG|cyclophosphamide|
48490722|NCT00003972|DRUG|melphalan|
48122180|NCT00220519|DRUG|Lactobacillus GG|
48122181|NCT04900766|DRUG|Mitoxantrone Hydrochloride Liposome Injection|20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
48327880|NCT06364956|DRUG|Tislelizumab combined with two predefined dose groups of palbociclib|Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
48490723|NCT00003972|DRUG|paclitaxel|
48490724|NCT00003972|DRUG|tamoxifen citrate|
48490725|NCT00003972|DRUG|thiotepa|
48490726|NCT00003972|PROCEDURE|peripheral blood stem cell transplantation|
48490727|NCT00003972|RADIATION|radiation therapy|
48490728|NCT03263039|DRUG|Pembrolizumab|Pembrolizumab 200 mg Q3W
48490729|NCT05480592|DRUG|HS-10380|Administered orally as a tablet
48490730|NCT05480592|DRUG|Placebo|Administered orally as a tablet
47973138|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 1. Group 1 receives treatment A\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B\*\* was applied to group 1 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
47973139|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 2. Group 2 receives treatment B\*\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A\* was applied to group 2 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
48122182|NCT03920592|BEHAVIORAL|Virtual Reality of Bullying|"Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~1. Classmates steal her personal diary~2. Classmates tear her clothing~3. Classmates insult her and steal her belongings~4. Classmates deliberately exclude her in class~Boys:~1. Classmates exclude him while playing with a ball~2. Classmates bother him in the dining room~3. Classmates insult and steal him in class~4. Classmates insult him and steal his belongings"
48122183|NCT06148831|DEVICE|Infant Carrier|"The assigned home visitor will provide a participant with an infant carrier and will watch a short training video on how to use the carrier, including a demonstration of safe and ergonomic use. The home visitor will support the client to practice using the carrier and will provide materials to support continued learning.~All home visitors participated in an infant carrier training developed by Nurturely, centered on carrying as a cultural practice, utilizing culturally relevant visuals as well as easy-to-remember acronyms to promote safe and ergonomic use (i.e., the STOP acronym developed by Nurturely, signifying that all knots are Secure, infant is attached high enough to kiss the top of their head and Tight to the caregiver's body, nose and mouth are visible and airway is Open, and hips are Positioned in an ergonomic spread squat)."
48122184|NCT04970446|DRUG|Antibiotics|All patients will receive a one week course of antibiotic therapy.
48122185|NCT04970446|DIETARY_SUPPLEMENT|Dietician designed diet|All patients will be recommended dietary modification 3 weeks prior to, and during, the study.
48122186|NCT04970446|DRUG|FMT|Anaerobically prepared stool. Dosing will vary according to mode of administration.
48122187|NCT04970446|OTHER|Placebo|Placebo will contain food colourant, 0.9% normal saline and glycerol.
48122188|NCT06189534|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy-based interventions were used to manage social media addiction and; to address associated problems with it. Psychoeducation, problem conceptualization, cognitive distortions and belief identification,Time management,Stress and distress management, Emotional and beliefs modification,Priority and Goal setting, Problem solving skills, Social skill training, Emotional and behavioral activation and Relapse prevention are techniques that will be used in the intervention.
48122189|NCT06518772|OTHER|hot application|The application procedure started with the application of hot gel packets at a temperature of 40-42°C to the soles of the feet of the women in the intervention group for 20 minutes when cervical dilation reaches 5 cm.
48122190|NCT01869946|DRUG|Ropivacaine|
48122191|NCT04630600|OTHER|No intervention|Normal waiting room without an aquarium
48122192|NCT04630600|OTHER|Partially-equipped aquarium in the waiting area|Waiting room with a partially-equipped Aquarium
48122193|NCT04630600|OTHER|Fully-equipped aquarium in the waiting area|Waiting room with a fully-equipped Aquarium
48327881|NCT06364956|DRUG|RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.|After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
48327882|NCT03058172|OTHER|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
48122194|NCT02139696|RADIATION|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
48122195|NCT05374681|OTHER|Medical treatment|Medical treatment alone
48122196|NCT05374681|OTHER|Surgical treatment|Surgical treatment alone
48122197|NCT05374681|OTHER|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
48122198|NCT04748939|BIOLOGICAL|recombinant subunit herpes zoster vaccine|vaccine administration
48122199|NCT01751958|RADIATION|Epidural steroid injection|Epidural steroid injection
48122200|NCT05536830|OTHER|Nutrition Status|Participants will be examined by a registered dietitian to assess nutrition status.
48122201|NCT02267824|DEVICE|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
48122202|NCT02267824|OTHER|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
48327883|NCT03058172|OTHER|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
48327884|NCT01117012|DRUG|Ivacaftor|
48327885|NCT01351402|PROCEDURE|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
48327886|NCT00002544|DRUG|docetaxel|
48327887|NCT00002544|DRUG|mitoxantrone hydrochloride|
48490731|NCT04796636|DRUG|Sodium Ascorbate|As previously described
48122203|NCT00763152|OTHER|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
48122204|NCT00595413|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
48122205|NCT00595413|DRUG|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
48122206|NCT00595413|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
48122207|NCT00595413|BIOLOGICAL|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
48122208|NCT02467166|DEVICE|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
48122209|NCT05871112|OTHER|Use of dynamic tensioner|Assessment of femoral component rotation with a use of a dynamic tensioner in extension and 90 degrees of flexion. The tensioner was put between tibial plane cut and posterior condyles of the femur and tensioned to the same thickness of insert as in the full extension
48122210|NCT03687892|DEVICE|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
48122211|NCT03687892|DEVICE|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
48122212|NCT03554460|DEVICE|dual-limb NIV|dual-limb NIV was served with servo i ventilator
48122213|NCT01285986|PROCEDURE|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
48327888|NCT01589510|DRUG|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
48122214|NCT05300542|OTHER|Topical Placebo Cream|Application of test products before and after irradiation
48122215|NCT05300542|OTHER|Topical Cream with 0.5% Active|Application of test products before and after irradiation
48327889|NCT02030613|GENETIC|Blood test|
48327890|NCT01205958|PROCEDURE|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
48327891|NCT02530957|DEVICE|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
48327892|NCT02530957|DEVICE|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
47973140|NCT03320954|BEHAVIORAL|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
48327893|NCT02789605|DRUG|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
47973141|NCT05000476|OTHER|eye mask and earplugs|Materials similar to those offered on long commercial flights
48122216|NCT05300542|OTHER|Topical Cream with 1% Active|Application of test products before and after irradiation
48122217|NCT03175172|BIOLOGICAL|CRS-207|Administered by IV infusion over approximately 1 hour.
48327894|NCT02789605|DRUG|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
47973142|NCT05000476|OTHER|Nurse Education and Environmental Regulation|providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
48122218|NCT03175172|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over approximately 30 minutes.
48327895|NCT02655445|PROCEDURE|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
48327896|NCT02655445|PROCEDURE|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
48327897|NCT02655445|PROCEDURE|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
48327898|NCT00176124|PROCEDURE|leukocyte depletion of whole blood|
48327899|NCT00176124|OTHER|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
48122219|NCT04847414|DIAGNOSTIC_TEST|HbA1C, other investigations|we will do some necessary investigations for prospective group
48122220|NCT03467386|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
48122221|NCT03467386|DRUG|Cyclophosphamide|Given IV
48122222|NCT03467386|BIOLOGICAL|Filgrastim|Administer according to City of Hope standard operating procedures
48122223|NCT03467386|OTHER|Laboratory Biomarker Analysis|Correlative studies
48122224|NCT03467386|OTHER|Quality-of-Life Assessment|Ancillary studies
48122225|NCT03467386|OTHER|Questionnaire Administration|Ancillary studies
48122226|NCT03467386|DRUG|Tacrolimus|Given CIV
48122227|NCT03467386|RADIATION|Total Marrow Irradiation|Undergo TMLI
48122228|NCT00867867|DRUG|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
48122229|NCT00867867|DRUG|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
48122230|NCT00867867|DRUG|Placebo|9.3 mg once per day, 6 days per week, for 9 months
47973143|NCT04659304|DRUG|Allocetra-OTS|Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
47973144|NCT04303832|OTHER|eye exercises|Eye exercises for correcting eye deviation
47973145|NCT04303832|DEVICE|eye glasses|Eye glasses for correcting eye deviation
48327900|NCT01181102|DRUG|edoxaban|
48327901|NCT01181102|DRUG|enoxaparin sodium|
48327902|NCT01653002|OTHER|No intervention|
48327903|NCT02790554|DEVICE|Moyo strap-on|Continous monitoring
48327904|NCT02790554|DEVICE|Hand-held Doppler|Intermittent monitoring
48327905|NCT05221788|PROCEDURE|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased \>10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but mean arterial pressure (MAP) \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
48327906|NCT00506571|DRUG|S-1, irinotecan, oxaliplatin|
48327907|NCT05289206|OTHER|Vaccine - ChAdOx1-S/nCoV-19 [recombinant]|ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
48327908|NCT05399550|DRUG|Balovaptan|Intravenous Solution
48327909|NCT05399550|DRUG|Placebo|Matching Intravenous Solution
48327910|NCT04402853|DIAGNOSTIC_TEST|Tears swab|rtPCR on tears swabs samples
48327911|NCT00993395|BEHAVIORAL|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
48327912|NCT03076125|BEHAVIORAL|SCORRE|3 components based on the Health Belief Model
48327913|NCT03076125|BEHAVIORAL|Attention-Control Activity|sexual health education
48327914|NCT05341635|DIAGNOSTIC_TEST|Swab sampling|Collection of three nose-pharyngeal and oral swabs
48327915|NCT02767856|DEVICE|IO-therapy Glasses|
48327916|NCT02465346|DEVICE|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
48327917|NCT02465346|DEVICE|Control stroke management|Conventional stroke management
48327918|NCT04562142|DEVICE|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
48327919|NCT01552187|DRUG|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery
47973146|NCT04347044|OTHER|Pulmonary Rehabilitation|Exercise training+ Optimal medication and clinical follow-up
47973147|NCT04347044|OTHER|Standart care|Optimal medication and clinical follow-up
47973148|NCT06201377|OTHER|Periodontal Access Surgery+ Suture with chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture coated with chlorhexidine (Novosyn Chlorhexidine). Standardized post-surgical recommendations will be followed.
47973149|NCT06201377|OTHER|Periodontal Access Surgery+ Suture without chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture (Novosyn). Standardized post-surgical recommendations will be followed.
47973150|NCT02671552|DRUG|Perflutren Protein-Type A Microspheres|Given IV
47973151|NCT02671552|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
47973152|NCT03406572|DEVICE|HFHO Group|"* Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~* Brand name: Airvo 2"
47973153|NCT03406572|DEVICE|Standard O2|Standard oxygen therapy
47973154|NCT06204913|OTHER|Menu label|Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
47973155|NCT06025097|DRUG|Combination Solution|Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
47973156|NCT04157439|OTHER|Control Group|"Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided"
48122231|NCT06267690|PROCEDURE|surgery|Patients with suspected pancreatic cancer who underwent contrast-enhanced CT and pathological examinations after the surgery.
48122232|NCT02310113|OTHER|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
48122233|NCT03127280|OTHER|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
48327920|NCT01552187|DRUG|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
48327921|NCT00303758|DRUG|cisplatin|
48327922|NCT00303758|DRUG|fluorouracil|
48327923|NCT00303758|DRUG|gemcitabine hydrochloride|
48327924|NCT00303758|DRUG|leucovorin calcium|
48327925|NCT01184846|BIOLOGICAL|10% liquid formulation of human immunoglobulin|
48327926|NCT05911464|DRUG|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
48327927|NCT03833622|OTHER|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
48327928|NCT01839175|BIOLOGICAL|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
48490732|NCT03561441|DRUG|Tailored aggressive hydration|"1. Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
48650471|NCT06641258|OTHER|Control Group (Standard Procedure)|"Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application."
48650472|NCT06641258|OTHER|Experimental Group|"Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied"
48650473|NCT06348147|BIOLOGICAL|Daratumumab|Daratumumab is a CD38-directed cytolytic antibody indicated for the treatment of adults with multiple myeloma. 1800 mg will be given subcutaneously according to its standard package insert schedule.
48650474|NCT06348147|DRUG|Lenalidomide|Lenalidomide will be administered, once daily orally on Days 1-21 of a 28-day
48650475|NCT06348147|DRUG|Bortezomib|Bortezomib is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma, will be given subcutaneously once weekly on days 1, 8, and 15 of every 28 day cycle.
48650476|NCT06348147|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid.
47973157|NCT04157439|OTHER|Experimental Group|"Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique \[sustain pressure, Post Isometric Relaxation (PIR) and SCS\]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided"
47973158|NCT00275184|DRUG|Senna|
47973159|NCT00275184|DRUG|Citramag powder|
47973160|NCT00275184|DRUG|Metoclopramide|
47973161|NCT02048891|DRUG|GnRH agonist trigger|
48490733|NCT03561441|DRUG|Tailored standard hydration|"1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
48490734|NCT05066763|OTHER|Non-interventional|non-interventional
48490735|NCT05628519|BEHAVIORAL|Captain Sonar Exposition|Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
48490736|NCT05628519|BEHAVIORAL|Monopoly Exposition|Participant will be invited to play to Monopoly during 60 min
48490737|NCT04058574|DEVICE|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
48490738|NCT03165877|OTHER|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (\<55%),consisting of salad, main course and dessert, respectively.
48490739|NCT03165877|OTHER|Control|Subjects ate standard lunches and dinners (\>60%),consisting of salad, main course and dessert, respectively.
48490740|NCT04987242|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
48490741|NCT04987242|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
48490742|NCT03970837|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.
48490743|NCT03970837|DRUG|Tofacitinib|Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.
48650477|NCT00605657|DRUG|Valproic Acid|Oral administration of valproic acid
48490744|NCT03970837|DRUG|Placebo|Placebo matching GSK3196165 and Tofacitinib was administered.
48490745|NCT03706170|BEHAVIORAL|Physiological recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
48327929|NCT01839175|BIOLOGICAL|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
48327930|NCT01839175|BIOLOGICAL|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
48327931|NCT01839175|BIOLOGICAL|RotaTeq|2 mL oral administration at 2, 3 and 4 months
48327932|NCT01839175|BIOLOGICAL|Nimenrix|0.5 mL intramuscular injection at 12 months
48490746|NCT03706170|BEHAVIORAL|EEG recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
48490747|NCT05705817|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|The ASSET program is a 15-session training program that combines specific skill training, structured learning, social performance training and a social hour to practice skills through a manualized group intervention. Specific skills taught within the program include communication, enthusiasm and attitude, teamwork, networking, problem-solving and critical thinking, and professionalism.
48490748|NCT02242565|DEVICE|ShangRing|ShangRing device for male circumcision
48490749|NCT05033366|DIAGNOSTIC_TEST|Proov Test|Rapid response urine PdG, FSH, E1G and LH test strips, Proov
48490750|NCT01206816|DRUG|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
48490751|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Analerg|
48490752|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Bronchi|
48327933|NCT01839175|BIOLOGICAL|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
48327934|NCT02241928|BIOLOGICAL|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
48327935|NCT02882763|OTHER|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
48327936|NCT04344379|DRUG|hydroxychloroquine|200 mg BID per day
48327937|NCT04344379|DRUG|azithromycin|250 mg per day
48327938|NCT04344379|DRUG|hydroxychloroquine placebo|200 mg BID per day
48327939|NCT05456152|DRUG|Sublingual Tablet|Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
48490753|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
48490754|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
48490755|NCT00317421|DRUG|Sildenafil citrate|
48490756|NCT05199766|DRUG|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease|This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
48490757|NCT02312063|DRUG|Sitagliptin|
48490758|NCT02312063|DRUG|Glimepiride|
48327940|NCT02625675|OTHER|Ultrasound scan|
48327941|NCT06031298|BIOLOGICAL|Dentin Graft|Dentin graft is a grafting technique of autogenous origin that uses the teeth extracted from the patient for the graft material preparation.
48490759|NCT01764282|BEHAVIORAL|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
48650478|NCT00605657|PROCEDURE|CT Scan|CT scans were done before and after treating the patient with valproic acid
48327942|NCT00825019|DRUG|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
48327943|NCT00825019|DRUG|placebo|oral administration in 12h intervals
48327944|NCT00825019|DRUG|paroxetine|oral administration of 20 mg/day
48327945|NCT02211183|PROCEDURE|Best Repair of torn Rotator Cuff|
48327946|NCT02211183|DEVICE|InSpace™ system|
48327947|NCT03563456|BEHAVIORAL|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
48327948|NCT03563456|BEHAVIORAL|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
48490760|NCT05346783|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
48490761|NCT05346783|OTHER|Placebo (vehicle)|1 drop 6 times a day
48490762|NCT05346783|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
48650479|NCT00605657|PROCEDURE|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
48490763|NCT05426304|DRUG|Agomelatine|agomelatine 25 mg/day for 180 days
47973162|NCT02048891|DRUG|hCG trigger|
48490764|NCT05426304|DRUG|Placebo Tablets|placebo 25 mg/day for 180 days
48490765|NCT04570397|DRUG|Ravulizumab|Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
47973163|NCT00114036|BEHAVIORAL|Quality improvement strategies|
48327949|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01|high brightness LED light box
48650480|NCT05540184|DRUG|Trimetazidine 35 mg|Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
48327950|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01 with filter|high brightness LED light box with filters that reduced lamp output to less than 50 lux
48327951|NCT06216587|DIETARY_SUPPLEMENT|BLa80|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BLa80.
48327952|NCT04752943|OTHER|Tips By Text Messages|Texts sent to caregivers meant to increase parent child interaction around literacy, sent to participants 3 x a week for 7 months
48327953|NCT04101435|BIOLOGICAL|AdimFlu-S (QIS)|This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
48327954|NCT01957787|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
48327955|NCT03402152|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
48327956|NCT03402152|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
48327957|NCT03402152|DRUG|Placebo|Placebo oral capsule
48327958|NCT02623296|DRUG|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
48327959|NCT02623296|DRUG|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
48327960|NCT02623296|DRUG|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
48327961|NCT02102984|DEVICE|covered biliary stents|endoscopic placement of covered biliary stents
48650481|NCT05540184|DRUG|Allopurinol 300 MG|allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
48650482|NCT05540184|DRUG|Normal saline|rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
47973164|NCT03132220|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
48327962|NCT02102984|DEVICE|uncovered biliary stents|endoscopic placement of uncovered biliary stents
48327963|NCT02219841|PROCEDURE|radiofrequency catheter ablation|
48327964|NCT05494749|OTHER|zirconomer|teeth meeting the inclusion criteria are assigned to receive Zirconomer® restorations
48327965|NCT05494749|OTHER|HVGI-Equia Forte|teeth meeting the inclusion criteria are assigned to receive HVGI-Equia Forte® restorations.
48327966|NCT04658420|DRUG|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
48327967|NCT04658420|OTHER|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
48327968|NCT02195817|DRUG|Selincro® 18 mg with continuous psychosocial support: Cohort A|
48327969|NCT02195817|OTHER|Initial psychosocial support: Cohort B|
48650483|NCT04562519|DEVICE|TENS|Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
48650484|NCT05862584|OTHER|Questionnaires|Distribution of questionnaires to patients to be completed on a weekly basis.
48327970|NCT04521335|DRUG|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
48327971|NCT04521335|DRUG|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
48327972|NCT05518669|DEVICE|Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)|Subjects with biopsy of peripheral pulmonary nodule using electromagnetic navigation bronchoscopy and mobile cone-beam CT.
48650485|NCT06434324|PROCEDURE|Saline Irrigation|250 cc waves of warmed saline irrigation (up to 2000 cc) through thoracostomy tube on a daily basis
48650486|NCT05715827|DEVICE|RAS prostatectomy and RAS cholecystectomy|"There are two types of interventions in the study.~Patients indicated for Robotic Assisted Surgery (RAS) for a prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.~Patients indicated for Robotic Assisted Surgery (RAS) for a cholecystectomy will have the RAS surgery using the Medtronic Hugo RAS system."
48122234|NCT04914442|DIAGNOSTIC_TEST|Microscopic examination|All the studies cases are microscopically examined using the ordinary stains (hematoxylin and eosin) then the eosinophilic infiltration are counted in 10 high power field manually
48650487|NCT02093520|PROCEDURE|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
48650488|NCT02093520|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
48650489|NCT03376529|DRUG|SPR741|400 mg IV over 1 hour
48327973|NCT02921763|DRUG|Dydrogesterone|
48327974|NCT05081596|BEHAVIORAL|PATH-Pain|"The goals of PATH-Pain are to: 1) Teach problem solving skills to reduce negative emotions, by using emotion regulation and problem- solving strategies to overcome these difficulties. 2) Use compensatory strategies and environmental adaptation tools (notes, checklists, calendars, etc.) to avoid limitations resulting from memory problems, help improve emotion regulation, and create an easier environment to live in. If found helpful and participant agrees, a tablet application called WellPATH will be used to help the subject with emotion regulation techniques. The tablet will be given at the beginning of treatment and will be returned at the end of treatment. 3) Invite caregiver participation, when appropriate.~Subjects in the PATH-PAIN group will receive 8 weekly sessions (first 8 weeks) with a study therapist and 6 monthly phone sessions (3 individual and 3 group) for 9-36 weeks. Each session will last approximately 50 minutes."
48327975|NCT03477071|PROCEDURE|Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.
48327976|NCT05157711|DRUG|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
48327977|NCT05157711|DRUG|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
48327978|NCT05157711|DRUG|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
48327979|NCT00976248|DRUG|RAD001|Taken orally once a day
48327980|NCT02162121|PROCEDURE|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
48327981|NCT02162121|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
48327982|NCT02162121|PROCEDURE|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
48327983|NCT02162121|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times a day
48122235|NCT02773693|BEHAVIORAL|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
48122236|NCT02773693|BEHAVIORAL|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
48122237|NCT02773693|BEHAVIORAL|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
48327984|NCT02162121|PROCEDURE|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS\>4
48327985|NCT02162121|DRUG|Mepivacaine 1%|
48122238|NCT04921293|BEHAVIORAL|Ketogenic diet|A diet with \<50gr of carbohydrates per day. Monosaturated fats consumption will encourage over saturated fats
48122239|NCT04921293|DIETARY_SUPPLEMENT|Exogenous ketones|Administration of ketone monoester 25 ml t.i.d
48122240|NCT04921293|BEHAVIORAL|Standard diet + placebo|A standard diet incorporating current recommendations (low in sodium and low in liquids) for heart failure patients.
48122241|NCT00175292|DRUG|Probiotic - VSL#3|
48327986|NCT02162121|DRUG|Levobupivacaine 0,5%|
48327987|NCT02162121|DRUG|Ropivacaine 0,2%|
48122242|NCT06445257|DRUG|zanubrutinib 160 mg BID orally|The ZRMT induction and maintenance regimen
48327988|NCT02162121|DRUG|Ketorolac 30mg|
48327989|NCT02162121|DRUG|Buprenorphine 0,2mg|
48327990|NCT02162121|DEVICE|Stimulong, Pajunk, Germany.|
48327991|NCT02162121|PROCEDURE|Continuous lumbar plexus: non-stimulating catheter|
48327992|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
48327993|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
48327994|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
48490766|NCT05619055|OTHER|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
48490767|NCT01718470|PROCEDURE|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
48650490|NCT03376529|DRUG|Ceftazidime|1.0 gram IV over 1 hour
48650491|NCT03376529|DRUG|Piperacillin/tazobactam|4.5 grams IV over 1 hour
48650492|NCT03376529|DRUG|Aztreonam|1.0 gram IV over 1 hour
48650493|NCT03836079|DEVICE|preCARDIA system|Intermittent occlusion of the SVC
48650494|NCT02709707|DEVICE|Blood glucose monitor|
48122243|NCT00609908|PROCEDURE|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
48122244|NCT00609908|PROCEDURE|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
48122245|NCT00609908|PROCEDURE|serial excision|as much scar as possible is excised, whereafter the wound is closed
48122246|NCT00609908|PROCEDURE|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
48122247|NCT00640250|BIOLOGICAL|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
48122248|NCT00317486|DRUG|bosentan|
48122249|NCT02275611|DRUG|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
48122250|NCT02275611|DRUG|Intranasal Placebo Spray|Intranasal Placebo Spray
48327995|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
48327996|NCT03627494|DRUG|GSK3439171A|Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
48327997|NCT03627494|DRUG|Placebo|Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
48327998|NCT04291872|OTHER|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
48327999|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B new Bulk vaccine|"1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma)~1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region."
48328000|NCT05482282|BIOLOGICAL|DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine|3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
48122251|NCT01595802|DEVICE|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device."
48122252|NCT01595802|DEVICE|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
48328001|NCT05482282|BIOLOGICAL|Recombinant Hepatitis B vaccine (Registered BioFarma)|1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
48328002|NCT05482282|BIOLOGICAL|Pentabio|3 doses of Pentabio
48328003|NCT03768141|PROCEDURE|Liver surgery|"All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)"
48328004|NCT05438459|BIOLOGICAL|Phase I part|Administration of GAIA-102 as a single agent or GAIA-102 and pembrolizumab in combination.
48328005|NCT05438459|BIOLOGICAL|Phase II part|Randomized into group of administration of GAIA-102 as a single agent or GAIA-102 or pembrolizumab in combination, group of standard treatment
48328006|NCT05460650|BEHAVIORAL|App Promoting Healthy Behaviours|Women on the study will receive two months access to the app.
48122253|NCT06433713|DRUG|Lidocaine IV|They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
48122254|NCT06433713|DRUG|Placebo|0.9% normal saline infusion
48122255|NCT05953870|OTHER|Music Therapy|slower tempo music that can quiet mind and make patients feel soothed
48122256|NCT00214240|DRUG|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
48122257|NCT01432613|PROCEDURE|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
48122258|NCT03167034|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
48328007|NCT00703469|DRUG|MDX1106-02|Single dose
48328008|NCT00703469|DRUG|Placebo|Placebo single dose
48122259|NCT03167034|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
48122260|NCT04626180|PROCEDURE|Extubation|Extubation is the removal of an endotracheal tube (ETT), which is the last step in liberating a patient from the mechanical ventilator.
48122261|NCT04626180|PROCEDURE|Manual Hyperinflation|Providing a larger tidal volume than baseline tidal volume to the patient and using a tidal volume which is 50% greater than that delivered by the ventilator
48328009|NCT05994313|DIETARY_SUPPLEMENT|Habitual potato consumption|Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
48328010|NCT05994313|DIETARY_SUPPLEMENT|Habitual non-nutrient-dense staple consumption|White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
48328011|NCT05399030|DRUG|ICP-332|ICP-332 will be administered as tablet
48328012|NCT05399030|OTHER|Placebo|Matching placebo will be administered as tablet
48328013|NCT05706649|BEHAVIORAL|Plant-based diet|21 day diet that excludes any form of meat and other animal products, including dairy products.
48328014|NCT04092998|PROCEDURE|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
48122262|NCT03356223|DRUG|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
48122263|NCT00010725|DRUG|MAK|
48122264|NCT00010725|DRUG|Vitamin Supplements|
48122265|NCT03276403|DEVICE|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
48122266|NCT00683696|DEVICE|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
48122267|NCT00397475|DRUG|Colecalciferol|
48328015|NCT05806021|DRUG|Triamcinolone Acetonide|Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
48328016|NCT04868370|OTHER|Assessment of the upper limb (VPIT + PPIT)|Assessment of the upper limb sensorimotor function (VPIT and PPIT)
48328017|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS|"Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind."
48328018|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device|HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
48328019|NCT05690269|DEVICE|SpO2 and SaO2 comparison|Several pulse oximeter will be place on patients fingers a few minutes before arterial blood gases. SpO2 will be recorded during that time and up to 10 minutes.
48328020|NCT04159077|DRUG|Tamsulosin Hydrochloride|"Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax"
48122268|NCT05286489|COMBINATION_PRODUCT|Qigong exercise|The qigong style they learned is known as 18 Forms Tai Chi Internal Qigong. It is a kind of physical and mental exercise (internal qigong) that focuses on relaxation, deep breathing, and slow and coordinated movements and uses the mind to guide these movements. There are a total of 18 upper and lower body movements, and all of the techniques are performed while either standing or semi squatting. qigong practice session was initiated immediately and continued for about 6 minutes. Each participant in the qigong group performed 18 Forms Tai Chi Internal Qigong once and was assessed immediately afterward in sitting (to measure the vascular outcomes) and lying (to measure the upper limb circumference) positions. The control participants were given no specific exercise instruction after the baseline assessment. Instead, they were asked to rest (sit quietly in the laboratory) for 6 minutes and then participated in the postassessment directly
47973165|NCT03132220|BEHAVIORAL|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
48122269|NCT00533546|DRUG|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
48328021|NCT04159077|DRUG|Placebos|Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
48328022|NCT04695899|DEVICE|Dental Implant|"See Section Procedures."
48328023|NCT02584413|DEVICE|Magnetic resonance imaging|-Standard of care
48328024|NCT02584413|DRUG|Gadolinium contrast|-Standard of care
48328025|NCT04511442|OTHER|Evaluation of food preferences during a standardized and validated buffet.|"The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants."
48328026|NCT01684891|DRUG|RG1662|multiple doses of RG1662
48328027|NCT02835677|BEHAVIORAL|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
48328028|NCT02142257|PROCEDURE|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
48328029|NCT02142257|DEVICE|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
48328030|NCT04735549|DEVICE|Laser Treatment|"Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth."
47973166|NCT03275012|DRUG|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and \>15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
47973167|NCT03275012|DRUG|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
47973168|NCT03938168|DIAGNOSTIC_TEST|Biopsy, fecal sample|Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
47973169|NCT03516994|BEHAVIORAL|Respecting Choices First Steps|Advance Care Planning Approach
47973170|NCT03516994|BEHAVIORAL|Five Wishes Form|Advance Care Planning Approach
47973171|NCT03159767|DEVICE|ViMove Spinal Sensor|Sensors will be used to measure spinal movement
48328031|NCT04735549|DRUG|Topical hormone estriol|Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
48122270|NCT06051175|OTHER|Bitter taste perception|"Participants will perform a bitter taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
48122271|NCT06051175|OTHER|Salty taste perception|"Participants will perform a salty taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
47973172|NCT04804475|OTHER|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
48122272|NCT06051175|OTHER|Sweet taste perception|"Participants will perform a sweet taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
48122273|NCT06051175|OTHER|Acid taste perception|"Participants will perform a acid taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
48122274|NCT06051175|OTHER|Umami taste perception|"Participants will perform a umami taste perception analysis. During the analysis of sensory attributes, participants will pass the solutions through the various regions of the tongue, and at the end, throw the contents away, not ingesting the solution. Between analyzing the various solutions, participants will rinse their mouth with water.~Simultaneously with the analysis of sensory attributes, each participant will be subjected to an assessment of brain activity and physiological activity through the following non-invasive methods: electroencephalography technique; electrocardiography technique; monitoring cardiac electrical activity; facial mimicry activity via video analysis and eye tracking; and electrodermal activity using galvanic skin response."
48122275|NCT01708798|DRUG|Eplerenone|
48122276|NCT01708798|DRUG|Placebo|
48122277|NCT05510895|DRUG|Binimetinib|Triplet combination administered neoadjuvant and adjuvant, depending on TRG
48122278|NCT04383730|DRUG|Intravenous sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
48122279|NCT04383730|DRUG|Inhaled sedation|Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
48490768|NCT01718470|PROCEDURE|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
48490769|NCT00005765|DRUG|nicotine|
48490770|NCT00005765|DRUG|alcohol|
48490771|NCT05342415|OTHER|Internally Focused Exercise|While performing the exercises participants will be instructed to focus on the muscle itself.
48490772|NCT05342415|OTHER|Externally Focused Exercise|While performing the exercises participants will be instructed to focus on the external target (towel, target line, etc.)
48490773|NCT01546935|DRUG|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
47973173|NCT05846945|OTHER|Threshold inspiratory muscle trainer device|The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
48122280|NCT00580593|DEVICE|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
48122281|NCT00580593|OTHER|sham-NIPPV|a sham-device
48122282|NCT04761146|RADIATION|DaRT Diffusing Alpha-emitters Radiation Therapy|DaRT is a brachytherapy treatment comprising stainless-steel 316LVM wires coated with radium-224 (Alpha DaRT seeds). The radioactive seeds are inserted directly into the tumour on the perineum and will be removed after 14 days.
48122283|NCT06515951|DIAGNOSTIC_TEST|STANDING algorithm|The STANDING algorithm is composed by four steps. The first phase consists in evaluating the presence of spontaneous nystagmus at rest for at least five minutes with and without Frenzel goggles in order to assess if a acute vestibular syndrome is present. If there is not a spontaneous nystagmus, then positional maneuvers (Pagnini-Mc Cure and Dix-Hallpike) have to be performed. Otherwise if spontaneous nystagmus is observed, its feature are fundamental to diagnose a central vertigo. If nystagmus characteristics suggest a peripheral form, the head impulse test is performed by instructing the patient to keep eyes on a fixed target and then turned the head quickly. An abnormal response is typical of vestibular neuritis. In any cases after the described maneuvers, the patient must be evaluated when standing up and walking: if this turn out to be impossibile, the test is indicative of central nervous system disease.
48122284|NCT01164098|DRUG|Rituximab|Induction therapy
48122285|NCT03608475|OTHER|Limited Ultrasound Imaging|Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits
48122286|NCT03608475|OTHER|Standard Ultrasound Imaging|Ultrasound imaging will be performed at all clinic visits
48328032|NCT04735549|DIAGNOSTIC_TEST|Сlinical blood analysis|Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
48328033|NCT04735549|DIAGNOSTIC_TEST|Сlinical urine test|Urine sampling for Clinical urine test (to include the participant in the study).
48328034|NCT04735549|DIAGNOSTIC_TEST|Vaginal smear|Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
48328035|NCT04735549|DIAGNOSTIC_TEST|Pelvic ultrasound|Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
48328036|NCT04735549|OTHER|Female Sexual Function Index|Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
48328037|NCT04735549|OTHER|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire|The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
48328038|NCT04735549|OTHER|Vulvovaginal Symptoms Questionnaire|Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
47973174|NCT05846945|OTHER|Adjusting mechanical ventilator trigger sensitivity|modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
48122287|NCT02332577|DRUG|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
48122288|NCT02332577|DRUG|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
48122289|NCT02332577|DRUG|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
48122290|NCT02332577|DRUG|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
48490774|NCT04056871|DIAGNOSTIC_TEST|Frailty Screening Tools|This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
48490775|NCT01460901|BIOLOGICAL|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
48490776|NCT02126930|OTHER|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
48490777|NCT02126930|OTHER|Routine care|Patients randomized to this arm will receive care in the habitual manner.
48490778|NCT01077466|DRUG|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
48490779|NCT05865808|OTHER|cervical spine mobilization|headache SNAGs, 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Eight weeks of treatment session will be provided and assessment of the improvement in cervicogenic headache will done at baseline, after 04, 06 and at the end of 8 week.
48490780|NCT05865808|OTHER|Rocabado 6x6|The Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique, which are to be performed 6 times in a day with 6 repetitions of each exercise in each session,
48122291|NCT02779998|OTHER|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
48328039|NCT04735549|DIAGNOSTIC_TEST|Vaginal Health Index|Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
47973175|NCT05846945|OTHER|Chest physiotherapy|Conventional chest physiotherapy
47973176|NCT05519410|DRUG|Sintilimab and Lenvatinib|Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
48122292|NCT02779998|OTHER|Standard oxygen therapy with facial mask|
48122293|NCT00370019|DRUG|Estradiol/Medroxyprogesterone acetate|
48122294|NCT02677129|OTHER|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
48650495|NCT00635050|DRUG|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
48122295|NCT05374889|OTHER|Open Kinetic Chain Proprioception Exercises|basketball-specific target shooting in open kinetic chain
48122296|NCT05445440|DRUG|Methotrexate|Specified dose on specified days
48650496|NCT04158258|DRUG|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
48650497|NCT04158258|DRUG|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
48650498|NCT04158258|DRUG|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
48650499|NCT04158258|DRUG|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
48650500|NCT04158258|DRUG|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
48650501|NCT04158258|DRUG|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
48650502|NCT04426513|OTHER|Kinesiotherapy with magnetotherapy|Individual kinesiotherapy. Parameters of magnetic field: 7 mT, f= 0-50 Hz, type of impulse: unipolar or bipolar, rectangular pulse
48650503|NCT04989166|DIETARY_SUPPLEMENT|Nano-curcumin|Nano-curcumin soft gels
48650504|NCT04989166|DRUG|Placebo|Placebo
48650505|NCT05280145|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilatation or hepatic steatosis
48650506|NCT05280145|DEVICE|Ultrasound device routinely used in the department|Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilatation or hepatic steatosis
47973177|NCT05519410|DRUG|HAIC-FOLFOX|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
47973178|NCT03485547|DRUG|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
47973179|NCT04964531|OTHER|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
47973180|NCT02333877|OTHER|Skinlink|suture using Skinlink
47973181|NCT02333877|OTHER|Nylon|conventional suture using nylon
47973182|NCT03120416|BEHAVIORAL|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
47973183|NCT03571815|DRUG|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
47973184|NCT03571815|OTHER|WATER ON TEETH|control group
47973185|NCT05346471|DEVICE|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
47973186|NCT02376361|DEVICE|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~1. Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~2. Recirculation, access flow will be performed according to HD03 Manual.~3. Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
47973187|NCT00302835|DRUG|non-phenacetin containing analgesics|
47973188|NCT02135302|DRUG|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
47973189|NCT02454296|DRUG|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
47973190|NCT02454296|DRUG|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
47973191|NCT06183424|PROCEDURE|Transcranial Direct Stimulation|2 mA, 20 min, 5 days
47973192|NCT04412369|DIAGNOSTIC_TEST|Non-invasive cardiac imaging|Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
48122297|NCT05445440|DRUG|Leucovorin|Specified dose on specified days
48122298|NCT05445440|DRUG|BMS-986371|Specified dose on specified days
48122299|NCT05445440|DRUG|Sulfasalazine|Specified dose on specified days
48122300|NCT06299228|OTHER|Experimental Group|Sensorimotor intervention, active range of motion, active assisted range of motion, strengthening
48122301|NCT06299228|OTHER|Control Group|Active range of motion, active assisted range of motion and strengthening
48122302|NCT01557335|DRUG|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
48122303|NCT01557335|DRUG|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
48122304|NCT01388777|DEVICE|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
48328040|NCT04735549|DIAGNOSTIC_TEST|Elastography (ultrasound investigation)|Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
48328041|NCT04735549|DIAGNOSTIC_TEST|Perineometry|Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
48122305|NCT01388777|PROCEDURE|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
48328042|NCT04735549|OTHER|Visual Analogue Scale (VAS)|Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
48490781|NCT05810558|PROCEDURE|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
48490782|NCT05810558|PROCEDURE|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
48490783|NCT03433716|OTHER|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
47973193|NCT05466162|OTHER|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
47973194|NCT05466162|OTHER|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
47973195|NCT00718835|BEHAVIORAL|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
47973196|NCT03284944|DEVICE|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
47973197|NCT03284944|DEVICE|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
47973198|NCT04782427|OTHER|COVID-19 infection|Case of nosocomial infection within the long-term care facility
47973199|NCT01502098|PROCEDURE|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
47973200|NCT01502098|OTHER|Sling|Sling for 4 weeks
47973201|NCT05641753|DRUG|Evolocumab Cartridge|Injectable PCSK9 inhibitor.
48122306|NCT01388777|PROCEDURE|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
48122307|NCT00552201|DRUG|Tacrolimus|Administration Twice a day after adjustment to blood level
48340194|NCT05321693|DEVICE|Transcranial Pulsed Current Stimulation|Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
48122308|NCT03981926|OTHER|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
48490784|NCT03655236|DRUG|K0706|low dose, orally, once-daily
48490785|NCT03655236|DRUG|K0706|high dose, orally, once-daily
48490786|NCT03655236|OTHER|placebo|placebo, orally, once-daily
48490787|NCT03475264|DIAGNOSTIC_TEST|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
48490788|NCT01962181|DRUG|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
48122309|NCT02036424|DRUG|Ozurdex|intravitreal steroid
48122310|NCT02036424|DRUG|Bevacizumab|antiVEGF
48122311|NCT01186159|DRUG|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
48122312|NCT04364139|OTHER|MAP goal less than or equal to 92 mm Hg|Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg
48122313|NCT04364139|OTHER|MAP goal 102-107 mm Hg|Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg
48122314|NCT04364139|DRUG|Ramipril|An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d
48122315|NCT04364139|DRUG|Amlodipine|A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d
48340195|NCT04673669|DIAGNOSTIC_TEST|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
47973202|NCT05641753|DRUG|Atorvastatin Calcium Tablets|HMG-CoA reductase inhibitor for oral use.
47973203|NCT05641753|DRUG|Ezetimibe Tablets|Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
47973204|NCT05641753|DRUG|18F-FDG|Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
47973205|NCT05641753|DEVICE|Angiocatheter 20IV|Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
47973206|NCT05641753|DEVICE|J-Wire|Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
47973207|NCT05641753|DEVICE|GlycoCheck Glycocalyx Measurement Software|Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
47973208|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
47973209|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
48490789|NCT01962181|DRUG|Placebo|
48490790|NCT05177562|OTHER|No intervention|There is no intervention in this study
47973210|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
47973211|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
48122316|NCT04364139|DRUG|Metoprolol|A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d
48122317|NCT04222946|OTHER|Dry needling|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
48122318|NCT01084031|DRUG|propofol|intravenous propofol with sevoflurane inhalation induction
48122319|NCT03622749|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
48122320|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
48122321|NCT01488734|DIETARY_SUPPLEMENT|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
48122322|NCT01488734|DIETARY_SUPPLEMENT|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
48122323|NCT01488734|DIETARY_SUPPLEMENT|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
48122324|NCT01488734|DRUG|Placebo|Placebo for the fortified mushroom arms
48340196|NCT03313856|DRUG|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
48340197|NCT03313856|DRUG|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
48490791|NCT05404412|PROCEDURE|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
48490792|NCT05543330|DRUG|M701 pleural infusion|M701 pleural infusion on Days 1,4,7 and 10.
48490793|NCT05543330|PROCEDURE|Pleural drainage|Pleural effusion drainage via Ultra-sound guidance on Day 1.
48490794|NCT05543330|DRUG|Cisplatin pleural infusion|Cisplatin pleural infusion (30-50mg/m2) on Day 1.
48122325|NCT06145568|OTHER|Pregnant Women|We want to quantify Minority Americans at risk of pregnancy complications
48122326|NCT04619290|DRUG|Sublingual Methylene blue|Patients will be received the treatment as follow: it will be placed Low Level Light Therapy (LLLT) NocUlite on the ventral side of the wrist on full power. Draw out 1ml of diluted Prexablu into a syringe. Activate this syringe LLLT device for 10 minutes. Then place 1ml of this activated solution of Prexablu sublingually. Patients must keep the solution under the tongue for 10 minutes before swallowing. Keep wrist pads on patients for 50 minutes.
48122327|NCT04619290|OTHER|Control patients|Control patients will be received the conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.
48122328|NCT04410367|DRUG|18F fluciclovine|18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus
48122329|NCT03532906|DRUG|TAP Block|Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
48122330|NCT03532906|DRUG|Control|Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
48122331|NCT01741441|PROCEDURE|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
47973212|NCT05601817|BEHAVIORAL|Vita|Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
47973213|NCT05601817|BEHAVIORAL|Com|Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
47973214|NCT05601817|BEHAVIORAL|Vita+Com|Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
47973215|NCT00302250|DRUG|ALT-711 (alagebrium chloride)|
47973216|NCT02223091|BEHAVIORAL|Consultation by a trained physician|
48122332|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Normal')|Energy Intake provision (60 kcal/kg FFM/day) to elicit 'normal' energy availability (45 kcal/kg FFM/day), with 60% from carbohydrates.
48122333|NCT05551455|OTHER|Nutritional/dietary intake manipulation ('Low')|Energy Intake provision (60 kcal/kg FFM/day), with 1.5 g/kg of carbohydrate and 70-80% fat intake, to elicit 'low' carbohydrate availability in energy balance (45 kcal/kg FFM/day).
48122334|NCT02628171|OTHER|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
48122335|NCT02628171|OTHER|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
48122336|NCT04980274|OTHER|Intervention focused on identified organ dysfunction(s)|Intervention focused on identified organ dysfunction(s)
48122337|NCT03896815|DRUG|INCB054329|
48122338|NCT00212134|DEVICE|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
48122339|NCT00212134|DEVICE|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
48340198|NCT05300854|PROCEDURE|Standard anesthesia in addition to serratus plane block|a US-guided SPB was performed after induction of general anesthesia with the patient lying supine.
48122340|NCT05015010|DRUG|Alectinib|600 mg p.o. (four 150 mg capsules) twice daily with food (within 30 minutes after a meal, in the morning and evening).
48122341|NCT00094822|OTHER|PI Discretion|PI Discretion
48122342|NCT00123903|DRUG|metoprolol xl|
48122343|NCT00123903|DRUG|carvedilol MR|
48122344|NCT00123903|DRUG|lisinopril|
48122345|NCT03090776|DRUG|Ketamine|low dose bolus and infusion ketamine, administered under general anesthesia
48122346|NCT03090776|OTHER|Placebo saline|bolus and infusion saline, administered under general anesthesia
48122347|NCT02331745|DRUG|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
48122348|NCT02331745|DRUG|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
48122349|NCT00687713|DRUG|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
48122350|NCT00687713|OTHER|Placebo|Placebo
47973217|NCT02223091|BEHAVIORAL|Consultation by an untrained physician|
48122351|NCT00812461|DRUG|Placebo|as-needed use, tablets, orally, 6 months
48122352|NCT00812461|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
48122353|NCT03206515|DEVICE|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
48122354|NCT03206515|DEVICE|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
48122355|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
48122356|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
48122357|NCT01239758|BIOLOGICAL|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
48122358|NCT04324450|DEVICE|MRI|"The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging"
48122359|NCT04324450|BEHAVIORAL|Cognitive assessment|Battery of neuropsychological tests
48340199|NCT05300854|PROCEDURE|Standard anesthesia in addition to para-vertebral block|Standard anesthesia in addition to para-vertebral block
48340200|NCT06423872|DRUG|ZT002|Participants will receive a single subcutaneous (SC) ZT002 injection.
48340201|NCT06423872|OTHER|Placebo|Participants will receive same volume as of the study drug.
48122360|NCT01093820|DRUG|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
48122361|NCT02560649|DRUG|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
48122362|NCT02560649|DRUG|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
48650507|NCT05280145|PROCEDURE|Ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
48328043|NCT01525940|DEVICE|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
48328044|NCT03539913|BIOLOGICAL|Probiotic : Saccharomyces boulardii|Treatment for 5 days
48328045|NCT03539913|BIOLOGICAL|Probiotic : Bacillus clausii|Treatment for 5 days
48490795|NCT01148641|DIETARY_SUPPLEMENT|LNS|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
48490796|NCT03045159|BEHAVIORAL|Strong Families Strong Forces|Parenting program
48490797|NCT03045159|BEHAVIORAL|Strong Parents|self-care program
48490798|NCT05435339|BIOLOGICAL|GEN1053|GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
48328046|NCT04843826|PROCEDURE|papilla reconstruction|subepithelial connective tissue graft for interdental papillary reconstruction around delayed
48328047|NCT02993458|OTHER|DASH diet|DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
48328048|NCT02993458|OTHER|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
48490799|NCT05585476|DEVICE|C02 microablative laser|The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.
48490800|NCT05585476|COMBINATION_PRODUCT|Regenerative topical treatment|It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.
47973218|NCT05256953|PROCEDURE|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
47973219|NCT05256953|PROCEDURE|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
47973220|NCT05416593|BEHAVIORAL|General exercise prescription (FITT)|The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
48122363|NCT02560649|DRUG|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
48328049|NCT02993458|OTHER|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
48490801|NCT04333472|DRUG|Piclidenoson|Piclidenoson 2 mg orally every 12 hours for up to 28 days
48490802|NCT04333472|DRUG|Placebo|Placebo orally every 12 hours for up to 28 days
48490803|NCT03968198|DRUG|Autologous ASC (for Adipose-derived Stem/Stroma Cell)|After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
48650508|NCT05645887|DRUG|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
48122364|NCT02560649|DRUG|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
48328050|NCT02993458|OTHER|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
48328051|NCT04953065|OTHER|COVID-19 vaccine hesitancy and acceptance survey|Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
48328052|NCT03400215|DIAGNOSTIC_TEST|Diagnostic Breast Cancer Scan|clinically indicated diagnostic breast MRI scans
48328053|NCT03400215|DIAGNOSTIC_TEST|Research Scan for Gradient-echo Spectroscopic Imaging (GSI)|15-min research MRI scan
48328054|NCT06528730|DIAGNOSTIC_TEST|DCM|Confirm degenerative cervical myelopathy by Orthopaedic surgeon and MRI
48328055|NCT05796804|PROCEDURE|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
48328056|NCT05796804|PROCEDURE|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
48328057|NCT05796804|PROCEDURE|spinal anesthesia|bupivacaine 0.5% 2.2 ml
48328058|NCT02437552|DEVICE|ergometer cycle exercise|
48328059|NCT02437552|OTHER|routine physiotherapy|routine physiotherapy
48328060|NCT05225051|OTHER|skin biopsy|skin biopsy
48328061|NCT05634096|DIAGNOSTIC_TEST|Oximetry|Children underwent oximetry simultaneously with video-polygraphy or video-polysomnography in routine clinical practice. The data are retrospectively collected from the patient's recording.
48328062|NCT03101046|DRUG|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
48328063|NCT03101046|DRUG|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
48328064|NCT03119246|OTHER|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
48328065|NCT03404635|DRUG|Apixaban|Apixaban as standard of care for VTE
48328066|NCT03404635|DRUG|Rivaroxaban|Rivaroxaban as standard of care for VTE
48328067|NCT02353039|DRUG|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
48328068|NCT02353039|DRUG|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
48328069|NCT02353039|DRUG|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
48328070|NCT02353039|DRUG|Placebo|Administer placebo t.i.d for 2 weeks
48328071|NCT03277703|BIOLOGICAL|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
48328072|NCT04391855|DRUG|Tramadol with ropivacaine|A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
48328073|NCT04391855|DRUG|Dexmedetomidine with ropivacaine|A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
48328074|NCT04391855|DRUG|Magnesium with ropivacaine|A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
48328075|NCT04391855|DRUG|Ropivacaine plus normal saline|A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
48328076|NCT03164785|DRUG|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
48328077|NCT04365894|OTHER|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
48328078|NCT03148158|DEVICE|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
48328079|NCT00869388|BIOLOGICAL|rBBX-01|
48328080|NCT05295745|BEHAVIORAL|Cognitive remediation therapy and multidisciplinary intervention|"The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included"
48328081|NCT02990819|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
48122365|NCT02560649|DRUG|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
48122366|NCT02560649|DRUG|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
48122367|NCT02560649|DRUG|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
48122368|NCT02560649|DRUG|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
48122369|NCT02459015|DEVICE|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
48122370|NCT05110105|BEHAVIORAL|Interactive board game health education|The interactive board game includes risk factors, symptoms, and acute management of stroke. It's a card game combined with (1) addition and subtraction game (risk factors). (2) gestures game (symptoms) (3) matching game (acute management), but in traditional Chinese. The game was implemented in a group (2\~6 individuals) for 40 minutes.
48122371|NCT05110105|BEHAVIORAL|Conventional health education|The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the stroke prevention video was collected from the internet. Participants were assigned to read the health education flier for 20 minutes. Then watch the stroke prevention video for 20 minutes.
48328082|NCT00676793|DRUG|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
48328083|NCT04922034|DRUG|Amoxicillin|Outcome of patients with negative oral challenge to amoxicillin
48328084|NCT05516693|OTHER|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
48328085|NCT01057914|DIETARY_SUPPLEMENT|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
48328086|NCT01057914|OTHER|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
48328087|NCT01057914|OTHER|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
48328088|NCT00049218|BIOLOGICAL|Autologous dendritic cell-adenovirus p53 vaccine|
48650509|NCT05645887|OTHER|Saline solution|Saline solution from day 0 to day 7.
48122372|NCT00103324|DRUG|lapatinib ditosylate|Given orally
48490804|NCT04531995|DEVICE|CANKADO PRO-React Onco|CANKADO PRO-React Onco is approved as class I medical device within the European Union (registration number DE /CA59 /371/2020-R/Hd) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B. The purpose of CANKADO PRO-React Onco is to be an automated digital support for patients to help them decide how urgent it is to contact the attending physician based on the symptoms they independently record in the system. It supports patients with cancer under systemic, anti-tumor or anti-hormonal therapy in adjuvant, neoadjuvant, post-neoadjuvant or palliative situations. It is unsuitable for patients undergoing radiotherapy, cell and gene therapy, surgical procedures or alternative healing methods.
48650510|NCT04287829|DRUG|Pembrolizumab|Infusion
48650511|NCT04287829|DRUG|Lenvatinib|Capsule
48650512|NCT02082782|PROCEDURE|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
48122373|NCT00103324|OTHER|laboratory biomarker analysis|Correlative studies
48122374|NCT02820116|DRUG|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
48650513|NCT06302985|PROCEDURE|atomized inhalation ICG before thoracoscope pneumonectomy|"Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed."
48122375|NCT03492424|DEVICE|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
48122376|NCT01308567|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
48328089|NCT00049218|DRUG|Carboplatin|
48328090|NCT00049218|DRUG|Etoposide|
48328091|NCT00351091|DRUG|RISEDRONATE|
48328092|NCT02087293|BEHAVIORAL|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
48122377|NCT01308567|DRUG|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
48122378|NCT01308567|DRUG|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
48122379|NCT03143842|DEVICE|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
48122380|NCT03029598|DRUG|Carboplatin|Given IV
48328093|NCT05568498|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
48650514|NCT02071732|DEVICE|real repetitive Transcranial Magnetic Stimulation|
48122381|NCT03029598|OTHER|Laboratory Biomarker Analysis|Correlative studies
48122382|NCT03029598|BIOLOGICAL|Pembrolizumab|Given IV
48122383|NCT04282824|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
48122384|NCT04282824|PROCEDURE|Computed Tomography|Undergo PET/CT
48122385|NCT04282824|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
48122386|NCT04282824|DIETARY_SUPPLEMENT|Monosodium Glutamate|Given PO
48328094|NCT05568498|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
48328095|NCT03178617|OTHER|Educational Intervention|Attend standard of care LIP
48328096|NCT03178617|OTHER|Educational Intervention|Attend HIP
48328097|NCT03178617|OTHER|Quality-of-Life Assessment|Ancillary studies
48328098|NCT03178617|OTHER|Questionnaire Administration|Ancillary studies
48328099|NCT03674333|DIETARY_SUPPLEMENT|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
48328100|NCT03674333|OTHER|Placebo|Placebo - a sugar pill
48328101|NCT01697852|OTHER|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
48328102|NCT01697852|OTHER|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
48340202|NCT04300881|DRUG|Eplerenone|Following intravitreal ocriplasmin therapy
48340203|NCT04557618|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
48122387|NCT04282824|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48122388|NCT01291381|DRUG|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
48122389|NCT01291381|DRUG|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
48122390|NCT05066958|BIOLOGICAL|boost anti-viral immunity after T-cell depleted HSCT|"* Registration and informed consent sign~* Screening clinical and laboratory examination, assessment of compliance with inclusion criteria~* Survey of the recipient and potential donors~* Donor selection~* The study of the immune response to relevant antigens in the donor and recipient~* Pre-transplant conditioning~* Stimulation of the donor and apheresis of peripheral blood mononuclear cells~* Graft processing~* The manufacturing of cell product~* Transplant Infusion~* Antigen-primed memory DLI infusion~* Inpatient care until day +30~* Outpatient monitoring and screening"
48122391|NCT00026234|DRUG|floxuridine|Given intra-arterially
48122392|NCT00026234|DRUG|dexamethasone|Given intra-arterially
48122393|NCT00026234|DRUG|oxaliplatin|Given IV
48490805|NCT04027374|PROCEDURE|Fetal surgery for MMC repair|Fetal surgery for MMC repair
48122394|NCT00026234|DRUG|capecitabine|Given orally
48122395|NCT03083067|DRUG|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
48122396|NCT03083067|DRUG|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
48328103|NCT05399849|BEHAVIORAL|Mindfulness Exercises and Meditations|Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
48328104|NCT02679196|DRUG|KA2237|PI3 Kinase p110β/δ inhibitor
48328105|NCT04938362|OTHER|FDG-PET|\[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess
48650515|NCT02071732|DEVICE|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
48328106|NCT04938362|OTHER|EEG|Electroencephalography (EEG) at 0-10 years after brain abscess
48328107|NCT04420910|OTHER|Non-Motor Symptoms|NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
48650516|NCT05743673|DEVICE|Shape II|cardiopulmonary exercise testing apparatus
48650517|NCT03552445|BIOLOGICAL|Tetanus-diphtheria (Td) and PCV13|154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
48340204|NCT04557618|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
48650518|NCT03552445|BIOLOGICAL|PCV13 alone|154 PCV13 recipients: one vaccine injection administered on Day 0
48650519|NCT03552445|BIOLOGICAL|Td alone|437 Td recipients: one vaccine injection administered on Day 0
48122397|NCT00176839|PROCEDURE|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
48122398|NCT00176839|DRUG|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
48122399|NCT00176839|DRUG|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
48122400|NCT00176839|DRUG|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
48122401|NCT00176839|DRUG|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
48122402|NCT00176839|DRUG|ATG|ATG will be administered to umbilical cord blood recipients.
48122403|NCT06518668|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.
48122404|NCT06518668|DRUG|Cyclophosphamide LD|"Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)"
48122405|NCT00343486|DRUG|Solabegron|
48122406|NCT03433586|DRUG|Aspirin 81 mg|81mg of aspirin to be taken daily for 10-14 days
48340205|NCT05905770|DRUG|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
48490806|NCT01121341|PROCEDURE|Vein harvesting|Endoscopic versus conventional vein harvesting
48490807|NCT04160845|PROCEDURE|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
48490808|NCT06422390|BIOLOGICAL|Platelet - Rich Plasma|Platelet - Rich Plasma is a biologic injection created from the patient's own blood. 52cc of the patient's blood is drawn then mixed with 8cc of anticoagulant. The blood mixture will be spun down using a centrifuge that can separate the platelet-rich plasma from the other contents in the blood. Once the centrifuge process is complete the Platelet - Rich Plasma is ready to be used.
48490809|NCT04674397|RADIATION|Radioisotope GFR test|
48490810|NCT03734406|OTHER|Videoclips|The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
48650520|NCT05422573|BEHAVIORAL|post-test cardiovascular genetic counseling with pre-test education by video|post-test cardiovascular genetic counseling with pre-test education by video
48122407|NCT03433586|DRUG|Placebo|Placebo pill (visually identical to aspirin pill) to be taken daily for 10-14 days
48122408|NCT04163536|DRUG|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
48122409|NCT04163536|DRUG|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
48122410|NCT00698919|OTHER|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
48122411|NCT01460667|DRUG|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
48122412|NCT01460667|DRUG|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
48122413|NCT01414738|RADIATION|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
48122414|NCT02201043|DRUG|Thalidomide 150mg|
48122415|NCT02201043|DRUG|Thalidomide 100mg|
48122416|NCT02201043|DRUG|Placebo|
48122417|NCT03145155|BEHAVIORAL|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
48122418|NCT03145155|BEHAVIORAL|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
48122419|NCT05075486|BEHAVIORAL|Collaborative quality improvement|Hospitals will receive standardized center-specific ECLS data report with benchmarking to feedback on their performance. Evidence-based potential better practice list will be established as a reference for all hospitals. During the intervention period, the hospitals will receive training in collaborative quality improvement method and then develop, implement, and document evidence-based practice changes to reduce adverse outcomes of neonatal ECLS treatment. Compliance with practice changes and neonatal outcomes will be monitored. All hospitals will have access to implementation support and collaborative activities.
48122420|NCT05198531|DRUG|TQB2858 Injection|TQB2858 Injection, a bifunctional fusion protein against Programmed death ligand 1 (PD-LI) and transforming growth factor-β (TGF-β). TQB2858 Injection blocks the PD-1/PD-L1 pathway and neutralizes TGF-β in the tumor microenvironment.
48122421|NCT05198531|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
48122422|NCT05198531|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride, cell cycle-specific antimetabolites, mainly acting on tumor cells in the DNA synthesis phase (S phase cell). Under certain conditions, it can prevent the progression from G1 phase to S phase.
48122423|NCT05198531|DRUG|Cisplatin Injection|After cisplatin enters cells, it reacts with DNA to form cross-links between two points or two strands in DNA, thereby inhibiting DNA replication and transcription, resulting in DNA breaks and miscoding.
48122424|NCT00130156|DRUG|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
48328108|NCT04420910|OTHER|Balance|To measure balance, the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used. The participants were asked to position themselves in a comfortable position on the platform, and their foot position coordinates were recorded. The participants focused on a characteristic dot on the monitor screen. Their task was to balance the body in such a way that the dot was in the center of a circle displayed on the monitor at the point of intersection of the coordinate axes. The test consisted of three 20 s trials, each separated by 10 s breaks. Measurements were conducted while their eyes were open and close, and the results were analyzed by calculating the average value of the measurements.
48650521|NCT05422573|BEHAVIORAL|required phone call with genetic counselor pre-test|REQUIRED phone call with genetic counselor pre-test.
48122425|NCT00130156|DRUG|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
48490811|NCT02435836|DRUG|Aripiprazole|
48490812|NCT04866277|OTHER|Fast-track referral for reference services|Activation of fast-track referral for specialized units and care programs for the four psychosocial and behavioural risk factors under study.
48490813|NCT03425487|BEHAVIORAL|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
48122426|NCT00130156|DRUG|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
48122427|NCT05640180|DRUG|Finerenone (Kerendia, BAY94-8862)|Retrospective cohort analysis using randomized clinical trials data.
48122428|NCT05640180|DRUG|Sodium-glucose cotransporter-2 inhibitors (SGLT2i)|Retrospective cohort analysis using United States Optum Electronic Health Records data.
48122429|NCT04277936|DRUG|Levetiracetam 500 mg|Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the hippocampus.
48122430|NCT00853918|OTHER|$20 cash|$20 cash incentive mailed with survey
48122431|NCT00853918|OTHER|$50 cash|$50 cash incentive mailed with survey
48122432|NCT00853918|OTHER|$50 check|$50 check incentive mailed with survey
48122433|NCT00853918|OTHER|$100 check|$100 check incentive mailed with survey
48328109|NCT04420910|OTHER|Lower Limb Strength|A Biodex® System 4 Dynamometer device was used to evaluate muscle strength. The participants' dominant extremity was determined by asking them the foot with which they most often hit the ball.The dynamometer arm of the device was placed at the lateral condyle level of the knee, and the belt at the distal end of the dynamometer was attached to the lower leg on the malleolus. Knee flexion and extension movements were evaluated in sitting position between 90ᵒ flexion and 0ᵒ extension angles. The individual was asked to perform it with the maximum strength, while the therapist motivated the individual with verbal stimulation.
48650522|NCT05422573|BEHAVIORAL|optional phone call with genetic counselor pre-test|OPTIONAL phone call with genetic counselor pre-test
47973221|NCT05416593|BEHAVIORAL|Affective regulation (AFFECT)|As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
47973222|NCT00314093|DRUG|RFT5pdgA|
47973223|NCT00878085|DEVICE|Robot Therapy Device|3x a week for 4 weeks
47973224|NCT00878085|BEHAVIORAL|Occupational Therapy|3x a week for 4 weeks
47973225|NCT06406283|BEHAVIORAL|High-Intensity Functional Training (HIFT)|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The training protocol will be designed based on Cross-Training workouts, emphasizing high-intensity interval training combined with functional resistance-training movements."
47973226|NCT06406283|BEHAVIORAL|Mindfulness-Based Stress Reduction Program (MBSR)|This intervention follows the official MBSR program designed by Jon Kabat-Zinn with some adaptations, as we did in Bermudo-Gallaguet, et al. (2022). The intervention will occur three days a week, including one 120-minute online synchronous session and two 20-40 min individual practices. The intensity of physical exercise will be adjusted to personal baseline characteristics.
47973227|NCT06406283|BEHAVIORAL|Qigong|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The program includes the Baduanjin sequence, considered one of the most ancient and beneficial forms for physical and mental health within the Qigong tradition."
47973228|NCT00767637|DRUG|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
47973229|NCT05666492|OTHER|Platelet rich plasma|Platelet-rich plasma will be placed on the olfactory epithelium topically.
47973230|NCT05666492|OTHER|Saline|Saline will be placed on the olfactory epithelium topically.
47973231|NCT03519425|OTHER|Optimised HIV screening and linkage to care|As described in group descriptions
47973232|NCT03519425|OTHER|Optimised tuberculosis screening and linkage to care|As described in group descriptions
47973233|NCT01153347|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
47973234|NCT01153347|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
47973235|NCT02387060|DRUG|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
47973236|NCT02387060|DRUG|Fentanyl|Intrathecal administration of fentanyl 25 mcg
47973237|NCT02150317|PROCEDURE|TACE+Sorafenib|TACE followed by Sorafenib
47973238|NCT02150317|PROCEDURE|TACE|TACE alone
47973239|NCT00692081|BEHAVIORAL|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
47973240|NCT00692081|BEHAVIORAL|Special vocational training|as provided in German special centres for vocational training
47973241|NCT00191789|DRUG|gemcitabine|1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
47973242|NCT00191789|DRUG|doxorubicin|60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
47973243|NCT00191789|DRUG|cisplatin|70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)
47973244|NCT00191789|PROCEDURE|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
47973245|NCT03467191|DRUG|Alcohol|target BAC .08%
47973246|NCT03467191|OTHER|Placebo|placebo beverage
47973247|NCT01109043|DRUG|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
47973248|NCT05894928|DRUG|LOXO-783|Administered orally.
47973249|NCT05894928|DRUG|Cholestyramine|Administered orally.
47973250|NCT03982628|DIAGNOSTIC_TEST|Abdominal CT imaging|Routine abdominal CT imaging
48328110|NCT04420910|OTHER|Functional mobility|The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
48328111|NCT03442348|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Participants in the bottom median of dietary fibre intake (\<15 g per day) will be randomised into one of two arms. Participants in the second arm (N\>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
48122434|NCT06553053|OTHER|"Harmonizing Shaoyang, nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
48122435|NCT06553053|OTHER|"Nourishing spleen and kidney with warmth Acupuncture Group"|Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.
48122436|NCT00373386|DRUG|growth hormone|Growth Hormone treatment
48122437|NCT00006198|DRUG|thalidomide|
48122438|NCT00006198|PROCEDURE|chemoembolization with doxorubicin/collagen|
48122439|NCT02224924|OTHER|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
48122440|NCT02224924|DEVICE|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
48122441|NCT04771351|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
48122442|NCT04771351|DRUG|Placebo|Diluent solution
48122443|NCT00394407|DRUG|sliding scale regular insulin|SSRI acqhs
48122444|NCT00394407|DRUG|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
48122445|NCT03319797|DRUG|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
48328112|NCT03442348|DIETARY_SUPPLEMENT|Inulin fibre|The participants in the control arm (N\>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
48328113|NCT03111017|OTHER|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
48328114|NCT01362699|DRUG|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
48328115|NCT01362699|DRUG|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
48328116|NCT06291506|OTHER|Radiofrequency ablation of heart atrial tissue.|Ablation with radiofrequency, advances techniques: contact force-guided, improved tissue temperature sensors, automark algorithms.
48328117|NCT00185354|DRUG|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
48328118|NCT00185354|DRUG|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
48328119|NCT04950140|PROCEDURE|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
48328120|NCT04950140|PROCEDURE|Laparoscopic Surgery for the Treatment of Parastomal Hernia|Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
48328121|NCT05573529|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
47973251|NCT02648776|DRUG|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
47973252|NCT05084521|DRUG|Famotidine 400 mg/50 mL|Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
47973253|NCT00002418|DRUG|Emivirine|
47973254|NCT00002418|DRUG|Hydroxyurea|
48340206|NCT04251819|DRUG|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
48490814|NCT03425487|BEHAVIORAL|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
47973255|NCT00002418|DRUG|Nevirapine|
47973256|NCT00002418|DRUG|Stavudine|
47973257|NCT00002418|DRUG|Didanosine|
47973258|NCT06409572|DIAGNOSTIC_TEST|GeneXpert MTB/RIF|Rapid and accurate method for detection of tuberculosis.
47973259|NCT02063360|DRUG|BMS-663068|BMS-663068
47973260|NCT02063360|DRUG|Darunavir (DRV)|Darunavir (DRV)
47973261|NCT02063360|DRUG|Ritonavir (RTV)|Ritonavir (RTV)
47973262|NCT02063360|DRUG|Etravirine (ETR)|Etravirine (ETR)
47973263|NCT01211002|RADIATION|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
47973264|NCT01211002|DRUG|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 \~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
48122446|NCT04643899|DEVICE|Muscle Electrostimulation|"* Scheduled sessions of 20 minutes per day; 5 days a week~* In physiotherapy or in their room for the most dependent patients~* Installation and monitoring by a physiotherapist or by the trained clinical research nurse~* Modalities:~  * Device program n ° 1: 20mn (2mn of warm-up, 15mn of work at 75hz, then 3mn of recovery)~ * 4 electrodes (2 per thigh): large model (5 \* 10 cm) for better comfort - Dura-Stick Plus model (reference 42200)~ * Gradual auto-increase of the intensity to the highest possible value tolerated, nevertheless allowing a contraction"
48650523|NCT04614662|BEHAVIORAL|SPARK Symptom Screening Linked to Feedback to Providers|Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
48650524|NCT05736887|DRUG|N-Acetylcysteine|N-Acetylcysteine in 600mg tablets
48650525|NCT05736887|DRUG|Placebo|Placebo in 600mg tablets
48650526|NCT02562703|DEVICE|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
48650527|NCT04624399|DRUG|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
48650528|NCT01534221|DEVICE|Biomatrix drug eluting stent|Biomatrix drug eluting stent
48650529|NCT06675045|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
48650530|NCT06225986|BEHAVIORAL|LMH-4-DCP|Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
48650531|NCT06225986|BEHAVIORAL|LMH-4-DCP access without reminiscence activities|Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
48650532|NCT06568393|OTHER|Calisthenic exercise|Calisthenic exercise program was included: jumping jack, burpee, mountain climber, squat thrust, squat, squat jump, split and alternate exercises.
48650533|NCT03816579|OTHER|PRO-A|30 g of beef protein will be consumed at each meal
48650534|NCT03816579|OTHER|PRO-B|30 g of complementary proteins will be consumed at each meal
48122447|NCT04248998|DIETARY_SUPPLEMENT|Fasting-mimicking diet|Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
48122448|NCT04248998|DRUG|Metformin|Metformin 850 mg twice a day
48122449|NCT04248998|DRUG|Preoperative chemotherapy|"Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq"
48122450|NCT02509637|DEVICE|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
48122451|NCT02509637|OTHER|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
48122452|NCT02509637|OTHER|Control|
48122453|NCT02509637|OTHER|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
48122454|NCT02509637|OTHER|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
48122455|NCT02509637|OTHER|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
48122456|NCT02509637|DEVICE|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
48490815|NCT03425487|OTHER|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
48490816|NCT04146506|OTHER|Muscle stretching exercises|Muscle stretching exercises consisting of static stretching exercises of the knee flexors
48490817|NCT01918631|DRUG|tenofovir disoproxil fumarate|
48490818|NCT01918631|DRUG|Entecavir|
48490819|NCT02448121|PROCEDURE|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
48490820|NCT01400620|DRUG|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
48650535|NCT03816579|OTHER|PRO-C|30 g of complementary proteins will be consumed over 24 hours
48490821|NCT03591939|DIAGNOSTIC_TEST|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
48650536|NCT01730729|DRUG|cabergoline|Given orally
48650537|NCT06675058|PROCEDURE|Indirect Pulp Treatment|Indirect pulp treatment is considered one of the most conservative pulp therapies, which preserves the pulp's vitality in teeth with reversible pulpitis. It has been chosen to be the intervention in both groups as the aim of this study is to assess the impact of caries location (proximal vs. occlusal caries) in influencing the success rate of IPT.
48122457|NCT02509637|OTHER|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
48122458|NCT01381406|DRUG|TIO|Patients receiving tiotropium bromide at index within the study period.
48122459|NCT01381406|DRUG|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
48122460|NCT01837927|DRUG|NVA237|Once daily for 52 weeks
48328122|NCT05573529|DEVICE|intraocular lens implantation|intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
48650538|NCT02356653|DEVICE|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
48328123|NCT03401294|DRUG|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
48328124|NCT04220385|OTHER|Group A|Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.
48650539|NCT02106546|DRUG|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
48650540|NCT02106546|DRUG|Veliparib|Capsules taken orally twice a day, 12 hours apart.
48650541|NCT02106546|DRUG|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
48650542|NCT02106546|DRUG|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
48650543|NCT04280783|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
48650544|NCT04280783|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
48650545|NCT06289049|OTHER|Experimental|"Three primary exercises will be included in the exercise sessions for participants randomized to this group: barbell back squat, bench press, and dead lift~The weight will be progressively increased overtime based on participants' perceived exertion and repetitions in reserve. Number of repetitions performed for each exercise will begin at 10 repetitions in weeks 1-2, with gradual progression to lifting heavier loads of 3-5 sets of 1-5 repetitions between weeks 6-12."
48650546|NCT06675305|DIETARY_SUPPLEMENT|Beetroot juice (James White, UK)|One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
48650547|NCT06675305|DIETARY_SUPPLEMENT|Placebo acute supplementation (James White, UK)|One serving 140 mL of BJ (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
48650548|NCT00488293|PROCEDURE|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
47973265|NCT05373368|BEHAVIORAL|multi purpose activities|
48122461|NCT01837927|DRUG|Tiotropium Respimat®|Once daily for 52 weeks
48122462|NCT00974831|OTHER|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
48122463|NCT00974831|OTHER|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
48122464|NCT04866238|DEVICE|Vestibular fixed appliances|The fixed appliances will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
48122465|NCT04866238|DEVICE|Clear aligners|The clear aligners will be applied in class1 malocclusion patients who have dental crowding, then they will be followed up for 12 months.
48122466|NCT05998252|DEVICE|Alveo HP Balloon Dilatation Catheter|Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
48328125|NCT04220385|OTHER|Group B|Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
48328126|NCT01792245|DEVICE|Phototherapy|
48122467|NCT05075213|BEHAVIORAL|contingency management (deposit contract)|Participants will deposit $30 of their own money to play QuitBet. Participants will submit a CO test once per day between the hours of noon and 11:59pm. Participants whose CO test is 6ppm or lower (indicating no smoking) on at least 24 of 26 days between day 3-28 of the game will be declared winners and split the pot of deposited money. Participants who submit at least 21 CO tests, regardless of the result, will be entered into a raffle to win a prize worth $75.
48122468|NCT05075213|BEHAVIORAL|leaderboard and social feed|Participants will have access to a discussion board on which participants can post and respond to messages to each other. Also, a game host will post educational information about smoking cessation and serve as a discussion moderator.
48328127|NCT05349942|DEVICE|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
48328128|NCT01879319|BIOLOGICAL|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
48328129|NCT01879319|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
48328130|NCT05008458|DIAGNOSTIC_TEST|von willebrand factor and copeptin|biomarkers increase in children with febrile seizures
48328131|NCT01769703|DRUG|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
48328132|NCT01692002|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate capsule or tablet
48328133|NCT01692002|DIETARY_SUPPLEMENT|Sodium Chloride|Placebo capsule or tablet
48328134|NCT01692002|PROCEDURE|Oral glucose tolerance test|
48328135|NCT01692002|PROCEDURE|Intravenous glucose tolerance test.|
48328136|NCT00971425|BIOLOGICAL|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
48328137|NCT00971425|BIOLOGICAL|Fluarix™|1 dose intramuscular injection
48328138|NCT00971425|BIOLOGICAL|Placebo|1 dose intramuscular injection
48328139|NCT00439153|DEVICE|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
48328140|NCT02610205|OTHER|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
48328141|NCT03361072|DIETARY_SUPPLEMENT|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
48328142|NCT05418569|DEVICE|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
48328143|NCT05418569|OTHER|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
48328144|NCT04154943|DRUG|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
48650549|NCT05630118|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
48122469|NCT05075213|BEHAVIORAL|smoking cessation resource list|Participants will have access to a list of smoking cessation resources
48122470|NCT05434273|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
48328145|NCT04342520|OTHER|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
48328146|NCT04765618|PROCEDURE|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
48328147|NCT05386121|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane deep to erector spinae muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the spinous process on a parasagittal plane, to visualize the erector spinae muscle and transverse process, directing the needle craniocaudally using the in-plane technique. The spread of the injectate will be observed to distribute within this plane.
48340207|NCT04251819|DRUG|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
48340208|NCT04251819|DRUG|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
48340209|NCT05845008|DRUG|Acetaminophen/Naproxen Sodium Fixed Combination|Acetaminophen/naproxen sodium fixed combination tablets, oral.
48340210|NCT06512831|DRUG|Isoniazid|Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
48328148|NCT05386121|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane between the quadratus lumborum and psoas major muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the L2 spinous process on an axial plane, to visualize the transverse process with psoas major muscle anterior, quadratus lumborum muscle lateral and erector spinae muscle posterior to it. The needle is inserted from the medial side of the probe and advanced laterally using the in-plane technique. The spread of the injectate will be observed to distribute within the target plane.
48328149|NCT05386121|DEVICE|Ultrasound Machine|Sonosite S-Nerve (USA) with a linear multi-frequency 6-13 MHz (hockey stick) transducer
48328150|NCT05386121|DEVICE|Echogenic needle|A 22-gauge 80 mm needle the sonoplex needle manufactured by PAJUNK (USA)
48328151|NCT05386121|DRUG|Fentanyl|Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
48328152|NCT05386121|DRUG|Pethidine|Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
48328153|NCT04627012|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48328154|NCT04627012|DRUG|Opdivo|3mg/mg intravenously every 3 weeks
48490822|NCT05241717|BEHAVIORAL|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
48490823|NCT02831959|DEVICE|NovoTTF-200M device|
48490824|NCT02831959|OTHER|Best Standard of Care|
48490825|NCT00331071|DRUG|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
48490826|NCT00331071|DRUG|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
48490827|NCT04346966|OTHER|Study Group|Video Based Exercises 64 young adults aged 18-40, who are socially isolated due to coronavirus, will be included in this group. A video-based exercise protocol was created for individuals to participate in the study. Each exercise session is planned as 30 minutes 7 days a week for 6 weeks. The protocol was planned to start with warm-up exercises and end with cooling exercises. The exercise protocol has also been determined as a combination of aerobic exercises, strengthening and posture exercises. Individuals will be classified at 4 levels according to their physical activity levels and will be shared with volunteers according to their level of exercise. Volunteers will be evaluated before and after 6 weeks of exercise.
48490828|NCT02849327|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
48490829|NCT02849327|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
48490830|NCT06332001|OTHER|Experimental Group|Listening of music of patient's choice during WB-MRI
48490831|NCT06332001|OTHER|Control Group|Standard care condition during WB-MRI
48490832|NCT04053465|OTHER|Heat acclimation|14 days of aerobic exercise in a hot environment
48490833|NCT04053465|OTHER|Exercise in a cool environment|14 days of aerobic exercise in a cool environment
48490834|NCT01946360|DEVICE|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
48490835|NCT02192164|BEHAVIORAL|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
48490836|NCT00971958|PROCEDURE|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
48490837|NCT00971958|DEVICE|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
48490838|NCT00971958|DEVICE|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
48490839|NCT00971958|DEVICE|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
48328155|NCT04627012|DRUG|Camrelizumab|200mg intravenously every 3 weeks
48328156|NCT04627012|DRUG|Keytruda|200mg intravenously every 3 weeks
48328157|NCT04627012|DRUG|Toripalimab|240mg intravenously every 3 weeks
48328158|NCT04627012|DRUG|Sintilimab|200mg intravenously every 3 weeks
48328159|NCT04627012|DRUG|Tislelizumab|200mg intravenously every 3 weeks
48328160|NCT02877849|DEVICE|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
48328161|NCT05893667|DIAGNOSTIC_TEST|Inflammatory markers|analysis of inflammatory scores
48328162|NCT06202001|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
48328163|NCT00476177|BIOLOGICAL|Infusion of donor dendritic cells|Given in the outpatient setting
48328164|NCT00476177|BIOLOGICAL|Infusion of donor lymphocytes|Given in outpatient setting
48328165|NCT04169854|DRUG|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
48340211|NCT02445703|BIOLOGICAL|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
48490840|NCT00131872|DEVICE|Expedial Vascular Access Graft|
48328166|NCT04169854|DRUG|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
48328167|NCT02790333|PROCEDURE|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
48328168|NCT02790333|PROCEDURE|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
48328169|NCT04600921|DRUG|Ertugliflozin 5 mg|The subject will receive Ertugliflozin 5mg orally once daily for 52 weeks.
48328170|NCT04600921|DRUG|Placebo 5mg|The subject will receive Placebo 5mg orally daily for 52 weeks.
48490841|NCT03474432|DEVICE|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
48490842|NCT02593448|PROCEDURE|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB."
48122471|NCT05434273|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. A governmental health education leaflet and a lecture video will be provided for reference.
48650550|NCT05630118|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
48650551|NCT03766906|BEHAVIORAL|Talk STEM Familia app|The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
48650552|NCT05645146|BEHAVIORAL|Smoking Cessation treatment delivered by Tobacco Free Florida Quitline|Phone counseling with the state tobacco quitline
48650553|NCT05645146|DRUG|Nicotine patch|Participants will be provided with a 12 week supply of nicotine patches
48122472|NCT03379740|OTHER|E-cigarette|Subject's own e-cigarette
48650554|NCT05645146|DRUG|Nicotine Lozenge|Participants will be provided with a 12 week supply of nicotine lozenges
48328171|NCT01122030|DRUG|Naldemedine|Tablets or solution for oral administration
48328172|NCT01122030|DRUG|Placebo|Tablets or solution for oral administration
48122473|NCT03379740|OTHER|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
48122474|NCT03379740|OTHER|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
48122475|NCT03379740|OTHER|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
48122476|NCT03379740|OTHER|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
48328173|NCT04564066|BIOLOGICAL|efgartigimod IV|intravenous infusions of efgartigimod
48328174|NCT04564066|BIOLOGICAL|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
48122477|NCT02931214|DRUG|GMI-1359|
48328175|NCT03013829|BEHAVIORAL|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
48328176|NCT03805971|DEVICE|Study of the pleural cavity with a confocal laser endomicroscope.|Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
48328177|NCT02543502|PROCEDURE|periodontal treatment|treatment of periodontal cleaning
48328178|NCT02030470|OTHER|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
48328179|NCT06446180|DIETARY_SUPPLEMENT|SsK12@Lip@GSH|SsK12@Lip@GSH powder contained no less than 5×10\^8 CFU viable cells of SsK12@Lip@GSH as the active ingredient.
48122478|NCT02931214|DRUG|Placebo|
48122479|NCT03416712|OTHER|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
48122480|NCT04705311|OTHER|Pain neuroscience education|Neurophysiological education of pain allows patients to explore a wider contribution to pain through the knowledge that pain is often an unreliable indicator of the extent or extent of tissue damage. This aims at reconceptualization from biomedical or structural models to actual biological psychosocial pain models.
48122481|NCT04705311|BEHAVIORAL|Rotator cuff repair rehabilitation|Postoperative rehabilitation programs include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
48122482|NCT03262935|DRUG|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
48122483|NCT03262935|DRUG|Physician's choice|See drug label
48122484|NCT06123871|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
48122485|NCT02184806|PROCEDURE|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
48122486|NCT02184806|PROCEDURE|heterotopic graft|"1. put under the skin~2. the ovarian fragments can be put under the skin of the abdomen"
48122487|NCT02214550|DRUG|cyclic microgestin 1/20|Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
48122488|NCT02214550|DRUG|continuous microgestin 1/20|Continuous OC use - Pills containing hormones will be taken every day for 1 year
48122489|NCT02974465|PROCEDURE|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
48122490|NCT02974465|PROCEDURE|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
48122491|NCT02974465|PROCEDURE|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,...), exercise programs, electrotherapy, myofascial techniques, etc...
48122492|NCT01885793|DEVICE|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
48122493|NCT01204346|OTHER|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
48122494|NCT01204346|OTHER|treatment as usual|less intensive and structured psychotherapeutic program
48122495|NCT06079515|PROCEDURE|Suprascapular Nerve Block|SSNB group: The patients were asked to sit comfortably in the chair, and the transducer was placed on the spine of the scapula in the coronal plane and moved laterally to observe the supraspinatus notch and the suprascapular nerve. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle on the suprascapular nerve, under the fascia of the supraspinatus muscle.
48328180|NCT00111930|DRUG|DHEA|
48122496|NCT06079515|PROCEDURE|Intraarticular Shoulder Injection|IAI group: The patients were asked to sit on the chair with their hands facing the opposite shoulder, and the transducer was placed slightly below the spina scapula. The humeral head was observed by moving laterally. The injection mixture was applied in-plane with a 22-gauge, 90-mm needle entering the skin at a 45-degree angle and applied to the joint space
48328181|NCT04843969|BEHAVIORAL|Stress induction|Exposure to a psychosocial stressor
48328182|NCT04843969|BEHAVIORAL|Control stress exposure|Exposure to a control task (no stress)
48328183|NCT04843969|BEHAVIORAL|Cue induction|Exposure to a smoking-related task
48650555|NCT05645146|BEHAVIORAL|Motivation and Problem Solving (MAPS) intervention|MAPS is a phone counseling approach to facilitating smoking cessation among cervical cancer survivors, which uses a combined motivational interviewing and social cognitive theory based approach to smoking cessation. Participants will receive 6 MAPS based counseling calls over 12 months, along with personally-tailored SMS-delivered text based messages delivered to the participants phone over 2 years.
48650556|NCT03851952|DEVICE|Optilume Drug Coated Balloon|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
48650557|NCT04620668|DEVICE|Wysa|Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
48650558|NCT05817344|BEHAVIORAL|Written Exposure Therapy - Integrated|A brief exposure-based psychotherapy for posttraumatic stress disorder integrated with harm reduction strategies for opioid use disorder
48122497|NCT02121002|DRUG|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
48122498|NCT02121002|DRUG|Voltaren Topical Gel, 1%|Opaque, white gel
48122499|NCT02121002|DRUG|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
48328184|NCT04843969|BEHAVIORAL|Neutral cue exposure|Exposure to neutral cues
48650559|NCT01407341|PROCEDURE|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
48328185|NCT00290589|DRUG|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
48328186|NCT00290589|DRUG|Placebo|Normal saline intramuscular injection
48650560|NCT01407341|PROCEDURE|bone graft|Receive beta tricalcium-phosphate bone graft
48650561|NCT01407341|PROCEDURE|quality-of-life assessment|Ancillary studies
48650562|NCT01407341|OTHER|questionnaire administration|Ancillary studies
48328187|NCT00745953|DRUG|Valsartan|Valsartan 320mg PO daily for 8 months
48328188|NCT00745953|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
48328189|NCT04800120|OTHER|Hyperbaric Oxygen Therapy|Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber
48650563|NCT05686551|DRUG|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks
48122500|NCT00407082|DRUG|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
48122501|NCT00407082|DRUG|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
48490843|NCT02593448|PROCEDURE|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
48490844|NCT02593448|PROCEDURE|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
48490845|NCT00708786|DEVICE|ICD|Ventricular arrhythmia treatment
48490846|NCT00708786|DEVICE|CRT-D|Ventricular arrhythmia treatment
48490847|NCT04231942|DEVICE|Graduated Compression Stocking: continuous using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
48490848|NCT04231942|DEVICE|Graduated Compression Stocking: intermittent using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
48490849|NCT02814435|OTHER|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
48490850|NCT02814435|OTHER|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
48490851|NCT01626521|OTHER|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
48490852|NCT00833742|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
48490853|NCT00853086|DRUG|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
48490854|NCT03021252|DEVICE|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
48490855|NCT03021252|DEVICE|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
48490856|NCT05717855|DIAGNOSTIC_TEST|Displaying optic chiasm for screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
48490857|NCT05414032|BIOLOGICAL|AZD2936|AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
48490858|NCT05215717|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
48490859|NCT05215717|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
48490860|NCT00304226|DRUG|valsartan|
48490861|NCT00304226|DRUG|amlodipine|
48490862|NCT05991830|PROCEDURE|General anesthesia|Older adults during elective surgery under general anesthesia with propofol, frontal EEG will recorded and a baseline plasma sample will be taken
48122502|NCT03576742|DIAGNOSTIC_TEST|potential biomarkers|facs analysis, microbiome analysis
48122503|NCT06113458|BEHAVIORAL|Standard and One-time Training|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
48122504|NCT06113458|BEHAVIORAL|Standard and Practice Facilitation|"Patient-level intervention: Patients in the standard group will receive automated reminder SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
48122505|NCT06113458|BEHAVIORAL|High-intensity and One-time Training|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the one-time training group will receive one-time training on standard work and algorithms, audit and feedback, and panel-based outreach."
48328190|NCT01725256|DRUG|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
48328191|NCT04571918|PROCEDURE|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
48328192|NCT04571918|PROCEDURE|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
48490863|NCT00384878|DRUG|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
48122506|NCT06113458|BEHAVIORAL|High-intensity and Practice Facilitation|"Patient-level intervention: Patients in the high-intensity group will receive personalized feedback SMS text messages and remote BP monitoring.~Clinic-level intervention: Clinics in the practice facilitation group will receive regular/ongoing training on standard work and algorithms, audit and feedback, and panel-based outreach."
48490864|NCT04941339|DRUG|MRG002|Administrated intravenously
48122507|NCT05115058|OTHER|relex Smile module|
48122508|NCT02597751|BEHAVIORAL|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
48122509|NCT02650791|DRUG|Tranexamic Acid|
48122510|NCT06450496|BEHAVIORAL|Positive parenting on-line program|Positive parenting on-line program focused on parenting and personal competences relevant for parents with adolescents exhibiting mental health problems
48490865|NCT05684471|PROCEDURE|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
48122511|NCT06311617|DIAGNOSTIC_TEST|Fundus photography and optical coherence tomography|Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints
48122512|NCT04055246|DIETARY_SUPPLEMENT|Inulin|9 grams of food grade inulin added to custom made fiber bars.
48122513|NCT04055246|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
48122514|NCT02283242|DRUG|Galantamine|Oral use for 12 weeks
48122515|NCT02283242|DRUG|Placebo (for galantamine)|Oral use for 12 weeks
48122516|NCT02421159|BEHAVIORAL|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
48122517|NCT02421159|BEHAVIORAL|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
48122518|NCT05654948|OTHER|computerised cognitive performance test : MindPulse|In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty
48340212|NCT02445703|BIOLOGICAL|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
48490866|NCT05684471|PROCEDURE|Ultrasound Guided Anterior Quadratus Lumborum Block|Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
48490867|NCT00054548|BIOLOGICAL|oblimersen sodium|Given IV
48490868|NCT00054548|DRUG|paclitaxel|Given IV
48490869|NCT00054548|OTHER|laboratory biomarker analysis|Correlative studies
48490870|NCT00054548|OTHER|pharmacological study|Correlative studies
48650564|NCT05686551|DRUG|Placebo|Matching placebo administered intrathecally every 16 weeks
48650565|NCT05686551|DRUG|Tominersen 100 mg|100 mg tominersen administered intrathecally every 16 weeks
48650566|NCT05727891|DRUG|Tonabersat|Two pills of Study Drug (80 mg tonabersat) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
48650567|NCT05727891|OTHER|Placebo|Two pills of Study Drug (placebo) is taken orally once daily. It is recommended the Study Drug be taken at bedtime. The first dose (two pills) will be taken at bedtime on the day the participant is randomized.
48650568|NCT03442972|DRUG|Teduglutide|Teduglutide
48650569|NCT03442972|DRUG|Placebo|Placebo
48650570|NCT04854317|PROCEDURE|Endoscopic gastroplasty|Endoscopic Gastroplasty
48490871|NCT03309007|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
48490872|NCT03309007|DRUG|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
48490873|NCT00379990|DRUG|GW274150|60 mg /day
48490874|NCT00379990|DRUG|Prednisolone|7.5 mg/day
48490875|NCT00379990|OTHER|Placebo|Placebo
48490876|NCT04952077|DEVICE|MRI|Magnetic Resonance Imaging (MRI)
48490877|NCT03880799|BEHAVIORAL|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
48490878|NCT02664233|BEHAVIORAL|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
48650571|NCT02386072|DRUG|mirabegron|oral
48650572|NCT02386072|DRUG|antimuscarinic medication|oral
48650573|NCT02380235|BIOLOGICAL|PEG-somatropin|0.20mg/kg/w
48650574|NCT02380235|BIOLOGICAL|PEG-somatropin|0.12mg/kg/w
48650575|NCT06391086|DEVICE|NaviFUS® Neuronavigation-guided focused ultrasound system|The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.
48328193|NCT04938388|DRUG|Semaglutide Pill|All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
48328194|NCT04938388|DIETARY_SUPPLEMENT|Fresh organic vegetables|Prescriptions of organic vegetables
48122519|NCT04141150|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
48122520|NCT00033098|DRUG|Metyrapone|
48650576|NCT04096235|OTHER|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
48650577|NCT03686982|OTHER|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
48650578|NCT03686982|OTHER|Placebo Bar|No active ingredients
48328195|NCT04856956|OTHER|Diagnostic decision support software|Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
48328196|NCT03685045|PROCEDURE|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
48328197|NCT04535154|OTHER|No interventions|No interventions
48328198|NCT03372603|DRUG|GSK2798745|GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).
48328199|NCT03372603|DRUG|Placebo|Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
48650579|NCT06674369|DEVICE|Peli prism for hemianopia|Peli prism uses high-powered prisms (40 Dioptre) that expand a hemianopic patient's awareness of their blind side. This awareness enables patients to better detect obstacles and navigate around them. Effect of the prism considered as temporary We investigated whether the effect persists after the prism is removed.To understand the persistence of the effect, we examined the changes in the visual field with CVF (Computerized visual field examination)before the prism was applied, with the prism and 1 week after the prism was removed.
48328200|NCT03374644|DEVICE|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
48328201|NCT00089271|DRUG|alvespimycin hydrochloride|Given IV
48328202|NCT00089271|OTHER|laboratory biomarker analysis|Correlative studies
48328203|NCT06016257|OTHER|Use of VirtuaCare™ for home program|Use of VirtuaCare™ system for the Home Program.
48328204|NCT00110123|DRUG|fotemustine|
48328205|NCT00110123|DRUG|isolated perfusion|
48328206|NCT02938221|DEVICE|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
48490879|NCT03256084|PROCEDURE|Blood and tumor samples|Blood and tumor samples
48490880|NCT06139718|BEHAVIORAL|ACT Guide Lite|ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
48490881|NCT03403166|BEHAVIORAL|DASH diet|Diet intervention
48490882|NCT03403166|BEHAVIORAL|Fruits and vegetables diet|Diet intervention
48490883|NCT03403166|BEHAVIORAL|Control diet|Diet intervention
48490884|NCT05712525|DIAGNOSTIC_TEST|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
48490885|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
48490886|NCT01029158|DRUG|RN1006 (Avotermin)|250 ng, intradermal injection, twice
48490887|NCT01029158|DRUG|RN1006 (Avotermin)|205 ng, Intradermal injection, once
48490888|NCT01029158|DRUG|RN1006 (Avotermin)|500ng, intradermal injection, once
48490889|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, intradermal injection, twice
48328207|NCT05049447|DRUG|Pascoflair|1 x 2 tablets (single-dose)
48328208|NCT05049447|OTHER|Placebo|1 x 2 tablets (single-dose)
48328209|NCT01286116|DEVICE|Parachute Implant|Mechanical ventricular partitioning
48328210|NCT02336139|DRUG|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
48328211|NCT05066867|OTHER|Smart sharps bin - collects data on compliance|collects compliance data
48328212|NCT04045574|PROCEDURE|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
48328213|NCT05296408|BEHAVIORAL|motor learning based therapy|Motor learning based therapy will include functional task/task component training and will be employed to practice hand-to-mouth, forward reach, grasp-release, and object manipulation. Training will include high repetition both in the clinic and during home exercise practice. Tasks will be decomposed into component parts and practiced in this manner with the goal of returning to full task performance as skill develops Training will be tailored to each individual subject's capability and progressed according to a motor control hierarchy to ensure adequate challenge. Training is always started at the appropriate level of challenge for an individual to ensure adequate challenge is delivered whether the individual is higher or lower functioning.
48328214|NCT05296408|BEHAVIORAL|MyoPro|The MyoPro supports motor learning-based training by reinforcing coordinated movement practice, allowing for finely incrementalized training progression, and encouraging high repetition of movement. Importantly, the device assists the user to move the paretic limb in a manner they may otherwise be unable to do. This further motivates the user to continue attempts to move the paretic limb. When a user attempts to volitionally contract a weak muscle, sensors embedded within the MyoPro detect the EMG signal, which triggers activation of a motor within the device. The motor assists the user to complete the desired movement (e.g. opening of the hand).Subjects experience real-time biofeedback through their ability to sense and see movement of the target joint(s) and via their interface with the software on a computer that provides visual feedback of the EMG level of the contracting muscle
48340213|NCT03481504|BEHAVIORAL|Acceptance & Commitment Therapy-Exposure and Perspective Taking|To increase patients' participation by improving their level of coping with chronic pain.
48490890|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
48490891|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
48490892|NCT01029158|DRUG|RN1006 (Avotermin)|500 ng, intradermal injection, twice
48490893|NCT01029158|DRUG|Placebo|Placebo
48490894|NCT00819975|DIETARY_SUPPLEMENT|Casein|
48490895|NCT00819975|DIETARY_SUPPLEMENT|Whey Isolate|
48122521|NCT04261231|PROCEDURE|Surgery and anesthesia|Elective surgery in adults
48122522|NCT00360386|DRUG|Clopidogrel|
48122523|NCT02522468|PROCEDURE|Radioactive Seed Localization|
48122524|NCT02522468|PROCEDURE|Wire Localization|
48490896|NCT00819975|DIETARY_SUPPLEMENT|Whey Hydrolysate|
48490897|NCT00819975|DIETARY_SUPPLEMENT|Alphalact-Albumin|
48490898|NCT00191633|DRUG|Atomoxetine|
48490899|NCT00000734|DRUG|Sulfamethoxazole-Trimethoprim|
48490900|NCT00000734|DRUG|Zidovudine|
48490901|NCT05289128|DEVICE|Experimental group|10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
48490902|NCT05289128|DEVICE|Sham Control|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
48490903|NCT04626752|DRUG|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
48490904|NCT04626752|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
48490905|NCT04626752|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
48490906|NCT00206765|DRUG|Risperidone|
48490907|NCT00206765|DRUG|Paroxetine|
48490908|NCT01530594|DRUG|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
48490909|NCT01530594|DRUG|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
48490910|NCT01530594|DRUG|Lenalidomide|Lenalidomide/Low dose Dex (LLD
48490911|NCT00004313|DRUG|dehydroepiandrosterone|
48490912|NCT04453098|BEHAVIORAL|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
48328215|NCT05296408|BEHAVIORAL|Home Exercise Program|Every subject will be assigned an individualized HEP. Therapy staff will create written handouts for the user to follow. The HEP will include photographs of the study participant performing his/her exercises/functional tasks along with written instructions. Each individual will have their own personalized HEP that will be created during their study participation and will be dispensed only to them. The HEP will reinforce in-clinic therapy. The HEP will be progressed regularly, and individuals will log practice time. The HEP for M+ML will include practice with and without the MyoPro; the HEP for ML-alone will include practice without MyoPro. Each HEP session will require approximately 90 minutes to complete.
48328216|NCT01097148|DRUG|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
48328217|NCT04825288|BIOLOGICAL|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
48328218|NCT05510609|DEVICE|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
48328219|NCT04254796|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
48490913|NCT03962582|DEVICE|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
48490914|NCT04171557|BEHAVIORAL|Bicycling|Total bicycling is reported in categories of: (0 - reference), (\>0 to \<60), (≤60 to \>150), (≤150 to \< 300) and (≥300) minutes/week
48490915|NCT04054128|DRUG|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
48490916|NCT04054128|DRUG|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
48490917|NCT01997229|BIOLOGICAL|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
48490918|NCT01997229|DRUG|Placebo|Placebo
48490919|NCT00757757|DRUG|MCS110|Anti-M-CSF antibody
48490920|NCT03096847|DRUG|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
48490921|NCT03096847|DRUG|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
48490922|NCT03096847|DRUG|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
48490923|NCT05203666|OTHER|percutaneous removable interspinous process|percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
48650580|NCT02722330|DEVICE|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
48650581|NCT01428713|DRUG|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
48650582|NCT01428713|DRUG|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
48650583|NCT00247039|DIETARY_SUPPLEMENT|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
48650584|NCT00247039|OTHER|Placebo capsules|placebo capsules
48650585|NCT01737723|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
48650586|NCT06638723|BEHAVIORAL|Balance and fall recovery training|Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.
48650587|NCT02361697|OTHER|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
48650588|NCT03400787|DEVICE|Latera Implant|Treatment with implant
48650589|NCT03400787|DEVICE|Sham Procedure|Sham procedure where the Latera delivery device is inserted but no implant delivered.
48650590|NCT06675656|OTHER|DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood.|DNA extraction from urine, stool and biopsy for microbiome analysis. Isolation of peripheral blood mononuclear cells from peripheral blood for immunophenotypic analysis, and isolation of serum for analysis of cytokines and bacterial metabolites.
48122525|NCT03850613|BEHAVIORAL|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
48122526|NCT01063972|BEHAVIORAL|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
47973266|NCT04569266|OTHER|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
48122527|NCT01063972|BEHAVIORAL|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
48122528|NCT05936177|OTHER|Patient education|The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
48122529|NCT06061575|DRUG|Acetaminophen|fever will be managed with acetaminophen
48122530|NCT06061575|DRUG|Ibuprofen|fever will be managed with ibuprofen
48122531|NCT04667780|DRUG|Colchicine|Colchicine tablet 0.5 mg
48122532|NCT04667780|DRUG|Standard COVID-19 care|As per the hospital guidelines
48490924|NCT06255301|DIAGNOSTIC_TEST|EYEPRIM|Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.
48650591|NCT06421285|BEHAVIORAL|Aerobic exercise, Strength training, Flexibility exercise|"Aerobic exercise: 30-40 minutes/time, 3-5 times a week, intensity of 4-6 points on the Rating of Perceived Exertion(RPE) 10-point scale(A simple conversation is possible during exercise, but the intensity is such that you feel out of breath) Strength training: 2-3 times a week, 3 sets of 10 repetitions per movement~* Upper extremities: Biceps brachii, triceps brachii, deltoid, pectoralis muscle exercise~* Lower extremities: gluteus maximus, hamstrings, quadriceps exercise Flexibility exercise: Stretching and mobility exercises reflecting post-surgery rehabilitation"
48650592|NCT02029612|DRUG|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
48650593|NCT02029612|BEHAVIORAL|Phone Counseling|Each participant counseled on quitting smoking at baseline.
48328220|NCT05244499|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
48328221|NCT05244499|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
48650594|NCT02029612|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
48650595|NCT02029612|BEHAVIORAL|Breath Test|Breath test performed at 3 month and 6 month visit.
48122533|NCT06361953|DEVICE|EEG Neurofeedback|neurofeedback training over five weeks, comprising 15 sessions. Each neurofeedback training session lasted 30 minutes.
48122534|NCT03766971|BEHAVIORAL|7 days of Tobacco Cessation|Participants will be randomly assigned to 7 days of tobacco cessation.
48122535|NCT03766971|BEHAVIORAL|21 days of Tobacco Cessation|Participants will be randomly assigned to 21 days of tobacco cessation.
48328222|NCT04142216|DIETARY_SUPPLEMENT|Chewing Gum|The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
48650596|NCT02029612|BEHAVIORAL|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
48650597|NCT02029612|BEHAVIORAL|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
48122536|NCT03766971|DRUG|Cannabis|Participants will receive cannabis.
48122537|NCT02224105|DRUG|BI 653048 BS|
48122538|NCT02224105|DRUG|Prednisolone low|
48122539|NCT02224105|DRUG|Prednisolone high|
48122540|NCT02224105|DRUG|Placebo|
48122541|NCT02224105|DRUG|sodium chloride infusion|
48122542|NCT02224105|DRUG|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
48122543|NCT01460446|DEVICE|Aviva Expert blood glucose meter|
48122544|NCT01460446|DEVICE|Aviva Nano blood glucose meter|
48122545|NCT03680417|BIOLOGICAL|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
48122546|NCT02704507|DRUG|Triamcinolone|topical application nightly to half the face for 4 weeks
48122547|NCT02704507|DRUG|Tretinoin|topical application nightly for 8 weeks
48122548|NCT02704507|DRUG|Emollient|topical application nightly to half the face for 4 weeks
48122549|NCT01973816|DRUG|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
48122550|NCT01973816|PROCEDURE|rectal shaving; rectal disc excision; colorectal resection|
48122551|NCT01973816|DRUG|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
48122552|NCT01973816|DRUG|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
48122553|NCT02412683|OTHER|oxaliplatin|
48328223|NCT04367441|DRUG|608|recombinant humanized anti-IL17A monoclonal antibody injection
48328224|NCT04367441|DRUG|Placebo|auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
48328225|NCT05096702|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150mg tablets)
48328226|NCT05096702|DRUG|Primaquine|Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
48328227|NCT05096702|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
48122554|NCT02541461|PROCEDURE|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
48122555|NCT05330234|DEVICE|OnTrack Tools|"The intervention is the OnTrack Tools system consisting of a graphical user interface (GUI) used to manage patients who are users of the OnTrack rehabilitation system. Participants will be asked to complete clinical and non-clinical tasks in simulation using OnTrack Tools. The themes for the scenarios of use presented in each of the three phases are summarised below:~Phase 1 - Account creation, system onboarding and general system navigation. Phase 2 - Individual patient management. Phase 3 - Content and data management."
48122556|NCT03700853|DIAGNOSTIC_TEST|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
48122557|NCT00422006|PROCEDURE|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
48122558|NCT00422006|PROCEDURE|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
48122559|NCT00422006|BEHAVIORAL|diet|diet
48122560|NCT00422006|OTHER|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
48122561|NCT06149819|OTHER|Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain|trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
48122562|NCT06295913|DIETARY_SUPPLEMENT|Group 1, hydroxytyrosol-rich extract capsule (Hytolive®)|Following a two-week washout period, the subjects will receive a bottle containing capsules (Hytolive®) (Group 1). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol apart from that provided by the capsule with (Hytolive®).
48122563|NCT06295913|DIETARY_SUPPLEMENT|Group 2, capsule of placebo|Following a two-week washout period, the subjects will receive a bottle containing capsules (Placebo) (Group 2). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol.
48122564|NCT02619786|DRUG|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
48122565|NCT04005482|OTHER|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
48122566|NCT02304055|DRUG|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
48122567|NCT02304055|DRUG|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
48122568|NCT00003540|DRUG|gemcitabine hydrochloride|
48122569|NCT01556724|DRUG|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
48122570|NCT01947088|BEHAVIORAL|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
48328228|NCT01993615|PROCEDURE|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
48328229|NCT01993615|PROCEDURE|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
48328230|NCT01724112|DRUG|LY2940094|Administered orally
48328231|NCT01724112|DRUG|Placebo|Administered orally
48328232|NCT04201938|COMBINATION_PRODUCT|Symbiter-Omega|Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
48122571|NCT01446497|DRUG|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
48122572|NCT01446497|DRUG|Timolol|Twice per day, 1 drop at each time
48122573|NCT03336515|DEVICE|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
48328233|NCT04201938|DIETARY_SUPPLEMENT|Placebo|Placebo
48490925|NCT01372241|BEHAVIORAL|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
48490926|NCT02852642|OTHER|Exercise|Plyometric training
48122574|NCT03336515|DEVICE|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
48122575|NCT03336515|BEHAVIORAL|Group A-General Recommendation|General recommendation not sleeping in supine position
48328234|NCT03994536|BEHAVIORAL|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
48328235|NCT03994536|OTHER|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
48328236|NCT03130023|DEVICE|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
48122576|NCT03452085|DEVICE|artificial saliva spray (AS)|cross over design
48122577|NCT03452085|OTHER|maritime throat spray (TT)|cross over design
48122578|NCT05378828|DEVICE|Using anti-collision Sensors on electric wheelchairs|use of anti-collision sensors on the electric wheelchair during 3 weeks
48122579|NCT05378828|OTHER|Use of an electric wheelchair without sensors|Use of an electric wheelchair without sensors for 3 weeks before using anti-collision sensors then during 3 weeks after using the anti-collision sensors.
48122580|NCT02015546|DRUG|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
48122581|NCT00130546|DEVICE|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
48122582|NCT00130546|DEVICE|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
48122583|NCT04531592|DRUG|Valproic acid|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
48122584|NCT04531592|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
48122585|NCT05143996|DRUG|CLN-049|\[FLT3\] x \[CD3\] bispecific T cell engager
48122586|NCT02438904|BIOLOGICAL|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
48122587|NCT02438904|DEVICE|Miltenyi device|Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
48122588|NCT06251570|OTHER|Evaluation of Dual Task Performance|"The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill."
48122589|NCT05749523|BEHAVIORAL|Exercise|Exercise vs non-exercise
48122590|NCT03588715|DRUG|Pegylated Interferon alpha 2b (peg-IFN-α2b)|Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
48122591|NCT03588715|DRUG|3BNC117 + 10-1074|Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
48122592|NCT00799552|DRUG|RX-10045|RX-10045 eye drop
48122593|NCT00799552|DRUG|Placebo|Placebo eye drop
48122594|NCT05358457|BEHAVIORAL|Familiar Metacognitive Training|The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
48122595|NCT02995460|BEHAVIORAL|interval training|4x4 high intensity interval training
48122596|NCT02239913|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
48122597|NCT02239913|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
48122598|NCT02239913|DRUG|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
48122599|NCT02239913|DRUG|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
48122600|NCT01625013|DEVICE|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
48328237|NCT04724304|DIAGNOSTIC_TEST|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
48490927|NCT02859948|DRUG|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
48122601|NCT02663778|BEHAVIORAL|Strength training|weight lifting to increase muscle strength
48122602|NCT02663778|BEHAVIORAL|Endurance training|treadmill walking to increase endurance
48122603|NCT02663778|BEHAVIORAL|Flexibility training|stretches to improve flexibility
48122604|NCT02663778|BEHAVIORAL|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
48122605|NCT02663778|BEHAVIORAL|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
48122606|NCT05123742|DIAGNOSTIC_TEST|COVID-19 Testing|Testing for the SARS-CoV-2 virus
48122607|NCT05771350|PROCEDURE|online hemodiafiltration|20 patients on regular hemodialysis received online hemodiafiltration
48122608|NCT05771350|PROCEDURE|high flux hemodialysis|20 patients on regular hemodialysis received high flux hemodialysis
48122609|NCT05771350|PROCEDURE|low flux hemodialysis|20 patients on regular hemodialysis received low flux hemodialysis
48122610|NCT04502901|DRUG|KX0826|investigational AR antagonist
48122611|NCT04502901|OTHER|Placebo|Placebo of KX-826
48122612|NCT05872724|DRUG|Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab|"* Radiation therapy:~  1. Irradiation mode and dose: 6MV-X-ray (6Megavoltage-X-ray), IMRT or RapidArc-IMRT were used for external radiotherapy. External radiotherapy dose: PTV (Planning Target Volume) 45-50Gy/25 times.~* Chemotherapy:~  1. Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~ 2. Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of consolidation chemotherapy plus immunotherapy are recommended for patients with high risk or MRDc0 (+). Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.~* Zimberelimab injection:~  240 mg, IV, q3w. Start the drug one day before the start of postoperative radiotherapy."
48122613|NCT05872724|DRUG|Chemoradiotherapy (small pelvic) + Zimberelimab|"Radiation therapy:~1. Target volume of radiotherapy for small pelvis: CTVp includes tumor bed area, paracentral area and part of vagina; CTVn includes bilateral internal iliac, external iliac and obturator lymphatic drainage areas. Upper boundary to sacroiliac joint level, lower boundary to 2cm below vaginal stump.~Chemotherapy:~Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w. Carboplatin or nedaplatin may be used in patients that cannot tolerate cisplatin.~Adjuvant chemotherapy: After the concurrent chemoradiotherapy, 4 cycles of adjuvant immunotherapy are recommended for patients in good general condition (ECOG: 0-1) with medium risk and MRDc0 (-).~Zimberelimab injection: 240 mg, IV, q3w. Start the drug one day before the start of posterior radiotherapy."
48122614|NCT00622856|BEHAVIORAL|psychological intervention|Psychological intervention
48122615|NCT00622856|BEHAVIORAL|Diabetes education|5 sessions with diabetes nurse
48122616|NCT00423098|DRUG|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
48122617|NCT00423098|DRUG|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
48122618|NCT00423098|DRUG|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
48122619|NCT01003405|DRUG|KUC-7483|
48122620|NCT06006611|DRUG|Azvudine|Received antiviral treatment with azvudine
48122621|NCT00945789|DRUG|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
48122622|NCT00945789|PROCEDURE|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
48122623|NCT00945789|BIOLOGICAL|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
48122624|NCT06103916|OTHER|Observational study. Prospective registration of ultrasound data in patients with ovarian tumors for which an ultrasound in according with the IOTA definitions is performed.|From all included patients, prospective data will be collected of the ultrasound(s) performed, the performed treatment and in case of surgery also the final pathological diagnosis. Participating patients will not be subjected to acts or additional procedures or examinations in this study, nor will rules of conduct be imposed.
48122625|NCT02991534|BEHAVIORAL|CV Toolkit Components|"* Patient completes a CV self screener.~* Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~* Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
48122626|NCT00920738|OTHER|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
48328238|NCT04724304|DIAGNOSTIC_TEST|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
48328239|NCT04046757|OTHER|Mechanical thrombectomy|Neuroradiological endovascular treatment
48328240|NCT01907841|OTHER|Ischemic Preconditioning|
48328241|NCT02467829|DEVICE|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
48328242|NCT02693236|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
48328243|NCT06204302|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using Komodo Research Database (KRD)
48328244|NCT06204302|DRUG|Enzalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
48328245|NCT06204302|DRUG|Apalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
48490928|NCT03528629|DRUG|Zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion.
48122627|NCT00920738|OTHER|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
48122628|NCT03465527|DRUG|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
48122629|NCT04676321|OTHER|Patient pathway|Investigation on the appropriateness and quality of NSCLC care among participating sites
48122630|NCT04820686|DRUG|VBR|VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
48122631|NCT04820686|DRUG|AB-729|AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
48122632|NCT04820686|DRUG|SOC NrtI|Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
48122633|NCT04192916|DRUG|DOACs|Direct Oral Anticoagulants
48650598|NCT04037644|PROCEDURE|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
48650599|NCT04037644|PROCEDURE|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
48650600|NCT01013259|DRUG|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
48650601|NCT01013259|DRUG|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
48328246|NCT03293628|PROCEDURE|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
48650602|NCT02338557|DEVICE|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
48650603|NCT02338557|DEVICE|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
48328247|NCT03155633|OTHER|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
48650604|NCT04968834|GENETIC|Genomic profiling|Genomic profiling using CLIA assay
48328248|NCT03155633|OTHER|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
48328249|NCT02017899|BIOLOGICAL|S. sonnei 1790GAHB|
48328250|NCT02017899|BIOLOGICAL|Placebo|
48328251|NCT04430283|DRUG|FDY-5301|FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
48490929|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane blend|1.8 gram per day of lions mane, consisting of 3 x 600mg capsules
48650605|NCT01872000|PROCEDURE|Cataract surgery|
48650606|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program A) intervention
48650607|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program B) intervention
48650608|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program A)
48650609|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program B)
48650610|NCT06386432|OTHER|Biospecimen Collection|Complete at-home saliva sample collection
48650611|NCT06386432|OTHER|Questionnaire Administration|Ancillary studies
48650612|NCT05207943|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
48328252|NCT04430283|OTHER|Placebo|Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
48650613|NCT05207943|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
48650614|NCT06675916|PROCEDURE|PENG Block with lidocaine hydrochloride|Intervention is ultrasound-guided PENG block analgesia with lidocaine hydrochloride
48650615|NCT06675916|PROCEDURE|Intra-articular infiltration with lidocaine hydrochloride|Intervention is intra-articular analgesia with lidocaine hydrochloride
48328253|NCT01928082|DRUG|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
48328254|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
48328255|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
48490930|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane and reishi blend|1.8 gram per day of lions mane and reishi blend, consisting of 3 x 600mg capsules
48490931|NCT06406946|DIETARY_SUPPLEMENT|Placebo|1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules
48490932|NCT05706194|DIAGNOSTIC_TEST|Early neurological prognostication with biomarkers, EEG and CT|Biomarker samples collected at 12, 24, 48 and 72 h after randomisation, CT and EEG performed as early as possible after 24 h post randomisation in patients still unconscious (defined as not awake and able to follow verbal commands)
48650616|NCT00908141|BIOLOGICAL|sargramostim|Given subcutaneously on varying schedule
48650617|NCT06571175|DIAGNOSTIC_TEST|High frame rate echocardiography|Conventional transthoracic echocardiography will be performed, with added 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.6) and in validated machine learning algorithms.
48328256|NCT01478893|BIOLOGICAL|SEL-068|Sub-cutaneous injection, multiple dose
48328257|NCT01478893|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
48328258|NCT03712800|OTHER|Rhythmical massage|Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
48328259|NCT03712800|BEHAVIORAL|HRV biofeedback|One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
48328260|NCT05871229|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
48490933|NCT02811263|DRUG|Normal saline placebo|Equal volume of normal saline to be used as placebo
48490934|NCT02811263|DRUG|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
48650618|NCT06571175|DIAGNOSTIC_TEST|MRI|Cardiac MRI will be performed. In all patients without contraindications, a gadolinium-based contrast agent will be given.
48122634|NCT01130246|DRUG|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
48328261|NCT05871229|OTHER|Standard treatment for peri-implantitis|Standard treatment for peri-implantitis as per international, national and clinic guidelines
48328262|NCT00267371|DEVICE|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
48650619|NCT06571175|DIAGNOSTIC_TEST|Blood test|Conventional brachial venous blood samples will be drawn. Hematocrit value {in %} will be used to calculate CMR-derived exttracellular volume (ECV)
48650620|NCT06571175|DIAGNOSTIC_TEST|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
48650621|NCT06571175|DIAGNOSTIC_TEST|6 min walking test|6 MWT will be performed, and the findings will be related to findings from CMRI/echocardiography.
47973267|NCT04569266|OTHER|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
48328263|NCT00267371|DRUG|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
47973268|NCT04464369|DRUG|itopride|itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
48122635|NCT01130246|DRUG|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
48122636|NCT04689685|OTHER|Wearing smartwatch and continous glucose sensor|Patients will be wearing a smartwatch and a continuous glucose meter (CGM) over a maximum duration of 3 months in an outpatient setting.
48122637|NCT02724956|DEVICE|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
48328264|NCT04266106|DRUG|SuperBio probiotic|One capsule po BID for 28 days
48328265|NCT04266106|DRUG|Placebo|One capsule po BID for 28 days
48328266|NCT02016729|DRUG|AMG 232|Given an an oral tablet in escalating doses.
48328267|NCT02016729|DRUG|Trametinib|Trametinib is an oral tablet given in a fixed dose.
48328268|NCT06123000|PROCEDURE|Modified Widman Flap (MWF)|At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.
48490935|NCT06131827|OTHER|Neural mobilization|Neural mobilization will be performed with twenty oscillations per minute being repeated three sets of one minute respecting one minute interval of rest between each set for 4 days weekly for six week
48490936|NCT06131827|OTHER|Task based activities|Task based activities consisted of different types task which will be performed with the dosage of 45 minute session 5 days weekly for six week.
48490937|NCT01031966|BIOLOGICAL|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
48490938|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
48490939|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
48490940|NCT01856361|DRUG|Ramipril|Angiotensin Converting Enzyme Inhibitor
48490941|NCT01856361|DRUG|Placebo|Placebo pill that will match the treatment pill
48490942|NCT05110807|DRUG|TQB3617|TQB3617 is a BET inhibitor.
48490943|NCT03801382|DEVICE|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
48490944|NCT03801382|DIAGNOSTIC_TEST|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
48650622|NCT06099769|DRUG|Enzalutamide|mouth once daily (160 mg/day)
48650623|NCT06099769|DRUG|Mifepristone|mouth once daily 300-mg tablet
47973269|NCT04464369|DRUG|Placebo|placebo pills matching the look and weight of the itopride tablets
48122638|NCT02724956|DEVICE|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
48122639|NCT02724956|DEVICE|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
48122640|NCT03197571|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
48122641|NCT03197571|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
48122642|NCT03197571|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
48122643|NCT03197571|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
48122644|NCT03197571|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48122645|NCT03197571|DRUG|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48122646|NCT03197571|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
48122647|NCT03197571|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
48122648|NCT03197571|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
48328269|NCT06123000|PROCEDURE|Fiber Retention Osseous Resective Surgery (FibReORS)|At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.
48122649|NCT03197571|DRUG|Lovaza|Omega-3-acid ethyl esters
48122650|NCT03197571|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
48122651|NCT03197571|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
48122652|NCT03197571|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
48122653|NCT03197571|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
48650624|NCT06099769|DRUG|TPC|"The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"
47973270|NCT01448278|PROCEDURE|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
48122654|NCT03197571|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
48122655|NCT03197571|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
48122656|NCT03197571|BIOLOGICAL|GI-4000|RAS yeast vaccine
48122657|NCT03197571|BIOLOGICAL|GI-6207|CEA yeast vaccine
48122658|NCT03197571|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
48122659|NCT03197571|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
48122660|NCT03344536|DRUG|Fulvestrant|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
48122661|NCT03344536|DRUG|Debio 1347|Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
48122662|NCT01629316|BEHAVIORAL|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
48328270|NCT05782582|DIAGNOSTIC_TEST|Package investigation|Investigations performed on a single visit, according to arm description
48328271|NCT05782582|DEVICE|Sound registration with Cadscore® and added risk calculation|Recording of cardiac diastolic sounds enabling the calculation of a risk score.
48328272|NCT05782582|DIAGNOSTIC_TEST|Standard investigation|Sequential investigations according to arm description
48328273|NCT02836483|DRUG|LCB01-0371 800mg, QD|Oral administration
48328274|NCT02836483|DRUG|LCB01-0371 400mg, BID|Oral administration
48328275|NCT02836483|DRUG|LCB01-0371 800mg, BID|Oral administration
48650625|NCT02520362|DRUG|denosumab|subcutaneous injection
48122663|NCT01629316|BEHAVIORAL|Standard of care - control arm|The control arm is standard of care for each subject.
48122664|NCT01558986|PROCEDURE|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
48122665|NCT01558986|PROCEDURE|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
48122666|NCT03289468|DIAGNOSTIC_TEST|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
48122667|NCT03372070|DEVICE|cNEP|soft silicon collar applied to anterior neck with negative pressure
48122668|NCT04408872|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|EGD: ENDOSCOPIC PROCEDURE DURING WHICH THE ESOPHAGUS, STOMACH AND DUODENUM ARE VISUALISED WITH A TINY CAMERA IMPLANTED AT THE END OF AN ENDOSCOPE.
48328276|NCT02836483|DRUG|Tubes 3~5Tablet, QD|Oral administration
48328277|NCT02836483|DRUG|Zyvox 600mg, BID|Oral administration
48122669|NCT04408872|DIAGNOSTIC_TEST|Endoscopic ultrasound (EUS)|EUS: SAME AS EGD, BUT IN ADDITION HAS AN INTEGRATED ULTRASOUND PROBE WHICH ALLOWS TO EXAMINE THE PANCREAS, LIVER AND BILIARY SYSTEM.
48328278|NCT02836483|DRUG|LCB01-0371 1200mg, QD|Oral administration
48328279|NCT00101153|DRUG|cytarabine|
48328280|NCT00101153|DRUG|daunorubicin hydrochloride|
48328281|NCT00101153|DRUG|tipifarnib|
48328282|NCT03450525|OTHER|No intervention|No intervention
48328283|NCT03089970|DIAGNOSTIC_TEST|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
48328284|NCT04635761|BEHAVIORAL|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
48328285|NCT04635761|BEHAVIORAL|Questionnaire Administration|Ancillary studies
48328286|NCT04282668|DRUG|TAS1440|Form: Capsule or Tablet Route of Administration: Oral
48328287|NCT04282668|DRUG|TAS1440 + ATRA|Form: Capsule or Tablet Route of Administration: Oral
48328288|NCT02988401|DRUG|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
48328289|NCT02988401|DRUG|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
48328290|NCT01962285|DRUG|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
48328291|NCT04889963|BIOLOGICAL|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
48328292|NCT02455778|DIETARY_SUPPLEMENT|Cinnamon|
48328293|NCT02455778|DIETARY_SUPPLEMENT|Placebo|
48328294|NCT01183312|DRUG|Flumazenil|Sublingual flumazenil
48328295|NCT04731623|DRUG|ION904|ION904 will be administered by SC injection.
48328296|NCT04731623|DRUG|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
48328297|NCT01617512|DEVICE|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
48328298|NCT01943422|DRUG|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
48328299|NCT01943422|DRUG|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
48328300|NCT04711759|DEVICE|High flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
48328301|NCT04711759|DEVICE|Standard oxygen therapy|Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
48328302|NCT04262622|DEVICE|Group TEA: thoracic epidural analgesia group|in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
48328303|NCT04262622|DEVICE|Group RSB: rectus sheath block group|Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
48328304|NCT04791033|PROCEDURE|Hysterectomy|Elective procedure with hysterectomy due to benign gynecological condition
48328305|NCT02272283|DEVICE|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
48328306|NCT02494778|DRUG|Pridopidine|45 mg BID
48122670|NCT04865146|DEVICE|TRIGEN™ INTERTAN™|Femoral fracture treated with INTERTAN 10S Nail
48328307|NCT03341611|BEHAVIORAL|Neuro-imaging during behavioral decision-making task|All participants will make simple decisions while in a scanner.
48328308|NCT00866892|PROCEDURE|Irrigation|irrigation
48328309|NCT00866892|PROCEDURE|No irrigation|no irrigation
48328310|NCT00003595|BIOLOGICAL|filgrastim|
48328311|NCT00003595|BIOLOGICAL|rituximab|
48328312|NCT00003595|DRUG|CHOP regimen|
48328313|NCT00003595|DRUG|cyclophosphamide|
48328314|NCT00003595|DRUG|doxorubicin hydrochloride|
48328315|NCT00003595|DRUG|prednisone|
48328316|NCT00003595|DRUG|vincristine sulfate|
48328317|NCT05536245|OTHER|Questionnaire|To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
48328318|NCT01641718|DRUG|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
48328319|NCT01641718|DEVICE|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
48328320|NCT02293993|DRUG|SGI-110|
48328321|NCT01524237|DRUG|LY2979165|Capsules administered orally
48328322|NCT01524237|DRUG|LY2140023|Tablets administered orally
48328323|NCT01524237|OTHER|Placebo|Administered orally
48328324|NCT01524237|OTHER|Ketamine|Administered intravenously (IV)
48328325|NCT02671461|DRUG|BMS-986141|
48328326|NCT02671461|DRUG|Aspirin|
48328327|NCT02671461|OTHER|Placebo|
48328328|NCT00305747|DRUG|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
48328329|NCT04871542|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
48328330|NCT04871542|OTHER|Questionnaire Administration|Complete questionnaires
48328331|NCT02611700|DRUG|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
48328332|NCT02611700|DRUG|Paclitaxel|175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
48328333|NCT02611700|DRUG|Cisplatin|60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
48650626|NCT02520362|DRUG|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate \[Fosamax®\], risedronate \[Actonel®\], ibandronate \[Boniva®/Bonviva®\] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate \[Reclast®/Aclasta®\].
48650627|NCT06230679|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
48650628|NCT06230679|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
48122671|NCT04413812|BEHAVIORAL|FREEBASE exercise programme|"The exercise programme will be initialized 1-10 months following bariatric surgery and last for 3 months. The programme will be mainly delivered in two groups consisting of 10-12 subjects each and will be held in the facilities of a fitness studio and remotely at home. The programme consists of 24 units (two per week, the lesson in the fitness studio lasting for 75 minutes and the remote lesson lasting for 45 minutes.This is due to the COVID-19-related social distancing restrictions. The intervention combines the following elements: a) exercise training in a group, b) interactive workshops on basic knowledge of training sciences and techniques of behavior change and c) an individual exercise counselling session.~The programme will be medically supervised and the content will be taught and instructed by members of the research team qualified in exercise science and sports physiology."
48328334|NCT02611700|DRUG|Placebo|400mg,day1,weekly,until disease progression or toxicity
48490945|NCT05301530|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
48490946|NCT05301530|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
48490947|NCT05301530|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
48490948|NCT05657236|OTHER|medical treatment|traditional medical treatment and regular follow-up
48490949|NCT05657236|OTHER|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
48490950|NCT05964192|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).
48490951|NCT02115217|DEVICE|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
48490952|NCT02115217|DEVICE|Sham kinesiotape|KT put with no effects
48490953|NCT01235702|BEHAVIORAL|12-week lifestyle modification|
48122672|NCT06515678|DRUG|arm A - angiotensin converting enzyme inhibitors (ACEi)|"Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril"
48122673|NCT06515678|DRUG|arm B - calcium channel blockers (CCBs)|"Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine"
48122674|NCT06515678|DRUG|arm R - angiotensin receptor blockers ARB|"Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil."
48122675|NCT05265481|DEVICE|Tourniquet|The investigators will apply a pressure cuff tourniquet inflated to 60 mmHg
48328335|NCT04248062|OTHER|Survey|Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
48328336|NCT04897438|PROCEDURE|Kidney allograft biopsy depending on donor-derived cell-free DNA levels|Kidney allograft biopsy is performed, when absolute levels of donor-derived cell-free DNA are above 50 copies/ml
48328337|NCT03728712|DIAGNOSTIC_TEST|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
48490954|NCT01700049|DRUG|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
48490955|NCT02790307|DEVICE|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
48490956|NCT03748849|PROCEDURE|Physiotherapy|
48490957|NCT04414436|BEHAVIORAL|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
48122676|NCT05265481|DEVICE|Manual Tapping|The investigators will apply tapping directly over the vein manually to increase the vein dimension.
48122677|NCT05265481|DEVICE|Device tapping|The investigators will apply tapping directly over the vein with a massage device to increase the vein dimension.
48122678|NCT03359967|DRUG|Entresto tablet|Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
48122679|NCT01714869|OTHER|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
48328338|NCT06315855|BEHAVIORAL|Telehealth Intervention (THI)|The THI is a 6-month intervention. On a monthly basis, the survivor will be queried via telehealth (zoom or smart phone) oral and health related symptoms by nurse practitioner or navigator. Based on the initial imaging and the monthly assessments, the patients will be provided with tools and instructions for oral health maintenance which may consist of mucositis management and/or diet and lifestyle counseling. All participants will be provided a Resource directory that is to be used to identify a dentist that is best suited for him/her. Post intervention, follow-up assessments will be conducted at 6-, 9- and 12-months post randomization.
48328339|NCT00168324|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
48328340|NCT00168324|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
48328341|NCT00168324|OTHER|Sham Injection|Sham injection on Day 0.
48328342|NCT00570440|DRUG|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
47973271|NCT01448278|PROCEDURE|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
48328343|NCT03629691|OTHER|lung cavitation|apatinib treated patients developed lung cavitation
48328344|NCT03689387|OTHER|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
48122680|NCT03608787|BEHAVIORAL|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
48122681|NCT00468806|DRUG|GSK598809, using [11C]-(+)-PHNO|
48328345|NCT01790009|DIETARY_SUPPLEMENT|Flavanol rich drink|
48328346|NCT01790009|DRUG|Acetaminophen|2x500 mg Acetaminophen
47973272|NCT03141476|DRUG|Cefuroxime 1,5g|Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime
47973273|NCT03141476|DRUG|Cefuroxime 3g|Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime
47973274|NCT03141476|DRUG|Cefuroxime 4,5g|Patients with BMI of \>50kg/m\*m: 4,5 g Cefuroxime
47973275|NCT04703335|DRUG|Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
47973276|NCT06123845|BEHAVIORAL|static CPAP 8 cmH2O|Set static CPAP or PEEP pressure level at 8 cmH2O
47973277|NCT06123845|BEHAVIORAL|static CPAP 5 cmH2O|Set static CPAP or PEEP pressure level at 5 cmH2O
48122682|NCT05217849|BEHAVIORAL|Tai Chi|Tai Chi is an ancient Chinese form of exercise/martial art that involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
48122683|NCT05217849|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is a gentle, mindful movement exercise program that integrates elements of Eastern and Western exercise modalities to develop mindful body awareness and enhance social connection.
48122684|NCT05217849|BEHAVIORAL|Health and Wellness Education|This on-line class will consist of hour-long lectures/talks about various topics related to healthy aging and wellness.
48122685|NCT04046536|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
47973278|NCT00281255|DRUG|Allopurinol|
47973279|NCT00281255|DRUG|Dobutamine|
48328347|NCT03487406|DRUG|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
48328348|NCT03487406|DRUG|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
48328349|NCT03487406|DRUG|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
48328350|NCT03487406|DRUG|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
48328351|NCT04939870|DIAGNOSTIC_TEST|Biochemical parameters evaluation|selected biochemical parameters
48328352|NCT05355428|OTHER|offering of breast milk feed 3 hours prior to p lanned surgery start|parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
48490958|NCT01359644|DRUG|PSI-7977|Tablets, oral, 400 mg, once daily
48490959|NCT01359644|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily
47973280|NCT01192516|BEHAVIORAL|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
48122686|NCT04046536|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
48328353|NCT02029638|BIOLOGICAL|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
47973281|NCT01192516|BEHAVIORAL|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
48122687|NCT02882035|OTHER|OFA|
48122688|NCT00002049|DRUG|Thymopentin|
48122689|NCT00048217|DRUG|T-1249|
48122690|NCT05351424|OTHER|Audiovisual Intervention- Radiation Therapy Education|A video with educational information will be shown regarding radiation therapy.
48122691|NCT05351424|OTHER|ASTRO Radiation Therapy for Breast or Prostate Cancer Brochure|Brochure with written information will be given to the subject regarding radiation therapy.
48328354|NCT02029638|DRUG|Fludarabine|Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
47973282|NCT02764515|DRUG|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
47973283|NCT02764515|DRUG|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
47973284|NCT02823431|DRUG|lidocaine gel|
47973285|NCT02823431|OTHER|Plain aqueous gel|
47973286|NCT02807532|OTHER|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
47973287|NCT02807532|OTHER|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
47973288|NCT03031678|DEVICE|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
47973289|NCT02250170|DRUG|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
47973290|NCT00821353|PROCEDURE|RF catheter ablation|RF catheter ablation
47973291|NCT00821353|DRUG|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
47973292|NCT06242951|DIAGNOSTIC_TEST|VO2 max assessment|Measurement of the maximum oxygen consumption (VO2max) by a cardiopulmonary exercise test (CPET)
47973293|NCT05577260|DRUG|magnesuim sulphate|magnesuim sulphate
47973294|NCT05577260|DRUG|Dexmedetomidine|Dexmedetomidine
47973295|NCT05577260|DRUG|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
48328355|NCT02029638|DRUG|Cyclophosphamide|"1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
48328356|NCT02029638|RADIATION|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
48328357|NCT02029638|DRUG|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
48328358|NCT02029638|DRUG|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
48328359|NCT02029638|DRUG|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
48328360|NCT02029638|BIOLOGICAL|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
47973296|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants|As per treatment allocation, PEG 4000 will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
47973297|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants|As per treatment allocation, PEG 3350 + Electrolytes will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
48122692|NCT05351424|OTHER|Audiovisual Intervention- Cancer Clinical Trials Education|A video with educational information will be shown regarding cancer clinical trials.
48122693|NCT05351424|OTHER|NCI Taking Part in Cancer Research Studies Brochure|Brochure with written information will be given to the subject regarding cancer clinical trials.
48122694|NCT05459233|PROCEDURE|Doppler-echocardiography|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further intervention will be based on Doppler-echocardiographic measurements. Balloon post-dilation with a non-compliant balloon will be performed in the presence of a residual mean gradient ≥20 mmHg as assessed by Doppler-echocardiography.
47973298|NCT02812160|DEVICE|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
47973299|NCT02352350|OTHER|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
47973300|NCT02352350|OTHER|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
47973301|NCT03253497|DRUG|Chlorobenzene Liquid|before induction will be used for oropharynx
47973302|NCT01064713|DRUG|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
48122695|NCT05459233|PROCEDURE|Invasive hemodynamic measurements|The TAVR (valve-in-valve) procedure will be performed with the SAPIEN 3 Ultra valve, with valve sizing according to current manufacturer recommendations. Following valve implantation, further interventions will be based on invasive hemodynamic measurements (with simultaneous aortic and ventricular pressure recording). Balloon post-dilation will be performed with a non-compliant balloon in the presence of a mean residual gradient ≥20 mmHg as assessed by hemodynamic measurements.
47973303|NCT05540405|DIETARY_SUPPLEMENT|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
47973304|NCT05540405|DIETARY_SUPPLEMENT|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
47973305|NCT05540405|DIETARY_SUPPLEMENT|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
47973306|NCT04073589|BIOLOGICAL|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
47973307|NCT05044390|PROCEDURE|Lung transplantation (single, lobar or bilateral lung transplantation)|Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
47973308|NCT05590013|DRUG|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
47973309|NCT03785002|OTHER|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
47973310|NCT03785002|OTHER|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
47973311|NCT03092609|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
47973312|NCT03092609|BEHAVIORAL|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
47973313|NCT00688753|DRUG|RAD001|
47973314|NCT05350111|BEHAVIORAL|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
47973315|NCT00798499|OTHER|Laboratory variables|1 visit
47973316|NCT00728871|PROCEDURE|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
47973317|NCT05745584|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
47973318|NCT04381598|DRUG|stevia rebaudiana bertoni|Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
47973319|NCT04381598|OTHER|placebo|A placebo without the active drug will be placed in the control sites.
47973320|NCT01654341|BEHAVIORAL|Exercise, dietary and educational program|
47973321|NCT02383277|OTHER|Stretching|Stretching of the rib cage muscles
48122696|NCT03832894|DRUG|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
48328361|NCT02029638|DRUG|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
47973322|NCT02383277|OTHER|Control|Rest without stretching (sham)
47973323|NCT02383277|OTHER|Exercise|Constant load exercise on a bike
47973324|NCT00763568|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
48122697|NCT01692483|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
48122698|NCT01692483|DRUG|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
48490960|NCT01359644|DRUG|Ribavirin|Tablets, oral, 200 mg
48490961|NCT03533127|DRUG|LY01008|LY01008+Carboplatin/Paclitaxel
47973325|NCT00763568|BIOLOGICAL|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
47973326|NCT03954756|DRUG|Apatinib and PD1|"1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks."
47973327|NCT00539136|DRUG|GSK561679 tablet or solution|
47973328|NCT00442078|DEVICE|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
47973329|NCT06013865|DRUG|Empagliflozin|SGLT2 Inhibitor
47973330|NCT06217055|DRUG|remimazolam based MAC|The surgery will be performed under monitored anesthesia care by maintaining spontaneous breathing using remimazolam.
47973331|NCT06217055|DRUG|general anesthesia with sevoflurane|The surgery will be performed under mechanical ventilation with inhalation general anesthesia
47973332|NCT00909051|DRUG|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
47973333|NCT04846621|DRUG|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
47973334|NCT04846621|DRUG|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
47973335|NCT02591589|OTHER|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 \> 70 mmHg or oxygen saturation greater than or equal to 92%.
47973336|NCT02591589|OTHER|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
47973337|NCT05300620|DEVICE|Custom Foot Orthotics EVA|these are custom foot orthotics made out of Ethyl Vinyl Acetate material
47973338|NCT05300620|DEVICE|Original Liner|these are original shoe liners
47973339|NCT05300620|DEVICE|Custom Foot Orthotics PU|these are custom foot orthotics made out of Expanded Poly Urethane Material
47973340|NCT05300620|DEVICE|Custom Hybrid Foot Orthotics|these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
48122699|NCT04701866|OTHER|Music|Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
47973341|NCT00651794|BEHAVIORAL|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
47973342|NCT00651794|BEHAVIORAL|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
47973343|NCT00651794|BEHAVIORAL|Skills practice with low-fidelity mannequin|
47973344|NCT00651794|BEHAVIORAL|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
47973345|NCT05746312|BEHAVIORAL|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
47973346|NCT00922181|DEVICE|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
47973347|NCT00922181|DEVICE|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
47973348|NCT05826652|OTHER|Single injection subcostal transversus abdominis plane block|Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
47973349|NCT05826652|OTHER|Multiple injection subcostal transversus abdominis plane block|Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
47973350|NCT05246761|DEVICE|Balloon catheter|In the two groups, if their bishop score \<6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
47973351|NCT02373215|DRUG|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
47973352|NCT01303107|DRUG|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
47973353|NCT04592315|DRUG|Lipovirtide Injection|Single dosage of Lipovirtide Injection
47973354|NCT02052674|DEVICE|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
48122700|NCT03204565|PROCEDURE|coronally advanced flap|coronally advanced flap alone (CAF- control)
48122701|NCT03204565|DEVICE|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
48122702|NCT03320746|DEVICE|Polar Loop 2 activity tracker|"The participants were instructed to aim to reach the daily activity goal, initially set at stage 1 as per the goals set by the trackers' manufacturer. The daily activity goal was based on user's typical daily activities, gender and age. The stage 1 daily activity goal corresponded to \~1h/day of jogging or \~2h/day of walking or \~7h/day household activities or a combination of these activities. The tracker gave an inactivity alert as a vibration and text it's time to move on the screen of the tracker if the user has been still for 55 minutes."
48122703|NCT00653276|DRUG|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
48122704|NCT00653276|DRUG|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
48122705|NCT03692780|DRUG|Careseng 1370|4,000mg granules in sachet
48122706|NCT03692780|DRUG|Placebo|4,000mg granules in sachet
48122707|NCT03017183|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
48328362|NCT02029638|DRUG|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
48122708|NCT03017183|PROCEDURE|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
48490962|NCT03533127|DRUG|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
48122709|NCT01411592|OTHER|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
48122710|NCT01411592|OTHER|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
48122711|NCT06004505|OTHER|Vestibular Rehabilitation|The patients received vestibular rehabilitation treatment in 4 sessions at 15-day intervals and applied the given exercise programs as home exercise in the form of 10 repetitions, 3 times a day. The exercises were performed sitting, standing and walking, respectively. Balance exercises were developed by changing the support area, support surface and arm positions. When they come to each session, the exercise programs are according to the patient's condition; alternating standing and walking forward, backward, tandem and semitandem positions.
48328363|NCT02029638|DRUG|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
48328364|NCT02029638|DRUG|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
48328365|NCT03665012|OTHER|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
48328366|NCT06086132|COMBINATION_PRODUCT|Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy|Follow-up visits at baseline, 3-months, and 1-year
48328367|NCT01916616|BEHAVIORAL|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
48490963|NCT05676086|BEHAVIORAL|indoor light intervention|"Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home with specific instructions to install it in a room where they spend most of their time, in order to supplement the existing indoor lighting. Thus, all people of the intervention arm will be equipped with the LUMIE Halo lamp. Utilizing both warm-white and cool-white LEDs, Lumie Halo delivers 10,000 lux at 20 cm at maximum brightness in Day Mode. The touch slider allows the user to adjust the brightness while mixing the color temperature of the light."
48122712|NCT06521567|DRUG|Cobolimab|Cobolimab will be administered
48122713|NCT06521567|DRUG|Dostarlimab|Dostarlimab will be administered
48122714|NCT03457948|PROCEDURE|Arterial Embolization|Undergo TAE
48122715|NCT03457948|BIOLOGICAL|Pembrolizumab|Given IV
48122716|NCT03457948|BIOLOGICAL|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
48122717|NCT03457948|DEVICE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
48122718|NCT01942018|PROCEDURE|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
48122719|NCT06394284|DRUG|MDMA-AT|As described above in arm description
48122720|NCT06394284|BEHAVIORAL|SEA-IT|As described in arm description
48328368|NCT04031404|DEVICE|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
48328369|NCT03049995|PROCEDURE|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
48490964|NCT05676086|BEHAVIORAL|no indoor light|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only. Exposure to the outdoor intervention will be taken into account in the analysis in three ways, (1) by locating the distance between people's home and the modified outdoor light, (2) by a question about the awareness of the change in outdoor light, timing, and duration of exposure and what they think of it, and (3) by recording the amount of light exposure over the 24 hours during two weeks at baseline and after the 1-year light interventions
48490965|NCT04149886|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
48122721|NCT05212181|DEVICE|H-Man|H-Man device will be deployed to patients for onboarding and home-based training.
47973355|NCT02052674|DEVICE|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
48122722|NCT01087255|DEVICE|Electronic Pillbox Monitoring System|Daily exposure for six months
47973356|NCT02532491|DRUG|Aripiprazole|Initial dose: 10 mg.
47973357|NCT02532491|DRUG|Risperidone|Initial dose: 2 mg.
47973358|NCT01167894|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
47973359|NCT00171730|DRUG|Pasireotide|
47973360|NCT00988611|OTHER|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
47973361|NCT01876797|DRUG|ticagrelor/prasugrel|
47973362|NCT00277836|DRUG|MST-997|
48122723|NCT01806116|DRUG|decitabine|
48122724|NCT00756067|BIOLOGICAL|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
48122725|NCT00756067|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
48122726|NCT04224792|OTHER|Center-based exercise program|A routine individualized exercise prescription and supervised exercise sessions at a minimum of once per week for 11 weeks with an exercise prescription updated monthly.
48122727|NCT04224792|OTHER|Home-based exercise program|A one-time supervised exercise session with Cardiac Rehabilitation staff and a routine individualized exercise prescription for exercises to do at home. Additionally, weekly telephone followup calls by a clinical exercise physiologist for 11 weeks consisting of an exercise tip.
48122728|NCT00814905|DRUG|saline|A saline infusion after delivery (one dose)
48122729|NCT00814905|DRUG|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
48122730|NCT00814905|DRUG|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
48122731|NCT00814905|DRUG|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
48122732|NCT04438343|OTHER|Impairment-specific and augmented intervention|Balance and lower extremities strength training
48122733|NCT04438343|OTHER|Conventional physical therapy|Trunk and upper extremity training
48122734|NCT05492409|BIOLOGICAL|GNR-069|Once a week as a subcutaneous injection.
48122735|NCT01266122|BEHAVIORAL|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
48122736|NCT03573518|DRUG|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
48328370|NCT03049995|PROCEDURE|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
48328371|NCT03049995|PROCEDURE|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
48328372|NCT03049995|PROCEDURE|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
48328373|NCT03049995|PROCEDURE|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
48328374|NCT03049995|PROCEDURE|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
48122737|NCT03573518|DRUG|Vehicle|Placebo
48122738|NCT04018859|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
48122739|NCT04018859|DRUG|Saline|intradermal injections to the eyebrows
48122740|NCT05618002|DRUG|Lemborexant|For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.
48328375|NCT03049995|PROCEDURE|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
48328376|NCT02741089|PROCEDURE|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
48328377|NCT05979233|PROCEDURE|staged managment|staged management
48122741|NCT02909439|DRUG|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
48122742|NCT02909439|DRUG|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
48122743|NCT00681603|DRUG|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
48122744|NCT04470375|BEHAVIORAL|Virtual Reality Pain Neuroscience Education|Use of virtual reality media to provide pain neuroscience education
48122745|NCT01836133|DRUG|Erlotinib 150 mg|
48122746|NCT06224946|DIAGNOSTIC_TEST|soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio|the soluble fms-like tyrosine kinase (sFlt-1) / placental growth factor (PlGF) ratio for pre-eclampsia diagnostic
48122747|NCT02467946|DRUG|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
48122748|NCT04933526|DRUG|Flumatinib|Flumatinib 600mg QD orally form 1 to 12 months
48122749|NCT04933526|DRUG|Dasatinib|Dasatinib 100mg QD orally form 1 to 12 months
48122750|NCT01603758|DRUG|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
48328378|NCT05979233|PROCEDURE|one session ERCP then LC|one session ERCP then LC
48328379|NCT05979233|PROCEDURE|one session LC then ERCP|one session LC then ERCP
48122751|NCT00194610|DRUG|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
48122752|NCT00194610|OTHER|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
48122753|NCT03427216|DRUG|Baclofen/diazepam|Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
48122754|NCT03427216|DRUG|Vaginal placebo|Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
48122755|NCT01157663|OTHER|Adapted balance training|during 8 weeks
48328380|NCT03438578|DEVICE|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
48328381|NCT01127295|DRUG|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
48328382|NCT02978664|PROCEDURE|Air insufflation|Air insufflation during colonoscopy including insertion phase
48328383|NCT02978664|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
47973363|NCT00954070|DEVICE|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
48328384|NCT02978664|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
47973364|NCT03608449|OTHER|questionnaires|questionnaire about mental health status during psychotherapy
48328385|NCT05396794|BEHAVIORAL|Standard weight loss education|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider.
47973365|NCT02401438|OTHER|5D ultrasound|
47973366|NCT02401438|OTHER|2D ultrasound|
47973367|NCT04815161|BEHAVIORAL|Adherence|Adherence to medication using an electronic pillbox
47973368|NCT01033968|PROCEDURE|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
47973369|NCT05669495|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
47973370|NCT00600483|DRUG|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
47973371|NCT03445104|OTHER|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
47973372|NCT03445104|OTHER|Placebo|During one of the two experimental sessions, participants will be given a placebo.
48122756|NCT01157663|OTHER|Balance Training|Balance training with unipedal standing during 8 weeks
48122757|NCT05616754|BIOLOGICAL|Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.
48122758|NCT05616754|BIOLOGICAL|Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
47973373|NCT02021240|DRUG|Ketamine|
48122759|NCT05520658|DRUG|combined digoxin and furosemide|one session every 2 weeks for maximum 6 sessions
48122760|NCT05520658|DRUG|5 fluorouracil|5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .
48122761|NCT02274142|PROCEDURE|Restoration with hand-mixed material|restoration with hand-mixed glass ionomer cement
48328386|NCT05396794|BEHAVIORAL|Standard weight loss education + Educational Video|Participants will be randomized and given the standard weight loss education by the Gynecologic Oncology provider followed by a 15-minute educational video detailing the benefits of weight loss.
48328387|NCT06342570|OTHER|There is no Intervention name to describe.|There is no Intervention name to describe.
48328388|NCT04186715|DEVICE|Near-infrared spectroscopy|The Near-infrared spectroscopy probes will be placed in the frontal region.
47973374|NCT02021240|DRUG|Dexamethasone|
47973375|NCT02021240|DRUG|Normal Saline|
47973376|NCT01207869|BIOLOGICAL|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
47973377|NCT01207869|OTHER|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
47973378|NCT02220205|OTHER|PelvicSim|
47973379|NCT02220205|DEVICE|Manufacturer model|
47973380|NCT04813406|DRUG|Anlotinib + Sintilimab|"Anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Sintilimab: 200 mg/time, intravenous injection, every 3 weeks is one cycle."
47973381|NCT01121237|DRUG|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
48328389|NCT03823599|BEHAVIORAL|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
48328390|NCT03823599|BEHAVIORAL|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
48328391|NCT00453180|DRUG|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
48328392|NCT00453180|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
48328393|NCT00236522|DRUG|levofloxacin|
48490966|NCT04149886|DEVICE|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
48122762|NCT02274142|PROCEDURE|Restoration with Encapsulated material|restoration with encapsulated ionomer cement
48122763|NCT02274142|DEVICE|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
48122764|NCT02274142|DEVICE|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
48122765|NCT05672888|DRUG|Jaktinib|100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
48122766|NCT05672888|DRUG|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
48122767|NCT02477605|DEVICE|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
48122768|NCT02477605|DEVICE|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
48122769|NCT02477605|PROCEDURE|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
48328394|NCT03103880|DEVICE|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.
48328395|NCT05489120|OTHER|Consumption of FLAVIS|Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
48328396|NCT06189170|DRUG|KP405|Experimental drug
48328397|NCT06189170|DRUG|Placebo|Placebo
47973382|NCT06158126|DRUG|Initiating daily oral PrEP during pregnancy|Group 1a, will include pregnant women who initiate oral PrEP at enrollment into the study.
47973383|NCT06158126|DRUG|Already using daily oral PrEP at the time of pregnancy diagnosis|Group 1b will include women already using daily oral PrEP at the time of pregnancy diagnosis and enrollment in the study.
47973384|NCT06158126|DRUG|Initiating injectable PrEP during pregnancy|Group 2a will include pregnant women who initiate injectable PrEP (CAB-LA) at enrollment into the study.
47973385|NCT06158126|DRUG|Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis|Group 2b will include women using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis.
47973386|NCT01663532|DRUG|Aripiprazole IM Depot|
47973387|NCT01663532|DRUG|Placebo|Matching Placebo
47973388|NCT01293357|DRUG|LEO 90105|Ointment
47973389|NCT01835587|DRUG|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
47973390|NCT03358121|DIAGNOSTIC_TEST|Clamp study|Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
47973391|NCT02759328|BEHAVIORAL|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
47973392|NCT02759328|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
47973393|NCT01456247|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
47973394|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
47973395|NCT01456247|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
47973396|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
47973397|NCT01456247|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
47973398|NCT01456247|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
47973399|NCT04847492|PROCEDURE|Traditional corticotomy|A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.
47973400|NCT04847492|PROCEDURE|Flapless corticotomy|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
48122770|NCT03988842|DRUG|Alteplase|Lyophilized powder for reconstitution in 50mg vials
48122771|NCT03988842|DRUG|Unfractionated heparin|Heparin sodium in 0.45% sodium chloride injection for intravenous use
48122772|NCT03988842|DRUG|Placebo|Saline solution reconstituted to mimic Alteplase 50mg vial
48122773|NCT03988842|DRUG|Apixaban|Apixaban tablet
48122774|NCT02206750|OTHER|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
48122775|NCT02206750|OTHER|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
48328398|NCT02707679|OTHER|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
48328399|NCT02707679|OTHER|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
48328400|NCT02707679|OTHER|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
48328401|NCT02707679|OTHER|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
48328402|NCT00329134|DRUG|Administration of quinine sulphate taste-masked pellets|
48328403|NCT05336006|OTHER|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
48328404|NCT05336006|OTHER|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
48328405|NCT00749164|PROCEDURE|MSC transplantation|1-2X10\^6 MSC per kg
48650629|NCT06673537|OTHER|Connective Tissue Massage (CTM)|"Connective Tissue Massage (CTM) was administered to the lumbar and abdominal regions by an experienced physiotherapist three times a week for 15 minutes over six weeks. The treatment started from the predicted day of ovulation (cycle length minus 14 days) until the onset of the next menstrual period. Both short and long strokes were utilized during CTM. Each stroke was repeated three times, first on the right side and then on the left side, across all manipulated areas. During the manipulation, the tip of the middle finger remained in contact with the patient's skin. The finger was positioned at a 45° angle, with the distal interphalangeal joint in flexion, and was moved to create traction.~During the lumbar region treatment, participants were instructed to sit upright with their hips, knees, and ankles flexed at 90°, ensuring that their thighs and feet were fully supported. For the abdominal region treatment, participants lay supine with pillows placed under their head and knees."
48650630|NCT06673537|OTHER|Spinal Manipulation|Spinal manipulation was performed by an experienced physiotherapist on the intervention group three times a week following Connective Tissue Massage (CTM). Participants in this group were positioned laterally, ensuring their lower leg remained straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, allowing an unopposed force to be applied at the selected joint. Following CTM, manipulation was carried out with high-velocity, low-amplitude (HVLA) force applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, accompanied by an audible sound from one or more joints.
47973401|NCT01882491|DRUG|Placebo|Solution for subcutaneous injection
47973402|NCT01882491|DRUG|gevokizumab|Solution for subcutaneous injection
48122776|NCT02330458|PROCEDURE|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall \>3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
48122777|NCT02655588|BEHAVIORAL|Interactive Media-Based Problems Solving Treatment|
47973403|NCT01936103|DRUG|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
47973404|NCT01936103|DRUG|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
48122778|NCT01555099|DRUG|AZD5423|oral inhaled
48490967|NCT02848911|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
48490968|NCT01679106|OTHER|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
48490969|NCT01679106|OTHER|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
48122779|NCT01555099|DRUG|Budesonide|oral inhaled
48122780|NCT01555099|DRUG|Placebo|oral inhaled
48328406|NCT05517356|PROCEDURE|Tailored management strategies|"Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved."
48328407|NCT01793519|DRUG|Etanercept|Subcutaneous
48122781|NCT04997616|DIETARY_SUPPLEMENT|Happy Lane Hemp Extract/CBD soft gels (25 mg/capsule)|Half of the study participants (5 women and 5 men) will be taking one gel capsule per day (25 mg/day dose), while the other half (5 women and 5 men) will be taking 2 gel capsules per day (50 mg/day dose). Study participants will be taking gel capsules for 10 consecutive days. At the end of this 10-day regimen, study participant will return to the TRI where blood specimen (up to 15 mL) will be collected within 2 to 6 hours after the last dose. Major plant cannabinoids and cannabinoid metabolites in each blood specimen will be determined using liquid chromatography-mass spectrometry.
48122782|NCT00505323|DEVICE|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
48122783|NCT00967434|DRUG|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
48122784|NCT00967434|DRUG|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
48122785|NCT00967434|DRUG|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
48122786|NCT02450344|BEHAVIORAL|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
48122787|NCT02450344|BEHAVIORAL|Passive health promotion|An electronic package of information related to alcohol
48122788|NCT02713906|DEVICE|X-Ray Knee Guide group|
48122789|NCT04730362|DEVICE|guedel airway|"Anesthesia will be conducted by induction with 1-2~• Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%. The goal is to maintain the patient spontaneous ventilation throughout the procedure. Monitoring of the patients is done by MRI compatible pulse oximetry for heart rate and oxygen saturation which is connected to MRI control room."
48122790|NCT04730362|DEVICE|supraglottic airway|supraglottic airway
48122791|NCT04730362|DRUG|propofol bolus and then anesthesia sevoflurane|Mg/kg of an IV propofol bolus and then anesthesia is maintained with an inhalational anesthesia with sevoflurane 2%-4%
48122792|NCT05209581|DIAGNOSTIC_TEST|Distance Visual Acuity Examination|Best spectacle-corrected distance visual acuity of refugees/immigrants will be examined via a web-based digital visual acuity chart
48122793|NCT01448512|BEHAVIORAL|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
48122794|NCT01448512|OTHER|Usual Care|4 time matched sessions focused on health education
48122795|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
48122796|NCT01842945|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
47973405|NCT04147130|OTHER|MultiPAP Plus|Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.
48122797|NCT02320877|DEVICE|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
48122798|NCT01407393|DEVICE|Glucosanol|2 tablets 3x daily for 12 weeks
48122799|NCT01407393|DEVICE|Placebo|2 tablets 3x daily for 12 weeks
47973406|NCT04147130|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
48122800|NCT03315481|PROCEDURE|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
48122801|NCT03315481|PROCEDURE|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
48122802|NCT04244500|PROCEDURE|swab sampling|Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections
48122803|NCT00440011|DRUG|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
48122804|NCT00440011|DRUG|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
48122805|NCT04943419|DIAGNOSTIC_TEST|Level of Myeloid-Derived Suppressor Cells|Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
48122806|NCT02639091|DRUG|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
48122807|NCT02639091|DRUG|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
48122808|NCT02639091|DRUG|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
48328408|NCT01793519|DRUG|Infliximab|Infusion
48328409|NCT01793519|DRUG|Adalimumab|Subcutaneous
48328410|NCT01793519|DRUG|Placebo|Matching Placebo
48328411|NCT00980785|DRUG|Ramipril|Ramipril 5 mg/day
48328412|NCT00980785|DRUG|Placebo|Matching Placebo
48328413|NCT01078519|DRUG|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
48328414|NCT02060318|DRUG|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
48328415|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
48328416|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
48122809|NCT03632616|OTHER|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, 6 and 12 months post-intervention.
48122810|NCT05075941|OTHER|Vaccination coverage|proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
48122811|NCT05357469|DEVICE|Immediate St (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
48122812|NCT05357469|DEVICE|Waitlist ST (Scrambler Therapy)|Participant will receive Scrambler Therapy one (1) time a day, Monday through Friday, for up to 2 weeks (a total of 10 ST treatments).
48122813|NCT02768545|DRUG|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
48122814|NCT04083664|DIAGNOSTIC_TEST|NGAL and Hepcidin|Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
48122815|NCT06222918|PROCEDURE|Deep Margin Elevation (G-ænial Universal Injectable)|Deep margin elevation (DME), or coronal margin relocation (CMR), is a procedure used to raise or reposition sub-gingival margins into supra-gingival margins using several materials to increase marginal integrity and bonding strength
48328417|NCT00730626|DIETARY_SUPPLEMENT|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
48328418|NCT06196918|DRUG|Rivaroxaban 10 MG|Patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.
48328419|NCT06196918|DRUG|Placebo|Patients with postoperative lower extremity dyskinesia are treated with placebo (10 mg/day) and compression stockings until 1 month after surgery.
48328420|NCT00922350|OTHER|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
48328421|NCT00922350|OTHER|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
48328422|NCT00922350|OTHER|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
48122816|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
48122817|NCT00809939|DRUG|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
48122818|NCT00809939|DRUG|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
48122819|NCT00809939|DRUG|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
48328423|NCT00922350|OTHER|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
48328424|NCT02574858|DRUG|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
48328425|NCT02758613|DRUG|Baricitinib|Administered orally.
48328426|NCT02758613|DRUG|Placebo|Administered orally.
48122820|NCT02023710|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
48122821|NCT02023710|DRUG|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
48328427|NCT02679495|BEHAVIORAL|Active measures of lifestyle modification|
48122822|NCT02023710|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
48122823|NCT05264844|OTHER|Masking tape|IV catheters will be fixed with masking tape
48122824|NCT04336059|PROCEDURE|pericapsular nerve group block|"The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane."
48122825|NCT02466516|DRUG|SEL|SEL tablet administered orally once daily
48122826|NCT02466516|BIOLOGICAL|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
48122827|NCT05554185|DIETARY_SUPPLEMENT|aspirin 100mg and probiotics 1 bag|taking aspirin 100mg and probiotics 1 bag per day from 14-16 weeks of pregnancy until 35 + 6 weeks of pregnancy or emergency delivery.
48122828|NCT04127669|DRUG|OSU 6162|The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is \> 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
48122829|NCT04127669|DRUG|Placebo oral tablet|Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
48122830|NCT03015896|OTHER|Laboratory Biomarker Analysis|Correlative studies
48122831|NCT03015896|DRUG|Lenalidomide|Given PO
48122832|NCT03015896|BIOLOGICAL|Nivolumab|Given IV
48328428|NCT01929265|DRUG|Bendamustine|"INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1\*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~\*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28"
48328429|NCT02394808|DEVICE|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
48328430|NCT02394808|DEVICE|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
48328431|NCT05941169|PROCEDURE|Cytoreductive Nephrectomy|The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
48328432|NCT01668030|DRUG|Enzymatic agent|Enzymatic agent
47973407|NCT03928600|COMBINATION_PRODUCT|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
47973408|NCT03928600|DRUG|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
47973409|NCT03928600|DRUG|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
48122833|NCT03311893|PROCEDURE|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
48122834|NCT02441881|DEVICE|Venefit|Endovenous radiofrequency device
48122835|NCT02441881|DEVICE|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
48122836|NCT02441881|DEVICE|Endovenous Radiofrequency|Endovenous radiofrequency device
48122837|NCT00014794|DRUG|15-O labeled water|
48122838|NCT00462358|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
48122839|NCT00462358|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
48122840|NCT02344641|DRUG|Exenatide|
48328433|NCT01668030|DRUG|Bacitracin|
48328434|NCT01463020|BEHAVIORAL|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
48328435|NCT01463020|OTHER|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
48328436|NCT00653913|DRUG|SCH 58235|SCH 58235 10 mg (once daily)
47973410|NCT04106960|OTHER|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
47973411|NCT02950532|OTHER|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
48122841|NCT03570437|DRUG|Paclitaxel|80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
48122842|NCT03570437|DRUG|Cediranib|20 mg per day
48122843|NCT03570437|DRUG|Olaparib|Olaparib tablets, 300 mg twice-daily
48122844|NCT03101930|DRUG|Liraglutide|subcutaneous liraglutide daily
48328437|NCT00653913|DRUG|pitavastatin|Pitavastatin 2 mg (once daily)
48650631|NCT06673537|OTHER|Sham Spinal Manipulation|Sham spinal manipulation was administered by an experienced physiotherapist to the Sham Manipulation group three times a week following Connective Tissue Massage (CTM). In this group, participants were positioned laterally with their lower legs straight and in contact with the treatment table. The contralateral or upper hip and knee were flexed and positioned so that they did not touch the table, thereby allowing an unopposed force to be applied at the selected joint. Following CTM, low-amplitude force was applied bilaterally to all clinically relevant vertebral levels from T10 to L5 and the sacroiliac joints, without creating an audible sound.
48490970|NCT05250674|DEVICE|CEM-guided biopsy|"The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation."
47973412|NCT05015608|DRUG|Savolitinib + Osimertinib|Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
48122845|NCT03101930|DRUG|Sitagliptin|oral sitagliptin daily
48122846|NCT03101930|OTHER|hypocaloric diet|Reduced calorie intake to achieve weight loss.
48328438|NCT05205278|OTHER|exercise training|The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
48490971|NCT06074484|DRUG|RC48-ADC|4 preoperative cycles of RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 6 cycles of postoperative RC48-ADC（2.0 mg/kg，intravenous (IV) infusion，Q3W）
48490972|NCT06074484|DRUG|AK104|4 preoperative cycles of AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，intravenous (IV) infusion，Q3W）
47973413|NCT05015608|DRUG|Pemetrexed + Cisplatin /Carboplatin|Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
47973414|NCT04832360|BEHAVIORAL|Financial Incentives|Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
47973415|NCT00112320|PROCEDURE|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
47973416|NCT00112320|PROCEDURE|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
47973417|NCT00359060|BEHAVIORAL|Physical activity|
48122847|NCT03101930|DRUG|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
48122848|NCT03101930|DRUG|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
48328439|NCT00036543|DRUG|Atrasentan|
48490973|NCT06092385|OTHER|Data collection|"Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)"
48490974|NCT04988152|BIOLOGICAL|sotrovimab|sotrovimab IV infusion, single dose
48490975|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
48490976|NCT04988152|BIOLOGICAL|sotrovimab|Sotrovimab IM injection, single dose
47973418|NCT00059982|DRUG|perifosine|
47973419|NCT06146452|OTHER|Not|Not
47973420|NCT05109156|OTHER|This is an observational study|This is an observational study
47973421|NCT01220375|DRUG|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
48122849|NCT04447209|OTHER|Dietary counselling on Food Groups according to IYC Feeding practices, WHO|Monitoring of Dietary diversity and growth
48122850|NCT00211419|DRUG|Anecortave Acetate 15 mg|
48122851|NCT00211419|DRUG|Triamcinolone Acetate 4 mg|
48122852|NCT00211419|PROCEDURE|Photodynamic Therapy with Verteporfin|
48122853|NCT00211419|PROCEDURE|Thermal Laser|
48122854|NCT05296213|DRUG|Silver diamine fluoride- potassium iodide|SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
48122855|NCT05296213|DRUG|Casein phosphopeptide amorphous calcium phosphate|CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
48122856|NCT05296213|DRUG|experimental tricalcium silicate|prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
48122857|NCT03964870|DIAGNOSTIC_TEST|Diagnostic of polymorphisms in malignant hyperthermia|Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.
48122858|NCT01316731|OTHER|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
48122859|NCT02035670|OTHER|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC\& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
48122860|NCT04580316|BEHAVIORAL|Parental active presence|The parents were allowed to stand close to their children, do handholding, eye contacting and help in explaining the dentist's instructions.
48490977|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
48490978|NCT04472247|DIAGNOSTIC_TEST|Continuous EEG and EMG monitoring, with derived variables|All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
48122861|NCT04580316|BEHAVIORAL|Parent passive presence|Parents were instructed to sit silently in the dental clinic behind the patient with no eye contact, and without a spoken word only to reassure their children
48650632|NCT01909245|BIOLOGICAL|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
47973422|NCT01220375|DRUG|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
47973423|NCT01220375|DRUG|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
48122862|NCT06408818|BEHAVIORAL|Media Aware Parent - Tween|Media Aware Parent - Tween, is an online program for parents of tweens ages 9-12 designed to help parents have effective conversations with their child about body image, sexual development, gender stereotypes, romantic relationships, and media.
48490979|NCT03660358|DEVICE|kinesiotape application|kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
48122863|NCT06408818|BEHAVIORAL|Active Control Resource|Parents will have access to medically-accurate information about topics such as body image, sexual development, gender stereotypes, and romantic relationships.
48122864|NCT02117752|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
48122865|NCT02117752|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
48122866|NCT02117752|DRUG|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
48122867|NCT02117752|DRUG|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
48122868|NCT03476811|DRUG|0.25% Marcaine at 2ml/hr and pain medications|Subcutaneous pain control with OnQ Subcutaneous Drug pump
48122869|NCT03476811|DEVICE|Placement of OnQ Drug pump|Subcutaneous placement of OnQ drug pump with normal saline infusion
48122870|NCT06278870|DRUG|disitamab vedotin|disitamab vedotin 2mg/kg iv q2w
48122871|NCT06278870|DRUG|Pyrotinib|pyrotinib 400mg po q28d
48122872|NCT06278870|DRUG|trastuzumab|trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
48122873|NCT06278870|DRUG|Pertuzumab|pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
48328440|NCT04035629|COMBINATION_PRODUCT|MagniXene, hyperpolarized 129Xe MRI|"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."
48490980|NCT04327856|PROCEDURE|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
48490981|NCT05005871|OTHER|Quadratus lumborum block after C-section surgery as postoperative pain management|To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
48490982|NCT01111019|DRUG|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
48650633|NCT01909245|DRUG|Immunosuppressive Agents|Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
48650634|NCT01909245|DRUG|Gastrin 17|Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
47973424|NCT01220375|DRUG|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
48122874|NCT06278870|DRUG|taxane drug|Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
48122875|NCT05738707|BIOLOGICAL|Recombinant protein vaccine and adenovirus vector vaccine|Administer recombinant protein vaccine and adenovirus vector vaccine
48122876|NCT02067949|DRUG|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
48122877|NCT03989024|DRUG|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
48328441|NCT04152148|BIOLOGICAL|500mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
48328442|NCT04152148|BIOLOGICAL|750mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
48328443|NCT04152148|BIOLOGICAL|900mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
48328444|NCT04152148|BIOLOGICAL|1000mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
48328445|NCT00818207|OTHER|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
48122878|NCT03989024|DRUG|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
48328446|NCT00818207|OTHER|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
48490983|NCT01484184|DRUG|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
48122879|NCT06412770|BEHAVIORAL|Tai chi|Participants will be asked to do Tai Chi for 30 minutes three times a week
48122880|NCT06412770|BEHAVIORAL|Tai Chi imagery|Participants will be asked to do Tai Chi imagery for 30 minutes three times a week
48328447|NCT04545099|DRUG|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
48328448|NCT04545099|DRUG|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
48328449|NCT03617029|DEVICE|Microcoil|Needle localization with microcoil
48328450|NCT03617029|DRUG|Lipiodol|Needle localization with contrast injection
48328451|NCT05589480|OTHER|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
48328452|NCT03894098|PROCEDURE|Nerve block|High ankle nerve block
48122881|NCT06412770|OTHER|no-intervention|The comparison group will be given usual care
48122882|NCT01996605|DRUG|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
48122883|NCT01996605|DRUG|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
48122884|NCT01996605|DRUG|Placebo|placebo will be administered spinally
48122885|NCT00780949|OTHER|intestinal biopsies|intestinal biopsies during routine endoscopy
48328453|NCT04424199|BEHAVIORAL|Rightward Attentional Shift (R-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.
48490984|NCT06024083|BEHAVIORAL|Dialectical Behavior Therapy skills video intervention|A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
48122886|NCT00963625|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
48122887|NCT00963625|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
48122888|NCT01437605|DRUG|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
48122889|NCT01437605|DRUG|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
48122890|NCT03240978|BEHAVIORAL|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
48328454|NCT04424199|BEHAVIORAL|Leftward Attentional Shift (L-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.
48328455|NCT03461432|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
48328456|NCT04973891|DRUG|Canagliflozin combined with metformin|"Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS."
48328457|NCT04973891|DRUG|metformin|Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
48328458|NCT03342937|DRUG|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
48328459|NCT06447571|OTHER|Trunk Rehabilitation|Activating and strengthening the trunk muscles.
48328460|NCT06447571|OTHER|Core Stability|Standard core stability fucus on lower trunk.
48328461|NCT01176370|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
48122891|NCT00180258|DEVICE|Cardiac Resynchronization Therapy with & without defibrillator|
48328462|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
48490985|NCT01048216|RADIATION|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
48490986|NCT05697055|DRUG|Azvudine|5mg orally, once a day, for no more than 14 days
48490987|NCT05697055|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
48490988|NCT04601038|DRUG|CORT108297|120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks
48490989|NCT04601038|DRUG|Placebo|Placebo taken as 2 tablets daily for 2 weeks
48490990|NCT05824741|BEHAVIORAL|Infant Cardiovascular Health (CVH) Promotion|The pilot infant CVH intervention will be delivered by Nurse-Family Partnership (NFP) staff starting no later than 1 month postpartum and lasting up to 6 months postpartum. The visit schedule will be consistent with the NFP visit structure to deliver intervention content at regularly scheduled visits that are typically 60 minutes long. This pilot study will include an enhanced version of the NFP standard care plan delivered by trained nurses to promote cardiovascular health by targeting soothing, feeding, sleep, and physical activity behaviors during infancy. The intervention delivered by trained visiting nurses will include behavior change strategies (e.g., goal setting, problem solving barriers). This pilot study will also examine the feasibility and acceptability of a digital device (infant foot worn actigraphy) during this same time period.
48490991|NCT01690221|DRUG|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
48490992|NCT01690221|DRUG|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
48490993|NCT02902718|DEVICE|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
48490994|NCT04309214|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
48490995|NCT00855803|RADIATION|radiation|Given in 1 or 5 fractions
48122892|NCT02055742|DEVICE|illumigene CT and NG assays, illumipro-10|
48122893|NCT05372146|PROCEDURE|GSV radiofrequency ablation with concomitant phlebectomy|Radiofrequency ablation with concomitant phlebectomy
48122894|NCT04277221|BIOLOGICAL|Autologous Dendritic Cell/Tumor Antigen, ADCTA|ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
48122895|NCT04126707|DRUG|[14C] HQP1351|Orally, single dose of 30mg
48328463|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
48490996|NCT02267668|BEHAVIORAL|STEP|Physical therapists guide participants through novel set of assigned exercises
48490997|NCT02267668|BEHAVIORAL|Control|Participants self-guide through standard exercises
48490998|NCT03325972|DRUG|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
48490999|NCT03325972|OTHER|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
48328464|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
48328465|NCT02128984|DIETARY_SUPPLEMENT|Symbiotic Formula with DHA and antioxidants|6 months intervention.
48491000|NCT02714933|OTHER|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
48491001|NCT00014625|DRUG|indisulam|
48328466|NCT02128984|DIETARY_SUPPLEMENT|Standard Formula|6 months intervention.
47973425|NCT02152033|BEHAVIORAL|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
48122896|NCT06520332|PROCEDURE|Dental Implant Surgery - short implant group (less than or equal to 6mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A short dental implant (experimental group) will be placed according to the standard protocol.~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
48491002|NCT02214784|DEVICE|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
48491003|NCT02214784|DEVICE|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
48491004|NCT00055614|DRUG|topotecan hydrochloride|
48491005|NCT00055614|PROCEDURE|adjuvant therapy|
48491006|NCT03405558|OTHER|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
48491007|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
48491008|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
48491009|NCT06020001|OTHER|Placebo|Twice a day
48491010|NCT03347552|BEHAVIORAL|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
48491011|NCT02724865|DEVICE|Somnodent® (Oral appliance therapy)|
48491012|NCT02724865|DEVICE|Herbst® (Oral appliance therapy)|
48328467|NCT01975077|DRUG|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
48328468|NCT02986919|DRUG|CPI-0610|"* Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~* CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
48328469|NCT04673604|DIAGNOSTIC_TEST|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
48491013|NCT02169349|OTHER|laboratory biomarker analysis|
48491014|NCT02169349|OTHER|Next Generation Sequencing|
48491015|NCT02169349|GENETIC|DNA Analysis|
48491016|NCT01302522|BEHAVIORAL|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
48491017|NCT05855486|DEVICE|Saline eye drops|Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
48491018|NCT00750308|DRUG|Ramipril|Ramipril 10 mg per day for three weeks
48491019|NCT00750308|DRUG|Tadalafil|tadalafil 10 mg every other day for three weeks
48491020|NCT00750308|DRUG|placebo|placebo matching ramipril
48491021|NCT00750308|DRUG|placebo|placebo matching tadalafil
48491022|NCT02030483|DRUG|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
48491023|NCT02030483|DRUG|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
48491024|NCT02030483|DRUG|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
48491025|NCT00015028|DRUG|Buprenorphine/naloxone|
48491026|NCT05120323|BEHAVIORAL|vDOT Intervention Group|The vDOT intervention group will submit video clips of doses of inhaled controller asthma medication via the Emocha® smartphone application with each prescribed dose of inhaled controller medication. Each video will include a date and time stamp of the medication dose. Participant videos will be evaluated by trained personnel using an inhaler technique checklist to score each dose and create a report detailing the steps that were taken to complete the medication dose.
48491027|NCT04097171|OTHER|Diet|Participants will consume each diet for 14 days in a crossover design.
48491028|NCT04765527|DIETARY_SUPPLEMENT|Turmeric Strength for Joint|Turmeric-based tablets
48491029|NCT04765527|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
48491030|NCT00408564|BIOLOGICAL|cetuximab|
48122897|NCT06520332|PROCEDURE|Dental Implant Surgery - Conventional implant group (greater than or equal to 10mm)|"A mucoperiosteal flap will be raised in edentulous ridge. A standard length implant ( comparative group) ( ≥10mm) will be placed according to the standard protocol in the augmented/native bone .~The platform of the implant will be placed 2 to 3 mm below CEJ of adjacent teeth.~The surgical wound closure will be coapted with mattress and single interrupted sutures"
48328470|NCT04673604|DRUG|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
48328471|NCT06106243|PROCEDURE|The conventional heat pressing temporary flexible maxillary removable partial denture|An intraoral scan will be made for each patient's maxillary and mandibular jaws in addition to digital bite registration using (Medit i700; Medit corp.) the resultant data will be exported in the form of a Standard Tessellation Language (STL) file. The denture base and the teeth will be designed using computer-aided design software (Partial Cad, Dental CAD software). Each patient will receive two RDPs, fabricated with two different manufacturing techniques. Based on randomization, the patients will start by receiving either partial denture that is fabricated by conventional heat pressing technique of 3D printed castable resin (Cast V1resin) followed by partial denture that is fabricated by 3D printing of printable resin (Flexo denture base, resin) and teeth (permanent crown,resin) or the other way around. In 3D-printed RDP, the artificial teeth will be attached to the fabricated denture bases using printable denture base resin material
48328472|NCT06106243|PROCEDURE|3D-printed and digitally designed temporary flexible maxillary removable partial denture|3D-printed and digitally designed temporary flexible maxillary removable partial denture
48328473|NCT01079286|DRUG|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
48328474|NCT05370742|PROCEDURE|Latarjet surgery|Results of using a screw-only plate for fixation of the corocoid bone in recurrent shoulder dislocations
48328475|NCT04374812|OTHER|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
48328476|NCT04374812|OTHER|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
48328477|NCT06197737|OTHER|Moderate Intensity Interval Training|Participants in this group will perform moderate intensity interval training in which they will perform stair climbing 3 times a week and for every 1 interval I will ask them to take rest for 3 minutes.
48328478|NCT06197737|OTHER|Sprint Interval Training|sprint interval training in which they will do stair climbing 3 times a week with a fast pace.
48328479|NCT06197737|OTHER|pharmacological treatment|They will be on pharmacological treatment as prescribed by their pulmonologist.
48328480|NCT02384395|DRUG|Dolutegravir 50 mg|Initial therapy for AHI
48328481|NCT02384395|DRUG|Lamivudine 300 mg|Initial therapy for AHI
48328482|NCT02384395|DRUG|Abacavir 600 mg|Initial therapy for AHI
48328483|NCT04087603|BEHAVIORAL|Weekend Morning Bright Light & Early Bedtime|
48122898|NCT05239013|DRUG|Nitroglycerin ointment|2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
48328484|NCT02253641|BEHAVIORAL|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
48328485|NCT02253641|BEHAVIORAL|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
48328486|NCT04781569|OTHER|data collection|Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.
47973426|NCT02152033|BEHAVIORAL|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
47973427|NCT03667261|DEVICE|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
47973428|NCT03667261|DEVICE|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
48122899|NCT05897632|BEHAVIORAL|Outpatient Evaluation|Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
48328487|NCT04781569|DIAGNOSTIC_TEST|blood draw|2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.
48328488|NCT04781569|DIAGNOSTIC_TEST|nose swabs|2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.
48328489|NCT04781569|DIAGNOSTIC_TEST|Intraoperative tissue samples|Intraoperative tissue samples from the site of infection during surgery will be taken in the patient.
48328490|NCT00920478|OTHER|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
48328491|NCT00920478|OTHER|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
48328492|NCT03674658|DRUG|Propafenone|oral, TID
48328493|NCT01207388|DRUG|Blinatumomab|Continuous intravenous infusion
48328494|NCT06195293|BIOLOGICAL|Neoantigen Polypeptide Vaccine|Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
48328495|NCT01022346|DRUG|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
48328496|NCT01022346|DRUG|RO5217790|RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
48328497|NCT02600000|RADIATION|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
48328498|NCT02600000|DEVICE|Cardiopulmonary test|Assessment of maximal functional capacity
48122900|NCT05897632|BEHAVIORAL|Hospitalization Evaluation|Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding.
48122901|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part One|Anti-human CCL24 monoclonal antibody (CM-101) - Part One
48328499|NCT02600000|DEVICE|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
48328500|NCT02600000|DEVICE|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
48328501|NCT02013128|DRUG|Ublituximab|Ublituximab (IV infusion)
48328502|NCT02013128|DRUG|Ibrutinib|Ibrutinib oral daily dose
48328503|NCT01530555|DRUG|Rabbit ATG, Thymoglobuline (Genzyme)|"1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
48328504|NCT04849819|DRUG|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
48328505|NCT04663984|BEHAVIORAL|publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation
48328506|NCT02751021|OTHER|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
48328507|NCT02751021|OTHER|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
48122902|NCT06044467|DRUG|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two|Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
48122903|NCT06044467|DRUG|Placebo - Study Part One|Placebo Comparator
48122904|NCT06044467|DRUG|Placebo - Study Part Two|Placebo Comparator
48122905|NCT03125863|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
48122906|NCT05073159|BIOLOGICAL|Allocating head-of-bed position|Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
48122907|NCT05893459|BEHAVIORAL|Debrief|Post-Stressor Discussion with a Friend
48122908|NCT01303445|DRUG|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
48122909|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
48122910|NCT01303445|DRUG|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
48122911|NCT01303445|DRUG|Omeprazole alone|omeprazole 80 once daily for 7 days
48122912|NCT01000597|DRUG|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
48122913|NCT03976570|BEHAVIORAL|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
48328508|NCT04437030|DEVICE|MSOT Acuity Echo device|The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
47973429|NCT04891874|RADIATION|Stereotactic radiotherapy|Radiation using stereotactic radiotherapy device.
47973430|NCT03566316|DRUG|Telmisartan/Amlodipine|
47973431|NCT03566316|DRUG|Rosuvastatin|
48122914|NCT02668250|PROCEDURE|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
47973432|NCT03566316|DRUG|Telmisartan|
47973433|NCT02346630|DRUG|Placebo|Placebo capsules daily for 3 weeks.
47973434|NCT02346630|DRUG|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
48122915|NCT02668250|PROCEDURE|Usual Care|Patients receive the usual care.
48122916|NCT00110864|DRUG|PN2034|
48122917|NCT00110864|DRUG|Insulin|
48122918|NCT03201861|DRUG|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
48328509|NCT05454397|OTHER|Observational study, no intervention|Observational study, no intervention
48328510|NCT03027141|BEHAVIORAL|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
48328511|NCT03229681|BEHAVIORAL|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
48491031|NCT00408564|DRUG|capecitabine|
48491032|NCT00408564|DRUG|oxaliplatin|
48491033|NCT00408564|PROCEDURE|conventional surgery|
48491034|NCT00408564|RADIATION|radiation therapy|
48491035|NCT00408564|DRUG|Gemcitabine|
48491036|NCT00667082|DRUG|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
48491037|NCT02639052|DRUG|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
48491038|NCT02639052|DRUG|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
48491039|NCT01934738|DRUG|PF-06273340|Tablets, 100 mg TID, 14 days
48491040|NCT01934738|DRUG|Placebo|Tablets, TID, 14 days
48491041|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
48491042|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
48491043|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
48491044|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
48491045|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
48491046|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
48491047|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
48491048|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
48491049|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
48491050|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
48491051|NCT05356143|DRUG|Rupatadine|Oral single dose 10 mg tablet
48491052|NCT01258166|PROCEDURE|Surgery or immobilization|
48650635|NCT05627492|BEHAVIORAL|Dialectical behavioral therapy|DBT will be conducted over 2 years. Participants and their treatment providers will decide on the frequency of sessions collaboratively. This may include individual and/or skills sessions in addition to phone coaching for those who attend individual sessions at least once per month. DBT consultation will also remain a component of the treatment. Participants may choose skills training, conducted in approximately 60 minute meetings, and individual therapy conducted in approximately 60 minute sessions. Family participation in skills training is highly encouraged. Skills training may include: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets.
47973435|NCT02346630|DEVICE|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
47973436|NCT00000443|DRUG|ondansetron (Zofran)|
48328512|NCT03229681|BEHAVIORAL|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
48328513|NCT00877604|DRUG|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
48328514|NCT00877604|DRUG|Placebo|identical placebo by oral route at the same dosing schedule
48491053|NCT01081314|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
48491054|NCT01081314|BEHAVIORAL|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
48491055|NCT05841446|DRUG|test apixaban tablets|specification: 2.5 mg, manufacturer: Disha Pharmaceutical Group Co., Ltd., Shandong, China
47973437|NCT01084369|DRUG|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
47973438|NCT02906618|DRUG|LY3039478|Administered orally
47973439|NCT02906618|DRUG|3C 15N 2H-LY3039478 IV|Administered IV
48328515|NCT01220505|PROCEDURE|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
48328516|NCT04699214|DRUG|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
48328517|NCT04699214|DRUG|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
48491056|NCT05841446|DRUG|reference apixaban tablets|specification: 2.5 mg, manufacturer: Bristol-Myers Squibb Manufacturing Company, USA
48491057|NCT01769339|DRUG|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
48491058|NCT00974961|DRUG|bupivacaine, levobupivacaine|intrathecal injection 15\~20mg(for Levobupivacaine) or 10\~15mg(for Bupivacaine) once
48491059|NCT06091852|DIETARY_SUPPLEMENT|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
48491060|NCT03714360|DRUG|Tranexamic Acid|patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
48491061|NCT03714360|DRUG|Sodium Chloride 0,9%|Sodium Chloride 0,9%
48491062|NCT01094249|DRUG|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
48491063|NCT01286389|OTHER|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
48491064|NCT01286389|BEHAVIORAL|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
47973440|NCT02487602|DEVICE|Gelesis100|Gelesis100 capsules
47973441|NCT02487602|OTHER|Placebo|Sucrose (sugar) capsules
48328518|NCT04162535|DRUG|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
48328519|NCT04162535|BIOLOGICAL|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
48328520|NCT04162535|DRUG|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
48328521|NCT04162535|DRUG|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
48328522|NCT00270998|BEHAVIORAL|Behavioral Therapy|Pelvic muscle training and exercises
48650636|NCT06564688|DIAGNOSTIC_TEST|Swallowing function test|"The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants."
48328523|NCT00270998|DEVICE|Intravaginal Pessary|Intravaginal pessary
48328524|NCT00270998|DEVICE|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
48328525|NCT01454479|DRUG|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
48328526|NCT05491655|DEVICE|High Intensity His Bundle pacing|All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
48491065|NCT03356028|BEHAVIORAL|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
48650637|NCT05198661|BIOLOGICAL|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
47973442|NCT04656691|DRUG|bamlanivimab|Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
48328527|NCT00956215|DRUG|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
48328528|NCT00956215|DRUG|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
48328529|NCT04320277|DRUG|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
48328530|NCT06393894|DIAGNOSTIC_TEST|Near infrared spectroscopy|Near infrared spectroscopy (NIRS) is an intravascular imaging technique. Patients after coronary angiography with or without angioplasty will undergo NIRS if deemed suitable by the interventionalist. NIRS has a high sensitivity and specificity for lipid core plaque detection.
48328531|NCT06393894|GENETIC|Genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.|Patients without explicit atherosclerosis risk factors and known genetic disorders will undergo genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 genes in order to evaluate the presence of gene variations as a cause for early atherosclerosis. MiRNA-126, -145 and -155 expression in patients serum samples will be evaluated and correlated with plaque lipid core in near infrared spectroscopy (NIRS) imaging.
47973443|NCT00148018|DRUG|Bortezomib|
47973444|NCT00148018|DRUG|Dexamethasone|
48328532|NCT06436625|OTHER|outpatient pulmonary rehabilitation|Patients undergo six weeks of an outpatient rehabilitation program in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
48328533|NCT01745601|DRUG|escitalopram 10 mg|Reference product
48328534|NCT01745601|DRUG|escitalopram 10 mg|Test product
48328535|NCT03350867|OTHER|Personalized Insole Group|Personalized Insole Group
48491066|NCT03356028|OTHER|salivary biological collection|Saliva sampling will be done using a specific kit
48491067|NCT03356028|BEHAVIORAL|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
48491068|NCT03356028|BEHAVIORAL|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
48491069|NCT03356028|BEHAVIORAL|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
48491070|NCT03356028|BEHAVIORAL|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
48491071|NCT03356028|BEHAVIORAL|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
48491072|NCT06383871|DRUG|HRS-7058 capsule/ HRS-7058 tablet|HRS-7058 capsule/ HRS-7058 tablet
47973445|NCT02557620|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
47973446|NCT02557620|DRUG|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
48491073|NCT00333879|DEVICE|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
48491074|NCT03003949|DRUG|Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release|Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
48491075|NCT03003949|DRUG|Placebo Patch|Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
48122919|NCT03201861|DRUG|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
47973447|NCT01213745|OTHER|Intervention|
47973448|NCT01213745|OTHER|Attention|
47973449|NCT01213745|OTHER|Control|
48122920|NCT04626011|PROCEDURE|Tooth extractions|After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
48328536|NCT03350867|OTHER|Placebo Group|Placebo Group
48328537|NCT02307539|PROCEDURE|Psychosocial Assessment and Care|Undergo PCPI
48491076|NCT03003949|DRUG|Progesterone Capsule|Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week
48491077|NCT03003949|DRUG|Placebo Oral Capsule|Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
48122921|NCT01837966|OTHER|Lavender oil|2 drops for aromatherapy
47973450|NCT06261385|BEHAVIORAL|typology-based intervention|A typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit
47973451|NCT01516554|DRUG|Testosterone undecanoate|40 mg twice daily
48328538|NCT02307539|OTHER|Palliative Therapy|Undergo PCPI
48328539|NCT02307539|OTHER|Quality-of-Life Assessment|Undergo QOL assessment
48328540|NCT02307539|OTHER|Questionnaire Administration|Undergo questionnaire administration
48328541|NCT03687086|OTHER|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
48328542|NCT03687086|OTHER|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
48328543|NCT03304327|BEHAVIORAL|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
48328544|NCT01113996|BEHAVIORAL|Protein supplementation and strength training|Protein supplementation and strength training
48328545|NCT01113996|DIETARY_SUPPLEMENT|Protein supplementation|Protein supplementation
48328546|NCT02625987|PROCEDURE|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
48491078|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology Pro|"The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population."
48491079|NCT04796779|DEVICE|Standard Care (SC)|Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
47973452|NCT01516554|DRUG|placebo|twice daily
47973453|NCT00825591|DIETARY_SUPPLEMENT|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
47973454|NCT00825591|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration before bed. 6 week duration.
47973455|NCT01605877|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
47973456|NCT06284174|DRUG|Povidone-iodine solution; chlorhexidine gluconate|Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
47973457|NCT05349175|DEVICE|Augmented Infant Resuscitator (AIR)|Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation
47973458|NCT03553667|DEVICE|Standard group|Use radial arterial line to monitor mean arterial pressure
47973459|NCT03553667|DEVICE|ClearSight|Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
48122922|NCT01837966|OTHER|Placebo|2 drops unscented mineral oil for aromatherapy
48122923|NCT06516250|OTHER|Virtual serious game GEMAS|Implement and evaluate a virtual serious game designed to improve the learning and retention of clinical knowledge in medicine and nursing students and residents through the simulation of clinical cases in a hospital emergency environment.
48122924|NCT03039803|PROCEDURE|uterine closure during cesarean section|
47973460|NCT03086889|OTHER|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
47973461|NCT03086889|OTHER|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
47973462|NCT02241174|DRUG|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
48328547|NCT02625987|PROCEDURE|Separated stitches|Appendectomy wound closure with a separated stitches.
48328548|NCT00904995|DRUG|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
48328549|NCT00904995|DRUG|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
48328550|NCT03803202|BIOLOGICAL|ASP3772|Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
48328551|NCT03803202|BIOLOGICAL|PCV13|Participants received a single dose of PCV13 intramuscularly.
48328552|NCT03803202|BIOLOGICAL|PPSV23|Participants received a single dose of PPSV23 intramuscularly.
48328553|NCT00960258|DRUG|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
48491080|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology V1.5|"The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features."
48491081|NCT03757273|PROCEDURE|FFF with CAD/CAM customized cutting guide|This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
48491082|NCT03757273|PROCEDURE|FFF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction."
48491083|NCT02337140|DEVICE|Pacemaker SORIN Group KORA DR|
48491084|NCT02337140|PROCEDURE|transcatheter aortic valve implantation (TAVI)|
48491085|NCT02524717|DRUG|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
48491086|NCT06069778|DRUG|BNT321 Dose Level 1|Intravenous infusion
48491087|NCT06069778|DRUG|BNT321 Dose Level 2|Intravenous infusion
48491088|NCT06069778|DRUG|mFOLFIRINOX|Intravenous infusion
48328554|NCT01244958|BIOLOGICAL|Rituximab|1000 mg Rituximab infusion
48328555|NCT01244958|DRUG|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
48328556|NCT02226978|DRUG|Tipranavir|
48328557|NCT02226978|DRUG|Ritonavir|
48328558|NCT02226978|DRUG|Valaciclovir|
48328559|NCT00187889|DRUG|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
48328560|NCT00187889|DRUG|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
48491089|NCT06069778|DRUG|BNT321 RP2D|Intravenous infusion
48328561|NCT06504251|DIAGNOSTIC_TEST|Delirium Diagnostic Tool-Provisional ( DDT-Pro )|The Delirium Diagnostic Tool-Provisional (DDT-Pro) is another tool created to assist in the diagnosis of delirium. It does not require specialist expertise. It can assess the main symptoms of acute confusion, including cognitive ability (Cognition), higher-level thinking skills (Higher level thinking), and the sleep-wake cycle (Sleep-wake cycle).
48328562|NCT00821665|DIETARY_SUPPLEMENT|Sucrose consumption|Sucrose
48328563|NCT00821665|DIETARY_SUPPLEMENT|water consumption|water
48328564|NCT01280266|DRUG|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
48328565|NCT05780593|OTHER|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
48328566|NCT05780593|OTHER|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
48328567|NCT04110860|DRUG|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
48328568|NCT04110860|DRUG|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
48328569|NCT04110860|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
48122925|NCT03194958|BEHAVIORAL|Specialized Quitline|Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
48122926|NCT03194958|BEHAVIORAL|Basic Needs Navigator|Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
48122927|NCT01307267|DRUG|PF-05082566|Intravenous, Dose escalation, once per month
48122928|NCT01307267|DRUG|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
48122929|NCT01307267|DRUG|PF-05082566|IV, Dose escalation, once per month
48122930|NCT01853410|DEVICE|gekoTM|
48328570|NCT05870319|DRUG|SKB264|intravenous (IV) infusion (Q2W)
48328571|NCT05870319|DRUG|Pemetrexed|500 mg/m2 intravenous (IV) infusion (Q3W)
48328572|NCT05870319|DRUG|Carboplatin|AUC 5 intravenous (IV) infusion (Q3W) 4cycles
48328573|NCT05870319|DRUG|Cisplatin|75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles
48328574|NCT03812523|DRUG|Duloxetine 60 mg qd|60 mg tablet Taken by mouth, Once Daily for 180 Days
48122931|NCT04775992|OTHER|gabapentoids|Preemptive analgesia
48328575|NCT03812523|DRUG|Lorcaserin|10 mg tablet Taken by mouth Twice Daily for 180 Days
48328576|NCT06086756|BEHAVIORAL|Exposure intervention plus positive mood induction|Positive mood induction followed by a brief VR exposure session for public speaking anxiety.
48328577|NCT06086756|BEHAVIORAL|Exposure intervention plus negative mood induction|Negative mood induction followed by a brief VR exposure session for public speaking anxiety.
48491090|NCT05987462|OTHER|Green walking|The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
48491091|NCT03582761|BIOLOGICAL|EV71 vaccine|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
48491092|NCT01103622|DRUG|AZD1656|Oral tablet bd, step-wise increased dosage
48491093|NCT01103622|DRUG|Digoxin|Oral tablet od on Day 4
48491094|NCT01103622|DRUG|Placebo|Oral tablet bd, step-wise increased dosage
48491095|NCT00010608|BEHAVIORAL|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
48491096|NCT00010608|BEHAVIORAL|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
48491097|NCT05761873|OTHER|Provision of audit and feedback via email and paper|Provision of A\&F reports by paper via the post (new intervention being trialled) and email (standard practice) to allocated practices depending on randomisation status.
48491098|NCT05761873|OTHER|Provision of audit and feedback via paper only|Provision of A\&F reports by email (standard practice in the region) to allocated practices depending on randomisation status.
48491099|NCT03762486|OTHER|TENS|4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
48122932|NCT05368831|DRUG|NST-1024|Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
48122933|NCT01082289|DRUG|Lurasidone|
48122934|NCT05582044|OTHER|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
48122935|NCT05582044|OTHER|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
48328578|NCT05070416|DEVICE|Lithium disilicate crowns|The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).
48328579|NCT02146248|DRUG|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
48328580|NCT02146248|DRUG|DepoProvera|injectable hormonal contraceptive
48328581|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (real stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
48328582|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
48328583|NCT01203787|DRUG|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
48328584|NCT01203787|DRUG|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
48328585|NCT05655858|OTHER|Management of allergic rhinitis|Collection of patient data in real-life
48328586|NCT00254735|DRUG|quetiapine fumarate|
48328587|NCT00254735|DRUG|SSRI/Clomipramine|
48328588|NCT03492645|BEHAVIORAL|Telephone-and technology-facilitated treatment protocol|"1. 8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~2. Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~3. Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
48328589|NCT03492645|BEHAVIORAL|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
48328590|NCT06165380|DRUG|Cardenilimab Combined With Chemotherapy|Cardenilimab Combined With Chemotherapy
48328591|NCT02816437|BIOLOGICAL|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
48328592|NCT05602285|DEVICE|Dislodgement device|Breakaway device that prevents IV dislodgement
48122936|NCT05582044|OTHER|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
48328593|NCT03498547|PROCEDURE|caudal block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
48328594|NCT03498547|PROCEDURE|saddle block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
48328595|NCT05271903|BEHAVIORAL|MAMA Intervention|"The MAMA intervention will be based on PRONTO International's simulation training program to improve obstetric care delivery. The PRONTO curriculum is based on simulation and debrief of clinical scenarios, case-based learning, skills stations, and interactive teamwork and communication activities. Through the training, providers review and learn clinical skills related to obstetric care and emergencies, while reflecting on and practicing principles of respectful maternity care. The simulation exercises give providers and opportunity to act as the patient and develop empathy for the patient experience, and debriefing after simulation includes a reflection and discussion about RMC principles. The training will be two full days, followed by a refresher training in the clinical setting after one month."
48328596|NCT02828007|DEVICE|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
48328597|NCT04969341|OTHER|Survey Administration|Complete survey
48328598|NCT04969341|OTHER|Electronic Health Record Review|Review of medical records
48328599|NCT02378246|DIETARY_SUPPLEMENT|Iodine|
48328600|NCT02378246|DIETARY_SUPPLEMENT|Placebo|
48122937|NCT03837886|DIETARY_SUPPLEMENT|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
48122938|NCT03837886|DIETARY_SUPPLEMENT|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
48328601|NCT04345406|DRUG|ACEIs|Captopril or enalapril
48328602|NCT04345406|DRUG|Conventional treatment|alexoquine
48328603|NCT00003856|DRUG|temoporfin|
48328604|NCT01446679|DRUG|atrovastatin|oral
48328605|NCT00806689|PROCEDURE|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
48122939|NCT06258824|DIAGNOSTIC_TEST|Small RNA Sequencing and Validation of candidate miRNAs|Samples were prepared for small RNA sequencing using Qiagen's QIAseq small RNA Library Prep kit, quality controlled using an Agilent Bioanalyzer 2100 and sequenced on an NextSeq 500 system (Illumina, San Diego, USA) using the default single-end 75 base pair protocol to include integrated unique molecular indices (UMIs). Validation was undertaken using Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) either using target-specific stem-loop primer assays (TaqMan) or universal reverse transcription (RT) and locked nucleic acid (LNA) enhanced specific primers with SYBR green I assay detection
48122940|NCT02983669|DIETARY_SUPPLEMENT|Thyme|Thyme capsule 350 mg twice daily
48122941|NCT02983669|OTHER|Placebo|Placebo capsule 350 mg twice daily
48122942|NCT01781585|PROCEDURE|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
48122943|NCT05792280|DEVICE|AI system|Patients will undergo EUS examination with the assistance of AI system.
48122944|NCT02657733|DEVICE|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
48328606|NCT00806689|DEVICE|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
48328607|NCT00649441|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
48122945|NCT02657733|DEVICE|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
48122946|NCT02657733|DEVICE|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
48122947|NCT01247831|PROCEDURE|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
48122948|NCT01238146|DRUG|bendamustine hydrochloride|Given IV
48122949|NCT01238146|DRUG|obatoclax mesylate|Given IV
48122950|NCT01238146|BIOLOGICAL|rituximab|Given IV
48122951|NCT04445870|OTHER|data record|Data record on registers without medical files
48328608|NCT00649441|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
48328609|NCT04624217|DRUG|SHR-1701|PDL1/TGFβ
48328610|NCT05915936|PROCEDURE|LVMR|laoparoscopic ventral mesh rectopexy
48328611|NCT05915936|PROCEDURE|PSR|perineal stapler resection
48491100|NCT03762486|OTHER|TAES|4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
47973463|NCT01129960|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
47973464|NCT01129960|DRUG|Placebo|Tablets will be used.
47973465|NCT00851500|DRUG|K-604|K-604 is given for 26 weeks
47973466|NCT00851500|OTHER|Placebo|placebo tablets are given for 26 weeks
47973467|NCT02852538|BEHAVIORAL|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
48122952|NCT00779870|OTHER|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
48122953|NCT02932761|DRUG|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
48122954|NCT02932761|PROCEDURE|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
48328612|NCT05987189|DIAGNOSTIC_TEST|miLungDx|At study enrollment a blood sample will be drawn prior to any invasive diagnostic study or treatment. On this blood sample a novel lung cancer test relying on small RNA signatures will be performed and evaluated.
48328613|NCT05825599|DEVICE|Hydroxypropyl methylcellulose eye drops|Hydroxypropyl methylcellulose (HPMC)-based eyedrops
48328614|NCT03911778|OTHER|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
48328615|NCT01066884|DRUG|erlotinib [Tarceva]|150mg po daily
48328616|NCT04297826|BEHAVIORAL|Harvest for Health|Please see previous description
48328617|NCT02711904|DRUG|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h."
48491101|NCT05953766|DRUG|Ropivacaine injection|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml
48491102|NCT05953766|DRUG|Normal saline injection|Sham block using 20 mL of normal saline
48491103|NCT00102687|DRUG|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
48122955|NCT06518876|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
48122956|NCT02111889|OTHER|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|\[11C\] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and \[15O\]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
48122957|NCT02262468|RADIATION|x ray|
48122958|NCT00972075|DRUG|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
48122959|NCT00972075|DRUG|placebo|one tablet per day 2 hours before going to bed
48122960|NCT04665440|OTHER|Voice alone|mother's voice without tactile stimuli
48122961|NCT04665440|OTHER|Voice + tactile stimuli|mother's voice with tactile stimuli
48122962|NCT03769870|DRUG|Teneligliptin 20mg/day|cross-over
48122963|NCT03769870|DRUG|Atorvastatin 40mg/Day|cross-over
48122964|NCT03769870|DRUG|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
48122965|NCT01339234|OTHER|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
48122966|NCT00004387|PROCEDURE|fetal nigral transplantation|
48122967|NCT04156789|DIAGNOSTIC_TEST|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
48491104|NCT01524913|DRUG|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
47973468|NCT03020160|DRUG|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
47973469|NCT03908697|DEVICE|Mira monitor comparison to ClearBlue monitor|Testing first morning urine with hormone test sticks at home
47973470|NCT01989078|DRUG|Losartan|"Adults and Children \>50 kg:~* Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~* Those with SBP \<100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children \<50 kg weight:~* Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
48122968|NCT02703246|PROCEDURE|abdominal morcellation|patients will be randomized to receive abdominal morcellation
48122969|NCT02703246|PROCEDURE|vaginal morcellation|patients will be randomized to receive vaginal morcellation
48491105|NCT01524913|DRUG|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
48491106|NCT01524913|DRUG|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
48122970|NCT02001818|DRUG|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
48122971|NCT02823938|OTHER|existing database on data collection.|This is an observational study on an existing database.
48122972|NCT03345901|DRUG|Pemafibrate|0.2 mg orally BID - twice daily
48122973|NCT03345901|DRUG|Placebo|orally BID - twice daily
48122974|NCT05798273|PROCEDURE|intra-arterial injection|"All patients will receive an intravenous injection of \[68Ga\]Ga-PSMA-11 (1.5 MBq/kg), followed by a synchronous PET/MRI scan (median duration approximately 50 min) at 45-60 min post-injection.~In case of a positive \[68Ga\]Ga-PSMA-PET signal at the tumor site, patients will return (in 2 weeks) for an intra-arterial injection (i.e., a neuro-interventional procedure) of 68Ga-PSMA-11 (1.5 MBq/kg), followed by a repeat synchronous PET/MRI scan (median duration 50 min) at 45-60 min post-injection."
48122975|NCT05798273|DEVICE|synchronous PET/MRI scan|Scan done at (median duration approximately 50 min) at 45-60 min post-injection.
48122976|NCT05798273|OTHER|Radiopharmacon Contrast agent|Type: \[68Ga\]Ga-PSMA-11 dosage: 1.5 MBq/kg
48122977|NCT01808768|DRUG|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
48491107|NCT06446466|DEVICE|PEMF ON-OFF|"In the experimental condition PEMF ON-OFF, the participants will start the exercise session with PEMF in ON modality. The PEMF device will be kept ON for 17 minutes. Then, it will be turned OFF while the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect on PEMF at the onset of the exercise. Data acquired in the first 17 minutes (PEMF ON) will be compared with those recorded in the last 17 minutes (PEMF OFF) of the exercise session."
48328618|NCT02711904|DRUG|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~* 20 years old - 9.0 mcg/Kg/h~* 30 years old - 8.5 mcg/Kg/h~* 40 years old - 8.0 mcg/kg/h~* 50 years old - 7.5 mcg/kg/h~* 60 years old - 7.0 mcg/kg/h~* 70 years old - 6.5 mcg/kg/h~* 80 years old - 6.0 mcg kg/h."
48122978|NCT04918758|DEVICE|Purastat Arm|"Generic name of device and principal intended use(s):~Still PuraStat from a CE mark perspective. PuraStat is an aqueous self-assembling peptide solution of 2.5% concentration RADA16~Indication for use:~PuraStat is indicated for haemostasis in the following situations encountered during surgery, when haemostasis by ligation or standard means is insufficient or impractical:~* Bleeding from small blood vessels and oozing from capillaries of the parenchyma of solid organs. Oozing from vascular anastomoses~* Bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures~* Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon."
48122979|NCT04918758|DRUG|Standard Care Arm|Sucralfate enemas 2g twice daily for 8 weeks, this is standard care in patients with haemorrhagic radiation proctopathy in the short term
48122980|NCT04863261|OTHER|Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App|The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
48122981|NCT04103723|PROCEDURE|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
48328619|NCT03686865|DEVICE|dental implants|extraction sockets regenerated with xenograft
48328620|NCT04107558|DEVICE|Virtual Reality|Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
48122982|NCT03964376|OTHER|Nasal High Flow|Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute
48328621|NCT06199622|OTHER|music|20 minutes of classical Turkish musicor classical western music
47973471|NCT05447715|DRUG|Fruquintinib|Fruquintinib sequential BEV+FOLFIRI vs. BEV+FOLFIRI sequential fruquintinib in the treatment of metastatic colorectal cancer that has failed previous fluorouracil/oxaliplatin therapy
47973472|NCT00352560|DRUG|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
48328622|NCT06071637|PROCEDURE|Double low-power laser therapy simultaneous applicated|Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
48328623|NCT01237028|DRUG|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
48328624|NCT04477109|DEVICE|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt
47973473|NCT00352560|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
47973474|NCT02438202|DEVICE|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
47973475|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
48328625|NCT04477109|OTHER|sham laser application in addition to diet recommendations|sham laser application in addition to diet recommendations
48328626|NCT02486367|DRUG|Clopidogrel|Standard ADP receptor blockade
48328627|NCT02486367|DRUG|Ticagrelor|High potency ADP receptor blockade
48328628|NCT05599698|OTHER|Chemotherapy|Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies
48328629|NCT03619291|OTHER|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
48328630|NCT03619291|OTHER|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
48328631|NCT03619291|OTHER|control|physical inactivity, reading sports science literature, total duration 15 minutes
48491108|NCT06446466|DEVICE|PEMF OFF-ON|"In the experimental condition PEMF OFF-ON, the participants will start the exercise session with PEMF in OFF modality. The PEMF device will be kept OFF for 17 minutes. Then, it will be turned ON and the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect of PEMF during the exercise, when the muscle will have worked for 17 minutes. Data acquired in the first 17 minutes (PEMF OFF) will be compared with those recorded in the last 17 minutes (PEMF ON) of the exercise session."
47973476|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
47973477|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
47973478|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
47973479|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
47973480|NCT02132091|OTHER|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
47973481|NCT02132091|DIETARY_SUPPLEMENT|400 IU Vitamin E|once each day in morning; oral pill form
47973482|NCT02132091|DIETARY_SUPPLEMENT|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
47973483|NCT04585386|OTHER|Visual analog scale|to measure the lumbar and radicular pain felt by the patient.
47973484|NCT04585386|OTHER|Mac Gill Pain Questionnaire|self-questionnaire that allows a qualitative assessment of chronic pain
48122983|NCT03964376|OTHER|Usual Care|Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
48328632|NCT03441347|BEHAVIORAL|Specific rehabilitation program|17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
48328633|NCT03441347|OTHER|Usual Care|Participants will receive their usual care for 17 weeks, which may vary for each individual
48328634|NCT01644955|DRUG|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
48328635|NCT01644955|PROCEDURE|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
48328636|NCT02709772|BEHAVIORAL|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
48122984|NCT04156204|OTHER|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
48328637|NCT05079763|OTHER|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
48328638|NCT05079763|OTHER|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
48328639|NCT02928926|OTHER|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
47973485|NCT04585386|OTHER|Roland and Morris Disability Questionnaire|functional disability scale for assessing low back pain
48122985|NCT04156204|DRUG|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
48122986|NCT00151567|DRUG|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
48122987|NCT00151567|DRUG|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
48122988|NCT00581854|DRUG|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
48328640|NCT02473835|OTHER|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
48328641|NCT02473835|OTHER|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
48328642|NCT02473835|OTHER|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
48328643|NCT05301023|OTHER|Individualized antibiotic therapy|Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (\<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.
47973486|NCT04585386|OTHER|Quebec questionnaire|To access the patient's perception of incapacity
47973487|NCT05272020|DIAGNOSTIC_TEST|CPET, 6MWT, QOL assessment|Preoperative and postoperative (6 months + 18 months) assessment
47973488|NCT05495906|BIOLOGICAL|Nonavalent HPV vaccine|Routine dosing form and dosage
48328644|NCT05301023|OTHER|Standard antibiotic therapy|Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
48328645|NCT03921047|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48328646|NCT03921047|OTHER|Laboratory Biomarker Analysis|Correlative studies
48328647|NCT04115618|RADIATION|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
48491109|NCT03557528|PROCEDURE|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
47973489|NCT04806724|BEHAVIORAL|Opening the Conversation|The intervention includes 5 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on reproductive and sexual health distress.
47973490|NCT04806724|BEHAVIORAL|Side by Side|The intervention includes 4 weekly sessions (1.5 hours each), plus participant educational materials, and is delivered to couples via videoconference by a trained interventionist. Participants are asked to complete home activities between sessions. Sessions focus on development of communication and coping skills, with a focus on general cancer-related distress.
48122989|NCT00110929|DRUG|AMG 073|
48122990|NCT04498234|PROCEDURE|ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %|One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
48328648|NCT03609736|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|"* A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push.~* After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v).~* Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL.~* At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base."
47973491|NCT06045897|DEVICE|EEG 64 channels|64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.
47973492|NCT06045897|DEVICE|Polysomnography 19 electrodes|Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.
47973493|NCT06045897|BEHAVIORAL|Light hypnosis|Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.
47973494|NCT06045897|BIOLOGICAL|Biological sampling|Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
47973495|NCT06045897|BEHAVIORAL|Virtual reality|Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.
47973496|NCT06045897|DEVICE|Voice recording|A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.
47973497|NCT02647203|DRUG|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
47973498|NCT00560859|PROCEDURE|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
48491110|NCT02494700|RADIATION|External Beam Radiation Therapy|Undergo orbital EBRT
48491111|NCT02494700|DRUG|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
48491112|NCT00290836|DRUG|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
48491113|NCT03245645|OTHER|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
48491114|NCT01988506|DRUG|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
48491115|NCT01915693|RADIATION|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
48650638|NCT06642844|DRUG|Avastin, 25 Mg/mL Intravenous Solution|"Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity."
48650639|NCT06674460|DRUG|sublingual edaravone dexborneol|One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.
48650640|NCT06674460|DRUG|Placebo|One placebo tablet, to be taken sublingually, twice daily
48650641|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
48650642|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
48650643|NCT03228732|DRUG|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
48650644|NCT03228732|DRUG|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
48650645|NCT03228732|DRUG|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
48650646|NCT05222789|PROCEDURE|TAP|The transverse abdominal plane (TAP) block is a regional anesthesia technique performed using ultrasound that blocks the afferent nerves of the anterolateral abdominal wall, injecting local anesthetic in the fascial plane between the deep oblique and the transversus abdominis muscles.
48650647|NCT01044459|DRUG|Aclidinium Bromide 200 µg|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
48650648|NCT01044459|DRUG|Aclidinium Bromide 400 µg|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
48650649|NCT02913326|DRUG|Dabigatran etexilate|
48650650|NCT02913326|DRUG|Warfarin|
48650651|NCT02062008|DEVICE|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
48650652|NCT05474859|DRUG|XT-0528|Once Daily
48328649|NCT03049007|DIAGNOSTIC_TEST|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
48328650|NCT00375960|DRUG|V3381|
48122991|NCT03248505|DEVICE|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
48328651|NCT00375960|DRUG|Placebo|
48328652|NCT05006339|DEVICE|Dental Monitoring|Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.
48328653|NCT05006339|OTHER|Clinic Review|Patients in this arm are required to attend in clinic appointments for their retention review
48328654|NCT04791787|OTHER|Standard weight maintaining diet|Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
48328655|NCT04791787|OTHER|Weight maintaining isocaloric ketogenic diet|Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
48328656|NCT04791787|DIETARY_SUPPLEMENT|Beta-hydroxy butyrate|A supplement of ketone ester of beta-hydroxy butyrate
48328657|NCT03050216|BIOLOGICAL|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
48328658|NCT00863980|DRUG|Micardis (Telmisartan)|40-80 mg/day oral administration
48328659|NCT00863980|DRUG|Blopress (Candesartan)|8-12 mg/day oral administration
48328660|NCT00691093|DRUG|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
48328661|NCT03598569|OTHER|dyspnea|dyspnea assessment
48328662|NCT03360045|DRUG|Tranexamic Acid|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
48328663|NCT03360045|DRUG|Normal saline|5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
48328664|NCT03360045|DEVICE|Merocel|Merocel packing is applied.
48328665|NCT02881879|BIOLOGICAL|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
48328666|NCT06410924|DRUG|DD01|Dual GLP-1 and glucagon receptor agonist
48328667|NCT06410924|DRUG|Placebo|Placebo matching DD01
48328668|NCT04503941|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
48328669|NCT04503941|DEVICE|False Needle treatment|False Needle treatment treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
48491116|NCT05089318|DIETARY_SUPPLEMENT|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
48491117|NCT03744702|DRUG|Ascorbic Acid|Patients will receive IV ascorbic acid.
48491118|NCT04460196|OTHER|survey|Each admitted patient will complete a questionnaire
48491119|NCT05689593|OTHER|Low-intensity ESWT Group|ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
48491120|NCT05689593|OTHER|Low-intensity laser Group|The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
47973499|NCT00560859|OTHER|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
48328670|NCT05631262|DRUG|SKB264|Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy
48122992|NCT03248505|DEVICE|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
48328671|NCT05631262|DRUG|Docetaxel|Part II Control group will receive docetaxel monotherapy.
48122993|NCT03248505|OTHER|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
48328672|NCT05186766|DEVICE|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
48328673|NCT00568282|PROCEDURE|phlebotomy|Standard of care
48328674|NCT05020093|PROCEDURE|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
48328675|NCT05020093|PROCEDURE|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
48328676|NCT06312046|OTHER|HiBalance-MS|See arm description for intervention group.
48328677|NCT02252237|BIOLOGICAL|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
48328678|NCT05974046|DRUG|[14C]IDV184001AN|\[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
48328679|NCT00061503|DRUG|Travoprost|
48122994|NCT03248505|DEVICE|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
48328680|NCT00842361|DRUG|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
48328681|NCT00842361|DRUG|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
48122995|NCT03248505|DEVICE|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
48122996|NCT03248505|OTHER|Placebo TENS|TENS device turned on, but with zero amplitude.
48122997|NCT02944760|OTHER|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
48122998|NCT03080324|DRUG|Fentanyl sublingual|Fentanyl sublingual
48122999|NCT03080324|DRUG|Fentanyl ev|Fentanyl ev
48328682|NCT04404023|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
48328683|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
48328684|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
48328685|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
48123000|NCT03080324|DRUG|Placebo sublingual|Placebo sublingual
48123001|NCT03080324|DRUG|Placebo ev|Saline
48123002|NCT01717820|DIETARY_SUPPLEMENT|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
48328686|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
48328687|NCT03944083|OTHER|Treatment as usual for ADHD|Children are given treatment according to diagnostic conclusion and clinical recommendations.
48650653|NCT03769948|OTHER|risk factors for diabetic retinopathy|Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count
48328688|NCT00646568|DRUG|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
48328689|NCT01208571|OTHER|"Booster session"|Motivational interview
48328690|NCT00797485|BIOLOGICAL|bevacizumab|Given IV
48328691|NCT00797485|DRUG|capecitabine|Given orally
48328692|NCT00797485|DRUG|fluorouracil|Given IV
48328693|NCT00797485|DRUG|irinotecan hydrochloride|Given IV
48328694|NCT00797485|DRUG|leucovorin calcium|Given IV
48328695|NCT04328922|OTHER|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
48328696|NCT04328922|OTHER|Placebo capsuls|capsules of glycerol and saline (placebo).
48328697|NCT06093945|DRUG|SHR2554 tablet dosing|SHR2554 350mg taken on Day 1 and Day 10
48328698|NCT06093945|DRUG|Omeprazole tablet dosing|Omeprazole taken from Days 5 to Day 10
48328699|NCT02090985|PROCEDURE|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
48328700|NCT02001363|DRUG|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
48650654|NCT05451810|DRUG|Epcoritamab|Subcutaneous Injection (SC)
48650655|NCT06671392|DRUG|DWC202405|5/20mg, 1 tablet, Oral, Once a day
48650656|NCT06671392|DRUG|DWC202405, DWC202314|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
48650657|NCT06671392|DRUG|DWC202405, DWC202314P|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
48123003|NCT02250118|DRUG|Bevacizumab|Intrapleural Bevacizumab
48328701|NCT02001363|DRUG|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
48328702|NCT05998655|OTHER|tele nursing|"In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets."
48328703|NCT05678842|OTHER|Descriptive|Descriptive
48328704|NCT01772836|DRUG|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
48328705|NCT01772836|DRUG|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
48328706|NCT01772836|DRUG|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
48328707|NCT05331456|DEVICE|Unilateral alveolar cleft repair|Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
48123004|NCT02624141|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
48328708|NCT03520439|DRUG|Mifepristone|Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
48328709|NCT03520439|DRUG|Placebo|Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
48328710|NCT02586077|DRUG|Exparel|
48328711|NCT02604615|DRUG|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
48328712|NCT02604615|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
48328713|NCT02604615|RADIATION|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
48328714|NCT01682577|DRUG|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
48328715|NCT01682577|DRUG|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
48328716|NCT04929418|OTHER|10 km continuous running|Trial participants will perform a 10 km continuous running exercise
48491121|NCT05689593|OTHER|Conventional Control Group|Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
48491122|NCT06047392|DIAGNOSTIC_TEST|CT coronary angiography|Patients will undergo a CTCA according to local, standard protocol.
47973500|NCT06321315|BEHAVIORAL|Case-based instruction|"Case-based instruction will be applied to the students in the intervention group. Student Information Form, Critical Thinking Motivation Scale, Academic Motivation Scale and Knowledge Assessment Form will be . All students will receive classical in-class theoretical education about such as hemorrhages, hyperemesis gravidarum, oligohydramnios and urinary system diseases. In the intervention group, after the theoretical teaching of each subject within the scope of the Risky Pregnancy and Care course, cases prepared on the basis of the subject taught to the students will be applied. Student Information Form (13th and 14th questions), Critical Thinking Motivation Scale, Academic Motivation Scale, Knowledge Assessment Form and Visual Comparison Scale will be applied to all students as post-test data after case-based teaching of four topics."
47973501|NCT03129984|DEVICE|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
47973502|NCT05385393|PROCEDURE|Arthroscopic posterior capsulotomy of the knee|"The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078."
47973503|NCT03910023|OTHER|Usual care comporting a home-exercise program (UCHE)|"The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program."
47973504|NCT03910023|OTHER|Spa therapy|the spa-therapy intervention consists of 18 consecutive days of spa-therapy (excepting Sundays), that must occur with 60 days of randomisation. The latter will combine mineral water with physical and hydrotherapeutic treatments, including massages, heat and water exercises.
47973505|NCT01007812|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
47973506|NCT01007812|DEVICE|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
47973507|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
47973508|NCT00254904|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
47973509|NCT00254904|DRUG|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
47973510|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
47973511|NCT00254904|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
48123005|NCT04504708|DRUG|ZX-101A|Once daily, oral dosing of ZX-101A at the assigned dose level for 28 consecutive days in a 28-day cycle
48123006|NCT04600752|DRUG|Augmentin (ES)-600|Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
48123007|NCT02063425|DRUG|Fluoxetine|1 pill of 20mg / day, during 3 months
48123008|NCT02063425|DRUG|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
48328717|NCT04929418|OTHER|1.5 km continuous swimming|Trial participants will perform a 1.5 km continuous swimming exercise.
48328718|NCT05197140|OTHER|food: cooked 85% lean ground beef|see arm description
48328719|NCT05197140|OTHER|food: Impossible Burger (R)|see arm description
48328720|NCT04522791|BEHAVIORAL|RFB|The RFB protocol entails a combination of 8 weekly, in-lab training sessions using HRV biofeedback software (Physiocom, Seattle, WA) and daily paced breathing homework using a mobile-based HRV biofeedback app (Inner Balance, HeartMath, LLC, CA).
48328721|NCT04522791|BEHAVIORAL|VSOP|The investigators will use the INSIGHT online program (Posit Science). The platform will be built for our study, including 5 tasks (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice different cognitive processes with PS/A as the shared domain.
48328722|NCT04522791|BEHAVIORAL|IR|Guided imagery relaxation, equal in dose and frequency to RF practice, will be used to control for relaxation effects that may occur via RFB (which could provide an alternative explanation for outcomes). IR activities will be facilitated using the Insight Timer mobile-based app, which emphasizes the use of visualization and imagery strategies to help the body relax.
48328723|NCT02683304|BIOLOGICAL|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
48328724|NCT02683304|DEVICE|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
48328725|NCT02305875|OTHER|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
48328726|NCT00259441|DRUG|Simvastatin|
48328727|NCT01213693|DRUG|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
48328728|NCT01213693|DRUG|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
48491123|NCT02856880|OTHER|Test zinc-IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
48491124|NCT02856880|OTHER|Test zinc non- IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
48650658|NCT06671392|DRUG|DWC202313, DWC202314|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
47973512|NCT06498401|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
47973513|NCT06504901|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
48123009|NCT05282472|DIAGNOSTIC_TEST|CPET without mask|Regular cardiopulmonary exercise tests were applied to all participants in phase 1.
48491125|NCT02856880|OTHER|Positive control|Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
48491126|NCT02856880|OTHER|SLS negative control|Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
48491127|NCT02856880|OTHER|non-SLS negative control|Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
48491128|NCT03605654|BIOLOGICAL|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
48491129|NCT03605654|DRUG|Immunosuppressive Agents|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
48491130|NCT02104336|DRUG|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
48123010|NCT05282472|DIAGNOSTIC_TEST|CPET with mask|A 3-layer surgical mask was placed on CPET device's mask and was fixed with a CPET tribune. In phase 2, as using this combined (surgical mask and device's mask) masks, CPETs were performed in all participants again, after 48 hours.
48491131|NCT05298878|OTHER|Intervention Group: Virtual home-based rehabilitation plus usual outpatient care|"14 supervised exercise virtual sessions with Kinesiologist and 10 independent exercise sessions. Each session lasts 40 minutes. The exercises consist of aerobic training; functional lower and upper body strengthening; balance; and flexibility exercises. During the first 10 minutes of the first session of each week, there is an educational session.~Week 1-2: three supervised virtual sessions Week 3-4: two supervised virtual sessions and one independent session. Week 5-8: one supervised virtual session and two independent sessions."
48491132|NCT00953108|DRUG|quetiapine|300 mg per day
48650659|NCT06671392|DRUG|DWC202313, DWC202314P|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
48123011|NCT03086369|DRUG|Olaratumab|Administered IV
48123012|NCT03086369|DRUG|Nab-paclitaxel|Administered IV
48328729|NCT02638870|DRUG|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
48123013|NCT03086369|DRUG|Gemcitabine|Administered IV
48123014|NCT03086369|DRUG|Placebo|Administered IV
48123015|NCT00521131|DRUG|Levocetirizine dihydrochloride|
48491133|NCT00953108|DRUG|escitalopram|escitalopram 10 mg per day
48491134|NCT00199771|DRUG|7.5% NaCl in 6% dextran 70 solution|
48491135|NCT05182255|DEVICE|Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered|To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
48491136|NCT00531349|PROCEDURE|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
48491137|NCT00531349|DRUG|Sevoflurane|General anesthesia
48491138|NCT05502692|BEHAVIORAL|CHARACTERISE|Cohort 1 Cohort 2
48491139|NCT05355766|DRUG|CN128 Tablets|Iron chelator, oral tablets
48650660|NCT03662529|BEHAVIORAL|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
48650661|NCT03662529|BEHAVIORAL|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
48123016|NCT05609734|OTHER|no intervention, only observational retrospective study|no intervention, only observational retrospective study
48123017|NCT00498511|PROCEDURE|upper gastrointestinal endoscopy, colonoscopy|
48123018|NCT00978042|DEVICE|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
48123019|NCT03405714|DRUG|Brivaracetam|"* Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml"
48123020|NCT06517459|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting,4 and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems.
48328730|NCT00643344|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
48328731|NCT04223401|OTHER|Prehabilitation|"Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up \& Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~1. Nutritional intervention~2. Psychological intervention~3. Exercise intervention"
48328732|NCT06078787|DRUG|Olaparib 150 MG|Olaparib should be dosed 2 x 150 mg tablets (300 BID)
48328733|NCT05752786|BEHAVIORAL|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
48328734|NCT05693038|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) monitoring will be performed, using the instrumentation available (Nemus 2, EB Neuro, Italy), to evaluate the occurrence of brachial plexus injury (BPI). EMG will be performed at the end of each pronation cycle. To rule out BPI at ICU admission, an EMG will be performed within two hours from the first pronation maneuver. Particularly, somatosensory evoked potential (SSEP) and sensory action potential (SAP) will be obtained from radial, ulnar, median and sural nerves. In case patients are awake, compound muscle action potential (CMAP) will be obtained as well.
48328735|NCT05693038|DIAGNOSTIC_TEST|Muscle strength measurement|Muscle strength measure willl be assessed at ICU discharge using hand-held dynamometer.
48328736|NCT00106821|DRUG|Tiotropium Bromide Inhalation Powder|
48328737|NCT05690971|BEHAVIORAL|App|"HORIZONS is self-administered with several features to promote engagement and health behavior change including gamification strategies, videos of chronic GVHD survivors, and optional content.~HORIZONS includes five interactive modules to be completed during an eight week period. HORIZONS also includes a sixth optional helpful resources section with a review of the domains and skills covered in the first five modules"
48328738|NCT05690971|BEHAVIORAL|Usual Care|Patients in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.
48328739|NCT01874249|OTHER|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
48328740|NCT01874249|OTHER|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
48328741|NCT01874249|OTHER|Transient elastography|Transient elastography values greater than 8 kPa
48328742|NCT01597011|PROCEDURE|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
48328743|NCT01597011|PROCEDURE|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
48328744|NCT03443609|DIAGNOSTIC_TEST|68Ga-HBED-CC-PSMA PET / CT|Patient will receive a specific PET / CT with PSMA
48328745|NCT05055570|OTHER|No intervention|No intervention
48650662|NCT03625037|BIOLOGICAL|Epcoritamab|Administered as specified in the treatment arm.
48650663|NCT00772525|DRUG|Nerispirdine|"form: tablet~Route: oral"
47973514|NCT06504901|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
47973515|NCT06504901|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
47973516|NCT06504901|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
47973517|NCT06504901|DRUG|Neupogen|rhG-CSF 5mcg/kg HD, QD d1-d14
47973518|NCT02174120|DRUG|propofol|
47973519|NCT02174120|DRUG|etomidate|
47973520|NCT05739097|DIAGNOSTIC_TEST|iron deficiency, coagulation abnormalities|avoid transfusions, where possible
47973521|NCT00197132|DRUG|Avandia|
47973522|NCT06501638|DRUG|Memantine Hydrochloride 10 MG|Take Memantine Hydrochloride for intervention First week, 5mg(half the tablet), p.o.，bid. Second to Sixth week, 10mg(one tablet), p.o., bid
48328746|NCT02850497|DEVICE|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
48328747|NCT00336778|DRUG|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
48328748|NCT00485589|DRUG|Methotrexate|Oral repeating dose
48328749|NCT00485589|DRUG|Ocrelizumab|Intravenous repeating dose
48328750|NCT00485589|DRUG|Placebo|Intravenous repeating dose
48328751|NCT05454930|OTHER|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
48328752|NCT05855681|OTHER|therapeutic exercises|strengthening exercise and stretching exercise
48328753|NCT05200052|DRUG|Colchicine 0.5 mg Oral Tablet|Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
48123021|NCT03593876|BEHAVIORAL|Strategy Training|This study will use an adapted form of strategy training for people with communication impairments.
47973523|NCT06501638|DRUG|Placebo|Take placebo for intervention First week, half the tablet, p.o., bid. Second to Sixth week, one tablet, p.o., bid
48123022|NCT04193969|DIAGNOSTIC_TEST|Pressure pain assessment using computer controlled cuff algometry|Pressure pain sensitivity is assessed. The pressure is gradually increased and pain is rated by the participant on an electronic visual analogue pain rating scale (VAS) which is connected to the equipment. The assessment is performed on the lower leg and the upper arm. The pain free leg and the left upper arm is used in the patient group. The leg used in the control group will be chosen in a balanced manner meaning that half will receive pressure on the left leg and the other half on the right leg. The pain detection threshold (PDT), pain pressure tolerance threshold (PPT) and pressure pain intensity perceived as 6 on the VAS (VAS6) at the leg site is registered. The PDT and PPT on the arm site is registered.
48123023|NCT04193969|DIAGNOSTIC_TEST|Temporal summation (TS)|10 repeated inflations on the lower leg with a 1 sec interval. The pressure used at each pressure is equivalent the PPT measured at baseline. Each inflation is rated on the VAS. TS is registered as the increase pain intensity.
48123024|NCT04193969|DIAGNOSTIC_TEST|Conditioned pain modulation (CPM)|The cuff on the upper arm is inflated until 70% of the PPT is reached. While the pressure on the arm is kept constant the cuff on the leg is inflated. PDT, PPT and VAS6 pressure at the leg site is registered during the tonic stimulation (pressure on the left arm). The procedure on the leg is repeated within 30 seconds after the pressure is released on the arm site.
48123025|NCT04193969|DIAGNOSTIC_TEST|Low back pain rating scale (LBPRS-pain)|A questionnaire measuring the intensities of low back pain and leg pain currently, on average the last two weeks and the worst pain within the same period.
48123026|NCT04193969|DIAGNOSTIC_TEST|Oswestry Disability Index|A questionnaire measuring the disability in relation to low back pain and leg pain.
48123027|NCT03288753|OTHER|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
48123028|NCT03288753|BEHAVIORAL|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
48328754|NCT05705895|PROCEDURE|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~* For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~* The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~* Vein valve/needleless connector will be used.~* Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~* Needle-free connectors will be replaced every 96 hours at the latest.~* If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~* Pulsatile give stop give stop technique will be used in the washing process."
48328755|NCT00370877|DRUG|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
48328756|NCT00370877|PROCEDURE|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
48328757|NCT05719051|DRUG|Albumin infusion|Albumin infusion was administrated according to the standard clinical practice
48328758|NCT05340322|DEVICE|Colposcopy using pocket colpscope and thermocoagulator|If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
48328759|NCT00884715|DRUG|Octreotide|short acting octreotide
48328760|NCT01503580|DRUG|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
48491140|NCT02668926|DRUG|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
48491141|NCT02668926|DRUG|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
48491142|NCT02668926|DRUG|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
48491143|NCT03118570|DRUG|setrusumab|Intravenous infusion
48491144|NCT03118570|DIETARY_SUPPLEMENT|Calcium|tablets
48491145|NCT03118570|DIETARY_SUPPLEMENT|Vitamin D|capsules
48491146|NCT03118570|DRUG|zoledronic acid (optional)|Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
48491147|NCT00793780|DRUG|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
48491148|NCT00793780|OTHER|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
48328761|NCT06524427|PROCEDURE|Robot-assisted lobectomy|Patients will receive robot-assisted lobectomy using Da Vinci surgical system
48328762|NCT06524427|PROCEDURE|Video-assisted lobectomy|Patients will receive video-assisted lobectomy
48328763|NCT02475395|DEVICE|TRAK device|Use of TRAK to attain sperm concentration measurement
48328764|NCT03201848|DRUG|Placebo|Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
48328765|NCT03201848|DRUG|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
48328766|NCT00225680|DEVICE|drug eluting coronary stent|
48328767|NCT00217516|DRUG|selenium|Given orally
48328768|NCT00217516|OTHER|placebo|Given orally
48328769|NCT02700139|DEVICE|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
48328770|NCT01654042|OTHER|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
48328771|NCT03190096|PROCEDURE|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
48650664|NCT00772525|DRUG|Placebo|"form: tablet~Route: oral"
48491149|NCT02304991|DRUG|Liquid Peanut Extract|5000mcg/ml peanut protein
48491150|NCT02304991|DRUG|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
48650665|NCT06673979|DIAGNOSTIC_TEST|Numeric Rating Scale|The patients are asked to rate their pain according to the Numeric Rating Scale (0=no pain; 10=worse possible pain).
48650666|NCT06058351|BEHAVIORAL|ABI-motion program|The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.
48650667|NCT06674018|DIETARY_SUPPLEMENT|Indole-3-propionic acid|A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
48650668|NCT06674018|DIETARY_SUPPLEMENT|Placebo|Two capsules of placebo will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
48650669|NCT04269785|DEVICE|Cryoballoon ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)
48328772|NCT04114513|DIETARY_SUPPLEMENT|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
48328773|NCT04114513|DIETARY_SUPPLEMENT|Inulin|BENEO-Orafti, white powder 5 weeks intervention
48328774|NCT04114513|DIETARY_SUPPLEMENT|Pectin|BANG \& BONSOMER GROUP OY, white powder 5 weeks intervention
48328775|NCT04114513|DIETARY_SUPPLEMENT|Beta-glucan|Tate \& Lyle, white powder 5 weeks intervention
48328776|NCT04114513|DIETARY_SUPPLEMENT|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
48328777|NCT02861053|OTHER|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
48328778|NCT02861053|OTHER|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
48328779|NCT05657951|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
48328780|NCT00897052|GENETIC|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
48491151|NCT02960919|DRUG|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
48491152|NCT02960919|DRUG|parenteral ampicillin/ penicillin|
48491153|NCT02960919|DRUG|gentamicin|
48491154|NCT01568320|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
48491155|NCT03976583|DRUG|Cpp-Acp|Remineralising agent
48491156|NCT03976583|OTHER|Pearl powder|Natural product
48491157|NCT02198326|DRUG|BIBN 4096 BS- in single rising doses|
48491158|NCT02198326|DRUG|Placebo|
48491159|NCT04378517|OTHER|psychosocial education in parents groups|psychosocial education
48491160|NCT04378517|OTHER|psychosocial parents support, interviews with APN|Family strength-oriented therapy conversation
48491161|NCT03848169|OTHER|Radiofrequency|See previous page
48650670|NCT04269785|DEVICE|Radiofrequency ablation|Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
48650671|NCT04511741|OTHER|no intervention, it is an observational study.|no intervention, it is an observational study.
48650672|NCT01641055|DIETARY_SUPPLEMENT|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
48650673|NCT01641055|DIETARY_SUPPLEMENT|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
48650674|NCT01641055|DIETARY_SUPPLEMENT|Cod protein|2.5g cod protein per day for 8wk.
48650675|NCT01641055|DIETARY_SUPPLEMENT|Milk protein|2.5g milk protein per day for 8wk.
48650676|NCT03777215|DRUG|Angiotensin-(1-7)|This is a biologically active beneficial hormone of the renin-angiotensin system.
48650677|NCT03777215|DRUG|Saline|Saline will be used as the placebo comparator.
48328781|NCT00897052|OTHER|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
48328782|NCT02882737|DRUG|Glucagon before exercise|
48328783|NCT02882737|DRUG|Glucagon after exercise|
48328784|NCT02882737|DRUG|Glucagon after resting|
48328785|NCT03678376|OTHER|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
48328786|NCT00609453|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
48650678|NCT06033859|DIAGNOSTIC_TEST|Clinical measurements|With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
48650679|NCT06033859|DIAGNOSTIC_TEST|Radiographic measurement|A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
48650680|NCT06033859|PROCEDURE|Dental prophylaxis or maintenance|Dental prophylaxis or maintenance will be performed every 3 months.
48650681|NCT04557150|DRUG|Forimtamig|Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
48123029|NCT03288753|BEHAVIORAL|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
48123030|NCT03288753|BEHAVIORAL|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
48650682|NCT06674070|GENETIC|Valproic Acid|syrup/ tablet EPIVAL (250mg
48123031|NCT04695197|DRUG|Artemether-lumefantrine (AL)|Current first line treatment of malaria. Dose: Bodyweight (kg) Dose (mg) of artemether + lumefantrine given twice daily for 3 days (total, six doses) 5 to \< 15 20 + 120 15 to \< 25 40 + 240 25 to \< 35 60 + 360 \>=35 80 + 480; Twice daily for 3 days (total, six doses)
48328787|NCT01273493|DRUG|Trabectedin|Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.
48650683|NCT02886364|BEHAVIORAL|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
48123032|NCT04695197|DRUG|Pyronaridine-artesunate (PA)|Antimalarial; Dose: Body weight (kg) Dose (mg) of pyronaridine + aresunate given once daily for 3 days (total, three doses) 5 to \< 8 60 + 20 8 to \<15 120 + 40 15 to \<20 180 + 60 20 to \<24 kg 180 + 60 24 to \<45 360 + 120 45 to \<65 540 + 180 \>=65 720 + 240; Once-daily for 3 days (total, three doses).
48123033|NCT01897870|BEHAVIORAL|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
48123034|NCT03335397|DEVICE|M-learning application|Mobile application with interactive contents available for android platform and Apple's operating system.
48328788|NCT01273493|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
48650684|NCT05505786|BEHAVIORAL|Normal stance width|Normal self-selected stance width when performing squat exercises.
48650685|NCT05505786|BEHAVIORAL|Wide stance width|Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
48650686|NCT06634862|OTHER|Normatec Air Compression|Intermittent pneumatic pressure has been used in other studies, usually for deep vein thrombosis and vascular disorders. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
48650687|NCT06634862|OTHER|Soft Tissue Mobilization|The soft tissue mobilisation technique has been investigated in other studies in terms of its effect on soft tissue and its role recovery. In this way, there is no comparison with other recovery interventions for post-exercise recovery applications.
48650688|NCT06634862|OTHER|Percussive therapy|Percussive therapy has been investigated in device research and athlete health. In this way, it has not been compared with other recovery interventions for post-exercise recovery applications.
48650689|NCT06570317|DRUG|Nintedanib|For patients with unresectable NSCLC, nidanib is administered during sequential radiotherapy
48328789|NCT01225367|DEVICE|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
48328790|NCT01756872|PROCEDURE|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
48328791|NCT02814864|DRUG|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale\>2) will receive Mesenchymal Stromal Cell (MSC) injections
48328792|NCT01768234|OTHER|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
48650690|NCT06674759|DRUG|Tongren-Dahuoluo Bolus|0.72g,2 times a day, oral, for 24 weeks.
48650691|NCT06674759|DRUG|Tongren-Dahuoluo Bolus Placebo|0.72g,2 times a day, oral, for 12 weeks.
48328793|NCT01333306|PROCEDURE|Transcranial direct current stimulation (tDCS)|
48328794|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
48328795|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
48123035|NCT03335397|OTHER|Traditional learning process|Traditional content available in university library.
48123036|NCT01865149|PROCEDURE|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
48123037|NCT05401474|DEVICE|High Flow Nasal Cannula at 30L/min|Flow will be set at 30L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
48328796|NCT01362686|DRUG|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
48328797|NCT01362686|DRUG|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
48328798|NCT01362686|DRUG|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
48328799|NCT04671342|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
48491162|NCT06461481|DEVICE|Withings Scanwatch|Data captured by the used smartwatches (Withings Scanwatch) includes activity-related data (step count, minutes in certain intensity levels), basic cardiovascular measurements such as heart rate, and sleep-related data (total time asleep, sleep efficiency and quality etc.).
48491163|NCT02651454|DRUG|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48491164|NCT02651454|DRUG|Chowiseungcheng-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
48650692|NCT04020263|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
48123038|NCT05401474|DEVICE|High Flow Nasal Cannula at 45L/min|Flow will be set at 45L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
48123039|NCT05401474|DEVICE|High Flow Nasal Cannula at 60L/min|Flow will be set at 60L/min, FiO2 will be adjusted manually to maintain SpO2within the target range
48123040|NCT00243529|BIOLOGICAL|autologous dendritic cell vaccine|
48491165|NCT02651454|DRUG|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48650693|NCT04020263|DRUG|Placebo|Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
48650694|NCT00660231|DRUG|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
48123041|NCT00296868|DRUG|ascorbic acid (vitamin C) versus placebo|
48123042|NCT04134793|PROCEDURE|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
48123043|NCT04750850|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
48123044|NCT04750850|OTHER|Usual care|Usual routine as walking and activities of daily living.
48123045|NCT05874830|OTHER|Fecal microbiota transplant or plasebo through endoscopy|Colonoscopy and gastroscopy
48123046|NCT04948801|DRUG|Epclusa (sofosbuvir and velpatasvir)|Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
48123047|NCT03828240|OTHER|HIP fracture REhabilitation Programme for the elderly with hip fractures|Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
48123048|NCT03886402|DEVICE|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
48123049|NCT05900765|DRUG|Zimberelimab 240mg|"AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV"
48123050|NCT06177444|DRUG|Antibiotic|Postoperative antibiotic treatment
48123051|NCT00132964|DEVICE|Below knee walking cast|Not required
48123052|NCT00132964|DEVICE|Removable ankle brace|not required
48328800|NCT01154881|DRUG|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
48328801|NCT00276770|OTHER|fluorine F 18 fluorothymidine|
48328802|NCT00276770|PROCEDURE|positron emission tomography|
48328803|NCT03831893|OTHER|Nopal food product 1|Dried Nopal incorporated in a food product
48328804|NCT03831893|OTHER|Nopal food product 2|Dried Nopal incorporated in a food product
48328805|NCT03831893|OTHER|control|Food Product without nopal
48328806|NCT02453438|OTHER|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
48123053|NCT04073199|PROCEDURE|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
48123054|NCT04073199|PROCEDURE|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
48328807|NCT01852929|OTHER|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
48328808|NCT04846348|COMBINATION_PRODUCT|Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.|Combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base (Vanicream).components: Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor
48328809|NCT03685552|OTHER|Prog: Purify-2|"Nutritional Supplements to be administered:~* Protein Shakes: one protein shake twice a day~* Probiotics (Bacillus Coagulans) once a day~* Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~* In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day"
48328810|NCT05421429|BIOLOGICAL|KN057 doseⅠ|KN057 subcutaneous (SC) injection
48328811|NCT05421429|BIOLOGICAL|KN057 dose Ⅱ|KN057 SC injection
48328812|NCT05421429|BIOLOGICAL|KN057 dose Ⅲ|KN057 SC injection
48650695|NCT00660231|DRUG|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
48650696|NCT06631053|OTHER|velocity-based FIT (VBFIT)|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study. Those assigned to the exercise group will perform a both high-intensity resistance and aerobic exercise three times per week"
48650697|NCT06631053|OTHER|No Exercise|"Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study."
48650698|NCT03725527|PROCEDURE|Rectus Sheath Block|Sonar guided RSB will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
48123055|NCT00485329|OTHER|Papain|15,000 USP U/ml
48123056|NCT00485329|OTHER|Papain|30,000 USP U/ml
48123057|NCT00485329|OTHER|Papain|60,000 USP U/ml
48123058|NCT04961749|OTHER|Whole body vibration training|Whole-body vibration training applies a vibration stimulus to an individual as they are standing on a side-alternating platform. The vibration creates small muscle contractions in the lower extremity musculature which has been shown to improve function and ambulatory function.
48123059|NCT00327561|PROCEDURE|Intensive periodontal therapy|
48328813|NCT02962219|BEHAVIORAL|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
48328814|NCT02962219|BEHAVIORAL|Home Exercise Programme (HEP)|Written advice on exercise at home
48328815|NCT01873443|DRUG|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10\~25mg/week Folic acid at least 5mg/week
48328816|NCT00855387|OTHER|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
48328817|NCT00067613|OTHER|Benchmarking Management Practices|"The Benchmarking intervention included:~1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~2. Training in Continuous Quality Improvement (CQI) Techniques~3. Review of best existing evidence~4. Site visits to the Centers with the Lowest Rates of BPD~5. Selection of Practices to change: Each site team selected practices for modification at their own center"
48328818|NCT00067613|OTHER|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
48328819|NCT02278081|DRUG|lansoprazole|the lansoprazole will be taken orally.
48328820|NCT02278081|DRUG|placebo|the lansoprazole placebo will be taken orally.
48328821|NCT02863705|DRUG|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
48328822|NCT02863705|DRUG|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
48328823|NCT04059406|DRUG|sapablursen|sapablursen administered subcutaneously
48328824|NCT05246670|DRUG|Palmidrol|Given PEA PO
48328825|NCT05246670|DRUG|Placebo Administration|Given PO
48328826|NCT05246670|OTHER|Quality-of-Life Assessment|Ancillary studies
48328827|NCT00406211|BIOLOGICAL|MMRV|
48328828|NCT00406211|BIOLOGICAL|MMR (Priorix®)|
48328829|NCT00406211|BIOLOGICAL|Varicella (Varilrix®)|
48328830|NCT02759861|DRUG|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
48328831|NCT05065307|DIAGNOSTIC_TEST|Venipuncture|Diagnostic venipuncture
48328832|NCT05423002|OTHER|Flickering light stimuli|The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
48328833|NCT05423002|OTHER|Constant light stimuli|The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
48650699|NCT05199688|DRUG|Satralizumab|Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
48650700|NCT05434754|OTHER|eHealth Tool|text messaging algorithm
48650701|NCT04393935|BEHAVIORAL|Pharmacy Delivered PrEP Intervention|Men who are eligible and agree to the clinical screener will be provided with a pre-packaged kit of self-administered tests for HIV, rectal chlamydia, syphilis and gonorrhea and creatinine and directed back to the private area of the pharmacy to perform their screenings. Participants will be asked to return the screening tests to the pharmacy technician. The pharmacy technician will process/ interpret the results of the rapid HIV test first in case a treatment referral needs to be set up. Then s/he will process/interpret the results of a rapid rectal chlamydia, syphilis, gonorrhea and rapid finger prick creatinine test. HIV negative customers will be provided with their results and be given a 30-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Participants will be contacted after 3 months to determine whether they continued PrEP use.
48328834|NCT05423002|OTHER|Dim light|This light condition is the baseline (≤10 lux).
48328835|NCT02491398|DRUG|Bendamustine + Rituximab|
48328836|NCT04689672|DIAGNOSTIC_TEST|Lung ultrasound|Bedside lung ultrasound
48328837|NCT02553317|BIOLOGICAL|Caplacizumab|"* First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
48328838|NCT02553317|BIOLOGICAL|Placebo|"* First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
48328839|NCT03329599|DRUG|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
48328840|NCT02322684|DEVICE|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
48328841|NCT03602261|DRUG|Calcifediol Oral Capsule|Capsule, weekly
48328842|NCT03602261|DRUG|Placebo oral capsule|Capsule, weekly
48650702|NCT03755154|DRUG|S65487- initial scheme|S65487 is administered as single agent via i.v. infusion once a week on a 3-week cycle.
48650703|NCT03755154|DRUG|S65487 - alternative scheme|S65487 is administered in 3 to 5 i.v. infusions the first week of each cycle then once a week on the rest of the 3-week cycle.
48328843|NCT00631540|DEVICE|Formula Balloon-Expandable Stent|renal artery stenting
48328844|NCT03393468|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
48328845|NCT02334670|DRUG|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
48328846|NCT03404271|DIETARY_SUPPLEMENT|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
48328847|NCT03404271|OTHER|Resistance Training|Performing supervised resistance training three times per week.
48328848|NCT03404271|DIETARY_SUPPLEMENT|Protein Supplementation|Consuming a protein supplement daily.
48328849|NCT03404271|BEHAVIORAL|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
48328850|NCT05374018|DIAGNOSTIC_TEST|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
48328851|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 1|Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
48328852|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 2|Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
48328853|NCT05955079|OTHER|Whole blood|3 samples (before, after surgery and before chemotherapy)
48328854|NCT01812070|BEHAVIORAL|ACT|
48328855|NCT01812070|BEHAVIORAL|CBT|
48328856|NCT06283173|DEVICE|ColActive Plus Collagen Matrix Dressing|"Induction phase: Test article applied with Hill Top chamber every 48+ hours over 3 weeks. Rest phase: 10-day rest period with no application.~Challenge phase: Test article applied for 48 hours and evaluated through 48 hours post removal.~The positive control is evaluated at Induction 1 only. The negative control is applied following the same schedule as the test article."
48328857|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
48328858|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
48328859|NCT01294982|DRUG|Placebo|Placebo Oral Capsules twice daily
48328860|NCT00159159|DRUG|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
48328861|NCT00159159|DRUG|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
48328862|NCT03736629|DRUG|Azithromycin|8 weeks of Azithromycin (250 mg) once daily by mouth
48328863|NCT03736629|DRUG|Placebo|Placebo
48328864|NCT01889888|OTHER|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
48328865|NCT02492087|DRUG|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
48328866|NCT02492087|DRUG|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
48328867|NCT04813276|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
48328868|NCT04813276|BEHAVIORAL|Enhanced Care as Usual|A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
48328869|NCT05460572|DIETARY_SUPPLEMENT|Peripheral Parental Nutrition|Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
48328870|NCT02155348|PROCEDURE|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
48328871|NCT02155348|PROCEDURE|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
48328872|NCT02155348|DEVICE|Lentis LS-313|
48328873|NCT02640066|OTHER|acupuncture|
48123060|NCT00327561|PROCEDURE|Community based periodontal therapy|
48328874|NCT03310736|DIAGNOSTIC_TEST|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
48328875|NCT03909555|OTHER|Complications assessment|Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
48328876|NCT03625154|PROCEDURE|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
48328877|NCT03625154|OTHER|non operative management|closed reduction and splinting followed by progressive weight bearing
48328878|NCT03745235|OTHER|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
48328879|NCT03745235|BIOLOGICAL|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
48328880|NCT03745235|OTHER|psychometric questionnaires|"* Cohen PSS' perceived stress scale~* Beck's anxiety and depression questionnaires~* Watson's affectivity questionnaire, positive affect and negative affect schedule~* optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~* IN-OUT DASQ dispositional affective style questionnaire"
48328881|NCT02675179|DEVICE|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
48328882|NCT02675179|DEVICE|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
48328883|NCT03159819|GENETIC|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
48123061|NCT02256254|DRUG|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
48123062|NCT02256254|DRUG|Placebo|2 placebo capsules every evening for 14 days
48123063|NCT00445315|DRUG|PF-00868554|300 mg BID
48328884|NCT05066035|DRUG|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
48328885|NCT05066035|DRUG|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
48328886|NCT02302144|BEHAVIORAL|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
48328887|NCT00321022|BEHAVIORAL|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
48328888|NCT04780945|DIAGNOSTIC_TEST|Functional RAD51 assay|ex vivo functional assay (RAD51 assay also known as Repair Capacity (RECAP) assay ) to test homologous recombination deficiencie (HRD) in viable tumor tissue
48328889|NCT04780945|DRUG|Olaparib Oral Product|300 mg bid
48123064|NCT00445315|DRUG|PF-00868554|450 mg BID
48328890|NCT02219711|DRUG|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
48328891|NCT02281981|DIETARY_SUPPLEMENT|Curcumin|333mg CurcuWin OAHTCUR002-2014
48328892|NCT02281981|DIETARY_SUPPLEMENT|Placebo|OAHTCUR005-2014
48328893|NCT02447458|DRUG|MLN3126|MLN3126 tablets
48328894|NCT02447458|DRUG|MLN3126 Placebo|MLN3126 placebo-matching tablets
48328895|NCT00944788|OTHER|qi-gong|Physical activity similar to tai-chi
48328896|NCT02532387|OTHER|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
48328897|NCT05785130|OTHER|background noise|Using sound machine for 3 days at bedtime for 7 hours(11p.m.- 6a.m.) in a decibel of 40-50.
48328898|NCT01664858|OTHER|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
48328899|NCT01664858|OTHER|SPECT|SPECT: Single Photon Emission Computed Tomography
48328900|NCT01664858|OTHER|CT calcium score|CT calcium score
48328901|NCT01664858|OTHER|CT coronary angiography|CT coronary angiography
48328902|NCT01664858|OTHER|X-Ray coronary angiography|X-Ray coronary angiography
48328903|NCT03713606|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
48328904|NCT03496129|BEHAVIORAL|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
48328905|NCT03496129|BEHAVIORAL|Personalized feedback and text messages|"Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions."
48328906|NCT03496129|BEHAVIORAL|Information Only|"Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message."
48328907|NCT02801422|OTHER|fMRI|
48328908|NCT01359046|DEVICE|silver SPC|subject randomized to receive silver alloy impregnated catheter
48328909|NCT01359046|DEVICE|standard SPC|subject randomized to receive standard catheter
48328910|NCT00599235|DRUG|sildenafil|50mg 3 times daily for 7 days
48328911|NCT00599235|DRUG|hydralazine|25mg 3 times daily for 7 days
48328912|NCT00599235|DRUG|placebo|3 times daily for 7 days
48123065|NCT00445315|DRUG|PF-00868554|100 mg BID
48123066|NCT00445315|DRUG|PF-00868554|300 mg TID
48123067|NCT00445315|DRUG|Placebo|Placebo
48123068|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
48123069|NCT05518253|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
48123070|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fasted|
48123071|NCT02133820|DRUG|4 mg 12 hourly capsule - strong pain killer fed|
48123072|NCT02133820|DRUG|12 hourly capsule strong painkiller with antagonist fasted)|
48123073|NCT02133820|DRUG|4 mg 12 hourly capsule strong painkiller with antagonist fed|
48328913|NCT01736631|BEHAVIORAL|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark \& Wells (Clark \& Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
48328914|NCT05227209|DRUG|SEP-4199 CR|SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
48328915|NCT02266732|DEVICE|Stimuplex HNS 12|
48328916|NCT00326222|BEHAVIORAL|Lifestyle counseling|Self-management group education
48328917|NCT00759746|BEHAVIORAL|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
48328918|NCT00759746|BEHAVIORAL|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
48328919|NCT00759746|BEHAVIORAL|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
48328920|NCT05859048|DIAGNOSTIC_TEST|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
48328921|NCT05859048|DIAGNOSTIC_TEST|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
48328922|NCT05859048|DIAGNOSTIC_TEST|electrocardiogram|tracing of electrical cardiac activity of the heart
48328923|NCT05859048|OTHER|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
48328924|NCT01238913|PROCEDURE|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
48328925|NCT05835713|DRUG|Remimazolam besylate|Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)
48328926|NCT05835713|DRUG|Propofol|Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
48328927|NCT06327620|COMBINATION_PRODUCT|Daivobet ointment, topical steroids|"Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information."
48328928|NCT02581982|OTHER|Laboratory Biomarker Analysis|Correlative studies
48328929|NCT02581982|DRUG|Paclitaxel|Given IV
48328930|NCT02581982|BIOLOGICAL|Pembrolizumab|Given IV
48328931|NCT03949140|PROCEDURE|Laser hair removal|Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
48328932|NCT05278676|DRUG|Dotinurad|Dotinurad oral tablet.
48328933|NCT00838006|DEVICE|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
48328934|NCT00838006|DEVICE|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
48328935|NCT00838006|DEVICE|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
48491166|NCT01289665|PROCEDURE|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
48491167|NCT01289665|PROCEDURE|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
48328936|NCT04011800|PROCEDURE|Catheter ablation|Pulmonary vein isolation, or additional left or right-sided atrial lesions.
48328937|NCT04011800|COMBINATION_PRODUCT|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
48328938|NCT03693118|BEHAVIORAL|Reh1,Reh2|The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
48328939|NCT01746940|DRUG|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
48328940|NCT01746940|DRUG|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
48328941|NCT01746940|DRUG|Placebo Topical Solution|Placebo Topical Solution
48328942|NCT04780256|PROCEDURE|Endoscopic resection|"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conditions of digestive tract. Endoscopic resection can be preformed by several techniques:~1. Endoscopic mucosal resection (EMR): it allows to remove mucosal lesions~2. Endoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions~3. Full-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
48328943|NCT01511432|DRUG|telaprevir formulation A|A single 1125-mg dose administered orally
48328944|NCT01511432|DRUG|telaprevir Formulation B|A single 1125-mg dose administered orally
48328945|NCT01511432|DRUG|telaprevir Formulation C|A single 1125-mg dose administered orally
48328946|NCT01511432|DRUG|telaprevir Formulation D|A single 1125-mg dose administered orally
48328947|NCT04325906|DEVICE|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
48328948|NCT04325906|PROCEDURE|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
48328949|NCT03685370|PROCEDURE|LOS|placement of epidural catheters with LOS technique
48328950|NCT03685370|PROCEDURE|X-ray placement|placement of epidural catheters with x-ray guide
48328951|NCT06436729|PROCEDURE|Splinting|The joining of two or more teeth into a rigid unit by means of a fixed or removable restorations/devices
48328952|NCT06436729|PROCEDURE|MINST alone|Minimally invasive non surgical therapy alone
48328953|NCT02493322|DRUG|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
48328954|NCT02493322|DRUG|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
48328955|NCT02493322|DRUG|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
48328956|NCT06042530|DIAGNOSTIC_TEST|Neuropsychological investigation|Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification
48328957|NCT06042530|DIAGNOSTIC_TEST|Optometric investigation|Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.
48328958|NCT06042530|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.
48491168|NCT01461226|BEHAVIORAL|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
48328959|NCT06042530|DIAGNOSTIC_TEST|Immunological biomarkers|Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.
48328960|NCT04616495|PROCEDURE|Liver transplantation|Chemotherapy and liver transplantation
48328961|NCT06261112|OTHER|kaleidescope|used to kaleideskope
48328962|NCT04917497|DRUG|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
48328963|NCT04696237|OTHER|Questionnaire|a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
48328964|NCT05836129|BEHAVIORAL|Transcendental Meditation (TM) practice|See previous description
48328965|NCT05836129|OTHER|Stress reduction class (online)|See previous description
48328966|NCT05035095|DRUG|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
48328967|NCT05035095|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
48328968|NCT02645279|OTHER|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
48328969|NCT02645279|DRUG|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
48328970|NCT05220761|DIAGNOSTIC_TEST|Cornell Assessment of Pediatric Delirium|Cornell Assessment of Pediatric Delirium is a diagnostic test for PICU delirium State Behavioral Scale and Richmond Agitation and Sedation Scale are diagnostic tests for sedation and agitation in children
48328971|NCT05246241|DEVICE|magnetic resonance imaging|Preoperative magnetic resonance imaging
48328972|NCT03059472|BEHAVIORAL|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
48328973|NCT03059472|BEHAVIORAL|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
48328974|NCT03682380|DRUG|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
48328975|NCT03682380|DRUG|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
48328976|NCT01596530|DRUG|Drug-AZD8931|Active drug for biological activity
48328977|NCT01596530|DRUG|Drug-Placebo|Placebo comparator for biological activity comparison
48328978|NCT03694054|OTHER|Care coordination tool|Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
48328979|NCT04712266|DRUG|Glucagon|calculated IV insulin:Glucagon molar ratio
48328980|NCT04712266|DRUG|Insulin|calculated IV Insulin dose infused at a constant rate
48328981|NCT04505150|BEHAVIORAL|Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption|Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
48328982|NCT06139887|BEHAVIORAL|BESST|The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
48328983|NCT06139887|OTHER|Standard Mental Health Care|Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
48328984|NCT03241238|OTHER|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
48328985|NCT01915108|DRUG|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
48328986|NCT04101578|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
48328987|NCT00181935|DRUG|risperidone (Risperdal)|
48328988|NCT00181935|DRUG|olanzapine (Zyprexa)|
48328989|NCT01606397|DRUG|Placebo|Administered orally (capsule)
48328990|NCT01606397|DRUG|LY2409021|Administered orally (capsule)
48328991|NCT04771026|DRUG|Dexamethasone|Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
48328992|NCT01847612|PROCEDURE|indocyanine green fluorescent cholangiography|
48328993|NCT01847612|DRUG|methylene blue|
48650704|NCT02471677|DRUG|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
48650705|NCT02471677|DRUG|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
48328994|NCT04564716|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
48328995|NCT04564716|OTHER|Placebo|placebo comparator
48328996|NCT04990375|DEVICE|tDCS|5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
48328997|NCT02168803|DRUG|Evacetrapib|Administered orally
48328998|NCT04197518|DIAGNOSTIC_TEST|neuro trax system and a neurology test.|"the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving."
48328999|NCT01692223|BEHAVIORAL|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
48329000|NCT04715048|DRUG|PrabotulinumtoxinA|Glabellar line correction
48329001|NCT04715048|DRUG|Onabotulinum toxin A|Glabellar line correction
48329002|NCT06051851|DRUG|Penpulimab|"Penpulimab 200mg IV D1~1 cycle every 21 days"
48329003|NCT06051851|DRUG|Anlotinib|"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"
48329004|NCT06051851|DRUG|Nab paclitaxel|"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"
48650706|NCT01603368|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
48650707|NCT01603368|DIETARY_SUPPLEMENT|Placebo|Oil drops without Lactobacillus reuteri
48650708|NCT06639555|PROCEDURE|PRP( platelet rich plasma)|regenerative therapy with PRP for vertical bone defects
48650709|NCT06639555|PROCEDURE|EMD (Enamel Matrix Derivative)|regenerative therapy with EMD for vertical bone defects
48650710|NCT06639555|PROCEDURE|Guided Tissue Regeneration (barrier membrane)|guided tissue regeneration with barrier membrane alone for vertical bone defects
48123074|NCT06285149|DRUG|Icaritin|This product is suitable for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse to receive standard treatment and have not received systemic treatment in the past, and the peripheral blood compound markers of patients meet at least two of the following detection indicatorsItem: AFP\>400 ng/mL; TNF-a\<2.5 pg/mL; IFN-y\>7.0 pg/mL.The conditional approval is based on data from an interim analysis of an enriched population in a randomized controlled Phase 11 clinical trial, and full approval for this indication will be subject to confirmation of the clinical benefit of the product in planned confirmatory trials.
48123075|NCT04571606|PROCEDURE|Single injection peripheral nerve block with liposomal bupivacaine (Exparel)|10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine
48329005|NCT06051851|DRUG|Gemcitabine|"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"
48329006|NCT00356057|DEVICE|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
48329007|NCT02027922|OTHER|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
48329008|NCT04535206|DIAGNOSTIC_TEST|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
48329009|NCT02679807|BIOLOGICAL|Bifidobacterium animalis subsp. lactis Bl-04|
48329010|NCT02679807|OTHER|sucrose|
48329011|NCT04370912|DIAGNOSTIC_TEST|Bed side Ultrasound|Handgrip strength will be measured using a digital grip strength dynamometer (Sammons Preston, Nottinghamshire, UK). This measurement is carried out three times using the subject's dominant hand, and then averaged
48329012|NCT00265967|DRUG|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
48650711|NCT06639555|PROCEDURE|Guided Tissue Regeneration(barrier membrane and PRP)|guided tissue regeneration with barrier membrane and PRP for vertical bone defects
48650712|NCT00998959|BEHAVIORAL|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
48329013|NCT05109702|DRUG|0.25% Tanfanercept Ophthalmic Solution|Tanfanercept ophthalmic solution.
48329014|NCT05109702|DRUG|Placebo|Placebo vehicle solution.
48329015|NCT01949298|PROCEDURE|dental implant placement|
48329016|NCT01670175|DRUG|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
48329017|NCT04231955|DIAGNOSTIC_TEST|numerical rating scale|patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.
48650713|NCT00998959|BEHAVIORAL|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
48650714|NCT05701345|DEVICE|OMNIFIT DTx-MDD|This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
48123076|NCT04571606|PROCEDURE|Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump|20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours
48329018|NCT04231955|OTHER|visual analogue scale|"Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
48329019|NCT04231955|OTHER|color analogue scale|"Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
48329020|NCT04231955|OTHER|faces rating scale|"Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
48329021|NCT04685499|DRUG|OBP-301|Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
48329022|NCT04685499|DRUG|Pembrolizumab|Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
48329023|NCT03277508|DEVICE|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
48329024|NCT03277508|DEVICE|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
48650715|NCT05701345|OTHER|standard treatment|"It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines."
48329025|NCT05953571|PROCEDURE|Dismembered Pyeloplasty|dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
48123077|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
48123078|NCT00639795|PROCEDURE|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
48123079|NCT03628235|BEHAVIORAL|Online survey|Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
48123080|NCT02746926|DRUG|tafamidis|
48123081|NCT05829525|OTHER|Evaluation of sleep quality, sleep duration, heart rate and step count|Evaluation of sleep quality with the Pittsburgh Sleep Quality Index Evaluation of sleep duration, heart rate, and step count with the Fitbit® Inspire 2 (Fitbit, Inc., San Francisco, California, USA) Evaluation of quality of life with the Nottingham Health Profile
48123082|NCT03074617|OTHER|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
48123083|NCT03074617|OTHER|sham field|no electromagnetic field
48123084|NCT01811706|DRUG|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
48123085|NCT01811706|DRUG|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
48123086|NCT02476435|DEVICE|Active rTMS|Strong electromagnetic fields (\~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
48123087|NCT02476435|DEVICE|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
48123088|NCT03300492|OTHER|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg."
48123089|NCT00963404|RADIATION|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
48123090|NCT03268213|BIOLOGICAL|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
48329026|NCT02906956|BEHAVIORAL|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
48329027|NCT03424577|DRUG|H3B-6527|Oral capsule
48329028|NCT06048367|DRUG|CNSI-Fe(II) 30 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
48329029|NCT06048367|DRUG|CNSI-Fe(II) 60 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
48650716|NCT06252987|OTHER|routine treatment|Routine medical treatment, basic rehabilitation training and individualized cognitive training
48123091|NCT03251222|DRUG|Dexmedetomidine|Intranasal aplication of dexmedetomidine
48123092|NCT03251222|OTHER|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
48123093|NCT01946386|DRUG|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
48123094|NCT01946386|DRUG|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
48123095|NCT01946386|DRUG|LEO 90100 Aerosol, foam, vehicle|
48123096|NCT01946386|DRUG|Daivobet® ointment|
48123097|NCT01946386|DRUG|Dermovate® cream|
48123098|NCT01946386|DRUG|Synalar® ointment|
48123099|NCT02395913|DRUG|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
48123100|NCT02395913|DRUG|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
48491169|NCT01461226|BEHAVIORAL|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
48491170|NCT01234792|DRUG|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
48491171|NCT01234792|DRUG|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
48650717|NCT06252987|OTHER|Non-invasive brain stimulation|tDCS\&rTMS
48123101|NCT02395913|DRUG|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
48123102|NCT02395913|DRUG|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
48123103|NCT05096806|OTHER|Acupuncture|Acupuncture is a non-pharmacological technique that consists in the stimulation of specific points located in the skin surface. Points are stimulated by piercing the skin with fine needles.
48123104|NCT05096806|DEVICE|TENS|TENS is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.
48491172|NCT01234792|DRUG|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
48329030|NCT06048367|DRUG|CNSI-Fe(II) 90 mg|The trial comprises a treatment period, including the DLT evaluation period with a duration of 21 days, and a maintenance treatment period. If the subject completes DLT evaluation without intolerable toxicity, an additional dose may be administered based on the investigator's determination of the benefits outweighing the risks. Three dose groups are planned \[based on Fe(II)\]: 30 mg, 60 mg, and 90 mg. A single tumor lesion amenable to intratumoral injection will be selected, regardless of tumor size, number, or location. The corresponding dose will be administered by intratumoral injection, with the injection volume determined according to the size of the injection lesion.
48329031|NCT04950842|BIOLOGICAL|JB-101|induced T cell with suppressive function
48329032|NCT01462916|DIETARY_SUPPLEMENT|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control \[I/C\] and control to intervention \[C/I\] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
48329033|NCT02663479|DIETARY_SUPPLEMENT|Cardiopressin|
48123105|NCT02371512|DEVICE|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
48123106|NCT02371512|PROCEDURE|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
48123107|NCT03346616|OTHER|Texting Group|See above in arm/group description
48123108|NCT03346616|OTHER|Non Texting Group|See above in arm/group description
48329034|NCT02663479|DIETARY_SUPPLEMENT|Placebo|
48329035|NCT02713789|DRUG|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
48329036|NCT02713789|DRUG|Placebo (PBS-20% sucrose)|
48329037|NCT04777019|OTHER|Not applicable as standard of care Colonoscopy|Not applicable since not an intervention
48329038|NCT03683056|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
48329039|NCT01713855|BIOLOGICAL|Inactivated Trivalent Influenza vaccine|
48329040|NCT02746848|BIOLOGICAL|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
48329041|NCT02765503|RADIATION|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
47973524|NCT03021122|DEVICE|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
48123109|NCT06104449|DRUG|Opevesostat|Tablets to be taken orally.
48123110|NCT06104449|DRUG|Dexamethasone|Tablets to be taken orally.
48123111|NCT06104449|DRUG|Fludrocortisone acetate|Tablet to be taken orally.
48123112|NCT06104449|DRUG|Hydrocortisone|Tablets to be taken orally as a recue medication.
48123113|NCT03046810|DEVICE|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
48123114|NCT01139944|GENETIC|DNA methylation analysis|
48123115|NCT01139944|GENETIC|polymerase chain reaction|
48123116|NCT01139944|OTHER|laboratory biomarker analysis|
48123117|NCT02365779|PROCEDURE|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
48123118|NCT02365779|DEVICE|endomicroscopy Cellvizio® system|
48123119|NCT06051955|OTHER|oral sodium sulfate|All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
48329042|NCT00383227|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
48329043|NCT05594433|DRUG|Lenograstim|Injection sub cutaneous of Lenograstim during 4 days, once per day
48329044|NCT00397176|DRUG|desvenlafaxine succinate sustained release (DVS SR)|
48329045|NCT01800279|OTHER|Physiotherapy Protocol|"Kinesitherapy~* Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~* Tongue in the palate for all applied exercises.~* Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
48329046|NCT01800279|OTHER|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~* Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~* Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~* Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
48123120|NCT03855397|OTHER|Microneedle|A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.
48123121|NCT03855397|OTHER|Hypodermic needle|30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
48329047|NCT06185894|PROCEDURE|Uterovesical tourniquet before uterine devascularization steps|Insertion of a Foley catheter tourniquet through broad ligament apertures \& tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
48329048|NCT06185894|PROCEDURE|Conventional conservative surgery|Conventional conservative surgery
48329049|NCT01769144|DEVICE|Acticoat Absorbent|wound dressing
48329050|NCT01769144|DEVICE|BCT|wound dressing
48329051|NCT02027415|DIETARY_SUPPLEMENT|Beet juice|2 cups of beet juice will be given before the car ride
48329052|NCT02027415|DIETARY_SUPPLEMENT|Orange juice|2 cups of orange juice will be given before the car ride
48329053|NCT05504577|DRUG|Tranexamic acid injection|Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
48329054|NCT05504577|DEVICE|apply the QCG|apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
48329055|NCT05504577|DEVICE|apply surgical gauze|apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
48329056|NCT05603754|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
48329057|NCT05603754|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
48329058|NCT01316029|PROCEDURE|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
48329059|NCT03986190|BEHAVIORAL|Healthy Juntos|"Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
48329060|NCT03594864|PROCEDURE|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
48329061|NCT03557515|BEHAVIORAL|Stress Management and CBT|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Cognitive Behavioral Therapy will focus on:~1. Intro to CBT-Tracking Automatic Thoughts~2. Identifying Distorted Thoughts~3. Challenging Distorted Thoughts~4. Core Beliefs/Relapse Prevention"
48329062|NCT03557515|BEHAVIORAL|Stress Management and Metta-Meditation|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Metta-Meditation will focus on:~1. Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~2. Intro to Brief Loving-Kindness Meditation and Self-Care~3. Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~4. Review/Plan for Future"
48329063|NCT00765713|DEVICE|Nasal continuous positive airway pressure|Nocturnal
48329064|NCT02898142|OTHER|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
48329065|NCT02739256|PROCEDURE|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
48329066|NCT03368040|DEVICE|Tcore|Monitoring system to measure body temperature based on heat-flux technology
48329067|NCT02822846|OTHER|lung ultrasound|
48329068|NCT03775590|PROCEDURE|Water|To evaluate using water in the treatment of atopic dermatitis
47973525|NCT03021122|DEVICE|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
48123122|NCT03855397|OTHER|Flat patch|A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
48123123|NCT02768467|PROCEDURE|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
48123124|NCT02768467|PROCEDURE|No Stitches|Subject will not receive stitches post buccal mucosa removal.
48123125|NCT05222399|DRUG|LY3871801|Administered orally.
48123126|NCT01347892|OTHER|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
48123127|NCT00678912|DEVICE|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
48650718|NCT06570226|DIETARY_SUPPLEMENT|hibiscus tea|Some cell and animal experiments have pointed out that drinking tea may be related to hypotension, body composition and vision problems, and there are more and more related advertisements, especially for hibiscus tea, which is rich in anthocyanins.
48329069|NCT03775590|PROCEDURE|Bleach|To evaluate using water + dilute bleach in the treatment of atopic dermatitis
48329070|NCT03775590|PROCEDURE|Acetic acid|To evaluate using water + vinegar in the treatment of atopic dermatitis
48329071|NCT04137419|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic strains
48329072|NCT04137419|OTHER|Placebo|Similar to ProlacSan lozenges in taste in colour
48329073|NCT03593863|BEHAVIORAL|Physical Education (PE) programme|The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
48329074|NCT05596786|DRUG|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
48329075|NCT05596786|OTHER|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
48329076|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
48329077|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
48329078|NCT02331615|DEVICE|SHAM|no meaningful stimulation will be given
48491173|NCT06123442|BEHAVIORAL|Cognitive Resilience Intervention|Participants will have 12 weeks to complete the program, and then before the post-assessment, there will be a one-month feedback period \[22\]. This includes twelve components: 1) preliminary routine, 2) significance of knowing yourself, 3) interpreting events and stressors, 4) taking autonomy over events, 5) practicing mindfulness and self-compassion, 6) learning adaptation skills, 7) building connection , 8) purpose in life and personal growth, 9) Regulation and disclosure of emotions, 10) practicing gratitude, and 11) positive Communication both intra and interpersonal, 12) overcoming obstacles and moving forward (in the context of current problems) and the conclusion/retrospection are addressed in 12 sessions while closure and post assessment will be done after a month
48491174|NCT00793494|OTHER|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
48491175|NCT00793494|OTHER|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
48498098|NCT05549518|OTHER|Core stabilization + Traditional Physical Therapy|"In addition to the traditional physical therapy training, core stabilization exercises will be applied 3 days a week for 6 weeks, and 20 minutes in each session under the supervision of a physiotherapist. Core stabilization exercises; will gradually progress from easy exercises to difficult ones. Exercises will be performed in supine, hook position, sitting position, on stable and mobile surfaces. Exercises will progress from 1 set to 3 sets, from 7 to 10 reps, contractions from 3 seconds to 10 seconds. All exercises will be performed with breathing control.~The exercises will be progressed by gradually increasing them every week."
48650719|NCT04289402|OTHER|Personalized tDCS|The participant will receive 10, 20-minutes sessions of personalized tDCS Monday-Friday, at approximately the same time of day, over two consecutive weeks.
48123128|NCT02283749|BIOLOGICAL|Xofigo|This is a radio-isotope
48123129|NCT01510977|DRUG|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
48123130|NCT01510977|DRUG|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
48123131|NCT06222983|PROCEDURE|CEA or CAS|After the patient is admitted to the hospital, the supervising doctor comprehensively evaluates the patient's general condition and adopts CEA or CAS treatment. The researcher does not provide advice to the supervising doctor and only observes safety and effectiveness
48650720|NCT04289402|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation Monday-Friday, at approximately the same time of day, over two consecutive weeks.
48650721|NCT06637995|DEVICE|Intraoperative Nerve Monitoring|Observational data collection from Locating, Stimulating, and Monitoring target nerves during a surgical procedure (clinician standard of care)
48650722|NCT05812300|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
48329079|NCT05076045|DEVICE|Personal sound amplification products|Participants will be tested with bilateral personal sound amplification products.
48329080|NCT06257537|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
48329081|NCT06257537|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
48329082|NCT06257537|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
48329083|NCT06257537|OTHER|SAM Patch|Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
48329084|NCT04449783|OTHER|pre-operative screening|reported symptoms plus nose and throat swabbing 48 hrs prior to surgery
48329085|NCT04449783|OTHER|telephone consult|telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
48329086|NCT02871401|DRUG|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
48329087|NCT02871401|DRUG|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
48329088|NCT00250406|DEVICE|Ureteral Stent|triclosan-eluting ureteral stent
48329089|NCT00250406|DEVICE|Ureteral Stent|Percuflex Plus Stent as the control
48329090|NCT01779713|GENETIC|Case-control transcriptomic study|No intervention
48498099|NCT05549518|OTHER|Traditional Physical Therapy|"Traditional physical therapy training will be given for 40 minutes each session, 3 times a week for 6 weeks under the supervision of a physiotherapist. As a traditional physical therapy program, a rehabilitation program that increases mobility and daily living activities will be applied to patients.~* Joint range of motion exercises~* Stretching exercises~* Strengthening exercises~* Bobath-based neurophysiological approaches~* Task-oriented training~* 15 minutes of neuromuscular electrical stimulation (NMES) application"
48123132|NCT06403956|OTHER|Training with video|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the video group with the hand washing video developed by the researchers within the scope of the course. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
48123133|NCT06403956|OTHER|Training with paint|The hand washing skills of the students in the three groups were evaluated by a researcher by observing the hand washing of the students in the sink with the Hand Washing Skills Checklist. After the students were given theoretical information about hand hygiene, including the importance of hand washing, the situations in which hands should be washed, and the steps of hand washing skills, the laboratory practice was started immediately afterwards. In the laboratory, hand washing training was given to the paint group with the demonstration method using acrylic paint instead of soap. Afterwards, the same researcher who made the first observation re-evaluated the handwashing skills of all students in the sink by filling out the Handwashing Skill Checklist.
48123134|NCT03085394|DRUG|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
48123135|NCT03085394|DRUG|Placebo|Preoperative intravenous administration of 10 ml saline
48123136|NCT05799742|PROCEDURE|Bilateral hernioplasty|
48123137|NCT04672018|OTHER|Houtou Jianweiling tablet|Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
48123138|NCT04672018|DRUG|Omeprazole Tablet|Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.
48123139|NCT05826860|BEHAVIORAL|Mindfulness Practice|Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
48329091|NCT02641314|DRUG|metronomic therapy|"* Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
48329092|NCT04777578|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
48329093|NCT03430583|DRUG|MZ101|Drug
48329094|NCT01078987|PROCEDURE|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
48329095|NCT06325306|BEHAVIORAL|Traditional APA|12 sessions of 1,5 hour are organized (once per week). The first session is primarily focused on the PL assessment, followed by a comprehensive introduction to physical conditioning exercises. Each of the subsequent sessions (n=10), participants will receive an intervention focused on the development of their physical fitness (endurance, strength, flexibility, balance). Each session will commence with a 15 minute warm-up comprising of a blend of cardiovascular and joint mobilization exercises. The core part of each session will be dedicated to session-specific exercises targeting key physical competencies such as endurance, strength, flexibility, and balance, along with other motor skills. . The size of the group will never exceed a number of 15 participants. At the conclusion of each session, participants will be guided through a return-to-calm sequence that included stretching and relaxation exercises.
48498100|NCT04914858|OTHER|Education|Its validity and reliability is a reliable scale in Turkey
48498101|NCT03499886|DRUG|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
48650723|NCT05257551|OTHER|Observation|No intervention
48650724|NCT05165927|DEVICE|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
48650725|NCT06675344|DEVICE|Apollo Neuro Device|The Apollo Neuro wearable device is an Apple Watch-sized wearable device that delivers vibration at set frequencies , termed transcutaneous vibratory stimulation, or TVS. These low volume sound waves feel like a soothing touch to the skin (TVS) and activate touch receptors. Apollo is controlled via smartphone and worn on the wrist or ankle. The Apollo is fitted with an adjustable band, made of a durable neoprene material with polyester overlays. Participants are asked to wear it daily for a minimum time period for 6 weeks. Users can choose from different modes of vibration, with some being energizing, others relaxing.
48650726|NCT06675344|DEVICE|Sham device|The Apollo Neuro is an Apple Watch-sized wearable device that delivers vibration, termed transcutaneous vibratory stimulation, or TVS. The sham device is identical in appearance to the active intervention, but provides a lower frequency vibration that has no known therapeutic benefit.
48123140|NCT05826860|BEHAVIORAL|Storytelling Workshop|Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
48123141|NCT04056624|DIETARY_SUPPLEMENT|High carotenoid juice|Juice with high carotenoids
48329096|NCT06325306|BEHAVIORAL|APA+PL|The general content and duration of this intervention is the same as in the traditional APA intervention, but with an extra particular and explicit emphasis on PL dimensions (6) during the sessions. While the dimension of physical competence is consistently incorporated into the sessions, the remaining 5 dimensions of PL are addressed twicely over the course of the semester with the setting of specific goals and intervention content. This could involve quizzes or games integrated into circuits or exercise workshops, role-play exercises simulating real-life situations, or social interactions between participants with a particular focus on PL-related topics. In addition to the sessions, a follow-up telephone call is scheduled between the educator and each participant during the 2 weeks following the initial PL assessment to share individual PL assessment results and assist participants in setting person-centered goals using a motivational interviewing technique.
48329097|NCT04794946|BIOLOGICAL|Covishield|2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
48329098|NCT02466165|BEHAVIORAL|Physical exercise|
48329099|NCT02576457|BIOLOGICAL|BMS-936559|
48329100|NCT02576457|OTHER|Placebo|
48329101|NCT00553553|DRUG|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
48329102|NCT00553553|DRUG|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
48329103|NCT00039741|DRUG|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
48329104|NCT00039741|DRUG|NNRTIs (EFV, NVP)|"Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor"
48329105|NCT00039741|DRUG|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|"Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor"
48329106|NCT05754697|OTHER|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
48123142|NCT04056624|DIETARY_SUPPLEMENT|Placebo control - Apple juice|Juice with negligible carotenoids
48123143|NCT01823536|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
48329107|NCT05754697|OTHER|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
48329108|NCT05754697|OTHER|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
48650727|NCT00382863|DEVICE|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
48329109|NCT01014949|OTHER|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine \[140 ug/kg/min\] to induce steady state maximal hyperemia."
48123144|NCT01017146|DRUG|Tazarotene foam|Tazarotene foam once a day application to the face
48123145|NCT01017146|DRUG|Vehicle Foam|Vehicle Foam once a day application to the face
48123146|NCT03960606|COMBINATION_PRODUCT|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
48123147|NCT03960606|COMBINATION_PRODUCT|Placebo|PUR1900 placebo
48123148|NCT04216394|PROCEDURE|Emergency general surgery|multidisciplinary surgery performed for traumatic and non-traumatic acute conditions during the same admission in the hospital.
48329110|NCT06461312|PROCEDURE|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
48123149|NCT02748317|DRUG|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
48123150|NCT02379936|DEVICE|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method"
48123151|NCT02379936|PROCEDURE|Traditional evaluation|Traditional way of evaluation
48123152|NCT02379936|DEVICE|iPhone 4S|
48329111|NCT06304519|DEVICE|Dynamic ankle-foot orthosis|customized, carbon fiber, passive ankle-foot orthosis
48329112|NCT02401087|PROCEDURE|Anaesthesiological procedure|
48329113|NCT04968964|DEVICE|DiviTum® TKa assay|-Determines serum enzymatic activity of TK1
48329114|NCT04968964|OTHER|Study Care Plans|-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
48329115|NCT06243315|DEVICE|Ellansé-S|It is indicated for subcutaneous implantation to correct moderate-to-severe NLFs
48329116|NCT03505749|BEHAVIORAL|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
48329117|NCT03505749|BEHAVIORAL|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
48329118|NCT05406557|PROCEDURE|Partial pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.
48329119|NCT05406557|PROCEDURE|Miniature pulpotomy|In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
48329120|NCT03700970|DRUG|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
48329121|NCT03700970|DRUG|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
48329122|NCT03356392|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
48329123|NCT02993913|DRUG|Simmiparib|Simmiparib Tablets, oral administration
48329124|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
48123153|NCT05231317|OTHER|Plant-based diet|16 days with all foods provided
48329125|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
48329126|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
48329127|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
48329128|NCT04794556|DEVICE|tight-fitting of KF94 mask with clip|The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
48329129|NCT03330041|DEVICE|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
48329130|NCT02920606|PROCEDURE|Pulpotomy|
48329131|NCT02920606|PROCEDURE|Endodontic treatment|
48329132|NCT04842890|RADIATION|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
48329133|NCT04715256|BEHAVIORAL|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
48329134|NCT04715256|GENETIC|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
48329135|NCT04715256|DIAGNOSTIC_TEST|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
48329136|NCT05275452|OTHER|No intervention|No intervention
48329137|NCT04173871|DEVICE|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
48329138|NCT06183632|BIOLOGICAL|blood sampling|3 x 7mL EDTA blood tubes
48329139|NCT01428999|DIETARY_SUPPLEMENT|probiotics|probiotics 1 pack (2g) bid for three weeks
48123154|NCT05231317|OTHER|Western diet|16 days with all foods provided
48123155|NCT04164316|DEVICE|Kinesio Tape|Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
48123156|NCT02579031|DEVICE|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
48329140|NCT03858608|DIETARY_SUPPLEMENT|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
48329141|NCT03858608|OTHER|Usual asthma care|Usual asthma management
48329142|NCT03838562|OTHER|Vestibular rehabilitation with virtual reality|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
48329143|NCT03838562|OTHER|Standard optokinetic stimulator or dynamic visual surround|"Both group follow three or four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
48329144|NCT05881460|DEVICE|Active vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
48329145|NCT05881460|DEVICE|Sham vibrotactile coordinated reset|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
48329146|NCT00002783|DRUG|cisplatin|
48329147|NCT00002783|DRUG|floxuridine|
48329148|NCT00002783|DRUG|fluorouracil|
48329149|NCT00002783|DRUG|leucovorin calcium|
48329150|NCT00002783|PROCEDURE|conventional surgery|
48329151|NCT06366295|DEVICE|subgingival mechanotherapy with perioscopy|Subgingival mechanotherapy using a machine scaler, curettes and a perioscope
48329152|NCT06366295|DEVICE|classical subgingival mechanotherapy|Subgingival mechanotherapy using a machine scaler and curettes
48329153|NCT00141856|BEHAVIORAL|Telephone care|
48329154|NCT04656418|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
48329155|NCT04656418|DRUG|Placebo|Buffer without active ingredient
48329156|NCT00344955|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
48329157|NCT01121003|BEHAVIORAL|weight maintenance, low sugar diet|
48329158|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet|
48329159|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet+ exercise|
48329160|NCT00288522|DRUG|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
48329161|NCT05271110|PROCEDURE|Liver resection (ablation)|Treatment of liver metastases from pancreatic cancer by surgery or ablation
48329162|NCT02297113|DEVICE|Macintosh blade|conventional endotracheal intubation
48329163|NCT02297113|DEVICE|C-MAC videolaryngoscope|
48329164|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
48329165|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
48329166|NCT02517853|DEVICE|Posterior tibial nerve stimulation|
48329167|NCT02517853|DEVICE|Sham posterior tibial nerve stimulation|
48329168|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet A|Healthy, balanced diet following Eatwell Guide recommendations
48329169|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet B|Healthy, balanced diet following Eatwell Guide recommendations
48329170|NCT05627570|BEHAVIORAL|Behavioural support intervention|Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
48329171|NCT05715944|DRUG|AZD 1222|Vaccine
48329172|NCT02787603|OTHER|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels \< 0,25ng/mL OR PCT \> 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
48329173|NCT05992168|DEVICE|Stent-Retriever|all the participants in this group will be performed with Stent-Retriever
48329174|NCT03427138|BEHAVIORAL|Jasper|Families in the joint attention intervention will receive 10 weeks of the JASPER (Joint Attention Symbolic Play Engagement Regulation) protocol. JASPER is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari at the Center for Autism Research and Treatment, at University of California, Los Angeles. Our research staff will be trained on the specific techniques of JASPER guided by Connie Kasari (consultant on project) and her colleagues The study's intervention involves 2 days/week of 60-minute sessions with a trained experimenter (which may take place in the lab or home, depending on the needs of the family). The primary goal for the intervention will be to increase the frequency and range/variety of joint attention and to advance the child to higher levels (e.g., from requesting to initiating joint attention acts).
48498102|NCT03499886|DRUG|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
48498103|NCT05765630|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
48498104|NCT02176408|BEHAVIORAL|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
48123157|NCT02579031|DEVICE|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
48329175|NCT03427138|BEHAVIORAL|Parent Education|Families in the parent education intervention. Parent education will be provided in group sessions. During the sessions information is presented about ASD, how to deal with behavioral difficulties and available services, and parents are given an opportunity to share experiences. Parents will attend a weekly session for 10 weeks. 10 different topics will be discussed, which include: causes and symptoms of autism, diagnosis process, treatment options, enhancing communicative abilities in children with autism, emotion regulation, dealing with distress, correcting behavior difficulties, applying structure and routines.
48123158|NCT05045196|BEHAVIORAL|Health promoting conversations|The Health-promoting conversations intervention is a conversation model between the patient, family members, and a trained nurse. Patients and families included in the study will, after submitting base-line-data, be randomized to
48329176|NCT05556551|OTHER|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
48329177|NCT05556551|OTHER|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
48329178|NCT04753047|OTHER|No intervention|No intervention
48329179|NCT04213040|DIAGNOSTIC_TEST|Serum levels of Procalcitonin, C-reactive protein, lactate|"Serum PCT, CRP, and lactate values were collected postoperatively every day starting on postoperative 12 hours, postoperative days 1 through 5.~After the operation, all postoperative complications were recorded during the first seven days period.~The relations between diagnostic tests and postoperative complications are sought by the use of the statistical analysis methods."
48329180|NCT06422429|DRUG|Traditional deep-fried Youtiao|45g 4 times a week for 4 months
48329181|NCT06422429|DRUG|PI Youtiao|45g 4 times a week for 4 months
48329182|NCT06016140|OTHER|Medication plan|Involved participants will jointly agreed on continued medication treatment (treatment aim, planned monitring and evaluation and responsibility, and the physician will document the plan in the electronic health record
48329183|NCT05560893|BEHAVIORAL|Relational Savoring Intervention|Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
48329184|NCT06118164|BEHAVIORAL|pursing- lip breathing combined with aerobic walking exercise|pursing- lip breathing combined with aerobic walking exercise
48329185|NCT06118164|BEHAVIORAL|pursing- lip breathing|pursing- lip breathing
48329186|NCT06118164|BEHAVIORAL|aerobic walking exercise|aerobic walking exercise
48329187|NCT05137886|DRUG|PD-1 inhibitor|decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
48329188|NCT03219892|DEVICE|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
48329189|NCT03219892|DEVICE|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
48329190|NCT04753138|DEVICE|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
48329191|NCT04753138|DEVICE|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
48329192|NCT05939037|DRUG|Zanubrutinib Oral Product|Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
48329193|NCT00000118|DEVICE|Sustained-Release Intraocular Drug Delivery System|
48329194|NCT04011124|DRUG|Fluzoparib|single dose on Day 1 and Day 12
48329195|NCT04011124|DRUG|Rifampicin|QD on Day 5-14 for 10 days
48329196|NCT05545904|BEHAVIORAL|Substance use brief intervention (BI)|The BI will be delivered in a single session (20-30 minutes) using motivational interviewing techniques and the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
48329197|NCT05545904|BEHAVIORAL|substance use education intervention|This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
48329198|NCT00660777|BEHAVIORAL|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
48329199|NCT00660777|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
48650728|NCT00382863|DRUG|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
48123159|NCT01672060|BEHAVIORAL|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
48123160|NCT01672060|BEHAVIORAL|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
48123161|NCT02411084|BIOLOGICAL|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
48123162|NCT02411084|BIOLOGICAL|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
48123163|NCT04313816|OTHER|questionnaire|no intervention at all apart from filling a brief questionnaire
48123164|NCT01850836|PROCEDURE|repetitive transcranial magnetic stimulation|
48123165|NCT04687293|DEVICE|HUBER (LPG Systems, France)|The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.
48123166|NCT02461264|DRUG|Single red blood packed cells Transfusion|
48123167|NCT02461264|DRUG|Two packed red blood cells Transfusion|
48123168|NCT00557206|DRUG|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
48123169|NCT02742571|OTHER|non applicable|
48123170|NCT04121936|OTHER|There will be no intervention|There will be no intervention
48491176|NCT02836626|PROCEDURE|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
48491177|NCT02836626|PROCEDURE|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
48650729|NCT05899959|DEVICE|Corsano CardioWatch 287-2|Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
48123171|NCT01261312|DRUG|SGI-110|"* SGI-110 subcutaneous injection administered on Days 1-5~* SGI-110 subcutaneous injection administered on Days 1-5 and 8-12"
48123172|NCT01261312|DRUG|SGI-110|"* SGI-110 administered weekly on Days 1, 8 and 15~* SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18"
48123173|NCT03109223|OTHER|sole source nutrition|Infant formula
48123174|NCT01405807|DRUG|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
48123175|NCT00788034|DRUG|Lu AA21004|5 or 10 mg/day
48123176|NCT00788034|DRUG|Placebo|Once daily
48123177|NCT04165967|DRUG|Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity."
48329200|NCT05670405|OTHER|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R\&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R\&R."
48329201|NCT02152358|DRUG|Aciclovir|Intravenous 15 mg/kg/d during 14 days
48329202|NCT02152358|DRUG|Ganciclovir|intravenous 10 mg/kg/d for 14 days
48329203|NCT02152358|DRUG|Placebo|
48491178|NCT01995266|DRUG|Asunaprevir|
48491179|NCT01995266|DRUG|Daclatasvir|
48491180|NCT03493776|BIOLOGICAL|VZV subunit vaccine|VZV subunit vaccine
48491181|NCT03358784|PROCEDURE|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
48491182|NCT03358784|PROCEDURE|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
48491183|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
48491184|NCT02415569|DRUG|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
48491185|NCT02415569|DRUG|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
48491186|NCT03533374|DIAGNOSTIC_TEST|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
48491187|NCT03440541|COMBINATION_PRODUCT|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
48491188|NCT06045819|BIOLOGICAL|Blood sampling for venetoclax drug dosage (venous puncture)|8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
48491189|NCT03329807|DEVICE|Transcranial Magnetic Stimulation|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
48491190|NCT03329807|BEHAVIORAL|conventional sensory therapy|Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week.
48491191|NCT05104463|DRUG|CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107|CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
48491192|NCT00002241|DRUG|Indinavir sulfate|
48491193|NCT00002241|DRUG|Ritonavir|
48491194|NCT00002241|DRUG|Lamivudine|
48491195|NCT00002241|DRUG|Stavudine|
48491196|NCT03760614|DRUG|Entinostat|Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
48491197|NCT03760614|DRUG|FOLFOX regimen|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
48650730|NCT06673446|PROCEDURE|vestibular socket therapy|"atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.~1. Access and Socket Preparation:~   * A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth. This creates a pouch for accessing the socket and surrounding bone.~  * Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone.~2. Immediate Implant Placement with Guide:~   \* A prefabricated surgical guide ensures precise positioning of the implants directly into the socket.~3. Bone Grafting and Membrane:~   * A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~  * A special 0.6 mm thick membrane is inserted through the access incision. This membra"
48650731|NCT05097989|DRUG|ALXN2050|Oral tablets
48491198|NCT03050008|OTHER|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
48491199|NCT03050008|OTHER|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
48650732|NCT05097989|DRUG|Placebo|Oral tablets
48650733|NCT05984992|DRUG|SRN-001|siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized
48650734|NCT05984992|DRUG|Placebo|0.9% Sodium Chloride(Normal saline)
48650735|NCT00057512|DRUG|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
48650736|NCT06642792|DRUG|AK129|Subjects receive AK129 intravenously.
48650737|NCT06642792|DRUG|AK117|Subjects receive AK117 intravenously.
48329204|NCT05443451|DEVICE|3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH|The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
48123178|NCT01574859|OTHER|levothyroxine|titration of T4 according to biochemical values
48123179|NCT00780234|PROCEDURE|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
48329205|NCT03625141|DRUG|Cobimetinib|60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
48329206|NCT03625141|DRUG|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1)."
48329207|NCT03625141|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
48329208|NCT00180271|DEVICE|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
48329209|NCT00180271|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
48329210|NCT03728140|PROCEDURE|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
48329211|NCT01894477|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
48329212|NCT01894477|DRUG|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
48329213|NCT01894477|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
48329214|NCT01894477|RADIATION|Total-Body Irradiation|Undergo TBI
48329215|NCT01894477|DRUG|Treosulfan|Intravenously administered Treosulfan
48329216|NCT01894477|OTHER|Laboratory Biomarker Analysis|Correlative Studies
48329217|NCT03676153|OTHER|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
48123180|NCT00780234|PROCEDURE|quantitative high resolution CT scan|High resolution CT scan of the chest
48329218|NCT03676153|OTHER|Integrative medicine treatment program|Integrative medicine treatment program
48329219|NCT05400187|BEHAVIORAL|Body composition assessment and smart-phone based counselling|"As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day)."
48491200|NCT02819141|DRUG|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
48123181|NCT00780234|DRUG|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
48123182|NCT00105807|BEHAVIORAL|participation in low intensity exercise|
48329220|NCT04453904|OTHER|"sequential radiochemotherapy in a sanwich mode"|Patients will randomized into two different modalities of radiochemotherapy.
48329221|NCT00719953|DIETARY_SUPPLEMENT|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
48491201|NCT02244879|DIETARY_SUPPLEMENT|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
48491202|NCT04173299|PROCEDURE|early tips|patients with early tips
48650738|NCT06374979|BIOLOGICAL|Ixekizumab|Participants will receive an initial dose of 160 mg (two injections of 80 mg) ixekizumab subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.
48650739|NCT06045247|DRUG|Prednisone|Given by IV (vein)
48650740|NCT06045247|DRUG|Rituximab|Given by IV (vein)
48650741|NCT06045247|DRUG|Cyclophosphamide|Given by IV (vein)
48650742|NCT06045247|DRUG|Vincristine|Given by IV (vein)
48650743|NCT06045247|DRUG|Epcoritamab|Given under the skin
48329222|NCT01017887|DEVICE|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
48329223|NCT01017887|DEVICE|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
48329224|NCT02243917|DRUG|CB-5083|
48329225|NCT04027101|DRUG|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
48329226|NCT04027101|DRUG|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
48123183|NCT00105807|BEHAVIORAL|participation in art and music activities|
48329227|NCT00405652|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
48329228|NCT02079558|DRUG|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
48329229|NCT02079558|DRUG|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
48329230|NCT00000341|DRUG|Buprenorphine|
48329231|NCT00834886|DIETARY_SUPPLEMENT|Melatonin|Capsules, 3 mg, once every night
48329232|NCT00834886|OTHER|Bright light|Bright light therapy 10.000 lux by Miljølys AS
48329233|NCT00834886|OTHER|Placebo red light|Red light 400 lux as placebo light
48329234|NCT00834886|OTHER|Placebo capsule|Capsules containing 3 mng rice flour, once every night
48329235|NCT05821348|DIAGNOSTIC_TEST|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
48491203|NCT02550730|BEHAVIORAL|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
48491204|NCT02550730|OTHER|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
48491205|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3|600 IU Vitamin D3 capsule daily
48123184|NCT02318901|DRUG|Pembrolizumab|
48123185|NCT02318901|DRUG|Trastuzumab|
48123186|NCT02318901|DRUG|ado-trastuzumab emtansine|
48123187|NCT02318901|DRUG|Cetuximab|
48329236|NCT03260907|PROCEDURE|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6\~13.9mA).
48329237|NCT03260907|PROCEDURE|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
48329238|NCT06364644|BEHAVIORAL|Community Champions|The UNLOAD-Heart Failure Program intervention includes problem solving training, community health worker support, and exercise support from health coaches at YMCAs.
48123188|NCT06439732|DEVICE|Acumen IQ cuff|Use of Acumen IQ cuff for haemodynamic monitoring
48123189|NCT00004440|DRUG|ibuprofen|
48123190|NCT00338442|DRUG|VariZIG™|Biological / Vaccine
48123191|NCT00616031|DRUG|carboplatin|
48123192|NCT00616031|DRUG|nitroglycerin|
48123193|NCT00616031|DRUG|paclitaxel|
48123194|NCT03094182|DRUG|Iron Isomaltoside 1000|Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
48123195|NCT03094182|DRUG|Normal saline|Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
48123196|NCT00203411|DRUG|Capecitabine (Xeloda)|1000mg/m\^2 administered orally twice daily for two weeks followed by one week rest period
48329239|NCT06364644|BEHAVIORAL|Homegrown Heroes|Monthly newsletters/videos on diabetes self-management, healthy lifestyle and heart failure prevention will be provided, as well as a membership to the local YMCA.
48329240|NCT02022033|DRUG|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
48329241|NCT01473329|OTHER|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
48329242|NCT05133544|DEVICE|Endocuff with AI|Use of endocuff with computer assisted polyp detection
48329243|NCT05133544|DEVICE|AI alone|Use of computer assisted polyp detection
48329244|NCT05871593|GENETIC|Molecular genetic diagnostic|With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
48329245|NCT04783285|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
48329246|NCT00544011|BIOLOGICAL|bevacizumab|
48329247|NCT00544011|DRUG|capecitabine|
48329248|NCT00544011|DRUG|fluorouracil|
48329249|NCT00544011|DRUG|irinotecan hydrochloride|
48329250|NCT00544011|OTHER|diagnostic laboratory biomarker analysis|
48329251|NCT02524756|PROCEDURE|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
48329252|NCT02524756|PROCEDURE|laparoscopic radical hysterectomy (type III/C2).|
48329253|NCT02658344|BIOLOGICAL|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection
48329254|NCT02658344|DRUG|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
48329255|NCT02636920|OTHER|Therapeutic Education to the Patient (TEP)|"* Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~* Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~* Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~* Assessing of the knowledges acquired by patients."
48329256|NCT00717535|OTHER|cryopreservation|
48329257|NCT00717535|OTHER|questionnaire administration|
48329258|NCT00717535|OTHER|study of socioeconomic and demographic variables|
48123197|NCT00203411|DRUG|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
48329259|NCT06105567|BEHAVIORAL|Training given according to the health promotion model by applying the Philips 66 technique|The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
48329260|NCT04496648|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
48329261|NCT04496648|PROCEDURE|Sham-percutaneous coronary intervention|Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
48329262|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
48329263|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
48329264|NCT00071422|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
48491206|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
48491207|NCT00571285|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given once a week
48123198|NCT00908505|PROCEDURE|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
48329265|NCT06303349|OTHER|Samples collection|"from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected.~1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it."
48329266|NCT00695708|BEHAVIORAL|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
48329267|NCT00695708|BEHAVIORAL|Cogpack|Computer-aided cognitive program for cognitive abilities
48329268|NCT01619163|DRUG|Placebo|
48329269|NCT01619163|DRUG|Prednisolone|low dose, 7.5 mg/day
48329270|NCT03718702|OTHER|ePain|Electronic pain management programme (ePain)
48329271|NCT01841528|OTHER|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
48491208|NCT00038649|DRUG|Gleevec|400 mg orally twice daily
48491209|NCT02515760|PROCEDURE|Bone marrow aspiration from the iliac crest|
48123199|NCT05557006|PROCEDURE|left bundle branch pacing|In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.
48123200|NCT05308056|DEVICE|Depth of anesthesia monitor, SedLine® (Masimo, Irvine, CA, USA)|The device monitors the patient's electroencephalogram using electrodes applied to the forehead.
48123201|NCT02201134|DRUG|sevoflurane|
48491210|NCT02515760|DEVICE|Illinois bone marrow aspiration neddle|
48491211|NCT04120090|DRUG|low dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
48491212|NCT04120090|DRUG|high dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
48491213|NCT01066091|OTHER|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
48491214|NCT01066091|OTHER|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
48123202|NCT05191810|BEHAVIORAL|Educational information|Educational information about non-pharmacological supporting treatment of functional constipation, involving recommendation of adequate for age fluid intake
48123203|NCT01967836|DEVICE|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
48123204|NCT01367405|PROCEDURE|Surgical decompression|Surgical decompression within 24 hour postinjury
48329272|NCT01841528|OTHER|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
48123205|NCT01367405|PROCEDURE|Conservative treatment|Usual conservative treatment without surgery
48329273|NCT01237561|OTHER|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
48329274|NCT05408117|DEVICE|5-0 Polypropylene epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
48329275|NCT05408117|DEVICE|5-0 Fast gut epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
48329276|NCT03752333|DRUG|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
48329277|NCT04675606|BEHAVIORAL|Regular diet|Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
48329278|NCT04675606|BEHAVIORAL|Low fiber diet|Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
48329279|NCT05096494|DRUG|SP-103|SP-103 topical system is worn daily for 12 hours per day for 28 days
48329280|NCT05096494|DRUG|Placebo|Placebo topical system is worn daily for 12 hours per day, for 28 days
48123206|NCT04987294|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
48123207|NCT04987294|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
48123208|NCT00078624|OTHER|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
48123209|NCT00078624|OTHER|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
48123210|NCT01634516|BEHAVIORAL|Dietary support|Face to face intervention plus subsequent telephone support
48123211|NCT01634516|BEHAVIORAL|No dietary support|No face to face intervention or subsequent telephone support
48123212|NCT01420458|DRUG|Experimental|Bioequivalence of two drug formulations
48123213|NCT06482632|PROCEDURE|Discectomy of Omohyoid|Will be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
48123214|NCT06482632|PROCEDURE|Control group no discectomy of Omohyoid|Will not be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
48123215|NCT02990117|OTHER|No Intervention|No Intervention
48329281|NCT02485548|DRUG|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
48329282|NCT02485548|DRUG|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
48329283|NCT02485548|DRUG|Cisplatin|All patients will receive concurrent cisplatin.
48329284|NCT02485548|RADIATION|IMRT|All patients will receive IMRT
48329285|NCT03046160|OTHER|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
48329286|NCT03046160|OTHER|neck and scapular exercises.|A program of 12 neck and scapular exercises.
48123216|NCT03292913|BEHAVIORAL|Positive Health Check|Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
48123217|NCT03292913|BEHAVIORAL|Standard of Care|Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
48123218|NCT02089763|BIOLOGICAL|pegylated recombinant human arginase|
48123219|NCT00741455|PROCEDURE|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
48123220|NCT00741455|DRUG|G-CSF|10 mcg/kg/day on days 5, 6, and 7
48123221|NCT00741455|DRUG|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
48123222|NCT00741455|DRUG|cyclophosphamide|1 g/m2/d IV on days -3 and -2
48123223|NCT00741455|DRUG|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
48329287|NCT03046160|OTHER|corrective tape|elastic tape used to correct the anterior tilt of the scapula
48123224|NCT00741455|DRUG|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
48123225|NCT04124042|BIOLOGICAL|XT-150|plasmid DNA
48123226|NCT04124042|DRUG|Placebo|Placebo is a sterile phosphate-buffered saline
48123227|NCT02830906|DRUG|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
48329288|NCT06138886|DEVICE|Pulsed electromagnetic therapy group|The appliance will be connected to electrical mains supplying 230V± 10%. The solenoids are adjusted to be over the upper abdominal area. The options of the appliance are adjusted with very low frequency (15 HZ), very low intensity (20 G) for 20 minutes, and 3 sessions / week for successive 3 months.
48329289|NCT02541448|DEVICE|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar \& Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
48329290|NCT04911699|BEHAVIORAL|breast adenocarcinoma receiving chemotherapy|for chemotherapy
48329291|NCT04911699|BEHAVIORAL|Control-for|hormonal drug treatment
48329292|NCT04879784|OTHER|No intervention|No intervention
48329293|NCT02317341|DRUG|Ketamine|Single intravenous dose
48329294|NCT02317341|DRUG|Placebo (saline)|Given intravenously over 40 minutes
48329295|NCT02317341|DRUG|Ketamine|Single intravenous dose given over 40 minutes
48123228|NCT02830906|DRUG|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
48123229|NCT01895699|OTHER|Contrast agent|
48123230|NCT02416115|DRUG|Ramosetron|Ramosetron was given iv.
48123231|NCT02416115|DRUG|Naloxone|Naloxone added to PCA was given iv.
48123232|NCT02416115|DRUG|saline|Saline was given iv.
48123233|NCT02416115|DRUG|Morphine|Morphine in the PCA was given iv.
48123234|NCT04292132|PROCEDURE|Implant placement|interforaminal placement of 2 implants
48123235|NCT04292132|PROCEDURE|immediate loading|immediate loading with a locator retained mandibular overdenture
48123236|NCT04292132|PROCEDURE|conventional loading|conventional loading with a locator retained mandibular overdenture 3 months postoperatively
48491215|NCT01066091|OTHER|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
47973526|NCT00873223|DRUG|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
48329296|NCT02317341|DRUG|Midazolam|Given intravenously over 40 minutes
48650744|NCT06640803|BEHAVIORAL|Stepped-Care including Cognitive Behavioral Case Management|Step 1:assessment and feedback, general engagement strategies, assessment of needs and social determinants of health, begin case management, goal setting. Step 2: TAU. Initiation of team-based care at community clinics and 'enhanced monitoring'. Step 3: atheoretically-based stress management skills (stress thermometer, coping skills and coping plans), problem solving strategies. Step 4: targeted intervention for CHRp. Initiation of formulation-based CBT modules, therapy consultation groups with the UC Davis team (UCD), regular meetings between clinic leadership and UCD. Participants may switch providers to increase level of early psychosis specialization. Step 5: add prescriber consultation groups with UCD. Step 6: assessment of trauma and family conflict then Family-Focused Therapy, Trauma-Focused Cognitive Behavioral Therapy, or CBT for CHR at UCD. Termination: At 24 months, referral to UCD coordinated specialty care clinic or other appropriate service for those still CHRp+.
48650745|NCT06671210|DEVICE|Urine and vaginal swab self-control|Each participant provided urine and vaginal swabs for HPV testing.
48650746|NCT00221221|DEVICE|Pedometer|
48491216|NCT04402775|OTHER|Tourniquet|A tourniquet will be used during surgery
48491217|NCT04205396|BEHAVIORAL|Written emotional disclosure|Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
48491218|NCT04205396|BEHAVIORAL|Resilience training|Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
48491219|NCT04205396|OTHER|No treatment|Participants will complete baseline and outcome assessments and no intervention will be conducted.
48650747|NCT00221221|DEVICE|Exercise guidebook|
48650748|NCT01714063|DEVICE|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
48650749|NCT02431026|DEVICE|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
47973527|NCT00873223|DRUG|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
47973528|NCT05188690|OTHER|Data collection from medical records|Data collection from medical records
47973529|NCT03647397|DEVICE|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
47973530|NCT01020227|BEHAVIORAL|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
47973531|NCT06331416|DEVICE|Telemonitoring|Patients will be asked to carry out one measurement (arterial pressure, oxygen saturation, body temperature, heart rate, spirometry) every 24 hours for 90 days. The system will be supplied by the company Vivisol. The telemonitoring data will be read once a day and the principal investigator will be alerted in case of alteration of any parameter. If vital parameters remain stable, a phone call will be performed every 5 days. In case of compromise of any parameter, the patient will be offered a phone call within the same day. In case of new occurrence of any respiratory or non-respiratory symptoms, the patient must contact the principal investigator and he will be offered a phone call or a video-assisted call within the same day. If the alterations or symptoms persist for 24 hours, or in any case upon decision of the investigator in charge, the patient will be offered an in-person evaluation in the same day. If deemed necessary according to usual care, the patient will be hospitalized.
48329297|NCT02317341|DRUG|Midazolam(placebo)|Given intravenously over 40 minutes
48329298|NCT03979027|DIETARY_SUPPLEMENT|Breakfast: ready-to-eat-cereal and milk|
48329299|NCT00516984|PROCEDURE|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
48329300|NCT00516984|PROCEDURE|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
48329301|NCT00516984|PROCEDURE|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
48650750|NCT06133270|DRUG|NNC0560-0004|NNC0560-0004, Oral administration (taken through the mouth)
48650751|NCT06133270|DRUG|Placebo (NNC0560-0004)|Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
48650752|NCT02414841|DRUG|Vonapanitase|
48650753|NCT02414841|DRUG|Placebo|
48650754|NCT04812015|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS) 15 minutes|Sham 60 minutes and taVNS active stimulation for 15 minutes
48650755|NCT04812015|DEVICE|taVNS 30 minutes|Sham 45 minutes and taVNS active stimulation for 30 minutes
47973532|NCT04059978|DRUG|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
47973533|NCT04059978|DRUG|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
48123237|NCT03344588|PROCEDURE|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
48329302|NCT01661166|DRUG|Fesoterodine|4 mg
48329303|NCT01661166|DRUG|Placebo oral tablet|Placebo
47973534|NCT04059978|DRUG|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
47973535|NCT05083962|BEHAVIORAL|Healthy Lifestyle Program|An intensive behavior change curriculum designed to help create and sustain healthy habits
47973536|NCT02054091|DIETARY_SUPPLEMENT|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
47973537|NCT03911804|PROCEDURE|bolus group and infusion group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
47973538|NCT00084721|DRUG|celecoxib|
47973539|NCT00084721|DRUG|irinotecan hydrochloride|
47973540|NCT03444961|DEVICE|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
47973541|NCT01801891|DEVICE|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
47973542|NCT01801891|OTHER|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
47973543|NCT05693896|BEHAVIORAL|Centering Appetite|A digital treatment of Appetite Awareness Treatment (AAT) and behavioral weight loss treatment (BWL) over 6 months, delivered remotely using Zoom. The goal of AAT is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain.
47973544|NCT01053416|PROCEDURE|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
47973545|NCT04374032|DRUG|metenkefalin + tridecactide|ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
47973546|NCT04374032|DRUG|The standard of care|The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
47973547|NCT00854477|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
47973548|NCT00111345|DRUG|Anthracyclines|3x12 mg/qm
47973549|NCT00111345|DRUG|liposomal daunorubicin|3x80 mg/qm
47973550|NCT00111345|DRUG|2-CDA|2x6 mg/qm
48123238|NCT03344588|PROCEDURE|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
48123239|NCT03567941|DRUG|Placebo|Tablet orally administered under fasting
48123240|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 1|Tablet orally administered under fasted conditions
48329304|NCT03517449|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
48329305|NCT03517449|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
48329306|NCT03517449|DRUG|Paclitaxel|80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
47973551|NCT00111345|DRUG|AI|AI
47973552|NCT04422470|OTHER|Non-interventional study|Non-interventional study
47973553|NCT04226001|OTHER|Quality of life questionnaire|Quality of life questionnaire
47973554|NCT01880840|DRUG|205.5 mcg of azelastine hydrochloride|nasal spray
48123241|NCT03567941|DRUG|Hydrocodon bitartrate-acetaminophen arm 2|Tablet orally administered under fed conditions
48123242|NCT03567941|DRUG|Reference|Tablet orally administered under fasted conditions
48123243|NCT06516328|OTHER|Observational|GCF and saliva samples obtained.
48329307|NCT03517449|DRUG|Doxorubicin|60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
48329308|NCT00936117|DRUG|Posaconazole|200 mg (liquid) by mouth 3 times per day.
48329309|NCT04235439|DRUG|Gan & Lee Insulin Lispro Injection|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
48329310|NCT02881983|OTHER|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
48329311|NCT05733364|DIETARY_SUPPLEMENT|Capsules with B vitamins & taurine|Administered orally in a span of 28 days between mealtimes
48329312|NCT05733364|OTHER|Microcrystalline cellulose placebo|Administered orally in a span of 28 days between mealtimes
48340214|NCT05430204|DEVICE|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
47973555|NCT01880840|DRUG|137 mcg of azelastine hydrochloride|nasal spray
48329313|NCT06332027|DIAGNOSTIC_TEST|Hystro-Salpingo-Foam-Sonography (HYFOSY)|antibiotic prophylaxis oral azithromycin 500 mg per day 3 days the patient lie in dorsal lithotomy cervix visualized by Cusco speculum, cleaned with betadine 7% 6-Fr pediatric Foley's balloon catheter will be introduced into the cervical canal inflated with 2 ml of saline to prevent backflow of contrast through the cervix TV-US probe will be introduced,The foam will be created by mixing 3-4ml of 2% rialocaine gel (lidocaine hydrochloride 2%, Riadh Pharma,Saudi Arabia) with 16-17 ml of saline shaking the mixture between two syringes until a whitish suspension 20ml of lidocaine foam infused into uterine cavity observing the flow in each fallopian tube using greyscale and power Doppler (PD) 2D ultrasound Foam flow over the whole length of the tube fimbrial outflow, or peritoneal spillage of contrast provided evidence of tubal patency Patients observed for15-30 min for any complication or increase in pain Comparison between results and that of laparoscopy in operative list
48329314|NCT03689881|DEVICE|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
48329315|NCT01877824|OTHER|Fast-track training|
48329316|NCT00292747|DRUG|Drotaverine|
48329317|NCT00292747|DRUG|Drotaverine Placebo|
48329318|NCT00292747|DRUG|Ibuprofen|
47973556|NCT03777878|DRUG|Carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
47973557|NCT03777878|DRUG|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
47973558|NCT03777878|DRUG|TA|2 ampoules of TA in 100 ml saline by slow infusion
47973559|NCT03777878|DRUG|placebo to carbetocin|placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
47973560|NCT03777878|DRUG|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
47973561|NCT03777878|DRUG|placebo to oxytocin|two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
47973562|NCT03036046|DRUG|F901318 with fluconazole low dose|adverse events
47973563|NCT03036046|DRUG|F901318 with fluconazole high dose|adverse events
47973564|NCT03036046|DRUG|F901318 with posaconazole|adverse events
47973565|NCT03752294|DRUG|Dabigatran|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
47973566|NCT03752294|DRUG|Placebo - Cap|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
47973567|NCT05571540|BIOLOGICAL|U-CAR-T Cells (LstCAR019)|"LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion."
47973568|NCT00888368|PROCEDURE|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
48329319|NCT00292747|DRUG|Ibuprofen Placebo|
48329320|NCT02513771|DRUG|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
48329321|NCT02513771|DRUG|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
48329322|NCT03120364|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
48329323|NCT03120364|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
48329324|NCT04863937|DEVICE|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
47973569|NCT00888368|PROCEDURE|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
48123244|NCT03067948|BEHAVIORAL|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
48329325|NCT05576610|PROCEDURE|Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
48491220|NCT05533398|OTHER|Stress ball use|They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work. Patients with arteriovenous fistula or arteriovenous graft were instructed to use the stress ball with the other hand, where there was no vascular access.
48491221|NCT04449757|DRUG|Bicarbonated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
48491222|NCT04449757|DRUG|Lactated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
47973570|NCT03933345|OTHER|Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.|At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
48123245|NCT04760938|BEHAVIORAL|Outdoor Behavioral Healthcare (OBH)|Participants in this intervention will participate in one of 7 programs that have been accredited by the Outdoor Behavioral Healthcare Council that specializes in 13-17 year old adolescents experiencing behavioral healthcare issues. Each program works in a unique wilderness setting in various United States National Forests and Parks (e.g., Washington, Oregon, New Mexico, Wisconsin, Utah). The average length of stay in an OBH wilderness program is 90 days, which is a total standard care time of 1,056 hours. All of the OBH programs have been accredited by the Association for Experiential Education Accreditation for Outdoor Behavioral Healthcare programs.
48123246|NCT04760938|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The 12-week treatment period will consist of 15 90-minute sessions that will be administered individually. Homework (including reading assignments) are given to encourage your child to practice the techniques learned during the weekly sessions. The total standard of care time for CBT is 22.5 hours of direct treatment hours not including time spent on homework over these twelve weeks. Those therapists that are selected to deliver treatment for the CBT group will be certified by a nationally recognized CBT organization and licensed to work as a therapist in the state where they are providing treatment. Therapy will be delivered in an outpatient setting or through Telehealth.
48123247|NCT00002383|DRUG|Saquinavir|
48123248|NCT04190316|OTHER|Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU|ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
48123249|NCT02742519|DRUG|ivacaftor|
48123250|NCT02742519|DRUG|Placebo|
48329326|NCT05576610|PROCEDURE|Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
47973571|NCT01335984|PROCEDURE|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
47973572|NCT01335984|PROCEDURE|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
47973573|NCT01335984|OTHER|control group|"- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
47973574|NCT03725280|PROCEDURE|IVF|None interventional study (Collection of ovarian follicular fluid during IVF treatment)
48491223|NCT05215080|DIETARY_SUPPLEMENT|Organic Formula Milk|Organic formula milk is given to the infants three times a day for three months. Each serving contains 7 spoons (1 spoon contain 4,6 grams) of milk powder and 210 ml of water.
48491224|NCT05355714|DEVICE|Sofwave|High-Frequency Non-Focused Ultrasound Device
47973575|NCT01900704|DRUG|SER120 750 ng|SER120 750 ng
48123251|NCT03062813|DRUG|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
48650756|NCT04812015|DEVICE|taVNS 45 minutes|Sham 30 minutes and taVNS active stimulation for 45 minutes
48650757|NCT04812015|DEVICE|taVNS 60 minutes|Sham 15 minutes and taVNS active stimulation for 60 minutes
48650758|NCT04812015|DEVICE|taVNS 75 minutes|Sham 0 minutes and taVNS active stimulation for 75 minutes
48650759|NCT04812015|DEVICE|taVNS 0 minutes|Sham taVNS 75 minutes
47973576|NCT01900704|DRUG|SER120 1500 ng|SER120 1500 ng
48123252|NCT03062813|DRUG|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
48123253|NCT02755116|DRUG|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
48123254|NCT02755116|DRUG|Placebo|placebo by mouth prior to anesthetic induction
48123255|NCT00411151|DRUG|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
48123256|NCT02584829|DRUG|Avelumab|Given IV
48123257|NCT02584829|OTHER|Laboratory Biomarker Analysis|Correlative studies
48123258|NCT02584829|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
48123259|NCT02584829|RADIATION|Radiation Therapy|Undergo radiation therapy
48123260|NCT02584829|BIOLOGICAL|Recombinant Interferon Beta|Given via intra-tumor injection
47973577|NCT01900704|DRUG|Placebo|Placebo
47973578|NCT00174278|DRUG|Somatropin|
47973579|NCT03438344|BIOLOGICAL|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
48329327|NCT04083001|DEVICE|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
47973580|NCT03438344|OTHER|Laboratory Biomarker Analysis|Correlative studies
47973581|NCT03438344|OTHER|Placebo|Given IM
47973582|NCT00314912|DRUG|Tramiprosate (3APS)|
47973583|NCT00350909|BEHAVIORAL|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
47973584|NCT06333145|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in adults of different BMI groups undergoing drug-induced sleep endoscopy
47973585|NCT06382792|PROCEDURE|proximal humeral resection for tumor and allograft prosthetic composite reconstruction|allograft prosthetic composite
47973586|NCT01129479|DRUG|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
48123261|NCT04728906|DEVICE|Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells|heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)
48123262|NCT00345150|DRUG|Ng-monomethyl-L-arginine (drug)|
48123263|NCT05631405|DRUG|Dexamethasone|Patients treated with dexamethasone
48123264|NCT05631405|DRUG|Placebo|Patients treated with placebo
48123265|NCT03023800|PROCEDURE|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
47973587|NCT01129479|DRUG|Placebo pill|Placebo pill each morning with food for 12 weeks.
47973588|NCT04051723|DRUG|The dexamethasone plus ropivacaine|The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
47973589|NCT04051723|DRUG|The ropivacaine|The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
47973590|NCT04655898|DRUG|[14C]CC-90001|Oral
48123266|NCT03023800|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
48123267|NCT05182385|DRUG|Blinatumomab|"All patients with hematological relapse will additionally receive Blinatumomab immunotherapy (first cycle: 9 ug/d c.i.v. on d1 until d7 and 28 ug/d c.iv. on d8 until d28; second cycle: 28 ug/d c.iv. on d1 to d28) in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab).~All patients with molecular relapse will additionally receive Blinatumomab immunotherapy at 28 ug/d c.iv. on d1 until d28 in six-week cycles (4 weeks on Blinatumomab, 2 weeks off Blinatumomab.)~Patients eligible for a second cycle shall not receive Blinatumomab starting dose independent from relapse type."
48123268|NCT05182385|DRUG|Venetoclax|"In phase I of the study all eligible patients will receive increasing doses of Venetoclax on days -7 to -1 (Venetoclax dose-titration) in the first cycle and continuous dosing of Venetoclax at a pre-specified target dose (TD, p.o., once daily, d1 to d42) in six-week cycles for a maximum of two cycles.~In phase II of the study all eligible patients will receive the recommended phase 2 dose (RP2D) of Venetoclax in six-week cycles for a maximum of two cycles. RP2D will be MTD.~Patients eligible for a second cycle shall not receive Venetoclax dose-titration independent from relapse type."
48123269|NCT00771160|DRUG|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
48491225|NCT05355714|DEVICE|Ultherapy|Microfocused Ultrasound with Visualization
48329328|NCT04255017|DRUG|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
48123270|NCT05079646|OTHER|class 1 and class 2 cavity preparation and restored with contemporary materials|class 1 and class 2 cavities prepared in extracted teeth after endodontic procedure and then these cavities were filled with new contemporary core buildup materials.
48123271|NCT04702256|DRUG|Obinutuzumab administration|"Obinutuzumab administration by intravenous infusion (IV), IV of methylprednisolone, oral mycophenolate mofetil, no prednisone (or if required for extrarenal manifestation(s): less than 10mg/day at any time, less than 7.5mg/day after 6 months and less than 5mg/day after 9 months).~Hydroxychloroquine will be strongly recommended for all the patients."
48123272|NCT04702256|DRUG|Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil|"IV of methylprednisolone, oral prednisone (according to the PNDS), and oral mycophenolate mofetil.~Hydroxychloroquine will be strongly recommended for all the patients."
48329329|NCT04255017|DRUG|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
48329330|NCT04255017|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
48329331|NCT00828503|DRUG|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
48329332|NCT00828503|DRUG|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
47973591|NCT04357678|OTHER|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
47973592|NCT04357678|OTHER|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
48123273|NCT04702256|DRUG|Administration of methylprednisolone, paracetamol and dexchlorpheniramine|Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
48123274|NCT00088413|BIOLOGICAL|PANVAC-V|Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.
48123275|NCT00088413|BIOLOGICAL|PANVAC-F|Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.
48123276|NCT00088413|DRUG|Sargramostim (GM-CSF, Leukine)|100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
48329333|NCT01103778|DRUG|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
48329334|NCT02562872|DRUG|DSM265|DSM265 400 mg single oral dose
48123277|NCT03005197|DEVICE|Laser Doppler Flowmetry|
48329335|NCT02562872|DRUG|Placebo|Placebo to match DSM265, single oral dose
48329336|NCT02562872|BIOLOGICAL|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
48329337|NCT02562872|BIOLOGICAL|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
48329338|NCT03296852|DIAGNOSTIC_TEST|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
48329339|NCT03296852|DRUG|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
48329340|NCT00526461|DRUG|HPPH|IV
48329341|NCT01095068|BEHAVIORAL|Physical exercise|
48329342|NCT05351333|OTHER|placebo|Sugar pill, with an essential-oil smell and of blue color used for conditioning.
48491226|NCT03846713|PROCEDURE|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
48491227|NCT03846713|PROCEDURE|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
48491228|NCT01689662|DRUG|Tc 99m EC20|
48491229|NCT04250948|DRUG|JS001|JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.
48329343|NCT05067452|OTHER|Food support|Diabetes-tailored food support. Project Open Hand will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
48329344|NCT05067452|OTHER|Case-management|"Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition"
48329345|NCT05466734|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
48329346|NCT05466734|DRUG|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
48329347|NCT02924818|OTHER|Clinical assessment|
48329348|NCT02924818|BEHAVIORAL|questionnaires|
48329349|NCT02924818|OTHER|pulmonary function test|
48329350|NCT02924818|BIOLOGICAL|blood test|
48329351|NCT02924818|BIOLOGICAL|microbiology|
48329352|NCT02924818|BIOLOGICAL|histology|
48329353|NCT02924818|OTHER|imaging|
48329354|NCT03771404|OTHER|blood sampling|Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
48329355|NCT01540968|BEHAVIORAL|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
48329356|NCT05867199|BEHAVIORAL|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
48329357|NCT04694625|OTHER|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
48329358|NCT04694625|OTHER|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
48329359|NCT00769236|OTHER|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
48329360|NCT00769236|OTHER|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
48329361|NCT00769236|OTHER|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
48329362|NCT03167164|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
48329363|NCT03167164|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
48329364|NCT03167164|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
48329365|NCT03167164|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
48329366|NCT03167164|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48329367|NCT03167164|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48329368|NCT03167164|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
48329369|NCT03167164|DRUG|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
48329370|NCT03167164|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
48329371|NCT03167164|RADIATION|Stereotactic Body Radiation Therapy|radiation
48329372|NCT03167164|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48329373|NCT03167164|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
48329374|NCT03167164|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
48329375|NCT03167164|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
48329376|NCT03167164|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
48329377|NCT04563819|GENETIC|Genom-wide association study (GWAS) and biological pathway analyses|
48329378|NCT02181036|OTHER|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
48329379|NCT03078023|DEVICE|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
48329380|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
48329381|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
48329382|NCT03310580|DRUG|AR-13324 Ophthalmic Solution Placebo|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
48329383|NCT02824848|BEHAVIORAL|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
48329384|NCT02824848|BEHAVIORAL|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
48329385|NCT01758211|PROCEDURE|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
48329386|NCT01758211|PROCEDURE|conventional resection|conventional resection in AVM patients
48329387|NCT03924310|DEVICE|FeetBack System Active|Commercially available hand prosthesis with feedback device turned on
48329388|NCT03924310|DEVICE|FeetBack System Passive|Commercially available hand prosthesis with feedback device turned off
48329389|NCT02238548|BIOLOGICAL|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
48329390|NCT02238548|OTHER|Raw milk|
48329391|NCT05982639|PROCEDURE|two lung ventilation|The intervention do not involve a drug or device. It will be compared two different approaches to ventilate the lungs during the procedure . In this arm both lungs will be ventilated inserting a disposable trocar into the pleural cavity, and insufflating CO2 into the thoracic cavity via an insufflator. The insufflation pressure and the flow rate will be set as 8 mmHg and 10 l.min-1, of the cavity with CO2. The insufflator will be adjusted for cavity pressure in 8mmHg and flow of 10L/min.
48329392|NCT05982639|PROCEDURE|one lung ventilation|In this arm only one lung (the contralateral lung) will be ventilated using a Carlens type orotracheal tube
48329393|NCT02079051|BEHAVIORAL|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
48329394|NCT02079051|BEHAVIORAL|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
48329395|NCT05666882|OTHER|Non-interventional|Non-interventional
48650760|NCT02757963|OTHER|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score \>=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
48329396|NCT00684112|DRUG|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
48329397|NCT00684112|DRUG|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
48329398|NCT01022385|DIETARY_SUPPLEMENT|24-hour low-residual diet|
48329399|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
48329400|NCT05637801|DEVICE|Sensory Stimulation System (GS120) - Sham|Sensory Stimulation System (GS120) - Sham settings
48329401|NCT04701047|DEVICE|vaginal pessary|insertion and follow up of a vaginal pessary
48491230|NCT04250948|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w
48491231|NCT04250948|DRUG|S1|S-1: 40\~60mg Bid，d1\~14, q3w
48491232|NCT04250948|DRUG|Capecitabine|Capecitabine: 1000mg/m2 Bid，d1-14, q3w
48491233|NCT02310243|DRUG|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
48491234|NCT02377063|DIETARY_SUPPLEMENT|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
48123278|NCT03844919|DEVICE|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
48123279|NCT03844919|BEHAVIORAL|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
48123280|NCT01620684|DRUG|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
48123281|NCT01620684|DRUG|placebo|placebo capsules
48123282|NCT02724592|DEVICE|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
48123283|NCT02724592|DEVICE|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
48123284|NCT01104675|DRUG|ENMD-2076|275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
48123285|NCT00071253|DRUG|Divalproex Sodium (Delayed-Release Tablets)|
48123286|NCT00071253|DRUG|Divalproex Sodium (Extended-Release Tablets)|
48123287|NCT00071253|DRUG|Olanzapine|
48329402|NCT04701047|PROCEDURE|Vaginal prolapse surgery|surgery and follow up after vaginal prolapse surgery
48123288|NCT00549848|DRUG|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
48123289|NCT00549848|DRUG|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
48650761|NCT02757963|OTHER|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score \>=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
48123290|NCT00833313|PROCEDURE|Atrial biopsy|Biopsy of left atrial free wall and possibly left atrial appendage
48123291|NCT00980473|PROCEDURE|Argon Laser Iridoplasty|
48123292|NCT00980473|DRUG|Travatan/ Timolol/Azopt|
48123293|NCT00640549|DRUG|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
48123294|NCT00640549|DRUG|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
48123295|NCT00338650|DRUG|adalimumab|
48329403|NCT05797363|OTHER|Continuous midwife support|The individuals included in the experimental group will be provided with consultancy services on many issues from the pre-pregnancy period to the postpartum period.
48650762|NCT01566565|DRUG|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
48650763|NCT06441188|DIAGNOSTIC_TEST|Thin layer conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin layer of conventional ultrasound coupling gel.
48650764|NCT06441188|DIAGNOSTIC_TEST|Thick layer of conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick layer of conventional ultrasound coupling gel.
48650765|NCT06441188|DIAGNOSTIC_TEST|Thin conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin conventional ultrasound coupling gel pad.
48650766|NCT06441188|DIAGNOSTIC_TEST|Thick conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick conventional ultrasound coupling gel pad.
48123296|NCT00035308|DRUG|Abetimus sodium (LJP 394)|
48329404|NCT02003729|DEVICE|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
48329405|NCT03496727|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
48329406|NCT03496727|PROCEDURE|Patient controlled analgesia|Patient-controlled analgesia
48329407|NCT01005056|DRUG|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
48329408|NCT04469803|BEHAVIORAL|Intra-Shift Napping|The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.
48329409|NCT02268448|DRUG|Clonidine|
48329410|NCT02268448|DRUG|Naltrexone|
48329411|NCT02038569|DRUG|LEO 80185 gel|
48329412|NCT03428256|DEVICE|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
48329413|NCT03428256|DEVICE|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
48329414|NCT02030444|PROCEDURE|PET-MRI and EBUS-TBNA|
48329415|NCT03707158|BEHAVIORAL|Therapist-led Face-to-Face Cognitive-Behavioral Therapy|Participants receiving face-to-face cognitive-behavioral therapy will participate in therapist-led, office-based or telehealth CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
48329416|NCT03707158|BEHAVIORAL|Digital Cognitive-Behavioral Therapy|Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
48329417|NCT05002699|DIAGNOSTIC_TEST|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
48329418|NCT00657722|OTHER|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
48329419|NCT05996783|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
48329420|NCT05996783|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
48329421|NCT01001364|DRUG|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
48329422|NCT01001364|DRUG|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
48329423|NCT05366257|OTHER|CAR-T|infusion of CAR-T therapy among patients with r/r DLBCL
48329424|NCT05366257|OTHER|Allo-HSCT cohort|Patients received allogeneic hematopoietic stem cell transplant
48329425|NCT03499080|BEHAVIORAL|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
48329426|NCT03499080|BEHAVIORAL|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
48329427|NCT03499080|BEHAVIORAL|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
48329428|NCT03556748|OTHER|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
48491235|NCT03018808|OTHER|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
48123297|NCT05800639|PROCEDURE|Ophthalmic surgery|Ophthalmic surgery will be performed as standard practice of our institution.
48329429|NCT00592917|DIETARY_SUPPLEMENT|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
48329430|NCT05608330|OTHER|PETRUSHKA tool|In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.
48329431|NCT05608330|OTHER|Usual Care|Any antidepressant prescribed by clinician based upon their clinical judgement.
48329432|NCT00799929|OTHER|in vitro fertilization (IVF/ICSI)|
48329433|NCT02424812|BEHAVIORAL|Lifebuoy School of Five Handwashing Intervention|
48329434|NCT06175442|DEVICE|Intraoperative intestinal decompression|Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
48329435|NCT03104998|DRUG|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
48329436|NCT00357149|DRUG|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
48329437|NCT00357149|DRUG|Concomitant cisplatin, 5-FU and radiotherapy|
48329438|NCT01179347|DRUG|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
48329439|NCT01179347|DRUG|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
48329440|NCT03299309|DRUG|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
48329441|NCT03650764|DRUG|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
48329442|NCT03650764|DRUG|Pembrolizumab|Pembrolizumab is commercially available
48329443|NCT03650764|OTHER|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
48329444|NCT03650764|OTHER|FACT H&N|-Screening, start of cycle 2, start of cycle 5
48329445|NCT03650764|PROCEDURE|Peripheral blood|-Baseline
48329446|NCT00460837|DRUG|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
48329447|NCT05096546|OTHER|No intervention|No intervention will be applied for the observational study.
48329448|NCT03279341|DRUG|polyethylene glycol|osmotic laxative
48329449|NCT03279341|DRUG|Bisacodyl|stimulant laxative
48329450|NCT03279341|DRUG|Prucalopride|prokinetic
48329451|NCT01201707|PROCEDURE|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
48123298|NCT05800639|PROCEDURE|General anesthesia|General anesthesia will be performed as standard practice of our institution.
48123299|NCT05705505|DRUG|Narazaciclib|Orange tablets, each containing 40 mg or 120 mg of narazaciclib as narazaciclib monolactate
48329452|NCT01201707|OTHER|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
48329453|NCT03371732|BEHAVIORAL|Motivational Intervention group|Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
48329454|NCT03371732|BEHAVIORAL|Educational advises group|Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
48329455|NCT03511820|DRUG|Lipo-AB® (amphotericin B) liposome|"1. Name: Lipo-AB® (amphotericin B) liposome for injection~2. Dosage form: Lyophilized powder 50 mg/vial~3. Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~4. Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
48491236|NCT03018808|OTHER|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
48491237|NCT03018808|OTHER|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
48491238|NCT03018808|PROCEDURE|Blood test|Blood samples will be collected at indicated time points
48123300|NCT05705505|DRUG|Letrozole 2.5mg|Tablet
48123301|NCT01694446|OTHER|Intraduodenal glucose or fructose|
47973593|NCT05342545|OTHER|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
48329456|NCT02827994|OTHER|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
48329457|NCT02884518|DEVICE|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
48329458|NCT02884518|BEHAVIORAL|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
48329459|NCT06024213|PROCEDURE|Sentinel lymph node identification|Intervention description: Intraoperative identification of sentinel lymph node
48329460|NCT06024213|DRUG|indocyanine green|Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route
48329461|NCT06024213|DRUG|methylene blue|1%), 2-5 mL administered by periareolar or peritumoural route
48650767|NCT02169258|PROCEDURE|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis \> 70% of the major epicardial vessels and bypass graft vessel or their major branches (\> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
47973594|NCT04448483|DEVICE|Paretic upper limb functional electric stimulation through RehaStim|"The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release."
47973595|NCT04448483|DEVICE|Non-invasive transcranial current stimulation through DC-Stimulator|Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
47973596|NCT03710538|DIETARY_SUPPLEMENT|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
47973597|NCT03710538|BEHAVIORAL|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
47973598|NCT03332654|OTHER|Determine prevalence of stress urinary incontinence|
47973599|NCT01154855|PROCEDURE|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
47973600|NCT01779401|DRUG|Clopidogrel 75mg|
47973601|NCT01779401|DRUG|Clopidogrel 150mg|
47973602|NCT01779401|DRUG|Aspirin 100mg|
47973603|NCT01779401|DRUG|Cilostazol 100mg|
47973604|NCT00000383|BEHAVIORAL|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
47973605|NCT00000383|BEHAVIORAL|Child-Centered Therapy|Client-directed supportive interventions
47973606|NCT00430690|PROCEDURE|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
47973607|NCT04758169|OTHER|Enhanced Homestead Food Production|Enhanced Homestead Food Production program will provide increased production and consumption of nutrient rich foods, increased income of the households through the sale of surplus produce, and increased self-efficacy and decision making by adolescents due to increased knowledge and skills- resulting increased food security and nutrition and ultimately delay of child marriage.
47973608|NCT04758169|OTHER|Control|Control group will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings.
48123302|NCT03764787|COMBINATION_PRODUCT|Radiation+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
48123303|NCT05633719|OTHER|Chemotherapy involving cisplatin or carboplatin|Chemotherapy
48123304|NCT00663624|DRUG|aspart insulin|subcutaneous aspart insulin every 2 hours
48123305|NCT00663624|DRUG|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
48123306|NCT02650544|DRUG|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
48123307|NCT02650544|DRUG|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
48123308|NCT02538458|DRUG|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
48123309|NCT02538458|DRUG|3 % hypertonic saline up to 24H|"* Treatment by inhalation of 3 % hypertonic saline, up to 24H.~* followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
48123310|NCT03260140|BEHAVIORAL|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
48123311|NCT03999034|DIAGNOSTIC_TEST|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
48123312|NCT02652806|DRUG|FG-4592|
48123313|NCT02652806|DRUG|Epoetin Alfa|
48123314|NCT00086775|BIOLOGICAL|alemtuzumab|
48123315|NCT00086775|BIOLOGICAL|rituximab|
48123316|NCT00086775|DRUG|fludarabine phosphate|
48123317|NCT05673434|BIOLOGICAL|TM4SF1-positive chimeric antigen receptor T-cell therapy|"Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min."
48123318|NCT00526006|DRUG|esomeprazole|40 mg od for 8 wks
48123319|NCT01406223|DRUG|Varenicline|
48329462|NCT06024213|DRUG|Technetium (99mTc)|(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
48329463|NCT01577199|DRUG|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
48491239|NCT03018808|OTHER|anthropometric measures|Anthropologic measures will be performed.
48491240|NCT03018808|OTHER|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
48650768|NCT04115293|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
48650769|NCT04115293|DRUG|Placebo|Daily subcutaneous (SC) injection
48650770|NCT04414930|DRUG|d-amphetamine|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.
48123320|NCT01406223|DRUG|Bupropion|
48650771|NCT04414930|DRUG|Placebo|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
48650772|NCT03571633|DRUG|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
48650773|NCT03571633|DRUG|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
48650774|NCT06577441|PROCEDURE|Biospecimen Collection|Undergo buccal swab and blood sample collection
48650775|NCT06577441|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48650776|NCT06577441|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48123321|NCT01406223|DRUG|Nicotine patches|
48123322|NCT01406223|OTHER|Placebo varenicline|
48123323|NCT01406223|OTHER|Placebo bupropion|
48123324|NCT01406223|OTHER|Placebo patch|
48123325|NCT01620203|OTHER|No intervention/treatment is given|
48123326|NCT00105092|DRUG|Enzastaurin HCL|
48123327|NCT05579054|DIAGNOSTIC_TEST|Foot Posture Index (FPI-6)|FPI-6 is a valid and reliable assessment tool for pediatrics in which 6 items are scored separately for the right and left feet while the patient was in an upright position in a relaxed posture with their body-weight evenly distributed on the both feet. Each item is scored as -2, -1, 0, 1, 2 and the assessment categorized as follows: 0 to +5 normal; +6 to +9 pronated; 10+ higly pronated; -1 to -4 supianted; and -5 to -12 higly supinated.
48123328|NCT05344807|DIAGNOSTIC_TEST|Renal DMSA Scintigraphy|patient injected with Tc99mDMSA then imaged after 2-4 hours by gamma camera
48123329|NCT04113798|OTHER|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
48123330|NCT04113798|OTHER|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
48329464|NCT01577199|DRUG|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
48329465|NCT00502632|DRUG|Urokinase and Dornase alfa|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
48491241|NCT01176214|PROCEDURE|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
48491242|NCT01176214|PROCEDURE|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
48650777|NCT06577441|DRUG|Decitabine and Cedazuridine|Given PO
48650778|NCT06577441|DRUG|Enasidenib|Given PO
48123331|NCT04113798|OTHER|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
47973609|NCT03519646|DRUG|Eliglustat|"1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
47973610|NCT03672747|DEVICE|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
47973611|NCT02550249|DRUG|Nivolumab|Intravenous administration of nivolumab
47973612|NCT03403660|OTHER|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
47973613|NCT05311618|DRUG|NGM438|NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
47973614|NCT05311618|DRUG|Pembrolizumab (KEYTRUDA ®)|Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
47973615|NCT05504564|GENETIC|The experiment does not required any intervention|The experiment does not required any intervention
47973616|NCT03323931|BEHAVIORAL|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
47973617|NCT03323931|BEHAVIORAL|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
48123332|NCT04113798|BEHAVIORAL|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
48123333|NCT04113798|BEHAVIORAL|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for the full duration of 30 minutes.
48123334|NCT04113798|OTHER|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur \~24 hours following Day 3, and lasts about 30 minutes.
48123335|NCT01339130|BEHAVIORAL|Computerized tests and Electrophysiological measurements|"* Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~* Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~* Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
48123336|NCT00637585|DRUG|Fexofenadine|
48123337|NCT04071756|DRUG|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
48329466|NCT00502632|DRUG|Urokinase|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days"
48329467|NCT02487277|DRUG|PEGPH20|
48329468|NCT02487277|DRUG|Gemcitabine|
48329469|NCT02487277|DRUG|Nab-paclitaxel|
48329470|NCT00442767|DRUG|Insulin|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
48491243|NCT04062474|PROCEDURE|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
48123338|NCT04071756|OTHER|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
48123339|NCT06233435|BEHAVIORAL|PADSS|Observe PADSS after total knee arthroplasty at 6 and 24 hours
48123340|NCT01680250|DRUG|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
48123341|NCT03516240|OTHER|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
48123342|NCT03516240|OTHER|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
48123343|NCT00038506|DRUG|abacavir/lamivudine/zidovudine|
48329471|NCT00442767|DRUG|Pramlintide + Insulin|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
48329472|NCT05161312|BEHAVIORAL|iACT-BC: Oncovox|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
47973618|NCT01003912|BIOLOGICAL|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
47973619|NCT04937673|DRUG|Camrelizumab+Albumin bound paclitaxel+Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
47973620|NCT04937673|DRUG|Camrelizumab+ Paclitaxel+ Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
47973621|NCT01919723|DRUG|Ticagrelor|Ticagrelor loading dose
47973622|NCT01919723|DRUG|Eptifibatide|i.v. infusion
47973623|NCT05858762|DIAGNOSTIC_TEST|Breast digital tomosynthesis|Introduction of an almost three-dimensional imaging technique called breast digital tomosynthesis
47973624|NCT01433614|DRUG|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
47973625|NCT01433614|DRUG|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
47973626|NCT01433614|DRUG|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
47973627|NCT04555291|DRUG|Ropivacaine injection|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
47973628|NCT04555291|OTHER|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
47973629|NCT06113809|DRUG|Palbociclib|"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"
47973630|NCT06113809|DRUG|Pembrolizumab|"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"
47973631|NCT05037734|DEVICE|Persona Partial Knee System|Unicompartmental Knee Replacement
47973632|NCT02720991|DRUG|Mifepristone|200 mg of oral mifepristone
47973633|NCT02720991|DRUG|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
47973634|NCT00122668|DRUG|non-nucleoside reverse transcriptase inhibitors|
47973635|NCT00122668|DRUG|nucleoside reverse transcriptase inhibitors|
47973636|NCT00122668|DRUG|protease inhibitor|
48123344|NCT00038506|DRUG|tenofovir|
48329473|NCT00377585|BIOLOGICAL|Fluarix|
48329474|NCT00377585|BIOLOGICAL|adjuvanted influenza vaccine|
48329475|NCT02181985|DRUG|Full dose TNK-tPA|
48329476|NCT02181985|DRUG|Half dose TNK-tPA|
47973637|NCT03608501|DRUG|Ixazomib|Ixazomib capsules.
48329477|NCT02181985|DRUG|Heparin|
48329478|NCT02181985|DRUG|Enoxaparin|
48491244|NCT00463242|DRUG|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
47973638|NCT03608501|DRUG|Thalidomide|Thalidomide capsules.
47973639|NCT03608501|DRUG|Dexamethasone|Dexamethasone tablets.
47973640|NCT03313791|DIETARY_SUPPLEMENT|Whey protein concentrate|see arm description
47973641|NCT03313791|DIETARY_SUPPLEMENT|Yoghurt|see arm description
47973642|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Standard)|see arm description
47973643|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Alternative)|see arm description
47973644|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate- WPH|see arm description
47973645|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate - Na-caseinate|see arm description
47973646|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate|see arm description
47973647|NCT03313791|DIETARY_SUPPLEMENT|UHT milk|see arm description
47973648|NCT03313791|DIETARY_SUPPLEMENT|Recombined milk|see arm description
47973649|NCT03313791|DIETARY_SUPPLEMENT|Recombined 50%whey milk|see arm description
47973650|NCT03313791|DIETARY_SUPPLEMENT|Ca-caseinate|see arm description
47973651|NCT03313791|DIETARY_SUPPLEMENT|Milk protein isolate|see arm description
47973652|NCT05123261|BEHAVIORAL|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
47973653|NCT04947449|DEVICE|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
48329479|NCT02181985|DRUG|Abciximab|
48491245|NCT00463242|DRUG|paroxetine|
48491246|NCT00463242|DRUG|placebo|
48123345|NCT04877496|DRUG|History of exposure to anti-CD20 treatment since 01/01/2010|Intravenous treatment history of anti-CD20 treatment since 01/01/2010
47973654|NCT04121377|OTHER|Resistance training|"Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected."
47973655|NCT03475537|DEVICE|transcranial direct current stimulation|the treatment of transcranial direct current stimulation
48123346|NCT04877496|BIOLOGICAL|Completion of COVID19 vaccine at least 4 weeks ago|Completion of COVID19 vaccination course at least 4 weeks ago.
48123347|NCT04386356|DEVICE|Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope|Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
47973656|NCT00646009|DRUG|budesonide/formoterol|
47973657|NCT00646009|DRUG|fluticasone/salmeterol|
47973658|NCT00646009|DRUG|albuterol|
47973659|NCT04143321|DRUG|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
47973660|NCT05228288|PROCEDURE|Conventional direct laryngoscopy (CDL)|This procedure is considered the gold standard for endotracheal intubation and is routinely used in the peri-operative setting as well as in intensive care and emergency medicine.
47973661|NCT05228288|PROCEDURE|Video assisted laryngoscopy with Macintosh-shaped blade (M-VAL)|This device is implemented in most german hospitals and used when conventional direct laryngoscopy is not sufficient. By positioning the camera at the tip of the blade, the achievable field of view onto the glottic plane is improved.
47973662|NCT05228288|PROCEDURE|Video assisted laryngoscopy with hyper-angulated blade (H-VAL)|The hyper-angulated blades are often used as a backup instrument when a view of the glottic plane cannot be achieved with the Macintosh blade due to anatomic abnormalities, even with a video-assisted laryngoscope.
47973663|NCT04343547|DRUG|DWP16001|Tablets, Oral, once daily single dose
47973664|NCT04343547|DRUG|DWC202001+DWC202002|Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
47973665|NCT04343547|DRUG|DWP16001+DWC202001+DWC202002|Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
48123348|NCT01456013|DEVICE|RenalGuard Therapy|Induced Diuresis with matched replacement
48123349|NCT01456013|DRUG|Standard Therapy|Standard of care for patients at risk of CIN
48123350|NCT04008550|PROCEDURE|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
48329480|NCT04007913|BEHAVIORAL|teleCBIT|Eight sessions of individual behavior therapy
48329481|NCT02148211|OTHER|Data collection|Initial and follow-up data was collected using questionnaires.
48329482|NCT02417896|DRUG|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
48650779|NCT04472468|DEVICE|Percutaneous Balloon Pericardiotomy|"* Subxiphoid approach under fluoroscopic guidance is used.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections."
48650780|NCT06640504|DIAGNOSTIC_TEST|serum albumin|Serum albumin ratios were calculated as the ratio between the estimated blood lactate, and serum levels of CRP and PCT divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR), CRP-to-albumin ratio (CAR) and procalcitonin (PCT)-to-albumin ratio (PAR).
48650781|NCT06640504|DIAGNOSTIC_TEST|C-Reactive Protein|The serum levels of C-reactive protein (CRP) are divided by the estimated serum albumin level to get the CRP-to-albumin ratio (CAR).
48650782|NCT06640504|DIAGNOSTIC_TEST|Serum procalcitonin|The serum levels of procalcitonin (PCT) are divided by the estimated serum albumin level to get the PCT-to-albumin ratio (PAR).
48650783|NCT06640504|DRUG|Blood Lactate|The serum levels of blood lactate are divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR).
48650784|NCT06663969|OTHER|Temporal Interference|Researchers applied temporal interference (TI) stimulation to the deep brain nuclei of patients who had undergone SEEG monitoring, recording changes in electrical activity detected by SEEG.
48650785|NCT02359565|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
48650786|NCT02359565|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo standard MRI
48650787|NCT02359565|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
48650788|NCT02359565|PROCEDURE|Diffusion Weighted Imaging|Undergo MR diffusion imaging
48650789|NCT02359565|PROCEDURE|Dynamic Contrast-enhanced MR Perfusion|Undergo DCE permeability MRI
48650790|NCT02359565|PROCEDURE|Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|Undergo DSC perfusion MRI
48650791|NCT02359565|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
48650792|NCT02359565|BIOLOGICAL|Pembrolizumab|Given IV
48123351|NCT04877067|BIOLOGICAL|Wharton jelly derived mesenchymal stem cell|WJ-MSC
48123352|NCT04877067|DEVICE|Repetitive electromagnetic stimulation|rEMS
48123353|NCT04372004|DIAGNOSTIC_TEST|diagnostic tests for COVID-19 infection|Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
48650793|NCT05215236|OTHER|Opiate Sparing|Subjects will receive non-opiate medications for pain control
48123354|NCT04447482|DEVICE|ENB with image-guided lung biopsy|Electromagnetic navigational bronchoscopy system with tip tracked instruments.
48123355|NCT04447482|PROCEDURE|Conventional Bronchoscopy guided by Fluoroscopy|Bronchoscopic lung biopsy with fluoroscopy.
48123356|NCT01159275|DRUG|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
48123357|NCT01159275|DRUG|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
48329483|NCT04934527|DRUG|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
48329484|NCT01932931|DIETARY_SUPPLEMENT|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
47973666|NCT05541172|DRUG|Testosterone Undecanoate|Testosterone undecanoate (1000 mg/4 ml) will be administered at a dose of 1 ml every 12 weeks for 6 months, 2 ml every 12 weeks for 6 months, 3 ml every 12 weeks for 6 months and 4 ml every 12 weeks for 6 months.
47973667|NCT01504035|DEVICE|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
47973668|NCT01504035|DEVICE|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
47973669|NCT05846932|BEHAVIORAL|OTEE HORS|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses
47973670|NCT05846932|BEHAVIORAL|OT Clinic|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic
47973671|NCT03150615|OTHER|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
47973672|NCT03150615|OTHER|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
47973673|NCT03150615|DEVICE|nasojejunal tube insertion|
47973674|NCT03150615|OTHER|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
47973675|NCT01699282|BEHAVIORAL|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
47973676|NCT01699282|BEHAVIORAL|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
47973677|NCT06498011|OTHER|Home Graded Repetitive Arm Supplementary Program (GRASP)|The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program focusing on stretching, arm strengthening, hand strengthening, coordination and hand skills. The Home Graded Repetitive Arm Supplementary Program will be delivered 2 hours/session, 3 times/week, for 6 weeks.
48123358|NCT02423798|DEVICE|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
48123359|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
48123360|NCT06010862|BIOLOGICAL|CEA CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
48123361|NCT04370314|OTHER|Dental prosthetics|Implant-supported crowns
48123362|NCT04080336|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
48123363|NCT04080336|DRUG|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
48123364|NCT04080336|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
48123365|NCT00726596|DRUG|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
48329485|NCT03216083|DRUG|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
48329486|NCT03216083|OTHER|Placebo|67mL IV normal saline
48650794|NCT05215236|OTHER|Opiate Based|Subjects will receive opiate based medications for pain control
48329487|NCT04269655|DEVICE|Cloud-Based Continuous Glucose Monitoring|The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
48491247|NCT02664363|BIOLOGICAL|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
48650795|NCT03790956|PROCEDURE|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
48650796|NCT03678389|OTHER|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
48650797|NCT06474962|BEHAVIORAL|Pause|7 days of no e-cigarette consumption
48650798|NCT02542215|DRUG|Cobiprostone|Cobiprostone 30 mcg oral spray
48491248|NCT04978064|BEHAVIORAL|e-health psychological counselling|"Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study)."
48491249|NCT03518892|DIAGNOSTIC_TEST|Resting Metabolic Rate|30 minute test to determine daily caloric needs
48650799|NCT02542215|DRUG|Placebo|Matching placebo oral spray
48329488|NCT04655963|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
48329489|NCT00226395|DRUG|Oxymorphone immediate release|
48491250|NCT03518892|DIAGNOSTIC_TEST|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
48491251|NCT03518892|BEHAVIORAL|Dietary Assessment|Self administered dietary logs
48491252|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
48491253|NCT00771745|DRUG|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
48650800|NCT02542215|DRUG|Standard Care - Chemotherapy|Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
48650801|NCT02542215|RADIATION|Standard Care - Radiation|Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
48650802|NCT06314048|OTHER|CGM and RPM|1. Implement the 4T program as standard of care at Stanford Diabetes clinics, including Continuous Glucose Monitoring (CGM) and Remote Patient Monitoring (RPM) within the first 30 days after T1D diagnosis to reduce the rise in HbA1c trajectory observed 4-12 months post-diagnosis.
48650803|NCT02411045|BEHAVIORAL|Take and send a selfie|Direction to take and send a selfie.
48329490|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - single-session
48123366|NCT03669913|OTHER|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
48650804|NCT02411045|BEHAVIORAL|Workout gears|Direction to wear workout gears.
48650805|NCT02411045|BEHAVIORAL|Exercise|Direction to complete a 30 minute workout.
48329491|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - multi-session
48329492|NCT00682240|PROCEDURE|laser treatment with PASCAL®|grid / focal laser treatment
48329493|NCT00682240|PROCEDURE|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
48329494|NCT01170702|DRUG|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
48650806|NCT05938569|DEVICE|Hair restoration|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
48650807|NCT06637592|OTHER|Calcaneal taping|Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.
48650808|NCT06637592|OTHER|Windlass taping|Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
48123367|NCT00711581|DEVICE|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
48123368|NCT06113770|OTHER|preparation of the tooth to receive ready made zirconia crown|"Occlusal reduction 1 to 2 mm using flame bur . Open the interproximal contacts. The tooth should be reduced circumferentially by approximately 0.5-1.5mm . The preparation margin should be carefully extended and refined to a feather-edge approximately 1-2mm subgingivally .~Crown size will be determined using try in kit ."
48123369|NCT06113770|OTHER|preparation of the tooth to receive CAD CAM PMMA custom made crown|"* Open the interproximal contacts .~* The tooth should be reduced circumferentially by approximately 0.5-1mm .~* The preparation margin should be carefully extended and refined to a feather- edge approximately 1-2mm subgingivally .~* Rubber base impression will be taken by BMS additional silicone kit to the prepared tooth and will be sent to the laboratory to be scanned and to design the crown .~* The final crown will be cemented using glass ionomer cement ."
48123370|NCT02363452|DRUG|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
48123371|NCT01127373|RADIATION|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
48123372|NCT01127373|BEHAVIORAL|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
48329495|NCT01170702|DRUG|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
48329496|NCT01170702|DRUG|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
48491254|NCT00933517|DRUG|vectibix|9mg/kg at D1 of each 21-days cycle
47973678|NCT06498011|OTHER|integrated Somatosensory-MOtor training using a COgnitive approach(iCOSMO)|The first training approach of iCOSMO will focus on integrated somatosensory-motor variables during reaching and object manipulation (60 minutes). The second training approach will focus on proprioceptive, motor and cognitive tasks using the Kinarm robotic exoskeleton (60 minutes). iCOSMO will be delivered 3 times per week (2 hours per session) for 6 weeks (Total: 36 hours of treatment).
47973679|NCT02164812|DRUG|Moxifloxacin|
48491255|NCT00933517|DRUG|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
48491256|NCT00933517|DRUG|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
47973680|NCT02164812|DRUG|Placebo|
47973681|NCT02164812|DRUG|Efavirenz|
47973682|NCT05799066|DIAGNOSTIC_TEST|Swinging Light test|The swinging light or pen light test with manual pupil measurements is the standard of care test for RAPD. This test consists of a light being shone in one eye for 3 to 4 seconds then shown in the other eye for 3 to 4 seconds, repeating 2 to 3 times. Pupils are measured manually immediately after the light test. Measurements are recorded in patient's medical record.
47973683|NCT05799066|DIAGNOSTIC_TEST|Virtual Reality Head-Mounted Display (VR HMD)|A light is shone from within the VR HMD, pupillary measurements are taken and recorded by the machine learning (ML) algorithm.
47973684|NCT05499312|DRUG|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
47973685|NCT05499312|DRUG|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
47973686|NCT05949008|DRUG|Metformin Extended Release (ER) Oral Tablet|Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.
47973687|NCT05949008|DRUG|Placebo|Matching placebo will be provided as 1000 mg capsules
47973688|NCT04932551|OTHER|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
47973689|NCT00552916|DEVICE|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
47973690|NCT00552916|DEVICE|Compex Motion Stimulator|'False' FES
47973691|NCT00577681|DRUG|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
47973692|NCT02310568|DRUG|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
47973693|NCT05399056|BEHAVIORAL|Telephonic Peer Coaching|Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing
47973694|NCT05399056|BEHAVIORAL|Storytelling|Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
47973695|NCT06236178|DRUG|Corticosteroid|1 ml of 40 mg methylprednisolone acetate
47973696|NCT06236178|DRUG|Autologous Blood|1 ml of autologous venous blood
47973697|NCT06236178|DRUG|Local Anesthetic|1 ml of 2% prilocaine HCl
48491257|NCT00933517|DRUG|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
48491258|NCT00933517|DRUG|docetaxel|100 mg/m2 at D1 of each 21 days cycle
48650809|NCT03004183|BIOLOGICAL|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
48650810|NCT03004183|DRUG|Valacyclovir|Prodrug of the antiviral drug acyclovir
48650811|NCT03004183|RADIATION|SBRT|Low-dose SBRT
48650812|NCT03004183|DRUG|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
48123373|NCT04565834|GENETIC|Analysis of Single nucleotide polymorphisms in each group.|The 6 single nucleotide polymorphisms (SNPs) determined will then be genotyped according to the Thermofisher Taqman technique ona 480 LightCycler (Roche Applied Science). 10% of the genotypes will be confirmed via Sanger sequencing on a 3500xl Thermofisher sequencer according to the manufacturer's recommendations.
48650813|NCT05722769|BEHAVIORAL|CSTOP Now!|Child sex trafficking stops with you. Implement and evaluate the effectiveness of a multi-level bystander-informed program (CSTOP Now!) aimed at Kentucky public middle school staff. Participants will be trained to use the See It To Stop It Indicator Tool (SITSII) by using tiers of concern (clear concern, possible concern, and monitor of emerging concern). The SITSII tool directs the bystander actions to Decide, Directly Intervene, Disrupt, Delegate, and Document.
48650814|NCT05722769|BEHAVIORAL|Prevent Child Abuse Kentucky Online Training|The Kentucky State Police, in association with Prevent Child Abuse Kentucky, have developed videos we invite active comparator schools to review which also include how to identify and report child sex trafficking.
48123374|NCT03090763|GENETIC|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
48123375|NCT00000675|DRUG|CD4-IgG|
48123376|NCT05704920|OTHER|IA|The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography
48123377|NCT05704920|OTHER|Not IA|The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography
48123378|NCT00075933|DRUG|ARQ 501|
48123379|NCT05517564|DRUG|GM-60106|The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
48123380|NCT05517564|OTHER|Placebo|Placebo-to-match GM-60106 capsules
48123381|NCT06133049|DRUG|Ozanimod|Women with MS who were exposed to ozanimod during pregnancy
48123382|NCT06133049|DRUG|Select DMTs other than ozanimod|Women with MS exposed to select DMTs other than ozanimod during pregnancy
48123383|NCT06133049|DRUG|No DMTs|Women with MS not exposed to any DMTs during pregnancy
48123384|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery
48123385|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions|Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery
48123386|NCT00225004|PROCEDURE|DEXA scan|orto
48123387|NCT00140790|DRUG|valsartan|valsartan 40 or 160 (80) mg per day
48123388|NCT06256640|DEVICE|Mandibular advancement Device|Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
48123389|NCT06107751|OTHER|Ramped position group|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
48123390|NCT06107751|OTHER|Sniffing position group|This position will be achieved by placing a 7 cm pillow under the occiput.
48123391|NCT04357951|DRUG|d-cycloserine|D-cycloserine is an FDA-approved antibiotic medication that has been shown to enhance extinction learning in several studies. It will be paired with 4 sessions of behavior therapy.
48123392|NCT04357951|DRUG|Placebo pill|A pill placebo serves as an active comparator. It will be paired with 4 sessions of behavior therapy.
48123393|NCT04357951|BEHAVIORAL|Behavior Therapy|All participants will receive 4 sessions of behavior therapy for tics (e.g., habit reversal training, comprehensive behavioral intervention for tics).
48329497|NCT01170702|DRUG|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
48329498|NCT00965146|DEVICE|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
48329499|NCT00813618|DRUG|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
48329500|NCT00813618|DRUG|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
48650815|NCT01143636|DEVICE|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
47973698|NCT01931124|BEHAVIORAL|High Intensity Training|
47973699|NCT01931124|BEHAVIORAL|Moderate Intensity Training|
48329501|NCT00813618|DRUG|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
48329502|NCT04591496|BEHAVIORAL|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
47973700|NCT00982878|DRUG|Maraviroc|150mg twice daily
47973701|NCT06190691|DRUG|Pirtobrutinib|Administered orally
48329503|NCT04591496|BEHAVIORAL|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
47973702|NCT05369637|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
47973703|NCT05369637|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
47973704|NCT05369637|BEHAVIORAL|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
47973705|NCT05369637|BEHAVIORAL|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
47973706|NCT05369637|OTHER|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
47973707|NCT03792581|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
47973708|NCT02164760|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
47973709|NCT02853110|RADIATION|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
47973710|NCT02353104|DIETARY_SUPPLEMENT|Onion-Pumpkin Extract|
47973711|NCT06046391|BIOLOGICAL|LP-003 dose 1|Liquid in vial
47973712|NCT06046391|BIOLOGICAL|LP-003 dose 2|Liquid in vial
47973713|NCT06046391|BIOLOGICAL|Placebo|Liquid in vial
47973714|NCT01327898|BEHAVIORAL|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
47973715|NCT01327898|BEHAVIORAL|individual resilience counseling|one individual resilience counseling session
47973716|NCT00833885|DEVICE|Masks|Wearing of surgical masks
47973717|NCT00833885|DEVICE|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
47973718|NCT00833885|OTHER|Control|General information about virus transmission in households and basic means to prevent it
48329504|NCT05155657|BIOLOGICAL|Conventional therapy plus low dose UCMSCs treatment|Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10\^6 UCMSCs/kg body)
48329505|NCT05155657|BIOLOGICAL|Conventional therapy plus medium dose UCMSCs treatment|Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10\^6 UCMSCs/kg body)
48329506|NCT05155657|BIOLOGICAL|Conventional therapy plus high dose UCMSCs treatment|Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10\^6 UCMSCs/kg body)
48329507|NCT04799067|OTHER|observational study|no study drug involved, observational study.
48650816|NCT06138158|PROCEDURE|Exercise and Education Group|Physical exercise and pain education
47973719|NCT04360915|DRUG|ASK120067|Take ASK120067 tablets orally in first day at 160 mg in fast condition.
48329508|NCT00803543|DRUG|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
48329509|NCT00803543|DRUG|Placebo|Dosage: Two tablets once a day for 24 weeks
48329510|NCT06182540|DIETARY_SUPPLEMENT|Mango puree|Mango puree 300g
48329511|NCT00187629|BEHAVIORAL|dietary phosphorus|varying amts dietary phosphorus
48329512|NCT02220946|DEVICE|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
48329513|NCT05285436|DEVICE|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
48329514|NCT04137562|BIOLOGICAL|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL
48329515|NCT04137562|OTHER|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
48329516|NCT01245205|DRUG|Akt inhibitor MK2206|Given PO
48650817|NCT01100580|DIETARY_SUPPLEMENT|low salt diet|Daily salt intake less than 4 g/day
48329517|NCT01245205|DRUG|lapatinib ditosylate|Given PO
48329518|NCT01245205|OTHER|pharmacological study|Correlative studies
48329519|NCT01245205|OTHER|laboratory biomarker analysis|Correlative studies
48329520|NCT00003809|BIOLOGICAL|cetuximab|
48329521|NCT00003809|DRUG|cisplatin|
48650818|NCT01100580|DIETARY_SUPPLEMENT|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
47973720|NCT04360915|DIETARY_SUPPLEMENT|ASK120067 in fed condition|Take ASK120067 tablets orally in first day at 160 mg in fed condition.
47973721|NCT01433991|DRUG|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
47973722|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
48329522|NCT04950192|DEVICE|ICE Image guidance|ICE image guidance will be used on all patients undergoing planned cardiac catheterization procedures
48329523|NCT06278129|DIAGNOSTIC_TEST|Vestibular myogenic potentials|observational study
48329524|NCT04591210|DRUG|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
48329525|NCT04591210|DRUG|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
48329526|NCT00250185|DRUG|Sodium Nitrate|
48329527|NCT00250185|DRUG|Acetylcholine|
48650819|NCT04784143|DRUG|Midomafetamine|120 mg midomafetamine HCl followed by a supplemental dose of 60 mg
48650820|NCT04784143|BEHAVIORAL|Psychotherapy|Manualized psychotherapy performed by therapist team
48650821|NCT06445439|DEVICE|Pacing rate of 80 bpm|Pacing rate of 80 bpm
48329528|NCT03583320|DIAGNOSTIC_TEST|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
48650822|NCT06445439|DEVICE|Pacing rate of 60 bpm|Pacing rate of 60 bpm
48650823|NCT00306098|DRUG|islets|Intraportal infusion of islets
47973723|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
47973724|NCT05693558|BIOLOGICAL|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
47973725|NCT04745429|OTHER|breathing exercises, cold exposure and meditation|It is a combination of exercises that include breathing exercises, cold exposure and meditation
48329529|NCT01932281|DIETARY_SUPPLEMENT|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
48329530|NCT01932281|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
48329531|NCT05100069|DRUG|Brigatinib|Brigatinib Tablets
48329532|NCT06014294|BEHAVIORAL|HIIT|Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.
48329533|NCT06014294|BEHAVIORAL|Baduanjin|As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.
48329534|NCT06014294|BEHAVIORAL|Workshop|Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
48329535|NCT00676208|BEHAVIORAL|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
48650824|NCT06248710|DRUG|Oxytocin nasal spray|Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant
48329536|NCT03219567|DEVICE|Optical Coherence Tomography (OCT)|"Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye."
48329537|NCT03219567|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in the body.
48329538|NCT05606978|BEHAVIORAL|FASTb|FAST blended
48329539|NCT05606978|BEHAVIORAL|FASTr|FAST regular
48329540|NCT02034552|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus
48329541|NCT02034552|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
48491259|NCT03490448|BEHAVIORAL|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
48491260|NCT04451603|PROCEDURE|Surgery|Surgical resection of the liver
48491261|NCT04451603|RADIATION|Radiation therapy|Y-90 radioembolization therapy is the main treatment
48491262|NCT04451603|DRUG|Drug treatment|Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
48491263|NCT00755859|DRUG|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
48491264|NCT00755859|DRUG|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
48491265|NCT03676699|DIAGNOSTIC_TEST|Ultrasound chest|Ultrasound detection of extravascular lung water
48491266|NCT06224322|OTHER|Assesment Scale|Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
48491267|NCT03898895|COMBINATION_PRODUCT|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
48491268|NCT03853018|DEVICE|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
48491269|NCT03853018|DEVICE|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
48491270|NCT03036319|DEVICE|Active tDCS|Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
48491271|NCT03036319|DEVICE|Sham tDCS|Participants will receive sham tDCS for up to 260 sessions
48491272|NCT03036319|BEHAVIORAL|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
48491273|NCT03036319|DEVICE|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
48491274|NCT03036319|DEVICE|Sham tACS|Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
48491275|NCT03036319|DEVICE|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
48491276|NCT03036319|DEVICE|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 260 sessions
48650825|NCT06248710|OTHER|Animal-Assisted Intervention|The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.
48650826|NCT06248710|DRUG|Placebo|The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
48650827|NCT00383032|DRUG|mifepristone|
48491277|NCT00753818|OTHER|DHA and ARA|various levels of DHA and ARA
48491278|NCT00753818|OTHER|Control|
48491279|NCT04594174|PROCEDURE|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
48491280|NCT03098914|OTHER|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
48491281|NCT00239655|DRUG|MK0812|
48329542|NCT02034552|DRUG|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
48329543|NCT02034552|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
48329544|NCT02487888|OTHER|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
48650828|NCT06284408|OTHER|Centralized Screening Unit Implementation|The CSU provides a proactive and comprehensive population health approach to screening. This includes core functions of a) patient identification, b) contact, c) engagement, education and support, d) referral and navigation to LDCT screening, e) post screening follow-up, and f) retention
48650829|NCT06674590|PROCEDURE|Proprioceptive Neuromuscular Facilitation|PNF of 30 minutes duration will given in a single session. Pelvic anterior elevation and posterior depression of the hemiplegic side. rhythmic initiation slow reversal agonistic reversals Pelvic anterior depression and posterior elevation of the hemiplegic side. The first diagonal (D1): Flexion and extension The second diagonal (D2): Flexion and extension 4 session per week
48650830|NCT06674590|PROCEDURE|Motor Relearning Program|Motor Relearning Programme (MRP) This is a task-oriented approach to help the control of movement, focusing on the relearning of daily activities.
48491282|NCT01610739|DRUG|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
48650831|NCT05679934|OTHER|Exercise Program|Stretching and strengthening exercises will be applied to the participants
48650832|NCT04986189|DIAGNOSTIC_TEST|Low dose CT thorax|A low dose CT scan of the thorax to screen for lung cancer
48650833|NCT03882801|DRUG|Gefapixant|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.
48650834|NCT03882801|DRUG|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
48650835|NCT06642701|DEVICE|Electrical Impedance Tomography|According to the results of traditional assessment, physiotherapists and clinicians discussed the EIT results to give respiratory rehabilitation chest physiotherapy
48650836|NCT06642701|BEHAVIORAL|chest physiotherapy|Conventional assessment by physical therapists was followed by respiratory rehabilitation chest physiotherapy.Chest physical therapy for respiratory rehabilitation includes postural drainage, cough technique, forced expiratory technique, positive expiratory pressure, high-frequency chest wall compression, chest tapping, vibration, active breathing cycle technique, etc. All chest physiotherapy was performed by 1 therapist.
48650837|NCT06076213|DRUG|Artesunate-amodiaquine|Tablets
48650838|NCT06076213|DRUG|Artemether-lumefantrine|Tablets
48329545|NCT02487888|OTHER|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
48329546|NCT01757977|DEVICE|double lumen endotracheal tube placement and use|
48329547|NCT01648829|DRUG|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
48329548|NCT01648829|DRUG|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
48329549|NCT02273037|DEVICE|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
48329550|NCT02273037|PROCEDURE|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
48329551|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to starchy meal|
48329552|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to liquid|
48329553|NCT02168296|DIETARY_SUPPLEMENT|No Plant-based ingredient|
48491283|NCT00999765|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
48329554|NCT01094951|BEHAVIORAL|ENGAGE|During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
48329555|NCT05505097|DRUG|Hydroxymethylquinoxalindioxyde|"Dioxidin (Hydroxymethylquinoxalindioxyde), solution for topical and external use, 0.25 mg/ml, applied as:~A - single rinsing of the oropharynx with 15.0 ml of the drug solution for at least 30 seconds B - single irrigation of the oropharynx by spraying the preparation 4 times with a spray nozzle C - irrigation of the skin on the back by spraying the preparation 4 times from a distance of 10 cm on 1% of the body surface using a spray nozzle and exposing the solution for 30 minutes or D - Dioxidin (Hydroxymethylquinoxalindioxyde), solution for infusion and external application, 5 mg/ml, single intravenous 5 mg/ml in 1 ml"
48329556|NCT04839536|DRUG|Sevoflurane inhalant product|Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
48491284|NCT03032861|OTHER|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
48491285|NCT03832036|DIAGNOSTIC_TEST|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
48650839|NCT05403268|DEVICE|DeltaScan|Twice daily DeltaScan observations
48650840|NCT03333889|OTHER|Vita Enamic hybrid crown|hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
48650841|NCT03333889|OTHER|emax hybrid crown|high srength glass ceramic that can be milled in sections up to 1mm .
48650842|NCT06124300|DIETARY_SUPPLEMENT|Female Hormone Balance Supplement|The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
48329557|NCT04671615|DRUG|palbociclib|As provided in real world practice
48491286|NCT02833376|OTHER|alcohol antisepsis|
48491287|NCT02833376|OTHER|chlorhexidine antisepsis|
48491288|NCT01677923|DRUG|Metformin|Metformin 500 mg BID for 12 months
48491289|NCT04815421|OTHER|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
48491290|NCT04815421|OTHER|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
48650843|NCT03001739|DRUG|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
48650844|NCT03925077|OTHER|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
48650845|NCT03925077|OTHER|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
48650846|NCT05968742|BEHAVIORAL|Abstinence of oral hygiene on select teeth|Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days
48650847|NCT02344472|DRUG|pertuzumab|HER2 targeted Therapy
48650848|NCT02344472|DRUG|Trastuzumab|HER2 targeted Therapy
48650849|NCT02344472|DRUG|Capecitabine|Chemotherapy
47973726|NCT02412475|DRUG|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
48491291|NCT05032521|BIOLOGICAL|collection of biological data|collection of biological data
48491292|NCT05032521|OTHER|collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data|These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.
48491293|NCT05032521|PROCEDURE|Standard treatment|usual management based on the use of drugs according to international recommendations
48491294|NCT05032521|PROCEDURE|stratified treatment according to algorithm|management based on arteriovenous CO2 gradient Stratification of drug use
48491295|NCT00040183|DRUG|Tarceva (erlotinib HCl, OSI-774)|
48491296|NCT03726281|DRUG|Nivolumab|Nivolumab 240 mg, IV
48491297|NCT00836017|OTHER|No Intervention|No intervention was administered as part of the study.
48650850|NCT02344472|DRUG|Paclitaxel|Chemotherapy
48650851|NCT02344472|DRUG|Vinorelbine|Chemotherapy
48491298|NCT01352130|DRUG|Ondansetron|Intravenous Ondansetron 8 mgs
48491299|NCT01352130|DRUG|Granisetron|Intravenous Granisetron 1 mgs
48650852|NCT02344472|DRUG|Docetaxel|Chemotherapy
48650853|NCT02344472|DRUG|Exemestane|endocrine therapy
48650854|NCT02344472|DRUG|Letrozole|endocrine therapy
48650855|NCT02344472|DRUG|Anastrozole|endocrine therapy
48650856|NCT02344472|DRUG|Fulvestrant|endocrine therapy
48650857|NCT02344472|DRUG|Ribociclib|CDK 4/6 inhibitor
48650858|NCT02344472|DRUG|nab-Paclitaxel|chemotherapy
48650859|NCT02344472|DRUG|eribulin|chemotherapy
48650860|NCT02344472|DRUG|leuprorelin|endocrine therapy
48650861|NCT02344472|DRUG|goserelin|endocrine therapy
48650862|NCT05225584|DRUG|KT-333|KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
48650863|NCT01373411|DRUG|ticagrelor|ticagrelor 90 mg BID for 90 days
48650864|NCT01373411|DRUG|Placebo|Placebo 1 pill BID for 90 days
48650865|NCT06172465|OTHER|EOIP|Ultrasound guided External oblique intercostal block will be performed bilaterally.
48650866|NCT06172465|OTHER|OSTAP|Ultrasound guided oblique subcostal transversus abdominis plane block will be performed bilaterally.
48650867|NCT03708510|DEVICE|Restorative materials- Filtek Silorane|Filtek Silorane
48650868|NCT03708510|DEVICE|Restorative materials-Kalore|Kalore
48650869|NCT03708510|DEVICE|Preparation-Er,Cr:YSGG Laser|Er,Cr:YSGG Laser
48650870|NCT03708510|DEVICE|Preparation- Diamond Bur|Bur
47973727|NCT02412475|DRUG|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
47973728|NCT02412475|DRUG|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
47973729|NCT02412475|DRUG|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
48650871|NCT03791060|DRUG|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
48650872|NCT05598515|BEHAVIORAL|Time-Restricted Feeding|Participants will be asked to eat for only 8 hours out of 24 hours in a day.
48650873|NCT05284617|DRUG|HU6|HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
47973730|NCT02412475|DRUG|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
47973731|NCT02412475|DRUG|Cytarabine|"Patient Age (years) IT Cytarabine Dose \> 1 30 mg~* 2 and \< 3 50 mg~* 3 and ≤ 18 70 mg \> 18 100 mg~given IT on day 0 or -1"
47973732|NCT02412475|DRUG|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
47973733|NCT02324569|DRUG|SYR-472|SYR-472 tablets
47973734|NCT02324569|DRUG|Placebo|Placebo tablets
47973735|NCT00894660|DRUG|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
47973736|NCT00894660|DRUG|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
47973737|NCT04617509|DRUG|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
48491300|NCT03814330|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
48650874|NCT05284617|DRUG|Placebo|Placebo
48650875|NCT06318169|BIOLOGICAL|Pegozafermin|Subcutaneous injection
48650876|NCT06318169|OTHER|Placebo|Subcutaneous injection
48650877|NCT03850301|DRUG|XBD173|7 days treatment
48650878|NCT03850301|DRUG|Etifoxine|7 days treatment
48650879|NCT05704322|OTHER|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
48650880|NCT06409013|OTHER|Non-Interventional Study|Non-interventional study
48650881|NCT06673849|OTHER|Rhythmic Stabilization|"Rhythmic Stabilization Program for Children with Cerebral Palsy Objective: Enhance upper extremity strength and stability through rhythmic stabilization exercises.~Program Overview:~Duration: 30-minute sessions Frequency: Once per week for 6 weeks~Exercise Steps:~Positioning: The child positions their upper extremity within their available range of motion.~Isometric Contraction: The child holds an isometric contraction, maintaining the position without movement.~Therapist's Role: Apply resistance that is sufficient to elicit a reaction but not enough to disrupt the isometric contraction.~Progression: Gradually increase the duration of the isometric hold. Increase the amount of resistance applied. Decrease the contact area between the therapist's hands and the child's upper extremity to enhance stability challenges. Monitoring and Adjustments: Assess the child's ability to maintain the contraction and adapt the resistance and support as needed. Encourage the child's engagement."
48650882|NCT06673849|OTHER|Ball Balancing|"Ball Balancing Program Objective: Improve balance and stability. Equipment: 48-inch gymnastic ball~Program Details:~* Duration: 6 weeks~* Frequency: As needed~Steps:~1. Initial Balance:~   * Eyes Open: Balance on hands for 10 seconds.~  * Progression: Increase to 3-5 repetitions of 60 seconds.~2. Eyes Closed: Repeat the above exercise with eyes closed.~3. Variations:~   * Both Hands on One Ball~  * Each Hand on Separate Balls~  * Weaker Arm on One Ball~4. Body Positions: Progress through four body positions with eyes open, then closed.~5. Correction: If the child misses a position, they open their eyes and reposition actively."
48650883|NCT06110910|DRUG|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
48650884|NCT05463731|DRUG|Remternetug (IV)|Administered IV
48650885|NCT05463731|DRUG|Remternetug (SC)|Administered SC
48650886|NCT05463731|DRUG|Placebo|Administered IV or SC
48650887|NCT03189927|DEVICE|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
48650888|NCT06039800|OTHER|No intervention|No intervention
48491301|NCT03814330|DIAGNOSTIC_TEST|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
48491302|NCT03814330|OTHER|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
48491303|NCT03814330|DEVICE|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
47973738|NCT04617509|DRUG|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
48491304|NCT05566964|DEVICE|ME&MGopen smartphone application|Smartphone application includes digital tests and e-questionnaires
48650889|NCT04999202|DRUG|BAY2416964|Oral, twice or three times daily
48650890|NCT04999202|DRUG|BAY2416964|The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
48650891|NCT04999202|DRUG|Pembrolizumab|Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
47973739|NCT02554357|DRUG|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
47973740|NCT02554357|DRUG|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
47973741|NCT04250883|OTHER|Low intra-abdominal pressure|8 mmHg
47973742|NCT04250883|OTHER|Deep neuromuscular blockade (NMB)|Deep NMB (PTC1-2)
48491305|NCT04093869|BEHAVIORAL|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
48491306|NCT04093869|BEHAVIORAL|Standard of Care plus Education (SOC-ED)|The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
48650892|NCT06642233|DIAGNOSTIC_TEST|Socio-demographic survey|Socio-demographic survey includes: age, sex, time of symptoms, work activity, hours of work activity, work position, activities with loads, physical activity, household chores, missing teeth, dental splints, dentures, smoking, alcohol consumption, whether they can reproduce their symptoms, hours during which they perform focal distance tasks, whether they have visual problems, whether they take painkillers or anti-inflammatory drugs, presence of headaches and their frequency), whether you can reproduce your symptoms, hours during which you perform tasks at focal distance, whether you have visual problems, whether you take analgesics or anti-inflammatory drugs, presence and frequency of headaches.
48650893|NCT06642233|DIAGNOSTIC_TEST|Visual Analogue Scale|VAS scale - The subject must indicate with a horizontal line their perception of pain on a scale (not numbered) of 100 millimetres, with 0 being the absence of pain and 100 the worst pain imaginable. The patient will complete the VAS scale, responding to the average, maximum and minimum pain experienced throughout its duration.
48650894|NCT06642233|DIAGNOSTIC_TEST|The World Health Organization Quality-of-Life Scale-BREF questionnaire|The WHOQOL-BREF questionnaire is used to assess domains quality of life: physical, mental, social functioning and functioning in the environment. Responses are on a 5-point scale (score range 1-5). In each field you can get maximum 20 points. The results of individual areas are positive (the higher the number of points, the higher the quality of life).
48650895|NCT06642233|DIAGNOSTIC_TEST|The International Physical Activity Questionnaire|The International Physical Activity Questionnaire (IPAQ) is a self-reported questionnaire for assessing physical activity and sedentary behavior for adults aged 15-69 years, across a range of socio-economic settings.
48650896|NCT06642233|DIAGNOSTIC_TEST|The Neck Disability Index questionnaire|The NDI evaluates the effect of neck pain on activities of daily living and social relationships. It consists of 10 items with 6 response options that are scored from 0 to 5 points each for a total possible score of 50. The classification of disability is based on the total score obtained, with higher number indicating greater disability.
48650897|NCT06642233|DEVICE|Body composition analysis using TANITA device|"TANITA device - body composition analyzer, the proportion of muscle mass and fat in the upper limbs~* Body height will be determined using a SECA 217 stadimeter.~* General and segmental body composition using the eight-electrode body composition analyzer by TANITA."
48650898|NCT06642233|DIAGNOSTIC_TEST|Cervical spine AROM (Active range of motion)|"Measurement of cervical spine AROM can be performed using the CROM system (Performance Attainment Associates, Roseville, MN, USA). Flexion, extension, side bending to the right and left, and rotation to the right and left of the cervical spine are examined.~The CROM measuring equipment consists of a helmet-shaped structure with the shape of glasses. These glasses adjust to the nasal septum thanks to the velcro on the back to fit them on the head. Three inclinometers for measuring on 3 cardinal planes were placed in the plastic construction."
48650899|NCT06642233|DIAGNOSTIC_TEST|Sagittal plane UCS AROM (Upper cervical spine active range of motion)|Measurement of sagittal plane UCS AROM can be performed using the CROM system. Flexion and extension of the upper cervical spine are examined.
48650900|NCT06642233|DIAGNOSTIC_TEST|Flexion-Rotation Test|The flexion-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is flexed.
48650901|NCT06642233|DIAGNOSTIC_TEST|Sidebending-Rotation Test|The sidebending-rotation test can be performed using the CROM system. Rotation of the upper cervical spine is tested while the cervical spine is in a lateral tilt.
48650902|NCT06642233|DIAGNOSTIC_TEST|Axial rotation test C0-C2|The Axial rotation test C0-C2 can be performed using the CROM system. Rotation of the C0-C2 is examined.
47973743|NCT04250883|OTHER|Standard intra-abdominal pressure|14 mmHg
47973744|NCT04250883|OTHER|Moderate neuromuscular blockade (NMB)|Moderate NMB (TOF 1-2)
47973745|NCT06372002|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|"The intervention will consist of the Spanish adapted version of Cognitive Stimulation Therapy (CST) followed by the Maintenance CST program.~CST is a cognitive intervention for treating mild to moderate dementia consisting of fourteen 45-minute group sessions that take place twice a week for 7 weeks. Each session follows a main topic (reminiscing about the person's life, current events, word games...) and is led by two group facilitators. The same structure is followed in every CST session: 1. Introduction (5 minutes). 2. Main Activity (25 minutes). 3. Closing (5 minutes).~The Maintenance CST program follows the principles and structure of the original CST program and consists of 24 sessions, one per week, that will be administered after the original program.~The topic, activities, and materials required for each session are specified in the CST-ES manuals, which also provide the key principles that should guide the intervention and other information necessary for its implementation."
47973746|NCT06237660|PROCEDURE|Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsy|These children who will be having a bronchoscopy (a long thin tube, with a camera at the end, which is put inside the lung to look at and collect samples) as part of their standard clinical management, determined by their own consultants or treating physicians. They will be having lung samples (washings from the lung and a tiny piece of tissue taken from the breathing tubes) taken as part of their usual medical management. The research team will ask for consent to use the leftover samples for the bronchoscopy, for the study
47973747|NCT06237660|DIAGNOSTIC_TEST|Skin prick test|To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months
48329558|NCT04093687|OTHER|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
48329559|NCT03843736|BEHAVIORAL|Lifestyle intervention|"1. Balance the diet;~2. Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~3. Monitor body weight, avoid sedentary, get more sun and regular activities;~4. Mental health regulation."
48329560|NCT03843736|DRUG|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
48329561|NCT03843736|DRUG|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
48329562|NCT00648141|DRUG|Celecoxib|200 mg oral capsule once daily for 12 weeks
48329563|NCT00648141|DRUG|Celecoxib|200 mg oral capsule twice daily for 12 weeks
48329564|NCT00648141|DRUG|Diclofenac|75 mg oral capsule twice daily for 12 weeks
48329565|NCT04043715|DEVICE|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
48491307|NCT04465630|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
48491308|NCT02263781|PROCEDURE|Blood draw|Blood draw
48491309|NCT02263781|PROCEDURE|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
48491310|NCT02599636|OTHER|None intervention|Investigators will study the usual medical assistance
48491311|NCT02914093|OTHER|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
48491312|NCT05042050|BEHAVIORAL|A-iMAPS|Imagery therapy targeting Psychosis-Related PTSD
48491313|NCT03367325|DEVICE|CDS-NVAF|The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is \< 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in \> 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
48491314|NCT06290518|DIETARY_SUPPLEMENT|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9.5 log10 cfu of the strain.
48491315|NCT06290518|DIETARY_SUPPLEMENT|Placebo|Oral administration of a capsule containing maltodextrin.
48491316|NCT00396799|DRUG|bazedoxifene/conjugated estrogens|
48491317|NCT05558995|OTHER|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
48491318|NCT03660436|DRUG|BMS-986165|Specified dose on specified days
47973748|NCT06237660|DIAGNOSTIC_TEST|Finger prick blood test|Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.
47973749|NCT06237660|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|Breathing test will be performed using forced oscillation technique (FOT), to see how the child's lungs work and to detect airway inflammation. The test will be explained to the child and completed using our established protocols. This test will only require the child to breathe in and out normally, and therefore can be done in preschool aged children. The current test that is used to check lung function called spirometry cannot be used in preschool children, as it involves following complicated instructions. The aim is to assess how well this newer lung function test is tolerated, in children aged 1-5 years.
47973750|NCT06237660|PROCEDURE|Sputum induction|Sputum induction is a test of obtaining phlegm after inhalation of salt water mist (saline nebuliser) and this will allow the research team to look for any relationships between infection in the lungs and the accuracy of the less invasive, nose and throat swabs. The research team will obtain phlegm samples, with a quick suction after patients have inhaled the salty mist (saline nebuliser) which will help loosen up their phlegm. If the child can cough it up, they will be encouraged to do it.
47973751|NCT06237660|DIAGNOSTIC_TEST|Oropharyngeal swab|Swabs from children's nose and throats (similar to swab tests that are done for Covid tests), that will be used to test for bacterial infection
48329566|NCT04043715|DEVICE|Epidural spinal stimulation|Physical therapy to improve standing and walking
48329567|NCT01837017|BEHAVIORAL|Home-based Exercise|This is a control group with no intervention
48329568|NCT02595840|DRUG|Afatinib|
48329569|NCT02595840|DRUG|Pemetrexed|
48650903|NCT06642233|DIAGNOSTIC_TEST|Tilting test C0-C1 and C2-C3|The Tilting test C0-C1 and C2-C3 can be performed using a goniometer. Lateral tilt of the C0-C1 and C2-C3 are examined.
48650904|NCT06642233|DIAGNOSTIC_TEST|Craniocervical flexion test|The test measures the level of activation of the deep neck flexors using a pressure biofeedback device, an air-filled manual pressure cuff (Stabilizer TM, Chattanooga Group, INC., USA).
48329570|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Plan + CHW|"* Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~* Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
47973752|NCT00492583|DRUG|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
47973753|NCT00492583|DRUG|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
48329571|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Management Plan|"* Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
48329572|NCT02190617|BEHAVIORAL|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
48329573|NCT06373276|OTHER|multiplanar balance training exercise with education|7 minute daily balance training exercises
48491319|NCT03660436|DRUG|MMF|Specified dose on specified days
48491320|NCT05372133|DRUG|Morphine|Children will be provided with morphine for at-home pain management following supracondylar fracture repair
48491321|NCT00817076|DRUG|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
48491322|NCT06052865|BEHAVIORAL|SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program
48650905|NCT06642233|DIAGNOSTIC_TEST|Craniovertebral angle|The test measure the craniovertebral angle using a telephone placed on a tripod and a computer program. The CVA measurement is defined as the angle a horizontal line passing the neural spine of C7 in relation to the line connecting the tragus and the neural spine of C7.
48650906|NCT03007693|DRUG|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
48329574|NCT06373276|BEHAVIORAL|education only|5 educational broshures
48650907|NCT03007693|DRUG|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
48650908|NCT01892189|DRUG|Ketamine|Ketamine intravenous administration.
48329575|NCT05414370|DRUG|Liquid oxygen|Liquid medical oxygen will be administered for 6 hours using high-flow nasal cannula delivery system with an Fi02 of 100% and flow rate of 60 litres per minute.
48329576|NCT05414370|DRUG|medical air|Synthetic medical air will be administered for 6 hours using high-flow nasal cannula delivery system with a flow rate of 60 litres per minute.
48329577|NCT01369849|DRUG|Akt Inhibitor MK2206|Given PO
48329578|NCT01369849|DRUG|Bendamustine Hydrochloride|Given IV
48329579|NCT01369849|OTHER|Laboratory Biomarker Analysis|Correlative studies
48329580|NCT01369849|BIOLOGICAL|Rituximab|Given IV
48650909|NCT01892189|DRUG|TAK-063|TAK-063 tablets
48650910|NCT01892189|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
48650911|NCT03191331|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
48650912|NCT05912725|PROCEDURE|Implant placement|"4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar"
48650913|NCT00934388|PROCEDURE|Pre peritoneal mesh placement|
48329581|NCT04655703|DEVICE|DJO X4 brace with Motion Intelligence Platform|The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
48329582|NCT02849626|DRUG|Perampanel|E2007
48329583|NCT01958879|DRUG|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
48329584|NCT01958879|DRUG|ringer without corticosteroid|200 mL Ringer solution
47973754|NCT02741024|DRUG|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
48329585|NCT02675725|DEVICE|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
48329586|NCT06315244|PROCEDURE|US Guided Perineural Injection and Neuroprolotherapy|Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
48329587|NCT03181074|OTHER|Non-Interventional|Non-Interventional
48329588|NCT01287481|BEHAVIORAL|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
48329589|NCT01287481|BEHAVIORAL|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
48329590|NCT01287481|BEHAVIORAL|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
48329591|NCT00538746|DEVICE|BIPAP|
48650914|NCT00934388|PROCEDURE|Laparoscopy|
48650915|NCT05274451|BIOLOGICAL|LYL797|LYL797 is an autologous, genetically (Gen-R™) and epigenetically (Epi-R™) reprogrammed ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy
48650916|NCT04204616|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
48650917|NCT05679622|OTHER|Fecal Microbiota Transplantation|In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
48329592|NCT00538746|DEVICE|PSV|
47973755|NCT02741024|DRUG|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
48329593|NCT00538746|DEVICE|PSV + CPAP|
48329594|NCT02714504|DRUG|Voriconazole or posaconazole|Azole with activity against molds
48329595|NCT01481909|DRUG|Rupatadin|20 mg, 28 days over 60 days
48329596|NCT02535637|OTHER|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
48329597|NCT00992186|DRUG|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
48329598|NCT02890043|PROCEDURE|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
48329599|NCT02890043|PROCEDURE|free-hand surgery|traditional free-hand surgery
47973756|NCT01654029|BEHAVIORAL|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
48123394|NCT01952769|BIOLOGICAL|MDV9300|"The study will be done in the following manner:~1. Evaluation of MDV9300 and radiation-~   1. Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~  2. Cohort B -3 patiens: if no toxicity \>grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity\> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity\> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~2. Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
48123395|NCT02887898|DEVICE|Automated bolus calculator|
48123396|NCT02887898|OTHER|Education|
48650918|NCT06639412|BEHAVIORAL|Networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention & control services.|The intervention will be networking the indigenous parent-teacher association and agriculture development agents with the PHC unit to enhance NCD prevention \& control services. In this major activity, the project team will establish the network by incorporating agricultural development agents and parents- teacher associations to the health post as foundational actors for educating the community on NCD prevention and control measures. We will implement tier system training to effectively create awareness on NCD and to enhance the NCD care-seeking behavior of the community.
48123397|NCT01198145|DRUG|sulfasalazine|Given orally
48123398|NCT01198145|OTHER|placebo|Given orally
48650919|NCT06639412|OTHER|Usual care|The community in the control group will get noncommunicable disease prevention and control measures given through the health care system.
48650920|NCT01767311|DRUG|Lecanemab 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
48329600|NCT02890043|DEVICE|TiRobot system|a robot-assisted spine surgery system
48123399|NCT01827917|BIOLOGICAL|rabies vaccine|Injection on day 0、7、21
48123400|NCT05049434|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
48329601|NCT03449121|BEHAVIORAL|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
48329602|NCT05533333|BEHAVIORAL|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
48491323|NCT06052865|BEHAVIORAL|SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.
48491324|NCT06052865|OTHER|Reference/ Standard of care|Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
48650921|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion
48329603|NCT01002053|PROCEDURE|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
48329604|NCT05797688|DEVICE|The Celution System|The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
48329605|NCT02750267|DEVICE|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
48650922|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
48650923|NCT01767311|DRUG|Lecanemab 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
48650924|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
48650925|NCT01767311|DRUG|Placebo|biweekly (once every 2 weeks) administered as i.v. infusion
48650926|NCT01767311|DRUG|Lecanemab 10 mg/kg|10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
48650927|NCT04628208|DIAGNOSTIC_TEST|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
48650928|NCT05300477|DRUG|Acetazolamide|Carbonic Anhydrase Inhibitor
47973757|NCT02205112|DRUG|Nemonoxacin|
47973758|NCT02205112|DRUG|Levofloxacin|
47973759|NCT03763214|DEVICE|Stenting with PTFE-coated stent (HILZO)|Placing a metal stent in the biliary tract by duodenoscopy
48123401|NCT05049434|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
48123402|NCT00798642|BEHAVIORAL|Hypnotherapy|8 weeks of gut-directed hypnotherapy
48123403|NCT00798642|BEHAVIORAL|Standard care|8 weeks of standard of care
48123404|NCT00798642|BEHAVIORAL|Mind Body Therapy|8 weeks of mind-body therapy
48123405|NCT03681522|PROCEDURE|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
48329606|NCT04578015|DRUG|Metronidazole|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
48329607|NCT04578015|DRUG|Placebo|Participants in this arm will receive placebo
48329608|NCT02366741|RADIATION|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
48650929|NCT05300477|DRUG|Erythropoietin|Hormone for red blood cell
48650930|NCT04467489|OTHER|observational|There is no intervention for any group in this observational study.
48650931|NCT05014126|BEHAVIORAL|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
48650932|NCT04887285|DEVICE|Virtual reality|Subjects in the virtual reality group will be offered a variety of immersive environments to choose from (mountains, beach, rainforest and temperate forest) in addition to local anesthetic.
48650933|NCT04887285|DRUG|Intravenous sedation|Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
48650934|NCT04887285|OTHER|Standard care|Patients will receive superficial local anesthetic with 1% lidocaine. Local anesthetic will be administered by the physician performing the procedure titrated to patient comfort.
48650935|NCT04016610|DEVICE|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
48650936|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
48329609|NCT01060683|BIOLOGICAL|Hemoglobin determination + NaCl 0.9% bolus|
48650937|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|
48650938|NCT01675440|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
48650939|NCT02759809|OTHER|Pasteurized donor human breastmilk|
48650940|NCT02759809|OTHER|Preterm formula|
47973760|NCT05114720|DRUG|standard adjuvant chemotherapy plus moxifloxacin|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days
48123406|NCT03681522|PROCEDURE|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
48329610|NCT01060683|BIOLOGICAL|hemoglobin determination + Venofundin bolus|
48329611|NCT02340468|DEVICE|diffuse optical spectroscopy|diffuse optical spectroscopy
48329612|NCT00022152|DRUG|vinorelbine tartrate|
48329613|NCT05322057|DRUG|Darvadstrocel|Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
48329614|NCT05536154|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
48329615|NCT05536154|DRUG|Cytarabine|Day 1\~Day 2: 200mg/m\^2, q12h
48650941|NCT06675734|DRUG|diclofenac sodium solution|The experimental group consisted of patients in whom diclofenac sodium was administered IM and the control group consisted of patients in whom diclofenac sodium was administered orally only.
48329616|NCT05536154|DRUG|PEG-rhG-CSF|Day 6: 6mg
48329617|NCT00881361|DRUG|systemic chemotherapy|
48491325|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
48650942|NCT01832038|DRUG|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
48650943|NCT03462121|DRUG|RPh201|RPh201 is a well-defined extract from a botanical source
48650944|NCT03462121|OTHER|Placebo|Inactive placebo consisting of the therapeutic vehicle
48650945|NCT05003700|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.
48650946|NCT05003700|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
48650947|NCT05003700|DRUG|Camrelizumab|200mg intravenously every 3 weeks.
48123407|NCT05152992|BEHAVIORAL|Viewing visual stimuli and electrical stimulation of the brain|View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
48123408|NCT00591708|DIETARY_SUPPLEMENT|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
48329618|NCT00881361|PROCEDURE|axillary lymph node dissection|
48329619|NCT00881361|PROCEDURE|neoadjuvant therapy|
48329620|NCT00881361|PROCEDURE|sentinel lymph node biopsy|
48329621|NCT00881361|PROCEDURE|therapeutic conventional surgery|
48329622|NCT00881361|PROCEDURE|ultrasound imaging|
48329623|NCT00640952|DRUG|acamprosate|333 mg 2 tabs tid
48329624|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
48329625|NCT01975246|DRUG|hydrochlorothiazide|tablet
48329626|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
48491326|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
48491327|NCT03856684|BEHAVIORAL|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
48491328|NCT03856684|BEHAVIORAL|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
48650948|NCT06321029|BEHAVIORAL|Diabetes Tune-Up Group|The eDTU and iDTU interventions will consist of 6 weekly group sessions lasting 90 minutes per session offered over a 6-8 week period. Each series will be co-facilitated by one diabetes care and education specialist and one behavioral health interventionist. Enrollment in each series will consist of 4-10 patients per group. The intervention components integrate key strategies that have been demonstrated to be effective in previous studies: motivational interviewing and introduction to stages of change; diabetes education; cognitive behavioral therapy with a particular emphasis on identification of cognitive distortions, thought stopping and cognitive reframing; emotional regulation; social support and miscarried helping; and behavioral strategies to support diabetes self-management. Each session will involve a psychoeducational portion, group discussion, and take-home assignments to be completed between sessions.
48329627|NCT01975246|DRUG|Placebo|placebo matching hydrochlorothiazide tablet
48329628|NCT00979680|RADIATION|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
48491329|NCT04749472|OTHER|Sling|Participants wore six different shoulder slings in a randomized order.
48491330|NCT00633516|DEVICE|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
48491331|NCT05876455|PROCEDURE|Conventional Subgingival Instrumentation|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
48329629|NCT00979680|RADIATION|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
48329630|NCT06315205|DRUG|Letrozole LEBE 75 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
48329631|NCT06315205|DRUG|Letrozole LEBE 150 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
48329632|NCT06315205|DRUG|Letrozole LEBE 225 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
48329633|NCT00560222|DIETARY_SUPPLEMENT|bovine lactoferrin|1gm of lactoferrin will be given each day
48329634|NCT00560222|DIETARY_SUPPLEMENT|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
48329635|NCT04015440|BEHAVIORAL|HBMT|Individual is presented with words with some letters missing and told to complete the word.
48329636|NCT04015440|BEHAVIORAL|Other Training|Alternative to HBMT training
48329637|NCT00393068|DRUG|Erlotinib|Erlotinib
48329638|NCT00393068|DRUG|Bevacizumab|Bevacizumab
48329639|NCT00393068|DRUG|Paclitaxel|Paclitaxel
48329640|NCT00393068|DRUG|Carboplatin|Carboplatin
48329641|NCT00393068|DRUG|5-FU|5-FU
48329642|NCT00393068|PROCEDURE|Radiation therapy|Radiation therapy
48650949|NCT05148247|BEHAVIORAL|The Perceive, Recall, Plan and Perform System of Intervention|The aim of the PRPP intervention is to enhance mastery in performance of needed or desired occupations, and extend traditional task training. Systematic instructions to support the clients' cognitive capacity to think about doing in different tasks and contexts are given by the OT, based on the results of PRPP Assessment stage 2. Further, the OT uses graded verbal, visual or physical prompts and cues directly during the participants task performance, progressing from content-free meta-prompts 'Stop' to alert the participant to process information required for the task, and for errorless learning. Then the OT prompt 'sense/attend, think and do', to more specific behavioural prompts selected by the therapist based on the components from the PRPP Assessment stage 2. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as the person internalize the strategies.
48329643|NCT00393068|PROCEDURE|Surgery|Surgery
48329644|NCT02584465|DRUG|Tamoxifen|Tamoxifen: 40 mg/day
48329645|NCT02584465|DRUG|Regorafenib|Stivarga; 120mg/day
48491332|NCT05876455|PROCEDURE|minimally invasive non-surgical periodontal therapy|minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
48491333|NCT01563419|DEVICE|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
48491334|NCT04957836|OTHER|reversal with sugammadex|reversal with sugammadex for immediate extubation in the operating room
47973761|NCT05114720|DRUG|standard adjuvant chemotherapy plus placebo|docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
48491335|NCT01775436|BEHAVIORAL|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
48491336|NCT01775436|BEHAVIORAL|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
48491337|NCT02362984|DRUG|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
48491338|NCT02362984|DRUG|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
48491339|NCT04060342|DRUG|GB1275|Oral
48491340|NCT04060342|DRUG|nab-paclitaxel and gemcitabine|IV infusion
48123409|NCT00591708|DIETARY_SUPPLEMENT|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
48123410|NCT00991107|DRUG|HE3286|HE3286 20 mg (10 mg BID) for 28 days
48329646|NCT01985373|DRUG|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
48329647|NCT00051129|DRUG|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
48329648|NCT00051129|OTHER|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
48329649|NCT06445894|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.
48650950|NCT04421001|DEVICE|I-port use|patient will use I-port device fo 2 months
48329650|NCT06445894|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
48329651|NCT04605939|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
48329652|NCT04605939|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
48329653|NCT00218140|DRUG|nicotine transdermal system|
48329654|NCT04441554|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI of cervical spine
48329655|NCT04490317|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to CO poisoned patients~2. Cardiac CT be taken to CO poisoned patients~3. TTE be taken to CO poisoned patients~4. Brain MRI be taken to CO poisoned patients~5. Neurocognitive function tests be taken to CO poisoned patients~6. Laboratory tests be taken to CO poisoned patients"
48491341|NCT04060342|DRUG|pembrolizumab|IV infusion
48491342|NCT05730907|DRUG|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
48329656|NCT04490317|PROCEDURE|Hyperbaric oxygen therapy|"1. Hyperbaric oxygen therapy be used for CO poisoned patients~2. Therapeutic hypothermia be used for CO poisoned patients"
48329657|NCT05688319|BEHAVIORAL|Problem-Solving Training|Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks. The duration of each training session was 60-90 minutes.
48329658|NCT05491044|DRUG|orelabrutinib|Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
48329659|NCT02644148|PROCEDURE|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
48123411|NCT05772923|RADIATION|Contact x-ray brachytherapy|With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.
48123412|NCT05772923|PROCEDURE|Local excision|Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
48329660|NCT02644148|PROCEDURE|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
48491343|NCT05566548|DIAGNOSTIC_TEST|Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species|It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
47973762|NCT04908878|PROCEDURE|Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
47973763|NCT04908878|PROCEDURE|Serratus anterior plane (SAP) block|Patients will receive US-guided SAP block after induction of general anesthesia.
47973764|NCT04006574|OTHER|Exercises|Core stabilization
47973765|NCT01306591|DRUG|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
48329661|NCT04343209|DIAGNOSTIC_TEST|Myocardial Perfusion Imaging Study|Evaluation of myocardial perfusion via PET imaging agent
48329662|NCT04343209|DRUG|AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]|Cardiac PET imaging agent
48329663|NCT00792701|DRUG|cisplatin|Given IV
48329664|NCT00792701|DRUG|gemcitabine hydrochloride|Given IV
48329665|NCT02320630|DRUG|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
48491344|NCT05587114|DIAGNOSTIC_TEST|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
48491345|NCT03957330|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
48491346|NCT02093221|BIOLOGICAL|180 mg/kg Alpha1-PI|
48491347|NCT02093221|BIOLOGICAL|90 mg/kg Alpha1-PI|
48491348|NCT02093221|BIOLOGICAL|Placebo|
47973766|NCT01306591|DRUG|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
47973767|NCT01185132|RADIATION|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
47973768|NCT01185132|RADIATION|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
48491349|NCT02566993|DRUG|Lurbinectedin (PM01183)|
47973769|NCT01322178|DRUG|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1~Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h~repeated every two weeks for 4.5 months(9 cycles)"
48123413|NCT00911521|DRUG|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
48491350|NCT02566993|DRUG|Doxorubicin (DOX)|
48491351|NCT02566993|DRUG|Cyclophosphamide (CTX)|
47973770|NCT04983654|DIAGNOSTIC_TEST|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis ( sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks,~* Analysis of cytokine and metalloproteases in the wound fluid,~* Assessment of healing according usual treatment"
48329666|NCT02320630|DRUG|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
48329667|NCT02320630|DRUG|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
48329668|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
48491352|NCT02566993|DRUG|Vincristine (VCR)|
48491353|NCT02566993|DRUG|Topotecan|
48491354|NCT00912093|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
48491355|NCT00912093|DRUG|Placebo|Single subcutaneous injection of matching placebo
48491356|NCT01835379|DEVICE|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
48491357|NCT01835379|OTHER|Standard|
48329669|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
48329670|NCT04721977|DRUG|Tucatinib|Tucatinib 300 mg administered BID via oral tablet
48491358|NCT04542265|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
48491359|NCT00470457|BIOLOGICAL|Allergen specific immunotherapy|
48491360|NCT01565772|RADIATION|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
47973771|NCT04983654|DIAGNOSTIC_TEST|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis (sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks"
47973772|NCT03640130|BEHAVIORAL|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
47973773|NCT00262574|DRUG|Nesiritide,|PCI
47973774|NCT02887885|DRUG|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
47973775|NCT00645060|OTHER|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
48491361|NCT01565772|DRUG|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
48650951|NCT04724252|DRUG|Gabapentin|Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
48650952|NCT04724252|OTHER|Placebo|Control Arm
48650953|NCT03284385|DRUG|Adavosertib|Given PO
48650954|NCT06641401|PROCEDURE|Endoscopic Flexor Hallucis Longus transfer for Acute Achilles tendon rupture|All patients have already undergone the same operation for the same disease. All data are to be collected retrospectively
48650955|NCT00670514|BEHAVIORAL|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
48650956|NCT00670514|BEHAVIORAL|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
48650957|NCT06031441|DRUG|RO7566802|RO7566802 solution for infusion will be administered as specified in each treatment arm.
48650958|NCT06031441|DRUG|Atezolizumab|Atezolizumab solution for infusion will be administered as specified in each treatment arm.
48650959|NCT06428357|DIETARY_SUPPLEMENT|Recombinant Bovine Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
47973776|NCT00645060|OTHER|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
47973777|NCT00645060|PROCEDURE|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
47973778|NCT00645060|PROCEDURE|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
47973779|NCT00645060|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
47973780|NCT04779840|OTHER|anemia assessment|evaluation of anemia status
47973781|NCT02495441|OTHER|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
48650960|NCT06428357|DIETARY_SUPPLEMENT|Bovine Milk-Derived Lactoferrin|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
47973782|NCT05975944|DRUG|Selinexor，Olaparib|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
48491362|NCT01565772|DRUG|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
48491363|NCT06140121|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
48491364|NCT06140121|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
48491365|NCT03233425|BEHAVIORAL|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
48491366|NCT01781520|BIOLOGICAL|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
48650961|NCT06428357|DIETARY_SUPPLEMENT|Placebo|Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
48123414|NCT05221281|BEHAVIORAL|Multimodal intervention consisting of four core components|"Core Component 1: Individualized Assessment: Each participant will undergo individualized assessment of their biopsychosocial risk profile (PIBD INTERMED), self-efficacy (IBD-SES-A), function (IBD-DI), transition readiness (TRAQ) and IBD knowledge (IBD-KID2), and depression, anxiety and activation.~Core Component 2: Transition Navigator: Participants will be assigned a transition navigators, who will have knowledge of IBD, an understanding of the care pathway involved in transitioning IBD patients, and the skills and ability to provide psychosocial support.~Core Component 3: Participant Skills-building: Skills-building materials delivered virtually. Navigators will also be trained as motivational coaches and will lead separate personalized virtual sessions targeting individual skills that have been identified as deficient during the assessment phase.~Core Component 4: eLearning Curriculum: Organized online eLearning modules with reinforcement of knowledge by the navigators."
48491367|NCT01781520|DRUG|S1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25-\<1.5 m2, 50 mg; and \>1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
48650962|NCT05723380|PROCEDURE|Erector spinae plane block|T2 ESPB group where ESPB is performed at T2 with local anesthetics 20ml
48650963|NCT06540495|BEHAVIORAL|Salaso Virtual Exercise Program|Salaso is a digital health technology company that has online, mobile and telehealth solutions enabling providers to 'prescribe' evidence-based exercise programs for patients to complete virtually.
48650964|NCT06478589|BEHAVIORAL|Adapted Patient Priorities Care (PPC) approach|Step 1 is a PPC facilitation encounter, at which the facilitator will help the participant identify patient priorities, such as clarifying values (what matters most); setting meaningful, specific, and realistic outcome goals; describing healthcare preferences (care that is helpful and/or burdensome) and tradeoffs; and discussing priorities with clinicians. The participant's healthcare priorities are then documented and transmitted to clinicians, in order to facilitate changes in the patient's care plan to align it with his/her priorities. In step 2, the clinician considers patient's priorities and potential healthcare options (options might include starting or stopping treatments; adding or removing medications; ordering more or fewer tests; recommending or removing self-management tasks). In step 3, the clinician discusses care options with the participant, using strategies for aligning care with patient priorities.
47973783|NCT04556695|OTHER|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
48329671|NCT04721977|BIOLOGICAL|Trastuzumab|Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose, administered via IV infusion
48329672|NCT04721977|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 administered BID via oral tablet
47973784|NCT04556695|DEVICE|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
48491368|NCT01781520|OTHER|Best supportive care|Best supportive care
48491369|NCT00173875|DRUG|Iressa|
48491370|NCT04549935|DRUG|Dextenza|Dextenza 0.4mg
48650965|NCT06478589|OTHER|Usual Care|Usual care for breast cancer survivorship includes regular visits with the oncology provider and yearly mammograms for surveillance.
48491371|NCT04549935|DRUG|Topical Prednisolone|Standard of care topical drop treatment
48491372|NCT05367726|OTHER|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
48491373|NCT00004997|DRUG|Leucovorin|
48329673|NCT02651792|DRUG|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
48329674|NCT02651792|DRUG|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
48329675|NCT04172311|OTHER|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
48329676|NCT04172311|DRUG|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
48650966|NCT03700125|PROCEDURE|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
48650967|NCT03478488|DRUG|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
48329677|NCT03410927|DRUG|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
48650968|NCT03478488|DRUG|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
48329678|NCT04779632|DIETARY_SUPPLEMENT|Experimental: Fish Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
48329679|NCT04779632|DIETARY_SUPPLEMENT|Comparator: Safflower Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.
48329680|NCT03874351|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|"Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right."
48650969|NCT03536858|BEHAVIORAL|COACH (Communicating about Choices in Transplantation)|COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
48650970|NCT01271231|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
48650971|NCT01271231|DRUG|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
48491374|NCT06341387|OTHER|Breath, urine and blood analysis|"breath sampling: all subjects exhale into two sterile Tedlar bags, connected to a mouthpiece, in a condition similar to traditional spirometry.~Urine will be collected usual urine container.~The blood sample (\~ 5 ml) will be taken with a serum separator tube."
48491375|NCT04371328|OTHER|RECOP unit patient|"All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.~30 days after inclusion, virological status and mortality will be collect"
48491376|NCT00193427|DRUG|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
48650972|NCT01271231|DRUG|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
48650973|NCT03981055|DEVICE|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
48650974|NCT03981055|DEVICE|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
48329681|NCT01686958|DEVICE|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
48329682|NCT05610917|COMBINATION_PRODUCT|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
48329683|NCT05610917|COMBINATION_PRODUCT|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
48329684|NCT00476996|DRUG|Leflunomide|Oral repeating dose
48329685|NCT00476996|DRUG|Methotrexate|Oral or parenteral repeating dose
48329686|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (200mg)
48329687|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (500mg)
48329688|NCT00476996|DRUG|Placebo|Intravenous repeating dose
48329689|NCT02624011|BEHAVIORAL|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
48329690|NCT03748277|PROCEDURE|Decompression|Bilateral decompression
48329691|NCT03748277|PROCEDURE|PLIF|Traditional open surgery
48329692|NCT03748277|PROCEDURE|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
48329693|NCT03748277|PROCEDURE|Screw Fixation|Transpedicular Screw Fixation
48491377|NCT00193427|DRUG|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
48491378|NCT00193427|DRUG|Carboplatin|AUC = 1.5 weekly x 7
48491379|NCT00193427|RADIATION|Radiation|To 63 Gy
48491380|NCT03983694|OTHER|Erythrocyte transfusion|The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
48491381|NCT02043665|BIOLOGICAL|CVA21/pembrolizumab|
48491382|NCT03880773|DEVICE|Stapler|for transection of the pancreas and pancreatic stump treatment
48491383|NCT03880773|DEVICE|ultrasonic shears|for transection of the pancreas and pancreatic stump treatment
48491384|NCT00361335|DRUG|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
48491385|NCT00361335|DRUG|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
48491386|NCT00361335|DRUG|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
48491387|NCT04064814|DRUG|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
48650975|NCT03981055|OTHER|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
47973785|NCT04556695|OTHER|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
47973786|NCT02521610|DRUG|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
47973787|NCT02521610|DRUG|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
47973788|NCT06436872|OTHER|informing patients with using a booklet|The intervention group was informed before discharge and was given an information booklet. A phone number was given so that the researcher could contact the nurse. In the 4th week, 8th week and 12th week, information was given according to the information needs of the patient and caregiver.
47973789|NCT03916120|GENETIC|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
47973790|NCT03527277|OTHER|Naturally-sweetened orange juice|Commercially-available ready-to-serve refrigerated orange juice
47973791|NCT03527277|OTHER|Sugar-sweetened beverage|Sugar-sweetened water flavored with Kool-Aid (TM)
48329694|NCT02681185|OTHER|Virtual Care|"Virtual Care consists of the following services and resources:~1. Have a virtual consult through online methods or telephone with one of the study endocrinologists~2. Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~3. Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~4. Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
48329695|NCT02681185|OTHER|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
48329696|NCT03070561|BIOLOGICAL|sublingual film with peanut extract|
48329697|NCT06229067|DRUG|Adebrelimab|Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks. Adebrelimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48329698|NCT06229067|DRUG|Vinorelbine|Metronomic oral vinorelbine 20 mg every other day. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48491388|NCT04064814|DRUG|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
48491389|NCT00243464|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
48123415|NCT05221281|BEHAVIORAL|Standard of care|"The control group will be provided a standardized version of routine care for transition. In addition to recruiting centers' standard of care, all participating centers will implement the following transition interventions:~1. A written letter explaining the goals of transition to the patient and family.~2. Completion of age-appropriate checklists to ensure adolescents are meeting milestones of transition (developed by the TRACC Network).51~3. Annual online live educational webinars on transition and adolescent issues (hosted by the CIDsCaNN Education Committee).~4. Completion of the Pediatric INTERMED,52 with appropriate biopsychosocial intervention.~5. Completion of a transfer-of-care summary letter sent to the receiving adult gastroenterologist using a standardized letter template.53~The Control Group may also receive any interventions currently in place in their participating care center, but will not receive the formal 4-component intervention described below."
48123416|NCT00434304|DRUG|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
48123417|NCT01077986|DRUG|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
48123418|NCT01077986|DRUG|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
48123419|NCT01077986|DRUG|Everolimus|Everolimus will be administered daily, starting on day 1.
48123420|NCT03451721|DEVICE|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
48123421|NCT01353001|BEHAVIORAL|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
48123422|NCT01353001|BEHAVIORAL|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
48123423|NCT01353001|BEHAVIORAL|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
48123424|NCT03195075|PROCEDURE|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
48123425|NCT03195075|PROCEDURE|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
48123426|NCT02578836|PROCEDURE|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
48123427|NCT00371787|DEVICE|Soft contact lens|Soft contact lens
48123428|NCT03855007|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
48123429|NCT03855007|DRUG|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
48329699|NCT06229067|DRUG|Cyclophosphamide (tablet)|Metronomic oral cyclophosphamide 50 mg daily. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48650976|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 year old) implemented by the MoH without DOT|Standard approach for SMC strategy used by the Ministry of Health (without directly-observed therapy) and without any interference of the study team. Implemented over 4 rounds, carried out in June-October 2023 with \~30 days between rounds.
48123430|NCT03855007|DRUG|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
48123431|NCT03855007|DRUG|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
48123432|NCT01593319|DRUG|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
48123433|NCT01593319|DRUG|Natrium chloride|Placebo injection of Natrium chloride solution
48123434|NCT04306705|DRUG|Tocilizumab|Administered as an intravenous infusion.
48329700|NCT06229067|DRUG|Capecitabine|Metronomic oral capecitabine 500 mg three times daily. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48329701|NCT02982486|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
48329702|NCT02982486|DRUG|Nivolumab|Ninolumab 240 mg IV every 2 weeks
48329703|NCT03636568|OTHER|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients \< 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients \>100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh \> 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~1. Serum Na level must be \< 145 mEq/l~2. Patient should be taking fluids by mouth~3. Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
48329704|NCT05046678|DIAGNOSTIC_TEST|Control|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking
48650977|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 5 years old) with DOT|SMC will be implemented with the same number of rounds and the same timing as in active comparator arm but village health workers will visit the participants at home to administer each dose of study treatment (with DOT-directly-observed therapy)
48650978|NCT05878366|OTHER|Seasonal Malaria Chemoprophylaxis (under 10 years old) with DOT|SMC will be implemented as in arm 2 but age of participants is extended up to 10 years: each dose of study treatment (with DOT-directly-observed therapy) distributed at home by village health workers.
48650979|NCT05052736|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 20 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
48650980|NCT03687671|OTHER|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
48650981|NCT03687671|OTHER|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
48650982|NCT05462821|DEVICE|Eye Patch|adhesive patch to cover eye
48650983|NCT06674889|OTHER|Rehabilitation-based intervention|Assessment of the subject by a specialty consultation and exercise program development.
48123435|NCT04306705|OTHER|Standard of care|Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.
48123436|NCT04306705|PROCEDURE|Continuous renal replacement therapy|Catheter insertion site is femoral vein.
48123437|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
48123438|NCT01479647|DRUG|PH-797804|Tablet, 1 mg, single dose
48123439|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
48123440|NCT01479647|DRUG|PH-797804|Tablet, 10 mg, single dose
48123441|NCT01479647|DRUG|PH-797804|Tablet, 24 mg, single dose
48329705|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontally healthy|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
48329706|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking
48329707|NCT05046678|DIAGNOSTIC_TEST|Smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
48123442|NCT01011946|DEVICE|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
48329708|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and nonsmokers if they had no previous history of smoking
48329709|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
48329710|NCT00363441|PROCEDURE|Intensity Modulated Radiotherapy|
48329711|NCT01018511|DRUG|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
48329712|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
48329713|NCT01018511|DRUG|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
48329714|NCT01018511|DRUG|tamsulosin hydrochloride OCAS 0.4 mg|tablet
48329715|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
48329716|NCT01018511|DRUG|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
48329717|NCT05269641|OTHER|Food: whole almonds|60g of whole almonds will be consumed daily.
48329718|NCT05269641|OTHER|Food: non-nut snack|A non-nut snack will be consumed daily.
48329719|NCT00793182|DRUG|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
48329720|NCT00793182|DRUG|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
48329721|NCT01927393|OTHER|palliative care|Receive PCPI
48329722|NCT01927393|BEHAVIORAL|educational intervention|Receive education sessions
48329723|NCT01927393|PROCEDURE|quality-of-life assessment|Ancillary studies
48329724|NCT01927393|OTHER|questionnaire administration|Ancillary studies
48329725|NCT01927393|BEHAVIORAL|telephone-based intervention|Receive telephone contacts
48329726|NCT01324934|DRUG|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
48329727|NCT05693870|DEVICE|Fixed space maintainer|Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
48491390|NCT00675064|DRUG|GSK369796|Anti-malarial
48650984|NCT00873886|DRUG|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
48123443|NCT01188369|DRUG|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
48123444|NCT01188369|DRUG|placebo drug|Intravenous infusion, colour identical to levosimendan
48123445|NCT03827369|DIAGNOSTIC_TEST|ICU patient|Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
48329728|NCT00274768|DRUG|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
48329729|NCT01529814|DEVICE|Implant with new abutment connection|New abutment connection implant system
48329730|NCT01529814|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
48329731|NCT00866515|DRUG|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
48329732|NCT00866515|DRUG|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
48329733|NCT03506100|OTHER|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
48491391|NCT00675064|DRUG|Placebo|Placebo matching GSK369796
48491392|NCT01079884|DRUG|esomeprazole 40 mg|40 mg daily for 4 weeks
48491393|NCT02938403|BEHAVIORAL|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
48123446|NCT00268671|DRUG|Docetaxel|
48123447|NCT00490100|DRUG|Increlex|
48123448|NCT02851667|BEHAVIORAL|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
48123449|NCT01715636|DRUG|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
48123450|NCT02545920|OTHER|no intervention|observational study
48123451|NCT05952895|PROCEDURE|Conventional quadrant-wise scaling and root planing (SRP)|SRP was conducted at baseline, after saliva collection and periodontal assessment, starting with the upper right quadrant and continuing clockwise over four visits at weekly intervals. SRP was performed under local anesthesia by the same periodontist (B.A.) by use of ultrasonic instruments (Mini Piezon, EMS, Nyon, CH) and manual periodontal curettes (Gracey curets, scaler Hu-Friedy, Chicago, IL). All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Self-performed plaque control measures consisted of toothbrushing using the modified Bass technique with a medium toothbrush and a regular toothpaste with fluoride twice a day and interdental cleaning using dental floss and/or interdental brushes once a day.
48123452|NCT05408572|BIOLOGICAL|SON-1010 (IL12-FHAB)|SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.
48123453|NCT05617742|DIAGNOSTIC_TEST|68Ga-FAPI-46|68Ga-FAPI-46 is a radioactive diagnostic agent for PET imaging in the detection of Fibroblast Activation Protein (FAP) positive tumor cells in cancer patients
48123454|NCT01420549|DRUG|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
48329734|NCT02483078|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
48329735|NCT02483078|DRUG|Placebo|
48329736|NCT02483078|DRUG|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
48491394|NCT02938403|BEHAVIORAL|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
48123455|NCT01420549|DRUG|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
48123456|NCT01613716|DRUG|Ozurdex|Ozurdex .7 mg injected into the treated eye
48123457|NCT01748110|BEHAVIORAL|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
48123458|NCT01748110|BEHAVIORAL|TRIMM|text message intervention.
48123459|NCT00301652|DRUG|mycophenolate mofetil|MMF,1.0g/d
48329737|NCT02527148|DEVICE|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
48329738|NCT02527148|DEVICE|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
48329739|NCT02527148|PROCEDURE|Total Knee Replacement|
48329740|NCT02527148|DEVICE|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including~* Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~* Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~* Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
48329741|NCT01788280|DRUG|Fluciclitite , PET imaging, and Bevacizumab|\[18F\] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
48491395|NCT01172483|PROCEDURE|general practice in primary care and education|education of chronic disorders in PC
48650985|NCT00873886|PROCEDURE|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
48650986|NCT05711797|DRUG|ZX-7101A 80mg|ZX-7101A a drug to treatment influenza in Chinese adults
48650987|NCT02884479|DRUG|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
48650988|NCT02884479|DRUG|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
48650989|NCT00970177|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
48650990|NCT04660682|OTHER|Modified static cross-body posterior shoulder stretching|For the modified cross-body position patient will be positioned in the side-lying position to limit the scapular abduction, and the patient aligned his/her forearms to limit the ER of the humerus while moving into horizontal adduction (HAdd). First, we will ask the patient to pull his/her arm into HAdd to the physiological barrier of the ROM, and then the patient will perform active-assistive static stretching with the help of the other hand for 30 seconds. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
48650991|NCT04660682|OTHER|Traditional static cross-body posterior shoulder stretching|For the traditional static cross-body posterior shoulder stretching, in the standing position, the patient will perform cross-body stretch alone by active-assistive pulling the humerus across the body into HAdd with the opposite arm, without concern for scapular stabilization for 30 sec. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
48123460|NCT04192305|PROCEDURE|LPV|LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
48123461|NCT04192305|PROCEDURE|routine LV|Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
48123462|NCT04218890|DIAGNOSTIC_TEST|Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin|urinary sample
48123463|NCT02376530|BEHAVIORAL|Nutrient profiling|Nutrient profiling system will be present during shopping session.
48123464|NCT02376530|BEHAVIORAL|Price Changes|Price changes will be present during shopping session.
48123465|NCT01392638|OTHER|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
48123466|NCT01392638|DRUG|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
48123467|NCT00780351|DEVICE|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
48123468|NCT01638026|DRUG|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
48123469|NCT02772471|DEVICE|HS-1000|
48123470|NCT04810260|BEHAVIORAL|Use mobile health app (WellXcel) to increase knowledge|Download the app (WellXcel) to the mobile device
48123471|NCT04048668|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
48123472|NCT06342154|BEHAVIORAL|Endorphin Massage|The person who will perform the endorphin massage opens his hands with his palms facing himself and draws a semicircle with the nails of his middle, ring and little fingers touching the sacrum. Then, a semicircle is drawn with the fingertips from each side of the spine, starting from the sacrum to the shoulder area, towards the waist area, As a result of this process, a palm shape is drawn on the back. Effleurage is applied from the shoulders to the arms up to the elbows. Effleurage is applied towards the shoulders by pressing from the elbows upwards with the back of the thumb. Effleurage is applied up to the sacrum by pressing circular movements with two thumbs on both sides of the spine. Effleurage is applied from the sacrum to the neck by pressing with two thumbs in a circular motion on both sides of the spine (approximately 1.5 cm apart). Lastly, effleurage is applied to the neck area and scalp, then petrissage (rubbing) is applied and the massage is completed.
47973792|NCT04243967|OTHER|Music therapy|"On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~* 1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~* 2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~* 3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H\&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter)."
48123473|NCT01244672|PROCEDURE|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
48123474|NCT01244672|PROCEDURE|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
47973793|NCT04243967|OTHER|Control|Standard perioperative management including perioperative care (without the use of music / music therapy)
47973794|NCT02268084|DEVICE|Magnetic EEG/ECG-guided Resonance Therapy|A coil delivers a pulsed magnetic field to the cortex of the brain
47973795|NCT02268084|DEVICE|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
48123475|NCT03432858|DRUG|Vancomycin|Vancomycin - 1-gram dosing
48123476|NCT03432858|DRUG|Cefazolin|2-gram dosing for patients \<120 kg 3-gram dosing for patients 120 kg or greater
48123477|NCT03432858|DRUG|Saline Solution|Placebo
48123478|NCT00237991|BIOLOGICAL|Hepatitis A|
48123479|NCT01777750|DEVICE|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
48123480|NCT04850768|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
48123481|NCT04850768|OTHER|gingival crevicular fluid|GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
48123482|NCT02729506|PROCEDURE|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
48123483|NCT02729506|PROCEDURE|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
48329742|NCT04496557|DEVICE|PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)|"Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax."
48329743|NCT00289744|BIOLOGICAL|TWINRIX™ ADULT|2 doses IM injection in primary study
48329744|NCT00289744|BIOLOGICAL|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
48123484|NCT00096915|DRUG|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
48123485|NCT01073358|PROCEDURE|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
48123486|NCT05698459|BIOLOGICAL|OH2 injection|OH2 injection administered by transcatheter Intraarterial infusion
48123487|NCT02190097|OTHER|Paleolithic diet|see procedures section for more details
48123488|NCT02190097|OTHER|American Diabetes Association diet|see procedures section
48123489|NCT00036244|DRUG|RG1068 (Synthetic Human Secretin)|
48123490|NCT00134069|DRUG|sorafenib tosylate|Given orally
48123491|NCT00134069|DRUG|cetuximab|Given IV
48123492|NCT00134069|DRUG|irinotecan hydrochloride|Given IV
48123493|NCT01625234|DRUG|Phase I: X-396 (ensartinib)|Oral, ALK inhibitor
48123494|NCT01625234|DRUG|Phase II: X-396 (ensartinib)|Expanded Cohort
48123495|NCT03237975|BEHAVIORAL|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
48123496|NCT03237975|OTHER|Routine health education|The control group will receive routine health education.
48123497|NCT01625104|OTHER|Non Intervention|Business as usual
48123498|NCT01625104|OTHER|Agressive Intervention Process Improvement Strategies|
48329745|NCT03796234|OTHER|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
48123499|NCT05293808|DRUG|aspirin 100 mg bis in die|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
48123500|NCT05293808|DRUG|aspririn 200 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
48123501|NCT05293808|DRUG|aspirin 100 mg once daily|Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
48650992|NCT04660682|OTHER|Control Group|In sham stretching, the patient will be positioned in the traditional static cross body posterior shoulder stretching position, and then the patient will perform active-assistive HAdd ROM without enough stretching of the relevant tissue. Active assistive ROM will be stopped before reaching the individual PST measurement result (in this way, sham stretching will be performed without proper stretching of the relevant tissue). The HAdd ROM exercise will be performed 5 times. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
48329746|NCT03796234|OTHER|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
48329747|NCT02748122|OTHER|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
48650993|NCT01333787|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
48650994|NCT06674317|BEHAVIORAL|Internet Delivered Cognitive Behavioral Therapy for Insomnia in Persons with Inflammatory Rheumatic Diseass|"Cognitive behavioral therapy for insomnia (CBTi) is considered a first-line treatment for insomnia. Access to this treatment option is limited therefore we have been developing an internet delivered cognitive behavioral therapy for insomnia (I-CBTi) to help overcome accessibility barriers.~The purpose of this study is to pilot test a tailored internet-delivered cognitive behavioral therapy for insomnia (I-CBTi) intervention for persons with Inflammatory Rheumatic Diseases showing symptoms of insomnia."
48650995|NCT06464913|RADIATION|With or without chest wall RT|Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
48650996|NCT06675123|PROCEDURE|Biopsy|Undergo optional tissue biopsy
48650997|NCT06675123|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48329748|NCT02307838|OTHER|Assessments arm|Protocol required assessments not provided in standard of care
48329749|NCT00018629|OTHER||
48650998|NCT06675123|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48329750|NCT02080156|DEVICE|CPAP|
48650999|NCT06675123|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
47973796|NCT01756547|DRUG|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
48329751|NCT03086681|DRUG|Endostar|Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
48651000|NCT06675123|DRUG|BTK Inhibitor|Given BTK inhibitor
48651001|NCT06675123|PROCEDURE|Computed Tomography|Undergo PET/CT
48651002|NCT06675123|DRUG|Pacritinib|Given PO
48651003|NCT06675123|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
47973797|NCT01756547|DRUG|Placebo|
47973798|NCT01118221|BEHAVIORAL|pulmonary rehabilitation|structured exercise program
47973799|NCT01300598|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
47973800|NCT03809143|DRUG|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
47973801|NCT03089450|DEVICE|CGBio stent|Percutaneous Coronary Intervention
47973802|NCT03089450|DEVICE|Biomatrix flex|Percutaneous Coronary Intervention
47973803|NCT02784808|DRUG|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
47973804|NCT02784808|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
47973805|NCT00545194|DRUG|Prostaglandin E2|
47973806|NCT00349440|DRUG|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
47973807|NCT00323921|DEVICE|dermatological infrared laser|
48123502|NCT06014697|DIAGNOSTIC_TEST|Optical Coherence Tomography|Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
48329752|NCT03086681|DRUG|DDP|DDP: 40mg /m2，per week, for 5 cycles
48651004|NCT05360225|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
47973808|NCT04410211|DRUG|Sevoflurane|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator"
47973809|NCT04410211|DRUG|Midazolam injection|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator."
47973810|NCT03308877|BEHAVIORAL|BMI|Four 45-minute, brief motivational sessions for substance use
48123503|NCT06014697|OTHER|Clinical assessment|Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
48491396|NCT01172483|OTHER|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
48491397|NCT02991170|PROCEDURE|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
48491398|NCT02991170|PROCEDURE|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
48491399|NCT04941482|BEHAVIORAL|Periodic health check program for post-stroke|The stroke survivors will be assessed their physical and mental health, recurrence risks, and harmful behaviors at 0, 1, 3, and 6 months by specific scales.
48491400|NCT04941482|BEHAVIORAL|Guiding the appropriate rehabilitation exercises|The appropriate rehabilitation exercises will be designed and guided for each patient and they will be followed up by the daily online report.
48491401|NCT04941482|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will carry out on post-stroke patients in the first three months (one time per week in the first month and one time per the second and third month). This intervention method aims to discover and resolve patient's conflicts by a standardized communication skill to improve their mental health and change negative behaviors.
48491402|NCT04941482|DEVICE|Functional near-infrared spectroscopy|The fNIRS devices as an effective monitoring and therapeutic tool, evaluating the evolution of neural activity and stroke rehabilitation and recovery. Moreover, the cortex hemodynamic measure by fNIRS may detect early various mental disorders such as depression, anxiety, schizophrenia... through cognitive tasks.
48491403|NCT00367003|DEVICE|Deep Brain Stimulation|The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
48491404|NCT02302313|DEVICE|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
48491405|NCT02099695|DRUG|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
48491406|NCT02099695|DRUG|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
48491407|NCT06320405|BIOLOGICAL|Axatilimab|Given IV
48491408|NCT06320405|PROCEDURE|Biopsy|Undergo tumor biopsy
48491409|NCT06320405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48491410|NCT06320405|PROCEDURE|Computed Tomography|Undergo CT scan
48491411|NCT06320405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48491412|NCT06320405|DRUG|Paclitaxel|Given IV
48491413|NCT06320405|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48491414|NCT06320405|BIOLOGICAL|Retifanlimab|Given IV
48491415|NCT04629768|DEVICE|PuraStat|Purastat is applied to the EMR defect
48491416|NCT04557306|BIOLOGICAL|CBT101 cells, every 2 weeks|CBT101 cells, every 4 weeks
48329753|NCT04789863|DEVICE|SMILe-Integrated Care Model|"Four self-management intervention modules will be delivered by human and technology: 1) monitoring \& follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare."
48329754|NCT04789863|OTHER|Usual Care|The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
48329755|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
48329756|NCT05387577|DRUG|Transdermal patch|Estradiol patch therapy for 8 weeks
47973811|NCT03308877|BEHAVIORAL|Stadard Care (SC)|Standard procedures at pretrial program + assessement
48329757|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol 1 mg BID for 8 weeks
48329758|NCT04157647|DEVICE|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
48651005|NCT01251211|DRUG|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
48329759|NCT04157647|DEVICE|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
48329760|NCT00553345|DRUG|selenium|
48329761|NCT00553345|DRUG|vitamin E|
48329762|NCT00553345|PROCEDURE|chemoprevention|
48329763|NCT03379480|BEHAVIORAL|Yoga arm|Yoga module developed for patients with Schizophrenia
48329764|NCT00502528|DRUG|Placebo|Peri-interventional
48491417|NCT04557306|BIOLOGICAL|CBT101 cells, every 4 weeks|CBT101 cells, every 4 weeks
48491418|NCT02773459|DRUG|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
48491419|NCT00336076|OTHER|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
48491420|NCT00937820|DRUG|YM150|oral
48651006|NCT02076009|DRUG|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
48123504|NCT06247046|DRUG|Live SK08 powder|Oral Powder
48123505|NCT06247046|DRUG|Placebo|Oral Powder
48123506|NCT03886116|OTHER|Exercise|3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
48123507|NCT03567252|BEHAVIORAL|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
48123508|NCT02403297|DEVICE|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
48329765|NCT00502528|DRUG|BQ-123|Peri-interventional
48329766|NCT05161182|OTHER|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
48329767|NCT05161182|OTHER|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
48329768|NCT02014727|BIOLOGICAL|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
48329769|NCT02014727|BIOLOGICAL|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
48329770|NCT02014727|BIOLOGICAL|Group B2 : Placebo|
48329771|NCT01590394|DEVICE|Large plastic biliary stent|Stent placement for bile duct obstruction.
48329772|NCT06336343|DRUG|Bimekizumab|Bimekizumab 320 mg via subcutaneous injections. Bimekizumab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to and neutralizes the biologic functions of both interleukin-17A (IL-17A) and IL-17F, which are known to increase inflammation.
48329773|NCT06015412|DIAGNOSTIC_TEST|Radiographic classification|disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
48329774|NCT01090219|PROCEDURE|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
48651007|NCT02076009|DRUG|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
48651008|NCT02076009|DRUG|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
48651009|NCT01588925|DEVICE|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
48651010|NCT01588925|DRUG|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
48329775|NCT01383642|OTHER|No intervention, observational study|
48123509|NCT03872635|OTHER|oral carbohydrate liquid|patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
48123510|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
48491421|NCT01727882|BEHAVIORAL|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
48651011|NCT01588925|DRUG|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
48123511|NCT01915459|BIOLOGICAL|Botulinum toxin type A(Botox®)|
48123512|NCT05251844|OTHER|receiving an email|The email informed that the employee has had been identified as having accessed a patient's electronic medical record without a known work-related purpose and that unauthorized access is a privacy violation.
48123513|NCT01332045|PROCEDURE|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
48123514|NCT01332045|PROCEDURE|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
48123515|NCT03809936|DEVICE|real tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
48123516|NCT03809936|DEVICE|sham tDCS|For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
48123517|NCT02960204|DRUG|Emricasan|
48123518|NCT02960204|DRUG|Placebo|
48123519|NCT06514482|DIAGNOSTIC_TEST|Diagnosis|Diagnosis
48123520|NCT02014831|DRUG|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
48123521|NCT02014831|DRUG|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
48123522|NCT00277355|DRUG|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart)
48123523|NCT00277355|DRUG|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
48123524|NCT06409117|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention with scaffold implantation in patients with NSTE/ACS
48329776|NCT01061320|DRUG|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
48329777|NCT01061320|DRUG|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
48329778|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
48329779|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet
48329780|NCT06207695|BEHAVIORAL|Brief Group Intervention|This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
48651012|NCT06669039|DEVICE|Computer-controlled Local Anesthetic delivery system|Local anesthesia will be delivered using Computer-controlled Local Anesthetic delivery system.
48123525|NCT04829604|DRUG|ARX788|The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269
48123526|NCT05237570|PROCEDURE|Interradicular septum window|In this group, the maxillary sinus will be accessed through a window in the interradicular septum and the membrane will be elevated, carrying out the regeneration of the area to facilitate subsequent implant placement.
48123527|NCT02056236|DRUG|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
48123528|NCT02056236|OTHER|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
48491422|NCT01727882|BEHAVIORAL|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
48651013|NCT06669039|PROCEDURE|Inferior Alveolar Nerve Block|Local anesthesia will be delivered using the conventional syringe
47973812|NCT03879226|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
48123529|NCT00765271|DRUG|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
48123530|NCT00765271|DRUG|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
48329781|NCT06236230|DRUG|levodopa/carbidopa/entacapone|"On Day 1, subjects will be treated with levodopa/carbidopa/entacapone. Based on previous regimen. The dosage of levodopa/carbidopa/entacapone will be equal to the previous total daily dose of LD, and the frequency of administration of levodopa/carbidopa/entacapone is three or four times a day.~Levodopa/carbidopa/entacapone could be titrated in next 2 weeks according to the investigator's judgment, based on individual clinical response and tolerability.~After 2-week titration, the dose of levodopa/carbidopa/entacapone will remain as constant as possible to the end of study."
48329782|NCT05904353|PROCEDURE|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
48329783|NCT05904353|PROCEDURE|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
48329784|NCT03655392|BEHAVIORAL|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
48329785|NCT03655392|DIAGNOSTIC_TEST|Induced sputum collection|All participants performed induced sputum collection
48329786|NCT03655392|DIAGNOSTIC_TEST|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
48329787|NCT03655392|DIAGNOSTIC_TEST|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
48329788|NCT03655392|OTHER|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
48123531|NCT00765271|DRUG|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
48123532|NCT01864889|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
48651014|NCT05061836|DRUG|Ringer acetate|Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate
48651015|NCT05061836|DRUG|1.25%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
48651016|NCT05061836|DRUG|2.5%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
48651017|NCT05061836|DRUG|Dextrose 5|5%dextrose in normal saline (5%DNSS) infused with maintenance rate
48123533|NCT04761536|OTHER|Rectal cancer case centralization|In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
48123534|NCT05959590|DRUG|Ferumoxides 11.2Mg Solution for Injection|the drug will be injected at a single dose of up to 7 mg/Kg and MRI will be performed after 24 hrs.
48123535|NCT02941484|PROCEDURE|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
48123536|NCT02941484|PROCEDURE|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
48329789|NCT03655392|OTHER|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
48651018|NCT06312358|BEHAVIORAL|Building Capacity for Infant Achievements in Child Care|All teacher participants will be assigned to the professional development intervention consisting of an interactive workshop and weekly coaching sessions.
48651019|NCT06256939|OTHER|Therapy BRIDGE Program|A standardized education and coaching intervention will be developed to promote optimal neurodevelopmental outcomes through caregiver empowerment. This pilot study will enroll up to 15 infants with IVH and their caregivers during their NICU stay. These infant-caregiver dyads will receive up to 10 sessions utilizing the Therapy BRIDGE program over a four-month period that spans the hospital to home transition.
48491423|NCT01187199|DRUG|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
47973813|NCT03879226|DEVICE|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
48123537|NCT02352675|OTHER|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
47973814|NCT00018837|BEHAVIORAL|Community Re-Entry Program: What is Schizophrenia|
48491424|NCT01187199|DRUG|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
48123538|NCT03000049|OTHER|bedside blood culture|
48123539|NCT01796067|BEHAVIORAL|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
48123540|NCT01796067|BEHAVIORAL|Basic Health Education|This group will receive the comprehensive basic health education intervention.
48329790|NCT03655392|DIAGNOSTIC_TEST|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
48491425|NCT01187199|DRUG|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
48491426|NCT01187199|DRUG|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
48491427|NCT01187199|DRUG|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
48491428|NCT01744093|DRUG|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
48491429|NCT01744093|DRUG|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
48123541|NCT01796067|BEHAVIORAL|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
48123542|NCT01796067|BEHAVIORAL|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
48329791|NCT03655392|DIAGNOSTIC_TEST|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
48329792|NCT06068296|DIAGNOSTIC_TEST|short term memory assessment|"Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered."
48329793|NCT06068296|DIAGNOSTIC_TEST|Oxford cognitive screen|Evaluation of the cognitive abilities of the patients with aphasia.
48329794|NCT06068296|DIAGNOSTIC_TEST|Token Test|Evaluation of the severity of the aphasia in patients with aphasia.
48329795|NCT06068296|DIAGNOSTIC_TEST|Montreal cognitive assessment|Evaluation of cognitive dysfunction in the group of healthy volunteers.
48329796|NCT00804843|DRUG|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
48123543|NCT04999917|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"A single intravenous injection of 18F-FDG (0.80 MBq/kg) is given between 30 minutes and 3 hours before tumor resection.~Surgical resection of the breast tumor (= main specimen) under general anesthesia.~The main specimen is imaged using the Aura 10 PET-CT Specimen Imager (XEOS Medical, Ghent, Belgium). In case of positive margins, the surgeon will perform oriented cavity shaving. The cavity shaves and lymph nodes (if any) are also imaged using the Aura 10 PET-CT Specimen Imager (for scientific purposes only).~The main specimen and if applicable the cavity shaves and lymph node(s) are processed following standard-of-care routine: from tissue samples to HE-stained and IHC-stained sections. The histopathological margin status shall be reported according to the ASCO-CAP guidelines, and shall be compared to the PET-CT images of the resected specimens."
48329797|NCT00804843|DRUG|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
48329798|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
48329799|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
48329800|NCT03907787|DIETARY_SUPPLEMENT|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
48329801|NCT00326417|DRUG|Fludarabine|Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
48329802|NCT00326417|DRUG|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
48329803|NCT00326417|DRUG|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
48329804|NCT00326417|DRUG|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
48491430|NCT06309446|DEVICE|Zoralan Wound|Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).
48329805|NCT00821145|PROCEDURE|conventional surgery|AAA patients operated using a conventional incision
48491431|NCT03095118|DRUG|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
48123544|NCT06137105|DRUG|eltrombopag and romiplastim|"Group I: eltrombopag and romiplastim~Group II : recived corticosteroid."
48329806|NCT00821145|PROCEDURE|laparoscopic AAA resection|laparoscopic AAA resection
48329807|NCT00821145|PROCEDURE|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
48329808|NCT03788187|OTHER|Blood test sample|
48329809|NCT03788187|OTHER|Peritumoral adipose tissue sample|
48491432|NCT04610463|DIAGNOSTIC_TEST|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
48491433|NCT03375294|DRUG|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
48491434|NCT04334486|OTHER|Super Smash Brothers Melee (Gamecube)|10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
48491435|NCT02031952|PROCEDURE|hepatectomy combined with lymphadenectomy|
48329810|NCT03293186|COMBINATION_PRODUCT|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
48329811|NCT00411086|BIOLOGICAL|Rituximab|375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.
48329812|NCT00411086|BIOLOGICAL|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
48329813|NCT02370940|OTHER|High phytate intake|
48491436|NCT02031952|PROCEDURE|hepatectomy alone|
48491437|NCT03285308|DRUG|Placebo|Placebo injected subcutaneously twice daily.
48491438|NCT03285308|DRUG|Relamorelin|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
48491439|NCT04667260|PROCEDURE|Maxillary sinus membrane elevation|Maxillary sinus membrane elevation with blood coagulum
48491440|NCT04667260|PROCEDURE|Maxillary sinus floor augmentation|Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
48491441|NCT03417193|DRUG|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
48491442|NCT01709279|BIOLOGICAL|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
48491443|NCT05017974|BEHAVIORAL|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement|MBSR+PS
48491444|NCT05017974|OTHER|Treatment as Usual|TAU
48491445|NCT00629265|DEVICE|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
48491446|NCT01913236|OTHER|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
48491447|NCT03731871|DIAGNOSTIC_TEST|Ultrasonography|ultrasound to evaluate parameters of fetal maturity during pregnancy
48491448|NCT00696579|DRUG|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
48491449|NCT00696579|DRUG|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
48123545|NCT01088659|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
48329814|NCT02370940|OTHER|Low phytate intake|
48329815|NCT04663139|DRUG|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
48329816|NCT04663139|DRUG|Placebo|Matching placebo
48329817|NCT04354779|DIAGNOSTIC_TEST|a specifically designed self-administered questionnaire|The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.
48329818|NCT03157921|RADIATION|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
48329819|NCT03157921|DIAGNOSTIC_TEST|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
48329820|NCT06192953|OTHER|Functional Proprioceptive Stimulation|Orthoses with a system of 12 stimulators producing mechanical oscillations are attached to the joints of the upper limbs (wrist, elbow and shoulder) or lower limb joints (ankle, knee, hip). These stimulators, which are all synchronized, deliver mechanical oscillations (FPS) that give the illusion of complex movements, while the patient is bedridden, neither moving nor producing effort.
48329821|NCT00013455|DEVICE|Hearing|
48329822|NCT03703271|DRUG|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
48329823|NCT03703271|PROCEDURE|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
48329824|NCT02472795|DRUG|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
48491450|NCT02000401|DRUG|Ketorolac Tromethamine|
48491451|NCT04094376|OTHER|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
48329825|NCT02472795|DRUG|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
48651020|NCT05772130|OTHER|Best Practice|Receive family letter and genomic test report
48651021|NCT05772130|OTHER|Electronic Health Record Review|Ancillary studies
48651022|NCT05772130|BEHAVIORAL|Personal Contact|Receive family letter and genomic test report with provider-mediated contact
48651023|NCT05772130|OTHER|Survey Administration|Ancillary studies
48329826|NCT03392987|GENETIC|OTL-200|OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
48329827|NCT01354613|DRUG|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
48329828|NCT01354613|DRUG|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
48329829|NCT05559073|PROCEDURE|Radiofrequency ablation|pulmonary vein isolation using radiofrequency ablation.
48491452|NCT04801953|DRUG|NiMODipine Injectable Solution|nimodipine solution is applied to cranial nerves during resection of vestibular schwannoma
48491453|NCT04801953|OTHER|Placebo|Sodium chloride solution is applied to cranial nerves during surgery
48491454|NCT05770505|BEHAVIORAL|Exercise training using an e-health tool|Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Personal Activity Intelligence (PAI) equivalents per week Control: No follow-up
47973815|NCT02161367|DRUG|Simethicone|"Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days"
47973816|NCT02161367|DRUG|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
48491455|NCT06387459|DEVICE|Fabric-Type Knee Extensor Muscle-Mimicking Orthosis|The intervention device is a fabric-based orthosis incorporating shape-memory alloy springs designed to mimic the action of knee extensor muscles. The primary function of this orthosis is to provide supplementary support to the knee joint during walking, aiming to stabilize the gait of elderly individuals affected by muscle weakness or degenerative joint conditions. Material: The orthosis is made from a lightweight, flexible fabric that allows for breathability and comfort during extended wear. Mechanism: Embedded within the fabric are shape- memory alloy springs that function similarly to biological muscles.
48491456|NCT00577902|OTHER|Observation|Head and neck cancer patients receiving chemoradiation
48491457|NCT04976998|DIAGNOSTIC_TEST|imaging|imaging by ultrasonography and nerve conduction studies will be done for both grups
47973817|NCT04366102|OTHER|Multisensory stimulation with soft tissue therapy|Multisensory stimulation with soft tissue therapy will be given. Multisensory stimulation consists of Auditory, vestibular, tactile, olfactive, oromotor, Visual, and Kinesthetic stimulation. Soft tissue therapy consists of stroking, effleurage, fingertip kneading, tapping, and skin rolling will be given. Total intervention will be given for 30 min. 5 times per week
47973818|NCT04366102|OTHER|Routine hospital care|Routine hospital care will be given to the preterm neonates
47973819|NCT03556150|OTHER|Manual Therapy protocol|"This protocol consists of:~* Six minutes of joint's mobilisation (two minutes of each technique).~* Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~* Three minutes of trigemino's nerve stretching."
48123546|NCT01088659|DRUG|placebo|orally daily, 96 weeks
48123547|NCT01088659|DRUG|tenofovir|245mg po daily, 96 weeks
48329830|NCT01809925|DIETARY_SUPPLEMENT|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
48491458|NCT05692076|DEVICE|High Velocity Nasal Insufflation|High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
48491459|NCT05690126|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
48651024|NCT06675396|OTHER|Antidepressants|control
48651025|NCT04309266|DEVICE|Amadeo by Tyromotion|Distal upper extremity/hand robot for robot-assisted therapy
48651026|NCT04309266|BEHAVIORAL|Active Learning Protocol for Stroke|Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
48651027|NCT02228330|PROCEDURE|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
48651028|NCT05129969|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
48651029|NCT03709472|BEHAVIORAL|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
48651030|NCT03709472|BEHAVIORAL|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
47973820|NCT03556150|OTHER|Effleurage|"The protocol consists of:~* Five minutes in temporal muscle.~* Ten minutes superficial massage in the neck and cheek of the most painful joint.~* Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside."
48651031|NCT01940744|PROCEDURE|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
48123548|NCT03638427|DIAGNOSTIC_TEST|Menstrual Blood Analysis (Menstrual Blood Analysis)|We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
48123549|NCT06145867|OTHER|Photobiomodulation therapy|deep red light therapy (670nm)
48123550|NCT05916001|OTHER|Placebo|A Placebo will be administered per os 3 times per day for 10 days before colorectal surgery
48123551|NCT05916001|DIETARY_SUPPLEMENT|Oral Impact Nestle|Oral Impact Nestle will be administered per os 3 times per day for 10 days before colorectal surgery
48123552|NCT05916001|PROCEDURE|Colorectal surgery|Colorectal surgery will include right colectomy, left colectomy, transverse colectomy, anterior rectal resection. All procedures will be performed according to the standard clinical practice.
48123553|NCT05208125|BIOLOGICAL|ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).|Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
48651032|NCT01940744|PROCEDURE|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
48123554|NCT05208125|OTHER|Normal saline solution|Intramuscular administration of normal saline solution
48123555|NCT05119491|DEVICE|uitrasonography and spirometry|chest uitrasonography and spirometry
48123556|NCT00182975|DRUG|DHEA replacement|
47973821|NCT04755127|PROCEDURE|Arthroscopic synovectomy of the wrist|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
47973822|NCT04755127|DRUG|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
47973823|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
47973824|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
47973825|NCT01218568|DRUG|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
47973826|NCT01218568|DRUG|Lactulose|Lactulose 30-60 ml in two or three divided doses.
47973827|NCT04107194|DRUG|Pantoprazole 40mg|Proton pump inhibitor
47973828|NCT04107194|DRUG|Amoxicillin 1000 MG|Antibiotic
47973829|NCT04107194|DRUG|Clarithromycin 500mg|Antibiotic
47973830|NCT04107194|DRUG|Metronidazole|Antibiotic
47973831|NCT04107194|DRUG|Tetracycline 125 MG|Antibiotic
48329831|NCT01809925|DIETARY_SUPPLEMENT|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
47973832|NCT04107194|DRUG|Bismuth Subcitrate|Antibiotic adjuvant
47973833|NCT04107194|DRUG|Rifabutin 150 MG|Antibiotic
48123557|NCT03081611|DEVICE|Ram cannula|Ventilatory support for preterm infants using Ram cannula
48123558|NCT03081611|DEVICE|Short nasal prongs|Ventilatory support for preterm infants using short nasal prongs
48123559|NCT02928354|DRUG|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
48329832|NCT04155658|OTHER|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
48329833|NCT04155658|OTHER|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
48123560|NCT02928354|DRUG|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
47973834|NCT04107194|DRUG|Levofloxacin 500mg|Antibiotic
47973835|NCT03067168|DRUG|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
48123561|NCT02928354|DRUG|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
48123562|NCT02931175|DRUG|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
48123563|NCT05493644|OTHER|Remedial treatment within 3 months|Remedial therapy was performed within 3 months
48329834|NCT04155658|OTHER|Toothpaste with no fluoride|Toothpaste with no fluoride
48329835|NCT00014911|PROCEDURE|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
48329836|NCT00014911|DRUG|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
48329837|NCT00014911|DRUG|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
48329838|NCT00014911|DRUG|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
48123564|NCT05493644|OTHER|Remedial treatment within 3 to 6 months|Remedial therapy was performed within 3 to 6 months
48123565|NCT05493644|OTHER|Remedial treatment within 6 to 12 months|Remedial therapy was performed within 6 to 12 months
48491460|NCT05690126|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
48491461|NCT00428779|PROCEDURE|running during 24 hours without sleep|patients running during 24 hours without sleep
48491462|NCT00428779|OTHER|no sleeping|patients without sleep during 24 hours
48491463|NCT04565613|DIETARY_SUPPLEMENT|Enteral protein supplementation|"The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue."
48491464|NCT03955471|DRUG|Niraparib|Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
48491465|NCT03955471|DRUG|Dostarlimab|TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
48491466|NCT04739696|BEHAVIORAL|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
48651033|NCT06047587|BEHAVIORAL|VR-TrAC|Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.
48329839|NCT00014911|DRUG|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
48329840|NCT00014911|DRUG|Ganciclovir|An antiviral used to kill viruses and stop viral replication
48329841|NCT00014911|DRUG|Trimethoprim|An antibacterial used to prevent opportunistic infections
48329842|NCT00014911|DRUG|Pentamidine|An antiprotozoal used to prevent disease
48329843|NCT02664207|PROCEDURE|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
48651034|NCT06047587|OTHER|Care as Usual|Care as usual as provided in prison.
47973836|NCT03067168|DRUG|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
47973837|NCT03679936|DIAGNOSTIC_TEST|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
48123566|NCT05493644|OTHER|Remedial treatment after 12 months|Remedial therapy was performed after 12 months
48123567|NCT05287217|OTHER|Comparison of medication administration for pain control|Measuring pain control following FESS surgery
48123568|NCT01969981|PROCEDURE|PICC placement with Sherlock 3CG|
48123569|NCT04223258|DEVICE|Automatic Oxygen control|The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.
48123570|NCT04223258|OTHER|Manual Oxygen Control|In the manual arm the oxygen is adjusted manually by the clinical team.
48123571|NCT01599793|DRUG|cabozantinib|Given PO
48329844|NCT06376370|OTHER|Application of computer-assisted cognitive rehabilitation program|Since the program will respond to the patient's specific needs, the activity may become easier or more difficult depending on the patient's performance. Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session. After determining the appropriate time and day for each patient in the experimental group, the intervention will continue for 6 weeks with 45-minute sessions once a week.
48123572|NCT01599793|OTHER|laboratory biomarker analysis|Correlative studies
48123573|NCT01599793|PROCEDURE|magnetic resonance imaging|Undergo MRI
48123574|NCT03403478|OTHER|LICE|No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
48123575|NCT03403478|OTHER|MICE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
48123576|NCT03403478|OTHER|HIIE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
48123577|NCT03403478|OTHER|Aquatic exercise training|"The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics."
48123578|NCT03448510|DEVICE|Irreversible electroporation|The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
48123579|NCT03448510|DRUG|Standard Medication|The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
48123580|NCT01429350|DRUG|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
48123581|NCT01429350|DEVICE|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
48123582|NCT00903851|DRUG|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
48123583|NCT03213327|DEVICE|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
48329845|NCT00425113|DRUG|Metronidazole|
48329846|NCT00425113|PROCEDURE|Blood Draw|
48329847|NCT00425113|PROCEDURE|CT Scan|
48329848|NCT00425113|PROCEDURE|PET Scan|
48329849|NCT06372197|DRUG|Psilocybin|Following Oregon Psilocybin Services (OPS) rules, participants will be placed in cohorts of five to six, which whom they will do two 90-minute preparation session, two psilocybin sessions, and two 90-minute integration sessions. All sessions will be guided by two licensed facilitators.
48329850|NCT01629901|DEVICE|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
48329851|NCT01972854|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
48329852|NCT01972854|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
48329853|NCT01972854|DEVICE|KXL System|30mW/cm2
48329854|NCT00141180|DRUG|CP-481,715|
48491467|NCT04739696|BEHAVIORAL|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
47973838|NCT00030810|RADIATION|Hyperfractionated|Hyperfractionated radiotherapy
47973839|NCT00030810|DRUG|Taxotere/Cisplatin|Taxotere/Cisplatin
48123584|NCT03279224|BIOLOGICAL|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
48329855|NCT04828369|PROCEDURE|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
48329856|NCT04828369|PROCEDURE|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
48329857|NCT00593658|DRUG|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
48329858|NCT05889351|DRUG|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
48329859|NCT05889351|DRUG|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
48329860|NCT05889351|DRUG|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
48329861|NCT00897936|GENETIC|DNA methylation analysis|
48329862|NCT00897936|GENETIC|comparative genomic hybridization|
48329863|NCT00897936|GENETIC|fluorescence in situ hybridization|
48329864|NCT00897936|GENETIC|microarray analysis|
48329865|NCT00897936|GENETIC|polymerase chain reaction|
48329866|NCT00897936|OTHER|diagnostic laboratory biomarker analysis|
48329867|NCT00897936|OTHER|immunologic technique|
48329868|NCT01797445|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
48329869|NCT01797445|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
48329870|NCT01797445|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
48329871|NCT01797445|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
48329872|NCT04649619|PROCEDURE|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
48329873|NCT01390480|DRUG|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
48329874|NCT00012883|BEHAVIORAL|Homewalking exercise program|
48491468|NCT03345394|BEHAVIORAL|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
48491469|NCT03345394|BEHAVIORAL|Standard treatment|Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
48491470|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
48329875|NCT03420443|DIETARY_SUPPLEMENT|Oat bran|45 g oat bran.
48329876|NCT03420443|DIETARY_SUPPLEMENT|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
48329877|NCT03420443|DIETARY_SUPPLEMENT|No oral supplementation|No oral supplementation.
48329878|NCT00873288|OTHER|Usual care mailing intervention|routine colposcopy reminder letter
48329879|NCT00873288|OTHER|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
48329880|NCT05877703|OTHER|close kinetic chain exercises|CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
48329881|NCT05877703|OTHER|open kinetic chain exercises|The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
48329882|NCT00030095|DRUG|2-methoxyestradiol|
48329883|NCT03046017|DEVICE|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
48329884|NCT03046017|OTHER|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
48329885|NCT03046017|OTHER|Control cream|A neutral cream will be applied as a control.
48329886|NCT04211844|DRUG|sofosbuvir plus daclatasvir|50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
48329887|NCT04211844|DRUG|Sofosbuvir plus Ledipasvir|50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.
48491471|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
48491472|NCT00321737|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
48491473|NCT03589521|BEHAVIORAL|ABCT_Military|15 Weekly Couple Therapy Sessions
48498105|NCT02176408|BEHAVIORAL|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
48651035|NCT02963818|OTHER|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
48329888|NCT01823770|DRUG|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
48123585|NCT03279224|BIOLOGICAL|Autologous FMT|"1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
48123586|NCT06176391|DEVICE|Spinal Cord Stimulation|Single lead placement in the posterior thoracic epidural space (T1-T4) connected to a subcutaneous battery
48123587|NCT05955989|OTHER|soft lining of complete denture processed by 3 different techniques.|soft lining for complete denture
48498106|NCT02176408|BEHAVIORAL|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
48329889|NCT01823770|DRUG|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
48123588|NCT01449617|DRUG|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
48123589|NCT05099341|OTHER|HDRS-17 depression scale|Measuring the severity of depression
48123590|NCT05099341|BIOLOGICAL|Blood sampling|3 tubes of 5 ml
48123591|NCT01586936|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
48123592|NCT00774852|DRUG|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
48123593|NCT00774852|DRUG|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
48329890|NCT00673686|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
48329891|NCT00673686|DRUG|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
48329892|NCT02448316|PROCEDURE|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
48123594|NCT00774852|DRUG|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
48123595|NCT00774852|DRUG|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
48123596|NCT00774852|DRUG|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
48123597|NCT00774852|DRUG|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
48123598|NCT01736514|DRUG|febuxostat|oral
48123599|NCT01736514|DRUG|Allopurinol|oral
48329893|NCT02448316|DRUG|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
48123600|NCT01068756|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
48123601|NCT01068756|DRUG|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
48123602|NCT01409824|OTHER|CDSS|Clinical Decision Support System
48123603|NCT00232180|DRUG|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
48329894|NCT02448316|DRUG|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
48329895|NCT02448316|BEHAVIORAL|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
47973840|NCT00030810|PROCEDURE|conventional surgery|conventional surgery
47973841|NCT04049396|OTHER|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
48123604|NCT03556085|DEVICE|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
48123605|NCT05155917|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|insulin glargine sc (0.25 U/kg body weight)
48123606|NCT03272087|DEVICE|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
48123607|NCT03272087|DEVICE|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
48123608|NCT01049503|OTHER|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
48123609|NCT00979121|DRUG|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
48123610|NCT00979121|DRUG|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
48123611|NCT00915564|DRUG|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
48123612|NCT00915564|OTHER|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily \[extremes included\]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
48123613|NCT02378896|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
48123614|NCT02378896|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
48123615|NCT02912208|DRUG|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
48123616|NCT02912208|OTHER|Placebo|The administration is the same of eltrombopag
48123617|NCT03510676|DEVICE|NiTiDES|
48123618|NCT01095822|DRUG|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
48123619|NCT00294840|DEVICE|PET-CT|
48123620|NCT01644916|PROCEDURE|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
48123621|NCT01644916|PROCEDURE|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
48123622|NCT00739531|DEVICE|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
48123623|NCT00580918|OTHER|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
48123624|NCT01673516|PROCEDURE|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
48123625|NCT01673516|DEVICE|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
48123626|NCT00982917|BEHAVIORAL|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
48123627|NCT00982917|BEHAVIORAL|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
48498107|NCT02905214|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
48498108|NCT00596037|DRUG|Growth hormone - LB03002|
48123628|NCT01627652|OTHER|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
48123629|NCT06107101|DRUG|Mepolizumab|100mg of mepolizumab every 4 weeks subcutaneously for 6 months
48123630|NCT06159569|DEVICE|LACRIACT|"LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit."
48123631|NCT03971851|OTHER|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
48123632|NCT03427346|PROCEDURE|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
48491474|NCT05158218|BEHAVIORAL|Robotic Exoskeleton Gait Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will be completed in a 60-minute sessions with rests as needed. The key components of the therapy will include: 1) optimally challenging activities of variable intensity that emphasize motor planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints, 2) task specific overground movements that promote building a repertoire of mobility strategies that can be utilized in the community, and 3) motor tasks requiring active control that increase participant therapeutic engagement. An overhead body weight support system or a gait-belt may be used for some individuals during the robotic exoskeleton gait training blocks.
48498109|NCT04682769|OTHER|Other|Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
48498110|NCT03641391|PROCEDURE|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
47973842|NCT01927367|OTHER|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
47973843|NCT03558776|DIETARY_SUPPLEMENT|linseed oil|linseed oil and defined background diet
47973844|NCT00563979|DIETARY_SUPPLEMENT|VitaluxPlus®|1 tablet daily
47973845|NCT00563979|DIETARY_SUPPLEMENT|Omega 3|1 tablet daily
47973846|NCT03241251|OTHER|questionnaire|Questionnaire of psychosocial risk factors
47973847|NCT00009698|BIOLOGICAL|aldesleukin|Given SQ and IV
48329896|NCT00122421|BEHAVIORAL|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
48329897|NCT00122421|OTHER|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
47973848|NCT04654676|DRUG|Vildagliptin|Vildagliptin added on to stable doses of pre-mixed insulin with or without metformin
47973849|NCT04786015|OTHER|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
47973850|NCT03053544|DRUG|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
47973851|NCT04172506|DRUG|AK105|Anti-PD-1 antibody
47973852|NCT04819646|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
47973853|NCT04819646|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
47973854|NCT02990910|DRUG|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
47973855|NCT02990910|DEVICE|conventional opioid analgesia|(b) all received 25μg/kg morphine
47973856|NCT04236830|DRUG|Silver diamine fluoride/ potassium iodide|Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
47973857|NCT04236830|DRUG|Silver diamine fluoride|Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
47973858|NCT04236830|DRUG|Resin modified glass ionomer cement|Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
47973859|NCT01068132|DRUG|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
47973860|NCT01068132|DRUG|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
47973861|NCT03346785|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
47973862|NCT03346785|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
47973863|NCT03346785|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
47973864|NCT02292277|DRUG|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
47973865|NCT00107445|DRUG|EF5|Given IV
47973866|NCT01437722|DRUG|1% SPL7013 Gel|vaginal gel
47973867|NCT01437722|DRUG|3% SPL7013 Gel|vaginal gel
47973868|NCT01437722|DRUG|placebo gel|vaginal gel
47973869|NCT01402544|DRUG|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
47973870|NCT03081065|DIETARY_SUPPLEMENT|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
47973871|NCT02498314|OTHER|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
48123633|NCT03427346|PROCEDURE|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
48329898|NCT01551472|DEVICE|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
48329899|NCT03368326|DIAGNOSTIC_TEST|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
48123634|NCT06522711|DEVICE|Virtual reality headset|A brief overview of all three virtual reality scenarios will be shown in a consolidated video prior to letting the participant select the preferred scenario. The participant's choice of scenario will then be documented. Once paravertebral blocks are completed and the participants are in supine position and the surgeon is ready to disinfect, the VR headset will be applied on the face of the participants in the intervention group and the chosen scenario will be started. If at any point the patient expresses a desire to stop using VR during the surgery, we will first offer them an alternate scenario. If they reiterate their willingness to stop, with or without having experienced the new scenario, the headset will be removed for the remainder of the surgery.
48123635|NCT06522711|OTHER|Standard of care|Standard of care in anesthesia with patient-controlled sedation.
48123636|NCT00774904|DRUG|Losartan|Angiotensin II Type 1 Receptor Blockers
48123637|NCT05177939|DRUG|NPB-01|NPB-01 will be administered for the treatment of autoimmune encephalitis
48123638|NCT05177939|DRUG|NPB-01-ME|NPB-01-ME will be administered for the treatment of autoimmune encephalitis
48123639|NCT02158819|DEVICE|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
48123640|NCT04805216|PROCEDURE|Blood test|"Participants will have blood tests at baseline (nearest 30 day incremental time point after 2nd dose of Covid-19 vaccine, +/- 7 days):~* T, B \& NK cells~* Full Blood Count and differential~* Serum Immunoglobulins~* Antibodies against VZV, CMV, Rubella~* Quantiferon assay (T-Cell response)~* Covid antibody assay (LIAISON® SARS-CoV-2 S1/S2 IgG quantitative assay)~Participants will have blood tests during follow up (after second dose of Covid-19 vaccine) with a window of +/- 7 days:~* Blood test 2 - performed at the next 30 day time point (Covid antibody assay)~* Blood test 3 - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~* Blood test 4 (optional) - performed at the next 30 day time point (Covid antibody assay)~* Blood test 5 (optional) - performed at the next 30 day time point (Covid antibody assay and quantiferon\* if final blood test)~  * Quantiferon assay will be only be performed where possible."
48123641|NCT05086354|BEHAVIORAL|JUMP|Warm-up, stretching, jumping rope, cool-down
48123642|NCT03892564|DRUG|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48329900|NCT03446989|BEHAVIORAL|Case management|completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
48329901|NCT00810459|DEVICE|Trilogy Ventilator|Exposure to one hour on the Trilog ventilator
48329902|NCT00810459|DEVICE|Standard of Care|Exposure of one hour on the Participants prescribed ventilator
48329903|NCT00334152|DRUG|casopitant|
48329904|NCT02659475|DRUG|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
48329905|NCT04383314|BEHAVIORAL|10-week exercise program on HA accumulation|A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists. Participants will have the choice of using a treadmill or a recumbent stepper. The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session. Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
48329906|NCT04219488|OTHER|Radial nerve mobilization|
48329907|NCT04219488|OTHER|Supervised home program|
48329908|NCT06034015|DRUG|APL-1202 and APL-1501 (Single ascending dose)|Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.
48329909|NCT06034015|DRUG|APL-1202 and APL-1501 (Multiple Ascending dose)|Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
48498111|NCT03641391|PROCEDURE|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
48123643|NCT03892564|DRUG|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48123644|NCT03892564|DRUG|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48123645|NCT03892564|DRUG|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48123646|NCT03892564|DRUG|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48123647|NCT03465813|BEHAVIORAL|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
48123648|NCT04739280|DEVICE|CardioFlux Magnetocardiography|Magnetocardiography
48123649|NCT03278379|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
48123650|NCT00257348|DRUG|Capecitabine|
48123651|NCT00257348|DRUG|Docetaxel|
48123652|NCT03380611|DIETARY_SUPPLEMENT|Wakame|Consumption of 4.8 grams wakame per day for 17 days
48123653|NCT03380611|DIETARY_SUPPLEMENT|Spirulina|Consumption of 4.8 grams spirulina per day for 17 days
48123654|NCT03380611|DIETARY_SUPPLEMENT|Control|Consumption of microcrystalline cellulose for 17 days
48123655|NCT00002446|DRUG|Posaconazole|
48123656|NCT00002446|DRUG|Fluconazole|
48123657|NCT05894252|OTHER|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
48123658|NCT04368312|OTHER|No intervention|No intervention, just of questionnaire including validated tests
48329910|NCT01947959|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
48329911|NCT01947959|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
48123659|NCT02740400|PROCEDURE|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
48329913|NCT00984880|DRUG|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
48329914|NCT03657810|DRUG|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
48329915|NCT03657810|DRUG|Norco|hydrocodone 5 mg/APAP 325 mg
48329916|NCT03657810|DRUG|Placebo|Placebo matching CL-108
48329917|NCT04874532|OTHER|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
48329918|NCT04874532|OTHER|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
48329919|NCT04981977|BEHAVIORAL|Care Transitions Intervention|CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
47973872|NCT02498314|OTHER|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
48123660|NCT02740400|PROCEDURE|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
48123661|NCT05715398|DRUG|BR790+anlotinib|BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle
48123662|NCT02711865|BIOLOGICAL|IGF1R antibody MK0646|
48123663|NCT02711865|OTHER|Saline solution|
48123664|NCT02252042|BIOLOGICAL|Pembrolizumab|200 mg intravenous (IV) on Day 1 of each 3-week cycle.
48123665|NCT02252042|DRUG|Methotrexate|40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle
48123666|NCT02252042|DRUG|Docetaxel|75 mg/m\^2 IV on Day 1 of each 3- week cycle
48123667|NCT02252042|BIOLOGICAL|Cetuximab|400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
48123668|NCT03399669|DRUG|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
48123669|NCT06520137|PROCEDURE|Tooth extraction|Extraction of maxillary third molars
48123670|NCT03661957|PROCEDURE|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
48123671|NCT03661957|PROCEDURE|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
48123672|NCT03297281|OTHER|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
48123673|NCT03297281|OTHER|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
48123674|NCT03668197|BIOLOGICAL|microbiological analysis|microbiological analysis of the peritoneal fluid
48123675|NCT00387452|BEHAVIORAL|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
48123676|NCT00387452|BEHAVIORAL|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
48123677|NCT03052335|DEVICE|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
48329920|NCT04981977|BEHAVIORAL|Care Transitions Intervention and Peer Support|The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
48329921|NCT04981977|OTHER|Usual Care|The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
48329922|NCT04509323|DRUG|Huperzine A for Injection|Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
48329923|NCT04285944|OTHER|Mavig X-ray Protective Drapes|Mavig X-ray Protective Drapes®
48329924|NCT02584777|BIOLOGICAL|Pacritinib|QD (Once a day)
48651036|NCT02963818|OTHER|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
48651037|NCT02963818|OTHER|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
48123678|NCT03052335|PROCEDURE|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
48123679|NCT04649021|BIOLOGICAL|BNT162b2|Intramuscular injection
48123680|NCT04649021|OTHER|Placebo|Intramuscular injection
48123681|NCT05694442|OTHER|Lipmatte K|Lipmatte K contain ingredients that may hydrate and brighten the lip
48123682|NCT01891084|DRUG|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
48123683|NCT01891084|DRUG|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
48123684|NCT01891084|DRUG|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
48329925|NCT04019769|DRUG|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
48329926|NCT02016469|OTHER|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
48329927|NCT02016469|OTHER|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
48329928|NCT02016469|DIETARY_SUPPLEMENT|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
48329929|NCT03962712|OTHER|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
48329930|NCT03962712|OTHER|No Increase in Minimum Wage|No increase in minimum wage
48329931|NCT03222440|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
48329932|NCT02299713|DEVICE|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
48491475|NCT05158218|BEHAVIORAL|Physical Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. An overhead body weight support system or a gait-belt may be used for some individuals during the gait training blocks
48491476|NCT01249365|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
48491477|NCT05121844|DEVICE|Continuous Glucose Monitor Device|Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
48498112|NCT05318430|DEVICE|Subcutaneous closed-suction drainage device|This subcutaneous closed-suction drainage device was designed to be placed subcutaneously when surgeons have completed all intra-abdominal operations and are about to suture subcutaneous layer and skin
47973873|NCT02498314|OTHER|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
47973874|NCT03729089|OTHER|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
47973875|NCT00368355|DRUG|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
47973876|NCT00368355|DRUG|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
47973877|NCT00368355|BIOLOGICAL|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
47973878|NCT00368355|RADIATION|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
47973879|NCT00368355|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
47973880|NCT03879707|DRUG|Melatonin 5 mg|Melatonin is known to induce sleep
47973881|NCT03879707|DRUG|Placebo Oral Tablet|Placebo
47973882|NCT03879707|DRUG|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
48123685|NCT02054923|PROCEDURE|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
48123686|NCT02054923|BEHAVIORAL|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
48123687|NCT05855291|DIAGNOSTIC_TEST|PET/MRI|The participants receive 18F-FDG PET/MRI before and after neoadjuvant chemoradiotherapy.
48123688|NCT02329639|GENETIC|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
48329933|NCT06530121|BEHAVIORAL|Toolbox trainings|Training given with a single page material, lasting between 10-15 minutes, aimed at on-the-job application.
48329934|NCT03411577|OTHER|Behavioral Intervention|
48329935|NCT00549510|DRUG|COREG CR and lisinopril (FDC)|
48329936|NCT04507776|DRUG|Etanercept|Patients with spondyloarthrosis as provided in real world practice
47973883|NCT00138996|DEVICE|automated direct feedback on CPR from defibrillator|
48123689|NCT03640949|DRUG|Vasopressin, Arginine|20 IE of vasopressin per dose for a maximum of four doses (80 IU)
48123690|NCT03640949|DRUG|Methylprednisolone|40 mg methylprednisolone once
48123691|NCT03640949|DRUG|NaCl|Placebo
48123692|NCT03531840|DRUG|Olaparib|All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity
48123693|NCT03531840|DEVICE|ClinOmics|Non-significant risk (NSR) device
48123694|NCT03898024|DRUG|SHR-1222|Pharmaceutical form: water injection; Route of administration: subcutaneous
48123695|NCT03898024|DRUG|Placebo|Pharmaceutical form: water injection; Route of administration: subcutaneous
48123696|NCT01933802|BIOLOGICAL|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
48123697|NCT02191098|DRUG|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
48123698|NCT05419570|OTHER|Fluid Loading|Hemodynamic and ventilatory parameters will be recorded at five time points (T1 - T5). After baseline meausrements (T1), additional 5 cmH2O PEEP will be applied to patients for 30 seconds (short time low peep challenge, SLPC). Prior to PEEP lowering T2 measurement will be performed. T3 measurement will be performed one minute after PEEP is decreased to its initial value and will be recorded as the second baseline. Thereafter, 100 ml isotonic saline will be infused over one minute (MFC). T4 measurement will be performed one minute after MFC is completed,. Lastly, T5 measurement will be performed three minutes after additional 400 ml of isotonic saline is infused within 10 minutes to complete 500 ml of fluid loading.
48123699|NCT02395978|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
48123700|NCT02395978|DRUG|placebo|Placebo contained corn starch.
48123701|NCT01052259|DRUG|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
48123702|NCT05752175|DRUG|WPV01|WPV01 tablets
48123703|NCT05752175|DRUG|Placebo|Placebo tablets
48123704|NCT00693121|DRUG|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
48123705|NCT00693121|DRUG|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
48123706|NCT03643900|DEVICE|pancreatic duct stenting|Place the pancreatic duct stent
48123707|NCT03643900|DRUG|rectal indomethacin|rectal indomethacin 100mg at preoperative 30min
48329937|NCT01641965|DEVICE|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.
48329938|NCT04021459|PROCEDURE|blood samples|"3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~* One on the arm vein (peripheral)~* One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method."
48329939|NCT00854555|OTHER|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
48329940|NCT00854555|OTHER|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
48329941|NCT05723458|COMBINATION_PRODUCT|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
48329942|NCT05723458|DRUG|Placebo|Placebo cream containing vaseline
48123708|NCT03733119|DRUG|Akt/ERK Inhibitor ONC201|Given PO
48123709|NCT03733119|DIETARY_SUPPLEMENT|Methionine-Restricted Diet|Given PO
48123710|NCT05937646|DEVICE|AWARE|AWARE is a platform with a visualization dashboard that sits on top of pre-existing, comprehensive EHR systems. AWARE provides clinical decision support tools for the ICU, Emergency Departments and other critical care areas right at the patient's bedside.
48123711|NCT05937646|DEVICE|Electronic Health Record (EHR)|An Electronic Health Record (EHR) is an electronic version of a patients medical history, that is maintained by the provider over time, and may include all of the key administrative clinical data relevant to that persons care under a particular provider, including demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data and radiology reports.
48123712|NCT00873613|PROCEDURE|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
48123713|NCT03858413|DIAGNOSTIC_TEST|No intervention|No intervention
48123714|NCT02616900|DEVICE|eSight Eyewear|primary intervention
48329943|NCT06119451|BEHAVIORAL|Traditional Music Therapy|Intervention using traditional music therapy as an alternative therapy for burnout syndrome
48651038|NCT00085839|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
48651039|NCT00085839|DRUG|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
48329944|NCT06265168|OTHER|Simulation|Physicians will participate in a simulated scenario of an adult comatose patient. The intervention will be presented as a learning situation where the physician interacts with a high-fidelity mannequin. The mannequin simulating the patient will manifest a Glasgow Coma Score of 3 (improving over time to a GCS of 4) and a range of physiological and pathological symptoms. Physicians will have access to emergency equipment, including intubation equipment, a defibrillator, and medications. A trained nurse will be present to assist with the simulation. After 20 minutes the patient will regain consciousness in order to avoid a frustrating experience for the physicians. After simulation termination, a senior physician will join the resident and ask him to report the current scenario and will stop the simulation. The entire scenario will be video-recorded.
48329945|NCT04129086|DRUG|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
48329946|NCT04129086|DRUG|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
48329947|NCT00000384|BEHAVIORAL|Cognitive Behavior Therapy|
48329948|NCT00000384|BEHAVIORAL|Educational Support|
48329949|NCT00000384|DRUG|Sertraline|
48329950|NCT02729077|DEVICE|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
48329951|NCT00880763|DRUG|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
48329952|NCT00880763|DRUG|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
48329953|NCT00880763|DRUG|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
48329954|NCT00880763|DRUG|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
48329955|NCT03444571|PROCEDURE|revision surgery|If DNA based diagnosis detects infection, standard revision surgery will be conducted
48329956|NCT01193816|DRUG|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
48329957|NCT01193816|DRUG|Placebo|Placebo
48329958|NCT05308758|OTHER|Game-based High-Intensity Interval Training|There will be two training sessions each week. In each training session, there will be four sets of training programs separated by 3 minutes of passive recovery in accordance with a previous study.Each set of activities will last for around 5 minutes; therefore, the total duration of each training session will be approximately 30 minutes. A small group size (4-6 children per group) will be adopted to facilitate individual supervision and adaption of the exercise program.
48329959|NCT05308758|OTHER|GameSAE|Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week. Six to eight stations of multidimensional exercises will be set up for each session. Adopting the train-the-trainer (TTT) model, training will be provided by front-line healthcare providers or trained helpers. Children will be instructed to finish the exercises in all stations one after another in a predetermined order.
48329960|NCT02726529|BEHAVIORAL|Brighter Bites|
48329961|NCT02726529|BEHAVIORAL|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
48651040|NCT00322218|DRUG|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
48123715|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
48123716|NCT02710851|BIOLOGICAL|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
48651041|NCT06569420|OTHER|Drug: Foritinib Succinate|SAF-189s: 160 mg QD, 21 days a cycle
48123717|NCT02710851|BIOLOGICAL|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
48123718|NCT02710851|BIOLOGICAL|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
48329962|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation.|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days"
48329963|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
48329964|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased."
48491478|NCT05792124|PROCEDURE|Erector spina area block|After anesthesia and surgical intervention, bilateral ESP passage will be performed with ultrasonography from the T10 level 3 cm lateral to the midline. After cleaning the area with povidone iodine before the block, T10 transverse output will be determined using a linear ultrasound probe. Local anesthetic will be applied to the erector spina with the use of the needle used for peripheral block procedures and transverse access. With the serum treatment from the local anesthesia application, the location of the needle will be correct with the hydrodissection method. After the location of the needle is confirmed, a mixture containing 20 ml of LA and serum will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA is bupivacaine 0.5%, after 20 ml serum content.
48123719|NCT04223388|DIETARY_SUPPLEMENT|Lactobacillus plantarum 276|5 Billion CFU/dose, serving size = 1 capsule/day
48491479|NCT05792124|PROCEDURE|Retrolaminar block|The patient is in the prone position and the high-frequency linear ultrasound transducer is in parasagittal orientation, but the entry point is determined more medial than the ESP block. The needle entry point is 1-1.5 cm lateral to the targeted spinos process. The echogenic needle is advanced until it contacts the lamina in the craniocaudal plane and 0.5-1 for control. By giving cc 0.9 nacl solution, it is observed that the fluid is distributed between the erector spina muscle and the lamina. After the location of the needle is confirmed, a mixture of 20 ml of LA and saline will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA will consist of bupivacaine 0.5% and 20 ml physiological saline.
48491480|NCT00004755|DRUG|allopurinol|
48123720|NCT04223388|OTHER|Placebo|Placebo product, serving size = 1 capsule/day
48491481|NCT00004755|DRUG|glucantime|
48491482|NCT00713999|DRUG|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
48491483|NCT02802618|OTHER|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
48491484|NCT00025636|BIOLOGICAL|filgrastim|
48491485|NCT00025636|DRUG|carmustine|
48123721|NCT05096559|DEVICE|Microcirculation cytocam|Visualization of tongue microcirculation
48123722|NCT00017472|BIOLOGICAL|apolizumab|Given IV
48123723|NCT00017472|OTHER|laboratory biomarker analysis|Correlative studies
48123724|NCT00017472|OTHER|pharmacological study|Correlative studies
48491486|NCT00025636|DRUG|cisplatin|
48491487|NCT00025636|DRUG|cyclophosphamide|
48491488|NCT00025636|DRUG|cytarabine|
48491489|NCT00025636|DRUG|dexamethasone|
48491490|NCT00025636|DRUG|etoposide|
48491491|NCT00025636|DRUG|melphalan|
48491492|NCT00025636|DRUG|methotrexate|
48651042|NCT06569420|OTHER|Drug: Crizotinib|Crizotinib: 250 mg BID, 21 days a cycle
48651043|NCT04706325|OTHER|ACUTE KIDNEY INJURY|KDIGO LEVELS
48651044|NCT00237627|DRUG|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
48651045|NCT00237627|DRUG|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
48651046|NCT00237627|DRUG|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
48651047|NCT03315026|DRUG|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
48123725|NCT03754959|DRUG|BI 1358894|Film-coated tablet
48123726|NCT03754959|DRUG|Placebo|Film-coated tablet
48123727|NCT03754959|DRUG|Midazolam|Solution for injection
48123728|NCT03310645|DRUG|BAY1817080|4 different doses over the course of study
48123729|NCT03310645|DRUG|Matching Placebo|Matching placebo for BAY1817080
48123730|NCT03840122|OTHER|ACB + IPACK block with injection of local anesthetic|"ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml"
48123731|NCT03840122|OTHER|ACB + IPACK block without injection|ACB + IPACK block without an injection of local anesthetic
48123732|NCT05490134|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
48123733|NCT05490134|DRUG|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
48123734|NCT00320762|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
48123735|NCT03980873|BEHAVIORAL|ESTEEM (Effective Sikills to Empower Effective Men)|"ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change"
48123736|NCT06433102|OTHER|Visual perceptual training based on the lateral masking paradigm|Visual perceptual training is a novel rehabilitation approach aimed at enhancing visual performance through practice of visual tasks. Patients received visual perceptual training based on the lateral masking paradigm every other day. Each training session consisted of 9 stages, totaling 900 trials, lasting 35 to 45 minutes. The stimuli consisted of a central Gabor patch with relatively low contrast positioned in the central fixation area, along with co-linear high-contrast Gabor patches distributed above and below the central stimulus. These stimuli were presented on a Liquid Crystal Display (LCD) monitor, with a training distance of 150 cm.
48123737|NCT04321603|BEHAVIORAL|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
48123738|NCT02627469|BEHAVIORAL|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
48123739|NCT02627469|DEVICE|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
48123740|NCT02627469|DEVICE|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
48123741|NCT02444858|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10\^5/kg) ，once a day,a total of three times.
48123742|NCT02444858|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
48123743|NCT02208596|DRUG|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
48123744|NCT02208596|DRUG|propofol|
48123745|NCT02208596|DRUG|Etomidate|
48123746|NCT04961021|PROCEDURE|Strabismus surgery|Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
48123747|NCT02387242|DRUG|Rifampicin|Single oral dose of rifampicin
48123748|NCT02265432|BEHAVIORAL|General physical activity educational materials|
48123749|NCT02265432|DEVICE|Wearable activity tracking devices (fitbit)|
48123750|NCT02265432|OTHER|online map|
48123751|NCT02265432|OTHER|Personalized text messages|
48123752|NCT02160951|DRUG|LGH447|LGH447, QD
48123753|NCT02825641|DRUG|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
48491493|NCT00025636|DRUG|vincristine sulfate|
48491494|NCT00025636|PROCEDURE|bone marrow ablation with stem cell support|
48491495|NCT00025636|PROCEDURE|peripheral blood stem cell transplantation|
48491496|NCT02139124|DRUG|Placebo|Oral placebo capsule
48123754|NCT02825641|DRUG|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes."
48123755|NCT04773678|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
48123756|NCT04773678|DRUG|Placebo|Placebo subcutaneous (SC) injection.
48123757|NCT06515834|DRUG|FE 999301|To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
48123758|NCT06515834|DRUG|Placebo|Placebo to assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
48123759|NCT02554786|DRUG|Indacaterol acetate/Mometasone furoate|
48123760|NCT02554786|DRUG|Mometasone furoate|
48491497|NCT02139124|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
48491498|NCT02139124|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
48651048|NCT03315026|BEHAVIORAL|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
48651049|NCT04246749|DRUG|[14C]-CRN00808|Investigational drug
48123761|NCT02554786|DRUG|Salmeterol xinafoate/fluticasone propionate|
48123762|NCT03872310|DEVICE|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm\^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
48491499|NCT02139124|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
48123763|NCT05608213|PROCEDURE|Lenvatinib Plus I-125 Seed Brachytherapy|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients. Iodion-125 seeds will be implanted into the the target lesions (viable intrahepatic tumor and/or vascular tumor thrombus) under CT guidance according to the pre-operative planning within 7 days after lenvatinib administration. Iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.
48123764|NCT05608213|DRUG|Lenvatinib|Lenvatinib (body weight ≥ 60 kg, 12mg P.O. QD; body weight \< 60 kg, 8mg P.O. QD) will be administered to the patients.
48123765|NCT02725294|OTHER|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
48123766|NCT01230450|PROCEDURE|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
48123767|NCT01230450|OTHER|stand standard mid-urethral sling (TVT-O)|
48329965|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
48329966|NCT06224972|DEVICE|Vlab|The study is observational, there is no intervention.
48651050|NCT04246749|DRUG|CRN00808|Investigational drug
48651051|NCT06162728|DRUG|Briquilimab|Subcutaneous Administration
48651052|NCT06162728|OTHER|Placebo|Placebo Comparator
48329967|NCT02017821|BEHAVIORAL|high intensity aerobic training|
48329968|NCT04768530|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
47973884|NCT05376124|OTHER|original therapy|* Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
47973885|NCT05376124|OTHER|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
48329969|NCT04768530|DRUG|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
48329970|NCT06418126|BIOLOGICAL|blood sampling before radiotherapy|A blood sample (20 ml) will be taken prior to radiotherapy
48329971|NCT06418126|BIOLOGICAL|blood sampling after the fourth radiotherapy session|A blood sample (20 ml) will be taken immediately after the 4th radiotherapy session.
48329972|NCT06418126|OTHER|collection of acute toxicity (radiodermatitis)|for the entire duration of radiotherapy
48329973|NCT06418126|OTHER|collection of late toxicity|every year for 5 years
48491500|NCT02139124|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
48491501|NCT05673213|OTHER|Three-stair positioning pillows group|The infant was cared for, fed and treated by the primary nurse responsible for the infant between 08:30 and 08:55. No intervention was made to the preterm infant between 09:00-12:00 and the infant was allowed to rest. Preterm infants were followed for 3 hours (09:00-12:00) with three-stair positioning pillows. Between these hours, the oxygen saturation and heart rate of the preterm infants in were counted by the researcher with a pulse oximeter device and recorded 18 times in 10 minutes. Sleep-wakefulness status was recorded by taking 15-second recordings with the Actigraphy measuring device.
48491502|NCT04977661|DRUG|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
48651053|NCT00781898|DRUG|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
48651054|NCT00781898|OTHER|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
48651055|NCT06522997|DRUG|BAY3283142|Tablet, intake orally once daily
48651056|NCT06522997|DRUG|Placebo|Matching with BAY3283142
48651057|NCT04499534|BIOLOGICAL|Seasonal influenza vaccine|To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination
48651058|NCT05350774|DRUG|IV normal saline|IV normal saline 250ml for 5 days
48651059|NCT05350774|DRUG|IV immunoglobulin|IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
48329974|NCT06418126|OTHER|collection of disease status|throughout the study
48651060|NCT01557569|DRUG|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
48123768|NCT06331494|DRUG|Butylphthalide|Butylphthalide Sodium Chloride injection for 10±3 days, oral Butylphthalide soft capsules for day 11±3 to day 180.
48123769|NCT06331494|DRUG|Placebo|Butylphthalide Placebo injection for 10±3 days, oral Butylphthalide Placebo soft capsules for day 11±3 to day 180.
48123770|NCT03072316|OTHER|3D surface imaging|3D photography
48123771|NCT03072316|OTHER|semi-structured interview|qualitative analysis using semi structured interview
48123772|NCT03072316|OTHER|applanation tonometry|measurement of breast compressibility
48123773|NCT01849978|BEHAVIORAL|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
48123774|NCT01849978|BEHAVIORAL|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
48123775|NCT01849978|BEHAVIORAL|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
48329975|NCT06418126|RADIATION|Radiotherapy - Breast +/- lymph node areas|40.05 Gy in 15 fractions of 2.67 Gy, one fraction per week, 5 days per week Or 50 Gy in 25 fractions of 2 Gy, one fraction per week, 5 days per week
48329976|NCT06418126|RADIATION|Radiotherapy - Boost operating bed|10 Gy in 4 fractions of 2.5 Gy, one fraction per week, 5 days per week Or 16 Gy in 8 fractions of 2 Gy, one fraction per week, 5 days per week
48329977|NCT02742857|BIOLOGICAL|BQ-A Peptide Extract|BQ-A Peptide Extract
48329978|NCT02742857|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells
48329979|NCT02742857|DEVICE|Transcranial Laser Therapy|Transcranial Laser Therapy
48329980|NCT02742857|DEVICE|Median Nerve Stimulator|Median Nerve Stimulator
48123776|NCT01849978|BEHAVIORAL|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
48123777|NCT01295697|DRUG|EZN-2208|Experimental
48123778|NCT01522794|DRUG|NOX-H94|single i.v. infusion
48123779|NCT01522794|DRUG|Placebo solution|single i.v. infusion
48329981|NCT02850952|OTHER|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
48491503|NCT04977661|DRUG|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
48329982|NCT01619592|DEVICE|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
48329983|NCT03495817|DRUG|ATI-50002|ATI-50002 Topical Solution
48329984|NCT04997824|PROCEDURE|Artificial Intelligence-based atrial fibrillation catheter ablation|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. AI-guided prediction for poor responder of AFCA in the outpatient clinic~3. Sharing information on the AI prediction with the patient and family member~4. AFCA after consent to the procedure~5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~6. Monitoring esophageal temperature~7. Evaluation of Procedure and ablation time, and complication afer procedure~8. Post-procedure rhythm follow-up is carried out according to the study design above."
48329985|NCT04997824|PROCEDURE|Medical Therapy|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. Decision for AFCA based on clinical guidelines and the experience of the attending physician~3. AFCA after consent to the procedure~4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~5. Monitoring esophageal temperature~6. Evaluation of Procedure and ablation time, and complication afer procedure"
48329986|NCT02528253|BIOLOGICAL|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
48329987|NCT02528253|BIOLOGICAL|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
48329988|NCT02528253|BIOLOGICAL|Tanezumab 5 mg SC|Tanezumab 5 mg SC
48491504|NCT04977661|DRUG|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
48651061|NCT01557569|DRUG|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
48651062|NCT04990947|OTHER|lifestyle / RYGB|No intervention, just 2 different groups will be included
48651063|NCT06380270|DIETARY_SUPPLEMENT|Oral probiotic Streptococcus salivarius eK12 sachet|Bactoblis® EVOL (containing 10 billion CFU of S. salivarius eK12)
48123780|NCT06169254|DEVICE|Transcranial current stimulation (tCS)|Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
48329989|NCT02528253|BIOLOGICAL|Tanezumab 10 mg SC|Tanezumab 10 mg SC
48329990|NCT02528253|BIOLOGICAL|Tramadol PR oral|Tramadol PR oral
48329991|NCT06103955|BEHAVIORAL|Digital Breathing Biofeedback system|The biofeedback system provides information to the patient and physio about the muscle coordination of breathing.
48329992|NCT02826993|DEVICE|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
48329993|NCT03968341|OTHER|Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients|"A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information."
48329994|NCT04072185|OTHER|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
48329995|NCT00424294|DRUG|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
48329996|NCT00424294|DRUG|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
48329997|NCT00424294|DRUG|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
48329998|NCT05630898|DIAGNOSTIC_TEST|CMV PCR|Saliva CMV PCR
48329999|NCT04759677|OTHER|Exercise with active video games|45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
48330000|NCT04370730|OTHER|clinical, neuroimaging and DNA assessments|Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
48330001|NCT01566591|DEVICE|Deep TMS Treatment|24 TMS treatments over 6 weeks .
48330002|NCT01566591|DEVICE|Sham Treatment|24 TMS treatments over 6 weeks
48330003|NCT03061045|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
48330004|NCT00131677|DRUG|tenofovir disoproxil fumarate|study product taken daily
48330005|NCT00131677|DRUG|placebo|study product taken daily
48491505|NCT04091958|PROCEDURE|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
48491506|NCT01401049|DRUG|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
48491507|NCT01401049|DRUG|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
48491508|NCT01660464|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
48491509|NCT05098002|BEHAVIORAL|Mindfulness program|6 week class designed to improve psychological well-being
48491510|NCT01019473|DRUG|AFQ056|
48491511|NCT01019473|DRUG|Placebo|
48491512|NCT01736436|DRUG|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
48491513|NCT01736436|PROCEDURE|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
48491514|NCT01736436|PROCEDURE|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
48330006|NCT03316872|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
48491515|NCT05690087|DRUG|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
48491516|NCT05690087|DRUG|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
47973886|NCT00203996|DEVICE|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
48330007|NCT03316872|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
48330008|NCT01313481|BEHAVIORAL|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
47973887|NCT00203996|DRUG|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
48123781|NCT00813657|BEHAVIORAL|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, \~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (\~8 minutes), followed by toning and very light resistance exercises (\~20 minutes) and a light intensity cool-down (\~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
48123782|NCT00000994|DRUG|Zidovudine|
47973888|NCT00203996|DRUG|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
47973889|NCT00203996|PROCEDURE|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
47973890|NCT00203996|PROCEDURE|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
47973891|NCT02028065|DRUG|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
47973892|NCT02028065|DRUG|Placebo|Placebo administered as a single IV bolus over 10 seconds
47973893|NCT02435784|OTHER|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
47973894|NCT02435784|OTHER|Treatment as usual|Patients will attend a psychiatric consultation as usual.
47973895|NCT02931968|DEVICE|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
47973896|NCT06497933|PROCEDURE|Atrial fibrillation ablation|Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
47973897|NCT02656784|BEHAVIORAL|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
48123783|NCT03647956|DRUG|Atezolizumab|Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
48123784|NCT03647956|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
48330009|NCT01313481|BEHAVIORAL|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
48330010|NCT06528743|RADIATION|RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.|Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
48330011|NCT01712217|DRUG|AT13387|HSP90 inhibitor
48330012|NCT01712217|DRUG|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
48491517|NCT02917330|OTHER|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
48491518|NCT00289874|DRUG|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
48330013|NCT03421574|DEVICE|MR-guided Focused Ultrasound|Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
48330014|NCT04060576|PROCEDURE|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
48651064|NCT06674109|DRUG|Empagliflozin 10 mg|For the empagliflozin arm, participants will take 10 mg daily.
48651065|NCT06674109|DRUG|Placebo|Participants in the placebo arm will take a placebo daily.
48330015|NCT04060576|PROCEDURE|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
48330016|NCT04060576|PROCEDURE|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
48491519|NCT00289874|DRUG|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
48491520|NCT01404871|DRUG|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including \> 8 weeks at 250 mg/daily
48491521|NCT01404871|DRUG|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including \>8 weeks at max dose 50mg daily
48491522|NCT01404871|DRUG|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including \>8weeks at 120mg daily
48491523|NCT00140621|DRUG|Agalsidase beta|
48491524|NCT04167176|PROCEDURE|Erector spinae plane block|Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
48491525|NCT04167176|PROCEDURE|Port site infiltration|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
48491526|NCT04167176|DEVICE|Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)|Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
48491527|NCT04167176|DRUG|Bupivacaine 0.5%|Bupivacaine 0.5% will be included in the injected LA mixture.
48491528|NCT04167176|DRUG|Lidocaine 2%|Lidocaine 2% will be included in the injected LA mixture.
48491529|NCT03592576|DRUG|Navitoclax|Tablet, Oral
48491530|NCT03592576|DRUG|Venetoclax|Tablet, Oral
48491531|NCT04464993|BEHAVIORAL|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
48491532|NCT04464993|BEHAVIORAL|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
48651066|NCT00553969|DRUG|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
48651067|NCT00553969|DRUG|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
48651068|NCT00553969|DRUG|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
48651069|NCT00553969|DRUG|placebo and placebo|capsule once daily for 9 months; dosage unknown
48651070|NCT06570291|DRUG|Mesenchymal progenitor cells|Allogenic adipose tissue-derived mesenchymal progenitor cells administrated for intra- articular use
48651071|NCT06570291|DRUG|Sodium Hyaluronate Injection|Sodium Hyaluronate administrated for intra-articular use
48330017|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)|The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
48330018|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)|The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
48330019|NCT04655209|BEHAVIORAL|MT only with sham tDCS (MT)|For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
48330020|NCT05511025|DRUG|AZD6234|Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
48330021|NCT05511025|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC or IV injection
48491533|NCT04464993|BEHAVIORAL|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
48491534|NCT04464993|BEHAVIORAL|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a \>5 min continuous bout of exercise (as defined by Fitbit minutes \>4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
48651072|NCT03088111|OTHER|Collection of samples|To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
48651073|NCT03088111|BIOLOGICAL|Obiltoxaximab|Obiltoxaximab standard of care
48651074|NCT02144337|BEHAVIORAL|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
48651075|NCT05269082|OTHER|No intervention|This is a non-interventional study.
48651076|NCT06675851|DRUG|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
48330022|NCT05511025|COMBINATION_PRODUCT|Acetaminophen|Participants will receive a single dose of acetaminophen as part of a meal
48330023|NCT02705768|DRUG|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
48330024|NCT02705768|DRUG|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
48330025|NCT02031432|DRUG|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
48330026|NCT02169804|DRUG|Androxal 25 mg|
48330027|NCT03594253|BEHAVIORAL|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
48330028|NCT00338065|BEHAVIORAL|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
48330029|NCT00338065|BEHAVIORAL|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
48330030|NCT00860418|BEHAVIORAL|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
48330031|NCT00860418|BEHAVIORAL|Standard asthma education|Standard asthma education during 2 home visits.
48330032|NCT01510834|BEHAVIORAL|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
48330033|NCT04286464|OTHER|No intervention|No intervention
48330034|NCT00034203|DRUG|efalizumab|
48330035|NCT05165550|DRUG|Elsulfavirine|Elsulfavirine (Elpida®) 20 mg capsules for oral administration
48330036|NCT04618926|DEVICE|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
48330037|NCT01891422|OTHER|Non-interventional.|
48330038|NCT01115075|OTHER|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
48330039|NCT01115075|BEHAVIORAL|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
48330040|NCT04372043|OTHER|Questionnaire|"Sleep Hygiene Index and demographic questions."
48330041|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
48330042|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
48330043|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
48330044|NCT00685841|DRUG|Salmeterol MDI|Salmeterol MDI 42 mcg BID
48330045|NCT00685841|DRUG|Placebo|Placebo BID MDI
48330046|NCT01436695|DEVICE|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
48330047|NCT04070118|PROCEDURE|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
48330048|NCT00206778|DRUG|Lamotrigine|
48330049|NCT00206778|DRUG|Sodium Valproate|
48651077|NCT06675851|DRUG|Cipralex (escitalopram)|Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
48651078|NCT06674005|OTHER|Cucurbita pepo L. Flowers Extract|2 mg twice per day for 1 month
48651079|NCT06674005|OTHER|Placebo|2 mg twice per day for 1 month
48123785|NCT03647956|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.
48330050|NCT03335787|OTHER|Intervention|Kinesio Tape apply to peroneal muscles in supine position starting from the peroneal muscle origin with using muscle activation technique by a certified KT1 and KT2 practitioner. Then ligament technique which will go through around ankle starting from medial and lateral metatarsophalangeal joints in order to improve ankle stability. Taping will be applied one week later and two weeks later prior to first application.
48330051|NCT03335787|OTHER|Control|Any sham taping was not applied to the control group in order to prevent the sensory stimulant effect of taping. In order to achieve patients' blinding both groups participant will sign a same consent but control group will be called for taping a month later after study data collection completed.
48330052|NCT02823600|DEVICE|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
48651080|NCT02834741|DRUG|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
48651081|NCT06081959|DRUG|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
48651082|NCT06081959|DRUG|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
48651083|NCT06081959|DRUG|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
48651084|NCT06081959|DRUG|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
48651085|NCT06081959|DRUG|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
48651086|NCT00449852|BEHAVIORAL|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
47973898|NCT02656784|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
47973899|NCT03055793|OTHER|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
47973900|NCT05028894|OTHER|No intervention|No intervention
47973901|NCT06241872|OTHER|Dry needling group|Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.
47973902|NCT04127864|PROCEDURE|Colorectal cancer surgery|All participants will undergo surgery for colorectal cancer.
47973903|NCT04079101|DRUG|BIIB104|Administered as specified in the treatment arm.
47973904|NCT04079101|DRUG|Placebo|Administered as specified in the treatment arm.
47973905|NCT02233647|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
47973906|NCT02233647|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
47973907|NCT00748501|DRUG|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
47973908|NCT03393637|BEHAVIORAL|Mentors Offering Maternal Support (M-O-M-S)|10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
47973909|NCT01506713|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
47973910|NCT01328925|DRUG|Nitazoxanide|"Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days"
47973911|NCT00386945|BEHAVIORAL|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
47973912|NCT02322398|DRUG|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
47973913|NCT02322398|DRUG|hMG|150-300 IU/d hMG
47973914|NCT06441994|DRUG|PSW-1025|PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
47973915|NCT05495516|GENETIC|without Intervention|without Intervention
47973916|NCT05466682|BEHAVIORAL|Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Relaxation technique delivered via RELAXaHEAD app.
47973917|NCT05466682|BEHAVIORAL|Monitored Usual Care (MUC)|Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
48123786|NCT03647956|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
48123787|NCT03586258|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
48123788|NCT03586258|OTHER|Brain Imaging|Anatomical, diffusion, and/or functional MRI
48651087|NCT01918358|DRUG|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
48651088|NCT01918358|DRUG|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
48651089|NCT01918358|DRUG|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
48651090|NCT01918358|DRUG|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
48651091|NCT01918358|DRUG|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
48651092|NCT01918358|DRUG|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
48651093|NCT01505803|DIETARY_SUPPLEMENT|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
47973918|NCT03369405|OTHER|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
48123789|NCT03586258|OTHER|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
48123790|NCT01571804|DRUG|Placebo|to receive two identical placebo capsules 1 hr before surgery
47973919|NCT03269864|PROCEDURE|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
47973920|NCT01327521|DEVICE|CyberKnife|Standard of Care
47973921|NCT01327521|PROCEDURE|TACE|Standard of Care
47973922|NCT01327521|DRUG|CT Contrast|Standard of Care
47973923|NCT01327521|DRUG|doxorubicin|Standard of Care
47973924|NCT01327521|DRUG|Epirubicin|Standard of Care
48123791|NCT01571804|DRUG|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
48123792|NCT01571804|DRUG|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
48123793|NCT04045782|DRUG|single arm|switch from originator (Humira) to biosimilar (Imraldi)
48491535|NCT04294420|BEHAVIORAL|Patient education program|The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
48491536|NCT04214925|OTHER|Tai Chi|Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
48491537|NCT01878487|DEVICE|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~1. At baseline~2. After thrombus aspiration with a thrombus extraction catheter~3. After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
48491538|NCT05970419|OTHER|high power laser acupuncture (HPLA)|High power laser therapy A Zimmer Opton pro, integrated High-power class IV laser device (serial N: 15200013306 \& REF: 4682, made in Germany, manufactured by Zimmer Medizin System). It emits radiation in the infrared range to deliver topical heating and raise tissue temperature. The simultaneous application of two wavelengths of laser light (810 and 980nm) provides the user with a huge variety of therapy options. The laser probe - with the small spacer (3.1cm2) , with parameters of 3 watts, 5Hz, 50% duty cycle, 20 joule/ point for 13 seconds with 6.4 j/cm2 . Although a maximum power of 8000 W was reported in two studies, the average power of the lasers used in t
48491539|NCT05970419|OTHER|conventional treatment|"Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used."
48491540|NCT05970419|OTHER|Sham laser|sham laser (Not active)
48491541|NCT00558909|DRUG|BI 44847|
48651094|NCT01505803|DIETARY_SUPPLEMENT|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
48651095|NCT01505803|DIETARY_SUPPLEMENT|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
48651096|NCT06505395|DRUG|SYHX2008 injection|The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
48651097|NCT06505395|DRUG|Sandostatin LAR@|The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
48651098|NCT05218434|DRUG|AX-158|Oral administrations of AX-158
48651099|NCT04910165|DRUG|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
48651100|NCT04910165|DRUG|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
48651101|NCT06675669|OTHER|Reflective thinking method|It will be applied to students in the initiative group for 1 hour per week for 7 weeks.
48651102|NCT06657612|OTHER|No intervention|No intervention
48651103|NCT06353841|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week in four weeks.
47973925|NCT01327521|DRUG|5-fluorouracil|Standard of Care
47973926|NCT01327521|DRUG|Mitomycin C|Standard of Care
47973927|NCT01327521|DRUG|Gemcitabine|Standard of Care
47973928|NCT01327521|DRUG|Cisplatin|Standard of Care
47973929|NCT01327521|DEVICE|SMANCS|Standard of Care
48330053|NCT03543670|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
48330054|NCT02451540|RADIATION|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
48651104|NCT06266351|DEVICE|This is observational IOP measurement|IOP measurement of patients having LASIK with both CATS and GAT
48651105|NCT06463028|DRUG|Sapanisertib|Oral
48651106|NCT06463028|DRUG|Serabelisib|Oral
48651107|NCT06463028|DRUG|Paclitaxel|Infusion
48651108|NCT02340546|DEVICE|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
48123794|NCT02290613|DRUG|Ambrisentan|"Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake."
48123795|NCT02290613|DRUG|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
48123796|NCT01510717|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
48123797|NCT01510717|DEVICE|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
48123798|NCT01893970|BEHAVIORAL|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
48123799|NCT01893970|BEHAVIORAL|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
48123800|NCT03924037|BEHAVIORAL|Intergenerational Knowledge Sharing group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
48123801|NCT03924037|BEHAVIORAL|Support group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
48123802|NCT02255877|DEVICE|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
48123803|NCT02255877|DEVICE|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
48123804|NCT02753738|DRUG|Escitalopram|Tablet 10mg, 21 days
48123805|NCT02753738|DRUG|Placebo|Tablet, 21 days
48123806|NCT02753738|OTHER|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
48123807|NCT02753738|BEHAVIORAL|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
48123808|NCT02753738|BEHAVIORAL|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
48123809|NCT03791008|OTHER|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
48491542|NCT00558909|DRUG|placebo for BI 44847|
48651109|NCT02278744|RADIATION|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
48651110|NCT02278744|DEVICE|MRI and/or CT|
48123810|NCT02622568|DRUG|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
48123811|NCT02622568|PROCEDURE|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
48123812|NCT02672930|DEVICE|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
48123813|NCT00585052|DRUG|Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
48123814|NCT00585052|DRUG|Lovastatin|Lovastatin, 80 mg, po, daily will be self-administered by the subject.
48123815|NCT02672722|DRUG|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
48123816|NCT02672722|OTHER|Exercise|
48123817|NCT02672722|OTHER|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
48123818|NCT02115828|DRUG|Vismodegib|
48123819|NCT03218306|DEVICE|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
48330055|NCT02451540|DRUG|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
48330056|NCT02451540|DRUG|Roflumilast|Roflumilast, once a day in the morning during 3 months
48330057|NCT06283992|OTHER|Digital Navigation|1:1 educational support at the bedside about the functions of the patient portal and telehealth that can help with care transitions.
48491543|NCT02564419|DEVICE|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
48651111|NCT03624556|DIETARY_SUPPLEMENT|EGCG FontUp|Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
48651112|NCT03624556|OTHER|Placebo FontUp|Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
48123820|NCT03218306|OTHER|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
48123821|NCT00304031|DRUG|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
48123822|NCT00304031|RADIATION|Concurrent radiation therapy|60 Gy in 2 Gy fractions
48123823|NCT00304031|DRUG|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
48123824|NCT00304031|DRUG|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
48123825|NCT00550394|DRUG|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
48123826|NCT00550394|DRUG|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
48123827|NCT05574075|DIAGNOSTIC_TEST|Diffusion tensor imaging|white matter imaging markers
48123828|NCT04860401|DEVICE|Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)|The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
48123829|NCT02894658|DEVICE|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
48123830|NCT02894658|PROCEDURE|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
48123831|NCT04373434|BEHAVIORAL|Health Homes/Healthy Families (HH/HF) Intervention|The HH/HF Intervention involves coaching calls, text messages and intervention materials that are designed to increase behavioral capability, self-efficacy and behavioral intention to improve the home food environment for healthy eating and weight gain prevention. The intervention is delivered over a 12 week period.
48123832|NCT04373434|BEHAVIORAL|Control|"Participants in the control condition will receive two mailings on healthy eating, the first from the Dietary Guidelines For Americans 2015-2020, 8th Edition and the second from Choose MyPlate. Additionally, both mailings will include a food diary from the Centers for Disease Control and Prevention. Mailings will be sent to participants one and six-weeks post-baseline. These materials focus on the same dietary outcomes being targeted in the HH/HF intervention, but without the home environment emphasis. Control group participants will receive their home environment profile with a list of healthy actions upon completion of the study."
48123833|NCT03475316|BEHAVIORAL|Social Dancing|90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
48123834|NCT03475316|BEHAVIORAL|Treadmill Walking|Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
48123835|NCT00088738|DRUG|[18F] SPA-RQ|
48123836|NCT00041938|DRUG|aspirin|325 mg per day
48330058|NCT01593228|DRUG|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution~Route of administration: Intravenous"
48330059|NCT01593228|DRUG|Carboplatin|"Pharmaceutical form:Solution~Route of administration: Intravenous"
48123837|NCT00041938|DRUG|Warfarin|INR 2.5-3.0; target INR 2.75
48330060|NCT01593228|DRUG|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution~Route of administration: Intravenous"
48330061|NCT01593228|DRUG|Gemcitabine|"Pharmaceutical form:Solution~Route of administration: Intravenous"
48330062|NCT01593228|DRUG|Irinotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
48330063|NCT01593228|DRUG|Paclitaxel|"Pharmaceutical form:Solution~Route of administration: Intravenous"
48330064|NCT01593228|DRUG|Topotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
48330065|NCT04470128|DRUG|Stage I: HSK21542 0.5 μg/kg|intravenous injection
48491544|NCT00307034|BIOLOGICAL|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
48491545|NCT00307034|BIOLOGICAL|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
48491546|NCT00307034|BIOLOGICAL|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
48491547|NCT04899193|DRUG|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
48491548|NCT04899193|DRUG|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
48491549|NCT04899193|DRUG|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
48491550|NCT04899193|DRUG|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
48330066|NCT04470128|DRUG|Stage I: HSK21542 1 μg/kg|intravenous injection
48330067|NCT04470128|DRUG|HSK21542 0.5 μg/kg|intravenous injection
48330068|NCT04470128|DRUG|HSK21542 1 μg/kg|intravenous injection
48491551|NCT00939120|DRUG|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
48491552|NCT00939120|DRUG|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
48123838|NCT06099249|DEVICE|ASUS ECG App|The procedure will commence with instructing the participants to become acquainted with the ASUS ECG App. Following this introduction, participants will be asked to sit quietly for a 5-minute resting period before undergoing a 12-lead ECG recording, which will last for approximately 30 seconds. The participant will be guided to simultaneously record a separate single-lead ECG using the ASUS ECG App. Both data streams will be synced together by the Study Staff. Each participant will undergo a total of three trials involving the simultaneous recording of a 12-lead ECG and a single-lead ECG using the ASUS ECG App.
48123839|NCT00421889|DRUG|belinostat|
48491553|NCT00939120|DRUG|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
48491554|NCT00407693|DRUG|[C-11]PRB28|
48491555|NCT04665375|DRUG|DOR/3TC/TDF|switch antiretroviral regimen to doravirine/lamivudine/tenofovir disoproxil fumarate once daily for 1 year
48491556|NCT03437915|RADIATION|NIBB: accuboost|28.5 Gy delivered in 5 daily fractions
48491557|NCT03437915|PROCEDURE|Partial mastectomy|4-12 weeks post NIBB
48491558|NCT02158611|OTHER|Lifestyle counseling|
48491559|NCT00326287|DRUG|Ceftobiprole medocaril|
48491560|NCT00326287|DRUG|Ceftriaxone with or without Linezolid|
48491561|NCT03649412|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
48491562|NCT03649412|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
48123840|NCT00421889|DRUG|Paclitaxel|
48123841|NCT00421889|DRUG|Carboplatin|
48123842|NCT03208868|DIETARY_SUPPLEMENT|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
48123843|NCT03208868|DIETARY_SUPPLEMENT|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
48330069|NCT04470128|DRUG|HSK21542 2 μg/kg|intravenous injection
48330070|NCT04470128|DRUG|Placebo|intravenous injection
48330071|NCT03553550|OTHER|biospecimen collection|Peripheral blood collection Archival tissue collection
48330072|NCT03585699|DIAGNOSTIC_TEST|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
48651113|NCT04996745|BEHAVIORAL|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
48651114|NCT03345225|DEVICE|SureFire Infusion System|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
48651115|NCT03345225|DEVICE|Standard Endhole Microcatheter|A Microcatheter with a single hole at the end for a infusion.
48651116|NCT04738266|DIAGNOSTIC_TEST|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
48651117|NCT06674408|OTHER|Traditional physical therapy|"Control group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Finger Ladder Exercise, Codman's Pendulum Exercise, Towel Stretch Exercise and Wand Exercises 10 reps x 2 sets per session,~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week of treatment for outcome measures."
48651118|NCT06674408|OTHER|Prioprioceptive group|"Experimental group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Plyometric CKC shoulder exercise 10 seconds each x 5 reps x 2 sets per session, CKC exercise on the ball 10 seconds each x 5 reps x 2 sets per session, Open KC exercises 10 seconds each x 5 reps x 2 sets per session, Hand-eye coordination exercises for 30 minutes/per day for 5x/per week, Hand Function Exercises for 30 minutes/per day for 5x/per week.~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week"
48651119|NCT06675162|OTHER|Pilates Reformer Training|Participants will perform a 60-minute Pilates Reformer muscle-strengthening session. The training will include a 7-10 minute warm-up, 35 minutes of muscle strengthening and mobility exercises and a 5-minute recovery. During the training, the physiological responses and the energy expenditure of the participants will be recorded.
48651120|NCT01299961|DRUG|abatacept|125 mg once a week up to 12 months.
48651121|NCT00216385|DRUG|Gatifloxacin combined regimen|
48651122|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
48651123|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
48123844|NCT00001017|DRUG|Fluconazole|
48651124|NCT05444439|GENETIC|detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :|Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 \& m2, respectively
48651125|NCT05444439|DIAGNOSTIC_TEST|Culture and sensitivity of endoscopic gastric biopsies:|During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.
48491563|NCT04556552|DEVICE|Non invasive VN stimulation (nVNS)|"Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained."
48491564|NCT04556552|DRUG|Oxygen (15-O) Water|Injection of radiolabelled water. H2\[15-O\] is a radioactive material. Each patient will have eight H2\[15-O\] blood flow scans. For each O-15 water scan 20 mCi of H2\[15O\] will be injected as an intravenous bolus.
48491565|NCT04556552|DEVICE|Sham Stimulation|"Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve."
48491566|NCT00907127|BEHAVIORAL|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
48491567|NCT04554797|OTHER|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
48491568|NCT03340753|DRUG|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
47973930|NCT06507891|DRUG|TQ-A3334 tablets|TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
47973931|NCT06507891|DRUG|TQ-A3334 tablets + Anlotinib capsules|"TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
47973932|NCT01888679|PROCEDURE|Head movement|Head movement in extension, flexion, right and left rotation
47973933|NCT02688140|DRUG|Arsenic trioxide|
48330073|NCT03585699|DIAGNOSTIC_TEST|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
48330074|NCT01249534|OTHER|gastroesophageal cancer surgery|gastroesophageal cancer surgery
48330075|NCT03746808|BEHAVIORAL|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
48330076|NCT06281379|PROCEDURE|Total mesogastrectomy|More extended resection type with better oncological outcomes when compared to standard technique
48330077|NCT03089658|DRUG|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
48330078|NCT05445479|DRUG|Doxycycline|Patient with doxycycline treatment during COVID-19 waves
48330079|NCT04800471|DEVICE|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
48330080|NCT04800471|OTHER|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
48330081|NCT04742920|DEVICE|Middle Meningeal Artery Embolization|MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management
48651126|NCT05444439|OTHER|Histopathological examination endoscopic gastric biopsies:|Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).
48651127|NCT05444439|PROCEDURE|Upper endoscopy|it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.
48651128|NCT05444439|DRUG|empirical H.pylori regimens|Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
48330082|NCT04742920|PROCEDURE|Standard Management|"Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation"
48651129|NCT05444439|DIAGNOSTIC_TEST|H.Pylori Ag in stool|"Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy."
48651130|NCT06383013|BIOLOGICAL|BB-101|Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.
48651131|NCT01123187|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
48651132|NCT03941093|DRUG|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
48651133|NCT03941093|DRUG|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
48651134|NCT06351020|DRUG|LM-302|LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
48330083|NCT02515708|DEVICE|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
48330084|NCT01019252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
48330085|NCT04649762|BEHAVIORAL|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
48330086|NCT04286828|OTHER|Position Sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
48330087|NCT04286828|OTHER|Balance|"To measure postural stability and Limits of Stability this study used a balance device, the Biodex Balance System.~Postural Stability: The participants were focused on a characteristic dot (COP, centre of pressure) on the monitor screen. The participant's task was to balance the body in such a way that the dot was in the centre of a circle displayed on the monitor at the point of intersection of the coordinate axes. Test consisted of three 20-second trials, each separated by 10-second breaks. Measurements were repeated three times while their eyes were open/close and analyzed by calculating the average value of measurements.~Limits of Stability: The participants are asked to complete the directional tasks displayed on a screen as quickly as possible, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s."
48330088|NCT04286828|OTHER|Dual Task Performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
48330089|NCT00805610|BIOLOGICAL|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
48330090|NCT06182930|OTHER|Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.|They will receive routine home health care follow-up.
48330091|NCT06178900|DIAGNOSTIC_TEST|Assisted by the AI-Gatekeeper software group|The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.
48330092|NCT05385627|PROCEDURE|Ankle block|Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
48330093|NCT01688635|DRUG|LY2963016|Administered subcutaneously
48651135|NCT06351020|DRUG|Apatinib|The subjects will receive Apatinib orally,qd
48651136|NCT06351020|DRUG|Irinotecan|The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
48651137|NCT04477837|DRUG|Apixaban 5 MG|frequency of heavy menstrual bleeding
48651138|NCT04477837|DRUG|Rivaroxaban 20 MG|frequency of heavy menstrual bleeding
48651139|NCT04477837|DRUG|Edoxaban 60 MG|frequency of heavy menstrual bleeding
48651140|NCT04477837|DRUG|Dabigatran 150 Mg Oral Capsule|frequency of heavy menstrual bleeding
48651141|NCT05272605|BIOLOGICAL|Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
48651142|NCT05272605|BIOLOGICAL|SARS-CoV-2 beta variant RBD mRNA vaccine|Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
48651143|NCT05272605|OTHER|Normal Saline|Placebo comparator
48651144|NCT04798768|DEVICE|mCRM Therapy System|Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
48651145|NCT05398666|DEVICE|White LED light|Participants will be exposed to white LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
48651146|NCT05398666|DEVICE|Green LED light|Participants will be exposed to green LED lights (4 lux) in a dark room for 1-2 hours per day for 10 weeks.
48651147|NCT06569745|OTHER|Verbal Explanation|In the verbal explanation group, a researcher wearing white coat provided oral and dental health education for 3 minutes using a jaw model
47973934|NCT02688140|DRUG|Idarubicin|
47973935|NCT02688140|DRUG|Cytarabine|
47973936|NCT02688140|DRUG|Tretinoin|
47973937|NCT02688140|DRUG|Mitoxantrone|
47973938|NCT02688140|DRUG|Mercaptopurine|
47973939|NCT02688140|DRUG|Methotrexate|
48330094|NCT01688635|DRUG|US Approved Lantus|Administered subcutaneously
48330095|NCT04378699|OTHER|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
48330096|NCT04378699|OTHER|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
48330097|NCT06415838|BEHAVIORAL|Brief Behavioral Activation|"A five-session brief behavioral activation treatment delivered face-to-face in the participants' home.~Session outline:~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
48330098|NCT06415838|OTHER|Care as Usual|Care as Usual provided by primary care and/or municipal care.
48330099|NCT00166517|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
48330100|NCT00166517|BIOLOGICAL|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
48330101|NCT02319213|OTHER|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
48330102|NCT02319213|OTHER|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
48330103|NCT02319213|OTHER|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
48330104|NCT02668744|BEHAVIORAL|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
48330105|NCT04977154|OTHER|Primary prevention|The primary prevention that the trainers put in place for the hockey players
48330106|NCT00050479|DRUG|Celecoxib (Celebrex)|
48330107|NCT03711877|DEVICE|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
48330108|NCT03711877|DEVICE|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
48330109|NCT05420415|OTHER|CSTME|Tumor microenvironment collagen signature
48330110|NCT02449408|OTHER|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
48330111|NCT06144242|BEHAVIORAL|Feedback on RTD metric|Clinicians in the experimental arm will receive feedback on the RTD metric while clinicians in the No intervention arm will not.
48330112|NCT05279716|DRUG|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
48491569|NCT03340753|DRUG|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
47973940|NCT00088478|DRUG|Intramuscular Olanzapine Depot|
47973941|NCT00088478|DRUG|Placebo|
48330113|NCT04565041|BEHAVIORAL|Social Support|Presence of an image of a social support figure (provided by participant) during a fear extinction procedure
48330114|NCT05530278|DRUG|Galicaftor|Oral
48330115|NCT05530278|DRUG|ABBV-576|Oral
48330116|NCT05530278|DRUG|Navocaftor|Oral
48330117|NCT05530278|DRUG|Midazolam|Oral
48330118|NCT03224910|OTHER|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
48330119|NCT03095404|DRUG|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
48330120|NCT03095404|DRUG|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
48330121|NCT06418776|OTHER|Intensive therapy|Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)
48491570|NCT01782508|DRUG|imatinib|a selectively inhibits the KIT protein tyrosine
47973942|NCT02760069|DRUG|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
47973943|NCT02760069|DRUG|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
48123845|NCT00001017|DRUG|Amphotericin B|
48330122|NCT06418776|OTHER|Low intensity therapy|Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)
48330123|NCT02593968|DRUG|Recombinant Human Interferon a-2b Gel|
48330124|NCT02593968|DRUG|Placebo|
48330125|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
48491571|NCT01782508|DRUG|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
48491572|NCT01131793|DEVICE|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
48491573|NCT01418482|DEVICE|Mepilex Border Ag|a silver dressing
48330126|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
48330127|NCT03470857|DIAGNOSTIC_TEST|Patients|The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland
48330128|NCT03914495|DIETARY_SUPPLEMENT|Inulin|Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
48491574|NCT05676060|COMBINATION_PRODUCT|quasi|block facet joint in back pain due to afacet cause
48491575|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
48491576|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
48491577|NCT00944749|DRUG|h-ATG (ATGAM )|
48491578|NCT00944749|DRUG|Cyclosporine (Gengraf )|
48491579|NCT03668821|OTHER|Questionnaire|Quality of life and frailty questionnaires
48491580|NCT00104091|DRUG|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
48491581|NCT01547364|DRUG|Saline|Injection of 10 ml of normal saline into the caudal epidural space
48330129|NCT03914495|DIETARY_SUPPLEMENT|Placebo|Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
48491582|NCT01547364|DRUG|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
48491583|NCT00982176|OTHER|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
48491584|NCT02251873|DRUG|TPV + RTV (low dose)|
48491585|NCT02251873|DRUG|TPV + RTV (high dose)|
48330130|NCT03945734|BEHAVIORAL|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
48330131|NCT02384772|OTHER|Survey|
48330132|NCT02182297|DRUG|BI 201335 NA in single rising doses|
48330133|NCT02182297|DRUG|Placebo|
48330134|NCT01343017|OTHER|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
48330135|NCT04193670|OTHER|Clinical examination|This is a classic dermatological clinical examination during a classic consultation
48330136|NCT04193670|PROCEDURE|Biopsies|"2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample."
48330137|NCT04193670|OTHER|Blood test|A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
48330138|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
48330139|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
48330140|NCT01784588|DEVICE|Solyx Single Incision Sling System|Solyx Single Incision Sling System
48491586|NCT02251873|DRUG|ddl|
48491587|NCT03258853|DEVICE|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
48491588|NCT03258853|OTHER|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
48491589|NCT02327117|DRUG|Tranexamic Acid|
48491590|NCT02327117|DRUG|Normal saline|
48491591|NCT05682846|DRUG|Sodium glycerophosphate pentahydrate solution|Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
48491592|NCT04761705|DRUG|JV-GL1|Experimental Treatment
48330141|NCT01784588|DEVICE|Obtryx II Sling System|Standard outside-in transobturator sling
48491593|NCT04761705|DRUG|Latanoprost 0.005% Ophthalmic Solution|Active Control
48491594|NCT02824718|DRUG|Teriparatide|human recombinant parathormone
48491595|NCT02824718|DRUG|Thiazide|Diuretic
48491596|NCT02824718|DRUG|Potassium sparing diuretic|Diuretic
48491597|NCT02824718|DRUG|Alfacalcidol|Belongs to the class of vitamin D and analogues
48491598|NCT06428630|DRUG|dexamethasone oral rinse|"The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study."
48330142|NCT00810095|DEVICE|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
48330143|NCT03967275|OTHER|bone marrow harvest|During bone marrow harvest, an additional 10 mL sample will be collected for the study.
48330144|NCT03814005|DRUG|Azacitidine|Azacitidine subcutaneous or intravenous injection.
48330145|NCT03814005|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
48330146|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
48330147|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
48330148|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
48330149|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
48651148|NCT06569745|OTHER|Animation Video Display|"In the animation group, oral and dental health education was presented to the children in the form of a cartoon lasting 1 minute and 17seconds. The animation video was created by the researcher using the test version of www.vyond.com. The animation featured a character voiced by one of the researchers, informative texts, and background music. The character conveyed information about oral and dental health education, using both voice and text content."
48330150|NCT01106482|OTHER|Serology blood draw|Blood draw only, no vaccine
48330151|NCT05487131|BEHAVIORAL|electrical stimulation|different types of weak electrical stimulation will be used
48491599|NCT06163599|BEHAVIORAL|Transdiagnostic Telenovela Intervention|The intervention constitutes nine videos depicting the main character, Esperanza, who is struggling with anxiety and depression, undergoing therapy involving the a trandiagnostic treatment, and completing worksheets relating to the weekly therapy sessions.
47973944|NCT02760069|DRUG|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
47973945|NCT02760069|DRUG|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
48330152|NCT04223063|BEHAVIORAL|Exercise program|As per the intervention arm
48330153|NCT01214317|PROCEDURE|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
48330154|NCT04874688|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrient supplement|Small Quantity Lipid-based Nutrient Supplement (SQ-LNS) is a food supplement rich in both macro and micronutrients (calories, proteins, fat and multivitamin mix). SQ-LNS is not considered a regulated drug product in Zimbabwe, or by the United States Food and Drug Administration (FDA). It is commercially available for prevention of chronic malnutrition, produced by Nutriset (https://www.nutriset.fr/products/en/enov-nutributter2). Each child will receive a daily sachet of 20g SQ-LNS between 6-12 months of age, consumed directly from the sachet or mixed with porridge.
48330155|NCT04874688|DIETARY_SUPPLEMENT|Provitamin A biofortified maize|Provitamin A Maize Meal is orange maize-meal processed from provitamin A-rich orange maize. PVA maize meal will be sourced from International Maize and Wheat Improvement Centre (CIMMYT). Children in the intervention arm will consume 13g - 128g of pro-vitamin A (PVA) maize meal, with added powders. Each family will receive a monthly ration of 5kg PVA maize and this ration takes into consideration of household sharing. Families with children in the IYCF arm will receive white maize meal.
48330156|NCT04874688|DIETARY_SUPPLEMENT|NUA-45 biofortified sugar beans|NUA 45 bean powder is ground from roasted iron and zinc-rich biofortified sugar beans. NUA 45 bean powder will be sourced from Sky Brands Ltd Company. Children will consume a daily dose of 5g - 15g of NUA 45 bean powder added to complementary foods.
48330157|NCT04874688|DIETARY_SUPPLEMENT|Moringa oleifera|Moringa oleifera is an edible plant abundant in dry tropic regions including Zimbabwe. It is known to be rich in micronutrients and has been widely used in Zimbabwe and around the world both as a food and a herb. Moringa oleifera leaf powder, is a dried and ground powder produced from Moringa oleifera leaves using traditional methods. It has been widely used to fortify complementary foods in the African region with the aim of improving micronutrient status. Moringa oleifera leaf powder will be sourced from Lemex Products Company. Children will receive a daily dose of 5g - 15g of Moringa leaf powder added to complementary foods.
48330158|NCT04874688|DIETARY_SUPPLEMENT|Whole egg powder|Egg Powder is hydrolysed non-genetically modified organism (GMO), fine and unflavoured whole egg powder. It is processed with no additives, preservatives, lecithin, added sugar, soy or monosodium glutamate. Egg powder will be sourced from France (A \& D Food Ingredients - distributor in South Africa). Children in the IYCF-plus arm will receive a daily dose of 14g egg powder. A 15% extra amount of egg powder will be provided to families taking into consideration of household sharing. Egg powder will be provided in sealed plastic jars similar to that of peanut butter and households will receive promotion messages to store the powder in a cool, dry place and avoiding contact with water or moisture during use.
48491600|NCT01393184|DRUG|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
48491601|NCT02989168|DRUG|GBT440|GBT440: Capsules which contain GBT440 drug substance in Swedish orange
48491602|NCT04732936|DEVICE|Temporary Peripheral Nerve Stimulator|Temporary Peripheral Nerve Stimulator to deliver 1-hr of electrical stimulation to injured nerves.
48491603|NCT05045352|DEVICE|echogenic needles for intravenous access|echogenic needles for intravenous access (subclavian vein) ultrasound guided procedure
48491604|NCT05983913|BEHAVIORAL|cognitive-motor training|The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.
48491605|NCT05983913|BEHAVIORAL|cognition training|The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.
48491606|NCT03184259|DEVICE|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
48330159|NCT04874688|DIETARY_SUPPLEMENT|White maize meal|Commercial white maize meal will be provided monthly. Infants age 6-8 months will receive 45g (3 tablespoons) daily; infants aged 9-12 months will receive 71g (4.5 tablespoons) daily.
48330160|NCT04303793|DEVICE|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
48330161|NCT03508661|OTHER|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
48330162|NCT04552717|OTHER|My Grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains four main sections: Learning, Self-assessment, Manage symptoms and Find support.
48330163|NCT03967756|DEVICE|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
48330164|NCT03230617|DEVICE|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
48330165|NCT04597892|DIAGNOSTIC_TEST|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
48330166|NCT06323694|BEHAVIORAL|quality of life|data collection through questionnaire and interview
48330167|NCT04829266|BEHAVIORAL|mental simulation|Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
48330168|NCT03558451|OTHER|Complex intervention in sexual health|EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
48330169|NCT03558451|OTHER|Usual care|According to available protocols applicable to the patient and the health service standardized portfolio
48330170|NCT06092632|OTHER|Pigmented rice|Cooked black rice
48330171|NCT06092632|OTHER|White Rice|Cooked white rice
48330172|NCT06372054|OTHER|Biological sample collection|Collection of biological samples (blood, urine, saliva) and clinical data
48330173|NCT05082064|DIAGNOSTIC_TEST|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
48330174|NCT05984810|PROCEDURE|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
48330175|NCT00212485|PROCEDURE|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
48330176|NCT00212485|PROCEDURE|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
48491607|NCT03184259|DEVICE|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
48491608|NCT04684303|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
48330177|NCT01351064|OTHER|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
48491609|NCT04684303|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
48491610|NCT00062010|BIOLOGICAL|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
48491611|NCT00062010|DRUG|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
48491612|NCT00062010|DRUG|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
48491613|NCT05161650|DIETARY_SUPPLEMENT|Ketone monoester (3-OHB)|Commercially available ketone supplement
47973946|NCT02188251|DIETARY_SUPPLEMENT|Activamp|
47973947|NCT02188251|OTHER|Placebo|
48330178|NCT01419015|DEVICE|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
48330179|NCT06371664|DRUG|Conventional Tray (1 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
48491614|NCT05161650|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
48491615|NCT03118388|BEHAVIORAL|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
48330180|NCT06371664|DRUG|Extended Tray (3 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
48330181|NCT03494426|PROCEDURE|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~1. antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~2. oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~3. the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
48330182|NCT03494426|DRUG|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
47973948|NCT05192681|DRUG|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
48330183|NCT04873869|DRUG|NBI-921352|Administered orally
48330184|NCT04873869|DRUG|Placebo|Administered orally
48330185|NCT03515018|DRUG|hydroxyurea|pulse therapy
48330186|NCT03515018|DRUG|Imatinib|400mg qd PO per day
48330187|NCT03487393|DEVICE|magnetic facial nerve stimulation|Magnetic stimulation of facial nerve.
48330188|NCT02013089|DRUG|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
48330189|NCT02013089|DRUG|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
48330190|NCT02013089|DRUG|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
48330191|NCT02013089|DRUG|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
48330192|NCT02013089|DRUG|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
48330193|NCT03703687|BEHAVIORAL|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
48330194|NCT04932044|BEHAVIORAL|Early Sleep Facilitation Program|It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.
48330195|NCT04932044|OTHER|Routine care|Receives routine care and provide general discharge care and nursing guidance.
48330196|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Hybrid Technique|The rotation flap of the Millard II technique was expanded by extending the incision into the columella - similar to the well-known Mohler technique. The caudal part of the advancement flap of the Millard II technique was lengthened by a wave cut as known from the Pfeiffer procedure. For the vermillion a Noordhoff plasty is applied.
48330197|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Millard 2 Technique|A curved incision is marked skirting the philtral ridge. If more length is required a back-cut incision can be performed. The C-flap is outlined by the incision just marked and the incision along red-white border up to the base of the columella. On the cleft side an advancement flap is designed. For the vermillion a Noordhoff plasty is applied.
48330198|NCT00004732|PROCEDURE|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
48330199|NCT00004732|DEVICE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
48330200|NCT00229229|OTHER|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
48330201|NCT00229229|OTHER|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
48330202|NCT00229229|OTHER|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
48330203|NCT00229229|OTHER|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
48330204|NCT01570933|DEVICE|NivNava|Non-invasive Nava ventilation mode on nasal cannula
47973949|NCT06417294|OTHER|3D health education model|explanation combined with 3D printed health education model
47973950|NCT06417294|OTHER|traditional education|Regular education
47973951|NCT04089384|OTHER|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
47973952|NCT04089384|OTHER|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
47973953|NCT04089384|OTHER|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
47973954|NCT02627144|DRUG|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
48330205|NCT01570933|DEVICE|Cpap|nasal Cpap on nasal cannula
48330206|NCT05931185|OTHER|low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|patients will receive low-frequency transcutaneous electrical stimulation for 15 minutes and therapeutic Ultrasound for 10 minutes as a treatment and patients will receive a total of 12 treatment sessions (3 sessions per week for 4 weeks and then follow-up will be done for the next 2 weeks) and the total duration of each session will be of 25 minutes.
47973955|NCT02627144|DRUG|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
47973956|NCT00785668|DRUG|AER 001|10 mg dry powder administered using a handheld device
48330207|NCT05931185|OTHER|Therapeutic Ultrasound|patients will receive a therapeutic ultrasound for 10 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
48330208|NCT05931185|OTHER|Low frequency transcutaneous electrical stimulation|participants will receive low-frequency transcutaneous electrical stimulation for 15 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
48330209|NCT03997929|DIAGNOSTIC_TEST|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
48330210|NCT00959530|PROCEDURE|lingualized occlusion|occlusal surface arranged by lingualized occlusion
48330211|NCT00959530|PROCEDURE|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
48330212|NCT05622344|BEHAVIORAL|Traditional Therapy|Exercises that teaches subjects to move their heads while viewing still or moving targets.
48330213|NCT05622344|DEVICE|SWAN|The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
48330214|NCT03998761|DRUG|Micronized Progesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
48491616|NCT03118388|BEHAVIORAL|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
48491617|NCT01791231|DRUG|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
48491618|NCT02056392|DRUG|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
47973957|NCT00765050|BIOLOGICAL|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
48491619|NCT02056392|DRUG|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
48491620|NCT02056392|DRUG|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
48491621|NCT06437665|BEHAVIORAL|The intervention name in this study is ADAS-integrated driver simulation training.|The intervention involves providing older drivers (≥65 years of age) with training sessions utilizing a high-fidelity driving simulator. This training focuses on the integration and use of Lane Departure Warning (LDW), Cruise Control (CC), and Forward Proximity Warning (FPW) technologies, collectively referred to as ADAS. The training is designed to familiarize participants with these advanced driver assistance systems, enabling them to effectively utilize these features while driving.
48491622|NCT06449326|DEVICE|Active Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
48491623|NCT06449326|DEVICE|Sham Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is an efficient form of transcranial magnetic stimulation that allows up to 10x more pulses to be delivered in a given timeframe compared to conventional stimulation patterns.
48491624|NCT04769687|BIOLOGICAL|probiotic Vivomixx®|Vivomixx® is in powder form packaged in sachets of 4.5.1011 bacteria. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days). For the study, the symbiotics will be packaged in the same sachet at the same doses as mentioned above.
48491625|NCT04769687|BIOLOGICAL|prebiotic Orafti®Synergy1|Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).
48491626|NCT04769687|OTHER|Placebo|Placebo
48491627|NCT05486455|DIAGNOSTIC_TEST|Low-dose chest CT scan|baseline, 1-year, 3-year and 5-year low-dose CT scan
48491628|NCT04064619|DRUG|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
48491629|NCT00946348|DRUG|Dronabinol|Dronabinol 10 mg or 15 mg
48491630|NCT00946348|DRUG|Cannabis|Cannabis cigarette
48491631|NCT01093664|BIOLOGICAL|AFFITOPE AD02|s.c. injection
48491632|NCT02749292|DRUG|Rituximab|re-dosing dependent on interventional arm parameter.
48491633|NCT03795714|DIAGNOSTIC_TEST|IVUS or OCT and Invasive physiologic indices|IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
48491634|NCT00630019|DRUG|1.5% levofloxacin ophthalmic solution|Topical application
48491635|NCT00630019|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
48491636|NCT05224934|RADIATION|ultra-hypofractionated radiotherapy|stereotactic ablative radiotherapy with 25 to 50Gy in five fractions given preoperatively
47973958|NCT00002210|DRUG|Delavirdine mesylate|
47973959|NCT00850564|DRUG|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
47973960|NCT06379178|PROCEDURE|Oral colostrum application 2 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 2 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
48330215|NCT03998761|DRUG|Micronized progesterone plus dydrogesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
48330216|NCT05448599|DRUG|6MW3211 injection with Intravenous Infusion|phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.
48330217|NCT02978209|DEVICE|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
48330218|NCT02818140|PROCEDURE|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
48330219|NCT02818140|PROCEDURE|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
47973961|NCT06379178|PROCEDURE|Oral colostrum application 4 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 4 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
47973962|NCT01755013|PROCEDURE|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
48330220|NCT02818140|DRUG|Ropivacaine|
48330221|NCT02818140|DRUG|Saline|
48330222|NCT02818140|DEVICE|Ultrasound|
48330223|NCT02727660|DRUG|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
48491637|NCT03021694|DIETARY_SUPPLEMENT|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
48491638|NCT05379855|DRUG|0.01% atropine eye drops|using 0.01% atropine eye drops for both eyes every night
48491639|NCT05379855|DRUG|placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)|using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night
48491640|NCT05379855|DRUG|0.05% atropine eye drops|using 0.05% atropine eye drops for both eyes every night
48491641|NCT00474851|DRUG|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
48651149|NCT06569745|OTHER|Peer-Led Reels Video Display|In the peer-led reels group, oral and dental health information was presented for 1 minute using a video created on the Instagram platform. The video showed oral hygiene information being provided to a child of a similar age to the target audience with the child then demonstrating the behaviour with music in the background. The video included some text, but did not feature the child's voice or information.
48651150|NCT05300607|OTHER|Cross-cultural adaptation, validity, and reliability|evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
48330224|NCT02727660|DRUG|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
48651151|NCT02797548|DRUG|Aspirin only|Aspirin only during surgery
48330225|NCT02727660|DRUG|FF MDI (PT005) 9.6 μg|Blinded Treatment
48330226|NCT03114878|OTHER|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
48330227|NCT03114878|BEHAVIORAL|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
48330228|NCT00054158|DRUG|dexamethasone|
48330229|NCT00054158|DRUG|doxorubicin hydrochloride|
48330230|NCT00054158|DRUG|thalidomide|
48330231|NCT00054158|DRUG|vincristine sulfate|
48330232|NCT01025687|DIETARY_SUPPLEMENT|water with noncalorie sweetener|
48330233|NCT01025687|DIETARY_SUPPLEMENT|water with glucose|
48330234|NCT01025687|BEHAVIORAL|TV program showed while feeding|
48651152|NCT02797548|DRUG|No antiplatelet therapy|No antiplatelet therapy will be during surgery
48651153|NCT04872946|DIETARY_SUPPLEMENT|Tea|Ashwagandha(Withania somnifera) root and leaf extract (32% Withania Oligosaccharides, 10% Withanolide Glycosides, 0.5% Withaferin A) 125 mg Saffron(Crocus Sativus) stigmas extract (3.48% Crocin and 0.03% Safranal) 28mg
48330235|NCT01025687|BEHAVIORAL|TV program showed while feeding|
48123846|NCT02730923|DRUG|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
48123847|NCT02730923|DRUG|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
48123848|NCT00869011|OTHER|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
48123849|NCT04131153|PROCEDURE|"three-step radiofrequency ablation"|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
48123850|NCT04131153|PROCEDURE|radiofrequency ablation|Conventional radiofrequency ablation
48123851|NCT03663036|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
48123852|NCT03459677|BEHAVIORAL|Back2School|Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
48123853|NCT03459677|OTHER|Treatment As Usual|Aarhus municipality's treatment as usual for youths presenting school absenteeism
48123854|NCT02814838|DRUG|Ladarixin|Ladarixin oral capsule
48123855|NCT02814838|DRUG|Placebo|Placebo oral capsule
48123856|NCT04599088|OTHER|Brain functional MRI with simplified urodynamics|"Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image."
48123857|NCT03658616|DRUG|WO3970|Application of cream to each axilla
48123858|NCT03658616|DRUG|Placebo (WO3988)|Application of cream to each axilla
48330236|NCT03289741|DRUG|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
47973963|NCT03321123|DRUG|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
47973964|NCT00301665|BIOLOGICAL|Botulinum toxin type A|
47973965|NCT01783301|DRUG|FSH|
48123859|NCT01714492|DEVICE|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
48123860|NCT00000223|DRUG|Buprenorphine|
48123861|NCT01131780|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
48123862|NCT02233595|RADIATION|Chemoradiation|
48123863|NCT03352024|OTHER|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
48123864|NCT03352024|OTHER|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
48123865|NCT02648503|DRUG|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
48123866|NCT02648503|DRUG|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
48123867|NCT03804580|DRUG|osimertinib|Non-randomized trial, all patients receive therapy
48123868|NCT06261710|OTHER|Sonography in labour|Using intrapartum sonography parameters in labour
48123869|NCT00065832|BEHAVIORAL|Reading Instruction|
48123870|NCT04042207|DEVICE|Low Glucose Predictive Suspend system|consists of sensor-augmented pump therapy (SAP) / Low Glucose Predictive Suspend system (with predictive low glucose management technology)
48123871|NCT04042207|DEVICE|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
48123872|NCT00424645|DRUG|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
48123873|NCT00424645|DRUG|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
48123874|NCT03167944|DEVICE|Low thermal electrosurgery system|PEAK Plasmablade
48123875|NCT03167944|DEVICE|Conventional Electrocautery|Conventional Electrocautery
48123876|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (combination)|
48123877|NCT02515305|DRUG|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
48123878|NCT02515305|DRUG|Placebo gel (combination)|
48330237|NCT03289741|DRUG|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
48491642|NCT00474851|DRUG|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
48491643|NCT00870649|BIOLOGICAL|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
48330238|NCT03289741|BEHAVIORAL|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
48330239|NCT04965506|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
48330240|NCT04965506|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
48330241|NCT04965506|OTHER|Dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
48330242|NCT04228562|OTHER|non-modifiable factor|the presence of an uncontrollable / unremovable risk factor for a disease
48330243|NCT04228562|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
48330244|NCT02378883|DEVICE|Apollo™ Onyx™ Delivery Micro Catheter|
48330245|NCT05589844|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo standard of care allogeneic hematopoietic stem cell transplant
48330246|NCT05589844|PROCEDURE|Biospecimen Collection|Correlative studies
48330247|NCT05589844|BIOLOGICAL|CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine|Given intradermally
48330248|NCT02120144|OTHER|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
48330249|NCT02120144|OTHER|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
48330250|NCT06147713|DEVICE|Vibrotactile foot device (Smart shoe)|A foot device deliver vibrotactile stimulation triggered by a foot pressure sensor.
48491644|NCT00870649|BIOLOGICAL|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
48491645|NCT01179698|PROCEDURE|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
48330251|NCT04742049|OTHER|Telerehabilitation-based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
48330252|NCT04742049|OTHER|Follow-up based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
48330253|NCT05718206|DEVICE|Magnetocardiography|Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
48330254|NCT03157440|DIAGNOSTIC_TEST|Ring oxymetry|a new type oxymetry wear on index finger like a ring
48330255|NCT06085287|DEVICE|Electromagnetic therapy|Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
48330256|NCT00210379|DRUG|rituximab|
48330257|NCT00210379|DRUG|CHOP|
48330258|NCT00210379|DRUG|intrathecal methotrexate|
48330259|NCT00210379|PROCEDURE|radiotherapy|
48330260|NCT00373100|DRUG|Zinc acetate|
48330261|NCT00373100|DRUG|Placebo|Placebo
48330262|NCT00936299|DRUG|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
48330263|NCT00936299|OTHER|Placebo|
48330264|NCT00345540|DRUG|NOV-002|60 mg / mL / day / 20-23 Days
48330265|NCT00345540|DRUG|Carboplatin|AUC 5 following IV bolus administration of NOV-002
48330266|NCT02372097|DRUG|SYR-472|SYR-472 25mg, 50mg
48330267|NCT05599854|PROCEDURE|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
48330268|NCT02170038|DRUG|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
48330269|NCT02170038|DRUG|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
48330270|NCT02066519|BEHAVIORAL|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
48330271|NCT04806633|DRUG|Dapagliflozin 5mg|Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.
48330272|NCT04806633|DRUG|Placebo|Patients randomized in this arm will receive placebo.
48330273|NCT04864678|OTHER|Referral to the Young People's Health Service immunisation nurse|Young people who have been referred to an immunisation nurse at the Young People's Health Service.
48330274|NCT05996380|DRUG|SHR-3167|SHR-3167, Single administration
48330275|NCT05996380|DRUG|SHR-3167 Placebo|SHR-3167 Placebo Single administration
48330276|NCT02776501|DRUG|Coppertone (BAY987521)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: Y49-103)
48330277|NCT02420301|OTHER|Tuina exercises|
48330278|NCT02420301|OTHER|Placebo Tuina exercises|
48491646|NCT01179698|PROCEDURE|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
48491647|NCT05717504|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
48491648|NCT05717504|OTHER|Quality of life survey|A quality of life survey will be performed at the end of the follow-up period. The survey will be done over the phone or in person if the follow-up visit is in person.
48123879|NCT02769819|DEVICE|Flexible fiberscope|"* Characteristics of patients will be assessed before induction of general anesthesia~* Glottic visualization will be evaluated by direct laryngoscopy.~* The endotracheal tube will be loaded onto the scope after silicon spray lubrication~* Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~* With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~* Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
48491649|NCT05072197|DEVICE|Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy|This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers.
48491650|NCT01566864|BEHAVIORAL|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
48651154|NCT04872946|OTHER|Serum|Aqua/Water/Eau, Glycerin, Propanediol, Diheptyl Succinate, Caprylic/Capric Triglyceride, Lactococcus Ferment Lysate, Sorbitol, Dimethicone, Steareth-21, Octyldodecyl Neopentanoate, Sodium Polyacrylate, Steareth-2, Caprylyl Glycol, Hydrogenated Polydecene, Trideceth-6, Octyldodecanol, Panthenol, Sodium PCA, Azelaic Acid, Bisabolol, Capryloyl Glycerin/Sebacic Acid Copolymer, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Caprylhydroxamic Acid, Phytic Acid, Aminomethyl Propanol, Lactic Acid, Sodium Chloride, Phenoxyethanol, Sodium Benzoate.
47973966|NCT04445545|DEVICE|High intensity laser therapy (HILT)|Laser application with powers greater than 500 milliwatts (mW) in the myofascial trigger point and muscle belly of the upper trapezius. Laser therapy will be applied to the upper trapezius muscle with a total energy delivery of 1,060J divided into 3 phases will be achieved (phase 1, 500J; phase 2, 60J; phase 3, 500J). It will work with an average power of 3W and an energy density of 50J/cm2. For the application of laser therapy, the 12W BTL-6000 equipment that emits infrared wavelengths of 1064nm will be used.
47973967|NCT04445545|DEVICE|Therapeutic Ultrasound (US)|Application of ultrasound therapy in the myofascial trigger point of the upper trapezius muscle. The ultrasound application will be performed with the person in a seated position. The ultrasound parameters will consist of a frequency of 1MHz, the intensity of 1.5 W/cm2, a Duty cycle of 100%, an ERA of 5cm2, and a treatment time of 6 minutes.
47973968|NCT04445545|PROCEDURE|Stretching exercise|t the end of the assigned treatment will be added a treatment protocol of upper trapezius stretching exercises for the evaluated limb with shortening. The stretches will consist of 4 series of 30 seconds with an interval of 30 seconds between series
48123880|NCT06232889|DIAGNOSTIC_TEST|Deuterium Glucose Metabolic Imaging with MRI spectroscopy|MRI spectroscopy of the liver, following ingestion of 20 mg deuterium glucose p.o., prior to and after radioembolization treatment for mCRC
47973969|NCT00878774|BIOLOGICAL|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
48123881|NCT05326607|DEVICE|Prototype of adaptive eyeglasses|The tested investigational medical device is a prototype of semi-integrated eyeglasses.
48123882|NCT05326607|DEVICE|Comparator|The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.
48123883|NCT01515436|OTHER|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
47973970|NCT00878774|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
47973971|NCT02090244|DRUG|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
47973972|NCT00413452|DRUG|Etanercept|50 mg once weekly
47973973|NCT05593393|DEVICE|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
47973974|NCT05284149|DIETARY_SUPPLEMENT|Hirsutella Sinensis Nutrient Supplements|"This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement."
48123884|NCT01515436|OTHER|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
48123885|NCT01263613|PROCEDURE|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
48123886|NCT05260359|DRUG|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation|SU E 101413 85
48123887|NCT05260359|DRUG|6% Bemotrizinol (BEMT) dispersion in petrolatum|SU-E-101413-82
48123888|NCT05260359|OTHER|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT|SU E 101413 91
48123889|NCT05260359|OTHER|Petrolatum vehicle|SU-E-101413-83
48123890|NCT05260359|OTHER|0.9% Saline|low irritancy control
48123891|NCT05260359|OTHER|Sodium Lauryl Sulfate 0.1% (SLS)|positive control
48330279|NCT00444080|PROCEDURE|Trabeculectomy|"Standard trabeculectomy procedure~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of a limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Creation of fistula 1mm x 2mm in size~5. Iridectomy~6. Suturing the scleral flap~7. Repositioning of conjunctiva with sutures After procedure, antibiotics \& steroids are administered topically; eye is covered with a pad - patient is discharged."
48330280|NCT00444080|DEVICE|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~5. Prior to implantation, a thorough mobility check should be performed~6. Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~7. Withdrawal of introducer~8. Tucking plate under the scleral flap, and verification of its position~9. Suturing scleral flap After implantation procedure, antibiotics \& steroids administered topically; eye is covered with a pad - patient is discharged."
48330281|NCT06528015|DRUG|probiotics combined with enteric-coated budesonide capsule|"In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
48330282|NCT06528015|DRUG|probiotics placebo combined with enteric-coated budesonide capsules|"In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
48330283|NCT05905757|PROCEDURE|Dexmedetomidin + bupivacaine|dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
48330284|NCT05905757|DRUG|Tramadol + Bupivacaine|tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
48330285|NCT01345851|RADIATION|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
48330286|NCT01345851|OTHER|laboratory biomarker analysis|Correlative studies
48330287|NCT01345851|RADIATION|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
48330288|NCT01345851|DRUG|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
48330289|NCT01345851|DRUG|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
48330290|NCT01345851|RADIATION|stereotactic body radiation therapy|Undergo hypofractionated RT
48330291|NCT04190212|BEHAVIORAL|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
48330292|NCT03645889|OTHER|PLTG|A combination of 13 herbal granules
47973975|NCT05284149|DIETARY_SUPPLEMENT|Placebo|"We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo."
47973976|NCT01918085|OTHER|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
47973977|NCT01918085|OTHER|Strata strip|An adhesive strip made of the Strata adhesive
47973978|NCT04775875|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
48330293|NCT03645889|OTHER|Placebo|90% starch filler and 10% PLTG
48330294|NCT05363670|DRUG|ARS-1|ARS-1
48330295|NCT05363670|DRUG|Albuterol MDI|180 mcg
48330296|NCT05363670|DRUG|Placebo|Placebo
47973979|NCT04208789|DIAGNOSTIC_TEST|Rapid Molecular Drug-Resistant Tuberculosis Test|"GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate."
47973980|NCT04208789|OTHER|Artificial Intelligent Model|The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
48330297|NCT02528968|BEHAVIORAL|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
48330298|NCT04093362|DRUG|TAS-120|TAS-120 is an oral FGFR inhibitor
48330299|NCT04093362|DRUG|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine is currently 1st line standard of care
48330300|NCT05506917|PROCEDURE|periodontal treatment|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
48330301|NCT05563714|BEHAVIORAL|Clinician Notification with Nurse Facilitation (CNNF)|An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.
48330302|NCT05563714|BEHAVIORAL|Wait list control|The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
48330303|NCT01767012|DEVICE|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
48330304|NCT01767012|DEVICE|Polylens EC-Y10-PAL (uncoated)|
48330305|NCT02204033|DRUG|99mTc - labelled hMAb BIWA 4|
48330306|NCT02204033|DRUG|186 Re - labelled hMAb BIWA 4|
48330307|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - low dose|
48330308|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - medium dose|
48330309|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - high dose|
48330310|NCT05394103|DRUG|Q901|The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
48330311|NCT05394103|DRUG|KEYTRUDA® (pembrolizumab)|KEYTRUDA® (pembrolizumab) will be administered Q6W
48330312|NCT00333697|OTHER|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
48330313|NCT00357422|PROCEDURE|Operation|No drug needed
48330314|NCT00357422|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
48491651|NCT01566864|BEHAVIORAL|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
48123892|NCT05260359|OTHER|Undosed patch|negative control
48651155|NCT04872946|OTHER|Moisturizer|Aqua/Water/Eau, Glycerin, Diisopropyl Dimer Dilinoleate, Coco-Caprylate, Lactococcus Ferment Lysate, Myristyl Myristate, Dimethicone, Propanediol, Behenyl Alcohol, Glyceryl Stearate SE, Potassium Cetyl Phosphate, Palmitic Acid, Ammonium Acryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer, Myristyl Laurate, Caprylyl Glycol, Hydroxyethylcellulose, Myristic Acid, Tocopherol, Ethylhexylglycerin, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Helianthus Annuus (Sunflower) Seed Oil, Trisodium Ethylenediamine Disuccinate, Lactic Acid, Sodium Hydroxide, Sodium Phosphate, Disodium Phosphate, Sodium Chloride, t-Butyl Alcohol, Phenoxyethanol, Sodium Benzoate.
48123893|NCT04353310|DRUG|Curcumin|Curcumin 1500mg PO BID
48330315|NCT00305604|DRUG|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
48330316|NCT00305604|DRUG|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
48330317|NCT01926470|PROCEDURE|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
48330318|NCT01926470|PROCEDURE|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
48330319|NCT05016791|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~1. Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~2. If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~3. If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
48330320|NCT04006912|PROCEDURE|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
48330321|NCT00350311|DRUG|nicotine transdermal patch/lozenge|
48330322|NCT01319916|DRUG|ATX-101|ATX-101 2mg/cm2
48330323|NCT01153841|BIOLOGICAL|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
48330324|NCT01153841|BIOLOGICAL|Infanrix hexa™|Intramuscular, 3 doses
48330325|NCT02016222|PROCEDURE|tears sampling|
48330326|NCT02452112|DRUG|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
48123894|NCT04353310|OTHER|Placebo|identical in appearance to curcumin
48330327|NCT02452112|DRUG|Placebo|Placebo patch to be placed on the site of pain
47973981|NCT04208789|DIAGNOSTIC_TEST|Drug Susceptibility Test|This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
47973982|NCT02299700|OTHER|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
48123895|NCT06284642|DRUG|Urokinase|On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
48123896|NCT06284642|DRUG|Placebo|On the basis of standard treatment for severe neurological conditions, the treatment of lumbar drainage combined with intrathecal placebo saline injection was started within 24 hours after aneurysm treatment, 3 ml placebo was injected into the subarachnoid space, 3 ml normal saline was flushed into the tube, and the tube was observed for 2 hours, once a day for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
48330328|NCT03685526|DEVICE|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
47973983|NCT01293721|DEVICE|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
47973984|NCT04885361|BIOLOGICAL|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
47973985|NCT00902408|DIETARY_SUPPLEMENT|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
47973986|NCT01912365|PROCEDURE|Above Elbow Cast|
47973987|NCT01912365|PROCEDURE|Long Arm Splint|
47973988|NCT02834507|DRUG|Placebo|Matching placebo capsules
47973989|NCT02834507|DRUG|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
47973990|NCT02834507|DRUG|Comtan®|Capsules containing entacapone 200 mg
47973991|NCT02834507|DRUG|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
47973992|NCT05412511|BEHAVIORAL|MB-TB|Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
48651156|NCT00944840|DRUG|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
48651157|NCT00944840|DRUG|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
48123897|NCT00004104|BIOLOGICAL|liposomal interleukin-2|
48123898|NCT00004104|BIOLOGICAL|polyvalent melanoma vaccine|
48123899|NCT00004104|BIOLOGICAL|recombinant interferon alfa|
48123900|NCT04965415|BEHAVIORAL|Health Links + Leadership Training|Help businesses undergo transactional (i.e., business management practices) and transformational (i.e., business leadership and culture) change. Transactional change component: Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.Transformational change component: The experimental arm includes TWH leadership training for small business owners and other senior leaders. This is a three-month training that includes assessments, in-person training, and virtual training transfer activities. The goal is to help the leader understand their organization's current approach to TWH, identify areas for improvement, and to take action.
48651158|NCT04798820|OTHER|Dietary education(nutritional counselling)|Dietary education provided to gastrectomy patients by dietitian.
47973993|NCT05412511|BEHAVIORAL|MB-NTB|Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
47973994|NCT06131034|OTHER|Music|Participant in the intervention group will receive music interventions perioperatively.
47973995|NCT00002916|BIOLOGICAL|human papillomavirus 16 E7 peptide|
47973996|NCT00002916|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
47973997|NCT00002916|PROCEDURE|adjuvant therapy|
47973998|NCT00002916|PROCEDURE|surgical procedure|
47973999|NCT00002916|RADIATION|radiation therapy|
47974000|NCT05848960|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral supplement|2 supplements per day
47974001|NCT05848960|OTHER|Mediterranean diet|Mediterranean diet
47974002|NCT01465997|DRUG|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
47974003|NCT01465997|DRUG|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
47974004|NCT04072302|DRUG|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
48123901|NCT04965415|BEHAVIORAL|Health Links|Health Links is an existing community-based intervention that seeks to help businesses - especially small and medium-sized businesses - create a culture of both safety and health. Health Links does this by helping businesses incorporate Total Worker Health (TWH) programming into their business practices through assessment, advising, and certification. There is evidence that this consultation intervention is effective at helping businesses develop and implement policies and programs.
48123902|NCT04425616|OTHER|Exercise|"At least one and up to three supervised sessions per week including:~* aerobic exercise at a rating of perceived exertion of 11-14 (6-20 scale) accumulating 20 minutes per session~* resistance exercise of 8-10 exercises for 2x 8-15 repetitions performed in a controlled manner and covering the whole body~* Range of motion exercise performed through pain free range of motion covering the whole body to be maintained in good alignment for 10-30 seconds, with some movements held for a second set of 10-30 seconds if stiff"
48330329|NCT03963713|RADIATION|Stereotactic radiotherapy|Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
48330330|NCT03963713|RADIATION|Conventionally-fractionated image- guided Intensity modulated radiotherapy|Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
48330331|NCT05464472|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
48330332|NCT04393077|BEHAVIORAL|Emotional Freedom Technique|EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
48123903|NCT04425616|BEHAVIORAL|Psychological and Behaviour Change Support|Instructors will be trained in Healthy Conversation Skills (HCS), Making Every Contact Count (MECC) or equivalent. This will enable them to deliver brief participant centred empowering interventions informed by social cognitive theory. This skill set will be used to support participants in adopting and maintaining the prescribed exercise and diet programme as well as adopting and practicing strategies to self-manage psychological well-being. Participants will be given the option to be provided with a SMARTER goal setting sheet to assist with goal planning. Applicable standardised psychological support resources will be made available to the participants though the Macmillan resource repository that they can access online or in alternative format as necessary, for example relaxation and mindfulness exercises
48330333|NCT01646463|BEHAVIORAL|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
47974005|NCT04072302|DRUG|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
47974006|NCT01864811|BEHAVIORAL|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
47974007|NCT01864811|BEHAVIORAL|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
48651159|NCT02367885|DRUG|TAK-850 0.5 mL injection|TAK-850 injection
47974008|NCT00112060|DRUG|PT-523 for Injection|
47974009|NCT02616055|DRUG|tesevatinib|
48651160|NCT02367885|DRUG|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
48651161|NCT03875443|OTHER|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
47974010|NCT06507982|DEVICE|EWL|the working length determination with EAL method
47974011|NCT06507982|DEVICE|SWL|In this method, an endodontic motor with a built-in EAL that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the WL. Thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. The motor of devices using this method has automatic apical reverse and automatic apical stop operation. In this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating.
47974012|NCT06507982|DEVICE|RWL|Radiographic method was used for determining the working length
47974013|NCT05447637|DIAGNOSTIC_TEST|Invitae multi-cancer gene panel|Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
47974014|NCT04572932|DRUG|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
47974015|NCT03534557|DIAGNOSTIC_TEST|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
48330334|NCT01646463|BEHAVIORAL|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
48330335|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
48330336|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
48330337|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
48330338|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
48491652|NCT01566864|BEHAVIORAL|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
48491653|NCT02996760|DRUG|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
48123904|NCT04425616|OTHER|Nutrition|Instructors will receive training in generic nutritional principles in line with recommendations from World Cancer Research Fund (WCRF) and British Dietetic Association, and will work with participant to review own diet and eating habits against WCRF recommendations to enable goal setting and identify links to existing resources reputable websites, outputs and on-line forums. These would include: principles of healthy eating ('eat well' advice), weight management, symptom management, prehab advice before treatment starts, rehab advice during and after treatment. The participant will be asked if they are eating and drinking well or have any concerns at the beginning of each exercise session. Further support will be provided to instructors to address participant concerns or requests for additional information.
48123905|NCT05359653|DRUG|Clemastine Fumarate|8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
48123906|NCT05359653|DRUG|Placebo|Matched sugar tablet
47974016|NCT02301052|DRUG|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
47974017|NCT02301052|DRUG|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
47974018|NCT02301052|DRUG|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
47974019|NCT00282594|DRUG|Novolin R (human recombinant Insulin)|
47974020|NCT02056314|OTHER|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
47974021|NCT02056314|OTHER|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
48123907|NCT03011489|DEVICE|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
48330339|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
48330340|NCT05632029|DEVICE|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
48491654|NCT03594695|DIAGNOSTIC_TEST|HSCRP and NLR|hs-CRP levels and NLR values will be studied from routine blood samples.
48651162|NCT03875443|OTHER|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
48651163|NCT04447222|OTHER|Quality-of-Life Assessment|Ancillary studies
48651164|NCT04447222|OTHER|Questionnaire Administration|Ancillary studies
48651165|NCT04447222|OTHER|Survey Administration|Complete survey
47974022|NCT03012802|PROCEDURE|Colorectal Surgery|Postoperative Audit
47974023|NCT04000490|OTHER|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
47974024|NCT02835404|DRUG|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
47974025|NCT02835404|RADIATION|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
47974026|NCT02835404|RADIATION|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
48123908|NCT03310866|DEVICE|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
48123909|NCT03310866|DEVICE|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
48123910|NCT00225797|DRUG|Oxymorphone Extended Release|
48123911|NCT02797184|DRUG|KNO3, potassium nitrate|Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
48123912|NCT02065193|BEHAVIORAL|ADOS/ADI-R/Clinical assessment|
48123913|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis before any systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after which physician choice adjuvant systemic therapy is permitted
48330341|NCT05632029|DEVICE|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
48330342|NCT03350841|PROCEDURE|Platelet rich plasma PRP|blood sample is collected to prepare platelet rich plasma injected in the canal
48330343|NCT03350841|PROCEDURE|root canal treatment|conventional root canal treatment and obturation with guttapercha
48330344|NCT06240494|PROCEDURE|Maxillary nerve and mandibular nerve pulsed radiofrequency|"For maxillary nerve pulsed radiofrequency, the lineer transducer is placed distal and parallel to the zygomatic arch, bridging the coronoid and condylar processes and a 22 gauge 6 mm RF cannula was inserted into the target area. With sensory stimulation, patients experienced a distinct sensation in upper jaw, teeth, and palate. Then, PRF treatment was performed at 42 °C for 240 seconds.~For mandibular nerve pulsed radiofrequency, the transducer was placed distally and parallel to the zygomatic arch, bridging the coronoid and condylar processes. The pterygopalatine fossa was visualized and the needle was inserted to target area. With sensory stimulation, patients experienced a distinct sensation in the lower jaw and teeth. With motor stimulation, a throwing movement of the jaw was observed with contraction of the masseter and temporal muscles. PRF treatment was performed at 42 °C for 240 s."
48491655|NCT03754374|OTHER|access to healthcare|use or non-use of dedicated health facilities
48491656|NCT03537274|BIOLOGICAL|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
48491657|NCT03537274|BIOLOGICAL|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
48491658|NCT03861793|BIOLOGICAL|ALKS 4230|SC injection administered in the back of the arm or the abdomen
48651166|NCT06670417|DEVICE|Low level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light|"Low level laser therapy watch:~The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light. It provides 18 individual laser beams used for extravascular blood irradiation (transcutaneous) through radial and ulnar vessels at the wrist site."
48651167|NCT06670417|OTHER|Buerger Allen exercise|Procedure-Keep the Buerger Allen exercise board on the cot. Elevate the lower extremities to an angle of 45 to 90 degree with the help of exercise board. Provided support to the lower extremities to maintain the position. Make the subject to maintain the same position in the same manner until the skin blanches (appears dead white). Lower the feet and the legs below the level of the rest of the body until redness appears (care should be taken that there is no pressure against the back of the knees). Place the legs flat on the bed for a few minutes. Ask the subjects to sit in a relaxed position while each foot is flexed and extended then inverted and everted for 3 minutes till the feet turns entirely pink. Ask the subject to rotate the feet in all the direction. Make the subject to lie quietly for 5 minutes, keeping legs warm with a blanket
48651168|NCT06670417|OTHER|Regular wound care|Regular wound care and dressing to the wound and ulcer
48651169|NCT06644963|DEVICE|Impella (5, 5.5 or CP)|Impella (5, 5.5 or CP) as an isolated circulatory support or combined with others Temporary Mechanical Circulatory Support
48651170|NCT00133432|DRUG|Zinc|
48123914|NCT05839912|PROCEDURE|Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy|Surgical intervention to remove the clinically detected lymph node metastasis after physician choice neo adjuvant systemic therapy. Physician choice adjuvant therapy is allowed after surgery
48123915|NCT05794568|DEVICE|OITcontrol app monitoring|App to monitor OIT patients
48123916|NCT06243094|DRUG|Antibiotic|All antibiotic therapy characteristics are monitored.
48651171|NCT06673719|RADIATION|99mTc-pertechnetate SPECT/CT|This procedure is similar to standard Meckel's diverticulum scan, with the addition of SPECT/CT acquisition to measure gastric volume.
48123917|NCT00886756|DRUG|AZD8529|Oral
48123918|NCT00886756|DRUG|Placebo|Oral
48491659|NCT03861793|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion over 30 minutes
48123919|NCT02954211|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
48491660|NCT02526511|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
48491661|NCT02526511|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
48491662|NCT02526511|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
48491663|NCT02526511|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
48123920|NCT02954211|BEHAVIORAL|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
48123921|NCT04772300|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter|PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery
48123922|NCT04772300|DEVICE|Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)|PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery
48123923|NCT01411631|DIETARY_SUPPLEMENT|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
48123924|NCT05967429|DIAGNOSTIC_TEST|The neutrophil-to- lymphocyte ratio|It was calculated by dividing the neutrophil count by the lymphocyte count.
48123925|NCT05967429|DIAGNOSTIC_TEST|Prognostic nutrition index|It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
48123926|NCT02370758|DRUG|Valganciclovir or Ganciclovir|
48123927|NCT00047931|DRUG|VRC-HIVDNA009-00-VP|
48123928|NCT01919450|DRUG|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
48123929|NCT01919450|RADIATION|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
48123930|NCT01172418|DRUG|Alemtuzumab|Alemtuzumab used as part of combined Induction.
48123931|NCT01172418|DRUG|Daclizumab|Daclizumab used as part of combined induction.
48123932|NCT01172418|DRUG|Thymoglobulin|Thymoglobulin used as part of combined induction.
48123933|NCT00204113|DEVICE|Multi-purpose rehabilitation frame|
48123934|NCT00204113|DEVICE|Surface Functional Electrical Stimulation|
48123935|NCT05319626|OTHER|compression socks|The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.
48123936|NCT05319626|OTHER|textured insoles|The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
48123937|NCT05319626|OTHER|smooth socks|The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
47974027|NCT01754623|DRUG|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
48123938|NCT05319626|OTHER|smooth insoles|The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
48123939|NCT04896034|DEVICE|MILTA Device|Patients in MILTA Device group will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
48123940|NCT04896034|DEVICE|" control 1  fake MILTA device"|Patients in group control 1 will each receive 2 sessions of PBM in this study, the first session within 24 hours of delivery, and the second session 24 hours after the first session.
48123941|NCT03447249|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
48123942|NCT03447249|DRUG|IVA|Participants received IVA orally once daily in the evening.
48123943|NCT03447249|DRUG|Placebo|Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
48123944|NCT06455488|PROCEDURE|Ventricular Tachycardia Ablation|This is a surgical ablation meant to reset patients irregular rhythm back to sinus.
48123945|NCT06455488|DEVICE|ICD Implant|A pacemaker or defibrillator implant to prevent SCD
48123946|NCT06455488|DRUG|Antiarrhythmic drug|Drug therapies
48123947|NCT06455488|DIAGNOSTIC_TEST|EKG|Monitoring EKG testing done on registry patients
48123948|NCT06455488|DIAGNOSTIC_TEST|Cardioversion|Monitoring cardioversions on registry patients
48123949|NCT06455488|DIAGNOSTIC_TEST|Echocardiogram|Monitoring echocardiogram testing done on patients
48123950|NCT05010655|DEVICE|Use of Eko DUO Electronic Stethoscope|Auscultation of heart sounds using electronic stethoscope
48123951|NCT04508972|DEVICE|Alexa Amazon|To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.
48123952|NCT04764006|DRUG|Surufatinib|Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
48123953|NCT01369004|BEHAVIORAL|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
48123954|NCT05796323|OTHER|No intervention.|The subjects will complete a survey related to workplace violance.
48123955|NCT02866968|PROCEDURE|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
48123956|NCT05992298|OTHER|7 T MRI vs 3 T MRI|Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
48123957|NCT01384240|DRUG|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
48123958|NCT01199133|DRUG|Dpte and Dfar Allergen Extracts|300 IR, once a day, for one year.
48123959|NCT01199133|DRUG|placebo|once a day, for one year.
48123960|NCT06324981|BEHAVIORAL|Generic text messages|The same unidirectional text message will be sent each week for 9 weeks.
48123961|NCT06324981|BEHAVIORAL|Interactive AI chatbot text messaging|Each week for 9 weeks, patients will be sent four messages that are specific to the LE8 topic for that week and with each message, they will be invited to engage with the chatbot to ask more questions about that topic. The first message of the week will be informational about the topic consistent with how the AHA provides information: 1) to understand readings and levels, 2) to encourage people to track levels, and 3) to offer specific skills building strategies. The fourth message will ask them to report out on short term (i.e., things they can do that week) plans for self-management for that topic and again invite their engagement with the chatbot to reinforce support for their plans.
48123962|NCT06324981|BEHAVIORAL|Proactive pharmacist support|Pharmacists that will proactively facilitate effective engagement with patients.
48123963|NCT01557985|DRUG|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
48123964|NCT05035004|DEVICE|Post exercise hot water immersion|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max), followed by a 10-minute transfer period and then 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
48123965|NCT05035004|DEVICE|Exercise|Participants will complete 30 minutes of cycling on a lode bicycle ergometer (50% of VO2max).
48330345|NCT03750240|DIAGNOSTIC_TEST|Sodium (Na) Magnetic Resonance Imaging (MRI)|"Two Na data will be acquired:~1. FLORET without Inversion Recovery (IR), and~2. FLORET with IR"
48330346|NCT03750240|DIAGNOSTIC_TEST|Dynamic Contrast- Enhanced (DCE) MRI|DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
48651172|NCT06673719|PROCEDURE|Combined High-Resolution Manometry-Nutrient Drink Test|Proximal gastric high-resolution manometry was done concurrently with nutrient drink test to measure proximal gastric function.
48651173|NCT05973656|DRUG|Alcohol|Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).
47974028|NCT01754623|DRUG|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
47974029|NCT01754623|DRUG|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
47974030|NCT01754623|RADIATION|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
47974031|NCT01754623|OTHER|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
48123966|NCT05035004|DEVICE|Hot water immersion|Participants will complete 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C), followed by a 10-minute transfer period and then an additional 30 minutes of whole-body hot water immersion in a hot tub (water temperature 40°C).
48123967|NCT04432389|BIOLOGICAL|ALLOB|After thawing, ALLOB® is a ready-to-use product for local administration at fracture site.
48123968|NCT04432389|OTHER|placebo|Placebo injected is a saline solution injectable grade (4 mL of 0.9% NaCl) filled in single-dose vial
48123969|NCT05993078|DRUG|0.9% NaCl 2000ml|The patient will undergo NS 2000ml intravenous infusion swiftly after IVT.
48330347|NCT00284349|DEVICE|Use of a rehabilitation brace instead of a plaster|
48330348|NCT05200455|DEVICE|Microelectrodes|Microelectrode implantation
48330349|NCT02287870|DRUG|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
48330350|NCT02287870|DRUG|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
48330351|NCT00003735|DRUG|topotecan hydrochloride|given by mouth
47974032|NCT01754623|PROCEDURE|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
48651174|NCT05973656|PROCEDURE|Biospecimen Collection|Undergo saliva, mouthwash, and cheek brush collection
48651175|NCT05973656|PROCEDURE|Breath Test|Undergo breathalyzer testing
48651176|NCT04269863|DRUG|Aspirin|control - 81mg. treatment - 81-325mg.
48651177|NCT06117631|BEHAVIORAL|Centering Parenting|See Arm description.
48651178|NCT06117631|BEHAVIORAL|Bright by Text|See Arm description.
47974033|NCT01754623|DRUG|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
48123970|NCT05993078|DRUG|0.9% NaCl 0ml|The patients receive an NS 200-400ml after IVT
48123971|NCT04106869|OTHER|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (\<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
48651179|NCT06674252|OTHER|Jiawei Bufei Tang granules|"Jiawei Bufei Tang is a traditional Chinese medicine formula applied by Professor Li Pingping to patients with lung cancer and qi yin deficiency syndrome. It consists of Huangqi, Codonopsis pilosula, Schisandra chinensis, Rehmannia glutinosa, Ziyuan, Mulberry bark, Snake berry, Half branch Lotus, White Hedyotis diffusa, etc. Bu Fei Tang is derived from the Yuan Dynasty's Yong Lei Ling Fang and consists of six ingredients: ginseng, astragalus, schisandra, Radix Rehmanniae, Ziyuan, and mulberry bark. It is mainly used to treat cough caused by lung qi deficiency. Jiawei Bufei Tang adds white Hedyotis diffusa, Scutellaria barbata, and snake berry to the original formula. White Hedyotis diffusa is more effective in dispelling carbuncles and detoxifying, Scutellaria barbata is more effective in dispelling phlegm and diuresis, and snake berry is more effective in dispelling scrofula and dispersing nodules, increasing the effect of clearing heat and detoxifying. This formula is particularly e"
48123972|NCT04106869|OTHER|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
48651180|NCT06674252|DRUG|Placebo|placebo
48123973|NCT03373708|DRUG|Epirubicin|100mg/m2
48123974|NCT03373708|DRUG|Cyclophosphamide|600mg/m2
47974034|NCT06136793|BEHAVIORAL|HomeStyles-China|2-arm \~10 week educational intervention
48123975|NCT03373708|DRUG|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
48123976|NCT03373708|DRUG|Goserelin acetate|3.6mg every month
48123977|NCT03373708|DRUG|Tamoxifen|10mg twice daily oral
48330352|NCT05766436|DRUG|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
48330353|NCT05766436|DRUG|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
48491664|NCT02140307|BEHAVIORAL|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
48491665|NCT06285968|BEHAVIORAL|Multidimensional Sleep Health Promotion Intervention|Multi-component multidimensional sleep health promotion intervention that includes sleep health and sleep hygiene education, behavioral coaching, personalized feedback, goal setting and establishment of a sleep health plan, self-monitoring, supportive accountability, and addressing light and noise in the sleep environment.
48491666|NCT05418166|DRUG|Evolocumab|evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.
48491667|NCT01868711|BEHAVIORAL|Cognitive Behavior Therapy|
48491668|NCT02479373|OTHER|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
48491669|NCT02479373|OTHER|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
48491670|NCT02479373|OTHER|Biodex dynamometer|To study muscle strength
48491671|NCT02479373|OTHER|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
48491672|NCT02479373|OTHER|Quality of life questionnaires|
48491673|NCT02680431|OTHER|Blood sample|10 mL venous blood sample for analysis of plasma
48491674|NCT04787393|DEVICE|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
48123978|NCT03373708|DRUG|Letrozole|2.5mg every daily oral
48123979|NCT01307085|PROCEDURE|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
48123980|NCT02120430|OTHER|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
48123981|NCT02853565|DRUG|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
48123982|NCT05622123|DRUG|68Ga-NODAGA-Exendin-4|PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
48123983|NCT01404598|DRUG|naproxcinod 750 bid|naproxcinod 750 bid
48123984|NCT01404598|DRUG|naproxcinod 3000 mg od|naproxcinod 3000 mg od
48123985|NCT01404598|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
48330354|NCT05766436|DRUG|Placebo|placebo ODF and 0.9% normal saline nebulizer
48651181|NCT03510715|DRUG|Alirocumab SAR236553 (REGN727)|"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
48651182|NCT03510715|DRUG|Atorvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
47974035|NCT04435132|DEVICE|PCL under fluoroscopy with the aid of the robotic device|During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
47974036|NCT00580190|DRUG|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
47974037|NCT00580190|OTHER|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
48123986|NCT03621735|DEVICE|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
48651183|NCT03510715|DRUG|Simvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
48651184|NCT03510715|DRUG|Fluvastatin|"Pharmaceutical form: capsule,~Route of administration: oral"
48651185|NCT03510715|DRUG|Pravastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
48651186|NCT03510715|DRUG|Lovastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
47974038|NCT00580190|DRUG|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
48123987|NCT03621735|DEVICE|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
48123988|NCT06187298|DIETARY_SUPPLEMENT|A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care|(Enterophytol® PLUS) alongside standard of care
48123989|NCT05530161|OTHER|hypocalcemia|hypocalcemia or normocalcemia
48123990|NCT02173717|DRUG|Dabigatran etexilate|150 mg Dabigatran etexilate
48651187|NCT03510715|DRUG|Rosuvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
48651188|NCT03510715|DRUG|Ezetimibe|"Pharmaceutical form: tablet,~Route of administration: oral"
47974039|NCT00081068|BIOLOGICAL|alemtuzumab|
47974040|NCT06076265|PROCEDURE|Radical Gastric Cancer Surgery|Laparoscopic (robotic) radical surgery for gastric cancer
47974041|NCT06088732|OTHER|Exercise Session|30 min cycling on bicycle ergometer at 60% peak power output
47974042|NCT06088732|DRUG|Ibuprofen 800 mg|A single oral dose of Ibuprofen
47974043|NCT06088732|OTHER|Rest|Resting for 30 min in chair
48123991|NCT02173717|DRUG|Rifampicin|600 mg Rifampicin
48330355|NCT01486004|DRUG|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
48651189|NCT03510715|DRUG|Cholestyramine|"Pharmaceutical form: oral suspension,~Route of administration: oral"
47974044|NCT06088732|DRUG|Placebo|Matched placebo
47974045|NCT02532972|DEVICE|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
47974046|NCT00404677|OTHER|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
47974047|NCT02697032|DRUG|Bicalutamide|150mg
47974048|NCT02697032|PROCEDURE|FDHT PET|PET scan
47974049|NCT02314897|DEVICE|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
47974050|NCT02314897|DEVICE|RV pacing|Conventional right ventricular pacing.
47974051|NCT02683161|DRUG|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
47974052|NCT02683161|BEHAVIORAL|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
47974053|NCT02683161|BEHAVIORAL|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
48330356|NCT01486004|DRUG|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
48330357|NCT05816694|DRUG|NAB-Paclitaxel plus Cisplatin|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
48651190|NCT03510715|DRUG|Nicotinic acid|"Pharmaceutical form: tablet,~Route of administration: oral"
48651191|NCT03510715|DRUG|Fenofibrate|"Pharmaceutical form: tablet,~Route of administration: oral"
48651192|NCT03510715|DRUG|Omega-3 fatty acids|"Pharmaceutical form: capsule,~Route of administration: oral"
48651193|NCT03409770|OTHER|Therapeutic hypothermia|Whole body cooling using a servo controlled device
48123992|NCT05180851|DRUG|Recombinant L-IFN adenovirus injection|Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
47974054|NCT01024634|BEHAVIORAL|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
47974055|NCT00477243|BEHAVIORAL|Questionnaire|8 questionnaires will take about 40 minutes to complete.
47974056|NCT04657120|PROCEDURE|YEARS algorithm|Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level \<1.0 μg/mL (\<1000ng/mL), and in patients with ≥1 items and a D-dimer level \<0.5 μg/mL (\<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.
47974057|NCT04657120|PROCEDURE|CTPA|Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
47974058|NCT00542854|DEVICE|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
47974059|NCT01975753|DRUG|Morphine|
47974060|NCT01975753|DRUG|Fentanyl|
47974061|NCT05890846|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
47974062|NCT05890846|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
48123993|NCT04886505|DEVICE|Electrolytic eCLIPs Bifurcation System|The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
48123994|NCT02561702|OTHER|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
48123995|NCT02561702|DRUG|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
48123996|NCT00843687|DRUG|Risperidone long-acting injectable|
48651194|NCT06579144|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
48651195|NCT06645145|BEHAVIORAL|Orthographic facilitation|Half of participants will receive orthographic support (text support) while learning new verbs. The investigators will compare learning with and without text support to determine if this aids verb learning.
48651196|NCT06637696|OTHER|Blood Culture Bundle|In this pre and post intervention study investigators aimed to evaluate the impact of a blood culture bundles on the incidence of blood culture contamination rates in NICU.
47974063|NCT05890846|BEHAVIORAL|traditional 1on1 course|Between every two iTBS sessions, the participant will receive a personalized 30-minutes one-on-one behavioral course, 2 courses per day, 5 days per week for 12 weeks.
47974064|NCT01923493|OTHER|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
47974065|NCT01923493|OTHER|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
47974066|NCT02315001|DRUG|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
47974067|NCT02315001|OTHER|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
47974068|NCT01745172|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
47974069|NCT04763798|OTHER|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
48123997|NCT01534494|DRUG|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
48123998|NCT00996229|BEHAVIORAL|Caloric restriction|20-30% CR for 6 months
48123999|NCT00996229|DIETARY_SUPPLEMENT|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
48651197|NCT01584297|DRUG|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
48651198|NCT01005979|DRUG|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles."
48124000|NCT00996229|DIETARY_SUPPLEMENT|Placebo|Daily corn oil capsules for 6 months
48124001|NCT00996229|DIETARY_SUPPLEMENT|Resveratrol|daily resveratrol for 6 months
48124002|NCT04625231|BEHAVIORAL|Educational Shared-Decision Making Tool|Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
48124003|NCT01003834|BEHAVIORAL|Computerized brief intervention|Intervention based on Motivational Interviewing technique
48330358|NCT05816694|DRUG|Cisplatin plus Epirubicin plus Cyclophosphamide|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
48330359|NCT02902029|DRUG|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
48330360|NCT02902029|DRUG|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
48330361|NCT02902029|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
48330362|NCT02576886|DEVICE|Gamma Camera|All images acquired with the General Electric Discovery 530c
48651199|NCT00586937|BEHAVIORAL|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
48651200|NCT03460704|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d. dosing).~The 1 MIU/ml CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (11 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d. (morning and evening) over aperiod of 12 month.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g. salbutamol/albuterol), supplied by the Sponsor, could be taken to improve tolerability."
48651201|NCT03460704|OTHER|Placebo|1 mL saline solution 0.45%. The placebo was made up of identical empty glass vials to which the same saline solution diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to mantain the blind.
48651202|NCT04976855|DRUG|INDV-2000|Capsule for oral administration
48651203|NCT04976855|DRUG|Placebo|Capsule for oral administration
48651204|NCT04976855|DRUG|SUBOXONE® sublingual film|Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
48124004|NCT01003834|BEHAVIORAL|Computerized health screening|Behavioral intervention
48330363|NCT02576886|PROCEDURE|Prone Imaging|
48330364|NCT00873808|DRUG|clodronate disodium|
48330365|NCT00873808|DRUG|demeclocycline hydrochloride|
48330366|NCT00873808|DRUG|ibandronate sodium|
48330367|NCT00873808|DRUG|tetracycline hydrochloride|
48330368|NCT00873808|DRUG|zoledronic acid|
48124005|NCT01003834|BEHAVIORAL|Computerized assessment|Behavioral intervention
48124006|NCT01003834|BEHAVIORAL|Therapist-delivered motivational intervention|Behavioral intervention
48124007|NCT00039000|DRUG|HSPPC-96 or Oncophage|
48124008|NCT00760136|PROCEDURE|Computed Tomography|CT imaging of bilateral knee
48124009|NCT06087549|DRUG|Pericapsular nerve group block using 0.2% ropivacaine|Unilateral ultrasound guided pericapsular nerve block using 0.5mL/kg 0.2% Ropimol (max 20mL)
48330369|NCT00873808|OTHER|laboratory biomarker analysis|
48330370|NCT00873808|PROCEDURE|adjuvant therapy|
48330371|NCT00873808|PROCEDURE|computed tomography|
48330372|NCT00873808|PROCEDURE|dual x-ray absorptiometry|
48330373|NCT06271239|OTHER|Intervention group (ViviFrail)|The participant will be guided to follow a daily exercise routine at home, lasting 30-45 minutes, from Monday to Friday, over six months. A one-week break every six weeks for reassessment, totaling seven months of activities, will be provided. They will be informed that every six weeks, they may receive new exercises in their exercise passport or continue with the same, based on their physical reassessment. Each exercise passport will have a wheel illustrating the exercise circuit for easy reference. An 'Activity Diary' will be provided for tracking progress and frequency. During 'CIRCUIT' sessions, participants should complete the entire circuit, while 'WALKING' sessions should focus solely on walking for that day. They will be motivated to keep this diary updated. The ViviFrail exercise passports cater to various levels of physical frailty and fall risk and can be accessed at https://vivifrail.com/en/materials-2/.
48330374|NCT06271239|OTHER|Group Suggestions for a Healthy Life (CG)|The participants in the group Suggestions for a healthy life (CG) will receive guidance on maintaining a healthy and independent lifestyle for three months. They will also be provided with a booklet containing strength, balance, and flexibility activities, suggesting that participants perform these activities five times a week, for around 30 minutes per day. At the end of the initial three complete months of the intervention (14 weeks), participants in the control group will commence the ViviFrail exercise protocol and will continue until the end of the study. Throughout the entire study period, participants in the control group will receive the same monitoring as the intervention group.
48491675|NCT04787393|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
48651205|NCT05018728|DRUG|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
48651206|NCT05067985|PROCEDURE|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
47974070|NCT04763798|OTHER|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
47974071|NCT04763798|OTHER|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
48124010|NCT06087549|DRUG|Erector Spinae Plane Block using 0.2% ropivacaine|Unilateral ultrasound guided erector spinae block using 0.5mL/kg 0.2% Ropimol (max 20mL)
48124011|NCT06087549|OTHER|Standard care|No erector spinae block and no pericapsular nerve group block
48651207|NCT06595238|DRUG|AZD6234|IMP injected subcutaneously, once a week. Unit dose strength as per CSP
48651208|NCT06595238|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once a week.
47974072|NCT01833520|DRUG|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
47974073|NCT02654522|DRUG|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
47974074|NCT04070989|DEVICE|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
47974075|NCT00280631|DRUG|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
48124012|NCT00055705|BIOLOGICAL|PV701|
48124013|NCT00390273|DRUG|Metformin|
48124014|NCT02730871|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
48124015|NCT02730871|DRUG|Brinzolamide/brimonidine vehicle|Inactive ingredients used as placebo comparator
48124016|NCT02730871|DRUG|Travoprost 0.004%/timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
48124017|NCT04131907|DEVICE|Optilume BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
48491676|NCT00894738|PROCEDURE|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
48491677|NCT04414839|DEVICE|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
48651209|NCT01931410|DRUG|Misoprostol|
48651210|NCT03686189|DEVICE|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
48651211|NCT05459753|RADIATION|(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET|Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.
48651212|NCT05459753|RADIATION|Dihydrotetrabenazine (DTBZ) PET|Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
47974076|NCT00727025|DEVICE|wound closure device (Steri-Strip™)|wound closure with steri-strip S
47974077|NCT01411904|DEVICE|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
47974078|NCT03598621|DRUG|Semaglutide, 0.5 mg/mL|A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
47974079|NCT03598621|DRUG|Semaglutide, 1.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
47974080|NCT03598621|DRUG|Semaglutide, 1.34 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
47974081|NCT03598621|DRUG|Semaglutide, 2.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
48124018|NCT04131907|DEVICE|Optilume Sham Device|21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
48124019|NCT00316953|DRUG|dasatinib|Given orally
48124020|NCT00316953|OTHER|pharmacological study|Correlative studies
48124021|NCT00316953|OTHER|laboratory biomarker analysis|Correlative studies
48124022|NCT04014439|DIAGNOSTIC_TEST|Ratio of Neutrophil to Lymphocyte|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
48124023|NCT04014439|DIAGNOSTIC_TEST|Level of Prealbumin Serum|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
48124024|NCT03772015|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
48124025|NCT03216213|OTHER|Frame|Vignette is framed in a way that nudges participant to leave a legacy
48330375|NCT04580212|BEHAVIORAL|Poultry hygiene intervention|The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
48124026|NCT03216213|OTHER|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
48124027|NCT05512052|DEVICE|Hannah Cervical Cup (2 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (2 mm Delta) displaces the cervical tissue by 2 mm.
48330376|NCT05710965|DEVICE|FRx-001|Wearable digital therapy
48491678|NCT04414839|DEVICE|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
48491679|NCT00598624|DRUG|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
48330377|NCT05710965|DEVICE|FRx-003|Wearable digital therapy
47974082|NCT03598621|DEVICE|DV3372, 0.5 mg/mL|DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
48491680|NCT04834843|OTHER|Observational study, no intervention|Observational study, no intervention
47974083|NCT03598621|DEVICE|DV3372, 1.0 mg/mL|DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
48491681|NCT03817801|DEVICE|NSE balloon|NSE (Goodman®) predilation + DCB (Sequent® Please) treatment
48491682|NCT03817801|DEVICE|NC balloon|NC balloon predilation + DCB (Sequent® Please) treatment
48330378|NCT05710965|DEVICE|FRx-004|Wearable digital therapy
47974084|NCT03598621|DEVICE|PDS290|PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
47974085|NCT03598621|DEVICE|NovoPen®4|NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
48330379|NCT02166229|DRUG|Divalproex sodium|
48330380|NCT03199508|DIAGNOSTIC_TEST|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
48330381|NCT03199508|DIAGNOSTIC_TEST|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
48330382|NCT04202549|DRUG|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
48491683|NCT05270200|DRUG|Azacitidine|Patients will recieve six courses of azacitidine 100mg through a needle under skin on Days 1-5.Each course is 28 days long.
48330383|NCT03396978|OTHER|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
48330384|NCT00193349|DRUG|Imatinib|
48330385|NCT00193349|DRUG|Irinotecan|
48330386|NCT00193349|DRUG|Carboplatin|
48330387|NCT05626244|BEHAVIORAL|Being a Parent|Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
48491684|NCT05270200|DRUG|Chidamide|Patients will recieve oral chidamide 5mg per day for no more than 2 years.
48491685|NCT06095141|DRUG|Cisplatin|Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
48651213|NCT06005623|DEVICE|SENS Motion + Motivational Feedback|"To weeks prior to surgery and in a 12-week period following discharge after TKA/UKA patients will be equipped with a discrete patch and built-in accelerometer (SENS Motion, Denmark, Copenhagen) attached on the thigh of the leg not undergoing surgery.~Following discharge after TKA/UKA patients randomized to the intervention-group will receive the app (SENS motion). On their provided app, patients will be able to choose between two tabs. Tab 1 will allow patients to view predefined goals, all of which are locations in a self-selected city. The sensor will measure the physical activity and daily rhythm of the patient, and accelerometer counts will be converted into daily steps, which will be visible to the patients. In Tab 2, patients will be able to see graphical representations of their daily activity as well as their history during the period in which they have worn the accelerometer. The graphical representations include: Daily steps, physical active minutes, and type of activity."
48651214|NCT05625802|PROCEDURE|Erector Spinae Plane Block (ESPB)|Up to 30 Cubic Centimeter (cc) of 0.5% ropivacaine administered by local injection into the erector spinae plane under ultrasound guidance
48651215|NCT05625802|DRUG|Ropivacaine|0.5% ropivacaine
48651216|NCT00085735|DRUG|Cisplatin|Given IV
48330388|NCT06048653|OTHER|A computer based cognitive rehabilitation program (Rehacom system)|"Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction~* Patients will receive training for four weeks, two sessions per week.~* Each patient will assume a comfortable sitting position on a chair in front of the screen.~* A report will be generated at the end of the session. It will be used for follow up.~* Session duration will range from 45 to 60 min. including rest period."
48330389|NCT06048653|DEVICE|Vagus nerve stimulation|stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.
48651217|NCT00085735|RADIATION|Craniospinal Irradiation|Undergo craniospinal Irradiation
48651218|NCT00085735|DRUG|Cyclophosphamide|Given IV
48330390|NCT06391944|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
48651219|NCT00085735|RADIATION|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
48651220|NCT00085735|OTHER|Laboratory Biomarker Analysis|Correlative studies
48651221|NCT00085735|DRUG|Lomustine|Given orally
48651222|NCT00085735|OTHER|Quality-of-Life Assessment|Ancillary studies
48651223|NCT00085735|RADIATION|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
48330391|NCT06391944|DRUG|Osimertinib tablet|Osimertinib 80 or 160mg po everyday
48330392|NCT04705337|DRUG|Levosimendan|administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
48491686|NCT01193036|BEHAVIORAL|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
48491687|NCT01193036|BEHAVIORAL|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
48491688|NCT01328236|DRUG|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
48491689|NCT01328236|DRUG|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
48491690|NCT01328236|DRUG|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
48651224|NCT00085735|DRUG|Vincristine Sulfate|Given IV
48651225|NCT06429657|DRUG|Ketamine with propofol|Propofol at a rate of 300 mcg/kg/hr (5 mcg/kg/min) with the addition of ketamine at a rate of 1000-5000 mcg/kg/hr (16.67 - 83.33 mcg/kg/min) (using weight at time of admission) with an additional 2 mg/kg (2000 mcg/kg) bolus of ketamine
48651226|NCT06429657|OTHER|Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam|Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the institutional SOC guidelines.
48651227|NCT06369155|DRUG|Azenosertib|Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
48651228|NCT01564030|OTHER|Empty|overnight fast
48651229|NCT01564030|OTHER|Fluid|250mL apple juice
48651230|NCT01564030|OTHER|Solid|breakfast
48651231|NCT01554709|DEVICE|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
48124028|NCT05512052|DEVICE|Hannah Cervical Cup (4 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (4 mm Delta) displaces the cervical tissue by 4 mm.
48124029|NCT05512052|DEVICE|Hannah Cervical Cup (6 mm Delta)|The Hannah Cervical Cup reverses and prevents early cervical change by improving cervical collagen function. It applies negative pressure to the cervix, placing it in a tensile strain. Collagen under tension elicits fibers to realign, creating initial stiffness. This enables the cervix to remain closed. Over time, the extracellular matrix becomes strengthened as tension increases collagen strength and synthesis, and decreases degradation and adhesions. It also decreases prostaglandins--inflammatory mediators that facilitate birth. The Hannah Cervical Cup will create stiffness and length in the cervix, provide a treatment for early rupture of fetal membranes, and will offer a mode of medication administration. It is simple in nature, non-invasive, may be used in low-income, low-resource settings, can be placed by a physician in inpatient and outpatient settings, and does not require anesthesia during placement. The Hannah Cervical Cup (6 mm Delta) displaces the cervical tissue by 6 mm.
48124030|NCT00516477|BIOLOGICAL|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
48124031|NCT06301204|DRUG|Tranexamic acid injection|tranexamic acid administration 250mg or 500 mg
48124032|NCT06301204|DRUG|Saline|onyl ıv saline (NaCl 0.09%)
48124033|NCT01189942|DRUG|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
48124034|NCT06074549|DEVICE|DynamX Novolimus-eluting Coronary Bioadaptor System|All patients will receive at least one DynamX Bioadaptor implant in a commercial setting in accordance with the product's Instructions for Use
48124035|NCT04372316|DRUG|methylcobalamin|methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks
48124036|NCT04085874|BEHAVIORAL|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
48330393|NCT04705337|OTHER|Placebo|administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
48124037|NCT04085874|BEHAVIORAL|Nutrition counseling from standard health services care|once nutrition counselling from health services
48124038|NCT05106946|BIOLOGICAL|ThisCART22 cells|0.2-60 x 10\^6 CAR T cells per kg body weight
48124039|NCT02204982|DRUG|Duvelisib|PI3K Inhibitor
48124040|NCT02204982|DRUG|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
48124041|NCT02204982|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
48124042|NCT01152398|BIOLOGICAL|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
48330394|NCT04179786|BIOLOGICAL|Sci-B-Vac™|Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
48330395|NCT03518632|BEHAVIORAL|Interval training|Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
48330396|NCT03518632|OTHER|Standard Oncologic care|Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
48330397|NCT00781963|BEHAVIORAL|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
48330398|NCT00781963|BEHAVIORAL|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
48330399|NCT04315493|DRUG|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
48330400|NCT04315493|DRUG|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
48330401|NCT02487134|DEVICE|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
48330402|NCT02487134|DEVICE|Control|Closure of the abdomen with conventional technique
48330403|NCT02198651|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
48330404|NCT02198651|OTHER|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
48124043|NCT05296772|BIOLOGICAL|JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody|Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
48124044|NCT05296772|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|200 mg, once every three weeks until disease progression, withdrawal or up to two years
48124045|NCT05175898|DEVICE|VA-ECMO|Treatment with veno-arterial extracorporeal membrane oxygenation
48124046|NCT05175898|DEVICE|ECMELLA|Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
48124047|NCT01188655|DRUG|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
48124048|NCT00000969|DRUG|Zalcitabine|
48124049|NCT00000969|DRUG|Didanosine|
48124050|NCT06116708|DEVICE|Kalogon AF Prototype Smart Cushion|The Kalogon cushion is a dynamic smart cushion that utilizes a combination of foam and 5 adjustable air cells to intelligently redistribute weight and increase comfort for users. The air cells are used to modulate interface pressures and adjust where support or pressure reductions are provided based on input from the controller's pressure sensing system.
48124051|NCT06116708|DEVICE|Standard Seat Cushion from Air Force|This is the standard seat cushion that was provided by the United States Air Force to use for this study. It is a high-density, molded polyurethane foam.
48124052|NCT05715437|DRUG|Bupivacaine plus Normal Saline|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
48124053|NCT05715437|DRUG|Bupivacain and ketamine|Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
48330405|NCT05897112|DRUG|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
48330406|NCT05897112|DRUG|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
48330407|NCT00109772|DRUG|lenalidomide|Two 5 mg capsules taken one time per day
48491691|NCT05845931|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
48124054|NCT03902132|OTHER|Core Stability exercises group|Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
48124055|NCT03902132|OTHER|Traditional low back physical therapy group|The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
48124056|NCT03646136|PROCEDURE|Retained fluid|Retained fluid
48124057|NCT03646136|PROCEDURE|Emptied fluid|Emptied fluid
48124058|NCT02472275|DRUG|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
48124059|NCT02472275|OTHER|Laboratory Biomarker Analysis|Correlative studies
48124060|NCT02472275|DRUG|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
48124061|NCT02472275|RADIATION|Radiation Therapy|Undergo radiation therapy
48124062|NCT06013137|OTHER|Therabot|The participants assigned to the experimental group will interact with an artificial intelligence therapy chatbot to alleviate symptoms associated with depression, anxiety, and eating disorders. The control group will not have access to this smartphone chatbot app.
48124063|NCT04414826|BEHAVIORAL|Mindfulness Alone (MO) Intervention|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.
48124064|NCT04414826|BEHAVIORAL|Mindfulness + Compassion Intervention (MC)|Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.
48330408|NCT00109772|DRUG|Placebo|Two placebo capsules taken one time per day
48330409|NCT04730310|PROCEDURE|NSQIP Lower Extremity Open (LEO) procedure-targeted dataset (i.e. undergoing Lower extremity open revascularization) from 2014-2019|Infrainguinal, open lower extremity revascularization procedures
48330410|NCT03582735|OTHER|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
48491692|NCT00560430|DRUG|telmisartan|80 mg per day, orally, weeks 1-14
48651232|NCT06585865|BEHAVIORAL|Resistance training|After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.
48124065|NCT05487118|DEVICE|Placebo PBMT + MCE|Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
48124066|NCT05487118|DEVICE|Active PBMT + MCE|Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
48124067|NCT02025257|OTHER|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
48124068|NCT00031694|DRUG|paclitaxel|Given IV
48330411|NCT03865511|DRUG|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
48124069|NCT00031694|DRUG|bryostatin 1|Given IV
48330412|NCT03865511|GENETIC|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~1. Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~   * C797S testing (digital PCR)~  * MET amplification (dPCR/FISH)~  * Histological examination of the tissue sample (to identify small cell transformation)~  * Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~2. At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
48330413|NCT03865511|GENETIC|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~* Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~* Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~* Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~* Kinetics studies of the alterations"
48330414|NCT02366390|BEHAVIORAL|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
48330415|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
48330416|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
48330417|NCT01548794|PROCEDURE|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
48330418|NCT04899960|DRUG|Clinical Pharmacist Intervention|Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
48330419|NCT00361894|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
48491693|NCT00560430|DRUG|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
48124070|NCT03128359|DRUG|Busulfan|Given IV
48651233|NCT06585865|DIETARY_SUPPLEMENT|Resveratrol 500 mg oral once daily.|Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
48124071|NCT03128359|DRUG|Cyclophosphamide|Given IV
48124072|NCT03128359|DRUG|Fludarabine Phosphate|Given IV
48330420|NCT00361894|DRUG|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
48651234|NCT06585865|DIETARY_SUPPLEMENT|Placebo|Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
48330421|NCT04048655|DRUG|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
48330422|NCT05145712|DIAGNOSTIC_TEST|Bowel readiness|"During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year"
48491694|NCT00560430|DRUG|placebo|placebo; orally weeks 1-14
48491695|NCT04003584|PROCEDURE|Coronary bypass surgery|Reviewed postoperative coronary bypass patients and compared postoperative pain levels
48491696|NCT00278187|BIOLOGICAL|volociximab|
48491697|NCT00278187|DRUG|erlotinib hydrochloride|
48124073|NCT03128359|PROCEDURE|Hematopoietic Cell Transplantation|Undergo PBSC HCT
48124074|NCT03128359|OTHER|Laboratory Biomarker Analysis|Correlative studies
48124075|NCT03128359|DRUG|Melphalan Hydrochloride|Given IV
48124076|NCT03128359|DRUG|Mycophenolate Mofetil|Given IV or PO
48124077|NCT03128359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
48124078|NCT03128359|OTHER|Quality-of-Life Assessment|Ancillary studies
48124079|NCT03128359|DRUG|Tacrolimus|Given IV
48124080|NCT03128359|RADIATION|Total-Body Irradiation|Undergo TBI
48124081|NCT04523922|DRUG|40 IU Intranasal Oxytocin|40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
48124082|NCT04523922|DRUG|Placebo|Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
48124083|NCT04523922|BEHAVIORAL|Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure|12 weekly sessions of COPE therapy for PTSD and AUD.
48124084|NCT04828590|OTHER|No intervention|Due to observational study
48124085|NCT01255501|DRUG|NI-0701|
48124086|NCT01255501|DRUG|Placebo|
48124087|NCT05901896|OTHER|there are no intervention|no intervention
48124088|NCT04251442|DEVICE|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
48124089|NCT02162225|DRUG|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
48124090|NCT04044651|DRUG|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
48124091|NCT04044651|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
48124092|NCT06287489|OTHER|Mediterranean diet|Mediterranean diet for three month
48124093|NCT06287489|OTHER|Regular diet|regular diet
48124094|NCT04842513|DRUG|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
48124095|NCT00099931|DRUG|vildagliptin|
48124096|NCT02351310|DRUG|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
48124097|NCT02351310|GENETIC|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
48124098|NCT00632749|DRUG|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
48124099|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
48124100|NCT00632749|DRUG|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
48124101|NCT00632749|DRUG|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
48124102|NCT04436900|PROCEDURE|Panretinal Photocoagulation (PRP)|PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
48124103|NCT01240434|PROCEDURE|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
48124104|NCT02311452|DEVICE|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
48124105|NCT00495677|DRUG|PF-00232798|Solution, 20 mg. once daily, 10 days
48124106|NCT00495677|DRUG|PF-00232798|Solution, 150 mg. once daily, 10 days
48124107|NCT00495677|DRUG|PF-00232798|Solution, 5 mg. once daily, 10 days
48124108|NCT00495677|DRUG|PF-00232798|Solution, 40 mg. once daily, 10 days
48124109|NCT00495677|DRUG|PF-00232798|Solution, 300 mg. once daily, 10 days
48124110|NCT00495677|DRUG|PF-00232798|Solution, 400 mg. once daily, 10 days
48124111|NCT02496325|PROCEDURE|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
48124112|NCT01291810|BIOLOGICAL|TNF Kinoid|TNF Kinoid
48124113|NCT01291810|BIOLOGICAL|WFI|WFI
48124114|NCT04856826|DEVICE|ultrasound guidance and therapeutic communication|insertion of a peripheral venous catheter with ultrasound guidance and therapeutic communication
48124115|NCT05801367|DRUG|Formocresol|Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)
48124116|NCT05801367|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
48124117|NCT01040689|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
48124118|NCT01040689|DRUG|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
48124119|NCT01040689|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
48124120|NCT01040689|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
48124121|NCT01040689|DRUG|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
48124122|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
48124123|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
48124124|NCT01118754|DRUG|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
48124125|NCT00692185|DRUG|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
48124126|NCT00692185|DRUG|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
48330423|NCT04278482|DIETARY_SUPPLEMENT|Dietary supplement, DHA or Placebo|Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
48330424|NCT00425711|DRUG|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
47974086|NCT01679860|PROCEDURE|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~* CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~* HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~* Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
47974087|NCT01679860|DRUG|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
47974088|NCT04718051|DRUG|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
48330425|NCT05507060|DEVICE|Vibrating MESH nebulizer (Aerogen Ultra)|Medication will be applied with Vibrating MESH nebulizer
48330426|NCT05507060|DEVICE|Jet nebulizers (Philips Respironics)|Medication will be applied with Jet nebulizers
48330427|NCT05979714|OTHER|Patient-centered injection site|CAB-RPV LA will be delivered in a trans-friendly injection clinic at Bridge HIV, which is centrally located in SF. The clinic is staffed by physicians, nurses, and peer navigators who are experienced working with the trans community and are experts in delivery of injectable formulations. For patients unable to attend follow-up clinic visits, arrangements will be made for a clinical provider and peer navigator to conduct a home visit for injection delivery. This implementation strategy will overcome structural barriers where it is difficult to get a visit appointment, and when appointments are missed, even harder to re-schedule. The central location in a quiet, safe and trans-affirming clinical site will make injections easy-to-access. Because the Bridge HIV clinic is not a primary care site, injections can be delivered with minimal wait times due to low patient load relative to clinical capacity.
48330428|NCT05979714|BEHAVIORAL|Patient-centered adherence support|A Trans peer navigator will support trans women living with HIV receiving long-acting injectable treatment through our delivery model. Peer navigators will reach out to trans women using our highly effective mobile SMS platform to provide additional support before and between visits. This platform provides automated weekly check-ins for streamlined support and bi-directional asynchronous texting with a peer navigator. Peer navigators will use this SMS platform to send appointment reminders, assess needs for re-scheduling, answer questions and triage concerns regarding CAB-RPV LA, and offer support for transportation or scheduling a home visit. This approach has demonstrated efficacy in improving ART adherence and viral suppression in people living with HIV as well as retention in care and adherence to PrEP.
48330429|NCT05979714|OTHER|Provider education|To support effective outreach to and education of providers on novel evidence-based practices, SFDPH has utilized public health detailing (brief educational visits via a nurse practitioner) to ensure providers are prepared to implement new interventions. This strategy has been effective in expanding the implementation of PrEP, RAPID ART initiation, and comprehensive STI screening across clinics in SF. For this study, we will develop educational materials on the CAB-RPV LA regimen, including a summary of results from Phase 3 trials (ATLAS20, FLAIR21), the FDA labeling indication, and details about SFDPH's implementation of CAB-RPV LA within our safety-net system and our new delivery model. These materials will include information on which patients will be eligible for this treatment modality and eligible for referral to our new delivery model, and how to make these referrals.
48330430|NCT05979714|BEHAVIORAL|Improved clinic communication strategies|For SFDPH clinics, Bridge HIV providers will communicate with primary care providers through EPIC, SFDPH's electronic health record (EHR), and one of the most common EHR systems used across clinic systems in the US. For this study, secure email and/or telephone encounters within EPIC will be used to facilitate efficient referrals of TGW living with HIV from their primary providers to the Bridge HIV injection clinic and ongoing secure communication between Bridge HIV clinicians and the primary care team. For non-SFDPH clinics, communication will be via secure email or other secure communication strategies.
48330431|NCT03384524|DRUG|Bromocriptine 2.5 MG|Administered daily
48330432|NCT03384524|DRUG|Metoprolol 25 MG|Administered daily
48491698|NCT04815330|OTHER|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
48491699|NCT04815330|OTHER|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
47974089|NCT04718051|DRUG|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
47974090|NCT06227845|OTHER|Fecal microbiota transplant|0.1-0.3 ml liquid containing 3.5 mg/ml of maternal fecal content, (0.35mg/kg)
47974091|NCT00650260|DEVICE|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
47974092|NCT00650260|DEVICE|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
48124127|NCT02494336|PROCEDURE|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
48124128|NCT02494336|PROCEDURE|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
48124129|NCT02494336|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
48124130|NCT01039155|DRUG|Azacitidine|Given IV
48330433|NCT03384524|DRUG|Tamsulosin 0.4 MG|Administered daily
48330434|NCT03384524|OTHER|Placebo|Three pills, matching active drugs to be administered daily
48124131|NCT01039155|OTHER|Laboratory Biomarker Analysis|Correlative studies
48124132|NCT01039155|DRUG|Oxaliplatin|Given IV
48330435|NCT02720653|PROCEDURE|Endoscopic sinus surgery|
48330436|NCT01286701|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
48330437|NCT04280887|DEVICE|MyPad|Ultrasound bed wetting alarm
48330438|NCT03028584|BEHAVIORAL|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
48330439|NCT03634878|OTHER|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
48330440|NCT04247815|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
48330441|NCT04247815|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
48330442|NCT04247815|DRUG|Methotrexate|7.5 mg to 25 mg weekly
48330443|NCT02607332|DRUG|Paclitaxel|
48491700|NCT06444932|PROCEDURE|Joint Mobilization|Patellofemoral and tibiofemoral joint mobilization
48330444|NCT03120728|DRUG|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
48330445|NCT05950971|DRUG|Amiodarone, diltiazem or esmolol|Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
48330446|NCT04240171|DRUG|Dapagliflozin 5Mg Tab|Dapagliflozin 5mg tablets daily
48330447|NCT04240171|DRUG|Glimepiride 4Mg Tab|Glimepiride Tablets daily
48330448|NCT05506904|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
48330449|NCT03654755|DRUG|ASN002|Daily dose of ASN002 for up to 110 weeks
48330450|NCT03118011|OTHER|No smoking|No smoking
48330451|NCT03118011|OTHER|Smoking|Ability to go out to smoke
48330452|NCT03095053|PROCEDURE|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
48124133|NCT01039155|OTHER|Pharmacological Study|Correlative studies
48330453|NCT04166656|BIOLOGICAL|Trumenba®|Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
48330454|NCT04166656|BIOLOGICAL|Bexsero®|Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
48491701|NCT06444932|PROCEDURE|Resistance Exercise Training|Lower limb resistance exercise training
48491702|NCT06444932|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|Transcutaneous Electric Nerve Stimulation (TENS)
48330455|NCT01969942|BIOLOGICAL|allogeneic stem cell transplantation|
48330456|NCT01969942|DRUG|Clyclophosphamide|
48330457|NCT01969942|DRUG|Fludarabina|
48330458|NCT01969942|DRUG|Busulfan|
48330459|NCT01969942|DRUG|Melphalan|
48491703|NCT06444932|DEVICE|Heating Pad|Heating pad for heat therapy
48491704|NCT05318209|OTHER|Exercise|Closed-chain Shoulder Girdle Scapular Depression Exercise
48491705|NCT02397005|DRUG|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
47974093|NCT02622308|DEVICE|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
47974094|NCT05950490|DRUG|Intravitreal injection of methotrexate|"Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years"
47974095|NCT02020330|DRUG|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
47974096|NCT02020330|DRUG|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
47974097|NCT01342302|BEHAVIORAL|Psychosocial Intervention for Couples|Intervention delivered on line
47974098|NCT05536986|OTHER|Stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
47974099|NCT00869674|PROCEDURE|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
47974100|NCT04887051|OTHER|pulmonory based home exercises|web based telerehablitation
47974101|NCT04736420|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure group
47974102|NCT04736420|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
47974103|NCT01028144|BEHAVIORAL|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
47974104|NCT01028144|BEHAVIORAL|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
47974105|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
47974106|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
48124134|NCT01890811|DIETARY_SUPPLEMENT|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
48124135|NCT00823472|DRUG|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
48124136|NCT02885636|DRUG|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
48124137|NCT02885636|OTHER|Saline placebo|Saline inhaled through a nebulizer as a single dose
48330460|NCT04397029|DEVICE|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
48330461|NCT05218577|OTHER|high selenium functional food|HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
48330462|NCT05218577|DIETARY_SUPPLEMENT|selenium supplement|20 microgram/day selenium suppplement powder.
48330463|NCT05218577|OTHER|Placebo|the placebo mocaf powder
48330464|NCT01601470|DRUG|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
48330465|NCT01601470|DRUG|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
48330466|NCT00001911|DRUG|Interleukin-12|
48491706|NCT02397005|DRUG|Placebo matching ZL-2102|
48330467|NCT04369768|PROCEDURE|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
48330468|NCT03373110|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy|see arm description
48330469|NCT03373110|BEHAVIORAL|Online Cognitive Behavioral Therapy|see arm description
48330470|NCT03373110|BEHAVIORAL|Fitbit Alone|see arm description
48491707|NCT00206830|DEVICE|Triage Profiler S.O.B. Panel|
48330471|NCT02389686|DEVICE|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
48330472|NCT02873364|DRUG|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
48330473|NCT02873364|DRUG|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
48330474|NCT04736329|DRUG|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
48330475|NCT00547898|DRUG|Crofelemer 125 mg|Crofelemer 125 mg
48330476|NCT00547898|DRUG|Crofelemer 250 mg|Crofelemer 250 mg
48330477|NCT00547898|DRUG|Crofelemer 500 mg|Crofelemer 500 mg
48330478|NCT00547898|DRUG|Placebo|Placebo
48330479|NCT00031499|DRUG|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
48651235|NCT05460286|OTHER|Chiropractic Manipulation|20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
48651236|NCT05460286|OTHER|Spinal Decompression Device Treatment|20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
48651237|NCT03729141|DIETARY_SUPPLEMENT|Added Cholesterol|Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
48124138|NCT00003542|BIOLOGICAL|pegylated interferon alfa|
48330480|NCT00031499|DRUG|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
48651238|NCT03729141|OTHER|No Added Cholesterol|Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
48651239|NCT00619918|DRUG|Nebulized 3% saline|4 ml inhaled q8h
48651240|NCT00619918|DRUG|Nebulized 0.9% saline|normal saline
48651241|NCT04619628|BIOLOGICAL|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
48651242|NCT04619628|OTHER|Placebo|normal saline
48651243|NCT06417229|DRUG|BMS-986365|Specified dose on specified days
48124139|NCT06160518|BEHAVIORAL|Virtual reality|artificial construction of 3D environment via mobile technology. It included a head-mounted device (HMD) with 3D-enabled goggles, sensory input devices and headphones, which together allow a multisensory experience to divert a child's attention.
48124140|NCT01791816|DRUG|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
48124141|NCT01791816|DRUG|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
48124142|NCT00220038|BEHAVIORAL|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
48330481|NCT00031499|DRUG|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
48330482|NCT03436771|GENETIC|JCAR017|No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
48330483|NCT03436771|GENETIC|JCARH125|No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
48330484|NCT00807300|RADIATION|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
48330485|NCT00807300|PROCEDURE|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
48330486|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
48330487|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
48330488|NCT00554138|DRUG|placebo|1 dd for 7-10 days
48330489|NCT00554138|DRUG|rosuvastatin|1 dd 20 mg for 7-10 days
48651244|NCT06417229|DRUG|Rabeprazole|Specified dose on specified days
48124143|NCT00558454|DRUG|Iron|Ferrous succinate mixture
48124144|NCT04953273|OTHER|Vigitrauma|Case management algorithm using early phone contact
48124145|NCT01264289|DRUG|Finasteride|Finasteride Tablets 5 mg
48124146|NCT05984212|DRUG|Ultrasound guided rectus sheath block with dexmedetomidine|Intervention Group: Ultrasound guided rectus sheath block with 0.5% ropivacaine 20ml at each side (bilateral)
48124147|NCT05984212|DRUG|Ultrasound guided rectus sheath block with normal saline|Control Group: Ultrasound guided rectus sheath block with 0.9% normal saline 20ml at each side (bilateral)
48124148|NCT01657604|DRUG|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
48124149|NCT01657604|DRUG|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
48124150|NCT00063713|DRUG|VELCADE TM (bortezomib) for Injection|
48330490|NCT06468111|BEHAVIORAL|Animal Assisted Therapy|Blood and dental extraction will be performed according to the usual protocol of the health center in both groups; with the additional assistance of the therapy dog in experimental group.
48330491|NCT00120653|DRUG|Metoclopramide|
48330492|NCT00171028|DRUG|valsartan|
48330493|NCT05479266|OTHER|Muscle Energy Technique|METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
48330494|NCT05479266|OTHER|Myofascial release|Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
48651245|NCT05768672|BEHAVIORAL|Experimental Task|The main task is an olfactory version of a traditional Go/No-Go task (Albayay et al., 2019): it includes the delivery of either an odour or clean air prior to the presentation of a visual target Moreover, all participants will be assessed with the italian version of the Stroop color and word test (Caffarra et al., 2004) to evaluate inhibition, together with selective and sustained attention. This neuropsychological test consists of three tables, showing color words (W), colored circles (C), and color words printed in incongruent ink (i.e., red printed in blue ink, CW), respectively. The Stroop effect consists of a delayed response when words have to be named according to the color of the ink, ignoring the meaning of the printed word.
48651246|NCT06383806|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.
48330495|NCT04976296|DIAGNOSTIC_TEST|MRD detection|The Geneplus OncoMRD lung assay is used to detect the MRD status.
48330496|NCT05814913|BEHAVIORAL|CaCBT for psychosis|The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms
48651247|NCT03059888|DRUG|Abatacept Injection|Subcutaneous administration of abatacept
48124151|NCT02227134|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
48651248|NCT04665765|DRUG|Carboplatin|Given IV
48330497|NCT05814913|BEHAVIORAL|Culturally adapted Family Intervention (CulFI) for psychosis|CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.
48491708|NCT01939925|OTHER|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
48491709|NCT01939925|OTHER|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
48124152|NCT01449123|DRUG|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
48124153|NCT01794858|OTHER|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
48124154|NCT05674136|DEVICE|INVSENSOR00061|Noninvasive pulse oximeter sensor
48124155|NCT05369936|OTHER|Aromatherapy|Lavender will be inhaled through three phases
48124156|NCT05369936|OTHER|Placebo|Vapors of the distal water will be inhaled through three phases
48651249|NCT04665765|DRUG|Etoposide|Given IV
48651250|NCT04665765|DRUG|Ifosfamide|Given IV
48330498|NCT05731232|DIETARY_SUPPLEMENT|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
48330499|NCT01236859|DRUG|Gabapentin|Neurontin®, Pfizer
48330500|NCT01153477|BEHAVIORAL|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
48330501|NCT03945032|OTHER|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
48330502|NCT05475600|BEHAVIORAL|Classical APA group:|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
48330503|NCT05475600|BEHAVIORAL|APA with Exergaming device|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
48491710|NCT02148861|DRUG|Insulin icodec|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
47974107|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
47974108|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
47974109|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
47974110|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
47974111|NCT04606082|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
47974112|NCT04606082|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
47974113|NCT02622321|DRUG|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
47974114|NCT02622321|DRUG|rFVIIa|Participants will continue to receive rFVIIa.
47974115|NCT02622321|DRUG|aPCC|Participants will continue to receive aPCC.
47974116|NCT05679232|DEVICE|Hydrogel coating|hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
47974117|NCT05679232|PROCEDURE|Control|standard cementless hip revision arthroplasty
47974118|NCT01444118|BIOLOGICAL|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
48124157|NCT00525486|DRUG|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
48491711|NCT02148861|DRUG|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
48491712|NCT02148861|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
48491713|NCT02719847|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
48651251|NCT04665765|DRUG|Polatuzumab Vedotin|Given IV
48651252|NCT04665765|BIOLOGICAL|Rituximab|Given IV
48124158|NCT05137834|OTHER|Exercise|Post-surgical exercise
48651253|NCT05885594|DRUG|[18F]NOS|\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
48651254|NCT05708508|DRUG|ROVALCYTE|"Immuno-guided strategy arm"
48651255|NCT03411044|DEVICE|Fitmore Hip Stem|
48651256|NCT02319915|DRUG|Tranexamic Acid|
48491714|NCT04309552|DRUG|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
48651257|NCT02319915|DRUG|Adrenalin|
48651258|NCT06501352|DRUG|Dexmedetomidine|Additive to Local anesthetic mixture
48651259|NCT06501352|DRUG|Neostigmine|Additive to Local anesthetic mixture
47974119|NCT01754610|BEHAVIORAL|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
47974120|NCT02146898|OTHER|Position|
47974121|NCT05392010|OTHER|no intervention|no intervention
47974122|NCT04020965|BEHAVIORAL|Water Treatment|"Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers."
47974123|NCT04020965|BEHAVIORAL|Sanitation|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits."
48651260|NCT06501352|DRUG|Saline|Control
48651261|NCT04594993|DEVICE|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
47974124|NCT04020965|BEHAVIORAL|Handwashing|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
47974125|NCT04020965|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
48124159|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with placebo.|Volunteers will be provided with the placebo. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
48124160|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP1.|Volunteers will be provided with the collagen-derived product CP1. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
48124161|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP2.|Volunteers will be provided with the collagen-derived product CP2. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
48651262|NCT05855746|DRUG|Colchicine Pill|"Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped."
48330504|NCT05475600|BEHAVIORAL|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
48491715|NCT04309552|DRUG|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
48491716|NCT04430855|DRUG|Upadacitinib|Tablet; Oral
48491717|NCT04430855|DRUG|Placebo|Tablet; Oral
48491718|NCT00949611|BEHAVIORAL|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
47974126|NCT01224431|DRUG|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
48491719|NCT00949611|BEHAVIORAL|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
48491720|NCT06221553|BIOLOGICAL|B7H3 specific CAR T cell with IL-7Ra signaling domain|Autologous T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) with additional of IL-7 receptor alpha signalingdomain given via indwelling central nervous system (CNS) catheter
48330505|NCT04088331|DEVICE|AMS 800 Artificial Urinary Sphincter|The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
48491721|NCT03672305|BIOLOGICAL|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
47974127|NCT04258722|OTHER|Resuscitation Personnel|Type of resuscitation team
47974128|NCT00911053|DRUG|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
47974129|NCT00911053|BEHAVIORAL|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
47974130|NCT00911053|BEHAVIORAL|Light|Subjects will be exposed to light.
47974131|NCT03817307|DIAGNOSTIC_TEST|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
47974132|NCT04567225|DRUG|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
47974133|NCT04567225|DRUG|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
47974134|NCT04567225|OTHER|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
47974135|NCT04567225|OTHER|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
47974136|NCT00723983|DRUG|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
47974137|NCT00723983|DRUG|NP101 Study Patch|NP101 study patch 4 hour application
48491722|NCT00001045|DRUG|Nevirapine|
47974138|NCT00109798|DRUG|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
47974139|NCT00109798|DRUG|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
47974140|NCT00380497|DRUG|PEG-Lyte®|
47974141|NCT00380497|DRUG|Pico-Salax®|
47974142|NCT02888444|DRUG|Varenicline|Two 0.5mg tablets taken twice daily
47974143|NCT02888444|BEHAVIORAL|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
47974144|NCT02888444|DRUG|Placebo|Two 0.5mg tablets taken twice daily
47974145|NCT00808977|DRUG|Dersalazine sodium|Dersalazine sodium 2400 mg daily
47974146|NCT00808977|DRUG|Mesalazine|Mesalazine 2400 mg daily
47974147|NCT00808977|DRUG|Placebo|Placebo matching active and experimental treatments
47974148|NCT01874613|DEVICE|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
47974149|NCT01874613|DEVICE|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
47974150|NCT02529345|DEVICE|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
47974151|NCT00119054|BEHAVIORAL|In Home Health Messaging Device|
48330506|NCT01245764|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
48330507|NCT01245764|BIOLOGICAL|Placebo|
48330508|NCT01913197|OTHER|An MRI-based technique to identify prostate cancer|
48491723|NCT00001045|DRUG|Zidovudine|
47974152|NCT02324062|OTHER|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
47974153|NCT02324062|OTHER|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
47974154|NCT00526513|DRUG|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
47974155|NCT06014034|OTHER|Programmed Weaning From Noninvasive Mechanical Ventilation|Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
47974156|NCT01073553|DRUG|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
47974157|NCT01073553|DRUG|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
47974158|NCT05181683|DRUG|Casirivimab+Imdevimab|Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
47974159|NCT06366620|BEHAVIORAL|FAST-B PEERS|FAST-B PEERS consists of trained Peer Support providing weekly check-in calls with families going through FAST-B behavioral parent training program. Peer Support are parents who have previously participated in a behavioral parent training program who have undergone 6-8 hours of additional dedicated training.
47974160|NCT06366620|BEHAVIORAL|FAST-B (First Approach Skills Training - Behavior)|5-week parent behavioral management training program
47974161|NCT03186560|DEVICE|gekoTM|The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
47974162|NCT04138654|DIETARY_SUPPLEMENT|Processed meat product|300 grams per day during 2 weeks
47974163|NCT04138654|DIETARY_SUPPLEMENT|White meat wash-out|300 grams per day during 2 weeks
47974164|NCT04138654|DIETARY_SUPPLEMENT|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
47974165|NCT04138654|DIETARY_SUPPLEMENT|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
48124162|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP3.|Volunteers will be provided with the collagen-derived product CP3. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
48124163|NCT05722158|DIETARY_SUPPLEMENT|Dietary supplementation with the collagen-based product CP4.|Volunteers will be provided with the collagen-derived product CP4. For each volunteer, a blood sample from digital puncture will be obtained, and collagen-derived amino acids, di-peptides and tri-peptides will be quantified by LC-MS.
48491724|NCT00001045|DRUG|Didanosine|
47974166|NCT02670837|DEVICE|Cellutome Epidermal Harvesting System|
48491725|NCT03928314|DRUG|ORIC-101|ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
47974167|NCT00803725|DRUG|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
47974168|NCT00803725|DRUG|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
47974169|NCT04750148|DIAGNOSTIC_TEST|6-minute walking test|The subject walks as far as possible for 6 minutes along a 30m long corridor.
47974170|NCT04750148|DIAGNOSTIC_TEST|2-minute walking test|The subject walks as far as possible for 2 minutes along a 30m long corridor.
47974171|NCT04750148|DIAGNOSTIC_TEST|10-meter walk test|The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).
47974172|NCT04750148|DIAGNOSTIC_TEST|One leg stance test|The time held in unipodal equilibrium is measured by the examiner.
47974173|NCT00630981|BEHAVIORAL|Psychotherapy|Specific psychotherapy for dissociative disorders
47974174|NCT00630981|DRUG|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
47974175|NCT04711447|DEVICE|kinesio-tape|Twenty-one individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).
47974176|NCT01780636|DRUG|botulinum toxin|
47974177|NCT01682057|DEVICE|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
48491726|NCT03928314|DRUG|Nab-paclitaxel|75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
48491727|NCT01955213|DRUG|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
48491728|NCT02287493|OTHER|Pharmacokinetic Analysis|
48491729|NCT03593811|DIAGNOSTIC_TEST|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
47974178|NCT01682057|DEVICE|ROX Anastomotic Coupler System (ACS)|
47974179|NCT01393704|DRUG|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
47974180|NCT05268900|DEVICE|Volume control ventilation group|Volume control ventilation mode
47974181|NCT05268900|DEVICE|Pressure control ventilation-volume guaranteed group|Pressure control ventilation-volume guaranteed mode
47974182|NCT03743389|DEVICE|12G pigtail catheter|12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
47974183|NCT03743389|DEVICE|16F chest tube|16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
47974184|NCT04352647|BEHAVIORAL|female athletes|The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
47974185|NCT04334031|GENETIC|Biobanking with genetic analysis|Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
47974186|NCT04334031|OTHER|SF-12 questionnaire|Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
47974187|NCT02197845|BEHAVIORAL|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
47974188|NCT02197845|BEHAVIORAL|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
47974189|NCT01991210|DRUG|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
47974190|NCT01991210|DRUG|PLD|PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
48491730|NCT03593811|DIAGNOSTIC_TEST|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
47974191|NCT05657834|DRUG|[14C]-TVB-2640|50 mg of TVB-2640 oral administration
47974192|NCT04937491|DEVICE|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
47974193|NCT06141395|DIAGNOSTIC_TEST|NGS-based assay for bacterial identification|A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
47974194|NCT05290415|DIAGNOSTIC_TEST|DNA methylation testing|DNA CDO1 and CELF4 methylation testing
47974195|NCT03675698|OTHER|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
48124164|NCT00418613|DRUG|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
48124165|NCT00418613|DRUG|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
48491731|NCT03593811|DIAGNOSTIC_TEST|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
48491732|NCT03593811|DIAGNOSTIC_TEST|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
48491733|NCT03593811|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
48491734|NCT03593811|DRUG|Ondansetron|Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
48330509|NCT01788982|DRUG|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
48124166|NCT02988089|DRUG|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
48330510|NCT01788982|DRUG|Placebo|
48330511|NCT06187311|DRUG|Rivaroxaban 20 MG|Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
48330512|NCT06187311|DRUG|Rivaroxaban 15 MG|Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
48330513|NCT01040754|OTHER|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
48330514|NCT06252766|BEHAVIORAL|Experiment (Clown)|Children included in the intervention group will be accompanied by a clown at the door from the moment they enter the intervention room and The child will be made to sit on the blood collection chair by playing games with them. Meanwhile, the nurse will take blood from the child. lasts for about 2-3 minutes. During this process, the clown is constantly playing games and foam will continue to distract you by blowing up balloons. The child's pain and anxiety score during the procedure the researcher will be evaluated by both the parent and the child. After the procedure is finished, the children will be will be taken out of the room and taken to the waiting area in the next room. Afterwards, the children will be asked how much pain and anxiety they felt during the blood collection procedure. After being allowed to rest for 1-2 minutes a questionnaire form will be applied to the children.
48491735|NCT03593811|DRUG|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
48491736|NCT04763018|DEVICE|iTEAR100|Neurostimulation external nasal nerve to stimulate tear production
48651263|NCT05855746|DRUG|Placebo|"Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision."
48330515|NCT02267226|DRUG|Octafibrin|
48330516|NCT01729572|OTHER|Tele-medicine monitoring of medication adherence|
48330517|NCT03379896|OTHER|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
48330518|NCT00196196|DEVICE|Codman VPV System|Valve Positioning Verification (VPV) System
48330519|NCT04449276|BIOLOGICAL|CVnCoV Vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
48651264|NCT01974947|OTHER|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
48651265|NCT03906708|OTHER|Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)|Infant lung function testing
48651266|NCT05178654|DRUG|[14C]PF-07321332|Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.
48651267|NCT05735119|DEVICE|Tapestry Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
48330520|NCT04449276|DRUG|Placebo|Participants will receive an intramuscular injection by needle in the deltoid area.
48330521|NCT01567891|BIOLOGICAL|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
48330522|NCT00345501|DRUG|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
48330523|NCT00345501|DRUG|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
48124167|NCT02988089|DRUG|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
48124168|NCT02988089|DRUG|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
48330524|NCT03234972|DRUG|Daratumumab|Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
48124169|NCT02988089|DRUG|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
48330525|NCT03234972|DRUG|Velcade|Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
48651268|NCT04222504|BEHAVIORAL|Provision of sexual health preventative services in the salon setting|"Participants at intervention salons will be offered a choice of receiving daily PrEP and/or contraceptives (oral and injectables). Participants that elect to receive at least PrEP or contraceptives will also be offered STI testing.~Follow-up visits will be planned for 3, 6, 9, and 12-months. Attendance at follow-up visits for monitoring and medication refill will be encouraged using text message reminders, WhatsApp support groups, and lottery-based incentives for free salon services."
47974196|NCT03725098|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
47974197|NCT03725098|DEVICE|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
47974198|NCT01828957|BIOLOGICAL|Pneumostem®|
47974199|NCT01828957|OTHER|Normal Saline|
47974200|NCT00775424|BIOLOGICAL|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
47974201|NCT00775424|BIOLOGICAL|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
47974202|NCT00775424|BIOLOGICAL|PLACEBO|PLACEBO
47974203|NCT00775424|BIOLOGICAL|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
47974204|NCT05776420|BEHAVIORAL|Food voucher|A voucher of $65 (or $85 for people in larger households) that can be redeemed for food at grocery stores.
47974205|NCT01949506|RADIATION|SBRT|Stereotactic Body Radiation Therapy
47974206|NCT04677374|OTHER|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
47974207|NCT04677374|BEHAVIORAL|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
47974208|NCT04677374|BEHAVIORAL|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
47974209|NCT04677374|BEHAVIORAL|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
47974210|NCT00812864|DRUG|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
48124170|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
48124171|NCT02988089|DRUG|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
48124172|NCT05000710|DRUG|Durvalumab|Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks
48124173|NCT05000710|DRUG|Tremelimumab|Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1
48124174|NCT05000710|RADIATION|Low dose irradiation|21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day
48124175|NCT00767559|DRUG|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery\*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
48330526|NCT03234972|DRUG|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
48330527|NCT05831527|DRUG|ARMRA™ Bovine Colostrum|"Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks."
47974211|NCT02644733|PROCEDURE|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
47974212|NCT02644733|PROCEDURE|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
47974213|NCT05409456|OTHER|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
47974214|NCT05409456|OTHER|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
48124176|NCT00767559|DRUG|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
48124177|NCT00767559|DRUG|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
48330528|NCT03119818|DEVICE|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
48124178|NCT02489695|DRUG|Axitinib|axitinib 10mg twice a day
48124179|NCT05756335|BEHAVIORAL|(Un)predictable and (un)attended stimuli|Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4) Auditory Predictable. In visual and auditory conditions subjects attend to visual or auditory stimuli and ignore the other domain, pressing a button when they detect an infrequently occurring stimulus inversion in the target domain. In unpredictable and predictable conditions, the attended domain either presents random (unpredictable) stimuli, or the same face or word stimuli repeated (predictable).
48124180|NCT01035034|PROCEDURE|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
48124181|NCT01035034|PROCEDURE|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
48330529|NCT03119818|OTHER|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
48330530|NCT01055418|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
48330531|NCT05647018|PROCEDURE|Primary Percutaneous coronary angiography|Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
48330532|NCT00888069|DRUG|CTAP101 Capsules|Single dose oral administration
48330533|NCT00888069|DRUG|CTAP101 Injection|single IV injection
48330534|NCT06230835|BEHAVIORAL|Intervention Group|Community Health Workers (CHWs) will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. CHWs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'. No any drugs will be used in the intervention group.
48330535|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
48330536|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
48330537|NCT01154595|DIETARY_SUPPLEMENT|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
48330538|NCT01154595|BEHAVIORAL|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
47974215|NCT02482506|BEHAVIORAL|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
47974216|NCT02482506|BEHAVIORAL|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
47974217|NCT02083952|OTHER|Swaddle Blanket|Two arms involve varying time spent in blanket
47974218|NCT00035334|DRUG|NC-503 (Anti-amyloidotic (AA) Agent)|
47974219|NCT01001377|DRUG|Cetuximab|Administered by intravenous infusion
47974220|NCT01001377|DRUG|Panitumumab|Administered by intravenous infusion
47974221|NCT04073498|DRUG|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
48491737|NCT00999648|OTHER|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
48651269|NCT06673888|OTHER|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) is utilized for a variety of purposes, as luting agents, liners/bases, and restorative materials. The RMGI is more aesthetically pleasing than the conventional glass ionomer while maintaining the clinical benefits of the former, such as the release of fluoride, recharging capabilities, prevention of decalcification of hard tooth tissue, inhibition of bacterial acid metabolism, and ease of clinical operation.
48124182|NCT02773524|DRUG|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
47974222|NCT04073498|DRUG|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
48651270|NCT06673888|OTHER|alkasite based restorative material|Cention forte is bioactive restorative material which has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release.
48124183|NCT02773524|OTHER|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
48124184|NCT06465446|BIOLOGICAL|Tislelizumab|IV infusion
48124185|NCT06465446|BIOLOGICAL|IMM01|2.0mg/kg, IV infusion
48124186|NCT06465446|DRUG|Bendamustine|IV infusion
48124187|NCT06465446|DRUG|Gemcitabine|IV infusion
48651271|NCT04367389|BEHAVIORAL|Physical activity promotion|Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
48651272|NCT04367389|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
48651273|NCT06001008|OTHER|PQA|PQA is a questionnaire consisting of 16 questions developed to measure the quality of anesthesia service received by patients based on their experiences. Patients will be asked to answer questions by the researcher 24 hours after surgery.
48330539|NCT04212052|RADIATION|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).
48124188|NCT04135885|DRUG|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
48124189|NCT04135885|DRUG|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
48330540|NCT04212052|DRUG|concurrent chemotherapy|Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.
48330541|NCT04212052|DRUG|consolidation immunotherapy|Patients without disease progression or persistent grade2+ toxicities after thoracic radiotherapy were recommended to receive consolidation immunotherapy
48491738|NCT00999648|OTHER|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
48491739|NCT02944942|PROCEDURE|General anesthesia|Patients undergoing general anesthesia
48651274|NCT06031402|PROCEDURE|Endoscopy|Endoscopy
48651275|NCT03412552|DRUG|MgSO4|Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
48651276|NCT06357715|OTHER|"slumpposition"|"neurodynamic sliding mobilisation in the slump position"
48651277|NCT06357715|OTHER|"no slump position"|placebo
48651278|NCT03060265|DRUG|Paracetamol|Administrating Paracetamol IV pre-cesarean section
48651279|NCT03060265|DRUG|PLACEBO|Administrating SALINE IV pre-cesarean section
47974223|NCT05130398|BIOLOGICAL|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
47974224|NCT05130398|DIETARY_SUPPLEMENT|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
48124190|NCT06336473|PROCEDURE|skin biopsy|Samples will be taken under local anaesthetic (after injection of 1 cc of Xylocaine without adrenaline) using a 4 mm diameter dermal biopsy punch. The biopsy will be performed on the buttocks. Fragments are stored in 15-mL polypropylene tubes in PBS at 4°C.
48124191|NCT06057116|OTHER|massage|Massage and acupressure were applied when cervical dilatation was 3-4, 5-7 and 8-10 cm in latent active and transitional phases.
48124192|NCT05298813|BIOLOGICAL|IBIO123|IBIO123 1 mg, 5 mg and 10 mg
48124193|NCT05298813|OTHER|Placebo|Matching Placebo
48124194|NCT01037985|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
48124195|NCT01037985|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
48124196|NCT05161585|DIAGNOSTIC_TEST|ctDNA dynamic monitoring|ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total.
48124197|NCT01064336|DRUG|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
48124198|NCT06324903|OTHER|echocardiography and percutaneous cardiac catheterization|pre- cardiac catheterization, intraprocedural and post-catheterization echocardiography.
48124199|NCT02118064|BIOLOGICAL|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
48124200|NCT05127681|RADIATION|HR-pQCT|Patients will have a unique HR-pQCT scanner imaging to study their bone microarchitecture
48124201|NCT05127681|BIOLOGICAL|Blood sample|Patients will have a unique blood sampling of 10 mL for the measurements of sera PINP, CTX-I, periostin levels
48124202|NCT05127681|RADIATION|Dual energy X-ray absorptiometry|A dual energy X-ray absorptiometry scan of lumbar spine, hip, distal radius and whole body, body composition, lateral spine will be performed.
48124203|NCT05127681|OTHER|medical data collection|Data of healthy men is already available
48124204|NCT02097069|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 mcg/day
48124205|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol|myo-inositol 2000 mg twice a day
48124206|NCT02097069|DIETARY_SUPPLEMENT|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
48124207|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
48124208|NCT00027729|BIOLOGICAL|etaracizumab|
48330542|NCT01338935|DRUG|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
48491740|NCT01344174|DRUG|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
48491741|NCT06067321|OTHER|abdominal ultrasound, insertion of naso-gastric tube|measurement antral cross sectional area, volume and pH of residual stomach contents
48651280|NCT06083454|DRUG|Durvalumab|Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate
48124209|NCT04240613|DEVICE|TVT-O|TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.
48124210|NCT01651767|DRUG|Placebo|Form=suspension, route=oral.
48124211|NCT01651767|DRUG|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
48124212|NCT01622400|OTHER|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
48491742|NCT00759902|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
48491743|NCT00759902|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
48124213|NCT01338675|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
48124214|NCT05280275|DRUG|Belantamab Mafodotin-Blmf|"Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes."
48124215|NCT05280275|DRUG|Daratumumab|Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
48124216|NCT05280275|DRUG|Lenalidomide|Lenalidomide will be administered per os.
48124217|NCT05280275|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
48124218|NCT05831969|DRUG|Lenalidomide|Lenalidomide: 10mg/d, 1-21d/28d orally; until disease progression or intolerable adverse reactions.
48124219|NCT00204646|DRUG|Adriamycin|
48124220|NCT00204646|DRUG|Ifosfamide|
48124221|NCT00204646|DRUG|Etoposide|
48124222|NCT00204646|DRUG|Carboplatin|
48124223|NCT05519202|DRUG|S-1,Oxaliplatin, Penpulimab|S-1 ( 40 mg/m2 bid po d1-14) and Penpulimab (200mg ivgtt d1) and Oxaliplatin ( 130 mg/m2 (d1)
48124224|NCT01331044|DIETARY_SUPPLEMENT|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered \~ 125 kcal/kg in 1st 24 hours, \~ 150 kcal/kg in 2nd 24 hours, then\~200k cal/kg by the third day).
48651281|NCT06083454|DRUG|Pharmacological ascorbate|Given intravenously in combination with Durvalumab
48330543|NCT01338935|DRUG|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
48124225|NCT01331044|DIETARY_SUPPLEMENT|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 2 feed per day \& khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed \& halwa 10gm/kg; 3 feed per day \& khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) \& halwa 20gm/kg; 3 feed per day \& khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
48124226|NCT01522924|OTHER|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
48124227|NCT00105963|BEHAVIORAL|Education about infant crying|
48124228|NCT05533658|DIETARY_SUPPLEMENT|VisionPure Dietary Supplement|Subjects will consume two softgels capsules of the Treatment (VisionPure) once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
48124229|NCT05533658|DIETARY_SUPPLEMENT|Placebo|Subjects will orally consume two softgel capsules of Placebo once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
48124230|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) at baseline|Detailed imaging of coronary arteries
48124231|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) after 1 year|Detailed imaging of coronary arteries
48124232|NCT05318066|DRUG|Ringer Lactate and Norepinephrine infusion|"Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation."
48124233|NCT03825575|DEVICE|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
48124234|NCT03368768|OTHER|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
48124235|NCT06435819|OTHER|Embodied Conversational Agent (ECA)|A computer-animated character that can explain a medical illustration to laypersons.
48124236|NCT06371170|DRUG|Rivaroxaban|Oral anticoagulation
48330544|NCT01338935|DRUG|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
48330545|NCT01472991|DRUG|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
48330546|NCT01472991|DRUG|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
48330547|NCT01472991|DRUG|Placebo|Placebo capsules will be taken once daily for 4 weeks
48491744|NCT04289506|DIAGNOSTIC_TEST|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
48651282|NCT06083454|PROCEDURE|Surgery (SOC)|Surgery SOC
48651283|NCT06186401|BIOLOGICAL|E-SYNC T Cells|Given IV
48651284|NCT06186401|DRUG|Cyclophosphamide (non-investigational)|Given IV
48330548|NCT02292498|DEVICE|FLIR ONE|
48330549|NCT02669199|BIOLOGICAL|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
48651285|NCT06186401|DRUG|Fludarabine (non-investigational)|Given IV
48651286|NCT06186401|PROCEDURE|Leukapheresis|Undergo leukapheresis
48651287|NCT06186401|PROCEDURE|Surgical resection|Undergo surgical resection of tumor tissue
48651288|NCT06642220|DEVICE|Y-90 Selective Internal Radiation Therapy (SIRT)|Y-90 radioembolization will be performed using glass spheres to treat non-metastatic RCC within the kidney.
48651289|NCT00234793|BEHAVIORAL|Problem-Solving Skills Training|
48651290|NCT06106568|PROCEDURE|EOB-MRI|Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan
48651291|NCT06106568|PROCEDURE|Surgery|Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan
48651292|NCT06106568|PROCEDURE|Open-close Laparotomy|Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan
48651293|NCT02881216|DEVICE|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
48124237|NCT01884805|DEVICE|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
48651294|NCT02881216|DEVICE|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
48124238|NCT04385680|DRUG|Chlorhexidine Gluconate vaginal solution 0.05%|preoperative vaginal preparation
48124239|NCT00737035|BEHAVIORAL|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
48124240|NCT00737035|BEHAVIORAL|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
48124241|NCT05435313|PROCEDURE|HAIC|After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
48124242|NCT05435313|DRUG|Fruquintinib|3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC
48124243|NCT05435313|DRUG|Tislelizumab|200mg, ivgtt, d1, 21 days for a cycle
48124244|NCT05435313|DRUG|Raltitrexed|2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles
48124245|NCT05435313|DRUG|Oxaliplatin|85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles
48124246|NCT05435313|DRUG|Irinotecan|120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
48124247|NCT06135246|DEVICE|High Intensity Laser Therapy|Participants will receive high-intensity laser therapy using an 810nm continuous wave diode laser (Multiwave locked System (MlS) provided by aSa). The laser applicator has a flat top hat beam profile with a spot size of 1cm2. The laser will be delivered in direct contact mode perpendicularly to the ulcer surface. Each 1cm2 area of the venous ulcer and a 1cm margin of periwound skin will be treated sequentially using a overlapping grid pattern to cover the entire ulcer area, with a 1 second exposure time per point. This results in a laser energy density of 4J/cm2 delivered to each point.
48330550|NCT04526067|BEHAVIORAL|CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.
48330551|NCT04526067|BEHAVIORAL|R-CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
47974225|NCT05130398|DIAGNOSTIC_TEST|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
48330552|NCT05976477|OTHER|educational intervention|"1. four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~2. Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~3. Four recipes for tasty easy-to-prepare meals, avoiding added salt."
48330553|NCT00388258|DRUG|Alvimopan|
48651295|NCT06355531|DRUG|FNP-223|Oral tablets
48651296|NCT06355531|DRUG|Placebo|Oral tablets
48651297|NCT01291160|DEVICE|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
47974226|NCT05130398|COMBINATION_PRODUCT|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
48124248|NCT06135246|OTHER|Standard Care|Participants will receive standard compression bandaging and wound care as per institutional protocols, without any laser therapy. The compression bandaging protocol is based on recommendations from the American Venous Forum and American College of Phlebology guidelines (O'Donnell et al., 2014). Multi-layer compression bandages will be applied weekly by trained nurses, with layers including orthopedic padding, elastic bandages, and cohesive bandages. Bandages will be applied with high pressure at the ankle gradually decreasing up the leg, with an ankle pressure of approximately 40 mmHg (Mosti et al., 2015).
48124249|NCT01953692|BIOLOGICAL|Pembrolizumab|IV infusion
48124250|NCT01953692|DRUG|Lenalidomide 20 mg|oral capsule
47974227|NCT05130398|BIOLOGICAL|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
47974228|NCT05130398|OTHER|Placebo|About 30 children do not receive diet, nor active pathogen detection
48124251|NCT01953692|DRUG|Lenalidomide 25 mg|oral capsule
48124252|NCT04377308|DRUG|Fluoxetine|Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
48124253|NCT03767452|DRUG|Xiaflex® 0.58 mg|0.25 mL injections.
48124254|NCT02711436|DEVICE|Computed Tomography Scan|
48330554|NCT00475800|DRUG|Lumiracoxib|
48330555|NCT01599702|DRUG|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
48330556|NCT01320956|BEHAVIORAL|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
48330557|NCT01320956|OTHER|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
48330558|NCT03779061|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
48330559|NCT03779061|DRUG|Propofol|Initial dose plus supplemental doses as necessary
48124255|NCT02711436|DEVICE|Fast Magnetic Resonance Imaging|
48491745|NCT01330420|BEHAVIORAL|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~* Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~* Examination and reversal of negative thought patterns.~* Physical movement, including stretching and yoga.~* Healthy eating and other positive lifestyle behaviors.~* Goal setting."
48491746|NCT01970865|DRUG|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
48491747|NCT01970865|DRUG|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
48491748|NCT00386126|DRUG|Iron Sucrose IV 200mg, once a week, for 5 weeks|
48491749|NCT00386126|DRUG|Ferrous sulfate 200mg PO TID, for 8 weeks|
48491750|NCT00283491|BEHAVIORAL|Active Lactobacillus plantarum 299v|10\^11 cfu/meal in 2 meals on 2 consecutive days
48124256|NCT03450200|OTHER|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
48124257|NCT03450200|OTHER|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
48124258|NCT01074567|DRUG|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
48124259|NCT05527912|DRUG|Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy|"All subjects received two courses of the following treatment:~Rituximab ，375mg/m²， D1； Chidamiade ，20mg ，biw， d1-14； Zanubrutinib ，160mg， bid， d1-21；~three weeks for a period of treatment, all subjects complete tumor assessment after two courses of treatment, patients which achieve complete remission continue for up to 8 sessions, patients achieve partial response and stable disease combined use of the following CHOP threapy to 6 courses, Patients with progressive disease dropped out of this research.~CHOP Therapy:~Cyclophosphamide， 750mg/m² ，D1； Vincristine， 1.4mg/m² ，D1 (maximum：2mg)； Doxorubicin or pirarubicin， 50mg/m²， D1； Prednisone ，30mg ，tid， D1-5."
48124260|NCT02880137|DRUG|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
48330562|NCT03879876|DRUG|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
48330563|NCT04923698|OTHER|yoga training|All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
48491751|NCT00283491|DIETARY_SUPPLEMENT|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
48491752|NCT06026111|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.
48330564|NCT04975672|OTHER|Myofuncional Therapy|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances The participant underwent a myofunctional therapy session every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system. The myofunctional therapy performed will be by an expert speech therapist
48491753|NCT06026111|BEHAVIORAL|Moderate-Intensity Continuous Training (MICT)|Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.
48491754|NCT04049617|DRUG|Evixapodlin|Tablets administered orally.
48491755|NCT06428435|DIAGNOSTIC_TEST|Vision Test|Remote vision testing via digital screen
48491756|NCT04419623|DRUG|TL-895|TL-895, administered by mouth
48491757|NCT02287129|DRUG|Oxaliplatin|130 mg/m2
48491758|NCT02287129|DRUG|Epirubicin|50 mg/m2
48491759|NCT02287129|DRUG|Capecitabine|625 mg/m2
48491760|NCT02287129|DRUG|5-FU|200 mg/m2
48330565|NCT00672295|DRUG|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m\^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
48330566|NCT02348424|DRUG|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
48651298|NCT01291160|OTHER|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
48651299|NCT02167347|BEHAVIORAL|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
48330567|NCT05884281|DRUG|Roflumilast|0.5 mg once daily for treatment period
48330568|NCT05884281|DRUG|Placebo|Placebo for treatment period
48491761|NCT02287129|DRUG|Carboplatin|2 mg/ml min
48491762|NCT02287129|DRUG|Paclitaxel|50 mg/m2
48651300|NCT02578537|DRUG|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
48651301|NCT02578537|DRUG|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
48651302|NCT00099814|PROCEDURE|Two different loop designs which deliver distinctive forces|
48651303|NCT06300437|PROCEDURE|jaw thrust|children who will receive jaw thrusting during fiberoptic intubation
48651304|NCT06300437|PROCEDURE|control (sub laxed jaw)|children who will not receive jaw thrusting (just sub laxed open mouth)
48651305|NCT04348630|OTHER|Simulated heatwave exposure|Older adults are exposed to a 8-hour simulated exposure
48651306|NCT04072939|OTHER|Patients having had a lens surgery|Dilated fundus exam
48651307|NCT03358173|PROCEDURE|Conservative Treatment|Conservative Treatment
48651308|NCT03358173|PROCEDURE|Operative Plate Fixation|Operative Plate Fixation
48651309|NCT02236013|DRUG|Gilteritinib|Oral
48651310|NCT02236013|DRUG|Idarubicin|lyophilized powder administered intravenously
48651311|NCT02236013|DRUG|Cytarabine|solution administered intravenously
48651312|NCT02236013|DRUG|Daunorubicin|solution administered intravenously
48651313|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
48651314|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
48651315|NCT01065454|DRUG|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
48651316|NCT01065454|DRUG|Placebo|Placebo three times a day
48651317|NCT05544409|DEVICE|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
48651318|NCT03097978|DEVICE|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
48651319|NCT03097978|DEVICE|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
48651320|NCT03097978|OTHER|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
48651321|NCT03097978|OTHER|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
48651322|NCT06638736|OTHER|Wound Closure with sutures vs staples|Closure of the wound with either sutures or staples depending upon the study arm
48651323|NCT01604798|OTHER|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
48651324|NCT01435642|OTHER|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
48651325|NCT06025708|DEVICE|Diagnostic Test: Quantra QStat Cartridge|Whole blood coagulation testing system
48651326|NCT05841771|DRUG|Venetoclax|"Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation."
48330569|NCT02278991|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
48330570|NCT01595438|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
48491763|NCT02287129|RADIATION|radiation|total dosage 41,4 Gy
48491764|NCT02287129|PROCEDURE|Biopsy|translational analysis
48491765|NCT02667171|BEHAVIORAL|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
48491766|NCT02667171|BEHAVIORAL|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group."
48491767|NCT04528030|DEVICE|WAVE device|WAVE applies a transcutaneous vibration to the soles of the foot and palms of the hand to elicit nerve signalling from pressure and other limb proprioceptor sensors to pontine, cerebellar, and medullary brain areas that coordinate limb movement and reflexively activate brain areas controlling breathing. The WAVE device is a battery-operated product to reduce the episodes of Apnoea of Prematurity by vibratory stimulation to the hand and foot.
48491768|NCT02809170|DIETARY_SUPPLEMENT|Arginine|Arginine is an amino acids
48491769|NCT02809170|DIETARY_SUPPLEMENT|Citrulline|Citrulline is an amino acid
48491770|NCT03072199|DRUG|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
48491771|NCT00207779|DEVICE|heparin impregnated central venous catheters|
48491772|NCT01059266|DRUG|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
48491773|NCT00535587|BEHAVIORAL|Exercise|
48491774|NCT00535587|DRUG|pyridostigmine|
48491775|NCT00535587|DRUG|Placibo|
48491776|NCT00535587|BEHAVIORAL|Attention Control|
48491777|NCT02420418|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
48491778|NCT02420418|OTHER|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
48491779|NCT02941276|DEVICE|Active Electrostimulator device|Patients who will receive a fully functioning device
48491780|NCT02941276|DEVICE|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
48491781|NCT05745792|OTHER|Description of clinical, immunological and tumor features of patients harboring Hu Abs|This observationnal study involves clinical data and bio. samples (DNA and tumors block). Demographic and clinical data already in French Reference Center on PNS database will be reviewed. Additional data will be obtained from the referral physicians. The results of diagnostic tests performed to detect Hu-Abs in the patients are already in this database and will be retrospectively analyzed. In addition, the 4 available techniques (immunofluorescence, commercial immunodot, Western blot, and CBA) will be performed from Jan. 2022 to Dec. 2022.Tumor samples from 2 cohorts will be analyzed: (i) tumors of patients with Hu-Abs and PNS, and (ii) tumors of patients without PNS (mostly SCLC). After selecting patients, the study will involve 3 steps: (i) pathological confirmation; (ii) DNA sequencing and CNV analysis (panel of genes involved in anti-Hu autoimmunity; mainly ELAVL1 to 4, encoding for HuA to HuD, the 4 main proteins of the Hu family); and (iii) whole-genome RNA sequencing.
48491782|NCT03762551|OTHER|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
48491783|NCT01006941|BIOLOGICAL|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
48491784|NCT00683267|DRUG|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
48491785|NCT00683267|DRUG|Placebo|One dose administered by direct instillation into the surgical site
48651327|NCT05841771|DRUG|Azacitidine or decitabine|azacytidine 32mg/m2 or decitabine 5mg/m2
48651328|NCT00353119|DRUG|Placebo comparator|Patients received placebo subcutaneously twice weekly
48651329|NCT00353119|DRUG|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
48651330|NCT05274919|DEVICE|Philips Achieva 7T MRI|Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
48651331|NCT05274919|DEVICE|X-ray (optional)|Optional X-ray scan to assess the safety for undergoing an MR examination.
48651332|NCT05274919|COMBINATION_PRODUCT|Additional contrast injection|Contrast agent administration for the additional 7T scan (optional).
48651333|NCT05274919|OTHER|Question list|Questionnaire for contra-indications for an MR examination.
48651334|NCT00894010|DRUG|carbamazepine 400mg|
48651335|NCT00894010|DRUG|levetiracetam 1000mg|
48330571|NCT01595438|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
48330572|NCT01595438|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
48330573|NCT01595438|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
48330574|NCT01398527|OTHER|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
48330575|NCT04142385|OTHER|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
48330576|NCT04142385|OTHER|Laboratory Biomarker Analysis|Correlative studies
48330577|NCT04142385|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
48330578|NCT04142385|PROCEDURE|Physical Examination|Undergo targeted physical exam
48330579|NCT04142385|PROCEDURE|Proctoscopy with Biopsy|Undergo HRA
48651336|NCT03982810|DRUG|Antibiotics|Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
48651337|NCT01205412|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
48330580|NCT04142385|OTHER|Questionnaire Administration|Ancillary studies
48330581|NCT01966263|PROCEDURE|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
48330582|NCT01966263|PROCEDURE|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
48330583|NCT01966263|PROCEDURE|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
48491786|NCT02765217|DRUG|Lactobacillus reuteri DSM 17938|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
48330584|NCT01966263|PROCEDURE|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
48491787|NCT02765217|DRUG|Placebo|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
48330585|NCT01425229|DRUG|Bosentan|"* Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
48330586|NCT05725330|OTHER|Gamification and education with mobile game application|This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
48491788|NCT02765217|DRUG|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
48651338|NCT06675630|BEHAVIORAL|Education|Consumers will receive monthly targeted educational materials on fibre
48651339|NCT06675630|BEHAVIORAL|Control|Consumers will receive educational materials on healthy eating at two timepoints
48330587|NCT02732353|DIETARY_SUPPLEMENT|Minced beef|Cow meat protein supplement
47974229|NCT02393508|OTHER|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
47974230|NCT02393508|OTHER|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
47974231|NCT04853511|DEVICE|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
47974232|NCT00102726|DRUG|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
47974233|NCT00102726|OTHER|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
47974234|NCT05160220|DRUG|Psilocybin|0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
47974235|NCT05160220|DRUG|Placebo|0.5 g dried edible non-psychoactive mushroom material.
47974236|NCT05213650|OTHER|non-abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
47974237|NCT05213650|OTHER|abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
48330588|NCT02732353|DIETARY_SUPPLEMENT|Hydrolyzed beef|Cow meat protein supplement
48330589|NCT00352950|DRUG|AMG 954/Panitumumab|
48330590|NCT00563368|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
48330591|NCT00563368|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
48330592|NCT00563368|DRUG|topiramate|topiramate 46 mg, po once daily
48330593|NCT00563368|DRUG|topiramate|topiramate 92 mg, po once daily
48330594|NCT00563368|DRUG|phentermine|phentermine 7.5 mg, po once daily
48330595|NCT00563368|DRUG|phentermine|phentermine 15 mg, po once daily
48330596|NCT00563368|DRUG|VI-0521|placebo, po once daily
48330597|NCT05520918|DIAGNOSTIC_TEST|the LIT test|The retained functional capacity of leukocytes (primarily neutrophils) to produce ROS in response to PMA in whole blood samples could provide a rapid 10-minute detection method for objectively determining onset or occurrence of severe COVID-19 and monitoring progression and treatment of COVID-19.
48651340|NCT03629678|OTHER|mobile health application|The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
48651341|NCT05434702|BEHAVIORAL|Digital Diet Diary|Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
48651342|NCT05434702|BEHAVIORAL|NHANES Food Frequency Questionnaire (FFQ)|Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
48651343|NCT05434702|BEHAVIORAL|Fitbit data collection|Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
48330598|NCT05750316|OTHER|Cowpea leaves mixed with Jam|6g of freeze-dried cowpea leaves, equivalent to 80g(a portion) of vegetables mixed with Jam and spread on bread
48330599|NCT05750316|OTHER|Jam mixed with green food colour|Jam with green food colouring spread on bread
48651344|NCT05434702|BEHAVIORAL|Quality of Life questionnaire|The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
48651345|NCT05434702|BEHAVIORAL|Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire|The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
48330600|NCT04712357|DRUG|Vitamin C 500 MG Oral Tablet|Vitamin C 500 MG per day for 10 days
48124261|NCT02880137|PROCEDURE|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
48491789|NCT03787576|DEVICE|Cataract surgery|Evaluation of patient satisfaction after bilateral cataract surgery with multifocal intraocular lens implantation
48491790|NCT04731870|OTHER|Survey research|This is not an intervention study. It involves social science research of surveys and focus groups.
48330601|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG per day for 10 days
48491791|NCT03439852|BEHAVIORAL|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
48330602|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
48330603|NCT03713957|DRUG|GRF6021|GRF6021 for IV infusion
48330604|NCT03713957|OTHER|Placebo|Placebo for IV infusion
48330605|NCT05281848|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.
48330606|NCT00769808|DEVICE|Bausch & Lomb 217z Excimer Laser|LASIK correction of myopia and myopic astigmatism
48330607|NCT03946293|DIETARY_SUPPLEMENT|White Bread|White bread made with commercial white flour with bran/fibre removed
48330608|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain bread|Wholegrain bread made with commercial wholegrain flour.
48330609|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain Enzyme|Wholegrain bread made with enzyme-treated commercial wholegrain flour.
48330610|NCT06552923|OTHER|ECHO Tele-Education|A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.
48330611|NCT01305304|OTHER|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
48330612|NCT01305304|OTHER|Other|No history of endurance sports activity
48330613|NCT01817647|PROCEDURE|Colorectal surgery|
48491792|NCT01324635|DRUG|Panobinostat|Given PO
48491793|NCT01324635|RADIATION|Stereotactic body radiation therapy|Undergo SBRT
48491794|NCT01324635|PROCEDURE|Quality-of-life assessment|Ancillary studies
48491795|NCT01324635|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
48491796|NCT04312269|OTHER|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
48330614|NCT04991064|OTHER|Complete denture base modified by Titanium dioxide nanoparticles.|Titanium dioxide nanoparticles will be mixed with resin powder of the denture base before mixing the powder and liquid of the heat cure denture base material.
48330615|NCT06387030|BIOLOGICAL|Blood sampling|3 tubes of blood for research purposes (maximum 9.6 mL for children weighing 5-12 kg, 16 mL between 12-20 kg, 24 mL between 20 and 30 kg, and 56 mL for those weighing over 30 kg) will be taken from the catheter necessary for general anaesthesia.
48330616|NCT06387030|BIOLOGICAL|Esophageal biopsies|4 additional esophageal biopsies will be taken during digestive endoscopy, in the pathological zone or in the lower third of the esophagus by default.
48330617|NCT06387030|BIOLOGICAL|Unstimulated saliva sampling|A esophageal brushing will be done during digestive endoscopy.
48330618|NCT06387030|BIOLOGICAL|Urine sampling|A urine sample will be collected during hospitalization for digestive endoscopy.
48330619|NCT06387030|BIOLOGICAL|Stool sampling|A stool sample will be collected during hospitalization for digestive endoscopy.
48330620|NCT04228887|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
48124262|NCT00087139|DRUG|ixabepilone|Given IV
48124263|NCT02555449|DRUG|[¹⁴C]-LY3202626|Administered as solution by mouth
48330621|NCT04228887|DEVICE|Balance Training|Balance training will provide with Biodex® Balance Training System
48651346|NCT05434702|BEHAVIORAL|Godin Exercise Leisure-Time questionnaire|The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
48491797|NCT04761874|OTHER|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
48330622|NCT04228887|DEVICE|Inspiratory Muscle Training|15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
48330623|NCT03979846|OTHER|Best Practice|Receive usual care
48330624|NCT03979846|OTHER|Computer Application|Use computer-based symptom reporting system
48330625|NCT03979846|OTHER|Questionnaire Administration|Ancillary studies
48330626|NCT03979846|OTHER|Quality-of-Life Assessment|Ancillary studies
48330627|NCT01577784|DRUG|Pazopanib|800 mg / day of pazopanib in monotherapy.
48124264|NCT05707624|OTHER|video education|In the study, there are 2 groups in total: the intervention group (n=50) which videos of approaching the febrile child was watched once a week and 2 videos, and the control group (n=49) which no other application is made except for the routine procedure of the hospital
48124265|NCT05707624|OTHER|the routine procedure|the routine procedure
48124266|NCT02713126|DRUG|Placebo|administered orally or inhaled, taken every 4 hours or 3 times per day during waking hours for 12 weeks
48124267|NCT02713126|DRUG|Sodium Nitrite|administered orally or inhaled, 40 mg, taken every 4 hours or 3 times per day during waking hours for 12 weeks
48124268|NCT02713126|DEVICE|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
48124269|NCT02713126|OTHER|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
48491798|NCT01222390|DEVICE|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
48491799|NCT04749836|PROCEDURE|His bundle pacing implantation, Left bundle branch area pacing implantation, Bachmann bundle pacing|"Different active fixation leads and the dedicated delivery sheaths are introduced via standard transvenous approach under fluoroscopic guidance. His bundle potential mapping is performed in a unipolar setting with the use of the electrophysiological system for His bundle pacing. After localizing the His bundle potential, the pacing is attempted before the lead fixation to confirm HB capture. The lead is then screwed into position. Acute HBP threshold ≤ 2.5V at 1ms is considered acceptable. On the other hand, the initial site for LBBP is approximately 1-1.5 cm distal to the HBP lead position in the RV septum along the line between the HBP site and RV apex in the right anterior oblique (30°) fluoroscopic view. Bachmann bundle pacing (upper atrial septum) will be performed with the J-stylet modification technique or with specialized catheter method using the SelectSecure active fixation lead.~Stepwise approach for conduction pacing will also be tested."
48491800|NCT02400424|RADIATION|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
48491801|NCT06034561|DRUG|Bortezomib|Patients should receive one or two courses of this regimen, aiming to achieve complete remission as a bridge to proceed with allogeneic HSCT.
48491802|NCT01272726|BEHAVIORAL|Education|Education on the genetics of ADHD and treatment options for ADHD
48651347|NCT05434702|BEHAVIORAL|Zoom interviews|A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
48651348|NCT05543174|DRUG|TAK-625|TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
48124270|NCT00770757|DRUG|CC-4047|
48124271|NCT03010631|DRUG|Cohort 1: Lubiprostone Capsule, Fasted|Lubiprostone soft gelatin capsule administered under fasted conditions
48124272|NCT03010631|DRUG|Cohort 1: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
48124273|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fed|Lubiprostone sprinkle formulation administered under fed conditions
48124274|NCT03010631|DRUG|Cohort 2: Lubiprostone Sprinkle Formulation, Fasted|Lubiprostone sprinkle formulation administered under fasted conditions
48124275|NCT01262339|DRUG|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
48124276|NCT02850744|DRUG|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
48124277|NCT05769764|OTHER|Archival tissue specimen and immunohistochemistry staining|This is a non-interventional study and no intervention will be administered.
48124278|NCT06266845|BEHAVIORAL|In-person Escape Room|The in-person escape room will be conducted in the nursing laboratory of a Higher Education Institution (HEI), equipped with a high-fidelity mannequin to simulate a critical patient and create a realistic environment. Participants will be divided into groups, with one group entering at a time as requested. During the in-person escape room, participants will interact with the patient mannequin, hospital equipment and devices, as well as with objects and clues in the environment. The game duration will be 30 minutes to ensure equal conditions among participants and prevent time distortions. Interactions and participants' performance will be recorded by the facilitator, guiding the feedback.
48491803|NCT00306423|PROCEDURE|Other: Exercise|exercise 3 times per week for 12 weeks
48491804|NCT02920918|DRUG|Canagliflozin|
48651349|NCT04951843|DIETARY_SUPPLEMENT|Black soybean koji product|Black soybean koji product
48651350|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection30mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)
48651351|NCT05941585|DRUG|HomoharringtonineD1-D7(2mg/m2/day)|Homoharringtonine intravenous infusion on D1-D7,2mg/m2/day in a 4-week treatment cycle.
48330628|NCT03276572|DRUG|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
48330629|NCT03751423|DRUG|PO Morphine|10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
48330630|NCT03751423|DRUG|IV Fentanyl|0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
48491805|NCT02920918|DRUG|Sitagliptin|
48330631|NCT03751423|DRUG|IV Ketamine|200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
48330632|NCT03751423|DRUG|PO Placebo|A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
48330633|NCT03751423|DRUG|IV Placebo|This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
48124279|NCT06266845|BEHAVIORAL|Virtual Escape-Room|The virtual escape room will be conducted in a classroom of an HEI, utilizing an online platform that allows the virtual reproduction of the game. Each group will have access to a tablet or computer to participate in the game provided by the researcher. During the game, participants will interact with the platform interface and solve challenges to escape the virtual room within 30 minutes. Thus, each group will have a maximum of 30 minutes to complete the escape room, ensuring equal conditions among participants. Records of interactions and participant performance will be logged for later analysis and feedback.
48330634|NCT05152277|DRUG|HRS9531|Administered SC once
48330635|NCT05152277|OTHER|placebo|Administered SC once
48330636|NCT05152277|DRUG|HRS9531|Administered SC for multiple dose
48330637|NCT05152277|OTHER|placebo|Administered SC for multiple dose
48330638|NCT03920865|DRUG|Risdiplam|5 milligram (mg) oral dose administered in fasted state
48330639|NCT00004210|OTHER|loss of heterozygosity analysis|
48330640|NCT00004210|OTHER|microsatellite instability analysis|
48330641|NCT00004210|OTHER|mutation analysis|
48330642|NCT00004210|OTHER|counseling intervention|
48491806|NCT01881113|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
48491807|NCT01881113|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
48491808|NCT02622451|BEHAVIORAL|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
48330643|NCT03106012|PROCEDURE|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
48491809|NCT02622451|BEHAVIORAL|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
48491810|NCT01219413|DRUG|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
48491811|NCT00971841|DRUG|Paclitaxel|
48330644|NCT03106012|PROCEDURE|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
48330645|NCT01867567|PROCEDURE|abdominal bandage|
48330646|NCT04829942|BEHAVIORAL|positive health behavior|Training on nutrition, physical activity, first aid, individual hygiene, violence and bullying will be provided to the initiative group.
48330647|NCT01957852|OTHER|FloSeal|
48330648|NCT02665078|OTHER|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
48330649|NCT06261242|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
48651352|NCT05941585|DRUG|Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)|Venetoclax d4-d12 (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)in a 4-week treatment cycle.
47974238|NCT05213650|OTHER|Efferdent|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.
47974239|NCT05213650|OTHER|Cleaning Crystals|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
47974240|NCT04635943|DRUG|Ivermectin|One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
47974241|NCT04635943|DRUG|Placebo|The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
47974242|NCT03364023|DEVICE|Neurothrombectomy|Medtronic Market-Released Neurothrombectomy Device
47974243|NCT04550390|DIAGNOSTIC_TEST|Saliva collection|2 saliva samples are self-collected by participants
47974244|NCT06254586|PROCEDURE|Aerobic exercises|This group received a single session of low-intensity cycling for 20 minutes. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
47974245|NCT06254586|PROCEDURE|Resisted exercises|This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with 30 sec to 1 minute rest period between sets. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
47974246|NCT06432920|DEVICE|ResWave|Prototype wearable in-phase chest wall vibration device
47974247|NCT00382577|DRUG|Itopride|
47974248|NCT00382577|DRUG|Placebo|
47974249|NCT01126450|DRUG|lenalidomide|Given orally
48330650|NCT04508062|PROCEDURE|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
48330651|NCT04508062|PROCEDURE|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
48330652|NCT01854593|DRUG|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
48330653|NCT01854593|PROCEDURE|Vitrectomy|vitrectomy of 25 gauge system.
48330654|NCT01854593|DEVICE|Sham injection|Sham injection one day before vitrectomy
48330655|NCT05019651|DEVICE|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
48330656|NCT02480894|DRUG|BMS-663068|BMS-663068
48330657|NCT02480894|DRUG|Maraviroc|Maraviroc
48330658|NCT00347893|PROCEDURE|Selective laser trabeculoplasty|
48330659|NCT00871572|DRUG|LY2409021|4 capsules by mouth taken once daily for 12 weeks
48651353|NCT05941585|DRUG|Cytarabine(standard-dose:d1-d7100mg/m2/day)|Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day
48651354|NCT05941585|DRUG|Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)|d1-d4100mg/m2/day, d5-d7 1g/m2
48651355|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection24mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (24mg/m2)
48651356|NCT06136403|DRUG|deucravacitinib|treatment by deucravacitinib in two phases of challenge
48651357|NCT05818930|DIAGNOSTIC_TEST|REMI|Diagnostic monitoring
48651358|NCT00019838|DRUG|7-hydroxystaurosporine|
48651359|NCT00019838|DRUG|fludarabine phosphate|
47974250|NCT01126450|BIOLOGICAL|cetuximab|Given IV
47974251|NCT01126450|OTHER|mutation analysis|Correlative studies
47974252|NCT01126450|OTHER|polymerase chain reaction|Correlative studies
47974253|NCT01126450|GENETIC|polymorphism analysis|Correlative studies
47974254|NCT03959358|DRUG|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
47974255|NCT03959358|DRUG|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
48330660|NCT00871572|DRUG|Placebo|4 capsules by mouth once daily for 12 weeks
48330661|NCT03289871|DEVICE|Excilor|
48651360|NCT06008093|DRUG|Durvalumab|Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles. Durvalumab will also be given during the maintenance phase q4w until disease progression or unacceptable toxicity and at week 16.
48651361|NCT06008093|DRUG|Tremelimumab|Participants will receive IV Tremelimumab q3w for four 21-day cycles. Tremelimumab will also be given during the maintenance therapy phase at week 16.
48651362|NCT06008093|DRUG|Pemetrexed|Participants will receive IV pemetrexed q3w for four 21-day cycles and q4w until disease progression or unacceptable toxicity. During the maintenance therapy phase, participants may receive an additional cycle of pemetrexed, where applicable, at Week 16.
47974256|NCT01029795|DRUG|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
47974257|NCT01029795|DRUG|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
47974258|NCT01029795|DRUG|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
47974259|NCT00808366|DRUG|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
47974260|NCT00808366|DRUG|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
48330662|NCT03289871|DRUG|Loceryl 5%|
48330663|NCT05682313|DIAGNOSTIC_TEST|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
47974261|NCT02098759|DEVICE|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
47974262|NCT04633694|DIETARY_SUPPLEMENT|insect, pea or whey protein|The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
47974263|NCT02254993|DRUG|C16G2|antimicrobial peptide
48124280|NCT02929147|DRUG|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
48124281|NCT02929147|DRUG|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
48330664|NCT06040307|PROCEDURE|SPI (Surgical Pleth Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by SPI during general anesthesia in the experimental arm.
48330665|NCT01385267|PROCEDURE|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
48491812|NCT01946191|BEHAVIORAL|24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts.|Participants were assigned to a specific coach, who contacted the participants via the EHR weekly for 1 month, biweekly in months 2 to 6, monthly in months 7 to 12, and quarterly in months 13 to 24, for a total of 24 scheduled contacts. Coaching group participants received brief questionnaires relevant to weight management, including a text field where they could discuss questions or barriers. On the basis of participant responses and self-monitoring data in the EHR flow sheets, coaches wrote a brief personalized note with advice on questionnaire topics and responses to any queries or barriers mentioned by the participant. Coaching participants who did not complete questionnaires or log information into the flow sheet for 2 weeks were considered inactive and were contacted by telephone or e-mail and invited to reengage at any time. Coaching participants were able to send secure messages to the coach.
48491813|NCT01946191|BEHAVIORAL|Online self-monitoring|Participants were encouraged to log in daily and enter data on weight, diet, and physical activity.
48651363|NCT06008093|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
48651364|NCT06008093|DRUG|Carboplatin|Participants will receive IV Carboplatin on Day 1 of each 21-day cycle for 4 cycles.
48651365|NCT06008093|DRUG|Cisplatin|Participants will receive IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles.
48651366|NCT06008093|DRUG|Pemetrexed|Participants will receive IV pemetrexed q3w for four 21-day cycles and q3w until disease progression or unacceptable toxicity for up to 24 months.
48651367|NCT04628494|BIOLOGICAL|Epcoritamab|Following mandatory pre-medication subject will be administered epcoritamab as a subcutaneous injection.
48330666|NCT04265898|DEVICE|The Digital Virginia Tech Carilion Cognitive Examination|Completion of a newly developed digital cognitive screen
48330667|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
48330668|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
48330669|NCT02017886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
48124282|NCT02929147|DRUG|Placebo|In the Group 3 the PCA will contain placebo.
48124283|NCT04319432|BEHAVIORAL|Voice rest|The first days will take place in hospitalization to assess patient complience to voice rest. Patients will be instructed to continue voice rest at home up to 7 days accourding to group allocation in the study. The confirmation of voice rest will relay on patient report (telephonic approval), after the voice rest period will end.
48124284|NCT04050644|DRUG|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
48124285|NCT04050644|DRUG|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
48124286|NCT02065024|DIETARY_SUPPLEMENT|b-cryptoxanthin plus phytosterols|
48330670|NCT02017886|DIETARY_SUPPLEMENT|Placebo|Placebo tablet twice daily for three weeks
48330671|NCT02248857|OTHER|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
48651368|NCT04628494|DRUG|Investigator's Choice Chemotherapy|Following mandatory pre-medication subject will be administered intravenously either BR or R-GemOx.
47974264|NCT05385731|OTHER|Nordic Walking (NWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
47974265|NCT05385731|OTHER|Free Walking (FWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
48124287|NCT05760235|PROCEDURE|Endoscopic sleeve gastroplasty (ESG)|ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.
48124288|NCT02280148|PROCEDURE|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
48124289|NCT02280148|DEVICE|Driving Simulator|
48124290|NCT02280148|DRUG|Propofol|2mg / kg
48124291|NCT03795194|DRUG|ampicillin/clavulanate|FDA-approved antibiotic
48124292|NCT04264013|BEHAVIORAL|Exercise|Participants will exercise in a supervised facility twice weekly and consume their habitual diet.
48124293|NCT04264013|BEHAVIORAL|Exercise plus diet (egg)|Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
48330672|NCT02248857|OTHER|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
48330673|NCT05351710|BEHAVIORAL|Exposure-Based Treatment for Perfectionism|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
48330674|NCT05351710|BEHAVIORAL|Stress Management|Videos focused on education about healthy habits and relaxation. Each session is approximately twenty minutes.
48330675|NCT02539303|DRUG|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
48330676|NCT05812937|PROCEDURE|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
47974266|NCT05385731|OTHER|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
48651369|NCT06324461|DRUG|Dulaglutide 0.75mg subcutaneous injection|Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 7 to 14 days prior to surgery
48651370|NCT05938283|DEVICE|Implantable Cardioverter Defibrillator implant|ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
47974267|NCT01339429|DEVICE|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
48124294|NCT05055700|BEHAVIORAL|Mobile app with prenatal genetic testing information|In the intervention group, participants will be asked to download, register, and review a mobile app on their own mobile phones before their appointment with maternal-fetal medicine specialists. This mobile app includes prenatal genetic testing information about amniocentesis, chorionic villus sampling, nuchal translucency screening, cell-free DNA, triple/quad/penta screening, anatomy ultrasound, and carrier screening.
48124295|NCT03825978|BEHAVIORAL|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
48124296|NCT06427863|DRUG|Ornidazole|Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days
48124297|NCT06427863|DRUG|Placebo|Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
48124298|NCT05456698|DRUG|Inotuzumab ozogamicin|"Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity."
48124299|NCT02253459|DRUG|UTD1 Injection plus capecitabine|
48124300|NCT02253459|DRUG|Capecitabine|
48124301|NCT02828943|BEHAVIORAL|IMT with High Resistance EMT|
48124302|NCT02828943|BEHAVIORAL|IMT with Low Resistance EMT|
48124303|NCT04002622|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48124304|NCT00127049|DRUG|gemcitabine, ifosfamide, cisplatin, G-CSF|
48124305|NCT00714714|DRUG|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
48124306|NCT00714714|DRUG|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
48491814|NCT01946191|BEHAVIORAL|Real-time updates to Primary Care physicians|Referring PCPs of coaching group participants received regular support, including real-time progress reports with counseling tips delivered via the EHR, notification of weight change in increments of at least 10 pounds, and annual progress reports at 12 and 24 months.
47974268|NCT03780855|DEVICE|nerve scaffold|It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
47974269|NCT03097094|DIAGNOSTIC_TEST|Male dog|Male dog extract
47974270|NCT03097094|DIAGNOSTIC_TEST|Female dog|Female dog extract
47974271|NCT02615366|DRUG|Tranexamic Acid|
47974272|NCT02615366|DRUG|Placebo|
48124307|NCT03401138|OTHER|Preoperative Stroke Volume(SV)-guided fluid optimization|"Preoperative SV-guided hemodynamic optimization will be commenced with patients receiving 250ml fluid challenges over five minutes aiming to maximize SV. Maximal SV is defined as absence of a sustained rise in SV by at least 10% in response to a fluid challenge.~PPI will be obtained from the Masimo Radical 7 (Masimo, Irvine, CA, USA) and NIRS from Invos 5100C (Medtronic, Minneapolis, MN, USA).~BV measurements will use pulse dye densitometry (PDD) with Indocyanine Green (ICG). We will use the Dye Densitogram 3300 analyser Nihon Kohden (Tokyo, Japan) for registration of the spectrophotometrical absorption of ICG and calculation of BV."
48124308|NCT04680520|OTHER|Experimental (Doublebase Gel® or Diprobase Cream®)|Emollient (Doublebase Gel® or Diprobase Cream®) use on the skin. The emollient should be applied at least once a day.
48491815|NCT05944120|COMBINATION_PRODUCT|Aromatherapy patches|This study anticipates that Staff-reported stress levels will decrease when nurses use strategies from the Crisis Intervention Cart while at work.
48491816|NCT00642694|DRUG|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
48491817|NCT00642694|DRUG|Ramelteon|Ramelteon 8 mg qd
48491818|NCT00642694|OTHER|Placebo|Matching placebo qd
48491819|NCT01630681|BEHAVIORAL|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
48491820|NCT02772952|OTHER|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
48491821|NCT02772952|OTHER|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
47974273|NCT01539850|DEVICE|OMS102|Subjects will receive implanted OMS102 System.
47974274|NCT03281486|DEVICE|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
47974275|NCT03281486|DEVICE|Placebo|Placebo formulation without the active ingredients
47974276|NCT02385552|BEHAVIORAL|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
47974277|NCT00660998|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
47974278|NCT00660998|DRUG|Placebo|Matching placebo
47974279|NCT03829982|BEHAVIORAL|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
48651371|NCT05951179|BIOLOGICAL|TARA-002|All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.
48124309|NCT04680520|OTHER|Best practice skin care advice booklet|This is a booklet containing advice on best practice skin care. This will contain information on avoiding soap etc.
48330677|NCT04257227|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be)."
48330678|NCT04273542|OTHER|liquid biopsy|Blood sample collection during follow-up of the three cohorts of patients
48491822|NCT04235452|DIAGNOSTIC_TEST|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
48491823|NCT06438536|BEHAVIORAL|Virtual Reality-based Social Cognitive Training|Virtual reality assisted social cognitive training embedded in cognitive behavioral therapy, that aims at enhancing social cognition and daily life functioning.
48491824|NCT02497313|DRUG|Isotonic saline|
48491825|NCT02497313|DRUG|Metformin placebo|
48491826|NCT02497313|DRUG|Cholecystokinin|
48651372|NCT06198777|DEVICE|Magnetometer|Inspection equipment for magnetocardiography
47974280|NCT03829982|BEHAVIORAL|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
47974281|NCT03151837|DIETARY_SUPPLEMENT|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
47974282|NCT03151837|DIETARY_SUPPLEMENT|Placebo control|Starch
47974283|NCT06112262|DRUG|Heparin|Comparison between heparin and hirudin
47974284|NCT02314611|DEVICE|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
47974285|NCT03737721|COMBINATION_PRODUCT|Avelumab and Radical radiotherapy|A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
47974286|NCT04783480|OTHER|Birthly|Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.
47974287|NCT04783480|OTHER|Standard of care|Subjects will participate in childbirth education at their own discretion.
47974288|NCT00482612|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
47974289|NCT00482612|DRUG|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
47974290|NCT01487551|DRUG|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
47974291|NCT05849389|DRUG|Vosoritide|Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
47974292|NCT00797472|DRUG|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
47974293|NCT00797472|DRUG|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
48330679|NCT05343741|OTHER|Psychological Intervention|The CPA provides outpatient psychological services to individuals: children, adolescents and adults, couples and families. At the CPA, care is carried out through the co-therapy model, which involves the participation of a professional clinical psychologist and a trainee. Psychotherapists with diverse theoretical and clinical backgrounds (mainly psychodynamic, cognitive, systemic and integrative), but a common constructivist approach, work in the center. The following elements are transversal in their practice: therapeutic alliance, healing environment, and a collaborative procedure between the client, the psychotherapist and the trainee co-therapist.
48330680|NCT06397742|OTHER|Physical activity|"Patients received a set of exercises to execute at home. The home exercise program comprised 12 exercises conducted in sequence:~1. Symmetrical shoulder raises with retraction~2. Rolling upper extremities using a ball~3. Symmetrical shoulder raises~4. Band exercises strengthening the upper girdle and arm~5. Exercise of the shoulder joint flexors~6. Side arm raises in supine position~7. Lateral arm raises in supine position~8. Head raises with rotation in supine position~9. Side arm raises in prone position~10. Front arm raises in prone position~11. Rising and lowering the upper girdle in prone position~12. Neck muscles stretches"
48330681|NCT06397742|OTHER|Physical therapy - myofascial techniques|"Physical therapy program comprised five parts. I. Fascial manipulation targeted three most active center of coordination - center of fusion points within head, neck, shoulder, shoulder blade, or chest - during each session, time depending on the patients' adaptability.~II. Manual mobilization of the scar area with each training session including: active myofascial stretching; manual scar mobilization by stretching perpendicularly and in parallel with the scar; soft tissue mobilization by rolling and pulling the surface tissues; myofascial relaxation by breaking through restrictions.~III. Relaxation of muscle contractures using post-isometric muscle relaxation of the scalene muscle, sternocleidomastoid muscle, and neck muscles - until the sessions provided no muscle elongation.~IV. Neuromuscular stimulation with proprioceptive neuromuscular facilitation - included scapula movement patterns, dynamic reversal, stabilizing reversal, upper extremity movement patterns."
48330682|NCT03182413|DRUG|Placebo|
48330683|NCT03182413|DRUG|Modafinil|
48651373|NCT01652404|BEHAVIORAL|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
48124310|NCT05489536|BEHAVIORAL|A web/smartphone-based lifestyle program package|"There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring"
48651374|NCT01652404|BEHAVIORAL|Conventional treatment|The antibiotics duration will be determined by treating physician.
47974294|NCT04653129|PROCEDURE|Autologous Fat Grafting|"* The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~* The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
48491827|NCT02497313|DRUG|Metformin|
48330684|NCT03182413|DRUG|THN102|
48330685|NCT03659760|OTHER|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
48330686|NCT01442701|OTHER|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
48330687|NCT05885009|GENETIC|Liquid Biopsy|Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy
48491828|NCT00789763|DRUG|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
48651375|NCT06119321|OTHER|Pentacam, Corvis ST and Scansys|morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST
48330688|NCT05885009|GENETIC|Archival Tumor DNA sequencing|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
48330689|NCT01877785|DRUG|MHAA4549A|Single-ascending dose of MHAA4549A
48330690|NCT01877785|DRUG|Placebo|Placebo to MHAA4549A
48330691|NCT00099788|DRUG|Ranolazine|IV to oral transition.
48330692|NCT00099788|DRUG|Placebo|IV to oral transition.
48491829|NCT00789763|RADIATION|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
48491830|NCT00789763|DRUG|Sorafenib|200-800 mg/day p.o. during 5 weeks
48491831|NCT01914055|DEVICE|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
48651376|NCT06128629|BIOLOGICAL|NTLA-2001|NTLA-2001 (55mg) by IV infusion
48651377|NCT06128629|DRUG|Placebo|Normal saline (0.9% NaCl) by IV infusion
48651378|NCT06642857|OTHER|Peripheral blood, tougue coating, saliva, and feces|Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
48651379|NCT06643208|DRUG|TACE-HAIC, Envafolimab and Lenvatinib|TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
48651380|NCT00438282|BEHAVIORAL|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
48651381|NCT06151717|OTHER|Non-Interventional Study|Non-interventional study
48330693|NCT00383578|DRUG|Vildagliptin 100 mg qd|
48330694|NCT00383578|DRUG|Metformin 1500 mg daily|
48330695|NCT03118076|DRUG|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
48330696|NCT03118076|DRUG|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
48124311|NCT06322043|DEVICE|Adipearl|Injection of the investigational device in subcutaneous tissue.
48124312|NCT01747070|OTHER|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
48124313|NCT01747070|OTHER|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
48330697|NCT06157372|DIAGNOSTIC_TEST|targeted next-generation sequencing (tNGS)|To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.
48330698|NCT06220552|DRUG|Sintilimab|Sintilimab 200mg D1, Q3W
48330699|NCT06220552|RADIATION|Low-dose Radiotherapy|Radiotherapy 1Gy/1F, D1/D2/D8/D15, Q3W
48330700|NCT03919838|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
48330701|NCT03919838|DIETARY_SUPPLEMENT|Placebo - No probiotics|A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
48330702|NCT02436044|PROCEDURE|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
48330703|NCT02436044|DRUG|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
48491832|NCT01914055|DEVICE|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
48651382|NCT06674174|OTHER|lower limb strength training|Experimental group will receive lower limb strength training treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
48651383|NCT06674174|OTHER|endurance training|Control group will receive endurance training, treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
48651384|NCT06536881|BEHAVIORAL|Fasting|The dietician will review the patient's chemotherapy schedule, and confirm the fasting window (as windows may be 24, 26 or 48 hours; and chemotherapy start times can vary from patient to patient).
48651385|NCT06673823|DEVICE|Mirror therapy|Mirror Therapy (MT) is a non-invasive treatment method aimed at addressing unilateral conditions impacting either the upper or lower limbs. This technique involves placing a mirror along the patient's sagittal plane, allowing the reflection of the unaffected limb to visually overlay the affected limb.
48651386|NCT06673823|OTHER|conventional therapy|conventional therapy
47974295|NCT04653129|PROCEDURE|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
48124314|NCT01747070|OTHER|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
48124315|NCT01747070|OTHER|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
48124316|NCT03336905|OTHER|Physical activity program and prevention after cancer|Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
48124317|NCT02740283|BEHAVIORAL|glycemic monitoring|
48124318|NCT02740283|DIETARY_SUPPLEMENT|dietary guide|
48124319|NCT04093752|DRUG|Tirzepatide|Administered SC
48124320|NCT04093752|DRUG|Insulin Glargine|Administered SC
48330704|NCT02436044|DRUG|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
48330705|NCT02436044|DRUG|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
48330706|NCT01371526|DRUG|depot tetracosactide|1mg, 3x weekly by sc injection
48330707|NCT03034057|DRUG|Sayana Press|Sayana Press in the Uniject injection system
48330708|NCT05993000|OTHER|432 Hertz frequency music|432 Hertz frequency music was played to patients through headphones during hotpack and TENS applications.
48330709|NCT05993000|OTHER|TENS|The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
48330710|NCT05993000|OTHER|Mobilization|Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
48330711|NCT05993000|OTHER|Exercises|The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
48330712|NCT05993000|OTHER|Hotpack|Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
48330713|NCT03852160|DRUG|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
48330714|NCT03852160|DRUG|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
48330715|NCT03852160|DRUG|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
48330716|NCT03852160|DRUG|Placebo|Participants will receive matching placebo as nasal spray.
48491833|NCT01584453|DRUG|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
48491834|NCT01584453|DRUG|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
48491835|NCT05034276|OTHER|MORE-VR|Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
48651387|NCT06569836|OTHER|12-week intervention|"Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)"
48651388|NCT06569836|OTHER|12-week attention control|The attention and waitlist control group will have weekly educational and virtual workshops for 12 weeks. Three topics will be covered, including online exercise class, cognitive training, leisure and recreational activities. Each session will be 30-45 minutes and each topic last for four weeks. Participants could access the virtual sessions by their electronic devices.
48651389|NCT04578418|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Hydrolyzed collagen supplementation twice daily
48651390|NCT04578418|OTHER|Heavy slow resistance training|Heavy slow resistance training 3 times weekly
48651391|NCT04578418|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation twice daily
48651392|NCT06569849|OTHER|De-Stress and Focus capsule- U001|Two capsules in sequence daily after meal for 60 days.
48651393|NCT06569849|OTHER|De-Stress and Focus capsule - I001|Two capsules in sequence daily after meal for 60 days.
48651394|NCT06569849|OTHER|Placebo capsules 001|Two capsules in sequence daily after meal for 60 days.
48651395|NCT04961580|DRUG|Ceftazidime Avitbatan Sodium|For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
48651396|NCT06399107|GENETIC|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan|An autologous CD34+ cell-enriched population from patients with sickle cell disease (SCD), which includes hematopoietic stem cells (HSCs) that have been transduced with the BAH243 lentiviral vector (LVV) carrying the βA-T87Q-globin gene, is preserved in a cryopreservation solution.
48651397|NCT02229682|RADIATION|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
48651398|NCT06445127|DEVICE|MRI|A non-invasive, non-contrast, renal MRI will be performed.
48651399|NCT05485961|DRUG|CSL300|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
48651400|NCT05485961|DRUG|Placebo|0.9% w/v NaCl
48651401|NCT05485961|DRUG|Placebo|Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
48651402|NCT03688763|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-i is an evidence-based treatment for insomnia. Participants will receive CBT-i via online program (Sleepio).
48124321|NCT00378222|PROCEDURE|Autologous Stem Cell Transplantation|
48124322|NCT03485950|DRUG|Cefepime|Given IV
48124323|NCT03485950|DRUG|Ceftolozane|Given IV
48124324|NCT03485950|OTHER|Laboratory Biomarker Analysis|Correlative studies
48124325|NCT03485950|DRUG|Meropenem|Given IV
48330717|NCT03852160|DRUG|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
48330718|NCT03852160|DRUG|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
48491836|NCT00622466|DRUG|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
48491837|NCT00622466|DRUG|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
48491838|NCT03161964|DRUG|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
48491839|NCT03161964|DRUG|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
48124326|NCT03485950|DRUG|Piperacillin-Tazobactam|Given IV
48124327|NCT03485950|DRUG|Tazobactam|Given IV
48124328|NCT00575614|DRUG|prucalopride|1 mg o.d.
48124329|NCT00575614|DRUG|placebo|o.d.
48124330|NCT03133234|DRUG|osimertinib|Oral dose of 80mg once daily
48124331|NCT03041584|PROCEDURE|Guided placement|implant placement with use of guide
48124332|NCT03041584|PROCEDURE|Non-guided placement|conventional implant placement
48124333|NCT03041584|DEVICE|Astra Tech TX implant|
48124334|NCT01598870|OTHER|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
48124335|NCT04110054|DRUG|S-600918|Tablets for oral administration
48330719|NCT03852160|DRUG|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
48330720|NCT03852160|DRUG|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
48330721|NCT03852160|DRUG|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
48330722|NCT03852160|DRUG|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
48330723|NCT03852160|DRUG|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
48330724|NCT01171287|PROCEDURE|Driving with an Aircast Walker|
48330725|NCT01171287|PROCEDURE|Driving with a walking cast|
48330726|NCT01171287|PROCEDURE|Driving with a running shoe|
48330727|NCT01332604|DRUG|GDC-0980|Oral escalating dose
48330728|NCT01332604|DRUG|bevacizumab|Intravenous repeating dose
48330729|NCT01332604|DRUG|capecitabine|Oral repeating dose
48124336|NCT04110054|DRUG|Placebo to S-600918|Tablets for oral administration
48124337|NCT04678375|DIAGNOSTIC_TEST|Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
48124338|NCT03032458|DRUG|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
48124339|NCT03032458|DRUG|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
48124340|NCT03032458|DRUG|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
48124341|NCT01869179|BEHAVIORAL|Community of Voices choir program|Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
48124342|NCT01869179|BEHAVIORAL|Wait-list control group|
48124343|NCT04185571|DEVICE|PEPA|
48124344|NCT03569982|OTHER|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
48124345|NCT04484753|OTHER|Home Exercise Sheet|Received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
48124346|NCT04484753|OTHER|Ipelvis mobile application|Received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
48124347|NCT04484753|BEHAVIORAL|Home exercise sheet + Pelvic Physiotherapy|Performed 12 Pelvic Physiotherapy sessions, in group, once a week and received a sheet with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
48124348|NCT04484753|BEHAVIORAL|Ipelvis mobile application + Pelvic Physiotherapy|Performed 12 pelvic physiotherapy sessions, in group, once a week and received the iPelvis® Application with pelvic floor muscle training guidelines to be performed at home. After 3 months all volunteers were reevaluated.
48124349|NCT04593056|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
48124350|NCT04593056|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure
48124351|NCT06006949|DRUG|Roxadustat|Roxadustat (150 mgqod)
48124352|NCT06006949|DRUG|Luspatercept|Luspatercept (1.0 mg/kg, subcutaneously injection every 3 weeks, adjusted according to blood pattern, up to 1.75mg/kg)
48124353|NCT00273624|DRUG|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
48124354|NCT00273624|DRUG|Placebo|placebo
48124355|NCT04423016|DEVICE|Near Infrared Spectroscopy monitoring|Non-invasive continuous monitoring of cerebral oxygenation
48124356|NCT04423016|DEVICE|Electrical velocimetry and pulse oximetry|Non-invasive continuous monitoring of cerebral oxygenation
48330730|NCT01332604|DRUG|mFOLFOX6|Intravenous repeating dose
48330731|NCT05145400|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab :10 mg/kg intravenous will be administered in cycle 1-24.
48330732|NCT05145400|DRUG|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR \> 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
48330733|NCT05145400|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
48330734|NCT04241146|DEVICE|Enteric Tube|A post pyloric feeding tube used in patients requiring enteral nutrition
48330735|NCT04241146|DEVICE|CORTRAK enteral access system|Electromagnetic guidance system for enteric feeding tube placement
48124357|NCT00704314|DRUG|Simvastatin|80 mg Simvastatin daily for 8 weeks
48330736|NCT03394079|PROCEDURE|PCI|Percutaneous Coronary Intervention
48330737|NCT06528054|OTHER|Development of a model for predicting 90-day mortality and to compare various treatment strategies for anastomotic leakage|The prediction model and comparison of various treatment strategies will be studies when the data is available for analysis.
48330738|NCT01610908|OTHER|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
48330739|NCT01610908|OTHER|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
48330740|NCT05779605|DEVICE|Home-based training|Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
48330741|NCT05779605|DEVICE|Center-based training|Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
48330742|NCT00002204|BIOLOGICAL|HIV p24/MF59 Vaccine|
48330743|NCT04958109|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Administration of a 75 gm oral glucose tolerance test
48330744|NCT04958109|DRUG|Kisspeptin|Intravenous administration of kisspeptin 112-121 x 16 hours
48330745|NCT04958109|DRUG|Placebo|Intravenous administration of Placebo 16 hours
48330746|NCT00637377|DRUG|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48651403|NCT04507581|OTHER|electrical impedance tomography during anaesthesia|Before induction of the anaesthesia, before the radiological procedure when the induction is terminated, after the termination of the radiological procedure, before transport to the Post anaesthesia Care Unite (PACU), and before the discharge from the PACU after 2 hours of monitoring ventilation distribution changes by thoracic electrical impedance tomography are measured (each measurement will last 1 min). For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated by an automated linearized Newton-Raphson reconstruction algorithm (9). Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity such as the global inhomogeneity index will be calculated as described previously, using customised software (Matlab R2013a, The MathWorks, Nattick, Massachusetts, USA)(10-12).
48124358|NCT00704314|DRUG|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
48124359|NCT01306500|PROCEDURE|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
48124360|NCT05370794|DRUG|rhCG= Ovitrelle®, 250g/0.5ml = 26000IU/ml, Merck-Serono|recombinant hCG
48124361|NCT05370794|DRUG|rFSH = Gonal F®, 300IU/0.5ml, Merck-Serono|recombinant FSH
48124362|NCT06430788|BIOLOGICAL|Emapalumab|Emapalumab is an interferon gamma (IFNγ) blocking antibody
48124363|NCT03859869|DRUG|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
48124364|NCT03859869|DRUG|Placebo|Placebo is administered orally as capsules with a meal or snack
48124365|NCT01255670|DRUG|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
47974296|NCT03305653|DEVICE|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
47974297|NCT06319508|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
47974298|NCT06319508|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
47974299|NCT06319508|DRUG|Lidocaine hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Once a day.
47974300|NCT06319508|PROCEDURE|Placebo injection|The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. 1 milliliter of normal saline will be used for injection.
47974301|NCT02432014|BEHAVIORAL|PMTO-PTC Group clinic-based|
47974302|NCT02432014|BEHAVIORAL|PMTO Individual home-based|
47974303|NCT02432014|BEHAVIORAL|PMTO Individual clinic-based|
47974304|NCT02432014|BEHAVIORAL|Services as Usual|
47974305|NCT06036771|DEVICE|Voice-activated Intelligent Personal Assistant (VIPA)|Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
47974306|NCT03548103|DIETARY_SUPPLEMENT|Green tea extract|Green tea extract 500 mg tid for 16 weeks
47974307|NCT03548103|DIETARY_SUPPLEMENT|Placebo|Placebo tid for 16 weeks
47974308|NCT02253251|GENETIC|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
48124366|NCT03065569|DRUG|Bupivacaine|16 mL of 0.125% bupivacaine
48124367|NCT01579916|BIOLOGICAL|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10\^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
48124368|NCT01579916|OTHER|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
48330747|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48491840|NCT02685202|DEVICE|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
48491841|NCT06088849|PROCEDURE|Venipuncture|The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
48491842|NCT06186102|DIETARY_SUPPLEMENT|Spermidine|Spermidine capsule of 8 mg x 3 capsules daily.
48491843|NCT06186102|OTHER|Placebo|Placebo capsule. 3 capsules daily.
48330748|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48491844|NCT04891965|BIOLOGICAL|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10\^9 CFU/capsule. Subjects will receive 1 capsule daily.
48491845|NCT04891965|DRUG|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
48491846|NCT00427713|DRUG|capecitabine|
48491847|NCT00427713|DRUG|oxaliplatin|
48491848|NCT00427713|PROCEDURE|adjuvant therapy|
48491849|NCT00427713|PROCEDURE|standard follow-up care|
48491850|NCT02229539|DRUG|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
48491851|NCT02229539|DRUG|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
48491852|NCT02229539|OTHER|Placebo|2.5 mL placebo and 2.5 mL water administered orally
48491853|NCT05875922|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
48651404|NCT04498273|DRUG|Apixaban 2.5 MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
48651405|NCT04498273|DRUG|Apixaban 5MG|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
48651406|NCT04498273|DRUG|Aspirin|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
48651407|NCT04498273|DRUG|Placebo|Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
48651408|NCT03269266|DIAGNOSTIC_TEST|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
48651409|NCT05790031|DEVICE|Intelligent Nighttime Brace|Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
48651410|NCT06675318|OTHER|Cross training for quadriceps muscle of contralateral lower limb|An isokinetic exercise program consisting of 20 sessions conducted five days a week. The program begins with five repetitions at a speed of 60°/s, followed by sets of 5-15 repetitions with incremental increases of 30°/s. Rest periods of 30 seconds were included between sets.
48651411|NCT06675318|OTHER|Quadriceps isometric exercises, along with hot pack and TENS for painful knee|10 repetitions of quadriceps isometric exercises in 3 sets, along with hot pack and TENS treatments for painful knee
48651412|NCT06549647|OTHER|low caloric diet|A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.
48651413|NCT06549647|OTHER|Placebo laser acupoint stimulation|Placebo laser acupoint stimulation will be used for all participants in group (A).
48651414|NCT06549647|OTHER|Laser Acupuncture|Eazyone EZ1 level laser will be used for the treatment procedures for all participants in group (B) only. Every participant in group (B) will be instructed briefly about the effect of laser acupoints therapy to gain her confidence and co-operation. It will be applied with infrared laser with 830 nm wavelength, 5 W power output and 0.5 J energy on the following acupoints while the patient lie in supine lying position. The head of the machine will be applied perpendicularly on each point for 1 min (17 min total), 3 times/ week for 4 weeks.
48491854|NCT05875922|DEVICE|IOL implantation active comparator (TECNIS Eyhance)|Implantation of EDOF IOL TECNIS Eyhance
48491855|NCT00222352|DIAGNOSTIC_TEST|Point of Care cTnL testing|"The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half."
48330749|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48330750|NCT04461028|DRUG|Liposomal bupivacaine|20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
48330751|NCT04461028|DRUG|Bupivacaine with Dexamethasone Solution|20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
48491856|NCT02398357|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
48491857|NCT01181271|DRUG|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
48491858|NCT01181271|DRUG|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
48491859|NCT01181271|DRUG|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
48491860|NCT01181271|DRUG|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
48491861|NCT01181271|OTHER|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
48491862|NCT01181271|DRUG|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
48491863|NCT01181271|DRUG|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
48491864|NCT01181271|DRUG|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
48651415|NCT04111601|DEVICE|Blue light imaging|Advanced virtual chromoendoscopy
48651416|NCT06433908|DRUG|Salbutamol HFA-152a|100 µg (ex-valve), given at 20-second intervals.
47974309|NCT04479423|PROCEDURE|Soda-water instead of pure water to observe gastric filling|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (\>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
47974310|NCT00530764|DRUG|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
47974311|NCT00530764|DRUG|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
47974312|NCT00530764|DRUG|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
47974313|NCT05637398|DRUG|Colchicine|The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
47974314|NCT00725569|DRUG|Bellis perennis and Staphysagria (C6)|homeopathic remedy
47974315|NCT00725569|DRUG|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
47974316|NCT00725569|DRUG|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
47974317|NCT05510804|COMBINATION_PRODUCT|ALISA|assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
47974318|NCT03410550|DEVICE|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
47974319|NCT03063372|DIETARY_SUPPLEMENT|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
47974320|NCT03063372|OTHER|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
47974321|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
47974322|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
47974323|NCT01995032|DRUG|750 mg metformin and 7.5 g L-citrulline daily p.o.|
48330752|NCT06001840|BEHAVIORAL|Promotion factors|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
47974324|NCT01995032|DRUG|Placebo|
47974325|NCT03379532|DEVICE|BCI-NMES|From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
47974326|NCT03379532|DEVICE|Sham-NMES|Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
47974329|NCT00071513|BEHAVIORAL|CAST-T/HSTS|Skills training small group.
47974330|NCT00071513|BEHAVIORAL|Brief Intervention|Assessment of needs and referral to services as needed.
47974331|NCT03872167|DEVICE|BIPAP, Intelligent automatic mode defined by assured volume with pressure support|Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
47974332|NCT03872167|DEVICE|BIPAP, manual tritration.|Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
47974333|NCT01096901|BEHAVIORAL|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
47974334|NCT00123396|BEHAVIORAL|BioCASES and BioTESTS|
47974335|NCT02345681|DRUG|Furosemide|
47974336|NCT05815940|BEHAVIORAL|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
47974337|NCT03876444|DRUG|Intravenous Methylprednisolone|Intravenous Methylprednisolone will be used in the intervention group
47974338|NCT03876444|DRUG|Oral Pednisolone|Oral Prednisolone will be used in the Control Group
47974339|NCT00435292|DRUG|Naproxen|nonsteroidal anti-inflammatory drug
47974340|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 250 mg|flavonoid mixture
47974341|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 500 mg|flavonoid mixture
47974342|NCT05349994|OTHER|Extended physiotherapy|At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
47974343|NCT06042452|GENETIC|Genetic|A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used.
47974344|NCT05950932|DIETARY_SUPPLEMENT|Melissa phytosome|Melissa phytosome® is composed of dry extract of Berberis aristata root (550mg/cpr), complexed with phospholipids (soy lecithin), Pisum sativa proteins, and proanthocyanidin oligomers from Vitis vinifera. 2 tablets of 200 mg Melissa phytosome will be provided to participants, to be taken 30 minutes before bedtime for 14 days.
47974345|NCT05950932|OTHER|Placebo|2 tablets with an equivalent form, color, flavor, and coating as the experimental product, to take 30 minutes before bedtime.
47974346|NCT03172455|DRUG|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
47974347|NCT05408949|BEHAVIORAL|Single exercise into pain (SEP) program|"* Baseline assessment \& commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Initial follow-up \& progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Second follow-up \& progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~* Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~* Functional rehabilitation program"
48491865|NCT01181271|OTHER|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight
48491866|NCT01181271|DRUG|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
48491867|NCT01181271|DRUG|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
47974348|NCT05408949|BEHAVIORAL|Shoulder Symptom Modification Procedure (SSMP)|\[1\] Finger on the sternum,\[2A\] Scapula modification \[3\] 'Humeral head' modification \[4\] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
47974349|NCT05408949|BEHAVIORAL|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
48491868|NCT01181271|DRUG|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
48651417|NCT06433908|DRUG|Salbutamol HFA-134a|100 µg (ex-valve), given at 20-second intervals.
48651418|NCT06527937|DRUG|DESF|DESF administered in the sublingual space.
48651419|NCT06527937|DRUG|Epinephrine Injection|Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
47974350|NCT05408949|BEHAVIORAL|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
48330753|NCT06001840|BEHAVIORAL|Mitigation strategies|"Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record)."
48330754|NCT01216397|DRUG|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
48330755|NCT01216397|DRUG|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
48330756|NCT03471481|OTHER|No Intervention. Study is Cross Sectional in nature|No Intervention. Study is cross sectional in nature
48330757|NCT03271307|BEHAVIORAL|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
48330758|NCT03271307|DIAGNOSTIC_TEST|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
48330759|NCT03271307|DIAGNOSTIC_TEST|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
48330760|NCT05856669|DEVICE|Virtual reality gaming|This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
48330761|NCT05825196|DIAGNOSTIC_TEST|tumor tissue and blood tests|In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
48330762|NCT03240718|PROCEDURE|Laser treatment|CORE fractional CO2 laser treatment
48330763|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
48330764|NCT02678312|DRUG|Enalapril|Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
48330765|NCT02678312|DRUG|Placebo of LCZ696|
48330766|NCT02678312|DRUG|Placebo of Enalapril|
48330767|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
48330768|NCT00556621|DRUG|cisplatin|
48330769|NCT00556621|DRUG|gemcitabine hydrochloride|
48330770|NCT00556621|PROCEDURE|biopsy|
48330771|NCT00556621|PROCEDURE|cystoscopy|
48330772|NCT00556621|PROCEDURE|therapeutic conventional surgery|
48330773|NCT00556621|RADIATION|radiation therapy|
47974351|NCT05408949|BEHAVIORAL|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
48330774|NCT00854256|PROCEDURE|Canaloplasty|Canaloplasty surgery
48330775|NCT00854256|PROCEDURE|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
48330776|NCT03581929|DIETARY_SUPPLEMENT|Memormax|Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
48330777|NCT03581929|OTHER|Placebo|Placebo comparator
48330778|NCT04095442|DEVICE|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
48330779|NCT04095442|DEVICE|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
48330780|NCT02786108|PROCEDURE|left gastric artery embolization|
48330781|NCT02786108|BEHAVIORAL|healthy diet and exercise|
48330782|NCT05438810|DRUG|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
48330783|NCT05438810|DRUG|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
48330784|NCT02427750|BIOLOGICAL|Aggripal®|TIV
48651420|NCT02408029|OTHER|Observational study - no intervention|
48651421|NCT04937153|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously (IV) once every 21 days.
48651422|NCT04937153|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered IV once every 21 days.
47974352|NCT04691453|PROCEDURE|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
47974353|NCT04691453|PROCEDURE|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
47974354|NCT00197964|BEHAVIORAL|Enhance asthma knowledge, self-efficacy, social support|
47974355|NCT03181581|BIOLOGICAL|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
47974356|NCT03181581|BIOLOGICAL|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
47974357|NCT00471068|DRUG|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
47974358|NCT00471068|DRUG|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
48491869|NCT04580121|DRUG|RO7283420|RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
48491870|NCT04580121|DRUG|RO7283420|RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
48491871|NCT04580121|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
48491872|NCT04580121|DRUG|Dasatinib|Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily \[BID\] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
48491873|NCT04580121|DRUG|Dexamethasone|20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
48491874|NCT04580121|DRUG|Paracetamol/acetaminophen|500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
48491875|NCT04580121|DRUG|Diphenhydramine|25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
48491876|NCT05507593|BIOLOGICAL|DLL3-CAR-NK cells|Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
48491877|NCT00000963|DRUG|Didanosine|
48491878|NCT02496819|OTHER|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
48651423|NCT04377919|DIETARY_SUPPLEMENT|Cranberry|The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
48651424|NCT04377919|DIETARY_SUPPLEMENT|Placebo|The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
47974359|NCT00471068|DRUG|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
47974360|NCT00691015|BIOLOGICAL|rituximab|Given IV
47974361|NCT00691015|DRUG|busulfan|Given IV
47974362|NCT00691015|DRUG|carmustine|Given IV
47974363|NCT00691015|DRUG|cyclophosphamide|Given IV
47974364|NCT00691015|DRUG|cytarabine|Given IV
47974365|NCT00691015|DRUG|etoposide|Given IV
47974366|NCT00691015|DRUG|fludarabine phosphate|Given IV
47974367|NCT00691015|DRUG|melphalan|Given IV
47974368|NCT00691015|RADIATION|total body irradiation (TBI)|Given once or twice daily
47974369|NCT00691015|DRUG|anti-thymocyte globulin IV|Given IV
47974370|NCT05779098|PROCEDURE|Extensive hepatectomy|Extensive hepatectomy
47974371|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
48491879|NCT02496819|OTHER|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
48491880|NCT02496819|OTHER|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
48491881|NCT02405949|GENETIC|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
48491882|NCT05980741|PROCEDURE|high-quality nursing|High-quality nursing
48330785|NCT06131229|BEHAVIORAL|Structured emotional education program (PEE)|The principal investigator, together with the class-tutor of the experimental groups, conducts the 20 activities of which the program is composed during the hour dedicated to tutorial action. The sessions are held at Lauro School on Monday mornings in the respective classrooms, with the possibility of using the courtyard and other multipurpose rooms if the activities so require. Each session lasts one hour and is held throughout the school year 23-24.
48124369|NCT04356820|OTHER|acupressure|Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
48491883|NCT05980741|PROCEDURE|Clinical Care Pathway|Clinical Care Pathway
48491884|NCT05980741|PROCEDURE|Roy Adaptation Model|Roy Adaptation Model
48491885|NCT03863483|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
48124370|NCT00495976|OTHER|A commercially produced cordial drink|
48491886|NCT03863483|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
48491887|NCT03863483|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
48491888|NCT03863483|DRUG|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
48491889|NCT04736563|DEVICE|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
48491890|NCT02751359|DRUG|Cannabidiol|200, 400, or 800 mg Cannabidiol
48491891|NCT02751359|DRUG|Placebo|0 mg Cannabidiol
48124371|NCT05942092|PROCEDURE|Breast conserving surgery|Breast conserving surgery after lesion's localization with ROLL or magnetic seed
48491892|NCT03412786|BIOLOGICAL|Bcl-Xl_42-CAF09b vaccine|The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
48491893|NCT02667288|DRUG|A-101 Solution|
48491894|NCT00786279|OTHER|ethanol|15 gm ethanol daily for 6 months
48491895|NCT00786279|OTHER|Ethanol-free beverage|0 grams ethanol daily for 6 months.
48491896|NCT02944370|BEHAVIORAL|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
48491897|NCT04696107|BEHAVIORAL|Psychoeducative intervention|"This workshop is centred in psychoeducational and training action in emotional self-regulation in a group modality and participatory character, aimed at patients with mCNCP to acquire basic knowledge in:~* Neurology and psychoneuroimmunology.~* The role of beliefs in our manifestation of the disease.~* Body language and modulation of pain perception.~* Relaxation body-mind techniques.~* Creative visualization for pain management.~* Mirror feed-back.~The workshop will take place at the Hospital San Juan de Dios del Aljarafe, in four weeks, once a week, three hours each. Until now, the attendance was 24 patients per workshop. After the pandemic, we will reduce to 15 to increase safety distance. We will also conduct a telephone survey of each patient on symptoms of Covid infection in the 24 hours prior to the workshop."
48124372|NCT03917303|DRUG|Adalimumab|episodic treatment with subcutaneous adalimumab for 6 months
47974372|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
47974373|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
48124373|NCT03917303|DRUG|standard step-up care|conventional step-up care starting with corticosteroids
48124374|NCT04108923|DEVICE|Ligasure|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
47974374|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
47974375|NCT00458198|BEHAVIORAL|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
47974376|NCT06348602|DRUG|Cyclosporine ophthalmic solution 0.1%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
47974377|NCT06348602|DRUG|Tacrolimus ophthalmic ointment 0.03%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
47974378|NCT06270498|DIETARY_SUPPLEMENT|Sucrosomial iron|"Sucrosomial iron with the addition at a fixed dose of vitamin C to promote iron absorption (SiderAL® Forte) will be administered orally once a day for 12 weeks.~The dose regimen for all participants will be calculated according to the haemoglobin (Hb) levels at baseline evaluation and to patient's body weight as follows:~Hb 14-15 g/dL: 1 tablet once a day, corresponding to 30 mg/daily, for 12 weeks; Hb 10-13.9 g/dL: 2 tablets once a day, corresponding to 60 mg/daily, for 12 weeks"
47974379|NCT06270498|OTHER|Placebo|"Placebo pills will be identical in shape, form and color of SI pills; they will contain the same components of SiderAL Forte® except for sucrosomial iron and vitamin D.~Placebo will be administered orally once a day for 3 months according to the same dose scheme in the intervention arm."
47974380|NCT04010357|DRUG|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
48124375|NCT04108923|PROCEDURE|Conventional vessel ligation|Conventional vessel ligation either tying and /or clipping of blood vessels
48491898|NCT06224712|BEHAVIORAL|Arogya Sangama|Using human-centered design, the investigators will work wit the community to develop a prototype Arogya Sangama model to identify methods to bring GPTF and HWC service providers to create ideas, systems, processes, services, and delivery strategies for the GPTFs. They will help identify and prioritize interventions and address barriers to usability. There will also be capacity building of GPTFs to implement the interventions identified.
48491899|NCT02824471|OTHER|SCD Group|No Intervention. Use of discard blood/tissue
47974381|NCT02584673|DEVICE|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
47974382|NCT01525368|BEHAVIORAL|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
48124376|NCT02226536|BEHAVIORAL|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
48124377|NCT06065332|OTHER|Velez Intense Hydration Mask® (biotech cellulose face mask)|Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
48124378|NCT01511159|DRUG|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
48124379|NCT01511159|DRUG|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
48124380|NCT01511159|DRUG|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
48491900|NCT02954926|DRUG|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
48124381|NCT01511159|DRUG|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
48124382|NCT01511159|DRUG|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
48124383|NCT01511159|DRUG|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
48124384|NCT01511159|DRUG|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
48491901|NCT05380076|OTHER|Mindfulness meditation|6 minutes of watching a video tape made for the study that inspire mindfulness like meditation just before entering the examination circuit.
48491902|NCT05380076|OTHER|Mobilization of inner resources|6 minutes of watching a video tape made for the study that provide psychological stimulation just before entering the examination circuit
48124385|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
48124386|NCT01470508|BEHAVIORAL|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
48124387|NCT03131869|OTHER|Thickened Beverages Nectar|Thickened beverages in nectar consistency
48124388|NCT03131869|OTHER|Thickened Beverage Honey|Thickened beverages in honey consistency
48124389|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
48124390|NCT03000842|DEVICE|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
48124391|NCT04353531|DEVICE|High-flow nasal cannula|High-flow nasal cannula is a modality of oxygen device that can provide gas flow meets or exceeds patient inspiratory flow demand (flow can be set at 10-60 L/min), it has been proven to improve oxygenation and reduce intubation rate in hypoxemic patients.
48124392|NCT04353531|DEVICE|Surgical mask|A procedure mask will be used to cover patient's face after HFNC is initiated.
48124393|NCT04353531|PROCEDURE|bronchoscopy examination|is a procedure that allows a doctor to examine the inside of the lungs, including the bronchi, which are the main pathways into the lungs. During a bronchoscopy, a doctor inserts a thin tube containing a light and camera into the lungs through the nose or mouth or via artificial airway such as intubation or tracheotomy tube
48124394|NCT04353531|PROCEDURE|intubation|Intubation is the process of inserting a tube, called an endotracheal tube (ET), through the mouth and then into the airway. This is done so that a patient can be placed on a ventilator to assist with breathing during anesthesia, sedation, or severe illness.
48124395|NCT04353531|PROCEDURE|tracheostomy|A tracheostomy is a medical procedure - either temporary or permanent - that involves creating an opening in the neck in order to place a tube into a person's windpipe. The tube is inserted through a cut in the neck below the vocal cords. This allows air to enter the lungs.
48124396|NCT04353531|DEVICE|nebulization|A nebulizer is a piece of medical equipment that a person with asthma or another respiratory condition can use to administer medication directly and quickly to the lungs
48124397|NCT04353531|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange.
48124398|NCT05493449|COMBINATION_PRODUCT|UHT Milk|In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group
48330786|NCT06131229|BEHAVIORAL|Incidental tutorial action based on the school's regular curriculum (PCO)|One hour tutorial action per week according to the regular school curriculum. This curriculum contemplates the incidental approach to the problems that arise in daily life and the work with the KIVA program.
48491903|NCT05380076|OTHER|Biofeedback|6 minutes of relaxing breathing exercise coupled with heart rate variability biofeedback guided on eMWave Pro software on a computer just before entering the examination circuit.
48651425|NCT04526158|BEHAVIORAL|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
48651426|NCT04526158|BEHAVIORAL|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
48651427|NCT05783466|OTHER|Low-fat dairy products|3-month intervention
48651428|NCT05783466|OTHER|Whole-fat dairy products|3-month intervention
48651429|NCT05783466|OTHER|Milk polar lipid enriched whole-fat dairy products|3-month intervention
48651430|NCT06643078|DRUG|HL231 Solution for Inhalation|HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
48124399|NCT05493449|COMBINATION_PRODUCT|Flavored Milk|In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
48124400|NCT00252369|DRUG|Infliximab|
48124401|NCT00252369|PROCEDURE|Instillation of fibrin glue|
48124402|NCT04290013|DRUG|norethisterone acetate|norethisterone acetate 15 mg daily from day 5 of the cycle to day 26.
48330787|NCT02637440|PROCEDURE|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
48330788|NCT02637440|PROCEDURE|Angio guided PCI|Patients receive PCI without FFR measurement
48330789|NCT04152642|DEVICE|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
48124403|NCT04290013|DRUG|tranexamic acid tablets|tranexemic acid 1 gm three times daily from the first day of the menstrual cycle up to 5 days .The dose can be increased but not exceeding 4 gm per day.
48124404|NCT01429805|DEVICE|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
48124405|NCT00459212|DRUG|GTI-2040|Given IV
48651431|NCT06643078|DRUG|Ultibro 110μg/50 μg|Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
48651432|NCT04485013|DRUG|TTX-080|Variable dose (Q3W)
48651433|NCT04485013|DRUG|TTX-080|Specified dose (Q3W)
48651434|NCT04485013|DRUG|pembrolizumab|Specified dose (Q3W)
48651435|NCT04485013|DRUG|cetuximab|Specified dose on specified days
48651436|NCT04485013|DRUG|FOLFIRI|Specified dose (Q2W)
48651437|NCT04485013|DRUG|cetuximab|Specified dose (Q2W)
48651438|NCT04485013|DRUG|TTX-080|Specified dose (Q2W)
48651439|NCT00257933|DRUG|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
48651440|NCT00257933|DRUG|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
48651441|NCT06571981|DEVICE|TUP ultraportable US with teleradiology capacities|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
48124406|NCT00459212|PROCEDURE|pharmacological study|Correlative study
48651442|NCT06571981|DEVICE|CUS conventional ultrasound|Comparison of abdominal ultrasound examinations in an at-risk population diagnosed with viral hepatitis: Ultraportable ultrasound with teleradiology capacities (TUP) versus conventional ultrasound (CUS).
48651443|NCT02695888|BEHAVIORAL|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
48651444|NCT02695888|BEHAVIORAL|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
48651445|NCT01384045|OTHER|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
48651446|NCT00153790|DRUG|PhosphoLean|
48124407|NCT00459212|PROCEDURE|laboratory biomarker analysis|Correlative study
48124408|NCT05546307|OTHER|SSEP|Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)
48330790|NCT04152642|OTHER|Water control|negative control
48124409|NCT05546307|OTHER|relaxation session|The relaxation session will be performed by one of the 5 nurses trained in relaxation
48124410|NCT06419569|OTHER|high power laser|Sessions will performed with scanning in longitudinal and perpendicular direction on the medial and lateral sides of the knee with Laser scanner machine. handpiece was positioned in contact and perpendicularly while the patient in a supine lying position with the knee flexed at 30° to open the joint surfaces to the laser beam (optical windows). The scanning was performed transversely and longitudinally in the anterior, medial, and lateral aspects of the knee joint with emphasis on the application on the joint line between the tibial and femoral epicondyles. The total energy delivered to the patient during one session was 1,250 J through three phases of treatment. The initial phase is performed with fast manual scanning with a total of 500 J. In the initial phase, the laser fluency is set to two successive subphases of 710 and 810 mJ/cm2 for a total of 500 J.
48330791|NCT04152642|DEVICE|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
48330792|NCT03101748|DRUG|Cyclophosphamide|Given IV
48330793|NCT03101748|DRUG|Doxorubicin|Given IV
48330794|NCT03101748|OTHER|Laboratory Biomarker Analysis|Correlative studies
48330795|NCT03101748|DRUG|Neratinib|Given PO
48330796|NCT03101748|DRUG|Paclitaxel|Given IV
48330797|NCT03101748|BIOLOGICAL|Pertuzumab|Given IV
48330798|NCT03101748|BIOLOGICAL|Trastuzumab|Given IV
48330799|NCT04890106|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
48330800|NCT04890106|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
48651447|NCT04467255|OTHER|Rehabilitative training|4 weeks aerobic treadmill training compared to endurance training with elastic thera band
48651448|NCT03517358|OTHER|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
48124411|NCT06419569|OTHER|low level laser|patients will receive laser with 0.5 W to gain energy density of 6 J/cm2, and total energy of 240 J during one session. LASER apparatus that will be used is Chattanoga Intelect Laser with 850nm wavelength and 200mW power Lasers. Same three phases like HPL with different energy dose. First phase: Fast manual scan 100 J. Second 10 point joint line phase with evey point 14 seconds and 4J to deliver a total of 40 J in this phase. Third phase: Slow manual scan 100 J.
48124412|NCT06419569|OTHER|conventional physical therapy|the patients will receive conventiobal physical therapy in the form of Exercise therapy program (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min with hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg raise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps strengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz frequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients will be placed in a supine position, and the US applied to the medial and lateral parts (5 min on each side) of the knee in circular movements with the probe at right angles to ensure maximum absorption of the energy.
48124413|NCT00799396|DRUG|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
48124414|NCT00799396|DRUG|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
48330801|NCT05668676|DRUG|Prednisone arm|2 tabs of 20 mg prednisone per day during 7 days added to usual care medications
48330802|NCT05668676|OTHER|Usual care|Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
48330803|NCT00961870|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
48330804|NCT02833519|BEHAVIORAL|group exercise|"1. Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~   The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~   The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~2. The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~3. A weekly supportive email."
48330805|NCT05049343|DRUG|SAGE-904|SAGE-904 oral solution.
48330806|NCT05049343|DRUG|Placebo|Placebo oral solution.
48330807|NCT05049343|DRUG|Ketamine|Ketamine intravenous (IV) infusion.
48330808|NCT00628758|DRUG|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
48491904|NCT04738682|OTHER|Digital dietary registration|"The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators."
48491905|NCT04738682|OTHER|Conventional dietary registration|The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
48491906|NCT03924011|DEVICE|Photobiomodulation therapy (PBMT)|PBMT sessions will be planned 2x/week after RT.
48491907|NCT03924011|DEVICE|Sham laser|Sham laser sessions will be applied 2x/week after RT.
48491908|NCT02979236|DEVICE|STENTYS Xposition S|
48651449|NCT04653376|PROCEDURE|Tonsillectomy surgery|The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
48651450|NCT03129997|DIETARY_SUPPLEMENT|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
48330809|NCT00628758|DRUG|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
48330810|NCT00488995|DRUG|CP-675,206|
48330811|NCT01473303|BIOLOGICAL|ganitumab|Given IV
48330812|NCT01473303|DRUG|fluorouracil|Given IV
48330813|NCT01473303|DRUG|irinotecan hydrochloride|Given IV
48330814|NCT01473303|DRUG|leucovorin calcium|Given IV
48330815|NCT01473303|DRUG|oxaliplatin|Given IV
48330816|NCT01473303|OTHER|placebo|Given IV
48330817|NCT01473303|OTHER|questionnaire administration|Completed on paper
48330818|NCT03437317|BEHAVIORAL|Perceptual Retraining|"Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point."
48330819|NCT03437317|BEHAVIORAL|Gender Discrimination|Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
48330820|NCT01450475|PROCEDURE|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
48124415|NCT02543125|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
48124416|NCT02543125|DEVICE|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
48330821|NCT01248403|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
48330822|NCT01248403|DRUG|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
48330823|NCT04662411|DIETARY_SUPPLEMENT|Placebo|acute intake of 0 mg butyrate and hexanoate
48330824|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 1|acute intake of 650 mg butyrate and hexanoate
48330825|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 2|acute intake of 1325 mg butyrate and hexanoate
48330826|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 3|acute intake of 2000 mg butyrate and hexanoate
48330827|NCT02294422|DEVICE|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
48330828|NCT02294422|DEVICE|LOR|
48651451|NCT05545527|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
48651452|NCT05545527|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
48651453|NCT05545527|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
48124417|NCT01766154|DRUG|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
48124418|NCT01737489|BEHAVIORAL|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
48124419|NCT01737489|BEHAVIORAL|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
48330829|NCT02294422|DEVICE|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
48330830|NCT00270413|DRUG|SU11248|sutent 50 mg daily 4w on 2w off
48330831|NCT00293150|DRUG|Eplerenone|
48330832|NCT04205695|PROCEDURE|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
48651454|NCT04805528|RADIATION|Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)|Twice weekly ALTENS therapy for 12 weeks
48330833|NCT04205695|PROCEDURE|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
48124420|NCT00277914|DRUG|Flibanserin|flibanserin flexible dosing
48651455|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fasting condition, 1 tablet at a time, once a day.
48651456|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
47974383|NCT04506021|DRUG|Bicarbonate Ringer's solution|According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
47974384|NCT04506021|DRUG|Other Crystalloid|According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
48330834|NCT04205695|PROCEDURE|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
48651457|NCT00421967|DRUG|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
48651458|NCT00421967|DRUG|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
48124421|NCT06070337|DEVICE|H-Guard|A novel Haemodialyser primer used for one treatment only
48124422|NCT04727840|DRUG|Sodium Zirconium Cyclosilicate Oral Product|"Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly."
48651459|NCT05626335|DIAGNOSTIC_TEST|Intraoral scan|On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0), using 3Shape Trios 4 (3Shape, Copenhagen, Denmark). The scans were repeated after a month. The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3).
48651460|NCT06636669|DRUG|Probiotic|Culturelle probiotic, one capsule daily to start following SOC surgical treatment for PJI during the initial 6 weeks of SOC antibiotic treatment.
48651461|NCT06636669|OTHER|Standard of care|Standard of care (SOC) treatment includes surgery and antimicrobials.
48651462|NCT03347669|DEVICE|Sudoscan®|Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
48330835|NCT02406053|GENETIC|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
47974385|NCT02363517|DRUG|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
47974386|NCT00705653|DRUG|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
47974387|NCT02789709|PROCEDURE|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
47974388|NCT01947205|DRUG|paracetamol|
47974389|NCT01947205|DRUG|dexketoprofen trometamol|
48651463|NCT06674746|BEHAVIORAL|SOLUTION FOCUSED APPROACH|The interviews with the control group were planned as eight sessions. There will be defined time intervals between sessions. It is estimated to take 6 months.
48651464|NCT01817946|OTHER|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
48651465|NCT05301192|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
47974390|NCT01947205|DRUG|suction curettage|
47974391|NCT01947205|DRUG|suction curettage|
48651466|NCT05301192|DRUG|Saline|Saline will be used as the placebo comparator.
48651467|NCT06673732|OTHER|Muscle Energy Technique with Stationary Bi-Cyclying|"MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition.~For PFS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times. Stationary cycling complements the routine."
47974392|NCT01947205|OTHER|without drug|
48124423|NCT04295915|DEVICE|Specimens that meet inclusion criteria|Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
48124424|NCT03903822|DRUG|PF-06700841|PF-06700841 topical cream
48330836|NCT04234763|BEHAVIORAL|Strategies to lower postprandial hyperglycemia in T2D patients|T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.
48330837|NCT04234763|BEHAVIORAL|Control group|Assess nutritional status and no active intervention is conducted.
47974393|NCT04286321|OTHER|Zero hard-boiled egg|No eggs will be consumed on test day
47974394|NCT04286321|OTHER|Two egg whites|Two egg whites will be consumed on test day
47974395|NCT04286321|OTHER|Two hard-boiled eggs|Two eggs will be consumed on test day
47974396|NCT04286321|OTHER|Vegetable oil|Vegetable oil will be consumed on test day
47974397|NCT00652405|DIETARY_SUPPLEMENT|alcohol|250 ml of white wine (13% vol; \~25 gram of alcohol per day)
47974398|NCT00652405|DIETARY_SUPPLEMENT|Placebo|250 ml of mineral water (Brand name: Vittel)
48124425|NCT03903822|DRUG|Vehicle (Placebo)|Vehicle topical cream
48124426|NCT06514937|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
48124427|NCT01185561|BEHAVIORAL|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
48124428|NCT02374307|OTHER|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
47974399|NCT03875885|BEHAVIORAL|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
47974400|NCT03875885|BEHAVIORAL|CONTROL|This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
47974401|NCT01573975|DRUG|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
47974402|NCT01573975|DRUG|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
47974403|NCT01573975|DRUG|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
47974404|NCT04928040|DIAGNOSTIC_TEST|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
48330838|NCT01611766|PROCEDURE|Secondary Cytoreductive Surgery|Complete Cytoreduction
48330839|NCT01611766|DRUG|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
48651468|NCT06673732|OTHER|Muscle Energy Technique without Stationary Cycling|MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition. Post FS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times without Stationary Cycling
48124429|NCT05908669|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
48330840|NCT03104985|DEVICE|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
48651469|NCT05412979|DRUG|ST-1891|ST-1891
48651470|NCT05412979|DRUG|Levothyroxine|Levothyroxine
48651471|NCT04791748|DIAGNOSTIC_TEST|Vestibular tests|Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
48651472|NCT04791748|OTHER|Virtual reality|Virtual reality protocol : doing tasks involving hand-eye coordination, in virtual reality, and in different sensory situations
47974405|NCT01847794|DEVICE|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
47974406|NCT02573350|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
47974407|NCT02573350|DRUG|OBR|Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
48651473|NCT05114057|OTHER|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
48651474|NCT03038919|DRUG|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
48651475|NCT03038919|OTHER|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
48124430|NCT05146271|PROCEDURE|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome|Complete mouth rehabilitation under general anesthesia in a group of Egyptian children with Down syndrome
48124431|NCT00016341|BIOLOGICAL|filgrastim|
48124432|NCT00016341|DRUG|cisplatin|
48124433|NCT00016341|DRUG|doxorubicin hydrochloride|
48124434|NCT00016341|DRUG|megestrol acetate|
48124435|NCT00016341|DRUG|paclitaxel|
48124436|NCT00016341|DRUG|tamoxifen citrate|
48330841|NCT03104985|OTHER|Conventional therapy|"* An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment"
48330842|NCT04178577|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
48330843|NCT05379868|PROCEDURE|Posterior column osteotomy|Apical full facet joint resection. Study intervention does not involve a device.
48330844|NCT05379868|PROCEDURE|No osteotomies|Standard treatment
48330845|NCT01058733|OTHER|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
48330846|NCT06442657|OTHER|Hydrocellular dressing|Application of hydrocellular dressings to at-risk areas prior to prone positioning. Assessment of pressure sores and their stage after prone positioning.
48330847|NCT06442657|OTHER|Hydrocolloids dressing|Application of hydrocolloids dressings to at-risk areas prior to prone positioning.
48330848|NCT05535764|DRUG|Pegylated interferon alpha2a|PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
48330849|NCT03014921|OTHER|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
48651476|NCT02914886|DRUG|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
48651477|NCT02914886|DRUG|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
48651478|NCT05983250|DRUG|TNX-103|oral levosimendan 1 mg
48651479|NCT05983250|DRUG|Placebo|Placebo
47974408|NCT02301494|DRUG|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
47974409|NCT02301494|DRUG|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
47974410|NCT02233816|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
47974411|NCT02233816|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
47974412|NCT02233816|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
47974413|NCT02233816|BIOLOGICAL|Placebo|A single dose of placebo
47974414|NCT05288075|DRUG|Indacaterol/glycopyrronium|"In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration."
48651480|NCT03177798|DRUG|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
48124438|NCT01079065|DRUG|Famotidine|Tablets
48330850|NCT03014921|OTHER|saline solution injection|Injection of a 250mL saline solution
48330851|NCT04724512|DEVICE|suture|a type of suture used in entropion surgery
48330852|NCT04377672|BIOLOGICAL|Anti-SARS-CoV-2 Human Convalescent Plasma|"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."
48330853|NCT06316687|OTHER|questionnaire for food consumption frequency|questionnaire about Food consumption frequency, Screen time , Dental neglect scale
48330854|NCT03448900|BEHAVIORAL|Multicomponent intervention|Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
48330855|NCT03448900|BEHAVIORAL|Brief advice|Brief advice (5-10minutes) and a self-help pamphlet
48330856|NCT04462536|DRUG|Placebo|Vehicle only
47974415|NCT00905697|PROCEDURE|Living donor lung transplantation|Living donor lung transplantation
48330857|NCT04462536|DRUG|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
48330858|NCT05647629|PROCEDURE|Total hip arthroplasty|hip prosthesis surgery
48330859|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
48330860|NCT01579552|BEHAVIORAL|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
48330861|NCT06268587|COMBINATION_PRODUCT|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS \&amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
48330862|NCT01249963|DIETARY_SUPPLEMENT|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
48330863|NCT01249963|DIETARY_SUPPLEMENT|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
48330864|NCT00728936|DRUG|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
48330865|NCT00728936|DRUG|Saline placebo|saline placebo given subcutaneously
48330866|NCT04188002|BEHAVIORAL|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
48651481|NCT03177798|DRUG|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
48330867|NCT04188002|OTHER|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
48330868|NCT03864536|BEHAVIORAL|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
48330869|NCT02773056|DEVICE|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
48330870|NCT02773056|DEVICE|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
48124439|NCT04048382|BEHAVIORAL|Patient Navigation|Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
48330871|NCT02773056|DEVICE|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
48330872|NCT03199638|DRUG|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
48330873|NCT03199638|BEHAVIORAL|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
48330874|NCT06046547|OTHER|Pulmonary rehabilitation integrating education about palliative care|"PR will include exercise training twice a week, and education and psychosocial support once per week during 12 weeks.~The intervention will include an education session on palliative care, a Peer-to-peer session, a Get-apart session and online sessions.~The education session on palliative care will be facilitated by two specialist healthcare professionals. The main topics that will be discussed are: concept of palliative care, symptom control, disease impact, psychosocial support and planning for the future.~Participants will be the primary communicators in the Peer-to-peer session, and the dialogue will be based on their suggestions. Those who feel more reluctant to reveal private thoughts in front of their loved ones will have the opportunity to discuss their issues in a Get-apart environment.~Individual cases will be referred to a specialist palliative care team or to any other health/social care professional according to the unmet needs identified."
48330875|NCT06046547|OTHER|Pulmonary rehabilitation|"Participants will receive the same PR program as the experimental group besides the education session on palliative care, the Peer-to-peer session, the Get-apart session and the online sessions (i.e. traditional pulmonary rehabilitation)."
48330876|NCT05247385|DRUG|Prasugrel|Compared platelet inhibition and adenosine levels at baseline and after 15 days
48330877|NCT05247385|DRUG|Ticagrelor|Compared platelet inhibition and adenosine levels at baseline and after 15 days
48330878|NCT00990249|DRUG|Busulfan|Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
48330879|NCT00990249|DRUG|Clofarabine|40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
48330880|NCT00990249|DRUG|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
48491909|NCT06004219|BEHAVIORAL|Peer counseling group|A community advisory board (CAB) will be set up for need assessment and to design the peer support program. Virtual meetings will be held quarterly for year 1 and 2. The group will consist of (up to 12 members) and will include at least 2 patient partners (patients with a recently diagnosed ulcer), 2 peer pals (patients with a healed DFU), family members or caregivers (limited to only 1 person per family represented on the CAB), healthcare workers (podiatrist, nurse, or case manager), medical equipment company representatives, and others. We will ask them about potential barriers at the first meeting, have flexible meeting times, and intentionally limit the number of healthcare providers. At the last meeting, we will seek feedback and input from the CAB. In addition, this group will have the opportunity to participate in a focus group which will be moderated with a trained, bilingual assistant and will last 40-60 minutes.
47974416|NCT05092724|PROCEDURE|fetal blood transfusion|transfusion of fetal blood
47974417|NCT03647033|DEVICE|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
48330881|NCT00990249|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
48330882|NCT06174883|DIETARY_SUPPLEMENT|Folic acid fortified iodized salt|addition of folic acid to iodized salt to be consumed daily and assess rise in serum folate levels.
48330883|NCT06252857|DRUG|Imiquimod Topical|Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
48330884|NCT02521298|OTHER|Strength Training|
48330885|NCT02521298|PROCEDURE|Placebo|
48330886|NCT02521298|DRUG|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
48330887|NCT02521298|PROCEDURE|Dry Needling|
48330888|NCT00520637|DRUG|EZN-2208|
48651482|NCT05286112|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
48651483|NCT05286112|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
48651484|NCT03464461|DRUG|Ketorolac|IV drug
48651485|NCT00979758|DRUG|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
48330889|NCT05279105|BEHAVIORAL|Program support|The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
47974418|NCT02206334|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
47974419|NCT01831193|DRUG|Curcumin|
48330890|NCT03783338|COMBINATION_PRODUCT|Aerobic exercises and Vitamin D supplementation|"Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks."
48491910|NCT01194336|DRUG|Huperzine A|dosage form: tablet dose frequency: once only
48491911|NCT01194336|DRUG|Donepezil|dosage form: tablet dosage frequency: once only
48491912|NCT01194336|DRUG|Galantamine|dosage form: tablet dosage frequency: once only
47974420|NCT04676282|OTHER|Hypothetical Scenario|Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
47974421|NCT05850572|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
48491913|NCT01194336|OTHER|Placebo|dosage form: tablet dosage frequency: once only
48491914|NCT02909738|OTHER|Volunteer to pedal a bicycle|
48651486|NCT04067622|DEVICE|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
48651487|NCT06608732|BIOLOGICAL|Inaticabtagene autoleucel|CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.
48651488|NCT00489359|DRUG|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
48651489|NCT00489359|DRUG|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
48124440|NCT04048382|OTHER|Usual Care|The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
48124441|NCT06298305|DEVICE|Quantib prostate (Quantib B.V. Rotterdam, The Netherlands) software|Quantib Prostate is an AI-driven solution that provides an intuitive workflow for assessment of prostate MRI. The product integrates essential prostate MRI reading features into one workflow making it easy for the user to read, assess and report each patient case from within the same software interface. With automatic forwarding in place, the software preprocesses the MRI right after scanning. This allows the user to access calculations and analysis immediately when they open the software interface. Thanks to these features, the professional may experience an accelerated workflow, making it easier to manage their heavier workload.
48124442|NCT03427021|DRUG|Oxaliplatin|Infusion
47974422|NCT05850572|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
48124443|NCT04005287|DRUG|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
48124444|NCT04005287|DRUG|WST-057 (4% pirenzepine) High Dose 4mL|Topical Solution
48124445|NCT04005287|DRUG|Placebo Low Dose|Topical Solution
48124446|NCT04005287|DRUG|Placebo High Dose|Topical Solution
48124447|NCT03071081|DRUG|TOP1288|Oral TOP1288
48124448|NCT03071081|DRUG|Placebo to TOP1288|Oral placebo to TOP1288
48124449|NCT05004558|OTHER|Remote-based Resistance Exercise Training|All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
48330891|NCT02213822|OTHER|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
47974423|NCT02788357|DRUG|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
47974424|NCT02788357|DRUG|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
47974425|NCT03766308|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet
47974426|NCT03766308|DIETARY_SUPPLEMENT|ADA diet|ADA diet
48124450|NCT03741517|RADIATION|18F-FDG-PET|Fludeoxyglucose F18
48124451|NCT03741517|RADIATION|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
48330892|NCT01225757|DEVICE|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
48491915|NCT02533375|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
47974427|NCT00005589|BIOLOGICAL|filgrastim|
47974428|NCT00005589|BIOLOGICAL|rituximab|
47974429|NCT00005589|DRUG|carmustine|
48124452|NCT03741517|RADIATION|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
48651490|NCT00489359|DRUG|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
47974430|NCT00005589|DRUG|cyclophosphamide|
48124453|NCT03741517|OTHER|Core needle biopsy|Core needle biopsy of metastatic lesions
47974431|NCT00005589|DRUG|cytarabine|
47974432|NCT00005589|DRUG|etoposide|
47974433|NCT00005589|DRUG|melphalan|
47974434|NCT00005589|PROCEDURE|bone marrow ablation with stem cell support|
47974435|NCT00005589|PROCEDURE|peripheral blood stem cell transplantation|
47974436|NCT04497805|BIOLOGICAL|ALLO-ASC-SHEET|Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
47974437|NCT01191398|DRUG|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
48124454|NCT03741517|OTHER|Phlebotomy|Phlebotomy from peripheral vein
48124455|NCT00971269|DEVICE|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
48124456|NCT01739270|PROCEDURE|supraclavicular brachial plexus block|
48124457|NCT04149808|DEVICE|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
48124458|NCT04149808|DEVICE|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
48124459|NCT05469841|OTHER|Systemic pain assessment|Pain will be evaluated via i) pupillometry with 3 successive measurements ii) Behaviour Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT) score evaluated by an investigator (physician) iii) evolution of physiological parameters (ie heart rate, blood pressure, respiratory rate) iv) Nociception Level Index (NOL) index.
48491916|NCT05931666|OTHER|Gong Mobilization|"Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
48330893|NCT03763799|PROCEDURE|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
48330894|NCT03763799|PROCEDURE|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
48330895|NCT03055572|OTHER|Olfactory Training with Essential Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
48330896|NCT03055572|OTHER|Olfactory Training with Pure Fragrance Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
48330897|NCT04687488|OTHER|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
48330898|NCT04687488|OTHER|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
47974438|NCT01191398|DRUG|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
47974439|NCT01191398|DRUG|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
47974440|NCT03647982|DRUG|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
47974441|NCT03647982|DRUG|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
47974442|NCT02810860|PROCEDURE|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
47974443|NCT00603889|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
47974444|NCT02475746|DRUG|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
47974445|NCT02475746|DRUG|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
47974446|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 8 Gy|
47974447|NCT02811250|RADIATION|Stereotactic radiotherapy 5 x 8 Gy|
47974448|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 10 Gy|
47974449|NCT02811250|RADIATION|Stereotactic radiotherapy 4 x 12 Gy|
47974450|NCT04188327|PROCEDURE|Stellate ganglion block|"While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
48330899|NCT03027843|DRUG|Growth Hormone|in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
48330900|NCT04006535|GENETIC|genetic analysis|Saliva sample collection for genetic analysis
47974451|NCT04188327|PROCEDURE|Sham Stellate ganglion block|"The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day for 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours"
47974452|NCT04580667|OTHER|Collection of plasma samples|Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
47974453|NCT04773483|DIETARY_SUPPLEMENT|Quorn Foods products|180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
47974454|NCT04773483|DIETARY_SUPPLEMENT|Meat/fish products|Standard meat/fish products matched to Quorn group for protein intake
48124460|NCT05382754|DIAGNOSTIC_TEST|Home sleep apnea test|Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.
48124461|NCT05382754|DIAGNOSTIC_TEST|In-lab polysomnography|Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
48330901|NCT02666508|OTHER|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
48330902|NCT02666508|OTHER|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
48651491|NCT00489359|DRUG|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
48124462|NCT00654316|BIOLOGICAL|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
48124463|NCT02424071|DRUG|Melatonin|
48330903|NCT03206112|OTHER|PAS25|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
48124464|NCT02424071|DRUG|placebo|
48124465|NCT05779215|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
48330904|NCT03206112|OTHER|PAS10|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
48330905|NCT03206112|OTHER|PAS25-cTBS150|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
48330906|NCT00789646|PROCEDURE|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
47974455|NCT01471236|DEVICE|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
48124466|NCT01505712|GENETIC|gene expression analysis|
48124467|NCT01505712|OTHER|laboratory biomarker analysis|
48330907|NCT00789646|PROCEDURE|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
48330908|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles \>=17 mm)
48330909|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period \[S6\]) until r-hCG day (at least 2 follicles \>=19 mm)
48330910|NCT01185704|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
48330911|NCT01185704|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
48330912|NCT01928563|DRUG|Dapoxetine|
48330913|NCT01928563|DRUG|Udenafil|
48330914|NCT01928563|DRUG|Udenafil+Dapoxetine|
48330915|NCT02294006|DRUG|Everolimus plus Octreotide LAR plus Metformin|Everolimus plus Octreotide LAR plus Metformin
48330916|NCT06108128|OTHER|Executive functioning observational tasks|Interventions take place solely at the measurement level, where children will be seen in observational tasks of general executive functioning and executive functioning around eating in which various food and non-food stimuli are presented and children's responses to task instructions are recorded.
48330917|NCT04732819|BEHAVIORAL|High touch multi-pronged behavioral intervention|"In this intervention, facilities will work with our research team to accomplish the following:~1. Identify and engage a Facility Opinion Leader.~2. Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~3. Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~4. Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~5. Acquire additional COVID-19 testing kits using funds provided by our research team."
48330918|NCT04920539|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.03 mg/kg) administered intravenously.
47974456|NCT01471236|PROCEDURE|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
47974457|NCT00948987|DRUG|Aspirin|325 mg enteric coated single dose p.o.
48330919|NCT00222417|PROCEDURE|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
48330920|NCT00222417|PROCEDURE|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
48330921|NCT05456412|OTHER|JAK inhibitor treatment|Standard care
48124468|NCT01886729|OTHER|transcranial direct current stimulation (tDCS)|
48124469|NCT06221436|BEHAVIORAL|Mental Imagery|"Olfactory mental imagery is the ability to detect an odor in the absence of any odor stimulus.~Participants will be asked to choose their 4 favorite fragrances from 20 different scents (such as rose, lavender scent) determined by the researcher and proven to have positive effects on mind-body therapy. The determined odors will be visualized by the researcher and picture cards measuring 15X12 cm (for example, a card with a rose picture for the rose smell, etc.) will be created. Participants will visualize the smell by looking at the picture cards, so they will be expected to make their breathing exercises more effective. Vagus breathing technique will be combined with olfactory mental imagery."
48124470|NCT04513314|DRUG|Valproate|Valproate sodium (enteral or intravenous) will be administered at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day.
48330922|NCT02409758|BEHAVIORAL|Voice therapy|Voice therapy applied during 6 weeks.
48651492|NCT06107413|DRUG|ABBV-400|Intravenous (IV) Infusion
48651493|NCT06107413|DRUG|Bevacizumab|IV Infusion
48651494|NCT06107413|DRUG|Folinic Acid|IV Infusion
48651495|NCT06107413|DRUG|Fluorouracil|IV Infusion
48651496|NCT06107413|DRUG|Irinotecan|IV Infusion
48330923|NCT00220584|DRUG|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
48330924|NCT00453856|DRUG|Sulfadoxine Pyrimethamine|
48330925|NCT03457480|OTHER|Computer-Assisted Intervention|Read computer messages
48330926|NCT03457480|BEHAVIORAL|Focus Group|Attend focus group
48491917|NCT05931666|OTHER|Kaltenborn Mobilization|"Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks."
48491918|NCT01356784|OTHER|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
48491919|NCT01356784|BEHAVIORAL|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
47974458|NCT00990236|DRUG|Enoxaparin dose adjusted Lovenox based on TEG|Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.
47974459|NCT00990236|DRUG|Enoxaparin 30 mg BID|Enoxaparin dose of 30 mg twice a day without any adjustments
48491920|NCT01356784|BEHAVIORAL|Health counselling|Health guidance (1,5h)
47974460|NCT02698839|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
47974461|NCT02698839|DEVICE|BuMA™|Stent platform: stainless steel
47974462|NCT05549570|DRUG|Sitagliptin/Metformin HCl 50/850 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
47974463|NCT01937728|DRUG|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA \< 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
47974464|NCT01937728|DRUG|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
47974465|NCT01937728|DRUG|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
47974466|NCT01937728|DRUG|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
47974467|NCT01937728|DRUG|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
47974468|NCT01937728|DRUG|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
47974469|NCT00247091|BIOLOGICAL|standard-titer measles vaccine|
47974470|NCT03124875|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
47974471|NCT02775721|OTHER|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
47974472|NCT02775721|OTHER|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
48330927|NCT03457480|OTHER|Informational Intervention|Receive text messages
48330928|NCT03457480|OTHER|Survey Administration|Complete surveys about experience
48330929|NCT02540772|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
48330930|NCT06368791|BEHAVIORAL|Box Breathing|Participants are guided to find a quite and comfortable spot to sit and unwind. They are then directed to inhale deeply for four seconds, hold that breath for another four seconds, and then exhale slowly over four seconds. Following a brief four-second pause, they begin the next cycle of breathing. To assist with this exercise, participants will have access to a video featuring a red dot tracing a square pattern, moving at the pace needed for the breathing technique.
48330931|NCT06368791|BEHAVIORAL|Breathing and Mindfulness Exercise|The second intervention involves a 10-minute session of guided breathing exercises that blend elements of mindfulness meditation with gentle body movements and controlled breathing. Participants are advised to find a quiet space, sit comfortably, and adopt an upright posture. They are then led through a series of brief exercises, incorporating mild stretches for the upper body and focused, mindful breathing.
48491921|NCT03277209|DRUG|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
48651497|NCT06060509|DIETARY_SUPPLEMENT|Phytosterol-rich Wheat and Corn Germ Blended Oil|Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.
48330932|NCT06368791|BEHAVIORAL|Everyday life control|Participants are instructed to not perform the anti-stress intervention and to proceed with their daily activities as usual.
48651498|NCT06060509|DIETARY_SUPPLEMENT|Peanut oil|Participants in the control group consumed peanut oil daily for cooking.
48651499|NCT06672809|BEHAVIORAL|Core Stability Training|Participants in this group undergo core stability training sessions targeting deep stabilizing muscles. The exercises are designed to enhance spinal support and core control by activating the transversus abdominis and other core muscles. Sessions involve the use of a Pilates reformer and other unstable surfaces, fostering proprioceptive engagement and improved muscle coordination. Training is conducted three times per week for eight weeks, with each session lasting 50 minutes.
48651500|NCT06672809|BEHAVIORAL|Aerobic Exercise|Participants in this group engage in aerobic exercise sessions that consist of warm-up, controlled-intensity walking, and a cool-down phase. This intervention serves as a comparative baseline, aiming to improve cardiovascular endurance without specifically targeting core stability. The aerobic routine is adjusted over time to increase exercise intensity, conducted three times per week for eight weeks, with each session lasting 50 minutes.
47974473|NCT02775721|OTHER|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
47974474|NCT02775721|OTHER|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
47974475|NCT02775721|OTHER|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
47974476|NCT02918175|BEHAVIORAL|mHealth|Personalized step count feedback and medication teaching tool.
48491922|NCT03826498|BIOLOGICAL|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
48491923|NCT03826498|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training etc.
48491924|NCT05009732|DRUG|GT0918|300mg once daily orally
48491925|NCT05009732|DRUG|Standard of care|Local standard of care per written policies or guidelines
48491926|NCT05009732|DRUG|Matching placebo|Matching placebo
48491927|NCT04177563|OTHER|whole body cryostimulation|Whole-body cryotherapy
48491928|NCT05438407|DRUG|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
48491929|NCT04525638|DRUG|177Lu-Dotatate|7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
48491930|NCT04525638|DRUG|Nivolumab|240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
48491931|NCT01825889|DRUG|Evacetrapib|
48491932|NCT01957566|PROCEDURE|APS|
48491933|NCT04866849|OTHER|examination|"The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
48330933|NCT01771367|BIOLOGICAL|Fluad|
48330934|NCT01771367|BIOLOGICAL|Agrippal|
48330935|NCT01771367|BIOLOGICAL|Placebo|
48491934|NCT00937482|DRUG|cediranib maleate|Given orally
48491935|NCT00937482|RADIATION|whole-brain radiation therapy|Undergo whole-brain radiotherapy
48491936|NCT01764230|DRUG|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
48491937|NCT05124561|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
48491938|NCT05124561|BIOLOGICAL|Placebo|Nebulized inhalation through the mouth
48491939|NCT06037226|BEHAVIORAL|Postpartum pelvic floor rehabilitation|biofeedback with Pelvic floor muscle training (PFMT)
48491940|NCT02771795|DRUG|Herceptin (trastuzumab)|Intravenous administration
48491941|NCT02771795|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
48491942|NCT03297671|DRUG|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
48491943|NCT03297671|DEVICE|ELDONCARD|ELDONCARD point-of-care test.
48491944|NCT03297671|DIAGNOSTIC_TEST|ELDONCARD Test|LHVs will perform ELDONCARD test.
48491945|NCT04969718|OTHER|LEADS Plus educational posters|This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms
48651501|NCT04044820|DRUG|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
48491946|NCT04969718|OTHER|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.
48651502|NCT03371225|DEVICE|Active tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
48651503|NCT03371225|PROCEDURE|Active Exercise|Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
48330936|NCT03838367|DRUG|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
48491947|NCT04969718|OTHER|Screening by Professionals programme plus educational posters|This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.
47974477|NCT04811989|BEHAVIORAL|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
47974478|NCT04811989|BEHAVIORAL|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
47974479|NCT04811989|BEHAVIORAL|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
48330937|NCT03838367|DRUG|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
48651504|NCT03371225|DEVICE|Sham tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
48330938|NCT03838367|DRUG|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
48330939|NCT03838367|DRUG|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
48330940|NCT03838367|DRUG|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
48330941|NCT02667457|RADIATION|99mTc-rhAnnexin V-128|
48330942|NCT02562950|DRUG|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
48330943|NCT02562950|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
48330944|NCT02562950|DRUG|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
48491948|NCT04969718|OTHER|educational posters|Six educational posters will be displayed in all schools in this cluster.
48124471|NCT04513314|DRUG|Quetiapine|Enteral quetiapine dosing on Day 3: 25 mg to 50 mg twice daily. Increase in increments of 50 mg/day to 100 mg/day divided two on Days 4 and 5 to range of 50-400 mg/day by Day 7. Further adjustments can be made in increments of 25-50 mg twice a day, in intervals of not less than 2 days. Recommended dose range is 150-750 mg/day.
47974480|NCT04811989|BEHAVIORAL|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
47974481|NCT01661296|OTHER|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
47974482|NCT01661296|DRUG|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
47974483|NCT02480023|RADIATION|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
47974484|NCT05144360|DRUG|Atenas|ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
47974485|NCT05144360|DRUG|Atenas placebo|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
47974486|NCT01877434|PROCEDURE|Reversed shoulder arthroplasty|
47974487|NCT03764501|DEVICE|Image fusion system|Image fusion system for the 3D preoperative planning
47974488|NCT03178877|OTHER|No intervention|
47974489|NCT06506201|DEVICE|Velys hip navigation|Computer assisted surgery
47974490|NCT06506201|PROCEDURE|Standard of care|surgery without navigation
47974491|NCT02246660|DRUG|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
47974492|NCT02246660|DRUG|Placebo|Placebo will be taken orally for 6 months.
48124472|NCT04513314|OTHER|Standard of Care|Standard of Care is a combination of IV dexmedetomidine (D), midazolam (M), ketamine (K) and propofol (P), at the discretion of treating physician.
48124473|NCT00355095|DRUG|Erythropoietin|intravenous daily 3.3 \*10\^4 Units, duration 3 days
48124474|NCT00957242|DRUG|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
48330945|NCT05564442|DRUG|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
48491949|NCT04969718|OTHER|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.
48491950|NCT00614926|DRUG|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
47974493|NCT05623098|DIETARY_SUPPLEMENT|dietary fiber nutrients|Whether to add nutrients containing dietary fiber
47974494|NCT03019822|DRUG|LSD|100ug per os, single dose
47974495|NCT03019822|DRUG|MDMA|125mg per os, single dose
47974496|NCT03019822|DRUG|Amphetamine|40.3mg per os, single dose
47974497|NCT03019822|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs
47974498|NCT01115634|BIOLOGICAL|Fibroblast|20 million cell in three injection
47974499|NCT01115634|BIOLOGICAL|fibroblast and gel|20 million cell in three injection plus filler
47974500|NCT02155608|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
47974501|NCT02155608|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
48330946|NCT05564442|DEVICE|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
48330947|NCT05564442|DRUG|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
48330948|NCT05564442|OTHER|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
48651505|NCT03371225|PROCEDURE|Sham Exercise|Participants will walk in a treadmill (as to keep at 10% within their baseline heart rate) for 30 minutes.
48124475|NCT00957242|DRUG|placebo|Oral placebo (1mg or 2.5mg)
48124476|NCT03580135|DRUG|Propolis|One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
48124477|NCT03580135|DRUG|Mineral Trioxide Aggregate|MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
48124478|NCT03664960|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
48124479|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
48124480|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
48124481|NCT01923480|DRUG|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
48124482|NCT00752713|PROCEDURE|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
48124483|NCT05391464|PROCEDURE|Peripheral Nerve Block|Utilized preoperatively with sedation during surgery, or postoperatively for additional anesthesia after GA.
48124484|NCT01254188|DRUG|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
48124485|NCT01464034|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
48124486|NCT01464034|DRUG|Pomalidomide|PO daily on Days 1-21, every 28 Days
48124487|NCT01464034|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
48124488|NCT05339113|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|Patients are scanned 10 minute, 30 minute and 1 hour after 68Ga-FAPI-46 as well as one hour 18-FDG injection within 2-3 days interval.
48124489|NCT04250935|DIAGNOSTIC_TEST|Patients with cognitive dysfunction|Mini Mental Test Those with a score below 21 points
48124490|NCT06075524|PROCEDURE|Biospecimen Collection|Undergo blood and optional stool/tissue sample collection
48124491|NCT06075524|OTHER|Electronic Health Record Review|Medical records are reviewed
48124492|NCT06522958|DIETARY_SUPPLEMENT|High Dissolving Transitional Food|Transitional foods are solid foods that rapidly change texture in the presence of moisture (e.g., water or saliva) or temperature change. Duration of consumption of the investigational agent will include the time of the surgery until the second post-operative evaluation. This is estimated to be approximately 1-2 months in total.
48124493|NCT04164459|DRUG|Xalost S|One drop one times a day in study eye
48124494|NCT04164459|DRUG|Xalatan|One drop one times a day in study eye
48124495|NCT04164459|DRUG|Taflotan-S|One drop one times a day in study eye
48124496|NCT04187599|DEVICE|Paragon CRT®100 Contact Lens|Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.
48124497|NCT01782170|DRUG|Iocide Oral Rinse|
48124498|NCT01782170|DRUG|Placebo|
48124499|NCT04542005|BEHAVIORAL|q3h albuterol|Using q3h albuterol as discharge criteria from hospital
48124500|NCT03324945|BEHAVIORAL|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
48124501|NCT04997213|OTHER|Biofeedback exercises|Biofeedback system is a center of pressure-controlled video game-based exercise system designed for patients with neurological and orthopedic diseases and provides balance training using auditory, visual, and pressure biofeedback. The system contains several games, each designed to focus on a different component of balance. Biofeedback is provided by means of a monitor in front of the patient. The balance exercises program was involved a total of 18 sessions, each lasting 20 min, three times a week for six weeks, and was individually tailored based on the patient's tolerance and current motor and sensorial capacities. All patients performed conventional exercises.
48124502|NCT04997213|OTHER|Conventional Exercises|Classic balance exercises were performed (two-leg stance, semi-tandem stance, tandem stance, standing on one leg, tandem walking, turning completely around, heel-to-toe stance, and standing with the eyes closed). Patients with balance disorder first could be commenced balance training in a seated position before progressing to standing exercises, to the extent that these could be tolerable.
48124503|NCT01037634|DRUG|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
48124504|NCT01932203|DRUG|aspirin|100mg once a day
48124505|NCT01932203|DRUG|cilostazol|200mg once a day
48124506|NCT00450359|PROCEDURE|breast imaging study|
48124507|NCT00450359|PROCEDURE|comparison of screening methods|
48124508|NCT00450359|PROCEDURE|radiomammography|
48124509|NCT04748575|DIETARY_SUPPLEMENT|Acai smoothie|Smoothie containing 150g acai pulp
48124510|NCT04748575|DIETARY_SUPPLEMENT|Placebo smoothie|Control smoothie matched nutritionally (macronutrients) and sensorially to the acai smoothie.
48124511|NCT02231983|GENETIC|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
48330949|NCT02174861|DRUG|Erenumab|Administered by subcutaneous injection once a month
48124512|NCT00484055|DRUG|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
48124513|NCT00484055|PROCEDURE|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
48124514|NCT03764475|DRUG|Roflumilast|Roflumilast cream 0.3% for topical application
48124515|NCT03201822|OTHER|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
48124516|NCT03201822|OTHER|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
48124517|NCT03201822|OTHER|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
48124518|NCT03201822|OTHER|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
48124519|NCT02810236|PROCEDURE|Ultrasound|Ultrasound will be performed.
48124520|NCT02810236|BEHAVIORAL|Discussion|Radiologist will discuss with the patient the findings on mammogram.
48330950|NCT03129412|RADIATION|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
48651506|NCT04789681|DRUG|Canakinumab|Given SC
48330951|NCT05414149|PROCEDURE|preoperative intravitreal injections of ranibizumab or conbercept|IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
48330952|NCT05146583|PROCEDURE|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
48330953|NCT05146583|PROCEDURE|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
48330954|NCT01309867|DEVICE|Investigational Toric Lens|Bausch \& Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.
48330955|NCT01309867|DEVICE|PureVision Toric Lens|Currently marked Bausch \& Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
48330956|NCT01342952|DRUG|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
48330957|NCT02151682|DRUG|Tapentadol prolonged release|
48124521|NCT06423534|BEHAVIORAL|Breastfeeding Health Educational Program|Breastfeeding is a mother's priceless gift to her infant and nature's own method of nurturing a baby. Therefore, this study will be conducted to evaluate the primigravida mother's breastfeeding's knowledge, attitude and corrective technique through the implementation of an educational program and to ascertain the efficacy of such a program.
48124522|NCT04404166|BEHAVIORAL|PINGS 2|Home BP monitoring, medication reminders using phone alerts, and patient education on hypertension, cardiovascular risk reduction \& stroke
48491951|NCT00614926|DRUG|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
48124523|NCT03671252|DRUG|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
48124524|NCT03671252|DRUG|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
48330958|NCT02151682|DRUG|Morphine prolonged release|
48330959|NCT02790463|BEHAVIORAL|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
48330960|NCT01610206|DRUG|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
48330961|NCT01610206|DRUG|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
48330962|NCT03364634|DIAGNOSTIC_TEST|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
48124525|NCT03671252|OTHER|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
48124526|NCT03671252|PROCEDURE|TME operation|TME operation
48124527|NCT03671252|PROCEDURE|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
48124528|NCT05334199|DEVICE|Biodegradable stent|Bronchoscopic placement of biodegradable stent in patients with airway complications after lung transplant
48124529|NCT02639286|DRUG|ISIS 304801|300 mg of ISIS 304801 administered as SC
48124530|NCT02639286|DRUG|Placebo|Placebo administered via SC
48124531|NCT00541268|DEVICE|ICD|Intracardioverter defibrillators from 2 different manufacturers
48124532|NCT00541268|OTHER|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
48330963|NCT01315002|DRUG|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
48330964|NCT01315002|DRUG|Placebo patch|Placebo patch
48330965|NCT06257329|OTHER|register|Multicentre prospective observational register
48330966|NCT00436982|DEVICE|Cemented Triathlon total knee system|Orthopaedic implant
48330967|NCT00436982|DEVICE|Duracon total knee system|Orthopaedic implant
48330968|NCT00110474|DRUG|Glucosamine sulfate|
48651507|NCT04789681|OTHER|Quality-of-Life Assessment|Ancillary studies
48124533|NCT03440034|DRUG|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
48124534|NCT04884295|DRUG|XVR011|Single dose of XVR011 via intravenous (IV) infusion
48124535|NCT03888768|DRUG|MonoFer|Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
48124536|NCT00452270|DRUG|Xylometazoline|
48124537|NCT01522898|PROCEDURE|AV nodal ablation|Percutaneous catheter ablation of the AV node.
48124538|NCT01522898|DRUG|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
48330969|NCT00110474|DRUG|Acetaminophen|
48330970|NCT06036641|DEVICE|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
48330971|NCT06036641|DEVICE|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
48330972|NCT06036641|OTHER|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
48330973|NCT04600687|OTHER|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
48330974|NCT04384432|OTHER|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
48330975|NCT04384432|OTHER|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
48330976|NCT03071380|DRUG|Repatoxaban|1 tablet contains 10 mg rivaroxaban
48330977|NCT03071380|DRUG|Xarelto|1 tablet contains 10 mg rivaroxaban
48330978|NCT06314165|OTHER|music medicine practice|Music medicine will be applied
48491952|NCT04948580|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
48491953|NCT06213714|DEVICE|5G Tele-Robotic-Assisted PCI|The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
48491954|NCT01776463|DRUG|Z-360|
48491955|NCT01776463|DRUG|placebo|
48491956|NCT03918109|DRUG|OTO-313|single intratympanic injection of gacyclidine
48491957|NCT03918109|DRUG|Placebo|single intratympanic injection of placebo
48330979|NCT02532426|PROCEDURE|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
48330980|NCT04670224|OTHER|QLB anesthesia|The QLB is a bilateral locoregional anesthesia technique, performed after surgery, under general anesthesia and in right and then left lateral decubitus.
48330981|NCT04670224|OTHER|Intravenous anesthesia without QLB|only intravenous anesthesia
48491958|NCT02658565|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
48491959|NCT04659252|OTHER|n/a - samples collected along routine care samples only|This is a non-interventional study.
48491960|NCT00390130|DRUG|Pentacel (DPTaP+Hib)|
48491961|NCT00390130|DRUG|Prevnar (conjugated pneumococcal vaccine)|
48491962|NCT05515016|PROCEDURE|chin enhancement with a fatty flap sculpted from the double chin|Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
48491963|NCT03966482|BEHAVIORAL|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
47974502|NCT04047498|DEVICE|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
48330982|NCT04250376|DEVICE|Focused Transcranial Ultrasound|The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).
48330983|NCT03179930|DRUG|Entinostat|All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
48330984|NCT03179930|DRUG|Pembrolizumab|pembrolizumab 200 mg IV on D1
48330985|NCT02356640|PROCEDURE|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
48330986|NCT02356640|PROCEDURE|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson \&Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
47974503|NCT04497688|DRUG|PEG-rhG-CSF|Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
47974504|NCT05218460|DEVICE|MRI examination|All subjects (healthy and pathological subjects) will have an MRI examination with a component of the MRI system under development.
47974505|NCT00540826|DRUG|Atomoxetine|in-label use
48330987|NCT02356640|DEVICE|Olympus UM 2000|
47974506|NCT00540826|DRUG|stimulants (any approved ADHD medication)|in-label use
47974507|NCT01485237|OTHER|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
47974508|NCT03275376|DRUG|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
47974509|NCT03275376|DRUG|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
47974510|NCT05324553|PROCEDURE|Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
47974511|NCT05324553|DIAGNOSTIC_TEST|Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
47974512|NCT05324553|DIAGNOSTIC_TEST|Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
47974513|NCT04350489|OTHER|Non-surgical periodontal treatment|Conventional non-surgical periodontal treatment were performed
47974514|NCT05276401|DRUG|5% Bisphosphocin Topical Gel|Topical Gel
47974515|NCT05276401|DRUG|Placebo Topical Gel|Topical Gel
47974516|NCT05276401|DRUG|10% Bisphosphocin Topical Gel|Topical Gel
47974517|NCT05984160|OTHER|Paragastric neural block|A block method used to control patients' symptoms of pain, nausea and vomiting after surgery.
47974518|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
47974519|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
47974520|NCT02300532|OTHER|No intervention|
47974521|NCT05809401|BEHAVIORAL|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
47974522|NCT05809401|BEHAVIORAL|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
47974523|NCT01158300|DRUG|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
47974524|NCT05606497|DRUG|Corticosteroid|Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
47974525|NCT02269241|DRUG|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
47974526|NCT00672867|DRUG|Clevudine|30mg
47974527|NCT00672867|DRUG|Adefovir dipivoxil|10mg
47974528|NCT03767816|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus
48330988|NCT02356640|DEVICE|B-D Quincke Type Point|
48330989|NCT02356640|DRUG|Levobupivacaine|
48330990|NCT01565434|OTHER|CR1 impact|
48330991|NCT05243277|OTHER|Oculomotor tests|"There will be four visits. Each visit is associated with a different exposure in terms of level of oculomotor conflict.~At each visit, several oculomotor tests will be performed, followed by a comfort questionnaire. The oculomotor tests are subjective tests during which the participant will be asked to fix his/her eyes on one or more targets that can move in space and to indicate the way he/she perceives this/these target(s). Depending on the test, lenses may be inserted between the participant and the target to modify his/her perception.~The comfort questionnaire consists to rate on a scale of 1 (not at all) to 5 (very much) the presence of visual symptoms, such as burning, watering or dryness.~The participant will then have to perform four different perceptual tasks. His/her level of accommodation (i.e. focus) will be monitored throughout the tasks.~Each exposure is followed again by eye tests and a comfort questionnaire."
47974529|NCT03767816|DRUG|Ultrasound erector spinae plane block|Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
47974530|NCT04094363|OTHER|Product A|Usual Brand, filtered combustible cigarette
47974531|NCT04094363|OTHER|Product B|CSD1902-11, an electronic nicotine delivery system
47974532|NCT04094363|OTHER|Product C|CSD1902-21, an electronic nicotine delivery system
47974533|NCT04094363|OTHER|Product D|4mg Nicotine gum
47974534|NCT01211327|DRUG|Cyclosporine A|Cyclosporine 2% eye drops
47974535|NCT01211327|DRUG|Dexamethasone|Dexamethasone 0,1% eye drops
47974536|NCT01842074|DRUG|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
47974537|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.
47974538|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
47974539|NCT02157467|DRUG|BMS-955176|
47974540|NCT02157467|DRUG|Ortho Cyclen|
48124539|NCT02505321|OTHER|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
48124540|NCT02505321|PROCEDURE|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
48330992|NCT04645862|DIAGNOSTIC_TEST|CT scans|4D CTA imaging
48651508|NCT06571929|OTHER|INTERACT|INTERACT is an individualized, task-specific training program that includes environmental enrichment, natural and augmented realities, and active training.
48330993|NCT04915326|PROCEDURE|rectal resection|every patients will undergo to the appropriate rectal resection
48330994|NCT02476344|OTHER|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~1. sack carrying exercise.~2. crawling exercise.~3. combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
48330995|NCT01602549|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
48330996|NCT01602549|DRUG|Placebo|matching placebo tablet
47974541|NCT00205738|DRUG|Risperidone, Olanzapine|
47974542|NCT01502059|OTHER|Pilates|Pilates training - twice a week (one hour per class) during 90 days
47974543|NCT05123768|DIAGNOSTIC_TEST|NGS|A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
47974544|NCT04770012|DRUG|Placebo|patients randomized to placebo study group will be dispensed placebo capsules to be taken daily for the duration of the treatment
47974545|NCT04770012|DRUG|aspirin|patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
47974546|NCT04770012|DRUG|Clopidogrel|patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
47974547|NCT04205071|DRUG|Lorcaserin|Given PO
48330997|NCT05557123|DEVICE|MEDI-app|MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
48330998|NCT05557123|DEVICE|conventional treatment|conventional treatment with rivoxaban
48330999|NCT05516160|DIAGNOSTIC_TEST|diagnostic of optical aberrations|diagnostic of optical aberrations with new device
48331000|NCT04572763|DRUG|Copanlisib|Intravenous infusion
48331001|NCT04572763|DRUG|Venetoclax|Tablet taken orally
47974548|NCT04205071|DRUG|Lorcaserin Hydrochloride|Given PO
47974549|NCT04205071|OTHER|Questionnaire Administration|Ancillary studies
47974550|NCT01803919|DEVICE|Silver Alloy-Coated Urinary Catheters|
47974551|NCT01803919|DEVICE|Conventional Urinary Catheter|
47974552|NCT06240975|OTHER|Theragun Technique|Use the Theragun for a designated duration per session, such as 5-10 minutes for one session per week for 6 weeks
47974553|NCT06240975|OTHER|Dry Needling Technique|Dry needle deep (20 mm) TrP acupuncture of myofascial duration per session, such as 5-10 minutes for one session per week for 6 weeks
47974554|NCT02035878|OTHER|Probiotics|probiotic intervention: 400mg of probiotic capsule
47974555|NCT02035878|DRUG|Placebo|placebo comparator
47974556|NCT04182360|DRUG|Carbetocin|Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.
47974557|NCT01516931|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
47974558|NCT01516931|BEHAVIORAL|counseling|Placebo monthly by general counseling for 12 months.
48124541|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg|Comparing PONV incidences in both arms
48124542|NCT04570592|DRUG|Granisetron 1 Mg/mL Intravenous Solution|Comparing PONV incidences in both arms
48124543|NCT05437653|OTHER|Nutritional Drink A|300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
48124544|NCT05437653|OTHER|Nutritional Drink B|300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
48124545|NCT03822988|OTHER|no intervention, only complete a survey|we will ask patients to answer to a survey
48331002|NCT05169346|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
48331003|NCT05169346|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
48331004|NCT04569799|DRUG|Lumason|2.4 mL per lesion
48331005|NCT00002908|DRUG|bryostatin 1|
48331006|NCT00002908|DRUG|vincristine sulfate|
48331007|NCT05059938|BEHAVIORAL|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
48331008|NCT00243685|OTHER|Laboratory Assay|Chemotherapy
48331009|NCT00243685|OTHER|Mick Assay|Chemotherapy doctor determined from results
48331010|NCT01637818|PROCEDURE|Lichtenstein's operation|
48331011|NCT01637818|PROCEDURE|Mesh Plug Repair|
48331012|NCT01637818|DRUG|Opiate|Postoperative pain therapy
48331013|NCT01637818|DRUG|Paracetamol|Postoperative pain therapy
48331014|NCT01637818|DRUG|non-steroidal anti-inflammatory drug|Postoperative pain therapy
48651509|NCT06206837|DRUG|vepdegestrant|Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
48651510|NCT06206837|DRUG|PF-07220060|Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
48651511|NCT02189629|DRUG|CD5789 (trifarotene)|
48331015|NCT05066633|DRUG|Metoprolol Succinate|Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
48331016|NCT05066633|DRUG|Placebo|Placebo will be in the form of identical tablets and will be administered orally once daily.
48331017|NCT04744610|DIAGNOSTIC_TEST|Add 4-hour delayed radiographs|Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
48331018|NCT03555240|OTHER|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
48331019|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo CARE
48331020|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo standard stretching program
48331021|NCT03284346|OTHER|Laboratory Biomarker Analysis|Correlative studies
48331022|NCT03284346|DEVICE|Monitoring Device|Receive Polar heart rate monitor
48331023|NCT03284346|OTHER|Quality-of-Life Assessment|Ancillary studies
48331024|NCT03284346|OTHER|Questionnaire Administration|Ancillary studies
48331025|NCT01754077|BEHAVIORAL|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
48331026|NCT01754077|BEHAVIORAL|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
48331027|NCT01754077|BEHAVIORAL|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
48331028|NCT06141811|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
48331029|NCT06141811|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.
48331030|NCT06180668|PROCEDURE|Trauma Laparotomy|Emergency abdominal surgery through midline incision to access abdominal and / or pelvic organs, to access identified injuries or exploratory diagnostic reasons
48651512|NCT04555239|PROCEDURE|Fascial Distortion Model (FDM)|"Only treatment of herniated trigger points, continuum distortions, and/or trigger bands will be performed.~* Herniated trigger points are single areas of sharp pain within soft tissue.~* Continuum distortions are single points of sharp pain overlying bony tissues.~* Trigger bands are lines of pain overlying either soft or bony tissues.~Treatment with FDM is performed using firm, direct pressure over the area of the patient's pain with the provider's thumb. This pressure is applied at a single point or area indicated by the patient for herniated trigger points and continuum distortions, and along the indicated line of pain for trigger bands."
48331031|NCT02661464|BIOLOGICAL|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
48331032|NCT02661464|BIOLOGICAL|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
48331033|NCT04026763|PROCEDURE|prostate biopsy|standard of care
48331034|NCT04026763|PROCEDURE|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy
48331035|NCT04026763|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
48331036|NCT01655238|OTHER|BMI|Screening guideline to assess body mass index.
48651513|NCT04555239|OTHER|Standard Care|"The usual standard of care for extremity pain varies from provider to provider and varies from patient to patient depending upon their comorbidities but often includes some combination of the following:~* X-rays, if suspicion for fracture exists~* Venous duplex ultrasound, if suspicion for DVT/SVT exists~* Computed tomography (CT) angiogram (CTA), if suspicion for arterial occlusion exists~* C-reactive Protein (CRP)/erythrocyte sedimentation rate (ESR)/arthrocentesis is suspicion if suspicion for septic arthritis exists~* Arthrocentesis if suspicion for gout exists~* Splinting/casting/immobilization~* NSAIDs, Tylenol, or opioids for pain control~* Possibly trigger point injections~* Possibly osteopathic manipulation~* Recommendations to use RICE (rest, ice, compression, elevation) at home~* Physical/occupational therapy referral~* Orthopedic referral"
48651514|NCT06675747|OTHER|Ultrasound imaging|To investigate the mechanism of action of occlusal splints, a routinely applied treatment method for myogenic temporomandibular disorders, ultrasound images will be taken from all patients before and after treatment, and measurements will be conducted based on these images.
48651515|NCT04231851|DRUG|Glasdegib|Given PO
48124546|NCT05413629|OTHER|Web-based patient education for the intrauterine insemination (IUI) treatment process|Web-based training is 60 minutes in total, including 4 modules. The web-based training content includes general information about fertility, infertility diagnosis-treatment methods, drugs used in IUI treatment and its application, and issues to be considered after IUI.
48124547|NCT03224390|OTHER|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
48124548|NCT05619952|DIETARY_SUPPLEMENT|Mushroom Powder|Ground shiitake mushrooms or ground white button mushrooms
48491964|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise HIIT|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
48491965|NCT06013579|BEHAVIORAL|Phase 1 Gym Exercise CME|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak172, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
48651516|NCT04231851|DRUG|CPX-351|Given IV
48651517|NCT05597397|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
47974559|NCT01490229|DRUG|Ezetimibe|os, 10 mg, once daily, 1 year
47974560|NCT01490229|DRUG|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
47974561|NCT02310061|PROCEDURE|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
47974562|NCT02310061|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
48124549|NCT01522573|PROCEDURE|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
48124550|NCT05875987|DEVICE|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
48124551|NCT00421070|PROCEDURE|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
48124552|NCT01061034|DRUG|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
48124553|NCT02582736|DRUG|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
48651518|NCT05272280|OTHER|External oblique intercostal (EOI) block|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
48331037|NCT06431178|OTHER|General Anesthesia|"General anesthesia will be induced by 6% sevoflurane with a face mask. An intravenous line(22-g cannula )will be inserted then fentanyl 1mcg-kg will be given . Endotracheal tube will be used to intubate the patient .Anesthesia will be maintained by 2%sevoflurane inhalation in an oxygen air compination 1:1 throught the operation . Crystalloid solution was used to replenish fluid according 4/2/1-rule. Monitoring during the procedure include , ejection fraction (EF),blood pressure, heart rate, respiratory rate, and O2 saturation are measured at baseline, after induction, 10 min after catheter insertion,30 min during procedure and post emergence."
48331038|NCT06431178|OTHER|Local anesthesia|A nasal cannula was placed and oxygen delivered at 2 to 3 L/minute. An intravenous line will be inserted (22-g cannula). The sedation regimen will include loading dose of dexmedetomidine (1 mcg/kg) and ketamine (1mg/kg) over 10 minutes . The patient will receive an infusion of dexmedetomidine at 0.7 mcg/kg per hour and ketamine 0.5 mg/kg/hr as maintenance sedation .Local infilteration of xylocaine 2% at dose 2mg/kg will be given for vascular access in cardiac catheterization . After completion of the procedure the infusion pump will be stopped to ensure that the patient is fully awake and vitally stable
48331039|NCT05500183|BEHAVIORAL|Cognitively enriched walking program|The PA+CA program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
48331040|NCT05500183|BEHAVIORAL|walking program|The PA only program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
48331041|NCT00118911|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
48331042|NCT00118911|OTHER|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
48331043|NCT03628950|PROCEDURE|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
48491966|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Coaching Text Messages|The coaching intervention will consist of daily text messages tailored to the individual participant's self-reported symptom experiences and barriers to exercise on that specific day. One daily message with a survey will be sent, and responses to survey items will determine the subsequent once daily motivational message.Tailored messages address a range of possible barriers to adherence based on past research, and will provide advice and guidance. Text messages will be varied each week so that even if participants continue to report the same barriers they receive different text messages.
48651519|NCT05272280|OTHER|Erector spinae plane block (ESPB)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
48651520|NCT06430684|DRUG|Empagliflozin 10 MG|Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older
48651521|NCT03494842|DEVICE|Transcutaneous nerve stimulation (TENS)|The active TENS unit (delivers electrical stimulation) with indicator light
48651522|NCT03494842|DEVICE|Placebo Transcutaneous nerve stimulation (TENS)|the placebo TENS unit (delivers no electrical stimulation) with indicator light
48651523|NCT00191698|DRUG|atomoxetine hydrochloride|
48651524|NCT00191698|DRUG|placebo|
48124554|NCT02582736|DRUG|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
48651525|NCT05291091|DRUG|Sevasemten 10 mg|Sevasemten is administered orally once per day
48651526|NCT05291091|DRUG|Sevasemten 5 mg|Sevasemten is administered orally once per day
48651527|NCT05291091|DRUG|Sevasemten 12.5 mg|Sevasemten is administered orally once per day
48124555|NCT02582736|DRUG|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
48124556|NCT02582736|DRUG|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
47974563|NCT02461303|OTHER|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
47974564|NCT04369521|OTHER|low free sugar diet|low free sugar diet with nutrition and exercise recommendation
47974565|NCT04074460|DRUG|Propofol|General Anaesthesia
47974566|NCT04074460|DRUG|isoflurane, sevoflurane or desflurane|General Anaesthesia
48124557|NCT04115423|DRUG|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
48124558|NCT04115423|DRUG|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
48651528|NCT05291091|DRUG|Placebo|Placebo is administered orally once per day
48651529|NCT03404505|BEHAVIORAL|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
48651530|NCT03404505|BEHAVIORAL|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
48651531|NCT06130553|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.
48651532|NCT05853406|DIAGNOSTIC_TEST|Functional Reach test|"The determination by statistical research is carried out during a usual physiotherapy assessment of the volunteers. Data patient demographics and standard tests (FRT, Tinetti test, Timed Up and Go test, unipodal station) will be noted.~A satisfaction questionnaire inspired by Patient rating of change will be sent to participants for the determination of the MCID by ANCHOR method.~Concerning the Delphi method, a questionnaire will be sent to physiotherapists with proven geriatric activity."
48651533|NCT05007158|OTHER|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
48651534|NCT06674148|DRUG|Qifangfeixian granules|The experimental group was treated with Qifangfixian granules
48651535|NCT06674148|OTHER|Placebo|The control group was treated with placebo
48651536|NCT00101738|DRUG|Myfortic|
48651537|NCT04498767|RADIATION|Stereotactic body radiotherapy|Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
48491967|NCT06013579|BEHAVIORAL|Phase 2 Home Exercise Control Text Messages|"The control group will receive general daily texts from the study team (i.e., Hope you are doing well!), and reminding them of their next study appointments. These text messages are primarily social/generic in content and serve to maintain involvement and enhance retention of the control group."
48491968|NCT05410158|DRUG|Ketamine in PECS block versus topical wound instillation|On arrival to the operating room, an intravenous line will be inserted in the contralateral upper limb to the side of surgery. Anesthesia will be induced for all participating patients with 2 μg/kg fentanyl, 2 - 3 mg/kg propofol and 1.5 mg/kg lidocaine. Endotracheal intubation will be facilitated by 0.15 mg/kg cis-atracurium.The patients will be randomly assigned into 2 groups ( pecs block group , topical instillation group) using a randomization-computer program . Anesthesia will be maintained by 1 - 1.5 MAC isoflurane in 50% oxygen/ air mixture and 0.03 mg/kg cisatrcurium, respectively, in ventilation parameters that maintain normocapnia. At the end of surgery, a reversal of the muscle relaxant will be done using neostigmine (0.04 mg/kg) and atropine (0.01 mg/kg). After extubation, all patients will be transmitted to the post anesthesia care unit (PACU) for follow up .
48491969|NCT00467636|PROCEDURE|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
48491970|NCT00467636|DRUG|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
48651538|NCT04498767|RADIATION|Palliative RT|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
48651539|NCT05713838|DRUG|Durvalumab|1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
48651540|NCT05713838|DRUG|FLOT|50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
48651541|NCT05713838|DRUG|mFOLFOX-6|85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
48651542|NCT05713838|RADIATION|Radiotherapy|5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
48651543|NCT04020185|DRUG|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
48651544|NCT04020185|DRUG|Immune checkpoint inhibitor (ICI)|Administered according to product label
48651545|NCT04020185|DRUG|Immuno-oncology (IO) therapy|Administered according to product label
48651546|NCT02953431|DEVICE|CPAP|CPAP will be administered with a CPAP machine
48651547|NCT06086873|DEVICE|Implant Type|"Patients enrolled in the study will be allocated to one of three implant groups:~* Group 1: NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)~* Group 2: BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)~* Group 3: TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)."
48331044|NCT03628950|PROCEDURE|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
48331045|NCT03742206|DEVICE|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
48331046|NCT03742206|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
48331047|NCT03384225|DRUG|Cladribine|
48331048|NCT03384225|DRUG|Fludarabine|
48331049|NCT03384225|DRUG|Busulfan|
48331050|NCT03384225|DRUG|Cytarabine|
48331051|NCT02522572|DRUG|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
48331052|NCT02522572|DRUG|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
48331053|NCT02522572|OTHER|plasmapheresis|Plasmapheresis will be administered based on group assignment.
48331054|NCT03375138|DRUG|belatacept|Specified dose on specified days
48331055|NCT01293006|DRUG|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
48331056|NCT01293006|DRUG|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
48331057|NCT00003091|BIOLOGICAL|aldesleukin|
48331058|NCT00003091|BIOLOGICAL|recombinant interferon alfa|
48331059|NCT03855033|BEHAVIORAL|Media Aware Sexual Health - High School|Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
48331060|NCT04771143|DRUG|AFQ056|oral administration
48331061|NCT04771143|DRUG|Placebo|matching placebo for oral administration
48331062|NCT03139929|DIAGNOSTIC_TEST|MSFP|MSFPhold and MSFParm
48331063|NCT05736978|DRUG|Azacitidine|75mg/m2 d1-7
48331064|NCT05736978|DRUG|Venetoclax|d1 100mg, d2 200mg, d3-28 400mg
48331065|NCT05736978|DRUG|Selinexor|if MRD positive in C1D14, selinexor 60mg D15, D22
48331066|NCT01412060|DRUG|Placebo|Placebo was supplied in capsules.
48331067|NCT01412060|DRUG|Cariprazine|Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
48651548|NCT01610401|DRUG|Metformin|metformin 500 mg three times a day, for 3 days
48331068|NCT00022958|DRUG|Iodine-131 Anti-B1 Antibody|
48331069|NCT01379170|DRUG|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
48331070|NCT02581124|DRUG|JTZ-951|
48331071|NCT02581124|DRUG|Lapatinib|
48331072|NCT01566201|DRUG|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
48331073|NCT01566201|DRUG|placebo|water for injection
48331074|NCT06123390|OTHER|The Responses to Illness Severity Quantification (RISQ) System|The RISQ System involves: \[1\] the RISQ score: calculated routinely using the \[2\] documentation record and linked to \[3\] score-matched recommendations. Introduction into clinical care is supported by \[4\] the RISQ System implementation package. During the 2 month prior to implementation, front-line staff in the intervention arm will be trained on and will practice the use of the RISQ System .
48331075|NCT05808842|OTHER|CeraVe|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
48331076|NCT05808842|OTHER|CeraVe and Calecim|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~* Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
48331077|NCT02617186|PROCEDURE|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
48331078|NCT02617186|PROCEDURE|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
48331079|NCT05220137|BEHAVIORAL|Modified A-B-C: Working with Events, Thoughts, and Feelings|The Modified A-B-C session teaches the Veteran how to draw connections between events, thoughts, and feelings and incorporates preliminary cognitive restructuring to help challenge stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
48331080|NCT05220137|BEHAVIORAL|Challenging Questions|The Challenging Questions session teaches the Veteran to question and confront maladaptive self-statements and stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
48331081|NCT05220137|BEHAVIORAL|Patterns of Problematic Thinking|The Patterns of Problematic Thinking session teaches the Veteran to identify counterproductive thinking patterns. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
48651549|NCT01610401|DRUG|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
48331082|NCT05220137|BEHAVIORAL|Challenging Beliefs|The Challenging Beliefs session teaches the Veteran to generate alternative thoughts based on the outcome of cognitive restructuring. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
48331083|NCT05220137|BEHAVIORAL|Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy)|The therapist will present the Module options to the Veteran and the Veteran will select one Module to work on. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
48491971|NCT03231319|PROCEDURE|Fascia iliaca compartment block with IV-PCA|1. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
48491972|NCT03231319|PROCEDURE|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"1. Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~2. Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
48491973|NCT03231319|PROCEDURE|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
48491974|NCT00871741|BIOLOGICAL|GSK2202083A vaccine|Intramuscular, three doses
48491975|NCT00871741|BIOLOGICAL|Infanrix hexa|Intramuscular, three doses
48491976|NCT00871741|BIOLOGICAL|Menjugate|Intramuscular, two doses
48331084|NCT01677624|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
48491977|NCT05178433|COMBINATION_PRODUCT|Use baby moisturizers by NeoChine|During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
48491978|NCT00017823|PROCEDURE|Acupressure|
48491979|NCT01402180|BIOLOGICAL|Nimotuzumab|
48491980|NCT01402180|RADIATION|Radiation therapy|
48491981|NCT01402180|RADIATION|radiation therapy|
48491982|NCT01402180|DRUG|chemotherapy|
48331085|NCT02564029|DRUG|PF-06372865|Single dose
48331086|NCT02564029|DRUG|Placebo|Placebo for PF-06372865 and placebo for lorazepam
48651550|NCT01610401|DRUG|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
48651551|NCT00006377|DRUG|carboplatin|
48331087|NCT02564029|DRUG|Lorazepam|2 mg single oral dose
48331088|NCT00543621|OTHER|daily enteral nutritional product and/or behavioral changes|
48651552|NCT00006377|DRUG|doxorubicin hydrochloride|
48651553|NCT00006377|DRUG|paclitaxel|
48124559|NCT04454879|DRUG|Roxadustat|Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
48124560|NCT05326789|DEVICE|REBOA catheter|balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
48124561|NCT01637246|DRUG|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
48331089|NCT05854069|BEHAVIORAL|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
48491983|NCT01402180|DRUG|chemotherapy|
48331090|NCT05854069|BEHAVIORAL|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
48331091|NCT01548417|DRUG|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
48651554|NCT00775671|DRUG|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
48651555|NCT00775671|DRUG|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
48651556|NCT00775671|DRUG|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
48651557|NCT03375320|DRUG|Cabozantinib S-malate|Given PO
48331092|NCT01548417|DRUG|Sugar Pill|600 mg/day, oral pill, 7 days
48331093|NCT01263314|DRUG|MK-8266|Oral capsules, 0.1 mg potency
48331094|NCT01263314|DRUG|Placebo|Oral placebo capsules to match MK-8266 capsules
48331095|NCT05652413|BEHAVIORAL|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
48331096|NCT03703362|OTHER|Resistance training|30 supervised training-sessions over 12 weeks
48491984|NCT02583893|DRUG|Sirolimus|Given PO
48491985|NCT02583893|DRUG|Mitoxantrone|Given IV
48651558|NCT03375320|PROCEDURE|Computed Tomography|Undergo CT
48651559|NCT03375320|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48651560|NCT03375320|OTHER|Placebo Administration|Given PO
48651561|NCT03375320|OTHER|Quality-of-Life Assessment|Ancillary studies
48651562|NCT03375320|PROCEDURE|X-Ray Imaging|Undergo x-ray
48651563|NCT06597344|DRUG|Gepotidacin|Gepotidacin will be administered.
48651564|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed 600mg/m2 body surface area per dose about every 12 hours
48651565|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA \>=60-70 mg\*h/L
48651566|NCT05753228|OTHER|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
48651567|NCT05753228|OTHER|Chalder Fatigue Scale|The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
48651568|NCT05753228|OTHER|Health Questionnaire (EQ-5D-5L)|"The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems."
48651569|NCT05753228|OTHER|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
48331097|NCT01231607|DRUG|1mg Finasteride active|1mg finasteride active, by mouth once daily
48331098|NCT01231607|DRUG|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
48331099|NCT01231607|DRUG|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
48331100|NCT01231607|DRUG|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
48331101|NCT01231607|DRUG|Finasteride placebo|finasteride placebo, by mouth once daily
48331102|NCT01231607|DRUG|Dutasteride placebo|dutasteride placebo, by mouth once daily
48331103|NCT04758598|DEVICE|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
48331104|NCT04758598|DEVICE|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
48491986|NCT02583893|DRUG|Etoposide|Given IV
48491987|NCT02583893|DRUG|Cytarabine|Given IV
48651570|NCT06673810|OTHER|Ankle Weighted Cuffs Training Along with Routine Physical Therapy Exercises|Group A will have free ankle weighted cuffs while performing routine physical therapy. These weighted cuffs will be above of the child's ankle and child will be encouraged to perform his/her routine physical activities. Ankle weights will correspond to 2% to 3% of the individual's body weight (sandbags) will be attached at 5 cm above the left and right ankle joints
48651571|NCT06673810|OTHER|Routine Physical Therapy Exercises|Group B will perform all the routine physical exercises which include jogging, walk/run interval training, treadmill training and cycling . Intervention period will be of 6 weeks comprising of 3 sessions per week of 30 to 45 minutes per session
48651572|NCT06168669|DIAGNOSTIC_TEST|xBar system|xBar system is surgical drain with embedded sensors. Collected data will be evaluated for an ability to identify anastomotic leaks. The xBar system does not have therapeutic indication.
48491988|NCT03022058|DEVICE|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
48331105|NCT06305221|DRUG|Opioid-free Analgesics (esketamine, dexmedetomidine)|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
48491989|NCT05266820|DRUG|Thalidomide|For the experimental group, the intervention was thalidomide（100mg PO Bid)
48491990|NCT05266820|DRUG|TAS-102|TAS-102
48491991|NCT04241666|DIAGNOSTIC_TEST|renal scintigraphy|Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
48491992|NCT04241666|DIAGNOSTIC_TEST|renal doppler sonography|doppler ultrasound of both kidneys
48491993|NCT01728402|PROCEDURE|blood draw, bone marrow procedure, or tissue biopsy|
48491994|NCT02520752|DRUG|INC280|
48491995|NCT02520752|DRUG|Midazolam|
48491996|NCT02520752|DRUG|Caffeine|
48491997|NCT04046796|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
48491998|NCT01019863|DRUG|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
48491999|NCT01679587|DRUG|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
48492000|NCT01679587|DRUG|Placebo|Single oral dose of matching placebo will be given in each treatment arm
48492001|NCT02963870|OTHER|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
48331106|NCT06305221|DRUG|Opioid Anesthetics (sufentanil and remifentanil)|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
48331107|NCT01946412|DRUG|Ivacaftor|
48124562|NCT06523205|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all patients. Clinical parameters will also be recorded. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist will record all clinical parameters using manual probing.~Following sampling, saliva samples will be stored at -80°C until analysis. Concentrations of Tenascin-C, IL-4, IL-6, and IL-1beta will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in saliva samples."
48124563|NCT03481816|BIOLOGICAL|ETBX-071; adenoviral PSA vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
48124564|NCT03481816|BIOLOGICAL|ETBX-061; adenoviral MUC1 vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
48124565|NCT03481816|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
48124566|NCT04572945|DIAGNOSTIC_TEST|kidney function test|laboratory and imaging
48331108|NCT02549963|DEVICE|WATCHMAN Left Atrial Appendage Occlusion Device|
48492002|NCT06428318|DIAGNOSTIC_TEST|Conventional Sputum culture|Sputum culture was done to patients and they received Antibiotics According to its results
48331109|NCT02549963|DRUG|Rivaroxaban|
48331110|NCT02022956|DRUG|Lorcaserin|
48331111|NCT00719225|DRUG|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
48492003|NCT06428318|DIAGNOSTIC_TEST|BioFire Pneumonia Panel (BFPP)|BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
48492004|NCT04583748|BEHAVIORAL|Sahaj Samadhi Meditation|Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
48492005|NCT04583748|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
48492006|NCT00026221|BIOLOGICAL|Recombinant Interferon Alfa|Given SC
48492007|NCT00026221|BIOLOGICAL|Bevacizumab|Given IV
48651573|NCT05308459|BEHAVIORAL|Data-driven health promotion at Vocational Education and Training schools (Data Health VET)|"The intervention consists of the following steps:~1. A local health profile is conducted among all students~2. Results are shortly hereafter presented and discussed with all student and staff, and the school decide what health problem they will work with during the next year~3. A participatory group model process based on a dynamic systems approach is conducted to develop sustainable and system changing activities to address the chosen health problem~4. The activities are implemented~5. A new health profile is conducted to a) evaluate the effects of the implemented activities and to b) determine if a new health problem warrant focus and new activities are needed (the process repeats itself)."
48651574|NCT01472185|DRUG|Ranolazine|Ranolazine tablets administered orally twice daily.
48651575|NCT01472185|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily.
48651576|NCT01472185|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
48651577|NCT01472185|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
48331112|NCT03255811|DRUG|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
48331113|NCT00934011|OTHER|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
48331114|NCT00934011|OTHER|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
48651578|NCT05526755|DRUG|Osimertinib 80 mg/40 mg|Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
48651579|NCT03508479|BIOLOGICAL|RG-HRV16|0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
48651580|NCT06464367|DRUG|Psilocybin|synthetic psilocybin 10 mg (oral)
48651581|NCT06464367|DRUG|Placebo|synthetic THC 2.5 mg (oral)
48651582|NCT06650566|DRUG|LM-299|Administered intravenously
48651583|NCT04132427|COMBINATION_PRODUCT|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
48651584|NCT04132427|COMBINATION_PRODUCT|placebo vancomycin, real magnesium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
48492008|NCT03687658|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
48492009|NCT00777413|DRUG|Minocycline 100mg Tablets|
48331115|NCT05194787|DIAGNOSTIC_TEST|Cognitive test scores, clinical diagnosis and blood biomarkers|"Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing.~Cognitive test score on CANTAB Blood biomarker (p-tau 181) level"
48331116|NCT01930929|PROCEDURE|Bariatric surgery|
48331117|NCT05264558|DEVICE|Xpert HCV Viral load finger stick point of care test (Cepheid)|Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.
48331118|NCT05264558|DRUG|Epclusa 400Mg-100Mg Tablet|Same day HCV test and treatment
48331119|NCT05264558|OTHER|Standard of care|Clinical services will receive additional education and have the option of providing incentives to attendees of service.
48331120|NCT04003181|DRUG|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
48331121|NCT04003181|DRUG|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
48331122|NCT00089479|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
48331123|NCT00089479|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
48331124|NCT00089479|DRUG|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
48331125|NCT02779881|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus LGG|
48331126|NCT02141217|DRUG|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
48331127|NCT02141217|DRUG|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
48331128|NCT00489034|BEHAVIORAL|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
48492010|NCT06476366|DRUG|Azathioprine|azathioprine will be started at 0.3mg/kg. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking initial safety profile)
48651585|NCT01808170|PROCEDURE|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
48492011|NCT06476366|DRUG|Methotrexate|Methotrexate will be started at 10mg/week and
48124567|NCT06337058|BEHAVIORAL|Experimental group (motivational interview)|"For the menopausal women with sexual dysfunction in the experimental group, pre-test data were obtained by applying the 'Personal Information Form', the 'Sexual Quality of Life Scale-Woman' and the 'Sexual Self-Efficacy Scale' before starting the motivational interviews. After the pre-test data were obtained, a total of 4 sessions of motivational interviews were provided, one session per week for four weeks. At the end of four weeks, post-test data were obtained by applying the Arizona Sexual Experiences Scale, Sexual Quality of Life Scale-Women and Sexual Self-Efficacy Scale.~The researcher received a training on motivational interview techniques before implementing the intervention for menopausal women in the experimental group."
48124568|NCT04244058|DRUG|Amantadine + L-DOPA|Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg
48492012|NCT01247246|DRUG|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
48492013|NCT01247246|DRUG|Placebo|Placebo
48492014|NCT03754465|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
48492015|NCT03754465|PROCEDURE|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
48492016|NCT02991430|DEVICE|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
48492017|NCT02991430|DEVICE|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
48492018|NCT00706381|DRUG|Sincalide|
48492019|NCT00706381|DRUG|Ursodiol|
48492020|NCT00706381|PROCEDURE|Fat Meal|600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate
48492021|NCT00706381|PROCEDURE|Carb meal|600 calorie meal containing 100% carbohydrate
48124569|NCT04244058|DRUG|NMDA blocker|NMDA blocker
48124570|NCT04670887|PROCEDURE|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
48124571|NCT04670887|PROCEDURE|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
48124572|NCT00185549|BEHAVIORAL|CF. DOC|
48492022|NCT00706381|DRUG|Placebo|IV and/or oral placebo
48492023|NCT05925673|OTHER|Mirror Therapy|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
48492024|NCT05925673|OTHER|Neuromuscular Stimulation (NMES)|Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
48492025|NCT05925673|OTHER|Mirror Therapy + NMES|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
48492026|NCT02995876|PROCEDURE|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
48492027|NCT02995876|PROCEDURE|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
48492028|NCT02969941|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
48492029|NCT01215513|DRUG|Degarelix|
48492030|NCT01199679|PROCEDURE|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
48492031|NCT01199679|PROCEDURE|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
48331129|NCT00489034|BEHAVIORAL|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
48124573|NCT02994316|OTHER|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
48124574|NCT04843475|DIAGNOSTIC_TEST|Echocardiography|Trans-thoracic Echocardiography
48331130|NCT00489034|BEHAVIORAL|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
48331131|NCT00983359|RADIATION|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
48331132|NCT02219997|DEVICE|Clear clip-on glasses|Clip-on glasses with no blue light filtering properties used as a placebo
48492032|NCT06165666|OTHER|Approach by functional objectives|The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
48492033|NCT06165666|OTHER|Treatment protocol|The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
48124575|NCT02530216|OTHER|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
48124576|NCT05810194|DEVICE|StrataXRT|StrataXRT® is a TGA-approved silicone-based topical preparation. StrataXRT is a self-drying, non-sticky, transparent, silicone gel formulation and when used as directed, dries to form an inert, thin, flexible wound dressing with a protective layer that is gas permeable and waterproof. It is the only self-drying topical silicone gel indicated for the use on radiation dermatitis, which hydrates and protects compromised skin areas and open wounds from chemical and microbial invasion. StrataXRT helps create an optimal wound healing environment which leads to faster re-epithelialization and a reduced inflammatory response. The product can be applied to fresh incisions and excisions, open wounds and compromised skin surfaces.
48124577|NCT05810194|DRUG|Calendula|Calendula creams are over-the-counter (OTC) skin care ointments that are non-greasy, non-sticky, and quickly absorbed by the skin. Calendula is a topical agent derived from a plant of the marigold family Calendula Officinalis and is used in cuts, scrapes, chafing and minor burns. Containing numerous polyphenolic antioxidants, calendula has been studied in both the laboratory and clinical setting for the use in treating and preventing radiation induced skin toxicity.
48331133|NCT02219997|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
48331134|NCT02219997|DEVICE|ACRYSOF® IQ IOL|AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
48331135|NCT02219997|DEVICE|Clear IOL|Clear IOL, previously implanted
48331136|NCT05666661|OTHER|Sound and light therapy (BBT and FL group)|During intervention, the participants close their eyes and wear an eye mask and stereo earphones. They then listen to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phone. The intervention music was first embedded in the participant's mobile phone and the BBT music application was purchased from the mobile phone app (Brainwave Studio software, Dalcoms Inc). When listening to music, 10 Hz light stimulation was added to the BBT and FL group (using a mobile phone). Table 1 shows the intervention status. The rhythmical photic stimulation program was a commercially available mobile phone app (Strobe Therapy software released by FuwhatSoft).
48331137|NCT05666661|OTHER|Sound therapy group (BBT)|Participants in the sound therapy group (BBT) listened to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phones. Except for rhythmical photic stimulation, the other steps were the same as the BBT and FL group.
48492034|NCT02416024|DEVICE|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
48492035|NCT05142371|OTHER|Best Practice|Continue current activities of daily living
48492036|NCT05142371|OTHER|Exercise Intervention|Participate in exercise intervention
48492037|NCT05142371|OTHER|Quality-of-Life Assessment|Ancillary studies
48331138|NCT05666661|OTHER|Relaxing music group|Participants listened to 30 minutes of relaxing music (the same as that of the experimental groups) through their mobile phone. Except for rhythmical photic stimulation and 10 Hz BBT, the other steps were the same as the experimental groups.
48331139|NCT00226967|DRUG|Sandostatin|Calculated per patient
48492038|NCT05142371|OTHER|Questionnaire Administration|Complete questionnaires
48492039|NCT02350244|BEHAVIORAL|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
48331140|NCT05622357|RADIATION|short course radiation therapy followed by 6 cycles of CAPOX then surgery|Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
48331141|NCT02287402|DRUG|AO-128|AO-128 tablet
48331142|NCT04740060|OTHER|Augmented Feedback without Virtual Reality(VR|"For Walking Speed:One-minute fast walking with visual augmented feedback without VR interface (we ask participants to look at a screen where their walking speed and distance are tracked and increase their speed).~For Step Length: Maximum step length with visual augmented feedback without VR interface in which we ask participants to look at a screen where their step length is displayed and attempt to increase their step length up."
48331143|NCT04740060|OTHER|Augmented Feedback with Non-Game based VR|"For Walking Speed:One-minute fast walking with basic VR interface (we ask participants to look at a screen where their avatar walker representative will be represented in a virtual walking environment and try to make the avatar walk faster).~For Step Length: Maximum step length with basic VR interface in which we ask participants to look at their avatar feet in a virtual stepping environment and step with the avatar foot as far as possible."
48492040|NCT01946776|DEVICE|implantable heart rate monitor|Implantation of Reveal XT
48492041|NCT04646486|BEHAVIORAL|Video debriefing|Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
48492042|NCT01527136|DRUG|entolimod|Given IM or SC
48651586|NCT01808170|PROCEDURE|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
48124578|NCT05810194|DRUG|Aquaphor|Aquaphor, containing 41 percent petrolatum (or petroleum jelly), temporarily protects minor cuts, scrapes, and burns; Aquaphor protects and helps relieve chapped or cracked skin and lips, as well as helps protecting from the drying effects of wind and cold weather.
48492043|NCT01527136|OTHER|pharmacological study|Correlative studies
48492044|NCT01527136|OTHER|laboratory biomarker analysis|Correlative studies
48492045|NCT03580122|DRUG|Arginine Aspartate|Asparten
48492046|NCT00240942|DRUG|Letrozole|
48492047|NCT00197496|PROCEDURE|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
48492048|NCT03219931|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
48492049|NCT03219931|DRUG|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
48492050|NCT03386565|DRUG|sodium chloride solution|intraoperative IV infusion
48492051|NCT03386565|DRUG|Lidocaine|intraoperative IV infusion
48492052|NCT01466452|DRUG|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
48651587|NCT05570162|OTHER|Diabetes educational program|30-minute long diabetes educational program
48651588|NCT06674330|OTHER|concentration of teicoplanin|post analysis of concentration of teicoplanin
48124579|NCT05958836|DEVICE|pacemaker|Micra TPS or traditional PM group
48124580|NCT02132559|DRUG|DHEA|
48124581|NCT05821569|OTHER|Standard approach|Adoption of standard approach (derived by Unicef guidelines) to breastfeed
48492053|NCT01466452|DRUG|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
48651589|NCT03917381|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
48124582|NCT05821569|OTHER|Biological nurturing|Adoption of biological nurturing approach to breastfeed
48492054|NCT01466452|DRUG|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
48492055|NCT04708639|DRUG|Alectinib|Use of ctDNA to establish response and resistance to alectinib.
48492056|NCT02757976|DEVICE|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave \> 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
48492057|NCT02757976|DEVICE|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
48492058|NCT05647226|COMBINATION_PRODUCT|Digital therapeutic and intensive lifestyle programme|Initial 12-week LED and behaviour education app.
48492059|NCT05647226|OTHER|Standard of care|Standard of care.
48331144|NCT04740060|OTHER|Augmented Feedback with Game based VR|"For Walking Speed: One-minute fast walking with the VR Racing exergame (we ask participants to look at a screen where their avatar walker representative present in a virtual racing environment with other avatar racers and try to beat the avatar racers).~For Step Length: Maximum step length with the VR Stepping Exergame (we ask participants to look at their avatar legs and avatar animals in a virtual stepping environment and try to step over the avatar animals without touching the animal."
48331145|NCT06185413|OTHER|Participatory system dynamics approach|First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
48331146|NCT06282419|OTHER|USE OF MOBILE ULTRASOUND|"First stage; Women and their partners who meet the research criteria are at the 32-35th week of pregnancy. was included in the study during the week. First, introductory information forms will be applied to the women and expectant fathers assigned to the experimental and control groups through face-to-face interview technique.~Then, fetal images and fetal heart sounds will be recorded from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images and fetal heart sounds taken with the portable USG device of their babies will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp twice a week for 4 weeks after birth."
48331147|NCT06282419|OTHER|ultrasound image taken from the internet|First stage; Fetal USG images and fetal heart sounds, not belonging to their babies, taken from the internet, will be sent to the fathers in experimental group 2 via WhatsApp application by the researcher twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp application twice a week for 4 weeks after birth.
48331148|NCT01729650|BEHAVIORAL|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
48331149|NCT02794090|BEHAVIORAL|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
48331150|NCT02794090|BEHAVIORAL|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
48331151|NCT00222742|PROCEDURE|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
48331152|NCT02883777|BEHAVIORAL|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
48331153|NCT02883777|BEHAVIORAL|Conventional Diet|Conventional diet over 1 year after transplantation.
48331154|NCT00599170|DRUG|Rituximab|375 mg/m2 IV
48331155|NCT04255277|DRUG|Combined oral contraceptives (COC)|A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
48331156|NCT04255277|DRUG|Moxifloxacin 400mg|A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
48331157|NCT04255277|DRUG|Cenerimod 0.5 mg|This will be administered orally as a film-coated tablet in the morning.
48651590|NCT03917381|BIOLOGICAL|Acasunlimab in combination with docetaxel (in a single expansion cohort)|Acasunlimab and docetaxel will be administered intravenously once every 21 days.
48331158|NCT04255277|DRUG|Cenerimod 4 mg|This will be administered orally as a film-coated tablet in the morning.
48331159|NCT04255277|OTHER|Charcoal, activated|Granules for oral suspension will be used and administered open-label.
48331160|NCT04255277|DRUG|Matching Placebo|Cenerimod matching placebo tablets will be administered once daily orally in the morning.
48492060|NCT05296382|DRUG|Tebipenem tablet form|Tebipenem tablets will be administered intact or crushed
48492061|NCT05296382|OTHER|Tube feeds|Tebipenem tablets will be administered with or without tube feeds
48651591|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)|Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
48651592|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
48651593|NCT01601561|DRUG|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
48651594|NCT05214508|DIAGNOSTIC_TEST|interleukin 6|assessment of serum IL-6 by ELISA
48124583|NCT03980496|DRUG|Omeprazole|
48331161|NCT06248697|BIOLOGICAL|αPD1/CTLA4-MSLN-CAR T cells|BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and CTLA4 antibody with dimethyl sulfoxide as medium. It can be used for direct intravenous infusion. Autologous CD3+ T cells were transfected with plasmids expressing anti-mesothelin-specific CAR, anti-PD1 nanoantibody and anti-CTLA-4 antibody by electroporation in vitro. Mesothelin-specific CAR is a single-domain antibody (VHH) derived from alpaca, which is composed of a binding domain and a CD28 and CD3ζ chain signal transduction domain.
48331162|NCT04172337|BEHAVIORAL|Healthier Choice Symbol|The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.
48331163|NCT04172337|BEHAVIORAL|Physical Activity Equivalent label|"For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images."
48331164|NCT04101448|OTHER|prevalence|percentage of bronchectasis in COPD and its effect as prognostic measure
48651595|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)|PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
48331165|NCT00525239|DRUG|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
48651596|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Sham Stimulator|Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
48651597|NCT06053320|OTHER|Gait Training|After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
48651598|NCT03449147|DRUG|Placebo|Placebo tablet administered orally BID
48651599|NCT03449147|DRUG|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
48124584|NCT00158782|DRUG|GW786034|GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
48651600|NCT03449147|DRUG|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
48651601|NCT03644758|DIAGNOSTIC_TEST|socio-demographic data and personal medical history|Socio-demographic data and personal medical history is a self-administered questionnaire.
48124585|NCT00158782|DRUG|lapatinib|Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
48124586|NCT04291092|DRUG|Immunotherapy|Immunotherapy for brain metastasis
48124587|NCT04291092|RADIATION|WBRT|local therapy for brain metastasis
48124588|NCT04291092|DRUG|Chemotherapy|Chemotherapy for brain metastasis
48124589|NCT00348751|DEVICE|CholGate|
48124590|NCT03305146|GENETIC|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( \<50ng) DNA."
48124591|NCT05424796|COMBINATION_PRODUCT|Physiological saline|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, hemostasis was achieved by checking the saline soaked cotton pellet.
48124592|NCT05424796|COMBINATION_PRODUCT|Hemostasis and cavity disinfection with NaOCl|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, 2.5% NaOCl soaked cotton pellets were placed over canal orifices.
48331166|NCT03920878|DRUG|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
48331167|NCT03920878|DRUG|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
48651602|NCT03644758|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.
48124593|NCT05424796|DEVICE|Hemostasis and cavity disinfection with KTP laser|Pulpotomy is a vital pulp treatment in which the vital coronal pulp tissue is surgically removed and the remaining radicular dental pulp is covered with an appropriate material. In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy).
48492062|NCT03560349|DRUG|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
48124594|NCT03632759|DRUG|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
48124595|NCT03632759|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
48124596|NCT00546754|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
48124597|NCT00546754|DRUG|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
48124598|NCT02134951|DRUG|Ketamine|intravenous infusion of saline solution with ketamine
48124599|NCT02134951|DRUG|Normal saline|Normal saline will be used for placebo in this group
48124600|NCT04623567|DRUG|Jiangtang Tiaozhi recipe|The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)
48124601|NCT04623567|DRUG|Metformin|The metformin tablets (500mg) will be administrated.
48492063|NCT03560349|DRUG|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
48124602|NCT04967742|BIOLOGICAL|UB-612|UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
48651603|NCT03644758|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.
48651604|NCT03644758|DIAGNOSTIC_TEST|Insomnia Severity Index (ISI)|Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.
48651605|NCT03644758|DIAGNOSTIC_TEST|stop-BANG questionnaire|Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
48651606|NCT06674642|OTHER|Traditional Indigenous Foods diet|A diet composed of traditional indigenous foods will be given to participants.
48651607|NCT05010005|DRUG|Ruxolitinib|Ruxolitinib 20mg BID
48124603|NCT02819414|DRUG|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
48124604|NCT02819414|OTHER|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
48124605|NCT01318967|DRUG|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
48124606|NCT01318967|OTHER|Placebo|
48124607|NCT01020643|DRUG|controlled administration of propofol|comparison of propofol sedation
48124608|NCT06495359|OTHER|immunization education program|The content of the immunization education program for parents was created by researchers based on the literature. Expert opinions will be obtained from 7 people who are experts in the fields of child health and disease nursing and public health nursing for the training program. The training program consists of 30 minutes. The education program will be delivered to parents in the form of a 30-minute training session using the face-to-face education model. Interactive education methods that enable parents' participation will be used.
48124609|NCT00973986|DRUG|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
48651608|NCT05010005|DRUG|Duvelisib|Duvelisib 25mg, 50mg, or 75mg BID
48651609|NCT03578172|DRUG|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
48331168|NCT05720273|DRUG|palicalcitol|This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.
48331169|NCT06355401|DRUG|Tamoxifen 20mg|maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
48331170|NCT02155361|DRUG|Topical Citrullus colocynthis fruit oil (1%)|
48331171|NCT02155361|DRUG|Topical vehicle oil|
48331172|NCT00532428|DRUG|Raloxifene|60 mg QD
48331173|NCT00532428|DRUG|Raloxifene|120 mg QD
48331174|NCT00532428|DRUG|Placebo|Placebo
48331175|NCT00113178|DEVICE|Catheter-based cardiac cryoablation|
48331176|NCT04298190|BEHAVIORAL|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
48331177|NCT04298190|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
48331178|NCT02401802|DIETARY_SUPPLEMENT|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
48331179|NCT02401802|DIETARY_SUPPLEMENT|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
48331180|NCT00615797|BIOLOGICAL|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
48331181|NCT00615797|DRUG|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
48331182|NCT01621854|DRUG|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
48331183|NCT03994393|DRUG|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
48331184|NCT03994393|DRUG|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
48331185|NCT01268033|DRUG|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
48331186|NCT01268033|DRUG|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
48492064|NCT04293978|BEHAVIORAL|CalmPlace|Self-contained VR application allowing the user to build and custom a relaxation session, with options to vary session length (9-20 minutes), music/sound, relaxation exercises, and specific nature environment (three available) including time of day and events (e.g. rain). Delivered using an Oculus Go devices in kiosk-mode.
48492065|NCT03832309|BEHAVIORAL|Do we speak to them in a way that convinces them to have the dream|During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
48492066|NCT03832309|BEHAVIORAL|Speaking to them as a regualar person|During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
48492067|NCT06259136|PROCEDURE|A transitional palliative care intervention|The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
48651610|NCT03578172|DRUG|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration \>60 days.
48651611|NCT03934684|DRUG|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~* Carfilzomib will be administered as a 30-minute infusion.~* Dexamethasone will be taken by mouth or intravenously."
48331187|NCT05720767|DRUG|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
48331188|NCT05720767|DRUG|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
48331189|NCT05720767|DRUG|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
48124610|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate|0.1g/kg of body weight (pre measured creatine) and 3mg/kg of body weight (pre measured micronized cellulose powder-caffeine placebo) self administered 1 hr prior to working out mixed in water.
48331190|NCT05605977|BEHAVIORAL|Traditional visual-motor training program|Traditional visual-motor program includes play and paper-and-pencil activities
48331191|NCT05605977|BEHAVIORAL|Computerized visual-motor training program|Computerized visual-motor training program includes tablet visual-motor games
48331192|NCT01798017|DRUG|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
48331193|NCT04943172|DEVICE|Hancock-Jaffe bioprosthetic venous valve (VenoValve®)|Surgical implantation of the VenoValve device
48331194|NCT00392119|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
48492068|NCT04761458|DIAGNOSTIC_TEST|Olfactory function testing|Olfactory function will be evaluated through the Burghart Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The extended version of this test will be used and consist of three tests of olfactory function, namely tests for odor threshold, odor discrimination and odor identification.
48492069|NCT04761458|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
48492070|NCT04761458|DIAGNOSTIC_TEST|Clinical Frailty Scale|The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
48492071|NCT04761458|DIAGNOSTIC_TEST|Neuropsychological test battery|Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
48492072|NCT05388240|OTHER|Education via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources."
48492073|NCT05388240|OTHER|Education and Exercise via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support."
48651612|NCT03934684|DRUG|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib will be administered as a 10 minute infusion.~* Lenalidomide will be taken orally.~* Dexamethasone will be taken by mouth or intravenously."
48651613|NCT06421441|OTHER|Self Management Skills Training|Nursing students will be given self-management skills training for a total of 12 hours, two days a week, two hours a day (60 min. + 60 min.) for three weeks.
48651614|NCT03119129|BEHAVIORAL|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
48331195|NCT05445518|BEHAVIORAL|Jump Start Plus COVID Support|The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
48331196|NCT05445518|BEHAVIORAL|Healthy Caregivers-Healthy Children (HC2)|The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
48331197|NCT05099237|DEVICE|OURA Ring|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
48331198|NCT05099237|DEVICE|WithingsScan Watch|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
48331199|NCT05099237|DRUG|Isansys Patient Status Engine|Participants in cohort 3 will also be asked to wear Isansys monitoring devices whilst they are in hospital. They will begin to wear the monitors prior to CAR T-cell therapy and continue for 28 days post infusion. Participants will be asked to wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.
48331200|NCT05099237|OTHER|Quality of Life Surveys|On a weekly basis participants will be asked to complete satisfaction surveys for the devices they are wearing (ring and watch) and report on their quality of life through standardised questionnaires. These surveys will be delivered electronically to participants via their smartphone or tablet device. There will be an option for participants to report adhoc symptoms via an app on their smartphone or tablet device.
48331201|NCT05099237|DIAGNOSTIC_TEST|Blood Samples|"COHORT 3 ONLY~Participants in Cohort 3 only will be asked to provide a series of blood samples to measure inflammatory molecules during the study. These will be requested at various intervals during face-to-face visits and whilst the patient is in hospital:~* Baseline blood sample during study enrolment~* Post-lymphodepletion and prior to CAR T-cell infusion (this may be on day -1 or day 0 as needed)~* Post CAR T-cell infusion:~  * Day 1~ * Day 3~ * Day 6~ * Day 9~ * Day 14 (if the participant remains in hospital)~A sample of blood will be taken at baseline and a further sample post lymphodepletion and prior to CAR T-cell infusion. Post CAR T-cell infusion, samples will be taken at two timepoints (morning and afternoon) on each of the sampling days."
48331202|NCT05099237|OTHER|Daily Weights|"COHORT 3 ONLY~During their inpatient stay, up to a maximum of 28 days, participants in Cohort 3 will be supported to weigh themselves daily using a Withings Body Scale."
48331203|NCT05560178|OTHER|SEXUAL HEALTH EDUCATION|Women in the intervention group will be given sexual health education once a week for 4 weeks
48331204|NCT05855395|DRUG|Glucocorticoid|standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
48331205|NCT01824693|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
48331206|NCT01824693|DRUG|Busulfan|Given IV
48331207|NCT01824693|DRUG|Cyclophosphamide|Given IV
48331208|NCT01824693|DRUG|Fludarabine Phosphate|Given IV
48331209|NCT01824693|OTHER|Laboratory Biomarker Analysis|Correlative studies
48331210|NCT01824693|DRUG|Melphalan|Given IV
48331211|NCT01824693|DRUG|Mycophenolate Mofetil|Given IV or PO
48651615|NCT01177306|DRUG|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
48124611|NCT04290819|DIETARY_SUPPLEMENT|Creatine Monohydrate and Caffeine|0.1g/kg body weight (pre measured creatine) and 3mg/kg body weight (pre measured caffeine) self administered 1hr prior to working out mixed in water.
48124612|NCT04290819|DIETARY_SUPPLEMENT|Caffeine|3mg/kg of body weight (pre measured caffeine) and 0.1g/kg of bodyweight (pre measured maltodextrin- creatine placebo) self administered 1 hr prior to working out mixed in water.
48124613|NCT04290819|DIETARY_SUPPLEMENT|Placebo|0.1g/kg of body weight (pre measured maltodextrin) and 3mg/kg of body weight (pre measured micronized cellulose powder) self administered 1 hr prior to working out mixed in water.
48124614|NCT00858117|BIOLOGICAL|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
48124615|NCT00858117|BIOLOGICAL|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
48124616|NCT05565508|PROCEDURE|new laparoscopic access technique for group a|new laparoscopic access technique through the epigastric region
48124617|NCT05565508|PROCEDURE|Hasson's technique for laparoscopic access in group b|Hasson's technique for laparoscopic access in group b
48124618|NCT04992585|DEVICE|Percutaneous transhepatic implantation of self-expandable metal stent|A self-expandable metal stent is inserted into the extrahepatic bile duct which is obstructed by malignant disease
48124619|NCT04433975|BEHAVIORAL|Psychosocial Pain Management (PPMI)|The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
48331212|NCT01824693|OTHER|Pharmacological Study|Correlative studies
48331213|NCT01824693|DRUG|Tacrolimus|Given IV or PO
48331214|NCT00740324|DRUG|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
48651616|NCT06638138|DEVICE|Flexband|Artelon FLEXBAND is a commercially available, polycaprolactone polyurethane urea (PCL/PUUR) multipolymer synthetic knitted mesh that is used for soft tissue reinforcement procedures. The device is biocompatible and degradable and has been used as an augmentation device in over 50,000 Orthopedic tendon and ligament reconstructive procedures. The FLEXBAND kits contain the device and all of the instrumentation needed to insert the device.
48651617|NCT05515575|DRUG|Niraparib|Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
48124620|NCT04433975|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
48124621|NCT04857294|PROCEDURE|TMJ unilateral discectomy|All patients underwent general anesthesia with nasotracheal intubation, managed in most cases with intravenous anesthesia protocol, usually with remifentanil infusion. Intraoperative steroids, usually dexamethasone, were administered primarily to minimize postoperative swelling. A classic preauricular incision or a root of helix inter tragus notch incision (RHITNI) was used in most cases, as previously described. No bandage or special care was performed after the surgery. No air washing restrictions were recommended.
48331215|NCT00740324|DRUG|NPO-11|NPO-11 after administration of NPO-11
48331216|NCT00740324|DRUG|NPO-11|1 mg glucagons after administration of NPO-11
48331217|NCT03302897|BIOLOGICAL|LEP-F1 + GLA-SE|Investigational vaccine
48331218|NCT02156804|DRUG|Nivolumab (BMS-936558)|
48331219|NCT02807844|DRUG|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
48651618|NCT04913116|DIAGNOSTIC_TEST|Comparison of antigen tests with RT-PCR as reference method|Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
48331220|NCT02807844|DRUG|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
48331221|NCT03853512|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
48331222|NCT03853512|OTHER|Semisolid vaseline|Product is applied to the other side of the inguinal region.
48331223|NCT00987090|BIOLOGICAL|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
48331224|NCT00987090|RADIATION|MRI|intervention at the inclusion and 18 months after
48331225|NCT00987090|PROCEDURE|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
48331226|NCT00987090|BIOLOGICAL|Apolipoprotein E genotyping|genotyping at the inclusion
48331227|NCT00987090|BIOLOGICAL|Study of cerebrospinal fluid|intervention at the inclusion
48331228|NCT05793216|BEHAVIORAL|VestibulOTherapy|"For this study, the following activity-orientated interventions will occur within the natural learning environments so that generous opportunities exist for neural plasticity and growth.~Each student will be engaged in 20-30 minutes/day of intermittent classroom activities, plus 20-30- minutes of daily stability work embedded into classroom routines including stabilizing self on a Hokki stool or t-stool or standing on a balance board during sedentary work, such as circle time or read-a-loud."
48331229|NCT03516955|DRUG|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
48331230|NCT04469816|BEHAVIORAL|Family Check-Up 4 Health|A parent-training intervention to improve child health, school readiness and manage obesity.
48331231|NCT04469816|OTHER|Services as Usual|Services/Treatment as usual.
48331232|NCT01913860|BEHAVIORAL|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
48331233|NCT00309257|DRUG|ACE I, ATA II and Statins|
48331234|NCT00309257|DRUG|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
48331235|NCT01337167|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
48331236|NCT01337167|BIOLOGICAL|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
48331237|NCT01337167|BIOLOGICAL|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
48331238|NCT01337167|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
48331239|NCT01337167|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
48331240|NCT01337167|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
48331241|NCT01337167|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
48331242|NCT01337167|BIOLOGICAL|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
48331243|NCT06499285|BIOLOGICAL|KER-050|KER-050 administered subcutaneously every 4 weeks
48331244|NCT06499285|DRUG|Placebo|Placebo administered subcutaneously every 4 weeks
48331245|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
48331246|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
48331247|NCT00597909|DRUG|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
48492074|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 1|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
48492075|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 2|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
48651619|NCT06675461|BEHAVIORAL|Gold Card Intervention|A 4-session manualized intervention consisting of weekly scheduled 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support.
48651620|NCT06675461|BEHAVIORAL|Treatment as usual|Access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
48124622|NCT01421667|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
48124623|NCT01421667|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion
48331248|NCT01771211|DEVICE|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
48331249|NCT03185104|DRUG|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
48331250|NCT03185104|DRUG|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
48331251|NCT01061736|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48331252|NCT01061736|DRUG|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48331253|NCT01061736|DRUG|Methotrexate|Same weekly dose as received prior to enrollment
48331254|NCT01061736|DRUG|Folic Acid|According to local standard
48331255|NCT03130712|DRUG|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
48124624|NCT05859152|OTHER|Zona Pellucida-Bound Sperm Selection for ICSI|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that was bound to the ZP of an immature oocyte.
48124625|NCT05859152|OTHER|Routine Embryologist Selected Sperm|one half of the patients' oocytes will be inseminated via the ICSI procedure with sperm that has been selected based on morphology and mobility characteristics by the embryologist per routine.
48124626|NCT03771352|DEVICE|RxSight RxLAL|The patients will be assessed for 6 months
48124627|NCT00370383|DRUG|Erlotinib|erlotinib 150 mg/day once daily
48124628|NCT00370383|DRUG|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
48331256|NCT01899586|OTHER|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
48331257|NCT01899586|OTHER|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at \>50% of heart rate reserve (HRR) for 45 minutes, three days per week.
48492076|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 3|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
48492077|NCT06457399|DRUG|Heliox|Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.
48492078|NCT06457399|DRUG|Oxygen|Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
48492079|NCT02088190|PROCEDURE|Sleeve gastrectomy|Type of bariatric surgery
48492080|NCT02579161|DRUG|cephalosporins|Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
48492081|NCT02579161|DRUG|Fluoroquinolones|If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
48492082|NCT02579161|DRUG|Clindamycin|If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
48492083|NCT02579161|DRUG|Ampicillin/Gentamicin|5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
48492084|NCT01593241|DRUG|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
48492085|NCT01593241|RADIATION|Involved node RT|Involved node RT
48492086|NCT00359242|BEHAVIORAL|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
48492087|NCT00359242|BEHAVIORAL|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
48492088|NCT05534308|PROCEDURE|Transoperative taping|The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.
48492089|NCT05534308|OTHER|No trasoperative taping|Patients will received only compression stockings after surgery
47974567|NCT02982876|PROCEDURE|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
47974568|NCT02982876|PROCEDURE|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
47974569|NCT02982876|DEVICE|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
48331258|NCT02270801|DRUG|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
47974570|NCT00001830|DRUG|Th2 cells in allo HSCTT|
47974571|NCT00001830|DRUG|Th2 Cells|
48124629|NCT00692042|DRUG|AZD1704|One dose, by mouth
48124630|NCT00897169|OTHER|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
48124631|NCT00897169|OTHER|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
48492090|NCT03582280|DRUG|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
48124632|NCT05747716|DRUG|SBRT, Fruquintinib, Cadonilimab|Radiation: Stereotactic body radiationtherapy (SBRT) for metastatic sites (less than 5) Fruquintinib: 5mg, po, everyday; Cadonilimab: 10mg/kg, iv, q3w
48124633|NCT01467375|DRUG|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
48331259|NCT04801797|DRUG|Cytarabine|Intravenous infusion
48331260|NCT04801797|DRUG|Idarubicin|Intravenous infusion
48331261|NCT04801797|DRUG|Daunorubicin|Intravenous infusion
48331262|NCT04801797|DRUG|Liposomal daunorubicin and cytarabine|Intravenous infusion
48331263|NCT04801797|DRUG|Venetoclax|Orally by mouth
48331264|NCT04801797|DRUG|Azacitidine|Intravenous infusion
48331265|NCT00307242|DRUG|Adefovir Dipivoxil|
48331266|NCT04720495|PROCEDURE|One stage ridge splitting with simultaneous implant placement|"A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure."
48331267|NCT04720495|PROCEDURE|Two-stage ridge splitting with implant placement|"The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting"
48331268|NCT02854553|PROCEDURE|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
47974572|NCT01479673|DIETARY_SUPPLEMENT|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
47974573|NCT02034110|DRUG|Dabrafenib|A 150 mg twice daily capsule administered orally on a continuous basis.
48331269|NCT02854553|PROCEDURE|rectus sheath block|ultrasound guided rectus sheath block
48331270|NCT02915887|OTHER|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
48651621|NCT06669702|BEHAVIORAL|12-week home based exercise|"Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an rating of perceived exertion in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.~Participants can break down the exercise time in a way that suits their time, i.e., they can do 3 × 10 minutes, 2 × 15 minutes, etc."
48651622|NCT06669702|BEHAVIORAL|Routine care|Participants in this group will continue with their current routine care and will be given a diary of exercises that they can do, which are usually given to them as part of their health care routine by physiotherapists or consultants. The diary has information about yoga-like stretching practices.
48651623|NCT04427345|OTHER|Predictive factors for clinical response in patients with COVID-19.|Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
47974574|NCT02034110|DRUG|Trametinib|A 2 mg once daily tablet administered orally on a continuous basis.
47974575|NCT02740764|OTHER|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
48331271|NCT05172037|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
48651624|NCT03078231|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
48651625|NCT03078231|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
48124634|NCT03021369|DEVICE|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
48124635|NCT03829852|DRUG|Regorafenib|Treatment was performed based on physician's discretion
48124636|NCT02909413|DRUG|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
48331272|NCT05172037|BIOLOGICAL|Placebo|Saline
48492091|NCT03077906|OTHER|Medical Files data extraction|Medical Files data extraction
48492092|NCT02494102|DRUG|Modafinil|Atypical Psychomotor stimulant
48492093|NCT02494102|DRUG|Placebo|
48492094|NCT06156345|DEVICE|Conservative with Denneroll|Denneroll cervical traction orthodontic traction for 3 to 15 minutes once daily with conservative management of stretching and relaxation.
48492095|NCT06156345|OTHER|Conservative|conservative management of stretching and relaxation with placebo traction.
48492096|NCT05136118|PROCEDURE|TAPB|TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
48331273|NCT03316677|PROCEDURE|Intraoperative testing of colorectal anastomoses|"1. Insert a Foley catheter through the anus into the rectum.~2. Insufflate the Foley balloon with 5 cc of air.~3. Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~4. Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~5. Remove the saline from the pelvic space.~6. Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~7. Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
48331274|NCT03316677|PROCEDURE|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
48331275|NCT01142453|DRUG|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
48331276|NCT06206902|DRUG|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
48331277|NCT06088407|DRUG|with Tranexamic acid|Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
48331278|NCT03788863|DRUG|Diflucortolone valerate (BAY866146)|Follow clinical administration
48331279|NCT05269472|PROCEDURE|Trigeminal Electrophysiology|This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
48331280|NCT03962556|OTHER|bimanual palpation|bimanual palpation....i..
48331281|NCT03036423|BEHAVIORAL|Online video education|
48331282|NCT03036423|BEHAVIORAL|Computerized mental exercises|
48651626|NCT03775109|DRUG|Canakinumab 150mg/ml solution for injection|Canakinumab 150mg/ml solution for injection
47974576|NCT00309387|DIETARY_SUPPLEMENT|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
48124637|NCT02909413|DRUG|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
48331283|NCT01429610|DRUG|Rituximab+mVPDL|"1. Induction:~   * Dauno 90 mg/m2/d by civ (d1-3)~  * Vinc 2 mg iv (d1, 8)~  * Pred 60 mg/m2/d po (d1-14)~  * for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~  * Rituximab 375mg/m2/d (d8)~2. Consolidation A (cycle1)~   * D 45 mg/m2/day by continuous iv (d1, 2)~  * V 2 mg iv (d1, 8)~  * P 60 mg/m2/day po (d1-14)~  * for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~  * Rituximab 375mg/m2/d (d8)~3. Consolidation B (cycles2\&4)~   * Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~  * Eto 150 mg/m2/d iv over 3 hr (d1-4)~  * Rituximab 375mg/m2/d d8~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~  * Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~  * Rituximab 375mg/m2/d (d8\&22)~5. Maintenance (for 2 years)~   - for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~6. Consider alloHCT"
48651627|NCT03775109|DRUG|Placebo|100ml 5% Dextrose
48651628|NCT05639725|PROCEDURE|maxillary Ist premolar extraction|Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling \& alignment.
48651629|NCT05639725|PROCEDURE|SURGICAL|Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
48651630|NCT00370578|DEVICE|repeated thrombus aspiration during primary PCI|
48651631|NCT06318546|DRUG|Dexmedetomidine Injection [Precedex],,,|patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
48651632|NCT06318546|DRUG|Fentanyl|will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
48651633|NCT02455726|DIETARY_SUPPLEMENT|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
47974577|NCT00309387|OTHER|Placebo|placebo tablets manufactured to mimic Centrum tablets.
48124638|NCT02335554|BEHAVIORAL|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
48124639|NCT02335554|BEHAVIORAL|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
48124640|NCT03498196|DRUG|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
48124641|NCT00310635|BIOLOGICAL|Meningococcal C conjugate vaccine|
48124642|NCT03003624|DEVICE|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
48331284|NCT01017341|DEVICE|PSU hip protector|hip protetor
48331285|NCT00103571|DRUG|Olanzapine|
48331286|NCT00103571|DRUG|Aripiprazole|
48331287|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
48331288|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
48331289|NCT00583661|DEVICE|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
48331290|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
48331291|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
48651634|NCT02455726|DIETARY_SUPPLEMENT|Fructose|Oral fructose 10 g twice a day
48651635|NCT02455726|DRUG|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
48651636|NCT02455726|DRUG|Pregabalin|Pregabalin 25 mg at 8 pm
48331292|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
48331293|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
48331294|NCT05831345|DRUG|Methadone Hydrochloride|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
48331295|NCT05831345|DRUG|Sufentanil Citrate|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
48331296|NCT00119236|DRUG|tanespimycin|
48331297|NCT00119236|DRUG|irinotecan hydrochloride|
48331298|NCT02227056|DRUG|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
48331299|NCT00160992|BIOLOGICAL|Melan-A analog peptide|
48651637|NCT02928835|DEVICE|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
48651638|NCT01475825|DRUG|mipomersen sodium 200 mg|Subcutaneous mipomersen 200 mg once weekly
48651639|NCT01475825|DRUG|Placebo|Placebo vehicle for subcutaneous injection.
48331300|NCT01015729|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
48331301|NCT01015729|DRUG|Esomeprazole|oral, single dose
48331302|NCT01015729|DRUG|ASA|Tablet, oral, single dose
48331303|NCT02288611|DIETARY_SUPPLEMENT|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
48331304|NCT02288611|DIETARY_SUPPLEMENT|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
48331305|NCT04638868|DEVICE|Microsieve device|Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
48331306|NCT04638868|DEVICE|Cell surface marker-based platform|Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
48331307|NCT04019795|DEVICE|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
48331308|NCT04019795|DEVICE|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
48331309|NCT04019795|DEVICE|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
48331310|NCT04019795|DEVICE|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
48331311|NCT03696940|DRUG|L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg|Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
48651640|NCT01475825|DRUG|mipomersen sodium 70 mg|Subcutaneous mipomersen 70 mg thrice weekly
48651641|NCT06413875|OTHER|education|Education Specific to Menopause Symptoms
48651642|NCT04808011|DEVICE|Intelligent Dialysis Assistant (IDA)|The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
48651643|NCT00593619|DRUG|Iron dextran|300mg in 250cc normal saline given over 2 hours
48651644|NCT00593619|DRUG|Iron sucrose|300mg in 250cc normal saline given over 2 hours
48651645|NCT05988619|DEVICE|Transcranial Magnetic Stimulation|TMS is a noninvasive method of brain stimulation administered by physicians in the UCLA TMS Clinical and Research Service. It is an FDA-approved treatment for Major Depressive Disorder.
48651646|NCT05988619|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy|This Way Up is an internet-based cognitive behavioral therapy (iCBT) for depression and anxiety. Participants learn about depression and anxiety symptoms, as well as behavioral strategies for addressing these symptoms. Participants are provided with homework exercises designed to help them engage in these strategies regularly.
48651647|NCT05988619|BEHAVIORAL|Psychoeducation|Stories of the Mind is an educational program that is freely available through the Public Broadcast Service (PBS). Participants view video testimonials in which individuals describe their personal experiences across a variety of mental health concerns.
48651648|NCT01063569|DRUG|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
48651649|NCT01063569|DRUG|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
48651650|NCT06646679|OTHER|Ultrasonic imaging|Ultrasonic imaging
48331312|NCT03696940|DRUG|Atorvastatin 10mg|Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
48331313|NCT00286364|DRUG|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
48331314|NCT02261883|DRUG|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
48331315|NCT02261883|DRUG|Placebo|Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
48331316|NCT01617655|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
48331317|NCT01617655|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
48331318|NCT01617655|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
48331319|NCT00498849|DEVICE|CPAP|
48331320|NCT05650515|OTHER|Co-creation|The development of a technology-based exercise intervention based on ideas of older adults and experts in the field of geriatric rehabilitation/research/medicine
48331321|NCT00880880|OTHER|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
48331322|NCT03794713|DEVICE|Patient support tool|The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
48331323|NCT03678584|OTHER|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
48124643|NCT03003624|DEVICE|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
48331324|NCT05653804|PROCEDURE|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
48331325|NCT04908241|OTHER|TRAIL|"Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended."
48331326|NCT04908241|OTHER|EDUCATION|"EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session."
48331327|NCT02591238|OTHER|non-smoker oral placebo|Participants oral placebo last 2 weeks.
48331328|NCT02591238|DRUG|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
48331329|NCT02591238|OTHER|smoker oral placebo|Participants oral placebo last 2 weeks.
48331330|NCT02591238|DRUG|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
48331331|NCT03060967|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
48331332|NCT03670498|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
48124644|NCT03003624|DEVICE|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
48331333|NCT03670498|DEVICE|2 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
48331334|NCT00393003|DEVICE|Closed-loop anesthesia system|
48331335|NCT00356395|DRUG|ramipril, candesartan|
48331336|NCT05567393|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
48331337|NCT05567393|DRUG|TAK-951|TAK-951 SC injection
48331338|NCT05285033|DRUG|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
48331339|NCT05238987|DIETARY_SUPPLEMENT|Ferrous sulphate|Single dose of ferrous sulphate (120 mg of elemental iron)
48331340|NCT00783172|DRUG|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
48331341|NCT00783172|BIOLOGICAL|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
48331342|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
48331343|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
48331344|NCT01691053|DRUG|Spironolactone|50mg once daily
48331345|NCT01691053|DRUG|Placebo|Placebo
48331346|NCT00556335|PROCEDURE|manual aspiration|air aspiration
48331347|NCT00556335|PROCEDURE|conventional drainage|drainage, pneumocath
48331348|NCT01826526|DEVICE|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
48331349|NCT02174016|DIETARY_SUPPLEMENT|Ketogenic diet|
48331350|NCT04263779|BEHAVIORAL|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
48331351|NCT04263779|BEHAVIORAL|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
48331352|NCT02299648|OTHER|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
48331353|NCT01379924|BEHAVIORAL|Parenting/Life Skills Intervention|Modules adapted from the Ansell-Casey Life Skills Assessment Curriculum, the Women's Negotiation Project Curriculum for Teen Mothers and the Nurturing Curriculum. Goal is to help teen mothers develop positive parenting skills, decrease repeat pregnancy and acquire skills of daily living. The series of five, one-hour long, structured, one-on-one interactive modules aims to help teens build positive, empathetic relationships with their children, while enhancing self-efficacy and increasing the sense of self- worth for parents and children. Domains addressed include child development/discipline, safety, house/money management, social relationships, career planning, substance abuse and community and interpersonal violence.
48331354|NCT01379924|OTHER|Teen-tot medical home|Medical, mental health, and social services provided to teen parents and their children
48331355|NCT03815123|DIAGNOSTIC_TEST|cardiac CT|The cardiac CT examinations are indicated by the referring physician. The participation in this study has no influence on the further diagnostic and therapeutic regimen.
48331356|NCT02810951|GENETIC|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.
48331357|NCT00045487|DRUG|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
48331358|NCT05871021|RADIATION|Dose escalation of radiation dose beyond the therapeutic standard|Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab
48331359|NCT05082506|BEHAVIORAL|Acupressure|Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
48331360|NCT05779345|PROCEDURE|surgery|short implant placement
48331361|NCT01206790|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
48651651|NCT05136027|OTHER|Combined training|Low-intensity interval training and resistance exercise
48651652|NCT03412591|DRUG|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
48651653|NCT06611696|DRUG|Avacopan, prednisolone and rituximab|Patients in the avacoapn group will be treated with avacoapn, short-term reduced-dose prednisolone and rituximab.
48331362|NCT02233907|DRUG|Ventilat® - metered dose inhaler|
48331363|NCT04883567|DIAGNOSTIC_TEST|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
48331364|NCT04804280|GENETIC|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1) will be investigated. Cord blood will be collected at birth for PT and FT, only for PT a peripheral blood sample will be collected at hospital discharge, during routine clinical procedures. Genomic DNA will be extracted from aliquots of 0. 2 ml of each blood sample with the GeneElute Blood Genomic DNA kit (Sigma) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
48651654|NCT06611696|DRUG|Prednisolone and rituximab|Patients in the glucocorticoid arm will be treated with reduced-dose prednisolone and rituximab.
48651655|NCT01213251|DEVICE|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
48651656|NCT01213251|DEVICE|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
48651657|NCT02973022|OTHER|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC\&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
48651658|NCT03272334|DRUG|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
48651659|NCT04550845|BEHAVIORAL|Focus group analyses|Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
48651660|NCT02489487|DRUG|VM-1500|VM-1500 40 mg
48651661|NCT02489487|DRUG|Darunavir|Darunavir 600 mg
48651662|NCT02489487|DRUG|Ritonavir|Ritonavir 100 mg
48331365|NCT04804280|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. a trained experimenter will apply tactile stimulation associated with affective touch characteristics to the child with a soft brush on the right anterior tibial region in proximal and distal directions. The length of the stimulated area will be measured to cover approximately 15 cm, and tactile stimulations will be applied at a rate of 5 cm/s for 15s, with randomized intervals between stimuli of 10-15s (resulting in 5 stimulations in a 15s block). A regular audio signal will help the researcher to keep a constant stroke velocity. Audio commands will also be used to direct the experimenter. Infant must be asleep (natural sleep) during the fMRI acquisition.
48124645|NCT00885924|DRUG|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
48331366|NCT04416945|OTHER|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
48331367|NCT04416945|OTHER|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~1. Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~2. Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
48331368|NCT04416945|OTHER|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~* Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~* At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
48331369|NCT06580730|PROCEDURE|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
48331370|NCT06580730|OTHER|Standard medical treatment|Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician.
48331371|NCT02373241|DRUG|Losartan|Standard dosing
48331372|NCT02373241|DRUG|Losartan|Experimental dosing
48331373|NCT02428972|DRUG|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
48331374|NCT02428972|DRUG|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
48331375|NCT03702426|DRUG|GMCSF|GMCSF 1.5mcg/Kg
48331376|NCT03702426|DRUG|Norfloxacin|Tablet Norfloxacin 400 mg
48331377|NCT00734812|PROCEDURE|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
48331378|NCT00734812|PROCEDURE|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
48331379|NCT04447534|DRUG|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
48124646|NCT00885924|DRUG|Placebo|NaCl 0.9%
48331380|NCT04447534|DRUG|zinc|Zinc tablets
48651663|NCT02489487|DRUG|Raltegravir|400 mg Raltegravir
48651664|NCT06275074|PROCEDURE|Dry Needling|Insertion of filiform needles into cervicothoracic multifidi, upper trapezius, and suboccipital muscles
48651665|NCT06275074|OTHER|Therapeutic Exercise|Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
48124647|NCT00364702|DRUG|methylphenidate|
48124648|NCT02787031|PROCEDURE|Neuraxial anesthesia|
48124649|NCT02787031|PROCEDURE|General anesthesia|
48124650|NCT01226849|DRUG|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
48124651|NCT00709423|DRUG|Moxaverine|
48124652|NCT00709423|DRUG|Moxaverin 150mg|intravenous administration
48124653|NCT00709423|DRUG|NaCl|intravenous administration
48124654|NCT02378922|BIOLOGICAL|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
48124655|NCT02378922|OTHER|Laboratory Biomarker Analysis|Correlative studies
48124656|NCT02378922|OTHER|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
48124657|NCT05957731|OTHER|Routine physical therapy|Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.
48124658|NCT05957731|OTHER|antagonist contract relax|antagonist contraction i used to improve spasticity and range of motion in stroke patients
48124659|NCT05957731|OTHER|agonist contract relax|agonist contraction is used to improve spasticity and range of motion in stroke patients
48331381|NCT04401397|PROCEDURE|Intensive early mobilization techniques|"Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques."
48331382|NCT02615067|DRUG|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
48331383|NCT02615067|DIAGNOSTIC_TEST|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
48124660|NCT04955431|BEHAVIORAL|Sleep Restriction|Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
48124661|NCT04955431|BEHAVIORAL|Normal Sleep|Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
48331384|NCT05200156|DIETARY_SUPPLEMENT|Phosphatidyl Choline|conventional management + phosphatidyl choline tablets
48124662|NCT00593489|OTHER|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
48124663|NCT03312322|OTHER|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
48124664|NCT03312322|OTHER|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s."
48124665|NCT03312322|OTHER|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
48124666|NCT04938752|DRUG|DA-2811|single dose administration (one tablet once a day)
48124667|NCT04938752|DRUG|DA-2811-R|single dose administration (one tablet once a day)
48124668|NCT03818893|DRUG|Combination of GEN0101 and Pembrolizmub|New Combination immunotherapy GEN0101 and Pembrolizmub
48124669|NCT04979715|PROCEDURE|physitherapy follow-up|preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
48124670|NCT04979715|OTHER|control|no intervention; preoperative patient informaiton and information leaflet
48124671|NCT03359317|BEHAVIORAL|jogging|Jogging as instructed for 1 year
48124672|NCT03818100|RADIATION|Intensity modulated radiotherapy (IMRT)|Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.
48124673|NCT03818100|DRUG|Endocrine therapy|Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
48124674|NCT03818100|PROCEDURE|Breast conserving surgery|Surgery carried out using local protocol following completion of endocrine therapy.
48331385|NCT03134924|BEHAVIORAL|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
48331386|NCT03134924|BEHAVIORAL|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
48331387|NCT02253017|OTHER|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
48651666|NCT06557811|DRUG|Semaglutide|After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.
48651667|NCT03607110|DRUG|Ketamine|sedation drugs
48651668|NCT03607110|DRUG|fentanyl|sedation drugs
48651669|NCT03607110|DEVICE|patient control analgesia|patient control analgesia
48651670|NCT05777863|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
48651671|NCT06640868|BEHAVIORAL|MyChart nurse message|Receipt of a MyChart nurse message around 34 weeks encouraging RSV vaccination
48651672|NCT06640868|BEHAVIORAL|SMFM video|Receipt of SMFM video around 34 weeks encouraging RSV vaccination
48651673|NCT06640868|BEHAVIORAL|Visual aid|Receipt of a visual aide encouraging RSV vaccination at 28-30 wks
48331388|NCT03165864|DRUG|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
48331389|NCT03165864|OTHER|Placebo|Saline .9%
48331390|NCT06364761|PROCEDURE|Bag in the lens cataract surgery|Cataract surgery using the Morcher 89A intraocular lens
48331391|NCT01265342|DRUG|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
48331392|NCT01265342|DRUG|Placebo|Placebo nebulised suspension twice a day for 10 days
48331393|NCT03384108|OTHER|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
48331394|NCT03384108|OTHER|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
48492097|NCT04222374|PROCEDURE|Intervention in the UroCCR sites|"1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~2. DNA extraction:~   * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~  * 1 aliquot for the UroCCR biobank.~  * For patients from other UroCCR centers, only 1 aliquot will be constituted:~  * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
48492098|NCT04222374|PROCEDURE|Intervention in the CRB of Bordeaux University Hospital|"1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~2. Overall packing of GWAS samples for shipment to the NCI.~3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
48651674|NCT05681078|BEHAVIORAL|A Matter of Balance: Managing Concerns about Falls|A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
47974578|NCT05526820|BIOLOGICAL|The live attenuated varicella vaccine and the inactivated hepatitis A vaccine|"The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd,the inactivated hepatitis A vaccine was manufactured by Sinovac Biotech Co., Ltd.~The live attenuated varicella vaccine:live varicella-zoster virus in 0.5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection.~The inactivated hepatitis A vaccine:250 U inactivated virus in 0.5mL of aluminium hydroxide solution per injection.~All subjects received hepatitis A vaccine in the upper left arm and varicella vaccine in the upper right arm."
48124675|NCT02241070|BEHAVIORAL|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
48492099|NCT04222374|PROCEDURE|Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital|Transfer of the data associated with the samples to the NCI.
48492100|NCT04222374|PROCEDURE|Subsequent intervention at the NCI (for information)|"1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
48124676|NCT05136170|DRUG|Oxervate|One drop of the test product will be instilled in both eyes TID
48124677|NCT05136170|OTHER|Vehicle|One drop of the placebo will be instilled in both eyes TID
48124678|NCT03197116|OTHER|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
48331395|NCT05737407|OTHER|LUS-guided choice of Peep|Choice of Peep guided by lung ultrasound to avoid atelectasis
48331396|NCT05737407|OTHER|Standard choice of Peep|Choice of Peep according to standard practice
48331397|NCT05736562|DIETARY_SUPPLEMENT|Ritual Epre Multimineral-Vitamin Supplement|The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.
48331398|NCT05736562|DIETARY_SUPPLEMENT|Placebo Control|This is a customarily designed blank placebo provided by Ritual.
48124679|NCT03197116|OTHER|No other|No additional reminder will be offered
48331399|NCT00482300|PROCEDURE|Systematic pelvic lymphadenectomy|
48331400|NCT02908633|PROCEDURE|canaloplasty and phacoemulsification|
48331401|NCT02999100|DRUG|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
48331402|NCT02999100|DRUG|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
48331403|NCT02999100|DRUG|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
48331404|NCT02999100|DEVICE|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
48331405|NCT01508494|DRUG|Galantamine|16 mg galantamine daily P/O
48331406|NCT01508494|DRUG|placebo|placebo
48331407|NCT00663598|DRUG|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
48331408|NCT03745300|DRUG|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
48331409|NCT03745300|DRUG|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
47974579|NCT06502535|DIETARY_SUPPLEMENT|Inulin|15 g inulin once daily for 4 weeks.
48124680|NCT02698813|BIOLOGICAL|umbilical cord mesenchymal stem cells and hyaluronic acid|
48492101|NCT02138292|DRUG|Trametinib (2mg)/Digoxin (.25mg)|"1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
48492102|NCT00343239|DRUG|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
48492103|NCT00343239|DRUG|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
48492104|NCT00343239|DRUG|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
48492105|NCT06426108|DRUG|Fluoride Varnishes|the investigators will utilize a fluoride varnish with a concentration of 22,600 ppm F. The application will be facilitated using a microbrush, ensuring thorough coverage over the entire length of the lesion for a duration of 30 seconds. Following application, the varnish will be finished with water to create a film on the tooth surface. After completing the interventions, patients will receive instructions to refrain from consuming hard foods and to postpone tooth brushing for at least four hours, adhering to the manufacturer's recommendations.
48492106|NCT06426108|DRUG|Varnishes placebo|the investigators will apply a placebo varnish without the active ingredient (fluoride), ensuring that it is packaged identically to the fluoride varnish and has the same taste and texture, thus maintaining consistency in application. The varnish will be applied using a microbrush, spreading it evenly over the entire length of the lesion for a duration of 30 seconds. Following the interventions, patients will receive instructions to avoid consuming hard foods and to delay tooth brushing for at least four hours after applying the varnish.
48651675|NCT04077086|DEVICE|Spectacles|Intervention group children in middle school Year 1 will receive spectacles in December 2024. Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone 32 months (December 2024 - July 2027) of treatment by the endpoint of the trial.
47974580|NCT06502535|DIETARY_SUPPLEMENT|Potassium nitrate and inulin|1300 mg potassium nitrate once daily for 4 weeks and 15 g inulin once daily for 4 weeks.
47974581|NCT04769440|DRUG|mg sulphate|mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
48124681|NCT02698813|DRUG|hyaluronic acid|
48124682|NCT01989741|OTHER|Sleep restriction|4 hours sleep by night during one week
48124683|NCT04406792|BEHAVIORAL|DPP only|Participation in the online DPP only with a mixed group of participants at risk for type 2 diabetes and doula divas are not the team leaders.
48124684|NCT04406792|BEHAVIORAL|Diabetes Prevention Program (DPP) online + doula divas|Participation in the DPP online intervention with doula divas as team leaders.
48124685|NCT01808339|DRUG|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
48124686|NCT01808339|DRUG|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
48331410|NCT03745300|DRUG|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
48331411|NCT03002103|DRUG|EndoTAG-1|
48331412|NCT03002103|DRUG|Paclitaxel|
48651676|NCT03759197|DRUG|188-0551 Spray|Topical Spray containing active drug
48651677|NCT03759197|DRUG|Vehicle Spray|Topical Spray containing no active drug
47974582|NCT03069807|OTHER|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
47974583|NCT03069807|OTHER|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
47974584|NCT00440219|DRUG|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
47974585|NCT00440219|DRUG|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
48331413|NCT03002103|DRUG|Gemcitabine Hydrochloride|
48124687|NCT05235906|DRUG|Surufatinib+Sintilimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
48124688|NCT05364216|BEHAVIORAL|Measurement of cognitive function|Patients undergoing thoracoscopic surgery underwent general anesthesia.MMSE and MoCA were assessed at one day before surgery, one day after surgery, and three months after surgery
48124689|NCT05364216|PROCEDURE|Thoracic paravertebral block|"The patient was placed in lateral supine position, and the T5 spinous process was moved 2 to 3 cm laterally to the operative side as the puncture point, and the pleura and T5 transverse process were observed, and the paraspinal space was observed on the lower lateral side of the transverse process. Using in-plane technique, the needle position was adjusted under ultrasound visualization to reach the paraspinal space. 20ml 0.375% ropivacaine was injected into the suction syringe when there was no blood or gas, and the drug liquid could be seen spreading outside the pleura. Landscape sign appeared, indicating successful block"
48124690|NCT05364216|BEHAVIORAL|The assessment of cognitive function|Participants were assessed for MMSE and MoCA at the same period as the group C
48124691|NCT01671267|BEHAVIORAL|Strength training|
48124692|NCT01671267|BEHAVIORAL|Ergonomic|
48124693|NCT00703820|DRUG|Cytarabine|See Detailed Description
48124694|NCT00703820|DRUG|Daunorubicin|See Detailed Description
48124695|NCT00703820|DRUG|Etoposide|See Detailed Description
48124696|NCT00703820|DRUG|Clofarabine|See Detailed Description
48331414|NCT01153906|OTHER|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
48331415|NCT05321966|OTHER|Visual video education|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
48492107|NCT06426108|RADIATION|Low-Intensity Laser 1J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 1 Joule, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
48492108|NCT06426108|RADIATION|Low-Intensity Laser 2J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 2 Joules, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
48492109|NCT02858492|DRUG|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
48492110|NCT02858492|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
48124697|NCT00703820|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
48124698|NCT05927896|DIAGNOSTIC_TEST|6-item Carpal Tunnel Syndrome Symptoms Scale|6-item Carpal Tunnel Syndrome Symptoms Scale is a self-reported 6 item questionnaire.
48124699|NCT04245644|BEHAVIORAL|use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins|enrolled patients will be asked details regarding their daily drug use, before and after diagnosis of pancreatic cancer
48124700|NCT02757898|DRUG|Biotin-Labeled Red Blood Cells (RBCs)|"500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
48331416|NCT02814695|DIETARY_SUPPLEMENT|Vit E|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
48492111|NCT01870245|DRUG|ACHN-975|Intravenous multiple dose
47974586|NCT00774644|DRUG|Clarithromycin 500mg|
47974587|NCT05562128|BEHAVIORAL|Active forest therapy|Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.
48331417|NCT02814695|DIETARY_SUPPLEMENT|Yeast|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
48331418|NCT02814695|DIETARY_SUPPLEMENT|Vit C 1|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
48331419|NCT02814695|DIETARY_SUPPLEMENT|Vit C 2|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
48331420|NCT02814695|DIETARY_SUPPLEMENT|Vit C 3|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
48492112|NCT01870245|DRUG|placebo|Intravenous multiple dose
48331421|NCT02747771|BEHAVIORAL|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
48331422|NCT05386927|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
48492113|NCT02299817|DRUG|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
48492114|NCT02299817|DRUG|Placebo|Placebo
48492115|NCT00006472|DRUG|carboplatin|Carboplatin AUC 6 days 1 and 22
48492116|NCT00006472|DRUG|fluorouracil|5FU 225mg/m2 continuous infusion on days 1-42 during radiation
48124701|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
48124702|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
48124703|NCT05031234|DRUG|anaesthesia without opiates|Anaesthesia without opiates for patients undergoing laparoscopic colectomy
48124704|NCT05031234|DRUG|anaesthesia with morphine|anaesthesia with morphine for patients undergoing laparoscopic colectomy
48124705|NCT05622110|PROCEDURE|Adhesive glue closure|Incision closure with adhesive glue
48331423|NCT02598505|DRUG|Indacaterol|
48492117|NCT00006472|DRUG|paclitaxel|taxol
48331424|NCT02598505|DRUG|Placebo|
48331425|NCT02928380|DEVICE|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
48331426|NCT02928380|DEVICE|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
48331427|NCT05768425|DIAGNOSTIC_TEST|Real-time quaking-induced conversion (RT-QuIC)|RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.
48331428|NCT05768425|DIAGNOSTIC_TEST|Cognitive test|Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
48492118|NCT00006472|PROCEDURE|conventional surgery|
48492119|NCT00006472|RADIATION|radiation therapy|The initial fields should be treated AP:PA when possible to a dose of 4500 cGy in 180 cGy fractions
48492120|NCT06227156|DRUG|Disitamab Vedotin Injection|2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle
48492121|NCT03865186|BEHAVIORAL|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
48492122|NCT03865186|BEHAVIORAL|no intervention|
48492123|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Individualized|Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
48124706|NCT05622110|PROCEDURE|Subcuticular closure|Incision closure with 3-0 vicryl subcuticular sutures
47974588|NCT05562128|BEHAVIORAL|Passive forest therapy|Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
48331429|NCT05768425|DIAGNOSTIC_TEST|Motor examination|Unified Parkinsons Rating Scale (UPDRS)
48331430|NCT05220241|BIOLOGICAL|Nasopharyngeal swab for RT-PCR SARS-CoV-2|2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
48331431|NCT04930211|DRUG|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
48331432|NCT06281405|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
48331433|NCT06281405|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
48331434|NCT06281405|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
48331435|NCT05995925|OTHER|Clinical Observation|Clinical Observation
48331436|NCT02136511|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
48331437|NCT02136511|DRUG|Rituximab|Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
48331438|NCT04559269|OTHER|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
48331439|NCT02746354|OTHER|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
48331440|NCT05971953|OTHER|Muscle Energy Technique|"They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins"
48331441|NCT05971953|OTHER|Conventional PT|"They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
48331442|NCT01147406|DRUG|N6022|This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
48331443|NCT01147406|DRUG|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
48331444|NCT00228930|DRUG|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
48331445|NCT01499719|BEHAVIORAL|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
48331446|NCT02398084|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
48331447|NCT05651217|DEVICE|disposable urinary catheter|The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
48331448|NCT05651217|DEVICE|super smooth antibacterial urinary catheter|the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
48331449|NCT02084069|DRUG|Atorvastatin|
48331450|NCT03607474|OTHER|Questionnaires of life quality for patients|"* the WhoQoL~* a specific scale of Cushing's syndrome~* The Beck II scale~* HAD scale~* Rosenberg questionnaire~* Stunkard, Sorensen and Schlusinger (1983) figurines~* Brief Cope scale"
48331451|NCT03607474|OTHER|Questionnaires of life quality for caregivers|"* the WhoQoL~* The Beck II scale~* HAD scale"
48331452|NCT01164592|DEVICE|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
48331453|NCT00255294|DRUG|Cellulose sulfate vaginal gel|
48331454|NCT04576247|BEHAVIORAL|Combined aerobic and resistance exercise|"The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program."
48331455|NCT04945213|DRUG|Biperiden|5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
48331456|NCT04945213|OTHER|Placebo|1ml sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
48492124|NCT05777161|BEHAVIORAL|Cognitive Behavior Therapy|Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
48492125|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Group (removed from study)|Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
48492126|NCT05645770|COMBINATION_PRODUCT|ECG, computerized task|ECG for cardiac waves computerized task for prospective memory
48492127|NCT05444686|DIAGNOSTIC_TEST|99mTc-FAPI|inject the tracer to subjects and perform SPECT/CT scans
48492128|NCT02608151|OTHER|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
48492129|NCT02608151|OTHER|massage without oil|
48492130|NCT01140490|PROCEDURE|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
48124707|NCT02503397|DEVICE|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
48124708|NCT04406701|OTHER|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
48331457|NCT01882244|BEHAVIORAL|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
48124709|NCT00797017|DRUG|fentanyl|Infection, starting with 12mcg/h (flexible dose)
48331458|NCT01882244|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
48331459|NCT04690257|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
48331460|NCT00128583|BIOLOGICAL|polyvalent melanoma vaccine|
48331461|NCT06528210|DRUG|Gonadotropin Releasing Hormone Agonists and Antagonists|Given PO, IM, Sub-Q injection or Sub-Q implant
48331462|NCT06528210|DRUG|Bicalutamide|Given PO
48331463|NCT06528210|PROCEDURE|Biopsy|Undergo prostate biopsy
48331464|NCT06528210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48331465|NCT06528210|PROCEDURE|Computed Tomography|Undergo CT scan
48331466|NCT06528210|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48331467|NCT06528210|BIOLOGICAL|Pembrolizumab|Given IV
48331468|NCT06528210|OTHER|Questionnaire Administration|Ancillary study
48651678|NCT04126785|OTHER|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
48651679|NCT04126785|OTHER|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
48124710|NCT00797017|DRUG|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
48651680|NCT04126785|OTHER|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
48651681|NCT06369662|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|CD155 expression by flow cytometric immunophenotyping
47974589|NCT01265290|DEVICE|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
48124711|NCT00797017|DRUG|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
48124712|NCT00797017|DRUG|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
48124713|NCT00797017|DRUG|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
48124714|NCT00797017|DRUG|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
48124715|NCT00797017|DRUG|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
48124716|NCT06383793|PROCEDURE|overlap|Π
48331469|NCT06528210|RADIATION|Radiation Therapy|Undergo radiation therapy
48331470|NCT06528210|PROCEDURE|Bone Scan|Undergo bone scan
48331471|NCT00002577|RADIATION|radiation therapy|
48331472|NCT03790384|DRUG|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
48331473|NCT05983835|PROCEDURE|Patients receive subsegmentectomy|Patients receive lobectomy
48331474|NCT00643357|DRUG|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
48331475|NCT00643357|DRUG|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
48331476|NCT05475912|OTHER|Group A, excercises|Each group will receive treatment three times per week for 3 weeks total 7 sessions.
48331477|NCT01768312|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
48331478|NCT02578472|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.
48331479|NCT02578472|DRUG|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
48331480|NCT02578472|DRUG|Placebo|Matching Placebo will be administered orally.
48331481|NCT01360853|DRUG|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
48331482|NCT01360853|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
48331483|NCT01360853|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
48331484|NCT03468049|BIOLOGICAL|Topical App. of Allium Cepa Extract|Topical Application of Allium Cepa Extract (oil)
48331485|NCT03468049|BIOLOGICAL|Phonophoresis of Allium Cepa Extract|Phonophoresis of Allium Cepa Extract (oil)
48331486|NCT03468049|BIOLOGICAL|Raw Mashed Allium Cepa Application|Raw Allium Cepa (onion bulb) Mashed
48331487|NCT03468049|OTHER|Standard Physiotherapy Group (SPG)|This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
48331488|NCT02504177|DRUG|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
48331489|NCT02504177|DRUG|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
48331490|NCT01637870|DEVICE|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
48651682|NCT06369662|DIAGNOSTIC_TEST|Complete blood count|Complete blood count with peripheral blood smear examination
48331491|NCT05317702|OTHER|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
48124717|NCT00443001|DEVICE|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
48331492|NCT03934710|DRUG|Placebo|Drug will be administered in solution form
48124718|NCT04328155|PROCEDURE|Hotpack Group|Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
47974590|NCT01265290|DEVICE|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
48331493|NCT03934710|DRUG|Serotonin agonist - 13ug|13ug lysergic acid diethylamide
48331494|NCT03934710|DRUG|Serotonin agonist - 26ug|26ug lysergic acid diethylamide
48331495|NCT00313027|RADIATION|PET scan|
48331496|NCT04066946|DEVICE|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
48331497|NCT04066946|OTHER|Standard of care|"Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
48124719|NCT04328155|PROCEDURE|Infrared Group|Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .
47974591|NCT06102239|DIAGNOSTIC_TEST|Bilirubin level sodium level c reactive protein level|detect level of bilirubin,sodium \&c-reactive protein as indicator of complicated appendicitis
47974592|NCT03972553|PROCEDURE|Sugarbaker technique for repairing parastomal hernia|The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
47974593|NCT03972553|PROCEDURE|Keyhole technique for repairing parastomal hernia|The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
48124720|NCT04328155|PROCEDURE|Ultrasound Group|Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
48124721|NCT04328155|PROCEDURE|Control|Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
48124722|NCT00532142|DRUG|Intravitreal Triamcinolone|
48124723|NCT00532142|PROCEDURE|Radial Optic Neurotomy|
48331498|NCT05075707|OTHER|Electromagnetic therapy.|Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.
48331499|NCT05075707|OTHER|Low level laser therapy (LLLT)|Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
47974594|NCT00822991|DEVICE|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
47974595|NCT00822991|DEVICE|B-mode US|screening by conventional B-mode US every 3-5 months
47974596|NCT01033591|BEHAVIORAL|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
47974597|NCT01033591|BEHAVIORAL|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
47974598|NCT05607277|PROCEDURE|Endovascular Repair of abdominal aortic aneurysms|Femoral artery access
47974599|NCT00080977|BIOLOGICAL|aldesleukin|
47974600|NCT03535844|OTHER|Wolfberry|Consumption of cooked dehydrated wolfberry as part of a mixed meal.
47974601|NCT03535844|OTHER|Healthy diet|Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
47974602|NCT03498300|BIOLOGICAL|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
48124724|NCT00532142|OTHER|Placebo - Sham Intravitreal Injection|
48124725|NCT04491201|OTHER|Customized questionnaire|A customized questionnaire will be delivered by the social software WeChat to the specific hospital which has been randomly sampled, and all physicians of Obstetrics and Gynecology in this hospital will fill the questionnaire anonymously.
48124726|NCT06435650|COMBINATION_PRODUCT|Cannabis suppositories and mindful-compassion for anal pain|This is a combined intervention that includes mindful-compassion and cannabis suppositories for anal pain
48124727|NCT06435650|BEHAVIORAL|Mindful-compassion|Mindful-compassion
48331500|NCT02770118|BEHAVIORAL|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
48331501|NCT02770118|BEHAVIORAL|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
48331502|NCT02770118|BEHAVIORAL|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
48331503|NCT06480188|DEVICE|deep brain stimulation|Group A was the GPi-DBS stimulation group； Group B was the STN-DBS stimulation group
48331504|NCT01747811|DEVICE|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
48331505|NCT01747811|DEVICE|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
48124728|NCT02867059|DRUG|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
48331506|NCT02910583|DRUG|ibrutinib|ibrutinib administered orally once daily (three 140 mg capsules)
48331507|NCT02910583|DRUG|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
48331508|NCT02910583|DRUG|Placebo|placebo capsules to match ibrutinib administered orally once daily
48331509|NCT02818127|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
48331510|NCT02894528|DRUG|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
48331511|NCT02894528|DRUG|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
48331512|NCT05364229|RADIATION|MR-guided Radiotherapy Boost|IMRT/VMAT prostate whole gland SBRT to 30 Gy in 5 fractions. MRL focal boost of 15 Gy in 1 fraction will be delivered either before or after whole gland SBRT.
48331513|NCT00650598|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
48331514|NCT00650598|DRUG|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
48331515|NCT06317922|DEVICE|Thealoz Duo;|THEALOZ DUO is a solution containing trehalose (3%), sodium hyaluronate (0.15%), sodium chloride, trometamol, hydrochloric acid, and water for injections; Hydraback is a solution containing a sodium chloride 0.9 %, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, water for preparations for injection.
48331516|NCT06317922|DEVICE|sham (Hydrabak)|Hydrabak is an ophthalmic solution containing: sodium chloride 0.9%, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, and water for injectable preparations
48331517|NCT01838590|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
48124729|NCT00092300|DRUG|MK0966, rofecoxib|
48331518|NCT01838590|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48331519|NCT01057134|DEVICE|Cutera Ultrasound Device|Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
48331520|NCT03367442|OTHER|no intervention|no intervention
48331521|NCT02251678|DIETARY_SUPPLEMENT|Elimune Capsules|2 capsules BID for 28 days
48331522|NCT03084718|DRUG|CHF 718 pMDI|Dose Response: Test one of three different doses of CHF 718 pMDI
48124730|NCT00092300|DRUG|Comparator: valdecoxib|
48331523|NCT03084718|DRUG|Placebo pMDI|Placebo Control
48331524|NCT03084718|DRUG|Beclomethasone Dipropionate (BDP)|Active Control
48124731|NCT01761201|DRUG|Levofloxacin|Levofloxacin
48331525|NCT00104156|PROCEDURE|External Qigong therapy|
48124732|NCT01761201|DRUG|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
48124733|NCT04267458|OTHER|evaluation of sofuspovir containing DAA regien expected insult on kidney|to use different kidney biomarkers to evaluate acute kidney damage after using sofuspovir containing DAA regimen in treatment of HCV
48331526|NCT00165581|DEVICE|High Dose Intracavitary Brachytherapy|
48331527|NCT01444313|DEVICE|narafilcon A contact lens|Soft contact lenses with UV protection
48331528|NCT01444313|DEVICE|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
48331529|NCT02128594|BEHAVIORAL|Serosorting Intervention|Single session, behavioral intervention
48331530|NCT02715583|DRUG|11C-Acetate|
48331531|NCT02073903|BEHAVIORAL|Patient Survey|
48331532|NCT02073903|BEHAVIORAL|Provider Survey|
48331533|NCT04294654|DRUG|Vortioxetine|Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
48331534|NCT00614653|DRUG|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
48331535|NCT00614653|DRUG|Erlotinib|100 mg by mouth Once Daily on days with radiation.
48331536|NCT00614653|DRUG|Capecitabine|400 mg/m\^2 PO Twice Daily on days with radiation.
48331537|NCT00614653|RADIATION|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
48331538|NCT05789849|DEVICE|Collecting blood pressure measurements with noninvasive blood pressure device|Noninvasive blood pressure measurements will collected based on the recommendations of the International Organization for Standardization (ISO) 81060-2:2018+A1:2020 Non-invasive sphygmomanometers -Clinical investigation of intermittent automated measurement type. This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
48124734|NCT03727958|DIAGNOSTIC_TEST|Lung and coronary CT assessment|Subjects will undergo simultaneous coronary arteries and thoracic CT assessment
48331539|NCT03780491|OTHER|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
48331540|NCT03336762|DIAGNOSTIC_TEST|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
48331541|NCT03336762|DIAGNOSTIC_TEST|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
48331542|NCT02800720|BEHAVIORAL|Meditation Awareness Training|8 Week Meditation Intervention
48331543|NCT02800720|BEHAVIORAL|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
48331544|NCT03858270|DRUG|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
48331545|NCT03858270|OTHER|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
48331546|NCT01035008|PROCEDURE|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
48331547|NCT00655161|BIOLOGICAL|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
48331548|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
48331549|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
48331550|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
48331551|NCT01258517|DEVICE|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
48331552|NCT04603040|DRUG|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
48651683|NCT06369662|DIAGNOSTIC_TEST|Bone marrow aspiration|Bone marrow aspiration at both diagnosis and follow up of patients
48651684|NCT06369662|DIAGNOSTIC_TEST|Cytogenetic testing|Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients
48124735|NCT03727958|DIAGNOSTIC_TEST|Coronary CT assessment|Subjects will undergo coronary arteries CT assessment only
48124736|NCT06180889|DRUG|Enoxaparin|40 mg enoxaparin administered as subcutaneous injection once daily
48331553|NCT03083275|OTHER|Resistance Training|
48331554|NCT03950999|OTHER|Placebo|Sugar pill
48331555|NCT05106218|DEVICE|SurroundScope|The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
48331556|NCT05106218|DEVICE|Standard Laparoscope|The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
48651685|NCT06369662|DIAGNOSTIC_TEST|FLT3-ITD using High resolution melting curve (HRM) analysis|Detection of FLT3-ITD mutation in AML patinets
48651686|NCT05680636|DIAGNOSTIC_TEST|temperature measurement|Differential Leg Skin Temperature Measured With Handheld Low-cost Infrared Thermometers.
48651687|NCT06294899|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed to patients with suspected lower respiratory tract infections.
48124737|NCT06180889|DRUG|KN060 Low|Single dose of KN060 administered as intravenous infusion
48124738|NCT06180889|DRUG|KN060 Middle|Single dose of KN060 administered as intravenous infusion
48124739|NCT06180889|DRUG|KN060 Hight|Single dose of KN060 administered as intravenous infusion
48331557|NCT05893121|OTHER|Cardiac coherence session|A cardiac coherence session consists of an exercise of six breaths per minute during five minutes.
48331558|NCT05893121|OTHER|Information note about MRI|explanatory note about MRI examination
48331559|NCT04491214|OTHER|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
48492131|NCT04436978|DRUG|30-day DAPT|DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
48492132|NCT04436978|DRUG|Guideline-directed therapy|Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
48651688|NCT06294899|DIAGNOSTIC_TEST|C-Reactive Protein Test|C-Reactive Protein Test will be performed to patients with suspected lower respiratory tract infections.
48651689|NCT05200338|DRUG|Engerix-B|Subjects are vaccinated with an accelerated scheme at 0, +1, +2 months with a booster at +12 months.
48651690|NCT06674811|OTHER|Wearing Smartwatch|Patients and their caregivers will be asked to start wearing a smartwatch prior to surgery and continuing to wear it for one year following surgery at all times except when bathing or swimming, eating, undergoing a procedure, or if refusing to wear them. The smartwatches collect motor activity by minutes spent being sedentary, active, or highly active, heart rate, and sleep duration and stages. Data from the smartwatches syncs with Garmin connect using Fitabase to allow the study team to review the data.
47974603|NCT06094569|PROCEDURE|Endovascular Therapy|Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices
48331560|NCT05911412|BEHAVIORAL|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
48331561|NCT04697602|DRUG|Stepwise dose titration of febuxostat and low-dose colchicine|Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
47974604|NCT00137748|DRUG|CMV-Ig|Drug: CMV-Ig
47974605|NCT05351762|DRUG|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
48331562|NCT04697602|DRUG|Fixed dose febuxostat and low-dose colchicine|Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
48331563|NCT04141215|BIOLOGICAL|BIOBank bone paste|BIOBank bone paste (PPT322)
48331564|NCT04141215|BIOLOGICAL|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
48331565|NCT04394143|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
48331566|NCT04394143|DRUG|Mannitol|Oral administration of two capsules before sleep for 7 days.
48651691|NCT06674811|OTHER|Patient Report Outcomes|To obtain patient-reported outcomes (PROs), questionnaires will be administered at time of enrollment, in the two weeks prior to surgery if applicable, and at 1, 2, 4, 8, 12, 16, 20, 24, 34, 44, and 54 weeks postoperatively. Questionnaires can be completed electronically, over the telephone or in person. The PedsQL Cancer Module and Patient Health Questionnaire depression scale (PHQ-9) will be utilized for questionnaires.
48651692|NCT06674811|OTHER|Blood Draw|When patients are having blood drawn as part of their regular care, extra blood may be drawn for this study. Participants may opt out of this. Blood draws will occur preoperatively and at intervals postoperatively for proteomic, metabolomic, and exposomic testing.
47974606|NCT05104320|PROCEDURE|MICS-CABG|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
47974607|NCT05104320|PROCEDURE|sternotomy CABG|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
47974608|NCT05255068|BEHAVIORAL|OPTIMAL|A person-centered mealtime care intervention
48331567|NCT01564667|BEHAVIORAL|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
48331568|NCT03205982|BEHAVIORAL|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
48331569|NCT03205982|BEHAVIORAL|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
48331570|NCT03424317|BEHAVIORAL|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
48492133|NCT02613325|DEVICE|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
48492134|NCT02613325|PROCEDURE|Standard of care surgical excision|
48492135|NCT02613325|DEVICE|Single cell photoacoustic microscopy|
48492136|NCT03008239|DEVICE|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
48492137|NCT03008239|DEVICE|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
48492138|NCT03040323|DRUG|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
48492139|NCT03040323|DRUG|Placebos|Placebos injected prior to ultrasound-guided biopsy
48651693|NCT06674811|OTHER|Clinical Data Review|Clinical data will be collected and stored in a database by study staff. This includes patient demographics, diagnosis characteristics including staging and risk group, treatment characteristics, and outcomes including length of stay following surgical intervention, readmissions, surgical complications including surgical site infection, time off therapy/time to resumption of chemotherapy.
47974609|NCT04376710|OTHER|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
47974610|NCT04376710|OTHER|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
47974611|NCT04376710|OTHER|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
47974612|NCT01338766|PROCEDURE|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
47974613|NCT01631578|PROCEDURE|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
48124740|NCT03840421|DRUG|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
48124741|NCT03840421|DRUG|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
48492140|NCT01739920|OTHER|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
48492141|NCT01739920|OTHER|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
48331571|NCT03424317|BEHAVIORAL|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
48331572|NCT06039995|PROCEDURE|Comprehensive Oral Care|"The intervention mentioned in this study involves a combination of oral care strategies for patients in the intervention group. These strategies include:~Chlorhexidine Mouthwash: Patients in the intervention group will receive Chlorhexidine mouthwash. Chlorhexidine is known for its effectiveness in maintaining oral hygiene.~Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.~Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.~These interventions aim to enhance oral care beyond traditional methods, potentially reducing the risk of Ventilator-Associated Pneumonia (VAP) and improving overall patient outcomes in the intensive care unit (ICU)."
48331573|NCT06039995|PROCEDURE|Traditional Oral Care|"In the control arm, patients receive the intervention known as Traditional Oral Care. This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene."
48331574|NCT06039995|DEVICE|Mechanical Tooth Brushing using 0.2% Chlorhexidine|Toothbrushing: In addition to Chlorhexidine mouthwash, patients in the intervention group will undergo toothbrushing. This involves cleaning the teeth and surrounding oral tissues to ensure thorough oral hygiene.
48331575|NCT06039995|DEVICE|Moisturizing Gel|Moisturizing Gel Application: The intervention group will also receive the application of moisturizing gel on the interior and exterior surfaces of the oral cavity. This helps in maintaining the moisture content of the oral tissues.
48331576|NCT06039995|DEVICE|Oral care using Cotton swab dipped in 0.2% Chlorhexidine|This involves the use cotton swab dipped in 0.2% Chlorhexidine mouthwash for oral hygiene
48331577|NCT01734096|OTHER|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
48331578|NCT01734096|DRUG|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
48331579|NCT03720301|PROCEDURE|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~1. Soft tissue massage to the posterior cervical musculature for approximately 1 minute~2. Muscle energy to the muscles of neck extension approximately 1 minute~3. Muscle energy to the Occipital Atlanto (OA) joint 1 minute~4. Muscle energy to the jaw. Approximately 1 minute~5. Occipital decompression approximately 1 minute~6. With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~1. Myofascial Steering wheel Technique~2. Sibson's Fascia Release~3. Occipital decompression"
48331580|NCT03720301|PROCEDURE|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
48331581|NCT01478295|BEHAVIORAL|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
48331582|NCT01478295|OTHER|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
48331583|NCT03903120|BEHAVIORAL|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
48331584|NCT00006372|DRUG|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
48331585|NCT00006372|DRUG|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
48331586|NCT00006372|DRUG|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
48651694|NCT06640686|OTHER|Exercise training|Inspiratory muscle training for increase strength of inspiratory muscle.
48331587|NCT00515580|PROCEDURE|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
48331588|NCT05453006|DEVICE|COPAN 552c.80 FLOQSwab|The study will implement HPV self-sampling as an option for cervical cancer screening alongside usual care for Somali women, and evaluate changes pre and post implementation, compared to Fairview intervention clinics.
48651695|NCT01946269|OTHER|Goal-directed Resuscitation Therapy (GDT)|"* A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~* The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~* When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.~* If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
48651696|NCT01946269|OTHER|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
48124742|NCT03840421|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
48124743|NCT03840421|DRUG|cisplatin|IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
48124744|NCT03501264|BEHAVIORAL|Online Game|LGBTQ Bullying game
48124745|NCT03501264|BEHAVIORAL|LGBTQ Resources|This group receives LGBTQ Resources
48124746|NCT03002675|DRUG|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
48124747|NCT03238261|RADIATION|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
48124748|NCT00991497|DEVICE|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
48124749|NCT05917015|DIETARY_SUPPLEMENT|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
48124750|NCT05917015|OTHER|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
48331589|NCT05610358|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory or cardiovascular diseases.
48651697|NCT06673264|DEVICE|Soft Neural Probe|sub-acute insertion of the soft neural probe with neural signal recording
48651698|NCT03453242|OTHER|Bone measurement by HR-pQCT and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites one measurement will be performed by HR-pQCT to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
48124751|NCT05591755|DRUG|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution|Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution
48124752|NCT05591755|DRUG|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)|Ketotifen fumarate ophthalmic solution 0.035% (n = 56)
48124753|NCT05591755|DRUG|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)|Brimonidine tartrate ophthalmic solution 0.025% (n = 56)
48651699|NCT02113878|DRUG|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
48651700|NCT02113878|DRUG|Cisplatin|Cisplatin is a chemotherapy drug
48124754|NCT05591755|DRUG|Experimental: Vehicle ophthalmic solution (n = 56)|Experimental: Vehicle ophthalmic solution (n = 56)
48651701|NCT02113878|RADIATION|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
48651702|NCT03366831|BEHAVIORAL|Thirty Million Words Initiative Newborn Intervention|The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
48651703|NCT00530257|DRUG|Placebo|Placebo (sugar pill)
48124755|NCT03974503|BEHAVIORAL|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
48124756|NCT03974503|BEHAVIORAL|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
48124757|NCT02623894|OTHER||No intervention study is an observational study
48331590|NCT04219969|DRUG|Fludeoxyglucose F-18|Given IV
48331591|NCT04219969|DEVICE|Magnetic Resonance Imaging|Undergo PET-MRI
48331592|NCT04219969|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
48331593|NCT06105203|PROCEDURE|Robotic-assisted total mesorectal excision|TME will be performed with the assistance of robot in rectal cancer
48331594|NCT06105203|PROCEDURE|laparoscopic-assisted total mesorectal excision|TME will be performed with the assistance of laparoscopy in rectal cancer
48651704|NCT00530257|DRUG|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
48651705|NCT02694263|DRUG|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
48651706|NCT02694263|DRUG|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
48651707|NCT02694263|DRUG|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
48651708|NCT02694263|DRUG|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
48651709|NCT02694263|DRUG|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
48651710|NCT06570382|OTHER|Videos: Taste messaging focused|Participants in this intervention will watch the taste focused videos.
48651711|NCT06570382|OTHER|Videos: Health messaging focused|Participants in this intervention will watch the health focused videos.
48651712|NCT05410314|DRUG|Myo-Inositol and D-Chiro-Inositol (MIC)|Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
48651713|NCT06671301|BEHAVIORAL|PSAI|Holistic stress management program implementing the pillars of Lifestyle Medicine
48651714|NCT06671301|OTHER|Usual Care|Usual care without specific treatment
48331595|NCT05848076|OTHER|TNE|McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explains the patient about their pain
48331596|NCT05848076|OTHER|core stability|McGill exercises for the low back.
48331597|NCT03332901|OTHER|this is an observational study, no intervention required|this is an observational study, no intervention required
48331598|NCT04117412|OTHER|Exercise|Same participants will undergo different one bout of exercise protocols
48331599|NCT03634917|DRUG|Acamprosate Calcium|1 capsule with 666 mg Acamprosate
48124758|NCT02917512|DRUG|HU00701|Cyclosporine 0.01% + 3% trehalose
48124759|NCT02917512|DRUG|HU007|Cyclosporine 0.02% + 3% trehalose
48124760|NCT02917512|DRUG|Restasis|Cyclosporine 0.05%
48124761|NCT02917512|DRUG|Placebo|Vehicle
48331600|NCT03634917|DRUG|Calcium Carbonate|1 capsule with 1500 mg Calcium Carbonate
48331601|NCT03634917|DRUG|Placebo|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
48331602|NCT03634917|DRUG|Placebo lead in|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
48331603|NCT03107598|DRUG|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
48331604|NCT01583985|OTHER|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
48331605|NCT01583985|OTHER|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
48331606|NCT01027013|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
48331607|NCT01027013|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
48331608|NCT00348413|DRUG|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
48331609|NCT05079867|DEVICE|Cochlear implantation|Electrode surgically implanted in patient's cochlea to improve hearing
48331610|NCT03179410|DRUG|Avelumab|10 mg/kg intravenously every 2 weeks
47974614|NCT01166113|DRUG|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
47974615|NCT04253184|DRUG|Micra AV Transcatheter Pacing System|The Micra AV Transcatheter Pacing System (TPS) is a miniaturized single chamber pacemaker that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart to provide bipolar sensing and pacing. The Micra AV system provides a form of VDD pacing that is based on mechanical atrial sensing utilizing a 3-axis accelerometer.
47974616|NCT05758051|PROCEDURE|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
47974617|NCT00935597|BIOLOGICAL|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
48331611|NCT02176304|DRUG|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
48331612|NCT02176304|DRUG|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
48331613|NCT01612377|DRUG|Prednisolone-Dipyridamole|Oral, QD
47974618|NCT04128176|DRUG|Rituximab combined with Omalizumab|Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
48331614|NCT01612377|DRUG|Prednisone|Oral QD Prednisone 5mg
48331615|NCT01612377|DRUG|prednisone|Oral, QD prednisone 7.5mg
48331616|NCT02111967|OTHER|Questionnaire administration|
48331617|NCT02111967|OTHER|Laboratory biomarker analysis|
48331618|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)|Oral administration
48331619|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)|Oral administration
48331620|NCT00241163|PROCEDURE|Fibrinogen (human) + thrombin (human) (TachoSil)|
48331621|NCT02992704|DRUG|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
48331622|NCT00347412|DRUG|Paclitaxel|"Paclitaxel is dosed at 200 mg/m2, as a 3 hour infusion.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first."
48492142|NCT01714375|DEVICE|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
48124762|NCT02740491|OTHER|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
48331623|NCT00347412|DRUG|NOV-002|"* Two 60 mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one~* For each nominal 21-day paclitaxel and carboplatin cycle:~  * 60 mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin~ * followed by 60 mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins~Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first."
48331624|NCT00347412|DRUG|Carboplatin|"Carboplatin is dosed at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel, as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing."
48331625|NCT00047307|DRUG|alvocidib|Given IV
48331626|NCT00047307|DRUG|gemcitabine hydrochloride|Given IV
48331627|NCT00047307|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
48492143|NCT04650113|COMBINATION_PRODUCT|MTA material|Partial pulpotomy is a procedure in which the inflamed tissue beneath an exposure is removed to a depth of 1 to 3 mm or deeper to reach healthy pulp tissue.
48492144|NCT01687348|DRUG|lidocaine aguettant|
48492145|NCT02381626|DEVICE|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
48492146|NCT02381626|BEHAVIORAL|questionnaires|
47974619|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
48492147|NCT02381626|OTHER|Log-book|PM and biological measurements
48492148|NCT02381626|OTHER|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
48492149|NCT06148571|DEVICE|left bundle branch area pacing|left bundle branch area pacing locates ventricular lead into the interventricular septum to capture left bundle branch areas.
47974620|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
47974621|NCT01598012|DRUG|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
47974622|NCT01598012|DRUG|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
48124763|NCT01007396|OTHER|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
47974623|NCT03767504|DIETARY_SUPPLEMENT|Thymol|Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
48124764|NCT04700189|DEVICE|ab interno canaloplasty|A modification of traditional canaloplasty procedure. Can be combined with or done without cataract surgery.
48124765|NCT01872078|DRUG|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
48124766|NCT01872078|DRUG|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
48124767|NCT03819829|OTHER|Blood sample|Blood sample
48124768|NCT00687856|PROCEDURE|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
48124769|NCT04746833|BEHAVIORAL|SUMMIT|multicomponent web-based application focused on pain self-management skills
48124770|NCT04746833|BEHAVIORAL|control|My Pain Diary app
48331628|NCT00047307|OTHER|laboratory biomarker analysis|Correlative studies
48331629|NCT03649334|DRUG|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
48331630|NCT03649334|DRUG|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
48331631|NCT00278941|DRUG|Quetiapine Fumarate Sustained Release|
48492150|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)|A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.
48331632|NCT01011218|BEHAVIORAL|BBT-I|Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
48331633|NCT01011218|BEHAVIORAL|Control|Control behavioral intervention is a sleep hygiene handout completed by participant.
48124771|NCT06136351|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
48124772|NCT06136351|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
47974624|NCT00553644|DRUG|Bortezomib|Given IV
48124773|NCT06136351|DRUG|Bendamustin|90mg/m\^2 ivgtt, D0 of each 28-day cycle
48124774|NCT00891332|DRUG|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
48124775|NCT02061501|OTHER|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
48124776|NCT02061501|OTHER|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
48124777|NCT01972724|DRUG|Pioglitazone|Pioglitazone tablets
48124778|NCT01972724|DRUG|Metformin|Metformin as prescribed in clinical practice
48124779|NCT01972724|DRUG|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
48124780|NCT02582424|OTHER|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
48124781|NCT02582424|OTHER|placebo|placebo
48124782|NCT03015311|DRUG|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
48124783|NCT03015311|DRUG|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
48124784|NCT05806060|DRUG|VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
48124785|NCT05806060|DRUG|nab-paclitaxel, with maintenance of capecitabine|Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
48331634|NCT01011218|DRUG|Armodafinil|150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
48124786|NCT05806060|DRUG|Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1|TPC
48124787|NCT05806060|DRUG|VEGFR and TPC|VEGFR bevacizumab and TPC
48124788|NCT01753986|BEHAVIORAL|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
48124789|NCT01753986|BEHAVIORAL|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
48124790|NCT06020313|DIETARY_SUPPLEMENT|Resveratrol Experimental|The amount of 500mg per day will be offered for seven days distributed in doses of 100mg per schedule (7am, 10am, 1pm, 4pm and 7pm).
48124791|NCT03419299|OTHER|Tube Feeding Application|A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
48331635|NCT02501902|DRUG|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
48331636|NCT02501902|DRUG|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
47974625|NCT00553644|OTHER|Laboratory Biomarker Analysis|Correlative studies
47974626|NCT00553644|DRUG|Lenalidomide|Given PO
47974627|NCT04669782|DIETARY_SUPPLEMENT|Vitamin K (MK7)|MK-7 will be administered at a dose of 375 microg / day
47974628|NCT04669782|DRUG|Teriparatide|Teriparatide will be administered as standard of care
48124792|NCT02318407|DRUG|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
48124793|NCT02318407|DRUG|Placebo|contains no active drug
48124794|NCT02616068|DRUG|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
47974629|NCT05187715|DRUG|Simvastatin 40mg|Simvastatin 40mg OD
47974630|NCT05187715|OTHER|Placebo|Placebo
47974631|NCT05187715|OTHER|Standard medical Treatment|Standard medical Treatment eccluding pentoxiphylline
47974632|NCT00310791|DRUG|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
47974633|NCT00310791|OTHER|Placebo (Sugar Pill)|Placebo (sugar pill)
48124795|NCT02616068|DRUG|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
48331637|NCT00646113|DEVICE|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
48331638|NCT02403713|DRUG|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
48331639|NCT02403713|DRUG|Formoterol|Formoterol
48331640|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
48331641|NCT02403713|DRUG|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
48331642|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
48331643|NCT05929638|BEHAVIORAL|lavender oil|The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
48492151|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid)|A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.
48492152|NCT03260075|OTHER|cat|Cat living at the ward
48492153|NCT03589235|PROCEDURE|A free gingival graft|A free gingival graft will be used for the treatment of gingival recession
48124796|NCT02616068|DRUG|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
48124797|NCT02616068|DRUG|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
48124798|NCT02617771|DRUG|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
48124799|NCT05293431|OTHER|Transcranial Alternate Current Stimulation|tACS utilizes low-amplitude alternating currents to modulate brain activity and entrain specific brain oscillations depending on the applied stimulation frequency
48124800|NCT05293431|OTHER|Sham stimulation|Sham stimulation will simulated the real tACS stimulation
48124801|NCT01407458|OTHER|Upper Limb Exercises|Upper limb exercises
48124802|NCT01407458|OTHER|Normal physical exercises|Exercises usually done by children in physical education classes
48124803|NCT03237416|DRUG|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
48124804|NCT03237416|DRUG|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
48124805|NCT03237416|DRUG|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
48124806|NCT02680457|DRUG|Insulin Degludec|Insulin Degludec 10 IU SC every 24 hours for 6 days
48124807|NCT02680457|DRUG|Insulin Glargine|Insulin Glargine 10 IU SC every 24 hours for 6 days
48124808|NCT04063514|OTHER|Focused Ultrasound|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
48124809|NCT00890305|DRUG|CT-011|
48124810|NCT00890305|DRUG|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
48124811|NCT03853161|OTHER|Vapotherm|A form of non invasive ventilation used in newborns
48124812|NCT03853161|OTHER|NIPPV|A form of non invasive ventilation used in newborns
48124813|NCT01477255|BEHAVIORAL|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
48124814|NCT06521151|DIETARY_SUPPLEMENT|egg based diet|egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).
48124815|NCT05950542|DRUG|Baricitinib|JAK inhibit0rs
48124816|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
48124817|NCT00706875|BEHAVIORAL|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
48124818|NCT05278533|DIETARY_SUPPLEMENT|BioPlete™ Advanced Formula|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
48124819|NCT05278533|DIETARY_SUPPLEMENT|Placebo|2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
48492154|NCT03589235|DEVICE|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
48492155|NCT03589235|DEVICE|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
48492156|NCT04586153|DRUG|Meplazumab for Injection|humanized antibody target CD147
48492157|NCT04586153|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
48492158|NCT00444457|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
48492159|NCT00444457|BIOLOGICAL|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
48492160|NCT01293760|OTHER|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
48124823|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
48331644|NCT02715999|PROCEDURE|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
48331645|NCT02715999|PROCEDURE|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
48331646|NCT05566288|DRUG|Cytisinicline|compressed film-coated tablet containing 3 mg cytisinicline
48331647|NCT05566288|DRUG|Placebo|Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
48331648|NCT05566288|DRUG|Moxifloxacin|400 mg tablets
48124824|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
48124825|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
48124826|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
48124827|NCT01309932|BIOLOGICAL|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
48331649|NCT02545491|BEHAVIORAL|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
48331650|NCT02545491|BEHAVIORAL|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
48492161|NCT01293760|OTHER|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
48331651|NCT05679609|DEVICE|incentive spirometry|It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.
48331652|NCT03437044|DRUG|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
48331653|NCT03437044|DRUG|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
48331654|NCT00184652|DRUG|somatropin|
48331655|NCT05594368|DEVICE|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
48331656|NCT04861311|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention|The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
48331657|NCT02521389|DRUG|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
48331658|NCT03723499|OTHER|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
48331659|NCT05400356|PROCEDURE|On-pump valve surgery or CABG|On-pump valve surgery or coronary arterial bypass grafting
48492162|NCT06294184|DEVICE|tdcs lDLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
48124828|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
48124829|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
48124830|NCT01309932|BIOLOGICAL|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
48124831|NCT01309932|DRUG|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
48124832|NCT01309932|DRUG|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
48124833|NCT01309932|DRUG|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
48124834|NCT01309932|DRUG|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
48124835|NCT01309932|DRUG|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
48492163|NCT06294184|DEVICE|tdcs rVLPFC|The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
48492164|NCT06294184|DEVICE|Sham|The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
48124836|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
48124837|NCT01309932|DRUG|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
48124838|NCT04015349|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
48124839|NCT00621634|DIETARY_SUPPLEMENT|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
48124840|NCT00621634|DIETARY_SUPPLEMENT|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
48124841|NCT01579370|OTHER|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
48124842|NCT01579370|OTHER|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
48124843|NCT01579370|OTHER|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
48124844|NCT01579370|OTHER|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
48124845|NCT00392249|BEHAVIORAL|Supervised Treatment of Schizophrenia by a family member|
48331660|NCT05008172|PROCEDURE|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
48331661|NCT03746067|DRUG|TS-134|5 mg, 10 mg, or 20 mg oral solution
48124846|NCT01866215|OTHER|exercise|cycling at 100W during 60 min
48331662|NCT03746067|DRUG|Placebo|Matched Placebo oral solution
48331663|NCT03026049|DEVICE|deep venous stenting|Deep venous stent
48331664|NCT01605383|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
48331665|NCT01605383|PROCEDURE|Standard treatment|Isolated core decompression
48331666|NCT02895412|BIOLOGICAL|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
48331667|NCT01403831|OTHER|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
48331668|NCT05934721|OTHER|Questionnaire and physical assessments|Participants will complete self-report questionnaires assessing pain (CSI) and RA severity (patient global VAS), as well as undergoing physical assessments of RA severity (physician global VAS, swollen/tender joint counts) and cognition (MoCA).
48331669|NCT03109756|DRUG|OV101|Single-dose 5 mg OV101
48331670|NCT05594212|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
48331671|NCT03823807|DRUG|SH-1028|Oral,100mg or 200mg ,QD, fasted
48331672|NCT03482128|DEVICE|Coagulation management guided by SONOCLOT|Application of blood products guided by SONOCLOT measurements
48492165|NCT03308539|RADIATION|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
48492166|NCT05555368|OTHER|Quality of Recovery Score|Descriptive
48492167|NCT02063243|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
48331673|NCT03482128|DEVICE|Standard coagulation management|Application of blood products based on clinical experience of the anesthesiologist in charge
48331674|NCT00753688|DRUG|PAZOPANIB|800 mg once daily orally
48331675|NCT00753688|DRUG|Placebo|matching placebo 800 mg once daily orally
48492168|NCT03150914|DRUG|Sirolimus|mTOR inhibitor or placebo
48492169|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
48492170|NCT03859141|BIOLOGICAL|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
48331676|NCT04197141|RADIATION|Conventionally-fractionated WPRT|Total dose: 45 Gy in 25 fractions WPRT
48331677|NCT04197141|RADIATION|Hypofractionated WPRT|Total dose: 25 Gy in 5 fractions WPRT
48331678|NCT04869176|DIAGNOSTIC_TEST|Electrocardiogram|Recording of the electrical activity of the heart during sleep; sleep phases were evaluated. The bed was initially in horizontal position and tilted for 30° head-up after 20 minutes of continuous tracing.
48331679|NCT04869176|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of heart rate, breathing frequency, arterial oxygen saturation and body temperature while recording ECG.
48331680|NCT04869176|DRUG|Caffeine Citrate 5 mg/kg|Caffeine in the form of suspension was given to the newborns.
48492171|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
48124847|NCT01866215|DIETARY_SUPPLEMENT|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
48331681|NCT00175162|DEVICE|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
48492172|NCT03859141|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
48492173|NCT00499174|PROCEDURE|conventional surgery|Radical prostatectomy
48492174|NCT00499174|RADIATION|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
48124848|NCT01866215|DIETARY_SUPPLEMENT|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
48492175|NCT00499174|RADIATION|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
48331682|NCT04919746|OTHER|Systemic acupuncture|Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
48331683|NCT00248378|DRUG|Smoked Cannabis|
48331684|NCT00790127|DRUG|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
48651715|NCT05867888|OTHER|conventional therapy|conventional therapy ( instructions, ice application, deep tissue massage, stretching exercises, joint mobilization and isometric exercises )
48651716|NCT05867888|OTHER|shock wave therapy|Acoustic waves (shock waves) that can carry energy and can propagate through tissues promote healing effects.
48651717|NCT05867888|OTHER|low level laser therapy|The application of light to a biologic system to promote tissue regeneration, reduce inflammation and relieve pain.
48651718|NCT06642272|DRUG|Empagliflozin 10 MG|Once daily
48651719|NCT06642272|DRUG|Dapagliflozin 10 MG|Once daily
48124849|NCT02531737|DRUG|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
48124850|NCT02531737|DRUG|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
48124851|NCT01796236|DEVICE|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
48124852|NCT01796236|DEVICE|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
48124853|NCT02745340|OTHER|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
48124854|NCT00819546|DRUG|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
48124855|NCT00819546|DRUG|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
48331685|NCT00790127|DRUG|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
48331686|NCT05730374|BEHAVIORAL|Benson's Relaxation technique|Each child in the study group had an individual interview with researchers, who demonstrated the Benson relaxation technique while teaching them. The child was then asked to demonstrate it. sit quietly in a comfortable position in separate room., close eyes, deeply relax all muscles, beginning at the feet and progressing up to the face and breathe through nose. Become aware of breathing pattern. As breathes out, say the word one silently to child. For example, breathe in, and then out, say one, in and out, and repeat one. Breathe easily and naturally. It is Continue for 10 minutes and repeated two times.
48331687|NCT05730374|BEHAVIORAL|Music therapy|"* The child lessen to a Mozart's music, which is played before and throughout the blood transfusion procedure. Ambient noise can be reduced by using headphones. As a result, it is easier to see how the intervention has succeeded.~* This intervention was done using an MP3 player during the blood transfusion procedure and immediately following the completion of the intervention to prevent the transmission of infections headphones were cleaned with disinfectant after each -use."
48492176|NCT00499174|PROCEDURE|Biopsies|Periodic repeat biopsies
48492177|NCT02831218|PROCEDURE|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
48651720|NCT06152003|BEHAVIORAL|Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)|We anticipate the intervention will contain the following: CBT for depression and trauma, Life-Steps for ART adherence, nutritional counseling, supplementary food parcels, case management, linkage to care. Specific intervention components will be informed by prior aims.
48651721|NCT05270031|DEVICE|Balloon dilation of the eustachian tube|Balloon dilation of the eustachian tube
48651722|NCT01969578|DRUG|bicalutamide + triptorelin|
48651723|NCT01969578|DRUG|Cisplatin + Doxorubicin|
48651724|NCT01969578|DRUG|Carboplatin + Paclitaxel|
48651725|NCT05795881|OTHER|Cyclic daytime enteral nutrition|The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.
48124856|NCT05600335|PROCEDURE|ERAS protocol|Patients with esophageal cancer have undergone RAME using ERAS protocol and conventional management strategy
48651726|NCT06675500|DRUG|Magnesium sulphate|Intravenous Magnesium sulphate followed by oral tablets of Magnesium sulphate
48651727|NCT06675500|DRUG|Placebo|Intravenous infusion of Normal saline 0.9 followed by starch oral tablets
48651728|NCT06675292|OTHER|Survey-based study|The demographic information of individuals with tension-type headaches, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test-6, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
48651729|NCT06674798|OTHER|School-based eHealth NCD Prevention Program|Students will participate in health-promoting sessions delivered by trained facilitators, with each session lasting 30 to 40 minutes. There will be a total of six health-promoting sessions conducted in the classroom for the intervention group, spanning two months with three sessions per month. The health-promoting videos from the school-based eHealth NCD prevention program will be shown in the classroom using multimedia. The drama-based videos will be developed in Urdu Language with English subtitles and will be based on based on contextually relevant content for the Pakistani secondary and higher secondary school students of age 13 to 18 years old. The content of these six sessions will be focused on the leading risk factors associated with NCDs as reported by different studies such as physical inactivity, unhealthy diet and overweight, obesity, harmful alcohol consumption and tobacco use.
47974634|NCT00310791|DRUG|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
48124857|NCT05208372|DIAGNOSTIC_TEST|CTC test|Circulating tumor cells test of ascites and blood for patients with gastric cancer.
48124858|NCT05208372|DIAGNOSTIC_TEST|ctDNA test|Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
48124859|NCT05920642|DRUG|Intrathecal morphine administration|Administration of morphine into the spinal canal.
48124860|NCT05920642|DRUG|Parenteral administration of analgesics|Standard postoperative pain management of analgesics using parenteral route of administration.
47974635|NCT03715764|OTHER|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
48124861|NCT05035446|PROCEDURE|single-incision plus one-port laparoscopic surgery|The investigators use the technique of adding one operation hole on the basis of single-port laparoscopy in some patients.
48124862|NCT05035446|PROCEDURE|conventional laparoscopic surgery|It usually requires 5 perforations ports and an auxiliary small incision to perform laparoscopic gastrectomy.
48124863|NCT02250430|DRUG|SB204|Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
48124864|NCT06407258|BEHAVIORAL|SLEEPAC|"6x individual blended-care counselling sessions:~* 1 x face-to-face kick-off sessions at study site (45 min)~* 1 x try-out exercise sessions at study site (45 min)~* 4 x online face-to-face sessions via zoom (30 min)~* Both the intervention and the waitlist control condition will continue with TAU.~Component 1: CBT-I: Sleep restriction, and cognitive therapy strategies with education about sleep-wake regulation, sleep hygiene, and pre-bedtime counter arousal methods.~Component 2: Circadian treatment: Morning bright light therapy with a gradual advanced sleep schedule and timed morning exercise.~Component 3: Physical activity counselling involves providing personalized guidance and support to individuals to help them adopt and maintain a physically active lifestyle tailored to their preferences and needs."
48124865|NCT00105313|DRUG|MEDI-507|
48124866|NCT05443737|BEHAVIORAL|Multi-component oncofertility care intervention|The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
48124867|NCT02717117|OTHER|Soup meal|Soup meal as above
48124868|NCT00973115|DRUG|Simvastatin CR|
48124869|NCT05188300|PROCEDURE|Freestyle pedicled perforators propellers flaps for meningomyelocele defects|Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
48124870|NCT04033107|DRUG|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
48331688|NCT05738772|DIAGNOSTIC_TEST|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
48651730|NCT05039489|DRUG|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
48124871|NCT04033107|DRUG|Metformin|Participants will orally take metformin 4g daily.
48124872|NCT01571570|DRUG|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
48331689|NCT02330107|OTHER|MAT & LAT|"For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
48492178|NCT02831218|PROCEDURE|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
48651731|NCT05039489|DEVICE|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
48651732|NCT05039489|DEVICE|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
48651733|NCT03627468|DRUG|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
48651734|NCT03627468|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
48651735|NCT03492385|DRUG|PB2452 Infusion|30 minute - 12 hour infusion
47974636|NCT03715764|OTHER|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
47974637|NCT02984748|DEVICE|Cochlear implant|
47974638|NCT04953468|DIAGNOSTIC_TEST|expression level of ANXA2 protein|The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
47974639|NCT02122562|DRUG|Ketamine|Treatment
48124873|NCT01571570|DRUG|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
48124874|NCT01571570|DRUG|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
48124875|NCT01571570|DRUG|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
48124876|NCT01571570|DRUG|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
48124877|NCT00359658|DRUG|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
48124878|NCT00359658|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
48124879|NCT00359658|DRUG|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
48124880|NCT02594631|PROCEDURE|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
48124881|NCT02594631|PROCEDURE|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
48124882|NCT00098319|DRUG|Folic acid (0.4mg vs. 4.0mg)|
48124883|NCT00774124|OTHER|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
48124884|NCT00774124|OTHER|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
48124885|NCT01840826|OTHER|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
48124886|NCT02436317|DEVICE|Point Of Care Ultrasound|Examination with an ultrasound machine
48124887|NCT01970813|DEVICE|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
48124888|NCT01970813|DEVICE|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
48124889|NCT03308292|OTHER|Exercise|Aerobic exercise program
48124890|NCT04246944|PROCEDURE|harvesting induced membrane|The induced membrane will be harvested during the second step of the bone reconstruction.
48124891|NCT03891316|DIAGNOSTIC_TEST|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of hexafluoroisopropanol and Sevoflurane are measured in urine by gas chromatography
48651736|NCT03492385|DRUG|Placebo - Sodium Chloride|30 minute - 12 hour infusion
48651737|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
48651738|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
48651739|NCT04846699|PROCEDURE|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
48651740|NCT06636799|DEVICE|Microneedling only|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left.
48651741|NCT06636799|OTHER|Microneedling and actives|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left. Group G3 received microneedling associated with active ingredients. This manipulated active ingredient was composed of growth factors (EGF Factor, TGFß3 Factor, and IDP-2 Peptide), Hydroxyprolisilane, and hyaluronic acid.
48651742|NCT04448847|DIETARY_SUPPLEMENT|Bif195|Active trial product with minimum 100 billion CFU daily dose
48651743|NCT04448847|OTHER|Placebo|Placebo similar to trial product but without Bif195
48651744|NCT04464538|BEHAVIORAL|WALC-R|Initial group education session and individualized coaching (remote)
48124892|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
48124893|NCT00914589|DRUG|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
48124894|NCT00914589|DRUG|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
48124895|NCT03209778|OTHER|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
48124896|NCT05028673|DRUG|Lu AG06466 Capsule|Hard capsule
48124897|NCT05028673|DRUG|Lu AG06466 Tablet|Film-coated tablet
48124898|NCT05028673|DRUG|Antacid|Oral suspension
48124899|NCT00274261|DRUG|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
48124900|NCT00274261|DRUG|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
48124901|NCT02376842|BEHAVIORAL|Severe sepsis early warning best practice alert|
48124902|NCT02376842|BEHAVIORAL|Standard care|
48124903|NCT04045938|OTHER|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
48124904|NCT01837394|PROCEDURE|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
48124905|NCT01837394|PROCEDURE|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
48651745|NCT04464538|OTHER|Information leaflet|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
48651746|NCT02260232|OTHER|exercise training|
48651747|NCT05187650|DEVICE|Ekso (EksoNR, Ekso Bionics)|The EksoNR is a powered exoskeleton designed to be used in a rehabilitation setting. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices and is used for gait training in neurorehabilitation.
48124906|NCT01837394|DRUG|Paracetamol|
48331690|NCT04777318|OTHER|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
48124907|NCT01837394|DRUG|Morphine|5 mg as needed
48124908|NCT01837394|DRUG|Ondansetron|4 mg i.v. as needed in the PACU
48124909|NCT01837394|DRUG|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
48331691|NCT04777318|OTHER|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.
48331692|NCT04777318|OTHER|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
48331693|NCT05419414|DEVICE|Shear wave elastography|Both groups were examined with shear wave elastography.
48331694|NCT06107036|DRUG|BI 1015550|BI 1015550
48331695|NCT06107036|DRUG|Moxifloxacin|Moxifloxacin
48331696|NCT06107036|DRUG|Placebo|Placebo-matching BI 101550
48331697|NCT00221429|DRUG|Lithium|lithium
48331698|NCT00221429|DRUG|sodium divalproex|Depakote
48331699|NCT00221429|OTHER|Placebo|Placebo
48331700|NCT06372808|OTHER|The Plyometric Exercise|The training group will perform plyometric exercises for eight weeks in addition to their regular training program.
48331701|NCT06372808|OTHER|The Regular Training|The control group's regular training includes basic strength training, cardiovascular training, technical and tactical training, and match-style wrestling.
48331702|NCT06495216|DEVICE|Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator|Pulsed field ablation balloon catheter and TRUPULSE generator will be used for PV ablation.
48331703|NCT06060067|BIOLOGICAL|TDV|TDV SC injection on Day 1 and Day 90 of the study
48331704|NCT06060067|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) SC injection on Day 1 and Day 90 of the study
48331705|NCT06187948|OTHER|Video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
48651748|NCT05187650|DEVICE|FES (RehaMove2, Hasomed)|RehaMove 2 sends electrical impulses via electrodes to nerves to evoke muscle contraction. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices.
47974640|NCT01931852|PROCEDURE|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
47974641|NCT01931852|OTHER|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
47974642|NCT02617745|OTHER|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
47974643|NCT03342105|PROCEDURE|Cettum|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.
47974644|NCT03342105|PROCEDURE|Acupuncture|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
47974645|NCT02870296|BEHAVIORAL|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
47974646|NCT02056340|DRUG|Atorvastatin|
47974647|NCT02056340|DRUG|Placebo|
48124910|NCT03576833|DEVICE|Elipse Balloon system|intragastic balloon
48124911|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 1|Search of positivity with anti-AGO antibodies test
48124912|NCT05966350|DIAGNOSTIC_TEST|Diagnosis of sensitive neuronopathy - phase 2|Title of anti-AGO antibodies
48124913|NCT05966350|OTHER|Comparison with Chi2 method|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
48124914|NCT05966350|OTHER|Comparison of data with parametric Test (T-test)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
48331706|NCT04781907|PROCEDURE|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
48331707|NCT03029897|OTHER|My eReport France|"patients are educated to the use of My eReport France application"
48331708|NCT05163717|COMBINATION_PRODUCT|INP105|A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)
48331709|NCT05163717|COMBINATION_PRODUCT|Placebo|A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)
48331710|NCT04048538|OTHER|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
48331711|NCT04048538|OTHER|usual standard of care|individuals will receive treatment as per the usual standard of care
48331712|NCT04207268|BEHAVIORAL|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
48331713|NCT04207268|BEHAVIORAL|Nutrition Advice|Participate in only nutrition advice
48331714|NCT01170221|DRUG|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
48331715|NCT01170221|DRUG|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
48331716|NCT03307863|DRUG|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
48331717|NCT03307863|DRUG|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
48331718|NCT03307863|DRUG|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
48331719|NCT06282536|DRUG|Iruplinalkib|60 mg on days 1-7, if tolerable, 180 mg from day 8 onwards.
48331720|NCT06282536|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
48331721|NCT06419361|DRUG|[68Ga]Ga-Sa-DABI-4|Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
48331722|NCT01659268|OTHER|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
48651749|NCT06191198|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
48651750|NCT06191198|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
48331723|NCT01659268|OTHER|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
48331724|NCT06507085|RADIATION|Radio-guided interventions to correct heart rhythm disorders|"All patients in the cohort will be undergoing one of the following radio-guided procedures :~* Insertion of a single-chamber pacemaker with lead~* Insertion of a dual-chamber pacemaker with lead~* Implantation of a multi-site pacemaker~* Implantation of a single-chamber endovascular defibrillator~* Implantation of a dual-chamber endovascular defibrillator~* Placement of multi-site defibrillator~* Typical Primary Atrial Flutter Ablation: Cavotricuspid Isthmus only~* Primo Ablation tachycardia by intra nodal re-entry~* Accessory pathway ablation~* Paroxysmal atrial fibrillation ablation (4 pulmonary veins only, all technologies combined~* Primo Ablation Persistent atrial fibrillation (4 pulmonary veins ± lines ± substrate"
48331725|NCT01010854|DRUG|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
48331726|NCT03097614|DEVICE|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
48331727|NCT03487328|PROCEDURE|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
48331728|NCT00214487|DEVICE|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
48331729|NCT00214487|DEVICE|Placebo Control|Single vision soft contact lenses
48331730|NCT01059396|DRUG|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
48331731|NCT01059396|DRUG|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
48331732|NCT01059396|DRUG|placebo|placebo propranolol / carvedilol
48492179|NCT02831218|PROCEDURE|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
47974648|NCT04743297|DRUG|Prostaglandin E2 (Propess)|Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
48331733|NCT03434418|DRUG|osimertinib|80 mg oral administration daily
48331734|NCT03154307|DEVICE|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
48331735|NCT02842788|PROCEDURE|Prone positioning|Turning the patient face down for several consecutive hours
48331736|NCT01993056|BEHAVIORAL|"FIFA 11+"|
48331737|NCT01993056|BEHAVIORAL|"no FIFA 11+"|
48331738|NCT01860963|PROCEDURE|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
48651751|NCT06554730|OTHER|Merck Belzutifan PAS in adult patients|There is no intervention for this study. This study will be collecting data from the EMR of consenting subjects who are taking Belzutifan.
48651752|NCT05521178|DIAGNOSTIC_TEST|Electrocardiogram|ECG to monitor electrical activities of the heart on each visit
48651753|NCT05521178|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 6 months
48651754|NCT05521178|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac MRI at baseline and 6 months
48331739|NCT03595384|BEHAVIORAL|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
48331740|NCT02482012|OTHER|Survey|This was a survey
48331741|NCT05094895|PROCEDURE|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
47974649|NCT04743297|DRUG|Prostaglandin E2 (Prostin)|Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
48124915|NCT05966350|OTHER|Comparison of data with non-parametric test (ANNOVA)|Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).
48124916|NCT02319434|DEVICE|Ostom-i Alert Sensor|Sensor on ostomy bag.
48331742|NCT05094895|PROCEDURE|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
48331743|NCT01896739|BIOLOGICAL|Eutravac|
48331744|NCT03246555|DRUG|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
48331745|NCT03246555|DRUG|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
48331746|NCT02333006|OTHER|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
48331747|NCT05367557|PROCEDURE|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
47974650|NCT05466526|PROCEDURE|High frequency deep sclerotomy (HFDS)|The surgery was performed using the abee® glaucoma tip of Oertli phacoemulsiﬁcation machine (Cata-rhex3, Switzerland) and goniolens. During the procedures, nasal six pockets penetrating 1mm deep from the trabecular meshwork to Schlemm's canal will be formed to promote the aqueous humor outflow.
47974651|NCT04140591|DRUG|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
47974652|NCT04140591|DRUG|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure \>90mmHg) PPI: Pariet EC 20mg/QDAC
47974653|NCT01236599|OTHER|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
47974654|NCT04744142|DRUG|Ketone supplementation|Subjects receive either placebo or ketone ester supplementation
47974655|NCT04744142|DIETARY_SUPPLEMENT|Increased protein intake|Subjects receive either normal or increased protein intake
48124917|NCT00243503|DRUG|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
48124918|NCT01871324|BEHAVIORAL|Lifestyle counseling|group therapy
48124919|NCT02818335|DRUG|LY3023414 Reference Fasted|Administered Orally
48331748|NCT05395741|DRUG|Regorafenib|Patients will receive regorafenib orally at doses adjusted for age, body surface area and pharmacokinetics. Treatment with regorafenib will be continued for up to 1 year or until disease progression, patient death, unacceptable toxicity, or study closure. Pharmacokinetics and safety profile of the investigational product (IP) will be determined throughout the course therapy. In the event of progression or relapse, patients in the control group will have the option to receive the IP along with the standard treatment of the next line.
48651755|NCT05521178|DEVICE|Mobile cardiac telemetry|Mobile cardiac telemetry at baseline and 6 months
48651756|NCT05521178|DIAGNOSTIC_TEST|Blood pressure monitoring|Home blood pressure monitoring three times per week
47974656|NCT00585819|PROCEDURE|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
47974657|NCT00585819|PROCEDURE|Freebreathing in Body fix mold|Freebreathing in Body fix mold
48124920|NCT02818335|DRUG|LY3023414 Test Fasted|Administered Orally
48124921|NCT02818335|DRUG|LY3023414 Test Fed|Administered Orally
48124922|NCT04978233|OTHER|sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID|The intervention consists of having confirmed COVID-19 infected participants register for the Opal app and complete a daily questionnaire on symptoms related to their physical and mental health as well as on certain key vital signs (e.g., oxygen saturation, heart rate, temperature). A nurse will check the questionnaire results each day and determine the need for a teleconsultation with an infectious disease physician. Participants will be followed up for a minimum of 14 days, depending on their symptoms.
48331749|NCT01553071|DRUG|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
48331750|NCT06027944|OTHER|Light exposure|Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
48331751|NCT02568163|OTHER|Non surgical periodontal treatment|
48651757|NCT05521178|DIAGNOSTIC_TEST|Blood draw|Blood draw at baseline, 3 and 6 months
48331752|NCT02452268|DRUG|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
47974658|NCT05240053|OTHER|enhanced recovery programe|Early postoperative analgesia , early oral intake , early mobilization , early removal of nasogastric tube \& drains if any. The patients in this group started clear fluid once they awaked from anesthesia , a full liquid diet on first postoperative day , normal diet on second day provided that there was no vomiting or abdominal distension. The patients in this group were instructed for early ambulation \& encouraged to stay out of the bed for 4 hours on first day postoperative , 6 hours in following day , 8 hours on subsequent days. Also they were encouraged to walk the length of 3 meters once on first day postoperative , twice on day 2 \& three times on subsequent days. Regarding analgesia in this group postoperatively , they were received fentanyl via an epidural catheter.
47974659|NCT04219553|BEHAVIORAL|Antimicrobial stewardship|The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
47974660|NCT04219553|OTHER|Comparator (no intervention)|No active intervention
47974661|NCT00499876|DRUG|mefloquine|250mg weekly PO for 6 months
47974662|NCT00499876|OTHER|placebo|1 tablet weekly PO for 6 months
47974663|NCT03648268|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation"
48331753|NCT02452268|DRUG|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
48331754|NCT01254578|OTHER|Laboratory Biomarker Analysis|Correlative studies
48331755|NCT01254578|DRUG|Lenalidomide|Given orally
48331756|NCT01254578|OTHER|Pharmacological Study|Correlative studies
48331757|NCT04833920|DEVICE|transcranial dirrect current brain stimuation|tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),
48492180|NCT02831218|PROCEDURE|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
48492181|NCT03531801|OTHER|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
48651758|NCT03161496|GENETIC|detection of genotype|detection of genotype by next generation sequencing
48492182|NCT03688282|DEVICE|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
48492183|NCT03688282|DEVICE|Sham, wearing belt|The device is worn, for a specified time. It will not be turned on during this period. It is only sham.
48651759|NCT01334567|DRUG|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
48651760|NCT02679274|DRUG|Placebo|Intermittent intramuscular injections of saline (males and females).
48651761|NCT02679274|DRUG|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
48651762|NCT05193383|BEHAVIORAL|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
48651763|NCT05193383|BEHAVIORAL|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
48651764|NCT05193383|BEHAVIORAL|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
48651765|NCT05193383|BEHAVIORAL|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
48651766|NCT05989269|OTHER|Modified lab reporting|If appropriateness of culturing i.e., clinical criteria for pneumonia testing does not meet the algorithm AND there is growth of one or more organism(s) that are not considered normal upper respiratory flora, during the intervention period, the result will be modified to reflect the likelihood of asymptomatic colonization.
48331758|NCT00870974|DRUG|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB
48331759|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
48124923|NCT04456751|OTHER|Redo op|Patients with a redo operation
48124924|NCT03159273|DIETARY_SUPPLEMENT|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
48331760|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
48331761|NCT01519401|DRUG|3 mg drospirenone and 20 µg ethinyl-estradiol|
48331762|NCT01519401|DRUG|3 mg drospirenone and 30 µg ethinyl-estradiol|
48492184|NCT03822507|DRUG|KHK7580|oral administration
47974664|NCT02049281|DRUG|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
48331763|NCT04559087|PROCEDURE|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
47974665|NCT04781998|DRUG|liraglutide 3 mg (Saxenda®) once-daily|Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
47974666|NCT01690208|OTHER|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
48331764|NCT03181841|DRUG|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
48124925|NCT05598554|OTHER|Telerehabilitation|Chair-based yoga with telerehabilitation was applied to the study group for 45 minutes a day, 2 days a week, for 6 weeks.
48124926|NCT05598554|OTHER|information|A one-session training was provided on the effects of exercise on quality of life.
48124927|NCT02462616|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
48331765|NCT03181841|DRUG|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
48331766|NCT04562558|DRUG|Methotrexate|50mg intramuscularly on Days 1, 3, 5, 7 . Repeat every 14 days
48331767|NCT04562558|DRUG|Leucovorin|15mg intramuscularly on Days 2, 4, 6, 8. Repeat every 14 days
48331768|NCT04562558|DRUG|Dactinomycin|1.25mg/m2 (2mg max dose)intravenous every 14 days.
48331769|NCT02023112|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
48331770|NCT02023112|DRUG|Ribavirin|Capsule
48331771|NCT01781871|BIOLOGICAL|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
48331772|NCT01781871|BIOLOGICAL|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
48492185|NCT03822507|DRUG|Cinacalcet Hydrochloride|oral administration
48492186|NCT00595686|DRUG|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
48124928|NCT02292329|DIETARY_SUPPLEMENT|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
48124929|NCT02292329|DIETARY_SUPPLEMENT|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
48331773|NCT01459068|BEHAVIORAL|Common Elements Treatment Approach|"CETA components include:~1. Engagement (encouraging participation)~2. Psychoeducation (introduction)~3. Anxiety Management Strategies (relaxation)~4. Behavioral Activation (getting active)~5. Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~6. Imaginal Gradual Exposure (talking about difficult memories)~7. In Vivo Exposure (Live exposure)~8. Suicide/Homicide/Danger Assessment and Planning (safety)~9. Screening and Brief Intervention for Alcohol (alcohol intervention)"
48124930|NCT03306368|BEHAVIORAL|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
48124931|NCT01812096|OTHER|Subcutaneous bortezomib|
48124932|NCT01812096|OTHER|Intravenous bortezomib|
48331774|NCT01670136|DRUG|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
48651767|NCT04378790|OTHER|Patching|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
48331775|NCT05129787|PROCEDURE|Surgical resection|Resection of metastasis
48331776|NCT05129787|PROCEDURE|Thermal ablation|Ablation of metastasis
48331777|NCT05247125|COMBINATION_PRODUCT|Blue light exposure + Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
48331778|NCT05247125|DRUG|Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed.
48492187|NCT02349971|DEVICE|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
48492188|NCT00238875|PROCEDURE|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
48492189|NCT01472328|PROCEDURE|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
48651768|NCT04378790|OTHER|Glasses|Eye Glasses are created and worn by patient to improve vision
48651769|NCT00400322|DRUG|Valganciclovir (Valcyte)|
48651770|NCT00400322|OTHER|Placebo|
48651771|NCT06471673|BIOLOGICAL|BC1 cell line|BC1 cell line is a different experimental, HER-2 positive, allogeneic, whole cell BC cell lines designed to secrete GM-CSF in situ and augment dendritic cell activity. Similar to the SV-BR-1-GM cell line (NCT03328026, IND 10312), the BC cell line is derived from the BC parent cell line, SV-BR-1, which expresses multiple tumor associated antigens (TAAs)
48651772|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab)|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
48651773|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab) expansion cohort|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
47974667|NCT01690208|OTHER|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment \& explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
47974668|NCT06502717|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
47974669|NCT02027896|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
47974670|NCT02915198|DRUG|Metformin XR|The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
47974671|NCT02915198|DRUG|Placebo|"For patients \< 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR \< 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
47974672|NCT05592964|DIETARY_SUPPLEMENT|Fasting|Standard fasting
47974673|NCT05592964|DIETARY_SUPPLEMENT|Water|In Group S, water was given 1 hour before the operation.
47974674|NCT05592964|DIETARY_SUPPLEMENT|Carbohydrate fluid|In Group K, carbohydrate fluid was given 1 hour before the operation.
47974675|NCT02898337|DEVICE|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
47974676|NCT05989763|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
48331779|NCT05247125|DEVICE|Blue light exposure|Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
48331780|NCT05247125|COMBINATION_PRODUCT|Placebo|Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
48331781|NCT05289154|OTHER|self- applied acupressure plus Qigong course plus advice literature|daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
48331782|NCT05289154|BEHAVIORAL|advice literature with naturopathy|advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
48331783|NCT03574415|DRUG|DWP14012|DWP14012 tablets
48331784|NCT03574415|DRUG|Placebo|DWP14012 placebo-matching tablets
48331785|NCT04313088|DRUG|Eluxadoline 100 mg|Eluxadoline 100mg by mouth twice daily with food
48331786|NCT06140277|PROCEDURE|extraction with chitosan particles as a replacement for bone graft with collagen membrane|to replace the bone at the extraction site we will put either chitosan or allograft particles
48492190|NCT01472328|PROCEDURE|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
48492191|NCT01833533|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
48331787|NCT06140277|PROCEDURE|extraction with placing of allograft particles with collagen membrane|to replace the bone at the extraction site we will put allograft particles
48331788|NCT06140277|PROCEDURE|tooth extraction only|hopeless tooth will be extracted without any intervention
48331789|NCT03552627|DRUG|Oxygen|Medical Oxygen
48331790|NCT01319019|DRUG|GSK961081|Comparison of different doses and dosing regimens of the drug
48331791|NCT01319019|DRUG|Salmeterol|Positive control
48331792|NCT01319019|DRUG|Placebo|Placebo arm
48331793|NCT02645591|PROCEDURE|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
48331794|NCT02645591|BIOLOGICAL|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
48331795|NCT02645591|BEHAVIORAL|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
48331796|NCT00198094|DRUG|Sertraline and Alprazolam XR|
48331797|NCT00648570|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
48331798|NCT00648570|DRUG|Lexapro® Tablets (20 mg|20mg, single dose fasting
48331799|NCT02538367|DRUG|YH12852 IR 0.05mg|
48331800|NCT02538367|DRUG|YH12852 IR 0.1mg|
48331801|NCT02538367|DRUG|YH12852 IR 0.3mg|
48331802|NCT02538367|DRUG|YH12852 IR 0.5mg|
48331803|NCT02538367|DRUG|YH12852 IR 1mg|
48331804|NCT02538367|DRUG|YH12852 IR 2mg|
48331805|NCT02538367|DRUG|YH12852 IR 3mg|
48331806|NCT02538367|DRUG|YH12852 DR1 0.5mg|
48331807|NCT02538367|DRUG|YH12852 DR1 1mg|
48492192|NCT01833533|DRUG|Ribavirin|Capsule
48124933|NCT01839331|BIOLOGICAL|4 mL injection of Ampion|4 mL Injection of Ampion
48331808|NCT02538367|DRUG|YH12852 DR1 2mg|
48331809|NCT02538367|DRUG|YH12852 DR1 4mg|
48651774|NCT01717274|PROCEDURE|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
48651775|NCT00281385|BEHAVIORAL|traditional vs. lifestyle exercise|
48331810|NCT02538367|DRUG|YH12852 DR2 8mg|
48331811|NCT02538367|DRUG|Prucalopride 2mg|
48331812|NCT02538367|DRUG|Placebo|
48331813|NCT01585493|OTHER|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
48331814|NCT01585493|BEHAVIORAL|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
48331815|NCT01585493|BEHAVIORAL|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
48331816|NCT00105560|RADIATION|radiation therapy|Radiation therapy with proton beam to standard doses
48124934|NCT01839331|BIOLOGICAL|10 mL Injection of Ampion|10 mL Injection of Ampion
48124935|NCT01839331|DRUG|4 mL Injection of Placebo|4 mL Injection of Placebo
48124936|NCT01839331|DRUG|10 mL Injection of Placebo|10 mL Injection of Placebo
48124937|NCT06028672|DRUG|Toripalimab|200mg q2w intravenous
48124938|NCT06028672|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
48331817|NCT03485222|DRUG|Empagliflozin|6 months
48331818|NCT03485222|DRUG|Placebos|placebo equivalent for 6 months
48331819|NCT02823080|DRUG|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
48331820|NCT01410799|DRUG|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
48331821|NCT01937481|BEHAVIORAL|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
48331822|NCT01277913|DRUG|Vitamin D3|1000 IU once daily for 12 months
48331823|NCT01277913|DRUG|Vitamin D3|500 IU once daily for 12 months
48331824|NCT00719862|DRUG|Placebo nasal spray|Placebo
48331825|NCT00719862|DRUG|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
48492193|NCT01833533|DRUG|Placebo for Ribavirin|Capsule
48492194|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 8g protein/100kcal|Enteral feed containing 8g protein/100kcal
48331826|NCT04197024|DEVICE|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
48492195|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 5g protein/100kcal|Enteral feed containing 5g protein/100kcal
48492196|NCT05626439|DRUG|Staccato alprazolam|Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
47974677|NCT05989763|DEVICE|Sham-TEA|Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
47974678|NCT05825521|OTHER|MRI|During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
48492197|NCT05626439|DRUG|Oral alprazolam|Study participants will receive single dose of oral alprazolam at pre-specified time points.
48492198|NCT04076384|BEHAVIORAL|Guided Self-Determination|Structured team-based consultations
48492199|NCT04076384|BEHAVIORAL|Standard care|Standard consultations
48492200|NCT05733520|BEHAVIORAL|Brain CareNotes|The Brain CareNotes mobile telehealth app is used by unpaid caregivers for BPSD management. It includes remote communication with an external human support person-a care coach-as well as features for users to independently perform health-related activities.
48492201|NCT05733520|BEHAVIORAL|Dementia Guide Expert|"Dementia Guide Expert provides education only and no interactive BPSD management support, coaching, assessment, or external response. It contains evidence-based expert information on what dementia is, types, contributing factors, risks, symptoms, stages, diagnosis, tests, treatment, management, communication techniques, and links to resources and support services."
48492202|NCT06216743|DIAGNOSTIC_TEST|MRI and CT|Patients will undergo an additional MRI, cineMRI and CineCT cscan.
48492203|NCT02119117|DIETARY_SUPPLEMENT|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
48492204|NCT02119117|DIETARY_SUPPLEMENT|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
48492205|NCT00741936|DRUG|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
48492206|NCT00741936|DRUG|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
48492207|NCT05148962|BIOLOGICAL|GRT-R910 10 mcg Dose (after AZ)|10 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
48492208|NCT05148962|BIOLOGICAL|GRT-R910 30 mcg Dose (after AZ)|30 mcg vaccine by intramuscular (IM) injection on Day 1 (required) and on Day 113 (optional)
48492209|NCT05148962|BIOLOGICAL|GRT-R910 10 mcg Dose (After Adenovirus based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
48492210|NCT05148962|BIOLOGICAL|GRT-R910 10 mcg Dose (after mRNA based vaccine)|GRT-R910 10 mcg vaccine by intramuscular (IM) injection on Day 1 and on Day 29
48492211|NCT04461119|DRUG|Evenamide|oral capsules for 4 weeks of treatment
48492212|NCT04461119|DRUG|Placebo|oral capsules for 4 weeks of treatment
48492213|NCT00115297|DRUG|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
48492214|NCT00115297|DRUG|Placebo|Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
48492215|NCT04030182|DIAGNOSTIC_TEST|Level of Vitamin D|3 ml of venous blood will be taken to determine the level of vitamin D
48492216|NCT00219583|DRUG|UK-390,957|
48492217|NCT02754466|OTHER|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
48492218|NCT02754466|OTHER|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
48492219|NCT03528785|DRUG|Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid|"* Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle"
48492220|NCT04710511|OTHER|Child and Youth Resilience Measure - Revised (CYRM-R)|(CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent
48492221|NCT01408628|BEHAVIORAL|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm."
48492222|NCT00644449|OTHER|placebo|placebo
47974679|NCT05557604|DRUG|Decapeptyl|STAD androgen deprivation
47974680|NCT01240720|DRUG|131I-F16SIP Radioimmunotherapy (RIT)|"* Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~* Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
47974681|NCT02402127|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
47974682|NCT02402127|DEVICE|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
47974683|NCT02402127|DEVICE|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
47974684|NCT03211416|OTHER|Laboratory Biomarker Analysis|Correlative studies
48651776|NCT06253312|PROCEDURE|Open surgery|Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass
48124939|NCT03431922|DEVICE|endovascular denervation|multi-electrode catheter-based endovascular denervation
48492223|NCT00644449|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
48651777|NCT06253312|PROCEDURE|Hybrid repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis
47974685|NCT03211416|BIOLOGICAL|Pembrolizumab|Given IV
47974686|NCT03211416|DRUG|Sorafenib Tosylate|Given PO
47974687|NCT02715674|DEVICE|Plasti-med TRIFLO|
47974688|NCT02715674|DEVICE|BIPAP VISION|
47974689|NCT02715674|DEVICE|Plasti-med oxygen therapy mask|
47974690|NCT04998474|BIOLOGICAL|FRAME-001 personalized vaccine|Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs.
47974691|NCT01538420|DRUG|GLPG0492|Oral solution
47974692|NCT01538420|DRUG|Placebo|Placebo oral solution
47974693|NCT05024591|DEVICE|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
47974694|NCT01694589|DRUG|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
47974695|NCT00733408|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
47974696|NCT00733408|BIOLOGICAL|bevacizumab|Given IV
47974697|NCT00733408|DRUG|erlotinib hydrochloride|Given PO
47974698|NCT04959344|BIOLOGICAL|Kleb4V target dose|Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
47974699|NCT04959344|BIOLOGICAL|Kleb4V target dose + AS03|Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
47974700|NCT04959344|BIOLOGICAL|Kleb4V low dose|Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
47974701|NCT04959344|BIOLOGICAL|Kleb4V low dose + AS03|Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
48651778|NCT06253312|PROCEDURE|Endovascular repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
48651779|NCT06240286|BEHAVIORAL|Sitting workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.
47974702|NCT04959344|BIOLOGICAL|Placebo|Two doses of the Placebo will be administered intramuscularly 2 months apart
47974703|NCT01009125|OTHER|$2 cash|$2 cash incentive will be included in the mailed survey
47974704|NCT01009125|OTHER|$5 cash|$5 cash incentive will be included in the mailed survey
47974705|NCT01085591|DRUG|CB-183,315|
47974706|NCT01085591|DRUG|Placebo|
47974707|NCT01085591|DRUG|Vancomycin|
47974708|NCT04473924|DRUG|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
47974709|NCT04473924|DRUG|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
48124940|NCT03224858|OTHER|SUMMIT intervention|See description in experimental arm.
48124941|NCT03224858|OTHER|Enhanced usual care|See description in active comparator arm.
48331827|NCT04197024|DEVICE|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
48492224|NCT00644449|OTHER|placebo|placebo
48492225|NCT00644449|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
48651780|NCT06240286|BEHAVIORAL|Standing workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.
47974710|NCT02632474|DRUG|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
47974711|NCT02603094|PROCEDURE|clear fluid ingestion|drinking of clear fluid in preoperative period
47974712|NCT00684593|DRUG|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
47974713|NCT00684593|OTHER|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
48331828|NCT06315582|PROCEDURE|Removal of uterine septum with hysteroscopic scissors without electrosurgery.|Hysteroscopic septoplasty utilizing scissors without electrosurgery followed by hysteroscopic morcellation of residual tissue
48331829|NCT06315582|PROCEDURE|Hysteroscopic septoplasty utilizing bipolar electrosurgery|Hysteroscopic septoplasty utilizing bipolar electrosurgery
48331830|NCT05005442|BIOLOGICAL|Pembrolizumab/vibostolimab coformuation|Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
48331831|NCT03956888|DRUG|N-acetylcysteine|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
48331832|NCT05401591|DIETARY_SUPPLEMENT|Protein shake|Participant will drink a protein shake made using each of the four protein types.
48331833|NCT04796428|DRUG|Canagliflozin|Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
48331834|NCT04796428|DRUG|Dapagliflozin|"Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used."
48492226|NCT06197958|OTHER|eccentric exercises|eccentric exercises like walking down stairs, lowering a weight during shoulder press, the downward motion of squatting, the downward motion of a push-up, lowering the body during a crunch, lowering the body during a pull-up 3 sets with 10 RM (repetition maximum) for six week training.
47974714|NCT04147208|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
48651781|NCT06240286|BEHAVIORAL|Stepping workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.
48651782|NCT06240286|BEHAVIORAL|Walking workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
47974715|NCT04147208|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
47974716|NCT04147208|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
47974717|NCT00000105|BIOLOGICAL|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
47974718|NCT00000105|BIOLOGICAL|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
47974719|NCT00000105|DRUG|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
47974720|NCT00000105|BIOLOGICAL|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
47974721|NCT05841394|DRUG|Esomeprazole 40mg|40 mg i.v. twice daily (q12h)
47974722|NCT05841394|DRUG|Ilaprazole Sodium|10 mg i.v. once daily, 20 mg i.v. in the first day.
47974723|NCT05841394|DRUG|Placebo 1|Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
47974724|NCT05841394|DRUG|Placebo 2|Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
47974725|NCT00888862|DRUG|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
47974726|NCT02664753|DRUG|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~\< à 60kg : 2g/day \> 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
48331835|NCT04796428|DRUG|Empagliflozin|"If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used."
48331836|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
48492227|NCT06197958|OTHER|concentric exercises|concentric exercises like walking upstairs, pushing up in a bench press, the beginning portion of a deadlift when you lift the barbell off the ground, sitting up in a sit up, pushing up from a lowered push-up and standing up in a back squat 3 sets with 10 RM.
48492228|NCT01753336|BIOLOGICAL|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
48651783|NCT06564740|DRUG|Stem Cell|UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.
47974727|NCT02664753|DRUG|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
48651784|NCT06564740|OTHER|Control|In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.
48651785|NCT03286569|DEVICE|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
48651786|NCT02522273|DEVICE|EKF Diagnostics 'SensPoint' Lactate Meter|
48651787|NCT06638268|PROCEDURE|Acute TAVI|TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.
48124942|NCT05748730|BEHAVIORAL|iCHART|"The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider."
48124943|NCT05748730|BEHAVIORAL|Treatment As Usual|Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
48124944|NCT01497704|DRUG|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
48124945|NCT00015067|DRUG|Methylphenidate|
48124946|NCT02487069|PROCEDURE|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
48124947|NCT02487069|PROCEDURE|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
48124948|NCT02487069|PROCEDURE|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
48124949|NCT02487069|DRUG|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
48492229|NCT05051501|DIETARY_SUPPLEMENT|Probiotics C2P|Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
47974728|NCT01244724|DRUG|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
47974729|NCT04675645|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
47974730|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D and calcium|
47974731|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D|
47974732|NCT02662491|DIETARY_SUPPLEMENT|Calcium|
47974733|NCT02662491|DIETARY_SUPPLEMENT|Placebo|
47974734|NCT01636804|DEVICE|Quicksite|St. Jude Medical produced lead called Quicksite
47974735|NCT01636804|DEVICE|Quickflex|St. Jude Medical produced lead called Quickflex
47974736|NCT05077397|DEVICE|StO2|InSpectra Tissue Spectrometer Model 1615 probe (Hutchinson Technology Inc. Hutchinson, MN, USA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices and StO2 values in the devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
47974737|NCT05077397|DEVICE|O3|O3TM Regional Oximeter System (O3 System, Masimo Corporation, Irvine, CA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
47974738|NCT02486432|DRUG|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
47974739|NCT02602496|OTHER|Fruits and Vegetables|5 servings of fruits or vegetables
47974740|NCT02602496|OTHER|Whole Grain|3 servings of whole grain
47974741|NCT02602496|OTHER|Control|3 servings of refined grain
47974742|NCT01220843|DRUG|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
47974743|NCT01220843|DRUG|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
47974744|NCT00433095|DRUG|Navelbine|
47974745|NCT00433095|DRUG|Herceptin|
47974746|NCT00433095|DRUG|Navelbine (oraly)|
47974747|NCT03517956|DRUG|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
47974748|NCT03517956|DRUG|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
47974749|NCT01543698|DRUG|LGX818|
47974750|NCT01543698|DRUG|MEK162|
47974751|NCT01543698|DRUG|LEE011|
47974752|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
47974753|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
48124950|NCT02487069|DRUG|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
48492230|NCT03940794|OTHER|Verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
47974754|NCT05518539|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
47974755|NCT03606408|DRUG|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
48492231|NCT01294475|BEHAVIORAL|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
47974756|NCT03296930|DRUG|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
47974757|NCT03296930|DRUG|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
48124951|NCT02487069|DRUG|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
48124952|NCT02487069|DRUG|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
48124953|NCT05264168|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
48124954|NCT05264168|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
48124955|NCT02263573|OTHER|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE \* 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC \* 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1."
48124956|NCT02263573|OTHER|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
48124957|NCT00926354|DRUG|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
48124958|NCT06154694|RADIATION|Stereo Radiographic EOS Measurements|"Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~1. Relaxed standing (0 degree of abduction)~2. 45 degree of abduction in the coronal plane~3. 90 degree of abduction in the coronal plane~4. 120 degree of abduction in the coronal plane~5. 45 degree anterior flexion in the sagittal plane~6. 90 degree anterior flexion in the sagittal plane~7. 120 degree of anterior flexion in the sagittal plane~8. 45 degree extension in the sagittal plane"
48124959|NCT04699786|OTHER|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A \& C participants will receive their risk estimate about two weeks after consent is signed and Arms B\& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing \& demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A \& C will have extra surveys at twenty-four months post disclosure.
48124960|NCT01036724|DEVICE|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.
48124961|NCT06290882|PROCEDURE|Robotic Heller Myotomy|Use five trocar technique with patient in the French position. Establish 12-15 mm Hg pneumoperitoneum. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 7 cm above gastroesophageal junction and 2 cm inferiorly over stomach. Measure myotomy length. Perform anterior fundoplication without mobilizeng fundus of the stomach by dividing short gastric vessels if not necessary. Suture fundus to both cut edges of myotomy, using non-resorbable material.
48331837|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
48331838|NCT02839941|DRUG|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
48331839|NCT02839941|DRUG|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
48331840|NCT02839941|DRUG|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
48331841|NCT02839941|DRUG|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
48331842|NCT04029324|PROCEDURE|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
48331843|NCT04029324|PROCEDURE|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
48331844|NCT04029324|PROCEDURE|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
47974758|NCT00325728|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
47974759|NCT00325728|DRUG|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
47974760|NCT05924620|DRUG|finerenone|Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
47974761|NCT01993654|PROCEDURE|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
47974762|NCT00674544|BEHAVIORAL|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
48331845|NCT04029324|PROCEDURE|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
47974763|NCT00307294|DRUG|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
47974764|NCT00307294|DRUG|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
47974765|NCT02151253|DRUG|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
47974766|NCT02151253|DRUG|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
47974767|NCT02847156|OTHER|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
47974768|NCT06504043|DRUG|HST101|Biological: HST101
47974769|NCT00718224|DRUG|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
47974770|NCT00718224|DRUG|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
47974771|NCT00718224|DRUG|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
47974772|NCT02468115|DRUG|VIS410|Single fixed IV dose of VIS410
48331846|NCT03058848|DIETARY_SUPPLEMENT|PKU Start|"PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian."
48331847|NCT05474807|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution."
48331848|NCT01962688|DEVICE|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
48331849|NCT01962688|DEVICE|Sham ultrasound|sham ultrasound to facilitate blinding
48331850|NCT01726712|OTHER|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
48331851|NCT00617591|DRUG|Lenalidomide|25 mg orally on days 1-21
48331852|NCT00617591|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)
48331853|NCT00617591|DRUG|Dexamethasone|40 mg orally on days on 1-4
48651788|NCT06638268|OTHER|Stabilization and subacute TAVI|Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.
48331854|NCT05424185|BEHAVIORAL|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
48651789|NCT03813121|DRUG|midazolam intravenous infusion|Participants will receive a single drug infusion
48651790|NCT03813121|DRUG|placebo intravenous infusion|Participants will receive a single placebo infusion
48651791|NCT03813121|DRUG|ketamine intravenous infusion|Participants will receive a single drug infusion
48651792|NCT05063136|DRUG|Capecitabine+endocrine therapy|Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
48651793|NCT05063136|DRUG|Placebo+endocrine therapy|Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
48651794|NCT06570889|DIETARY_SUPPLEMENT|Cholecalciferol D3|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
48651795|NCT06570889|OTHER|Olive oil|Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
48651796|NCT04535362|DRUG|Nicotine|session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
48651797|NCT02184286|DRUG|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
48651798|NCT02184286|DRUG|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
48651799|NCT03692169|PROCEDURE|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
47974773|NCT02468115|DRUG|Placebo|Single IV dose of placebo
47974774|NCT01532414|DRUG|Androxal|oral, capsules, taken one time daily, for 3 months
47974775|NCT01532414|DRUG|Placebo|Oral capsule taken one time daily for 3 months
48331855|NCT04688216|OTHER|risk factors of infection with multidrug-resistant organisms|"1. General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~2. Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~3. The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
48331856|NCT04371627|DRUG|Viaskin Peanut|Daily epicutaneous delivery
48331857|NCT00003129|DRUG|valrubicin|
48331858|NCT02024841|DRUG|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
48331859|NCT01017822|BIOLOGICAL|conatumumab|
48331860|NCT01017822|DRUG|capecitabine|
48331861|NCT01017822|DRUG|gemcitabine hydrochloride|
48331862|NCT01017822|RADIATION|3-dimensional conformal radiation therapy|
48331863|NCT00810589|DRUG|Levemir|0,4 IE per kg bodyweight
48331864|NCT00810589|DRUG|Humalog NPL Insulin|0,4 IE per kg bodyweight
48492232|NCT04973553|OTHER|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
48492233|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|Measuring the effect of the buddy and gamification components separately. During the A1 phase (baseline) and the A2 phase (reversal), participants will be asked not to use the 'Move it, Move ID' intervention: the app will be blocked. After an A phase, the app will be unblocked. During the B1 and B2 intervention phase, participants use the 'Move My it, Move ID' intervention only consisting of the buddycomponent. During the intervention period, adolescents and buddies are asked to wear an accelerometer. During the first AB pair we examine whether the buddy component has an effect on PA compared to no intervention. In the A2 reversal phase possible carryover effects can be measured. It will be informative to investigate whether some parts of the intervention are automatized or internalized and will still have some effect even when participants have no access to the intervention anymore (i.e. A2 phase). The study duration is 32 days; each phase will have a duration of minimum 5 days.
48492234|NCT05149443|BEHAVIORAL|theory-based mHealth-intervention (app)|"After the first study, other participants will be recruited. In a second study, the set-up remains the same, but the A1 and A2 phase this time consist of the buddy component (i.e. control phase) and in the B1 and B2 phase the gamification component will be added. This way, we can determine whether the gamification component has an effect on PA compared to the baseline buddy component intervention.~The study duration is 32 days for all participants. The duration of the 4 different phases of the design will vary between participants, but each phase will have a duration of minimum 5 days."
48492235|NCT01951885|DRUG|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
48331865|NCT05269732|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
48331866|NCT04254432|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
48331867|NCT04740333|OTHER|No intervention- observational study|No intervention- observational study
48331868|NCT00206401|DRUG|Lantus and short acting analogs Vs NPH and short acting analogs|
48331869|NCT00651612|DRUG|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
48331870|NCT00651612|DRUG|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
48331871|NCT06396572|PROCEDURE|IVR-Procedure|Using immersive virtual reality to learn urinary catheterisation procedure
47974776|NCT04249674|DIAGNOSTIC_TEST|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
47974777|NCT04249674|GENETIC|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
47974778|NCT04475653|BEHAVIORAL|Physical Activity using an Activity Tracker|
48492236|NCT01951885|DRUG|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
48492237|NCT01951885|DRUG|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients \>40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
48124962|NCT06290882|PROCEDURE|Peroral Endoscopic Myotomy|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
48124963|NCT01184326|DRUG|pazopanib|
48124964|NCT01184326|DRUG|everolimus|
48124965|NCT01494922|DRUG|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
48124966|NCT06070714|DEVICE|Holmium laser with pulse modulation|The holmium laser with pulse modulation emits two separate laser pulses with a short time interval between them. The first pulse divides the water between the laser fiber tip and the stone and the second pulse hits the stone unobstructed.
48124967|NCT06070714|DEVICE|Thulium fiber laser|The thulium fiber laser has a different wavelength then the holmium laser with pulse modulation and thus has slightly different energy properties. It has also been shown to increase ablative volume and decrease retropulsion without any safety concerns.
48124968|NCT05664204|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
48124969|NCT05077618|OTHER|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
48124970|NCT05444426|OTHER|Shoulder Rehabilitation|hot pack, conventional TENS (COMPEX Rehab 400), 1 MHz frequency, 1.5 W/cm² intensity ultrasound (Chattanooga Intelect Ultrasound), active assistive and active range of motion exercises, stretching exercises for the shoulder muscles at the pain limit and posture exercises will be applied.
48124971|NCT00004243|DRUG|docetaxel|
48124972|NCT00004243|DRUG|oxaliplatin|
48124973|NCT01183936|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
48124974|NCT01183936|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
48331872|NCT06396572|PROCEDURE|Nursing Clinical Laboratory practice|Using nursing clinical laboratory sessions to learn urinary catheterisation procedure
48331873|NCT00722709|DRUG|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
48331874|NCT00722709|DRUG|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
48492238|NCT01951885|DRUG|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
48651800|NCT04576754|DEVICE|WB001|The WB001 treatment consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools. The lessons teach PPD-specific information to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of having recently given birth. Patients complete up to 30 psychoeducational lessons. In addition, patients access and apply core CBT-based tools upon endorsing a negative mood. These tools are core to CBT and are considered transdiagnostic. Examples include thought challenging, behavioral activation, mindfulness, and self-care.
48651801|NCT04576754|DEVICE|Educational|The Comparison Condition provides educational only material about various mental and physical topics, delivered in an interactive smartphone application that is accessible anytime of day.
48651802|NCT00748527|DRUG|carboplatin|Given IV
48331875|NCT05840978|DIETARY_SUPPLEMENT|Probiotics|Oral capsules
48331876|NCT05840978|DIETARY_SUPPLEMENT|Placebo|Oral capsules
48651803|NCT00748527|DRUG|decitabine|Given IV
48651804|NCT06473714|DEVICE|tDCS|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will be made at 1,5mA
48651805|NCT06473714|DEVICE|SHAM|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will not be made. The electrodes are placed on the skull and a slight but non-continuous intensity is applied.
48651806|NCT03868280|PROCEDURE|Antegrade femoral nailing Supine Position|Antegrade femoral nailing in Supine Position using a Fracture Table
48651807|NCT03868280|PROCEDURE|Antegrade Femoral Nailing Lateral Position|Antegrade femoral nailing in Lateral Position using a Free drape
48124975|NCT05899270|OTHER|3D reconstruction automatic matching system|it is an automatic comparison software for 3D reconstruction based on CT data (3DRACS). It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size and depth of the DLT for lung isolation.
48124976|NCT05899270|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and weight and the height is used to guide the depth of DLT insertion.
48124977|NCT04146519|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
48124978|NCT04146519|OTHER|Placebo|Saline solution
48124979|NCT01193894|OTHER|Profermin|Medical Food (food for special medical purposes)
48124980|NCT01193894|OTHER|Fresubin|Medical food (food for special medical purposes)
48124981|NCT05402813|OTHER|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
48124982|NCT05402813|OTHER|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
48124983|NCT00006786|BIOLOGICAL|bevacizumab|
48124984|NCT00006786|DRUG|fluorouracil|
48124985|NCT00006786|DRUG|irinotecan hydrochloride|
48124986|NCT00006786|DRUG|leucovorin calcium|
48124987|NCT02207972|DEVICE|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
48124988|NCT02207972|PROCEDURE|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
48124989|NCT05050383|OTHER|Pharyngeal Manometry|Catheters will be passed into the nose and advanced to the pharynx to measure airway pressures during drug-induced sleep.
48124990|NCT05050383|OTHER|Submental Ultrasound|Ultrasound of airway soft tissues
48124991|NCT04029909|DRUG|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
48124992|NCT04029909|DRUG|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
48124993|NCT04029909|DRUG|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
48124994|NCT01602640|DRUG|Morphine infusion|Conventional dose
48124995|NCT01602640|DRUG|Fentanyl and Midazolam infusion|Conventional dose
48124996|NCT03705234|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
48124997|NCT03705234|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
48124998|NCT03333018|DRUG|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
48124999|NCT03333018|DRUG|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
48125000|NCT03333018|DRUG|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
48125001|NCT03296540|DRUG|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
48492239|NCT05046639|DRUG|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine.
48125002|NCT03296540|DRUG|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
48125003|NCT02678936|BIOLOGICAL|PRP|Application of platelet-rich plasma during surgery
48125004|NCT01913691|DRUG|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
48125005|NCT03582722|DRUG|Orlistat|Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
48125006|NCT03582722|DRUG|Placebo capsule|Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.
48125007|NCT03582722|DIETARY_SUPPLEMENT|Multivitamin|A multivitamin will be provided to be taken once daily, at bedtime.
48125008|NCT01643499|DRUG|oxaliplatin|Given IV
48125009|NCT01643499|DRUG|irinotecan hydrochloride|Given IV
48125010|NCT01643499|DRUG|leucovorin calcium|Given IV
48125011|NCT01643499|DRUG|fluorouracil|Given IV
48125012|NCT01643499|OTHER|laboratory biomarker analysis|Correlative studies
48125013|NCT05900921|DRUG|Trilaciclib|IV infusion, d1
48125014|NCT05900921|DRUG|Carboplatin|IV infusion, d1
48125015|NCT05900921|DRUG|Paclitaxel|IV infusion, d1
48125016|NCT05900921|DRUG|Tislelizumab|IV infusion, d1
48125017|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 23 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 23 cm.
48125018|NCT05205798|BEHAVIORAL|Washout period|No interventional food consumption for 1 week
48125019|NCT05205798|BEHAVIORAL|Food consumption using plates with a diameter of 31 cm.|In the experiment, individuals will consume the amount of pasta with sauce offered in the open buffet in the amount they will determine (ad libitum), using plates with a diameter of 31 cm.
48125020|NCT05555719|DEVICE|Mandibular Protraction Appliance|Mandibular Protraction Appliance was installed on fixed orthodontic appliance
48492240|NCT05046639|DRUG|10 mL preservative free saline|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.
48651808|NCT05607589|DRUG|DWP213388|immunosuppressant
48651809|NCT05607589|OTHER|Placebo|Placebo
48651810|NCT03469609|OTHER|mucous fistula refeeding|Transfer of infants' own stool
48331877|NCT00352313|DRUG|ATN-161|Given IV
48331878|NCT00352313|DRUG|carboplatin|Given IV
48331879|NCT00003157|DRUG|cisplatin|
48331880|NCT00003157|DRUG|gemcitabine hydrochloride|
48331881|NCT00003157|RADIATION|radiation therapy|
48331882|NCT00436202|BEHAVIORAL|Iron supplement|
48331883|NCT03945903|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
48492241|NCT04216758|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48492242|NCT04216758|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
47974779|NCT03183076|OTHER|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
47974780|NCT03183076|DRUG|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
47974781|NCT04758780|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
47974782|NCT00000938|DRUG|ceftriaxone|
47974783|NCT00000938|DRUG|doxycycline|
48331884|NCT05974007|DRUG|Neoadjuvant immunochemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
48331885|NCT05974007|DRUG|Neoadjuvant chemotherapy|Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
48492243|NCT04216758|DRUG|tegafur|Patients secondly receive tegafur Body surface area \< 1.25 m\^2, 60 mg/d;Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d;Body surface area ≥ 1.5 m\^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48492244|NCT01064323|DEVICE|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
48492245|NCT02280226|DEVICE|magnetic resonance imaging (MRI)|
48492246|NCT04968860|OTHER|This study is observational|"* Clinical evaluation of the oral health condition~* Microbiota evaluation by analyzing the collected saliva~* Application of questionnaires of quality of life"
48651811|NCT06413069|DIETARY_SUPPLEMENT|Raw whole almonds|Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks. Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
47974784|NCT01929434|OTHER|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
47974785|NCT01929434|BIOLOGICAL|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
47974786|NCT02305056|DRUG|C13 N15 Valine|C13 N15 Valine administration
48331886|NCT03297333|OTHER|Resistance training|The resistance training group
48331887|NCT03297333|OTHER|Aerobic interval training|The aerobic interval training group
48492247|NCT05579574|DRUG|BMS-986322|Specified dose on specified days
48492248|NCT05579574|DRUG|Loestrin|Specified dose on specified days
48492249|NCT00531141|OTHER|examination only|OCT performed twice
48651812|NCT06675188|DRUG|PF-07275315|PF-07275315 solution for injection (single use only)
48651813|NCT06675188|OTHER|Placebo|Placebo solution for injection (single use only)
48651814|NCT03968042|DRUG|Nerve Growth Factor|Intramuscular injection for 2 weeks
48331888|NCT02621619|DRUG|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
48331889|NCT02621619|DRUG|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
48331890|NCT05135351|DIETARY_SUPPLEMENT|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
48331891|NCT05135351|DIETARY_SUPPLEMENT|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
48651815|NCT03968042|DRUG|Edaravone|Intravenous injection for 2 weeks
48651816|NCT03968042|DRUG|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
48651817|NCT03832985|GENETIC|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
48651818|NCT03832985|GENETIC|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
48125021|NCT05555719|DEVICE|PowerScope Appliance|PowerScope Appliance was installed on fixed orthodontic appliance
48125022|NCT05517616|DRUG|[14C ]APG-2575|orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575
48651819|NCT03832985|GENETIC|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
48125024|NCT04032353|OTHER|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
48125025|NCT03561519|OTHER|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
48125026|NCT03561519|OTHER|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
48125027|NCT00975585|DEVICE|senofilcon A|soft contact lens, 2-week replacement indicated
48125028|NCT00975585|DEVICE|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
48331892|NCT03779633|DRUG|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
48331893|NCT03779633|OTHER|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
48331894|NCT05480254|OTHER|clamped catheter|Q3 clamped catheter protocol is applied before urinary catheter removal
48331895|NCT01760759|BEHAVIORAL|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
48331896|NCT01760759|BEHAVIORAL|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
47974787|NCT02270957|BIOLOGICAL|Abatacept|
48331897|NCT05677295|DRUG|duloxetine|Duloxetine 30 mg per day
48331898|NCT05677295|DRUG|Imipramine|Imipramine 25 mg per day
48651820|NCT02126891|PROCEDURE|Tests|Individual parameters of echocardiography and heart rate variability
48331899|NCT01646398|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
48331900|NCT01646398|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
48651821|NCT03918291|OTHER|Addition of whole-body vibration to squat training|
48651822|NCT03918291|OTHER|Squat training|squatting exercises for 12 weeks, 3x/week
48651823|NCT05643430|DEVICE|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
48651824|NCT06238401|DRUG|ACR246 for injection|80 mg/vial
47974788|NCT02270957|OTHER|Placebo|
47974789|NCT05526430|DRUG|Harmine Hydrochloride Capsules|capsules taken orally
47974790|NCT01266512|DRUG|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
47974791|NCT01266512|RADIATION|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
47974792|NCT01266512|DRUG|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
47974793|NCT00208091|DRUG|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
48125029|NCT04613700|DRUG|Secretin|Native hormone
48125030|NCT04613700|OTHER|Placebo|Saline
48125031|NCT00371670|DRUG|balicatib (AAE581)|
48331901|NCT04948814|BIOLOGICAL|Fecal microbiota transplantation|FMT utilizing stool from healthy children
48331902|NCT04948814|DRUG|Vancomycin|40mg/kg/day
48331903|NCT04656288|DRUG|BI 764198 - Formula A|BI 764198
48125032|NCT04498624|PROCEDURE|inverted flap|full thickness macular hole surgery
48125033|NCT04498624|PROCEDURE|peeling internal limiting membrane (ILM)|full thickness macular hole surgery
48125034|NCT02075736|PROCEDURE|KTP laser|
48125035|NCT02075736|PROCEDURE|TUR-P|device
48125036|NCT04802382|DRUG|Placebo administration|patients will receive the placebo treatment in addition to Standard of Care
48125037|NCT04802382|DIAGNOSTIC_TEST|Confirm SARS-CoV-2 infection|patients will be tested for SARS-CoV-2 on days 1, 14 and 28
48125038|NCT04802382|PROCEDURE|Physical Examination|patients will undergo a physical examination on days 1-14 and day 28
48125039|NCT04802382|PROCEDURE|Vital Signs|patient's vital signs will be measured on days 1-14 and day 28
48125040|NCT04802382|DIAGNOSTIC_TEST|Hematology blood test|patients will provide a blood sample for a hematology blood test on days 1-14 and day 28
48125041|NCT04802382|DIAGNOSTIC_TEST|Biochemistry blood test|patients will provide a blood sample for a biochemistry blood test on days 1-14 and day 28
48125042|NCT04802382|OTHER|NEWS score|patient's NEWS score will be evaluated on days 1-14 and day 28
48125043|NCT04802382|DIAGNOSTIC_TEST|PK test|PK test will be performed on day 1 only (only in Brazil sites)
48125044|NCT04802382|DIAGNOSTIC_TEST|blood test for inflammatory markers|patients will provide a blood sample for an inflammatory markers blood test (IL-6, IL-1β, IL-12, TNF α, IFN-γ) on days 1-7, day 14, and day 28
48331904|NCT04656288|DRUG|BI 764198 - Formula B|BI 764198
48331905|NCT04656288|DRUG|BI 764198 - Formula C|BI 764198
48331906|NCT04656288|DRUG|BI 764198 - Formula D|BI 764198
48331907|NCT04871581|DEVICE|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
48331908|NCT04871581|DEVICE|Placebo|Similar to Device, but having no influence on clenching intensity
48331909|NCT03673696|DRUG|HEC74647PA Capsule|Capsule administered orally once daily
48331910|NCT03673696|DRUG|placebo|Matching Placebo Capsule
48331911|NCT04249167|DRUG|Atezolizumab|Given IV
48331912|NCT04249167|PROCEDURE|Cryosurgery|Undergo cryoablation of the primary tumor
48331913|NCT04249167|DRUG|Nab-paclitaxel|Given IV
48331914|NCT03701204|BEHAVIORAL|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~1. App on their smartphone~2. Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~3. Next Step debit card to receive financial incentives~4. Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~5. Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~6. The amount of coins and funds are available on a progressive variable reward schedule."
48331915|NCT02769078|DRUG|dabigatran|
48492250|NCT06181799|DIAGNOSTIC_TEST|Mass spectrometry using the PTR TOF-1000 (IONICON PTR-TOF-MS - Trace VOC Analyzer, Eduard-Bodem-Gasse 3, 6020 Innsbruck, Austria (Europe).|"Once enrolled in the study, all participants are scheduled to undergo the following tests:~The analysis of volatile organic compounds obtained from exhaled air will be carried out by a combination of real-time analytical methods, the use of a real-time mass spectrometer with ionization by the proton transfer method. Machine learning models will be employed to analyze the patterns identified in the exhaled air volatilome data.~Before and immediately after the exercise test, all patients are scheduled to record a single-lead ECG and pulse wave, using a portable single-lead recorder (Cardio-Qvark) (Russia, Moscow). Single lead-ECG and pulse wave parameters will be interpreted using machine learning models."
48492251|NCT02800213|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
48492252|NCT02800213|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
48492253|NCT02453906|OTHER|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
48492254|NCT02453906|OTHER|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
48492255|NCT02453906|OTHER|Control 2|stimulation at 5 control points
47974794|NCT04740788|DEVICE|Monofocal IOL|Patients are already implanted with a monofocal lens
47974795|NCT05743946|DRUG|Trikafta|Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
48331916|NCT02769078|DRUG|rivaroxaban|
48331917|NCT02769078|DRUG|apixaban|
48331918|NCT02769078|DRUG|warfarin|
48331919|NCT03841487|DEVICE|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
48331920|NCT03475901|OTHER|Virtual Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
48331921|NCT01560611|DEVICE|Near infrared spectroscopy|
48331922|NCT04045626|PROCEDURE|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
48331923|NCT05200884|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale
48331924|NCT05200884|DRUG|Articaine 4%|The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
48492256|NCT02453906|OTHER|Control 3|no stimulation at 5 control points
48492257|NCT03971266|DEVICE|Activity Monitor|Wear a Fitbit
48492258|NCT03971266|OTHER|Media Intervention|Complete smartphone based PRO diary
48331925|NCT05628155|OTHER|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
48651825|NCT06643819|DRUG|sacubitril/valsatran(dose maintenance)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
48125045|NCT04802382|DIAGNOSTIC_TEST|D-dimer test|patients will provide a blood sample for D-dimer blood test on days 1, day 2, day 7, day 14, and day 28
48125046|NCT04802382|OTHER|VAS scale|patient's VAS scale will be evaluated on days 1-14, day 21, and day 28
48492259|NCT05406063|RADIATION|SBRT|Stereotactic multiple fraction radiotherapy
48492260|NCT03074747|DIAGNOSTIC_TEST|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
48125047|NCT04802382|DIAGNOSTIC_TEST|Urine pregnancy test for women of childbearing potential|patients will provide a urine sample for a urine pregnancy test on days 1, and day 28
48125048|NCT04802382|PROCEDURE|ECG|patients will undergo an ECG examination on days 1, and day 28
48125049|NCT04802382|OTHER|COVID-19-Impact on Quality of Life Questionnaire|patients will answer the COVID-19-Impact on Quality of Life Questionnaire on days 1, 7,14,21 and 28
48125050|NCT04802382|DRUG|CimetrA-1|patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
48125051|NCT04802382|DRUG|CimetrA-2|patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
48331926|NCT05660213|DRUG|Huaier granule|Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
48492261|NCT00399971|PROCEDURE|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
48492262|NCT00399971|DRUG|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
48492263|NCT03052322|DRUG|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
48492264|NCT03052322|DRUG|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
48492265|NCT02083237|BEHAVIORAL|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
48492266|NCT01727986|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
48492267|NCT00402454|DRUG|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
48651826|NCT06643819|DRUG|sacubitril/valsartan(dose increasing)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
48651827|NCT06643819|DRUG|Valsartan|During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
48125052|NCT00681213|DRUG|Tacrolimus/Sirolimus|
48125053|NCT00681213|DRUG|Tacrolimus/MMF|
48492268|NCT05154032|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
48125054|NCT00681213|DRUG|Neoral/Sirolimus|
48125055|NCT04919057|DEVICE|GelPOINT®|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
48125056|NCT04718909|DRUG|Regorafenib + sintilimab|"Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w."
48125057|NCT04718909|DRUG|Regorafenib|160 mg p.o. qd for 3 weeks of every 4 week cycle.
48125058|NCT00227994|DRUG|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
48125059|NCT00227994|DRUG|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
48331927|NCT05660213|DRUG|Atezolizumab + Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
48125060|NCT02779634|DRUG|ubiquinol|Ubiquinol three times daily
48492269|NCT03533257|DRUG|AMX0035|Combination Therapy of TUDCA and Sodium Phenylbutyrate
48492270|NCT03533257|DRUG|Placebo|Placebo
48125061|NCT02779634|DRUG|Placebo|Sugar pill three times daily
48125062|NCT01203306|DRUG|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
48125063|NCT05576857|OTHER|Doppler ultrasonography|All volunteers will be monitored with cerebral oximeter, asked to answer the Montreal cognitive assessment test and cervical blood flow values and optic nerve sheath diameter will be determined with Doppler ultrasonography.
48492271|NCT00774696|DRUG|clarithromycin 500mg tablets|
48331928|NCT05660213|DRUG|Camrelizumab+Apatinib|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
48651828|NCT00202241|PROCEDURE|testosterone injection|
48125064|NCT01421407|DEVICE|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
48125065|NCT03375892|OTHER|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
48125066|NCT03375892|OTHER|Free breathing during radiation|The patient will be instructed to breathe freely.
48125067|NCT03096236|DEVICE|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
48331929|NCT05660213|DRUG|Sintilimab+Bevacizumab|Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
48331930|NCT00400439|DRUG|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
48331931|NCT00400439|DRUG|placebo|po daily for 24 weeks
48331932|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
48331933|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
48331934|NCT03201367|DRUG|Rivaroxaban|Rivaroxaban 10 mg/12 hour
48331935|NCT03201367|OTHER|symptomatic therapy for ascites, abdominal pain|
48492272|NCT06011616|OTHER|Sensory training|sensory training includes superficial sensory and deep sensory activities i.e. play with dough, painting with finger, recognizing objects with blocked vision, recognizing the drawn figure on palm, oint compression, bearing the weight on the paretic hand, leaning on the paretic side, walking with hand, rolling the heavy objects, dough squeezing etc.
48492273|NCT06011616|OTHER|Motor training|Motor training would involve activitoes such as throwing and catching a ball, targeted ball throwing, hand in hand ball transferring, ball rolling, hitting a ball to ground and wall, hand roller etc.
48492274|NCT06011616|OTHER|Conventional exercises|stretching exercises, muscle strengthening exercises, static weight bearing exercises, positioning
48492275|NCT03596931|DRUG|Statins (Cardiovascular Agents)|Prescribed with statins
48492276|NCT05542979|DRUG|HH-003 injection|HH-003 injection is administrated via I.V. infusion
48492277|NCT05542979|DRUG|Placebo|Placebo is administrated via I.V. infusion
48492278|NCT05012865|DRUG|avelumab|as provided in real world practice
48651829|NCT06641310|PROCEDURE|Endurance Exercise Therapy|"* Exercise: Endurance exercise therapy comprising treadmill walking administered by exercise physiologists via a study-kit which includes a smart-watch (activity tracker), heart rate monitor, blood pressure cuff, body composition scale, and etablet)~* Exercise escalation trial testing 3 exercise levels (150, 225, and 300 minutes per week), with one de-escalation exercise of 90 minutes per week, if required.~* The phase 1b trial will evaluate the highest feasible exercise level and one exercise below identified in the phase 1a study."
48651830|NCT03193138|DRUG|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
48651831|NCT05486065|DRUG|Semaglutide|Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
48331936|NCT03032510|DRUG|Eravacycline|
48651832|NCT05486065|DRUG|Placebo|Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.
48651833|NCT04342546|DEVICE|NovaGray RILA Breast® test|The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
48492279|NCT05012865|DRUG|axitinib|as provided in real world practice
48492280|NCT04969159|OTHER|no intervention|standard treatment in the clinical routine
48492281|NCT06354855|OTHER|Group is doing breathing exercises while watching videos|Group is doing breathing exercises while watching videos: A video consisting of 30-minute exercises will be shot for these patients. And each patient will be asked to do the breathing exercise for 30 minutes by watching this video.
48492282|NCT06354855|OTHER|Medium pace walking group|Medium pace walking group: 30 minutes daily. Walking at a moderate pace is required. Physical activity levels will be monitored with the ActiGraph GT3X+ Accelerometer.
48492283|NCT02756026|DIETARY_SUPPLEMENT|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
48492284|NCT00376194|DRUG|DMSA|
48492285|NCT05767606|BIOLOGICAL|NVX|Administration of NVX
48492286|NCT05767606|BIOLOGICAL|PCV20|Administration of PCV20
48492287|NCT05767606|BIOLOGICAL|Placebo|No intervention
48125068|NCT03097679|DEVICE|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
48125069|NCT03097679|DEVICE|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
48125070|NCT02355275|PROCEDURE|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
48125071|NCT00533910|DRUG|Rifaximin|550mg BID rifaximin for 8 weeks
48331937|NCT03032510|DRUG|Ertapenem|
48331938|NCT03032510|DRUG|Placebo|
48331939|NCT03032510|DRUG|Levofloxacin|
48331940|NCT06100549|OTHER|No intervention|No intervention will be provided.
48331941|NCT06527209|OTHER|Coffee and agave inulin-based beverage (A)|"Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g"
48331942|NCT06527209|OTHER|Control beverage (B)|"Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g."
48331943|NCT01984736|DRUG|Experimental: EVP-6124|
48125072|NCT00533910|DRUG|placebo|same as the experimental arm
48125073|NCT02869334|DEVICE|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
48125074|NCT02869334|DEVICE|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
48331944|NCT03705312|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
48331945|NCT03705312|OTHER|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
48331946|NCT05431569|DRUG|6MW3211|6MW3211 injection ,30mg/kg,iv drip，Q2W
48331947|NCT00303615|DRUG|Fluoxymesterone 10 mg|
48331948|NCT00303615|DRUG|Anastrozole 1 mg|
48331949|NCT03748342|DEVICE|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
48651834|NCT04427111|DEVICE|Non-titratable-customized mandibular advancement device|The most comfortable protruded mandibular position situated between 60-75% of MMPV was determined according to patient response with 6mm of the vertical interocclusal dimension between maxillary and mandibular central incisors and registered. The upper and lower acrylic resin splints were secured to each other in the posterior region with auto polymerizing acrylic resin and NTC-MADs were obtained. The patients were instructed to wear their non-titratable-customized mandibular advancement device every night.
48651835|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
48651836|NCT00656643|DRUG|Placebo|Two subconjunctival injections of placebo.
48651837|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
48331950|NCT00650182|DRUG|fentanyl; naltrexone|
48331951|NCT04578119|PROCEDURE|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
48331952|NCT01273987|PROCEDURE|rONB|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
48331953|NCT04676542|OTHER|Exercise|One hour of a beginning martial art class ,and a one hour walk at 4.0 mph pace.
48331954|NCT01098825|OTHER|web-based survey|Anonymous web-based survey
48331955|NCT01267604|DRUG|Recombinant FSH (rFSH)|225IU
48331956|NCT01267604|DIETARY_SUPPLEMENT|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
48331957|NCT05778019|OTHER|Case Scenarios of complications to be ranked / classified according to classifications (for the severity grading of events)|Test the feasibility, applicability and logic of a novel instrument for the grading of unexpected events in pediatric surgery (Clavien-Madadi classification) compared to the Clavien-Dindo classification for the grading of postoperative complications in general surgery
48331958|NCT00930709|DRUG|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
48331959|NCT00930709|BEHAVIORAL|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
48331960|NCT04712799|DRUG|Otrivin|oxymetazoline nasal spray
48651838|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
48651839|NCT05507437|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Recombinant human CD39 enzyme
48125075|NCT02869334|BEHAVIORAL|Auditory Remediation|Computer program designed to improve discrimination between sounds
48125076|NCT02869334|BEHAVIORAL|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
48125077|NCT02634892|DEVICE|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
48331961|NCT03957356|DEVICE|HLBLS-200|The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
48651840|NCT05507437|OTHER|Placebo|0.9% sterile sodium chloride solution
48651841|NCT03795519|DRUG|[14C]-olinciguat|oral capsule
48125078|NCT04019444|BIOLOGICAL|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
48125079|NCT04019444|OTHER|Placebo|0.9% Sodium Chloride, USP injection.
48125080|NCT04019444|BIOLOGICAL|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
48331962|NCT04217083|DIAGNOSTIC_TEST|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
48331963|NCT03384628|DEVICE|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
48331964|NCT03384628|DEVICE|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
48651842|NCT03579316|DRUG|Adavosertib|Given PO
48651843|NCT03579316|DRUG|Olaparib|Given PO
48651844|NCT03579316|DRUG|Ceralasertib|Given PO
48125081|NCT01981031|DRUG|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
48125082|NCT01981031|DRUG|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
48125083|NCT00997490|DRUG|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
48125084|NCT00997490|DRUG|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
48125085|NCT00226889|DRUG|bosentan|
48125086|NCT01203995|BEHAVIORAL|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
48125087|NCT01203995|BEHAVIORAL|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
48125088|NCT00998881|DRUG|Teneligliptin 20 mg|
48125089|NCT00998881|DRUG|Placebo|
48125090|NCT01327664|BIOLOGICAL|AIN457|
48125091|NCT00339131|DRUG|Ultratrace iobenguane I 131|
48125092|NCT04766034|BEHAVIORAL|Simulated Grocery Shopping Exercise|Participants will click a link and simulate a shopping experience by selecting a week's worth of Supplemental Nutrition Assistance Program (SNAP)-eligible groceries for their household in a web-based supermarket platform
48125093|NCT01696916|PROCEDURE|6-minute walking test|submaximum exercise test
48125094|NCT03716336|OTHER|Resistance exercise|Resistance exercise were performed for all participants in group (A) only included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
48125095|NCT03716336|OTHER|Aerobic exercise|aerobic exercise were performed on treadmill. For 20 minutes. All patients in both groups (A,B) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
48125096|NCT03716336|DIETARY_SUPPLEMENT|diet restriction|All participants in both groups (A,B) were instructed to follow a moderate restricted diet limited to (1800-2000) kcal/ day under supervision of a certified dietician. The diet contained: Protein and fibers: 20% carbohydrate: 50-60%, fat: low 20%.
48331965|NCT03384628|DEVICE|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
48125097|NCT00079846|DRUG|Implitapide|
48125098|NCT02300675|BEHAVIORAL|therapeutic education program|
48125099|NCT01576029|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
48125100|NCT01576029|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
48125101|NCT06005857|OTHER|Standard hand therapy + home digital application-based exercises|Standard post-operative hand rehabilitation and home digital application-based exercises
48125102|NCT06005857|OTHER|standard hand therapy + home paper-based exercises|Standard post-operative hand rehabilitation and home paper-based exercises
48125103|NCT05134324|OTHER|active rTMS|Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
48125104|NCT05134324|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
48125105|NCT05134324|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
48125106|NCT05134324|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
48125107|NCT04797923|DRUG|1. Treatment: IP chemotherapy + Systemic chemotherapy|1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
48125108|NCT04797923|PROCEDURE|2. Response evaluation after 4 cycles of IP + systemic chemotherapy|"2. Response evaluation after 4 cycles of IP + systemic chemotherapy~* Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~* If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~* IP chemotherapy should not exceed total of 8 cycles."
48125109|NCT05443464|BIOLOGICAL|OSSM-001|Direct IV infusion of OSSM-001
48125110|NCT01858831|DRUG|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
48492288|NCT04993300|DEVICE|transcranial magnetic stimulation (TMS)|The methamphetamine user will undergo a one-month TMS intervention. In Week 1, subjects will attend continuously 5 daily TMS sessions. From Week 2 to Week 4, subjects are treated once a week. Each session will have 40 repeats of 4-second train and 15-sec train interval.
48492289|NCT04629859|PROCEDURE|mandibular setback and maxillary advancement|12 patients will undergo mandibular setback and maxillary advancement
48125111|NCT01858831|DRUG|Atovaquone|Atovaquone
48125112|NCT03035994|OTHER|Real-Time Biofeedback|A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
48125113|NCT04659018|BIOLOGICAL|blood collection|A 5ml blood sample will be taken in a dry tube when the venous line necessary for the general anaesthesia for the colonoscopy is placed.
48125114|NCT05952258|DEVICE|Magnetic stimulation|The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
48125115|NCT05952258|DEVICE|Sham Magnetic stimulation|The sham arm will receive up to 5% intensity at each treatment session
48331966|NCT05439018|OTHER|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
48125116|NCT04556981|BIOLOGICAL|M72/AS01E Mycobacterium tuberculosis vaccine|Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
48125117|NCT04556981|BIOLOGICAL|Placebo|Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
48331967|NCT05439018|OTHER|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
48331968|NCT04801394|PROCEDURE|hernioplastic and insertion of FLaPp® composite mesh|"After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a neo-peritoneum; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space."
48651845|NCT03885206|OTHER|Level of healthcare services|Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
48651846|NCT05095285|OTHER|Swaddling|"* Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~* Common procedure steps:~  * Legal representatives of the infants will sign an informed consent form.~ * İncubator cover and nesting~ * Endotracheal suction(ES) was performed in the supine position.~ * ES was done at the time of care the baby needed.~ * No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~ * Aspiration was performed sterile at 80 mmHg pressure.~ * A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~ * The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~ * Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
48125118|NCT02178241|DRUG|Eribulin Mesylate|Given IV
48125119|NCT02178241|DRUG|Gemcitabine Hydrochloride|Given IV
48125120|NCT06396598|OTHER|Educational Activity|Review education materials
48125121|NCT06396598|OTHER|Electronic Health Record Review|Ancillary studies
48125122|NCT06396598|OTHER|Internet-Based Intervention|Participate use the electronic symptom monitoring program to log symptoms
48125123|NCT06396598|OTHER|Media Intervention|Watch a video
48125124|NCT06396598|OTHER|Survey Administration|Ancillary studies
48125125|NCT05310916|DRUG|Dapagliflozin 10mg Tab plus another oral hypoglycemic agent|Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
48125126|NCT05310916|DRUG|Two oral hypoglycemic agents other than dapagliflozin|Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
48125127|NCT04620421|OTHER|Rhythm-based Multitask Training|Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
48125128|NCT02551536|DRUG|Montelukast|
48125129|NCT02551536|DRUG|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
48331969|NCT04776564|OTHER|Participation in the couple enhancement program|Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
48651847|NCT05095285|OTHER|Oropharyngeal colostrum|"* Common procedure steps~* In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
48651848|NCT00896844|BEHAVIORAL|emotional disclosure|writing about emotional events from the past
48651849|NCT00896844|BEHAVIORAL|placebo writing|writing about how they spent their time the previous day
48651850|NCT04031677|PROCEDURE|Surgery|Large en-bloc curative-intent surgery
48331970|NCT03005041|OTHER|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
48331971|NCT03005041|OTHER|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
48125130|NCT02551536|DRUG|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
48125131|NCT05741645|OTHER|Kinesiotaping|During the kinesio taping of the erector spina vs multifidus muscles, the patient is in a standing position. Kinesiotape is applied with 50% tension and stays in the patient for 30 minutes.
48125132|NCT05741645|OTHER|Sham Kinesiotaping|The elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
48331972|NCT01932658|BIOLOGICAL|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
48331973|NCT01300364|DRUG|Reboxetine|8mg/day.
48331974|NCT01300364|DRUG|citalopram (SSRI)|30mg/day
48331975|NCT01699295|BEHAVIORAL|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
48331976|NCT01699295|BEHAVIORAL|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
48331977|NCT01572818|PROCEDURE|phlebotomy|7 ml/kg without exceeding 500 mL
48331978|NCT01572818|BEHAVIORAL|dietary and lifestyle counseling|dietary and lifestyle counseling
48331979|NCT03149926|OTHER|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
48331980|NCT00450164|PROCEDURE|esofagic varices ligation|
48125133|NCT01828554|DRUG|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
48125134|NCT04578496|DRUG|Afamelanotide|
48125135|NCT03189472|DEVICE|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
48331981|NCT00450164|DRUG|Nadolol|
48331982|NCT00450164|DRUG|Isosorbide mononitrate|
48331983|NCT00450164|DRUG|Prazosin|
48331984|NCT04075539|OTHER|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~* 1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~* a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~* 3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
48331985|NCT04075539|OTHER|usual care|A prescription of 6 sessions of outpatient physiotherapy
48331986|NCT03210220|PROCEDURE|Pecs II block|After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
48331987|NCT03411707|DIAGNOSTIC_TEST|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
48331988|NCT03185416|OTHER|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
48331989|NCT04318379|BIOLOGICAL|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
48331990|NCT02819349|BEHAVIORAL|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
48331991|NCT05521464|OTHER|cast|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
48492290|NCT04629859|PROCEDURE|mandibular setback|12 patients will undergo mandibular setback
48125136|NCT03189472|DEVICE|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
48492291|NCT06455436|DEVICE|Standard healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive a standard healing abutment
48125137|NCT05367336|DRUG|Morphine|second group will be receiving morphine
48125138|NCT05367336|DRUG|Fentanyl|third group receiving fentanyl
48125139|NCT03810859|BIOLOGICAL|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
48125140|NCT01043601|DRUG|Inhaled PT005|inhaled, twice daily for 1 week duration
48125141|NCT01043601|DRUG|Inhaled Placebo|inhaled, twice daily for 1 week duration
48331992|NCT05521464|OTHER|Robert Jones Bandage|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
48331993|NCT03056807|OTHER|25° head-up position|Angle person is positioned for procedure.
48331994|NCT03056807|OTHER|55° head-up position|Angle person is positioned for procedure.
48331995|NCT06041685|PROCEDURE|local warming|local warming on the site for arterial catheterization using forced air warmer
48331996|NCT05069805|PROCEDURE|PECS II block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to PECS II block
48331997|NCT05069805|PROCEDURE|ESP block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to ESP block
48331998|NCT02436733|PROCEDURE|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
48331999|NCT02436733|DRUG|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
48332000|NCT05572346|OTHER|Home-based telerehabilitation program delivered through digital devices|To evaluate the effects of digital home-based telerehabilitation program on functional and spirometric measures as well as on quality of life in patients with chronic respiratory disease
48332001|NCT03831815|DRUG|Cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
48332002|NCT05057741|BEHAVIORAL|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
48332003|NCT05274828|DEVICE|H7-Coil Deep TMS for CUD|The Study group will receive dTMS treatment three times a day for ten days.
48332004|NCT01357980|BIOLOGICAL|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
48332005|NCT01357980|DRUG|Placebo|Intra detrusor injection on Day 1 (single dose)
48332006|NCT06057636|BEHAVIORAL|Self-Administered Hypnosis|Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.
48492292|NCT06455436|DEVICE|Individualized healing abutment|Participants will undergo a surgery to place an immediate klockner dental implant and will be receive an individualized healing abutment
48492293|NCT05335291|OTHER|Questionnaire study|The Turkish validity and reliability of the questionnaire will be examined.
48125142|NCT01043601|DRUG|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
48125143|NCT03942445|PROCEDURE|Gastrocnemius muscle biopsy|In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
48125144|NCT05043805|DRUG|Dextromethorphan|add on therapy
48125145|NCT05043805|OTHER|placebo|add on therapy
48125146|NCT00002287|DRUG|Zidovudine|
48125147|NCT02755415|DEVICE|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
48125148|NCT02755415|OTHER|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
48125149|NCT02076659|DRUG|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
48125150|NCT02076659|DRUG|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
48125151|NCT00067496|DRUG|Modafinil|
48125152|NCT05758012|DRUG|oxytocin|Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
48125153|NCT05758012|DRUG|Carbetocin|Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
48125154|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 10 µg)
48125155|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 10 µg|Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)
48125156|NCT04602975|BIOLOGICAL|Injection Adjuvanted Placebo|Intramuscular injection of Placebo with alhydrogel
48125157|NCT04602975|BIOLOGICAL|Injection Placebo|Intramuscular injection of the not adjuvanted Placebo
48125158|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg Adjuvanted|Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
48125159|NCT04602975|BIOLOGICAL|Injection SF2A-TT15 2 µg|Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
48125160|NCT02232295|DEVICE|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
48125161|NCT02232295|DEVICE|Mirror Box|A resource used for many pain and disability states of the hands and feet.
48125162|NCT05237453|RADIATION|Photons|MR-guided adaptive radiotherapy
48125163|NCT05207241|OTHER|provides guidance on gravitationally assisted breastfeeding|Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
48125164|NCT04781790|OTHER|Bone Marrow Failure|without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
48125165|NCT01078285|BEHAVIORAL|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
48125166|NCT01078285|BEHAVIORAL|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
48125167|NCT03217240|PROCEDURE|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
48125168|NCT03217240|OTHER|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
48125169|NCT03217240|OTHER|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
48125170|NCT06434441|PROCEDURE|Autogenous bone augmentation|Maxillary alveolar bone reconstruction
48332007|NCT06057636|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
48125171|NCT02215707|BIOLOGICAL|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
48125172|NCT01472900|DEVICE|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
48125173|NCT01472900|DRUG|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
48125174|NCT02035605|DRUG|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
48125175|NCT02035605|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
48125176|NCT04185961|DEVICE|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
48125177|NCT04185961|DEVICE|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
48125178|NCT01168544|DIETARY_SUPPLEMENT|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
48125179|NCT01168544|DIETARY_SUPPLEMENT|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
48125180|NCT01168544|DIETARY_SUPPLEMENT|Vitamin D 800 IU /day|800 IU vit D3/day
48125181|NCT02891915|DRUG|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
48332008|NCT04595357|PROCEDURE|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
48125182|NCT02891915|DRUG|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
48492294|NCT01335997|DRUG|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
48651851|NCT04031677|DRUG|Preoperative chemotherapy|"* High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same."
48125183|NCT02891915|DRUG|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
48125184|NCT02891915|OTHER|Placebo|Placebo
48125185|NCT01854151|OTHER|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
48492295|NCT01335997|DRUG|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
48492296|NCT01335997|DRUG|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
48492297|NCT01335997|DRUG|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
48492298|NCT01335997|DRUG|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
48492299|NCT03474250|DIAGNOSTIC_TEST|Magnetic Resonance test for kidney|Magnetic Resonance test for kidney
48125186|NCT01086813|DRUG|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
48125187|NCT01813773|DRUG|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
48125188|NCT06224517|OTHER|Rehabilitation|The intervention includes daily physical and occupational therapy sessions tailored to each patient's functional status. In this study, stroke patients will undergo a four-week rehabilitation therapy program comprising 60-minute daily sessions of physical and occupational therapy. The physical therapy includes balance training, mobility and strengthening exercises, while occupational therapy covers sensorimotor and fine motor training, and ADL activities.
48332009|NCT03292393|BEHAVIORAL|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
48332010|NCT03292393|BEHAVIORAL|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
48332011|NCT03292393|DEVICE|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
48332012|NCT03292393|DEVICE|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
48332013|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
48332014|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
48332015|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
48332016|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
48332017|NCT01584258|PROCEDURE|Prostatectomy|Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.
48332018|NCT01584258|RADIATION|Conventionally Fractionated Prostate Radiotherapy|"Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions"
48332019|NCT01584258|RADIATION|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
48492300|NCT01805830|DRUG|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
47974796|NCT02781493|DRUG|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
48492301|NCT01805830|DRUG|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
48492302|NCT01699386|OTHER|Control Study Formula|feed as lib
47974797|NCT02781493|DRUG|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
48125189|NCT02797444|OTHER|semi-structured interviews|
48332020|NCT01225120|OTHER|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
48332021|NCT06530238|PROCEDURE|Russian Currents|Currents are delivered in rectangular bursts. The electrode placement will be at the Tibialis Posterior muscle. Treatment will be given for 10 minutes, 30 minutes during the 3 consecutive days / 4 weeks.
48492303|NCT01699386|OTHER|Experimental Study Formula|feed as lib
48492304|NCT06356363|OTHER|Data collection|data collection
48492305|NCT04874675|DRUG|diclofenac / acetaminophen /codeine|routine pain medication used post extraction of third molars
48492306|NCT04874675|DRUG|ibuprofen/acetaminophen/codeine|routine pain medication used post extraction of third molars
48492307|NCT01984203|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
48492308|NCT01984203|OTHER|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
48492309|NCT01222286|DRUG|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
48492310|NCT00261963|DEVICE|ultraviolet light|
48492311|NCT00236067|DRUG|Gabitril|
48492312|NCT01668693|OTHER|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
48492313|NCT01668693|OTHER|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
48492314|NCT01668693|OTHER|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
48492315|NCT01661179|DRUG|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
48492316|NCT02039466|PROCEDURE|volume controlled ventilation|
48492317|NCT02039466|PROCEDURE|pressure controlled ventilation|
48492318|NCT05384717|OTHER|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
48492319|NCT05384717|OTHER|Control group|No intervention
48492320|NCT00557076|BEHAVIORAL|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
48492321|NCT00557076|BEHAVIORAL|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
48492322|NCT01055132|DEVICE|Etafilcon A toric contact lens|contact lens to correct astigmatism
48492323|NCT01055132|DEVICE|Nelfilcon A toric contact lens|contact lens to correct astigmatism
48492324|NCT00712985|DRUG|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
48492325|NCT03626506|DRUG|Spironolactone|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
48492326|NCT03626506|DRUG|Indapamide|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
48492327|NCT03626506|DRUG|Amlodipine|After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
48492328|NCT01763749|DRUG|Closone|Closone 75mg/100mg, 4weeks, PO
48492329|NCT01763749|DRUG|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
48492330|NCT03061682|DEVICE|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
48492331|NCT01969448|PROCEDURE|Inframammary Fold Incision or Lateral Radial Incision|
48492332|NCT01969448|PROCEDURE|Lateral Radial Incision|
48492333|NCT01969448|PROCEDURE|Inframammary Fold Incision|
48492334|NCT01969448|DEVICE|Laser-assisted fluorescence angiography|
48492335|NCT01969448|DRUG|Indocyanine Green|
48492336|NCT06041841|DRUG|LB54640|LB54640 QD Oral
48492337|NCT04391530|BEHAVIORAL|emotional freedom technique, breathing therapy|emotional freedom technique, breathing therapy
48651852|NCT06675214|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
48492338|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
48492339|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
48492340|NCT01571076|OTHER|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
48492341|NCT01571076|OTHER|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
48651853|NCT06675214|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.
48332022|NCT02174783|OTHER|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
48332023|NCT02174783|OTHER|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
48332024|NCT02174783|OTHER|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
48332025|NCT01287546|DRUG|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
48332026|NCT01287546|DRUG|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
48332027|NCT01287546|DRUG|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
48651854|NCT06675214|RADIATION|Standard-dose IMRT|GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82y CTV2: 54.12Gy/33Fr/1.64Gy
48332028|NCT01287546|DRUG|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
48492342|NCT06447337|DIAGNOSTIC_TEST|Continous body temperature monitoring|The investigational product will be placed on the participants' body in axilar joint and connected to the mobile phone. The values of the current temperature will apear on the monitor and it will be recorded in the database with date and time for each record. In parallel, study staff will occasionally measure the temperature using standard hospital thermometer.
48492343|NCT06214533|DRUG|Ropivacaine 0.5%|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 mL of 0.5% ropivacaine hydrochloride + 1:400000 adrenaline.
48492344|NCT06214533|DRUG|Normal Saline|Prior to the end of the laparoscopic surgery and any additional procedures, the bilateral celiac plexus block will be performed by the surgeon after identification of the aorta at the superior border of body of pancreas. A 22-gauge spinal needle will be inserted into the retroperitoneal fat on either side of the aorta under direct vision. Needle aspiration will be performed to exclude entry into vessels before administration of the interventional drug. The block will contain 20 ml of 0.9% normal saline + 1:400000 adrenaline.
48492345|NCT03936673|PROCEDURE|Percutaneous nephrostomy|
48492346|NCT06157762|PROCEDURE|Erector spinae plane block|ultrasound guided lumbar erector spinae plane block
48651855|NCT06675214|RADIATION|Gradient Fractionated IMRT|GTVresidue: 68Gy/30Fr/2.27Gy GTVmcr: 60Gy/30F/2Gy CTV1:54Gy/30F/1.8Gy CTV2: 48GY/30F/1.60Gy
48651856|NCT06675214|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
48651857|NCT06429735|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface
48651858|NCT06429735|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
48651859|NCT06571331|OTHER|De-Stress & Snooze Gummies-U001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
48651860|NCT06571331|OTHER|De-Stress & Snooze Gummies-I001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
48651861|NCT06571331|OTHER|Placebo Gummies 002|Two gummies daily in sequence 30-45 minutes before bed for 60 days
48651862|NCT04751357|DIAGNOSTIC_TEST|ECA-Test (Clot-Pro)|Thrombelastometric ECA-Test performed on Clot-Pro
48651863|NCT06637618|BEHAVIORAL|up front use of mineralocorticoid receptor antagonist|the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
48332029|NCT01760187|DRUG|lomitapide|
48332030|NCT00503542|DRUG|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
48651864|NCT06443242|DEVICE|Low-Dose Laser Acupuncture (LLA)|The intervention utilizes the xS-998D06 semiconductor laser acupoint therapeutic device specifically designed for targeted acupoint therapy. This device is critical in delivering precise low-dose laser therapy at a controlled wavelength and power. The laser treatment is directed towards enhancing neurological function and potentially alleviating symptoms of insomnia and depression by stimulating specific acupoints associated with mental health and sleep.
47974798|NCT00847860|DRUG|Cilostazol|Cilostazol 100 mg bid for 12 months
48332031|NCT00503542|DRUG|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
48332032|NCT00503542|DRUG|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
48332033|NCT00503542|OTHER|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
48332034|NCT02376491|DEVICE|Transcranial magnetic stimulation|
48332035|NCT01652937|DRUG|BIIB057|Oral
48332036|NCT01652937|DRUG|Placebo|Oral
48492347|NCT06157762|PROCEDURE|Erector spinae plane block performed by surgeon|Erector spinae plane block performed by surgeon
48332037|NCT03963804|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
48332038|NCT04084340|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
48125190|NCT03257410|DEVICE|Theranova 400 dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
48125191|NCT03257410|DEVICE|Elisio-17H dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
48125192|NCT03487172|DEVICE|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
48125193|NCT03487172|DEVICE|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
48125194|NCT00529789|DRUG|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is \>40 kg, initial dose is 30 mg, then titrated up.
48125195|NCT00000119|DEVICE|Heparin Surface-Modified Intraocular Lens|
48125196|NCT06229301|PROCEDURE|AI-predicted Nomogram|
48125197|NCT05172323|DEVICE|3DCT-scan|A contrast CT-scan of the coronary arteries will be performed and 3D analyzed to determine the best angle for the C-arm during Percutaneous Coronary Intervention (PCI) for stent implantation. Furthermore determining the amount and localization of calcium in the right coronary artery (RCA) and diameter and length of RCA. The use of IVUS will be used to determine the degree of calcium.
48125198|NCT05172323|OTHER|Angiography guided PCI|Standard of care is angiography guided PCI of the ostium of the RCA. The use of IVUS will be used to determine the degree of calcium.
48125199|NCT05443685|DRUG|ADX-629|"Subjects 10-50 years old will be administered ADX-629 250 mg tablets twice daily.~Subjects 5-9 years old will be administered ADX-629 125 mg tablets twice daily."
48332039|NCT04084340|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
48332040|NCT03831737|BEHAVIORAL|stretching exercises|"Head/neck stretches~* Head tilt side to side~* Cross-chest stretch Torso stretches~* Side stretch~* Mid-back stretch Lower limb~* Standing quadriceps stretch~* Standing hamstring stretch"
48332041|NCT04501835|OTHER|Diagnostic and treatment evaluation|No intervention, description of the diagnostic evaluation and the treatment
48332042|NCT00703859|DRUG|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
48332043|NCT03559192|DRUG|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
48651865|NCT06443242|DEVICE|Sham Laser Acupuncture (SLA)|Sham laser acupuncture serves as a control to assess the placebo effect of the laser treatment. It involves the same procedure as LLA but uses a non-emitting laser probe. This intervention is designed to mimic the LLA setup without delivering actual laser therapy, allowing for an evaluation of the psychological and physiological effects of the placebo compared to the active laser treatment.
48125200|NCT01322477|OTHER|F18-FDG PET/CT|
48125201|NCT05494294|PROCEDURE|Intraorally de-epithelialization|In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
48125202|NCT05494294|PROCEDURE|Extraorally de-epithelialization|In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
48125203|NCT05210569|DEVICE|Vivity|Vivity intraocular lens (IOL)
48332044|NCT03559192|DRUG|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
48332045|NCT03655587|DEVICE|Solid ankle foot orthotic|
48332046|NCT03655587|DEVICE|Resting night splint|
48332047|NCT04051476|OTHER|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
48332048|NCT04051476|OTHER|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
48332049|NCT04051476|OTHER|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
48332050|NCT04051476|OTHER|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
48332051|NCT01875705|DRUG|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
48125204|NCT05736185|DEVICE|PEEP selection|Electric impedance tomography-guided PEEP titration
48332052|NCT01875705|DRUG|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
48332053|NCT03465176|OTHER|Aromatherapy Blend|The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
48332054|NCT03465176|OTHER|Placebo|The placebo substance is an odorless vegetable oil derived from avocados.
48332055|NCT02091947|DEVICE|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
48332056|NCT05473104|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Social training targeting adolescents with ASD and focused on making and keeping friends
48332057|NCT00225888|BEHAVIORAL|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
48492348|NCT03838861|BEHAVIORAL|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
48492349|NCT05709041|OTHER|Individualized lung-protective ventilation|"Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released."
48492350|NCT05709041|OTHER|Standard lung-protective ventilation|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
48492351|NCT02775474|DRUG|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
48492352|NCT02775474|DRUG|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
48492353|NCT01553279|BIOLOGICAL|V419|Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.
48332058|NCT02780479|DRUG|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
48332059|NCT02780479|DRUG|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
48332060|NCT00339118|DRUG|doxorubicin, cytoxan|
48332061|NCT03250156|BEHAVIORAL|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
48492354|NCT01553279|BIOLOGICAL|PREVNAR 13®|Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
48492355|NCT01553279|BIOLOGICAL|MCC-TT|Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
48492356|NCT01553279|BIOLOGICAL|MCC-CRM|Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
48332062|NCT03250156|BEHAVIORAL|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
48332063|NCT04432844|PROCEDURE|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
48125205|NCT06111924|OTHER|Task oriented circuit training based telerehabilitation|Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
48332064|NCT04088708|OTHER|Aerobic Exercise Training|Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.
48332065|NCT04088708|OTHER|Attention Control|The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
48125206|NCT06111924|OTHER|Clinic based Task oriented circuit training|Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
48125207|NCT04644341|COMBINATION_PRODUCT|cardiovascular and respiratory systems monitoring|only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
48125208|NCT03014375|DRUG|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
48332066|NCT02360553|BEHAVIORAL|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
48332067|NCT02360553|BEHAVIORAL|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
48332068|NCT01666145|DEVICE|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
48332069|NCT01445964|DRUG|Atenolol|Atenolol oral administration
48332070|NCT01445964|DRUG|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
48332071|NCT01445964|DRUG|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
48332072|NCT02322099|DRUG|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
48332073|NCT02322099|DRUG|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
48332074|NCT02322099|DIETARY_SUPPLEMENT|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
48332075|NCT02322099|DRUG|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
48332076|NCT05411328|DEVICE|virtual reality|All children in the two groups received physical therapy protocol for 30 minutes in addition to virtual reality game traditional physical therapy group traditional physical therapy group
48332077|NCT03742115|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
48125209|NCT00589875|BIOLOGICAL|CAN-2409|Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
48125210|NCT00589875|DRUG|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
48125211|NCT00589875|DRUG|Temozolomide|Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
48125212|NCT00589875|RADIATION|Radiation therapy|Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
48125213|NCT00867256|DEVICE|Large Diameter Metal on Metal|
48125214|NCT06519682|DRUG|Nivolumab|All patients will be administered Nivolumab with or without radiation
48125215|NCT06519682|RADIATION|Radiation|Radiation
47974799|NCT00847860|DRUG|Aspirin|Aspirin 100 mg qd for 12 months
48125216|NCT03488394|GENETIC|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10\^6 CD34+ cells/Kg, with a minimum dose of 4x10\^6 CD34+ cells/Kg and a maximum dose of 35x10\^6 CD34+ cells/Kg.~The product will be injected intravenously."
48125217|NCT02911441|BEHAVIORAL|Cognitive Behavioral Therapy|
48125218|NCT03755752|PROCEDURE|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
48332078|NCT03742115|DRUG|Dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
48332079|NCT03742115|DRUG|Etoposide|150 mg/m2 weekly
48332080|NCT03742115|DRUG|IVIG|0.5 g/kg, once every 4 weeks
48332081|NCT00306241|BIOLOGICAL|HPV-16/18 L1 VLP AS04|
48332082|NCT02995122|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)"
48492357|NCT01553279|BIOLOGICAL|Hib-MCC|Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
48492358|NCT01553279|BIOLOGICAL|MMR Vaccine|Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
48125219|NCT00409799|DRUG|I-0401 (a new bone graft substitute)|1 time application
48125220|NCT02035046|PROCEDURE|Samplings of blood|
48492359|NCT03230500|PROCEDURE|Computer guided implant placement|Implant will be placed immediately using computer aided surgical guide
48125221|NCT02035046|PROCEDURE|Sampling of urine|
48125222|NCT02035046|PROCEDURE|Measure of the blood pressure|
48125223|NCT02035046|PROCEDURE|glycemia test|
48125224|NCT02555475|OTHER|community based hepatitis C care and treatment|
48125225|NCT02107261|DRUG|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
48125226|NCT02107261|DRUG|Placebo|matching placebo
48125227|NCT01379482|DRUG|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
48332083|NCT02995122|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
48332084|NCT00095511|DRUG|aripiprazole|
48332085|NCT00658710|BEHAVIORAL|physical therapy sessions|two physical therapy sessions per week for two months
48651866|NCT06443242|DRUG|Standard Medication Management (Control Group)|This intervention involves the continued use of standard pharmacological treatment with SSRIs for managing symptoms of depression. It serves as a control to evaluate the effects of laser acupuncture against conventional medical treatment without the introduction of additional therapeutic modalities. Participants' adherence to their prescribed medication regimen is monitored and documented, ensuring an accurate comparison of treatment effects across groups.
48651867|NCT03557905|DEVICE|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
48651868|NCT03557905|DEVICE|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
48651869|NCT05281653|BEHAVIORAL|Neuromuscular exercise Training|Progressive neuromuscular exercise training
48651870|NCT05281653|BEHAVIORAL|Routine training sessions|Routine training sessions
48651871|NCT02967692|BIOLOGICAL|Spartalizumab|Spartalizumab powder for solution is used in Part 1 and Part 2, and as concentrate for solution for infusion for Part 3. Spartalizumab is administered via intravenous infusion over 30 minutes once every 4 weeks
48651872|NCT02967692|OTHER|Placebo|Placebo is administered via intravenous infusion over 30 minutes once every 4 weeks
48651873|NCT02967692|DRUG|Dabrafenib|Dabrafenib 150 mg capsules BID is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions.
48651874|NCT02967692|DRUG|Trametinib|Trametinib 2 mg tablets QD is administered orally for Days 1-28 of a 28-day cycle, in fasting conditions
48332086|NCT01051115|DRUG|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
48332087|NCT06517862|DRUG|Zinc sulfate|Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
48332088|NCT06517862|DRUG|Ursodeoxycholic acid|Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
48332089|NCT01241955|BEHAVIORAL|video decision aid|video of CPR
48332090|NCT03760276|DRUG|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
48332091|NCT02644837|DEVICE|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
48332092|NCT02644837|DEVICE|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
48492360|NCT00675636|OTHER|study of socioeconomic and demographic variables|database, no intervention
48492361|NCT00675636|PROCEDURE|evaluation of cancer risk factors|database, no intervention
48492362|NCT00675636|PROCEDURE|study of high risk factors|database, no intervention
48492363|NCT03365011|DRUG|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
48492364|NCT03365011|DRUG|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
48492365|NCT05370755|DRUG|ICP-189|Administered orally
48332093|NCT02644837|DEVICE|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
48332094|NCT02644837|DEVICE|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
48332095|NCT02644837|DEVICE|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
48332096|NCT02644837|DEVICE|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
48125228|NCT01138254|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
48125229|NCT01138254|OTHER|no intervention|no intervention
48125230|NCT02374463|BEHAVIORAL|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
48332097|NCT02644837|DEVICE|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
48332098|NCT02644837|DEVICE|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
48332099|NCT06199505|DRUG|GZR101|Once daily
48332100|NCT06199505|DRUG|insulin degledec/insulin aspart|Once daily or twice daily
48332101|NCT03053726|PROCEDURE|Variable Frequency Stimulation|vary the frequency of the stimulation parameter
48332102|NCT02832596|DRUG|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
48332103|NCT02832596|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
48332104|NCT02570646|BEHAVIORAL|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
48332105|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
48332106|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
48332107|NCT06130410|BIOLOGICAL|COMIRNATY intramuscular injection|Booster injection in the muscle, 1 dose
48332108|NCT03479216|DRUG|Precedex|10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
48332109|NCT03479216|DRUG|Magnesium Sulfate|10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
48332110|NCT05987345|DEVICE|PEF|PEF device treated in the trial.
48332111|NCT05987345|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
48332112|NCT00085917|DRUG|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
48332113|NCT00085917|DRUG|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
48332114|NCT02165345|DRUG|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly
48332115|NCT04137146|DEVICE|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
48332116|NCT00529698|BIOLOGICAL|Biologically active recombinant Tat protein|
48332117|NCT01788150|DEVICE|Coronary Stenting|
48332118|NCT01626053|BEHAVIORAL|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
48332119|NCT01626053|OTHER|Control Group|no intervention
48332120|NCT00627770|DEVICE|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
48332121|NCT04673487|DIAGNOSTIC_TEST|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
48332122|NCT05794789|BEHAVIORAL|Social Identity|This group will receive the same content as the education+planning as well as two additional sessions. This includes short overviews of the benefits of PA as a family, brainstorming how a family can each assist each other in PA, and an activity for developing a family PA action plan. Behavior change techniques such as identity salience, identity similarity, and identity fit and contrast are included in the coaching session include. This will be supplemented by an organization of fun family PA roles for all members (e.g., activity planner, goal setter, supporter, etc.) to instill involvement as well as items (creation of a family PA t-shirt, family PA photos and display, etc.) to instill distinctiveness, which is a central feature of a social identity. Worksheets and discussion will be included. The second session will involve only the parent(s) to focus on parental support identity and the content is based on the behavior change principles of self-identity theory.
48332123|NCT06271928|DRUG|Yijing Keli|Once enrolled, participants will be administrated Yijing Keli
48332124|NCT04213508|DRUG|Isotonic Saline ( 0.9% Sodium Chloride Saline)|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
48332125|NCT04213508|DRUG|Hypertonic Saline ( 3% Sodium Chloride Saline)|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
48651875|NCT06675591|OTHER|Rapid sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
48125231|NCT02374463|BEHAVIORAL|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
48125232|NCT00001958|DRUG|Hydroxyurea|
48125233|NCT06472453|DEVICE|Allograft/Xenograft|Alveolar ridge preservation of a single extraction socket site with vallomix™ (demineralized cortical bone substitute and Bio-Oss®)
48125234|NCT06472453|DEVICE|Allograft|Alveolar ridge preservation of a single extraction socket site with vallos™ (mineralized cortico-cancellous bone substitute)
48125235|NCT02303327|RADIATION|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
48125236|NCT02303327|RADIATION|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
48125237|NCT02303327|DRUG|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
48332126|NCT04717778|DIETARY_SUPPLEMENT|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
48332127|NCT03182842|DEVICE|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
48332128|NCT03182842|DEVICE|SMBG - Blinded Sensor|Insulin dosing based on SMBG
48492366|NCT01449279|DRUG|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
48651876|NCT06675591|OTHER|Slow sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
48651877|NCT06064617|DEVICE|Contact Lens|Coopervision Biofinity Multifocal Lens
48651878|NCT04925375|DRUG|Abatacept|Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
48125238|NCT06440642|DEVICE|tonopen|Intraoculer pressure will be measured in the supine position after intubation (T1), during pneumoperitoneum (T2), when placed in steep trendelenburg posıtıon (T3), at the end of the operation when pneumoperitoneum is terminated (T4), after being placed back in the supine position (T5), and 10 minutes after being placed back in the supine position (T6).
48125239|NCT05486598|DRUG|AL8326 tablets|"Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals.~Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach."
48125240|NCT00991549|BEHAVIORAL|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
48332129|NCT06391658|OTHER|Functional Training|Functional training was performed for eigth weeks. The group participated on the supervised training once a week and twice a week at home. The training was arranged in a circuit method, consisting of three to four blocks with two to three exercises each, with an execution time of two minutes and recovery of thirty seconds between exercises and one minute between each block. The exercises emphasized integrated, functional and multi-joint movements for mobility, flexibility, strength, power and muscular endurance with overload, as well as agility, speed and balance exercises.
48492367|NCT01449279|RADIATION|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
48125241|NCT03104036|OTHER|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
48492368|NCT03997071|OTHER|functional outcome measurement|functional outcome measured in terms of joint position sense analysis, isokinetic muscle strength measurements, gait analysis, drop jump and single leg hop tests, and balance tests
48492369|NCT01832207|DEVICE|Transcutaneous electrical nerve stimulation|
48492370|NCT01832207|DEVICE|Placebo transcutaneous electrical nerve stimulation|
48125242|NCT03104036|DRUG|Mesalazine 4G Enema|Standard mesalazine enema
48125243|NCT00073255|DRUG|hokt3g1 (ALA-ALA)|
48125244|NCT03578536|DEVICE|Recovery Rapids|This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
48651879|NCT04925375|OTHER|Placebo|The composition of the placebo for Orencia is the same as the active study drug without the abatacept. The placebo will be packaged and labeled as described above for the Orencia prefilled syringes. To maintain the blind, injection volumes will be the same as the active treatment.
48651880|NCT06297902|RADIATION|Dose painting|Dose painting
48125245|NCT00767754|DRUG|Paxil CR|12 week treatment of Paxil(20-40mg)
48125246|NCT00832169|DRUG|AZD1386|1 dose of oral solution
48651881|NCT03196479|DRUG|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
48125247|NCT04924218|PROCEDURE|endoscopic surgical intervention|The researchers investigated whether endoscopic surgical procedures performed due to various indications (hematuria, urinary tract stone, suspected bladder mass) in the patient group who had undergone radical prostatectomy, caused a change in urinary incontinence level. The researchers divided the endoscopic instruments used into 3 groups and evaluated whether there was a difference in urinary incontinence level between rigid cystoscope, flexible cystoscope and ureterorenoscope groups.
48125248|NCT03580369|BIOLOGICAL|Ligelizumab|Liquid in vial
48125249|NCT03580369|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
48125250|NCT03580369|OTHER|Placebo|Liquid in vial
48125251|NCT04425863|DRUG|Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.
48492371|NCT03241381|DIAGNOSTIC_TEST|vitamin D serum assay study and control groups|Serum- vitamin D assay
48492372|NCT03241381|DIAGNOSTIC_TEST|Photometry|Serum- Hemoglobin assay
48651882|NCT03196479|DRUG|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
48651883|NCT06534723|DRUG|Wujia Yizhi granules|Drug: Wujia Yizhi granuless
48651884|NCT06534723|DRUG|Placebo|Placebo
48651885|NCT04119037|PROCEDURE|Cordotomy|Undergo cordotomy
48651886|NCT04119037|DRUG|Morphine|Given via injection
48651887|NCT04119037|OTHER|Questionnaire Administration|Ancillary studies
48651888|NCT04119037|PROCEDURE|Sham Intervention|Undergo fake cordotomy
48492373|NCT03241381|OTHER|Russels periodontal index|Clinical examination for periodontitis
48492374|NCT05232084|DRUG|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
48492375|NCT02124941|DRUG|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
48492376|NCT02124941|DIAGNOSTIC_TEST|[18F]FDG PET scan|All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
48492377|NCT02124941|DIAGNOSTIC_TEST|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
48492378|NCT02124941|DIAGNOSTIC_TEST|[11C]APP311 PET scan|All subjects will undergo \[11C\]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
48332130|NCT01887106|DRUG|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
48332131|NCT01887106|DRUG|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
48332132|NCT01887106|DRUG|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
48125252|NCT04425863|OTHER|Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator
48125253|NCT04425863|OTHER|Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.|48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
48125254|NCT03484910|OTHER|Exercise therapy|Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
48332133|NCT01887106|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
48332134|NCT06295068|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|Replacement of the aortic valve with use of the OpSens SavvyWire
48492379|NCT01699763|DEVICE|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48125255|NCT01532388|BEHAVIORAL|eScreen|Web based self-monitoring of problematic alcohol and drug use.
48492380|NCT01699763|DEVICE|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48492381|NCT01699763|DEVICE|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48492382|NCT03660293|DRUG|Atorvastatin|cardio-protective agents
48492383|NCT03660293|DRUG|Captopril|cardio-protective agents
48125256|NCT05436119|DIETARY_SUPPLEMENT|GrowBaby|Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
48125257|NCT01006434|OTHER|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
48125258|NCT01612312|PROCEDURE|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
48125259|NCT01612312|PROCEDURE|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
48125260|NCT02059616|DRUG|Amlodipine 5mg|Daily oral administration for 8 weeks
48332135|NCT06295068|DEVICE|Balloon Aortic Valvuloplasty (BAV)|Dilation of the narrowed aortic valve by balloon inflation with use of the OpSens SavvyWire
48332136|NCT01957709|OTHER|Laboratory Biomarker Analysis|Correlative studies
48332137|NCT01957709|BIOLOGICAL|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
48332138|NCT01743885|DRUG|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
48332139|NCT01743885|DRUG|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
48332140|NCT04965168|PROCEDURE|phacoemulsification of the lens|all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
48492384|NCT03660293|DRUG|L-carnitine|cardio-protective agents
48492385|NCT06360315|OTHER|Incentive letter for pneumococcal vaccination to the patient and to the GP|Incentive letter for pneumococcal vaccination to the patient and to the GP
48492386|NCT00931268|DEVICE|Macrolane VRF 30|One administration
48125261|NCT02059616|DRUG|Amlodipine 10mg|Daily oral administration for 8 weeks
48125262|NCT02059616|DRUG|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
48125263|NCT02059616|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
48125264|NCT00162422|DRUG|albuterol|
48125265|NCT03481751|DIAGNOSTIC_TEST|Diagnostic test: Ultrasound|Transabdominal ultrasound of the bowel for categorization of disease activity
48125266|NCT00639860|DEVICE|OSSIX-Plus|resorbable collagen membrane
48125267|NCT02721901|BEHAVIORAL|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
48125268|NCT02721901|BEHAVIORAL|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
48125269|NCT04790357|OTHER|Current guidelines|doppler ultrasound and/or angio CT-scan of the cervical arteries, angio CT-scan of the intracranial arteries, TTE wich can be supplemented by a TEE at the discretion of the investigator. The TEE is not mandatory
48125270|NCT04790357|OTHER|cc-MRI|of one-shot cardiac-cervical-intracranial MRI: cardiac MRI with late-enhancement, angio-MRI of the cervical and intracranial arteries
48498113|NCT05912361|BEHAVIORAL|receiving a one hour theoretical and hands on training session before using an AI-based platform|The students at the experimental group will receive a one-hour hands-on training session before logging in to the online platform. The session will be presented by a dentist with AI experience and this session will present basic aspects of AI in radiology, deep learning (DL) applications for cariology and endodontics, as well as basics of excavation therapy and pulp exposure. the theoretical part will be followed by a hands on session on which each participant will check 11 cases of teeth with deep caries and will find the closest line between caries and pulp. their performance will be supervised by the training session presenter and the correct line will be shown them in case of making wrong line.
48498114|NCT05960318|DEVICE|KalobaNaso spray|Nasal spray, 2 puff per nostril, 3 times a day
48651889|NCT03531541|DEVICE|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
48651890|NCT03531541|DEVICE|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
48125271|NCT03927820|OTHER|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
48125272|NCT05384470|DRUG|Marihuana|Two doses of marijuana given.
48332141|NCT01003353|BEHAVIORAL|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
47974800|NCT03640845|OTHER|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~* the transmission, the collection and the organization of the data,~* the analysis of the data and their confrontation with the referential and recommendations~* the writing of a Personalized Pharmaceutical Plan"
47974801|NCT02460614|PROCEDURE|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
47974802|NCT02460614|PROCEDURE|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
48492387|NCT06166316|DEVICE|overdenture retained by locator attachments.|"• Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing."
48492388|NCT04598048|BEHAVIORAL|Questionnaire|Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
48492389|NCT05787054|OTHER|Third trimester ultrasound|Third Trimester U/S on indication (TT-Indication) vs Late Third Trimester Protocol (Late-TT)(Trial n°2).
48492390|NCT01762930|DRUG|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
48492391|NCT03373136|DEVICE|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
48492392|NCT01524250|DRUG|corticosteroids|1250mg of oral prednisone daily for 3 days
48492393|NCT01524250|DRUG|corticosteroids|1000mg IV methylprednisolone daily for 3 days
48492394|NCT02548611|DRUG|Prasugrel|see arm description
48492395|NCT02548611|DRUG|Clopidogrel|see arm description
47974803|NCT02460614|OTHER|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
47974804|NCT01482884|DRUG|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
47974805|NCT01482884|DRUG|placebo|2 sc injections of every 2 weeks for 12 weeks.
47974806|NCT00688974|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
47974807|NCT00688974|PROCEDURE|Adjustable gastric band|Laparoscopic adjustable gastric band
48492396|NCT00891839|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
47974808|NCT01554150|BEHAVIORAL|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
47974809|NCT05000060|OTHER|Timing/1 week|Time of restart of antiplatelet therapy is one week after injury
47974810|NCT05000060|OTHER|Timing/3 weeks|Time of restart of antiplatelet therapy is left to treating clinician discretion
47974811|NCT00331682|DRUG|alvocidib|Given IV
47974812|NCT00331682|DRUG|docetaxel|Given IV
47974813|NCT04231357|DRUG|platelet rich plasma|platelet rich plasma prepared from peripheral blood using single spin centrifugation
48492397|NCT00891839|DRUG|Rituximab|Patients receive 375 mg/m\^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
48492398|NCT00423319|DRUG|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
48492399|NCT00423319|DRUG|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
48492400|NCT00423319|DRUG|Enoxaparin-matching placebo|Administered as injection
48492401|NCT00423319|DRUG|Apixaban-matching placebo|Administered as oral tablets
48492402|NCT04918316|OTHER|Corneal gas permeable lens|Fit in corneal gas permeable contact lens first.
48498115|NCT05960318|DEVICE|KalobaNaso junior spray|Nasal spray, 1 puff per nostril, 3 times a day
48125273|NCT05384470|DEVICE|BID2 Instrument - breathalyzer|The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
48332142|NCT01104363|PROCEDURE|Snow white plaster 2|Test. Plaster impression not splinted.
47974814|NCT02384889|DRUG|Difluoromethylornithine|Active Therapy with DFMO
48492403|NCT04817566|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
48492404|NCT04817566|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
48492405|NCT04817566|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
48492406|NCT00121316|DRUG|Pimecrolimus|Pimecrolimus Cream 1 %
48492407|NCT00121316|DRUG|Placebo|Vehicle cream (placebo cream)
48492408|NCT03117036|DRUG|Chemotherapy|Systemic chemotherapy with curative intent
48492409|NCT05164666|BIOLOGICAL|TAK-103|TAK-103 intravenous infusion
48492410|NCT03559621|BEHAVIORAL|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
48492411|NCT04882631|DRUG|PBI-100 Topical Cream|A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
48492412|NCT04882631|DRUG|Positive Control - Sodium laurel sulfate (SLS)|Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
48492413|NCT04882631|OTHER|PBI-100 Topical Cream, Vehicle|Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
48492414|NCT04882631|OTHER|Negative Control|A blank patch was applied daily (excluding weekends) as a negative control test site.
47974815|NCT02384889|DRUG|Placebo|Placebo Comparitor
47974816|NCT04255602|DRUG|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
47974817|NCT04255602|DRUG|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
48332143|NCT01104363|PROCEDURE|Primopattern LC gel + PVS|Control PVS impression
48332144|NCT01296698|DRUG|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
48332145|NCT01296698|DRUG|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
48332146|NCT02067741|DRUG|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
48332147|NCT02703987|OTHER|Fermented infant milk formula|
48332148|NCT02703987|OTHER|Non-fermented infant milk formula|
48492415|NCT03036241|DEVICE|Conventional angioplasty|Angioplasty with conventional balloon
48492416|NCT03036241|DEVICE|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
48492417|NCT03480126|OTHER|Herbal Teas|Steeped tea ingested 3 times a day for 3 mos
48492418|NCT02872363|OTHER|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
48492419|NCT02872363|OTHER|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
47974818|NCT03763253|COMBINATION_PRODUCT|Standard of Care|Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
48332149|NCT05886179|OTHER|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
48332150|NCT05194501|OTHER|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
48492420|NCT04700163|BIOLOGICAL|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
48492421|NCT00888459|DRUG|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
48492422|NCT00888459|DRUG|placebo NRT|Placebo nicotine lozenges
48492423|NCT03716245|PROCEDURE|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
48492424|NCT03716245|RADIATION|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
48492425|NCT04093635|DEVICE|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
48492426|NCT00303394|DRUG|IL-1Ra|
48492427|NCT00448136|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
48492428|NCT00448136|DRUG|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
48492429|NCT00448136|DRUG|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
48125274|NCT03873896|DIAGNOSTIC_TEST|Stimulated skin wrinkling test|Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
48125275|NCT03873896|PROCEDURE|Digital Nerve Block|A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
48125276|NCT03598946|DEVICE|Urinary test|Women use a home urinary test themselves
48125277|NCT03182816|BIOLOGICAL|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
47974819|NCT03763253|PROCEDURE|Minimally Invasive Ablative Therapy (MIAT)|"MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use."
48125278|NCT00557492|DRUG|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
48125279|NCT00557492|DRUG|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
48125280|NCT00557492|RADIATION|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
48125281|NCT01989455|DRUG|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
48125282|NCT01989455|DRUG|Placebo|Placebo: normal saline solution.
48125283|NCT05412316|OTHER|Intervention: Short-wave diathermy|The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application, and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.
48125284|NCT02576275|DRUG|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
48125285|NCT02576275|DRUG|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
48125286|NCT02576275|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
48125287|NCT02576275|DRUG|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
48125288|NCT04436289|BEHAVIORAL|Home Link|In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.
48125289|NCT00377182|DRUG|Copegus|1000/1200mg po daily for 4 weeks
48332151|NCT01078714|DRUG|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
48651891|NCT03531541|DEVICE|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
47974820|NCT03763253|PROCEDURE|Radical Therapy (Prostatectomy or Radiotherapy)|"Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use."
47974821|NCT05501730|DIAGNOSTIC_TEST|Quantra QPlus System|Coagulation monitoring system
48125290|NCT00377182|DRUG|PEGASYS|180 micrograms sc weekly for 4 weeks
48125291|NCT00377182|DRUG|RO5024048 1500mg|1500mg po bid for 4 weeks
48125292|NCT00377182|DRUG|RO5024048 3000mg|3000mg po bid for 4 weeks
48125293|NCT05979922|BEHAVIORAL|Mindfulness-based Cognitive Coping|Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.
48125294|NCT05979922|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
48125295|NCT04611932|DRUG|CKD-330 Tab. and D090 Tab.|1T
48125296|NCT04611932|DRUG|CKD-333 Tab.|1T
48125297|NCT04044807|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
48125298|NCT01227265|DRUG|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
48125299|NCT01227265|DRUG|Placebo|Preladenant-matching placebo oral tablet taken twice daily
48125300|NCT00402259|DRUG|Esomeprazole IV|
48125301|NCT00402259|DRUG|Omeprazole IV|
48125302|NCT00186849|DRUG|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
48492430|NCT00448136|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
48492431|NCT02243267|OTHER|sample collection|
48332152|NCT04782037|DRUG|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
48332153|NCT00875303|BEHAVIORAL|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
48332154|NCT00875303|BEHAVIORAL|Control|Routine primary care.
48332155|NCT05493540|DRUG|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~1. Moderate/Severe PDA on Echocardiography~2. Prolonged ventilation or Increased ventilatory setting~3. Prolonged use of inotropes or vasopressors or escalating dose~   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
48332156|NCT05493540|DRUG|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
48332157|NCT00106288|DRUG|Micafungin|IV
48332158|NCT00106288|DRUG|Liposomal Amphotericin B|IV
48332159|NCT01270958|DRUG|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
48492432|NCT05789719|BIOLOGICAL|STEM-OA|Combination of autologous or allogeneic MSC(AT)s and fat
48492433|NCT01678001|DRUG|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
48492434|NCT00069836|DRUG|Rosiglitazone/metformin|
48492435|NCT06295328|DRUG|Terbinafine|terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
48492436|NCT06295328|DRUG|Placebo|Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
48492437|NCT06295328|DRUG|Tenofovir|Tenofovir 245mg standard of care
48492438|NCT05918978|DRUG|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
48492439|NCT04840966|DIAGNOSTIC_TEST|Flavor test|A simplified self-administrable flavor test has been proposted to all the enrolled subjects
48492440|NCT04840966|OTHER|Self-assesment questionnaire|"Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception."
48492441|NCT01558297|BEHAVIORAL|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
48492442|NCT01558297|BEHAVIORAL|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
48492443|NCT01558297|BEHAVIORAL|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
48492444|NCT00129051|PROCEDURE|Tomotherapy|
48492445|NCT03792360|DRUG|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
48498116|NCT00763438|DRUG|Sertindole|Flexible dose
48125303|NCT00186849|PROCEDURE|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
48125304|NCT04601974|GENETIC|lentiviral gene therapy|lentiviral gene therapy to treat drug resistant epilepsy
48125305|NCT04255290|OTHER|Leg Squat Lounge|The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
48125306|NCT04255290|OTHER|Control group|The subjects included in the control group will perform an eccentric work protocol
48125307|NCT02010944|DRUG|solifenacin succinate|oral
48125308|NCT02010944|DRUG|mirabegron|oral
48651892|NCT03531541|DEVICE|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
48651893|NCT06675578|DRUG|Tulsi gel|After scaling and root debridement, 4% of Tulsi gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
48651894|NCT06675578|DRUG|Chlorhexidine gel|After scaling and root debridement, 1% of Chlorhexidine gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
48651895|NCT02532452|BIOLOGICAL|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \> 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus"
47974822|NCT03576924|BEHAVIORAL|MICT|Individuals randomized to MICT will be asked to engage in only MICT 5 times/week for 30 min/session at 60-70% of heart rate max, consistent with physical activity guidelines of 150 min/week of moderate activity. Individuals are asked to engage in only MICT exercise during the 4-week supervised and unsupervised exercise sessions. During the supervised exercise the intensity will be based on the heart rate (HR) monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
47974823|NCT03576924|BEHAVIORAL|HIIT|Individuals randomized to HIIT will be asked to engage in only HIIT 5 times/week for 4 weeks. HIIT consists of 5 repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods. A 3-min warm-up and 2-min cool-down are also included, for a total session duration of 15 minutes. This matches the guidelines of 75 min of vigorous exercise per week. During the supervised exercise sessions, intensity will be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
47974824|NCT03576924|BEHAVIORAL|CHOICE|Participants will first be familiarized with HIIT and MICT in a randomized, counter-balanced order during supervised sessions 1 and 2, and will subsequently self-select the exercise type for the supervised and unsupervised exercise sessions. The HIIT and MICT protocols will match to the parallel imposed conditions. During the supervised exercise, intensity will also be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
47974825|NCT03910842|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
48125309|NCT02010944|DRUG|mirabegron/solifenacin succinate|oral
48125310|NCT05087758|OTHER|Matrion|Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
48125311|NCT05087758|OTHER|Conventional Care Wound Management|Advanced wound care with debridement and dressings
48125312|NCT03606915|BEHAVIORAL|pain evaluation|collect CSF during spinal anesthesia
48125313|NCT00006349|DIETARY_SUPPLEMENT|vitamin E|
48125314|NCT00006349|DRUG|donepezil hydrochloride|
48125315|NCT00006349|OTHER|placebo|
48125316|NCT04562675|BEHAVIORAL|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
48125317|NCT04562675|OTHER|brochure-only|brochure-only for control group (CG)
48125318|NCT00174252|DRUG|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
48125319|NCT01582100|DEVICE|Reletex|Neuromodulation device worn on the wrist
48332160|NCT05289856|DRUG|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
48332161|NCT00877006|DRUG|bendamustine|
48332162|NCT00877006|DRUG|rituximab|
48332163|NCT00877006|DRUG|vincristine|
48332164|NCT00877006|DRUG|prednisone|
48332165|NCT00877006|DRUG|cyclophosphamide|
48332166|NCT00877006|DRUG|doxorubicin|
48332167|NCT00148421|DRUG|Darbepoetin alfa and Epoetin alfa|
48492446|NCT00968292|DEVICE|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
48492447|NCT05050890|OTHER|ctDNA level during neoadjuvant chemotherapy|ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure
48492448|NCT01524965|PROCEDURE|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
48492449|NCT01524965|PROCEDURE|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
48492450|NCT01524965|DEVICE|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
48492451|NCT02397642|PROCEDURE|IVF/ICSI|
48492452|NCT02397642|DRUG|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
48492453|NCT00910091|DRUG|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
48492454|NCT00910091|DRUG|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
48492455|NCT00823121|PROCEDURE|freezing embryos by vitrification|vitrification by Cryotop method
48492456|NCT00823121|PROCEDURE|fresh embryo transfers|fresh embryo transfers
47974826|NCT01405248|DRUG|Butylphthalide|20 mg/time per os three times a day. 180days
47974827|NCT01405248|DRUG|Placebo|20 mg/time per os three times a day. 180days
47974828|NCT04717115|GENETIC|Genetic diagnosis|No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
47974829|NCT01045720|DRUG|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
47974830|NCT01045720|DRUG|Placebo|Placebo (starch)
47974831|NCT06384768|OTHER|Video training|A 4 week support program consist of videos for fear of childbirth
47974832|NCT04785014|PROCEDURE|interventional|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
47974833|NCT03099421|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
48332168|NCT04893928|OTHER|QUECOMIICAT survey|IBD-related knowledge. It will be assessed using the recently validated QUECOMIICAT (Qüestionari Coneixements Malaltia Inflamatòria Intestinal Catalunya) questionnaire (27) originally developed in Spanish. Compared with the most well-known CCKNOW (Eaden JA et al in 1999)(28), it incorporates IBD updated data (29).
48332169|NCT04893928|OTHER|Self-Efficacy for Appropriate Medication Use Scale|Treatment adherence and compliance. It will be assessed using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a 13-item self-administered scale previously translated into Spanish and validated by Bozada-Gutiérrez K et al on a Mexican population (3). According to 13 situations asked by the items, patients stratify the level of confidence about correctly taking their medications: 1, not at all confident; 2, somewhat confident; 3, very confident. The sum of results ranges from 13 to 39 points, where higher scores indicate optimal self-efficacy for taking the pharmacological treatment.
48492457|NCT00823121|DRUG|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
47974834|NCT03249727|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
47974835|NCT05786820|DIETARY_SUPPLEMENT|Pycnogenol|daily consumption of a pycnogenol-containing capsule
47974836|NCT05786820|DIETARY_SUPPLEMENT|Placebo|Daily consumption of a placebo capsule
48492458|NCT00823121|DRUG|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
48492459|NCT00823121|DRUG|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
48492460|NCT01389466|BIOLOGICAL|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
47974837|NCT03851068|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
47974838|NCT00314392|BEHAVIORAL|Information (behavior)|
47974839|NCT06408025|OTHER|Syrenity App|"Currently, the Syrenity App has two active interventions. One is an exposure-based intervention called Face your fears. Another is an intervention based on behavioral activation called Get better. The app also provides self-report questionnaires for tracking mood along with psychoeducation on a variety of topics relevant to mental health."
47974840|NCT02198742|DEVICE|Miller blade|To participate in the study the subjects must have \>500 intubations with the miller blade.
48492461|NCT01389466|BIOLOGICAL|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
48492462|NCT02177136|DRUG|Obeticholic Acid (OCA)|
48492463|NCT02177136|DRUG|Placebo|
48492464|NCT05055895|DRUG|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
48492465|NCT02939950|DEVICE|Bausch + Lomb Samfilcon A Soft Contact Lens|soft contact lenses
48492466|NCT02939950|DEVICE|Bausch + Lomb Pure Vision Soft Contact Lens|soft contact lenses
48492467|NCT01117766|DRUG|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
48492468|NCT01117766|DRUG|Placebo|BID dosing for 28 days
48492469|NCT03578237|DEVICE|Cryoneurolysis (active)|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
48492470|NCT03578237|DEVICE|Sham cryoneurolysis procedure|"Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.~Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature"
48492471|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
48492472|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
48492473|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
48492474|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
48492475|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
48492476|NCT04838236|OTHER|MASP app + NRT|MASP is a mobile intervention that targets anxiety sensitivity among African American smokers (Mobile Anxiety Sensitivity Program for Smoking: MASP). Our intervention is framed within the cultural context of interoceptive stress among African American smokers, which is supported by theory, empirical evidence, and characteristics of this group. The MASP app employs a variety of features to educate its users on how to deal with stress, anxiety, and nicotine withdrawal symptoms. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos. MASP also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time.
48492477|NCT04838236|OTHER|QuitGuide app + NRT|Quitguide is a smartphone-based National Cancer Institute (NCI) app for standard mobile smoking cessation treatment. The app contains features that allows its' users to better understand their smoking patters, and build skills needed to becomes and stay smoke free. The app allows users to track their cravings, and delivers motivational messages to users for each craving they track.
48492478|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock|CONTROL
48492479|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock|TEST
48492480|NCT03359577|DIETARY_SUPPLEMENT|Psorax35|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
48492481|NCT03359577|DIETARY_SUPPLEMENT|MCT oil|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
48492482|NCT04779541|OTHER|observation|observation of the mechanisms of acceptance or rejection of the vaccine
48492483|NCT00285948|DEVICE|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
48492484|NCT00405613|DRUG|Aspirin|
47974841|NCT02198742|DEVICE|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
48125320|NCT03190603|DRUG|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
48332170|NCT04893928|OTHER|ICTs preferences and barriers survey|"Information and communication technologies (ICTs) preferences and barriers. It will be assessed using an ad-hoc inventory designed by the authorship. It has 45 questions mainly answered through a 5-points Likert scale. This inventory was inspired by the surveys used by Mauer M et al on an international population with urticaria (11), and those used by Reich J et al (30) and Chowdhary TS et al (31) on American patients with IBD. Survey approaches aspects related to:~* Frequency of use of ten different ICTs for personal purposes;~* Frequency of use of ten different ICTs for IBD-related purposes;~* A free question about others ICTs that the patient uses for IBD-related purposes;~* Eight specific IBD-related purposes ICTs are used to;~* Assessment of ICTs for eight IBD-related purposes;~* Eight Features an IBD-related App must comprehend."
48332171|NCT04893928|OTHER|Focus group and IBD mobile App for health support (MAHS) development and validation|In stage II, a qualitative study will be performed using focus group discussion to explore the experiences and perceptions of patients with IBD using ICTs for health support in different contexts. Focus groups will be established following the Krueger and Casey guidelines (32). Collected data will address the development of an IBD MASH. The developed IBD MASH will be validated on a randomised pilot study along stage III. Methodology and ethical aspects of stage II and III will be defined in another proposal, after stage I preliminary findings.
47974842|NCT02198742|DEVICE|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
48332172|NCT03024840|DRUG|Sevoflurane|Sevoflurane: 1%\~2%
48332173|NCT03024840|DRUG|Propofol|Propofol: 9-15 mg/kg/h
48332174|NCT00525785|DRUG|5-Fluorouracil|"2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
48332175|NCT00525785|DRUG|Folinic Acid|200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
48332176|NCT00525785|DRUG|Oxaliplatin|"100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
48332177|NCT00525785|RADIATION|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
48332178|NCT00525785|PROCEDURE|Surgery|4-6 weeks after completion of chemoradiotherapy, restaged \& surgical resection of the primary tumor and lymph nodes attempted.
48332179|NCT00108797|DRUG|eptacog alfa (activated)|
48332180|NCT00108797|DRUG|Feiba VH|
48332183|NCT00431821|BEHAVIORAL|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
48332184|NCT00431821|OTHER|Stroke education|Stroke education program with matched attention phone calls
47974843|NCT01867424|DRUG|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
47974844|NCT04851249|PROCEDURE|Hallux Valgus - chevron osteotomy, lapidus procedure|The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
47974845|NCT00954434|DIETARY_SUPPLEMENT|red wine|intake of red wine on a daily basis
48332185|NCT03411668|OTHER|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
48332186|NCT02111512|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
47974846|NCT04342897|DRUG|LY3127804|Administered IV
48125321|NCT06212843|OTHER|plyometric training|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step."
48125322|NCT06212843|OTHER|conventional exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises would be performed.~1. Pushups.~2. Situps.~3. Lunges 4.500m running.~5.Squats"
48125323|NCT03094169|DRUG|AVID100 IV|AVID100 is administered once every 3 weeks
48125324|NCT00083967|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
48125325|NCT04497766|DRUG|Nebulized Magnesium sulfate|MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
48125326|NCT04497766|DRUG|Intravenous magnesium sulphate|pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
48125327|NCT04785950|DRUG|Low-dose levonorgestrel intrauterine systems (LNG-IUS)|Any low-dose intrauterine system (IUS) marketed in Spain
48125328|NCT05262738|DRUG|50 Micrograms Vaginal Misoprostol (Intervention)|Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.
48125329|NCT05262738|DRUG|25 Micrograms Vaginal Misoprostol (Control)|Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
48492485|NCT05161806|DRUG|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
48492486|NCT05161806|DEVICE|Prefilled Syringe (PFS)|Prefilled Syringe (PFS)
48492487|NCT05038332|RADIATION|Ultra-hypofractionated radiation therapy|34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
48492488|NCT05038332|RADIATION|Moderately Hypo-fractionated Radiation Therapy|55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
48492489|NCT01233921|BIOLOGICAL|palifermin|Given IV
48651896|NCT06674707|OTHER|Agility Training with Foot mobilization.|Agility training with foot mobilization with the frequency of 3 sets of 10 repetitions thrice per week for a total six weeks. Pre and post intervention values will be taken on 1st day and after six weeks. Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. TJM is a grade III Maitland technique and is applied with a high amplitude from the end range and 1s of vibration in the middle range of the joint through a linear motion to where tissue resistance is felt in the prone position, the patient is supported by a towel placed under the foot. Two sets of 5 min total were performed for 6weeks.
48651897|NCT06674707|OTHER|Agility Training without Foot mobilization|Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. Comprising of Hot pack and TENS for 10 minutes and Ultrasound for 5 minutes . Comprising of conventional exercises were given for 3 sessions per week for 6 weeks. It includes semi squat, quadriceps isometric, terminal knee extension with elastic band, terminal knee extension in supine position, and adductor squeeze in crook lying (squeeze the ball).
47974847|NCT04342897|DRUG|Placebo|Administered IV
47974848|NCT03292588|BIOLOGICAL|Mepolizumab|"Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
47974849|NCT03292588|DRUG|Placebo|"Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
47974850|NCT02954237|DEVICE|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
47974851|NCT02399501|PROCEDURE|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
47974852|NCT02399501|DEVICE|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
47974853|NCT02399501|DEVICE|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
48492490|NCT01233921|OTHER|flow cytometry|Correlative studies
48492491|NCT01233921|OTHER|laboratory biomarker analysis|Correlative studies
48492492|NCT01233921|OTHER|pharmacological study|Correlative studies
48492493|NCT03816215|BEHAVIORAL|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
48492494|NCT05050006|BIOLOGICAL|ITIL-168|ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
48332187|NCT02228564|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
48492495|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
48492496|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
48492497|NCT04463303|OTHER|lung ultrasound|patient with or without weaning induced pulmonary adema
48492498|NCT04927026|BEHAVIORAL|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|The WIPT include weekly face-to-face group sessions including mindfulness-based training and solution focused brief therapy (SFBT) involving psychoeducation and structured life review therapy catered to the personal needs of the participants.
48492499|NCT03559166|DRUG|BLD-2660|Randomized to active product or placebo
48492500|NCT04701515|OTHER|Chart review|Chart review
48651898|NCT00980798|DRUG|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
47974854|NCT02399501|DEVICE|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
48332188|NCT02228564|DEVICE|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
48651899|NCT00980798|DRUG|Placebo|placebo tablet once daily for 16 weeks
48651900|NCT02661347|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
48651901|NCT02661347|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
48651902|NCT05811013|DEVICE|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
48651903|NCT05811013|DEVICE|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
48651904|NCT00408174|DRUG|Balsalazide disodium|
48651905|NCT05688111|DRUG|Tranexamic acid injection|Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
48125330|NCT04138394|DRUG|Ascorbic Acid|Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
47974855|NCT00826215|DEVICE|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
48125331|NCT04138394|DRUG|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
47974856|NCT00826215|DEVICE|Sham laser acupuncture|Sham laser acupuncture
47974857|NCT04367636|BEHAVIORAL|Behavioral: OCAT-sham|Placebo version of the online contingent attention training preceded by psycho-education movieclip.
48125332|NCT00981643|BEHAVIORAL|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
48125333|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
48125334|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
48125335|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
47974858|NCT04367636|BEHAVIORAL|Behavioral: OCAT|Online contingent attention training preceded by psycho-education movieclip.
48125336|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
48125337|NCT06034522|DEVICE|Adipearl|Injection of the investigational device in the face.
48125338|NCT04545918|DEVICE|Follicle Clarity|Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
48125339|NCT05277441|DIAGNOSTIC_TEST|Novel severity grading system of unexpected events in pediatric surgery|Classification of unexpected events according to the Clavien-Madadi classification for pediatric surgical patients and simultaneously the non-modified Clavien-Dindo classification in more than 10.000 patients who have been treated at a single center from 2017 to 2022.
48125340|NCT04554108|OTHER|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
48125341|NCT02955719|DRUG|Sertraline|
48125342|NCT02955719|DRUG|Venlafaxine|
47974859|NCT04367636|OTHER|psycho-education video|Both groups get to see a psycho-education video before the smartphone training starts.
47974860|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
47974861|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
47974862|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
47974863|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
47974864|NCT00752232|OTHER|PBS|IM injection, Day 1, month 3, 6, 9, 12
47974865|NCT00271583|DRUG|CDB-2914|
47974866|NCT00271583|DRUG|levonorgestrel|
47974867|NCT06451978|OTHER|Nature-based intervention|The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.
47974868|NCT01652703|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
47974869|NCT01652703|OTHER|Placebo|Administered by subcutaneous injection
47974870|NCT00371137|DRUG|Xyrem®|two doses
47974871|NCT00371137|DRUG|Placebo|Oral Solution
48125343|NCT02955719|OTHER|CBT/Psychological Therapy|
48125344|NCT02955719|OTHER|Psychiatric Consultation|
48651906|NCT05688111|OTHER|Glucose water 5%|Placebo group 30ml will be received 12 hourly for 48 hours
48651907|NCT05303857|DRUG|Semaglutide Pen Injector|Injection of the semaglutide once weekly
47974872|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
47974873|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
47974874|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
47974875|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
47974876|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
48125345|NCT02955719|OTHER|Lifestyle Intervention Resources|
48125346|NCT04177147|OTHER|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
48651908|NCT05303857|DRUG|Placebo|Injection of placebo once weekly
47974877|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
48651909|NCT03989284|BEHAVIORAL|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
48651910|NCT01228032|OTHER|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
48651911|NCT06675279|OTHER|Survey-based study|The demographic information of individuals with migraines, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
47974878|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given 2 doses intravenously
47974879|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
47974880|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
48125347|NCT05239650|DRUG|HLX07|1000mg
48125348|NCT05239650|DRUG|HLX10|200mg
48125349|NCT05239650|DRUG|mFOLFOX6|OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
48125350|NCT02460393|DRUG|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people"
47974881|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
48125351|NCT02460393|OTHER|placebo|Subcutaneous injection of different doses for healthy people
48125352|NCT03041064|OTHER|50/100|SPF
48125353|NCT03041064|OTHER|100/50|SPF
48125354|NCT00300131|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
48125355|NCT04307511|DRUG|Ticagrelor|60mg ticagrelor based DAPT vs 90mg ticagrelor based DAPT vs 90mg ticagrelor monotherapy
48125356|NCT04307511|DRUG|Aspirin|Aspirin
48125357|NCT00110552|DRUG|Salvia officinalis (sage)|oral dosage
48125358|NCT02867072|PROCEDURE|Open appendectomy|
48332189|NCT03258632|BEHAVIORAL|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
48332190|NCT01532570|DRUG|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
47974882|NCT00635960|DRUG|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
47974883|NCT00635960|DRUG|Placebo|Same as for Growth hormone group
47974884|NCT05732688|DIAGNOSTIC_TEST|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
47974885|NCT01426373|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
47974886|NCT05163600|OTHER|Blod flow restriction training|includes one strength and one endurance training
47974887|NCT03254004|DRUG|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
47974888|NCT02634229|GENETIC|blood sample|
48125359|NCT02867072|PROCEDURE|Laparoscopic appendectomy|
48125360|NCT05391061|DRUG|Abrocitinib|Tablets
48125361|NCT04099875|DIAGNOSTIC_TEST|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
48332191|NCT01136863|DRUG|Felodipine|
48125362|NCT05376436|DIAGNOSTIC_TEST|Exercise challenge test (ECT)|Baseline demographic, clinical and rest lung functions were recorded. ECT was performed on treadmill according to fixed protocol. Clinical data during ECT was recorded. (visit 1- performed with nose clip, visit 2- performed without nose clip). Lung function were measured and recorded at fixed time after ECT and after bronchodilator administration.
48125363|NCT01150916|PROCEDURE|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
48125364|NCT01962090|OTHER|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
48125365|NCT01962090|OTHER|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
48125366|NCT06521541|BEHAVIORAL|Multimodal prehabilitation program|Patients adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.Patients were evaluated for changes during neoadjuvant therapy and postoperative recovery
48332192|NCT01136863|DRUG|Placebo|
48332193|NCT02671955|DRUG|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
47974889|NCT00139009|DRUG|Cyclosporine A|
47974890|NCT02554266|DEVICE|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
47974891|NCT02968953|DRUG|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
48125367|NCT06521541|BEHAVIORAL|ERAS program|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
48125368|NCT05311527|DEVICE|Urolift|Urolift Implant
48125369|NCT05311527|RADIATION|SABR|Stereotactic Body Radiation Therapy for prostate cancer
48332194|NCT03388086|DRUG|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
48332195|NCT02911818|BEHAVIORAL|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
48332196|NCT02911818|DRUG|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
48332197|NCT02911818|OTHER|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
48332198|NCT02911818|DRUG|Placebo Oral Tablet|
48492501|NCT04644094|OTHER|Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration|"A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.~B. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length/weight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA."
48651912|NCT02500836|DRUG|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
48651913|NCT02500836|DRUG|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
48651914|NCT02500836|DRUG|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
48332199|NCT02911818|DRUG|Phentermine 15 MG|
48332200|NCT02911818|BEHAVIORAL|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
48332201|NCT04426994|DRUG|proton pump inhibitor use|Patients using long term proton pump inhibitor
48332202|NCT04182789|DRUG|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
48332203|NCT01730287|DRUG|Control|The teeth in this group restored only by filling material,without liner application.
48332204|NCT01730287|DRUG|Calcium Hydroxide|Calcium Hydroxide paste applied.
48332205|NCT01730287|DRUG|Mineral Trioxide Aggregate(MTA)|MTA applied .
48332206|NCT01730287|DRUG|CEM cement|CEM cement applied .
48492502|NCT02925806|OTHER|Non-interventional study - retrospective database review|
48651915|NCT01321684|OTHER|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
48651916|NCT01321684|OTHER|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
47974892|NCT03445650|DRUG|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
48332207|NCT02571608|DRUG|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
48332208|NCT02571608|DRUG|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
48492503|NCT06018974|DEVICE|Yetitablet gaming|Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
48492504|NCT04002505|OTHER|Concussion and Brain Bleed App (CBB)|Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
48492505|NCT04569448|DRUG|Brexpiprazole|Adjunctive variable dose (1-3 mg/day) Brexpiprazole
48492506|NCT06064292|DEVICE|INSPIRATORY MUSCLE TRAINING|After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
48332209|NCT05426018|DRUG|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
48332210|NCT01882777|BEHAVIORAL|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
48332211|NCT05278286|BEHAVIORAL|Crawling stimulation with the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
48332212|NCT05278286|BEHAVIORAL|Tummy time without the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
48332213|NCT02640118|DRUG|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
48492507|NCT04129320|BIOLOGICAL|enoblituzumab|anti-B7-H3 antibody
48492508|NCT04129320|BIOLOGICAL|MGA012|anti-PD-1 antibody
48492509|NCT04129320|BIOLOGICAL|MGD013|PD-1 X LAG-3 bispecific DART protein
48492510|NCT02091323|PROCEDURE|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
48651917|NCT06641115|BEHAVIORAL|HOPE Therapy|Helping Opioid Use and PTSD with Exposure (HOPE) therapy is an integrated 10-12 week treatment for opioid use disorder and trauma/posttraumatic stress disorder
48332214|NCT02640118|DRUG|Lixisenatide-Placebo|
48332215|NCT02640118|OTHER|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
48332216|NCT00505752|DRUG|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
48332217|NCT00505752|DRUG|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
48332218|NCT00505752|DRUG|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
48492511|NCT02980874|DRUG|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
48492512|NCT02980874|DRUG|suprachoroidal sham|suprachoroidal sham procedure
48492513|NCT02980874|DRUG|IVT aflibercept|2 mg intravitreal injection of aflibercept
48492514|NCT06002971|DEVICE|Blood pressure measurement|Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.
48492515|NCT04125121|DRUG|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
48492516|NCT02304458|BIOLOGICAL|Ipilimumab|Given IV
48492517|NCT02304458|OTHER|Laboratory Biomarker Analysis|Correlative studies
48651918|NCT04078568|DRUG|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
48651919|NCT04078568|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
48651920|NCT04078568|DRUG|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
48651921|NCT04062552|BEHAVIORAL|Virtual Learning Collaborative|"Patients undergo a palliative care assessment, participate in up to 6 ENABLE telehealth sessions with an ENABLE coach (20-45 minutes each), and complete up to 6 monthly follow-up calls over a 26-week period.~The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for up to 15 months."
48651922|NCT04062552|BEHAVIORAL|Technical Assistance|"Patients undergo a palliative care assessment, participate in up to 6 ENABLE telehealth sessions with an ENABLE coach (20-45 minutes each), and complete up to 6 monthly follow-up calls over a 26-week period.~The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for up to 15 months."
48332219|NCT00505752|DRUG|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
48332220|NCT00505752|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[\>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of \>= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).
48332221|NCT02205918|OTHER|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
48332222|NCT02205918|OTHER|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
48332223|NCT04689841|OTHER|Vojta Therapy|"Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically."
48332224|NCT04689841|OTHER|placebo|In the control group, a placebo intervention is administered, similar to an experimental intervention
48651923|NCT05144737|BEHAVIORAL|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
48651924|NCT02042144|DRUG|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
48651925|NCT05555693|OTHER|Collecting clinical data, EGG，Brain Metabolomic Characteristics(with Magnetic Resonance Spectroscopy), blood gas data and blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），Magnetic Resonance Spectroscopy data (before induction of anesthesia and first day after surgery)blood gas data(before induction of anesthesia and first day after surgery) and blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
48651926|NCT01842347|OTHER|Fecal microbiota|
48651927|NCT04279093|OTHER|No intervention, but participants will use a smartphone app daily to complete the EPDS|No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
48651928|NCT04624230|DRUG|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
48651929|NCT05185453|BEHAVIORAL|Strengthening Connections for Change|Strengthening Connections for Change is a 12-session curriculum designed to strengthen adolescent-adult support networks, build leadership skills, foster community engagement, and challenge attitudes and behaviors that foster violence involvement. During the program, youth ages 13-17 years invite their self-identified key adult supports to jointly participate in programming including youth-focused, adult-focused and jointly focused activities. Towards the end of programming participants design and carry out a community project to strengthen intergenerational connections and promote community engagement.
48651930|NCT05185453|BEHAVIORAL|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
48332225|NCT03842215|DEVICE|smart physical exam|Use smart physical exam to collect functional performance
48651931|NCT05949385|DRUG|ZX-7101A|Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
48332226|NCT03713216|DRUG|Naldebain|150 mg Nalbuphine sebacate
48332227|NCT03713216|DRUG|Morphine|Morphine
48332228|NCT01544686|DEVICE|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
48492518|NCT02304458|BIOLOGICAL|Nivolumab|Given IV
48492519|NCT02304458|OTHER|Pharmacological Study|Correlative studies
48492520|NCT00834652|DRUG|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
48332229|NCT03611998|BEHAVIORAL|Occupation-based programming|Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
48332230|NCT00927719|BIOLOGICAL|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
48332231|NCT03278652|OTHER|Consumption of drugs for analgesic use|"* Regular assessment of pain~* Drug data will be collected (name, dosage, route of administration, time of delivery)"
48332232|NCT00200512|DRUG|apomorphine HCl injection|
48332233|NCT05592418|DRUG|Rintatolimod|100 to 400 mg twice weekly
48332234|NCT05592418|OTHER|Placebo / Normal Saline|40 to 160 mL twice weekly
48332235|NCT04583761|BEHAVIORAL|questionnaire|Mailed structured regarding current and former tobacco consumption and use of alternative nicotine delivery systems
48332236|NCT01754597|DRUG|Peptide Natriurétique de type B|Peptide Natriurétique de type B
48332237|NCT01788072|DRUG|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
48332238|NCT01788072|DRUG|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
48651932|NCT02019173|BEHAVIORAL|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
48651933|NCT02320071|OTHER|Examination of abdominal wall strength changes over time|
48492521|NCT00834652|DRUG|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
48492522|NCT01074762|BEHAVIORAL|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
48492523|NCT00076804|BEHAVIORAL|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
48492524|NCT06484634|DRUG|Low molecular weight heparin|A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
48332239|NCT06121362|DIETARY_SUPPLEMENT|Protocatechuic Acid or PCA|PCA 1000 mg capsule
48332240|NCT06121362|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
48332241|NCT00798577|DRUG|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
48332242|NCT00798577|DRUG|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
48332243|NCT01082367|DRUG|TOBI|TOBI (tobramycin inhaled solution)
48332244|NCT01082367|DRUG|Placebo|Placebo
48492525|NCT02123212|OTHER|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
48492526|NCT02123212|OTHER|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
48492527|NCT02123212|OTHER|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
48492528|NCT00080405|DRUG|Bortezomib|
48492529|NCT02654171|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
48492530|NCT02654171|DRUG|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
48492531|NCT04355663|BEHAVIORAL|Motor program activating therapy|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
48492532|NCT04355663|BEHAVIORAL|Vojta's reflex locomotion|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
48492533|NCT04355663|BEHAVIORAL|Functional electric stimulation|Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
48492534|NCT01771471|BIOLOGICAL|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
48492535|NCT01771471|OTHER|Placebo|0.9% w/v Sodium Chloride for Injection, USP
48492536|NCT03566576|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
48492537|NCT03566576|DRUG|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
48492538|NCT03566576|DRUG|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
48492539|NCT03562741|PROCEDURE|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
48125370|NCT02475343|DEVICE|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
48125371|NCT02475343|DEVICE|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
48125372|NCT02475343|DEVICE|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
48125373|NCT02475343|DEVICE|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
48125374|NCT02475343|DEVICE|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
48125375|NCT02475343|DEVICE|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
48125376|NCT05229835|OTHER|Time restricted eating and exercise|We apply time restricted eating, exercise alone and combined
48125377|NCT05814146|DRUG|Dialysate bicarbonate concentration|"Assess how a lower dialysate bicarbonate affects:~* QTc duration during and between hemodialysis sessions~* PVC burden during and between hemodialysis sessions~* Clinically significant arrhythmia during and between hemodialysis sessions~* Intradialytic hypotension~* Adverse symptoms during hemodialysis sessions"
48125378|NCT05814146|DEVICE|Dialysate bicarbonate concentration - telemetry monitoring|Patients will be monitored with telemetry on both arms of the trial.
48125379|NCT06340100|OTHER|find association between vestibular impairment , cognitive fiunction with concussin|SCOAT 6 is a standardized tool used for evaluating athletes suspected of having a concussion. It includes a variety of components such as symptom evaluation, cognitive assessment, balance evaluation, and a neck examination. it helps in assessing the severity of the injury, tracking recovery, and making return-to-play decisions. Dr. Robert Cantu, a prominent figure in sports concussion research, has proposed guidelines for the management of concussions. These guidelines typically involve recommendations for the evaluation, treatment, and return-to-play decisions for athletes who have sustained concussions
48332245|NCT02783417|OTHER|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
48332246|NCT00618995|DRUG|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
48332247|NCT00618995|DRUG|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
48332248|NCT00618995|DRUG|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
48651934|NCT06637670|OTHER|Kinesiology taping|'Y shaped' kinesiology taping was applied on quadriceps femoris muscle, based on facilitation technique with 25-50% stretching.
48651935|NCT06637670|OTHER|Placebo taping|A tape without tension was applied perpendicular on the quadriceps femoris muscle.
47974893|NCT03445650|DRUG|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
48332249|NCT00618995|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
48332250|NCT00744848|DRUG|Bupivacaine HCl|100 mg Bupivacaine HCl
48332251|NCT00744848|DRUG|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
48332252|NCT00407173|DRUG|HCV-796|HCV-796 1000mg single dose
48332253|NCT02600494|DRUG|ITI-007 (Lumateperone)|
47974894|NCT05494333|OTHER|no intervention|NO intervention
48332254|NCT02600494|DRUG|Placebo|
48332255|NCT02752724|DRUG|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
48332256|NCT02752724|DRUG|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
48651936|NCT04629196|DRUG|Ustekinumab|A second IV weight-based induction dose of Stelara at week 8
47974895|NCT03846596|BIOLOGICAL|Additional blood tube|Additional blood tube during care
47974896|NCT02045134|DIETARY_SUPPLEMENT|Placebo|Soluble corn flour not rich in anthocyanins
47974897|NCT02045134|DIETARY_SUPPLEMENT|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
48332257|NCT02356146|DRUG|Tacrolimus C12|
48332258|NCT04848415|OTHER|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
48332259|NCT00003777|DRUG|amifostine trihydrate|
48332260|NCT00003777|DRUG|cisplatin|
48332261|NCT00003777|DRUG|fluorouracil|
48332262|NCT00003777|PROCEDURE|surgical procedure|
48332263|NCT00003777|RADIATION|radiation therapy|
48332264|NCT02604810|BIOLOGICAL|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
48332265|NCT02604810|BIOLOGICAL|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
48332266|NCT05561894|OTHER|pulse pressure variation index guided fluid therapy|maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either \>12% or \>16%
48332267|NCT01520584|DIETARY_SUPPLEMENT|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
48332268|NCT00532714|DRUG|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
48332269|NCT02562183|DRUG|kallikrein|Using kallikrein
48332270|NCT03965871|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
48492540|NCT00195234|BIOLOGICAL|HIV CTL MEP 1000 micrograms, 19 months per subject|
48332271|NCT03965871|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
48492541|NCT05089474|DEVICE|Streamline Surgical System|The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
48492542|NCT02929446|PROCEDURE|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
48492543|NCT02929446|PROCEDURE|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
48651937|NCT04629196|DRUG|Ustekinumab|A standard 90mg subcutaneous dose of Stelara at week 8
48125380|NCT03210454|OTHER|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
48332272|NCT03965871|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
48332273|NCT03965871|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
48492544|NCT04309253|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
48492545|NCT04309253|DRUG|AV45|F-18 AV45 PET Imaging
48651938|NCT04629196|DRUG|Ustekinumab|All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
48651939|NCT04781972|DRUG|Methylphenidate|single dose of 10 mg or 15 mg
48651940|NCT04781972|DRUG|Placebo|Matching placebo
47974898|NCT02876354|DRUG|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
47974899|NCT02817191|DRUG|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
47974900|NCT02817191|DRUG|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
47974901|NCT01442675|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
48332274|NCT02146833|DRUG|Selinexor|Comparison of different dosages and dosing schedules of drug.
48332275|NCT04359342|DIETARY_SUPPLEMENT|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
48492546|NCT04622397|DRUG|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
48492547|NCT04622397|DRUG|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
48492548|NCT03500653|DIETARY_SUPPLEMENT|Curcumin|4 gr curcumin
48492549|NCT03500653|DIETARY_SUPPLEMENT|Placebo|4 gr placebo
48492550|NCT03340064|DRUG|Levetiracetam|levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
48492551|NCT00968760|PROCEDURE|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
48651941|NCT03907891|BEHAVIORAL|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
47974902|NCT00673465|DRUG|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
48492552|NCT00968760|PROCEDURE|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
48125381|NCT03210454|OTHER|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
48332276|NCT04359342|DIETARY_SUPPLEMENT|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
48125382|NCT01074294|DRUG|OPDC-34712|OPDC-34712 tablets, daily, Orally.
48332277|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
48125383|NCT01074294|DRUG|Placebo|Matching-placebo tablets, daily, Orally.
48125384|NCT01074294|DRUG|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
48125385|NCT05055752|DRUG|Pharmaceutical-lipid aspirin (PL-ASA)|Subjects receive the first drug, followed by a 7-day washout period, then receive the second drug.
48125386|NCT04654598|OTHER|BPA levels|BPA (bisphenol A) in urine, blood and follicle fluid samples
48125387|NCT00025610|DRUG|carboplatin|
48125388|NCT00025610|DRUG|cyclophosphamide|
48125389|NCT00025610|DRUG|doxorubicin hydrochloride|
48125390|NCT00025610|DRUG|etoposide|
48125391|NCT00025610|DRUG|vincristine sulfate|
48125392|NCT04589520|BEHAVIORAL|HeartBot App|HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
48125393|NCT00205179|DRUG|Novasoy|100mg/day soy isoflavones
48332278|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
48332279|NCT06415162|OTHER|Cooling Pillowcases|No intervention will be given to the patients in the control group.
48332280|NCT03129633|OTHER|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
48332281|NCT04532073|OTHER|Eurythmy Therapy|A mindfulness-oriented movement therapy
48125394|NCT00205179|DRUG|Placebo|100mg/day matching placebo
48125395|NCT05634382|DRUG|Intravenous thrombolysis agents|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA，alteplase) or TNK-tPA (Tenecteplase，Metalyse)
48332282|NCT04532073|OTHER|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
48332283|NCT04532073|OTHER|Standard Care|Treatment process that a clinician should follow for a certain type of patient
48332284|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
48332285|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
48332286|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
48332287|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
48332288|NCT00523653|OTHER|blood test|looking at DNA
48332289|NCT04913441|OTHER|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
48492553|NCT00968760|PROCEDURE|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
48125396|NCT05634382|PROCEDURE|endovascular thrombectomy|endovascular mechanical thrombectomy with nonspecific device
48125397|NCT06387381|DRUG|68Ga-PSFA|Each subject receives a single intravenous injection of 68Ga-PSFA.
48125398|NCT01306786|DRUG|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
48125399|NCT01306786|DRUG|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
48125400|NCT04524494|OTHER|biopsy of intestinal tissue|4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)
48125401|NCT04524494|OTHER|blood draw|40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)
48125402|NCT04524494|OTHER|urine collection|Midstream Urine collection
48125403|NCT03636334|BEHAVIORAL|Computer-based decision support system|At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
48332290|NCT04913441|OTHER|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
48651942|NCT03907891|BEHAVIORAL|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
48651943|NCT03907891|BEHAVIORAL|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
48651944|NCT06644976|PROCEDURE|femoral neck CRIF|femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
48651945|NCT00804154|DRUG|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose-escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
47974903|NCT00673465|DRUG|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
48332291|NCT04913441|OTHER|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
48332292|NCT05551091|DIETARY_SUPPLEMENT|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
48332293|NCT01331720|DRUG|hMG-HP|
48332294|NCT04961086|OTHER|energy drink|An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
48332295|NCT02572011|OTHER|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
48332296|NCT00764946|DRUG|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
48332297|NCT03019705|OTHER|Observation|
48332298|NCT05491447|DRUG|BMX-010|Ointment
48125404|NCT02009215|DRUG|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
48332299|NCT05491447|DRUG|Placebo|Ointment
48332300|NCT00316654|BIOLOGICAL|Meningococcal C conjugate vaccine|
47974904|NCT00673465|DRUG|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
47974905|NCT04134013|DIETARY_SUPPLEMENT|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
47974906|NCT04134013|OTHER|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
48125405|NCT00533494|BEHAVIORAL|physician feedback (A)|Feedback information to physicians
48332301|NCT02171949|BIOLOGICAL|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
48332302|NCT01225172|DRUG|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
48332303|NCT01225172|DRUG|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
48332304|NCT04749576|DIETARY_SUPPLEMENT|saffron supplement for IBD|anti inflammatory effect
48492554|NCT00968760|DRUG|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
48492555|NCT00968760|DRUG|Carmustine|300 mg/m\^2 IV over 1 hour on Day -6
48492556|NCT00968760|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2
48492557|NCT00968760|DRUG|Cytarabine|200 mg/m\^2 by vein over 1 hour every 12 hours on Days -5 to -2.
48492558|NCT00968760|DRUG|Melphalan|140 mg/m\^2 IV over 30 minutes on Day -1
48492559|NCT02722148|DEVICE|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
48492560|NCT01524614|PROCEDURE|nasal mask|nasal mask use instead of face mask
48492561|NCT03318276|DRUG|SID142|SID142 is administrated to patients with PAD for 12 weeks
48492562|NCT03318276|DRUG|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
48492563|NCT00537927|PROCEDURE|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
48492564|NCT00679926|DRUG|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
48492565|NCT00376025|DIETARY_SUPPLEMENT|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
48492566|NCT00982449|OTHER|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
48492567|NCT00982449|OTHER|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
48332305|NCT02224638|DEVICE|TheraHoney HD|Honey
48332306|NCT02224638|DEVICE|SkinTegrity|Hydrogel
48332307|NCT03299036|DEVICE|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
48332308|NCT02889757|DRUG|Acteylcysteine|randomized into three arms
48332309|NCT01691287|BEHAVIORAL|Michael Method|
48332310|NCT01081717|DRUG|systemic non-biological treatments|as prescribed
48332311|NCT01081717|BIOLOGICAL|anti-TNF biologics|as prescribed
48332312|NCT01081717|BIOLOGICAL|golimumab|as prescribed
48125406|NCT02035631|BEHAVIORAL|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
48332313|NCT01081717|BIOLOGICAL|non-anti-TNF biologics|as prescribed
48332314|NCT01081717|OTHER|general population|non-treated cohort
48332315|NCT03182127|RADIATION|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
48332316|NCT03182127|DEVICE|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
48332317|NCT05752071|DEVICE|Gastric electric pacemaker|Mounting of a temporary gastric pacemaker
48332318|NCT02501837|DRUG|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
48332319|NCT01601951|OTHER|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
48332320|NCT01319279|DRUG|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
48125407|NCT02035631|BEHAVIORAL|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
48332321|NCT02825147|DRUG|Pegaspargase|
48332322|NCT02825147|DRUG|Methotrexate|
48332323|NCT02825147|DRUG|Dexamethasone|
48332324|NCT02825147|DRUG|Etoposide|
48332325|NCT02825147|RADIATION|radiotherapy|
48332326|NCT02467855|OTHER|No Intervention|No intervention was administered in this study.
48125408|NCT02035631|BEHAVIORAL|Minimal diet intervention|Some basic diet recommendations
48332327|NCT05453448|DRUG|tenofovir alafenamide|Antiviral therapy
48332328|NCT05453448|DRUG|Entecavir|entecavir
48332329|NCT01634945|DRUG|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
48332330|NCT01634945|DIETARY_SUPPLEMENT|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
48332331|NCT01634945|DRUG|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
48332332|NCT01634945|DIETARY_SUPPLEMENT|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
48332333|NCT01634945|OTHER|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
48332334|NCT00516412|DRUG|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
48332335|NCT00516412|GENETIC|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
48332336|NCT03522194|DRUG|Sevoflurane|Anesthesia maintenance with Sevoflurane
48332337|NCT03522194|DRUG|Propofol|Anesthesia maintenance with Propofol
48332338|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
48332339|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
48332340|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
48332341|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
48332342|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
48332343|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
48332344|NCT01367314|DRUG|NVC-422|Dermal Gel applied 3 times per day for 7 days
48332345|NCT02030665|BEHAVIORAL|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
48332346|NCT02030665|BEHAVIORAL|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
48332347|NCT02030665|BEHAVIORAL|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
48332348|NCT04374266|DIAGNOSTIC_TEST|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
48332349|NCT00812240|DRUG|Masitinib|
48332350|NCT00812240|DRUG|Imatinib|imatinib 400 mg or 600 mg per day, per os
48332351|NCT02223429|DRUG|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
48332352|NCT02223429|DRUG|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
48332353|NCT02223429|DRUG|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
48332354|NCT00004938|DRUG|fluconazole|
48332355|NCT05444985|OTHER|Pain Management|Regional anesthetic techniques for peri-operative pain management after surgery.
48332356|NCT03111342|DRUG|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
48332357|NCT03111342|PROCEDURE|Dry-needling|A placement of thin needle into the cervix without substance injection
48332358|NCT01847261|DIETARY_SUPPLEMENT|Soy Dairy Protein Blend|
48332359|NCT01847261|DIETARY_SUPPLEMENT|Positive Control (Dairy Whey Protein)|
48651946|NCT01460277|PROCEDURE|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
48332360|NCT00397878|DRUG|saracatinib|Given orally
48125409|NCT02035631|BEHAVIORAL|Minimal physical activity intervention|Some basic recommendations on physical activity
48651947|NCT01460277|PROCEDURE|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
48651948|NCT06402721|DRUG|BAY3283142|Single oral dose.
48125410|NCT05178459|DIAGNOSTIC_TEST|Neuropathy measurement|Patient will step on Withings WBS08 and on the Sudoscan to get their sudomotor dysfunction caused by the neuropathy evaluated.
48332361|NCT00397878|OTHER|laboratory biomarker analysis|Correlative studies
48332362|NCT06055127|PROCEDURE|osseodensifiction internal sinus lift / sticky bone graft material|"The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing."
48332363|NCT06055127|PROCEDURE|piezoelectric internal sinus lift / sticky bone graft material|"In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field."
48492568|NCT02133586|OTHER|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
48492569|NCT02133586|OTHER|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
48651949|NCT06640322|OTHER|Reliability and validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Non-specific Neck Pain
47974907|NCT04818398|DRUG|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
48492570|NCT03772431|OTHER|Female Voice|The survey was narrated by a female voice
48651950|NCT05737706|DRUG|MRTX1133|KRAS G12D Inhibitor
48651951|NCT02489617|OTHER|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
48651952|NCT05023902|OTHER|Pilates|Pilates has been performed to all participants two times a week in order to compare the effects of NIA
48651953|NCT05023902|OTHER|Neuromuscular Integrative Action|NIA was the experimental group of this study.
48125411|NCT03500393|BEHAVIORAL|Remotely Supervised Exercise (REM)|REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
48332364|NCT03954977|DIAGNOSTIC_TEST|PICC line ultrasound|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
48332365|NCT01329289|DRUG|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
48332366|NCT01329289|DRUG|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
48332367|NCT01329289|DRUG|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
48332368|NCT01340391|DEVICE|Omnicast|dorsal splint 2-5 weeks
48332369|NCT00603213|PROCEDURE|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
48332370|NCT03009240|DRUG|Decitabine|Given IV
48332371|NCT03009240|OTHER|Laboratory Biomarker Analysis|Correlative studies
48332372|NCT03009240|DRUG|Pevonedistat|Given IV
48492571|NCT03772431|OTHER|Motivational Introduction|The survey introduction was worded to include motivational content
48651954|NCT05272774|BEHAVIORAL|FOREST+|The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.
48651955|NCT04315922|DIAGNOSTIC_TEST|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
48651956|NCT03878602|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
48651957|NCT03878602|PROCEDURE|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
48651958|NCT03034811|DEVICE|Persona Partial Knee system|Fixed bearing partial knee
48125412|NCT03500393|BEHAVIORAL|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
48125413|NCT02007590|DEVICE|Aerosure 25 Hz|Active Aerosure device
48125414|NCT02007590|DEVICE|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
48125415|NCT00000234|DRUG|Buprenorphine|
48125416|NCT03017625|OTHER|Blood is drawn|Blood analyses
48332373|NCT03009240|OTHER|Pharmacological Study|Correlative studies
48332374|NCT05321095|DIAGNOSTIC_TEST|Albuminuria test|During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
48332375|NCT05321095|DIAGNOSTIC_TEST|HbA1c test|During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
48332376|NCT05321095|DIAGNOSTIC_TEST|Creatinine test|During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).
48332377|NCT00829127|DRUG|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
48492572|NCT03772431|OTHER|Male Voice|The survey was narrated by a male voice
48492573|NCT03772431|OTHER|Informational Introduction|The survey introduction was worded to include informational content
48651959|NCT01531036|DEVICE|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
48651960|NCT03380273|BEHAVIORAL|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~1. Antibiotic prophylaxis~2. Perioperative antibiotics~3. Oxygen administration~4. Patient temperature~5. Surgeon protective wear~6. Patient operative skin preparation~7. Suction drains~8. Blood glucose level~9. Red cell transfusion~10. Dressing changes"
48651961|NCT06132308|PROCEDURE|PENG Block with 0.25% bupivacaine|Peng block was performed.
48651962|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.4 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
48651963|NCT04424251|DRUG|Experimental: stage I：HSK21542 1 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
48651964|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
48651965|NCT04424251|DRUG|Experimental: stage I：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
48651966|NCT04424251|DRUG|Experimental: stage II：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
48651967|NCT04424251|DRUG|Experimental: stage II：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
48651968|NCT04424251|DRUG|Placebo|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
48651969|NCT03800901|OTHER|Continuing Medical Education|CME or ABIM MOC credits
48125417|NCT00412308|PROCEDURE|Tidal volume used in mechanical ventilation|
48332378|NCT00829127|DRUG|Placebo|Oral suspension
48332379|NCT05108688|DRUG|Mirtazapine|Mirtazapine 30 mg tablet once daily for 3 successive days
48492574|NCT01874795|DEVICE|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
48492575|NCT01874795|DEVICE|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
48492576|NCT06420791|OTHER||
48492577|NCT05960240|DRUG|AB-101|AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
48492578|NCT05960240|DRUG|Placebo|A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
48492579|NCT05960240|DRUG|Nucleos(t)ide Analogue|Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
48125418|NCT02808767|DRUG|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
48332380|NCT05108688|DRUG|Sumatriptan|Sumatriptan 50 mg tablet once daily for 3 successive days
48332381|NCT05108688|OTHER|Placebo|Placebo tablets once daily for 3 successive days.
48492580|NCT00002321|DRUG|Aldesleukin|
48492581|NCT02900963|OTHER|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
48492582|NCT05600504|OTHER|no intervention|no intervention
48492583|NCT02011750|DRUG|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
48651970|NCT03800901|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control."
48651971|NCT06325852|OTHER|DBS programing|The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
48332382|NCT05304819|DEVICE|AchilloCordPLUS™ System Implant|AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
48332383|NCT02535078|DRUG|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
48332384|NCT04902898|DEVICE|Circumcision in adults using sterile single-use circular stapling device|Circumcision in adults using sterile single-use circular stapling device CIRCCURER II (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
48332385|NCT04902898|PROCEDURE|Circumcision in adults|Circumcision in adults
48332386|NCT06418334|DIAGNOSTIC_TEST|Thoracal hyperkyphosis study form|Thoracal hyperkyphosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
48332387|NCT06418334|DIAGNOSTIC_TEST|Scoliosis graphy|Patients whose forward bending test and clinical evaluation results are compatible with hyperkyphosis and scoliosis radiographs are requested. Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
48332388|NCT06418334|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help participant healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
48332389|NCT06418334|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter-cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
48332390|NCT03538132|OTHER|dental regenerative techniques|dental regenerative techniques
48332391|NCT01752972|DIETARY_SUPPLEMENT|Spirulina|10 g/day orally for 12 weeks
48332392|NCT02448004|DRUG|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
48332393|NCT05730257|PROCEDURE|Robot-Assisted Kidney Transplantation|Robot-Assisted Kidney Transplantation takes place with the patient under general anaesthesia. Several ports are placed in the lower abdomen, for the entry of the camera, surgical instruments and manuel access. The DaVinci robot is placed between the patient's legs and docked to the ports. The iliac vascular bed is prepared and a peritoneal cavity created laterally. The kidney is introduced through the handport, regional hypothermia obtained via iceslush in the cavity and the vessel lumens flushed with heparin. The vessels are blocked during suturing with the kidney graft vessels anastomosed end-to-side to the external iliac vessels. The kidney graft is placed in the retroperitoneal cavity and a ureterovesical anastomosis performed ad modem Woodruff over double J stent. The ureter is placed extra peritoneally, fascia closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
48332394|NCT05730257|PROCEDURE|Open Kidney Transplantation|Open Kidney Transplantation takes place with the patient under general anaesthesia. A jockey-stick (Gibson) incision is made in the left or right iliac fossa and the peritoneum is displaced. With the kidney under hypothermia, the iliac vascular bed is prepared, the vessel lumens flushed with heparin and a vascular clamp instrument is used to block the vessels during suturing. The kidney graft vessels are anastomosed end-to-side to the external iliac vessels and the ureterovesical anastomosis performed ad modem Woodruff over a double J stent. The kidney graft is placed in the cavity and the fascia is closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
48332395|NCT04693520|DRUG|ALZ-801|ALZ-801 265 mg twice daily (BID)
48492584|NCT02011750|DRUG|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
48492585|NCT00532818|DRUG|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
48492586|NCT00532818|DRUG|Placebo|Cisplatin + Topotecan plus placebo
48492587|NCT00334061|DEVICE|Penumbra System|
48332396|NCT05409768|PROCEDURE|Short axis out of plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance short axis visualisation out of plane approaches.
48332397|NCT05409768|PROCEDURE|Anteroposterior short axis in plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance anteroposterior short axis visualisation in plane approaches.
48332398|NCT00879437|DRUG|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
48332399|NCT00879437|DRUG|Bevacizumab|All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
48332400|NCT00879437|RADIATION|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
48332401|NCT05186987|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
48332402|NCT05186987|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
48332403|NCT02700919|DRUG|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
48332404|NCT02700919|DRUG|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
48332405|NCT00408759|BEHAVIORAL|hypnosis|
48332406|NCT06229587|PROCEDURE|furlow with buccinator flap|Assessment of speech and the middle ear function of patients between the age of 3 and 7 years surgically treated by ARC (Furlow z-palatoplasty with a buccinator myomucosal flap) was done
48332407|NCT02573233|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
47974908|NCT04818398|DRUG|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
47974909|NCT01104350|OTHER|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~* Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~* Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~* Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
47974910|NCT03954236|DRUG|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
47974911|NCT03954236|OTHER|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
48125419|NCT02808767|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
48125420|NCT03338868|OTHER|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
48125421|NCT03338868|OTHER|Physical activity level|assessed by the International Physical Activity Questionnaire-7
48125422|NCT03338868|OTHER|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
48332408|NCT02573233|DRUG|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
48332409|NCT02573233|DRUG|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
48332410|NCT02573233|DRUG|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
48332411|NCT02573233|DRUG|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
47974912|NCT03057431|DRUG|Placebo oral capsule|Once daily for 3 years
47974913|NCT03057431|DRUG|12.5 mg hydrochlorothiazide|Once daily for 3 years
47974914|NCT03057431|DRUG|25.0 mg hydrochlorothiazide|Once daily for 3 years
47974915|NCT03057431|DRUG|50.0 mg hydrochlorothiazide|Once daily for 3 years
47974916|NCT04541862|OTHER|Intensive care|intensive care for critically ill patients in the intensive care units
48125423|NCT03338868|OTHER|Quality of life|assessed by the Nottingham Health Profile
48125424|NCT03338868|OTHER|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
48125425|NCT03338868|DIAGNOSTIC_TEST|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
48125426|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 250 mg IM Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
48125427|NCT04183452|DRUG|17-Hydroxyprogesterone Caproate 275 mg SC Dose|17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
48125428|NCT02799134|DRUG|Dexamethasone|
48125429|NCT02799134|DRUG|Vitamin C|
48332412|NCT00648661|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
48332413|NCT00648661|DRUG|Lexapro® Tablets 20 mg|20mg, single dose fed
48332414|NCT04225884|OTHER|DTx for pain software|Software with active intervention
48332415|NCT04225884|OTHER|Control software|Software without active intervention
48332416|NCT04225884|OTHER|Standard care|Pain medication
48332417|NCT01440907|OTHER|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
48125430|NCT03807661|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
48332418|NCT05568927|OTHER|SEARCH algorithm|The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
48332419|NCT04261049|DRUG|Triamcinolone Acetonide Extended-Release Injectable Suspension|A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
48332420|NCT00801138|DRUG|saline|2 ml 0.9% saline (placebo)
48332421|NCT00801138|DRUG|Dexamethasone|dexamethasone 8 mg (2 ml)
48332422|NCT00801138|DRUG|ropivacaine|30 ml 0.5% ropivacaine
48492588|NCT03058653|PROCEDURE|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
48492589|NCT03058653|DEVICE|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
48492590|NCT00879892|DRUG|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
48492591|NCT00879892|OTHER|Hypothermia|24 hour, target core temperature 33
48492592|NCT04727437|OTHER|No treatment|Withholding anticoagulation for at least 3 months.
48492593|NCT04727437|DRUG|Warfarin|anticoagulation drug given for at least 3 months.
48125431|NCT03807661|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
48492594|NCT04727437|DRUG|direct oral anticoagulants|anticoagulation drug given for at least 3 months.
48651972|NCT06123676|DEVICE|Y90-PET-CT scan|40 min extra PET-CT scan - no extra injection of radiotracer. We image the Y90-microspheres administered to these patients during the therapy
48651973|NCT06380504|BEHAVIORAL|R-SWITCH integrated intervention package|"1. Monthly group meetings of Alliance for Development (AFD) community groups) and their members (caregivers of children 0-59 months of age):~   * Introduction and refresher of Family-led MUAC~  * Active screening of wasting by AFD~  * Group SBCC on Infant and Young Child Feeding (IYCF), health and Water, Sanitation and Hygiene (WaSH) with a focus on SAM~  * Promotion of health services such as GMP~2. Introduction of weight-for-age Z-score \<-3 as screening criterion for passive screening by health extension workers at any contact with children (e.g. during GMP)~3. Promotion of Family-led MUAC screening and SAM awareness to fathers during male agricultural/pastoralist extension activities and by community and religious leaders (creating social support)~4. Follow-up and counselling during home visits by AFD leaders of i) earlier referred cases of SAM, ii) cases enrolled in SAM OTP, iii) and recovered SAM cases discharged from OTP~5. Strengthening communication between HEW and AFDs"
48651974|NCT01585207|DRUG|vigabatrin|3 tablets, bid for 8 weeks
48125432|NCT02376244|OTHER|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
48125433|NCT02376244|OTHER|Standard care|Standard care cardiac rehabilitation according to current guidelines
48332423|NCT00801138|DRUG|Bupivacaine|30 ml 0.5% bupivacaine
48332424|NCT05666440|PROCEDURE|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.|A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.
48332425|NCT05666440|PROCEDURE|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.|A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
48332426|NCT05892263|OTHER|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
48332427|NCT02650297|OTHER|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
48332428|NCT02650297|DEVICE|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
48492595|NCT04727437|DRUG|Low molecular weight heparin|anticoagulation drug, subcutaneous injection given for at least 3 months.
48332429|NCT03922893|OTHER|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
48125434|NCT05607823|OTHER|Core Stabilization Training|Core Stabilization training will be based on dynamic neuromuscular stabilization and consists of three stages. In the first session, it is to teach the simultaneous activation of the transversus abdominis, pelvic floor, multifidus and diaphragm muscles and to improve muscle coordination and proprioception in the entire spinal region. In the second and third phases, exercises will be made more intense to improve muscular endurance and stability. The difficulty of the exercises will be increased by working in different positions, using resistance bands, exercise balls and body weight, and adding movements to the extremities. A total of 10 sessions of treatment program will be applied to the patients for ten weeks, once a week.
48332430|NCT03922893|GENETIC|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
48332431|NCT03922893|GENETIC|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
48332432|NCT03922893|OTHER|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
48332433|NCT03661892|DRUG|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
48332434|NCT00588887|DEVICE|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
48332435|NCT00588887|DEVICE|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
48492596|NCT05054218|BIOLOGICAL|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
48492597|NCT03511170|DRUG|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
48492598|NCT03511170|DRUG|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
48332436|NCT03943173|DRUG|Chemotherapy|Given standard chemotherapy
48332437|NCT03943173|DRUG|Olaparib|Given PO
48492599|NCT06048666|BIOLOGICAL|Intra ovarian by platelet rich plasma|On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
48492600|NCT03421808|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS
47974917|NCT05833191|DEVICE|Auricular vagus stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
47974918|NCT05833191|DEVICE|Tibial Nerve Stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
47974919|NCT05227027|BEHAVIORAL|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
47974920|NCT05227027|BEHAVIORAL|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
47974921|NCT02312661|DRUG|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
47974922|NCT02312661|DRUG|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
47974923|NCT02312661|DRUG|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
47974924|NCT04650360|BEHAVIORAL|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
48332438|NCT03943173|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48332439|NCT01925612|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
48332440|NCT01925612|DRUG|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
48332441|NCT01925612|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
48332442|NCT01925612|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
48332443|NCT01925612|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
48332444|NCT01925612|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
48332445|NCT01925612|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
48332446|NCT06253234|BIOLOGICAL|personalized dendritic cell injection ZSNeo-DC1.1|Sequence A: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 3 weeks as a dosing cycle, a total of 6 dosing cycles Sequence B: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 2 weeks as a dosing cycle, a total of 6 dosing cycles
48332447|NCT01541501|DEVICE|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
48125435|NCT05607823|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
48332448|NCT05824455|COMBINATION_PRODUCT|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
48332449|NCT01693718|DRUG|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
48332450|NCT01693718|DRUG|5- Fluorouracil|"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.~Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."
48492601|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
48492602|NCT03090997|DIETARY_SUPPLEMENT|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
48492603|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
48492604|NCT03457649|BIOLOGICAL|ARGX-113|
48492605|NCT03457649|BIOLOGICAL|Placebo|
48492606|NCT00704730|DRUG|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
48492607|NCT00704730|DRUG|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
48492608|NCT03214341|RADIATION|MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses
48651975|NCT03226665|DIAGNOSTIC_TEST|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.~Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.~This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
48651976|NCT02946983|OTHER|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
48332451|NCT01693718|DRUG|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output \> 100 cc/ hour.
48332452|NCT04586556|DIAGNOSTIC_TEST|Polyps detection by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
48332453|NCT03748485|BEHAVIORAL|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
48332454|NCT03748485|DRUG|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
48332455|NCT01998438|DRUG|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
47974925|NCT00313391|DRUG|Risperdal Consta|
47974926|NCT03750799|DEVICE|Whole body vibration|Whole body vibration was applied on the right lower extremity in the experimental group.
47974927|NCT03750799|DEVICE|Sham vibration|Sham vibration was applied on the right lower extremity in the Control sham group
47974928|NCT01914198|OTHER|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
48492609|NCT05865080|DRUG|Ketamine|0.3 mg/kg of ketamine IV diluted to 10 ml followed by infusion 0.1 mg/kg/hr. as 20 ml solution before spinal anesthesia
48492610|NCT05865080|DRUG|Placebo|Normal saline
48492611|NCT00003174|DRUG|bryostatin 1|
48492612|NCT00003174|DRUG|cladribine|
48492613|NCT04229524|PROCEDURE|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least\> 30.
48492614|NCT05980286|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 16 weeks.
48492615|NCT05980286|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 16 weeks.
48492616|NCT03763552|OTHER|arthroscopic wrist arthrodesis|Cases of midcarpal wrist arthritis treated surgically with arthroscopic partial wrist fusion with cannulated screws
48651977|NCT02946983|OTHER|Control|Intragastric administration of distilled water
47974929|NCT00928603|PROCEDURE|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
48492617|NCT03796039|BEHAVIORAL|Standing|Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
48651978|NCT04804033|DRUG|BHV-3500 (zavegepant)|BHV-3500 (zavegepant) softgel capsule.
48651979|NCT04804033|DRUG|Placebo|Matching placebo softgel capsule.
48651980|NCT01229202|DRUG|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
48651981|NCT02254460|DIETARY_SUPPLEMENT|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
48651982|NCT02254460|OTHER|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
48651983|NCT05571514|DIETARY_SUPPLEMENT|Mother-of-pearl|"The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation."
48651984|NCT05571514|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate is a source of calcium.
48651985|NCT03554330|OTHER|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
48651986|NCT03554330|OTHER|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
48651987|NCT05174169|DEVICE|Signatera test|Central ctDNA testing for all patients
48651988|NCT05174169|DRUG|mFOLFOX6 3-6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles
48125436|NCT05607823|OTHER|Conventional Physiotherapy|Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.
48492618|NCT00208806|OTHER|congestive heart failure patients|observational echo data on congestive heart failure patients
48492619|NCT05886452|DEVICE|DT1fA contact lenses|Subjects will be fitted with DT1fA contact lenses
48651989|NCT05174169|DRUG|CAPOX 3 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
48651990|NCT05174169|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
48651991|NCT05174169|DRUG|mFOLFOX6 6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
48651992|NCT05174169|DRUG|CAPOX 6 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
48651993|NCT01582581|BEHAVIORAL|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
48651994|NCT01582581|BEHAVIORAL|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
48651995|NCT06506513|OTHER|High-intensity interval training|High-intensity interval training
48651996|NCT06506513|OTHER|Moderate intensity exercise training|Moderate intensity exercise training
48651997|NCT06506513|OTHER|Low intensity exercise training|Low intensity exercise training
48651998|NCT01548326|DRUG|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
48651999|NCT01548326|DRUG|placebo|one Placebo tablet orally per day for 10 days
48652000|NCT00637156|DEVICE|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
48652001|NCT00637156|DEVICE|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
48652002|NCT03523585|DRUG|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
48652003|NCT03523585|DRUG|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
48652004|NCT03523585|DRUG|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
47974930|NCT06093698|BIOLOGICAL|Recombinant Anti-EpCAM-CD3 Antibody Injection|Intravenous Infusion
47974931|NCT04478955|DIAGNOSTIC_TEST|Schirmer test|Tear tests Meibomian gland grading test
48492620|NCT01338649|DEVICE|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
48652005|NCT03523585|DRUG|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
48652006|NCT05836025|DRUG|Rapamycin|5mg/week of rapamycin orally for 12 weeks
48125437|NCT04629625|BIOLOGICAL|End-range mobilization|End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension
48125438|NCT04629625|BIOLOGICAL|Non end-range mobilization|Non end-range mobilization performed in tibiofemoral joints' loose position
48125439|NCT04629625|BIOLOGICAL|Placebo|Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
48125440|NCT03753308|BIOLOGICAL|Blood Sampling|5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
48125441|NCT03753308|BIOLOGICAL|Liver biopsy|"The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is\> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen"
48125442|NCT03068624|BIOLOGICAL|Aldesleukin|Given SC
48125443|NCT03068624|BIOLOGICAL|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion via central catheter
48125444|NCT03068624|DRUG|Cyclophosphamide|Given IV
48125445|NCT03068624|BIOLOGICAL|Ipilimumab|Given IV
48125446|NCT04219215|DEVICE|100% O2 in oxygen chamber|Application of 100% O2 in an hyperbaric oxygen chamber
48125447|NCT04219215|DEVICE|21% O2 in oxygen chamber|Application of ambient air (21% O2) in an hyperbaric oxygen chamber
48492621|NCT01338649|DEVICE|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
48652007|NCT05836025|OTHER|Placebo|5mg/week of placebo orally for 12 weeks
48125448|NCT03591159|OTHER|Membran Sweeping|Cervical Membrane Sweeping by digital examination
48125449|NCT04834141|OTHER|FlexiCurve ruler method to assess thoracic kyphosis angle|The determination that the effect of thoracic kyphosis posture on trunk biomechanical alignment may be related to balance may contribute to new treatment recommendations in this area. The aim of this study is to investigate whether the thoracic kyphosis posture has an effect on static balance.
48125450|NCT01595789|DRUG|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
48125451|NCT01595789|DRUG|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
48652008|NCT06673992|OTHER|This study does not involve any interventions|This study does not involve any interventions
48125452|NCT04164940|OTHER|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
48125453|NCT04453332|DRUG|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
48125454|NCT04453332|DRUG|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
48125455|NCT00634075|DRUG|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
48125456|NCT00634075|DRUG|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
48125457|NCT06409299|DRUG|Azithromycin 40 MG/ML|Maintenance Antibiotic treatment
48125458|NCT06409299|OTHER|Placebo|Placebo
48125459|NCT01650896|OTHER|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
48125460|NCT05384366|DRUG|Neoadjuvant chemotherapy|doublet of taxane and carboplatin
48125461|NCT01661569|OTHER|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
48125462|NCT01421836|PROCEDURE|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
48125463|NCT01421836|PROCEDURE|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
48492622|NCT02312713|BEHAVIORAL|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
48492623|NCT02312713|BEHAVIORAL|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
48652009|NCT02673060|DRUG|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
48125464|NCT02409667|BIOLOGICAL|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
48332456|NCT03579225|DEVICE|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
48332457|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 18 months.
48332458|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
48332459|NCT03807115|OTHER|Implementation of stroke mobility guidelines|Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
48492624|NCT03034655|DEVICE|CDP|Vestibular rehabilitation using CDP
48492625|NCT03034655|DEVICE|Mobile posturography|Vestibular rehabilitation using mobile posturography
48492626|NCT03034655|OTHER|10 sessions|Vestibular rehabilitation, ten sessions
48492627|NCT03034655|OTHER|5 sessions|Vestibular rehabilitation, five sessions
48492628|NCT04713098|DEVICE|Peripheral Nerve Stimulation|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
48492629|NCT04713098|DEVICE|Sham|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
48492630|NCT01150617|DRUG|Insulin glargine plus insulin analogues|"* Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up."
48492631|NCT00254852|PROCEDURE|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
48492632|NCT00254852|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
48492633|NCT00254852|PROCEDURE|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
48492634|NCT00254852|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
48492635|NCT00254852|PROCEDURE|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
48652010|NCT01917370|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
48652011|NCT00167531|BEHAVIORAL|treadmill walking with partial weight support|
48652012|NCT00167531|BEHAVIORAL|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
48652013|NCT04426357|DRUG|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
48125465|NCT00000936|DRUG|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
48125466|NCT00000936|DRUG|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
48125467|NCT00000936|DRUG|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
48125468|NCT00198315|COMBINATION_PRODUCT|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
48492636|NCT04625595|DRUG|350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
48492637|NCT04625595|DRUG|700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
48492638|NCT04625595|DRUG|1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
48492639|NCT04625595|DRUG|1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule|Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily
48492640|NCT05611450|OTHER|disease self-management application|The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
48652014|NCT01992939|OTHER|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
48332460|NCT04319406|PROCEDURE|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
48332461|NCT04319406|PROCEDURE|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
48332462|NCT04368468|OTHER|biomarker evolution|analysis of a list of biomarkers on triple negative breast tumors samples before and after neoadjuvant therapy
48125469|NCT00198315|PROCEDURE|Tumor surgical excision|Patients have their tumor surgically removed.
48652015|NCT01992939|OTHER|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
48332463|NCT06335498|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
48332464|NCT06335498|DEVICE|Periodic ECG triggered measurement|Subject triggers AFGen1 to perform an extended measurement during wear period
48332465|NCT01856842|PROCEDURE|Angiography and embolotherapy|
48332466|NCT00865189|DRUG|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
48332467|NCT00865189|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m\^2) as a 2-hour IV infusion.
48332468|NCT00865189|DRUG|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m\^2 as a 2-hour infusion.
48332469|NCT00865189|DRUG|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m\^2 as an IV bolus, then at a dose of 600 mg/m\^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m\^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
48332470|NCT00865189|RADIATION|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
48332471|NCT00865189|PROCEDURE|Surgery|Radical rectal excision based on the TME technique.
47974932|NCT02209389|DEVICE|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
47974933|NCT01340898|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
47974934|NCT01340898|BIOLOGICAL|SynflorixTM|Intramuscular injection
48332472|NCT01726283|DEVICE|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
48652016|NCT01706315|DRUG|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
48652017|NCT01706315|DRUG|Placebo|Matching placebo will be available
48652018|NCT03379584|DRUG|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
47974935|NCT01340898|BIOLOGICAL|Infanrix-IPV/HiberixTM|Intramuscular injection
47974936|NCT00165776|DRUG|BOTULINUM TOXIN TYPE B|
47974937|NCT06327347|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
47974938|NCT02687945|PROCEDURE|Outpatient physiotherapy|
47974939|NCT02687945|PROCEDURE|Self-guided physiotherapy|
47974940|NCT03501069|DRUG|TAK-418|TAK-418 capsules.
47974941|NCT03501069|DRUG|TAK-418 Matching Placebo|TAK-418 matching placebo capsules.
47974942|NCT00646776|DRUG|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
47974943|NCT00646776|DRUG|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
47974944|NCT06058481|DEVICE|Blockbuster|The investigator inserted the BlockBuster in Group A patients.
47974945|NCT06058481|DEVICE|Proseal-LMA|The investigator inserted the Proseal-LMA in Group B patients.
48125470|NCT00544752|OTHER|16|indoor temperature of 16 degrees celcius
48125471|NCT00544752|OTHER|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
48125472|NCT00544752|OTHER|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
48332473|NCT01726283|DRUG|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
48332474|NCT04097015|DEVICE|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
48332475|NCT00633308|DEVICE|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
48332476|NCT01709981|DRUG|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
48332477|NCT01709981|DRUG|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
48332478|NCT05275296|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
48332479|NCT01135017|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
48332480|NCT01135017|DRUG|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
48332481|NCT05053126|DRUG|Pregabalin 300mg|Participant will receive an oral dose of pregabalin 300 mg
48332482|NCT05053126|DRUG|pregabalin 450 mg|Participant will receive an oral dose of pregabalin 450 mg
48332483|NCT05053126|DRUG|Pregabalin 300 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
48652019|NCT00023972|DRUG|exatecan mesylate|
48652020|NCT00023972|DRUG|gemcitabine hydrochloride|
48652021|NCT01772771|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva/buccal swab samples
48652022|NCT01772771|OTHER|Genetic Testing|Correlative studies
48652023|NCT01772771|OTHER|Medical Chart Review|Review of medical records
48652024|NCT05462496|PROCEDURE|Biopsy|Pre-treatment tumor biopsy
48125473|NCT01337622|PROCEDURE|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
47974946|NCT01155232|DRUG|Teriparatide|Forteo (teriparatide)pen daily for 24 months
48125474|NCT01337622|PROCEDURE|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
47974947|NCT04540601|OTHER|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
47974948|NCT02231723|DRUG|BBI608|Administered continuously twice daily with doses separated by 12 hours
47974949|NCT02231723|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
47974950|NCT02231723|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
47974951|NCT02231723|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
47974952|NCT02231723|DRUG|Leucovorin|Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
47974953|NCT02231723|DRUG|Irinotecan|Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
47974954|NCT02231723|DRUG|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
47974955|NCT02231723|DRUG|MM-398|MM-398 70 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
47974956|NCT01874054|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
48125475|NCT00308997|DEVICE|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
47974957|NCT01874054|DRUG|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
47974958|NCT04448288|OTHER|Static stretching|Static stretchings were performed by subjects that involved varied repetitions of 30-s static-stretches and 20-s relax period.
47974959|NCT03940612|DIETARY_SUPPLEMENT|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
47974960|NCT03940612|DIETARY_SUPPLEMENT|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
47974961|NCT03656328|DIETARY_SUPPLEMENT|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
47974962|NCT03656328|DIETARY_SUPPLEMENT|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
47974963|NCT02945683|DIETARY_SUPPLEMENT|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
47974964|NCT02945683|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
47974965|NCT01777100|DRUG|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
47974966|NCT04849455|DRUG|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
47974967|NCT04849455|DRUG|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
47974968|NCT04849455|DRUG|Spinal Morphine|200-300 mcg of spinal morphine
47974969|NCT01138553|DRUG|Mifepristone|200mg capsules daily for 5-28 days
47974970|NCT00214708|PROCEDURE|Screening for Tuberculosis|
47974971|NCT00118963|DRUG|Metformin|Tablets of 500 mg; 1000 mg two times daily.
48125476|NCT00308997|DEVICE|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
48125477|NCT03394885|DRUG|Atezolizumab|1200mg IV q3weeks
48125478|NCT03394885|DRUG|Carboplatin|5-6mg/ML IV q3 weeks
48125479|NCT03394885|DRUG|Paclitaxel|70-80 mg/m2 IV q1 week
48125480|NCT03394885|DRUG|Bevacizumab|15 mg/kg IV q3 weeks
48332484|NCT05053126|DRUG|pregabalin 450 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
48332485|NCT05053126|DRUG|oxycodone 20 mg|Participant will receive an oral dose of oxycodone 20 mg
48125481|NCT05437952|DIETARY_SUPPLEMENT|Taurine and Exercise (Tau+Ex)|"Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks"
47974972|NCT00118963|DRUG|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
47974973|NCT00118963|DRUG|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
47974974|NCT00118963|DRUG|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
47974975|NCT00118963|DRUG|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
47974976|NCT04152161|BIOLOGICAL|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
48125482|NCT05437952|OTHER|Placebo and Exercise (PL+Ex)|"Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks."
48125483|NCT05437952|DIETARY_SUPPLEMENT|Taurine (Tau)|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
48125484|NCT05437952|OTHER|Placebo (PL)|Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
48125485|NCT02306954|BIOLOGICAL|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
48332486|NCT05053126|DRUG|Placebo|Participant will receive an oral dose of placebo
48332487|NCT01425749|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
48332488|NCT00129792|DRUG|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
48332489|NCT00129792|BEHAVIORAL|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
48332490|NCT03802656|DEVICE|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
48332491|NCT00851253|RADIATION|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
47974977|NCT04152161|BIOLOGICAL|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
47974978|NCT03903705|DRUG|Fruquintinib in Combination with Sintilimab|"Fruquintinib plus Sintilimab:~Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing~Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing~Fruquintinib monotherapy arm:~Fruquintinib 5 mg QD, oral dosing, 3 weeks on/1 weeks off~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
47974979|NCT02521636|OTHER|Antibiotic therapy randomization|
47974980|NCT02521636|OTHER|Serum PCT dosage|
47980536|NCT05984732|BEHAVIORAL|Reminiscence with digital storytelling|The older and young adult participants will be randomly assigned into the intervention (reminiscence) or control (social wellness) groups and then be randomly matched as dyads within each group. Older adults in the intervention group will receive 10 sessions of life-review with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). During weeks 1-6, a life history interview will be carried out with different themes in each week: major turning points in life (W1), family history (W2), life/career accomplishments (W3), history of loves and hates (W4), stress experiences (W5), and meaning and purpose of life (W6). During weeks 7-10, the dyads will develop the DST together using tablets already owned by the UTA School of Social Work. The contents of sessions 7-10 will be structured as: outline/script, plan and storyboard (W7), film and record (W8), evaluate, integrate and finalize (W9), and publish/share (W10).
48332492|NCT00284739|DRUG|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
48332493|NCT00284739|OTHER|saline|saline injection twice daily for three days
48332494|NCT05843812|DRUG|Magnesium Sulfate 10 MG/ML|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
48332495|NCT04751968|OTHER|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
48125486|NCT02306954|RADIATION|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
48652025|NCT05462496|DRUG|FOLFIRINOX|"Patients will receive FOLFIRINOX chemotherapy every 2 weeks for 5 cycles. One cycle of mFOLFIRINOX = 14 days.~Cycles of mFOLFIRINOX are delivered as follows\*:~* Oxaliplatin: 85 mg/m2 IV over 2 hours on Day 1, followed by,~* Irinotecan: 150 mg/m2 IV over 90 minutes on Day 1, followed by,~* Leucovorin\*\*: 400 mg/m2 IV over 2 hours on Day 1, followed by,~* 5FU: 2400 mg/m2 IV over 46-48 hours on Days 1-3"
48492641|NCT04061642|DEVICE|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
48652026|NCT05462496|DRUG|Ciprofloxacin|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer ciprofloxacin 500mg PO BID on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
48652027|NCT05462496|DRUG|Metronidazole|Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.
48652028|NCT05462496|DRUG|Pembrolizumab|Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.
48652029|NCT05462496|PROCEDURE|Surgical Resection|Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
48652030|NCT06311734|DRUG|LW231 tablets|P.O.
48652031|NCT06311734|DRUG|Placebo|P.O.
48652032|NCT03070834|DEVICE|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
48125487|NCT02213744|DRUG|MM-302|
48125488|NCT02213744|DRUG|Gemcitabine|
48125489|NCT02213744|DRUG|Capecitabine|
48332496|NCT04751968|BEHAVIORAL|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
48332497|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
48332498|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
48332499|NCT03428451|DRUG|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
48492642|NCT00626717|PROCEDURE|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
48492643|NCT00626717|PROCEDURE|Sham treatment|Fluorescein eye drops. Exposure with blue light
48492644|NCT01527084|PROCEDURE|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
48492645|NCT00914459|BIOLOGICAL|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
48652033|NCT05931835|DEVICE|VERAFEYE System|The VERAFEYE System will be used during standard of care, catheter-based treatments for atrial flutter or atrial fibrillation; or left atrial appendage/atrial septal defect closure procedures.
48652034|NCT06251973|BIOLOGICAL|AgenT-797|AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors
48652035|NCT06251973|BIOLOGICAL|Botensilimab|Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody
48652036|NCT06251973|DRUG|Balstilimab|Botensilimab is supplied as a sterile, single-use solution for IV administration
48125490|NCT02213744|DRUG|Vinorelbine|
48125491|NCT02213744|DRUG|Trastuzumab|
48125492|NCT00198146|DRUG|Zenapax|
48492646|NCT00914459|PROCEDURE|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
48492647|NCT01102374|DRUG|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
48125493|NCT04334746|OTHER|Balance measurement tools|Timed Up and Go Test Functional Reach Test One-leg Stance Test Berg Balance Scale
48125494|NCT01178034|GENETIC|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
48125495|NCT03898310|DIETARY_SUPPLEMENT|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
48125496|NCT03898310|DIETARY_SUPPLEMENT|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
48332500|NCT00274040|DRUG|Tiotropium|
48332501|NCT00274040|DRUG|Ipratropium|
48332502|NCT01039636|DRUG|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
48332503|NCT05247541|DRUG|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
48125497|NCT01655563|DRUG|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
47974981|NCT00587054|DRUG|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
47974982|NCT03068481|DRUG|KDT-3594|Oral administration
47974983|NCT03068481|DRUG|Placebo|Oral administration
47974984|NCT03158116|DRUG|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
48125498|NCT01294215|DRUG|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
48125499|NCT04784026|OTHER|Gait assessment (single)|The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.
48125500|NCT04784026|OTHER|Dual task gait assessment (motor+motor)|The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.
47974985|NCT03048968|PROCEDURE|Gait, sit-to-stand movement, stair climbing and treadmill gait|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
48125501|NCT04784026|OTHER|Dual tak gait assessment (motor+cognitive)|The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.
48332504|NCT03230513|OTHER|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
48332505|NCT03230513|OTHER|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
48332506|NCT01674192|DRUG|prucalopride|single dose of 2 mg prucalopride
48332507|NCT02209038|BEHAVIORAL|Expanded AD Choice|
48332508|NCT02209038|BEHAVIORAL|Expanded Life-sustaining Therapy Choice|
48332509|NCT04725539|PROCEDURE|hypoxic exposure|"Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m"
48332510|NCT00943254|OTHER|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
48332511|NCT00943254|OTHER|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
48332512|NCT05553912|BEHAVIORAL|QBSafe|an intervention comprised of (a) a set of conversation cards (QBSafe ASK) designed to enable patients to identify aspects of life with diabetes important to them and to share them with their clinician to obtain their input; and (b) materials that help clinicians respond to patient concerns.
48332513|NCT00456885|DRUG|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
48332514|NCT00456885|DRUG|Placebo|Twice daily injection of placebo
48332515|NCT03256071|DRUG|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
48492648|NCT01102374|DRUG|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
48492649|NCT01102374|DRUG|Placebo|Placebo monthly
47974986|NCT03048968|PROCEDURE|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
48125502|NCT02262767|DRUG|PF-06649751|Experimental Pfizer compound.
48332516|NCT03256071|DRUG|Modified BUCY|"1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
48332517|NCT03248050|BEHAVIORAL|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
48125503|NCT02262767|DRUG|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
48332518|NCT01322451|DRUG|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
48332519|NCT01322451|DRUG|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
48492650|NCT01102374|DIETARY_SUPPLEMENT|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
48492651|NCT04390659|PROCEDURE|myomectomy|The myomectomy was done by conventional technique but timing of myomectomy either before or after delivery of the baby varied between different cases .Infusion of oxytocin during the operation and for 24 h later.
48332520|NCT04746560|DEVICE|TEG®6S device with its Platelet mapping® cartridge|Platelet function monitoring using the TEG®6S device with its Platelet mapping® cartridge
48332521|NCT02433860|BEHAVIORAL|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately \> 36 weeks gestation or at delivery."
48332522|NCT06114004|DRUG|Selinexor 20 MG|After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor
48492652|NCT01745705|OTHER|Cervical Spine Manipulation|
48492653|NCT01745705|OTHER|Manual Contact|
48492654|NCT00018811|BEHAVIORAL|Relaxation training & thermal biofeedback|
48492655|NCT00018811|BEHAVIORAL|Surface EMG biofeedback|
48492656|NCT00771381|DRUG|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
47974987|NCT03048968|DEVICE|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
47974988|NCT03048968|DEVICE|treadmill|Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
47974989|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
47974990|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
47974991|NCT02061982|DIETARY_SUPPLEMENT|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
47974992|NCT02471430|DRUG|Panobinostat|Panobinostat will be administered orally.
48332523|NCT06114004|DRUG|Gemcitabine|Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
48492657|NCT00771381|DRUG|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
48492658|NCT05354830|OTHER|Foot Massage|Foot Massage
48492659|NCT02933970|OTHER|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
48492660|NCT00920517|BIOLOGICAL|rDEN2/4delta30(ME) vaccine|10\^3 PFU dose
48492661|NCT00920517|BIOLOGICAL|Placebo|placebo for rDEN2/4delta30(ME) vaccine
48492662|NCT00183937|DRUG|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
48492663|NCT00183937|DRUG|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
48492664|NCT02257294|DRUG|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
47974993|NCT02471430|DRUG|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
48125504|NCT06518369|OTHER|Prehabilitation|"Prehabilitation program for 4-6 weeks before surgery will include:~* Review of the frailty risk analysis calculator score obtained in the frailty study (#2212-74)~* Review of lab results including complete blood count, creatinine, albumin, and prealbumin~* Review of chronic conditions.~* An office visit or telehealth visit to review instructions on instructions on nutrition, exercise, smoking cessation, and optimization of chronic disease.~* Drinking surgery immunonutrition drinks twice daily for 5 days before surgery.~* Educational information and video instruction~* Weekly phone calls to motivate, ensure adherence, and assess progress.~* Measurements of hand grip strength and body weight"
48125505|NCT03749785|OTHER|Regular carbohydrate feeding|60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
48125506|NCT03749785|OTHER|Single carbohydrate bolus|60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
48125507|NCT03415360|PROCEDURE|cryoablation|cryoablation of nerve responsible for phantom limb pain
48125508|NCT01119313|DRUG|LAS 41002|LAS 41002, once daily
48125509|NCT01119313|DRUG|Active|Active, once daily
48125510|NCT06302920|DEVICE|Kinesiotape|Lymphatic correction technique
48125511|NCT04034771|DRUG|Melatonin 10 MG Oral Tablet|Melatonin tablets
48125512|NCT04034771|DRUG|Propofol|propofol amp
48125513|NCT04034771|DRUG|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
48125514|NCT01639131|DRUG|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
48125515|NCT01639131|DRUG|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
48125516|NCT01639131|DRUG|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
48125517|NCT05114967|OTHER|mPAS questionnaire|The modified Preoperative Anxiety Scale (mPAS) questionnaire as given in the article by Viola et al will be used after permission from the authors
48125518|NCT05783843|BEHAVIORAL|Pictorial Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
48332524|NCT01170312|BIOLOGICAL|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
48492665|NCT02257294|OTHER|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
47974994|NCT05655962|OTHER|STARS|STARS is a structured framework for assessment of rehabilitation and sicklisting, applied by primarily the rehabilitation coordinators working at the primary health care centers.
47974995|NCT05471778|BEHAVIORAL|Watching comedy movie|A 25-minute comedy film created by the researchers was watched.
47974996|NCT05471778|BEHAVIORAL|listening to music|25 minutes of music created by the researchers was played.
47974997|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
47974998|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
47974999|NCT00467571|DRUG|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
47975000|NCT03854305|DRUG|PRV-6527|Treatment
47975001|NCT03854305|DRUG|Placebo|Comparator
47975002|NCT03674749|OTHER|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
47975003|NCT03513562|DRUG|Ibrutinib|Given PO
47975004|NCT03513562|OTHER|Laboratory Biomarker Analysis|Correlative studies
47975005|NCT03513562|DRUG|Venetoclax|Given PO
47975006|NCT00284271|DRUG|Cyclophosphamide|
47975007|NCT00284271|DRUG|Adramycin|
47975008|NCT00284271|DRUG|Procarbacine|
48125519|NCT05783843|BEHAVIORAL|Text Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
48125520|NCT05783843|BEHAVIORAL|No Warnings (Control)|Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
48125521|NCT03722316|OTHER|Immersive Nature Video|"An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg-Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
48125522|NCT03722316|OTHER|Neutral Video|"This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., \<1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
48125523|NCT06288607|DEVICE|High intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China)|Patients are randomly assigned to be treated with high-intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) on one side, and the other side is not treated.Before treatment, patients are allowed to sign an informed consent form. Before and after treatment, the L\*a\*b\* values of the lesion area and the area around the lesion are detected using 3nh HIGH-QUALITY COLORMETER colorimeter (Konica-Minolta Company, Japan), and photos of the patient's treatment area and dermatoscope observation results are taken. Before treatment, a 2-3mm thick medical condensation gel is evenly applied on the face. During the process, D4.5+D3.0 transducer are used.
48125524|NCT02005406|DEVICE|Experimental group and control groupl|JET
48332525|NCT01170312|OTHER|Normal saline|Normal saline injection
48492666|NCT03227614|BEHAVIORAL|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
48492667|NCT00005918|DRUG|Efavirenz|
48492668|NCT00005918|DRUG|Lamivudine|
48492669|NCT00005918|DRUG|Stavudine|
47975009|NCT00284271|DRUG|Prednisone|
47975010|NCT00284271|DRUG|Vincristine|
47975011|NCT00284271|DRUG|Bleomycin|
47975012|NCT00284271|DRUG|Erythropoietin beta|
47975013|NCT05730751|PROCEDURE|spinal anesthesia|spinal anesthesia
48332526|NCT05767372|OTHER|Coherent Breathing Exercise|"Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths."
48125525|NCT03122236|BEHAVIORAL|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
48125526|NCT03122236|BEHAVIORAL|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
48332527|NCT05767372|DEVICE|Inspiratory muscle training|"The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~1. After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~2. Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~3. Progress slowly and monitor carefully.~4. As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~5. Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~6. Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~7. The session was repeated three times per week for 12 weeks."
48332528|NCT05507645|DRUG|Recombinant Human Prourokinase for Injection (rhPro-UK)|15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
48332529|NCT05507645|DRUG|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
48332530|NCT00889811|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
48332531|NCT02846805|PROCEDURE|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
48332532|NCT05128526|BEHAVIORAL|exercise|Short foot exercises without respiratory exercises
48332533|NCT05128526|BEHAVIORAL|respiratory|Short foot exercises with respiratory exercises
48332534|NCT00901381|DRUG|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
48332535|NCT04896307|OTHER|Survey|Survey
48332536|NCT04766983|DIAGNOSTIC_TEST|bronchoalveolar lavage|BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)
48492670|NCT05211076|OTHER|Music Group|"The Introductory Information Form will be filled in by researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.On the 1st day of the post-op,mothers will be able to listen to Classical Turkish Music works in the forms of Saz Semaisi,Peşrev,Medhal in Rast,Uşşak,Kürdi,Muhayyer makams for 30 minutes via their phone at 11:00am.~While the mother continues to listen to the music,at the 16th minute,the researcher will manually milk the mother for at least 15 minutes until milk comes out.At the end of the milking process,the milk accumulated in the container will be measured by the researcher with injector,recorded in the Breast Milk Follow-up Form.At the end of the music session,it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~The same procedure will be applied to the mother atb05:00pm.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
48652037|NCT06251973|DRUG|Ramucirumab|Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
48652038|NCT06251973|DRUG|Paclitaxel|Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
48652039|NCT03726879|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
48652040|NCT03726879|DRUG|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
48652041|NCT03726879|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
48332537|NCT04992546|DRUG|PRN473 (SAR444727)|White to off-white gel suspension
48332538|NCT04992546|DRUG|Placebo|White to off-white gel suspension
48332539|NCT04060810|OTHER|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
48652042|NCT03726879|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
48652043|NCT03726879|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
48652044|NCT03726879|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
48652045|NCT03726879|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
48652046|NCT03726879|DRUG|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
48332540|NCT04396288|DEVICE|ultrasound imaging at the forearm and at the tibia|ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
48125527|NCT03122236|DEVICE|Sham Transcranial Direct Current Stimulation (Sham tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
48125528|NCT03122236|DEVICE|Active Transcranial Direct Current Stimulation (Active tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
48332541|NCT01312324|DRUG|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
48332542|NCT02620709|BEHAVIORAL|Hula intervention|Hula and heart health education
48332543|NCT02945800|DRUG|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)
48332544|NCT02945800|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m\^2 intravenously (IV)
48332545|NCT03856658|DRUG|Floxuridine (FUDR)|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
48332546|NCT03856658|DEVICE|Hepatic Artery Infusion Pump|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
48332547|NCT03856658|DRUG|Heparinized Saline|Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
48332548|NCT03332303|DRUG|Estrace® Cream|Estrace® Cream
48332549|NCT03332303|DRUG|Estradiol Vaginal Cream|Estradiol Vaginal Cream
48332550|NCT03332303|DRUG|Vehicle Cream|Vehicle Cream
48332551|NCT01259635|DEVICE|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
48332552|NCT01754675|BEHAVIORAL|Soccer|Watching the soccer match at the time that the favorite team is playing
48332553|NCT01754675|BEHAVIORAL|Movie|Watching a movie at the time that the favorite team is playing
48332554|NCT01152489|DEVICE|Device: Buzzy|"Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back."
48332555|NCT01152489|DEVICE|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
48332556|NCT05601908|OTHER|Virtual Reality Relaxation|Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
48332557|NCT01946789|BIOLOGICAL|ALT-803|Intravenous infusion for dose level 1-5; subcutaneous injection for dose level 5a-8; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
48492671|NCT05211076|OTHER|Marmet Technique Group|"Consent will be obtained from those who agree to participate in the study. The Introductory Information Form will be filled by the researcher using face-to-face interview technique.~It will be ensured that the mother fills the State Anxiety Scale with her own statement.~The Marmet Technique will be applied to the mothers at 11:00am for 20-30 minutes by the researcher.~At the end of the milking process performed in accordance with the technique, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement.~At 05:00pm, the same procedure will be applied to the mother. At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
48652047|NCT01821014|OTHER|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
48652048|NCT01821014|OTHER|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
48652049|NCT05533437|DEVICE|dry needling|the dry needle inserted to area of pain
48652050|NCT05533437|OTHER|kinesio taping|kinesio taping
48652051|NCT02869009|DRUG|clopidogrel|
47975014|NCT05730751|PROCEDURE|caesarean section|LSCS
48332558|NCT02309814|DEVICE|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
48125529|NCT03697733|PROCEDURE|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
48125530|NCT02515071|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
48125531|NCT02515071|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
48125532|NCT04778670|DIAGNOSTIC_TEST|AI CAD|The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
48125533|NCT04778670|DIAGNOSTIC_TEST|Radiologist reading|Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)
48125534|NCT03002428|DRUG|Teriparatide (PF708)|Subcutaneous injection
48332559|NCT01771536|OTHER|Decision Aid|
48652052|NCT02869009|DRUG|Aspirin|
48652053|NCT06213298|DRUG|Kava|75 mg kavalactones
48652054|NCT06213298|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
48125535|NCT03002428|DRUG|Teriparatide (Forteo)|Subcutaneous injection
48652055|NCT02759510|DRUG|Norepinephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
48652056|NCT02759510|DRUG|Phenylephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
48652057|NCT05592743|DRUG|Vorasidenib|Oral therapy
48125536|NCT03208881|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
48332560|NCT00314080|DRUG|Botulinum AntiToxin|
48332561|NCT00314080|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
48332562|NCT00314080|PROCEDURE|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
48652058|NCT04520230|DRUG|Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
48652059|NCT04520230|DRUG|Tiotropium 18 mcg capsule inhaled once daily + Budesonide|inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
48652060|NCT04520230|DRUG|Formoterol/Tiotropium|long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
48652061|NCT02150863|DEVICE|Ultrapulse Carbon Dioxide Laser|
48652062|NCT02150863|DEVICE|Cellutome epidermal harvesting system|
48652063|NCT06639815|OTHER|clinical and radiographic examination|clinical and radiographic examination
48652064|NCT06145711|OTHER|hiPSC-DAP|Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
48652065|NCT00298155|DRUG|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
48652066|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
48652067|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
48652068|NCT06569797|DIETARY_SUPPLEMENT|oligosaccharides and multiple nutrients|The effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years
48125537|NCT00826475|BEHAVIORAL|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
47975015|NCT05343351|OTHER|Technique of injection method|"In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel."
48332563|NCT00418210|RADIATION|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
48652069|NCT06569797|DIETARY_SUPPLEMENT|no oligosaccharides and optimizing multiple nutrients|The effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.
47975016|NCT04857905|PROCEDURE|Microsurgical resection|Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
48652070|NCT06569797|DIETARY_SUPPLEMENT|breastfeeding|The impact of breastfeeding on the growth and development of infants aged 0-1 years old.
47975017|NCT04857905|PROCEDURE|Gamma Knife radiosurgery|Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
47975018|NCT05252117|DRUG|Articaine Hydrochloride 40 MG/ML|Analysis of uterovaginal plexus block with articain for intrauterine device placement
47975019|NCT05252117|DRUG|Mepivacaine|Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
47980537|NCT05984732|BEHAVIORAL|Social wellness with scrapbook or journal|Older adults in the control group will have general social wellness discussion with the young adult volunteers, instead of structured reminiscence guidelines. The topics are: diet and health (week 1); exercise/activity and health (week 2); emotions and health (week 3); religious/spiritual practices and health (week 4); family/friend relationships and health (week 5); and social activities/engagement and health (week 6). For weeks 7-10, instead of DST, the young adult volunteer will work with the older adult to create an unstructured, non-digital record of the social visit related to wellness in later life (e.g. wellness scrapbook/journal).
48125538|NCT00826475|BEHAVIORAL|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
48125539|NCT04910698|DRUG|Antibiotic|Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
48492672|NCT05211076|OTHER|Control group|"The Introductory Information Form will be filled by the researcher using face-to-face interview technique.It will be ensured that the mother fills the State Anxiety Scale with her own statement.The mothers will milk the mother manually by the researcher at 11:00am for at least 15 minutes until the milk does not come.~At the end of the milking process, the milk accumulated in the container will be measured with an injector and recorded in the Breast Milk Follow-up Form in ml.~Then, it will be ensured that the mother fills in the State Anxiety Scale with her own statement. At 05:00pm, the same procedure will be applied to the mother.~At the end of the 4th day, the satisfaction of the mother will be evaluated on the Mother Satisfaction Evaluation Scale.This process will be carried out 8 times in total,at 11:00am and 05:00pm for 4days."
48652071|NCT03908294|DIAGNOSTIC_TEST|Lab tests, non-invasive fibrosis (Fibroscan/ARFI)|Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
48652072|NCT05584137|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
48332564|NCT02855242|BEHAVIORAL|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
48652073|NCT05584137|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
48652074|NCT03983239|DRUG|Fedratinib|Fedratinib
48652075|NCT03983239|DRUG|Rifampin|Rifampin
48652076|NCT03983239|DRUG|Efavirenz|Efavirenz
48652077|NCT05665881|DRUG|Ephedrine|vasopressor
48125540|NCT02570022|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
48332565|NCT02855242|OTHER|Controls Group|Subjects not participating in any lifestyle counseling
48125541|NCT02570022|PROCEDURE|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
48125542|NCT02570022|DRUG|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
48332566|NCT01677507|DRUG|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
48332567|NCT02404896|DRUG|Metreleptin|Metreleptin open-label treatment
48332568|NCT06063239|OTHER|Test Group|Subjects will receive orally administred probiotics based on L. plantarum and L. rhamnosus for 90 days
48652078|NCT05665881|DRUG|Phenylephrine|vasopressor
48652079|NCT05665881|DRUG|Norepinephrine|vasopressor
48652080|NCT01055119|DIETARY_SUPPLEMENT|Omega-3 fatty acids|duration: 4 month
48652081|NCT06675331|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
48652082|NCT03288935|BEHAVIORAL|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R\&P service period (i.e., 60 days).
47975020|NCT04314778|BEHAVIORAL|social incentive-based gamification|At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
47975021|NCT00543504|DRUG|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
47975022|NCT00543504|DRUG|Sorafenib|200 mg By Mouth Daily for 28 Days
47975023|NCT00543504|DRUG|Erlotinib|50 mg By Mouth Daily for 28 Days.
48125543|NCT01203813|OTHER|Electronic Decision Support|"Physicians randomized to the intervention will receive:~1. Electronic alerts during office visits for patients with chronic kidney disease~2. Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
48332569|NCT06063239|OTHER|Positive Control|Subjects will receive orally administred probiotics based on placebo 90 days
48125544|NCT00211731|BEHAVIORAL|Chronic Disease Self Management Course|
48125545|NCT04458454|DIAGNOSTIC_TEST|Relaxin ELISA Kit|Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
48125546|NCT03106922|DRUG|PMF104|"Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
48125547|NCT03106922|DRUG|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
48332570|NCT06063239|OTHER|Negative Control|Subjects will receive esclusively instruction to perform oral hygiene procedures properly.
48332571|NCT06528899|BEHAVIORAL|Physical Therapy|Assessment and/or treatment by physitoherapist during the visit
48125548|NCT03939312|DRUG|Atogepant|Atogepant Tablets
48332572|NCT05646888|BIOLOGICAL|Blood sampling|the blood sample will be taken during a planned blood sampling
48332573|NCT03628521|DRUG|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
48332574|NCT02282176|DRUG|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
48332575|NCT02282176|DRUG|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
48652083|NCT03288935|BEHAVIORAL|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation \& resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
47975024|NCT00543504|DRUG|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
47975025|NCT00543504|DRUG|Lapatinib|250 mg By Mouth Daily for 21 Days.
48125549|NCT00700986|DRUG|AZD9056|Oral tablet, 800mg, one single administration
48332576|NCT00661570|DEVICE|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
48652084|NCT04747431|DRUG|PBFT02|PBFT02
48652085|NCT03707340|DRUG|Flibanserin Pill|Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
48652086|NCT02584738|DRUG|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
48652087|NCT02584738|DRUG|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
48652088|NCT02584738|DRUG|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
48652089|NCT02584738|DRUG|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
48125550|NCT00700986|DRUG|Placebo|Single dose
48125551|NCT05851677|DRUG|Disitamab vedotin|recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
48332577|NCT01537094|DIETARY_SUPPLEMENT|Placebo|
48332578|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 250 mg once daily|
48332579|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 1,000 mg once daily|
48332580|NCT01922245|DEVICE|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
48332581|NCT01453998|BIOLOGICAL|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
48332582|NCT01453998|BIOLOGICAL|Prevenar 13|Single co-administered dose, intramuscular into left thigh
48332583|NCT01453998|BIOLOGICAL|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
48332584|NCT00351819|DRUG|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
48332585|NCT00351819|OTHER|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
47975026|NCT00543504|DRUG|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
47975027|NCT00543504|DRUG|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
47975028|NCT00719134|DRUG|Maxalt|anti-migraine drug
48332586|NCT05291572|BEHAVIORAL|speech therapy only|fluency shaping technique
47975029|NCT00719134|DRUG|placebo pill|placebo pills
48332587|NCT05291572|DEVICE|hyperbaric oxygen therapy|chamber system using oxygen with pressure
48332588|NCT05291572|DRUG|medical treatment|brain stimulant
48332589|NCT02712281|BEHAVIORAL|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
48652090|NCT02584738|DRUG|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
48652091|NCT06641440|DRUG|Prednisone|patients will be treated for three months in the two groups with the two different protocols for three months both
48652092|NCT02920047|DRUG|Fimasartan/Amlodipine|Treatment B
48652093|NCT02920047|DRUG|Fimasartan + Amlodipine|Treatment A
48652094|NCT02199912|PROCEDURE|Biopsy of adipose and muscular tissue|
48332590|NCT02712281|BEHAVIORAL|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
48332591|NCT02481063|OTHER|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
48332592|NCT02481063|OTHER|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
48332593|NCT00430963|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|
48652095|NCT02199912|OTHER|Blood sampling|
48652096|NCT02199912|OTHER|Calorimetry|
48652097|NCT02199912|OTHER|Impedance measure|Evaluation of physical composition (non-invasive method)
48332594|NCT00430963|DRUG|Placebo|
48332595|NCT04880265|DEVICE|BraveHeart wearable life sensors|Collection of EKG data
48332596|NCT02016898|PROCEDURE|Placement of the sponge|
48332597|NCT02016898|DRUG|Mitomycin-C|
48332598|NCT01184456|DIETARY_SUPPLEMENT|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
48332599|NCT01184456|DRUG|Placebo|1 capsule per day for 90 days.
48332600|NCT05976932|DRUG|pegylated liposomal doxorubicin|All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
48332601|NCT05220371|DIETARY_SUPPLEMENT|Collagen|Participants ingest 15 grams of either specific collagen peptides or Placebo daily
48652098|NCT02199912|OTHER|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
48652099|NCT02199912|OTHER|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
48652100|NCT02199912|OTHER|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
48652101|NCT02199912|OTHER|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
47975030|NCT00719134|DRUG|placebo pills|placebo pills
47975031|NCT04404374|PROCEDURE|A-PRF/EMD|Comparing healing effect of an autologous and a xenogenic product
47975032|NCT00989378|BEHAVIORAL|baseline study|normal bedtimes
47975033|NCT01022632|DIETARY_SUPPLEMENT|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
48332602|NCT05220371|OTHER|Concurrent training|Both arms undergo a 12-week trainingintervention 3x/week
48332603|NCT02917629|OTHER|Laboratory Biomarker Analysis|Correlative studies
48332604|NCT02917629|DRUG|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
48332605|NCT02917629|OTHER|Pharmacological Study|Correlative studies
48332606|NCT02917629|OTHER|Placebo|Given PO
48332607|NCT02685657|DRUG|Drug: Selumetinib|
48125552|NCT02186743|OTHER|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
47975034|NCT01022632|DRUG|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
47975035|NCT01022632|DIETARY_SUPPLEMENT|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
47975036|NCT04980040|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
47975037|NCT05545215|DEVICE|Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
47975038|NCT05738668|OTHER|Description of clinical characteristic|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
47975039|NCT04214054|OTHER|Moldable self-hardening biphasic calcium phosphate graft|Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.
47980538|NCT01953120|DRUG|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
48125553|NCT01113931|DRUG|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
48125554|NCT01113931|DRUG|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
48125555|NCT03918967|DRUG|CT-G11|oral tablet of CT-G11 Experimental Drug
48125556|NCT03918967|DRUG|CT-G20|oral tablet of CT-G20 Experimental Drug
48125557|NCT03918967|DRUG|CT-G11 Placebo|oral tablet of Placebo
48125558|NCT03918967|DRUG|CT-G20 Placebo|oral tablet of Placebo
48125559|NCT02641938|DRUG|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
48125560|NCT02641938|DRUG|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
48125561|NCT06374004|OTHER|Exercise Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes.
48332608|NCT02685657|DRUG|Doxorubicin|
48332609|NCT02685657|DRUG|Cyclophosphamide|
48332610|NCT02685657|DRUG|Docetaxel|
48332611|NCT05885022|DEVICE|Calibreye System|Implantation of a glaucoma device to reduce intraocular pressure
48332612|NCT01778400|PROCEDURE|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
48332613|NCT01778400|PROCEDURE|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
48332614|NCT00163904|BEHAVIORAL|High mono-unsaturated fat/low carbohydrate diet|
48652102|NCT02199912|OTHER|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
48652103|NCT05059626|DRUG|simvastatin 10mg|Simvastation acts as a systemic LOX inhibitor.
47975040|NCT04214054|PROCEDURE|No graft material placed - Blood Clot only|A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
48332615|NCT00163904|BEHAVIORAL|High carbohydrate/low fat diet|
48332616|NCT00454272|DRUG|Teicoplanin|
47975041|NCT04201860|DIAGNOSTIC_TEST|Arterial blood gas analyses and haemostasis measures|Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
47975042|NCT04949477|DRUG|Dexmedetomidine|the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
47975043|NCT04949477|DRUG|paracetamol|the patient will receive paracetamol orally \[Rx paracetamol 250 mg/ml\] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
47975044|NCT03683108|DRUG|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
47975045|NCT03683108|OTHER|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
47975046|NCT03779802|OTHER|Device programming of ABBOTT CRT pacemaker or defibrillator|Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
47975047|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
47975048|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
48125562|NCT06374004|OTHER|Thoracic Mobilization Group|The exercises will be given as a home program and each exercise will be performed 2 times a day for a total of 12 weeks. Participants will perform the exercises 1 day a week under the supervision of a physiotherapist. The exercise program lasts approximately 30 minutes. Thoracic mobilization will be applied to segments where passive accessory movement is insufficient or painful. 30 repetitions/4 sets will be applied to each determined segment. Thoracic mobilization will be performed with the patient lying prone position.
48125563|NCT02390570|OTHER|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
48332617|NCT00454272|DRUG|Vancomycin|
48652104|NCT05059626|DRUG|Bazedoxifene 20/Estrogens,Con 0.45Mg Tb|Duavee is a selective estrogen receptor modulator.
48652105|NCT05316740|OTHER|No intervention|Repeated clinical evaluation and sample collection
48332618|NCT03644108|DRUG|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
48332619|NCT03256838|DRUG|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
48332620|NCT06108245|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts twice a day over four weeks.
48332621|NCT06108245|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the psychological placebo group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to clutter and organization.
48332622|NCT02423460|OTHER|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
48332623|NCT02711605|DEVICE|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
48652106|NCT05686980|DRUG|ABBV-552|Oral Capsule
48652107|NCT00767208|OTHER|oral glucose load|oral ingestion of 13C labeled glucose
48652108|NCT05830539|DRUG|IN10018+PLD|IN10018 orally once daily; PLD 40mg/m2, Q4W
48652109|NCT05830539|DRUG|IN10018+PLD+Toripalimab|IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
48652110|NCT02457598|DRUG|Tirabrutinib|Capsules or tablets administered orally
48652111|NCT02457598|DRUG|Idelalisib|Tablets administered orally twice daily
48652112|NCT02457598|DRUG|Entospletinib|Tablets administered orally
48652113|NCT02457598|DRUG|Obinutuzumab|Administered intravenously
48652114|NCT04903769|BEHAVIORAL|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
48125564|NCT03933371|DEVICE|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
48332624|NCT01372449|DRUG|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
48332625|NCT01372449|DRUG|Placebo|
48332626|NCT00278096|BEHAVIORAL|occupational therapy|
47975049|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
47975050|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
47975051|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
47975052|NCT05665478|OTHER|Dose prediction using population pharmacokinetic models|Dose prediction using population pharmacokinetic models.
47975053|NCT00358124|DRUG|insulin glargine|
47975054|NCT00358124|DRUG|rosiglitazone|
47975055|NCT00358124|DRUG|metformin|
47975056|NCT01073891|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
47975057|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
47975058|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
47975059|NCT03806998|DIETARY_SUPPLEMENT|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
47975060|NCT03806998|DIETARY_SUPPLEMENT|Placebo|Provision of placebo capsules similar to active supplement
47975061|NCT00056524|DRUG|AVP-923|
47975062|NCT01689701|DIETARY_SUPPLEMENT|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
47975063|NCT01689701|DIETARY_SUPPLEMENT|Placebo|Placebo(1.3g/d)
47975064|NCT02696473|DIETARY_SUPPLEMENT|Carrot|
47975065|NCT03617445|DRUG|FMT oral capsule|FMT oral capsules, single dose of 5 capsules
47975066|NCT03617445|DRUG|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
47975067|NCT03617445|DRUG|FMT oral placebo|Placebo oral capsules, single dose of 5 capsules
48125565|NCT02846909|DRUG|Progesterone|400mg progesterone pessaries
47975068|NCT03617445|DRUG|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
47975069|NCT02316808|DIETARY_SUPPLEMENT|Plant stanol ester|Smoothie that contains plant stanol ester
47975070|NCT02316808|DIETARY_SUPPLEMENT|placebo|Smoothie that contains placebo
47975071|NCT01526798|DEVICE|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
47975072|NCT01526798|DEVICE|Conventional high-flux dialyzer|
47975073|NCT02870582|DRUG|Donafenib|treatment drug
47975074|NCT02870582|DRUG|Placebo|Best support treatment
48125566|NCT04059042|BEHAVIORAL|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
48125567|NCT03298789|OTHER|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
48125568|NCT03298789|OTHER|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
48332627|NCT03939611|OTHER|Foot Reflexology|Reflexology is one of the complementary health approaches; it is based on systematic pressure and stimulation with fingers to energy points in feet and hands and is a topic nowadays studied. Reflexology argues that the reflex maps in the hands and feet with all of the parts of the body are in contact. The pressure applied to each point stimulates the circulation of blood and energy like a sensor, gives a sense of relaxation, provides homeostasis. With a touch that is a different way of communication with children, is supported to create physical awareness via reflexology techniques, and is provided healthy nutrition of the stimulated tissue.
48332628|NCT03939611|OTHER|Placebo Foot Reflexology|Placebo reflexology was performed by touch without pressure to the same rotation and to the same points as foot reflexology application. It was performed only to compare foot reflexology with a placebo effect.
48332629|NCT03082053|DRUG|varlitinib|IMP
48332630|NCT03082053|DRUG|capecitabine|Companion Medication
48332631|NCT01388868|OTHER|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
48332632|NCT01388868|OTHER|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
48332633|NCT01388868|OTHER|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
47975075|NCT03890172|OTHER|20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly|topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
47975076|NCT03890172|OTHER|standard treatment|Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
47975077|NCT03440021|DRUG|ORM-12741|Novel selective alpha2c adrenoceptor antagonist
47975078|NCT03440021|DRUG|Placebo|Identical in appearance to experimental drug, not psycho-active
47975079|NCT00276744|BIOLOGICAL|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
48332634|NCT05957588|OTHER|Proning group|"Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed."
48652115|NCT00916526|PROCEDURE|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~1. Apply nose clip and subject should be directed to breathe through the mouth~2. Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~3. The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~4. At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~5. At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~6. Insert 5 mg capsule into inhalation device, and proceed as above~7. Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
47975080|NCT00276744|DRUG|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975081|NCT00276744|DRUG|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975082|NCT00276744|DRUG|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975083|NCT00276744|DRUG|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975084|NCT00276744|DRUG|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975085|NCT00276744|DRUG|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975086|NCT00276744|DRUG|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975087|NCT00276744|PROCEDURE|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
47975088|NCT01307007|DRUG|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
47975089|NCT01307007|DRUG|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
47980539|NCT01639651|OTHER|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
48125569|NCT02343029|OTHER|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
48332635|NCT05957588|OTHER|Control group|A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
48332636|NCT04850612|OTHER|Survey|Delphi Survey on core outcomes, CSDH definition and data elements
48332637|NCT01353755|DRUG|Grass pollen specific immunotherapy|"* Strength 1 (0.78μg/mL)~* Strength 2 (6.25μg/mL)~* Strength 3 (50μg/mL)~* Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
48332638|NCT01353755|DRUG|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
48332639|NCT05752708|DIAGNOSTIC_TEST|Diagnostic Test|Evaluation of perioperative anxiety in parents of children undergoing thoracic surgery using standardized tests: The Amsterdam Preoperative Anxiety and Information Scale (APAIS), the State-Trait Anxiety Inventory (STAI).
48332640|NCT05163067|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
48332641|NCT03587584|DRUG|liposomal bupivacaine|Experimental
48332642|NCT03587584|DRUG|Bupivacaine|Active Comparator
48332643|NCT01513863|DRUG|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
48332644|NCT01513863|DRUG|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
48332645|NCT01513863|DRUG|Placebo|Placebo applied to affected area once a day for 70 days
48332646|NCT06051825|DIAGNOSTIC_TEST|Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels|Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
48332647|NCT04639843|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.
47980540|NCT01639651|OTHER|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
48125570|NCT02343029|OTHER|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
48332648|NCT04639843|DRUG|Duvelisib|Duvelisib by oral intake at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of the 1st cycle then days 1-14 of Cycles 2-8 of each 21- day cycle (max 8 cycles).
48332649|NCT04639843|DRUG|Romidepsin|Romidepsin (12mg/m2) will be administered on days 1 and 8 of each cycle through a peripheral or central intravenous catheter for 8 cycles.
48332650|NCT04639843|DRUG|Doxorubicin|Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
48332651|NCT05060172|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
48332652|NCT02685397|DRUG|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
48332653|NCT02685397|DRUG|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
48332654|NCT02685397|DRUG|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
48125571|NCT04160936|DRUG|Marcaine Injectable Product|Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
48125572|NCT05869617|OTHER|Aquatic exercise|"Participants in the aquatic therapy group will receive aquatic therapy in a HydroWorx aquatic therapy pool at Hydrathletics.~In the aquatic therapy group the 20 minutes of aerobic exercise at each visit will involve walking on an underwater treadmill. The intensity of the walking will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on movement patterns that simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or increasing resistance."
48332655|NCT02685397|DRUG|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
48332656|NCT02685397|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
48332657|NCT05353868|OTHER|No intervention|No intervention
48332658|NCT03682939|BIOLOGICAL|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
48332659|NCT03682939|BIOLOGICAL|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
48332660|NCT05072756|OTHER|Applying a questionnaire|The participants have to answer a questionnaire addressing their opinion on menopausal hormone replacement therapy
48332661|NCT00289549|DRUG|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
48492673|NCT06323486|DEVICE|active accelerated bilateral sequential theta burst stimulation and sham treatment|"We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions."
48652116|NCT06347978|DEVICE|Deep Brain Stimulation|"Subjects will be randomized to either ON-OFF (Stimulation-Sham) or OFF-ON (Sham-Stimulation) arms. Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period. Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.~After completion of the first phase of the trial, patients will undergo another washout phase until they are within 20% of their pre-treatment Y-BOCS II score or 4 weeks have passed, whichever comes first. The purpose of the washout is to eliminate any residual effect of stimulation in the ON group.~Patients will then be advanced to the crossover phase. The participants who were initially randomized to the ON-OFF arm will be moved onto the sham (OFF) period, and the participants who were initially randomized to the OFF-ON group will be moved onto stimulation (ON) period for up to 12 weeks."
48492674|NCT06456944|OTHER|stretching exercises|stretching exercises of the plantar fascia, gastrocnemius and soleus
47975090|NCT06440395|BEHAVIORAL|Behavioural: Small Steps for Big Changes Diabetes Prevention Program|The 4-week behaviour change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 4-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the YMCA). The supervised session will include brief behavioural counselling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
47975091|NCT05316142|PROCEDURE|AGV implantation|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
47975092|NCT04173078|BEHAVIORAL|Computerized Distress Intolerance Intervention|
47975093|NCT04173078|BEHAVIORAL|Computerized Healthy Behaviors Intervention|
47975094|NCT02048787|DRUG|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
47975095|NCT04554667|BEHAVIORAL|Exercise Intervention|Heavy Lifting Strength Training
47975096|NCT02673437|OTHER|This is a non-interventional study|This is a non-interventional study
47980541|NCT04171778|OTHER|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
48652117|NCT06643026|OTHER|Food preference|Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.
48652118|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
47975097|NCT05798650|BEHAVIORAL|facial dissatisfaction|"Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs."
48652119|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
48652120|NCT01462331|OTHER|Sucrose|12g/dose, three times a day
48652121|NCT06352567|OTHER|European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire|"It consists of a total of 20 items each is scored from 1: not at all to 4: very much in a 4-point Likert scale. Individuals are requested to fill out by considering their last week. Sensory, motor, and autonomic subscales are reported within its constructs. A total of 9, 8, and 3 items are referred to as sensory, motor, and autonomic disturbances, respectively"
48652122|NCT03647137|OTHER|Detailed motor testing, including FoG, in PD subjects|"Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state."
48652123|NCT05209295|DRUG|Onureg|Specified dose on specified days
48652124|NCT06229093|DEVICE|Gamma|For the OAg group, the visual component of multimodal stimulation will have the same properties as for the other group, except it will also be additionally amplitude-modulated in the gamma-band (30-60 Hz) range, resulting in a detectable flicker over-and-above the beat-level modulation.
48652125|NCT06229093|DEVICE|Synchrony|For the OA group, the lights will be tuned to delta-band frequencies (1-4 Hz) in the music, which corresponds to the beat-level frequency in most music. Thus, the lights automatically adapt to the rhythm of the music, pulsing on the beat and changing color on strong beats.
48652126|NCT04910022|DRUG|NMS-03305293|Route of administration: Oral
48652127|NCT04910022|DRUG|Temozolomide|"Route of administration: Oral~Commercially available temozolomide"
47975098|NCT06289998|DRUG|Tamibarotene|Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.
47975099|NCT06289998|DRUG|Placebo|Subjects are administrated to placebo in daily for 52 weeks.
47975100|NCT01344005|OTHER|caregiver-related intervention or procedure|
47975101|NCT01344005|OTHER|questionnaire administration|
47975102|NCT01344005|PROCEDURE|quality-of-life assessment|
47975103|NCT01344005|PROCEDURE|radiography|
47975104|NCT03459248|OTHER|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
47975105|NCT03459248|OTHER|Monotherapy|10 mg metoclopramide
47975106|NCT03459248|OTHER|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
47975107|NCT02075229|DEVICE|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
47975108|NCT03425123|OTHER|Regenerative Endodontic Procedure (REP)|Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
47975109|NCT00793598|DRUG|Placebo|
47975110|NCT00793598|DRUG|Brincidofovir|
47975111|NCT01748032|BEHAVIORAL|Cognitive training|20 minutes/day for 5 sequential working days
48492675|NCT06456944|DEVICE|ultrasound|therapeutic ultrasound upon the most painful point on the medial calcaneal tubercle. The parameters involved a pulsed mode (duty cycle 50%) using an intensity of 1.5 W/cm2 and a 1 MHz of frequency for 5 minutes
48652128|NCT06164301|DIETARY_SUPPLEMENT|Elemental amino-acids|mono peptide oral protein formula
47975112|NCT01499745|BEHAVIORAL|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
47975113|NCT03605459|DEVICE|Comfort Plug™|
47975114|NCT01325636|OTHER|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
47975115|NCT01116011|DRUG|AZD7268|Capsule, Oral, BID
47975116|NCT01116011|DRUG|Placebo|Capsule, Oral, BID
47975117|NCT00230607|DRUG|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
47975118|NCT01402492|DRUG|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
47975119|NCT01402492|DRUG|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
47975120|NCT00408356|DRUG|Zinc|
47975121|NCT01818921|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
47975122|NCT01818921|DRUG|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
47980542|NCT02989675|DRUG|10% dextrose|Bolus of 10% dextrose 5mls/kg
48125573|NCT05869617|OTHER|Land-based Exercise|"Traditional land-based training will take place the Hydrathletics gym with similar exercises provided to the aquatic therapy group.~The aerobic exercise for the land-based therapy group will be 20 minutes of treadmill walking. The intensity will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on similar movement patterns to the aquatic therapy group to simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or the resistance used for the exercise."
48125574|NCT06211972|BEHAVIORAL|OpiVenture|"OpiVenture, a targeted psychosocial intervention, complements opioid agonist therapy for opioid use disorder. Adapted from proven interventions like PreVenture, it unfolds over three sessions. Session one covers introductions, an ice-breaker, trait overview, strengths/limitations discussion, goal setting, and homework. Session two reviews homework, explores coping strategies, weighs alternatives, introduces hot thoughts, reviews trait-specific hot thoughts, and assigns homework. The concluding session involves reviewing homework, identifying personal hot thoughts, challenging them through a cognitive-behavioral exercise, applying insights to goal setting, and concluding with a wrap-up."
48125575|NCT01645033|OTHER|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
48125576|NCT01645033|OTHER|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~* Teaching about the treatment program~* Teaching important ideas about sexual behaviors risks~* Increasing knowledge about specific sexually transmitted diseases~* Discussions of ways to reduce or minimize spread of diseases related to drug use \[for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)\]"
48125577|NCT03610789|DEVICE|REDAPT|REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
48125578|NCT02431273|DRUG|TDF IVR|
48125579|NCT02431273|DRUG|TDF-FTC IVR|
47975123|NCT01818921|DRUG|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
47975124|NCT04338698|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
47975125|NCT04338698|DRUG|Oseltamivir|Oseltamivir (75 mg orally twice a day for 5 days)
47975126|NCT04338698|DRUG|Azithromycin|Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
48492676|NCT06456944|OTHER|rigid tape|low-dye tapping will be done to provide mechanical correction to plantar fascia and medial longitudinal arch
48492677|NCT06456944|OTHER|mobilization|mobilization techniques for the talocrural joint in weight bearing and non-bearing positions and subtalar joint
48492678|NCT06456944|OTHER|myofascial release|deep tissue release of the plantar fascia and flexor hallucis longus in a stretched position of the plantar fascia
47975127|NCT02144051|DRUG|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
47975128|NCT05711953|OTHER|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
47975129|NCT01528488|OTHER|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
47975130|NCT01528488|OTHER|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
47975131|NCT04201002|PROCEDURE|Resection plus intraoperative radiotherapy|En-bloc resection plus intraoperative radiotherapy
47975132|NCT05241496|DIAGNOSTIC_TEST|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
48492679|NCT06456944|OTHER|strengthening exercise|strengthening exercise of the plantar intrinsic muscles using short foot exercise and strengthening of the Achilles tendon and windlass mechanism using unilateral heel raise exercises
47975133|NCT05806814|BIOLOGICAL|Sipuleucel-T|Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.
48332662|NCT03544632|DRUG|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
48332663|NCT04101734|DEVICE|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
48332664|NCT04101734|DEVICE|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
48332665|NCT04020406|BIOLOGICAL|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
48332666|NCT01115088|DIETARY_SUPPLEMENT|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
48332667|NCT01115088|DIETARY_SUPPLEMENT|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
48492680|NCT06070974|DIAGNOSTIC_TEST|CMR and blood collection|All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
48492681|NCT06213870|DIAGNOSTIC_TEST|Surgical criteria|"In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication."
48492682|NCT02901613|DEVICE|Negative-pressure wound therapy|
48492683|NCT02833545|DEVICE|Ozone gas|Injection of ozone gas intra articularly
48652129|NCT02594072|RADIATION|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
48652130|NCT02594072|RADIATION|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
48652131|NCT02594072|DRUG|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
48652132|NCT05558085|BEHAVIORAL|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
48652133|NCT01515215|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
48652134|NCT06230991|DIETARY_SUPPLEMENT|SIM05|SIM05 contains a blend of food-grade Bifidobacterium and Lactobacillus strains plus prebiotics
47975134|NCT03700671|OTHER|High intensity interval training|Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
48125580|NCT02431273|DRUG|TDF-FTC-MVC IVR|
48652135|NCT06674291|DRUG|No intervention (observational study)|This is an observational registry conducted in the real world clinical setting and there is no intervention in this study. Treatment of MDR-END Regimen and the follow-up of subjects will be conducted in the clinical judgment of the investigator.
48652136|NCT05869955|DRUG|CC-97540|Specified dose on specified days
48652137|NCT05869955|DRUG|Fludarabine|Specified dose on specified days
48652138|NCT05869955|DRUG|Cyclophosphamide|Specified dose on specified days
48652139|NCT05869955|DRUG|Tocilizumab|Specified dose on specified days
48652140|NCT01355666|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
48125581|NCT00581035|BIOLOGICAL|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
48125582|NCT00581035|BIOLOGICAL|Prevenar|1 dose at 2,3.5,6 and 12 months
48125583|NCT00581035|BIOLOGICAL|Meningitec|1 dose at 2,6 and 12 months
48125584|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
48125585|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
48125586|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
48492684|NCT02833545|DRUG|Steroid injection|Injection of steroids (diprospan) intra articularly
48492685|NCT04320550|DIAGNOSTIC_TEST|abdominal ultra sound|non invasive tests to exclude pathological causes
48492686|NCT02446327|OTHER|Blood sampling for biomarker assessment|
48652141|NCT06644482|OTHER|Exercise group in a hospital setting|Participants will exercise in a group once a week for 16 weeks in a hospital setting.
48125587|NCT02355236|DRUG|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
48125588|NCT02355236|DRUG|Celecoxib 200mg|Capsule, o.d.
48125589|NCT02355236|DRUG|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
48125590|NCT02355236|DRUG|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
48332668|NCT01115088|DIETARY_SUPPLEMENT|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
48332669|NCT04103775|BEHAVIORAL|Cognitive Remediation|See Cognitive Remediation Arm description.
48332670|NCT04103775|BEHAVIORAL|Active Control|See Active Control Arm description.
48332671|NCT01349985|OTHER|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
48332672|NCT01349985|OTHER|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
48332673|NCT04307173|DRUG|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
48332674|NCT04307173|DRUG|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
48332675|NCT00391807|DRUG|Norethindrone acetate/ethinyl estradiol|one tablet per day
48652142|NCT04869514|PROCEDURE|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
48652143|NCT06641622|DIAGNOSTIC_TEST|Prediction of delayed graft function|Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
48332676|NCT04866095|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram (TTE) is a widely used and validated imaging technique which involves the study of the heart and great vessels through multiple examination windows. In particular, the subcostal window represents the gold standard for evaluating the diameter of the inferior vena cava (IVC) and its compliance, allowing the physician to obtain valuable information on the volume status of patients. Acquiring images in the subcostal window with a transthoracic echocardiogram (TTE) can be, in some cases, difficult or impossible due to the presence of drainages or surgical wounds: in such cases an alternative could be represented by the trans-hepatic window. This has not been validated in the scientific litterature.
48332677|NCT04866095|DEVICE|Clear Sight system|"The Clear Sight System is a non-invasive blood pressure (BP) monitoring system, where the CO is determined analysing the photo-plethysmography curve by a miniaturized pressure cuff and infrared LEDs.~Its main advantage is to assess CO continuously in a completely non-invasive way, following its variations and thereby contributing to the detection of hypovolaemia. Other visualized parameters are: the stroke volume (SV), the systemic vascular resistance (SVR) as well as the BP and the heart rate (HR)."
48492687|NCT00131378|DRUG|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
48492688|NCT00131378|DRUG|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
48652144|NCT05792345|PROCEDURE|Transversus Thoracic Muscle Plane Block|The transversus thoracic muscle plane block It is most commonly performed following cardiothoracic surgeries (or any surgeries requiring sternotomy) to provide analgesia to the anterior chest wall. he TTMPB, and thoracic fascial plane blocks, are increasingly being employed as part of enhanced recovery after surgery (ERAS) protocols for cardiothoracic procedures. They have been shown to significantly reduce both the time to extubation and the incidence of acute and chronic perioperative pain
47975135|NCT03700671|OTHER|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
48125591|NCT00031785|DRUG|megestrol acetate|
48125592|NCT00031785|RADIATION|radiation therapy|
48125593|NCT02352909|OTHER|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
48125594|NCT02352909|OTHER|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
48125595|NCT02352909|OTHER|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
48125596|NCT03111537|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
48125597|NCT03111537|OTHER|E-Cigarette|Use of E-cigarette: multiple flavors offered.
48125598|NCT03111537|OTHER|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
48125599|NCT05463913|DRUG|18F-FDG|Patients will receive a single intravenous injection of 3 MBq/kg 18F-FDG
48492689|NCT01239446|OTHER|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
48492690|NCT00166036|DRUG|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
48125600|NCT05463913|RADIATION|PET/CT imaging|Patient will undergo 2 CT acquisitions and multiple PET emission scans.
48492691|NCT00166036|DRUG|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
48492692|NCT05994820|BEHAVIORAL|Happy Baby Programme -Vaccine Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi.
48652145|NCT05792345|PROCEDURE|Control|Infiltration by surgeon
48652146|NCT01173003|DRUG|Mifepristone, misoprostol|
48652147|NCT05379946|DRUG|D-1553|D-1553 is a oral dosed novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation
48652148|NCT05379946|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day
48652149|NCT06290778|BEHAVIORAL|Brief Unified Protocol|The Brief Transdiagnostic Treatment of Emotional Disorders Unified Protocol.
48332678|NCT05143567|OTHER|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
48332679|NCT05143567|OTHER|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
48125601|NCT05565534|BEHAVIORAL|Nurse-practitioner led intervention|"* Face-to-face or virtual consultation with NP during chemotherapy infusion with individualized recommendations/medications AND patient education through the Patient Activated Learning System (PALS).~* Weekly follow-ups from NP via phone, Zoom, or in-person (patient directed) for 12 weeks/course of chemotherapy."
48332680|NCT05143567|OTHER|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
48332681|NCT01125657|DRUG|YM150|oral
48332682|NCT01679561|DRUG|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
48332683|NCT06342648|DRUG|Sterile Water Injection|Injection of intracutaneous sterile water
48332684|NCT06342648|DRUG|Diclofenac Sodium injection|Injection of intramuscular diclofenac sodium
48332685|NCT03823040|DRUG|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
48332686|NCT03823040|DRUG|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
48332687|NCT00815204|PROCEDURE|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
48332688|NCT00815204|PROCEDURE|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
48332689|NCT00671983|PROCEDURE|Neurocognitive Testing|
48332690|NCT00282867|DRUG|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
48332691|NCT00282867|OTHER|standard care|usual care
48125602|NCT05778526|BEHAVIORAL|Virtual reality|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session of the Social VR intervention lasts for a maximum of 20 minutes. The intervention contains three real-life virtual scenarios, including (1) a classroom and playground, (2) an MTR station and compartment, and (3) a supermarket and restaurant.
48332692|NCT00050960|DRUG|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
48332693|NCT00050960|DRUG|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
48332694|NCT00779311|DRUG|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
48332695|NCT00779311|DRUG|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
48492693|NCT05994820|BEHAVIORAL|Happy Baby Programme- Vaccine ++ Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi as part of a holistic healthy baby approach that includes nutrition and sanitation.
48492694|NCT04232241|DRUG|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
48492695|NCT04993677|DRUG|SEA-CD40|Given into the vein (IV; intravenously); schedule is cohort-specific
48492696|NCT04993677|DRUG|pembrolizumab (KEYTRUDA®)|Given by IV; schedule is cohort-specific.
48492697|NCT04993677|DRUG|pemetrexed|Given by IV on Day 1 of each 21-day cycle.
48492698|NCT04993677|DRUG|carboplatin|Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
47975136|NCT03729960|OTHER|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
48125603|NCT05778526|BEHAVIORAL|Traditional social skills training|There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
48125604|NCT03192215|DRUG|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
48332696|NCT00779311|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
48332697|NCT01167153|DRUG|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
48492699|NCT05685901|DIETARY_SUPPLEMENT|High polyphenolic olive oil. (Early harvest olive oil).|High polyphenolic olive oil is normal olive oil obtained from early harvest olives, this early harvest olive oil has been widely used for culinary purposes for centuries. The investigators wanted to study if oromucosal immunoprophylaxis with small quantities of high polyphenolic olive oil (2 mL of olive oil equivalent to 5 mg of polyphenols) adiministered twice a day could have clinical mitigating effects on the disease caused by SARS-CoV-2 infection.The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity.
48652150|NCT06290778|BEHAVIORAL|Psychoeducation|Psychoeducation regarding mental health challenges in fire service.
48652151|NCT06344923|PROCEDURE|Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. A support rod, made of a 24# silicone drainage tube with a 1ml syringe was passed through the mesentery of the small intestine. The support rod was removed two weeks after surgery. It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches.
47975137|NCT05134012|DRUG|[O-15]-Water PET Myocardial Perfusion Imaging (MPI)|\[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
47975138|NCT06221293|DIAGNOSTIC_TEST|immunoenzyme analysis|immunoenzyme analysis with EVOLIS system
47975139|NCT00784992|PROCEDURE|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
47975140|NCT03140553|DRUG|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
47975141|NCT04938804|DEVICE|Low-dose computed tomography|The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
47975142|NCT04449198|DRUG|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
47975143|NCT04449198|OTHER|Placebo|placebo for 12 weeks
47975144|NCT05289180|OTHER|Questionnaires|A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
48332698|NCT01167153|DRUG|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
48332699|NCT00540306|DEVICE|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
48332700|NCT01313832|OTHER|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
48332701|NCT04254055|OTHER|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
48332702|NCT05845307|DRUG|Control Group|Given by PO
47975145|NCT00002862|DRUG|perillyl alcohol|
47975146|NCT00493324|DRUG|alefacept|Intramuscular
47975147|NCT00493324|DRUG|polyvalent pneumococcal vaccine|Injection
48125605|NCT03192215|DRUG|Aspirin|Aspirin 81 mg by mouth once daily.
48125606|NCT02639975|DRUG|PBF-677|once daily oral administration
48125607|NCT02639975|DRUG|Placebo|once daily oral administration
48125608|NCT02831361|DRUG|Gemigliptin|
48125609|NCT02831361|DRUG|Gemigliptin placebo|
48125610|NCT02831361|DRUG|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
48332703|NCT05845307|DRUG|TTI-101|Given by PO
48332704|NCT01297309|DRUG|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
48125611|NCT02831361|PROCEDURE|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
48125612|NCT02139436|OTHER|FES-row-training|
48125613|NCT02139436|OTHER|Arms-only-row training|
48125614|NCT02139436|OTHER|Time Control|
48125615|NCT00446459|DRUG|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
48125616|NCT01290185|DEVICE|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
48332705|NCT00751179|DRUG|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
48332706|NCT00751179|DRUG|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
47975148|NCT05099874|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
48332707|NCT00751179|DRUG|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
48332708|NCT04540835|DRUG|Calcium phosphate desensitizer|Calcium phosphate containing desensitizing agent that creates hydroxyappatite
48332709|NCT03398733|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
48652152|NCT06344923|PROCEDURE|Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing|The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. The seromuscular layer of the ileum or the mesentery was intermittently sutured with peritoneum and the anterior sheath of the rectus abdominis circumferentially with 8-10 stitches (3-0 silk thread). It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches
48652153|NCT06643663|PROCEDURE|Endodontic Micro-Surgery|Pt with apico-marginal defects with interproximal bone loss receiving Endodontic surgery following failure of non surgical root canal treatment.
47975149|NCT00231075|DRUG|Paraplatin|
47975150|NCT00231075|DRUG|Paclitaxel|
48125617|NCT04502472|BIOLOGICAL|Convalescent plasma transfusion|Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
48125618|NCT01030107|BEHAVIORAL|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
48125619|NCT01030107|BEHAVIORAL|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
48125620|NCT06100185|DEVICE|PeakSleep|The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of \<14 minutes with a maximum dose of 1mA (500uA per electrode pair).
48332710|NCT04783220|BEHAVIORAL|Comprehensive structured parent intervention|"1. Educational sessions and coaching on infants' behavior cues~2. Skills on motor stimulation~3. Written instructions for play and stimulation activities at discharge~4. Multidisciplinary follow-up~5. Developmental tracking and advice via a mobile app"
48332711|NCT01948869|DEVICE|Phoenix II (BAY81-2996)|
48332712|NCT01948869|DEVICE|Phoenix I (BAY81-2996)|
48332713|NCT01043848|PROCEDURE|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
48332714|NCT00225056|DRUG|docetaxel and capecitabine|
48332715|NCT02966353|DRUG|ruxolitinib|Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)
48332716|NCT06165523|OTHER|Water|340 mL plain tap water consumed immediately following glycogen depleting exercise
48332717|NCT06165523|OTHER|Flavored Kefir|320 mL kefir consumed immediately following glycogen depleting exercise
48332718|NCT06165523|OTHER|Flavored Milk|240 mL flavored milk consumed immediately following glycogen depleting exercise
48332719|NCT06310837|DRUG|Adalimumab Biosimilars Injection|Adalimumab biosimilars: 80 mg was subcutaneously injected for the first time in the first week, and then 40 mg was subcutaneously injected every two weeks from the first week to the 48 th week.
48125621|NCT06100185|DEVICE|Sham|Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
47975151|NCT03659812|OTHER|MACS technique|MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
47975152|NCT00318110|PROCEDURE|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
48125622|NCT05510310|PROCEDURE|Breast stimulation|By breast pump
48125623|NCT05510310|BIOLOGICAL|Oxytocin|Oxytocin will be administered intravenously and titrated
48125624|NCT05356676|OTHER|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
48125625|NCT05356676|OTHER|Combination Therapy|"1. In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~2. the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~   This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~3. in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
48492700|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
48492701|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
48492702|NCT03565393|COMBINATION_PRODUCT|Fibersol-2|A placebo-controlled, randomized; double-blind 2 arm trial
48492703|NCT02775136|DEVICE|HS-1000 recording|
48492704|NCT01295866|DEVICE|nasal nitric oxide|
48492705|NCT00168311|DEVICE|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
47975153|NCT00002054|DRUG|Pentamidine isethionate|
47975154|NCT03236974|DRUG|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
47975155|NCT03236974|DRUG|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
47975156|NCT00867009|DRUG|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
47975157|NCT00867009|DRUG|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
48492706|NCT00168311|DEVICE|sham TMS|
47975158|NCT00867009|DRUG|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
47975159|NCT03759847|OTHER|Fluid intake app|Use of fluid app to monitor intake of fluids
47975160|NCT03759847|OTHER|Survey|A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
47975161|NCT01447602|BEHAVIORAL|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
48332720|NCT06310837|DRUG|Corticosteroid|Patients received no less than 1 mg / kg.d glucocorticoid at week 0, then implemented according to the standard reduction scheme.
48332721|NCT06310837|DRUG|Immunosuppressive Agents|Mycophenolate mofetil 1g bid for more than 3 months, maintenance dose not less than 0.5g bid
48492707|NCT05709977|OTHER|Acupuncture|Fixed set of acupuncture points
48492708|NCT05709977|DRUG|Antihistamine nasal spray|Carelastin® (1 mg/ml) azelastine nasal spray
48652154|NCT06642818|OTHER|protocolized interview and prevention messages|This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
47975162|NCT04897308|PROCEDURE|Local injection of shoulder joint|Under ultrasound guidance , local shoulder joint injection will be done
48332722|NCT04598711|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
48332723|NCT04598711|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
48332724|NCT04598711|BEHAVIORAL|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
48492709|NCT05397561|OTHER|Turkish Translation of Physical Activity Barriers and Facilitators Scale|Participants to be included in the study will be listed under a special code (traffic code of their city of birth, date of birth and order of participation). The socio-demographic characteristics, age, gender, body weight, height and Body Mass Index (BMI) of the participants will be evaluated and recorded with a specially prepared evaluation form. All participants in the study will complete the Turkish version of the PABFS, the Physical Activity Disability Scale (PADS), the Motivation for Participation in Physical Activity Scale (MPPAS), and the International Physical Activity Questionnaire (IPAQ) at their first visit. Participants will complete the BFYPA again after 7 days.
48492710|NCT05862636|BEHAVIORAL|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
48332725|NCT04598711|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
48492711|NCT04570540|DIAGNOSTIC_TEST|Sleep Study|Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
48492712|NCT04570540|DIAGNOSTIC_TEST|Pulmonary Function Test|Bodyplethysmographic assessment
48492713|NCT04570540|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
48492714|NCT04570540|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
48332726|NCT04598711|BEHAVIORAL|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
48332727|NCT03222622|DRUG|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
48332728|NCT03222622|DRUG|Placebo cream|Apply topically twice daily for 12 consecutive weeks
48492715|NCT00005965|DRUG|bryostatin 1|
48492716|NCT00005965|DRUG|cisplatin|
48492717|NCT00555035|DRUG|GSK1349572|
48492718|NCT02353052|OTHER|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
48492719|NCT05351554|DRUG|Namilumab|Namilumab administered subcutaneously
48492720|NCT05351554|DRUG|Placebo|Placebo administered subcutaneously to match namilumab dosing
48492721|NCT05351554|DRUG|Open label Namilumab|Namilumab administered subcutaneously
48652155|NCT06001697|BEHAVIORAL|Park prescription|The park prescription given by the patients care-provider includes information about the health benefits of spending time in nature and detailed information about the parks in the neighboring area. As well as access to a web-based platform called ParkRx which includes information and details about events in the parks in the study area. Together with information about the frequency and duration of visits to the parks.
48652156|NCT06001697|BEHAVIORAL|Regular health advice|Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.
48332729|NCT05405907|OTHER|PuraBond haemostatic agent|Application of Purabond to surgical field
48652157|NCT01415687|DRUG|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
48492722|NCT05351554|DRUG|Prednisone|Prednisone or equivalent
48492723|NCT05499780|DEVICE|Sentinox|The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
48332730|NCT04154371|DEVICE|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
48332731|NCT01707329|DRUG|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
47975163|NCT04682015|OTHER|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
48332732|NCT01707329|DRUG|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
48332733|NCT04320290|DRUG|Direct Acting Antivirals|8 weeks of DAA treatment
48332734|NCT01345370|DRUG|Temozolomide|According to sites procedures
48332735|NCT01345370|RADIATION|Radiation Therapy|According to sites procedures
48332736|NCT01188538|DRUG|Epiduo gel|Once daily application on the face in the evening for 12 weeks
48332737|NCT01188538|DRUG|BPO|Once daily application on the face in the evening for 12 weeks
48332738|NCT02790710|DRUG|Propanolol|Active treatment
48332739|NCT02790710|DRUG|Placebo|
48652158|NCT01415687|DRUG|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
48332740|NCT06094972|BEHAVIORAL|Adolescent Community Reinforcement Approach, A-CRA|A-CRA consists of eighteen treatment modules/procedures that is delivered in weekly sessions over 12-14 weeks. The overarching goal is to decrease substance use behaviours and other related, problematic behaviours such as acting out when experiencing anger, and to increase prosocial and sober behaviours, relationships and activities. The procedures are: 1) Introduction to A-CRA/treatment agreement, 2) Happiness scale and treatment goals, 3) Homework, 4) Systematic encouragement, 5) Functional analysis of substance use behaviour, 6) Functional analysis of prosocial/sober behaviour, 7) Increasing prosocial activities, 8) Drink/drug refusal, 9) Relapse prevention, 10) Sobriety sampling, 11) Communication skills, 12) Problem-solving, 13) Caregiver sessions, 14) Relationship skills, 15) Couple relationship skills, 16) Job-seeking skills, 17) Anger management, 18) Medication adherence and monitoring. Youths' individual goals and problems guide treatment planning.
48332741|NCT06094972|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care in Sweden. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT and PULS, a program for reducing violence and criminal behavior. Also, individually tailored interventions will be included, such as counselling or other psychological interventions. TAU will be thoroughly registered during the study since the sites in the trial differs slightly in what they offer.
48492724|NCT02776579|OTHER|Girls-only resistance training|
48652159|NCT02399995|BEHAVIORAL|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~* Baseline sociodemographic and clinical variable data sheet (RSA)~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~* EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~* Post surgical follow up disease status and treatment assessment questionnaire~* At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
48652160|NCT03728686|OTHER|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
48652161|NCT03808077|DRUG|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
48652162|NCT03808077|DRUG|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
48652163|NCT06638645|PROCEDURE|VATS/RATS anatomical lung resection|Perioperative care according to the ERAS protocol for lung surgery
48652164|NCT06511193|DRUG|Budenoside/Glycopyrronium/Formoterol|Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
48652165|NCT01417988|DRUG|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
48652166|NCT01417988|DRUG|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
47975164|NCT02076698|PROCEDURE|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
47975165|NCT02076698|DRUG|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
48125626|NCT02424318|DRUG|Topiramate|topiramate 25mg twice 1 week -\> topiramate 50mg twice 7 weeks
48125627|NCT03826875|DRUG|Fluoxetine|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life
48125628|NCT03826875|DRUG|Placebo|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
48125629|NCT00077675|DRUG|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
48125630|NCT00077675|DRUG|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
48125631|NCT04512482|DRUG|Bromelain|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
48125632|NCT04512482|OTHER|Powdered sugar|The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
48125633|NCT06389435|PROCEDURE|Patients will be randomized to undergo TKR or RTKR|Total knee replacement (control group)
48652167|NCT06640400|DEVICE|Cardiovascular ultrasound|Participants in the intervention group will be treated with a medical LIPUS device (838C-M-L-I/II, Shenzhen, China) for 10 days in addition to conventional medical treatment. The ultrasound therapy instrument is equipped with a sound head comprising 5 transducer units, operating at an ultrasonic frequency of 0.84MHz with a sound intensity range of 1 W/cm2 -1.25 W/cm2. The therapeutic ultrasound sessions necessitate a controlled environmental temperature. Patients will assume the supine position, exposing the precordial region, with the five-pronged head positioned parallel to the heart\&amp;amp;amp;amp;#39;s long axis, covering the entire precordial region including the right and left coronary arterial trunks and the aortic root. The ultrasound therapy device operates in a pulsed mode, with each treatment session lasting 20 minutes, comprising 2 daily sessions for a total of 20 treatments.
48125634|NCT01130194|OTHER|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
48125635|NCT05558423|BEHAVIORAL|Time Restricted Eating|Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
48125636|NCT00806169|DRUG|triamcinolone and bevacizumab|
48332742|NCT03040817|PROCEDURE|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
48332743|NCT03040817|DRUG|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
48332744|NCT03624764|PROCEDURE|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
48332745|NCT03624764|PROCEDURE|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
48332746|NCT01504971|OTHER|symptom questionaire|GerdQ questionaire
48332747|NCT01504971|PROCEDURE|pH monitoring|24-hour pH monitoring
48332748|NCT01504971|PROCEDURE|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
48332749|NCT01504971|DRUG|rabeprazole|10mg, bid, p.o.
48332750|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 1|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
48332751|NCT05446194|DEVICE|Non invasive neuromodulation device pattern 2|The study device consists of a headset, which looks like a music earphone headset, and a base station that powers the headset. The headset has metallic earpieces that fit into the ear canals. When activated, the study device will deliver a prescribed stimulation pattern for approximately 20 minutes.
48125637|NCT01798667|DRUG|DA-8031|
48125638|NCT01798667|DRUG|Placebo|Placebo of DA-8031, undistinguishable
48125639|NCT02222493|BIOLOGICAL|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
48125640|NCT02222493|BIOLOGICAL|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
48125641|NCT00468052|DRUG|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
48125642|NCT00468052|DRUG|fentanyl|1 microgram/kilogram as a bolus
48125643|NCT04915261|BEHAVIORAL|Lenient Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
48332752|NCT01303458|BEHAVIORAL|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
48492725|NCT03512262|DRUG|Abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
48125644|NCT04915261|BEHAVIORAL|Strict Arm Restriction|The study will crossover between either strict arm restriction guidelines for patients or lenient arm restrictions.
48125645|NCT03498768|OTHER|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
48125646|NCT06513975|DEVICE|CART BP|A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.
48125647|NCT06513975|DEVICE|sphygmomanometer|Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.
48125648|NCT04736485|DRUG|perioperative treatment|FLOT + Spartalizumab
48125649|NCT00503906|DRUG|Avastin|
48125650|NCT00503906|DRUG|Gemcitabine|
48125651|NCT00503906|DRUG|Abraxane|
48125652|NCT06118749|DIAGNOSTIC_TEST|Antigen detection Rapid Diagnostic Test prototype|The study will focus on the usability and diagnostic performance of the RDT in blood and/or urine from patients with visceral leishmaniasis.
48125653|NCT05246124|OTHER|Zumba dance exercise|The intervention was Zumba dance done 3 times a week during the 2-week self-isolation period, with each session lasting for 50 minutes. The participants did exercise by following instructions from Zumba video shown
48125654|NCT05521672|DRUG|Adipose derived allogenic mesenchymal stem cells (adAMSC)|adAMSC will be administered in the perilesional adipose tissue, through a laparoscopic procedure
48125655|NCT03014518|OTHER|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
48125656|NCT03014518|OTHER|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
48125657|NCT06130228|DIETARY_SUPPLEMENT|Multi-ingredient supplement (PDT-MIS)|Supplementation with active PDT-MIS daily
48125658|NCT06130228|DIETARY_SUPPLEMENT|Placebo (PLA)|Supplementation with inactive placebo
48125659|NCT02500758|PROCEDURE|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
48125660|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
48125661|NCT02500758|PROCEDURE|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
48125662|NCT03401372|DRUG|Doxycycline|Oral doxycycline 100mg twice daily
48332753|NCT06060756|OTHER|questionnaires completion|"Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):~* Pain-related questionnaire~* Endometriosis-specific questionnaire~* Hospital Anxiety and Depression scale~* Questionnaire McGill on Quality Of Life~* Insomnia-related questionnaire"
48332754|NCT01998880|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
47975166|NCT05229601|DRUG|HFB301001|"Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation."
48332755|NCT01998880|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
47975167|NCT03462082|OTHER|Asymmetric STN-DBS|Asymmetric deep brain stimulation
47975168|NCT00449020|DRUG|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
47975169|NCT00449020|DRUG|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
47975170|NCT00449020|DRUG|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
48125663|NCT03401372|DRUG|Bortezomib|1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
48332756|NCT01998880|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
48332757|NCT00000324|DRUG|Tryptophan|
48492726|NCT03512262|DRUG|Placebo|Abaloparatide-matched placebo.
48125664|NCT03401372|DRUG|Cyclophosphamide|300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
48332758|NCT04377269|OTHER|Taping and Bandaging|Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
48332759|NCT03039920|OTHER|Electronic cigarette|Smoking of electronic cigarette
48652168|NCT04316650|BEHAVIORAL|Evaluation Scales|"* PATHOS / PEACCE : hypersexuality diagnostic scale~* PDQ-4+: Personality Diagnostic Questionnaire version 4~* AUDIT~* Life trajectory : THQ~* Cognitive function (MoCA, Stroop)~* ISDSS: and self report of sexual activity and desire~* BARS: Brief Adhesion Rating Scale (treatment observance)~* SF-36 scale : quality of life~* BDI-II : Beck Depression Inventory~* BSSI ; Beck suicidal Inventory~* Cognitive functioning evaluation : Molest and Rape Scale~* Empathy: EMPAT~* Evaluation of Cognitive functioning: denial evaluation and Mc Kibben minimization~* Baratt Impulsivity Scale~* CSBI~* Static 99 and Stable 2007"
48332760|NCT03039920|OTHER|Conventional cigarette|Smoking tobacco cigarette
48332761|NCT05759546|DRUG|Fluzoparib|Parp inhibitor
48332762|NCT05759546|DRUG|Dalpiciclib|CDK4/6 inhibitor
48332763|NCT05759546|DRUG|Fulvestrant/AI|Endocrine therapy
48332764|NCT06375252|OTHER|Central Jugular Vein Catheter Lumen Holder Apparatus|Participants will experience the central jugular vein catheter lumen holder apparatus, perform walking, sitting, supine, right and left side lying activities and fill out the evaluation forms prepared by the researcher. They will then experience the same activities without the apparatus.
48492727|NCT05341297|BEHAVIORAL|ParentKIT|The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
48492728|NCT04872972|OTHER|Simulation based learning|Faculty development courses on simulation based learning
48332765|NCT02919735|DRUG|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
48332766|NCT02919735|DRUG|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
48332767|NCT00489372|DRUG|Se-methyl-seleno-L-cysteine|Given orally
48125665|NCT03401372|DRUG|Dexamethasone|40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
48125666|NCT00179751|DRUG|CC-5013|
48492729|NCT05609123|DIAGNOSTIC_TEST|Endothelial glycocalyx damage assessment|Degradation products of endothelial glycocalyx will be assessed in the blood and urine.
48492730|NCT03522571|BEHAVIORAL|Experimental gingivitis|Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
48492731|NCT03493542|BIOLOGICAL|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
48492732|NCT06456619|OTHER|Tooth restoration|Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
48492733|NCT04797520|DEVICE|Eko CORE Stethoscope|Eko CORE stethoscope will be used as a visual and auditory means of confirming placement of ETT
48492734|NCT04797520|DEVICE|Point of care ultrasound|"Point of care ultrasound will be used as a means of confirming placement of ETT. This is the gold standard used in standard of care"
48492735|NCT00229736|GENETIC|AAV-hAADC-2|9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
48492736|NCT00229736|GENETIC|AAV-hAADC-2|3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
48652169|NCT04316650|OTHER|osteodensitometry|Osteodensitometry
48125667|NCT00179751|DRUG|gemcitabine|
48332768|NCT00489372|OTHER|placebo|Given orally
48332769|NCT00489372|OTHER|pharmacological study|Correlative studies
48332770|NCT00489372|OTHER|laboratory biomarker analysis|Correlative studies
48492737|NCT00468728|DRUG|PAR-101/OPT-80|capsules
48492738|NCT00468728|DRUG|Vancomycin|Capsules
48492739|NCT05550883|OTHER|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
48492740|NCT05550883|DRUG|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
48492741|NCT04890951|PROCEDURE|Hysteropexy|Uterine preservation through suspension
48125668|NCT05973279|OTHER|Tecno Body Prokin Isokinetic Balance System|It provides objectively measurable data in static and dynamic balance measurements. The moving balance platform of the system, which is driven by air piston servo motors, can measure at a working angle of 15 degrees in all directions. The results can be monitored and recorded live on the screen on the device. From these data, each individual's static and dynamic balance score is obtained by summing the forward-backward standard deviation and right-left standard deviation.
48125669|NCT05973279|OTHER|Restorative Therapies RT300 leg/arm/cor:|RT300 is a motorised treatment system. In general there are 3 systems; Passive therapy, Active therapy and a combination of active therapy with some assistance from the motor. The device can be used from a chair, wheelchair or bed and there are two variants that can be used separately; Leg system, Arm system. Electrodes placed on the skin over specific muscle groups are connected via a cable or wirelessly to the RT300. These are used to stimulate peripheral motor nerves, causing the muscles to work. The software of the SAGE controller unit of the RT300 monitors the treatment process, including the stimulation patterns sent to the arms or legs, and the operation of the ergometer motor to produce smooth cycling motion. Contraindicated in the presence of lower limb fractures or pregnancy.
48652170|NCT04316650|BIOLOGICAL|blood samples|"* Lipid profile (total cholesterol, triglycerides, HDL cholesterol)~* Liver function (ASAT, ALAT, total bilirubin, transferase gamma-glutamyl et alcalin phosphatases~* Kydney function~* Blood count~* Biological Measurements and Measurement of Systematic Plasma Testosterone and TeBG Levels in Sex Offenders check for pathology of the Gonadotropin Axis~* Biological Measurements of Plasma Prolactin level"
48125670|NCT05973279|OTHER|CSMI (CYBEX) Humac Norm Isokinetic Test and Exercise System|22 isolated joint movement models, 4 resistance modes (isokinetic, isotonic, isometric and passive) and a large number of reports to meet the measurement and exercise needs of today's clinicians and researchers. The exercise modes of the device include; Continuous passive movement, multi-angle isometry, proprioception training, standard and eccentric focused isokinetic strengthening, deceleration training, dynamic isotonic training, strength training. Test modes of the device include; Proprioceptive, co-measured, standard isokinetic, concentric/eccentric isokinetic, intermittent stroke isokinetic test.
48125671|NCT01647581|DEVICE|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
48125672|NCT01647581|DEVICE|NO hemoclip placement|No hemoclip placement (placebo / sham)
48125673|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
48125674|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
48652171|NCT04316650|OTHER|ECG|ECG (heart rate, search for cardiac conduction disorders or cardiac arrhythmias)
48125675|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
48125676|NCT01412736|DRUG|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
48652172|NCT04316650|GENETIC|Blood and saliva samples|Blood and saliva samples
48125677|NCT00220675|DRUG|Erythropoietin infusion|
48652173|NCT06023498|OTHER|Manual Therapy and Exercise|"The 20-minute manual therapy procedures will include:~* Distraction-manipulation: manually assisted segmental lumbar traction manipulation using a specialized treatment table~* Neural mobilization: rhythmic stretches of the sciatic and femoral nerves75~* Hip, sacroiliac and lumbar facet mobilizations to improve joint mobility~* Soft tissue mobilization of lumbopelvic and lower extremity muscles using manual pressure over taut bands/myofascial trigger points and post-isometric (contract-relax) stretching techniques."
48652174|NCT06023498|OTHER|Intramuscular Electroacupuncture|As described previously
48652175|NCT01996046|OTHER|FDG PET/CT scan|\[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
48652176|NCT06305403|DIAGNOSTIC_TEST|serum creatinin level|Serum creatinine and urine amounts will be checked for five days.
48652177|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
48125678|NCT00249769|BIOLOGICAL|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
48332771|NCT01234896|DRUG|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
48332772|NCT01234896|DRUG|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
48652178|NCT00552279|BIOLOGICAL|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
48652179|NCT06643000|DRUG|furmonertinib|furmonertinib (240 mg/d,po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy / pemetrexed (500 mg/m²) intravenous chemotherapy, administered every 3 weeks.
48332773|NCT01234896|DRUG|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
48332774|NCT01234896|DRUG|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
48492742|NCT04890951|PROCEDURE|Hysterectomy and vaginal vault suspension|Uterine removal and sewing the vagina upwards
48492743|NCT00449826|PROCEDURE|Computed Tomographic Angiography|CT scan
48652180|NCT04562805|DEVICE|DynamX Bioadaptor|DynamX Bioadaptor Treatment
48652181|NCT04562805|DEVICE|Resolute Onyx|Resolute Onyx Treatment
48652182|NCT04559464|DEVICE|AeriSeal|The AeriSeal Foam functions by blocking both small airways and collateral channels causing absorption atelectasis in the treated region of the lung. Occlusion with the foam also yields a targeted fibrotic response which durably reduces lung hyperinflation. The reduction in hyperinflation allows the healthier parts of the lung to re-inflate and improve breathing mechanics and gas exchange. In this study, the AeriSeal delivery will be limited to three segments that contain the collateral channel(s) between lung lobes. A minimum 10 mL volume of AeriSeal will be delivered per segment, with a total delivered volume limit of 40 mL per subject (including re-treatment, if needed) in a total of three segments.
47975171|NCT00449020|RADIATION|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
47975172|NCT02132130|DRUG|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
47975173|NCT05737303|DRUG|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
47975174|NCT02992106|OTHER|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~* Children aged 0-6 years old:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Ages and Stages Questionnaire~ 5. Strengths and Difficulties Questionnaire~ 6. Questionnaire on developmental milestones~ 7. Questionnaire on behaviour~* Children older than 6 years:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Pediatric Quality of Life Questionnaire~ 5. Children's Behaviour Questionnaire in Dutch~ 6. Questionnaire on developmental milestones~ 7. Developmental Coordination Disorder Questionnaire~ 8. Strengths and Difficulties Questionnaire"
47975175|NCT02992106|OTHER|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
47975176|NCT02992106|OTHER|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
47975177|NCT02992106|OTHER|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
47975178|NCT02992106|OTHER|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
47975179|NCT02992106|OTHER|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
47975180|NCT02992106|OTHER|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
47975181|NCT05531084|DEVICE|Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)|Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
47975182|NCT05433792|DEVICE|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
47975183|NCT05433792|DEVICE|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
47975184|NCT06334471|OTHER|no intervention needed|no intervention needed
47975185|NCT02892071|DRUG|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
47975186|NCT02892071|DEVICE|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
48332775|NCT00141037|DRUG|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
48332776|NCT00141037|DRUG|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m\^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m\^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
48332777|NCT00141037|DRUG|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing \<40 kg and 1.5 mg/kg/day in subjects weighing \>40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
48492744|NCT03342599|DIETARY_SUPPLEMENT|Alpha Lipoic Acid Supplement|Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
48125679|NCT00249769|BIOLOGICAL|Measles Vaccine (MV)|"The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979."
48125680|NCT04729972|COMBINATION_PRODUCT|NT-501 CNTF implant|Single implantation of CNTF-secreting NT-501 device into one eye
48125681|NCT01082575|DEVICE|Oxygen Monitoring|No intervention
48125682|NCT04065958|BEHAVIORAL|Yoga-mindfulness|Body-mind therapy
48125683|NCT04065958|BEHAVIORAL|Patient education and physiotherapy|Lectures and physiotherapy
48125684|NCT02189915|DRUG|Creatine monohydrate|
47975187|NCT02892071|DEVICE|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
48125685|NCT00558506|DRUG|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
48125686|NCT04658693|DEVICE|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
48492745|NCT03342599|DIETARY_SUPPLEMENT|Placebo|Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
48652183|NCT04559464|DEVICE|Zephyr Valves|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
47975188|NCT03258021|DEVICE|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
47975189|NCT05741320|OTHER|questionnaire|27 questions will be asked to public to find out what is the role of anesthetists after the covıd pandemic
47975190|NCT02516683|OTHER|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
47975191|NCT04454268|PROCEDURE|cyst extirpation|complete removal of the cyst without rupture
47975192|NCT02023398|DEVICE|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
48125687|NCT01302158|DRUG|ASP1941|oral
48125688|NCT01302158|DRUG|Glimepiride|oral
48125689|NCT05297175|DEVICE|Trammpolin medial meniscus prosthesis|Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
48125690|NCT01691846|DRUG|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
48125691|NCT01691846|DRUG|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
48652184|NCT05928572|OTHER|CGM initiation approach|Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
48652185|NCT04373551|BEHAVIORAL|Cultural adaptation of a patient-provider communication tool|Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
48652186|NCT05064423|BEHAVIORAL|Clinical Trials Education Program|The Community Health Educator (CHE) will provide CT education and outreach to increase clinical trial knowledge and the importance of clinical trials research and participation. The clinical trials educational activities will include the use of NCI Colorectal Cancer resources and materials, including a PowerPoint presentation, clinical trials information, and online resources. The CHE will tailor the PowerPoint slides to ensure that they are culturally tailored, visually appealing, low-literacy, language appropriate and include appropriate visuals. The CTs educational sessions will be delivered in Spanish and English and will take approximately 45 minutes to 1 hour.
47975193|NCT02023398|DEVICE|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
48125692|NCT00276601|DRUG|arsenic trioxide|
48125693|NCT00276601|DRUG|cytarabine|
48125694|NCT00276601|DRUG|daunorubicin hydrochloride|
48125695|NCT00276601|DRUG|mercaptopurine|
48125696|NCT00276601|DRUG|methotrexate|
47975194|NCT00286403|DRUG|Fenoldopam Mesylate and/or MESNA|
48125697|NCT00276601|DRUG|tretinoin|
48125698|NCT02356341|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
48125699|NCT05003778|OTHER|Traditional equipment resistance training|Participants will undergo 6 weeks of traditional equipment resistance training
48125700|NCT05003778|OTHER|Minimal equipment resistance training|Participants will undergo 6 weeks of minimal equipment resistance training
48125701|NCT05003778|OTHER|Blood flow restriction training|Participants will undergo 6 weeks of blood flow restriction training
48125702|NCT04086849|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
48125703|NCT02538653|OTHER|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
48125704|NCT02538653|OTHER|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
48125705|NCT03401320|DRUG|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
48125706|NCT04695483|DRUG|Corifollitropin alfa|Controlled ovarian stimulation long-acting protocol
47975195|NCT00048555|DRUG|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
47975196|NCT03793777|DIETARY_SUPPLEMENT|Aronia|daily supplementation
47975197|NCT03793777|DIETARY_SUPPLEMENT|Placebo|daily supplementation
48332778|NCT00141037|DRUG|Tacrolimus|Taken orally from immediately preoperatively to those\>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects \<age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) \&5-7 ng/mL \>= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 \& 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
48332779|NCT00141037|DRUG|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
48332780|NCT00141037|DRUG|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
48332781|NCT00141037|DRUG|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
48332782|NCT05444413|BIOLOGICAL|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
48332783|NCT06027879|BIOLOGICAL|Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
48332784|NCT05130372|OTHER|Static Stretching Method Group|Static stretching has been the most common stretching method applied to the ankle in healthy older adults, and different protocols have proven to increase ankle range of motion. In this study, the static stretching method was actively applied while standing.
48332785|NCT05130372|OTHER|PNF Stretching Method Group|The contract-relax technique was used in the PNF stretching method.
48652187|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (intervention group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
48652188|NCT06563674|OTHER|Acceptance-based healthy lifestyles program (control group)|The acceptance-based healthy lifestyles program consists of 4 biweekly 60-min face-to-face interactive workshops to cover the knowledge of pneumoconiosis, exercise to maintain lung function, health diet, and home safety.
48332786|NCT05130372|OTHER|Myofascial Relaxation Method Group- Roller Massage|A theraband roller massager (Theraband®, The Hygenic Corporation, Akron, OH) was used for the myofascial relaxation method.
47975198|NCT02350790|PROCEDURE|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
48125707|NCT04695483|DRUG|Follitropin Beta|Daily controlled ovarian stimulation protocol
48125708|NCT04221828|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles. For clinical administration, the NanoPac powder in vial is suspended with Sterile Reconstitution Solution (1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP) and then further diluted with 0.9% Sodium Chloride for Injection, USP, to achieve the final clinical formulation.
48125709|NCT02345720|DEVICE|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
48125710|NCT02251652|DRUG|Ingenol Mebutate|Ingenol mebutate 0.05% gel
48125711|NCT02251652|PROCEDURE|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
48125712|NCT02974322|DRUG|GED-0301|GED-0301
48125713|NCT02974322|DRUG|Placebo|Placebo
48332787|NCT01768338|DRUG|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
48332788|NCT04347278|DRUG|Patients with the treatment agains COVID19|"Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise."
47975199|NCT02350790|PROCEDURE|Robotic excision|Robotic excision of endometriosis
48125714|NCT01622868|OTHER|Laboratory Biomarker Analysis|Correlative studies
48125715|NCT01622868|DRUG|Lapatinib Ditosylate|Given PO
48125716|NCT01622868|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48125717|NCT01622868|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
48125718|NCT04553523|DEVICE|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
48125719|NCT04553523|PROCEDURE|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
48125720|NCT04553523|DEVICE|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
48125721|NCT00404742|DRUG|Placebo|PO BID
48125722|NCT00404742|DRUG|LX211|0.2 mg/kg, twice a day (BID)
47975200|NCT05205005|DRUG|Endocalyx|3,712mg (six capsules) of DSGP for eight weeks.
48125723|NCT00404742|DRUG|LX211|0.4 mg/kg, twice a day (BID)
47975201|NCT05205005|DRUG|Placebo|Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
47975202|NCT00717691|DEVICE|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
47975203|NCT00717691|OTHER|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
47975204|NCT03907358|PROCEDURE|phacoemulsification|
47975205|NCT04966715|PROCEDURE|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
47975206|NCT03383198|DRUG|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
47975207|NCT03383198|DRUG|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
48125724|NCT00404742|DRUG|LX211|0.6 mg/kg, twice a day (BID)
48125725|NCT04452318|DRUG|REGN10933 + REGN10987|Subcutaneous (SC) or Intramuscular (IM) injections
48125726|NCT04452318|DRUG|Placebo|SC or IM injections
48125727|NCT00254657|DRUG|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
48125728|NCT00254657|DRUG|Placebo|
48125729|NCT03589625|OTHER|Solar Suitcase|"The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly."
48125730|NCT00115089|DRUG|R926112|
48125731|NCT00115089|DRUG|Beclomethasone dipropionate|
47975208|NCT04943185|DEVICE|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
47975209|NCT05764759|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
47975210|NCT05764759|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
47975211|NCT04566991|DRUG|Deferoxamine|"There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine."
48125732|NCT05395403|DEVICE|Blood pressure measurement device|The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
48125733|NCT00822367|DIETARY_SUPPLEMENT|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
48125734|NCT00645359|PROCEDURE|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
48125735|NCT02378779|OTHER|Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)|The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
48125736|NCT02378779|OTHER|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
48125737|NCT02378779|OTHER|Humour|Use the humour to approach the subject of premature ejaculation
48125738|NCT02378779|OTHER|Take the drama out|Take the drama out to approach the subject of premature ejaculation
48125739|NCT02378779|OTHER|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
48125740|NCT02378779|OTHER|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
48125741|NCT02378779|OTHER|Help to verbalize|Help for the patient to speak about premature ejaculation
48125742|NCT02192242|OTHER|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
48125743|NCT02807805|DRUG|Abiraterone Acetate|Given PO
48125744|NCT02807805|DRUG|Niclosamide|Given PO
48125745|NCT02807805|DRUG|Prednisone|Given PO
48125746|NCT01298934|DRUG|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
48125747|NCT06357234|DRUG|Aprepitant|Two doses of 40mg (2ml) Aprepitant. One to be given on the morning of surgery and the second on the morning of post-op day 1
48125748|NCT06357234|DRUG|Placebo|Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
48125749|NCT03791905|DRUG|Paclitaxel|chemotherapy drug
48125750|NCT03791905|DRUG|Cisplatin|chemotherapy drug
48125751|NCT03791905|DRUG|Oxaliplatin|chemotherapy drug
48652189|NCT04570943|COMBINATION_PRODUCT|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
48652190|NCT04570943|RADIATION|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
48652191|NCT05043831|DEVICE|DSLT|Direct-SLT is applied via the limbus to the trabecular meshwork
47975212|NCT04566991|DRUG|Placebo|There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
47975213|NCT02674152|DRUG|BI 836880|
48652192|NCT01251757|OTHER|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
47975214|NCT03744611|DIETARY_SUPPLEMENT|CE|550mg capsule (Eucommia ulmoides Oliver extract)
48125752|NCT03791905|DRUG|5-FU|chemotherapy drug
48125753|NCT03791905|DRUG|Leucovorin|chemotherapy drug
48125754|NCT03791905|RADIATION|Intensity-modulated radiotherapy|radiotherapy technique
48125755|NCT03791905|DEVICE|PET|Using PET to evaluate response to induction chemotherapy
48332789|NCT04438772|OTHER|Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia|Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
48332790|NCT04629638|OTHER|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
48332791|NCT02783144|PROCEDURE|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
48332792|NCT02783144|OTHER|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
48492746|NCT05889234|DEVICE|Modified Electroconvulsive Therapy|MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions
47975215|NCT03744611|DIETARY_SUPPLEMENT|Placebo|550mg capsule (Placebo)
47975216|NCT01906008|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
47975217|NCT01906008|DRUG|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
47975218|NCT01906008|BEHAVIORAL|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
47975219|NCT01906008|BEHAVIORAL|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
48125756|NCT06384820|DRUG|cemiplimab|Administered Intravenous (IV) infusion every three weeks (Q3W)
48125757|NCT06384820|DRUG|fianlimab|IV infusion Q3W
48125758|NCT06239012|DEVICE|Position measurement with BePow|14 measurements taken with the device
48125759|NCT06239012|OTHER|Position measurement with MCPAA scale|MCPAA : measurement of seated postural control in adults in French 12 measurements taken with the goniometer
48125760|NCT05594511|PROCEDURE|Muscle-energy mandibular technique|A single session will be used with the mandibular musculoenergy technique. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
48125761|NCT05594511|PROCEDURE|Sham technique|A single session with a sham technique simulating the suboccipital muscle inhibition technique will be used. It will last approximately 2-3 minutes and will be performed by a physiotherapist.
48125762|NCT03991754|PROCEDURE|transcatheter aortic valve implantation|transcatheter aortic valve implantation
48125763|NCT05990816|DIAGNOSTIC_TEST|Blood works for homocysteine levels|In a single patient group of 80 people, the natural course of homocysteine after total joint arthroplasty will be examined by blood work analyzes at the 1,2,3,4 and 6th weeks after operation
48125764|NCT01091740|DEVICE|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
48125765|NCT01091740|DEVICE|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
48125766|NCT02036112|PROCEDURE|conventional ELAPE|device
48125767|NCT02036112|PROCEDURE|Individual ELAPE|device
48125768|NCT05546710|DEVICE|miraDry treatment|The miraDry device is non-invasive and uses microwave energy, focused at the dermal/hypodermal interface, to thermally impact the sweat glands. The treatment area is identified (hair bearing area of the axilla) and high-volume anesthesia is delivered. The miraDry template is selected based upon the size of the treatment area and temporarily applied to the patient's skin. A new miraDry bioTip is attached to the miraDry Handpiece for each treatment session. The Handpiece is then placed on the surface of the skin in the area to be treated. The treatment cycle is activated by a button on the Handpiece. Multiple placements of the Handpiece are required to treat a full axilla in one treatment session.
48125769|NCT03966898|DRUG|SHR6390 Tablets|SHR6390 Tablets
48652193|NCT01251757|OTHER|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
47975220|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Induction Phase|To each of two test sites, approximately 20 μl/cm\^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm\^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm\^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
47975221|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Challenge Phase|5 μl/cm\^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm\^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm\^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
47975222|NCT04579185|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
47975223|NCT01740193|PROCEDURE|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
47975224|NCT01740193|PROCEDURE|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
47975225|NCT03766633|DIAGNOSTIC_TEST|Liver volumetry of the graft on CT|Preoperative liver volumetry using the CT images of the potential living liver donors.
47975226|NCT01648101|DRUG|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
47975227|NCT01648101|DRUG|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
48125770|NCT03966898|DRUG|Placebo Tablets|Placebo Tablets
48125771|NCT03966898|DRUG|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
48125772|NCT03865056|DEVICE|Optiflow (High-flow Nasal Cannula)|Optiflow will be applied for 20 minutes
48125773|NCT03865056|DEVICE|Non-invasive Ventilation|non-invasive ventilation will be applied for 20 minutes
48125774|NCT00790413|DRUG|iodine I 131 metaiodobenzylguanidine|
48125775|NCT00790413|DRUG|Fludarabine|
48125776|NCT00790413|DRUG|Thiotepa|
48652194|NCT06188247|DEVICE|NightOwl home-monitoring|The NightOwl™ system consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl™ software. The sensor is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl™ sensor acquires accelerometer data and reflectance-based photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
48125777|NCT00790413|PROCEDURE|T-cell depletion|
48652195|NCT06440538|DEVICE|PCMS + Contralateral Motor Training|PCMS + Contralateral Motor Training will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2 Hz) to the weaker first dorsal interosseous (FDI) muscle immediately before a session of ballistic index finger abduction training at the opposite, stronger FDI muscle.
48652196|NCT06440538|DEVICE|PCMS + Rest|PCMS + Rest will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2Hz) to the weaker FDI followed by a 30-min rest.
48125778|NCT00790413|PROCEDURE|Haploidentical stem cell transplantation|
48125779|NCT00790413|PROCEDURE|Donor Lymphocyte Infusion|
48125780|NCT00790413|DRUG|Rituximab|
48125781|NCT00790413|PROCEDURE|Co-transplantation of mesenchymal stem cells|
48125782|NCT03707236|BEHAVIORAL|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
48652197|NCT06440538|DEVICE|Sham PCMS + Contralateral Motor Training|360 TMS pulses will be delivered at a location 10-cm posterior to the participant's head (into the air, 0.2Hz) and no PNS pulses will be generated, followed by a session of 30-min ballistic index finger abduction training at the opposite, stronger FDI muscle.
48652198|NCT03403790|DRUG|Quetiapine|Oral (extended-release tablet)
47975228|NCT01648101|OTHER|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
47975229|NCT06508216|DRUG|Dato-DXd|Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days
47975230|NCT06508216|DRUG|Durvalumab|Patients in module 2 only will receive Durvalumab 1120mg every 21 days
47975231|NCT02547454|DRUG|Methoxy polyethylene glycol-epoetin beta|
47975232|NCT04834076|DIAGNOSTIC_TEST|ELISA|ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.
47975233|NCT04834076|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
48125783|NCT00168753|DRUG|Alefacept|IM
48125784|NCT02389855|PROCEDURE|NeuroBlate® System Therapy|
48652199|NCT04366531|BEHAVIORAL|START-VET|prison reentry program
47975234|NCT04834076|DIAGNOSTIC_TEST|Sequencing|DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.
47975235|NCT02498184|OTHER|acupuncture|
47975236|NCT04868890|BIOLOGICAL|Ampion|Inhaled Ampion
47975237|NCT04868890|OTHER|Placebo|Inhaled Placebo
48125785|NCT04294862|DRUG|TNP-2092|TNP-2092 for injection 100mg/vial
48125786|NCT02426138|OTHER|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
48652200|NCT04366531|OTHER|Treatment as usual|This intervention involves no additional services above what is provided by the local health care system
48652201|NCT06569628|COMBINATION_PRODUCT|Envita Stories Methodology in Long-term care Centres for old adults|Collaborative intervention program in long-term care Centres for old adults between professionals, old adults, families and volunteers that aims to foster person-centered care and promote meaningful relationships through the digitization of life stories and life project methodologies in a timeline.
48125787|NCT02426138|OTHER|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
48125788|NCT02752659|PROCEDURE|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
48125789|NCT01506934|DRUG|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
48125790|NCT02754596|DRUG|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
48125791|NCT02754596|DRUG|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
48125792|NCT02754596|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
48125793|NCT05493969|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
48652202|NCT06569628|BEHAVIORAL|Contact Methodology in Long-term Care Centres for old adults|Professionals know and use Envita Stories Methodology but do not apply it directly with these people.
48652203|NCT02990702|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
48125794|NCT06037993|DIETARY_SUPPLEMENT|Ultra-micronized Palmitoylethanolamide (PEA)|"Palmitoylethanolamide (PEA) is an N-acylethanolamine (AE), produced on demand by different cell types as a response to actual or potential damage, proven to down-regulate central and peripheral activity of mast cells and non-neuronal cells (e.g., astrocytes, microglia) and to exert protective functions against glutamate neuro-toxicity, accounting for its naturally-occurring anti-inflammatory, analgesic, and anticonvulsant properties. Due to the shared pharmacodynamic properties, PEA is considered as the endogenous equivalent of Cannabidiol (CBD). A growing body of literature has confirmed the role of PEA in most neurobiological mechanisms underpinning several neuropsychiatric conditions both in clinical and preclinical settings. The effect of PEA over neuroinflammation and glutamate signaling may represent a promising biobehavioral mechanism underlying the clinical utility of its oral supplementation in CHR state."
48652204|NCT02990702|OTHER|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
48652205|NCT02990702|DRUG|Bupivacaine|
48652206|NCT02990702|DEVICE|Ultrasound|
48652207|NCT06501209|BEHAVIORAL|5A-5R-based counselling session|"The 5As (Ask, Advise, Assess, Assist, Arrange) summarize all the activities that a healthcare provider can do to help a tobacco user (both smoking within 3-5 minutes in a primary care setting. This model can guide you through the right process to talk to respondents who are ready to quit tobacco use and deliver advice.~The 5 R's - relevance, risks, rewards, roadblocks, and repetition - are the content areas that should be addressed in a motivational counseling intervention to help those who are not ready to quit."
48652208|NCT06501209|BEHAVIORAL|Counseling through mobile phone call and text message|Participants will get weekly a phone call and a text message
48652209|NCT05488964|BEHAVIORAL|Exercise|Supervised endurance training with moderate-to-high intensity 3-4 times weekly.
48652210|NCT06424119|BEHAVIORAL|Traditional Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to TCR arm, they will attend 36 sessions of the program at one of three locations.
47975238|NCT03198234|BIOLOGICAL|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
47975239|NCT02612324|BEHAVIORAL|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
47975240|NCT02612324|BEHAVIORAL|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
48125795|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
48652211|NCT06424119|BEHAVIORAL|Intensive Cardiac Rehabilitation|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm, they will attend 72 sessions of the program at one of three locations.
48652212|NCT06424119|OTHER|C2life® Food|Patient must have a qualifying cardiovascular event and eligible for ICR. Once patient is randomized to ICR arm with food, they will receive the food at the beginning of the second week of their respective program. Food will be delivered by mail weekly for a total of 11 weeks to the patient's home address.
48652213|NCT05796193|OTHER|Alpha-cypermethrin and PBO LLIN|Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
48332793|NCT02783144|DRUG|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
47975241|NCT05931861|DEVICE|T2769|T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
47975242|NCT03957720|DRUG|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
47975243|NCT03957720|DRUG|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
47975244|NCT03957720|DRUG|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
47975245|NCT03957720|DRUG|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
47975246|NCT00791245|BIOLOGICAL|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
47975247|NCT01277263|DEVICE|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
47975248|NCT03421119|DRUG|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
47975249|NCT03421119|DRUG|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
47975250|NCT03421119|DRUG|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
47975251|NCT01411774|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
47975252|NCT01411774|DRUG|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
48332794|NCT00030355|DRUG|homoharringtonine|
48492747|NCT05889234|DRUG|Conventional pharmacotherapy|Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
47975253|NCT01411774|DRUG|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
47975254|NCT06485882|BEHAVIORAL|Self-Care Training|Animation films are watched children about self-care and social competence
48492748|NCT00593632|DIETARY_SUPPLEMENT|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
47975255|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
47975256|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
47975257|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
47975258|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
47975259|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
47975260|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
47975261|NCT00039832|DRUG|Abciximab (ReoPro) and Reteplase (Retavase)|
47975262|NCT03021408|OTHER|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
47975263|NCT03021408|OTHER|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
48332795|NCT00030355|PROCEDURE|chemotherapy|
48332796|NCT05610657|DRUG|Mitapivat|Mitapivat tablets
48332797|NCT06049615|DEVICE|CLAAS® System|The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
48332798|NCT01920438|PROCEDURE|Percutaneous Endoscopic Gastrostomy|PEG
48492749|NCT01391741|OTHER|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
48125796|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
48332799|NCT01920438|PROCEDURE|Radiologically-guided insertion of Gastrostomy|RIG
48332800|NCT02762019|DEVICE|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
48332801|NCT02762019|DEVICE|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
48492750|NCT01391741|OTHER|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
47975264|NCT03021408|OTHER|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
48492751|NCT05667350|OTHER|Blood drawing|Blood drawing before anti-cancer therapy
47975265|NCT01575769|DRUG|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
47975266|NCT01428544|DRUG|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
47975267|NCT04860453|GENETIC|WES via Illumina NextSeq 550 sequencing system|Sequencing will be performed on an Illumina sequencing system
47975268|NCT04860453|DIAGNOSTIC_TEST|Blood Draw|Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory
47975269|NCT04860453|DIAGNOSTIC_TEST|Skin biopsy|Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory
47975270|NCT04860453|DIAGNOSTIC_TEST|Saliva Sample|Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
47975271|NCT04446520|PROCEDURE|autogenic drainage|breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)
47975272|NCT03262818|DEVICE|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
48125797|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
48332802|NCT02939599|DRUG|QCC374|0.015mg and 0.06mg
48332803|NCT05772442|DIAGNOSTIC_TEST|Extra blood samples (5-10 mL) drawn|Extra blood samples will be sent for metabolomics analysis.
48332804|NCT02670018|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg \* 2 tablets, for 1 day
48492752|NCT05667350|OTHER|Blood drawing|Blood drawing before radical treatment
48492753|NCT04375865|DRUG|AD-2111|celecoxib 200mg
47975273|NCT03262818|DEVICE|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
47975274|NCT06340815|DEVICE|Radiation: Proton Therapy System (ProBeam)|"All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.~And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA."
47975275|NCT00964860|DEVICE|Glide dental floss|Glide waxed dental floss
47975276|NCT05773963|DEVICE|Irilens; Iridina; Afomill Lubricating Eye Drops|"* Irilens (with 0.4% HA as key ingredient);~* Iridina (with 0.4% HA as key ingredient);~* Afomill Lubricating Eye Drops (with 0.2% HA as key ingredient and distilled water of Chamomile)."
47975277|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
48125798|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
48125799|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
48125800|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
48125801|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
48125802|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
48125803|NCT00624442|DRUG|Placebo|IV infusion for 2 hours
48125804|NCT00624442|DRUG|Placebo|IV infusion for 24 hours
48332805|NCT02670018|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg \* 2 tablets, for 1day
48332806|NCT00133835|PROCEDURE|Extracorporeal shock wave lithotripsy|
48332807|NCT00133835|PROCEDURE|Endoscopic drainage of the main pancreatic duct|
48492754|NCT04375865|DRUG|AD-2112|Tramadol 150mg
48125805|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
48332808|NCT05994963|DRUG|sisunatovir|Administered as either capsules in fasted state or tablet in fasted or fed state.
48332809|NCT01924299|DRUG|Baricitinib|Administered orally
48332810|NCT01924299|DRUG|Ketoconazole|Administered orally
48492755|NCT03582826|BEHAVIORAL|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
48492756|NCT03582826|BEHAVIORAL|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
48125806|NCT00624442|DRUG|Placebo|IV infusion for 72 hours
48492757|NCT06150456|PROCEDURE|extraction|extraction: in all groups, extraction will be performed
48125807|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
47975278|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
47975279|NCT00220870|BEHAVIORAL|Decision aid|
47975280|NCT03909256|OTHER|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
47975281|NCT01554553|PROCEDURE|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
47975282|NCT01110434|DRUG|Topiramate|Topiramate (200 mg daily)
47975283|NCT01110434|DRUG|Placebo|Placebo (daily)
47975284|NCT04419584|DRUG|Modified Qing-Ying Decoction|Herbal granules
47975285|NCT04419584|DRUG|Identical looking placebo|Placebo granules
47975286|NCT01150864|DEVICE|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
47975287|NCT03107754|DRUG|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
47975288|NCT03107754|DRUG|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
47975289|NCT04913402|OTHER|Sufentanil administered by paramedics after the phone call consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
47975290|NCT04913402|OTHER|Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
47975291|NCT02302027|DEVICE|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 \* 67 \* 36 cm
47975292|NCT03090113|DRUG|Shuxuetong Injection|intravenous drip
47975293|NCT03090113|DRUG|Placebo Injection|intravenous drip
47975294|NCT02755558|BEHAVIORAL|Low energy density|Low energy density milk served
47975295|NCT02755558|BEHAVIORAL|High energy density|High energy density milk served
47975296|NCT02755558|BEHAVIORAL|Small portion|Small portion of milk served
47975297|NCT02755558|BEHAVIORAL|Large portion|Large portion of milk served
47975298|NCT02839070|OTHER|Sleep/Wake Schedule|Timing of sleep and wake
47975299|NCT00830596|OTHER|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
47975300|NCT00830596|OTHER|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
47975301|NCT00830596|OTHER|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
47975302|NCT06040125|BEHAVIORAL|Supervised Circuit Training|16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.
47975303|NCT05578391|BIOLOGICAL|Convalescent plasma|Admistration of one unit of convalescent plasma
47975304|NCT03116893|DRUG|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
48492758|NCT06150456|RADIATION|low level laser therapy|extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
47975305|NCT03116893|DRUG|Itraconazole|Administration of itraconazole together with BI 685509
47975306|NCT03116893|DRUG|Rifampin|Administration of rifampicin together with BI 685509
47975307|NCT03116893|DRUG|BI 685509 Fasted Conditions|BI 685509, given alone
47975308|NCT00543140|DEVICE|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
47975309|NCT05588232|PROCEDURE|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
47975310|NCT02875756|PROCEDURE|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
48125808|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
47975311|NCT02875756|PROCEDURE|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
47975312|NCT06054698|DRUG|HRS9531 injection|HRS9531 injection , QW，36 weeks
48125809|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
48125810|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
48332811|NCT01924299|DRUG|Fluconazole|Administered orally
48332812|NCT03385499|BIOLOGICAL|blood additional samples|additional samples of mother's blood and umbilical cord at delivery
48332813|NCT02613702|PROCEDURE|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
48332814|NCT02613702|PROCEDURE|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
48652214|NCT05796193|OTHER|Alpha-cypermethrin and Clorfenapyr LLIN|Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
48125811|NCT03762434|OTHER|mobile application|"Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management."
48652215|NCT05796193|OTHER|Alpha-cypermethrin only LLIN|reference: standard pyrethroid LLIN
48125812|NCT01156155|RADIATION|Digital xray of jaw and teeth|one time xray of jaw and teeth
48125813|NCT01156155|PROCEDURE|Blood draw|Three to four tablespoons of blood drawn.
48125814|NCT01156155|OTHER|questionnaires|completed questionnaires regarding patient's health and functional ability.
48125815|NCT01156155|PROCEDURE|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
48125816|NCT01156155|OTHER|Bilateral digital xray of hands|One time digital xray of hands
48125817|NCT01935544|DEVICE|Botulinum toxin injection|
48125818|NCT04547413|BEHAVIORAL|STI/HIV Intervention Behavioral Intervention Program|In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
48652216|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.
48652217|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
48125819|NCT03177044|BEHAVIORAL|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
48125820|NCT01501604|DRUG|BKM120|100 MG PO QD in cycles of 28 days
48125821|NCT03102853|OTHER|Nordic diet|
48125822|NCT03102853|OTHER|Control diet|
48125823|NCT02492516|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
48492759|NCT06150456|BIOLOGICAL|Plenum® OSShp and Plenum® Guide|extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
48652218|NCT03583710|DRUG|Cisplatin|Given IV
48652219|NCT03583710|DRUG|Etoposide|Given IV
48652220|NCT03583710|DRUG|Mitotane|Given PO
48125824|NCT04949503|DRUG|nimotuzumab|Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).
48125825|NCT03283371|DRUG|Natalizumab|As specified in the treatment arm.
48125826|NCT03283371|OTHER|Placebo|As specified in treatment arms.
48125827|NCT01902147|OTHER|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
48125828|NCT01562834|DRUG|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
48125829|NCT01562834|DRUG|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
48125830|NCT04577924|OTHER|Interview|"Trained research assistants would abstract the data as per a preset proforma. The data would be collected from the patient (if coherent), pre-hospital care provider or primary care provider.~Data would was also obtained from patient records and the proforma filled by the attending doctors on duty.~Follow up of cases would be done until discharge from the hospital."
48125831|NCT04739137|DIAGNOSTIC_TEST|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
48125832|NCT04739137|DIAGNOSTIC_TEST|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
48125833|NCT01905462|OTHER|Data Collection|Analyses of data collected within the CPRD GOLD database.
48125834|NCT01905462|BIOLOGICAL|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
48125835|NCT01951807|BEHAVIORAL|Psychotherapy|
48125836|NCT01991301|DRUG|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
48125837|NCT01605773|DRUG|repaglinide|Dose individually adjusted and conducted according to labeling
48652221|NCT03583710|OTHER|Quality-of-Life Assessment|Ancillary studies
48652222|NCT06637384|DRUG|Hyaluronic Acid (HA)|Gengigel Gingival Gel 20ml, Ricerfarma, Milan, Italy
48652223|NCT06637384|DRUG|Corticosteroid Injection|Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals, Pakistan
48652224|NCT05294523|PROCEDURE|Rocuronium priming dose|Add the priming dose of rocuronium after the first supramaximal stimulation data measured
48652225|NCT04753359|OTHER|Med|Mediterranean diet
48652226|NCT04753359|OTHER|WL|Measuring change in weight
48652227|NCT03906071|BIOLOGICAL|Nivolumab|Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
48652228|NCT03906071|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
48652229|NCT03906071|DRUG|Docetaxel|Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
48125838|NCT01605773|DRUG|glyburide|Dose individually adjusted and conducted according to labeling
48332815|NCT02613702|PROCEDURE|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
48492760|NCT03798665|DRUG|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
48492761|NCT05376670|DRUG|Intravesical aminoglycoside instillations|Overnight instillation of an aminoglycoside (CIC), varying treatment regimens
48492762|NCT03749629|OTHER|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
48492763|NCT03749629|OTHER|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
48125839|NCT02910713|DEVICE|Intranasal Tear Neurostimulator|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
48125840|NCT00971724|DRUG|Placebo|Oral administration, once daily, for 15 days
48125841|NCT00971724|DRUG|Prednisolone|Oral administration
48125842|NCT00150813|DRUG|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
48125843|NCT04750070|DRUG|Dopamine|Children will receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
48125844|NCT04750070|DRUG|adrenaline|Children will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
48125845|NCT04750070|DRUG|Blood Transfusion|Children will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
48332816|NCT02467023|DEVICE|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
48332817|NCT02467023|DEVICE|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
48332818|NCT02467023|PROCEDURE|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
48332819|NCT02467023|DRUG|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
48492764|NCT02327741|DRUG|plavix|taking plavix more than 12 months
48492765|NCT02327741|DRUG|plavix|taking plavix less than 12 months
48492766|NCT03096275|DRUG|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
48492767|NCT03096275|DRUG|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
48492768|NCT03096275|DRUG|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
48492769|NCT03096275|DRUG|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
48492770|NCT03096275|DRUG|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
48492771|NCT03052413|DIETARY_SUPPLEMENT|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
48492772|NCT03052413|DIETARY_SUPPLEMENT|placebo|Eligible subjects will receive Placebo to take daily for 180 days
48492773|NCT05843799|DRUG|ILB-202|Single i.v. infusion
48125846|NCT00752453|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
48125847|NCT00752453|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
48125848|NCT00752453|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
48125849|NCT06257680|BIOLOGICAL|ReT01 ACT|Patients were infused with ReT01 ACT injection after pretreatment, and subjects were closely observed for 24 hours after each infusion.
48492774|NCT05843799|DRUG|Placebo|Single i.v. infusion
48652230|NCT03809533|DRUG|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
48125852|NCT06521944|BIOLOGICAL|RSV Vaccine|RSV Vaccine approved for administration to pregnant individuals between 32 weeks, 0 days and 36 weeks, 6 days of gestation
48125853|NCT06521944|OTHER|Non-exposure to RSV Vaccine|Pregnant individuals who are not exposed to the RSV vaccine
47975313|NCT06054698|DRUG|HRS9531 injection Placebo|HRS9531 injection Placebo，QW，36 weeks
48125854|NCT04549831|GENETIC|Massive parallel sequencing of host genome|Massive parallel sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing different clinical outcomes from asymptomatic to severely affected patients in order to identify the genetic determinants of severe COVID-19 and the genetic protective factors.
48125855|NCT02795052|PROCEDURE|Intravenous and Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
48125856|NCT04434742|OTHER|Complex interventions|An advanced practice nurse (APN) from a hospital discharge team visited them to familiarize him/herself with their condition and prepare a discharge plan. A face-to-face or telephone call handover between the APN and the project nurse case manager (NCM) was performed before the client was discharged. The past and current medical conditions, medical and nursing management, and follow-up appointments were discussed. After discharge home, the NCM, functioning as the leader of health-social care team, conducted the initial assessment in the first home visit to identify the client's health and social problems within one week of discharge. Community workers, supervised by both the nurse case manager and social worker, provided telephone follow-up and subsequent home visits to monitor the client's progress and provide support when necessary.
48125857|NCT04434742|OTHER|Usual care|Social call was given to this group.
48125858|NCT06150833|BIOLOGICAL|Boya IVIG|"The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:~* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;~* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days"
48125859|NCT00039234|BIOLOGICAL|aldesleukin|
48125860|NCT00039234|DRUG|histamine dihydrochloride|
48125861|NCT05848609|DIAGNOSTIC_TEST|Geriatric Assessment|Geriatric assessment to evaluate cognitive function, functional status and quality of life before and after surgery
48125862|NCT04751838|OTHER|no intervention|no intervention
48125863|NCT00003834|DRUG|fluorouracil|
48125864|NCT00003834|DRUG|leucovorin calcium|
48125865|NCT00003834|DRUG|oxaliplatin|
48125866|NCT02934789|PROCEDURE|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
47975314|NCT02695498|OTHER|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class \[9 total classes.\] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
47975315|NCT02695498|OTHER|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
47975316|NCT03205033|DRUG|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
47975317|NCT03205033|DRUG|Placebo oral capsule|1 capsule/day 1 hour before go to bed
47975318|NCT01650623|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
47975319|NCT01650623|BEHAVIORAL|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
47975320|NCT04287244|DEVICE|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
47975321|NCT02165774|DEVICE|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
47975322|NCT02165774|DEVICE|Turning ON the neuromodulator|
47975323|NCT03674996|OTHER|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
47975324|NCT03674996|OTHER|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
47975325|NCT03674996|OTHER|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
48125867|NCT02934789|DRUG|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
48125868|NCT04534400|RADIATION|thoracic CT-scan|Automated measurement
48125869|NCT01881412|DRUG|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
48125870|NCT01881412|OTHER|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
48125871|NCT00912600|OTHER|Intensive Care Unit admission|Intensive Care Unit admission
48125872|NCT05945017|DIETARY_SUPPLEMENT|Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748|
48125873|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
48125874|NCT00709098|DRUG|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
48332820|NCT02467023|DRUG|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
48332821|NCT02467023|DRUG|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
48332822|NCT02467023|OTHER|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
48332823|NCT02467023|DEVICE|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
48332824|NCT00003194|BIOLOGICAL|filgrastim|
48492775|NCT00804817|BEHAVIORAL|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
48332825|NCT00003194|DRUG|carboplatin|
48332826|NCT00003194|DRUG|cyclophosphamide|
48332827|NCT00003194|DRUG|etoposide|
48332828|NCT00003194|DRUG|thiotepa|
48492776|NCT00804817|BEHAVIORAL|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
48492777|NCT03597360|RADIATION|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
48492778|NCT03365167|RADIATION|LANAP (Laser Assisted New Attachment Procedure)|radiation of Nd:YAG laser in periodontal pocket
48125875|NCT03055689|BEHAVIORAL|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
48125876|NCT03055689|BEHAVIORAL|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
48332829|NCT00003194|DRUG|topotecan hydrochloride|
48332830|NCT00003194|PROCEDURE|peripheral blood stem cell transplantation|
48332831|NCT04568187|DEVICE|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
48332832|NCT04568187|DEVICE|placebo|radiofrequency with 3000 Hz
48332833|NCT04373785|RADIATION|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
48332834|NCT04373785|DRUG|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
48332835|NCT04373785|DRUG|NG101m|Oral NG101m capsule continuously twice daily.
48332836|NCT01867866|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
48332837|NCT01867866|DRUG|Trifluridine|35 mg/m2, orally, single dose
48332838|NCT01639391|PROCEDURE|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
48332839|NCT06178887|DIAGNOSTIC_TEST|imaging|cardiac angioRMN
48332840|NCT05684588|DIAGNOSTIC_TEST|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
48332841|NCT02899624|BIOLOGICAL|Extra blood draw samples|
48332842|NCT02899624|BIOLOGICAL|additional tissue samples|
48332843|NCT03395756|DRUG|Depot-Medroxyprogestereone Acetate|Administration of 150 mg intramuscular depot medroxyprogesterone acetate
48332844|NCT05561712|OTHER|Laboratory method validation|Test several sampling conditions
48332845|NCT04263194|DEVICE|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
48332846|NCT04263194|DEVICE|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
48492779|NCT03365167|RADIATION|LANAP off|radiation of Nd:YAG laser in off mode in periodontal pocket
48492780|NCT05863143|BEHAVIORAL|Nutritional and Exercise|Provide Nutritional Education Program and Falls Module Exercise (FME) to the intervention group
48492781|NCT03181698|DIAGNOSTIC_TEST|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
48492782|NCT01485666|OTHER|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
48492783|NCT02182869|DRUG|Combivent® HFA inhalation aerosol|
48492784|NCT02182869|DRUG|Combivent® CFC inhalation aerosol|
48492785|NCT03764436|BEHAVIORAL|LEAPS-NCHD Program|The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
48492786|NCT03192241|OTHER|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
48492787|NCT03192241|OTHER|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
48492788|NCT01173471|DRUG|AZD4017|tablet, oral, one tablet once daily, 28 days
48492789|NCT01173471|DRUG|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
48492790|NCT01173471|DRUG|AZD4017|tablet, oral 2 tablets twice daily, 28 days
48492791|NCT01173471|DRUG|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
47975326|NCT01786044|BEHAVIORAL|MasterMed|An online interactive educational program
48492792|NCT03923530|DRUG|Eplerenone|Eplerenone 50 mg daily
48492793|NCT05485935|DEVICE|Investigational device - intermittent catheter with micro-hole zone|Intermittent male catheter with micro-hole zone for urinary drainage
47975327|NCT01786044|BEHAVIORAL|Usual Care|
47975328|NCT01965496|DRUG|PEX168|A injection administered subcutaneously
47975329|NCT04061915|BEHAVIORAL|Infographic Intervention|The intervention consists of participants viewing an HIV self-testing infographic.
47975330|NCT04061915|BEHAVIORAL|Paper-based HIV self-testing information|The control arm will read paper-based HIV self-testing instructions.
47975331|NCT00039364|DRUG|imatinib mesylate|
47975332|NCT01129609|DEVICE|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
48125877|NCT00972049|DRUG|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
48125878|NCT00972049|DRUG|Placebo|Capsule administered once orally
48332847|NCT03529929|DRUG|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
48332848|NCT02245867|DRUG|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
48332849|NCT00605722|DRUG|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
48332850|NCT00605722|DRUG|erlotinib (Tarceva)|150 mg orally (po) daily.
48332851|NCT00089999|DRUG|Lapatinib|
48332852|NCT05648838|DEVICE|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
48332853|NCT05226351|DRUG|Dronabinol 2.5 mg|single administration of 2.5mg Dronabinol oral (oily solution)
48332854|NCT05226351|DRUG|Placebo|single administration of placebo oral (oily solution)
48332855|NCT00028106|DRUG|[131]I-MIBG|
48332856|NCT00028106|DRUG|6-[18F]Fluorodopamine|
48332857|NCT00028106|DRUG|[123]I-MIBG|
48332858|NCT03983226|PROCEDURE|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
48332859|NCT03983226|DRUG|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
48332860|NCT03983226|DRUG|Niraparib|Niraparib maintenance therapy
48492794|NCT05485935|DEVICE|Comparator - standard intermittent catheter|SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
48492795|NCT06289803|DEVICE|probe confocal laser endomicroscopy|probe confocal laser endomicroscopy will be used to identify the tumor behavior
48492796|NCT03185013|BIOLOGICAL|VGX-3100|1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
48492797|NCT03185013|BIOLOGICAL|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
48492798|NCT03185013|DEVICE|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
48492799|NCT06062797|DEVICE|Mixed Reality Viewer|The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.
48332861|NCT05141734|DIAGNOSTIC_TEST|The relationship between the vestibulo-ocular reflex (VOR) gains and the slow phase velocity (SPV)|The vestibulo-ocular reflex (VOR) gains were measured by video Head Impulse Test (vHIT) in both the study group and the control group. The slow phase velocity (SPV) values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
48332862|NCT01383109|DRUG|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
48332863|NCT01223326|DRUG|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
48332864|NCT01223326|DRUG|Saline|Na Cl 0.9% infusion
48332865|NCT04774614|PROCEDURE|anterior laminate veneers|VITA ENAMIC multiColor
48332866|NCT03258463|OTHER|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
48125879|NCT04870749|DIAGNOSTIC_TEST|IPP,IPSS,VPSS|Prostate volume, IPSS, VPSS and IPP were determined after urological examinations of the patients.
48332867|NCT05941663|OTHER|Dental implant surface|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
48332868|NCT01213498|DRUG|Atorvastatin|Zarator, 80 mg pr. day for 5 days
48332869|NCT01213498|DRUG|Unikalk|1 tablet Unikalk pr day for 5. days
48332870|NCT02924688|DRUG|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
48332871|NCT02924688|DRUG|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
48332872|NCT02924688|DRUG|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
48492800|NCT06062797|DEVICE|X-ray or CT scan|X-ray or CT scan enables the visualization of the fracture in 2D.
48492801|NCT01551641|OTHER|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
48492802|NCT01551641|DRUG|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
47975333|NCT06410820|DEVICE|Procedure/Surgery: Ultrasound method group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
48125880|NCT04576975|DRUG|Ketamine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
48125881|NCT04576975|DRUG|Dexmedetomidine|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
48332873|NCT02924688|DRUG|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
48332874|NCT02924688|DRUG|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
48492803|NCT01551641|OTHER|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
48492804|NCT00003851|BIOLOGICAL|proteolytic enzymes|
48492805|NCT00003851|DRUG|gemcitabine hydrochloride|
48492806|NCT00003851|PROCEDURE|Gonzalez regimen|
48492807|NCT00793026|DRUG|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
48492808|NCT04616547|OTHER|Questionnaire Administration|Ancillary studies
48492809|NCT04616547|RADIATION|Tin Sn 117m Pentetate|Given IV
48492810|NCT01632111|OTHER|Lung function measurement|Spirometry
48332875|NCT02924688|DRUG|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
48125882|NCT04576975|DRUG|Normal Saline 0.9%|compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
48332876|NCT02924688|DRUG|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
48332877|NCT02924688|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
48332878|NCT02924688|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
48332879|NCT02924688|DEVICE|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
48332880|NCT02924688|DEVICE|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
48332881|NCT00924729|DRUG|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
48332882|NCT00924729|DRUG|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
48332883|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
48332884|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
48125883|NCT02095717|DRUG|Curcumin|
48332885|NCT02565732|BIOLOGICAL|Placebo comparator|Placebo, Dose C, Topical
48332886|NCT03140683|DEVICE|non-stress test|antepartum fetal monitoring
48332887|NCT01828099|DRUG|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule. Ceritinib (LDK378) was the investigational treatment and is referred to as the investigational study treatment/drug.
48332888|NCT01828099|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m2 as an iv infusion on Day 1 of each 21-day cycle to patients randomized to the chemotherapy arm.
48332889|NCT01828099|DRUG|Cisplatin|Cisplatin was administered by IV at a dose of 75 mg/m2 every 21 days for up to 4 cycles.
48332890|NCT01828099|DRUG|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
48332891|NCT03890393|DEVICE|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
48332892|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
48332893|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
48332894|NCT02876679|DRUG|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
48492811|NCT03947424|DEVICE|LP Er:YAG|LP Er:YAG applied to oral mucosa
48125884|NCT02095717|DRUG|Placebo|
48125885|NCT02095717|DRUG|Taxotere|
48125886|NCT04854772|BEHAVIORAL|Mind Body Syndrome Therapy for Long Covid|The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
48125887|NCT02542683|OTHER|structured physical activity program|a structured modest physical activity program
48125888|NCT01355549|BIOLOGICAL|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
48492812|NCT03947424|DEVICE|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
48492813|NCT03947424|DEVICE|sham|Er:YAG laser applied to oral mucosa with no energy
48125889|NCT05674149|DEVICE|camera|photographs using multi-spectral camera
48125890|NCT01408524|DRUG|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
48125891|NCT01408524|DRUG|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
48332895|NCT02876679|DRUG|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
48332896|NCT02876679|DRUG|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
48332897|NCT00695500|DRUG|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
48332898|NCT00695500|DRUG|Placebo|Placebo tablets, 0 mg per day for 3 weeks
48332899|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
48332900|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
48332901|NCT03487887|DEVICE|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
48332902|NCT03472599|OTHER|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
48332903|NCT01118715|DEVICE|Compression glove|A compression glove worn during recovery from distal radius fracture
48332904|NCT04018703|DRUG|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
48492814|NCT00000396|BEHAVIORAL|Patient self-care education|
48125892|NCT02886195|DRUG|pemetrexed|500mg/m2 ivgtt d1, per three weeks
48125893|NCT02886195|DRUG|cisplatin|80mg/m2 ivgtt d1, per three weeks
48125894|NCT02886195|DRUG|Erlotinib|150mg po. every day
48125895|NCT04522466|DRUG|Hydroxychloroquine (HCQ)|"Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ)."
48125896|NCT01811394|RADIATION|protons|Treatment is performed using 16 x 4 GyE protons
48332905|NCT04018703|DRUG|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
48332906|NCT03148106|DEVICE|Somatosensory Electrical Stimulation|We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
48492815|NCT05753670|DRUG|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
48492816|NCT05753670|DRUG|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
48652231|NCT00989495|DEVICE|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
48652232|NCT06638970|DRUG|Secretome|3 ml Injection of secretome for 4 times two weeks apart
48125897|NCT01811394|RADIATION|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
48125898|NCT05836116|OTHER|Evaluation of Muscle Activation|"Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application."
48125899|NCT06221059|DRUG|HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo|Drug：HRS-1780 tablet Drug：Henagliflozin Proline tablet Drug：HRS-1780 tablet placebo Drug：Henagliflozin Proline tablet placebo
48125900|NCT01006577|PROCEDURE|side-to-end anastomosis|Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
48125901|NCT01006577|PROCEDURE|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
48125902|NCT01289314|PROCEDURE|TLH|Total laparoscopic hysterectomy (TLH)
48125903|NCT01289314|PROCEDURE|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
48125904|NCT05646004|DEVICE|Cataract surgery|Implantation of 621 lens
48125905|NCT04592393|DIAGNOSTIC_TEST|Abbreviated PB MRI|Annual non-contrast PB MRI.
48125906|NCT04592393|GENETIC|Gene mutation test|K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.
48125907|NCT04592393|DIAGNOSTIC_TEST|Conventional follow-up|Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
48125908|NCT02198469|DRUG|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
48332907|NCT03326869|DEVICE|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
48332908|NCT03141892|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
48492817|NCT00342836|PROCEDURE|Akt levels|
48492818|NCT00097877|DRUG|biphasic insulin aspart|
48492819|NCT00097877|DRUG|insulin glargine|
48492820|NCT00831636|DRUG|CP-4055|D1-5 and D8(+2)-12(+2) q4w
48652233|NCT04066829|BEHAVIORAL|Default setting intervention|The new default settings will be implemented only for patients in the experimental arm.
48652234|NCT06260774|DRUG|TTX-MC138|The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.
48652235|NCT01503177|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
48652236|NCT01503177|OTHER|laboratory biomarker analysis|Correlative studies
48652237|NCT01503177|PROCEDURE|single photon emission computed tomography|Correlative studies
48492821|NCT00831636|DRUG|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
48652238|NCT01503177|PROCEDURE|computed tomography|Correlative studies
48652239|NCT01639690|GENETIC|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.
48125909|NCT02198469|DRUG|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
48125910|NCT04134273|DRUG|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
48125911|NCT04134273|DRUG|Clindamycin|Clindamycin Phosphate topical gel 1%
48125912|NCT04134273|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
48492822|NCT04619992|DEVICE|Currently marketed Hydrophillic Intermittent Catheter|Currently marketed Hollister standard with tip hydrophilic intermittent catheter
48652240|NCT05634343|OTHER|experimental group 1|Laughter therapy, also called therapeutic laughter, is used to relieve pain and stress and to promote a general sense of well-being. Laughter therapy is simply a method of 'laughing for no reason' in which the person interacts in a group setting with improvisation or pantomime-like exercises and childish games without humour, jokes or funny events. The aim is thus to benefit from laughter.
48652241|NCT05634343|OTHER|experimantal group 2|Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
48652242|NCT04583553|DIAGNOSTIC_TEST|Vikor Scientific Urine-IDTM|Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.
48652243|NCT06063551|PROCEDURE|Testicular Biopsy|Testicular biopsy for clinical storage and laboratory research.
48652244|NCT04585581|BEHAVIORAL|time-restricted eating|Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
48652245|NCT04585581|BEHAVIORAL|high intensity exercise|Participants will be encouraged to exercise with high intensity 2-3 times per week
48652246|NCT04585581|OTHER|Standard Care|Standard clinical care
48652247|NCT00982579|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
48652248|NCT06637982|PROCEDURE|ridge splitting with the use of allograft and pericardium membrane|ridge splitting with the use of allograft and pericardium membrane
48652249|NCT06637982|PROCEDURE|ridge splitting with the use of extended platelet rich fibrin|ridge splitting with the use of extended platelet rich fibrin
48652250|NCT06189365|DEVICE|Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
48652251|NCT06639607|BIOLOGICAL|PEP-CMV vaccine|Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
48652252|NCT06639607|BIOLOGICAL|Tetanus booster|Td 5 flocculation units, Lf
48652253|NCT06639607|BIOLOGICAL|Nivolumab|Administered intravenously
48652254|NCT06639607|DRUG|Temozolomide|Administered orally
48652255|NCT06641869|DIETARY_SUPPLEMENT|procyanidin C1|Proprietarily extracted procyanidin C1
48652256|NCT06641869|DIETARY_SUPPLEMENT|Cellumiva|Cellumiva is a novel senolytic complex blend invented by Mrs. Patricia Mayer. It's a complext of grape seed extract(its key active component later identified asPCC1), Pterostilbene and Spermidine.
48652257|NCT06641869|DIETARY_SUPPLEMENT|Placebo|Placebo
48652258|NCT04071236|DRUG|Avelumab|Given IV
48652259|NCT04071236|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48652260|NCT04071236|PROCEDURE|Bone Scan|Undergo bone scan
48652261|NCT04071236|PROCEDURE|Computed Tomography|Undergo CT
48652262|NCT04071236|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48652263|NCT04071236|DRUG|Peposertib|Given PO
48652264|NCT04071236|OTHER|Questionnaire Administration|Ancillary studies
48652265|NCT04071236|RADIATION|Radium Ra 223 Dichloride|Given IV
48652266|NCT06642454|OTHER|Transcutaneous auricular vagus nerve stimulation|"Stimulation Target: Left cymba conchae.~25 Hz Non-Expiratory Gated taVNS: Stimulation is delivered for 30 seconds at a frequency of 25 Hz, followed by a 30-second interval.~25 Hz Expiratory Gated taVNS: One second of stimulation occurs during exhalation at a frequency of 25 Hz.~100 Hz Expiratory Gated taVNS: One second of stimulation is administered during exhalation at a frequency of 100 Hz."
48652267|NCT00413712|DRUG|Calcium Channel Blocker & Adenosine|
48652268|NCT06524180|DEVICE|Telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
48652269|NCT06524180|OTHER|Usual care|Participants will be followed up as usual by face-to-face consultation with the doctors
48652270|NCT03635866|DIAGNOSTIC_TEST|Fluciclovine PET/MRI|It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
48125913|NCT00081601|DRUG|CEP-701|
48125914|NCT03063866|DRUG|Propofol|Propofol 1 mg/kg i.v
48125915|NCT03063866|DRUG|Midazolam|Midazolam 3 mg i.v
48125916|NCT03063866|DRUG|Fentanyl|fentanyl 0.5 ug/kg
48125917|NCT04608305|BIOLOGICAL|IIBR-100, low dose (prime)|Single administration of IIBR-100 1\*10E5 pfu/ml
48492823|NCT04619992|DEVICE|Test Hydrophilic Intermittent Catheter|Hollister standard with tip hydrophilic intermittent catheter with design enhancements
48125918|NCT04608305|BIOLOGICAL|IIBR-100 medium dose (prime)|Single administration of IIBR-100 1\*10E6 pfu/ml
48125919|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime)|Single administration of IIBR-100 1\*10E7 pfu/ml
48125920|NCT04608305|BIOLOGICAL|IIBR-100 low-dose (prime-boost)|Two administrations of IIBR-100 1\*10E5 pfu/ml, 28 days apart
48125921|NCT04608305|OTHER|Saline Placebo (single)|Single administration of saline placebo
48125922|NCT04608305|OTHER|Saline Placebo (double)|Two administrations of saline placebo, 28 days apart
48125923|NCT04608305|BIOLOGICAL|IIBR-100 medium-dose (prime-boost)|Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart
48125924|NCT04608305|BIOLOGICAL|IIBR-100 high-dose (prime-boost)|Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart
48125925|NCT04608305|BIOLOGICAL|IIBR-100 top-dose (prime-boost)|Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
48125926|NCT04605731|BIOLOGICAL|Durvalumab|Given IV
48652271|NCT05852340|DRUG|Ritlecitinib|"ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)"
48125927|NCT04605731|BIOLOGICAL|Tremelimumab|Given IV
48125928|NCT00479700|DRUG|SAM-531|
48125929|NCT03440008|OTHER|Dynamic 3D bone motion capture|Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment
47975334|NCT06410820|DEVICE|Landmark method group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
48125930|NCT03440008|DEVICE|wedged insole|medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
48125931|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
48125932|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
48125933|NCT01070940|DRUG|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
48125934|NCT01070940|DRUG|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
48125935|NCT02029235|DRUG|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
48125936|NCT02029235|DRUG|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
48125937|NCT00202436|PROCEDURE|Phlebotomy|Removal of 500 ml whole blood
47975335|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple|Active juice with added fibre and ginseng
47975336|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple control|Control products without active ingredients
47975337|NCT06355154|OTHER|Nutritional intervention|The intervention will contain a diet with a reduced amount of carbohydrates compared to the standard treatment today but without caloric restriction.
47975338|NCT04256798|DRUG|Chlorhexidine mouthwash|0.2% Chlorhexidine digluconate
47975339|NCT04256798|DRUG|Oxygen|Oxygen 80-100%
47975340|NCT04256798|DRUG|Oxygen|Oxygen 21-30 %
47975341|NCT06095453|OTHER|Pain control regimens|Narcotics in cholecystectomy and hernia repairs
48125938|NCT00202436|PROCEDURE|Erythrocytapheresis|machinal removal of erythrocytes
48125939|NCT04476810|DEVICE|kahook dual blade|Combined Phacoemulsification and Excisional Goniotomy with the Kahook Dual Blade
48125940|NCT04556539|DRUG|SC10914|400mg TID, oral admination on fasting condition
48492824|NCT03485053|DRUG|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
48492825|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
48652272|NCT03696693|DEVICE|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
48652273|NCT05535972|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
48125941|NCT00946413|BEHAVIORAL|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
48125942|NCT00946413|BEHAVIORAL|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
48125943|NCT05401513|OTHER|Pilates Group|The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
48125944|NCT00002036|DRUG|Anti-HIV Immune Serum Globulin (Human)|
48125945|NCT06366399|BEHAVIORAL|Resistance Exercise Timing|1 resistance exercise session consisting of 3 sets, 10 repetitions per set, on 12 different exercises
48125946|NCT00281554|DRUG|RSD1235|IV
48492826|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
48492827|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
48492828|NCT00430495|DRUG|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
48125950|NCT05223517|DEVICE|Acupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
48492829|NCT06306235|OTHER|Questionnaire|Part A: 30 patients will be interviewed. Part B: 300 patients will complete written questionnaire on tablet.
48492830|NCT04407494|BIOLOGICAL|Reporting of anosmia, ageusia and other clinical symptoms|Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
48492831|NCT05496543|DEVICE|acupuncture|All acupoints will be routinely sterilized at first. After the insertion of the needles, manipulations of lifting, twirling, and thrusting are performed on all needles to reach de qi, which is a sensation typically associated with needling including soreness, numbness, swelling, heaviness, and other feelings. This is considered to be an important component of the therapeutic effect of acupuncture.
48125951|NCT05223517|DEVICE|Sham Acupuncture|"Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks."
48125952|NCT00550823|DEVICE|Cardiac CT 0BRILLIANT 64|Cardiac CT
48125953|NCT02294617|OTHER|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
48492832|NCT05496543|DEVICE|sham acupuncture|"The placebo needles chosen for this study are flat-tipped needles without a tip, which could not be pierced into the skin. In the meanwhile, an external patch device will fix the needles, which are visually pierced into the skin. After the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball so that the patient can feel the pulling out of the needle."
48492833|NCT00324480|DRUG|alvocidib|Given IV
48492834|NCT00324480|DRUG|vorinostat|Given orally
48492835|NCT00324480|OTHER|pharmacological study|Correlative studies
48125954|NCT02294617|OTHER|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
48652274|NCT06640192|DRUG|Standardised triple antiretroviral therapy|patients have to use Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor. There are many types of drugs within this group, so they are not specified.
48652275|NCT06640192|DRUG|High doses Triple therapy antiretroviral drugs|dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h
48125955|NCT00441298|DRUG|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
48652276|NCT03716973|DEVICE|High Density Programming|Patients implanted with Medtronic spinal cord stimulator will have high density programming.
48125956|NCT00441298|DRUG|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
48125957|NCT03307278|BIOLOGICAL|House dust mite|As a stimulant to induce inflammasome activation
48125958|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
48125959|NCT00707772|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
48125960|NCT03406936|DRUG|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
48125961|NCT04255979|DRUG|HY209|6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
48125962|NCT02574806|PROCEDURE|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
48125963|NCT00654589|DRUG|Deferasirox|
48492836|NCT03805503|DRUG|Chloroprocaine 1% Injectable Solution|"standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed."
48492837|NCT01691820|PROCEDURE|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
48492838|NCT01691820|PROCEDURE|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
48492839|NCT01691820|PROCEDURE|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
48492840|NCT05965531|DRUG|Trifluridine/Tipiracil|TAS-102 is given in a dose of 35 mg/m2, twice daily on the 1st to 5th and 8th to 12th days of the period of neoadjuvant radiotherapy.
48492841|NCT05965531|RADIATION|intensity-modulated radiotherapy|intensity-modulated radiotherapy
47975342|NCT02902198|DIETARY_SUPPLEMENT|Placebo|Tap water 200ml
47975343|NCT02902198|DIETARY_SUPPLEMENT|Glucose|25g Glucose in 200ml tap water
47975344|NCT02902198|DIETARY_SUPPLEMENT|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
47975345|NCT02902198|DIETARY_SUPPLEMENT|Quinine|17mg quinine in 200ml tap water
47975346|NCT05924204|RADIATION|Photobiomodulation|Application of photobiomodulation
47975347|NCT05924204|OTHER|Simulation of Photobiomodulation|Simulation of photobiomodulation
47975348|NCT02370160|BIOLOGICAL|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
47975349|NCT05219214|OTHER|Chinese medicine|There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
47975350|NCT04944953|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
47975351|NCT04944953|DRUG|Botulinum toxin type A injection [HG-102]|Single administration, Day 0, 20 units
47975352|NCT01170858|DRUG|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
47975353|NCT01170858|DRUG|glucose solutions|
47975354|NCT01448811|DEVICE|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI\>40, titrate up propofol dosage, AAI\<25, titrated down propofol dosage.
47975355|NCT01448811|PROCEDURE|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
47975356|NCT06070298|DIAGNOSTIC_TEST|Computer algorithms|Collection of lightweight computer algorithms called ausculto™ that is designed to perform real-time heart sound analysis to detect heart murmur.
47975357|NCT03038191|DEVICE|Neuroelectrics Enobio 8(R)|Monitoring
47975358|NCT03519932|DEVICE|comfilcon A toric lens|Contact lens
47975359|NCT03519932|DEVICE|samfilcon A toric lens|Contact lens
48125964|NCT03617315|DRUG|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
48125965|NCT02463448|BIOLOGICAL|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
48125966|NCT04174768|PROCEDURE|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
48125967|NCT06315985|OTHER|Experimental group: Listenning to the Turkish Classical Music to pregnant women diagnosed with preeclampsia|The music to be used in the research will be applied together with midwifery practices and is not a treatment option, tool or treatment option for any disease. Although listening to Classical Turkish music has no effect on treatment and care, it does not have a harmful effect on pregnant women. The participant can withdraw from the study at any time without giving any reason. The Personal Information Form, Perceived Stress Scale, and Pittsburgh Sleep Quality Index (PSQI) will be administered to the pregnant women in both groups participating in the study by face-to-face interviews with the individuals on the first day of their admission to the clinic. At the end of the third day, the Perceived Stress Scale and Pittsburgh Sleep Quality Index (PSQI) scales will be re-administered to both groups.
48125968|NCT05898191|OTHER|vaginal laser treatment|non-ablative vaginal laser application
48125969|NCT05381233|OTHER|Gross motor function classification System (GMFCS)|assessment
48125970|NCT05381233|OTHER|Arabic Version of Zarit burden Inventory measure|assessment
48125971|NCT05381233|OTHER|Arabic Version of Chalder Fatigue Scale (CFQ version 11)|assessment
48125972|NCT05125874|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
48125973|NCT00414024|DRUG|Tegaserod|
48125974|NCT00603954|DRUG|Conditioning regimen: TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
48125975|NCT00603954|DRUG|Conditioning regimen:TLI (8 Gy) + ATG|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
48125976|NCT01535690|OTHER|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
48125977|NCT04974567|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
48125978|NCT03493724|OTHER|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
48125979|NCT03748186|DRUG|STRO-002|intravenous antibody drug conjugate
48125980|NCT02798367|BEHAVIORAL|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
48125981|NCT02798367|DRUG|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
48125982|NCT02798367|DRUG|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
48125983|NCT02379819|DEVICE|Nucleus Hybrid L24 Implant|
48125984|NCT05937685|BEHAVIORAL|BP REACH Intervention|Educational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist
48125985|NCT03366506|OTHER|Observation|
48125986|NCT02632071|DRUG|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
48125987|NCT02632071|DRUG|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
48125988|NCT06499441|OTHER|Myofascial induction in gastrocnemius|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
48125989|NCT06499441|OTHER|Preassure release|Also called ischaemic pressure. Three cycles of pressure are applied to the trigger point of the gastrocnemius muscle until the pain disappears on pressure.
48125990|NCT02545738|DRUG|Liraglutide|active treatment
47975360|NCT04397653|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
48125991|NCT02545738|DRUG|placebo|placebo
48125992|NCT02847013|DRUG|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
48125993|NCT02847013|PROCEDURE|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
48125994|NCT00611559|BIOLOGICAL|Infanrix™ penta|Subjects received a booster dose
48125995|NCT00611559|BIOLOGICAL|Infanrix™ hexa|Subjects received a booster dose
48125996|NCT05307536|COMBINATION_PRODUCT|Autologous BMMNCs transplantation and educational intervention|"Biological/ Vaccine: Autologous bone marrow-derived mononuclear cell infusion (BM-MNCs) will be administrated at baseline, and the second infusion will be performed six months after the first administration. For each transplantation, the bone marrow will be harvested through an anterior iliac crest puncture under general anesthesia in the operating theatre. The volume collected depends on the patient's body weight based on our experience from a previous study as follows: 8 ml/kg for patients under 10 kg; \[80 ml + (body weight in kg - 10) x 7 ml\] for patients above 10 kg but no more than 250 ml in total.~Educational intervention: 6 months based on the Early Start Denver Model"
48125997|NCT05307536|COMBINATION_PRODUCT|Educational intervention|Educational intervention: 6 months based on the Early Start Denver Model
48125998|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
48125999|NCT06084104|DRUG|DZD9008|A single oral dose of 200mg DZD9008
48126000|NCT03644849|DEVICE|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
48126001|NCT03644849|OTHER|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
48126002|NCT00152087|DEVICE|Brachytherapy|
48126003|NCT03432338|OTHER|inquiries|Inquires reported to clinician.
48126004|NCT03569072|RADIATION|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
48126005|NCT06229730|DIAGNOSTIC_TEST|video Head Impulse Test|For v-HIT, the Synapsys v-HIT Ulmer device is used.
48492842|NCT04874636|DRUG|LY3556050|Administered orally
48492843|NCT04874636|DRUG|Placebo|Administered orally
48126006|NCT06229730|DIAGNOSTIC_TEST|Cervical Vestibular Evoked Myogenic Potential|For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
48332909|NCT02382783|OTHER|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
48332910|NCT00001777|DRUG|Sertraline|
47975361|NCT04397653|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
48332911|NCT01165697|OTHER|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
48332912|NCT01522443|DRUG|cabozantinib|Tablets taken orally once daily.
48332913|NCT01522443|DRUG|mitoxantrone|Given by IV once every 3 weeks.
48332914|NCT01522443|DRUG|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
48332915|NCT02867722|DRUG|aminolevulinic acid HCl|Drug will be administered to consented patients
48332916|NCT04323150|DEVICE|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
48332917|NCT04323150|DEVICE|Conventional suction system|The using of open (conventional) suctioning
48332918|NCT04172701|DRUG|Long-acting Muscarinic Antagonists (LAMA)|drug
48332919|NCT04172701|DRUG|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
48332920|NCT00994162|DEVICE|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
48332921|NCT02760160|OTHER|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) \[114, 217, 343, 500, 619, 848\].
48652277|NCT02971137|BEHAVIORAL|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
48332922|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 6:00-10:00.
48332923|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 20:00-24:00.
48652278|NCT02971137|BEHAVIORAL|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
48652279|NCT05479227|PROCEDURE|Management of bile duct injury|There are different options for BDI management, we analyzed their utilization and results
48652280|NCT01338597|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
48652281|NCT06371378|PROCEDURE|PEEP 0|PEEP 0 CMH20 will be used During Surgery
48652282|NCT06371378|PROCEDURE|PEEP 4|PEEP 4 CMH20 will be used During Surgery
48652283|NCT06371378|PROCEDURE|PEEP 8|PEEP 8 CMH20 will be used During Surgery
48652284|NCT06434636|DRUG|Transamine 10% IV/IM Solution for Injection|10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
48652285|NCT06434636|DRUG|%0.9 Saline|100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes
48652286|NCT03683082|DRUG|Oxygen supplementation|40% FiO2 via Venturi mask
48652287|NCT03683082|DRUG|Sham O2 (medical air)|Medical air supplementation via Venturi mask
48652288|NCT02621944|DRUG|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
48652289|NCT02621944|OTHER|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
47975362|NCT04397653|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
47975363|NCT03592199|DRUG|Sunitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
47975364|NCT05002010|DEVICE|Echo|Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.
47975365|NCT03579732|DRUG|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. \< 150 mg daily
47975366|NCT03579732|OTHER|No drug|Non-consumers
47975367|NCT01356472|DRUG|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
47975368|NCT00965718|BIOLOGICAL|Activated T lymphocyte|Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
47975369|NCT01033266|DIAGNOSTIC_TEST|CPET|CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
47975370|NCT05647434|PROCEDURE|sustained inflations|Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
48332924|NCT00378976|DRUG|valacyclovir|500 mg twice-daily oral
48332925|NCT00378976|DRUG|matching placebo|twice daily as per experimental drug
48332926|NCT05149612|OTHER|Heat Therapy|Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
48332927|NCT05868980|OTHER|vital signs by postpartum position|Evaluation of vital signs and NIRS values in 4 different positions after birth
48332928|NCT01861145|DEVICE|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
48332929|NCT01861145|DRUG|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
48332930|NCT03076918|DEVICE|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
48332931|NCT03076918|DEVICE|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
48332932|NCT03393689|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
48332933|NCT02639403|RADIATION|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
47975371|NCT02414750|DRUG|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
47975372|NCT02414750|DEVICE|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
47975373|NCT02414750|PROCEDURE|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
47975374|NCT02414750|PROCEDURE|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
47975375|NCT03944460|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any excipients.
47975376|NCT01089062|DRUG|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
47975377|NCT01089062|DRUG|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
47975378|NCT01089062|DRUG|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
47975379|NCT01089062|DRUG|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
47975380|NCT02104713|BIOLOGICAL|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
47975381|NCT01513473|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
48332934|NCT03934424|BEHAVIORAL|Weight stigma|Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day
48332935|NCT03934424|BEHAVIORAL|Ethnic stigma|Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
48652290|NCT02621944|OTHER|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
48652291|NCT02621944|BEHAVIORAL|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
47975382|NCT01513473|DRUG|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
47975383|NCT01513473|DRUG|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
47975384|NCT04728074|OTHER|The Entering Employment and Sustaining Work Program|A structured, motivation and self-awareness based group intervention
48332936|NCT02494219|PROCEDURE|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
48332937|NCT04857788|OTHER|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
48332938|NCT03015025|GENETIC|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
48126007|NCT06229730|DIAGNOSTIC_TEST|Ocular Vestibular Evoked Myogenic Potential|For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
48126008|NCT06229730|DIAGNOSTIC_TEST|Computerized Dynamic Posturography|To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.
48332939|NCT03124901|DEVICE|DCI pulse oximeter sensor|
48332940|NCT00168909|DRUG|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
48332941|NCT00168909|DRUG|placebo|placebo once daily, oral, for 3 years
48332942|NCT02267278|DRUG|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
48332943|NCT02267278|DRUG|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
48332944|NCT02267278|BEHAVIORAL|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
48332945|NCT04189991|DEVICE|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
48332946|NCT05249712|DRUG|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
48332947|NCT05249712|OTHER|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
48332948|NCT05152290|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48332949|NCT04798313|DRUG|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
48332950|NCT04798313|DRUG|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
48332951|NCT02690324|BEHAVIORAL|cognitive stress (serial 7)|
48332952|NCT06056128|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways for the purpose of biopsying lung lesions
48126009|NCT06229730|OTHER|Dizziness Handicap Inventory for patient caregivers|DHI is a caregiver-reported 21-item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
48332953|NCT04655053|BEHAVIORAL|Goal intention|Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.
48332954|NCT04655053|BEHAVIORAL|Implementation intention to initiate the behavior|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
48332955|NCT04655053|BEHAVIORAL|Implementation intention to manage the goal preference (avoiding behavior or not)|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
48126010|NCT03172234|OTHER|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
48332956|NCT05178693|DRUG|ASTX727|Cedazuridine 100mg + 35mg decitabine
48332957|NCT05178693|RADIATION|Lutathera|Peptide receptor radionuclide therapy (PRRT)
48332958|NCT03351478|DRUG|Sotagliflozin|Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
48332959|NCT03351478|DRUG|Empagliflozin|Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
48332960|NCT03351478|DRUG|Placebo|Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
48652292|NCT01399645|DRUG|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
48126011|NCT03172234|DRUG|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
48126012|NCT03172234|DRUG|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
48126013|NCT01236560|BIOLOGICAL|Bevacizumab|Given IV
48126014|NCT01236560|DRUG|Temozolomide|Given PO
48126015|NCT01236560|DRUG|Vorinostat|Given PO
48126016|NCT01762475|DRUG|Sildenafil|
48126017|NCT03786211|PROCEDURE|IANB by the guide of Panoramic|IANB will be injected by the guide of panoramic radiograph
48126018|NCT03786211|PROCEDURE|IANB without the guide of Panoramic|IANB will be injected without the guide of panoramic radiograph, in the routine way.
48126019|NCT05705856|DRUG|Ustekinumab|Patients will receive an intravenous induction (adjusted 6 mg/kg dose) followed by subcutaneous 90 mg every 12 or 8 weeks, and will receive dose escalation when response is not effective enough.
48126020|NCT03285542|DEVICE|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
48126021|NCT03285542|DEVICE|Staples|staples for skin closure
48126022|NCT03176654|PROCEDURE|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
48652293|NCT02462057|OTHER|Email message regarding the HealthyFood benefit|
48126023|NCT03176654|PROCEDURE|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
48126024|NCT00006017|DRUG|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
48126025|NCT00809068|DRUG|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
48126026|NCT00809068|DRUG|tibolone|tibolone 2.5 mg daily 23 weeks
48126027|NCT04256512|DEVICE|Medical Device Usage and Evaluation|Wear Elasto Gel Therapy Mittens and Foot Wraps
47975385|NCT04728074|OTHER|vocational rehabilitation|An individual based, focused on desired job or occupation, face-to-face intervention
47975386|NCT02674529|DRUG|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
48126028|NCT04256512|OTHER|Questionnaire Administration|Ancillary studies
47975387|NCT02674529|DRUG|Placebo|Placebo
47975388|NCT02674529|BEHAVIORAL|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
47975389|NCT04498013|DRUG|Cyclodynon|Cyclodynon 1 tablet a day during 6 menthes period.
48126029|NCT05447871|PROCEDURE|Ultrasound guided single injection modified 4 in 1 block technique|A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.
48126030|NCT05447871|PROCEDURE|Ultrasound guided adductor canal block technique|The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.
48126031|NCT05447871|DRUG|Bupivacaine 0.25%|bupivacaine 0.25%
48126032|NCT00962702|DEVICE|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
48126033|NCT02892214|PROCEDURE|Pelvic floor physical therapy|
48126034|NCT02892214|DRUG|estriol cream (ovestin)|
48126035|NCT02892214|PROCEDURE|Low-level-laser therapy|
48126036|NCT06083766|BEHAVIORAL|hormone therapy|Determine how gender affirming hormone therapy affects muscle physiology
48126037|NCT03926039|BEHAVIORAL|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
48126038|NCT03311516|OTHER|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
48126039|NCT03311516|OTHER|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
48652294|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
48652295|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
48652296|NCT06642961|OTHER|Placebo|The placebo will be administered SC.
48652297|NCT01202357|BEHAVIORAL|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
48652298|NCT02624687|BEHAVIORAL|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
48652299|NCT02624687|OTHER|No intervention|No contact control
48652300|NCT03982693|DRUG|Edetate Disodium|The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
48652301|NCT03982693|OTHER|Placebo|Placebo infusions consist of 500 ml normal saline.
48332961|NCT03351478|DRUG|Placebo|Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
48332962|NCT05611515|PROCEDURE|TORS|"* Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~* Arm 2: Trans-oral Laser Microsurgery (TLM)~* Arm 3: Trans-oral Robotic Surgery (TORS)"
48652302|NCT00970710|BEHAVIORAL|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
48126040|NCT02499159|DRUG|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
48332963|NCT02581618|OTHER|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
48332964|NCT04839224|DRUG|carbogen|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
48332965|NCT04839224|DRUG|phenylephrine|Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
48332966|NCT01884961|OTHER|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
48332967|NCT04454580|DRUG|Venetoclax|treatment with azacitidine or decitabine in combination with venetoclax
48332968|NCT04639908|OTHER|Interview|interview with patient
48332969|NCT04575831|BEHAVIORAL|Exercise, Nutrition, and Palliative Symptom Management|"1. Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~2. Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~3. Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
48332970|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
48332971|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
48332972|NCT06011980|DRUG|Growth Inhibitor|growth inhibitors for 250-500μg/h, ivgtt. for 5 days
48332973|NCT01639456|BIOLOGICAL|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
48332974|NCT01639456|BIOLOGICAL|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
48332975|NCT01639456|DEVICE|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
48332976|NCT01639456|DEVICE|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
48126041|NCT02499159|DRUG|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
48126042|NCT02200094|DRUG|Low dose of Telmisartan, once daily|
48332977|NCT01639456|DRUG|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
48332978|NCT01639456|DRUG|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
48332979|NCT01639456|DRUG|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
48652303|NCT05547464|BIOLOGICAL|BNT164a1|Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection
47975390|NCT04498013|BEHAVIORAL|Lifestyl modification|Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
47975391|NCT02221193|OTHER|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
47975392|NCT04280133|BEHAVIORAL|Educational Video Tool|The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
47975393|NCT01911871|BIOLOGICAL|Blood sample|a blood sample was taken on the day of inclusion
47975394|NCT05028478|DRUG|CN202|Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
47975395|NCT05935852|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses
47975396|NCT04522362|OTHER|Control task and Trier Social Stress Task|Same as Arm
47975397|NCT04963777|DIETARY_SUPPLEMENT|Prebiotic|Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)
47975398|NCT04963777|DIETARY_SUPPLEMENT|Placebo|Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
47975399|NCT04255524|DEVICE|Optic coherence tomography angiography (OCTA)|Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
47975400|NCT05059210|BEHAVIORAL|Coach McLungs Intervention|Practices have received implementation of Coach McLungs
47975401|NCT02222974|DRUG|BIIR 561 CL|
47975402|NCT02222974|DRUG|Placebo|
47975403|NCT04324073|DRUG|Sarilumab|(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
47975404|NCT02039492|PROCEDURE|Sympathetic Renal Denervation|
47975405|NCT02039492|DRUG|Treatment with aldactone|
47975406|NCT03863249|PROCEDURE|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
47975407|NCT03863249|DRUG|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
47975408|NCT03863249|DIAGNOSTIC_TEST|MICROBIAL SAMPLING|"1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
47975409|NCT03458273|PROCEDURE|Zero fluoroscopy ablation|Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
47975410|NCT03458273|PROCEDURE|Conventional ablation without 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
47975411|NCT03458273|PROCEDURE|Conventional ablation with 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
48332980|NCT00654953|DRUG|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
47975412|NCT04899921|DRUG|Ipilimumab|Intravenous injection
47975413|NCT04899921|DRUG|Nivolumab|Intravenously (IV) into the vein
47975414|NCT04899921|DRUG|Troriluzole|Taken orally
47975415|NCT04899921|DRUG|Placebo|Taken orally
47975416|NCT04983264|DRUG|GBT021601|Tablets and capsules which contain GBT021601 drug substance
47975417|NCT00133614|PROCEDURE|Prone Positioning|
47975418|NCT06127953|PROCEDURE|intermediate cleft rhinoplasty|intermediate cleft rhinoplasty using open approach and combined techniques of Tajima, Dibbell and Potter's Rhinoplasty
47975419|NCT05325554|BEHAVIORAL|Multimodal rehabilitation|Multimodal rehabilitation
47975420|NCT04258397|DRUG|Pirfenidone|Pirfenidone vs. matching placebo
48332981|NCT00654953|DRUG|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
48492844|NCT01521039|PROCEDURE|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
48652304|NCT05547464|BIOLOGICAL|BNT164b1|RNA vaccine for active immunization against tuberculosis administered as intramuscular injection
48652305|NCT05547464|OTHER|Placebo|Placebo
48652306|NCT06636825|OTHER|Graded hypercapnia|Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each
48652307|NCT06636825|DRUG|Caffeine|400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
48652308|NCT06636825|DRUG|Placebo|Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
48332982|NCT00654953|DRUG|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
48332983|NCT04560140|BEHAVIORAL|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
48332984|NCT03573440|OTHER|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
48332985|NCT01977339|DRUG|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
48332986|NCT01977339|DRUG|Bupivacaine|20 cc of 0.25% bupivacaine
48332987|NCT00510484|DRUG|Pancrelipase Delayed Release|24000 unit Capsule
48332988|NCT00510484|DRUG|Placebo Comparator|Placebo
48332989|NCT05632848|DRUG|Chidamide combined with Zimberelimab|Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.
48332990|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
48332991|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
48332992|NCT05542693|BIOLOGICAL|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
48332993|NCT05542693|BIOLOGICAL|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
48332994|NCT04348539|OTHER|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
48332995|NCT01142193|DRUG|USL255|
48332996|NCT01142193|DRUG|Placebo|
48332997|NCT01119157|BIOLOGICAL|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
48332998|NCT05482035|DEVICE|wrist blood pressure monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
48332999|NCT01433120|DIETARY_SUPPLEMENT|Lactobacillus paracasei ssp paracasei F19|10\^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
48333000|NCT01433120|DIETARY_SUPPLEMENT|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
48333001|NCT01433120|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
48333002|NCT00818311|DEVICE|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
48652309|NCT06006546|BIOLOGICAL|426c.Mod.Core-C4b|100 mcg and 300 mcg
47975421|NCT04258397|DRUG|matching placebo|matching placebo
47975422|NCT00375076|DRUG|enoxaparin|
47975423|NCT05035953|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
48333003|NCT02897869|DRUG|POL7080|7 doses of POL7080 alone over 2.5 days
47975424|NCT05035953|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to thrombolysis
48333004|NCT02897869|DRUG|Amikacin|3 doses of Amikacin alone over 2.5 days
48333005|NCT02897869|DRUG|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
48333006|NCT00606853|BEHAVIORAL|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
48333007|NCT05843071|DEVICE|Nasal sprays with sea salts|Nasal sprays for nasal congestion and dryness
48333008|NCT00671723|DRUG|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
48333009|NCT00671723|DRUG|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
48333010|NCT00671723|DRUG|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
47975425|NCT05420077|BIOLOGICAL|RVM-V001 10 µg|Low Dose
47975426|NCT05420077|BIOLOGICAL|RVM-V001 30 µg|Mid Dose
47975427|NCT05420077|BIOLOGICAL|RVM-V001 60 µg|High Dose
47975428|NCT00090974|PROCEDURE|quality-of-life assessment|
48333011|NCT06420999|OTHER|Diaphragmatic ultrasound and data collection|At the inclusion visit, anamnestic data available in the medical record and clinical data (vitals, chest X-ray) will be collected. At the same time, a diaphragmatic ultrasound will be performed in the half-seated position to measure diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm at rest. A follow-up visit will be made on the day of discharge from intensive care, during which diaphragmatic ultrasound will be performed At D90 (+/- 15 days), the following information will be collected by consulting the electronic medical record, or by telephone if the information is not available in the record: date of discharge from hospital, date of death, date and reason for readmission to hospital or intensive care, possible introduction of long-term non-invasive ventilation, new respiratory complication after discharge from intensive care (pneumonia, atelectasis).
48652310|NCT06006546|OTHER|Adjuvant 3M-052-AF+Alum|5 mcg
48652311|NCT00185614|PROCEDURE|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
48652312|NCT00185614|PROCEDURE|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
48652313|NCT00185614|DRUG|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
48333012|NCT05082402|DIAGNOSTIC_TEST|Swept Source Optical Coherence Tomography Angiography|The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
48333013|NCT02899377|RADIATION|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
47975429|NCT01993147|BEHAVIORAL|Dual task paradigm pilot|
48333014|NCT02899377|RADIATION|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
48333015|NCT02899377|PROCEDURE|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
48333016|NCT02899377|PROCEDURE|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
48333017|NCT01847898|PROCEDURE|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
48333018|NCT01847898|PROCEDURE|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
48333019|NCT00346255|DRUG|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
48333020|NCT03549117|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
48333021|NCT03549117|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
47975430|NCT05404295|OTHER|Umbilical cord blood platelel lysate gel|For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
47975431|NCT00327678|DRUG|Rituximab|
47975432|NCT00327678|DRUG|Imatinib Mesylate|
47975433|NCT06361030|DRUG|surufatinib combined with gemcitabine plus nab-paclitaxel|"Surufatinib capsules: oral, once daily. Combination treatment period: 200 mg each time, every 4 weeks for a treatment cycle(Q4W). If all the chemotherapy drugs were stopped during the maintenance treatment period, only surufatinib was left, the dose of Surufatinib could be increased to 300 mg per dose according to the patient\&#39;s condition.~Gemcitabine: iv, 1000 mg/m2, days 1, 8, and 15 of each treatment cycle, Q4W. Paclitaxel (albumin-bound), iv, 125mg/m2, on days 1, 8 and 15 of each treatment cycle, Q4W.~All they will be used until disease progression, death, intolerable toxicity, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, or any other protocol-specified event requiring treatment discontinuation or study closure, whichever occurred first.~But If surgical resection was performed, they will be only maintained for 6 months after surgery."
47975434|NCT00790855|DRUG|Bendamustine|Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
47975435|NCT02454400|OTHER|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~1. Active physiotherapy according to a treatment based classification:~   1. Specific exercises and mobilization~  2. Motor control exercises~  3. Traction~2. Tailor-made general supervised exercise program~3. Behavioral approach to reduce fear avoidance and increase activity level.~4. Standardized information about:~   1. the surgery~  2. post-surgery rehabilitation~  3. to stay active"
47975436|NCT02454400|OTHER|Waiting-list|"Standardized information about:~1. the surgery~2. post-surgery rehabilitation~3. to stay active"
47975437|NCT02479178|DRUG|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
48333022|NCT00500838|DEVICE|Transthoracic Impedance|Impedance measures will be automatically collected via the device
48333023|NCT02907086|OTHER|blood collection|Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
48333024|NCT03097029|DRUG|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
48333025|NCT06251869|PROCEDURE|total hip arthroplasty with electrocoagulation|using normal technique
48333026|NCT06251869|PROCEDURE|total hip arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
48333027|NCT06251869|PROCEDURE|total knee arthroplasty with electrocoagulation|using normal technique
48333028|NCT06251869|PROCEDURE|total knee arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
48333029|NCT06229483|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|Tranexamic acid 20 mg/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, for the duration of surgery. Treatment is blinded.
48333030|NCT06229483|OTHER|Placebo|0.9% normal saline 20ml/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 ml/kg/hr infusion of 0.9 % sodium chloride for the duration of surgery. Treatment is blinded.
48333031|NCT05588180|PROCEDURE|FVD/FAD ratio guided|Ultrasound-guided ratio
48333032|NCT05588180|PROCEDURE|PPV|PPV
48333033|NCT00367029|BEHAVIORAL|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
48333034|NCT01887756|DEVICE|Tele Rehabilitation|
48333035|NCT04477915|OTHER|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
48333036|NCT04477915|OTHER|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
48333037|NCT05446623|DRUG|Dexmedetomidine|Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
48333038|NCT05446623|DRUG|Sufentanil|The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
48333039|NCT05570799|OTHER|Augmented Reality and Kahoot game learning|"* An augmented reality (AR) mobile application with image based will be used by the participants in the experimental group.~* Also, students will participate in Kahoot game. Students will participate in the game using their own devices by going to https://kahoot on their phones and entering their password and password."
48333040|NCT03714347|DEVICE|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
48333041|NCT03714347|DEVICE|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
48333042|NCT00832312|OTHER|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
48333043|NCT00832312|OTHER|placebo (saline)|Injection of 1cc of saline into the knee joint
48333044|NCT03036111|DRUG|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
48333045|NCT03036111|PROCEDURE|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
48652314|NCT00185614|DRUG|Filgrastim|"* Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
48652315|NCT00185614|DRUG|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
48652316|NCT00185614|RADIATION|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
48652317|NCT00185614|PROCEDURE|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
48652318|NCT00185614|DRUG|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
47975438|NCT05079139|PROCEDURE|surgical technique of Musset|"The one-stage rectovaginal fistula cure according to Musset is an intervention indicated in the treatment of simple post-obstetrical or simple post-surgical rectovaginal fistulas.~The procedure consists in performing a perineal section to the perineal section to the fistula pathway in order to perform local excision followed by a repair plane by plane with rectal and anal closure, then of the external sphincter of the anus, and interposition of the deep and superficial transverse elevator and perineal muscles before closing the vagina and perineum."
47975439|NCT04366453|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
48333046|NCT00188968|PROCEDURE|Nasal Continuous Positive Airway Pressure|
48333047|NCT00188968|PROCEDURE|Synchronized Nasal Positive Pressure Ventilation|
48333048|NCT04984512|DRUG|Mitizodone Phosphate tablets|Mitizodone Phosphate tablets will be administered with food.
48333049|NCT04984512|DRUG|Placebo-matching tablets|Placebo will be administered with food.
48333050|NCT04869670|PROCEDURE|Gastric peroral endoscopic myotomy.|Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.
48333051|NCT04869670|PROCEDURE|Sham Gastric peroral endoscopic myotomy.|Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
48333052|NCT04886193|DRUG|FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)|"* FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year."
48333053|NCT06177119|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
48126043|NCT02200094|DRUG|High dose of Telmisartan, once daily|
48126044|NCT04351828|PROCEDURE|Blood draw once a time|Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
48126045|NCT02437006|OTHER|exercise|cycle ergometry
48126046|NCT03676582|DIAGNOSTIC_TEST|Acoustic analysis plus pulse oximetry|Acoustic analysis plus pulse oximetry
48126047|NCT00764335|PROCEDURE|total hip arthroplasty one side|unilateral total hip arthroplasty
48126048|NCT00764335|PROCEDURE|total hip arthroplasty both sides|bilateral total hip arthroplasty
48126049|NCT02421185|DRUG|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
48126050|NCT00737542|DRUG|lidocaine|
48126051|NCT00737542|DRUG|NACL 0.9%|
48126052|NCT04008316|DRUG|Colchicine|colchicine 1mg/day
48333054|NCT06177119|DRUG|Placebos during SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.
48333055|NCT06177119|DRUG|Placebos after SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
48333056|NCT06177119|DRUG|Metronidazole during SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
48333057|NCT06177119|DRUG|Amoxicillin during SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
48333058|NCT06177119|DRUG|Metronidazole after SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
48333059|NCT06177119|DRUG|Amoxicillin after SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
47975440|NCT03608592|BIOLOGICAL|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
47975441|NCT03608592|BIOLOGICAL|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
48126053|NCT01929759|DRUG|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
48126054|NCT00199407|DRUG|Istradefylline (KW-6002)|
48126055|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
48333060|NCT01817114|DEVICE|Auto Remote Ischemic Conditioning (AutoRIC) device|
48333061|NCT05322915|OTHER|line dancing|The intervention included 60-minute sessions, two days a week for four weeks for a total of eight sessions. All sessions were administered by the physiotherapist who has 26 years of experience in dance therapy. The dance was performed on a one to one basis with minimal support from the therapist. The line dancing sequence, which was specially created for this training program, was designed as a structured goal-oriented dance. Line dancing movements/steps are comprised of moving forward and backward, or sideways and turns and scuff. In addition, the fact that one foot is always in contact with the ground makes it ideal for patients with multiple sclerosis, who may have balance problems.
48333062|NCT03801811|PROCEDURE|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
48126056|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
48126057|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
48126058|NCT02714075|OTHER|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
48126059|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
48333063|NCT01189799|BEHAVIORAL|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
48126060|NCT02714075|OTHER|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
48126061|NCT01013584|DIETARY_SUPPLEMENT|cholecalciferol|daily dose
48126062|NCT03352596|OTHER|low frutose diet|
48126063|NCT01691079|DRUG|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
48126064|NCT01691079|DRUG|Placebo|Inhaled placebo administered before exercise.
48126065|NCT04826094|BIOLOGICAL|Env-C Plasmid DNA|2 mg per dose. Administered by intramuscular injection.
48126066|NCT04826094|BIOLOGICAL|HIV Env gp145 C.6980 protein|100 µg per dose. Administered by intramuscular injection.
48126067|NCT04826094|DRUG|Rehydragel®|Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
48126068|NCT04826094|BIOLOGICAL|ALF43|Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
48126069|NCT04826094|BIOLOGICAL|dmLT|Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
48126070|NCT04826094|DRUG|Placebo (IM)|0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
48126071|NCT04826094|DRUG|Placebo (TCl)|Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
48126072|NCT03244449|OTHER|No apply|
48126073|NCT06203873|DEVICE|Biodegradable occluder|Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
48126074|NCT06203873|DEVICE|Metal occluder|Patients assigned in this group will receive metal occluder for PFO occlusion
48126075|NCT01808534|DRUG|palifosfamide|Given IV
48126076|NCT00937131|DRUG|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
48126077|NCT04303325|DRUG|Esketamine|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to esketamine 0.2mg/kg.
48126078|NCT04303325|DRUG|Saline Solution|All depression patients undergoing breast cancer operation will be to the treatment intervention with general anesthesia as an adjunct to saline.
48126079|NCT02058108|DRUG|Telbivudine|Patients of any age and weight\< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
48126080|NCT02058108|DRUG|Placebo|Patients of any age and weight \< 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients \< 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
48126081|NCT01278420|DEVICE|Tecnis MF|30 subjects will be implanted with the Tecnis MF
48126082|NCT01278420|DEVICE|ReSTOR|30 subjects will be implanted with ReSTOR
48126083|NCT03028389|PROCEDURE|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
48333064|NCT01189799|BEHAVIORAL|Dual Recovery Anonymous/Tx as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
47975442|NCT02617628|DRUG|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
48333065|NCT06151860|OTHER|Static stretching|Stretching exercises performed by maintaining the point of muscular discomfort without changing position for a certain period of time.
48333066|NCT06151860|OTHER|Pilates stretching|Stretching exercises performed dynamically, following the six basic principles of Pilates: concentration, control, center, precision, breathing and fluidity.
47975443|NCT01385215|DRUG|Fluzone|0.5 ml/15 micrograms
48126084|NCT00642850|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
48126085|NCT02987816|DEVICE|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
48126086|NCT02987816|DEVICE|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
48126087|NCT02697201|DRUG|Intralipid|0.55 ml/kg/h
48126088|NCT02697201|DRUG|Saline|0.55 ml/kg/h for
48126089|NCT02567656|DRUG|RP6530|Tablet starting at 200 mg
48126090|NCT04074096|RADIATION|Stereotaxic radiosurgery (SRS)|For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases \>5 mm).
48126091|NCT04074096|DRUG|Binimetinib Oral Tablet|All patients: binimetinib 45 mg PO BID.
48126092|NCT04074096|DRUG|Encorafenib Oral Capsule|All patients: encorafenib 450 mg PO QD
48126093|NCT04074096|DRUG|Pembrolizumab|All patients: pembrolizumab 200 mg IV Q3W
48126094|NCT02942862|DRUG|Orcein staining|Prognostic value of venous emboli detected by orcein staining
48333067|NCT00471003|DRUG|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
48333068|NCT00738829|DRUG|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
48333069|NCT00738829|DRUG|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
48333070|NCT00738829|BIOLOGICAL|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
48333071|NCT04451291|BIOLOGICAL|Decidual Stromal Cells (DSC)|DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
48333072|NCT02533193|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~7. Intravenous patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. No nasogastric tube~10. No drain insertion~11. Patients will be discharged at POD#4 if there's no problem"
48333073|NCT02533193|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Drainage tube insertion if needed"
48333074|NCT00003882|DRUG|anhydrovinblastine|
48333075|NCT06364384|COMBINATION_PRODUCT|PD-1 and CRT|Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.
48333076|NCT03852121|BEHAVIORAL|Bibliotherapy|"Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves."
48333077|NCT02958904|OTHER|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
48333078|NCT04297293|DRUG|Ramosetron|Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
48333079|NCT02284022|DEVICE|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
48333080|NCT04950205|DRUG|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
48333081|NCT03923075|DRUG|Dexmedetomidine|INFUSION BEFORE INDUCTION OF ANAESTHESIA
48333082|NCT03923075|OTHER|0.9% saline|INFUSION BEFORE INDUCTION OF ANAESTHESIA
48333083|NCT02706119|DRUG|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
48652319|NCT06088914|DEVICE|Anodal transcranial direct current stimulation|Anodal tDCS will be delivered for 5 consecutive days. Participants will receive 2 mA of stimulation for 20 minutes with the anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
48652320|NCT06088914|DEVICE|Sham transcranial direct current stimulation|Sham tDCS will be delivered for 5 consecutive days. Participants will receive sham stimulation for 20 minutes with the current intensity ramping down after 30 seconds of stimulation. The anodal electrode placed on the ipsilesional primary motor cortex (M1) and the cathodal electrode placed over the contralateral supraorbital area.
48652321|NCT06519994|DRUG|Artesunate vaginal inserts|Subjects will self-administer 200 mg of Artesunate vaginal insert daily for 5 days, on weeks 1, 3, 5.
48652322|NCT06519994|DRUG|Placebo vaginal inserts|Subjects will self-administer a placebo vaginal insert daily for 5 days, on weeks 1, 3, 5.
48652323|NCT01381679|DRUG|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
48652324|NCT03436732|DRUG|LMB-100|administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
48652325|NCT03436732|DRUG|SEL-110|administered on day 1 of each cycle for up to 4 cycles
48652326|NCT05654181|DRUG|PF-07328948|investigational drug administered orally
48652327|NCT05654181|DRUG|Placebo|Placebo matching active drug administered orally
47975444|NCT01385215|DRUG|Fluzone|0.5 ml/60 micrograms
47975445|NCT05448053|PROCEDURE|Ilizarov|Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
48333084|NCT02706119|DRUG|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
48333085|NCT04125173|OTHER|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
48333086|NCT04125173|OTHER|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
48333087|NCT04125173|OTHER|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
48333088|NCT04238572|DEVICE|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
48333089|NCT04238572|DEVICE|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
48333090|NCT03228498|DRUG|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
48333091|NCT03228498|DRUG|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
48333092|NCT03905668|OTHER|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
48333093|NCT03905668|OTHER|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
48333094|NCT03905668|OTHER|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
48333095|NCT03905668|OTHER|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
48333096|NCT03905668|OTHER|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
48333097|NCT06561438|DRUG|Vortioxetine 20Mg Tab|20 mg oral vortioxetine tablet 2 hours before the procedure
48333098|NCT06402903|OTHER|Observation|"The clinical, post-surgical and anthropometric variables of the patients, as well as the time spent in the Intensive Care Unit and on the hospital ward (in days) were collected in the Clinical Histories.~The collection of data from the Clinical Histories will be carried out by the principal investigator, an employee of the Hospital Universitario Central de Asturias, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the patients whose data were collected.~The data from the Clinical Histories will be exported to an Excel file which will subsequently be anonymised. Access to the Excel file will require a password access that will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialties)."
48333099|NCT00605696|DRUG|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
48333100|NCT01090869|BEHAVIORAL|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
48333101|NCT03203954|BEHAVIORAL|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
48333102|NCT03203954|BEHAVIORAL|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
48333103|NCT03203954|BEHAVIORAL|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
48333104|NCT02980692|DRUG|SUNPG1623 I|injection
48333105|NCT02980692|DRUG|SUNPG1623 II|injection
48333106|NCT02980692|DRUG|SUNPG1623 III|injection
48333107|NCT02980692|DRUG|SUNPG1623 IV|injection
48333108|NCT02980692|DRUG|PLACEBO|injection
48333109|NCT00247572|DRUG|NRP104|
48333110|NCT02358564|PROCEDURE|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
48333111|NCT02358564|PROCEDURE|Upper Endoscopy|
48333112|NCT02358564|PROCEDURE|Rectal Barostat and Infusion of Fats|Feeding tube will be placed, as well as a small balloon in the rectum.
48333113|NCT06124885|DIAGNOSTIC_TEST|AKI risk screening using RenaFAST POCT test kits|"Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed."
48333114|NCT04443296|DRUG|CCRT+TIL|Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
48333115|NCT01444898|DRUG|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
48333116|NCT05572788|PROCEDURE|EUS-guided fine needle aspiration of pancreatic cysts|Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
48333117|NCT03162393|PROCEDURE|nerve transfer|
48333118|NCT04681729|DRUG|Dupilumab SAR231893|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
48333119|NCT04681729|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
48333120|NCT04681729|DRUG|Non sedating H1-antihistamine|Pharmaceutical form: Tablet Route of administration: Oral
48333121|NCT04681924|OTHER|Diet intervention|Low carb diet group are compared to low fat diet group and followed up for 6 months
48652328|NCT04449874|DRUG|GDC-6036|The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
48652329|NCT04449874|DRUG|Atezolizumab|A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
48652330|NCT04449874|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
48333122|NCT03917082|DRUG|Tamoxifen Citrate|current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
48333123|NCT02428673|OTHER|Assisted Standing Treatment Program|
48333124|NCT03009812|PROCEDURE|Longitudinal uterine incision|
48333125|NCT03009812|PROCEDURE|Transverse uterine incision|
48333126|NCT06014580|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
48333127|NCT03521661|PROCEDURE|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
48333128|NCT00169910|DRUG|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
48333132|NCT00833677|BEHAVIORAL|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
48333133|NCT01541111|DRUG|Magnesiun|75mg pills; each 12h; 12wk
48333134|NCT00125372|DRUG|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
48333135|NCT02277340|PROCEDURE|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
48333136|NCT05501288|DRUG|Huashi Baidu granule|Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
48333137|NCT05501288|DRUG|compound pholcodine oral solution|Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
48333138|NCT03291158|DRUG|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
48333139|NCT05525832|OTHER|Normal saline|Nasopharyngeal washes with NaCl 0.9%
48333140|NCT04262141|DRUG|IMG-7289|Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
48333141|NCT00351169|DRUG|Quetiapine SR|
48333142|NCT00351169|DRUG|Escitalopram|
48652331|NCT04449874|DRUG|Bevacizumab|A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
48333143|NCT02035579|BEHAVIORAL|Aerobic Training Intervention|
48333144|NCT02035579|BEHAVIORAL|Stretching Intervention|
48333145|NCT01084330|DRUG|AUY922|70mg/m2
48333146|NCT01084330|DRUG|Docetaxel|Docetaxel 75mg/m2
48333147|NCT01084330|DRUG|Irinotecan|Iriniotecan 350mg/m2
48333148|NCT01721512|OTHER|Breastfeeding|
48333149|NCT01721512|OTHER|Infant formula|
48333150|NCT01833741|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
48333151|NCT01511510|DRUG|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
48333152|NCT01511510|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
48333153|NCT01511510|DRUG|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
48652332|NCT04449874|DRUG|Erlotinib|150 mg of erlotinib will be administered PO QD in 21 day cycles.
48333154|NCT01511510|DRUG|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
48333155|NCT01511510|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
48333156|NCT05474469|OTHER|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
48333157|NCT05474469|OTHER|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
48333158|NCT02549248|OTHER|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
48333159|NCT02549248|OTHER|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
48333160|NCT02549248|OTHER|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
48333161|NCT02549248|OTHER|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
48333162|NCT02549248|OTHER|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
48333163|NCT06527261|OTHER|Real-time electronic data input into REDCap|"During usual care sessions, clinicians will real-time capture information about the intervention session into REDCap. This information is related to the multi-dimensional dose articulation framework e.g., content of the session and difficulty of the task, session length, episode length, and number of repetitions.~The usual care motor upper limb intervention the patient receives is determined by the clinician providing the care. The therapy may include but is not limited to strength training, task specific retraining, constraint induced movement therapy, mirror box, and electrical stimulation."
48333164|NCT05252923|DRUG|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
48333165|NCT04226287|DEVICE|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
48492845|NCT00944112|BIOLOGICAL|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
48492846|NCT00944112|BIOLOGICAL|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
48652333|NCT04449874|DRUG|GDC-1971|The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
48652334|NCT04449874|DRUG|Inavolisib|The starting dose of inavolisib will be determined from its single-agent dose escalation.
48333166|NCT02249026|DRUG|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
48126095|NCT06520449|DRUG|68Ga-NTA-476|The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.
48126096|NCT02333513|DRUG|Lomustine/Vincristine/Procarbazine|
48333167|NCT02249026|DRUG|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
48333168|NCT04600843|OTHER|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
48333169|NCT04600843|OTHER|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
48333170|NCT01624688|PROCEDURE|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
48333171|NCT01994317|OTHER|Algorithm|IV sedation dosing calculated by algorithm
47975446|NCT01476371|BEHAVIORAL|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here \& Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
47975447|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
47975448|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
48126097|NCT04255693|BEHAVIORAL|diet adherence|"This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes."
48126098|NCT04255693|BEHAVIORAL|No diet adherence|"A-posteriori established intervention based on the examinations at the end-point"
48126099|NCT04255693|BEHAVIORAL|Change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
48333172|NCT01994317|OTHER|Standard care|IV sedation dosing calculated by standard care.
48126100|NCT04255693|BEHAVIORAL|No change in physical activity|The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
48126101|NCT04255693|BEHAVIORAL|Use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes."
48333173|NCT02064205|DIETARY_SUPPLEMENT|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
48333174|NCT02064205|DIETARY_SUPPLEMENT|glucose syrup|Glucose syrup is used a control product for the polydextrose
47975449|NCT00062374|DRUG|Cisplatin|Given IV
47975450|NCT00062374|PROCEDURE|Computed Tomography|Undergo FDG and FLT PET/CT
47975451|NCT00062374|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
48333175|NCT04183387|DRUG|Simvastatin 40mg|
48333176|NCT05004350|DRUG|Encorafenib|oral hard capsule
47975452|NCT00062374|OTHER|Fluorothymidine F-18|Undergo FLT-PET/CT
48333177|NCT05004350|DRUG|Cetuximab|intravenous infusion
47975453|NCT00062374|DRUG|Irinotecan Hydrochloride|Given IV
47975454|NCT00062374|PROCEDURE|Positron Emission Tomography|Undergo FDG and FLT PET/CT
47975455|NCT00062374|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
47975456|NCT03340701|DRUG|vaginal progesterone suppository|200mg vaginal suppository micronized progesterone
47975457|NCT04416594|OTHER|Data collection|Only data collection
47975458|NCT01125683|DRUG|AZD1446|Capsule, oral single and multiple dose
47975459|NCT01125683|DRUG|Donepezil|Capsule, oral and single dose
48126102|NCT04255693|BEHAVIORAL|No use of antisecretory agents|"This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data."
48126103|NCT02978716|DRUG|Trilaciclib|G1T28
48126104|NCT02978716|DRUG|Gemcitabine|Gemcitabine
48126105|NCT02978716|DRUG|Carboplatin|Carboplatin
48126106|NCT02966275|DEVICE|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
48333178|NCT05004350|DRUG|FOLFIRI|"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"
48492847|NCT04605263|DEVICE|STN-PPN DBS Surgery|Subject will undergo standard bilateral STN DBS surgery and have 2 additional leads placed in the same burr with bilateral PPN targets
48652335|NCT06636331|OTHER|Continuous Suprainguinal Fascia Iliaca Compartment Block|Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
48652336|NCT06636331|OTHER|Continuous Epidural|Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.
48652337|NCT04576559|OTHER|Modified dental visual aids|Modified Dental visual aids in the form of pictures created by the main investigator
47975460|NCT01125683|DRUG|Placebo|Capsule, oral and single dose
47975461|NCT00261664|DEVICE|telehomecare|
47975462|NCT02304172|DEVICE|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
48126107|NCT02966275|DEVICE|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
48333179|NCT00065442|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
48333180|NCT00065442|BIOLOGICAL|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
48333181|NCT02191280|DRUG|Antistax®, low dose|
48333182|NCT02191280|DRUG|Antistax®, high dose|
47975463|NCT02304172|DEVICE|Harmonic (Group B)|hemostatic device utilized intraoperatively
47975464|NCT05945524|OTHER|Bone marrow sampling|Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
47975465|NCT05169749|PROCEDURE|Control-Service Nurse Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
47975466|NCT05169749|PROCEDURE|Nursing Visiting Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
47975467|NCT00824512|DRUG|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
48333183|NCT02191280|DRUG|Placebo|
48333184|NCT05550896|DIAGNOSTIC_TEST|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
48492848|NCT04605263|PROCEDURE|Deep Brain Stimulation Surgery (DBS)|DBS lead implantation of bilateral STN
48492849|NCT02993770|PROCEDURE|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
48492850|NCT02993770|PROCEDURE|External DCR|External DCR
48492851|NCT03056820|OTHER|25° head-up position|Participant will be positioned at 25° angle for procedure.
48492852|NCT03056820|OTHER|55° head-up position|Participant will be positioned at 55° angle for procedure.
48652338|NCT04576559|OTHER|Regular dental visual aids|Regular dental visual aids
48652339|NCT05073432|OTHER|Experimental|Usability of the Discussion Prioritization Tool (DPT) by completing Geriatric Assessment and Conjoint Analysis
48652340|NCT01681641|OTHER|A psycho-social intervention|
48652341|NCT06211868|BEHAVIORAL|Digital wearable and AI-human symbiotic lifestyle intervention|Digital wearable and AI-human symbiotic lifestyle intervention
48652342|NCT05124236|RADIATION|preoperative radiosurgery|single fraction radiosurgery
48652343|NCT05124236|RADIATION|postoperative hypofractionated stereotactic radiotherapy|5 fraction stereotactic radiotherapy /fractionated radiosurgery
48652344|NCT04855435|DRUG|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
48333185|NCT02784977|DEVICE|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
48333186|NCT02784977|DEVICE|Intraoral device (IOD)|Treatment of OSA with IOD
48333187|NCT02784977|PROCEDURE|Uvuloplasty|Uvuloplasty
48333188|NCT02784977|OTHER|Conservative treatment|No active intervention
48492853|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit \[SRAK-02 kit\] and third arm accessory).
48333189|NCT03357666|DRUG|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
48333190|NCT03357666|DRUG|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
48333191|NCT03357666|DRUG|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
48333192|NCT03357666|DRUG|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
48333193|NCT03357666|DRUG|Placebo|Vaginal administration, two tablets once a day for 7 days
48492854|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
48492855|NCT04860050|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
48652345|NCT06570525|BEHAVIORAL|NurseNET|"Nurse-Delivered Narrative Exposure Therapy (NurseNET). Narrative Exposure Therapy (NET) is a brief, low-cost, trauma-focused treatment modality that is effective in treating mobile populations with complex PTSD. In NurseNET, NET is facilitated by a clinically experienced nurse, while peers/program support specialists offer scaffolded support, fostering trust, engagement, and retention. NurseNET begins with administration of a diagnostic battery and psychoeducation. Then, in subsequent NurseNET sessions, using gradual imaginative exposure, the nurse guides the participant to verbally express and re-frame their personal trauma narratives to shift unhelpful beliefs/symptoms around trauma. NurseNET utilizes a racism-conscious approach to create relational spaces in which narratives of WEH are positioned to challenge dominant social narratives. Each NurseNET session offers a brief soulfulness-based stress reduction activity to prompt emotional/affective grounding."
47975468|NCT00824512|DRUG|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
47975469|NCT02490228|PROCEDURE|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
47975470|NCT05231395|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
48333194|NCT02157246|OTHER|Pimonidazole|
48333195|NCT02157246|OTHER|F-MISO PET|
48333196|NCT02157246|OTHER|pCT|
48333197|NCT02157246|OTHER|Functional MRI|
48333198|NCT02157246|PROCEDURE|Biopsy|
48333199|NCT02157246|PROCEDURE|Blood sample|
48333200|NCT04145713|DIETARY_SUPPLEMENT|Probiotic mixture|The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
48333201|NCT04145713|OTHER|Placebo|The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
48333202|NCT01753830|DEVICE|Durolane|4.5 mL
48333203|NCT01753830|DEVICE|PBS|4.5 mL
48333204|NCT00856986|DRUG|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
48333205|NCT00856986|DRUG|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
48492856|NCT04860050|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
48492857|NCT02351544|DRUG|Botulinum Toxin Type A|
48492858|NCT02351544|PROCEDURE|Surgery|
48492859|NCT02351544|OTHER|Daily headache diary|
48492860|NCT02351544|OTHER|Migraine Disability Assessment Test (MIDAS)|
48492861|NCT02351544|OTHER|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
48492862|NCT02351544|OTHER|Migraine-Specific Quality of Life Questionnaire (MSQ)|
48492863|NCT01806818|DRUG|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
48492864|NCT00986180|DRUG|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
48492865|NCT00986180|DRUG|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
48492866|NCT03602443|BEHAVIORAL|LSVT®BIG Intervention|Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
48492867|NCT03602443|BEHAVIORAL|Waitlist Control|Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
48492868|NCT05568693|BIOLOGICAL|0.3ml of mRNA vaccine|Subjects received 0.3ml of mRNA vaccine intramuscularly
48492869|NCT02171676|DRUG|Docetaxel|
48492870|NCT02171676|DRUG|BIBW 2992|
48333206|NCT00856986|DRUG|metformin|Metformin tablets, at least 1500 mg/day
48333207|NCT03159013|OTHER|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
48333208|NCT03406364|DRUG|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy."
48333209|NCT03267771|DRUG|Progesterone Suppositories Vaginal|progesterone vaginal suppository
48126108|NCT04437641|OTHER|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
48333210|NCT03267771|DRUG|Dydrogesterone Oral Tablet|oral progesterone drug
48333211|NCT03267771|DEVICE|doppler ultrasound|pulsed doppler ultrasound
48333212|NCT02954302|PROCEDURE|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
48333213|NCT02954302|PROCEDURE|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
48333214|NCT00838721|OTHER|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
48333215|NCT00429390|BEHAVIORAL|Ramadan Fasting|
48333216|NCT04593875|DEVICE|Active LIFUP Treatment|Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.
48333217|NCT04593875|DEVICE|Sham LIFUP Treatment|The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
48333218|NCT03342456|DRUG|Doxycycline Hyclate Enteric-Coated Capsules|group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
48492871|NCT00003436|DRUG|amsacrine|
47975471|NCT05231395|OTHER|Control Group|"Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program.~Control group will be followed-up by telephone once a week"
48126109|NCT03949101|DRUG|Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
48126110|NCT03949101|DRUG|atropine 0.01% eye drop|use one drop into subconjunctiva
48126111|NCT06516809|DEVICE|DormoTech Vlab SpO2 sensor|The Dormotech Vlab sensor was applied to one of the subject's forehead. Reference pulse oximeters were applied to the right fingers. Blood gas analysis to determine hemoglobin saturation (SaO2) was performed using an ABL-90 Flex Plus multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). The ABL90 Flex Plus contains factory calibration standards and automatically performs regular quality controls.
48126112|NCT05398861|DRUG|Utidelone Combined with Bevacizumab|Utidelone： 30 mg/m2/day, IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle Bevacizumab：10mg/kg (IV), on day 1 of each 21 days.
48333219|NCT03342456|DRUG|Amoxicillin Capsules|group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）
47975472|NCT06008457|DEVICE|Labcorp COVID-19+Flu+RSV Test Home Collection Kit|The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.
47975473|NCT01938677|RADIATION|Initial Gamma knife radiosurgery|
48333220|NCT03342456|DRUG|Ilaprazole Enteric-Coated Tablets|group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
48333221|NCT03342456|DRUG|Furazolidone Tablets|group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
48492872|NCT00003436|DRUG|asparaginase|
48492873|NCT00003436|DRUG|cytarabine|
48492874|NCT00003436|DRUG|daunorubicin hydrochloride|
48492875|NCT00003436|DRUG|etoposide|
48492876|NCT00003436|DRUG|methotrexate|
48492877|NCT00003436|DRUG|mitoxantrone hydrochloride|
48333222|NCT03342456|DRUG|Potassium Citrate Tablets|group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
48333223|NCT01125293|DRUG|Everolimus|
48333224|NCT01125293|DRUG|Rituximab|
48333225|NCT01125293|DRUG|Bortezomib|
48492878|NCT00003436|DRUG|therapeutic hydrocortisone|
48492879|NCT00003436|PROCEDURE|allogeneic bone marrow transplantation|
48492880|NCT03142906|DIAGNOSTIC_TEST|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
48492881|NCT01721811|OTHER|Hyperoxia|
48492882|NCT01721811|OTHER|Glucose|
48492883|NCT04489758|DIAGNOSTIC_TEST|X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis|Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
48492884|NCT03044041|DRUG|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
48492885|NCT00477295|DRUG|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
48652346|NCT06570525|OTHER|PAL|"Peer Active Listening (PAL). In the PAL active comparator/control, peers/program support specialists meet individually with participants in active listening sessions, along the same visit sequence as NurseNET. During PAL sessions, peers/program support specialists allow participants to set each conversational agenda while practicing the tenets of active listening, including attending to body language, paraphrasing the participant's verbal expressions, reflecting feelings, and using tactful repetition. PAL sessions are not intended to center on topics of trauma, but rather designed to offer a supportive relationship (attentional control)."
48652347|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)|Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
48126113|NCT03035396|DEVICE|Diassess Influenza A and B Test|
48126114|NCT02008916|DRUG|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
48333226|NCT03943108|DIAGNOSTIC_TEST|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
48333227|NCT01545024|DRUG|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
48492886|NCT00477295|DRUG|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
48492887|NCT02756936|DRUG|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
48492888|NCT02756936|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
48492889|NCT03463486|BEHAVIORAL|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
48492890|NCT01882075|DRUG|Open loop|
48652348|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)|Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
48333228|NCT05839847|DEVICE|Low-intensity focused ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can reduce reactions to sensory stimuli.
48492891|NCT01882075|DEVICE|Closed-loop|
48652349|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)|Nasal continuous positive airway pressure alone
48652350|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)|nasal continuous positive airway pressure alone
48652351|NCT06640348|OTHER|No intervention|No intervention
48652352|NCT05892393|DRUG|Zirconium Zr 89-DFO-YS5|Given IV
48652353|NCT05892393|PROCEDURE|Positron Emission Tomography / Computed Tomography (PET/CT)|Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image
48652354|NCT05892393|PROCEDURE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)|Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.
48126115|NCT02008916|DRUG|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
48126116|NCT04657172|DRUG|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
48333229|NCT05839847|DEVICE|Low-intensity focused ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
48333230|NCT01045928|DRUG|lenalidomide|Given orally
48333231|NCT01045928|BIOLOGICAL|rituximab|Given IV
48333232|NCT01045928|GENETIC|polymerase chain reaction|Correlative study
48333233|NCT01045928|GENETIC|nucleic acid sequencing|Correlative study
48333234|NCT01045928|GENETIC|polymorphism analysis|Correlative study
48333235|NCT01045928|OTHER|flow cytometry|Correlative study
48333236|NCT01045928|OTHER|laboratory biomarker analysis|Correlative study
48333237|NCT00886717|DRUG|carboplatin|
48333238|NCT00886717|DRUG|paclitaxel-loaded polymeric micelle|
48492892|NCT04781387|DRUG|CRS3123|Study drug dosed at 200 mg PO BID (treatment arm A) or 400 mg PO BID (treatment arm B) for total of 10 days
48126117|NCT04657172|DRUG|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
48333239|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
48492893|NCT04781387|DRUG|Active Comparator|Active comparator is administered 125 mg PO QID
48492894|NCT04726319|OTHER|FHAMe Intervention|Patients will receive an invitation email prior to their scheduled clinical visit which includes information about the study, a link to the YouTube patient presentation, and a link to the consent form and questionnaire. Patients will be invited to fill out the questionnaire prior to their appointment. After patients complete the initial questionnaire, physicians will receive an EMR message on the day of patient's clinic visit alerting them that patient family history information is available and to complete the Family History Action Form. They will be prompted to respond to the message which will open the action form and ask what action the provider intends to take with this family history information. The form will then link to management support tools for use during the patient visit. All participants will attend their clinical visit after which they will receive a post-visit electronic survey regarding their clinical visit and whether family history was reviewed with their provider.
48492895|NCT01208220|DEVICE|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
48492896|NCT01208220|BIOLOGICAL|Collagenase Ointment|Apply TIW
48652355|NCT05892393|OTHER|Fludeoxyglucose F-18|Given IV
48652356|NCT05787782|DEVICE|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
48652357|NCT02320552|OTHER|No intervention|no intervention
48126118|NCT05122546|DRUG|Cabozantinib S-malate|Given PO
48126119|NCT05122546|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
48652358|NCT01390103|OTHER|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
48652359|NCT05679557|OTHER|Perioperative geriatric assessment and intervention|The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
48652360|NCT03960346|PROCEDURE|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
48652361|NCT04847037|PROCEDURE|Connected tools|Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
48652362|NCT05934396|BEHAVIORAL|Safety Planning|Prior to discharge and following the conclusion of all Virtual Reality (VR) sessions, the participant will develop a safety planning intervention for school settings in collaboration with relevant individuals (e.g., the researcher, a school professional).
48652363|NCT05934396|BEHAVIORAL|VR Enhanced Affect Regulation|Participants will receive an overview of affect regulation in VR and then have the opportunity to practice using affect regulation in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
48652364|NCT05934396|BEHAVIORAL|VR Enhanced Cognitive Restructuring|Participants will receive an overview of cognitive restructuring in VR and then have the opportunity to practice using cognitive restructuring in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
48652365|NCT05934396|BEHAVIORAL|VR Enhanced Problem Solving|Participants will receive an overview of problem solving in VR and then have the opportunity to practice using problem solving in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
48333240|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
48492897|NCT00522171|DEVICE|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
48652366|NCT05934396|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
48652367|NCT06192797|PROCEDURE|HAIC|administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.
48652368|NCT06192797|DRUG|Lenvatinib plus pucotenlimab|lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
48652369|NCT05305573|BIOLOGICAL|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
48126120|NCT05122546|BIOLOGICAL|Nivolumab|Given IV
48126121|NCT06004765|DRUG|Lenalidomide|10mg/d \*21 days, 28 days for 1 course
48126122|NCT06004765|DRUG|Azacitidine|75mg/m2/d\*5 days, 28 days for 1 course
48126123|NCT04144335|BIOLOGICAL|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
48126124|NCT04144335|BIOLOGICAL|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
48126125|NCT00575549|OTHER|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
48126126|NCT06154876|DEVICE|Cough assist device|"Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise."
48126127|NCT02559362|BEHAVIORAL|Survey|
47975474|NCT02397785|DEVICE|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
47975475|NCT02397785|DEVICE|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
48652370|NCT05305573|BIOLOGICAL|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
48126128|NCT03158805|DRUG|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
48126129|NCT03158805|OTHER|Placebo|Placebo injection
48126130|NCT03022994|OTHER|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
48126131|NCT00175864|DRUG|Seletracetam (ucb 44212)|
48126132|NCT04663698|OTHER|Baseline|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH
48126133|NCT04663698|OTHER|MESH-Resistor 5|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (5hPa/L) to create laminar airflow
48126134|NCT04663698|OTHER|MESH-Resistor 10|Lung funtion testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with mesh-resistor (10hPa/L) to create laminar airflow
48652371|NCT03383874|COMBINATION_PRODUCT|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10\^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10\^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
48126135|NCT04663698|OTHER|Perforated Resistor 7|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 7mm) to create a turbulent airflow
48126136|NCT04663698|OTHER|Perforated Resistor 11|Lung function testing with MasterScreen™ Body, CareFusion Germany GmbH, Mouthpiece with perforated resistor (inside diameter 11mm) to create a turbulent airflow
48126137|NCT05297851|DRUG|Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)|10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
48126138|NCT05297851|DRUG|Control|Standard treatment accordind to the routine clinical practice
48652372|NCT03383874|OTHER|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
48652373|NCT06642012|OTHER|Cash only|Households received 1 mobile cash transfer per month for 6 months.
48652374|NCT06642012|OTHER|Cash + Social Behavior Change Communication|Households received 1 mobile cash transfer per month for 6 months but mothers also received an SBCC package that included interpersonal communication (1:1 consultations for mothers), bi-monthly group sessions on key health and nutrition topics, and cooking demonstrations.
48652375|NCT06642012|OTHER|Cash + top-up cash|Households received 1 mobile cash transfer per month for 6 months, receiving the base cash amount plus an additional cash top-up amount.
47975476|NCT06037395|BIOLOGICAL|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
47975477|NCT06037395|BIOLOGICAL|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
47975478|NCT01975545|DRUG|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
47975479|NCT01975545|DRUG|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
47975480|NCT05812612|DRUG|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
47975481|NCT00801632|PROCEDURE|Kidney Transplantation|Surgical transplantation of donor kidney
48126139|NCT00154011|DRUG|rosiglitazone (drug)|
48126140|NCT00569387|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
48126141|NCT02187536|DRUG|Telmisartan|
48126142|NCT02187536|DRUG|Simvastatin|
48126143|NCT02187536|DRUG|Telmisartan placebo|
48126144|NCT00448734|DRUG|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
48126145|NCT00448734|DRUG|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
48126146|NCT02362139|DRUG|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
48126147|NCT01718041|DRUG|Experimental: VRS-317|Active treatment arm
48126148|NCT04890067|OTHER|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
48126149|NCT00972439|DRUG|Oral Contraceptive: Ortho-Novum® 1/35|
48126150|NCT00972439|DRUG|Oral Contraceptive: Ovcon Fe®|
48333241|NCT00973622|DEVICE|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
48333242|NCT01699412|DRUG|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
47975482|NCT00801632|PROCEDURE|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
48126151|NCT03947346|OTHER|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
48126152|NCT02548806|DRUG|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
47975483|NCT00801632|BIOLOGICAL|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
48126153|NCT02548806|DRUG|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
47975484|NCT00801632|DRUG|cyclophosphamide|60 mg/kg infusion on days -5, -4
48126154|NCT02548806|DRUG|Catapres 100μg|Catapres tablet 100μg, single dose
48126155|NCT02670109|DRUG|Carmustine|300mg/m2, IV, in 3 hours, during day -4
48126156|NCT02670109|DRUG|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
48126157|NCT02670109|DRUG|Carboplatin|1400/m2, IV, in 1 hour, during day -3
48126158|NCT02670109|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
48333243|NCT01699412|DRUG|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
48333244|NCT05739357|DEVICE|NIRS, EEG|During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
48333245|NCT04041141|DIAGNOSTIC_TEST|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
48492898|NCT02930486|DEVICE|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
48652376|NCT05372068|OTHER|Concrete household floor|Household soil floors will be replaced with concrete floors
48652377|NCT06255782|GENETIC|ECUR-506|ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.
48652378|NCT03403738|BEHAVIORAL|Bounce Back Now|web/smartphone-based intervention for disaster victims
47975485|NCT00801632|BIOLOGICAL|rituximab|375 mg/m\^2 infusion on days -7, -2, 5, and 12
48126159|NCT02670109|DRUG|Busulfan|16mg/kg, Oral, during day -4
48126160|NCT04010435|DEVICE|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
48126161|NCT04010435|DEVICE|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
48126162|NCT06326931|DEVICE|thermal pulsation|Single, in-office bilateral treatment with Systane iLux thermal pulsation
47975486|NCT00801632|DRUG|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
47975487|NCT00801632|DRUG|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
48126163|NCT06326931|OTHER|warm compress|Twice daily, 10-minute at-home treatment with Bruder warm compress mask for 8 weeks
48126164|NCT06349655|DRUG|Azvudine|Antiviral drug
48126165|NCT06349655|DRUG|Paxlovid|Antiviral drug
48652379|NCT03403738|BEHAVIORAL|enhanced usual care|enhanced usual care with list of resources
48652380|NCT00000354|DRUG|Lofexidine|
48652381|NCT02125422|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
47975488|NCT00801632|RADIATION|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
47975489|NCT00487773|DRUG|budesonide|budesonide
47975490|NCT00487773|DRUG|D3 vitamin|D3 vitamin
47975491|NCT00487773|DRUG|montelukast sodium|montelukast sodium
47975492|NCT00487773|DRUG|salbutamol|salbutamol
47975493|NCT04500002|DRUG|Isonicotinic Acid Hydrazide|total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
47975494|NCT04500002|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
47975495|NCT01928394|BIOLOGICAL|Nivolumab|
47975496|NCT01928394|BIOLOGICAL|Ipilimumab|
47975497|NCT01928394|DRUG|Cobimetinib|
47975498|NCT05127434|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
48126166|NCT04129203|DEVICE|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
48126167|NCT04850586|OTHER|Education Group|The patients in the training group were given structured training by a multidisciplinary team. After the content of the structured education was prepared, three experts were consulted for their opinions in terms of the scope and content. Necessary adjustments were made in line with their recommendations. Patients in this group were visited in their rooms at least 12 hours before undergoing surgery by a multidisciplinary team consisting of a surgeon, an anesthesiologist, and a nurse. The multidisciplinary team visited the patients at the same time and provided their education after introducing the team. Structured verbal education and written documents were given to the patients for 30 minutes on preoperative preparation, anesthesia, intubation, mobilization, deep breathing and coughing exercises, nutrition and fluid management, the postoperative recovery process, clinical practice guideline and operating room protocols.
48652382|NCT05874037|DRUG|Fluvoxamine|Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
48652383|NCT03151668|DRUG|Dexmedetomidine|
48333246|NCT04041141|DEVICE|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
48333247|NCT04735965|DRUG|Dexmedetomidine|Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
48333248|NCT04735965|DRUG|Meperidine|Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
48333249|NCT04735965|DRUG|Placeb|Equal volume of normal saline to dexmedetomidine and meperidine group.
48333250|NCT00387348|DRUG|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
48333251|NCT00387348|DRUG|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
48333252|NCT05884476|OTHER|Treatment-as-usual|Veterans in the TAU-only control condition will remain engaged in their normal standard of mental health care throughout their participation in this study. Veterans in the TAU condition will have access to and receive referrals for any of the following services normally afforded to patients at this VA hospital: VA Office of Connected Care web-based training programs and mobile mental health applications; primary care appointments; PCMHI consultation; outpatient mental health individual and group therapies; psychiatry appointments; inpatient hospitalization in the event of a suicidal crisis during study participation; and post-discharge mental health follow-up appointments following inpatient hospitalization for medical or mental health reasons.
48652384|NCT06640920|BIOLOGICAL|Cohort A|Administered IV High dose
48652385|NCT06640920|BIOLOGICAL|Cohort B|Administered SC Low Dose
47975499|NCT05127434|DRUG|mRNA-1345|Sterile liquid for injection
47975500|NCT02852408|PROCEDURE|Laparoscopic cholecystectomy|
47975501|NCT03478267|DIAGNOSTIC_TEST|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
47975502|NCT05023772|PROCEDURE|Stereotactic Laser Ablation|MR Guided laser ablation therapy
47975503|NCT05023772|RADIATION|Stereotactic Radiosurgery|Precise delivery of radiation to spinal tumor
47975504|NCT05023772|DIAGNOSTIC_TEST|MRI guided laser ablation|Surgery will take place in intraoperative suite to include operating room and MRI scanner
47975505|NCT02236832|DEVICE|transcranial magnetic stimulation|
48126168|NCT05297136|PROCEDURE|Pancreatic Stenting|Pancreatic stent of appropriate size and length is inserted to the pancreatic duct before distal pancreatectomy
48333253|NCT05884476|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|"REST is a brief, computerized intervention designed to mitigate psychological inflexibility associated with the experience of suicidal ideation. Most individuals complete the intervention in under one hour. REST provides psychoeducation to correct common misconceptions about suicidal ideation and help Veterans de-catastrophize the occurrence and meaning of these thoughts. This includes information about the prevalence of suicidal ideation among Veterans, a conceptualization of suicidal ideation as a response to stress, normalizing emotional reactions to suicidal ideation, and framing suicidal ideation as thoughts and conjectures as opposed to truth and reality. These components were chosen to directly address emotional distress related to suicidal thoughts, which is central to the construct of psychological inflexibility. Veterans randomized to receive REST will have access to and be encouraged to utilize any and all of these options described in the TAU-only condition."
48333254|NCT01988597|OTHER|Dry eyes|
48333255|NCT02286492|DRUG|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
48333256|NCT05060796|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
48333257|NCT00390494|PROCEDURE|Hysterectomy|
48333258|NCT00390494|PROCEDURE|Myomectomy|
48333259|NCT00390494|PROCEDURE|Uterine Fibroid Embolization|
48333260|NCT04946162|DRUG|Tadalafil Pill|Each patient will be given tadalafil 40 mg one time
48333261|NCT01721148|DRUG|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
48333262|NCT00051090|DRUG|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
48333263|NCT00051090|DRUG|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
48652386|NCT06640920|BIOLOGICAL|Cohort C|Administered SC Mid Dose
48652387|NCT06640920|BIOLOGICAL|Cohort D|Administered SC High Dose
48652388|NCT04854499|DRUG|Magrolimab|Administered intravenously
48652389|NCT04854499|DRUG|Pembrolizumab|Administered intravenously
48652390|NCT04854499|DRUG|Docetaxel|Administered intravenously
48652391|NCT04854499|DRUG|5-FU|Administered intravenously
48652392|NCT04854499|DRUG|Cisplatin|Administered intravenously
48652393|NCT04854499|DRUG|Carboplatin|Administered intravenously
48652394|NCT04854499|DRUG|Zimberelimab|Administered intravenously
48652395|NCT03662373|RADIATION|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
47975506|NCT02236832|OTHER|MRI imaging|
47975507|NCT02236832|OTHER|EEG recording|
47975508|NCT02236832|BEHAVIORAL|Neuropsychological examination|
47975509|NCT05182138|OTHER|Unfortified potato plus placebo|Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.
47975510|NCT05182138|OTHER|Zinc Biofortified potato plus placebo|Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.
47975511|NCT05182138|OTHER|Unfortified potato plus zinc supplement|Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
47975512|NCT02857543|OTHER|Plant-Based Diet|
47975513|NCT02857543|OTHER|American Heart Association Diet|
47975514|NCT02857543|OTHER|Mediterranean Diet|
48652396|NCT03662373|RADIATION|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
48652397|NCT04833738|DRUG|Hyaluronic acid|
48652398|NCT04833738|DRUG|Corticosteroids Triamcinolone Acetonide|triamcinolone acetonide, 40 mg/ml, single dose
48652399|NCT04833738|OTHER|Electrotherapy|electrotherapy
48126169|NCT05297136|PROCEDURE|No Stent|No preoperative stenting with distal pancreatectomy alone
48333264|NCT00051090|DRUG|Efavirenz|Administered orally at a daily dose of 600 mg
48333265|NCT00051090|DRUG|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
48333266|NCT00051090|DRUG|Abacavir|Administered orally twice daily in doses of 300 mg
48333267|NCT03555071|BIOLOGICAL|Vaccine manufactured at commercialized scale|Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
48333268|NCT03555071|BIOLOGICAL|Vaccine manufactured at trial-scale|Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
48333269|NCT02972957|BIOLOGICAL|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
48333270|NCT02972957|DRUG|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
48333271|NCT04391972|DEVICE|SAV|SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
48333272|NCT04965870|DRUG|Trifluridine/Tipiracil|Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
48333273|NCT05599412|DRUG|Lorviqua|As provided in real world practice
48333274|NCT00162526|DRUG|Tocopherol|
48333275|NCT03825107|OTHER|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
48333276|NCT03825107|OTHER|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
48333277|NCT03007719|DRUG|Fluorine F 18 Ara-G|Given IV
48492899|NCT02930486|DEVICE|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
47975515|NCT01550302|PROCEDURE|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
47975516|NCT01550302|DRUG|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
47975517|NCT00193154|DRUG|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
47975518|NCT00193154|DRUG|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
48126170|NCT05951140|OTHER|Usage of the PROTEIN-Application|Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
48126171|NCT00257998|PROCEDURE|Mobilization|manualtherapy techniques
48126172|NCT03865199|BEHAVIORAL|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
48126173|NCT01892683|DRUG|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
48126174|NCT03813433|OTHER|Revascularization|a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
48126175|NCT06499558|OTHER|Classical Training|Students in the education group will practice family planning education skills in the professional skills laboratory.
48126176|NCT06499558|OTHER|Standard Patient Interviews|Students in the standardized patient education group will receive training involving a family planning counseling scenario with standardized patients.
48333278|NCT03007719|PROCEDURE|Positron Emission Tomography|Undergo PET/MR imaging
48333279|NCT03007719|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR imaging
48333280|NCT04643665|PROCEDURE|Double-lung transplantation|
48333281|NCT02137837|DRUG|Fulvestrant|
48333282|NCT02137837|DRUG|Anastrozole|
48333283|NCT02137837|DRUG|Everolimus|
48333284|NCT02137837|DRUG|Placebo - Anastrozole|
48333285|NCT02137837|DRUG|Placebo - Everolimus|
48333286|NCT03263741|DRUG|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1."
48333287|NCT05876104|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
48333288|NCT03999541|OTHER|Freeze-all policy|A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
48333289|NCT01570608|DRUG|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
48333290|NCT01570608|DRUG|Verteporfin|Verteporfin photodynamic therapy standard fluence
48492900|NCT01923623|DRUG|Ropivacaine block|
48492901|NCT01922167|DIETARY_SUPPLEMENT|Leucine|
48492902|NCT01922167|DIETARY_SUPPLEMENT|Alanine|
48492903|NCT01296659|DRUG|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
48492904|NCT05985733|OTHER|Biochemical analysis|Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
48492905|NCT02107326|DEVICE|Webdia Software|
48492906|NCT04524052|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
48492907|NCT04524052|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
48492908|NCT04014855|DRUG|Iron Supplement|in iron deficiency anemia
48333291|NCT00903370|PROCEDURE|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
48333292|NCT00903370|DEVICE|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
48333293|NCT03235375|DRUG|MEDI0382|MEDI0382 administered subcutaneously
48333294|NCT04809272|BEHAVIORAL|ParentChat for parents of children ages 2-17|The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
48333295|NCT01469091|BEHAVIORAL|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
48333296|NCT05468762|PROCEDURE|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
48652400|NCT04421963|DRUG|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
48652401|NCT06077513|PROCEDURE|CAD-CAM designed and preprinted Ti-Mesh frame|CAD-CAM technology which is the process of designing and manufacturing a custom-made dental device, or a patient-specific dental device from an industrialized product, with the aid of a computer.will be used to plan and preprint a 3-D Ti-Mesh frame prior to the surgery.
48652402|NCT06077513|PROCEDURE|Conventional chairside fabrication of Ti-Mesh frame|A three-dimensional frame or cage of Ti-Mesh or Ti-reinforced d-polytetrafluoroethylene (PTFE) will be fashioned during the surgery to contain, shape and stabilize the bone graft materials (the internal scaffold). This 3-D frame will be custom fabricated from a perforated Ti Mesh sheet material at the time of surgery which takes considerable time and skill.
48652403|NCT04606316|DRUG|Nivolumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
48126177|NCT02269475|DRUG|MEDI3250|MEDI3250
48492909|NCT03820934|DIAGNOSTIC_TEST|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
48126178|NCT02269475|DRUG|Placebo|Placebo
48333297|NCT06138990|DIAGNOSTIC_TEST|Pharmacoscopy|Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
48333298|NCT06138990|DRUG|Clinical standard-of-care (physician's choice)|Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
48333299|NCT00360048|DRUG|oxytocin|
48333300|NCT02285504|DRUG|SAGE-547|Intravenous injection
48492910|NCT04393766|DRUG|Normal Saline|normal saline(crystalloids)
48492911|NCT01490931|DRUG|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
48652404|NCT04606316|DRUG|Nivolumab|Given as intravenous (IV) infusion into a vein.
48333301|NCT00036062|DRUG|Sivelestat|
48333302|NCT02141113|DRUG|Guanfacine Hydrocholride|"1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)"
48492912|NCT05993117|DEVICE|G114R VNS system|All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
48652405|NCT04606316|DRUG|Ipilimumab-Placebo|Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.
48652406|NCT04606316|DRUG|Ipilimumab|Given as intravenous (IV) infusion into a vein.
48652407|NCT04606316|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
48652408|NCT06674629|DEVICE|High flow oxygen therapy|Application of high flow oxygen therapy through asymmetric cannula at 40 and 60 L/m
48652409|NCT03917901|OTHER|Anxiety Sensitivity Training|Computerized Single-Session Anxiety Sensitivity Reduction Program
48652410|NCT03917901|OTHER|Health Control|Computerized Single-Session Health Information Control
48652411|NCT05115825|BEHAVIORAL|Behavioral Intervention|Attend Mobile Pain Coping Skills Training
48652412|NCT05115825|OTHER|Quality-of-Life Assessment|Ancillary studies
48652413|NCT05115825|OTHER|Questionnaire Administration|Ancillary studies
48652414|NCT01726608|PROCEDURE|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
48652415|NCT06641947|PROCEDURE|Whipple procedure|Typically used for treating pancreatic cancer, particularly tumors located in the head of the pancreas.
48126179|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
48126180|NCT01228669|DRUG|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
48652416|NCT05670756|OTHER|Survey|Parents/guardians will complete a survey about when the medication allergy was identified and the exact symptomatology that resulted in determination of the allergy.
48333303|NCT02141113|DRUG|Guanfacine Hydrocholride|"1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)"
48333304|NCT01125540|DEVICE|Acuvue (Standard Daily Disposable Contact Lens)|
48333305|NCT01125540|DEVICE|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
48333306|NCT05923892|DRUG|OPS-2071|There are 3 dose groups of OPS-2071，OPS-2071 tablets, 50 mg、100mg、200mg. Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
48333307|NCT05923892|DRUG|placebo|Take 4 tablets/bid, after meals in the morning and evening, with an interval of at least 8 hours for 2 weeks(The dosing interval will be 12 hours from Day 5 to Day 7).
48333308|NCT02855138|DRUG|oral isotretinoin|
48492913|NCT04416620|OTHER|The PCOS pharmaceutical care service|"The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects."
47975519|NCT04631081|PROCEDURE|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
48126181|NCT01228669|DRUG|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
48126182|NCT01286714|DEVICE|CLIP OST|
48126183|NCT00496743|DEVICE|Low-dose total skin electron beam therapy (4 Gy)|
48126184|NCT01790672|DIETARY_SUPPLEMENT|Ethanol|Vodka Absolut
48126185|NCT01790672|OTHER|Water|Lemon-flavored water
48126186|NCT01790672|DIETARY_SUPPLEMENT|Alcoholized wine|Wine 13º or wine 8º
48126187|NCT01790672|DIETARY_SUPPLEMENT|De-alcoholized wine|Wine 0º
48126188|NCT06094231|BEHAVIORAL|Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor|The patients will be educated on how to implement a therapeutic carbohydrate restriction, which consists of 50 to 130 grams of carbohydrate per day, simultaneously they will continue to receive the SGLT-2-Inhibitor dapagliflozin.
48126189|NCT06288334|OTHER|1-3 Cetirizine Pharmacokinetic samples|Limited sampling strategy was used in this study. For each child, only 1\~3 blood samples were collected before and after cetirizine administration.
48126190|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET CT|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a GE MI4 PET/CT camera, with low dose CT and 120 MBq injected activity. Dynamic imaging between 0-60 minutes and 100-120 minutes (patients) and 0-70 minutes and 90-120 minutes (healthy volunteers).~Venous sampling between 5-120 minutes will be obtained through a second catheter, 6 venous samples will be taken.~In healthy up to 5 control subjects, full arterial sampling (0-120 minutes,) will also be done.~If patient comfort allows, after the dynamic cardiac scan 2 hours post-injection field dynamic scan, a fast late timepoint whole body PET/CT will be taken (2 min/bed position, 11 mAs low dose CT; estimated 10-12 minutes)."
48333309|NCT04545398|OTHER|Food. Beef, Pasture-raised|Pasture-raised beef
48333310|NCT04545398|OTHER|Food. Beef, Grain-fed|Grain-fed beef
48333311|NCT04545398|OTHER|Food. Meat alternative|Meat alternative
48333312|NCT04545398|OTHER|Food, Lamb|Lamb
48333313|NCT06173661|DRUG|Fremanezumab|The intervention will be active medication.
48333314|NCT06173661|OTHER|Placebo|The intervention will be placebo injection.
48333315|NCT04077411|OTHER|Observational|This is an observational study with no interventions.
48333316|NCT00749268|DEVICE|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
48126191|NCT06120049|DIAGNOSTIC_TEST|[18F]-FE-PE2I PET CT or PET MRI|"\[18F\]-FE-PE2I will be performed at the University Hospital Leuven with the GE Signa simultaneous PET/MR with acquisition at 50-70 minutes postinjection or at the University Hospital in Gent using a Siemens PET/CT, GE MI4 PET/CT.~Injected activity: 120 MBq"
48126192|NCT06120049|DIAGNOSTIC_TEST|[123I]-MIBG SPECT CT|"\[123I\]-MIBG SPECT/CT (low dose CT) will be performed at the local nuclear medicine department of each participating center.~Injected activity: 111 MBq"
48333317|NCT00749268|DEVICE|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
48333318|NCT06122987|DRUG|Angiotensin II and hydrocortisone sodium succinate|Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
48333319|NCT04294095|OTHER|My Baby My Move +|This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.
48333320|NCT04294095|OTHER|Control|This is a 12-week basic prenatal education class.
48333321|NCT05186272|BEHAVIORAL|Stress reduction program 'A'|Participants will use stress reduction program 'A' app 10-20 min per day for 6 weeks.
48333322|NCT05186272|BEHAVIORAL|Stress reduction program 'B'|Participants will use stress reduction program 'B' app 10-20 min per day for 6 weeks.
48333323|NCT06006910|BEHAVIORAL|Column-based nudge in the EHR|The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer. The nudge flag can pop up when hovered over to remind surgeons of the Choosing Wisely criteria and to consider omission of SLNB.
48333324|NCT06006910|BEHAVIORAL|No column-based nudge in the EHR|No intervention control period prior to nudge deployment.
48333325|NCT03614819|PROCEDURE|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
48333326|NCT03614819|PROCEDURE|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
48333327|NCT05589129|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
48333328|NCT05589129|DIETARY_SUPPLEMENT|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
48333329|NCT01743170|OTHER|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
47980543|NCT05496387|OTHER|Sciatic nerve neuromobilization techniques|Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
48126193|NCT06120049|DIAGNOSTIC_TEST|[18F]-MFBG PET dosimetry scans|"\[18F\]-MFBG will be acquired at the Leuven University hospital on a Siemens Truepoint or GE MI4 PET/CT camera or equivalent newer camera, with low dose CT and 120 MBq injected activity.~Three segments of consecutive whole-body scanning with increasing bed position duration will be carried out up to 3 half-lives (physical half-life T1/2 for 18F = 110 minutes): from 0-90 minutes (scan 1-8), 120-150 (scan 9) and 300-330 (scan 10) minutes post injection. In total 10 whole body biodistribution scans will be taken. Urine will be collected and its total activity measured to measure bladder excretion for correction of integrated bladder organ residence. Before each segment, a low dose whole body CT scan (11 mAs) will be acquired for attenuation correction and organ delineation."
48492914|NCT03898830|DEVICE|eon™ FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
48492915|NCT04414306|OTHER|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
48652417|NCT06645158|DEVICE|Transcutaneous bilirubin level monitoring|self-monitoring by parents long-term: from birth to 30 days of age
48652418|NCT06638567|OTHER|Basal bolus insulin regimen|Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively
48652419|NCT03277872|DEVICE|Laryngoscopy with GlideScope (GVL) Blade|"1. st Laryngoscopy with GVL Blade~2. nd Laryngoscopy with MAC Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
48652420|NCT03277872|DEVICE|Laryngoscopy with MacIntosh (MAC) Blade|"1. st Laryngoscopy with MAC Blade~2. nd Laryngoscopy with GVL Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
48652421|NCT06673745|OTHER|IASTM|"Group A received IASTM treatment, which will be given by the Edge tool, that is an ergonomically designed stainless steel instrument and offers several different hand holds, eliminating operator fatigue. Prior to the treatment, the IASTM therapeutic effects will be explained. The scanning assessment will be done to identify areas of restrictions directed by the gritty sensations using the Edge tool. Each restriction will be treated with the tool for 30-60 sec and given. This treatment will be given for 30 minutes for 3 days per week for 4 weeks"
48126194|NCT00103363|OTHER|cytology specimen collection procedure|
48126195|NCT00103363|OTHER|physiologic testing|
48126196|NCT00103363|PROCEDURE|annual screening|
48126197|NCT00103363|PROCEDURE|study of high risk factors|
48126198|NCT06366984|OTHER|plastibell|plastibell used for circumcision
48126199|NCT06366984|OTHER|open method|open method used for circumcision
48126200|NCT03434496|DEVICE|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
48126201|NCT04743440|DEVICE|Bronchoscopic endotracheal intubation through a supraglottic airway device|Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
48333330|NCT04291924|DIAGNOSTIC_TEST|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
48333331|NCT06333236|OTHER|Food for Special Medical Purposes: Kron®|Citicoline 40mg/ml + Nicotinamide 15 mg/ml oral solution
48333332|NCT05982834|DRUG|Disitamab Vedotin combined with fruquintinib and Tislelizumab|Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
48333333|NCT04390568|DRUG|Spesolimap|Spesolimap
48333334|NCT00082329|DRUG|AMD 3100 (Mozobil plerixafor)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
48333335|NCT00082329|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
48333336|NCT02479438|OTHER|Diagnosed with GERD|Recording of patient outcomes
48333337|NCT00561587|DRUG|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
48652422|NCT06673745|OTHER|Dynamic cupping therapy|On the contrary, group B the patient will be seated in a chair with the elbow flexed on the plinth to relax the forearm muscles. The area around the elbow joint will be cleaned with alcohol to remove any foreign bodies from the treated area. Dynamic cupping therapy for elbow stiffness will begin with an assessment of the patient\&amp;#39;s condition, where factors such as the extent of stiffness and range of motion in the elbow joint will be evaluated. Following this assessment, lubricant will be applied to the skin surrounding the elbow to facilitate smooth movement of the cups. Cups of suitable size and material will then be strategically placed around the elbow joint, and suction will be created inside each cup to create a vacuum effect. Once thesecurely attached, the practitioner will move them around the elbow area using gentle techniques such as gliding or pumping motions.
48652423|NCT05629572|DIAGNOSTIC_TEST|i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity|Paired whole blood and plasma samples collected at multiple time points.
48652424|NCT06636812|DRUG|Losartan potassium|Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo
48652425|NCT06636812|OTHER|Placebo|Single tablet encapsulated identically to placebo
48652426|NCT03676270|OTHER|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
48652427|NCT06638021|BEHAVIORAL|Targeted EHR-based Communication of Diagnostic Uncertainty (TECU)|The Targeted EHR-based Communication about Uncertainty (TECU) strategy will be activated in the electronic health record (Epic) every time an ED clinician enters an uncertain diagnosis for a patient being discharged, and will notify the clinician to counsel the patient about uncertainty while additionally triggering automated 1) insertion and printing of the patient handout and 2) provision of a hyperlink for the clinician-facing checklist to guide the discharge conversation.
48652428|NCT00456365|DRUG|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
48652429|NCT00456365|DRUG|Placebo|Placebo daily
48652430|NCT06495099|OTHER|Russian electrical stimulation|Type of Medium frequency current with 2500 Hz frequency modulated at 50 Hz with 50% Duty cycle training protocol is (10 sec. on time - 50 sec. off time - 10 minutes total time)
48126202|NCT01400958|DRUG|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
48333338|NCT04593836|DRUG|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
48333339|NCT04593836|DRUG|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
48333340|NCT02839824|PROCEDURE|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
48333341|NCT01494415|DRUG|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
48333342|NCT01494415|DRUG|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
48333343|NCT01494415|RADIATION|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
48333344|NCT02424006|DEVICE|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
48333345|NCT02424006|DEVICE|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
48492916|NCT04414306|OTHER|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
48492917|NCT04414306|OTHER|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
48652431|NCT03165500|DRUG|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
48652432|NCT03165500|DRUG|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
48126203|NCT01400958|DRUG|Placebo|Placebo x 42 days; THEN, No More Placebo
48126204|NCT00402428|DRUG|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
48333346|NCT06528808|OTHER|Simple reality simulator application|Women in the intervention group will be given an application aimed at breast cancer awareness with a simple valid simulator.
48333347|NCT04409301|OTHER|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
48126205|NCT00402428|DRUG|peginterferon alfa-2a|180 mcg once a week for 48 weeks
48126206|NCT00402428|DRUG|Ribavirin|"1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)"
48126207|NCT02426229|DRUG|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
48333348|NCT04409301|BEHAVIORAL|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
48333349|NCT03457740|DIETARY_SUPPLEMENT|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
48333350|NCT03457740|DIETARY_SUPPLEMENT|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
48333351|NCT03457740|DIETARY_SUPPLEMENT|Placebo|Placebo comparison
48333352|NCT00445250|DRUG|Calcipotriol|
48333353|NCT01742078|DRUG|LY2541546 - IV|Administered IV
48333354|NCT01742078|DRUG|LY2541546 - SC|Administered SC
48333355|NCT01742078|DRUG|Placebo|Administered IV or SC
48333356|NCT04458363|BIOLOGICAL|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.
48333357|NCT04458363|DRUG|Standard COVID-19 therapies|If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
48333358|NCT02119468|DRUG|ixazomib citrate|Given orally
48333359|NCT02119468|DRUG|dexamethasone|Given orally
48333360|NCT02119468|DRUG|pomalidomide|Given orally
48333361|NCT00191737|DRUG|Atomoxetine|
48333362|NCT03638557|OTHER|Nutritious Lunch|"The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
48333363|NCT01893684|BEHAVIORAL|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
48333364|NCT01893684|BEHAVIORAL|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
48492918|NCT04414306|OTHER|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
48492919|NCT00008151|DRUG|cyclosporine|
48492920|NCT00008151|DRUG|fludarabine phosphate|
48492921|NCT00008151|DRUG|gemtuzumab ozogamicin|
48492922|NCT00008151|DRUG|methotrexate|
48492923|NCT00008151|DRUG|mycophenolate mofetil|
48492924|NCT00008151|PROCEDURE|allogeneic bone marrow transplantation|
48492925|NCT00008151|PROCEDURE|peripheral blood stem cell transplantation|
48492926|NCT00008151|RADIATION|radiation therapy|
48492927|NCT05892146|DRUG|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
48492928|NCT05892146|DRUG|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
47980544|NCT04756791|PROCEDURE|SAPB|local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.
47980545|NCT04756791|PROCEDURE|Local Injection Anesthesia|Anesthesia is injected directly into the tissue that is will be numbing.
48126208|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
48126209|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
48492929|NCT01718548|DIETARY_SUPPLEMENT|Cordyceps Sinensis (CS) and Lingzhi|
48492930|NCT01718548|DIETARY_SUPPLEMENT|Tea and Flour|Placebo
48492931|NCT02450708|GENETIC|KIR genotyping|
48492932|NCT02450708|GENETIC|HLA genotyping|
48333365|NCT01893684|BEHAVIORAL|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (\~ 18% of energy intake) with a ratio of carbohydrates/protein \> 3.5 and dietary lipids at \~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
48333366|NCT00122304|DRUG|eculizumab|
48333367|NCT01770899|DRUG|Montelukast|
48126210|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
48126211|NCT01634789|DRUG|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
48126212|NCT05880355|DRUG|Dapansutrile|Oral inhibitor of NLRP3
48126213|NCT05880355|OTHER|Placebo|Non-active placebo
48126214|NCT01612949|OTHER|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
48126215|NCT02229812|DRUG|alteplase|
48126216|NCT03149302|OTHER|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
48333368|NCT01770899|DRUG|Placebo|Gelatin capsule given every 24 hours
48492933|NCT02843594|PROCEDURE|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
48652433|NCT03165500|DRUG|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
48652434|NCT03165500|PROCEDURE|Third molar extraction|Anxious patients in need of third molar extraction
48126217|NCT03149302|OTHER|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
48126218|NCT03149302|OTHER|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
48126219|NCT03149302|OTHER|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
48652435|NCT05918185|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48652436|NCT05918185|OTHER|Comprehensive Geriatric Assessment|Undergo cGA
48652437|NCT05918185|OTHER|Electronic Health Record Review|Medical records are reviewed
48652438|NCT05918185|OTHER|Survey Administration|Complete surveys
48652439|NCT02933151|DIETARY_SUPPLEMENT|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
48652440|NCT06619236|DRUG|Rina-S|IV infusion
48652441|NCT06619236|DRUG|Paclitaxel|IV infusion
48126220|NCT00931710|DRUG|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
48126221|NCT00931710|DRUG|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
48126222|NCT04030624|DEVICE|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
48126223|NCT02229721|DRUG|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
48333369|NCT00006063|DRUG|pancrelipase with bicarbonate|
48333370|NCT00003085|PROCEDURE|laparoscopy|
48333371|NCT00003085|PROCEDURE|ultrasound imaging|
48333372|NCT01349972|DRUG|alvocidib|Given IV
48333373|NCT01349972|DRUG|daunorubicin hydrochloride|Given IV
48333374|NCT01349972|DRUG|mitoxantrone hydrochloride|Given IV
48333375|NCT01349972|DRUG|cytarabine|Given IV
48492934|NCT02843594|PROCEDURE|Standard Phaco Control|
48492935|NCT01398943|DRUG|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
48492936|NCT01398943|DIETARY_SUPPLEMENT|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
48126224|NCT02229721|DRUG|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
48126225|NCT01894074|BEHAVIORAL|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
48126226|NCT01894074|BEHAVIORAL|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
48126227|NCT05931510|OTHER|Myofscual release|I will apply myofascial release on group A patients and observse its effects on shin splint
48126228|NCT05931510|OTHER|Post isometric relaxation.|I will apply post isonetric relaxation on group b patients and observe effects on shin splint
47975520|NCT04631081|OTHER|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
48126229|NCT03247842|PROCEDURE|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
48333376|NCT05126940|DIAGNOSTIC_TEST|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis|Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
47975521|NCT04655391|DRUG|Bosutinib Monohydrate|Given PO
47975522|NCT04655391|DRUG|Decitabine|Given IV
47975523|NCT04655391|DRUG|Enasidenib Mesylate|Given IV
47975524|NCT04655391|DRUG|Gilteritinib Fumarate|Given PO
47975525|NCT04655391|DRUG|Glasdegib Maleate|Given PO
47975526|NCT04655391|DRUG|Ivosidenib|Given PO
47975527|NCT04655391|DRUG|Venetoclax|Given PO
48126230|NCT04241952|OTHER|Exercise|Bedcycling
48126231|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 100 mg/day
48126232|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 150 mg/kg/ twice daily
48126233|NCT01821989|DIETARY_SUPPLEMENT|Placebo|in form of distilled water
48126234|NCT06518070|DIAGNOSTIC_TEST|Cerviray AI|Patient was screened using Cerviray AI, Cerviray AI evaluation by expert anc compared to VIA test in the same day.
48126235|NCT00402246|OTHER|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
48126236|NCT00402246|OTHER|In-Office Care|Routine in-office care
47975528|NCT03817177|PROCEDURE|high flow nasal cannula oxygenation|high flow nasal cannula application in PACU
47975529|NCT03817177|PROCEDURE|nasal prong|conventional nasal prong application in PACU
48126237|NCT03117582|OTHER|Stool specimen|"The following stool specimen will be collected for this study:~1. 4, 3mL stool specimen from patient~2. 1, 25mL stool aliquot from donor"
48126238|NCT03210896|DIETARY_SUPPLEMENT|Orange juice|Sub group I will drink Orange juice and have repeat measures.
48333377|NCT04733872|DIETARY_SUPPLEMENT|placebo|subjects drank 50 ml , 1 bottle a day for 8 week
48333378|NCT04733872|DIETARY_SUPPLEMENT|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
47975530|NCT00590720|BIOLOGICAL|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
47975531|NCT00590720|OTHER|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
47975532|NCT05286281|DRUG|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
47975533|NCT02860169|BEHAVIORAL|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
48126239|NCT02778659|DRUG|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
48126240|NCT02778659|DRUG|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
48126241|NCT05166070|DRUG|RD133|The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
48492937|NCT02857738|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
48492938|NCT02857738|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
48652442|NCT06619236|DRUG|Topotecan|IV infusion
48652443|NCT06619236|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
48652444|NCT06619236|DRUG|Gemcitabine|IV infusion
48652445|NCT05057546|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
47975534|NCT01980368|OTHER|Educational Intervention|Receive readings and attend book club
47975535|NCT01980368|BEHAVIORAL|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
47975536|NCT01980368|OTHER|Questionnaire Administration|Ancillary studies
47975537|NCT04011761|OTHER|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
47975538|NCT01990404|DRUG|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
48333379|NCT03714503|DEVICE|Retina re-attachment repair using C3F8 gas tamponade|Assigning a one day post-operative head positioning
48333380|NCT00939939|DRUG|sitagliptin|sitagliptin 100 mg/d for 10 weeks
48333381|NCT00939939|DRUG|glimepiride|glimepiride 1 mg/d for 10 weeks
48333382|NCT02533219|DRUG|18 F-DOPA|Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
48652446|NCT00434811|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
48652447|NCT00434811|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
48652448|NCT00434811|DRUG|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
48652449|NCT00434811|DRUG|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
48652450|NCT00434811|BIOLOGICAL|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
48652451|NCT00434811|PROCEDURE|Islet Transplantation|Transplantation of pancreatic islet cell
48652452|NCT00434811|BIOLOGICAL|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
48652453|NCT03921528|BIOLOGICAL|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
48652454|NCT06496607|DRUG|Biological: Solrikitug Low Dose|Solrikitug Low Dose subcutaneous injection
48652455|NCT06496607|DRUG|Biological: Solrikitug Mid Dose|Solrikitug Mid Dose subcutaneous injection
48652456|NCT06496607|DRUG|Biological: Solrikitug High Dose|Solrikitug High Dose subcutaneous injection
48652457|NCT06496607|OTHER|Placebo|Placebo subcutaneous injection
47975539|NCT01990404|DRUG|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
47975540|NCT01286298|PROCEDURE|Laser gingivectomy|Gingivectomy by diode laser
48126242|NCT05406765|DRUG|Bupivacaine Injection|One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
48126243|NCT01335828|DEVICE|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
48126244|NCT05439395|DEVICE|Sternum Closure after Cardiac Surgery|Sternal closure using Steelex® Sternum Set after CABG or cardiac valve replacement / reconstruction.
48126245|NCT03840902|DRUG|M7824|Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
48126246|NCT03840902|DRUG|Placebo|Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
48333383|NCT02204813|DRUG|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
48333384|NCT02204813|DRUG|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
48333385|NCT02204813|DRUG|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
48333386|NCT02204813|DRUG|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
48333387|NCT02890732|DEVICE|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
48333388|NCT05931133|OTHER|NO INTERVENTION|NO INTERVENTION WILL BE GIVEN
47975541|NCT01286298|PROCEDURE|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
48333389|NCT02422082|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
48333390|NCT02422082|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo twice daily for 12 months
48333391|NCT00376246|DRUG|Ezetimibe|
47975542|NCT02279420|DEVICE|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
47975543|NCT02868320|OTHER|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing."
47975544|NCT02868320|OTHER|Instruction booklet|General detailed instructions addressing the same SMS categories.
48126247|NCT03840902|DRUG|Durvalumab|Participants received intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
48126248|NCT03840902|DRUG|Etoposide|Participants received etoposide 50 mg/m\^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
48126249|NCT03840902|DRUG|Pemetrexed|Participants received pemetrexed at a dose of 500 mg/m\^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
48126250|NCT03840902|DRUG|Carboplatin|Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
48126251|NCT03840902|DRUG|Paclitaxel|Participants received paclitaxel intravenously at a dose of 45 mg/m\^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
48126252|NCT03840902|DRUG|Cisplatin|In combination with etoposide, participants received cisplatin 50 mg/m\^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
48126253|NCT03840902|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray \[Gy\]).
48333392|NCT02660866|DRUG|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
48333393|NCT02660866|DRUG|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
48333394|NCT02277522|BIOLOGICAL|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
48333395|NCT06028425|DRUG|LOXO-783|Administered orally.
48333396|NCT01376401|DRUG|Bendamustine|
48333397|NCT01376401|DRUG|Velcade|
47975545|NCT03937310|DIAGNOSTIC_TEST|Next-generation sequencing of swabs collected during surgery|Traditional swabs for culturing as well as swabs for NGS testing will be collected
48333398|NCT01376401|DRUG|Prednisone|
48333399|NCT00315978|DEVICE|Heart-to-Heart Decision Aid|
48333400|NCT05037669|BIOLOGICAL|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
48492939|NCT00336765|DRUG|XL647|Tablets supplied in 50-mg strength administered orally daily
47975546|NCT05545696|DEVICE|AI on algorithm|The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
48652458|NCT04678544|DEVICE|Scalp cooling system 2|"The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.~After the RCT, 34 patients who were expected to receive 4, 6, or 8 cycles of chemotherapy with an anthracycline regimen were further enrolled in the intervention group as a single-arm trial."
48652459|NCT05692011|DEVICE|blood purification(PS)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days
47975547|NCT05545696|DEVICE|AI off algorithm|The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
48652460|NCT05692011|DEVICE|blood purification(AN69ST)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
48652461|NCT05609253|DRUG|Itraconazole in capsule form|Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
48652462|NCT05609253|DRUG|Itraconazole in solution form|Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
47975548|NCT01965275|DRUG|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
47975549|NCT00235898|DRUG|CoFactor|
47975550|NCT00235898|DRUG|5-FU|
48333401|NCT06000436|OTHER|Cardiovascular disease risk assessment|"Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application."
47975551|NCT00235898|DRUG|Leucovorin|
48126254|NCT04431375|BIOLOGICAL|Plasma Exchange|Plasma exchange 2 sessions alternate day followed by FMT for 7 days and Tenofovir \[antiviral\] 300mg PO once a day .
48333402|NCT06000436|OTHER|Training and Consultancy|Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
48492940|NCT04397445|DRUG|Ranitidine|Ranitidine 300 mg
48492941|NCT04397445|DRUG|Placebo|Oral placebo tablet
48492942|NCT04397445|OTHER|Low nitrite/NDMA meals|Meals containing low levels of nitrites and NDMA
48492943|NCT04397445|OTHER|High nitrite/NDMA meals|Meals containing higher levels of nitrites and NDMA
48492944|NCT02570113|DEVICE|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
48492945|NCT02212912|BEHAVIORAL|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
48492946|NCT02212912|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
48492947|NCT00004800|BIOLOGICAL|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
48492948|NCT00004800|BIOLOGICAL|diphtheria-tetanus vaccine|
48492949|NCT02418143|DEVICE|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
48652463|NCT06097299|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
48652464|NCT06097299|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48652465|NCT05335434|DEVICE|THOR LX2.3 with LED Lollipop|The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
48652466|NCT02748174|BEHAVIORAL|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
47975552|NCT01074112|DEVICE|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
47975553|NCT01074112|DEVICE|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
47975554|NCT01074112|PROCEDURE|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
47975555|NCT01074112|DEVICE|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
47975556|NCT01074112|DEVICE|Cardiac Ultrasound|Ultrasound views of the heart
47975557|NCT05912621|DRUG|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
48126255|NCT04431375|DRUG|Tenofovir|Tenofovir \[antiviral\] 300mg PO once a day .
48126256|NCT04431375|OTHER|Fecal Mircobiota Transplantation|FMT for 7 days
48126257|NCT03449173|DRUG|Sunitinib|small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
48126258|NCT03682250|DEVICE|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
48126259|NCT03682250|DEVICE|Holter monitor|A Holter monitor will be used to measure heart's activity
48126260|NCT05953363|DEVICE|BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes|Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
48126261|NCT00266448|DRUG|Chlorhexidine solution 4%|
48126262|NCT00409838|DRUG|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg \<60 kg); (750 mg 60-100 kg); (1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
48126263|NCT00409838|DRUG|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
48126264|NCT00409838|DRUG|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
48492950|NCT02996045|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored \>4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
48492951|NCT00601666|DRUG|Zolpidem|
48492952|NCT04323241|OTHER|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
48492953|NCT03734211|DRUG|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
48652467|NCT05612945|OTHER|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
48652468|NCT05612945|OTHER|Low-to-moderate intensity training group (LowMod group)|"Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
48652469|NCT05547542|DRUG|CVL-354|Oral solution/capsule
48652470|NCT05547542|DRUG|[11C]-LY2795050|IV injection
48652471|NCT05547542|DRUG|[11C]-carfentanil|IV injection
47975558|NCT03347877|PROCEDURE|autologous osteo-periosteal cylinder graft transplantation|Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
47975559|NCT03347877|PROCEDURE|autologous osteochondral graft transplantation|Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
47975560|NCT03347877|DEVICE|autologous osteo-periosteal cylinder graft|Autologous osteo-periosteal cylinder graft is taken from ilium.
47975561|NCT03751488|DRUG|LY03010|Single Dose of LY03010 at 351 mg or 156 mg or 117mg
47975562|NCT03751488|DRUG|Invega Sustenna 156 MG in 1 ML Prefilled Syringe|Single Dose at 156mg
47975563|NCT04458974|DEVICE|Transcranial direct current stimulation|"The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour."
48126265|NCT00409838|DRUG|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
48126266|NCT00409838|DRUG|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
48126267|NCT05879705|OTHER|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
48126268|NCT05837455|DEVICE|VENTANA MIB-1 Ki67 assay|Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9) (VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and at time of surgery in accordance with the International Ki67 in Breast Cancer Working Group guidelines.
48126269|NCT05837455|DEVICE|Oncotype DX® Recurrence Score|Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including 16 cancer-related genes and 5 reference genes - will be performed as standard of care in a central laboratory (Exact Sciences) on RNA extracted from formalin-fixed paraffin-embedded core-biopsy samples.
48492954|NCT03734211|DRUG|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
48492955|NCT01765582|DRUG|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m\^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
48492956|NCT01765582|DRUG|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
48492957|NCT01765582|DRUG|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
48652472|NCT02719730|BEHAVIORAL|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
48652473|NCT02609503|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
48652474|NCT02609503|RADIATION|Intensity Modulated Radiation Therapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
48652475|NCT01586715|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
48652476|NCT05668923|BEHAVIORAL|Speech sound stimulation|Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
47975564|NCT04458974|PROCEDURE|Neuropsychological rehabilitation|"The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session)."
47975565|NCT02254187|DRUG|Salmeterol capsule - low|
47975566|NCT02254187|DRUG|Salmeterol capsule - high|
47975567|NCT02254187|DRUG|Salmeterol via Serevent® Diskus®|
47975568|NCT04673864|DRUG|CKD-386|QD, PO
47975569|NCT04673864|DRUG|D012, D326, D337|QD, PO
47975570|NCT02003820|BEHAVIORAL|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
47975571|NCT05339568|OTHER|Patients' whole process follow-up and management platform|Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
48652477|NCT04632173|OTHER|non interventional study|There is no intervention
47975572|NCT04934397|OTHER|Study Infant Formula|Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
47975573|NCT06334510|BIOLOGICAL|One dose of quadrivalent influenza virus split vaccine was administered|"Safety observation: All 4900 vaccine recipients participated in the safety observation after vaccination, and were followed up for adverse events (AE) within 30 minutes and 0-30 days after vaccination, and SAEs within 6 months after vaccination.~In addition to 1050 recipients aged 18-59 years who were included in the first layer test, 350 recipients aged 3-17 years and 350 recipients aged ≥60 years were randomly selected from each group. Blood samples were collected before and 30 days after vaccination for influenza virus HI antibody detection."
47975574|NCT02332850|BIOLOGICAL|Isatuximab|Given IV
47975575|NCT02332850|DRUG|Carfilzomib|Given IV
47975576|NCT02332850|DRUG|Dexamethasone|Given IV or PO
47975577|NCT06245135|BEHAVIORAL|TIME at Home|"Sessions involve a 15-minute pre-video safety check and social time; streaming a 1-hour pre-recorded exercise video; and a 15-minute post-video social time. Two trained facilitators run each class, with a maximum group size of 10 people.~The 1-hour exercise videos include a seated warm-up and cooldown, and 40 minutes of functional, self-paced exercises. In the video, 2 healthcare professionals demonstrate a lower and higher difficulty level of each exercise. The program starts with a level 1 video and switches to a level 2 video midway.~A registered healthcare professional, called the healthcare partner, visits select classes and serves as a resource to participants and facilitators."
47975578|NCT03853265|BEHAVIORAL|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
47975579|NCT02959931|OTHER|High Potassium Meal|Breakfast meal that provides \~2400 mg of dietary potassium. Meals are isocaloric.
47975580|NCT02959931|OTHER|Low Potassium Meal|Breakfast meal that provides \~540 mg of potassium. Meals are isocaloric.
47975581|NCT04244721|OTHER|Preschool Autism Communication Therapy (PACT)|Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
48492958|NCT01765582|DRUG|irinotecan|Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
48492959|NCT01765582|DRUG|folinic acid|Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.
48652478|NCT02115971|OTHER|Jumping exercise|Total 120min exercise
48652479|NCT02115971|OTHER|Strength exercise|Total 120 min exercise
47975582|NCT04244721|OTHER|Treatment As Usual (TAU)|Children will receive therapies available in the community as speech language therapist or occupational therapist.
48126270|NCT05837455|DEVICE|PAM50-based Prosigna breast cancer gene signature assay|This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular subtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE) core-biopsy samples.
48333403|NCT06000436|OTHER|Mobile Application|"To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume \<5 g less per day to prevent cardiovascular diseases."
48333404|NCT06000436|OTHER|Monitoring|Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
48333405|NCT05496218|DIAGNOSTIC_TEST|Blood samples|At study entry, we will collect morning blood samples from fasting women. participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS). In addition, women will be asked to report about their usual weekly food consumption in the previous year. Information on the diet will be based on a reproducible and valid food frequency questionnaire. Energy and mineral and macro-and micronutrient intakes will be estimated using the most recent update of an Italian Food Consumption Database.
48333406|NCT03807076|OTHER|GIP-A|GIP-A
48333407|NCT03807076|OTHER|Placebo|Placebo
48333408|NCT05860998|DIAGNOSTIC_TEST|Presence of Toxoplasma gondii IgG Antibodies|Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
48333409|NCT05658263|DIETARY_SUPPLEMENT|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
48333410|NCT05658263|DIETARY_SUPPLEMENT|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
48333411|NCT05216913|BEHAVIORAL|Lifestyle modification|Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake
48333412|NCT05216913|DRUG|Cardiovascular Agents, Other|Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine
48333413|NCT05216913|OTHER|QRISK 3 Score|Could include a combination of lifestyle measures and/or cardiovascular agents as described above
48333414|NCT02505815|PROCEDURE|Surgery|
48333415|NCT02505815|PROCEDURE|Cortisol Level Measurement|
48652480|NCT02895984|BEHAVIORAL|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
47975583|NCT04984083|DIETARY_SUPPLEMENT|vitamin k|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
47975584|NCT01053884|DRUG|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC \> 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
47975585|NCT00424671|DRUG|Licarbazepine|
48126271|NCT05837455|DRUG|Anastrozole|Standard of care
48126272|NCT05837455|DRUG|Combination anthracycline and/or taxane based treatment|Standard of care
48333416|NCT02505815|PROCEDURE|Neurocognitive Testing|
48333417|NCT00209872|DRUG|Gabapentin|
48333418|NCT00209872|DRUG|Lidocaine|
48333419|NCT00209872|DRUG|S-ketamine|
48333420|NCT00209872|PROCEDURE|Epidural analgesia|
48333421|NCT01767181|OTHER|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
48333422|NCT01767181|OTHER|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
48333423|NCT00062647|DRUG|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
48126273|NCT02872480|OTHER|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
48126274|NCT01323686|OTHER|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate \<30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
48333424|NCT00062647|DRUG|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
48333425|NCT00179517|DRUG|Anastrozole 1mg|
48652481|NCT04744792|OTHER|Short Form - 36|"Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients"
48652482|NCT04744792|OTHER|WHODAS-II|"The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients."
48652483|NCT01157494|OTHER|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
48652484|NCT04105361|PROCEDURE|Posterior neurectomy|Cut of posterior nasal nerve
48652485|NCT06644404|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
48652486|NCT06644404|DRUG|DWC202407 1,000mg|1 tablet, Orally, Twice daily
47975586|NCT01036841|DRUG|desmopressin tablet|Administration of desmopressine tablet
48126275|NCT06092255|RADIATION|Postoperative radiotherapy for SVZ|GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
48333426|NCT00179517|DRUG|Placebo Oral Tablet|
48333427|NCT03958994|OTHER|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
48333428|NCT05964504|PROCEDURE|Blood Specimen|Blood will be drawn via venipuncture
47975587|NCT01036841|DRUG|desmopressin MELT formulation|Administration of desmopressine MELT formulation
47975588|NCT01053221|DRUG|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
47975589|NCT01053221|DRUG|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
47975590|NCT06024356|DRUG|Thymalfasin|Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
48126276|NCT03433690|BEHAVIORAL|HIIT|High Intensity Interval Training for twelve weeks
48126277|NCT03433690|BEHAVIORAL|Moderate training|Moderate training for twelve weeks
48126278|NCT04135040|DIETARY_SUPPLEMENT|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
48126279|NCT05150912|OTHER|Manual therapy|strching neck
48333429|NCT06380790|PROCEDURE|Laser-aided csf|Laser-aided csf before leveling and alignment
48333430|NCT06380790|OTHER|placebo laser-aided csf|placebo laser-aided csf before leveling and alignment
48333431|NCT03271957|PROCEDURE|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
48333432|NCT00461422|DRUG|Ganirelix|sc injection of Ganirelix 0.25 mg per day
48333433|NCT02800772|DIETARY_SUPPLEMENT|acetic acid|
48333434|NCT02800772|DIETARY_SUPPLEMENT|saline|
48333435|NCT03465384|BEHAVIORAL|Comet|The intervention is a behaviorally based and manualized parent training program.
47975591|NCT05246501|OTHER|Simulation|A case scenario with a diagnosis of dementia was used in the study. The scenario consisted of preliminary preparation, implementation and evaluation parts. Psychiatric nursing laboratory practice was applied to the students in the scenario study group. An elderly female standard patient who was diagnosed with dementia took part in the scenario. During this simulation, students were expected to perform mental state examination of the patient, use therapeutic communication techniques and ensure environmental safety.
48333436|NCT04391088|OTHER|vaccine coverage assessment|vaccine coverage assessment
48333437|NCT01906957|OTHER|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
48652487|NCT06644404|DRUG|DWC202408 2mg|1 tablet, Orally, Once daily single dose
48652488|NCT04963296|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
48652489|NCT04963296|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
48652490|NCT04963296|DRUG|Acetaminophen/Paracetamol|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
48652491|NCT04963296|DRUG|Diphenhydramine hydrochloride|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
47975592|NCT05246501|OTHER|No simulation|The students in the control group did not receive simulation training.
48333438|NCT01906957|OTHER|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
48333439|NCT03753815|DEVICE|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
48333440|NCT03753815|DEVICE|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
48333441|NCT00819104|DRUG|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
48333442|NCT00819104|DRUG|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
48333443|NCT00819104|DRUG|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
48333444|NCT00819104|DRUG|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
48333445|NCT00819104|DRUG|Amlodipine 5mg|tablet,oral,OD,8 weeks
48652492|NCT04963296|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
48652493|NCT06598761|COMBINATION_PRODUCT|Immunotherapy+radiotherapy|"Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used."
48652494|NCT06598761|OTHER|surveillance alone|Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.
48652495|NCT00726479|DRUG|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
47975593|NCT01539694|DEVICE|LD118033 contact lens|Multifocal contact lens worn on a daily wear basis for 1 week
47975594|NCT01539694|DEVICE|PureVision multifocal contact lens|PureVision multifocal contact lens worn on a daily wear basis for 1 week.
47975595|NCT05966181|BEHAVIORAL|experimental group|"Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation."
47975596|NCT04380168|PROCEDURE|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
47975597|NCT00050934|DRUG|oxcarbazepine|
48333446|NCT00927329|BIOLOGICAL|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
48652496|NCT02743221|DRUG|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
48652497|NCT02743221|DRUG|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
47975598|NCT05960266|BIOLOGICAL|Polvac Grass+Rye|Aqueous suspension of a co-precipitate of allergen extract and tyrosine
48333447|NCT01241656|BEHAVIORAL|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
48652498|NCT01926509|DRUG|MK-8892|
48652499|NCT01926509|DRUG|Placebo for MK-8892|
48652500|NCT06638593|PROCEDURE|MIRRORS-FROZEN Protocol.|Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.
47975599|NCT04647578|DEVICE|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
47975600|NCT02465216|OTHER|Placebo|Placebo
48652501|NCT06638593|PROCEDURE|Standard open surgery|A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
48652502|NCT00138242|DRUG|carboplatin|
48652503|NCT00138242|DRUG|docetaxel|
48652504|NCT00138242|PROCEDURE|adjuvant therapy|
48652505|NCT05904119|DRUG|Lomustine|Oral administration of Lomustine
48652506|NCT05904119|RADIATION|Reirradiation|Given at least 6 months after the end of prior radiotherapy
48652507|NCT06675877|OTHER|virtual reality camera|The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.
47975601|NCT02465216|BIOLOGICAL|ID93 + GLA-SE|ID93 + GLA-SE
47975602|NCT04812691|BIOLOGICAL|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
47975603|NCT04910802|BIOLOGICAL|Gardasil9|Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.
47975604|NCT02389348|DRUG|DSM265|Single oral doses of DSM265
47975605|NCT02389348|DRUG|OZ439|Single oral doses of OZ439
47975606|NCT06304194|OTHER|Analysis of biological samples|"The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization:~* hot spot on DNa (ddPCR/Sanger)~* fusion genes on RNA (target resequencing)~* Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10%~* Tumor type-associated gene sequence analysis by Sanger sequencing and NGS"
47975607|NCT04512404|DRUG|HMG-CoA Reductase Inhibitor|
47975608|NCT02940977|OTHER|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
47975609|NCT01148784|PROCEDURE|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
48333448|NCT01241656|BEHAVIORAL|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
48333449|NCT01241656|BEHAVIORAL|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
48333450|NCT04718584|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
48333451|NCT05377307|GENETIC|Pell's lentiviral-based gene-edited immune cell therapy|No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
48333452|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
48333453|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
48333454|NCT02854007|DEVICE|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
48333455|NCT03717116|DIAGNOSTIC_TEST|parathormone level|From the patients, blood will be taken preoperatively and postoperatively.
48333456|NCT06146842|DRUG|Bupivacaine Hydrochloride|Each subject will receive allocated dose of bupivacaine
48333457|NCT04757922|PROCEDURE|Opportunistic salpingectomy / bilateral salpingectomy|An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
48333458|NCT06020573|DEVICE|Clip-on electrode with fiber optics|The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
48652508|NCT04336566|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg
48492960|NCT01765582|DRUG|oxaliplatin|Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
48333459|NCT00219518|PROCEDURE|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
48333460|NCT03957746|OTHER|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
48492961|NCT00031083|GENETIC|Interferon-beta|
48492962|NCT03056261|PROCEDURE|Combined general and epidural|Combined general and epidural anaesthesia
48492963|NCT03056261|PROCEDURE|General anaesthesia|General anaesthesia
48492964|NCT04273581|DRUG|placebo|100mg/d，qn，for 14 days.
48492965|NCT04273581|DRUG|Thalidomide|100mg/d，qn，for 14 days.
48492966|NCT00238849|DRUG|Oxaliplatin|
48492967|NCT01439230|DRUG|Donepezil|10 mg Tablet
48492968|NCT01439230|DRUG|Aricept®|10 mg Tablet
48492969|NCT05325593|DRUG|romiplostim plus dexamethasone|Patients will be reviewed weekly for 8 weeks (56 days). After Week 8, patients will be reviewed every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
48492970|NCT05325593|DRUG|Dexamethasone|Patients will be reviewed weekly until the completion of dexamethasone cycles and for a minimum of 8 weeks (56 days). After that, every 2 weeks (14 days) for 8 additional weeks and then monthly until Week 52 (365 days) from randomization.
48492971|NCT04898491|OTHER|Pain assessment using a behavioral scale|"The pain of the subjects will be evaluated by two independent observers and with a blind result between them, coinciding with the application of two painful procedures used in routine practice: suction of tracheal secretions and the pressure in the nail bed by means of a pressure algometer. In addition, a painless procedure will also be performed to establish an element of control with the procedures painful. This will consist of the application of gentle friction with a cloth gauze, on a part of healthy skin tissue of the patient. The measurement will be performed twice for each patient and procedure depending on the level of sedation, so that the first measurement will be performed with a deeper sedation level and the second with a change in sedation level to moderate-mild.~In turn, the pain assessment will be carried out in three moments: first or baseline measurement, during the application of the painless and 15 minutes after finishing the procedures."
48492972|NCT00120536|DRUG|vildagliptin|
48492973|NCT06007547|DRUG|Poractant Alfa|Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
48492974|NCT00400361|DRUG|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
48492975|NCT03736213|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
48333462|NCT04492787|DRUG|Changkang Granule|Take Changkang granule before meals twice a day , one bag for each time
48333463|NCT04492787|DRUG|Changkang Placebo Granule|Take Changkang Placebo granule before meals twice a day , one bag for each time
48333464|NCT03067194|DRUG|Celecoxib 100 MG|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
48333465|NCT03067194|DRUG|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
48333466|NCT02045251|DRUG|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
48333467|NCT02629614|DEVICE|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
48333468|NCT02533687|PROCEDURE|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
48333469|NCT02533687|PROCEDURE|Bipolar TURP-2|Bipolar TURP
48492976|NCT03736213|BEHAVIORAL|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
48492977|NCT04572126|BEHAVIORAL|Mindfulness Intervention|The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
48492978|NCT04572126|BEHAVIORAL|Control Intervention|The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
48492979|NCT04340921|BIOLOGICAL|COVID-19 exposure|Observation only
48492980|NCT00204958|DRUG|nutritional supplement|
48492981|NCT00204958|DRUG|glutamine popsicle|
48333470|NCT02533687|PROCEDURE|Monopolar TURP|Monopolar TURP
48333471|NCT01069367|BIOLOGICAL|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
48492982|NCT04802902|OTHER|home-based hospitalization|management in a hospital-at-home programme of patients treated by immunotherapy and chimiotherapy combo for bronchial cancer
48126280|NCT04194710|BIOLOGICAL|Autologous Cytokine Rich Serum|"Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis.~Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle.~Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days.~This process will take place at outpatient clinics."
48126281|NCT04194710|PROCEDURE|Arthroscopic Resection|"Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center.~This process will take place at the major ambulatory surgery center of the investigator's hospital."
48126282|NCT04884165|DEVICE|Remote monitoring of home mechanical ventilation (NIV) using SRETT|Patients will use the SRETT device attached to their home ventilator.
48126283|NCT04884165|OTHER|Home mechanical ventilation (NIV) without remote monitoring|Usual care
48126284|NCT00995904|DRUG|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
48126285|NCT00995904|DRUG|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
48126286|NCT00995904|DRUG|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
48126287|NCT04531800|PROCEDURE|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
48126288|NCT04531800|PROCEDURE|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
48126289|NCT05255835|DEVICE|Semiconductor Knee Sleeves|semiconductor elements germanium and carbon within the cotton fabric
48126290|NCT05255835|DEVICE|Cotton Knee Sleeves (Placebo)|cotton fabric knee sleeves
48126291|NCT04203394|OTHER|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
48126292|NCT04203394|OTHER|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
48126293|NCT02438059|BEHAVIORAL|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
48126294|NCT03111160|PROCEDURE|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
48126295|NCT03111160|PROCEDURE|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
48126296|NCT02387658|PROCEDURE|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
48492983|NCT06492200|OTHER|Psyllium husks|Patients in the intervention group will receive nutritional counseling and will be asked to take 10g (one tablespoon) of ground psyllium husks daily to significantly increase the fiber content of their diet.
48492984|NCT02897986|DRUG|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
48492985|NCT03734666|BEHAVIORAL|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
48492986|NCT03734666|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
48492987|NCT00798187|BEHAVIORAL|Group Meetings|10 weekly group meetings lasting 2 hours.
48492988|NCT00798187|BEHAVIORAL|Questionnaire|Surveys
48492989|NCT00631852|DRUG|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
48492990|NCT03695861|DIAGNOSTIC_TEST|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
48492991|NCT00003144|DRUG|amifostine trihydrate|
48492992|NCT00003144|DRUG|cisplatin|
48492993|NCT00003144|DRUG|gemcitabine hydrochloride|
48126297|NCT04290533|DEVICE|Active High Definition transcranial Direct Current Stimulation (HD-tDCS)|TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
48126298|NCT04290533|DEVICE|Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)|For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
48126299|NCT01957969|DEVICE|Sacral Nerve Stimulation|
48126300|NCT06027489|BEHAVIORAL|Music|In the second and third months, participants listened to a song that lasted 29 minutes and 32 seconds for four days (three days before menstruation and the first day of menstruation). The song to be played was determined by examining the literature, the song was composed by researcher Juan Sebastian Martin-Saavedra and was named Occasio Adolore (Music Piece No. 5-559-355 and Phonogram No. 12-105-295) by the author copyright institution of Colombia. registered under. While the researcher is composing the song, it is to create a piece of music that will reduce the pain felt, activate positive emotions and relax the person. The composed song is available online within the scope of the published article (https://soundcloud.com/jss-martin/occasio-adolore).
48492994|NCT01580813|DRUG|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
48492995|NCT01580813|DRUG|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
48652509|NCT04336566|DIETARY_SUPPLEMENT|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
48652510|NCT05532163|DRUG|Natalizumab|Administered as specified in the treatment arm
48652511|NCT05273736|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
48652512|NCT04085731|PROCEDURE|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
48652513|NCT02393625|DRUG|Ceritinib (LDK378)|
48492996|NCT02568566|OTHER|Laboratory Biomarker Analysis|Correlative studies
48492997|NCT02568566|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
48492998|NCT02016313|OTHER|physiotherapy|
48492999|NCT00026286|DRUG|conjugated estrogens|
48493000|NCT00026286|DRUG|medroxyprogesterone|
48493001|NCT03161548|DRUG|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
48493002|NCT03161548|PROCEDURE|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
48652514|NCT02393625|DRUG|Nivolumab|
47975610|NCT00524784|BIOLOGICAL|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
47975611|NCT01880398|OTHER|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
47975612|NCT05225766|OTHER|bupivacaine|used for peripheral block
47975613|NCT03180723|DRUG|Rituximab|Intravenous injection
48126301|NCT06027489|BEHAVIORAL|Drawing Group|: In the second and third months, the participants will be asked to paint for 29 minutes and 32 seconds (the duration of the intervention was determined in parallel with the music group in order not to create variability between the groups) for four days (three days before menstruation and the first day of menstruation). The type of paint to be used in the drawn picture (dry pen, crayon or watercolor) is left to the availability of the participants, and it will be stated that they prefer colors and drawings that will raise their emotions, focus their drawings and feed positive emotions in the picture to be drawn.
48126302|NCT01981174|PROCEDURE|30-gauge needle|
47975614|NCT03180723|DRUG|Cyclosporin|Oral tablets
47975615|NCT02455232|PROCEDURE|upper limb muscle block|
47975616|NCT02455232|DRUG|4cc of lidocaïne®|
48126303|NCT01981174|PROCEDURE|32-gauge needle|
48126304|NCT00477893|DRUG|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
48493003|NCT03161548|RADIATION|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
48493004|NCT00124995|DRUG|terbutaline|
48126305|NCT00477893|DRUG|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
48126306|NCT03257644|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
48493005|NCT04370951|PROCEDURE|Erector Spinae Plane Block - Ultrasound guided|20mls 0.25% Levobupivicaine ultrasound guided bilaterally
48493006|NCT03166683|OTHER|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
48493007|NCT03166683|OTHER|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
48493008|NCT00377936|DRUG|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
48493009|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
48493010|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
48493011|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
48652515|NCT06637228|BEHAVIORAL|Move Your Hands, Feet, and Brain: Integrated Exercise Intervention Based on Taipei City Elderly Physical Activity Guidelines|"This video is tailored for fitness exercises for both healthy and sub-healthy elderly individuals and features various physical activity themes, including warm-up routines, balance and coordination drills, aerobic coordination exercises, strength training using chairs and water bottles, and cool-down routines. We selected a 3-month duration with sessions held three times a week to align with established effective intervention periods and to ensure participant adherence.~Integrated exercise sessions were conducted by the staff at the dementia care centers/service bases and lasted 50 minutes. Considering the impact of dementia and aging on the ability of older adults to engage in physical activities, the staff provided simple instructions, and participants performed the exercises while seated to prevent falls. Meanwhile, the control group continued with their usual treatment and daily activities."
48652516|NCT00941395|OTHER|Survey Administration|Complete surveys
48652517|NCT06673927|DRUG|YZJ-1139|Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
47975617|NCT00952679|DEVICE|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
47975618|NCT02375113|DIETARY_SUPPLEMENT|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
47975619|NCT00634530|BEHAVIORAL|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
48126307|NCT02828618|PROCEDURE|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
48126308|NCT02828618|PROCEDURE|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
48126309|NCT02828618|PROCEDURE|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
48493012|NCT00270348|DRUG|ciclesonide|
48493013|NCT03875937|DRUG|Tranexamic 1 gram|To be administered intramuscularly (2 injections)
48493014|NCT04601298|OTHER||
48493015|NCT06164314|DRUG|Dexmedetomidine|In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
48652518|NCT06673927|DRUG|YZJ-1139|Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg
48126310|NCT02828618|PROCEDURE|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
48333472|NCT04322162|OTHER|ASAP Intervention Quality Improvement Protocol|The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography \[PSG\]/home sleep test \[HST\], in-laboratory PSG, direct to auto-titrating \[auto\]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
48126311|NCT02828618|DRUG|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
48652519|NCT06673927|DRUG|Placebo|Placebo administration
48652520|NCT06640049|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
48652521|NCT06641648|DRUG|NK cell|Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.
48652522|NCT06640634|DEVICE|active in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
48652523|NCT06640634|DEVICE|sham in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. In the sham tDCS groups, the duration and electrodes application were the same of active in therapeutic tDCS (Th-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
48126312|NCT01218490|PROCEDURE|ovarian cancer surgery|
48126313|NCT06178588|PROCEDURE|Biopsy|Undergo tumor biopsy
48126314|NCT06178588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48126315|NCT06178588|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48126316|NCT06178588|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48126317|NCT06178588|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48126318|NCT06178588|BIOLOGICAL|Sacituzumab Govitecan|Given IV
48126319|NCT00117026|DRUG|Placebo|Placebo for benfotiamine
48126320|NCT00117026|DRUG|Benfotiamine|300mg/day
48333473|NCT01536652|DRUG|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
48333474|NCT01716026|DRUG|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
48126321|NCT03185052|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
48126322|NCT05000424|OTHER|Clary Sage Massage Oil|This massage oil contains clary sage oil. Five drops will be used daily.
48126323|NCT05000424|OTHER|Inert Massage Oil|This massage oil consists entirely of plant based oils. Five drops will be used daily.
48126324|NCT02210442|BEHAVIORAL|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
48126325|NCT02210442|OTHER|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
48493016|NCT02116959|DRUG|Melphalan|
48493017|NCT02116959|DRUG|Carboplatin|
48333475|NCT04117399|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
48333476|NCT00002718|BIOLOGICAL|anti-thymocyte globulin|
48333477|NCT00002718|BIOLOGICAL|filgrastim|
48333478|NCT00002718|DRUG|cyclophosphamide|
48333479|NCT00002718|DRUG|cytarabine|
48333480|NCT00002718|DRUG|methylprednisolone|
48333481|NCT00002718|DRUG|thiotepa|
48333482|NCT00002718|PROCEDURE|in vitro-treated bone marrow transplantation|
48333483|NCT00002718|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48333484|NCT00002718|RADIATION|radiation therapy|
48333485|NCT04183946|BEHAVIORAL|Online Cognitive Behavioural Therapy|"The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script."
48333486|NCT03928860|OTHER|OMT session|Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
48333487|NCT02902822|PROCEDURE|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
48333488|NCT02902822|DEVICE|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~1. bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~2. fungal skin infections (tinea corporis, cruris, pedis);~3. pigmented tumors (melanoma);~4. non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
48333489|NCT02762799|BIOLOGICAL|Leucostim®|Leucostim® is filgrastim biosimilar.
48333490|NCT02762799|BIOLOGICAL|Neupogen®|
48333491|NCT04811001|DRUG|Osimertinib|TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
48333492|NCT04811001|DRUG|Dacomitinib|Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
48493018|NCT02116959|DRUG|Etoposide|
48652524|NCT06640634|DEVICE|active in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
48652525|NCT06640634|DEVICE|sham in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. In the sham tDCS groups, the duration and electrodes application were the same of active in preventive tDCS (Pr-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
48333493|NCT03519399|DEVICE|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
48333494|NCT04871919|DRUG|Filgotinib|Tablets are administered in accordance with the product label
48333495|NCT03148756|DRUG|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
48333496|NCT03148756|DRUG|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
48333497|NCT03688685|DRUG|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
48333498|NCT02685995|DEVICE|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
48493019|NCT02116959|DRUG|Vincristine|
48493020|NCT00390221|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|SC injection
48493021|NCT00390221|DRUG|Placebo|Placebo SC injection
48493022|NCT02400671|BEHAVIORAL|SMS messaging|
48493023|NCT04673513|OTHER|Psychotherapy|In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
48333499|NCT02685995|DEVICE|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
48126326|NCT03721913|OTHER|participation-based intervention|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
48126327|NCT06398600|PROCEDURE|Caudal|In the prone position , linear transducer will be first positioned transversely on the middle line. The two sacral cornua appear as two hyperechoic structures ,two hyperechoic band structures are present between the two sacral cornua. The superficial is the sacrococcygeal ligament (SCL) and the deep is the dorsal surface of the sacrum. The sacral hiatus is a hypoechoic area between two band-like hyperechoic structures. In longitudinal view, the block needle will be inserted using the in plane technique .The block needle can be visualized in real time piercing the SCL entering the hiatus but cannot be visualized beyond the apex of the hiatus. It is therefore proposed to limit the extension of the needle tip beyond the tip of the sacral hiatus to 5 mm to avoid perforating the dura mater. After the needle is inserted in the caudal canal, 20 ml of 0.25% bupivacaine will be injected.
48126328|NCT06398600|PROCEDURE|Quadratus lumborum plane block|The patient is placed in the prone position , under aseptic conditions with the sterile convex probe is placed in a transverse view at the triangle of the QL muscle and the middle thoracolumbar fascia. The projected needle path is advanced in-plane until the needle tip is visualized between the middle thoracolumbar fascia and the QL muscle . After confirming the location of the needle with 2-3 ml of saline and then aspiration, 20 ml of 0.25% bupivacaine is injected in this plane with confirmation by visualizing hydro dissection . the procedure is applied to the opposite side using the same dose to achieve bilateral block.
48333500|NCT02942706|DRUG|Cetuximab|anti-EGFR monoclonal antibody
48333501|NCT02942706|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
48333502|NCT02942706|DRUG|FOLFIRI|Irinotecan+LV5FU2
48333503|NCT00745381|OTHER|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
48333504|NCT00071851|BIOLOGICAL|VRC-HIVDNA009-00-VP|
48493024|NCT03970486|PROCEDURE|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
48493025|NCT03370731|PROCEDURE|adenotonsillectomy|Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
48493026|NCT03370731|OTHER|Nonsurgical management|Nasal Irrigation or inhaled corticosteroids, etc.
48493027|NCT00468650|DRUG|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
48493028|NCT01752543|DRUG|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
48493029|NCT01752543|DRUG|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
48493030|NCT01618188|DRUG|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
48493031|NCT01618188|DRUG|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
48652526|NCT00052897|BIOLOGICAL|HspE7|
48126329|NCT01205048|DEVICE|Emervel Classic Lidocaine|20 mg/mL + 0.3% lidocaine
48126330|NCT01205048|DEVICE|Juvederm® Ultra|24mg/mL
48126331|NCT03877159|OTHER|There is no intervention.|There is no intervention. This is a retrospective study analysing archived tumour samples.
48333505|NCT04403529|DRUG|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
48333506|NCT04403529|DRUG|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
48333507|NCT00444470|DRUG|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
48333508|NCT00444470|DRUG|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
48333509|NCT00497354|DRUG|Variation in volume of local anesthetic|
48126332|NCT05877807|DRUG|Baclofen|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
48333510|NCT00497354|PROCEDURE|Ultrasound-guided interscalene brachial plexus block|
48333511|NCT04871230|DIAGNOSTIC_TEST|3G DBS|Collection of capillary blood samples for the 3G q-PCR test
48493032|NCT05234957|PROCEDURE|Bilateral Lateral Rectus Recession|Symmetric bilateral lateral rectus muscle recession involves equal recession of both lateral rectus muscles. Asymmetric bilateral lateral rectus muscle recession involves recession of the lateral rectus muscle by 2mm more in the non-dominant eye.
48493033|NCT02969993|OTHER|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
48493034|NCT03647683|OTHER|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
48652527|NCT01793129|DEVICE|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
48333512|NCT04871230|DIAGNOSTIC_TEST|Sputum Test|Collection of sputum for test culture, microscopy, GeneXpert
48333513|NCT04871230|DIAGNOSTIC_TEST|3G Veinous Blood|Collection liquid veinous blood for the 3G q-PCR test
48652528|NCT01793129|PROCEDURE|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
48652529|NCT06671626|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
48652530|NCT03683251|DRUG|PDS Implant with Ranibizumab 100 mg/mL|Will be administered as per the schedule described in individual arm
48652531|NCT03116022|DRUG|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
48652532|NCT03116022|DRUG|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
48652533|NCT03116022|DRUG|Vaginal Gel|Women using a base water gel lubricant during intercourse
48652534|NCT02565394|OTHER|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
48652535|NCT02808884|GENETIC|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
48333514|NCT05304598|DRUG|Dexmedetomidine|a single intravenous (i.v.) dose of dexmedetomidine, 0.2 mcg/kg over 10 minutes
48333515|NCT05304598|OTHER|Usual Care|routine awake intubation as per current unit standard of care,
48333516|NCT03700268|OTHER|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
48333517|NCT03764579|BEHAVIORAL|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
48333518|NCT02992301|DRUG|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
48333519|NCT06025617|OTHER|Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders|The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
48333520|NCT06025617|OTHER|Diagnostic as usual|"Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP."
48333521|NCT06377072|DRUG|Shenqi Sherong Pill|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
48333522|NCT06377072|DRUG|Placebo|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
48333523|NCT06527508|OTHER|Non-Interventional|This study has a observational design
48652536|NCT05550428|OTHER|home-based-exercise|"All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.~sessions."
48652537|NCT05550428|DEVICE|active pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 PEMF sessions per participant, each leg receiving 8 exposures.
48652538|NCT05550428|DEVICE|shame pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 sham PEMF sessions per participant, each leg receiving 8 exposures.
48126333|NCT05877807|OTHER|Placebo|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
48126334|NCT03756571|OTHER|Ankle Foot Orthoses-Footwear Combination|This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
48126335|NCT03756571|OTHER|Traditional Solid Ankle AFO (TSAFO)|This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
48126336|NCT00510302|BEHAVIORAL|Questionnaire|Questionnaire regarding melanoma risk-reduction.
48126337|NCT00510302|BEHAVIORAL|Interview|Interview via telephone about topics related to melanoma risk-reduction.
48126338|NCT00000777|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
48126339|NCT00858650|OTHER|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
48333524|NCT01808404|BEHAVIORAL|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
48333525|NCT02538939|DRUG|Sodium thiosulfate|
48652539|NCT06675825|DEVICE|BougieCap|The BougieCap is attached to the tip of the endoscope, offers direct visual and tactile control and the endoscope acts as a carrier of the radial and longitudinal force vectors for the dilation.
48126340|NCT02941575|OTHER|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
48126341|NCT02941575|OTHER|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
48126342|NCT03136042|OTHER|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
48126343|NCT03136042|OTHER|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
48126344|NCT03136042|OTHER|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
48126345|NCT02813369|DRUG|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
48126346|NCT02813369|DRUG|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
48126347|NCT01837238|DIETARY_SUPPLEMENT|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
48126348|NCT01837238|DIETARY_SUPPLEMENT|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
48126349|NCT02523716|OTHER|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
48126350|NCT02523716|OTHER|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
48126351|NCT00167999|DRUG|piperacillin-tazobactam|
48126352|NCT00687219|BIOLOGICAL|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
48126353|NCT00687219|DRUG|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks
48333526|NCT04833868|OTHER|hippotherapy and schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise
48333527|NCT04833868|OTHER|schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
48333528|NCT05193877|PROCEDURE|autologous bone marrow aspirate concentrate by centrifugation|"50 cc bone marrow aspirates concentrate after centrifugation with final volume up to 7 cc.~Assess total nucleated count and viability. Bone marrow aspirate concentrate is chosen as a source of mesenchymal stem cells, because of safe and easy procedure.~Bone marrow aspiration is done under local or general anesthesia, depending on the individual case. Around 50 cc of bone marrow is aspirated from the posterior iliac crest after proper sterilization using bone marrow aspiration needle (size according to the patient) and collected in heparinized syringes. Mononuclear cells (MNCs) are obtained by centrifugation. The isolated MNCs are checked for viability manually and confirmed on automated cell count machine.~The separated MNCs is administered intra-articularly immediately after centrifugation."
48333529|NCT05724017|BEHAVIORAL|Street Games Intervention|The children to be included in the study will be grouped in groups of 10 according to their age groups. Groups of 10 people consist of six sessions in total, two days a week for three weeks. Applications will be made in the school garden. In the meetings, games that attract the attention of children will be discussed, suitable games will be played, origami, painting and story sharing will be made. In the study, the independent variable street games intervention will be applied.
48333530|NCT00239356|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
48333531|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
48333532|NCT04645823|DRUG|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
48333533|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
48333534|NCT06527625|BEHAVIORAL|Cultural Arts Program|9-session group art program using Chinese calligraphy as the channel for gaining emotional awareness and facilitating expression
48126354|NCT03639896|DRUG|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
48126355|NCT03639896|DRUG|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
48333535|NCT06527625|BEHAVIORAL|Treatment as usual|Treatment as usual provided in local community aged care centres
48333536|NCT06124092|OTHER|neurocognitive tests|Cohort study: all parents and participants will have questionnaires to complete, based on participant's age.
48333537|NCT05480839|PROCEDURE|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
48333538|NCT05480839|PROCEDURE|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
48493035|NCT03647683|OTHER|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
48493036|NCT03647683|OTHER|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
48333539|NCT05480839|PROCEDURE|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
48333540|NCT03526315|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
48333541|NCT03526315|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily.
48333542|NCT03526315|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
48333543|NCT02301754|BIOLOGICAL|INVAC-1|intradermal injection combined with electroporation
48333544|NCT04140604|OTHER|Lactobacillus salivarius AP-32|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
48333545|NCT04140604|OTHER|Bifidobacterium animalis subsp. lactis CP-9|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
48333546|NCT04140604|OTHER|Placebo|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
48493037|NCT03647683|OTHER|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
48493038|NCT05808153|RADIATION|radiotracer injection|MRI with radiotracer injection
48493039|NCT03729076|OTHER|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
48493040|NCT03729076|OTHER|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
48493041|NCT02121275|DEVICE|Ultrasound of the lungs|Ultrasound examination of the lungs
48126356|NCT02169869|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
48126357|NCT02169869|DEVICE|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
48126358|NCT04124120|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
48126359|NCT04124120|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
48126360|NCT02422615|DRUG|Ribociclib|Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
48126361|NCT02422615|DRUG|Fulvestrant|Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
48126362|NCT02422615|DRUG|Placebo|Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
47975620|NCT06471452|DEVICE|Interaktor|"In the app (Interaktor), the patients will report frequency and distress on common symptoms and concerns.~Free text comments will also be possible to make to cover the patients' other potential needs. Information about the concerns will be included in the app containing; a) general information about why they have the side effects and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents, web pages or YouTube videos.~Supportive Care delivered from a study-specific nurse. During the health dialogues with a nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and needs and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patient's journal."
48126363|NCT06431347|BEHAVIORAL|Social Determinants of Health Questionnaire|Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
48126364|NCT00871130|PROCEDURE|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
48126365|NCT00192946|PROCEDURE|Temporary cardiac resynchronization therapy|
48126366|NCT01773746|OTHER|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
48333547|NCT02407912|DRUG|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
48126367|NCT04279366|BEHAVIORAL|Lifestyle intervention|The 14 week courses takes place at a Danish folk high school (Ubberup), specialized in lifestyle interventions targeting a 10% weight loss. Adult individuals with obesity sign up for the course. They stay at the School for the whole course period and the total cost amounts to 300-400 Euros per week plus loss of income.
48333548|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation without the support of the RAYVOLVE app|"Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated."
47975621|NCT00254449|DRUG|NGX-4010|
47975622|NCT05531760|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK-operated eyes
48126368|NCT05551286|OTHER|A rehabilition programme for young adult cancer survivors|The programme consists of 22 sessions focusing on; 1) everyday life (energy conservation, cognitive challenges, fatigue); 2) Physical activity; 3) psychological issues; 4) work and study d; 5) sexuality and relationship; 7) rights and finance, and 8) goal setting. The sessions include both education, workshops, and engagement in different activities and will be delivered by a multidisciplinary team.
48126369|NCT02930200|BEHAVIORAL|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
48126370|NCT02930200|BEHAVIORAL|QuitGuide|NCI QuitGuide Treatment App
48126371|NCT02930200|BEHAVIORAL|Smart-T|Smart-Treatment App
48126372|NCT06234956|BIOLOGICAL|BIMERVAX|BIMERVAX
48126373|NCT03717467|DRUG|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
48126374|NCT03717467|DRUG|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
48126375|NCT03305536|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
48126376|NCT00903162|DRUG|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
48126377|NCT00903162|DRUG|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
48126378|NCT00903162|DRUG|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
48126379|NCT06347575|DEVICE|Implantation of the caverStim device|Implantation of caverStim in SCI patients.
48493042|NCT02121275|DEVICE|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
48126380|NCT05288959|DEVICE|Session 2: Single-pulse TMS (spTMS)|Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
48126381|NCT05288959|DEVICE|Sessions 3 - 5: Paired associative stimulation (PAS)|During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
48493043|NCT02381951|DEVICE|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
48493044|NCT01892657|DRUG|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
48493045|NCT03812705|BIOLOGICAL|fecal microbiome transplantation|"1. Stop antibiotics treatment 1 day before fecal microbiome transplantation;~2. Fasting food 6 hours before fecal microbiome transplantation;~3. Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~4. Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~5. Perform up to 4 times if patient response;~6. Stop if no response after twice fecal microbiome transplantation."
48493046|NCT06062849|DEVICE|nephrostomy tube|we will investigate if a nephrostomy tube really necessary after PNL operations
48333549|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation with the support of the RAYVOLVE app|The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
48333550|NCT05097833|BEHAVIORAL|Enhanced Saint Francis Fatherhood FIRE Program|Fathers receive an enhanced series of pro-parenting, relationship, and economic stability workshops over 16 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success and the Nurturing Fathers enhancement program.
48333551|NCT05097833|BEHAVIORAL|Services as Usual Saint Francis Fatherhood FIRE Program|Fathers receive the services as usual approach which includes a series of pro-parenting, relationship, and economic stability workshops over 13 weeks. Workshop series are based on a diverse curricula including a combination of either 24/7 Dad or Parent Project and Connections to Success.
48333552|NCT03446001|DRUG|TRx0237 16 mg/day|Oral TRx0237 4-mg tablets administered twice daily
48333553|NCT03446001|DRUG|Placebo|Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
48333554|NCT03446001|DRUG|TRx0237 8 mg/day|Oral TRx0237 4-mg tablet administered twice daily
48333555|NCT03443895|DRUG|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
48333556|NCT03443895|DRUG|Placebo oral capsule|Matching placebo capsule
48333557|NCT02923908|OTHER|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
48333558|NCT02923908|OTHER|Voice Recording|A voice recording will be made for the duration of the tasting period.
48652540|NCT06675825|DEVICE|Savary-Bougie (A) or balloon dilation (B)|"A: In the Savary- Bougie treatment, dilators of different sizes are advanced to dilate the stenosis. The same procedure is then repeated with the next larger dilator, with the position of the dilator being checked radiologically each time.~B: In the case of balloon dilation, a balloon is inserted and inflated at the level of the stenosis. Depending on the age of the child and possibly also the etiology of the stenosis, different balloons sizes are applied, which are then maintained inflated for about one until three minutes and the respective pressure. This procedure could take place under endoscopic or radiological control."
48652541|NCT04030650|OTHER|Functional analyses|2-minute walking test 200-metre walking test
48652542|NCT04030650|OTHER|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
48333559|NCT02923908|OTHER|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
48493047|NCT06062849|DEVICE|double J stent|we will investigate if a JJ stent really necessary after PNL operations
48493048|NCT06062849|PROCEDURE|totally tubless|we will not insert any device after the procedure and investigate if a nephrostomy tube or JJ stent really necessary after PNL operations
48493049|NCT02240342|DRUG|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
48493050|NCT03012672|DRUG|Cladribine|Given IV
48493051|NCT03012672|DRUG|Cytarabine|Given IV
48493052|NCT03012672|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Given SC
48493053|NCT03012672|DRUG|Mitoxantrone Hydrochloride|Given IV
48493054|NCT03012672|OTHER|Quality-of-Life Assessment|Ancillary studies
48493055|NCT03012672|OTHER|Questionnaire Administration|Ancillary studies
48652543|NCT04030650|OTHER|Functional analyses|400-metre walking test 200-metre walking test
48333560|NCT02923908|OTHER|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
48652544|NCT06549985|BEHAVIORAL|PEEPS|Participants will participate in the PEEPS program in addition to usual care.
48333561|NCT06068179|DRUG|Mycophenolate Mofetil, Oral, 250 Mg|Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
48333562|NCT06068179|DRUG|methimazole, oral, 10mg|Methimazole 15-30mg daily initially then titrate to maintenance dose.
48333563|NCT00961116|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
48333564|NCT00961116|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
47975623|NCT05712928|BEHAVIORAL|Dance/movement therapy (eMove)|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
48333565|NCT05106335|DRUG|camrelizumab + famitinib|camrelizumab for intravenous injection; famitinib malate capsules for oral administration
48333566|NCT05106335|DRUG|famitinib|famitinib malate capsules for oral administration
48333567|NCT05106335|DRUG|docetaxel|docetaxel for intravenous injection
48333568|NCT04099849|DIETARY_SUPPLEMENT|Diet-ZnBfR: Zinc biofortified rice-based diet|Diet-ZnBfR: Zinc biofortified rice-based diet
48333569|NCT04099849|DIETARY_SUPPLEMENT|Diet- CR: Conventional rice-based diet|Diet- CR: Conventional rice-based diet
48333570|NCT04099849|DIETARY_SUPPLEMENT|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
48333571|NCT01874873|DRUG|Anlotinib|
48333572|NCT01255306|OTHER|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day"
48333573|NCT01255306|DRUG|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
48333574|NCT06403748|DIETARY_SUPPLEMENT|Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients.|The study will be conducted in male and female subjects, at least 18 and less than 70 years of age, with suboptimal level of LDL-Cholesterol (LDL 115-190 mg/dL) randomized into two groups to receive a preconstituted food supplement (NUT) combination containing (Red yeast rice 160 mg + Berberis aristate 449,7 mg + Folic acid 200 μg and others) in combination with a standard Mediterranean diet at low cholesterol content (\<200 mg/day) (Standard of Care - SOC) \[group 1\], or a PLACEBO in combination with hypo-cholesterol diet (healthy Mediterranean diet following the indication of the European Atherosclerosis Society guidelines) \[group 2\].
48333575|NCT06403748|OTHER|Placebo|Placebo
48333576|NCT04169685|PROCEDURE|bronchoscopy|during flexible bronchoscopy
48333577|NCT02759562|DRUG|Andecaliximab|Administered via subcutaneous injection
48652545|NCT06549985|BEHAVIORAL|Education|Participants will receive an educational handout on endometriosis in addition to usual care.
48652546|NCT06641297|BEHAVIORAL|Music video game|The video game \&#39;Guitar Hero\&#39; will be used as the platform for training for participants to acquire a new \&#39;skill\&#39;
48652547|NCT05949892|BEHAVIORAL|Expanded Health Belief Model-Based Intervention|A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
48333578|NCT02759562|DRUG|Placebo|Administered via subcutaneous injection
48333579|NCT03174613|DRUG|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
48493056|NCT04899817|DRUG|Granisetron|The drug is given after induction of general anesthesia
48652548|NCT04775979|DRUG|diphenylcyclopropenone (DPCP)|Depigmenting agent
47975624|NCT04160897|DRUG|Entecavir|entecavir naive for chronic hepatitis B patients
47975625|NCT04160897|DRUG|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
48333580|NCT03174613|DRUG|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
48333581|NCT03079245|OTHER|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
48493057|NCT03001752|DEVICE|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
48493058|NCT03001752|DEVICE|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
48493059|NCT03001752|DEVICE|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
48652549|NCT00621114|DEVICE|GamCath® central venous catheter|Choice of central venous catheter type
48652550|NCT00621114|DEVICE|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
48652551|NCT00527631|RADIATION|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
47975626|NCT03627624|OTHER|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
47975627|NCT05173402|DEVICE|dentoalveolar compensation method|orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw
48126382|NCT05604391|PROCEDURE|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
48333582|NCT03079245|OTHER|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
48333583|NCT03079245|OTHER|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (\>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
48333584|NCT04154657|PROCEDURE|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
48333585|NCT06402279|DEVICE|Efferon CT|"Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross- linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.~Hemoperfusion procedures were performed using the Efferon CT device no later than 6 hours after the start of invasive ventilation. Hemosorption was performed twice within 12 hours, with an interval of 24 hours between hemoperfusion."
47975628|NCT05173402|DEVICE|face mask|orthopedic treatment was performed using a face mask.
47975629|NCT01876030|DEVICE|FES|
48333586|NCT04001309|OTHER|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
48493060|NCT05873361|OTHER|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
47975630|NCT02782975|DRUG|aducanumab|
47975631|NCT05806788|BEHAVIORAL|Binge Eating Syndrome Treatment (BESTOW)|The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
47975632|NCT04412824|DRUG|Intravenous blood draw|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
47975633|NCT01186354|BEHAVIORAL|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
47975634|NCT04825418|DEVICE|Artic Sun|"1. Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)~2. Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia~3. Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃"
47975635|NCT01369797|OTHER|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
48126383|NCT05604391|PROCEDURE|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
48493061|NCT05256134|DRUG|Gantenerumab|Gantenerumab will be administered as per the dosing schedule described in the Arm description.
47975636|NCT05837819|DEVICE|Active Lighting Intervention|Lighting intervention using high light levels designed to effect the circadian system
47975637|NCT05837819|DEVICE|Control Lighting Intervention|Lighting intervention using low light levels designed to not effect the circadian system
47975638|NCT00186030|BEHAVIORAL|HIV Skills-based Prevention|
47975639|NCT04970888|OTHER|Cognitive training|"The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions.~Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general."
48126384|NCT03890848|BEHAVIORAL|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
48126385|NCT03890848|BEHAVIORAL|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
48333587|NCT06446518|DEVICE|Virtual reality exposure|Assessing immersive virtual reality as a distraction tool in anxiolysis and pain modulation.
48333588|NCT05735613|PROCEDURE|osteotome crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
48333589|NCT05735613|PROCEDURE|osseodensification crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
48333590|NCT05735613|PROCEDURE|piezoelectric crestal sinus lifting|initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
48333591|NCT06580470|BEHAVIORAL|Tailored Cognitive Behavioral Therapy for Menopause|Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.
48333592|NCT01332019|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
48333593|NCT04020276|RADIATION|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
48333594|NCT03620435|DRUG|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
48333595|NCT00456833|DRUG|RAD001|
48333596|NCT00456833|DRUG|erlotinib|
48333597|NCT00943085|BEHAVIORAL|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
48333598|NCT00943085|BEHAVIORAL|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
48333599|NCT05895695|PROCEDURE|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
48493062|NCT05256134|DRUG|Placebo|Placebo will be administered as per the dosing schedule described in the Arm description.
48493063|NCT04134923|DRUG|[11C] Pittsburgh Compound-B (PIB)|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
48493064|NCT03884374|BEHAVIORAL|Focused Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
48493065|NCT03884374|BEHAVIORAL|Standard Breathing and Attention Training (BAT)|Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
48493066|NCT03884374|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
48493067|NCT03884374|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
48493068|NCT05921513|PROCEDURE|Free Gingival Graft Procedure|This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
48493069|NCT05370820|DRUG|Tranexamic acid|IV 2 minutes, IV 10 minutes, IM
48333600|NCT05895695|PROCEDURE|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
48493070|NCT04310839|PROCEDURE|Colectomy|colectomy due to neoplastic (stage 1) or diverticulosis
48493071|NCT02603978|BEHAVIORAL|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
48333601|NCT02938546|RADIATION|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
48333602|NCT03358654|DRUG|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
48333603|NCT04466072|DIAGNOSTIC_TEST|Stool test for microbial analysis|Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
48333604|NCT03145597|DEVICE|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
48333605|NCT03145597|DEVICE|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
48333606|NCT03841526|DRUG|Glucagon RTU Injection With Insulin Pump Reduction|0.15 mg injection with 50% pump reduction
48333607|NCT03841526|OTHER|Vehicle for Glucagon RTU Injection With Insulin Pump Reduction|vehicle injection with 50% pump reduction
48333608|NCT03841526|DRUG|Glugaon RTU Injection Without Insulin Pump Reduction|0.15 mg injection without pump reduction
48333609|NCT05090683|BEHAVIORAL|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
48333610|NCT05425095|OTHER|Buteyko Breathing Technique|Group A will be treated with Buteyko Breathing Technique. Patient in a relaxed sitting position will ask to take a gentle breath in (2 sec), breath out (3sec) followed by pinching the nose with hands to hold the breath. The therapist will count the no. of seconds the patient can comfortably hold the breath until feels the need to breathe in again. Followed by releasing the nose and continue breathing.
48333611|NCT05425095|OTHER|Corpse-Pose Technique|Group B will be treated with Corpse-Pose Technique for 15-20 min.
48333612|NCT00003203|BIOLOGICAL|filgrastim|Given IV
48333613|NCT00003203|DRUG|carboplatin|Given IV
48333614|NCT00003203|DRUG|cisplatin|Given IV
48333615|NCT00003203|DRUG|cyclophosphamide|Given IV
48493072|NCT02603978|BEHAVIORAL|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
47975640|NCT04970888|OTHER|Exercise training|Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.
48333616|NCT00003203|DRUG|vincristine sulfate|Given IV
48333617|NCT00003203|PROCEDURE|adjuvant therapy|
48333618|NCT00003203|RADIATION|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT\*
48333619|NCT05274594|RADIATION|Radiotherapy|Patients who are candidate for radiotherapy and received neoadjuvant chemotherapy for breast cancer were evaluated after neoadjuvant chemotherapy. Cases that do not have clinical response received radiotherapy before surgery in order to increase complete response.
48333620|NCT05399108|PROCEDURE|Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.
47975641|NCT04970888|OTHER|Usual care|All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.
48333621|NCT05399108|PROCEDURE|Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
48333622|NCT04335708|DIETARY_SUPPLEMENT|Postibiotic formulation|5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
48493073|NCT02603978|BEHAVIORAL|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
48333623|NCT04335708|DIETARY_SUPPLEMENT|Placebo formulation|5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
48333624|NCT01812122|DRUG|Glimepiride|
48333625|NCT01812122|DRUG|Vildagliptin|
48333626|NCT05005091|DIETARY_SUPPLEMENT|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
48493074|NCT01087632|DIETARY_SUPPLEMENT|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
48493075|NCT00725114|BIOLOGICAL|Tetrodotoxin|30 µg twice daily for 4 days
48493076|NCT00725114|BIOLOGICAL|Placebo|2 mL subcutaneous injection twice daily for 4 days
48493077|NCT03797820|OTHER|Our study type is observational|Our study type is observational
48493078|NCT01876550|DRUG|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
47975642|NCT02669381|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
48333627|NCT05121831|DRUG|DGX-001Dose 1|Dose level 1 of DGX-001
48333628|NCT05121831|DRUG|DGX-001 Dose 2|Dose level 2 of DGX-001
48333629|NCT05121831|DRUG|DGX-001 Dose 3|Dose level 3 of DGX-001
48333630|NCT05121831|DRUG|DGX-001 Dose 4|Dose level 4 of DGX-001
48333631|NCT05121831|DRUG|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
48333632|NCT00716326|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
48333633|NCT00716326|DEVICE|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
48333634|NCT03461185|DRUG|EGFR-TK Inhibitor|EGFR-TKIs include but are not limited erlotinib, gefitinib
48333635|NCT03461185|DRUG|Anti-Angiogenic Drugs|Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
48333636|NCT06456515|DRUG|Regorafenib and Sintilimab in combination with electroacupuncture|Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
48333637|NCT05753007|DRUG|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
48493079|NCT01876550|DRUG|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
48493080|NCT01876550|DRUG|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
48493081|NCT05572970|DRUG|Balstilimab|An anti-programmed death 1 (PD-1) monoclonal antibody.
48493082|NCT05572970|DRUG|Zalifrelimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
48493083|NCT01672944|OTHER|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
48493084|NCT01672944|OTHER|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
48493085|NCT03898921|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
48652552|NCT05998564|DEVICE|Connecting patients to both non-invasive monitors to observe and compare the monitor's capabilities.|All patients will be connected to the NOL monitor and the SCA monitor during general anesthesia.
48652553|NCT02121639|DRUG|Placebo|
48333638|NCT05753007|DRUG|Placebo|Placebo solution
48333639|NCT00795171|DRUG|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
48333640|NCT00795171|DRUG|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
48333641|NCT00795171|DRUG|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
48333642|NCT01684683|DRUG|Theophylline|Theophylline 0.1 bid
48333643|NCT01684683|DRUG|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
48333644|NCT05955157|BIOLOGICAL|Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy|DC+CIK immunotherapy will be administrated with S-1 chemo drug as maintenance treatment for patients with advanced PDAC
48333645|NCT05955157|DRUG|Tegafur Only Product|Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care
48333646|NCT05652972|OTHER|Ketogenic diet|1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
48333647|NCT05652972|OTHER|Control diet|1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
48333648|NCT03911869|DRUG|encorafenib|taken orally
48333649|NCT03911869|DRUG|binimetinib|taken orally
48333650|NCT02232594|DRUG|Berodual®|
48333651|NCT02428907|BEHAVIORAL|simulation training|teamtraining of endoscopy staff
48333652|NCT00933192|DEVICE|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
48333653|NCT03372564|PROCEDURE|Hip Capsule Repair|In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
48493086|NCT03898921|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 3 times.
48493087|NCT04503395|DEVICE|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
48493088|NCT04503395|DEVICE|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
48493089|NCT00210236|PROCEDURE|Conventional surgery|
48493090|NCT02516410|DRUG|VX-661 plus ivacaftor combination|
48493091|NCT02516410|DRUG|Ivacaftor|
48493092|NCT02516410|DRUG|Placebo (matched to VX-661 plus ivacaftor combination)|
48652554|NCT02121639|DRUG|AZD5363|
48333654|NCT05161754|PROCEDURE|Hemostasis|Hot hemostasis include bipolar and monopolar diathermy. Cold hemostasis include surgical knotting of the tonsil pillar and compression.
48333655|NCT01854671|OTHER|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
48333656|NCT00324688|DRUG|Viread|
48333657|NCT02354092|PROCEDURE|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
48333658|NCT02354092|PROCEDURE|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
48333659|NCT02354092|PROCEDURE|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
48333660|NCT02354092|PROCEDURE|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
48333661|NCT02354092|BEHAVIORAL|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
48333662|NCT02354092|DRUG|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
48333663|NCT01961089|DEVICE|Galilei Lens Professional|Measurement device
48333664|NCT01961089|DEVICE|IOLMaster|Measurement device
48333665|NCT01961089|DEVICE|Lenstar|Measurement device
48333666|NCT01664819|DIETARY_SUPPLEMENT|Antioxidant|
48333667|NCT01664819|DIETARY_SUPPLEMENT|Placebo|
48493093|NCT02516410|DRUG|Placebo (matched to ivacaftor)|
48493094|NCT03915730|OTHER|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
48493095|NCT06218264|DIETARY_SUPPLEMENT|Ingestion of an amino acid supplement|Oral intake of a supplement containing amino acids
48333668|NCT05871372|DEVICE|Brain Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care, respectively, The depression cohort will also have deep brain stimulation (DBS) leads implanted as part of their trial. We will deliver stimulation via the DBS and sEEG electrodes. We will adhere to well known safety parameters.
48333669|NCT05871372|DEVICE|sEEG Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care. We will deliver stimulation via the sEEG electrodes. We will adhere to well known safety parameters.
48333670|NCT03303287|BEHAVIORAL|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
48493096|NCT02709252|DEVICE|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
48493097|NCT03465917|COMBINATION_PRODUCT|Renal Denervation|Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
48333671|NCT04324788|OTHER|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
48333672|NCT04324788|OTHER|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
48333673|NCT04446871|DRUG|0.9% sodium chloride|Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
48333674|NCT04446871|DRUG|Methylene Blue|Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
48333675|NCT04079387|DEVICE|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°"
48333676|NCT04079387|DEVICE|ENDOTRACHEAL TUBE ALONE|intubating the trachea with an endotracheal tube alone
48493098|NCT00225121|DRUG|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
48333677|NCT01565590|DRUG|Dexmedetomidine|0.2-1.5 mcg/kg/hr
48333678|NCT01565590|DRUG|propofol|5-80 mcg/kg/min
48333679|NCT02514772|BIOLOGICAL|GP2013 - A Proposed biosimilar rituximab|
48333680|NCT02514772|BIOLOGICAL|Originator rituximab - Rituxan ® or MabThera ®|
48333681|NCT01383187|PROCEDURE|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
48493099|NCT02885649|DRUG|Enzalutamide|Given PO
48493100|NCT02885649|OTHER|Laboratory Biomarker Analysis|Correlative studies
48493101|NCT02885649|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
48493102|NCT03230799|PROCEDURE|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
48493103|NCT03230799|PROCEDURE|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
48126386|NCT04717544|BEHAVIORAL|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
48126387|NCT00000834|DRUG|Lamivudine|
48126388|NCT00000834|DRUG|Methotrexate|
48126389|NCT00000834|DRUG|Zidovudine|
48126390|NCT03282526|DIAGNOSTIC_TEST|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
48126391|NCT02879760|BIOLOGICAL|Ad-MAGEA3|Intramuscular injection
48333682|NCT01383187|PROCEDURE|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
48652555|NCT06569927|PROCEDURE|Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.|Key elements included formation of a multidisciplinary team，perioperative postural management, preoperative sleeping posture adaptability training, neck movement training, standardization of head position angles and head suspension time during surgery, use of protective headrests, attention to transfer and handover procedures, and specially designed pillows.
48652556|NCT01030809|OTHER|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
48652557|NCT03302429|OTHER|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
48126392|NCT02879760|BIOLOGICAL|MG1-MAGEA3|Intravenous infusion
48652558|NCT03302429|OTHER|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
48126393|NCT02879760|BIOLOGICAL|Pembrolizumab|Intravenous infusion
48126394|NCT01402531|DRUG|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
48652559|NCT03713411|PROCEDURE|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
48126395|NCT05425953|OTHER|No intervention other than obtaining biopsies|Biopsies will be obtained.
48126396|NCT03595969|DIAGNOSTIC_TEST|Relative copy number of mitochondrial DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
48126397|NCT06445699|OTHER|Photodynamic therapy|A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.
48652560|NCT01480765|DRUG|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
48652561|NCT01480765|DRUG|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
48652562|NCT01480765|DRUG|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
48652563|NCT01480765|DRUG|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
48652564|NCT03373513|PROCEDURE|Robotic single-site Hysterectomy|Robotic assisted Periumbilical single incision hysterectomy
48652565|NCT03373513|PROCEDURE|Laparoscopic hysterectomy|Multiport laparoscopic hysterectomy
48652566|NCT04817436|OTHER|physical activity program (APA)|adapted physical activity program (APA)
48652567|NCT06170242|DRUG|EDP-323 Dose Regimen 1|EDP-323 capsule
48126398|NCT06445699|OTHER|Hydrogel dressing|Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.
48126399|NCT05893719|DEVICE|iNedit, iNdeep, iNtercept|Patients to undergo mechanical thrombectomy with iNedit, iNdeep and iNtercept
48126400|NCT06061744|OTHER|Minimally invasive surgery|laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
48126401|NCT00209742|DRUG|UFT|P.O. everyday
48126402|NCT00209742|DRUG|USEL/Leucovorin|P.O. everyday
48126403|NCT00209742|DRUG|Krestin|P.O. everyday
48126404|NCT06060119|DEVICE|microneedling|The operative sites will be anaesthetized with 2% lignocaine hydrochloride with adrenaline(1:80,000).Electric microneedling pen device model THAPPINKTM is used. Microneedling is carried out on the isolated site involving one tooth mesially and distally and 1.5mm apical to marginal gingiva each for 30-40 second intermittently. When pin point bleeding observed on the area of gingiva it is irrigated with sterile saline solution. Patient will be instructed to refrain from consuming hot beverage and brushing in that area for one day to avoid mechanical trauma. A total of 4 session of micro needling procedure will be carried out in one subject at 10 days intervals upto 40days
48333683|NCT02077946|DRUG|liraglutide|No treatment given.
48333684|NCT02077946|DRUG|sitagliptin|No treatment given.
48333685|NCT03550742|OTHER|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
48333686|NCT02702947|DIETARY_SUPPLEMENT|Prunus domestica extract|Prosman 1 capsule twice a day
48333687|NCT03771690|BEHAVIORAL|Standardised meal|A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
48333688|NCT04656392|DIAGNOSTIC_TEST|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
48333689|NCT01467661|DRUG|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
48333690|NCT03000634|DRUG|Elotuzumab|Administered through a small tube that goes directly into the vein
48652568|NCT06170242|DRUG|EDP-323 Dose Regimen 2|EDP-323 capsule
48126405|NCT02847715|DEVICE|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
48126406|NCT02101281|DRUG|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
48126407|NCT02101281|DRUG|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
48126408|NCT05136157|DRUG|Rapid-Acting Insulin|50 IU of rapid acting insulin taken by a 100 units (1ml) insulin syringe will be added to a 50 ml syringe containing normal saline (NS) to have a total volume of 50 ml with a concentration of 1 IU of insulin per 1 ml of NS
48126409|NCT02164240|DRUG|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
48126410|NCT02164240|DRUG|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
48126411|NCT00968149|DRUG|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
48126412|NCT00968149|DRUG|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
48126413|NCT00002156|DRUG|Fomivirsen sodium|
48126414|NCT00002156|DRUG|Ganciclovir|
48126415|NCT05680389|DRUG|Minocycline|100 mg twice daily for 3 months
48126416|NCT05680389|DRUG|Placebo|twice daily for 3 months
48333691|NCT03000634|DRUG|Bortezomib|Administered as a subcutaneous injection under the skin
48333692|NCT03000634|DRUG|Lenalidomide|Capsule taken by mouth
48333693|NCT03000634|DRUG|Dexamethasone|Taken by mouth
48333694|NCT01053702|DRUG|R475|IV
48333695|NCT01053702|DRUG|Placebo|Placebo
48333696|NCT01563107|RADIATION|Plasma Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
48333697|NCT01563107|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
48333698|NCT01563107|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
48333699|NCT04063072|PROCEDURE|ERAS protocol|In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
48333700|NCT02468206|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
48652569|NCT06170242|DRUG|Placebo|Placebo capsule
48652570|NCT02909257|DRUG|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
48652571|NCT02909257|DRUG|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
48126417|NCT01553058|DRUG|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
48126418|NCT01553058|DRUG|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
48126419|NCT01553058|OTHER|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
48126420|NCT04929067|DRUG|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma|immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
48126421|NCT04833179|BIOLOGICAL|fecal transplant|"Healthy donors will be selected by the fecal transplant unit, in Tel-Aviv medical center. All donors will undergo a screening process that will include a detailed medical history, blood work and fecal tests. Only after passing the screening, the donor will be added to the groups of donors that will participant in this study.~The treatment will be givenin the form of fecal capsule. Each capsule will contain a double capsule with 2 layers to ensure that the fecal material will be contained. The treatments will include 30 capsules for the first treatment, that will be taken in two consecutive days, each day 15 capsules. The second, third and fourth treatments will all include 15 fecal capsules. There will be 2 weeks intervals between each treatment."
48126422|NCT04833179|OTHER|placebo|placebo
48126423|NCT05429307|OTHER|Population|Turkish Validity and Reliability of The Exercise Sensitivity Questionnair Scale to Turkish society and to make its validity and reliability in Turkish.
48333701|NCT02468206|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
48333702|NCT02468206|DRUG|N-butyl-2-cyanoacrylate|
48333703|NCT02468206|DRUG|Lauromacrogol|
47975643|NCT03740711|PROCEDURE|Left atrial venting|The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
48333704|NCT04994080|DRUG|Paricalcitol|Paricalcitol QD Treatment
48333705|NCT04994080|DRUG|Placebo|Placebo QD or TIW
48333706|NCT03673956|DRUG|Mupirocin|30mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
48333707|NCT03673956|DRUG|Tobramycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
48333708|NCT03673956|DRUG|Levofloxacin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
48333709|NCT03673956|DRUG|Vancomycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
48333710|NCT00617838|OTHER|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
48333711|NCT04854577|PROCEDURE|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
48493104|NCT01333280|BEHAVIORAL|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
48493105|NCT01333280|BEHAVIORAL|Treatment as usual|Receive usual treatment at the programs
48493106|NCT01295294|DRUG|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
48493107|NCT01295294|DRUG|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
48652572|NCT04658680|DRUG|BCG vaccination at first health facility contact|"Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region.~The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres."
48652573|NCT02848027|BIOLOGICAL|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
48652574|NCT05603780|BEHAVIORAL|exploratory protocol|physiological and cognitive evaluations
47975644|NCT05993260|BEHAVIORAL|Behavioural science-informed text messages|Behaviourally-informed content in vaccination eligibility reminder text messages
47975645|NCT05993260|BEHAVIORAL|Control|Control vaccination eligibility reminder text message
48333712|NCT04854577|PROCEDURE|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
48333713|NCT06155240|BEHAVIORAL|Therapeutic yoga|Yoga interventions include yoga poses, breathing, and meditation
48333714|NCT01094990|DRUG|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
48333715|NCT00445731|BEHAVIORAL|exercise intervention|
48333716|NCT00445731|PROCEDURE|management of therapy complications|
48333717|NCT00445731|PROCEDURE|observation|
48333718|NCT04086602|DRUG|IZD334|Active Drug
48333719|NCT04086602|DRUG|Placebos|Placebo to Match
48333720|NCT04606641|OTHER|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
47975646|NCT03002766|PROCEDURE|Breast conservative surgery|
47975647|NCT01108302|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
48333721|NCT04606641|OTHER|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
48333722|NCT05949268|DEVICE|Small bowel capsule endoscopy|Patients with gastrointestinal bleeding receive small bowel capsule endoscopy after bleeding could not be located in gastroscopy or colonoscopy.
48333723|NCT00655057|DRUG|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
48333724|NCT00655057|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
48333725|NCT00655057|PROCEDURE|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
48493108|NCT01295294|DRUG|Placebo|3 times daily per oral during bleeding/spotting episodes
48493109|NCT01295294|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
48493110|NCT04427644|PROCEDURE|Laparascopic Sleeve Gastrectomy|Operations performed for complciation of laparascopic sleeve gastrectomy
48493111|NCT04427644|PROCEDURE|İnterventional radiologic drainage|İnterventional radiologic drainage of gastric leakage
48333726|NCT06120309|DIAGNOSTIC_TEST|CRS scoring|For pathological evaluation, the omental specimens resected during the IDS were stained with haematoxylin and eosin (H\&E) and reviewed independently by two gynecologic pathologists, both blinded to the clinical data and each other's results. The pathology slide obtained from omentum, usually the site with the most viable tumor, was selected for CRS assessment according to the three-tiered CRS system recommended by 2019 ESMO ovarian cancer guidelines
48333727|NCT06120309|DIAGNOSTIC_TEST|Routine blood laboratory testing before treatment|The routine blood tests and tumor marker measurements, including CA125, HE4, and inflammation-related serum biomarkers including neutrophils, lymphocytes, monocytes, fibrinogen, and platelets, were conducted within three days before the first NACT.
48333728|NCT01934933|DRUG|celebrex|
48333729|NCT01934933|DRUG|Enbrel|
48333730|NCT01934933|DRUG|Enbrel plus Celebrex|
48493112|NCT04427644|DIAGNOSTIC_TEST|Complte Blood Count and Biochemical evaluation|blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
47975648|NCT05033353|DIAGNOSTIC_TEST|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
48493113|NCT04427644|DIAGNOSTIC_TEST|Computed tomography|Admitted to observe leakage
47975649|NCT04697524|BEHAVIORAL|Support Group Therapy|Virtual group meetings
47975650|NCT04697524|BEHAVIORAL|Symptom Management Service (SMS) Consultation|Virtual individual meetings with symptom management service (SMS) over 5 minutes
47975651|NCT04697524|OTHER|Quality of Life (QOL) Questionnaires|Administered at each study visit
47975652|NCT04697524|OTHER|Interview|Virtual exit interview at end of study
48333731|NCT01037972|BEHAVIORAL|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
48333732|NCT01037972|BEHAVIORAL|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
48493114|NCT04722601|DRUG|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
48493115|NCT04722601|DRUG|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
48493116|NCT04722601|DRUG|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
48652575|NCT06458998|BEHAVIORAL|Patient Navigation|Clinical Resource Hub (CRH) providers include a small group of nurses, advance practice providers, and physicians who work to improve care across a range of measures using virtual PN. CRH providers will 1) use existing dashboards to identify at-risk Veterans, 2) conduct Veteran outreach (two calls, one letter) to provide education, problem solve, and offer screening, 3) order and schedule HCC or CRC screening tests, and 4) provide reminders and follow up on results.
48652576|NCT06458998|BEHAVIORAL|Implementation Facilitation|Facilitators will provide 20 hours of virtual facilitation to site teams, through 1-hour meetings every other week and ad hoc meetings, over 12 months. They will guide site teams through a seven-step playbook called Getting To Implementation (GTI), which uses a series of tools to select context-specific strategies.
48333733|NCT05102331|OTHER|Lavender Oil Aromatherapy|"Participants will be given a dental bib to wear. Three drops of the lavender oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~The lavender oil is produced by doTERRA and has Gas Chromatography Mass Spectrometry analysis showing 35.66% linalool without any contaminants"
48333734|NCT05102331|OTHER|Placebo oil|"Participants will be given a dental bib to wear. Three drops of the placebo oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~Refined jojoba oil which has no color or smell"
48333735|NCT05102331|PROCEDURE|BMAB procedure|SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit
48493117|NCT04178265|OTHER|Electroacupuncture|needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
47975653|NCT05387031|DRUG|Ustekinumab|The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
47975654|NCT04358120|DEVICE|Hyaluronic Acid Combined With Chondroitin Sulfate|"Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits.~Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments.~Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection"
48126424|NCT02195297|OTHER|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
48126425|NCT05363449|DRUG|UHE-103 Cream|UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
48126426|NCT05363449|DRUG|Naftin (naftifine hydrochloride) Cream|Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug
48126427|NCT04704258|PROCEDURE|TAVI (Transcatheter Aortic Valve Implant)|Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
48126428|NCT04704258|DEVICE|FLOWer Embolic Protection System|FLOWer Embolic Protection System
48126429|NCT03786042|BEHAVIORAL|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
48126430|NCT03786042|OTHER|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
48126431|NCT00775294|DRUG|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
48126432|NCT04082624|BEHAVIORAL|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
48333736|NCT00848445|DEVICE|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
48333737|NCT00848445|DEVICE|Atrial pacing preference turned on or off|programing changes in the device
48333738|NCT05726448|BEHAVIORAL|Telehealth solution|Mobile-friendly nutrition education platform
48652577|NCT06644950|OTHER|Efficacy and safety of administering 1 or two cartridges of anesthesia|"The investigator will administer the first anesthesia for NDI block with a cartridge of 4% articaine anesthetic at 1:100,000 . At the end, an envelope containing the assignment to the experimental or control group will be opened.~In the control group, only the first anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without the needle, in the same area, counting up to 30 seconds.~In the experimental group two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block."
48333739|NCT00861588|DRUG|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
48333740|NCT00861588|DRUG|placebo|starch placebo
48652578|NCT00974272|DRUG|Exenatide|Single subcutaneous injection (10 μg)
47975655|NCT02556814|DRUG|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
47975656|NCT02556814|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
47975657|NCT02556814|DRUG|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
47975658|NCT01962805|DRUG|Proellex Formulation A|
47975659|NCT01962805|DRUG|Proellex Formulation B|
47975660|NCT01261689|DRUG|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
47975661|NCT01261689|OTHER|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
47975662|NCT00557960|DRUG|Mixed salts of a single-entity amphetamine|
47975663|NCT00557960|DRUG|Atomoxetine hydrochloride|
47975664|NCT06201559|DRUG|Albendazole IP 400 mg|Albendazole IP 400 mg tablets will be administered under fed conditions
47975665|NCT06201559|DRUG|Albendazole 400 mg|Albendazole 400 mg tablets will be administered under fed conditions
47975666|NCT05773508|DEVICE|Video regulation and emergency kit|Video regulation and emergency kit
47975667|NCT04316715|BEHAVIORAL|Lifesteps for PrEP|Four weekly nurse delivered counseling sessions plus two optional booster sessions. Sessions last approximately 40-50 minutes each. Sessions employ cognitive behavioral (CBT) techniques, motivational interviewing (MI), and psychoeducation.
47975668|NCT04316715|BEHAVIORAL|Daily text message reminders|Participants get daily text messages on their cell phone reminding them to take their PrEP medication.
48126433|NCT04082624|BEHAVIORAL|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
48126434|NCT04082624|BEHAVIORAL|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
48126435|NCT04082624|BEHAVIORAL|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
48126436|NCT04047719|DIAGNOSTIC_TEST|Karius Test|Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
48126437|NCT06338540|OTHER|Black color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the black caries color related to history of pain , ICDAS , pulp exposed and microbial load
48126438|NCT06338540|OTHER|dark brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the dark brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
48126439|NCT06338540|OTHER|light brown color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the light brown caries color related to history of pain , ICDAS , pulp exposed and microbial load
48333741|NCT00294827|PROCEDURE|Liver transplantation and colo-rectal cancer|Liver transplantation
48333742|NCT04754113|OTHER|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
48333743|NCT02483455|DRUG|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
48333744|NCT02483455|DRUG|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
48333745|NCT02316626|DRUG|Subcutaneous progesterone|25 mg daily for 14 days
48333746|NCT02316626|DRUG|Vaginal progesterone|90 mg daily for 14 days
48333747|NCT04679558|DRUG|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
48652579|NCT00974272|OTHER|Normal Saline|Single subcutaneous injection
48652580|NCT06644261|DRUG|Bupivacaine injection|Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivicaine will be injected bilaterally.
48333748|NCT04679558|BEHAVIORAL|Preventive protocol|Preventive protocol
48652581|NCT03749018|DRUG|Cyclophosphamide|Given IV
48652582|NCT03749018|DRUG|Doxorubicin Hydrochloride|Given IV
48652583|NCT03749018|DRUG|Etoposide|Given IV
48333749|NCT01875510|DIETARY_SUPPLEMENT|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
47975669|NCT03432754|BEHAVIORAL|Mindfulness-Based Attention Training|The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
47975670|NCT03432754|BEHAVIORAL|Lifestyle Education|"The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework."
47975671|NCT05563233|OTHER|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
47975672|NCT05563233|DEVICE|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
47975673|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
47975674|NCT03478358|DRUG|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
47975675|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
47975676|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
47975677|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
47975678|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
47975679|NCT03984097|DRUG|TAK-079|TAK-079 subcutaneously.
47975680|NCT03984097|DRUG|Lenalidomide|Lenalidomide orally.
48333750|NCT01875510|DIETARY_SUPPLEMENT|soybean-oil emulsion|soybean-oil emulsion
48333751|NCT05355935|DRUG|Brensocatib|Oral tablet.
48333752|NCT05355935|DRUG|Moxifloxacin|Oral tablet.
48333753|NCT05355935|DRUG|Placebo|Oral tablet.
47975681|NCT03984097|DRUG|Dexamethasone|Dexamethasone orally.
47975682|NCT03984097|DRUG|Bortezomib|Bortezomib subcutaneously.
47975683|NCT03984097|DRUG|Pomalidomide|Pomalidomide orally.
47975684|NCT00981734|OTHER|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
47975685|NCT00737282|DRUG|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
47975686|NCT00737282|DRUG|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
47975687|NCT03918720|BEHAVIORAL|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
48333754|NCT01786863|PROCEDURE|Neuromuscular blockade|
48333755|NCT03663140|DIAGNOSTIC_TEST|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
48333756|NCT04397692|DEVICE|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
48333757|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
48333758|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
48493118|NCT01124344|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
48493119|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
48652584|NCT03749018|BIOLOGICAL|Nivolumab|Given IV
48652585|NCT03749018|DRUG|Prednisone|Given PO
47975688|NCT02055716|DRUG|Sulforadex|
47975689|NCT02055716|DRUG|alpha-cyclodextrin|
48493120|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
48493121|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
48493122|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
48493123|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
48493124|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
48652586|NCT03749018|BIOLOGICAL|Rituximab|Given IV
48652587|NCT03749018|DRUG|Vincristine Sulfate|Give IV
48652588|NCT06195956|OTHER|exercise|Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months
48652589|NCT01162785|DRUG|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
47975690|NCT04186039|DIAGNOSTIC_TEST|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
47975691|NCT03158376|DRUG|Gabapentin|
48126440|NCT06338540|OTHER|yellow color of caries|observation of the dental caries color will be confirmed with standardized photographs illustrating , the yellow caries color related to history of pain , ICDAS , pulp exposed and microbial load
47975692|NCT03158376|DRUG|Placebo|
47975693|NCT01871532|DRUG|Gonal-f®|
48126441|NCT03284567|BEHAVIORAL|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors"
48126442|NCT00374192|DRUG|Eszopiclone|3 mg per day
48126443|NCT00374192|DRUG|Placebo|Placebo
48126444|NCT00710775|PROCEDURE|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
48126445|NCT02996136|DEVICE|Flu Symptoms|Flu Symptoms
48126446|NCT05230459|GENETIC|AB-1003 dose level 1|Single intravenous infusion of AB-1003 gene therapy at dose level 1
48126447|NCT05230459|GENETIC|AB-1003 dose level 2|Single intravenous infusion of AB-1003 gene therapy at dose level 2
48126448|NCT05230459|OTHER|Placebo|Single intravenous infusion of Placebo
48126449|NCT05564611|DRUG|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
48126450|NCT05744596|OTHER|Incisura biopsy analysis|a pathologist blinded to the other biopsies analyzes the biopsy from the incisura
48126451|NCT04133337|DRUG|Apatinib|Apatinib Mesylate Tablets
48126452|NCT04133337|DRUG|SHR-1210|Camrelizumab for Injection
48333759|NCT06313853|BEHAVIORAL|COACH-Cog|Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
47975694|NCT05062798|PROCEDURE|Standart bottle|"1. After the surgery, standard bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
47975695|NCT05062798|PROCEDURE|Squeezable bottle|"1. After the surgery, squeezable bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
47975696|NCT02635945|DRUG|PBF-680|
48333760|NCT05816291|DIETARY_SUPPLEMENT|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
48333761|NCT01814826|DRUG|MLN4924|"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"
48493125|NCT01124344|DRUG|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
47975697|NCT02635945|DRUG|Placebo|
48126453|NCT05050799|DEVICE|Central Venous Access|The Surfacer® Inside-Out® Access Catheter System is intended to obtain central venous access to facilitate catheter insertion into the central venous system for patients with upper body venous occlusions or other conditions that preclude central venous access by conventional methods.
48126454|NCT03230643|DEVICE|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.~In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
48126455|NCT05938426|DEVICE|ET-101|Patients have training sessions twice a day. Each training session takes about 10\~25 minutes. Cognitive training programs include meditation, cognitive training, and cognitive testing.
48126456|NCT05938426|DEVICE|Sham Device|Sham device has only cognitive function test excluding training programs.
48126457|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
48126458|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
48126459|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
48126460|NCT04113096|DRUG|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
48126461|NCT04113096|DRUG|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
48126462|NCT04113096|DRUG|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
48126463|NCT04113096|DRUG|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
48126464|NCT04113096|DRUG|Cancer of the Prostate Placebo|20 mg once daily for 6 months
48126465|NCT02345603|PROCEDURE|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
48126466|NCT01690572|DEVICE|Paclitaxel coated balloon catheter|Dilatation of the target lesion
48126467|NCT01690572|DEVICE|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
48126468|NCT05889299|DRUG|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
48126469|NCT05946421|DEVICE|exhaled breath analysis|non invasive technology to measure components of exhaled breath
48126470|NCT05451095|DRUG|BI 474121|BI 474121
48126471|NCT05451095|DRUG|Placebo|Placebo
48126472|NCT05451095|DRUG|Ketamine hydrochloride|Ketamine hydrochloride
48126473|NCT01643616|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
48126474|NCT01643616|DRUG|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
48126475|NCT01643616|DRUG|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
48126476|NCT01643616|DRUG|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
48126477|NCT01643616|DEVICE|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
48126478|NCT01643616|DEVICE|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
48652590|NCT04802590|DRUG|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
48126479|NCT01053793|OTHER|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
48126480|NCT06175520|BEHAVIORAL|Preconception care (PCC)|The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
48126481|NCT04894851|BEHAVIORAL|Contingency Management|Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
48126482|NCT00133458|DRUG|Albendazole|
48126483|NCT00212693|DRUG|ONO-2506PO|
48126484|NCT02586090|BEHAVIORAL|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
48126485|NCT02586090|BEHAVIORAL|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
48333762|NCT01814826|DRUG|Azacitidine|"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"
48333763|NCT00323024|DRUG|NX1011|
48333764|NCT01141127|DRUG|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
48333765|NCT03917225|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
48126486|NCT06035536|DEVICE|Symphony™ plus Off-loading|Application of Symphony™
48126487|NCT06035536|DEVICE|Wound Dressing comprising of calcium alginate Fibracol|Application of Wound Dressing comprising of calcium alginate Fibracol.
48126488|NCT05720455|DRUG|Fexofenadine HCL and pseudoephedrine HCL|Extended-Release Tablets
48126489|NCT01471756|PROCEDURE|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
48126490|NCT00276796|DRUG|cisplatin|
48126491|NCT00276796|DRUG|paclitaxel|
48126492|NCT00276796|DRUG|topotecan hydrochloride|
48652591|NCT04802590|DRUG|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
48652592|NCT04802590|DRUG|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
48652593|NCT04802590|DRUG|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
48333766|NCT03917225|DRUG|Placebo|Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
48652594|NCT05267600|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
48652595|NCT05267600|OTHER|placebo|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
48652596|NCT05267600|DRUG|Prednisone|Oral Prednisone
47975698|NCT03274440|DRUG|Cannabis|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
48493126|NCT01200264|DRUG|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
48126493|NCT03420196|OTHER|Supervised exercise program|"It will consist in a supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
48126494|NCT03420196|OTHER|Non supervised exercise program|"It will consist in a non supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
47975699|NCT03274440|OTHER|Placebo|Placebo control group, not receiving THC or CBD.
47975700|NCT01535053|BIOLOGICAL|Dactinomycin|Given IV
47975701|NCT01535053|DRUG|Leucovorin Calcium|Given PO
47975702|NCT01535053|DRUG|Methotrexate|Given IV and IM
47975703|NCT01535053|OTHER|Quality-of-Life Assessment|Ancillary studies
47975704|NCT01823185|DRUG|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
47975705|NCT01823185|DRUG|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
48126495|NCT01990508|BEHAVIORAL|Targeted beverage education and financial incentives|
48126496|NCT01990508|BEHAVIORAL|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
48652597|NCT01838226|BEHAVIORAL|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
48652598|NCT06569095|OTHER|Multiparametric Flow Cytometry for the detection of Myelodysplastic syndromes with Measurable residual disease|To observe whether multiparametric flow cytometry for the detection of bone marrow and peripheral blood MRD monitoring can predict the prognosis of MDS patients
48652599|NCT00124358|DRUG|Buprenorphine|
47975706|NCT05582746|BEHAVIORAL|Tri-City COVID Attitudes Study|We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
47975707|NCT04441021|OTHER|Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
48333767|NCT01939964|OTHER|Activation Mist|Activation Mist topical spray
47975708|NCT04029948|PROCEDURE|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
47975709|NCT04029948|PROCEDURE|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
48126497|NCT03005119|DRUG|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
48126498|NCT03005119|DRUG|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
48126499|NCT01704196|DRUG|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
48126500|NCT01704196|DRUG|Placebo|
48126501|NCT05048758|OTHER|No intervention|No intervention
48333768|NCT00975026|PROCEDURE|Massages ± Stretches|Chair Massage
48126502|NCT02187887|BEHAVIORAL|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
48126503|NCT02529839|PROCEDURE|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
48126504|NCT02529839|DRUG|Fludarabine|30mg/m2 on days -6 through -3
48126505|NCT02529839|DRUG|Cyclophosphamide|50mg/kg on days -5 through -4
48126506|NCT02529839|DRUG|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
48333769|NCT00326157|DRUG|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
48333770|NCT00223288|DRUG|Lexapro|
48333771|NCT00989612|BIOLOGICAL|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
48333772|NCT00216268|DRUG|Ribavirin|
48493127|NCT00378404|DRUG|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
48493128|NCT00378404|RADIATION|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
48493129|NCT04328571|DIETARY_SUPPLEMENT|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
48493130|NCT04328571|DIETARY_SUPPLEMENT|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
48652600|NCT00124358|BEHAVIORAL|Integrated HIV care and office-based opioid dependence treatment|
48126507|NCT02119650|DRUG|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
48126508|NCT02119650|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
48126509|NCT02119650|DRUG|Pemetrexed|500 mg/m\^2 administered as an intravenous infusion over 10 minutes
48126510|NCT02119650|DRUG|Cisplatin|75 mg/m\^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
48333773|NCT04693923|PROCEDURE|Fluid challenge|Fluid challenge according to the assigned group
48126511|NCT02647905|DEVICE|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
48126512|NCT05363436|DRUG|Oxycodone|Providers had to prescribe 15 oxycodone pills to each patient discharge
48333774|NCT05904691|DRUG|OCU-10-C-110 for Injection|OCU-10-C-110 for Injection in one of 3 doses
48333775|NCT03069898|BEHAVIORAL|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
48333776|NCT00554476|DRUG|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
48333777|NCT00362050|DRUG|Treatment with 3 dose groups of RBx11160 over 7 days|
48333778|NCT04969432|OTHER|Client-centered|Rehabilitation
48333779|NCT01924156|BIOLOGICAL|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
48333780|NCT03590704|DEVICE|Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
48333781|NCT05656287|OTHER|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if \>90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if \>90% medication adherence.
48333782|NCT05656287|OTHER|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
48333783|NCT05656287|OTHER|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
48333784|NCT00503737|BEHAVIORAL|National Colorectal Cancer Roundtable Toolbox|
48333785|NCT04913480|DRUG|Durvalumab|Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
48493131|NCT04328571|DIETARY_SUPPLEMENT|OLE|OLE (Olive leaf extract) + maltodextrin
47975710|NCT02697812|PROCEDURE|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
47975711|NCT05307419|PROCEDURE|Rectal suction biopsy.|Suction biopsy performed
48333786|NCT04913480|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
48333787|NCT00158223|DRUG|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
48333788|NCT00158223|DRUG|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
48333789|NCT00364819|DRUG|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
48493132|NCT03525730|DRUG|Valproic Acid|Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
48493133|NCT03525730|DRUG|Pyrimethamine|Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
47975712|NCT05307419|PROCEDURE|Full-thickness rectal biopsy.|Full-thickness biopsy performed
47975713|NCT02747095|DEVICE|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
47975714|NCT06499155|DEVICE|Use of periacryl in gingival recession closure procedures|Unlike the traditional procedure, periacryl tissue adhesive will be used in both the recipient and donor areas.
47975715|NCT06499155|PROCEDURE|Use of sutures in gingival recession closure procedures|Both recipient and donor areas will be closed with traditional suturing techniques.
47975716|NCT02376088|DRUG|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
47975717|NCT04829903|DRUG|Dulaglutide|Dulaglutide injections
47975718|NCT04829903|DRUG|Liraglutide|Liraglutide injections
47975719|NCT03275662|BEHAVIORAL|Dietary Fiber|
47975720|NCT03275662|BEHAVIORAL|Fermented Foods|
47975721|NCT06074068|BEHAVIORAL|Fathers for Change|18 week individual therapy focused on fathers' emotion regulation, reflective functioning and family communication.
48126513|NCT03577223|OTHER|Whole Eggs|3 whole eggs per day for 4 weeks
48126514|NCT03577223|OTHER|Egg White-Based Egg Substitute|3-egg equivalent of egg white-based egg substitute per day for 4 weeks
48126515|NCT01408394|DRUG|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
48126516|NCT01408394|DRUG|90 mg controlled release form|This is the 90 mg controlled release form
48126517|NCT01408394|DRUG|180 mg controlled release form|This is the 180 mg controlled release capsule
48126518|NCT04484675|DRUG|Milrinone inhalation|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
48333790|NCT03736811|DEVICE|Polyglactin 910 or polydioxanone|Vicryl or PDS II
48126519|NCT04484675|DRUG|Milrinone infusion|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
48126520|NCT01579968|DRUG|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
48126521|NCT00548418|DRUG|Topotecan|
48126522|NCT00548418|DRUG|Cisplatin|
48126523|NCT00548418|DRUG|Bevacizumab|
48333791|NCT03736811|DEVICE|Polyester or polypropylene|Ethibond Excel or prolene
48333792|NCT05441540|DEVICE|Internal Jugular Vein Compression Collar|The current FDA approved internal jugular vein compression collar, marketed as the Q collar, is manufactured by Q30 Innovations Home. It is designed to be worn around the neck of individuals aged 13 and older. It functions by lightly compressing the internal jugular vein's bilaterally, safely increasing intracranial volume and intracranial pressure. The FDA approved neck collar device is made of a thermoplastic elastomer that is specifically fitted to an individual to provide mild internal jugular vein compression. The product was developed and confirmed with ultrasonography to confirm appropriate fit and compression of the vein based on an athlete's neck circumference.
48652601|NCT05761964|BEHAVIORAL|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
48493135|NCT04145583|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
48652602|NCT05761964|BEHAVIORAL|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
48652603|NCT06124924|DRUG|SGLT2 inhibitor|a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
48652604|NCT04458194|OTHER|Standard Care|Standard Care is used as a control condition. Cancer survivors assigned to this arm continue to receive standard care from their medical providers.
48652605|NCT04458194|BEHAVIORAL|YOCAS©® yoga|Yoga for Cancer Survivors, YOCAS©®, intervention is a low to moderate intensity mode of exercise that draws from two basic types of yoga; gentle Hatha and Restorative yoga. The program includes specific physical postures and mindfulness exercises focused on breathing and meditation. Cancer survivors will participate in 8 virtual YOCAS sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)
48652606|NCT06641362|DEVICE|Ultra High Frequency Electrocardiogram (UHF-ECG)|Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.
48652607|NCT06365346|BEHAVIORAL|Dyadic video-assisted gamified group-based music breathing therapy|Dyadic video-assisted gamified music breathing therapy comprising six 75-min weekly sessions delivered in a group size of 6-8 (first sessions: parents only; reminding 5 sessions: parent-child dyads).
48652608|NCT06365346|BEHAVIORAL|Online educational modules|Six weekly educational modules on ADHD and its management via email.
48126524|NCT00038454|DRUG|Hemolink (hemoglobin raffimer IV solution)|
48126525|NCT03490045|OTHER|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
48126526|NCT03490045|OTHER|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
48126527|NCT06282822|OTHER|Transthoracic echocardiography|All enrolled patients underwent noninvasive transthoracic echocardiography.
48126528|NCT03698084|PROCEDURE|venepuncture|sample collection for analysis
48126529|NCT03698084|PROCEDURE|nasopharyngeal swab|sample collection for analysis
48126530|NCT02894879|DEVICE|BreatheMAX®|"Modify chest physical therapy~* oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~* oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
48126531|NCT02894879|OTHER|Routine treatment|"Routine chest physical therapy~* Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~* Coughing with splinting 3 times/set~* Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
48126532|NCT06142357|OTHER|Secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled
48126533|NCT01671449|DRUG|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
47975722|NCT06074068|BEHAVIORAL|Duluth BIP|18 week individually delivered psychoeducation and CBT focused program focused on intimate partner violence
48333793|NCT01236794|BEHAVIORAL|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a \~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (\~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
47975723|NCT02509247|DEVICE|Telemonitoring|Wireless telemonitoring
47975724|NCT02637752|BEHAVIORAL|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
47975725|NCT00850824|BEHAVIORAL|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
47975726|NCT03069547|OTHER|Quadriceps Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc."
48126534|NCT01671449|DRUG|Cisplatin|60 mg/m2/day Day 1
48126535|NCT01671449|DRUG|Oxaliplatin|130 mg/m2/day Day 1
48126536|NCT01391832|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
48126537|NCT01391832|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
48126538|NCT01391832|DEVICE|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
48126539|NCT03813498|BEHAVIORAL|HCV articles|The intervention group receive a targeted short article on HCV from WeChat weekly.
48126540|NCT03813498|BEHAVIORAL|general health articles|The control group receive a general health article with no mention of HCV from WeChat weekly.
48126541|NCT03784170|DEVICE|FemPulse System|Device therapy with the FemPulse System
48126542|NCT01739244|DRUG|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
48126543|NCT01739244|DRUG|Placebo|Ocular topical administration of placebo for 14 consecutive days
48126544|NCT06516705|BEHAVIORAL|Hypoglycemia education|Hypoglycemia education : incleded introduction to blood glucose, hypoglycemia symptoms and treatment (15-15 rule), prevention of hypoglycemia (diet and exercise), and medication treatment.
48493136|NCT04145583|DRUG|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
48652609|NCT05201495|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
48126545|NCT03760354|DRUG|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
48126546|NCT03760354|OTHER|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
48652610|NCT03057340|BIOLOGICAL|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
48652611|NCT05169957|DRUG|Ipilimumab|Ipilimumab administered IV over 85-100 minutes at 3 mg/kg (combined with nivolumab administered IV over 30-60 minutes at 1 mg/kg) every 3 weeks for a total of 4 doses or until progression or unacceptable toxicity.
48652612|NCT05169957|DRUG|Nivolumab|Nivolumab administered IV over 30-60 minutes at 1 mg/kg (combined with ipilimumab administered IV over 85-100 minutes at 3 mg/kg) every 3 weeks for a total of 4 doses of the combination therapy or until progression or unacceptable toxicity. Subjects may receive maintenance dosing of nivolumab alone administered IV over 30-60 minutes at 240 mg every 2 weeks or 480 mg every 4 weeks for a maximum of 52 weeks or until progression or unacceptable toxicity.
48652613|NCT05169957|PROCEDURE|Stereotactic Body Radiation Therapy|24-45 Gy delivered in three fractions to up to 4 liver metastases
48126547|NCT01956552|OTHER|biopsy or cytopuncture|
48126548|NCT00933257|DRUG|LACTIC ACID(ND)|Treatment duration 5 weeks
48126549|NCT05325931|DEVICE|kalifilcon A Daily Disposable Multifocal|kalifilcon A Daily Disposable Multifocal low add and high
48126550|NCT05325931|DEVICE|samfilcon A for Presbyopia|Ultra for Presbyopia Low and High Add Contact Lenses
48333794|NCT02648243|BEHAVIORAL|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
48333795|NCT03432611|OTHER|Self-care information feature|The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
48333796|NCT03432611|OTHER|Self-acupressure feature|The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
48333797|NCT04202978|DRUG|Camrelizumab|Camrelizumab ：200mg intravenous injection d1 q3w
48333798|NCT04202978|DRUG|Apatinib Mesylate|Apatinib：250mg/d P.O ,qd ,3weeks
48333799|NCT04202978|DRUG|Capecitabine|capecitabine:850mg/m2 P.O ,bid ,d1-d14
48333800|NCT04202978|DRUG|Oxaliplatin|oxaliplatin:130mg/m2 intravenous injection d1 q3w
48333801|NCT04202978|RADIATION|radiofrequency ablation|radiofrequency ablation:between first cycle and second cycle percutaneous
48333802|NCT06413368|DRUG|Maralixibat 9.5 MG/ML [Livmarli]|Within Study subjects receiving 2 weeks of treatment with Maralixibat 9.5 MG/ML \[Livmarli\] and compare to baseline treatment.
48333803|NCT01902537|DRUG|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
48333804|NCT03902041|DRUG|Eltrombopag|The patients will receive Eltrombopag treatment after transplantation
48333805|NCT03288740|DRUG|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
48333806|NCT03288740|DRUG|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
48493137|NCT00365937|BIOLOGICAL|Immunological peptides and immunological adjuvants|
48493138|NCT00365937|BIOLOGICAL|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
48333807|NCT03288740|DRUG|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
48333808|NCT03288740|DRUG|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
48652614|NCT06452511|DRUG|Metformin|In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.
48652615|NCT06452511|DRUG|pep2dia|In the Pep2dia arm of this study, 50 overweight women diagnosed with polycystic ovary syndrome (PCOS) and experiencing infertility will receive a combination treatment of Letrozole and Pep2dia. Letrozole, utilized to induce ovulation, will be administered according to a specified dosage regimen, along with Pep2dia, a peptide-based therapy tailored to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and a final evaluation of ovulation rates and pregnancy outcomes at the conclusion of the study period. This arm seeks to ascertain the effectiveness of Pep2dia as an adjunct to Letrozole in enhancing ovulation induction and pregnancy rates among overweight women with PCOS.
48652616|NCT06674980|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
48126551|NCT06518915|DEVICE|baroloop system|Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
48126552|NCT03516942|OTHER|Quality-of-Life Assessment|Ancillary studies
48126553|NCT03516942|OTHER|Questionnaire Administration|Ancillary studies
48126554|NCT00984048|OTHER|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
48126555|NCT01951170|DRUG|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
48126556|NCT02034916|DRUG|talazoparib|
48126557|NCT06237816|OTHER|Patient Education Intervention|Multimedia Educational Videos
48126558|NCT06237816|OTHER|Provider Education Intervention|Provider workshops via zoom
48126559|NCT00504023|DRUG|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
48126560|NCT00504023|PROCEDURE|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
48126561|NCT00504023|PROCEDURE|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
48126562|NCT05294393|DRUG|Placebo Comparator: N/S 0.9%|12 ml N/S 0.9% at the end of surgery
48126563|NCT05294393|DRUG|Ropivacaine 10%|12 ml solution of 100mg ropivacaine at the end of surgery
48126564|NCT05294393|DRUG|Ropivacaine 10% plus magnesium sulphate 10mg/kg|12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
48126565|NCT03945123|DIETARY_SUPPLEMENT|Red ginseng|Red ginseng tablet 120g
48126566|NCT01087359|DRUG|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
48126567|NCT05481905|DRUG|ENX-101|Adjunctive treatment to current antiseizure medication
48333809|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
48333810|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
48333811|NCT01192711|DEVICE|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
48333812|NCT03457311|DRUG|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
48333813|NCT03962946|OTHER|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient's utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
48333814|NCT03962946|OTHER|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
48493139|NCT00365937|BIOLOGICAL|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
48652617|NCT06674980|OTHER|AM/Single|Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
48126568|NCT04741113|OTHER|An online 15-minute educational module|"An online 15-minute educational module with four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz.~The module will be based on relevant literature and expert opinion"
48126569|NCT02176538|DRUG|Product 0405|Product 0405 will be administered topically twice daily for 28 days
48493140|NCT00365937|BIOLOGICAL|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
48126570|NCT02176538|DRUG|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
48126571|NCT01577225|DEVICE|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
48126572|NCT01577225|DEVICE|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
48126573|NCT04705675|BEHAVIORAL|Breastfeeding Education|The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
48126574|NCT05496842|BEHAVIORAL|Multimodal pulmonary rehabilitation|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
48126575|NCT00199082|DRUG|Adriamycin|
48126576|NCT00199082|DRUG|Cyclophosphamide|
48126577|NCT00199082|DRUG|Cytarabine|
48126578|NCT00199082|DRUG|Dexamethasone/Prednisolone|
48126579|NCT00199082|DRUG|VP16|
48126580|NCT00199082|DRUG|Ifosfamide|
48126581|NCT00199082|DRUG|Methotrexate|
48126582|NCT00199082|DRUG|G-CSF|
48126583|NCT00199082|DRUG|Rituximab|
48126584|NCT00199082|DRUG|Vincristine/Vindesine|
48126585|NCT00199082|PROCEDURE|Irradiation (in specific conditions)|
48126586|NCT02901197|BEHAVIORAL|Education and Reminder Posters|See arm description
48126587|NCT02901197|OTHER|Policy Change|See arm description
48493141|NCT01714349|PROCEDURE|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
48333815|NCT03792802|PROCEDURE|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
48333816|NCT03379428|DRUG|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
48333817|NCT03379428|DRUG|Ibrutinib 560 mg|560 mg by mouth daily
48333818|NCT03379428|DRUG|Ibrutinib 840 mg|840 mg by mouth daily
48333819|NCT03379428|DRUG|Ibrutinib 420 mg|420 mg by mouth daily
48333820|NCT03618602|DRUG|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
48333821|NCT04590560|DIAGNOSTIC_TEST|screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice|women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
48333822|NCT02312115|DRUG|Furosemide|Diuretic
48333823|NCT02312115|DRUG|Placebo|Saline
48493142|NCT04040153|BEHAVIORAL|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
48493143|NCT05033574|DIAGNOSTIC_TEST|Biochemical study of hormone levels|Biochemical study of the level of follicle-stimulating hormone, luteinizing hormone, estradiol, total testosterone, prolactin, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, cortisol, insulin, thyroid-stimulating hormone, tetraiodothyronine, thyr
48493144|NCT05033574|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
48652618|NCT06674980|OTHER|AM/Double|Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
48333824|NCT03848676|DIAGNOSTIC_TEST|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
48333825|NCT03768895|RADIATION|MRI|"The technique used was coronal and axial T1 and T2\*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2\*WI."
48333826|NCT00944216|DRUG|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
48333827|NCT00536848|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
48333828|NCT00536848|DIETARY_SUPPLEMENT|Placebo|
48333829|NCT00536848|DRUG|Metronidazole|
48333830|NCT04355494|BIOLOGICAL|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
48333831|NCT04928391|DRUG|Dexmedetomidine|A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
48333832|NCT04928391|DRUG|Nalbuphine|A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
48333833|NCT04928391|OTHER|0.9% saline|Same volume of saline placebo IV at the end of surgery
48333834|NCT00260429|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
48333835|NCT02147509|DRUG|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
48652619|NCT00859885|DRUG|Antithrombotic treatment|antiplatelets, anticoagulants
48652620|NCT00859885|DEVICE|percutaneous device closure of PFO|umbrella device for PFO closure
48652621|NCT04127110|DRUG|Lorlatinib|Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
48652622|NCT05246839|BEHAVIORAL|Brief Video|Videos about colorectal cancer screening.
48652623|NCT05246839|BEHAVIORAL|Brief Video Plus|Videos about colorectal cancer screening and modalities.
48333836|NCT02147509|DRUG|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
48333837|NCT02147509|OTHER|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
48333838|NCT02147509|DRUG|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
48126588|NCT03358446|OTHER|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
48126589|NCT03358446|OTHER|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
48126590|NCT00056966|DRUG|ANTI-CD45|400ug/kg Day-5 through Day-2
47975727|NCT03069547|OTHER|Hip Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc."
48126591|NCT00056966|DRUG|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
47975728|NCT04235478|DRUG|Combination Product: triamcinolone and saline|a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
48126592|NCT00056966|DRUG|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
47975729|NCT04847505|DIAGNOSTIC_TEST|68Ga-DOTA-TATE|The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
47975730|NCT05138497|OTHER|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
48126593|NCT00056966|DRUG|Fludarabine|Day-8 through Day-5 30 mg/m2
48126594|NCT00056966|RADIATION|Total Body Irradiation|Day-1 single dose 450 cGy
48126595|NCT00056966|PROCEDURE|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
48126596|NCT00761553|OTHER|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
48126597|NCT00761553|DIETARY_SUPPLEMENT|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
48333839|NCT05193968|OTHER|Sympathoexcitatory stressors|Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
47975731|NCT02837016|DEVICE|Wearable biofeedback|
47975732|NCT02837016|BEHAVIORAL|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
47975733|NCT03053323|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
47975734|NCT00642460|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (patients\>=30kg) or 12mg/kg (patients \<30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
47975735|NCT00642460|DRUG|Placebo|iv every 2 weeks for 12 weeks
47975736|NCT00642460|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
47975737|NCT00642460|DRUG|methotrexate|as prescribed
47975738|NCT00642460|DRUG|corticosteroids|orally, as prescribed
47975739|NCT04150913|DRUG|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
47975740|NCT04150913|DRUG|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
47975741|NCT04021940|PROCEDURE|ULOD|ULOD
47975742|NCT04625309|OTHER|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
48126598|NCT00091650|DRUG|Olanzapine|
48126599|NCT00091650|DRUG|placebo|
48126600|NCT03752034|OTHER|Muscle Fiber Fragments (MFFs)|During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.
48126601|NCT00329264|DRUG|Quetiapine fumarate|
48126602|NCT05862246|OTHER|Clinical examination|No intervention, only clinical examination
48126603|NCT00936182|DRUG|Fluconazole|Fluconazole daily for 30 days
48126604|NCT00990808|DRUG|anacetrapib|\[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
48126605|NCT00990808|DRUG|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
48126606|NCT00990808|DRUG|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
48126607|NCT00990808|DRUG|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
48126608|NCT04093895|DRUG|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
48126609|NCT04080141|DIAGNOSTIC_TEST|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
48126610|NCT04080141|PROCEDURE|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
48126611|NCT01388361|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
48126612|NCT01388361|DRUG|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
48333840|NCT05193968|DRUG|Sodium Nitroprusside|Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
48333841|NCT05193968|DRUG|Acetylcholine|Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
48333842|NCT05193968|DRUG|Terbutaline|Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
48493145|NCT05033574|RADIATION|Radiography of the hands|Determination of bone age using radiography of the hands
48493146|NCT05033574|BEHAVIORAL|Consultation of a medical psychologist|Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
48493147|NCT00134043|DRUG|vorinostat|Given orally
47975743|NCT03229850|DRUG|Insulin lispro|Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
47975744|NCT04381403|OTHER|Bio-descaling D-Tart toothpaste|Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
47975745|NCT04381403|OTHER|Crest® toothpaste|Patients received Crest toothpaste; Anti-tartar toothpaste
47975746|NCT03234686|DRUG|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
47975747|NCT03234686|DRUG|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
47975748|NCT00804791|OTHER|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
47975749|NCT00804791|OTHER|Unisol 4 Saline Solution|saline solution for irrigating the cornea
47975750|NCT05112432|DEVICE|Cognitive and Social Cognitive Training|"The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. Exercises continuously adjust difficulty level to user performance to maintain an approximately 80% current performance rate. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory."
47975751|NCT05112432|BEHAVIORAL|Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App|The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.
47975752|NCT05112432|OTHER|Early Psychosis Coordinated Specialty Care|Participants will continue to receive treatment as usual at their early psychosis coordinated specialty care clinics. These clinics may follow the NAVIGATE model, as an example.
47975753|NCT06040372|DRUG|LB64640|The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
47975754|NCT06040372|DRUG|Placebo|Placebo is provided as a matching placebo
48493148|NCT01138865|DEVICE|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
47975755|NCT03217487|PROCEDURE|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
47975756|NCT03217487|PROCEDURE|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
47975757|NCT03217487|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
47975758|NCT03217487|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
48333843|NCT05193968|DRUG|Norepinephrine|Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
48333844|NCT04787211|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
48126613|NCT01388361|DRUG|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
48126614|NCT03122158|DRUG|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
48126615|NCT02512250|OTHER|Registry|
48126616|NCT03108703|RADIATION|SBRT|35-40 Gy delivered in 5 fractions
48126617|NCT01733862|OTHER|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
48126618|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
48126619|NCT01222039|OTHER|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
48126620|NCT01095796|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
48126621|NCT01095796|DRUG|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
48126622|NCT01095796|DRUG|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
48126623|NCT01095796|DRUG|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
48126624|NCT02219568|PROCEDURE|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
48126625|NCT02219568|DEVICE|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
48126626|NCT00051571|DRUG|SGN-15|
48126627|NCT00051571|DRUG|Docetaxel|
48126628|NCT03142672|PROCEDURE|pulpotomy|vital endodontic procedure
48126629|NCT03142672|PROCEDURE|tooth filling|tooth filling
48126630|NCT04542733|DRUG|Everolimus|Everolimus will be given with tacrolimus.
48126631|NCT04542733|DRUG|reduced dose tacrolimus|Reduced dose tacrolimus will be given with or without leflunomide
48126632|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
48126633|NCT01472510|DRUG|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
48126634|NCT04702568|DRUG|BCX9930|BCX9930 for oral administration
48126635|NCT02432950|DIETARY_SUPPLEMENT|Dietary Intervention|Participate in the PNP
48126636|NCT02432950|OTHER|Educational Intervention|Participate in the PNP
48126637|NCT02432950|OTHER|Laboratory Biomarker Analysis|Correlative studies
48493149|NCT01138865|DEVICE|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
48493150|NCT02551666|OTHER|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
48126638|NCT02432950|OTHER|Quality-of-Life Assessment|Ancillary studies
48126639|NCT00137722|BEHAVIORAL|Education of providers and their staff|
48126640|NCT00137722|BEHAVIORAL|Case management|
48126641|NCT00137722|BEHAVIORAL|Payment for desired behaviors|
48333845|NCT04787211|DRUG|Placebo|Placebo given by intravenous administration
48333846|NCT06174961|DRUG|Unfractionated heparin|15,000 units of unfractionated heparin administered in the thigh
48333847|NCT06174961|BEHAVIORAL|Double-legged cycle ergometer exercise|One hour of double-leg cycle ergometer exercise
48126642|NCT05783791|DIAGNOSTIC_TEST|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
48493151|NCT02551666|OTHER|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
48493152|NCT00232271|DRUG|Clexane|
48126643|NCT00432016|DRUG|zidovudine|
48126644|NCT00432016|DRUG|amdoxovir|
48126645|NCT00432016|PROCEDURE|pharmacokinetic sampling|
48126646|NCT04092205|DRUG|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
48126647|NCT06140732|DRUG|camrelizumab and apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
48126648|NCT00274469|DRUG|fulvestrant|500 mg intramuscular injection
48126649|NCT00274469|DRUG|anastrozole|1 mg oral tablet
48126650|NCT03609008|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
48126651|NCT03609008|DRUG|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
48126652|NCT03785405|DRUG|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules \[12.5 mg (4 granules), 31.25 mg (10 granules), in capsules\] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
48126653|NCT02446340|DRUG|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
48126654|NCT02446340|DRUG|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
48126655|NCT00257049|DRUG|levofloxacin|
48126656|NCT01646450|DRUG|Icotinib|Icotinib: 125mg, oral administration, three times per day.
48126657|NCT03450434|DRUG|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
48126658|NCT03450434|DRUG|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
48493153|NCT01851018|RADIATION|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
48493154|NCT01851018|RADIATION|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
48493155|NCT01787539|DRUG|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
47975759|NCT05078008|PROCEDURE|Physiotherapy modalities|parafango in the lumbar region 20min/day; High frequency Transcutaneous Electrical Nerve Stimulation (TENS), 100 Hz, 0,04-0,2mseg, 20 min/day; lumbar flexibility self-exercise plan
47975760|NCT05078008|PROCEDURE|Balneotherapy modalities|Immersion in a thermal pool with 15 minutes of automatic hydromassage and 15 minutes of spine flexibility exercises; thermal steam treatment to spinal column; hydromassage bath with Vichy thermal water
47975761|NCT06033794|DEVICE|Fluorescence laparoscopic system|Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
47975762|NCT06158594|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
47975763|NCT02823301|BEHAVIORAL|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
47975764|NCT00573469|DRUG|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
47975765|NCT00573469|DRUG|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
47975766|NCT00573469|DRUG|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
47975767|NCT05388214|BEHAVIORAL|E-Co|The E-Co intervention will integrate active components of a mobile health exercise intervention (GO-EXCAP) into a cognitive rehabilitation intervention (MAAT-G).
47975768|NCT00546637|DRUG|Fesoterodine|Fesoterodine 4mg or 8mg
47975769|NCT00546637|DRUG|Placebo|Placebo
47975770|NCT03729505|PROCEDURE|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
47975771|NCT03729505|PROCEDURE|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
47975772|NCT05557799|RADIATION|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
48126659|NCT04677192|COMBINATION_PRODUCT|Microwave Ablation combination with chemotherapy|Microwave Ablation combination with chemotherapy. Maximum tumor diameter ≤ 3cm, single microwave needle, maximum tumor diameter\> 3cm, double ablation needle, the ablation range completely covers the lesion ≥ 0.5cm in order to obtain a satisfactory ablation margin. After the operation, contrast ultrasound is performed again to confirm the ablation edge. Enhanced MRI or CT to evaluate the ablation effect 4 weeks after surgery. Selection of chemotherapy regimen refers to the 2020 NCCN Guidelines for Pancreatic Cancer. First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen: If first-line chemotherapy based on gemcitabine, 5-FU-based regimen for second-line, If 5-FU-based regimen for first-line, gemcitabine for second-line.
48333848|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
48333849|NCT06174961|BEHAVIORAL|Single-legged cycle ergometer exercise, with unfractionated heparin injection in the non-exercising leg|One hour of single-leg cycle ergometer exercise, after unfractionated heparin injection in the ipsilateral leg
48333850|NCT06174961|BEHAVIORAL|No exercise|No exercise
48333851|NCT04488081|DRUG|Remdesivir|Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
47975773|NCT05557799|RADIATION|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
48333852|NCT04488081|DRUG|Imatinib Mesylate|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
48333853|NCT04488081|DRUG|Dexamethasone|6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
48652624|NCT06673654|DRUG|Ruxolitinib Topical Cream 1.5%|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
48652625|NCT06673654|DRUG|OPZELURA (Ruxolitinib) Cream|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
48652626|NCT06673654|DRUG|Placebo|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
47975774|NCT06140927|DRUG|Ketamine|Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
47975775|NCT05077722|DEVICE|Garmin|A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
48333854|NCT04488081|DRUG|Cenicriviroc|Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
48333855|NCT04488081|DRUG|Icatibant|Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
47975776|NCT00203125|DRUG|rasagiline mesylate|0.5 or 1 mg oral, once-daily
47975777|NCT00203125|OTHER|tyramine|50 mg once daily
48333856|NCT04488081|DRUG|Apremilast|oral, 30 mg bid × 14 days.
48333857|NCT04488081|BIOLOGICAL|dornase alfa|"For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
48493156|NCT02691793|DRUG|Sunitinib|sunitinib 37.5mg QD
48652627|NCT03856918|PROCEDURE|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
47975778|NCT03326765|OTHER|Questionnaires|"* Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary"
48126660|NCT02168400|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
48126661|NCT05865561|OTHER|VOC sampling|"* Systematic sampling during the day: Samples every 3 hours (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period.~* Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time.~The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it."
48126662|NCT01495624|OTHER|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
48126663|NCT01495624|OTHER|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
48126664|NCT00093015|DRUG|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
48126665|NCT00093015|DRUG|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
48126666|NCT05591872|DRUG|LD+I+TRB|Same as in the arm description
48126667|NCT05239156|DEVICE|Janesse|"Device: Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.~The subjects will receive at baseline the first investigational medical device by the Investigator in accordance with the clinical investigation plan."
48126668|NCT00107159|BIOLOGICAL|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
48126669|NCT06102616|DIAGNOSTIC_TEST|measure Osteocalcin level|in gingival crevicular fluid before and during orthodontic tooth movement
48126670|NCT03220100|OTHER|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
47975779|NCT03326765|PROCEDURE|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
47975780|NCT03326765|PROCEDURE|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
47975781|NCT03326765|PROCEDURE|Actigraphy|type of sleep study based on bracelet around the wrist
47975782|NCT02374801|DEVICE|"SonR automatic optimization feature turned ON (AV+VV)."|
47975783|NCT01525537|DRUG|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
47975784|NCT01525537|DRUG|sufentanil|sufentanil was given at standard practise
47975785|NCT04346602|OTHER|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
47975786|NCT00070174|DRUG|asparaginase|
47975787|NCT00070174|DRUG|busulfan|
47975788|NCT00070174|DRUG|cyclophosphamide|
48126671|NCT05736133|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management or presented with group exercise options. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations such as comorbidity or frailty. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral. All individuals may have their medications reviewed by a physician if deemed appropriate by the PT or requested by the participant."
48333858|NCT04488081|DRUG|Celecoxib|Oral: 400 mg BID for 7 days.
48493157|NCT01339663|DRUG|cyclophosphamide|Given IV
48493158|NCT01339663|BIOLOGICAL|aldesleukin|Given SC
48493159|NCT01339663|BIOLOGICAL|autologous tumor cell vaccine|Receive T-APC via IV
48493160|NCT01339663|OTHER|laboratory biomarker analysis|Correlative studies
48493161|NCT01339663|OTHER|immunologic technique|Correlative studies
48493162|NCT01339663|OTHER|immunohistochemistry staining method|Correlative studies
48493163|NCT01339663|GENETIC|polymerase chain reaction|Correlative studies
47975789|NCT00070174|DRUG|cyclosporine|
47975790|NCT00070174|DRUG|cytarabine|
47975791|NCT00070174|DRUG|daunorubicin hydrochloride|
47975792|NCT00070174|DRUG|etoposide|
47975793|NCT00070174|DRUG|gemtuzumab ozogamicin|
47975794|NCT00070174|DRUG|methotrexate|
47975795|NCT00070174|DRUG|mitoxantrone hydrochloride|
47975796|NCT00070174|PROCEDURE|allogeneic bone marrow transplantation|
47975797|NCT03501316|DEVICE|Hand Instrumentation Treatment|Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
47975798|NCT03501316|DEVICE|Ultrasonic Instrumentation Treatment|Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
47975799|NCT00023764|DRUG|bortezomib|Given IV
48126672|NCT05736133|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
48126673|NCT03513367|OTHER|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
48126674|NCT03513367|OTHER|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
48126675|NCT01730352|DRUG|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
48126676|NCT01765231|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
48126677|NCT01765231|DRUG|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
48126678|NCT04207424|PROCEDURE|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
48126679|NCT03778515|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
48126680|NCT06009458|DEVICE|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
48126681|NCT04962750|DEVICE|Low level laser therapy|Low level laser therapy from suitable machine
47975800|NCT02141243|PROCEDURE|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
47975801|NCT02141243|PROCEDURE|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
47975802|NCT02141243|PROCEDURE|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
47975803|NCT05739305|OTHER|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
47975804|NCT00090480|BIOLOGICAL|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
48126682|NCT04962750|OTHER|Sham device|The device wasn't working
48333859|NCT04488081|DRUG|Famotidine|Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
48333860|NCT04488081|BIOLOGICAL|IC14|intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
48126683|NCT01094184|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
48126684|NCT01094184|DRUG|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
48126685|NCT01094184|DRUG|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
48126686|NCT03272399|OTHER|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
48126687|NCT02876016|DEVICE|functional MRI|locate the cerebral bases in functional imaging
48126688|NCT00909324|DRUG|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
48126689|NCT00909324|DRUG|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
48126690|NCT03221959|DEVICE|Medical Device Vittamed 205|Intracranial pressure measurement
48333861|NCT04488081|DRUG|Aviptadil|Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
48333862|NCT04488081|BIOLOGICAL|narsoplimab|Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
48493164|NCT01339663|BIOLOGICAL|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
48652628|NCT03856918|PROCEDURE|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
48126691|NCT02125110|DEVICE|MRI|
48126692|NCT02125110|OTHER|neuropsychological assessment|
48126693|NCT00917202|DRUG|Methylenblue|
48126694|NCT06522178|OTHER|Patient' ages|Patients were divided into two groups according to their ages.
48126695|NCT00494949|DRUG|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
48126696|NCT00494949|DRUG|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
48126697|NCT02420431|BEHAVIORAL|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
48126698|NCT02420431|BEHAVIORAL|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
48126699|NCT05618132|DIAGNOSTIC_TEST|Acetylcholine rechallenge|"STEP 1 consists of verapamil 1mg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is given (step 2). If verapamil suppresses spasm, ACH rechallenge (ACHR) is performed after 3 minutes.~In STEP 2, patients with persistent spasm after verapamil or with spasm after ACHR receive NTG 200µg IC. Angiography after 60 seconds, if spasm persists, NTG 200µg IC is delivered again. If refractory spasm occurs, atropine 1mg IV is given. Coronary spasm is considered suppressed once ACHR can no longer provoke spasm. NTG 200µg IC is given as final drug regardless of spasm.~ACHR consists of ACH 100 or 200µg IC depending on the dose that previously provoked the coronary artery spasm (both microvascular and epicardial spasm)."
48333863|NCT04488081|DRUG|Cyproheptadine|4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
48333864|NCT04488081|DRUG|Cyclosporine|Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
48333865|NCT03094611|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
48333866|NCT00518401|BIOLOGICAL|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
48333867|NCT00881790|OTHER|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
48126700|NCT01792934|DRUG|XELOX regimen according to standard procedures|
48126701|NCT01792934|DRUG|FOLFOX regimen according to standard procedures|
48126702|NCT01792934|PROCEDURE|Surgery|
48126703|NCT01792934|OTHER|radiofrequency ablation (RFA)|
48126704|NCT01792934|OTHER|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
48126705|NCT01792934|RADIATION|stereotactic body radiation therapy (SBRT)|
48126706|NCT01792934|DRUG|Bevacizumab|may be added to both regimens according to standard procedures
48126707|NCT01792934|PROCEDURE|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
48126708|NCT05592028|DEVICE|transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy|XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
48126709|NCT00684242|DRUG|Lenalidomide|10 mg by mouth daily
48126710|NCT06545565|DRUG|sodium acetate group will receive sodium acetate in the neonatal PN.|This group will receive sterile sodium acetate daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
48333868|NCT04451317|OTHER|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
48333869|NCT04042038|BEHAVIORAL|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
48493165|NCT06039384|DRUG|INCB099280|Administered as specified in the treatment arm description
48493166|NCT06039384|DRUG|adagrasib|Administered as specified in the treatment arm description
48493167|NCT05129436|DRUG|Vaxigrip Tetra 2020/2021|vaccine against seasonal influenza
48493168|NCT00074776|DRUG|Lithium|Participants will receive lithium.
47975805|NCT04810312|OTHER|Combined exercise and nutrition intervention|Back extensor strengthening exercise and nutritional supplementation for 12 weeks
47975806|NCT02677467|BIOLOGICAL|Blood-pressure variability|Day to Night Blood pressure variability
48126711|NCT06545565|DRUG|sodium chloride group will receive sodium chloride in the neonatal PN.|This group will receive sterile sodium chloride daily in the neonatal PN for the duration the patient will receive parenteral nutrition, a maximum of 28 days of life.
47975807|NCT05228262|OTHER|Cohort follow-up|"* Inclusion medical consultation,~* Inclusion clinical examination,~* Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping,~* Calculation of the Kauppila score on profile spine radiographs by the rheumatologist,~* Cardiovascular investigations (FMD, Flow-Mediated Dilation); measurement of digital volume increase (RHI, Reactive hyperhemia index); measurement of microcirculatory perfusion of the skin at the hand (FLD, Flow Laser Doppler) ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV),~* Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength,~* Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire."
47975808|NCT04232124|BEHAVIORAL|Hypertension Management Model|"1. Blood Pressure readings by barbers~2. Clinical Pharmacist evaluation and counseling~3. Blood pressure measurement~4. Point of care basic metabolic panel measurement"
47975809|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked.
47975810|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized.
47975811|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked.
47975812|NCT04693884|DRUG|Cannabis|Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized.
47975813|NCT00064194|DIETARY_SUPPLEMENT|selenium|
47975814|NCT00064194|DIETARY_SUPPLEMENT|soy protein isolate|
47975815|NCT00064194|DIETARY_SUPPLEMENT|vitamin E|
47975816|NCT01958008|DRUG|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
47975817|NCT01958008|DRUG|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
47975818|NCT01958008|DRUG|BI 113608 high dose b.i.d.|Film-coated tablet
47975819|NCT01958008|DRUG|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
47975820|NCT01958008|DRUG|BI 113608 low dose b.i.d.|Film-coated tablet
47975821|NCT01958008|DRUG|BI 113608 medium dose b.i.d.|Film-coated tablet
47975822|NCT02292602|BEHAVIORAL|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
48126712|NCT00164216|DRUG|mefloquine plus artesunate|
48126713|NCT03877198|DEVICE|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
48126714|NCT03877198|DEVICE|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
48126715|NCT00790894|DRUG|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
48126716|NCT00790894|DRUG|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
48126717|NCT03563690|OTHER|treatment1|"1. Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~2. operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
48493169|NCT00074776|DRUG|Lamotrigine|Participants will receive lamotrigine.
48652629|NCT03856918|PROCEDURE|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
48652630|NCT02970058|OTHER|Platelet-rich Plasma|The active group will receive Platelet-rich Plasma following spinal injection
48652631|NCT02970058|OTHER|Control|The control group will receive saline as a placebo
48652632|NCT06633549|OTHER|Home Accidents Prevention Training|Mothers in the education group who participated in the study were informed about the research and their written consent was obtained. Mothers filled out the 'Information Form' then completed the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6 Years'. Mothers were helped when filling out the form and their questions were answered. The training program was organized so that there would be a maximum of 5 mothers in each group. The trainings were conducted face-to-face with a PowerPoint presentation and lasted about 40-45 minutes. Question-answer and discussion methods were used during the training. After the training, the mothers were asked to fill out the same scale again one month later. One month after the training, the mothers were interviewed face-to-face and the scale was filled in again and the changes they made at home were recorded.
48126718|NCT03563690|OTHER|treatment2|"1. Acupoints：Needling points are the same to the above group~2. operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
47975823|NCT02768012|BEHAVIORAL|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
47975824|NCT04238598|PROCEDURE|Pulse Radiofrequency|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.
48126719|NCT03563690|OTHER|treatment3|"1. Acupoints：treating points are the same to the above group~2. Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
48126720|NCT03563690|OTHER|treatment4|"1. Acupoints：Needling points are the same to the above group~2. Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
48126721|NCT03563690|OTHER|treatment5|"1. points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~2. Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 \* 25mm single-use needle with the depth of 1-2mm."
48126722|NCT03563690|DRUG|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
48652633|NCT06633549|OTHER|Control Group|Mothers in the control group were informed about the research and the 'Informed Consent Form' was signed. The mothers filled out the 'Information Form' and this process took about 15-20 minutes. Mothers were helped when filling out the form and their questions were answered. In addition, mothers were asked to complete the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6' by introducing. A month later, they were informed that they had to fill out this scale again. A month later, the mothers were interviewed face-to-face and allowed to fill out the scale again. After the last test, the mothers in the control group were given 'Home Accidents and Prevention Training for Children in the 0-6 Age Group' and the output of the training presentation was distributed.
47975825|NCT04238598|PROCEDURE|Standard of Care Intra- Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.
47975826|NCT04238598|PROCEDURE|Placebo Intra-Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.
47975827|NCT02941978|BEHAVIORAL|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
47975828|NCT02941978|BEHAVIORAL|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
48126723|NCT05360901|BEHAVIORAL|IntelliCare with automated motivational messaging|Digital mental health intervention with automated motivational messaging
48126724|NCT06480825|OTHER|Performance of ultrasonographic scan|Ultra-high frequency ultrasonographic scan of gingival tissues
48126725|NCT00976495|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
48126726|NCT00976495|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
48126727|NCT00976495|DRUG|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
48126728|NCT00077493|DRUG|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
48126729|NCT00077493|PROCEDURE|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
48126730|NCT00077493|PROCEDURE|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
48126731|NCT00077493|PROCEDURE|monoclonal antibody therapy|administered intravenously over 30 minutes.
48126732|NCT05519670|DRUG|Niraparib Oral Product|Niraparib + capecitabine treatment
48652634|NCT03673930|DIETARY_SUPPLEMENT|Zanthozylum armatum|Zanthozylum armatum MCT oil extract
48126733|NCT06152640|DEVICE|Deep transcranial magnetic stimulation|"Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling is used to obtain a greater depth of stimulation, up to about 6 cm below the cortex.~dTMS intervention: The intervention targets are at the left and right ACC, once per day, for 28 days. A total of 28 treatments are given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses."
47975829|NCT02116907|DRUG|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
47975830|NCT02740777|BIOLOGICAL|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
47975831|NCT01417273|DIETARY_SUPPLEMENT|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
47975832|NCT01417273|DRUG|Drug: placebo|1 cap placebo/day for 12 month
47975833|NCT02425657|BEHAVIORAL|Training of junior doctors|Training program
48493170|NCT03205930|BIOLOGICAL|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
48493171|NCT03083236|OTHER|Standard PBI|Standard Parent Based Intervention (PBI)
48126734|NCT06152640|DEVICE|Sham deep transcranial magnetic stimulation|"Neuronavigation: The sham coil is positioned 4 cm in front of the scalp point and foot motor cortex, corresponding to the ACC.~Sham dTMS intervention: The intervention targets are at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), once per day, for 28 days. A total of 28 treatments are given."
48126735|NCT06152640|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
48126736|NCT04719858|BEHAVIORAL|#LIFEGOALS|"Digital health behaviour change intervention including:~1. self-regulation component with Fitbit: goal setting, monitoring, feedback;~2. narrative component: every week participants receive a new episode (2-5 minutes) of a youth series modeling the target behaviours;~3. chatbot component: automated virtual coach that will send encouraging messages and give an automated answer to user questions.~Participants install the #LIFEGOALS app on their own mobile phone and are asked to use the app during 12 consecutive weeks. Three times per week a notification will be sent to encourage engagement with the intervention."
48333870|NCT01886885|BEHAVIORAL|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
48652635|NCT03673930|DIETARY_SUPPLEMENT|Placebo|sunflower oil matched for appearance
48652636|NCT04537156|BIOLOGICAL|Nonavalent HPV vaccine|Nonavalent HPV vaccine (270μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48652637|NCT04537156|BIOLOGICAL|Bivalent HPV vaccine|Bivalent HPV vaccine (60μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48652638|NCT03896568|BIOLOGICAL|Oncolytic Adenovirus Ad5-DNX-2401|Given IA
48652639|NCT03896568|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
47975834|NCT03125343|PROCEDURE|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~* PET-CT is optional, but can be performed at inclusion~* Pelvic MRI including diffusion weighted imaging according to appendix C.~* Clinical examination~* Endoscopy (flexible sigmoidoskopy) with photodocumentation~* CEA~After two years the patients will be followed every six month with:~* Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~* Clinical examination~* Endoscopy with photodocumentation~* CEA"
47975835|NCT03125343|PROCEDURE|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
47975836|NCT03125343|DEVICE|MRI|
47975837|NCT05854082|DRUG|Lidocaine 2% Polyampoule|Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
47975838|NCT02885753|DRUG|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
47975839|NCT02885753|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
47975840|NCT02885753|DRUG|Folinic acid|400 mg/m² in intravenous
47975841|NCT02885753|DRUG|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
47975842|NCT02885753|DRUG|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
47975843|NCT02885753|DRUG|Bevacizumab|5 mg/kg at each cycle in intravenous
47975844|NCT02885753|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
47975845|NCT02885753|DRUG|Irinotecan|150 mg/m² intravenous
47975846|NCT05699239|DRUG|TS-172 10mg bid|oral administration of TS-172 10 mg bid
47975847|NCT05699239|DRUG|TS-172 30mg bid|oral administration of TS-172 30 mg bid
47975848|NCT05699239|DRUG|TS-172 60mg bid|oral administration of TS-172 60 mg bid
47975849|NCT05699239|DRUG|TS-172 20mg tid|oral administration of TS-172 20 mg tid
47975850|NCT05699239|DRUG|Placebo|oral administration of placebo
47975851|NCT06179797|DEVICE|remote ischemic conditioning|suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
47975852|NCT02127879|DEVICE|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
48126737|NCT03079700|BIOLOGICAL|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
48126741|NCT03822234|PROCEDURE|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
48126742|NCT04095715|OTHER|Haemostasis consultation|Haemostasis consultation
48126743|NCT04095715|BIOLOGICAL|Standard management of patients suspected of thrombopathy|Standard management of patients suspected of thrombopathy
48126744|NCT03208491|OTHER|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
48126745|NCT03208491|OTHER|usual care|usual care of patient
48126746|NCT01609218|DRUG|LY2140023|
48126747|NCT01609218|DRUG|Aqueous activated charcoal|
48333871|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
48126748|NCT03742050|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
48126749|NCT05045534|DRUG|Comparison of TB-840 treatment with Placebo|Single dose or Multiple Dose of TB-840 treatment
48333872|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
48333873|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
48126750|NCT04679662|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
48126751|NCT04030533|DRUG|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
48126752|NCT04030533|DRUG|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
48126753|NCT04030533|DRUG|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
48126754|NCT04030533|DRUG|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
48126755|NCT04030533|DRUG|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
48333874|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
48333875|NCT02866734|OTHER|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
48333876|NCT02866734|OTHER|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
48493172|NCT03083236|OTHER|Enhanced|Enhanced Parent Based Intervention (EPBI)
48493173|NCT04238988|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.
48493174|NCT04238988|DRUG|Carboplatin|Chemotherapy medication
47975853|NCT02127879|DEVICE|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
47975854|NCT00320411|DRUG|lapatinib|Lapatinib 1500mg QD
48333877|NCT02866734|OTHER|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
48333878|NCT03431909|DRUG|Human urinary kallidinogenase (HUK)|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
48333879|NCT03431909|DRUG|aspirin® , clopidogrel® , atorvastatin®|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
48333880|NCT03820726|DRUG|Nintedanib|Bid
47975855|NCT06066658|DEVICE|cranial electrotherapy stimulation (Alpha-Stim AID)|Alpha-Stim AID
48333881|NCT03039738|DEVICE|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) \& Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
48333882|NCT03039738|DEVICE|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
48333883|NCT00870038|DEVICE|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
48493175|NCT04238988|DRUG|Taxol|Chemotherapy medication
48493176|NCT01303705|DRUG|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
47975856|NCT02364973|OTHER|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
47975857|NCT03906123|DRUG|NBP|NBP soft capsules
47975858|NCT03906123|DRUG|Placebos|Soft capsules manufactured to mimic NBP
47975859|NCT00002904|DRUG|trabectedin|
48126756|NCT03685071|OTHER|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~* patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~* correlation between the outcome and CBC will be done."
48126757|NCT05700487|OTHER|PELVIC FLOOR EXERCISES|Regular Pelvic floor exercises was performed three times a day for six months in the postoperative period
48126758|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^4 pfu delivered intramuscularly
48126759|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^5 pfu delivered intramuscularly
48126760|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^6 pfu delivered intramuscularly
48126761|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^7 pfu delivered intramuscularly
48493177|NCT01303705|RADIATION|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
48493178|NCT01303705|DRUG|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
48493179|NCT00692718|DRUG|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
48493180|NCT06307782|DIETARY_SUPPLEMENT|whey protein intake before surgery|Total Hip Arthroplasty whey protein intake,Total Hip Arthroplasty, whey protein intake,CRP,cortisol insulin resistance
48126762|NCT04794218|OTHER|Placebo/Diluent|N/A delivered intramuscularly
48652640|NCT05552573|BIOLOGICAL|low-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of low-dose(30µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
48126763|NCT02703558|DRUG|Phenazopyridine|
48126764|NCT02703558|DRUG|Fluorescein|
47975860|NCT03471650|DRUG|18F-DCFPyL Injection|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
47975861|NCT01954550|BEHAVIORAL|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
48126765|NCT00084552|RADIATION|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
48126766|NCT01541436|DEVICE|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
48126767|NCT03117426|DEVICE|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
48126768|NCT03117426|DEVICE|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
48126769|NCT04867824|DIETARY_SUPPLEMENT|Case (use of inhaled vanilla essential oil)|Use of inhaled vanilla essential oil during frenotomy for a tongue-tie
48126770|NCT04867824|DIETARY_SUPPLEMENT|Control (use of inhaled lavender essential oil)|Use of inhaled lavender essential oil during frenotomy for a tongue-tie
48126771|NCT05953675|DRUG|Ethanol 70%|Once a week, the catheter will be closed with 3 mL ethanol 70% lock-solution after a completed hemodialysis. The fluid will stay in the catheter until next hemodialysis (ca. 48 hours). The fluid will be aspirated before the hemodialysis. Standard lock-solution of isotonic saline with heparin will be used for the remaining two hemodialysis procedures of the week.
48126772|NCT05953675|DRUG|Isotonic saline with heparin|Standard procedure of isotonic saline used as lock-fluid after completed hemodialysis.
48126773|NCT00988858|DRUG|LY2603618|150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
48126774|NCT00988858|DRUG|Pemetrexed|500 mg/m\^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
48126775|NCT03991286|DIETARY_SUPPLEMENT|Astaxanthin 8 mg|experimental
48126776|NCT03991286|OTHER|placebo|Matching placebo pill
48126777|NCT03447236|BEHAVIORAL|Feuerstein Program|Mediated learning cognitive enhancement program
48126778|NCT02752503|DRUG|Nalmefene|
48126779|NCT00566735|DRUG|Razadyne|The starting dose of study medication is 4 mg twice a day
48126780|NCT00566735|DRUG|Placebo|4 mg, 2 times a day
48126781|NCT02334436|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
48126782|NCT02334436|OTHER|0.9% sterile, unpreserved saline|Placebo Comparator Arm
48126783|NCT04079244|BEHAVIORAL|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
48493181|NCT06307782|DIETARY_SUPPLEMENT|Water before surgery|Total Hip Arthroplasty water before surgery,Total Hip Arthroplasty, water intake,CRP,cortisol insulin resistance
48493182|NCT00074737|DRUG|cenersen|cenersen with standard of care
48333884|NCT00870038|DEVICE|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
47975862|NCT01954550|BEHAVIORAL|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
48333885|NCT00870038|DEVICE|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
48493183|NCT00074737|DRUG|Idarubicin|standard of care for AML
48493184|NCT00074737|DRUG|Cytarabine|standard of care Ara-C and High dose Ara-C
48652641|NCT05552573|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO Cell)|This vaccine is Positive-controlled vaccine and 3 doses (0.5ml) at the schedule of 0, 28, 56 days.
48333886|NCT01317693|DEVICE|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
48333887|NCT01562678|DRUG|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
48333888|NCT01562678|DRUG|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
47975863|NCT01441206|DRUG|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth \< 32 weeks - PNA \< 14 days: 10 mg/kg QD GA at birth \< 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA \< 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
47975864|NCT01903187|DEVICE|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
47975865|NCT01903187|PROCEDURE|Sham|Renal artery angiogram
47975866|NCT03916276|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
47975867|NCT03916276|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
47975868|NCT03916276|BEHAVIORAL|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
47975869|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
47975870|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
47975871|NCT04199611|PROCEDURE|Liposuction|This is a type of fat removal procedure used in plastic surgery.
47975872|NCT04199611|BEHAVIORAL|Cognitive Behavioral Therapy|This is a psycho-social intervention that aims to improve mental health.
47975873|NCT02737189|PROCEDURE|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
47975874|NCT02737189|DRUG|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
48333889|NCT04146337|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
48333890|NCT03457766|DEVICE|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
48333891|NCT00559416|DRUG|Cell Transfer|
48493185|NCT03683524|DRUG|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
48493186|NCT03683524|DRUG|Current ART|To continue with their current ART
48493187|NCT00878514|DRUG|Alprazolam|Alprazolam 1 mg tablet
48493188|NCT00878514|DRUG|Xanax|Xanax 1 mg tablet
47975875|NCT05479084|OTHER|Kinesiotaping|Kinesio taping will be applied on the lower part of the trapezius.
48493189|NCT04120584|DEVICE|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
47975876|NCT05546645|OTHER|Questionnaire|Hypersecretion questionnaire
48493190|NCT01599130|DRUG|Entecavir|entecavir 0.5mg per day
48493191|NCT01599130|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
47975877|NCT05765240|DRUG|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
47975878|NCT05765240|PROCEDURE|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
48493192|NCT01009671|DRUG|ART 44|
48493193|NCT01009671|DRUG|ART 50|
48493194|NCT01078337|PROCEDURE|bone marrow aspiration|
48493195|NCT01078337|PROCEDURE|peripheral blood sampling|
48493196|NCT03291353|DRUG|pembrolizumab|200 mg IV given every three weeks
48493197|NCT01403974|DRUG|BI 836845|Intravenous infusion once every week
48652642|NCT05552573|BIOLOGICAL|high-dose LYB001|This vaccine is prepared through gene recombination and 3 doses of high-dose(60µg/0.5ml) LYB001 at the schedule of 0, 28, 56 days.
48652643|NCT06541587|BEHAVIORAL|mindfulness based virtual reality|mindfulness based virtual reality
48126784|NCT04079244|BEHAVIORAL|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
48126785|NCT06521619|PROCEDURE|Femoral and sciatic nerve blocks|Patients receiving Adductor canal block and infiltration of posterior capsule of knee
48126786|NCT03649243|DRUG|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
48126787|NCT02559349|OTHER|Stool Collection|
48126788|NCT00677469|DRUG|Cholestyramine|2 grams BID
48126789|NCT00677469|DRUG|Cholestyramine|1 gram BID
48126790|NCT00677469|DRUG|Placebo powder|1 gram BID
48126791|NCT02538341|BIOLOGICAL|Herpes Zoster (HZ) Vaccine|
47975879|NCT00903695|DRUG|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
47975880|NCT00903695|DRUG|placebo|placebo comparator
47975881|NCT03210168|OTHER|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
47975882|NCT03013478|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
47975883|NCT03013478|BEHAVIORAL|CBT4CBT program|
47975884|NCT03008681|DEVICE|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
47975885|NCT05042167|OTHER|Resistance exercise|4 total resistance exercises that target all major muscle groups.
48126792|NCT02538341|DRUG|Placebo|
48126793|NCT03655262|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete x day(s) of neuro-reinforcement.
48126794|NCT06083155|DIAGNOSTIC_TEST|Coronary Function Test|All participants are referred for a clinically indicated coronary function test
47975886|NCT01613404|OTHER|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
48652644|NCT06541587|BEHAVIORAL|mindfulness based audio practice|mindfulness based audio practice
48652645|NCT03312543|DEVICE|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
47975887|NCT00241813|BEHAVIORAL|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
48652646|NCT03312543|DEVICE|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
47975888|NCT00241813|BEHAVIORAL|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
47975889|NCT00241813|BEHAVIORAL|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
47975890|NCT02986399|OTHER|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
47975891|NCT02240251|OTHER|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
47975892|NCT03352622|OTHER|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
48126795|NCT06083155|OTHER|Patient questionnaires|All participants that consent will receive yearly followup questionnaires for 5 years after their initial consent
48126796|NCT05007587|DRUG|Lenvatinib|8mg lenvatinib (weight\<60kg) or 12mg lenvatinib (weight\>60kg) QD
48126797|NCT05007587|DRUG|mFOLFOX regimen|HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.
48126798|NCT05007587|DRUG|ROX regimen|HAIC was performed every 3 weeks. The ROX regimen was administered via hepatic artery: oxaliplatin , 100mg/m2 , from hour 0 to 4 on day1 ;raltitrexed , 3mg/m2 , from hour 4 to 5 on day 1.
48126799|NCT04024176|OTHER|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
48126800|NCT05957016|PROCEDURE|CIETAI-R|"1. phase I: (1) Chemo-Immulo-embolization via Tumor Arterial, CIETAI: DSA guided tumor artery infusion of oxaliplatin 130 mg/m2+PD-1 inhibitor (Tirelizumab) 200mg, followed by gelatin sponge particles (350-560um) embolization~2. phase II: Chemoradiotherapy: IMRT：45Gy/25f/5w+capecitabine 1000，po. Bid d1-14, q3w Tirelizumab)200mg ivggt, d1, q3w"
48126801|NCT00150241|DRUG|CP-526,555 (varenicline)|
48126802|NCT01294956|OTHER|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
48126803|NCT01294956|OTHER|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
48333892|NCT06526806|OTHER|Kahoot game strategy|"Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified. Measurements will be made with data collection tools in the first week, ninth (after the midterm exam) and eighteenth weeks (after the final exam) of the course."
48126804|NCT01404585|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
48126805|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
48126806|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
48126807|NCT05490524|DEVICE|GATEKEEPER|The GATEKEEPER is a digital platform that allows patients and caregivers to record their day-to-day symptoms and other parameters such as quality of life using means such as apps and wearable devices that record both self-report (quality of life, depression, anxiety) and physiological data (mobility, pain, sleep patterns, heart rate), and allows healthcare professionals to monitor these data and tailor healthcare so to prevent and intervene in symptoms that may be occurring.
48126808|NCT06375603|OTHER|Ultrasound scans|Clinical experts will conduct non-invasive ultrasound scans from the specified nerve or plane block views and record the acquired data.
48126809|NCT03773835|DRUG|HSK3486|Mmanual IV bolus injection completed in 1 minute.
48126810|NCT03669822|OTHER|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
48126811|NCT03706521|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
48333893|NCT04253808|BEHAVIORAL|Carbohydrate-restricted, high-fat diet|"Diet composition was \~45% fats, \~30% carbohydrates, and \~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~* Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~* Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~* Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided."
48333894|NCT04253808|BEHAVIORAL|Regular composition diet|The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
48493198|NCT02706782|DRUG|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
47975893|NCT03352622|OTHER|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
47975894|NCT01948622|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
47975895|NCT01948622|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
47975896|NCT05955729|BEHAVIORAL|On-duty Nap|For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.
48652647|NCT06640543|OTHER|Kinesiotape|Postnatal women with low back pain will be treated with kinesiotape, three times per week for 4 weeks
47975897|NCT05955729|BEHAVIORAL|Control condition (30-min rest)|For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.
48126812|NCT01646749|DIETARY_SUPPLEMENT|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
47975898|NCT05955729|DEVICE|EndoPAT|"The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording."
47975899|NCT05955729|DEVICE|Popmeter®|The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.
48126813|NCT03484416|DRUG|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
48126814|NCT05706870|DRUG|GN-037|GN-037
48126815|NCT05706870|DRUG|Clobetasol 17-propionate|Clobetasol 17-propionate
48126816|NCT05706870|DRUG|Placebo|Placebo
48493199|NCT02158312|DEVICE|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
48493200|NCT04205370|DEVICE|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
47975900|NCT05955729|DEVICE|Panasonic EW3109|Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
47975901|NCT05955729|DEVICE|ECG Holter|The Holter takes an ECG during the subject's daily activities at home.
48126817|NCT03348722|OTHER|Active surveillance|PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years
48333895|NCT01423955|DRUG|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
47975902|NCT05955729|BIOLOGICAL|Fasting blood sample|15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).
47975903|NCT05955729|OTHER|Pichot fatigue scale|The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.
47975904|NCT05955729|OTHER|French version of the Recovery Needs Scale (BRD)|BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.
48126818|NCT03348722|PROCEDURE|Radical prostatectomy|Radical prostatectomy (open, laparoscopic or robotic)
48126819|NCT03348722|RADIATION|Radiotherapy|External radical radiotherapy or brachitherapy
48333896|NCT01423955|DRUG|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
48493201|NCT04205370|DEVICE|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
48493202|NCT03596736|PROCEDURE|Elbow Hemiarthroplasty|
47975905|NCT05955729|OTHER|The Short-Form 36 (SF-36)|The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
47975906|NCT05955729|OTHER|Pittsburgh Sleep Quality Index (PSQI)|24-question sleep quality assessment scale, a score \> 5 indicates poor sleep quality
47975907|NCT05955729|OTHER|Epworth questionnaire|8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness
47975908|NCT05955729|OTHER|The Karolinska Sleepiness Scale|The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated.
47975909|NCT05955729|DEVICE|Actimeter|An actimeter will be worn on the non-dominant wrist, uninterrupted day and night, for 7 consecutive days.
47975910|NCT06431490|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
47975911|NCT03145285|DRUG|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
47975912|NCT02289040|PROCEDURE|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
47975913|NCT06376799|OTHER|Self-questionnaire|Provision of a self-questionnaire in digital or paper format for the patient. The patient will be asked to indicate their preferences regarding the primary and secondary objectives of the study.
47975914|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation|A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.
47975915|NCT05777876|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.
48333897|NCT02255617|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
48333898|NCT04406012|PROCEDURE|paravertebral block|paravertebral block group
48333899|NCT04252248|DRUG|Dacogen|Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
48333900|NCT05246475|DIAGNOSTIC_TEST|PET-MRI|Simultaneous PET-MRI measurement
48333901|NCT03073408|DRUG|Propofol|Closed loop control for propofol administration guided by the BIS.
48333902|NCT03073408|DRUG|Propofol|Manual control group: Propofol administration adjusted manually.
48493203|NCT03596736|PROCEDURE|Total Elbow Arthroplasty|
48493204|NCT04604743|BEHAVIORAL|Intervention, TBN|The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
48126820|NCT03348722|PROCEDURE|Other radical treatments|High intensity focal ultrasound, cryotherapy, others
48126821|NCT05801198|DIETARY_SUPPLEMENT|Artemisia afra or Annua 10g oral infusion/tea per day for 14 days|Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
48126822|NCT00352976|DRUG|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
48126823|NCT00352976|DRUG|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m\^2 intravenous (IV)
48126824|NCT00352976|PROCEDURE|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
48126825|NCT00352976|PROCEDURE|Bone Marrow Transplantation|A target of 5 \* 10\^6/kg and a minimum of 4 \* 10\^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
48126826|NCT00352976|DRUG|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 \* 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
48126827|NCT00352976|DRUG|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
48126828|NCT03262831|OTHER|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
48126829|NCT03262831|PROCEDURE|Blood draw|"* Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
48126830|NCT03262831|BEHAVIORAL|FACT-G questionnaire|"* 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much"
48126831|NCT03262831|PROCEDURE|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
48126832|NCT03262831|BEHAVIORAL|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
48493205|NCT04514965|OTHER|Blood sampling|Blood sampling
47975916|NCT05777876|DEVICE|Motor cortex stimulation|Receive stimulation in the motor cortex stimulation instead of deep brain.
47975917|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation with closed-loop|Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
48126833|NCT03262831|BEHAVIORAL|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
47975918|NCT00022139|DRUG|carboplatin|
47975919|NCT00022139|DRUG|fluorouracil|
48126834|NCT01499316|PROCEDURE|High Flow oxygen|10 minute shigh flow oxygen
48126835|NCT01499316|PROCEDURE|Room Air|Room air breathing
48126836|NCT00710567|DEVICE|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanted in using open heart surgery
48126837|NCT01250769|DEVICE|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
48126838|NCT01250769|DEVICE|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
48126839|NCT04986475|OTHER|Music Therapy|Music therapy was performed by listening to the ney sound during the non-stress test procedure.
48126840|NCT01111513|DRUG|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
48126841|NCT01111513|DRUG|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
48126842|NCT01111513|DRUG|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
48126843|NCT00289835|DEVICE|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
48333903|NCT00126854|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|
48333904|NCT00607126|DEVICE|Lokomat|locomotor training using body weight support on a treadmill
48333905|NCT00607126|PROCEDURE|resistive training|resistive training using theraband and/or weights
48493206|NCT04514965|DEVICE|Fibroscan|Measurement of liver stiffness
48493207|NCT04514965|OTHER|Question|Question about pruritus
48493208|NCT03330912|DEVICE|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
48493209|NCT03330912|DEVICE|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
47975920|NCT00022139|DRUG|paclitaxel|
47975921|NCT00022139|PROCEDURE|conventional surgery|
47975922|NCT00022139|RADIATION|radiation therapy|
47975923|NCT02877420|OTHER|Non-Technical Skills Training Curriculum|
47975924|NCT02877420|OTHER|Conventional Simulation Training Group|
47975925|NCT06074315|DEVICE|Nail Genesis DLSO Product|Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
48126844|NCT01737021|OTHER|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
48652648|NCT06640543|OTHER|Myofascial release|Postnatal women with low back pain will be treated with myofascial release for 25 minutes three times per week for 4 weeks
48652649|NCT01986023|BEHAVIORAL|SMS- Short Messaging Service|
48652650|NCT06369545|OTHER|EXERCISE|All participants included in this group will receive Exercises
48652651|NCT06369545|OTHER|TENS|All participants included in this group will receive TENS
48493210|NCT03330912|DEVICE|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
47975926|NCT06074315|DEVICE|Nail Genesis DLSO Product (vehicle only)|The Nail Genesis DLSO product poly-urethane vehicle
47975927|NCT00616395|DEVICE|No intervention|
48126845|NCT05746754|RADIATION|CSI|30 Gy in 10 fractions to CNS
48493211|NCT03330912|DEVICE|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
48493212|NCT03330912|DEVICE|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
48493213|NCT02059018|DRUG|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
48493214|NCT02059018|DRUG|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
47975928|NCT03259776|OTHER|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
48493215|NCT02059018|DRUG|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
48493216|NCT01207505|BEHAVIORAL|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
48493217|NCT02993692|DEVICE|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
48652652|NCT06369545|OTHER|ESWT|All participants included in this group will receive ESWT
48652653|NCT01628952|DRUG|Transversus Abdominis Plane|PIA coelioscopic
48652654|NCT01628952|DRUG|Curare|IAP coelioscopic
48652655|NCT05471128|PROCEDURE|Standard of Care Biopsy|Patients will be evaluated with multiparametric MRI prostate followed by ExactVu micro-ultrasound to identify target lesions all of which will be biopsied by the examiner
47975929|NCT03951844|DEVICE|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
47975930|NCT05258175|OTHER|KT|Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.
47975931|NCT05258175|OTHER|Standardized physiotherapy protocol|3 sets with five repetitions per day for total of 15 days.
47975932|NCT01366209|DRUG|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
47975933|NCT01366209|DRUG|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
47975934|NCT04203238|OTHER|Reduced Meat High Potato Diet|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.
48333906|NCT06134869|PROCEDURE|Bone augmentation|Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
48333907|NCT05461183|OTHER|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
48333908|NCT02811796|OTHER|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
47975935|NCT04203238|OTHER|Reduced Meat High Pulses Diet|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
47975936|NCT01078012|BEHAVIORAL|Trained counselling|
47975937|NCT00494182|DRUG|Carboplatin|Given IV
48333909|NCT00435357|DEVICE|mobile-bearing TKA|
48333910|NCT00435357|DEVICE|fixed- bearing TKA|
48493218|NCT04606836|DRUG|Bupivacaine Hydrochloride|See group descriptions
48493219|NCT04415736|OTHER|No intervention, observational study|
48493220|NCT05495035|DRUG|Olverembatinib, APG-2575, Dexamethasone|"* Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~* Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~  2) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~  3) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
48652656|NCT03695315|DEVICE|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
48652657|NCT06358326|OTHER|Dry needling|In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.
48652658|NCT06358326|OTHER|Control group|The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.
48652659|NCT04060238|DIAGNOSTIC_TEST|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
48652660|NCT06638801|BEHAVIORAL|Coach-led caregiver-implemented early literacy and developmental programming|Caregivers will receive training about child brain development in the first 3 years of life. The training will emphasize the areas of spoken words, physical education, pointer-finger concept, focus and label, reading lessons, and mathematics.
48126846|NCT01057459|OTHER|laboratory biomarker analysis|Correlative studies
48652661|NCT06638801|BEHAVIORAL|Reach Out and Read Training|Reach Out and Read parent training
48652662|NCT04775108|DEVICE|Epygon™ Transcatheter Mitral Valve System|"The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent."
48126847|NCT03983759|DRUG|sintilimab maintenance|the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
48126848|NCT03728764|OTHER|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
48652663|NCT00000373|DRUG|olanzapine + fluoxetine|
48126849|NCT02338024|BEHAVIORAL|Modified Antiretroviral Treatment Access Study intervention|
48126850|NCT02645942|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
48126851|NCT02645942|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
48126852|NCT05621499|DRUG|HAIC|Oxaliplatin 85 mg/m2, LV 400 mg/ m2, 5-FU 400 mg/m2 bolus and then 2400 mg/m2 as 46h continuous infusion，Q3W，a total of 2 cycles
48126853|NCT05621499|DRUG|Sintilimab|200mg，iv，d1，q3w，a total of 3 cycles
48126854|NCT05621499|DRUG|Lenvatinib|12 or 8mg/kg，po，qd，a total of 3 cycles
48126855|NCT03759236|BEHAVIORAL|Health Messaging via SMS|This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
48126856|NCT03759236|BEHAVIORAL|CDC Health Pamphlets|This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
48126857|NCT05237752|DRUG|LG00034053|a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
48126858|NCT02140645|DRUG|linagliptin|non-randomized
48126859|NCT06241716|PROCEDURE|Ultrasound-assisted localization, US-AS|In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.
48126860|NCT06241716|PROCEDURE|Real-time ultrasound guidance, US-RTG|In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.
48126861|NCT01955226|OTHER|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
48493221|NCT03168594|DRUG|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
48493222|NCT03168594|DRUG|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
48493223|NCT00000569|DRUG|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
48652664|NCT00000373|DRUG|placebo + fluoxetine|
48652665|NCT05538858|PROCEDURE|Mechanical Ventilation|Positive pressure mechanical ventilation
48652666|NCT06317662|DRUG|Asparaginase Erwinia chrysanthemi|Given recombinant crisantaspase IM or crisantaspase IM or IV
48126862|NCT01955226|OTHER|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
48493224|NCT00000569|OTHER|Placebo|Placebo
48493225|NCT01772264|DRUG|PF-05089771|titration from 150mg BID to 450mg BID
48652667|NCT06317662|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48652668|NCT06317662|BIOLOGICAL|Blinatumomab|Given IV
48652669|NCT06317662|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48652670|NCT06317662|DRUG|Calaspargase Pegol|Given IV
48126863|NCT00961831|DRUG|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
48126864|NCT00961831|DRUG|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
48126865|NCT05679479|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
48126866|NCT05679479|OTHER|Normal saline|0.9% normal saline
48126867|NCT04944563|PROCEDURE|Segmentectomy|Patients receive segmentectomy
48126868|NCT04944563|PROCEDURE|Lobectomy|Patients receive lobectomy
48493226|NCT01772264|DRUG|Placebo|matched placebo
48493227|NCT00233506|DRUG|CpG 7909|
48493228|NCT01152866|DRUG|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
48493229|NCT00649727|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
48493230|NCT00649727|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
48652671|NCT06317662|PROCEDURE|Computed Tomography|Undergo CT
48652672|NCT06317662|DRUG|Cyclophosphamide|Given IV
48652673|NCT06317662|DRUG|Cytarabine|Given IT or IV
48652674|NCT06317662|DRUG|Daunorubicin|Given IV
48652675|NCT06317662|DRUG|Dexamethasone|Given PO or NG or IV
48652676|NCT06317662|DRUG|Doxorubicin|Given IV
48652677|NCT06317662|PROCEDURE|Echocardiography|Undergo ECHO
48652678|NCT06317662|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
48652679|NCT06317662|DRUG|Leucovorin|Given PO or NG or IV
48126869|NCT05654467|BIOLOGICAL|Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)|The nOPV3 vaccine containing approximately 10\^5.5, 10\^6.0, or 10\^6.5 CCID50 per dose.
48126870|NCT05654467|BIOLOGICAL|Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)|The Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 control and challenge vaccine (mOPV3) containing ≥ 10\^5.8 CCID50 per dose.
48126871|NCT05713526|BEHAVIORAL|Telehealth service|Researchers will send educational materials (video and e-brochures) about childhood vaccinations to the participants' mobile phones at regular intervals, answer their questions over the phone and send reminder messages before the vaccination appointment.
48126872|NCT01189149|PROCEDURE|IV fluids|Infants will be allocated to IV fluids
48126873|NCT01189149|PROCEDURE|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
48126874|NCT05804994|DEVICE|Elgydium Clinic Sensileave Gel (V063B - DP3003)|Tested product is applied/used only once a day before whitening tray wear.
48126875|NCT03205072|DEVICE|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
48126876|NCT05090631|GENETIC|DNA analysis|GWAS
48126877|NCT02588313|DIETARY_SUPPLEMENT|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
48126878|NCT04859296|DRUG|Placebo|Vaporized placebo
47975938|NCT00494182|DRUG|Paclitaxel|Given IV
47975939|NCT00494182|DRUG|Sorafenib|Given PO
47975940|NCT03376022|OTHER|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
47975941|NCT05532839|OTHER|High intensity interval training|The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.
48126879|NCT04859296|DRUG|Low CBG|Vaporized CBG (5 mg)
48126880|NCT04859296|DRUG|High CBG|Vaporized CBG (15 mg)
48126881|NCT04859296|DRUG|Low THC|Vaporized THC (5 mg)
48126882|NCT04859296|DRUG|High THC|Vaporized THC (15 mg)
48126883|NCT00002381|DRUG|Nelfinavir mesylate|
48126884|NCT00002381|DRUG|Nevirapine|
48126885|NCT00002381|DRUG|Stavudine|
48126886|NCT01763853|DRUG|4% albumin|
48126887|NCT02624258|BIOLOGICAL|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
48652680|NCT06317662|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48652681|NCT06317662|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48652682|NCT06317662|DRUG|Mercaptopurine|Given PO or NG
48652683|NCT06317662|DRUG|Methotrexate|Given IT or IV or PO or NG
48652684|NCT06317662|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48652685|NCT06317662|DRUG|Pegaspargase|Given IV or IM
48126888|NCT01485887|DRUG|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
48126889|NCT04803409|DEVICE|Splenic Ultrasound|Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
48652686|NCT06317662|DRUG|Prednisolone|Given PO or NG
48652687|NCT06317662|DRUG|Prednisone|Given PO or NG
48652688|NCT06317662|DRUG|Therapeutic Hydrocortisone|Given IT
48652689|NCT06317662|DRUG|Thioguanine|Given PO or NG
48652690|NCT06317662|DRUG|Venetoclax|Given PO or NG
48652691|NCT06317662|DRUG|Vincristine|Given IV
48333911|NCT05630560|OTHER|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
48333912|NCT05148169|DRUG|SSRIs|One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
48333913|NCT05148169|DIETARY_SUPPLEMENT|SSRI plus Sulforaphane|"One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
48333914|NCT01608607|OTHER|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
48333915|NCT05325398|DIETARY_SUPPLEMENT|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
48493231|NCT01959035|DRUG|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
48493232|NCT02629913|DEVICE|mementor somnium|
48493233|NCT02629913|OTHER|wait list|delayed access to mementor somnium
48652692|NCT03107182|DRUG|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
48652693|NCT03107182|DRUG|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
48652694|NCT03107182|DRUG|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
48652695|NCT03107182|DRUG|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
48652696|NCT03107182|DRUG|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
48126890|NCT03829436|DRUG|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
48493234|NCT04178161|DEVICE|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
48652697|NCT03107182|DRUG|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
48652698|NCT03107182|DRUG|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
48652699|NCT03107182|DRUG|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
48493235|NCT04694183|DRUG|Camrelizumab|200mg, intravenous drip administration, d1, every 3 weeks.
48652700|NCT03107182|DRUG|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
48652701|NCT03107182|DRUG|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
48652702|NCT03107182|PROCEDURE|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
48652703|NCT03107182|RADIATION|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
48333916|NCT05325398|DIETARY_SUPPLEMENT|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
48333917|NCT02015806|BEHAVIORAL|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
48652704|NCT03107182|RADIATION|Chemoradiotherapy|"Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
48652705|NCT03469960|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
48652706|NCT03469960|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
48652707|NCT05001113|PROCEDURE|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
48652708|NCT05001113|PROCEDURE|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
48652709|NCT00123942|DRUG|MEDI-507|
48652710|NCT06675422|DRUG|JY231 injection|Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.
48652711|NCT05145491|PROCEDURE|Immediate Vitrectomy|Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
48652712|NCT05145491|PROCEDURE|Deferred Vitrectomy|"Vitrectomy may be performed only if at least one of the following criteria is met:~1. Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM~2. Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM~   a. Visits must be at least one month apart~3. Participant actively requests surgery due to worsening symptoms~4. Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)"
48652713|NCT03940521|OTHER|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
48333918|NCT02015806|BEHAVIORAL|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
48126891|NCT03829436|DRUG|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
48126892|NCT03829436|DRUG|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
48126893|NCT03829436|DRUG|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
48333919|NCT02015806|BEHAVIORAL|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
48652714|NCT06363981|DEVICE|Active rTMS over the left DLPFC and over the left DMPFC|Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.
48652715|NCT06363981|DEVICE|Active rTMS over the left DLPFC|Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.
48652716|NCT06363981|DEVICE|Sham rTMS|Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.
48333920|NCT03509623|DIAGNOSTIC_TEST|Blood sampling through direct peripheral venous puncture|Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
48333921|NCT04781452|OTHER|standard treatment|there ist no Intervention but our standart Treatment in the center
48333922|NCT05521971|OTHER|multifaceted pharmacist-led intervention|"* Educational sessions were provided to the physicians and nursing staff.~* Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~* Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~* The patient's primary care physician and, if applicable, the nursing home were informed by phone."
48333923|NCT05521971|OTHER|Usual care group|all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
48333924|NCT02409056|BEHAVIORAL|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
48652717|NCT03085290|OTHER|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
48333925|NCT02409056|BEHAVIORAL|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
48333926|NCT05494983|OTHER|Screening visit|The participants will be screened for inclusion and exclusion criteria and will be asked to fill the following questionnaires : Pittsburgh Sleep Quality Index, State and Trait Anxiety Questionnaire, Pain Catastrophizing Scale Fear of Pain Questionnaire, Perceived Stress Scale, Beck Depression Inventory, and questionnaires to assess their health status and the use of medications. A blood sample (to measure pro- and anti-inflammatory cytokines and perform metabolomic analyses) will be obtained. Enrolled participants will be given a wearable actimeter to assess daily total sleep duration during one week before the first experimental session. They will also be requested to complete daily a sleep diary during one week before each experimental session, and a food diary before the first experimental session. A fecal sample (to assess gut microbiota composition and perform metabolomic analyses) will be collected between the screening visit and the first experimental session.
48493236|NCT04694183|DRUG|S-1|Oral, d1-14, every 3 weeks.
48493237|NCT04694183|DRUG|Oxaliplatin|130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
48493238|NCT04694183|DRUG|Paclitaxel|Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
48493239|NCT05114837|DRUG|allogeneic CAR19 regulatory T cells (CAR19-tTreg)|A single dose administration of CAR19-tTreg
48652718|NCT03085290|OTHER|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
48652719|NCT03862417|OTHER|Schroth exercises|An exercise program begun individually and then continued in groups.
48652720|NCT02669641|DIETARY_SUPPLEMENT|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
48652721|NCT06168006|BEHAVIORAL|Exercise|The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.
48652722|NCT06168006|BEHAVIORAL|Control|They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
48652723|NCT00157261|DRUG|tenecteplase|
48126894|NCT00665340|DRUG|Placebo|Matching placebo
48126895|NCT00665340|DRUG|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
48652724|NCT03489083|OTHER|Strength training|Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted \~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
48652725|NCT03489083|OTHER|No Training|"Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort."
48652726|NCT05049824|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
48126896|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the modified approach|The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
48126897|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the traditional approach|The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
48126898|NCT02765100|DRUG|Minocycline|Minocycline 100 mg twice a day
48126899|NCT02076568|BEHAVIORAL|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
48126900|NCT02454283|DRUG|Vanoxerine HCl|
48333927|NCT05494983|OTHER|Peripheral sensitization session|The extent of neurogenic inflammation induced by topical capsaicin will be used as a measure of the susceptibility to sensitize at peripheral level. A solution of capsaicin will be applied to the skin of the left or right volar forearm for 30 minutes. The capsaicin-induced neurogenic inflammation can be quantified by assessing the intensity, extent and duration of the capsaicin-induced cutaneous flare response using thermal infrared imaging. Using heat stimuli delivered to the treated skin and surrounding skin, the intensity and duration of the capsaicin-induced hyperalgesia will also be assessed. The experimental session will last approximately two hours.
48333928|NCT05494983|OTHER|Central sensitization session|The extent of secondary mechanical hyperalgesia induced by high-frequency electrical stimulation (HFS) of the skin of the left or right volar forearm will be used as a measure of the susceptibility to develop central sensitization. The stimulation will be delivered using a multi-pin electrode designed to preferentially activate epidermal free nerve endings. The strength, spatial extent and duration of the HFS-induced changes in pinprick sensitivity will be characterized by using calibrated mechanical pinprick stimuli. The experimental session will last approximately one hour.
48333929|NCT00747539|DRUG|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
48652727|NCT06642779|BEHAVIORAL|VFQ- 25 (Visual Function Questionnaire)|VFQ-25 questionnaire was used to evaluate patient satisfaction at the M3 and M12 visits.
48652728|NCT06642779|DIAGNOSTIC_TEST|Optical Biometry|Axial length, anterior chamber depth and corneal keratometric values K1-K2. All these parameters were measured at the screening visit and at the month 3 follow-up visit, using the ARGOS® Biometer or the ANTERION® Cataract App
48652729|NCT06642779|DIAGNOSTIC_TEST|Slit lamps / Fundoscopy / Biomicroscopy|The fundus and other ocular structures, such as the cornea, anterior chamber, iris, pupil, crystalline lens / IOL alignment, corpus ciliare and choroid were examined at screening visit, on the day of the surgery, and at the follow up visits D1, M1, M3, M6, and M12, using the slit lamp binocular indirect ophthalmoscopy.
48652730|NCT06642779|DIAGNOSTIC_TEST|UDVA|Monocular and binocular Uncorrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
48126901|NCT02454283|DRUG|Placebo|
48126902|NCT03741049|DEVICE|Scalpel Bougie technique (plastic laryngeal model)|ScalpelBougie Set
48126903|NCT03741049|DEVICE|Seldinger technique (plastic laryngeal model)|Melker Set
48126904|NCT03741049|DEVICE|Surgical technique (plastic laryngeal model)|Scalpel and speculum
48126905|NCT03741049|DEVICE|Scalpel Bougie technique (porcine laryngeal model)|ScalpelCric Set
48126906|NCT03741049|DEVICE|Surgical technique (porcine laryngeal model)|Scalpel and speculum
48493240|NCT05114837|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 is administered as an intravenous (IV) infusion per institutional guidelines once a day on 4 consecutive days (Day -5, Day -4, Day -3 and Day -2)
48652731|NCT06642779|DIAGNOSTIC_TEST|CDVA|Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
48333930|NCT05222295|OTHER|Supervised Pulmonary Telerehabilitation|For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
48652732|NCT06642779|DIAGNOSTIC_TEST|UIVA / DCIVA|Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.
48652733|NCT06642779|DIAGNOSTIC_TEST|UNVA / DCNVA|Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.
48652734|NCT06642779|DIAGNOSTIC_TEST|Manifest Refraction|Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.
48652735|NCT06642779|DIAGNOSTIC_TEST|IOP|Intraocular pressure (IOP) was measured at all visits (preoperative, D1, M1, M3, M6 and M12), using a non-contact tonometer.
47975942|NCT05532839|OTHER|Moderate intensity continuous training|The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
48333931|NCT05222295|OTHER|Cognitive Telerehabilitation|These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
48493241|NCT05114837|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m\^2 is administered as an IV infusion per institutional guidelines once a day on 2 consecutive days (Day -5, and Day -4)
48493242|NCT01551888|DRUG|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
48493243|NCT01551888|DRUG|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
48493244|NCT02145026|DRUG|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
48493245|NCT00705692|DRUG|Levamisole|
48652736|NCT06642779|DIAGNOSTIC_TEST|VADC|Visual Acuity Defocus Curve (VADC) was taken monocularly at M3, monocularly and binocularly at M6 and binocularly at M12, using the Multifocal Lens analyzer - MLA application.
48652737|NCT06642779|DIAGNOSTIC_TEST|CSDC|Contrast Sinsitivity Defocus Curve (CSDC) was taken under photopic conditions at M6 and M12, using the Multifocal Lens Analyzer - MLA application
48493246|NCT00705692|DRUG|Placebo|
48126907|NCT01255514|DRUG|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
48126908|NCT05209555|DIAGNOSTIC_TEST|MoCA|MoCA test to identify Mild Cognitive Impairment
48126909|NCT05209555|DEVICE|BAMCOG|Three games, compared to the MoCA to identify Mild Cognitive Impairment
48652738|NCT06642779|DIAGNOSTIC_TEST|CSV-1000|"Contrast Sensitivity was measured using the CSV-1000 with distance correction in place at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd). Measurements were taken under four different light conditions:~* Photopic (M3 monocular and binocular, M6 binocular and M12 monocular)~* Mesopic (M6 binocular)~* Photopic with backlight (M6 binocular)~* Mesopic with backlight (M6 binocular)"
48652739|NCT06642779|DIAGNOSTIC_TEST|Tear film stability|Tear film stability was assessed at screening visit and at follow-up visits M1, M3, M6, and M12 using the non-invasive Tear break Up Time (TBUT) with fluorescein dye.
48652740|NCT06642779|DEVICE|IOL implantation|The investigational device (877PEY) and the comparator (877PAY) intraocular lens models were implanted, using sutureless, small-incision phacoemulsification surgery.
48652741|NCT00431379|DRUG|Tenecteplase|
48652742|NCT01754740|DRUG|Uréia|"The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
47975943|NCT06020378|DRUG|Hydroxychloroquine|Hydroxychloroquine was administered during pregnancy
48126910|NCT05209555|DIAGNOSTIC_TEST|DeltaScan|EEG to detect acute encephalopathy
48126911|NCT05209555|DIAGNOSTIC_TEST|Salivette|To collect saliva for cortisol analysis
48126912|NCT05209555|DIAGNOSTIC_TEST|Pilocarpine iontophoresis|To collect sweat for cortisol analysis
48493247|NCT00211991|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
48493248|NCT01515930|BEHAVIORAL|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding monitoring diabetes care.
48652743|NCT01754740|DRUG|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
48652744|NCT06076226|OTHER|No intervention, observation study|No intervention, observation study
48652745|NCT01681849|DRUG|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
48652746|NCT01681849|DRUG|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
48652747|NCT01681849|OTHER|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
48652748|NCT06642324|DIAGNOSTIC_TEST|Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing|Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.
48652749|NCT03410745|BEHAVIORAL|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
47975944|NCT02418026|OTHER|hypnosis|Conversational hypnotic induction and therapeutic suggestions
47975945|NCT04644627|DRUG|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
47975946|NCT04165434|OTHER|Concurrent Training|Strength training and interval aerobic training in the same training session
47975947|NCT02185833|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
47975948|NCT02185833|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
47975949|NCT00837811|BIOLOGICAL|LY2127399|60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks
48652750|NCT00260338|BIOLOGICAL|stem cell|mesenchymal stromal cell
48652751|NCT02463435|BEHAVIORAL|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
47975950|NCT02856503|DRUG|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
47975951|NCT01595698|OTHER|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
47975952|NCT01595698|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
47975953|NCT05261074|OTHER|No intervention|No intervention (retrospective study)
48493249|NCT01515930|BEHAVIORAL|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding diabetes care.
48493250|NCT01515930|BEHAVIORAL|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
47975954|NCT01410032|PROCEDURE|Plate fixation|Reconstruction plate
47975955|NCT01410032|PROCEDURE|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
47975956|NCT04252456|PROCEDURE|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
47975957|NCT06072170|DRUG|Kratom|Single administration thirty minutes after the start of a high-fat breakfast
47975958|NCT06072170|DRUG|Placebo|Single administration thirty minutes after the start of a high-fat breakfast
47975959|NCT02670083|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
47975960|NCT02670083|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
48126913|NCT04669028|DRUG|NE3107|NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
48126914|NCT04669028|DRUG|Placebo|capsules that do not contain NE3107
48126915|NCT00002755|BIOLOGICAL|filgrastim|
48333932|NCT03136484|DRUG|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
48333933|NCT03136484|DRUG|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
48493251|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
48493252|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
48493253|NCT03207841|OTHER|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake.
47975961|NCT02187185|OTHER|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
47975962|NCT02187185|OTHER|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
47975963|NCT02756689|OTHER|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
47975964|NCT02756689|OTHER|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
47975965|NCT04693234|DRUG|Tislelizumab|Administered as specified in the treatment arm
47975966|NCT04693234|DRUG|Ociperlimab|Administered as specified in the treatment arm
47975967|NCT05825820|BEHAVIORAL|Enhanced Outreach Intervention (EOI) plus Care as Usual|"The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~A phone call (or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if you have suicidal thoughts, and (c) discuss participants' plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals give for individuals who present to the ED with suicidal thoughts."
47975968|NCT04517474|BEHAVIORAL|CANreduce|"CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying no to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised."
47975969|NCT04517474|BEHAVIORAL|psychological support|psychological support
48126916|NCT00002755|DRUG|CMF regimen|
48126917|NCT00002755|DRUG|cyclophosphamide|
48126918|NCT00002755|DRUG|doxorubicin hydrochloride|
48126919|NCT00002755|DRUG|fluorouracil|
48126920|NCT00002755|DRUG|methotrexate|
48126921|NCT00002755|DRUG|tamoxifen citrate|
48126922|NCT00002755|DRUG|thiotepa|
48126923|NCT00002755|PROCEDURE|autologous bone marrow transplantation|
48126924|NCT00002755|PROCEDURE|peripheral blood stem cell transplantation|
48126925|NCT00002755|RADIATION|low-LET cobalt-60 gamma ray therapy|
48126926|NCT00002755|RADIATION|low-LET electron therapy|
48126927|NCT00002755|RADIATION|low-LET photon therapy|
48126928|NCT00505934|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~* Ages ≥ 1 month to \< 6 months: 14 mg/kg/day (7 mg/kg twice daily).~* Ages ≥ 6 months to \< 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
48126929|NCT00861770|OTHER|Ultrafiltration|Ultrafiltration based on standard of care.
48126930|NCT00861770|OTHER|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
48126931|NCT04689178|OTHER|Invitation letter + GP reminder|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years
48126932|NCT04689178|OTHER|Invitation letter|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
48333934|NCT03136484|DRUG|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
48493254|NCT00001253|BEHAVIORAL|cognitive tests and scales|
48493255|NCT04774887|BIOLOGICAL|HPV vaccine, Merck|Vaccination against HPV will be offered to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
48493256|NCT01584206|DRUG|Ezetimibe|10mg ezetimibe/day, at least 4 months
48652752|NCT02463435|OTHER|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
47975970|NCT05283668|BIOLOGICAL|i-PRF|"* Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~* The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
47975971|NCT05283668|PROCEDURE|Diode Laser|"Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
48126933|NCT03323203|DEVICE|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
47975972|NCT00602953|OTHER|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
48493257|NCT01680497|DEVICE|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
48493258|NCT03119506|BEHAVIORAL|Recess|Recess timing and duration effects on lunch intake
47975973|NCT02837198|DRUG|FYU-981|
47975974|NCT02837198|DRUG|Topiroxostat|
48126934|NCT04418973|OTHER|VOCs analysis in exhaled air|using an electronic nose and a mass spectrometry
48126935|NCT05729503|DRUG|Lidocaine 2% Injectable Solution|Cotton tip applicator pre-soaked with lidocaine
48126936|NCT05729503|DRUG|Placebo|Cotton tip applicator pre-soaked with saline
48126937|NCT00007163|DRUG|J695|
48333935|NCT03136484|DRUG|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
48333936|NCT03027219|DRUG|Alprostadil|Vasodilator for anastomosis-site of free flap
48333937|NCT05191732|COMBINATION_PRODUCT|Platelet-Rich Plasma; Bone marrow concentrate|Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
48333938|NCT01525303|BEHAVIORAL|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
48493259|NCT02899832|DEVICE|NIRS|Near Infra Red Spectroscopy
48493260|NCT03242460|DRUG|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
48493261|NCT03242460|DRUG|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
48493262|NCT03242460|DRUG|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
48493263|NCT04304365|OTHER|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
48493264|NCT04304365|OTHER|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
48126938|NCT02574442|DEVICE|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
48126939|NCT04788212|BEHAVIORAL|Group Behavioral Activation Therapy for Autism Spectrum Disorder|This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
48126940|NCT00203554|GENETIC|Poly methylmetacrylate, PMMA|
48493265|NCT04304365|OTHER|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
48652753|NCT02463435|DIETARY_SUPPLEMENT|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
48652754|NCT06637462|DIAGNOSTIC_TEST|Endoscopy|Standard of care endoscopy
48652755|NCT04945330|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Follow clinical practice
48652756|NCT06308926|DRUG|MRG-001 (Low-dose)|MRG-001 is subcutaneously administered.
48652757|NCT06308926|DRUG|MRG-001 (High-dose)|MRG-001 is subcutaneously administered.
48652758|NCT06308926|OTHER|Placebo|Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
48652759|NCT06570668|DRUG|CDD-2101|All subjects will receive 4 sachets of CDD-2101 and/or placebo at a time based on the computer-generated randomization. An unblinded pharmacist will mix the assigned dose of CDD-2101 and/or placebo with 400 mL of water at 70-80°C, cool it to a comfortable temperature and keep it at room temperature for not longer than 1 h. A blinded study nurse or investigator will dispense the suspension to the assigned subject. The subject will drink it under supervision within 15 minutes.
48652760|NCT01487161|DRUG|FX006|Single 3 mL intra-articular injection
48126941|NCT04672967|DIAGNOSTIC_TEST|BioROSA MAP test|The BioROSA MAP test is a blood test that is being developed to predict ASD risk
48126942|NCT06209684|PROCEDURE|Titanium|Spinal stabilization using titanium screws and rods
48126943|NCT06209684|PROCEDURE|Carbofix|Spinal stabilization using CarboFix screws and rods
48126944|NCT01477268|DRUG|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
48126945|NCT00186784|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
48126946|NCT04638816|DEVICE|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
48126947|NCT04638816|DEVICE|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
48126948|NCT02182336|DRUG|BI 201335 NA|"1. 480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~2. 240 mg BI 201335 NA bid from day 11 to 23"
48126949|NCT02182336|DRUG|Caffeine|days 1, 10 and 19
48126950|NCT02182336|DRUG|Warfarin sodium|days 1, 10 and 19
48126951|NCT02182336|DRUG|Vitamin K|days 1, 10 and 19
48126952|NCT02182336|DRUG|Omeprazole|days 1, 10 and 19
48126953|NCT02182336|DRUG|Dextromethorphan hydrobromide|days 1, 10 and 19
48126954|NCT02182336|DRUG|Midazolam HCl solution|Days 3 and 21
48126955|NCT02182336|DRUG|Midazolam HCl oral syrup|days 1, 10 and 19
48126956|NCT02182336|DRUG|Digoxin|Days 2 and 20
48126957|NCT00040313|DRUG|pegaptanib sodium (Macugen)|
48126958|NCT03050957|DIETARY_SUPPLEMENT|menthol|Alimentary bolus supplemented with menthol
48126959|NCT01658241|DRUG|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
48333939|NCT02048267|PROCEDURE|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
48493266|NCT05414292|DRUG|Rapamune (sirolimus) 1Mg Tablet|Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
48493267|NCT05414292|BEHAVIORAL|Unilateral resistance exercise training|Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
48493268|NCT00044980|PROCEDURE|nutritional support|
48493269|NCT00044980|PROCEDURE|quality-of-life assessment|
48652761|NCT01487161|DRUG|TCA IR|Single 1 mL intra-articular injection
48126960|NCT04105712|BEHAVIORAL|Dietary Change (low in highly processed foods)|For post-dietary change, food is provided for 3 days (participants provide own food and do food journals the other 2 days to confirm adherence). University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. Low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc.); baked / dairy desserts (cookies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, etc.) are included in diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
48126961|NCT01401023|DRUG|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
48126962|NCT05054920|OTHER|concentric exercises|concentric exercises for rotator cuff. internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
48333940|NCT04969211|DRUG|VHX-896 and iloperidone|oral tablet
48333941|NCT04969211|DRUG|Iloperidone and VHX-896|oral tablet
48333942|NCT01565811|PROCEDURE|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
48333943|NCT05185284|DRUG|Favipiravir|400 mg, lyophilizate for preparation of concentrate for solution for infusion
48126963|NCT05054920|OTHER|eccentric exercises|Eccentric exercises exercises for rotator cuff internal rotators, external rotators and abductors Patient will do 3 sets of 10 repetitions resistance will be personalized to each patients
48126964|NCT05054920|OTHER|Stretching|stretching exercise for posterior capsule and pectoralis minor each stretch will be done for 30 seconds and repeated 3 times
48126965|NCT03177824|DRUG|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
48126966|NCT03177824|DRUG|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
48126967|NCT02517892|PROCEDURE|Biopsy|
48126968|NCT02254720|DRUG|BEA 2180 BR solution for infusion|
48126969|NCT02254720|DRUG|Placebo|Intravenous infusion
48126970|NCT02254720|DRUG|BEA 2180 BR solution for inhalation|
48126971|NCT02254720|DEVICE|Respimat®|
48126972|NCT02484599|BEHAVIORAL|Computerized attention training (CAT)|Three sessions of active computerized attention training.
48126973|NCT02484599|BEHAVIORAL|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
48126974|NCT00004831|DRUG|cysteine hydrochloride|
48333944|NCT05185284|DRUG|Favipiravir|200 mg coated tablets
48333945|NCT05185284|DRUG|Remdesivir|100 mg, lyophilizate for preparation of concentrate for solution for infusion
48493270|NCT01797835|BEHAVIORAL|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
47975975|NCT02728076|RADIATION|Phase II - Preoperative Radiation followed by Lumpectomy.|Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
47975976|NCT01622790|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
47975977|NCT01622790|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
47975978|NCT01622790|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
47975979|NCT00819611|BEHAVIORAL|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
47975980|NCT00819611|BEHAVIORAL|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
47975981|NCT03623802|OTHER|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
47975982|NCT03623802|OTHER|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
47975983|NCT02066870|DRUG|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
48126975|NCT05965141|DRUG|Aribulin;carboplatin;bevacizumab|Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.
48126976|NCT03079817|OTHER|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
48126977|NCT03079817|OTHER|Proprioceptive Drills|Active balance and proprioception drills
48126978|NCT04336436|BEHAVIORAL|Mindfulness training|Mindfulness training
48333946|NCT00002257|DRUG|Ganciclovir|
48333947|NCT01804114|PROCEDURE|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
48333948|NCT01804114|PROCEDURE|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
48333949|NCT00246064|DRUG|infliximab|
47975984|NCT02066870|DRUG|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
48493271|NCT01797835|BEHAVIORAL|usual care|Youth receive a brochure with information on AOD use.
48493272|NCT03187366|OTHER|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
48493273|NCT01644110|DRUG|INCB018424/CC-4047|"Cohort 1: For patients (1-41) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.~Cohort 2: For patients (42-90) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; the starting dose of pomalidomide is 0.5 mg po once daily."
48493274|NCT04943978|OTHER||just observational blood and liver sampling
47975985|NCT01355341|DRUG|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
47975986|NCT00006080|DRUG|fenretinide|
47975987|NCT03591198|BEHAVIORAL|Qigong Training|Eight-Section Brocades
47975988|NCT03591198|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
47975989|NCT05845684|OTHER|Physiotherapy application|massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.
48126979|NCT04336436|BEHAVIORAL|Nutritional consult|Nutrition counseling and development of a personalized nutrition plan
48333950|NCT05016804|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48333951|NCT05211258|DEVICE|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (\>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
48333952|NCT05301803|DEVICE|Electrophysiology procedure|Electrophysiology testing and cardiac ablation of arrhythmia
48126980|NCT00830934|PROCEDURE|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
48126981|NCT00830934|PROCEDURE|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
47975990|NCT05845684|OTHER|Control Group|standard daily applications will be performed on patients
47975991|NCT03932227|DEVICE|Cardioskin|Subjects will have a 24h recording with Cardioskin, next will be unequipped.
47975992|NCT03932227|DEVICE|Holter|Subjects will have a 24h recording with Holter, next will be unequipped.
47975993|NCT01103791|DRUG|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
48126982|NCT02809599|BEHAVIORAL|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
48126983|NCT06322212|DIETARY_SUPPLEMENT|Thiamine|Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.
48333953|NCT00971633|DRUG|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
48333954|NCT00971633|DRUG|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
48652762|NCT06637475|DEVICE|Electric stimulation|"Patients with baseline assessments will be followed up for 8 weeks within a planned treatment program. Treatment protocol for the ES group:~external ES wearable apparatus will be applied three days a week for 30 minutes with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 s contraction and 5 s rest, with a current intensity ranging from 0-100 mA while the patients are in the supine position. The device will be attached to the patients in such a way that it wraps around the upper thigh, the electrodes will be attached to the anterior and posterior of the right and left thigh, the right-left pelvic side and the right-left gluteal region. The current intensity in each session will be determined as the maximum current intensity that will not cause pain and discomfort in individuals."
48652763|NCT06177431|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
48652764|NCT05143619|OTHER|Survey Administration|Complete surveys
48652765|NCT06097897|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
47975994|NCT00899262|OTHER|immunohistochemistry staining method|
47975995|NCT00899262|OTHER|laboratory biomarker analysis|
47975996|NCT00899262|OTHER|sputum cytology|
47975997|NCT00899262|PROCEDURE|Fourier transform infrared spectroscopy|
47975998|NCT00899262|PROCEDURE|diagnostic bronchoscopy|
47975999|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.
47976000|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
47976001|NCT03284827|DRUG|NOAC|edoxaban (60 mg once daily \[OD\]) for at least 6 months
47976002|NCT03284827|DRUG|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
48333955|NCT00971633|DRUG|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
48333956|NCT02581670|RADIATION|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
48493275|NCT06250049|OTHER|Diabetic foot care protocol|Introduction of the diabetic foot care protocol in Primary Care in Salamanca, sensitization, and training of nursing professionals in Health Centers (HC).
48493276|NCT06250049|OTHER|Group education sessions for patients and/or caregivers|Conducting group education sessions for patients and/or caregivers on Diabetic Foot Care at the Health Centers.
48652766|NCT06571812|DEVICE|TSX|Treatment of tooth loss with TSX dental implants
48652767|NCT05708521|DRUG|Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery|POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
48652768|NCT05708521|DRUG|Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery|SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
48652769|NCT06640699|OTHER|exercise|exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
48652770|NCT06375499|DEVICE|T2769|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
48652771|NCT06375499|DEVICE|Hylo-Forte®|Daily dose regimen: 1 drop in each eye, from 3 to 6 times daily.
48652772|NCT06644846|RADIATION|Spatially fractionated radiation therapy|"Spatially fractionated radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of hot and cold spots within the tumour, thereby sparing nearby organs at risk."
48126984|NCT06322212|OTHER|Placebo|Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.
48126985|NCT01521052|DEVICE|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
48126986|NCT01279668|DRUG|Montelukast|10mg tablets, once per day for 28 days.
48126987|NCT01279668|DRUG|Placebo|tablets, once per day for 28 days.
48652773|NCT03206450|PROCEDURE|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
48652774|NCT03206450|OTHER|Laboratory Biomarker Analysis|Correlative studies
48652775|NCT03206450|OTHER|Questionnaire Administration|Ancillary studies
48652776|NCT06641726|OTHER|Not applicable- observational study|This is non-interventional, cross-sectional observational study and thus there is no intervention.
48652777|NCT06549452|DEVICE|mHealth Intervention|Our HIPPA-compliant texting platform is linked to the Fitabase Interface. Real time activity data are transmitted from the participant's smartphone to Fitabase via cellular network. Participants will receive 3-5 texts/day in sync with their preferred schedule defined at enrollment and taking into account school schedules as relevant. These texts use personal, disease-specific, and provider information to deliver two types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
48652778|NCT06549452|DEVICE|Usual Care|Routine medical care
48652779|NCT06642688|OTHER|Sacroiliac Joint Manipulation|The patient was asked to tie his arms while he was in the side lying position. The patient's upper knee was flexed and positioned such that it was placed in the popliteal fossa of the lower knee, while the lower knee was in full extension. Pushing maneuver was performed with HVLA from posterior to anterior and from medial to lateral with pelvic rotation. The contact point of the sacroiliac joint was PSIS.
47976003|NCT04104945|RADIATION|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
47976004|NCT02338661|DEVICE|SBG hip stem|
47976005|NCT02338414|DRUG|Romiplostim|Subcutaneous Romiplostim (weekly injection) -\> if titrated with maintaining PLT count between 50-200 x 10\^9/L -\> Subcutaneous Romiplostim (biweekly injection)
48126988|NCT02612233|DRUG|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
48126989|NCT02216552|DIETARY_SUPPLEMENT|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
48126990|NCT02216552|DIETARY_SUPPLEMENT|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
48126991|NCT00609297|OTHER|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
48126992|NCT00609297|OTHER|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
48126993|NCT00609297|OTHER|survey administration|Given to patient and caregivers throughout the study
48126994|NCT00094016|DRUG|beclomethasone dipropionate|
48126995|NCT05838677|BEHAVIORAL|Pain at Work Toolkit|Online toolkit providing advice and signposting to help people self-manage chronic or persistent pain at work. Access to optional phone call support from an occupational therapist providing individually tailored advice.
48126996|NCT05838677|OTHER|Active control|Treatment as usual which will vary depending on the employing organisation but may include, for example, line manager support, occupational health input etc. Access to optional non-specialist phone call support from a study researcher.
48126997|NCT01121991|DRUG|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
48126998|NCT00220740|DRUG|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
47976006|NCT05153668|DRUG|Everolimus Oral Tablet|Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
47976007|NCT05821114|OTHER|Head elevation_H|High flow_Head-elevation
47976008|NCT05821114|OTHER|Supine_H|High flow_Supine
47976009|NCT05821114|OTHER|Head elevation_L|Low flow_head elevation
47976010|NCT05821114|OTHER|Supine_L|Low flow_supine
47976011|NCT01295502|DRUG|Carboplatin|Given IV
47976012|NCT01295502|DRUG|Cisplatin|Given IV
47976013|NCT01295502|RADIATION|External Beam Radiation Therapy|Undergo EBRT
47976014|NCT01295502|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
47976015|NCT01295502|DRUG|Paclitaxel|Given IV
48126999|NCT00220740|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
47976016|NCT00553514|DRUG|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
48127000|NCT04444804|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
48127001|NCT04444804|DRUG|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
48127002|NCT00050063|BIOLOGICAL|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
47976017|NCT00553514|DRUG|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
47976018|NCT00553514|DRUG|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
47976019|NCT00553514|DRUG|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
47976020|NCT00553514|DRUG|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
48333957|NCT01629979|PROCEDURE|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
48333958|NCT01629979|RADIATION|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
48333959|NCT05189132|DIAGNOSTIC_TEST|Periodontal Diagnosis|All participants, in the test group and in the control group, will undergo an initial periodontal evaluation. The clinical evaluation will always be carried out by the same examiner, the author of the study, in order to guarantee calibrated observations. During data collection, intra-observer calibration will be performed, as recommended by the WHO (WHO, 1993), in order to minimize diagnostic variability and verify agreement
47976021|NCT00553514|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to \[=\<\] 3 follicles with a mean diameter of greater than or equal to \[\>=\] 14 millimeter \[mm\], and one or two of these follicles with a diameter of \>= 17 mm).
47976022|NCT01970449|BIOLOGICAL|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
47976023|NCT01970449|BIOLOGICAL|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10\^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
47976024|NCT01970449|BIOLOGICAL|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
48127003|NCT02332512|DRUG|Apatinib|
48127004|NCT02332512|DRUG|Placebo|
48127005|NCT03610594|OTHER|Kalaripayattu|Combination of Exercise, breathing, meditation, combat practices
48127006|NCT02979184|OTHER|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
48127007|NCT06394375|DRUG|Dexmedetomidine|OFA
48127008|NCT06394375|DRUG|Fentanyl|Given as analgesia in opioid balanced anesthesia (control) group
48127009|NCT05284565|DEVICE|Reading of the skin prick allergy test|"A double reading of the forearm will be performed with the Nexkin DSPT device. Also, two healthcare professionals will perform, consecutively, the manual reading according to their usual practice. Nexkin DSPT device provides a semi-automatic wheal detection, presenting the user an initial set of potential wheals and information about them (as their measure).~Healthcare professional can then discard, add and/or confirm wheals by visual validation, and add/edit wheal information. The device automates the test reading process, digitises the results, and quantifies."
48127010|NCT00650104|DRUG|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
48127011|NCT05514275|DRUG|Endostatin and Capecitabine|Patients received radiotherapy Combined With Endostatin(37.5mg/m2, continuous intravenous infusion for 120h, D-7, D8, D22, D36) and Capecitabine( 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles)
48127012|NCT00999167|DRUG|HPN-100|Part B: 6 mL BID for 16 weeks.
48333960|NCT05189132|DIAGNOSTIC_TEST|Microbiological analysis|"Microbiological analysis will be performed using a sample of subgingival bacterial plaque. The sample will be collected at the tooth and at the location with the highest probing depth values in each quadrant.~A sterilized paper tip from the microbiological kit will be introduced to the bottom of the bag, with the aid of tweezers, remaining in the same position for 10 seconds. After collecting the sample, the paper tip will be placed in an individual transfer tube, properly identified. Afterwards, the sample will be sent to the laboratory, where a polymerase chain reaction (PCR) test is performed to identify the following bacteria - A. actinomycetemcomitans, T. forsythia, T. denticola, P. gingivalis, P. intermedia and F. nucleatum."
48127013|NCT00999167|DRUG|Placebo|Part B: same as experimental arm
47976025|NCT01970449|BIOLOGICAL|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
48127014|NCT01859559|PROCEDURE|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
48127015|NCT01859559|PROCEDURE|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
48333961|NCT05189132|DIAGNOSTIC_TEST|Inflammatory mediators|"The evaluation of inflammatory mediators will be performed with the aid of an absorbent paper strip, which is placed inside the periodontal pocket, for about 30 seconds. The sample will be taken from the tooth that has the highest probing depth values.~The collected sample will be placed and stored in an individual transfer tube properly identified and in accordance with the laboratory's instructions. Afterwards, the sample will be sent to the laboratory, where the ELISA test is performed to quantify the following inflammatory mediators - IL-1β, IL-6 and TNF-α."
48493277|NCT01884922|DRUG|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
48493278|NCT01884922|DRUG|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
48493279|NCT01484613|DEVICE|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
47976026|NCT01970449|BIOLOGICAL|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
47976027|NCT01970449|BIOLOGICAL|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
47976028|NCT01970449|BIOLOGICAL|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
48127016|NCT03189589|DRUG|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
48333962|NCT04101669|DEVICE|RESET Liner|The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
48652780|NCT06642688|OTHER|Cervical Spine Manipulation|Cervical SM was applied supine to restrictions found on motion palpation, according to the technique described by Bergmann and Peterson28 The participant's head and neck were simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7) -to the end of passive ROM. Thereafter, a high-velocity, low-amplitude thrust was delivered in the direction of restricted movement. Participants with more ROM restriction in the lateral plane were given more lateral-to-medial directed thrusts; participants with more restriction in rotation were given thrusts in the direction of restricted axial rotation; and participants with more restriction in extension were given more anteriorly directed thrusts.
48652781|NCT01256047|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
48493280|NCT02606175|OTHER|Taking questionnaires and tests|"At predefined timepoints:~* 2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~* 1 test for medication adherence: BAASIS~* 1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~* 1 test about medication knowledge"
47976029|NCT01970449|DEVICE|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
47976030|NCT04975685|BEHAVIORAL|SMART|SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
47976031|NCT04975685|BEHAVIORAL|Sham brain training (Sudoku)|Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
47976032|NCT01202474|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
47976033|NCT01202474|DRUG|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
47976034|NCT02289898|DRUG|Demcizumab|administered intravenously
48127017|NCT03189589|DRUG|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
47976035|NCT02289898|DRUG|Abraxane®|administered intravenously
47976036|NCT02289898|DRUG|gemcitabine|administered intravenously
47976037|NCT02289898|DRUG|Placebo|
47976038|NCT04014712|DRUG|Tetrahydrobiopterin|Oral, Single dose
47976039|NCT04014712|DRUG|Placebo oral tablet|Single dose
47976040|NCT05722483|OTHER|Virtual Intensive Outpatient Program|Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
47976041|NCT01000389|DEVICE|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
47976042|NCT00845689|DRUG|placebo|NaCl 0,9 %
47976043|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0, 2 %
47976044|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0,2 %
47976045|NCT00845689|PROCEDURE|Liver resection|Liver resection with Pringle maneuver
47976046|NCT03900351|PROCEDURE|Wii fit protocol of virtual reality games|the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .
47976047|NCT03900351|PROCEDURE|Regular exercise rehabilitation protocol|It will be according to the criterion of Adams et al. (2012).
47976048|NCT02829450|OTHER|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
47976049|NCT06211478|DRUG|Vitamin E|Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
47976050|NCT03224572|DRUG|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
47976051|NCT03224572|OTHER|normal saline|500ml normal saline, once per week, and total 4-week treatment
47976052|NCT01255657|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
47976053|NCT03242057|OTHER|NAVA|Infant will be extubated to NAVA, settings based per protocol
47976054|NCT03242057|OTHER|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
47976055|NCT02851758|OTHER|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
47976056|NCT04630171|DEVICE|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
47976057|NCT04630171|DEVICE|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
48127018|NCT00005943|BIOLOGICAL|aldesleukin|
48127019|NCT00005943|BIOLOGICAL|staphylococcal enterotoxin B|
48333963|NCT04101669|OTHER|Sham|Patient receives upper endoscopy but no treatment
48333964|NCT03214926|DEVICE|Moving Through Glass intervention|
48127020|NCT01149707|DRUG|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
48127021|NCT01149707|DRUG|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
48652782|NCT06397612|OTHER|Low Dose|Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
48652783|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Verum Tablets"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
47976058|NCT04630171|OTHER|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
48127022|NCT01149707|DRUG|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
48127023|NCT01149707|DRUG|Placebo Enema|Placebo Enema, once-daily, intrarectally
48127024|NCT04319913|DEVICE|analgesia nociception index|Analgesia nociception index (ANI) could objectively monitor how pain the participant is. In the experimental group, the care provider would decrease the dose of narcotics (remifentanil) if the ANI value is above 70, and increase the dose if the ANI value is under 50.
48127025|NCT01432106|DRUG|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
48127026|NCT03980613|OTHER|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
48127027|NCT05944224|DRUG|SPH4336|SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle
48127028|NCT05944224|DRUG|Cadonilimab|Intravenous infusion, 6mg/Kg,28 days/cycle
48127029|NCT03884296|BIOLOGICAL|FluMist|Quadrivalent, live, attenuated influenza vaccine, intranasal spray
48127030|NCT03619642|OTHER|Robotic assessment of finger proprioception|The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
48333965|NCT05537610|BEHAVIORAL|CDT|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
48493281|NCT03895723|PROCEDURE|laparoscopic and robotic liver resection|laparoscopic and robotic procedure for liver resection
48652784|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Placebo Tablets"|The placebo will be a matched control.
48652785|NCT05792462|DRUG|Baricitinib|Baricitinib will be taken orally with a dose of 4mg once daily until the disease relapses or week 48, with a final evaluation at week 52.
48652786|NCT06637553|COMBINATION_PRODUCT|Adlay formula|The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily
48652787|NCT06637553|COMBINATION_PRODUCT|Placebo|Same weight as the adlay formula but did not include the active compound
47976059|NCT04630171|DEVICE|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure|Group #4: VerTouch utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
48127031|NCT03928522|DRUG|hand mixed vancomycin|hand mixed vancomycin powder into cement
48127032|NCT03928522|DRUG|hand mixed tobramycin|hand mixed tobramycin into cement
48127033|NCT03928522|DEVICE|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
48127034|NCT05741489|DEVICE|Continuous glucose monitoring (CGM)|The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
48493282|NCT03895723|PROCEDURE|open surgery|using open surgery procedure for liver resection
48493283|NCT00500747|BIOLOGICAL|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
48493284|NCT00500747|DRUG|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
48127035|NCT04762758|DRUG|(RS)-baclofen, naltrexone hydrochloride and D-sorbitol|oral fixed dose combination
48127036|NCT04762758|DRUG|Placebo|liquid oral solution
48127037|NCT00739908|DRUG|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
48127038|NCT00739908|DRUG|Placebo|Six capsules administered three times a day for six weeks.
48127039|NCT02555215|DRUG|dimethyl fumarate|administered orally
48493285|NCT03681327|OTHER|Sensory stimulation during sleep|Sensory stimulation during sleep
48493286|NCT06030141|OTHER|sesame oil application|sesame oil application
48493287|NCT06030141|OTHER|nigella sativa oil application|nigella sativa oil application
48493288|NCT02074592|BEHAVIORAL|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
48493289|NCT02074592|BEHAVIORAL|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
47976060|NCT04630171|DEVICE|Group #5: Ultrasound (US) utilized for identification of site for lumbar puncture procedure|Ultrasound (US) utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
47976061|NCT04630171|OTHER|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure|Group #6: Control group, palpation utilized for identification of site for lumbar puncture procedure for patients undergoing a therapeutic lumbar puncture
47976062|NCT03809117|DIAGNOSTIC_TEST|Biofire Film Array Gastrointestinal Panel|The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
47976063|NCT00911820|DRUG|Bevacizumab|
47976064|NCT00911820|DRUG|Cisplatin|
47976065|NCT00911820|DRUG|Irinotecan|
47976066|NCT00911820|DEVICE|Docetaxel|
47976067|NCT00700960|DRUG|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
47976068|NCT01790256|DEVICE|Cereve Sleep System at 30 degrees C|
48333966|NCT05537610|BEHAVIORAL|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
48333967|NCT03755999|OTHER|The premature infant oral motor intervention (PIOMI)|The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
47976069|NCT01790256|DEVICE|Cereve Sleep System at 14-16 degrees C|
47976070|NCT01447095|DRUG|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
47976071|NCT01447095|DRUG|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
47976072|NCT01447095|DRUG|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
47976073|NCT02090569|DEVICE|Functional micro-Doppler Sonography (fmDS)|"1. Craniotomy according to MRI images~2. Dura opening~3. Sulcal Localization using neuronavigation~4. Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~5. Exeresis of the dysplasic tissue~6. Control using fmDS before wound closure"
47976074|NCT03965962|BIOLOGICAL|VRVg-2|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
48127040|NCT03428620|OTHER|High Velocity Low Amplitude mobilization|Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
47976075|NCT03965962|BIOLOGICAL|Purified Inactivated Rabies Vaccine|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
48333968|NCT06359704|BEHAVIORAL|Caregivers Of dementia Processing Emotions (COPE) program|a dual-modal (face-to-face and online approaches), client-customized Caregivers Of dementia Processing Emotions (COPE) program
47976076|NCT03965962|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"
48127041|NCT03428620|OTHER|Exercise protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
48127042|NCT04137497|DIAGNOSTIC_TEST|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
48333969|NCT04518345|DRUG|Azacitidine|Given IV
48333970|NCT04518345|DRUG|Dubermatinib|Given PO
48333971|NCT00908622|PROCEDURE|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
47976077|NCT03965962|BIOLOGICAL|Rabies immune globulin (human)|"Pharmaceutical form: Solution for injection;~Route of administration: IM"
47976078|NCT01003730|OTHER|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
47976079|NCT01896544|DIETARY_SUPPLEMENT|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
47976080|NCT01896544|DIETARY_SUPPLEMENT|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
47976081|NCT00569569|DRUG|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
48333972|NCT00908622|PROCEDURE|Cardiac revascularization|Cardiac revascularization
47976082|NCT04216095|DEVICE|Electroconvulsive Therapy (n=30)|Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.
47976083|NCT04216095|DEVICE|Magnetic Seizure Therapy (n=30)|High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.
47976084|NCT02846779|OTHER|Low intensity|Low intensity telepharmacy outreach
47976085|NCT02846779|OTHER|Moderate intensity|Moderate intensity telepharmacy outreach
47976086|NCT02846779|OTHER|High intensity|High intensity telepharmacy outreach
48333973|NCT06071390|BEHAVIORAL|Animated- assisted video|"For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure."
48333974|NCT02678637|OTHER|MRI and muscle dynamometer|
48333975|NCT02628951|DRUG|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
48333976|NCT02628951|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
48493290|NCT05501366|DIETARY_SUPPLEMENT|Ketone Supplement|Four different exogenous ketone products at two serving sizes or a non-ketogenic placebo (one study product per test day). 1) Monoester of BHB (R)-1,3 butanediol (BHB Mono-ester), 2) diester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol (C6 Di-ester) 3) diester of AcAc and (R,S)-1,3 butanediol (AcAc Di-ester) \& 4) (R) -1,3 butanediol only (BDO). All products will be delivered in 2 different dosages 180mg/kg and 360mg/kg on separate testing days.
48493291|NCT05501366|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
48493292|NCT05501366|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of each Test Day, and removed at the end of each Test Day, Blood samples will be collected according to the schedule in Figure 1. Cannula will be flushed with a small volume of saline after each sample to maintain patency. We will draw 504 mL of blood, which is about 2.1 cups throughout the 4-week intervention
48493293|NCT05501366|OTHER|Breath Reading|Participants will breathe into a commercially available handheld breath acetone analyzer according to the schedule. Participants will wear a fitted face mask attached to a metabolic cart for a 10-minute period every 60 minutes
47976087|NCT04267367|BEHAVIORAL|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process\[27\]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
48127043|NCT03165175|BEHAVIORAL|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
48127044|NCT01204359|RADIATION|Iodine 131|iodine 131，185、370、555mBq，6 months
48333977|NCT04404803|OTHER|questionnaire|Patients will be asked to complete a questionnaire about the reasons why they agree / decline to take part in research.
48333978|NCT01535612|DEVICE|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
48493294|NCT05501366|OTHER|Heart Rate Variability|Participants will wear a Bluetooth heart rate monitor chest strap throughout the test day.
48493295|NCT05501366|OTHER|CGM/CKM|Continuous Ketone Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day
47976088|NCT03240614|DEVICE|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
48333979|NCT01718964|DRUG|Cortisol 20 mg|
48333980|NCT01718964|DRUG|Mannitol|Mannitol used as placebo
48333981|NCT02785146|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
48333982|NCT02785146|DRUG|Oxaliplatin|85 mg/m², ivdrip, D1
48333983|NCT02785146|DRUG|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
47976089|NCT03240614|DEVICE|Bag-valve-mask|This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
48333984|NCT02785146|DRUG|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
48333985|NCT03061812|DRUG|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
48333986|NCT03061812|DRUG|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
48333987|NCT03061812|DRUG|Dexamethasone|Oral tablet.
48333988|NCT00089102|DRUG|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
48333989|NCT00089102|DRUG|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
48493296|NCT05501366|RADIATION|DXA|Lean Body Mass will be assessed once via DXA
48493297|NCT05501366|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
48333990|NCT04309838|COMBINATION_PRODUCT|Treprostinil via implanted pump|Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.
48333991|NCT03363919|DEVICE|NeuroStar TMS Therapy® System|The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
48333992|NCT03363919|DEVICE|NeuroStar XPLOR®|NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
48333993|NCT01162304|DRUG|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
48333994|NCT01162304|DRUG|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
48493298|NCT01550744|DRUG|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
48493299|NCT01550744|DRUG|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
48493300|NCT01550744|DRUG|Placebo|Form = Injection, route = subcutaneous
48493301|NCT00797329|OTHER|chart review|"* cholesterol~* cognitive profiles~* violent behavior"
48493302|NCT04336514|DEVICE|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
48493303|NCT02257541|DRUG|BGJ398|
48652788|NCT01783288|OTHER|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
48652789|NCT01783288|OTHER|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.
48652790|NCT01783288|PROCEDURE|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
48652791|NCT01783288|OTHER|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
48652792|NCT01501500|DRUG|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
48652793|NCT01501500|DRUG|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
48652794|NCT04022213|DRUG|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
47976090|NCT03240614|DEVICE|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
47976091|NCT02803489|DEVICE|medical device intervention|
47976092|NCT05838105|DRUG|GnRH agonist|125 mcg once at the day mentioned
47976093|NCT05838105|DRUG|hCG|dose as mentioned
48127045|NCT03075254|DEVICE|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
47976094|NCT05838105|DRUG|Progesterone 100Mg Vag Tab|dose as mentioned
48127046|NCT03075254|DEVICE|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
48333995|NCT03970018|OTHER|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
48493304|NCT02257541|DRUG|Imatinib Mesylate|
48493305|NCT03073395|DRUG|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
48493306|NCT02151812|DEVICE|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
48493307|NCT02151812|DEVICE|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
48493308|NCT02438852|OTHER|Placebo|Given IV
48493309|NCT02438852|OTHER|Questionnaire Administration|Ancillary studies
48493310|NCT02438852|DRUG|Ropivacaine Hydrochloride|Given IV
48493311|NCT03275636|BIOLOGICAL|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
48493312|NCT01742520|DRUG|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
48493313|NCT01742520|DRUG|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
48493314|NCT02715934|OTHER|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
48493315|NCT02715934|OTHER|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
48652795|NCT04022213|RADIATION|WAP-IMRT|Group A participants will receive WAP-IMRT approximately 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
48652796|NCT04221477|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
48652797|NCT04221477|DRUG|MMF|MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
48652798|NCT04221477|DRUG|Prednisone|Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
48652799|NCT04221477|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
48652800|NCT04221477|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
48652801|NCT04221477|DRUG|Acetaminophen|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
48652802|NCT04221477|DRUG|Diphenhydramine|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
47976095|NCT04931745|DEVICE|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
47976096|NCT04931745|DEVICE|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
48333996|NCT00463879|DRUG|Galantamine|
48493316|NCT04050150|BEHAVIORAL|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
48493317|NCT00169819|DRUG|Abciximab|
48493318|NCT02423356|PROCEDURE|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
48493319|NCT03738852|DEVICE|Continuous Glucose Monitor (CGM)|Continuous Glucose Monitor (CGM)
48493320|NCT03738852|DRUG|Insulin|standard insulin regimen
48493321|NCT05162365|BIOLOGICAL|IBI314|Low/medium/high dose, intravenously, once, on Day 1
48493322|NCT05162365|OTHER|Placebo|Placebo, intravenously, once, on Day 1
48652803|NCT01987999|DIETARY_SUPPLEMENT|Acetogenins|
47976097|NCT04931745|OTHER|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
48652804|NCT06150898|PROCEDURE|Prospective data and sample collection|Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity
48652805|NCT06150898|DRUG|Ketorolac 10 Mg Oral Tablet|Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
48652806|NCT06150898|DRUG|Pregabalin 75mg|Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
48652807|NCT04279587|BEHAVIORAL|Residential camp|Intensive education at a residential camp.
48652808|NCT00450840|DRUG|Simvastatin|
47976098|NCT00161083|DRUG|ursodeoxycholic acid|
48493323|NCT01031953|DRUG|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
48493324|NCT01031953|DRUG|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
48493325|NCT01031953|OTHER|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
48652809|NCT05327569|OTHER|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
48652810|NCT04510740|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
48652811|NCT04501705|DRUG|Apatinib Mesylate|"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."
48127047|NCT03075254|DEVICE|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
48333997|NCT03984838|DRUG|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
48333998|NCT03385694|DIAGNOSTIC_TEST|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
48333999|NCT02479295|DEVICE|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
48334000|NCT02858284|DEVICE|TUG|Therapeutic Ultrasound for Glaucoma
48334001|NCT02858284|DEVICE|Sham|
48334002|NCT01809678|BEHAVIORAL|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
48334003|NCT01809678|BEHAVIORAL|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
48334004|NCT01809678|OTHER|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
48334005|NCT03550365|OTHER|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
48334006|NCT03550365|OTHER|Rye bread intervention|4 week dietary intervention rich in rye bread
48334007|NCT03550365|OTHER|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
48334008|NCT02099487|RADIATION|Radiation|hypofractionated IMRT
48334009|NCT02195609|DIETARY_SUPPLEMENT|Omega-3|600 mg oral twice a day
48334010|NCT02195609|DIETARY_SUPPLEMENT|Soy Isoflavones|54.4 mg oral twice a day
48334011|NCT02865265|PROCEDURE|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
48334012|NCT06310070|DEVICE|3D Printed Personalized Ostomy Appliance|Study procedures will include getting your stoma scanned, receiving personalized ostomy appliances in the mail, receiving a personalized ostomy template, which will be printed using a 3D printer, in the mail, and completing a daily symptom diary along with a weekly survey for 4 weeks.3D printing is done using a machine that takes the 3D image from the computer and prints a replica of the image using plastic or other materials.
48652812|NCT04403776|DRUG|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
48652813|NCT04403776|DRUG|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
48652814|NCT04909801|DRUG|Abatacept|Abatacept SC (125 mg) once weekly
48652815|NCT04909801|DRUG|Adalimumab|Adalimumab SC (40 mg) once every 2 weeks
48493326|NCT01031953|PROCEDURE|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
48493327|NCT01816919|OTHER|collecting breath samples|
48493328|NCT00127036|DRUG|XELOX|XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
48652816|NCT04909801|DRUG|Methotrexate|Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
48652817|NCT00708981|OTHER|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL \> 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
48652818|NCT00459550|DRUG|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
48127048|NCT04559126|DRUG|EDP-297|EDP-297 Oral solution
48127049|NCT04559126|DRUG|Placebo|placebo to match EDP-297
48127050|NCT01075152|DRUG|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
48127051|NCT01075152|BIOLOGICAL|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
48334013|NCT04083118|DIAGNOSTIC_TEST|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
48334014|NCT04083118|DIAGNOSTIC_TEST|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
48334015|NCT04399980|DRUG|Mavrilimumab|Treatment infusion
48334016|NCT04399980|DRUG|Placebos|Placebo infusion
48334017|NCT00004685|DRUG|albuterol|
48334018|NCT03549429|DEVICE|Medical tapes: TegadermTM and EyeGard®|TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
48334019|NCT01633229|PROCEDURE|Bone Marrow Stromal Cell Infusion|
48493329|NCT00127036|DRUG|XELIRI|XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
48493330|NCT00127036|DRUG|Bevacizumab|7.5 mg/kg intravenously (IV)
48493331|NCT00943462|RADIATION|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2-Gy fractions, for a total of 30 fractions
48127052|NCT04703283|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
48127053|NCT03562338|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
48127054|NCT03562338|OTHER|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
48127055|NCT03000101|OTHER|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
48127056|NCT03000101|OTHER|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
48334020|NCT02414971|OTHER|There is no intervention|There is no intervention
48334021|NCT01146548|DRUG|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
48334022|NCT04661267|DIETARY_SUPPLEMENT|Stem Cell Support Formula|This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
48334023|NCT04661267|DIETARY_SUPPLEMENT|Placebo|The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
48334024|NCT03331224|DEVICE|OTSC|OTSC placement
48334025|NCT03331224|DEVICE|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
48334026|NCT04668092|OTHER|Functional dry needling|functional dry needling applied to hamstring for 1 minute and post interventional data collected
47976099|NCT05735132|PROCEDURE|Conventional Line-blocking|Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.
48127057|NCT05983185|BEHAVIORAL|Prism adaptation therapy|The investigators' research and clinical group is the US leader in implementing this intervention for spatial neglect and have brought it to more than 50 clinical centers, hospitals, and treatment organizations.
48334027|NCT06177171|DRUG|Olaparib|Given orally
48334028|NCT06177171|DRUG|ASTX727|Given Orally
48334029|NCT02500277|DEVICE|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
47976100|NCT05735132|PROCEDURE|Bar-blocking|Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.
47976101|NCT05735132|PROCEDURE|V-blocking|Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
47976102|NCT04610840|PROCEDURE|Puncture of the caliceal system|Puncture of the caliceal system under ultrasound/Xray control
48127058|NCT02463214|OTHER|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
48127059|NCT00431834|DEVICE|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
48334030|NCT02500277|DEVICE|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
48334031|NCT04203940|PROCEDURE|Cyanoacryale|mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
48334032|NCT04203940|PROCEDURE|Suture|mesh fixation was done with polypropylene 2/0 sutures
48334033|NCT00247559|BIOLOGICAL|Botulinum toxin type A|
48334034|NCT04454138|DEVICE|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
48334035|NCT03264833|OTHER|TempTraq|no intervention
48334036|NCT03194620|OTHER|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
48334037|NCT03194620|OTHER|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
48334038|NCT03194620|OTHER|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
48334039|NCT03194620|OTHER|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
48334040|NCT03194620|OTHER|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
48334041|NCT03194620|OTHER|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
48334042|NCT03194620|OTHER|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
48334043|NCT03194620|OTHER|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
48334044|NCT04209400|BIOLOGICAL|Sci-B-Vac®|Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
48334045|NCT04209400|BIOLOGICAL|Engerix-B®|Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
48334046|NCT04989088|DEVICE|ProComp5 Infiniti System w/BioGraph Infiniti Software|Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
48334047|NCT04989088|DEVICE|ProComp5 Infiniti System w/recorded videos|Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
48334048|NCT00373412|BIOLOGICAL|VCL CT02 pDNA vaccine|
48127060|NCT00431834|PROCEDURE|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
48127061|NCT00436631|BEHAVIORAL|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
48334049|NCT00373412|BIOLOGICAL|Towne CMV vaccine|
48334050|NCT01277471|BEHAVIORAL|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
48652819|NCT00459550|DRUG|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
47976103|NCT01634971|PROCEDURE|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
48334051|NCT01277471|BEHAVIORAL|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
48127062|NCT03792932|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
48334052|NCT06129942|DEVICE|Bright light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 09:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
48334053|NCT06129942|DEVICE|Dim Light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 09:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
48334054|NCT03672357|PROCEDURE|Laparoscopic liver resection|Laparoscopic hepatectomy
48334055|NCT03672357|PROCEDURE|Open liver resection|Traditional open hepatectomy
48334056|NCT02726126|DRUG|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
48334057|NCT00567060|DRUG|Piracetam|
48334058|NCT04991272|OTHER|prewarming and warmed fluid infusion|prewarming with forced air warming system and warmed fluid infusion.
48334059|NCT03052387|OTHER|assigned intervention|"\* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~* Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~* Using fissure bur to harvest the graft for the defect.~* Closure using vicryl 3-O sutures."
48334060|NCT02858102|BEHAVIORAL|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
47976104|NCT00720837|PROCEDURE|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
48334061|NCT00778726|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
48334062|NCT04783870|DRUG|Dapagliflozin|Dapagliflozin 10 mg PO QD
48334063|NCT04783870|DRUG|Placebo|Placebo
48334064|NCT00228943|DIETARY_SUPPLEMENT|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
48652820|NCT06640413|DRUG|[177Lu]Lu-OncoFAP-23|3.7, 7.4, or 11.1 GBq to define the RD
48652821|NCT06640413|DRUG|L19IL2|22.5 Mio IU
48652822|NCT03923270|DRUG|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
48652823|NCT03923270|DRUG|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
48652824|NCT03923270|DRUG|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
48652825|NCT03923270|RADIATION|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
47976105|NCT00240162|DRUG|PTK787/ZK 222584|
47976106|NCT00005094|DRUG|celecoxib|Given orally
47976107|NCT00005094|OTHER|placebo|Given orally
48652826|NCT03923270|DRUG|Tremelimumab|Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
48127063|NCT03792932|PROCEDURE|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
48493332|NCT00943462|DRUG|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
48493333|NCT01918540|PROCEDURE|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
48493334|NCT01918540|PROCEDURE|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
48493335|NCT01918540|DEVICE|MS-30 femoral stem|This is the stem used in the study.
48652827|NCT06111742|DEVICE|Bedside Entertainment and Relaxation Theater (BERT)|BERT is a Nebula Capsule Max portable projector that creates a familiar theater experience designed for children to divert attention away from procedures. It is fitted with a remote control that can be utilized to manage on-screen activities. BERT can be used with any wall, ceiling, or projector screen to create the theater experience with a large screen. It can also be used with assist devices, such as steering wheel and noise-canceling headphones.
48493336|NCT00000660|DRUG|Etoposide|
48652828|NCT06162507|BIOLOGICAL|CM310|CM310 injection
48652829|NCT03828526|OTHER|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
48652830|NCT03828526|OTHER|Traditional teaching strategy|Classroom-based strategy
47976108|NCT02782780|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
48127064|NCT01782846|DRUG|Ixprim®|
48127065|NCT01782846|DRUG|Dafalgan-Codeine®|
48493337|NCT05648786|BEHAVIORAL|Laddr® plus Behavioral- Group and individual counseling|"Smartphone application utilizing the Community Reinforcement Approach (CRA) to facilitate social support in substance use treatment.~Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services."
48493338|NCT05648786|BEHAVIORAL|Behavioral- Group and individual counseling|The active control condition consists of standard outpatient treatment for substance use disorders. Outpatient treatment will include a range of services, including group counseling, individual counseling, medication treatment, and other recovery support services.
48493339|NCT01625130|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
48127066|NCT06461390|DRUG|Norepinephrine|NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\&gt;5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
48127067|NCT06461390|DRUG|Ringer's Lactate|Fluid Group will receive ringer lactate bolus 20 ml/ kg only. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed
48127068|NCT03000595|DRUG|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
48127069|NCT03000595|DRUG|Placebo|The vehicle cream
48127070|NCT03245424|DRUG|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
48127071|NCT03160521|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
48493340|NCT01625130|DIETARY_SUPPLEMENT|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
48652831|NCT06570356|DIAGNOSTIC_TEST|Geriatric Depression Scale - 15|a validated screening tool designed to identify depression in older adults. It consists of 15 simple yes/no questions that assess depressive symptoms.
48652832|NCT01040026|OTHER|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
48652833|NCT04179084|DRUG|fruquintinib|5mg qd, 2weeks on, 1week off
48652834|NCT04179084|DRUG|Sintilimab|200mg q3w
48652835|NCT05931822|OTHER|Silver Diamine Fluoride 38%|silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar
48652836|NCT05931822|OTHER|fluoride varnish|fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
48652837|NCT04482062|DEVICE|Edwards EVOQUE System|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
48652838|NCT04482062|DRUG|Optimal Medical Therapy|Optimal Medical Therapy
48334065|NCT00228943|DIETARY_SUPPLEMENT|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
48334066|NCT05516719|OTHER|Positron Emission Tomography (PET) scan using BU99008 tracer|A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
48334067|NCT05516719|OTHER|FP-CIT Single-photon Emission Computed Tomography (SPECT) scan|A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
48334068|NCT05516719|OTHER|Magnetic Resonance Imaging (MRI) Scan|MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
48334069|NCT05516719|OTHER|Lumbar puncture|A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
48334070|NCT03915912|BEHAVIORAL|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
48334071|NCT02970227|OTHER|Observation|None, observation only
48334072|NCT02040155|DEVICE|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
48334073|NCT03226548|OTHER|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
48334074|NCT00377533|DEVICE|wheelchair rear anti-tip device|assistive device
48334075|NCT01620450|DRUG|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
48334076|NCT05351463|PROCEDURE|papila suture technique|simple interupted vs internal horoizontal matress suture
48334077|NCT02376595|DRUG|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
48334078|NCT05633680|DIAGNOSTIC_TEST|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
48334079|NCT05167721|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells administered intrathecally
48334080|NCT05167721|OTHER|Placebo|Placebo administered intrathecally
48334081|NCT06117917|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
48493341|NCT01461564|PROCEDURE|Colonoscopy|Screening colonoscopy
48493342|NCT01470612|DRUG|CP-690,550|5 mg tablets, BID, for at least 12 months
48493343|NCT01470612|DRUG|CP-690,550|10 mg tablets, BID, for at least 12 months
48493344|NCT04190030|BEHAVIORAL|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
48652839|NCT01962753|DRUG|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
48334082|NCT06117917|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
48334083|NCT03385408|DEVICE|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
48334084|NCT03385408|DEVICE|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
48334085|NCT05250518|PROCEDURE|argon plasma coagulation|After hot snare polypectomy, participants will be randomized assigned to the APC group for argon plasma coagulation to prevent colorectal post-procedure bleeding.
48334086|NCT05250518|PROCEDURE|clip closure|After hot snare polypectomy, participants will be randomized assigned to the Clip group for complete closure(spacing between adjacent clips \< 1cm) to prevent colorectal post-procedure bleeding.
48334087|NCT06392750|BEHAVIORAL|Collection of tumor tissue specimens|Collection of tumor tissue specimens during surgery
48652840|NCT03362632|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
48493345|NCT04190030|BEHAVIORAL|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
48493346|NCT04944719|DIAGNOSTIC_TEST|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
48652841|NCT06579092|DRUG|AZD5004|AZD5004 film-coated tablet once daily during 36 weeks
48652842|NCT06579092|DRUG|Placebo|Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
48652843|NCT03349996|DEVICE|LifeStream Peripheral Stent Graft System|Patients will be treated with the LifeStream Peripheral Stent Graft System
48334088|NCT00143962|BEHAVIORAL|Low Carbohydrate Diet|
48334089|NCT00669032|DEVICE|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
48334090|NCT00669032|OTHER|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
48334091|NCT04016688|PROCEDURE|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
48334092|NCT01186003|DRUG|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
48334093|NCT02591888|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
48334094|NCT02591888|DRUG|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
48652844|NCT05313373|OTHER|Virtual Reality|In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
48652845|NCT06642623|DRUG|Enavogliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
48652846|NCT06642623|DRUG|Dapagliflozin or Empagliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
48652847|NCT01929603|PROCEDURE|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
48652848|NCT01929603|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
48652849|NCT01929603|DRUG|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
48652850|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with no arthroscopy|The two procedures, with and without arthroscopy, only differ by the method of assessing cartilage removal. Cartilage removal will be assessed arthroscopically in the procedure with arthroscopy. In the procedure without arthroscopy, cartilage removal will be assessed via direct visualization through a mini arthrotomy procedure. After use of the cartilage burr the surgeon will make a small dorsal portal and use this opening to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint.
48652851|NCT06570590|PROCEDURE|Minimally invasive lapidus procedure with arthroscopy|After removal of the cartilage with the cartilage burr, a 3.0 arthroscope will be inserted to inspect the joint for all cartilage removal. Any residual cartilage pieces will be removed to ensure complete cartilage debridement from the subchondral bone and fragments removed from the joint.
48652852|NCT00276315|BIOLOGICAL|Botulinum toxin type A|
48652853|NCT06640582|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
48127072|NCT03160521|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
48334095|NCT04026971|PROCEDURE|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
48334096|NCT03177785|BEHAVIORAL|EverydayMatters|
48334097|NCT00511849|DRUG|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
48334098|NCT00861380|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
48652854|NCT06640582|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
48652855|NCT06640582|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
48652856|NCT06640582|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
48652857|NCT06640582|DRUG|Pembrolizumab|Intravenous (IV) infusion
48652858|NCT02002715|DRUG|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
48127073|NCT03160521|DRUG|Placebo of Risperidone ISM|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
48127074|NCT00334776|BIOLOGICAL|MART-1 antigen|
48127075|NCT00334776|BIOLOGICAL|gp100:209-217(210M) peptide vaccine|
48127076|NCT00334776|BIOLOGICAL|therapeutic autologous dendritic cells|
48127077|NCT00334776|BIOLOGICAL|tyrosinase peptide|
48334099|NCT00861380|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children \< 12 months of age at the time of first study vaccination."
48493347|NCT05946954|PROCEDURE|Immediate Dentoalveolar Restoration|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
48493348|NCT05946954|PROCEDURE|Ice cream cone technique|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
48493349|NCT00724490|PROCEDURE|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
48493350|NCT00351598|RADIATION|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
48652859|NCT03270228|OTHER|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
48493351|NCT04744350|PROCEDURE|Treatment of FFP type IIb and IIc|Patients will either be randomized in the surgical or conservative group.
48127078|NCT03246724|DRUG|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg"
48493352|NCT06303973|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48493353|NCT06303973|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48493354|NCT04764136|DEVICE|Scoliometer (scolioscope)|Individuals with scoliosis will participate in this study. The device will be used to determine spinal rotation on the transverse plane. Repeated measures will be taken.
48652860|NCT03026777|DRUG|intravenous crystalloid fluid, 500 mL|
48652861|NCT02645370|DRUG|Danzhen|
48652862|NCT02645370|DRUG|Topiramate|
48652863|NCT05494619|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
48652864|NCT05494619|DRUG|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
48652865|NCT05494619|DRUG|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
48652866|NCT04874597|DRUG|Ocrelizumab|Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
47976109|NCT01101932|DRUG|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
47976110|NCT01101932|DRUG|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
47976111|NCT01101932|DRUG|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
48127079|NCT03246724|DRUG|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg"
48652867|NCT06636773|BEHAVIORAL|Diet|A reduced energy diet ranging from 1200-2100 kilocalories per day will be recommended for participants.
48127080|NCT03246724|DRUG|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule"
48493355|NCT05417503|OTHER|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
48652868|NCT06636773|BEHAVIORAL|Aerobic Exercise|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress from an initial amount of 100 minutes per week to 300 minutes per week across the initial 6 months of the intervention, with this level of physical activity continuing to be recommended between months 7-12.
48652869|NCT06636773|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly group-based behavioral session for months 1-6, with these sessions being offered twice per month during months 7-12 to assist in supporting recommended changes in energy intake (diet) and physical activity.
48652870|NCT06636773|BEHAVIORAL|Aerobic + Yoga Exercise|Physical activity will be recommended in the form of a combination of aerobic types of activity, such as brisk walking, and yoga. Aerobic activity will progress from 60 minutes per week to 180 minutes per week across the initial 6 months of the intervention. Yoga will progress from 40 minutes per week to 120 minutes per week across the initial 6 months of the intervention. When combined this will progress from a total of 100 minutes per week to 300 minutes per week across the initial 6 months of treatment. This level of physical activity will continue to be recommended between months 7-12.
48652871|NCT05870111|DRUG|Citicoline (cytidine diphosphate-choline)|2000mg/day citicoline, administered orally, for 4 weeks
48652872|NCT05870111|DRUG|Placebo oral capsule|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
48652873|NCT06384261|DRUG|Cusatuzumab|CD70 monoclonal antibody
48652874|NCT06384261|DRUG|Venetoclax|BCL-2 inhibitor
48652875|NCT06384261|DRUG|Azacitidine|Hypomethylating agent
48127081|NCT03246724|DRUG|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
48127082|NCT00162344|DRUG|Technetium Tc99m Sestamibi|
48652876|NCT05989477|OTHER|At-home Breast Oncology care Delivered with E-health solutions - ABODE|The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
48652877|NCT00373360|DRUG|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
48127083|NCT02973594|DRUG|Ivabradine|
48127084|NCT02973594|DRUG|Placebo|
48127085|NCT03836222|DRUG|PCS499|MR tablet
48127086|NCT03836222|DRUG|Trental|comparator tablet
48127087|NCT05299346|OTHER|Follow up|Comprehensive follow up in dedicated follow up unit
48127088|NCT03298074|DRUG|Apatinib|Apatinib, 500mg,po qd for continuous administration
48127089|NCT03298074|DRUG|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
48127090|NCT05891366|DRUG|WAL0921|Investigational product WAL0921
48652878|NCT00742690|DRUG|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
48652879|NCT00742690|DRUG|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
48652880|NCT06373718|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
48127091|NCT05891366|DRUG|Placebo|Placebo product
48127092|NCT06266936|OTHER|No intervention|The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
48334100|NCT00861380|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children \>= 12 months of age at the time of first study vaccination.
48334101|NCT06079034|PROCEDURE|Venovenous ECMO|Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
48334102|NCT06079034|PROCEDURE|Venoarterial ECMO|Initial support type of venoarterial ECMO
48493356|NCT05417503|OTHER|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
48652881|NCT06284681|BEHAVIORAL|Weight-focused health coaching|Following the definition of structured lifestyle interventions within the current obesity clinical practice guidelines, the weight-focused health coaching intervention will be delivered as a multi-component behavior change intervention intended to produce clinically-important weight loss through consuming a healthy, energy-restricted diet and increasing physical activity.
48334103|NCT06396455|PROCEDURE|interscalene block group|The ISB group scanning was done by linear ultrasound probe just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle; the skin was disinfected, and the transducer was positioned in the transverse plane to identify the carotid artery. Once the artery was identified, the transducer was moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles. 3 ml lidocaine 1% was injected at puncture site The needle was then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction. After a careful aspiration, 20 ml of bupivacaine 0.25% was injected.
48334104|NCT06396455|PROCEDURE|Suprascapular nerve block group|After cleaning the skin with an antiseptic solution, an ultrasound probe was put in sagittal orientation at the superior medial border of the scapula to identify the pleura and then moved laterally; when it was parallel to the spine of the scapula, the transducer was moved cephalad and the suprascapular fossa was identified, and then the transducer was moved lateral to locate the suprascapular notch. The suprascapular nerve was a round hyperechoic structure beneath the transverse scapular ligament in the scapular notch. 3 ml lidocaine 1% was injected at puncture site then the needle was inserted along the longitudinal axis of the ultrasound beam, and 10 ml of bupivacaine 0.25% was injected.
48334105|NCT01444508|DRUG|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
48493357|NCT03178032|BIOLOGICAL|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
48652882|NCT06284681|BEHAVIORAL|Weight-neutral health coaching|Dietary and physical activity prescriptions for the weight-neutral health coaching intervention will be similar to the weight-focused intervention except the diet prescription will be designed to fully meet daily estimated energy requirements rather than creating a negative energy balance and producing weight loss. Health coaches will not emphasize changes in body weight as an explicit goal or as a mediator of improved cardiometabolic health. Rather, health coaches will emphasize achieving diet and exercise behavioral goals as a direct means to improving cardiometabolic health independently of changes in body weight.
48652883|NCT06284681|BEHAVIORAL|Intensify lifestyle approach|Participants identified as non-responders to initial health coaching interventions may be re-randomized to receive a 4-month membership to the local YMCA and health coaches will assist participants in identifying and enrolling in at least 2 weekly group fitness classes at the YMCA.
48493358|NCT03677791|OTHER|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
48493359|NCT03677791|OTHER|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
48127093|NCT03666468|OTHER|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
48493360|NCT02140723|RADIATION|preoperative short course radiation|
48493361|NCT03121430|DEVICE|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
48652884|NCT06284681|OTHER|Augment with enhanced medical management|Participants identified as non-responders to initial health coaching interventions may be re-randomized to meet with the primary care provider and health coach to consider additional or revised medication plans to address their weight and weight-related chronic conditions.
48127094|NCT03666468|OTHER|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
48127095|NCT03666468|OTHER|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
48127096|NCT05461313|OTHER|Constrained Liner|Subjects in this arm will receive a constrained liner with one of the following implants: Freedom Constrained Acetabular Liner (Zimmer Biomet), G7 Freedom Constrained Acetabular Liner (Zimmer Biomet) or Lubinus Acetabular Cup with a safety ring (LINK)
48334106|NCT01444508|DRUG|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
48334107|NCT00444964|DRUG|Nutropin AQ|0.0125 mg/kg/day
48493362|NCT03121430|DEVICE|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
48493363|NCT05622292|DEVICE|HARKIT I-Care Application|HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
48493364|NCT05913466|DRUG|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
48493365|NCT05913466|DRUG|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
48493366|NCT05425693|OTHER|Hybrid Warm-up|Dynamic + stretching exercises
48493367|NCT05425693|OTHER|Dynamic Warm-up|Dynamic exercises
48493368|NCT05425693|OTHER|Stretching Warm-up|Stretching exercises
48652885|NCT05599321|DIAGNOSTIC_TEST|Virtual Navigation System|The Virtual Navigator guidance computer is interfaced to the bronchoscopy hardware to tap off the live bronchoscopy and EBUS video feeds. The standard OR medical team (technicians, clinical fellows, et al.) is on hand, and standard clinical facilities (e.g., fluoroscopy, CT/PET image viewer) are available. Our technical team is also present to record all procedural video and computer display information. It also operates the guidance computer during the guided procedure and offers any assistance in case of unanticipated issues. The participant's clinical bronchoscopy will be recorded by the radiology imaging management system.
48652886|NCT06639711|DRUG|Taurine|Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
48652887|NCT04804345|OTHER|standard of care|retrospective study: standard of care
48652888|NCT06674941|DRUG|Teprotumumab|Administered as an SC injection.
48652889|NCT03568123|DEVICE|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
48652890|NCT03568123|DEVICE|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients \>65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
48127097|NCT05461313|OTHER|Dual Mobility|Subjects in this arm will receive a dual mobility cup with the following implant: Avantage Dual Mobility Cup (Zimmer Biomet)
48127098|NCT05397275|OTHER|progressive muscle relaxation+breathe exercises|progressive muscle relaxation+breathe exercises
48127099|NCT05397275|OTHER|breathe exercises|breathe exercises
48127100|NCT01700296|BEHAVIORAL|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~1. 10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~2. Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
48127101|NCT05871658|BEHAVIORAL|electroacupuncture|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
48127102|NCT01426698|PROCEDURE|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
48127103|NCT00329862|PROCEDURE|Laparoscopic Truncal Vagotomy|
48652891|NCT03020316|BEHAVIORAL|Peer Mentor|A volunteer with a similar disease as the subject
48127104|NCT01635712|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
48652892|NCT03020316|BEHAVIORAL|Transcendental Meditation|A meditation technique
48652893|NCT02542371|OTHER|Arterial Imaging|
48334108|NCT01607294|DRUG|ETC-1002|ETC-1002 Daily for 4 weeks
48334109|NCT01607294|DRUG|Placebo|Placebo Daily for 4 weeks
48334110|NCT03973203|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
48334111|NCT02468141|DRUG|SJDBT|Sipjeondaebo-tang
48334112|NCT02468141|DRUG|Placebo|Placebo
48334113|NCT03310437|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
48334114|NCT04433156|DRUG|Bortezomib|1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48334115|NCT04433156|DRUG|Rituximab|375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48334116|NCT04433156|DRUG|Epirubicin|70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48334117|NCT04433156|DRUG|Cyclophosphamide|750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48334118|NCT04433156|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
48334119|NCT04173039|DIAGNOSTIC_TEST|Serum anti-CarP antibodies detection|Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
48334120|NCT03743207|OTHER|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
48334121|NCT03743207|OTHER|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
48334122|NCT00602511|DRUG|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
48334123|NCT00602511|DRUG|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
48334124|NCT03318601|PROCEDURE|Blood taking|"Blood taking in 2 times :~* J0 : 15 mL~* J14 : 5 mL 20 mL in total volume"
48334125|NCT00250081|PROCEDURE|Upper Extremity Tendon transfer|
48127105|NCT03459989|DIAGNOSTIC_TEST|Ultrasound|Samsung H60 Ultrasound
48127106|NCT01910896|DEVICE|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
48334126|NCT00250081|PROCEDURE|Botulinum Toxin injections in Upper Extremity|
48334127|NCT00250081|PROCEDURE|Regularly ongoing therapy|
48334128|NCT02843919|OTHER|Electroencephalography and Electrocardiography|
48334129|NCT04944381|BIOLOGICAL|SARS-Cov-2 mRNA vaccine immunization|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd and .
48334130|NCT04944381|BIOLOGICAL|Inactivated SARS-Cov-2 vaccine immunization|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
48334131|NCT02375984|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10\^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
48334132|NCT01495923|PROCEDURE|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
48334133|NCT01495923|PROCEDURE|Sham epidural steroid injection|Injection of saline into the back muscles
48334134|NCT01495923|DRUG|Gabapentin|Titration of gabapentin to effect
48334135|NCT01495923|DRUG|Placebo gabapentin|Titration of placebo gabapentin
48334136|NCT02596685|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
48334137|NCT02596685|OTHER|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
48334138|NCT02596685|OTHER|Laboratory Biomarker Analysis|Correlative studies
48127107|NCT00976105|DRUG|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
48127108|NCT00976105|DRUG|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
48127109|NCT00311714|DRUG|CS-8958 formulated as dry powder|
48127110|NCT00311714|OTHER|Placebo|
48334139|NCT02596685|OTHER|Questionnaire Administration|Ancillary studies
48334140|NCT01438307|DRUG|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
48493369|NCT02865252|OTHER|MWM Treatment|
48493370|NCT02865252|OTHER|MWM Sham|
48334141|NCT01438307|DRUG|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
48334142|NCT04745078|OTHER|Caboxy30|carboxy30 to periorbital dark halos
47976112|NCT05182489|DEVICE|Medtronic Adaptix™ titanium implants|Patients who will be having a spinal fusion procedure as part of their standard of care treatment will be randomized to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON DBM DBF. In order to assess fusion, patients will undergo a research-only CT Scan at 6 months post-surgery.
48334143|NCT04745078|OTHER|Caboxy60|carboxy60 to periorbital dark halos
48334144|NCT02629328|DEVICE|CardioCel|Treatment with CardioCel implant
48334145|NCT04472637|DRUG|Atorvastatin|atorvastatin 10 mg, as one tablet /day for 24 weeks.
48493371|NCT05222503|DEVICE|Knee Brace + OPUM Digital Knee|Knee Brace + OPUM Digital Knee
48652894|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through single incision|Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
47976113|NCT05182489|DEVICE|Medtronic CAPSTONE® PEEK cage|Medtronic CAPSTONE® PEEK cage
47976114|NCT03793933|PROCEDURE|Liver resection|Surgery for the liver
47976115|NCT04897932|DEVICE|RS - WP06|Ad hoc use of handheld urinal
47976116|NCT03804047|OTHER|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
47976117|NCT03682445|OTHER|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
47976118|NCT03081260|OTHER|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
47976119|NCT03081260|OTHER|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
47976120|NCT05786885|PROCEDURE|Microneedling will be done with application of topical vitamin C paste for depigmentation|"A Dermapen device will be used to microneedle the gingival tissue (model M8) with 24 microneedles arranged in rows, which is adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min.~It will be used in intermittent motion on the affected area for 30-40 seconds / tooth.~Once bleeding points are observed on all areas of the pigmented gingiva, it will be irrigated using saline solution and dried using sterile gauze.~Topical vitamin C powder (1000 mg/ml) will be mixed with saline, and the resultant slurry mix will then be applied to the gingiva for 10 minutes."
47976121|NCT05786885|PROCEDURE|Vitamin C injection|"1-1.5 ml Vitamin C will be injected into the gingiva, using an insulin syringe, once weekly, for 3 weeks.~All the injection procedures will be performed by the same operator. The treated area will be left without dressing in both groups."
48334146|NCT04472637|DRUG|Placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
47976122|NCT02438098|DRUG|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
47976123|NCT01647620|DRUG|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
47976124|NCT01647620|DRUG|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
48334147|NCT01821547|DRUG|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
48334148|NCT00023712|DRUG|bortezomib|Given IV
48334149|NCT00023712|OTHER|laboratory biomarker analysis|Correlative studies
48493372|NCT05222503|DEVICE|Knee Brace|Knee Brace without OPUM Digital Knee
47976125|NCT01860651|BEHAVIORAL|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
48127111|NCT00753493|DRUG|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
48334150|NCT00023712|OTHER|pharmacological study|Correlative studies
48334151|NCT06184542|BIOLOGICAL|DTacP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on Day 0
48334152|NCT06184542|BIOLOGICAL|DTacP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
48334153|NCT06184542|BIOLOGICAL|DT (one-dose booster)|Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
48334154|NCT06184542|BIOLOGICAL|DTaP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
48334155|NCT06184542|BIOLOGICAL|PENTAXIM (one-dose booster)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
48334156|NCT06184542|BIOLOGICAL|DTaP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
48334157|NCT06184542|BIOLOGICAL|PENTAXIM (three-dose primary vaccination)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
48334158|NCT05127291|OTHER|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
48334159|NCT03872193|OTHER|Exercise|Virtual Reality Exercies
48334160|NCT03808428|DEVICE|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
48334161|NCT02145832|DRUG|Fluconazole|
48334162|NCT02145832|DRUG|Micafungin|
48334163|NCT03509844|BEHAVIORAL|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
48334164|NCT01600001|DRUG|KWA-0711|
48334165|NCT01600001|DRUG|Placebo|
48334166|NCT00344760|DRUG|Enfuvirtide|subcutaneously twice a day
48334167|NCT00344760|DRUG|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
48334168|NCT06580860|DRUG|Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids|Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
48334169|NCT02789826|PROCEDURE|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
48334170|NCT02789826|PROCEDURE|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
48334171|NCT04970849|OTHER|observation|IBD doctors who perform the endoscopy perform the questionnaire
48334172|NCT00781872|BIOLOGICAL|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
48334173|NCT03330600|BEHAVIORAL|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
48334174|NCT03330600|BEHAVIORAL|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
48334175|NCT05713825|PROCEDURE|Endovascular embolization or surgery|"* Endovascular embolization may be done with coils, remodeling technique (coils and balloon), stent and coils, flow-diverter, endosaccular devices. The access is through the femoral or radial artery.~* Surgery is considered the standard neurosurgical procedure of aneurysm clipping."
48652895|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through double incision|Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
48652896|NCT03201094|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
48127112|NCT00290069|DRUG|Tacrolimus|
48127113|NCT00290069|DRUG|Rapamycin|
48127114|NCT05427305|DRUG|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
48127115|NCT05427305|DRUG|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
48334176|NCT04777604|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
48127116|NCT01010685|PROCEDURE|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
48127117|NCT03608995|DIAGNOSTIC_TEST|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
48493373|NCT03997214|DEVICE|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
48127118|NCT03608995|DIAGNOSTIC_TEST|Quikcheck fFN ™|- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
48127119|NCT02035904|DRUG|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
48127120|NCT02035904|DRUG|saline|patient controlled infusion from the 2nd day after surgery
48127121|NCT02035904|DRUG|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
48127122|NCT02035904|DEVICE|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
48127123|NCT02035904|DRUG|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
48127124|NCT02035904|DRUG|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
48127125|NCT01755936|OTHER|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
48127126|NCT01755936|OTHER|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
48127127|NCT01755936|OTHER|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
48127128|NCT00933712|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
48127129|NCT04710849|DIAGNOSTIC_TEST|Serum metabolic markers|Ultraperformance liquid chromatography / mass spectrometry (LC-MS) and gas chromatography / mass spectrometry (GC-MS) methods for analysis of the metabolites in AECOPD patients and compare the metabolites profiles between patients with systemic glucocorticoid treatment success and treatment failure.
48127130|NCT01615770|BEHAVIORAL|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
48127131|NCT01470300|OTHER|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).
48127132|NCT02343913|DEVICE|PAC checklist|
48127133|NCT04116372|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
48127134|NCT00352131|DRUG|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
48127135|NCT02183506|DRUG|Metformin|
48127136|NCT02183506|DRUG|BI 1356 BS|
48334177|NCT00418899|BEHAVIORAL|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
48334178|NCT03320538|OTHER|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
48127137|NCT00910338|DEVICE|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~* Twice a week for the first 4 weeks~* Once a week for the next 8 weeks"
48334179|NCT03320538|OTHER|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
48334180|NCT03320538|DRUG|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
48334181|NCT01422512|BIOLOGICAL|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
48334182|NCT01063218|OTHER|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
48334183|NCT05285267|BEHAVIORAL|Behavioral Parent Support|Parent training on effective child management strategies
48334184|NCT05285267|BEHAVIORAL|Shared Parent-Child Activities|Structured parent-child activities
48334185|NCT05285267|BEHAVIORAL|COACHES|This intervention involves practice of parenting strategies with facilitator monitoring and support.
48334186|NCT06211127|DEVICE|Cold laser plaque ablation|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
48334187|NCT06211127|DEVICE|The excimer laser|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
48334188|NCT05834101|OTHER|Myofacial Release|Illiopsoas , quadriceps, hamstrings, hip adductors, hip abductors ,tensor fasciae lata and gluteus, Foot flexors and extensors received thirty seconds flexibility by foam rolling.Although there appears to be a correlatiomuscle goups between higher SMR length and bigger impact size, the exact link between SMR duration and effect size is uncertain. The time was 30 seconds each muscle group was chosen since it is more realistic than the 60 seconds utilized by MacDonald et al., and it was also used by Peacock et al. Similar to the Grid roller, a commercially available foam roller had net diameter of 12.7 cm and a 5-mm thick empty core of plastic coated with a 12-mm layer of dense foam. In this study, participants were instructed to do the motions in sequenced and save manner, covering the complete muscular area, applying consistent pressure that was felt comfortable. For a total of 16 minutes, the therapy lasted 8 minutes on one leg and 16 minutes on both legs
48334189|NCT05834101|OTHER|Dynamic streching|The regimen included ten dynamic workouts lasting 10 minutes and varying in intensity from medium to high. At a distance of 13 meters, each Dynamic stretching exercise was completed. Before each workout, the subjects were given a 10-second rest time. During the exercises, the participants were given verbal comments on their posture, and video recordings of the activities were displayed to them. Dynamic stretching included High knee walk, Straight-leg march, Hand walk, Lunge walks, Backward lunge, High-knee skip, Lateral shuffle, Back pedal, Heel-ups, and High-knee run
48334190|NCT04503863|DRUG|NPC-22|Single administration of middle dose NPC-22
48334191|NCT04503863|DRUG|NPC-22|Single administration of high dose NPC-22
48334192|NCT04503863|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
48334193|NCT01874119|DRUG|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
48493374|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
48493375|NCT01347866|DRUG|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
48493376|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
48334194|NCT03407170|BIOLOGICAL|pembrolizumab|200 mg by IV infusion Q3W for up to 24 months
48493377|NCT01347866|DRUG|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
48334195|NCT04340960|OTHER|Home Monitoring|Patients in this group will receive home monitoring for NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and pain scores. These will be monitored 4 times a day for 2 weeks following surgery.
48334196|NCT00709124|DEVICE|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
48334197|NCT00709124|DEVICE|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
48334198|NCT04830410|DIETARY_SUPPLEMENT|Fructan reintroduction|Patients will reintroduce fructan powder after 14-day of a low FODMAP diet
48652897|NCT03201094|DIETARY_SUPPLEMENT|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
48652898|NCT06100276|DRUG|AMT-162|AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
48652899|NCT06569589|DIAGNOSTIC_TEST|23NaMRI Scan|23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
48334199|NCT04830410|DIETARY_SUPPLEMENT|Placebo reintroduction|Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
48334200|NCT03999112|OTHER|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
48334201|NCT00977587|DRUG|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
48334202|NCT00977587|DRUG|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
48652900|NCT02909114|RADIATION|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
48652901|NCT01893450|DRUG|Methimazole|
48652902|NCT01893450|DRUG|Bromocriptine|
48652903|NCT01893450|DRUG|Pentoxifylline|
48334203|NCT06017778|DEVICE|whole body vibration|patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).
47976126|NCT03818828|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
47976127|NCT03818828|OTHER|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
48127138|NCT03750214|DEVICE|Biop Colposcopy System|"The procedure stages:~1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~4. A questionnaire completed by the user after the Biop procedure, with regards to system usage~5. Image Registration analysis"
48127139|NCT03592602|PROCEDURE|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
48652904|NCT05896202|OTHER|taVNS Video|One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
47976128|NCT03818828|OTHER|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
47976129|NCT05484739|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
47976130|NCT05484739|OTHER|Fan|Participants will be exposed to a fan throughout the climate chamber exposure.
47976131|NCT05484739|OTHER|Water Spray and Fan|Participants will receive both water spraying and a fan throughout the climate chamber exposure.
47976132|NCT05484739|OTHER|Control|Participants will NOT receive either water spray or a fan exposure.
47976133|NCT00157534|DRUG|Celgosivir|
47976134|NCT04477902|OTHER|none - observational|online survey
47976135|NCT00166478|DRUG|Exisulind Therapy|
47976136|NCT00786682|DRUG|docetaxel|
47976137|NCT00786682|DRUG|hydroxychloroquine|
47976138|NCT00016016|DRUG|cytarabine|Given IV
48127140|NCT00000587|PROCEDURE|erythropoietin, recombinant|
48334204|NCT06017778|OTHER|traditional exercise group|10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
48334205|NCT05862948|DEVICE|ENDO-Aid by Olympus|Colonoscopy assisted by ENDO-AID device
48334206|NCT00340834|DRUG|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
48334207|NCT00340834|DRUG|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
47976139|NCT00016016|DRUG|mitoxantrone hydrochloride|Given IV
47976140|NCT00016016|DRUG|alvocidib|Given IV
47976141|NCT00016016|OTHER|pharmacological study|Correlative studies
47976142|NCT00016016|OTHER|laboratory procedure|Correlative studies
47976143|NCT05209984|DRUG|ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg|Participant will receive for two (2) weeks one (01) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsule once daily + one (01) sibutramine placebo capsule 10mg; after that 2 weeks, participants will receive one (01) placebo capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) 10mg sibutramine placebo capsule; after this period, they will receive two (02) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 10mg of sibutramine and 50mg of topiramate) + a placebo capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once a day + one (one) 10mg sibutramine placebo capsule, taken once daily, for two (02) additional weeks, on the titration scheme. On the treatment period, will receive one (01) ADF Sibutramine IR/Topiramate XR 15mg/75mg capsule + one (01) Sibutramine IR 15mg placebo capsule (Sibus®) + one (01) Topiramate XR 100mg placebo capsule, once daily, for 52 weeks.
48127141|NCT02369289|OTHER|bone mineral density test|
48127142|NCT02297919|BEHAVIORAL|Effectiveness of Internet Based Obesity Control Programme|
48127143|NCT04413838|DRUG|NIVOLUMAB|IV injection within 30 minutes of 24ml file (=240 mg) containing NIVOLUMAB BMS(Bristol-Myers Squibb) 10mg/ml (immune check point inhibitor targeting PD-1) on top of routine standard of care for COVID-19 infection
48127144|NCT04413838|OTHER|Routine standard of care|No intervention is planned in this arm. Patients will follow routine standard of care for the COVID-19 treatment
48127145|NCT03936023|DRUG|Saxagliptin|Saxagliptin dispensing claim is the exposure
48127146|NCT03936023|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
48652905|NCT05896202|OTHER|Educational materials|Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
48652906|NCT05896202|OTHER|TMS Video|One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
48652907|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
48652908|NCT05548361|COMBINATION_PRODUCT|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
48652909|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
48652910|NCT05605093|DRUG|Shionogi Protease Inhibitor (S-217622)|S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
48652911|NCT05605093|DRUG|placebo|Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
48652912|NCT06312254|DRUG|Topical lidocaine 5%|Drug is used to pharmacologically modulate peripheral sensory afferents
48652913|NCT06312254|DRUG|Topical Phenytoin 10%|Drug is used to pharmacologically modulate peripheral sensory afferents
48652914|NCT06312254|DRUG|Topical Mepyramine 2%|Drug is used to pharmacologically modulate peripheral sensory afferents
48652915|NCT06312254|OTHER|Topical Placebo|Drug is used as control
48652916|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^4 TCID50
48652917|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 \^5 TCID50.
48652918|NCT00493285|BIOLOGICAL|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10\^6 TCID50.
48652919|NCT05674565|DRUG|Magnesium sulfate loading with maintenance dose|4 gm MgSo4 loading over 20 minutes followed by 1 gm per hour maintenance till delivery
48652920|NCT05674565|DRUG|Magnesium sulfate loading dose only|4 gm MgSo4 loading over 20 minutes within one hour before delivery
48334208|NCT00340834|DRUG|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
48652921|NCT00892866|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48652922|NCT00892866|OTHER|Laboratory Biomarker Analysis|Correlative studies
48652923|NCT02932280|DRUG|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
48652924|NCT04098146|PROCEDURE|Surgical Resection and Reconstruction|"One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.~Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction."
48652925|NCT01491919|DRUG|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
48652926|NCT05988281|PROCEDURE|Type I Dental implant placement.|Placement of dental implant.
47976144|NCT05209984|DRUG|ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg|Participant will receive for two (02) weeks one (01) capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once daily + one (01) capsule of placebo sibutramine 10mg; after this initial period of 2 weeks, participants will receive (02) ADF sibutramine IR/topiramate XR 5mg/25mg capsules (totaling 10mg of sibutramine and 50mg of topiramate) + one (01) 10mg sibutramine placebo capsule, taken once daily, for two (02) weeks; after this period, they will receive three (03) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 15mg of sibutramine and 75mg of topiramate) + one (01) capsule of 10mg sibutramine placebo, taken once daily, for two ( 02) additional weeks, on titration scheme. On the treatment period, will receive one (01) Sibutramine IR 15mg capsule (Sibus®) + one (01) Topiramate XR 100mg capsule + one (01) ADF placebo capsule sibutramine IR/topiramate XR 15mg/75mg, taken once daily, taken once daily, for 52 weeks.
48127147|NCT05452902|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
48127148|NCT05452902|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
48127149|NCT03480776|DRUG|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
48127150|NCT03480776|OTHER|Placebo|One tablet PO daily
48652927|NCT05988281|PROCEDURE|Type II Dental implant placement.|Placement of dental implant.
48652928|NCT05988281|PROCEDURE|Type III/IV dental implant placement.|Placement of dental implant.
48652929|NCT01430715|OTHER|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, \> 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
48652930|NCT05530304|DEVICE|Triple inner branched arch stentgraft|New findings regarding treatment planning and management of patients with aortic arch pathologies.
48652931|NCT06511648|DRUG|Erdafitinib monotherapy|Patients will receive treatment with erdafitinib alone (cohort 1)
48652932|NCT06511648|DRUG|Cetrelimab and Erdafitinib combination|Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
48652933|NCT03888287|DEVICE|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
48652934|NCT03888287|OTHER|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
48652935|NCT00811850|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
48652936|NCT00811850|DRUG|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
48652937|NCT04104477|OTHER|Range of Motion Tasks|Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
47976145|NCT05209984|DRUG|SIB Group Sibus (Sibutramine) 15mg|Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.
47976146|NCT05209984|DRUG|Placebo Group|participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
47976147|NCT02562053|DRUG|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
47976148|NCT02562053|DRUG|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
48493378|NCT04978116|DIAGNOSTIC_TEST|Chest X-Ray (CXR)|"The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm."
48493379|NCT04978116|DIAGNOSTIC_TEST|Low-dose CT scan (LDCT)|See above in CXR paragraph
48493380|NCT04978116|DIAGNOSTIC_TEST|Lung ultrasonography (LUS)|See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
48493381|NCT02232490|BIOLOGICAL|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
48493382|NCT02232490|BIOLOGICAL|Placebo|
48334209|NCT06279325|BEHAVIORAL|Computerized cognitive stimulation program|"* The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level."
48334210|NCT06279325|BEHAVIORAL|Face-to-face training-explanatory session|The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
48127151|NCT00891631|BEHAVIORAL|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
47976149|NCT02562053|DRUG|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
47976150|NCT02562053|DRUG|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
47976151|NCT01442493|OTHER|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
47976152|NCT01442493|OTHER|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
47976153|NCT01458652|DRUG|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
47976154|NCT02332278|PROCEDURE|Early feeding|Fluid diet four hours after cesarean section
47976155|NCT02332278|PROCEDURE|Late feeding|Fluid diet 12 hours after cesarean section
47976156|NCT02239978|BEHAVIORAL|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
47976157|NCT01354951|OTHER|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
47976158|NCT06346964|OTHER|Health education|Health education prepared for chronic disease self-management aims to improve the health behaviors of older adults.
48334211|NCT00925691|DEVICE|RV lead|The RV lead is implanted at the apex or at the interventricular septum
48652938|NCT04104477|OTHER|Strength Tasks|Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
48652939|NCT00515229|DRUG|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
48652940|NCT04725110|DRUG|Instilled T3|The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.
48652941|NCT04725110|OTHER|Placebo Therapy|A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.
47976159|NCT03577691|OTHER|Training for use of web based Decision Aid|Subjects will be guided during a 30 minutes training session to use the website
47976160|NCT03577691|OTHER|No training for use of web based Decision Aid|Subjects will not be guided during a 30 minutes training session to use the website
47976161|NCT03577691|OTHER|Pretest surveys and posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
47976162|NCT03577691|OTHER|Only posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
48334212|NCT06161857|OTHER|No intervention|There is no intervention this is an observational study to develop a diagnostic test
48127152|NCT00891631|BEHAVIORAL|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
48127153|NCT06058767|DIAGNOSTIC_TEST|Otoacoustic Emissions Testing|An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
48334213|NCT00610285|OTHER|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
48334214|NCT02899741|DRUG|Omega-3|1000mg every day for 90 days
47976163|NCT05163444|DEVICE|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
47976164|NCT05163444|DEVICE|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
47976165|NCT03812094|DEVICE|Enurad 400|Alarm treatment
47976166|NCT03812094|BEHAVIORAL|Basic Bladder advice|Pre-specified Basic bladder advice
47976167|NCT00684307|DRUG|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
47976168|NCT00684307|DRUG|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
47976169|NCT00684307|DRUG|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
47976170|NCT03988985|OTHER|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
47976171|NCT03988985|OTHER|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
47976172|NCT04740502|PROCEDURE|Parahtyroidectomy|Parathyroidectomy
47976173|NCT00516438|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
47976174|NCT00516438|DRUG|Topotecan|intravenous infusion
47976175|NCT06139432|DEVICE|Active tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* The stimulation level is 2mA for 20 minutes.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
47976176|NCT06139432|DEVICE|Sham tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
47976177|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
47976178|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Standard treatment
47976179|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Intensified treatment
47976180|NCT05454592|BEHAVIORAL|Stress and Coping Online Outreach Program|3 videos and a resource library disseminated over the course of 9 weeks.
47976181|NCT01713972|DRUG|dabrafenib|Given PO
47976182|NCT01713972|DRUG|pazopanib hydrochloride|Given PO
47976183|NCT01713972|OTHER|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
47976184|NCT05322876|BEHAVIORAL|Healthy Hearts Family Program|Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
48127154|NCT06058767|DIAGNOSTIC_TEST|Pure Tone Audiometry|The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
48334215|NCT04914767|DRUG|Nigella|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
48334216|NCT04914767|DRUG|Placebo|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
48334217|NCT04381572|BEHAVIORAL|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
47976185|NCT02326961|DEVICE|Celution Device|ADRCs Prepared using the Celution Device
47976186|NCT02326961|OTHER|Placebo|Inactive Placebo
47976187|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning
47976188|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning
47976189|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning
47976190|NCT03755102|DRUG|Dacomitinib|"Cohort 1 Dacomitinib Dosing:~Dose level 1: Dacomitinib 45mg daily Dose level -1: Dacomitinib 30mg daily Dose level -2: Dacomitinib 15mg daily~Cohort 2 Dacomitinib Dosing:~Dose level 1: Dacomitinib 30 mg daily Dose level -1: Dacomitinib 15 mg daily"
48127155|NCT05614349|DRUG|Paxlovid|This adaptive platform trial will assess therapeutics for SARS-CoV-2 in out-patient settings. The first intervention arm is Paxlovid.
48127156|NCT05614349|DRUG|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
48127157|NCT05614349|OTHER|Other|As this trial progresses, therapeutics for SARS-CoV-2 in out-patient settings to be evaluated will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee, which will evaluate the latest evidence on new therapeutics and makes recommendations to the Steering Committee.
48334218|NCT01672528|OTHER|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
48334219|NCT01672528|OTHER|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
48334220|NCT02566109|DIAGNOSTIC_TEST|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
48334221|NCT03722472|BIOLOGICAL|ID93 + GLA-SE|The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
48334222|NCT04562532|DEVICE|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
48334223|NCT04562532|DEVICE|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"* Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~* Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~* Sirolimus eluting stents (Orsiro- Biotronik)"
48334224|NCT06166888|DRUG|AK131|AK131 is an anti-PD-1 and CD73 bispecific antibody
48334225|NCT03998904|PROCEDURE|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
48493383|NCT06429319|DEVICE|"hydrous biopolymer with silver ions Argiform"|Patients will receive an injection of MD NOLTREX™ into the target knee joint. MD will be administered in accordance with the instructions for use of MD NOLTREX™: 4.0 ml per injection (2.5 + 1.5 ml, or 2.0 + 2.0 ml from two syringes through one needle \[one puncture\]) at intervals of one week. The course within this open study is a maximum of 2 injections. The number of injections is determined by the doctor depending on the stage of gonarthrosis and the clinical response
48493384|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
48493385|NCT00899470|DRUG|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
48334226|NCT03998904|PROCEDURE|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
48334227|NCT01148693|DRUG|gentamicin|10mg per 10ml of contrast media
48334228|NCT01148693|DRUG|Placebo|Distilled water
48334229|NCT03776097|OTHER|observational study|Observational study
48334230|NCT02335203|DRUG|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
48334231|NCT02335203|OTHER|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
48334232|NCT01854489|DRUG|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
48334233|NCT01854489|DRUG|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
48334234|NCT01854489|DRUG|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
48334235|NCT04190589|DEVICE|Robot-assisted laparoscopic extended right colectomy|An extended right hemicolectomy with total mesocolic excision and meticulous central dissection as described by Hohenberger will be performed with the DaVinci Xi robot by one of two dedicated surgeons
48334236|NCT05851794|PROCEDURE|endomanometric guided LNF|use of endomanometry during LNF
48334237|NCT05851794|PROCEDURE|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication alone
48334238|NCT00003340|DRUG|cyclophosphamide|
48334239|NCT00003340|DRUG|topotecan hydrochloride|
48334240|NCT01082978|DEVICE|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
48334241|NCT01082978|DEVICE|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
48493386|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
48493387|NCT00899470|DRUG|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
48334242|NCT03396926|BIOLOGICAL|Bevacizumab|Given IV
48334243|NCT03396926|DRUG|Capecitabine|Given PO
48334244|NCT03396926|OTHER|Laboratory Biomarker Analysis|Correlative studies
48334245|NCT03396926|BIOLOGICAL|Pembrolizumab|Given IV
48334246|NCT03012282|DIAGNOSTIC_TEST|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
48334247|NCT02755142|BIOLOGICAL|Gliolan|
48493388|NCT02316249|DRUG|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
48493389|NCT02316249|OTHER|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
48493390|NCT04243434|DRUG|Vincristine Sulfate Liposome|Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
48334248|NCT01090102|DRUG|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
48334249|NCT01090102|DRUG|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
48334250|NCT03029858|OTHER|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
48127158|NCT02006758|DEVICE|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
48127159|NCT00419341|BIOLOGICAL|Human Normal Immunoglobulin for Subcutaneous Administration|
48127160|NCT00002945|BIOLOGICAL|aldesleukin|IV
48334251|NCT01807949|DRUG|Placebo|Matching placebo tablet
48334252|NCT01807949|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
48334253|NCT01807949|DRUG|Ivacaftor|Film-coated tablet
48334254|NCT02670915|DRUG|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
48334255|NCT02670915|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
48493391|NCT04243434|COMBINATION_PRODUCT|CHOP|CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
48493392|NCT04243434|COMBINATION_PRODUCT|R-CHOP|R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
48127161|NCT00002945|BIOLOGICAL|filgrastim|IV
48334256|NCT02670915|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
48334257|NCT05306353|DRUG|Placebo for VIB4920|26 participants will receive VIB4920 placebo administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including tumor necrosis factor alpha inhibitor (TNFi) (double-blinded)
48334258|NCT05306353|DRUG|VIB4920 with TNFi|52 participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 while continuing background rheumatoid arthritis (RA) therapy including Tumor necrosis factor alpha inhibitor (TNFi) (double blinded)
48334259|NCT05306353|DRUG|VIB4920 without TNFi|Participants will receive 1500 mg administered intravenously at weeks 0, 2, 4, 8, and 12 but discontinue necrosis factor alpha inhibitor (TNFi) while continuing all other background rheumatoid arthritis (RA) therapy (evaluator-blinded)
48334260|NCT01790789|BEHAVIORAL|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
47976191|NCT03755102|DRUG|Osimertinib|"In cohort 2, participants will begin on dacomitinib orally daily in combination with Osimertinib~Dose level Osimertinib Dosing:~Dose level 1: Osimertinib 80 mg daily Dose level -1: Osimertinib 40 mg daily"
48127162|NCT00002945|DRUG|cyclophosphamide|IV
48127163|NCT00002945|DRUG|cytarabine|IV
48127164|NCT00002945|DRUG|etoposide|IV
48127165|NCT00002945|DRUG|idarubicin|IV
48127166|NCT00002945|DRUG|melphalan|IV
48127167|NCT00002945|PROCEDURE|peripheral blood stem cell transplantation|IV
48127168|NCT00002945|RADIATION|radiation therapy|delivered to the cancer cells
48127169|NCT05121467|OTHER|Pain Assessment|Visual Analogue Scale (VAS) were included in the study
48127170|NCT05121467|OTHER|Assessment of Muscular Endurance|The endurance of the 9 muscles/muscle groups including cervical flexor, extensor, deep flexor muscles, trunk flexor, extensor, lateral flexor, and stabilizer muscles, upper extremity, and scapular muscles (mm. serratus anterior and trapezius) were evaluated based on the assessment instructions given in the studies of Edmonston et al., Grimmer et al., Evans et al., Reece et al., ACSM guideline
48334261|NCT01790789|OTHER|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
48334262|NCT01052519|OTHER|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
48334263|NCT03459404|COMBINATION_PRODUCT|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
48334264|NCT06394557|PROCEDURE|In-office Dental Bleaching Conventional|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 7 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
48334265|NCT06394557|PROCEDURE|In-office Dental Bleaching Alternative|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 2 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
48334266|NCT02846051|PROCEDURE|venous mapping|clinical examination + doppler echo
48652942|NCT03035214|DRUG|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
48652943|NCT06641375|DEVICE|Anti reflux endoscopic theraphy|"o the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated."
48652944|NCT06641375|OTHER|Endoscopy|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
47976192|NCT00573911|PROCEDURE|Endoscopy and pH study|endoscopy and PH study done one time
48334267|NCT06202339|DEVICE|DaRT seeds|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
47976193|NCT06219512|BEHAVIORAL|CPET exercise prescription|Exercise mode: walk Frequency: 5 times/week
47976194|NCT06219512|BEHAVIORAL|6MWT exercise prescription|Exercise mode: walk Frequency: 5 times/week
47976195|NCT06219512|BEHAVIORAL|Regular exercise|Regular exercise
47976196|NCT02266225|OTHER|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
47976197|NCT05283421|DIAGNOSTIC_TEST|Estrogen|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
48334268|NCT05924516|BEHAVIORAL|Adhera® Fatigue Digital Program|The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
48334269|NCT02575677|OTHER|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
48334270|NCT02349737|OTHER|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
48334271|NCT02026518|DIETARY_SUPPLEMENT|Soy isoflavones|
47976198|NCT05283421|DIAGNOSTIC_TEST|Placebo|Women will receive active estrogen treatment or placebo prior to the colposcopic examination
47976199|NCT00777478|DRUG|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
47976200|NCT02667574|DRUG|ERIVEDGE|
47976201|NCT04069494|OTHER|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
48334272|NCT02026518|DIETARY_SUPPLEMENT|cholecalciferol|
48334273|NCT02026518|DIETARY_SUPPLEMENT|Placebo of soy isoflavones|
47976202|NCT00756860|DRUG|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
47976203|NCT00756860|DRUG|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
47976204|NCT04346537|DEVICE|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
47976205|NCT04234581|DIETARY_SUPPLEMENT|Lysulin|Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
47976206|NCT02966990|DEVICE|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
47976207|NCT02835820|DIETARY_SUPPLEMENT|Ketogenic Diet|12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
48127171|NCT05121467|OTHER|Assessment of Neck Awareness|The Turkish version of the Fremantle Neck Awareness Questionnaire (FreNAQ) which was developed by Wand et al. to assess neck awareness in patients with chronic neck pain was used in this study
48334274|NCT02026518|DIETARY_SUPPLEMENT|placebo of cholecalciferol|
47976208|NCT05799729|DRUG|Ketamine|CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
47976209|NCT04953377|BEHAVIORAL|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
48334275|NCT02859987|PROCEDURE|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
48334276|NCT02859987|PROCEDURE|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
48652945|NCT00814983|PROCEDURE|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
48652946|NCT00814983|PROCEDURE|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
48652947|NCT00814983|DEVICE|Isolex device from Baxter|
48127172|NCT05121467|OTHER|Assessment of Fear of Movement|The fear of movement was assessed by the Turkish version of the Tampa Scale of Kinesiophobia which originally developed by Kori et al.
48127173|NCT02639637|DRUG|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
48334277|NCT02859987|DEVICE|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
48334278|NCT06295601|OTHER|Traditional rehabilitation|The program consists of a joint treatment in which lower extremity strengthening and balance exercises are carried out synchronously. The program will include a total of 5 minutes of warm-up, 5 minutes of cool-down and 30 minutes of exercises related to the program. The difficulty of the program will increase by changing the number of exercises and increasing the weight in strengthening exercises. Progress in balance and coordination exercises will vary by changing the ground, increasing the standing time, and keeping the eyes open and closed.
48334279|NCT06295601|OTHER|Action observation therapy and motor imagery|In the experimental group, in addition to traditional telerehabilitation, action observation and motor imagery of 4 exercises will be performed in each session. A video will be prepared for 4 exercises. Then, the participant will perform 2 minutes of action observation of each movement, followed by 1 minute of motor imagery. In addition to the traditional telerehabilitation program, a 12-minute combination of action observation and motor imagery will be performed in each session. Exercises will be changed every two weeks, gradually increasing the difficulty.
48334280|NCT05034471|DEVICE|Mi-Chord™ Device Technologies|Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
48334281|NCT06090448|DEVICE|EarSwitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
48334282|NCT06067308|DIAGNOSTIC_TEST|Performance of CTPA|Exposure to CT scan and injection of IV contrast
48334283|NCT05578768|OTHER|No intervention|Patients will receive standard of care.
48334284|NCT04876586|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
48652948|NCT03497702|DRUG|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
48652949|NCT03497702|DRUG|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
48652950|NCT03497702|DRUG|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
48652951|NCT03497702|DRUG|Letrozole|2.5 mg once daily preoperably
48652952|NCT03497702|DRUG|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
47976210|NCT04446546|PROCEDURE|Vascular access by pass using a cold stored venous allograft|Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
47976211|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
48127174|NCT02639637|DRUG|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
48127175|NCT02639637|DRUG|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
48652953|NCT05056818|OTHER|Electronic Health Record Review|Review of medical records and past imaging examinations
48652954|NCT06384352|DRUG|YL211|Patients will be treated with YL211 intravenous (IV) infusion.
48652955|NCT01854762|DRUG|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
48652956|NCT01854762|DRUG|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
48127176|NCT02639637|DRUG|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
48127177|NCT02639637|DRUG|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
48127178|NCT03124017|OTHER|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
48127179|NCT01150656|GENETIC|gene expression analysis|
48127180|NCT01150656|GENETIC|microarray analysis|
48334285|NCT04466787|DIAGNOSTIC_TEST|Spectral Photon Counting Computed Tomography (SPCCT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm."
48334286|NCT04466787|DIAGNOSTIC_TEST|Dual Energy CT (DECT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips"
48334287|NCT02915068|BEHAVIORAL|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
48334288|NCT02989311|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
48493393|NCT05949671|OTHER|mediterranean, gluten-free and mediterranean gluten-free diet intervention|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
48493394|NCT03120533|DRUG|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
48652957|NCT01416831|OTHER|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
48652958|NCT01416831|DRUG|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
48652959|NCT06640231|OTHER|sealer activation after cleaning and shaping with XP-Endo Finisher|activation of sealer before the obturation of root canals
47976212|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
47976213|NCT05951673|OTHER|Safe Space based life skills training program|This is a Safe Space based life skills training program given to adolescent girls. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change.
47976214|NCT05951673|OTHER|Safe Space based life skills training program + Digital Skills|This is a Safe Space based life skills training program given to adolescent girls complemented with a digital literacy training program. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change. The adolescent girls in this group also receive a digital literacy training program that covers content on word processing. database management and analysis, online marketing, online safety and programming.
47976215|NCT04459091|DIETARY_SUPPLEMENT|Amino Essential Acid|8 gr die in two administration
48334289|NCT02989311|DIETARY_SUPPLEMENT|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
48334290|NCT02573337|DEVICE|Emervel Classic Lidocaine|Treatment of wrinkles and folds
48334291|NCT02573337|DEVICE|Emervel Deep Lidocaine|Treatment of wrinkles and folds
48334292|NCT01978509|DRUG|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
48334293|NCT01978509|DRUG|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
48334294|NCT01978509|DRUG|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
48334295|NCT01770041|OTHER|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
48334296|NCT05186012|DRUG|APG-1252|APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
48334297|NCT05186012|DRUG|Chidamide|Chidamide 30mg orally BIW. Every 28 days as a cycle.
48334298|NCT01072448|DRUG|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
48334299|NCT01072448|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
48334300|NCT05153447|BEHAVIORAL|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
48334301|NCT05153447|OTHER|Usual Care|Participants randomized to the usual care arm will receive standard of care.
48334302|NCT00038272|DRUG|Mycophenolate mofetil|
47976216|NCT04459091|DIETARY_SUPPLEMENT|placebo|8 gr die in two administration
47976217|NCT01658072|PROCEDURE|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
47976218|NCT01658072|PROCEDURE|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
48334303|NCT00038272|DRUG|Amdoxovir|
48334304|NCT02558985|PROCEDURE|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
48334305|NCT06272630|DRUG|DWJ1464|DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
48334306|NCT06272630|DRUG|Placebo of DWJ1464|Placebo of DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
48334307|NCT04549415|DRUG|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
48652960|NCT06640231|OTHER|negative control where canals are obturated directly without sealer activation|sealer after cleaning and shaping before the obturation without using activation method
47976219|NCT04658953|OTHER|Ultrasound guided infiltration|In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
47976220|NCT04658953|OTHER|Fluoroscopy guided infiltration|In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
47976221|NCT02551757|DEVICE|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
48127181|NCT01150656|GENETIC|protein expression analysis|
48127182|NCT01150656|GENETIC|reverse transcriptase-polymerase chain reaction|
48334308|NCT04549415|OTHER|lifestyle modification|Lifestyle modification Standard Principles
48334309|NCT01231126|DRUG|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
48334310|NCT00649051|DRUG|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
48127183|NCT01150656|GENETIC|western blotting|
48127184|NCT01150656|OTHER|laboratory biomarker analysis|
48127185|NCT01150656|OTHER|pharmacological study|
48127186|NCT00448669|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
48127187|NCT00448669|DRUG|Placebo Oral Tablet|
48334311|NCT00649051|DRUG|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
48334312|NCT06424392|OTHER|General Health Questionnaire (GHQ-28)|Anxiety and depression self-reported scales for both parents
48334313|NCT06424392|OTHER|State-Trait Anxiety Inventory (STAI-Y)|Anxiety and depression self-reported scales for both parents
48334314|NCT06424392|OTHER|Revised Children's Manifest Anxiety Scale (RCMAS)|Anxiety and depression self-reported scales for children
48334315|NCT06424392|OTHER|World Health Organization Quality of Life (WHOQOL-BREF)|Quality of life self-reported scales for parents
48334316|NCT06424392|OTHER|Quality of life measure for children (KIDSCREEN-27)|Quality of life self-reported scales for children
48127188|NCT05048680|PROCEDURE|Hypoxia and/or Exercise|Hypoxia at rest versus normoxia at rest; Hypoxia during exercise versus Normoxia during exercise.
48127189|NCT03095872|DEVICE|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
48334317|NCT06424392|OTHER|"Parental Educational Competence Self-Evaluation Questionnaire Questionnaire d'Auto-Évaluation de la Compétence Éducative Parentale (QAECEP)"|Parental Educational Competence Self-Evaluation self-reported Questionnaire for parents
48334318|NCT06424392|OTHER|Parental interview|The interview will only last about ten minutes and will take place during the first call, if the parents have agreed and are sufficiently available to answer. If the parents are not available, an appointment can be made at a later date
48334319|NCT05306184|PROCEDURE|Electroconvulsive therapy (ECT)|ECT
48334320|NCT03682406|BEHAVIORAL|CAMS-G|Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
48652961|NCT03587090|DIAGNOSTIC_TEST|echocardiography|echocardiography by subcostal and transhepatic views
48652962|NCT05544695|DEVICE|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
48652963|NCT04467853|BIOLOGICAL|LCAR-C18S cells|Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
48652964|NCT06639581|DEVICE|20 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute
47976222|NCT02551757|DEVICE|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
47976223|NCT05976750|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
47976224|NCT05976750|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
47976225|NCT04274842|OTHER|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
47976226|NCT05184244|OTHER|Activity Limitation Assessment|The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
47976227|NCT05924295|DIETARY_SUPPLEMENT|Ketone Supplement|Participants will be given 360mg/kg
47976228|NCT05924295|BEHAVIORAL|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale|Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale will be administered at beginning and end of testing day to tests palatability of supplement
47976229|NCT05924295|BIOLOGICAL|Blood Draw|IV cannula will be inserted at the start of Test Day, and removed at the end of Test Day. Blood samples will be collected at 7 timepoints (possibly 1 more). Cannula will be flushed with a small volume of saline after each sample to maintain patency.
47976230|NCT05924295|OTHER|Urine Analysis|Prior to consumption of the Study Product, participants will be asked to completely void bladder. And hydration status will be determined via urine specific gravity (USG) reporting \<1.025. Urine passed after the ingestion of the study product will be collected in a plastic container; participants will be asked to void their bladder and collect urine at the end of the test day. The volume produced will be recorded at the end of the study and aliquots will be frozen and stored for future analysis
47976231|NCT01533025|PROCEDURE|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
48652965|NCT06639581|DEVICE|30 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute
47976232|NCT00400751|BEHAVIORAL|FAMCON (Family Consultation)|
47976233|NCT02051608|DRUG|Placebo|Participants received Placebo SC injection Q4W.
47976234|NCT02051608|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
47976235|NCT04488484|OTHER|Serology test follow-up|"The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.)."
47976236|NCT04024020|OTHER|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
47976237|NCT03590106|BEHAVIORAL|Peer Recovery Support Program|See above
47976238|NCT02235480|DRUG|Experimental Tazarotene Gel|
47976239|NCT02235480|DRUG|Placebo|
47976240|NCT06249191|PROCEDURE|Biopsy|Undergo tumor biopsy
47976241|NCT06249191|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47976242|NCT06249191|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
47976243|NCT06249191|PROCEDURE|Computed Tomography|Undergo CT scan
47976244|NCT06249191|DRUG|Cyclophosphamide|Given IV
48493395|NCT03120533|DRUG|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
48652966|NCT06639581|DEVICE|40 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute
48652967|NCT03551119|BEHAVIORAL|Exercise|See previous description
48652968|NCT03551119|OTHER|Enhanced usual care|See previous description
48652969|NCT04783571|OTHER|Placebo|Auditory stimulation will not be delivered during the nap
47976245|NCT06249191|DRUG|Doxorubicin|Given IV
48127190|NCT03095872|DRUG|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
48334321|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with ABV feedback|At the beginning of each session, participants will complete 45 standard dot-probe trials as described above. Participants' ABV on these trials will be calculated and set as their personal baseline (see below for ABV calculation). In the following 165-training trials, participants will receive feedback: when their online-calculated ABV will be below their baseline screen background will be green whereas its color will be red when their online ABV score will be higher than their baseline. Patients will be instructed to try to keep the background green for as long as possible.
48334322|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with yoked sham feedback|Participants in this group will be exposed to the same task as in the active group but will receive sham feedback that is unrelated to their ABV during task performance. They will be presented with a feedback that is yoked to the one given to a participant in the training group.
48334323|NCT01455415|DRUG|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
48334324|NCT01455415|DRUG|placebo|matching placebo 3 time a day
48334325|NCT00154219|DRUG|Lumiracoxib (drug)|
48334326|NCT00869219|DRUG|Nevanac|1 drop of NEVANAC at random eye
48334327|NCT00869219|DRUG|Acular LS|One drop of Acular LS
48334328|NCT04587596|OTHER|Pain education|70 minute lecture about chronic pain and one focus group afterwards
48127191|NCT03095872|DRUG|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
48127192|NCT03640195|OTHER|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
48127193|NCT02376790|DRUG|Etanercept|Etanercept was administered by subcutaneous injection once a week
48334329|NCT02655406|OTHER|Class 2 compression stockings|
48334330|NCT00578604|DEVICE|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
48334331|NCT02037451|PROCEDURE|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
48334332|NCT04539691|DEVICE|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
48334333|NCT00996593|BIOLOGICAL|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
48334334|NCT00293046|BIOLOGICAL|ALK Grass tablet - use of compliance device|
48334335|NCT00885885|DRUG|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
48334336|NCT00885885|DRUG|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
48334337|NCT02919410|DEVICE|iodophor-impregnated adhesive drapes|
48334338|NCT02919410|OTHER|No adhesive drapes|
48652970|NCT04783571|OTHER|Auditory Stimulation|Auditory stimulation will be delivered during the nap
47976246|NCT06249191|PROCEDURE|Echocardiography|Undergo echocardiography
47976247|NCT06249191|DRUG|Etoposide|Given IV
47976248|NCT06249191|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47976249|NCT06249191|BIOLOGICAL|Mosunetuzumab|Given IV
47976250|NCT06249191|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
47976251|NCT06249191|PROCEDURE|Positron Emission Tomography|Undergo PET scan
47976252|NCT06249191|DRUG|Prednisone|Given PO
47976253|NCT06249191|DRUG|Vincristine|Given IV
47976254|NCT02290561|PROCEDURE|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
47976255|NCT02290561|DEVICE|MRI|
47976256|NCT02290561|DEVICE|high intensity focused ultrasound (HIFU)|
48127194|NCT02376790|DRUG|Methotrexate|Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
48652971|NCT03624400|BEHAVIORAL|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
48334339|NCT05599113|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
48334340|NCT03137017|DRUG|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
48127195|NCT02376790|DRUG|Placebo to Etanercept|Placebo to etanercept was administered by subcutaneous injection once a week.
48127196|NCT02376790|DRUG|Placebo to Methotrexate|Placebo to methotrexate capsules taken orally once a week.
48127197|NCT02883660|GENETIC|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
48334341|NCT03137017|DRUG|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
48652972|NCT03624400|BEHAVIORAL|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
48334342|NCT03410134|DEVICE|NeoMTA|NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
48334343|NCT01612442|BEHAVIORAL|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
48127198|NCT05209477|OTHER|lung ultrasound assessment|"In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~1. baseline, in supine position under protective ventilation~2. after two minute of recruitment maneuver in pressure controlled ventilation~3. at 1 hour following prone positioning application"
48127199|NCT03470376|DIETARY_SUPPLEMENT|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
48127200|NCT03470376|BEHAVIORAL|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
48127201|NCT02448576|RADIATION|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
48127202|NCT06003517|PROCEDURE|Screening with PSI check list|Screening PSI with institutional check list
48127203|NCT03822520|DRUG|Celecoxib|Celecoxib 400mg capsule
48127204|NCT03822520|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet
48127205|NCT03822520|OTHER|Water|Pure water 150ml
48127206|NCT01644994|COMBINATION_PRODUCT|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
48334344|NCT01612442|BEHAVIORAL|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
48334345|NCT00884221|DRUG|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
48652973|NCT03673982|BEHAVIORAL|iCASK|Materials and support to aid transitions
48127207|NCT00402896|DRUG|ZD6474|300 mg/day orally for 10 weeks.
48652974|NCT00745355|BEHAVIORAL|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
48652975|NCT01550887|OTHER|No intervention|No intervention will be performed on this study
48127208|NCT00676091|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
48127209|NCT00676091|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
48127210|NCT01571466|DRUG|Vaccination|"* Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~  -\~ 1 x 10e8 pfu/ml~* 3 immunisations at week 0, 4 and 16"
48127211|NCT01571466|DRUG|Placebo|3 immunisations at week 0, 4 and 16
48127212|NCT05048251|DEVICE|cTBS|continuous theta burst stimulation
48127213|NCT05048251|DEVICE|iTBS|intermittent theta burst stimulation
48127214|NCT05048251|DEVICE|sham|sham stimulation
48127215|NCT01974102|BEHAVIORAL|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
48127216|NCT01974102|BEHAVIORAL|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
48127217|NCT04646031|DRUG|T89 capsule|T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
48334346|NCT00884221|DRUG|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
48652976|NCT05559385|DEVICE|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
48652977|NCT05559385|PROCEDURE|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
48652978|NCT06634823|DRUG|Triamcinolone Acetonide Injectable Suspension|Triamcinolone injection into deltoid muscle (arm)
48334347|NCT03558971|DRUG|Cortisol|Participants determine when to administer 5-day regimens of cortisol
48334348|NCT01441791|PROCEDURE|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
48334349|NCT00830154|DRUG|pagoclone|0.30 mg BID, 0.60 mg BID
48334350|NCT00830154|OTHER|placebo|placebo
48652979|NCT06634823|DRUG|Saline injection|Saline injection into deltoid muscle (arm)
48652980|NCT03593278|DRUG|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
48127218|NCT03609359|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
48127219|NCT03609359|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
48127220|NCT02837796|PROCEDURE|transobturator tape|
48127221|NCT00350792|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
48127222|NCT00350792|DRUG|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
48127223|NCT04770649|BIOLOGICAL|COVID-19 vaccine|Any vaccine for COVID-19
48652981|NCT05856526|DRUG|Spesolimab - solution for infusion|Solution for infusion
48652982|NCT05856526|DRUG|Placebo matching to spesolimab - solution for infusion|Solution for infusion
47976257|NCT03530098|DEVICE|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
48127224|NCT05639400|DEVICE|Thoraflex Hybrid|Thoraflex Hybrid is designed for the open surgical repair of aneurysms and/or dissections in the aortic arch and descending aorta with or without involvement of the ascending aorta. There are two types of Thoraflex Hybrid implants, namely the Plexus 4 and the Ante-Flo versions. Each patient receives one Thoraflex Hybrid device (either the Plexus 4 or Ante-Flo).
48334351|NCT02747446|DIETARY_SUPPLEMENT|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
47976258|NCT01962207|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
47976259|NCT05018299|BIOLOGICAL|FB704A placebo|Placebo
48127225|NCT05639400|DEVICE|RelayPro NBS|The RelayPro NBS Thoracic Stent-Graft System is an endovascular device intended for treatment of thoracic aortic pathologies such as aneurysms, pseudoaneurysms, dissections, penetrating ulcers and intramural hematoma.
48334352|NCT00702910|DRUG|Placebo|comparator
48334353|NCT00702910|DRUG|GW642444|investigational drug or placebo
48334354|NCT00702910|DRUG|Magnesium Stearate|Magnesium Stearate
48334355|NCT03636113|DEVICE|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
48652983|NCT05856526|DRUG|Spesolimab - solution for injection|Solution for injection
48652984|NCT05856526|DRUG|Placebo matching to spesolimab - solution for injection|Solution for injection
48652985|NCT01246518|DRUG|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
48652986|NCT05715762|BEHAVIORAL|prone postion|ventilation at prone positioning
47976260|NCT05018299|BIOLOGICAL|FB704A|Anti-IL-6 antibody
47976261|NCT00602706|BIOLOGICAL|sargramostim|
47976262|NCT00602706|DRUG|melphalan|
47976263|NCT00602706|PROCEDURE|autologous hematopoietic stem cell transplantation|
47976264|NCT00602706|PROCEDURE|peripheral blood stem cell transplantation|
47976265|NCT00602706|RADIATION|samarium Sm 153 lexidronam pentasodium|
47976266|NCT00275990|DEVICE|rheolytic thrombectomy with direct stenting|
47976267|NCT00275990|DEVICE|direct stenting|
47976268|NCT02669732|DRUG|DS-8500a|tablets
47976269|NCT02669732|DRUG|placebo|tablets
47976270|NCT03123653|DRUG|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
48127226|NCT04718610|OTHER|Osteopathic intervention|Nerve vagus stimulation
48334356|NCT05371938|PROCEDURE|Volar locking plate|Volar locking plate is the intervention
48334357|NCT05371938|PROCEDURE|external fixation|surgery with external fixation
48334358|NCT05569564|PROCEDURE|Ridge splitting followed by ossedensificaion|Ridge splitting followed by ossedensificaion with osseodensifying burs.
48334359|NCT05569564|PROCEDURE|Osseodensification|Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
48652987|NCT05715762|DRUG|NO inhalation|NO inhalation at 20 ppm
48652988|NCT05566769|DEVICE|NMOSDCopilot smartphone application|NMOSDCopilot includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to pain, fatigue, quality of life, bladder and bowel dysfunction, depression
48334360|NCT02916810|DEVICE|Active rTMS stimulation|Participants will receive two rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two rTMS sessions.
48334361|NCT02916810|DEVICE|Sham rTMS stimulation|Participants will receive two sham rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two sham rTMS sessions.
48652989|NCT05061823|DRUG|Bintrafusp alfa|Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
48334362|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
48334363|NCT02131545|DRUG|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
48334364|NCT02131545|DRUG|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
48652990|NCT02088086|BEHAVIORAL|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
48652991|NCT02088086|BEHAVIORAL|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
48652992|NCT02088086|BEHAVIORAL|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
47976271|NCT05693779|BEHAVIORAL|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
47976272|NCT02487693|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
47976273|NCT02487693|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
48127227|NCT04718610|BIOLOGICAL|CRP assessment|Blood CRP will be assessed during trial
48127228|NCT04718610|BEHAVIORAL|QLQ-C30 questionnaire|Completion of QLQ-C30
48127229|NCT03788200|PROCEDURE|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
48334365|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
48334366|NCT03772340|DRUG|Tradipitant|Oral capsule
48334367|NCT03772340|DRUG|Placebo|Oral capsule
48334368|NCT03791268|PROCEDURE|Gastric cancer surgery|Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.
48334369|NCT04078529|OTHER|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
48334370|NCT04078529|OTHER|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
48334371|NCT04078529|OTHER|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
48334372|NCT01769495|OTHER|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
48334373|NCT01646801|DEVICE|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
48334374|NCT02481596|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
48334375|NCT02481596|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
48334376|NCT02481596|BEHAVIORAL|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
48334377|NCT03724617|DRUG|umbilical cord mesenchymal stem cells combined with collagen scaffold|3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
48334378|NCT00143988|BEHAVIORAL|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
48334379|NCT00143988|BEHAVIORAL|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
48334380|NCT05276765|PROCEDURE|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
48334381|NCT05276765|PROCEDURE|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
48334382|NCT02674165|BEHAVIORAL|HART|Skills based sexual education intervention plus PTSD awareness
48334383|NCT00422890|DRUG|5-Azacytidin|in case of decreasing CD34 chimerism
48334384|NCT01618422|OTHER|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
48493396|NCT00286819|DRUG|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
48493397|NCT02288390|PROCEDURE|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
48493398|NCT03134443|DRUG|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
48493399|NCT03134443|DRUG|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
48493400|NCT02356003|DEVICE|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
48493401|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04+PreforPro|One 15mg capsule taken orally each day
48493402|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04|One 15mg capsule taken orally each day
48493403|NCT04511221|OTHER|Placebo|One 15mg capsule taken orally each day
48652993|NCT00310141|BEHAVIORAL|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
48652994|NCT00310141|OTHER|Counseling intervention|In-person counseling (5 sessions)
47976274|NCT03939884|DRUG|MuscleCare Topical Product|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
47976275|NCT03939884|DRUG|Voltaren Topical|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
48493404|NCT02010788|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
48493405|NCT01950234|DRUG|ACTH|Acthar gel
48493406|NCT01950234|DRUG|Placebo|Placebo
48493407|NCT06394843|OTHER|Ultrafiltration|Patients are selected depending on need of ultrafiltration
48493408|NCT03317665|DEVICE|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
48493409|NCT02067429|PROCEDURE|Limbal Relaxing Incisions|
48493410|NCT02067429|DEVICE|Toric Intraocular Lens|
48493411|NCT01799863|DRUG|Ketorolac trometamol 0.45% with carboxymethylcellulose|
48493412|NCT01799863|DRUG|Preservative free artificial tear|
48652995|NCT00310141|DRUG|Nicotine patch|6-week supply of the nicotine patch
48652996|NCT00879372|DRUG|tianeptine|tianeptine 12,5mg TID
48652997|NCT00879372|DRUG|Placebo|Placebo 12.5 mg TID
48652998|NCT02274233|DRUG|SP-420|
48652999|NCT00022854|PROCEDURE|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
48127230|NCT03788200|PROCEDURE|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
48127231|NCT03101371|DRUG|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
47976276|NCT03939884|DRUG|Nivea, Topical Cream|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
47976277|NCT04356664|DRUG|GnRH agonist|One or two intramuscular injections of Decapeptyl 3 mg
48127232|NCT03101371|PROCEDURE|Standard of care catheter insertion|Catheter inserted right out of package.
48127233|NCT06357559|DEVICE|OCTA|Optical Coherence Tomography Angiography
48334385|NCT01618422|OTHER|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
48334386|NCT03429322|BEHAVIORAL|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
48653000|NCT00022854|PROCEDURE|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
48127234|NCT02040363|PROCEDURE|Muscular biopsy|
48127235|NCT02040363|OTHER|5-10 weeks sport training|
48127236|NCT03137836|BEHAVIORAL|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
48334387|NCT03429322|OTHER|Usual Care|Participants will receive and provide usual and customary care in their communities.
48334388|NCT03094819|BEHAVIORAL|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
48334389|NCT03094819|BEHAVIORAL|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
48493413|NCT02006628|DRUG|Placebo|Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
48493414|NCT02006628|DRUG|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
48653001|NCT00022854|PROCEDURE|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
48653002|NCT06644248|DIAGNOSTIC_TEST|Colposcopy|The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
47976278|NCT03764865|PROCEDURE|day 3 uterine transfer|uterine transfer of embryo on day 3 after fertilization (cleavage stage)
47976279|NCT03764865|PROCEDURE|day 5 uterine transfer|uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
47976280|NCT00429104|DRUG|Herceptin|4 mg/kg IV Over 90 Minutes
47976281|NCT00429104|DRUG|GM-CSF|250 mcg/m\^2 Subcutaneously
47976282|NCT02240238|DRUG|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
47976283|NCT02240238|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
47976284|NCT05671185|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magstim TMS system is delivered at the left dorsolateral prefrontal cortex
47976285|NCT01148823|OTHER|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
47976286|NCT01148823|OTHER|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
48127237|NCT05297214|DIAGNOSTIC_TEST|serum creatinine and Other investigations will be done according to the case|following up AKI patients with serum creatinine,Urine out put, CBC,Serum electrolytes,renal functin test,Liver function test,urine analysisand specific investigations according to case
48127238|NCT05685433|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
48493415|NCT05771675|DRUG|Simvastatin|40Mg Oral Tablet
48493416|NCT05771675|DRUG|Placebo|Matching Simvastatin Placebo tablet
48493417|NCT03074253|DIAGNOSTIC_TEST|Echocardiography|Patients are undergoing echocardiography
48493418|NCT03074253|DIAGNOSTIC_TEST|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
48493419|NCT03074253|DIAGNOSTIC_TEST|computed tomography|Patients are undergoing computed tomography
47976287|NCT00905073|DRUG|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
47976288|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
47976289|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
48127239|NCT06330298|BEHAVIORAL|Treatment social cognition and emotion regulation (T-ScEmo)|T-ScEmo is a multifaceted treatment protocol that has the overall aim to improve social cognition, regulation of social behaviour and social participation in everyday life (Westerhof et al., 2017; 2019). The treatment includes, in addition to practicing social cognitive skills throughout the treatment, close involvement of a significant other, and homework assignments. The treatment consists of three modules that address 1) perception of social information including facial expressions of emotions, 2) perspective taking and understanding of social information and 3) regulation of social behaviour. The treatment contains 15-one hour live treatment sessions with a neuropsychologist and 5 online practice sessions, once or twice a week. In the online sessions, the patient can practice the information at home as a neuropsychologist is available for questions. When patients find it too difficult to practice individually at home, there is a opportunity to offer these sessions as live sessions
48127240|NCT02291913|DRUG|Everolimus|
48127241|NCT02291913|DRUG|Exemestane|Anti-estrogen therapy
48653003|NCT05855759|OTHER|Acellular Dermal Matrix|Patinets will be treated with acellular dermal matrix with standard arthroscopic technique performed as per normal clinical practice. For the tendon repair the acellular dermal matrix patch will be placed over the repaired tendon with dedicated sutures and anchors.
47976290|NCT05159700|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
48653004|NCT05855759|OTHER|Acellular Dermal Matrix with autologous orthobiologics|Patinets will be treated with acellular dermal matrix enriched with autologous humeral bone marrow concentrate and subacromial bursa with standard arthroscopic technique. Humeral bone marrow concentrate will be harvested from the proximal humeral head inthe operating room and concentrated by an automatic close system.
48653005|NCT05902975|DEVICE|Fiber reinforced composite resin space maintainer|Bonding of fiber reinforced with composite resin on primary second molar and primary canine under rubber dam isolation
48653006|NCT06105398|OTHER|clinical evaluation|clinical evaluation tests
47976291|NCT05593120|DIAGNOSTIC_TEST|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
47976292|NCT05593120|DIAGNOSTIC_TEST|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
47976293|NCT01706081|PROCEDURE|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
47976294|NCT01706081|PROCEDURE|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
47976295|NCT03352830|BEHAVIORAL|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
47976296|NCT03352830|OTHER|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
47976297|NCT00369616|BIOLOGICAL|CYT002-NicQb|
47976298|NCT05186064|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing will be performed on tumor material after re-resection per standard of care
47976299|NCT00003081|BIOLOGICAL|filgrastim|
47976300|NCT00003081|DRUG|busulfan|
47976301|NCT00003081|DRUG|melphalan|
47976302|NCT00003081|DRUG|thiotepa|
47976303|NCT00003081|PROCEDURE|peripheral blood stem cell transplantation|
48127242|NCT02291913|DRUG|Tamoxifen|Anti-estrogen therapy
48127243|NCT02291913|DRUG|Fulvestrant|Anti-estrogen therapy
48127244|NCT02291913|DRUG|Anastrozole|Anti-estrogen therapy
48127245|NCT02291913|DRUG|Letrozole|Anti-estrogen therapy
48127246|NCT02291913|DRUG|Toremifine|Anti-estrogen therapy
47976304|NCT00003081|RADIATION|radiation therapy|
47976305|NCT06129071|PROCEDURE|US guided block of maxillary nerve|Extraoral ultrasound-guided block of the maxillary nerve will be performed in the examined group using an ultrasound device and local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL).
47976306|NCT03362398|DRUG|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
48653007|NCT06637852|BEHAVIORAL|SUFICS-PACT|SUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
48653008|NCT00997659|DIETARY_SUPPLEMENT|chromium picolinate|1000 mg per day
47976307|NCT03362398|DRUG|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
47976308|NCT00320892|DRUG|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
47976309|NCT04689633|PROCEDURE|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
47976310|NCT00592384|DRUG|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
47976311|NCT00592384|DRUG|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
47976312|NCT01127074|BIOLOGICAL|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
47976313|NCT02829515|PROCEDURE|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
48493420|NCT03074253|DIAGNOSTIC_TEST|blood withdrawl|Peripheral blood samples are being collected from all patients
48127247|NCT04048681|BEHAVIORAL|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
48127248|NCT04048681|BEHAVIORAL|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
48127249|NCT04048681|BEHAVIORAL|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
48127250|NCT03752151|DEVICE|MARVEL 2 Algorithm Monitor Mode then Adaptive Mode|Software download into implanted Micra device and programmed to MARVEL 2 Monitor Mode then MARVEL 2 Adaptive Mode
48127251|NCT04811924|DRUG|Application of 0.02% MMC over 60 seconds post corneal crosslinking.|Topical application of 0.02% MMC on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after MMC application.
48127252|NCT04811924|DRUG|Corneal crosslinking without the application of 0.02% MMC|Topical application of placebo on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after placebo application.
48127253|NCT02247817|DEVICE|Hybrid CRT-D/P implantation|
48127254|NCT01596933|DIETARY_SUPPLEMENT|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
48127255|NCT01596933|DIETARY_SUPPLEMENT|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
48127256|NCT04907513|OTHER|Assessment of the Motivational State|A motivational interviewing algorithm developed in Rothschild Hospital for this study will be used. The results range between 0% (worst motivational state) to 100% (best motivational state).
48127257|NCT02209246|OTHER|PROMIS CAT Pain Interference|
48127258|NCT02209246|OTHER|PROMIS CAT Pain Behavior|
48127259|NCT02209246|OTHER|PROMIS CAT Physical Function|
48653009|NCT00414557|PROCEDURE|Quadriceps strengthening|
47976314|NCT02382393|OTHER|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
47976315|NCT02382393|OTHER|Computerized Assessment|a validated, computerized cognitive assessment tool
48127260|NCT02209246|OTHER|MISS-21|
48127261|NCT04553458|DEVICE|Radiofrequency ablation|Radiofrequency ablation of the tumour
48127262|NCT04553458|DRUG|Trance-arterial chemoembolization|Trance-arterial chemotherapy
48127263|NCT04553458|PROCEDURE|Liver resection|non-anatomical or anatomical liver resection
48127264|NCT04553458|COMBINATION_PRODUCT|Combined radiofrequency ablation + percutaneous ethanol injection|combined therapy
48127265|NCT04553458|DRUG|Percutaneous ethanol injection|Percutaneous ethanol injection of HCC
48127266|NCT04553458|DRUG|Systemic chemotherapy|Systemic chemotherapy
48127267|NCT04553458|DRUG|Sorafenib|Sorafenib
48127268|NCT04553458|DIETARY_SUPPLEMENT|Viscum|Viscum for HCC
48127269|NCT04553458|DRUG|Symptomatic treatment|Symptomatic treatment
48127270|NCT04180579|DEVICE|PAXMAN Scalp Cooler|Scalp cooling will occur with each dose of chemotherapy.
48127271|NCT02590432|DRUG|Linaclotide|Linaclotide capsules, orally, once daily.
48127272|NCT02155868|OTHER|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood \< 35 mmHg; mean arterial pressure \< 60 mmHg; central venous pressure \> 10 mmHg; cardiac index \< 2.0 l/min/m2; mixed venous oxygen saturation \< 60%; hemoglobin \< 65 g/L during cardiopulmonary bypass or hemoglobin \< 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
48127273|NCT02155868|OTHER|Standard treatment|Standard treatment
48334390|NCT01047046|OTHER|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
48493421|NCT03584984|PROCEDURE|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
48493422|NCT03584984|PROCEDURE|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
48493423|NCT03584984|PROCEDURE|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
48493424|NCT03570086|DIAGNOSTIC_TEST|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
48493425|NCT04819035|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
48493426|NCT03535675|DRUG|Muscadine Plus|Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
48493427|NCT03535675|DRUG|Placebos|The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
48493428|NCT00063414|DRUG|Alicaforsen|
48334391|NCT02521857|DRUG|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
48493429|NCT04559971|DRUG|SLN124|SLN124 for subcutaneous (s.c.) injection
48493430|NCT04559971|DRUG|Placebo|Sodium chloride for s.c. injection
47976316|NCT03554746|OTHER|GC group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps~3. Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~   1. clam ex. without resistance~  2. single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~   <!-- -->~   1. maintain 3rd to 4th ex.~  2. single leg standing on rock board to maintain balance 6th:~   <!-- -->~   1. maintain 5th ex.~  2. lunge ex. without hip internal rotation"
47976317|NCT03554746|OTHER|CG group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps"
47976318|NCT06062953|DRUG|Melatonin|3-9 mg flexible dosing before bed time
47976319|NCT06062953|DRUG|Quetiapine|50-150 mg flexible dosing before bed time
47976320|NCT06062953|DRUG|Placebo|1-3 capsules flexible dosing before bed time
47976321|NCT00248989|DRUG|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
47976322|NCT00248989|DRUG|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
48127274|NCT05866978|BEHAVIORAL|Integrated Approach to Health, Wellbeing, and Productivity at Work (ITASPA)|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish context among blue-collar workers.
48127275|NCT04788459|BIOLOGICAL|COVID-eVax|Plasmid DNA Vaccine for COVID-19
48127276|NCT04788459|DEVICE|Cliniporator® and EPSGun|IGEA Electroporation Device
48127277|NCT00960024|BEHAVIORAL|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
48127278|NCT00960024|BEHAVIORAL|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
48127279|NCT06108024|DRUG|SM-020 gel 1.0%|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
48127280|NCT06108024|DRUG|Vehicle gel|Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
48127281|NCT02479217|DRUG|Docetaxel|
48127282|NCT02479217|DRUG|Xeloda|
48127283|NCT00439413|DRUG|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
48127284|NCT00439413|DRUG|Placebo|Matching placebo via transdermal system
48127285|NCT00439413|BEHAVIORAL|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
48127286|NCT05845515|PROCEDURE|laparoscopic orchiopexy|laparoscopic or open orchiopexy and comparison between the two groups
48127287|NCT00507884|PROCEDURE|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
48127288|NCT00004257|DRUG|fluorouracil|
48127289|NCT00004257|DRUG|oxaliplatin|
48493431|NCT06296654|BEHAVIORAL|Empowerment-Based Interventions|The Empowerment-Based Interventions was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group d
48653010|NCT06553885|DRUG|Enfortumab Vedotin|Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.
48127290|NCT00004257|PROCEDURE|conventional surgery|
48127291|NCT00004257|RADIATION|radiation therapy|
48127292|NCT03042039|OTHER|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
48127293|NCT05018013|DRUG|Ammoxetine hydrochloride enteric-coated tablets|Ammoxetine hydrochloride enteric-coated tablets
48127294|NCT05018013|DRUG|Duloxetine hydrochloride enteric-coated capsules|Duloxetine hydrochloride enteric-coated capsules
48127295|NCT05018013|DRUG|Placebo to Ammoxetine|Placebo to Ammoxetine
48127296|NCT05018013|DRUG|Placebo to Duloxetine|Placebo to Duloxetine
48127297|NCT05663346|OTHER|Cannabis & Cancer digital educational intervention|The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.
48127298|NCT05663346|OTHER|Standard information regarding cannabis use in oncology|Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
48127299|NCT03287713|DRUG|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
48127300|NCT02477813|DRUG|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
48127301|NCT02368626|DEVICE|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
48127302|NCT02172872|DRUG|standard combination chemotherapy|"1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days"
48127303|NCT02172872|DRUG|decitabine|"1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~2. Cycle 2~   1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~3. Cycle 3~   1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
48127304|NCT02245555|DRUG|Tamsulosin|
48127305|NCT03800212|DRUG|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
48127306|NCT03848572|DIAGNOSTIC_TEST|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
48127307|NCT00112359|DRUG|AZLI 75 mg three times a day (TID)|
48127308|NCT00112359|DRUG|Placebo three times a day (TID)|
48127309|NCT04350541|OTHER|High-intensity interval training|Exercise with high-intensity intervals followed by active rest
48127310|NCT04350541|OTHER|Continuous aerobic training|Interval Moderate-intensity aerobic training without intervals
48127311|NCT04067219|PROCEDURE|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
48127312|NCT06392412|BEHAVIORAL|fi-VR Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. Participants in the fi-VRCT will use the virtual reality system with head-mounted display and handheld controllers. The fi-VRCT will be administered by an experienced research assistant.
48127313|NCT06392412|BEHAVIORAL|Traditional Cognitive Training|All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. The CT control program will include cognitive board games designed to improve various cognitive capacities. Certified community occupational therapists will lead the CT control group.
48127314|NCT02697877|DRUG|Regadenoson|
48127315|NCT05692817|DEVICE|Low-Intensity Pulsed Ultrasound|"The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol."
48127316|NCT02417376|DEVICE|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
48127317|NCT02417376|DEVICE|Gracey curettes|set of 7 instruments number #1-14
48127318|NCT02782507|BEHAVIORAL|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon \& Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
48127319|NCT03778541|DRUG|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
48127320|NCT03778541|RADIATION|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
47976323|NCT02968407|OTHER|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
48127321|NCT04547764|DRUG|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
48334392|NCT00755872|DRUG|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
48334393|NCT00755872|DRUG|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
48334394|NCT00755872|DRUG|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
48334395|NCT00755872|DRUG|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
48334396|NCT01330641|PROCEDURE|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
48334397|NCT04617899|DIAGNOSTIC_TEST|Intravascular imaging|Use of imaging catheter
48334398|NCT00767845|OTHER|questionnaire/survey administration|
48334399|NCT04153643|PROCEDURE|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
48334400|NCT03217201|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
48334401|NCT03217201|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
48334402|NCT03368599|PROCEDURE|Bronchoscope guided advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~3. Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~4. Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~5. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
48334403|NCT03368599|PROCEDURE|Conventional advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~1. Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~2. Rotate Lt. DLT 90 degrees to the left side.~3. Advance Lt. DLT blindly to main bronchus level.~4. After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
48334404|NCT01626534|DRUG|Clopidogrel|600mg loading dose then 75mg/day
48493432|NCT06296654|BEHAVIORAL|Standard Health Education|Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
48493433|NCT06166238|PROCEDURE|Millard and Tension Randal Technique|Millard recognized that the majority of Cupid's bow, one philtral column, and the philtral dimple were intact on the medial aspect of a unilateral cleft lip but required rotation to shift the tissue into a normal anatomic position (Millard, 1964b) The Tennison-Randall technique involves a back-cut that extends from the cleft Cupid's bow peak toward the center of the philtrum that is filled by a laterally based triangular flap whose width is the measured deficiency in lip height.
48493434|NCT02109510|DRUG|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
48127322|NCT04547764|DRUG|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
48493435|NCT02109510|DRUG|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
48493436|NCT02109510|PROCEDURE|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
48127323|NCT02664558|DRUG|ubenimex|
48334405|NCT01626534|DRUG|trigagrelor|180 mg loading dose then 90 mg Twice a day
48334406|NCT00472017|DRUG|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
48334407|NCT03460925|RADIATION|SBRT plus chemotherapy|Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
48127324|NCT02664558|OTHER|placebo|
48127325|NCT03279406|DEVICE|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
47976324|NCT00121602|DRUG|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
47976325|NCT05124964|OTHER|PedsQL 4.0 Scale|The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
48127326|NCT01784575|OTHER|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
48127327|NCT03112135|DRUG|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
48127328|NCT03112135|DRUG|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
48127329|NCT03112135|DRUG|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
48127330|NCT03445364|OTHER|Use of different injection pressure during primary PCI|Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
48127331|NCT01824420|DRUG|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
48127332|NCT01824420|DRUG|Detrusitol 4mg QD|Control group
48127333|NCT02241538|DEVICE|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
48127334|NCT02241538|DEVICE|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
48127335|NCT02241538|DEVICE|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
48127336|NCT02241538|DEVICE|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
48127337|NCT00920972|DRUG|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
48127338|NCT00920972|DRUG|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day... Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
48127339|NCT00920972|DRUG|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
48334408|NCT04392869|BEHAVIORAL|The CRAFT program (adapted due to COVID-19)|"The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context."
48334409|NCT04392869|BEHAVIORAL|The MBSR program (adapted due to COVID-19)|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context."
48334410|NCT06279663|PROCEDURE|Revascularization|revascularization
48334411|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
48334412|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
48334413|NCT01502358|BIOLOGICAL|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
48334414|NCT00033371|DRUG|Celecoxib|Given 400 mg PO twice a day
48653011|NCT04918771|DRUG|Raphamin|"Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days."
48127340|NCT00920972|DRUG|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
48127341|NCT04420767|DEVICE|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
48653012|NCT04918771|DRUG|Placebo|Oral administration - not with food. Placebo using Raphamin scheme.
48653013|NCT04785352|DIETARY_SUPPLEMENT|Nutrition Intervention|One egg per day for six months
47976326|NCT05124964|OTHER|Short Form-36|Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
47976327|NCT05124964|OTHER|Chinese Wechsler Intelligence Scale for Children|The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests \[Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)\] and five performance tests \[Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)\]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
47976328|NCT05038423|BEHAVIORAL|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., \& Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., \& Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
48653014|NCT04785352|BEHAVIORAL|Grandi Byen|Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
48653015|NCT03053232|DEVICE|Purse string suture device|Using purse string suture device to close gastrointestinal perforation under endoscopy.
48653016|NCT03053232|DEVICE|Endoclips|Using endoclips to close gastrointestinal perforation under endoscopy.
47976329|NCT05038423|BEHAVIORAL|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
48127342|NCT04420767|DEVICE|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
48127343|NCT04420767|BEHAVIORAL|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
48127344|NCT01742169|BEHAVIORAL|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
48127345|NCT03628885|BEHAVIORAL|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (\< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
48127346|NCT03628885|BEHAVIORAL|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (\< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
48653017|NCT04922879|BEHAVIORAL|Individualized lung rehabilitation|Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
48653018|NCT06632860|DRUG|68Ga-TATE-RGD|Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.
48653019|NCT06632860|DRUG|18-FDG|Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.
48127347|NCT03103048|DIAGNOSTIC_TEST|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
48127348|NCT03103048|DIAGNOSTIC_TEST|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
48653020|NCT01564329|DRUG|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
48653021|NCT06326541|BEHAVIORAL|music therapy|Listening to the Holy Quran.
47976330|NCT06289491|PROCEDURE|Hydrus Microstent|Patients will have a Hydrus Microstent inserted into the canal of Schlemm at the time of cataract surgery
48127349|NCT03103048|DIAGNOSTIC_TEST|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
48127350|NCT03103048|DIAGNOSTIC_TEST|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
47976331|NCT06289491|PROCEDURE|Incisional goniotomy|Patients will have incisional goniotomy to open the trabecular meshwork with a Sinskey hook at the time of cataract surgery
47976332|NCT06289491|PROCEDURE|Excisional goniotomy|Patients will have excisional goniotomy to remove the trabecular meshwork with a Kahook Dual Blade at the time of cataract surgery
47976333|NCT04013139|DIAGNOSTIC_TEST|CPET|CPET
47976334|NCT01765205|DEVICE|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
47976335|NCT05040321|DRUG|MIB-626|Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.
47976336|NCT05040321|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 500mg MIB-626 twice daily orally.
47976337|NCT03752580|DEVICE|User Instructions of novel nasal mask|User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
47976338|NCT02769455|OTHER|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
47976339|NCT02769455|OTHER|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
47976340|NCT03453710|PROCEDURE|Bankart Repair plus Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
47976341|NCT03453710|PROCEDURE|Latarjet coracoid transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
48127351|NCT01483066|DEVICE|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
48127352|NCT03058445|DEVICE|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
48127353|NCT03058445|DEVICE|CVC|Injection of 5 ml of saline
48127354|NCT03548857|OTHER|Lung transplantation|Single or double lung transplantation in patients with COPD
48127355|NCT02962284|DRUG|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
48127356|NCT04544982|OTHER|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
48127357|NCT04544982|OTHER|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
48127358|NCT00588471|DRUG|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
48127359|NCT00588471|DRUG|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
48653022|NCT03186820|OTHER|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
48653023|NCT06549335|DRUG|Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)|"Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles."
48334415|NCT00033371|OTHER|Placebo|Given PO to match DFMO
48334416|NCT00033371|DRUG|eflornithine|Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of \> 2.6 = 1,250 mg/day).
48334417|NCT00033371|OTHER|Laboratory biomarker analysis|Correlative studies
48334418|NCT00033371|OTHER|Questionnaire administration|Ancillary studies
48334419|NCT02197598|DRUG|nalmefene|
48334420|NCT01496170|DRUG|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
48334421|NCT01496170|DRUG|Placebo|Placebo capsules, orally, once per day for 7 days
48653024|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+8Gy x 3f|Radiotherapy: 8Gy x 3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
47976342|NCT02707991|BEHAVIORAL|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
47976343|NCT04233645|OTHER|5-minute educational video|The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
47976344|NCT04233645|OTHER|Usual Care|The groups will be given a standard scripted verbal and identical written instructions as per usual care.
48127360|NCT01521169|OTHER|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
48127361|NCT01521169|OTHER|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
48127362|NCT01521169|OTHER|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
48127363|NCT00223067|DRUG|TAIZ|
48334422|NCT00003635|DRUG|nelarabine|
48334423|NCT01306032|DRUG|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
48334424|NCT01306032|DRUG|Cyclophosphamide|
48334425|NCT02836132|BEHAVIORAL|Weight Watchers Online|
48334426|NCT02836132|BEHAVIORAL|Experience Success Virtual Reality Platform|
48334427|NCT01896388|DRUG|Ifenprodil Tartrate|
48334428|NCT01896388|DRUG|Placebo|
48334429|NCT04746209|DEVICE|Alpha/Beta T-cell and B-cell depleted HCT|Device: Alpha/Beta T-cell and B-cell depletion
47976345|NCT03421392|OTHER|non interventional study|non interventional study
48127364|NCT03239301|PROCEDURE|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
48127365|NCT03239301|PROCEDURE|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
48127366|NCT05783570|BIOLOGICAL|EU307 CAR-T Cell|"* Dose to be administered: a single dose~* IV administration~* Dosing rate: To be administrated at a rate of approximately 2 mL/min"
48127367|NCT02799875|OTHER|Higher permissive hypercapnia|"* pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~* pH ≥ 7.20 from a capillary or arterial blood sample;"
48334430|NCT04746209|DRUG|Blinatumomab|28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD
48334431|NCT05386264|OTHER|Expanded autologous T regulatory cells|A 3+3 dose escalation design with expanded T regulatory cells administered on Day 1 and Day 15
48334432|NCT03437213|DRUG|Total intravenous anesthesia group|Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
48334433|NCT03437213|DRUG|Total intravenous plus block group|Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
48127368|NCT02799875|OTHER|Lower Permissive Hypercapnia|"* pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~* pH ≥ 7.25 from a capillary or arterial blood sample;"
48127369|NCT02480205|DEVICE|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:~* On conventional NIPPV device with the clinically prescribed settings (30 min)~* With NeuroPAP and no change of Pmin (=peep) (60 min)~* With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~* During CPAP delivered with NeuroPAP device (15 min)~* Again with original NIPPV device and settings for 30 minutes"
48127370|NCT01334489|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
48334434|NCT05771506|OTHER|Balance Assessment|"Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded."
48334435|NCT05771506|OTHER|Pulmonary function test|"Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values."
48334436|NCT05771506|OTHER|Respiratory muscle strength test|Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
48334437|NCT05771506|OTHER|Peripheral muscle strength test|Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
48334438|NCT05771506|OTHER|6-minute walk test|Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
47976346|NCT03731611|PROCEDURE|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
47976347|NCT03923855|DEVICE|BTL-899|BTL-899 therapy
48334439|NCT05771506|OTHER|Cognitive assessment|Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
48493437|NCT04213976|PROCEDURE|Ileostomy|Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
48493438|NCT00515931|RADIATION|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
47976348|NCT00848081|DRUG|Tadalafil|5 mg taken by mouth once daily for 12 weeks
48334440|NCT05765292|DIETARY_SUPPLEMENT|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
48334441|NCT05765292|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
48493439|NCT00045175|DRUG|7-hydroxystaurosporine|
48493440|NCT00045175|DRUG|topotecan hydrochloride|
48493441|NCT05777460|DEVICE|Thoracic endovascular aortic repair (TEVAR)|The TEVAR procedure involves the placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
47976349|NCT00848081|DRUG|Placebo|By mouth once daily for 12 weeks
48334442|NCT01683084|DRUG|Telmisartan|
48334443|NCT01683084|DRUG|Placebo|
48334444|NCT03447821|DRUG|400 mg Rifamycin SV dosage|
48334445|NCT03447821|DRUG|800 mg Rifamycin SV dosage|
48334446|NCT03447821|DRUG|1200 mg Rifamycin SV dosage|
48334447|NCT01997697|OTHER|behavior change program|behavior change program among patients with obesity
47976350|NCT00603993|BIOLOGICAL|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
47976351|NCT06138301|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a psychotherapeutic intervention that focuses on challenging and changing cognitive distortions (such as thoughts, beliefs, and attitudes) and their associated behaviours to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, patients with SI will undergo 8 sessions of CBT (45 min, once a week), remotely. Techniques and strategies of the intervention will be based on a short telepsychotherapy protocol previously published by our group (Biagianti et. al., 2021). Instead, the content of each session will be adapted to the psychopathology associated with social isolation and the age of the subject. The psychotherapeutic sessions of the patients will be audio-recorded in order to conduct retrospective analyzes of the patient's speech.
48493442|NCT00297856|BIOLOGICAL|Boostrix®|Single dose
48493443|NCT00297856|BIOLOGICAL|Td (Tetanus diphtheria) vaccine|Single dose
48493444|NCT03192865|PROCEDURE|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
48493445|NCT05556070|OTHER|Arm 1|: Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
48493446|NCT05556070|OTHER|Arm 2|Boxes of fresh fruits and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks.
48493447|NCT05556070|OTHER|Arm 3|subjects in this arm will receive the usual standard of care at the clinic for the study period
48127371|NCT00585156|DRUG|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
48127372|NCT03003572|OTHER|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
48127373|NCT03443661|DRUG|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
48127374|NCT02652442|BEHAVIORAL|Centrifugation Distance|To determine optimal distance off-axis, participants were rotated in a darkened rotary chair booth with 1 ear positioned 3.5 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period. Following a 2-week washout period, participants were rotated in a darkened rotary chair booth with 1 ear positioned 7.0 cm off-axis and the other ear positioned on-axis for 1 minute. Participants received 5 sessions in a 1-week period.
48334448|NCT03872557|DIETARY_SUPPLEMENT|Tyrosine (TYR) Supplementation|L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
48653025|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+16Gy x 1f|Radiotherapy: 16Gy x 1f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
47976352|NCT06138301|BEHAVIORAL|Cognitive Remediation (CR)|The cognitive training will consist of 10 hours (30 minutes/session) of computer-based exercises focusing on working memory, attention, executive functions and social cognition, which will be performed online using BrainHQ software. This software allows for the customization of the training based on the specific characteristics of each subject. For example, it allows automatic adjustment of the difficulty of the exercises, trial by trial and session by session, in order to guarantee an adequate level of attention and motivation for the entire duration of the training and therefore favor optimal learning rates.
47976353|NCT05083442|DEVICE|Low Level Laser Therapy|Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
47976354|NCT05083442|OTHER|Sham (placebo)|Use of sham (placebo) option
47976355|NCT01929915|PROCEDURE|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
47976356|NCT01929915|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
47976357|NCT01851616|DIETARY_SUPPLEMENT|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
47976358|NCT01851616|DIETARY_SUPPLEMENT|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
47976359|NCT01811160|DRUG|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
47976360|NCT01811160|DRUG|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
47976361|NCT02273024|BEHAVIORAL|Exercise|
47976362|NCT01119885|DRUG|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
48127375|NCT02652442|BEHAVIORAL|Centrifugation Duration|To determine optimal duration, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes. Participants received 5 sessions in a 1-week period.
47976363|NCT01119885|DRUG|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
47976364|NCT03974945|DEVICE|Passive-elastic prosthetic foot|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
47976365|NCT03974945|DEVICE|Powered ankle-foot prosthesis|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
47976366|NCT00647790|PROCEDURE|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
48127376|NCT02652442|BEHAVIORAL|Centrifugation Schedule|To determine optimal schedule, after a two week washout period, participants were rotated off-axis at 3.5 cm (determined to be optimal in Exp 1) for 3 minutes (determined to be optimal in Exp 2). Participants received biweekly sessions for a total of 5 sessions.
47976367|NCT01899300|DEVICE|Metal Stent (WallFlex™ Esophageal RX)|
48334449|NCT02425280|BEHAVIORAL|Narrative Exposure Therapy|
48334450|NCT02425280|BEHAVIORAL|Treatment as Usual|
48334451|NCT02407314|PROCEDURE|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
48127377|NCT00818246|DEVICE|Sham light|
48127378|NCT00818246|DEVICE|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
48493448|NCT05556070|OTHER|Brighter Bites app|"Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
48493449|NCT05070871|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
48493450|NCT05070871|OTHER|Placebo|Pure maltodextrin.
48493451|NCT05070871|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
48493452|NCT01370135|DRUG|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
48493453|NCT00856830|DRUG|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
48493454|NCT00343343|DEVICE|NovoFine® needle 6 mm|
48493455|NCT00343343|DEVICE|NovoFine® needle 4 mm|
48493456|NCT05502965|OTHER|dietary pattern|Reprocessed and intolerant foods were removed from the dietary pattern, and the food were cooked at home for experimental subjects.
48493457|NCT05502965|OTHER|EEN|All energy and nutrients are obtained from exclusive enteral nutrition.
48493458|NCT00673387|DRUG|pramlintide acetate|subcutaneous injection, twice a day
48493459|NCT00673387|DRUG|metreleptin|subcutaneous injection, twice a day
48493460|NCT00673387|DRUG|placebo-P|subcutaneous injection, twice a day
48493461|NCT00673387|DRUG|placebo-M|subcutaneous injection, twice a day
48493462|NCT03905564|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
48493463|NCT03905564|DRUG|Diclegis (Registered Trademark)|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
48493464|NCT01298401|BIOLOGICAL|ganitumab|
47976368|NCT05171595|DEVICE|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
47976369|NCT05171595|DIAGNOSTIC_TEST|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
47976370|NCT04561193|OTHER|Observational|Observational
47976371|NCT04540224|DIAGNOSTIC_TEST|Flow-Cytometric analysis|Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
47976372|NCT05861921|OTHER|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
47976373|NCT04221841|OTHER|descriptive|correlation
47976374|NCT03356990|DIETARY_SUPPLEMENT|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
48127379|NCT06364553|DEVICE|Esophageal self-expandable metal stent|The Leufen Esophageal aixstent ® (Leufen Medical GmbH) is indicated for the treatment of malignant esophageal strictures and postoperative stenosis. It is comprised of two components: an implantable metallic stent and the delivery system. After the procedure, the stent remains at the intended location, within the patient while the delivery system is removed.
48127380|NCT03556449|DIAGNOSTIC_TEST|High resolution ultrasound|Using a high-frequency linear array transducer (18L6 HD)
48127381|NCT02696161|OTHER|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
48127382|NCT02696161|OTHER|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
48127383|NCT04460807|DRUG|Exemestane|Exemestane in addition to standard therapy, in Experimental arm.
48127384|NCT04460807|OTHER|Placebo oral tablet|Placebo in addition to standard therapy, in Control arm.
48127385|NCT02863315|DEVICE|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
48493465|NCT01298401|DRUG|capecitabine|
48493466|NCT01298401|DRUG|gemcitabine hydrochloride|
48493467|NCT01298401|RADIATION|3-dimensional conformal radiation therapy|
48493468|NCT01321008|RADIATION|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
48493469|NCT01321008|DRUG|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
48334452|NCT02407314|DEVICE|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
48127386|NCT05838469|OTHER|Pediatric Strip Crown and High Viscosity Glass Ionomer Cement|"Following the decision on the appropriate size of celluloid strip crown, the tooth will be isolated using roll cottons and the cavity conditioner (GC, Japan) will be applied to all surfaces for 10 seconds, washed away and dried with cotton pellets. The selected celluloid strip crown will be filled with a fluoride-releasing bulk fill hybrid glass ionomer cement (EQUIA Forte, GC, Japan) prepared by mixing for 10 seconds in an automatic mixer and placed on the tooth with light pressure. The excess material on the crown margins will be removed with a hand instrument, and the celluloid strip crown will be removed from the tooth. If necessary, the restoration will be polished using a polishing discs. After the crown surface is washed and dried, a nano-filled surface sealant (EQUIA Forte Coat, GC, Tokyo, Japan) will be applied for 10 seconds with a micro-tipped applicator and light cured for 20 seconds."
48127387|NCT05532475|DIAGNOSTIC_TEST|measurement of vitreous level of tumor necrosis factor alpha|measurement of vitreous level of tumor necrosis factor alpha using ELISA technique
48127388|NCT04929106|DEVICE|mHealth support tool|The final app is named Active Leisure and consists of an advanced activity planner based on the platform developed by the ideal company Smart Cognition AS. The app offers different interface options (symbols only, easy to read text, plain text, and read aloud). The activity planner will mostly be used by the individual with IDs and a support person (caregiver or health care provider). After completing an activity, a simple reward is available (e.g., a smiling face or to share a picture with other users of the app). The use of tailored communication through personalization: the use of individuals first name in the activity planner, adaptation: individually chosen activities, adjusted communication (symbols, easy-to-read text or plain text), preparation and planning, and feedback: rewarding and positive feedback (after activities have been performed) is expected to increase motivation, and thereby lead to higher levels of PA.
48127389|NCT03167736|OTHER|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.
48127390|NCT03167736|OTHER|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
48334453|NCT02407314|OTHER|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
48334454|NCT02407314|OTHER|Six minute walk distance|Assessment of the walking distance in 6 minutes.
48334455|NCT02407314|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid \[ASA\], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
48334456|NCT02407314|DRUG|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
48653026|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+2.67Gy x 15f|Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
48653027|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f|Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
48334457|NCT03942237|PROCEDURE|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified."
48334458|NCT03942237|PROCEDURE|Placebo Control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified"
48334459|NCT02905916|DRUG|PEG-rhG-CSF|
48334460|NCT01896856|DRUG|SGI-110 Dose Escalation|"* Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support"
48334461|NCT01896856|DRUG|Regorafenib|160 mg taken orally
48334462|NCT01896856|DRUG|TAS-102|35 mg/m\^2 taken orally
48334463|NCT01896856|DRUG|SGI-110|45 mg/m\^2 administered as a subcutaneous injection
48334464|NCT01896856|DRUG|Irinotecan|125 mg/m\^2 administered IV
48493470|NCT01321008|DRUG|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
48493471|NCT01321008|DRUG|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
48493472|NCT01321008|DRUG|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
48493473|NCT00997139|DRUG|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
48493474|NCT04469621|DRUG|SAR443122|Pharmaceutical form:capsule Route of administration: oral
48127391|NCT04761042|OTHER|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
48127392|NCT04761042|OTHER|WAYA-Holiday|"An attention control group (information in Detailed description)"
48127393|NCT00766649|DRUG|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
48127394|NCT00995631|PROCEDURE|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
48127395|NCT02433782|OTHER|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
48127396|NCT04564365|DRUG|beta-blocker|To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
48127397|NCT02564536|DRUG|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
48127398|NCT02564536|DRUG|Decitabine|-From commercial stock
48127399|NCT04308083|PROCEDURE|dental implant placement|Implants will be placed according to the manufacturer recommendations. Implants will be placed at 1.5 to 2.0 mm from the adjacent natural tooth. However, these distances will be directed by the prosthetic crown needed and they will be recorded in the CRF.
48127400|NCT00386958|DRUG|Povidone-Iodine|
48127401|NCT00587275|DRUG|AST-120|Oral, sachet, 2 grams daily for 4 weeks
48127402|NCT00587275|DRUG|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
48127403|NCT04039906|DEVICE|Removal of needle with using ANDYs|"1. ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~2. Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~   Identify the number of syringes processed by ANDY.~3. After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
48127404|NCT05910411|DEVICE|Inelastic compression|Inelastic compression used in the treatment of lymphedema
48127405|NCT00630487|DRUG|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
48127406|NCT00630487|DRUG|Somatropin|Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
48127407|NCT03875040|BEHAVIORAL|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
48493475|NCT04469621|DRUG|Placebo|Pharmaceutical form:capsule Route of administration: oral
48493476|NCT01087671|DRUG|tafluprost|prostaglandin analogue
48493477|NCT02932514|DEVICE|Eversense (Senseonics) Continuous Glucose Monitoring System|"* Evaluate accuracy of Eversense CGM System to SMBG Meter.~* Compare performance between abdomen and arm insertion sites.~* Determine the usability of the Eversense System in a home-use setting for 180 days."
48493478|NCT04002336|BEHAVIORAL|Traditional Voice therapy|Traditional method of voice therapy
48493479|NCT04002336|BEHAVIORAL|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
48493480|NCT00727727|DRUG|Piribedil|
48334465|NCT04077229|BEHAVIORAL|Intervention arm: Text Message Intervention|Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
48334466|NCT00801892|DEVICE|Continuous Positive Airway Pressure (CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
48334467|NCT00801892|DEVICE|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
48334468|NCT05320380|DRUG|Anti-CD123 ADC IMGN632|Given IV
48334469|NCT05320380|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
48334470|NCT05320380|DRUG|Cytarabine|Given IT and IV
48334471|NCT05320380|DRUG|Fludarabine Phosphate|Given IV
48334472|NCT05320380|DRUG|Hydrocortisone Sodium Succinate|Given IT
48334473|NCT05320380|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48334474|NCT05320380|DRUG|Methotrexate|Given IT
48334475|NCT05320380|DRUG|Prednisolone|Given IT
48334476|NCT04942119|OTHER|Multifactorial intervention|"1. Correction of magnesium and/or potassium deficit and the underlying disease.~2. Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~3. Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR)."
48334477|NCT00888615|DRUG|Elesclomol Sodium|Given IV
48334478|NCT00888615|DRUG|Paclitaxel|Given IV
48334479|NCT04030897|BEHAVIORAL|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
48334480|NCT04030897|BEHAVIORAL|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
48334481|NCT04030897|BEHAVIORAL|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
48334482|NCT05376995|DIAGNOSTIC_TEST|Graston technique|Graston technique among patient of knee osteoarthritis
48334483|NCT05376995|DIAGNOSTIC_TEST|muscle energy technique|muscle energy technique among patient of knee osteoarthritis
48334484|NCT01883804|DRUG|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
48127408|NCT06181916|BEHAVIORAL|Amp|Amp is a virtual support system mHealth app that provides information and social support to help young Black men who have sex with men (YBMSM) living with HIV achieve better HIV care continuum outcomes and overall well-being.
48127409|NCT01761487|DEVICE|Gentamicin and polymyxin E|
48127410|NCT00702884|DRUG|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
48334485|NCT05201768|OTHER|balance tests,questionnaire|Individuals will be tested and recorded.
48334486|NCT06311110|OTHER|Vancouver symptom score for dysfunctional elimination symptoms Questionnaire|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.
48334487|NCT06311110|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.
48334488|NCT06311110|OTHER|Questionnaire concerning impaired toilettraining and comorbities|Unvalidated, complementary questions concerning impaired toilettraining and comorbidities. Questions were based on ICCS standardisation guidelines (Austin et al., 2015). The questionnaire is filled in by the parents of the child.
48334489|NCT06053619|OTHER|GaitTrainer and Virtual Reality|"Realization of Gait Trainer-assisted robot walking rehabilitation sessions without and with the addition of an immersive VR device. The proposed virtual stage will be a natural space (i.e. forest) of 360°. The subject will be able to explore the environment without moving. The created scene represents a straight path crossing a landscape composed of different natural elements. A fluid movement is obtained with the help of two sensors (trackers) of the HTC Vive device, placed at the level of the subject's feet. Moreover, thanks to these sensors the individual has a virtual representation of his lower limbs.~Post-stroke patients will perform 3 conventional sessions (Gait Trainer alone) and 3 sessions with the immersive VR device (Gait Trainer + VR)."
48493481|NCT05190653|OTHER|Early palliative and supportive care|The intervention itself will be predominantly the provision of education and information. It is possible that patients in the intervention arm may receive treatment recommendations to help manage symptoms.
48493482|NCT02139371|OTHER|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
48493483|NCT06253819|OTHER|survey and physical test|6 min. walking test respiratory function test 30 second sit-stand test respiratory muscle test tıme up and go corbin posture analysis Waist/Hip Circumference Ratio Glucose and Cholesterol values Lanss Neuropathic Pain Scale
48127411|NCT03333109|BIOLOGICAL|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
48127412|NCT03333109|OTHER|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
48127413|NCT05606484|OTHER|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
48127414|NCT05606484|OTHER|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
48127415|NCT01032668|DRUG|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
48127416|NCT00485459|DRUG|Atomoxetine Hydrochloride|
48127417|NCT00485459|DRUG|Placebo|
48653028|NCT06570538|DRUG|Ropivacaine|300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
48653029|NCT06570538|DRUG|Sufentanil|Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
48653030|NCT02531451|DRUG|Ibuprofen|
48653031|NCT02531451|DRUG|Acetylsalicylic acid|
48653032|NCT06640517|DRUG|Netakimab|netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
48493484|NCT00975286|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48653033|NCT06640517|DRUG|Placebo|placebo will be administered subcutaneously at a scheme masking netakimab treatment
48653034|NCT06640517|DRUG|Adalimumab|adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
48653035|NCT05142319|BIOLOGICAL|Homologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
48653036|NCT05142319|BIOLOGICAL|Heterologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
48653037|NCT05142319|BIOLOGICAL|COVAXIN|Single intradermal injection at 6ug (0.5ml) per dose.
47976375|NCT02108470|OTHER|Dental consultation using OHIP|The S-OHIP\[M\] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
47976376|NCT03503955|OTHER|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
47976377|NCT03503955|OTHER|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
47976378|NCT02994979|OTHER|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
47976379|NCT02994979|OTHER|Sham comparator|Usual care plus sham visits by CNA
48493485|NCT00975286|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48493486|NCT00975286|DRUG|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
48493487|NCT00975286|DEVICE|Pen auto-injector|Lantus® SoloStar® OptiClik®
48493488|NCT00975286|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
48493489|NCT00975286|DRUG|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
48493490|NCT02833766|DRUG|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
48493491|NCT04407091|DRUG|14C]AZD4831 Oral Solution|10 mg dose of \[14C\]AZD4831 Oral Solution
48493492|NCT00006235|DRUG|carboplatin|
48493493|NCT00006235|DRUG|pegylated liposomal doxorubicin hydrochloride|
48493494|NCT04161014|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150mg twice daily for 3 years
48493495|NCT06217484|BEHAVIORAL|delayed feedback|participants learn through either immediate or delayed feedback during a computer task
48493496|NCT00001993|DRUG|Butyldeoxynojirimycin|
48493497|NCT00001993|DRUG|Zidovudine|
48493498|NCT00729274|DRUG|normal saline solution|Two 4ml nebulizations with 30 minute interval
48653038|NCT05142319|BIOLOGICAL|Nuvaxovid|Single intradermal injection at 5mcg (0.5mL) per dose.
48653039|NCT02607722|DRUG|Nintedanib|
48653040|NCT03032809|OTHER|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
48653041|NCT02419911|PROCEDURE|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
48653042|NCT02419911|DEVICE|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
48493499|NCT00816361|DRUG|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
48493500|NCT00862238|BEHAVIORAL|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, \& C
48493501|NCT00862238|OTHER|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, \& C
48493502|NCT02199340|OTHER|iStep exercise test|newly developed submaximal exercise test
48493503|NCT02199340|OTHER|CPET exercise test|maximal gold standard exercise test
48127418|NCT01211184|DIETARY_SUPPLEMENT|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
48127419|NCT01211184|DIETARY_SUPPLEMENT|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
48127420|NCT01211184|BEHAVIORAL|Fasting.|The patient is fasting from midnight before the surgery.
48334490|NCT03714009|BEHAVIORAL|Fasting|"Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters)."
48127421|NCT00918203|BIOLOGICAL|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
48653043|NCT02419911|DEVICE|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
48653044|NCT02264821|DRUG|ropivacaine infiltration|wound infiltration
48653045|NCT02264821|DRUG|intrathecal morphine|100 µg added to the spinal anaesthesia
48653046|NCT02264821|DRUG|placebo|placebo in spinal anaesthesia and in wound infiltration
48653047|NCT03652428|DRUG|Gemcitabine|see arm description
47976380|NCT05944874|DEVICE|high definition transcranial direct current stimulation|Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.
48127422|NCT00918203|DRUG|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
48127423|NCT00918203|DRUG|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
48127424|NCT02596919|OTHER|photography|photography of meibomian glands
48127425|NCT03438903|DEVICE|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
48127426|NCT00160498|DRUG|Lercanidipine|
48127427|NCT03815136|OTHER|Chewing Gum|Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
48334491|NCT03714009|BEHAVIORAL|No fasting|Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
48334492|NCT05374837|BEHAVIORAL|Infant and young child feeding voice messaging intervention|A mobile voice and text messaging intervention aimed at improving IYCF practices will be delivered to mothers and fathers with young children (6-23 months). A total of 16 voice and text message, with the same content, will be sent over a 16-week period (1 voice + 1 text messages (with same content) per week x 16 weeks). Two types of messages will be included: 1) eight scripted and 2) eight unscripted messages from positive deviants. The content of the messages include: breastfeeding until two years of age, consuming a variety of foods within a given meal, the consistency of porridge (thick rather than thin), limiting sweets and fried foods, the importance of animal source foods, consuming vitamin A rich fruits and vegetables, consuming leafy greens, handwashing and feeding infants and young children fruits and vegetables produced by the household.
48334493|NCT04090268|OTHER|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
48334494|NCT02030587|PROCEDURE|Radiofrequency Ablation|
48334495|NCT02030587|PROCEDURE|Laparoscopic Adrenalectomy|
48334496|NCT04616404|DIETARY_SUPPLEMENT|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
48334497|NCT04616404|OTHER|Placebo|Tablets with no active ingredient
48334498|NCT01027104|OTHER|Education|Firearm injury prevention anticipatory guidance curriculum
48334499|NCT04828356|OTHER|Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applied to the reflex points, the energy blockages are broken and this energy flow is distributed in a balanced way to the relevant organs.
48493504|NCT06035471|DIAGNOSTIC_TEST|MeD-seq|MeD-seq analyse: DNA treatment bisulfite --\> unmethylated C-nucleotide trabsformed in uracil.--\> PCR --\> next generation sequencing (NGS) --\> localization methylated nucleotides (enzym LpnPI).
48653048|NCT03652428|RADIATION|Hypofractionated Ablative Proton Therapy|see arm description
48653049|NCT04679987|DIAGNOSTIC_TEST|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
48334500|NCT00334646|DRUG|Oral GW679769|150mg oral, once daily on days 1-3
48653050|NCT04535115|PROCEDURE|Starting LRM (Lung Recruitment Maneuver)|The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).
48653051|NCT04535115|PROCEDURE|Starting VtC (Tidal Volume Challenge)|The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
48653052|NCT06639113|BEHAVIORAL|Self-administration medicines|Management of drugs' administration by the patient
48653053|NCT03579719|DRUG|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
47976381|NCT04207970|OTHER|Adapted Structured Clinical Management|Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
48127428|NCT03815136|OTHER|Control|The control group will not chew chewing gum while undergoing capsule endoscopy
48334501|NCT00334646|DRUG|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
48127429|NCT03578198|DRUG|Rituximab + MG4101|"1. Induction phase:~   * Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~  * MG4101 3x107 cells/kg IV Weekly (X4)~2. Maintenance phase~   * Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~  * MG4101 3x107 cells/kg IV q 4 weeks (X4)"
48127430|NCT05758766|DIETARY_SUPPLEMENT|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
48127431|NCT02740231|DRUG|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
48127432|NCT02740231|DEVICE|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
48127433|NCT04738201|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
48334502|NCT04612803|DRUG|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
48127434|NCT04027439|DRUG|Part A: RPL554|1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
48334503|NCT04671069|DRUG|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
48334504|NCT04671069|DRUG|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
48334505|NCT04035538|DRUG|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
48334506|NCT06164613|DRUG|Cinnamomum Verum oil extract|one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
48334507|NCT06164613|DRUG|Placebo|400 mg PO Canola oil soft gel capsule
48334508|NCT00082043|DRUG|Dutasteride|
48334509|NCT00082043|DRUG|Placebo oral capsule|
48493505|NCT02785224|DRUG|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
48493506|NCT00354250|DRUG|ispinesib|Given IV
47976382|NCT05118503|BEHAVIORAL|Customized education|Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
47976383|NCT05118503|BEHAVIORAL|Standard of care discharge education|Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
48334510|NCT00907972|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3
47976384|NCT03032146|PROCEDURE|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
48334511|NCT00907972|OTHER|Placebo|Placebo
48334512|NCT01125618|OTHER|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
48334513|NCT01125618|OTHER|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
48334514|NCT00776321|DRUG|Eprotirome|
48334515|NCT00776321|DRUG|Placebo|
47976385|NCT01311570|DRUG|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
47976386|NCT01705639|DRUG|Melatonin|All subjects receive the same dose of melatonin
47976387|NCT00475358|DRUG|Duloxetine|
47976388|NCT00475358|DRUG|Placebo|
48127435|NCT04027439|DRUG|Part B: RPL554|Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
48127436|NCT04027439|DRUG|Placebos|"Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A."
48127437|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m\^2 IV q4w after Myozyme infusion for 6 months.
48127438|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m\^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m\^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
48334516|NCT01072968|DRUG|BF2.649|1 capsule per day in the morning before the breakfast
48334517|NCT01072968|DRUG|Placebo|1 capsule per day in the morning before the breakfast
48334518|NCT06066840|DRUG|Basiliximab|Basiliximab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
48493507|NCT01180439|DEVICE|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
48493508|NCT05574231|PROCEDURE|Periodontal treatment|It includes surgical and non-surgical procedures depending on patient as well as tooth level.
48493509|NCT04001920|OTHER|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
48653054|NCT03579719|DRUG|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
48653055|NCT03255200|DEVICE|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
48127439|NCT05865834|OTHER|A smartphone application|app will have 2 modules: Chill zone and sleep; Chill zone has 9 sub-modules which are meditation, breathing techniques, family time, art time, funny sayings, reframe stress and relax, diet and cooking tips, mini courses and how to become better. The sub-modules of sleep are: wind down, sleep music, storytelling, nature sounds and beautiful nature. These modules will be approved by a clinical psychologist to help people with symptoms of depression and anxiety. Skills learned include emotion recognition, emotional management, behavioral activation (being active), recognizing and challenging unhelpful thoughts and cognitive restructuring to plan for their future.
48127440|NCT05865834|OTHER|Pictorial educational leaflets|the control group will receive self-reading educational leaflets, the majority of which are pictorial. These leaflets will be approved by a clinical psychologist to help people with symptoms of depression and anxiety.
48127441|NCT03791593|DRUG|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
48127442|NCT04294173|BEHAVIORAL|video education|tracheostomy care will be given to student nurses with video training
48127443|NCT04816175|BEHAVIORAL|Acquire Therapy|This intervention is an operant conditioning based neurorehabilitation protocol for the promotion of psychomotor function
48653056|NCT06640439|DEVICE|photobiomodulation|830 nm LED was used to irradiate the post-extraction area
48653057|NCT06640439|DRUG|Antibiotic|ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
48127444|NCT02809794|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
48127445|NCT06371508|BEHAVIORAL|Education based on breast cancer and breast examination|Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
48127446|NCT00596336|DRUG|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
48127447|NCT00596336|DRUG|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
48334519|NCT06066840|DRUG|Vedolizumab|Vedolizumab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
48334520|NCT04183894|BEHAVIORAL|Personalized Intervention|Participants will receive a personalized intervention based on their personalized network.
48334521|NCT02971527|DEVICE|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
48334522|NCT02971527|DEVICE|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
47976389|NCT00644995|BEHAVIORAL|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
48493510|NCT00776165|BIOLOGICAL|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
48493511|NCT00776165|BIOLOGICAL|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
48493512|NCT00057213|DRUG|Radafaxine|
48653058|NCT06108609|OTHER|Administration of the French version of the COSI and IOI-HA questionnaires|"Inclusion (D0):~* Audiometry (as part of treatment)~* Clinical evaluation (as part of treatment)~* Passing the French version of the COSI and IOI-HA questionnaires Visit 1 (D0 +3±1 week): only for 35 patients Second administration of the French version of the COSI and IOI-HA questionnaires either by telephone, or during a second consultation or hospitalization, if this occurs within a compatible time frame."
48653059|NCT05157997|DRUG|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
47976390|NCT00644995|BEHAVIORAL|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
47976391|NCT00309569|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
47976392|NCT00309569|DRUG|Methotrexate|Methotrexate 40mg/m2
47976393|NCT00309569|DRUG|Fluorouracil|Fluorouracil 600mg/m2
47976394|NCT00309569|DRUG|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
47976395|NCT00309569|OTHER|Surgery|Surgery
47976396|NCT05360576|DRUG|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|To prevent pregnancy
47976397|NCT05360576|DRUG|NuvaRing Vaginal Ring|To prevent pregnancy
47976398|NCT03677531|OTHER|Quality-of-Life Assessment|Ancillary studies
47976399|NCT03677531|OTHER|Questionnaire Administration|Ancillary studies
47976400|NCT03677531|RADIATION|Radiation Therapy|Undergo RT
47976401|NCT03677531|OTHER|Video|Watch video of choice during RT
47976402|NCT00002378|DRUG|Ritonavir|
47976403|NCT00002378|DRUG|Nelfinavir mesylate|
47976404|NCT00002378|DRUG|Saquinavir|
47976405|NCT00002378|DRUG|Delavirdine mesylate|
47976406|NCT00002378|DRUG|Lamivudine|
47976407|NCT00002378|DRUG|Stavudine|
47976408|NCT00002378|DRUG|Zidovudine|
47976409|NCT02321644|DRUG|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
47976410|NCT02671396|BEHAVIORAL|Virtual reality based intervention|Virtual reality based balance training
47976411|NCT02671396|BEHAVIORAL|Conventional intervention|Conventional balance training
47976412|NCT04802278|BIOLOGICAL|COVID-19 vaccine|Any COVID-19 vaccine
48127448|NCT04327843|BEHAVIORAL|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
48127449|NCT04327843|DRUG|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
48127450|NCT01259557|DRUG|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
48127451|NCT06150508|BEHAVIORAL|O2O digital healthcare service|The O2O service includes a mobile app and web-based portal that allows patients to monitor their blood glucose levels, track their medication use and physical activity, receive personalized feedback and education, and communicate with healthcare providers. The treatment group will receive a blood sugar checker and blood pressure checker that send the records automatically to the application through Bluetooth.
48127452|NCT04286269|OTHER|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
48127453|NCT04286269|OTHER|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
48127454|NCT00804648|DRUG|Timolol Maleate in Sorbate|0.5%
48127455|NCT00804648|DRUG|Timolol hemihydrate|0.5%
48127456|NCT00804648|DRUG|Timolol maleate gel forming solution|0.5%
48127457|NCT05512182|DRUG|Chemotherapy|Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
48127458|NCT05126342|DRUG|Niraparib|Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.
48127459|NCT05126342|DRUG|Dostarlimab|Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.
48127460|NCT02901522|OTHER|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
48127461|NCT02901522|OTHER|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
48493513|NCT01513564|DRUG|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
48653060|NCT05040932|DRUG|YH004|IV infusion once every 3 weeks (Q3W).
48653061|NCT00918398|DRUG|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
48653062|NCT00918398|DRUG|AZD1981|514 mg oral solution, single dose
48653063|NCT00918398|DRUG|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
48653064|NCT00918398|DRUG|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
48653065|NCT04493138|DRUG|Azacitidine|Given SC or IV
48653066|NCT04493138|DRUG|Quizartinib|Given PO
47976413|NCT04150393|DRUG|MaaT033 capsule|Oral capsule
47976414|NCT01709162|BIOLOGICAL|Ipilimumab|
47976415|NCT01709162|DRUG|Chemotherapy|
48653067|NCT02065986|DRUG|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
48653068|NCT06643624|OTHER|Vision Training Program|Vision training (experimental) group; vision training program was applied in addition to routine training programs. For 8 weeks, 5 sessions per week for a total of 40 sessions of vision training were applied by a physiotherapist. In the first 2 weeks, each movement was applied for 1 minute for a total of 10 minutes. In the 3rd week, each movement was practiced for 1.5 minutes for a total of 15 minutes. In weeks 4-8, each movement was performed for 2 minutes each for a total of 20 minutes.
48653069|NCT06643624|OTHER|Routine Training Program|All athletes performed their routine training for wrestling 6 days a week.
48653070|NCT06637644|DEVICE|Right-sided ventricular assist device|Percutaneous device for right heart support
48653071|NCT06636734|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48653072|NCT06636734|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48653073|NCT06636734|DRUG|Lovastatin|Given PO
48653074|NCT06636734|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47976416|NCT03591471|DRUG|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
48493514|NCT01513564|DRUG|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
48127462|NCT02901522|OTHER|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
48127463|NCT02901522|OTHER|Teleconsultation|The general practioner received phone call to asthma care.
48127464|NCT06444984|OTHER|Fasting Trial|Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.
48127465|NCT06444984|OTHER|Fed Trial|Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).
48127466|NCT04011813|OTHER|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
48127467|NCT00258297|DRUG|gefitinib|
48127468|NCT00258297|PROCEDURE|conventional surgery|
48127469|NCT00258297|PROCEDURE|enzyme inhibitor therapy|
48127470|NCT00258297|PROCEDURE|neoadjuvant therapy|
48127471|NCT00258297|PROCEDURE|protein tyrosine kinase inhibitor therapy|
48127472|NCT00258297|PROCEDURE|surgery|
48127473|NCT03697707|BIOLOGICAL|DCP-001|allogeneic dendritic cell vaccine
48127474|NCT04827524|OTHER|Anthropometric measurement|The demographic information and birth histories of the subjects included in the study will be taken first. Anthropometric measurements of all subjects will be measured with the Star Scanner device. The Star Scanner 3 dimensional data collection system is a scanning system that enables the anthropometric head measurements of the baby to be taken in just 2 seconds. The advantages of this device is that it does not emit any harmful beams during evaluation, it does not have any harmful effects on health, and that it is an application that will not disturb babies.
48127475|NCT03447496|PROCEDURE|Closed reduction|The children were treated with closed reduction.
48127476|NCT03447496|PROCEDURE|Open reduction|The children were treated with Open reduction.
48653075|NCT06636734|BIOLOGICAL|Pembrolizumab|Given IV
48653076|NCT06636734|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48653077|NCT03453541|DRUG|Ketorolac Tromethamine|Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
48653078|NCT03453541|DRUG|0.9% Normal Saline|0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
48653079|NCT02167126|DEVICE|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
48653080|NCT02167126|DEVICE|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
48653081|NCT04854473|DEVICE|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~* Smart drain - a surgical drain with added sensing electrodes~* Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~* Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
48127477|NCT04530149|DRUG|Acetaminophen|receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
48127478|NCT04530149|DRUG|Bupivacain|The injection of bupivicaine into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
48127479|NCT04530149|DRUG|Saline|The injection of saline into the chest muscle is performed with an ultrasound machine which can see the needle as it enters the muscle.
48127480|NCT03750968|DRUG|Carotenoid Group|Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil
48127481|NCT03750968|DIETARY_SUPPLEMENT|Control Group|Placebo ingredients: Safflower oil
48127482|NCT00476385|DRUG|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
48127483|NCT00879333|DRUG|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
48127484|NCT00879333|DRUG|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
48127485|NCT00879333|DRUG|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
48127486|NCT04062396|DEVICE|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
48127487|NCT04062396|DEVICE|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
48653082|NCT05421494|BEHAVIORAL|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
48127488|NCT05661708|DRUG|Chitosan|Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
48127489|NCT05111951|BEHAVIORAL|Mobile health-delivered physical exercise and support for physical activity|Mobile health-delivered physical exercise sessions, prescription of an individual exercise-regime and support for physical activity through behavior change techniques.
48127490|NCT05111951|BEHAVIORAL|Mobile health-delivered behavior change techniques.|Mobile health-delivered behavior change techniques following the core elements of the Swedish model for physical activity on prescription.
48127491|NCT02395744|OTHER|Paclitaxel administration using the OPC|
48127492|NCT03006367|DRUG|NFC-1 100 mg|
48127493|NCT03006367|DRUG|NFC-1 200 mg|
48127494|NCT03006367|DRUG|NFC-1 400 mg|
48127495|NCT03006367|DRUG|NFC-1 800 mg|
48127496|NCT00111631|DRUG|DPP-IV Inhibitor|Escalating doses po bid
48127497|NCT00111631|DRUG|Metformin|As prescribed
48127498|NCT00111631|DRUG|Placebo|po bid
48127499|NCT04725136|BIOLOGICAL|FURESTEM-AD inj|Repeated administration group: 3 times high or low dose at 4 week intervals. Single administration group: 1 time high or low dose, 2 times placebo injection at 4 week intervals Placebo: 3 times placebo injection at 4 week intervals.
48127500|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
48127501|NCT01422603|DRUG|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
48127502|NCT03492866|DRUG|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
48127503|NCT02462759|DRUG|Nusinersen|Administered by intrathecal injection.
48127504|NCT02462759|PROCEDURE|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
48127505|NCT04091178|DIETARY_SUPPLEMENT|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
48653083|NCT05421494|BEHAVIORAL|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
48127506|NCT02400931|PROCEDURE|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
48127507|NCT02400931|PROCEDURE|no mask ventilation|
48127508|NCT02400931|DRUG|Rocuronium|
48127509|NCT00670046|DRUG|valproic acid|given orally
48127510|NCT00670046|OTHER|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
48127511|NCT03746938|DEVICE|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
48127512|NCT02824458|DRUG|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
48127513|NCT02824458|DRUG|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
48127514|NCT02824458|DRUG|Placebo|
48127515|NCT04758416|PROCEDURE|biopsy or surgical pathology in metastases|biopsy or surgical pathology in extrahepatic/liver/brain metastases
48127516|NCT04758416|DRUG|68Ga-HER2 affibody,18F-FDG, 18F-FES|68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
48127517|NCT04511767|OTHER|Do not take any interventions|Do not take any interventions
48127518|NCT00879749|BIOLOGICAL|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
48127519|NCT00879749|BIOLOGICAL|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
48653084|NCT06642870|OTHER|Non-interventional study|The study will consist of focus groups and a large scale patient survey
48653085|NCT06638229|DEVICE|The StimaWELL 120MTRS system|A standardized current (dynamic deep wave stimulation) was applied to all patients. Additionally, the mat, which reached a temperature of 40°C, provided heat therapy with electrical stimulation
48653086|NCT04642430|DRUG|Apixaban|Refer to Apixaban group
48127520|NCT00879749|BIOLOGICAL|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
48127521|NCT00879749|BIOLOGICAL|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
48127522|NCT00879749|BIOLOGICAL|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
48127523|NCT00879749|OTHER|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
48127524|NCT00570466|BEHAVIORAL|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
48127525|NCT00570466|BEHAVIORAL|Web and DVD knowledge|Web and DVD based knowledge games
48127526|NCT00415402|DRUG|Vitamin D3|
48653087|NCT04642430|DRUG|Rivaroxaban|Refer to Rivaroxaban group
48127527|NCT01154387|DRUG|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
48127528|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
48127529|NCT01154387|DRUG|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
48127530|NCT01154387|DRUG|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
48127531|NCT01154387|DRUG|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
48127532|NCT01154387|DRUG|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
48127533|NCT00225407|DRUG|Smoking of cannabis cigarettes (different strength)|
48127534|NCT02392234|DRUG|VX-661/Ivacaftor|Fixed dose combination tablet, oral use
48127535|NCT02392234|DRUG|Ivacaftor|Tablet, oral use
48127536|NCT02392234|DRUG|Placebo matched to VX-661/ ivacaftor|Fixed dose combination tablet, oral use
48127537|NCT02392234|DRUG|Placebo matched to Ivacaftor|Tablet, oral use
48127538|NCT06282107|PROCEDURE|BiSAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into bilateral adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
48127539|NCT06282107|PROCEDURE|traditional triple antihypertensive treatment|traditional triple antihypertensive treatment
48127540|NCT02520349|DEVICE|MarkTen and e-Go e-cigarettes|
48127541|NCT01074788|BEHAVIORAL|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
48127542|NCT03762772|DRUG|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
48127543|NCT03912831|DRUG|KITE-439|A single infusion of E7 TCR T cells (KITE-439).
48127544|NCT03912831|DRUG|Cyclophosphamide|Administered intravenously.
48653088|NCT05749094|DIAGNOSTIC_TEST|Optic nerve sheath ultrasound|The patients are examined in a supine relaxed position. The probe is gently placed on the closed eyelid with a standard ultrasound gel and adjusted to a suitable angle to display the optic nerve entry into the eyeball. Measurements are done 3mm distal to the posterior aspect of the ocular globe. Ultrasosonographic 14L5 probe is used with a safe thermal index, mechanical index and intensity limit. All patients will also undergo a bedside fundoscopic examination. Official ophthalmology consultation will be requested in patients with visual symptoms or abnormal fundoscopy.
48653089|NCT05749094|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assesment, blood test review, temporal/axillary artery ultrasound
47976417|NCT03591471|DRUG|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
47976418|NCT03591471|DRUG|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
48127545|NCT03912831|DRUG|Fludarabine|Administered intravenously.
48127546|NCT03912831|DRUG|Interleukin-2|Administered subcutaneously.
48493515|NCT04116853|BEHAVIORAL|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
48127547|NCT02530190|DEVICE|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
48127548|NCT02530190|PROCEDURE|massage|20 minutes of massage to lower extremities
48127549|NCT01676558|DRUG|131I-rituximab|
48127550|NCT04881175|DEVICE|Non-Invasive Treatment|Single-arm group using the FlexSure Applicator device.
48127551|NCT03643055|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
48127552|NCT00391196|DRUG|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
48127553|NCT00391196|DRUG|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
48127554|NCT00391196|DRUG|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
48334523|NCT03958539|DEVICE|3D printed insoles for normal footware|"Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan."
48334524|NCT03859960|DIAGNOSTIC_TEST|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
48493516|NCT04116853|BEHAVIORAL|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
48493517|NCT01252719|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin was administered as a single IV dose.
48493518|NCT01252719|DRUG|IV Vancomycin|Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
48127555|NCT06322446|OTHER|Exercise|16-week exercise intervention: At the beginning of the intervention, we will conduct a face-to-face familiarisation session with the exercises of the training programme. The intervention will consist of 2 sessions/week for 16 weeks. Each session consists of three stages: (i) Warm-up: 10 min of joint mobility and low intensity exercises involving the musculature to be worked in that session; (ii) Main part: circuit training mainly composed of strength exercises targeting the different muscle groups of the body and playing activities (iii) Cool down: 10 min with guided breathing work and stretching of the main muscle groups worked
48127556|NCT00466869|DRUG|Betahistine|
48127557|NCT06143501|DIAGNOSTIC_TEST|Blood Sample|6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
48127558|NCT06143501|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
48127559|NCT06143501|DIAGNOSTIC_TEST|Urine Sample|8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
48334525|NCT03859960|DIAGNOSTIC_TEST|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
48334526|NCT00001127|BIOLOGICAL|Influenza virus vaccine (CAIV-T)|
48334527|NCT06362447|DRUG|Gentamicin Injectable Solution|Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
48334528|NCT03057951|DRUG|Empagliflozin|once daily
48653090|NCT06105255|DRUG|D-1553|D-1553 is a novel, targeted KRASG12C inhibitor.
48653091|NCT03066739|DRUG|Remifentanil|0.1 micrograms/kg/mL
48653092|NCT03066739|DRUG|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
48653093|NCT03066739|DRUG|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
48653094|NCT05489458|PROCEDURE|Resection|Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.
48653095|NCT05489458|PROCEDURE|No Resection|Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
47976419|NCT03591471|DRUG|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
47976420|NCT03591471|DRUG|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
47976421|NCT03591471|DRUG|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
47976422|NCT03591471|DRUG|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
48653096|NCT04637347|DEVICE|Catheterization approach|In plane infraclavicular subclavian vein VS in plane supraclavicular subclavian vein catetherization
47976423|NCT03591471|DRUG|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
47976424|NCT02302001|DEVICE|Silicone Implant|
47976425|NCT05062382|BEHAVIORAL|Complementary feeding intervention|"The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign."
47976426|NCT02684760|DRUG|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
47976427|NCT00759031|DRUG|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
47976428|NCT00759031|DRUG|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
47976429|NCT04982198|PROCEDURE|ROSA assisted TKA|Robotic assisted total knee arthroplasty
47976430|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
47976431|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
47976432|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
47976433|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
47976434|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
47976435|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
48127560|NCT01898585|DRUG|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
48334529|NCT03057951|DRUG|Placebo|once daily
48334530|NCT01040338|DRUG|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
48493519|NCT01252719|DRUG|Placebo|Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
48334531|NCT05138341|DEVICE|Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation|"Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood."
48334532|NCT05766293|DEVICE|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
48334533|NCT05766293|OTHER|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
48334534|NCT01149343|BIOLOGICAL|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
48127561|NCT03287622|BEHAVIORAL|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
48127562|NCT03287622|BEHAVIORAL|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
48127563|NCT03790215|DRUG|Dydrogesterone|The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
48127564|NCT01384890|RADIATION|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
48127565|NCT01384890|RADIATION|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
48127566|NCT01771484|DEVICE|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
48127567|NCT00257075|DRUG|Risperidone, oral tablets|
48127568|NCT03941119|OTHER|VR-therapy|Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
48127569|NCT05698758|DRUG|Dextrometropine and 0.9% sodium chloride solution|Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery
48127570|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
48127571|NCT02405013|DRUG|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
48127572|NCT02405013|DRUG|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
48127573|NCT02405013|DRUG|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
48127574|NCT01965665|DEVICE|MediHoney HCS dressing|
48127575|NCT03819166|DEVICE|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
48127576|NCT03819166|DEVICE|without deep touch pressure application|The deep touch pressure will not be applied.
48127577|NCT00774397|DRUG|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
48127578|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
48127579|NCT00774397|DRUG|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
48127580|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
48127581|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
48127582|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
48127583|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
48334535|NCT03275428|DEVICE|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
48334536|NCT00310349|BIOLOGICAL|23 valent pneumococcal polysaccharide vaccine|
48334537|NCT05579119|DRUG|Sitagliptin 100mg|Sitagliptin 100 mg po once daily.
48127584|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
48653097|NCT06644716|DIAGNOSTIC_TEST|[18F]F-FAPI PET-CT|Each patient will receive a FAPI PET-CT.
48127585|NCT00774397|DRUG|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
48127586|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
48127587|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
48127588|NCT00774397|DRUG|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
48127589|NCT00774397|DRUG|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
48127590|NCT00774397|DRUG|Placebo|Placebo
48127591|NCT04775667|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
48127592|NCT06438094|PROCEDURE|Root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
48334538|NCT05579119|DRUG|Glargine|Glargine once daily.
48334539|NCT05579119|DRUG|Lispro|Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
48334540|NCT00555568|BEHAVIORAL|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
48127593|NCT06438094|PROCEDURE|Reconstruction of the CEJ with a composite restoration followed by root coverage surgery by means of a coronally advanced flap combined with a connective tissue graft|Reconstruction of the CEJ with a composite restoration will be performed in B+ and B- defects prior to root coverage surgery. A root coverage surgery will be performed using Zucchelli et al.'s coronally advanced flap combined with a connective tissue graft from the palate.
48334541|NCT00555568|BEHAVIORAL|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
48334542|NCT06380582|OTHER|Temperature and Airflow combination|23C 40%Relative Humidity (RH) low airflow, 23C 40%RH high airflow, 35C 40%RH low airflow, 35C 40% high airflow
48334543|NCT00422903|DRUG|lapatinib|1500 mg administered orally daily
48334544|NCT00422903|DRUG|letrozole|2.5 mg administered orally daily
48334545|NCT00422903|OTHER|placebo|1500 mg administered orally daily
48334546|NCT02490943|OTHER|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
48334547|NCT02490943|OTHER|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
48334548|NCT03966729|OTHER|Time (outcome)|
48334549|NCT01977248|BEHAVIORAL|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
48334550|NCT03118453|BEHAVIORAL|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
48127594|NCT02292004|DEVICE|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
48127595|NCT02292004|PROCEDURE|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
48127596|NCT05588817|GENETIC|PCR polymorphism|PCR polymorphism in Rhomatoid arthritis patients in Egypt
48127597|NCT01102673|DRUG|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
48334551|NCT03118453|BEHAVIORAL|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
48334552|NCT02268071|DRUG|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
48334553|NCT04749563|DRUG|IGC AD1|IGC AD1 oral Solution
48334554|NCT04749563|DRUG|Placebo|Placebo of IGC AD1 oral Solution
48127598|NCT01102673|DRUG|Placebo|Placebo to match PF-04991532 will be provided
48127599|NCT01376700|BIOLOGICAL|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
48127600|NCT01631851|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
48127601|NCT06403020|PROCEDURE|Block|qadratus lumboroum (QL) block
48334555|NCT03241667|DEVICE|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
48127602|NCT06407882|BEHAVIORAL|Conductive Exercises|Conductive education (CE) is a useful educational system for the management of motor disabled individuals whose disability and dysfunction was due to the damage to the central nervous system, mainly at the pre-, peri- or post-natal period of life. Conductive exercises basically include task-oriented learning within highly structured programs and conductors who are trained in special education and therapy administer the conductive education program
48127603|NCT06407882|BEHAVIORAL|Routine Physical Therapy|Group B will perform routine physical therapy (RPT) alone. Active and passive movements, Passive stretching, strengthening exercises, weight bearing exercises.
48127604|NCT00996749|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
48127605|NCT00996749|OTHER|bone scan|Correlative studies
48127606|NCT00996749|OTHER|dual x-ray absorptometry|Correlative studies
48334556|NCT01539213|DRUG|secukinumab (AIN457)|anti-IL-17 antibody
48334557|NCT03044470|OTHER|cryotherapy|Role of cryotherapy in reduction of post operative pain
48334558|NCT02879981|DRUG|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
48653098|NCT06232590|DEVICE|Control Lens (comfilcon A)|Multifocal monthly replacement contact lens for 1 month
48127607|NCT00996749|OTHER|laboratory biomarker analysis|Correlative studies
48127608|NCT00996749|PROCEDURE|biopsy|Correlative studies
48127609|NCT01435252|DRUG|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
48127610|NCT00435318|PROCEDURE|Iontophoresis|
48127611|NCT01345422|OTHER|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
48127612|NCT01346254|DRUG|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
48127613|NCT01346254|DRUG|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
48334559|NCT02879981|DRUG|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
48127614|NCT01346254|BEHAVIORAL|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
48127615|NCT01183598|DRUG|tocilizumab [RoActemra/Actemra]|maintenance dose
48127616|NCT04733833|DRUG|VB-201 + Standard of care|Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
48127617|NCT04733833|DRUG|Standard of care|Standard of care
48127618|NCT00204672|DRUG|Achipex|
48127619|NCT05815030|OTHER|video informational/educational intervention|Videos relating to PrEP use, its benefits, side effects, and other information. The educational/round-table video will highlight individuals from diverse backgrounds and identities who will share their experiences using PrEP, including perceived benefits and effectiveness, experienced barriers to PrEP uptake, their reasons for using PrEP, and their own self-efficacy. The control group's (generic / standard video) materials will be focused on PrEP uptake without a kink identity perspective. The treatment group's materials, however, will include videos that feature kink-identified individuals who discuss PrEP uptake through a kink perspective.
48334560|NCT02879981|DRUG|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
48334561|NCT06374862|OTHER|mobilization|specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine
48127620|NCT01838343|OTHER|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
48493520|NCT06051565|DRUG|Polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
48493521|NCT01300052|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
48127621|NCT00002893|DRUG|fluorouracil|
48127622|NCT00002893|DRUG|leucovorin calcium|
48127623|NCT00002893|DRUG|raltitrexed|
48127624|NCT02320370|DEVICE|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
48493522|NCT01300052|DRUG|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
48493523|NCT05056610|OTHER|food antigens on duodenal mucosa|Administration of food antigens on duodenal mucosa and determining the response through confocal laser endomicroscopy
47976436|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
48127625|NCT04405921|DRUG|Hydroxychloroquine 200 Mg Oral Tablet|orally or via gastric tube
48127626|NCT04405921|DRUG|Azithromycin 250 MG|orally or via gastric tube
48127627|NCT00073749|DRUG|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
48127628|NCT00074919|BIOLOGICAL|alglucosidase alfa|20 mg/kg qow
48127629|NCT00257881|DRUG|CMD-193|
48127630|NCT03351699|DRUG|MK-4250|MK-4250 tablets for oral administration
48127631|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
47976437|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
48127632|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
48127633|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
48127634|NCT05106270|DIAGNOSTIC_TEST|Atrial pressure measurement using transseptal puncture sheath|both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
48334562|NCT06374862|OTHER|no effect|"a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect."
48334563|NCT03600493|DRUG|Dexmedetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
48334564|NCT03600493|DRUG|Lidocaine|Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
48127635|NCT04036955|OTHER|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
48127636|NCT00874536|DIETARY_SUPPLEMENT|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
48127637|NCT00874536|DIETARY_SUPPLEMENT|Placebo|
48127638|NCT04762238|OTHER|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
48127639|NCT00281892|BIOLOGICAL|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
48127640|NCT00281892|DRUG|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
48127641|NCT02129283|BEHAVIORAL|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
48127642|NCT05049421|DIAGNOSTIC_TEST|Echocardiography|Full 2D and 3D echocardiography with special focus on right ventricular function
48127643|NCT00792636|DRUG|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
48334565|NCT05019495|BEHAVIORAL|PrOMOTE|This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.
48127644|NCT00792636|DRUG|sumatriptan tablet|sumatriptan 85mg
48127645|NCT00792636|DRUG|naproxen sodium tablet|Naproxen sodium 500mg
48127646|NCT01874964|BEHAVIORAL|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
48127647|NCT01874964|BEHAVIORAL|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
48127648|NCT03394534|OTHER|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
48127649|NCT06358534|BEHAVIORAL|psychoeducation based on acceptance and commitment therapy|psychoeducation based on acceptance and commitment therapy prepared by the researchers was applied individually to the patients
48127650|NCT02339519|DEVICE|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
48127651|NCT02339519|DEVICE|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
48127652|NCT02339519|DEVICE|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
48127653|NCT00623194|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
48127654|NCT00623194|DRUG|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
48127655|NCT03862963|BEHAVIORAL|Standard of diabetes care|The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
48334566|NCT03842956|PROCEDURE|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
48334567|NCT03406715|DRUG|Nivolumab|Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
48334568|NCT03406715|DRUG|Ipilimumab|Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
47976438|NCT01678677|DRUG|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
47976439|NCT01169974|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 \& 3 minutes
47976440|NCT06364449|OTHER|No intervention|No intervention
47976441|NCT03541720|DRUG|18F-DA|18F-DA is an investigational PET radiotracer
47976442|NCT05439226|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
47976443|NCT01262053|OTHER|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
47976444|NCT01262053|OTHER|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
47976445|NCT01262053|OTHER|Control|Parallel control with no intervention
47976446|NCT00840346|DRUG|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
47976447|NCT04386421|OTHER|Video on oral hygeine instructions|A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
47976448|NCT04386421|DRUG|Plaque disclosing tablets|"Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %"
47976449|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
47976450|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is turned off.
47976451|NCT05591274|DEVICE|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
47976452|NCT06243809|DRUG|Linagliptin 5 mg Oral Tablet|Linagliptin 5 mg Oral Tablet
47976453|NCT06243809|DRUG|Trajenta 5 MG Oral Tablet|Linagliptin 5 mg Oral Tablet (Trajenta )
47976454|NCT05036551|DIAGNOSTIC_TEST|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
47976455|NCT00085631|DRUG|cisplatin|Given IV
47976456|NCT00085631|PROCEDURE|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
47976457|NCT00085631|RADIATION|brachytherapy|Patients undergo brachytherapy for 2-3 days
47976458|NCT00085631|RADIATION|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
48334569|NCT03406715|BIOLOGICAL|Dendritic Cell based p53 Vaccine|Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
48493524|NCT05115591|DIAGNOSTIC_TEST|Spinal Ultrasound|Spinal Ultrasound is performed by an observer who records ultrasound characteristics of the intervertebral space chosen by the anesthetist who will practice spinal anesthesia
48334570|NCT01998399|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
48334571|NCT01998399|DRUG|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
48653099|NCT06232590|DEVICE|Test Lens (lehfilcon A)|Multifocal monthly replacement contact lens for 1 month
48653100|NCT04497155|DRUG|Norepinephrine|Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
48653101|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention|Receive active EFT stimulus
48127656|NCT03862963|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
48127657|NCT04122885|COMBINATION_PRODUCT|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
48127658|NCT04122885|PROCEDURE|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
48127659|NCT04037813|PROCEDURE|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
48127660|NCT01245400|DEVICE|Z-Lig|ACL replacement
48127661|NCT01245400|DEVICE|allograft|ACL replacement
48127662|NCT04132167|PROCEDURE|perturbation training|exercises for body stability in different positions (bridge, sitting, quadrupedal, half- kneeling, kneeling, standing, monopodalic) performed with visual biofeedback; transfers training performed in front of a mirror; ambulation training with courses drawn on the ground in a straight line and with more complex tracks with visual controlin particular using the protocols seated balance/strength training, standing bal- ance/weight-bearing training, mobility training and closed-chain training;
48334572|NCT06210438|DRUG|SHR-A1921 + Bevacizumab|SHR-A1921 + Bevacizumab
48334573|NCT03900741|PROCEDURE|Submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a submerged healing protocol
48334574|NCT03900741|PROCEDURE|Non-submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a non-submerged healing protocol
48334575|NCT00966693|DRUG|Dexamethasone|Given PO
48334576|NCT00966693|DRUG|Lenalidomide|Given PO
48334577|NCT00966693|DRUG|Thalidomide|Given PO
48334578|NCT06147453|DEVICE|Aerobika OPEP device|16 week twice daily use of the Aerobika OPEP device
48127663|NCT05092113|DRUG|a compound glutamine capsule/a compound glutamine capsule simulated placebo|A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
48334579|NCT00005812|DRUG|temozolomide|
48334580|NCT06507761|OTHER|Sham|An unrefrigerated room temperature Cold Pack will be wrapped in a towel and applied to the patient's posterior neck and back for 15 minutes while the patient is lying face down.
48334581|NCT06507761|OTHER|Hot Pack|Hot pack (55-60 degrees) application will be wrapped in a towel and applied to the back side neck and back of the patient for 15 minutes while the patient is lying face down.
48334582|NCT06507761|OTHER|Cold Pack|Cold pack application (2-4 degrees) will be wrapped in a towel and applied to the patient's back side neck and back for 15 minutes while the patient is lying prone.
48334583|NCT02899806|OTHER|Written Information|A written information on peridural anesthesia is delivered
48334584|NCT02899806|OTHER|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
48334585|NCT00807014|DRUG|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
48334586|NCT00807014|DRUG|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
48493525|NCT05115591|PROCEDURE|Spinal Anesthesia|Spinal anesthesia is performed by an anesthetist after the observer recorded ultrasound characteristics of the intervertebral space chosen by the anesthetist, who is blinded to the ultrasound evaluation.
48493526|NCT04247152|OTHER|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
48493527|NCT04804865|OTHER|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
48493528|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
48493529|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
48493530|NCT01988961|BIOLOGICAL|Golimumab|SC injections
48653102|NCT05825001|BEHAVIORAL|Smoking Cessation Intervention (control)|Receive control EFT stimulus
48653103|NCT05825001|OTHER|Medical Device Usage and Evaluation|Use iCOquit Smokerlyzer carbon monoxide monitor
48653104|NCT03843073|DEVICE|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
48653105|NCT05127265|OTHER|Video Monitoring|continuous video monitoring
48334587|NCT06058936|OTHER|exercises using virtual reality technology|this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
48127664|NCT02261649|DEVICE|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
48127665|NCT02261649|PROCEDURE|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
48127666|NCT02261649|DEVICE|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
48127667|NCT02261649|OTHER|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
48127668|NCT03199404|DEVICE|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
48334588|NCT05671315|DRUG|Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue|"1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
48334589|NCT05671315|DRUG|Nucleos(t)ide analogue|"NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
48493531|NCT03737565|DEVICE|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
48653106|NCT05127265|OTHER|Accelerometer Monitoring|continuous accelerometer monitoring of patient movements
47976459|NCT01624389|DRUG|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
47976460|NCT03528993|OTHER|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
47976461|NCT03528993|OTHER|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
47976462|NCT03528993|OTHER|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
47976463|NCT02284594|BEHAVIORAL|text message|series of text messages regarding influenza vaccination
47976464|NCT06072729|OTHER|comparison of magnesium sulphate versus cold compression|This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
47976465|NCT00872534|DRUG|acetylsalicylic acid|325mg once a day for 7 days
47976466|NCT02279901|BEHAVIORAL|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~1. OSA program~2. CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
48127669|NCT00936416|PROCEDURE|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
48127670|NCT01964300|BIOLOGICAL|peginterferon alfa-2b|Given subcutaneously (SC)
48127671|NCT01964300|OTHER|laboratory biomarker analysis|Correlative studies
48127672|NCT01611337|OTHER|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
48127673|NCT04989296|DIAGNOSTIC_TEST|Peripheral blood samples were obtained following the standard procedures.|Taking 4 ml of peripheral blood from patients on an empty stomach.
48127674|NCT03402854|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
48127675|NCT03402854|BEHAVIORAL|bimanual training|Participants will engage in movements that use both hands, by playing with toys and games.
48127676|NCT02831231|DRUG|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
48127677|NCT02831231|DRUG|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
48334590|NCT02061579|BEHAVIORAL|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
48334591|NCT02877667|DEVICE|planar acoustic wave device|accessory to laser treatment
48334592|NCT03358498|OTHER|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
48334593|NCT01877941|DEVICE|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
48334594|NCT01877941|DEVICE|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
48334595|NCT01877941|DEVICE|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
48334596|NCT06056765|DEVICE|"Minilith, Storz, Swiss"|shock waves
48334597|NCT06460168|OTHER|Mulligan(MWM) MobilizationTechnique|"Mulligan Mobilization program in MWM , a therapist-applied pain free accessory gliding force combined with active movement.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets."
48334598|NCT06460168|OTHER|Maitland Mobilization technique|"will receive (Maitland mobilization program manipulative physiotherapy in which chain of oscillatory joint mobilization grades l-lV based on the pathological limit of tissue are used) In this, the exercises will be performed in 3 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session)"
48334599|NCT05114148|DEVICE|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
48334600|NCT05094076|RADIATION|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis \[ILO, 1980\]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
48334601|NCT04117568|OTHER|Blood sampling|Blood sampling at 3-5 occasions per admission
48493532|NCT01867944|BEHAVIORAL|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
48493533|NCT01867944|BEHAVIORAL|Educational Control|Education on conventional treatment options for chronic constipation.
48653107|NCT05127265|OTHER|Noise Level Monitoring|continuous environmental noise monitoring
48653108|NCT05127265|OTHER|Light Level Monitoring|continuous environmental light monitoring
48653109|NCT05127265|OTHER|Air Quality Monitoring|continuous environmental air quality monitoring
48127678|NCT01767350|PROCEDURE|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
48127679|NCT03486574|DIAGNOSTIC_TEST|Positive result from pathological test|Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
48127680|NCT03717506|DRUG|GDC 268 Lotion|GDC 268 is a topical lotion
48653110|NCT05127265|OTHER|EKG Monitoring|continuous EKG monitoring
48653111|NCT05127265|OTHER|Vitals Monitoring|continuous vitals monitoring (heart rate, oxygen saturation)
48127681|NCT03717506|DRUG|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug product
48127682|NCT03717506|DRUG|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
48127683|NCT05064124|DEVICE|CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
48653112|NCT05127265|OTHER|Biosample Collection|blood and urine samples collected once on Day 1 and once on Day 2
48127684|NCT02132949|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
48127685|NCT02132949|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
48653113|NCT05127265|OTHER|Delirium Motor Subtyping Scale 4 (DMSS-4)|done daily on delirious patients to subtype delirium
48653114|NCT01443026|DRUG|Lycopene 30mg|Lycopene 30 mg.
48653115|NCT01443026|DRUG|Placebo|Placebo
48653116|NCT02136355|RADIATION|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
48653117|NCT06637865|DRUG|IMP761|Experimental
48653118|NCT06637865|DRUG|Placebo|Placebo
48334602|NCT06388135|DRUG|Serplulimab Combined With Nab-paclitaxel and Cisplatin|Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
48334603|NCT06388135|DRUG|nab-paclitaxel，Cisplatin|nab-paclitaxel，Cisplatin
48334604|NCT04628273|PROCEDURE|encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsy|
48334605|NCT03418064|DEVICE|Fanfilcon A toric lens|Contact lens
48334606|NCT03418064|DEVICE|Lotrafilcon B toric lens|Contact lens
48334607|NCT06244537|RADIATION|MR-linac|Patients enrolled will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX chemotherapy.
48334608|NCT01732107|DRUG|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
48334609|NCT02806947|DRUG|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m\^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
48334610|NCT02806947|DRUG|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
48334611|NCT03923439|DEVICE|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
48334612|NCT02718391|BIOLOGICAL|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
48334613|NCT04132648|DRUG|Curcumin|Oral supplement one time at 2,000 mg
48334614|NCT04132648|OTHER|Placebo|Oral supplement one time at 2,000 mg
48334615|NCT00812604|DRUG|Ping On Ointment|Ping On Ointment
48334616|NCT00812604|DRUG|Vaseline|Placebo
48334617|NCT01779596|DRUG|Bosentan|
48334618|NCT01779596|DRUG|Placebo|
48127686|NCT02132949|DRUG|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.
48334619|NCT01752725|DEVICE|BiCision®|
48334620|NCT01752725|DEVICE|Ultracision® Har-monic Scalpel(Ethicon)|
48334621|NCT01431261|OTHER|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
48334622|NCT01431261|BEHAVIORAL|Pain management|Educational sessions in pain management 4 times
48334623|NCT03579030|DRUG|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
48334624|NCT03579030|DRUG|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
48334625|NCT05690698|DRUG|Quatiapine|Atypical antipsychotic
48334626|NCT05690698|DRUG|Haloperidol|Antipsychotic
48334627|NCT06379438|COMBINATION_PRODUCT|Photodynamic therapy (indocyanine green+laser)|Photodynamic therapy with indocyanine green
48334628|NCT05826990|DRUG|cefepime and enmetazobactam combination|Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
48334629|NCT01080144|OTHER|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
48334630|NCT00085488|BIOLOGICAL|autologous tumor cell vaccine|
48334631|NCT00085488|BIOLOGICAL|therapeutic autologous dendritic cells|
48334632|NCT02856906|OTHER|occlusal adjustment|
48334633|NCT00562016|DEVICE|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
48334634|NCT00562016|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
48334635|NCT03162029|OTHER|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
48334636|NCT04108819|DIETARY_SUPPLEMENT|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
48334637|NCT03819218|DRUG|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
48334638|NCT00897741|GENETIC|microarray analysis|
48334639|NCT00897741|OTHER|laboratory biomarker analysis|
48334640|NCT03667508|PROCEDURE|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
48334641|NCT03667508|PROCEDURE|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
48334642|NCT02238288|DRUG|Aminocaproic acid|Crushed tablet in the dental socket
48334643|NCT02238288|OTHER|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
48334644|NCT02238288|DRUG|lidocaine and epinephrine|2%
48334645|NCT02238288|DRUG|Paracetamol|750 mg
48334646|NCT05484427|OTHER|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
48334647|NCT02216890|DRUG|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
48334648|NCT02375269|DEVICE|RIPC with a tourniquet|
48653119|NCT06564701|DEVICE|Phonak Roger TouchScreen Microphone|Transmitter microphone system operating on the 2.4 GHz band, which allows for low-delay and reliable long-range broadcast to a compatible Roger receiver, desgined to be used in educational settings. It features six microphones and adaptive technology in which speech signals are increased when background noise increases to ensure that the speech signal is always above the noise level.
48334649|NCT04962672|DRUG|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
48334650|NCT04962672|DRUG|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
48334651|NCT00961662|DRUG|D-Tagatose|powder to be dissolved in water prior to dosage.
48334652|NCT04868227|DIETARY_SUPPLEMENT|FULTIUM D3 VITAMIN D3|VITAMIN D3 SUPPLEMENT
48334653|NCT06376838|DEVICE|DLMR01|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
48334654|NCT06376838|DEVICE|Rejuran|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
48334655|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
48334656|NCT01892644|OTHER|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
48334657|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
48334658|NCT06034912|DEVICE|Low-Intensity Red Light Therapy|myopia and amblyopia comprehensive treatment instrument red light feeding treatment
48334659|NCT04664140|OTHER|QFR-based virtual PCI|Procedural planning of PCI based on the pullback trace given by the QFR systems in order to obtain an optimized functional result after PCI
48334660|NCT04664140|OTHER|angiography-based PCI|PCi according to international guidelines, local protocols and practice
48334661|NCT00707460|BEHAVIORAL|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
48334662|NCT06302998|DRUG|DEX-PRESSIN|This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
48334663|NCT06302998|DRUG|Standard of Care|This group will receive conventional treatment according to the SSC 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive DEX.
48334664|NCT02740218|OTHER|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
48334665|NCT05015738|OTHER|Traditional education|Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.
48653120|NCT06564701|DEVICE|Phonak Partner Mic|Wireless microphone that uses Phonak proprietary AirStream technology to connect to Phonak hearing aids. It uses a fixed directional microphone, and is paired to the hearing aids such that the hearing aid microphones are attenuated at a fixed level when the microphone is in use.
48334666|NCT05015738|DEVICE|Diabetes Education supported by digital tools|Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
48334667|NCT02062398|DEVICE|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
48334668|NCT02131246|DRUG|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
48334669|NCT02131246|DRUG|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
48653121|NCT03752372|PROCEDURE|hematopoietic stem cell transplantation|"1. Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~2. All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~3. Umbilical cord blood transplantation"
48127687|NCT02132949|DRUG|Doxorubicin|Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
48127688|NCT02132949|DRUG|Epirubicin|Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.
48653122|NCT06450314|DRUG|Discontinuation of the anti-HER2 maintenance therapy|Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
48127689|NCT02132949|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.
48127690|NCT02132949|DRUG|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
48127691|NCT02132949|DRUG|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
48334670|NCT01797315|DRUG|Sirolimus|
48334671|NCT00976729|DRUG|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
48334672|NCT00976729|DRUG|NOX-E36|single SC doses, at safe and tolerable dose level
48334673|NCT00976729|DRUG|Placebo|
48334674|NCT02597491|BEHAVIORAL|TLC monthly|Tobacco longitudinal care monthly
48334675|NCT02597491|BEHAVIORAL|TLC quarterly|Tobacco longitudinal care quarterly
48334676|NCT02597491|BEHAVIORAL|MTM|Medication management therapy
48493534|NCT06300671|OTHER|Foot Posture Index-6|Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.
48493535|NCT04043130|BEHAVIORAL|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
48127692|NCT00530153|BEHAVIORAL|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
48334677|NCT02597491|BEHAVIORAL|4 week assessment|4 week assessment
48334678|NCT02597491|BEHAVIORAL|8 week assessment|8 week assessment
48334679|NCT04406389|DRUG|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
48493536|NCT01452711|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
48493537|NCT01452711|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
48493538|NCT01452711|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
48127693|NCT00530153|DIETARY_SUPPLEMENT|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
48653123|NCT06450314|DEVICE|Monitoring with signatera test|"ctDNA test will be performed at 1.5 month after inclusion and every 3 months during 2 years.~Note: For the ctDNA negative patients who become ctDNA positive: ctDNA test will be performed once, 3 months after restarting treatment (+/-1 week)."
48334680|NCT04406389|DRUG|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
48334681|NCT04406389|DRUG|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily"
48334682|NCT04406389|DRUG|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
48334683|NCT00249795|DRUG|Irbesartan|oral administration (tablets) once daily
48334684|NCT00249795|DRUG|placebo|oral administration (tablets) once daily
48334685|NCT06347783|DEVICE|Insulin pump|Continuous subcutaneous insulin therapy.
48334686|NCT02855112|BIOLOGICAL|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
48334687|NCT03601793|BEHAVIORAL|Alcohol Help Center|An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
48334688|NCT03601793|BEHAVIORAL|Assistance from a health educator|This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
48334689|NCT00841269|DRUG|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
48334690|NCT01229891|DIETARY_SUPPLEMENT|plain yogurt drink|daily intake of two bottle of plain yogurt drink
48334691|NCT01229891|DIETARY_SUPPLEMENT|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
48334692|NCT01229891|DIETARY_SUPPLEMENT|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
48334693|NCT03869671|BEHAVIORAL|PrEP uptake/adherence intervention|The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
48334694|NCT03869671|BEHAVIORAL|Harm reduction standard of care|Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
47976467|NCT02279901|BEHAVIORAL|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
47976468|NCT06163313|OTHER|Observation of patients suffering from kidney stones who undergo endoscopic surgery|Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
48127694|NCT02633215|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
48334695|NCT03202745|OTHER|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
47976469|NCT01324765|BEHAVIORAL|TARGET|12-session group therapy twice weekly 6 weeks
47976470|NCT01324765|BEHAVIORAL|SGT|12 sessions supportive group therapy twice weekly 6 weeks
47976471|NCT02176330|OTHER|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
48334696|NCT03202745|OTHER|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
47976472|NCT02176330|OTHER|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
48127695|NCT03910855|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
48127696|NCT03910855|OTHER|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
48127697|NCT06120218|PROCEDURE|Emergent Stenting|Emergent Stenting in acute ischemic stroke caused by tandem occlusions
48127698|NCT02827474|OTHER|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
48334697|NCT02656901|DEVICE|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
48334698|NCT02656901|DEVICE|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
48334699|NCT02656901|DEVICE|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
48653124|NCT03753074|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
48653125|NCT04306120|OTHER|Traditional Rehabilitation Therapy|The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
48127699|NCT02827474|OTHER|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
48127700|NCT05834894|OTHER|exposure(s) of interest : intensive care unit|Low muscle mass is highly prevalent at hospital admission, and muscle mass generally decreases during hospital stay, especially in critically-ill patients. We would like to mesure muscle mas in critically ill patients and determine the association between outcomes.
48653126|NCT05734807|DRUG|Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)|Subjects will receive NrtIs therapy for 24 weeks.
48653127|NCT05734807|DRUG|HH-003 and NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.
48653128|NCT05734807|DRUG|HH-003, NrtIs and PEG-IFN-α|Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.
48653129|NCT04133038|OTHER|Questionnaire|Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
48493539|NCT01452711|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
48127701|NCT05100784|BIOLOGICAL|HSSA test|Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.
48334700|NCT02656901|DEVICE|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
48334701|NCT04435561|OTHER|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
48334702|NCT04435561|OTHER|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
48334703|NCT04397796|BIOLOGICAL|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
48334704|NCT04397796|BIOLOGICAL|Placebo|plasmalyte and human albumin
48334705|NCT05915325|PROCEDURE|Physical training|"1. Supervised Physical Training in SeniorGym for 12 weeks: 1) Aerobic exercise: Patient-tailored intensity-modulated ergometer training for the limbs; 2) Resistance exercise: Patient-tailored resistance exercise by Theraband for the limbs~2. Nutrition intervention for 24 weeks: Dietitian consultation, education and intervention for 24 weeks"
48334706|NCT04376099|DIAGNOSTIC_TEST|Transcutaneous oxygen pressure measurement during the treadmill test|"Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg."
48334707|NCT01549457|OTHER|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
48334708|NCT04257604|DRUG|Perampanel|Perampanel tablets.
48334709|NCT05389384|DEVICE|Passive shoulder exoskeleton|Participants complete overhead working task with support of exo
47976473|NCT01817621|BEHAVIORAL|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
47976474|NCT01817621|BEHAVIORAL|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
47976475|NCT01761331|OTHER|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
47976476|NCT00150449|DRUG|Pregabalin|
48127702|NCT05723666|OTHER|Group watching virtual reality glasses|A nature video will be watched with virtual reality glasses.
48334710|NCT05389384|BEHAVIORAL|Fatigue protocol|Participants complete a fatiguing protocol
48493540|NCT00362479|DRUG|DR-1021|1 tablet daily
48653130|NCT01715870|BEHAVIORAL|Life style and food habits questionnaire|
48653131|NCT06634615|OTHER|VR patient education video|The educational video is created by converting the information provided by the service nurses into a video when the patient is admitted to the ward for surgery. The video will show a 2-3 minute animation of a nurse giving information. In a patient room, the service nurse will come to the newly admitted patient and explain the concept of cholecystectomy, the reasons for removing the gallbladder, how laparoscopic cholecystectomy is performed, the advantages of laparoscopic surgery compared to open surgery, the preparation process before and on the day of surgery, the conditions to be monitored after surgery, the importance of nutrition and fluid intake, defecation, the importance of early mobilization and discharge.
48653132|NCT06634615|OTHER|VR family interview|Patients will have a 5-minute video call with their families in a 360° designed home environment using virtual reality glasses in the operating room waiting area.
48653133|NCT01003327|DEVICE|I-gel|intubation with I-gel airway
48653134|NCT01003327|DEVICE|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
48127703|NCT00570700|DRUG|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
48334711|NCT05389384|DEVICE|No exoskeleton support|Exoskeleton is worn, but no support provided
48334712|NCT05389384|BEHAVIORAL|No peripheral fatiguing protocol|Participants complete no fatiguing protocol
48334713|NCT03466112|OTHER|endurance training|endurance training with stationary bicycles
48334714|NCT03466112|OTHER|balance and tone program|flexibility, core strength, balance, relaxation
48334715|NCT02234557|BEHAVIORAL|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
48493541|NCT05880836|DEVICE|nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen|nebulized delivery of bronchodilator via in-line drug delivery maintaining high-flow nasal cannula oxygen
48493542|NCT05880836|DEVICE|standard jet nebulization (SJN) with face mask|standard jet nebulization delivery of bronchodilator
48493543|NCT01475006|DRUG|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
48127704|NCT05570838|DEVICE|Functional Electrical Stimulation|Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
48334716|NCT03525626|BEHAVIORAL|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
48653135|NCT05336565|OTHER|Electronic medical record analysis|"Medical information system (MIS) BARS will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. Incidence rates and patterns of PIM prescription, polypharmacy, and PDDIs in the time of COVID-19 pandemic will be studied."
48653136|NCT06641570|OTHER|Aquatic Exercise Program|This intervention will include 16 sessions of an aquatic-exercise program, twice a week, over 8 weeks at a water temperature between 32-34°C. Each session will be conducted in groups of 8 to 12 patients and will last about 45 minutes.
48127705|NCT05570838|DEVICE|Hand Robotic-Assisted Therapy|The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
48334717|NCT01109550|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
48334718|NCT00382213|DRUG|Olmesartan medoxomil|
48653137|NCT06641570|OTHER|Land-based Exercise Program|This intervention will include 8 sessions in 8 weeks, once a week. Each session will last between 25 to 35 minutes and will be divided into two components: core stability exercises and stretching of the trunk and lower limbs.
48653138|NCT06466096|OTHER|no intervention|this is an observation study, no intervention
48653139|NCT03340506|DRUG|dabrafenib|dabrafenib is available in capsules (50mg and 75mg) taken twice a day
48653140|NCT03340506|DRUG|trametinib|trametinib is available in tablets (0.5mg, 2mg dose)
48653141|NCT00385515|DRUG|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
48653142|NCT00385515|DRUG|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
48653143|NCT06327165|OTHER|observation|The ANI monitor calculates heart rate variability mediated by changes in the parasympathetic nervous system.
48653144|NCT03895476|DIAGNOSTIC_TEST|palatal wound will be cover with collagen and sutures|after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site
48653145|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
48653146|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
48653147|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
48653148|NCT06564922|OTHER|Counselling|Counselling was given for treatment group.
48653149|NCT06644092|OTHER|Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft Transplantation Operation|The treatment protocol to be applied to the patients after surgery was determined. The protocol includes; cold application, game ready device application, CPM device application, patellar mobilization, soft tissue mobilization application, TENS, conventional TENS and NMES application, ultrasound application, stretching exercises, strengthening exercises, mobilization exercises, balance and proprioception exercises, walking training and kinesio taping.
48653150|NCT06225544|DRUG|Lumasiran|Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
48653151|NCT06225544|DRUG|0.9% Sodium Chloride (placebo)|Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
48653152|NCT01397591|BIOLOGICAL|Ofatumumab|Given intravenously
48653153|NCT01397591|DRUG|Bortezomib|Given intravenously
48653154|NCT05116345|DRUG|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
48653155|NCT05116345|DRUG|Topical Dexamethasone|topical dexamethasone drops
48653156|NCT04620980|DIAGNOSTIC_TEST|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
48653157|NCT04914273|DRUG|Inhalation Spray|400 mcg salbutamol administered per metered dose inhaler
48334719|NCT00382213|DRUG|Placebo|
48334720|NCT00860990|OTHER|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
47976477|NCT05783778|DIAGNOSTIC_TEST|Free testosterone levels and toxoplasma igG|Free testosterone levels and toxoplasma igG in serum by ELISA
47976478|NCT01797601|DRUG|Human Insulin|160 U of insulin
48127706|NCT03304834|DEVICE|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
48127707|NCT00829036|DEVICE|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
48127708|NCT01637402|DRUG|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
48334721|NCT02006498|DRUG|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
48653158|NCT04914273|DRUG|Tablet|8 mg salbutamol administered per tablet for ingestion
48653159|NCT01798225|DRUG|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
48653160|NCT01798225|DRUG|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
48653161|NCT06331468|DRUG|Cisplatin|A total of two IV infusions of cisplatin will be administered on Day 1 and again on Day 8 +/- 1 day. Cisplatin starting dose is 40 mg/m2. Dose reduction is allowed (30 mg/m2) as needed for management of toxicities.
48334722|NCT02006498|DRUG|Placebo|Placebo capsule with same appearances as study drug
48334723|NCT04868136|BEHAVIORAL|Exercise|30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
48493544|NCT03063762|DRUG|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
48653162|NCT06331468|RADIATION|intensity modulated radiation therapy (IMRT)|given once daily Monday-Thursday, four fractions per week for 2 weeks. The radiation dose is 4.56 Gy x 8 fractions.
48653163|NCT06331468|RADIATION|high-dose-rate (HDR) brachytherapy|administered 2x weekly (allow at least 72-hours window between sessions); weekdays only for 2 weeks. The radiation dose is 7 Gy x 4 fractions.
48653164|NCT06642064|BEHAVIORAL|Intervention group|"• Intervention group:~Participants were invited to participate in a 20-minute interactive learning course (PPT lecture) and a 25-minute physical activity.The intervention lasted for 12 weeks, twice a week, 45 minutes each time, for a total of 1080 minutes."
48653165|NCT05516147|BEHAVIORAL|SAFE at Home|SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
48653166|NCT06569732|OTHER|Homemade oral nutrition supplements|The homemade oral nutrition supplement is made of soy milk, whey protein powder, vegetable oil, and fruit juices
48653167|NCT06569732|OTHER|Commercial oral nutrition supplements|The commercial oral nutrition supplement is kidney-specific oral nutrition supplement that is high in energy and protein, but low in electrolytes and fluid
48653168|NCT05815264|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
48653169|NCT05815264|BIOLOGICAL|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
48653170|NCT04269265|BIOLOGICAL|Yellow Fever Vaccine|YF-VAX®, Yellow Fever Vaccine, for subcutaneous use
48653171|NCT00380146|DRUG|sulfadoxine-pyrimethamine|
47976479|NCT01797601|DRUG|Placebo|Insulin dilution medium without insulin
48127709|NCT01637402|DRUG|Prednisone|5 mg, twice daily, oral administration
48127710|NCT06016400|DRUG|Alfacalcidol Oral Solution|Alfacalcidol Oral Solution 1ug a day
48127711|NCT06016400|DRUG|Placebo|Placebo
48493545|NCT03063762|DRUG|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
48653172|NCT05249660|OTHER|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
48127712|NCT00215787|DRUG|lansoprazole|Lansoprazole 30 mg BID for 1 year
48334724|NCT01877590|DRUG|alpha-lipoic acid|
48334725|NCT01742533|BIOLOGICAL|human umbilical cord mesenchymal stem cells|
48334726|NCT01742533|BIOLOGICAL|hUCMSCs and hCBMNCs|
48334727|NCT01742533|BIOLOGICAL|human cord blood mononuclear cells|
48334728|NCT01742533|DRUG|Hormone Replacement Therapy|
48334729|NCT06311357|DIETARY_SUPPLEMENT|Ensure|Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.
48334730|NCT05382702|OTHER|Test meal description changed|Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
48493546|NCT03063762|DRUG|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
48493547|NCT03306953|PROCEDURE|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
48493548|NCT01438528|DEVICE|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
48334731|NCT04666025|PROCEDURE|Biospecimen Collection|Undergo collection of nasopharyngeal swabs, blood, and saliva samples
48493549|NCT03489161|DRUG|Buprenorphine|buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
48493550|NCT00203970|BEHAVIORAL|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
48334732|NCT04666025|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48334733|NCT04666025|OTHER|Electronic Health Record Review|Medical charts are reviewed
48334734|NCT04666025|OTHER|Questionnaire Administration|Complete questionnaire
48493551|NCT01624441|DRUG|Dinaciclib|Given IV
48493552|NCT01624441|DRUG|Epirubicin Hydrochloride|Given IV
48334735|NCT06013267|OTHER|Chin tuck against resistance exercise|The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
48334736|NCT01223040|OTHER|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
48334737|NCT05459792|PROCEDURE|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
48493553|NCT01624441|OTHER|Laboratory Biomarker Analysis|Correlative studies
48493554|NCT02273336|OTHER|cytology specimen collection procedure|Undergo tissue and blood sample collection
48493555|NCT02273336|OTHER|laboratory biomarker analysis|Correlative studies
48493556|NCT05084508|BIOLOGICAL|Investigational varicella vaccine low potency|1 dose of a low-potency investigational varicella vaccine administered subcutaneously in the upper arm
48493557|NCT05084508|BIOLOGICAL|Investigational varicella vaccine medium potency|1 dose of a medium-potency investigational varicella vaccine administered subcutaneously in the upper arm
48493558|NCT05084508|BIOLOGICAL|Investigational varicella vaccine high potency|1 dose of a high-potency investigational varicella vaccine administered subcutaneously in the upper arm
48334738|NCT05459792|PROCEDURE|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
48334739|NCT05459792|PROCEDURE|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
48493559|NCT05084508|BIOLOGICAL|Marketed varicella vaccine Lot 1|1 dose of a marketed varicella vaccine of Lot 1 administered subcutaneously in the upper arm
48127713|NCT05122468|PROCEDURE|Connective tissue Harvest and CAF|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level. In control sites, the graft will be adapted to cover each exposed root to the CEJ, and stabilized with either 6-0 resorbable sutures (with the knot placed under the papillary area) or a non-resorbable suture with the knot on the palatal side. For suturing of the graft, interrupted sutures or sling sutures (anchored to periosteum apical to the graft and hanging around the neck of the experimental teeth) may be used.
48127714|NCT05122468|PROCEDURE|Connective tissue Harvest and Tunnel|"A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. The dimensions of the graft achieve 3 to 5 mm mesial and distal from the lateral teeth with an ideal thickness about 1 to 1.5 mm. Donor tissue will be taken at premolar and molar level.~In test sites, the graft should be slid through the tunnel. To accomplish the adequate position of the graft into the tunnel, 2 sutures are first placed, 1 at the most mesial and the other at the most distal aspect of the tunnel. The needles should pass underneath the tunnel and exit through the largest or most central gingival recession, the one through which the grafting tissue will be introduced. With these 2 sutures already inside the tunnel, the graft is bitten on both ends with vertical mattress sutures."
48127715|NCT04804566|OTHER|This is a non-interventional study|This is a non-interventional study
48334740|NCT04980898|DEVICE|WoundEL medical device|"The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment."
48127716|NCT05246943|DIAGNOSTIC_TEST|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
48127717|NCT03908060|DRUG|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
48653173|NCT05249660|OTHER|Comparator: Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
48653174|NCT06284304|RADIATION|De-escalated radiotherapy|5 fraction de-escalated dose SBRT protocol
48653175|NCT06627049|OTHER|Focus group|Focus group to evaluate the facilitators and barriers to the use of virtual reality.
48653176|NCT06627049|OTHER|Implementing facilitating strategies|Implement strategies to facilitate the integration of virtual reality into rehabilitation sessions.
48653177|NCT06627049|OTHER|Focus group|Evaluate the strategies used to facilitate VR implementation.
48653178|NCT06627049|OTHER|Interviews|Interviews to evaluate the facilitators and barriers to the use of virtual reality.
48653179|NCT06627049|OTHER|Interviews|Evaluate the strategies used to facilitate VR implementation.
48653180|NCT04756232|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
48127718|NCT03908060|DRUG|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
48334741|NCT04980898|OTHER|Standard cares|Cleaning and monitoring
48334742|NCT03850418|DRUG|azacitidine|azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
48493560|NCT05084508|BIOLOGICAL|Marketed varicella vaccine Lot 2|1 dose of a marketed varicella vaccine of Lot 2 administered subcutaneously in the upper arm
48493561|NCT05084508|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of a measles, mumps, and rubella vaccine administered subcutaneously in the upper arm
48493562|NCT05084508|BIOLOGICAL|Hepatitis A vaccine|1 dose of a hepatitis A vaccine administered intramuscularly in the right anterolateral thigh
48493563|NCT05084508|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly in the left anterolateral thigh
48127719|NCT03155113|OTHER|blood drawing|Before starting therapy a blood sample will be collected from any subject.
48127720|NCT04776096|DRUG|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
48127721|NCT04776096|DRUG|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
48334743|NCT03214328|DIAGNOSTIC_TEST|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
48334744|NCT00003852|BIOLOGICAL|filgrastim|
48334745|NCT00003852|DRUG|carboplatin|
48334746|NCT00003852|DRUG|cyclophosphamide|
48493564|NCT03728218|DEVICE|Contact lenses (Orthokeratology)|Contact lenses
48493565|NCT03728218|DEVICE|Contact lenses (Soft Multifocal)|Contact lenses
48493566|NCT02195466|DRUG|Tipranavir (TPV)|500 mg bid on days 7-14
48653181|NCT04756232|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
48653182|NCT04452877|DRUG|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-21 of a 21-day cycle.
48653183|NCT04452877|DRUG|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-21 of a 21-day cycle
48653184|NCT05454891|DRUG|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
48653185|NCT05454891|DRUG|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
48653186|NCT04108156|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
48653187|NCT04108156|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
48653188|NCT04108156|DRUG|Ranibizumab refill exchange|Will be administered as per the schedule described in individual arm.
48127722|NCT01777009|PROCEDURE|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
48127723|NCT00913289|BIOLOGICAL|adipose tissue derived stromal cells|dosage
48334747|NCT00003852|DRUG|epirubicin hydrochloride|
48334748|NCT00003852|DRUG|etoposide|
48334749|NCT00003852|DRUG|ifosfamide|
48334750|NCT00003852|DRUG|paclitaxel|
48334751|NCT00003852|DRUG|thiotepa|
48334752|NCT00003852|PROCEDURE|bone marrow ablation with stem cell support|
48334753|NCT00003852|PROCEDURE|peripheral blood stem cell transplantation|
48334754|NCT02295306|DEVICE|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
48334755|NCT05841108|DEVICE|force feedback rehabilitation robot (SEM™ Glove)|In the experimental group, the therapists were asked to illustrate and demonstrate the motor points of the cylindrical grasping and spherical grasping movements, and the patients were instructed to imitate them with nonparalytic hand, while the latter patients wore SEM™ Glove were used for task-oriented training, such as inserting pegs, grasping a ball into a barrel, and drinking water exercises. The difficulty of task-oriented training can be adjusted according to the patient's actual condition, such as changing the shape, weight, size of the target or changing the distance, duration, and so on during training
48493567|NCT02195466|DRUG|Ritonavir (RTV)|200 mg bid on days 7-14
48493568|NCT02195466|DRUG|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
48493569|NCT03250494|DRUG|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
48493570|NCT03250494|DRUG|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
48653189|NCT06643494|DIETARY_SUPPLEMENT|N-111|A combination of Acetogenins
48653190|NCT06643494|OTHER|Placebo|Placebo
48653191|NCT00697385|DRUG|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
48653192|NCT00500331|DRUG|GSK189075|Experimental Drug
48653193|NCT00500331|DRUG|pioglitazone|Active Control
48653194|NCT00500331|OTHER|Placebo|Placebo Comparator
48653195|NCT05720351|PROCEDURE|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
48653196|NCT05720351|PROCEDURE|Staircase maneuver|Patients undergone Undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
48127724|NCT05168085|DIETARY_SUPPLEMENT|Eggs|Providing 1 egg per day fo 6 months to infants
48127725|NCT04147494|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48127726|NCT04147494|RADIATION|Gallium Ga 68 FAPi-46|Given IV
48127727|NCT04147494|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
48127728|NCT04147494|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48653197|NCT04408638|DRUG|Obinutuzumab|Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
48653198|NCT04408638|DRUG|Glofitamab|Participants will receive IV glofitamab for up to 12 cycles.
48653199|NCT04408638|DRUG|Rituxumab|Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
48653200|NCT04408638|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
48653201|NCT04408638|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
48127729|NCT04147494|RADIATION|18F-FDG|Given IV
48653202|NCT04408638|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
48653203|NCT01879826|DEVICE|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
48653204|NCT01879826|DEVICE|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
48653205|NCT04905641|PROCEDURE|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
48653206|NCT02067156|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
48127730|NCT02583113|DEVICE|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
48127731|NCT06417892|DRUG|PD-1inhibitor|PD-1 antibody was selected according to first-line drug use
48127732|NCT04783025|BEHAVIORAL|Blended Gaming COVID-19 Training System (BGCTS)|"BGCTS is a blended training programme integrated with games and short video clips for Residential Care Home staffs to learn the principles of infection control and reinforce actions needed to stop the spread of COVID-19 within the RCHs, and to care for those residents suspected of having COVID-19. The contents of the training will refer to the evidence-based contents from The COVID-19 Risk Communication Package For Healthcare Facilities.~Dosage of the intervention. Staffs are encouraged to learn each topic independently in 15 minutes. It will take a total of 120 minutes to complete all eight topics in 2 weeks. Staffs will attend two 30-minute face-to-face group sessions conducted by research nurse (and the Infection Control Officer of the RCH) to clarify concepts (one per week; after playing the games). Scores and progress bar will be shown to the staff so as a form of motivation to encourage continuous participation in the training."
48334756|NCT05841108|OTHER|assisted by a therapist|The control group received task-oriented training assisted by a therapist to complete the same task as the experimental group. Therapists need to instruct patients to try to grasp items and give appropriate assistance to guarantee their completion of the grasping task. If finger extension is weak, the therapist assists the patient in extension of the digits before grasping the items, and if the finger flexion angle does not meet the grasp function needs, it should assist in flexion finger movements
48334757|NCT01293084|DRUG|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
48334758|NCT01293084|DRUG|7% saline|5mL 7% saline inhaled once over 20 minutes
48653207|NCT04873362|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
48653208|NCT04873362|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
48653209|NCT04873362|DRUG|Placebo|Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
48653210|NCT04873362|DRUG|Trastuzumab|Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
48653211|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Active|The patients will be treated with cTBS and usual medical treatment after endovascular treatment
48653212|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Sham|The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment
48334759|NCT04271670|OTHER|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
48334760|NCT04271670|OTHER|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
48334761|NCT04271670|OTHER|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
48334762|NCT05284058|OTHER|Cardiac Magnetic Resonance Imaging (MRI)|Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
48334763|NCT01573403|DRUG|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
48334764|NCT01573403|DRUG|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
48334765|NCT01573403|DRUG|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
48653213|NCT03135067|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
48334766|NCT03274180|OTHER|Nursing consultation|travel preventive consultation was performed by nurse
48334767|NCT06456138|DRUG|Trametinib|Trametinib will be administrated orally every day.
48334768|NCT06456138|DRUG|Anlotinib|Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.
48334769|NCT06456138|DRUG|Tislelizumab|Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
48334770|NCT02150213|PROCEDURE|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
48334771|NCT02150213|PROCEDURE|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
48334772|NCT02150213|PROCEDURE|Sonogram|Sonogram of the uterus (females only)
48653214|NCT04978467|DEVICE|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
48653215|NCT04114825|BIOLOGICAL|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
48653216|NCT04114825|OTHER|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
48653217|NCT06188975|DRUG|DRUG: ABBV-CLS-484|
48334773|NCT02150213|PROCEDURE|Biopsy|Uterine endometrial biopsy (females only)
48493571|NCT03250494|DRUG|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
48653218|NCT02731482|OTHER|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.~* Aerobic training in stepping training.~* Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.~* Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
48334774|NCT02150213|DRUG|BGG492|No study-drug was administered in this study
48334775|NCT00042562|DRUG|duloxetine|
48334776|NCT04814472|DRUG|BLD-0409|Randomized to active product.
48334777|NCT04813978|OTHER|Music|For the interventional group, in addition to normal nursing care, patients will listen to instrumental relaxing music genre consist of pitch, rhythm and tone color for 30 minutes pre-operatively, using mp3 player and over-ear headphones to reduce outside interference, at a volume of the patient's preference.
48334778|NCT01285063|OTHER|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
48334779|NCT02260895|DIETARY_SUPPLEMENT|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
48334780|NCT00435994|DRUG|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
48334781|NCT00435994|OTHER|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
48653219|NCT02731482|OTHER|Control Group|"* The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.~* Participants will not receive any supervised physical training.~* Once a week, patients will receive a phone call to provide support and general advice."
48653220|NCT05558267|DIETARY_SUPPLEMENT|Standard Table Salt|Standard Table Salt is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis.
48493572|NCT03178565|OTHER|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
48127733|NCT04783025|BEHAVIORAL|Usual care, infection control briefing|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staffs. Usually the briefing is irregular, non-standardized and determined by ICOs, depending on when the ICOs receive the information about infection control practice from Centre for Health Protection of the Hong Kong government. The format and duration of this briefing is determined by the ICO. Some ICOs deliver the infection control information in the form of posters or a written document, and circulate these materials to all staffs.
48493573|NCT03178565|OTHER|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
48653221|NCT05558267|DIETARY_SUPPLEMENT|Salt Substitute|"Salt Substitute is available as a crystalized powder. It substitutes potassium chloride for sodium chloride, and thus contains about 50% less sodium than standard table salt.~Salt Substitute is administered orally. It is transferred to unmarked saltshakers by non-blinded research coordinators. The unmarked saltshaker is delivered to the participant during dialysis."
48653222|NCT06641102|OTHER|Self-Guided Program (Tier 1)|"The study intervention is a smartphone application.~Tier 1: self-guided program, includes videos, guided meditations, and worksheets that are delivered to users in 10 different topical modules. Two modules are delivered per week, with email reminders. It will emphasize that PRT is a practice that requires users to come back to the material regularly to help retrain the brain often (just like how you need to practice and complete exercises between PT sessions)."
48127734|NCT00139984|DEVICE|24 hour blood pressure measurement|
48127735|NCT02920710|DRUG|Repository Corticotropin Injection|"* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
48127736|NCT02326181|DEVICE|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
48127737|NCT02326181|DEVICE|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
48127738|NCT04025164|RADIATION|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
48127739|NCT04025164|RADIATION|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
48127740|NCT00909649|PROCEDURE|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
48127741|NCT02109575|DIAGNOSTIC_TEST|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
48127742|NCT04987801|OTHER|Drug Toxicity|Patients who took over dose of Drugs
48493574|NCT04236726|OTHER|Questionnaire|HRQoL questionnaires
48127743|NCT03196882|DRUG|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
48127744|NCT03196882|DRUG|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
48127745|NCT03196882|DRUG|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
48127746|NCT04747561|DRUG|18F-PEG3-FPN|For clinically suspected or confirmed melanoma patients and healthy volunteers, integrated PET/MR imaging was performed using targeted melanin-specific imaging agent 18F-PEG3-FPN. Meanwhile, the general imaging agent 18F-FDG was compared with MR multi-sequence and multi-parameters
48127747|NCT00574834|DRUG|Ramipril|Ramipril 20 mg once daily for 6 months
48127748|NCT00574834|DRUG|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
48127749|NCT00574834|DRUG|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
48493575|NCT04346420|OTHER|Standard interface|The standard interface for administering oxygen (nasal cannula or oxygen mask) is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
48493576|NCT04346420|DEVICE|Double-Trunk Mask|The standard nasal cannula interface accompanied with the DTM is worn by the patient. Oxygen output is adapted to reach a SpO2 target of 94%.
48493577|NCT02452541|OTHER|Prognostic tests|"* Brain CT-Scan on day 1, 3 and 7~* Brain MRI on day 7~* SomatoSensory Evoked Potentials on day 7~* Electroencephalogram on day 7~* Serum biomarkers on day 1, 3 and 7~* Daily clinical exams"
48493578|NCT01799122|DEVICE|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
48127750|NCT03793413|PROCEDURE|Lingual frenotomy|A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
48493579|NCT00507286|DRUG|combination of various doses of sildenefil and alprostadil|
48493580|NCT05469217|OTHER|fMRI brain imaging|Structural MRI of gray and white matter, functional MRI during performance of the N-back task
48334782|NCT00035477|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
47976480|NCT03295578|OTHER|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
48127751|NCT05783531|OTHER|VMood|VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
48334783|NCT00035477|DRUG|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
48334784|NCT03108625|DRUG|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
48334785|NCT00295737|PROCEDURE|bronchoscopy, allergen/endotoxin instillation|
48334786|NCT04297410|RADIATION|177Lu-PSMA-I&T Radionuclide|Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I\&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
48334787|NCT02595268|DRUG|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
48493581|NCT04962984|PROCEDURE|blood sampling|additional blood sampling for coagulation tests
48493582|NCT01529398|OTHER|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
48493583|NCT01529398|OTHER|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
48653223|NCT06641102|OTHER|Coach Assisted Program (Tier 3)|"The study intervention is a smartphone application.~Tier 3: one-on-one coaching program that sets users up with trained PRT coaches who will walk them through the program individually. Users will meet with the assigned coaches once per week for an hour-long Zoom-hosted session that covers the same information as Tier 1, however in a completely personal and individualized way, focusing on the content that is most relevant for the user/patient at the time of the session. Tier 3 users will also receive materials from their coaches (e.g. videos, meditations, etc.) to support their own practice between session."
48653224|NCT06641102|OTHER|Standard of Care (SOC)|SOC is defined as a comprehensive clinical care plan, including a consultation with physiatrist and prescribed interventions, which will capture a comparison representative of all potential interventions that are recommended for an individual.
48653225|NCT05748834|DRUG|Tucatinib|Participants will receive tucatinib 300mg by mouth twice daily continuously (days 1-28) of each 28 day cycle.
48653226|NCT05748834|DRUG|Doxil|Participants will receive Doxil 40mg/m2 intravenously on day 1 of each 28 day cycle (with a maximum cumulative dose of 550mg/m2).
48127752|NCT05783531|OTHER|Enhanced treatment as usual|Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
48127753|NCT02134262|DRUG|Cyclophosphamide or Bendamustine|Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.
48127754|NCT02134262|GENETIC|Dose Level -1|CD19-CAR-T \[1 x 10\^5 cells/kg x 1 day and 2 x 10\^5 cells/kg x 1 day Intravenous (IV)\] are administered.
48127755|NCT02134262|GENETIC|Dose Level 1|CD19-CAR-T \[1/3 x 10\^6 cells/kg x 1 day and 2/3 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
48127756|NCT02134262|GENETIC|Dose Level 2|CD19-CAR-T \[1 x 10\^6 cells/kg x 1 day and 2 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
48127757|NCT02134262|GENETIC|Dose Level 3|CD19-CAR-T \[1/3 x 10\^7 cells/kg x 1 day and 2/3 x 10\^7 cells/kg x 1 day Intravenous (IV)\] are administered.
48493584|NCT01529398|OTHER|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
48493585|NCT02746471|DEVICE|Reveal LINQ|
48127758|NCT03693066|OTHER|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
48334788|NCT02595268|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
48334789|NCT04687007|BEHAVIORAL|SMART-ALD|At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.
48334790|NCT04687007|BEHAVIORAL|Waiting list|At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
48334791|NCT05224440|BEHAVIORAL|TSMV Sponsorship Initiative|Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
48334792|NCT02043184|BEHAVIORAL|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
48334793|NCT04239170|DRUG|Camrelizumab(SHR-1210)|Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
48334794|NCT03024255|DRUG|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
48334795|NCT03024255|DRUG|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
48334796|NCT03024255|DRUG|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
48334797|NCT03024255|DRUG|Vehicle (Placebo)|Placebo, applied once to each axilla daily
48334798|NCT00432211|DRUG|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
48334799|NCT01432093|OTHER|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
48334800|NCT01432093|OTHER|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
48334801|NCT05616169|DEVICE|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
48334802|NCT00313755|PROCEDURE|Narrow Band Imaging|
48334803|NCT00418717|DRUG|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
48493586|NCT05918224|DRUG|Streptococcus salivarius K12|The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
48493587|NCT05918224|DRUG|Streptococcus salivarius K12 simulants|Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
48493588|NCT04623775|BIOLOGICAL|Nivolumab|Specified dose on specified days
48493589|NCT04623775|BIOLOGICAL|Relatlimab|Specified dose on specified days
48653227|NCT04416815|OTHER|Integrating Health promotion with and for Older People - eHealth|The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
48653228|NCT03930511|PROCEDURE|Pulmonary Rehabilitation|According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
48653229|NCT06637787|OTHER|Pads|A specially desigend pad is used to collect information about leakage and body movement at night.
48127759|NCT03693066|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
48127760|NCT03693066|OTHER|Control|
48127761|NCT06326125|BEHAVIORAL|TICK-B|TICK-B as art-based distraction
48127762|NCT06326125|DRUG|TKTX-Cream|TKTX-Cream as local anesthesia cream
48127763|NCT06326125|OTHER|TICK-B and TKTX-C|TICK-B and TkTx-C as combined intervention approche (pharmacology and non-pharmacology)
48127764|NCT03638674|OTHER|DXA + CT|Two dual-energy X-ray scans + CT scan
48334804|NCT00083343|DRUG|MK0991, caspofungin acetate/Duration of Treatment: variable|
48334805|NCT04813302|PROCEDURE|Coronally advanced flap and connective tissue graft|CAF+CTG treatment will be performed by starting with two vertical releasing incisions lateral to the teeth to be treated and split-full-split thickness flap will be raised beyond the MGJ. The periosteum will be cut, and a blunt dissection into the vestibular lining mucosa will be carried out to eliminate muscle tension so that the mucosal flap can be passively positioned above the level of CEJ on the tooth. The papillae adjacent to the involved teeth will be de-epithelialized. CTG of 1mm in thickness will be harvested from the posterior palate by means of disepithelization of a free gingival graft, cut to the exact size of the defect, and placed over the dehisced defect, sutured to the interdental papillae and subsequently covered with CAF. Sling sutures will be placed to stabilize the flap in a coronal position about 1-2 mm above the CEJ , followed by interrupted sutures to close the releasing incisions.
48334806|NCT04733001|DRUG|HSG4112|Once-daily oral administration
48334807|NCT02522650|DRUG|Amiloride|5mg twice a day for 8 weeks
48334808|NCT02522650|DRUG|Triamterene|50mg twice a day for 8 weeks
48334809|NCT05215314|BEHAVIORAL|mHealth Meditation|Participants will receive access to the 4-week Healthy Minds Program (HMP) Foundations module. The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). The full HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose. At post-treatment, participants will be given access to additional HMP content to support their continued practice.
48334810|NCT06344871|DEVICE|NeuroLF|NeuroLF Scan
48334811|NCT06344871|DEVICE|Conventional PET scan|Scan on conventional PET system
48334812|NCT05584904|OTHER|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
48334813|NCT00030030|DRUG|Silymarin (milk thistle)|
48334814|NCT00271934|BIOLOGICAL|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
48334815|NCT02793089|OTHER|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
48334816|NCT00209326|DRUG|FE200440|
48334817|NCT05031429|OTHER|Time Limited Eating|Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
48334818|NCT06144970|BIOLOGICAL|TG-C High Dose|High Dose - 1 mL of the combined TG-C cells
48653230|NCT04370886|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
48334819|NCT06144970|BIOLOGICAL|TG-C Mid Dose|Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
48334820|NCT06144970|BIOLOGICAL|TG-C Low Dose|Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
48334821|NCT06144970|BIOLOGICAL|Sham Control|Single subcutaneous injection of normal saline
48334822|NCT00602381|DRUG|Lithium|
48334823|NCT04415619|PROCEDURE|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
48334824|NCT04636320|DEVICE|Contrast-enhanced CMR|Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
48334825|NCT04636320|DIAGNOSTIC_TEST|Exercise test ECG|"A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls."
48334826|NCT04636320|BIOLOGICAL|Blood sample|"A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers."
48334827|NCT04636320|DIAGNOSTIC_TEST|Resting 12 lead ECG|A resting 12 lead ECG will be performed at Day 0 visit.
48653231|NCT01212692|BEHAVIORAL|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
48127765|NCT00733811|DRUG|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
48127766|NCT00733811|DRUG|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
48653232|NCT02997007|DEVICE|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
48653233|NCT02997007|DEVICE|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
48653234|NCT03543423|OTHER|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
48653235|NCT03543423|OTHER|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
47976481|NCT03295578|OTHER|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
48127767|NCT01108003|DRUG|broccoli sprout extract|Given orally
48127768|NCT01108003|OTHER|laboratory biomarker analysis|Correlative studies
48127769|NCT01108003|OTHER|Mango Juice|given orally
48127770|NCT02217514|DRUG|Midazolam|
48127771|NCT02217514|DRUG|BI 44370 low dose|
48653236|NCT05500521|DIAGNOSTIC_TEST|Caloric irrigation|In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
48127772|NCT02217514|DRUG|BI 44370 medium dose|
48127773|NCT02217514|DRUG|BI 44370 high dose|
48127774|NCT00052364|DRUG|oxaliplatin|Given IV
48127775|NCT00052364|OTHER|laboratory biomarker analysis|Correlative studies
48127776|NCT05213312|DRUG|Nivolumab|Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;
48334828|NCT04636320|DIAGNOSTIC_TEST|24 hour Holter ECG|A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
48334829|NCT00612989|DRUG|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose."
48334830|NCT05103241|DRUG|[14C] GP681|40 mg suspension containing 100μCi of \[14C\]GP681
48334831|NCT06275997|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
48334832|NCT03731546|PROCEDURE|Delayed cord clamping|Cord clamping 60 seconds after delivery of fetus in preterm infants
48334833|NCT00367432|DRUG|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
48334834|NCT04568018|DRUG|Surfactant|Inhalation of surfactant emulsion at 150 mg
48127777|NCT05213312|DRUG|Cisplatin|80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
48127778|NCT05213312|DRUG|Paclitaxel|175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
48127779|NCT05213312|DRUG|5Fluorouracil|800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
48127780|NCT05213312|PROCEDURE|Esophagectomy (minimally invasive)|4-6 weeks after neoadjuvant therapy.
48127781|NCT00504322|GENETIC|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
48127782|NCT00504322|GENETIC|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
48127783|NCT01638975|BEHAVIORAL|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
48127784|NCT00258609|DRUG|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
48127785|NCT03329612|PROCEDURE|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
48334835|NCT03990259|OTHER|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
47976482|NCT03295578|DEVICE|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
48127786|NCT05343715|BIOLOGICAL|Agalsidase beta from Biosidus 1 mg/kg|Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
48127787|NCT05343715|BIOLOGICAL|Fabrazyme (agalsidase beta) 1 mg/kg|Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
48127788|NCT04393389|DEVICE|"AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd."|All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
48334836|NCT01009021|DRUG|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
48493590|NCT04623775|DRUG|Carboplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
48127789|NCT03590275|DRUG|FOLFIRINOX|Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study
48127790|NCT04532450|DEVICE|Branched / fenestrated aortic stent graft|Endovascular repair of an aortic aneurysm with a branched/fenestrated stent graft to revascularise all visceral arteries together with exclusion of the aortic aneurysm.
48493591|NCT04623775|DRUG|Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
48127791|NCT00545519|DRUG|thymoglobulin|
48334837|NCT01789658|OTHER|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
48493592|NCT04623775|DRUG|Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
48493593|NCT04623775|DRUG|Nab-Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
48493594|NCT04623775|DRUG|Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
48493595|NCT00266071|BEHAVIORAL|Cutaneous response|
48493596|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
48493597|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
48493598|NCT02291770|BIOLOGICAL|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
48493599|NCT02161822|DRUG|simvastatin|simvastatin 80mg qd for 5weeks
48493600|NCT00761865|DEVICE|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
48493601|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given intravenously only once at dose of 10 mg
48493602|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
48493603|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
48493604|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
48493605|NCT00275938|DRUG|interferon alpha 2b plus ribavirin|
47976483|NCT03552315|DIETARY_SUPPLEMENT|Carbonated water with amino acids and chromium|The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
47976484|NCT03552315|DIETARY_SUPPLEMENT|Placebo Carbonated Water|The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
47976485|NCT01432080|DRUG|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
47976486|NCT01432080|DRUG|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
47976487|NCT01432080|DRUG|Montelukast|Montelukast 10 mg PO qhs for 3 months
47976488|NCT01432080|DRUG|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
47976489|NCT00230230|DRUG|SCH 486757|
48127792|NCT02652091|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
48127793|NCT02652091|DEVICE|BETACONNECT device|Used to apply Betaseron.
48493606|NCT00275938|DRUG|interferon alpha 2b plus placebo|
48127794|NCT02458924|BIOLOGICAL|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
48127795|NCT04291638|BEHAVIORAL|Remote Caregiver Training|The remote caregiver training is a 5-hour videoconferencing-based training program that focuses on teaching cognitive behavioral therapy skills to the caregivers of children with selective mutism in a group format across 3 sessions.
48334838|NCT03524911|BEHAVIORAL|CHFFF nutrition education|
48334839|NCT03947567|DRUG|Recombinant Human Coagulation FVIII|Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
48493607|NCT00567866|DRUG|Quetiapine|50 or 100 mg of quetiapine orally
48493608|NCT02512926|DRUG|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
48493609|NCT02512926|DRUG|Cyclophosphamide|
48334840|NCT06508437|BIOLOGICAL|Influenza Vaccination|Standard Dose QIV (15µg Hemagglutinin) - VaxigripTetra Suspension for injection, 0,5ml prefilled syringe
48334841|NCT02654470|DEVICE|Watchman FLX|Patients who are receiving the Watchman FLX device
48334842|NCT05488704|DIAGNOSTIC_TEST|Stress Parameters Measurement|"Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~* Measurement of vital parameters~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~* Centrifugation and analysis of saliva samples taken"
48334843|NCT00958516|DRUG|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
48334844|NCT03380338|BEHAVIORAL|Combined aerobic and strength exercise|
48334845|NCT03277625|PROCEDURE|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
48334846|NCT04917120|DEVICE|Virtual Reality|The procedure will consist of a virtual reality program associated with suggestions of hypnoanalgesia, be added to usual care. Included patients will benefit from the Virtual Reality program combined with hypnoanalgesia suggestions for a period of 20 minutes. We will use a helmet with a built-in screen and an audio headset connected to a control room. Patients will watch an Virtual Reality sequence while listening to narratives designed for the hypnoanalgesia of the present pain.
48334847|NCT05751694|PROCEDURE|Visceral manual treatment|The patient will be placed in a reclining sitting position and triple flexion of the lower limbs to keep the abdominal region relaxed. The therapist will be placed to the right of the patient at the height of the abdomen, with the hands placed in the epigastric area. He will make a skin fold that reduces tension in the area, so that the contact is focused on the visceral tissue of the area. The patient will be asked to take deep breaths, and during the exhalation, the therapist will perform a zigzag movement with vibration of the hands while pulling the tissue caudally. This procedure will be performed for 5 minutes.
48334848|NCT05751694|PROCEDURE|Respiratory listening|The patient and the therapist will be placed in the same position as in the experimental group. The therapist will place his hands in contact with the lower rib cage, and the patient will be asked to take a deep breath. The therapist will not exert any pressure, nor place restrictions on the tissues or movements of the ribcage.
48334849|NCT02474823|OTHER|polysomnogram|all participants will undergo PSG for assessment of OSA
48493610|NCT02512926|DRUG|Etoposide|
48493611|NCT02923882|OTHER|'$100Kitchen and improved cookstove'|
48493612|NCT00497952|BIOLOGICAL|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
48653237|NCT05500521|DIAGNOSTIC_TEST|vHIT|This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
48653238|NCT05500521|DIAGNOSTIC_TEST|VEMP|Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
48653239|NCT04502108|BEHAVIORAL|Covid19|Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
48493613|NCT03914950|DIAGNOSTIC_TEST|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
48493614|NCT00004218|DRUG|chlorambucil|
48493615|NCT00004218|DRUG|cyclophosphamide|
48493616|NCT00004218|DRUG|doxorubicin hydrochloride|
48493617|NCT00004218|DRUG|fludarabine phosphate|
48493618|NCT00004218|DRUG|prednisolone|
48493619|NCT00004218|DRUG|vincristine sulfate|
48493620|NCT02619877|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
48653240|NCT06560138|DRUG|SHR-4602|SHR-4602 will be administered through IV infusion.
48653241|NCT05475925|DRUG|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
48653242|NCT06577675|BEHAVIORAL|Group programme for DBT training|This programme comprises 16 sessions over approximately 5 to 6 months, with one 2.5-hour session every week in a closed group of 8 patients. These sessions will be supervised by two or four carers trained in DBT.
48493621|NCT02619877|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
48493622|NCT02269163|BIOLOGICAL|Immune Globulin Intravenous|Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
48493623|NCT02269163|BIOLOGICAL|Prometic's Immune Globulin Intravenous 10%|Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
48493624|NCT06227013|BEHAVIORAL|Whistleblowing intervention|the participated nurses will receive session about Whistleblowing
48334850|NCT02474823|OTHER|home sleep test|all participants will undergo HST for assessment of OSA
48334851|NCT02474823|OTHER|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
48334852|NCT03621306|DEVICE|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
48334853|NCT00714298|OTHER|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
48334854|NCT02521909|DEVICE|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
48334855|NCT02521909|DEVICE|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
48334856|NCT02521909|DEVICE|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
48334857|NCT02790294|DEVICE|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
48334858|NCT05928676|DIETARY_SUPPLEMENT|Vascanox® HP|Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
48334859|NCT00125437|DRUG|spironolactone|
48334860|NCT04110184|OTHER|Systemic lupus erythematosus disease activity index (SLEDAI)|The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
48334861|NCT03096444|DRUG|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
48334862|NCT03096444|DRUG|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
48334863|NCT03096444|DRUG|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
48334864|NCT03096444|COMBINATION_PRODUCT|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
48334865|NCT03096444|DRUG|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
48334866|NCT05764460|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests for general cognition, social cognition and language.
48334867|NCT04087408|DRUG|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU."
48334868|NCT03212807|DRUG|Durvalumab|Investigational Medicinal Product
48334869|NCT03212807|DRUG|Lenalidomide|Investigational Medicinal Product
48334870|NCT01367860|PROCEDURE|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
48653243|NCT06240455|DRUG|WP1302|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
48334871|NCT01367860|PROCEDURE|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
48334872|NCT01525056|RADIATION|ct and mri scans|ct and mri scan preradiation and postradiation
48493625|NCT03572166|DIAGNOSTIC_TEST|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
48493626|NCT03572166|DIAGNOSTIC_TEST|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
48493627|NCT06280378|DRUG|KL003 Cell Injection Drug Product|Administered by intravenous infusion after myeloablative conditioning with busulfan.
48493628|NCT05187702|OTHER|Functional exersize|Participants will be given balance and strengthening exercises covering the balance exercise protocol.
48493629|NCT05187702|OTHER|Aerobic exersize|60% of the maximum heart rate is given 3 walking eccentricity per week
48493630|NCT01155453|DRUG|BKM120|
48493631|NCT01155453|DRUG|GSK1120212|
48493632|NCT03332927|OTHER|Egg based breakfast foods|Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.
48493633|NCT03332927|OTHER|Non-egg based breakfast foods|Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
48493634|NCT00792870|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
48493635|NCT02185651|DRUG|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
48493636|NCT02335736|DRUG|Gonadotropins releasing hormone antagonist|
48493637|NCT00211120|DRUG|Epoetin Alfa|
48653244|NCT06240455|DRUG|WP1302 placebo|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
48653245|NCT06240455|COMBINATION_PRODUCT|methimazole|Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
48653246|NCT00088699|DRUG|Ketamine|
48653247|NCT00088699|DRUG|Placebo|
48653248|NCT04838652|DRUG|Pembrolizumab plus Chemotherapy (ICE or DHAP)|Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP
48334873|NCT01525056|RADIATION|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
48493638|NCT02951442|BIOLOGICAL|Biological sample|
48493639|NCT02951442|PROCEDURE|Non invasive Arterial investigations|
48493640|NCT02951442|PROCEDURE|Abdominal tomodensitometry|
47976490|NCT02283697|BEHAVIORAL|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
48493641|NCT02027675|OTHER|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
48493642|NCT02027675|OTHER|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
48493643|NCT04435821|DRUG|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection.
48493644|NCT01053234|DIETARY_SUPPLEMENT|Standardised meals|
48334874|NCT01525056|RADIATION|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
48493645|NCT03564418|PROCEDURE|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|"Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
48653249|NCT05524480|BEHAVIORAL|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
48334875|NCT04101344|OTHER|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
48334876|NCT00308321|DRUG|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
48127796|NCT04291638|BEHAVIORAL|Remote Intensive Group Behavioral Treatment (IGBT)|The remote IGBT is a 5-day videoconferencing-based treatment program that delivers cognitive behavioral therapy to children and their caregivers in a group format across 2-3 hours per day.
48334877|NCT00308321|DRUG|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
48334878|NCT02722629|PROCEDURE|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
48334879|NCT05301413|BEHAVIORAL|Culturally Tailored Diabetes Prevention Program|This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
48334880|NCT05301413|BEHAVIORAL|Culturally Tailored DPP Enhanced with Socioeconomic Supports|This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources
48653250|NCT05524480|BEHAVIORAL|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
48653251|NCT01321905|DIETARY_SUPPLEMENT|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
48653252|NCT06639269|OTHER|fertility health education program|"The intervention group will be implemented with a fertility health education program for which a literature information document will be created. In the training; booklets and brochures will be prepared. The control unit will include information on programming and data collection forms to be used. Those selected from the intervention group will be divided into groups of 10-15 people. The training program will consist of 3 sessions. Training sessions will be planned on days and hours that are convenient for the researcher, classrooms and students. For students who cannot attend group training, make-up training will be provided within a week. In this study, the time between sessions will be planned as 1 week. The sessions in this study will be planned to be in groups of 10-15 people and will last 50 minutes."
48653253|NCT02184013|PROCEDURE|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
48653254|NCT06645301|BIOLOGICAL|Group A|BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
48653255|NCT06645301|BIOLOGICAL|Group B|BGT007 6.0×10\^8cells,Intravenous infusion，6 subject is planned to be enrolled
48653256|NCT04270019|DRUG|Polyethylene Glycol 3350|In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
48653257|NCT04270019|DRUG|Normal Saline|Standard solution of sterile normal saline.
48334881|NCT05301413|BEHAVIORAL|Diabetes Prevention Program|This is the CDC TD2 evidence-based Diabetes Prevention Program
48334882|NCT01410162|DRUG|Tacrolimus|tacrolimus extended release capsules vs Prograf
47976491|NCT02283697|OTHER|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
47976492|NCT03583489|DRUG|APD421|10 mg IV
47976493|NCT03583489|DRUG|Placebo|IV
47976494|NCT03583489|DRUG|Ondansetron|4 mg IV
47976495|NCT01813591|DRUG|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
47976496|NCT03915496|DRUG|PF-04965842 200 mg|PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
47976497|NCT03915496|DRUG|PF-04965842 100 mg|PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
47976498|NCT03915496|DRUG|Placebo|Placebo administered as two tablets to be taken orally once daily for 12 weeks
48127797|NCT02629679|BEHAVIORAL|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
48127798|NCT02629679|BEHAVIORAL|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
48127799|NCT03628313|OTHER|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
48127800|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
48127801|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
48127802|NCT02019459|OTHER|Very low nicotine content cigarettes|
48127803|NCT02019459|OTHER|standard nicotine content cigarettes|
48127804|NCT02405559|DRUG|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
48127805|NCT03494959|DRUG|Pentaglobin|Antimicrobial treatment active against the multidrug-resistant strain should be started in case of neutropenic fever (oral temperature ≥38.3°C or temperature ≥38.0°C sustained over a one-hour period). Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days. Empirical treatment should be subsequently streamlined according to microbiological results (both positive and negative). Pentaglobin should be started within 12h from the onset of fever, regardless of the presence of hemodynamic stability.
48127806|NCT01863485|DRUG|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
48127807|NCT04354389|DRUG|DAS181|4.5 mg b.i.d
48127808|NCT04354389|DRUG|Placebo|q.d. or b.i.d.
48127809|NCT04354389|DRUG|DAS181|4.5 mg q.d.
48127810|NCT03803748|DEVICE|Eyestil Plus®|• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
48127811|NCT05912088|BEHAVIORAL|Intervention Group|Subjects will participate in groups of about 14 to implement the program.
48127812|NCT05912088|BEHAVIORAL|Control Group|Subjects will receive the usual care advice
48127813|NCT01463176|BEHAVIORAL|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
48127814|NCT03976557|DEVICE|BIP CVC|Central venous access with noble metal coated CVC
48334883|NCT05610722|DEVICE|DreaMed Endo Digital|The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
48334884|NCT03982745|DEVICE|bonfils|bonfils intubation
47976499|NCT05397821|PROCEDURE|UNC technique|In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
47976500|NCT03291054|DRUG|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
47976501|NCT03291054|DRUG|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
47976502|NCT01634360|DRUG|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
48127815|NCT03976557|DEVICE|Standard CVC|Central venous access with standard uncoated CVC
48127816|NCT00018096|BIOLOGICAL|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
48127817|NCT05225753|DIAGNOSTIC_TEST|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
48127818|NCT03166085|DRUG|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
48127819|NCT03166085|DRUG|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
48127820|NCT02040831|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
48127821|NCT02040831|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
48127822|NCT02877797|DEVICE|Cap|cap assisted esophagogastroduodenoscopy
48334885|NCT04853589|DEVICE|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
48334886|NCT04853589|DEVICE|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
48334887|NCT00531492|BEHAVIORAL|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
48334888|NCT00531492|OTHER|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
48493646|NCT03564418|PROCEDURE|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|"Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
48653258|NCT05440565|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test can concentrate the high-risk population.
48334889|NCT00048789|PROCEDURE|Extracorporeal Photopheresis|
48334890|NCT02565498|RADIATION|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
48334891|NCT02565498|RADIATION|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
48334892|NCT01699646|DEVICE|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
48334893|NCT01699646|PROCEDURE|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
47976503|NCT02820272|PROCEDURE|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
47976504|NCT02820272|PROCEDURE|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
48334894|NCT00665678|DRUG|paroxetine|treatment for three months with paroxetine
48653259|NCT05440565|DIAGNOSTIC_TEST|APCS score|APCS score can concentrate the high-risk population.
47976505|NCT02820272|PROCEDURE|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
47976506|NCT00023634|BIOLOGICAL|KLH|100 mcg w/EGFRvIII
47976507|NCT00023634|BIOLOGICAL|GMCSF|arm 1: 100 mcg w/EGFRvIII
47976508|NCT01214811|DEVICE|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
47976509|NCT04285879|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
47976510|NCT01366690|BEHAVIORAL|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
47976511|NCT03730246|PROCEDURE|cesarean sectio|consecutive parturients due for cesarean sectio
48334895|NCT00665678|DRUG|placebo|treatment for three months with placebo
48334896|NCT02964988|DRUG|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
47976512|NCT02031107|DEVICE|cTBS|
48334897|NCT02964988|DEVICE|PET/CT|Whole body PET/CT
47976513|NCT02031107|DEVICE|cathodal tDCS|
48334898|NCT00927758|DRUG|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
48334899|NCT05817955|DRUG|Azacitidine (AZA) with Ruxolitinib|"1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture."
48334900|NCT00756704|BEHAVIORAL|Smoking cessation guideline implementation|"1. a tutorial on brief cessation counseling for ED nurses and physicians~2. use of an ED algorithm that includes recommended tobacco counseling items~3. fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~4. group feedback to ED staff"
48334901|NCT02313922|DRUG|etanercept combined with methotrexate or etanercept combined with placebo|
47976514|NCT02031107|DEVICE|sham stimulation|
47980546|NCT04426981|BEHAVIORAL|Behavioral Activation|Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
47980547|NCT00508807|DRUG|RTA 402|5 mg by mouth (PO) daily for 21 days
48334902|NCT04083950|BIOLOGICAL|Vivotif Typhoid Oral Vaccine|One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
48334903|NCT04083950|DRUG|Aspirin (Positive Control)|Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
48334904|NCT05287607|DIAGNOSTIC_TEST|Urine sample for carbonic anydrase (I) levels|Point of care diagnostic device used routinely for non-invasive estimation of serum bilrubin level.
48334905|NCT00018018|DRUG|CD34+ cells transduced with ADA retrovir|
48334906|NCT04167514|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
48334907|NCT04167514|DRUG|Placebo|Albumin solution administered intravenously
48334908|NCT02077504|OTHER|MEG and MRI|CONDUCTOME
48334909|NCT02177175|DRUG|Carvedilol|
48334910|NCT02177175|OTHER|placebo|
48334911|NCT05304572|DIAGNOSTIC_TEST|Multi-Detector CT angiography|Multiphasic CT within 4 weeks interval prior to TACE will be done including non-enhanced, arterial, portal and venous phases using IV bolus injection of a 75-100-mLiodinated contrast material iopamidol at a rate of 3.0 mL/s. The images of arterial phase will be transferred to workstation to produce 3D angiographic reconstruction images .
48334912|NCT05304572|PROCEDURE|Trans-arterial chemoembolization and DSA|Percutaneous arterial access is achieved through the common femoral artery (19 G needle) under local anesthesia with placement of a 5-Fr sheath. A 5-Fr Cobra (C2) or sidewinder (SIM1) catheter was used for catheterizing the coeliac trunk and SMA. Then celiac and superior mesenteric angiography was done by injecting 24 mL of iopamidol using forced manual injection method or using a pump at a rate of 6 mL/s according to the operator preferences.Then a microcatheter was used for selective and super-selective access of the hepatic arteries. The micro-catheter was placed in the feeding artery as close as possible to the tumor.The chemotherapeutic drugs (Doxorubicin 50 mg) solved within 5 ml of iodinated non-ionic contrast media and then mixed with 10 ml of iodized oil (lipiodol) will be delivered through the feeding hepatic artery and then embolized using Poly-vinyl Alcohol (PVA) particles.
48334913|NCT03082417|OTHER|Implementation|"The PAINFREE Initiative is a Multifaceted intervention:~1. Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures~2. Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures~3. Inform the patients and their family about how to better manage the pain after a fracture"
48334914|NCT03419936|DIAGNOSTIC_TEST|Endoscopic biopsy|"1. Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~2. Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~3. Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~4. Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy."
48334915|NCT00105755|DEVICE|personal dermal thermometer (DT)|
48334916|NCT00105755|DEVICE|Device|
48334917|NCT05733260|BEHAVIORAL|Exercise|10 weeks of resistance training.
48334918|NCT00209170|BEHAVIORAL|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
48334919|NCT00209170|DRUG|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
48334920|NCT00209170|DRUG|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
48334921|NCT06081699|DRUG|TNP-2198|Oral
48334922|NCT06081699|DRUG|TNP-2198 Placebo|The placebo for TNP-2198 active drug
48334923|NCT01924962|DEVICE|revascularisation|revascularisation of chronic occluded coronary artery
48334924|NCT00157170|BEHAVIORAL|supervised exercise|
48334925|NCT03770195|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
48334926|NCT01878097|BEHAVIORAL|Green Dot Bystander Intevention|Intervention allocated at the school level
48334927|NCT01878097|BEHAVIORAL|Control|Awareness Education
48334928|NCT03273504|OTHER|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
48334929|NCT03273504|OTHER|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
48334930|NCT01451398|DRUG|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
48334931|NCT01451398|DRUG|Technosphere Powder|Placebo Comparator
48334932|NCT03626740|OTHER|TheraCal|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
48334933|NCT03626740|OTHER|MTA|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
48334934|NCT05989295|DIETARY_SUPPLEMENT|probiotic LRa05|treatment about 12 weeks
48334935|NCT01985971|RADIATION|PET/CT Imaging|
48334936|NCT01535768|DRUG|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
48334937|NCT01110226|DRUG|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
48334938|NCT01110226|DRUG|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
48334939|NCT04009460|DRUG|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
48653260|NCT04650893|DRUG|Intravenous Ketorolac|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
48653261|NCT04650893|DRUG|Intravenous Dexamethasone|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
48653262|NCT04650893|DRUG|Placebo|Control
48653263|NCT00615160|DRUG|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
48334940|NCT06527196|BEHAVIORAL|Team Communication Training|Participants in the experimental arm will receive enhanced Team Communication Training developed during Aim I of the trial. This will occur over a period of six months.
48334941|NCT06527196|BEHAVIORAL|Early Identification Universal Depression Screening|Providers in the early identification universal depression screening condition will be asked to continue communications and response to depression screening as currently implemented.
48334942|NCT03242304|OTHER|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
48334943|NCT03365947|DRUG|ARO-HBV|sc injection
48334944|NCT03365947|OTHER|Sterile Normal Saline (0.9% NaCl)|sc injection
48334945|NCT03365947|DRUG|JNJ-56136379|oral tablets
48334946|NCT01001728|RADIATION|Imaging investigations (with radiation)|
48493647|NCT01501136|OTHER|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
48493648|NCT01501136|OTHER|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
48266501|NCT04723576|BEHAVIORAL|Stress First Aid|"Stress First Aid (SFA) is an evidence-based intervention to mitigate the psychosocial impact of COVID-19 on Health Care Workers (HCWs). SFA was initially developed for the United States Navy and Marine Corps as a framework of actions for peer support delivered by individuals without mental health training. SFA is designed to teach simple, supportive actions that can be seamlessly integrated into work environments. SFA training focuses on five essential principles: cover (restore and support a sense of safety), calm (encourage simple strategies such as breathing), connect (engage in and promote social support), competence (improve ability to address crucial needs and concerns), and confidence (increase hope and limit self-doubt and guilt). In this study, we are adapting the SFA model to include HCW-specific examples of SFA actions and case scenarios specific to the COVID-19 pandemic and will implement SFA using a train-the trainer model."
48334947|NCT00809861|PROCEDURE|volar locking plating|open reduction and internal fixation
48334948|NCT00809861|PROCEDURE|external immobilisation|closed reduction and external fixation
48334949|NCT01052181|DRUG|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
48334950|NCT01052181|DRUG|placebo|2 sachets monthly for an year
48334951|NCT03936270|DRUG|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
48334952|NCT03936270|DRUG|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
48334953|NCT06045728|OTHER|Pilates exercises|Pilates is a group of low impact muscle exercises that strengthen abdominal muscles, back, hips and pelvic floor muscles. the exercise consists of 10 min warm up, 40 min exercise and 10 min cooling down. the exercises that will be included: spine twist, double leg stretch, double leg circles, side leg circle, curl up, shoulder bridges and pelvic curl.
48334954|NCT06045728|BEHAVIORAL|Mediterranean diet|it is a type of diet used for obesity management based on high vegetable intake, olive oil as a source of fat, the consumption of grains, legumes, and nuts with high amounts of pulp, low-medium consumption of fish, low consumption of red meat.
48334955|NCT00900445|DRUG|Daunorubicin Hydrochloride|Given IV
48334956|NCT00900445|OTHER|Pharmacological Study|Correlative studies
48334957|NCT00900445|DRUG|Prednisolone|Given orally
48334958|NCT00900445|DRUG|Prednisone|Given orally
48334959|NCT00900445|DRUG|Vincristine Sulfate|Given IV
47980548|NCT04533698|OTHER|Assessment of reason for resternotomy|No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
47980549|NCT04533698|OTHER|Assessment of reason for avoidance of resternotomy|No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
48334960|NCT00425100|DRUG|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
48334961|NCT04821960|BEHAVIORAL|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
48653264|NCT00615160|DRUG|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
48653265|NCT02695186|PROCEDURE|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
48334962|NCT04821960|BEHAVIORAL|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
48334963|NCT05959304|OTHER|brolucizumab|There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
48334964|NCT02320968|OTHER|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
48334965|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-NA)|Root canal treatment procedures explained in arm descriptions.
48334966|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-EA)|Root canal treatment procedures explained in arm descriptions.
48334967|NCT06403293|PROCEDURE|Root canal treatment (BC-NA)|Root canal treatment procedures explained in arm descriptions.
48334968|NCT06403293|PROCEDURE|Root canal treatment (BC-EA)|Root canal treatment procedures explained in arm descriptions.
48334969|NCT01274117|PROCEDURE|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
48334970|NCT00443937|DRUG|enteric-coated mycophenolate sodium|oral
48334971|NCT00443937|DRUG|everolimus|oral
48334972|NCT00967226|DRUG|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
48334973|NCT00967226|DRUG|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
48334974|NCT02617017|DRUG|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
48334975|NCT02617017|DRUG|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
48334976|NCT04467632|OTHER|Validation of the mobility assessment by IMU wearable sensors|"The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4."
48493649|NCT01501136|OTHER|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
48493650|NCT01501136|OTHER|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
48334977|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity)."
48334978|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Intervention phase~* Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~  * Day #1: baseline assessment of outcome measures;~ * Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~ * Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~* Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~* Phase B (11 days): similar as in phase A:~  * Day #1: similar as in phase A;~ * Days #2 to #6: reverted conditions compared to phase A.~ * Days #7 to #11: reverted conditions compared to phase A."
48493651|NCT01501136|RADIATION|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
48493652|NCT02961166|DRUG|IgM enriched Immunoglobulins|Treatment for 3 days
48493653|NCT04284995|DRUG|RUC-4 Compound|All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
48493654|NCT04146311|DRUG|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
48493655|NCT04146311|DRUG|isotonic saline|A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
48493656|NCT04146311|OTHER|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
48653266|NCT03164993|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
48653267|NCT03164993|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
48653268|NCT03164993|DRUG|Cyclophosphamide|Chemotherapy
48653269|NCT03164993|OTHER|Placebo|Placebo
48653270|NCT06636903|OTHER|Acupressure|Before pressing directly on the point for acupressure, a gentle warming, relaxing and preparatory process of approximately 15 seconds should be performed on the point area. In this case, manual pressure with the thumb, index finger and/or middle finger will be applied sequentially (in the rhythm of breathing) without lifting the finger for an average of 1.5 minutes on each point, at a frequency that does not disturb the person, does not cause pain and has a calming effect. Before the suturing procedure, acupressure will be applied to the HT7 and Li4 points by a researcher (EB) who has an acupressure certificate.
48653271|NCT06636903|OTHER|Acupressure|Before and after acupressure, vital signs and before acupressure, anxiety scores will be checked using the Spielger State Anxiety Scale. In addition, vital signs and anxiety scores will be checked again immediately after the stitching procedure.
48653272|NCT06549608|DRUG|Mavacamten|As per product label
48653273|NCT04606290|DEVICE|O2matic HOT|Automated oxygen titration with O2matic HOT
48653274|NCT04606290|DEVICE|Oxygen concentrator|Fixed dose oxygen flow from concentrator
47976515|NCT03924973|BEHAVIORAL|ESDM followed by treatment as usual|"The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration)."
48127823|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
48127824|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
47976516|NCT03542981|DEVICE|Interferential Current|
47976517|NCT03542981|DEVICE|Sham Interferential Current|
47976518|NCT00748683|OTHER|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
48127825|NCT00649805|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
48127826|NCT00649805|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
48127827|NCT02627391|OTHER|Early surgical aortic valve replacement|
48334979|NCT04154917|OTHER|HOME|HOME's focus is on the person's functional ability, safety and transition from hospital to home. HOME will be delivered by a community-based clinician (OT who will be involved in the hospital discharge planning) trained by the PI. Training will include two sessions covering assessment of functional ability, goal setting and home safety. The clinician will keep a record of recommendations provided, length of home visit and any adverse events during the intervention. Twice over the course of the study, the PI leader will observe the clinician conducting HOME interventions to assess adherence to the study protocol using a fidelity checklist. The HOME intervention comprises 4 phases, which are described in the arms section.
48334980|NCT05875246|BEHAVIORAL|Micro-interventions|Group 1: No intervention Group 2: Brief stress reduction messages Group 3: App based stress reduction audio activity
47976519|NCT05471622|BEHAVIORAL|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
47976520|NCT06066684|OTHER|n/a, observational|n/a, observational study
47976521|NCT03983291|BEHAVIORAL|FaReWell Depression|Facial massage and force exercise
48127828|NCT02627391|OTHER|Delayed Surgical aortic valve replacement|
48127829|NCT03789734|BIOLOGICAL|BLS-M22|BLS-M22 250mg/capsule
48127830|NCT03789734|OTHER|Placebo|BLS-M22 placebo 250mg/capsule
48334981|NCT04429321|DRUG|Nivolumab|Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone
48334982|NCT04429321|DRUG|Ipilimumab|ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab
48334983|NCT04429321|DEVICE|bland embolization|Lipiodol:ethanol embolization of their primary or target tumor
48334984|NCT05625633|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20
48334985|NCT05625633|OTHER|Normal Saline|0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
48493657|NCT01045174|DEVICE|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
48493658|NCT04906083|DRUG|Avatrombopag|"Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d."
48493659|NCT04906083|DRUG|Standard medical treatment|Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
48493660|NCT01007942|DRUG|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
48493661|NCT01007942|DRUG|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
48493662|NCT01007942|DRUG|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
48334986|NCT00395213|DRUG|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
48334987|NCT05670249|PROCEDURE|suboccipital decompressive craniectomy|extensive bilateral suboccipital decompressive craniectomy with duraplasty
48334988|NCT06216197|DRUG|FENT group|Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
48334989|NCT06216197|DRUG|DEX group|The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
48334990|NCT03439111|DIETARY_SUPPLEMENT|Standardized Lycium chinense Fruit Extract (LCF) capsules|All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
48334991|NCT02185248|BEHAVIORAL|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
48334992|NCT01287598|DRUG|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
48334993|NCT01287598|DRUG|Warfarin|CYP 2C9 (warfarin) at Cycle 1
48493663|NCT01007942|DRUG|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
48493664|NCT00361062|BEHAVIORAL|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
48493665|NCT01841775|DRUG|interferon α 2b + ribavirin|"1. interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~2. ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
48127831|NCT03631238|DIAGNOSTIC_TEST|Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.|"all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer."
48493666|NCT00712426|DRUG|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
48334994|NCT01287598|DRUG|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
48334995|NCT01287598|DRUG|Midazolam|CYP 3A4 (midazolam) at Cycle 1
48493667|NCT00712426|DRUG|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
48334996|NCT01287598|DRUG|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
48334997|NCT06170281|BEHAVIORAL|Migraine Behavioral Treatment|Migraine Behavioral Treatment involving daily activities
48334998|NCT04712487|DIAGNOSTIC_TEST|Microbiological culture, viral PCR, histopathological analysis|"Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue"
48334999|NCT06453772|PROCEDURE|Liposuction|Primary or secondary liposuction is performed by the surgical staff. The study analyzed variables including weight, height, BMI, preoperative hemoglobin, and aspirated volume. Additionally, preoperative hemoglobin (Hb), hematocrit (Hto), platelets, prothrombin time (Tp), partial prothrombin time (TpT), and International Normalized Ratio (INR) were evaluated. Hb and Hto levels were reassessed 24 hours post-surgery to monitor changes.
48335000|NCT02979366|DRUG|S64315 once a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
48493668|NCT03693573|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
47976522|NCT03495362|DIETARY_SUPPLEMENT|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
48127832|NCT00201149|BEHAVIORAL|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
48127833|NCT02663219|BEHAVIORAL|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
48127834|NCT03973034|DIAGNOSTIC_TEST|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
47976523|NCT03495362|OTHER|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
47976524|NCT03266094|DEVICE|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
47976525|NCT02809456|DRUG|Nicorandil|oral intake
47976526|NCT04580953|DEVICE|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
48127835|NCT03951805|DRUG|Insulin icodec|Administered subcutaneously SC once weekly. Starting dose will be 70U.
48127836|NCT03951805|DRUG|Insulin Glargine|Administered subcutaneously SC once daily.The starting dose will be 10U.
48127837|NCT01222442|DRUG|AZD3199|Single dose, oral inhalation
48127838|NCT01222442|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
47976527|NCT06254404|DRUG|Low dose protamine|Administration of 70% of the normal dose of protamine
48127839|NCT01222442|OTHER|Placebo comparator|Single dose, oral inhalation
48127840|NCT01541059|DRUG|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
48127841|NCT01541059|DRUG|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
48127842|NCT04680845|BEHAVIORAL|Self-affirmation|According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
48127843|NCT03746470|PROCEDURE|ACL reconstruction preserving insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.
47976528|NCT03024450|DRUG|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
48335001|NCT02979366|DRUG|S64315 twice a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
48335002|NCT04984564|OTHER|None. As this was an observational study.|Observational study.
47980550|NCT02329249|BEHAVIORAL|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
48127844|NCT03746470|PROCEDURE|ACL reconstruction detaching insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
48127845|NCT02984332|OTHER|Lower limb immobilisation (leg brace)|
48127846|NCT05780619|DIAGNOSTIC_TEST|Transcranial Doppler|Measurement of resistance index on the middle cerebral artery (MCA) (index test) and the Holter (reference test). Patients will be randomized for order of tests
48127847|NCT01581372|OTHER|Pharmacist care|Pharmacist prescribing, education, drug management
48127848|NCT05927220|DIAGNOSTIC_TEST|Biopsy Specimens Histopathology|paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
48127849|NCT01715194|DEVICE|Telemedicine intervention|Patients undergoing telemedicine intervention
48127850|NCT02731599|PROCEDURE|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
48127851|NCT05142046|DRUG|Fluid balance|The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
48127852|NCT00212251|BEHAVIORAL|moderate exercise and healthy, low-fat diet|
47980551|NCT02329249|OTHER|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
48127853|NCT01718600|BEHAVIORAL|Neuropsychological testing|
47980552|NCT03084029|DRUG|Oxytocin|40 international units
48653275|NCT05686486|OTHER|Tai Chi inspired gymnastics|"The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance."
48653276|NCT06642116|DEVICE|OCEAN|Biodegradable nasal dressing
48653277|NCT03186157|PROCEDURE|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
48653278|NCT03186157|PROCEDURE|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
48653279|NCT00070083|BIOLOGICAL|oblimersen sodium|
48653280|NCT00070083|BIOLOGICAL|rituximab|
48127854|NCT05176054|OTHER|Health service program|The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
48127855|NCT03814369|DEVICE|AmplifEYE|AmplifEYE colonoscopy
48127856|NCT00769353|BEHAVIORAL|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
48127857|NCT00769353|BEHAVIORAL|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
48127858|NCT03992274|OTHER|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
48127859|NCT03750539|RADIATION|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
48127860|NCT03750539|RADIATION|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
48127861|NCT03750539|PROCEDURE|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
48127862|NCT00423020|DRUG|Erythropoietin|
48127863|NCT05222646|DRUG|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
48335003|NCT03048942|DRUG|Cabazitaxel|3 weekly cyctotoxic chemotherapy
48493669|NCT03693573|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
48653281|NCT00070083|DRUG|cyclophosphamide|
48653282|NCT00070083|DRUG|doxorubicin hydrochloride|
48653283|NCT00070083|DRUG|prednisone|
48127864|NCT02966613|DEVICE|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
48127865|NCT04045301|BIOLOGICAL|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
48127866|NCT04045301|BIOLOGICAL|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
48127867|NCT04045301|BIOLOGICAL|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
48127868|NCT04045301|OTHER|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
48127869|NCT05602207|DRUG|Abrocitinib|100 mg Abrocitinib once daily (QD) for 12 weeks
48127870|NCT02362867|DEVICE|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
48127871|NCT00003222|BIOLOGICAL|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
48127872|NCT00003222|BIOLOGICAL|gp100 antigen|
48127873|NCT00003222|BIOLOGICAL|incomplete Freund's adjuvant|
48335004|NCT03048942|DRUG|Paclitaxel|Weekly cyctotoxic chemotherapy
48335005|NCT03610906|PROCEDURE|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
48335006|NCT04310878|OTHER|Survey among perioperative nurses and surgeons|Online survey
48653284|NCT00070083|DRUG|vincristine sulfate|
48653285|NCT06643039|BIOLOGICAL|Nasopharyngeal swab|Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.
48653286|NCT06643039|OTHER|Questionnaire|questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
48653287|NCT01166698|DRUG|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
48653288|NCT01166698|DRUG|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
48653289|NCT01166698|DRUG|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
48127874|NCT00003222|BIOLOGICAL|sargramostim|
48127875|NCT00003222|BIOLOGICAL|tetanus peptide melanoma vaccine|
48127876|NCT00003222|BIOLOGICAL|tyrosinase peptide|
48127877|NCT05566249|DEVICE|ArtiSential|Articulating laparoscopic instrument
48127878|NCT00998413|BEHAVIORAL|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
48127879|NCT04121546|BEHAVIORAL|Telecare Intervention|Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
48127880|NCT03488745|BEHAVIORAL|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
48127881|NCT04352400|DRUG|Nafamostat Mesilate|administered intravenously as a continuous infusion
48127882|NCT04352400|DRUG|Placebo|administered intravenously as a continuous infusion
48127883|NCT01816672|DEVICE|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
48127884|NCT01816672|OTHER|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
48127885|NCT00800579|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
48127886|NCT00800579|DRUG|Placebo|Inhaled volume-matched placebo in sterile saline
48127887|NCT05051982|DEVICE|Sedline EEG in View|EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
48335007|NCT01613508|PROCEDURE|Direct Anterior Approach|
48335008|NCT01613508|PROCEDURE|Mini-Posterior Approach|
48653290|NCT06454188|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day.
48653291|NCT06454188|DRUG|Placebo|15mg tablet once per day.
48127888|NCT06328868|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48127889|NCT06328868|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48335009|NCT02284230|DRUG|Liraglutide|
48335010|NCT02284230|DRUG|Placebo|
48335011|NCT05129761|DRUG|Syrup Hydryllin|( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
48335012|NCT06258863|PROCEDURE|incision type|Total mastectomy was performed using one of the four incision types
48335013|NCT05242978|OTHER|Nutrition|acute single dose nutrition intervention
48335014|NCT05506696|DIETARY_SUPPLEMENT|Fultium|3200IU Fultium
48335015|NCT00091962|BEHAVIORAL|Psychoeducation; Treatment recommendations|Counseling program
48335016|NCT00091962|DRUG|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
48335017|NCT00091962|OTHER|Usual Care|Physicians' Usual care
48335018|NCT00271271|DRUG|oxaliplatine / gemcitabine / Vinorelbine|
48335019|NCT03824535|PROCEDURE|Computed Tomography|Undergo PET/CT
48335020|NCT03824535|DRUG|Fludeoxyglucose F-18|Given IV
48335021|NCT03824535|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
48335022|NCT03824535|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48493670|NCT00128414|DRUG|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
48493671|NCT00128414|DRUG|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
48653292|NCT06539442|DEVICE|Versius Surgical System|Urological minimal access surgery performed with Versius Surgical System
48653293|NCT06010719|DRUG|Azithromycin|oral azithromycin (20 mg/kg, single directly observed dose, oral suspension),
48653294|NCT06010719|DRUG|Amoxicillin|Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
48653295|NCT06010719|OTHER|Placebo|A 7-day, twice-daily course of placebo will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
48653296|NCT03241615|OTHER|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
48653297|NCT01821872|DRUG|Administration of paracetamol|Administration of 1g intravenous paracetamol
48653298|NCT01486329|BIOLOGICAL|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
48653299|NCT01486329|BIOLOGICAL|Placebo|Drink solution
48653300|NCT03538457|DRUG|Paracetamol|Patients are tested for their normal prescription paracetamol medication
48653301|NCT03340116|PROCEDURE|Burn surgery|Burn surgery including wound debridement, skin grafting
48653302|NCT03340116|DIAGNOSTIC_TEST|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
48653303|NCT06642285|PROCEDURE|Non Invasive Respiratory Support bundle|premature neonates who will receive evidence-based guidelines for prevention of nasal pressure injuries associated with non invasive respiratory support till weaning
48127890|NCT06328868|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
47976529|NCT06051929|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
47976530|NCT00284050|DRUG|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
47976531|NCT00284050|DRUG|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
48335023|NCT02670928|BEHAVIORAL|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
47976532|NCT00284050|DRUG|Sham injection|Non-treatment control for sham intravitreal injection.
48127891|NCT03529305|DEVICE|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
48335024|NCT01925391|DRUG|Tono-pen XL Applanation tonometer + Ocu-film +|
48335025|NCT02681718|BEHAVIORAL|Community health worker education|Diabetes self-management education by community health workers
48335026|NCT02681718|BEHAVIORAL|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
48335027|NCT01929213|DRUG|Udenafil|Udenafil is administered
48335028|NCT01929213|DRUG|Bosentan|Bosentan is administered
48335029|NCT01929213|DRUG|Udenafil/Bosentan|Udenafil and Bosentan are administered
47976533|NCT03066089|DRUG|Fenfuro|
47976534|NCT05660551|OTHER|Demostration|This group will be demonstrated on a model after the theoretical training. The maneuvers used in the management of shoulder dystocia will be shown to the students on the model, respectively.
47976535|NCT05660551|OTHER|Telesimulation|After the theoretical training for this group, telesimulation will be applied. A scenario will be created for the telesimulation experience and a video will be shot with this scenario. These videos will be watched by the students in groups of 4 on Microsoft Teams and a case discussion will be made through this scenario.
48127892|NCT03529305|OTHER|Physical therapy|Receive physical therapy
48266502|NCT05708391|DRUG|Realgar-Indigo Naturalis Formulation|"Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight"
48335030|NCT06508177|OTHER|İnterfascial plane block|Interfascial plane blocks will be added to the routine analgesia plan as part of multimodal analgesia.
48335031|NCT06508177|OTHER|Standart analgesia plan|This is the routine analgesia plan applied in our clinic.
48335032|NCT01726816|DRUG|Probucol 250mg/day|Probucol 250mg + Placebo
48335033|NCT01726816|DRUG|Probucol 500mg/day|Probucol 500mg + Placebo
48335034|NCT01726816|DRUG|Placebo|Probucol matching placebo
48653304|NCT04642976|DEVICE|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
48653305|NCT00543127|DRUG|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
48653306|NCT00543127|DRUG|Anastrozole|1 mg oral Anastrozole per day during 5 years.
48653307|NCT02075684|PROCEDURE|Renal Biopsy|
48653308|NCT03066180|DEVICE|Viveve SUI treatment|Non-ablative radiofrequency treatment with surface cooling
48335035|NCT00215241|DRUG|sertraline and risperidone|
48335036|NCT03380000|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
48335037|NCT03380000|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
48335038|NCT01800851|OTHER|Energy expenditure evaluation in calorimetric chamber|
48335039|NCT01875913|BEHAVIORAL|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
48335040|NCT01875913|BEHAVIORAL|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
48493672|NCT00666783|DRUG|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
47976536|NCT05660551|OTHER|Kahoot Game|Kahoot, a game-based program, will be applied to this group one week after the theoretical training. The game will be organized according to the learning objectives and achievements related to shoulder dystocia.
48493673|NCT00666783|DRUG|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
48653309|NCT05809700|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
48653310|NCT02370342|PROCEDURE|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
48335041|NCT01960829|DRUG|Everolimus|
48335042|NCT03177967|BEHAVIORAL|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
48335043|NCT03177967|OTHER|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
48653311|NCT02370342|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
48493674|NCT00682682|OTHER|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
48493675|NCT00682682|OTHER|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
48493676|NCT06405282|OTHER|Manual Lymphatic Drainage|MLD is a gentle manual technique used to decongest swollen areas and redirect lymphatic flow to non-congested areas
48493677|NCT06405282|DEVICE|Near infrared spectroscopy|Oxygen saturation measurement
48493678|NCT06405282|DEVICE|Temperature|Thermal imaging
48493679|NCT06405282|DEVICE|Tissue Dialectic Constant|TDC captured by lymphatic fluid scanning device
48493680|NCT03247517|DRUG|Placebo|Placebo was administered once daily
48493681|NCT03247517|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
48653312|NCT02370342|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
48653313|NCT02370342|DEVICE|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
48653314|NCT04147286|DRUG|Atorvastatin 40mg|12 weeks of 40 mg atorvastatin therapy per os
48653315|NCT04147286|DRUG|Placebo oral tablet|Identical placebo
48653316|NCT06639152|DRUG|oil-based contrast medium|In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.
47976537|NCT04942691|OTHER|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
47980553|NCT03084029|DRUG|Placebo|40 international units
48335044|NCT03177967|OTHER|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
48493682|NCT03247517|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
48493683|NCT03195777|DEVICE|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, \[FDG\] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
48653317|NCT06639152|DRUG|water-based contrast medium|In water group, Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml) was used as the contrast medium for hysterosalpingography.
48653318|NCT02402647|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
48127893|NCT04646733|OTHER|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
48127894|NCT04646733|OTHER|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
48493684|NCT02188511|OTHER|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to \< 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
48493685|NCT02188511|OTHER|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
48653319|NCT02402647|BEHAVIORAL|Exposure Therapy (ET)|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
47976538|NCT02128178|DRUG|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
47976539|NCT02128178|DRUG|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
47976540|NCT02588807|DRUG|Spirit1|Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
47976541|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills|Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
47976542|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills Placebo|Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
47976543|NCT05284214|BIOLOGICAL|Sargramostim|Sargramostim for injection
47976544|NCT05284214|BIOLOGICAL|Ipilimumab-containing therapy|Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..
47976545|NCT05496257|OTHER|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
47976546|NCT03535116|DRUG|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
47976547|NCT03535116|DRUG|Saline|injectable normal saline
47976548|NCT00881582|DRUG|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
47976549|NCT03446469|OTHER|Fascial Manipulation|Myofascial release of densified centers of coordination
47976550|NCT00890006|PROCEDURE|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
47976551|NCT00003170|DIETARY_SUPPLEMENT|glutamine|
47976552|NCT00003170|OTHER|placebo|
47976553|NCT01832987|DRUG|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
47976554|NCT03861351|DEVICE|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
47976555|NCT06066554|DEVICE|Puva (psoralin and uva )|Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
47976556|NCT00194064|DRUG|Olanzapine|
47976557|NCT03639298|DEVICE|Intendu|intensive training with Motion Based Cognitive Video Games Software
47976558|NCT05137106|OTHER|Active Dry Needling|All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
47980554|NCT01549444|OTHER|presence of maternal risk factor for hypertension|
48127895|NCT00754000|OTHER|Observation|AE monitoring and EPIC QOL survey
48127896|NCT03612375|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
48127897|NCT03612375|OTHER|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
48127898|NCT01778907|OTHER|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
48653320|NCT06570330|DIETARY_SUPPLEMENT|SuperHMO|Super HMO Prebiotic Mix: five major types of human milk oligosaccharides including 2'-Fucosyllactose (2'-FL), Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), 6'-Sialyllactose (6'SL), and 3'-Sialyllactose (3'SL)
48653321|NCT06570330|DIETARY_SUPPLEMENT|Non-GMO corn Maltodextrin, Rapid Absorption|he composition and absorption properties are similar to the investigational product and will be given in the same dosage (2.1g/day for days 1-5 and increasing to 4.2 g/day for days 6-30) and route of administration as the investigational product.
48653322|NCT06190379|OTHER|Essential oil blend|an aroma stick containing a blend of essential oils
48653323|NCT06190379|OTHER|Placebo|an aroma stick containing an inert blend of oils
48653324|NCT06150742|DEVICE|Niyad (nafamostat mesylate)|Niyad (nafamostat mesylate) lyophilized
47976559|NCT05137106|OTHER|Sham Dry needling|All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
47976560|NCT06171633|BEHAVIORAL|E-STOP online educational program (treatment condition)|Participants access online video modules through an online learning platform. Program includes modules on civility and upstander interventions and education about sexual harassment, microaggressions, and implicit bias.
47976561|NCT06171633|BEHAVIORAL|E-STOP online educational program (control condition)|Participants access online video modules through an online learning platform. Program includes authorship ethics only.
47976562|NCT06310720|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
47976563|NCT04620993|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
47976564|NCT04620993|OTHER|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
47976565|NCT04620993|OTHER|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
47976566|NCT03334448|DRUG|LY900014-U200|Administered SC
47976567|NCT03334448|DRUG|LY900014-U100|Administered SC
48127899|NCT01462149|DRUG|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
48127900|NCT01462149|DRUG|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
48127901|NCT03277404|PROCEDURE|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
48127902|NCT03277404|PROCEDURE|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
48127903|NCT00934817|DRUG|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
48335045|NCT01062828|DIAGNOSTIC_TEST|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
48335046|NCT01062919|PROCEDURE|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
47976568|NCT03415191|DRUG|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
47976569|NCT03415191|DRUG|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
48127904|NCT00934817|DRUG|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
48127905|NCT00032435|DRUG|PAL-40 Active|
48127906|NCT00032435|DRUG|PAL-40 Placebo|
48335047|NCT01062919|PROCEDURE|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
48335048|NCT02566616|DEVICE|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
48653325|NCT06150742|DEVICE|Placebo (0.9% NaCl)|0.9% NaCl
48653326|NCT05033561|BIOLOGICAL|nOPV2|Novel Oral Poliomyelitis Type 2 Vaccine
48335049|NCT05685719|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
48127907|NCT02796586|OTHER|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
48127908|NCT02587169|DRUG|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
48127909|NCT04172038|BEHAVIORAL|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
48127910|NCT04172038|BEHAVIORAL|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
48127911|NCT04172038|BEHAVIORAL|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~1. Mindfulness~2. Cognitive reappraisal~3. Savoring of positive experiences"
48127912|NCT02745249|BEHAVIORAL|Maternal Nutrition Behavior change|
48335050|NCT05685719|DRUG|Itraconazole|A strong CYP3A4 inhibitor
48335051|NCT05685719|DRUG|Rifampin|A strong CYP3A4 inducer
48335052|NCT04432740|PROCEDURE|Conservative Treatment of Distal Radius Fracture|The purpose of this prospective randomized study was to compare a new reverse sugar tong splint technique that does not immobilize the elbow with a below-arm cast, in terms of patient radiological and clinical outcomes and the ability to maintain fracture reduction.
48335053|NCT03970941|OTHER|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
48335054|NCT03970941|OTHER|Questionnaire|The quality of life of patients will be measured.
48335055|NCT03617913|DRUG|Avelumab|Given IV
48335056|NCT03617913|DRUG|Cisplatin|Given IV
48335057|NCT03617913|DRUG|Fluorouracil|Given IV
48335058|NCT03617913|DRUG|Mitomycin|Given IV
48127913|NCT04124432|DRUG|Cannabis|Cannabis will be smoked
48127914|NCT04124432|DRUG|Nicotine|Nicotine will be smoked or vaporized
48127915|NCT04216381|DIAGNOSTIC_TEST|Trauma Specific Frailty Index Questionnaire|questionnaire to assess patient's pre-injury health condition
48127916|NCT05398055|DRUG|Azithromycin + Doxycycline|azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
48127917|NCT05398055|DRUG|Placebo + Doxycycline|doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
48127918|NCT03807752|DIETARY_SUPPLEMENT|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
48127919|NCT03807752|DIETARY_SUPPLEMENT|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
48127920|NCT02550951|PROCEDURE|lymphangiography|
48127921|NCT00277277|BEHAVIORAL|Healthium|
48335059|NCT03617913|OTHER|Quality-of-Life Assessment|Ancillary studies
48335060|NCT03617913|RADIATION|Radiation Therapy|Undergo RT
48335061|NCT02750579|PROCEDURE|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
48335062|NCT00313248|DRUG|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
48335063|NCT00313248|DRUG|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
48335064|NCT05565157|PROCEDURE|Zygomatic implants|A robotic assisted new strategy for positioning zygomatic implants will be performed and its efficacy and accuracy will be assess
48335065|NCT04378257|BEHAVIORAL|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform.The link will direct the participant directly to a screen where they will be able to see and interact with the psychologist once a week. The sessions will be conducted in the Arabic or English languages.Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion"
48493686|NCT02188511|OTHER|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
48493687|NCT02188511|OTHER|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
48127922|NCT00278304|RADIATION|brachytherapy|
48335066|NCT04378257|BEHAVIORAL|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice. The participants will be requested to use this information to manage any distress that they might experience. On the sixth week, the participants in the control group will be assessed on their mood and anxiety symptoms. Participants will also be requested to provide information on other self-help remedies that participants used to improve or manage their functionality (example, access to other websites, communication with close friends or family etc.)
48335067|NCT05799209|DEVICE|Float Pool|Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
48335068|NCT05799209|DEVICE|Float Chair|Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
48335069|NCT05340062|DEVICE|bedside sonography|TCD and ONSD sonography twice a day per 2 days
48335070|NCT02567357|BEHAVIORAL|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
48335071|NCT02567357|BEHAVIORAL|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
47976570|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
48653327|NCT06637761|DRUG|NeoMTA2|Bio-active bio-ceramic mineral trioxide aggregate
47976571|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
47976572|NCT01411111|DRUG|Rosuvastatin 10 mg|days 1-14
47976573|NCT01411111|DRUG|GSK2190915 30mg|1x30mg tablet, days 8-14
47976574|NCT01411111|DRUG|GSK2190915 100mg|1x100mg tablet, days 8-14
47976575|NCT03918590|DRUG|nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|NSAID
47976576|NCT03918590|DRUG|Theratears tear drop, (Akron, Ann 111 Arbor, MI)|preservative-free Artificial Tears
47976577|NCT03918590|OTHER|patching|no drug/ patching
47976578|NCT02285790|DEVICE|Reflectance confocal microscopy|
47976579|NCT02285790|PROCEDURE|Punch biopsy|
48127923|NCT00278304|RADIATION|radiation therapy|
48127924|NCT00811941|DRUG|Placebo|as-needed use, tablets, orally, 52 weeks
47976580|NCT02285790|PROCEDURE|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
47976581|NCT03454893|DRUG|AVR-RD-01|Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.
47976582|NCT02970422|OTHER|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
47976583|NCT02259868|DRUG|BILR 355 BS /1B, current low dose formulation|
47976584|NCT02259868|DRUG|BILR 355 BS /1B, current high dose formulation|
47976585|NCT02259868|DRUG|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
48127925|NCT00811941|DRUG|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
48127926|NCT01746641|DRUG|Remifentanil|
48335072|NCT00259038|DRUG|Carperitide|
48335073|NCT00259038|DRUG|Placebo|
48335074|NCT05906992|BIOLOGICAL|CT-P53|Intravenous(IV) infusion
48335075|NCT05906992|BIOLOGICAL|US-Ocrevus|Intravenous(IV) infusion
48335076|NCT05906992|BIOLOGICAL|EU-Ocrevus|Intravenous(IV) infusion
48335077|NCT02533778|DEVICE|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
48335078|NCT05552807|DRUG|SCT-I10A|Administered intravenously
48335079|NCT05552807|DRUG|SCT200|Administered intravenously
48335080|NCT05552807|DRUG|paclitaxel|Administered intravenously
48653328|NCT06637761|DRUG|WMTA|White Mineral trioxide aggregates
48653329|NCT03196778|RADIATION|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
48653330|NCT02593214|DEVICE|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
48127927|NCT01746641|DRUG|Propofol|
48127928|NCT04977700|BEHAVIORAL|Intervention Group|Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
48127929|NCT00977249|BEHAVIORAL|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
48127930|NCT00977249|DRUG|varenicline|
48127931|NCT00977249|DRUG|placebo|
48127932|NCT01514149|DRUG|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
48335081|NCT05552807|DRUG|docetaxel|Administered intravenously
48335082|NCT02527187|BIOLOGICAL|10 HEP/mL Betula verrucosa allergen extract|The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
48653331|NCT06549777|BEHAVIORAL|SE-group|Psychoeducation and information about treatment possibilities + SE-treatment
48335083|NCT02527187|BIOLOGICAL|25 HEP/mL Betula verrucosa allergen extract|The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
48335084|NCT02527187|BIOLOGICAL|50 HEP/mL Betula verrucosa allergen extract|The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
48335085|NCT02527187|BIOLOGICAL|100 HEP/mL Betula verrucosa allergen extract|The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
48335086|NCT04903704|DIAGNOSTIC_TEST|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
48335087|NCT01144195|DRUG|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
48653332|NCT06549777|BEHAVIORAL|Control|Psychoeducation and information about treatment possibilities + Phone
47976586|NCT02259868|DRUG|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
47976587|NCT02259868|DRUG|BILR 355 BS - Suspension low dose|
47976588|NCT02259868|DRUG|BILR 355 BS - Suspension high dose|
47976589|NCT02259868|DRUG|Ritonavir|
47976590|NCT05311540|DRUG|Zinc Sulfate|
47976591|NCT01890356|DEVICE|Transcranial electrical stimulation|
47976592|NCT05993468|OTHER|TMC Treatment Approach|The TMC approach consists of 16 weekly group sessions, each lasting 2 hours. The first 10 sessions focus mainly on building mindfulness capacities, and the last 6 sessions on developing compassion toward self and others. Between sessions, participants are encouraged to do exercises with the support of audio files. The approach was developed with a transdiagnostic perspective, including clients with a variety of trauma-related symptoms.
47976593|NCT03866005|DIETARY_SUPPLEMENT|Diabetes Visual Function Study (DiVFuSS) softgels|The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).
47976594|NCT03866005|OTHER|canola oil placebo softgels, 2 per day|Placebo containing canola oil, 2 softgels per day
47976595|NCT00081640|DRUG|PRO 2000/5 Gel (P)|
47976596|NCT04918433|PROCEDURE|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
47976597|NCT01548521|DRUG|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
47976598|NCT01584102|BEHAVIORAL|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
48493688|NCT02188511|OTHER|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
48493689|NCT01592305|DRUG|atazanavir|multiple oral doses
48493690|NCT01592305|DRUG|danoprevir|multiple oral doses
48493691|NCT01592305|DRUG|ritonavir|multiple oral doses
48653333|NCT06641791|RADIATION|Standard Radiotherapy (SRT)|2400 cGy in 3 fractions - day 0/7/21, OR, 2500 cGy in 5 fractions over 1 week
48653334|NCT06641791|RADIATION|Stereotactic Body Radiotherapy (SBRT)|4500 cGy in 5 fractions (twice a week to primary and nodal GTV, OR, 4000 cGy in 5 fractions twice a week if organs at risk.
48653335|NCT06569459|DRUG|Trilaciclib Injection [Cosela]|Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
47976599|NCT01584102|BEHAVIORAL|group fitness classes only|15 weeks biweekly group fitness
47976600|NCT03032315|DRUG|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
47976601|NCT03032315|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
47976602|NCT03032315|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
47976603|NCT01675414|OTHER|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
47976604|NCT03171415|DRUG|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
47976605|NCT03171415|DRUG|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
47976606|NCT06093295|DEVICE|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation)|"The repetitive transcranial magnetic stimulation device will generate successive magnetic pulses to the left dorsolateral prefrontal cortex (experimental condition) and the vertex (control condition).~The theta burst stimulation protocol is as follows:~* Total stimulation time \~190 seconds~* Intensity: 80% of active motor threshold~* 2 seconds train, repeated every 10 seconds~* In every 2-second train, 3 pulses of stimulation are delivered at 50 Hz, repeated every 200 milliseconds (i.e., 5 Hz) for a total of 600 pulses"
47976607|NCT00420927|BIOLOGICAL|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
48266503|NCT05708391|RADIATION|Radiotherapy|Radiotherapy
48266504|NCT04817501|OTHER|Taking 5 ml of venous blood at different time intervals|
48493692|NCT01592305|DRUG|tenofovir disoproxil fumarate|single oral doses
48653336|NCT06569459|DRUG|Placebo|Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
48127933|NCT01514149|DRUG|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
48127934|NCT00940524|DRUG|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC \> 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
48335088|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
48493693|NCT02165865|PROCEDURE|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
48493694|NCT01795274|RADIATION|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
48493695|NCT03198975|DIAGNOSTIC_TEST|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
48493696|NCT00017719|DRUG|Lamivudine|
48493697|NCT00017719|DRUG|Lamivudine/Zidovudine|
48493698|NCT00017719|DRUG|Nelfinavir mesylate|
48653337|NCT04773457|OTHER|Surgical Site Infection|infection at the site of the surgery (spine or abdomen)
48653338|NCT01424137|DEVICE|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
47976608|NCT00420927|DRUG|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
47976609|NCT00420927|BIOLOGICAL|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
47976610|NCT02933125|BEHAVIORAL|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
47976611|NCT02933125|BEHAVIORAL|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
47976612|NCT03873233|DEVICE|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
47976613|NCT03873233|DEVICE|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
47976614|NCT03839745|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
47976615|NCT06278467|DIAGNOSTIC_TEST|visual pain scale (VASpain/fatigue), Beck depression index (BDI),|VAS (0-10)
47976616|NCT06278467|DIAGNOSTIC_TEST|Pain catastrophizing scale, sleep quality with a single Likert type question in the Pittsburgh questionnaire|PCS (Pain catastrophizing scale); sleep quality with a single Likert type question in the Pittsburgh questionnaire (0-3)
47976617|NCT06278467|DIAGNOSTIC_TEST|Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36),|functional disability level with Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36)
48127935|NCT02378649|DRUG|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
48127936|NCT02378649|DRUG|Placebo|Placebo comparator concomitant with best practice usual care
48127937|NCT04514718|DEVICE|Holmium laser|low energy holmium laser
48127938|NCT05562089|DEVICE|A Paclitaxel Drug-Coated Balloon|Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
48266505|NCT04817501|OTHER|Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any|
48266506|NCT00159432|DRUG|Oxaliplatin|
48653339|NCT01424137|DEVICE|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
48266507|NCT00159432|DRUG|Bevacizumab|
48266508|NCT00159432|DRUG|Capecitabine|
48493699|NCT00017719|DRUG|Nevirapine|
48653340|NCT01424137|DEVICE|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
48653341|NCT06126900|OTHER|Smartphone medication intake reminder + educational and motivational text messaging|The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
48653342|NCT02995200|BEHAVIORAL|Accelerometer Based Feedback|
48127939|NCT05857020|DEVICE|Auricular Acupressure|"Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study."
48127940|NCT05381532|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
48127941|NCT03753984|OTHER|Low-level laser therapy|In both arms will be applied Low-level laser therapy and induced muscle fatigue.
48335089|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
48493700|NCT00017719|DRUG|Zidovudine|
47976618|NCT06278467|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale (MOCA); Standard Mini mental test (SMMT)|cognitive status was measured by Montreal Cognitive Assessment Scale (MOCA) and Standard Mini mental test (SMMT)
47976619|NCT00439660|BIOLOGICAL|Oral Rotavirus Vaccine 116E Live Attenuated|
47976620|NCT01092611|PROCEDURE|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
47976621|NCT01092611|BIOLOGICAL|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
47976622|NCT02193568|PROCEDURE|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
47976623|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
47976624|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Undergo craniotomy
48335090|NCT06403813|OTHER|Control Tooklit|The toolkit will have the same screening questions, with information, but without any decision support functions.
48335091|NCT01263093|DRUG|Clopidogrel|
48335092|NCT01263093|DRUG|LY2216684|
47976625|NCT02193568|OTHER|Arm II (intubated general anesthesia)|Ancillary studies
47976626|NCT02193568|PROCEDURE|Arm I (light sedation)|Undergo craniotomy
47976627|NCT02193568|OTHER|Arm I (light sedation)|Ancillary studies
48493701|NCT02804711|BIOLOGICAL|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
47976628|NCT02498860|DRUG|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
47976629|NCT02498860|DRUG|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
47976630|NCT00031863|DRUG|rofecoxib|
47976631|NCT00031863|PROCEDURE|adjuvant therapy|
48493702|NCT02804711|BIOLOGICAL|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
48493703|NCT02804711|BIOLOGICAL|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
48493704|NCT02804711|BIOLOGICAL|Placebo|
47976632|NCT01925053|OTHER|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
47976633|NCT01925053|OTHER|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
47976634|NCT00355693|DEVICE|Pump for propofol delivery|
47976635|NCT01353326|DEVICE|Cormet|Cementless hip resurfacing system
47976636|NCT01353326|DEVICE|Conserve|Cemented hip resurfacing system
47976637|NCT03582540|PROCEDURE|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
47976638|NCT02593474|DRUG|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
47976639|NCT02670564|GENETIC|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
47980555|NCT04017585|DIETARY_SUPPLEMENT|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
48127942|NCT04325685|DRUG|Control|Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
48127943|NCT04325685|DRUG|Antiseptic Solution|Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
48493705|NCT03801538|DRUG|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
48493706|NCT03801538|DRUG|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
48127944|NCT04325685|DRUG|Bacteriophage|Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
48127945|NCT00824642|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
48335093|NCT05113498|DIETARY_SUPPLEMENT|(-)-Epicatechin|Administration of a capsule with 150 mg of pure (-)-epicatechin after 48h low-flavanol diet.
48335094|NCT06104319|DRUG|GSK4532990|GSK4532990 will be administered
48493707|NCT03621059|BEHAVIORAL|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
48493708|NCT03668561|DEVICE|Caligaloc|15 days of wearing of the Caligaloc orthosis
47976640|NCT02670564|OTHER|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~-\>For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~-\>For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-\> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
47976641|NCT01785550|OTHER|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
47976642|NCT03348033|BIOLOGICAL|Chronic Myeloid Leukemia + NK cell|Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
47976643|NCT04981743|DIETARY_SUPPLEMENT|Nigella Sativa capsule twice daily|investigate the safety and efficacy of Nigella Sativa versus Vitamin D3 versus Nigella Sativa / vitamin D3 combination as supplement for management of COVID-19 .
47976644|NCT03749070|DIETARY_SUPPLEMENT|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
47976645|NCT04542785|OTHER|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
47980556|NCT04017585|DIETARY_SUPPLEMENT|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
48127946|NCT00824642|DEVICE|placebo|placebo TENS applied prior to exercise
48127947|NCT03631433|DRUG|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
48127948|NCT03631433|DRUG|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
48127949|NCT04141514|OTHER|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
48127950|NCT04430634|OTHER|Myblu variant A|Use of Myblu e-cigarette with flavor A 2.4% nicotine
48127951|NCT04430634|OTHER|Myblu variant B|Use of Myblu e-cigarette with flavor B 3.6% nicotine
48335095|NCT04562545|DEVICE|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
48335096|NCT04562545|DEVICE|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
48493709|NCT01335373|DRUG|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
48493710|NCT01401257|DRUG|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
48493711|NCT01401257|DRUG|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
48493712|NCT01401257|DRUG|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
48493713|NCT01401257|OTHER|Placebo|Liquid,5 ml, twice a day, 12-month treatment
48493714|NCT04232813|DRUG|Estradiol 10 MCG Vaginal Tablet [VAGIFEM]|To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
48493715|NCT04232813|DRUG|Promestriene Vaginal|To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
48127952|NCT04430634|OTHER|Myblu variant C|Use of Myblu e-cigarette with flavor C 2.5% nicotine
48127953|NCT04430634|OTHER|Myblu variant D|Use of Myblu e-cigarette with flavor D 4.0% nicotine
48127954|NCT04430634|OTHER|Myblu variant E|Use of Myblu e-cigarette with flavor E 3.6% nicotine
48127955|NCT04430634|OTHER|Myblu variant F|Use of Myblu e-cigarette with flavor F 2.4% nicotine
48335097|NCT06386211|DRUG|MAGNE-B6 Oral Solution|Oral solution.
48335098|NCT06386211|DRUG|MAGNE-B6 New Formulation Tablet|New formulation tablet.
48335099|NCT02571972|DRUG|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
48127956|NCT04430634|OTHER|Myblu variant G|Use of Myblu e-cigarette with flavor G 4.0% nicotine
48127957|NCT04430634|OTHER|Myblu variant H|Use of Myblu e-cigarette with flavor H 3.6% nicotine
48127958|NCT06151314|PROCEDURE|Dental implants.|5 conventional implants measuring from 4 to 5 mm in width and 7 to 10mm in length according to the bone width were inserted in the mandible from right premolar area to left premolar area
48335100|NCT01307553|DEVICE|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
48653343|NCT04684862|DEVICE|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
48127959|NCT02695264|DEVICE|HS-1000 recording|
48335101|NCT04114344|PROCEDURE|TAPP|Trans Abdominal Pre Peritoneal approach
48335102|NCT04114344|PROCEDURE|TEP|Total Extra Peritoneal approach
48335103|NCT02595424|DRUG|Capecitabine|Given PO
48335104|NCT02595424|DRUG|Carboplatin|Given IV
48127960|NCT03467529|OTHER|Non interventional study|Non interventional study
48335105|NCT02595424|DRUG|Cisplatin|Given IV
48493716|NCT04183647|DEVICE|whole body vibration / local vibration|Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
48493717|NCT00857584|DRUG|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
48493718|NCT00857584|DRUG|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
48127961|NCT01605448|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
48127962|NCT01550549|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
48266509|NCT05596019|PROCEDURE|specific neurodynamic exercises|Specific neurodynamic exercises in women older than 65 years with neck pain
48493719|NCT00857584|DRUG|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
48493720|NCT03529578|PROCEDURE|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
48493721|NCT00003592|DRUG|methotrexate|
48493722|NCT00003592|DRUG|paclitaxel|
48653344|NCT02758626|DRUG|ataluren|Powder formulation
48653345|NCT02758626|DRUG|Placebo|Powder formulation
48266510|NCT05596019|PROCEDURE|multimodal exercise|Multimodal and nonspecific exercises in women older than 65 years with neck pain
48266511|NCT01124487|DIETARY_SUPPLEMENT|The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers|
48335106|NCT02595424|DRUG|Etoposide|Given IV
48335107|NCT02595424|OTHER|Laboratory Biomarker Analysis|Correlative studies
48335108|NCT02595424|DRUG|Temozolomide|Given PO
48335109|NCT04019457|OTHER|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
48335110|NCT02562989|DRUG|[18F]MK-6240, ~185 MBq|IV dose of \~185 MBq \[18F\]MK-6240
48335111|NCT02562989|DRUG|[18F]MK-6240, ~160 MBq|IV dose of \~160 MBq \[18F\]MK-6240
48335112|NCT00621088|PROCEDURE|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
48335113|NCT02213549|DIETARY_SUPPLEMENT|Placebo|
48335114|NCT02213549|DIETARY_SUPPLEMENT|Ume paste and ginger powder|
48653346|NCT02437526|OTHER|Analytic treatment interruption|
48653347|NCT06332352|BIOLOGICAL|PRP|Intra-articular hip injection of PRP, Blood Collection 45mL, Processed Neutrophil-Poor PRP, 1 injection to one hip joint.
48335115|NCT05100108|BEHAVIORAL|Dog-assisted therapy|The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
48493723|NCT00281606|DRUG|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
48335116|NCT05897060|DEVICE|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
48335117|NCT00358501|DRUG|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
48493724|NCT05758480|BIOLOGICAL|Blood sample (at inclusion and 6 months later)|(56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT
48493725|NCT05758480|OTHER|Patient questionnaires (at inclusion and 6 months later)|(4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.
48493726|NCT04043936|BEHAVIORAL|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
48493727|NCT04043936|BEHAVIORAL|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
48493728|NCT04043936|BEHAVIORAL|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, \& treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
48493729|NCT02647736|OTHER|Hypertonic saline infusion|
48493730|NCT01544738|OTHER|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
48493731|NCT01544738|OTHER|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
47976646|NCT05695443|BEHAVIORAL|Motivational Interviewing|This study investigates the effects of an intervention based on Motivational Interviewing (MI) on oral hygiene, oral cleaning routines, and attitudes towards own oral health. The first step is for the dental staff to ask open questions to the prisoner about their oral health or oral health behavior. The next step is to confirm to the prisoner what he or she is doing. The third step is called reflection. At this stage, dental staff tries to provide reflections on what the prisoner have said, for example by repeating what the prisoner have said or say the same using synonyms (simple reflection), by extracting the underlying opinion or feeling (complex reflection), or by illuminate both negative and positive sides of the situation (double sided reflection). The final step is to summarize the conversation. In addition, the intervention includes a change plan, in which the prisoner and dental staff agrees on specific behavior that the prisoner should follow based on the MI conversation.
47976647|NCT01613729|DRUG|Rosuvastatin 5 mg|Rosuvastatin 5 mg
47976648|NCT01613729|DRUG|Rosuvastatin 10 mg|
47976649|NCT04575922|DRUG|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
47976650|NCT04575922|DRUG|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
47976651|NCT04575922|RADIATION|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
47976652|NCT01417234|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
47976653|NCT05989984|DIETARY_SUPPLEMENT|ODF Iron Supplement|ODF iron supplement will be admistered daily for 8 weeks.
47976654|NCT05989984|DIETARY_SUPPLEMENT|Iron Supplement in Capsules|Iron supplement in capsule will be admistered daily for 8 weeks.
47976655|NCT04300114|DRUG|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
47976656|NCT04300114|DRUG|Placebo|Placebo capsules po. twice daily
48335118|NCT01841294|DRUG|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
48335119|NCT01841294|DRUG|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
48493732|NCT06271720|OTHER|visceral manipulation|"visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius"
48493733|NCT06271720|OTHER|integrated neuromuscular inhibition|It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
48493734|NCT03947671|DEVICE|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
48493735|NCT03947671|DRUG|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
48493736|NCT06014749|PROCEDURE|undergo|regional anesthesia
48653348|NCT04878757|BEHAVIORAL|CFI - Classwide Fraction Intervention|40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
48653349|NCT06641895|GENETIC|BBM-D101|BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.
48653350|NCT06041139|DIAGNOSTIC_TEST|Visual Acuity|Measurement of distance, intermediate and near visual acuity.
48335120|NCT00628316|DIETARY_SUPPLEMENT|caffeine|caffeine daily intake will be reduced form 150 ml per day
48335121|NCT00006030|DRUG|tamoxifen citrate|
48493737|NCT06014749|DEVICE|ultrasound|ultrasound guided
48493738|NCT06014749|DRUG|Local anesthetic|local anesthetic
48493739|NCT06182904|DEVICE|Dynamic compression plate|Fixation of fibula in some cases with dynamic compression plate
48493740|NCT02473783|DRUG|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
48493741|NCT02473783|OTHER|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
48493742|NCT05476107|DRUG|AMT-126|Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
48493743|NCT05476107|DRUG|Placebo|Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
48493744|NCT05476107|OTHER|Radioactive Tablet (Part 2 Only)|Single dose in two periods in Part 2 (optional)
48493745|NCT00004421|DEVICE|implanted pulse generator|
48493746|NCT03382314|COMBINATION_PRODUCT|HDDO-1614|"* Combination drug (Bazedoxifene + Cholecalciferol)~* Incrementally modified drug~* Not market authorized product"
48653351|NCT06041139|DIAGNOSTIC_TEST|Defocus Curve|Measurement of visual acuity performed from +1.00 to -4.00 in 0.50 diopter steps and with +0.25 and -0.25 added.
48653352|NCT06041139|DIAGNOSTIC_TEST|Halo and Glare testing|Measurement to quantify degree of visual loss caused by either halo and/or glare.
47976657|NCT04506554|DRUG|AMVAC + Nivolumab|Nivolumab 240mg will be administered intravenously for 3 doses - on days 1, 15 and 29. AMVAC will be dosed intravenously every 2 weeks for 3 doses on days 1, 15 and 29 with Neulasta or equivalent. Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.
47976658|NCT03059823|DRUG|retifanlimab|Anti-PD-1 monoclonal antibody
48335122|NCT00006030|PROCEDURE|conventional surgery|
48335123|NCT00006030|RADIATION|radiation therapy|
48335124|NCT00720824|BEHAVIORAL|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
48335125|NCT00720824|BEHAVIORAL|Office routine|Standard vaccine administration
48335126|NCT00858936|DRUG|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
48335127|NCT00858936|DRUG|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
48335128|NCT04489004|PROCEDURE|Driver ablation+CPVI|Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
48335129|NCT04489004|PROCEDURE|Stepwise ablation|Patients receive stepwise ablation.
48335130|NCT04114539|DRUG|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
48335131|NCT01414517|DIETARY_SUPPLEMENT|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
48653353|NCT06041139|OTHER|Patient Questionnaires|Patients will complete a series of questionnaires to record self-reported visual disturbances, visual acuity satisfaction, level of spectacle independence and any issues with glare, halos, and/or starbursts.
48653354|NCT06168448|OTHER|Oral and written information|Legal oral and written information given by physicians concerning additional examinations
48653355|NCT06168448|OTHER|Video information|Explanatory video applied after physician's formal information
48493747|NCT03382314|DRUG|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
48493748|NCT02091141|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
48493749|NCT02091141|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
48493750|NCT02091141|DRUG|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
48493751|NCT02091141|DRUG|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
48493752|NCT02091141|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
48653356|NCT06640270|DEVICE|Diabetes Treatment|Lucie™ is an innovative medical device for measurement by bio-impedancemetry. It has been developed specifically to meet medical needs in nephrology. The aim of the study is to compare its performance with a reference device validated in nephrology nephrology, the Body Composition Monitor® (BCM) from Fresenius.
48653357|NCT06541119|OTHER|Selective Peroneus longus excercise|Weight bearing peroneus longus exercise
48127963|NCT02189434|OTHER|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
48127964|NCT01932970|DRUG|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
47976659|NCT00936910|DRUG|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome \[2 mg/ml\]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
47976660|NCT03585998|DRUG|Durvalumab|Concurrent radiotherapy Maintenance therapy
47976661|NCT05659797|DEVICE|BPET/DBT imaging|Imaging of the breast with a novel device combining dedicated Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DBT) following intravenous injection of \[18F\]-Fluoroestradiol (FES).
47976662|NCT05659797|DRUG|18F-FES|Radiolabelled fluoroestradiol for PET imaging
47976663|NCT03547869|DEVICE|Active tDCS|Active tDCS will be adminestered
47976664|NCT03547869|DEVICE|Sham tDCS|Sham tDCS will be administered
47976665|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
47976666|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
47976667|NCT04119492|BEHAVIORAL|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
47976668|NCT04224649|DEVICE|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
47976669|NCT04224649|DEVICE|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
47976670|NCT03327649|DEVICE|low level transcutaneous vagus nerve stimulation|Stimulation of the auricular branch of the vagus nerve
47976671|NCT01778218|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
47976672|NCT02029625|DRUG|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
48127965|NCT05792293|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
48127966|NCT05792293|OTHER|Placebo|Placebo
48127967|NCT05038618|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
48127968|NCT04166487|DRUG|Pembrolizumab|predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
48127969|NCT04166487|DRUG|PEMETREXED|administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
48653358|NCT06541119|OTHER|Conventional physical therapy programme|"* Passive abduction of the Hallux with traction~* short foot exercise~* toe spread outs"
48653359|NCT06494644|DRUG|AZD6793|Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
47976673|NCT02029625|DRUG|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
47976674|NCT00494078|DEVICE|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
47976675|NCT00494078|DRUG|intensive insulin therapy|intensive insulin therapy according to an algorithm
48335132|NCT01414517|DIETARY_SUPPLEMENT|Maltodextrin|a non-prebiotic carbohydrate
48493753|NCT02091141|DRUG|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
47980557|NCT02857933|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
48127970|NCT04166487|DRUG|CARBOPLATIN|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
48493754|NCT02091141|DRUG|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
48127971|NCT04166487|DRUG|PACLITAXEL|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
48127972|NCT04166487|DIAGNOSTIC_TEST|InVision|Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
48127973|NCT05477316|RADIATION|Radiation treatment|Radiation treatment of IMRT to the cerebellum and SRS to the cerebrum
48127974|NCT02023346|BEHAVIORAL|surveys and cognitive tests|
48127975|NCT04770324|DEVICE|Interposition supraciliary implant|Surgical placement of 2 interposition supraciliary implant in the supraciliary space
48127976|NCT03904069|DRUG|AMG 553|AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
48493755|NCT02091141|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
48493756|NCT04375683|DRUG|Flumatinib|Flumatinib 600mg per day, taken on empty stomach
48493757|NCT01429051|DRUG|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
48493758|NCT01429051|DRUG|Placebo|Matching intranasal placebo spray
48127977|NCT00945321|DRUG|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
48127978|NCT00945321|DRUG|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
48127979|NCT00945321|DRUG|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
48335133|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every week
48127980|NCT00945321|DRUG|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
48127981|NCT03388840|BIOLOGICAL|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
48127982|NCT03388840|BIOLOGICAL|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
48127983|NCT03830567|OTHER|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
48127984|NCT03830567|OTHER|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
48127985|NCT06038695|DEVICE|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|"* Fibro-Gide is the Volume-Stable Collagen Matrix.~* Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S."
48127986|NCT02616276|OTHER|Control breakfast|It consists of 350 ml of water at room temperature.
48335134|NCT01101243|RADIATION|Broadband UVB|UVB dose: 4 SED every second week
48335135|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every second week
48335136|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every month
48335137|NCT01101243|OTHER|Control group|No intervention
48335138|NCT04024462|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
48335139|NCT04024462|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
48335140|NCT04024462|DRUG|Pertuzumab and Trastuzumab FDC SC|The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
48335141|NCT04024462|DRUG|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
48335142|NCT04024462|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
48493759|NCT01229735|DRUG|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
48493760|NCT01229735|DRUG|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
48493761|NCT05314114|PROCEDURE|No axillary surgery|No axillary surgery
48493762|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation|Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.
48653360|NCT06494644|DRUG|Itraconazole|Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
48127987|NCT02616276|OTHER|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
48127988|NCT02616276|OTHER|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
48335143|NCT04024462|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
48493763|NCT06024200|OTHER|transcutaneous electrical acupoint stimulation sham stimulation|Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.
47976676|NCT01612936|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
48493764|NCT01664221|DRUG|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
47976677|NCT01612936|PROCEDURE|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
47976678|NCT00328757|BEHAVIORAL|Regular diet as the first postoperative meal|
47976679|NCT00820690|DRUG|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
47976680|NCT00820690|DRUG|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
47976681|NCT00820690|DRUG|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
47976682|NCT00820690|PROCEDURE|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
48127989|NCT06475248|OTHER|Placebo Technique|For the technique performed in the control group, the researcher will come into contact with the volunteers' chests. This contact will be maintained for the same period of time as the experimental group (6 minutes).
48335144|NCT04024462|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
48493765|NCT01507155|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
48653361|NCT06494644|DRUG|AZD6793+ Itraconazole|Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
48653362|NCT06570629|DEVICE|Oronasal CPAP|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
48335145|NCT04024462|RADIATION|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
48493766|NCT00453427|DRUG|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (\> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
48653363|NCT06570629|DEVICE|Nasal CPAP plus Chinstrap|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
48653364|NCT03823482|DRUG|Lidocaine|Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
48653365|NCT05042479|OTHER|Usual distraction and pain prevention techniques.|"For the first painful procedure, the child will benefit usual distraction and pain prevention techniques.Pain prevention and management techniques commonly used in the conduct of care:~* Application of a patch or anaesthetic cream 1 hour before the treatment~* Vigilant sedation using a premedication for lumbar punctures: Midazolam /Nalbuphine/Hydroxyzine/Morphine.~* Apart from care using VR, MEOPA can be given to the child for all assessed care on prescription.~* Apart from care using VR, the usual distraction techniques are left to the patient's choice (electronic tablet, smartphone, games, songs...)~* The presence of the parents"
48653366|NCT05042479|OTHER|Virtual reality|For the 2nd painful procedure, the child will use a VR (virtual reality) headset as well as pain prevention techniques (excluding oxygen-nitrous oxide mixtures). The child will choose the application he/she wishes to use according to his/her age.
48127990|NCT06475248|OTHER|Stretching technique|"Stretching technique for the upper trapezius and sternocleidomastoid: the volunteer will be in supine position on the couch, the researcher will perform the technique from the contralateral side of the muscle to be treated, the hand will contact the ipsilateral shoulder to stabilize, meanwhile, with the other hand, contact the upper trapezius and perform a rhythmic pull in contralateral rotation. This technique is performed bilaterally."
48127991|NCT06475248|OTHER|Inhibition of the suboccipital|"Inhibition of the suboccipital: the participant is in the supine position, the researcher will position himself behind the patients head. In this technique, contacts will be made on the suboccipital area with the 2nd, 3rd and 4th fingers of both hands. Make a slight pull with your body backwards and wait that there is relaxation of muscular tensions."
48335146|NCT04024462|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
48493767|NCT05966220|DEVICE|Hip surgery with FH Ortho devices|"This study is a real-life observatory designed to collect long-term clinical data on patients who have undergone hip joint replacement or repair following hip trauma.~In this type of intervention, one or more medical devices distributed by FH ORTHO Company may be used by surgeons."
48493768|NCT03951896|BIOLOGICAL|PRP|A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.
48493769|NCT03951896|OTHER|Saline injection|2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
48493770|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
48493771|NCT01020136|DRUG|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
48493772|NCT04746911|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
48335147|NCT00216775|DRUG|interferon-alfa-2b and ribavirin|
48335148|NCT04213937|DRUG|nab-paclitaxel|Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
48493773|NCT00276549|DRUG|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
48493774|NCT00276549|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
48127992|NCT00275392|BEHAVIORAL|Vestibular rehabilitation|vestibular adaptation and substitution exercises
48493775|NCT05569603|BEHAVIORAL|Chronobiology-guided lifestyle interventions|1) timed bright light exposure using blue-enriched white light glasses, 2) recommendations for meal timing, and 3) sleep hygiene education
48493776|NCT02075671|DRUG|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
48493777|NCT02075671|DEVICE|Blu-U Light Therapy|Intervention used in experimental and sham arms
48493778|NCT02075671|OTHER|Placebo vehicle only|Intervention only includes the placebo vehicle solution
48493779|NCT03954314|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
48493780|NCT03234894|DEVICE|SiteSeal Endovascular|to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
48493781|NCT00325195|OTHER|placebo|placebo by intravenous infusion every 2 weeks
48493782|NCT00325195|BIOLOGICAL|pegloticase|8 mg pegloticase by intravenous infusion
48493783|NCT03481218|OTHER|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
48127993|NCT00275392|BEHAVIORAL|Placebo|placebo vestibular exercises
48127994|NCT05986734|DRUG|Cutaquig|Subcutaneous immunoglobulin products are administered at the same monthly dose (0.4-0.8 g/kg), evenly divided into 3-5 administrations per month, subject to monitoring of the pre transfusion IgG level with target IgG values of at least 7 g/L.
48335149|NCT04213937|DRUG|Topotecan|Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
48335150|NCT00067821|DRUG|2-Flourodeoxyglucose|
48335151|NCT03789968|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
48335152|NCT02088541|DRUG|Selinexor|Selinexor oral tablet.
47976683|NCT00005937|DRUG|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
47976684|NCT00005937|DRUG|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
48127995|NCT05423119|BEHAVIORAL|conventional therapy|upper limb rehabilitation with and without technologies
48127996|NCT00351299|DRUG|Dexmedetomidine|dexmedetomidine infusion titrated to effect
47976685|NCT00967772|DRUG|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
47976686|NCT00070278|DRUG|cyclophosphamide|
47976687|NCT00070278|DRUG|epirubicin hydrochloride|
47976688|NCT00070278|DRUG|gemcitabine hydrochloride|
47976689|NCT00070278|DRUG|paclitaxel|
48127997|NCT00351299|OTHER|Standard of Care|Standard of care per treating physician preference
48127998|NCT05971875|PROCEDURE|vNOTES vs Vaginal Hysterectomy|Comparison of vNOTES vs VH
48335153|NCT02088541|DRUG|Hydroxyurea|
48335154|NCT02088541|DRUG|Ara-C|Ara-C Subcutaneous Injection.
47976690|NCT00070278|GENETIC|comparative genomic hybridization|
47976691|NCT00070278|GENETIC|microarray analysis|
47976692|NCT00070278|GENETIC|mutation analysis|
48335155|NCT06314997|DRUG|panitumumab (EGFR inhibitors)|Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
47976693|NCT00070278|PROCEDURE|conventional surgery|
47976694|NCT00070278|PROCEDURE|neoadjuvant therapy|
48335156|NCT02178306|DRUG|Telmisartan low dose|
47976695|NCT04118166|DRUG|Ipilimumab|Ipilimumab 1 mg/kg, injection
47976696|NCT04118166|PROCEDURE|Cryoablation|Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
48127999|NCT05971875|PROCEDURE|vNOTES vs Laparoscopic Hysterectomy|Comparison of vNOTES vs LH
48128000|NCT02337036|OTHER|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
48128001|NCT02337036|OTHER|Pharmacogenetic|Pharmacogenetic study
48128002|NCT02337036|DRUG|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
48128003|NCT00124735|DRUG|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
48335157|NCT02178306|DRUG|Telmisartan high dose|patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment
48335158|NCT02178306|DRUG|Placebo|Run-in phase
48335159|NCT03886441|DRUG|Beclomethasone propionate|Beclomethasone propionate inhaled twice daily during radiotherapy
48493784|NCT03481218|OTHER|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
48493785|NCT03481218|OTHER|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
48493786|NCT02674061|BIOLOGICAL|Pembrolizumab|Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
48493787|NCT00885521|OTHER|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
48493788|NCT03893474|DIAGNOSTIC_TEST|OCT|Optical Coherence Tomography of study eye.
47976697|NCT04118166|DRUG|Nivolumab|Nivolumab 3 mg/kg, injection
47976698|NCT00992576|DRUG|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
47976699|NCT00992576|DRUG|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
47976700|NCT02407704|DRUG|Venlafaxine XR|
47976701|NCT02407704|OTHER|Aerobic Exercise|
47976702|NCT02407704|DRUG|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
47976703|NCT06476262|BEHAVIORAL|This research has only one arm. The intervention focuses on occupational issue|During the post-stroke consultation, each participant is invited to complete questionnaires on occupational gaps, mood disorders, fatigue, cognition, and quality of life.
47976704|NCT03768960|DRUG|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
47976705|NCT05304065|BEHAVIORAL|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
47976706|NCT05304065|BEHAVIORAL|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
47976707|NCT03893799|DRUG|RBT-1|intravenous administration
47976708|NCT04245332|DIETARY_SUPPLEMENT|Fish oil|Fish oil-derived omega-3 polyunsaturated fatty acids (4g fish oil concentrate: 2g EPA+ 1g DHA)
47976709|NCT04245332|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil (4g/d)
48128004|NCT00124735|DRUG|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
48128005|NCT05398289|DRUG|4-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
48335160|NCT06089070|DEVICE|FreeStyle Libre Continuous Glucose Monitor System|Continuous Glucose Monitor System for people with Type 2 Diabetes
48335161|NCT06054503|DEVICE|prototype of sensor|The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters
48335162|NCT02198989|BEHAVIORAL|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
48335163|NCT01676441|DRUG|cellgram-spine|Mesenchymal stem cells transplantation
48335164|NCT01281189|DRUG|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
48335165|NCT01281189|DRUG|Placebo|Oral tablet twice daily for up to 18 months.
48493789|NCT03893474|DIAGNOSTIC_TEST|Visual Acuity|Visual acuity measured by ETDRS
48493790|NCT03217396|PROCEDURE|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
48493791|NCT05284461|DEVICE|dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)|Dental implants with transepithelial abutments with distinct morphology
48493792|NCT01534923|BEHAVIORAL|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
48128006|NCT05398289|DRUG|6-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
48128007|NCT05751161|OTHER|conventional gait training|The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
48128008|NCT06371300|DEVICE|Red LLLT|Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed
48128009|NCT06371300|DEVICE|Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm to facial and eyelid regions with their eyes closed
48128010|NCT06371300|DEVICE|Sham Red LLLT|Mask with LEDs emitting at wavelengths of 633nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
48128011|NCT06371300|DEVICE|Sham Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
48128012|NCT00133250|DRUG|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
48128013|NCT00133250|OTHER|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
48128014|NCT01181154|DRUG|rituximab (Mabthera®)|1000 mg at day 1 and day 15
48128015|NCT01181154|DRUG|Placebo|equivalent volume total
48128016|NCT00112034|DRUG|Methotrexate|
48128017|NCT00112034|DRUG|IV methylprednisolone|
48128018|NCT02247375|DRUG|Low dose of BIIL 284 BS tablets|
48128019|NCT02247375|DRUG|High dose of BIIL 284 BS tablets|
48335166|NCT03481387|DEVICE|Aortic Valve Replacement with Perceval S sutureless heart valve|Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
48335167|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
48335168|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
48335169|NCT03543527|OTHER|no intervention|no intervention
48335170|NCT03488238|DEVICE|ORi sensor|Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
48335171|NCT04859972|DIAGNOSTIC_TEST|Diagnosis of IBS|Diagnosis of IBS according to ICD-10
48128020|NCT02247375|DRUG|Placebo|
48128021|NCT01236846|DIETARY_SUPPLEMENT|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
48128022|NCT01236846|DIETARY_SUPPLEMENT|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
48128023|NCT05850975|OTHER|intervention with this name in MindEase app|MindEase is an app which provides interventions against anxiety. The interventions are based on mindfulness, acceptance and commitment therapy, and cognitive behavioural therapy.
48128024|NCT05850975|OTHER|reading about anxiety|Participants are given an educational text to read about anxiety.
48128025|NCT05435794|DEVICE|CPAP|Fixed-pressure CPAP device for the treatment of sleep apnea with optional humidification and heated circuit. This device is a Class II device. It has a remote monitoring function allowing service providers to track the use of the device.
48128026|NCT05435794|DEVICE|MAD|mandibular device orthosis made to measure from the dental impressions of patients, made by the specialist in the masticatory apparatus for the treatment of sleep apnea.
48653367|NCT05042479|OTHER|Choice between usual distraction or virtual reality|"For the 3rd painful procedure, the child will choose his/her favorite technique between :~Usual distraction and pain prevention techniques or virtual reality"
48128027|NCT02808351|DRUG|Berberine|
48128028|NCT00862043|DRUG|Sildenafil Citrate|40 mg t.i.d.
48128029|NCT00862043|DRUG|Placebo|Placebo t.i.d.
48128030|NCT03234374|COMBINATION_PRODUCT|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
48128031|NCT03234374|DRUG|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
48128032|NCT05224557|OTHER|No intervention|No intervention
48128033|NCT03572803|OTHER|Group of Dry Needling|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
48128034|NCT03572803|OTHER|Group of Electrolysis|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
48128035|NCT03572803|OTHER|Control Group|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
48128036|NCT01643538|BEHAVIORAL|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
48128037|NCT01643538|BEHAVIORAL|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
48128038|NCT01643538|BEHAVIORAL|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
48128039|NCT01643538|BEHAVIORAL|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
48128040|NCT05660356|DRUG|Growth Hormone|Pfizer provided GH therapy
48128041|NCT05660356|DRUG|Placebo|Pfizer provided placebo
48653368|NCT06638918|DEVICE|Virtual Reality|The virtual reality (VR) intervention administers graded motor imagery (GMI) treatment for phantom limb pain. It consists of three stages: left right sorting task (a sorting task where participants sort images of left and right feet), explicit motor imagery (a series of guided imagery exercises administered via audio to facilitate focus on the phantom limb), and the limb simulation task (where participants perform a series of exercises with virtual legs to create the illusion of movement in their phantom limb). The limb simulation stage can also be conducted with leg trackers to generate a higher degree of illusion in the virtual legs.
48653369|NCT03112928|DEVICE|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~1. Pain evaluation~2. Placement of the electrodes and fiducial marker~3. Practice of motor execution in Augmented Reality (AR)~4. Gaming using phantom movements~5. Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
48653370|NCT03112928|DEVICE|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
48653371|NCT06638554|BEHAVIORAL|Active Choice|The participant will be send a letter inviting them to complete a SDM visit either in-person or via telehealth.
48653372|NCT06638554|BEHAVIORAL|Telehealth Only|The participant will be send a letter inviting them to complete a SDM visit via telehealth only.
48653373|NCT06638554|BEHAVIORAL|Low Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging.
48653374|NCT06638554|BEHAVIORAL|High Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging in combination with synchronous telephone-based digital care coordination.
48653375|NCT04099290|OTHER|Blood and tumor samples|Blood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
48653376|NCT04522739|DRUG|Spironolactone|Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
47976710|NCT04044235|BEHAVIORAL|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
47976711|NCT04952402|BIOLOGICAL|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
48128042|NCT06274086|PROCEDURE|Two-session catheter-directed sclerotherapy|"After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~* An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~* A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~* A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook)."
48128043|NCT03136172|DEVICE|NIRS (near Infra-red spectroscopy)|"1. NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~2. Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~3. Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
48128044|NCT06214442|OTHER|Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle|Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
48128045|NCT06270628|BEHAVIORAL|Exercise group|Live-remote exercise sessions, personalized to the patients main side-effect
48128046|NCT05585346|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
48128047|NCT05585346|DRUG|Oral vitamin B1|Oral vitamin B1 10mg, times/day
48128048|NCT04119063|DEVICE|powered orthosis|Novel powered leg brace to provide assistance during walking.
48128049|NCT06371456|PROCEDURE|epidural catheter placement|after sterilization of the back, local anesthesia injection (xylocaine 5 ml) at lumbar 4-5 level, then advancing the epidural needle till loss of resistance by air occurs and the epidural catheter inserted then aspiration through the catheter will be done to confirm that no accidental cerebrospinal fluid or blood are aspirated and to observe the dew sign inside the outer portion of the epidural catheter near the back of the patient
48128050|NCT00137098|DRUG|Caffeine|
48335172|NCT06168825|OTHER|Mind Over Matter (MOM)|"Each participant's involvement in the study will include:~* Attending a Pre-Program Orientation which will be held a week before the first MOM Session.~* Completing 5 weekly sessions of MOM~* Completing 2 surveys; one will be given before the start of the intervention (a pre-test) and the other will be given after the last MOM Session (a post-test)~Participants will also have the option to participate in an optional Focus Group session which will occur a week after the last MOM Session ends~Participants will spend about 6 weeks in this study. If they decide to participate in the optional session, they will spend about 7 weeks in this study.~Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits."
47976712|NCT04952402|BIOLOGICAL|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
47976713|NCT04952402|BIOLOGICAL|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
48335173|NCT03514888|PROCEDURE|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
47976714|NCT06055647|GENETIC|immunohistochemical approach|Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
48335174|NCT05239312|DRUG|Antimicrobial|Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
48335175|NCT04436588|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
48335176|NCT05448989|DRUG|1% atropine 5+3|A method for myopia control using high-concentration atropine
48335177|NCT02670850|OTHER|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
48335178|NCT01009918|DRUG|Coreg CR®|Given orally
48335179|NCT01009918|DRUG|lisinopril|Given orally
47976715|NCT03780283|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
48335180|NCT01009918|OTHER|placebo|Given orally
48335181|NCT06087588|DRUG|0.9%sodium chloride|PENG sham block with 20ml 0,9% normal saline
48335182|NCT06087588|DRUG|95% ethanol|PENG neurolysis with 2.5ml of 95% ethanol
48653377|NCT04522739|DRUG|Placebo|A placebo to match spironolactone will be taken orally once per day for 12 months.
48335183|NCT02995213|BEHAVIORAL|Accelerometer based feedback about paretic arm use|
48335184|NCT05474872|DEVICE|BIS monitoring|The depth of anesthesia will be monitored using Bispectral Index values.
48335185|NCT00255879|DRUG|Quetiapine|
48335186|NCT00255879|DRUG|Risperidone|
48335187|NCT00255879|DRUG|Olanzapine|
48335188|NCT00947843|DRUG|aspirin + pregrel (Clopidogrel resinate)|
48335189|NCT00947843|DRUG|aspirin + placebo|
48335190|NCT00947843|DRUG|aspirin + plavix (Clopidogrel bisulfate)|
48335191|NCT01192204|DRUG|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
48335192|NCT01192204|DRUG|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
48335193|NCT05953207|OTHER|Medical hypnosis|Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
48335194|NCT05953207|OTHER|Standard Of Care|Sleep hygiene and safety education session
48335195|NCT03628599|DEVICE|Delefilcon A contact lenses|Water Gradient silicon hydrogel daily disposable contact lenses
48335196|NCT03628599|DEVICE|Senofilcon A contact lenses|Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
48493793|NCT02733315|BEHAVIORAL|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
48493794|NCT02384941|DRUG|Placebo|Placebo once daily, before first meal of the day.
48493795|NCT02384941|DRUG|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
48493796|NCT03499418|OTHER|modified Silverman scale|Clinical assessment of severity of respiratory failure
48493797|NCT03499418|DIAGNOSTIC_TEST|echocardiography|echocardiographic evaluation of haemodynamic problems
48493798|NCT05065983|BIOLOGICAL|CHIKV VLP, adjuvanted|Adjuvanted formulation includes aluminum hydroxide
48335197|NCT00574444|PROCEDURE|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
48335198|NCT05800509|BEHAVIORAL|Clips Intervention|A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
48335199|NCT05800509|DEVICE|Structured Questionnaire Only|A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
48335200|NCT01022151|DRUG|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
48335201|NCT01022151|DRUG|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
48335202|NCT01022151|DRUG|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
48335203|NCT01022151|DRUG|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
48335204|NCT01022151|DRUG|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
48335205|NCT01022151|DRUG|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
48335206|NCT03091426|DRUG|Omiganan|Omiganan 1%
48335207|NCT03091426|DRUG|Omiganan|Omiganan 1.75%
48335208|NCT03091426|DRUG|Omiganan|Omiganan 2.5%
48335209|NCT03091426|DRUG|Placebo|Vehicle
47976716|NCT06384040|PROCEDURE|platelet-rich plasma knee injection|platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder
48335210|NCT06031376|DRUG|Fruquintinib|5mg once daily for 14 days on/7 days off, over a 21-day cycle
48335211|NCT06031376|DRUG|PD-1 inhibitors|The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.
48128051|NCT04595474|DEVICE|Transient Elastography|Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis
48128052|NCT05308069|DEVICE|Single vision contact lens|Subjects will wear a single vision soft contact lens only during the study visit
48128053|NCT05308069|DEVICE|Multifocal contact lens|Subjects will wear a multifocal soft contact lens only during the study visit
48335212|NCT06031376|DRUG|Trifluridine/Tipiracil|TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
48335213|NCT06031376|DRUG|Bevacizumab|Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
48335214|NCT02053558|DRUG|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
48335215|NCT02053558|DRUG|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
48653378|NCT06308211|OTHER|MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY|Subjects will be instructed to watch the video provided and recorded by investigator.In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.Participants will be than instructed to carry out the task in verbal commands given whenever necessary.The unaffected limb will be placed in front of the mirror so that the reflected illusion of the limb would be hallucinated to represent the affected limb and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions).
48128054|NCT00145470|DRUG|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
48128055|NCT00145470|DRUG|Placebo|Placebo fast dissolving SL tablets, BID
48335216|NCT01174888|DRUG|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
48335217|NCT01174888|DRUG|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
48128056|NCT01834846|PROCEDURE|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
48335218|NCT01174888|DRUG|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
48335219|NCT01174888|DRUG|etoposide|Patients receive etoposide IV over 1 hour
48335220|NCT01174888|DRUG|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
48335221|NCT01618526|DIETARY_SUPPLEMENT|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
47976717|NCT04616378|OTHER|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
48335222|NCT01618526|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
48653379|NCT06308211|OTHER|MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY|"Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training. Patient will be asked to practice task in both sitting and standing~* supine to side-lying to sitting~* looking up at ceiling (ensure that centre of body mass does not move back when head is tilted back)~* without moving one's feet, turning to gaze over each other's shoulders and scanning the surroundings for specific items, reaching motions in multiple directions while moving the head and trunk, scooting in bed, altering the base of support (standing with your feet together, in tandem, with one foot on a step, or on one leg)~* squatting to pick up an object and cross over stepping and routine physical therapy includes Passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions)."
48653380|NCT05725434|BIOLOGICAL|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
48653381|NCT05725434|BIOLOGICAL|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
47976718|NCT04616378|OTHER|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
47976719|NCT04616378|OTHER|Phase 3 No Prosthesis|No prosthetic device is attached.
47976720|NCT04616378|OTHER|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
48128057|NCT01834846|PROCEDURE|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
48128058|NCT04941703|DRUG|Magnesium Citrate plus probiotic|296 ml magnesium citrate
48128059|NCT05220943|BEHAVIORAL|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
48335223|NCT02418767|DRUG|MOD-4023|
48653382|NCT05986487|DEVICE|CPAP or usual practice|CPAP (continuous positive airway pressure) is a machine that uses mild air pressure to keep breathing airways open while you sleep.
48653383|NCT05986487|DEVICE|Monitoring and intervention in follow-up|Each participating center can incorporate monitoring and intervention in the follow-up of patients into their work dynamics. Through the use of mobile applications, you can monitor the variables of: weight, diet, lifestyle, exercise and sleep. This intervention will help the patient to improve in different aspects of their health.
47976721|NCT04616378|OTHER|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
47976722|NCT00076284|DRUG|GW873140|
47976723|NCT02059486|BEHAVIORAL|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
48128060|NCT01074359|DRUG|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
48128061|NCT01074359|DRUG|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
48335224|NCT02418767|DRUG|Placebo|
48335225|NCT01945268|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
48493799|NCT05500118|OTHER|Patients Decision Aids|Patient Decision Aids (PDAs) are an important way to facilitate making decision by patients, helping patients make specific and prudent choices by providing information about treatment options and corresponding outcomes, including benefits and risks, related to their health status. The purpose of PDAs is to encourage patients to participate in decision-making. It makes it easier for patients and doctors to discuss treatment options. It effectively promotes communication between patients and doctors. It can help patients combine their own needs and professional advice to make better, more individualized diagnosis and treatment options.
48493800|NCT01431859|BIOLOGICAL|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
48493801|NCT01431859|OTHER|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
48493802|NCT01598350|DEVICE|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
48128062|NCT00090519|DRUG|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
48128063|NCT00090519|DRUG|placebo|QD oral for up to 36 months
48128064|NCT06324786|BEHAVIORAL|IBMT|IBMT is an effortless mindfulness technique
48128065|NCT06324786|BEHAVIORAL|NF|NF is a mental training technique.
48653384|NCT06346132|DEVICE|Virtual reality application|In this group, virtual reality will be added to usual care
48653385|NCT04581577|OTHER|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
48653386|NCT06641089|DRUG|Sonelokimab|Sonelokimab
48653387|NCT06641089|DRUG|Placebo|Placebo
48653388|NCT06641089|DRUG|Risankizumab|Active comparator
48653389|NCT02512939|PROCEDURE|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
48653390|NCT06189313|DEVICE|Cleaner Pro Thrombectomy System|"The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister."
48653391|NCT05655078|RADIATION|Proton beam therapy|5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
48653392|NCT03526666|OTHER|Peripheral blood collection|Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
48653393|NCT05933603|DRUG|Atomoxetine and Oxybutynin (ato-oxy)|0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
48653394|NCT05798585|PROCEDURE|ESP block|US guided ESP infiltration (saline solution vs Ropivacaine 0.375% according to randomization): unilateral injection of 0,4 ml kg -1 (ideal weight)2 under US guidance between the deep fascia of erector spinae muscle and the two transverse processes at the level of the 5th thoracic vertebrae. Duration approximately 10-15 minutes
48128066|NCT05910203|OTHER|The effectiveness of education|Training will be provided on smoking cessation.
48128067|NCT03230903|OTHER|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
48128068|NCT03230903|OTHER|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
48335226|NCT01945268|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
48335227|NCT00004898|BIOLOGICAL|filgrastim|
48335228|NCT00004898|DRUG|cyclophosphamide|
48335229|NCT00004898|DRUG|etoposide|
48335230|NCT00004898|PROCEDURE|peripheral blood stem cell transplantation|
48335231|NCT00004898|RADIATION|radiation therapy|
48335232|NCT02970396|BEHAVIORAL|self-management|
48653395|NCT06641453|BIOLOGICAL|GPC3-CART cells|"Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D."
48653396|NCT06641453|DRUG|Fludarabine Phosphate for Injection|Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
48653397|NCT06641453|DRUG|Cyclophosphamide for Injection|Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
48653398|NCT02133872|DRUG|Minocycline dose escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
48653399|NCT01933555|BEHAVIORAL|Empowerment Program|
48493803|NCT04553861|DEVICE|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
48335233|NCT00189787|DRUG|tacrolimus|
48335234|NCT02907671|PROCEDURE|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
48335235|NCT03210064|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
48335236|NCT03210064|DRUG|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
48335237|NCT00695513|DIETARY_SUPPLEMENT|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
48335238|NCT00054184|DRUG|docetaxel|
48493804|NCT04553861|DEVICE|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
48493805|NCT01573169|DRUG|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
48493806|NCT01573169|OTHER|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
48335239|NCT00054184|DRUG|paclitaxel poliglumex|
48335240|NCT04306978|OTHER|CareLink Express RM system|CareLink Express remote monitoring system consists of implantable pacemaker CareLink Express station for implanted Medtronic cardiac devices and provides remote data transmissions
48335241|NCT04306978|OTHER|Standard follow-up|Follow-up will be provided according to the standard guidelines (HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations; 2008)
48493807|NCT05167604|DRUG|Adjuvants, Pharmaceutic|Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
48493808|NCT02196519|DEVICE|Sylys Surgical Sealant|
48335242|NCT01521806|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to snack foods
48335243|NCT00860119|DRUG|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
48493809|NCT05227612|DRUG|Psilocybin|Participants will receive two doses of psilocybin (10mg, 25mg) as well as 12 sessions of CBT.
48493810|NCT04319159|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
48335244|NCT00860119|DRUG|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
48335245|NCT03037606|DRUG|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
48335246|NCT03037606|DRUG|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
48335247|NCT04702984|DEVICE|LID021201 contact lenses|Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
48335248|NCT04702984|DEVICE|OPTI-FREE multipurpose solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
48335249|NCT01203722|DRUG|Fludarabine|Fludarabine 30 mg/m2/day
48335250|NCT01203722|DRUG|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
48335251|NCT01203722|RADIATION|Total Body Irradiation|400 cGy TBI administered in a single fraction
48493811|NCT05435716|DEVICE|C-wave™ peripheral seismic waveguide system|In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
47976724|NCT00805103|RADIATION|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
47976725|NCT02113592|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
47976726|NCT00642876|DEVICE|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
48493812|NCT05435716|DEVICE|Peripheral vascular balloon dilatation catheter (PTA)|Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
48493813|NCT00541970|BIOLOGICAL|Cervarix|Intramuscular injection, different dosing /schedule
48493814|NCT00541970|DRUG|Placebo|Intramuscular injection, different dosing /schedule
48493815|NCT01509742|DRUG|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
48493816|NCT01509742|DRUG|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
48493817|NCT00005614|DRUG|Gemcitabine hydrochloride|Gemcitabine via IV
48493818|NCT01870882|BEHAVIORAL|Attentional retraining|
48493819|NCT01870882|BEHAVIORAL|Control condition|
48493820|NCT02293330|DRUG|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
48493821|NCT02293330|DRUG|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
48493822|NCT03983252|DRUG|[F-18]PBR06|PET radiopharmaceutical
47976727|NCT00642876|DEVICE|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
47976728|NCT02344485|PROCEDURE|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
48335252|NCT01203722|PROCEDURE|Allogeneic Blood or Marrow Transplant|
48335253|NCT01203722|PROCEDURE|Peripheral Blood Stem Cell Transplant|
48335254|NCT01203722|DRUG|Mycophenolate Mofetil|15mg/kg by mouth three times daily
48335255|NCT01203722|DRUG|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
48335256|NCT01203722|DRUG|Tacrolimus|Tacrolimus 1mg intravenously, daily
48335257|NCT05185817|BIOLOGICAL|Pasocovac vaccine|All enrolled post-Allo-SCT participants who meet the inclusion criteria are recruited to study from 3 to 12 months after Allo-HSCT and vaccinated with 2 doses of Pastucovac, with a 4-week (±7 days) interval and a booster dose at an 8-week (±7 days) interval from the second dose.
48335258|NCT00571688|DRUG|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score \> 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
48128069|NCT06510595|OTHER|Active Treatment Arm|"Electrotherapy:~Transcutaneous Electrical Nerve Stimulation (TENS) will be placed across the fracture segments. The setting will be adjusted to 2±0.4 Hz sinusoidal wave, with a pulse width set between 50-200 microseconds, and each session will last between 20-30 minutes.~Active Elbow Flexion Exercise:~Following the electrotherapy session, the child will perform active assisted elbow flexion exercises with the forearm in a neutral position. This exercise will consist of 3 sets of 15 repetitions to enhance the role of the horizontal components of the brachioradialis muscle force."
48128070|NCT06510595|OTHER|Control Treatment Arm|The child will wear a brace as a conservative treatment method.
48335259|NCT00571688|DRUG|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
48335260|NCT04016103|DEVICE|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
47976729|NCT04161989|DRUG|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
48335261|NCT03351010|BEHAVIORAL|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
48335262|NCT03351010|DEVICE|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
48493823|NCT03095313|OTHER|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol \[Omnipaque™\]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
47976730|NCT04161989|DRUG|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
47976731|NCT00125801|DRUG|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
47976732|NCT05021991|DRUG|100 mg PRAX-944|Once daily oral treatment with titration
47976733|NCT05021991|DRUG|60 mg PRAX-944|Once daily oral treatment with titration
47976734|NCT05021991|DRUG|Placebo|Once daily oral treatment
47976735|NCT05021991|DRUG|Flexibly dosed 20 mg to 100 mg PRAX-944|Once daily oral treatment
47976736|NCT03130361|DEVICE|Non-Invasive Ventilation|
47976737|NCT02224040|DRUG|ceftriaxone|
47976738|NCT02224040|DRUG|ceftriaxone and azithromycin|
48128071|NCT01995903|DIAGNOSTIC_TEST|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
48128072|NCT01693211|DEVICE|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
48128073|NCT01693211|DEVICE|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
48128074|NCT03377205|DEVICE|Compression screws and neutralization plate|Open reduction and internal fixation with screws and plate
48128075|NCT03377205|DEVICE|Acumed Fibular Rod System|intramedullary nailing of fibula
48335263|NCT03347006|DIETARY_SUPPLEMENT|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~* Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups \[this will be on a 1:1:1:1:1:1:1:1 ratio\]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
48335264|NCT05859360|OTHER|Physical performance and cardiovascular health measures|"* Retinal vessel analysis~* Muscle ultrasound~* Knee extension~* Voluntary activation~* spiroergometry"
48493824|NCT06319937|DIAGNOSTIC_TEST|Ultrasound|Ultrasound
48128076|NCT02355041|BEHAVIORAL|Meal Replacement-based Weight Loss Diet|
48335265|NCT04507178|DRUG|Nadroparin Injectable Product|high dose LMWH compared to prophylactic dose LMWH
48335266|NCT01262599|DEVICE|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
47976739|NCT02224040|DRUG|azithromycin|
47976740|NCT02224040|DRUG|azithromycin and cefixime|
47976741|NCT05619081|BEHAVIORAL|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
47976742|NCT01655472|DEVICE|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
47976743|NCT01655472|DEVICE|imaging follow up: Ultrasonographic examination|
47976744|NCT00468182|DRUG|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
47976745|NCT01129648|DRUG|Placebo|Administered daily for 21 days
47976746|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976747|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976748|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976749|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
47976750|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976751|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
48335267|NCT01262599|DEVICE|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
48493825|NCT01168765|BEHAVIORAL|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
48493826|NCT00000607|DEVICE|Left ventricular assist device|A type of implantable heart pump
48493827|NCT00000607|DEVICE|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
48653400|NCT05211466|OTHER|Digital healthcare platform|In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
48653401|NCT04603287|DRUG|SI-B001|Administration by intravenous infusion.
48653402|NCT02132260|DRUG|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
48653403|NCT02132260|DRUG|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
48335268|NCT06301594|BEHAVIORAL|Systematic simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week"
48335269|NCT03771443|DRUG|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
48493828|NCT05631834|PROCEDURE|Thoracic epidurale|Epidurale Perioperative infusion of Ropivacaine
48493829|NCT05631834|PROCEDURE|Erector spinae block|erector spinae interfascia Perioperative infusion of Ropivacaine
48493830|NCT00611481|BEHAVIORAL|Tai Chi|a set of pre-designed Tai Chi Movements
48493831|NCT00611481|BEHAVIORAL|Strength training|Lower-extremity strength training exercises
48493832|NCT00611481|BEHAVIORAL|Low-Impact Exercise Control|a set of chair-based low-impact exercises
48653404|NCT02132260|DRUG|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
48493833|NCT06395779|BEHAVIORAL|Neuromuscular Exercise Group|A 12-week Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns will be created for the participants in Group 1.
48493834|NCT06395779|BEHAVIORAL|Dance Therapy Group|Participants in Group 2 will be given dance training by a dance instructor in the gym for 1 hour a day, 2 days a week, for a total of 12 weeks. In dance therapy practices, simple and basic movements are appropriate to the level of the participants, and special attention will be paid to the rhythm of the music not being fast. Latin dances were applied to the participants; selected rumba, merengue, bachata, and salsa movements. Dance therapy will start with a warm-up exercise (10 minutes), then dance exercises will be applied and the activity will end with a cool-down exercise (10 minutes).
48493835|NCT06007131|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
48493836|NCT03138226|PROCEDURE|uterus transplantation|
48493837|NCT00142233|DIETARY_SUPPLEMENT|ANTOX (vers.)1.2|"300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)"
48493838|NCT00142233|DRUG|Magnesium|"15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)"
48493839|NCT00142233|OTHER|Placebo ANTOX (vers)1.2|Placebo ANTOX (vers)1.2
48493840|NCT00142233|OTHER|Placebo Magnesiocard (2.5 mmol)|Placebo Magnesiocard (2.5 mmol)
48493841|NCT02737332|DRUG|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
48653405|NCT04878471|DRUG|Pudexacianinium chloride|Intravenous
48653406|NCT04878471|DRUG|Placebo|Intravenous
48653407|NCT00694590|DRUG|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
47976752|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976753|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
48335270|NCT04992637|BEHAVIORAL|ClockWork|ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity \& Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.
47976754|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
48335271|NCT04992637|OTHER|Usual Care|Usual Care consists of the standard care that postpartum women receive without any additional intervention components.
47976755|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976756|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976757|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
47976758|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976759|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976760|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
47976761|NCT01129648|DRUG|BCX4208|Adminstered daily for 21 days
47976762|NCT01852578|DRUG|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
47976763|NCT04016285|DEVICE|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
47976764|NCT04016285|DEVICE|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
47976765|NCT03576976|BEHAVIORAL|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
47976766|NCT02566434|DIETARY_SUPPLEMENT|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
47976767|NCT01102400|DRUG|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
47976768|NCT02322034|OTHER|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
48335272|NCT00886106|DRUG|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
48653408|NCT04297735|OTHER|Standard of care group|Visits every 6 months is standard of care.
47976769|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
47976770|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
48653409|NCT04297735|BEHAVIORAL|Telemedicine group|Conduct monthly telemedicine 'skype' visit
48653410|NCT04297735|BEHAVIORAL|Telemedicine|Review details of medication indication and use, activity recommendations and changes, and knowledge of arrhythmia changes and activities which are helpful with arrhythmia changes.
48653411|NCT05299671|BEHAVIORAL|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
48128077|NCT02355041|BEHAVIORAL|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
48128078|NCT04185636|DEVICE|MolecuLight i:X imaging|The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.
48128079|NCT03290859|PROCEDURE|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
48128080|NCT03821636|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
48128081|NCT03821636|PROCEDURE|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
48128082|NCT03500822|PROCEDURE|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
48128083|NCT03500822|PROCEDURE|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
48128084|NCT00698113|PROCEDURE|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
48128085|NCT00698113|OTHER|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
48128086|NCT05447936|DIETARY_SUPPLEMENT|Jarlsberg cheese|Jarlsberg cheese is a regular cheese for free sale in grocery stores. The allotted amount of cheese was taken orally each day
48128087|NCT02129595|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
48128088|NCT02129595|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
48128089|NCT04209712|BIOLOGICAL|haploid allogeneic NK cell therapy|NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.
48128090|NCT02097381|DRUG|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
48128091|NCT02419703|DEVICE|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
48128092|NCT02348866|OTHER|method of laundering and donning scrubs|
48128093|NCT04325711|DRUG|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
48128094|NCT05022615|DIAGNOSTIC_TEST|Topcon Camera|Standard 7 field imaging
48335273|NCT00886106|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
47976771|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
47976772|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
47976773|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
47976774|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
47976775|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
48335274|NCT02577367|DRUG|Levothyroxine|Administer Levothyroxine
48493842|NCT02737332|DRUG|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
48493843|NCT02812979|DEVICE|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
48493844|NCT02812979|DEVICE|Mask|Usual nebulization of salbutamol with mask
48335275|NCT05468723|DEVICE|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses \[which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)\] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
48335276|NCT01705587|DRUG|teriparatide|20 microgram once-daily subcutaneous injection
48493845|NCT02812979|DEVICE|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
48493846|NCT03972449|BEHAVIORAL|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
48493847|NCT03972449|BEHAVIORAL|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
48493848|NCT03784521|DEVICE|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
48493849|NCT03784521|DEVICE|Standard care|Patients are treated with standard intravenous solutions and vascular access management
48493850|NCT00801359|PROCEDURE|Phacoemulsification|
48493851|NCT00801359|DRUG|BSSPlus solution|
48493852|NCT00801359|DRUG|Lactated Ringer's solution|
48493853|NCT02643017|DRUG|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
48493854|NCT02643017|DRUG|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
48493855|NCT00204165|PROCEDURE|MRI of the small bowel|
48493856|NCT03952611|PROCEDURE|Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
48493857|NCT03952611|DEVICE|distal Cap|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
47976776|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
47976777|NCT00321945|PROCEDURE|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
48493858|NCT03952611|DEVICE|Endocuff|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
48493859|NCT06278571|BEHAVIORAL|Educational intervention with App and web site education|This group will only receive intervention with access to the educational website from home, where they will review the different modules focused on diabetes care, nutrition and exercise. in addition to the usual medical care by your treating physician.
48493860|NCT06278571|BEHAVIORAL|Educational interventión with web site education|This group will receive, in addition to nutritional therapy, diabetes education through an educational site, to learn more about the most important aspects of diabetes care. In addition to the usual medical care by your treating physician.
47976778|NCT00870571|DRUG|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
47976779|NCT00870571|DRUG|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
47976780|NCT05654753|DRUG|active FMT|MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.
47976781|NCT05654753|DRUG|Placebo|Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
47976782|NCT06140784|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48335277|NCT03906175|DEVICE|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
48335278|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
48493861|NCT06278571|OTHER|Control group with nutritional therapy|This group will receive only the usual medical care by your treating physician.
48493862|NCT02558231|DRUG|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
48493863|NCT02558231|DRUG|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
48493864|NCT02558231|DRUG|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
48493865|NCT03780231|OTHER|non-ischemic scar|"non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR"
48493866|NCT04149795|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
48493867|NCT02702713|DIETARY_SUPPLEMENT|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
48493868|NCT02702713|DIETARY_SUPPLEMENT|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
48493869|NCT02702713|DIETARY_SUPPLEMENT|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
47976783|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
47976784|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48128095|NCT05022615|DIAGNOSTIC_TEST|Optos Camera|Ultrawide field imaging
48128096|NCT05022615|DIAGNOSTIC_TEST|Clarus Camera|Ultrawide field imaging
48128097|NCT03637296|OTHER|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
48128098|NCT02987192|DEVICE|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
48128099|NCT02987192|DEVICE|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
48128100|NCT02672891|DEVICE|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
47976785|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48128101|NCT06455683|PROCEDURE|Glaucoma Surgery|"One of 5 Types of Interventions will be performed~1. Trans-trabecular meshwork surgery with or without an implant~2. Trans-scleral surgery with or without implant~3. Ciliary Body Treatment~4. Suprachoroidal surgery with or without implant~5. External Non Incisional Treatment"
48128102|NCT05165459|DEVICE|Venous leg ulcer treatment with adipous SVF|The Celution® System isolates approximately maximum 30 million SVF cells per 100 mL of adipose tissue to be processed. Approximately 1-3 million cells per injection (total 8-30) will be administered locally, in the target ulcer.
48128103|NCT04467671|COMBINATION_PRODUCT|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
48128104|NCT00176800|DRUG|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
48128105|NCT00176800|PROCEDURE|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
48128106|NCT00176800|PROCEDURE|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
48128107|NCT02790281|PROCEDURE|Blood sampling|Blood sample collected at a single visit
48128108|NCT05171985|PROCEDURE|Dexmedetomidine sedation|72 cases sedated on Propofol infusion 50-200 mg/h + Fentanyl infusion 25-250 mcg/h guided by hemodynamics in addition to Dexmedetomidine infusion 0.2 - 1 mcg/kg/h, and also guided by hemodynamics.
48128109|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg|
48128110|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 75µg|
48128111|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 100µg|
48128112|NCT05674669|DRUG|Placebo/Lysergic Acid Diethylamide (LSD) 75µg|
48493870|NCT02702713|DIETARY_SUPPLEMENT|Bakery placebo|Bakery placebo: Biscuits without enrichment
48493871|NCT02702713|DIETARY_SUPPLEMENT|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
48493872|NCT02702713|DIETARY_SUPPLEMENT|Egg placebo|Egg placebo: Frozen pancakes without enrichment
48493873|NCT00393965|DRUG|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
48493874|NCT03863093|DEVICE|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
48493875|NCT03863093|DEVICE|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
47976786|NCT02257944|BEHAVIORAL|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
47976787|NCT02257944|OTHER|Treatment as Usual|treatment as usual
47976788|NCT02707874|DRUG|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
47976789|NCT02707874|DRUG|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
47976790|NCT05085652|PROCEDURE|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
47976791|NCT03030508|OTHER|No intervention|
48128113|NCT05674669|DRUG|Lysergic Acid Diethylamide (LSD) 50µg/75µg|
48128114|NCT05459701|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once daily for 24 weeks.
48128115|NCT05459701|OTHER|Placebo|Placebo
48335279|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
48335280|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
48493876|NCT04766736|PROCEDURE|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
48128116|NCT01189929|DRUG|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
48128117|NCT01189929|DRUG|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
48128118|NCT01189929|DRUG|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
48128119|NCT01091649|DRUG|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
48128120|NCT01091649|DRUG|ritonavir|ritonavir see Arm Description for more information
48128121|NCT01091649|DRUG|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
47976792|NCT03007576|BIOLOGICAL|RegStem|RegStem, 1.5 ml, one injection
47976793|NCT01753791|DRUG|80 mg PF-06473871|80 mg of PF-06473871 or placebo
47976794|NCT01753791|DRUG|160 mg PF-06473871|160 mg of PF-06473871 or placebo
47976795|NCT01753791|DRUG|320 mg PF-06473871|320 mg of PF-06473871 or placebo
47976796|NCT01753791|DRUG|480 mg PF-06473871|480 mg of PF-06473871 or placebo
47976797|NCT06382298|OTHER|COTTONSEED OIL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as cottonseed oil for 28 days.
47976798|NCT06382298|OTHER|MATCHED PUFA DIET|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs from oils with similar fatty acid composition as CSO for 28 days.
47976799|NCT06382298|OTHER|CONTROL|Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
47976800|NCT01533389|DRUG|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
47976801|NCT01533389|DRUG|Placebo|dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
47976802|NCT02551276|DRUG|Salbutamol|
47976803|NCT02551276|DRUG|Placebo|
47976804|NCT02551276|OTHER|Resistance training|
47976805|NCT06391723|DEVICE|Active rTMS|rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)
47976806|NCT06391723|DEVICE|Sham rTMS|Sham rTMS will be administered over the left dorsolateral prefrontal cortex
47976807|NCT03268720|OTHER|FODMAP low diet|2 week FODMAP low diet
47976808|NCT03268720|OTHER|gluten-free diet|2 week gluten-free diet
47976809|NCT02883153|DRUG|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
47976810|NCT00007969|BIOLOGICAL|Detox-B adjuvant|
47976811|NCT00007969|DRUG|verteporfin|
47976812|NCT02902419|OTHER|Wound dressing removal.|
47976813|NCT01760707|BEHAVIORAL|exercise training|
47976814|NCT01760707|BEHAVIORAL|usual care|
47976815|NCT00721552|DRUG|Sitagliptin 100 mg|28 days administration of 100 mg daily
47976816|NCT00721552|DRUG|Prednisolone 30 mg|14 days administration of 30 mg daily
48128122|NCT04503772|PROCEDURE|Preoperative SRS|Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.
48128123|NCT00730509|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
48128124|NCT00331136|DRUG|Pyronaridine-Artesunate|Once a day for 3 days
48335281|NCT01080612|DRUG|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
48335282|NCT02847845|DIETARY_SUPPLEMENT|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
48335283|NCT02847845|DIETARY_SUPPLEMENT|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
47976817|NCT00721552|DRUG|Sitagliptin-placebo|28 days administration once daily
47976818|NCT00721552|DRUG|Prednisolone-placebo|14 days administration once daily
47976819|NCT06231615|OTHER|Fascia exercises|Fascia exercises are slow and calm movements similar to yoga performed by the person herself/himself.
47976820|NCT06231615|OTHER|Conventional physiotherapy and breathing exercises|Head and neck exercises and breathing exercises
47976821|NCT01923220|DRUG|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
47976822|NCT01923220|OTHER|Aloe Vera Jel|To be applied topically once daily
47976823|NCT02079181|RADIATION|fluorine F 18 d-FMAU|Given IV
47976824|NCT02079181|PROCEDURE|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
47976825|NCT02079181|PROCEDURE|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
47976826|NCT00081484|DRUG|epoetin alfa or beta|iv or sc, as prescribed
48493877|NCT03610568|BEHAVIORAL|Growing up GREAT! Intervention|The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
48493878|NCT01411865|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
48493879|NCT01411865|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
48493880|NCT01646047|DIETARY_SUPPLEMENT|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
48128125|NCT03450460|BEHAVIORAL|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
47976827|NCT00081484|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
48128126|NCT06165146|DRUG|Repaglinide|Administered orally.
48128127|NCT06165146|DRUG|Pirtobrutinib|Administered orally.
48128128|NCT00276276|DRUG|topotecan|
48128129|NCT04017793|BEHAVIORAL|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
48335284|NCT00546234|DRUG|tiotropium|18 mcg daily via Handihaler
48335285|NCT00546234|DRUG|long acting beta agonist|Turbohaler, 6 \& 12 mcg
48335286|NCT01902004|DRUG|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
48493881|NCT01646047|DIETARY_SUPPLEMENT|multi-component dietary supplement|placebo capsules
47976828|NCT00742534|DRUG|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
47976829|NCT02033694|DEVICE|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
47976830|NCT06352281|BIOLOGICAL|CAR-T cells|CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
47976831|NCT00720434|DRUG|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
47976832|NCT00720434|DRUG|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
47976833|NCT00720434|DRUG|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
47976834|NCT00720434|DRUG|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
47976835|NCT03716024|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
48128130|NCT04017793|BEHAVIORAL|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
48128131|NCT00051298|DRUG|Olanzapine|
48128132|NCT00051298|DRUG|Placebo|
48335287|NCT01902004|DRUG|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
48335288|NCT01902004|DRUG|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
47976836|NCT03716024|DRUG|Linezolid|Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
48335289|NCT00323310|DRUG|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
48335290|NCT00093756|RADIATION|3-dimensional conformal radiation therapy|
48335291|NCT00093756|DRUG|bortezomib|Given IV
48128133|NCT03656211|OTHER|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
48128134|NCT00147719|DRUG|Colesevelam hydrochloride|
48128135|NCT01690416|PROCEDURE|Traditional palpation technique|
48128136|NCT01690416|PROCEDURE|Ultrasound DNTP|
48128137|NCT04409470|DIAGNOSTIC_TEST|Blood gas sampling from artery and vein|Patients included in this study are treated according to clinical routine. After inclusion, sampling of an arterial blood gas and a venous blood gas is performed simultaneously or as close in time as possible. Because the venous blood gas analysis sample can be taken directly from the patient's peripheral venous catheter, no additional venous puncture is usually required and the additional amount of blood that may be required is approx. 1 ml (the assay requires about 500 µl). In the very rare cases where it is not possible to establish a peripheral venous catheter within a reasonable time, the sample will be acquired from a new venous puncture together with other venous routine samples.
48128138|NCT05065203|PROCEDURE|planned or unplanned Cesarean, operative, or non operative delivery|All types of delivery
48128139|NCT05729997|OTHER|Listening to live classical music|The group of musicians perform music in the hemodialysis room while patients receive treatment.
48128140|NCT04851743|OTHER|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
48128141|NCT06145802|BIOLOGICAL|GT316|Autologous Tumor Infiltrating Lymphocyte Injection
48128142|NCT04897633|DEVICE|transcranial electric stimulation|Simon's task assessment when under tDCS
47976837|NCT06359470|OTHER|Positioning technique|"First time of testing: Firstly, the patients were scanned in the conventional neutral supine position and a 3D-CT scan was taken.~Second time of testing: after 10 minutes, the patients were scanned in the modified reversed contralateral rotation (side-lying on a hard pillow with side bending to the non-affected side and rotation to non affected side). This is achieved through instructing the participant to first lie on the side lying on a wedge pillow (that is flexible with dimensions of 30 cm in height and 75 cm in length) to achieve trunk side bending to non-affected side this pillow is the same for all patients, then the patient/participant rotated to the affected side (pelvis on the trunk rotation), and 3D-CT scan.~Third time of testing: after 48 hours, the patients were scanned in the modified reversed contralateral rotation."
47976838|NCT05612789|BEHAVIORAL|Exercise Program (Cohort A Prehab)|Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
48128143|NCT02132455|PROCEDURE|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
48128144|NCT02127749|DRUG|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
48128145|NCT02127749|DRUG|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
48128146|NCT01721291|DRUG|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
48128147|NCT02852824|DRUG|BI 655130 (spesolimab)|
48128148|NCT02852824|DRUG|Placebo|
48128149|NCT06514417|OTHER|US-guided external oblique intercostal block|"After induction of general anesthesia, external oblique intercostal block will be performed (8) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz).~the patient will be positioned supine, and a linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib. 20 ml of bupivacaine 0.25% will be injected between the plane of the external oblique and the intercostal muscles. The drug will be injected after a negative aspiration.~The contralateral side block will be performed in a same manner."
48128150|NCT04761016|OTHER|Usual Care|The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.
48128151|NCT04761016|OTHER|I-POP + CHW navigation|Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
48493882|NCT00417404|DRUG|Aquasol A|IM Aquasol A 10,000IU three times weekly
48493883|NCT00417404|DRUG|aquasol A|10,000 IU three times weeks, by intramuscular injection
48653412|NCT05516134|BEHAVIORAL|SAFE at Home|The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
48653413|NCT02458118|DRUG|Secretin|Secretin 1 IU/kg over 3 min
48128152|NCT03036176|BEHAVIORAL|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
48128153|NCT03036176|OTHER|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
48128154|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 5.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
48128155|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 10.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
48128156|NCT06109493|BEHAVIORAL|ACT|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
48128157|NCT03782870|DIAGNOSTIC_TEST|echocardiography, lab tests|
48128158|NCT02261506|OTHER|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
48128159|NCT02261506|OTHER|14 days of adequate antibiotic treatment durations|
48128160|NCT02009228|PROCEDURE|Ovarian cystectomy|
48128161|NCT02572700|OTHER|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
48128162|NCT04800042|DIAGNOSTIC_TEST|Diagnostic test|Blood iron status : ferritin and transferrin saturation factor
48128163|NCT03230006|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion, over 16 sessions, following the published therapist guide with minor refinements for application in the proposed comorbid population.
48335292|NCT00093756|DRUG|paclitaxel|Given IV
48653414|NCT06447480|DRUG|ISOtretinoin 5 MG|"The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d.~After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended."
47976839|NCT05612789|BEHAVIORAL|Exercise Program (Cohort B Rehab)|All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
47976840|NCT05004766|OTHER|Robot assisted gait training with virtual reality|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
47976841|NCT03740061|DIAGNOSTIC_TEST|Ultrasonographic assessment of muscle|Ultrasonographic assessment of quadriceps muscle
47976842|NCT03649750|DRUG|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
48335293|NCT00093756|DRUG|carboplatin|Given IV
48335294|NCT06304363|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
48335295|NCT04716478|OTHER|Clinical and radiological data collection|No specific intervention. Data of the usual care will be collected as the demographic data, the medical history, imaging report, etc.
47976843|NCT01008007|DIETARY_SUPPLEMENT|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
47976844|NCT01008007|DRUG|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
48128164|NCT03230006|BEHAVIORAL|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
47976845|NCT03938389|DRUG|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
47976846|NCT03938389|DRUG|Valsartan 160mg|Participant will take Valsartan for 26 weeks
47976847|NCT03938389|DRUG|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
48128165|NCT04531059|DRUG|Esomeprazole|Proton pump inhibitor
48128166|NCT04531059|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
48128167|NCT04531059|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
48128168|NCT04531059|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
48128169|NCT01321164|DEVICE|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
48128170|NCT01321164|DRUG|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
48128171|NCT03411941|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|IVT(Intravitreal) aflibercept treatment in routine clinical practice.
48128172|NCT04295382|DEVICE|Software Application|A software application targeting suicidal ideation via interactive exercises.
48128173|NCT01125124|DRUG|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
48128174|NCT04337931|DRUG|sotigalimab|Sotigalimab is a CD40 agonistic monoclonal antibody
47976848|NCT06508424|OTHER|PulseOn|PulseOn - 1 week washout period between interventions 75g crackers
47976849|NCT06508424|OTHER|Wheat flour control|Control -1 week washout period between interventions 75g crackers
47976850|NCT01850524|DRUG|Ixazomib|IXAZOMIB capsules.
47976851|NCT01850524|DRUG|Placebo|IXAZOMIB matching-placebo capsules.
47976852|NCT01850524|DRUG|Dexamethasone|Dexamethasone tablets.
48128175|NCT02928172|DEVICE|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
48128176|NCT02928172|DEVICE|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
48128177|NCT02848794|DRUG|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
48128178|NCT02109601|OTHER|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
48128179|NCT02109601|OTHER|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
48128180|NCT00735852|DRUG|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
47976853|NCT01850524|DRUG|Lenalidomide|Lenalidomide capsules.
47976854|NCT03018171|DRUG|Clonidine|Intrathecal clonidine addiction
47976855|NCT03018171|DRUG|Sufentanil|Intrathecal
47976856|NCT03508921|DRUG|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
48128181|NCT02809989|DRUG|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
48128182|NCT03592732|OTHER|Blood sample|Blood sample
48128183|NCT04286113|BEHAVIORAL|control group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
48128184|NCT04286113|BEHAVIORAL|Lifestyle management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
48128185|NCT06371755|DEVICE|Ultrasound examination with REMS technology|The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
47976857|NCT03508921|DRUG|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
47976858|NCT03508921|PROCEDURE|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
48128186|NCT00882934|OTHER|Induction to efficient treatment|Informative letters.
48493884|NCT00417404|OTHER|sham injection|sham injection
48493885|NCT01303536|DRUG|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
48493886|NCT01622374|BEHAVIORAL|Music|Ten minutes of music or silence were applied prior to dental procedures
48493887|NCT00973401|OTHER|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
48493888|NCT05134896|DEVICE|Spatial light modulator|This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.
48493889|NCT01775865|DRUG|Salsalate|4 weeks of daily salsalate
48493890|NCT01775865|DRUG|Placebo (for salsalate)|4 week of daily placebo
48493891|NCT01587937|OTHER|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
48493892|NCT02060474|DRUG|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
48493893|NCT05387707|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
48493894|NCT05387707|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
48493895|NCT05387707|DRUG|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
48493896|NCT05387707|DRUG|Placebo|Oral Placebo tablets administered twice daily
48493897|NCT05387707|DRUG|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
48493898|NCT04998019|BEHAVIORAL|PositiveLinks|"The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB)."
47976859|NCT04412720|OTHER|Aerobic and Breathing Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.
48128187|NCT00882934|OTHER|Doubt to the efficacy of treatment|Informative letters.
48128188|NCT00882934|OTHER|Induction to ineffective treatment|Informative letters
48128189|NCT02438137|DRUG|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
48128190|NCT02438137|DRUG|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
48493899|NCT04724044|DRUG|Tablets|Oral tablets of similar appearance to active study drug
48493900|NCT04724044|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
48493901|NCT03752944|PROCEDURE|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
48493902|NCT06284577|DIETARY_SUPPLEMENT|Multistrain Probiotic|Participants will recieve a multi-strain probiotic daily for 6 months
48493903|NCT06284577|DIETARY_SUPPLEMENT|Placebo - maltodextrin|Participants will recieve placebo/ maltodextri daily for 6 months
48493904|NCT04060719|DRUG|BI 894416|tablet
48493905|NCT04060719|DRUG|Rifampicin|tablet
48493906|NCT06242002|PROCEDURE|Set up of sensor|Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
48493907|NCT02468492|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
48493908|NCT02468492|OTHER|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
48493909|NCT03876977|PROCEDURE|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
48493910|NCT05236920|DEVICE|Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device|In-hospital use of a REBOA catheter device during advanced cardiac life support
48493911|NCT04271020|DEVICE|UroLift|"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."
48653415|NCT06447480|DRUG|Topical cream|Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
48128191|NCT04826978|BEHAVIORAL|Auditory environment|Auditory environment
48653416|NCT03546257|DEVICE|magnifying endoscopy with narrow band imaging (ME-NBI)|A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
48128192|NCT02691169|DRUG|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
48128193|NCT04060017|DRUG|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
48128194|NCT04060017|OTHER|Placebo|Placebo
48128195|NCT05121259|OTHER|ExerciseGuide Intervention Group|The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
48128196|NCT01515501|PROCEDURE|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
48128197|NCT03253367|OTHER|Blood is obtained, mostly during routine venipuncture|
48128198|NCT01343459|RADIATION|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~* IOERT is performed on mobile or fixed linacs~* Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~* must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~* In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~* Single reference dose per fraction: 2,7 Gy (ICRU)~* Number of fractions: 15, Number of fractions per week: 5~* Total WBRT dose: 40,5 Gy"
48128199|NCT03604146|BEHAVIORAL|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
48653417|NCT06010251|OTHER|tDCS and bodily illusions|"Participants will be required to perform (in person) 10 interventions over a time frame of 2-4 weeks. They can perform this everyday or for a minimum of 2-3 times per week over 4 weeks.~Two types of illusions will be used 15 min each, the rubber hand illusion and the walking illusion to target upper and lower limbs. These procedures will impact the body representation of the participants resulting in bodily illusions."
47976860|NCT04412720|OTHER|Aerobic and Stretching Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
47976861|NCT00001596|DRUG|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
47976862|NCT00001596|DRUG|Placebo|Placebo (3 pills), three times daily.
48128200|NCT02240420|BEHAVIORAL|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
48128201|NCT03209700|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
48128202|NCT03411174|RADIATION|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
48128203|NCT05141136|PROCEDURE|Ultrasound probe sagittal group|Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
48128204|NCT05141136|PROCEDURE|Ultrasound probe transverse group|Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
48128205|NCT03614273|DRUG|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
48128206|NCT03614273|DRUG|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
48128207|NCT04679675|OTHER|Usual Care|Subjects will receive Kaiser Permanente Washington standard of care.
48653418|NCT00220077|PROCEDURE|Endoscopy|
48128208|NCT04679675|BEHAVIORAL|Education|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
48128209|NCT04679675|BEHAVIORAL|Direct Mail|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
47976863|NCT01223001|DRUG|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
47976864|NCT01223001|DRUG|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
47976865|NCT02786446|DRUG|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
48128210|NCT04679675|BEHAVIORAL|Opt-in|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
48128211|NCT00347204|DRUG|ketorolac (Acular LS)|
48128212|NCT00347204|DRUG|Nepafenac (Nevanac)|
48128213|NCT05766540|DRUG|Aripiprazole 10 MG|Aripiprazole hroup will receive Aripiprazole 10 mg/day along with Clozapine and Metformin
48653419|NCT02440165|BEHAVIORAL|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
48128214|NCT00467272|DRUG|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
48128215|NCT03776500|DRUG|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
48128216|NCT03776500|DRUG|Placebo|matching placebo supplied as powder for oral solution
48128217|NCT05088798|DRUG|18F-Fluoro Dopa PET/MRI Imaging|The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
48335296|NCT05073172|DRUG|Calendula Ointment|Applied topically
48493912|NCT01586403|BIOLOGICAL|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
48493913|NCT01586403|BIOLOGICAL|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
48493914|NCT01586403|BIOLOGICAL|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
48493915|NCT01586403|BIOLOGICAL|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
48653420|NCT06207162|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task. There will also be a Resting state: Participants are not presented with any specific stimulus.
48653421|NCT02821650|OTHER|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
48653422|NCT03201380|OTHER|TEP scanner with choline|
48653423|NCT03889535|DEVICE|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
48128218|NCT04138316|DRUG|Candesartan|Treatment with Candesartan
48128219|NCT05618951|OTHER|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
48128220|NCT04351386|DEVICE|AF Detection|Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
48128221|NCT05470088|OTHER|Neuroimaging (MRI)|Multimodal magnetic resonance imaging
48128222|NCT05295342|BEHAVIORAL|No Means No intervention Girls' Curriculum|"The No Means No (NMN) Girls' Curriculum is a violence prevention program designed for adolescent girls and young women 10-20 years old. This curriculum has been designed specifically for safer implementation during the COVID-19 pandemic. NMN Girls' programming is deeply rooted in Empowerment Self-Defense, which is a uniquely holistic, survivor-centered, feminist approach to self-protection skills. Youth educators called Instructors deliver the curriculum to young people in schools. This 8-hour intervention is comprised of classes that teach young people mental, verbal and physical self-defense skills that can be used to prevent sexual assault and other forms of gender-based violence."
48128223|NCT05295342|BEHAVIORAL|No Means No intervention Boys' Curriculum|"The No Means No (NMN) Boys' Curriculum is a violence prevention curriculum that has been designed specifically for implementation during the COVID-19 pandemic. Designed for adolescent boys and young men age 10-20. Like the girls program it is delivered by youth educators called Instructors in schools. This 8-hour intervention is comprised of classes that teach young people gender equitable attitudes, skills to defend equality and how to avoid violence as a power paradigm."
48128224|NCT05295342|BEHAVIORAL|Active comparator: Life Orientation|The standard school-based Life Orientation curriculum
48335297|NCT05073172|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied topically
48335298|NCT05073172|OTHER|Polyethylene Glycol Hydrogel|Applied topically
48335299|NCT05073172|DRUG|Silicone-based Film Forming Topical Gel|Applied topically
48493916|NCT05369286|DRUG|"MAX-40279-01 and Toripalimab"|"MAX-40279-01combined with Toripalimab"
48335300|NCT05073172|DRUG|Silver Sulfadiazine|Applied topically
48335301|NCT05073172|DRUG|Topical Hydrocortisone|Applied topically
48335302|NCT04505878|DRUG|Vitamin C|Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
40781332|NCT03543124|DEVICE|cap|A commercially available transparent cap (Olympus) will be fitted to the end of the colonoscope.
40781333|NCT03543124|OTHER|Water|Using water instead air to help insertion
48335303|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
47976866|NCT02786446|DRUG|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
47976867|NCT02786446|DRUG|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
48128225|NCT05681234|RADIATION|18F-RD2|Patients will receive 5-10 mCi 18F-RD2
48335304|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
48335305|NCT00724815|DRUG|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
48335306|NCT00724815|DRUG|Placebo|NP101 Placebo iontophoretic transdermal patch
48335307|NCT03616847|OTHER|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
48335308|NCT03616847|OTHER|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
48335309|NCT03532776|DRUG|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
48335310|NCT03532776|DRUG|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
48335311|NCT03532776|DRUG|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
48335312|NCT00640276|DRUG|pitavastatin|Pitavastatin 2mg daily once
48335313|NCT00640276|BEHAVIORAL|Lifestyle Modification|conducting mainly exercises and diet
48335314|NCT05711680|DEVICE|Device|To develop an e-health system to remotely monitor patients with chronic HIV infection and conduct early screening for COVID-19 through a telemonitoring, teleconsultation and periodic remote visit system.
48335315|NCT06185608|DRUG|0.25% ropivacaine|A total of 15 ml of 0.25% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
48335316|NCT06185608|DRUG|0.5% ropivacaine|A total of 15 ml of 0.5% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
48128226|NCT05915000|DIAGNOSTIC_TEST|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
48128227|NCT02295189|DRUG|Ketorolac Tromethamine|anti-inflammatory injection
48335317|NCT06185608|DRUG|1% ropivacaine|A total of 15 ml of 1% ropivacaine will be administered and distributed strategically among the specific nerves: 6 ml for the tibial nerve, 3 ml for the deep peroneal nerve, and 2 ml each for the superficial peroneal nerve, saphenous nerve, and sural nerve.
48335318|NCT00829218|OTHER|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
48335319|NCT00829218|OTHER|Placebo diet|Juice with nothing added.
48335320|NCT03067480|DEVICE|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
48335321|NCT01250652|DRUG|Levocetirizine|20 mg levocetirizine for 5 days
48335322|NCT01250652|DRUG|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
48335323|NCT00259467|BEHAVIORAL|Home-Based Behavorial Intervention|
48335324|NCT04218604|PROCEDURE|Personalized atrial fibrillation ablation|Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)
48128228|NCT02295189|DRUG|Triamcinolone Acetonide|corticosteroid injection
48128229|NCT04965272|DRUG|Cariprazine 0.75 mg/day|Oral Capsule
48128230|NCT04965272|DRUG|Cariprazine 1.5 mg/day|Oral Capsule
48128231|NCT04965272|DRUG|Cariprazine 3.0 mg/day|Oral Capsule
48335325|NCT05703139|PROCEDURE|TRIANGLE procedure|The Triangle procedure aims to develop a novel method for patients with locally advanced pancreatic cancer after neoadjuvant therapy and was described in 2017. The basis of this operation is the notice that after neoadjuvant therapy conventional imaging fails to differentiate between actual tumor encasement and only fibrotic residual tissue mainly to the arterial structures
48335326|NCT04589962|OTHER|access axillary or brachial artery|access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
48335327|NCT06139536|DRUG|BAT4706 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
48335328|NCT06139536|DRUG|BAT1308 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
48493917|NCT01186601|DRUG|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
47976868|NCT03291808|BEHAVIORAL|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
47976869|NCT02299297|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
47976870|NCT01767155|DRUG|AEZS-108 / zoptarelin doxorubicin|267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
47976871|NCT01767155|DRUG|doxorubicin|60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
47976872|NCT01950507|DRUG|Budesonide|Entocort EC 3 mg given orally three times daily for at least 14 days
47976873|NCT01950507|DRUG|Fluconazole|400 mg orally once daily for CrCl greater than or equal to 50 ml/min
47976874|NCT01950507|DRUG|Voriconazole|Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
48128232|NCT04965272|OTHER|Placebo|Oral Capsule
48128233|NCT05623033|OTHER|The study is an observational study without intervention|The study is an observational study without intervention
48128234|NCT05677594|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|Magnetic resonance imaging of the entire body from skull base through distal thighs/knees without contrast material
48128235|NCT04386772|PROCEDURE|PVE with coils plus TAGM|PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
48128236|NCT04386772|PROCEDURE|PVE with multiple coils|Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
48128237|NCT04900467|BIOLOGICAL|Pfizer|BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
48128238|NCT04900467|BIOLOGICAL|Moderna|mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
48128239|NCT04558723|OTHER|ICD/CRT-D implantation|ICD/CRT-D implantation (if indicated)
48128240|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
48128241|NCT02078232|DEVICE|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
48128242|NCT02629224|DRUG|ASP8825|Oral
48128243|NCT00986375|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
48128244|NCT00986375|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
48128245|NCT03331575|RADIATION|Arm1 (Hypofractionated radiotherapy)|hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
48128246|NCT03932162|DRUG|Insulin-Like Growth Factor 1|Growth factor protein
47976875|NCT01950507|DRUG|Micafungin|Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
47976876|NCT00686192|DIETARY_SUPPLEMENT|Calcium Carbonate|1500 mg per day
47976877|NCT01092559|DRUG|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
47976878|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
48128247|NCT03932162|OTHER|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
48128248|NCT03001440|OTHER|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
48128249|NCT03602950|BIOLOGICAL|PRP|autologous PRP will be injected subcutaneously before skin closure at time of elective CS
48128250|NCT05420480|PROCEDURE|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
48128251|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
48128252|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
48128253|NCT00999336|DRUG|Betrixaban|80 mg betrixaban qd for 8 days
48128254|NCT04694014|BEHAVIORAL|EI Open ended Pre-Survey and Semi Structured Interview|Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
48128255|NCT04694014|BEHAVIORAL|Behavioral and Cognitive Assessment|Use Predictive index for both cognitive and behavioral assessment of the paticipants
48128256|NCT04694014|BEHAVIORAL|Geneva Emotional Competence Test (GECO)|Administer the Geneva Emotional Competence Test to each participant
48128257|NCT02755805|BEHAVIORAL|CO-OP|
48128258|NCT02755805|BEHAVIORAL|Attention Control|
48335329|NCT06295406|OTHER|Neuropsychological assessment|Neuropsychological tests assessing reading abilities, skills of motor coordination, postural stability, manual dexterity, including graphomotor skills, and estimation of time will be performed
48335330|NCT02692313|DRUG|Epinephrine|Dose response of epinephrine infusion
48493918|NCT04560348|OTHER|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
48493919|NCT03332238|DEVICE|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
48128259|NCT02190149|BIOLOGICAL|ADVATE (Antihemophilic Factor [Recombinant])|
48128260|NCT02190149|BIOLOGICAL|RIXUBIS (Coagulation Factor IX [Recombinant])|
48128261|NCT00982436|DRUG|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
48128262|NCT00982436|RADIATION|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
48335331|NCT02692313|OTHER|Saline infusion|Placebo
48335332|NCT06047106|RADIATION|multiparametric MRI|"For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment."
48493920|NCT03332238|DEVICE|Ringer's solution|Ringer's solution
48493921|NCT04476719|DRUG|ATAFENOVIR 200 MG KAPSUL|A 200 mg capsule 0ral administration with 240 ml water
48493922|NCT04476719|DRUG|ARBIDOL 100 MG KAPSUL|Two 100 mg capsules will be administrated with 240 ml water orally.
48493923|NCT03939299|PROCEDURE|OCT|Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
48493924|NCT03400072|OTHER|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
48128263|NCT00982436|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
48128264|NCT00530569|PROCEDURE|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
48128265|NCT02002845|DEVICE|robotic surgery using the da Vinci Surgical System|
48128266|NCT00391898|DRUG|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
48128267|NCT00391898|DRUG|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
48128268|NCT00613405|OTHER|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
48128269|NCT00613405|OTHER|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
48493925|NCT03400072|OTHER|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
48128270|NCT02387645|PROCEDURE|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
48128271|NCT00459524|BEHAVIORAL|Questionnaire|Questionnaires taking about 30 minutes to complete.
47976879|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
48128272|NCT00459524|BEHAVIORAL|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
48128273|NCT02031185|BEHAVIORAL|FitBit only|Participants will use the FitBit device
48128274|NCT02031185|BEHAVIORAL|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
47976880|NCT04988646|DRUG|Acyclovir 200 MG|Administered with 240 mL of water
48128275|NCT02986984|OTHER|There is no intervention|There are no interventions
48128276|NCT03781375|DRUG|Etanercept|Administered by subcutaneous injection twice a week
48128277|NCT03781375|DRUG|Placebo to Etanerceot|Administered by subcutaneous injection twice a week
48335333|NCT06047106|PROCEDURE|kidney graft biopsy|Biopsy of the graft itself prior to transplantation in the recipient.
48335334|NCT06047106|BIOLOGICAL|blood samples|"For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant)."
48493926|NCT02618408|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
47976881|NCT04988646|DRUG|Acyclovir 400 MG|Administered with 240 mL of water
47976882|NCT04988646|DRUG|Zovirax 200 MG Tablet|Administered with 240 mL of water
47976883|NCT04988646|DRUG|Zovirax 400 MG Tablet|Administered with 240 mL of water
47976884|NCT04231864|BIOLOGICAL|Durvalumab|Given intravenously (IV)
47976885|NCT04231864|DRUG|Epacadostat|Given orally (PO)
47976886|NCT04775459|DRUG|Surfactant administration until 2020|Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
47976887|NCT04775459|DRUG|Surfactant administration since 2021|Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
47976888|NCT03063567|DEVICE|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
48335335|NCT06047106|BIOLOGICAL|urine specimens|"For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant)."
48493927|NCT02618408|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
48493928|NCT02618408|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
48493929|NCT00503711|DRUG|Vandetanib|100 mg every other day, 100mg once daily
48493930|NCT00503711|DRUG|Vandetanib 300 mg|300mg once daily
48493931|NCT03829137|DEVICE|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
48335336|NCT05918588|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
48335337|NCT05918588|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
48335338|NCT03419000|GENETIC|blood sample|Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
48335339|NCT00981747|DRUG|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
48335340|NCT00981747|DRUG|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
47976889|NCT02608710|DRUG|RDEA3170 4.5 mg|
47976890|NCT02608710|DRUG|RDEA3170 6 mg|
47976891|NCT02608710|DRUG|RDEA3170 12 mg|
47976892|NCT04873791|DIAGNOSTIC_TEST|Assessment of geriatric individuals living in home environment and nursing home.|Assessments explained in the arm section were made as described in one session in both group
47976893|NCT00666029|DRUG|atorvastatin|40 m.g. o.d. tablets for 6 months
47976894|NCT00666029|DRUG|placebo|Placebo
47976895|NCT00004760|BEHAVIORAL|Exercise|
47976896|NCT03132207|OTHER|Non interventionel study|Only one questionnaire will be done for women and professional
48128278|NCT03781375|DRUG|Methotrexate|Administered orally or subcutaneously once a week at the same dose as prior to study entry
48128279|NCT04682288|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
48128280|NCT01534741|OTHER|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
48128281|NCT01534741|DEVICE|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
48128282|NCT01143142|BEHAVIORAL|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
48128283|NCT04225507|BEHAVIORAL|Diet and exercise coaching|All participants will receive diet and exercise goals and coaching.
48128284|NCT04225507|OTHER|CPAP Treatment|CPAP treatment for sleep apnea and CPAP education and adherence coaching.
48335341|NCT00981747|DRUG|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
48335342|NCT00981747|DRUG|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
48335343|NCT01799304|PROCEDURE|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
48335344|NCT01799304|PROCEDURE|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
48335345|NCT01799304|PROCEDURE|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
48335346|NCT01799304|PROCEDURE|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
48335347|NCT00086216|DRUG|Atiprimod|Oral, once a day, 14 days on 14 days off
48335348|NCT06046365|DIAGNOSTIC_TEST|lymphoscintigraphy|lymphoscintigraphy
48335349|NCT06046365|DIAGNOSTIC_TEST|circumference measurement|circumference measurement
48335350|NCT06046365|DIAGNOSTIC_TEST|sonography|B-mode sono and elastography
48335351|NCT06046365|DIAGNOSTIC_TEST|DXA body composition analysis|DXA body composition analysis
48493932|NCT03829137|DEVICE|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
48493933|NCT04404452|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
48493934|NCT03727659|BEHAVIORAL|SHADE therapy + CONNECT FaceBook support|"See study arms description."
48493935|NCT02159170|BIOLOGICAL|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
48128285|NCT00756405|BEHAVIORAL|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
48128286|NCT00756405|DIETARY_SUPPLEMENT|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
48128287|NCT00756405|DIETARY_SUPPLEMENT|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
48335352|NCT05832099|RADIATION|Radiation|The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
48335353|NCT03949998|DEVICE|Dry Needling|Comparison between dry needling and/or manual therapy of the cervical region.
48335354|NCT03949998|OTHER|Manual Therapy|soft tissue release, cervical traction and/or cervical mobilization
48335355|NCT03222219|PROCEDURE|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
48335356|NCT00013767|BEHAVIORAL|Individual and Community education|
48335357|NCT04759313|BEHAVIORAL|Image Narrative|Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
48335358|NCT02959112|DRUG|Epinephrine|
48335359|NCT02959112|OTHER|Sterile water|
48335360|NCT02959112|DRUG|Indomethacin Rectal Suppository|
48335361|NCT00026585|DRUG|Tamoxifen|
48335362|NCT05523804|PROCEDURE|interval cytoreductive surgery|cytoreductive surgery after 3-4 cycles of chemotherapy
48335363|NCT05523804|PROCEDURE|delayed cytoreductive surgery|surgery after \>5 cycles of chemotherapy
48335364|NCT05523804|OTHER|no surgery|no cytoreductive surgery (\>5 cycles of chemotherapy alone)
48335365|NCT01332097|DRUG|BCT197|
48335366|NCT01332097|DRUG|Prednisone placebo|capsules
48335367|NCT01332097|DRUG|BCT197 placebo|capsules
48493936|NCT04636359|BEHAVIORAL|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
48493937|NCT03055702|OTHER|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
48653424|NCT03889535|DEVICE|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
48335368|NCT01332097|DRUG|Prednisone|capsules
48653425|NCT04225871|DRUG|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
48335369|NCT00003613|DRUG|O6-benzylguanine|Given IV
48335370|NCT00003613|DRUG|carmustine|Given topically
48335371|NCT00003613|OTHER|laboratory biomarker analysis|Correlative studies
48335372|NCT05022043|DIAGNOSTIC_TEST|Serum Presepsin|Estimation of Serum Presepsin at time of admission
48335373|NCT04675736|PROCEDURE|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
48335374|NCT00601146|PROCEDURE|chest computed tomography scan|Once a year for three years
48335375|NCT03822702|OTHER|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
48335376|NCT03822702|OTHER|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
48335377|NCT04142749|DRUG|Oltipraz|Total 90mg, By mouth, TID
48335378|NCT04142749|DRUG|Placebos|Total 90mg, By mouth, TID
48493938|NCT00437632|DRUG|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
48653426|NCT05292287|DEVICE|Polar Ignite Wearable Activity Monitor|A wearable activity monitor capable of monitoring outcomes relating to physical activity sedentary time, heart rate, and sleep quality. The watch synchronises to a corresponding mobile app called Polar Flow- Sync and Analyze or to the Polar FlowSync data transfer software on a computer.
48335379|NCT05420194|OTHER|Postural stability measurement|Postural stability of the participants will be evaluated with the NeuroCom Balance Master Static Posturography device. Evaluations will be carried out in the presence of two physiotherapists to prevent the patient from falling. Posturography devices allow us to quantitatively evaluate posture and balance and obtain objective results by measuring postural sway.
48335380|NCT05420194|OTHER|Timed Up and Go test|During the Timed Up and Go test, which is applied to evaluate dynamic balance and performance, the participant is asked to get up from the chair, walk 3 meters and sit back on the chair. The participant's time to complete the test is recorded. Completion of the test for more than 10 seconds indicates an increased risk of falling
48335381|NCT06077201|OTHER|HBCR hands-off|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
48335382|NCT06077201|OTHER|HBCR interactive|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
48335383|NCT04521309|BIOLOGICAL|SARS-CoV-2 antibody based IVIG therapy|"Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics"
48335384|NCT01494987|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
48335385|NCT01494987|DRUG|Placebo|Placebo to match ranolazine for the duration of the study
48335386|NCT01494987|DRUG|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
48335387|NCT01494987|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
48493939|NCT00437632|DRUG|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
48653427|NCT06642935|DEVICE|Totally implantable cochlear Implant|Totally implantable cochlear Implant
48653428|NCT04506892|BEHAVIORAL|Meditation|meditation
48653429|NCT05936151|DRUG|Retatrutide|Administered SC
48653430|NCT05936151|DRUG|Placebo|Administered SC
48653431|NCT03202173|DIAGNOSTIC_TEST|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
48653432|NCT06564038|DRUG|AZD0486|AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).
48653433|NCT06564038|DRUG|Acalabrutinib|Acalabrutinib tablet will be administered orally twice daily.
48653434|NCT06564038|DRUG|Prednisone|Prednisone will be administered either oral or IV infusion as per standard of care.
48493940|NCT00437632|DRUG|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
48493941|NCT04884867|BEHAVIORAL|CBT-based supportive skills delivered by phone by lay coaches|8-10 weekly coaching sessions delivered by telephone
48493942|NCT00424775|DRUG|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
48653435|NCT06564038|DRUG|Rituximab|Rituximab will be administered as IV infusion as per standard of care.
48653436|NCT06564038|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as IV infusion as per standard of care.
48653437|NCT06564038|DRUG|Vincristine|Vincristine will be administered as IV infusion as per standard of care.
48653438|NCT06564038|DRUG|Doxorubicin|Doxorubicin will be administered as IV infusion as per standard of care.
48128288|NCT00644514|BIOLOGICAL|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
47976897|NCT03074591|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
48493943|NCT00486018|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
47976898|NCT03074591|DRUG|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
48128289|NCT04449835|PROCEDURE|Intracept Procedure|radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
48128290|NCT02316301|DRUG|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
48128291|NCT02316301|DRUG|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
48493944|NCT00486018|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
47976899|NCT01817998|OTHER|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
47976900|NCT06102759|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
47976901|NCT02343627|DRUG|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
47976902|NCT02343627|DRUG|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
47976903|NCT06124144|DRUG|Oleylphosphocholine|The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.
48335388|NCT01494987|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
48493945|NCT00486018|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
48493946|NCT01745211|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser with array handpiece
48493947|NCT02431182|BEHAVIORAL|Memory Training Workshop|"1. Presentation of the workshop: Objectives and Methodology~2. Explanation of the different types of memory and its implication in normal life~3. Strategies for gathering and codification of the information~4. Strategies for selection and storage the information~5. Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~6. Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~7. Strategies for recuperation according to the individual profile. Improving self-esteem~8. Strategies for recuperation Social skills.~9. Personal and social skills~10. New contexts and opportunities~11. Evaluation of the workshop"
48493948|NCT00242736|DRUG|Esomeprazole|
48493949|NCT02436993|DRUG|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
48493950|NCT02436993|DRUG|Paclitaxel|80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
48493951|NCT02436993|DRUG|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
48493952|NCT02436993|DRUG|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
48493953|NCT02436993|DRUG|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
48493954|NCT02903719|DRUG|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
48493955|NCT00516009|DRUG|DEXAMETHASONE|
48493956|NCT00516009|OTHER|PLACEBO|
48493957|NCT01094418|OTHER|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
48493958|NCT00349557|DRUG|bevacizumab, bicalutamide and goserelin|
48493959|NCT00349557|PROCEDURE|intensity modulated radiation therapy (IMRT)|
48493960|NCT00329472|DRUG|gemcitabine, cisplatin|
48493961|NCT00494039|PROCEDURE|Radioactive seed implant to prostate|
48335389|NCT05960513|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
48653439|NCT01931826|PROCEDURE|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
48653440|NCT01931826|PROCEDURE|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
48653441|NCT04396574|DRUG|Lasmiditan|Administered orally
48335390|NCT05774197|BEHAVIORAL|Cognitive Behavioral Therapy for pain|Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
48493962|NCT05589519|DEVICE|Partial rehabilitation using PEEK|A 3-unit implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis for partial rehabilitation of edentulous jaws.
48493963|NCT02880020|BIOLOGICAL|Ipilimumab|Given IV
47976904|NCT06244472|DEVICE|Experiment 1: visual and auditory attention task|We will use the FYNA Research system on 20 healthy volunteers with a visual and auditory attention task to evaluate the system's performance in recording brain signals complex frequency content.
47976905|NCT06244472|DEVICE|Experiment 2: language production and rest tasks|We will use the FYNA Research system on 20 healthy healthy volunteers with a language production task to assess the system's functional mapping capabilities and a resting task to assess the system's ability to identify resting networks.
47976906|NCT06244472|DEVICE|Experiment 3: visuo-motor task|We will use the FYNA Research system in 20 healthy volunteers with a visuo-motor task to evaluate the system's performance in recording brain signals when the subject moves, inducing perturbations that affect the classical system (loss of spatial precision) and the FYNA Research system (low-frequency artifacts).
48335391|NCT04742972|RADIATION|SABR|SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
48335392|NCT04742972|OTHER|SOC|"Three options:~1. Continuation of Enzalutamide~2. Observation~3. Switch to next line treatment"
48335393|NCT02142504|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
48335394|NCT02142504|DRUG|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
48335395|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
48335396|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
48653442|NCT05255666|DRUG|Pembrolizumab|400 mg intravenously
48335397|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
48335398|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
48335399|NCT00092677|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
48493964|NCT02880020|OTHER|Laboratory Biomarker Analysis|Correlative studies
48493965|NCT02880020|BIOLOGICAL|Nivolumab|Given IV
48493966|NCT00000212|DRUG|Desipramine|
48493967|NCT04009538|OTHER|Rehabilitation program|exercise program twice a week
48493968|NCT02981303|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
48653443|NCT05255666|DRUG|Liposomal Irinotecan|Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
48653444|NCT05541861|BIOLOGICAL|BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
48653445|NCT05541861|BIOLOGICAL|BNT162b4 5 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
48653446|NCT05541861|BIOLOGICAL|BNT162b4 10 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
48653447|NCT05541861|BIOLOGICAL|BNT162b4 15 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
48128292|NCT06436326|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set) and 33 weeks of pregnancy to before delivery (second set), respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear."
48128293|NCT06436326|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.
48128294|NCT06436326|OTHER|Blood glucose meters (BGM)|"Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 14 days of glucose monitoring at 24-32 weeks of pregnancy, a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at 33 weeks to before delivery , another glucose monitor report will be given to the participants."
48128295|NCT05854446|OTHER|Survey|In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
48128296|NCT06367023|BEHAVIORAL|Rajyoga Meditation Practice|The intervention will be given for 3 months, For 6 days one hour per day Rajyoga meditation basic course will be provided, followed by 1 hour daily spiritual lesson, Positive thinking and motivation classes will be provided to the intervention group and in control group standard treatment will be given.
48128297|NCT04402736|BEHAVIORAL|The modified Barthel Index-based rehabilitation nursing program|The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
48128298|NCT04402736|BEHAVIORAL|Usual care|Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
48128299|NCT00645034|DRUG|placebo|placebo by mouth as a single dose
48128300|NCT00645034|DRUG|sildenafil|sildenafil 100 mg by mouth as a single dose
48128301|NCT05806476|DIETARY_SUPPLEMENT|caffeine|1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
48128302|NCT05806476|DIETARY_SUPPLEMENT|placebo|1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days
48128303|NCT00426829|DRUG|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
48128304|NCT00426829|RADIATION|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
48128305|NCT00578916|DRUG|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
47976907|NCT06244472|DEVICE|Experiment 4: brain activity at rest|We will be using the FYNA Research system on 20 concussed male athletes volunteers to assess the system's ability to detect modulations in the frequency content of resting brain activity.
47976908|NCT00664391|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
48335400|NCT00092677|DRUG|Comparator: Placebo|matching Placebo
48335401|NCT01347632|DRUG|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
48653448|NCT05541861|BIOLOGICAL|BNT162b4 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
47976909|NCT00677612|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
48128306|NCT03380494|OTHER|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
48128307|NCT03380494|OTHER|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
48128308|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
48335402|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
48335403|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
48493969|NCT02981303|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
47976910|NCT01901497|DEVICE|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
47976911|NCT03902821|OTHER|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
47976912|NCT01443988|DEVICE|iStent|Implantation of two iStent devices
47976913|NCT01443988|DRUG|Travoprost|Travoprost drops
47976914|NCT06112015|OTHER|Bulgarian split squat exercise variations|The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
47976915|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
47976916|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
47976917|NCT01214629|DRUG|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
47976918|NCT02421315|BEHAVIORAL|CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment|CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
47976919|NCT00959621|DRUG|Aspirin|ASA 100 mg once daily per os
47976920|NCT00959621|DRUG|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
47976921|NCT00959621|DRUG|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
47976922|NCT01382953|DEVICE|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
48335404|NCT00830115|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
47976923|NCT05516602|OTHER|Peer Support|"Peer-led support groups over the weekend will include the following activities:~* Peer leader counselling on oral PrEP and HIV risk reduction~* Peer leader discussion to dispel myths and misconceptions around oral PrEP~* Peer leader sharing of experiences of daily pill taking~* Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~* 1-2 role plays per support group session."
48493970|NCT03421158|BEHAVIORAL|breastfeeding|Newborns were breastfed during the procedure
48493971|NCT03421158|DIETARY_SUPPLEMENT|oral sucrose|Newborns were given oral sucrose during the procedure
48493972|NCT03421158|BEHAVIORAL|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
48493973|NCT03421158|BEHAVIORAL|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
47976924|NCT06069284|OTHER|No intervention|No intervention
47976925|NCT00290888|PROCEDURE|Acromioplasty|
47976926|NCT00006361|DRUG|semaxanib|
48493974|NCT06155058|PROCEDURE|SYREBO|Serial ADL training of upper extremities with robotic aid
48493975|NCT06155058|PROCEDURE|Conventional Mirror Method|Serial ADL training of upper extremities assisted by physical therapist
48653449|NCT05541861|BIOLOGICAL|BNT162b2 Monovalent (OMI XBB.1.5) 30 µg|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
48653450|NCT05504083|DRUG|D-0120|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
48493976|NCT05637320|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems|The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
47976927|NCT01235247|BEHAVIORAL|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
47976928|NCT00935753|DRUG|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
47976929|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|"This is a 36-hour group training involving 4 theoretical + 11 practice online sessions using video-feedback, the core component of MISC original trainings.~Session 1: MISC presentation; Session 2: Bases of the interaction and MISC culture-context components; Session 3: The emotions in the interaction and MISC emotional components; Session 4: MISC cognitive components and implications for learning; Session 5: Practice with you-tube examples of interaction; Session 6: Practice with trainer's examples of video-feedback. Sessions 7 to 14: Practice with participants' video-recordings. Session 15: End of the intervention, last video-feedback training and preparing for post-assessment."
47980558|NCT06367790|OTHER|Experimental group|"The athletes included in the experimental group will undergo an intervention using a plyometric exercise protocol, 2 days a week, and dry needling of the gastrocnemius muscles will be applied in a weekly session.~To perform the dry needling intervention, 0.3x50mm disposable steel needles will be used, applying the quick in-and-out technique. To do this, first of all, the intervention area will be cleaned with alcohol and sterile gloves will be used to perform the manoeuvre in complete safety. The active or latent trigger point is then located within the taut band by inserting the needle deeper and deeper, and then moving the needle up and down in search of a local contraction response. A maximum of 8 insertions or up to the athlete's tolerance limit will be applied."
48128309|NCT05656560|OTHER|Clinician education|Brief, online education module for primary care clinicians
48128310|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
48335405|NCT05382962|BEHAVIORAL|iCanCope Post Op Application|The iCanCope program is designed to enhance pain self-management and self-efficacy, defined as perception of one's ability to successfully produce a desired effect in a task or behavior affecting their life. The intervention will be delivered on the iOS or Android smartphone platform depending on the participant's device. Usage of app features will be centrally tracked by the research team using Analytics Platform to Evaluate Effective Engagement (APEEE), developed at the Centre for Global eHealth Innovation. Participants will receive alerts through iCanCope to complete a pain diary check-in once per week preoperatively, twice per day over the initial 2-week postoperative period, and once per day for the subsequent 2-week period.
48493977|NCT02468622|OTHER|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
48493978|NCT04022928|OTHER|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
48493979|NCT01458730|DRUG|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
48493980|NCT00739986|DRUG|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
48653451|NCT05504083|DRUG|Benzbromarone|Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
48653452|NCT06641284|DRUG|Spironolactone|All patients will receive Spironolactone as a part of their GDMT for Heart Failure
48493981|NCT00739986|DRUG|Semapimod|Semapimod 60 mg IV x 3 days
48493982|NCT00739986|DRUG|Placebo|placebo IV x 3 days
48493983|NCT01968694|DRUG|IV Lidocaine|
48653453|NCT04849273|DRUG|TPX-0131|Oral TPX-0131 tablets
48653454|NCT06640972|DRUG|RDX-002|Gut-specific microsomal triglyceride transfer protein (MTP) inhibitor
48653455|NCT06640972|DRUG|Placebo|Matching placebo
48653456|NCT03977155|DRUG|BOS-589|oral tablets
48653457|NCT03977155|DRUG|Placebo|oral tablets
48653458|NCT06098508|OTHER|Osteopathic Manual Treatment|This study will be using osteopathic manual therapy as the primary intervention. Osteopathic manual therapy (OMT) is a hands-on treatment that is performed by a specially trained physician known as a Doctor of Osteopathic Medicine (DO). This treatment can be used to diagnose and treat somatic dysfunctions, which are palpable areas of tightness, misalignment, and/or restricted motion within the musculoskeletal system and its related vascular and neural structures. A combination of myofascial release, strain/counterstain, soft tissue, balanced ligamentous release, facilitated positional release and muscle energy techniques will be used for the OMT treatment.
48653459|NCT06098508|OTHER|Sham Treatment|The sham treatment will include a hands-on evaluation typically used to diagnose somatic dysfunctions, but no treatment will be performed. The sham treatment will assess the upper extremities/scapulae, ribs, cervical spine, thoracic spine, thoracic inlet, and occipital-atlantal regions.
48653460|NCT06636266|OTHER|Survey using a questionnaire.|This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).
48653461|NCT06075277|DRUG|BI 1810631|BI 1810631
48653462|NCT03136302|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation
48653463|NCT03849144|BEHAVIORAL|Therapy dog activity|Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
48653464|NCT03849144|BEHAVIORAL|Low impact exercise|The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
48128311|NCT00679770|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
48128312|NCT00679770|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
48128313|NCT00679770|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
48128314|NCT00679770|DRUG|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
48128315|NCT05438992|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|local anesthetic drug injection for postoperative pain
48128316|NCT06091449|OTHER|High fidelity simulation|Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
48128317|NCT06091449|OTHER|Virtual reality|"For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups."
48128318|NCT05076942|RADIATION|Radiotherapy combined with cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
48493984|NCT01968694|DRUG|IV diphenhydramine|
48493985|NCT02160275|DEVICE|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
47980559|NCT06367790|OTHER|Control group|The athletes included in the control group will perform an intervention using a plyometric exercise protocol, 2 days a week, under the same conditions as the experimental group.
48128319|NCT05076942|DRUG|Cisplatin|Inguinofemoral radiotherapy combined with weekly cisplatin
48128320|NCT04355221|PROCEDURE|pulsed radiofrequency|Pulsed radiofrequency of the trigeminal nerve using NeuroTherm NT 1100 RF generator device
48128321|NCT03539952|DRUG|Penicillamine (D1-W12)|Penicillamine during baseline period (D1-W12)
48128322|NCT03539952|DRUG|TETA 4HCL (W12-60)|TETA 4HCL during post randomisation and 1st extension period (W12-W60)
48128323|NCT03539952|DRUG|Penicillamine (W12-W60)|Penicillamine during rondomisation and 1st extension period period (W12-W60)
48493986|NCT02160275|DEVICE|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
48493987|NCT05229653|DRUG|Ketamine|Participants in this arm will receive intravenously (IV) ketamine (0.6 mg/kg) while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver 0.6 mg/kg ketamine over at least 30 minutes.
48493988|NCT05229653|DRUG|Placebo|Participants in this arm will receive intravenously (IV) matching equal dose of placebo while recovering in the post anesthesia care unit (PACU) on the day of the surgery after subject has been deemed to be stable (hemodynamically stable, awake). The study physician will administer the study intervention via an intravenous pump to deliver equal volume saline over at least 30 minutes.
48493989|NCT01853930|BEHAVIORAL|Platform for Administering Eye-movement Control Training|The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
48128324|NCT03539952|DRUG|TETA 4HCL (60-<W108)|TETA 4HCL during 2nd extension period (W60-\<W108)
48128325|NCT01662154|DEVICE|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
48128326|NCT01662154|DEVICE|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
48128327|NCT03243006|DRUG|Paracetamol|2 tablets of 500mg of paracetamol
48128328|NCT03243006|DRUG|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
48128329|NCT03243006|DRUG|Placebo Oral Tablet|2 tablets of placebo
48335406|NCT05942664|BEHAVIORAL|Sleep|Sleep will be restricted to 60% normal sleep duration
48335407|NCT00045630|DRUG|carboplatin|
48335408|NCT00045630|DRUG|gemcitabine|
48335409|NCT00045630|DRUG|paclitaxel|
48335410|NCT00045630|PROCEDURE|surgery|
48335411|NCT05823870|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
48335412|NCT00347477|DRUG|HyperHAES vs. RA-solution/NaCl|
48335413|NCT01012349|DRUG|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
48335414|NCT01012349|DRUG|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
48128330|NCT03647241|DEVICE|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
48128331|NCT03647241|DEVICE|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
48128332|NCT03647241|PROCEDURE|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
48128333|NCT00731614|BEHAVIORAL|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
48653465|NCT05707260|BEHAVIORAL|CKD SMS|The intervention begins with a face-to-face or digitally assisted session, entry into improving the knowledge and self-management of CKD through, using the four sources of manipulation of self-efficacy (achievement of performance, indirect experience, verbal persuasion, and self-evaluation). In this session, participants will be asked to identify their problems related to CKD and establish, based on these two goals, that they are real and achievable according to their priorities. These goals will be recorded in the monitoring format and will be monitored in the telephone or WhatsApp follow-ups. This using the performance achievement manipulation source, said session lasts 60 minutes, as does the final session at week 16.
48653466|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
48128334|NCT00731614|BEHAVIORAL|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
48335415|NCT00374270|BEHAVIORAL|Lifestyle Counselling; Opinion Leader Influence Statements|
48493990|NCT02582866|DRUG|Lacosamide|"* Pharmaceutical Form: Oral tablets~* Concentration: 50 mg~* Route of Administration: Oral administration"
48493991|NCT00415194|DRUG|pemetrexed|500 mg/m\^2, IV, every 21 days, six 21 day cycles
48653467|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
48653468|NCT02233569|DEVICE|Ventralight ST implant|
48653469|NCT02233569|DEVICE|ETHICON PHYSIOMESH®|
48653470|NCT03320993|OTHER|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
48653471|NCT03615131|DIAGNOSTIC_TEST|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
48653472|NCT05384483|DRUG|Cariprazine|Cariprazine 1.5 to 3 mg per day
48653473|NCT05384483|DRUG|Placebo|Matching placebo
48653474|NCT03748472|PROCEDURE|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
47976930|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 36-hour individual training involving 25-weekly online, individual, self-administered 50' sessions (21h) + 4 online 1.5-hour group meetings with a supervisor (6h) and 9h of between sessions work (readings, video-recordings for later video-feedback, reflection exercises). Session 1 (Supervisor): Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC: Session 9 (Supervisor): Summary, online group exercises and keys for forward recordings; Sessions 10-11 (Christmas Homework): Recording daily life interactions; Sessions 12-17 (SA): guided reflection with video-feedback; Session 18 (Supervisor): Control session for doubts and video-feedback group training. Sessions 19-28 (SA): guided reflection with video-feedback. Session 29 (Supervisor): Final online video-feedback group training.
48128335|NCT00731614|BEHAVIORAL|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
48128336|NCT00732966|DRUG|losartan|with losartan 50 mg once daily for one month
48128337|NCT00732966|DRUG|valsartan|valsartan 160 mg once daily
48128338|NCT01288443|DRUG|Alirocumab|Two SC injections in the abdomen only.
48128339|NCT01288443|DRUG|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
48128340|NCT01288443|DRUG|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
48128341|NCT00299572|DRUG|alendronate (Fosamax)|
48128342|NCT04768712|BEHAVIORAL|Weight bearing aerobic exercise|Weight bearing aerobic exercise three times per week.
48128343|NCT06009393|DRUG|SHR-1918|Three administration
48128344|NCT00586313|DEVICE|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
48128345|NCT00586313|PROCEDURE|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
48128346|NCT05878470|BEHAVIORAL|video|A brief (119 seconds) social contact-based video. The video presented a young Black man in his early twenties, a professional actor, sharing his scripted personal story of struggles with psychotic illness and raising themes of recovery and hope.
48335416|NCT05388955|OTHER|None, transplantation recipients|None, observational
48493992|NCT00415194|DRUG|cisplatin|75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
48493993|NCT00415194|DRUG|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
48493994|NCT02731417|OTHER|acupuncture|Acupuncture for women with post partum urinary retention
48493995|NCT02731417|DEVICE|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
48653475|NCT03748472|PROCEDURE|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
48653476|NCT05689099|DRUG|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
48653477|NCT05689099|DRUG|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
48653478|NCT05078411|BEHAVIORAL|Test treatment|"Test treatment will consist of a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on periodontal risk level (as calculated with the PerioRisk tool proposed by Trombelli et al. 2009) and profile (i.e., the magnitude of the contribution of each PerioRisk parameter to generate the patient risk level); (iii) information on treatment plan and oral hygiene instructions, with emphasis to treatment goals based on the PerioRisk output.~The operators will be trained to administer test treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
48653479|NCT05078411|BEHAVIORAL|Control treatment|"Control treatment will consist in a single session structured as follows: (i) information on periodontal diagnosis (as formulated according to the classification system of the 2017 World Workshop for the Classification of Periodontal Diseases and Conditions); (ii) information on treatment plan and oral hygiene instructions, and treatment goals. Although the general concept of risk of periodontitis incidence/progression will be explained, no mention will be made to the patient risk level as calculated with PerioRisk or any other tool.~The operators will be trained to administer control treatment in approximately 8 minutes, but the duration of the session will be extended for additional questions and answers upon patient request."
48128347|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
48128348|NCT01109498|DRUG|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
48128349|NCT01109498|GENETIC|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
48128350|NCT01109498|DRUG|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
48335417|NCT02682160|OTHER|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
48335418|NCT04984213|DEVICE|Karma Posterior Fixation Device|Posterior Fixation
48335419|NCT02394418|DRUG|Sevoflurane|Treatment of delirium by inhaled sevoflurane
48335420|NCT02394418|DRUG|Propofol|Treatment of delirium by propofol i.v. infusion
48335421|NCT02394418|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
48653480|NCT06340360|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
48653481|NCT06340360|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
48653482|NCT05362305|BEHAVIORAL|Essential Coaching for Every Mother|Daily text messages for the first six-weeks postpartum.
48128351|NCT01267370|DIETARY_SUPPLEMENT|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and \> 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
48128352|NCT00002697|BIOLOGICAL|filgrastim|
48128353|NCT00002697|BIOLOGICAL|sargramostim|
48128354|NCT00002697|DRUG|carboplatin|
48335422|NCT04582604|DRUG|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
48335423|NCT04686877|PROCEDURE|STAPLE|Stereotactic aspiration plus urokinase clot irrigation
48335424|NCT03339401|OTHER|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
48335425|NCT03339401|DRUG|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
48335426|NCT05307341|DRUG|sufentanil|One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
48128355|NCT00002697|DRUG|etoposide|
48128356|NCT00002697|DRUG|ifosfamide|
48128357|NCT00002697|PROCEDURE|autologous bone marrow transplantation|
48128358|NCT00002697|PROCEDURE|bone marrow ablation with stem cell support|
48128359|NCT00002697|PROCEDURE|peripheral blood stem cell transplantation|
48128360|NCT00002697|RADIATION|radiation therapy|
48128361|NCT00589277|BEHAVIORAL|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
48128362|NCT00589277|BEHAVIORAL|Standard care counseling + standard materials|Standard messages for quitting smoking
48128363|NCT05733507|PROCEDURE|IVT with tenecteplase or alteplase|Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
47976931|NCT06150313|OTHER|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|This is an equivalent 36-hour online self-administered training involving 27 x 45' individual online sessions (20.25h), mostly based on reflection exercises around brief readings, animated shorts, or pills, but not video-feedback. This is complemented with 2 x 1.5h online group face-to-face sessions with a supervisor (3h) and 13h of between-sessions work based on looking for new information, adult-child activities (but not for video-feedback) or out-of-line guided reflective exercises. Session 1 (Supervisor): group meeting for program presentation; Sessions 2-28 (Self-Administered): Online self-administered sessions doing readings or watching pills; Session 29 (Supervisor): Final doubts session to close de course.
48335427|NCT03909672|OTHER|Cupping Therapy|application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
48335428|NCT00689169|DRUG|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
48335429|NCT00689169|PROCEDURE|ASCT|ASCT : D0
47976932|NCT06350825|PROCEDURE|Cytoreductive prostatectomy or brachytherapy|local treatment+SOC for metastatic prostate cancer
47976933|NCT06350825|DRUG|ADT+second-generation antiandrogens ± chemotherapy|SOC(Triplet or doublet therapy) for mHSPC
47976934|NCT02181023|DRUG|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
47976935|NCT02181023|DRUG|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
47976936|NCT04908176|DRUG|Avapritinib|avapritinib tablets
47976937|NCT04908176|DRUG|midazolam|midazolam syrup
47976938|NCT05659095|OTHER|autologous hair follicle derived mesenchymal stem cell suspension|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
47976939|NCT06000098|OTHER|Restrictive fluid therapy|"0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down)."
48128364|NCT05733507|PROCEDURE|Intervention Name : Tirofiban and IVT with tenecteplase or alteplase|IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
48335430|NCT00689169|DRUG|Rituximab|Rituximab 250 mg/m² :D-21 D-14
48335431|NCT02168881|DRUG|Misoprostol|
48335432|NCT02168881|DRUG|Dinoprostone|
48335433|NCT06360471|OTHER|fertility preservation|If a patient have a desire to fertility preservation, oocyte freezing or embryo freezing will be offered.
48335434|NCT05286996|DEVICE|Iovera - Cryoneurolysis|Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.
48335435|NCT05286996|DRUG|Local anesthetic|Placebo - local anaesthesia
48335436|NCT05569616|OTHER|Hand massage|Hand massage is a simple comfort intervention that involves touch and conveys care that can easily be incorporated independently into routine nursing care activities. Hand massage is a western technique that includes five basic classical massage manipulations, including eufluorage, petrissage, friction, tapotman and vibration. Kolcaba et al. (2006) hand massage procedure will be applied with baby oil for 20 minutes, three times a week (12 times in total) for 4 weeks.
47976940|NCT00296478|DRUG|Endometrin|Endometrin 100mg BID x 10weeks
48335437|NCT05569616|OTHER|Play activity|The number of people for the Jenga game was determined as two people in order to strengthen the social relationship among the elderly and to strengthen their psychomotor skills. Each game will be played with two people. For this reason, the elderly will be divided into five separate groups, two people each.These groups will be played the Jenga game for one hour a week on a certain day of the week, accompanied by the researcher, during the activity hours determined by the nursing home. After the game activity (Jenga) application is completed at the end of the fourth week, the post-test scales will be re-administered to the elderly by the researcher.
47976941|NCT00296478|DRUG|Endometrin|Endometrin 100mg TID x 10weeks
47976942|NCT00296478|DRUG|Crinone|Crinone QD x 10weeks
47976943|NCT01264588|OTHER|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
47976944|NCT04632108|DRUG|ASKB589 Injection|ASKB589 Injection with dose escalation stage of 0.3mg/kg up to10mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
48128365|NCT00175812|DRUG|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
48128366|NCT00175812|DRUG|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
48128367|NCT00175812|DRUG|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
48128368|NCT01311622|DRUG|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
48128369|NCT01311622|DRUG|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
48128370|NCT02638337|DRUG|Ospemifene|60 mg tablet
48128371|NCT02638337|DRUG|Placebo|Tablet identical to the ospemifene tablet without drug
48335438|NCT02347852|DRUG|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
48653483|NCT00721110|DRUG|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
48653484|NCT00721110|DRUG|Placebo|Placebo boluses and infusions will be substituted
48653485|NCT00721110|DRUG|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
48653486|NCT00721110|DRUG|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
48653487|NCT06300528|DRUG|Pemigatinib|Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
47976945|NCT04610268|DEVICE|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
47976946|NCT02152696|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
47976947|NCT02152696|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
47976948|NCT02152696|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
47976949|NCT04244331|DIAGNOSTIC_TEST|CCO|Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
48128372|NCT04518813|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
48335439|NCT03498118|DRUG|20 mL of bupivacaine 0.25%|"In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
48493996|NCT03501914|BEHAVIORAL|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome \& introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
48493997|NCT05341882|BEHAVIORAL|Mindfulness|Participants took part in a live, facilitated Zoom-delivered training that involved learning mindfulness and education about moral injury. The participants were interviewed regarding the program.
48653488|NCT05027789|BEHAVIORAL|Self-Guided|People in this arm will come to 15 information sessions. These sessions will provide training and education on memory support strategies and healthy lifestyles. You will decide how you want to implement this information into your daily life.
48653489|NCT05027789|BEHAVIORAL|Structured Group|People in this group will come to 15 information sessions. The study will provide recommended behavior targets (like how much exercise you should have each week). Participants in this group will either receive an iPad or have a special application installed on their own personal device. They will receive training on how to use the application, and will be asked to use the application to record their activities and receive reminders.
48128373|NCT00233090|DRUG|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
48128374|NCT00233090|DRUG|Placebo|daily dose of placebo for four weeks.
48128375|NCT00262782|DRUG|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
48335440|NCT04220138|PROCEDURE|Anterior chamber illumination in cataract surgery|This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
48335441|NCT04714723|BEHAVIORAL|Programmed smartphone intervention|Interactive programmed lifestyle education based on smartphone for six month
48335442|NCT04714723|BEHAVIORAL|Programmed smartphone plus dietitian intervention|Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
48335443|NCT01271413|BEHAVIORAL|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
48335444|NCT03418272|DIAGNOSTIC_TEST|Culture/PCR Analysis|"Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis"
48653490|NCT06569810|DEVICE|Repeated Low-Level Red Light (RLRL) therapy|In our study, we do not implement any interventions; rather, we collect follow-up information from patients who, due to insufficient response to traditional myopia control therapies, have transitioned to Repeated Low-Level Red Light (RLRL) therapy. The data gathered will reflect treatment patterns as per the approved indications for RLRL therapy, where subjects may have undergone treatment sessions twice daily, each lasting for 3 minutes with a minimum interval of 4 hours between sessions. Our analysis will focus on the real-world outcomes, specifically evaluating the proportion of participants who have achieved effective myopia control (defined as AL elongation of less than 0.1mm per year or SER progression of less than 0.25 diopter per year) after 12 months of documented RLRL therapy use among the collected data from eligible subjects.
48653491|NCT04309682|PROCEDURE|crestal sinus approach technique|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
47976950|NCT04481581|OTHER|Electronic Alerts|When FiO2 remains =\>0.4 and SpO2 =\>94% for more than 45 minutes, an electronic health record based alert will be sent to respiratory therapists to titrate oxygen per decision support tool.
47976951|NCT04077983|DRUG|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses."
47976952|NCT00068471|DRUG|anidulafungin|
48128376|NCT00727909|DEVICE|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
48128377|NCT02101138|DRUG|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
48128378|NCT01807481|DRUG|Mircera|Once Monthly Mircera
48128379|NCT02612142|BEHAVIORAL|physical exercise|endurance-training or stretching (sham exercise)
48128380|NCT01605409|PROCEDURE|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
48266512|NCT00809380|BEHAVIORAL|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
48653492|NCT04309682|PROCEDURE|Lateral sinus approach|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
48653493|NCT06591728|DIETARY_SUPPLEMENT|Oral PCA|Administration of 1,000 mg BID of oral PCA in individuals with knee prosthetic joint infection prior to revision surgery
48653494|NCT05274477|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
48653495|NCT05274477|DRUG|Placebo|no active component
48653496|NCT05771155|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46
47976953|NCT00327249|DRUG|imexon|
47976954|NCT05090137|OTHER|Diuretics|As per group descriptions
47976955|NCT05422703|DEVICE|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
47976956|NCT05422703|OTHER|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
48335445|NCT05985070|DIETARY_SUPPLEMENT|Oral Ferric pyrophosphate|30 mg capsule
47976957|NCT05422703|DEVICE|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
47976958|NCT05422703|PROCEDURE|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
47976959|NCT05422703|DRUG|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
47976960|NCT05422703|DRUG|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
47976961|NCT05422703|DRUG|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
48335446|NCT05985070|DIETARY_SUPPLEMENT|Oral Sodium ferric pyrophosphate|30 mg capsule
47976962|NCT05422703|DIETARY_SUPPLEMENT|Soft cold diet|For the day of surgery
47976963|NCT05426902|BEHAVIORAL|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
47976964|NCT06013670|PROCEDURE|Endoscopy+NSBBs|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure\>90mmHg and heart rate\>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
47976965|NCT06013670|PROCEDURE|Transjugular intrahepatic portosystemic shunt|TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
47976966|NCT02863029|PROCEDURE|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
47976967|NCT03239288|OTHER|Control digestible carbohydrate|Single serving of control product
47976968|NCT03239288|OTHER|Test resistant starch type 4|Single serving of test product
47976969|NCT00226161|PROCEDURE|Inguinal herniorrhaphy|
47976970|NCT02852785|BEHAVIORAL|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
48335447|NCT05985070|DIETARY_SUPPLEMENT|Oral Ferric maltose|30 mg Tablet
48335448|NCT03472794|OTHER|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
47976971|NCT02852785|BEHAVIORAL|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
47976972|NCT02852785|BEHAVIORAL|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
48335449|NCT00268463|DRUG|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
48335450|NCT00268463|DRUG|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
48335451|NCT00268463|DRUG|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
48335452|NCT06271694|OTHER|Vestibular Rehabilitation|Standard vestibular rehabilitation
48335453|NCT01153308|OTHER|Observational Study|This is an Observational study
48335454|NCT00232505|BIOLOGICAL|cetuximab|Given IV
48335455|NCT00232505|DRUG|carboplatin|Given IV
48335456|NCT03838003|PROCEDURE|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
48653497|NCT02276040|DRUG|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
48653498|NCT03518060|DRUG|JULUCA|JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
48266513|NCT00809380|BEHAVIORAL|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
48335457|NCT05688072|OTHER|trunk oriented exercise|trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation
48335458|NCT05688072|OTHER|whole body vibration|WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
48653499|NCT05705258|DRUG|Aflibercept (Eylea, BAY86-5321)|Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
48653500|NCT00467493|DRUG|Anastrozole|
48653501|NCT05006755|COMBINATION_PRODUCT|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
48653502|NCT05006755|COMBINATION_PRODUCT|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
48653503|NCT06637033|BEHAVIORAL|Chewing Food|Daily foods like candies and dumplings will be cut into small pieces. Patients will chew them before each feeding and then spit them out, with each training session lasting ten minutes.
48653504|NCT06637033|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
48653505|NCT06637033|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48653506|NCT06638346|OTHER|Shortened FIFA 11+ warm-up exercise program|"The shortened FIFA11+ incorporates 5 exercises from the original FIFA11+ part 2 and 3: Sideways bench, single-leg stance, squats, jumping and plant and cut (refer to FIFA 11+ manual). All exercises, except plant and cut, have three levels of difficulty. Difficulty progression will follow FIFA11+ guideline option C where all players progress to the next level of all exercises after 3 or 4 weeks. This program is done on artificial turf.~Coaches will be trained on FIFA guidelines by the primary investigator and provided with explanatory placards and the FIFA 11+ manual. The primary investigator will conduct checks twice a week with the coaches to address any questions and review the program. Only the shortened FIFA11+ group will receive verbal feedback as per FIFA11+ guidelines."
48653507|NCT06638346|OTHER|Brazilian warm-up exercise program|"The control group engages in a Brazilian warm-up. The warm-up consists of exercises performed in standing and while running including the following:~* Performed in standing: Circular Arms (20-30 sec total), Opening and closing of the hips (20-30 sec total).~* Performed while running back and forth on the field: Jogging (2 times), high kicks (2 times), glute kicks (2 times)~* Performed while running forward (exercise), then small jog back without performing the exercise: hand-to-heel touches (2 times), knee and heel touches (2 times each side), side leg swings (2 times) and progressive sprint 80-90% speed (2 times).~Coaches will supervise the session but will not be allowed to give verbal feedback. This program is done on artificial turf."
48653508|NCT05960201|DRUG|[18F]fluoroestradiol (FES)|F-18 FES 111\~222 MBq(megabecquerel) injection
48653509|NCT06569940|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 42 minutes.
48266514|NCT01014403|DRUG|enoxaparin|Enoxaparin 30 mg sq q 12 hours
48266515|NCT01014403|DRUG|placebo|vehicle
48493998|NCT05341882|BEHAVIORAL|Educational Support|As an active control condition, the investigators developed an education support (ES) group, which ran concurrently to the mindfulness intervention group. Within the military community, peer support and psychoeducation are considered critical components of alleviation of suffering from traumatic exposure.
48493999|NCT04751292|OTHER|Exposure to high altitude|permanence at high (\>2500 m) altitude; permanence is defined as being born and living at high altitude with the total time spent at lower altitudes not exceeding 2 years in the past 10 years
47976973|NCT02852785|BEHAVIORAL|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
48128381|NCT01605409|PROCEDURE|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
48494000|NCT01998672|DRUG|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
48494001|NCT01998672|DRUG|Placebo|Drinking solution
47976974|NCT05833789|DEVICE|Magnetic Flexible Endoscope (MFE)|After colonoscopy has been completed with the legacy colonoscope, the MFE will be introduced into the colon and traverse from the rectum to the cecum.
47976975|NCT00639054|PROCEDURE|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
48494002|NCT04919863|DRUG|NTP42:KVA4|Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
48494003|NCT04919863|DRUG|Placebo|Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
48494004|NCT00798876|DIETARY_SUPPLEMENT|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
48494005|NCT00798876|DIETARY_SUPPLEMENT|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
47976976|NCT00639054|PROCEDURE|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
47976977|NCT04140292|DRUG|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
47976978|NCT04140292|DRUG|Vitamin D3|"D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result"
47976979|NCT01113983|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transapical and transfemoral approach
48494006|NCT00798876|DIETARY_SUPPLEMENT|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
48266516|NCT06097520|OTHER|VR Intervention|For the VR Intervention a VR head-mounted display, the Pico G2 4K, will be used. This intervention involves wearing VR glasses and experiencing non-interactive videos with sound through a headset. The footage consists of different immersive 360-degree scenarios from natural environments (e.g., forest), while corresponding sounds, meditation or classical music harmoniously tuned to these scenarios and are played through noise-cancelling headphones.
47976980|NCT02507505|PROCEDURE|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
47976981|NCT02507505|PROCEDURE|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
47976982|NCT01953198|OTHER|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
48266517|NCT03611426|DRUG|rhThrombin ( Topical )|Active Substance
48266518|NCT03611426|DRUG|placebo|saline solution
48494007|NCT00798876|DIETARY_SUPPLEMENT|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
48494008|NCT00798876|OTHER|Medical Examination|Subjects will have a routine medical exam.
48494009|NCT00798876|OTHER|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
48494010|NCT00798876|OTHER|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
48494011|NCT00798876|PROCEDURE|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
47976983|NCT00297375|DRUG|tramadol HCl/acetaminophen|
48494012|NCT05532059|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Lenvatinib, tislelizumab, gemcitabine and cisplatin
48494013|NCT05532059|DRUG|gemcitabine and cisplatin|gemcitabine and cisplatin
48494014|NCT00455611|DEVICE|CPAP (Continuous Positive Airway Pressure)|
48494015|NCT04361149|DRUG|Capsaicin Topical Cream (0.075%)|Capsaicin cream will be administered as a topical skin cream
48128382|NCT05530317|BEHAVIORAL|Cardiac Rehabilitation|Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Participants are asked to commit to attending at least 24 sessions, of which 12 (one per week for 12 weeks) must be in person. Participants will be allowed to select a fully in-person approach (36 sessions) or hybrid approach (12-24 in person, 12-24 virtual for up to 36 total sessions).
48128383|NCT00366249|DRUG|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
48128384|NCT00366249|DRUG|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
48494016|NCT04361149|DEVICE|Delsys Trigno Galileo System|A wireless surface EMG device. The sensors will be placed on the trapezius and the infraspinatus muscle, and a recording will be performed.
48494017|NCT04361149|DEVICE|Excaliber, Natus Medical|Intramuscular EMG machine. The intramuscular electrode will be inserted into the trapezius and a recording will be performed.
48128385|NCT04139434|DRUG|LP-108|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
48128386|NCT04139434|DRUG|LP-108 and azacitidine|For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
48128387|NCT04095884|PROCEDURE|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
48128388|NCT01954836|BEHAVIORAL|initial fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
48128389|NCT01954836|BEHAVIORAL|Secondary fasting|modified fasting with daily caloric intake of \<400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
48128390|NCT03894436|COMBINATION_PRODUCT|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
48128391|NCT03833440|DRUG|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
48128392|NCT03833440|DRUG|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
48128393|NCT03833440|DRUG|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
48128394|NCT03833440|DRUG|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
48494018|NCT04361149|OTHER|Placebo Cream|Placebo cream will be administered as a topical skin cream
48494019|NCT05641974|BEHAVIORAL|Helpers Stay Quit Training|"The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step helping conversation. The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot make anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting."
47976984|NCT04090450|RADIATION|chemo-radiotherapy|The study will not have a direct intervention. It will recruit patients who have had chemo-radiation as part of their standard of care treatment for rectal cancer.
47976985|NCT00001723|DRUG|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
47976986|NCT00001723|DRUG|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
47976987|NCT05950009|OTHER|No intervention (observational studies)|No intervention (observational studies)
47976988|NCT01385553|BEHAVIORAL|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
47980560|NCT03132376|DIETARY_SUPPLEMENT|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
48128395|NCT03833440|DRUG|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
48128396|NCT03833440|DRUG|Savolitinib|"600 mg QD~1 cycle = 28 days"
48128397|NCT01797666|DRUG|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
48128398|NCT03039244|OTHER|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
48128399|NCT03039244|OTHER|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
48128400|NCT03039244|DEVICE|Diode Laser|
48128401|NCT05462067|DEVICE|AT LARA IOL|EDOF IOL for treatment of cataract
48128402|NCT05462067|DEVICE|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
48128403|NCT02763449|BEHAVIORAL|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
48128404|NCT01664806|DEVICE|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
48128405|NCT04693949|OTHER|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
48128406|NCT04693949|OTHER|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
48128407|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
48128408|NCT01900249|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
48128409|NCT01900249|DRUG|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
48128410|NCT00001752|DRUG|L-arginine|
48494020|NCT00602277|OTHER|Laboratory Biomarker Analysis|Correlative studies
48494021|NCT00602277|BIOLOGICAL|Wild-type Reovirus|
48494022|NCT00354341|DRUG|Epoetin beta|
48494023|NCT04104854|DEVICE|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds
48494024|NCT04979286|OTHER|Kinesiotaping|"Y strip kinesiotaping will be applied to both the gastrocnemius muscles while keeping the participant's ankle in full dorsiflexion. The tape will start from the plantar surface of the toe and continue proximally. The medial Y tail will be applied along the medial border of the gastrocnemius and the lateral Y tail along the lateral border of the gastrocnemius, at approximately 20% tension from the resting length. End points will end just below the popliteal crease."
47976989|NCT01385553|BEHAVIORAL|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
48494025|NCT04979286|OTHER|Placebo Kinesiotaping|Placebo kinesiotaping, approximately 5x5 cm in size, will be applied to the body of both gastrocnemius muscles without any tension.
47976990|NCT04613063|OTHER|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
47976991|NCT01429753|OTHER|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
47976992|NCT01429753|DEVICE|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
47976993|NCT01586676|BEHAVIORAL|SAU|Supervision-as-usual
47976994|NCT01586676|BEHAVIORAL|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
48128411|NCT00001752|DRUG|Estrogen|
48128412|NCT02538900|BEHAVIORAL|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
48128413|NCT02538900|OTHER|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
48494026|NCT02444793|DRUG|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
48494027|NCT02444793|DRUG|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
47976995|NCT05885204|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted laparoscopic radical cystectomy
47976996|NCT05885204|PROCEDURE|Conventional laparoscopic radical cystectomy|Conventional laparoscopic radical cystectomy
47976997|NCT04571138|BIOLOGICAL|SCRI-CAR22v2|Single infusion of SCRI-CAR22v2
48128414|NCT03624972|BEHAVIORAL|Starting the Conversation Video|The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
47976998|NCT04085809|OTHER|AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
47976999|NCT04359550|BIOLOGICAL|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
47977000|NCT04359550|OTHER|placebo|placebo
48128415|NCT03624972|BEHAVIORAL|Sexual and Menopausal Health Resources|Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal \& sexual health clinic.
48128416|NCT04532749|DRUG|Seltorexant|Participants will receive Seltorexant tablets.
48128417|NCT04532749|DRUG|Placebo|Participants will receive matching placebo tablets.
48128418|NCT06299670|DRUG|Thalidomide|Patients will get only Thalidomide
48128419|NCT06299670|DRUG|Hydroxy Urea|Patients will get only Hydroxyurea
48128420|NCT06299670|DRUG|Combinations|Combination Of Thalidomide \& Hydroxyurea
48128421|NCT01260870|DEVICE|Cotavance Paclitaxel Coated Balloon|
48128422|NCT01260870|DEVICE|Standard balloon angioplasty|
48128423|NCT02755259|DRUG|Acetazolamide|
48128424|NCT02755259|DRUG|Placebo|
48128425|NCT06520306|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound-guided fascia iliaca block using different concentrations of methylene blue combined with ropivacaine
48128426|NCT06134349|DEVICE|lithium MRSI|lithium magnetic resonance spectroscopy imaging
48128427|NCT01433315|BEHAVIORAL|sleep restriction|restricted sleep
48335459|NCT05972395|OTHER|Localized vs Widespread Mechanical Pain Hypersensitivity|Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).
48335460|NCT04904380|OTHER|Active peer learning|HMS, HBS and peer learning in combination with AIR and PRISMS
48335461|NCT00799760|DRUG|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
48494028|NCT02754908|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
48494029|NCT02754908|BEHAVIORAL|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
48128428|NCT02299349|DRUG|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
47977001|NCT01950650|BEHAVIORAL|No treatment given|Survey conducted through computer-assisted telephone interviewing.
48128429|NCT02299349|DRUG|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
48128430|NCT06345170|OTHER|The DIR/Floortime™ Therapy Program|The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks
48128431|NCT06345170|OTHER|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program|The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program will be applied by the parents at home, 2 days a week, for an average of 30 minutes a day, for 12 weeks
48266519|NCT05031741|OTHER|Peer Leader Model|Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liason via text messages throughout the study.
48335462|NCT00799760|DRUG|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
48335463|NCT00799760|DRUG|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
48335464|NCT03525457|PROCEDURE|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
48494030|NCT01058720|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU orally once daily for 12 weeks
47977002|NCT01950650|BEHAVIORAL|survey|Survey conducted via the Internet.
47977003|NCT05371743|DIAGNOSTIC_TEST|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆_Ct) method
47977004|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
47977005|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
48494031|NCT05348980|DRUG|Phenylephrine Hydrochloride 4 mg|Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
47977006|NCT04022902|OTHER|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
47977007|NCT05846191|DIAGNOSTIC_TEST|serum pentraxin 3 and high sensitive CRP|serum pentraxin 3 and high sensitive CRP
47977008|NCT01907815|DRUG|Akt Inhibitor GSK2141795|Given PO
48335465|NCT01539278|PROCEDURE|Adenotonsillectomy|Tonsils and adenoids are surgically removed
48335466|NCT01539278|OTHER|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
48335467|NCT05221255|OTHER|spinal magnetic stimulation|"* Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
48335468|NCT04874844|BIOLOGICAL|Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)|"The ratio of subjects in the experimental drug group to the placebo control group is 1:1, and you will have a 50% probability of receiving JY025 combined with gefitinib or erlotinib, and a 50% probability of receiving placebo combined with gefitinib Or erlotinib.~Blind people, researchers, nurses, research assistants, inspectors, applicants and blind statisticians involved in clinical trials."
48335469|NCT04840368|OTHER|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
48335470|NCT03012633|DEVICE|Lysis timer|Lysis Timer compared with standard laboratory test to diagnose hyperfibrinolysis during liver transplantation.
47977009|NCT01907815|OTHER|Laboratory Biomarker Analysis|Correlative studies
48335471|NCT04379609|OTHER|Masticatory efficiency|"Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency."
48335472|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
48335473|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
48653510|NCT06637410|DEVICE|High intensity laser therapy|HILT was performed by a single physiotherapist experienced in using a laser device. During HILT application, the patients were seated comfortably on chairs and their shoulders were in neutral position. The wavelength of the laser light used was 1064 nanometers. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. A standard frequency of 25 Hz is applied. During the first four therapy sessions, it was aimed to provide an analgesic effect by using 8 W power and 12 J/cm dose. The rays were applied to the rotator cuff muscles area in a circle from outside to inside for 2.5 minutes, for a total energy of 300 J, on an area of 25 cm2. For the biostimulation effect, the continuous wave method was used in phase II. n the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles.
47977010|NCT01907815|DRUG|Trametinib|Given PO
47977011|NCT06220682|DIAGNOSTIC_TEST|The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs|using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
47977012|NCT01315678|DRUG|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
47977013|NCT01315678|DRUG|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
47977014|NCT01918930|BIOLOGICAL|MGA271|MGA271 anti-B7-H3 monoclonal antibody
47977015|NCT00003128|BIOLOGICAL|filgrastim|
47977016|NCT00003128|DRUG|ifosfamide|
47977017|NCT00003128|DRUG|paclitaxel|
47977018|NCT00794131|BIOLOGICAL|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
47977019|NCT01818908|DRUG|DA-EPOCH|DA-EPOCH regimen
48128432|NCT04734600|DEVICE|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
48128433|NCT04734600|OTHER|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
48128434|NCT05465382|DEVICE|Saline Lavage|Three rounds of 10cc of sterile 0.9% normal saline will be injected into the injured ankle joint and withdrawn from the joint using an anteromedial 16-gauge needle attached to a 10cc syringe.
48128435|NCT02673216|OTHER|No intervention|
48128436|NCT06514183|OTHER|Clinical diagnosis of recurrence|Clinical diagnosis of recurrence
48653511|NCT06637410|DEVICE|Ultrasound therapy|US therapy was performed by a single physiotherapist experienced in using US device. Calibration and control of the device are performed regularly. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.
48653512|NCT06637410|OTHER|Therapeutic Exercise|ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
48653513|NCT04635280|DEVICE|any closed-loop automatic insulin delivery system (or artificial pancreas) European Conformity (CE)-marking|A closed-loop automatic insulin delivery system includes a combination of an insulin pump, a continuous glucose monitoring system and an algorithm.
48653514|NCT01743144|DRUG|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
47977020|NCT00948129|OTHER|Laboratory Biomarker Analysis|Correlative studies
48494032|NCT05348980|DRUG|Phenylephrine Hydrochloride 8 mg|Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
48335474|NCT00696436|DRUG|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
48335475|NCT00696436|DRUG|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
48335476|NCT00696436|DRUG|Placebo|Matching placebo, orally, once daily for up to six weeks.
48335477|NCT01018693|DRUG|VAK694; Alutard Avanz SQ|
47977021|NCT00948129|BEHAVIORAL|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
47977022|NCT00948129|BEHAVIORAL|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
47977023|NCT00948129|OTHER|Tobacco Cessation Counseling|Undergo smoking cessation counseling
47980561|NCT03132376|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
48335478|NCT01018693|DRUG|VAK694 placebo infusion; Alutard Avanz SQ|
48335479|NCT01018693|DRUG|VAK694 placebo infusion; Saline|
48335480|NCT01688440|OTHER|#1 Respiratory Care Solution|Respiratory care solution.
48335481|NCT01091051|DRUG|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
47914258|NCT04610593|BEHAVIORAL|Mindfulness-based Intervention|A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
47977024|NCT05577390|OTHER|Intraneural Facilitation Therapy Treatment|Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
47977025|NCT05577390|OTHER|Standard Physical Therapy Treatment|The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
47977026|NCT01087190|DRUG|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
47977027|NCT01439191|DRUG|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
47977028|NCT01439191|DRUG|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
48128437|NCT05738369|DIETARY_SUPPLEMENT|Biogaia L. reuteri Prodentis® lozenges|Participants were instructed to use the lozenges twice daily after brushing their teeth; once in the morning and once in the evening
48335482|NCT01091051|DRUG|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
48335483|NCT00891761|DRUG|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
48335484|NCT00891761|DRUG|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
48335485|NCT00891761|DRUG|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
48335486|NCT00891761|DRUG|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
48335487|NCT00891761|DRUG|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
48335488|NCT01407848|DRUG|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
48335489|NCT01407848|DRUG|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
48335490|NCT06304675|OTHER|no intervention|no intervention
48335491|NCT03412500|DRUG|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
48335492|NCT03412500|DRUG|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
48335493|NCT02361619|DRUG|Caffeine|probe
48335494|NCT02361619|DRUG|Diclofenac|probe
48335495|NCT02361619|DRUG|Esomeprazole|probe
48335496|NCT02361619|DRUG|Metoprolol|probe
48335497|NCT02361619|DRUG|Midazolam|probe
48335498|NCT02361619|DRUG|Dabigatran|probe
48335499|NCT02361619|DRUG|Clarithromycin|perpetrator
48335500|NCT00518843|BEHAVIORAL|FBT-BN|Mobilizing parents to curtail binge eating and purging
48335501|NCT00518843|BEHAVIORAL|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
48335502|NCT03846973|DRUG|Tranexamic Acid|intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
48335503|NCT03846973|OTHER|Placebo|placebo (normal saline) infusion to be given and completed over 8 h in the hospital
48335504|NCT00474825|DRUG|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
48335505|NCT00474825|DRUG|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
47977029|NCT04772911|DEVICE|Optical Coherence Tomography (OCT)|OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.
48128438|NCT05738369|DIETARY_SUPPLEMENT|Hersheyland Ice Breakers Mints sugar free lozenges|Hersheyland Ice Breakers Mints sugar free lozenges
48128439|NCT00002900|PROCEDURE|management of therapy complications|
48494033|NCT05001711|DEVICE|Aria CV Acute PH System|The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.
48494034|NCT05322499|DRUG|Camrelizumab|200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);
48494035|NCT05322499|DRUG|Irinotecan|100-125mg/m2，d1，d8；q21d
48494036|NCT05322499|DRUG|Paclitaxel|135-175mg/m2，d1，Q3W
48494037|NCT05322499|DRUG|Paclitaxel-albumin|100-135mg/m2, d1、d8，Q3W
48653515|NCT01743144|DRUG|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
48653516|NCT03502200|DEVICE|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
48653517|NCT03502200|OTHER|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
47977030|NCT03758352|PROCEDURE|remote ischemic preconditioning (rIC)|Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
47977031|NCT03758352|OTHER|non remote ischemic preconditioning (non-rIC)|Retrospective group who have not undergone intervention.
47977032|NCT02837575|BIOLOGICAL|VCL-HB01|Investigational Product
47977033|NCT02837575|OTHER|Phosphate-buffered saline|Placebo
47977034|NCT04069091|BEHAVIORAL|'Enjoy your Bump' (iloodottaa.fi) online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi)."
47977035|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
47977036|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
47977037|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
48653518|NCT03126630|BIOLOGICAL|Anetumab Ravtansine|Given IV
47914259|NCT01254708|DRUG|Ambisome ®|liposomal amphotericin B
47914260|NCT01254708|DRUG|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
47914261|NCT04245683|PROCEDURE|Bowel/rectal resection|surgical removal of the portion of the rectum where the tumor was originally identified
47977038|NCT01291173|DRUG|Placebo|Placebo capsule taken once daily for up to 11 weeks
48128440|NCT03710798|DIETARY_SUPPLEMENT|Low carbohydrate high fat diet|Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet
48128441|NCT03882450|PROCEDURE|Flexible fiberoptic laryngoscopy|Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
48128442|NCT03882450|PROCEDURE|Laryngeal ultrasonography|Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
48494038|NCT05322499|DRUG|Docetaxel|60-75mg/m2，d1，Q3W
47914262|NCT04245683|OTHER|non-operative follow up|patients who choose the non-operative option will be required to adhere to a very intensive follow up protocol, including endoscopy and CT imaging
48128443|NCT01762059|DEVICE|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
48128444|NCT01762059|OTHER|Usual care|
48128445|NCT04351932|BIOLOGICAL|bone marrow mesenchymal stem cells|intrarticular bone marrow mesenchymal stem cells injection
48128446|NCT04351932|BIOLOGICAL|Adipose Mesenchymal stem cells|intrarticular adipose mesenchymal stem cells injection
48494039|NCT05322499|DRUG|Anlotinib|12mg，qd，d1-d14，q3w
48494040|NCT01855074|DRUG|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
48494041|NCT04729192|OTHER|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
48494042|NCT00969631|DRUG|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
48653519|NCT03126630|OTHER|Laboratory Biomarker Analysis|Correlative studies
48653520|NCT03126630|BIOLOGICAL|Pembrolizumab|Given IV
48653521|NCT03126630|OTHER|Pharmacological Study|Correlative studies
48653522|NCT06459583|OTHER|eHealth Platform|The eHealth Platform consists of the ADWebPortal and ADChatbot for receiving Alzheimer's-related test results
48653523|NCT06459583|OTHER|Videoconference Telehealth Platform|Participants will have a video telehealth visit with a healthcare provider to receive Alzheimer's-related test results
48653524|NCT03899428|DRUG|Durvalumab|Durvalumab 1500 mg IV (intravenous infusion)
48653525|NCT03899428|DRUG|Sorafenib|Prescribed by physician.
48128447|NCT04351932|BIOLOGICAL|bone marrow & adipose mesenchymal stem cells injection|intrarticular bone marrow and adipose stem cells injection.
48128448|NCT04400136|DRUG|Lansoprazole oral tablets 30 mg|Post operative prescription
48128449|NCT04244942|DEVICE|CERAMENT BVF|CERAMENT BONE VOID FILLER is a synthetic biphasic bone graft substitute.
48128450|NCT03554889|BIOLOGICAL|NK Cell adaptive transfer|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
48128451|NCT03554889|DRUG|Nimotuzumab|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
48128452|NCT01238042|DRUG|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
48494043|NCT00969631|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
48494044|NCT02500641|DRUG|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
47914263|NCT05721599|BEHAVIORAL|Integrated care with nutrition and lifestyle counselling|The structured care includes specialist care, integrated assessment, group health education, one-on-one nutrition and lifestyle guidance, online and face-to-face support group and case management.
47977039|NCT01955733|DRUG|BI 695500|
47977040|NCT03998189|OTHER|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
47977041|NCT03998189|OTHER|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
47977042|NCT03998189|OTHER|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
47977043|NCT03998189|OTHER|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
47977044|NCT03998189|OTHER|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
47977045|NCT03998189|OTHER|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
47977046|NCT01877070|BEHAVIORAL|assessments|
47977047|NCT00326456|DRUG|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
48128453|NCT01623908|DRUG|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
48128454|NCT05728034|BEHAVIORAL|Injectable PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.
48128455|NCT05728034|BEHAVIORAL|Oral PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
48128456|NCT01243814|DEVICE|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
48128457|NCT01243814|DEVICE|placebo injection|joint injection with saline solution for placebo
48128458|NCT03986840|OTHER|Exercise training|A multicomponent exercise program
48494045|NCT02500641|DRUG|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
48494046|NCT02500641|DRUG|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
48653526|NCT03899428|DRUG|Lenvatinib|Prescribed by physician.
47914264|NCT02404025|DRUG|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
47914265|NCT02404025|DRUG|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
47914266|NCT02404025|DRUG|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
47914267|NCT01387542|DRUG|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
48128459|NCT04921488|DEVICE|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
47914268|NCT01970098|DRUG|KPS-0373, High dose|28 weeks
47914269|NCT01970098|DRUG|KPS-0373, Low dose|28 weeks
47914270|NCT01970098|DRUG|Placebo|28 weeks
47914271|NCT04748367|DEVICE|Virtual Reality Headset|Virtual Reality Headset running SILVER software
47914272|NCT05552417|OTHER|Pectointercostal facial plan block|Pectointercostal facial group (PI) (n=--) where --children will have bilateral Pectointercostal Block.
47914273|NCT02983201|OTHER|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
47914274|NCT02983201|OTHER|thumbtack needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
48128460|NCT05170620|PROCEDURE|laser ablation|Laser ablation will be done for the squamous intraepithelial lesions of the lower anogenital tracts.
48128461|NCT01144559|PROCEDURE|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
48653527|NCT03899428|DRUG|Regorafenib|Prescribed by physician.
48128462|NCT01144559|PROCEDURE|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
48128463|NCT03743649|DRUG|Haloperidol|Given IV
48128464|NCT03743649|DRUG|Lorazepam|Given IV
48128465|NCT03743649|OTHER|Placebo|Given IV
48128466|NCT03743649|OTHER|Quality-of-Life Assessment|Ancillary studies
48335506|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
48335507|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
48335508|NCT05840341|DRUG|QingyiHuaji optimized formula|Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
48335509|NCT01825226|OTHER|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
48335510|NCT05380713|DRUG|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
48653528|NCT03899428|DRUG|Cabozantinib|Prescribed by physician.
48653529|NCT00860496|DRUG|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
48653530|NCT00860496|DRUG|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
48128467|NCT03743649|OTHER|Questionnaire Administration|Ancillary studies
48266520|NCT05764148|BEHAVIORAL|behavioral activation|"Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring.~Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions."
48335511|NCT05380713|DRUG|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
48335512|NCT05380713|DRUG|Durvalumab|tremelimumab-durvalumab in adjuvant setting
48335513|NCT06280612|OTHER|Pet therapy|The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.
48335514|NCT02194556|DRUG|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
48335515|NCT02194556|DRUG|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
48653531|NCT05913167|PROCEDURE|laparoscopic nephrectomy|laparoscopic nephrectomy
48653532|NCT06645041|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|The hypertensive patients with vitamin D deficiency will receive a Vitamin D capsule with a dose of 25,000 IU. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
48653533|NCT06645041|DIETARY_SUPPLEMENT|Placebo Capsule(s)|The hypertensive patients with vitamin D deficiency will receive a Placebo capsule. They will be asked to receive a capsule per week for 8 subsequent weeks and re-visit the hospital two weeks from the final dose.
48653534|NCT00609349|DEVICE|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
48653535|NCT06641804|PROCEDURE|Pessary care, change of pessary|Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
48653536|NCT06644144|OTHER|No Interventions|No intervention so not applicable.
48653537|NCT06357377|DRUG|NEO100|"NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol."
48653538|NCT04588883|BEHAVIORAL|Kuja Pamoja - HIV|Information has been provided in the treatment arm description.
48335516|NCT05452109|OTHER|Blood Flow Restriction|Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
48335517|NCT05452109|OTHER|Classical Training Alone|Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
48335518|NCT03612947|DRUG|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
48335519|NCT03612947|DRUG|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
48335520|NCT05668637|OTHER|Artificial Intelligence-based Decision support|Decision support to optimise invasive mechanical ventilation settings
48335521|NCT01045434|DRUG|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
48335522|NCT00554463|DRUG|Filgrastim|5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
48335523|NCT00554463|DRUG|Pegfilgrastim|6 mg via subcutaneous injection days 46 and 67
48335524|NCT00554463|DRUG|Etoposide|Concurrent: 120 mg/m\^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m\^2, IV on days 43-45 and days 65-66.
48266521|NCT01817738|BIOLOGICAL|CV9104|Intradermal injection of CV9104
48335525|NCT00554463|DRUG|Cisplatin|Concurrent: 60 mg/m\^2, IV on days 1 and 22. Adjuvant: 60 mg/m\^2, IV on days 43 and 64.
48335526|NCT00554463|RADIATION|radiation therapy|A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
48494047|NCT02500641|DRUG|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
48266522|NCT01817738|BIOLOGICAL|Placebo|Intradermal injection of placebo
48335527|NCT02633046|DRUG|Acthar Gel|Acthar Gel 80 U/mL solution for subcutaneous injection
48335528|NCT03409419|DRUG|[18F] CFA|pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
48494048|NCT02500641|DRUG|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
48494049|NCT01098864|DEVICE|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
48335529|NCT05463159|OTHER|Transcutaneous electrical nerve stimulation|All children received 30 min of conventional TENS (continuous stimulation with all parameters constant) with a frequency of 100 Hz and a pulse width of 200 µs.
48335530|NCT03419910|DRUG|BMS-986165|Specified dose on specified days
48335531|NCT03419910|DRUG|Cyclosporine|Specified dose on specified days
48494050|NCT00042458|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
48494051|NCT00042458|DRUG|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
48494052|NCT02239341|OTHER|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
48494053|NCT02239341|OTHER|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
48494054|NCT01519986|DIETARY_SUPPLEMENT|Vitamin D3|Supplement of vitamin D3
48335532|NCT05849896|DEVICE|Acquisition of HD sEMG signals using the WPM-SEMG device|The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.
48335533|NCT03949621|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
48335534|NCT02911623|DEVICE|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
48335535|NCT03904784|BEHAVIORAL|school withdrawal teenagers|The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
48335536|NCT05294341|DRUG|Norethindrone Acetate 5 MG|As specified in arm design
48335537|NCT05294341|DRUG|Norethindrone 0.35 MG|As specified in arm design
48335538|NCT06249009|DEVICE|Non invasive ventilation|CPAP and increasing flows of HFNC will be compared during a 30-minutes period each
48335539|NCT05676801|DRUG|Photodynamic Therapy|PDT with methyl aminolevulinate (MAL) as the prodrug for the photosensitizer Pp IX
48335540|NCT00129194|DRUG|KP-1461|
48653539|NCT05936437|DEVICE|Subjects treated with Newest medical device|"Newest is a sterile, non-pyrogenic, viscoelastic gel for single use for intradermal infiltrations. Newest is a medical device containing 2ml of the original association of polynucleotides (10mg/ml) and hyaluronic acid (10mg/ml).~Total number of treatments will consist in 4 Newest administrations: at T0 - basal, at T1- 2 weeks, at T2 - 4 weeks, at T3- 6 weeks."
47977048|NCT00326456|DRUG|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
48128468|NCT01261052|DEVICE|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
48128469|NCT01261052|DEVICE|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
48128470|NCT02918591|DRUG|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
48128471|NCT02137616|DRUG|risperidone|Risperdal tablets
48128472|NCT02137616|DRUG|olanzapine|olanzapine tablets
48128473|NCT02137616|DRUG|Quetiapine|quetiapine tablets
48128474|NCT02137616|DRUG|Aripiprazole|Aripiprazole tablets
48128475|NCT06262282|BIOLOGICAL|mycobacteriophage|mycobacteriophage phage that has been found effective in killing participants NTM infection
48128476|NCT04380558|OTHER|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
48128477|NCT00127387|DRUG|Enbrel|
48128478|NCT04190108|DIAGNOSTIC_TEST|Fecal calprotectin assay|FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
48128479|NCT04235738|OTHER|Observational|"ER2 is a simple and standardized clinical tool. The results of the questionnaires performed in ER2 study will be used. The assessment component of ER2 consists of 6 very simple closed-ended format questions (i.e., yes versus no) which are: Age category (≥ 85), male, polypharmacy (≥ 5 different medications per day), use of formal (health care or social professional) and/or informal (family and/or friend) home support, use of a walking aid regardless of its type, and temporal disorientation (inability to give the current month and/or year). A score of five points is assigned to the items use of walking aid and temporal disorientation, whereas, for the other items, the assigned score is one point. The weighting of points for ER2 items is based on the results of our previous studies. Scores range from 0 (lowest risk) to 14 (highest risk). ER2 scores stratify the risk for short-term ED adverse events into three levels: low, moderate and high."
48128480|NCT06000800|OTHER|Group B|Umbilical cord clamping at 30 seconds
48128481|NCT06000800|OTHER|Group C|Umbilical cord clamping at 60 seconds
48128482|NCT06000800|OTHER|Group D|Umbilical cord clamping at 90 seconds
48494055|NCT01519986|DIETARY_SUPPLEMENT|Placebo|Placebo
48494056|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
47977049|NCT00326456|DRUG|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
47977050|NCT05506891|BEHAVIORAL|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
47977051|NCT05506891|DRUG|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
47977052|NCT02908555|OTHER|No intervention|This is a descriptive study with no intervention
47977053|NCT04900220|DRUG|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
47977054|NCT04900220|DRUG|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
47977055|NCT06166355|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
47977056|NCT06166355|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
47977057|NCT06166355|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
47977058|NCT05604118|DRUG|Aspirin|1 week of aspirin supplementation prior to sampling
47980562|NCT03132376|DIETARY_SUPPLEMENT|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
48128483|NCT06000800|OTHER|Group A|Umbilical cord clamping immediately after birth (5 second)
48128484|NCT01920191|BIOLOGICAL|IMA 950|
48128485|NCT01920191|BIOLOGICAL|Poly ICLC|
48128486|NCT01920191|OTHER|Immunomonitoring|Blood samples, DTH analysis
48128487|NCT02969759|OTHER|Skin Biopsy|
48335541|NCT01299610|DRUG|GW870086 2.0%|White to slightly colored opaque cream
48128488|NCT04667858|DEVICE|Home Ovulation Test|Visual read home ovulation test
48335542|NCT01299610|DRUG|GW870086 0.2%|White to slightly colored opaque cream
48128489|NCT02884245|DRUG|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
48128490|NCT02767765|DRUG|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
48128491|NCT03305445|DRUG|Ipilimumab|Ipilimumab (1mg/kg)
48128492|NCT03305445|DRUG|Nivolumab|Nivolumab (3mg/kg)
48128493|NCT01461759|DRUG|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
48128494|NCT01461759|DRUG|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
48128495|NCT01595282|DRUG|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
48335543|NCT01299610|DRUG|FP 0.05%|White cream
48335544|NCT01299610|DRUG|Placebo|White to slightly colored opaque cream
48653540|NCT05064722|DEVICE|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
48653541|NCT06469242|DEVICE|Serafilcon A multifocal contact lenses|Investigational multifocal soft contact lenses
48653542|NCT06469242|DEVICE|Senofilcon A multifocal contact lenses|Commercially available multifocal soft contact lenses
48128496|NCT01595282|DRUG|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
48128497|NCT00263549|BIOLOGICAL|House dust mite Novo Helisen Depot|
48128498|NCT03176888|BEHAVIORAL|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
48128499|NCT03176888|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey \& Greer (2012)
48128500|NCT06451016|DIETARY_SUPPLEMENT|Vitamin D supplements|70 mcg/day (equal to 2800 IU) of cholecalciferol
48128501|NCT06451016|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
48128502|NCT05145205|PROCEDURE|Sleeve gastrectomy|"Bougie was applied over the lower curvature to adjust the gastric tube then longitudinal amputation of the stomach was performed for about 4 to 6 cm per pecker of the pylorus to the corner of His. No supportive materials were used, and over-suturing of the basic line performed only over the points of bleeding.~All resected specimens were sent to histopathology laboratory for examination."
48128503|NCT05145205|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|An antecolic and antegastric RYGB become executed with a 150 cm alimentary limb with both a linearly or circularly kink (25 mm) gastrojejunostomy in step with the desire of the surgeon. A 50-cm-lengthy biliopancreati
48335545|NCT06308146|DIETARY_SUPPLEMENT|Bacillus subtilis ATCC 122264|One capsule (5 billion CFU) per day for 8 weeks.
48335546|NCT06308146|DIETARY_SUPPLEMENT|Placebo|One capsule per day for 8 weeks.
48335547|NCT02661620|DEVICE|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7.5 year post op telephone call to assess stem status and adverse events.
48335548|NCT03432117|OTHER|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
48335549|NCT03432117|OTHER|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
48335550|NCT03025893|DRUG|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
48335551|NCT03025893|DRUG|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
48335552|NCT01690104|DRUG|Rifampicin|
48335553|NCT01690104|DRUG|Placebo|
48335554|NCT00129207|DRUG|bortezomib|
48335555|NCT04354441|DRUG|hydroxychloroquine sulfate 200 MG|Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.
48653543|NCT06469242|DEVICE|CLEAR CARE® Cleaning & Disinfecting Solution|Hydrogen peroxide-based contact lens cleaning and disinfection system
48128504|NCT02522312|OTHER|No Intervention|No drug is administered in this study
48335556|NCT04354441|DRUG|Placebo oral tablet|Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
48335557|NCT00686010|DRUG|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
48335558|NCT00686010|DRUG|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
48335559|NCT00686010|DRUG|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
48335560|NCT00686010|DRUG|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
48335561|NCT02264171|DRUG|Tamsulosin HCl|
48335562|NCT02264171|DRUG|Ketoconazole|
48653544|NCT06640452|OTHER|RecoveryFun system|The system components were: VR headset; wereable biosensors, clinical platform, caregiver app and smart services.
48653545|NCT02704858|DRUG|Perillyl alcohol|Intranasal administration
48653546|NCT04788615|DRUG|Ofatumumab|20mg Subcutaneous injection
48128505|NCT02993094|DRUG|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
47977059|NCT05017766|OTHER|analysis of antimicrobial resistance|"In samples from patients infected with one of the focus pathogens (E. coli, Klebsiella species, S. aureus, P. aeruginosa) will be:~(i) isolated and pathogenic bacteria characterized; (ii) pathogen in-situ properties at single-cell and bulk average determined; (iii) human metabolites, proteins and cells determined (iv) antibiotic concentration determined (v) bacterial growth monitored~Deducted from the data will be:~1. relevant human components and pathogen properties that are common to most patients with similar indication~2. underlying regulatory networks and triggers in pathogen cells and human tissues.~Clinical outcomes (survival/mortality) and treatment response (response or failure) will be correlated to the in vitro retrieved host and bacterial data."
48128506|NCT02993094|DRUG|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
48128507|NCT03261908|GENETIC|detection of genotype|detection of genotype by next generation sequencing
48128508|NCT04876417|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
48128509|NCT04876417|DEVICE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
48128510|NCT00138541|DRUG|vildagliptin|
48128511|NCT04162457|DIETARY_SUPPLEMENT|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
48335563|NCT05430672|DEVICE|The Thoracic Aortic Stent Graft System (Zylox-Tonbridge Medical Technology Co., Ltd. )|This is a objective performance criteria-controlled study, all subjects meet the criteria will receive the same treatment using the thoracic aortic stent graft system (Zylox-Tonbridge Medical Technology Co., Ltd. ).
48335564|NCT03958318|OTHER|Exercise plus nutritional suplementation|For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
48494057|NCT00548093|DRUG|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
48494058|NCT05919121|OTHER|Therapeutic exercise|"1. Stretching exercise of posterior shoulder capsule~2. Strengthening exercises: consists of 6 strengthening exercises all of which have been recommended as essential for any shoulder rehabilitation program.~3. The remaining 2 exercises are the seated press-up and the elbow push up. Both will be performed to fatigue or for a maximum of 25 repetitions. The quality of all repetitions of each exercise will continuously monitored by the investigator of the study"
48494059|NCT05919121|OTHER|hydrocortisone phonophoresis|In this study, the effective area of radiation (ERA) in the mode continuous (100 percent) is 5 cm2, in 1 MHz and 0.7 W/cm2, with four ERA treated areas. Therapy lasted five minutes (three minutes in the insertion of the supraspinatus and 37 two minutes in the infraspinatus insertion) three times weekly over 6 weeks in addition to therapeutic exercises
48494060|NCT05919121|OTHER|hydrocortisone iontophoresis|A direct current electrical stimulation unit will be used to apply iontophoresis. The unit has two electrodes; one electrode is for the negative current, and one is for the positive current. The Active (Negative) electrode will be placed on the anterolateral aspect of the shoulder joint. The passive electrode: will be placed on the upper arm region. Intensity of the current: Between the range of 3-5 mA at the point of sensation of patient was set. Treatment duration: Calculated accordingly with intensity of current. Method of application: hydrocortisone gel 10% will be administered by applying on the active rubber electrode for each session three times weekly over 6 weeks in addition to therapeutic exercises.
48653547|NCT04788615|DRUG|First line DMT|any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
48128512|NCT04162457|DIETARY_SUPPLEMENT|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
48128513|NCT04162457|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
48128514|NCT04162457|DIETARY_SUPPLEMENT|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
48128515|NCT03471585|DRUG|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
48128516|NCT03471585|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
48335565|NCT03958318|OTHER|Exercise|For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
48335566|NCT03476382|DEVICE|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
48494061|NCT00250900|BEHAVIORAL|Prescription Fill Status|
48494062|NCT04666415|OTHER|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
48494063|NCT06206382|PROCEDURE|Whipple operation|Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction
48494064|NCT05805735|OTHER|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
48494065|NCT00601874|DRUG|Pilocarpine|
48653548|NCT06538012|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
48653549|NCT06538012|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
48335567|NCT06236308|BIOLOGICAL|TTAX03 10mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
48335568|NCT06236308|BIOLOGICAL|TTAX03 25mg|TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.
48335569|NCT06236308|BIOLOGICAL|Placebo Comparator: Control Saline|2 mL Sterile, preservative free 0.9% NaCl
48335570|NCT03381209|DRUG|Sugammadex|sugammadex given based on 3 measurements of body weights
48335571|NCT02954445|BIOLOGICAL|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
48335572|NCT06298188|DRUG|Risankizumab|Risankizumab
48335573|NCT00331955|DRUG|doxorubicin hydrochloride|Given IV
48335574|NCT00331955|DRUG|vorinostat|Given orally
48335575|NCT00331955|OTHER|pharmacological study|Correlative studies
48335576|NCT00331955|OTHER|laboratory biomarker analysis|Correlative studies
48335577|NCT02657187|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
48335578|NCT02657187|DRUG|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
48335579|NCT00878891|DEVICE|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
48335580|NCT00789295|OTHER|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
48335581|NCT05933798|OTHER|ICOPE|The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings
48335582|NCT05933798|OTHER|Usual Care|Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
48335583|NCT00716339|BEHAVIORAL|motivation|
48335584|NCT03226561|PROCEDURE|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
48335585|NCT01746810|RADIATION|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
48335586|NCT03337425|BEHAVIORAL|Psychoeducational group therapy|The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
48335587|NCT03337425|BEHAVIORAL|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
48335588|NCT03337425|OTHER|Standard treatment|Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
47977060|NCT06287411|DIAGNOSTIC_TEST|FAPI PET/MR combined with gadoxetate disodium|Patients with clinical suspected hepatic malignancies will receive the FAPI PET/MR.
48335589|NCT00132314|DRUG|IM risperidone|long-acting injectable risperidone
48335590|NCT00132314|DRUG|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
48335591|NCT03161782|OTHER|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
48335592|NCT03161782|OTHER|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
48335593|NCT03161782|OTHER|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
48335594|NCT03161782|OTHER|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
48494066|NCT01859130|DEVICE|Zimmer Persona Total Knee System|
48653550|NCT06538012|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
47977061|NCT00068497|DRUG|gefitinib|Given orally
48128517|NCT05412017|DIAGNOSTIC_TEST|Hepatitis C Point of Care Testing and Treatment|Pharmacy led hepatitis C point of care testing
48128518|NCT00557596|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
48653551|NCT06538012|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
48653552|NCT06538012|DRUG|Pembrolizumab|Intravenous (IV) infusion
48653553|NCT06154265|DEVICE|TEE probe|Transesophageal echocardiography, ultrasound probe
48653554|NCT05081609|DRUG|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
48335595|NCT04112771|DRUG|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
48335596|NCT04112771|OTHER|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
48335597|NCT06326671|DRUG|Tiotropium Bromide Inhalation Powder|It's a generic product of Spiriva HandiHaler.
48335598|NCT06326671|DRUG|Spiriva HandiHaler|Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.
48653555|NCT05081609|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
48653556|NCT05081609|DRUG|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
48653557|NCT05081609|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
48653558|NCT05081609|PROCEDURE|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
48653559|NCT05081609|DRUG|Trastuzumab|Trastuzumab will be administered as an intravenous (IV) infusion
48653560|NCT05081609|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion
48335599|NCT01917240|OTHER|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
48335600|NCT03817840|PROCEDURE|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
48335601|NCT05848180|OTHER|Ankle proprioceptive training (APT)|"APT comprise of exercises including towel curls, uni-leg stance on foam with activity, writing alphabets on gym ball with toes, picking marbles with toes.~BT includes tendem walk, side leg raises, sit to stand, side walk, back leg raise"
48653561|NCT05406453|OTHER|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
48653562|NCT03766399|DRUG|AZD0449|Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
47977062|NCT01446900|DRUG|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
47977063|NCT01446900|DRUG|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
47977064|NCT04842266|DEVICE|IlluminOss pelvic implant for oncologic indication|Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis
47977065|NCT04842266|DEVICE|IlluminOss pelvic implant for geriatric trauma indication|Pelvic fragility fracture in a geriatric patients (age 65 or older)
48335602|NCT05848180|OTHER|Balance training (BT)|Balance training exercises comprising of side walk, tandem walk, standing on one leg, walking with alternating arm raise up to 90 degrees
48335603|NCT03620253|DRUG|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
48494067|NCT05808075|OTHER|NovaProTM Fill Universal Dental Composite|NovaProTM Fill Universal ,Nanova product
48494068|NCT00804713|DRUG|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
48653563|NCT03766399|DRUG|Placebo|Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
47977066|NCT00672412|DRUG|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
47977067|NCT00672412|DRUG|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
47977068|NCT00672412|DRUG|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
47977069|NCT00672412|DRUG|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
47977070|NCT01276353|DRUG|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
48653564|NCT00748605|DRUG|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
48653565|NCT00748605|DRUG|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
48653566|NCT00748605|DRUG|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
48653567|NCT00748605|OTHER|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
48653568|NCT00748605|OTHER|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
48653569|NCT06541132|OTHER|Observational study without human intervention|Observational study without human intervention
48653570|NCT05479981|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
48653571|NCT05479981|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
48335604|NCT03620253|DRUG|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
48335605|NCT01039818|RADIATION|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
48335606|NCT01039818|RADIATION|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
48335607|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
48335608|NCT05054179|OTHER|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
48335609|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
48335610|NCT05668026|DRUG|Venetoclax|In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
48335611|NCT00156910|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
48335612|NCT00156910|OTHER|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
48335613|NCT02399904|OTHER|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
48335614|NCT01809197|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
48335615|NCT01809197|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
48335616|NCT01809197|DEVICE|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
48335617|NCT01809197|DEVICE|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
48335618|NCT02808507|OTHER|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
48335619|NCT02043236|BEHAVIORAL|Healthy bones pamphlet|written educational material
48335620|NCT02043236|BEHAVIORAL|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
48335621|NCT02043236|BEHAVIORAL|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
48494069|NCT00804713|DRUG|TST|Administer TB Skin test (TST)
48494070|NCT00804713|OTHER|QFT|Perform QFT TB test
48494071|NCT00804713|OTHER|T-spot|Perform T-Spot TB test
48494072|NCT01943721|DRUG|VISION5 Product|
48494073|NCT02251691|DRUG|Advagraf|Compare the drug compliance between once daily or twice daily regimen
48335622|NCT05621590|DRUG|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
48494074|NCT02251691|DRUG|Prograf|Compare the drug compliance between once daily or twice daily regimen
48494075|NCT00826449|DRUG|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
48335623|NCT05621590|DRUG|Placebo|placebo capsules filled with stevia sweetened powder
48335624|NCT00004999|DRUG|Lamivudine/Zidovudine|
48335625|NCT00004999|DRUG|Capravirine|
48335626|NCT00004999|DRUG|Nelfinavir mesylate|
48494076|NCT00826449|DRUG|Erlotinib|150 mg by mouth daily every 21 day cycle.
48494077|NCT03355014|DRUG|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
48494078|NCT03355014|DRUG|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
48494079|NCT06233084|DRUG|Desogestrel-Test product|Desogestrel Tablets 0.075 mg Manufactured by: POND'S CHEMICAL THAILAND R.O.P., Thailand
48494080|NCT06233084|DRUG|Desogestrel-Reference product|Desogestrel Tablets 0.075 mg Manufactured by: N.V. Organon, The Netherlands
48494081|NCT01270165|DRUG|telbivudine|600mg, oral daily over 12 months
48494082|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
48494083|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
48494084|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
48494085|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
48494086|NCT01008852|DRUG|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
48494087|NCT00002040|DRUG|Fluconazole|
48494088|NCT02254161|DRUG|Matching placebo|Tablet
48494089|NCT02254161|DRUG|BI 1181181 healthy elderly|Tablet
48494090|NCT02254161|DRUG|BI 1181181 Healthy young|Tablet
48494091|NCT03123861|DRUG|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
48335627|NCT03001323|DRUG|Degludec|"Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
48494092|NCT03123861|DRUG|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
47977071|NCT01276353|DRUG|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
48128519|NCT04807790|OTHER|Telerehabilitation based structured home program applications|"The structured home program will consist of activities determined by the family members according to the functional level of the child and the activities he / she can not do, and which are determined according to the goals specific to the child. In order to ensure that the structured home program created can be implemented by the family, a 1 hour family training will be provided.~After the structured home program training, a 45-minute video interview will be held with one of the family members (mother-father-caregiver) once a week, in order to check by the physiotherapist whether the home program is implemented correctly. Video interviews will be the telerehabilitation part of the study."
48128520|NCT00004840|DRUG|thyrotropin-releasing hormone|
47977072|NCT03776383|OTHER|Antibiotic use feedback letter|Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
47977073|NCT03018704|DRUG|Topiramate|anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
47977074|NCT03018704|DRUG|placebo|inactive medication. the doses of placebo were titrated the same as the active intervention.
47977075|NCT03146715|OTHER|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
48128521|NCT06445244|DIETARY_SUPPLEMENT|Alpha-ketoglutarate supplied as 1000mg capsule|AKG Double Wood® + lifestyle modification AKG Double Wood®: 500mg, qd, for one months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
48128522|NCT06445244|BEHAVIORAL|Behavioral: Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
48128523|NCT04132141|OTHER|Virtual Reality Headset with curated content|clinicians will wear VR immersive headset for up to 15 minutes during their break
48128524|NCT00962234|OTHER|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
48128525|NCT00962234|BIOLOGICAL|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
48128526|NCT00962234|PROCEDURE|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
48128527|NCT02426996|PROCEDURE|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
48128528|NCT04215172|DRUG|Macrolides|administration of azithromycin three times weekly for six months
48128529|NCT05443542|DEVICE|Virtual Reality|Game to be played is a commercially available VR game
48128530|NCT05443542|OTHER|Control intervention|Sodoku, crossword puzzles
48128531|NCT01300975|DRUG|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
48128532|NCT01300975|PROCEDURE|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
48128533|NCT01300975|DRUG|placebo cream|topical emollient crean 3 times a day during 21 days
47977076|NCT05723237|OTHER|Breast Cancer Education|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
47977077|NCT00573534|DRUG|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
47977078|NCT05990114|OTHER|The structured caregiver support program|It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
47977079|NCT00399776|RADIATION|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
47980563|NCT03132376|DIETARY_SUPPLEMENT|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
48653572|NCT06639880|OTHER|usual care exercise|the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise
48653573|NCT06639880|OTHER|triple attack protocol|a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
48653574|NCT00236665|DRUG|topiramate|
47977080|NCT02503553|BEHAVIORAL|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
48653575|NCT04700800|OTHER|Exercise|Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
48653576|NCT04700800|OTHER|Infusion of Amino Acids|Intravenous infusion of mixture of amino acids
48653577|NCT01686321|DRUG|Bendamustine and subcutaneous rituximab|
48128534|NCT04000516|BEHAVIORAL|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
48128535|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
48335628|NCT03001323|DRUG|Standard long-acting|"Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
48335629|NCT05678270|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 5mg, orally.
48335630|NCT04105647|BEHAVIORAL|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
48494093|NCT00506649|OTHER|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
48494094|NCT03077035|OTHER|glass ionomer sealants|
48653578|NCT02732496|BEHAVIORAL|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
48653579|NCT02732496|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
48653580|NCT05712395|BEHAVIORAL|Exercise|Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
48653581|NCT04575298|DIETARY_SUPPLEMENT|Acceptability, tolerance study for an infant formula with human milk oligosaccharides|Prospective study
48653582|NCT06642636|DEVICE|Intensive Care Unit-specific Virtual Reality|The Intensive Care specific Virtual Reality (ICU-VR) film is designed so that patients received relevant and truthful information regarding their ICU treatment with the aim to reduce stress and anxiety. The final film lasts approximately 12 minutes. Real ICU nurses and ICU physicians re-enacting a typical day/treatment for a mock patient undergoing ICU treatment. The module will be watched via HMD-VR glasses (PICO G2 VR; Pico Technology, Beijing, China) with the SyncVR Relax \& Distract application (SyncVR, Utrecht, the Netherlands).
48653583|NCT06641960|DRUG|Probiotics|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
48653584|NCT06641960|PROCEDURE|Traditional treatment|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction without probiotic lozenges.
47977081|NCT02503553|BEHAVIORAL|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
48494095|NCT03077035|OTHER|resin-based sealant|
48494096|NCT04823962|DRUG|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
48494097|NCT04823962|DRUG|Placebo hydrogel|Placebo hydrogel
48494098|NCT04823962|OTHER|Standard care|Compression therapy and neutral dressings
48653585|NCT02333292|DRUG|Telaprevir|Initiation of a regimen containing TVR
48653586|NCT02333292|DRUG|Boceprevir|Initiation of a regimen containing BOC
48653587|NCT02333292|DRUG|Sofosbuvir|Initiation of a regimen containing SOF
48653588|NCT02333292|DRUG|Simeprevir|Initiation of a regimen containing SMV
48653589|NCT02333292|DRUG|Daclatasvir|Initiation of a regimen containing DCV
48653590|NCT02333292|DRUG|Ledipasvir|Initiation of a regimen containing LDV
48653591|NCT02333292|DRUG|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
48653592|NCT02333292|DRUG|Dasabuvir|Initiation of a regimen containing DBV
48653593|NCT02333292|DRUG|Velpatasvir|Initiation of a regimen containing VPV
48335631|NCT04105647|BEHAVIORAL|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
48335632|NCT02126670|DRUG|ACT01|
48335633|NCT02126670|DRUG|Comp01|
48335634|NCT02126670|DRUG|Comp02|
48335635|NCT02126670|DRUG|Comp03|
48335636|NCT02126670|DRUG|Comp04|
48335637|NCT06353360|DEVICE|Tumor Treating Fields|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the Day 1 of cycle 1 (C1D1), throughout the entire course of treatment.
48335638|NCT06353360|DRUG|Tislelizumab|Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.
48335639|NCT06353360|DRUG|Temozolomide (TMZ)|The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
48494099|NCT05286723|OTHER|Multicomponent Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
48335640|NCT03914534|DRUG|Valproic Acid 500 MG|Administration of 500 mg of Valproic Acid
48494100|NCT01150890|BIOLOGICAL|Brodalumab|Administered as as an intravenous (IV) infusion over at least 30 minutes.
48494101|NCT01150890|DRUG|Placebo|Administered as as an intravenous (IV) infusion over at least 30 minutes.
48494102|NCT01520532|OTHER|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
48494103|NCT00672165|BIOLOGICAL|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
48494104|NCT05649241|DRUG|Nicotine patch|Nicotine replacement therapy patch
48494105|NCT05649241|DRUG|Nicotine gum|Nicotine replacement therapy gum
48653594|NCT02333292|DRUG|Elbasvir|Initiation of a regimen containing EBV
48494106|NCT05649241|BEHAVIORAL|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
48494107|NCT01062737|DRUG|ASU|
48494108|NCT04132583|DRUG|Deflox®|Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
48494109|NCT04132583|DRUG|Cataflam DD®|Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
48494110|NCT05484843|BEHAVIORAL|telenursing training based on self-care theory|"* A training guide based on the self-care theory specific to individuals diagnosed with stroke was prepared.~* Identification of the study/control group (randomization)~* Patients were informed and consents were obtained.~* Sample suitability was evaluated in line with the cognitive levels and inclusion criteria of patients diagnosed with stroke.~* All patients included in the sample group were pre-tested before discharge.~* Training was offered for the study group patients in line with the guide prepared based on self-care theory.~* Tele-nursing training was applied to the study group patients.~* Control group patients were followed up~* Post-tests were administered at the end of the 12-week period~* The training of the control group patients was completed~* Your data has been evaluated"
48653595|NCT02333292|DRUG|Grazoprevir|Initiation of a regimen containing GZR
48494111|NCT05484843|BEHAVIORAL|just observation|For 3 months, patients were observed without intervention. The standard discharge training of the clinic was given.
48653596|NCT06187714|PROCEDURE|caudal block rate|optic nerve sheath diameter measurement according to caudal block rate
47977082|NCT05022108|BIOLOGICAL|Alpha bisabolol gel|Using alpha bisabolol gel with a concentration of 0.5%, 2,5% or 5% to treat sensitized area with histamine.
48128536|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
48335641|NCT03914534|DRUG|Valcote 500 mg|Administration of 500 mg of Valproic Acid
48335642|NCT01235728|DRUG|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
48335643|NCT01235728|DRUG|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
48335644|NCT01235728|DRUG|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
48335645|NCT00431496|DRUG|Cinacalcet|Cinacalcet tablets
48335646|NCT02905825|DEVICE|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
48335647|NCT02905825|DRUG|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
48335648|NCT02905825|DIAGNOSTIC_TEST|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
48335649|NCT03886922|DRUG|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
48335650|NCT03886922|DRUG|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
48335651|NCT02794623|DEVICE|Tinnitus masking|Tinnitus masking via CI system
48335652|NCT06527859|DRUG|Levothyroxin|The disease group were divided into two groups ,25ugLT4 (HA group, n=17) and 50ugLT4 (HB group, n=17) respectively.
48335653|NCT04348994|DEVICE|Non-ablative thermal-only Er:YAG laser therapy|"Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions."
48335654|NCT06015568|DRUG|MCLA-129: 1500mg or 2000mg IV Q2W|Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
48494112|NCT04070586|DEVICE|4DCBCT images|Images are acquired and assessed offline
48494113|NCT00418821|BIOLOGICAL|Laronidase|dose of 0.58mg/kg body weight intravenously (IV) every week
48494114|NCT04648124|DEVICE|IRMf-r (séquence resting state)|Functional MRI of functional brain networks
48494115|NCT05188053|DRUG|HTX-011|Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
48653597|NCT04601493|BEHAVIORAL|Choice Architecture Nudge|"During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic)."
47977083|NCT03571152|OTHER|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
48335655|NCT06015568|DRUG|Befotertinib: 75 mg or 100 mg Po QD|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs."
48335656|NCT01062009|DRUG|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
48335657|NCT04983810|DRUG|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
48494116|NCT05188053|DRUG|ropivacaine , epinephrine , ketorolac diluted in sodium chloride|Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
48494117|NCT00459121|DRUG|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
48494118|NCT00459121|DRUG|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
48494119|NCT00459121|DRUG|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
48494120|NCT00459121|PROCEDURE|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
48494121|NCT02575911|DEVICE|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
48653598|NCT04601493|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
47977084|NCT03742934|OTHER|Short peptide|Short peptide formula during bowel preparation
47977085|NCT03742934|OTHER|Liquid diet|Liquid diet during bowel preparation
47977086|NCT02263989|DRUG|Telmisartan film coated tablet|
47977087|NCT02263989|DRUG|Telmisartan conventional tablet|
48494122|NCT02575911|PROCEDURE|LASIK surgery|
48494123|NCT04764656|DRUG|Brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
47977088|NCT02010554|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
48335658|NCT02680392|PROCEDURE|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
48494124|NCT04155307|DEVICE|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
48653599|NCT06567262|DEVICE|CAD/CAM metallic removable partial denture|"Make digital scans using an intraoral scanning device. Scan the maxillary (antagonistic scan) and mandibular (pre-preparation scan) arches, as well as an initial digital record of the inter-occlusal relation (occlusal scan).~Analyse the digital cast using CAD software. Primary electronic surveying will be carried out to ensure if the tooth preparations will be needed.~Make a definitive intraoral scan only of the prepared teeth and record the maxillary-mandibular relationship.~The virtual cast is digitally surveyed and the design of the framework is done using computer software. The wax pattern 3D framework information will be converted into a standard tessellation language (STL) file and transfer to a rapid prototyping (RP) system to be printed and finally cast using the conventional technique to produce RPD framework."
48653600|NCT06567262|DEVICE|Conventional metallic removable partial denture|"Primary impressions will be taken, the impressions will be poured to construct a study casts.~Maxillary Face-bow record and diagnostic bite will be taken. The study casts will be mounted on semi adjustable articulator to check inter-arch space.~Surveying of the study cast will be done. Required mouth preparation will be carried out then secondary impression will be taken using special tray.~Secondary impression will be poured to obtain master cast which will be surveyed to confirm proper mouth preparation, blocked out and then wax pattern will be designed and constructed.~A metallic framework will be obtained using the conventional lost wax technique and casting.~Intraoral try in of the framework will be done followed by bite registration record.~The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally."
48653601|NCT06171789|DRUG|PRO1107|Intravenous infusion of PRO1107
48653602|NCT02816112|DRUG|Ciprofloxacin|Antibiotic
48653603|NCT02816112|DRUG|Neupogen|Granulocyte-colony stimulating factor
48653604|NCT00378287|DRUG|rabeprazole sodium|
48653605|NCT00174629|DRUG|Docetaxel/DDP|
48653606|NCT00174629|DRUG|docetaxel/gemcitabine|
48653607|NCT02261792|PROCEDURE|24 hours Trendelenburg position|Trendelenburg position
48653608|NCT02261792|PROCEDURE|24 hours bed rest|24 hours bed rest after EBP
48653609|NCT02261792|PROCEDURE|EBP|Autologous Epidural Blood Patch
48653610|NCT06639295|DRUG|611|611 subcutaneous (SC) injection.
48653611|NCT06639295|DRUG|Placebo|Placebo subcutaneous (SC) injection.
48653612|NCT04573478|DRUG|Atrasentan|Film-coated tablet
48653613|NCT04573478|DRUG|Placebo|Film-coated tablet
48653614|NCT06641674|DRUG|18F-LF13|18F-LF13 PET/CT: after intravenous injection of 1.85 - 3.7 MBq/kg body weight of quality-controlled 18F-LF13, a Siemens Biograph PET/CT scan will be applied within 0.5 h, and the scan range will be from the top of the head to 1/3 of the upper thigh, 2 h to 4 h delayed scanning can be added if necessary.
48653615|NCT06564532|BEHAVIORAL|Evaluatively conditioning participant to like partner|The intervention is a computerized learning task that leads the participant to associate the partner with positive stimuli
48653616|NCT06564532|BEHAVIORAL|Evaluatively conditioning partner to like participant|The intervention is a computerized learning task that leads the partner to associate the participant with positive stimuli
48653617|NCT02445365|DEVICE|AutoRIC device|
48653618|NCT06559540|RADIATION|Hypofractionated radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes,
48653619|NCT06559540|RADIATION|Ultra-hypofractionated breast/chest wall and regional nodal radiation|External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes
48653620|NCT06175533|PROCEDURE|ultrasound guided 60 degree CRF for plantar fasciitis|ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
48653621|NCT03689179|BEHAVIORAL|Time for Living and Caring (TLC)|"Time for Living \& Caring (TLC) is an online, self-administered intervention. It includes three types of modules: 1) virtual coaching module (defined as a series of prompts, reminders, and suggestions that guide caregivers through assessment, goal setting, and goal review activities) to monitor respite time-use and time-use goals, 2) an interactive calendar that can be used to schedule and track respite time, 3) resource pages (including links, printable forms, video guides) that provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?."
48653622|NCT06641206|DRUG|Triamcinolone Acetonide|1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
48653623|NCT06641206|DRUG|Bupivacaine Hydrochloride|20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
48653624|NCT06641206|DRUG|Dexmedetomidine|Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
48653625|NCT04862403|PROCEDURE|Umbilical cord clamping distance|Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
48653626|NCT04421664|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
48653627|NCT04421664|DRUG|Placebo oral tablet|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
48653628|NCT06506422|DRUG|Empagliflozin 10 MG|10mg Empagliflozin daily for 12 weeks
48494125|NCT04155307|DIAGNOSTIC_TEST|Anal Manometry|Anal Manometry done in standard care
47977089|NCT02010554|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
47977090|NCT02824874|DRUG|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
47977091|NCT02824874|DRUG|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
47977092|NCT05612984|COMBINATION_PRODUCT|Calcium aspirin multiple micronutrients|Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
48128537|NCT05577936|DEVICE|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
48128538|NCT05577936|OTHER|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
48128539|NCT01297894|DRUG|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
47977093|NCT05612984|DIETARY_SUPPLEMENT|Iron-folic Acid|Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
48494126|NCT04155307|DIAGNOSTIC_TEST|Defecography|Defecographydone in standard care
48128540|NCT01297894|DRUG|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
48128541|NCT03791736|PROCEDURE|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
48128542|NCT00868504|OTHER|no intervention|no intervention
48494127|NCT04155307|DIAGNOSTIC_TEST|Electromyogram|Electromyogram done in standard care
47977094|NCT00136617|DRUG|chlordiazepoxide|
48128543|NCT04274881|PROCEDURE|Catheterization of internal jugular vein|"The right internal jugular vein will be cannulated under transesophageal echocardiographic (TEE) guidance in order to place the catheter tip in the mid-SVC.~The length of the catheter required to place the tip at the mid-SVC as guided by TEE will be regressed on the C-length or on the distance from the entry point to the surface point corresponding to the mid-SVC on the chest wall in order to obtain a predictive equation.~The accuracy of either equation will be assessed by estimation of the standard error of the estimate (SEest)."
48335659|NCT02680392|DRUG|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
48494128|NCT05376852|COMBINATION_PRODUCT|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
48494129|NCT04650152|DRUG|Tricor (fenofibrate), 145 mg, film-coated tablet|Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
48494130|NCT01751035|BEHAVIORAL|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
48494131|NCT01751035|BEHAVIORAL|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
48494132|NCT01272362|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
47977095|NCT05870020|OTHER|Questionnaire (DBS-QoLs)|"The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~* the inclusion~* 15 days after the inclusion~* 1 year after the inclusion"
47977096|NCT02743559|DEVICE|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
47977097|NCT03487276|DRUG|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
48494133|NCT02276014|DIETARY_SUPPLEMENT|Beta-carotene|
48653629|NCT06506422|DRUG|Placebo|10mg Placebo daily for 12 weeks
47977098|NCT03487276|DRUG|Placebo|Placebo
47977099|NCT01894191|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
48128544|NCT05736094|DEVICE|SURF|Dual-frequency ultrasound
47977100|NCT01894191|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
47977101|NCT01894191|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
47977102|NCT05564689|PROCEDURE|Intracoronary flow and pressure|Measurement of absolute coronary flow and resistance
48335660|NCT01611480|DRUG|Imiquimod (topical use)|
47980564|NCT03132376|DIETARY_SUPPLEMENT|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
48128545|NCT04038736|DEVICE|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
48128546|NCT00224406|DRUG|repertaxin|
48128547|NCT04019509|DIAGNOSTIC_TEST|blood test|blood test for thyroid antibodies and thyroid function (TSH, FT4)
48128548|NCT04019509|OTHER|follow up treatment outcome|questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
48128549|NCT05900505|OTHER|Social Navigator|The social navigator will assess patient/family needs and help them to access community resources (specific to their community) to address these, while promoting their engagement and self-efficacy.
48128550|NCT02455765|OTHER|Rice and Amino Acid mixtures|Rice and amino acid mixture
48128551|NCT02424201|DRUG|Misoprostol|experimental
48128552|NCT02424201|DRUG|vitamin c|control
48128553|NCT00439270|DRUG|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
48128554|NCT00439270|DRUG|Docetaxel|Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
48494134|NCT02987101|PROCEDURE|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
48494135|NCT02987101|OTHER|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
48494136|NCT02987101|DRUG|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
47980565|NCT00450450|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
47980566|NCT00450450|OTHER|laboratory biomarker analysis|Correlative studies
48128555|NCT05273944|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
48128556|NCT04228913|OTHER|Root Canal Obturation Technique|This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy
48128557|NCT04544319|DRUG|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
48494137|NCT01305174|DEVICE|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
48494138|NCT06072365|OTHER|nutritional intake questionnaire|patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
48494139|NCT04974866|DRUG|EGFR-TK Inhibitor|epidermal growth factor receptor tyrosine kinase inhibitors
48494140|NCT00063635|DRUG|Metformin|500 mg, twice daily
48494141|NCT00063635|DIETARY_SUPPLEMENT|Vitamin E|400 IU, twice daily
48494142|NCT00063635|DRUG|Matching placebo|Twice daily
48494143|NCT00406042|DRUG|prednisolone acetate 1%|
48128558|NCT04544319|DRUG|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
48128559|NCT01939691|DRUG|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
48128560|NCT01939691|DRUG|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
48128561|NCT01939691|DRUG|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
48128562|NCT03344094|DRUG|ocrelizumab|FDA-approved MS drugs
48128563|NCT02686398|BIOLOGICAL|Fluad|
48128564|NCT02686398|BIOLOGICAL|Agrippal|
48335661|NCT04698109|OTHER|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
48335662|NCT04698109|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
48335663|NCT04698109|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
48335664|NCT04376515|BEHAVIORAL|HOPE intervention|Online peer support community of peers trained in behavior change science
48335665|NCT02727517|PROCEDURE|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
48335666|NCT02727517|PROCEDURE|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
48494144|NCT02556983|RADIATION|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
48494145|NCT03569150|OTHER|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
48653630|NCT05910424|OTHER|collection of saliva, gum fluid and/or dental plaque samples|Non-invasive sampling of dental plaque, crevicular fluid and/or saliva, using an examination probe, paper tips and saliva swabs
48653631|NCT06264154|OTHER|E-cigarettes|All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.
48653632|NCT06478693|DRUG|MT-303|MT-303
48653633|NCT05775042|BIOLOGICAL|CM338|CM338 injection
48653634|NCT06563596|DRUG|Zanubrutinib|Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
47977103|NCT03477877|BEHAVIORAL|Indashyikirwa Couples Training|A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
48494146|NCT05552170|OTHER|day-case surgery|Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
48494147|NCT04757038|DEVICE|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
48494148|NCT06278740|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|Upper extremity pathologies of participants with ultrasound
48653635|NCT06563596|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.
48653636|NCT06563596|DRUG|Epcoritamab|Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
48653637|NCT05393427|DRUG|BL-B01D1|Administration by intravenous infusion
48653638|NCT05836909|DIETARY_SUPPLEMENT|Swisse plus cholesterol capsule|Swisse plus cholesterol capsule per day orally for 12 weeks
48494149|NCT05145582|BEHAVIORAL|The Self-Guided PSP Wellbeing Course|An unguided version of a transdiagnostic ICBT program that has shown promising initial outcomes in prior research (https://doi.org/10.2196/27610).
48494150|NCT05145582|BEHAVIORAL|Online Discussion Forum|An online discussion forum designed to provide an opportunity for participants to support one another in their use of the ICBT program.
48653639|NCT05836909|DIETARY_SUPPLEMENT|Placebo|Placebo
48653640|NCT01851798|OTHER|Home sleep test administered to all enrolled subjects|
48653641|NCT05646693|DIETARY_SUPPLEMENT|Drusen Mega®|It consists of a dietary supplement composed of Vitamin C 60.0mg, Vitamin E 30.0mg, Zinc 12.5mg, Copper 1.0mg, Astaxanthin 4.0mg, Zeaxanthin 2.0mg, Lutein 10.0mg and Omega 3 Acids 500.0mg. It is suggested to consume one capsule per day, preferably with food. This supplement is indicated for nutritional deficiencies and in patients with ophthalmological pathologies.
48653642|NCT05646693|DRUG|Sertraline|It consists of a drug capsule composed of Sertraline Hydrochloride 50mg. In adults it is suggested to consume one to four capsule(s) per day, administering (preferably) the highest dose in the evening, before going to bed. This drug is indicated in the treatment of depressive states with anxiety or moderate to severe agitation, which are accompanied by tension, excitement, insomnia, obsessive and hypochondriac traits. It is also indicated in obsessive-compulsive disorder, panic attacks, stress disorder, post-traumatic disorder, social anxiety disorder and used to relieve the symptoms of premenstrual dysphoric disorder.
48653643|NCT05646693|DRUG|Placebo|It consists of a placebo capsule composed of Magnesium Oxide 100mg. This component is inert in the dose at which it will be administered.
47977104|NCT03477877|BEHAVIORAL|Indashyikirwa Activist Training|This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
47980567|NCT00450450|BIOLOGICAL|filgrastim|Given IV
48494151|NCT04408430|DEVICE|Transseptal ViMAC|Transseptal TMVR using balloon-expandable aortic transcatheter valves.
48128565|NCT06210659|BEHAVIORAL|Theory of Planned Behavior Based Training Program|"Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. First session; It will consist of the definition, symptoms and treatment approaches of primary dysmenorrhea. Content of the second session; It will consist of lifestyle interventions in dysmenorrhea. Content of the third session; It will consist of the importance of physical activity in primary dysmenorrhea. The fourth session consists of a group walk.~Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles."
48128566|NCT01426412|DRUG|LY3015014 IV|Administered IV over 30-90 minutes
48128567|NCT01426412|DRUG|Placebo IV|Administered IV only over 30-90 minutes
48128568|NCT01426412|DRUG|LY3015014 SC|Administered SC
48128569|NCT01426412|DRUG|Placebo SC|Administered SC
48128570|NCT03259516|DRUG|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
48128571|NCT03259516|DRUG|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
48128572|NCT03259516|DRUG|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
48128573|NCT03259516|DRUG|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
48128574|NCT03259516|DRUG|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
48128575|NCT03259516|DRUG|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
48128576|NCT03259516|DRUG|Sildenafil|20 mg per os three times a day during the whole course of treatment
48335667|NCT04296916|DRUG|IOP lowering eye drops|"1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops."
48335668|NCT06345599|RADIATION|Radiotherapy|This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.
48494152|NCT05731791|RADIATION|Radiation Therapy to partial breast|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
48653644|NCT06334146|OTHER|Tap dance program|Participants will take part in a weekly adapted tap dance class, for one hour per week, for eight weeks.
48653645|NCT06191445|PROCEDURE|Conventional Landmark Technique|The investigator will perform spinal anesthesia using the conventional landmark technique.
48653646|NCT06191445|PROCEDURE|Ultrasound Assisted Technique|The investigator will perform spinal anesthesia using the ultrasound assisted technique.
48128577|NCT03259516|DRUG|Melphalan|2 mg per os daily during the whole course of treatment
48653647|NCT06191445|PROCEDURE|Real-Time Ultrasound Guided Technique|The investigator will perform spinal anesthesia using the real-time ultrasound-guided technique.
48653648|NCT01197300|DRUG|Zoledronic acid|intravenous infusion
48653649|NCT01500135|DRUG|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
48653650|NCT01500135|DRUG|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
48653651|NCT06365463|BEHAVIORAL|Telerehabilitation|The training will last for 6 weeks, with two 60-minute sessions of balance and mobility training per week. Two consecutive groups will participate.
47977105|NCT03477877|BEHAVIORAL|Indashyikirwa Opinion Leader Training|"Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network."
47980568|NCT00464087|DRUG|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
48128578|NCT05283408|DRUG|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
48128579|NCT05283408|DRUG|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
48128580|NCT05283408|DRUG|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
48335669|NCT06345599|DRUG|Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab|GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
48335670|NCT06345599|DRUG|Chemotherapy:Albumin-bound paclitaxel、Gemcitabine|Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
48335671|NCT05048199|DEVICE|pressure regulated volume-controlled mode of ventilation|"Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6)."
48335672|NCT05048199|DEVICE|volume-controlled mode of ventilation|"Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6)."
48335673|NCT01395355|BEHAVIORAL|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
48335674|NCT01395355|BEHAVIORAL|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
48494153|NCT06180265|DIAGNOSTIC_TEST|presepsin, procalciton, endotoxin|measurement of presepsin, procalciton, endotoxin plasmatic levels
48653652|NCT06672341|DIAGNOSTIC_TEST|Endometrial Cytology Testing|Endometrial Cytology Examination Liquid-based endometrial cytology is an emerging minimally invasive screening technique. This method involves collecting endometrial cells and tissues from the uterus and its downstream anatomical structures. The samples are preserved and analyzed using either liquid-based cytology techniques or tissue smear methods to reach a pathological diagnosis. Compared to invasive procedures such as fractional curettage, liquid-based cytology offers advantages in the screening of endometrial cancer, including being minimally invasive, convenient, and low-risk.
48653653|NCT06672341|DIAGNOSTIC_TEST|Cervical Methylation Testing|Cervical Cell Methylation Testing Cervical cell methylation testing is another promising method for methylation-based screening of endometrial cancer. This approach targets specific genes that undergo methylation in the early stages of endometrial cancer. The combined methylation analysis of four genes (CD01, BHLHE22, ACTB, and SEPTIN9) uses menstrual blood or vaginal secretions as samples, offering advantages such as safety, non-invasiveness, and self-collection. This method has shown high sensitivity and specificity for the early detection of endometrial cancer. Ongoing research suggests that the sensitivity and specificity of cervical cell methylation testing can reach 93.2% and 96%, respectively, although this data is yet to be published.
48653654|NCT06132204|DRUG|HRS-7535 Tablets|HRS-7535 Tablets
48653655|NCT05044819|DRUG|Cannabidiol|Oral Cannabidiol solution 100 mg/mL
48653656|NCT05896826|DEVICE|Magnetometer|inspection equipment for magnetocardiography
48653657|NCT02615275|PROCEDURE|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
48335675|NCT06145893|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
48335676|NCT06145893|DRUG|Hemay005|Hemay005 tables 45mg bid p.o;
48335677|NCT06145893|DRUG|Placebo|placebo to Hemay005 tables bid p.o
48335678|NCT01773798|DRUG|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
48335679|NCT01773798|DRUG|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
48653658|NCT02615275|PROCEDURE|Computed Tomography|Undergo CT
48653659|NCT02615275|PROCEDURE|Positron Emission Tomography|Undergo PET
48653660|NCT02615275|OTHER|Quality-of-Life Assessment|Ancillary studies
48653661|NCT02615275|OTHER|Questionnaire Administration|Ancillary studies
48653662|NCT02615275|RADIATION|Radiation Therapy|Undergo RT
48653663|NCT00850330|OTHER|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
48653664|NCT01838733|OTHER|Observational study|
48653665|NCT06489431|DRUG|Chlorhexidine|Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
48653666|NCT06489431|DRUG|Gentamicin|Aminoglycoside antibiotic irrigation
48653667|NCT06489431|DRUG|Rifampin|Antibacterial known to inhibit DNA-dependent RNA polymerase
48653668|NCT04548219|DRUG|Mirikizumab|Reference and test formulations of mirikizumab administered as a SC injection.
48653669|NCT04019327|DRUG|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
48653670|NCT04019327|DRUG|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 \& 4 - 100 mg/m2 QD Days 2-8 Level 5 \& 6 - 125 mg/m2 QD Days 2-8"
48653671|NCT06641999|DEVICE|Tinnitus Implant System|Implanted with Tinnitus Implant System: Active Implantable Medical Device
48653672|NCT01127958|DEVICE|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
48653673|NCT01127958|DEVICE|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
47977106|NCT03477877|OTHER|Indashyikirwa Women's Spaces|"Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network."
48128581|NCT01354444|DRUG|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
48128582|NCT01354444|DRUG|Placebo|a pill that will look like the active drug but will not contain any carvedilol
48335680|NCT01773798|DRUG|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
48335681|NCT01773798|DRUG|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
48335682|NCT01773798|DRUG|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
48335683|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
48335684|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
48335685|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
48335686|NCT00611611|BIOLOGICAL|fluzone|once
48335687|NCT00611611|BIOLOGICAL|pneumovax|once
48335688|NCT05886309|DIAGNOSTIC_TEST|Collection of Blood samples|"The following samples will be drawn from each study participant immediately after the venipuncture performed for the whole blood donation:~* 1 sample with no anticoagulant (5 ml) for SF measurement with the CDMS method~* 1 EDTA (Ethylendiamintetraazetat) sample (7,5 ml) for a complete blood count with red blood cell indices and reticulocytes~* 1 EDTA sample (2,7 ml) for the measurement of hepcidin~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of SF with the ECLIA (Electrochemiluminescence-enzymeimmunoassay) and of the complete set of iron biomarkers (Transferrin Saturation, serum iron, Soluble Transferrin Receptor)~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of CRP (C-reactive Protein)~* 1 sample with no anticoagulant (5 ml) for the measurement of SF with the CMIA (Chemiluminescence Immunoassay)~* 1 sample with no anticoagulant (5 ml) for storage"
48335689|NCT01077869|PROCEDURE|endoscopic examination|on a weekly basis during 7 weeks
48335690|NCT01077869|PROCEDURE|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
48335691|NCT05226897|DRUG|YYC405-T|Subjects take the investigational products once a day for 24 weeks.
48653674|NCT03342222|DEVICE|Interference Screws|tibial fixation for ACL reconstruction
48653675|NCT03960736|OTHER|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
47977107|NCT03477877|BEHAVIORAL|Village Savings and Loan Association (VSLA)|A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
48653676|NCT03960736|OTHER|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
48653677|NCT04785820|DRUG|Lomvastomig|2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.
47977108|NCT03902574|DRUG|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
47977109|NCT03902574|DRUG|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
48335692|NCT05226897|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
48335693|NCT05226897|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
48335694|NCT05226897|DRUG|YYC405-T placebo|Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
48335695|NCT04682678|PROCEDURE|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
48335696|NCT01907776|DRUG|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
48335697|NCT01907776|DRUG|ME1100 placebo inhalation solution|Vehicle placebo
48335698|NCT03223493|OTHER|No treatment given|Completion of a questionnaire
48335699|NCT03670901|BIOLOGICAL|JHL1101|JHL1101, 100mg/10mL
48494154|NCT00584844|BIOLOGICAL|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).
48494155|NCT01971970|BIOLOGICAL|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
48335700|NCT03670901|BIOLOGICAL|MabThera|Rituximab, 100mg/10mL
48335701|NCT01894763|DEVICE|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
48335702|NCT01693497|BEHAVIORAL|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
48335703|NCT01693497|BEHAVIORAL|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
48335704|NCT05142449|DRUG|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
48653678|NCT04785820|DRUG|Tobemstomig|2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
48128583|NCT05082636|OTHER|Observational Study ( Tissue Biopsy )|control study includes a total of 90 subjects. Of them 54 patients with early stage lung (stage I, II) cancer (Group 1) were selected from the Chest Department of Assiut University Hospital, besides 36 healthy controls; who were clinically suspicious with chest masses and proven histopathologically to be negative cancer (Group 2).obtained by fiberoptic bronchoscopy
48128584|NCT00491959|PROCEDURE|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
48335705|NCT05142449|OTHER|Placebo|Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
48335706|NCT02527941|DRUG|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
48335707|NCT00220454|DRUG|Climara|
48494156|NCT01971970|BIOLOGICAL|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
48653679|NCT04785820|DRUG|Nivolumab|240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
48335708|NCT00220454|DRUG|Hydrocortone|
48335709|NCT02658981|BIOLOGICAL|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
48653680|NCT02256033|DRUG|Istradefylline|One 40 mg-tablet administered on Day 1
48653681|NCT05571839|DRUG|PF-08046049|Given into the vein (IV; intravenous)
48653682|NCT04045145|DRUG|Crinecerfont|Crinecerfont administered orally for 14 consecutive days.
47977110|NCT03902574|DRUG|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
47977111|NCT01691001|DRUG|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
47977112|NCT01691001|DRUG|normal saline|
47977113|NCT00366288|DRUG|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
47977114|NCT01937559|BIOLOGICAL|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
48128585|NCT05877872|PROCEDURE|Reduced-target resection|Patients receive surgery according to pSTV-post-IC.
48128586|NCT05877872|PROCEDURE|Full-target resection|Patients receive surgery according to pSTV-pre-IC.
48335710|NCT02658981|BIOLOGICAL|Anti-PD-1|Given IV
48335711|NCT02658981|OTHER|Pharmacological Study|Correlative Studies
48335712|NCT02658981|OTHER|Laboratory Biomarker Analysis|Correlative Studies
48335713|NCT02658981|BIOLOGICAL|Anti-CD137|Given IV
48335714|NCT05200429|DRUG|Trikafta|Highly Effective CFTR Modulator Therapy
48335715|NCT03242590|DRUG|LPCN 1021|Oral testosterone undecanoate
48335716|NCT06300346|DRUG|Propofol|Ondansetron
48335717|NCT06186804|DRUG|ABSK021|Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
48335718|NCT04281017|DRUG|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
48335719|NCT04281017|DRUG|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
48653683|NCT03992872|BIOLOGICAL|Chikungunya|Virus Like Particle
48653684|NCT06149559|DRUG|rozanolixizumab|rozanolixizumab solution for injection
48494160|NCT04792775|BEHAVIORAL|PE+ER|PE includes the following components: a) psychoeducation about the common reactions to traumatic events and presentation of the treatment rationale b) repeated in vivo exposure to traumatic stimuli, c) repeated, prolonged, imaginal exposure to traumatic memories, and d) relapse prevention strategies and further treatment planning (session 12). DBT Emotion Regulation Skills is integrated as part of this intervention. DBT training provides skills to understand, name, experience and tolerate emotions, as well as skills to change negative emotional responses and to reduce vulnerability to emotion dysregulation (Linehan et al., 2015). The current project includes an adapted 3- session individual emotion regulation skills training intervention to be implemented concurrently with PE which consists of initial teaching/instruction and brief skills review for the remainder of PE treatment.
48494161|NCT05134506|BEHAVIORAL|Dance for PD® classes|The intervention consisted of 16 60-min classes, performed twice weekly over a period of 8 weeks and instructed by a single researcher who had the approval to use it for research reasons.
48494162|NCT00580216|DRUG|Idrabiotaparinux sodium|"Pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
48494163|NCT00580216|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
48494164|NCT00580216|DRUG|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
48494165|NCT00580216|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
48494166|NCT00580216|DRUG|Avidin|"Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes"
48494167|NCT00580216|DRUG|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes"
48494168|NCT02218970|BEHAVIORAL|strength training|
48494169|NCT02218970|BEHAVIORAL|no training (control)|
48494170|NCT00452517|PROCEDURE|Percutaneous Coronary Intervention|
48494171|NCT04335526|DRUG|Cholestyramine Resin|Change bile acid pool by cholestyramine treatment
48494172|NCT02359747|GENETIC|Polymerase Chain Reaction and Whole Genome Amplification|Polymerase Chain Reaction and Whole Genome Amplification
48494173|NCT05861336|DRUG|Losartan|Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
48494174|NCT05861336|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days
48494175|NCT05861336|DRUG|Nab paclitaxel|nab-paclitaxel 125 mg/m2 on days 1, 8, and 15
48494176|NCT05861336|RADIATION|Stereotactic Body Radiation Therapy|7 consecutive fractions for a total dose of 35-42 Gy
48494177|NCT06044532|OTHER|Experimental|At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
47977115|NCT01937559|DRUG|Normal saline|
48128587|NCT05877872|DRUG|Adjuvant immunotherapy|Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
48494178|NCT04846517|DEVICE|Transcranial Magnetic Treatment|"iTBS treatment: Trains of 50 Hz pulses every 200 ms lasting 2 s, with an 8 s intertrain interval (ITI), repeated 60 times 1800 total pulses each day Treatment Duration: 9 minutes Location: Left DLPFC~LF-rTMS treatment: Delivered immediately after iTBS treatment as described above.~SMA will involve a continuous train of 1 Hz stimulation for a total of 1200 pulses lasting 20 minutes Treatment Duration: 20 minutes Location: SMA"
48494179|NCT05276882|OTHER|Hypnosis|"It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing."
48494180|NCT05276882|OTHER|pre-surgery consultation|"Dialogue with the patient to clarify her expectations.~* Answers to the patient's questions~* Precision on the organization of the hospitalization if necessary~* Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~* Information on relaxation techniques and their interest (abdominal breathing)"
48494181|NCT03580174|OTHER|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.
48494182|NCT03580174|OTHER|Routine physiotherapy group|Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
48494183|NCT03769883|BEHAVIORAL|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
48494184|NCT03769883|BEHAVIORAL|Diet|Dietary intervention
47977116|NCT04412408|DRUG|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
47980569|NCT01829230|DEVICE|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
48128588|NCT06350812|DRUG|PB-119|Administered subcutaneously once a week
48128589|NCT06350812|DRUG|Placebo|Administered subcutaneously once a week
48335720|NCT00004234|PROCEDURE|management of therapy complications|
48335721|NCT00004234|RADIATION|radiation therapy|
48494185|NCT03071094|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4
48494186|NCT03071094|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
48494187|NCT04671030|DRUG|Neostigmine and Glycopyrrolate|Intravenous followed by transdermal administration of the two drug combination.
48494188|NCT04671030|DEVICE|Iontophoresis|Application of direct current to skin using an FDA-approved device
48494189|NCT05466006|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), SCTG will be harvested from the palate and sutured to the flap. Simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
48494190|NCT05466006|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), VCMX will be sutured to the flap and simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
48494191|NCT04573764|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
48494192|NCT04573764|DIETARY_SUPPLEMENT|Placebo|Taste-matched water
48494193|NCT06263062|BEHAVIORAL|Awareness-Based Coping with Fear of Cancer Programme|The content of the Training Program was created by researchers based on MBSR, in line with high-level research results and international guides.Then, the necessary arrangements were made bytaking the opinions of 10 experts ( faculty members of the department of obstetrics and gynaecology nursing, psychiatry specialist, faculty members of the gynaecology oncology department, oncology clinic psychologist, obstetrics and gynaecology clinic charge nurse). Content concluded in accordance with the comments received.
48494194|NCT04771663|OTHER|Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger|The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
48494195|NCT01857765|BEHAVIORAL|Rehabilitation|Range of motion stretching exercises
48494196|NCT01857765|BEHAVIORAL|Follow-up|Follow-up with surgeon's clinic
48494197|NCT03961022|DIETARY_SUPPLEMENT|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
48335722|NCT04262908|OTHER|Telephone call|Patients who did not return to work after the SL prescribed initially and had an extension of the SL will be called at 4 months postoperatively to collect infomation
48335723|NCT03527316|DRUG|MDMA|125 mg MDMA per os, single dose
48494198|NCT02928718|PROCEDURE|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
48494199|NCT05497193|DRUG|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
48494200|NCT06248541|DEVICE|treatment with low-level laser therapy|low-level laser therapy (wavelength of 620 - 640nm)
48494201|NCT06248541|DEVICE|treatment with conventional light diodes|conventional light diodes
48494202|NCT02890030|BEHAVIORAL|Questionnaire|"* Neurotoxicity~* Medications of interest~* General health~* Family history"
48494203|NCT03565458|DRUG|Gemigliptin|zemiglo 50mg,LG Chem
48494204|NCT03565458|DRUG|Dapagliflozin|forxiga, dapagliflozin 10mg
48128590|NCT04570072|DIETARY_SUPPLEMENT|Probiotic|Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
48335724|NCT03527316|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
48335725|NCT06317220|BIOLOGICAL|Vedolizumab|Administered over 30 minute infusion at MGH main campus
48335726|NCT01779648|DEVICE|DVT-3000|
48335727|NCT01779648|DEVICE|SCD Express|
48494205|NCT03565458|DRUG|Empagliflozin|jardiance 25mg, empagliflozin
48653685|NCT04722809|DRUG|Botulinum toxin injection|Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
48653686|NCT04722809|OTHER|QOL-Brux|Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
48128591|NCT04570072|DIETARY_SUPPLEMENT|Placebo|Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
48128592|NCT02310152|BEHAVIORAL|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
48128593|NCT02310152|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
48335728|NCT02098057|DIETARY_SUPPLEMENT|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
48335729|NCT02098057|DRUG|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
48335730|NCT03876145|OTHER|Minimal ovarian stimulation|After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
48494206|NCT02982031|PROCEDURE|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
48494207|NCT02982031|PROCEDURE|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
48494208|NCT02527928|OTHER|None intervention|
48494209|NCT01601366|DEVICE|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
48494210|NCT01601366|DRUG|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
48494211|NCT03573505|DRUG|BG00011|Administered as specified in the treatment arm.
48494212|NCT03573505|DRUG|Placebo|Administered as specified in the treatment arm.
48494213|NCT00220987|OTHER|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
48494214|NCT00220987|OTHER|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
48494215|NCT04793048|DEVICE|a noninvasive intraoral electrotherapy device|a noninvasive intraoral electrotherapy device to treat periodontal disease at-home for 20 minutes a day
48494216|NCT04793048|DEVICE|a sham device|a sham device to be used at-home for 20 minutes a day
48653687|NCT04722809|OTHER|Muscular strength of the jaw|"Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection."
48653688|NCT04722809|OTHER|Intensity and frequency of episodes of nocturnal bruxism|Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
48653689|NCT04722809|OTHER|visual analogue pain scale|Evaluation of jaw pain. At inclusion and 3 months post-injection
48653690|NCT04722809|OTHER|Endobuccal and linea alba photographs|"anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion"
48494217|NCT03511443|DIAGNOSTIC_TEST|hsRDT|Testing highly sensitive RDT detection for low parasitemia
48494218|NCT01316302|DRUG|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
48494219|NCT01316302|DRUG|Placebo|Matching placebo, taken QD for 12 weeks.
48494220|NCT06049836|OTHER|Holograms|Clinical decision making based on visualising liver 3D holographic augmented reality liver models
48653691|NCT03533283|DRUG|Glofitamab|Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
47977117|NCT01713686|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48494221|NCT06049836|OTHER|PDF|Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
48494222|NCT04981496|OTHER|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs|Observational Study during Clinical and Simulated arrhythmias in patients with ICDs
48494223|NCT05637346|PROCEDURE|Intra-operative ultrasound measurement|A patient-specific 3D model will be created using an available pre-operative CT scan. Anatomical target points are selected on this virtual model before the start of the surgery. Prior to surgery, a patient-reference electromagnetic (EM) sensor will be placed between the patient and the matrass on the operating table to account for patient movement during acquisition. Intra-operatively, an initial point registration of the 3D model with the electromagnetic tracking system (EMTS) will be performed based on ultrasound (US) imaging of the arterial bifurcations by the surgeon. Then, the surgeon will acquire multiple US sweeps of the pelvic arteries (abdominal aorta and left and right iliac arteries). For validation purposes, the pre-operatively defined anatomical target points will be visualized on US imaging and by pinpointing the EM tracked pointer. All tracking and US data will be recorded and stored for post-operative analysis.
48653692|NCT03533283|DRUG|Atezolizumab|Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
48653693|NCT03533283|DRUG|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
48653694|NCT03533283|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
48653695|NCT03533283|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
47977118|NCT02744235|DEVICE|Polysomnography Data|
47977119|NCT02744235|DEVICE|Jawbone UP®|
47977120|NCT02744235|DEVICE|Fitbit Charge ®|
48128594|NCT05607199|DRUG|AUR103|Twice Daily
48335731|NCT02673723|DRUG|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
48335732|NCT02673723|DRUG|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
48335733|NCT04836507|BIOLOGICAL|CRC01|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
48335734|NCT04836507|DRUG|Fludarabine|Administered according to package insert
48494224|NCT04267107|OTHER|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
48128595|NCT05079126|DRUG|Trans Sodium Crocetinate|Single IV Bolus
48335735|NCT04836507|DRUG|Cyclophosphamide|Administered according to package insert
48494225|NCT02249312|DRUG|BIIL 284 BS|
48494226|NCT02249312|DRUG|Placebo|
48494227|NCT02910674|DEVICE|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
48494228|NCT06412588|DRUG|Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days|Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.
48494229|NCT06412588|DRUG|Vonoprazan+Amoxicillin|Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.
48128596|NCT05079126|DRUG|Placebo|Single IV Bolus
48494230|NCT06412588|DRUG|Vonoprazan+doxycycline|Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
48494231|NCT00968786|DEVICE|Home monitoring|automated measuring devices for patients using at home
48494232|NCT05201196|OTHER|Conventional physical therapy|Targeted muscle stretching and Strengthening (flexors, Extensors, abductors, internal and external rotators, of Shoulder, Elbow, forearm (supination \& pronation) and hand 10 repetitions×1 set, 4 days/ week. Transcutaneous Electrical nerve Stimulation for 10-20 min, 4 days/ week. Total of 16 sessions were given each consisting of 45 mins.
48335736|NCT01228188|PROCEDURE|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
48335737|NCT05565014|DRUG|Virus Activated Killer immune Cells|The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.
48335738|NCT05565014|DRUG|Saline|The use of saline was the same as VAK group.
48335739|NCT02963896|DRUG|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
48653696|NCT03533283|DRUG|89Zr-Df-IAB22M2C|Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
48128597|NCT02379260|OTHER|Interview with a sociologist|
48128598|NCT02398487|DEVICE|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
48335740|NCT03010722|DRUG|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
48653697|NCT03660449|COMBINATION_PRODUCT|Moderately hypofractionated conformal radiation combined With S-1|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
48653698|NCT02640131|BEHAVIORAL|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
48128599|NCT02398487|DEVICE|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
48128600|NCT00327119|DRUG|ABX-EGF (panitumumab)|
48335741|NCT03371251|DRUG|BOS161721|SC administration
48128601|NCT05260398|BEHAVIORAL|Mightier Online Gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
48335742|NCT03371251|DRUG|Placebo|SC administration
48335743|NCT02729805|DRUG|Saline|10ml bolus injection of saline followed by intravenous infusion of saline during the operation
48335744|NCT02729805|DRUG|Ketamine 0.5mg/kg|0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
47977121|NCT06232811|BEHAVIORAL|Assessment|Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
48128602|NCT02413866|BEHAVIORAL|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
48128603|NCT02413866|BEHAVIORAL|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
48128604|NCT00093496|DRUG|gemcitabine hydrochloride|Given IV
48335745|NCT02729805|DRUG|Ketamine 0.75mg/kg|0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
48335746|NCT03967509|BEHAVIORAL|Comet|
48335747|NCT05742841|DRUG|moderate- or high-intensity statin/ rosuvastatin|moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
48335748|NCT03908905|DIAGNOSTIC_TEST|Polysomnography|Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
48335749|NCT05008068|DRUG|Simvastatin|Simvastatin with PRF at site of osteotome
48335750|NCT03043209|GENETIC|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
48335751|NCT02867163|DRUG|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
48335752|NCT04169113|OTHER|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
48335753|NCT04169113|OTHER|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
48335754|NCT05970978|DRUG|regular treatment|IBI112 200mg s.c. at week 0, 12, 24 and 36.
48653699|NCT02640131|BEHAVIORAL|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
48128605|NCT00093496|DRUG|tanespimycin|Given IV
48128606|NCT04527094|DIAGNOSTIC_TEST|Prediction of postoperative respiratory failure using a machine learning|The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
48128607|NCT01925365|DIETARY_SUPPLEMENT|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
48128608|NCT01925365|DIETARY_SUPPLEMENT|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
48128609|NCT04075396|DRUG|Lazertinib|Participants will receive Lazertinib tablets once daily.
48335755|NCT05970978|DRUG|Intensive treatment|IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.
48335756|NCT04841694|DIETARY_SUPPLEMENT|Probiotic|Bacillus indicus
48335757|NCT04394689|BIOLOGICAL|Measles Rubella Vaccine (MRV-SC)|One dose as subcutaneous injection of a WHO prequalified MR vaccine
48335758|NCT04394689|BIOLOGICAL|MRV-MNP|One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch
48335759|NCT04394689|OTHER|PLA-MNP|One placebo dose of a dissolving microneedle patch
48335760|NCT04394689|OTHER|PLA-SC|Placebo saline as subcutaneous injection
48335761|NCT04329000|DRUG|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
48335762|NCT04329000|DRUG|Esomeprazole|Continuous Esomeprazole 40 mg QD
48335763|NCT04776915|DIAGNOSTIC_TEST|Ultrasound and Hysterosalpingography|Ultrasound and Hysterosalpingography
47977122|NCT03283852|GENETIC|blood sample|search for genetic mutations
47977123|NCT02256904|PROCEDURE|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
48128610|NCT02972359|DRUG|Neridronic acid|Neridronic acid administered as intravenous infusion.
48128611|NCT04523701|DRUG|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
48128612|NCT02747394|OTHER|Working Memory Training|
48128613|NCT03074656|OTHER|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
48335764|NCT00510068|DRUG|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
48335765|NCT00510068|DRUG|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
48335766|NCT05803369|BEHAVIORAL|Regulating Together (RT)|Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
48335767|NCT05803369|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
48335768|NCT04273009|DEVICE|Renew VS PTNS|These will be prescribed and applied as described above.
48335769|NCT02500368|DEVICE|silicone hydrogel lens (test)|contact lens
48335770|NCT02500368|DEVICE|enfilcon A lens (control)|contact lens
48128614|NCT03074656|OTHER|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
48335771|NCT04266158|DEVICE|Myoelectric UE Device-UE Orthosis-No Device|all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
48335772|NCT04530396|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
48335773|NCT04530396|OTHER|placebo|placebo comparator
48335774|NCT05188599|DIAGNOSTIC_TEST|İsokinetic assessment|Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
48335775|NCT00438464|DRUG|Finasteride|Given PO
48335776|NCT00438464|OTHER|Placebo|Given PO
48494233|NCT05201196|OTHER|Task Oriented Training|"Experimental group was given Task oriented protocol including activities such as Table-top polishing, Arm cradling, Reach forward and pick-up or touch an object, Reached sideway to pick-up an object and transferring it to a table in front, Pouring~½ cup of water from a measuring pot into wide mouth glass held in opposite hand, Picking up pen from thumb and first two fingers, lifting a basket and placing it on the table 10 repetitions×1 set for each activity, 4-5days/week. Total of 16 sessions were given each consisting of 45 mins"
47977124|NCT02256904|PROCEDURE|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
47977125|NCT00217386|BIOLOGICAL|anti-thymocyte globulin|
47977126|NCT00217386|BIOLOGICAL|etanercept|
47977127|NCT01803204|OTHER|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
47977128|NCT04095845|DEVICE|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
47977129|NCT04095845|DEVICE|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
47977130|NCT05177978|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)
47977131|NCT05177978|DIETARY_SUPPLEMENT|Placebo|Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
47977132|NCT06298110|BIOLOGICAL|Platelets Rich plasma of the same patient|on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
47977133|NCT00084565|DRUG|estramustine phosphate sodium|
47977134|NCT00084565|DRUG|paclitaxel|
47977135|NCT00084565|DRUG|topotecan hydrochloride|
47977136|NCT03982368|DRUG|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
47977137|NCT03982368|DRUG|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
47977138|NCT03982368|OTHER|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
47977139|NCT03962920|DRUG|Tigecycline 50 MG|Local instillation of drug directly to the tumour tissue
47977140|NCT03962920|OTHER|Placebo|Local instillation of sterile water directly to the tumour tissue
47977141|NCT05152589|DIAGNOSTIC_TEST|hearing test|Auditory Brainstem Response (ABR) Test
47977142|NCT01530568|OTHER|Xpert|This arm receives the GeneXpert test
47977143|NCT01530568|OTHER|Smear|This arm receives smear microscopy
47977144|NCT00671697|DRUG|Arsenic Trioxide|
47977145|NCT00671697|DRUG|Decitabine|
47977146|NCT02419053|OTHER|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
47977147|NCT02097576|OTHER|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
48335777|NCT00438464|PROCEDURE|Prostatectomy|Undergo prostatectomy
48335778|NCT00438464|OTHER|Laboratory biomarker analysis|Correlative studies
48335779|NCT00291499|DRUG|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
48335780|NCT00291499|OTHER|Placebo|800 mg placebo/day for 6 months
48335781|NCT03156855|DRUG|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
48335782|NCT03156855|DRUG|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
48335783|NCT01482572|PROCEDURE|biopsy|percutaneous lung biopsy and aspiration
48335784|NCT06343025|OTHER|Pilates Exercises Group|Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises.
47977148|NCT02097576|OTHER|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
48128615|NCT05057936|BIOLOGICAL|COVID vaccine|The enrolled patients will received COVID-19 vaccine according to the vaccine protocol in Thailand ie The ChAdox-1 nCOV-19 vaccine (day 1, day 84, 12 weeks duration) or Corona vac 2 doses (day 2, day 21, 3 weeks duration) of the study. All the participants underwent blood drawn for antibody and cellular immunity measurement before the final dose of vaccination, with 7 days before first vaccine dose and eight weeks after the second doses
48128616|NCT02564744|DRUG|Debio 1562|Administered as IV Infusion.
48128617|NCT02564744|DRUG|Rituximab|Administered as IV Infusion.
48494234|NCT03202979|DRUG|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
48128618|NCT02345174|DRUG|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
48128619|NCT02345174|DRUG|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
48128620|NCT01145729|BEHAVIORAL|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
48128621|NCT03266081|DRUG|0.75% bupivacaine|topical anesthetic
48128622|NCT01865474|DRUG|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
48128623|NCT01865474|DRUG|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
48128624|NCT02084420|DRUG|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
48128625|NCT02084420|DRUG|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
48128626|NCT03329482|OTHER|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
48128627|NCT03329482|OTHER|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
48128628|NCT02380105|BEHAVIORAL|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
48128629|NCT02380105|DEVICE|Interocclusal Appliances|Patients were treated using interocclusal appliances
48128630|NCT00004149|DRUG|arsenic trioxide|
48335785|NCT06343025|OTHER|Tai Chi Exercises Group|Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises.
48335786|NCT03625297|OTHER|shelter cat|families will adopt a shelter cat
48335787|NCT00103597|DRUG|Fludrocortisone|
48335788|NCT00103597|DRUG|Domperidone|
47977149|NCT04372030|OTHER|Online questionnaire|this is an online questionnaire collecting retrospective data on health care use and non-use
48128631|NCT04307550|DRUG|Isopropyl alcohol|10 inhalations of an isopropyl alcohol pad
48128632|NCT04307550|OTHER|Placebo|10 inhalations of a sterile saline pad
48128633|NCT03660618|DEVICE|laser speckle flowgraphy|blood flow state of the skin as real time two dimensional image
48128634|NCT00843934|DRUG|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
47977150|NCT05740644|DEVICE|CM-1600|Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.
48335789|NCT00103597|BEHAVIORAL|Conservative Measures for Orthostatic Hypotension|
48335790|NCT02117804|OTHER|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
48335791|NCT06306326|DIAGNOSTIC_TEST|3dMD technology|By taking photos using 3dMD, we obtained preoperative, immediate postoperative, and long-term postoperative three-dimensional data of patients. The software automatically fused the data to obtain the volume difference of facial volume at different time points, and then divided it to obtain the objective data of facial volume improvement rate. To improve the reliability of the measurements, two researchers measured independently and took the average value.
47977151|NCT06065995|DEVICE|StoMakker|A mobile application that offers age dependent information, a peer support platform and a game
47977152|NCT04323787|OTHER|observational|No Intervention
47977153|NCT05963217|BIOLOGICAL|TBI-2001|"Phase-I portion:~cohort 1: 3×10\^5 cells/kg, cohort 2: 1×10\^6 cells/kg, cohort 3: 3×10\^6 cells/kg). Phase-Ib portion: The dose of Phase-Ib will be determined during the phase I portion."
48494235|NCT03202979|DRUG|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
48494236|NCT03202979|DRUG|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
48335792|NCT05595603|PROCEDURE|4mg ZOL loaded gentamicin PMMA|During surgery, 4mg ZOL will be mixed with gentamicin (1000mg) PMMA cement (40g) by surgeon under sterile conditions to prepare ZOL loaded bone cement, and then it will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
48335793|NCT05595603|PROCEDURE|gentamicin PMMA|During surgery, gentamicin (1000mg) PMMA (40g) was prepared by surgeon under sterile conditions and will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
48335794|NCT06530108|BEHAVIORAL|PLISSIT model based sexual health education|the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
48335795|NCT02994381|DRUG|RPC1063|
48335796|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 200J (® Zoll)|Cardioversion
48335797|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 360J (® Physio-Control)|Cardioversion
48335798|NCT04138212|DRUG|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
48335799|NCT04138212|RADIATION|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23
48335800|NCT01328197|DEVICE|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
48335801|NCT00702247|PROCEDURE|Hematopoietic Stem Cell Transplantation|
48335802|NCT01759160|PROCEDURE|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
48335803|NCT01759160|PROCEDURE|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
48335804|NCT06402786|DEVICE|Kitea ICP Sensor|Kitea ICP Sensor placed in brain during shunt surgery.
48494237|NCT05935436|DEVICE|Cardiac Shock Wave Therapy|When operating CSWT, it is necessary to determine the target myocardium for treatment, adjust the height of the water bladder, set the energy that the patient can tolerate, and then start the treatment. During the treatment, the vital signs of the subjects should be detected.
48335805|NCT00594087|DRUG|eszopiclone|eszopiclone 2mg or 3mg at bedtime
48335806|NCT00594087|OTHER|placebo|2 mg or 3 mg at bedtime
48335807|NCT02967484|DEVICE|acupuncture|"1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
48494238|NCT00968799|PROCEDURE|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
48494239|NCT00968799|PROCEDURE|Cytoreduction|"Surgical removal of tumor nodules~including resection of organs infested with tumor"
48494240|NCT00968799|DRUG|Cisplatin|Cisplatin is applied as chemotherapy during surgery
48335808|NCT06291467|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.
48335809|NCT06291467|OTHER|questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion.~* MINI 7.0 Mini-International Neuropsychiatric Interview :~* MADRS (Montgomery Asberg Depression Scale)~* C-SSRS (Columbia-Suicide Severity Rating Scale)~* FAST (Functioning Assessment Short Test)~Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) :~* STAI-Y (State-Trait Anxiety Inventory )~* PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain)~* SHAPS (Snaith-Hamilton-Pleasure Scale )~* CTQ (Childhood Trauma Questionnaire)~* ESUL : Echelle de solitude de l'université de Laval~* BIS-11 : (Barratt Impulsiveness Scale)~* QIDS (Quick Inventory of Depressive Symptomatology)"
48335810|NCT05277116|OTHER|Genome Informed Risk Assessment (GIRA) report|A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
48335811|NCT05308615|DIETARY_SUPPLEMENT|Rhea® Health Tone|Rhea® Health Tone
48335812|NCT03825172|DIAGNOSTIC_TEST|Caudal Epidural Ultrasonography|Ultrasonographic Measurement
48335813|NCT01194869|DRUG|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
48335814|NCT01194869|DRUG|Cisplatin|75 mg/m² given IV
48335815|NCT01194869|DRUG|Paclitaxel|175 mg/m² given IV
48335816|NCT02379312|DIETARY_SUPPLEMENT|Very low energy aerated beverage|
48494241|NCT03551496|COMBINATION_PRODUCT|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
48335817|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 1|
48128635|NCT00843934|DRUG|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
47977154|NCT05963217|DRUG|Cyclophosphamide|IV Cyclophosphamide (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
48128636|NCT04243941|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
48128637|NCT02260024|OTHER|High fat, high caloric meal|
48128638|NCT02260024|DRUG|Pramipexole IR tablets|
48335818|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 2|
48335819|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 3|
47977155|NCT05963217|DRUG|Fludarabine|IV Fludarabine (for 3 days) will be administered as conditioning before cell infusion with TBI-2001.
47977156|NCT03724760|OTHER|personalized repeated feedback approach|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
47977157|NCT04957693|BEHAVIORAL|vegan diet and lifestyle changes|vegan diet and lifestyle changes
47977158|NCT01288495|DIETARY_SUPPLEMENT|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
47977159|NCT01288495|DIETARY_SUPPLEMENT|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
47977160|NCT06104670|DIETARY_SUPPLEMENT|Synaquell(TM)|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
47977161|NCT06104670|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
47977162|NCT00029614|DRUG|Atomoxetine|
47977163|NCT03980106|OTHER|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
47977164|NCT03980106|OTHER|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
48494242|NCT03551496|DEVICE|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
47977165|NCT03545165|DRUG|177Lu-PSMA-617|\[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)\]
47977166|NCT03545165|DRUG|177Lu-J591|\[1.35 GBq/m2 or 36.5 mCi/m2\]
47977167|NCT03545165|DRUG|68Ga-PSMA-HBED-CC|\[185 ±74MBq or 5 ±2 mCi\]
48128639|NCT02260024|DRUG|Pramipexole SR C|
48128640|NCT02260024|DRUG|Pramipexole SR C2|
48335820|NCT00428883|DRUG|N-acetylcysteine (NAC)|
48335821|NCT02441192|OTHER|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
48335822|NCT02441192|OTHER|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
48335823|NCT02441192|OTHER|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
48335824|NCT04572581|OTHER|Donor Breast Milk|Donor breast milk will be given to the newborn if supplementation is required
48494243|NCT04465552|OTHER|Patients received standard of care treatment during hospitalization|All patients admitted with covid-19 will be enrolled and followed for the duration of their hospitalization as well as during outpatient follow for up to 6 months, in those recovered, to assess clinical outcomes.
48494244|NCT05393843|DIETARY_SUPPLEMENT|omega-3 fatty acids, anthocyanins and alpha-cyclodextrins|administration for 12 weeks
47977168|NCT05427695|DRUG|Lactobacillus sakei proBio65|Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
47977169|NCT05427695|OTHER|Isotonic Saline Solution|Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
47977170|NCT01114178|OTHER|questionnaire|self completed questionnaire supervised by a technician
47977171|NCT03957382|DEVICE|Accero® (heal) Stent|The Accero® (heal) Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
47977172|NCT04870593|BEHAVIORAL|Information|Elder informed about vaccination.
48128641|NCT02260024|DRUG|Pramipexole SR C2A|
48128642|NCT02260024|DRUG|Pramipexole SR C2B|
48128643|NCT05792488|BEHAVIORAL|Coach|Coaching to a healthy lifestyle
48128644|NCT05792488|BEHAVIORAL|App|The app will coach people to a healthy lifestyle
48128645|NCT05792488|OTHER|Standard of care|Patients will receive standardized lifestyle advice by their specialist
48128646|NCT00144287|DRUG|Tipranavir/Ritonavir|
48128647|NCT00253890|DRUG|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
48128648|NCT00253890|DRUG|Placebo|1-3 at bedtime
48128649|NCT00405054|DRUG|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
48128650|NCT01048476|DIETARY_SUPPLEMENT|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
48128651|NCT01048476|DIETARY_SUPPLEMENT|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
48335825|NCT00829777|DRUG|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
48494245|NCT05393843|BEHAVIORAL|diet|12 weeks of personalized diet according to the Mediterranean standard diet referrals, the Healthy Eating Plate recommendations of Harvard University School of Public Health, and the reference intake levels of nutrients and energy for the Italian population (LARN) for pregnant women
48494246|NCT05393843|OTHER|placebo|sunflower oil as placebo for Omega3 fatty acids; isomaltulosio as placebo for Anthocyanins and Alpha-cyclodextrins; administration for 12 weeks
48494247|NCT02982798|DRUG|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
48653700|NCT02640131|BEHAVIORAL|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
48335826|NCT02918656|OTHER|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
48653701|NCT06637839|BEHAVIORAL|Moderate-Intensity Locomotor Training Program|The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.
48128652|NCT01048476|DIETARY_SUPPLEMENT|placebo|Dietary Supplement: placebo; daily supplementation one year
48335827|NCT02918656|OTHER|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
48335828|NCT02918656|OTHER|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
48335829|NCT02969694|OTHER|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction."
48335830|NCT03135288|DEVICE|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
48335831|NCT03013257|DEVICE|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
48335832|NCT03652272|BEHAVIORAL|EMC2|"1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~2. Patients will receive a Medication Guide + Summary with their After Visit Summary~3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
48335833|NCT06366334|DRUG|Ketamine Hydrochloride|See arm description
48335834|NCT06366334|DRUG|Normal saline|See arm description
48494248|NCT02982798|DRUG|JLP-1310|administration of JLP-1310
48494249|NCT01945073|BEHAVIORAL|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
48494250|NCT01945073|OTHER|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
48653702|NCT06637839|BEHAVIORAL|High-Intensity Locomotor Training Program|The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.
48653703|NCT06637839|BEHAVIORAL|High-Step Count Locomotor Training Program|The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.
48128653|NCT01048476|DRUG|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
48494251|NCT04997941|DRUG|Tamoxifen Oral Product|Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
48494252|NCT04997941|DIAGNOSTIC_TEST|Assessment of Ki-67|Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
48653704|NCT02006290|DRUG|PF-06412562|single oral split dose 30+20 mg QD
48653705|NCT02006290|DRUG|Placebo|tablet, matching placebo, QD
48128654|NCT00942487|DRUG|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
48128655|NCT00942487|DRUG|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
48335835|NCT03256409|OTHER|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
48335836|NCT03256409|OTHER|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
48335837|NCT04896190|OTHER|Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position|Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
48335838|NCT00962754|PROCEDURE|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
48335839|NCT04643795|DRUG|MGL-3196|Once daily oral dose for 6 days
48335840|NCT05552859|DRUG|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
48335841|NCT05552859|DRUG|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
48335842|NCT05236959|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Following an initial interview session, patients are offered eight weekly group-based session, delivered via videoconferencing, and asked to engage in regular daily home practice of mindfulness meditation
48335843|NCT05236959|OTHER|Treatment as Usual|Following an initial interview session, patients continue with their usual care
48335844|NCT04401904|DRUG|Dapagliflozin 10 mg|10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
48653706|NCT06641492|BEHAVIORAL|Chatbot-delivered interventions tailored to one's stage of changes|The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
47977173|NCT04870593|BEHAVIORAL|Buddy|"Elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
48335845|NCT04401904|BEHAVIORAL|Nutritional counseling|10 participants randomized to receive 12 weeks of weekly counseling on nutrition
48335846|NCT05434104|OTHER|Vaginal lactoferrin|Lactoferrin vaginal pessaries to insert nightly for seven nights
48335847|NCT05434104|DRUG|Usual care|Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
48335848|NCT06338046|OTHER|Corthellus Shiitake(Mushroom) Extract|topical treatment with Corthellus Shiitake(Mushroom) Extract
48335849|NCT06338046|OTHER|Placebo|topical treatment with a placebo cosmetic formula
48653707|NCT06641492|BEHAVIORAL|Chatbot-delivered standard interventions|The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
48653708|NCT05837897|DRUG|Vedolizumab IV|Vedolizumab IV infusion
47977174|NCT04870593|BEHAVIORAL|Gossip intervention|"Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders. If buddy intervention assigned in community, gossips also asked to encourage their communities to use the buddy system to get elders vaccinated."
47977175|NCT04870593|BEHAVIORAL|Information assigned in community|Information intervention assigned for other elders in community.
47977176|NCT04870593|BEHAVIORAL|Buddy assigned in community|Buddy intervention assigned for other elders in community.
48128656|NCT04971070|OTHER|Observation and follow-up|Observation and follow-up study
48335850|NCT01002742|DRUG|Mycophenolate Mofetil|"Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
48335851|NCT01002742|DRUG|Placebo|"Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
48335852|NCT04430686|OTHER|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
48335853|NCT05190744|DRUG|PB|500mg twice daily (BID) followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.
47977177|NCT00205790|DEVICE|Vascular graft|
47977178|NCT01497691|DEVICE|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
47977179|NCT01497691|DEVICE|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
48128657|NCT02634450|DEVICE|Alere q|
48335854|NCT05133336|DRUG|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
48335855|NCT05133336|DRUG|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
48335856|NCT05133336|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
48335857|NCT02931526|DRUG|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
48335858|NCT01616784|OTHER|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
48335859|NCT01616784|OTHER|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
48335860|NCT03057132|DEVICE|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
48335861|NCT01229514|OTHER|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
48335862|NCT02988492|DEVICE|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
48653709|NCT05837897|DRUG|Placebo|Vedolizumab placebo-matching IV infusion
47977180|NCT01497691|DEVICE|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
48335863|NCT00636441|DRUG|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
47977181|NCT00187876|PROCEDURE|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
47977182|NCT00187876|PROCEDURE|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
48494253|NCT04997941|PROCEDURE|Surgery|The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
48494254|NCT01806506|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
48494255|NCT01806506|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
47977183|NCT02266121|DEVICE|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
47977184|NCT02399826|DEVICE|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
48494256|NCT04257552|BEHAVIORAL|Healthy Beyond Pregnancy|Web-based application grounded in tenants of behavioral economics.
47977185|NCT02399826|PROCEDURE|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
47977186|NCT05657314|DIETARY_SUPPLEMENT|Active Comparator|Consists of 15 grams of pea protein
47977187|NCT02255604|DRUG|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
47977188|NCT02255604|DRUG|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
47977189|NCT02255604|DRUG|0.1 ml Isoton saline|4 injection into a lymphnode
48335864|NCT06129136|OTHER|Nature-based exposure by biodiversity component in lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
48335865|NCT06129136|OTHER|Placebo group using colored lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
48335866|NCT06122246|BEHAVIORAL|Community Health Worker (CHW)|Participants will receive the additional support of a Community Health Worker (CHW).
48335867|NCT06122246|OTHER|Remote Blood Pressure (BP) Management Program (RBPM)|Participants will receive a medical model of remote BP management (RBPM).
48335868|NCT02969967|DEVICE|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
48335869|NCT03261063|DEVICE|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
48335870|NCT04150354|BEHAVIORAL|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
48494257|NCT04257552|BEHAVIORAL|Pre-Scheduled Postpartum Visit|Participants will have their postpartum visit scheduled while they are still in the hospital after delivery.
48653710|NCT05716087|DRUG|Rocbrutinib|Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
48653711|NCT06641518|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
48653712|NCT05621837|OTHER|MDSC quantification|Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
48494258|NCT04257552|OTHER|Attention Control|Participants will receive texts related to infant care to mirror the attention participants receive in the Healthy Beyond Pregnancy intervention.
48494259|NCT00363753|DRUG|aspirin versus clopidogrel|
48494260|NCT05321225|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa is used to test the level of biomarker in blood.
48494261|NCT00838435|DRUG|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
48494262|NCT05294939|DIETARY_SUPPLEMENT|Ketone monoester|Consumption of 800mg/kg body weight of ketone monoester, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, every hour they should consume 90g of carbohydrates.
48494263|NCT05294939|DIETARY_SUPPLEMENT|Control product consumption|Consumption of placebo product (carbohydrates) masked with citric, divided in two intakes. The mixture will be prepared with bicarbonate. In addition, 90g of carbohydrates should be consumed every hour.
48494264|NCT04271579|PROCEDURE|Salvage Lymphnode dissection|"A salvage lymphnode dissection is performed in all study patients (both arms)using standard surgical techniques (openly or DaVinci).In patients who were randomized to the bilateral pelvic lymphnode dissection group, a salvage lymphadenectomy was also performed on the opposite side with resection of the corresponding fields that were removed on the PSMA-PET positive side (th Blinding must be guaranteed during pathological assessment)"
48494265|NCT01349582|PROCEDURE|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
48494266|NCT01349582|OTHER|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
48494267|NCT01349582|PROCEDURE|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
48494268|NCT01349582|PROCEDURE|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
48653713|NCT05935150|PROCEDURE|Omit SLNB|All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
48128658|NCT04504136|PROCEDURE|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
48128659|NCT06069700|OTHER|Non-pharmacological Individualized rehabilitative therapy|Treatments will be standardized but components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. \*Physiological group - Participants will receive supervised sub-symptom aerobic exercise 20-minutes twice per week and mindfulness-based training 20-minutes twice per week. \*Cervical group - Participants will receive physical therapy to the cervical spine. Physical therapy will include soft tissue therapy directed to the cervical myofascial tissues, and graded cervical spine facet mobilizations. \*Vestibulo-Ocular group - Patients classified to vestibulo-ocular subgroup will receive bi-weekly 30-minute individualized oculomotor, vestibular and balance exercises including adaptation exercises, gaze stability exercises, visual-vestibular integration exercises, habituation exercises, static and dynamic balance exercises.
48494269|NCT01349582|PROCEDURE|surgical clipping|clipping of the aneurysm following invasive brain surgery
48494270|NCT00821873|OTHER|CR Plug|CR Plug will be placed in the harvest site
48494271|NCT02023736|OTHER|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
48494272|NCT02023736|OTHER|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
48494273|NCT01826786|DRUG|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
48494274|NCT01826786|DRUG|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
48494275|NCT00554775|DRUG|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
48494276|NCT00554775|DRUG|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
48653714|NCT05988229|OTHER|Toolkit to improve discharge equity|Linguistically appropriate discharge teaching aids: a medication calendar, pictographics added to the after visit summary (AVS), and an audio recording of the discharge teaching.
48653715|NCT04129021|DEVICE|High-resolution retinal imaging through adaptive optics|The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
48494277|NCT00006055|DRUG|anti-thymocyte globulin|
48494278|NCT00006055|DRUG|cyclophosphamide|
47977190|NCT02066246|DEVICE|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
47977191|NCT02066246|DEVICE|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
47977192|NCT05538221|DIAGNOSTIC_TEST|SILEMA|SILEMA consists of a webcam connected to a laptop, a LED reflector, and a software. To carry out gait analysis with SILEMA, an Evaluator must place six yellow auto-adhesive markers over certain anatomical landmarks in the lower limbs, namely, greater trochanter, external femoral condyle, head of the fibula, lateral malleolus and base and head of the fifth metatarsal. The patient is asked to walk barefoot through an eight meter walkway at a self-selected speed, while a webcam connected to a laptop records a video. Then, an Operator, making use of the software, processes the video, obtaining spatio-temporal and joint kinematic parameters.
47977193|NCT02015871|DRUG|Degarelix|
47977194|NCT00754260|BEHAVIORAL|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
48335871|NCT04443842|BEHAVIORAL|Financial and social incentives|"Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support."
48335872|NCT01343355|DRUG|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
48335873|NCT01866345|PROCEDURE|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
48335874|NCT01866345|PROCEDURE|Conventional orthodontic treatment|Conventional orthodontic Procedure
48335875|NCT00948038|DIETARY_SUPPLEMENT|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
48335876|NCT00948038|DIETARY_SUPPLEMENT|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
48335877|NCT05263544|OTHER|measuring uterocervical angle and uterine dimensions|in both groups with and without displaced IUD, uterus size, uterine width, cervical canal length, endometrial canal length, endometrial canal width, and the angle at the intersection of the imaginary lines corresponding to the middle of the endometrium and cervical canal, which can be detected by transvaginal ultrasound will be measured
48335878|NCT03810521|BIOLOGICAL|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
48335879|NCT02077842|DEVICE|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
48335880|NCT02077842|DEVICE|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
48335881|NCT01268943|DRUG|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
48335882|NCT01268943|DRUG|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
48494279|NCT00006055|DRUG|cyclosporine|
47977195|NCT05115734|DIAGNOSTIC_TEST|Serum acylcarnitine profiling|"Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA)."
47977196|NCT03713970|PROCEDURE|celtra duo press|celtra duo press ingot
47977197|NCT03713970|PROCEDURE|IPS e.max press|IPS e.max press ingot
47977198|NCT03628703|DEVICE|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
47977199|NCT03210818|DEVICE|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
47977200|NCT00637481|DRUG|atorvastatin calcium|Given orally
48335883|NCT01268943|DRUG|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
48335884|NCT01268943|DRUG|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
48335885|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48335886|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48335887|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48335888|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48494280|NCT00006055|DRUG|filgrastim|
48494281|NCT00006055|DRUG|methylprednisolone|
48494282|NCT00006055|DRUG|prednisone|
48494283|NCT00006055|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplantation|
48494284|NCT05854823|RADIATION|dose-reduced radiotherapy|Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
48494285|NCT04006314|OTHER|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
47977201|NCT00637481|OTHER|laboratory biomarker analysis|Correlative studies
48128660|NCT06069700|OTHER|Non-pharmacological Usual care therapy|"All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator NM. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
48128661|NCT03055559|DIETARY_SUPPLEMENT|Globifer Forte|
48128662|NCT00043966|DRUG|Lopinavir/ritonavir|
48128663|NCT00043966|DRUG|Tenofovir DF|
48128664|NCT00043966|DRUG|Emtricitabine|
48128665|NCT06151301|DIAGNOSTIC_TEST|serum procalcitonin|predicting the severity of intoxication
48128666|NCT06151301|DIAGNOSTIC_TEST|C-reactive protein|predicting the severity of intoxication
48128667|NCT06497374|DRUG|Efgartigimod Alfa Injection|Efgartigimod+IVMP; IVMP; Efgartigimod
48128668|NCT06497374|DRUG|High-dose intravenous methylprednisolone|Efgartigimod+IVMP; IVMP; Efgartigimod
48128669|NCT06225310|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
48128670|NCT06225310|DRUG|Ruxolitinib|elective inhibitor of Janus kinase (JAK)
48128671|NCT06225310|DRUG|Methylprednisolone|Glucocorticoid, steroid
48128672|NCT03925649|BIOLOGICAL|HB-adMSCs|single infusion of HB-adMSCs
47977202|NCT02611557|PROCEDURE|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
47977203|NCT01438424|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily
47977204|NCT01438424|DRUG|Lamivudine|Oral, 100 mg, daily
47977205|NCT03880071|BEHAVIORAL|DBT+ACT|- The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.
48128673|NCT05379075|OTHER|26 styles of Chen Taichi training based on Relaxation guidelines|The arms and legs and the spine should rotate follow the arrow tips in order to cause a stretch reflex slightly. And then, the exerciser should use relaxation skills to eliminate the stretch reflex, such as exhaling, drop the control of body
48128674|NCT05379075|OTHER|26 styles of Chen Taichi training based on Coordination guidelines|"When the posture needs to open the arms should accompany with inhale and when the posture needs to close the arms should accompany with exhale. Similarly, if the arm is lifting should accompany with inhale, and the put down should accompany with exhale."
48128675|NCT04674995|PROCEDURE|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
48128676|NCT01895582|OTHER|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
48128677|NCT01125254|DRUG|Amlodipine|5mg po for 12 months
48128678|NCT02044809|DRUG|Cannabidiol|
48128679|NCT02044809|DRUG|Placebo|
48128680|NCT03049319|DEVICE|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
48128681|NCT03049319|DEVICE|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
48128682|NCT03049319|DEVICE|Psoriashield|The psoriashield will be applied to patient's back.
48128683|NCT03049319|DEVICE|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
48128684|NCT03049319|DEVICE|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
48128685|NCT03049319|DEVICE|Xtrac laser|The Xtrac laser will be applied to patient's back.
48128686|NCT04056702|DRUG|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
48128687|NCT00515814|DEVICE|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation \& mobility.
48128688|NCT00083551|DRUG|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
48128689|NCT00083551|DRUG|Ara-C|"Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).~Start infusion 30 minutes after completion of BCNU on day -5."
48128690|NCT00083551|DRUG|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
47977206|NCT03880071|BEHAVIORAL|DBT|"The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)"
48128691|NCT00083551|DRUG|Cisplatin|"Cisplatin\* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin\* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)~\*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) \< 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) \> 3.0 mg/dl"
48128692|NCT00083551|DRUG|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
48128693|NCT00083551|DRUG|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as \< 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
48128694|NCT00083551|DRUG|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
48128695|NCT00083551|DRUG|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
48128696|NCT00083551|DRUG|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
48128697|NCT00083551|DRUG|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
48128698|NCT00083551|DRUG|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
48128699|NCT00083551|DRUG|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
48128700|NCT00083551|DRUG|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
48128701|NCT05134649|DRUG|BOTOX|Intramuscular Injection
48128702|NCT05491135|BIOLOGICAL|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
48128703|NCT02139813|PROCEDURE|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~* a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~* a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~* an Omega loop of 200 cm~* a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
48653716|NCT04129021|DEVICE|High-resolution retinal imaging through holographic systems|The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
48653717|NCT06637800|DEVICE|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)|The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
48653718|NCT05995600|DRUG|Antiplatelet Drug|Clopidogrel ± other antiplatelet drug
48653719|NCT05995600|DRUG|Warfarin|Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
48653720|NCT06555081|DRUG|Ruxolitinib IR|Tablet
48653721|NCT06555081|DRUG|Ruxolitinib XR|Tablet
48653722|NCT05691829|DRUG|Pembrolizumab|Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
48653723|NCT05691829|RADIATION|Radiation|One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.
48653724|NCT05691829|DRUG|Chemotherapy|Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
48653725|NCT06571240|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
48653726|NCT00800345|DRUG|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
48653727|NCT00800345|DRUG|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
48494286|NCT04226573|OTHER|Preoperative anxiety levels|"Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale."
48128704|NCT02139813|PROCEDURE|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
48128705|NCT04046159|DRUG|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
48128706|NCT04046159|RADIATION|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
48128707|NCT01202513|DRUG|Bimatoprost 0.03% topical ophthalmic solution|
48128708|NCT04423796|DEVICE|Robotic-assisted early mobilization|The early mobilization is done by robotic assistance devices.
48128709|NCT04423796|OTHER|Early mobilization|Early mobilization by health care professionals without robotic assistance.
48128710|NCT00829634|DRUG|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
48128711|NCT00829634|DRUG|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
48128712|NCT02770326|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|
48128713|NCT04870398|PROCEDURE|Vital Pulp therapy-Partial pulpotomy|Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material
48128714|NCT03532165|DIAGNOSTIC_TEST|Lower extremity Ultrasound|One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
48128715|NCT01101594|DRUG|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 \& 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
48128716|NCT01219790|RADIATION|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
48128717|NCT01219790|DRUG|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
48128718|NCT04164784|BEHAVIORAL|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,the investigators give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
47980570|NCT06155409|DEVICE|Anterior cervical interbody fusion|Anterior cervical interbody fusion indicates a surgical approach in the cervical spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height.
47980571|NCT00664976|PROCEDURE|Electroconvulsive therapy|Electroconvulsive therapy
48128719|NCT06321224|OTHER|Breathing exercises|Breathing exercises will be performed 3 days a week during 2 menstrual periods.
48128720|NCT06321224|OTHER|Control|No intervention will be made to the control group and they will be asked to continue their routine lives.
48128721|NCT03017469|OTHER|ARISE|"1. Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) \[Shepell\], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~2. Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~3. Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~4. Five online, instructor-guided mindfulness sessions (Zoom)"
48128722|NCT03480451|OTHER|Multi-Disciplinary Patient Centered Rehab and Education|"This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
48128723|NCT00939510|BIOLOGICAL|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
48128724|NCT00939510|DRUG|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
48128725|NCT00939510|OTHER|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
48128726|NCT02526576|BIOLOGICAL|Stromal Vasular Fraction|The stromal vascular fraction obtained from adipose tissue will be added to the graft
48128727|NCT02526576|PROCEDURE|Biopsy|A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
48335889|NCT05334550|OTHER|Home Based Early Intervention by Parent|Through a video communication program called ZOOM, the parents of intervention group are educated once every two weeks for three months. Parent education consists of a program developed by our pediatric rehabilitation therapist to help premature infants develop motor skills. Parents provide daily exercise training to their children as educated.
48653728|NCT06279182|BEHAVIORAL|Barre Stretching Intervention|The Barre stretching intervention will consist of a 15-minute recorded video session with static and isometric movements focused on the hands, wrists, shoulders, and neck combined with breathing exercises throughout each movement. A 15-minute Barre stretching video will be selected for this study because static and isometric stretching should be held for 10-15 seconds per movement and repeated 2-3 times for increasing blood flow and circulation which can improve heart rate variability (HRV), increase muscle suppleness in preparation for muscle activation through patient care, and reduce stress levels through regulation of the rate, depth, and pattern of breathing. The duration of 15-minutes provided the participants with adequate time to complete each stretching movement for a total of 45 seconds with 15 seconds rest between movements. There will be fifteen targeted stretching movements focused on the hands, wrists, shoulders, and neck region.
48653729|NCT05450237|BEHAVIORAL|Psychometric Evaluations|"The main evaluation scales we will use are the Beck Depression Inventory-II (BDI II), the State-Trait Anxiety Inventory (STAI), The twenty-item Toronto Alexithymia scale- I (TAS-20), The fatigue severity scale (FSS), Modified Fatigue Impact Scale (MFIS), The Multiple Sclerosis Impact Scale (MSIS-29), The Epworth Sleepiness Scale (ESS) (Johns MW. 1991), The Pittsburgh Sleep Quality Index (PSQ1), The Multiple Sclerosis quality of life Inventory (MSQOLI), The work productivity and activity impairment instrument (WPAI), Frailty Index.~These rating scales will be administered in person, by telephone and / or by sending them electronically."
48653730|NCT06179446|BIOLOGICAL|pdmFlu vaccine|Intramuscular injection
48335890|NCT00032617|PROCEDURE|Prolonged Exposure|trauma-focused exposure therapy
48335891|NCT00032617|PROCEDURE|Present Centered Therapy|therapy that focuses on current problems
48653731|NCT06179446|BIOLOGICAL|Placebo|Intramuscular injection
48653732|NCT06179446|BIOLOGICAL|Licensed influenza vaccine|Intramuscular injection
48653733|NCT06122948|DRUG|The midazolam group|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
48335892|NCT00006234|PROCEDURE|peripheral blood stem cell transplantation|
48335893|NCT00006234|RADIATION|holmium Ho 166 DOTMP|
48335894|NCT04277832|DIAGNOSTIC_TEST|Questionary|All patients will answer two different questionary (TUPAST, TOPAS 2)
48335895|NCT04159818|DRUG|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
48335896|NCT04159818|DRUG|Cisplatin|40mg/m2, weekly for two weeks
48653734|NCT06122948|DRUG|The midazolam ketamine group|the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
48335897|NCT04159818|DRUG|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
48335898|NCT05945745|DRUG|Chemotherapy|different treatments based on the molecular analysis
48653735|NCT00330733|DRUG|Salsalate|Participants were randomized to 12-week treatment with up to 4 g/day.
48335899|NCT02576925|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
48653736|NCT00330733|DRUG|Placebo|Participants were randomized to 12-week treatment matching the active salsalate arm.
48653737|NCT06638047|PROCEDURE|robotic-assisted TKA|Robotic-assisted TKA means that TKA surgery is operated with the guidance of robotic system.
48653738|NCT06638047|PROCEDURE|CI-TKA|TKA operated with conventional instruments
48653739|NCT06640842|DIAGNOSTIC_TEST|A combination of various test and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy in brain health in midlife.|Participants will be asked to complete a blood draw, 5-lead ECG, MRI, a series of cognitive assessments, dietary assessments, monitor sleep and physical activity and DXA scan.
48653740|NCT04797481|PROCEDURE|Exercise|Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.
48335900|NCT01378299|DRUG|Testosterone Cypionate|"Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61."
48335901|NCT05595551|BEHAVIORAL|"The intervention Aan Tafel in 1, 2, 3 euro"|"The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card."
48494287|NCT04252898|BEHAVIORAL|Front-of-pack nutrition label Nutri-Score|The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
48653741|NCT04797481|PROCEDURE|Self-managed exercise|Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.
48653742|NCT01344655|DRUG|Atimos®|Formoterol 12 μg pMDI
48653743|NCT01344655|DRUG|Serevent™|Salmeterol 25 µg pMDI
48335902|NCT05969912|OTHER|Graston Technique (Instrumented assisted soft tissue mobilization)|"They would received Graston technique (Instrumented assisted soft tissue mobilization) as follow:~Using lubricant (Vaseline) on the skin then a stainless steel instrument to relax the fascia and muscles. Frequency: 60 reps per min for 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Graston technique (Instrument assisted soft tissue mobilization)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
48335903|NCT05969912|OTHER|Bowen's Technique(Soft tissue technique)|"They would received Bowen's technique (Soft tissue technique) as follow:~Bowen moves (15 - 20 times) with 2 mins gap between each set. Frequency: 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Bowen's technique (Soft tissue technique)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
48494288|NCT02681224|OTHER|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
48494289|NCT02681224|OTHER|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
48494290|NCT02681224|OTHER|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
48494291|NCT02681224|OTHER|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
48494292|NCT02839148|DIETARY_SUPPLEMENT|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
48653744|NCT01344655|DRUG|Placebo|placebo
48653745|NCT04543617|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
48653746|NCT04543617|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
48653747|NCT04543617|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
48653748|NCT04543617|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
48653749|NCT04205812|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
48653750|NCT04205812|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
48653751|NCT04205812|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
48335904|NCT04592848|OTHER|Questionnaires|"Four Questionnaires in French will be sent to participants :~* 1 questionnaire about sexual and urinary symptoms before and after the surgery ;~* 1 validated questionnaire Female Sexual Function Index to assess sexual function over the past 4 weeks ;~* 1 validated questionnaire Body Image Scale to assess body image during the past week ;~* 1 validated questionnaire Stoma Quality of Life, only for patients with incontinent urostomy.~If the questionnaires are not returned 15 days after sending, a follow-up phone call will be made by one of the investigators.~The data collection will include both the answers to the questionnaires and the patients' computerized medical data:~* Pathology responsible for the urological disorders and date of onset of the disorders~* Date and Type of surgery performed~* Patient's age at the time of surgery~* Post-operative complications within one month of surgery"
48335905|NCT00037544|DRUG|ReFacto AF|
48653752|NCT04205812|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
48653753|NCT04205812|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
48653754|NCT04205812|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
48653755|NCT04205812|DRUG|nab-Paclitaxel|nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
48494293|NCT04341649|OTHER|Manual Head Massage|Duration 10 minutes.
48494294|NCT04341649|DEVICE|BREO Helmet Massager|Duration 10 minutes.
48494295|NCT04341649|DEVICE|Low Laser Therapy (LLT)|Duration 7 minutes.
48494296|NCT04341649|DEVICE|Sham LLT|Duration 7 minutes.
48494297|NCT04341649|DEVICE|TENS ear stimulation|Duration 7 minutes.
48494298|NCT04341649|BEHAVIORAL|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
48494299|NCT04341649|BEHAVIORAL|Relaxed Reading time|Duration 10 minutes.
48494300|NCT01043120|DRUG|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
48335906|NCT06214624|BEHAVIORAL|Two types of exercise interventions|"* HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at \~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~* HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (\~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions."
48335907|NCT05260606|DIAGNOSTIC_TEST|F-18 FDG PET/CT|"1. 1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2. 2nd scan: interim~   * Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~  * Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3. 3rd scan: optional (3rd scan can be performed when disease progression is suspected)~4. Imaging~   * Fasting: at least 6 hours~  * Blood glucose level: \< 200 mg/dL~  * F-18 FDG 0.14 mCi/kg (IV)~  * Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~  * PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~  * First and second scans have to be performed with same scan."
48335908|NCT02109068|BEHAVIORAL|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
48335909|NCT02109068|BEHAVIORAL|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
48494301|NCT01043120|DRUG|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
48494302|NCT04029441|OTHER|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
48494303|NCT05757739|PROCEDURE|Tenex|In the Tenex procedure, the surgeon inserts a special needle into the damaged portion of the tendon under ultrasound guidance. Ultrasonic energy vibrates the damaged tissue and it can be suctioned out. This procedure is done with local anesthesia in surgeon's office.
48494304|NCT05778552|DEVICE|Home-based pelvic muscle training devices or traditional PFMT at hospital|Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
48653756|NCT06640166|DRUG|encorafenib + cetuximab + FOLFIRI|"encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI) as follows:~* encorafenib 300 mg (75 mgx4 hard capsules) orally once daily;~* cetuximab 500 mg/sqm iv every 14 days;~* FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours)."
48653757|NCT06643286|DEVICE|Digizorg Melanoma app|The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.
48653758|NCT06497140|DRUG|Ethiodized Oil-based emulsion|Embolization of genicular arteries
48653759|NCT06497140|PROCEDURE|Sham-operation|Mimicked catheterization and embolization of genicular arteries
48653760|NCT04953026|DIAGNOSTIC_TEST|Diagnositic test|The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.
48653761|NCT01904279|DRUG|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
48653762|NCT06640946|DRUG|Topical lidocaine|Topical lidocaine cream prior to laser follicle ablation
48653763|NCT06640946|DRUG|Sham cream|Placebo cream without lidocaine will be placed and removed before laser.
48653764|NCT02003703|BIOLOGICAL|Recombinant Hepatitis B Virus Vaccine|
48653765|NCT05338320|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia and Ultrasound Guided Erector Spinae Plane Block
48653766|NCT05338320|DRUG|Intrathecal morphine|General anesthesia and intrathecal morphine
48653767|NCT05338320|OTHER|General anesthesia using intravenous fentanyl (1µg/kg)|General anesthesia using intravenous fentanyl (1µg/kg)
48653768|NCT05583864|DEVICE|CONDUIT Porous Titanium Spinal Cage|Already included in arm/group descriptions.
48653769|NCT05583864|DEVICE|PROTI 360 Titanium-Coated PEEK Spinal Cage|Already included in arm/group descriptions.
48335910|NCT05134597|GENETIC|Genetic assessment|Blood samples will be collected in 3-mL K3 EDTA vacutainer tubes. Peripheral blood mononuclear cells will be isolated via density gradient centrifugation within 2 hours of sample collection. Primary CD4+ T cells will be purified from the peripheral blood lymphocytes using a magnetic cell sorting CD4+ T cell isolation kit, according to the manufacturer's instructions. RNA extraction will be performed. Total RNA will be quantified, and the quality of RNA will be assayed using formaldehyde agarose gel electrophoresis and by determining the 260/280 absorbance ratio. One microgram of total RNA from each sample will be subjected to reverse transcription. One microliter of cDNA will be amplified via real-time PCR and 10 pmol of primers specific to IL23R, IL17, SGK1, RANBP1, TFGB. Real-time PCR assays will be performed in triplicate The specificity of the PCR products will be determined via melting curve analysis.
48653770|NCT03014414|BEHAVIORAL|Fun First|Learn key enjoyable maintenance skills before losing weight
47977207|NCT01655615|BEHAVIORAL|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
47977208|NCT06373991|BIOLOGICAL|ATHENA CAR-T|Phase 1 dose escalation (3+3): dose 1 and dose 2.
47977209|NCT06373991|DRUG|Fludarabine|Intravenous injection of fludarabine.
48653771|NCT03014414|BEHAVIORAL|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
48653772|NCT01208766|DRUG|Bortezomib, Melphalan, Prednisone (VMP)|"* Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32~* Melphalan _ 9 mg/m² _ p.o. _ days 1-4~* Prednisone _ 60 mg/m² _ p.o. _ days 1-4"
48653773|NCT01208766|DRUG|1 or 2 cycle(s) HDM (High Dose Melphalan)|"- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2\*~\*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR."
48653774|NCT01208766|DRUG|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|"* Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11~* Lenalidomide _ 25 mg _ p.o. _ days 1-21~* Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12"
48653775|NCT04066504|DRUG|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
48653776|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via telehealth|Intervention includes clinical care delivered via telehealth
48653777|NCT05660187|OTHER|Multiple Sclerosis Clinical Care Delivery via standard in clinic visits|Intervention includes clinical care delivered via standard in clinic visits
47977210|NCT06373991|DRUG|Cyclophosphamide|Intravenous injection of cyclophosphamide.
47977211|NCT05967156|DRUG|Empagliflozin10Mg Tab|10 mg daily
47977212|NCT00510120|BEHAVIORAL|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
47980572|NCT00664976|OTHER|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
48335911|NCT01744457|DEVICE|Measurement of tear film osmolarity with the TearLab® instrument|
48335912|NCT01744457|OTHER|Schirmer I test|
48335913|NCT01744457|OTHER|Tear break up time|
48335914|NCT01744457|DEVICE|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
48335915|NCT01744457|OTHER|Ocular Surface Disease Index|
48335916|NCT00389441|DRUG|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
48335917|NCT00587301|DEVICE|Lap-Band|Obesity and adolescents
48335918|NCT03499613|OTHER|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
48335919|NCT03347240|PROCEDURE|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
48335920|NCT03347240|PROCEDURE|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
48335921|NCT03347240|DEVICE|Deep brain stimulation|Bilateral DBS
48653778|NCT01435356|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
48494305|NCT01294826|DRUG|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
47980573|NCT05585697|OTHER|None - crossectional|None - crossectional
48335922|NCT03347240|DEVICE|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
48494306|NCT01294826|DRUG|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
48653779|NCT01435356|BIOLOGICAL|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
48494307|NCT05223296|DEVICE|Compare between two procedure for II-IV degree pile excision|LigaSure or diathermy excision of III-IV degree pile?
48494308|NCT02621918|OTHER|Progressive resistance training|
48494309|NCT02621918|OTHER|Aerobic training|
48653780|NCT06637306|DRUG|Dupilumab|Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
48653781|NCT06637306|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
48335923|NCT04586296|OTHER|Telemedicine|IVR will consist of a 3 minute call at a decreasing interval from the time of surgery. Questions will assess pain control, signs of infection, prosthesis failure.
48335924|NCT01742091|DRUG|LY2541546 - SC|Administered SC
48335925|NCT01742091|DRUG|LY2541546 - IV|Administered IV
48335926|NCT01742091|DRUG|Placebo - SC|Administered SC
48335927|NCT01742091|DRUG|Placebo - IV|Administered IV
48335928|NCT03032289|BEHAVIORAL|Active Transport|Active transport, most commonly walking or cycling, is the use of physical activity to commute.
48335929|NCT00206011|PROCEDURE|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
48335930|NCT00991224|BIOLOGICAL|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
48335931|NCT00991224|BIOLOGICAL|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
48335932|NCT00991224|OTHER|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
48494310|NCT02621918|OTHER|Placebo training|
48494311|NCT03540771|OTHER|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~1. Patient/caregiver understanding of diagnosis, illness and prognosis~2. Symptom assessment and management~3. Psychosocial assessment and management~4. Distress screening and management~5. Discussion of goals of care~6. Advanced directives"
48494312|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate and Vitamin C|28 mg iron 240 mg vitamin C
48494313|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate|28 mg iron
48494314|NCT04469010|DIETARY_SUPPLEMENT|Placebo|Matched placebo
48494315|NCT04588311|DRUG|Epoetin Alfa 40000 UNT/ML|Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.
48653782|NCT06637306|DRUG|Paclitaxel|Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
48653783|NCT06637306|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
48653784|NCT06122909|DRUG|Group VTI|Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.
48653785|NCT06122909|DRUG|Group IVC|Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.
48494316|NCT04588311|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.
48335933|NCT04653389|DRUG|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
48335934|NCT04653389|DRUG|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
48494317|NCT04792190|DRUG|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
48494318|NCT04792190|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
48494319|NCT00658827|OTHER|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
48335935|NCT04653389|RADIATION|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
48335936|NCT02267369|BEHAVIORAL|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
48335937|NCT02267369|BEHAVIORAL|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
48335938|NCT02267369|BEHAVIORAL|Basic fitness program|Participants can register workshops online and track program participation.
48335939|NCT02626364|DRUG|crenolanib|single-agent crenolanib at 100 mg PO TID
48335940|NCT02722772|DRUG|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
48335941|NCT02722772|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
48335942|NCT00079820|BIOLOGICAL|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
48335943|NCT01250457|DRUG|topical Timolol|topical Timolol 0.5% solution applied twice daily
48335944|NCT05316480|DRUG|Nimotuzumab|nimotuzumab 200mg/week
48335945|NCT01242254|BIOLOGICAL|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
48335946|NCT03098524|PROCEDURE|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
48335947|NCT03098524|PROCEDURE|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
48335948|NCT03098524|PROCEDURE|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
48335949|NCT00002657|BIOLOGICAL|bleomycin sulfate|5 mg/m\^2
48335950|NCT00002657|BIOLOGICAL|recombinant interferon alfa|3.0 x 10\^6 IU/m\^2
48335951|NCT00002657|DRUG|cyclophosphamide|650 mg/m\^2
48335952|NCT00002657|DRUG|cytarabine|300 mg/m\^2
48335953|NCT00002657|DRUG|doxorubicin hydrochloride|25 mg/m\^2
48494320|NCT01066689|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
48494321|NCT01066689|DRUG|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
48494322|NCT02070874|BEHAVIORAL|telehealth enhanced pain management|
48494323|NCT04600466|OTHER|Molecular testing for all participants.|Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
48494324|NCT04600466|OTHER|Germline Testing|Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
48653786|NCT06644547|BEHAVIORAL|Gezond en goed met elkaar|"The intervention 'Gezond en goed met elkaar' focuses on improving (positive) health literacy and literacy. The six domains of positive health are the focus of the intervention meetings. This intervention has been made available for citizens of Almere, Zwolle, Gouda, Nunspeet and Leusden through collaboration with these municipalities. Lifestyle coaches working in these municipalities implement the intervention."
48335954|NCT00002657|DRUG|etoposide|120 mg/m\^2
48335955|NCT00002657|DRUG|methotrexate|120 mg/m\^2
48335956|NCT00002657|DRUG|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.
48653787|NCT06119217|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
48653788|NCT06119217|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
47977213|NCT00510120|BEHAVIORAL|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
48335957|NCT00002657|DRUG|vincristine sulfate|1.4 mg/m\^2
48335958|NCT00002657|PROCEDURE|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
48335959|NCT00002657|RADIATION|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
48335960|NCT04884672|DEVICE|SMILE|Small incision lenticule extraction, a refractive surgery procedure for the corrcetion of myopia with or without astigmatism
48335961|NCT01297946|DEVICE|Conventional continuous subcutaneous insulin infusion therapy|
48494325|NCT04600466|OTHER|Survey|Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
48494326|NCT03054259|DRUG|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
48494327|NCT03054259|DRUG|Methylprednisolone|100mg infusion on days 1 and 15
48494328|NCT03054259|DRUG|Normal Saline|250ml infusion on days 1 and 15
48653789|NCT06119217|COMBINATION_PRODUCT|Nab-Paclitaxel and gemcitabine|Dose and schedule per protocol
48653790|NCT03913637|BEHAVIORAL|Strategy Training|Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
48653791|NCT03913637|OTHER|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
48335962|NCT01297946|DEVICE|Dual-hormone closed-loop|
48335963|NCT05106595|DEVICE|Bimanual Arm Trainer|tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
48335964|NCT01665872|BEHAVIORAL|Cognitive-Behavioral Group Therapy|CBT Group
48335965|NCT02666690|DEVICE|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
48335966|NCT00184158|PROCEDURE|decompression|Conservative, simple decompression and nerve transfer
48335967|NCT06178094|BEHAVIORAL|Video Training|The participants in the Training Group is to sent a total of eight episodes of the Diabetes Training Videos prepare by the researcher, twice a week, through smartphones after the first interview
48335968|NCT01966861|OTHER|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score \>14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required \[CPIS\>6\], hemglobin\>8g/dl triggers transfusion)
48335969|NCT05612594|DRUG|Bexagliflozin 20 mg|15mg once daily
48335970|NCT05612594|DRUG|Placebo|matching placebo once daily
48335971|NCT02471209|DRUG|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
48335972|NCT06065345|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
48335973|NCT02151968|PROCEDURE|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
48335974|NCT02151968|PROCEDURE|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
48335975|NCT00091026|BIOLOGICAL|cetuximab|Given IV
48494329|NCT05530148|BEHAVIORAL|Martial Arts Training Group|Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.
48653792|NCT05013736|DEVICE|Magnetic Resonance Imaging|3 Tesla Discovery MR750 MRI scanner (GE Healthcare, Waukesha, WI) will be used to perform structural imaging, diffusion MRI, relaxometry and microstructural imaging. The exact scan length and parameters of each scan type (T1, T2, DWI) will be set for this study to optimize the quality of data and decrease the length of scanning session for each type of scan. All of the imaging methods have been previously implemented at UW-Madison. Each sequence will take approximately 5-10 minutes.
48653793|NCT05013736|BEHAVIORAL|Behavioral Assessments|The behavioral assessments (GMA: General Movements Assessment; HINE: Hammersmith Infant Neurological Examination; Baby Observation of Selective Control AppRaisal (BabyOSCAR); Bayley-4 / Bayley Scales of Infant and Toddler Development 4th ed; Pediatric Evaluation of Disability Inventory -Computer Adaptive Test (PEDI-CAT)) are infant and age-specific and will be administered by trained pediatric occupational and physical therapists.
48653794|NCT05013736|DEVICE|Non invasive Transcranial Magnetic Stimulation|TMS will be used to assess cortical excitability and circuitry (not as a neuromodulation intervention). Single-pulse TMS (Magstim 200², Magstim, UK) with a scalp surface coil will be used to assess how the brain is developing and how connected the tract is, between the brain and a target muscle on the arm. 10-20 TMS stimulation pulses will be delivered at a range of stimulation intensities (50-100%) increasing by 5% maximal stimulator output (MSO) at each stage. In sum, around 150 stimulation pulses per hemisphere are expected for TMS assessment for each infant.
48653795|NCT05351229|DRUG|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
48653796|NCT05351229|OTHER|Placebo|Sterile saline, placebo
48653797|NCT05602727|DRUG|MK-1942|MK-1942 oral capsule
48653798|NCT05602727|DRUG|Placebo|Placebo oral capsule
48653799|NCT02781558|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
48653800|NCT02781558|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
47977214|NCT00510120|BEHAVIORAL|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
48128728|NCT03959813|OTHER|Psychomotricity by touching and passive mobilizations|"The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.~Before and after the session, two evaluations will be offered to the patient and performed by a nurse:~* A questionnaire, based on the physical experience,~* The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.~A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity."
48128729|NCT02682485|DRUG|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
48128730|NCT02682485|PROCEDURE|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
48128731|NCT02682485|DRUG|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
48128732|NCT03941067|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
48128733|NCT03921866|DRUG|Palbociclib|Palbociclib
48128734|NCT03392038|PROCEDURE|Thin ADM|Use of soft tissue allograft for root coverage
48128735|NCT03392038|PROCEDURE|Thick ADM|Periodontal surgical procedure to coronally position the tissue over the ADM allograft
48128736|NCT02088372|DEVICE|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
48128737|NCT05206058|PROCEDURE|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
48128738|NCT01800487|DRUG|silymarin|140 mg three times a day for 4 weeks
48335976|NCT00091026|DRUG|gemcitabine hydrochloride|Given IV
48128739|NCT01800487|DRUG|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
48128740|NCT04257487|DRUG|Sulodexide|2 soft capsules of Vessel® 250 LSU BID for 12 months
48335977|NCT00091026|BIOLOGICAL|bevacizumab|Given IV
48335978|NCT00091026|DRUG|erlotinib hydrochloride|Given orally
48128741|NCT04257487|DRUG|Sulodexide and placebo|1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
48335979|NCT05745025|DEVICE|Repeated Transcranial Magnetic Stimulation|rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at 10 Hz. Coil orientation will be optimized for stimulation of the abductor pollicis brevis. Stimulation targeting will be identified using motor-evoked potentials (MEP) of the first dorsal interossei that will be monitored using electromyography (EMG) (Motion Lab Systems Inc., Baton Rouge, LA). The motor threshold (MT) of the muscle will then be identified by systematically adjusting the pulse intensity. The MT will be considered the lowest stimulation intensity at which 5 out of 10 MEPs have a peak-to-peak amplitude of at least 50 microvolts. rTMS will be performed at the identified optimal location at 10Hz using an intensity that is 80% of the MT. Pulse trains will be delivered for 10 seconds, with a 30-second rest for 20 repetitions.
48494330|NCT05530148|BEHAVIORAL|Flexing, Toning and Balance|Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
48494331|NCT00114166|DRUG|topotecan hydrochloride|
48494332|NCT04188314|DRUG|Desflurane|The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
48494333|NCT04188314|DRUG|Isoflurane|The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
48494334|NCT03382730|OTHER|Chlorhexidine Mouth Rinse|Oral chlorhexidine gluconate oral rinse
48494335|NCT03382730|OTHER|Chlorhexidine Mouth Rinse De-Adoption|Multifaceted education and audit/feedback.
48335980|NCT05745025|DEVICE|Sham Repeated Transcranial Magnetic Stimulation|Sham rTMS will be performed using the same methods as the active group, but a sham Air Film coil (Magstim Inc., Eden Prairie, MN) will be used. This coil looks and sounds like the active coil, but it does not deliver magnetic pulses.
48494336|NCT03851926|RADIATION|Hypofractionated volumetric radiotherapy in 20 fractions|Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
48494337|NCT01527617|OTHER|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
48653801|NCT04024488|BEHAVIORAL|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
48653802|NCT04024488|BEHAVIORAL|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
48494338|NCT01527617|OTHER|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
48494339|NCT05986331|DRUG|BCD-201|up to 8 treatment cycles
48494340|NCT05986331|DRUG|Keytruda|up to 8 treatment cycles
48494341|NCT06353711|BEHAVIORAL|CA-LINC Intervention|Participants received the CA-LINC intervention.
48494342|NCT06353711|BEHAVIORAL|Treatment as Usual|Participants received Treatment as Usual
48494343|NCT05837572|OTHER|Standardized meal|"Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions."
48653803|NCT06277219|DRUG|LAT010|LAT010 monotherapy
48494344|NCT04059224|DRUG|Trametinib|Trametinib 2 mg once a day by mouth.
48494345|NCT04059224|DRUG|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
48494346|NCT01965470|OTHER|Combination Prevention|
48653804|NCT06277219|DRUG|LAT010 + ICI|LAT010 combination with PD-1 inhibitor
48494347|NCT01965470|OTHER|Enhanced Care|
48494348|NCT00797537|PROCEDURE|Echography|Echography
48494349|NCT00937378|DRUG|SER120|Nasal Spray, once a day
48494350|NCT00937378|DRUG|Placebo|Nasal Spray
48494351|NCT01216852|DRUG|Losartan Potassium|100 mg tablet
48494352|NCT00115557|OTHER|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
48653805|NCT05700617|DRUG|1:1 Randomization to receive milrinone or dobutamine|Randomized to receive either inotropic agent: milrinone or dobutamine
48653806|NCT05700617|DRUG|1:1 Randomization to receive dobutamine or milrinone|Randomized to receive either inotropic agent: milrinone or dobutamine
48653807|NCT06371352|DEVICE|iTBS|Active iTBS over the left DLPFC to induce the long term potentiation of stimulated area.
48653808|NCT06371352|DEVICE|cTBS|Active cTBS over the right DLPFC to induce the long term potentiation of stimulated area.
48494353|NCT00115557|OTHER|Practice intervention 2|Performance feedback only.
48494354|NCT03435718|DRUG|Oxfendazole|oral suspension
48494355|NCT03435718|DRUG|Albendazole|tablet
48128742|NCT04257487|DRUG|Placebo|Sugar pill manufactured to mimic sulodexide 250 LSU
48335981|NCT05745025|OTHER|Rehabilitation|"Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
48335982|NCT00561613|OTHER|SILCS and lubricant|
48335983|NCT00561613|OTHER|SILCS and spermicide|
48335984|NCT04698512|DEVICE|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
48494356|NCT03185442|DEVICE|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
47977215|NCT01717560|OTHER|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
47977216|NCT02412423|DRUG|post-transplantation cyclophosphamide|
47977217|NCT05288231|DIAGNOSTIC_TEST|Diagnostic of ECG|All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography
47977218|NCT01593215|DRUG|Yohimbine|Yohimbine capsule
48335985|NCT03734562|PROCEDURE|Ablation|Substrate-based radiofrequency catheter ablation
48335986|NCT03734562|DRUG|Antiarrhythmic drug|Amiodarone or sotalol therapy
48335987|NCT03138512|BIOLOGICAL|nivolumab|Specified dose on specified days
48335988|NCT03138512|BIOLOGICAL|ipilimumab|Specified dose on specified days
47977219|NCT01743053|DEVICE|Standard Care plus ReCell|
47977220|NCT01743053|OTHER|Standard Care|
48494357|NCT00472121|DEVICE|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
48494358|NCT01736241|DRUG|LY3053102|
48494359|NCT01736241|DRUG|Placebo|
48494360|NCT01350843|DIETARY_SUPPLEMENT|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
48653809|NCT06371352|DEVICE|Sham|Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.
48335989|NCT03138512|DRUG|nivolumab placebo|Specified dose on specified days
48335990|NCT03138512|DRUG|ipilimumab placebo|Specified dose on specified days
48335991|NCT06479434|DRUG|Metformin|Females diagnosed with polycystic syndrome will be given metformin tablets for 8 weeks and followed up. Blood samples will be collected along with anthropometric data (weight (kg), height (m) etc)
48335992|NCT02580240|DRUG|Hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
48494361|NCT05174494|DIAGNOSTIC_TEST|Evaluation of serum CRP and NT-proBNP|All patients were evaluated to 6-months post-treatment reduction of serum CRP and NT-proBNP
48494362|NCT04244669|DEVICE|IPG with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.
47977221|NCT02280785|DRUG|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
47977222|NCT00086320|DRUG|Paliperidone ER|
47977223|NCT03023475|DEVICE|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
47977224|NCT03023475|DEVICE|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
47977225|NCT05089760|OTHER|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
47977226|NCT06463210|DEVICE|Virtual reality as a distraction technique|A 360º relaxing video with music was displayed through a VR headset
48128743|NCT02036177|DEVICE|SCu300A IUB intrauterine device|Spherical copper IUD
48128744|NCT02036177|DEVICE|T380A IUD|T-shaped copper IUD
48128745|NCT03760913|DRUG|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
48128746|NCT03760913|DRUG|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
48128747|NCT03760913|OTHER|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
48128748|NCT03760913|OTHER|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
48128749|NCT04613375|DIAGNOSTIC_TEST|Urine sample collection|Serotype specific UAD (urinary antigen detection) test
48335993|NCT02580240|DRUG|saline|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
48335994|NCT04231513|DRUG|E2814|E2814, intravenous infusion.
48335995|NCT04231513|DRUG|E2814-matched placebo|E2814-matched placebo, intravenous infusion.
48335996|NCT05818384|BEHAVIORAL|Wakaya: Rising Up for Choctaw Youth Curriculum|An experiential, outdoor, nature-based program grounded in Choctaw values. It is a multi-level intervention that increases individual motivation and leadership skills to make healthy behavioral choices for behavior and exercise.
48335997|NCT00000248|DRUG|Pergolide|
48335998|NCT02050906|BEHAVIORAL|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
48335999|NCT02050906|BEHAVIORAL|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
48336000|NCT02050906|OTHER|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
48336001|NCT02050906|BEHAVIORAL|telephone based counseling|Undergo behavioral activity and nutritional counseling
48336002|NCT02050906|PROCEDURE|quality-of-life assessment|Ancillary studies
48336003|NCT02050906|OTHER|questionnaire administration|Ancillary studies
48336004|NCT04550936|DRUG|Isavuconazole|antifungal agent
48336005|NCT00145912|BEHAVIORAL|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
48336006|NCT00145912|BEHAVIORAL|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
48336007|NCT03769337|DIAGNOSTIC_TEST|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
48336008|NCT05885048|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in blood
48336009|NCT05885048|DIAGNOSTIC_TEST|Sperm samples for analysis|Spermiogram
48336010|NCT05885048|OTHER|Satisfaction evaluation|Participant satisfaction assessment
48336011|NCT05885048|OTHER|Quality of Life questionnaire|The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
48336012|NCT06376929|OTHER|oral carbohydrate containing fluid|administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting
48336013|NCT00371540|OTHER|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
48336014|NCT04867200|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
48494363|NCT04244669|DEVICE|IPG with SCS DTM|In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
48336015|NCT04867200|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
48494364|NCT02453776|DRUG|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
48653810|NCT02069847|DRUG|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
48128750|NCT04613375|DIAGNOSTIC_TEST|Saliva collection|Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
48336016|NCT03733457|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
48336017|NCT01594567|OTHER|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
48336018|NCT06053970|OTHER|Assessing postural responses induced by visual stimulation (Visual Evoked postural responses, VEPR)|"The intervention will last 60 minutes and will include an assessment of the Berg Balance Scale (BBS), the collection of stabilometric data, the collection of the numerical difficulty scale, the Fast Motion Sickness Scale (FMS) and will end with a break after exposure to VR.~The various conditions will be carried out in this order:~* Eyes open with VR headset simulating a static environment~* Eyes closed with VR helmet off~* Eight measurements on a stabilometry platform will be taken for each of the VR signals, in random order"
48336019|NCT03212599|DRUG|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
48336020|NCT04583969|BIOLOGICAL|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
48336021|NCT04583969|OTHER|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
48336022|NCT04583969|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
48336023|NCT00912340|DRUG|Everolimus|
48336024|NCT00912340|BIOLOGICAL|Trastuzumab|
48336025|NCT01890317|PROCEDURE|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
48336026|NCT00653328|DRUG|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
48336027|NCT00653328|DRUG|doxil|50 mg/m2 intravenously every 28 days
48336028|NCT03915106|DEVICE|Brace|Wear a rigid brace
48336029|NCT03915106|PROCEDURE|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
48653811|NCT06645379|OTHER|Platelet-Rich Plasma (PRP) Injections|Transvaginal or laparoscopic injection for ovarian diseases (Premature ovarian insufficiency and Poor ovarian response). Intrauterine perfusion or sub-endometrium injection for uterine diseases (intrauterine adhesion, thin endometrium, and repeated implantation failure)
48336030|NCT03966495|OTHER|Sustainability of a research program in risk management|"No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)"
48336031|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
48336032|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
48336033|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
48336034|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
48336035|NCT02140892|PROCEDURE|respiratory physical therapy manual technique- Autogenic Drainage|
48336036|NCT02140892|DEVICE|respiratory physical therapy technique- IPV|
48336037|NCT05215119|PROCEDURE|natural cycle endometrial preparation|Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (\>20 IU/L) and a corresponding rise in progesterone (\>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached \>16 mm (and LH was \<20 IU/L).
48336038|NCT05263687|DIAGNOSTIC_TEST|Maximal exercise test|Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
48336039|NCT00396825|BEHAVIORAL|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
48336040|NCT03536923|DEVICE|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
48653812|NCT05589597|DRUG|EO4010|Sequential assignment
47977227|NCT05076903|DRUG|OFA|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
47977228|NCT05076903|DRUG|Control|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
47977229|NCT06374160|BEHAVIORAL|Exercise intervention|Exercise
48336041|NCT05168852|OTHER|Formlabs Permanent CB Resin|Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer
48653813|NCT04037137|OTHER|Questionnaire|Caregiver Difficulties Scale, Impact on Family Scale, WHOQOL-BREF Quality of Life Assessment, Nottingham Health Profile, Fatigue Severity Scale, Beck Depression Scale
48653814|NCT06638697|OTHER|Free walking|The free walking training program will last 32 weeks. The intensity of the training will be controlled by the scale of perceived exertion (Borg). The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
48336042|NCT04147507|OTHER|Passive Music Therapy|Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
48336043|NCT04147507|BEHAVIORAL|Control|Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
48336044|NCT01359852|DRUG|[11C] JNJ-42491293|Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
48336045|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
47977230|NCT05029440|OTHER|Pulsed Electromagnetic Field|PEMF was administered to the whole body for PEMF groups using a 1.8×0.6m mat 30 minutes/day, 3 times/week for 3 months.
47977231|NCT05029440|OTHER|Exercise Program|The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.
48128751|NCT05395234|BEHAVIORAL|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura \& McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction \& flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
48128752|NCT02097394|DRUG|Combizym|Combizym( 1 tablet, po, tid)
48128753|NCT02097394|DRUG|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
48128754|NCT02097394|DRUG|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
48336046|NCT01359852|DRUG|[11C] JNJ-42491293 + JNJ-40411813|"Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
48336047|NCT01359852|DRUG|[11C] JNJ-42491293|Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
48336048|NCT06378060|DRUG|Modified transplantation system|Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
48336049|NCT01376362|DRUG|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
47977232|NCT05029440|OTHER|Pulsed High Laser Therapy|High Laser was delivered with a total dose of energy of 3000 J was delivered in two treatment phases. The initial phase was performed with fast manual scanning at 510, 610, and 710 mJ/cm2 in three successive subphases and 500 J in each subphase for a total of 1500 J. The final phase was the same as the initial phase except that the scanning was slow. The average area for the upper thigh or lower back was 200 cm2 with an average fluency of 15 J/cm2 and the application time for each area was 18 min. HILT was applied using a HIRO 3 device (ASA, Arcugnano, Vicenza, Italy).
47977233|NCT03026452|PROCEDURE|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
47977234|NCT00725023|DEVICE|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
48128755|NCT04238858|BIOLOGICAL|Platelet rich plasma|blood is drawn from the patient's antecubital vein and inserted into four 3.0 ml vacutainer tubes that contain trisodium citrate. These four tubes were placed in a centrifuge machine, and centrifugation was carried out at 2500 rpm (580×g) for 8 min within a 30-min blood collection period. As a result of centrifugation, the plasma was separated in the vacutainer tubes from the remaining blood components. Three different layers formed in the tubes: red blood cells at the bottom, aPRP in the middle layer, and aPPP in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe, and it was immediately injected into the subtenon space of each eye.
48336050|NCT01092026|OTHER|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
48336051|NCT03134612|DRUG|Ondansetron 8 mg|
48336052|NCT03134612|DRUG|Lidocain 40 mg|
48336053|NCT02626455|DRUG|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
48128756|NCT02909192|DEVICE|Light Therapy Device|
48128757|NCT02614235|DEVICE|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
48128758|NCT02672033|RADIATION|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
48128759|NCT02672033|RADIATION|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
48128760|NCT02672033|OTHER|Laboratory Biomarker Analysis|Correlative studies
48128761|NCT02672033|PROCEDURE|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
48336054|NCT02626455|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
48336055|NCT02626455|DRUG|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
48336056|NCT02626455|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
47977235|NCT00725023|DEVICE|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
47977236|NCT00298051|PROCEDURE|Delayed umbilical cord clamping|
47977237|NCT00488436|DRUG|Antithymocyte globulin|
48128762|NCT06364852|DRUG|LY007|FC and LY007 infusion
48494365|NCT03362918|BEHAVIORAL|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~* High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~* Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
48494366|NCT03362918|BEHAVIORAL|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
48494367|NCT03712839|OTHER|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
48494368|NCT05556759|PROCEDURE|control|patient will be operated under general anesthesia
48336057|NCT02626455|DRUG|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
48336058|NCT02626455|DRUG|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
47977238|NCT00488436|DRUG|Cyclosporine|
47977239|NCT04771442|DRUG|Stromal vascular fraction|Single dose
48494369|NCT05556759|PROCEDURE|IPS|patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
48494370|NCT05556759|PROCEDURE|Supra-iliac QL|patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
47977240|NCT04078113|OTHER|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
48336059|NCT02626455|DRUG|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
48336060|NCT02626455|DRUG|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
48128763|NCT01318694|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
48128764|NCT01318694|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
48336061|NCT02590419|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
48336062|NCT02925559|DRUG|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
48653815|NCT06638697|OTHER|Nordic walking|The Nordic walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
48128765|NCT01318694|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
48336063|NCT02925559|DRUG|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
48336064|NCT06453863|OTHER|Greater plantar feedback shoes|Shoes providing enhanced plantar feedback
48128766|NCT01318694|DRUG|ALV Placebo|ALV placebo soft gel capsules administered orally
48128767|NCT03304041|DIETARY_SUPPLEMENT|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
48128768|NCT03304041|DIETARY_SUPPLEMENT|Traditional dietary advice|"Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks"
48128769|NCT01079949|DRUG|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
48336065|NCT06453863|OTHER|Neutral gym shoes|Regular gym shoes
48336066|NCT06453863|OTHER|Barefoot|For the acute evaluation, barefoot will be considered as an active comparator for enhanced plantar feedback
48336067|NCT06365372|DIAGNOSTIC_TEST|Western blot|Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
48128770|NCT01079949|DRUG|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
48128771|NCT01079949|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
48128772|NCT01079949|DRUG|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
48336068|NCT05340101|BEHAVIORAL|ROGRESSIVE MUSCLE RELAXATION EXERCISE|"In the application, Relaxation Exercises CD Audio Recordings prepared by the Turkish Psychological Association were used. In the the second part of 30 minutes were explained with the sound of the PKGE stream and verbal instructions. Audio recordings in the second part were used in this study. In line with the PCGE sound recordings, each muscle group starting from the hands to the feet, and then the facial and whole body muscles were stretched for about 10 seconds. The exercise was applied by taking deep breaths while tensing each muscle group, and releasing this breath slowly during relaxation. The relaxation lasted 10-20 seconds before the next muscle group was stretched. In this way, the muscles groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, face and whole body were voluntarily stretched and relaxed, respectively, and the students were relaxed."
48336069|NCT06449846|DIAGNOSTIC_TEST|circulating tumor cell DNA detection|circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
48336070|NCT06112912|OTHER|REAL Essentials Advance|"REA is a relationship education curriculum developed by the Center for Relationship Education for high school-age youth. REA teaches youth critical relationship skills and practical approaches for navigating the social dynamics of friendship and love. The curriculum draws on several theories of behavior change, including social cognitive theory, theory of planned behavior, social inoculation theory, social norms theory, and behavior change theory.~REA includes 87 lessons organized into 10 units. The units cover topics such as healthy relationships, effective communication, commitment, planning for the future, job readiness, and sexual health."
48494371|NCT02128217|DRUG|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
48494372|NCT02128217|DRUG|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
48494373|NCT02128217|DRUG|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
48494374|NCT02252718|OTHER|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (\<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
48494375|NCT05581290|DEVICE|AI-Flex|A flexible multi-modal bio-sensing device with integrated AI capability used to measure ECG (heart's electrical activity), body temperature, and PPG (blood volume in tissue); primarly mounted on the wrist and chest.
48494376|NCT03298295|DEVICE|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
48494377|NCT01566357|OTHER|Toothpaste|
48494378|NCT01566357|DIETARY_SUPPLEMENT|Milk|
48653816|NCT06638697|OTHER|Dance|The Dance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
48336071|NCT05702398|DRUG|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
48336072|NCT05702398|DRUG|Nicotinamide|500 mg NAM twice a day for 6 months
48128773|NCT02919449|BIOLOGICAL|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
48128774|NCT02919449|BIOLOGICAL|Atezolizumab|Atezolizumab will be administered every 3 weeks
48128775|NCT03640299|PROCEDURE|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
48128776|NCT02230137|BEHAVIORAL|Text message arm|Text message sent before each injection of insulin
48128777|NCT03447457|DEVICE|High-flow oxygen|HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%
48128778|NCT03447457|DEVICE|Standard oxygen|nasal cannula, face mask or non-rebreathing reservoir mask
48128779|NCT04691024|OTHER|Exercise|Spinal stabilization exercises
48128780|NCT01302600|DRUG|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
48336073|NCT05702398|OTHER|Other: Placebo|Identical placebo pills twice a day
48128781|NCT01302600|DRUG|Placebo|0.1ml/kg once a day with food at dinner.
48128782|NCT01431430|DRUG|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
48128783|NCT01431430|DRUG|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
48653817|NCT06638697|OTHER|Physical exercise for cognition|The Physical exercise for cognition training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
48128784|NCT03754036|BEHAVIORAL|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
48128785|NCT05680649|OTHER|Breathing exercise|Diaphragmatic breathing exercises were taught to the individuals by the researcher and they were asked to start breathing exercises before starting PIVC. While the PIVC was being placed, the individuals continued the breathing exercise and the breathing exercise was terminated at the end of the application.
48128786|NCT02644369|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
48128787|NCT01290341|DRUG|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
48128788|NCT01290341|DRUG|Placebo|Topical; applied once daily for two weeks.
48128789|NCT04537741|PROCEDURE|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
48128790|NCT04537741|PROCEDURE|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
48128791|NCT00084396|DRUG|letrozole|
48128792|NCT00084396|PROCEDURE|conventional surgery|
48128793|NCT05590559|DRUG|Morphine|Opiates
48128794|NCT05590559|OTHER|Ultrasound-guided erector spinae plane block|PVB
48128795|NCT06282354|OTHER|Type of post-operative appointment|remote post-operative appointment for small or medium urooncology procedures
47977241|NCT03421028|DEVICE|Electromyography Biofeedback|EMG-Biofeedback- assisted training is a method in which electrodes situated on the surface of the skin detect small voltage changes which arise from the working muscles (in this case masseter and temporalis muscles). The voltage is transformed into a visual or sound time-variable signal which gives the patient feedback as he willingly tries to change the muscle tension (in this case to lower the excessive masseter tension)
48128796|NCT04200287|BEHAVIORAL|Online decision aid tool|The decision aid intervention will be presented via a website
48128797|NCT00592345|RADIATION|Proton Beam Radiation|Administered over a period of 12 weeks.
48128798|NCT00592345|RADIATION|Photon Beam Radiation|Administered over a period of 12 weeks.
48128799|NCT00592345|RADIATION|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
48128800|NCT01198431|BEHAVIORAL|Sleep duration|Duration of sleep per night
48128801|NCT06408077|OTHER|Water administration|Intravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
48128802|NCT06408077|OTHER|NaCl-Administration|Intravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
48128803|NCT05915715|OTHER|McGill stabilization exercise|"McGill Curl Up Lie down on your back.~The Side Bridge Lie on your side.~The Bird Dog."
48336074|NCT06349850|DIAGNOSTIC_TEST|serum uric acid level to plasma HDL-c level ratio (UHR)|high UHR is considered to be a risk factor for development of DKI in type 2 DM
48336075|NCT05694793|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
48336076|NCT05764876|DRUG|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
48336077|NCT05764876|DRUG|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
48494379|NCT01566357|DIETARY_SUPPLEMENT|Fluoridated Milk|
48494380|NCT01566357|DRUG|Tooth Mousse|
48494381|NCT01566357|DRUG|MI Paste Plus|
48494382|NCT01566357|DRUG|Elmex Erosion Protection|
48494383|NCT00760565|DRUG|RO4905417|3mg/kg iv every 28 days for 3 infusions
48494384|NCT00760565|DRUG|RO4905417|20mg/kg iv every 28 days for 3 infusions
48494385|NCT00760565|DRUG|RO4905417|7mg/kg iv every 28 days for 3 infusions
48494386|NCT00760565|DRUG|placebo|3mg/kg iv every 28 days for 3 infusions
48494387|NCT00760565|DRUG|placebo|7mg/kg iv every 28 days for 3 infusions
48128804|NCT05915715|OTHER|Proprioceptive neuromuscular facilitation technique|. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively.
48653818|NCT06638697|OTHER|Balance|The Balance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
48336078|NCT02313415|PROCEDURE|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
48336079|NCT01141218|OTHER|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
48336080|NCT00087048|DRUG|topotecan hydrochloride|
48336081|NCT00005808|DRUG|motexafin lutetium|Given IV
48336082|NCT00005808|DRUG|photodynamic therapy|Undergo laser therapy
48336083|NCT00005808|PROCEDURE|loop electrosurgical excision procedure|Undergo LEEP
48336084|NCT00005808|OTHER|laboratory biomarker analysis|Correlative studies
48336085|NCT02333669|OTHER|no intervention|no intervention
48653819|NCT06638697|OTHER|Aquatic physiotherapy|The Aquatic Physiotherapy training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
48336086|NCT01972594|PROCEDURE|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
48336087|NCT01972594|DEVICE|Accelerometer(ActivPAL)|
48336088|NCT02186561|DEVICE|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
48494388|NCT00760565|DRUG|placebo|20mg/kg iv every 28 days for 3 infusions
48653820|NCT06638697|OTHER|Multicomponent gymnastics|The Multicomponent Gymnastics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
47977242|NCT03421028|OTHER|Classic treatment for myogenous TMD|Combination of physiotherapy (manual therapy), stabilization occlusal splint usage and counseling
47977243|NCT03935100|PROCEDURE|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
47977244|NCT03935100|OTHER|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
47977245|NCT02927522|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
47977246|NCT02927522|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
47977247|NCT00228059|DRUG|Licarbazepine|
47977248|NCT05306938|BEHAVIORAL|Adolescent Wellness Visit|Adolescent Wellness Visits (AWVs) are a new health service platform for reaching young adolescents with HTC and other evidence-based prevention services which are clinic-based and school-facilitated. The AWVs bundle the following health screenings, education, and counseling on: nutrition, vision, dental, mental health (depression), contraception, sexually transmitted infections, and optional HIV testing.
47977249|NCT01524692|DRUG|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
47977250|NCT02088255|PROCEDURE|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
47977251|NCT02088255|PROCEDURE|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
47977252|NCT00680381|BEHAVIORAL|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
47977253|NCT00680381|BEHAVIORAL|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
47977254|NCT00680381|BEHAVIORAL|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
47977255|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
47977256|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
48653821|NCT06638697|OTHER|Water aerobics|The Water Aerobics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
48653822|NCT06638697|OTHER|Hydroposture|The Hydroposture training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
48653823|NCT06638697|OTHER|deep water walking|The deep water walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
48653824|NCT06638697|OTHER|Weight training|The weight training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
48653825|NCT06638697|OTHER|Mat pilates|The MAt pilates program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
48336089|NCT01046656|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
48336090|NCT04581863|DEVICE|pulse oximeter|Patients will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is \>3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
48336091|NCT04581863|OTHER|COVID Watch|Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.
48336092|NCT02078661|DRUG|PG101|A topical gel containing either 1% or 0.25% PG101 active.
48336093|NCT04397315|PROCEDURE|Pulpotomy to the level of canal orifices|Pulp tissue will be removed till the level of canal orifices.
48336094|NCT04397315|PROCEDURE|Pulpotomy up to superficial 2-3 mm of pulp chamber|Only superficial pulp from the chamber will be removed
48336095|NCT02293824|DRUG|Caffeine|Given per standard of care.
48336096|NCT02382653|DRUG|oral perixicam|Oral adminstration of buccal perixicam
48336097|NCT02773368|DRUG|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
48336098|NCT02773368|DRUG|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
48336099|NCT06408246|DRUG|Guanfacine|Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
48336100|NCT06408246|DRUG|Sertraline|Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.
48336101|NCT00605072|DRUG|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
48336102|NCT00605072|DRUG|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
48336103|NCT00605072|DRUG|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
48336104|NCT00605072|DRUG|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
48336105|NCT00605072|DRUG|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
48336106|NCT01778270|DEVICE|Body Bioimpedance Sensor|
48336107|NCT06057610|DRUG|SHR-A1811 Injection|SHR-A1811 Injection
48336108|NCT06057610|DRUG|SHR-A1811 Injection ； Pertuzumab Injection|SHR-A1811 Injection ； Pertuzumab Injection
48336109|NCT06057610|DRUG|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
48336110|NCT03990090|DRUG|TG103|Administered SC
48336111|NCT03990090|DRUG|Placebo|Administered SC
48494389|NCT02922881|OTHER|Ulcerative Colitis Diet (UCD)|The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
47977257|NCT01240447|BIOLOGICAL|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
48336112|NCT04988321|PROCEDURE|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
48336113|NCT04227067|DEVICE|TENS|An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
48336114|NCT04227067|DEVICE|SHAM TENS|A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
48336115|NCT04493593|BEHAVIORAL|SilverCloud|"'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed."
48336116|NCT00418730|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
48336117|NCT04911829|BEHAVIORAL|Psychotherapy|
48336118|NCT05281068|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
48336119|NCT05281068|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
48494390|NCT03265613|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
48494391|NCT00001026|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
48653826|NCT06502418|OTHER|Acupuncture therapy|7 acupuncture points will be used to managed pain and improved patient's experience
48653827|NCT01287208|DEVICE|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
48653828|NCT01287208|DEVICE|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
47977258|NCT01240447|OTHER|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
48336120|NCT02693327|OTHER|Biological Sample|A one time sample will be collected.
48336121|NCT02693327|OTHER|Blood Sample|A one time blood sample will be collected.
48336122|NCT02426112|DRUG|Azithromycin|
48653829|NCT02016885|DRUG|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
48653830|NCT02016885|DRUG|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
48653831|NCT02016885|DRUG|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
48336123|NCT02426112|DRUG|Placebo|
48494392|NCT00001026|BIOLOGICAL|rgp120/HIV-1IIIB|
48653832|NCT02016885|DRUG|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
48494393|NCT00001026|BIOLOGICAL|rgp120/HIV-1MN|
48494394|NCT00001026|BIOLOGICAL|rgp120/HIV-1 SF-2|
48494395|NCT00001026|BIOLOGICAL|HIVAC-1e|
48494396|NCT00158600|BIOLOGICAL|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
48494397|NCT00158600|DRUG|Placebo|Placebo Comparator; qow for 78 weeks.
48494398|NCT00700609|BEHAVIORAL|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
48494399|NCT03835143|PROCEDURE|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
48653833|NCT02016885|OTHER|Vehicle|Vehicle Topical Wipes
47977259|NCT03833115|OTHER|vaginal gel containing or not sodium lauryl sulfate|Prevention
47977260|NCT01904591|DIETARY_SUPPLEMENT|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
47977261|NCT01904591|DIETARY_SUPPLEMENT|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
47977262|NCT02315716|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
47977263|NCT02315716|DRUG|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
48494400|NCT02815449|OTHER|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
48494401|NCT02815449|OTHER|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
48336124|NCT00979108|OTHER|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
48336125|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
48336126|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
48336127|NCT02357888|DRUG|V0018|Oromucosal - Single dose
48336128|NCT02357888|DRUG|Placebo|Oromucosal - Single dose
48336129|NCT03738189|OTHER|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
48336130|NCT06219668|PROCEDURE|Omentopexy group|Omentopexy and Clips on staple line during LSG
48336131|NCT05023850|PROCEDURE|TLIPB|Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
48336132|NCT05023850|PROCEDURE|ESPB|Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
48494402|NCT02815449|OTHER|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
48336133|NCT02186756|OTHER|EMG-Biofeedback and Usual care|Please refer to arm description
48336134|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
48336135|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
48336136|NCT01253187|DRUG|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
48128805|NCT05398224|DRUG|Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab|"Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients \>65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion."
47977264|NCT01427504|DRUG|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
47977265|NCT03998033|BIOLOGICAL|ET140202 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
47977266|NCT00489021|PROCEDURE|sub-acute hospitalization|
47977267|NCT02106091|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
47977268|NCT01044862|DRUG|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
47977269|NCT01044862|DRUG|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
47977270|NCT01044862|DRUG|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
47977271|NCT02525341|OTHER|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
47977272|NCT02525341|OTHER|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
47977273|NCT02525341|OTHER|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
47977274|NCT04023851|DEVICE|Mobile application Brain4U|Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
48336137|NCT02077803|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
48336138|NCT02077803|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
48336139|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
48336140|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
47977275|NCT05739955|OTHER|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
47977276|NCT05739955|OTHER|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
47977277|NCT05739955|OTHER|Routine Disinfection|Routine disinfection at the study hospital
47977278|NCT02322918|GENETIC|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
47977279|NCT00869349|BEHAVIORAL|IFS|"The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline."
48128806|NCT01634919|DEVICE|chronic hepatitis C|acoustic radiation force impulse ultrasonography
47977280|NCT00869349|OTHER|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
47977281|NCT05893173|BEHAVIORAL|Sleep Deprivation|Ten individuals (aged 18-85) with a DSM-V diagnosis of MDD will undergo baseline GluCEST imaging prior to and following approximately 30 hours of total sleep deprivation.
48128807|NCT01700205|OTHER|Type of Formula|infant formula
48128808|NCT01695954|DRUG|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
48128809|NCT01695954|DRUG|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
48128810|NCT01695954|DRUG|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
48336141|NCT00978679|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
48336142|NCT00978679|DEVICE|Spectacles|Daily use of single vision lenses to correct refractive errors
48128811|NCT01695954|DRUG|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
48128812|NCT01616888|DEVICE|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
48128813|NCT01630226|DRUG|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
48128814|NCT00930306|DRUG|AZD2066|12 doses, Given as capsule, 2 mg \& 8 mg
48128815|NCT00930306|DRUG|Caffeine|2 doses, Given as Tablet, 2x50 mg
48128816|NCT00930306|DRUG|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
48128817|NCT00930306|DRUG|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
48128818|NCT00930306|DRUG|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
48128819|NCT00051792|BEHAVIORAL|yoga|
48128820|NCT04175405|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
48128821|NCT01784744|OTHER|Hydroworx Pool at 98 degrees Fahrenheit|
48128822|NCT01784744|OTHER|Hydroworx Pool at 102 degrees Fahrenheit|
48128823|NCT05021341|DIETARY_SUPPLEMENT|Berberine|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (500 mg of berberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
48128824|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 200|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (200 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
48128825|NCT05021341|DIETARY_SUPPLEMENT|Dihydroberberine 100|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (100 mg of dihydroberberine) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
48494403|NCT04875611|DRUG|Opdivo|Dose of Nivolumab is constant and is 240 mg .All patients will undergo maximum of 12 cycles of investigation product's infusion ( around 6 month of treatment).Each cycle will be done in intervals of 14 day (no less than 12 days after previous infusion and no longer than 42 day/6 weeks after previous infusion).
48653834|NCT06199882|DRUG|SBRT Sequential Surufatinib Combined With Immunotherapy|"1. SBRT :~   Bioequivalent total dose \> 75Gy, completed within 2 weeks (once daily, 5 times a week).~2. Drug treatment (every 3 weeks is a treatment cycle) :~1) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle."
48653835|NCT06183541|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
48653836|NCT03463681|DRUG|Cabometyx|cabozantinib 60 mg orally once daily
48653837|NCT06258512|OTHER|Intervention with a narrative approach.|"Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient\&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system."
48653838|NCT06644625|OTHER|Blood draw for the laboratory assessment|Screening blood sample collection to test for MGUS
48336143|NCT06252246|DEVICE|Phacoemulsification machine|type of phacoemulsification machine is different
48336144|NCT02691364|PROCEDURE|Blood withdrawal|
48336145|NCT03652545|BIOLOGICAL|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
48128826|NCT05021341|DIETARY_SUPPLEMENT|Placebo|For each visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10 hr fast. Participants will ingest the double-blinded supplement (Maltodextrin placebo) at specific times, the day before and morning of study visits 2 - 5. For each visit, participants will have their heart rate, blood pressure, body mass, and height measured. After final ingestion of their assigned supplementation dose, standard multiple sample phlebotomy approaches will be used to collect 10 mL of venous blood from a forearm vein at 0, 20, 40, 60, 90, and 120 minutes post-supplement ingestion. After donating baseline blood sample (0-min) a standard test meal, white bread, and glucose powder mixed in 250 mL of water. The complete nutritional breakdown of the test meal is anticipated to be 382 kcal, 3.2 grams of fat, 80.6 grams of carbohydrate, and 7.64 grams of protein.
48128827|NCT00894543|DRUG|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
48128828|NCT00894543|OTHER|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
48336146|NCT06058884|DRUG|Alteplase|Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
48336147|NCT01360229|PROCEDURE|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
48336148|NCT01360229|OTHER|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
48128829|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
48336149|NCT04569084|DRUG|MT-1186|Oral edaravone
48128830|NCT02731846|DRUG|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
48336150|NCT04569084|DRUG|Placebo|Oral
48336151|NCT05471206|OTHER|Milk and SmartPill intakes|During visit V2, the subject will ingest the SmartPill capsule. Then, subjects will drink milk.
48336152|NCT02967770|OTHER|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
48336153|NCT02967770|DRUG|Standard of Care Second Line Therapy|
48336154|NCT03854851|DRUG|Naldebain|In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
48336155|NCT03854851|DRUG|Morpine|In Morphine group, patients will receive morphine as needed after surgery.
48653839|NCT06454916|DEVICE|Small Bowel Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: small bowel anastomosis creation in subjects undergoing laparoscopic small bowel surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically into two different sections of small bowel that are intended to be anastomosed. An OTOLoc device will be deployed into the small bowel wall in one section of the small bowel to provide access for the deployment of a Flexagon SFM into that section of bowel. The process is repeated at the second section of bowel. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two sections of bowel until the anastomosis is fully formed.
48336156|NCT01441518|OTHER|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
48336157|NCT01441518|OTHER|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
48494404|NCT05483803|BEHAVIORAL|Adhera® Caring digital intervention for Type 1 Diabetes|The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
48653840|NCT06289582|DRUG|[F-18]DPA714 administration IV|brain PET/MRI imaging after \[F-18\]DPA-714 administration
48653841|NCT06183528|PROCEDURE|Pericapsular Nerve Group (PENG) Block|With ultrasonography-guided PENG block, the femoral, obturator and accessory obturator nerve branches that provide sensory innervation of the anterior surface of the hip joint capsule are blocked .
48653842|NCT06193382|BEHAVIORAL|PCIT|Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
48653843|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/100|5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
48653844|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/10|5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
48653845|NCT03213405|BIOLOGICAL|rBCG-N-hRSV full dose|1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
48128831|NCT02731846|DRUG|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
48653846|NCT03213405|BIOLOGICAL|Conventional BCG full dose|2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
48653847|NCT05059665|DIAGNOSTIC_TEST|Helio Liver Test|De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
48653848|NCT03742726|DEVICE|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
48128832|NCT02731846|DEVICE|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
48128833|NCT02731846|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
48128834|NCT00575016|BIOLOGICAL|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U \> Week 12; injection into the detrusor
48128835|NCT00575016|BIOLOGICAL|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
48128836|NCT00575016|BIOLOGICAL|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
48128837|NCT00575016|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
48266523|NCT02606578|OTHER|Questionnaires|"The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.~At your clinical follow-up visits (\~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.~You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back."
48336158|NCT00848770|DRUG|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
48336159|NCT00848770|DRUG|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
48336160|NCT00848770|DRUG|manipulation of SAP|Esmolol or NPS or NOR
48336161|NCT00683007|OTHER|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
48653849|NCT01145183|DRUG|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
48653850|NCT01145183|DRUG|Placebo|Matched placebo daily dosing
48653851|NCT02007161|DRUG|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
48653852|NCT05396287|DEVICE|MRI|Participants will undergo an MRI scan while participating in two breathing tests (hypercapnia and hypoxia) to measure brain blood flow.
48653853|NCT04428905|OTHER|Quality-of-Life Assessment|Ancillary studies
48653854|NCT04428905|OTHER|Questionnaire Administration|Ancillary studies
48653855|NCT04428905|OTHER|Survivorship Care Plan|Receive personalized care plan/resource manual
48653856|NCT04428905|OTHER|Telemedicine|Participate in telehealth sessions
48653857|NCT06642051|DEVICE|High Intensity focused ultrasound|Sonablate High Intensity Focused Ultrasound system to ablate incompetent veins of the periphery
48653858|NCT03906084|PROCEDURE|Corticotomy and low laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
48653859|NCT03906084|PROCEDURE|Corticotomy facilitated Orthodontics|Corticotomy is carried out under local anesthesia in right side.
48128838|NCT04310514|DIETARY_SUPPLEMENT|Fructose/glucose/xylitol/saccharose|"1. Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~2. Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~3. Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~4. Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
48128839|NCT00310973|BEHAVIORAL|Social Network Intervention|
48336162|NCT00683007|OTHER|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
48653860|NCT03756961|DRUG|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
48494405|NCT02257463|DRUG|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
48494406|NCT02257463|OTHER|peripheral muscles exercise training|
48336163|NCT04080492|OTHER|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
48336164|NCT00006190|DRUG|Nelfinavir mesylate|
48336165|NCT00006190|DRUG|Stavudine|
48494407|NCT02257463|DEVICE|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
48494408|NCT06168565|DEVICE|Intermittent pneumatic compression (AirRelax)|Moderate pressure (around 80mmHg); high pressure (around 200mmHg), both applied on the lower-limbs
48494409|NCT02884349|PROCEDURE|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
48653861|NCT03756961|BEHAVIORAL|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
48653862|NCT03756961|DRUG|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
48336166|NCT00006190|DRUG|Lamivudine|
48336167|NCT00006190|DRUG|Efavirenz|
48336168|NCT05903950|DEVICE|Air cleaners with HEPA filter|PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters
48336169|NCT05903950|DEVICE|Air cleaners without HEPA filter|Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
48336170|NCT04605159|BIOLOGICAL|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
48336171|NCT04605159|DRUG|Placebo|One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
48336172|NCT04104295|DIAGNOSTIC_TEST|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
48336173|NCT00608842|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
48336174|NCT00608842|DRUG|Placebo|Matching vehicle placebo administered via intralipomal injection.
48336175|NCT04373707|DRUG|Enoxaparin|"For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg"
48128840|NCT01670474|DRUG|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
48128841|NCT01670474|DRUG|rt-PA|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
48128842|NCT02034292|DRUG|Clopidogrel|
48128843|NCT02034292|DRUG|Aspirin|
48128844|NCT02034292|DRUG|APD791|
48128845|NCT02034292|DRUG|Placebo|
48128846|NCT05527613|OTHER|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
48128847|NCT01855516|DRUG|Heparin|
48128848|NCT02761616|OTHER|eBC treated participants|No intervention administered in this retrospective observational study.
48128849|NCT01727375|OTHER|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
48128850|NCT00401869|DRUG|Epoetin alfa|
48128851|NCT06124573|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
48336176|NCT04373707|DRUG|Enoxaparin|For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
48336177|NCT00498225|DRUG|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
48128852|NCT05103618|DRUG|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, \[F-18\] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
48128853|NCT05103618|BEHAVIORAL|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
48336178|NCT00498225|DRUG|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
48336179|NCT00498225|DRUG|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
48336180|NCT04402619|BEHAVIORAL|Cognitive behavior therapy|"The ten modules cover:~* Psychoeducation about sleep, sleep problems, and associations with alcohol~* How to keep and use a sleep diary~* Sleep hygiene~* Sleep compression~* Cognitive restructuring~* Emotional regulation~* Preparing for the future"
48336181|NCT05625646|OTHER|quality assurance program|The program consists of an online quiz using a multiple choice questionnaire (MCQ) design. The participants are expected to complete the online MCQ at 3, 6, 9, and 12 months following baseline. The MCQ includes still-pictures and video sequences of the 10 application specific POCUS examinations from the course curriculum. Through 15-20 questions, the quiz tests the OSAUS dimentions Each question has four possible answers of which up to three answers are correct. Each MCQ will have ten questions pertaining to pathologies within the ten applications of the curriculum. Further, there will be five to ten questions relating to image recognition, image optimisation, ultrasound artifacts. Once each MCQ is finalized, the participating GP's will receive feed-back on the answers with suggestions for improvement and guidance toward continuing self-directed learning.
48336182|NCT03064347|DIETARY_SUPPLEMENT|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48494410|NCT06429839|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy,40-50.4Gy/20-28f. Nimotuzumab 400mg,ivgtt,W2d. Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.
48494411|NCT05502523|PROCEDURE|Pulmonary Artery-First Surgical Technique|Undergo pulmonary artery first surgical technique
48128854|NCT00196521|DEVICE|Tension-free vaginal tape obturator system|
48128855|NCT01784328|DEVICE|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
48128856|NCT02789020|DRUG|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
48494412|NCT05502523|PROCEDURE|Biospecimen Collection|Correlative studies
48494413|NCT03276221|BEHAVIORAL|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
48494414|NCT00073242|DRUG|Leptin|leptin administration
48494415|NCT00073242|BEHAVIORAL|Dietary modification|Subjects lose 10% of body weight via dietary restriction
48494416|NCT00073242|DRUG|T3 repletion|administer T3
48336183|NCT03064347|DIETARY_SUPPLEMENT|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48128857|NCT02789020|OTHER|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
48128858|NCT02789020|DEVICE|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
48128859|NCT02789020|DEVICE|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
48494417|NCT04641065|OTHER|Music listening|An expert on the particular type of music will do the selection of the playlist of Traditional Turkish Military music, and this playlist will be listened to the patients by the researchers.
48494418|NCT03984292|PROCEDURE|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
48128860|NCT02789020|OTHER|Physical Function Performance Test|This test will be performed at baseline and one year.
48128861|NCT06463249|BEHAVIORAL|CORE Helpline|All participants will receive the Core Helpline program (CORE) for 2 months, which includes written weight loss material, use of a smartphone app, weekly text messages and email reminders and 1 optional participant-initiated coaching call per month.
48128862|NCT06463249|BEHAVIORAL|Extended Helpline|Those who achieved 2% weight loss at 2-month, will continue to Extended Helpline, where the participants can continue receiving all CORE resources including1-on-1 coaching through 1 optional participant-initiated call per month for 6 months.
48128863|NCT06463249|BEHAVIORAL|Enhanced Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 1 optional participant-initiated call/month for 6 months. Additionally, the participants will receive 2 individualized coach-scripted feedback emails per month, and the option to receive daily text message reminders.
48128864|NCT06463249|BEHAVIORAL|Intensive Helpline|Those who do not reach 2% weight loss at the end of 2 months will be randomized. Participants will continue to receive all CORE resources plus 2 scheduled coaching calls/month for 6 months. Additionally, the participants will receive 2 individual coach-scripted feedback emails per month, and the option to receive daily text message reminders.
48128865|NCT05641506|DRUG|Yangzheng Xiaoji|Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.
48336184|NCT03064347|DIETARY_SUPPLEMENT|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48336185|NCT03064347|DIETARY_SUPPLEMENT|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48336186|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48494419|NCT01176110|DEVICE|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
48494420|NCT00110162|DRUG|antiandrogen therapy|
48494421|NCT00110162|DRUG|releasing hormone agonist therapy|
48494422|NCT00110162|PROCEDURE|orchiectomy|
48494423|NCT06352229|BEHAVIORAL|Playful Learning in Infancy Program|Research-based knowledge on play with babies delivered to the parents systematically by public health visitors based on a manual, activity cards, and video clips at four time points from 0 to 12 months postpartum.
48653863|NCT03756961|DRUG|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
48653864|NCT03756961|DEVICE|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
48653865|NCT03756961|DRUG|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
48653866|NCT03756961|DRUG|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
48128866|NCT05641506|DRUG|Niraparib|"Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL."
48128867|NCT03175159|BEHAVIORAL|IMPACT|Ten counseling sessions
48128868|NCT03175159|BEHAVIORAL|Standard of Care|Two counseling sessions
48128869|NCT03908775|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for nasotracheal intubation in children undergoing dental interventions. Nasotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
48128870|NCT03908775|DEVICE|Direct Laryngoscope|An intubating device that is used for nasotracheal intubation. Nasotracheal intubation was applied by anesthesiologist with direct laryngoscope.
48128871|NCT00167765|DRUG|Abciximab|
48128872|NCT01756924|DRUG|CEM-102|
48336187|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48336188|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48336189|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
48336190|NCT00343109|BIOLOGICAL|HER-2/neu intracellular domain protein|Given ID
48336191|NCT00343109|PROCEDURE|leukapheresis|Optional correlative studies
48336192|NCT00343109|OTHER|laboratory biomarker analysis|Correlative studies
48336193|NCT00343109|BIOLOGICAL|sargramostim|Given ID
48336194|NCT00343109|OTHER|immunologic technique|Correlative studies
48653867|NCT03756961|DRUG|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
47977282|NCT01259505|BIOLOGICAL|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
47977283|NCT02067169|BIOLOGICAL|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
47977284|NCT04885972|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
48128873|NCT01756924|DRUG|IV or Oral standard of care antibiotics|
48336195|NCT00343109|BIOLOGICAL|synthetic tumor-associated peptide vaccine therapy|Given ID
48653868|NCT03756961|DRUG|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
48653869|NCT02264756|OTHER|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
48128874|NCT01756924|DRUG|Rifampin|
48128875|NCT00180934|PROCEDURE|Reirradiation with concomitant chemotherapy|
48336196|NCT05609851|OTHER|Short Physical Performance Batary|"The SPPB includes usual walking speed over 4 m, five chair-stands test, and balance test. A score (scale: 0-4) was assigned to performance on time to rise five times from a seated position, standing balance, and 4-m walking velocity. Individuals received a score of 0 for each task they were unable to complete. Participants coded in the unable to perform category included (a) those who tried but were unable and (b) the interviewer or participant felt it was unsafe. Summing the three individual categorical scores, a summary performance score was created for each participant (range: 0-12), with higher scores indicating better lower body function."
48128876|NCT05808595|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
48128877|NCT05808595|OTHER|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
48128878|NCT06101875|OTHER|Health Coach (Health coaching)|Patients will be assigned a health coach and be eligible to 8 times, 1 hour sessions over a 12 week period. The health coach will use techniques to increase their ability to self-manage, motivation levels and commitment to change their behaviour.
48494424|NCT06352229|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
48128879|NCT06101875|OTHER|Digital Toolkit (Control)|This is an online website, unsupervised, 12-week self-management programme.
48128880|NCT00332319|DRUG|GW679769|
48128881|NCT02540525|DEVICE|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
48494425|NCT02440022|COMBINATION_PRODUCT|Lutonix DCB|
48494426|NCT02440022|DEVICE|Standard Balloon Angioplasty Catheter|
48653870|NCT05752032|GENETIC|ICM-203|Long term follow-up
48653871|NCT05752032|DRUG|Placebo|Long term follow-up
48653872|NCT01017900|PROCEDURE|local excision|surgical excision by orthopaedic surgeon under local anesthesia
48653873|NCT06590610|DEVICE|Radial pressure wave (RPW) - Intelect RPW2 Chattanooga|RPW treatment on one leg at the Gastrocnemius and NMES electrostimulation on the opposite leg. RPW or NMES treatment on each leg will be randomized prior to application with each device having an equal chance of being placed on the either leg (dominant and non-dominant).
48653874|NCT00949039|DRUG|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
47977285|NCT04885972|DRUG|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
47977286|NCT04885972|DRUG|Placebo|Vehicle solution
48336197|NCT05609851|OTHER|Occupational Balance Self-Assessment|"The Occupational Self-Assessment (OSA) is a self-reported assessment tool consisting of 21 items in which the patient rates their occupational competence (i.e., how well they do) and value (i.e., how important it is to them). The first 11 items are related to skills and occupational performance, the next five items concern habitation (including habits and roles), and the last five items correspond to volition (including personal causation, values, and interests). In the OSA, each item is scored on two separate 4-point scales, one for occupational competence (1 = I have a lot of problems doing this; 4 = I do this extremely well) and the other for value (1 = This is not important to me; 4 = This is most important to me).~The individual item scores are summed to obtain separate total scores for competence and value. Higher total scores indicate higher occupational competence and value."
48336198|NCT05563051|DEVICE|i-ED COIL|The i-ED COIL System (i-ED COIL and detachment box) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
48653875|NCT00949039|RADIATION|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
48653876|NCT00949039|PROCEDURE|Surgery|
48653877|NCT06256016|OTHER|Neck pain massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
47977287|NCT05377385|BEHAVIORAL|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
47977288|NCT02799511|BIOLOGICAL|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
47977289|NCT01929278|DRUG|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
47977290|NCT01929278|OTHER|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
47977291|NCT01929278|OTHER|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril \[approximately 2 cm x 2 cm\]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
47977292|NCT05918692|DRUG|BMF-500|Investigational Product
47977293|NCT02905552|OTHER|No intervention|
47977294|NCT01332474|DRUG|BOTOX|BOTOX
47977295|NCT01681225|OTHER|Esophageal-pressure guided mechanical ventilation|
47977296|NCT01681225|OTHER|High PEEP mechanical ventilation|
47977297|NCT03789318|DRUG|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
48336199|NCT03242161|DIAGNOSTIC_TEST|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
48336200|NCT03934203|DRUG|BI 409306|Film-coated tablet
47977298|NCT03789318|DRUG|Placebo|Each cohort will use placebo reconstituted in saline.
48336201|NCT03934203|DRUG|Moxifloxacin|Film-coated tablet
48336202|NCT03934203|DRUG|Placebo matching to BI 409306|Film-coated tablet
47977299|NCT03789318|DRUG|Bupivacaine Hydrochloride|0.25% administered pre-surgery
47977300|NCT03789318|DRUG|Hydromorphone|0.02 mg/kg IV administered intraoperatively
47977301|NCT03789318|DRUG|Fentanyl|100 mcg IV administered intraoperatively
47977302|NCT03789318|DRUG|Acetaminophen|1000 mg IV administered intraoperatively
47977303|NCT03789318|DRUG|Oxycodone|5-10 mg PO administered post-surgery
48653878|NCT06256016|OTHER|Neck and thoracic massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
48128882|NCT02540525|DEVICE|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
48128883|NCT01296646|DRUG|Naltrexone|50 mg oral naltrexone once/day
48494427|NCT02440022|PROCEDURE|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
48494428|NCT02701166|DRUG|Bezafibrate|bezafibrate 400mg per day
48494429|NCT02701166|DRUG|Placebo|placebo 400mg per day
48494430|NCT01075841|DRUG|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
48494431|NCT04386174|OTHER|Neurofeedback|Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
48494432|NCT01006564|OTHER|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
48494433|NCT01006564|OTHER|Other|Insertion of gold seeds into prostate for image registration.
48494434|NCT01145430|OTHER|Laboratory Biomarker Analysis|Correlative studies
48494435|NCT01145430|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48494436|NCT01145430|OTHER|Pharmacological Study|Correlative studies
48128884|NCT01296646|BEHAVIORAL|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
48128885|NCT01296646|DRUG|Placebo|An inactive pill to control for non-pharmacological responses.
48128886|NCT02776475|PROCEDURE|Sacral neuromodulation device turned off|Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
48128887|NCT06499766|OTHER|Biodiversity intervention by inactivated microbial extract|Participants use the lotion including microbial extract on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
48128888|NCT06499766|OTHER|Placebo intervention by colored lotion|Participants use the lotion including safe, non-active coloring ingredient on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
48336203|NCT05459207|OTHER|Moderate Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a normal/moderate fat meal.
48336204|NCT05459207|OTHER|High Fat Meal|A liquid meal consisting of powdered protein and complex carbohydrates blended with coconut oil and peanut butter in ratios required to achieve the desired calorie and macronutrient distributions of a high-fat meal.
48336205|NCT02091921|DRUG|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
48336206|NCT00501462|DRUG|GSK189075|single 250 mg dose of drug
48336207|NCT01128881|BIOLOGICAL|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
48494437|NCT01145430|DRUG|Veliparib|Given PO
48494438|NCT02796937|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
48494439|NCT04639713|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
48494440|NCT00466908|DEVICE|Pentacam and IOL Master|Pentacam and IOL Master
48494441|NCT05627167|OTHER|day time cyclic nutrition|Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube
48494442|NCT05627167|OTHER|continuous nutrition|Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
48494443|NCT03842579|OTHER|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
48494444|NCT03842579|OTHER|High-protein diet|Daily supplementation with milk-based protein-rich products
48494445|NCT03842579|OTHER|Recommendations|Provided with the official national recommendations on nutrition
48128889|NCT00978016|DRUG|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
48128890|NCT00978016|DRUG|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
48128891|NCT00978016|DRUG|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
48128892|NCT00978016|DRUG|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
48128893|NCT00978016|DRUG|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
48128894|NCT00978016|DRUG|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
48128895|NCT03426800|OTHER|Acupuncture and training|Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
48128896|NCT06464224|BEHAVIORAL|low respiratory effort|patients under respiratory effort lower than -1,5 cmH2O (P0,1) and/or -7 cmH2O (Pocc)
48128897|NCT06464224|BEHAVIORAL|high respiratory effort|patients under respiratory effort higher than -3,5 cmH2O (P0,1) and/or -15 cmH2O (Pocc)
48128898|NCT05408624|PROCEDURE|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
48336208|NCT06332040|DRUG|Gentamicin|random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
48336209|NCT05706961|OTHER|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
48128899|NCT05408624|PROCEDURE|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
48128900|NCT01746706|DEVICE|PET amyloid tracer (Florbetapir F18 AV45 F18|
48653879|NCT04547075|OTHER|Turkish validity and reliability|"1. Contact with developers and formation of steering committee~2. Translation from English to Turkish~3. Back translation from Turkish to English~4. Comparison of translation~5. Review of translated versions.~6. Reaching consensus and development of pilot version~7. Testing in clinical setting~8. Revision of pilot version~9. Testing of final version"
48336210|NCT05706961|OTHER|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
48336211|NCT00708747|DRUG|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
48336212|NCT00708747|DRUG|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
48128901|NCT00324350|DRUG|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
48128902|NCT03155100|DRUG|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
48128903|NCT03155100|DRUG|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
48128904|NCT03155100|DRUG|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
48128905|NCT03360513|OTHER|general group|The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
48128906|NCT05985590|DRUG|BMS-986278|Specified dose on specified days
48128907|NCT05985590|DRUG|Drospirenone/Ethinyl Estradiol|Specified dose on specified days
48336213|NCT03729661|BEHAVIORAL|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
48336214|NCT03514238|BEHAVIORAL|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
48653880|NCT03075228|DEVICE|IntelliCap|Sampling of the small intestine using a samling capsule.
48653881|NCT02160808|DRUG|Secretin|Drug to stimulate pancreatic secretion
48653882|NCT02160808|DRUG|Placebo|
48653883|NCT06643780|DRUG|Denosumab|60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
48653884|NCT06643780|DRUG|Zolendronic Acid|5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
48653885|NCT04639726|DIETARY_SUPPLEMENT|Whey Protein Micro Gel|The test product is whey protein microgels 10g, reconstituted in 125ml water.
47977304|NCT03789318|DRUG|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
47977305|NCT03789318|DRUG|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
47977306|NCT00218465|DRUG|GW468816|Pharmacotherapies for Relapse Prevention
47977307|NCT00218465|DRUG|Placebo Comparator: Placebo|
48128908|NCT04471441|DRUG|Everolimus Tab.|After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/mL.
48494446|NCT05094245|PROCEDURE|Stellate Ganglion Block Group|Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
48494447|NCT01155024|DEVICE|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
48494448|NCT01155024|DEVICE|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
48494449|NCT04072016|DEVICE|Beacon Aqueous Microshunt|The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
48653886|NCT04639726|OTHER|Water without Whey Protein.|A matching placebo (125ml of water without whey protein) will be used as control.
48653887|NCT06644898|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
48653888|NCT06644898|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
48653889|NCT06644898|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
48653890|NCT05245071|DRUG|Tusamitamab ravtansine|Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
48653891|NCT04670484|OTHER|Wearing Mask|Participants wearing masks as per federal guidelines to prevent Coronavirus spread
48653892|NCT05981040|DRUG|ZYIL1 capsules 25 mg and 50 mg Placebo|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
48653893|NCT05981040|DRUG|ZYIL1 capsules 50 mg and 25 mg Placebo|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
48653894|NCT05981040|DRUG|ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
48653895|NCT05981040|DRUG|Matching placebo 25 mg and Matching placebo 50 mg|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
48653896|NCT06434350|DRUG|Enfortumab Vedotin|Given by IV
48653897|NCT06434350|RADIATION|Radiation Therapy|Given by Radiation Therapy
48653898|NCT01613885|OTHER|No Intervention|This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
48653899|NCT06035120|DEVICE|AeriSeal System|The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
48653900|NCT05668624|OTHER|Clean household energy|LPG stoves/fuel for cooking and solar electricity for lighting
48653901|NCT02559856|DRUG|Apixaban|
48653902|NCT02559856|DRUG|Rivaroxaban|
48653903|NCT02955082|DRUG|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
48653904|NCT05770245|DEVICE|The novel electrolyzed water spray|The researcher used electrolyzed water or piped water to treat the diseased area two times a day for five days. The trial consists of 7 study visits (day 1-day 7). The reduction in the disease area of discomfort or itching scores and promoting healing of the damaged skin of patients with mild dermatophytosis event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
47977308|NCT05485376|DEVICE|Pulmonary Artery Catheter|The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
47977309|NCT06115213|BEHAVIORAL|Patient counselling|Patient counseling, lifestyle modifications, medication evaluation, and adherence
47977310|NCT03697629|DRUG|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
47977311|NCT02501473|DRUG|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
48653905|NCT02825563|DRUG|Anlotinib|in the fasting state
47977312|NCT02501473|DRUG|Pembrolizumab|PD-1 Inhibitor
47977313|NCT02501473|DRUG|Rituximab|Rituximab (anti-CD20 antibody)
47977314|NCT01596400|DRUG|granisetron transdermal system|patch
47977315|NCT01596400|DRUG|Granisetron IV|IV
48128909|NCT04471441|DRUG|Mycophenolate mofetil Tab./Cap.|Up to 1.5g BID(total 3g daily), PO
48653906|NCT02825563|DRUG|Anlotinib|in the high fat diet
48653907|NCT05074381|OTHER|Dry Needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leadi
48653908|NCT05074381|OTHER|Sham Needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
48653909|NCT03287063|OTHER|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
48653910|NCT06645288|OTHER|Emergency Reflex Action Drill|Emergency Reflex Action Drill in performing Emergency Surgical Airway
48653911|NCT06638489|OTHER|High-Intensity-Focused-Electromagnetic-Therapy (HIFEM)|The HIFEM stimulation was administered using an Emsella instrument (manufactured by BTL Industry Inc., Boston, MA). The frequency ranged between 50 and 60Hz, and the intensity was as high as the patient could tolerate, which was usually up to 100%.
48128910|NCT03803475|DRUG|Ga-68 labeled PSMA-11|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
48128911|NCT03803475|DEVICE|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
48128912|NCT03803475|DEVICE|Positron emission tomography-magnetic resonance imaging (PET/MRI)|A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
48653912|NCT06638489|OTHER|Pelvic-Floor-Muscle-Training (PFMT)|The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.
48494450|NCT01163448|RADIATION|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
48494451|NCT05968560|BEHAVIORAL|CBT Skills Group for CHR Youth|"CBT skills group is designed to boost peer support, reduce isolation, normalize psychotic-like experiences to lessen distress, reduce cognitive biases, facilitate positive beliefs, and enhance reasoning and decision-making. CBT skills group uses CBT to Prevent Paranoia manual to teach individuals to make adaptive appraisals of their experiences (e.g. voices and other cognitive intrusions) to prevent the perception of such events as threatening."
48653913|NCT04265651|DRUG|Infigratinib 0.016 mg/kg|"Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
48128913|NCT02259049|DIETARY_SUPPLEMENT|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
48128914|NCT02259049|DIETARY_SUPPLEMENT|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
48653914|NCT04265651|DRUG|Infigratinib 0.032 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
48653915|NCT04265651|DRUG|Infigratinib 0.064 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
48653916|NCT04265651|DRUG|Infigratinib 0.128 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
48653917|NCT04265651|DRUG|Infigratinib 0.25 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
48653918|NCT05012124|OTHER|Collaborative care|Receive u-CoCM
48653919|NCT05012124|OTHER|Interview or Focus Group|Participate in an interview or focus group
48653920|NCT05012124|OTHER|Media/technology Intervention with collaborative care|Use t-CoCM digital platform with collaborative care
48128915|NCT04324099|OTHER|neuroimaging session (with simultaneously acquired eye-tracking)|neuroimaging session, including two functional neuroimaging paradigms (ca. 15-20 minutes each) and a short structural image acquisition (mprage) for coregistration. Functional Magnetic Brain Imaging (fMRI) and simultaneous eye-tracking data will be collected during the paradigms: 1) an emotion processing paradigm (adapted from Passamonti et al., 2010); and 2) an emotional Go/noGo paradigm (adapted from Hare et al., 2008).
48653921|NCT05012124|OTHER|Survey Administration|Complete surveys
48653922|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Alpha|Rhythmic alpha stimulation
48653923|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Theta|Rhythmic theta stimulation applied
48653924|NCT06252532|DEVICE|Sham Direct cortical stimulation (DCS)|Arrhythmic stimulation paradigm applied
48128916|NCT04324099|OTHER|Questionnaire (for children) assessing traumatic experiences (Childhood trauma questionnaire (CTQ))|The Childhood Trauma Questionnaire is a brief survey of six early traumatic experiences (death, divorce, violence, sexual abuse, illness or other), and assesses individual's understanding of their childhood trauma.
48128917|NCT04324099|OTHER|Social and Health Assessment (SAHA) questionnaire (for children)|Self reported survey assessing social and mental health with four aspects of parenting determined (parental involvement, parental warmth, parental control, and inconsistency of parenting).
48266524|NCT00621504|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
47977316|NCT02652520|PROCEDURE|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
48266525|NCT00621504|DRUG|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
48336215|NCT03514238|BEHAVIORAL|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
48336216|NCT03514238|BEHAVIORAL|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
48336217|NCT02592668|DEVICE|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
48336218|NCT01708616|DRUG|RO5285119|multiple doses
48336219|NCT01708616|DRUG|RO5285119 placebo|multiple doses
48128918|NCT04324099|OTHER|Massachusetts Youth Screening Instrument (MAYSI-2) (for children)|"The Massachusetts Youth Screening Instrument (MAYSI-2) is a screening instrument developed for detecting mental health needs in youth aged 12-17. Designed as a low-cost, easily administered tool, it screens for multiple issues and can be administered in 10-15 minutes. It is divided into seven scales composed of 52 questions that are designed to detect alcohol/drug use, angryirritable behavior, depression-anxiety, somatic complaints, suicide ideation, thought disturbance, and traumatic experience. Youths answer YES or NO concerning whether each item has been true for them within the past few months."
48128919|NCT04324099|OTHER|Interpersonal Reactivity Index (IRI) (for children)|The Interpersonal Reactivity Index is a measure of dispositional empathy that takes as its starting point the notion that empathy consists of a set of separate but related constructs. The instrument contains four seven-item subscales (seven Likert items each), each tapping a separate facet of empathy (Empathic Concern, Perspective Taking, Personal Distress, and Fantasy). The 28-item IRI contains four subscales
48336220|NCT01708616|DRUG|risperidone|single dose
48494452|NCT05968560|BEHAVIORAL|Individual CBT sessions|CBT skills learned in group are personalized in individual sessions focused on: a) facilitating learning of CBT skills; b) tailoring CBT skills to personal goals; c) facilitating successful interaction with peers in the group; and d) providing academic and vocational support. Youth may opt to invite family members to join individual sessions as needed.
48494453|NCT05968560|BEHAVIORAL|CBT Skills Group for Families|"Family members are taught the same CBT skills that are taught to CHR youth to facilitate use of CBT skills at home. Family members also learn how to prompt CHR youth to use CBT skills through effective communication, such as empathic listening and encouraging alternative explanations. CBT skills group for family members uses a combination of didactic learning (skills are described in CBT Skills for Families manual and demonstrated via video examples) and practice (skills are role-played). Youth attend one group session and one individual session per week, and family members attend one group session per week."
48494454|NCT00891748|GENETIC|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
48494455|NCT00548938|DRUG|Gliadel wafer|Implanted at surgery
47977317|NCT02063022|DRUG|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
47977318|NCT02063022|DRUG|Intensified chemotherapy|"* Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~* Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~* Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
47977319|NCT01152242|DRUG|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
47977320|NCT01152242|DRUG|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
47977321|NCT01987505|DRUG|Rituximab|1400 mg will be injected subcutaneously (SC).
47977322|NCT00549965|DRUG|Risedronate Sodium|
47977323|NCT03920579|DRUG|CKD-386 formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
47977324|NCT03920579|DRUG|CKD-386 formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
47977325|NCT03920579|DRUG|D326, D337 and D013|A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
48336221|NCT01708616|DRUG|risperidone placebo|single dose
48336222|NCT05445141|BEHAVIORAL|Little ACF [in Swedish: Lilla ABC]|Little ACF is a modified version of the program called All Children in Focus \[in Swedish: Alla Barn i Centrum (ABC)\] that originally is developed for parents with children 3-12 years of age. The content is based on positive developmental psychology and involves role plays, discussions and exercises to try at home with the child. Printed material will be provided to the parents at each meeting/session. Little ACF is offered once a week during four weeks. Each session is 60 minutes, thereafter the parents can stay in the facility for 30 minutes to continue discussing with each other.
48494456|NCT00548938|DRUG|Temozolomide|During External Beam Radiation
48494457|NCT00548938|RADIATION|External Beam Radiation Therapy|60 Gy
47977326|NCT04925037|BEHAVIORAL|self-questionnaire to patients undergoing SpAax follow-up|On the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing SpAax follow-up
47977327|NCT05662228|DRUG|Lorazepam|Lorazepam will be administered as an oral pill over the first 15 days of study in a daily titration, starting at 0.5 mg BID and increasing to up to 2 mg three times daily, as tolerated. Dosing will continue at the maximum tolerated dose through the 12-week endpoint. Participants will be titrated off lorazepam over at least four weeks after completing the endpoint visit. Taper will be tailored to individuals for safety reasons with a goal of decreasing dosage by 25% weekly. Phone check ins will be conducted every three days to monitor patient.
48336223|NCT05445141|BEHAVIORAL|Lectures|The lectures are pre-recorded and available during four weeks. Each lecture is 10 minutes and the content is similar to, but more superficial than, the content in Little ACF.
48336224|NCT00481741|DEVICE|SafeSeal(TM) Hemostasis Patch|
48336225|NCT01374672|OTHER|laboratory biomarker analysis|Correlative studies
48336226|NCT01191281|BEHAVIORAL|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
48336227|NCT01191281|OTHER|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
48336228|NCT04447118|DRUG|Pyrotinib|400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.
48336229|NCT04447118|DRUG|Docetaxel|75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.
48336230|NCT03028467|DRUG|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
48128920|NCT04324099|OTHER|Youth Psychopathic Traits Inventory (YPI) (for children)|self-report screening measures to assess psychopathic traits in youth assessing 10 core personality traits associated with the construct (grandiosity, lying, manipulation, callousness, unemotionality, impulsivity, irresponsibility, dishonest charm, remorselessness, and thrill seeking). Each item is scored on an ordinal 4-point Likert scale (1 = Does not apply at all, to 4 = Applies very well). Higher scores reflect an increased presence of psychopathic traits.
48128921|NCT04324099|OTHER|Reactive Proactive Questionnaire (RPQ) (for children)|The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
48128922|NCT04324099|OTHER|Emotion Regulation Questionnaire (for children)|10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
48336231|NCT03028467|DRUG|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
48336232|NCT03028467|DRUG|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
48336233|NCT03028467|DRUG|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
48336234|NCT03028467|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
48336235|NCT03028467|DRUG|Folic acid|Folic acid tablet 5 mg per week is given orally.
48336236|NCT02220361|DRUG|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
48336237|NCT02220361|DRUG|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
48336238|NCT02220361|DRUG|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes"
48336239|NCT00167362|BEHAVIORAL|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
48336240|NCT00167362|BEHAVIORAL|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
48336241|NCT04231032|OTHER|Asynchronous dual chamber pacing (DOO) with paced ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
48336242|NCT04231032|OTHER|Asynchronous atrial pacing (AOO) with intrinsic ventricular activation|Alteration of the participant's existing pacemaker mode to either paced or intrinsic ventricular activation (in an order based upon randomisation).
48336243|NCT02666040|DEVICE|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
48336244|NCT02666040|DEVICE|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
48653925|NCT06252532|DEVICE|Direct cortical stimulation (DCS) In-Phase Theta|Rhythmic in-phase theta stimulation applied
48336245|NCT02666040|PROCEDURE|Detecting the mode of admission to hospital|Ordinary admission or day surgery
48336246|NCT02666040|PROCEDURE|Duration of surgery|Time operating room
48336247|NCT02666040|PROCEDURE|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
48336248|NCT02274415|BIOLOGICAL|Vaccination with the combined vaccine (Prevenar13 ®)|
48653926|NCT06252532|DEVICE|Direct cortical stimulation (DCS) Anti-Phase Theta|Rhythmic anti-phase theta stimulation applied
48653927|NCT06645067|BEHAVIORAL|Measuring energy balance|"The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA."
48336249|NCT02274415|BIOLOGICAL|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
48653928|NCT00111735|DRUG|Thyroxine|
48336250|NCT01269047|DRUG|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
48336251|NCT01269047|DRUG|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
48336252|NCT01269047|DRUG|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
48336253|NCT05224817|OTHER|Necrotizing soft tissue infections (NSTIs)|There will be no direct interaction with subjects and involves no interventions; study is conducted completely via review of electronic health records. Our site will only collect data from the Methodist Dallas Medical Center.
48336254|NCT00972972|DIETARY_SUPPLEMENT|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
48336255|NCT00972972|DIETARY_SUPPLEMENT|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
48336256|NCT02829008|DRUG|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
48336257|NCT02829008|DRUG|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
48336258|NCT00004226|RADIATION|radiation therapy|
48336259|NCT02932644|OTHER|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
48336260|NCT02932644|OTHER|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
48336261|NCT03767998|OTHER|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
48336262|NCT03767998|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
48336263|NCT03767998|OTHER|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
48653929|NCT06529237|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
47977328|NCT05662228|DRUG|Intravenous immunoglobulin (IVIG)|IVIG will be administered as a series of four intravenous infusions at a dose of 1 mg/kg with pre-infusion medications of 1 mg/kg diphenhydramine and 15 mg/kg acetaminophen. The first two infusions occur at baseline and one day after (induction dosing), followed by one infusion at 4 weeks and one infusion at 8 weeks.
48128923|NCT04324099|OTHER|Basic Empathy Scale (BES) (for children)|The Basic Empathy Scale (BES) measures 20 items (affective and cognitive empathy) on a Five-point Likert-type scale.
48336264|NCT05525741|OTHER|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
48336265|NCT05525741|OTHER|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
48336266|NCT02061748|DRUG|Observational|Retrospective Chart Review
48336267|NCT01817660|PROCEDURE|Open repair of popliteal artery|
48653930|NCT06529237|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|Routine malaria rapid diagnostic tests
47977329|NCT05662228|DRUG|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
47977330|NCT03247530|DRUG|Placebo|Placebo was administered once daily
47977331|NCT03247530|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
47977332|NCT03247530|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
47977333|NCT05490329|BEHAVIORAL|Tough Talks COVID|Intervention participants will download the TT-C app from the iOS or Google Play store and complete the intervention within one month.
48128924|NCT04324099|OTHER|Pubertal Development Scale (PDS) (for children)|self-report measure of physical development which has been shown to be correlated with measures of pubertal development derived from physical examination. Responses are coded on 4-point scales (1 = no development and 4 = completed development). For girls, a yes-no question about onset of menarche is weighted more heavily (1 = no and 4 = yes). For both genders, ratings are then averaged to create an overall score for physical maturation.
48128925|NCT04324099|OTHER|Alabama Parenting Questionnaire (APQ) (for parents)|The APQ measures five dimensions of parenting that are relevant to the etiology and treatment of child externalizing problems: (1) positive involvement with children, (2) supervision and monitoring, (3) use of positive discipline techniques, (4) consistency in the use of such discipline and (5) use of corporal punishment (42 self-reported responses, rated on a 5-point Likert scale- 1 (never) to 5 (always) for both child and parent forms)
48128926|NCT04324099|OTHER|Inventory of Callous Unemotional Traits (ICU) (for parents)|24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits.The ICU has three subscales: Callousness, Uncaring, and Unemotional. The ICU is made up of statements with a 4-point Likert scale, ranging from 0 (Not at all true) to 3 (Definitely True), with higher scores indicating greater CU traits.
48128927|NCT04324099|OTHER|Child Behavior Checklist (CBCL) (for parents)|"The eight empirically-based syndrome scales are:~1. Aggressive Behavior~2. Anxious/Depressed~3. Attention Problems~4. Rule-Breaking Behavior~5. Somatic Complaints~6. Social Problems~7. Thought Problems~8. Withdrawn/Depressed. Higher scores indicate greater Problems."
48336268|NCT01817660|PROCEDURE|Endovascular repair of popliteal artery|
48336269|NCT03707262|BIOLOGICAL|Donor CD34+ and CD3+ cells|Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
48336270|NCT00690417|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
48336271|NCT02708992|DRUG|Azithromycin|
48336272|NCT02708992|DRUG|Cefixime|
48336273|NCT04163055|DEVICE|Moleculight i:X|This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
48336274|NCT02178163|OTHER|cytology specimen collection procedure|Correlative studies
48336275|NCT02178163|OTHER|laboratory biomarker analysis|Correlative studies
48336276|NCT06067932|RADIATION|Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.
48336277|NCT06067932|DIAGNOSTIC_TEST|Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed
48336278|NCT04425460|DRUG|Favipiravir|Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
48494458|NCT03308266|DIAGNOSTIC_TEST|electromyography|
48494459|NCT00521417|BEHAVIORAL|short-term dynamic therapy|
48336279|NCT04425460|OTHER|Placebo|Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
48336280|NCT00086736|DRUG|bicalutamide|
48336281|NCT00086736|DRUG|eflornithine|
48336282|NCT00086736|DRUG|oral eflornithine placebo|
48336283|NCT00086736|DRUG|oral bicalutamide placebo|
48336284|NCT01734278|OTHER|No intervention|This is a non-interventional study.
48336285|NCT03148964|BIOLOGICAL|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
48336286|NCT00055575|DRUG|Scopolamine Nasal Spray|
47977334|NCT05001386|BIOLOGICAL|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
48336287|NCT00056836|DRUG|rhuFab V2 (ranibizumab)|
48336288|NCT03690947|DRUG|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
48336289|NCT03690947|PROCEDURE|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
48336290|NCT03690947|DRUG|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
48336291|NCT02820558|DRUG|Substance P|
48336292|NCT05554718|BEHAVIORAL|Self-help Smartphone App|The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.
48494460|NCT00521417|BEHAVIORAL|long-term dynamic therapy|
48494461|NCT03713879|DEVICE|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
48494462|NCT03713879|DRUG|Indomethacin|rectally administered indomethacin before or after ERCP
48494463|NCT03275766|OTHER|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
48494464|NCT03275766|OTHER|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
48494465|NCT03275766|OTHER|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
48336293|NCT05554718|BEHAVIORAL|Therapist-guided App Use|In addition to using the app, patients receive a total of 8 video-based therapy sessions over the course of 12 weeks. The sessions include topics such as video feedback and behavioral experiments.
48336294|NCT00443846|BIOLOGICAL|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
48336295|NCT00443846|BIOLOGICAL|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
48336296|NCT03012594|DRUG|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
48336297|NCT01867645|DRUG|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
48336298|NCT01867645|DRUG|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
48336299|NCT02398981|OTHER|Clinical decision support tool|
48336300|NCT02460978|DRUG|Dapagliflozin|Tablets
48336301|NCT02460978|OTHER|Placebo for dapagliflozin|Tablets
48336302|NCT05837325|PROCEDURE|Oocyte Pick Up - Out of Study|Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.
48336303|NCT05837325|PROCEDURE|Denudation - Out of Study|All oocytes are denuded together. Maturational stages are recorded.
48336304|NCT05837325|PROCEDURE|ICSI|One oocyte injected at a time.
47977335|NCT06248632|OTHER|Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)|Expression of inflammatory markers obtained from circulating monocytic cells of XLH
47977336|NCT02193867|DRUG|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
48128928|NCT04324099|OTHER|Griffith Empathy Measure (GEM) (for parents)|self-report 23-item measure of empathy in which the respondent answers each item on a nine-point Likert scale from strongly disagree to strongly agree
48128929|NCT04324099|OTHER|Social Responsiveness Scale (SRS) (for parents)|Social Responsiveness Scale (SRS) measures social ability of children from 4 years to 18 years old. It is used primarily with individuals with Autism Spectrum Disorder (ASD), family members of individuals with ASD, and others who have social impairments. Parent or teacher questionnaire (65 items on a 4-point Likert scale). High scores are associated with more severe social impairments.
48266526|NCT00621504|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
48336305|NCT05837325|PROCEDURE|Culture|One embryo per culture drop. Individual follow-up of the embryo development.
48336306|NCT05837325|GENETIC|Biopsy|One embryo per culture drop.
48336307|NCT05837325|PROCEDURE|Vitrification|One embryo per vitrification straw.
48336308|NCT05837325|PROCEDURE|OPU - Study Group|Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).
48336309|NCT05837325|PROCEDURE|Denudation - Study Group|Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.
48336310|NCT03810378|BEHAVIORAL|Mediterranean Diet (Med-Plus)|Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
48336311|NCT03810378|BEHAVIORAL|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
48494466|NCT03275766|OTHER|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
48494467|NCT06304025|BIOLOGICAL|Wharton's jelly mesenchymal stem cells (WJ-MSCs)|Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days
48336312|NCT00555282|DEVICE|central venous catheter|coated central venous catheter
48336313|NCT00555282|DEVICE|central venous catheter|standard central venous catheter
48336314|NCT01952093|BEHAVIORAL|Home-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
48336315|NCT01952093|BEHAVIORAL|Clinic-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
48494468|NCT01912274|DRUG|Pracinostat|Elderly newly diagnosed patients will all receive pracinostat
48494469|NCT01912274|DRUG|Azacitidine|Elderly newly diagnosed patients will all receive azacitadine
48494470|NCT01878162|OTHER|Exercise|
48494471|NCT03732261|OTHER|Exercise and dietary|The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
48494472|NCT02122120|DIETARY_SUPPLEMENT|HEN|Patients with tube feeding with FSMP for at least twelve months
48494473|NCT05407025|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and tissue samples
48494474|NCT05407025|OTHER|Questionnaire Administration|Complete risk factor questionnaire
48336316|NCT03980626|BEHAVIORAL|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
48336317|NCT01505972|OTHER|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
48336318|NCT01505972|OTHER|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
48336319|NCT04198519|OTHER|Weight Loss|The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.
48336320|NCT00582699|BEHAVIORAL|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
48494475|NCT06144151|DEVICE|NeurOptics® NPi®-300 Pupillometer|The pupilometer is a non-invasive device which will be placed in front of your eyes, one at a time. It looks like a handheld spotlight or scanner, with a small plastic guide sticking out that will be placed against your cheek to help keep the device in place during the scan. It will not touch your eye. Both your left and right eyes will be measured with the device each time. Scanning with the pupilometer will take less than 5 minutes total for both eyes.
48494476|NCT06275191|BEHAVIORAL|Multicomponent intervention|The multicomponent intervention consists of (1) a single 45-60-minute academic detailing session with provider participants, plus (2) provision of patient post-extraction instruction materials and (3) provision of blister-packaged acetaminophen and ibuprofen for distribution to adolescent/young adult patients after tooth extraction in the course of clinical practice
48494477|NCT06275191|OTHER|Usual care|No intervention.
48494478|NCT03760250|DRUG|Imiquimod 5% cream|Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
48494479|NCT00231257|DEVICE|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
48494480|NCT00231257|PROCEDURE|Brachytherapy|Brachytherapy
48494481|NCT02309775|OTHER|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
48494482|NCT02273687|DEVICE|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
48494483|NCT01598441|DRUG|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
48494484|NCT01598441|DRUG|distilled water|1-2 ml aerosolized distilled water inhalation per session
48494485|NCT04278898|DRUG|N-Acetylcysteine|N-acetylcysteine Single Dose 2700 mg taken orally
48336321|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
48336322|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G\>A or c.2846A\>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
48494486|NCT05887895|DRUG|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
48494487|NCT06258759|BIOLOGICAL|autologous platelet-rich plasma supplement|the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
48494488|NCT06258759|BIOLOGICAL|no autologous platelet-rich plasma supplement|the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
48494489|NCT03334617|DRUG|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
48494490|NCT03334617|DRUG|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
48494491|NCT03334617|DRUG|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
48494492|NCT03334617|DRUG|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
48494493|NCT03334617|DRUG|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
48494494|NCT03334617|DRUG|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
48494495|NCT03334617|DRUG|trastuzumab deruxtecan|Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
48494496|NCT03334617|DRUG|cediranib|cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
48494497|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
48494498|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
48494499|NCT03334617|DRUG|AZD6738 (ceralasertib) (240 mg or 160 mg)|AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
48266527|NCT00621504|DRUG|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
48494500|NCT03334617|DRUG|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
48494501|NCT04338217|DEVICE|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
48494502|NCT04338217|DEVICE|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
48494503|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
48494504|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
48494505|NCT00548951|OTHER|Control|Receive no sessions in a Snoezelen Room.
48494506|NCT04603170|OTHER|DRUG|taking drug medication prescribed by psychiatrists for at least one month
48494507|NCT03340142|DEVICE|VIVO™|Diagnose the area of a PVC or VT onset
48494508|NCT03457155|OTHER|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~* At intensive care admission time~* 24h after admission time~* In case of FA occurrence~* In case of sinusal rhythm recovery (in patients with new onset FA)"
48494509|NCT05484453|DIAGNOSTIC_TEST|Complete Eye Examination by Ophthalmologist|complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
48266528|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre 2|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre 2
48336323|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
48336324|NCT01614912|DRUG|SM-13496|40 or 80 mg once daily orally
48336325|NCT00263835|BEHAVIORAL|Empowerment|
48336326|NCT05244538|DEVICE|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
48494510|NCT05879198|BEHAVIORAL|Computer-based Intervention|The current project proposes to pilot a computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
48128930|NCT04611334|BEHAVIORAL|heart rate variability biofeedback|Heart rate variability biological feedback training is carried out in the outpatient meeting room of the hospital, including once a week, 30 minutes of hospital training each time, using Medea physiological feedback device portable Bluetooth physiological signal Feedback system (Medical Device Input No. 027390). Designed as two stages, stage one (the first week) first teaches the subject how to perform abdominal breathing, and connects the physiological feedback device to monitor the patient's breathing and heart rate changes, and sets the breath per minute according to the subject's resonance frequency . Stage two (second-four weeks) guide the case to understand the resonance relationship between breathing and heart rate, and then achieve the effect of matching heart and breath. It is also equipped with a pressure relief device (Helico Inc., New York, NY, USA) for self-practice at home.
48128931|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
48266529|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre pro iQ|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre pro iQ
48266530|NCT02676830|DRUG|K-312 100 mg|Single oral dose
48494511|NCT03460769|OTHER|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
48494512|NCT01432418|OTHER|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
48494513|NCT05701137|OTHER|EMDR-RTE|The experimental group will have EMDR recent traumatic event.
48494514|NCT05701137|OTHER|TAU|The comparator group will have usual psychological intervention.
47977337|NCT01655706|DRUG|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
47977338|NCT01655706|DRUG|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
47977339|NCT03547687|DEVICE|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
47977340|NCT03547687|DEVICE|Neuromuscular Electrical Stimulation Treatment|"If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each"
48494515|NCT04751539|DRUG|AND017 single dose|AND017 administrated as oral single-dose on Day 1 in Part A
48494516|NCT04751539|DRUG|AND017 multiple dose|AND017 administrated once daily from Day 1 to Day 10 in Part B
48494517|NCT04751539|DRUG|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
48494518|NCT06207214|OTHER|Self-help book for university students.|"The intervention being tested, is a self-help book for university students based on Acceptance and Commitment Therapy. The book was published in 2021 and is called The Unbreakable Student: 6 Rules for Staying Sane at University. The book is by Dr Nic Hooper.~The self-help book will be posted in paper form to all participants. There are 8 chapters in the book and participants will be given eight weeks to read the book at home (with a suggestion of reading one chapter per week)."
48494519|NCT00147602|DRUG|atorvastatin|
48494520|NCT00505375|DRUG|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
48494521|NCT00505375|OTHER|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
48494522|NCT05041621|DEVICE|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
48494523|NCT01839630|DRUG|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
48653931|NCT05402072|PROCEDURE|Autologous matrix-induced chondrogenesis (AMIC)|AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
48653932|NCT05845580|OTHER|Red yeast rice extract initial therapy followed later on by statin therapy|Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of \<2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.
48653933|NCT05845580|OTHER|Statin therapy|Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
48494524|NCT04971265|BEHAVIORAL|Low SES/High Supports|Participant will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
48653934|NCT05202782|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given IV
48266531|NCT02676830|DRUG|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes
48266532|NCT02794220|DEVICE|CN electronic cigarette 10 mg|Inhalation
48266533|NCT02794220|DEVICE|CN electronic cigarette 15 mg|Inhalation
48266534|NCT02794220|DEVICE|Nicorette Inhalator 15 mg|Inhalation
48266535|NCT02794220|OTHER|Cigarette|Inhalation
48336327|NCT05244538|DRUG|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
48336328|NCT04282070|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
48336329|NCT04282070|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
48336330|NCT04282070|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
48336331|NCT04282070|DRUG|Albumin Paclitaxel|Maximum 6 cycles for combined therapy.
48653935|NCT05202782|OTHER|Quality-of-Life Assessment|Ancillary studies
48653936|NCT05202782|OTHER|Questionnaire Administration|Ancillary studies
48653937|NCT05202782|DRUG|Zanubrutinib|Given PO
48653938|NCT05580406|BEHAVIORAL|Outreach messaging|Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.
48653939|NCT04974476|OTHER|HIIT Exercise Training|The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, \>80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
48653940|NCT04730271|DEVICE|Total Knee Replacement|Subjects will be implanted with an ATTUNE Primary total knee replacement.
48653941|NCT05199844|DEVICE|Apple Watch|Apple Watch device measures heart rate and oxygen saturation
48266536|NCT00113243|DRUG|adult stem cells|
48336332|NCT05003141|DRUG|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
48336333|NCT05845489|DRUG|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
48336334|NCT05845489|OTHER|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
48336335|NCT01422772|BIOLOGICAL|VM202RY|0.5mg intramuscular injection
48336336|NCT01422772|BIOLOGICAL|VM202RY|1mg intramuscular injection
48336337|NCT01422772|BIOLOGICAL|VM202RY|2mg intramuscular injection
48336338|NCT01851863|DRUG|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
48336339|NCT01851863|DRUG|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
48336340|NCT01851863|DRUG|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
48336341|NCT01851863|DRUG|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
48336342|NCT03588611|DRUG|Bivalirudin|0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
48336343|NCT03588611|DRUG|Bivalirudin|0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
48128932|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
48336344|NCT00254878|DRUG|Methylphenidate hydrochloride|
48336345|NCT04630964|DRUG|Psilocybin|psilocybin 25 mg Single Oral Dose
48336346|NCT04630964|DRUG|Niacin|niacin 100mg Single Oral Dose
48494525|NCT04971265|BEHAVIORAL|Low SES/ Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a janitor in a residential building, while Kim works as a cashier in a supermarket. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
48494526|NCT04971265|BEHAVIORAL|High SES/High Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, all parents have 12 weeks of paid parental leave, access to free full-day center-based daycare for children aged 0 to 3, free full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten), and free parenting classes.
48653942|NCT05880004|BEHAVIORAL|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
48653943|NCT05886478|DRUG|No intervention|As this is an observational study, no intervention will be administered.
48653944|NCT04482803|DRUG|Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes|Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
48336347|NCT04146051|DRUG|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
48336348|NCT05071443|OTHER|Negative pressure wound therapy (NPWT)|"The therapeutic intervention being tested is the use of a negative pressure wound therapy (NPWT) device. Several medical devices are currently being used and are based on the same principle. They involve applying negative pressure, generally between -100 and -150 mmHg, to a wound using a dressing (mostly a polyurethane foam dressing with hydrophobic pores), which hermetically covers the wound's surface and is connected to a container for collecting the fluids drained off. These devices are widely available and used to treat post-operative wounds.~Duration of treatment: the use of NPWT will be maintained until the recovery of the skin has been achieved by the skin graft. An average duration of 3 weeks' treatment is expected in the intervention group."
48336349|NCT05071443|OTHER|Conventional dressing|"Conventional dressings will be performed from randomization to skin grafting and applied every day based on the methods normally used in the participating centres, and also until the recovery of the skin has been achieved by the skin graft.~This generally involves local care provided on a daily basis, ensuring gentle mechanical and chemical debridement by covering the wound with alginate type or other dressings, according to the condition of the wound. The methods used to apply these conventional dressings will be recorded."
48336350|NCT00718523|DRUG|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
48336351|NCT00718523|DRUG|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
48336352|NCT06006780|DEVICE|Porcine acellular dermal matrix|Coronally advanced flap associated with the porcine acellular dermal matrix for root coverage
48336353|NCT06006780|OTHER|Coronally advanced flap (CAF)|Coronally advanced flap for root coverage
48128933|NCT04492475|DRUG|Interferon beta-1a|Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
48336354|NCT00535444|OTHER|Parish nurse visit|One visit with the parish nurse in 2 weeks
48336355|NCT04116216|COMBINATION_PRODUCT|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
48336356|NCT04116216|COMBINATION_PRODUCT|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
48336357|NCT04116216|COMBINATION_PRODUCT|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
48494527|NCT04971265|BEHAVIORAL|High SES/Low Supports|Participants will read the following scenario: Michael and Kim are a young couple living with their 2-year-old child. Michael works as a lawyer in a private company, while Kim works as a manager at a bank. Where they live, parents have 1 week of paid parental leave, full-day center-based daycare for children aged 0 to 3 is available for around $900 per month, full-day preschool for children aged 3 to 5 (early education programs to prepare for kindergarten) is available for around $1400 a month, and they can take parenting classes for $50 per hour.
48494528|NCT02035839|DEVICE|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
48494529|NCT02035839|DEVICE|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
48494530|NCT02035839|DEVICE|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
48653945|NCT03802851|PROCEDURE|Holmium Laser Enucleation of Prostate (HoLEP)|Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
48128934|NCT04492475|OTHER|Placebo|The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
48128935|NCT04492475|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
48128936|NCT03484741|BIOLOGICAL|MSC and PRP|MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
48128937|NCT03611075|OTHER|No Intervention|No interventions are administered in this study
48128938|NCT01099566|DRUG|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
48336358|NCT00248105|BEHAVIORAL|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
48336359|NCT06145659|BEHAVIORAL|Preschool and Me|Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
48128939|NCT01099566|DRUG|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
48336360|NCT02157012|DRUG|The effectiveness of Xeljanz in rheumatoid arthritis patients|
48336361|NCT06306352|OTHER|Vibrotactile feedback|The ABLE exoskeleton is accompanied by a vibrotactile feedback belt which users wear around their chest to receive real-time feedback during the double support phase. This feedback can assist them in their weight shift during the double support phase.
48336362|NCT02293941|DRUG|JKB-122 5mg|Participants were randomized to receive JKB-122 5mg for 12 weeks
48336363|NCT02293941|DRUG|JKB-122 15mg|Participants were randomized to receive JKB-122 15mg for 12 weeks
48336364|NCT02293941|DRUG|JKB-122 35mg|Participants were randomized to receive JKB-122 35mg for 12 weeks
48128940|NCT01232959|DEVICE|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
48128941|NCT02273999|DEVICE|RecoveryRx™|Appliance of the device after surgery
48128942|NCT02523222|DIETARY_SUPPLEMENT|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
48128943|NCT06215391|DEVICE|3d printed mask|"* Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.~* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).~* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.~* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.~* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted."
48128944|NCT01876966|DRUG|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
48128945|NCT01876966|DRUG|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
48128946|NCT01876966|DRUG|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
48128947|NCT00910832|DRUG|Eductyl suppository|one suppository every morning during 21 days
48128948|NCT00910832|DRUG|Placebo suppository|placebo suppository every morning during 21 days
48128949|NCT00989196|BIOLOGICAL|Human-cl rhFVIII|50 IU/kg for PK dose
48128950|NCT00989196|BIOLOGICAL|Kogenate FS|50 IU/kg for PK dose
48128951|NCT06014372|DRUG|Envafolimab|Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
48128952|NCT06014372|DRUG|CAPEOX|The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
48336365|NCT02293941|DRUG|Placebo|Participants were randomized to receive comparable placebo for 12 weeks
48336366|NCT03792165|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
48336367|NCT03792165|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
48128953|NCT03794024|DEVICE|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
48128954|NCT03794024|DEVICE|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
48128955|NCT00171769|DRUG|Certoparin|
48128956|NCT00319293|DRUG|Metformin|
48128957|NCT05089461|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m\^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
48128958|NCT03214185|PROCEDURE|IVF/ICSI|in vitro fertilization or intracytoplasmatic sperm injection
48128959|NCT03214185|GENETIC|PGS 2.0|Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.
48336368|NCT05359809|BEHAVIORAL|Graspin Palmar Reflex Stimulation|The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
48494533|NCT02753491|BEHAVIORAL|Motivational short interview|New designed motivational short interview model
48494534|NCT00517179|DRUG|Vardenafil 10mg|
48128960|NCT03214185|OTHER|Conventional embryo morphology evaluation|Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
48128961|NCT04838860|DRUG|Siltuximab|Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
48494535|NCT00118131|DRUG|cisplatin|
48494536|NCT00118131|DRUG|docetaxel|
48494537|NCT00054912|BIOLOGICAL|EP2101|
48494538|NCT04450576|DIAGNOSTIC_TEST|Glycosylated hemoglobin|Glycosylated hemoglobin levels associated with correlative measures of diastolic cardiac function
48653946|NCT05888233|DRUG|Allopurinol|Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
48494539|NCT03670264|BEHAVIORAL|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
48336369|NCT05032417|OTHER|implementation of evidence-based nutrition practice guidelines|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
48336370|NCT01832857|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
48336371|NCT02582931|DEVICE|MRI-guided SBRT|
48336372|NCT02582931|BEHAVIORAL|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
48336373|NCT02582931|BEHAVIORAL|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
48336374|NCT06305026|DIAGNOSTIC_TEST|Muscle- and skin biopsies|RA patients with and without concomitant fibromyalgia will be examined with muscle and skin biopsies.
48336375|NCT01306851|DRUG|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
48336376|NCT02627833|OTHER|observation|Record lung function, Lung clearance index, inflammatory status
48494540|NCT03670264|BEHAVIORAL|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
48494541|NCT03670264|BEHAVIORAL|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
48494542|NCT03670264|BEHAVIORAL|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
48494543|NCT04321954|DRUG|LENVATINIB|Orally
48494544|NCT02534844|DRUG|Parts A/B: Adrabetadex|900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
48494545|NCT02534844|OTHER|Parts A/B: Sham Control|No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
48128962|NCT03177941|OTHER|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
48336377|NCT03117309|DRUG|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
48336378|NCT03117309|DRUG|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
48336379|NCT03117309|DRUG|Nivolumab 3mg/kg|In combination with Ipilimumab
48128963|NCT00228475|DRUG|Pulmicort (budesonide) Turbuhaler|
48336380|NCT03117309|DRUG|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
48336381|NCT00440336|DRUG|Cosopt|
48336382|NCT00440336|DRUG|Xalatan|
48336383|NCT05872256|DRUG|0.045% Tazarotene/0.01% Halobetasol Lotion|FDA approved drug for psoriasis treatment
48336384|NCT01803711|DRUG|Desvenlafaxine|
48336385|NCT01803711|DIETARY_SUPPLEMENT|Omega 3 Fatty acids|
48336386|NCT01803711|DRUG|Placebo (for Omega 3 fatty acid supplement)|
48336387|NCT06221072|DRUG|JMT103|120 mg by subcutaneous injection every 4 weeks
48336388|NCT06221072|DRUG|zoledronic acid|4 mg by intravenous drip (100mL:4mg) every 4 weeks
48336389|NCT03470311|BIOLOGICAL|Benralizumab|30mg in 1mL pre-filled syringe
48336390|NCT03470311|BIOLOGICAL|Placebo|Matched placebo (1mL) in pre-filled syringe
48336391|NCT02796612|OTHER|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
48494546|NCT05643248|DRUG|NEX-20A|Subcutaneous prolonged-release injection
48494547|NCT00548509|DRUG|Menatetrenone (Vitamin K2)|
48494548|NCT04421586|BEHAVIORAL|VISTA|VISTA will be an educational intervention.
48494549|NCT02608138|OTHER|Iodine status among portuguese school children|
48653947|NCT06640894|OTHER|MegaPower training|See arm/group descriptions
48653948|NCT06640894|OTHER|Usual Care|See arm/group descriptions
48128964|NCT06090513|COMBINATION_PRODUCT|Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation|TSO500; detect single nucleotide variants (SNV), INDELs, copy number alterations (CNAs), microsatellite instability (MSI), and tumor mutation burden (TMB) in eligible patients; ELIA software to interface clinic EMR to lab; Consultations and molecular tumor boards by molecular genetic pathologist (MGP)
48653949|NCT06640062|OTHER|Erector spinae plane block|Patients received ultrasound-guided erector spinae plane block.
48128965|NCT06090513|DIAGNOSTIC_TEST|limited genetic testing or no testing|Minimal genetic testing for eligible patients or treatment without testing
48494550|NCT03251963|DRUG|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
48494551|NCT03251963|DRUG|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
48494552|NCT01781741|COMBINATION_PRODUCT|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
48494553|NCT01781741|OTHER|quality-of-life assessment|Ancillary studies
48494554|NCT03668236|DRUG|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
48494555|NCT00004890|BIOLOGICAL|aldesleukin|
48494556|NCT00004890|DRUG|Biomed 101|
48653950|NCT06640062|OTHER|Oblique subcostal transversus abdominis plane block|Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
48653951|NCT03612531|PROCEDURE|Manual Therapy|Receive manual therapy
48653952|NCT06635226|DRUG|ID110521156|ID110521156 capsules taken orally once daily
48128966|NCT03951142|DRUG|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
48128967|NCT04379869|DRUG|NNZ-2591|Single dose of NNZ-2591
48128968|NCT04379869|DRUG|Placebo|Comparator for double-blind MAD
48128969|NCT00708045|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer to assess brain tumor metabolism
48494557|NCT00605735|DRUG|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
48653953|NCT06635226|DRUG|Placebo of 110521156|ID110521156 placebo capsules taken orally once daily
48653954|NCT02082977|DRUG|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
48653955|NCT01245023|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
48653956|NCT01245023|PROCEDURE|Placebo-surgery|skin incisions without laparoscopy or related procedures
48653957|NCT06640959|PROCEDURE|Procedure - blood, urine and stool sample collection|Samples will be collected (blood, urine, stool and optional rectal swab) at baseline (prior to the start of radiotherapy), weekly during radiotherapy for 4 weeks, 6-8 weeks and 12 weeks from start of radiotherapy, and at 6-month and 12-month follow-up appointments
48653958|NCT02302222|DEVICE|Customizable Dressing with ActiV.A.C. Therapy Unit|
48128970|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received one drain.|patients who underwent two level lumbar decompression with BESS procedure received one drain.
48494558|NCT00605735|DRUG|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
48494559|NCT04811365|OTHER|Screening|After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
48494560|NCT02390141|DRUG|ZP4207|
48494561|NCT02390141|DRUG|Placebo|
48494562|NCT00400621|DRUG|acetaminophen|
48494563|NCT04842136|OTHER|Scales and indexes|Patients with TMD regardless of diagnosis with sleep bruxism were assessed with the Jaw Function Limitations Scale (JFLS), Neck Disability Index (NDI), Pittsburgh Sleep Quality Index (PSQI), Fatigue Severity Scale (FSS), and Headache Impact Test-6 (HIT-6) scales.
48494564|NCT02351960|DRUG|Dexlansoprazole|Dexlansoprazole capsules
48653959|NCT02302222|DEVICE|Standard of Care Dressing|
48653960|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
48128971|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received two drain.|patients who underwent two level lumbar decompression with BESS procedure received two drains
48128972|NCT00246805|DEVICE|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
48128973|NCT05089266|DRUG|CAR T cells|αPD1-MSLN-CAR T Cells
48128974|NCT01557036|DEVICE|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
48128975|NCT04688060|DIAGNOSTIC_TEST|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
48128976|NCT02148185|DRUG|MT-1303|
48336392|NCT02796612|BEHAVIORAL|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
48336393|NCT02796612|BEHAVIORAL|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
48336394|NCT03638115|DEVICE|VaSecure™|Drug Coated PTA Balloon Catheter
48336395|NCT03175562|OTHER|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
48336396|NCT03175562|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
48336397|NCT06426498|DEVICE|Brainsonix Bx Pulsar machine tFUS|This is a tFUS device, delivering ultrasound at a dose within the FDA safety guidelines.
48494565|NCT01948986|DRUG|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
48494566|NCT05492253|OTHER|Infant fruit|Infants will be fed prune puree
48494567|NCT05492253|OTHER|Infant vegetable|Infants will be fed carrot puree
48128979|NCT02523170|DEVICE|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
48128980|NCT03877016|PROCEDURE|TENS|TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
48128981|NCT02136641|DRUG|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
48128982|NCT02136641|DRUG|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
48128983|NCT02136641|DRUG|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
48266537|NCT01069445|DIETARY_SUPPLEMENT|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
48266538|NCT01069445|DIETARY_SUPPLEMENT|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
48266539|NCT01069445|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad ...) and a large glass of water
48266540|NCT01069445|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
48266541|NCT04181879|BEHAVIORAL|Intervention|"* GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~* The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~* GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste')."
48266542|NCT00508391|DEVICE|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
48266543|NCT06429930|DRUG|L608 Liposomal inhalation solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
48266544|NCT06429930|DRUG|Placebo Solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
48266545|NCT00121628|DRUG|AMG 706|
48266546|NCT06177366|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be collected at diagnosis, in the same time as BOM is performed
48266547|NCT05322213|DRUG|THC|2-Week, once daily, flexible dose, inhaled THC
48266548|NCT05322213|DRUG|Placebo|2-Week, once daily, flexible dose, inhaled placebo
48266549|NCT04928261|DRUG|Trastuzumab|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery will be treated with HER2 targeted therapy for a total of 9 treatments every 3 weeks (or its equivalent if given weekly) including the treatment received preoperatively.
48266550|NCT03072160|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.
48336398|NCT04089436|DIAGNOSTIC_TEST|CSF sampling|CSF sampling by lumbar puncture
48336399|NCT04089436|DIAGNOSTIC_TEST|Blood sampling|Blood sampling by blood test
48128984|NCT01503372|DRUG|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
48128985|NCT01503372|DRUG|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
48128986|NCT01819571|DRUG|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
48128987|NCT00328692|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
48128988|NCT00328692|DRUG|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
48128989|NCT05631808|OTHER|Epicardial adipose tissue volume and attenuation|Epicardial adipose tissue volume and attenuation assessed by CT are the exposure factors in this study.
48128990|NCT00571298|PROCEDURE|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
48128991|NCT00571298|DRUG|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
48128992|NCT00571298|DRUG|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
48128993|NCT00571298|DRUG|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
48128994|NCT00571298|DRUG|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
48128995|NCT00571298|PROCEDURE|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
48128996|NCT03035851|BEHAVIORAL|Aerobic exercise|
48336400|NCT04089436|DIAGNOSTIC_TEST|Nasopharyngeal and rectal sampling|Nasopharyngeal and rectal sample by swabbing
48336401|NCT04914871|BEHAVIORAL|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
48336402|NCT04914871|BEHAVIORAL|Educational session accident prevention and wound management|It will be provided to the control group
48336403|NCT01457924|DRUG|Ofatumumab 3mg|3mg of investigational product
48336404|NCT01457924|DRUG|Ofatumumab 30mg|30mg of investigational product
48336405|NCT01457924|DRUG|Ofatumumab 60mg|60mg of investigational product
48336406|NCT01457924|DRUG|Placebo|Placebo
48336407|NCT01915017|BEHAVIORAL|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
48128997|NCT03035851|BEHAVIORAL|Stretch and Strength|
48128998|NCT01953224|BEHAVIORAL|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
48653961|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
48336408|NCT01915017|BEHAVIORAL|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
48653962|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers earned independent of cocaine use
48653963|NCT01000116|PROCEDURE|Fibrin glue|Tissucol 2 ml
48128999|NCT01953224|DEVICE|Smartphone|
48336409|NCT01915017|BEHAVIORAL|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
48336410|NCT01915017|OTHER|Treatment as Usual|Standard medication follow up and limited case management
48336411|NCT05466981|BEHAVIORAL|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
48653964|NCT01000116|PROCEDURE|Tacks|Protacks
48653965|NCT05059327|DRUG|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
48653966|NCT05059327|DRUG|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
48653967|NCT04478890|DIAGNOSTIC_TEST|Hemodynamic assessment|Hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter
48653968|NCT05175001|DRUG|Diprospan|Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
48129000|NCT02118870|DRUG|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
48129001|NCT02118870|DRUG|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
48129002|NCT00948168|DRUG|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
48129003|NCT02907905|BIOLOGICAL|capillary sampling|"After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results"
48129004|NCT02955407|OTHER|no intervention|observational case-control study
48129005|NCT06145932|DEVICE|real rTMS|treated with 1HZ rTMS 1800 pulses / day,for 10 days
48129006|NCT06145932|DEVICE|sham rTMS|treated with sham rTMS 1800 pulses / day,for 10 days
48129007|NCT01577524|DRUG|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
48336412|NCT00987610|DEVICE|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
48494568|NCT05492253|OTHER|Infant meat|Infants will be fed beef puree
48653969|NCT05175001|DRUG|Ropivacaine|Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block
48494569|NCT05492253|OTHER|Infant grain|Infants will be fed oatmeal cereal
48494570|NCT03911518|PROCEDURE|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
48494571|NCT03911518|PROCEDURE|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
48494572|NCT03446911|RADIATION|SABR|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
48494573|NCT03446911|COMBINATION_PRODUCT|SABR + pembrolizumab|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
47977341|NCT01606930|BEHAVIORAL|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
47977342|NCT00462267|BEHAVIORAL|Enriched lifestyle intervention|Multi-component lifestyle intervention
47977343|NCT00468689|DRUG|SB-751689 oral tablets (100 and 400 ng)|
47977344|NCT00468689|DRUG|Ketoconazole (NIZORAL) oral tablets (200 mg)|
47977345|NCT03233503|DIAGNOSTIC_TEST|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
47977346|NCT03142568|DRUG|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
47977347|NCT03142568|OTHER|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
47977348|NCT00694993|DRUG|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
47977349|NCT00694993|DRUG|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
47977350|NCT00811538|PROCEDURE|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
47977351|NCT00811538|PROCEDURE|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
47977352|NCT00160251|DRUG|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
47977353|NCT00160251|BIOLOGICAL|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
47977354|NCT00160251|DRUG|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
47977355|NCT03900078|OTHER|Incisional negative pressure wound therapy|A negative pressure dressing is applied to the skin incision.
47977356|NCT03900078|OTHER|Wound dressing with adhesive tapes|Regular adhesive wound tapes are applied over the closed skin.
47977357|NCT00666627|DRUG|Ibandronate|once monthly
47977358|NCT00666627|DRUG|Risedronate|Risedronate 35mg once weekly
48129008|NCT01577524|DRUG|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
48129009|NCT01170624|DEVICE|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
48129010|NCT03322124|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
48129011|NCT03322124|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
48266551|NCT04523532|OTHER|Dietary folate and hazelnut oil|Intervention with folate-rich diet and hazelnut oil supplement in capsule
48266552|NCT02688348|OTHER|Quality-of-Life Assessment|Ancillary studies
48336413|NCT05376527|BIOLOGICAL|Double Recombinant Vaccinia Virus VV-GMCSF-Lact|"Intratumoral injections:~1\*107 PFU (calculated at minimal ED on mice); 2\*107 PFU; 4\*107 PFU; 6\*107 PFU; 8\*107 PFU; 10\*107 PFU;"
48336414|NCT04898894|DRUG|Venetoclax|Given orally (PO)
48336415|NCT04898894|DRUG|Selinexor|Given Orally (PO)
48336416|NCT04898894|DRUG|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
48653970|NCT05879055|DRUG|PM8002|IV infusion
48653971|NCT05879055|DRUG|FOLFIRI|IV infusion
48653972|NCT00576745|PROCEDURE|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
48653973|NCT00576745|DEVICE|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
47977359|NCT00666627|DRUG|Alendronate|Alendronate 70mg once weekly
48129012|NCT04579250|BIOLOGICAL|VRC-FLUNPF0103-00-VP (H10ssF-6473)|The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
48129013|NCT05835375|OTHER|EQ-778|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
48336417|NCT04898894|DRUG|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
48653974|NCT03093415|DRUG|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
48653975|NCT05437055|DEVICE|Mechanical Thrombectomy (Penumbra System with Thunderbolt)|Subject will receive Penumbra System with Thunderbolt
48653976|NCT01927848|DIETARY_SUPPLEMENT|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
48653977|NCT01927848|DIETARY_SUPPLEMENT|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
48653978|NCT05998759|BIOLOGICAL|Telitacicept|subcutaneous telitacicept 160 mg weekly for 24 weeks.
48653979|NCT05998759|DRUG|Placebo|subcutaneous placebo weekly for 24 weeks.
47977360|NCT03529916|OTHER|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
47977361|NCT01516697|PROCEDURE|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
47977362|NCT01516697|PROCEDURE|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
48129014|NCT05835375|OTHER|Placebo|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
48336418|NCT04898894|BIOLOGICAL|Filgrastim|Given subcutaneous (SubQ, SC)
48336419|NCT04898894|DRUG|Methotrexate|Given intrathecal (IT)
48336420|NCT04898894|DRUG|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
47977363|NCT03651921|BEHAVIORAL|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
47977364|NCT00656110|DRUG|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
48336421|NCT01471639|DRUG|intranasal ketorolac|15 mg
48336422|NCT02251158|DRUG|Tipranavir oral solution|
48336423|NCT02251158|DRUG|Tipranavir capsules|
48336424|NCT02251158|DRUG|Ritonavir oral solution|
48336425|NCT02251158|DRUG|Ritonavir soft gel capsules|
48336426|NCT02251158|OTHER|High fat breakfast|
48336427|NCT00796003|DRUG|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
48336428|NCT00796003|DRUG|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
48336429|NCT01645865|BEHAVIORAL|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
48336430|NCT01645865|BEHAVIORAL|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
48336431|NCT02785991|PROCEDURE|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
48336432|NCT03771807|DIETARY_SUPPLEMENT|Beauty From Within|one scoop of product mixed in 8-16 ounces of water consumed once daily
48336433|NCT03771807|OTHER|Placebo|one scoop of product mixed in 8-16 ounces of water consumed once daily
48653980|NCT01484756|DIETARY_SUPPLEMENT|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
48653981|NCT01484756|DIETARY_SUPPLEMENT|Placebo|calcium carbonate 500 mg
48653982|NCT06501313|DEVICE|Photobiomodulation|Soft laser therapy
48336434|NCT03771807|OTHER|Facial cleansing|All subjects will use a cosmetic instrument to clean on one half of their face daily
48336435|NCT04486989|BEHAVIORAL|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
48494574|NCT04736043|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
48494575|NCT00370357|DRUG|3% w/w SPL7013 Gel (VivaGel™)|
48653983|NCT05833542|BEHAVIORAL|Health education materials|Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.
48653984|NCT05833542|BEHAVIORAL|Patient-provider decision tool|Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
48129015|NCT00176202|DRUG|Divalproex Sodium|Divalproex sodium is a mood stabilizer
48129016|NCT00176202|DRUG|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
48653985|NCT03202303|DRUG|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
48653986|NCT03202303|DRUG|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
48129017|NCT03947216|DRUG|Active drug: pimavanserin 17mg (2 strength tablets)|Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
48129018|NCT03947216|DRUG|Placebo: 2 tablets containing same excipients except active compound|Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
48266553|NCT02688348|OTHER|Questionnaire Administration|Ancillary studies
48266554|NCT04039997|DEVICE|CPRMeter|teaching resuscitation with application of cpr feedback device
48336436|NCT04486989|OTHER|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
48336437|NCT02458677|DRUG|PRX003|
48336438|NCT02458677|OTHER|Placebo|
48336439|NCT04591145|OTHER|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
48336440|NCT05793957|OTHER|Questionnaire Administration|Ancillary studies
48336441|NCT05793957|BEHAVIORAL|Telephone-Based Intervention|Use smartphone
48336442|NCT05793957|OTHER|Virtual Technology Intervention|Use VR headset
48653987|NCT04383639|OTHER|No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)|The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
48336443|NCT06506838|DRUG|Anlotinib|For patients with the soft tissue sarcoma, the standard doxorubicin monotherapy regimen involves administering 37.5 mg/m² intravenously on days 1-2 of every 3 week . The treatment includes 3 cycles of neoadjuvant chemotherapy before surgery and 3 cycles of adjuvant chemotherapy after surgery, totaling 6 cycles. Anlotinib is administered at 12mg/d QD，day1\~14, 21d/cycle. Neoadjuvant radiotherapy is conducted before surgery, starting after the second chemotherapy cycle, using stereotactic body radiation therapy (SBRT) with a dose of 4\*10 Gy. Radical resection surgery is performed after the third chemotherapy cycle.
48336444|NCT00602771|DRUG|tipifarnib|Given orally
48336445|NCT00602771|DRUG|etoposide|Given orally
48336446|NCT03536650|DEVICE|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
48494576|NCT01517659|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
48653988|NCT06641778|OTHER|Fecal Microbiota Transplantation|Patients in the experimental group received conventional antibiotic therapy plus fecal microbiota transplantation, and the efficacy was compared with that in the control group
48653989|NCT04875754|GENETIC|ICM-203|Intra-articular injection
48653990|NCT04875754|DRUG|Placebo|Intra-articular injection
48653991|NCT01045733|DEVICE|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
48653992|NCT01045733|DEVICE|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
48653993|NCT01045733|PROCEDURE|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
48653994|NCT05442047|DRUG|NNC6019-0001|Participants will receive i.v infusionof NNC6019-0001.
48653995|NCT05442047|DRUG|Placebo (NNC6019-0001)|Participants will receive i.v. infusion of placebo (NNC6019-0001).
48653996|NCT04111536|DRUG|liothyronine|Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
48653997|NCT04111536|OTHER|Placebo|Each treatment period of placebo was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - LT3.
48653998|NCT04106635|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
48653999|NCT04106635|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
48654000|NCT06572774|BEHAVIORAL|C3Link Strategies|Education sessions and community liaison support to link to services
48654001|NCT04456673|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48654002|NCT04456673|DRUG|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
48654003|NCT04456673|DRUG|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
48654004|NCT04456673|DRUG|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
48654005|NCT04456673|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48654006|NCT06088043|DRUG|TAK-279|Specified drug on specified days.
48654007|NCT06088043|DRUG|Placebo|Specified drug on specified days.
48266555|NCT04039997|OTHER|Manual chest compression|Manual chest compression
48266556|NCT02069002|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
48266557|NCT02069002|BEHAVIORAL|Applied relaxation group therapy|
48266558|NCT02069002|BEHAVIORAL|Information session (psychoeducation)|
48266559|NCT05488860|DRUG|Triamcinolone acetonide(scar)/5-ALA(others)|For scar, the drug is triamcinolone acetonide.
48266560|NCT05488860|PROCEDURE|Piezoelectric drived microneedling|Piezoelectric drived microneedling
48266561|NCT05488860|DRUG|5-ALA (a photosensitizer for photodynamic therapy).|For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
48266562|NCT01515033|OTHER|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
48654008|NCT06088043|DRUG|Apremilast|Specified drug on specified days.
48654009|NCT04681885|DEVICE|Tapered bristles A|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .
48654010|NCT04681885|DEVICE|Tapered bristles B|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
48129019|NCT03947216|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
48129020|NCT03947216|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
48129021|NCT03947216|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
48129022|NCT03947216|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
48129023|NCT03947216|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
48129024|NCT03947216|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
48129025|NCT03947216|PROCEDURE|Blood analysis|Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
48129026|NCT03947216|PROCEDURE|Cardiac monitoring|Electrocardiogram will be realized at day 0, 28 and 56.
48129027|NCT04905797|DIAGNOSTIC_TEST|Emotional Stop Signal Task|Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.
48129028|NCT04905797|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
48129029|NCT04905797|OTHER|World Health Organizations Disability Assessment Schedule (WHODAS 2.0)|Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
48129030|NCT04905797|DIAGNOSTIC_TEST|Personality Inventory for DSM-5 (PID-5)|Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
48336447|NCT01822223|DEVICE|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
48129031|NCT04905797|DIAGNOSTIC_TEST|Stop Signal Task (CANTAB)|The estimate of time where an individual can successfully inhibit their responses 50% of the time.
48129032|NCT04905797|DIAGNOSTIC_TEST|Intra-Extra Dimensional Set Shift (CANTAB)|"1. The number of trials for which the outcome was an incorrect response (subject pressed the incorrect button within the response window), calculated across all assessed trials.~2. The total number of times that the subject chose a wrong stimulus - i.e. one incompatible with the current rule, adjustment for every stage that was not reached."
48654011|NCT04681885|DEVICE|End rounded bristles|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
48129033|NCT04905797|DIAGNOSTIC_TEST|Spatial Working Memory Test (CANTAB)|"1. The number of times the subject incorrectly revisits a box in which a token has previously been found. Calculated across all assessed four, six and eight token trials.~2. The number of times a subject begins a new search pattem from the same box they started with previously. If they always begin a search from the same starting point, we infer that the subject is employing a planned strategy for finding the tokens. Therefore, a low score indicates high strategy use (1 = they always begin the search from the same box), a high score indicates that they are beginning their searches from many different boxes. Calculated across assessed trials with 6 tokens or more."
48654012|NCT00336063|DRUG|Azacitidine|Given SC
48654013|NCT00336063|OTHER|Laboratory Biomarker Analysis|Correlative studies
48654014|NCT00336063|OTHER|Pharmacological Study|Correlative studies
48654015|NCT00336063|DRUG|Vorinostat|Given PO
48654016|NCT00020176|BIOLOGICAL|filgrastim|
48654017|NCT00020176|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48654018|NCT00020176|DRUG|cyclophosphamide|
48654019|NCT00020176|DRUG|cyclosporine|
48654020|NCT00020176|DRUG|fludarabine phosphate|
48654021|NCT00020176|PROCEDURE|peripheral blood stem cell transplantation|
48336448|NCT00105209|DRUG|Aspirin|
48336449|NCT00105209|DRUG|clopidogrel|
48336450|NCT00047008|DRUG|cisplatin|100 mg/m\^2 intravenously on days 1, 22
48336451|NCT00047008|RADIATION|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
48336452|NCT00047008|RADIATION|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
48336453|NCT00047008|PROCEDURE|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
48336454|NCT00398307|DRUG|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:~Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD~Pharmacokinetic Phase (Part 1):~On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.~Treatment will be followed by 1 week of recovery (Days 15 through 21).~Extension Phase (Part 2):~S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
48336455|NCT03518489|DRUG|Lappaconitine Adhesive Patch|to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
48336456|NCT03518489|DRUG|standard care|Standard care will include mouth wash with antibiotics.
48336457|NCT04516577|OTHER|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
48336458|NCT02169713|DRUG|Mirabegron|Oral
48336459|NCT02169713|DRUG|Solifenacin succinate|Oral
47977365|NCT00656110|DRUG|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
47977366|NCT01474057|BEHAVIORAL|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
47977367|NCT01474057|OTHER|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
48336460|NCT02169713|DRUG|Tamsulosin HCl|Oral
48336461|NCT02169713|DRUG|Placebo|Oral
48336462|NCT00651313|DRUG|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
48336463|NCT00651313|DRUG|Placebo|Placebo vaginal gel administered once daily for 4 days
48336464|NCT00048009|DRUG|Dual Integrin Antagonist|
47977368|NCT03353493|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams \& Teasdale (2013).
48336465|NCT05808023|OTHER|FODMAP powder reintroduction|The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
48336466|NCT01567423|DRUG|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
48336467|NCT01567423|DRUG|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~1. tab/dose for children 5 to 14.9 kg (total 6 tabs)~2. tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
48494577|NCT00425334|DRUG|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
48494578|NCT00425334|DRUG|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
48494579|NCT02433054|DEVICE|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
47977369|NCT03353493|OTHER|TAU|Treatment as usual (TAU)
47977370|NCT03907553|DIAGNOSTIC_TEST|targeted genome sequencing|
47977371|NCT02170051|BEHAVIORAL|CBSST-CCT|
47977372|NCT02170051|BEHAVIORAL|Goal focused supportive contact|
48336468|NCT03625089|DRUG|Atorvastatin|"Group 1 patients will be prescribed statin when FRS \> 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS\>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
47977373|NCT01244425|DRUG|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
47977374|NCT01244425|OTHER|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
48654022|NCT02398799|BEHAVIORAL|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
48654023|NCT03527979|PROCEDURE|IVF/ICSI|IVF/ICSI
47977375|NCT02365090|OTHER|patching|covering the sound eye with a patch to force use of the amblyopic eye
47977376|NCT02365090|OTHER|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
47977377|NCT02813564|BEHAVIORAL|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
47977378|NCT01494194|OTHER|Air Structuring Protein|A novel food protein preparation
47977379|NCT01494194|OTHER|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
47977380|NCT04443725|DRUG|Hydroxychloroquine , Sofosbuvir, daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.
48494580|NCT00858962|DRUG|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
48494581|NCT00521027|DEVICE|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
47977381|NCT04443725|DRUG|Standard of care treatment|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
47977382|NCT06428669|DRUG|Nitro-Bid 2 % Topical Ointment|Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
47977383|NCT02520076|DRUG|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14"
48494582|NCT00521027|PROCEDURE|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
48494583|NCT00039962|DRUG|thymalfasin (thymosin alpha 1)|
48494584|NCT00039962|DRUG|PEGinterferon alfa-2a|
48494585|NCT03041649|OTHER|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
48654024|NCT05335057|BEHAVIORAL|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
48654025|NCT05335057|BEHAVIORAL|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
48654026|NCT05335057|BEHAVIORAL|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
48494586|NCT03041649|OTHER|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
48494587|NCT02807168|OTHER|NT-proBNP (Cardiac Biomarkers)|
48494588|NCT02434432|BEHAVIORAL|music therapy selected by mothers|mothers' choice of music
48494589|NCT02434432|BEHAVIORAL|Music therapy recorded lullaby|recorded lullaby
48494590|NCT04016792|DRUG|Placebo|Placebo will be administered once daily
48336469|NCT06211452|DRUG|ARM A: Active Comparator Drug|Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8, 15, 22; cytarabine 75 mg/m2/d, on days 3-6, 10-13, 17-20, 24-27, 31-34, 38-41; intrathecal cytarabine on days 1, 15, 29, 43; cyclophosphamide 500 mg/m2/d, days 29, 43.
48336470|NCT06211452|DRUG|ARM B: Blocks Therapy Drug|"Blocks AI Cytarabine 500 mg/m2 as 24 infusion infusion x 4 d; Idarubicin 7 mg/m2 on days 3 and 5; Intrathecal cytarabine on days 0 and 6.~haM Cytarabine 1 g/m2 every 12 hours for 3 days; Mitoxantrone 10 mg/m2 days 4 and 5; Intrathecal cytarabine days 6 and 15."
48336471|NCT02052141|BIOLOGICAL|CINRYZE 500|500 Units of CINRYZE administered by IV injection
48336472|NCT02052141|BIOLOGICAL|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
47977384|NCT01384253|OTHER|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
47977385|NCT01384253|BIOLOGICAL|trastuzumab|4 mg/kg.
48336473|NCT00953004|DIETARY_SUPPLEMENT|fiber drink and fiber bread|fiber drink or fiber bread three times daily
48336474|NCT01221818|DRUG|E6007|E6007 25mg single dose or matching placebo
48336475|NCT01221818|DRUG|E6007|E6007 50mg single dose or matching placebo
47977386|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
47977387|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
47977388|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
47977389|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
47977390|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
48336476|NCT01221818|DRUG|E6007|E6007 100mg single dose or matching placebo
48336477|NCT01221818|DRUG|E6007|E6007 200mg single dose or matching placebo
47977391|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
47977392|NCT00599924|DRUG|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
48129034|NCT04905797|DIAGNOSTIC_TEST|Multitasking Test (CANTAB)|"1. The number of trials for which the outcome was an incorrect response.~2. The median latency of response (from stimulus appearance to button press). Calculated across all correct, assessed trials.~3. The difference between the median latency of response on the trials that were congruent versus the trials that were incongruent. A positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials. A higher incongruency cost indicates that the subjects take longer to process conflicting information.~4. The difference between the median latency of response during assessed blocks in which both rules are used versus assessed blocks in which only a single rule is used. A positive score indicates that the subject responds more slowly during multitasking blocks and indicates a higher cost of managing multiple sources of information."
48336478|NCT01221818|DRUG|E6007|E6007 400mg single dose or matching placebo
48336479|NCT01221818|DRUG|E6007|E6007 600 mg single dose or matching placebo
48336480|NCT05653856|DRUG|64Cu-PSMA I&T|Radiolabeled Receptor-Targeted Diagnostic Product
48336481|NCT00385034|DEVICE|Interactive computer based health-risk survey before doctor's visit|
48336482|NCT02920281|OTHER|Polysomnography|
48336483|NCT02565446|PROCEDURE|Magnetic Resolution Elastography (MRE)|Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
48336484|NCT06200285|OTHER|Registry of patients with accidental hypothermia|
48336485|NCT02150512|DEVICE|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV \>10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still \>10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
48336486|NCT02150512|DEVICE|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
47977393|NCT00395369|DRUG|intraoperative aprotinin administration|
47977394|NCT03111602|OTHER|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
47977395|NCT01450436|OTHER|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
47977396|NCT05506085|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of Globus Pallidus interna
47977397|NCT04557397|DRUG|Fruquintinib|oral VEGFR inhibitor
47977398|NCT04557397|DRUG|Itraconazole|a synthetic triazole antifungal agent
47977399|NCT04557397|DRUG|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
47977400|NCT04430543|BEHAVIORAL|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
48336487|NCT03825510|RADIATION|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to \<=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
48336488|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy and Famitinib|camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
48336489|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy|Camrelizumab Plus Chemotherapy
48494591|NCT04016792|DRUG|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
48494592|NCT01333891|DRUG|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
47977401|NCT04430543|BEHAVIORAL|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
48336490|NCT01930240|DRUG|TRIA-662|1-MNA Chloride
48336491|NCT01930240|DRUG|Placebo|Double-blind placebo
48336492|NCT03287869|DRUG|Brexpiprazole|Brexpiprazole tablets
48336493|NCT04977973|BEHAVIORAL|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
48336494|NCT04977973|BEHAVIORAL|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
48494593|NCT01333891|DRUG|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
48494594|NCT01333891|DEVICE|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
47977402|NCT01119612|DIETARY_SUPPLEMENT|Iron|Daily oral dose of 60 mg from enrollment until delivery
48129035|NCT04905797|DIAGNOSTIC_TEST|Cambridge Gambling Task Test|"1. The proportion (0 - 1) of all trials where the subject chose the majority box color. Calculated over all assessed trials from both the ascending and descending conditions in which the number of boxes of each color differed.~2. Risk adjustment is a measure of sensitivity to risk, based on the ability to modify choices in the light of information about the probability of different outcomes and to track the optimal outcome on eaeh trial. The measure is calculated from the average proportion of points that the subject ehose to bet with, taking into aeeount the number of colored boxes in the majority.~3. Allows for the dissociation between risk taking and impulsivity by determining whether subjects simply just place a bet at the first opportunity. Calculated as CGT Risk Taking for all trials from the descending condition minus CGT Risk Taking for all trials from the ascending condition."
48129036|NCT05611060|BEHAVIORAL|Building Healthy Life Skills Program|The intervention provides education and training in the long-term mental and physical health consequences of childhood adversity and emotion regulation skills.
48129037|NCT04316936|DRUG|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
48129038|NCT04316936|DRUG|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
48129039|NCT04316936|DRUG|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
48129040|NCT04316936|DRUG|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
48129041|NCT03861052|DRUG|Tirzepatide|Administered SC
48494595|NCT01333891|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
48494596|NCT01333891|DEVICE|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
48494597|NCT02669758|DRUG|ALKS 3831|Tablets were administered for daily dosing
48494598|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
48494599|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
48129042|NCT03861052|DRUG|Dulaglutide|Administered SC
48336495|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
48494600|NCT01401621|BEHAVIORAL|Control|No scratch-off element
47977403|NCT01119612|OTHER|Placebo|Daily oral dose from enrollment until delivery
47977405|NCT05004610|DRUG|Sodium Lactate Solution|continuous intravenous infusion of half-molar sodium lactate
48129043|NCT03987243|BEHAVIORAL|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
48336496|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
48336497|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
48336498|NCT01579149|DRUG|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
48336499|NCT01579149|DRUG|Placebo|Single subcutaneous (SC) dose of placebo
48336500|NCT02360371|DRUG|Within-subject test of blinded study medication|Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
48494601|NCT00523224|PROCEDURE|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
48494602|NCT00523224|BIOLOGICAL|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
48494603|NCT05922475|DIETARY_SUPPLEMENT|Protein|"Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep."
48654027|NCT05335057|BEHAVIORAL|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
47977406|NCT03483051|DRUG|Potassium Nitrate|Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
48336501|NCT01599806|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
48336502|NCT01599806|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
48494604|NCT05922475|OTHER|Placebo|Resistance exercise training only group did not consume supplemental protein.
48494605|NCT02700711|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
48494606|NCT02700711|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
48494607|NCT02700711|DRUG|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
48494608|NCT00200759|DRUG|Cranberry juice and capsules|
48494609|NCT01660399|DRUG|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
48494610|NCT01660399|DRUG|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
48654028|NCT01755403|DRUG|Benznidazole|
48654029|NCT00000845|BIOLOGICAL|P3C541b Lipopeptide|
48494611|NCT00319982|DRUG|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
48494612|NCT00319982|DRUG|Placebo|Placebo comparator (double-blind allocation of study medication)
48494613|NCT02235038|BEHAVIORAL|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
48494614|NCT02235038|BEHAVIORAL|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
48494615|NCT02235038|BEHAVIORAL|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
48494616|NCT00058721|DRUG|I-123-5-IA85380|
48494617|NCT03025490|DEVICE|Capnographic monitoring|Capnographic monitoring is used during the sedation.
48494618|NCT01936623|BEHAVIORAL|Computerized Brief Intervention|No additional information needed.
48494619|NCT01182558|OTHER|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
48336503|NCT01599806|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
48336504|NCT01599806|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
48336505|NCT02427100|BEHAVIORAL|Diet/Physical Activity|Diet/Physical Activity Intervention
48336506|NCT01209975|PROCEDURE|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
47977407|NCT03483051|DRUG|Potassium Chloride|Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
47977408|NCT03073044|DIAGNOSTIC_TEST|BELASTUNGSFRAGEBOGEN PARKINSON KURZVERSION (BELA-P-K)|"we proposed the translation and validation of Bela-p-K, a questionnaire that evaluates the Quality of Life in parkinsonian patients.~we applied the method of translation and back-translation at dutch version of questionnaire. after, we evaluated 103 PD patients with Bela-p-K and PDQ39.~The internal consistency of questionnaire was analyzed calculating alpha-Chronbach. We also evaluated the construct validity correlating Bela-p-K and PDQ39"
47977409|NCT01463540|DEVICE|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
47977410|NCT01463540|DEVICE|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
47977411|NCT05448833|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
47977412|NCT02206568|DRUG|URAL|
47977413|NCT00642577|DRUG|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
47977414|NCT00642577|DRUG|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
47977415|NCT00642577|DRUG|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
47977416|NCT00642577|DRUG|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
48129044|NCT03987243|OTHER|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
48494620|NCT01182558|OTHER|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
47977417|NCT05604092|DIAGNOSTIC_TEST|VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.
47977418|NCT05604092|OTHER|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR
47977419|NCT03369392|OTHER|Panda application|A smartphone-based postoperative pain management tool
47977420|NCT00380757|PROCEDURE|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
48336507|NCT03380507|DRUG|Triple therapy group|Refer to arms description
48336508|NCT02228824|DRUG|Very low nicotine content cigarettes|0.07 mg nicotine delivery
48336509|NCT02228824|DRUG|Normal nicotine content cigarettes|0.8 mg nicotine delivery
47977421|NCT04355845|DRUG|Sumatriptan|25 milligrams (mg) single dose tablet
47977422|NCT04355845|DRUG|PF-06651600|PF-06651600 400 mg single dose
48129045|NCT02103361|DRUG|Ustekinumab|
48129046|NCT02103361|DRUG|Guselkumab|
48129047|NCT02967861|BEHAVIORAL|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
48129048|NCT02967861|PROCEDURE|Scaling and root planing|It is a mechanical debridement of dental plaque.
48336510|NCT05210972|RADIATION|Cardiac catheterization|All the study population will be exposed to diagnostic coronary angiography and invasive coronary intervention as per standard guidelines.
48336511|NCT04460248|DRUG|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
48336512|NCT00305812|DRUG|dexamethasone|
48336513|NCT00305812|DRUG|lenalidomide|
48336514|NCT00305812|DRUG|melphalan|
48654030|NCT01182246|DRUG|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
48654031|NCT05787041|OTHER|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
48654032|NCT05787041|OTHER|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
47977423|NCT00679302|DRUG|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
47977424|NCT00679302|DRUG|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
47977425|NCT06158789|PROCEDURE|MR guided low intensity focused ultrasound|Low intensity focused ultrasound opens the blood brain barrier
47977426|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
47977427|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
47977428|NCT01596868|DRUG|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
47977429|NCT01596868|DRUG|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
47977430|NCT06026761|DEVICE|Skiin garment and pods|"Participants will be asked to wear two pieces of equipment to record physiological data:~1. A Skiin garment that contains IMU and ECG sensors~2. A Cosmed K5 metabolic cart that will record breathing rate data~Participants will then be asked to perform various tasks of daily living (e.g. watching TV, sweeping the floor), general strength exercises (e.g. squats, triceps dips, lunges), and aerobic exercises (e.g. walking, running) as instructed by researchers"
47977431|NCT03673553|OTHER|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
48129049|NCT02848105|DRUG|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
48129050|NCT04840433|DEVICE|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
48129051|NCT03340909|DRUG|Prednisolone|Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
48336515|NCT03295604|PROCEDURE|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
48336516|NCT03295604|PROCEDURE|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
48336517|NCT00000339|DRUG|Risperidone|
48494621|NCT01182558|OTHER|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
48129052|NCT03340909|OTHER|Placebo|Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
48129053|NCT03985774|PROCEDURE|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
48129054|NCT00144066|DRUG|platinum-based chemotherapy alone (up to six cycles)|
48129055|NCT00144066|DRUG|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
48129056|NCT06505954|OTHER|Survey study|Survey study among medical students about lower urinary tract symptoms
48129057|NCT02972788|DRUG|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
48129058|NCT02972788|OTHER|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
48129059|NCT01291628|DEVICE|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
48494622|NCT01182558|OTHER|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
48494623|NCT04191837|OTHER|Self-administered acupressure treatment group|Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
48494624|NCT04191837|OTHER|Knee health education control group|Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
48494625|NCT01884662|BEHAVIORAL|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
48494626|NCT01884662|BEHAVIORAL|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
48494627|NCT04688931|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
48494628|NCT04688931|PROCEDURE|TURBT|The current standard of care for treatment of LG-IR-NMIBC is TURBT under general anesthesia.
48129060|NCT02394106|DRUG|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
48129061|NCT02394106|OTHER|Placebo|Normal saline, 1000 ml, administered once
48129062|NCT02023866|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
48336518|NCT05320328|DEVICE|Radio frequency ablation|Radiofrequency ablation (RFA) uses heat to kill cancer cells. High-frequency electrical currents are passed through a special needle or probe called a needle electrode. The electrical current from the probe heats a small area containing cancer cells to high temperatures, killing the cancer cells. The area around the tumour is also usually treated because it may contain cancer cells.
48494629|NCT03842813|DEVICE|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
48494630|NCT00132171|DRUG|Sequential therapy|
48654033|NCT00833703|DRUG|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
48129063|NCT04802018|DEVICE|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
48129064|NCT01805219|OTHER|GPS and accelerometer recording (s) during exercises|
48336519|NCT00838370|DRUG|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD\*2A. Patients heterozygous or homozygous mutant for DPYD\*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
48336520|NCT02384304|BEHAVIORAL|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
48336521|NCT02384304|BEHAVIORAL|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
48336522|NCT02384304|BEHAVIORAL|Self help|A self help program consisting of 8 modules
48336523|NCT01512472|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
48129065|NCT03064594|PROCEDURE|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
48336524|NCT05119088|OTHER|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
48336525|NCT03491930|DEVICE|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
48336526|NCT03491930|BEHAVIORAL|Telephone Coaching|Weekly Telephone Coaching
48494631|NCT02208674|OTHER|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
48494632|NCT01211080|DRUG|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
48494633|NCT04100174|RADIATION|focal brachytherapy boost to SBRT|As above
48494634|NCT04832321|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
48494635|NCT05697926|OTHER|No intervention|This is a preclinical study. No intervention will be performed.
48494636|NCT06132217|DRUG|Simmitinib|Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
48654034|NCT00833703|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
48336527|NCT03491930|BEHAVIORAL|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)"
48336528|NCT04521920|DRUG|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
48336529|NCT04521920|DRUG|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
48336530|NCT03235726|DRUG|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
48129066|NCT01964534|DRUG|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
48129067|NCT01964534|DRUG|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
48336531|NCT03235726|DRUG|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
48336532|NCT00004360|DRUG|chlorothiazide|
48336533|NCT00014170|DRUG|gefitinib|Given orally
47977432|NCT03673553|OTHER|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
48129068|NCT01964534|DRUG|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
48336534|NCT00014170|OTHER|pharmacological study|Correlative studies
48129069|NCT02675244|PROCEDURE|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
48336535|NCT00014170|OTHER|laboratory biomarker analysis|Correlative studies
47977433|NCT00634894|DRUG|Femara|2.5 mg by mouth daily x 12 weeks
47977434|NCT00634894|DRUG|Placebo|Placebo capsule by mouth daily x 12 weeks
48129070|NCT02675244|PROCEDURE|MVS|MVS will be performed using standard surgical techniques
48129071|NCT02285270|DEVICE|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
48336536|NCT00014170|OTHER|questionnaire administration|Ancillary studies
48336537|NCT00014170|PROCEDURE|quality-of-life assessment|Ancillary studies
48336538|NCT00317876|DRUG|cyclophosphamide|
48654035|NCT02951819|DRUG|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
48654036|NCT02951819|DRUG|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
48654037|NCT02951819|DRUG|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
48129072|NCT04876495|DIETARY_SUPPLEMENT|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~* Tropicana Trop50 Orange Juice 207mL~* Water 43 mL~* Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
48129073|NCT04876495|DIETARY_SUPPLEMENT|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~* Tropicana Trop50 Orange Juice 250mL~* Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
48129074|NCT04876495|DIETARY_SUPPLEMENT|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~* Tropicana Trop50 Orange Juice 183mL~* Water 67mL~* Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
48336539|NCT00317876|DRUG|cyclosporine|
48336540|NCT00317876|DRUG|methotrexate|
48336541|NCT00317876|PROCEDURE|allogeneic bone marrow transplantation|
48494637|NCT06132217|DRUG|SG001|Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
48494638|NCT00712205|DRUG|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
48494639|NCT00712205|DRUG|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
48494640|NCT02399930|OTHER|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
48494641|NCT00523536|BEHAVIORAL|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
48336542|NCT00317876|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
48336543|NCT06006442|BEHAVIORAL|Vaping|Subjects will be smoking the vapnig products that they admitted to using at baseline in the personal life prior to this study
48336544|NCT05870670|DRUG|NNC0519-0130|Administered subcutaneously.
48336545|NCT05870670|DRUG|Placebo|Administered subcutaneously.
48336546|NCT02901340|DIETARY_SUPPLEMENT|one to two liters of water daily|
48336547|NCT00377104|DRUG|alvocidib|Given IV
48336548|NCT00377104|OTHER|pharmacological study|Correlative studies
48336549|NCT00377104|OTHER|laboratory biomarker analysis|Correlative studies
48494642|NCT05093036|OTHER|Variations in PrEP care delivery at public health services|Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
48494643|NCT04881630|BEHAVIORAL|Automated Mobile Contingency Management (CM)|Financial incentives contingent upon smoking abstinence
48654038|NCT02951819|DRUG|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
48654039|NCT06319053|DEVICE|Turbine-based insufflator|The use of a turbine-based insufflator instead of a conventional insufflator
48654040|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
48654041|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement|(List No- P968/Z0)
48654042|NCT02523027|OTHER|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
48654043|NCT06449547|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
48654044|NCT02637674|PROCEDURE|Uterus Transplant|
48654045|NCT04733495|OTHER|Counseling|Receive group-based behavioral counseling
48654046|NCT04733495|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary counseling
48654047|NCT04733495|OTHER|Quality-of-Life Assessment|Ancillary studies
48654048|NCT04733495|OTHER|Questionnaire Administration|Ancillary studies
48654049|NCT04733495|OTHER|Resistance Training|Undergo personalized resistance exercises
48129075|NCT05243784|BEHAVIORAL|MOVI-HIIT intervention|"Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 20 at high intensity (85-90% of HR -heart rate- max) followed by 10 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities."
48129076|NCT03200808|DRUG|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
48129077|NCT03358433|OTHER|Exercise|
48654050|NCT06643949|DIAGNOSTIC_TEST|Echocardiography|The registry will focus on the diagnostic and prognostic value of of echocardiographic features of patients with takotsubo syndrome
47977435|NCT03344250|DRUG|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
47977436|NCT03344250|DRUG|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
47977437|NCT00945048|DEVICE|electrical velocimetry|determination of cardiac output by electrical velocimetry
47977438|NCT00945048|DEVICE|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
47977439|NCT00945048|DEVICE|spirometry|spirometry for testing the ventilatory function
47977440|NCT00945048|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
47977441|NCT06245330|DRUG|AST-001|liquid formulation for Intravenous infusion
48336550|NCT01274312|PROCEDURE|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
48336551|NCT03275415|DRUG|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
48336552|NCT03275415|DRUG|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
48654051|NCT02684474|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
48654052|NCT03242031|PROCEDURE|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
48654053|NCT03242031|PROCEDURE|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
48654054|NCT06108050|DRUG|JZP898|Investigational drug monotherapy
48654055|NCT06108050|DRUG|Pembrolizumab|Approved anti-PD1 antibody
48654056|NCT05085756|BEHAVIORAL|Puma|One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
47977442|NCT05352334|DIAGNOSTIC_TEST|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
48129078|NCT00166322|PROCEDURE|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
48129079|NCT00245791|DRUG|Levofloxacin|
48129080|NCT00003459|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
48129081|NCT00943917|OTHER|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
48129082|NCT00943917|DRUG|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
47977443|NCT01776333|BEHAVIORAL|video decision aid|
47977444|NCT02708160|DRUG|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
47977445|NCT02708160|DRUG|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
47977446|NCT02708160|DRUG|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
47977447|NCT01342796|BIOLOGICAL|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
48129083|NCT00943917|OTHER|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
48494644|NCT04881630|OTHER|Standard Care (SC)|Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
48494645|NCT00039520|DRUG|docetaxel|
48494646|NCT00039520|DRUG|sulindac|
48654057|NCT05155085|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
48654058|NCT05155085|OTHER|Placebo|Placebo
48336553|NCT05112484|DIAGNOSTIC_TEST|Measurement of concentrations of orally-used DMDs|"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."
48336554|NCT05112484|DIAGNOSTIC_TEST|Genetic testing|One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
48336555|NCT05112484|DIAGNOSTIC_TEST|Parameters for routine use of DMDs|"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."
48336556|NCT05112484|OTHER|Side effects of orally used DMDs|"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."
48336557|NCT04751058|GENETIC|genetic analysis|"Intervention details: sampling in peripheral blood for the Methodology:~1. Automatic DNA extraction (ChemagicTM 360)~2. Mass sequencing using SeqCap EZ Choice Library capture technology (NimbleGen) and NextSeq sequencer (Illumina).~3. Bioinformatic analysis:.~   * Identification of point mutations and small deletions or insertions~  * Analysis of CNVs using the BEDtools program package~  * Search of the identified variants in the following public databases: 1000G, dbSNP, ExAC, EVS, GenomADm CSVS and DGV. Those with a MAF\> 1% have been considered benign, in public or private databases of our population.~The analysis process has focused exclusively on the genes described to date as associated with the pathology under study and included in the panel used. The reference sequences used for these genes are: determination of possible mutations, nucleotics, etc."
48336558|NCT00611988|BEHAVIORAL|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
48336559|NCT00611988|OTHER|Control group|Attention control group will receive routine follow-up phone calls
48336560|NCT05521646|OTHER|Quality Improvement Collaborative|Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
48494647|NCT01404715|DRUG|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
48494648|NCT01404715|DRUG|Imatinib|A single oral dose of 600 mg of imatinib
48494649|NCT04821531|OTHER|PT Pal|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength balance and mobility
48494650|NCT04821531|OTHER|Exercise Manual|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength, balance and mobility
48494651|NCT05320341|PROCEDURE|TIVA|During the anesthesia maintenance of the TIVA group, 3 μg.kg-1 fentanyl, 0.01-0.05 mg.kg-1 midazolam, and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40 and 60, approximately once every 45 minutes.
48494652|NCT05320341|PROCEDURE|SEVO|During the anesthesia maintenance of the SEVO group, 2-3% sevoflurane (1-2 MAC), 3 μg.kg-1 fentanyl and 0.2 mg.kg-1 rocuronium bromide were applied throughout the operation to keep BIS between 40-60.
48654059|NCT04981145|DRUG|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
48654060|NCT04981145|DRUG|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
48654061|NCT05780606|OTHER|Exposed to UV|Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
48654062|NCT02940119|DEVICE|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
48654063|NCT05515237|BEHAVIORAL|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
48129084|NCT05933213|DRUG|Mescaline sodium enteric-coated tablets|Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d
48494653|NCT02018926|DRUG|Mocetinostat|Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
48494654|NCT02018926|DRUG|Azacitidine|Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
48494655|NCT04648566|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
48494656|NCT04648566|PROCEDURE|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
48129085|NCT05933213|DRUG|Morte-mescaline|Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d
48129086|NCT05933213|DRUG|Glucocorticoids|glucocorticoids
48129087|NCT04463875|DIETARY_SUPPLEMENT|magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10|Supplementation per os
48129088|NCT03582592|BEHAVIORAL|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
48129089|NCT03452982|OTHER|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
48129090|NCT00903474|OTHER|questionnaire administration|
48129091|NCT00903474|OTHER|study of socioeconomic and demographic variables|
48129092|NCT00903474|PROCEDURE|CAM exercise therapy|
48129093|NCT00903474|PROCEDURE|psychosocial assessment and care|
48129094|NCT00903474|PROCEDURE|quality-of-life assessment|
47977448|NCT01342796|BIOLOGICAL|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
47977449|NCT00958152|DRUG|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
47977450|NCT00958152|DRUG|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
47977451|NCT00958152|DRUG|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
47977452|NCT00958152|DRUG|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
47977453|NCT02743520|DEVICE|The Lifestar Act III|The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
47977454|NCT05651451|DEVICE|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
48129095|NCT00903474|PROCEDURE|stress management therapy|
48129096|NCT02324296|DRUG|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
48129097|NCT05465018|DEVICE|Happy Flow / Baseline|Baseline (without make-up or mask)
48129098|NCT05465018|DEVICE|Make-up|To test device on participant who is wearing facial make-up
48129099|NCT05465018|DEVICE|Sunglasses|To test device on participant who is wearing sunglasses
48129100|NCT05465018|DEVICE|Face mask|To test device on participant who is wearing a facial mask
48129101|NCT05465018|DEVICE|Minimum requirements camera|To test the minimum requirements of the camera
48129102|NCT05465018|DEVICE|Worst case hardware|To test if software still works with an older smartphone
48129103|NCT05465018|DEVICE|Damaged lens|To test if software is still working when the lens of the smartphone is damaged
48129104|NCT05465018|DEVICE|Face or chest outside test frame|To test software if the participants face or chest is outside the test frame
48129105|NCT01728974|OTHER|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
48336561|NCT03286296|BIOLOGICAL|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
48336562|NCT02574481|DEVICE|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
48336563|NCT02574481|DEVICE|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
48129106|NCT06515691|PROCEDURE|M-TAPA block|After the wound closure is completed and the patient is still under genaral anesthesia the M-TAPA block ill be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied on each side. The total volume will be 60 ml.
48129107|NCT06515691|PROCEDURE|Postoperative pain management|ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
48129108|NCT05766319|DEVICE|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~* Measurement of peripheral oxygen saturation (%)~* Automatic recording of heart rate (beats/min)~* Automatic recording of activity (step count) (numbers/day)"
48129109|NCT05766319|DEVICE|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
48129110|NCT05766319|DEVICE|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
48129111|NCT00152672|DEVICE|nCPAP vs oral appliance|
48129112|NCT04169256|DRUG|HYR-PB21|HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
48129113|NCT04169256|DRUG|Liposomal bupivacaine|Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
48129114|NCT04169256|OTHER|Normal Saline|Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
48336564|NCT06443749|PROCEDURE|appendectomy|the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node
48336565|NCT04570514|PROCEDURE|PCI|percutaneous coronary intervention (PCI)
48336566|NCT00124332|DRUG|Rimonabant (SR141716)|
48336567|NCT00124332|DRUG|Placebo|
48336568|NCT02452710|OTHER|Placebo|Open-label placebo
48336569|NCT04683172|DEVICE|Active Transcranial Direct Current Stimulation|"tDCS consists of delivering a low-intensity (1 to 2 milliamperes) direct electrical current by means of a pair of electrodes (anode and cathode) applied to the scalp. Electrodes generally have a diameter (round electrode) or a diagonal (rectangular electrodes) ranging from 2 to 3.5 cm.~To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode. In this study, the stimulation intensity will be 1.5 mA using round sponge electrodes 3.5 cm in diameter."
48336570|NCT04683172|DEVICE|Sham Transcranial Direct Current Stimulation|"The tDCS device has a Sham mode that allows for true placebo stimulation. A simulated session is thus designed as a real stimulation session without its effects. Sensations similar to tDCS are created by generating currents only at the start of the session.~Same modalities as for the Active tDCS procedure will therefore be put in place: a pair of electrodes (anode and cathode) are applied to the scalp.To stimulate a given cortical zone, the anode is placed over of the selected zone, generally identified by means of an EEG headset (10/20 System Positioning). For the treatment of pain, the anode is placed over the primary motor cortex (M1) on the contralateral side to the pain or on the left side in patients with diffuse pain. The cathode is placed over a supposedly neutral cortical zone, usually the contralateral supraorbital cortex with respect to the anode."
48336571|NCT04322955|DRUG|Cabozantinib|2 x 20 mg capsules taken orally daily
48336572|NCT04322955|DRUG|Nivolumab|480mg IV on first day of each 28-day cycle
48336573|NCT04322955|PROCEDURE|Cytoreductive nephrectomy|Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.
48336574|NCT03358615|PROCEDURE|cesarean section|assessment of the indications of cesarean section according to Robson criteria
48336575|NCT00921427|BEHAVIORAL|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
48336576|NCT00921427|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
48336577|NCT04489537|BIOLOGICAL|MarzAA|A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
48336578|NCT02929628|DEVICE|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
48336579|NCT02667522|BEHAVIORAL|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
48494657|NCT05476653|OTHER|MRI procedure|Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
48654064|NCT03794635|BEHAVIORAL|Weekly 45 minute Sessions|"The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention."
48129115|NCT04946487|PROCEDURE|total laminectomy|Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
48336580|NCT05067712|PROCEDURE|Open Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~* Follicular tissue is removed from the exposed crown area~* The flap is repositioned back and sutured~* The area over the exposed canine crown is excised leaving a window with the crown uncovered.~* If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~* The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~* Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~* When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
48494658|NCT03659526|DIAGNOSTIC_TEST|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
48494659|NCT00727948|DRUG|Aspirin|325 mg tablets, once daily for 45 days
48494660|NCT00153608|BIOLOGICAL|WT1 126-134 peptide|
48129116|NCT00124254|PROCEDURE|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
48129117|NCT00124254|OTHER|Usual care|Non-surgical usual care
48129118|NCT01594957|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
48129119|NCT03144518|OTHER|Positive Affect Intervention|See Previous Description
48129120|NCT03144518|OTHER|Neutral Control Intervention|See Previous Description
48129121|NCT03144518|BIOLOGICAL|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
48129122|NCT01158417|DRUG|Placebo|oral
48129123|NCT01158417|DRUG|Resveratrol 40 mg oral three times a day|Drug
48129124|NCT01158417|DRUG|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
48129125|NCT06244875|OTHER|Sampling|Blood and cerebrospinal fluid sampling during the diagnostic visit
48129126|NCT00732849|DRUG|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
48129127|NCT03693937|RADIATION|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
48129128|NCT04720794|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
48129129|NCT03576521|COMBINATION_PRODUCT|CT + Ocoxin-Viusid|"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
48129130|NCT03576521|COMBINATION_PRODUCT|CT + Placebo|"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
48129131|NCT01645566|BEHAVIORAL|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
48129132|NCT04422236|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
48129133|NCT02766517|DRUG|Capsaicin|Administered topically
48129134|NCT01217905|DRUG|AZD7687|Oral suspension
48129135|NCT06135922|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.
48129136|NCT06389890|PROCEDURE|Pancreatic resection procedure|Pancreatic resection procedure
48129137|NCT00468156|BEHAVIORAL|written materials only|related to fruit/vegetable servings/day
48129138|NCT00468156|BEHAVIORAL|written materials|related to fruit/vegetable servings/day
48129139|NCT00468156|BEHAVIORAL|telephone support|related to fruit/vegetable servings/day
48654065|NCT06644313|DRUG|Vebreltinib|Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
48654066|NCT06053580|DRUG|Valsartan 40 mg|Valsartan 40mg twice daily for 24 weeks.
47977455|NCT05651451|DIETARY_SUPPLEMENT|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
47977456|NCT05407402|BEHAVIORAL|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
47977457|NCT05407402|BEHAVIORAL|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
47977458|NCT02637453|PROCEDURE|PVI|Pulmonary vein isolation
47977459|NCT02637453|PROCEDURE|CPVI+6L|After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
47977460|NCT01773785|DRUG|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
47977461|NCT01773785|DRUG|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
47977462|NCT06508073|OTHER|Neural Therapy|The injection was prepared using a solution of lidocaine 2% and saline 0.9%. A 0.4% lidocaine solution was prepared by diluting 1 cc of lidocaine with 4 cc of saline.
48129140|NCT03631290|BEHAVIORAL|Deprescribing Intervention|"The deprescribing program was implemented as a clinical quality improvement project for patients receiving dialysis. Patients taking specific potentially inappropriate medications (PIMs) were identified in the medical record. The PIMs of interest included gabapentinoids, clonidine, alpha blockers, muscle relaxants, and Z-drugs. If their nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing. This discussion included patient education materials about the risk of the medication. If the patient agreed, they were provided taper instructions (if indicated) and were followed up at 1 month and 3 months.~The patient was also invited to enroll in a study to be interviewed about the deprescribing decision and experience, and undergo brief assessment of geriatric problems at baseline and at 3 months."
48129141|NCT04810767|OTHER|Questionnaire|Pain experienced assessed by questionnaire described by Nikolajsen et al, 2004
48129142|NCT01418794|DEVICE|High dose rapamycin stent|Concentration of rapamycin is 2.5%
48129143|NCT01418794|DEVICE|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
48129144|NCT06045208|OTHER|Foot exercise|This group will engage in an 8-week foot intrinsic strengthening training
48336581|NCT05067712|PROCEDURE|Closed Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~* Follicular tissue is removed from the exposed crown area.~* An attachment with a chain is bonded to the exposed canine crown.~* The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~* The extraction of the primary canine (if present) made before or in connection with the surgical exposure~* Ten to fifteen days later the sutures are removed.~* Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
48336582|NCT02685787|BEHAVIORAL|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
47977463|NCT03867006|DIETARY_SUPPLEMENT|Protein|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.
47977464|NCT03867006|DIETARY_SUPPLEMENT|Protein and Carbohydrate|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
47977465|NCT01954602|PROCEDURE|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
47977466|NCT01954602|PROCEDURE|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
47977467|NCT00294268|BEHAVIORAL|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
47977468|NCT05695898|DRUG|XmAb22841|Given intravenously (IV)
47977469|NCT05695898|DRUG|XmAb23104|Given intravenously (IV)
47977470|NCT04108533|BEHAVIORAL|Text-Based Support|Text-based breastfeeding support as described in arm/group descriptions
47977471|NCT05916495|OTHER|Hybrid care arm|Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
47977472|NCT05916495|OTHER|Standard of care arm|Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
47977473|NCT03085420|DIAGNOSTIC_TEST|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
48129145|NCT06045208|OTHER|Lower Extremity Exercise|This group will engage in an 8-week lower extremity strengthening training
47977474|NCT04343261|BIOLOGICAL|Convalescent Plasma|treatment with 2 Units of convalescent plasma
47977475|NCT04766580|BEHAVIORAL|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
48129146|NCT01917942|DEVICE|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
47977476|NCT03015389|PROCEDURE|Diagnostic Test|WATS3D brush biopsy
47977477|NCT02272491|DEVICE|ZrO2 (Straumann CARES)|"1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
47977478|NCT02272491|DEVICE|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
47977479|NCT01652898|DRUG|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
47977480|NCT01652898|DRUG|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
48129147|NCT01917942|OTHER|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
48129148|NCT01083316|DRUG|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
48129149|NCT01083316|DRUG|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
48129150|NCT01083316|DRUG|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
48129151|NCT03053505|BIOLOGICAL|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
48129152|NCT03053505|DRUG|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
48129153|NCT06294756|OTHER|Inhalation of Sulfurous Thermal Water|Active Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a conventional thermal water aerosolization Faset™system (Faset Spa, Trezzano sul Naviglio, Milan, Italy) delivering particles of TW with a diameter between 0.6 µm \<MMAD \< 5 µm. Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs.
48129154|NCT06294756|OTHER|Inhalation of Sterile Distilled non-pyrogenic Water|Placebo Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a modified thermal water aerosolization Faset™system, previously disconnected from the hydraulic circuit that supplied TW and connected to non-pyrogenic sterile water reservoirs (Highly depurated water- Pharmaceutical grade FU-for external and internal use, Makeitlab, Canosa di Puglia, BT, Italy). Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs delivering particles of SDW with a diameter between 0.6 µm \<MMAD \< 5 µm.
48129155|NCT04044859|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 alone or in combination with either nivolumab 480 mg IV every four weeks or pembrolizumab 400mg IV every 6 weeks
48129156|NCT01248260|DIETARY_SUPPLEMENT|Folic Acid|4mg of higher strength folic acid once a day until delivery
48129157|NCT02611609|BIOLOGICAL|MultiStem|
48336583|NCT02685787|BEHAVIORAL|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
48336584|NCT00609804|DRUG|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
48336585|NCT00609804|DRUG|Erlotinib|Erlotinib 150 mg once daily by mouth
48336586|NCT04491240|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
48336587|NCT04491240|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
48336588|NCT04491240|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
48336589|NCT00005092|DRUG|Cyclophosphamide|IV over 2 hours on days 2 and 3
48336590|NCT00005092|DRUG|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
48336591|NCT00005092|DRUG|Thiotepa|IV over 2 hours on day 1
48336592|NCT00005092|PROCEDURE|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
48336593|NCT00005092|PROCEDURE|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
48336594|NCT00005092|RADIATION|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
48129158|NCT02611609|BIOLOGICAL|MultiStem|
48129159|NCT02611609|BIOLOGICAL|Placebo|
48129160|NCT03547102|DIETARY_SUPPLEMENT|Cherry concentrate|
48129161|NCT03547102|DIETARY_SUPPLEMENT|Placebo concentrate|
48129162|NCT00476463|DRUG|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
48129163|NCT01814839|DRUG|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
48129164|NCT01814839|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
48129165|NCT04957849|PROCEDURE|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
48129166|NCT04957849|PROCEDURE|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
48336595|NCT00816283|DRUG|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
48336596|NCT00816283|DRUG|vorinostat|100 mg orally 2 times per day
48336597|NCT00816283|GENETIC|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
48129167|NCT00229658|DRUG|pramlintide acetate|Subcutaneous injection prior to each major meal
48129168|NCT06109454|DRUG|Huaier granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
48129169|NCT06109454|OTHER|Control|The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
48129170|NCT00462475|DRUG|Recombinant Growth Hormone, Genotropin (Pfizer)|
48129171|NCT00180791|DRUG|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
48129172|NCT05296889|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.
48336598|NCT00816283|GENETIC|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
47977481|NCT01652898|DRUG|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
47977482|NCT05127473|DRUG|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
47977483|NCT05127473|DRUG|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
47977484|NCT05127473|DRUG|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
47977485|NCT01892293|DRUG|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
47977486|NCT00479609|DRUG|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
47977487|NCT00479609|DRUG|Placebo|Placebo gel
47977488|NCT03724955|DRUG|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
47977489|NCT03724955|OTHER|Placebo|The placebo group will receive placebo oral daily for 6 months
47977490|NCT00367094|DRUG|Benazepril plus hydrochlorothiazide|
47977491|NCT02710565|OTHER|Cohort|Obtaining additional EBUS TBNA samples for cell culture
47977492|NCT01120223|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
47977493|NCT04770350|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
47977494|NCT00969202|RADIATION|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
47977495|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
48336599|NCT00816283|GENETIC|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
47977496|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
47977497|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
47977498|NCT03606733|PROCEDURE|Custom suorachoroidal needle|Custom made Supra Choroidal Space needle
48129173|NCT04707001|OTHER|Catheterization based on ultrasound|Bladder volume ultrasound
48129174|NCT04707001|OTHER|Catheterization based on evaluation of symptoms|Ask for symptoms: Need to urinate, lower abdominal pain
48129175|NCT01198366|BIOLOGICAL|AERAS-402 1.5 x 10^10 vp|
48129176|NCT01198366|BIOLOGICAL|AERAS-402 3.0 x 10^10 vp|
48336600|NCT00816283|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
48336601|NCT00816283|OTHER|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
48336602|NCT00816283|OTHER|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
47977499|NCT06150560|DRUG|Losartan|50mg administered orally once daily for 52 weeks.
47977500|NCT06150560|DRUG|Amlodipine|5mg Amlodipine administered orally once daily for 52 weeks.
48129177|NCT01198366|BIOLOGICAL|AERAS-402 1.0 x 10^11 vp|
48129178|NCT01198366|BIOLOGICAL|Placebo|
48129179|NCT04824274|DRUG|fentanyl|Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
48129180|NCT04824274|DRUG|morphine|Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
48129181|NCT04824274|PROCEDURE|Transversus abdominis plane block|Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
48129182|NCT04824274|PROCEDURE|Sham block|Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
48129183|NCT05879419|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (RZV)|RZV comprise 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant system (which contains 50 μg of 3-O-desacyl-4'-monophosphoryl lipid A \[MPL\] and 50 μg of Quillaja saponaria Molina, fraction 21 (QS21, licensed by GSK from Antigenics, a subsidiary of Agenus)). Vaccine will be administered (0.5 ml) into the deltoid muscle at inclusion and 6 weeks (two doses).
48129184|NCT05879419|OTHER|MTX Discontinuation|Evaluation of discontinuation of the use of methotrexate (MTX) for 2 weeks after each vaccine dose in ARD patients: patients using MTX at a stable dose for at least 12 weeks, prednisone maximum dose of 5 mg/day, in association or not with other drugs except rituximab will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MTX for 2 weeks after each vaccine dose (MTX-withhold) and other that will maintain stable therapy (MTX-maintain).
48129185|NCT05879419|OTHER|MMF Discontinuation|Evaluation of discontinuation of the use of mycophenolate mofetil (MMF) for one week after each vaccine dose in ARD patients: patients using MMF at a stable dose for at least 12 weeks, prednisone maximum dose of 7.5 mg/day, not associated with other immunosuppressive therapy, will be consecutively evaluated at outpatient clinics regarding disease activity. Those considered to be at stable disease (at remission or low disease activity according to specific standardized disease activity indexes) will be randomized (1:1) into two arms: one that will withhold MMF for 2 weeks after each vaccine dose (MMF-withhold) and other that will maintain stable therapy (MMF-maintain).
48129186|NCT05879419|OTHER|Placebo|Patients with ARDs who received the placebo at study entry (P2). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
48129187|NCT05879419|OTHER|MTX maintain|MTX dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MTX-withhold group.
48129188|NCT05879419|OTHER|MMF maintain|MMF dose will be held stable after the two vaccine doses for comparison of vaccine immunogenicity and disease activity with the MMF-withhold group.
48129189|NCT03466242|DRUG|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
48129190|NCT03466242|DRUG|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
48129191|NCT05342246|PROCEDURE|Endodontic retreatment|retreatment of the patent root canal only without attempt to retrieve the separated instrument
48129192|NCT03948542|OTHER|Outcome|"Nerve Recovery~* NCV~* Funcional assessment"
48129193|NCT05749224|DIAGNOSTIC_TEST|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
48654067|NCT06053580|DRUG|Placebo|Placebo twice daily for 24 weeks.
47977501|NCT06150560|DRUG|Placebo|Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
47977502|NCT03630172|PROCEDURE|Dry needling|Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
47977503|NCT02759432|OTHER|High-intensity interval exercise training|
47977504|NCT01922128|DRUG|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
48129194|NCT05538494|OTHER|BFR intervention|"Training is applied to this group using low-load exercises with restriction of blood flow. Based on the variables used by the major part of the protocols used in studies on the ERFS, the protocol that will be applied to this group will consist of the following parameters.~* Training: 1 series of 30 repetitions followed by 3 series of 15 repetitions of squats~* Rest between series: Duration of 45 seconds.~* Workload: 30% of 1RM.~* Cadence: 2 seconds for the concentric phase and 2 seconds for the eccentric phase (2:2).~* Cuff pressure: The inflation pressure will be individualized for each individual.~A pressure equivalent to 80% of the minimum pressure necessary for the total occlusion of the femoral artery.~• Cuff placement: proximal quadriceps."
48336603|NCT02972112|BEHAVIORAL|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
48336604|NCT02972112|OTHER|Sham|standard birth preparation sessions.
48654068|NCT05293002|DEVICE|Restorer Iliac Stent System|Not applicable (only one intervention)
48336605|NCT01999907|DIETARY_SUPPLEMENT|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
48336606|NCT01999907|DIETARY_SUPPLEMENT|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
48336607|NCT01999907|OTHER|Placebo|placebo given in a 2ml dose by mouth at baseline.
48336608|NCT00701103|DRUG|Dalotuzumab|IV infusion
48336609|NCT00989404|DRUG|Zanamivir|Rotahaler placebo 10mg BID 5 days
48336610|NCT00989404|DRUG|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
48336611|NCT00989404|DRUG|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
48336612|NCT03514004|BEHAVIORAL|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
48336613|NCT01601704|DRUG|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
48336614|NCT01601704|DRUG|PBO|Placebo. Administered in addition to the weight management program.
48336615|NCT01601704|BEHAVIORAL|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
48336616|NCT00623285|DRUG|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
48336617|NCT00623285|DRUG|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
48654069|NCT00692328|BEHAVIORAL|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
47977505|NCT03688165|DEVICE|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
47977506|NCT03049280|DEVICE|Transoral robotic surgery|Transoral robotic surgery for T1 \& T2 oropharyngeal cancers
48336618|NCT00272545|BEHAVIORAL|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
48336619|NCT00272545|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
48336620|NCT05412212|OTHER|LTBI video intervention|3-minute educational video about latent tuberculosis and importance of taking and completing treatment
48336621|NCT01570309|DRUG|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
48336622|NCT01570309|OTHER|Sugar pill|Oral capsule, once a week, 12 weeks
48336623|NCT00721617|OTHER|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
48336624|NCT00721617|OTHER|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
48336625|NCT00721617|OTHER|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
48336626|NCT03466307|DEVICE|Ultrasonography|Ultrasonographic examination of shoulder
48336627|NCT01089816|BIOLOGICAL|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
48336628|NCT01914783|OTHER|ultrafine particles|exposure to ultrafine particles
48336629|NCT01914783|OTHER|ultrafine particles and ozone|exposure to ultrafine particles and ozone
48336630|NCT01914783|OTHER|clean air|Exposure to clean air.
48336631|NCT03327519|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
48129195|NCT05538494|OTHER|High load intervention|"A program will be applied to this group of exercise with high loads as a method of treatment in which the following will be applied parameters:~* Training: 4 series of 12 repetitions of squats.~* Rest between series: Duration 2 minutes.~* Workload: 70% of 1RM."
48129196|NCT03575936|DEVICE|Home INR Monitoring|The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
48129197|NCT03575936|PROCEDURE|Standard of Care|The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
48129198|NCT04379375|BEHAVIORAL|Nudge|Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
47977507|NCT01958320|OTHER|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
48129199|NCT03895515|DRUG|Fiasp®|Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
47977508|NCT01958320|OTHER|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
47977509|NCT01958320|DRUG|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
47977510|NCT03383679|DRUG|Darolutamide|treatment with darolutamide
47977511|NCT03383679|DRUG|Capecitabine|treatment with capecitabine
47977512|NCT04368767|BEHAVIORAL|Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
47977513|NCT01010516|DRUG|High-dose rosuvastatin|40 of rosuvastatin daily
47977514|NCT01010516|DRUG|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
47977515|NCT01010516|DRUG|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
47977516|NCT05234151|OTHER|NEWS|Newborn Early Warning Score
47977517|NCT04351321|PROCEDURE|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
47977518|NCT04351321|PROCEDURE|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
47977519|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 50mg|
47977520|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 25mg|
47977521|NCT04782024|DIETARY_SUPPLEMENT|Placebo|
48129200|NCT01340859|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
48129201|NCT00461019|PROCEDURE|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
48129202|NCT05508607|OTHER|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
48654070|NCT05638217|COMBINATION_PRODUCT|Silver diamine fluoride 38% followed by Sodium fluoride varnish 5%|"1)Completely drying of the affected area 2)10 microliters of silver diamine fluoride 38% (CaviGuard®) will be placed on the affected area 3)The affected area should be immediately covered with 20 microliters of fluoride varnish 5% (CaviGuard®) 4)Repeat steps 1-3 one or two more times for large caries at intervals of at least 2 days apart 5)Follow up evaluation of treatment success visits will be conducted at 6 and 12 months from the initial treatment.~NOTE: This is a single intervention using the device registered as Caviguard® to apply both products (Silver diamine fluoride 38% followed by Sodium fluoride varnish 5% (®)) in sequence."
48654071|NCT04755387|DRUG|Ticagrelor 90mg|Standard strategy initially receive ticagrelor 90mg twice daily for 12 months.
48129203|NCT01154192|DRUG|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
48129204|NCT01154192|DRUG|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
48129205|NCT05909072|DRUG|Hyaluronic acid combined with tranexamic acid microneedling|1 ml of TXA, available as a 500 mg/5 ml ampoule, will be applied on the right side of the face after microneedeling and left to dry
48129206|NCT05909072|DRUG|tranexamic acid microneedling|On the left side of face, 0.5 ml of HA 3.5% will be used 1st followed by microneedling then 1 ml of TXA will be applied
48129207|NCT03953859|GENETIC|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
48129208|NCT04004494|OTHER|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
48129209|NCT03574103|BEHAVIORAL|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
48654072|NCT04755387|DRUG|Ticagrelor 60/45mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.
48129210|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
48129211|NCT03574103|BEHAVIORAL|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
48129212|NCT03570970|DRUG|Banapenem|Banapenem to be used anti-infection
48129213|NCT03150446|DEVICE|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
48336632|NCT03327519|BEHAVIORAL|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
48654073|NCT03758612|DRUG|TBI-223 50mg|TBI-223 50 mg supplied for oral administration.
48654074|NCT03758612|DRUG|Placebo for TBI-223 50mg|Matching placebo for TBI-223 50mg supplied for oral administration.
48654075|NCT03758612|DRUG|TBI-223 100, 300, 600, 1200, 2000, 2600 mg|TBI-223 100, 300, 600, 1200, 2000, 2600 mg supplied for oral administration.
48336633|NCT06193694|BEHAVIORAL|Coaching|Formal coaching program followed by the Coaching Fidelity Tool, to be taken by the study group after program completion contains 12 questions, predominantly multiple choice and yes/no, although there is one question that requires a short answer as well as a place to write additional comments. These questions are meant to elicit responses about their experience with their assigned coach during their one-on-one coaching sessions.
48654076|NCT03758612|DRUG|Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg|Matching placebo for 100, 300, 600, 1200, 2000, 2600 mg TBI-223 supplied for oral administration.
48654077|NCT03758612|DRUG|TBI-223 300 mg capsule|TBI-223 300 mg capsule supplied for oral administration
48336634|NCT00264667|DRUG|GW677954|
48336635|NCT02580838|DRUG|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
48336636|NCT02559557|OTHER|Educational Intervention|Participate in focus groups
48336637|NCT02559557|OTHER|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
48336638|NCT02559557|OTHER|Quality-of-Life Assessment|Answer questionnaires
48654078|NCT03758612|DRUG|Placebo for TBI-223 300 mg capsule|Placebo for TBI-223 300 mg capsule supplied for oral administration
48654079|NCT03758612|DRUG|TBI-223 Prototype 1 SR Tablet|Prototype 1 TBI-223 600 mg sustained-release (SR) tablet
48654080|NCT03758612|DRUG|TBI-223 Prototype 2 SR Tablet|Prototype 2 TBI-223 600 mg SR tablet
48654081|NCT03758612|DRUG|TBI-223 Prototype 3 SR Tablet|Prototype 3 TBI-223 900 mg SR tablet
48129214|NCT01939899|DRUG|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
48336639|NCT02559557|OTHER|Questionnaire Administration|Answer questionnaires
48336640|NCT01213264|OTHER|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
48336641|NCT01213264|DRUG|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
48336642|NCT01213264|DRUG|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
48336643|NCT05898750|DIETARY_SUPPLEMENT|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
48336644|NCT05986825|OTHER|Verneuil questionnaire Validation|Request patient to Complete the questionnaire for validation of the French version
48336645|NCT04517227|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
48336646|NCT04517227|PROCEDURE|Transcatheter Hepatic Arterial Chemoembolization (TACE)|TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.
48129215|NCT00328666|BEHAVIORAL|Iyengar yoga|
48129216|NCT00328666|BEHAVIORAL|Enhanced nutritional care classes|
48129217|NCT05917275|DRUG|Amlodipine|4 weeks of Amlodipine
48129218|NCT05917275|DRUG|Olmesartan|4 weeks of Olmesartan
48336647|NCT04517227|PROCEDURE|Ablation|In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).
48336648|NCT04179019|DRUG|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
48336649|NCT02339857|PROCEDURE|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
48336650|NCT05603494|DEVICE|NuvoAir|Use of NuvoAir in pulmonary function monitoring during asthma attack
48336651|NCT03057912|BIOLOGICAL|TALEN|TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
48336652|NCT03057912|BIOLOGICAL|CRISPR/Cas9|CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
48336653|NCT01256203|DRUG|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
48336654|NCT01256203|PROCEDURE|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
48336655|NCT00446758|DIETARY_SUPPLEMENT|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
48654082|NCT03758612|DRUG|TBI-223 IR Tablet|TBI-223 1000 mg immediate release (IR) tablet
48654083|NCT04090606|OTHER|FTC Method Smoking Regimen|cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
48654084|NCT04090606|OTHER|Massachusetts Method Smoking Regimen|45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
48654085|NCT04090606|OTHER|Health Canada Intense Smoking Regimen|55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
48654086|NCT06644794|DRUG|Progesterone-modified natural cycle preparation for frozen embryo transfer|A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.
48129219|NCT05917275|DRUG|Hydrochlorothiazide|4 weeks of Hydrochlorothiazide
48129220|NCT05917275|DRUG|Amlodipine/Olmesartan|4 weeks of Amlodipine/Olmesartan
48129221|NCT03169413|GENETIC|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
48129222|NCT02829931|RADIATION|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
48129223|NCT02829931|DRUG|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
48129224|NCT02829931|DRUG|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
48336656|NCT03929523|DEVICE|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
48336657|NCT03929523|DEVICE|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
48336658|NCT06022146|DRUG|Rifampin and Isoniazid|3HR regimen of isoniazid and rifampicin once daily for three months
48336659|NCT06022146|DRUG|isoniazid and rifapentine|12-dose ultra-short TPT 1H3P3 regimen of isoniazid and rifapentine 3 times a week for one month
48336660|NCT00520299|DRUG|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
48336661|NCT06508528|BEHAVIORAL|a 12-week growth mindset intervention|This is a 12-week growth mindset intervention for the nursing students during clinical rotation practice. It aims at promoting the core self-evaluation and professional sefl-efficacy for them. The intervention has 12 themes, with each intervention lasting 15 to 20 minutes. Intervention will be carried out through a combination of online and offline methods.
48336662|NCT06508528|OTHER|Hospital mentoring|The control group will receive guidance from the hospital. Including self-regulation of stress, self-protection in clinical practice, and so on
48336663|NCT03581682|OTHER|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
48654087|NCT06644794|DRUG|Hormone replacement therapy cycle preparation for frozen embryo transfer|A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
47977522|NCT02445092|OTHER|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~* Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~* Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~* Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
47977523|NCT00002602|RADIATION|3D-CRT|3 dimensional conformal radiation therapy
48129225|NCT02829931|DRUG|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
48129226|NCT03466931|OTHER|Milk|Meals containing Milk and Milk
48129227|NCT01913314|DRUG|[^14C]-LY2835219|Administered as oral solution
48129228|NCT00359606|DRUG|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
48129229|NCT00359606|OTHER|Laboratory Biomarker Analysis|Correlative Studies
48129230|NCT00359606|OTHER|Pharmacological Study|Correlative Studies
48129231|NCT00359606|DRUG|Tetrahydrouridine (THU)|Given PO and IV
48129232|NCT05422846|OTHER|standard treatment|The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.
48129233|NCT05422846|OTHER|aerobic exercise|The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.
48129234|NCT05422846|OTHER|exercise protocol|The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
48129235|NCT02179268|DRUG|sertraline|50mg, 50-150mg/d,qd for one year
48129236|NCT02179268|DRUG|citalopram|20mg, 20-40mg/d,qd,for one year
48129237|NCT02179268|DRUG|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
48129238|NCT02179268|DRUG|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
48129239|NCT02179268|BEHAVIORAL|control|50min, every week for three months, every month, for nine months
48129240|NCT04255706|DEVICE|biometric measurement IOLMaster 700|Three biometric measurements will be performed with 3 devices for all the patients included
48129241|NCT04255706|DEVICE|biometric measurement Lenstar LS 700|Three biometric measurements will be performed with 3 devices for all the patients included
48129242|NCT04255706|DEVICE|biometric measurement Anterion Heildelberg|Three biometric measurements will be performed with 3 devices for all the patients included
48129243|NCT05820594|BIOLOGICAL|Intradermal BCG (bacillus calmette-guerin) vaccine AJV|Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
48129244|NCT02180815|DEVICE|ReVENT Sleep Apnea System|
48129245|NCT04970511|BEHAVIORAL|BBAT (Basic Body Awareness Therapy)|The group I: BBAT Face-to-Face Training (60 min) will be provided.
48129246|NCT04970511|BEHAVIORAL|Online BBAT training|The group II: Online BBAT training (60 min) will be provided.
48129247|NCT04749784|DIETARY_SUPPLEMENT|High Dose Arterin Cholesterol|240mg active ingredient daily
48129248|NCT04749784|DIETARY_SUPPLEMENT|Low Dose Arterin Cholesterol|120mg active ingredient daily
48129249|NCT04749784|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
48129250|NCT05793307|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
48129251|NCT05113095|BIOLOGICAL|Darvadstrocel|Darvadstrocel injection
48129252|NCT02291094|DRUG|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
48129253|NCT02291094|DRUG|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
48129254|NCT01998958|DRUG|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
48129255|NCT01998958|DRUG|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
48129256|NCT01998958|DRUG|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
48129257|NCT01998958|DRUG|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
48129258|NCT01998958|DRUG|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
48129259|NCT05676346|GENETIC|LUTS|Patients included in this group are subjects with lower urinary tracto symptoms. An oral mucosa swab will be used to extract a genetic specimen
48129260|NCT02860741|BEHAVIORAL|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
48129261|NCT02860741|OTHER|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
48129262|NCT01066767|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
48129263|NCT00707473|DRUG|Carboplatin|Given IV
48129264|NCT00707473|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
48129265|NCT00707473|DRUG|Cisplatin|Given IV
48129266|NCT00707473|PROCEDURE|Definitive Surgical Resection|Undergo surgery
48129267|NCT00707473|DRUG|Docetaxel|Given IV
48129268|NCT00707473|DRUG|Fluorouracil|Given IV
48129269|NCT00707473|PROCEDURE|Quality-of-Life Assessment|Correlative studies
48129270|NCT00707473|RADIATION|Radiation Therapy|Undergo radiation therapy
48129271|NCT04981600|DEVICE|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
48129272|NCT04981600|DEVICE|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
48129273|NCT00163046|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
48129274|NCT00163046|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
48129275|NCT01378416|DRUG|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.
48129276|NCT00785915|DRUG|AZD6765|single administration and once daily for 5 days
48129277|NCT00785915|DRUG|Placebo|single administration and once daily for 5 days
48336664|NCT00602069|BEHAVIORAL|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
48336665|NCT00602069|BEHAVIORAL|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
48129278|NCT05800236|PROCEDURE|Gastrectomy|Patients operated on for curative purposes at the Bordeaux University Hospital for gastric adenocarcinoma of any type or stage and Collection of two venous blood tubes
48129279|NCT02476409|DRUG|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
48129280|NCT02476409|OTHER|Placebo|Placebo for tolvaptan
48129281|NCT02586272|DEVICE|Daifert|
48129282|NCT02586272|PROCEDURE|Control Group|
48129283|NCT00418795|DRUG|recombinant human porphobilinogen deaminase (Porphozym)|
47977524|NCT00120770|DRUG|Cellulose Sulfate Vaginal Gel (Microbicide)|
47977525|NCT00483223|DRUG|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
47977526|NCT00483223|DRUG|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
47977527|NCT02708121|BEHAVIORAL|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
47977528|NCT02708121|OTHER|Comparator Intervention|Participants informed that they have access to weight loss treatment.
47977529|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
47977530|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
47977531|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
47977532|NCT05812898|OTHER|exercises|strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles
47977533|NCT05812898|OTHER|myofascial release|myofascial release using instrument assisted soft tissue mobilization
47977534|NCT01279278|OTHER|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
47977535|NCT01279278|OTHER|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
47977536|NCT01728701|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
47977537|NCT01728701|BIOLOGICAL|Normal Saline (NS)|Normal saline
48494661|NCT01070459|BEHAVIORAL|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
47977538|NCT06034470|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47977539|NCT06034470|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
47977540|NCT06034470|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
47977541|NCT06034470|DRUG|Cytarabine|Given IV
47977542|NCT06034470|PROCEDURE|Echocardiography|Undergo ECHO
47977543|NCT06034470|DRUG|Fludarabine|Given IV
47977544|NCT06034470|DRUG|Granulocyte Colony-Stimulating Factor|Given SC
47977545|NCT06034470|DRUG|Idarubicin|Given IV
47977546|NCT06034470|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
47977547|NCT06034470|DRUG|Pivekimab Sunirine|Given IV
47977548|NCT00380614|DRUG|Lamivudine|
47977549|NCT01152086|OTHER|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)"
47977550|NCT05854732|OTHER|Inclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and increased inclination of 1% after every one minute for 30 minutes ending with Cool down for 5 minutes.
48336666|NCT04460040|BEHAVIORAL|Exercise training|"The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake."
48336667|NCT05212402|DIETARY_SUPPLEMENT|Cannabinol|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
48336668|NCT05212402|OTHER|Placebo|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
47977551|NCT05854732|OTHER|Uninclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a active comparator with fixed speed of 5.0 mph and fixed inclination. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and fixed inclination for 30 minutes ending with Cool down for 5 minutes.
47977552|NCT02694510|OTHER|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
48336669|NCT01180764|DRUG|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
48654088|NCT06571643|OTHER|Lower Abdomen MRI|The patients will undergo a lower abdomen MRI to assess the size of the psoas muscle and derive the PMI
47977553|NCT00033215|DRUG|S-3304|
48129284|NCT03562325|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
48129285|NCT01824056|DRUG|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
48336670|NCT01180764|DRUG|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
48494662|NCT01070459|BEHAVIORAL|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
48494663|NCT01070459|BEHAVIORAL|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
48654089|NCT00837135|OTHER|Screening|"A. SCREENING~1. Consent~2. Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~3. Physical Exam, History, Blood Tests~4. Skin Test (for allergy to saccaromyces cerevisiae) yeast.~5. Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~1. Consent~2. Chemotherapy~3. GI-4000 Vaccine #1 + Prevnar + Activated T Cells~4. GI-4000 Vaccine #2~5. Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
48654090|NCT00837135|BIOLOGICAL|GI-4000 Vaccine|"1. Chemotherapy and Radiation~2. GI-4000 Vaccine #3~3. GI-4000 Vaccine #4"
48654091|NCT00837135|BIOLOGICAL|GI-4000 Vaccine + Activated T Cells|"1. Apheresis #2~2. Chemoradiation~3. Activated T Cells + GI-4000 Vaccine #3~4. GI-4000 Vaccine #4"
48654092|NCT00837135|BIOLOGICAL|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
48129286|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
48494664|NCT01070459|BEHAVIORAL|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
48494665|NCT01070459|BEHAVIORAL|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
48494666|NCT00845819|DRUG|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) \& nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
47977554|NCT05713747|OTHER|Life Skills Boot Camp|"The boot camp is designed to be taken by undergraduate students across all disciplines with no pre-requisite coursework and students who participated in the Life skills 101 course and have selected to participate in a boot camp training as part of their Individual Self Development Plan. The boot camp will consist of 3 training programs with 4 sessions (1.5 hour per session) each, including an introductory and a closing part.~Content The boot camp was designed by a team of academics having several years of experience in clinical psychology, educational psychology, and health psychology. The focus of the bootcamp is to teach students practical skills in three different domains of soft skills: a) Interpersonal Skills, b) Resilience and Flexibility and c) Emotion Regulation."
47977555|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
47977556|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
47977557|NCT03580694|DRUG|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
47977558|NCT03580694|DRUG|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
47977559|NCT01519414|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
47977560|NCT01519414|OTHER|Placebo|Given PO
48129287|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
48129288|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
48336671|NCT02067572|OTHER|Saline mouthwash|
48336672|NCT02067572|OTHER|Salvia mouthwash|
48336673|NCT00064077|DRUG|Cisplatin|Given IV
48336674|NCT00064077|DRUG|Gemcitabine Hydrochloride|
48336675|NCT00064077|DRUG|Paclitaxel|Given IV
48336676|NCT00064077|OTHER|Quality-of-Life Assessment|Ancillary studies
48336677|NCT00064077|DRUG|Topotecan Hydrochloride|Given IV
48336678|NCT00064077|DRUG|Vinorelbine Tartrate|Given IV
48336679|NCT05146037|OTHER|CO2 and saline flushing|TAVI valves will be prepared by flushing with CO2 to displace any retained air during manufacturing and preparation. The valves will then be flushed with saline as per IFU.
48336680|NCT05146037|OTHER|Saline flushing|TAVI valves will be flushed with saline only as per IFU.
48336681|NCT03447119|BEHAVIORAL|Living Well with a Disability|Implementation of an adapted health promotion program.
48336682|NCT04858503|OTHER|internet-based cardiac rehabilitation enhancement intervention|Participants in the intervention group will receive a 12-week i-CARE intervention, which will be designed to cover the core elements of CAD self-care: self-care maintenance, self-care monitoring and self-care management. The intervention will comprise: 1) a single individualized face-to-face session and 2) an internet-based intervention through a mobile application. Various behaviour change techniques will be used to increase the self-efficacy of CAD patients in enacting self-care behaviours.
48336683|NCT01671891|RADIATION|radiation therapy|45-55Gy
48336684|NCT01671891|DRUG|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
48336685|NCT03916029|BEHAVIORAL|facilitator|Training and employment of community members to assist the diagnosis and management of otitis media
48336686|NCT03892525|DRUG|Selicrelumab|escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
48336687|NCT03892525|DRUG|Atezolizumab|1200mg IV every 3 week until progression or relapse for maximum 1 year
48336688|NCT01624610|OTHER|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
48336689|NCT00480207|DIETARY_SUPPLEMENT|folic acid|
48336690|NCT00480207|DIETARY_SUPPLEMENT|omega-3|
48336691|NCT00480207|DIETARY_SUPPLEMENT|vit B12|
48336692|NCT00480207|OTHER|folic acid placebo|
48336693|NCT00480207|OTHER|omega-3 placebo|
48336694|NCT03127436|DRUG|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
48336695|NCT01787955|PROCEDURE|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
48336696|NCT01787955|PROCEDURE|conventional PPPD|
48336697|NCT04026945|DRUG|Lidocaine|Sustained-release lidocaine injection
48336698|NCT02589743|DEVICE|Sealant|Application of preventive agent
48336699|NCT02589743|DEVICE|Adhesive and Sealant|Application of preventive agent and technique for control moisture
48336700|NCT00100646|BEHAVIORAL|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
48336701|NCT00100646|DRUG|Lamivudine|300 mg tablet taken orally daily
48654093|NCT05478837|DRUG|Cyclophosphamide|Given IV
48654094|NCT05478837|DRUG|Fludarabine|Given IV
47977561|NCT01519414|DRUG|Tivantinib|Given PO
47977562|NCT02512237|DRUG|ARX788|ARX788, an antibody drug conjugate
47977563|NCT02272920|PROCEDURE|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
47977564|NCT02950025|DEVICE|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
47977565|NCT02950025|DEVICE|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
47977566|NCT02950025|OTHER|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"* 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
47977567|NCT00349284|DRUG|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
48129289|NCT01510236|BEHAVIORAL|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
48336702|NCT00100646|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
48336703|NCT00100646|DRUG|Stavudine|Dosage dependent on weight
48336704|NCT00100646|BIOLOGICAL|Rabies de novo antigen|Vaccine injected intramuscularly
48494667|NCT00845819|DRUG|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
48494668|NCT02358343|BEHAVIORAL|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
48494669|NCT02358343|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
48494670|NCT02358343|DRUG|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
48494671|NCT04666714|DRUG|Praga formulation|Praga formulation tablet
48494672|NCT04666714|OTHER|Placebo pregabalin 75mg|Placebo pregabalin 75mg tablet
48494673|NCT04666714|OTHER|Placebo Pregabalin 150mg|Placebo Pregabalin 150mg tablet
48494674|NCT04666714|DRUG|Pregabalin 75mg|Pregabalin 75mg tablet
48494675|NCT04666714|DRUG|Pregabalin 150mg|Pregabalin 150mg tablet
48494676|NCT04666714|OTHER|Placebo Praga formulation|Placebo Praga formulation tablet
48494677|NCT06299124|DRUG|RGT-419B|RGT-419B will be administered orally
48494678|NCT05061576|BEHAVIORAL|Standard of Care advice on physical activity|Oral advice on exercise from a physician.
48494679|NCT05061576|BEHAVIORAL|Structured advice on physical activity|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
48494680|NCT03335293|DRUG|100 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
48336705|NCT05706818|OTHER|Validity and reliability study|Validity and reliability assessment of the Community Integration Questionnaire-revised
48336706|NCT01500941|DIETARY_SUPPLEMENT|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
48336707|NCT01500941|OTHER|maltodextrin|sachets
48336708|NCT05171881|OTHER|Intervention for cerebral hypoxia|For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
48336709|NCT01792297|DIETARY_SUPPLEMENT|Bovine colostrum|
48494681|NCT03335293|OTHER|normal saline|placebo comparator
48494682|NCT03335293|DRUG|200 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
48494683|NCT05759936|DIETARY_SUPPLEMENT|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
48494684|NCT05759936|OTHER|Placebo|4 week placebo supplement of 1 capsule per day
48336710|NCT01792297|DIETARY_SUPPLEMENT|Whey protein|
48336711|NCT00577915|OTHER|Radiology/MRI scan|MRI spectroscopy
48336712|NCT02255643|DEVICE|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
48494685|NCT00435396|BIOLOGICAL|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
48494686|NCT03178526|DRUG|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
48494687|NCT03178526|DRUG|Placebo|placebo gel
48654095|NCT05478837|BIOLOGICAL|Autologous Anti-H3.3K27M TCR-expressing T-cells|Given IV
47977568|NCT05558514|OTHER|Place-based cochlear implant mapping|Pre-operative, 3D CT scans of the temporal bone will be uploaded into a deep learning-based tool which automatically resamples, crops, segments, analyzes, and measures the patient's specific cochlear anatomy. These measurements will be input into an individualized pitch mapping function to determine a patient-specific tonotopic distribution of frequencies (place-based map). At device activation (approximately 1 month post-surgery) CIs will be programmed according to the place-based map.
47977569|NCT05558514|OTHER|Default cochlear implant mapping|At device activation (approximately 1 month post-surgery) CIs will be programmed according to the clinical default program.
48336713|NCT04204798|DRUG|Dexmedetomidine|"1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
48494688|NCT06050473|PROCEDURE|Nerve-sacrificing procedure|Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.
48494689|NCT06050473|PROCEDURE|Nerve preserving procedure|Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
48494690|NCT04737070|BIOLOGICAL|Prenatal test for Trisomy 21 screening|prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
48494691|NCT06398821|DIETARY_SUPPLEMENT|G3P-01|Nutritional supplement to promote healthy aging
48494692|NCT06398821|DIETARY_SUPPLEMENT|Placebo|Placebo
48494693|NCT03449836|COMBINATION_PRODUCT|Streptococcus salivarius 24SMBc + Strept. oralis 89a|nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
48494694|NCT03449836|COMBINATION_PRODUCT|fluticasone + mometasone|nasal spray based on fluticasone + mometasone
47977570|NCT01730391|OTHER|Data collection|Collection of demographic data and vaccination history
47977571|NCT01730391|OTHER|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
48129290|NCT00599469|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
48494695|NCT03449836|OTHER|placebo|nasal spray based on isotonic solution
48494696|NCT01168206|DIETARY_SUPPLEMENT|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
48494697|NCT01168206|DIETARY_SUPPLEMENT|1 capsule, 3 times per day|Placebo
48494698|NCT06464432|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR); Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD) consisting of 4 therapeutic modules: 1. Emotion Regulation, 2, Self-concept, 3. Relationship Patterns, 4. Prolonged Exposure.
48494699|NCT02770677|OTHER|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
48494700|NCT04331444|DEVICE|CGM|Using the CGM during the entire study period of 12 months.
48654096|NCT03101267|DRUG|ASP4070|Intradermal vaccination at 2-week intervals
47977572|NCT01514812|DRUG|YM150|oral - modified release formulation of YM150
47977573|NCT01514812|DRUG|placebo|oral
47977574|NCT01514812|DRUG|digoxin|oral
47977575|NCT04325581|DRUG|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
47977576|NCT04325581|DRUG|Placebos|Normal Saline SC daily
47977577|NCT02890446|BEHAVIORAL|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
47977578|NCT00602342|DRUG|Terbinafine|
47977579|NCT01899690|DRUG|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
47977580|NCT01080521|PROCEDURE|Cognitive Assessment|Ancillary studies
47977581|NCT01080521|OTHER|Quality-of-Life Assessment|Ancillary studies
48129291|NCT05166590|BEHAVIORAL|Sleep Restriction|Sleep Deprivation
48336714|NCT04204798|DRUG|Placebo|"1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~2. Propofol sedation is administered when considered necessary."
48336715|NCT05190536|PROCEDURE|Ho:YAG lasers|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
48336716|NCT05190536|PROCEDURE|TFL|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
48336717|NCT05848973|OTHER|Healthy Diet|The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.
48336718|NCT05848973|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
48494701|NCT04331444|BEHAVIORAL|training course|The participants in the three groups will attend a three-hour training course with different content depending on the group allocation. The aim of this training course is to ensure that the participants have the knowledge, support and confidence to work collaboratively with their HCPs to increase TIR and decrease HbA1c.
48494702|NCT04331444|BEHAVIORAL|Peer-support|The peer-support will be facilitator-led by the primary investigator with peer exchange in group sessions (3 sessions over the study period, 3 hours per session) with 6-8 participants in every group.
48494703|NCT01371266|DIETARY_SUPPLEMENT|Honey|60.7 grams orally daily times 14 days
48494704|NCT01371266|DIETARY_SUPPLEMENT|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
48494705|NCT01371266|DIETARY_SUPPLEMENT|CHO (sugar)|50 grams daily orally times 14 days
48494706|NCT05753761|BEHAVIORAL|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS) intervention|Using baseline accelerometry data, personalized goals of replacing sedentary time with stepping time will be developed.
48494707|NCT04191655|DEVICE|High Definition Colonoscopy|A colonoscopy that used high definition (HD) camera
48494708|NCT04191655|DEVICE|Dye Spraying Chromocolonoscopy|A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
48494709|NCT05615688|PROCEDURE|Pain Intensity following Placement of Orthodontic Separators|Elastomeric separators will be placed on the mesial and distal of lower first permanent molars for a total of four separators per subject. Subjects will wear receive an activity monitor prior to placement of elastic separators and instructed to wear it 24/7 unless showering or swimming. Subjects will complete a recurrent Pain Scale Questionnaire 2-4 hrs after placement of elastics and every 24 hrs from day 2- 7.
48494710|NCT01829841|DRUG|Famitinib|Famitinib 25 mg p.o. qd
48494711|NCT01829841|DRUG|Sunitinib|Sunitinib 50 mg p.o. qd
48494712|NCT02158286|OTHER|Measuring emptying rate from the gastric tube|
48494713|NCT05755152|OTHER|polyphenol-lecithin precipitate (PLP)|Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).
48129292|NCT04664998|DIAGNOSTIC_TEST|Diagnostic test for NG/CT|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
48336719|NCT03648463|PROCEDURE|arthroscopy of the affected knee/ Bone Marrow Concentrate Injection|Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
48494714|NCT05755152|OTHER|control formulation|Chewing gum made with material produced from conventional technology (e.g cranberry extract).
48494715|NCT03915366|DRUG|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
48494716|NCT03915366|DRUG|Tuberculostatic Agents|Treatment for tuberculosis
48494717|NCT06111274|DRUG|Pimicotinib (ABSK021)|The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
48494718|NCT04527653|DEVICE|Tixel|Non-invasive thermo-mechanical treatment
48494719|NCT03484117|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
48494720|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
48129293|NCT04664998|DIAGNOSTIC_TEST|HIV testing|All participants will receive diagnostic testing for NG/CT at each quarterly visit.
48129294|NCT05316766|OTHER|Physical rehabilitation|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on conventional therapy
48129295|NCT05316766|OTHER|Physical rehabilitation interactive table|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on multi-user touch surface
48129296|NCT00156208|DRUG|Asoprisnil|10mg Tablet, oral Daily for 18 months
48129297|NCT00156208|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 18 months
48494721|NCT01064141|BIOLOGICAL|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
48494722|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
48494723|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
48494724|NCT05592392|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
48654097|NCT03101267|DRUG|Placebo|Intradermal vaccination at 2-week intervals
48336720|NCT02206321|PROCEDURE|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
48336721|NCT02206321|PROCEDURE|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
48336722|NCT05375162|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the Opt2Move self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the 24-week study period. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the Opt2Move study app and provide Fitbit data to the study team in real-time.~The core Opt2Move study app will support YACS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
48336723|NCT05375162|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
48336724|NCT05375162|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the Opt2Move app.
48336725|NCT05375162|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the Opt2Move app.
48336726|NCT05375162|BEHAVIORAL|Buddy|Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the Opt2Move app modules the participant has access to for their assigned condition. The Opt2Move app will include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcasts (one every 3 weeks) during the first 12 weeks of the intervention. Each podcast will provide social support training and peer discussion of challenges and successes in providing YACS with MVPA support.
48336727|NCT03970707|OTHER|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25\*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
48336728|NCT03970707|OTHER|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25\*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
48494725|NCT04412265|OTHER|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
48494726|NCT02045992|DIETARY_SUPPLEMENT|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
48494727|NCT01832935|DRUG|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
48494728|NCT01832935|DRUG|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
48494729|NCT04940949|DRUG|Lu AF90103|Lu AF90103 - powder for solution for infusion
48494730|NCT04940949|DRUG|Placebo|Placebo - powder for solution for infusion
48494731|NCT06205017|DIETARY_SUPPLEMENT|Foods for Special Medical Purposes|"In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet."
48494732|NCT03891966|PROCEDURE|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
48494733|NCT03891966|PROCEDURE|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
48494734|NCT02394730|DRUG|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
48494735|NCT02394730|DRUG|Placebo|Sugar pill taken orally once daily for 12 weeks
48129298|NCT05416827|PROCEDURE|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
48129299|NCT00995696|BEHAVIORAL|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
47977582|NCT03265275|OTHER|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
48129300|NCT05004207|DIAGNOSTIC_TEST|99mTc Scintigraphy|"After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.~Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device."
48129301|NCT03347851|OTHER|MRI|Enrolled patients will complete a non-contrast cardiac MRI
48129302|NCT03347851|OTHER|Transthoracic echocardiography exam|Enrolled patients will complete a transthoracic echocardiography exam.
48129303|NCT03892317|BEHAVIORAL|Pharmacist led medication adherence interventions|Medication adherence interventions which will be tailored to individual patient need
48129304|NCT04338399|DRUG|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
48129305|NCT04611373|DRUG|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
48129306|NCT00604955|DRUG|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
48129307|NCT05304624|DEVICE|laser|these lasers are routinely used in dental practice
48129308|NCT06085989|BEHAVIORAL|Infant directed singing|In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
48129309|NCT06085989|BEHAVIORAL|Standard care|Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
48129310|NCT03380013|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
48129311|NCT00378300|DRUG|Oral Probiotics|
48129312|NCT05695469|DEVICE|Smart resuscitation glove (ResuGlove)|Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
48129313|NCT05695469|OTHER|Traditional CPR|Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
47977583|NCT02734238|DRUG|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
48129314|NCT01768793|BEHAVIORAL|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
48129315|NCT01768793|BEHAVIORAL|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
48129316|NCT05124613|OTHER|Survey|"Information collected and stored in Survey:~* Type of knee surgery the patient is waitlisted for~* Demographics: age, sex, recent weight gain~* Validated and bespoke questions:~  1. EQ-5D survey (a validated questionnaire on health)~ 2. Bespoke questions on knee pain today~ 3. Bespoke questions on knee function today~ 4. Bespoke questions on change in knee pain since being waitlisted for surgery~ 5. Bespoke questions on change in knee function since being waitlisted for surgery~ 6. Bespoke questions on coping mechanisms patients use to manage symptoms~ 7. Bespoke questions on what support they would find beneficial whilst they wait for their surgery~ 8. Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)"
48129317|NCT02549807|DEVICE|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
48494736|NCT04714320|DRUG|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
48494737|NCT04714320|DRUG|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
47977584|NCT02734238|DRUG|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
47977585|NCT05763550|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
48129318|NCT00476905|DEVICE|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
48129319|NCT04755920|DRUG|SGM-101|Fluorescence-guided surgery
48129320|NCT05113810|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
48129321|NCT05113810|OTHER|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
48336729|NCT00732641|DRUG|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
48336730|NCT00954057|DRUG|LIPO-102|intraorbital injection
48336731|NCT00954057|DRUG|Placebo|intraorbital injection
48336732|NCT04373213|DIAGNOSTIC_TEST|Pleth variability index|The usefulness of Pleth variability index in predicting fluid response in patients with COVID 19
48336733|NCT03684070|BEHAVIORAL|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
48336734|NCT03684070|BEHAVIORAL|Self-monitoring|Self-monitoring of data from wearable step count tracker
48336735|NCT05007223|DRUG|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
48494738|NCT03595631|OTHER|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
48494739|NCT03595631|OTHER|Physical Therapy plus Neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
48494740|NCT02077439|DEVICE|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
47977586|NCT05763550|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
47977587|NCT05763550|DRUG|Pregabalin 150mg|pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
47977588|NCT03552263|DRUG|T89 capsule|T89 capsules (75mg), orally, twice daily.
47977589|NCT03552263|DRUG|Placebo capsule|Placebo capsules (0mg), orally, twice daily.
47977590|NCT02054221|PROCEDURE|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
47977591|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
48494741|NCT02077439|DEVICE|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
48494742|NCT02077439|OTHER|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
48494743|NCT02122406|OTHER|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
48494744|NCT03724526|BEHAVIORAL|Text messaging|"Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care."
47977592|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
47977593|NCT01285674|DRUG|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
48129322|NCT00370942|DRUG|GW823093C A|A=45 mg
48129323|NCT00370942|DRUG|GW823093C B|B=30 mg
48129324|NCT00370942|DRUG|GW823093C C|C=25 mg
48336736|NCT01390038|DEVICE|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
48336737|NCT06112067|DEVICE|deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
48336738|NCT05767229|DRUG|Carvedilol|Carvedilol 0.2 mg/kg for 1.5 hrs
48336739|NCT06397534|OTHER|Education|"In the experimental group, students will be administered the Introduction Characteristics Form, Stoma Care Knowledge Assessment Form (pre-test), and the General Self-Efficacy Scale (pre-test). Subsequently, digital materials (such as stoma care presentation materials and stoma care demonstration videos) will be prepared by the researchers. The video content will be uploaded to the 'Edpuzzle' program, which is accessible via internet connection or downloadable to devices. The video content in the 'Edpuzzle' program will consist of stoma care procedural steps. Following this, students will apply the stoma care skill in the skills laboratory under the supervision of instructors. To reinforce the implementation in the experimental group, online activities such as word clouds and quizzes will be sent. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online."
48336740|NCT06014957|DRUG|spinal anesthesia|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), immediately positioned supine with one pillow supporting the head and shoulders
48336741|NCT06014957|DRUG|saddle block|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders
48336742|NCT04841252|DEVICE|FDA approved GE LOGIQ E9 (LE9) ultrasound|Ultrasound
48336743|NCT04841252|DEVICE|Alpinion clinical ultrasound machine|Ultrasound
48336744|NCT02378493|BIOLOGICAL|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
48494745|NCT05419830|BEHAVIORAL|BBTI|Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
48494746|NCT05419830|OTHER|PM antihypertensive dosing or Chronotherapy|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
48494747|NCT05419830|OTHER|AM antihypertensive dosing|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
48494748|NCT02987959|DRUG|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
48336745|NCT03704805|BEHAVIORAL|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
48336746|NCT03704805|OTHER|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
48336747|NCT00473044|BEHAVIORAL|Sisters in Motion|
48336748|NCT02135900|DRUG|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
48494749|NCT03055663|OTHER|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
48494750|NCT03055663|PROCEDURE|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
48494751|NCT03055663|DRUG|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
48494752|NCT05935566|OTHER|health questionnaire|Telephone interview with patient to verify medical history, including tonsillectomy and adenoidectomy.
48494753|NCT01011244|BIOLOGICAL|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
48494754|NCT02876783|OTHER|Observational - No intervention|
48494755|NCT01565850|DRUG|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
48494756|NCT01565850|DRUG|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
48494757|NCT01565850|DRUG|COBI|COBI 150 mg tablet administered orally once daily
47977594|NCT04533438|DEVICE|RhinAer Stylus|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.
47977595|NCT04533438|DEVICE|Sham|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
47977596|NCT01382823|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
47977597|NCT01705184|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
47977598|NCT01705184|DRUG|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
48129325|NCT05058677|DRUG|aerosolized 2% lidocaine (20mg/ml)|The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
48129326|NCT05058677|DRUG|instilled 0.9% sodium chloride (NS)|The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
48494758|NCT01565850|DRUG|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
48494759|NCT01565850|DRUG|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
48654098|NCT06563687|DEVICE|Dexcom ONE+|In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
48129327|NCT05058677|DRUG|instilled 2% lidocaine solution|The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
47977599|NCT01705184|DRUG|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
48494760|NCT01565850|DRUG|DRV Placebo|DRV placebo tablet administered orally once daily
48494761|NCT01565850|DRUG|COBI Placebo|COBI placebo tablet administered orally once daily
48494762|NCT01565850|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
48654099|NCT00398879|DRUG|Perifosine|Perifosine 50 mg/d qd
48654100|NCT00398879|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
48654101|NCT00398879|OTHER|Perifosine Placebo|Placebo to Perifosine 50 mg/d qd
48654102|NCT03439072|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
48494763|NCT03427502|DRUG|Bupivacaine-epinephrine|10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
48654103|NCT03439072|DRUG|Lilly Glucagon|1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
48654104|NCT04005833|DIAGNOSTIC_TEST|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
48654105|NCT06638671|DRUG|Metformin Hydrochloride|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
48654106|NCT06638671|DRUG|Placebo|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
48654107|NCT00802906|DEVICE|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
48654108|NCT00802906|DRUG|bevacizumab|1.5 mg initial intravitreal injection
48654109|NCT05615883|OTHER|AEP Group Walking Sessions|The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
48494764|NCT03427502|DRUG|normal saline|normal saline
48494765|NCT03250676|DRUG|H3B-6545|Oral capsules by mouth once daily
48494766|NCT02945670|BEHAVIORAL|Focus Group|We had recruited 64 women and completed 7 focus group sessions
48494767|NCT01109563|BEHAVIORAL|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
48494768|NCT00709839|DRUG|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
48654110|NCT05615883|OTHER|CEP Group Walking Sessions|The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
48654111|NCT06643091|DRUG|Nintedanib|Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)
48129328|NCT05058677|PROCEDURE|Endotracheal Suctioning (ETS)|ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
48336749|NCT05730101|OTHER|Cognitive-behavioral treatment (CBT)|In the first individual session (CBT1), together with the therapist, participants develop a behavioral and conditional model of their procrastination behavior. In the next 2 group sessions (CBT2 and CBT3), participants receive psychoeducation on procrastination. The focus is on learning the method of starting on time. In the third group session (CBT4), participants identify key procrastination-promoting thoughts and are supported to develop alternative thoughts; deepened in the second individual session (CBT5). In the next 2 group sessions (CBT 6 and CBT7), participants are informed about action planning with focus on learning to plan realistically. The last group session is a concluding session: Experiences with the methods learned and an outlook on further steps and goals are discussed. At the end of both individual sessions (CBT1 and CBT5), participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
48494769|NCT00709839|DRUG|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
48494770|NCT05964712|PROCEDURE|Medical surgery therapy|De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
48494771|NCT00405886|DRUG|Neramexane|Oral tablets, duration: 16 weeks
48494772|NCT00405886|DRUG|Placebo|Oral tablets, duration: 16 weeks
48494773|NCT04095949|DIETARY_SUPPLEMENT|Artichokes|Approximately 200 g of cooked artichokes
48494774|NCT05578365|OTHER|Pilates method|Individuals in the Pilates group will perform specific exercises online. There will be 16 sessions, lasting 60 minutes, with 10 minutes of warm-up, 30 to 40 minutes of exercises focusing on the trunk stabilizers muscles, and 10 minutes of cool-down with relaxation, stretching, or meditation. In addition, the individuals will have access to the same information of the control group.
48654112|NCT02268656|DRUG|propofol concentration|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
48494775|NCT05578365|OTHER|Pain education|Individuals in the control group will receive information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
48494776|NCT02442674|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
48494777|NCT02442674|OTHER|Placebo|Placebo tablet matching active drug
48494778|NCT05567484|DRUG|Itraconazole|100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered
48494779|NCT04275765|BEHAVIORAL|Arm 2:Behavioral Intervention with nudges & Facebook interaction|Participants will receive nudges and be enrolled to Facebook group for self-learning.
48654113|NCT05833139|DRUG|BI 1810631|BI 1810631
48654114|NCT05833139|DRUG|Itraconazole|Itraconazole
48654115|NCT05315752|PROCEDURE|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~* Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~* Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~* for patients with a BMI \>40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss \>7%) or~* for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
48654116|NCT06352073|DRUG|Dupilumab|300mg weekly subcutaneous injection
48494780|NCT04275765|OTHER|Arm 3: Community Intervention with individualised teleconferencing sessions and phone calls.|Participants will receive individualised teleconferencing sessions and phone calls by skilled midwives.
48494781|NCT03514654|PROCEDURE|Mastectomy|Removal of the whole breast.
48494782|NCT03514654|PROCEDURE|Therapeutic Mammoplasty|Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
48654117|NCT03184025|OTHER|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
48654118|NCT06641921|DEVICE|Seerlinq haemodynamically-guided heart failure treatment|Heart failure treatment of participants in the Seerlinq intervention arm will be haemodynamically-guided based on the results from the Seerlinq telemedical monitoring system.
48654119|NCT01767987|DRUG|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
48654120|NCT01767987|DRUG|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
48654121|NCT05580679|OTHER|Abdominal massage|"Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration"
48654122|NCT05498909|OTHER|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
48654123|NCT06437457|RADIATION|ceus|MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.
48654124|NCT00991978|OTHER|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
48654125|NCT01720836|BIOLOGICAL|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
48654126|NCT02014103|DRUG|Prograf|Administration of each formulation will be determined by sequence.
48654127|NCT02014103|DRUG|Tacrolimus, Sandoz|Administration of each formulation will be determined by sequence.
47977600|NCT00859053|DRUG|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
47977601|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Safe Sleep Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.
48654128|NCT02014103|DRUG|Tacrolimus, Reddy Laboratory|Administration of each formulation will be determined by sequence.
48654129|NCT02014103|DRUG|Tacrolimus, Mylan|Administration of each formulation will be determined by sequence.
48654130|NCT02014103|DRUG|Tacrolimus, Accord|Administration of each formulation will be determined by sequence.
48654131|NCT02014103|DRUG|Tacrolimus, Pancea Biotech Limited|Administration of each formulation will be determined by sequence.
48654132|NCT05512143|DEVICE|Transcranial magnetic stimulation|Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
48654133|NCT03617939|PROCEDURE|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
48654134|NCT03617939|OTHER|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
48654135|NCT03617939|OTHER|Medical Chart Reviews|Data taken directly from the patients' medical charts.
48654136|NCT06641752|DIAGNOSTIC_TEST|Blood drop sampling|The process: blood drop sampling Technique: capillary sampling Frequency: Once Time: 5 minutes Sample collection volume: 1mL Total collection volume: 1 mL
48654137|NCT01955356|PROCEDURE|Scratching|Endometrial biopsy
48654138|NCT05078437|BEHAVIORAL|Medication therapy management|The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
48654139|NCT06638164|OTHER|Control|No attempt was made to increase knowledge, skills and satisfaction. Standard procedure (oral explanation) was applied.
47977602|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Car Seat Safety Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
48336750|NCT05730101|OTHER|Imaginary pill treatment (IP)|In the first session (IP1), participants will be asked about the nature of their procrastination behavior and receive a procedure to take an imaginary pill following a rationale of 5 steps. In the second IP session (IP2), experiences with taking the IP are discussed and the procedure of taking the IP is adapted according to previous experiences and current needs. The rationale of the second session encompasses the same five steps with small modifications: 1) discussing IP sensitive problem and adapting it if necessary, 2) building trust/belief/reality of the IP, 3) discussing the personally meaningful IP and adapting it if necessary, 4) taking the IP, 5) adapting the procedure for self-administering the IP in real life on daily basis if necessary and building adherence. At the end of both sessions, participants receive a link to an online survey to rate their treatment expectations (treatment expectation 1 and 2).
48336751|NCT01311895|DRUG|H2O|2 mg IV hydromorphone
48336752|NCT01311895|DRUG|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
48336753|NCT06063512|OTHER|sweet orange oil inhalation|sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
48336754|NCT00756678|DRUG|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
48336755|NCT00756678|DRUG|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
48654140|NCT06638164|OTHER|Virtual reality glasses|In order to increase knowledge, skills and satisfaction, isolation training was given with virtual reality glasses.
48654141|NCT00539500|DRUG|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
47977603|NCT06399978|BEHAVIORAL|Brain Blossom - Gamified Differential Outcome Training|Digital cognitive training with a gamified DOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
47977604|NCT06399978|BEHAVIORAL|Gamified Non-Differential Outcome Training|Digital cognitive training with a gamified NDOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
48336756|NCT05409846|DIAGNOSTIC_TEST|Alfa-galactosidase activity and genetic testing for Fabry diagnosis|Dry blood spot analysis and blood sample (if necessary)
48336757|NCT03162341|PROCEDURE|ultrasonography|The tophus volume will be assess using ultrasonography.
48336758|NCT03162341|PROCEDURE|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
48336759|NCT00005945|DRUG|cyclophosphamide|Given IV
48336760|NCT00005945|DRUG|cytarabine|Given IT
48336761|NCT00005945|DRUG|daunorubicin hydrochloride|Given IV
48336762|NCT00005945|DRUG|dexamethasone|Given PO
48336763|NCT00005945|DRUG|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
48336764|NCT00005945|DRUG|mercaptopurine|Given PO
48336765|NCT00005945|DRUG|methotrexate|Given PO and IT
48336766|NCT00005945|DRUG|pegaspargase|Given IM
48336767|NCT00005945|DRUG|thioguanine|Given PO
48654142|NCT00539500|DRUG|Etoposide|300 mg/m\^2 by vein over 24 hours for 4 days
48654143|NCT00539500|DRUG|Melphalan|70 mg/m\^2 Intravenous Bolus for 3 Days
48654144|NCT00539500|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.
48654145|NCT00539500|DEVICE|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
48654146|NCT05793502|DEVICE|Solia S and Selectra 3D Developed by BIOTRONIK|LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK
48654147|NCT06346119|OTHER|this arm will received relaxing touch (hands, feet, head) during 30 minutes twice a day|Patients who will be included in this arm will receive massage twice a day of the head (10 minutes), feet (10 minutes) and hands (10 minutes)
48654148|NCT06062355|DRUG|HRS-9815 injection|HRS-9815 injection
48336768|NCT00005945|DRUG|vincristine sulfate|Given IV
48654149|NCT06637280|DEVICE|High - flow nasal cannula|"High flow nasal cannula (HFNC), a device first introduced in neonates and pediatric care, is currently used in a wide range of indications in adult respiratory and critical care medicine (5-7). It is a relatively new method in bronchoscopy with several notable theoretical advantages over low flow oxygen via conventional nasal cannula (CNC):~* High flow up to 60 liters per minute ensures a more stable FiO2 and better matches the increased patient's inspiratory flow~* High flow generates a small positive expiratory airway pressure (up to 5 cm H2O) which could stabilize the upper airways during sedation and have a beneficial effect in the lower airways~* High flow reduces dead space in the upper airways and increases alveolar ventilation."
48654150|NCT06637280|DEVICE|Standard nasal cannula|Standard method for supplementing oxygen during EBUS bronchoscopy
48336769|NCT00005945|RADIATION|radiation therapy|Undergo radiation therapy
48336770|NCT05351905|DRUG|CBD oil ( MPL-001)|MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
48654151|NCT05402345|DRUG|GlcNAc-GlcN|GlcNAc powder - weight-dependent dose
48654152|NCT05402345|OTHER|Placebo|Placebo xylose
47977605|NCT00447161|DRUG|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water
48654153|NCT06572020|OTHER|education|simulation-based training on blood pressure and ECG measurement
48654154|NCT06642896|DEVICE|pupillometer|describe the feasibility of pupillometry measurements in sedated but non-cerebrosed children
48654155|NCT06642896|DEVICE|pupillometer|Pupillometry measurements at 5 and 25 minutes for children treated with osmotherapy, followed by measurements twice a day during hospitalization in the intensive care unit
47977606|NCT00447161|DRUG|Placebo|Matched placebo
47977607|NCT03388879|DEVICE|Taylor Spatial Frame|Circular external fixator
47977608|NCT03388879|DEVICE|Intramedullary nail|Antegrade intramedullary nail
47977609|NCT05146401|OTHER|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
47977610|NCT00289471|OTHER|No intervention delivered.|No intervention delivered.
47977611|NCT02345694|DEVICE|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
47977612|NCT02345694|DEVICE|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
48336771|NCT05351905|DRUG|CDB+THC oil (MPL-005)|MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
48336772|NCT05351905|DRUG|Placebo oil|The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
48336773|NCT03175016|PROCEDURE|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
48336774|NCT03175016|DRUG|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
48336775|NCT03175016|DEVICE|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
48336776|NCT00222248|BEHAVIORAL|Pelvic floor muscle training and bladder training|
48336777|NCT05954260|DIAGNOSTIC_TEST|Blood sampling|We will collect blood samples from the patients included in the study on ICU days 1, 3 and 5. We will measure gene expression (mRNA) and plasma levels of various elements involved in the immunological synapse.
48336778|NCT05666908|DEVICE|HFNO|After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) \> 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
48336779|NCT00064636|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
48336780|NCT06238115|DRUG|Tirofiban|Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
48336781|NCT06238115|DRUG|aspirin, clopidogrel|aspirin 100 mg/day, clopidogrel 75 mg/day
48336782|NCT04714489|OTHER|NO.|NO.
48336783|NCT00137670|DEVICE|Video-based HIV/STD prevention intervention|
48129329|NCT03959384|DRUG|Curosurf 80Mg/Ml Intratracheal Suspension|CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
47977613|NCT02030392|BEHAVIORAL|Intervention group|Cognitive-behavioral intervention
47977614|NCT02030392|BEHAVIORAL|Active control group|Education and information
47977615|NCT01672697|BEHAVIORAL|Physical Therapy (PT) and Behavioral Therapy (BT)|"1. Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~2. Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment."
48336784|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
48336785|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.
47977616|NCT02839707|DRUG|Atezolizumab|Given IV
47977617|NCT02839707|BIOLOGICAL|Bevacizumab|Given IV
48129330|NCT03959384|OTHER|Ambient Air|Ambient air aspirated in sterile syringes
48129331|NCT03417479|OTHER|Gabapentin|
48336786|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) and Celecoxib (oral 200mg twice daily for 6 months) followed by surgical resection.
48336787|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
48494783|NCT00158756|BIOLOGICAL|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
48494784|NCT00158756|BIOLOGICAL|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
48129332|NCT05353894|DRUG|GNS561 oral tablets and capsules|Two formulations and Two dosage will be compared
48494785|NCT00158756|BIOLOGICAL|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
48494786|NCT00158756|BIOLOGICAL|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
48494787|NCT00158756|BIOLOGICAL|Engerix™-B|GSK Biologicals' hepatitis B vaccine
48494788|NCT00158756|DRUG|Placebo|Placebo for the Rotarix™ vaccine
48129333|NCT03024034|DRUG|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
48336788|NCT02873208|DRUG|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
48336789|NCT03312361|DRUG|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
48336790|NCT01369225|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
48336791|NCT01369225|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
48494789|NCT06219226|PROCEDURE|Chlorine dioxide mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
48494790|NCT06219226|PROCEDURE|Chlorhexidine mouthwash|This one rinsing will last 2x15 seconds(2x12,5ml).
48494791|NCT01097525|PROCEDURE|WFG PRK|
48494792|NCT01097525|PROCEDURE|WFG LASIK|
48494793|NCT01097525|PROCEDURE|WFO PRK|
48129334|NCT05948449|DRUG|S-1, Oxaliplatin, Cadonilimab|3 cycles of neoadjuvant therapy will be administered: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
48129335|NCT00585624|DIETARY_SUPPLEMENT|Impact Advanced Recovery|Nutritional supplement
48494794|NCT01097525|PROCEDURE|WFO LASIK|
48494795|NCT02613741|OTHER|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
48129336|NCT00585624|DIETARY_SUPPLEMENT|No supplement|No supplement
48336792|NCT01369225|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
48494796|NCT05145686|DIAGNOSTIC_TEST|Matris metalloproteinase -2, -8, -9 expressions|. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.
48494797|NCT03591003|DIAGNOSTIC_TEST|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
48494798|NCT03949244|DRUG|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
48129337|NCT02094560|DRUG|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
48336793|NCT01369225|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
48336794|NCT01369225|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
48336795|NCT05308160|DRUG|Dapagliflozin 10Mg Tab|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
48494799|NCT03949244|DRUG|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
48494800|NCT03949244|DRUG|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
48654156|NCT06637267|DIAGNOSTIC_TEST|Proclarix®|The aim of the study is the implementation of new biomarkers (Proclarix®) in order to increase the sensitivity and specificity of PSA-based Prostate cancer early detection avoiding unnecessary prostate biopsies thus decreasing the associated morbidity (infections, bleeding, urinary retention, etc.). PSA values, Proclarix and mpMRI findings will be correlated with the results of the prostate biopsy in order to improve patient selection for future biopsies in order to avoid unnecessary prostate biopsies, but still be able to detect relevant carcinomas at an early stage. The null hypothesis in our observational study is the lack of superiority in PCa early detection when using the Proclarix over PSA alone.
48654157|NCT06640673|DIAGNOSTIC_TEST|Hd-EEG|Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging
47977618|NCT02839707|PROCEDURE|Computed Tomography|Undergo CT
47977619|NCT02839707|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
47977620|NCT02839707|OTHER|Quality-of-Life Assessment|Ancillary studies
48129338|NCT00247351|PROCEDURE|Cryoablation|
48129339|NCT00042731|DIETARY_SUPPLEMENT|Lycopene|Daily administration as outlined in treatment arm(s)
48336796|NCT05308160|DRUG|Placebo|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
48336797|NCT00317057|PROCEDURE|Patient education and disease management|
48494801|NCT03949244|DIAGNOSTIC_TEST|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
48494802|NCT04335318|DEVICE|AI-assisted colonoscopy|Colonoscopies performed with assistance of an AI tool that highlights the areas that are susceptible to be a polyp.
48494803|NCT05726461|DEVICE|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
48494804|NCT05726461|DEVICE|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
48654158|NCT04154332|OTHER|Sample collection|Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
47977621|NCT06401395|DEVICE|DIGIPARK MONITOR|remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
47977622|NCT02354989|DEVICE|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
48129340|NCT00042731|DIETARY_SUPPLEMENT|Multivitamin|Daily administration as outlined in treatment arm(s)
48129341|NCT00042731|DIETARY_SUPPLEMENT|Soy isoflavones|Daily administration as outlined in treatment arm(s)
48336798|NCT03228706|BEHAVIORAL|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska \& Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen \& Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
48336799|NCT00782301|DRUG|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
48336800|NCT00782301|DRUG|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
48336801|NCT00888680|DRUG|BGC20-1531|BGC20-1531 administered orally
48129342|NCT03594500|OTHER|PockeTalker|The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
48336802|NCT00888680|DRUG|Lactose|Placebo administered orally
48336803|NCT00964262|DRUG|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
48336804|NCT00964262|DRUG|Placebo|Plcacebo of each doasage, single subcutanoeus injection
48336805|NCT05955430|OTHER|Therapeutic exercise|It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
48336806|NCT05955430|OTHER|Pain education|A therapeutic pain education program for patients will be implemented. There will be four 30-minute face-to-face sessions (one session per week). The objective is to change the participants' conceptualization of pain. From seeing pain as a marker of tissue damage to a marker of the body's perceived need for protection. Contents include basic structure of the nervous system, distinction between nociception and pain, peripheral and central sensitization, neuroplasticity and benefits of exercise.
48336807|NCT05955430|OTHER|Percutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four needles located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
48494805|NCT05340777|DEVICE|Training Obstetric staff on Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to ensure staff are trained on the newly registered and provided medical device. We will gather feedback on how to improve the training curriculum from participants. We will also gather information from the healthcare workers immediately post-use of an Ellavi UBT device following their management of a refractory PPH case. These surveys will help us to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of PPH care.
48494806|NCT02927977|OTHER|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
47977623|NCT02354989|DEVICE|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
48129343|NCT03594500|OTHER|No PockeTalker|The control group will not receive PockeTalkers while they receive care in the ED
48129344|NCT01088841|DIETARY_SUPPLEMENT|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
48129345|NCT00288288|PROCEDURE|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
48129346|NCT00288288|PROCEDURE|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
48129347|NCT02866942|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
48494807|NCT02927977|OTHER|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
48494808|NCT03607526|OTHER|Barriers|NGT sessions identifying barriers to vegetable intake.
48129348|NCT03961841|RADIATION|chemoradiation with weekly 5Fu and oxaliplatin|5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
48129349|NCT03961841|DRUG|Perioperative mFLOT|Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
48129350|NCT03961841|DRUG|Perioperative FOLFOX|Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
48129351|NCT06394206|OTHER|Specialized Unit|The participant will be visited every three months for one year
47977624|NCT05384015|DRUG|Lenvatinib|"Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance)."
47977625|NCT05384015|DRUG|Pembrolizumab|"Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion"
47977626|NCT05384015|DRUG|Etoposide|"Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles"
47977627|NCT05384015|DRUG|Carboplatin|"Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles"
47977628|NCT01260285|DRUG|Vardenafil|10 mg PO once
47977629|NCT05426577|DIAGNOSTIC_TEST|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
47977630|NCT01035515|DRUG|Placebo|Single dose oral capsule placebo comparator
47977631|NCT01035515|DRUG|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
47977632|NCT01035515|DRUG|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
48129352|NCT06394206|OTHER|Usual Follow-Up|The participant will be visited as usual, it means they will be visited at Digestive Consultation
47977633|NCT00587639|DEVICE|rTMS Treatment|Active rTMS treatment.
47977634|NCT04745754|OTHER|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
47977635|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be guided by a physiotherapist.
47977636|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be performed at home.
47977637|NCT01880385|BIOLOGICAL|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
48129353|NCT03148652|OTHER|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
48129354|NCT00100698|DRUG|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
48129355|NCT00100698|DRUG|placebo|placebo subcutaneously once a day, 18 months
48494809|NCT03607526|OTHER|Facilitators|NGT sessions identifying facilitators to vegetable intake.
47977638|NCT01880385|DRUG|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
47977639|NCT01880385|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
47977640|NCT01880385|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
48129356|NCT03311360|DEVICE|drug-coated balloon|Orchid and Dahlia DCB
48129357|NCT03311360|DEVICE|bare metal stent|any type of bare metal stent
48129358|NCT01286636|OTHER|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
48129359|NCT01286636|OTHER|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
48336808|NCT05955430|OTHER|Transcutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four patches located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
48494810|NCT04206514|BEHAVIORAL|Person Centered Care - Post Abortion Support|Post abortion phone based support
48494811|NCT01953939|OTHER|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
48494812|NCT02058212|DRUG|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
48336809|NCT05955430|OTHER|Placebo stimulation|To perform the dry needling placebo, modified needles will be used according to the validation performed by Mitchell et al. 2018, since they generate more puncture sensation than normal needles, which has been shown to generate more analgesia and to be more effective as a placebo. To perform placebo TENS, the protocol established by Rakel et al. 2010 will be used, which consists of applying a TENS of 100 Hz and 100 ms for 30 seconds and then lowering the intensity during the following 15 seconds. Eight sessions will be held during a month (two per week).
48336810|NCT04720690|DEVICE|Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output|Measurement of arterial stiffness and cardiac output
48336811|NCT04720690|DEVICE|NICaS|Measurement of cardiac output
48336812|NCT04720690|DEVICE|Echocardiography and ultrasound of arteries|Measurement of cardiac output; measurement of intima-media thickness of arteries
48336813|NCT03249753|DRUG|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
48336814|NCT03249753|DRUG|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
48336815|NCT05979155|BIOLOGICAL|NWY001|Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
48336816|NCT05979155|BIOLOGICAL|NWY001|Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
48336817|NCT02738762|OTHER|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
48494813|NCT00306150|DRUG|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
48494814|NCT00306150|DRUG|Placebo|Placebo is used according to the description of Arm 1
48494815|NCT03894748|DRUG|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
48494816|NCT00044109|DEVICE|Magnets|
47977641|NCT01880385|DRUG|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
47977642|NCT01880385|BIOLOGICAL|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
47977643|NCT04167202|PROCEDURE|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
47977644|NCT04167202|PROCEDURE|RICE|RICE protocol
47977645|NCT05633420|DRUG|Pyramax|"Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)"
47977646|NCT04019665|OTHER|MMSE (mini mental state examination)|mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
47977647|NCT04019665|OTHER|SAGE (Self-Administered Gerocognitive Exam)|SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
47977648|NCT04803825|OTHER|Heavy Slow Exercises|"* Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~* Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~* Number of sets: 3~* Rest between sets: 2 - 3 min.~* Number of exercise interventions: 2~* Duration of experimental period: 12 weeks~* Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~* Rest in-between repetitions: No~* Range of motion: Full range of motion~* Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between."
48336818|NCT04539925|OTHER|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
48336819|NCT03483116|BIOLOGICAL|RV3-BB|Oral administration
48336820|NCT03483116|BIOLOGICAL|Placebo|Oral administration
48336821|NCT04494958|DRUG|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
48336822|NCT00468611|DRUG|MBP8298|500mg MBP8298 IV every six months for a period of two years
48494817|NCT05813366|OTHER|Acupuncture|Tony disposable, single-use 0.20×40 mm Chinese needles will be used. The needle penetrates the skin sufficiently to reach the required depth and elicit de qi. The needles remains for 30 min, with gentle rotational movements applied three times during the session.
48494818|NCT05813366|OTHER|Tryptophan-Rich Diet|"All participants in both groups (A and C) will be treated by high protein foods rich with tryptophan including: chicken , turkey, red meat, salmon, fish, tuna, beans, milk, cheese, seeds, nuts, egg, banana, kiwi, leafy greens, mushroom, broccoli and peas, etc.~Total daily calorie intake will be calculated for each participant in both groups (A and C) before diet description. All females will serve the meals that met their required kilocalorie levels and physical activity levels so that the participants will not lose weight, feel hungry or be over-fed."
48494819|NCT05813366|OTHER|Vitamin B6 Supplementation|All participants in all groups (A, B and C) will receive a tablet of vitamin B6 60mg once/day for 8 weeks, starting from the first day of their menstrual cycle, throughout two menstrual cycles.
48494820|NCT00640679|DRUG|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
48129360|NCT00116649|DRUG|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
48129361|NCT00795184|DEVICE|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
48129362|NCT00795184|DEVICE|HDWLE|
48336823|NCT05690672|DIAGNOSTIC_TEST|Delirium Screening|Either 3D-CAM or 4AT
48336824|NCT05944159|BEHAVIORAL|Study Group|Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.
48336825|NCT05944159|OTHER|Control Group|Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
48336826|NCT00185536|BEHAVIORAL|Packaging and identification of source|
48336827|NCT06189248|BEHAVIORAL|Resourcefulness intervention|Teaching personal and social resourcefulness skills.
48336828|NCT04374578|DRUG|Dulaglutide 1.5 MG/ML|Dulaglutide 1.5Mg qw sc injection for 4 weeks
48336829|NCT01734707|DIETARY_SUPPLEMENT|Allicor|
48336830|NCT01734707|DRUG|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
48494821|NCT00640679|DRUG|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
48494822|NCT03377764|PROCEDURE|Landmark Technique Control group|Spinal Anesthetic
48494823|NCT03377764|PROCEDURE|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
48654159|NCT06644807|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
47977649|NCT04803825|DEVICE|Extracorporeal Shock wave therapy|Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
47977650|NCT04803825|OTHER|Information and advice|Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
47977651|NCT02421276|OTHER|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
48129363|NCT00795184|DEVICE|pCLE|
47977652|NCT02005445|DEVICE|CPAP|Continuous positive airway pressure
48129364|NCT03580200|OTHER|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
48129365|NCT04756440|BEHAVIORAL|Education Program and Music Therapy|After the intervention, it is expected that their awareness of Romana cervical cancer will increase, their perception of obstacle towards screening tests will decrease and they will be tested.
48336831|NCT04334512|DRUG|Hydroxychloroquine|Treatment with hydroxychloroquine
48336832|NCT04334512|DRUG|Azithromycin|Treatment with azithromycin
48336833|NCT04334512|DIETARY_SUPPLEMENT|Vitamin C|Treatment with vitamin C
47977653|NCT02005445|BEHAVIORAL|HLSE|Healthy living and sleep education
47977654|NCT00674700|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
48336834|NCT04334512|DIETARY_SUPPLEMENT|Vitamin D|Treatment with vitamin D
48336835|NCT04334512|DIETARY_SUPPLEMENT|Zinc|Treatment with Zinc
48336836|NCT04122586|DRUG|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
48336837|NCT03460288|BEHAVIORAL|Retraining (AAT)|The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
48494824|NCT02711683|DRUG|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
48494825|NCT02711683|DRUG|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
48654160|NCT06644807|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
48129366|NCT03680638|OTHER|Control (Lactated Ringer's)|This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
48129367|NCT03680638|DRUG|Tempol|This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
48129368|NCT03680638|DRUG|Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
48336838|NCT01590212|OTHER|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
48336839|NCT01590212|OTHER|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
48336840|NCT03483376|PROCEDURE|Dental prophylaxis|Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
48336841|NCT03483376|DEVICE|Antimicrobial photodynamic therapy (aPDT)|Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
48336842|NCT01191632|RADIATION|one time radiation|"Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
48336843|NCT01191632|RADIATION|No Radiation|Control group with 0Gy
48336844|NCT03450993|OTHER|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
48336845|NCT01990703|DRUG|Levonorgestrel IUD|Timing of IUD insertion
48336846|NCT06085430|DEVICE|Kubota Glass|Kubota Glass employs white light producing micro-LEDs covered by masks which create a patterned target. The patterned images are defocused by micro-lenslets and projected to the retinal periphery by a central mirror. Parameters of interest to evaluate in this investigation include but are not limited to dioptric amount of defocus, brightness (cd/m2), spectrum of illumination, and shape of the target mask. In each scenario, right eyes will be exposed to the stimulus, whereas left eyes serve as controls. The order of exposures to the various stimuli will be randomized to participant and investigator.
48336847|NCT00813917|DRUG|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
48336848|NCT00813917|DRUG|placebo|12 weeks of placebo (double blinded) by mouth twice per day
48336849|NCT00753597|DRUG|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
48336850|NCT05820009|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with the GORE® VIABIL® Biliary Endoprosthesis.
48336851|NCT05820009|DEVICE|GORE® VIABIL® Short Wire Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with GORE® VIABIL® Short Wire Biliary Endoprosthesis
48336852|NCT04814524|DEVICE|Fitbit|Wear Fitbit
48336853|NCT04814524|OTHER|Questionnaire Administration|Ancillary studies
48336854|NCT04814524|DEVICE|Virtual Reality Device|Use VR
48336855|NCT00405717|DRUG|atorvastatin,pravastatin|
48336856|NCT05457738|OTHER|E-REVA® app|Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
48336857|NCT05457738|OTHER|No E-REVA® app|No use smartphone
48336858|NCT03611049|DIETARY_SUPPLEMENT|High dose Vitamin D3|High dose arm- 5000IU given daily
48336859|NCT03611049|DIETARY_SUPPLEMENT|Low dose Vitamin D3|Low dose arm-800 IU given daily
48494826|NCT06195696|BEHAVIORAL|employs questionnaires|The first phase is a quantitative study that employs a questionnaire to investigate the current state of illness perception and the distribution of coping styles in kidney transplant recipients, and to explore the differences in illness perception between positive coping and negative coping patients after kidney transplantation; The second phase involves a descriptive qualitative study that utilizes face-to-face, semi-structured, in-depth interviews to investigate the causes of differences in illness perceptions of different coping styles in kidney transplant recipients who experience idiosyncrasies.
47977655|NCT00674700|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
48129369|NCT03680638|DRUG|Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
48129370|NCT02415088|PROCEDURE|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
48336860|NCT05245994|DRUG|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
47977656|NCT00674700|DRUG|Placebo tablet|One sublingual tablet daily for one year
48336861|NCT02285712|DEVICE|Vascular ultrasound system|
48336862|NCT03115788|OTHER|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
48336863|NCT03115788|OTHER|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
48336864|NCT03115788|DEVICE|iPad|
48336865|NCT04203017|BIOLOGICAL|allogeneic fecal microbiota|All patients receive autoHSCT with RIC (Cyclophosphamide, Antithymocyte globulin, Rituximab). After immune system reconstitution (approximately starting D+60 up to D+120), patients will receive FMT from healthy donor via po capsules.
48336866|NCT06502145|DRUG|Azacitidine Level -1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
48336867|NCT06502145|DRUG|Azacitidine Level 0|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
48336868|NCT06502145|DRUG|Azacitidine Level 1|Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.
48336869|NCT06502145|DRUG|Iadademstat Level -1|75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.
48336870|NCT06502145|DRUG|Iadademstat Level 0|75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
48336871|NCT06502145|DRUG|Iadademstat Level 1|100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.
48336872|NCT05445882|DRUG|Bintrafusp alfa|Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
48494827|NCT05620602|OTHER|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
48336873|NCT05445882|DRUG|N-803|N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
48336874|NCT05445882|BIOLOGICAL|BN-Brachyury|BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
48336875|NCT06406140|DRUG|Niacin tablets 500 mg|tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
48494828|NCT05620602|OTHER|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
47977657|NCT02630498|PROCEDURE|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
47977658|NCT01656785|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
48336876|NCT01700881|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
48336877|NCT01700881|OTHER|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
48336878|NCT01917708|DRUG|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
48336879|NCT01080456|DRUG|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
48336880|NCT02352103|PROCEDURE|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
48336881|NCT02352103|PROCEDURE|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
48336882|NCT02352103|DEVICE|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
48654161|NCT06644807|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
47977659|NCT01059799|DRUG|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
48336883|NCT00719537|DRUG|Aspirin|Aspirin 81 mg once a day
48336884|NCT00719537|DRUG|Placebo Oral Tablet|Placebo 1 tab Daily
48336885|NCT00719537|DRUG|Progesterone|Oral Progesterone 200 mg Twice Daily
48336886|NCT03725293|DEVICE|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
48336887|NCT03725293|DEVICE|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
48336888|NCT04925947|DRUG|KN046|KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
48336889|NCT06297798|OTHER|Telerehabilitation|"The telerehabilitation program will be implemented using Whatsapp and Zoom applications for 40 minutes, 5 days a week. Posture and stabilization exercises will be performed, and the exercises will be performed for 10 weeks.~Posture and Stabilization Exercise Program:~1. Stretching of neck flexor, extensor, and lateral flexor muscles (30 seconds each)~2. Pectoral muscle stretching (30 seconds, 3 repetitions)~3. Isometric neck exercises (10 seconds, 10 repetitions)~4. Rhomboid strengthening exercise (bringing shoulder blades closer together against resistance using a TheraBand) (10 seconds, 10 repetitions)~5. Stretching of hamstring, lumbar lordosis and gastrocnemius muscles (sitting and standing) (30 seconds, 3 repetitions)~6. Pelvic posterior tilt exercise (10 seconds, 10 repetitions)~7. Bridge exercise (20 seconds, 10 repetitions)~8. Single-leg bridge exercise (Right-Left) (10 seconds, 10 repetitions)~9. Plank (starting with 60 seconds, increasing by 10 seconds each week)"
47977660|NCT01059799|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
48129371|NCT02415088|PROCEDURE|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
48336890|NCT04301583|DIETARY_SUPPLEMENT|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
48336891|NCT06380348|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
48336892|NCT06380348|DRUG|Osimertinib tablet|Osimertinib 160mg once po everyday
48336893|NCT06380348|DRUG|Cisplatin injection|Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
48336894|NCT06380348|DRUG|Pemetrexed injection|Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
48336895|NCT03936478|RADIATION|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
48336896|NCT01433692|BEHAVIORAL|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
48336897|NCT00511121|DRUG|STI571 and PEG INTRON|
48336898|NCT05031572|OTHER|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
48654162|NCT06644807|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
48654163|NCT02598973|BEHAVIORAL|Exercise|Aerobic walking
47977661|NCT04792164|PROCEDURE|Ultra sound guided nerve block|Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.
47977662|NCT04792164|PROCEDURE|Usual infiltration|Usual infiltration by lidocaine before open inguinal hernia repair.
47977663|NCT01488682|PROCEDURE|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
47977664|NCT01488682|PROCEDURE|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
48129372|NCT02697305|DIETARY_SUPPLEMENT|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
47977665|NCT01493570|DRUG|BI 409306|Film-coated tablet
47977666|NCT01493570|DRUG|Placebo|Film-coated tablet
47977667|NCT03718585|OTHER|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
47977668|NCT02122393|DRUG|Sertraline|
47977669|NCT02122393|BEHAVIORAL|Cognitive Behavioural Therapy|
48129373|NCT02697305|DIETARY_SUPPLEMENT|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
48129374|NCT02697305|OTHER|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
48129375|NCT03901989|DEVICE|zeolite|given for a period of 12 months
48129376|NCT03901989|DEVICE|cellulose|given for a period of 12 months
48129377|NCT03592524|BEHAVIORAL|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
48129378|NCT01588951|DRUG|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
48129379|NCT01588951|DRUG|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
48336899|NCT03983213|PROCEDURE|mpfl reconstruction|Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
48336900|NCT04099706|PROCEDURE|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
48336901|NCT02540876|DRUG|Ilorasertib|Given PO
48336902|NCT02540876|OTHER|Laboratory Biomarker Analysis|Correlative studies
48336903|NCT05034614|DIAGNOSTIC_TEST|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
48336904|NCT05034614|DIAGNOSTIC_TEST|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
48129380|NCT01333605|DRUG|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
48129381|NCT06318507|COMBINATION_PRODUCT|Fecal microbial diversity|Fecal microbiome diversity via 16S rRNA and metagenomic sequencing
47977670|NCT03970798|DRUG|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
48336905|NCT06425263|BIOLOGICAL|adipose tissue fragmented|harvested from the case form buccal pad of fat
48336906|NCT03854812|DRUG|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
48336907|NCT03854812|DRUG|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
47977671|NCT03970798|DRUG|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
47977672|NCT03970798|DRUG|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
47977673|NCT03970798|DRUG|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
47977674|NCT02597894|PROCEDURE|Biopsy of Prostate|Undergo biopsy
48654164|NCT06196034|GENETIC|No intervention|No intervention
48654165|NCT02407938|OTHER|Rice meal|
48129382|NCT03081013|BEHAVIORAL|Social information|Social comparison information will be provided to the study participants weekly via SMS
48129383|NCT03081013|DEVICE|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
48129384|NCT05605613|DRUG|PD-1 Antibody|PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1
48129385|NCT05605613|DEVICE|BACE|Bronchial Arterial Chemoembolization
48129386|NCT03516370|DRUG|Saccharomyces Boulardii 250 MG|all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
48129387|NCT01988935|BEHAVIORAL|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
48129388|NCT01988935|BEHAVIORAL|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
48654166|NCT06645262|OTHER|Cryotherapy|cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
48654167|NCT04593745|DEVICE|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
47977675|NCT02597894|OTHER|Laboratory Biomarker Analysis|Correlative studies
47977676|NCT02236195|DRUG|Mocetinostat|
47977677|NCT01331798|DEVICE|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
47977678|NCT01331798|PROCEDURE|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
47977679|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
47977680|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
47977681|NCT06437860|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
47977682|NCT06437860|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
47977683|NCT02057406|DRUG|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
47977684|NCT02057406|DRUG|High EPA|
47977685|NCT02057406|OTHER|Placebo|
47977686|NCT02071251|PROCEDURE|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
47977687|NCT05071989|BEHAVIORAL|Sleep Education|A single-blind school- based randomized controlled design
47977688|NCT02600702|OTHER|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
48129389|NCT06447389|OTHER|retraction cordu (SURE-CORD®PLUS)|The evaluation of the effectiveness of retraction cords in determining the restoration margin in the fabrication of short fixed partial dentures for patients with missing teeth.
48129390|NCT06514677|PROCEDURE|Ultrasonic Carbon Tip|Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment
48129391|NCT06514677|PROCEDURE|Titanium Curette|Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
48336908|NCT03854812|DRUG|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
48336909|NCT01727557|PROCEDURE|regional anesthesia|Regional anesthesia will be compared to local anesthesia
48336910|NCT01727557|PROCEDURE|local anesthesia|Regional anesthesia will be compared to local anesthesia
48336911|NCT01089569|DRUG|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
48129392|NCT01185041|DIETARY_SUPPLEMENT|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
48129393|NCT01437319|DEVICE|lotrafilcon A|To be used during run-in phase only.
47977689|NCT02600702|OTHER|Physical modalities|
47977690|NCT01401283|DEVICE|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
47977691|NCT00489541|DEVICE|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
47977692|NCT01282268|DRUG|arbaclofen|orally disintegrating tablet
47977693|NCT01282268|DRUG|placebo|orally disintegrating tablet
47977694|NCT01119391|BEHAVIORAL|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
47977695|NCT02324894|PROCEDURE|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
47977696|NCT06089928|PROCEDURE|vertical augmentation|sandwich osteotomy with an Interpositional inlay graft
47977697|NCT03935529|BEHAVIORAL|Behavioural Activation|"Participants will receive five sessions of Behavioural Activation. Behavioural Activation uses strategies such as activity scheduling, mastery and pleasure ratings, and graded task assignments to change a participant's perception of specific situations.~Behavioural Activation is based on the behavioural model of depression (Lewinsohn \& Shaffer, 1971). Specifically, that depression is a result of reduced positive reinforcement, particularly in social relationships. Behavioural Activation aims to reduce depressive symptoms by implementing a schedule of positive reinforcement by altering a participant's behaviour and/or their environment. As, in certain environmental contexts, behaviours that reduce depression will continue to occur through reinforcement and those that increase depression will decrease over time (Roane, Fisher, \& Carr, 2016).~Behavioural Activation has been shown to be an effective intervention for the reduction of depressed mood."
47977698|NCT03585608|PROCEDURE|Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.
47977699|NCT04579731|DRUG|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
47977700|NCT03466697|OTHER|Glucose injection/Normal saline injection|Before each PET scan, subject will be injected either glucose or normal saline.
47977701|NCT00719121|DRUG|Talarozole|Topical Application (20 mg)
47977702|NCT00719121|DRUG|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
47977703|NCT02483520|BEHAVIORAL|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
47977704|NCT03355651|DIETARY_SUPPLEMENT|PROGEN|Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
47977705|NCT02850029|OTHER|Observational study, no intervention|
47977706|NCT03861975|OTHER|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
47977707|NCT00615758|DRUG|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
47977708|NCT03095014|PROCEDURE|Cesarean Myomectomy|Myomectomy was done during Cesarean section
47977709|NCT03095014|PROCEDURE|Cesarean section|Cesarean delivery
47977710|NCT01749514|DRUG|Luspatercept|Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
47977711|NCT02052284|OTHER|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
47977712|NCT06507319|DEVICE|Direct bone anchored pull distal slider|distalization from the palatal side only.
47977713|NCT06507319|DEVICE|Indirect bone anchored dual force distalizer.|distalization from the palatal and buccal sides.
48129394|NCT01437319|DEVICE|comfilcon A|To be assigned at randomization at phase 2 only.
48129395|NCT01437319|DEVICE|balafilcon A|To be assigned at randomization during phase 2 only.
48129396|NCT01437319|OTHER|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
48129397|NCT02766946|DEVICE|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
48129398|NCT02766946|DEVICE|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
48129399|NCT02766946|OTHER|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
48129400|NCT02766946|OTHER|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
48129401|NCT06026800|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
48129402|NCT03907306|PROCEDURE|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
48129403|NCT00167921|DRUG|Premarin® Vaginal Cream|
48129404|NCT00167921|DRUG|Premarin® oral tablets|
48129405|NCT01235806|RADIATION|MRI|MRI of the scaphoid bone fracture suspicion
48129406|NCT00405158|PROCEDURE|Acupuncture treatment|
48129407|NCT00405158|PROCEDURE|Administration of oxytocin nasal spray|
48129408|NCT00405158|PROCEDURE|Improved breast milk removal|
48129409|NCT00405158|PROCEDURE|Warmth applied to breasts|
48129410|NCT00405158|PROCEDURE|Breast massage|
48129411|NCT00405158|DRUG|Anti-pyretic medication, paracetamol|
48494829|NCT05620602|OTHER|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
48129412|NCT00405158|DRUG|cefadroxil|
48129413|NCT00405158|DRUG|penicillin|
48129414|NCT00405158|DRUG|flucloxacillin|
48129415|NCT01065506|BEHAVIORAL|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
48129416|NCT01065506|DRUG|Nicotine Patch|Nicotine Patch
48129417|NCT01065506|BEHAVIORAL|Wellness Program|Wellness Program
48129418|NCT01065506|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise
48129419|NCT00746655|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
48129420|NCT00746655|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
48129421|NCT05652075|PROCEDURE|pericapsular nerve group and lateral femoral cutaneous nerve block|Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.
48129422|NCT05652075|PROCEDURE|lumbar plexus block|Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.
48129423|NCT00231504|PROCEDURE|Blood samples|Blood samples
48129424|NCT00960141|DRUG|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
48129425|NCT00960141|DRUG|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
48129426|NCT00960141|DRUG|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
48129427|NCT05099549|DRUG|AFM24|Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.
48129428|NCT05099549|BIOLOGICAL|SNK01|Patient-specific ex-vivo expanded autologous natural killer cells.
48129429|NCT04540003|OTHER|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
48129430|NCT01574716|DRUG|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
48129431|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
48129432|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
48129433|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
48129434|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
48129435|NCT01574716|DRUG|Placebo|
48129436|NCT01323166|PROCEDURE|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
48129437|NCT04175899|OTHER|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
48129438|NCT04229368|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D will be given at doses commonly given to patients with low vitamin D levels
48129439|NCT00849238|DRUG|mycophenolate mofetil|
48129440|NCT00989469|DRUG|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
48129441|NCT00280228|BEHAVIORAL|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
48336912|NCT01089569|DRUG|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
47977714|NCT06034236|OTHER|Resistance training|"Task oriented resistance training will be performed, there will be 10 workstations:~1. Sitting at a table and reaching in different directions for objects located beyond arm's length.~2. Sit to stand from various chair heights~3. Stepping forward, backward and sideways onto blocks of various heights.~4. Heel lifts in standing~5. Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~6. Reciprocal leg flexion and extension.~7. Sit ups~8. Standing up from chair, walking a short distance and returning to the chair.~9. Walking races between participants~10. Walking over various surfaces and obstacles"
48129442|NCT00280228|BEHAVIORAL|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
48129443|NCT02130557|DRUG|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
48129444|NCT02130557|DRUG|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
48129445|NCT05949359|OTHER|Nintendo RingFit-augmented exercise program|"Participants in the NRE group received an 8-week exercise training program using the Nintendo RingFit (60 minutes for each session, two sessions a week). In each session, the participants first performed 5 minutes of walk-up exercises (i.e., simple jogging), followed by 50 minutes of Nintendo RingFit exercises and 5 minutes of cool down exercises.~The exercise intensity, in terms of repetitions, holding time of the exercise and advancement to difficult tasks, progressed gradually in 8 weeks."
48129446|NCT03060317|BEHAVIORAL|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
48129447|NCT05271994|PROCEDURE|endoscopic biliary drainage|endoscopic biliary drainage
48129448|NCT05946213|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48129449|NCT05946213|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48129450|NCT05249842|DIAGNOSTIC_TEST|Spirometric evaluation|Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75
48129451|NCT05249842|DIAGNOSTIC_TEST|Physical component summary|Evaluation of the physical component summary of SF-36 quality of life
48129452|NCT05249842|DIAGNOSTIC_TEST|6MWT|6 minute walk test
48129453|NCT01797354|BEHAVIORAL|Cognitive-behavioral therapy and hypnosis group|
48129454|NCT01797354|BEHAVIORAL|Support group|
48129455|NCT03718013|DEVICE|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
48129456|NCT03718013|DEVICE|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
48129457|NCT05770427|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by parents and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching parents to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
48129458|NCT01268306|DEVICE|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
48129459|NCT00651859|DRUG|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
48129460|NCT00651859|DRUG|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
48129461|NCT00651859|DRUG|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
48129462|NCT00006241|BIOLOGICAL|filgrastim|
48129463|NCT00006241|DRUG|chemotherapy|
48336913|NCT00139607|DRUG|Paracoxib|
48129464|NCT00006241|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48336914|NCT02822651|BIOLOGICAL|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
48336915|NCT02822651|OTHER|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
48336916|NCT01766219|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
48336917|NCT05693688|DRUG|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
48336918|NCT04261881|DIETARY_SUPPLEMENT|ATP-Fuel|5 capsules daily with breakfast and 5 capsules daily with lunch
48336919|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast
48336920|NCT04261881|DIETARY_SUPPLEMENT|ATP-II|3 capsules daily with breakfast and 3 capsules daily with lunch
48336921|NCT04438304|DRUG|64Cu-SARTATE|64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
48336922|NCT02290340|DRUG|Placebo|Participants will receive placebo intramuscularly.
48336923|NCT02290340|DRUG|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
48129465|NCT00006241|PROCEDURE|peripheral blood stem cell transplantation|
48129466|NCT00006241|RADIATION|radiation therapy|
47977715|NCT06034236|OTHER|Otago Exercises|"It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks"
48129467|NCT02930954|DRUG|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
48129468|NCT02930954|DRUG|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
48129469|NCT02930954|DRUG|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
48129470|NCT02075554|DEVICE|CALIBER|Expandable interbody spacer
48129471|NCT03932513|DRUG|inarigivir soproxil|Inarigivir 200mg and 400mg oral tablets, once daily
48129472|NCT03355534|DRUG|Intravenous dexmedetomidine|drug is intravenously infused to patients
48129473|NCT03355534|DRUG|nasal dexmedetomidine|drug is nasally given to patients
47977716|NCT03053804|RADIATION|MR/PET|MR/PET with contrast media and FDG-18
48129474|NCT03355534|DRUG|intravenous saline|saline is given to patients intravenously
48336924|NCT02290340|DRUG|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
48336925|NCT02290340|DRUG|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
48129475|NCT03355534|DRUG|nasal saline|normal saline is given to patients nasally
47977717|NCT01230944|PROCEDURE|Laparoscopic Nissen fundoplication|
47977718|NCT01230944|PROCEDURE|Open Nissen fundoplication|
47977719|NCT04793685|DRUG|Prazosin|Prazosin (16mg/day) versus Placebo comparator, with a 2 week titration period, 9 weeks at full dose and a 5-day taper in week 12.
47977720|NCT04793685|BEHAVIORAL|12-Step Facilitation with Relapse Prevention and Contingency Management|12-Step Facilitation and relapse prevention weekly support and Contingency Management with vouchers for each weekly appointment to support treatment attendance for all subjects.
48129476|NCT03434587|PROCEDURE|Syndactyly|Syndactyly
47977721|NCT04829708|OTHER|MRI Surveillance|Receive MRI surveillance
48129477|NCT03434587|PROCEDURE|Reduction and inmobilization|Closed reduction and inmobilization with splint
48129478|NCT04452201|BEHAVIORAL|Guided Participation|GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
48129479|NCT03681366|DEVICE|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
48129480|NCT02080754|OTHER|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
48129481|NCT02080754|OTHER|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
48129482|NCT00786513|OTHER|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
47977722|NCT04829708|RADIATION|Prophylactic Cranial Irradiation|Receive PCI
47977723|NCT02877615|DRUG|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
48129483|NCT00786513|OTHER|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
48129484|NCT02461628|BEHAVIORAL|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
48129485|NCT05673746|PROCEDURE|Acupuncture|acupuncture administration
48336926|NCT01256983|BEHAVIORAL|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
48336927|NCT01256983|BEHAVIORAL|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
48494830|NCT05620602|OTHER|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
47977724|NCT02877615|DRUG|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
48129486|NCT05673746|DRUG|treatment of physician choice, according to the standard of care|treatment of physician choice, according to the standard of care for the treatment of chemotherapy-induced peripheral neuropathy, including neuropathic pain
48129487|NCT01298076|DRUG|bevacizumab|Anti-VEGF drug for intravitreal injection
48129488|NCT01298076|DRUG|dexamethasone|Slow-release steroid formulation for intravitreal injection
48129489|NCT05786352|PROCEDURE|ERAS protocol|The combination of interventions explained in arm descriptions.
48336928|NCT01361880|BEHAVIORAL|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
48129490|NCT05663801|DRUG|Use of Bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
48336929|NCT03048357|DEVICE|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
48336930|NCT03048357|OTHER|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
48336931|NCT03874195|BEHAVIORAL|Access to PCforMe for review|Intervention Arm subjects will receive access to PCforMe.
48336932|NCT03874195|BEHAVIORAL|Access to three nationally-recognized Palliative Care websites for review|Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
48336933|NCT05254652|DRUG|Duloxetine 30mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
48336934|NCT05254652|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
48336935|NCT04909216|OTHER|Mindful Attention Workshop|The 90-minute workshop will include a 15-minute break and include up to 15 participants. The workshop will be led by peer support staff, fire department psychologists, and/or fire department doctoral psychology practicum students. Each workshop will be facilitate by up to 3 workshop leaders. The workshop will provide (1) psychoeducation regarding common mental health concerns among firefighters, (2) introduction to the concept of mindful attention, why it is relevant to firefighters, and how it can prevent or decrease mental health symptoms, (3) 5 experiential mindful attention training exercises, and (4) discussion. Workshop co-leaders will teach 5 mindful attention exercises, and firefighters will practice each exercise and then engage in discussion about their experiences and provide feedback regarding the utility of the exercise for them personally and for firefighters, generally.
48336936|NCT02295800|OTHER|Standard of care|
48494831|NCT06423638|BEHAVIORAL|Virtual Tai Chi Easy|"The TCE intervention will be delivered asynchronously online. Participants can complete the classes at a time and in a location that is convenient for them. The classes will be offered for one hour twice weekly and were developed and recorded by a certified Tai Chi Easy practice leader.~TCE is a simple form of mind-body self-care that focuses on four components:~* Mindful movements that help to stretch, and relax the body while improving balance and coordination~* Breathing practices that reduce stress by inducing a relaxation response while improving energy and circulation and enhancing innate healing responses~* Self-applied massage to stimulate blood flow, relax the body, and improve circulation and energy~* Meditation practices to relax the body, center the mind, and calm the emotions"
48494832|NCT03776253|BEHAVIORAL|Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components)|Attend CFS
48494833|NCT03776253|OTHER|Questionnaire Administration|Ancillary studies
48494834|NCT02497118|DRUG|Endostatin|Endostatin,7.5mg/m\^2,intravenous, d1-14;
47977725|NCT02877615|DRUG|Placebo|Two sachets of placebo twice a day
47977726|NCT05178524|DRUG|BIFICO|Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
48336937|NCT02295800|OTHER|Semi-structured interviews|
48336938|NCT05185648|BEHAVIORAL|standard trauma care taining|trauma care training
48336939|NCT02910219|DRUG|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
48336940|NCT02843750|BEHAVIORAL|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~1. Breathing Awareness~2. Upper and Lower Extremity Exercise.~3. Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~4. Practice at home"
48336941|NCT02843750|OTHER|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
48494835|NCT02497118|DRUG|Vinorelbine|vinorelbine,25mg/m\^2,intravenous, d1, d8;
48494836|NCT02497118|DRUG|Cisplatin|Cisplatin，75mg/m\^2 intravenous,divide into d1-3
47977727|NCT00583778|DRUG|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
47977728|NCT02552199|OTHER|gravimetric|
47977729|NCT05715593|OTHER|health education intervention|health education intervention
47977730|NCT03145350|OTHER|High-fat, low-carbohydrate|Dietary intervention: 4 week
48494837|NCT02636192|DRUG|No Intervention|This is an observational study and participants did not receive any intervention in this study.
47977731|NCT03145350|OTHER|Low-fat, high-carbohydrate|Dietary intervention: 4 week
47977732|NCT06422130|OTHER|Pregnant women and their offspring without intervention|Pregnant women and their offspring with those exposures of interest determined in specific research based on the database
48129491|NCT05663801|DRUG|use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
48336942|NCT05340491|DRUG|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
48336943|NCT05340491|DRUG|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
48336944|NCT05340491|RADIATION|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
48494838|NCT05829213|PROCEDURE|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. Creating the seromuscular flap (arch-bridge)~4. The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
48494839|NCT02934763|DRUG|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
48494840|NCT02934763|DRUG|Saline|Saline as placebo
48494841|NCT03246126|DEVICE|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
48494842|NCT04360044|DRUG|THC ~5%|4 puffs of vaporized flower containing THC \~5%
48494843|NCT04360044|DRUG|CBD ~12%|4 puffs of vaporized flower containing CBD \~12%
48494844|NCT04360044|DRUG|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC \~5% and CBD \~12%
48494845|NCT04360044|DRUG|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
48494846|NCT04530240|PROCEDURE|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
48494847|NCT03055442|OTHER|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
48494848|NCT03055442|OTHER|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
48336945|NCT03295591|DIAGNOSTIC_TEST|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
48336946|NCT04297345|DEVICE|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
48336947|NCT00606528|OTHER|No intervention|None. This is an observational study.
48494849|NCT02253836|DRUG|Tipranavir|TPV
48494850|NCT02253836|DRUG|Ritonavir|RTV
48494851|NCT02253836|DRUG|Atazanavir|TAZ
47977733|NCT05065177|BIOLOGICAL|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
47977734|NCT05065177|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
47977735|NCT04956497|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
48336948|NCT01053572|PROCEDURE|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
47977736|NCT02034279|DRUG|Albumin|Intravenous infusion of 20% albumin
48336949|NCT04328012|DRUG|Losartan|administered 14 days
48336950|NCT04328012|DRUG|Placebo|administered 14 days
48336951|NCT00701246|DRUG|ferrous sulfate|
48336952|NCT00701246|DRUG|folic acid|
48336953|NCT00701246|DRUG|placebo (folic acid)|
48494852|NCT00267943|DRUG|telmisartan 80 mg + hydrochlorothiazide 25 mg|
48494853|NCT06141824|DEVICE|Lucira COVID-19 & Flu Test|The Lucira COVID-19 \& Flu Test is a rapid, single-use, molecular test for the qualitative detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viral RNA in nasal swab samples.
48494854|NCT04404946|OTHER|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
48494855|NCT04404946|OTHER|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
48494856|NCT04404946|OTHER|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
48494857|NCT04215848|DRUG|Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
47977737|NCT03198117|DRUG|Huaier Granule|a Chinese traditional medicine
47977738|NCT03198117|OTHER|placebo|placebo
48494858|NCT04215848|DRUG|Budesonide 200Mcg Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
48494859|NCT05120206|PROCEDURE|Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).|Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
48494860|NCT04434664|DRUG|Amlodipine Besylate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
48494861|NCT04434664|DRUG|Metoprolol Succinate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
48494862|NCT05217706|DRUG|Ketamine|The treatment group will receive Ketamine 0.2mg/kg IV once
48494863|NCT05217706|DRUG|normal Saline|The placebo group will receive normal saline IV in a matched syringe
48494864|NCT01860911|DRUG|Insulin|
48494865|NCT01860911|DRUG|NG-monomethyl-L-arginine|
47977739|NCT05673278|DIAGNOSTIC_TEST|Bowel Ultrasound Scan|"Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~+ Image quality"
47977740|NCT00295906|OTHER|educational intervention|
47977741|NCT00295906|OTHER|internet-based intervention|
47977742|NCT02554669|BEHAVIORAL|postprandial and postabsorptive physical activity on treadmill|
47977743|NCT05127005|PROCEDURE|Trapeziectomy|Surgical excision of trapezoideum
47977744|NCT05127005|PROCEDURE|Sham|Skin incision only
47977745|NCT04217876|DIAGNOSTIC_TEST|post-processing analysis of cardiac imaging (strain echocardiography)|"A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment.~The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion."
47977746|NCT05843123|OTHER|Respiratory support a|Invasive mechanical ventilation mode
48336954|NCT02326389|BEHAVIORAL|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
48494866|NCT03629379|DRUG|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
48494867|NCT03629379|DRUG|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
48494868|NCT01483859|OTHER|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
48494869|NCT02387983|DRUG|Posaconazole|Posaconazole 300 mg solid oral tablet
48494870|NCT00112866|DRUG|cilengitide|Given IV
48494871|NCT00112866|PROCEDURE|therapeutic conventional surgery|Undergo tumor resection
48494872|NCT00112866|OTHER|pharmacological study|Correlative studies
48494873|NCT00112866|OTHER|laboratory biomarker analysis|Correlative studies
48494874|NCT01703884|DRUG|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (\> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
48494875|NCT00026364|DRUG|fluorouracil|
48494876|NCT00026364|DRUG|gefitinib|
48494877|NCT00026364|DRUG|irinotecan hydrochloride|
48494878|NCT00026364|DRUG|leucovorin calcium|
48336955|NCT02326389|BEHAVIORAL|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
48336956|NCT00216515|DRUG|galantamine hydrobromide|
48494879|NCT02145312|DRUG|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
47977747|NCT05843123|OTHER|Respiratory support b|Invasive mechanical ventilation mode
47977748|NCT00441883|DRUG|PF-03187207 and Latanoprost Vehicle|
47977749|NCT00441883|DRUG|Latanoprost 0.005% and PF-03187207 Vehicle|
48336957|NCT00905372|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
48336958|NCT00905372|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
48129492|NCT05663801|DRUG|Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
48494880|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
48129493|NCT00047528|DRUG|Alcon Investigational Agent|
48129494|NCT06519617|DRUG|Yi Qi Yang Yin Decoction|The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
48129495|NCT06519617|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
48129496|NCT01086982|DRUG|Octreotide acetate LAR|30 mg, single dose
48336959|NCT01001858|OTHER|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
48336960|NCT05477225|DEVICE|NovoSorb® BTM|a biodegradable polyurethane porous matrix adhered to a transparent sealing membrane. The sealing membrane is designed to physiologically close the wound limiting evaporative moisture loss during integration of the matrix.
48336961|NCT05477225|DEVICE|Human Cadaveric Allograft|"The donated human tissue (Allograft) used in this study are from Maxxeus Medical, Kettering, OH . Tissue grafts are recovered from deceased human donors. All tissue is recovered, processed, stored and distributed for use in accordance with the standards of the American Association of Tissue Banks (AATB). Tissue is manufactured in a clean room environment, following rigorous quality assurance standards. The procedures executed to manufacture this graft including recovery, donor screening, testing, processing, packaging, labeling, storage, and distribution were performed in compliance with all applicable local, state, and federal regulations, including the U.S. Food and Drug Administration (FDA) regulations published at 21 CFR Part 1271, and the current edition of the American Association of Tissue Banks Standards for Tissue Banking.~The current sizes that are available for this study: 103 sq cm., 154 sq cm and 232 sq. cm"
48336962|NCT02045056|DRUG|Gemfibrozil|
47977750|NCT05403905|PROCEDURE|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
48129497|NCT01086982|DRUG|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
48129498|NCT05350904|OTHER|Hybrid of telehealth and in-person physical therapy services|The experimental group will receive a hybrid of telehealth and in-person physical therapy services to address an in-home functional skill in children with moderate to severe disability.
48129499|NCT03851367|PROCEDURE|Sling suspension using red cord|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
48129500|NCT03851367|PROCEDURE|Gym ball exercises|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
48129501|NCT05043272|BIOLOGICAL|SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
48129502|NCT01619410|BIOLOGICAL|Linezolid|Linezolid 600 mg every 12 hours for 7 days
48129503|NCT01619410|BIOLOGICAL|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
48129504|NCT06413095|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
48129505|NCT06413095|COMBINATION_PRODUCT|MK-0482 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
48129506|NCT06413095|COMBINATION_PRODUCT|MK-4830 + Pembrolizumab|Intratumoral microdose injection by the CIVO device.
48129507|NCT00010777|PROCEDURE|Multiple Component Mind/Body therapy|
48129508|NCT02854241|PROCEDURE|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
48129509|NCT02854241|PROCEDURE|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading."
48129510|NCT02854241|PROCEDURE|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
48129511|NCT04396782|OTHER|Physioterapy rehabilitation with IVR|This program includes: static bicycle with virtual reality glasses, analytical lower limb exercises, global lower limb exerciseswith virtual reality glasses and activities to be done at home.
48336963|NCT02045056|DRUG|Placebo|
48336964|NCT01425853|DRUG|Chondroitin/Glucosamine (Droglican)|Experimental
48336965|NCT01425853|DRUG|Celecoxib|Active comparator
48336966|NCT03290170|PROCEDURE|Measured Resection|Bony landmarks are used to set femoral component rotation.
48336967|NCT03290170|PROCEDURE|Gap Balancing|Relies on ligament releases prior to bone cuts.
48336968|NCT01630798|DRUG|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
48336969|NCT01363258|BEHAVIORAL|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
48336970|NCT01363258|PROCEDURE|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
48336971|NCT01879254|DEVICE|Deep Brain Stimulation|
48336972|NCT01488409|DRUG|Acipimox|250 mg by mouth (PO) three times daily
48336973|NCT01488409|DRUG|Placebo|0 mg by mouth (PO) three times daily
48336974|NCT01630941|DRUG|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
48336975|NCT04848012|DEVICE|Auto-titrating non-invasive ventilation|A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
48336976|NCT01463657|DEVICE|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
48336977|NCT01463657|DEVICE|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
48494881|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
48494882|NCT00667810|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
47977751|NCT05403905|PROCEDURE|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
47977752|NCT05999045|OTHER|Singing activity|The singing activity will involve a 1-hour performance, rehearsal, or lesson.
48129512|NCT04396782|OTHER|standard physiotherapy rehabilitation|"static bicycle, analytical lower limb exercises, global lower limb exercises and activities to be done at home.~This group will perform only five minutes of virtual reality play, but will not use their lower limbs. This way, the results of rehabilitation will not be affected and therapists and patients will be blinded."
48129513|NCT05690152|DEVICE|EyeSimplify web-browser-based visual field test|All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
48336978|NCT05229991|DRUG|Lonafarnib|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
48336979|NCT05229991|DRUG|Ritonavir|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
48336980|NCT01864317|DEVICE|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
48336981|NCT01864317|OTHER|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
48336982|NCT01864317|OTHER|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
47977753|NCT05154006|BEHAVIORAL|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply \[5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)\]
47977754|NCT05154006|BEHAVIORAL|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) \[4.1 Instruction on how to perform a behavior (Michie et al., 2013)\]"
48129514|NCT02059538|OTHER|Adipose tissue biopsies (omental and subcutaneous) liver|
48129515|NCT02059538|RADIATION|CT-scan|
48129516|NCT02059538|OTHER|Stools sampling|
48336983|NCT01864317|OTHER|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
48336984|NCT01864317|OTHER|Humphrey Perimetry|Visual Field Testing
48336985|NCT01864317|OTHER|Applanation Tonometry|Measurement of Intraocular Pressure
48336986|NCT03020264|DEVICE|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
48336987|NCT00006299|DRUG|Celebrex|
48336988|NCT03091595|DRUG|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
48494883|NCT00130455|DRUG|escitalopram|
48494884|NCT03535779|BIOLOGICAL|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
48494885|NCT03535779|BIOLOGICAL|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
48494886|NCT03956836|DIAGNOSTIC_TEST|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
48129517|NCT02059538|OTHER|DNA sampling|
48129518|NCT02059538|OTHER|Blood sampling|
48129519|NCT02059538|OTHER|Urine sampling|
48129520|NCT02059538|RADIATION|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
48129521|NCT01448681|OTHER|No Interventions|
48129522|NCT02282709|DRUG|Daclatasvir|60 mg once daily
48129523|NCT02282709|DRUG|asunaprevir|100 mg BID
48336989|NCT03091595|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
48336990|NCT02299804|DRUG|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
48336991|NCT02299804|DRUG|Placebo|No active ingredient
48336992|NCT03446612|DRUG|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
48336993|NCT03446612|DRUG|Darbepoetin alfa|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
48336994|NCT03446612|DRUG|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
48336995|NCT03446612|DRUG|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
48336996|NCT03446612|DRUG|L-N-monomethyl arginine acetate (L-NMMA)|L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
48336997|NCT03930303|BEHAVIORAL|Multimedia- based patient education|Patients will receive a 5 minutes video education before D\&C
48494887|NCT03506984|DEVICE|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
48494888|NCT03506984|DEVICE|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
48494889|NCT00033124|BEHAVIORAL|Behavior Therapy|
48494890|NCT00222989|DRUG|PPI|
48494891|NCT06172166|BEHAVIORAL|Transdisciplinary Care for Transition|Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
47977755|NCT05154006|BEHAVIORAL|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). \[6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)\]
48129524|NCT00755144|DEVICE|LCS Knee|Cementless total knee arthroplasty with LCS Knee
48129525|NCT00755144|DEVICE|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
48336998|NCT00014547|DRUG|BBR 3464|
48336999|NCT00346138|PROCEDURE|Corneal transplantation|
48337000|NCT05225480|BEHAVIORAL|Illness perception conversation|A conversation based on the indvidual's knee pain related illness perceptions
48337001|NCT05225480|BEHAVIORAL|research motivation conversation|A conversation based on the indvidual's motivation for participating in research
48337002|NCT06436209|BEHAVIORAL|Multitask Practice Intervention (MPI)|Multitask practice intervention (MPI) includes multiple behavioral testing sessions during which participants receive practice with multitasking two tasks using the psychological refractory period procedure.
48337003|NCT06436209|BEHAVIORAL|Single-task Practice Intervention (SPI)|Single task practice intervention (SPI) includes multiple behavioral testing sessions during which participants receive separate practice on two tasks.
48337004|NCT00361218|DRUG|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
48337005|NCT02472015|PROCEDURE|telemedicine|psycho-behavioural care by telemedicine
48494892|NCT02854111|OTHER|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
48494893|NCT02854111|OTHER|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
48129526|NCT00575419|DRUG|N-acetylcysteine|"* Dose Level 1: 150 mg/kg/day~* Dose Level 2: 300 mg/kg/day~* Dose Level 3: 600 mg/kg/day~* Dose Level 4: 900 mg/kg/day~* Dose Level 5: 1200 mg/kg/day"
48129527|NCT03479411|DRUG|Itraconazole Powder|Itraconazole administered as a dry powder for inhalation (PUR1900)
48129528|NCT03479411|DRUG|Itraconazole 200 mg|Sporanox® Oral Solution
48337006|NCT06070636|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
48337007|NCT06070636|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48337008|NCT06070636|DRUG|Sintilimab|200mg intravenously every 32 weeks
48337009|NCT01250756|BIOLOGICAL|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
48337010|NCT01250756|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
48337011|NCT01250756|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
48129529|NCT03954275|OTHER|no intervention|no intervention
48494894|NCT05038579|PROCEDURE|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
48337012|NCT05564676|DIETARY_SUPPLEMENT|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
48337013|NCT05564676|DIETARY_SUPPLEMENT|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
48337014|NCT01335698|DRUG|Atazanavir Sulphate|
48337015|NCT01335698|DRUG|Ritonavir|
48337016|NCT00024193|BIOLOGICAL|filgrastim|
48337017|NCT00024193|DRUG|busulfan|
48494895|NCT04365114|DIAGNOSTIC_TEST|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
48129530|NCT06510790|DEVICE|Double J stent|Double J ureteral catheter has been used to prevent upper urinary tract obstructions or strictures and to facilitate stone clearance after procedures such as percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), and ureteroscopic lithotripsy (URSL).
48129531|NCT01536834|DEVICE|Medical Device|
48494896|NCT04365114|DIAGNOSTIC_TEST|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
48494897|NCT04365114|DIAGNOSTIC_TEST|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
48494898|NCT02731326|DEVICE|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
48494899|NCT02731326|BEHAVIORAL|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
48494900|NCT04414761|DRUG|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
48266563|NCT03904797|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|"Participants were primary caregivers (n=149) recruited from a large, urban early intervention program. All caregivers were approached by early intervention staff the month prior to the child's annual evaluation of progress.~Each caregiver confirmed his or her eligibility online by verifying that they were at least 18 years old; could read, write, and speak English or Spanish; had internet access; and had a child between 0-3 years old who had received early intervention for at least 3 months.~Participants enrolled online and provided consent, signed a HIPAA authorization for service record release, and then proceeded to completing a demographic questionnaire and YC-PEM e-PRO to receive an online report of their responses to share with their child's EI team."
48337018|NCT00024193|DRUG|cisplatin|
48337019|NCT00024193|DRUG|cyclophosphamide|
48337020|NCT00024193|DRUG|doxorubicin hydrochloride|
48337021|NCT00024193|DRUG|etoposide|
48337022|NCT00024193|DRUG|melphalan|
48337023|NCT00024193|DRUG|vincristine sulfate|
48337024|NCT00024193|PROCEDURE|conventional surgery|
48337025|NCT00024193|PROCEDURE|peripheral blood stem cell transplantation|
48337026|NCT03815812|DRUG|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
48337027|NCT03815812|DRUG|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
48337028|NCT04763590|BEHAVIORAL|Cognitive Behavioral Therapy|"This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful."
48337029|NCT00438919|DEVICE|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
48337030|NCT05586815|DRUG|Colistin|150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
48337031|NCT05586815|DRUG|Minocycline|200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
48337032|NCT05586815|DRUG|Placebo|Capsule without active compound
48337033|NCT06044129|DEVICE|Mri scan of fetal head and pelvis|The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
48337034|NCT04374201|OTHER|2 zirconia FDPs|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
48337035|NCT04374201|OTHER|1 zirconia FDP|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
48337036|NCT03819270|DRUG|LY3372689|Administered orally
48337037|NCT03819270|DRUG|Placebo|Administered orally
48337038|NCT02904187|OTHER|Positron Emission Tomography (PET)|
48337039|NCT02904187|OTHER|Electroencephalogram (EEG)|
48337040|NCT04390789|PROCEDURE|Non surgical Single visit Retreatment|Non-surgical endodontic retreatment will be carried out in single visit.
48494901|NCT04414761|DRUG|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
48494902|NCT04977063|DEVICE|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
48494903|NCT04977063|DEVICE|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
48494904|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
48494905|NCT02991027|DEVICE|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
48129532|NCT02837211|BEHAVIORAL|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
48129533|NCT02837211|BEHAVIORAL|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
48337041|NCT04390789|PROCEDURE|Multi visit Retreatment with calcium hydroxide dressing|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
48337042|NCT04589338|OTHER|Endurance training|This group will perform aerobic type exercises. Initially, patients will perform continuous exercises of progressive intensity in order to adapt to this kind of effort. Next, we will introduce interval exercises.
48337043|NCT04589338|OTHER|Resistance training|Patients in this group will perform lower limb strengthening exercises to improve the maximum strength of different muscle groups.
48337044|NCT02465255|DRUG|Ketorolac|
48337045|NCT02465255|DRUG|Tramadol|
48337046|NCT02465255|DRUG|Acetaminophen|
48337047|NCT02096042|DRUG|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
48337048|NCT02096042|DRUG|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
48337049|NCT05483660|OTHER|Lactobacillus plantarum|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
48337050|NCT05483660|OTHER|Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
48494906|NCT05438498|DRUG|Evusheld (tixagevimab+cilgavimab) IM or IV|Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
48337051|NCT05483660|OTHER|Lactobacillus plantarum + Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
48337052|NCT05483660|OTHER|Placebo|Adult milk powder 15 g pertime, three times daily and half an hour before meal.
48337053|NCT05438251|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks"
48337054|NCT04018612|DRUG|Acetaminophen|Acetaminophen is an analgesic and antipyretic
48337055|NCT04018612|OTHER|Placebo|Saline
48494907|NCT03296436|BIOLOGICAL|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
48129534|NCT04877340|DEVICE|needle punction|EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge
47977756|NCT05154006|BEHAVIORAL|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. \[3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).\]
47977757|NCT03823352|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
47977758|NCT06166303|DIAGNOSTIC_TEST|sFlt-1/PGIF|Index of sFlt-1/PGIF
47977759|NCT04661085|DIAGNOSTIC_TEST|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
47977760|NCT01005745|PROCEDURE|Surgery|Surgery to remove a tumor for growth of TIL
47977761|NCT01005745|DRUG|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
47977762|NCT01005745|OTHER|Adoptive Cell Transfer|T-cell infusion
47977763|NCT01005745|DRUG|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
47977764|NCT06151834|PROCEDURE|KeriFuse implant implantation|The surgery is an arthrodesis of finger or thumb (for patients with finger osteoarthritis) and involves implanting the KeriFuse implant.
47977765|NCT02917304|BIOLOGICAL|GC3110A vaccine|0.5mL, Intramuscular
48129535|NCT02545634|DIETARY_SUPPLEMENT|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
48129536|NCT02545634|OTHER|Placebo|
48129537|NCT00263159|PROCEDURE|Pharmaceutical care for asthma patients|
48494908|NCT04238832|OTHER|Salt Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
48494909|NCT04238832|OTHER|Free Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
47977766|NCT01812824|BEHAVIORAL|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
47977767|NCT00696696|DRUG|Gemcitabine|1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
48129538|NCT03350698|BIOLOGICAL|Gardasil-9|3 vaccine series
48129539|NCT04726449|OTHER|Screening for acute confusional state|The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted
48129540|NCT00951691|BEHAVIORAL|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
48337056|NCT00759083|DRUG|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
47977768|NCT00696696|DRUG|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
47977769|NCT00696696|DRUG|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
48129541|NCT00951691|BEHAVIORAL|Treatment as usual|Standard treatment with physical and occupational therapies
47977770|NCT01357187|OTHER|Scheduled removal of posterior instrumentation with AmnioFix|
48494910|NCT01565616|DRUG|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
48494911|NCT03599271|DEVICE|Drug-Coated Device|3000 mcg mometasone furoate-coated sinus dilation device
48494912|NCT03599271|DEVICE|Control Device|Sinus dilation device without drug
48494913|NCT05870137|DEVICE|HoloLens2TM|Participants assigned to Mixed Reality-supported care used the HoloLens2 device, which provided support using technology that was permitted by the device. This support included remote assistance and holographic versions of patient-specific investigation results, such as radiological findings, biochemistry, and guidelines for completing the procedure (insertion of chest drain).
48494914|NCT05870137|OTHER|Standard care|The standard care for the intervention involved participants performing the invasive technical procedure to treat a tension pneumothorax using their standard clinical skills and knowledge, without the aid of the HoloLens2 device. The participants in the standard care group did not receive any additional support or guidance beyond what is typically available in a clinical setting. The goal of the study was to compare the effectiveness of the standard care approach with the use of Mixed Reality-supported care using the HoloLens2 device.
48494915|NCT05480163|OTHER|Measurement records|Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
48494916|NCT06417736|DRUG|Megestrol Acetate 40 MG|160mg/one time/day
47977771|NCT01357187|OTHER|Scheduled removal of posterior instrumentation without AmnioFix|
47977772|NCT01508858|DRUG|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
47977773|NCT01508858|DRUG|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
47977774|NCT01508858|DRUG|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
47977775|NCT03682666|DEVICE|Kinesiotaping|Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
47977776|NCT03682666|BEHAVIORAL|modified Constraint Induced Movement Training|A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.
47977777|NCT03682666|DEVICE|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
48337057|NCT06374524|PROCEDURE|greater occipital nerve block|Patients will receive an ultrasound-guided bilateral GONB (distal approach) of 5 mLs of injectate of bupivacaine 0.25% (5 mLs) + depomedrol 40 mg in 1 mL (3 mLs to each side).
48337058|NCT01229241|DRUG|local anesthetic|"postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml"
48337059|NCT00708903|DRUG|neratinib|HKI-272
48337060|NCT00708903|OTHER|Placebo|Placebo
48337061|NCT00708903|DRUG|Moxifloxacin|
48337062|NCT03167541|DRUG|Test|RB naproxen sodium tablets (2x220mg)
48337063|NCT03167541|DRUG|Reference|Aleve naproxen sodium tablets (2x220mg)
48337064|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
48337065|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
48337066|NCT00820807|OTHER|Placebo|oral consumption in beverage
48337067|NCT04819581|DRUG|SP-103|lidocaine topical system 5.4%
48337068|NCT04819581|DRUG|ZTlido|lidocaine topical system 1.8%
48337069|NCT01955395|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
47977778|NCT04581161|DEVICE|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
48337070|NCT03822338|PROCEDURE|Pneumoperitoneum preconditioning|Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
48337071|NCT03822338|PROCEDURE|Sham-Pneumoperitoneum preconditioning|Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
48654168|NCT06466642|BEHAVIORAL|Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©|The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.
48337072|NCT00292955|DRUG|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
47977779|NCT06506734|OTHER|Questionnaires|"*  Psychosocial Impact of Dental Aesthetics Questionnaire  PMID 24280547~*  Orofacial Esthetic Scale  PMID 30856637~*  Orofacial Esthetic Scale  PMID 34231057~* A photograph of the patient's smile will be sent to 2 dentists who will also assess the presence or absence of dental dyschromia."
47977780|NCT02573298|DEVICE|ice|local ice application for 30 minutes
47977781|NCT02573298|DEVICE|cold gas|local cold gas application for 2 minutes
48337073|NCT01205919|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
47977782|NCT01813578|OTHER|Exercise|Intensive aerobic and muscle endurance exercise
47977783|NCT02692716|DRUG|semaglutide|For oral use once daily.
47977784|NCT02692716|DRUG|placebo|For oral use once daily.
48494917|NCT03476369|DRUG|Fentanyl|Premedicated with Fentanyl (at least 25mcg by IV)
48494918|NCT03476369|DRUG|Ticagrelor 90Mg Tablet|Ticagrelor administered crushed vs non-crushed
48494919|NCT03903926|BIOLOGICAL|5000 volunteers (6-35 months)-EV71 vaccine|two doses EV71 vaccines will be administrated on day 0, 30 respectively
47977785|NCT02998593|DRUG|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
47977786|NCT02998593|DRUG|Placebo|Oral use of placebo capsules by patients for 3 months.
48337074|NCT01205919|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
48337075|NCT04355026|DRUG|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
48337076|NCT02518776|BEHAVIORAL|Neuropsychological tests|Neuropsychological tests
48337077|NCT01544478|BIOLOGICAL|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
48337078|NCT01668381|PROCEDURE|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
48129542|NCT00068458|DIETARY_SUPPLEMENT|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
48337079|NCT06409611|DEVICE|neuromuscular electrical stimulation|Application of neuromuscular electrical stimulation using the NeuroDyn III device (IBRAMED, Amparo - SP)
48337080|NCT04464577|DRUG|Fluconazole|Specified Dose on Specified Days
47977787|NCT04784949|PROCEDURE|portland cement|pulpotomy with PRF and white Portland cement
48129543|NCT00068458|OTHER|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
48129544|NCT00068458|OTHER|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
48129545|NCT02282657|DEVICE|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
48129546|NCT02282657|OTHER|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
48129547|NCT02282657|DEVICE|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
48129548|NCT02282657|OTHER|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
48337081|NCT04464577|DRUG|Bupropion|Specified Dose on Specified Days
48337082|NCT04464577|DRUG|Itraconazole|Specified Dose on Specified Days
48337083|NCT04464577|DRUG|BMS-986235|Specified Dose on Specified Days
48337084|NCT04298931|OTHER|Series of ventilator settings|"Before a planned fluid administration, the investigators will apply a series of 10 ventilator settings for 30 seconds each.~The settings are the following combinations of respiratory rate (RR) and tidal volume (TV):~RR (min\^-1), TV (ml/kg predicted body weight)~31, 6~31, 8~24, 6~24, 8~17, 6~17, 8~10, 4~10, 6~10, 8~10, 10~(the order of the respiratory rates: 17 to 31, will be randomized. 10/min will always be last. Tidal volume is always applied from lowest to highest for each respiratory rate)."
48337085|NCT04008199|OTHER|Super Abbu|The investigators have developed, piloted, and propose to expand and to experimentally evaluate a speech-based service that connects expectant fathers to doctors and to each other over a simple phone call. This service is dubbed Super Abbu (Super Dad in English).
48337086|NCT04661852|DRUG|Cabozantinib|PO (dose and schedule based upon dose level and nomogram)
48337087|NCT04661852|DRUG|Topotecan|IV, over 30 minutes (schedule based upon dose level)
48337088|NCT04661852|DRUG|Cyclophosphamide|IV, over 30 minutes (schedule based upon dose level)
47977788|NCT04784949|PROCEDURE|Mineral trioxide aggregate|pulpotomy with PRF and white Mineral trioxide aggregate
47977789|NCT04784949|PROCEDURE|Biodentine|pulpotomy with PRF and Biodentine
48129549|NCT02282657|OTHER|Respiratory Rate|RR will be kept what it was at baseline
48129550|NCT02282657|OTHER|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
48129551|NCT02282657|OTHER|Ventilation will be adapted|If PaCO2\> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
48129552|NCT02282657|OTHER|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
48337089|NCT04661852|DRUG|Myeloid growth factor|subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
48337090|NCT05195268|PROCEDURE|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
48337091|NCT03448042|DRUG|Runimotamab|Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
48337092|NCT03448042|DRUG|Trastuzumab|Trastuzumab will be administered via IV infusion
48337093|NCT03448042|DRUG|Tocilizumab|Participants will receive IV tocilizumab if needed
48337094|NCT05512312|PROCEDURE|Conventional Esthetic crown lengthening|Conventional Surgical Esthetic Crown Lengthening
48337095|NCT05512312|PROCEDURE|Computer guided Esthetic crown lengthening|Computer guided Esthetic crown lengthening
48337096|NCT02193672|DRUG|[18F] Fluciclatide|\[18F\] Fluciclatide given by vein before PET/CT scan.
47977790|NCT04492202|OTHER|Survey|The survey will be sent to health professionals via online link.
47977791|NCT03530904|OTHER|mobilization|Early mobilization after CIED implantation
47977792|NCT05194592|DRUG|Dapagliflozin|The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.
48129553|NCT04195919|DRUG|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
48129554|NCT04195919|DRUG|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
48129555|NCT05371275|DRUG|Palbociclib|125 mg of palbociclib once daily for 21 consecutive days
48129556|NCT01678079|DIETARY_SUPPLEMENT|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
47977793|NCT05194592|DRUG|Gemigliptin|The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
47977794|NCT06001476|PROCEDURE|Cold snare polypectomy|For eligible patients, use cold snare polypectomy to resect 5-9mm short-pedicled, broad-pedicled or sessile small bowel polyps
47977795|NCT00821977|DRUG|Vildagliptin|
47977796|NCT00821977|DRUG|Vildagliptin|
47977797|NCT00821977|DRUG|Placebo|
47977798|NCT00972569|DRUG|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
47977799|NCT00972569|DRUG|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
47977800|NCT06023823|OTHER|Toe spread out|toe-spread-out exercise.
47977801|NCT06023823|OTHER|Dry needling+Toe spread out|The group will be given 3 sessions of dry needling with Seirin branded 0.6\*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.
47977802|NCT00005970|DRUG|Aromatase Inhibition Therapy|Given orally
47977803|NCT00005970|DRUG|Cyclophosphamide|Given IV
47977804|NCT00005970|DRUG|Doxorubicin Hydrochloride|Given IV
47977805|NCT00005970|OTHER|Laboratory Biomarker Analysis|Correlative studies
47977806|NCT00005970|DRUG|Paclitaxel|Given IV
47977807|NCT00005970|DRUG|Tamoxifen Citrate|Given orally
47977808|NCT00005970|BIOLOGICAL|Trastuzumab|Given IV
47977809|NCT02297477|DRUG|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
47977810|NCT02297477|DRUG|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
47977811|NCT02448420|DRUG|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
47977812|NCT02448420|DRUG|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
47977813|NCT02448420|DRUG|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
48337097|NCT02193672|PROCEDURE|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
47977814|NCT02448420|DRUG|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
47977815|NCT02448420|DRUG|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
47977816|NCT04508478|BEHAVIORAL|Aerobic training|Aerobic training
47977817|NCT04508478|BEHAVIORAL|Resistance training|Resistance training
47977818|NCT04508478|BEHAVIORAL|Control physical exercise|Control physical exercise
47977819|NCT05855252|OTHER|No intervention|No intervention
47977820|NCT06286904|DEVICE|Skiin Garment system|Individuals will be asked to wear a Skiin Garment system for the duration of their hospitalization (minimum one day).The system will collect accelerometer, ECG, temperature, heart rate, steps and sleep metrics data if enable. Then, they will be asked to answer a questionnaire about their experiences with the device and the study.
47977821|NCT05255406|DRUG|Furmonertinib (160mg)|160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
47977822|NCT04934384|DIAGNOSTIC_TEST|prehospital extended focused assessment sonography for trauma|Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients
47977823|NCT04666584|DEVICE|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
47977824|NCT04666584|DEVICE|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
47977825|NCT01896440|DRUG|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
47977826|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
47977827|NCT01101646|DRUG|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
47977828|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
47977829|NCT02856230|DEVICE|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
47977830|NCT03500627|DRUG|OP-101|Intravenous Injection of OP-101 in healthy volunteers.
47977831|NCT01917474|DIETARY_SUPPLEMENT|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
47977832|NCT01917474|DIETARY_SUPPLEMENT|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
47977833|NCT05614128|OTHER|IVIg|Patients will be treated with IVIg as recommended by expert guidelines for treatment of CIDP under care of their primary neurologist. This will not be provided by the study.
47977834|NCT04541550|DRUG|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
47977835|NCT04541550|DRUG|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
47977836|NCT04541550|DRUG|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
48129557|NCT01678079|DIETARY_SUPPLEMENT|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
48129558|NCT03933800|DEVICE|High flow nasal cannula|High flow nasal cannula therapy
48337098|NCT02193672|BEHAVIORAL|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
47977837|NCT00856154|BIOLOGICAL|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~1. Gag150 RLLNAWVKV~2. Gag433 FLGKIWPV~3. Env 67 NIWATHACV~4. Pol606 KLGKAGYVV~5. Vpu66 ALVEMGHHV~6. Vif101 GLADQLIHL~7. Vif23 SLVKHHMYV~8. Gag298 KRWIILGLNKIVRMY~9. gp41 VWGIKQLQARVLAVERYLKD~10. Padre AKXVAAWTLKAAA"
47977838|NCT04128267|DEVICE|IPC-1000|Delivers pressure to thumbnail for five seconds at a time
48129559|NCT03933800|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure therapy
48129560|NCT03217669|DRUG|Epacadostat|Epacadostat tablet: 100mg or 300mg
48129561|NCT03217669|DRUG|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
48654169|NCT06643312|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
48654170|NCT04722315|DIETARY_SUPPLEMENT|Modified Atkins diet|12 weeks of modified Atkins diet
48654171|NCT06636786|DRUG|Cyclobenzaprine HCl|TNX-102 SL (cyclobenzaprine HCl sublingual tablets) taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
48654172|NCT06636786|DRUG|Placebo|Placebo sublingual tablets taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
47977839|NCT04128267|DEVICE|Magnetic resonance imaging|Scan of brain using Magnetic resonance imaging
47977840|NCT04128267|OTHER|Correlative Studies|Administration of questionnaires via computer
47977841|NCT00040664|DRUG|ritonavir|ritonavir oral capsules or oral solution
47977842|NCT00040664|DRUG|fosamprenavir|fosamprenavir oral suspension or tablet
47977843|NCT01088945|BEHAVIORAL|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
47977844|NCT02964351|BIOLOGICAL|High PSA levels|
47977845|NCT04455802|DRUG|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
47977846|NCT04455802|DRUG|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
47977847|NCT05131646|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
47977848|NCT03196934|DRUG|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
47977849|NCT01184794|DRUG|levobupivacaine|40 ml over 48 hours
47977850|NCT05909098|COMBINATION_PRODUCT|autologous NK cell|autologous NK cell
47977851|NCT04062175|DRUG|cephalosporin|72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
48337099|NCT00226278|DRUG|ORG 34517|
48654173|NCT02786329|DRUG|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
48654174|NCT02786329|DRUG|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
47977852|NCT04062175|DRUG|Azithromycin Tablets|72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
47977853|NCT05729659|DIETARY_SUPPLEMENT|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
47977854|NCT05729659|DIETARY_SUPPLEMENT|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
47977855|NCT03546192|BIOLOGICAL|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
47977856|NCT01916213|PROCEDURE|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
47977857|NCT05167214|DEVICE|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain
48129562|NCT06521424|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
48129563|NCT06521424|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
48337100|NCT05744323|OTHER|Functional training|Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
48494920|NCT01618136|DRUG|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
48494921|NCT01618136|DRUG|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
48654175|NCT02786329|DRUG|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
48337101|NCT04478110|BEHAVIORAL|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
48337102|NCT04478110|BEHAVIORAL|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
48337103|NCT00094835|BIOLOGICAL|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
48337104|NCT00094835|DRUG|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
48337105|NCT00094835|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.
48337106|NCT00094835|DRUG|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
48337107|NCT03934541|BIOLOGICAL|MPER-656 Liposome Vaccine|Administered by intramuscular injection
48337108|NCT03934541|BIOLOGICAL|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
48337109|NCT05477446|BIOLOGICAL|CD207 CAR-T cells|Single dose of CD207 CAR-T cells administered IV
48337110|NCT06260904|DRUG|Prednisolone|prednisolone 0.75mg/kg/day (a maximum dose of 30mg at baseline) orally
48654176|NCT02786329|DRUG|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
48337111|NCT06260904|DRUG|Apremilast|Apremilast 30 mg twice daily orally
48654177|NCT05277571|BIOLOGICAL|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
48654178|NCT05277571|DRUG|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
48337112|NCT06260904|DRUG|Methotrexate|Methotrexate 15 mg weekly orally
48337113|NCT03870009|OTHER|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
48337114|NCT02036268|BEHAVIORAL|Standard|Standard ostomy education
48337115|NCT02036268|BEHAVIORAL|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
48337116|NCT02036268|BEHAVIORAL|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
48337117|NCT06357884|PROCEDURE|Callus debridement|Eligible patients will be seated on a podiatry couch. Standard skin preparation procedure will be done with 2% Chlorhexidine gluconate in 70% isopropyl cleansing to all areas of feet. The same researcher will perform sharp debridement in all participants to minimize the variance between procedures. The procedure will comply with Infection Control Guideline (Podiatry) . A sterile scalpel handle loaded with a single-use No. 15 blade will be used to carry out sharp debridement using aseptic technique. Hyperkeratotic tissue will be debrided until smooth transition with adjacent skin is achieved and underlying pinkish normal skin is visible. Used scalpel will be unloaded and disposed by a QlickSmart ® BladeFLASK scalpel blade remover.
48337118|NCT03114098|OTHER|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
48337119|NCT01784003|DEVICE|Powered ankle-foot prosthesis|
48337120|NCT04658810|OTHER|Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)|Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder
48337121|NCT04084405|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
48494922|NCT01618136|DRUG|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
48494923|NCT00321828|BIOLOGICAL|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
48494924|NCT00321828|DRUG|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
48494925|NCT00321828|DRUG|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
48494926|NCT00321828|DRUG|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
48654179|NCT06271057|DRUG|golcadomide|golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
47977858|NCT03178864|DRUG|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
48494927|NCT01246622|DRUG|cytarabine|Given IV
48129564|NCT00722046|BIOLOGICAL|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
48494928|NCT01246622|DRUG|lenalidomide|Given PO
47977859|NCT03178864|DRUG|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
48129565|NCT00722046|BIOLOGICAL|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
48129566|NCT00722046|BIOLOGICAL|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
48129567|NCT00722046|DRUG|Placebo|Placebo every 60 days (10 doses total)
48129568|NCT00722046|BIOLOGICAL|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
48337122|NCT03349580|BEHAVIORAL|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
48337123|NCT00033592|OTHER|placebo|
48337124|NCT00033592|DRUG|bupropion hydrochloride|
48337125|NCT00033592|DRUG|nicotine|
48337126|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness through use of audio and visual virtual technology aid|Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).
48337127|NCT04281836|BEHAVIORAL|Interoceptive breathing awareness without use of audio or visual virtual reality|Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
48494929|NCT04310618|OTHER|No intervention|No intervention
47977860|NCT01635972|DRUG|Isavuconazole|oral
48494930|NCT03453567|PROCEDURE|Valve Replacement|Aortic valve replacement
48494931|NCT03625518|DRUG|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
48494932|NCT03625518|DEVICE|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
48494933|NCT05559775|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
48654180|NCT06640712|DIAGNOSTIC_TEST|Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria.|The same psychiatrist administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to all participants. Oral health examinations were performed by a trained dental student and a specialist dentist using a portable dental chair, artificial light, and a dental mirror. Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria. This index included the number of decayed, missing (due to caries, excluding 3rd molars), and filled teeth in the permanent dentition. The oral health examiners were blinded to each participant's substance use type and sociodemographic information.
47977861|NCT01635972|DRUG|bupropion hydrochloride|oral
47977862|NCT05030038|BIOLOGICAL|Fecal swab collection|Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
47977863|NCT05030038|BIOLOGICAL|Blood samples|Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
47977864|NCT00237198|DRUG|Letrozole|
47977865|NCT03117101|DRUG|Lucitanib|
48129569|NCT00722046|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
48129570|NCT00662519|DRUG|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
48129571|NCT00662519|DRUG|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
48129572|NCT00662519|DIETARY_SUPPLEMENT|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
48129573|NCT00662519|OTHER|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
48129574|NCT00662519|OTHER|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
48129575|NCT01440166|DRUG|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
48129576|NCT01440166|OTHER|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
48129577|NCT03869970|BEHAVIORAL|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
48266564|NCT01662440|BIOLOGICAL|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
48266565|NCT01662440|BIOLOGICAL|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
48266566|NCT01662440|OTHER|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
48494934|NCT00846521|DRUG|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
48129578|NCT03869970|BEHAVIORAL|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
48129579|NCT03869970|BEHAVIORAL|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
48129580|NCT02707666|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
48129581|NCT02707666|DRUG|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
48129582|NCT01053325|DRUG|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
48129583|NCT01053325|DRUG|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
48129584|NCT02746549|OTHER|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
48129585|NCT02011854|DEVICE|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
48129586|NCT02011854|DEVICE|Acupuncture|
48129587|NCT06225336|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
48129588|NCT04820049|DRUG|F573|F573 for injection
48654181|NCT06640712|DIAGNOSTIC_TEST|Substance Use Disorder Diagnosis|This intervention involves a psychiatric evaluation conducted by a licensed psychiatrist to diagnose Substance Use Disorder according to the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The psychiatrist performs a comprehensive assessment of each participant's substance use history and related behaviors. This diagnosis step is essential for identifying participants with specific substance use disorders, such as Methamphetamine, Cannabis, or Polysubstance Use Disorders, before proceeding with the dental health examination.
48129589|NCT04820049|OTHER|Placebo|Water for injection
48129590|NCT05842382|DRUG|Active Ingredient|IV Vitamin C (12g/day)
48129591|NCT05842382|DRUG|Placebo|IV dextrose 5%
48494935|NCT04988074|DRUG|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
47977866|NCT00208611|DIETARY_SUPPLEMENT|Vitamin B12 Supplementation|1000 micrograms daily
48129592|NCT00879710|DRUG|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
48494936|NCT00725205|BIOLOGICAL|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms \[mcg\]/killogram \[kg\]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
48654182|NCT02937571|DRUG|Carfilzomib|
48654183|NCT02937571|DRUG|Lenalidomide|
48654184|NCT02937571|DRUG|Dexamethasone|
47977867|NCT00797030|DRUG|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
47977868|NCT00797030|DRUG|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
48129593|NCT00537212|OTHER|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
48129594|NCT00537212|OTHER|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
48129595|NCT00537212|OTHER|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
48129596|NCT05421117|PROCEDURE|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
48129597|NCT00171431|DRUG|Tegaserod|
48129598|NCT04327752|OTHER|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
48337128|NCT01373918|DRUG|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
48494937|NCT00725205|DRUG|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
48494938|NCT00469768|DRUG|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
48494939|NCT00469768|DRUG|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
48654185|NCT06561776|OTHER|Physical Evaluations of individuals|Participants will be evaluated on cough strength, physical activity and balance. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
48266567|NCT02100605|DEVICE|Phytosun, decongestant, nasal spray|one time application of the nasal spray
48129599|NCT03657316|BEHAVIORAL|nutrition education|"The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages"
48129600|NCT01303510|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
48129601|NCT00003867|DRUG|capecitabine|
48129602|NCT00003867|DRUG|irinotecan hydrochloride|
48129603|NCT02806674|DEVICE|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
48129604|NCT02806674|DEVICE|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
48129605|NCT06404723|DIAGNOSTIC_TEST|Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio|to detect their relation to disease activity to use as predective and prognostic tools
48129606|NCT01094626|DRUG|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
48129607|NCT04595305|DEVICE|Cardiac resynchronization therapy by CRT-P or CRT-D implantation|Clinically indicated implantation of a CRT-P or CRT-D device as per standard of care
48129608|NCT01340716|OTHER|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
48129609|NCT01340716|OTHER|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
48129610|NCT05101954|PROCEDURE|Concentrated Growth Factors (CGF)|Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
48129611|NCT05101954|PROCEDURE|Platelet-Rich Fibrin (PRF)|Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
48129612|NCT00140400|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
48337129|NCT01373918|DRUG|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
48337130|NCT03924648|OTHER|Endocan levels|Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
48654186|NCT06240728|DRUG|NPX887|NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years
48654187|NCT05930535|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens|"PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other."
48129613|NCT04810975|DEVICE|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
48129614|NCT05629845|PROCEDURE|endoscopic ultrasound-guided therapy|EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
48494940|NCT00469768|OTHER|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
48129615|NCT05629845|PROCEDURE|conventional endoscopic therapy|conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
48129616|NCT05092841|DRUG|PXT3003|Patients will be administered PXT3003 twice daily (bid) at 10mL.
48129617|NCT05092841|DRUG|PXT3003 placebo|Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
48129618|NCT02022800|OTHER|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
48129619|NCT05502094|OTHER|Heart Rate Variability Measurement|The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
48494941|NCT04689919|DRUG|Rivaroxaban 20 MG Oral Tablet|The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
48494942|NCT03715075|PROCEDURE|Caesarean Section|Caesarean Section
48494943|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
48129620|NCT00902213|BEHAVIORAL|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
48129621|NCT00902213|BEHAVIORAL|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
48129622|NCT05986305|BEHAVIORAL|Go Act|Go Act sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.
48129623|NCT05986305|BEHAVIORAL|Peer|During Peer sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
48129624|NCT05413889|BEHAVIORAL|Epic 30-day unplanned readmission risk score|If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
48129625|NCT04826822|DRUG|Spironolactone + Dexamethasone|Low doses of orally administered spironolactone and dexamethasone
48129626|NCT04826822|DRUG|Standard-of-care SARS-CoV-2 treatment|Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
48129627|NCT04847375|DRUG|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
48337131|NCT04450641|OTHER|GuessWhat Mobile Application|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
48337132|NCT04446442|DEVICE|tDCS|A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
47977869|NCT01647815|PROCEDURE|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
47977870|NCT00477282|DRUG|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
47977871|NCT00477282|DRUG|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
47977872|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
47977873|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
47977874|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
47977875|NCT01619774|DRUG|GSK2118436|Starting dose 150 mg by mouth twice a day.
47977876|NCT01619774|DRUG|GSK1120212|2 mg by mouth daily.
47977877|NCT04445922|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
47977878|NCT04445922|DRUG|reference-anastrozole tablet|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
47977879|NCT04404751|COMBINATION_PRODUCT|Iodised salt with Iron, Folic acid and Vitamin B12|Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
47977880|NCT05495256|DEVICE|Respimetrix|The Respimetrix device has a low resistance airflow sensor with an inhaler to measure patients inspiratory airflow and volume. This device will thereby provide quantifiable measures of lung function and bronchodilator delivery.
47977881|NCT05486676|BEHAVIORAL|VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
48129628|NCT03002259|DRUG|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
47977882|NCT05552560|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist.~This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients."
48129629|NCT03469596|DIAGNOSTIC_TEST|MRI sequence|several MRI sequence before and after contrast product injection.
48266568|NCT02762487|DEVICE|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
48266569|NCT06339398|BEHAVIORAL|Aerobic exercise|Standardized volume of aerobic exercise, measured as METs-minutes/week
47977883|NCT01674270|DRUG|Degarelix|
48266570|NCT01671345|BEHAVIORAL|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
48129630|NCT03700034|OTHER|mHealth Integrated Model of Antenatal Care|"In the intervention facilities, antenatal care (ANC) will be provided to all pregnant women using the mIRA electronic decision support system (EDSS) by ANMs (Auxiliary Nurse Midwife), Staff nurses, or Medical Officers (MOs). These frontline healthcare workers (FHWs) will be trained to use the EDSS and will also be provided refresher training on the guideline-recommended processes of ANC. This training will enable them to use the mIRA EDSS in the provision of ANC. Non-physician FHWs (ANMs and staff nurses) will screen, detect, and refer PIH, GDM, and severe anemia cases. They will not prescribe treatments, but will carry out all other duties including diagnosis, referral to the MO to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans."
48129631|NCT03399604|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
47977884|NCT01674270|DRUG|Casodex|
47977885|NCT01674270|DRUG|LHRH Agonist|
47977886|NCT06454383|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47977887|NCT06454383|DRUG|Cholestyramine|Given PO
47977888|NCT06454383|PROCEDURE|Computed Tomography|Undergo CT
47977889|NCT06454383|PROCEDURE|Diagnostic Imaging|Undergo imaging scans
47977890|NCT06454383|DRUG|Gemcitabine|Given IV
47977891|NCT06454383|DRUG|Leflunomide|Given PO
47977892|NCT06454383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47977893|NCT03942848|DRUG|zicotinide followed by placebo|The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
47977894|NCT03942848|DRUG|Placebo followed by zicotinide|The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
47977895|NCT05693441|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
47977896|NCT05693441|OTHER|Reference berry-like product|Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
47977897|NCT00126568|DRUG|sorafenib tosylate|Given orally
47977898|NCT00531999|DRUG|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
47977899|NCT00531999|DRUG|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
47977900|NCT00873756|DRUG|FOLFOX regimen|Intravenous repeating dose
48129632|NCT04400734|OTHER|No intervention, observational study|no intervention
48266571|NCT01671345|BEHAVIORAL|Control|Attention control
48337133|NCT05966246|DRUG|Arm I : Experimental (Prucalopride succinate group)|Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
48337134|NCT05966246|DRUG|Arm II : Control (Mosapride citrate group)|Control gourp taking mosapride citrate from day 1 day 5 after surgery
48337135|NCT01261598|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
48337136|NCT02840526|PROCEDURE|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
48337137|NCT02840526|DRUG|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
48337138|NCT02840526|DRUG|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
48337139|NCT02840526|DRUG|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
47977901|NCT00873756|DRUG|bevacizumab|Intravenous repeating dose
48337140|NCT02840526|DRUG|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
48494944|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
48494945|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
47977902|NCT00873756|DRUG|dulanermin|Intravenous repeating dose
47977903|NCT04386980|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
47977904|NCT04386980|DRUG|Placebo|Diluent in normal saline
47977905|NCT02234089|DRUG|Degarelix|According to medical practice
47977906|NCT02234089|DRUG|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
47977907|NCT06471816|OTHER|Dialogue Based Early Detection|Before the biannual parent-teacher meeting, both the kindergarten teacher and the parents will complete the Early Worry Questionnaire containing 39 items related to development and well-being of the individual child. For each item the respondents are asked to indicate if they during the last three months have been concerned. In the parent-teacher meeting they will discuss their possible concerns and try to reach an agreement on how to evaluate the child. If necessary, possible supportive interventions or further assessments locally in the kindergarten or in the public services will be decided.
47977908|NCT06471816|OTHER|Traditional parent-teacher meeting|This is an annual or biannual meeting that is prepared by the kindergarten teacher where (s)he reports on the child's appearance / behaviour and possible challenges as to development and behaviour from an educationalist's view. There are no common templates for the agenda of such meetings, however, usually the kindergarten teacher's perspective and opinion will dominate.
48129633|NCT03323775|DIAGNOSTIC_TEST|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
48129634|NCT05080413|DEVICE|Laser shoes|Path Finder® is a device that is fixed to the noses of the patient's shoes using a rubber strap, and laser-marks the place to be stepped on the ground of the opposite foot when walking. It is installed on both feet to relieve the symptoms of freezing of gait.
48129635|NCT05080413|DEVICE|Metronome|The metronome, which makes a sound with a constant beat, is known to have an effect on the symptoms of Freezing of Gait in Parkinson's disease patients. At a rate of 80 beats per minute, the volume of sound that the patient can fully recognize is set to resolve the freezing of gait using the metronome sound.
48129636|NCT05960994|OTHER|Intervention period|"During the intervention period, three interventions will be implemented through telemedicine.~1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.~2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.~3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety."
48129637|NCT05629793|OTHER|Experimental tests|Walking for 6 minutes, sitting down and getting up from a chair for 1 minute and finally the cold test (Cold pressor) where the hand is introduced for 1 minute in water at 4ºC. The patient will be monitored by means of a Polar H10 chest strap, as used in sports, continuously and 02 saturation, TA and voice (exhalation while saying /a/ and dry cough) will be collected before and after the tests. Finally, skin conductance will be monitored by performing baseline tracing and then control while performing the cold test.
48129638|NCT01072838|RADIATION|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
48129639|NCT01072838|DEVICE|Contura MLB Breast Brachytherapy Catheter|
48129640|NCT04801199|DRUG|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
48129641|NCT04801199|DRUG|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
48129642|NCT03048994|DIETARY_SUPPLEMENT|Glutamine|"* Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~* IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~* An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
48337141|NCT02840526|DRUG|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
48337142|NCT02840526|DEVICE|Intubation|Intratracheal intubation with a single lumen endotracheal tube
48337143|NCT02840526|DRUG|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
48337144|NCT02840526|DRUG|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
48337145|NCT02840526|DRUG|Ketonal|100 mg ketoprofen intravenously every 12 hours
48337146|NCT02840526|DRUG|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
48494946|NCT04757701|OTHER|Social Behavioral surveys, interviews, and focus groups|Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
48337147|NCT01230918|RADIATION|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
48337148|NCT03267407|OTHER|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
48337149|NCT02879370|PROCEDURE|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
48129643|NCT03048994|DIETARY_SUPPLEMENT|Placebo|"* Nutritional support will be continued as per managing ICU team discretion.~* Management of severe sepsis will be continued as per managing ICU team discretion.~* Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~* To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
48129644|NCT02477514|DRUG|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
48129645|NCT02477514|DRUG|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
48129646|NCT02477514|DRUG|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
48129647|NCT03019835|DRUG|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
47977909|NCT04565860|OTHER|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
47977910|NCT04473014|BEHAVIORAL|Heat Pain Paradigm|A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
48129648|NCT03019835|OTHER|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
48129649|NCT02796729|PROCEDURE|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
48129650|NCT02796729|DRUG|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
48337150|NCT04614350|BIOLOGICAL|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
48337151|NCT04614350|BIOLOGICAL|AlloDerm|AlloDerm tissue matrix
47977911|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: exposure in vivo|Behavioral, chronic pain rehabilitation therapy
47977912|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: graded activity|Behavioral, chronic pain rehabilitation therapy
47977913|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: acceptance and commitment therapy|Behavioral, chronic pain rehabilitation therapy
47977914|NCT01104493|BIOLOGICAL|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
47977915|NCT01104493|OTHER|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
48129651|NCT02796729|DRUG|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
48129652|NCT05374642|BEHAVIORAL|cognitive training|tablet-based cognitive training for 12 weeks, 30 minutes each time, at least 5 times a week
48129653|NCT05374642|BEHAVIORAL|active control|tablet-based cognitive training tasks with weak or no difficulty changes, 5 times a week, 30 minutes each time for 12 weeks
48129654|NCT06020352|DRUG|KN046 plus Axitinib|KN046 combined with axitinib as a neoadjuvant treatment regimen
48129655|NCT01194011|BEHAVIORAL|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
48129656|NCT02379715|DRUG|Remifentanil|
48129657|NCT02379715|DRUG|Desflurane|
48129658|NCT05097001|OTHER|DBS programming|DBS readjustment based on COMPUTER or CLINICAL program
48129659|NCT04124185|DIAGNOSTIC_TEST|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
48129660|NCT05224024|PROCEDURE|Retzius-repairing robot-assisted radical prostatectomy|Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
48129661|NCT01485406|BIOLOGICAL|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
48129662|NCT01485406|BIOLOGICAL|Synflorix™|1 dose administered intramuscularly
48129663|NCT04038424|OTHER|Art therapy|Art therapy including coloring, painting and listening to music
48129664|NCT04633941|OTHER|Standard Care|Standard Care
48129665|NCT00448552|DRUG|capecitabine|
48129666|NCT00448552|DRUG|oxaliplatin|
48129667|NCT04737291|DEVICE|drug coated balloon|use of drug coated balloon in treatment of critical limb ischemia
48129668|NCT01526954|DEVICE|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
48129669|NCT06075017|PROCEDURE|dental implant placement|Comparing the amount and type of biofilm on zirconia vs. titanium implants
48129670|NCT04699058|DIAGNOSTIC_TEST|COVID-antibody test|Questionnaire and COVID-antibody test for all participants
48129671|NCT00862706|DRUG|Telbivudine/LDT600A|Oral once daily
48337152|NCT01280019|PROCEDURE|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
48129672|NCT04823754|OTHER|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
48129673|NCT04508010|OTHER|IVR|Participants will receive an IVR survey
48129674|NCT04508010|OTHER|CATI|Participants will receive a CATI survey
48129675|NCT01220869|DRUG|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
48129676|NCT05461053|DRUG|LMX 4 Topical Cream|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
48654188|NCT04883047|OTHER|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
48654189|NCT03263533|DRUG|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
47977916|NCT00750204|DEVICE|APRV|"APRV Protocol~* Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~* Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~* Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~* P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~* Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~* If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
47977917|NCT00750204|DEVICE|Conventional MV|Low tidal-volume mechanical ventilation
47977918|NCT05505214|DRUG|Bacterial decolonization|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
48129677|NCT05014035|BEHAVIORAL|Resistance Exercise|This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
48129678|NCT00000749|BIOLOGICAL|rgp120/HIV-1 SF-2|
48129679|NCT01627561|BIOLOGICAL|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
48129680|NCT01627561|BIOLOGICAL|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
48129681|NCT01627561|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
48129682|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
48129683|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
48337153|NCT02929862|DRUG|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
48337154|NCT06195098|OTHER|Nutritional educational intervention|The interventional activities were targeted to the local population, according to their educational level and culture and it was composed by a theoretical part and a more practical part. The objective was to improve nutritional knowledge and their awareness about the role of food in connection to the human health. According to the theoretical part: to make the activities more appealing, three informative graphic posters were drafted. According to the practical part: a cooking class activities were conducted, involving women of the Ampanithosa and Bevoko villages. The researchers teaching them how to use a bamboo steamer and how to process vegetables, grew up in the organic gardens built by the Kukula team. The activities were carried out in each village thanks to a local enumerators involvement.
48337155|NCT00879983|DRUG|azithromycin (Zithromax)|"1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg"
48654190|NCT03263533|DRUG|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
48654191|NCT03701074|DRUG|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
48129684|NCT05394636|OTHER|None, pure observational study|None, pure observational study
48129685|NCT00588406|DRUG|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
48129686|NCT00588406|DRUG|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
48129687|NCT00588406|DRUG|Ipratropium bromide|2.5 mg, one dose
48129688|NCT00588406|DRUG|Prednisone|60mg PO
48129689|NCT03997994|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter coated with a proprietary coating containing the drug and carriers.
48129690|NCT04362046|PROCEDURE|Hysteroscopic uterine resection|"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."
48129691|NCT05521386|DRUG|Caffeine|Single pill in an acute dose of 5 mg per kg of body mass
48129692|NCT05521386|DRUG|Placebo|Single pill in an acute dose of 5 mg per kg of body mass
48129693|NCT01340066|DRUG|UISH001|sublingual dosing, 1 drop 3 times a day
48129694|NCT01340066|DRUG|matching placebo|sublingual dosing,1 drop 3 times a day
48129695|NCT02831816|DRUG|ZuraPrep|Apply topically.
48129696|NCT02831816|DRUG|ChloraPrep|Apply topically.
48129697|NCT02831816|DRUG|ZP Vehicle|Apply topically.
48129698|NCT00470314|DRUG|L-Ornithine L-Aspartate|
48129699|NCT04043169|DIAGNOSTIC_TEST|Clearblue pregnancy test|Urine pregnancy test
48654192|NCT03701074|DRUG|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
48654193|NCT01795157|DEVICE|CCADSS|Questionnaire is transferred wireless to the physician's PC
48654194|NCT01795157|DEVICE|pen-paper|Questionnaire completed and transferred to the physician using standard methods
48129700|NCT06053606|DEVICE|cryoablation of atrial fibrillation using only 28 mm size balloon|all applications in all PVs are done with 28 mm balloon
48129701|NCT06053606|DEVICE|cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)|first applications in LSPV and RSPV are done with 31 mm balloon
48494947|NCT03274674|OTHER|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
48494948|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection|Administered one time via subcutaneous route.
48494949|NCT05304611|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB) intravenous injection|Administered one time via intravenous route.
48654195|NCT02054728|OTHER|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
48654196|NCT00835042|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
48654197|NCT00835042|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
47977919|NCT05505214|DRUG|Mometasone furoate 0.1% cream|Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
47977920|NCT05505214|DRUG|Bacterial decolonization and Mometasone furoate 0.1% cream|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
47977921|NCT00976092|DRUG|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
48129702|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet and exercise advice
48129703|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
48129704|NCT02502461|PROCEDURE|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
48129705|NCT02520219|DRUG|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.
48129706|NCT02520219|BIOLOGICAL|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
48129707|NCT02348632|DRUG|JZP-110|
48129708|NCT02238769|DEVICE|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
48129709|NCT00781118|DEVICE|Guardian System|There is no intervention in this study. The device is a diagnostic only.
48129710|NCT01471691|DRUG|ranibizumab 0.5mg|Standard dose
48129711|NCT01471691|DRUG|ranibizumab 1.0mg|High dose
48129712|NCT02404441|BIOLOGICAL|PDR001|anti-PD1 antibody
48654198|NCT06638580|DIAGNOSTIC_TEST|Clinical Periodontal Measurements (plaque index, gingival index, bleeding index, clinical attachment level), Optical Coherence Tomographic Measurements, Serum IL1-β, TNF-α, IL-10, TAS, TOS, OSİ levels|"Probing pocket depth (PPD) was measured as the distance between the deepest point of the sulcus (or pocket) and the gingival margin, and clinical attachment level (CAL) was measured as the distance between the base of the pocket and the cementoenamel junction. PPD and CAL were measured at six different points (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) in each tooth, and other index scores were taken at four different points (mesial, distal, vestibular and palatinal).~Serum IL1-β, TNF-α, and IL-10 levels were measured via immunosorbent assay method using human-specific kits according to the kit manufacturer's instructions.~Serum total antioxidant status (TAS) and total oxidant status (TOS) levels were mea-sured by a spectrophotometric method using specific kits.~Retinal and choroidal imaging and measurements were performed with optical coherence tomography (SS-OCT) with swept-source (SS) technology and non-invasive OCT angiography."
48654199|NCT06088979|DRUG|TOUR006 - 20 MG|TOUR006 20 MG
48129713|NCT06186375|OTHER|Patients with planned biotherapy|Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
48129714|NCT04553549|DEVICE|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
48494950|NCT05304611|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
48654200|NCT06088979|OTHER|Placebo|Placebo
48654201|NCT06088979|DRUG|TOUR006 - 50 MG|TOUR006 - 50 MG
48129715|NCT03449771|OTHER|self-administered questionnaire|The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
48337156|NCT00879983|DRUG|azithromycin (Zithromax)|"1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g"
48654202|NCT05050669|OTHER|No Intervention for this observational study|No Intervention for this observational study
48654203|NCT06501976|DRUG|Lurbinectedin|2.6 mg/m2 , Given IV, every 21 days
48654204|NCT06501976|RADIATION|Radiation Therapy|Thoracic radiotherapy
48654205|NCT02412982|DRUG|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
47977922|NCT00976092|DRUG|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
47977923|NCT00976092|DRUG|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
47977924|NCT00976092|DRUG|Heparin|i.v. bolus of 70-100 IU/kg body weight
47977925|NCT02216188|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
48337157|NCT04506944|OTHER|No intervention|No specific exposure is explored.
48494951|NCT02448706|DEVICE|Hearing Aid Fitting A|
48654206|NCT02412982|DRUG|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
48654207|NCT06211374|BEHAVIORAL|Communication Bridge|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
48654208|NCT06570174|DIETARY_SUPPLEMENT|oral protein supplements|Participants in this group received an oral protein supplement providing 18g of protein per day. The supplement was administered postoperatively and continued throughout the study period. The goal was to assess the impact of protein supplementation on protein intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed. These outcomes were measured at three specific time points: before surgery, at discharge, and during the outpatient visit.
48654209|NCT06570174|GENETIC|placebo|Participants in this group received a placebo supplement containing carbohydrates instead of protein, which was identical in appearance and taste to the protein supplement to maintain the study's double-blind design. The placebo was administered postoperatively and continued throughout the study period. The aim was to serve as a control to evaluate the effects of the protein supplement on outcomes including nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed, measured at three key time points: before surgery, at discharge, and during the outpatient visit.
47977926|NCT02216188|OTHER|Control|Untreated control group
47977927|NCT03721601|DEVICE|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
47977928|NCT03721601|DEVICE|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
48494952|NCT02448706|DEVICE|Hearing Aid Fitting B|
48494953|NCT01379001|DRUG|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
48494954|NCT01379001|DRUG|Placebo|IM or PO placebo
48494955|NCT01379001|DRUG|Donepezil|donepezil 5mg PO x 1
48494956|NCT02054130|DRUG|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
48654210|NCT00834782|PROCEDURE|IOP measurement|Measuring IOP
48494957|NCT02054130|DRUG|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
48494958|NCT02054130|DRUG|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
48337158|NCT05687708|OTHER|Non-Nutritive Sucking|NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
48494959|NCT02054130|DRUG|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
48494960|NCT02369900|DRUG|Esmolol|
48494961|NCT02369900|OTHER|Saline|
48494962|NCT04492826|PROCEDURE|Postoperative infections rate|Assess the postoperative infection rate after otolaryngology bone flap surgery.
48494963|NCT01193127|DRUG|OMS302 Solution|
48494964|NCT01193127|DRUG|OMS302 Mydriatic Solution|
48494965|NCT01193127|DRUG|OMS302 Anti-inflammatory Solution|
48494966|NCT01193127|DRUG|Balanced Salt Solution (BSS) Solution|
48494967|NCT05640219|DEVICE|laparoscopic trocar 12mm|long laparoscopic trocar 12mm (36 french) with central hole from its tip till its handle with transparent sheath
48494968|NCT06113926|OTHER|Bystander Acknowledgment|"The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist... acknowledgment of the participants experience, ...this shouldn't have happened, and I'm really sorry it did... an apology, and ...I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action."
48494969|NCT02501434|DRUG|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
48494970|NCT00848107|DRUG|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
48494971|NCT04860063|DRUG|Berberine|Participants randomly assigned to the intervention group will be provided with Berberine 500 mg administrated per os three times a day for six months
48494972|NCT04860063|DRUG|Placebo|Participants randomly assigned to the Placebo group will be provided with placebo administrated per os three times a day for six months
48494973|NCT04583449|BEHAVIORAL|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
48494974|NCT02129296|DEVICE|Air filled balloon|Balloon filled with air according to the manufacturing company orders
48494975|NCT02129296|DEVICE|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
48494976|NCT02068521|DRUG|somavaratan|Subcutaneous injection
48494977|NCT00860366|DRUG|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
48494978|NCT00860366|OTHER|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
48494979|NCT02906241|BEHAVIORAL|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
48494980|NCT02906241|BEHAVIORAL|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
48494981|NCT05968443|DEVICE|ophthalmic surgery|any ophthalmic surgery using Dafilon® suture
48494982|NCT04567914|DIAGNOSTIC_TEST|Bilaterally abdominal muscle thickness with ultrasonography|AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
48494983|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
48654211|NCT04475380|DEVICE|Percutaneous coronary intervention|PCI for treatment of coronary or bypass graft lesions
48337159|NCT01577355|RADIATION|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
48494984|NCT04023903|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
48494985|NCT03678324|OTHER|Functional MRI and fast bound-pool fraction imaging|"Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey."
48494986|NCT04699526|OTHER|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
48494987|NCT02196701|DRUG|Adalimumab|Administered by subcutaneous injection every other week.
48494988|NCT02196701|DRUG|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
48494989|NCT02876575|DEVICE|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
48494990|NCT00808964|DRUG|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
48494991|NCT05197218|DIETARY_SUPPLEMENT|Prebiotic|Combination of a polyphenol rich extract of chokeberry (Aronia melanocarpa) and a polyphenol rich extract of cranberry (Vaccinium macrocarpon Aiton) will be administered for 18 days.
47977929|NCT00382278|PROCEDURE|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
47977930|NCT00848705|BEHAVIORAL|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
48129716|NCT02910973|DEVICE|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
48129717|NCT02910973|DEVICE|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
48129718|NCT00002748|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
48129719|NCT00002748|BIOLOGICAL|interleukin-2 gene|
48129720|NCT04305821|OTHER|Dosage of S100β protein|Dosage of S100β protein
48129721|NCT02448524|DEVICE|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
48494992|NCT00102518|DRUG|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
48494993|NCT03544996|COMBINATION_PRODUCT|TD Insulin|Human Insulin USP formulated in a solution capable of transdermal delivery.
48494994|NCT05885191|OTHER|2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture|Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.
48337160|NCT02408926|BIOLOGICAL|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
48494995|NCT01941940|DRUG|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
48494996|NCT01941940|DRUG|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
48494997|NCT00003079|DRUG|bryostatin 1|
48494998|NCT00003079|DRUG|cytarabine|
48494999|NCT04336124|DRUG|CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)|"Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur."
48495000|NCT00212121|RADIATION|high dose boost|high dose boost
48495001|NCT00212121|PROCEDURE|boost|low dose versus high dose
48654212|NCT01760863|OTHER|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
48495002|NCT02804230|DEVICE|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
48495003|NCT01346774|DRUG|Cranberry powder capsules|2 cranberry powder capsules twice a day
48654213|NCT05363930|DEVICE|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
48654214|NCT05363930|DEVICE|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
48654215|NCT04759404|OTHER|Deep Oscillation Treatment|Deep oscillation to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
48654216|NCT04759404|OTHER|Myofascial Release Treatment|Myofascial release to the lumbar region and stretching and strengthening exercise for waist, back and abdominal
48654217|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
48129722|NCT02448524|DEVICE|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
48129723|NCT06082635|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
48129724|NCT06082635|DRUG|Crizotinib|Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
48129725|NCT04896736|OTHER|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase \>/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
48129726|NCT04896736|OTHER|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
48654218|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
48654219|NCT06570421|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct transcutaneous, electrical stimulation of the peroneal nerve
48654220|NCT00773591|DRUG|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
48654221|NCT06637735|OTHER|education|pregnant women will be given a 4-week training and the pre-test post-test will be analyzed
48654222|NCT05739994|OTHER|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
48654223|NCT05739994|OTHER|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
48129727|NCT05374525|DRUG|APRETUDE|Available as intramuscular injection.
48654224|NCT00967252|DRUG|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
48654225|NCT00967252|DRUG|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
48129728|NCT05374525|DRUG|Cabotegravir OLI|Available as marketed orally administered tablets.
48654226|NCT00967252|DRUG|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
48654227|NCT00967252|DRUG|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
48654228|NCT00967252|OTHER|Control|No statin being taken
48654229|NCT06502119|OTHER|Designed Questionnaire|Participants in this study, comprised solely of obstetricians and gynecologists practicing in Egypt, will complete a self-administered questionnaire designed to assess their knowledge, attitudes, and practices related to operative vaginal birth. The questionnaire includes four sections: the first gathers demographic data such as name, gender, and years of experience in childbirth care; the second focuses on participants' practices regarding the frequency and types of operative vaginal birth used (forceps, ventouse) and reasons for their use; the third evaluates knowledge of outcomes associated with operative vaginal birth through multiple-choice questions; and the fourth explores attitudes towards operative vaginal birth, including opinions on hospital rates and policy appropriateness. Completion and return of the questionnaire, which takes approximately 5 to 10 minutes, will be considered as consent to participate in the study.
48654230|NCT02298946|DRUG|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
48129729|NCT04755179|PROCEDURE|Laparoscopic appendectomy|"Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~1. Conventional laparoscopy (three-trocar technique)~2. In case of purulent fluid: Suction and no peritoneal lavage procedure~3. Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~4. Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~5. Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~6. No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~7. Closure of wounds as appropriate"
48129730|NCT04755179|PROCEDURE|Open appendectomy|"Open appendectomy will be performed according to the following standardized key points:~1. Gridiron incision at the right lower quadrant. (McBurney's point)~2. After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~3. The appendiceal stump will be closed by ligation, not a purse string suture.~4. Closure of wounds as appropriate"
47977931|NCT02523898|DRUG|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
48129731|NCT04755179|PROCEDURE|Non-operative treatment|"Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~1. Combination A:~   1. Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children \<40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children \> 40 kg~  2. Gentamicin 7mg/kg once daily~2. Combination B:~   1. Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~  2. Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical."
48129732|NCT04755179|PROCEDURE|Direct appendectomy|laparoscopic or open appendectomy as described
48129733|NCT04842253|DEVICE|High flow nasal cannula|HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.
48129734|NCT04592185|DEVICE|Fenestrated Anaconda™ Device|Treatment of complex abdominal aortic aneurysms
48129735|NCT05365191|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Participants undergo sentinel lymph node biopsy for breast cancer, and use blue dye/Tc99m radioisotope as primary tracer. Indocyanine green near infrared fluorescence as secondary tracer for mapping.
48129736|NCT06274099|OTHER|nursing care|It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
48129737|NCT04719026|OTHER|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
48129738|NCT01182649|DEVICE|coronary stent|coronary angioplasty with stent implantation
48129739|NCT01182649|DEVICE|stent|coronary angioplasty with stent implantation
48129740|NCT05460741|OTHER|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
48129741|NCT05460741|OTHER|educational program|educational program related to menstrual cycle will be given to females.
48129742|NCT05979038|DRUG|Metformin|Patients in the intervention arm will take metformin 500mg three times a day
48129743|NCT03352726|DRUG|DBV712 IHRP|DBV712 Solution for Skin Prick Test
48129744|NCT03695757|BIOLOGICAL|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
48129745|NCT03695757|BIOLOGICAL|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
48129746|NCT00697060|DRUG|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
48129747|NCT03648190|DIAGNOSTIC_TEST|Flowcytometry analysis of platelets surface receptors|"BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs)."
48129748|NCT03877575|OTHER|No specific intervention. Collection of clinical data|
48129749|NCT04033315|DEVICE|L-PLUS meter|Blood Glucose Monitoring System
48129750|NCT02128113|DRUG|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
48129751|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
48129752|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
48129753|NCT05484648|DRUG|Dexamethasone|"Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers."
48129754|NCT05484648|DRUG|Dexmedetomidine|Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
48129755|NCT05599282|DRUG|Amino Acid Supplement|Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
48129756|NCT05599282|OTHER|Placebo|Four capsules of Placebo will be taken once a day for 90 days.
48129757|NCT06426966|DIETARY_SUPPLEMENT|Berberine|Berberine is an alkaloid derived from plants native to China called Rhizoma coptidis, Cortex phellodendrine and Hydrastis canadensis. These plants are used in the treatment of infectious diarrhea, inflammation, DM2, non-alcoholic fatty liver disease, dyslipidemias, cardiovascular diseases, and obesity. They have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)
48129758|NCT06426966|DIETARY_SUPPLEMENT|Gymnema sylvestre|"Gymnema sylvestre also known as meshashringi, is a plant from central and southern India. The leaf extract has been used as a laxative, diuretic, and cough suppressant; Likewise, it has antimicrobial, antihypercholesterolemic, and hepatoprotective activities. It is associated with antioxidant properties . Its adjuvant effect has been reported in the therapy of type 2 diabetes, revealing how its active compounds can influence glucose regulation and improve insulin sensitivity."
48129759|NCT02964741|DEVICE|Active Comparator|non-invasive brain stimulation (active protocol)
48129760|NCT02964741|DEVICE|Sham Comparator|non-invasive brain stimulation (sham protocol)
48129761|NCT02284113|DEVICE|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
48129762|NCT02284113|DEVICE|iovera° Sham|iovera° device used for sham treatment
48129763|NCT00255307|DRUG|CVT-E002 ginseng extract|
48129764|NCT02313675|DRUG|Acetaminophen|
48654231|NCT02298946|RADIATION|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
48654232|NCT02298946|DRUG|Cyclophosphamide|200mg/m(2) IV on day 0.
48654233|NCT06174649|DIAGNOSTIC_TEST|Reveal|Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in \~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for \~90% of organisms causing Gram negative blood stream infections (BSI).
48654234|NCT06405581|OTHER|Edmonton frailty scale calculation|"The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile"
48654235|NCT00684294|BIOLOGICAL|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
48654236|NCT05440786|DRUG|Abemaciclib|Orally
48654237|NCT05440786|DRUG|Irinotecan|IV
48654238|NCT05440786|DRUG|Temozolomide|Orally
47977932|NCT02523898|DRUG|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
48129765|NCT02313675|DRUG|Ketorolac Tromethamine|
48129766|NCT02313675|DRUG|Saline|
48129767|NCT05587699|DRUG|CKD-843 A 45mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
48129768|NCT05587699|DRUG|CKD-843 A 45mg|Single Injection
48129769|NCT05587699|DRUG|CKD-843 A 55mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
48129770|NCT05587699|DRUG|CKD-843 A 55mg|Single Injection
47977933|NCT02523898|DRUG|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
47977934|NCT01737944|DRUG|Methotrexate (MTX)|Vibex MTX Device
47977935|NCT00113217|DRUG|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
47977936|NCT00572585|DRUG|AEB071|
47977937|NCT00572585|DRUG|Placebo|
48129771|NCT05587699|DRUG|CKD-843-R|0.5mg/day, 9 Month
48129772|NCT05326971|PROCEDURE|gastroscopy|Gastroscopy to evaluate the effect of long term exposure of TDF or TAF on enterocytes
48129773|NCT02700269|OTHER|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
48129774|NCT05128968|PROCEDURE|endotracheal intubation|Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.
48495004|NCT01346774|DRUG|Placebo powder capsules|2 placebo capsules twice a day
48495005|NCT03493516|DIAGNOSTIC_TEST|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer \[18F\]-LMI1195
48495006|NCT00327288|DRUG|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
48495007|NCT00327288|DRUG|docetaxel|IV once every 21 days for duration of study
48495008|NCT01458821|BEHAVIORAL|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
48495009|NCT06358170|BEHAVIORAL|Circuit Training Combine with Square-Stepping Exercise|Circuit Training Combine with Square-Stepping Exercise
48495010|NCT05402774|DIAGNOSTIC_TEST|point-of-care ultrasound|point-of-care ultrasound
48129775|NCT01450657|DIETARY_SUPPLEMENT|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 \& 4, three capsules three times daily (270 CFU's). Months 5 \& 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 \& 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
48129776|NCT04930406|OTHER|Physical therapy|Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
48129777|NCT00457119|DRUG|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
48129778|NCT02020694|DRUG|Vitamin D|
48129779|NCT02020694|DRUG|Placebo (for vitamin D)|
48654239|NCT06644859|DEVICE|Daily Activity Patterns Using Wearable Tri-Axial Sensors|This intervention uniquely focuses on the prediction of injurious falls by combining daily life gait (DLG) measures (e.g., gait speed, cadence, variability) with daily life physical activity (DLPA) measures (e.g., activity levels, activity fragmentation). Unlike other studies, this analysis leverages data from a large cohort of older women (n=17,466) enrolled in the Women's Health Study (WHS), where participants wore a tri-axial accelerometer for 1 week. Additionally, the study links accelerometer data to long-term health outcomes, specifically fall-related injuries from Centers for Medicare \&amp; Medicaid Services (CMS) records. This is the first study to explore whether combining DLG and DLPA measures, derived from wearable technology, can predict fall-related injuries in an aging population, applying advanced machine learning techniques to this large, anonymized dataset.
48129780|NCT00115011|DRUG|Escitalopram|
48129781|NCT03158415|BEHAVIORAL|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
48129782|NCT03676413|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
48129783|NCT03676413|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
48129784|NCT03676413|DRUG|Placebo|twice daily inhalation throughout the study
48129785|NCT04255212|OTHER|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
48129786|NCT04255212|OTHER|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
48654240|NCT05894746|DIETARY_SUPPLEMENT|gluten-free|see info in arm description
48129787|NCT04255212|OTHER|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
48337161|NCT02408926|BIOLOGICAL|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
48337162|NCT02408926|BIOLOGICAL|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
48337163|NCT02408926|BIOLOGICAL|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
48654241|NCT05894746|DIETARY_SUPPLEMENT|probiotic|see info in arm description
47977938|NCT03194321|DRUG|Tacrolimus Extended-Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
47977939|NCT06499077|DIAGNOSTIC_TEST|Sampling of exhaled breath|Exhaled breath of all participants is collected following our standardized procedure
47977940|NCT05708287|DEVICE|HFNC|The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation \>90%, were commenced on HFNC therapy
47977941|NCT05937204|OTHER|Nursing Teaching|A nursing teaching scheme refers to a systematic and structured plan developed by nurses to provide teaching and instruction to patients. The components of a nursing teaching scheme typically include assessing learning needs, setting learning objectives, developing teaching materials, delivering information using various teaching methods, demonstrating skills, providing written instructions, assessing learning outcomes, and conducting follow-up
48337164|NCT05946707|DRUG|restrictive oxygen supply|Oxygen supply will be limited to guarantee normoxia at the beginning of OLV.
48337165|NCT05946707|DRUG|liberal oxygen supply|Oxygen supply will be maximized to 100% at the beginning of OLV
48654242|NCT05894746|DIETARY_SUPPLEMENT|gluten|see info in arm description
48654243|NCT06535607|BIOLOGICAL|Volrustomig|IV Infusion
48654244|NCT03443401|PROCEDURE|Standard physical therapy care|standard plan of care delivered to patient with chronic low back within scope of licensure
48129788|NCT04255212|OTHER|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
48337166|NCT03836352|OTHER|DPX-Survivac|SubQ injection (q9w)
48129789|NCT05047458|DRUG|ALXN2050|Powder-in-capsule (PIC).
48337167|NCT03836352|DRUG|Cyclophosphamide|PO (BID)
48337168|NCT03836352|DRUG|Pembrolizumab|IV Infusion (q3w)
48337169|NCT00654212|PROCEDURE|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
48654245|NCT03238053|PROCEDURE|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
47977942|NCT00004196|BIOLOGICAL|recombinant interferon alfa|
47977943|NCT00004196|PROCEDURE|lymphangiography|
47977944|NCT00004196|DRUG|Observation|
47977945|NCT04294472|DRUG|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
47977946|NCT04294472|OTHER|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
47977947|NCT02483728|OTHER|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
47977948|NCT05241106|DRUG|HYML-122|each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
47977949|NCT00221598|PROCEDURE|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
47977950|NCT01995825|DRUG|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
47977951|NCT01995825|DRUG|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
47977952|NCT05237154|OTHER|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
47977953|NCT05237154|OTHER|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
47977954|NCT00788476|OTHER|Survey|"Survey packets to adult (\>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
47977955|NCT05358951|BEHAVIORAL|STEP-YA with Coaching|Online instruction on behavioral changes to improve sleep with 2 additional individually coached session
47977956|NCT05358951|BEHAVIORAL|STEP-YA without Coaching|Online instruction on behavioral changes to improve sleep without additional individually coached session
47977957|NCT05148754|DRUG|Elsulfavirine|Elsulfavirin 200 mg tablets.
47977958|NCT00450684|DEVICE|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
48129790|NCT05047458|DRUG|Placebo|PIC.
48129791|NCT02933294|PROCEDURE|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
48129792|NCT02933294|PROCEDURE|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
48129793|NCT04989842|BEHAVIORAL|Curriculum Hannover|The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of a face-to-face or a digital psychosomatic aftercare basing upon the concept of the Curriculum Hanover. A control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups).
48129794|NCT00188045|DRUG|Propranolol - Spironolactone|
48129795|NCT02071043|DRUG|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
48129796|NCT02071043|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
48337170|NCT00654212|PROCEDURE|open approach|emergency open surgery
48337171|NCT01816256|PROCEDURE|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
48495011|NCT00955136|DEVICE|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
48129797|NCT01141972|DIETARY_SUPPLEMENT|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
48129798|NCT01141972|OTHER|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
48129799|NCT05070559|OTHER|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone \& wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
48129800|NCT05070559|OTHER|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
48129801|NCT03139331|DRUG|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
48129802|NCT03139331|DRUG|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
48129803|NCT03139331|DRUG|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
48129804|NCT05279066|DEVICE|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
48129805|NCT00047190|DRUG|tipifarnib|Given PO
48129806|NCT00047190|OTHER|laboratory biomarker analysis|Correlative studies
48129807|NCT03916146|BEHAVIORAL|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
48337172|NCT00612339|DRUG|Avastin and Temozolomide|This is Phase II study with the combination of Avastin \& Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin \& Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI \& repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy \& requests discontinuation, patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT therapy, \& future therapy after 4 cycles will be at discretion of patient \& treating physicians.
48654246|NCT03238053|DEVICE|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
48337173|NCT03771495|OTHER|Joint Mobilization|Manual Therapy Intervention, commonly used by physiotherapists
48337174|NCT03771495|OTHER|Laying on of Hands|Sham Hip Joint Mobilization
48654247|NCT03238053|DEVICE|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
48337175|NCT02121444|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|
48337176|NCT02121444|DEVICE|BETACONNECT auto-injector.|
48337177|NCT05307627|DRUG|low-dose naltrexone|LDN doses \<20 mg/day
48495012|NCT01996943|DRUG|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
48495013|NCT01996943|DRUG|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
48495014|NCT05813288|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
48654248|NCT06253858|DEVICE|Catheter Placement with Solopass System|This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
48129808|NCT06008236|BEHAVIORAL|Progressive Muscle Relaxation and Breathing Exercises|Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
48129809|NCT02275416|DRUG|Ipilimumab|
48129810|NCT02275416|BIOLOGICAL|UV1 vaccine|
48129811|NCT02275416|BIOLOGICAL|GM-CSF|
48337178|NCT02254551|DRUG|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
48337179|NCT02254551|DRUG|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
48654249|NCT06632613|DRUG|ENN0403 capsules, low dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
48654250|NCT06632613|DRUG|ENN0403 capsules, high dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
48654251|NCT06632613|DRUG|Placebo|Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
48654252|NCT04103814|DRUG|magnesium-cannabidiolic acid cream|Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
48337180|NCT03949010|OTHER|Kinesiotaping with space correction technique|Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program
48654253|NCT04103814|DRUG|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
48654254|NCT02657343|DRUG|Ribociclib|
48654255|NCT02657343|DRUG|T-DM1|
48654256|NCT02657343|DRUG|Trastuzumab|
47977959|NCT00450684|DEVICE|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
47977960|NCT03903848|OTHER|Exercise|Single session of treadmill walking and resistance exercise
47977961|NCT02530554|DRUG|CHG|Single application
47977962|NCT04867603|DRUG|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.
47977963|NCT04867603|DEVICE|PET/CT imaging|PET/CT imaging procedure
48129812|NCT00035100|DRUG|epothilone b|
48129813|NCT04496388|BEHAVIORAL|exercise|different type of exercise
48129814|NCT04496388|BEHAVIORAL|No exercise intervention|No exercise intervention
48129815|NCT02752230|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
48129816|NCT02752230|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
48129817|NCT01362075|PROCEDURE|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
48129818|NCT01362075|PROCEDURE|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
48337181|NCT03949010|OTHER|Kinesiotaping with muscle inhibition technique|Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program
48337182|NCT03949010|OTHER|Home exercise program|Home exercise program which consists of stretching exercises towards neck area
48337183|NCT02979028|DEVICE|TEAS|Transcutaneous electrical acupoint stimulation
48337184|NCT04796025|DRUG|Sintilimab; Bevacizumab Biosimilar|1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
48337185|NCT01313078|DRUG|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
48654257|NCT02657343|DRUG|Fulvestrant|
48654258|NCT05103605|DRUG|Osimertinib|Single arm treated by osimertinib
48654259|NCT03090165|DRUG|ribociclib|400mg PO
48654260|NCT03090165|DRUG|ribociclib|600mg PO
48129819|NCT05320874|BIOLOGICAL|KM257 Bispecific antibody|"Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7"
48129820|NCT02167958|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (\< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) \* (Wt in kg) \* (0.85 if female) / (72 \* Cr)~Fludarabine dosage should be reduced per standard of care."
48129821|NCT02167958|DRUG|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide \[50mg/kg\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
48129822|NCT02167958|DRUG|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
48129823|NCT02167958|RADIATION|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
48266572|NCT01384682|DRUG|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
48654261|NCT03090165|DRUG|Bicalutamide|150mg PO
48337186|NCT01664156|DRUG|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
48495015|NCT05813288|DRUG|Placebo|Oral administration of placebo tablet
47977964|NCT05236010|DEVICE|rTMS|Transcranial magnetic stimulation is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. During an rTMS session, an electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain being targeted.
47977965|NCT05236010|DEVICE|HD-tDCS|Transcranial direct current stimulation (tDCS), is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. A constant, low intensity current is passed through two electrodes placed over the head which modulates neuronal activity.
47977966|NCT05236010|OTHER|Attention Process Training|Attention Process Training (APT) is a multi-session exercise designed to help improve the ability to focus on relevant material while ignoring irrelevant distractions. Further, it helps improve the speed of processing information.
48337187|NCT01664156|DRUG|Placebo|
48337188|NCT02249208|DEVICE|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
48337189|NCT02249208|DEVICE|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
48337190|NCT02249208|DEVICE|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
48495016|NCT05154812|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
48495017|NCT05154812|DRUG|Routine medical care|Routine medical care
48495018|NCT04174976|PROCEDURE|wall hernia repair|Wall hernia repair with mesh
48495019|NCT04213872|BEHAVIORAL|Meditative Movement|The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
48495020|NCT06190535|DRUG|Etamsylate|Enteral administration of Etamsylate as solution galenic form
48654262|NCT06644937|DRUG|TACE combined with Acoradine|"Transcatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible.~Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) ."
48654263|NCT05422482|BIOLOGICAL|GC1123|ICV-administered Hunterase, Idursulfase-ß
48654264|NCT03314896|PROCEDURE|Laparoscopic surgery|
48654265|NCT06636851|DEVICE|Pacemaker and defibrillator|Permenant pacemaker implantation with lead fixed to the RV Septal location
47977967|NCT02972489|DEVICE|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
47977968|NCT02972489|DEVICE|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
47977969|NCT03481322|DIETARY_SUPPLEMENT|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
47977970|NCT04606173|OTHER|Team Education for Adopting Changes in Healthcare (TEACH)|TEACH, an educational strategy which includes evidence-based strategies to improve task-specific teamwork will occur across 4 brief (20-30 minutes) team meetings over a 12-week period.
47977971|NCT01113281|BIOLOGICAL|VPM1002 live vaccine|
47977972|NCT01113281|BIOLOGICAL|commercially available live vaccine BCG|
48129824|NCT02167958|OTHER|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
48495021|NCT04727814|OTHER|Computer-aided detection system overlaid colonoscopy videos analysis|Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
48129825|NCT02167958|DRUG|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
48129826|NCT02167958|DRUG|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
48129827|NCT02167958|DRUG|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is \> 1,000/mm3 for three consecutive days.
48129828|NCT00047125|RADIATION|radiation therapy|
48129829|NCT00810849|DRUG|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
48129830|NCT00810849|BIOLOGICAL|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
48129831|NCT04098575|DRUG|Empagliflozin|drug
48129832|NCT05968170|DEVICE|CliniMACS® device|CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
48129833|NCT04053270|DRUG|Afamelanotide|16mg subcutaneous implant
48129834|NCT04053270|DRUG|Placebo|Placebo subcutaneous implant
48129835|NCT05454475|OTHER|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
48129836|NCT04587648|OTHER|NA, observational study|NA, observational study
48129837|NCT00410254|DRUG|HCV-796|
48129838|NCT00410254|DRUG|midazolam|
47977973|NCT01651195|DIETARY_SUPPLEMENT|Probiotic|
48129839|NCT04379557|PROCEDURE|Catheter Ablation|Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
48129840|NCT02785029|DEVICE|OCT|
48129841|NCT04160741|OTHER|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
48129842|NCT04160741|OTHER|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
48129843|NCT04160741|RADIATION|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
48266573|NCT03820557|OTHER|Educational Intervention|Undergo Decision Counseling Program
48266574|NCT00060255|DRUG|busulfan|iv
48654266|NCT06636851|DEVICE|Pacemaker and defibrillator|Description: Permenant pacemaker implantation with lead fixed to the RV Apical location
48654267|NCT04070040|DRUG|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
48654268|NCT01648322|DRUG|F-627|subcutaneous injection given 1 per chemotherapy.
48654269|NCT01648322|DRUG|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
48337191|NCT01627223|DRUG|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
47977974|NCT01651195|OTHER|Placebo|
47977975|NCT02619955|OTHER|samples with DNA|
47977976|NCT06503224|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 0.5-3 x10\^6 CART cells/kg）.
47977977|NCT01228760|DRUG|ASG-5ME|IV
47977978|NCT00004814|DRUG|copolymer 1|
47977979|NCT04671407|DRUG|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
47977980|NCT04432194|DIETARY_SUPPLEMENT|Nutritional supplementation and Pulmonary Rehabilitation|Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
47977981|NCT04276792|BEHAVIORAL|TCU Opioid-Treatment Linkage Model (O-TLM)|The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.
47977982|NCT04940351|PROCEDURE|GROUP - A: PIEZOCISION GROUP|This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
47977983|NCT04940351|PROCEDURE|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
47977984|NCT02155842|BEHAVIORAL|High intensity endurance exercise|
47977985|NCT02155842|BEHAVIORAL|Moderate continuous endurance exercise|
48337192|NCT01627223|DRUG|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
47977986|NCT01885143|RADIATION|Digital Breast Tomosynthesis|
47977987|NCT00227695|BIOLOGICAL|rituximab|comparing two maintenance schedules of Rituximab
47977988|NCT03418415|DEVICE|Renal denervation|multi-electrode catheter-based renal denervation
47977989|NCT04757064|OTHER|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
47977990|NCT01402791|OTHER|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
48266575|NCT00060255|DRUG|carboplatin|iv
48266576|NCT00060255|DRUG|carmustine|iv
48337193|NCT02691481|DIETARY_SUPPLEMENT|Oatmeal breakfast|
48337194|NCT02691481|DIETARY_SUPPLEMENT|Glucerna formula|
48337195|NCT02691481|DIETARY_SUPPLEMENT|Ultra Glucose Control formula|
48129844|NCT04160741|OTHER|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
48129845|NCT03391024|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
48129846|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection|Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
48129847|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection placebo|Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
48129848|NCT05310968|DRUG|Aspirin|Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
48129849|NCT06435169|DIAGNOSTIC_TEST|Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.|The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.
48129850|NCT05742815|OTHER|No intervention|This is an observational collection of data from purchased donor milk samples
48129851|NCT02481466|BEHAVIORAL|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
48266577|NCT00060255|DRUG|cyclophosphamide|iv
48266578|NCT00060255|DRUG|etoposide|iv
48495022|NCT06414070|BEHAVIORAL|Jenga Dada|Jenga Dada aims to empower women participating in community-based economic groups by training them to recognize inequality, challenge it, and work toward positive changes in their lives related to finances, health, and relationships and increase social support on these issues within the groups. Jenga Dada is expected to include eight modules: 1) overview of the intervention, 2) gender roles, 3) economic control and abuse, 4) intimate partner violence (IPV), 5) reproductive coercion (RC), 6) family planning (FP), 7) financial literacy, and 8) life goals. The Jenga Dada intervention is group discussion-based and draws on two effective interventions: ARCHES (a facility-based contraceptive counseling intervention providing support for RC and IPV) and Girls Invest (a mobile health application with integrated modules on gender, IPV, and financial literacy). The intervention will be facilitated by a local NGO in partnership with group leaders.
48495023|NCT00486317|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
48495024|NCT02721836|BEHAVIORAL|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
48495025|NCT02721836|BEHAVIORAL|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
48495026|NCT05991648|PROCEDURE|Kangaroo Care (skin-to-skin contact)|Skin-to-skin contact between the mother and the child. The naked newborn, wearing only a diaper and a hat, is placed in a vertical position in direct contact between the mother's breasts. An elastic fabric support (made of cotton or synthetic elastic fiber) will be used to facilitate the position.
48495027|NCT00057993|BIOLOGICAL|trastuzumab|
48495028|NCT00057993|DRUG|exemestane|
48495029|NCT04921020|OTHER|Photography|Facial photographs and blinking videos are taken
48495030|NCT03854786|DIETARY_SUPPLEMENT|Oxyjun|Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
48495031|NCT03854786|DIETARY_SUPPLEMENT|Pacebo|Methyl Crystalline Cellulose
48654270|NCT05726968|DRUG|Pilocaine 2% (1.5 ml) and 25 ug fentany|"Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~* Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~* Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~* Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)."
48654271|NCT06457217|DIAGNOSTIC_TEST|Magnetic resonance spectroscopic imaging|High-resolution 3D metabolic imaging was performed using the SPICE 1H-MRSI sequence.
48266579|NCT00060255|DRUG|melphalan|oral
48495032|NCT02960061|DRUG|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
48495033|NCT02960061|PROCEDURE|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
48495034|NCT02960061|DRUG|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
48495035|NCT02960061|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
48654272|NCT06386107|BIOLOGICAL|Thrombin Generation Assay (TGA)|Hemostasis is a complex process in which genetic or environmental conditions can cause shifts either towards pro-thrombotic states resulting in thrombosis, or towards pro-hemorrhagic states resulting in uncontrolled bleeding. Tests to assess a more global hemostatic profile, such as the TGA, have appeared as a more reliable alternative to assess the real hemostatic capacity of an individual. TGA is a global dynamic assay simultaneously and continuously measuring thrombin generation. It monitors the cleavage of a fluorigenic substrate that is simultaneously compared to the known thrombin activity in a non-clotting plasma sample.
48654273|NCT05289544|BEHAVIORAL|Phone-Based Walk With Ease|6 week phone-delivered Walk With Ease Program
48654274|NCT03223987|DIETARY_SUPPLEMENT|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
48129852|NCT02481466|BEHAVIORAL|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
48654275|NCT04573504|DRUG|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
48654276|NCT04573504|DRUG|Placebo|Placebo
48654277|NCT06642987|DRUG|Vonoprazan Test 20mg|1 tablets orally once a day
47977991|NCT06103357|OTHER|blood sample collection|Before and after angioplasty, blood samples upstream and downstream of the coronary lesion will be taken, arterial sampling at the aortic root level will be performed, and peripheral venous blood will be collected.
47977992|NCT02766725|DRUG|preparation F12 sildenafil in situ gel|in situ vaginal gel
47977993|NCT02766725|DRUG|preparation F2 sildenafil in situ gel|in situ vaginal gel
47977994|NCT02766725|DRUG|placebo gel|vaginal gel
47977995|NCT04884854|DEVICE|Efferon LPS|Efferon LPS is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.
47977996|NCT02311582|BIOLOGICAL|MK-3475|-Patients currently on pembrolizumab beyond the 2 year/35 cycle limit at the time of the approval of Amendment 13 (approved 07/28/2021) may continue to receive pembrolizumab unless there is progression, toxicity or agreement by the patient and PI to come off therapy. Participants who discontinue pembrolizumab after receiving 35 doses are eligible for retreatment with pembrolizumab if they progress during follow-up provided they meet the requirements. Participants may receive an additional 17 cycles (12 months) of pembrolizumab during the Second Course Phase (Retreatment).
47977997|NCT02311582|DEVICE|MRI-guided laser ablation|
47977998|NCT02311582|PROCEDURE|Surgical resection/debulking|"* Optional~* Standard of care"
47977999|NCT02311582|PROCEDURE|Biopsy|"* If no surgical resection/debulking~* Phase II patients only"
47978000|NCT02311582|PROCEDURE|Blood draw for research purposes|"* Phase II patients only~* Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment"
47978001|NCT02311582|PROCEDURE|Cervical lymph node fine needle aspiration|"* Optional~* Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure"
47978002|NCT03790488|DRUG|JTX-4014|Specified dose on specified days
48266580|NCT00060255|DRUG|thiotepa|iv
48266581|NCT00060255|PROCEDURE|autologous bone marrow transplantation|iv
48266582|NCT00060255|PROCEDURE|bone marrow ablation with stem cell support|iv
48266583|NCT00060255|PROCEDURE|peripheral blood stem cell transplantation|iv
48266584|NCT00060255|RADIATION|radiation therapy|body x-ray
48266585|NCT04620330|DRUG|avutometinib (VS-6766)|Monotherapy
47978003|NCT06190639|DRUG|sintilimab|200 mg once on day 1, every 21 days
48654278|NCT06642987|DRUG|Vonoprazan Reference 20mg|1 tablets orally once a day
48337196|NCT02391974|DEVICE|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
48337197|NCT01350011|BEHAVIORAL|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
48495036|NCT03858738|DEVICE|Thermographic breast examination performed by Braster device|Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
48495037|NCT06394349|COMBINATION_PRODUCT|PRP+308nm|PRP+308nm
48495038|NCT06394349|COMBINATION_PRODUCT|NS+308nm|NS+308nm
48495039|NCT03433144|DRUG|Tranexamic Acid Injectable Solution|the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
48129853|NCT02481466|BEHAVIORAL|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
48654279|NCT06587230|BEHAVIORAL|Teachers Leading the Frontlines|"1. During 3-day training, Knowledge and attitudes toward child mental health care are measured pre-training, post-training, and post-intervention.~2. The teachers select students whom they believe have the highest mental health needs to receive care.~3. Teachers analyze chosen students' symptoms.~4. Teachers analyze students' behavior with the AABC Chart.~5. Teachers develop a targeted response using a behavior plan called the 4Cs plan (Cause, Change, Connect, and Cultivate). In the 4Cs, teachers select therapeutic techniques to deliver from a menu of evidence-based therapeutic options for each category of behavior.~6. Throughout the year, teachers receive supervision through monthly site visits supplemented by as-needed telephone and digital discussions to guide their care from the study team. Teachers encourage the use of the 4Cs plan at home."
48654280|NCT06587230|BEHAVIORAL|Responding to Students' Emotions Through Education|"All processes for RE-SEED are the same as in Tealeaf except...~1. Teachers receive only 1 day of training~2. The study team does not provide supervision to the teachers, allowing only the school counselor to provide supervision~This less resource-intensive approach will allow for an ethical comparator to Tealeaf, where the schools would like for teachers to have some skills to support identified students."
47978004|NCT04802460|DEVICE|Virtual reality headset (The Guided Meditation VR App through Oculus Go headset)|Patients assigned to the VR condition will engage with the VR using The Guided Meditation VR App through Oculus Go headset. They will enjoy up to a 10 minute video of an environment of their choosing. During this video they will listen to calming music and a guided meditation session.
47978005|NCT06502574|OTHER|mobile application|The mobile application prepared for rational drug use andchronic disease self-management, suitable for use by olderadults, will be required to be used for 6 months.
47978006|NCT05814978|OTHER|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
48129854|NCT02481466|BEHAVIORAL|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
48266586|NCT04620330|DRUG|avutometinib (VS-6766) and Defactinib|Combination therapy
48266587|NCT00146263|BEHAVIORAL|Savyon|Computerized cognitive training
48337198|NCT01350011|BEHAVIORAL|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
48337199|NCT00361023|DRUG|losartan|
48337200|NCT03608046|DRUG|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
48337201|NCT03608046|DRUG|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
48337202|NCT03608046|DRUG|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
48337203|NCT00830804|DRUG|Raltegravir|400 mg tablet taken orally twice daily
48337204|NCT00830804|DRUG|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
48337205|NCT01765946|DRUG|Metformin|Metformin tablets 500 mg tris in die (tid)
48337206|NCT01765946|DRUG|placebo|
48495040|NCT03433144|OTHER|Placebo (normal saline 0.9%)|An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
48495041|NCT01190943|OTHER|Laboratory Biomarker Analysis|Correlative studies
48495042|NCT01002014|PROCEDURE|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
48495043|NCT02637375|DRUG|Ganetespib|
48495044|NCT02637375|DRUG|Paclitaxel|
48495045|NCT02637375|DRUG|Doxorubicin|
48495046|NCT02637375|DRUG|Cyclophosphamide|
48495047|NCT05989724|DRUG|SON-DP|Solution for IV administration
48337207|NCT05103475|BEHAVIORAL|Rage Against the Pain (RAP)|The sets of body positions used in the RAP program will mirror those used in the Hatha Yoga classes, but the RAP program will differ from this traditional yoga practice in a number of ways: (1) the classes will be set to rock/heavy metal music; (2) meditation will not be incorporated; (3) yoga terms will not be used to describe the body positions (rather, positions will be cued in plain descriptive English terms); (4) the culminating activity for the class will be called a 'cool down' (rather than the savasana exercise typically used in yoga practice).
48495048|NCT02831647|DIETARY_SUPPLEMENT|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
48495049|NCT02673996|DRUG|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
48495050|NCT02673996|DRUG|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
48495051|NCT01434186|DRUG|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
48495052|NCT01434186|DRUG|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
47978007|NCT02282020|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
48495053|NCT01434186|DRUG|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
48495054|NCT01434186|DRUG|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
48654281|NCT06597513|DRUG|auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab|"Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision."
47978008|NCT02282020|DRUG|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
47978009|NCT05602181|BEHAVIORAL|ALL Phonics Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech.
47978010|NCT05602181|BEHAVIORAL|ALL Sight Word Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech. This group will only use the sight word lessons, as well as the library for sight word books. No phonics instruction will be provided through the app.
47978011|NCT01606514|BEHAVIORAL|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
47978012|NCT02899988|DRUG|Mirikizumab|Administered SC
47978013|NCT02899988|DRUG|Placebo|Administered SC
48129855|NCT00873782|OTHER|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
48129856|NCT02506270|DEVICE|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
48129857|NCT02506270|DEVICE|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
48266588|NCT00146263|BEHAVIORAL|Control|Usual activity
48495055|NCT03703648|RADIATION|Radiotherapy (curative) for head and neck cancer|Curative intent radiotherapy for head and neck cancer. Doses will be prescribed by an independent Clinical Oncology team. There will be no alteration or experimentation of radiotherapy dosage
48495056|NCT00345657|DRUG|Niacin Extended Release/Lovastatin|
48495057|NCT04413864|OTHER|Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration|"Assigned Interventions:~* Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~* CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)"
48495058|NCT03710720|BEHAVIORAL|TIPS app|Psycho-educational electronic application
48495059|NCT03710720|BEHAVIORAL|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
48495060|NCT02466230|DEVICE|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
47978014|NCT02228785|BIOLOGICAL|G17DT|
47978015|NCT01161147|DRUG|Meloxicam|Meloxicam Tablets 15 mg
47978016|NCT03985631|OTHER|Rehabilitation intervention|Rehabilitation sessions based on Tai Chi through telerehabilitation
48495061|NCT02924727|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
48495062|NCT02924727|DRUG|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
48654282|NCT06637085|DEVICE|LLLT|low level laser therapy Probe laser device: (Laserklasse2M, EN60825-1, +A2:2002, W.L= 635-670nm, P\<6mW, German):low level laser therapy It will be used to stimulate vagus nerve .
47978017|NCT04461678|DIAGNOSTIC_TEST|HPV Genotyping Nucleic Acid Assay Kit|The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.
48129858|NCT04345068|BEHAVIORAL|Calm Meditation Mobile App|The Calm app is downloadable by participants onto their smartphone. The Calm app is used to deliver the meditation intervention to experimental group participants.
48129859|NCT04345068|BEHAVIORAL|Health Education Podcast Mobile App|The health education podcast mobile app mirrors the intervention group's app experience, but provides educational content via podcasts as an active comparator.
48129860|NCT05494866|DRUG|Cobicistat Oral Tablet|Cobicistat Oral Tablet
48129861|NCT05494866|DRUG|Gemcitabin|Gemcitabin
48495063|NCT02924727|DRUG|Placebo of LCZ696|Matching placebo of LCZ696 tablets
48495064|NCT02924727|DRUG|Placebo of ramipril|Matching placebo of ramipril capsule
47978018|NCT04425161|OTHER|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
48129862|NCT05494866|DRUG|Nab paclitaxel|nab-Paclitaxel
48129863|NCT00995592|BEHAVIORAL|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
48129864|NCT02190708|DRUG|PQ912|from day2 up to day6 twice daily oral dose of PQ912
48129865|NCT02190708|DRUG|Midazolam|single oral dose on day1 and day 6
48129866|NCT02190708|DRUG|Omeprazole|single oral dose on day1 and day6
48129867|NCT03753932|DEVICE|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
48129868|NCT03190850|OTHER|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
48129869|NCT03190850|OTHER|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
48129870|NCT04289324|PROCEDURE|regular lung recruitment|stepwise oxygenation-guided lung recruitment at regular (twelve hours) intervals during high frequency oscillation ventilation
48495065|NCT02924727|DRUG|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
48495066|NCT02924727|DRUG|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
48495067|NCT06483542|OTHER|bioenergetic balance|Bioenergetic balance is calculated for all patients who had a resting energy expenditure measurement with indirect calorimetry.
48495068|NCT02998970|DRUG|Empagliflozin|single oral tablet once daily.
48337208|NCT05103475|BEHAVIORAL|Control|The control group will comprise a program akin to Hatha yoga with chair modifications available to all Veterans who choose/need to use them.
48337209|NCT05159362|OTHER|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
48495069|NCT02998970|DRUG|Placebo|single oral tablet once daily.
48495070|NCT03938714|PROCEDURE|Hemorrhoidectomy|Excision of third and fourth degree hemorrhoids
48495071|NCT04967963|PROCEDURE|HAM|Transplantation of HAM
48495072|NCT05989113|OTHER|Administration of the IPAQ-SF questionnaire|Administration of the IPAQ-SF questionnaire at the patient's consultation and upon return home
48495073|NCT01587586|BIOLOGICAL|PEGASYS 180 µg Q1W|48 doses, solution, 48 weeks
48495074|NCT01587586|BIOLOGICAL|P1101 180 µg Q1W, 48 doses|48 doses, solution, 48 weeks
47978019|NCT02464462|DIETARY_SUPPLEMENT|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
47978020|NCT02464462|OTHER|Placebo|Rice powder pills
48495075|NCT01587586|BIOLOGICAL|P1101 270µg Q1W, 48 doses|48 doses, solution, 48 weeks
48495076|NCT01587586|BIOLOGICAL|P1101 450µg Q2W, 24 doses|24 doses, solution, 48 weeks
48495077|NCT00929331|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
48495078|NCT01653561|DRUG|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
48495079|NCT03795896|DIAGNOSTIC_TEST|Optic nerve sheath diameter|The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
48654283|NCT06637085|OTHER|traditional physical therapy|traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)
48654284|NCT06637085|DEVICE|ACU TENSE|Acu-TENS device (Digital TENS, EAF20, JERF20BD0604, add manufacturing country): It will be used to stimulate vagus nerve throug h the acupoint PC6 .
48654285|NCT00347971|DRUG|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
48654286|NCT02584933|DRUG|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
48129884|NCT06413693|DRUG|PF-07293893|A single dose of PF-07293893 administered orally as tablets
48129885|NCT06413693|DRUG|Placebo|A single dose of Placebo administered orally as tablets that look the same as PF-07293893
48337210|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
48337211|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
48495080|NCT05754307|PROCEDURE|Access Flap|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
48495081|NCT05754307|PROCEDURE|Closed Surgical Technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
48337212|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
48337213|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.
48337214|NCT02963415|BEHAVIORAL|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
48495082|NCT01558336|DRUG|praziquantel|praziquantel 40 mg/kg oral tablets
48495083|NCT03751956|DRUG|HSK3486|The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
48495084|NCT03422367|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
48495085|NCT04790838|DRUG|Test|2 inhalations of Test and Reference product in each study period
48495086|NCT04790838|DRUG|Reference|2 inhalations of Test and Reference product in each study period
48495087|NCT02075827|BEHAVIORAL|Competitive video game|1 hour playing video game
48495088|NCT02075827|BEHAVIORAL|Little Big Planet|1 hour playing video game
48495089|NCT00409318|DRUG|Etanercept|50 mg SC q week
48495090|NCT00409318|DRUG|Placebo|SC q week
48495091|NCT06014918|DEVICE|A new smart device application (Smart APS)|The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
48495092|NCT04269564|DEVICE|stepwise PEEP|"* a PEEP of 4 cmH2O will be used after intubation till 5 minutes after pneumoperitonium, and adjusted in a step wise approach after lung ultrasound by adding 2 cmH2O, repeating ultrasound 5 minutes after every change in peep till no lung collapse is detected by lung ultrasound with a maximal peep of 10 cmH2O, or if hemodynamic instability occurs.~* Lung ultrasound examination will be performed at a minimum three times in each patient; the first will be performed 1 min after starting mechanical ventilation of the lungs, 5 minutes after pneumoperitonium, 5 min after every peep increase in stepwise peep group and the last time at the end of the surgery.~We define anaesthesia-induced atelectasis to be significant if any region has a consolidation score of ≥ 2."
48495093|NCT02987023|PROCEDURE|uterus transplantation|Uterus transplantation from live donor
48654287|NCT05907291|DRUG|CRN04894|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
48654288|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
48337215|NCT00586638|BEHAVIORAL|Video game based training|36 one-hour sessions over 12 weeks
48129889|NCT04464759|DRUG|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
48129890|NCT04464759|DRUG|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
48129891|NCT04464759|DRUG|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
48129892|NCT02457936|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
48129893|NCT02754115|OTHER|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
48337216|NCT00005061|BIOLOGICAL|bevacizumab|
48337217|NCT00063310|DRUG|Leuprolide acetate|
48337218|NCT05109078|DRUG|[14C]- Rongliflozin|Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
48337219|NCT03858296|BEHAVIORAL|Internet-delivered emotional awareness training|Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
48337220|NCT03858296|BEHAVIORAL|Internet-delivered Cognitive reappraisal training|Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
48337221|NCT03858296|BEHAVIORAL|Internet-delivered awareness and reappraisal training|Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
48654289|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
48495094|NCT02590835|PROCEDURE|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
48495095|NCT02590835|PROCEDURE|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
48654290|NCT06636578|DRUG|dexmedetomidine|will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
48337222|NCT01985919|OTHER|Obtaining human tissue for basic research or biospecimen bank|
48337223|NCT01708707|DRUG|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
48337224|NCT01708707|DRUG|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
48337225|NCT03712527|OTHER|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
48495096|NCT00486564|DRUG|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
48654291|NCT06636578|DRUG|ropivacaine|will receive 30 ml of 0.25% of plain ropivacaine for each side.
48654292|NCT06636578|DRUG|fentanyl|will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
48654293|NCT06643650|DIETARY_SUPPLEMENT|CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML|Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.
47978021|NCT00300937|DIETARY_SUPPLEMENT|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
48654294|NCT04569032|DRUG|brentuximab vedotin|1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
48654295|NCT04569032|DRUG|cyclophosphamide|750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
48654296|NCT04569032|DRUG|doxorubicin|50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
48654297|NCT04569032|DRUG|prednisone|100 mg daily administered orally on Days 1-5 of each cycle
47978022|NCT00883116|DRUG|Ixabepilone|
48337226|NCT03712527|OTHER|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
48337227|NCT01227304|DEVICE|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
48337228|NCT03043807|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
48337229|NCT03043807|DRUG|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
48337230|NCT03043807|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
48337231|NCT03043807|RADIATION|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
48337232|NCT03043807|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
48337233|NCT03895970|DRUG|Lenvatinib plus Pembrolizumab|Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
48337234|NCT01858896|DRUG|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
48337235|NCT01858896|OTHER|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
48337236|NCT05315141|OTHER|No Intervention|No Intervention
48337237|NCT06248463|DIAGNOSTIC_TEST|BP measurement in waiting room for 20 minutes|"Measured of BP will be performance in waiting room for 20 minutes every 3 minutes and report by an mobile app. After 24h-ABPM device will be implanted. Results of SBP and DBP obtained in office will be compared with 24-h, diurnal and nocturnal SBP/DBP mean.~BP will be measured automatically and repeatedly every 3 minutes in the waiting room for 20 minutes. Subsequently, a SpaceLab ABPM monitor will be implanted."
48337238|NCT04587921|DEVICE|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
48337239|NCT04926844|DRUG|Levetiracetam|Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
48654298|NCT06644001|DIETARY_SUPPLEMENT|Bacillus coagulans GBI-30,6086 (BC GBI-30)|2g powder/sachet, consists of bacillus coagulans at a dose of 1x10\^9 CFU, taken once daily before a meal.
47978023|NCT00883116|DRUG|Doxorubicin|
47978024|NCT00883116|DRUG|Paclitaxel|
48654299|NCT06644001|DIETARY_SUPPLEMENT|Placebo|2g powder/sachet, consists of maltodextrin only, taken once daily before a meal.
48337240|NCT04926844|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
48337241|NCT04926844|DRUG|Placebo|Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
48337242|NCT04511078|DRUG|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
48337243|NCT02923310|BIOLOGICAL|Platelets Rich Plasma|
48337244|NCT02923310|BIOLOGICAL|Leucocyte - Platelets Rich Plasma|
48337245|NCT02923310|DRUG|Hialuronic Acid|
48337246|NCT01709968|DRUG|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
48337247|NCT01709968|DRUG|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
48337248|NCT00513994|DRUG|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
48337249|NCT00854438|OTHER|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
48337250|NCT02046382|DRUG|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
48337251|NCT02046382|DRUG|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
48337252|NCT04424316|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
48337253|NCT04424316|BIOLOGICAL|Placebo|Placebo
48337254|NCT00633802|DRUG|Risperidone|1 mg/d risperidone for 10 weeks or placebo
48337255|NCT00484276|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
48337256|NCT04359225|OTHER|3D Telemedicine|Telemedicine using 3D broadcast to clinician
48495097|NCT02887300|BEHAVIORAL|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
48495098|NCT01749917|OTHER|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
48495099|NCT01749917|OTHER|Control intervention|Active upper limb range of movement exercises for 15 minutes.
48337257|NCT04359225|OTHER|2D Telemedicine|Standard care with 2D telemedicine
48337258|NCT00127088|DRUG|docetaxel|
48337259|NCT00127088|PROCEDURE|laparoscopic radical prostatectomy|
48337260|NCT00162513|BIOLOGICAL|Allogeneic tumor cell vaccine|
48337261|NCT04315597|DRUG|Laif® 900, BAY98-7108|1 x daily, 1 tablet, 900 mg
48337262|NCT04315597|DRUG|Placebo|1 x daily, 1 tablet, 900 mg
48337263|NCT00909519|DRUG|naproxcinod|naproxcinod 750 mg bid
48495100|NCT00423475|DRUG|goserelin acetate|
48337264|NCT00909519|DRUG|Naproxen|Naproxen 500 mg bid
48337265|NCT00909519|DRUG|placebo|placebo
48337266|NCT00909519|DRUG|furosemide|furosemide
48495101|NCT00423475|PROCEDURE|adjuvant therapy|
48495102|NCT00423475|RADIATION|radiation therapy|
48495103|NCT00070057|DRUG|celecoxib|Given orally
47978025|NCT06163170|DRUG|Nivolumab +/- ipilimumab|Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
48129895|NCT04097561|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
48337267|NCT00519883|OTHER|Exercise|
48495104|NCT00070057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48495105|NCT00070057|OTHER|pharmacological study|Correlative studies
48495106|NCT00070057|OTHER|laboratory biomarker analysis|Correlative studies
48495107|NCT00714961|DRUG|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
48495108|NCT00714961|DRUG|Placebo|plus acetylsalicylic acid (ASA)
48495109|NCT00712738|DRUG|Nifedipine|
48495110|NCT00712738|PROCEDURE|Phlebotomy|
48495111|NCT00712738|PROCEDURE|Urinalysis|
48495112|NCT00712738|PROCEDURE|Echocardiogram|
47978026|NCT06163170|DRUG|Nivolumab|Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
47978027|NCT02075450|DEVICE|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
47978028|NCT02075450|OTHER|Just in Time Video|CPR Just in Time training video administered before the simulation case
47978029|NCT03507894|BEHAVIORAL|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
48337268|NCT00519883|OTHER|Supportive Care|
48337269|NCT03932019|DRUG|Jitongning tablet(High-dose )|Jitongning tablet,3tablets,bid,treat 12 weeks
48337270|NCT03932019|DRUG|Jitongning tablet(Low-dose )|Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
48337271|NCT03932019|DRUG|Placebo|Jitongning tablet placebo,3tablets,bid,treat 12 weeks
48337272|NCT00964600|PROCEDURE|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
48337273|NCT02882022|DEVICE|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
48337274|NCT00192595|DRUG|Tenofovir|
48337275|NCT00192595|DRUG|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
48337276|NCT05887557|OTHER|Active Referral|As an implementation science study, all clinical intervention components will be delivered as part of routine clinical care at participating clinical sites. Clinicians and staff at referral sites throughout San Francisco and Alameda counties (emergency departments, psychiatric emergency services, community clinics, care navigation and case management programs, and community-based services) will refer eligible patients who are out of care and are interested in linking to drop-in and/or mobile care services at one of the study sites. Clinical referrals will include basic patient information and contact/locator information to facilitate linkage to care. Referrals will be site-specific based on the site where the patient is interested in accessing care.
48337277|NCT05887557|OTHER|Drop-In Multidisciplinary HIV Care|Each site will independently implement a drop-in multidisciplinary site-based HIV care model. Core intervention features include drop-in care (no appointments), panel management to review clinical progress for all referred patients, and case management. Each site may include adaptations to the care model determined during Aim 1 formative work.
48495113|NCT00712738|PROCEDURE|Electrocardiogram|
48495114|NCT00368901|DRUG|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
48495115|NCT01270737|DIETARY_SUPPLEMENT|Whole soy (soy flour)|40g soy flour per day for six months
48495116|NCT01270737|DIETARY_SUPPLEMENT|daidzein|66mg daidzein per day for six months
48495117|NCT01270737|DIETARY_SUPPLEMENT|milk powder|40g low-fat dry milk per day for six months
48495118|NCT05030766|DRUG|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
48495119|NCT05030766|BEHAVIORAL|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
48654300|NCT05454566|GENETIC|ICM-203|Intra-articular injection
48654301|NCT05603143|DRUG|Obeldesivir|Tablets administered orally without regard to food.
48337278|NCT05887557|OTHER|Mobile HIV Care|Each site will independently implement a mobile care model using site-specific resources. At a minimum, the mobile care team will include a clinical nurse with telemedicine (video visit) consultation with a clinician (MD/NP/PA). Mobile teams will also administer medications (including long-acting ART when available) and collect laboratory specimens (e.g. HIV viral loads)
48337279|NCT05887557|OTHER|Staged Care|Clinical decision rules to escalate/de-escalate care intensity will be finalized developed during Aim 1 formative work, though will be based on a combination of clinical assessment and patient preference.
48337280|NCT05887557|OTHER|Identify and prepare champions at referral sites|Identify implementation champions at each referral site. Champions will receive marketing materials to promote uptake of clinical referrals to a drop-in/mobile care site by referral site providers/staff. This strategy is aimed at improving referring provider confidence in the value of referral to the care model, reduce perceived referral complexity/improve provider capability to refer, and provide positive peer pressure to promote referrals.
48337281|NCT05887557|OTHER|Audit and feedback at referral sites|Investigators will provide monthly reports to implementation champions at each referral site on aggregate number of referrals and the success of referrals (proportion linking to care). This strategy is aimed at improving perceived value of the intervention and increasing provider motivation to refer.
47978030|NCT03276156|DRUG|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
48337282|NCT05887557|OTHER|Build a coalition among referral and clinical sites|Investigators will facilitate formation of a coalition of referral and clinic sites to improve cross-site collaboration and promote positive peer pressure to improve intra-site communication and increase referrals.
48337283|NCT05887557|OTHER|Assess for readiness and identify barriers|Investigators will conduct patient in-depth interviews and clinical team focus group discussions to assess barriers to implementation of the clinical intervention. Findings from interviews and focus group discussions will inform site-specific implementation plans and adaptation of the intervention.
48337284|NCT05887557|OTHER|Promote adaptability|During a co-design workshop among drop-in/mobile care site teams and site-specific meetings, the study team will collectively finalize core clinical intervention components and outline site-specific adaptations (i.e. adaptable periphery of clinical intervention).
48495120|NCT05030766|BEHAVIORAL|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
48654302|NCT05603143|DRUG|Obeldesivir Placebo|Placebo tablets administered orally without regard to food.
47978031|NCT03253250|DRUG|ETV；TDF；ADV|NAs
47978032|NCT03253250|DRUG|Peginterferon Alfa-2a|peginterferon
47978033|NCT02775162|DEVICE|Normothermic Machine Perfusion (NMP)|
47978034|NCT02775162|OTHER|Standard of Care (Ice)|
47978035|NCT04887714|OTHER|Mask|Mask wearing
47978036|NCT03957304|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
47978037|NCT01656473|OTHER|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
47978038|NCT01656473|OTHER|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
47978039|NCT04633460|DIETARY_SUPPLEMENT|Ketone ester|A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
47978040|NCT04633460|DIETARY_SUPPLEMENT|placebo drink|KE free placebo drink
47978041|NCT01574040|BEHAVIORAL|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
47978042|NCT01574040|BEHAVIORAL|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
47978043|NCT01574040|BEHAVIORAL|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
47978044|NCT01574040|BEHAVIORAL|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
47978045|NCT04309188|DEVICE|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
47978046|NCT04309188|OTHER|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
47978047|NCT03157258|BEHAVIORAL|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
47978048|NCT03157258|BEHAVIORAL|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
47978049|NCT05532592|OTHER|Perceptions and attitudes towards COVID-19 and COVID-19 vaccine|Attitude towards COVID-19; Knowledge about COVID-19 vaccine
47978050|NCT04938193|DIAGNOSTIC_TEST|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
48129896|NCT06062875|DRUG|Adalimumab|Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
48337285|NCT05887557|OTHER|Develop a formal implementation blueprint|With each drop-in/mobile care team, develop site-specific implementation plan that includes defining care team and leadership structure, clinic workflow, implementation timeline, and progress measures. This process, and the resulting blueprint, will incorporate site-specific barriers and facilitators to implementation.
48337286|NCT05887557|OTHER|Develop educational materials; conduct ongoing training|Compile a manual that includes detailed description of core intervention features, planned local adaptations, and implementation guidance. We will conduct site-specific meetings to provide training on this manual. We will also conduct regular (at least monthly) meetings between the study team and the clinic site to provide technical assistance and coaching.
48337287|NCT05887557|OTHER|Create a learning collaborative|Create a cross-site learning collaborative with periodic meetings and workshops throughout the study period to facilitate cross-site communication, sharing of best practices and encourage positive peer pressure to support implementation.
48337288|NCT03249948|PROCEDURE|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
48337289|NCT03249948|PROCEDURE|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
48495121|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
47978051|NCT03919214|OTHER|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg.
47978052|NCT01189903|DRUG|Regorafenib|
47978053|NCT02582502|OTHER|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
47978054|NCT04967833|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
47978055|NCT01218230|DRUG|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
47978056|NCT01171339|OTHER|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
47978057|NCT04894773|OTHER|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
47978058|NCT04894773|OTHER|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
47978059|NCT03898154|DRUG|Dexamethasone|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone
47978060|NCT03898154|DRUG|Methylprednisolone|Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
47978061|NCT03757897|DRUG|Dexmedetomidine|The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
47978062|NCT04675840|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted surgery
47978063|NCT01456468|DRUG|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
47978064|NCT02433483|DRUG|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
47978065|NCT02433483|DRUG|Intrathecal Triples|given IT.
47978066|NCT02433483|BIOLOGICAL|HPC-A|Given IV.
47978067|NCT04947553|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
47978068|NCT04947553|DRUG|Placebo|Placebo tablets, taken twice daily
47978069|NCT00007657|PROCEDURE|Intensive medical therapy|
47978070|NCT00007657|PROCEDURE|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
48266589|NCT06548698|OTHER|escape room|Nursing students in the intervention group analyzed the breast cancer surgery case with the escape room experience.
47978071|NCT02663674|DRUG|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
47978072|NCT02663674|OTHER|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
48266590|NCT00578643|DRUG|Busulfan|"Days -9 through -6~1 mg/kg initially (based on weight)"
48266591|NCT00578643|BIOLOGICAL|Alemtuzumab|"Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg"
48337290|NCT03412123|BEHAVIORAL|group lifestyle-integrated functional exercise|Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
48129898|NCT04013802|BIOLOGICAL|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
48129899|NCT06459193|DRUG|Trimetazidine|Trimetazidine 35 mg tab once daily
48129900|NCT06459193|DRUG|Placebo|Placebo once daily
48129901|NCT05512962|DRUG|Triamcinolone Acetonide|Single suprachoroidal Administration of Triamcinolone acetonide
48129902|NCT05512962|DEVICE|Semi-automated Suprachoroidal Microcatheter|Ophthalmic Adminstration Device
48337291|NCT01527110|DRUG|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
48337292|NCT03775174|DRUG|Mepsevii|
48337293|NCT00241878|BEHAVIORAL|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
48495122|NCT05607641|DRUG|Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets|"These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day."
48495123|NCT05607641|DRUG|Neospastil, solution for injection then Neospastil, film-coated tablets|"These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day."
48495124|NCT03929341|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (CCTA)|Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
48654303|NCT06441305|BEHAVIORAL|SWITCH intervention package|"* Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up."
48654304|NCT04206943|BIOLOGICAL|Car-T Cell Therapy|"Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements."
48129903|NCT03771313|DRUG|Ceftaroline|Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.
48129908|NCT05869734|BEHAVIORAL|Sleep health promotion|We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.
48129909|NCT05869734|BEHAVIORAL|Urologic health promotion|We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).
48654305|NCT03044795|DRUG|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
48654306|NCT03855540|DIAGNOSTIC_TEST|ECHOcardiography|"ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease"
48337294|NCT00241878|BEHAVIORAL|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
48654307|NCT03855540|DIAGNOSTIC_TEST|Peripheral blood samples for plasmatic biomarkers|"1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499"
48654308|NCT03855540|DIAGNOSTIC_TEST|Athens insomnia scale questionnaire|Athens insomnia scale questionnaire
48654309|NCT03855540|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives ECG Holter monitor if included to the control group
48654310|NCT03855540|DIAGNOSTIC_TEST|ECG event recorder|Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
48654311|NCT01839409|BEHAVIORAL|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
48654312|NCT05319197|OTHER|No Interventions|No Interventions
48654313|NCT01514578|DRUG|TRV130A|Intravenous infusion of 1 hour duration
48654314|NCT01514578|DRUG|Dextrose in Water|Intravenous infusion of 1 hour duration
48654315|NCT05863455|DRUG|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
48654316|NCT05863455|DRUG|control|ntravenous injection of an equivalent volume of saline before radial artery cannulation.
48495125|NCT03929341|OTHER|Cardiac Link|Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
48129910|NCT05869734|BEHAVIORAL|Pelvic floor muscle training|We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).
48495126|NCT01629966|DRUG|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
48654317|NCT03914833|OTHER|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
48266592|NCT00578643|DRUG|Cyclophosphamide|"Days -5 through -2~50 mg/kg"
48266593|NCT00578643|DRUG|Fludarabine|"Day -5 through Day -2~30 mg/m\^2"
48495127|NCT01629966|DRUG|Vilazodone|Vilazodone, 20mg, oral administration once per day.
48495128|NCT01629966|DRUG|Vilazodone|Vilazodone, 40mg, oral administration once per day.
48495129|NCT02245061|OTHER|paired pulses cortical electrical stimulation|
48495130|NCT02489019|DRUG|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
48495131|NCT02489019|DRUG|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
48495132|NCT03429517|DIAGNOSTIC_TEST|Lipogram|liporgram samples
48495133|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
47978073|NCT03552198|BEHAVIORAL|Alternative health advice|These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
48129911|NCT05948813|DRUG|TY-9591|The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
48129912|NCT05948813|DRUG|Osimertinib|The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
48337295|NCT02268136|DRUG|BIII 890 CL|
48337296|NCT02268136|DRUG|Placebo|
48337297|NCT00416312|DEVICE|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (\^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by \^131I tositumomab IV over 20 minutes on approximately day 7."
48495134|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
48495135|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
47978074|NCT04648956|OTHER|Standard treatment|Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
47978075|NCT05853198|OTHER|ctDNA analysis|ctDNA amount and mutations analysis
47978076|NCT01441505|DRUG|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
47978077|NCT01441505|DRUG|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
47978078|NCT00019578|PROCEDURE|Sterotactic radiosurgery|
47978079|NCT02882009|DRUG|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
47978080|NCT02882009|DRUG|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
47978081|NCT00671892|BIOLOGICAL|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU"
47978082|NCT04712305|OTHER|No intervention required|No intervention required
48495136|NCT01471119|BIOLOGICAL|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
48129914|NCT05613088|DRUG|MORAb-202|Specified dose on specified days
48129915|NCT05613088|DRUG|Paclitaxel|Specified dose on specified days
48495137|NCT02681744|BEHAVIORAL|Resistance Training|24-weeks of progressive strength training
48495138|NCT00450619|RADIATION|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
47978083|NCT05377983|OTHER|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes|During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
47978084|NCT03611764|BEHAVIORAL|Body Scan|-All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies
47978085|NCT03611764|OTHER|Rotterdam Symptom Checklist|"* 39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~* For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent"
47978086|NCT03611764|OTHER|Practice Logs|-Describe frequency of the Zen Den
48129916|NCT05613088|DRUG|Pegylated Liposomal Doxorubicin (PLD)|Specified dose on specified days
48129917|NCT05613088|DRUG|Topotecan|Specified dose on specified days
48266594|NCT00578643|DRUG|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
48337298|NCT00416312|DEVICE|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (\^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after \^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
48337299|NCT01192841|OTHER|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
48337300|NCT06020833|DRUG|Roxadustat in combination with retinoic acid|Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
48495139|NCT00450619|BIOLOGICAL|Sargramostim|100 mcg/injection x 4 days given subcutaneously
48495140|NCT00450619|BIOLOGICAL|Recombinant vaccinia-TRICOM vaccine|2 x 10\^8 PFU given subcutaneously on day 1.
48495141|NCT00450619|BIOLOGICAL|Recombinant fowlpox-TRICOM vaccine|1 x 10\^9 PFU given subcutaneously on days 15 and 29
48129918|NCT06110468|OTHER|CoreDISTParticipation|CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
48495142|NCT00334100|BEHAVIORAL|Exercise|Treadmill exercise
48495143|NCT01083810|DRUG|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
47978087|NCT00378196|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
48129921|NCT03519464|BIOLOGICAL|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
48129922|NCT06332534|DRUG|Upadacitinib|Oral Solution/ Extended-Release Tablets
48129923|NCT03960099|BEHAVIORAL|Pictograph in Banner and Verification Alert|Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
48129924|NCT06427590|DRUG|ASC47|single subcutaneous injection of ASC47
48129925|NCT06427590|DRUG|Matching placebo|single subcutaneous injection of Placebo
48129926|NCT03692065|DRUG|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
48495144|NCT04628520|PROCEDURE|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
48129928|NCT01553942|DRUG|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
48654318|NCT03914833|OTHER|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
48654319|NCT06568562|DRUG|XL092|XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.
47978088|NCT00378196|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
47978089|NCT05014763|PROCEDURE|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
47978090|NCT02450903|DRUG|LDK378|Oral LDK378 750mg once daily
47978091|NCT05985889|OTHER|Robot|You have to walk with a robot mounted on your lower limb. To move, to change direction.
48129929|NCT01553942|RADIATION|Radiation|Daily, Monday-Friday
48129930|NCT01553942|DRUG|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
48129931|NCT01553942|DRUG|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
48129932|NCT01553942|PROCEDURE|Surgery|Surgery to remove tumor
48654320|NCT06183567|PROCEDURE|Sedoanalgesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under sedoanalgesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
48654321|NCT06183567|PROCEDURE|general anesthesia|In Acute Ischemic Stroke Patients Undergoing Endovascular Thrombectomy, the procedure was performed under general anesthesia. The procedure was continued with mean arterial pressure, heart rate, pulse oximetry and BIS monitoring.
48495145|NCT04628520|PROCEDURE|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
48495146|NCT04628520|PROCEDURE|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
47978092|NCT05985889|OTHER|Fizio|Patients do state-funded physical therapy.
47978093|NCT05985889|OTHER|EXE1|Patients undergo intensive virtual reality therapy once a day.
48495147|NCT06168877|DIAGNOSTIC_TEST|Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.|PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
48495148|NCT03358745|OTHER|Standard meal, bread/butter as starter|Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
48495149|NCT03358745|OTHER|Standard meal with soup as starter|Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
48495150|NCT03358745|OTHER|Standard meal with cheese as starter|Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
48495151|NCT03358745|OTHER|Standard meal with salad as starter|Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
48495152|NCT02543619|OTHER|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
48129953|NCT06393374|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg intravenous (IV) infusion q6w
48129954|NCT06393374|BIOLOGICAL|sac-TMT|sac-TMT 4 mg/kg IV infusion q2w
48129955|NCT06393374|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
48129956|NCT04564443|OTHER|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
48129957|NCT04564443|OTHER|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
48129958|NCT04564443|OTHER|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
48129959|NCT04564443|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
48654322|NCT06612866|DIETARY_SUPPLEMENT|Keratin hydrolysate|The clinical study will be conducted in two phases. The first phase will aim at characterizing the metabolites present in human serum after consumption of the Kera-Diet® ingredient and at determining the overall absorption peak of the tested ingredient. The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human skin cell and intestinal epithelial cell cultures.
48654323|NCT06643897|OTHER|Qualitative Interview|40-50 minute-qualitative interview.
48129960|NCT04564443|OTHER|Fibracol Wound Dressing|Application of a collagen alginate dressing
48129961|NCT03092726|DRUG|ASP8062|ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
48129962|NCT03092726|DRUG|Placebo|Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
48129963|NCT06498414|DRUG|rifampin standard arm|120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)
48129964|NCT06498414|DRUG|rifampin double dose|60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)
48129965|NCT06498414|DRUG|levofloxacin and rifapentine|30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)
48129966|NCT04270045|DEVICE|Non-invasive forced airway oscillometry|This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
48495153|NCT05633108|OTHER|No Intervention|No intervention will be administered.
48654324|NCT03777020|BEHAVIORAL|Service Dog Training Program|Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
48654325|NCT03777020|OTHER|Dog Training Education|Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
48654326|NCT06323083|OTHER|Emotional Freedom Technique|Emotional freedom techniques is a psychophysiological intervention that combines psychological methods from traditional therapies with somatic stimulation. EFT involves tapping acupuncture points to desensitize negative emotions by focusing on the emotion.
47978094|NCT05985889|OTHER|EXE2|Patients undergo intensive virtual reality therapy twice a day.
48495154|NCT04353765|DRUG|Cabozantinib monotherapy|Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
48129969|NCT06111586|DRUG|Frexalimab|Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102
48129970|NCT06111586|DRUG|Placebo|IV Infusion at Day 1 and SC Injection from W2 to W102
48129971|NCT06111586|DRUG|Insulin|SC injection, dose and frequency will be established and/or adjusted by investigator
48495155|NCT04353765|DRUG|All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC|As per authorized FDA label in advanced RCC
48495156|NCT00757848|DRUG|AZD9668|60 mg, oral tablet, twice daily for 28 days
48495157|NCT00757848|DRUG|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
48495158|NCT05577819|DIAGNOSTIC_TEST|99mTc-pyrophosphate Scintigraphy|Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
48495159|NCT02008786|DRUG|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
48495160|NCT02008786|DRUG|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
48495161|NCT02008786|DRUG|placebo|Placebo
48495162|NCT02433262|OTHER|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
48495163|NCT02433262|OTHER|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
48495164|NCT02802774|OTHER|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
48495165|NCT02802774|OTHER|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
48495166|NCT02802774|OTHER|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
48495167|NCT00977730|DIETARY_SUPPLEMENT|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
48495168|NCT00977730|DIETARY_SUPPLEMENT|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
48495169|NCT04613674|DRUG|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
48654327|NCT04427670|OTHER|Group intervention|Group intervention programme designed for stroke survivors with dysarthria and their carers. The programme was eight weeks long, with weekly two sessions, each session lasting for two hours, lead by speech language therapist and was comprised of activities which addressed participants education about their dysarthria and stroke. The role of family , peer and professional was to provide support and communication practice.
48654328|NCT04427670|OTHER|Regular speech therapy|Regular speech therapy will be provided to the controlled group.Regular speech therapy is one to one speech therapy session,conducted twice a week for the duration of eight weeks.This intervention is implemented to patients with dysarthria following stroke in a format of one patient and one therapist per session.
48654329|NCT02796911|DRUG|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
48654330|NCT02796911|DRUG|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
48654331|NCT06008080|DEVICE|Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
48654332|NCT05812170|BEHAVIORAL|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
48654333|NCT05102448|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12 months;~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
48654334|NCT05102448|DRUG|Methotrexate|"1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
48495170|NCT04613674|DRUG|placebo+chemotherapy|placebo+chemotherapy
48337301|NCT06318221|DIETARY_SUPPLEMENT|Experimental (Immunonutrition) Group|"Immunonutrition was given to the patients in the intervention group and ready-to-use liquid in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day as taken between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. The ready-to-use immunonutrition product was given to the patients in the intervention group."
48495171|NCT04041349|DRUG|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
48495172|NCT03858192|PROCEDURE|Colorectal surgery procedure|Elective admission for colorectal surgery
48495173|NCT03858192|PROCEDURE|Emergency abdominal surgery|Emergency admission necessitating emergency surgery
48495174|NCT03858192|DRUG|Antibiotics|Treatment for infection and reason for admission
48495175|NCT00186758|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
48495176|NCT05966675|DEVICE|conduction system pacing|Implantation of cardiac implantable electronic device (CIED) with conduction system pacing (left bundle branch area pacing or his bundle pacing).
48495177|NCT05966675|DEVICE|right ventricular or biventricular pacing|Implantation of cardiac implantable electronic device with right ventricular or biventricular pacing according to left ventricular ejection fraction and current ESC guidelines.
48495178|NCT04681066|DRUG|CM-4620 Injectable Emulsion or CM-4620-IE|Auxora is to be administered as an IV infusion and is supplied as a translucent, white to yellowish colored, sterile, non-pyrogenic emulsion containing 1.6 mg/mL of the active pharmaceutical ingredient CM4620. CM4620-IE is supplied as an 80 mL fill in a 100 mL, single-use glass vial. The drug product is formulated as an emulsion due to the low solubility of CM4620 in aqueous solution. CM4620-IE contains egg phospholipids, medium chain triglycerides, glycerin, edetate disodium salt dehydrate (EDTA), sodium hydroxide (as needed to adjust pH), and sterile water for injection.
48495179|NCT04681066|OTHER|Placebo|Matching Placebo is to be administered as an IV infusion and is supplied as a translucent, white to yellowish, sterile, non-pyrogenic emulsion carrier containing no active pharmaceutical ingredient. Placebo is supplied as an 80 mL fill in a 100 mL single-use vial. Placebo contains the same ingredients as Auxora except that it does not contain CM4620.
48654335|NCT06644508|OTHER|Strict adherence to European guidelines|"The goal is to maintain a neutral fluid balance throughout the course of intubation if clinical practice allows. Therefore:~* From the start of mechanical ventilation, the maximum maintenance fluids is 65% of the maintenance fluids proposed by the Holliday \& Segar formula. Fluid resuscitation in the first hours after intubation is at the discretion of the attending physician.~* Any other interventions to maintain a neutral fluid balance (e.g., starting diuretics, reducing fluid boluses, decreasing creep fluids, or using more concentrated enteral feeding) are at the discretion of the attending physician.~* Throughout the intervention, the attending physician decides if clinical practice allows for a decrease in fluid balance, and international feeding goals must always be met."
48337302|NCT06318221|DIETARY_SUPPLEMENT|Active Comparator Group ( Standard enteral nutrition)|"Standard enteral nutrition was given to patients in the control group in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. Liquid standard enteral nutrition was given to the patients in the control group."
48495180|NCT03261765|OTHER|Assessment of adhesions|Modified Nair scoring system
48337303|NCT00002707|DRUG|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
48654336|NCT01933763|DRUG|REGN1193|
48495181|NCT02468063|DRUG|Low dose terlipressin|Terlipressin-2mg (low dose )
47978095|NCT05985889|OTHER|EXE+ROB|The patients intensively performed 1 virtual reality therapy and 1 robotic therapy every day.
47978096|NCT05991076|OTHER|Latin Dance|The Activate Bailando class is a dance-focused exercise class that is offered once per week for one hour. The program has been developed by dance educators in the Madison area.
47978097|NCT02389933|DRUG|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
47978098|NCT04403971|DRUG|0.12% Chlorhexidine Oral Liquid Product|The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
47978099|NCT04403971|DRUG|Listerine Oral Liquid Product|The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
47978100|NCT04403971|OTHER|Normal Saline Product|The control group received 10ml normal saline for oral rinse twice a day.
48495182|NCT02468063|DRUG|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
48129984|NCT03911531|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
48337304|NCT00002707|DRUG|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
48337305|NCT00002707|DRUG|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
48337306|NCT00002707|DRUG|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
48495183|NCT02468063|DRUG|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
48337308|NCT02408185|DRUG|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
48654337|NCT01933763|OTHER|Placebo|
48654338|NCT04692597|DEVICE|Phoenix Thera-Lase System|Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.
48654339|NCT04692597|DEVICE|SHAM Phoenix Thera-Lase System|Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
48654340|NCT02255656|DRUG|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
48337309|NCT02408185|DRUG|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
48337310|NCT01847079|OTHER|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
48495184|NCT03321162|DIAGNOSTIC_TEST|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
48495185|NCT06084962|BIOLOGICAL|DeepTag-GPRC5D Targeted CAR T-cells|Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion
48495186|NCT02288182|DEVICE|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
48495187|NCT02288182|DEVICE|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
48495188|NCT04567030|DEVICE|Dental monitoring (DM)|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
48654341|NCT03002857|DEVICE|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
48654342|NCT03002857|DEVICE|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
48654343|NCT03002857|DEVICE|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
48654344|NCT06643910|BIOLOGICAL|Single drug group A|9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled
48654345|NCT06643910|BIOLOGICAL|Combined treatment group B|9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled
48654346|NCT06645236|DEVICE|therascreen® KRAS RGQ PCR Kit|The investigational device, therascreen® KRAS RGQ PCR Kit, will be used to determine the KRAS G12C mutation status of patients during the screening period of Amgen's clinical trial (20210081)
48129985|NCT03911531|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
48129986|NCT05966012|DRUG|Tranexamic acid|Recent data suggests that antifibrinolytics like tranexamic acid (TXA) might be able to lessen the inflammation of the nervous system caused by surgery and CPB through the inhibition of plasmin production, thereby stabilising the blood brain barrier.
48495189|NCT05436717|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
47978101|NCT03592108|OTHER|CSR remote monitoring|The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
48129987|NCT05063864|OTHER|Nursing Support Program|"Within the scope of the nursing support program, counselling services were provided to women by making regular phone calls that lasted 15-20 minutes once a week. Within the scope of the support program, two training booklets titled Life After Hysterectomy Surgery and Women's Health During Menopause were prepared by reviewing the literature."
48495190|NCT00000583|BIOLOGICAL|hepatitis B vaccines|
47978102|NCT00846430|DRUG|Peg-Interferon alpha-2b|age and weight dependant
47978103|NCT00846430|DRUG|Celecoxib (Celebrex)|age and weight dependant
47978104|NCT00846430|DRUG|Temozolomide (temodar)|age and weight dependant
47978105|NCT00846430|DRUG|Vincristine Sulfate (Oncovin)|age and weight dependant
47978106|NCT05390281|DIAGNOSTIC_TEST|increase in serum creatinine|any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
47978107|NCT05433805|OTHER|Fasting-mimicking diet (FMD) and physiotherapy|"FMD is a diet held monthly during five days with the restriction of calories to less than 1000 kcal, glucose and proteins.~Physiotherapy will be organized as home-based exercises explained by the physiotherapeutist at the beginning of the study."
47978108|NCT03806140|BEHAVIORAL|text messages|receive about one health-related text message a day for 16 weeks
47978109|NCT00258531|DEVICE|Olympus ScopeGuide®, 3-dimentional magnetic imager|
47978110|NCT05109689|BEHAVIORAL|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
47978111|NCT05109689|BEHAVIORAL|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
47978112|NCT06226753|PROCEDURE|Type of anaesthesia used|Spinal anaesthesia will be used for closure of loop ileostomy
47978113|NCT05133453|DRUG|Pirfenidone|drug intake three times daily for one year
47978114|NCT03658655|BIOLOGICAL|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
48129988|NCT04899024|BEHAVIORAL|PARTI|PARTI will provide positive affect skills. Each 1-hour session delivered via Zoom consists of a didactic portion with in vivo skills practice and participants are asked to complete home practice of the skills between sessions. Many sessions include formal exercises that have been utilized in Mindfulness-Based Relapse Prevention to cultivate mindfulness and meta-cognitive awareness.
48129989|NCT04899024|BEHAVIORAL|Attention-Control|Attention-Control will provide a core set of coping and affect measures as well as neutral writing exercises. Each 1-hour attention-control session will be administered via Zoom.
48129990|NCT04899024|BEHAVIORAL|Contingency Management for PrEP Adherence|Participants will complete a 12-week contingency management protocol via their smartphone that consists of uploading brief videos taking PrEP medications up to four times per week. Total possible contingency management incentive for completing 48 observed PrEP doses is $360.
48495191|NCT01088802|RADIATION|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
48495192|NCT01088802|DRUG|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
48654347|NCT04937166|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
48654348|NCT04937166|DRUG|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
48495193|NCT01088802|DRUG|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
48495194|NCT03416803|RADIATION|Radiotherapy|Radiotherapy
48495195|NCT05234372|BEHAVIORAL|mivacunaLA|Based on their stated language preference in the baseline survey, eligible participants in the program received a text message or email twice a week (Monday and Wednesday at noon). The short text messages (\<160 characters in length) provided a link to a 2-3 min video (Monday) and a short educational content around 500 words (Wednesday). Content was organized by week with the following topics: 1) what is COVID-19 and how COVID-19 vaccines works, 2) COVID-19 vaccine myths and facts, 3) COVID-19 vaccine safety and efficacy in children, and 4) how to obtain COVID-19 vaccines in your community. Every week we provided information about how to get vaccines with links to local vaccine sites \& resources.
48495196|NCT01237925|DRUG|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
48495197|NCT01237925|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
48495198|NCT01224730|DRUG|perifosine|100 mg daily
48495199|NCT05341466|OTHER|Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
48129997|NCT04623554|BEHAVIORAL|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
48129998|NCT00973505|DRUG|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
48129999|NCT03631407|DRUG|Vicriviroc|Vicriviroc tablets administered orally, QD at dose level 1 or 2.
47978115|NCT00751751|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
48130000|NCT03631407|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.
48130001|NCT03428698|DEVICE|Aminogam|A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
48654349|NCT04937166|DRUG|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
48654350|NCT06407232|DRUG|Letermovir|480 mg taken orally once daily, for 84 days
47978116|NCT00751751|DRUG|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
48495200|NCT05341466|OTHER|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
48654351|NCT06639282|DRUG|Siponimod|Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
48130004|NCT04428710|OTHER|assessment with psychometric questionnaire|"At the initial genetic consultation patients are informed about hereditary cancer risk and the genetic testing process. At the second genetic counseling appointment, after patients done tests, all participants were informed about the study purpose, and they signed the informed consent before the psychometric assessment. Those patients who agreed to participate, they were given the questionnaires to fill in. Also, background characteristics were reported including age, marital relationship, level of education, psychiatric antecedents.~The time for completion the self-report measures was about 10 minutes. The psychometric assessment was occurred prior to delivering the results of genetic testing."
48654352|NCT06639282|DRUG|Placebo|A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
48654353|NCT06637436|BEHAVIORAL|Motivational Interviewing (MI)|This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
48654354|NCT06637436|BEHAVIORAL|Contingency Management (CM)|Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
47978117|NCT02520843|DRUG|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
47978118|NCT00764153|PROCEDURE|Bipolar hemiarthroplasty|Lateral approach. FWB.
48495201|NCT05656001|OTHER|Real-time functional magnetic resonance imaging Neurofeedback and Real-time Biofeedback|Participants will take part in three runs of real-time functional magnetic resonance imaging feedback (rt-fMRI-NF) training with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive biofeedback will take part in three runs of biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
48130007|NCT02999763|DEVICE|SlimShape|SlimShape radiofrequency treatment to the abdomen
48130008|NCT00213395|DEVICE|Interface for noninvasive ventilation|
48130009|NCT00826995|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
48130010|NCT06420570|PROCEDURE|Thoracic Surgery|Patients will either undergo thoracic surgery, specifically thoracotomy (traditional method of chest surgery using a large surgical incision) or video-assisted thoracic surgery (minimally invasive method using video cameras)
48130011|NCT06030700|OTHER|Controlled Conditions|Use of FoodImage app to take pictures of food and/or receipts.
48130012|NCT00008242|DRUG|dexamethasone|
48130013|NCT00008242|DRUG|doxorubicin hydrochloride|
48130014|NCT00008242|DRUG|thalidomide|
48495202|NCT05656001|OTHER|Sham functional magnetic resonance imaging neurofeedback and sham biofeedback|Participants will take part in three runs of sham neurofeedback with 4-8 days apart, which will be conducted at the Center for Medical Image Science and Visualization (CMIV) at the university hospital in Linköping. Participants who receive sham biofeedback will take part in three runs of sham biofeedback with 4-8 days apart conducted in the lab at the Center for Social and Affective Neuroscience (CSAN) at Linköping university. Participants will be given instructions and basic psychoeducation of brain function and the rational for down-regulating the area of the brain that drives emotion, as well as the physiological reaction that is triggered in response to emotional stimuli. The emotional stimuli are emotional pictures from the International Affective Picture System (IAPS) and the Open Affective Standardized Image Set (OASIS).
48495203|NCT06300814|OTHER|Progressive relaxation exercise group|A video containing the progressive relaxation exercise was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group to whom progressive relaxation exercise would be applied, and the children applied progressive relaxation exercise (15 minutes of progressive relaxation exercise before bedtime for a total of 4 weeks, 5 days a week).
47978119|NCT00764153|PROCEDURE|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
47978120|NCT03157778|OTHER|Obese men|Biological measures before, just before, and after lunch, in obese men
47978121|NCT03157778|OTHER|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
47978122|NCT01112241|DRUG|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
47978123|NCT02747589|PROCEDURE|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
47978124|NCT02192931|DRUG|Creatine monohydrate|
48130017|NCT06284213|OTHER|No interventions|This is an observational study with no interventions.
48130018|NCT00291954|BIOLOGICAL|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
48130019|NCT00291954|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
48130020|NCT06449859|DRUG|TQC2938 Injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
48130021|NCT06449859|DRUG|TQC2938 Placebo|TQC2938 Placebo is a placebo comparator
47978125|NCT01804296|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
48130022|NCT04287985|DRUG|Dose-Placebo|Unit Dose Strength - 0.9%.
48130023|NCT04287985|DRUG|Low Dose-VIS649|Dose Level = Low
48130024|NCT04287985|DRUG|Medium Dose-VIS649|Dose Level = Medium
48130025|NCT04287985|DRUG|High Dose-VIS649|Dose Level = High
48130026|NCT04994795|OTHER|Predictive models (data collection)|Machine learning predictive models
48130027|NCT04353089|OTHER|Basic life support courses|4 hours certified basic life support courses
48130028|NCT02492412|DRUG|HE 10|
48130029|NCT02492412|DRUG|Restasis|
48130030|NCT02357472|DRUG|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
48130032|NCT05730621|DRUG|Sarpogrelate Sustained Release/Aspirin|Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
48130033|NCT05730621|DRUG|Aspirin|Aspirin 100mg qd for 12 weeks
48130034|NCT04875767|DEVICE|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
48654355|NCT05669846|DRUG|Fecal Microbiota Transplant (FMT)|FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy. The FMT consists of introducing normal bacterial flora contained in the stool collected from a donor into the small intestine. In this case, the donors are patients with advanced metastatic non-small cell lung cancer (NSCLC) who have undergone PD-1 therapy (nivolumab or pembrolizumab) and are currently in a durable remission that is ongoing. The FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.
48266595|NCT00578643|PROCEDURE|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10\^8/kg recipient weight; for cord blood ≥ 3 X 10\^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10\^/kg CD34+ cells.
48337311|NCT05145803|DEVICE|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
48337312|NCT06445465|DRUG|[18F]MNI-1216|\[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
48337313|NCT04159922|OTHER|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
47978126|NCT03568760|BEHAVIORAL|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
48337314|NCT04342429|RADIATION|Proton-beam Therapy for Small Cell Lung Cancer|The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
48337315|NCT04602689|DRUG|Human fibrinogen concentrate|Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
48337316|NCT01729104|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
48337317|NCT01729104|DRUG|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
48337318|NCT01729104|DRUG|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
48337319|NCT05385575|DRUG|KN056 (0.1mg)|The participants will receive assigned single dose of KN056 on Day 1
48337320|NCT05385575|DRUG|KN056 (0.3mg)|The participants will receive assigned single dose of KN056 on Day 1
48337321|NCT05385575|DRUG|KN056 (1.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
48337322|NCT05385575|DRUG|KN056 (3.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
48337323|NCT05385575|DRUG|KN056 (6.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
48337324|NCT05385575|DRUG|KN056 (12.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
48337325|NCT05385575|DRUG|KN056 (18.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
48337326|NCT06410469|PROCEDURE|rug weaving-like plication technique|anterior vaginal wall repair with the rug weaving-like plication technique in cystosel
48495204|NCT06300814|OTHER|Music recital group|The link of the music recital (link) was sent to the phones of the mothers of children diagnosed with epilepsy in the intervention group, where the music concert will be applied, and the children listened to it (music concert was applied for 15 minutes before going to bed, 5 days a week for a total of 4 weeks).
48495205|NCT05386082|OTHER|Modified Delphi process|The study involves a brief demographics survey and Delphi process, i.e. three rounds of information and surveys, in which participants will be asked to score/rank potential metrics.
48495206|NCT05315635|OTHER|Questionnaire|"Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~* Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~* Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~* Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~* Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)"
48337327|NCT01670682|PROCEDURE|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
48337328|NCT01670682|PROCEDURE|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
48337329|NCT01670682|DEVICE|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
48337330|NCT03209362|COMBINATION_PRODUCT|SI-613|SI-613 will be repeated intra-articularly administered.
48337331|NCT03209362|COMBINATION_PRODUCT|Placebo|Placebo will be repeated intra-articularly administered.
48337332|NCT01126502|DRUG|alvespimycin hydrochloride|Given IV
48337333|NCT01126502|OTHER|diagnostic laboratory biomarker analysis|
48337334|NCT01126502|OTHER|pharmacogenomic studies|
48337335|NCT01126502|OTHER|pharmacological study|
48337336|NCT00978224|DIETARY_SUPPLEMENT|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
48337337|NCT00978224|DIETARY_SUPPLEMENT|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
47978127|NCT03568760|BEHAVIORAL|Comprehension training|Reading and hearing comprehension
48337338|NCT04037007|PROCEDURE|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
48337339|NCT04037007|PROCEDURE|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
48337340|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
48337341|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
48337342|NCT02279979|DEVICE|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
48337343|NCT01803113|DEVICE|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
48337344|NCT00391781|PROCEDURE|Temperature of contrast medium|
48337345|NCT02337686|OTHER|Laboratory Biomarker Analysis|Correlative studies
48337346|NCT02337686|BIOLOGICAL|Pembrolizumab|Given IV
48337347|NCT02337686|OTHER|Pharmacological Study|Correlative studies
48337348|NCT02337686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48337349|NCT05467488|PROCEDURE|photofunctionalization|UVA and UVC photofunctionalization of dental implants
48337350|NCT04839393|DRUG|PF-06882961 followed by PF-06882961/PF-06865571|Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.
48337351|NCT04839393|DRUG|PF-06882961/PF-06865571 followed by PF-06882961|Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.
48337352|NCT04839393|DRUG|PF-06882961 + PF-06865571|Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
48654356|NCT05669846|DRUG|Pembrolizumab|Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.
48654357|NCT06563830|OTHER|educational application|The content of the training to be applied to nurses will include: definition of MDRPI, etiology, prevalence and cost, staging, risk factors, nursing initiatives to be implemented to prevent MDRPI.
48654358|NCT05723263|BEHAVIORAL|Standard Pay-it-forward|400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).
48654359|NCT05723263|BEHAVIORAL|Community Engaged Pay-it-forward|400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)
47978128|NCT05776199|DIAGNOSTIC_TEST|Sonoelastography, tensiomyography and mechanosensitivity|To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
48495207|NCT02310711|OTHER|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
48495208|NCT05631353|DEVICE|Carriere Motion Appliance|"Patient will be randomly allocated into two groups:~Group I: conventional mandibular anchorage using passive lingual arch. Group II: anchorage by direct mini-screws. In the group I, Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with passive lingual arch in the lower arch as anchorage means.~In the group I, Class II elastics will be attached from the maxillary canine to mandiular miniscrews bilaterally.~For each patient, two CBCT radiographs will be obtained: one preoperatively and another after completion of distalization."
48266596|NCT06385704|PROCEDURE|DMR Procedure|Endoscopic procedure
48654360|NCT05723263|OTHER|Control arm|400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 USD per test) and no community engagement component
48654361|NCT06175832|DRUG|Elonva®|Single injection
48654362|NCT06175832|DRUG|Puregon®|Multiple injections
48654363|NCT06175832|DRUG|Orgalutran®|Multiple injections
48654364|NCT06175832|DRUG|Gonapeptyl®|Double injection
48654365|NCT06175832|DRUG|Cerazette®|Oral tablet
47978129|NCT04906213|DRUG|Empagliflozin10Mg Tab|Empagliflozin10 Mg daily or placebo daily for 18 months
48266597|NCT01709188|BEHAVIORAL|Musical Dual Task Training|
48266598|NCT01709188|BEHAVIORAL|Walking and Talking|
48266599|NCT02939157|OTHER|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
48337353|NCT00436020|DEVICE|TMS|Transcranial Magnetic Stimulation
48337354|NCT00436020|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
48337355|NCT01195194|DRUG|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
48337356|NCT06095544|PROCEDURE|Enhanced recovery for SPK recipients|Pre-operative, perioperative and post-operative were consisted of evidenced-based systematic optimization approaches.
48337357|NCT05968872|BEHAVIORAL|no intervation|it is observational, no intervention was taken
48337358|NCT01485432|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
48495209|NCT01021358|DRUG|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
48337359|NCT03658798|PROCEDURE|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
48337360|NCT01040845|DRUG|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
48337361|NCT01040845|DRUG|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
48337362|NCT01040845|DRUG|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
48337363|NCT05678088|BEHAVIORAL|Oropharyngeal Exercises|The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
48337364|NCT05678088|BEHAVIORAL|Sham Exercises|The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
48337365|NCT04694716|OTHER|No intervention|No intervention will be applied.
48495210|NCT01021358|DRUG|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
48495211|NCT00553592|DRUG|Bicifadine|600mg/day
48495212|NCT00553592|DRUG|Bicifadine|placebo tablet
48495213|NCT00553592|DRUG|Bicifadine|1200 mg
48654366|NCT04150497|BIOLOGICAL|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
48654367|NCT04150497|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
48654368|NCT04977986|DRUG|ZYN002 - transdermal gel|Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
48654369|NCT04977986|DRUG|Placebo|"Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery)~Other Names:~Placebo Comparator Matching Placebo"
48654370|NCT06644027|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
48654371|NCT06644027|DEVICE|Molicare Premium Bed Mat|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
48654372|NCT06149442|OTHER|Dose of five-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (five incisions).
47978130|NCT04906213|DRUG|Placebo|10Mg Placebo Tab
47978131|NCT02727751|DRUG|Tenapanor|
48337366|NCT01763983|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
48337367|NCT01763983|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
48337368|NCT01400139|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
48337369|NCT05182424|BEHAVIORAL|Myndlift BPT App & As-Needed Therapist Support|"BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods to facilitate positive behaviors in their child and reduce challenging behaviors. Myndlift BPT translates established content and processes into a digital format to be delivered through a mobile app. Myndlift content consists of 10 components, designed to be completed in a self-directed manner by parents, over the course of approximately 10 weeks (total weeks depends upon parent's pace through the program).~In this project, trained and supervised doctoral- and masters-level students will serve as study therapists and meet with parents via a secured, password-protected Zoom platform to introduce parents to the Myndlift BPT (first session before start of the BPT), to support and problem solve BPT skills acquisition (during the Myndlift BPT), and at the end of the Myndlift BPT (to review the intervention content and consider the maintenance of skills)."
48337370|NCT05117749|DRUG|Saffron 100|to Mild and Moderate UC patients
48337371|NCT05117749|DRUG|Saffron 50|to Mild and Moderate UC patients
48337372|NCT05117749|DRUG|Placebo|to Mild and Moderate UC patients
48337373|NCT05649410|OTHER|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
48337374|NCT05649410|OTHER|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
47978132|NCT05109650|DRUG|BAT6026|IV infusions
48266600|NCT01724437|DEVICE|catheter based pulmonary vein isolation|catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
48266601|NCT02998723|OTHER|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
48337375|NCT02051738|DRUG|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
48266602|NCT02998723|OTHER|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
48654373|NCT06149442|OTHER|Dose of ten-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (ten incisions).
48495214|NCT06167590|DIAGNOSTIC_TEST|GAPsy protocol|Each participant will undergo a 7 T multimodal neuroimaging session, including T1-weighted, 1H-MRS and fMRI. Each participant will also be assessed through a structured clinical interview (SCID-I e SCID-II) and will be administered scales such as HAM-A, HAM-D, BPRS and MADRS.
48495215|NCT00392236|DEVICE|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
48495216|NCT00392236|BEHAVIORAL|Treatment as usual|Participants will receive treatment as usual.
48495217|NCT03912441|BIOLOGICAL|BCD-147|Bispecific anti-HER2 monoclonal antibody
47978133|NCT05109650|DRUG|BAT1308|Ⅳ infusions
48495218|NCT04785859|DIAGNOSTIC_TEST|BPD prediction|"The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time."
48495219|NCT05214963|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode
47978134|NCT02049957|DRUG|Sapanisertib|Sapnisertib capsules
47978135|NCT02049957|DRUG|Fulvestrant|Fulvestrant IM injection.
47978136|NCT02049957|DRUG|Exemestane|Exemestane tablets.
48495220|NCT05214963|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode
48130041|NCT01208116|OTHER|Cardiovascular events|"* Coronary intervention~* Infarction~* Congestive heart failure~* Stroke~* Cardiac death"
48130042|NCT06550401|OTHER|BREAST-Q Physical Well-Being|This BREAST-Q domain measures pain or tightness and difficulty with mobility, such as lifting arms or running. The preoperative survey contains 10 items, whereas the postoperative survey contains 11 items. Values for BREAST-Q subscales are converted to summary scores, ranging from 0 to 100, via Q-Score software. Higher scores correlate with better patient quality of life. 37 This survey is administered as part of standard care for all patients.
48266603|NCT03932552|OTHER|Exercise|aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.
48266604|NCT03932552|OTHER|nutritional therapy|individualised nutritional intervention
48337376|NCT02051738|DRUG|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
48337377|NCT06269718|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
48337378|NCT06269718|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
48337379|NCT04673188|PROCEDURE|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
48337380|NCT02680106|DEVICE|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.
48495221|NCT00307606|DRUG|Solu-medrol 125 mg|
48495222|NCT06436040|OTHER|Pathological response assessment|The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.
48495223|NCT01072474|PROCEDURE|Capnography|Capnographic monitoring
47978137|NCT03048565|BEHAVIORAL|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
47978138|NCT01135199|DRUG|pomalidomide (CC-4047|
47978139|NCT02838303|OTHER|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
47978140|NCT02838303|OTHER|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
47978141|NCT01928524|DRUG|DOS2w Dose level 1A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
47978142|NCT01928524|DRUG|DOS2w Dose level 2A|Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
47978143|NCT01928524|DRUG|DOS2w Dose level 3A|Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
47978144|NCT01928524|DRUG|DOS2w Dose level 4A|Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
47978145|NCT01928524|DRUG|DOS3w Dose level 1B|Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
47978146|NCT01928524|DRUG|DOS3w Dose level 2B|Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
47978147|NCT01928524|DRUG|DOS3w Dose level 3B|Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
47978148|NCT04261751|OTHER|Clinician Questionnaire|Nurses will take the Clinician Questionnaire electronically
47978149|NCT00186381|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
48130043|NCT06550401|OTHER|QuickDASH|QuickDASH, also known as the Arm and Shoulder Range of Motion survey within MSK Engage is an 11-item survey that measures physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. It is currently standard of care for breast cancer surgery patients. It is a valid, reliable, and responsible survey that can be used for clinical and/or research purposes. Higher scores indicate greater disability.
48495224|NCT01072474|PROCEDURE|Standard monitoring|Standard monitoring
48654374|NCT06149442|OTHER|Dose of fifteen-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (fifteen incisions).
47978150|NCT02245308|DRUG|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
48130045|NCT06381739|BIOLOGICAL|ChAd-triCoV/Mac|Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.
48495225|NCT00210873|DRUG|topiramate|
47978151|NCT02245308|BEHAVIORAL|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
47978152|NCT02245308|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
47978153|NCT02245308|DRUG|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
47978154|NCT02245308|DRUG|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
47978155|NCT05485038|PROCEDURE|Tumor resection in awake patient|Surgeon performs critical steps of tumor removal in awake patient and controls his/her motor functions by brain mapping and assessing of voluntary movements
47978156|NCT05485038|PROCEDURE|Tumor resection in asleep patient|Surgeon removes tumor in asleep patient and controls his/her motor functions by brain mapping
47978157|NCT00789139|DEVICE|ICM Implantation|Sub cutaneous implantation of the ICM
48130046|NCT06381739|OTHER|Control|A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.
48495226|NCT03548649|DEVICE|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
48495227|NCT01789827|OTHER|Laboratory Biomarker Analysis|Correlative studies
48495228|NCT01789827|PROCEDURE|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
47978158|NCT03071770|DRUG|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
47978159|NCT04848545|OTHER|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
48495229|NCT01789827|BIOLOGICAL|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
48495230|NCT06156735|OTHER|Passive Music Therapy (P)|Music Therapy Intervention
48495231|NCT06156735|OTHER|Active Music Therapy (A)|Music Therapy Intervention
48495232|NCT06156735|OTHER|Standard Care Control Condition (C)|Without any intervention
48495233|NCT00351975|DRUG|Belinostat|Given IV
48495234|NCT00351975|DRUG|Azacitidine|Given SC
48495235|NCT00351975|OTHER|Laboratory Biomarker Analysis|Correlative studies
48654375|NCT06024226|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
48495236|NCT05579275|BIOLOGICAL|JCXH-212 Injection|Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
48654376|NCT06644885|PROCEDURE|TIVAD implantation complications|Follow up and post operative outcome of patients with devices implantation
48654377|NCT04396236|DRUG|Lasmiditan|Administered orally
48654378|NCT04396236|DRUG|Placebo|Administered orally
48495237|NCT03816514|PROCEDURE|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
48495238|NCT03816514|PROCEDURE|Conventional management|Conventional management without SpHb monitoring
48495239|NCT03443388|DEVICE|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
48495240|NCT03920176|DIAGNOSTIC_TEST|Computed tomography coronary angiography|CTCA \>64 detector row scanner
48495241|NCT03920176|OTHER|ASSIGN Score|ASSIGN Cardiovascular Risk Score
48495242|NCT05177874|DEVICE|Traumacel FAM Trium|Absorbable Hemostat (oxidized non-regenerated cellulose)
48495243|NCT05177874|DEVICE|Surgicel Fibrillar|Absorbable Hemostat (oxidized regenerated cellulose)
48495244|NCT03537716|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
48654379|NCT06045793|DRUG|TNX-1300 (Injection)|Patients will receive a single IV injection of TNX-1300.
47978160|NCT05433714|OTHER|Assesment|The figure of walk test, Berg Balance scale, Timed 25-Foot Walk, Timed up and go test, Foursquare walk test
47978161|NCT06043440|DRUG|Oxygen|Active nocturnal oxygen concentrator
48130052|NCT04772963|GENETIC|blood sample|During the arteriography a peripheral venous sampling
48130053|NCT03874819|DEVICE|Medium cut-off dialyzer|Treatment using a Medium Cut-Off Dialyzer
48130054|NCT03874819|DEVICE|High-flux dialyzer|Treatment using a high-flux dialyzer
48130055|NCT05139017|BIOLOGICAL|Zilovertamab vedotin|Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg
48130056|NCT05139017|BIOLOGICAL|Rituximab|IV Infusion 375 mg/m\^2
48130057|NCT05139017|DRUG|Gemcitabine|IV Infusion 1000 mg/m\^2
48130058|NCT05139017|DRUG|Oxaliplatin|IV Infusion 100 mg/m\^2
48130059|NCT05139017|DRUG|Bendamustine|IV Infusion 90 mg/m\^2
48495245|NCT04810403|BEHAVIORAL|SOMEBODY Eating Disorder Prevention Program|Participants will receive daily activities to complete on their most frequently used social media platform for 14 consecutive days. Daily activities have been adapted from the Body Project - an intervention that has been demonstrated to reduce internalization of the thin ideal and reduce risk for eating disorders. Examples of activities to be piloted include unfollowing social media accounts the participant perceives as reinforcing the thin-ideal and posting a selfie without makeup or editing. Based on feedback from participants, the intervention may be altered to improve acceptability, feasibility, and preliminary evidence of potential efficacy.
48130061|NCT05011045|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48130062|NCT05011045|OTHER|Neurocognitive Assessment|Undergo neurocognitive function assessment
48130063|NCT05011045|OTHER|Quality-of-Life Assessment|Complete questionnaires
48130064|NCT05011045|OTHER|Questionnaire Administration|Complete questionnaires
48495246|NCT06406517|DRUG|Gadopiclenol|Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.
48495247|NCT06406517|DRUG|Gadobenate dimeglumine|Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.
48495248|NCT00621049|DRUG|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
47978162|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
47978163|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
47978164|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
47978165|NCT05285605|DRUG|Ulipristal Acetate|Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse
48495249|NCT00621049|DRUG|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
48495250|NCT04943484|PROCEDURE|imaging fluorescence NIR/ICG|"Preoperative upper GI endoscopy (UGE) UGE with submucosal injection of 2ml of ICG 0.125mg/ml solution to four peritumoral sites 15-20 hours before surgery Surgery D2 Distal gastrectomy with dissection of 1, 3, 4sb, 4sd, 5, 6, 7, 8a, 9, 11p, 12a lymph node stations (LNS) D2 Total gastrectomy with dissection of 1, 2, 3, 4sa, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, 11d, 12a LNS Intraoperative NIR/ICG technology, change of surgical conduct (CSC) A visualization of the operative field (OF) with NIR/ICG technology is performed at the beginning of surgery and before to dissect each LNS. Subsequently, surgery is performed with the naked eye.~At the end, a visualization of the OF is performed using NIR/ICG technology to verify whether residual lymph nodes in each D2 nodal station exist. CSC is defined as the occurring of the following situation: in case of persistence of nodal fluorescence in D2 nodal stations, the completion of the dissection of the residual nodal fluorescent structures."
48654380|NCT06045793|DRUG|Placebo (Injection)|Patients will receive a single IV injection of placebo with usual care (UC).
48130070|NCT04885257|DRUG|Methylphenidate|Methylphenidate oral pill. Dosing instructions given to
48130071|NCT04885257|DRUG|Placebo|Placebo arm
48130076|NCT04100538|BEHAVIORAL|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
48130077|NCT04958317|OTHER|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
48130078|NCT04958317|OTHER|Late exercise|Participants will exercise for 30 minutes after an evening meal.
48495251|NCT04629417|DEVICE|Smart Physiotherapy Activity Recognition System (SPARS)|Wearable smart watch that records inertial data such as (accelerometer, gyroscope magnetometer) while patients are performing physiotherapy exercises.
48130084|NCT06121479|DRUG|Branched-chain amino acid|Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
48654381|NCT03396861|DRUG|Aflibercept|Subconjunctival aflibercept
48654382|NCT06637657|OTHER|No intervention (observational study)|No intervention, only guideline implementation (observational study)
48654383|NCT06644014|BEHAVIORAL|Exercise|"Participant will communicate with a chatbot-like proprietary AI to receive exercise instructions. The AI will provide personalized advice according to the user's needs, aiming for 2-3 hours of steady-state zone 2 -effort aerobic exercise. Instructions will also be tailored to the user's exercise preferences and limitations (for example, suggest cycling, if running is not convenient)."
47978166|NCT04669639|OTHER|Block procedures for shoulder surgery analgesia|"The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~* In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~* control group: patients will receive only general anesthesia"
47978167|NCT01479699|DIETARY_SUPPLEMENT|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
47978168|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
47978169|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
47978170|NCT01782495|DRUG|ribavirin|tablet
47978171|NCT03578159|OTHER|Chhatralaya|Chhatralaya, home for children provide living resources along with spiritual practices.
47978172|NCT02117648|DRUG|Abemaciclib|Administered orally
47978173|NCT02117648|DRUG|Clarithromycin|Administered orally
47978174|NCT03856164|DRUG|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
48130085|NCT03510104|DRUG|MRX-2843|MRX-2843 capsules
48495252|NCT00903448|DRUG|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
48495253|NCT00903448|DRUG|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
48495254|NCT06026020|OTHER|Biological samples collection|Samples of blood, faeces, saliva are collected for analysis.
48495255|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Automatic adjustment of oxygen through the Free O2 device.~* FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
48495256|NCT02027181|DEVICE|Device FreeO2 v2.0|"* Manual adjustment of oxygen without the assistance of the FreeO2 device.~* Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
48130091|NCT00563134|DRUG|GR270774|
47978175|NCT03856164|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
48130092|NCT04447287|DRUG|ASP8062|Oral
48130093|NCT04447287|DRUG|Placebo ASP8062|Oral
48130094|NCT04447287|DRUG|buprenorphine/naloxone|Sublingual
47978176|NCT00251550|DRUG|Pemetrexed|
47978177|NCT00251550|DRUG|Cisplatin|
47978178|NCT05810142|DRUG|furquimatinib and sintilimab|furquimatinib and sintilimab
47978179|NCT01497132|DRUG|Vitamin D3|Oral drops 30000 IU weekly
47978180|NCT01497132|DRUG|Placebo|Matching placebo
47978181|NCT02942394|DEVICE|sinus-Obliquus Stent System|
47978182|NCT01549860|DEVICE|MIST Therapy|Non-contact low frequency ultrasound therapy
47978183|NCT00000507|DRUG|streptokinase|
48495257|NCT02148341|OTHER|Community of Practice Facilitation|
48495258|NCT02148341|OTHER|Usual Care|
48654384|NCT06644014|BEHAVIORAL|Exercise|Supervised HIIT -cycling twice a week. Intensities for cycling intervals will are based on the participants fitness-level determined at first visit. Intensity will gradually increase over the 12-week period
48654385|NCT06644014|DEVICE|Smart Ring|Participants will only receive an Oura Ring, but will not change anything about their normal physical activity.
48654386|NCT03608631|DRUG|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
48654387|NCT06603571|DRUG|LY3841136|Administered SC
47978184|NCT05122520|OTHER|Questionnaire|The HMBT-Q is a 26-item questionnaire, split into four main sections: food related symptoms; general digestive symptoms; extra-intestinal symptoms and co-morbidities and Medication and onset.
48654388|NCT06603571|DRUG|Tirzepatide|Administered SC
47978185|NCT01675271|OTHER|individual exercise|individual exercise and dietary prescription
47978186|NCT01675271|OTHER|general exercise|general exercise counselling
47978187|NCT05313594|DIAGNOSTIC_TEST|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
47978188|NCT05313594|DIAGNOSTIC_TEST|MRI|MRI imaging
47978189|NCT05313594|DIAGNOSTIC_TEST|DEXA|DEXA scan
47978190|NCT05313594|DEVICE|Freestyle Libre|Continuous blood glucose measurement
47978191|NCT05313594|DEVICE|ActivPAL3|Continuous physical activity measurement
47978192|NCT03920033|RADIATION|Salvage radiation therapy|Salvage radiation therapy for biochemical recurrence
48130098|NCT06000813|BEHAVIORAL|REACH-Es|REACH-Español is a mobile health platform adapted from the original REACH intervention to a Latino population with type 2 diabetes. The goal of REACH-Español is to improve diabetes medication adherence and glycemic management in this population.
48130099|NCT06000813|BEHAVIORAL|ETAU|Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
48130100|NCT04922242|BEHAVIORAL|Welch Emotional Connection Screen for Neonatal Intensive Care Unit|The Welch Emotional Connection Screen (WECS) is an investigational developmental screening tool, developed to rate the quality of the emotional connection that formed between mother and child. The screen is administered in 2-3 minutes by observing a mother and child interact, and requires the rater to critically assess 4 sub-domains of emotional connection. The NICU WECS is a clinical tool adapted for use with neonates in the NICU. Reliability of NICU staff WECS scoring will be calculated via intra-class correlations with key scores. The WECS is scored on intervals of 0.5, with a minimum of 1 (rarely--low level of connection) and maximum of 3 (mostly--high connection). Scores are used to determine the level of need for intervention.
48130101|NCT04922242|OTHER|NICU WECS Training|"WECS Training is an educational module consisting of an introduction of the concepts of emotional connection and autonomic co-regulation as studied by The Nurture Science Program, as well as an illustration of how these experiential constructs differ from traditional care plans that focus on educating parents to encourage bonding as opposed to autonomic emotional connection within the NICU. An introduction to the domains of the WECS screen as well as illustrations of these domains through video will augment the training designed for NICU staff."
48130102|NCT05475717|DRUG|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
48495259|NCT03145402|BIOLOGICAL|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
48130104|NCT05104866|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
48130105|NCT05104866|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
48130106|NCT05104866|DRUG|Gemcitabine|IV Infusion. Active comparator
48130107|NCT05104866|DRUG|Eribulin|IV Infusion. Active comparator
48130108|NCT05104866|DRUG|Vinorelbine|IV Infusion. Active comparator
48130109|NCT03367754|OTHER|Placebo|Placebo
48130110|NCT03367754|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, or placebo via intravenous (IV) infusion, single dose.
48130111|NCT06127602|BEHAVIORAL|Reactive balance training with Neuromuscular Electrical Stimulation|REACT-NMES group: The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level. NMES will be delivered to the vastus lateralis synchronously with the perturbation, which will always occur 50 ms after slip-onset and last for 450 ms including the period between liftoff to touchdown of the first compensatory step.
48130112|NCT06127602|BEHAVIORAL|Reactive balance training without Neuromuscular Electrical Stimulation|REACT group: The REACT group will undergo the same reactive balance training (in terms of type, dosage: intensity, frequency) as the REACT-NMES group. The only difference will be that the REACT group will receive ShamNMES for same time after the compensatory step touchdown. The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level.
48130113|NCT04154384|BEHAVIORAL|Life Care Specialist (LCS) Intervention|The Life Care Specialist (LCS) uses a two-arm approach to education by initially assessing participants general understanding of opioids upon which targeted education is tailored and applied and secondly, building a longitudinal relationship with each patient to increase the saliency of administered opioid education during postoperative follow-up. Information includes proper disposal, common symptoms of opioid use, signs of dependence and overdose and use of naloxone. Information is disseminated orally with adjunct physical resource guides including visual representations and literature.
48130114|NCT04154384|OTHER|Clinical Coordination with Referrals|The Life Care Specialist (LCS) can help arrange a referral for the participant, should a medical or social issue be identified during LCS intervention, including mental health services, addiction medicine services, housing insecurity referrals, food insecurity referrals, and amputee support. When giving referrals, the LCS works closely with physicians and nurses to make sure that the participant is a good fit for the referral program.
48130115|NCT04154384|BEHAVIORAL|Pilot Study of Pain Management Strategies|Orthopedic trauma patients will work with a Life Care Specialist (LCS) and will receive personalized pain management strategies to avoid potential opioid misuse.
48130116|NCT04612244|DEVICE|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
48130117|NCT04612244|DEVICE|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
48495260|NCT03145402|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
48495261|NCT00987753|DRUG|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
48495262|NCT06287606|DRUG|CTP0302-A|Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
47978193|NCT00865774|BEHAVIORAL|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
47978194|NCT00865774|BEHAVIORAL|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
47978195|NCT04541940|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
48130118|NCT06285422|DRUG|SC262|SC262 is an allogeneic CAR -T cell therapy
48130119|NCT04777357|DRUG|Cariprazine|Oral Capsule
48130120|NCT04777357|DRUG|Placebo|Oral Capsule
48495263|NCT06287606|DRUG|CTP0302-B|Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
48130122|NCT06545643|DEVICE|Dreem headband|The Dreem headband is an EEG-based wearable tool that can be used to reliably assess the relationship between sleep and epilepsy over extended observation periods.
48130123|NCT05793996|DRUG|Ferinject|The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
48130124|NCT05793996|OTHER|Diet therapy|Patients will receive diet therapy to correct latent iron deficiency
48495264|NCT06287606|DRUG|Conventional OST|Subjects randomized into group Conventional OST will take a bowel preparation from the evening until the following morning.
48495265|NCT04350320|DRUG|Colchicine Tablets|standard therapy for COVID-19 according to the stablished hospital protocols.
48130127|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
48337381|NCT02680106|DEVICE|JELONET / IBU Biatain|The patient's DSW will be dressed by JELONET/IBU Biatain
48337382|NCT04743271|OTHER|High-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
48337383|NCT04743271|OTHER|Low-Fat Diet|The diet will consist of a breakfast, lunch, dinner, and snack
48337384|NCT04584931|PROCEDURE|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
48495266|NCT04350320|DRUG|Standard therapy for COVID-19 according to the stablished hospital protocols.|standard therapy for COVID-19 according to the stablished hospital protocols.
47978196|NCT04541940|OTHER|In-person Rehabilitation Therapy|Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
47978197|NCT00031057|DRUG|Thiamine hydrochloride|
47978198|NCT00031057|DRUG|Riboflavin|
47978199|NCT02499302|BEHAVIORAL|Mental training|
47978200|NCT01485770|DRUG|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
47978201|NCT01485770|DRUG|Placebo|Placebo to match ADX-N05 once a day for 2 consecutive weeks
47978202|NCT03130868|OTHER|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
47978203|NCT01887873|DEVICE|Hyaluronan Thiomer i.o. implant|
47978204|NCT03627533|PROCEDURE|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
47978205|NCT02957877|DRUG|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
48337385|NCT04584931|PROCEDURE|restorative intervention|colored composite restoration to camouflage the gingival recession defect
48337386|NCT04191213|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic to be consumed early morning in daily basis for 12 weeks
48337387|NCT04191213|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
48337388|NCT04625985|DRUG|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
48495267|NCT01898325|DEVICE|Fibroscan|Fibroscan
48495268|NCT04585984|DIETARY_SUPPLEMENT|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10\^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
48495269|NCT04585984|DIETARY_SUPPLEMENT|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
48495270|NCT04040023|DRUG|Iron and vitamin Deficiencies Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation"
48495271|NCT04040023|OTHER|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
48654389|NCT06603571|DRUG|Placebo|Administered SC
48654390|NCT06421311|DRUG|nivolumab|According to approved product label (France)
47978206|NCT02957877|DRUG|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
47978207|NCT04353076|OTHER|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
47978208|NCT04353076|OTHER|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
48130128|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
48130129|NCT05779761|BEHAVIORAL|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
48495272|NCT06095336|OTHER|telerehabilitation|The individuals included in the research will be divided into three groups. Group 1 (experiment): This is the exercise group followed by the telerehabilitation method. Group 2 (experiment): This is the group where traditional physical therapy methods will be applied. The 3rd group will be taken as the control group, there will be no intervention and they will be asked to continue their daily lives.
48495273|NCT01780987|DRUG|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
48495274|NCT01780987|DRUG|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
48495275|NCT01780987|DRUG|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
48495276|NCT03466359|BEHAVIORAL|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
48495277|NCT03466359|BEHAVIORAL|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
48495278|NCT03606876|DRUG|BAT1806 injection|Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
48495279|NCT05863884|BEHAVIORAL|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
48495280|NCT06444945|DEVICE|Heating pad|Heating pad will be used for heating purpose.
48495281|NCT06444945|DEVICE|Transcutaneous electrical nerve stimulation(TENS)|TENS is used for symptomatic pain relief
48654391|NCT06636422|DRUG|Motherwort injection|Patients will be given motherwort injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
48495282|NCT06444945|PROCEDURE|Mulligan mobilization with movement (MWM)|It provides short term pain relief and to restore pain-free, functional movements by achieving full range at the joint
48495283|NCT06444945|PROCEDURE|Kaltenborn joint mobilization|The purpose of joint mobilization is to restore normal, painless joint function. In restricted joints, this involves the restoration of joint play to normalize the roll-gliding that is essential to active movement.
48654392|NCT04029662|BEHAVIORAL|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
48654393|NCT05317936|DRUG|Pirtobrutinib|Given by PO
48654394|NCT05317936|DRUG|Venetoclax|GIven by PO
48495284|NCT06444945|PROCEDURE|Resistance Training exercise|Resistance training increases muscle strength by making your muscles work against a weight or force.
48495285|NCT00923000|DRUG|Nalbuphine|Nalbuphine 10mg with oral administration
48495286|NCT00923000|DRUG|Morphine|Morphine 10mg with oral administration
48495287|NCT00923000|DRUG|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
48495288|NCT00923000|DRUG|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
48495289|NCT00923000|DRUG|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
48495290|NCT04662138|DRUG|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
48337389|NCT04625985|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
48495291|NCT01246011|DRUG|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
48337390|NCT05410197|DRUG|Envofolimab|400mg by subcutaneous injection every 3 weeks
48337391|NCT05410197|DRUG|Lenvatinib|8 mg orally once a day
48337392|NCT05410197|DRUG|Gemcitabine|1000mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
48337393|NCT05410197|DRUG|Cisplatin|25mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
48337394|NCT04339322|OTHER|Follow up|Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
48495292|NCT01280409|DRUG|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
48495293|NCT01280409|DRUG|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
48495294|NCT00300625|PROCEDURE|Application of the San Francisco Syncope Rule|
48495295|NCT04555850|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.
48495296|NCT04555850|OTHER|Placebo|3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
47978209|NCT01087398|DRUG|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
47978210|NCT01087398|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
47978211|NCT01087398|DRUG|Cyclosporin, Methotrexate (GVHD prophylaxis)|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
47978212|NCT01405599|DRUG|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
47978213|NCT00636142|BIOLOGICAL|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
47978214|NCT00004482|DRUG|Cyclosporine|
47978215|NCT00004482|DRUG|methylprednisolone|
48337395|NCT04447924|DIETARY_SUPPLEMENT|Bif195|Daily intake of Bif195 dietary supplement
48337396|NCT04447924|OTHER|Placebo|Daily intake of Placebo
48495297|NCT04968665|DIAGNOSTIC_TEST|gait testing, functional MRI|diagnostic tests including the gait testing and functional MRI
47978216|NCT00004482|DRUG|Muromonab-CD3|
47978217|NCT00004482|DRUG|prednisone|
48495298|NCT01007565|PROCEDURE|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
48495299|NCT01262742|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
48495300|NCT01262742|DRUG|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
48130133|NCT06648785|DRUG|oxaliplatin|85 mg/m2 oxaliplatin
48130134|NCT06648785|DRUG|Fluoropyrimidine|oral fluoropyrimidine 1000mg/m2
48495301|NCT01262742|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
48495302|NCT01262742|DRUG|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
48130137|NCT06464692|DRUG|ABBV-400|Intravenous (IV) Infusion
48130138|NCT05517655|DRUG|129Xe|Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
48130139|NCT05672095|PROCEDURE|Biopsy|Undergo needle or core biopsy
48337397|NCT03023241|PROCEDURE|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
48337398|NCT02297646|BEHAVIORAL|Endurance Training|
48337399|NCT03777085|DRUG|TQB2303|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
48337400|NCT03777085|DRUG|Rituximab|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
48337401|NCT06262594|DRUG|Lemborexant|Drug is administered
48337402|NCT06262594|DRUG|Placebo|Drug is administered
48337403|NCT02840513|OTHER|Smartphone app/CO self-monitoring|Smartphone app and carbon monoxide self-monitoring (personal device)
48337404|NCT03785444|OTHER|WHODAS 2.0|WHO Disability Score
48337405|NCT03785444|OTHER|EQ5D|Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
48337406|NCT03785444|OTHER|IADL|The Lawton Instrumental Activities of Daily Living
48495303|NCT01262742|DRUG|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
48495304|NCT00123955|DRUG|Spironolactone|25mg tablet daily for 9 months
48337407|NCT03785444|OTHER|Barthel-Score|Barthel Score of the patient
48130140|NCT05672095|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48130141|NCT05672095|DRUG|Niraparib|Given PO
48130142|NCT05672095|OTHER|Questionnaire Administration|Ancillary studies
48130143|NCT05672095|DIETARY_SUPPLEMENT|Selenium|Given IV
48337408|NCT03785444|OTHER|SF-36|Short Form Health 36
48337409|NCT03785444|OTHER|MoCA Blind|Montreal Cognitive Assessment
48337410|NCT01024920|DRUG|BIBF 1120|VEGF inhibitor
47978218|NCT01023750|DRUG|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
48130144|NCT01815242|DRUG|nab-Paclitaxel|
48130145|NCT01815242|DRUG|Gemcitabine|
48130146|NCT01815242|DRUG|Carboplatin|
48130147|NCT02990481|BIOLOGICAL|TRK-950|Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
48130148|NCT02990481|BIOLOGICAL|TRK-950|"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"
48130149|NCT02990481|BIOLOGICAL|TRK-950|Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
48495305|NCT00123955|DRUG|Placebo|Placebo tablet daily for 9 months
48495306|NCT01233648|OTHER|rate control via CRT-D and AVN ablation|rate control
48337411|NCT01024920|DRUG|sunitinib|VEGF inhibitor
48337412|NCT04030949|OTHER|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
48337413|NCT03043846|OTHER|Follow-up every 3 months during 1 year (data collection in eCRF)|
48337414|NCT03043846|OTHER|Follow-up every month to follow the pre-defined strategy|
48337415|NCT03029676|DRUG|benzodiazepines|sedative
48337416|NCT03029676|DRUG|opioid|analgetic, sedative
48337417|NCT03029676|PROCEDURE|spinal anesthesia|
48337418|NCT03383627|DEVICE|Continuous Glucose Monitoring|"* The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~* CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
48337419|NCT06154499|PROCEDURE|Radical prostatectomy|Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
48337420|NCT00460629|PROCEDURE|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
48337421|NCT01617928|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
48130152|NCT06086054|BEHAVIORAL|Navigation and EMR referral to childcare facility|See arm description
48130153|NCT02957799|BEHAVIORAL|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
48130154|NCT02957799|BEHAVIORAL|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
48495307|NCT01233648|OTHER|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
48495308|NCT05219461|DRUG|Single dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
48495309|NCT05219461|DRUG|Single dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
48130158|NCT04436250|DRUG|Active comparator|The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
48337422|NCT01617928|DRUG|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
48337423|NCT01617928|DRUG|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
48495310|NCT05219461|DRUG|Single dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
48654395|NCT05902741|BEHAVIORAL|RiSE|RiSE provides participants with a platform to share the emotional impact of race-based stress and to offer supportive listening to their peers. Participants explicitly discuss the experiences they have as African American women, taking into account the ways which the interaction between their racial and gender identities shapes their experiences. Facilitators review difficulties associated with addressing racism and unique experiences of Black women at interpersonal and structural levels, and provide evidence of strategies to promote effective communication and internal emotional regulation regarding experiences of racism. Facilitators provide psychoeducation on intersectionality, structural racism, overt racism, microaggressions, and internalized racism. Following this education, facilitators help participants utilize cognitive-behavioral strategies to understand consequent thoughts, feelings, and actions associated with such experiences.
48130159|NCT04436250|DRUG|S-Ketamine Low dose|The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
48130160|NCT04436250|DRUG|S-Ketamine High dose|The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
48130161|NCT06383390|DRUG|Retatrutide|Administered SC
48130162|NCT06383390|DRUG|Placebo|Administered SC
48130163|NCT05115864|DEVICE|PFMT with device|The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
48495311|NCT05219461|DRUG|Multiple dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
48495312|NCT05219461|DRUG|Multiple dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
48495313|NCT05219461|DRUG|Multiple dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
48495314|NCT03047837|DRUG|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
48495315|NCT03047837|DRUG|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
48495316|NCT03047837|OTHER|Placebo|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
48495317|NCT05357092|DEVICE|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
48495318|NCT02902536|OTHER|No interventions|
48495319|NCT01633736|OTHER|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
48654396|NCT05902741|BEHAVIORAL|HEP|The HEP group will consist of classes focusing on wellness promotion. Expert speakers provide the HEP classes (e.g dietician, pharmacist).
48337424|NCT00706394|DEVICE|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
48337425|NCT01879813|DIETARY_SUPPLEMENT|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
48654397|NCT06639256|DRUG|Test Product HY07121|HY07121 should be administered intravenously at recommended dose.
48654398|NCT06640660|DEVICE|Mindlenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
48654399|NCT06640660|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
47978219|NCT05784064|BEHAVIORAL|Survey|This is a nationalwide survey developed in order to know the management of patients diagnosed of acute uncomplicated diverticulitis.
48130174|NCT05624450|DRUG|Tozorakimab|Single IV dose of tozorakimab on Day 1.
48130175|NCT05624450|DRUG|Placebo|Single IV dose of matching placebo on Day 1.
48130176|NCT03394105|DRUG|intrapleural docetaxel administration|intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
48130177|NCT06124963|DRUG|WX390|WX390 tablet, 0.9 mg once a day
48130178|NCT06124963|DRUG|Toripalimab|240 mg, Day 1, every 3 weeks
48130179|NCT05618574|DIETARY_SUPPLEMENT|210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)|The investigators propose to study the benefits nitrite therapeutics, using nitrate-rich beetroot juice to increase serum nitrite. The investigators hypothesize that increased nitrite will improve functional metrics and reduce fatigability in Veterans with long COVID as a result of enhanced skeletal muscle mitochondrial respiration. Participant will receive 210 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14 days vs the placebo.
48130185|NCT05140876|BEHAVIORAL|START mHealth Intervention|The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
48337426|NCT01879813|DIETARY_SUPPLEMENT|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
48130187|NCT05737121|DRUG|VNX001|VNX001 (alkalinized lidocaine HCl and heparin sodium)
48130188|NCT05737121|DRUG|Placebo|Inactive placebo for VNX001
48130189|NCT05737121|DRUG|Lidocaine|Alkalinized lidocaine hydrochloride
48130190|NCT05737121|DRUG|Heparin|Alkalinized heparin sodium
48495320|NCT05623943|PROCEDURE|Endovascular treatment|Patients treated with endovascular treatment, including balloon angioplasty alone and balloon angioplasty plus stenting.
48495321|NCT02603302|RADIATION|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
48130193|NCT06465485|DRUG|Benralizumab|Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be enrolled into this single arm treatment.
48495322|NCT02603302|PROCEDURE|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
48495323|NCT01714232|DEVICE|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48495324|NCT01714232|DEVICE|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48495325|NCT01714232|DEVICE|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48495326|NCT01714232|DEVICE|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48130199|NCT03234478|OTHER|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
48130202|NCT03238755|OTHER|Cardiac MRI/MRS|whole blood, plasma, and serum
48495327|NCT01714232|DEVICE|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
48495328|NCT05103189|OTHER|4D-flow sequence|all patients will be referred for a complete cardiac MRI exam with the addition of a 4D Flow sequence (does not require supplementary injection of a contrast agent and does not extend the duration of the examination) followed promptly (within the same hour) by a Doppler-echocardiography.
48130207|NCT05370287|OTHER|oxygen inhalation|Subjects will breath 100% oxygen through a mask.
48130208|NCT05370287|DEVICE|Adaptive optics imaging|Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
48130209|NCT05769413|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
48130211|NCT06648395|BEHAVIORAL|CBT Text Messages|CBT text messages will be sent 3 times per week for 4 weeks
48130212|NCT06648395|BEHAVIORAL|Supportive Messages|Supportive text messages will be sent 3 times per week for 4 weeks
48130213|NCT05500690|DIETARY_SUPPLEMENT|Folic Acid Tablet|5 mg folic acid supplement
48130214|NCT06355063|DEVICE|CellFX® nsPFA™ Cardiac Surgery System|Adult patients presenting to the investigational center that are to undergo non-emergent concomitant cardiac surgical procedure(s), scheduled to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, ascending aortic aneurysms, or coronary artery bypass procedures with history of documented atrial fibrillation within one year prior to enrollment will be evaluated for eligibility and participation in the study.
48130215|NCT06461286|DRUG|PYC-001|Single Group Assignment
48130216|NCT06211036|DRUG|Tarlatamab|Intravenous (IV) infusion
48130217|NCT06211036|DRUG|Durvalumab|IV infusion
48130218|NCT06563310|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with real neurofeedback and answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
48130219|NCT06563310|OTHER|fMRI with Sham-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with neurofeedback that looks similar to real neurofeedback but does not reflect their true brain signal. Afterwards, they will answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
48130220|NCT06312137|BIOLOGICAL|Sacituzumab tirumotecan|Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 40 weeks
48130221|NCT06312137|BIOLOGICAL|Pembrolizumab|Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
48337427|NCT02067533|PROCEDURE|soft tissue repair in flexion position|
48495329|NCT00630097|DRUG|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
48495330|NCT05116462|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
48495331|NCT05116462|DRUG|Carboplatin|AUC 5 or 6 mg/ml/min D1 IV Q3W
48495332|NCT05116462|DRUG|Paclitaxel|175 or 200 mg/m2 D1 IV Q3W
48495333|NCT05116462|DRUG|Sintilimab|200 mg D1 IV Q3W
47978220|NCT01266954|DRUG|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
47978221|NCT03354611|RADIATION|Contrast Enhanced Cone Beam Breast CT Scan|"* Pre-contrast scan~* Begin contrast injection (and saline chaser)~* Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)"
47978222|NCT03354611|DRUG|Contrast Dye, Iodinated|"1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement."
47978223|NCT05427253|DRUG|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
47978224|NCT05427253|DRUG|Placebo|Placebo for C106 solution
47978225|NCT00188149|DRUG|Combined chemotherapy (ABVD, BACOPP-D)|
47978226|NCT00188149|PROCEDURE|Radiation therapy|
47978227|NCT05236569|DRUG|Tranexamic acid injection|The tranexamic acid injection was given intradermally to the facial skin
48495334|NCT05116462|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
48495335|NCT05116462|DRUG|Nab paclitaxel|100 mg/m2 D1, 8, 15 IV Q3W
48495336|NCT05116462|DRUG|Placebo|20 ml D1 IV Q3W
48495337|NCT00105976|DRUG|MM-093|
48495338|NCT00005595|DRUG|arsenic trioxide|
48654400|NCT06570070|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
48337428|NCT02067533|PROCEDURE|soft tissue repair in extension position|
48654401|NCT06570070|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
48654402|NCT06570070|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
47978228|NCT05236569|DRUG|Injection Water|The 0.9% normal saline injection was given intradermally to the facial skin
47978229|NCT04276597|DRUG|177Lu-DOTATOC|177Lu labeled somatostatin receptors targeting ligand
47978230|NCT05822713|DRUG|Amisulpride|5mg/2ml
47978231|NCT05822713|DRUG|Amisulpride Placebo|2ml
47978232|NCT03382145|OTHER|No intervention|No intervention
47978233|NCT03981211|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
47978234|NCT03981211|DRUG|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
47978235|NCT05568472|OTHER|Best Practice|Standard of care hormone therapy and standard visit with clinician
47978236|NCT05568472|PROCEDURE|Biospecimen Collection|Undergo correlative studies
47978237|NCT05568472|PROCEDURE|Endocrine Drug Therapy|Undergo endocrine therapy
47978238|NCT05568472|BEHAVIORAL|Health Education|Receive list of websites
47978239|NCT05568472|OTHER|Questionnaire Administration|Ancillary studies
48337429|NCT03883490|DIAGNOSTIC_TEST|ECG|A 12-lead ECG will be taken for each participant.
48337430|NCT03883490|DIAGNOSTIC_TEST|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
48337431|NCT03883490|DIAGNOSTIC_TEST|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
48337432|NCT03883490|DIAGNOSTIC_TEST|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
48337433|NCT03883490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
48337434|NCT01085019|DIETARY_SUPPLEMENT|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
48337435|NCT01085019|DIETARY_SUPPLEMENT|Oregano|2.8g/day of oregano in capsules during 4 weeks.
48337436|NCT01085019|DIETARY_SUPPLEMENT|Ginger|2.8g/day of ginger in capsules during 4 weeks.
48337437|NCT01085019|DIETARY_SUPPLEMENT|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
48337438|NCT01085019|DIETARY_SUPPLEMENT|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
48337439|NCT01085019|DIETARY_SUPPLEMENT|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
48337440|NCT01947894|OTHER|Non Interventional Study|Non Interventional Study
48337441|NCT00802867|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
48337442|NCT00553657|DRUG|DETROL LA (drug)|
48337443|NCT01484561|DRUG|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
48337444|NCT01484561|DRUG|Placebo|Placebo BID orally, approximately 72 days
48337445|NCT04182906|BEHAVIORAL|Care Coordination|Screening and referral for basic needs and adult mental health
48337446|NCT04182906|BEHAVIORAL|Resiliency Clinic|Mindfulness-based caregiver-child group medical care
48337447|NCT04182906|BEHAVIORAL|Usual Care|Usual Primary Pediatric Care
48337448|NCT06185478|DIAGNOSTIC_TEST|MRI scan|MRI scan
48337449|NCT00142402|DRUG|Modafinil|
48130222|NCT06312137|DRUG|Cisplatin|Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
47978240|NCT05568472|OTHER|Symptom Specific Assessment Tool|Receive a weblink via email or text message and asked 6 brief questions about symptoms
47978241|NCT00814190|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
48337450|NCT05099536|DRUG|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
48337451|NCT04104373|OTHER|Observational Cohort|
48337452|NCT03986242|DEVICE|rolling|use non- vibration rolling and the total time is 20 minutes.
48337453|NCT03986242|DEVICE|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
48337454|NCT03986242|OTHER|static stretching|static stretching and the total time is 20 minutes.
48337455|NCT01476761|DEVICE|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
48130223|NCT06312137|DRUG|Pemetrexed|Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
48337456|NCT03583788|BEHAVIORAL|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
48337457|NCT03583788|OTHER|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
48337458|NCT03422640|DRUG|Apremilast|Open label treatment with apremilast
48337459|NCT02186457|DRUG|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
48337460|NCT02186457|OTHER|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
48495339|NCT05889468|DRUG|Aspirin 81Mg Ec Tab|Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
48495340|NCT05889468|DRUG|Placebo|Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
48495341|NCT01850095|DRUG|treatment azelaic acid (azelan)|treatment for 6 months
48495342|NCT01850095|DRUG|dorspirenone/ethynil estradiol|
48495343|NCT04068649|RADIATION|Palliative Radiation Therapy|Undergo palliative RT
48495344|NCT04068649|OTHER|Quality-of-Life Assessment|Ancillary studies
48654403|NCT06570070|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
48130224|NCT06312137|DRUG|Gemcitabine|Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
48495345|NCT04068649|OTHER|Questionnaire Administration|Ancillary studies
48654404|NCT06570070|BEHAVIORAL|Counselor individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
48130225|NCT06312137|DRUG|Carboplatin|Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
48337461|NCT04202276|OTHER|diet assessment|Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
48337462|NCT04690712|BEHAVIORAL|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
48337463|NCT04968353|DEVICE|Incisally-beveled attachment|Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
48337464|NCT04968353|DEVICE|Gingivally-beveled attachment|Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
48337465|NCT04968353|DEVICE|Optimized attachment|Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
48337466|NCT04968353|DEVICE|Horizontal attachment|Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
48337467|NCT04777474|DIAGNOSTIC_TEST|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
48337468|NCT04777474|DIAGNOSTIC_TEST|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
48337469|NCT04777474|DIAGNOSTIC_TEST|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
48495346|NCT04068649|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48654405|NCT04725513|DEVICE|Shockwave Therapy|Participants will receive shockwave therapy once a week for three weeks
48654406|NCT04725513|DEVICE|Photobiomodulation Therapy|Participants will receive photobiomodulation therapy twice a week for three weeks
48654407|NCT04725513|OTHER|Physical Therapy|Participants will enroll in physical therapy and complete an at-home exercise protocol
48654408|NCT06639321|DEVICE|Percutaneous Ventricular Assist System|Percutaneous Ventricular Assist System provides intraoperative circulatory support during high-risk PCI.
48654409|NCT06639321|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO provides intraoperative circulatory support during high-risk PCI.
48654410|NCT06322901|PROCEDURE|Flap|Different flap designs for implant placement
48337470|NCT01153893|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
48337471|NCT01153893|BIOLOGICAL|InfanrixTM|Intramuscular injection, 1dose
47978242|NCT02455622|DRUG|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
47978243|NCT01571427|BEHAVIORAL|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
47978244|NCT01571427|BEHAVIORAL|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
47978245|NCT04042337|BEHAVIORAL|Pivotal Response Treatment|PRT will target functional communication abilities
47978246|NCT01018186|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
47978247|NCT01018186|DRUG|Fluticasone propionate|Inhaled corticosteroid
48337472|NCT02818413|OTHER|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
48337473|NCT02062242|OTHER|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
48337474|NCT02062242|OTHER|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
48337475|NCT02062242|OTHER|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
47978248|NCT05781607|COMBINATION_PRODUCT|Patient education combined with drug therapy|Receive a health education by a specialist therapist, including explaining the anatomy and function of TMJ; Explain the etiology, prognosis, treatment plan and prognosis of TMD; Correct the patients' daily oral habits, such as unilateral chewing, habitual clenching, eating too much hard food, etc; Instruct the patient to understand the rest position of the temporomandibular joint and correct the bad posture of the neck and shoulder. At the same time, corresponding medication should be given, and NSAIDS should be taken orally or externally for patients with pain.
47978249|NCT05781607|COMBINATION_PRODUCT|Individualized comprehensive physical therapy|Physical factor therapy and/or manual therapy
47978250|NCT03746873|BEHAVIORAL|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
47978251|NCT03548909|DIAGNOSTIC_TEST|VITROS Immunodiagnostic Products|NT-proBNP II assay
47978252|NCT06048445|DEVICE|intraoperative plancement of Biliary Drainage Stent|plancement of Biliary Drainage Stent in liver transplantation of pediatric patients
47978253|NCT05996198|DEVICE|Oculus Rift headset|The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.
48337476|NCT02062242|OTHER|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
48130226|NCT06312137|DRUG|Paclitaxel|Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
48337477|NCT02539719|DRUG|SC-003|
48337478|NCT02539719|DRUG|SC-003 in combination with ABBV-181|
48337479|NCT02097485|DRUG|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
48654411|NCT04023058|PROCEDURE|Mitral surgery|Guidelines approved mitral surgery
48495347|NCT05027243|PROCEDURE|bilateral temporomandibular joint arthroscopy|The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.
48495348|NCT05027243|DRUG|Xeomin® (Merz)|For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
48495349|NCT05132036|OTHER|lung ultrasound|"Subjects are enrolled during their usual session in the hemodialysis unit of the Amiens University Hospital. Before starting the hemodialysis, lung ultrasound according to the 8 sites score and a measure of bioimpedance will be performed in dorsal decubitus. In a 2nd time, an echocardiography is realized. During haemodialysis session, biological analysis and clinical score will be assessed"
48495350|NCT00697684|DRUG|Antithymocyte Globulin|
48495351|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
48495352|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
48495353|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
48495354|NCT02508753|DRUG|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
47978254|NCT05996198|DEVICE|Exoskeleton Device|The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
47978255|NCT04508244|DRUG|Placebo|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
47978256|NCT04508244|DRUG|Propranolol|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
47978257|NCT03280420|PROCEDURE|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
48495355|NCT02508753|DRUG|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
48495356|NCT02508753|DRUG|Moxifloxacin|400 mg tablet
48495357|NCT02508753|DRUG|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
48130229|NCT04797767|DRUG|Cladribine|Given IV
48130230|NCT04797767|DRUG|Cytarabine|Given IV
48130231|NCT04797767|DRUG|Mitoxantrone|Given IV
48130232|NCT04797767|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
48130233|NCT04797767|DRUG|Venetoclax|Given PO
48130234|NCT03890289|DRUG|Idelalisib|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
48130235|NCT03890289|DRUG|Obinutuzumab|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
48130236|NCT06064097|PROCEDURE|Biopsy|Undergo tissue biopsy
48130237|NCT06064097|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
48130238|NCT06064097|PROCEDURE|Chest Radiography|Undergo chest x-ray
48130239|NCT06064097|DRUG|Cisplatin|Given IV
48337480|NCT02097485|DRUG|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
48337481|NCT05966493|DRUG|lufepirsen|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
48337482|NCT05966493|DRUG|Vehicle|Matching vehicle without lufepirsen.
48337483|NCT06380764|PROCEDURE|Greater Occipital Nerve Block|"The occipital artery was localized, while the patient was setting with flexed neck, at the point of meeting of the medial third and the lateral two-thirds of a line drawn extending from the ipsilateral mastoid process to the external occipital protuberance and the GON was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline.~For assurance of GON localization, pressure was applied and the resultant tenderness indicated the site of the nerve. Injection procedure was performed as distal injection at the site of nerve localization and proximal injection was performed at 1.5 cm lateral to the sagittal plane and 3 cm below to the level of the external occipital protuberance."
48337484|NCT06380764|PROCEDURE|Bilateral suboccipital intramuscular injection|Sub-occipital intramuscular injection of the prepared solution was carried out on both sides while the patient was setting with maximally flexing the neck to expose these muscles.
48337485|NCT06380764|PROCEDURE|Epidural Blood Patch|Patients showed manifestations of block failure within 24-h after block, received lumbar Epidural blood patch under non-invasive monitoring in the theater. Patient was positioned in the lateral decubitus position, lumbar area was sterilized and the epidural space previously used for receiving the previous neuraxial anesthesia was identified. Fifteen ml of venous blood was obtained aseptically and slowly injected while patient was monitored for the extent of pain severity until complete pain relief.
48337486|NCT06380764|DRUG|Normal Saline 10 mL Injection|Placebo drug
48337487|NCT06380764|DRUG|Lidocaine 2% Injectable Solution|Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration
48337488|NCT05319223|BEHAVIORAL|patient blood management|three pillars of patient blood management will be applied
48337489|NCT05982145|OTHER|Individual interviews|Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems
48337490|NCT05982145|OTHER|Focus groups|Identify facilities and difficulties in link with the prescription and implementation of the compression therapy everyday
48337491|NCT05982145|OTHER|Questionary and measures|To take measurement of patients who lives in institution or at their home and take measure of hydration and some other measures like the Group Iso Resource (GIR) and the capacity of the person to getting out of the bed.
48337492|NCT06277583|BEHAVIORAL|Urban care farming|An intervention curriculum has been designed using horticulture therapy combined with urban farming techniques. The sessions will use plants and interaction with nature to engage and rehabilitate participants. Both the intervention and control group participants will undergo the intervention. But the intervention group will start with the urban care farming intervention first, and the control group will follow once the intervention group completes the program.
48337493|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
48337494|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
48337495|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder \[moderate or severe pain 15 minutes after dose\] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
48337496|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
48337497|NCT05825092|DRUG|Androgel Topical Product|AndroGel® will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. AndroGel® will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, AndroGel® will be administered in hospital wards to complete the 28 days of treatment or until hospital discharge
48337498|NCT05825092|DRUG|Placebo|Placebo gel will be applied daily to the upper arms/shoulders at 9:00 am. The daily dose will be 101.25 mg in men and 20.25 mg in women. Placebo gel will be administered within 24 hours after inclusion for a period of 28 days or until hospital discharge. For patients discharged from ICU before day 28, Placebo gel will be administered in hospital wards to complete the 28 days of
48337499|NCT05825092|DIAGNOSTIC_TEST|Physical performance|"Physical performance at 3, 6 months and 1 year after ICU admission~6 minute walk distance 3 months after ICU admission, at 6 months and at 1 year Percentage of patients with Short Physical Performance Battery \< 10 at 3, 6 months and 1 year Physical component of SF 36 (Medical Outcomes Study 36 Item Short Form Health Survey) at 3, 6 months and 1 year"
48337500|NCT05825092|DIAGNOSTIC_TEST|Muscle strength|"Muscle strength at ICU discharge at 3, 6 months and 1 year after ICU admission~Handgrip: Kg and percent of the predicted force Medical Research Council testing (MRC)"
48337501|NCT05825092|DIAGNOSTIC_TEST|Muscular mass|"Muscular mass at 3, 6 months and 1 year after ICU admission~Mid-arm muscle circumference (MAMC)"
48337502|NCT05825092|DIAGNOSTIC_TEST|Test: Functional status|"Functional status at 3, 6 months and 1 year after ICU admission~• Composite score of 11 items of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)"
48337503|NCT05825092|DIAGNOSTIC_TEST|Oxygen muscular consumption|"Oxygen muscular consumption at ICU discharge and at 3 months after ICU admission~Ventilation free days at day 28 Length of stay in ICU Length of stay in hospital Mortality rate at day 28 Mortality rate at day 90 ICU mortality rate Hospital mortality rate"
48337504|NCT04018157|DRUG|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
48337505|NCT05405218|DEVICE|CTR-US|Carpal Tunnel Release with Ultrasound Guidance
48337506|NCT05405218|PROCEDURE|mOCTR|Mini Open Carpal Tunnel Release
48337507|NCT04982419|DEVICE|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
48337508|NCT04982419|DEVICE|Sham remote ischemic conditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
48495358|NCT02187510|PROCEDURE|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
48495359|NCT02187510|PROCEDURE|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
48495360|NCT02767830|BEHAVIORAL|Excercise and Nutrition Program|
48495361|NCT01921530|PROCEDURE|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
48495362|NCT01921530|PROCEDURE|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
48495363|NCT04406597|DEVICE|the New Tissue Containment System|Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
48495364|NCT01412372|DRUG|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
47978258|NCT03280420|PROCEDURE|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
47978259|NCT00352144|DRUG|Eszopiclone|Eszopiclone 3 mg
48495365|NCT01412372|DRUG|Placebo|This is an inactive pill
48495366|NCT03035721|DIETARY_SUPPLEMENT|Low protein formula|Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
48495367|NCT03035721|DIETARY_SUPPLEMENT|Standard protein formula|Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
48337509|NCT00158405|PROCEDURE|Structured Treatment Interruption|
48337510|NCT00158405|DRUG|Zidovudine (ZDV)|
48337511|NCT00158405|DRUG|Lamivudine (3TC)|
48337512|NCT00158405|DRUG|Efavirenz (EFV)|
48337513|NCT00158405|DRUG|Ritonavir (NRV)|
48337514|NCT00158405|DRUG|Indinavir (IDV)|
48337515|NCT00279032|DRUG|GW406381|
48337516|NCT00415519|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
48337517|NCT00415519|DRUG|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
48337518|NCT02379611|PROCEDURE|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
48337519|NCT04095468|RADIATION|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
47978260|NCT00352144|DRUG|Placebo|Placebo tablet
48130240|NCT06064097|PROCEDURE|Computed Tomography|Undergo CT
48130241|NCT06064097|PROCEDURE|Echocardiography|Undergo ECHO
48130242|NCT06064097|OTHER|Electronic Health Record Review|Ancillary studies
48130243|NCT06064097|OTHER|Fluciclovine F18|Given IV
48130244|NCT06064097|DRUG|Gemcitabine|Given IV
48130245|NCT06064097|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48130246|NCT06064097|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48130247|NCT06064097|BIOLOGICAL|Nivolumab|Given IV
47978261|NCT01032642|DEVICE|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
48130248|NCT06064097|PROCEDURE|Positron Emission Tomography|Undergo PET
48337520|NCT05182125|BIOLOGICAL|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
48337521|NCT05182125|BIOLOGICAL|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
48337522|NCT05182125|BIOLOGICAL|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
48337523|NCT05182125|BIOLOGICAL|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
48337524|NCT05182125|BIOLOGICAL|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
48337525|NCT06195904|OTHER|NA (No intervention)|NA (No intervention)
48337526|NCT01729663|BIOLOGICAL|CSF470 vaccine, BCG, Molgramostim|
48654412|NCT06317987|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients follow up on substance use treatment plans that are established by care coordinators in the health system by reducing barriers to accessing treatment. This includes advocating for patients to reduce disparities based on language, income or geographical barriers, and cultural preferences (i.e., linkage to available services); and using motivational enhancement techniques to help patients maintain their motivation to obtain substance use treatment while working through these barriers (i.e., motivational intervention). Thus, the care navigator's role is to take the care plan developed between the patient and the mental health care coordinator forward and connect the patient to available services and provide motivational enhancement techniques to help direct the patient toward completion of the care plan.
48654413|NCT05983705|BEHAVIORAL|AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.|The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
48654414|NCT05520736|BEHAVIORAL|Appointment reminders, motivational interviewing and targeted vaccine drives|Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence
48654415|NCT05942222|BIOLOGICAL|dupilumab|Subcutaneus injections in standard doses, i.e. 300 mg s.c. every 2 weeks.
48654416|NCT05942222|BIOLOGICAL|mepolizumab|Subcutaneus injections in standard doses, i.e. 100 mg s.c. every 4 weeks.
48654417|NCT05510167|BEHAVIORAL|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
47978262|NCT05798429|OTHER|compassion education|6 weeks of compassion training
48130249|NCT06064097|OTHER|Quality-of-Life Assessment|Ancillary studies
48130250|NCT06064097|OTHER|Questionnaire Administration|Ancillary studies
48130251|NCT06064097|RADIATION|Radiation Therapy|Receive radiation therapy
48337527|NCT01729663|DRUG|interferon alpha 2b|
48337528|NCT05107518|BEHAVIORAL|Children Participation Assessment Scale|Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
48130252|NCT06064097|PROCEDURE|X-Ray Imaging|Undergo dental x-ray
48495368|NCT03996642|BEHAVIORAL|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
48495369|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
48337529|NCT01999023|DIETARY_SUPPLEMENT|Low protein formula group|Low protein formula formula (28.5 g) twice a day
48495370|NCT00639847|BEHAVIORAL|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
48130256|NCT04815993|DRUG|SYN-020 delayed release capsule|SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
47978263|NCT06476561|OTHER|- Sociodemographic Assessment - Psychological Assessment - Quality of Life Assessment - D|"The study involves several assessments to evaluate the impact of various factors on dual-task performance in elderly individuals:~1. Sociodemographic Assessment: Collection of data on age, gender, education, income, marital status, and other relevant factors.~2. Psychological Assessment: Use of the Depression Anxiety Stress Scales-21 (DASS-21) to measure levels of depression, anxiety, and stress.~3. Quality of Life Assessment: Utilization of the World Health Organization Quality of Life Brief Form (WHOQOL-BREF) to assess physical health, psychological health, social relationships, and environment.~4. Dual-Task Performance Evaluation: Measurement of the ability to perform a cognitive task (counting backward by threes) simultaneously with a motor task (Nine-Hole Peg Test). The dual-task cost (DTC) is calculated to quantify the impact of cognitive load on motor performance."
48495371|NCT03698448|DRUG|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
48495372|NCT01662349|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
48495373|NCT00784186|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
48495374|NCT00784186|DRUG|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
48495375|NCT00784186|DRUG|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
48337530|NCT03284021|DEVICE|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
48337531|NCT04463446|BEHAVIORAL|Use of the CHD app|Use of the CHD app
48337532|NCT04463446|BEHAVIORAL|Nurse-led intervention|Teaching session with clinic nurse
48337533|NCT00188357|BEHAVIORAL|Education|
48337534|NCT00647972|DRUG|Olanzapine Tablets 20 mg|20mg, single dose fasting
48337535|NCT00647972|DRUG|Zyprexa® Tablets 20 mg|20mg, single dose fasting
48495376|NCT03804502|DEVICE|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
48495377|NCT02241421|DRUG|Amoxicillin|
47978264|NCT04342364|OTHER|Vitrification via slush nitrogen|oocytes will be vitrified using slush nitrogen
48495378|NCT02241421|DRUG|Vancomycin|
48495379|NCT02241421|OTHER|Placebo|
48495380|NCT01939496|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
47978265|NCT04342364|OTHER|Vitrification via liquid nitrogen|oocytes will be vitrified using liquid nitrogen which is currently routine practice
47978266|NCT01324999|DRUG|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
47978267|NCT05796297|DEVICE|Transcutaneous Capnography|Transcutaneous Capnography will be realized at patient home to monitoring nocturnal concentration of carbon dioxide during nocturnal sleeping ventilation
47978268|NCT01868685|DRUG|BYM338|BYM338
48495381|NCT01939496|DRUG|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
48495382|NCT00495547|DRUG|Azacitidine|Azacitidine
48495383|NCT00495547|DRUG|Beta Erythropoietin|Beta Erythropoietin
47978269|NCT01868685|DRUG|Placebo|Placebo
47978270|NCT01384968|DIETARY_SUPPLEMENT|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
48495384|NCT03155386|OTHER|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~* The intensity of lesion enhancement~* The presence and type of artefacts on the recombined images.~* The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
47978271|NCT06381882|PROCEDURE|Pancreatic resection|Any kind of pancreatic resection will be included
47978272|NCT04057391|DIAGNOSTIC_TEST|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
47978273|NCT03874247|DRUG|pelubiprofen 45mg|bid for 3 days after meal
47978274|NCT03874247|DRUG|pelubiprofen placebo|bid for 3 days after meal
47978275|NCT03847233|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
48495385|NCT03052959|BEHAVIORAL|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
48495386|NCT03052959|OTHER|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
48495387|NCT03253835|DIAGNOSTIC_TEST|Single Group Assignment|
47978276|NCT01523860|DRUG|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
47978277|NCT04378751|BEHAVIORAL|Decision aid video|Decision aid video
47978278|NCT04378751|BEHAVIORAL|Genetic counseling informational brochure|Genetic counseling informational brochure
47978279|NCT03186222|DIAGNOSTIC_TEST|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
48130276|NCT04259047|BEHAVIORAL|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
48130277|NCT04259047|BEHAVIORAL|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
48130278|NCT05805826|BIOLOGICAL|C. difficile vaccine (previously studied formulation).|Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
48130279|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 1.|C. difficile vaccine formulation 1 given as an intramuscular injection
48130280|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 2.|C. difficile vaccine formulation 2 given as an intramuscular injection
48337536|NCT05940441|DRUG|Capecitabine 500Mg Oral Tablet|650 mg/m² body surface area twice daily for 1 year
48337537|NCT01647425|BEHAVIORAL|physician assessment|"* Socio-economic conditions and general features: educational level, professional status...~* Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~* in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~* Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~* Assessment of current use of cannabis using the Cannabis Abuse Screening Test~* Psychiatric assessment using the MINI 5.0"
48337538|NCT01320813|PROCEDURE|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
48337539|NCT01320813|PROCEDURE|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
48337540|NCT02306161|DRUG|Cyclophosphamide|Given IV
48337541|NCT02306161|DRUG|Doxorubicin|Given IV
48495388|NCT03320421|RADIATION|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used."
48495389|NCT00537420|DRUG|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
48495390|NCT00537420|DRUG|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
47978280|NCT02366520|DEVICE|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
47978281|NCT05104892|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
47978282|NCT05104892|DRUG|placebo|Pharmaceutical form: Tablet Route of administration: Oral
47978283|NCT01733771|OTHER|CAM treatments|CAM treatments last 10-30 minutes
47978284|NCT05830851|OTHER|real tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters
47978285|NCT05830851|OTHER|sham tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
47978286|NCT02281461|DEVICE|Male circumcision using a non-surgical device|Male Circumcision
47978287|NCT02573857|DRUG|DSM265|Oral suspension from bulk powder
47978288|NCT02573857|DRUG|OZ439|Oral suspension from powder in a bottle
47978289|NCT02395380|OTHER|C-reactive protein dosage|
47978290|NCT04225611|DRUG|Dexamethasone|The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
47978291|NCT03383172|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
47978292|NCT03381846|PROCEDURE|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
48130281|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 3.|C. difficile vaccine formulation 3 given as an intramuscular injection
48130282|NCT05805826|OTHER|Saline Placebo.|0.9% sodium chloride solution given as an intramuscular injection
48495391|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
48495392|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
48266605|NCT06348082|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|MBTI will be administered in 8 weekly sessions. Session 1 consists of introductions and an overview. Subsequent sessions consist of mindfulness concepts/practice and behavioral strategies for sleep. Each session will begin with guided formal meditation followed by discussion. Mindfulness practice (at home) expectations are 30-45 minutes of meditation/day at least 5 days during the period of the intervention, followed by 20 minutes/day until the final follow-up assessment (at 16 weeks). Mindfulness concepts: Overview of Mindfulness, Mindfulness of the Body, Obstacles to Mindfulness,Working with Difficult Emotions, Cultivating Positive Emotions, Working with Difficult Thoughts, Mindful Interactions.
48266606|NCT01903499|OTHER|Other: Bean patty|
48266607|NCT01903499|OTHER|Other: Beef patty|
48337542|NCT02306161|DRUG|Doxorubicin Hydrochloride|Given IV
48337543|NCT02306161|DRUG|Etoposide|Given IV
48337544|NCT02306161|DRUG|Etoposide Phosphate|Given IV
48337545|NCT02306161|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48337546|NCT02306161|BIOLOGICAL|Ganitumab|Given IV
48337547|NCT02306161|DRUG|Ifosfamide|Given IV
48337548|NCT02306161|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
48337549|NCT02306161|PROCEDURE|Therapeutic Surgical Procedure|Undergo surgery
48337550|NCT02306161|DRUG|Vincristine|Given IV
48337551|NCT02306161|DRUG|Vincristine Sulfate|Given IV
48495393|NCT00537420|DRUG|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
48495394|NCT00537420|DRUG|Sibutramine|Sibutramine will be taken once daily with or without food
48495395|NCT00643565|DRUG|Standard chemotherapy|As prescribed
48495396|NCT00643565|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
48495397|NCT04390295|DRUG|Placebo|Once daily, 24 weeks
48495398|NCT04390295|DRUG|SHR3824|Once daily, 52 weeks
48495399|NCT04390295|DRUG|metformin|Three times daily, 52 weeks
48495400|NCT00006466|DRUG|beta alethine|
48495401|NCT02671227|DRUG|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
48495402|NCT02671227|DRUG|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
48337552|NCT05004519|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine or remifentanil during laparoscopic gastric bypass
17045547|NCT06361849|DEVICE|Trocar Placement Assist Device (TPAD)|The TPAD is an experimental device used to assist with placement of Veress needle and trocar during laparoscopic surgery.
48337553|NCT05004519|DRUG|Remifentanil|dexmedetomidine or remifentanil during laparoscopic gastric bypass
48337554|NCT00425126|DRUG|Epoetin Alfa|
48337555|NCT03527771|DEVICE|Video-assisted CPR|Emergency call using a Software capable of video Transmission for Video assistance in CPR
48337556|NCT03527771|DRUG|telephone-assisted CPR|Emergency call with telephone assistance in CPR
48337557|NCT00321009|DRUG|Enoxaparin|
48495403|NCT00678041|DRUG|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
48495404|NCT00678041|DRUG|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
48495405|NCT02253030|DEVICE|Optical Coherence Tomography|
48495406|NCT04400331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
48495407|NCT01415765|DRUG|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
48495408|NCT01415765|DRUG|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
48495409|NCT01415765|DRUG|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
48495410|NCT01415765|DRUG|Vincristine|CIV on days 1-4 of every 21 day cycle
47978293|NCT03381846|PROCEDURE|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
47978294|NCT02573311|DRUG|tamsulosin hydrochloride|
47978295|NCT03633682|BEHAVIORAL|Headspace - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
47978296|NCT03633682|BEHAVIORAL|Stop, Breathe, & Think - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
48266608|NCT06444646|OTHER|Adipose tissue biopsy|From each patient, two biopsies will be taken during surgery; one from the subcutaneous and one from the visceral adipose tissue.
48495411|NCT01415765|DRUG|Cyclophosphamide|IV on day 5 of each 21 day cycle
47978297|NCT02733068|BIOLOGICAL|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
47978298|NCT02733068|BIOLOGICAL|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
47978299|NCT00002416|DRUG|Emtricitabine|
47978300|NCT00002416|DRUG|Lamivudine|
48266609|NCT06444646|OTHER|Blood sampling|From each patient, two venous blood samples (citrate, LiHe and EDTA plasma) will be taken before surgery.
48266610|NCT06444646|OTHER|Questionnaire|Before bariatric surgery, every patient will fill out questions about general health (physical activity, sedentary behavior, sleeping pattern, ...), physical condition before surgery (nausea, food intake, ...), etc.
48266611|NCT06444646|OTHER|Patient phenotyping|Length and weight will be measured to calculate body mass index (BMI). Waist and hip circumference will be assessed, as well as blood pressure (both systolic and diastolic) and heart rate at rest. Body composition will be determined using a bioelectrical impedance analysis (BIA) in the hospital. Medication use and comorbidities (that are allowed within the in-/exclusion criteria) will also be derived from the patient's medical files with patient's permission.
48266612|NCT02901431|DRUG|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
48266613|NCT02901431|DRUG|RO5285119|Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
48495412|NCT01415765|DRUG|Doxorubicin|CIV on days 1-4 of each 21 day cycle
48495413|NCT01415765|DRUG|Rituximab|IV on day 1 of each 21 day cycle
48495414|NCT01415765|DRUG|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
48266614|NCT03029013|DRUG|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
48266615|NCT02594488|DEVICE|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
48266616|NCT03088865|DIAGNOSTIC_TEST|aspirating first blood volume into a regular blood collection tube|order of blood drawing
48266617|NCT02673645|OTHER|SAGA Innovations|An intensive math tutoring program.
48266618|NCT04417829|DEVICE|Biological prosthesis in the aortic valve|Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
48266619|NCT02312947|DEVICE|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
48266620|NCT02312947|DEVICE|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
48337558|NCT06300567|OTHER|data collection|"collection of data of generated by real world follow up"
47978301|NCT04320446|BEHAVIORAL|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
47978302|NCT04320446|BEHAVIORAL|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
48654418|NCT03925246|DRUG|Nivolumab|"Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity."
47978303|NCT00020475|DRUG|gp100 antigen|
47978304|NCT00020475|DRUG|interleukin-2|
48337559|NCT05455736|OTHER|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
48654419|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol|Patients would begin taking myoinositol upon recruitment
48654420|NCT06575868|DIETARY_SUPPLEMENT|Myo-inositol placebo|Patients would begin taking placebo upon recruitment
48654421|NCT05442879|BEHAVIORAL|Knowledge Translation Intervention|The KT intervention utilizes the communications between the teams and the researchers to promote implementation of the ACL-IPPs. The meetings will provide opportunities for mutually beneficial learning from the researchers, and feedback from the coaches on how to best implement strategies through local barriers in order to facilitate necessary changes to promote ACL-IPP usage while adhering to clinical practice guideline recommendations.
48654422|NCT05442879|BEHAVIORAL|Educational handout|Educational handout describing a commonly cited ACL-IPP.
48654423|NCT04974398|DRUG|Penpulimab|Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.
48654424|NCT04974398|DRUG|placebo|Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per treatment cycle and then followed by placebo monotherapy as maintenance treatment, Q3W. Subjects in Arm B will have the opportunity to crossover to open-label treatment with penpulimab monotherapy after radiographic disease progression.
48654425|NCT04007679|OTHER|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
48654426|NCT05849844|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure
48654427|NCT05677347|DRUG|GSK3923868|GSK3923868 will be administered
48654428|NCT05677347|DRUG|Placebo|Placebo will be administered
48654429|NCT04025957|DRUG|SHR-1501|Administered subcutaneously
48654430|NCT00802503|DIETARY_SUPPLEMENT|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is \< 60% of energy target in order to reach 100% of energy target by peripheral or central line.
47978305|NCT00020475|DRUG|MART-1 antigen|
47978306|NCT00020475|DRUG|Montanide ISA-51|
47978307|NCT02292979|DRUG|Doxorubicin|25mg/m2
47978308|NCT02292979|DRUG|Bleomycin|10mg/m2
47978309|NCT02292979|DRUG|Vinblastine|6mg/m2
48266621|NCT02494596|DRUG|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
47978310|NCT02292979|DRUG|Dacarbazine|375mg/m2
47978311|NCT02292979|DRUG|Brentuximab Vedotin|1.2 mg/kg
47978312|NCT03476694|PROCEDURE|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
47978313|NCT01842698|DEVICE|ultrasoundguided paravertebral catheter|
48266622|NCT02494596|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
48266623|NCT02320487|DRUG|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.
48266624|NCT02320487|DRUG|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
48266625|NCT01502904|DEVICE|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
48654431|NCT06585891|BIOLOGICAL|VRC-HIVMAB0121-00-AB|The CAP256J3LS bispecific antibody (bsAb) targets the V2-apex and CD4-binding sites of the HIV-1 envelope. It is composed of CAP256V2LS antibody with the light chain linked to the llama nanobody J3, which has broad CD4-binding site-directed neutralization.
48337560|NCT00045812|DRUG|SCH-58235|
48337561|NCT01938001|DRUG|Rituximab|Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
48337562|NCT01938001|DRUG|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
48337563|NCT01938001|DRUG|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
48337564|NCT00966069|OTHER|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
48337565|NCT00966069|OTHER|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
48337566|NCT01223768|DRUG|Acetyl-l-Carnitine|2g per day
47978314|NCT00459953|DRUG|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
47978315|NCT02156596|DRUG|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
48495415|NCT00080938|DRUG|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
48654432|NCT04511494|DIETARY_SUPPLEMENT|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
48337567|NCT01223768|DRUG|placebo|twice per day
48337568|NCT00706615|BIOLOGICAL|Ad-sig-hMUC-1/ecdCD40L vaccine|
48337569|NCT00426933|DRUG|Daptomycin|
48337570|NCT00426933|DRUG|Vancomycin|
48337571|NCT01661309|DIETARY_SUPPLEMENT|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
48337572|NCT01661309|DIETARY_SUPPLEMENT|Methylcobalamin|Aimed at reducing plasma tHcy.
48337573|NCT00385463|DRUG|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
48495416|NCT00080938|RADIATION|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
48337574|NCT02519062|OTHER|No intervention|This is a retrospective study
48654433|NCT04501120|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
48654434|NCT04501120|DRUG|Reduced-dose HHT|1mg IV QD on Days 1-14 (28-day cycle).
48654435|NCT04501120|DRUG|standard-dose HHT|2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
48654436|NCT04501120|DRUG|Azacitidine|75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
47978316|NCT02156596|DRUG|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
47978317|NCT02156596|DRUG|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
48337575|NCT04149847|PROCEDURE|inguinal hernia repair|patients 18 years and above presenting with primary inguinal hernia
48337576|NCT02699671|DEVICE|Bioresorbable Vascular Scaffold|
48337577|NCT03326583|DRUG|Patiromer|Patiromer will be orally self-administered by participants.
48337578|NCT03718676|PROCEDURE|Ferric sulphate|Teeth were pulpotomized with ferric sulphate in this group.
48337579|NCT03718676|PROCEDURE|Ortho-MTA|Teeth were pulpotomized with Ortho-MTA in this group.
48654437|NCT04501120|DRUG|APG-2575|APG-2575 orally once daily for 14 days, every 28 days as a cycle.
48654438|NCT04471727|BIOLOGICAL|MK-6070|IV infusion
48654439|NCT04471727|BIOLOGICAL|Atezolizumab|IV infusion
48654440|NCT04471727|BIOLOGICAL|Ifinatamab Deruxtecan (I-DXd)|IV infusion
48654441|NCT06198010|OTHER|Best Practice|Receive enhanced usual care
48654442|NCT06198010|OTHER|Educational Intervention|Receive ASCENT guide
48654443|NCT06198010|OTHER|Questionnaire Administration|Ancillary studies
48654444|NCT06198010|OTHER|Electronic Health Record Review|Ancillary studies
47978318|NCT02156596|DRUG|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
47978319|NCT01174303|DRUG|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
47978320|NCT01174303|DRUG|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
48337580|NCT03718676|PROCEDURE|Retro-MTA|Teeth were pulpotomized with Retro-MTA in this group.
48337581|NCT02057068|BEHAVIORAL|SLEEP-E Dyads Intervention|Described in arm/group description
48337582|NCT02468960|DEVICE|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
48337583|NCT02468960|DEVICE|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
48337584|NCT02468960|DEVICE|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
48337585|NCT02468960|PROCEDURE|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
48337586|NCT02468960|OTHER|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
48337587|NCT03940456|OTHER|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
48337588|NCT00971360|OTHER|conversion disorder|Proinflammatory cytokine levels in conversion disorder
48337589|NCT02403141|OTHER|Questionnaire|
48337590|NCT00492414|DRUG|Paroxetine CR|
48654445|NCT06198010|PROCEDURE|Health Telemonitoring|Attend video or phone calls with a CHW and/or PCM
48654446|NCT06198010|BEHAVIORAL|Cancer Pain Management|Receive personalized pain management plan
48654447|NCT05253196|DEVICE|Use of the foley catheter assistive device|All participants will use the foley catheter assistive device when performing their daily enema
48337591|NCT03000686|BIOLOGICAL|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
48337592|NCT03000686|OTHER|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
48337593|NCT04978480|OTHER|no intervention|There is no intervention. We are only collecting standard of care data.
47978321|NCT06023472|DEVICE|microfluidic chip|Microfluidic chip method has been used for sperm sorting in order to select the most motile and morphologically normal sperm for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
48337594|NCT00133172|DRUG|Tacrolimus|IV
48337595|NCT00133172|DRUG|mycophenolate mofetil|IV
48337596|NCT00133172|DRUG|Prednisone|IV
48337597|NCT02638272|PROCEDURE|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
48337598|NCT03504436|DEVICE|LEO +|LEO +: self-expanding intracranial stent
48337599|NCT00360685|DRUG|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
48337600|NCT00360685|DRUG|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
48337601|NCT04705987|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg/24h Treatment 8 weeks
48337602|NCT04705987|DRUG|Placebo|Placebo 1c/24h Treatment 8 weeks
48337603|NCT00004041|BIOLOGICAL|Ad5CMV-p53 gene|
48495417|NCT04787874|BEHAVIORAL|Prehabilitation Program|"Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity."
48495418|NCT01026155|OTHER|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
48495419|NCT02034058|DEVICE|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
48495420|NCT04086836|DEVICE|TAVR|Patient recieving a TAVR
48495421|NCT03686449|PROCEDURE|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
48495422|NCT03686449|PROCEDURE|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
48337604|NCT00004041|PROCEDURE|conventional surgery|
48337605|NCT05713942|DIAGNOSTIC_TEST|The Sport Concussion Assessment Tool 5th Edition (SCAT5)|The SCAT5 is a standardized tool for use by healthcare professionals in the evaluation of individuals 13 years old or older, who are suspected of having sustained a sports-related concussion. It comprises a neuropsychological test battery that assesses attention and memory function through 8 different domains 1) Symptom number, 2) Symptom severity, 3) Orientation, 4) Immediate memory, 5) Concentration, 6) Neurological examination, 7) Balance errors, 8) Delayed recall.
48337606|NCT05713942|DIAGNOSTIC_TEST|The Immediate Post-Concussion Assessment and Cognitive Testing tool version 4 (ImPACT)|The ImPACT is a computer-based neurocognitive test battery that provides an objective measure of neurocognitive functioning as an assessment aid in the management of concussion in individuals ages 12-80 years
48337607|NCT02678728|DRUG|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
48337608|NCT02678728|DRUG|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
48495423|NCT03686449|PROCEDURE|Split skin graft|Traditional method for treatment of post-burn raw area
47978322|NCT06023472|DEVICE|density gradient centrifugation|Density-gradient centrifugation is a commonly used method for sperm separation and purification. It is a technique that involves layering a semen sample on top of a gradient of different densities of a solution, typically a mixture of colloidal silica and sucrose, and then centrifuging the sample. The centrifugal force causes the sperm to migrate through the gradient, where they become separated based on their density.
47978323|NCT06300060|DIETARY_SUPPLEMENT|Synbiotic|Combination of a probiotic and prebiotic. Daily administration in a single dose in powder form.
48337609|NCT02945306|PROCEDURE|Adenotonsillectomy|
48495424|NCT03050203|OTHER|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
47978324|NCT06300060|DIETARY_SUPPLEMENT|Placebo|Placebo. Daily administration in a single dose in powder form.
47978325|NCT06293755|DEVICE|Microneedle patch|with 20 units botulinum toxin
47978326|NCT06293755|DEVICE|Intradermal injection|with 20 units botulinum toxin
48337610|NCT02945306|DRUG|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
48337611|NCT02679794|BEHAVIORAL|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
48337612|NCT02679794|BEHAVIORAL|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
47978327|NCT04068090|OTHER|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
48130285|NCT05571384|BEHAVIORAL|high intensity body-weight circuit|"Bodyweight and suspension training equipment (TRX® Fit System) with modified movements. Modified Squats: participants will be instructed to hold the handles of the band with arms extended, participants will then lean back in a standing position and perform a squat within a comfortable range of motion while weight is being distributed to the band. Modified Rows: participants will grab the bands with arms and legs extended. They will find a comfortable angle by which to perform a row (pulling the handles to the rib cage) with arms at a 45-degree angle. Modified Push-Ups: perform push-ups on their knees with a flat back and hands underneath their shoulders. They will be instructed to lower their chest towards the ground in a controlled manner and as far as comfort will allow them. Modified Crunches: participants will lay on their back with feet approximately 8-10 inches from their buttocks, and asked to lift their shoulders slightly off the ground."
48130286|NCT06097091|OTHER|Self-management education|A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).
48130287|NCT06097091|BEHAVIORAL|pain neuroscience education|"Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, Explain Pain by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content."
48130288|NCT06190717|DEVICE|EchoMark/EchoSure|Subjects assigned to the Diagnostic Arm will have the EchoMark implanted at the time of AVF creation. The subject will return every 2 weeks for a follow-up assessment to include an EchoSure scan until fistula maturation and/or permanent access use is achieved. The EchoSure scans are to be reviewed by the investigator(s) or delegated study staff and aid in the determination when a further assessment, including a physical exam, is required to determine cannulation clearance or if an intervention(s) may be required to prevent failure of fistula maturation. All physical exams will include assessing the fistula for bruit and thrill. The subject's medical history will be reviewed at each visit and will include all interventions, cannulation attempts, and adverse event reporting.
48130289|NCT06190717|PROCEDURE|Standard of Care|Subjects are assessed using standard of care per KDOQI guidelines, which includes a physical exam at the 2-week follow-up visit and at the 4-6-week follow-up visit. All follow-up visits will include an assessment of adverse events and medical history review to include all interventions, cannulation attempts, and laboratory results. If evaluation yields an abnormal finding, subjects will undergo a Duplex ultrasound assessment and treatment under the institution's standard of care. All SOC Arm subjects will be followed per the institution's standard of care until fistula maturation occurs and/or permanent access use is achieved but no more frequently than once per month.
48495425|NCT03050203|OTHER|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
48495426|NCT01631175|BEHAVIORAL|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
48495427|NCT00375349|PROCEDURE|Ultrasound to demonstrate existence of fatty liver|
48495428|NCT02637635|PROCEDURE|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
48130294|NCT05929833|BEHAVIORAL|BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)|The six components of BETTER include: 1) assessment of patient/family needs and referral to community-based resources; 2) patient goal setting and review of goals; 3) health care coordination; 4) availability of clinical interventionist to patient/family; 5) training on self- and family-management and brain injury coping skills; and 6) warm hand off/referral to the state-affiliated Brain Injury Association at the end of the intervention for additional resources.
48130295|NCT05929833|OTHER|Usual Care|Usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments)
48495429|NCT02637635|PROCEDURE|Expander prosthesis|breast reconstruction with expander prosthesis.
48495430|NCT04732481|PROCEDURE|passive leg lift test|passive leg lift test
48337613|NCT02979444|BEHAVIORAL|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
48337614|NCT00635557|DRUG|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
48337615|NCT00704431|DRUG|SB-480848 (darapladib)|160 mg darapladib
48495431|NCT04102852|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG ATCC 53103|probiotic administration at two different doses for 1 month
47978328|NCT04068090|OTHER|Blood Collection|biomarker analysis
48495432|NCT04399928|DEVICE|Total Hip Arthroplasty|Total hip arthroplasty with the R3 Acetabular Hip system.
48495433|NCT05882279|OTHER|No Intervention|This is a non-interventional study.
48495434|NCT01271751|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
48495435|NCT01271751|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
48495436|NCT05495828|DRUG|Orelabrutinib|Orelabrutinib, 150mg, po, qd
48495437|NCT00105300|DRUG|Adalimumab|
48495438|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|As a experimental vaccine for 6 months to 5 years old.
48130298|NCT04280289|DRUG|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
48495439|NCT06314685|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 6-11 months and 12-23 months.
48495440|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 2-5 years.
48495441|NCT05610592|PROCEDURE|total mesorectal exicision|
48130302|NCT03919110|DIAGNOSTIC_TEST|Collection of biological samples|"Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses."
48495442|NCT02190474|BEHAVIORAL|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
48495443|NCT05816057|BIOLOGICAL|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
48495444|NCT03761680|DIETARY_SUPPLEMENT|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
48495445|NCT03761680|DIETARY_SUPPLEMENT|Control Intervention|Patients receive ONS between meals or at their request as usual
48495446|NCT03822065|DRUG|LY03005|80 mg oral tablet single dose
48495447|NCT00073619|BEHAVIORAL|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
48495448|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
48495449|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
48130305|NCT03842085|DRUG|Recombinant Humanized Bispecific Monoclonal Antibody MBS301|The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
48130306|NCT03642106|BEHAVIORAL|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
48130307|NCT00369109|OTHER|biologic sample preservation procedure|
48654448|NCT05046730|DEVICE|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
48654449|NCT05346718|OTHER|Ragweed pollen, birch pollen, clean air (placebo)|Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.
48130308|NCT00369109|OTHER|immunohistochemistry staining method|
48495450|NCT02003521|DEVICE|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
48495451|NCT00918138|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
48495452|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
48495453|NCT00918138|DRUG|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
48495454|NCT00918138|DRUG|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
48495455|NCT00918138|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
48495456|NCT02890654|OTHER|First time measure|"* Initial Interview~* Initial Survey,~* Quality of life Scale~* Kinesitherapy Review~* Anxiety Scale"
48495457|NCT02890654|OTHER|Second time measure|"* Kinesitherapy review~* Second survey including numeric scale of pain~* Anxiety scale~* Scoliosis Research Society 22 quality of life scale"
48495458|NCT02890654|OTHER|Third time measure|"* Scoliosis Research Society 22 quality of life Scale~* Anxiety scale~* Numeric scale of pain~* Kinesitherapy review"
48654450|NCT06640725|DRUG|Avelumab administration at 10mg/kg|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)"
48654451|NCT06640725|DRUG|Cetuximab (Erbitux)|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])"
48654452|NCT05600751|PROCEDURE|Radiosurgery of ganglion stellatum|Patients will undergo radiosurgery of ganglion stellatum (left one or both)
48654453|NCT04586660|DRUG|XGEVA®|Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
47978329|NCT03064360|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
48654454|NCT06565039|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
48130309|NCT00369109|OTHER|laboratory biomarker analysis|
48130310|NCT00369109|PROCEDURE|biopsy|
48130311|NCT02397096|DRUG|Doravirine, Tenofovir, Lamivudine|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
47978330|NCT03064360|DEVICE|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
47978331|NCT03064360|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
48130312|NCT02397096|DRUG|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
48130313|NCT02397096|DRUG|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
48130314|NCT02397096|DRUG|Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
48130315|NCT02397096|DRUG|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
48130316|NCT02317783|DRUG|[18F]Flutemetamol|Brain scan with imaging tracer that binds to amyloid plaques
48130317|NCT02317783|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
48130318|NCT02317783|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Brain scan to assess regions of abnormal volume and density
48337616|NCT05428449|DRUG|GT20029 Gel|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
48495459|NCT05803928|DRUG|lenvatinib + anti-PD-1 antibodies|A ablation treatment group B ablation+ lenvatinib + anti-PD-1 antibodies treatment group
48495460|NCT05803928|PROCEDURE|ablation|radiofrequency ablation or microwave ablation
48495461|NCT01708590|DRUG|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
48495462|NCT01708590|DRUG|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
48495463|NCT01708590|DRUG|placebo|Placebo administered subcutaneous (SC)
48495464|NCT00573781|DIETARY_SUPPLEMENT|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
48495465|NCT00573781|DIETARY_SUPPLEMENT|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
48495466|NCT00573781|DIETARY_SUPPLEMENT|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
48495467|NCT05521139|DIAGNOSTIC_TEST|drug sensitivity results|drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
48495468|NCT04972123|DRUG|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
47978332|NCT02047890|DRUG|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
47978333|NCT02047890|DRUG|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
48266626|NCT01502904|DEVICE|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
48266627|NCT01502904|DRUG|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
48495469|NCT04972123|DIAGNOSTIC_TEST|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
48495470|NCT04972123|DRUG|Placebo|Placebo for CPC
48495471|NCT02563587|OTHER|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
48495472|NCT02563587|OTHER|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
48654455|NCT00740675|OTHER|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~1. Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~2. Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~3. Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
48654456|NCT06113289|DRUG|ASTX727|Given by PO
48654457|NCT06113289|DRUG|ASTX029-01|Given by PO
48654458|NCT04973319|DRUG|Pyrotinib|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.
48654459|NCT04973319|DRUG|Trastuzumab|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
47978334|NCT03510884|DRUG|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
47978335|NCT03510884|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
47978336|NCT03510884|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
47978337|NCT03510884|DRUG|Simvastatin|Pharmaceutical form:Tablet Route of administration: Oral
47978338|NCT03510884|DRUG|Pravastatin|Pharmaceutical form:Tablet Route of administration: Oral
47978339|NCT03510884|DRUG|Lovastatin|Pharmaceutical form:Tablet Route of administration: Oral
47978340|NCT03510884|DRUG|Fluvastatin|Pharmaceutical form:Capsule Route of administration: Oral
47978341|NCT03510884|DRUG|Ezetimibe|Pharmaceutical form:Tablet Route of administration: Oral
47978342|NCT03510884|DRUG|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
48654460|NCT05272488|OTHER|Manual therapy and vagus nerve stimulation|A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
47978343|NCT03510884|DRUG|Nicotinic acid|Pharmaceutical form:Tablet Route of administration: Oral
47978344|NCT03510884|DRUG|Fenofibrate|Pharmaceutical form:Tablet Route of administration: Oral
48654461|NCT05272488|OTHER|Manual therapy|Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
48495473|NCT02563587|DRUG|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
48495474|NCT00658658|BIOLOGICAL|Panitumumab|Panitumumab administered by intravenous infusion
48495475|NCT03651258|BEHAVIORAL|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
48654462|NCT02678377|DRUG|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
48495476|NCT01914068|OTHER|Supervised exercise in hospital|
48654463|NCT02678377|DRUG|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
48654464|NCT03894462|BEHAVIORAL|Attempted Suicide Short Intervention Program|ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.
48654465|NCT03894462|BEHAVIORAL|Zero Suicide Usual Care|Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged.
48654466|NCT05336760|DIAGNOSTIC_TEST|Iowa Oral Performance Instrument (IOPI)|IOPI measures the peak pressure of the tongue strength and endurance using a disposable bulb placed on a hard palate behind the front teeth or at the base of the tongue. The participants will be asked to press the bulb with their tongue with maximum pressure, three times. To measure the endurance, the participants will be asked to hold the pressure for as long as they can.
48495477|NCT05727371|COMBINATION_PRODUCT|Regen Matrix-PRP-XLHA|Single intra-articular injection at Day 0
48495478|NCT05727371|DEVICE|Hylan G-F 20|Single intra-articular injection at Day 0
48654467|NCT05336760|DIAGNOSTIC_TEST|Mann Assessment of Swallowing Ability (MASA)|MASA is a standard clinical swallowing assessment protocol including general patient examination, on-the-outside visible signs of oral preparatory and transportation phase and pharyngeal phase of swallowing function.
48495479|NCT05727371|DRUG|Placebo|Single intra-articular injection at Day 0
48654468|NCT05336760|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|The subjects will ingest up to 10 boluses ranging in thickness and volume (from thin to extremely-thick and a cookie).
48654469|NCT05336760|DIAGNOSTIC_TEST|Respiratory function measurements|Respiratory function measurements will include forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP), all expressed in percentage of predicted values. Conventional methods of testing will be applied.
48654470|NCT06645418|DIAGNOSTIC_TEST|relative Hand grip strength|To perform this study the relative handgrip strength (rHGS) index was used. The rHGSi is defined as the sum of the handgrip strength of both hands divided by body mass index (BMI), and it is considered a better prognostic tool than handgrip strength. rHGS was measured by Jamar hand dynamometer. The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
48337617|NCT05428449|DRUG|GT20029 Gel Placebo|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
48337618|NCT04157075|DRUG|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
48654471|NCT06645418|DIAGNOSTIC_TEST|senior fitness test|The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
48495480|NCT03664518|DRUG|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50\~150×109/L，the eltrombopag dose Maintain. platelet count between 150\~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
48495481|NCT00925080|DEVICE|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
48495482|NCT01523223|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
48495483|NCT05695677|PROCEDURE|Capacitive-Resistive Radiofrequency therapy of the neck muscles|Capacitive-Resistive Radiofrequency therapy of the neck muscles as a non-invasive technique for treating PDPH.
48495484|NCT04650503|OTHER|No intervention|No intervention
48495485|NCT03239886|OTHER|imatinib discontinuation|imatinib discontinuation
48654472|NCT01166646|DRUG|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
48654473|NCT01166646|DRUG|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
48654474|NCT06636006|BEHAVIORAL|Aerobic Exercise|50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13)
48654475|NCT06636006|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I includes some therapies, including sleep restriction therapy, stimulus control therapy, sleep hygiene education, relaxation and cognitive therapy\[19\]. Traditionally, CBT-I is applied in person (individually or in a group) by a trained psychologist or psychiatrist. However, several studies show similar effects when CBT-I is performed remotely, and online (digital)
48654476|NCT05864469|OTHER|12-week psychosocial dyadic intervention|Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
48654477|NCT05338268|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.
48654478|NCT05338268|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
48654479|NCT06468826|DRUG|Avacopan|Oral capsules
47978345|NCT03510884|DRUG|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
48495486|NCT06125574|OTHER|Osteopathic Manipulative Medicine|Individuals in the experimental cohort will undergo a systematic osteopathic manipulative treatment protocol encompassing paraspinal inhibition, rib raising, and condylar decompression techniques.
48654480|NCT05860751|PROCEDURE|Dry Needling with electrical stimulation|Administered for a total of 2 sessions at a frequency of once per week. The target muscles to be needled will include the gastronemius, soleus, vastus lateralis, rectus femoris, anterior tibialis, posterior tibialis, biceps femoris, and gluteus medius.
47978346|NCT03510884|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous injection
48337619|NCT05865210|OTHER|Kegel Exercise|Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
48337620|NCT05865210|OTHER|Myofascial release technique|Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
48654481|NCT04543786|DEVICE|Transcutaneous spinal cord stimulation|Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
48495487|NCT05567120|OTHER|PATH-Care|Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
47978347|NCT06436508|BEHAVIORAL|Early mobilization protocol|"* Step 1 - Day 1: Bed rest, elevation of the head end to 30°~* Step 2 - Day 2: Bed rest, elevation of the head end to 60°~* Step 3 - Day 3: Bed rest, elevation of the head end to 80°~* Step 4 - Day 4: Sitting on the edge of the bed~* Step 5 - Day 5: Sitting in a chair, standing up~* Step 6 - Day 6: Walking with or without assistance~* Step 7 - Day 7: Walking with or without assistance from today"
48495488|NCT03621358|OTHER|Control gummy with free flavour (without encapsulating)|12 g/day (3 gummies)
47978348|NCT06436508|BEHAVIORAL|Standard care|During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.
47978349|NCT01283360|OTHER|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
47978350|NCT01283360|DRUG|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
47978351|NCT02734940|DRUG|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
47978352|NCT02734940|DRUG|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
48337621|NCT00050622|DRUG|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
48337622|NCT00050622|BEHAVIORAL|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
48654482|NCT06476548|BEHAVIORAL|EMI|Participants will complete 3 counseling sessions (30 minutes), download and use a smartphone app for 4 weeks, complete 2 online surveys, and a brief phone call at the end of the study to provide feedback. In the first 3 weeks, participants will use the prototype app every day to complete ecological momentary assessments (EMAs), receive brief mindful skills, and practice formal mindfulness meditations (5-20 minutes). In the final week, participants will continue completing EMAs. Participants will also be provided with nicotine patches.
48495489|NCT03621358|OTHER|Experimental gummy with 50% free/50% encapsulated flavour|12 g/day (3 gummies)
48654483|NCT06638437|BEHAVIORAL|Cognitive-behavioral therapy|"The mobile application will include the following modules:~1. Psychoeducation: information about what to expect from each phase of the surgical process (i.e., pre-operative, the surgery itself and the post-operative).~2. Activation control techniques: to teach different activation control techniques such as relaxation, breathing techniques and mindfulness training.~3. Cognitive restructuring and problem solving: to teach how to change maladaptive pain-related beliefs for more adaptive ones and how to better cope with pain.~4. Exercises and tasks: to encourage the use of the learning strategies we will offer a number of exercises and tasks~5. Parent's module: to teach parents about the surgical process and how they can help their children during the process"
48654484|NCT01854775|DRUG|E/C/F/TAF|Tablets administered orally with food.
48654485|NCT01854775|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg STR administered once daily orally with food.
48654486|NCT06449378|DEVICE|Transorb™ Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for repair of open ventral hernia.
48654487|NCT04886856|BEHAVIORAL|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
47978353|NCT02734940|DRUG|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
47978354|NCT02734940|DRUG|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
48337623|NCT00050622|DRUG|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
48337624|NCT00050622|DRUG|Placebo|
48337625|NCT00050622|DRUG|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
48337626|NCT00050622|BEHAVIORAL|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
48337627|NCT04750655|DRUG|Moxifloxacin (Topical)|We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
48337628|NCT06040476|BIOLOGICAL|hUCB|hUCB
48495490|NCT03621358|OTHER|Experimental gummy with 100% encapsulated flavour|12 g/day (3 gummies)
48495491|NCT03287336|DRUG|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
48495492|NCT04928274|OTHER|ball attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
48495493|NCT04928274|OTHER|locator attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
48495494|NCT04928274|OTHER|telescopic attachment to retain mandibular over denture|each patient in group receive 3 telescopic attachment for over denture retention
48495495|NCT01775852|BEHAVIORAL|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
48495496|NCT03682224|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
48495497|NCT03682224|DRUG|Bupivacaine-Epinephrine|Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
48337629|NCT04186663|DRUG|Silver Diamine Fluoride|38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
48337630|NCT02591043|PROCEDURE|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
48654488|NCT04886856|BEHAVIORAL|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
48654489|NCT06639516|DIETARY_SUPPLEMENT|Bifidobacterium longum|Bifidobacterium longum
48654490|NCT06639516|DIETARY_SUPPLEMENT|Placebo|Placebo
48654491|NCT06639516|COMBINATION_PRODUCT|Standard clinical treatment|Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).
48654492|NCT06017986|OTHER|Ultra-processed food - Picture Set Meal|A meal containing ultra-processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
48654493|NCT06017986|OTHER|Ultra-processed food - Additives Meal|A meal containing ultra-processed foods that very on degree of additives.
48654494|NCT06017986|OTHER|Ultra-processed food - Ingredients Meal|a meal containing ultra-processed foods that very on degree of processing but not ingredients.
48654495|NCT06017986|OTHER|Minimally Processed Food - Picture Set Meal|a meal containing minimally processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
48654496|NCT06017986|OTHER|Minimally Processed Food - Additives Meal|A meal containing minimally processed foods that very on degree of additives.
48654497|NCT06017986|OTHER|Minimally Processed Food - Ingredients Meal|A meal containing minimally processed foods that very on degree of processing but not ingredients.
47978355|NCT02734940|DRUG|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
47978356|NCT00025766|DEVICE|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
48654498|NCT06099405|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
48337631|NCT02983799|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily
48654499|NCT06099405|BEHAVIORAL|Traditional yoga|Participants will perform controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
47978357|NCT00025766|BEHAVIORAL|Optimal Medical Therapy|Participants will receive optimal medical therapy.
47978358|NCT06175091|DEVICE|alarm management left to the discretion of the nurse|alarm management left to the discretion of the nurse in charge of the patient
47978359|NCT06175091|DEVICE|restrictive alarm use strategy|more restrictive protocol for the use of alarms
47978360|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Hyoid Bone(DSHB)|Hyoid bone-skin distance Other Name: DSHB
47978361|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Vocal Cord Anterior Commissura(DSAC)|Vocal cord anterior commissura-skin distance Other Name: DSAC
47978362|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Epiglottic(DSE)|Skin-epiglottic distance Other Name: DSE
47978363|NCT00382460|DRUG|PRAVASTATIN SODIUM|
47978364|NCT02407821|DRUG|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
47978365|NCT02407821|DRUG|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
47978366|NCT03187197|DRUG|Pradaxa®|Dabigatran etexilate
47978367|NCT02415660|PROCEDURE|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
48337632|NCT03633591|DRUG|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
48337633|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
48337634|NCT03633591|DRUG|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
48337635|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
48337636|NCT00083629|PROCEDURE|PET|
48337637|NCT04553367|DRUG|Meropenem|all patients in both groups receive meropenam and put on the ventilators for 2 weeks
48337638|NCT04553367|PROCEDURE|bronchoscopy|Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period
48495498|NCT01935466|DRUG|Pioglitazone|Ever users of Pioglitazone
48495499|NCT00250796|DRUG|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
48654500|NCT05468177|COMBINATION_PRODUCT|neoadjuvant chemotherapy|"Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy."
48495500|NCT00250796|DRUG|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
48266628|NCT01502904|DRUG|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
48337639|NCT04553367|DEVICE|ventilator|ventilator
47978368|NCT02415660|PROCEDURE|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
47978369|NCT02415660|BEHAVIORAL|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
47978370|NCT02415660|BEHAVIORAL|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
48337640|NCT05702970|DRUG|Sucrosomial iron|Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.
48337641|NCT05702970|DRUG|Vitamin D|administration Vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks in combination with of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily in Sucrosomial iron and vitamin D group
48337642|NCT05702970|DRUG|Ferric Carboxymaltose 50 MG/ML|Control group \[standard of care\]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
48495501|NCT04007770|OTHER|Acupuncture|10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window
48495502|NCT04007770|OTHER|Sham Acupuncture|10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
48495503|NCT04007770|OTHER|16 week waiting period + optional Acupuncture|Optional real acupuncture after 16 weeks waiting period. This arm is Closed to accrual.
48495504|NCT02202863|DIETARY_SUPPLEMENT|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
48495505|NCT04625426|DEVICE|3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant|Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant
48495506|NCT04625426|DEVICE|Conveen EasiCleanse and Conveen Critic Barrier|Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
48654501|NCT05509777|DRUG|Mirikizumab|Administered IV or SC
48654502|NCT03682484|DRUG|MA-0211|oral
48337643|NCT05665660|BEHAVIORAL|CARE|CARE is a culturally tailored mammography education module.
48495507|NCT04625426|DEVICE|Standard cleansing and Conveen Critic Barrier|Hospital's standard care for IAD management
48654503|NCT03682484|DRUG|Placebo|oral
48654504|NCT02926846|DRUG|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
48654505|NCT02926846|DRUG|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
48654506|NCT03863574|DRUG|Saroglitazar Magnesium 2mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
48654507|NCT03863574|DRUG|Saroglitazar Magnesium 4mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
47978371|NCT02415660|PROCEDURE|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
47978372|NCT02415660|DEVICE|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
48495508|NCT00796679|DRUG|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
48495509|NCT01494935|BEHAVIORAL|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
48495510|NCT01494935|BEHAVIORAL|Control diet|Normal fat, normal fat diet
48495511|NCT00457899|DRUG|Quetiapine IR (Immediate Release)|oral
48654508|NCT03863574|DRUG|Placebos|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
48495512|NCT02037035|DRUG|Ketamine|
48495513|NCT02493777|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
48495514|NCT02493777|DRUG|Placebo|
48495515|NCT05632211|BIOLOGICAL|AVT05|Pre filled syringes filled with AVT05
48495516|NCT05632211|BIOLOGICAL|Simponi|Pre filled syringes filled with Simponi
48495517|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
48495518|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
48495519|NCT01338948|PROCEDURE|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
48495520|NCT02571166|BIOLOGICAL|HSV529|Live, Replication-defective HSV-2 virus
47978373|NCT06088706|PROCEDURE|Intra-articular injection of ozone|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
48495521|NCT02571166|DRUG|Valacyclovir|500 mg orally, once daily for 4 weeks
48495522|NCT02743234|OTHER|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
48337644|NCT05665660|BEHAVIORAL|CARE + COACH|CARE + COACH is a culturally tailored mammography education module + access to an Apache paraprofessional women's health coach who functions as a patient navigator
48337645|NCT00207012|DRUG|BMS-599626|
48337646|NCT03239639|BEHAVIORAL|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
47978374|NCT06198868|PROCEDURE|Operable|Enrolled patients capable of surgical treatment
47978375|NCT05292040|DRUG|LY3857210|Administered orally.
47978376|NCT03680573|DRUG|Control: Lacated Ringers|This site will serve as the control site
47978377|NCT03680573|DRUG|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
48495523|NCT02743234|DRUG|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
48495524|NCT02743234|DRUG|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
48130325|NCT00001258|DRUG|Oxygen-15 Water|
48495525|NCT03538119|OTHER|High Intensity Interval Training Program|"The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
48495526|NCT03538119|OTHER|Moderate Intensity Continuous Training Program|"The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
48337647|NCT03239639|OTHER|Wait list control|No intervention
48337648|NCT00205751|DRUG|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
48337649|NCT01451151|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
48337650|NCT04165733|DIAGNOSTIC_TEST|Online questionnaire|Clinical psychologists in Germany currently working with patients with mental disorders
48337651|NCT02281968|DRUG|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
48337652|NCT02281968|DRUG|Placebo|
48495527|NCT05135052|DEVICE|Rhenium-SCT|Rhenium-SCT irradiation device
48495528|NCT03296384|OTHER|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
48495529|NCT05974436|OTHER|Blood and dialysate sampling|"Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations."
48495530|NCT03337165|BIOLOGICAL|tolerogenic dendritic cells|dose-escalation
48130326|NCT00860236|OTHER|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
48130327|NCT00860236|BEHAVIORAL|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
48130331|NCT02161146|DRUG|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
48130332|NCT02161146|DRUG|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
48130333|NCT02161146|DRUG|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
48337653|NCT03431142|DRUG|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
48130334|NCT02143375|DEVICE|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
48654509|NCT06570395|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic Manipulative Therapy (OMT) is a hands-on approach to treating conditions that affect all areas of the body. Physicians trained in OMT (Doctors of Osteopathic Medicine or DO) use OMT to correct structural imbalances in the body, relieve pain, and improve circulation. It is not only used as a treatment modality, but also to diagnose and prevent disease and improve overall functioning. There are over 40 OMT techniques that all involve gentle manipulation of the muscles, soft tissues, and joints in several ways to optimize alignment, improve blood flow, restore balance, and improve range of motion (Osteopathic Manipulative Therapy \& OMT. Cleveland Clinic)."
48654510|NCT06146062|DRUG|Mesenchymal Stromal Cells (MSC)|3 injections one week apart
48654511|NCT06146062|DRUG|placebo|3 injections one week apart
48654512|NCT05036330|OTHER|Clinical Evaluation|Undergo speech and swallow evaluation
48654513|NCT05036330|PROCEDURE|Physical Examination|Undergo examination of TEP and laryngectomy stoma
48654514|NCT05036330|OTHER|Quality-of-Life Assessment|Complete questionnaires
48654515|NCT05036330|OTHER|Questionnaire Administration|Complete questionnaires
48654516|NCT03295786|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
48654517|NCT03295786|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
48654518|NCT05604586|DIETARY_SUPPLEMENT|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
48654519|NCT05604586|DIETARY_SUPPLEMENT|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
48337654|NCT03431142|DRUG|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
48337655|NCT01196312|BEHAVIORAL|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
48337656|NCT03465046|COMBINATION_PRODUCT|intensive therapies(CIMT/BIT): protocol 1 or protocol 2|"The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family"
48337657|NCT02157103|DRUG|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
48337658|NCT01082003|DRUG|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
48337659|NCT04429412|BEHAVIORAL|MCT+|Metacognitive training
48337660|NCT04208646|BIOLOGICAL|Mesenchymal progenitor cells|Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use
48337661|NCT04208646|BIOLOGICAL|No mesenchymal progenitor cells|No mesenchymal progenitor cells for intra- articular use
48337662|NCT05581485|PROCEDURE|Non-intubated Laryngomicrosurgery|Non-intubated LMS was performed with assistance of Optiflow(HFNO).
48337663|NCT00786097|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
48337664|NCT01992666|GENETIC|Blood sampling|Immunologic and genetic analysis from a single blood sample.
48337665|NCT03405155|BIOLOGICAL|Nivolumab|Given IV
48337666|NCT04423757|DRUG|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
48654520|NCT02441400|DEVICE|EndoStim LES Stimulation System|
48654521|NCT04696575|BIOLOGICAL|Atezolizumab|Given IV
48654522|NCT04696575|DRUG|Carboplatin|Given IV
48654523|NCT04696575|DRUG|Etoposide|Given IV
48654524|NCT04696575|DRUG|Lamivudine|Given PO
48654525|NCT03735121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
48654526|NCT03735121|DRUG|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
48654527|NCT06639009|OTHER|940nm diode laser photobiomodulation|"The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes"
47978378|NCT03680573|DRUG|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
47978379|NCT03680573|DRUG|BH4|This site will be use to locally supplement BH4.
48654528|NCT06639009|OTHER|Conventional non -Invasive management in Oral Submucous fibrosis|"Brief behavioral Tobacco, areca nut and alcohol habit cessation counseling as per WHO 5As and 5Rs technique at baseline and each follow up.~Oral prophylaxis Removal of oral irritational factors like sharp teeth, appliances or prosthesis, impacted buccoverted third molars, parafunctional habits Oral hygiene maintenance instructions Oral physiotherapy Control of systemic conditions Removal of all predisposing factors for oral candida infection Advocacy for safe sexual practices Nutrition and diet counseling( seasonal and regional food rich in nutrients, vitamins, antioxidants avoidance of spicy /sour/ hot foods and drinks) Regular surveillance for malignant transformation"
48654529|NCT06644599|DEVICE|wireless monitoring|The monitoring wireless system will continuously monitor the heart rate, oxygen saturation (SpO2), respiratory rate, and blood pressure and in selected patients electrocardiography (ECG).
48130340|NCT04570358|OTHER|Static stretching|During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.
48130341|NCT04570358|OTHER|Proprioceptive neuromuscular facilitation stretching|During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
48130342|NCT05078255|DRUG|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
48130343|NCT05078255|DRUG|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
48130344|NCT05078255|OTHER|Semaglutide 1.34 mg/ml placebo|Saline
48130345|NCT05078255|OTHER|GIP placebo|Saline
48130346|NCT04111510|DRUG|Tumor infiltrating lymphocytes (TIL) LN-145|"The TIL autologous therapy with LN-145 is comprised of the following steps:~1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization)."
48130347|NCT00912964|DRUG|Mirabegron|Mirabegron tablets
48130348|NCT00912964|DRUG|Placebo|Matching mirabegron placebo tablets.
48495531|NCT03203486|OTHER|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
48130350|NCT04779216|DRUG|Romosozumab Prefilled Syringe|Romosozumab 210mg Injection monthly for 12 months
48130351|NCT04779216|DRUG|Placebo|Placebo Injection monthly for 12 months
48130352|NCT04779216|DRUG|Alendronate 70Mg Tab|Alendronate 70mg PO weekly starting at 12 months through 24 months.
48495532|NCT01790035|DRUG|LGG|
48495533|NCT01790035|DRUG|Placebo|
48130355|NCT06492135|DRUG|survodutide|survodutide
48130356|NCT06263881|DRUG|Raphamin|Tablet for oral use.
48337667|NCT04423757|DRUG|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
47978380|NCT03680573|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
47978381|NCT03680573|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
48130357|NCT06263881|DRUG|Placebo|Tablet for oral use.
48130358|NCT06578728|DRUG|Methotrexate|25mg/mL intralesional injection into nail bed/nail matrix
48130359|NCT06578728|DRUG|Triamcinolone Acetonide 10mg/mL|10mg/mL intralesional injection into nail bed/nail matrix
48130360|NCT06578728|DRUG|Saline|saline intralesional injection into nail bed/nail matrix
48130361|NCT06288854|OTHER|weight gain each group|weight gain after 12 Weeks
48495534|NCT02516527|DRUG|Ipilimumab|
48130363|NCT06352619|OTHER|Conservative SBP Control|No or minimal treatment; if there is a need to treat a patient with a very-high (\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg
48130364|NCT06352619|OTHER|Moderate SBP Control|If the patient has a very high (\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated
48130365|NCT06352619|OTHER|Intensive SBP Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher
48130366|NCT06053424|DRUG|AZD7798|Solution
48130367|NCT06053424|DRUG|[11C]AZ14132516|Radioligand
48266629|NCT01502904|DRUG|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
48337668|NCT01655745|PROCEDURE|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
48495535|NCT06320808|OTHER|FDA template PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
48495536|NCT06320808|OTHER|Decision Critical PMI|Intervention is an information format viewed by participants. The patient medication information format was designed according to a proposed FDA template and modified, according to decision science principles, to include benefit information, which provides information about safe and effective use of a medication. No drug or device is included as part of this intervention.
48654530|NCT04950153|BEHAVIORAL|Peer navigation|Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)
48337669|NCT01635036|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
48337670|NCT04705610|OTHER|Video-oculography / Social cognition tasks / Neuropsychological evaluations|"* Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~* Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~* Neurological evaluation~* Neuropsychological evaluations~* Social cognitions tasks~* Behaviour assessment"
48337671|NCT02352532|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
48337672|NCT02352532|OTHER|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
48337673|NCT04054102|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
48337674|NCT04054102|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
48337675|NCT03758872|DIAGNOSTIC_TEST|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
48337676|NCT04857892|DRUG|GSK3640254|GSK3640254 will be administered via oral route.
48130368|NCT04858035|BEHAVIORAL|Perceptual training|"Perceptual training involves self-paced presentation of auditory stimuli via a computerized software program.~Stimuli are organized into three separate tasks:~Tasks 1 and 3 will train category goodness judgment: Participants will hear 75 naturally produced speech tokens containing /r/ from various speakers, with a balance of correct and incorrect productions. They will classify each /r/ as correct or incorrect and receive feedback on the accuracy of their classification. Tasks 1 and 3 differ in that task 1 will feature a subset of items designed to provide focused practice on a specific context (e.g., initial /r/ as in red; /r/ as syllable nucleus as in sir), with increasing difficulty over time, whereas task 3 will feature randomly selected items representing all contexts and difficulty levels.~Task 2: Participants will hear 75 items drawn from the synthetic rake-wake continuum used in the identification task administered at baseline."
48130369|NCT04858035|BEHAVIORAL|Production training|"Instruction: Discuss tongue shapes for /r/. Pre-practice: relatively unstructured, highly interactive elicitation; provide models and placement cue and KP on every trial.~Structured syllable practice: Practice will occur in blocks of 10 consecutive trials on the same syllable (e.g., 10 /ra/), after which a new syllable will be addressed (e.g., 10 /re/--but note that in the fully blocked condition, the same syllable should occur in two consecutive blocks of 10)."
48130370|NCT05922904|DRUG|Brentuximab vedotin|Given by IV (vein)
48130371|NCT05922904|DRUG|Doxorubicin Hydrochloride|Given by IV (vein)
48130372|NCT05922904|DRUG|Pembrolizumab|Given by IV (vein)
48130373|NCT05922904|DRUG|Dacarbazine|Given by IV (vein)
48495537|NCT06320808|OTHER|Standard Information|The intervention is an information format viewed by participants. This patient medication information format is the current standard of care patient medication information that is included with the drug. No drug or device is included as part of this intervention.
48337677|NCT04857892|DRUG|DTG|DTG will be administered via oral route.
48337678|NCT04857892|DRUG|GSK3640254/DTG|GSK3640254/DTG will be administered via oral route.
48337679|NCT02687360|DEVICE|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
48337680|NCT02687360|DEVICE|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
48337681|NCT06532253|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
48495538|NCT04540354|DRUG|Optimal Medical Therapy (OMT)|Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
48654531|NCT04950153|BEHAVIORAL|SMS Text messaging|Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART
48654532|NCT04950153|BEHAVIORAL|Social Media Engagement|HIV testing outreach using social media platforms to promote HIV testing.
48337682|NCT03148587|BEHAVIORAL|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
48337683|NCT03148587|BEHAVIORAL|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
48654533|NCT04950153|BEHAVIORAL|Testing Peer Navigation|Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
48654534|NCT06535100|BEHAVIORAL|Art therapy|artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
48654535|NCT06319872|DRUG|Oral disulfiram|250 mg/day
48654536|NCT06589128|DIETARY_SUPPLEMENT|Astaxanthin Oral Capsule|Once daily supplementation of oral astaxanthin capsule for 24 weeks
48654537|NCT06589128|DIETARY_SUPPLEMENT|Placebo|Once daily supplementation of olive oil capsule for 24 weeks
48654538|NCT04966585|DRUG|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
47978382|NCT03680573|DRUG|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
48130377|NCT03440346|OTHER|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
48130378|NCT05470231|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
48130379|NCT06445972|BIOLOGICAL|Ramucirumab|8 mg/kg IV Infusion
48130380|NCT06445972|DRUG|Paclitaxel|80 mg/M\^2 IV infusion
48130381|NCT06445972|BIOLOGICAL|MK-2870|3 mg/kg or 4 mg/kg IV Infusion
48337684|NCT01576120|OTHER|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
48495539|NCT04540354|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
47978383|NCT00925912|PROCEDURE|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
47978384|NCT00925912|PROCEDURE|Perianal block|0.25% bupivacaine injected at perianal region
47978385|NCT05184140|PROCEDURE|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
47978386|NCT01923701|BEHAVIORAL|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
47978387|NCT03107325|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
47978388|NCT03107325|DRUG|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
47978389|NCT00144092|PROCEDURE|stem cell source|
47978390|NCT01396720|DRUG|fluvoxamine|Fluvoxamine 100mg daily, 7 days
47978391|NCT01396720|DRUG|citalopharm|Citalopharm 20mg daily, 7 days
48654539|NCT04966585|DRUG|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
48130383|NCT06176443|PROCEDURE|One anastomosis gastric bypass with combined fundoplication|FundoRingOAGB
48654540|NCT03653546|DRUG|AZD3759|AZD3759 200mg PO BID.
48654541|NCT03653546|DRUG|Erlotinib|SoC EGFRTKI Erlotinib 150 mg PO Q.D
48654542|NCT03653546|DRUG|Gefitinib|SoC EGFRTKI Gefitinib 250 mg PO Q.D
48654543|NCT04336969|BEHAVIORAL|4T Education and Care|CGM data will be used to create customized weekly feedback to the participant/family by secure MyChart message.
48654544|NCT06560736|BEHAVIORAL|Show Me FIRST coping skills intervention|Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
48654545|NCT03436849|DRUG|ESN364|ESN364 will be administered orally.
48654546|NCT03436849|DRUG|Placebo|Placebo will be administered orally.
48654547|NCT05377723|DEVICE|Neodyne Device|See Arm Description: Neodyne Device
48654548|NCT05453968|DRUG|Berotralstat|Administered orally once daily at a weight-based dose in up to 4 cohorts
48654549|NCT05135260|BEHAVIORAL|Virtual reality therapy|Participants will watch a video allowing them to view nature, dinosaurs, animals, and human interactions in three dimensions during a session lasting 11 minutes.
48654550|NCT05135260|BEHAVIORAL|Questionnaires|Questionnaires will be completed regarding stress, pain and affect
48654551|NCT05135260|PROCEDURE|Measure heart rate|To be measured prior to starting treatment and halfway through the 11 minute Video
48654552|NCT05135260|BEHAVIORAL|Cyber sickness measurement|To be measured using the fast motion sickness scale
48654553|NCT06511024|OTHER|Blood sample|Serial blood sampling to monitor immune cells in patient with COVID 19 infection and compare with control group who have no evidence of COVID-19 infection
48654554|NCT05334940|OTHER|not applicable, observational study|Patients do not receive intervention
48654555|NCT04418154|DRUG|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
48654556|NCT04418154|DRUG|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
48654557|NCT04418154|DRUG|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
48130384|NCT06176443|PROCEDURE|One anastomosis gastric bypass without combined fundoplication|OAGB
48337685|NCT01576120|OTHER|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
48337686|NCT03476434|DEVICE|chromoendoscopy with indigo carmine|the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
48337687|NCT00500812|DRUG|Cethrin|
48337688|NCT04379947|PROCEDURE|Fractional Flow reserve|Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
48337689|NCT04088565|OTHER|Paired-Associative Stimulation (PAS)|Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
48337690|NCT04088565|OTHER|Vagus Nerve Stimulation (VNS)|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
48337691|NCT04088565|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
48495540|NCT02593773|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
48495541|NCT06493149|OTHER|Massage therapy|Participants receive a Swedish massage based on the tensegrity principle.
48654558|NCT04418154|DRUG|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
48654559|NCT05811832|OTHER|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
47978392|NCT03441776|OTHER|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
47978393|NCT03441776|OTHER|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
48130385|NCT04814108|DRUG|ZN-c3|ZN-c3 is an investigational drug.
48495542|NCT05472662|DRUG|Placebo 152a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
48495543|NCT05472662|DRUG|Placebo 134a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
48495544|NCT01364181|DRUG|Udenafil|Udenafil 50mg qd po
48495545|NCT05506410|DRUG|Rituximab|Young patients (\< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
48495546|NCT04430257|OTHER|HIV and PrEP education|Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.
48337692|NCT02851368|DEVICE|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
48337693|NCT02851368|DRUG|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
48337694|NCT03387891|DEVICE|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
48495547|NCT04430257|BEHAVIORAL|Motivational interviewing|Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.
48495548|NCT04430257|BEHAVIORAL|Problem-solving and planning|Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.
48495549|NCT04430257|BEHAVIORAL|Patient navigation|Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites
48337695|NCT04938271|DEVICE|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
48337696|NCT02021851|DRUG|Dexamethasone and aprepitant|
48337697|NCT02021851|DRUG|Dexamethasone and ondansetron|
48337698|NCT03622541|DRUG|Sorafenib 200mg|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
48337699|NCT00750178|DRUG|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
48337700|NCT06087523|OTHER|Multidisciplinary discussion|"Multidisciplinary discussion: Participants will be diagnosed and categorized in regards of pulmonary disease on basis of medical record, PFT, HRCT, and questionnaires.~PFT: Participants will undergo body plethysmography (with diffusion) and six-minute walk test.~Analysis of circulating biomarkers: We will store glasses with serum and glasses with plasma and analyse them for circulating biomarker.~Questionnaires: Participants will complete Danish versions of three questionnaires.~* Saint George's Respiratory Questionnaire Interstitial Pulmonary Fibrosis~* Systemic Lupus Activity Questionnaire~* Lupus Impact Tracker~Review of medical record and clinical investigation with focus on SLE and pulmonary disease.~Thoracic and diaphragmatic ultrasound: The participants will undergo a 14 zone protocol, and be evaluated for b-lines and pleural thickening/irregularities. Diaphragm function will be evaluated according to the M-mode method, area method, and for thickening."
48337701|NCT01521572|DRUG|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
48337702|NCT06156904|DEVICE|Bone grafting for the treatment of surgically created bone defects or bone defects/voids resulting from traumatic injury to promote healing in the pelvis, upper and lower extremities.|"All patients enrolled in this clinical investigation will undergo a reconstruction of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone as per the standard of care at the investigational sites. Patients will be treated with b.Bone which will be used as a bone substitute in isolation or as a graft expander to promote healing in the pelvis, upper and lower extremities.~b.Bone is a bone substitute without initial mechanical properties, therefore it is to be used in conjunction with internal/external fixation devices suitable for primary stabilization."
48337703|NCT05300893|OTHER|No night splint|Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
48337704|NCT00203255|DRUG|Soy Isoflavones|
48337705|NCT02705443|OTHER|No Intervention|Standard of Care Only
48337706|NCT00601679|OTHER|NT-proBNP guided care|knowledge of NT-proBNP results
48337707|NCT04071171|DRUG|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
48337708|NCT04071171|DRUG|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
48337709|NCT04071171|DRUG|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
48337710|NCT04071171|DRUG|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
48337711|NCT01015820|PROCEDURE|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
48337712|NCT01015820|DEVICE|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
48337713|NCT04898127|DIAGNOSTIC_TEST|SARS-CoV-2 antigen rapid test|Rapid test before access to mass gathering event (concert), provided the test result is negative.
48337714|NCT04943666|OTHER|Hemorrhoid Disease Questionnaire|a new patient specific questionnaire (HDQ) with appropriate sensitivity and specificity to use for screening of patients with haemorrhoids in Russia in clinical practice for wider screening of haemorrhoids in population and for increasing patients' awareness of the disease and prompting them to seek professional advice.
48337715|NCT00081939|DRUG|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
48337716|NCT00081939|DRUG|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
48495550|NCT04430257|OTHER|PrEP information|A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
48495551|NCT04430257|OTHER|Referrals|Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
48495552|NCT00380692|DRUG|Atomoxetine|
48495553|NCT00380692|DRUG|Placebo|
48337717|NCT02384993|BEHAVIORAL|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
48337718|NCT00211874|BEHAVIORAL|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
48495554|NCT02964949|DRUG|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
48495555|NCT00587600|PROCEDURE|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
47978394|NCT04327557|BEHAVIORAL|MBCP Childbirth Education Course|The MBCP program is a fully manualized childbirth and parenting preparation course. Developed in 1998 in a clinical context, MBCP is an enhanced version of the Mindfulness Based Stress Reduction (MBSR) program tailored for addressing the concerns of pregnancy and early parenting. Through MBCP, pregnant women and their partners learn mindfulness skills for coping with the anxiety and stress of pregnancy and parenting, and the pain and fear of childbirth. They are given explicit instruction in skills for cultivating positive emotion and developing mindful, sensitive parenting. MBCP groups meet weekly for 9 weeks, with a retreat day between weeks 6 and 7.
47978395|NCT04327557|BEHAVIORAL|Non-MBCP Childbirth Education Course|TAU control participants will undergo standard (real-world) hospital- or community-based childbirth education that does not have a mindfulness focus. They will be able to choose whichever class they want from the list. If they prefer a class that is not on the list, then study staff will obtain the syllabus for that class to check whether there is a mindfulness component.
47978396|NCT05577481|COMBINATION_PRODUCT|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
47978397|NCT05577481|COMBINATION_PRODUCT|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
47978398|NCT00438113|DRUG|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
47978399|NCT04719754|DIAGNOSTIC_TEST|Vaginal swab|The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
48337719|NCT00358709|BEHAVIORAL|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
48337720|NCT05024617|OTHER|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
48337721|NCT05967208|BEHAVIORAL|CONSORT referrals|"Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts."
48337722|NCT05967208|BEHAVIORAL|Card referrals|"Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts."
48337723|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
48495556|NCT00587600|PROCEDURE|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
48495557|NCT04102813|BEHAVIORAL|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
48495558|NCT00415441|PROCEDURE|Physiotherapy program|
48495559|NCT00415441|PROCEDURE|Placebo physiotherapy treatment|
47978400|NCT05113472|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.
47978401|NCT01633333|OTHER|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
47978402|NCT01633333|OTHER|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
47978403|NCT05782608|DRUG|IV ibuprofen|Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
47978404|NCT05782608|DRUG|IV ketorolac|Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
48495560|NCT00794391|BEHAVIORAL|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
47978405|NCT03028714|BEHAVIORAL|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
47978406|NCT03054389|OTHER|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
47978407|NCT03054389|OTHER|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
48495561|NCT00794391|BEHAVIORAL|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
47978408|NCT01314443|OTHER|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
47978409|NCT01314443|DIETARY_SUPPLEMENT|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
47978410|NCT01314443|OTHER|Placebo|Participants will take placebo for 7 days
47978411|NCT01314443|BEHAVIORAL|Smoking cessation|Participants will quit smoking without any pharmacological aids
47978412|NCT01084746|BEHAVIORAL|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
47978413|NCT01084746|BEHAVIORAL|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
47978414|NCT00816985|PROCEDURE|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
47978415|NCT00816985|OTHER|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
47978416|NCT04084301|PROCEDURE|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
47978417|NCT00277290|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
47978418|NCT00766480|DRUG|cisplatin|Given IV
47978419|NCT00766480|DRUG|fluorouracil|Given IV
48495562|NCT05865821|PROCEDURE|Negative pressure drainage|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
48654560|NCT03901365|OTHER|Neuroscience pain education|In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
47978420|NCT00766480|RADIATION|radiation therapy|Patients undergo radiotherapy
47978421|NCT02566655|BIOLOGICAL|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
47978422|NCT03732001|DRUG|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
47978423|NCT03732001|DRUG|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
47978424|NCT03668314|DRUG|RDN-929|Single dose from 2 mg to TBD
47978425|NCT03668314|DRUG|Placebo oral capsule|Matching placebo Single dose
47978426|NCT03668314|DRUG|RDN-929 TBD dose|Fed vs fast dose TBD based upon results of previous cohorts
47978427|NCT03668314|DRUG|RDN-929|Multiple dose based on results of previous cohorts
47978428|NCT03668314|DRUG|Placebo oral capsule|Matching placebo multiple dose
47978429|NCT03724084|DRUG|Cytarabine|Given IV
47978430|NCT03724084|DRUG|Daunorubicin|Given IV
47978431|NCT03724084|DRUG|Daunorubicin Hydrochloride|Given IV
47978432|NCT03724084|DRUG|Pinometostat|Given IV
47978433|NCT02006745|DRUG|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
48130393|NCT05827016|DRUG|Iberdomide|Specified dose on specified days
48130394|NCT05827016|DRUG|Lenalidomide|Specified dose on specified days
48130396|NCT05620914|DRUG|Patritumab deruxtecan|Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
48654561|NCT03901365|OTHER|Traditional patient education|In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
48654562|NCT03901365|OTHER|Manual therapy|Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
48654563|NCT05356130|BEHAVIORAL|Written Educational Material on BLT|Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.
48654564|NCT05356130|BEHAVIORAL|Enhanced BLT Encouragement and Adherence Promotion|BLT phone coaches will follow a four-step approach in engaging with Arm 3 participants: (a) provide encouragement to consider using BLT; (b) provide guidance regarding light box purchase and assist with obtaining compensation for purchase; (c) educate participants about ideal BLT use to obtain maximum benefit; and (d) provide ongoing brief telephonic adherence promotion and motivational interviewing (MI) where warranted to maximize persistent and appropriate BLT use.
48654565|NCT06571799|OTHER|BENEV Exosome Regenerative Complex+|BENEV Exosome Regenerative Complex+® is an intensive dual-action complex formulated to absorb quickly into the skin and scalp delivering the concentrated power of stem cell derived lyophilized exosomes, potent growth factors, peptides, coenzymes, minerals, amino acids and vitamins.
48654566|NCT05938946|DRUG|L608 Inhalation Solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
48654567|NCT05938946|DRUG|Placebo solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
48654568|NCT05941429|DRUG|Nano-Silver Fluoride|NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
48654569|NCT05941429|DRUG|Silver diamine fluoride|38% silver diamine fluoride
47978434|NCT02006745|DRUG|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA \>25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA \>1000 iU/mL at week 4).
47978435|NCT05562076|DEVICE|the spot stent(ZENFLEX ® Pinto) system|the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
47978436|NCT05562076|DEVICE|the bare stent( Everflex) system|the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
47978437|NCT06427031|DRUG|TJO-083|Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
47978438|NCT06427031|DRUG|Diquafosol ophthalmic sodium solution 3%|Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
47978439|NCT01785732|PROCEDURE|Renal Denervation|Sympathetic renal denervation via renal arteries
48337724|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
48337725|NCT04011319|BEHAVIORAL|group culture|Four embryos were cultured in the same droplet by a special dish.
48130402|NCT06097728|DRUG|Volrustomig|MEDI5752: Administered as IV infusion
48130403|NCT06097728|DRUG|Pemetrexed|Alimta: Administered as IV infusion
48130404|NCT06097728|DRUG|Carboplatin|Paraplatin: Administered as IV infusion
48337726|NCT03127579|BEHAVIORAL|Longer meal duration|Participants have 50% more time to eat than usual
48337727|NCT04817761|DRUG|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2."
48337728|NCT02821091|OTHER|Interactive Dynamic Balance Training|
48654570|NCT06637111|PROCEDURE|Ultrasound guided office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem. The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.~Transabdominal ultrasound will be used to guide the access of the hysteroscope to the uterine cavity"
47978440|NCT06239376|PROCEDURE|GnRHa+AI - AC|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
47978441|NCT06239376|PROCEDURE|Artificial cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
47978442|NCT03571269|PROCEDURE|Optical coherence tomography-guided reperfusion strategy|Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
48130405|NCT06097728|DRUG|Cisplatin|Platinol: Administered as IV infusion
48130406|NCT06097728|DRUG|Nivolumab|Opdivo: Administered as IV infusion
48130407|NCT06097728|DRUG|Ipilimumab|Yervoy: Administered as IV infusion
48495563|NCT05865821|OTHER|No pressure drain|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure
48495564|NCT05813314|COMBINATION_PRODUCT|BMN 111 administration via Injector Pen|BMN 111 Injection will be given using an injector pen
48495565|NCT05813314|DRUG|BMN 111 administration via vial and syringe|BMN 111 Injection will be given using vial and syringe
48495566|NCT01822574|PROCEDURE|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
48495567|NCT01822574|PROCEDURE|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
48495568|NCT01822574|PROCEDURE|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
48495569|NCT03952234|DRUG|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
48654571|NCT06637111|PROCEDURE|Conventional office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem . The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia."
48654572|NCT05148338|OTHER|Comprehensive risk factor treatment|"1. Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~2. Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~3. Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~4. Smoking cessation at specialized outpatient clinic~5. Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~6. Motivation and education through a digital health platform"
48654573|NCT05148338|OTHER|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
48654574|NCT04733079|OTHER|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
48654575|NCT04733079|OTHER|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
48654576|NCT06305390|DIAGNOSTIC_TEST|PET/MRI|18F-PSMA PET/MRI
48654577|NCT06433947|DRUG|OPN-6602|orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
48654578|NCT06433947|DRUG|Dexamethasone|Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
48654579|NCT02103179|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
48266630|NCT01502904|DRUG|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
48266631|NCT02940067|OTHER|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
48337729|NCT01753700|DIETARY_SUPPLEMENT|UHT treated milk|
48337730|NCT02720250|DIETARY_SUPPLEMENT|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
48337731|NCT02720250|DIETARY_SUPPLEMENT|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
48337732|NCT03835988|DEVICE|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
48654580|NCT06625060|BIOLOGICAL|IPN10200|Lyophilised powder
48654581|NCT06625060|OTHER|Placebo|Excipients without active substance, Lyophilised powder
48654582|NCT06625060|BIOLOGICAL|IPN10200 dose A|Lyophilised powder
48654583|NCT06625060|BIOLOGICAL|IPN10200 dose B|Lyophilised powder
48337733|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients \> 45 kg/99 lbs: idebenone 900 mg/day
48337734|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
48654584|NCT00432965|DEVICE|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
48654585|NCT00432965|DEVICE|VAC Therapy|VAC Therapy
48654586|NCT06343376|PROCEDURE|Biopsy|Undergo tissue biopsy
48337735|NCT00537680|DRUG|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
48654587|NCT06343376|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48654588|NCT06343376|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48337736|NCT03125018|DEVICE|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
48337737|NCT05221593|DRUG|Lithium Carbonate|400 mg tablet in controlled released formula
48495570|NCT01325181|DRUG|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
48654589|NCT06343376|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48654590|NCT06343376|PROCEDURE|Computed Tomography|Undergo CT
48654591|NCT06343376|DRUG|Cyclophosphamide|Given IV
48654592|NCT06343376|PROCEDURE|Echocardiography|Undergo ECHO
48654593|NCT06343376|BIOLOGICAL|EGFRt/19-28z/IL-12 CAR T-lymphocytes|Given IV
48654594|NCT06343376|DRUG|Fludarabine Phosphate|Given IV
48654595|NCT06343376|PROCEDURE|Leukapheresis|Undergo leukapheresis
48654596|NCT06343376|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48654597|NCT06343376|PROCEDURE|Positron Emission Tomography|Undergo PET
48654598|NCT06402136|DRUG|83-0060|Oral MPro inhibitor
48654599|NCT06402136|DRUG|Placebo|Placebo
48654600|NCT04726527|DRUG|Florbetapir F 18|A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
48130420|NCT06463977|OTHER|Survey|The study consisted of a 3 × 3 online factorial experiment employing a survey instrument hosted via Qualtrics presenting describing three patient vignettes. The three patient vignettes varied by various clinical characteristics including age, gender, performance status, smoking history, extent of disease, symptoms and molecular status. Each patient had advanced non-small cell lung cancer (aNSCLC). Each vignette had two parts: Part 1 described the case history for one of the three patients, after which prognostic estimates and medical decision-making was assessed (i.e. 1, 2, 3). Part 2 immediately followed and described the same vignette from the same patient with added information from a hypothetical ML predictive algorithm (i.e. A, B, C). The order of the vignettes in each survey was randomized with regard to presentation strategies for the ML risk predictions, so that there were 6 versions of the survey to which each participant was randomized.
48130421|NCT06330064|DRUG|Ifinatamab deruxtecan|Intravenous administration
48495571|NCT01325181|DRUG|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
48495572|NCT04768166|DRUG|Miglustat 100 MG|100mg/TID in 4w then 200mg/TID in 8 w
48654601|NCT04726527|DEVICE|Positron Emission Tomography|PET Scan for brain imaging
48654602|NCT05129735|DIETARY_SUPPLEMENT|Meal replacement shake|Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
47978443|NCT06306040|DRUG|Nalbuphine Versus Magnesium Sulfate|"Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions."
48337738|NCT04822311|BEHAVIORAL|Experimental: Investigate the effects of an exercise intervention on retired APF players|Enrolled participants will perform a 18 months exercise intervention which involves 90 exercise rehabilitation training visits. In addition, participants will also be tested on various measures of health and function both at baseline (prior to intervention), at 6 months, 12 months, and 18 months (post intervention).
48654603|NCT06644196|DEVICE|Acquisition of images/videos of the bilateral fundus with the holographic doppler laser|Acquisition of images/videos of the bilateral fundus with the holographic Doppler laser
48654604|NCT01141764|PROCEDURE|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
47978444|NCT00779467|DRUG|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
47978445|NCT00779467|DRUG|Bupivacaine|
48495573|NCT02993315|BIOLOGICAL|nDC vaccination|
48495574|NCT02993315|BIOLOGICAL|placebo injection|
48495575|NCT02161120|OTHER|Traditional Finnish rye bread|
48337739|NCT03619837|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
48495576|NCT02161120|OTHER|Low FODMAP rye bread|
48495577|NCT02767882|DRUG|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
48495578|NCT02767882|DRUG|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
48495579|NCT05376709|DIETARY_SUPPLEMENT|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
48495580|NCT00486616|DEVICE|electrical impedance tomography|
48654605|NCT01141764|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
48495581|NCT00486616|PROCEDURE|double-lumen tube placement|
48495582|NCT04616339|DRUG|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
48495583|NCT00324649|DRUG|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
47978446|NCT00779467|DRUG|fentanyl|fentanyl 2 mcg/ml
48495584|NCT00324649|DRUG|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
47978447|NCT02101476|DRUG|Percocet|10mg/650mg
47978448|NCT02101476|DRUG|Xartemis|15mg/650mg
47978449|NCT02974166|OTHER|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
47978450|NCT02974166|OTHER|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
47978451|NCT02974166|DRUG|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
47978452|NCT02974166|DRUG|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
47978453|NCT00221273|PROCEDURE|ACL surgery|
47978454|NCT02291198|DEVICE|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
47978455|NCT06136741|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
47978456|NCT06136741|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
47978457|NCT03626623|DEVICE|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
47978458|NCT03626623|OTHER|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
47978459|NCT04184869|DRUG|Belinostat|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
48130431|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
48130432|NCT04499248|OTHER|Lumigan|Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
48130433|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
48130434|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
48337740|NCT03619837|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
48654606|NCT01141764|OTHER|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
48654607|NCT01163942|DRUG|G-CSF|Yes/no addition of G-CSF
48337741|NCT02654275|OTHER|Proprioceptive Intervention|
48337742|NCT05817981|OTHER|Semi-structured interview|Before the questionnaire survey, 30 cancer survivors and 30 clinical oncology medical staff will respectively participate in different semi-structured interview individually.
48495585|NCT05496335|DRUG|AGN-151586|Intramuscular Injection
48495586|NCT05496335|DRUG|BOTOX|Intramuscular Injection
48654608|NCT01163942|DRUG|Early retreatment with ATG|Yes/no early retreatment with ATG
48654609|NCT04379921|DEVICE|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
48654610|NCT06596005|DRUG|TJ0113|200 mg or 400 mg Capsule, Once Daily
48654611|NCT06596005|DRUG|Placebo|Capsule, Once Daily
48654612|NCT06644534|DRUG|TTI-0102|(cysteamine-pantetheine disulfide)
48654613|NCT06644534|DRUG|Placebo|Pearlitol® 100 SD (mannitol)
48654614|NCT06014983|DIETARY_SUPPLEMENT|Ferrous fumarate|Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
48654615|NCT06014983|DIETARY_SUPPLEMENT|Ferrous bisglycinate|Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
47978460|NCT04184869|DRUG|Atazanavir|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
48495587|NCT05496335|DRUG|Placebo|Intramuscular Injection
48654616|NCT05583721|DRUG|[13N]NH3|Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
47978461|NCT03043131|DRUG|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
47978462|NCT03043131|DRUG|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
47978463|NCT01897740|DRUG|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
47978464|NCT04140851|DIETARY_SUPPLEMENT|Dietary fiber intervention|Dietary intervention
47978465|NCT04140851|DIETARY_SUPPLEMENT|Normal diet|Normal diet
47978466|NCT01634815|PROCEDURE|The Edge|measuring blood lactate
47978467|NCT00398892|DRUG|Lipoic acid|Lipoic acid capsules
47978468|NCT00088985|BIOLOGICAL|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
47978469|NCT00088985|BIOLOGICAL|trastuzumab|4 mg/kg intravenously, every 14 days
47978470|NCT00088985|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
47978471|NCT02342327|OTHER|switch to non-menthol cigarettes prior to cessation attempt|
48130435|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
48130436|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
48654617|NCT05583721|DRUG|Lexiscan|Given IV prior to PET stress test
48654618|NCT05583721|DIAGNOSTIC_TEST|Positron emission tomography|Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.
48654619|NCT05219487|DRUG|Risdiplam|"Risdiplam is administered orally once daily and the recommended dosage is determined by age and body weight (see Table 1) \[as outlined in the US Prescribing Information for EVRYSDI™(risdiplam)\].~Table 1 Adult and Pediatric Dosing Regimen by Age and Body Weight: US Prescribing Information~Age and Body Weight (Recommended Daily Dosage): 2 months to less than 2 years of age (0.2 mg/kg); 2 years of age and older weighing less than 20 kg (0.25 mg/kg); 2 years of age and older weighing 20 kg or more (5 mg)"
47978472|NCT02342327|OTHER|continue smoking menthol cigarettes prior to cessation attempt|
47978473|NCT02151760|DRUG|18F-DCFPyL|
47978474|NCT02689388|PROCEDURE|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
47978475|NCT02562430|DRUG|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
48495588|NCT03487783|DRUG|Aripiprazole Oral Solution|Aripiprazole 2-20 mg/day (2-20 mL/day)
47978476|NCT02562430|DRUG|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
47978477|NCT04993092|OTHER|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
47978478|NCT04993092|OTHER|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
47978479|NCT02603614|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
47978480|NCT02603614|DRUG|Placebo|Placebo control
47978481|NCT00783250|DRUG|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
47978482|NCT00783250|DRUG|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
48130437|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
48495589|NCT03487783|DRUG|Placebo Oral Solution|Placebo 2-20 mg/day (2-20 mL/day)
48495590|NCT01549106|DRUG|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
48495591|NCT01549106|DRUG|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
48495592|NCT00257218|BEHAVIORAL|Life style modification|
48130438|NCT04911166|COMBINATION_PRODUCT|Atezolizumab and Interleukin-12 Gene Therapy|To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
48130439|NCT06576037|DRUG|CBP-1019|Given by vein (IV)
48495593|NCT03627507|BIOLOGICAL|Hepa-B|Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.
47978483|NCT00004978|DRUG|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
47978484|NCT03128892|DEVICE|Oxygen Reserve Index - RD Lite Sensors|
47978485|NCT03938532|DEVICE|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
47978486|NCT03938532|DEVICE|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
47978487|NCT00933374|DRUG|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
47978488|NCT00933374|DRUG|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
47978489|NCT02916108|OTHER|Reading EEG|EEG recording for 5 minutes (not an intervention)
47978490|NCT02739204|DRUG|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
47978491|NCT00379574|DRUG|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
47978492|NCT00379574|DRUG|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
47978493|NCT00379574|DRUG|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
47978494|NCT00379574|DRUG|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
47978495|NCT00379574|DRUG|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
47978496|NCT00379574|DRUG|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
47978497|NCT04982887|OTHER|Exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
47978498|NCT04091022|DRUG|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
47978499|NCT02028624|BEHAVIORAL|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
47978500|NCT03027778|OTHER|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
47978501|NCT04931862|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide (ASO)
47978502|NCT04931862|DRUG|Placebo|Artificial cerebrospinal fluid (aCSF)
47978503|NCT04348734|DIAGNOSTIC_TEST|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
47978504|NCT04930016|BEHAVIORAL|Quality of life diagnosis and therapy during the completed RCT DIQOL|Quality of life measurement, diagnosis, and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
47978505|NCT05778916|PROCEDURE|5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.
47978506|NCT01065623|DRUG|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
47978507|NCT06386250|PROCEDURE|regional block|In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
47978508|NCT06386250|PROCEDURE|Caudal block|In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
47978509|NCT06386250|PROCEDURE|Epidural|In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
47978510|NCT06311968|RADIATION|Proton radiotherapy|Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
47978511|NCT06311968|OTHER|combined platinum based chemotherapy|combined platinum based chemotherapy
47978512|NCT02356068|OTHER|ROTEM analysis|3 blood samples for ROTEM analysis
48130440|NCT06576037|DRUG|Oxaliplatin|Given by vein (IV)
48130441|NCT06576037|DRUG|Leucovorin|Given by vein (IV)
48130442|NCT06576037|DRUG|5-FLUOROURACIL|Given by vein (IV)
48130443|NCT06576037|DRUG|Bevacizumab|Given by vein (IV)
48130444|NCT06576037|DRUG|Pembrolizumab|Given by vein (IV)
48130445|NCT06576037|DRUG|Enzalutamide|Given by mouth
48495594|NCT03627507|BIOLOGICAL|Engerix B|.'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
48495595|NCT04008966|DRUG|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
48495596|NCT04008966|DRUG|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
48495597|NCT04008966|DRUG|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
48130446|NCT03486600|OTHER|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
48654620|NCT06645028|BEHAVIORAL|Intensive treatment programme|"Intervention Group: 8-day intensive treatment where each treatment day consists of the following schedule:~Physical activity: 30 minutes Prolonged Exposure (PE): 90 minutes Physical activity: 30 minutes Lunch Physical activity: 60 minutes Eye Movement Desensitization and Reprocessing (EMDR): 90 minutes Physical activity: 30 minutes (omitted on days 4 and 8) Dinner Psychoeducation (omitted on days 4 and 8) Participants stay at the SÄS patient hotel during the treatment (with a three-day weekend break between treatment days 1-4 and 5-8). The treatment concept includes therapist rotation, meaning that participants switch therapists between PE and EMDR sessions. The purpose of this is to increase focus on the processing process rather than the relationship between the therapist and the client."
48654621|NCT06645028|BEHAVIORAL|Treatment as Usual (TAU)|Control group: 16 treatment sessions (90 minutes in duration) either Eye movement desensitisation and reprocessing (EMDR) or Prolonged Exposure (PE) in a standard outpatient format-weekly sessions. Participants can choose to attend 6 sessions of Psychoeducation for PTSD in a group format before starting EMDR or PE.
48654622|NCT03573089|DRUG|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
48130447|NCT06405841|OTHER|Survey|All patients will be asked to complete a survey at 1, 2, 4, 12 and 24 weeks from the trauma to assess their quality of life
48130448|NCT06405841|OTHER|Pain management|All patients will be asked about their pain management at 1, 2, 4, 12 and 24 weeks from the trauma to assess if they are under medication and what kind of medication are they taking
48495598|NCT04008966|DRUG|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
48495599|NCT04008966|DRUG|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
48495600|NCT04008966|DRUG|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
48495601|NCT04008966|PROCEDURE|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
48130453|NCT06268015|DRUG|Botensilimab|75 mg IV every 6 weeks for up to 4 doses
48130454|NCT06268015|DRUG|Balstilimab|240 mg IV every 2 weeks
48130455|NCT06268015|DRUG|Oxaliplatin|85 mg/m2 IV every 2 weeks
48130456|NCT06268015|DRUG|Leucovorin|400 mg/m2 IV every 2 weeks
48130457|NCT06268015|DRUG|Fluorouracil|400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
48130458|NCT06268015|DRUG|Bevacizumab|5 mg/kg IV every 2 weeks
48130459|NCT06268015|DRUG|Panitumumab|6 mg/kg IV every 2 weeks
48130460|NCT06228573|PROCEDURE|Yoga|Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
48495602|NCT04008966|PROCEDURE|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
48495603|NCT04008966|DRUG|natural Progesterone|400 mg twice daily per vagina
48495604|NCT03236415|DEVICE|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
48495605|NCT03236415|DEVICE|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
48495606|NCT05389683|BEHAVIORAL|Elimination Diet|An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
48495607|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (low dose)|
48495608|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (high dose)|
48130461|NCT06396975|PROCEDURE|robotic surgery|robotic surgery
48495609|NCT00794976|DRUG|Dexamethasone Passive Patch|
48495610|NCT00794976|DRUG|Placebo Patch|
48130463|NCT03629171|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48130464|NCT03629171|DRUG|Venetoclax|Given PO
48495611|NCT02613013|DEVICE|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
48130466|NCT00750620|DRUG|YM178|oral
48495612|NCT02613013|DEVICE|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
48495613|NCT02613013|DRUG|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
48495614|NCT02613013|PROCEDURE|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
48495615|NCT02613013|DRUG|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
48495616|NCT02613013|PROCEDURE|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris \>0.1mm. and patency was determined by direct visualization of the posterior chamber.
48495617|NCT03858166|DRUG|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
48495618|NCT06030219|DRUG|Omadacycline|10-day course
48495619|NCT06030219|DRUG|Vancomycin Pill|10-day course
48495620|NCT06030219|DRUG|Moxifloxacin|10-day course
48495621|NCT01211418|BEHAVIORAL|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB \& IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
48654623|NCT03573089|DRUG|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
48337743|NCT05817981|OTHER|Questionnaires set|Except for participants who participated in semi-structured interviews, other cancer survivors who met the inclusion criteria will be asked to respond to the demographic information sheet, the cancer related sexual and reproductive health knowledge and attitudes questionnaire, and the access methods and demand for cancer-related fertility information.
48337745|NCT00263250|PROCEDURE|watchful waiting or tension-free hernia repair|
48337746|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
48337747|NCT04667052|DRUG|JNJ 64304500|Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
48337748|NCT04126603|DRUG|Semaglutide|0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
48337749|NCT04126603|DRUG|Placebos|Placebo injection
48337750|NCT02120352|DRUG|CAB Oral Tablets|White to almost white oval shaped film coated 30 mg tablets for oral administration.
48337751|NCT02120352|DRUG|CAB LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
48337752|NCT02120352|DRUG|ABC/3TC Oral tablets|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
48337753|NCT02120352|DRUG|RPV Oral Tablets|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
48337754|NCT02120352|OTHER|HAART|Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.
48337755|NCT02120352|DRUG|RPV|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
48337756|NCT04606407|DEVICE|LungFit™|Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
48337757|NCT00753961|OTHER|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
48337758|NCT00753961|OTHER|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
48337759|NCT00198458|DRUG|Vitrase|
48337760|NCT02019017|DRUG|Botulinum Toxin Type A 25 IU|
48337761|NCT02019017|DRUG|Botulinum Toxin Type A 50 IU|
48337762|NCT05441943|PROCEDURE|Lymphovenous anastomosis|"Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed."
48337763|NCT00825149|DRUG|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
48337764|NCT00825149|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
48337765|NCT00825149|DRUG|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
48337766|NCT00825149|DRUG|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
48130469|NCT03853538|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one hemiface.
48337767|NCT00825149|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
48337768|NCT00825149|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
48337769|NCT00825149|DRUG|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
48337770|NCT05750238|OTHER|no intervention|no intervention, survey was applied to the participants
48337771|NCT02439736|OTHER|Blood draw within 12 hours of head injury|
48337772|NCT00823160|PROCEDURE|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
48337773|NCT00823160|PROCEDURE|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
48337774|NCT02709109|DRUG|VX-371 + HS|
47978513|NCT04077645|BEHAVIORAL|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
47978514|NCT04077645|BEHAVIORAL|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
47978515|NCT04077645|BEHAVIORAL|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
47978516|NCT02589184|OTHER|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
47978517|NCT02589184|OTHER|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
47978518|NCT02589184|OTHER|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
47978519|NCT02260921|DEVICE|iovera°|
47978520|NCT02260921|DEVICE|Sham Comparator|
47978521|NCT05135897|DEVICE|Electroconvulsive therapy|Treatment with Electroconvulsive therapy
47978522|NCT05135897|DEVICE|rTMS|repetitive Transcranial Magnetic Stimulation
47978523|NCT04525664|DRUG|Clarithromycin 500mg|500 mg per os twice daily for 14 consecutive days.
47978524|NCT04525664|DRUG|Amoxicillin 1000 MG|1000 mg per os twice daily for 14 consecutive days.
48337775|NCT02709109|DRUG|Hypertonic saline|
47978525|NCT04525664|DRUG|Omeprazole 40 MG|40 mg per os twice daily for 14 consecutive days.
47978526|NCT04525664|DRUG|Omeprazole 20 MG Oral Tablet|20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
47978527|NCT01823523|DRUG|Cefazolin, Cephalexin, Clindamycin|
47978528|NCT02509156|BIOLOGICAL|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
48130470|NCT03853538|OTHER|Semisolid vaseline|Product is applied to one hemiface.
48337776|NCT02709109|DRUG|Placebo|
48337777|NCT02709109|DRUG|Orkambi|
48337778|NCT02709109|DRUG|VX-371|
48337779|NCT05837650|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
48337780|NCT01279980|OTHER|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
48337781|NCT01279980|OTHER|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
48337782|NCT04860011|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin 10mg once daily
48654624|NCT06643533|OTHER|Fecal Microbiota Transplantation|The FMT capsules will be prepared by matching the gut microbiome profiles of healthy donors with those of patients who achieved a complete response to the triple therapy. The FMT capsules will be taken orally at a dosage of 30 capsules per day for the first 3 days of each treatment cycle. The FMT intervention will be administered in 6 cycles, with each cycle lasting for 21 days (Q3W). The duration of the treatment will be determined by the response to therapy, with a maximum of 6 cycles or until disease progression, intolerable toxicity, or participant withdrawal of consent. The FMT capsules are intended to modify the gut microbiome to reverse the resistance to the triple therapy and enhance the therapeutic response.
48654625|NCT01534819|DEVICE|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
48654626|NCT01534819|PROCEDURE|endovascular treament|implantation of a device inserted through an artery
48654627|NCT06631391|BIOLOGICAL|umbilical cord blood NK cells|This is a phase I prospective clinical trial, including phase Ia and phase Ib. Phase Ia include 3 dose levels, utilizing a 3+3 design principle, and each dose level will enroll at least 3 subjects. The recommended dose for phase Ia was used in phase Ib. Each patient receives two courses of umbilical cord blood NK cell therapy (a total of 8 infusions of umbilical cord blood NK cells).
47978529|NCT02509156|BIOLOGICAL|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
47978530|NCT03025503|OTHER|nipple stimulation|
47978531|NCT03782272|DIETARY_SUPPLEMENT|Enterade|enterade® (an amino acid-based oral rehydration solution \[AA-ORS\]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
47978532|NCT03782272|DIETARY_SUPPLEMENT|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
47978533|NCT00809276|DRUG|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
47978534|NCT02228629|DEVICE|CrocsRx Medical Silver cloud clogs|
48130471|NCT06509646|OTHER|Tia Chi Exercise|"• Yang style 24-posture short-form (16) for 30 minute It consists of 24 unique movements that are performed in a sequence. The form is designed to be easy to learn and can be completed in about six minutes.~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
48130472|NCT06509646|OTHER|Frenkel's Exercise|"Frenkel's exercises 30 minutes (Through these exercises, the patients would learn how to stay balanced and prevent falls by using their visual, somatosensory, and vestibular systems).~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
48130473|NCT05602194|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48130474|NCT05602194|DRUG|Calaspargase Pegol|Given standard of care calaspargase pegol
48130475|NCT05602194|DIETARY_SUPPLEMENT|Levocarnitine|Given PO or IV
48337783|NCT04860011|DRUG|Metolazone Tablets|Metolazone 5MG or 10MG once daily
48337784|NCT03305757|DRUG|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
48337785|NCT03305757|PROCEDURE|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
48337786|NCT03305757|PROCEDURE|Conventional|Conventional closure after mastectomy
48337787|NCT00379236|DEVICE|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
48337788|NCT00379236|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
48130476|NCT05602194|DRUG|Pegaspargase|Given standard of care pegaspargase
48130477|NCT05602194|OTHER|Quality-of-Life Assessment|Ancillary studies
48130478|NCT06054555|DRUG|ABP 206|ABP 206 will be given intravenously over a period of 30 or 60 minutes, every 4 weeks (Q4W) for a total of 24 months.
48130479|NCT06054555|DRUG|Nivolumab|Nivolumab will be given intravenously over a period of 30 or 60 minutes, Q4W for a total of 24 months.
47978535|NCT01294293|DRUG|TLR8 Agonist VTX-2337|Given SC
47978536|NCT01294293|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48495622|NCT01211418|BEHAVIORAL|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
47978537|NCT01294293|OTHER|Pharmacological Study|Correlative studies
47978538|NCT01294293|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
47978539|NCT01294293|DRUG|Paclitaxel|Given IV
47978540|NCT01125384|OTHER|additional swabbing|physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
47978541|NCT01490476|DRUG|RAD001|10 mg per os / day or 05mg per os / day with 12 month
47978542|NCT02555189|DRUG|Enzalutamide|Given PO
48130486|NCT06264531|DRUG|Bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
48130487|NCT06264531|DRUG|Placebo|NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
48130488|NCT01705886|PROCEDURE|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
48130489|NCT01705886|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
48130490|NCT01705886|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
48130491|NCT01705886|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
48130492|NCT01705886|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
48130493|NCT05784194|PROCEDURE|Intervention for correct discharge medication list|As above
48130494|NCT02923206|DEVICE|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
48130495|NCT03468634|DIAGNOSTIC_TEST|endoscopy|Oesophageal endoscopy with biopsy
48130496|NCT03510169|DEVICE|NeoVest|Negative pressure ventilation with NeoVest
48130498|NCT03273894|DIAGNOSTIC_TEST|Coagulation testing|"* body temperature before the intervention~* body temperature during the intervention including the way of measuring, each 15 minutes~* body temperature at the end of surgery, signs of the patient's heat discomfort~* body temperature during resting time in the postanesthesia care~* standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~* blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~* if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
48130499|NCT05212298|DIETARY_SUPPLEMENT|The gel contains a mixture of glucose and maltodextrin|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
48130500|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound low-dose|The total amount of herbal compound capsules is 557 mg.
48130501|NCT05212298|DIETARY_SUPPLEMENT|Herbal compound high-dose|The total amount of herbal compound capsules is 1114 mg.
48130502|NCT01991275|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
48130503|NCT01991275|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
48130504|NCT05166577|DRUG|Nanatinostat|Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week
48130505|NCT05166577|DRUG|Nanatinostat|Nanatinostat at the confirmed RP2D
48130506|NCT05166577|DRUG|Valganciclovir|Valganciclovir starting at 900 mg orally daily
48130507|NCT05166577|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
48130508|NCT06192433|DEVICE|High-frequency repetitive transcranial magnetic stimulation (40Hz)|Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
48337789|NCT06212206|DEVICE|PillBot|The PillBot System uses active, motorized propulsion technology to facilitate the navigation and positioning of the capsule within the stomach anatomy for imaging of the gastric mucosa by an operator.
47978543|NCT02555189|DRUG|Ribociclib|Given PO
47978544|NCT02555189|OTHER|Laboratory Biomarker Analysis|Correlative studies
47978545|NCT02555189|OTHER|Pharmacological Study|Correlative studies
47978546|NCT02555189|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47978547|NCT02555189|PROCEDURE|Biopsy|Undergo tumor biopsy
47978548|NCT02555189|PROCEDURE|Echocardiography|Undergo ECHO
47978549|NCT02555189|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
47978550|NCT02555189|PROCEDURE|Bone Scan|Undergo bone scan
47978551|NCT02555189|PROCEDURE|Computed Tomography|Undergo CT
47978552|NCT02555189|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47978553|NCT03156543|DEVICE|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
47978554|NCT03156543|OTHER|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
47978555|NCT01082406|DRUG|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
47978556|NCT01082406|DRUG|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
47978557|NCT02042885|DRUG|OPB-111001|
47978558|NCT00159471|DRUG|capecitabine, gemcitabine, docetaxel|
47978559|NCT03705676|BEHAVIORAL|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
47978560|NCT03705676|DEVICE|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
47978561|NCT03705676|DEVICE|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
47978562|NCT00937612|RADIATION|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
47978563|NCT01727453|DRUG|warfarin|Warfarin in anticoagulant dose
47978564|NCT01727453|DRUG|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
47978565|NCT02664441|DRUG|Exenatide|Weekly injections of active drug.
47978566|NCT02664441|DRUG|placebo|Weekly placebo injections
47978567|NCT04762433|DEVICE|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
47978568|NCT03147014|BIOLOGICAL|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
47978569|NCT00004860|DRUG|leucovorin calcium|
47978570|NCT00004860|DRUG|tegafur-uracil|
48130509|NCT06192433|DEVICE|Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)|Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
48495623|NCT00527865|DRUG|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
48495624|NCT00527865|DRUG|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
48495625|NCT01454908|DEVICE|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
48495626|NCT02161250|DIETARY_SUPPLEMENT|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
48130514|NCT00914966|BIOLOGICAL|C1 inhibitor (human) [C1 INH]|
48130515|NCT04691323|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
48130516|NCT06207565|PROCEDURE|Vestibular Flap Group|Achieving the vestibular flap, a 1-cm long horizontal vestibular access incision using a 15c blade 3-4mm apical to the mucogingival junction of the hopeless tooth, exposing the alveolar bone. Flap dissection in a coronal direction to detach the periosteum is completed, forming a sub-periosteal tunnel.
48130517|NCT06207565|PROCEDURE|Single Flap Approach group|A modified envelope flap originally reported as an access flap for single implant insertion in areas of esthetic relevance will be performed. A sulcular incision on the labial aspect extending at least one tooth mesial and distal to the implant site (permitting enough accessibility for bone augmentation) is done. The flap is reflected by performing a split-thickness flap elevation starting from the interproximal incisions, leaving the anatomical papillae in situ. While the full-thickness flap elevation is performed on the labial aspect of the included surgical area, starting at the sulcus, and reaching at least 3 mm apical to the bone crest.
48654628|NCT02800785|DRUG|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
47978571|NCT05916391|GENETIC|FT-003|Administration via intraocular injection
47978572|NCT03330769|DRUG|New course of treatment|Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
48337790|NCT02025803|DRUG|TAS-114/capecitabine|"Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
48337791|NCT03078959|OTHER|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
48337792|NCT00562640|BIOLOGICAL|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
48337793|NCT00562640|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
48337794|NCT00562640|DRUG|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
48337795|NCT00562640|OTHER|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
48337796|NCT01022645|DEVICE|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
48337797|NCT01022645|DEVICE|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
48337798|NCT04463225|OTHER|Internet-Delivered Brief Intervention|The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
48495627|NCT02161250|DIETARY_SUPPLEMENT|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
48495628|NCT02375139|DRUG|DA-1229_01|complex single administration
48130518|NCT01780675|RADIATION|Radiation Prophylactic Cranial Irradiation|
48495629|NCT02375139|DRUG|E+M|co-administration of 2 drugs
48495630|NCT00573404|DRUG|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
48654629|NCT02800785|PROCEDURE|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
48654630|NCT02088554|DEVICE|Model 400 aortic valve bioprosthesis|
48130519|NCT01780675|RADIATION|Radiation Hippocampal Avoidance PCI|
48130520|NCT02213146|DRUG|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
48130521|NCT02213146|DRUG|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
48130522|NCT02213146|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
48130523|NCT04931524|DRUG|carbon-14-[14C]-ANG-3777|Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
48130524|NCT05759260|OTHER|Observation|Observation
48495631|NCT00573404|DRUG|sunitinib malate|
48495632|NCT00573404|OTHER|pharmacological study|
48495633|NCT03778658|BEHAVIORAL|Physical Activity Intervention|Participants will engage in a multimodal aerobic and strength training intervention.
48495634|NCT03835221|DEVICE|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
48130525|NCT06192043|BEHAVIORAL|Behavioral Psychoeducational Intervention|Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
48654631|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection
48495635|NCT03835221|DEVICE|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
48495636|NCT06140043|OTHER|Patient consultation|Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
48130528|NCT04579198|BEHAVIORAL|Caregivers' Aid to Accelerate Recovery after pediatric Emergencies (CAARE)|The intervention, CAARE (Caregivers' Aid to Accelerate Recovery after pediatric Emergencies), consists of four components: First, all caregivers of PTI patients (ages 0-11) will be given brief education in the hospital related to children's and caregivers' emotional recovery. Second, all families will receive an in-hospital risk-reduction session. These sessions will address avoidance and trauma triggers; scheduling of pleasurable activities; and coping strategies. Third, all caregivers will receive the CAARE app-based components before discharge. The app will engage caregivers for 30 days via an automated SMS system. MHealth components of care will reinforce risk-reduction strategies. Fourth, 30 days post-discharge, a brief behavioral health screen will be completed by caregiver and child to assess need for more intensive screening by a mental health provider. Caregivers/children reporting elevated symptom levels will receive a comprehensive screening and referral process.
48337799|NCT06065904|BEHAVIORAL|Nutrilect|This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.
48337800|NCT04783714|DIETARY_SUPPLEMENT|Swisse Nutra+ Cholesterol Balance|Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
48654632|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection
48654633|NCT05051345|OTHER|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
48654634|NCT05051345|OTHER|Informational Intervention|Receive tobacco cessation self-help materials
48654635|NCT05051345|OTHER|Informational Intervention|Receive Smoke-Free Homes mailings
48654636|NCT05051345|OTHER|Media Intervention|Download and use the Wellness app
48654637|NCT05051345|OTHER|Questionnaire Administration|Ancillary studies
48654638|NCT05051345|BEHAVIORAL|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
48654639|NCT05051345|OTHER|Survey Administration|Ancillary studies
48654640|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive telephone counseling sessions
48654641|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
48654642|NCT05051345|OTHER|Tobacco Cessation Counseling|Receive telephone counseling sessions
48130529|NCT04540588|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
48130530|NCT06050252|PROCEDURE|Biopsy|Undergo tissue biopsy
48130531|NCT06050252|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48130532|NCT06050252|DRUG|Cisplatin|Given IV
48130533|NCT06050252|PROCEDURE|Computed Tomography|Undergo CT scan
48130534|NCT06050252|BIOLOGICAL|Durvalumab|Given IV
48130535|NCT06050252|DRUG|Gemcitabine|Given IV
48495637|NCT00048204|DRUG|GW597599B|
48495638|NCT00048204|DRUG|paroxetine|
48495639|NCT01775969|OTHER|Text Message|A text message with instructions is sent to the patient
48495640|NCT01775969|OTHER|Voicemail|A voicemail with instructions is sent to the patient
48654643|NCT06201611|DRUG|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
48654644|NCT06201611|DRUG|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
48654645|NCT06201611|DRUG|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
48654646|NCT04825600|DIAGNOSTIC_TEST|anti-Toxoplasma gondii IgG and IgM dosage|blood sample performed to check the toxoplasma serological diagnosis
48654647|NCT04825600|DIAGNOSTIC_TEST|cellular test|blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
48654648|NCT06018519|OTHER|Clinical endpoints|"1. Number of epileptic seizures~2. Change in antiepileptic treatment (increase or decrease)~3. Visual analogical scale on a target symptom defined with the parents,~4. CGI,~5. Actimetry data over 24 hours,~6. Podometry data over 24 hours,~7. 6 minutes' walk test,~8. Clinical examination~9. Feasibility of performing an MRI without any anesthesia on a mock scanner"
48337801|NCT04783714|DIETARY_SUPPLEMENT|Placebo|Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
47978573|NCT03180151|PROCEDURE|piezotome assisted orthodontic tooth movement|"Surgical procedure~1. After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~2. The incisions will be kept minimal.~3. The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~4. A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~5. As we will not use bone graft so we don't need use suturing after cortication.~6. We give patient antibiotic and analgesic cover."
47978574|NCT00192205|BIOLOGICAL|CAIV-T or TIV|
47978575|NCT05841251|DRUG|Topical Phenylephrine Solution|phenylephrine-soaked pack using the whole 5 ml of the solution provided with.5% phenylephrine will be applied after induction of surgery and intubation, 15 minutes before surgery. 100 ml of normal saline will be given.
47978576|NCT05841251|DRUG|intravenous tranexamic acid|patients will receive intravenous Single dose of tranexamic acid 15 mg/kg in 100 mL normal saline over 10 minutes. Saline-soaked pack will be applied.
47978577|NCT06214104|BEHAVIORAL|Acupressur|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
47978578|NCT01125865|DEVICE|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
47978579|NCT01125865|DEVICE|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
47978580|NCT01180491|DEVICE|K101 nail solution|
47978581|NCT02590848|DIETARY_SUPPLEMENT|Walnut intake|Nutritional intervention: 30g walnut kernels per day
47978582|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level|50g added sugar
48337802|NCT03230721|PROCEDURE|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
48337803|NCT03230721|PROCEDURE|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
48337804|NCT03230721|PROCEDURE|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
48654649|NCT06018519|OTHER|Parental questionnaires|"10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)"
47978583|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + one serving sugar sweetened beverage|90 grams added sugar
47978584|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + two servings sugar sweetened beverage|130 grams added sugar
47978585|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + three serving sugar sweetened beverage|170 grams added sugar
48337805|NCT03379376|OTHER|Questionnaire Administration|Receive questionnaire
48337806|NCT03379376|PROCEDURE|Supportive Care|Undergo eHealth mindful moving and breathing
48337807|NCT00054236|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
48337808|NCT00054236|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
47978586|NCT05243862|DRUG|PolyPEPI1018|PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.
47978587|NCT05243862|DRUG|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
47978588|NCT03235076|DRUG|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
47978589|NCT04937621|DIAGNOSTIC_TEST|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
47978590|NCT04937621|DRUG|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
47978591|NCT04937621|BIOLOGICAL|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
47978592|NCT04937621|OTHER|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
47978593|NCT04980690|BIOLOGICAL|IBC0966|IBC0966 is an investigational product.
47978594|NCT01602146|OTHER|ultramarathon running|"* blood samples before and after ultramarathon~* urinary samples before and after ultramarathon~* voluntary ant electrically muscular forces measuring before and after ultramarathon~* Broadband ultrasound Attenuation before and after ultramarathon"
47978595|NCT06076057|DIAGNOSTIC_TEST|vital signs monitoring|Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors
47978596|NCT02278198|DRUG|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
47978597|NCT06142045|DEVICE|RespirACT RA-MR System|RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.
48337809|NCT00054236|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
48337810|NCT00054236|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
48337811|NCT00054236|PROCEDURE|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
48337812|NCT00054236|DRUG|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
48337813|NCT04961879|PROCEDURE|Reversed Cross Finger Flap|"distal dorsal finger defect will be reconstructed by reversed cross finger flap~- reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger ."
48337814|NCT04961879|PROCEDURE|reversed island homo-digital flap|"distal dorsal finger defect will be reconstructed by reversed island homo-digital flap~- this flap is harvested from the same finger ."
48337815|NCT03689868|BEHAVIORAL|Virtual Reality|Virtual Reality headset with calming scenery
47978598|NCT03846011|OTHER|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
47978599|NCT03580655|DRUG|Avapritinib|Avapritinib tablet
47978600|NCT05895747|DRUG|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
48654650|NCT06018519|OTHER|Quality of life scale|18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
48337816|NCT00354939|DRUG|Insulin glargine|
48337817|NCT04807101|DRUG|midazolam alone|elimination of fentanyl from conscious sedation
48337818|NCT00533611|DRUG|MK0524A, /Duration of Treatment : 4 Weeks|
48337819|NCT00533611|DRUG|Comparator : niacin /Duration of Treatment : 1 Weeks|
48337820|NCT05214404|OTHER|Patients diagnosed with ulcerative colitis|Patients with ulcerative colitis diagnosed by endoscopy and histopathology
48337821|NCT03126279|PROCEDURE|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
48337822|NCT00388167|DRUG|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
48337823|NCT05565326|DEVICE|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system using CE marked low-field MR coils as provided by the company will be taken for volunteers in phase I. In phase II and III, after therapy beginning those images will be taken once per week per subject using CE marked low-field MR coils as provided by the company. This is done over the entire course of radiotherapy, which takes between 3 and 6 weeks.
48337824|NCT04535505|DIAGNOSTIC_TEST|Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology|This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
48337825|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
48337826|NCT03136900|DIETARY_SUPPLEMENT|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
47978601|NCT05895747|DRUG|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
48337827|NCT02448797|DRUG|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
48495641|NCT00569530|DRUG|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
48495642|NCT00569530|DRUG|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
47978602|NCT05895747|DRUG|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
47978603|NCT05895747|DRUG|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
47978604|NCT05895747|DRUG|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
47978605|NCT04030754|COMBINATION_PRODUCT|amniotic membrane|amniotic membrane is a biological dressing
47978606|NCT04030754|COMBINATION_PRODUCT|duoderm dressing|duoderm dressing is a synthetic dressing
47978607|NCT01217840|DRUG|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
47978608|NCT01217840|DRUG|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
48130536|NCT06050252|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
48337828|NCT02448797|DRUG|Chemotherapy|Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
48337829|NCT00430391|OTHER|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
48337830|NCT00430391|OTHER|Routine Control|Participants are assigned to the routine, standard consent.
48337831|NCT02275520|DEVICE|NIO Adult device|IO access-1
48337832|NCT02275520|DEVICE|Bone Iniection Gun|IO access-2
48337833|NCT02275520|DEVICE|EZ-IO|IO access-3
48337834|NCT02275520|DEVICE|Jamshidi Intraosseous Needle|IO access-4
48337835|NCT02275520|DEVICE|Cook Intraosseous Needle|IO access-5
48495643|NCT02925585|OTHER|Pre/post imaging|
48495644|NCT04798612|DRUG|Pegasys|45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between
47978609|NCT04086862|PROCEDURE|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
47978610|NCT02123498|DRUG|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
47978611|NCT02123498|DRUG|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
47978612|NCT02123498|DRUG|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
48337836|NCT06263660|DIETARY_SUPPLEMENT|Keto-like supplement|Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
48337837|NCT06263660|DIETARY_SUPPLEMENT|Placebo|Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
48495645|NCT04798612|DRUG|Saline|0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between
48495646|NCT05126355|BEHAVIORAL|On the Move group exercise|The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
47978613|NCT02123498|PROCEDURE|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
47978614|NCT02123498|PROCEDURE|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
48495647|NCT03254030|OTHER|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
48495648|NCT03805100|BIOLOGICAL|Ranibizumab|Intravitreal injection
48495649|NCT04236570|DEVICE|Thermode(hot plate) and cold water bath|Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
48654651|NCT06018519|OTHER|Cognitive assessments|"19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible~20- CPM-BF~21- Simple reasoning task on tablet (match-to-sample task)~22- Implicit rules learning (modified Brixton),~23- 4 sub-tests from the WPPSI-IV (zoo location to assess spatial memory, block design to assess visuo-constructive abilities, bug search , cancellation),~24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),~25- Elementary visuo-spatial perception (on tablets)"
47978615|NCT04464356|DEVICE|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
48495650|NCT04236570|DEVICE|TENS(transcutaneous electrical nerve stimulation)|TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
48495651|NCT01483469|DRUG|RO4917523|orally daily, 14 days
48495652|NCT01483469|DRUG|RO5011232|\[11C\]-RO5011232 intravenously
47978616|NCT00617123|DRUG|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
47978617|NCT00617123|DRUG|Placebo|matching placebo oral tablet
47978618|NCT02822768|PROCEDURE|Packing|The patient will receive packing as part of their wound care
47978619|NCT02822768|OTHER|No packing|The patient will not receive packing as part of their wound care
47978620|NCT05718128|PROCEDURE|Endocardiomyocardial biopsy|Endocardiomyocardial biopsy
47978621|NCT02657174|DEVICE|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
48130537|NCT06050252|PROCEDURE|Resection|Undergo surgical resection
48337838|NCT02699853|OTHER|Questionnaire Administration|Ancillary studies
48337839|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo RRC
48337840|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo ORC
48337841|NCT03529370|RADIATION|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
48495653|NCT01616953|BIOLOGICAL|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
48654652|NCT06018519|OTHER|Language assessments|"26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),~27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),~28- Automatic language analysis (during a 10 minutes interaction, play)."
48337842|NCT01937624|DEVICE|Diagnostic Ultrasound|
48337843|NCT01937624|RADIATION|X-ray imaging|
48337844|NCT03879993|OTHER|Exercise group|Resistance training 3 times per week (45-60 minutes of resistance training)
48495654|NCT01616953|PROCEDURE|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
48130538|NCT04810546|DIETARY_SUPPLEMENT|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
48654653|NCT06018519|OTHER|Motor assessments|"29- Kinematic task (specifically designed),~30- Purdue-Pegboard test,~31- Renzi test"
48130539|NCT03102034|BIOLOGICAL|D46/NS2/N/ΔM2-2-HindIII|10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
48130540|NCT03102034|BIOLOGICAL|Placebo|Isotonic diluent; administered as nose drops
48495655|NCT00870597|PROCEDURE|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
48130542|NCT05142189|BIOLOGICAL|BNT116|intravenous injection
48495656|NCT00870597|PROCEDURE|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
48495657|NCT03191110|OTHER|No intervention: observational study|
48654654|NCT06018519|OTHER|Social assessments|"32- Eye-tracking analysis of social visual scenes and social preference index (movies),~33- theory of mind assessment,~34- ADOS scale (Autism Spectrum Disorder),~35- sensitivity to inequality,~36- pro-social behaviors (help of the psychologist)"
48654655|NCT06018519|OTHER|3T MRI|37- Structural, metabolic and functional data
47978622|NCT02657174|DEVICE|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
48654656|NCT06018519|OTHER|Cardiac assessments|"38- ECG~39- Ultrasound"
47978623|NCT03735225|DRUG|Dasiglucagon|Dasiglucagon injection
48130543|NCT05142189|BIOLOGICAL|Cemiplimab|intravenous infusion
48130544|NCT05142189|DRUG|Docetaxel|intravenous infusion
48130545|NCT05142189|DRUG|Carboplatin|intravenous infusion
48130546|NCT05142189|DRUG|Paclitaxel|intravenous infusion
48495658|NCT04213352|OTHER|Wrist Splint|Neutral position and volar supported wrist orthosis which limits the flexion and deviation while allowing pronation, supination, and extension of the wrist.
48495659|NCT04213352|OTHER|Rigid Taping|Rigid taping in the neutral position will be performed to allow pronation, supination, and extension of the wrist while limiting the flexion and deviation.
48654657|NCT06018519|OTHER|Biological collection|"40- Blood sample~41- Urinary sample~42- Superficial skin biopsy"
47978624|NCT03735225|DRUG|Placebo|Placebo for Dasiglucagon injection
47978625|NCT00321802|DRUG|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
47978626|NCT00321802|DRUG|Placebo|Placebo
47978627|NCT01798004|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
48495660|NCT04072380|DRUG|SUVN-G3031|SUVN-G3031 Tablets
48495661|NCT04072380|DRUG|Placebo|Placebo Tablets
48495662|NCT04385966|PROCEDURE|Interscalene brachial plexus block|Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
48495663|NCT04385966|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|"Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999)."
48495664|NCT00103311|DRUG|ispinesib|Given IV
48495665|NCT00103311|OTHER|laboratory biomarker analysis|Correlative studies
48654658|NCT03435107|DRUG|Durvalumab|"Study treatment consists of durvalumab 1500 mg Q4W for patients \> 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
47978628|NCT01798004|DRUG|Busulfan|Given IV
47978629|NCT01798004|DRUG|Cisplatin|Given IV
47978630|NCT01798004|DRUG|Cyclophosphamide|Given IV
47978631|NCT01798004|DRUG|Doxorubicin Hydrochloride|Given IV
47978632|NCT01798004|DRUG|Etoposide|Given IV
47978633|NCT01798004|RADIATION|External Beam Radiation Therapy|Undergo EBRT
47978634|NCT01798004|BIOLOGICAL|Filgrastim|Given SC or IV
47978635|NCT01798004|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
47978636|NCT01798004|DRUG|Melphalan|Given IV
47978637|NCT01798004|DRUG|Mesna|Given IV
47978638|NCT01798004|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
47978639|NCT01798004|OTHER|Pharmacological Study|Correlative studies
48130547|NCT05142189|BIOLOGICAL|CTLA4 antibody|intravenous infusion
48130548|NCT03933137|OTHER|Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score|P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
48130549|NCT06383572|DRUG|Cyclophosphamide|Given by IV
48130550|NCT06383572|DRUG|Fludarabine phosphate|Given by IV
48130551|NCT06383572|DRUG|Decitabine|Given by IV
48130552|NCT00121849|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
48337845|NCT01998152|PROCEDURE|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
48337846|NCT04907422|DIAGNOSTIC_TEST|CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction|new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
48337847|NCT04907422|DIAGNOSTIC_TEST|non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction|conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
48337848|NCT01181141|DRUG|DU-176b (edoxaban)|
48337849|NCT01181141|DRUG|Enoxaparin sodium 20mg|
48337850|NCT00659126|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
48337851|NCT00659126|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
48337852|NCT00659126|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
48337853|NCT00659126|DRUG|Ferumoxytol|Given IV
48337854|NCT00659126|DRUG|Gadolinium|Given IV
47978640|NCT01798004|DRUG|Topotecan Hydrochloride|Given IV
47978641|NCT01798004|DRUG|Vincristine Sulfate|Given IV
48337855|NCT00659126|PROCEDURE|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
48337856|NCT00659126|PROCEDURE|Susceptibility Weighted Imaging|Undergo SWI
48337857|NCT04972825|BEHAVIORAL|Mind the Gap|This intervention will help parents with children newly diagnosed with autism or other neurodevelopmental disorders learn how to navigate the system of acquiring services for their child. These parents will be assisted by a coach, an employee at the child's agency, that will help them through this process.
48337858|NCT05625880|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
48654659|NCT06181058|BEHAVIORAL|escape room game|Participants will be informed about the game (15 minutes). They will complete the game by solving puzzles within the framework of the oncology patient scenario (approximately 30 minutes). There will be a debriefing session at the end of the escape game (15 minutes).
48654660|NCT05670704|BIOLOGICAL|ARGX-119|Patients receiving ARGX-119 IV or SC
48654661|NCT05670704|OTHER|Placebo|Patients receiving Placebo IV or SC
48654662|NCT01793233|OTHER|Laboratory Biomarker Analysis|Correlative studies
48337859|NCT02641639|DRUG|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
48337860|NCT02641639|DRUG|Placebo|Saline for infusion
48337861|NCT01263444|DRUG|Brinzolamide 1% / timolol 0.5% Fixed Combination|
48337862|NCT01263444|DRUG|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
48654663|NCT01793233|OTHER|Questionnaire Administration|Ancillary studies
48654664|NCT03283956|DEVICE|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
48654665|NCT06643546|OTHER|theoretical training|received only theoretical breastfeeding training
48654666|NCT06643546|OTHER|model simulation training|theoretical breastfeeding training and model simulation training accompanied by scenarios
48654667|NCT06643546|OTHER|live-simulation|theoretical breastfeeding training and live simulation training with scenarios
48654668|NCT02446457|OTHER|Laboratory Biomarker Analysis|Correlative studies
48654669|NCT02446457|DRUG|Lenalidomide|Given PO
47978642|NCT01581931|DRUG|Linagliptin/metformin|FDC
47978643|NCT01581931|DRUG|Metformin|single tablet Metformin
47978644|NCT01581931|DRUG|Linagliptin|single tablet Linagliptin
47978645|NCT01849380|DRUG|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
47978646|NCT01849380|DRUG|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
48337863|NCT01909609|OTHER|AAP Documents|
48337864|NCT01909609|OTHER|Parent Survival Guide|
48337865|NCT00469209|DRUG|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
48337866|NCT00469209|DRUG|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
48337867|NCT00469209|DRUG|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
48337868|NCT00469209|DRUG|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
48654670|NCT02446457|BIOLOGICAL|Pembrolizumab|Given IV
48654671|NCT02446457|BIOLOGICAL|Rituximab|Given IV
48654672|NCT05517421|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
48654673|NCT05517421|DRUG|Placebo|Matching Placebo
48495666|NCT01763684|DEVICE|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
48495667|NCT01763684|PROCEDURE|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
48130557|NCT05674929|DRUG|BPL-003|A single dose administered intranasally
48495668|NCT00316147|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
48495669|NCT04763694|DEVICE|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
48654674|NCT05515224|OTHER|5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.
48654675|NCT05515224|OTHER|Enhanced usual care|A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
48654676|NCT06070012|DRUG|Tebentafusp|An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
48654677|NCT05662722|OTHER|percutaneous needle electrolysis|It´s an intervention of physiotherapy. It´s an invasive technique.
48654678|NCT05662722|OTHER|Dry needling|It´s an intervention of physiotherapy. It´s an invasive technique.
47978647|NCT02915497|BEHAVIORAL|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
47978648|NCT05634304|BEHAVIORAL|A mobile app self-management (mSM) program|The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
47978649|NCT06044285|OTHER|Low UP (meals provided)|"This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
48495670|NCT03014180|DEVICE|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
48495671|NCT02302664|PROCEDURE|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
48495672|NCT02302664|PROCEDURE|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
48495673|NCT00415844|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
48130564|NCT06285253|COMBINATION_PRODUCT|miroliverELAP treatment|Subject's blood will be perfused through a bioengineered liver graft via an extracorporeal blood circuit.
48130565|NCT02000089|DRUG|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
48130566|NCT02000089|DIAGNOSTIC_TEST|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
48130567|NCT02000089|OTHER|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
48654679|NCT05662722|OTHER|Sham needling|It´s an intervention of physiotherapy. It´s an invasive technique simulation.
48654680|NCT05311423|DIAGNOSTIC_TEST|QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra|Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
48654681|NCT06639737|PROCEDURE|preoperative stroke volume optimization|Stroke volume optimization using transthoracic echocardigraphy (sub aortic velocity time integral) before induction of total intravenous anesthesia. Fluids bolus of 250 ml of cristalloids will be successively administered until the sub aortic velocity time integral increase will be \< 10%
48130571|NCT06294223|DEVICE|Exercise follow up with near-infrared spectroscopy|Exercises will be followed by near-infrared spectroscopy. Fatigue protocol will be applied.
48337869|NCT03954990|DRUG|Metronidazole Oral|4 tablets (2 g of metronidazole)
48337870|NCT03954990|DRUG|Placebo Oral Tablet|4 tablets
48337871|NCT00961441|DRUG|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
48337872|NCT05666570|DEVICE|Avelle NPWT|wound management therapy
48130572|NCT05563766|DRUG|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
48495674|NCT02803229|DRUG|Adderall-XR|
48495675|NCT02803229|DRUG|Matched placebo|matched placebo provided for placebo arm
48495676|NCT03214874|DRUG|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
48495677|NCT03214874|DRUG|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
48495678|NCT00589030|RADIATION|brachytherapy|The target dose of TheraSphere® is 80-150Gy
47978650|NCT06044285|OTHER|Low UP (self-guided)|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat a low UP diet according to study provided nutritional guidance.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
47978651|NCT06044285|OTHER|Active Control|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat as they normally do.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
48337873|NCT06122753|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
48495679|NCT00589030|RADIATION|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
48337874|NCT06122753|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
48337875|NCT01477138|PROCEDURE|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
48495680|NCT00658749|DRUG|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
48495681|NCT00658749|DRUG|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
48495682|NCT05757323|OTHER|infant formula based on hydrolyzed protein|infant formula based on hydrolysed protein
48130575|NCT04504721|OTHER|light therapy|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
48130576|NCT05111574|PROCEDURE|Biospecimen Collection|Undergo blood, stool and tissue sample collection
48130577|NCT05111574|DRUG|Cabozantinib S-malate|Given PO
48495683|NCT05757323|OTHER|infant formula based on intact protein|infant formula based on intact protein
47978652|NCT02728050|DRUG|Cladribine|Given IV
47978653|NCT02728050|DRUG|Cytarabine|Given IV
47978654|NCT02728050|BIOLOGICAL|Filgrastim|Given SC
47978655|NCT02728050|OTHER|Laboratory Biomarker Analysis|Correlative studies
47978656|NCT02728050|OTHER|Quality-of-Life Assessment|Ancillary studies
48130578|NCT05111574|PROCEDURE|Computed Tomography|Undergo CT
48130579|NCT05111574|PROCEDURE|Echocardiography|Undergo ECHO
48130580|NCT05111574|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48130581|NCT05111574|BIOLOGICAL|Nivolumab|Given IV
48130582|NCT05111574|DRUG|Placebo Administration|Given PO
48130583|NCT05111574|PROCEDURE|Positron Emission Tomography|Undergo PET
48495684|NCT06214169|DRUG|Cisatracurium Besylate|Addition of cisatracurium to plain lignocaine for IVRA.
48495685|NCT06214169|DRUG|Lignocaine|Plain Lignocaine for IVRA
48495686|NCT05420974|PROCEDURE|NIR fluorescence imaging of the vascular perfusion of the meniscus using ICG|NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green
48495687|NCT04319718|COMBINATION_PRODUCT|MK-2048 High Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)"
47978657|NCT02728050|DRUG|Mitoxantrone|Given IV
47978658|NCT02728050|DRUG|Sorafenib|Given PO
48337876|NCT06268483|DIETARY_SUPPLEMENT|HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg + cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group I: an oral preparation (capsule) of HA 100 mg, CS 400 mg, N-Acetylglucosamine 200 mg and vitamin C 80 mg once a day in the morning plus an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
47978659|NCT05071456|OTHER|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
47978660|NCT02050776|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
47978661|NCT02016560|DRUG|florbetapir F 18|
48337877|NCT06268483|DIETARY_SUPPLEMENT|cranberry, D-mannose, propolis extract, tumeric and Boswellia|Group C: an oral preparation of cranberry, D-mannose, propolis extract, tumeric and Boswellia twice a day for three months.
48337878|NCT03421509|OTHER|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
48495688|NCT04319718|COMBINATION_PRODUCT|MK-2048 Low Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)"
48495689|NCT00084448|DRUG|celecoxib|
48495690|NCT00084448|DRUG|paclitaxel|
48495691|NCT03325465|DRUG|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
48495692|NCT03325465|DRUG|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
47978662|NCT02016560|DRUG|Flortaucipir F18|
47978663|NCT02016560|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
47978664|NCT00987220|DRUG|Placebo|Oral
48337879|NCT01095341|OTHER|No intervention performed|
48337880|NCT01620697|PROCEDURE|Colorectal surgery|Colorectal surgery
48337881|NCT02529670|PROCEDURE|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
48337882|NCT02529670|PROCEDURE|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
48337883|NCT02529670|PROCEDURE|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
48337884|NCT03698422|DIAGNOSTIC_TEST|Blood and urine samples|Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
48337885|NCT05635370|DRUG|Pentoxifylline|Pentoxifylline claim is used as the exposure group.
48337886|NCT05635370|DRUG|Cilostazol|Cilostazol claim is used as the reference group.
48654682|NCT06639737|PROCEDURE|Post induction stroke volume optimization|Optimization of stroke volume following induction of general anesthesia using oesophageal stroke volume measurement. 250 ml bolus of cristalloids succesively administered until the stroke volume increase \<10%
48654683|NCT01881958|DRUG|DiaPep277®|
48654684|NCT06641219|DRUG|One single intravenous injection of [177Lu]Lu-BQ7876|One single intravenous injection of 600-800 MBq \[177Lu\]Lu-BQ7876 in prostate cancer patients.
48654685|NCT00002515|BIOLOGICAL|filgrastim|
48654686|NCT00002515|DRUG|carboplatin|
48654687|NCT00002515|DRUG|thiotepa|
48495693|NCT04647721|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
47978665|NCT00987220|DRUG|donepezil (Aricept)|5mg oral
47978666|NCT02753023|OTHER|no intervention|No intervention related
47978667|NCT04518150|DEVICE|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
47978668|NCT04518150|PROCEDURE|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
47978669|NCT06131697|OTHER|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.
47978670|NCT06131697|OTHER|McKenzie Exercises with Mulligan Mobilization|"McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.~Along McKenzie exercises Sustained Natural Apophyseal Glide will be given with the tip of thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. This exercise will be performed for three sets of six repetitions twice a week for the time period of four weeks."
47978671|NCT04300127|DRUG|Pioglitazone 30 mg|Patients will received 30 mg of Pioglitazone once a day for 8 weeks
47978672|NCT05292846|DRUG|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
48495694|NCT04647721|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection.
48495695|NCT03958123|DRUG|100 μg cebranopadol|Encapsulated 100 μg cebranopadol tablet.
48495696|NCT03958123|DRUG|200 μg cebranopadol|Encapsulated 200 μg cebranopadol tablet.
48495697|NCT03958123|DRUG|400 μg cebranopadol|Encapsulated 400 μg cebranopadol tablet.
48495698|NCT03958123|DRUG|Placebo to cebranopadol encapsulated tablets|Matching placebo to cebranopadol encapsulated tablet.
48654688|NCT00002515|DRUG|topotecan hydrochloride|
48654689|NCT00002515|PROCEDURE|autologous bone marrow transplantation|
48654690|NCT00002515|PROCEDURE|bone marrow ablation with stem cell support|
48130584|NCT05814653|BEHAVIORAL|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
48495699|NCT03958123|DRUG|400 mg Moxifloxacin|Encapsulated 400 mg moxifloxacin tablet.
48495700|NCT03958123|DRUG|Placebo to moxifloxacin encapsulated tablets|Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
48654691|NCT00002515|PROCEDURE|in vitro-treated bone marrow transplantation|
47978673|NCT06243991|DEVICE|in vivo Corneal Confocal Microscopy|CCM was performed using the Heidelberg Retinal Tomograph 3 with the Rostock Cornea Module (HRT3-RCM, Heidelberg Engineering GmbH, Germany) under topical anesthesia. A viscous gel (Viscotears, Novartis Pharmaceuticals UK) served as a coupling agent between the cornea and the applanation cap. The subjects were instructed to focus on the fixation light with the unexamined eye to ensure proper positioning. Five high-quality images of the SNP were selected and analyzed using the automated tracing of nerve fibers program (ACCMetrics, M.A. Dabbah, Imaging Science and Biomedical Engineering, Manchester, England).
47978674|NCT06243991|DIAGNOSTIC_TEST|Corneal Sensitivity|Corneal sensitivity was evaluated using a Cochet-Bonnet esthesiometer (Luneau Ophtalmologue, Chartres, France), comprising a nylon filament measuring 60 mm in length and 0.12 mm in diameter. Participants were instructed to maintain a forward gaze while the esthesiometer gently made perpendicular contact. The procedure involved gradually decreasing the filament length in 5 mm increments, starting from 60 mm, until the initial response from the subject was detected.
47978675|NCT06243991|DEVICE|Non invasive tear break up time|Noninvasive tear break-up time (NI-TBUT) was assessed using a Sirius Scheimpflug camera (CSO, Florence, Italy) and the device automatically provided the average NI-TBUT value
47978676|NCT06243991|DIAGNOSTIC_TEST|Ocular Surface Disease Index Qestionnaire|The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = \[(sum of scores for all questions answered) × 100\] / \[(total number of questions answered) × 4\].
47978677|NCT06243991|DEVICE|Corneal tomography|Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.
47978678|NCT00118365|OTHER|placebo|Given orally
47978679|NCT00118365|DRUG|eflornithine|Given orally
47978680|NCT00118365|DRUG|sulindac|Given orally
47978681|NCT00118365|OTHER|laboratory biomarker analysis|Correlative studies
47978682|NCT01466855|DRUG|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
47978683|NCT00376662|DRUG|Hormone Replacement Therapy and Etidronate|
47978684|NCT03628560|DEVICE|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
47978685|NCT03628560|DEVICE|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
48130585|NCT05814653|BEHAVIORAL|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
48495701|NCT03301532|DRUG|Triheptanoin|Dietary supplementation with triheptanoin
48495702|NCT01307839|DRUG|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
48495703|NCT01307839|DRUG|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
47978686|NCT03628560|DEVICE|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
47978687|NCT03628560|DEVICE|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
47978688|NCT03628560|DEVICE|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
47978689|NCT03470818|OTHER|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
48495704|NCT04902625|DRUG|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
48495705|NCT03373734|DEVICE|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
48495706|NCT00283790|DRUG|zolpidem tartrate|
48654692|NCT06640218|DEVICE|sealer activation with Eddy sonic and AF max|activation of sealer after cleaning and shaping, before the obturation
48495707|NCT03792087|DRUG|SmofKabiven Peripheral|Total Parenteral Nutrition
48495708|NCT03792087|DRUG|Hospital compounded emulsion|Total Parenteral Nutrition
48495709|NCT03832881|DIAGNOSTIC_TEST|ADAMTS13, VWF assay|
48495710|NCT01533766|DRUG|CombiflexOmega|intravenously over 5 days infusion
48495711|NCT01533766|DRUG|SmofKabiven|intravenously over 5 days infusion
48495712|NCT04158661|PROCEDURE|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
48337887|NCT05499598|PROCEDURE|Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
48337888|NCT05499598|PROCEDURE|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
48337889|NCT02227472|OTHER|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
48337890|NCT02227472|OTHER|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
48337891|NCT05440487|OTHER|Iron chelator|There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
48337892|NCT04246125|PROCEDURE|Interventional radiology : skin dose measurements|"Therapeutic interventional radiology procedure for the following anatomical regions:~* cerebral (neuroradiology)~* thoracic (cardiology, lungs)~* abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program."
48337893|NCT03765710|OTHER|Recommended protein intake|Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
48337894|NCT03765710|OTHER|Elevated protein intake|Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
48337895|NCT01350713|DRUG|povidone iodine|one local application of 10% povidone iodine ointment
48495713|NCT04158661|PROCEDURE|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
48495714|NCT04158661|PROCEDURE|no thymectomy (control)|routine medical care
48495715|NCT00815256|PROCEDURE|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
48495716|NCT00378183|DRUG|risperidone|
48654693|NCT06640218|OTHER|without AF max or Eddy sonic sealer activation|sealer without activation
48654694|NCT05616910|DRUG|inhaled nitric oxide|iNO will be provided by ventilator or nasal cannula for 4 hours each day.
48654695|NCT06641661|DRUG|Hybutimibe 10mg QD|Hybutimibe was added to the conventional treatment
48654696|NCT06548724|OTHER|assessment of quality of life before and after anal surgery|"Preoperatively, the state of continence will be assessed using Wexner Incontinence Score (WIS) . Also, the basal state of quality of life (QoL) will be assessed using a validated disease-specific tool known as Quality of Life in patients with Anal Fistula Questionnaire (QoLAFQ) (Ferrer-Márquez et al., , faecal incontinence quality of life (FIQL)~Surgical Techniques:~The selection of surgical technique depends on the type of fistula , patient choice and commitment to guidelines . Follow-up Patients will be followed-up in the outpatient clinic weekly in the first month, then every two weeks in the second month, then at 3, and 6 months postoperatively. The continence state and QoL change will be assessed using QoLAF-Q and GIQLI 3 months and6 months postoperatively."
48130588|NCT05433415|BEHAVIORAL|Black Girls Move|Goal setting and monitoring. All BGM daughters will self-monitor their progress towards PA goals using a PA device, Fitbit®. Additionally, BGM daughters will self-monitor their progress towards diet goals using a mobile application, Start Simple with My Plate®. Further, all BGM mothers will use Fitbit® and Start Simple with My Plate® for self monitoring, however, mothers' data will not be analyzed for this study. Since the daughter/ mother relationship is critical to achieving behavioral change, BGM mothers will utilize Fitbit® and Start Simple with My Plate® as a mechanism to communicate, problem solve and support daughters' behavioral goals.BGM is situated within the contexts of environmental, cultural, interpersonal, and developmental factors impacted by structural racism. Intentionally engaging mothers and daughters in an asset based program provides a framework for mothers to model responses to structural racism i.e. racial socialization.
48654697|NCT06642259|RADIATION|Echocardiography|ECHO
48130590|NCT06161415|DRUG|Laquinimod eye drops|n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned
48654698|NCT00831883|BEHAVIORAL|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
48654699|NCT00831883|BEHAVIORAL|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
48130591|NCT04102865|DEVICE|Negative-Pressure Wound Therapy (NPWT)|Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.
48495717|NCT05007314|BEHAVIORAL|Biocriminological Evidence|Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
48495718|NCT02327416|DRUG|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
48130595|NCT05180591|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
48495719|NCT02327416|DRUG|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
48654700|NCT06296355|BEHAVIORAL|Health Warning Label|"Message displayed on warning label is: WARNING: Consuming ultra-processed food and drinks can cause weight gain, which increases the risk of obesity and type 2 diabetes."
48495720|NCT02327416|DRUG|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
48495721|NCT05080101|OTHER|Conventional Therapy Program|Patients in control group (n=14) will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation (TENS) which will be applied to lumbar region with a frequency of 100 Hz, 50-100 μsec current duration for 20 minutes, hotpack which will be applied to lumbar region for 20 mins, and ultrasound application which will be applied to the lumbar region with a Chattanooga Intelect Mobile device at a frequency of 1 MHz, at a dose of 1.5 W/cm2, for 6 minutes using a 10 cm2 head.
48654701|NCT06296355|BEHAVIORAL|Identity Warning Label|"Message displayed on warning label is: WARNING: Ultra-processed food."
48654702|NCT06296355|OTHER|Barcode Label|Barcode is displayed.
48654703|NCT06644079|DRUG|Tranexamic acid|Participants will self-apply topical tranexamic acid to the area where their disease is located 3 times daily for 21-28 days prior to their scheduled Moh's or excision surgery.
48654704|NCT05798663|DRUG|Atezolizumab|Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.
47978690|NCT03470818|OTHER|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
47978691|NCT04912050|DEVICE|Tablo Hemodialysis System|Renal Replacement Therapy between 12\< to ≤ 24 hours.
47978692|NCT03374878|OTHER|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
47978693|NCT03374878|OTHER|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
47978694|NCT02976428|PROCEDURE|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
47978695|NCT02976428|PROCEDURE|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
47978696|NCT03053284|DRUG|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
47978697|NCT03053284|DRUG|Saline Solution|Saline Solution injection will be given once per study visit
47978698|NCT04395469|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
47978699|NCT03789344|OTHER|acupuncture|Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
47978700|NCT03789344|OTHER|Psychotherapy|Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
47978701|NCT03789344|OTHER|blank control|Blank control subjects would be observed only during this investigation.
47978702|NCT02061267|DIETARY_SUPPLEMENT|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
48130596|NCT05180591|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
48495722|NCT05080101|OTHER|Basic Body Awareness Therapy Group Program|Patients in study group (n=14) will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and various cognitive exercises in supine, position, sitting position and standing position. These exercises will be consist of exercises such as body scanning, breathing, sound resonance.
48495723|NCT05690503|DRUG|CI-581a|Medication infusion intravenously over 90 minutes.
48495724|NCT05690503|DRUG|CI-581b|Medication infusion intravenously over 90 minutes.
48495725|NCT01287039|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
48130601|NCT05071300|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
48654705|NCT05798663|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
47978703|NCT02061267|DIETARY_SUPPLEMENT|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
47978704|NCT02061267|DIETARY_SUPPLEMENT|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
47978705|NCT02061267|DIETARY_SUPPLEMENT|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
47978706|NCT01698801|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
47978707|NCT01698801|DRUG|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
48495726|NCT01287039|DRUG|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
48130603|NCT04524247|DEVICE|Physician Modified Endografts|"Modification procedure Description of modified device is detailed in Section 3.5 of IDE. In summary, the steps involved in modification of the Zenith Alpha thoracic stent grafts are;~1. Unsheathing of the stent graft~2. Retrieval of a trigger wire from the inner cannula of the delivery system~3. Rerouting of the trigger wire along the stent graft~4. Removal of proximal barbs.~5. Creation of fenestrations and/or branch cuffs~6. Placement of radiopaque markers around the fenestrations/ branch cuffs~7. Placement of temporary and/or permanent diameter constraining ties~8. (Optional) Placement of preloaded wires through the fenestrations/branch cuffs"
48495727|NCT00160641|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
48495728|NCT05087862|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After the ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% bupivacaine.
48495729|NCT05087862|PROCEDURE|Pericapsular local anesthetic infiltration of the hip|Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
48495730|NCT01046266|DRUG|RO5083945|700mg iv weekly
48495731|NCT01046266|DRUG|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
48495732|NCT04258475|DRUG|Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.|Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.
48130610|NCT02387866|DRUG|AG-221|
48495733|NCT04258475|DRUG|Calcium carbonate antacid tablet|PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
48130612|NCT01613053|DRUG|Glivec|800 mg per day
48130613|NCT06221969|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
48130614|NCT06221969|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
48130615|NCT06221969|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
48495734|NCT06131749|OTHER|No intervention|No intervention, observational cohort study
48495735|NCT02747862|OTHER|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of \> 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
48495736|NCT04748523|DRUG|Mirtazapine|arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.
48495737|NCT04748523|DRUG|Placebo Oral Tablet|arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
48495738|NCT04941521|DRUG|Exenatide 2 mg [Bydureon]|Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
48495739|NCT04941521|BEHAVIORAL|Drug Counseling|Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.
48130622|NCT05531565|DRUG|Litifilimab|Administered as specified in the treatment arm.
48130623|NCT05531565|DRUG|Placebo|Administered as specified in the treatment arm.
48130624|NCT00831688|DEVICE|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
48130625|NCT00831688|DEVICE|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
48130626|NCT05370885|BIOLOGICAL|VE202|VE202 is a rationally defined, live biotherapeutic product for oral administration.
48130627|NCT05370885|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection
48130628|NCT05370885|OTHER|VE202 Placebo|VE202 Placebo
48130629|NCT05370885|OTHER|Vancomycin Placebo|Vancomycin Placebo
48495740|NCT03011190|BEHAVIORAL|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
48495741|NCT02893137|DEVICE|Optune|For further information see www.optune.com
48130632|NCT02877303|BIOLOGICAL|Blinatumomab|Given IV
48130633|NCT02877303|DRUG|Cyclophosphamide|Given IV
48130634|NCT02877303|DRUG|Cytarabine|Given IT and IV
48130635|NCT02877303|DRUG|Dexamethasone|Given PO
48130636|NCT02877303|DRUG|Doxorubicin Hydrochloride|Given IV
48130637|NCT02877303|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
48130638|NCT02877303|OTHER|Laboratory Biomarker Analysis|Correlative studies
48130639|NCT02877303|DRUG|Mercaptopurine|Given PO
48130640|NCT02877303|DRUG|Methotrexate|Given IT, IV, and PO
48130641|NCT02877303|BIOLOGICAL|Ofatumumab|Given IV
48130642|NCT02877303|DRUG|Prednisone|Given PO
48130643|NCT02877303|BIOLOGICAL|Rituximab|Given IV
48130644|NCT02877303|DRUG|Vincristine Sulfate|Given IV
48495742|NCT02893137|PROCEDURE|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
48495743|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
48495744|NCT03986736|DIAGNOSTIC_TEST|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
48495745|NCT04710966|PROCEDURE|arthroscopic debridement|For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.
48495746|NCT04710966|PROCEDURE|arthroscopic repair|For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
48495747|NCT02475941|OTHER|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
48130663|NCT03502785|BIOLOGICAL|INO-5401|INO-5401 (9 milligram \[mg\] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
48130664|NCT03502785|BIOLOGICAL|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
48130665|NCT03502785|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
48130666|NCT03502785|DEVICE|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
48130667|NCT05927623|BEHAVIORAL|Multifaceted Virtual Fracture Prevention Program|"* Personalized exercise prescription: Comprised of muscle strengthening and balance exercises to perform three times a week, delivered and monitored remotely via the MisterFit app, a branded version of the secure commercially available Wibbi app (wibbi.com) and monthly virtual exercise consultations.~* Virtual nutrition counseling from a registered dietitian in months 2, 4 and 6: to encourage participants to meet daily targets for calcium and vitamin D (preferably from diet), and protein intake to support muscle accretion and target weight maintenance~* Virtual interactive information sessions in month 4 and 8: to education participants on topics identified as important by the Misterfit patient partner advisory committee."
48130668|NCT05927623|BEHAVIORAL|Attention Control|"* Encouraged to meet the 24-Hour Movement Guidelines for adults aged 65 years or older (https://csepguidelines.ca) with telephone contacts at the same frequency that the Misterfit online group receives virtual exercise consultations~* Nutritional fact sheets: sent by e-mail at the same frequency that the Misterfit online group meets with the research dietitian.~* Educational fact sheets: sent by e-mail at the same frequency that the Misterfit Online group has virtual interactive information sessions"
48495748|NCT02475941|OTHER|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
48495749|NCT05428410|OTHER|IL-4R|IL-4R was injected subcutaneously.
48130671|NCT04763759|DRUG|TRL1068, a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
48130672|NCT00004847|DRUG|([18F]-DOPA)|is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
48130673|NCT00004847|DRUG|([18F]-6F-DA)|is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
48130674|NCT06308562|DEVICE|Fuzzy Wale Compression Stockinet|EdemaWear is a tubular, circular knit elastic stockinet fabricated with elastic, vertically oriented fuzzy wales, with the compression provided by the elastic, horizontal oriented Lycra® spandex yarns knitted in between. The stockinet is applied from the foot to the popliteal crease, over the affected area. EdemaWear can be applied in direct contact with the skin or over a wound care dressing. Sizing is based on leg circumference. EdemaWear is indicated for edema management of various etiologies (lymphedema, chronic venous insufficiency, congestive heart failure), and optimizing wound healing. The stockinette is often combined with other boxed compression sets. The manufacturer's stated dosage of EdemaWear is 8-12mmHg when used alone.
48495750|NCT05428410|OTHER|Placebo|Placebo was injected subcutaneously.
48337896|NCT02330913|PROCEDURE|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
48337897|NCT05924126|OTHER|empiric antibiotic therapy|septic ICU patient given broad spectrum antibiotic therapy
48337898|NCT01302691|DRUG|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
48337899|NCT01302691|DRUG|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
48337900|NCT01302691|DRUG|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
48495751|NCT02279693|OTHER|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
48130679|NCT06406114|DRUG|Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing|Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), cefotaxime (100 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), cefotaxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), pre-pen (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), cefotaxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls.
48337901|NCT01302691|DRUG|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
48337902|NCT01302691|DRUG|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
48495752|NCT02279693|OTHER|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
47978708|NCT06190223|PROCEDURE|Anterior cruciate ligament (ACL) reconstruction with a periost-patellar-tendon-bone (PPTB) autograft and a tibial press-fit technique|A longitudinal incision will be performed starting from the central part of the patella. A ruler will be used to mark a tendon thickness of 10mm from the middle of the patellar tendon. Superiorly, the patellar periosteum will be marked with a length of 30-40mm and a width of 10mm. Inferiorly, the tibial tubercle will be marked in a trapezoidal shape with a length of approximately 35mm, a superior narrow base of 10mm and an inferior wider base of 12mm. After extraction, the superior part of the graft will be prepared with reinforced sutures in a whipstitch pattern, while the bone block will be shaped according to the planned tunnel width. After adequate preparation, the femoral end of the graft will be shuttled in with an adjusted fixation device, while the tibial end will be hammered in with a small mallet, in a press-fit fashion, stopping short of the joint surface, but tensioned appropriately. The femoral adjustable device will then be tensioned to ensure proper graft sitting.
47978709|NCT00275054|DRUG|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
47978710|NCT00275054|DRUG|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
47978711|NCT00275054|BIOLOGICAL|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d"
47978712|NCT05480085|BEHAVIORAL|School-based extracurricular intervention focusing on screen media use and time spent with friends|"The intervention includes the following components:~1. Within each class parents will engage in two meetings combining education and parent-to-parent communication about 1) the children's leisure time activities, and 2) family and class screen time culture. Parents will engage in a short exercise focusing on screen media dilemmas conducted by the teacher in the beginning of 4th grade.~2. Children will engage in school hour workshops focusing on the class culture related to screen media use and leisure time activities.~3. Afterschool club personal will engage in mini actions learning program consisting of three workshops aimed to increase participation rate in the afterschool club.~4. Local stakeholders, e.g., parents, school- and afterschool club personal and others relevant to children's leisure time (e.g., sports clubs) will engage in workshops to adjust the predetermined intervention components (1-3 above) to fit their local context and to develop a local action plan."
47978713|NCT02760199|DRUG|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
47978714|NCT02760199|DEVICE|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
47978715|NCT01195415|DRUG|Gemcitabine Hydrochloride|Given IV
47978716|NCT01195415|OTHER|Laboratory Biomarker Analysis|Correlative studies
48337903|NCT01302691|DRUG|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
48337904|NCT04213183|DIAGNOSTIC_TEST|Hepatobiliary Disorders|The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
48337905|NCT01449955|DRUG|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study."
48337906|NCT01449955|DRUG|Placebo|Inactive
48337907|NCT01369407|OTHER|No Intervention|Not an interventional study
48337908|NCT02820441|DRUG|Zopiclone|
48337909|NCT02820441|DRUG|Placebo|
48337910|NCT01020032|OTHER|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
48337911|NCT01766544|OTHER|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
48337912|NCT01766544|OTHER|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
48495753|NCT02279693|RADIATION|IGRT Associated With IMRT|
48495754|NCT04971798|BIOLOGICAL|Cell-free Stem Cell-derived Extract Formulation (CCM)|Intraarticular injection
48495755|NCT03174951|DRUG|IVIg|Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
48130680|NCT06406114|DRUG|Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge|After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
48130681|NCT06406114|DRUG|Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
47978717|NCT01195415|DRUG|Vismodegib|Given PO
47978718|NCT00242489|DRUG|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
47978719|NCT00242489|DRUG|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
47978720|NCT00853866|DRUG|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
47978721|NCT00853866|DRUG|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
47978722|NCT00853866|DEVICE|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
47978723|NCT00853866|DEVICE|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
47978724|NCT05573789|GENETIC|Tumor molecular profiling|Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic
47978725|NCT05791344|DEVICE|ECG monitoring|Intra-procedural ECG changes during TAVR
47978726|NCT03194022|OTHER|Blood sample|measurement of electrolytes and blood count
47978727|NCT06049784|DEVICE|Visual Biofeedback using self operated home ultrasound device|participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.
47978728|NCT06049784|DEVICE|Visual Biofeedback using ultrasound at hospital|A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
47978729|NCT00678054|DRUG|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
47978730|NCT04990154|BEHAVIORAL|a 12-week intradialytic exercise|a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
47978731|NCT03096054|DRUG|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
47978732|NCT06395974|OTHER|fetal ultrasound|2D, 3D , Doppler ultrasound
47978733|NCT05046171|OTHER|Pharmacist-led deprescribing|A pharmacist recruited onto the study will review the patient's current medication list and develop a list of targeted recommendations for deprescribing using the 3-step potentially inappropriate medications identification method.
47978734|NCT05046171|OTHER|Patient education|Subjects receive a written pamphlet about deprescribing.
47978735|NCT03629132|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
47978736|NCT03629132|PROCEDURE|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
47978737|NCT05168488|BEHAVIORAL|Fasted morning resistance exercise|On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.
48337913|NCT03395223|DRUG|Methylene Blue|Administration of Methylene Blue to treat acquired methaemoglobinaemia
48337914|NCT03147599|DRUG|Coloverin|Mebeverine hydrochloride 135 mg
47978738|NCT05168488|BEHAVIORAL|Afternoon resistance exercise|On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
47978739|NCT04978740|OTHER|Ophthalmological examination|"Eye examination :~Ocular tonometry to determine intraocular pressure Refraction assessment Retina examination Slit lamp examination Visual acuity Schirmer's test Corneal topography Funduscopic examination Optical coherence tomography"
47978740|NCT00002990|BIOLOGICAL|BCG vaccine|
47978741|NCT03958955|DRUG|Delgocitinib cream|Cream for topical application.
47978742|NCT03958955|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
47978743|NCT03016754|DEVICE|Wearable Cardioverter Defibrillator|LifeVest Wearable Cardioverter Defibrillator
47978744|NCT02058576|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
47978745|NCT02058576|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
48130682|NCT06406114|DRUG|Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge|Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge.
48130683|NCT06406114|DRUG|Amoxicillin double-blind placebo-controlled drug challenge|Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well.
48495756|NCT04060043|DRUG|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
48130685|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
48130686|NCT04097145|DRUG|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
48130687|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
48130688|NCT04097145|DEVICE|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
48130689|NCT04929795|BEHAVIORAL|Rhythmic auditory stimulation (RAS)|"The song named 'Sign of The Times' is played and recorded by the research personnel beforehand. The beat of the song will serve as RAS. The computer software Audacity will be used to adjust tempi of RAS. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo. For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Participants in the experimental groups are required to use their right hand to pick up beads from source bowls to the target bowl when listening to the song. The 3-week intervention program will include 21 40-minute daily training sessions."
48130690|NCT04929795|BEHAVIORAL|no RAS|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
48495757|NCT04765774|OTHER|Ekspressive touch|Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
48495758|NCT04765774|OTHER|Music|The music chosen by the patient will be played in the music group.
48337915|NCT03147599|DRUG|Placebo|Placebo
48337916|NCT05098418|DRUG|Poison|standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
48337917|NCT03375723|OTHER|Information on anatomy and physiology, and breathing technique|The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
48337918|NCT03375723|OTHER|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
48337919|NCT00868335|DEVICE|Activ C disc prosthesis|cervical disc prosthesis
48337920|NCT00868335|PROCEDURE|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
48495759|NCT04549714|PROCEDURE|High AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.
47978746|NCT05526495|BEHAVIORAL|Reducing preoperative low-value test ordering|A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
47978747|NCT00709046|DRUG|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
48130693|NCT04572906|COMBINATION_PRODUCT|NTX-001|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
48495760|NCT04549714|PROCEDURE|Middle AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.
48495761|NCT04549714|PROCEDURE|Low AI in paroxysmal atrial fibrillation|Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
48495762|NCT01547949|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|
48130694|NCT01721343|BEHAVIORAL|telephone-based intervention|Undergo telephonic monitoring
48130695|NCT01721343|OTHER|case management|Participate in an individualized conditioning program with an RCM
48130696|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
48130697|NCT01721343|PROCEDURE|physical therapy|Participate in an individualized conditioning program with an RCM
48130698|NCT01721343|OTHER|questionnaire administration|Ancillary studies
48130699|NCT01721343|PROCEDURE|quality-of-life assessment|Ancillary studies
48130700|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care
48130701|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care
48495763|NCT01547949|DIETARY_SUPPLEMENT|placebo cherry fruit drink|
47978748|NCT00709046|DRUG|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
47978749|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
47978750|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
47978751|NCT05953220|OTHER|Exclusive tobacco smoking|No intervention, participants own tobacco products
47978752|NCT05953220|OTHER|Exclusive e-cigarette use|No intervention, participants own e-cigarette products
47978753|NCT05953220|OTHER|Dual use of e-cigarettes and tobacco smoking|No intervention, participants own tobacco and e-cigarette products
47978754|NCT05953220|OTHER|No use of e-cigarettes or tobacco smoking|No intervention
47978755|NCT00456521|DRUG|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
47978756|NCT00456521|DRUG|Placebo|
47978757|NCT00456521|BEHAVIORAL|Intensive group lifestyle modification counseling|
48130702|NCT01721343|OTHER|educational intervention|Participate in an individualized conditioning program with an RCM
48130703|NCT01721343|PROCEDURE|management of therapy complications|Undergo enhanced usual care with an RCM
48130704|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM
48130705|NCT01721343|PROCEDURE|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
48495764|NCT04852900|OTHER|Decompression with 30%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
48495765|NCT04852900|OTHER|Decompression with 40%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
48495766|NCT04852900|OTHER|Decompression with 50%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
48495767|NCT01672112|DRUG|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
48495768|NCT01672112|DRUG|Codeine|Oral Codeine 60mg 6hrly/prn
48495769|NCT04942158|PROCEDURE|Non-instrumentation technique with use of CTZ paste|After local anesthesia and rubber dam isolation, the pulp chamber will be accessed. After the location of root canals entrance, an initial irrigation will be conducted using 1% sodium hypochlorite. Then, a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste) will be placed in the pulp chamber floor, into the root canal entrances. Then, a layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
47978758|NCT01325415|DRUG|NKTR-118|25 mg tablet
47978759|NCT01325415|DRUG|moxifloxacin|400 mg tablet
47978760|NCT01325415|DRUG|Placebo|tablet
47978761|NCT01082120|DRUG|AZD1656|Tablets orally, twice daily for 10 days
47978762|NCT01082120|DRUG|Pioglitazone|Tablet oral single dose for 10 days
47978763|NCT02709785|DRUG|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
47978764|NCT02709785|DRUG|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
47978765|NCT02709785|DRUG|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
47978766|NCT05145452|DIETARY_SUPPLEMENT|Fish-oil derived n-3 polyunsaturated fatty acids|4.2 g/d (7 pills with 600 mg each)
47978767|NCT05277740|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
48130716|NCT04724421|DRUG|Voxelotor|tablet or powder for oral suspension
48130717|NCT04566263|DEVICE|Neuroform EZ Stent System|The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
48130719|NCT06150924|DRUG|Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD|Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks
48130720|NCT06150924|DRUG|Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD|Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks
48495770|NCT04942158|PROCEDURE|Instrumentation technique and filling with Zinc Oxide and Eugenol paste|After anesthesia and rubber dam isolation, pulp chamber will be accessed with burs, and the root canals entrance will be prepared using a Gates Glidden bur. The root canal length determination will be done subtracting 1 mm from the radiographic measurements performed on the different roots. The instrumentation will be performed with 21mm stainless steel endodontic hand K-files, with International Organization for Standardization (ISO) tip ranging from #08 to #35. Irrigation will be performed using 1% sodium hypochlorite. After the last file, a final irrigation will be conducted with ethylenediaminetetraacetic acid and tegentol (EDTA-T) and 0.9% sodium chloride solution, and the root canals will be dried with paper points. Then, the root canals will be filled with a Zinc Oxide and Eugenol paste (ZOE paste), inserted into the root canals with a lentulo spiral. A layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
48495771|NCT05703373|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|Multiple micronutrient supplementation (MMS) which includes iron, folic acid, and additional micronutrients,
48495772|NCT06495515|DRUG|Dalpiciclib，Toremifen|"1. Dalpiciclib : 150mg orally, once a day, taken for 3 weeks, stopped for 1 week, with a cycle of 4 weeks. It is recommended to take medication at the same time every day, with warm water for delivery. It is recommended to do so on an empty stomach and fast for at least 1 hour before and after taking the medication.~2. Toremifen: 60mg orally, once a day If it is a premenopausal or perimenopausal patient, it is necessary to combine with OFS (OFS includes bilateral ovariectomy or GnRHa drugs)."
48495773|NCT04539886|DEVICE|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
48495774|NCT04539886|DEVICE|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
48495775|NCT05430126|DRUG|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
48495776|NCT04597294|COMBINATION_PRODUCT|FLOT + HIPEC + Surgery|HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
48130728|NCT00500994|DEVICE|MRI|The imaging study will use a block design to (i) optimize amygdala activation to emotionally valenced images, (ii) to optimize analysis of PPI and (iii) to optimize the go/no-task design. G. T2-sensitive functional images will be obtained on a MRI system with a 1.5 Tesla superconducting magnet and a standard head coil. An echo planar image sequence (TR=2500msec, TE=33 msec, 90 flip angle) with 30 contiguous 2mm thick coronal oblique slices with 1 mm interslice gap centered over the amygdala, tilted 30 to the anterior, to improve susceptibility artifact. Three-dimensional anatomical images will be taken for the co-registration of the functional images.
48130729|NCT03821506|DEVICE|Dynamic Light|Dynamic Lighting system
48130730|NCT03821506|DEVICE|Usual care|Standard lighting system
48130731|NCT05617014|RADIATION|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
48130732|NCT05617014|RADIATION|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
48130733|NCT05617014|RADIATION|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
48130734|NCT05617014|RADIATION|MK-6240|Tau PET imaging with MK-6240 injection
48130735|NCT05617014|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
48130736|NCT05617014|RADIATION|PI-2620|Tau PET imaging with PI-2620 injection
48130737|NCT05840887|PROCEDURE|Knee osteotomy associated with meniscal allograft transplantation|Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.
48130738|NCT05840887|PROCEDURE|Knee osteotomy|Knee osteotomy
48130739|NCT04303377|BIOLOGICAL|Evolocumab|Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)
48130740|NCT01858285|GENETIC|Exome and/or whole genome sequencing|
48130741|NCT05386108|DRUG|Elacestrant|300 mg, 400 mg
48130742|NCT05386108|DRUG|Abemaciclib|100 mg, 150 mg
48130743|NCT03427866|DRUG|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
48130744|NCT03821935|DRUG|Livmoniplimab|Liquid for intravenous infusion.
48654706|NCT06639932|BEHAVIORAL|We-INtervention|The We-INtervention focuses on the relationship dynamics of HIV-serodiscordant male couples. In developing the intervention, we reviewed relevant theories and frameworks, such as the cognitive transactional model, the systemic transactional model, the dyadic illness management model, and the intersectional framework of stigma. The three weekly 60-minute sessions are Session 1: We-disease appraisal. Despite stigma related to their dual minority identities, couples develop a perception of HIV as a shared disease, enhancing illness control. Session 2: Couple communication. Couples undertake skill-building exercises on effective communication techniques to strengthen their relationship. Session 3: Dyadic coping. Couples learn to optimize preference and value assessments in HIV management. A few skill-building exercises help them mobilize and maintain mutual support and develop joint problem-solving skills.
48130745|NCT03821935|DRUG|Budigalimab|Lyophilized powder for solution for intravenous infusion.
48495777|NCT04597294|COMBINATION_PRODUCT|FLOT + Surgery|Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
48337921|NCT04907864|COMBINATION_PRODUCT|Multi-modal intervention|Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day, oral nutritional supplement (HAMONILAN SOLN) 200 ml twice a day Weekly physical exercise by physiatrist (60 minutes per visit) Biweekly psychiatric intervention Nutritional counselling total four times during the study period
48130752|NCT05599048|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
48130753|NCT05599048|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
48130754|NCT03542279|PROCEDURE|Plasma exchange (PE)|PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.
48130755|NCT03542279|DRUG|intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)|IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
48130756|NCT06474143|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
48495778|NCT02704780|DRUG|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
48495779|NCT05142098|DRUG|Dexamethasone|Intramuscular
48495780|NCT05142098|DRUG|Etoricoxib 60 mg|Orally
48495781|NCT03529461|DEVICE|Non-invasive positive pressure ventilation through nasal mask|Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
48654707|NCT06639932|BEHAVIORAL|Usual Care Group|The participants in the control condition will receive health information pamphlets. The HIV-seropositive partners will receive information on HIV-related knowledge (e.g., symptoms, comorbidity, stages, and opportunistic infection), treatment (e.g., ART and side effects), and management (e.g., nutrition and mental health). The HIV-seronegative partner will receive information on HIV transmission (e.g., risk factors), prevention (e.g., safe sex and PrEP), and testing.
48654708|NCT03030534|COMBINATION_PRODUCT|Educational package and software package|Using Information and communication technology to deliver health promoting activities
47978768|NCT03632525|DRUG|Ferric carboxymaltose|Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
47978769|NCT03140644|OTHER|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
47978770|NCT06000514|DRUG|Sm29 Protein, Schistosoma Mansoni|Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
47978771|NCT06000514|DRUG|Pentavalent antimony (Sbv)|Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
47978772|NCT01979016|DRUG|Dupilumab|
47978773|NCT01979016|DRUG|Placebo|Matching placebo
47978774|NCT01979016|OTHER|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
47978775|NCT06112782|DEVICE|Keravive by Hydrafacial Treatments|Scalp hydradermabrasion
47978776|NCT02167893|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
47978777|NCT03210597|OTHER|Exercise|The subjects performed training in aquatic environment
48495782|NCT03529461|DEVICE|Rescue non-invasive positive pressure ventilation through nasal mask|If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
48130763|NCT03357926|DIAGNOSTIC_TEST|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
48130764|NCT05560659|DRUG|177Lu-PSMA|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Numerous retrospective series initially demonstrated high clinical activity and limited normal tissue toxicity using PSMA-617 and PSMA-I\&T, which are the most advanced small molecule inhibitors of PSMA, radiolabelled with 177Lu
48337922|NCT00414505|DEVICE|Intradermal Acupuncture Treatment|
48337923|NCT04570969|PROCEDURE|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
48337924|NCT03146403|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
47978778|NCT01784640|DRUG|Hsp90 inhibitor AUY922|Given IV
47978779|NCT01784640|DRUG|pemetrexed disodium|Given IV
47978780|NCT01784640|OTHER|pharmacological study|Correlative studies
47978781|NCT01784640|OTHER|laboratory biomarker analysis|Correlative studies
47978782|NCT02569723|DRUG|Carbon C 14 Oxaliplatin|Intravenous infusion
47978783|NCT02569723|DRUG|Oxaliplatin|Intravenous infusion
47978784|NCT03281681|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
47978785|NCT03068130|DRUG|Bardoxolone methyl|Capsules of Bardoxolone methyl
47978786|NCT05714813|BEHAVIORAL|High-Speed Circuit Resistance Training|Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
47978787|NCT05714813|BEHAVIORAL|Lecture on Diet, Exercise and Cognition|Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
47978788|NCT02095587|DRUG|IPI-145|25 mg single oral capsule
48130765|NCT05048186|BEHAVIORAL|Attention Deficit Hyperactivity Disorder Treatment Decision Aid|The parent pre-visit cards from the Cincinnati Children's Hospital's Attention Deficit Hyperactivity Disorder (ADHD) Treatment for School Age Children Decision Aid were used in this study. The 6 pre-visit cards provide an overview of ADHD treatment options, the respective benefits and downsides of each option, and questions to elicit goals/preferences. The four different treatment options presented were: (1) watchful waiting, (2) behavioral treatment, (3) medication treatment, and (4) combined treatment (behavioral and medication together).
48130766|NCT02285114|DRUG|F/TAF|F/TAF tablets administered orally once daily
48130767|NCT02285114|DRUG|3rd ARV agent|A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG).
48130768|NCT02285114|DRUG|Boosted PIs|Boosted PIs of the participant's pre-existing regimen may include one of the following: ATV, LPV, or DRV.
48130769|NCT05172271|DEVICE|MagPro TMS Stimulator and coil|TMS measurements of cortical excitability pre and post study intervention
48654709|NCT03030534|OTHER|Health promotion tips|Give general information on health promotion
48130770|NCT05172271|DEVICE|Thymatron(R) System IV|The Thymatron(R) System IV (Somatics LLC, Venice, FL, USA) is an FDA 510(k)-cleared ECT device. For TESt, we will be using it in a non FDA-approved manner--stimulating without intending to induce seizures.
48337925|NCT03146403|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
48337926|NCT03146403|OTHER|0.9% normal saline|Placebo
48337927|NCT02758119|OTHER|Serious Game|
48654710|NCT06642428|DRUG|Neoadjuvant therapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
48654711|NCT06642428|DRUG|Neoadjuvant therapy|Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
48654712|NCT02999659|DEVICE|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
48654713|NCT02944331|PROCEDURE|Endovenous steam ablation|
48654714|NCT06635122|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. The TIPS-dedicated stent (Gore, Arizona, USA)was emplaced within the liver and gradually expanded utilizing a balloon with a diameter ranging from 6 to 10 millimeters, aiming for a decrease in portal-venous pressure gradient to less than 12 mmHg or achieve a reduction of 25 to 50% relative to the baseline pressure.
48654715|NCT06635122|PROCEDURE|Endoscopic treatment|Endoscopic variceal ligation, endoscopic injection sclerotherapy, endoscopic variceal histoacryl injection therapy , or a combination of several methods were selected according to the location, size, and shape of the patient's varicose veins.Treatment failure can be transferred to TIPS therapy.
48654716|NCT06641713|PROCEDURE|TACE|TACE was carried out under the guidance of digital subtraction angiography, and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The emulsion of the selected drug and the embolization agents was therefore injected infused into tumor-feeding arteries via the selective microcatheter. A final arteriography confirmed the success of the procedure. The endpoint of the TACE procedure was reached when there was no flow in the tumor-feeding vessels.
48654717|NCT06641713|PROCEDURE|HAIC|HAIC was carried out under the guidance of digital subtraction angiography, 990and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
48654718|NCT06120842|DRUG|Bimatoprost Implant System (High Dose)|Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
48337928|NCT02758119|OTHER|Online course|
48337929|NCT03081598|DRUG|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
47978789|NCT02648178|DEVICE|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
47978790|NCT05153239|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
47978791|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
47978792|NCT05153239|DRUG|Irinotecan|For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk
47978793|NCT05153239|DRUG|Topotecan|Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk
47978794|NCT05153239|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
47978795|NCT02978261|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
48130771|NCT05172271|DEVICE|Magnetic Resonance Imaging Scanner|Conventional MRI studies in this protocol are considered non-significant risk (NSR) devices. While operated in research mode, the MRI will be under the International Electrotechnical Commission (IEC) 60601-2-33 First Level Controlled Operating Mode, which allows for research pulse sequences to be used within the FDA/IEC safety limits for MRI devices.
47978796|NCT02234960|DRUG|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
48337930|NCT03081598|OTHER|Placebo|Placebo soft gelatine capsule
48337931|NCT03717636|OTHER|medical evaluation|return of medical evaluation after discharge
47978797|NCT06197854|PROCEDURE|Hernioplasty|Surgical hernioplasty
47978798|NCT06195163|DRUG|Transdermal Gel in Sachet Dosage Form|Transdermal testosterone gel application prior to ovarian stimulation in the study group.
48130772|NCT05172271|OTHER|ECT device without stimulation|Anesthesia alone
48337932|NCT04368897|DIAGNOSTIC_TEST|CAG length <22|CAG repeat length in exon 1 of AR gene
48337933|NCT04368897|DIAGNOSTIC_TEST|CAG length >=22|CAG repeat length in exon 1 of AR gene
48337934|NCT06213610|DRUG|Perindopril tablet|Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.
48337935|NCT06213610|DRUG|Prestarium® A tablet|Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
48337936|NCT02103881|DRUG|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
48654719|NCT06120842|DRUG|Bimatoprost Implant System (Low Dose)|Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
48130773|NCT01368744|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Groups: OSNA Breast Cancer System"
48495783|NCT03529461|OTHER|Secondary rescue maneuvers|If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat \> 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase \> 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
48654720|NCT06120842|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol Maleate Ophthalmic Solution 0.5% BID
47978799|NCT06195163|DRUG|No pretreatment|No pretreatment prior to the ovarian stimulation in the control group.
48495784|NCT01345175|DRUG|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
48337937|NCT02103881|DRUG|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
48337938|NCT04035265|PROCEDURE|Blood test|Carpus and fingers of non-dominating hand MRI with gadolinium contrast
48337939|NCT00000937|DRUG|Antibiotics|
48654721|NCT06120842|DEVICE|Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL|Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
48654722|NCT06120842|DEVICE|SpyGlass IOL|SpyGlass Intraocular Lens
47978800|NCT04981951|DRUG|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
48337940|NCT05151367|BEHAVIORAL|Text message reminder|Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
48337941|NCT04628598|BEHAVIORAL|Antenatal care and prenatal education with a home visit|Providing prenatal education and care by home visits to pregnant women
48337942|NCT03086538|DRUG|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
48130778|NCT05766462|OTHER|Pacemaker lower rate setting|Pacemaker lower rate is set by physician and may be adjusted according to the physician diagnosis.
48130779|NCT06025344|DRUG|PanCytoVir™ 100 mg/mL oral suspension|Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
48130780|NCT06025344|DRUG|Probenecid 500 mg|Single oral dose of 1000 mg under fasted conditions
48337943|NCT03086538|DRUG|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
48337944|NCT01660230|BIOLOGICAL|3K3A-APC, diluted in 0.9% sodium chloride in water|
48337945|NCT01660230|DRUG|0.9% NaCl in water|
48337946|NCT00763243|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
48495785|NCT01345175|DRUG|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
47978801|NCT05117320|DEVICE|AI support|Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
47978802|NCT05255172|OTHER|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
47978803|NCT00241280|DEVICE|etafilcon A|
47978804|NCT00241280|DEVICE|galyfilcon A|
47978805|NCT01824394|DEVICE|nMARQ Navigation Catheters|
47978806|NCT01824394|DEVICE|NaviStar ThermoCool Catheters|
47978807|NCT05712616|DRUG|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
47978808|NCT05712616|DRUG|Lacto-N-Hexaose|Placebo look alike drug
47978809|NCT00246727|DRUG|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
47978810|NCT02115789|BEHAVIORAL|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
47978811|NCT04235270|COMBINATION_PRODUCT|FDC of Macitentan and Tadalafil|Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.
47978812|NCT04235270|DRUG|Macitentan|Macitentan 10 mg tablet will be administered orally as free combination.
47978813|NCT04235270|DRUG|Tadalafil|Tadalafil 40 mg tablet will be administered orally as free combination.
47978814|NCT01502449|BEHAVIORAL|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
47978815|NCT01502449|OTHER|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
47978816|NCT01952275|PROCEDURE|Collection of biological samples|
47978817|NCT05990972|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
47978818|NCT06151795|DIAGNOSTIC_TEST|XTR006|Single dose intravenous injection of XTR006. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
47978819|NCT00045123|DRUG|tarenflurbil|
47978820|NCT00045123|PROCEDURE|adjuvant therapy|
47978821|NCT03848650|DEVICE|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
47978822|NCT03848650|PROCEDURE|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
47978823|NCT04053205|DRUG|Gentuximab|Administered intravenously (IV)
47978824|NCT04053205|DRUG|Paclitaxel|Administered intravenously (IV)
47978825|NCT01408004|DRUG|Pazopanib|Tablet 800mg qd til progression
48130782|NCT03868579|PROCEDURE|Biopsy|Undergo biopsy
47978826|NCT01408004|DRUG|Everolimus|tablet 10 mg qd til progression
47978827|NCT01408004|DRUG|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
47978828|NCT01408004|DRUG|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
48130783|NCT03868579|OTHER|Medical Chart Review|Review medical chart
48130784|NCT03868579|PROCEDURE|Thoracoscopy|Undergo pleuroscopy
48130786|NCT06334107|BEHAVIORAL|Exercise|Participants will be asked to follow a moderate-intensity aerobic exercise training program for 4-5 days per week for 40-60 minutes each session.
48130787|NCT05824871|DRUG|Sudapyridine|Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.
48337947|NCT00647257|DRUG|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
47978829|NCT01408004|DRUG|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
48337948|NCT00647257|DRUG|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
48495786|NCT04997226|DEVICE|tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 1 and 3.
48495787|NCT04997226|DEVICE|Sham tDCS or tACS over the left DLPFC with adaptive memory game|This intervention is described in arms 2 and 4.
48495788|NCT01163630|DRUG|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
48495789|NCT03738514|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
47978830|NCT01408004|DRUG|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
48130788|NCT05824871|DRUG|Bedaquiline|Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.
48130789|NCT06296992|BEHAVIORAL|12-week TEAM peer mentor program|A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
47978831|NCT06152978|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
47978832|NCT06152978|DRUG|Chemotherapy|Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
48130790|NCT04210037|DRUG|APG-1252|APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
47978833|NCT04068662|BEHAVIORAL|Pregnant Moms' Empowerment Program|The Pregnant Moms' Empowerment Program is a five session group therapy program designed for pregnant women with a recent history of exposure to intimate partner violence. One session is administered each week with a duration of 2 hours each, for a total of ten contact hours across the course of the intervention. Intervention topics includes safety planning, social support, resilience, psychoeducation about intimate partner violence, cognitive and behavioral strategies for remediating distress, infant sleep and breastfeeding, responsive parenting, and co-parenting.
47978834|NCT04068662|BEHAVIORAL|Nondirective Support Group|Participants in the non-directive support group condition participate in groups of the same size and with the same total contact time as women in Intervention 1. In contrast to the structured, manualized content delivered as a part of the Pregnant Moms' Empowerment Program, however, group leaders in this condition facilitate open conversation on topics that women identify together as a group.
47978835|NCT02197715|BEHAVIORAL|Computer-adaptive SAFE|
47978836|NCT02197715|BEHAVIORAL|Face-to-face SAFE|
47978837|NCT02197715|BEHAVIORAL|Usual Care|
48130791|NCT04210037|DRUG|Paclitaxel|80 mg/m˄2 on days 1 and 8 of a 21-day cycle
48130792|NCT06522893|OTHER|Percutaneous neuromodulation|Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
48495790|NCT03738514|OTHER|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
48130794|NCT06648135|PROCEDURE|Immediate implants with bone grafts|Immediate implants with bone grafts
48337949|NCT05229419|OTHER|complete blood count|complete blood count will be done for corrosive cases
48337950|NCT02646150|PROCEDURE|Magnetic Resonance Perfusion Imaging|
48337951|NCT01933321|BIOLOGICAL|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
48337952|NCT03271060|PROCEDURE|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
48337953|NCT03271060|PROCEDURE|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
48337954|NCT02583516|DRUG|vemurafenib and cobimetinib|Comparison between different treatment regimens
48337955|NCT04971369|DIAGNOSTIC_TEST|89Zr-NY001|89Zr-NY001 injection followed by 89Zr-NY001 PET scan
48337956|NCT03908580|DRUG|Meditoxin|Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
48337957|NCT02023268|DEVICE|T2762|1 drop in each eye 3 to 6 times daily during 84 days
48337958|NCT02023268|DEVICE|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
48495791|NCT03738514|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
48495792|NCT03028740|DRUG|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
48495793|NCT03028740|DRUG|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
48495794|NCT04145453|BEHAVIORAL|Intervention genotype personalized nutritional recommendations|Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
48130795|NCT06648135|PROCEDURE|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
48495795|NCT04145453|BEHAVIORAL|Control Group 1 personalized nutritional recommendations|Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
48130797|NCT01738438|DRUG|Cabozantinib|
48495796|NCT04145453|BEHAVIORAL|Control Group 2 general nutritional recommendations|Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
48495797|NCT03982472|OTHER|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
48495798|NCT05594303|BIOLOGICAL|Autologuos transplantation of bronchial basal cells|Autologuos transplantation of bronchial basal cells
48495799|NCT00146341|DRUG|Telmisartan/HCTZ|
48495800|NCT00146341|DRUG|Telmisartan|
48495801|NCT00001586|BIOLOGICAL|Rituximab|Rituxan
47978838|NCT02032810|DRUG|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
47978839|NCT02032810|DRUG|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
47978840|NCT00859404|DRUG|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
47978841|NCT02814851|DEVICE|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
47978842|NCT02814851|DEVICE|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
47978843|NCT02814851|DEVICE|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
47978844|NCT02814851|DEVICE|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
47978845|NCT06193720|DRUG|Arnica montana|Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
47978846|NCT06193720|OTHER|Placebo|Patients will take placebo drug after surgeries
47978847|NCT01385202|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
47978848|NCT01561365|BEHAVIORAL|Ottawa ankle rules|Ottawa ankle rules implementation
47978849|NCT04097002|BIOLOGICAL|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
47978850|NCT03378362|PROCEDURE|Partial denervation of the wrist joint|Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
47978851|NCT01847222|BIOLOGICAL|SANGUINATE™|PEG-bHb-CO
47978852|NCT01847222|DRUG|Normal Saline Solution|Placebo
48130804|NCT06145100|DIAGNOSTIC_TEST|Ultrasound including color doppler ultrasound|Patients with CVID receive color doppler ultrasound of the liver including assessment of portal vein diameter, portal vein flow velocity, hepatic vein diameter and assessment of arterial perfusion. Further liver and spleen stiffness measurement by transient elastography is performed.
48495802|NCT00001586|DRUG|Fludarabine phosphate|Fludara
48337959|NCT04124055|DIAGNOSTIC_TEST|Therapeutic drug monitoring (TDM)|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
48130807|NCT00145236|DRUG|Nebivolol|
48130808|NCT05162716|DEVICE|Single-chamber pacemaker implantation with left bundle branch area pacing|A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
48130809|NCT04169542|OTHER|Questionnaire Administration|Complete questionnaires
48130810|NCT01894217|GENETIC|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele; reporting of test results to provider and participant
48130811|NCT06321952|DEVICE|ROSA robotic assist TKA|total knee replacement with ROSA robotic assist
48130812|NCT06321952|PROCEDURE|iassist TKA|total knee replacement with iassist
48337960|NCT05134636|OTHER|Text triage|The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
48337961|NCT03497611|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
48337962|NCT02397590|DRUG|Fimasartan|
48337963|NCT02397590|DRUG|Atorvastatin|
48337964|NCT01923649|DRUG|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
48337965|NCT01923649|DRUG|Placebo|Placebo for somatuline slow release 90 mg
48495803|NCT00001586|OTHER|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
48337966|NCT06306924|RADIATION|Radiation therapy|Subjects with metastatic cancer receive radiation therapy.
48337967|NCT03027193|BIOLOGICAL|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
48495804|NCT04822233|DEVICE|Hall Technique (HT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swap and dispensed in a transport medium for microbial analyses.The preformed metal crown (PMC) will placed without local anesthetic and without crimping or trimming. When the contact points are tight, an orthodontic elastic separator will be placed for 2 hours prior to PMC placement. The PMCs will be cemented with glass ionomer Ketac cem.
47978853|NCT01894451|DRUG|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
48130815|NCT01044888|DRUG|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
48130816|NCT04411888|OTHER|observation|observation
48495805|NCT04822233|DEVICE|Modified Hall Technique (MHT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses.This group will in addition to all the procedures for the Hall will have the Caries lesions treated with 30% Silver Diamine Fluoride (SDF) before cementation of the stainless-steel crowns.
48130818|NCT05176392|DEVICE|Active rTMS|Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.
48130819|NCT05176392|BEHAVIORAL|Headache Management Therapy|Therapy will be provided on headache management.
48130820|NCT05176392|DEVICE|Sham rTMS|Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.
48130821|NCT05176392|BEHAVIORAL|Headache Education Control|In the control, educational sessions on headaches will be provided.
48495806|NCT04822233|DEVICE|Conventional Technique (CT)|Prior to each restoration, a bacterial sample of the lesion will be obtained with a cotton swab and dispensed in a transport medium for microbial analyses. Conventional occlusal, proximal slicing and when necessary buccal and lingual surfaces will be carried out under local anesthesia and dental dam isolation local anesthesia.The PMC will be trimmed and crimped at the gingival margin to improve the fit, and cemented with Ketac cem.
48495807|NCT05875220|OTHER|No intervention|No intervention
48337968|NCT03027193|BIOLOGICAL|MVA HAV|The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
48337969|NCT01598207|DRUG|Marinol|5mg BID, orally for 1 month
48337970|NCT01598207|DRUG|Placebo|5mg BID, orally for 1 month
48495808|NCT01099527|DRUG|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
48495809|NCT01099527|DRUG|Capecitabine|dose escalation of capecitabine, everolimus
48495810|NCT03149939|DRUG|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
48495811|NCT02021370|DRUG|BAY85-3934|25mg Tablet
48495812|NCT02021370|DRUG|Placebo|Matching placebo tablet
48495813|NCT00070538|DRUG|cytarabine|
48130824|NCT04649996|PROCEDURE|Appendectomy|comparison between operative and conservative treatment
47978854|NCT01894451|PROCEDURE|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
47978855|NCT01894451|PROCEDURE|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
47978856|NCT01894451|PROCEDURE|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
47978857|NCT03382392|OTHER|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
47978858|NCT00662363|DRUG|Lubiprostone|24 µg po BID given with meals for 6 days
47978859|NCT00662363|DRUG|Senna|2 tabs daily for 6 days
47978860|NCT04462549|BEHAVIORAL|Resource Facilitation|"RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification."
47978861|NCT02981498|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
47978862|NCT02981498|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
47978863|NCT01744054|DEVICE|PET/MR|
47978864|NCT01744054|DEVICE|PET/CT|
47978865|NCT04774640|DEVICE|MaterniT GENOME|
47978866|NCT01396148|DRUG|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
47978867|NCT01396148|DRUG|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
47978868|NCT03684811|DRUG|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
47978869|NCT03684811|DRUG|Azacitidine|Azacitidine will be administered per the site's standard of care.
47978870|NCT03684811|BIOLOGICAL|Nivolumab|Nivolumab will be administered per the site's standard of care.
47978871|NCT03684811|DRUG|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
47978872|NCT00836290|BEHAVIORAL|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
47978873|NCT00836290|BEHAVIORAL|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
47978874|NCT04912947|DIETARY_SUPPLEMENT|Immusystem|Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6
47978875|NCT04912947|OTHER|Placebo|Maltodextrin placebo capsule
47978876|NCT00776958|OTHER|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
47978877|NCT01847417|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
47978878|NCT01847417|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
47978879|NCT01847417|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
48130825|NCT05728840|OTHER|Immersive virtual reality gamified cognitive activities|This intervention will include 20 sessions of training with the experimental rehabilitation program using immersive VR cognitive gamified activities, in addition to the standard of care.
48130826|NCT05728840|OTHER|Double neuropsychological standard activities|This intervention will include 20 sessions of training using a standard neuropsychological rehabilitation program, in addition to the standard of care.
48130827|NCT06081738|DRUG|Neostigmine|a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
48495814|NCT00070538|DRUG|laromustine|
48130828|NCT06081738|DRUG|Sugammadex|2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
48130829|NCT05281744|BEHAVIORAL|Dementia Care Consultation program|The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
48130830|NCT06099548|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
47978880|NCT01847417|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
47978881|NCT03092154|DRUG|Lipid-lowering agents (Artovastatin)|Artovastatin 20 mg /day, orally, 12 consecutive weeks.
48130831|NCT05321992|BEHAVIORAL|eCHEC program|The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
48130832|NCT01754636|OTHER|No intervention|
48337971|NCT06270563|OTHER|Postural advice|The patients received advice about maintaining good posture when sitting, standing, reading, driving, or lifting; taking breaks; sleeping on back or side with a pillow supporting head/neck; avoiding prolonged phone use; adjusting car seat; reading stand for upright posture; keeping objects close when lifting; and using pillows for support when breastfeeding.
48337972|NCT06270563|OTHER|Traditional exercise treatment|The exercise program included strengthening of deep flexor muscles and shoulder retractors while stretching of cervical extensors and pectoral muscles.
48337973|NCT06270563|OTHER|Scapular stabilization exercises|Scapular Stabilization exercise was composed of four exercise programs, including scapula retraction exercise, scapula mobilization exercise, and scapula dynamic stabilization exercise I and II.
48495815|NCT00536263|DRUG|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
48495816|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
48495817|NCT00536263|DRUG|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
48495818|NCT05296486|PROCEDURE|phacovitrectomy surgery with silicone oil tamponade|Patients in this study will receive phacovitrectomy surgery with silicone oil tamponade.
48495819|NCT05296486|PROCEDURE|phacovitrectomy surgery with gas tamponade|Patients in this study will receive phacovitrectomy surgery with gas tamponade
48495820|NCT05296486|PROCEDURE|phacovitrectomy surgery with balanced saline solution tamponade|Patients in this study will receive phacovitrectomy surgery with balanced saline solution tamponade
48130833|NCT05888792|OTHER|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
48130834|NCT01638000|DRUG|Mirabegron|oral tablet
48130835|NCT01638000|DRUG|Solifenacin succinate|oral tablet
48495821|NCT05296486|PROCEDURE|phacoemulsifacation surgery without vitrectomy|Patients in this study will receive phacoemulsifacation surgery without vitrectomy.
48130837|NCT01432769|DIETARY_SUPPLEMENT|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
48495822|NCT03267875|PROCEDURE|Blood Test|draw out 2 blood tubes from a patient
48495823|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
48495824|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
48495825|NCT01506544|DRUG|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
48495826|NCT03850951|DEVICE|Lingual appliances|Patients with moderate crowding will be treated without extraction using lingual appliances.
47978882|NCT06234657|BEHAVIORAL|Telerehabilitation for stroke patient|The subjects of the study were intervened by telerehabilitation through video instructions and online group training via Online meeting software. The content of the intervention program included upper limb exercises, transfer, and ambulation functions. This training program was designed based on the clinical practice guidelines for post-stroke physiotherapy management from the United States Department of Veterans Affairs and the guidelines for the diagnosis, and treatment of rehabilitation stroke patients of the Vietnam Ministry of Health. The training results of the subjects will be evaluated by the Barthel Index
47978883|NCT01338792|DRUG|oxaliplatin|Given IV
47978884|NCT01338792|DRUG|pemetrexed disodium|Given IV
47978885|NCT01338792|OTHER|questionnaire administration|Ancillary studies
47978886|NCT01338792|OTHER|laboratory biomarker analysis|Correlative studies
47978887|NCT01338792|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
47978888|NCT01338792|GENETIC|polymorphism analysis|Correlative studies
47978889|NCT01514929|DRUG|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
47978890|NCT01514929|DRUG|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
47978891|NCT01514929|DRUG|Moxifloxacin|400mg oral pill given once
47978892|NCT01514929|DRUG|Placebo|Placebo oral pill given once
48495827|NCT03850951|DEVICE|Labial appliances|Patients with moderate crowding will be treated without extraction using labial appliances.
47978893|NCT06337188|DEVICE|Experimental AAC|Participant receives an AAC system comprising 2 wearable sensors for movement-mediated cursor control and muscle activity mediated cursor selection that is integrated with an adaptive and individualized keyboard to test communication performance.
47978894|NCT06337188|DEVICE|Generic AAC|Participant receives an AAC system that is similar to that used to satisfy their normal daily communication needs such as an eye-tracking device with a generic AAC keyboard to test communication.
47978895|NCT02612974|BIOLOGICAL|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
48495828|NCT05020613|PROCEDURE|Procedure: Early removal group|Participants assigned this arm will have their urethral catheters removed at 2 days after low anterior resection of the rectum
48495829|NCT05020613|PROCEDURE|Procedure: Late removal group|Participants assigned this arm will have their urethral catheters removed after 48.th hours after Low anterior resection of the rectum
48495830|NCT02728752|DRUG|Octagam 10%|Patients to be treated with Octagam 10%
48495831|NCT02728752|OTHER|Placebo|Patients to be treated with a Placebo
48495832|NCT01985074|BEHAVIORAL|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
48495833|NCT06176066|PROCEDURE|CEST PH MRI based resection of glioblastoma|Using pre-operative amine chemical exchange saturation transfer pH weighted MRI, regions of interest that correspond to infiltrating glioblastoma will be identified and via intraoperative neuronavigation, guide resection of glioblastoma
48495834|NCT01880125|DRUG|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
48495835|NCT01792219|OTHER|Interprofessional collaboration in health care module|An educational module
47978896|NCT06166160|OTHER|Bulk fill flowable composite SDR Dentsply sirona|caries removal in class II cavities of primary molars and application of experminted restorations
47978897|NCT03582124|PROCEDURE|Near-Infrared Fluorescence Imaging|Undergo imaging
47978898|NCT03582124|DRUG|Panitumumab-IRDye800|Given IV
47978899|NCT03582124|OTHER|Pharmacokinetic Study|Correlative studies
47978900|NCT03582124|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
47978901|NCT02980445|BEHAVIORAL|Outdoor activity 1|40-minute outdoor activity
47978902|NCT02980445|BEHAVIORAL|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
47978903|NCT03053076|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
47978904|NCT03053076|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
47978905|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
47978906|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
47978907|NCT02642289|OTHER|Placebo|Innocuous substance
48495836|NCT03547336|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
48495837|NCT03547336|DEVICE|FX800 Dialyzer|Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
48495838|NCT06469489|OTHER|Liver Disease of all etiologies|No intervention
48495839|NCT05142566|DEVICE|MANTA Vascular Closure Device|Evaluate the safety of ultrasound guided deployment of MANTA VCD.
48495840|NCT00885014|BEHAVIORAL|CBT|Telephone cognitive-behavioral therapy
48495841|NCT00885014|BEHAVIORAL|EAP|Employees Assistance Program
48130852|NCT01231971|DRUG|Florbetapir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
48130853|NCT01231971|DRUG|Flortaucipir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
48130854|NCT06251674|OTHER|long-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
48130855|NCT06251674|OTHER|short-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
48130856|NCT01701401|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
47978908|NCT02959944|DRUG|ibrutinib|Ibrutinib capsules administered orally daily
48130857|NCT01701401|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48130858|NCT00482742|DEVICE|CiTop(TM) Guidewire|
48130859|NCT06163300|DIAGNOSTIC_TEST|MRI advanced techniques|Participants will be submitted to MRI studies at diagnosis, during disease evolution and after treatment. Data collected will be analysed by two different neuroradiologists using advanced techniques.
48130860|NCT06482112|DRUG|Efinopegdutide|SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
48130861|NCT02072499|PROCEDURE|KTP Green Light Prostatectomy|
48130862|NCT02072499|DEVICE|Green Light|
48130863|NCT02072499|PROCEDURE|Open prostatectomy|
48130864|NCT00070694|DRUG|MDL100.907|
48130865|NCT01870830|OTHER|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
47978909|NCT02959944|DRUG|Placebo|Placebo capsules administered orally daily
47978910|NCT02959944|DRUG|Prednisone|Prednisone administered daily
47978911|NCT04939402|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
47978912|NCT05579821|DIAGNOSTIC_TEST|Typhoid DPP assay|The index test used in this study diagnose typhoid fever by detecting IgA antibodies against LPS and HlyE antigen in patient's serum.
47978913|NCT06436482|DEVICE|Optical Coherence Tomography|Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
47978914|NCT00545168|DRUG|Spinosad|10 minute topical application of product, followed by a complete rinse off.
47978915|NCT00545168|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
47978916|NCT00545168|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
47978917|NCT05086991|OTHER|Follow up|like group descriptions
47978918|NCT02417701|OTHER|Laboratory Biomarker Analysis|Correlative studies
47978919|NCT02417701|OTHER|Pharmacological Study|Correlative studies
47978920|NCT02417701|DRUG|Sapanisertib|Given PO
47978921|NCT02922556|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
47978922|NCT02922556|OTHER|Commercially available computerized training|
47978923|NCT02390895|PROCEDURE|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
47978924|NCT00817024|DRUG|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
47978925|NCT00817024|DRUG|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
47978926|NCT00817024|DRUG|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
47978927|NCT03762824|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccination during antirheumatic treatment
48130866|NCT00993174|PROCEDURE|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
48130867|NCT00993174|PROCEDURE|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
48130868|NCT05225376|OTHER|Physical activity sessions for pregnant women|"The physical activity sessions will take place once a week at the Estaing UHC, in the room used for the childbirth and parenting preparation classes of the outpatient obstetrics-gynecology clinic; and twice a week on Zoom. These sessions will be supervised by an APA professional (degree in STAPS and APA).~The measurement of the women's physical conditions will make it possible to adapt and individualize the PA sessions to each woman's level."
48130869|NCT06539312|OTHER|APP assessment and management of asthma|APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.
48495842|NCT03058419|DRUG|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1\*100 mg + 1\*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
48495843|NCT03058419|DRUG|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6\*100 mg capsules) orally on Day 8.
48654723|NCT05385289|BEHAVIORAL|A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism|"The B-experimental phase consists in a 6-session intervention targeting rumination and lasting for 3 weeks. The intervention was derived from 3 manuals: Rumination-Focused Cognitive-Behavioral Therapy for Depression (Watkins, 2016), Overcoming Perfectionism (Shafran et al., 2010), and Cognitive-Behavioral Treatment of Perfectionism (Egan et al., 2014). Participants will attend 2 sessions per week at home. Each week will end with an individual 30 minutes-debriefing session with an experimenter, to ascertain understanding of session content and homework.~Intervention sessions will be given in paper format to participant after the A-baseline-phase. A paper diary was also provided for homework, in addition to the session content caneva. Each session contains (a) theoretical content on ruminations linked to perfectionism, (b) exercises to create alternative habits to ruminations, and (c) homework to become aware of ruminations and to experiment with alternatives."
48130876|NCT01943994|DRUG|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
48130877|NCT01943994|DRUG|Nicotine Replacement Therapy (NRT)|
48495844|NCT03058419|DRUG|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion \[2 (milligram per milliliter (mg/mL)\] as a drug cocktail on Day 1, 7 and 11.
48495845|NCT03058419|DRUG|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2\*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
47978928|NCT03762824|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccination during antirheumatic treatment
47978929|NCT04066673|DIAGNOSTIC_TEST|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
47978930|NCT05586529|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol is vitamin D derivative and as our population already vit D deficient so post-operative hypocalcemia can be prevented.
47978931|NCT03773679|PROCEDURE|Daily Exercise|Daily Exercise Programme
47978932|NCT01031069|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
47978933|NCT01031069|BIOLOGICAL|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
47978934|NCT01643655|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
47978935|NCT02362217|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
47978936|NCT02362217|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
47978937|NCT02362217|BIOLOGICAL|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
48654724|NCT06640907|BEHAVIORAL|Personalized e-Perinatal mHealth intervention integrated in maternal routine care|The mHealth app provides psychoeducational materials, video-guided physical activities, mood tracking features, personalized recommendations, and community features. Additionally, professionals involved in this group are specifically trained to incorporate the mHealth app into their routine care practices, enhancing their ability to support mental health during the perinatal period.
48654725|NCT06640907|OTHER|Usual perinatal care with general prenatal and postnatal health information|Usual prenatal and postnatal health care, including regular health check-ups. They also gain access to public health resources and perinatal information distributed via email.
48654726|NCT03829488|DRUG|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
47978938|NCT02362217|BIOLOGICAL|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
47978939|NCT03942627|BEHAVIORAL|Mindfulness Program|The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
47978940|NCT03942627|BEHAVIORAL|Infant Health Education Program|The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
47978941|NCT01735682|DEVICE|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
47978942|NCT01735682|BEHAVIORAL|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
47978943|NCT01735682|BEHAVIORAL|Control|The control treatment involves exercises of the upper limbs.
47978944|NCT02177305|DRUG|0.02 mcg tiotropium solution|
47978945|NCT02177305|DRUG|0.04 mcg tiotropium solution|
47978946|NCT02177305|DRUG|0.08 mcg tiotropium solution|
48495846|NCT03058419|DRUG|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1\*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
48495847|NCT03058419|DRUG|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1\*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
48495848|NCT03058419|DRUG|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1\*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
48337974|NCT06270563|OTHER|High intensity Laser therapy|"There were two phases in every session, the wavelength is 1064 nm, size of spacer is 60 mm in both phases:~Phase I (analgesic phase): the application was made by moving the applicator perpendicular to the skin in continuous circular movements at trigger points detected by acupuncture, power was 8.00 w with a dosage of 5 J/cm2, surface area 50 cm2, frequency 25 HZ, treatment time in this phase was 3 minutes and total energy received at this phase was 250 J.~Phase II (bio stimulation): the application was made at the pain inflicting region by using continuous linear movements and prevent static application, The power was 8.00 w with a continuous frequency, dosage of 50 J/cm2, surface area 50 cm2, treatment time in this phase was 5 minutes and the total energy that was delivered to the patient during this phase was 2500 J."
48337975|NCT05382988|DRUG|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
48495849|NCT03058419|DRUG|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
48130882|NCT06019000|COMBINATION_PRODUCT|CYR-064|CYR-064 is a nasal solution.
48337976|NCT04323423|BEHAVIORAL|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
48337977|NCT04510402|DRUG|Povidine iodine nasal swabs|Daily versus twice daily nasal application
48337978|NCT00702728|DRUG|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
48130883|NCT06549296|DRUG|RD06-04 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
48495850|NCT03174262|BEHAVIORAL|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
48495851|NCT05181332|OTHER|Prediction model|Clinical models were developed and validated to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis.
48495852|NCT02296853|DRUG|TAF|25 mg tablet administered orally
48495853|NCT03305406|OTHER|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
48495854|NCT03305406|OTHER|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
48495855|NCT05998941|DRUG|TQB2868 injection|TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
48495856|NCT05998941|DRUG|Paclitaxel injection|Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
48495857|NCT05998941|DRUG|Cisplatin injection|Cisplatin injection can inhibit the DNA replication process of cancer cells
48654727|NCT03829488|DRUG|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
48654728|NCT05555329|DRUG|Pomalidomide 4 mg every day in cycle 1|Pomalidomide 4 mg every day, on days 1-21 in a cycle of 28 days
48654729|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 2|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
48654730|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 2|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
48654731|NCT05555329|DRUG|Pomalidomide 2 mg every day in cycle 3|Pomalidomide 2 mg every day, on days 1-28 in a cycle of 28 days
48130889|NCT02787005|BIOLOGICAL|Pembrolizumab|Intravenous infusion
48495858|NCT05998941|DRUG|Carboplatin injection|Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
48495859|NCT05998941|DRUG|Bevacizumab injection|Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
48130892|NCT06319430|OTHER|robots|LEGO robots with adaptation according to child's age and developmental skills.
48130893|NCT06319430|OTHER|conventional|A pack of conventional play tools consists of dolls, teddy bears, miniature wild animals, and small cars. All are available, and the child can choose to play with them.
48495860|NCT00704574|DRUG|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
48495861|NCT01685073|DRUG|Zolpidem extended-release|nightly administration of zolpidem extended-release
48495862|NCT01685073|BEHAVIORAL|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
48130894|NCT02313350|DEVICE|Chemonucleolysis with Discogel|Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
48495863|NCT03438214|DRUG|Vancomycin Continuous infusion|Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
48654732|NCT05555329|DRUG|Pomalidomide 4 mg every other day in cycle 3|Pomalidomide 4 mg every other day, on days 1-21 in a cycle of 28 days
48654733|NCT02117076|DRUG|Gabapentin immediate release|up to 1200 mg per day
48654734|NCT02117076|DRUG|Gabapentin enacarbil extended release|up to 1200 mg per day
47978947|NCT02177305|DRUG|0.16 mcg tiotropium solution|
47978948|NCT02177305|DRUG|0.28 mcg tiotropium solution|
47978949|NCT02177305|DRUG|0.40 mcg tiotropium solution|
48130895|NCT02313350|PROCEDURE|open discectomy|The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
48495864|NCT03438214|DRUG|Vancomycin Intermittent infusion|Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
48495865|NCT04870138|DRUG|Azithromycin|Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
48495866|NCT04870138|DRUG|Ceftriaxone|Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
48495867|NCT04870138|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
48495868|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
48495869|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA7527|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
48495870|NCT02072148|PROCEDURE|PET/CT|PET scan or CT scan q 4 months for 5 years
48495871|NCT02072148|RADIATION|Radiotherapy|Postoperative XRT 5000 cGy
48495872|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
48495873|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
48495874|NCT01949961|OTHER|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for \~30 minutes, using a Bracco infusion pump.
48495875|NCT01949961|OTHER|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
48495876|NCT02702479|OTHER|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
48495877|NCT02702479|OTHER|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
48495878|NCT03222752|DEVICE|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
47978950|NCT02177305|DRUG|Placebo solution|
47978951|NCT03003936|BEHAVIORAL|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
47978952|NCT00555321|DRUG|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
47978953|NCT00555321|DRUG|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
47978954|NCT00555321|DRUG|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])"
47978955|NCT00555321|DRUG|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
47978956|NCT00555321|DRUG|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
47978957|NCT00162201|DRUG|Abatacept|Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.
47978958|NCT02356224|DRUG|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
47978959|NCT02356224|DRUG|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
47978960|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
47978961|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
47978962|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
48130898|NCT06390163|OTHER|Sensory-Motor Integration Training|An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.
48130899|NCT00469339|BEHAVIORAL|Family Health History|
48130900|NCT01237496|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
48654735|NCT04049214|OTHER|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
47978963|NCT00864214|DRUG|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
47978964|NCT05732454|DRUG|etrasimod|PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
47978965|NCT05732454|DRUG|Placebo|PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
47978966|NCT05965310|BEHAVIORAL|Virtual Psychological Intervention: Cognitive Behavioral Therapy|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
47978967|NCT05208255|OTHER|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
47978968|NCT04880525|OTHER|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
47978969|NCT02568085|DEVICE|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
47978970|NCT02208557|PROCEDURE|Reinforcement with Absorbable Mesh|
48495879|NCT03222752|DEVICE|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
47978971|NCT02208557|RADIATION|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
48130901|NCT05063045|BEHAVIORAL|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
48130902|NCT04863677|BEHAVIORAL|High Intensity Interval Training(HIIT）|Last 12 weeks (3 sessions per week)
47978972|NCT02208557|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
47978973|NCT01380873|DRUG|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
48495880|NCT00476554|DRUG|Sapacitabine|Sapacitabine
48495881|NCT00228423|DRUG|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
48495882|NCT00228423|DRUG|water pill daily|Daily dose of water pill (placebo)
47978974|NCT01380873|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
48495883|NCT02519335|DRUG|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
48495884|NCT02201238|DRUG|Diclofenac sodium|Diclofenac sodium
48495885|NCT02201238|DRUG|Menthol|Menthol
48495886|NCT03438825|PROCEDURE|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
48495887|NCT00930371|OTHER|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
48495888|NCT00930371|OTHER|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
48495889|NCT00726154|BEHAVIORAL|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
48495890|NCT00726154|BEHAVIORAL|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
48495891|NCT03590392|BIOLOGICAL|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
48654736|NCT06571552|PROCEDURE|Single Plasma Exchange followed by Double Filtration Plasmapheresis|Double Filtration Plasmapheresis followed by Single Plasma Exchange
48130903|NCT04863677|BEHAVIORAL|Moderate Intensity Continuous Training(MICT）|Moderate Intensity Continuous Training(MICT）
48495892|NCT00000117|DRUG|Immunoglobulin|
48130904|NCT05148988|DIAGNOSTIC_TEST|EchoPIV|All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
48495893|NCT03356574|PROCEDURE|Single-ventricle palliation surgery|Single-ventricle palliation surgery
48654737|NCT05559047|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
47978975|NCT01380873|DRUG|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
48654738|NCT05559047|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
48130905|NCT05148988|DIAGNOSTIC_TEST|4D flow MRI|A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
48495894|NCT05296356|DRUG|OSU6162|OSU6162
48495895|NCT05124197|OTHER|prone position|extension of prone position duration
47978976|NCT00609492|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
48495896|NCT06324318|BEHAVIORAL|Parenting in 2 Worlds (P2W)|P2W is a culturally-adapted parenting intervention designed specifically for urban American Indian families. It is a 10-week, 10-lesson manualized curriculum with accompanying videos, designed to be facilitated by American Indians from the local communities. The workshop lessons cover topics like the identification of family values, culturally influenced child rearing values and traditions, sources of support for parents, and ways to improve parenting skills to communicate with, monitor, and guide adolescents to avoid substance use, unprotected sex and other risk behaviors
48495897|NCT06324318|BEHAVIORAL|Healthy Families in 2 Worlds (HF2W)|HF2W is a 10-week informational family health program. The workshop lessons cover topics such as oral health, CPR and first aid, dating safety, and teen mental health.
48130909|NCT06143709|OTHER|DNA sample collection|Patients will be asked to provide a blood or mouth wash sample for DNA extraction
48495898|NCT01376817|DRUG|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
48495899|NCT01376817|DRUG|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
48495900|NCT01268332|DRUG|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
47978977|NCT00609492|BIOLOGICAL|Infanrix™-IPV/Hib|Single dose, intramuscular injection
47978978|NCT04190394|OTHER|Intermittent retraining program.|Patient benefits from an intermittent retraining program for 8 weeks, with three 45-minute sessions per week.
47978979|NCT05156853|DIETARY_SUPPLEMENT|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
47978980|NCT05156853|DIETARY_SUPPLEMENT|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
48495901|NCT00861198|OTHER|ERCP as per medical indication|ERCP as per medical indication
48495902|NCT00658645|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
48495903|NCT00658645|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
48337979|NCT00702728|DRUG|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
48337980|NCT01619605|PROCEDURE|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
48495904|NCT00658645|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
48495905|NCT04470336|OTHER|Collagen Supplement|Three capsules post-breakfast Three capsules post-dinner
48495906|NCT04470336|OTHER|Glucosamine chondroitin|Three capsules post-breakfast Three capsules post-dinner
48495907|NCT04470336|OTHER|Placebo|Three capsules post-breakfast Three capsules post-dinner
48130918|NCT03206086|DRUG|Eltrombopag|Daily dose - Non-Asian (\>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (\>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg
48130919|NCT01291472|DRUG|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
48130920|NCT03657693|DIAGNOSTIC_TEST|NICU MRI|MRI device that is not FDA approved.
48130921|NCT03657693|DIAGNOSTIC_TEST|Polysomnography|Polysomnography to better determine obstruction index in the airway.
48130922|NCT04844879|DEVICE|NextAR TKA system|The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
48495908|NCT05028049|DRUG|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
48130924|NCT05224765|OTHER|Fall prevention class|Participants attend fall prevention discharge class per hospital protocols
48654739|NCT05908760|DEVICE|CO2 ReHaler|The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
48654740|NCT04649749|DIAGNOSTIC_TEST|MRI|MRI scan
48654741|NCT03345550|DRUG|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
48654742|NCT03345550|DRUG|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
48654743|NCT06461494|OTHER|baseline treatment|hot pack will be applied for 10 minutes
48654744|NCT06637956|DRUG|Nitroglycerin (NTG)|Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
48654745|NCT06511076|DRUG|Zilucoplan|Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.
47978981|NCT00360789|BEHAVIORAL|Conventional UK physical therapy|
47978982|NCT00360789|BEHAVIORAL|Increased intensity of UK conventional physical therapy (PT)|
47978983|NCT00360789|BEHAVIORAL|UK conventional PT plus functional strength training|
47978984|NCT05660772|DEVICE|Microfragmented Adipose Tissue|Microfragmented Adipose Tissue derived using Lipogems® Kit
48130925|NCT05525455|DRUG|TT-816|TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors
48130926|NCT05525455|DRUG|A PD-1 inhibitor|Programmed death receptor-1 (PD 1)-blocking antibody
48495909|NCT05028049|DRUG|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
48495910|NCT05028049|OTHER|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
48495911|NCT05028049|OTHER|plateau areas|Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)
47978985|NCT05660772|DRUG|Corticosteroid|intra-articular knee injection of corticosteroid
47978986|NCT01829191|DEVICE|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
48495912|NCT01064154|DRUG|Carvedilol|Carvedilol Tablets 25 mg
48654746|NCT06402162|OTHER|exercise|The study will include 40 tennis players diagnosed with rotator cuff lesions who meet the inclusion criteria. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week for 8 weeks.
48654747|NCT05226052|DIETARY_SUPPLEMENT|Saccharomyces boulardii (Floratil 600mg)|PGIC and PGIS assessment
48654748|NCT05226052|DIETARY_SUPPLEMENT|3 capsules of placebo|PGIC and PGIS assessment
48654749|NCT05090865|DIETARY_SUPPLEMENT|Liberalized dietary potassium via fruits and vegetables|On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
47978987|NCT01829191|DEVICE|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
48495913|NCT04171271|BEHAVIORAL|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
48495914|NCT04171271|BEHAVIORAL|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
47978988|NCT02515058|DEVICE|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
48337981|NCT06376188|OTHER|communication training|The intervention group received a communication training session prior to the prebriefing and familiarization of the scenario, including advice on how to improve communication skills as well as how to create an optimal setting for difficult medical conversations. This communication training session has been created on the basis of an in-depth literature research.(Brock et al., 2019; Chumpitazi et al., 2016; Collins et al., 2018; Grant et al., 2016; Tobler et al., 2014; Vaidya et al., 1999; Yuan et al., 2019)
48495915|NCT03891186|BEHAVIORAL|Metacognitive Training in Schizophrenia (MCT)|"MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt)."
48495916|NCT03891186|OTHER|Treatment As Usual (TAU)|In both groups will be maintained the TAU.
48495917|NCT02774096|DRUG|xenon|
48495918|NCT01374126|DRUG|Artesunate|Artesunate alone
48495919|NCT01374126|DRUG|Azithromycin + Artesunate|Combination of azithromycin + artesunate
48495920|NCT04299451|OTHER|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
48495921|NCT04218500|OTHER|Niacinamide 4%|cream moisturizer
48495922|NCT04218500|OTHER|Virgin Coconut oil 30%|cream moisturizer
48495923|NCT04067336|DRUG|Ziftomenib|Oral administration
48495924|NCT00476632|BEHAVIORAL|Questionnaire|50 Minute Interview
47978989|NCT02515058|DEVICE|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
47978990|NCT05779293|DEVICE|Non-invasive auricular vagus nerve stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.
48130929|NCT00429338|PROCEDURE|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
48130930|NCT00429338|PROCEDURE|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
48337982|NCT02345044|DRUG|CS-3150|
48337983|NCT02345044|DRUG|placebo|
48337984|NCT02345044|DRUG|eplerenone|
48495925|NCT06273839|DRUG|Tafamidis 61 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
48495926|NCT06273839|DRUG|Tafamidis 70 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
48495927|NCT06273839|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
48495928|NCT04505293|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
48654750|NCT05090865|DIETARY_SUPPLEMENT|Standard dietary potassium restriction|Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
48654751|NCT03413995|DRUG|Rucaparib|Continuous dosing
48654752|NCT02965313|PROCEDURE|SSLS Procedure|Synthetic suture repair
48654753|NCT02965313|PROCEDURE|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
48654754|NCT03847012|OTHER|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
48654755|NCT05596812|OTHER|New Care Pathway|The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
48654756|NCT06643260|DRUG|piclidenoson|Piclidenoson is a selective A3AR agonist, supplied as tablets.
48654757|NCT06643260|DRUG|Placebo|Inactive control
48337985|NCT02081560|DRUG|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
48337986|NCT05117593|DRUG|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
48654758|NCT05910554|DRUG|Metformin|Patients randomized to metformin will be assigned the active arm.
48654759|NCT05910554|DRUG|Cellulose|Patients randomized to cellulose will be assigned the placebo arm.
48654760|NCT01816399|PROCEDURE|Routine coronary angiography|
48654761|NCT06641414|DRUG|Lisaftoclax (APG-2575)|QD, oral administration.
48654762|NCT06641414|DRUG|Azacitidine Injection|QD, hypodermic or intravenous injection.
48654763|NCT06641414|OTHER|Placebo|QD, oral administration.
47978991|NCT05779293|OTHER|Conventional therapy|"Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks."
48495929|NCT02477163|OTHER|Ayurveda treatment|"1. Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~2. Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~3. Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~4. Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~5. Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~6. Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch."
48495930|NCT03426566|OTHER|retrospective observational study with no intervention|no intervention
48130933|NCT06514794|BIOLOGICAL|WU-CART-007|A single IV infusion of WU-CART-007 cells on Day 1
48495931|NCT02945605|OTHER|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~1. Eye-Head coordination, gaze stability and convergence exercises~2. Sitting balance~3. Standing static balance (i.e. feet-in-place)~4. Dynamic balance (feet moving, but not walking)~5. Ambulation (gait exercises)~6. Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
48654764|NCT04672616|BEHAVIORAL|Group psychotherapy|The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
48495932|NCT02945605|OTHER|Standard of Care|Standard care as directed by a physician.
48130936|NCT04489355|PROCEDURE|coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)|
48337987|NCT05117593|DRUG|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
48337988|NCT00703170|DRUG|Temsirolimus|
48337989|NCT00703170|DRUG|Pegylated liposomal doxorubicin|
48337990|NCT05300646|BEHAVIORAL|Prenatal mindfulness-based stress reduction|An adapted mindfulness-based stress reduction (MBSR) program with a particular focus on pregnancy and early motherhood.
48337991|NCT01920971|RADIATION|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
48337992|NCT01100645|DRUG|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
48337993|NCT01100645|DRUG|Placebo|Excipient
48337994|NCT03431506|BEHAVIORAL|Vestibular rehabilitation|Vestibular Rehabilitation Exercises
48337995|NCT01060098|DRUG|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
48337996|NCT02814448|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
48337997|NCT02814448|DEVICE|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
48337998|NCT02814448|DEVICE|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
48337999|NCT02701179|DRUG|Lignocaine 1% concentration solution|
48338000|NCT02701179|DRUG|Lignocaine 2% concentration solution|
48338001|NCT00567957|DRUG|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
48338002|NCT00567957|DRUG|Saline|same volume iv bolus before induction followed by same volume infusion
48338003|NCT03549468|DEVICE|Low level tragus stimulation|All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
48338004|NCT06145087|DIETARY_SUPPLEMENT|"NOVOS Core supplement"|The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.
48338005|NCT06145087|DIETARY_SUPPLEMENT|Placebo|The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
48338006|NCT00568204|DEVICE|Mexyn-A|Atomised topical self-chilled pressurised spray
48338007|NCT02561780|BEHAVIORAL|Curriculum|A mental health educational resource delivered in the classroom by trained educators
48338008|NCT02561780|BEHAVIORAL|eLearning Follow-up|An online mental health education module that students access individually
48338009|NCT03314012|DEVICE|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
48338010|NCT01105780|DRUG|Placebo|Matching placebo
48338011|NCT01105780|DRUG|JNJ-41443532|250mg tablet once daily for 1 day
48338012|NCT00925145|PROCEDURE|Single Incision Laparoscopic Appendectomy|
48495933|NCT03861403|DRUG|TRX518|Administered by IV infusion
48495934|NCT03861403|DRUG|Cyclophosphamide|Administered by IV infusion
48495935|NCT03861403|DRUG|Avelumab|Administered by IV infusion
47978992|NCT02548650|DRUG|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
48130937|NCT06449677|DEVICE|iLet Bionic Pancreas System (BP)|The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor.
48130938|NCT06449677|DEVICE|Usual Care (UC)|Usual Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump.
48130939|NCT05509855|GENETIC|Genetic: WU-CART-007|No study drug is administered in this study. Patients who have received WU-CART-007 will be enrolled in this study for Long Term Safety and Efficacy
48130940|NCT06275477|DIAGNOSTIC_TEST|68Ga-FAPI46|Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).
48130941|NCT04248322|BEHAVIORAL|Semi-structured interview|Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
48495936|NCT01183221|DRUG|Syntocinon|One dose of 24 IU (3 sprays/nostril)
48495937|NCT01183221|DRUG|Placebo|Intranasal Placebo
48495938|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
48495939|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
48338013|NCT04241172|DEVICE|Experimental: Immersive Virtual Reality (HIVR)|"the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~* Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~* Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback."
48338014|NCT04241172|PROCEDURE|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~* exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* water walking exercises."
48338015|NCT04241172|PROCEDURE|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~* exercises with a patient sitting on a chair (3 minutes per exercise):~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* walking (with and without aids)."
48338016|NCT05293171|DRUG|1.25 mg/kg BL-8040 + BL-8040-matching placebo|Administered via subcutaneous (SC) injection
48654765|NCT06635642|BEHAVIORAL|Dichotic Interaural Intensity Difference (DIID) Training|A total of five trials will be presented in a sequence and there will be 10 sequences per training session. Each of the 25 consonant-vowel-consonant words or digits 1 through 10 (excluding 7) will be presented to each ear during the session. The pairs will be randomized every time, and a word will never be paired with itself. After a sequence is completed, the difficulty of the task will be adjusted, in real time, based on performance on the prior task. If the child scored 4 or 5 of 5 correct in the poorer ear, then the IID will be decreased by 2 dB making the task more difficult. If the child scores 0, 1, or 2 of 5 correct, then the IID will be increased by 2 dB making the task easier. Last, if the child scores 3 of 5 correct, then the IID will remain unchanged for the next sequence.
48654766|NCT04375826|DEVICE|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
47978993|NCT02548650|DRUG|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
47978994|NCT02548650|DRUG|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
48495940|NCT06418685|DEVICE|Treatment with Vibrating Capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
48130947|NCT06239532|DRUG|HAIC+TAE|Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
48130948|NCT06239532|DRUG|Tislelizumab|Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks
48130949|NCT06239532|DRUG|Surufatinib|Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
48338017|NCT05293171|DRUG|2 mg/kg BL-8040|Administered via subcutaneous (SC) injection
48495941|NCT03664648|BIOLOGICAL|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
48495942|NCT03868462|DEVICE|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
48130952|NCT06349577|OTHER|Non-pulsatile blood flow|Non-pulsatile blood flow generated by constant centrifugal pump flow rate during cardiopulmonary bypass
48130953|NCT06349577|OTHER|Pulsatile blood flow|Pulsatile blood flow generated by variable centrifugal pump flow rate during cardiopulmonary bypass
48130954|NCT05018910|OTHER|Skin to Skin|During routine Skin-to-skin sessions, the heart rate variability of the infant will be measured.
48495943|NCT03868462|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
48130956|NCT05208567|DIAGNOSTIC_TEST|Echocardiogram|Cardiac Ultrasound Scan - using an abbreviated protocol
48130957|NCT06066528|DRUG|Survodutide|once weekly subcutaneous injection
48130958|NCT06066528|DRUG|Placebo|once weekly subcutaneous injection
48130959|NCT06127121|BEHAVIORAL|Digital Art Activity|"* complete a symptom questionnaire~* complete another activity such as listening to meditative music for 10 minutes~* fill out the symptom questionnaire and engage in the digital art activity again"
48495944|NCT01833091|OTHER|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand \& arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
48495945|NCT00552383|PROCEDURE|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff \[this includes 3 of the investigators\], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
48495946|NCT04461366|DEVICE|Monopolar radiofrequency|The RF electrode was moved randomly for 30 seconds over each scar. The total duration of the treatment session is only 5 minutes for each cheek. It takes 15 minutes if the forehead and 2 cheeks are affected.
48495947|NCT04461366|DEVICE|Pulsed dye laser|PDL was applied for the affected areas with no pre-treatment regimens or topical anaesthetics. There was no requirement for skin cooling.
48130964|NCT06127147|DEVICE|IMT|The IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure.
48130965|NCT06127147|DEVICE|Sham-IMT|The sham IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc) without intensity.
48495948|NCT03052218|DEVICE|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
48495949|NCT01455363|PROCEDURE|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
48495950|NCT01455363|OTHER|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
48495951|NCT01455363|OTHER|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
48654767|NCT04375826|DEVICE|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
48130968|NCT06101927|DRUG|Whole body study and SPECT with [99mTc]Tc-BQ0413|One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
48495952|NCT01468805|PROCEDURE|Cockroach mitigation/extermination|
48495953|NCT01327144|DRUG|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
48495954|NCT01327144|DRUG|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
48130972|NCT03501303|PROCEDURE|No touch technique|Veins for CABG is harvested with the no touch technique
48130973|NCT03501303|PROCEDURE|Control technique|Veins for CABG is harvested with the Control technique.
48130974|NCT01948661|DIETARY_SUPPLEMENT|Mirtoselect® + Meriva®|
48130975|NCT01948661|DIETARY_SUPPLEMENT|Placebo|
48130976|NCT01367236|DRUG|standard care|"* atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*"
48130977|NCT01367236|DRUG|novel treatment|"* darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily"
48495955|NCT01069991|BEHAVIORAL|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
48495956|NCT01069991|BEHAVIORAL|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
48495957|NCT04588714|BEHAVIORAL|Resilience-based, Energy Management to Enhance Wellbeing (RENEW)|The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
48654768|NCT04925024|BIOLOGICAL|Lomecel-B medicinal signaling cells|A single administration of Lomecel-B will be performed via 6-10 intramyocardial injections into the right ventricle during the participant's standard of care stage II palliation. Dosing is based on body weight. Each patient will be given 2.5 x 10\^5 cells per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
48495958|NCT04683666|PROCEDURE|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. \^Postoperative complications were assessed.
48495959|NCT05711836|GENETIC|HLA-genotyping|HLA genotyping in DNA samples from peripheral blood of patients and controls
48495960|NCT01305148|DEVICE|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
48495961|NCT05644015|OTHER|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
48495962|NCT04739150|DRUG|nintedanib|nintedanib
48495963|NCT02684708|DRUG|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
48495964|NCT02684708|DRUG|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
48338018|NCT05293171|DRUG|BL-8040-matching placebo|Administered subcutaneous (SC) injection
48338019|NCT05293171|DRUG|400 mg Moxifloxacin (1x400 mg tablet)|Administered orally
48338020|NCT01804491|OTHER|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
48338021|NCT04637191|DEVICE|MentalPlus®|A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
48654769|NCT06539728|DIAGNOSTIC_TEST|Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces|Participants will drop a saline solution with proteins onto the testing device. They will wait for it to dry and then report on the tactile sensation and overall feel of the surface. Feedback will include comparisons with the two reference surfaces. The primary goal is to determine the presence of mock COVID antigen in synthetic saliva using the device, which aligns with the goals of diagnostic testing.
48495965|NCT05201352|DRUG|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
48495966|NCT05201352|DRUG|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
48495967|NCT04168190|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
48495968|NCT04168190|BIOLOGICAL|Pneumovax™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
48130989|NCT06120855|DRUG|Regulated cannabis from authorized pharmacies|"The intervention group is allowed to purchase regulated cannabis in authorized pharmacies. The intervention includes various offers: Participants can choose between cannabis sorts and delivery methods, and they are encouraged to shift from smoking cannabis to vaping cannabis-containing e-liquids, vaporizing cannabis blossoms or using oral cannabis. Vaping / vaporizing electronic devices are also recommended. At the same time, pharmacists offer opportunistic smoking cessation and problematic cannabis, alcohol use and further drug use counseling that conforms to motivational interviewing principles.~Study participants can choose between different cannabis-containing products such as dried cannabis flowers, cannabis concentrates (colloquially called hashish or hash), e-liquids and oral cannabis. Besides the cannabis products, participants can buy vaping or vaporizing electronic devices at the pharmacy (they are not considered as study products)."
48130990|NCT06120855|DRUG|Cannabis from the illicit market|The control group receives no intervention and is expected to continue purchasing cannabis from the illicit market.
48130993|NCT03894566|OTHER|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
48338022|NCT05134168|PROCEDURE|bone marrow mononuclear cell injection|bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract
48338023|NCT05134168|PROCEDURE|LIFT|The fistula tract is ligated in the intersphincteric space
48338024|NCT04309604|BIOLOGICAL|IC14|monoclonal antibody directed against CD14
48338025|NCT03132441|OTHER|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
48338026|NCT02645071|BEHAVIORAL|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
48338027|NCT02168712|OTHER|Moderate continuous exercise training|
48338028|NCT02168712|OTHER|Interval exercise training|
48495969|NCT02528123|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
48338029|NCT00194727|DRUG|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
48338030|NCT00194727|DRUG|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
48338031|NCT01604096|OTHER|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~* brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~* posters (same distribution as brochures)~* short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~* radio-spots transmitted in local radio stations~* advertisements in local newspapers~* banners on websites of local newspapers~* newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~* training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
48338032|NCT00493480|DRUG|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
48495970|NCT02528123|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
48654770|NCT06539728|DIAGNOSTIC_TEST|Biomechanical Measurements|Participants may have biomechanical measurements recorded, such as placing samples on a scale to measure downward force or using medical tape with a flexible wire to track finger motion. These measurements are likely aimed at objectively assessing how participants interact with the surfaces and their physical responses to tactile stimuli.
48338033|NCT00493480|DRUG|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
47978995|NCT01224067|DRUG|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
47978996|NCT05511051|DRUG|Fruquintinib|Fruquintinib
47978997|NCT05511051|DRUG|HAIC|HAIC
48338034|NCT04048629|DEVICE|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
48495971|NCT02528123|DRUG|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
48495972|NCT02528123|DRUG|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
47978998|NCT04953546|OTHER|No Intervention|This is an observation study, with no intervention
47978999|NCT03780907|DRUG|E2007|1 mg of E2007 was administered by mouth once daily.
47979000|NCT03780907|DRUG|E2007|2 mg of E2007 was administered by mouth once daily.
48338035|NCT04048629|OTHER|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
48338036|NCT01989819|OTHER|skin biopsy|
48495973|NCT02528123|DRUG|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
48495974|NCT06337253|DRUG|Sulfadoxine/pyrimethamine plus amodiaquine|Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.
48495975|NCT04013230|BEHAVIORAL|Usual care|Visit doctor and nurse at the clinic.
48495976|NCT04013230|BEHAVIORAL|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
48495977|NCT02547155|PROCEDURE|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
47979001|NCT03780907|DRUG|Placebo|Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
47979002|NCT02563353|OTHER|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
47979003|NCT02563353|DRUG|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
47979004|NCT05884723|DIETARY_SUPPLEMENT|Ketogenic Diet|4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
47979005|NCT05157984|PROCEDURE|ZPOEM|Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
47979006|NCT00256893|DRUG|ropinirole|
47979007|NCT00709683|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
47979008|NCT00704054|DRUG|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
47979009|NCT05759676|DEVICE|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
48338037|NCT02690389|DRUG|Flumazenil|used alone or with acupuncture
48338038|NCT02690389|PROCEDURE|Acupuncture|used alone or with flumazenil
48338039|NCT02621255|DRUG|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
48338040|NCT02621255|DRUG|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
48338041|NCT03371927|OTHER|SINC Feeding Protocol|Safe individualized nipple-feeding competence protocol for premature infants
47979010|NCT02187250|DRUG|metformin|
48495978|NCT02547155|PROCEDURE|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
48495979|NCT00263991|DEVICE|EEC-techniques|
47979011|NCT02187250|DRUG|liraglutide|
47979012|NCT02187250|DRUG|roflumilast|
48130994|NCT06356311|BIOLOGICAL|Sacituzumab tirumotecan|Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.
48130995|NCT06356311|DRUG|Trifluridine-Tipiracil|Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
48130996|NCT06356311|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.
47979013|NCT05012839|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
47979014|NCT05493527|DEVICE|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~1. a frequency of 10 Hertz ( range, 8-12 Hz);~2. an inspiratory time of 50% (1:1)~3. an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~4. Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~5. fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
48130997|NCT06356311|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.
48130998|NCT06356311|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.
48338042|NCT04998851|DRUG|Ocrelizumab|Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.
48338043|NCT03991182|OTHER|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
48338044|NCT03991182|OTHER|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
48338045|NCT03991182|BEHAVIORAL|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
48338046|NCT03991182|OTHER|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
48338047|NCT00035152|DRUG|Paclitaxel and carboplatin|
48338048|NCT02281344|DRUG|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
48338049|NCT05878691|DRUG|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
48495980|NCT06489457|DRUG|Semaglutide|Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)
48495981|NCT06489457|DRUG|Testosterone Undecanoate|Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks
48495982|NCT03516214|DRUG|EGF816|Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
48495983|NCT03516214|DRUG|Trametinib|Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
47979015|NCT05493527|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~1. Peep ranging from 5 to 10 cmH2O,~2. Peak inspiratory pressure range 15-25 cmH2O~3. Rate range 40-50 breath/minute~4. FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
47979016|NCT02655939|DIETARY_SUPPLEMENT|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
47979017|NCT02655939|DIETARY_SUPPLEMENT|Placebo|Fructose,Orange flavor and sucralose
47979018|NCT00022308|DRUG|cisplatin|
47979019|NCT00022308|DRUG|irinotecan hydrochloride|
47979020|NCT00022308|RADIATION|radiation therapy|
48495984|NCT02777112|OTHER|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
47979021|NCT03303534|DIETARY_SUPPLEMENT|ScandiShake|weight gain supplement low in protein
47979022|NCT00697762|DRUG|RWJ-333369|200 mg tablet twice daily for 12 weeks
48338050|NCT05878691|DRUG|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
47979023|NCT00697762|DRUG|RWJ-333369|100 mg tablet twice daily for 12 weeks
48338051|NCT05878691|DRUG|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
48495985|NCT02777112|OTHER|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
48495986|NCT02777112|OTHER|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
48495987|NCT02227147|DRUG|rhNGF 20µg/ml|
48495988|NCT02227147|OTHER|Placebo|Formulation containing antioxidant
47979024|NCT00697762|DRUG|Placebo|Placebo tablet twice daily for 12 weeks
47979025|NCT03256565|DIAGNOSTIC_TEST|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
47979026|NCT01521208|DEVICE|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
48338052|NCT03063853|OTHER|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
48338053|NCT03063853|PROCEDURE|Elective cesarean delivery|non emergent elective cesarean delivery
48338054|NCT01574937|DRUG|Cabozantinib|28 day cycle
48338055|NCT01574937|DRUG|Abiraterone|28 day cycle
48338056|NCT00432913|DRUG|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
48338057|NCT00432913|PROCEDURE|Endoscopy|At baseline, month 3 and month 6.
48338058|NCT00432913|PROCEDURE|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
48338059|NCT00432913|PROCEDURE|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
48338060|NCT00432913|PROCEDURE|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
48338061|NCT00432913|PROCEDURE|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
48338062|NCT00432913|PROCEDURE|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
48495989|NCT03038594|DRUG|Somatropin|
48495990|NCT03038594|DRUG|0.09% Saline Solution|
48495991|NCT04131543|DRUG|Cabozantinib 20 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
48495992|NCT04131543|DRUG|Cabozantinib 40 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
47979027|NCT01521208|OTHER|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
47979028|NCT02108353|DRUG|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
47979029|NCT02108353|DRUG|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
48338063|NCT00432913|PROCEDURE|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
48338064|NCT00432913|PROCEDURE|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
48338065|NCT05750888|BEHAVIORAL|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
48338066|NCT05750888|BEHAVIORAL|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
48338067|NCT05645653|BEHAVIORAL|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
48338068|NCT04625361|DRUG|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
48338069|NCT02780596|OTHER|Item1|Does CHILD NAME often wake one or more times during the night?
48130999|NCT06356311|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
48338070|NCT02780596|OTHER|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
48131000|NCT06356311|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
48131001|NCT06533865|DRUG|Romosozumab|Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
48131002|NCT06533865|DRUG|Placebo|Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
48131003|NCT06533865|DRUG|Zoledronic acid|One intravenous infusion
48131004|NCT04448366|BEHAVIORAL|Cognitive behavioral therapy|Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
48495993|NCT04131543|DRUG|Cabozantinib 60 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
48495994|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Active|"Treatment protocol:~* EFD 0.096 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
48131007|NCT06389357|BEHAVIORAL|training and counselling|It includes 4 modules that develop children's communication, coping and social life skills and psychosocial preparation for the return to school process. The modules include theoretical explanations, stories, workshops and counselling sessions.
48338071|NCT02780596|OTHER|Item3|Do you think CHILD'S SLEEP is a problem?
48495995|NCT06076850|DEVICE|Low-Intensity Extracorporeal Shockwave Therapy (LiEWST) - Sham|"Treatment protocol:~* EFD 0 mJ/mm2~* 2 sessions / week; 5000 shocks / session~* 6 weeks treatment~* total: 12 sessions~* Li-ESWT to start after removal of indwelling catheter"
48495996|NCT01956617|OTHER|lumbar plexus block|
48495997|NCT02699684|DEVICE|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
48495998|NCT02699684|DEVICE|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
48495999|NCT02699684|DEVICE|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
48131008|NCT06576843|DRUG|INDV-6001|Extended-release subcutaneous injection
48131009|NCT06576843|DRUG|Suboxone|Oral sublingual film
48131010|NCT06576843|DRUG|Sublocade|Extended-release subcutaneous injection
48338072|NCT02780596|OTHER|Item4|Do you think CHILD NAME has a sleep problem?
48338073|NCT02780596|OTHER|Item5|Do you have any concerns about CHILD NAME'S sleep?
48496000|NCT02699684|DEVICE|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
48496001|NCT02699684|DEVICE|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
48496002|NCT02955017|BEHAVIORAL|traditional follow_up|"* Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~* Two days of a complete medical check at 9 and 15 months"
48338074|NCT06201169|PROCEDURE|implant placement|All patients received four implants in the lower arch
48338075|NCT01929707|DRUG|LY3050258|
48338076|NCT01929707|DRUG|Placebo|
48338077|NCT05251298|OTHER|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
48338078|NCT05795868|DEVICE|Compression stocks|Pregnant women in the compression stockings group will wear the socks given for 3 weeks.
48338079|NCT05795868|OTHER|Knee socks|Pregnant women in the Knee socks group will wear the socks given for 3 weeks.
48338080|NCT04994704|DRUG|Propfol group|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
48338081|NCT04994704|DRUG|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
48338082|NCT02012881|BEHAVIORAL|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
48338083|NCT02012881|BEHAVIORAL|Usual practice|Normal curriculum
48338084|NCT03355404|OTHER|standing patient|patient goes standing to the surgery room
48338085|NCT02334553|DRUG|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
48496003|NCT02955017|BEHAVIORAL|"distance follow-up new technologies"|"* Multidisciplinary support with long distance monitoring Mobile apps.~* Two days of a complete medical check at 9 and 15 months"
48338086|NCT02334553|DRUG|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
48338087|NCT01886404|DRUG|Efavirenz|"HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well."
48496004|NCT00512382|DEVICE|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
48131012|NCT00001168|BEHAVIORAL|Balanced diet|Dietary studies for the diagnosis of post-prandial hyperlipidemia will include a 3 week period while subjects are on a baseline, isoweight, 15% fat, 42% carbohydrate, normal polyunsaturated fat ratio (0.1-0.3) 250-300 mg cholesterol diet.
48496005|NCT04405895|OTHER|Breakfast Diet|Breakfast Diet (3Mdiet) consist on high-energy breakfast and reduced in energy and carbohydrate (CH) dinner. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 3Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 3Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
48496006|NCT04405895|OTHER|Allday Diet|Allday Diet (6Mdiet) consist in 6 small meals: breakfast, lunch and dinner and 3 snacks, with calories and carbohydrates (CH) evenly distributed throughout the day. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 6Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 6Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
48496007|NCT02838121|DRUG|Aclasta|Aclasta once annually for 2 years
48496008|NCT02838121|DRUG|Placebo|No IV aclasta
48496009|NCT05526326|DEVICE|Transplant with normothermic machine perfused (NMP) donor liver|The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®
48338088|NCT06164587|DRUG|K8|sustained released intravitreal implants
48338089|NCT04252261|DRUG|sulforaphane|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
48338090|NCT04252261|DRUG|placedo|To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
48338091|NCT01679522|PROCEDURE|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
48338092|NCT01679522|PROCEDURE|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
48496010|NCT00456430|DRUG|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
48496011|NCT04883970|OTHER|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
48496012|NCT00278889|DRUG|AZD2171|oral tablet
48496013|NCT00278889|DRUG|5-fluorouracil|intravenous infusion
48654771|NCT06539728|BEHAVIORAL|Psychophysical Tasks|Participants may alternatively be asked to perform standardized psychophysical tasks, such as Two Alternative Forced Choice tests, Odd-Man Out tests, or Magnitude Estimation tests. These tasks will provide structured comparisons and quantitative data on participants' perception and preferences regarding tactile qualities. The tasks are designed to evaluate participants' perception and preferences regarding tactile qualities, which involves behavioral responses to sensory stimuli.
48654772|NCT06281769|DIAGNOSTIC_TEST|3D multi-parametric ultrasound targeted biopsy pathway using PcaVision|The procedure of 3D multiparametric ultrasound consists of 3 components: (1) intravenous administration of ultrasound contrast; (2) rectal multi-parametric ultrasound imaging; (3) PCaVision: artificial intelligence algorithm analyzing the images.
47979030|NCT05748756|OTHER|Enucleation and filling by Bone marrow aspirate|"The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique."
47979031|NCT05748756|OTHER|Conventional enucleation only|patients were treated conventionally by enucleation and plain collagen sponge only.
47979032|NCT01293175|DIETARY_SUPPLEMENT|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
47979033|NCT02669433|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
47979034|NCT02669433|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
47979035|NCT02669433|DRUG|Placebo|once daily, oral, matching tablets
47979036|NCT04893967|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
47979037|NCT04893967|DEVICE|kinesiology tape|Kinesiology Tape is applied without creating any tension over low back
48496014|NCT00278889|DRUG|Leucovorin|intravenous infusion
48131013|NCT04560946|BEHAVIORAL|Personalized Augmented Cognitive Training (PACT)|Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
48496015|NCT00278889|DRUG|Oxaliplatin|intravenous infusion
48496016|NCT00278889|DRUG|Bevacizumab|intravenous infusion
47979038|NCT03428789|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
47979039|NCT04716569|DRUG|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
48131014|NCT04560946|BEHAVIORAL|Enhanced Treatment As Usual|"Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software."
48496017|NCT04848311|PROCEDURE|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
48496018|NCT01904617|OTHER|Dextrose|
48496019|NCT01904617|OTHER|Normal Saline|
48496020|NCT01031459|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
48496021|NCT06110728|BEHAVIORAL|Habit Change|Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
48654773|NCT06281769|DIAGNOSTIC_TEST|MRI targeted biopsy pathway|MRI sequences will include at least T1-weighted, T2-weighted, Diffusion-weighted imaging (DWI) and calculation of apparent diffusion coefficient (ADC) maps. Scoring of suspicion will be performed using the European Society of Urogenital Radiology (ESUR) PI-RADS standardized scoring system. All lesions will be marked and delineated for MRI-TRUS fusion 3D multiparametric ultrasound (mpUS).
48654774|NCT03845036|BEHAVIORAL|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
48654775|NCT03845036|BEHAVIORAL|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
47979040|NCT01658670|BEHAVIORAL|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
47979041|NCT01658670|BEHAVIORAL|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
48496022|NCT03244943|PROCEDURE|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
47979042|NCT03981263|DEVICE|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
48131015|NCT04683315|DRUG|mFOLFIRINOX Treatment Regimen|This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
48131016|NCT04683315|DRUG|Gemcitabine/Nab-paclitaxel Treatment Regimen|This regimen will be nab-paclitaxel and gemcitabine.
47979043|NCT03981263|DEVICE|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
48131017|NCT04683315|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
48496023|NCT04078880|DIETARY_SUPPLEMENT|Sucrosomial iron plus ascorbic acid|A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
48496024|NCT06477484|DIAGNOSTIC_TEST|Blood biomarker|Blood biomarker
48496025|NCT05589961|DRUG|TMZ|After enrollment, temozolomide 50mg/m2 was given orally for QD until progression, and radiotherapy and PF 0.2g/ time for TID were started one week later until progression. Pembrolizumab 200mg once every 3 weeks until progression; The radiotherapy regimen depends on the patient's recurrence and initial treatment.
48338093|NCT05833555|BEHAVIORAL|MH task-sharing training|Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
48338094|NCT05833555|BEHAVIORAL|Supervision|Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
47979044|NCT04432857|DRUG|AN0025|oral administration
48131021|NCT05682950|RADIATION|online adaptive radiotherapy|CTV covers pelvis.
48131022|NCT06088758|DEVICE|Normothermic machine perfusion (NMP) of steatotic liver|Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
48131023|NCT05874414|DRUG|GNS561 + Trametinib|GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
48338095|NCT05833555|BEHAVIORAL|Learning Collaborative|A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
48338096|NCT05833555|OTHER|Technology Intervention|To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
48338097|NCT02994095|BEHAVIORAL|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
48338098|NCT02053519|DRUG|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
48338099|NCT02053519|DRUG|Mygliol Oil|Matched placebo comparator
48338100|NCT01807767|DRUG|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
48338101|NCT01807767|DRUG|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
48338102|NCT04902768|OTHER|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
48496026|NCT01403064|BIOLOGICAL|ALD518|IV
47979045|NCT04432857|DRUG|Pembrolizumab|Infusion
47979046|NCT05132920|DRUG|Dexamethasone|3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21
47979047|NCT05132920|DRUG|Placebo|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
47979048|NCT00155350|DRUG|pioglitazone|
48496027|NCT01403064|DRUG|0.9% saline|IV Infusion
48131025|NCT05580003|DRUG|PF-07817883|Oral suspension or solid oral formulation(s)
47979049|NCT03208855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
48131026|NCT05580003|DRUG|Placebo|Placebo suspension
48131027|NCT05580003|DRUG|Midazolam|midazolam oral solution
48131028|NCT05580003|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet
48131034|NCT03509909|BEHAVIORAL|Hatha yoga|Manualized hatha yoga
48131035|NCT03509909|BEHAVIORAL|Supportive physical activity|Manualized stretching and strengthening
48131036|NCT05828082|PROCEDURE|Biopsy|Undergo biopsy
48131037|NCT05828082|PROCEDURE|Biospecimen Collection|Correlative studies
48131038|NCT05828082|PROCEDURE|Computed Tomography|Undergo CT
48131039|NCT05828082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48131040|NCT05828082|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI or PET/CT
48338103|NCT06057649|OTHER|Effleurage Abdominal Massage|perform the effleurage massage by following these steps: Lie in supine position with knee slightly flexed. Start from the right lower quadrant, using gentle pressure, rub in tiny clockwise circular motions using any non-analgesic cream, towards right rib cage then towards upper left side, moving down the left side to hip bone. Keep up the circular massage while moving inward, toward your belly button for three minutes. After three minutes, use a little more pressure, continuing the circular movements for 10 minutes. Massage for 10 minutes a day for two months during the first 3 days of the menstrual cycle.
48496028|NCT02583386|BEHAVIORAL|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
47979050|NCT04081168|DEVICE|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
47979051|NCT04081168|DEVICE|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
47979052|NCT04070274|PROCEDURE|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
48131041|NCT05828082|DRUG|Tuvusertib|Given PO
48131042|NCT05828082|PROCEDURE|Ultrasound Imaging|Undergo U/S
48496029|NCT02583386|OTHER|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
48338104|NCT04121689|DIETARY_SUPPLEMENT|Milk Protein Concentrate|The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-\[1-13C\]phenylalanine and L-\[1-13C\]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
48338105|NCT01154738|DRUG|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
48338106|NCT01154738|DRUG|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
48338107|NCT03650712|DIAGNOSTIC_TEST|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
48338108|NCT03650712|DIAGNOSTIC_TEST|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
48338109|NCT03650712|DIAGNOSTIC_TEST|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
48338110|NCT06162871|BEHAVIORAL|Presentations and interactive debate sessions, with intergenerational exchange|Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
48338111|NCT03796884|DRUG|Linaclotide|Given PO
48338112|NCT03796884|OTHER|Placebo|Given PO
48338113|NCT05698108|DEVICE|Instrument Assisted Soft Tissue Mobilization (IASTM)|Tools designed for soft tissue mobilization
48338114|NCT05698108|OTHER|Conventional Physical Therapy|Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
48338115|NCT06109519|PROCEDURE|implant supported overdenture|patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
48338116|NCT04436783|DEVICE|Virtual Reality Epley Maneuver System (VREMS)|The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.
48338117|NCT04436783|OTHER|Instructional Handout (IH)|Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
48654776|NCT06352099|DIETARY_SUPPLEMENT|Dietary supplement with micronised diosmin, hesperidin and herbal extracts|Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.
48654777|NCT01711099|DEVICE|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
48654778|NCT01889251|DRUG|Ocriplasmin|
48654779|NCT01889251|DRUG|Sham injection|
48654780|NCT05051228|DEVICE|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
48654781|NCT05250908|DEVICE|INTIBIA Therapeutic|INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
48654782|NCT05250908|DEVICE|INTIBIA Non-Therapeutic|INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
48338118|NCT04679441|DEVICE|The Computerized Functional Skills Assessment and Training Program|The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
48338119|NCT04679441|DEVICE|Brain HQ Double Decision|Cognitive speed training program
48654783|NCT04737265|OTHER|Biomarker Guided Intervention|NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
48654784|NCT04878185|OTHER|Exercise|Preoperative exercise
47979053|NCT02618889|BEHAVIORAL|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
47979054|NCT01599234|DRUG|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
48131044|NCT04340479|DIAGNOSTIC_TEST|Ultrasound lung imaging as part of FAST+ evaluation|"FAST+ evaluations will expand on the traditional FAST exam to systematically survey bilateral lung fields. Traditional FAST evaluation will survey the perihepatic, perisplenic, pelvic, and pericardial areas. Representative images will be saved by the performing provider for further evaluation. Up to sixteen areas in total will be included in FAST+ evaluation:~1. Anterior midclavicular right and left (apical, medial, basal)~2. Posterior paraspinal right and left\* (apical, medial, basal)~   \*Posterior lung evaluation will be omitted if patients are at risk for further traumatic injury from repeated side rolling.~3. Lateral axillary medial right and left (apical and basal)~Specifically, we will document the presence or absence of bilateral, diffuse pleural line abnormalities, subpleural consolidations, white lung areas and thick, irregular vertical artifacts in these lung fields by ultrasound and will record these findings."
47979055|NCT01599234|DRUG|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
47979056|NCT03232047|DEVICE|Combined executive function and memory training|Computerized combined executive function and memory training
47979057|NCT00735956|BEHAVIORAL|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
47979058|NCT04984798|DRUG|Vitamin E|Twice daily oral supplementation with Vitamin E for 6-9 weeks.
47979059|NCT01849224|OTHER|Pelvic and lower extremity exercise|
48496030|NCT04514536|DEVICE|Health monitors|"* The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~* The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~* The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~* The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~* The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together."
48496031|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
47979060|NCT05331274|OTHER|exercise group|"1 stage~* In a sitting position, pull the leg up and extend the knee forward~* Standing, bending forward and bending the knee~* Supine, tucked legs~* Maintaining spinal smoothness in crawling~* Prone heel pull to buttock~Stage 2~* Prone on forearms-hands~* Extending the supine hands to the knees~* Rounding and hollowing the waist in crawling~* Progressive sit-stand~* Standing up from sitting and putting on and taking off socks~* Reaching up while standing and maintaining the straightness of the spine~* Squatting~* Climbing and descending stairs~Stage 3~* Maintaining standing, arms forward~* Slipping hands on the bed while standing~* Initiating the standing throw and maintaining the position until the final interval~* Putting on and taking off socks while standing~* Taking weight towards the ground from a certain height~* Picking up different weights from the ground~* Push-pull items~* Crossing obstacles of certain height~* Walking a certain distance"
47979061|NCT05331274|OTHER|pain training group|"The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group."
47979062|NCT03102255|PROCEDURE|Sniffing position|All procedure is done under sniffing position.
47979063|NCT03102255|PROCEDURE|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
47979064|NCT01463553|PROCEDURE|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
47979065|NCT04268810|PROCEDURE|Bladder instillations|bladder instillations with either solution (DMSO or Uracyst)
47979066|NCT03423095|BEHAVIORAL|Active Jaw Exercise with Relaxation|This is the control group that will complete exercises unrelated to the primary outcome measures.
47979067|NCT03423095|BEHAVIORAL|Active Tongue Exercise|This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
47979068|NCT03423095|BEHAVIORAL|Active Tongue Exercise + Mental Practice|This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
47979069|NCT03423095|BEHAVIORAL|Mental Practice Tongue Exercise|This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
47979070|NCT00002942|PROCEDURE|autologous bone marrow transplantation|
47979071|NCT00002942|PROCEDURE|peripheral blood stem cell transplantation|
47979072|NCT05524155|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
47979073|NCT05524155|DRUG|Sintilimab|200mg IV d1,Q3W
47979074|NCT05524155|DRUG|Regorafenib|80mg/day,PO,QD,d1～21,Q4W
47979075|NCT01366170|GENETIC|microarray analysis|
47979076|NCT01366170|GENETIC|protein expression analysis|
47979077|NCT01366170|GENETIC|western blotting|
47979078|NCT01366170|OTHER|flow cytometry|
47979079|NCT01366170|OTHER|immunohistochemistry staining method|
47979080|NCT01366170|OTHER|laboratory biomarker analysis|
47979081|NCT01366170|OTHER|mass spectrometry|
47979082|NCT02013791|DRUG|Vehicle|Vehicle of cyclosporine administered as per protocol
47979083|NCT02013791|OTHER|Sham|Sham administered to non-study eye as per protocol on Day 1
47979084|NCT02013791|DRUG|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
48496032|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
48496033|NCT00251719|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
48338120|NCT04459494|PROCEDURE|Flapless implant surgery.|"Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
48338121|NCT04459494|PROCEDURE|Conventional implant surgery.|"Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film."
48496034|NCT04302558|BEHAVIORAL|Exercise Blood Flow Restriction training|While exercising, an Inflatable cuff, similar to a blood pressure cuff, is applied to the proximal aspect of the femur of the affected lower extremity inflated to occlude blood flow
48496035|NCT04302558|BEHAVIORAL|SHAM Exercise Blood Flow Restriction training|While exercising Inflatable cuff, similar to a blood pressure cuff, applied to the proximal aspect of the femur of the affected lower extremity with limited inflation pressure to not occlude blood flow
48496036|NCT02138019|PROCEDURE|Fibrin Glue assisted external eye surgery|
48496037|NCT02138019|DEVICE|Fibrin glue|
48496038|NCT03900065|PROCEDURE|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
48496039|NCT03452332|BIOLOGICAL|Durvalumab|Given IV
48131048|NCT04187573|DEVICE|Neqstent|Adjunctive device providing stable aneurysm neck coverage for the placement of embolization coils within the aneurysm sac and long term stable occlusion of the aneurysm.
48496040|NCT03452332|OTHER|Laboratory Biomarker Analysis|Correlative studies
48496041|NCT03452332|RADIATION|Stereotactic Radiosurgery|Undergo SABR
48496042|NCT03452332|BIOLOGICAL|Tremelimumab|Given IV
48496043|NCT01020344|PROCEDURE|Lung volume reduction surgery|Lung volume reduction surgery
48496044|NCT05340543|PROCEDURE|Confocal optical coherence tomography - OCTAVE|"An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function"
48496045|NCT06412263|PROCEDURE|Routine root canal treatment/ retreatment|It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment
48496046|NCT06458842|DRUG|Ketamine|
48338122|NCT05158530|OTHER|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
48496047|NCT06458842|OTHER|Placebo|
48496048|NCT03806374|DRUG|Ketamine|ketamine
48496049|NCT03806374|DRUG|Propofol|propofol
48496050|NCT03806374|DRUG|Fentanyl|fentanyl
48496051|NCT03806374|DRUG|Cisatracurium|cisatracurium
48496052|NCT03806374|DRUG|Lidocaine|lidocaine
48496053|NCT00436904|DRUG|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
48496054|NCT00436904|DRUG|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
48496055|NCT04309318|PROCEDURE|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
48131056|NCT05086432|OTHER|Sputum-guided management|As previously described.
48131057|NCT05086432|OTHER|Standard of Care|As previously described.
48131058|NCT04359784|BIOLOGICAL|Anakinra|Given IV (previously SC)
48131059|NCT04359784|PROCEDURE|X-Ray Imaging|Undergo x-ray
48131060|NCT04359784|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48131061|NCT04359784|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
48496056|NCT04309318|PROCEDURE|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
48496057|NCT04863222|DEVICE|Biodentine|During a patients procedure, one tooth will receive Biodentine instead of MTA.
48131062|NCT04359784|PROCEDURE|Bone Marrow Aspiration|Undergo BMA
48131063|NCT04359784|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48131064|NCT04359784|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48131065|NCT04359784|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48131066|NCT00667316|BEHAVIORAL|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
48496058|NCT04863222|BIOLOGICAL|mineral trioxide aggregate (MTA)|mineral trioxide aggregate (MTA)
48496059|NCT01080443|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
48496060|NCT00397163|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
48496061|NCT00397163|PROCEDURE|Placebo|Deflated cuff on upper arm and thigh for 20 min
48496062|NCT05392335|OTHER|Myofascial stretch|Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
48654785|NCT06641531|OTHER|Screening pap smear test|"The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.~The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain"
48338123|NCT05158530|OTHER|Pulmonary Exercises|"4 weeks protocol~1. Deep breathing Exercises\* 10 Reps 3 sets~2. Postural drainage (10 minutes \* 2 sets /day)~3. Incentive spirometry\* 10 Reps 3 sets~4. Bed activities (Active ankle and hand pumping exercise \* 10 Reps 3 sets)"
47979085|NCT06508125|DRUG|cross-linked hyaluronic acid|cross-linked hyaluronic acid injection with physical therapy
47979086|NCT06508125|DRUG|non-cross-linked hyaluronic acid|non-cross-linked hyaluronic acid injection with physical therapy
47979087|NCT01753856|DRUG|Teriparatide|Administered SC
47979088|NCT01753856|DRUG|Denosumab|Administered SC
47979089|NCT01753856|DRUG|Demeclocycline|Administered orally
48496063|NCT05392335|OTHER|Functional massage along with myofacial stretch|In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
47979090|NCT01753856|DRUG|Tetracycline|Administered orally
48131068|NCT04555577|DRUG|Peposertib|Given PO
48131069|NCT04555577|RADIATION|Radiation Therapy|Undergo radiation therapy
48131070|NCT04555577|PROCEDURE|Resection|Undergo surgical resection
48131071|NCT04555577|DRUG|Temozolomide|Given PO
48131072|NCT05092009|OTHER|Tissue and blood|Tissue and blood will be derived from patient during a standard of care procedure
48338124|NCT03392441|OTHER|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
48338125|NCT03030768|DRUG|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
48496064|NCT04562480|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48496065|NCT04562480|OTHER|Quality-of-Life Assessment|Ancillary studies
48654786|NCT06571162|OTHER|Clinical Pharmacy Team|Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.
48654787|NCT06571162|OTHER|Usual Care|Patient will receive usual care for their LDL-C management.
48654788|NCT06643403|DRUG|Oxygen 100% Gas for Inhalation|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes"
47979091|NCT01753856|DRUG|Calcium Supplement|Administered orally
47979092|NCT01753856|DRUG|Vitamin D|Administered orally
47979093|NCT01905657|BIOLOGICAL|Pembrolizumab|IV infusion
47979094|NCT01905657|DRUG|Docetaxel|IV infusion
47979095|NCT02915276|PROCEDURE|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
47979096|NCT02915276|PROCEDURE|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
47979097|NCT05782465|PROCEDURE|Blood Collection, processing and analyses|20ml of blood will be drawn from study participant at the baseline visit for molecular analyses.
47979098|NCT05782465|PROCEDURE|Gastroscopy and biopsies collection|Study participant will undergo gastroscopy with collection of gastric mucosal biopsies at the baseline visit to ascertain OLGIM status and for molecular analyses. Study participant will undergo surveillance gastroscopy for gastric cancer at years 2 and 4 to assess whether they have reached endpoint.
48131073|NCT05111613|DEVICE|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
48131074|NCT05111613|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
48131075|NCT04816955|BEHAVIORAL|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
48131076|NCT02966665|OTHER|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
48131077|NCT02966665|DRUG|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
48131078|NCT02966665|DRUG|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
48131079|NCT02966665|DRUG|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
47979099|NCT05782465|DIAGNOSTIC_TEST|Urea Breath Test|Study participant will fast for 6 hours or overnight before undergoing the Urea Breath Test (UBT) to test for current H. pylori infection. Breath collection will be performed before ingestion of 13C urea, and at specified time intervals after ingestion.
48131080|NCT02966665|OTHER|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
48131081|NCT02966665|DRUG|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
48131082|NCT02966665|DRUG|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
48131083|NCT02669771|DRUG|enzalutamide|oral
48131084|NCT05896774|DRUG|Maplirpacept|Study drug will be administered intravenously with adjustment for body weight weekly over 28-day cycles.
48131085|NCT05683990|DRUG|Diamyd|4 μg (0.1 mL) of Diamyd administered 1 month apart.
48496066|NCT04562480|OTHER|Questionnaire Administration|Ancillary studies
48496067|NCT04562480|PROCEDURE|Resection|Undergo surgical resection
48496068|NCT00276861|DRUG|gemcitabine hydrochloride|
48496069|NCT00276861|DRUG|oxaliplatin|
48496070|NCT02563821|PROCEDURE|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
48496071|NCT02563821|DRUG|Levobupivacaine|
48496072|NCT02563821|DRUG|sufentanil|
48496073|NCT02563821|DRUG|clonidine|
48654789|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using Memsorb|Sevoflurane administration at 0.2L.min-1 (minimal gas flow)
47979100|NCT05010577|DRUG|BX004-A|Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa
47979101|NCT05010577|DRUG|Placebo|Nebulized placebo
47979102|NCT00863603|OTHER|oxygen|5 Liter/minute by nasal cannula for 6 wks
47979103|NCT01618994|PROCEDURE|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
48131087|NCT02646774|DRUG|Micafungin|Injection
48131088|NCT06052332|RADIATION|Short course radiotherapy|Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
48131089|NCT06052332|DRUG|Adjuvant chemotherapy (optional)|The choice of the adjuvant chemotherapy is to the investigator's discretion.
48131090|NCT06052332|PROCEDURE|Total mesorectal excision|"Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment."
48131091|NCT06052332|COMBINATION_PRODUCT|Total neoadjuvant therapy|"The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)"
48131092|NCT03927196|BEHAVIORAL|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
48131093|NCT05446870|BIOLOGICAL|Pembrolizumab|200 mg by IV infusion on Day 1 of each 21-day cycle
48131094|NCT05446870|DRUG|Paclitaxel|175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
48131095|NCT05446870|DRUG|Carboplatin|AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle
48496074|NCT02563821|DEVICE|epidural catheter|
48496075|NCT02184559|DRUG|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
48496076|NCT02184559|DEVICE|The infiltration continues catheter|
48496077|NCT05583136|DEVICE|Parietal tACS combined with visuo-attentional training|Parietal tACS combined with visuo-attentional training
48496078|NCT05583136|DEVICE|Sham (placebo) tACS combined with visuo-attentional training|Sham (placebo) tACS combined with visuo-attentional training
48496079|NCT05583136|DEVICE|Sham (placebo) tACS combined with phonics training|Sham (placebo) tACS combined with phonics training
48496080|NCT03479463|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
48496081|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).
48496082|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).
48496083|NCT02926430|DRUG|Placebo|Participants will receive placebo as formulation buffer.
48496084|NCT05553899|RADIATION|PET-MRI|magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
48654790|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using classical Dräegersorb|Sevoflurane administration at 2L.min-1 (classical gas flow)
48654791|NCT03314584|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
47979104|NCT01267734|DEVICE|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
48496085|NCT05430984|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|"Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh."
48131096|NCT05446870|BIOLOGICAL|Avastin|According to local practice and at the choice of the investigator.
48338126|NCT03030768|BEHAVIORAL|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
48131097|NCT05446870|BIOLOGICAL|MK-4830|800 mg by IV infusion on Day 1 of each 21-day cycle
48131098|NCT05446870|DRUG|Docetaxel|75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle
48338127|NCT05768542|DRUG|Metoprolol Injection|If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
48338128|NCT05768542|DRUG|Saline|5 ml given IV
48338129|NCT02575300|DRUG|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
48338130|NCT05875389|OTHER|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
48496086|NCT05604248|OTHER|Intervention|Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil
48496087|NCT03522610|BEHAVIORAL|ADAPT|Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
48496088|NCT02649985|DRUG|[F-18]PBR06|PET radiopharmaceutical
47979105|NCT01267734|DEVICE|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
48496089|NCT02649985|DRUG|[C-11]PBR28|PET radiopharmaceutical
48338131|NCT01517412|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
48338132|NCT01517412|DEVICE|Self-injector pen device (OptiClik®)|
48338133|NCT01517412|DRUG|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
48654792|NCT03314584|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
47979106|NCT01267734|DRUG|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
47979107|NCT01267734|DRUG|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
48131100|NCT04796337|BIOLOGICAL|Sotatercept|Sotatercept subcutaneous injection at a dose of 0.3 to 0.7 mg/kg.
48496090|NCT05464043|DIAGNOSTIC_TEST|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
48496091|NCT00631449|DRUG|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
48131103|NCT06540443|DRUG|MPB-2043 of 0.5 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
48131104|NCT06540443|DRUG|MPB-2043 of 1.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
48496092|NCT00631449|DRUG|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
48496093|NCT01574482|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
48496094|NCT01574482|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
48496095|NCT01763814|PROCEDURE|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
48496096|NCT01763814|PROCEDURE|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
48496097|NCT01763814|PROCEDURE|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
48496098|NCT02447796|DRUG|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
47979108|NCT05124301|BEHAVIORAL|Perceptual learning|Reaching task with visual feedback offset from target finger position.
47979109|NCT05124301|BEHAVIORAL|Control|Reaching task with unmanipulated feedback.
48338134|NCT01924741|PROCEDURE|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
48338135|NCT00959881|DRUG|Donepezil plus placebo|5- and 10-mg tablets, single dose
48338136|NCT00959881|DRUG|Donepezil|5- and 10-mg tablets, single dose
48338137|NCT00959881|DRUG|Begacestat|6 x 50-mg capsules, single dose
48338138|NCT01843634|DRUG|ODSH|
48338139|NCT02896192|DRUG|Setmelanotide|Once daily SC injection
48338140|NCT02896192|DRUG|Placebo|Once daily SC injection
48338141|NCT01025297|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
47979110|NCT06304753|DEVICE|Telebot|"This is a mini-program based on a personal messenger, which is controlled by text commands in a chat on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses."
48654793|NCT03314584|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Brain imaging will be done via MRI prior to the first rTMS/Sham TMS session. Imaging will allow investigators to target specific areas in the brain.
48654794|NCT01327729|DRUG|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
47979111|NCT00225173|DRUG|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
47979112|NCT00225173|DRUG|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
47979113|NCT00225173|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
47979114|NCT00225173|DRUG|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
47979115|NCT00225173|DRUG|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
47979116|NCT00225173|DRUG|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
47979117|NCT00225173|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
47979118|NCT00225173|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
47979119|NCT00225173|DRUG|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
47979120|NCT04988724|BEHAVIORAL|Exercise training|Exercise training with aerobic and strength training, 30 min per session
47979121|NCT05945914|PROCEDURE|Oncoplastic Entirely Robot-Assisted Approach (OPERA)|Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
47979122|NCT04563923|DRUG|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
47979123|NCT04563923|OTHER|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
48654795|NCT00879398|DRUG|Toviaz treatment|4 mg starting then can be followed by 8 mg
48654796|NCT01756742|OTHER|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~* Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~* Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
47979124|NCT01971411|DRUG|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
48496099|NCT02447796|DRUG|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
48496100|NCT02728570|OTHER|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
48654797|NCT01756742|OTHER|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
47979125|NCT01971411|PROCEDURE|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
47979126|NCT01971411|BEHAVIORAL|Usual sun exposure documentation|
47979127|NCT01971411|BEHAVIORAL|Dietary intake of calcium, vitamin D, magnesium|
47979128|NCT00525460|BEHAVIORAL|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
47979129|NCT02931487|BEHAVIORAL|Attentional Bias Modification|Computerized
47979130|NCT02931487|BEHAVIORAL|Sham Comparator|Computerized
48654798|NCT03113188|DRUG|CBP501|CBP501, CDDP plus Nivolumab
48654799|NCT06184880|BEHAVIORAL|behavioral|International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
47979131|NCT00884312|DRUG|Carfilzomib|Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
47979132|NCT01138033|DRUG|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
47979133|NCT06166849|DEVICE|Experimental Fluoride Application|The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
47979134|NCT02692703|DRUG|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
47979135|NCT02916342|PROCEDURE|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
47979136|NCT02916342|PROCEDURE|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
47979137|NCT01508650|BEHAVIORAL|Usual care|Usual care control group
47979138|NCT01508650|BEHAVIORAL|Rehabilitation intervention|Multi-domain rehabilitation intervention
47979139|NCT01247740|DRUG|NuTRIflex Lipid peri|parenteral nutrition
47979140|NCT01247740|DRUG|compounded monobag|parenteral nutrition
47979141|NCT00638378|DRUG|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
47979142|NCT03075540|BEHAVIORAL|Genetic Counseling and Testing YouTube Video|Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
48338142|NCT03954249|PROCEDURE|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
48338143|NCT03954249|PROCEDURE|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
48338144|NCT03693404|DRUG|Marcaine, Duramorph , ketorolac|Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
48338145|NCT03693404|DRUG|Bupivacaine (Marcaine)|0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
48338146|NCT03693404|DRUG|General Anesthetics|Placebo group will only receive standard of care general anesthesia
48338147|NCT06334172|DRUG|Oxytocin|Oxytocin
48338148|NCT06334172|OTHER|Placebo|Saline
48338149|NCT04831567|RADIATION|MIBG-I131|Radiopharmaceutical
48338150|NCT00442260|DRUG|DOXIL|
48338151|NCT00442260|DRUG|Abraxane|
48338152|NCT06401798|DRUG|placebo gel|Methylcellulose gel was applied topically to the pocket
48338153|NCT06401798|DRUG|CWP gel|Methylcellulose gel combined with CWP was applied topically to the pocket
48338154|NCT06401798|DRUG|NCWP gel|Methylcellulose gel combined with NCWP was applied topically to the pocket
48338155|NCT02620735|DEVICE|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
48338156|NCT02620735|BEHAVIORAL|Exercise Only|12 week exercise program
48338157|NCT02620735|BEHAVIORAL|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
48496101|NCT02728570|OTHER|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
48338158|NCT02620735|BEHAVIORAL|Health Coaching|10 over the phone health coaching sessions.
48338159|NCT01709214|DRUG|Cebranopadol (GRT6005) Low-Dose Range|Capsules
48654800|NCT06184880|OTHER|Sedentary|Actimetry (cumulative time without movement over 24h, prolonged sedentary periods \>30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
48654801|NCT06267768|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
47979143|NCT06426121|DIAGNOSTIC_TEST|test Aerobic/F Culture Vials|an additional blood sample will be collected compared to clinical routine of blood culture, inoculated into the test culture vial, and compared with the blood culture results of the control vial collected from the same site and the same puncture point
48338160|NCT01709214|DRUG|Cebranopadol (GRT6005) High-Dose Range|Capsules
48338161|NCT01709214|DRUG|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
48338162|NCT01709214|DRUG|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
48338163|NCT05369546|DIAGNOSTIC_TEST|q3CB|The q3CB/ncCEM/DBT acquisition protocol consists of a combination of DBT volume reconstructions and projection dual-energy mammograms acquired with a clinical contrast enhanced mammography (CEM) protocol, without contrast administration agent.
48338164|NCT01969513|PROCEDURE|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
48338165|NCT01969513|PROCEDURE|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
48338166|NCT00300534|DEVICE|Abbott Laboratories Determine test for syphilis|
48338167|NCT00300534|DEVICE|Investigational syphilis immunochromatographic strip test|
48338168|NCT01264068|DRUG|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
48338169|NCT05957848|DRUG|Guanfacine Extended Release Oral Tablet|Target dose 4 mg daily
48338170|NCT05957848|BEHAVIORAL|Residential withdrawal|4-14 days in residential withdrawal treatment
48338171|NCT05957848|BEHAVIORAL|Engagement with alcohol and other drug services|Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study
48338172|NCT05957848|DRUG|Placebo|Placebo capsule taken daily
48338173|NCT05680818|DRUG|Encaleret|Administered as film-coated tablet for oral use
48338174|NCT05680818|DIETARY_SUPPLEMENT|Standard of Care|Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
48496102|NCT01297465|DRUG|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
47979144|NCT06426121|DIAGNOSTIC_TEST|control Aerobic/F Culture Vials|according to the clinical routine of blood culture, this blood sample should be collected and inoculated into the control vial, and its culture result will be collected
47979145|NCT05551559|PROCEDURE|bariatric surgery|bariatric surgery
47979146|NCT05615012|DRUG|BMS-986322|Specified dose on specified days
48131105|NCT06540443|DRUG|MPB-2043 of 2.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
48131106|NCT06540443|DRUG|MPB-2043 of 3.0 mg/kg|Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
48496103|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
48496104|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
48496105|NCT01297465|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).
48496106|NCT04059458|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
48338175|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
48338176|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
48338177|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
48338178|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
48338179|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg|
48338180|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg X 2|
48338181|NCT01785108|DRUG|Vitamin D|
48338182|NCT01785108|DRUG|Ibuprofen|
48338183|NCT02299271|DRUG|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
47979147|NCT05615012|DRUG|Rosuvastatin|Specified dose on specified days
48496107|NCT04059458|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
48496108|NCT03203135|BEHAVIORAL|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
48496109|NCT03081234|DRUG|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
48338184|NCT02299271|DRUG|Saline|Saline as a one-time, 60 milliliter injection.
47979148|NCT05615012|DRUG|Metformin|Specified dose on specified days
47979149|NCT05615012|DIETARY_SUPPLEMENT|Glucose|Specified dose on specified days
47979150|NCT05615012|DRUG|Methotrexate|Specified dose on specified days
48496110|NCT03081234|DRUG|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
47979151|NCT05615012|DRUG|Leucovorin|Specified dose on specified days
48338185|NCT03300219|BEHAVIORAL|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
48338186|NCT01676792|DRUG|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
48338187|NCT00088972|DRUG|celecoxib|Given orally
48338188|NCT00088972|OTHER|placebo|Given orally
48496111|NCT03081234|DRUG|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
48338189|NCT04826913|DEVICE|Organoids|"Use of an innovative device to improve the management of patients with NSCLC for precision medicine.~The different drugs used can be conventional chemotherapy (cisplatin, carboplatin, pemetrexed), targeted therapies or immunotherapy molecules. It is also planned to use radiotherapy on our drug testing device."
48338190|NCT05968716|OTHER|Social needs screening protocol|Pediatric hospital ward stakeholders will develop and implement a social needs screening protocol designed to screen families of hospitalized children for social risk factors and then provide resources to address their social needs. The intervention will consist of the protocol that is developed and implemented.
48338191|NCT05191849|DIAGNOSTIC_TEST|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2\~4 cycles of chemotherapy, or at the time of disease progression.
48338192|NCT01202760|DRUG|LY2127399|
48338193|NCT01202760|DRUG|Placebo|
48338194|NCT01042938|DRUG|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
48338195|NCT01042938|DRUG|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
48338196|NCT05541523|BEHAVIORAL|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
48338197|NCT05541523|BEHAVIORAL|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
48338198|NCT05687916|DRUG|TAK-861|TAK-861 tablets.
48338199|NCT05687916|DRUG|Placebo|TAK-861 placebo matching tablets.
48338200|NCT05062551|PROCEDURE|three steps hysteroscopic resection of an isthmocele|removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
48338201|NCT02733679|DRUG|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
48338202|NCT02733679|DRUG|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
48338203|NCT05656391|DIETARY_SUPPLEMENT|Treatment vs control bread|Consumption of 200 grams per day of either treatment or control bread for eight weeks
48338204|NCT03943446|DRUG|TAK-018|TAK-018 immediate-release tablets.
48338205|NCT03943446|DRUG|TAK-018 Placebo|TAK-018 placebo-matching tablets.
48338206|NCT00139841|DRUG|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
48338207|NCT01376245|DRUG|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
48338208|NCT01376245|DRUG|Placebo|matching placebo
48338209|NCT00259246|DRUG|Peptide YY infusion|
48338210|NCT05166395|DEVICE|Er:YAG laser|2940 nm Er:YAG laser treatment spread over 3 sessions within 4 weeks on participant's scar on either the head/neck, trunk or extremities.
48338211|NCT05073913|DIAGNOSTIC_TEST|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
47979152|NCT01770626|OTHER|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
48338212|NCT03305601|OTHER|application on smarthphone|application on smarthphone
48338213|NCT03126578|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
48654802|NCT00962338|BEHAVIORAL|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
47979153|NCT02303301|DIETARY_SUPPLEMENT|Probiotics|Cultures from the oropharynx
47979154|NCT02303301|DIETARY_SUPPLEMENT|Placebo|Cultures from the oropharynx
47979155|NCT00822835|BIOLOGICAL|ILV-095|
47979156|NCT00822835|BIOLOGICAL|Placebo|
48338214|NCT03126578|DRUG|Midazolam|Benzodiazepine
48338215|NCT03203590|DRUG|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
48338216|NCT03203590|DRUG|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
48338217|NCT01466478|DRUG|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
48338218|NCT01466478|DRUG|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
48338219|NCT01466478|DRUG|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
48338220|NCT01466478|DRUG|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
48338221|NCT01466478|DRUG|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
48338222|NCT01466478|DRUG|Daivonex® ointment|once daily application, 4 weeks
48338223|NCT01466478|DRUG|Diprosone® ointment|once daily application, 4 weeks
48338224|NCT03708757|OTHER|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
48496112|NCT02426853|BEHAVIORAL|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
48338225|NCT03708757|OTHER|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
48338226|NCT00007982|BIOLOGICAL|filgrastim|
48338227|NCT00007982|DRUG|carmustine|
48338228|NCT00007982|DRUG|cisplatin|
48338229|NCT00007982|DRUG|cyclophosphamide|
48338230|NCT00007982|DRUG|etoposide|
48338231|NCT00007982|DRUG|thiotepa|
48338232|NCT00007982|PROCEDURE|adjuvant therapy|
48338233|NCT00007982|PROCEDURE|autologous bone marrow transplantation|
48496113|NCT02426853|OTHER|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
48496114|NCT02426853|BEHAVIORAL|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
48496115|NCT02254213|OTHER|EEG recording|A short EEG recording is performed 10 times over the span of three months.
48496116|NCT05662735|DEVICE|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
48338234|NCT00007982|PROCEDURE|bone marrow ablation with stem cell support|
48338235|NCT00007982|PROCEDURE|peripheral blood stem cell transplantation|
48338236|NCT04203108|DRUG|ATG|In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
48338237|NCT04203108|DRUG|CsA|In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
48496117|NCT05662735|PROCEDURE|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
48496118|NCT03168971|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
48496119|NCT03514641|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
48496120|NCT03514641|DRUG|Placebo|Placebo (inactive) tablet to match the active drug
48496121|NCT00440466|DRUG|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
48131119|NCT05213624|DRUG|BI 764198|BI 764198
48131120|NCT05213624|DRUG|Placebo|Placebo matching BI 764198
48131121|NCT06066359|DRUG|Fludarabine phosphate|Given by (IV) vein
48338238|NCT04203108|DRUG|MTX|In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
48496122|NCT00440466|DRUG|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
48338239|NCT04203108|DRUG|MMF|In both groups, MMF will be administrated at a dose of 1.0g/d.
48338240|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
48338241|NCT04090983|BEHAVIORAL|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
48338242|NCT00204412|DIETARY_SUPPLEMENT|Flax lignan|543 mg SDG per day
48338243|NCT00204412|BEHAVIORAL|Exercise (walking)|walking 45 minutes per day 5 days per week
48496123|NCT00440466|DRUG|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
48496124|NCT00567047|DRUG|vildagliptin|
48496125|NCT03097835|DRUG|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
48496126|NCT03097835|DRUG|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
48496127|NCT03097835|OTHER|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
48496128|NCT05525793|OTHER|Transitional care model|The patients who were assigned to this group with the transitional care model, 6 weeks of counseling and intervention training provided continuity of care and a safe transition, and patients were encouraged about symptom management and a healthy lifestyle.
48338244|NCT02925208|OTHER|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
48338245|NCT05387798|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
48338246|NCT05218304|BIOLOGICAL|Blood sample|A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
48338247|NCT02918955|PROCEDURE|up-front neck dissection|
48338248|NCT02918955|RADIATION|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
48338249|NCT02918955|DRUG|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
48338250|NCT02918955|PROCEDURE|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
48338251|NCT04018586|DEVICE|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
48338252|NCT04018586|DEVICE|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
48338253|NCT04018586|DEVICE|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
48338254|NCT04571476|PROCEDURE|Ultrathin bronchoscope|Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
48338255|NCT04571476|PROCEDURE|Thin bronchoscope|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
48338256|NCT04571476|PROCEDURE|Virtual bronchoscopic navigation combined with endobronchial ultrasound|VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
48338257|NCT04571476|PROCEDURE|Guide sheath|GS is a cannula with the thinnest outer diameter of 1.95 mm.
48338258|NCT05239884|OTHER|ENDS Product A with 1.5% nicotine|P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48338259|NCT05239884|OTHER|ENDS Product B with 1.5% nicotine|P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48338260|NCT05239884|OTHER|ENDS Product C with 1.5% nicotine|P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48496129|NCT05304286|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
48338261|NCT05239884|OTHER|ENDS Product D with 1.5% nicotine|P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48496130|NCT05355649|DEVICE|PREGNOLIA SYSTEM|"The Pregnolia System is composed of two products: an active device (Pregnolia Control Unit) and a single-use sterile probe (Pregnolia Probe).~The intended use of the Pregnolia System is to provide information about the mechanical properties of the uterine cervix by assessing the tissue stiffness through a proxy parameter (the closing pressure, denominated CSI, or Cervical Stiffness Index, in mbar). The Pregnolia System is intended to be used in conjunction with the information obtained from the clinical evaluation of the patient and in addition to other standard examinations."
48496131|NCT00218166|DRUG|GABA Agonists|GABA drugs administered acutely by mouth
48496132|NCT03277235|BEHAVIORAL|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
48496133|NCT00661141|DRUG|Antizol|
48496134|NCT00661141|DRUG|Placebo|
48496135|NCT00661141|OTHER|Ethanol|oral dose of ethanol (0.5 g/kg)
48496136|NCT00874003|DRUG|mirtazapine|oral tablet, 30 mg daily
48338262|NCT05239884|OTHER|ENDS Product E with 1.5% nicotine|P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48338263|NCT05239884|OTHER|ENDS Product F with 1.5% nicotine|P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48338264|NCT05239884|OTHER|ENDS Product G with 1.5% nicotine|P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48338265|NCT05239884|OTHER|ENDS Product H with 1.5% nicotine|P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
48338266|NCT03073343|DIETARY_SUPPLEMENT|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
48496137|NCT00874003|DRUG|placebo|oral tablet, 1 daily
48496138|NCT03123536|DEVICE|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
48654803|NCT06636864|PROCEDURE|Intrathecal morphine|The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.
48131122|NCT06066359|DRUG|Cyclophosphamide|Given by (IV) vein
48338267|NCT04863313|DIETARY_SUPPLEMENT|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
48338268|NCT04863313|DIETARY_SUPPLEMENT|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
48338269|NCT02757092|OTHER|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
48338270|NCT04724681|DEVICE|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
48338271|NCT00278863|DRUG|S-1|
48338272|NCT00278863|DRUG|Capecitabine|
48338273|NCT03878225|DIETARY_SUPPLEMENT|H.V.M.N. Ketone Ester|The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
48338274|NCT03878225|OTHER|Placebo|The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
48496139|NCT01710553|OTHER|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
48654804|NCT06636864|PROCEDURE|Intrathecal saline injection|After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.
48654805|NCT06636864|PROCEDURE|TAPB|The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
48654806|NCT04962113|OTHER|TUBE BATH|Wrap Tube Baht (immersion)
48654807|NCT04174482|PROCEDURE|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
48654808|NCT06334796|DIAGNOSTIC_TEST|Virtual Assistant|Stage 1 focused on safety, using only medical information from clinical records for the virtual assistant. In Stage 2, which evaluated accuracy, participants interacted with the virtual assistant post-medical stabilization. Additionally, participants also provided initial symptom details for Chat-GPT input. Nine neurologists specializing in emergency participated in the study. In Stage 1, they assessed the virtual assistant's performance using clinical history information. In Stage 2, they analyzed the results from participant interactions with the assistant and performed a comparative evaluation of Chat-GPT. The virtual assistant functioned as a chatbot on WhatsApp and Telegram, using Spanish and incorporating advanced algorithms, decision trees, and large language models for interaction. For comparison, we utilized Chat-GPT versions 3.5 and 4, employing two prompt types in natural Spanish: one incorporating clinical record data and the other based on participant narratives.
48654809|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
48496140|NCT01710553|OTHER|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
48496141|NCT04557202|DRUG|Tamsulosin Oral Capsule|To assess the efficacy of peri-operative alpha1 blockers on improving the success rate and decreasing complications of non-stented ureteroscopic laser lithotripsy for ureteric stones.
48496142|NCT04557202|DRUG|Placebo|Placebo - control group
48131123|NCT06066359|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by (IV) vein
48338275|NCT02884271|PROCEDURE|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
48654810|NCT02317419|DRUG|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
48654811|NCT02317419|DRUG|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
48654812|NCT02317419|DRUG|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
48654813|NCT03658304|DRUG|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
48654814|NCT06518928|OTHER|Artificial Intelligence assisted sperm selection|SiD software for sperm selection
48654815|NCT06643390|DRUG|MK-2225|Subcutaneous administration
48654816|NCT06643390|OTHER|Placebo|Subcutaneous administration
48654817|NCT03809000|RADIATION|Radiation Therapy|daily fractions
48654818|NCT03809000|DRUG|Enzalutamide|tablet
48654819|NCT03809000|DRUG|Bicalutamide|tablet
48654820|NCT03809000|DRUG|GnRH analog|Injection
48654821|NCT02624856|DRUG|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
47979157|NCT04376372|DIAGNOSTIC_TEST|Functional testing, Magnetic resonance imaging, Electromyography|Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
47979158|NCT05914714|DRUG|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
47979159|NCT00221728|DEVICE|Radiofrequency|
47979160|NCT00221728|PROCEDURE|conservative surgery|
48654822|NCT02624856|DRUG|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
48654823|NCT04330859|OTHER|NeoRehab Bundle|The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
48654824|NCT04330859|OTHER|Routine care|Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
48338276|NCT02122926|OTHER|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge."
48654825|NCT05080790|DRUG|Dinutuximab Beta, Zoledronic acid, Interleukin-2|Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
48654826|NCT03897075|DRUG|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
48654827|NCT03897075|DRUG|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
47979161|NCT01793649|DRUG|GS-5737|A single dose of GS-5737 in 2.8% saline
47979162|NCT00661882|OTHER|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
48338277|NCT04965116|DRUG|Progestin Only Contraceptive Pills|Daily pill (placebo or active tablet)
48338278|NCT01053403|DRUG|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
48338279|NCT00102934|DRUG|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
48338280|NCT06045143|DEVICE|Patients undergoing DDD pacemaker implantation|compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
48654828|NCT05192070|OTHER|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
48654829|NCT05192070|OTHER|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
48654830|NCT05192070|OTHER|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
48654831|NCT00011635|DRUG|Silymarin (milk thistle)|
48496143|NCT03966248|OTHER|Chinese Tuina therapy|"1. The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~2. The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~3. Massage the spleen and stomach meridians of the affected lower extremes;~4. Roll the soft tissues around the affected knee;~5. Relax the gastrocnalis muscle~6. The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~7. Push the patella and do the passive movement of the affected knee;~8. Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
48496144|NCT03966248|OTHER|Physical Manual therapy|"1. Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~2. Activity training: Mainly about the knee joint flexion and extension movement training.~3. Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
48131126|NCT04530110|DRUG|Fremanezumab|"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months."
48496145|NCT03416244|DRUG|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
48131128|NCT03204357|OTHER|Fresh Autologous whole Blood|Subjects randomized this arm will receive fresh autologous whole blood
48131129|NCT03204357|OTHER|Standard of Care Expectant management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
48496146|NCT03416244|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
48496147|NCT01836406|DRUG|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
48496148|NCT00044421|DRUG|Ruboxistaurin mesylate|
48496149|NCT00915928|DRUG|Perindopril|2,5 mg daily for 3 months
48496150|NCT00915928|DRUG|Placebo|Placebo dayli for 3 months
48496151|NCT04614246|DRUG|BAY1817080|Tablet, oral administration
48131136|NCT06015880|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48131137|NCT06015880|PROCEDURE|Computed Tomography|Undergo PET/CT
48131138|NCT06015880|DRUG|Lenalidomide|Given PO
48131139|NCT06015880|BIOLOGICAL|Mosunetuzumab|Given IV
48131140|NCT06015880|DRUG|Polatuzumab Vedotin|Given IV
48131141|NCT06015880|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48496152|NCT04614246|DRUG|Elagolix|Tablet, oral administration
48496153|NCT04614246|DRUG|Placebo|Tablet, oral administration
48496154|NCT02518919|OTHER|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
48496155|NCT02518919|OTHER|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
48131145|NCT00238901|DRUG|Basiliximab|
48131146|NCT05159453|BIOLOGICAL|Human Insulin|International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.
48131147|NCT05159453|DEVICE|Finger-actuated, Metered Pump Sprayer|Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.
48496156|NCT01108406|DEVICE|Sonitus SoundBite System|Non Surgical Bone Conduction Device
48496157|NCT01108406|DEVICE|SoundBite Hearing System|
48496158|NCT06240520|DRUG|Panobinostat 20 MG Oral Capsule|Panobinostat 20mg will be administered once orally
48496159|NCT06240520|DRUG|Pyrimethamine 200mg Oral Tablet|Pyrimethamine 200mg will be administered once orally
48496160|NCT06240520|DRUG|Lenalidomide 25 MG Oral Capsule|Lenalidomide 25mg will be administered once orally
48496161|NCT01400386|OTHER|Coffee bioavailability trial|Coffee bioavailability trial
48496162|NCT02349243|DRUG|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
48496163|NCT02349243|DRUG|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
48496164|NCT03929549|DEVICE|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
48654832|NCT02543385|DRUG|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
48131148|NCT06527755|DRUG|Eplontersen Solution for Injection|an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.
48496165|NCT03456895|OTHER|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
48496166|NCT03456895|OTHER|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
48496167|NCT03456895|OTHER|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
48496168|NCT03456895|OTHER|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
48496169|NCT03456895|OTHER|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
48496170|NCT04390542|BEHAVIORAL|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
48496171|NCT03709459|DRUG|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
48496172|NCT04551430|DRUG|Cabozantinib|Cabozantinib will be supplied by Exelixis.
48496173|NCT04551430|DRUG|Nivolumab|Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
47979163|NCT00661882|OTHER|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
47979164|NCT00661882|OTHER|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
47979165|NCT00661882|PROCEDURE|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
47979166|NCT02056782|DRUG|Dociparstat sodium|"The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
47979167|NCT03055260|DEVICE|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
47979168|NCT03055260|DEVICE|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
47979169|NCT00369993|DRUG|fluticasone propionate/salmeterol|
47979170|NCT02935088|DEVICE|Fractional Flow Reserve|Measurement of physiologic parameters
47979171|NCT03950648|BEHAVIORAL|Spatial Cognitive Training|map reading and route-learning skills
48496174|NCT04551430|DRUG|Ipilimumab|Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
48496175|NCT05084703|OTHER|Functional tests|"* Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test"
48496176|NCT05279365|BIOLOGICAL|Pfizer/BioNTech (BNT162b2)|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
48496177|NCT05279365|BIOLOGICAL|Moderna|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
48131149|NCT03387189|OTHER|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
48131150|NCT05823922|BEHAVIORAL|Clinician Delivered CBT|Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
48496178|NCT03595085|PROCEDURE|catheter directed fragmentation and thrombolysis|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
48496179|NCT03595085|DRUG|Streptokinase|intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
48131151|NCT05823922|BEHAVIORAL|Supplemental MAYA App|"The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.~Participants will attend weekly sessions with their clinician as well as using the MAYA application for at least 20 minutes twice a week"
48496180|NCT04223531|DRUG|Normal Saline 0.9% Infusion Solution Bag|Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.
48496181|NCT00604136|BIOLOGICAL|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
48496182|NCT06367855|DRUG|Dexamethasone|long-acting corticosteroid IV route
48496183|NCT06367855|DRUG|Normal saline|normal saline
48496184|NCT03150849|DIAGNOSTIC_TEST|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
48496185|NCT01608386|PROCEDURE|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
48496186|NCT01157559|DRUG|Ziprasidone|8 week prospective study
48496187|NCT01983917|BEHAVIORAL|Diabetes Mobile Application|
48496188|NCT05280132|PROCEDURE|Personalized antibiotic treatment|Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
48496189|NCT05280132|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
48496190|NCT02715206|BEHAVIORAL|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
48496191|NCT02715206|BEHAVIORAL|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
48496192|NCT02715206|BEHAVIORAL|control|control group continues to teach whatever prevention curriculum they were using prior to study
48496193|NCT04312295|BEHAVIORAL|ACP-SCT program|The ACP-SCT program was designed to improve nurses' knowledge and competence in discussing ACP with Chronic Kidney Disease patients.
48496194|NCT03698266|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
48496195|NCT00050232|DRUG|AVP-923|
48338281|NCT05710770|DEVICE|Immunoadsorption|IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
48338282|NCT04905823|DIAGNOSTIC_TEST|blood test|assessment of humoral, immune cell response and glycemia
48496196|NCT02005887|DRUG|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
48496197|NCT02005887|DRUG|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
48496198|NCT02005887|DRUG|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
48338283|NCT01395641|DRUG|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
48338284|NCT06218199|DRUG|Furosemide|oral administration
48338285|NCT06218199|DRUG|Torsemide|oral administration
48338286|NCT06218199|DRUG|Bumetanide|oral administration
48338287|NCT06218199|DRUG|sacubitril/valsartan|oral administration
48338288|NCT06218199|DRUG|Hydralazine|oral administration
48338289|NCT06218199|DRUG|Isosorbide Dinitrate|oral administration
47979172|NCT00774618|DEVICE|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
47979173|NCT02733991|DEVICE|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
47979174|NCT02733991|DEVICE|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
47979175|NCT01443650|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
48338290|NCT04163913|OTHER|Change in User interfaces of Cirvo compression device application.|Comparison of 2 versions of the Circo user interface
48338291|NCT04163913|OTHER|Change in Satisfaction in use of Cirvo device|Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
48338292|NCT00005806|DRUG|carboplatin|
48338293|NCT00005806|DRUG|gefitinib|
48496199|NCT04780841|DRUG|RDX013|RDX013 is an experimental drug that is a potassium secretagogue
48496200|NCT04780841|DRUG|Placebo|Placebo treatment that looks identical to experimental treatment
48496202|NCT05259878|OTHER|Adverse Childhood Events|"• The Adverse Childhood Events (ACE) scale is a validated 10-item binary questionnaire (yes or no) that retrospectively measures domains of physical, emotional, and sexual abuse in the first 18 years of life. Scores range from 0 to 10 with higher scores indicating more adverse experiences during patients' childhood."
48496203|NCT01663935|DRUG|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
48496204|NCT00004450|DRUG|glyceryl trierucate|
48496205|NCT00004450|DRUG|glyceryl trioleate|
48496206|NCT00004450|DRUG|interferon beta|
48496207|NCT00004450|DRUG|thalidomide|
47979176|NCT04720820|OTHER|Early Supported discharge with home based Rehabilitation|Treatment by Physiotherapist and occupational therapist at least 30 minutes each, per week provided at home.
48338294|NCT00005806|DRUG|paclitaxel|
48338295|NCT00565812|DRUG|SD-6010|200 mg tablets once a day for 2 years
48338296|NCT00565812|DRUG|SD-6010|50 mg tablets once a day for 2 years
48338297|NCT00565812|DRUG|Placebo|Placebo tablets once a day for 2 years
48338298|NCT01176188|OTHER|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
48338299|NCT01176188|OTHER|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
48338300|NCT00753623|DRUG|Ramelteon|ramelteon (8 mg)
48338301|NCT00753623|DRUG|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
48496208|NCT01374295|OTHER|video|watch a 3 minute video
48496209|NCT01374295|OTHER|standard education|Receives standard verbal education from healthcare provider
48496210|NCT03906162|BEHAVIORAL|Motivational interviews|"During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph."
48654833|NCT02392442|OTHER|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
48654834|NCT02392442|BIOLOGICAL|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
48654835|NCT03603808|DEVICE|Electroporation|Undergo electroporation
48654836|NCT03603808|BIOLOGICAL|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
48654837|NCT03603808|OTHER|Laboratory Biomarker Analysis|Correlative studies
48131152|NCT06527703|OTHER|no intervention|"Patients have to answer a questionnaire. The following data will be recorded:~Patient Number:~Informed Consent: ☐ yes ☐ no~Screening for eligibility Age \>/= 18 years: ☐ yes ☐ no Gender: ☐ M ☐ F Patient undergoing elective procedure: ☐ yes ☐ no~Time of arrival in the operating room _________________~Procedure:~General surgery ☐ Orthopaedic surgery ☐ Neurosurgery ☐ Cardiac surgery ☐ Vascular ☐ Urology ☐ ENT/ dental/ maxillo-facial ☐ Obstetrics and Gynaecology surgery ☐ Ophthalmic surgery ☐ Non-operating room anaesthesia ☐ Endoscopy ☐ Other ____________________~Type of Anaesthesia (choose 1):~GA ☐ Sedation ☐ Regional ☐~Date and Time at which clear fluids were last consumed:_______________________"
48496211|NCT03906162|BEHAVIORAL|Base intervention|"The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity."
48496212|NCT01197430|OTHER|exercise training|
48496213|NCT00767065|RADIATION|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate \<70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
48131156|NCT04390724|DEVICE|Y90 radioembolization|Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
48496214|NCT00767065|OTHER|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
48131158|NCT03018561|OTHER|Exercise and Cognitive testing|Maximal cardiopulmonary test Rest cognitive testing
48496215|NCT01103466|DEVICE|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
48496216|NCT01103466|DEVICE|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
48131161|NCT06580275|DEVICE|CLAAS|All eligible subjects will have an LAA closure attempt using the CLAAS device guided by ICE technology.
48131162|NCT06585150|DRUG|Obeldesivir|Tablet administered orally
48131163|NCT06585150|DRUG|Obeldesivir Placebo|Tablet administered orally
48131165|NCT06366490|BIOLOGICAL|Innocell Autologous Cellular Immunotherapy|Innocell Autologous Cellular Immunotherapy
48131166|NCT06422689|DRUG|Albuterol and budesonide inhalation aerosol|Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
48338302|NCT03865238|BIOLOGICAL|EV71vac|Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
48131167|NCT06082323|DRUG|LT-002-158/Placebo oral tablet(s)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
47979177|NCT04720820|OTHER|Conventional rehabilitation|Treatment will be provided according to current hospital's stroke rehabilitation program.
47979178|NCT01352299|DEVICE|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
47979179|NCT01352299|DEVICE|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
47979180|NCT01352299|DEVICE|Miller|Laryngoscopy performed with Miller Laryngoscope
48338303|NCT03865238|BIOLOGICAL|Placebo|Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
48338304|NCT05869786|DEVICE|Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)|In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
48338305|NCT05869786|OTHER|conventional rehabilitation program|conventional rehabilitation program
48338306|NCT05869786|BEHAVIORAL|Exercise|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
48338307|NCT01400074|DRUG|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
48338308|NCT00656084|DRUG|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
48496217|NCT01103466|DEVICE|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
47979181|NCT01352299|DEVICE|TrueView|Laryngoscopy performed with TrueView laryngoscope
47979182|NCT01652560|DRUG|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
47979183|NCT02519192|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
47979184|NCT02519192|PROCEDURE|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
47979185|NCT02519192|PROCEDURE|ostomy bag|Non Vac Arm will receive ostomy bag applications.
47979186|NCT02519192|PROCEDURE|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
47979187|NCT01879332|DRUG|Placebo|Matching placebo tablets for oral administration
48338309|NCT00656084|DRUG|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
48338310|NCT00656084|DRUG|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
48338311|NCT02992873|DEVICE|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
48338312|NCT02992873|DEVICE|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
48496218|NCT05494645|DRUG|Exparel|Liposomal bupivicaine
48496219|NCT05494645|DRUG|Peripheral Nerve Block|Peripheral nerve block without Exparel
48496220|NCT02733952|DRUG|Tranexamic Acid|
48496221|NCT02733952|PROCEDURE|Pericervical Tourniquet|
48496222|NCT05855083|DRUG|Biological: narsoplimab|Treatment with narsoplimab 4 mg/kg will be administered
48496223|NCT01229644|DRUG|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
48496224|NCT06053775|DEVICE|Transcranial Direct Current Stimulation|tDCS+OCT
47979188|NCT01879332|DRUG|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
47979189|NCT01879332|DRUG|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
47979190|NCT00231725|DRUG|insulin lispro injection [rDNA origin] Low Mix|
47979191|NCT03398967|BIOLOGICAL|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"1. Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~2. Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~3. Other: Laboratory Biomarker Analysis"
47979192|NCT01122836|OTHER|Massage|Therapeutic Massage
47979193|NCT01723592|DIETARY_SUPPLEMENT|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
47979194|NCT01723592|DIETARY_SUPPLEMENT|Oral lactose placebo|Placebo
47979195|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
47979196|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
47979197|NCT00189254|DRUG|Imiquimod|No defined treatments were given during this study.
47979198|NCT00851383|BIOLOGICAL|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
48338313|NCT04580160|DEVICE|Duo Venous Stent System|Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
48338314|NCT05172531|DRUG|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
48266632|NCT05345925|DEVICE|Moderato|Several algorithms comprising CNT will be delivered by the Moderato Implantable Pulse Generator. Each application will last approximately 3 min with 2 minutes baseline (regular pacing) between them. Hence, each subject will serve as its own control (during pacing) and test (during CNT application). Furthermore, the average control value for the whole group will be compared with the average test values of CNT algorithms at the different ventricular lead locations for efficacy assessments. Stratification of subjects by initial hemodynamic parameters (such as Ejection Fraction, for example) would be possible depending on the total number of subjects in each group.
48338315|NCT05172531|DRUG|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
48496225|NCT06053775|DEVICE|Transcranial Alternating Current Stimulation|tACS+OCT
48496226|NCT06053775|DEVICE|tES sham|tES sham + OCT
48496227|NCT06053775|DEVICE|Online Cognitive Training|OCT
48496228|NCT04275206|OTHER|Harkány medicinal water|The aim is to prove the effectiveness of Harkány medicinal water on patients suffering from psoriasis and rheumatoid arthritis. The control group is treated with tap water.
48496229|NCT04275206|OTHER|Tap water (placebo control)|The control group is treated with tap water.
48496230|NCT06410170|DEVICE|MIRA Device|At home diagnostic testing
48654838|NCT04714255|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
48496231|NCT06007066|DRUG|HSK16149 capsule|Subjects will be given 40mg or 60mg of HSK16149 orally.
48496232|NCT06007066|DRUG|Placebo|Subjects will be given HSK16149 placebo orally.
47979199|NCT00851383|BIOLOGICAL|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
47979200|NCT04684498|DRUG|Oseltamivir phosphate capsules|Treatment group vs. Control group
47979201|NCT02496897|BIOLOGICAL|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
47979202|NCT02496897|OTHER|Placebo|Placebo
47979203|NCT02496897|OTHER|IC31® Adjuvant|IC31® Adjuvant
47979204|NCT02303288|DEVICE|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
47979205|NCT02538250|DIETARY_SUPPLEMENT|Nutricomp Drink Plus|Oral nutritional supplementation
47979206|NCT04341389|BIOLOGICAL|Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Intramuscular injection
47979207|NCT04341389|OTHER|Placebo|Intramuscular injection
47979208|NCT00001598|DRUG|Dehydroepiandrosterone|
47979209|NCT06045767|DRUG|Pembrolizumab 50 MG Injection [Keytruda]|Chemo-immunotherapy combination
47979210|NCT00468325|PROCEDURE|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
47979211|NCT00468325|PROCEDURE|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
47979212|NCT00468325|PROCEDURE|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
47979213|NCT01827397|BIOLOGICAL|EN41-UGR7C HIV vaccine|
47979214|NCT01827397|BIOLOGICAL|NaCl|
47979215|NCT02042378|DRUG|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
47979216|NCT04120545|DEVICE|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
48654839|NCT04201873|BIOLOGICAL|Dendritic Cell Tumor Cell Lysate Vaccine|Given ID
48654840|NCT04201873|BIOLOGICAL|Pembrolizumab|Given IV
48654841|NCT04201873|OTHER|Placebo Administration|Given IV
48654842|NCT04201873|DRUG|Poly ICLC|Given IM
48654843|NCT01734122|OTHER|Questionnaires / Observational Assessments|Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
47979217|NCT04120545|DEVICE|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
47979218|NCT02104700|DRUG|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
47979219|NCT02118389|DIETARY_SUPPLEMENT|Glucerna|Glucerna 52g meal replacement
47979220|NCT04883190|OTHER|Fulfilling Questionaires|Fulfilling Questionaires PHQ-D (brief) and FSMC
47979221|NCT01011634|DRUG|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
47979222|NCT02326025|DRUG|Olaratumab|Administered IV
48338316|NCT06099353|BEHAVIORAL|Heart Age|Heart Age is the phenotypic age based on the risk of the patient participant using a modified tool for CVD risk from the Framingham risk Score. The Heart Age is the age at which an individual would be expected to develop CVD in the next ten years relative to another individual of the same sex and age if all the current CVD risk factors were to be eliminated.
48496233|NCT05327192|OTHER|No intervention, only sampling|No intervention
48496234|NCT02916043|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
48496235|NCT03899311|OTHER|protein-sparing modified fast diet|a PSMF diet follow the usual care format in the Center
48496236|NCT03531398|OTHER|Metabolic test meal challenge|Metabolic test meal challenge
48496237|NCT05686083|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
48496238|NCT05686083|DIETARY_SUPPLEMENT|Novel ketone di-ester|Novel ketone di-ester
48496239|NCT01169532|DRUG|ridaforolimus|Given PO
48496240|NCT01169532|DRUG|vorinostat|Given PO
48496241|NCT01169532|PROCEDURE|biopsy|Optional correlative studies
48496242|NCT01169532|OTHER|pharmacological study|Correlative studies
48496243|NCT01169532|OTHER|laboratory biomarker analysis|Correlative studies
48496244|NCT04596228|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
48496245|NCT01911663|DIETARY_SUPPLEMENT|KRG|500 mg Korea red ginseng (KRG)
48496246|NCT01911663|DIETARY_SUPPLEMENT|Placebo|500 mg placebo
48654844|NCT06625931|DRUG|NTCB01-1|3 Days infusion
48654845|NCT06625931|DRUG|NTCB-P|3 Days infusion
48654846|NCT05702450|BIOLOGICAL|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
48654847|NCT04200963|DRUG|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
48654848|NCT04200963|DRUG|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
48496247|NCT01175811|DRUG|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
48496248|NCT01175811|DRUG|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
48496249|NCT01175811|DRUG|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
48496250|NCT00462059|BEHAVIORAL|Treatment|
48496251|NCT00857792|DRUG|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
48496252|NCT00960830|DRUG|mirtazapine|mirtazapine 15 mg daily tablets
48496253|NCT00960830|DRUG|mirtazapine|15 mg daily
48496254|NCT04746300|PROCEDURE|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
48496255|NCT04746300|PROCEDURE|Blood sample|Blood samples will be taken for additional translational research
48654849|NCT06628960|BEHAVIORAL|Su Jok Therapy|Su Jok Therapy
48654850|NCT03517800|OTHER|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
48654851|NCT05937243|BEHAVIORAL|Base self-help CBT program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating over 12 weeks. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participant to set personalized goals each week. Modules will be completed in succession over the course of 12-weeks and a new module will be made open each week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
48654852|NCT05937243|BEHAVIORAL|Just-in-time, adaptive intervention (JITAIs) system|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
48654853|NCT05937243|BEHAVIORAL|Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
48654854|NCT06642467|DEVICE|BGEM|BGEM is an ai driven model to predict blood glucose using ppg sensor
48654855|NCT06207019|DEVICE|Hyflex EDM , The XP-endo Shaper, Primary WaveOne Gold|rotary single files
48654856|NCT01019915|DEVICE|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
48131170|NCT03249142|DRUG|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
48131171|NCT03249142|DRUG|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
48338317|NCT06099353|BEHAVIORAL|Heart Age-HOPE-CVD App|Patient participants will use an online mobile, evidence-based behavioural change psychoeducation application for 24 weeks. New psychoeducational content is released every week. The first seven weeks of the programme seeks to resolve ambivalence about initiating a lifestyle change and increase the readiness and motivation to change. Between Weeks 8 and 15, the platform will support action planning and guide users to execute their preferred self-care behaviour safely and effectively. The remaining nine weeks will provide the user with the skills that will help them with coping and planning to manage relapses and temptations.
48338318|NCT06099353|BEHAVIORAL|Communication of Genetic Risk Score|General practitioners will draw 3ml of blood from each patient participant for analysis of the patient's genetic risk score of having cardiovascular disease. This genetic risk score will be communicated to the patient, and the communication will include informing patients what cardiovascular disease genetic risk is, what their genetic risk category compared to the population in Singapore is, and what their score means for the future.
48338319|NCT05073627|DRUG|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
48654857|NCT06570200|PROCEDURE|PMPR+iPRF|locally applied iPRF in the periodontal pocket
48654858|NCT06570200|DRUG|PMPR+iPRF+Vit.D|locally applied iPRF plus vitamin D in the periodontal pocket
48654859|NCT06570200|PROCEDURE|PMPR only|scaling and root planing only will be done for the periodontal pocket for the control group
48654860|NCT06420336|PROCEDURE|Quadratus lumborum block|After induction of anesthesia and securement of appropriate airway device, the patient will be placed in position for the QL block. Using ultrasound guidance, the pediatric anesthesiology attending will perform unilateral QL block on the side of the anterior iliac bone graft harvest. The dose will be 0.2% ropivacaine, 1 mL per kilogram to a max of 20 mL with an additive of dexamethasone 4 mg. Ultrasonography will be used to identify external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A 50 mm-150 mm block needle will be advanced under ultrasound guidance. Ropivacaine will be injected slowly with frequent aspiration to rule out incorrect needle placement. The anesthetic is deposited at the lateral edge of the QL after penetrating the transversus abdominus aponeurosis. Injection will continue to be observed with real time US guidance.
48654861|NCT06420336|PROCEDURE|Local anesthetic infiltration|After induction of anesthesia and securement of appropriate airway device the patient will be turned over to the surgical team to proceed with the operation. The surgeon will proceed with usual injection of local anesthetic as their standard of care; this medication will be charted by the circulating nurse in the Medication Administration Record with local anesthetic type and amount. At the conclusion of the procedure, to maintain the blind, the patient will have a bandage placed where the QL block would have been performed.
48654862|NCT04473196|OTHER|weightbearing|immediate weightbearing
47979223|NCT02326025|DRUG|Doxorubicin|Administered IV
47979224|NCT02267811|OTHER|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
48654863|NCT03301506|DRUG|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
48654864|NCT03301506|DRUG|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group unless there are tolerability issues.
47979225|NCT02267811|DEVICE|OrthoPulse™|Participants carry out daily OrthoPulse™ treatments at home.
47979226|NCT04153240|DEVICE|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
47979227|NCT05717374|DRUG|caudal block using dexamethasone|patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
47979228|NCT05717374|DRUG|caudal block using methylprednisolone|patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
47979229|NCT02663323|DEVICE|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
47979230|NCT02659306|DRUG|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
47979231|NCT02287272|DRUG|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
47979232|NCT02287272|DRUG|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
48496256|NCT05969379|GENETIC|Analysis of biomarkers and their correlation with clinical characteristics and outcome|"This is a non-interventional study involving clinical data, neuroimaging analysis, and biological samples. Demographics and clinical data are collected in the database of the French Reference Centre. Additional or missing data will be obtained by contacting the referral physicians. All the neuroimages available will be analysed by dedicated software. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids). Additional samples for genetic testing will be collected upon explicit written consent."
48496257|NCT04982874|DRUG|Furosemide 40 mg|Administered with 240 mL of water
47979233|NCT04013724|BEHAVIORAL|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
48338320|NCT01458496|BEHAVIORAL|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
48338321|NCT05267418|DEVICE|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
48338322|NCT01733836|DRUG|Metformin|
48496258|NCT04982874|DRUG|Lasix® 40 mg Tablet|Administered with 240 mL of water
47979234|NCT04337749|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
47979235|NCT04337749|DEVICE|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
47979236|NCT04337749|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
47979237|NCT04337749|DEVICE|Placebo socks|Placebo socks were given to patients for 2 weeks
48338323|NCT01733836|DRUG|placebo|
47979238|NCT04723745|BEHAVIORAL|V-TRACTS Assessment/Feedback|The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
47979239|NCT04723745|BEHAVIORAL|OPTIONAL Brief Assessment of Thinking|A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
48338324|NCT02683707|OTHER|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
48338325|NCT02683707|DRUG|Fentanyl|IV peri-procedural analgesia
48338326|NCT02683707|DRUG|Lidocaine|Local Anesthetic
48338327|NCT02683707|DRUG|Midazolam|IV sedation
48496259|NCT00466453|BEHAVIORAL|knowledge-adaptive Web-based instruction|
48496260|NCT01916590|DRUG|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
48496261|NCT01916590|DRUG|placebo|
48496262|NCT01508754|PROCEDURE|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
48496263|NCT06285630|OTHER|Observational, no intervation will be made|No intervention will be made, only longitudinal sample collection.
48496264|NCT02721693|DEVICE|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
48496265|NCT00290160|BEHAVIORAL|Protein supplementation|
48496266|NCT04808466|DRUG|Paclitaxel|Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
48338328|NCT05839639|DRUG|NrtIs|Subjects will receive NrtIs therapy for 24 weeks.
48338329|NCT05839639|DRUG|HH-003|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
48338330|NCT05839639|DRUG|HH-003+NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
48338331|NCT02005783|DRUG|DBD|DBD:one dose of medicine twice per day, orally
48338332|NCT02005783|DRUG|Epirubicin|Epirubicin:90mg/m2, d1, q3w\*4
48338333|NCT02005783|DRUG|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w\*4
48338334|NCT02005783|DRUG|Docetaxel|Docetaxel:75mg/m2, d1, q3w\*4
48654865|NCT05531942|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
48654866|NCT05531942|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
48654867|NCT00267488|DRUG|topotecan|
48654868|NCT00000307|DRUG|Naltrexone|
48338335|NCT00000608|BEHAVIORAL|diet, fat-restricted|
48654869|NCT04010344|BEHAVIORAL|Enhanced Usual Care Group|"Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~1. Reminders~2. Participant to CHO messaging~3. Home BP tracking~4. Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~5. CHO provider portal- The provider portal will include decision support tools."
48654870|NCT04010344|OTHER|Usual Care Group|Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
48338336|NCT00000608|BEHAVIORAL|diet, sodium-restricted|
48338337|NCT06118762|DRUG|Fruquintinib|Fruquintinib capsule is taken orally once a day, 5 mg each time, and taken for 2 weeks and stopped for 1 week, every 21 days (3 weeks) for a cycle. Raltitrexed: 3 mg/m2 intravenously, on the first day of each cycle, for a treatment cycle of 3 weeks. Combination treatment until toxicity becomes intolerable, disease progression, or death.
48338338|NCT06173609|PROCEDURE|CABG|"During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then, the surgeon uses that piece of blood vessel (called a graft) to reroute blood around the blocked artery."
48338339|NCT03010267|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
48338340|NCT03010267|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
48654871|NCT00684684|DEVICE|Chartis System|Assessment of airway flow and pressure
48654872|NCT06636955|OTHER|biobank|"* nasopharyngeal swab collection~* nasopharyngeal nasal washes collection, during hospitalization, if any"
48338341|NCT03010267|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
48338342|NCT03636308|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
48338343|NCT03636308|DRUG|S1|S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
48338344|NCT03636308|DRUG|Gemcitabine|Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
48338345|NCT05822648|BEHAVIORAL|Project Health|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
48654873|NCT06636955|OTHER|follow up|- one year follow up: after 1 month, 3 months, 6 months et 12 months
48654874|NCT03847519|DRUG|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
48654875|NCT03847519|DRUG|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
48654876|NCT06643325|DIAGNOSTIC_TEST|Gastric ultrasound|Serial, gastric sonography
48654877|NCT06192966|DIETARY_SUPPLEMENT|Food supplement|Probiotic formulation containing Lactobacillus plantarum, cranberry and vitamine C for 6 months 1 capsule/day
48654878|NCT06192966|DIETARY_SUPPLEMENT|Placebo|Placebo composed of maltodextrin for 6 months 1 capsule/day
48654879|NCT06637150|DRUG|Dalpicilib|Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
48338346|NCT05822648|OTHER|Educational Video Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
48338347|NCT05691712|DRUG|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
48338348|NCT05691712|DRUG|Placebo|Administered SC as add-on to the pre-trial background medication.
48338349|NCT00931060|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
48338350|NCT03029949|BEHAVIORAL|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
48654880|NCT06637150|DRUG|endocrine therapy|standard endocrine therapy
48654881|NCT06639126|DIETARY_SUPPLEMENT|Wild thyme extract|All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months
48654882|NCT06639126|OTHER|Placebo|600 mg/day microcrystalline cellulose
48338351|NCT03029949|BEHAVIORAL|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
47979240|NCT04723745|BEHAVIORAL|OPTIONAL STEP-Home-Brief|STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
47979241|NCT04723745|BEHAVIORAL|OPTIONAL At-home Exercise Program|This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
47979242|NCT04723745|BEHAVIORAL|OPTIONAL Referral to 12-week STEP-Home|Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
47979243|NCT04723745|BEHAVIORAL|OPTIONAL Clinical Referral|Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
47979244|NCT02730455|DRUG|natalizumab|Administered as specified in the treatment arm
47979245|NCT02730455|DRUG|Placebo|Matched placebo
47979246|NCT02365792|PROCEDURE|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
47979247|NCT04557371|OTHER|Serum|Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
47979248|NCT04557371|OTHER|Lotion|Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
47979249|NCT04557371|OTHER|Cream|Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
47979250|NCT01934530|PROCEDURE|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
47979251|NCT00643227|DRUG|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
47979252|NCT00643227|DRUG|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
47979253|NCT02855333|OTHER|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
47979254|NCT02120729|OTHER|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
47979255|NCT00504933|DRUG|bilastine|20 mg (encapsulated) tablets QD/14days
47979256|NCT00504933|DRUG|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
47979257|NCT00504933|DRUG|Placebo|(encapsulated) Tablets QD/14 days
47979258|NCT04907721|DIAGNOSTIC_TEST|Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon|"The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD."
47979259|NCT01995240|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
47979260|NCT01250834|DRUG|Atorvastatin|Administered orally.
47979261|NCT01250834|BIOLOGICAL|LY2189265|Administered subcutaneously.
48338352|NCT03029949|OTHER|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
48338353|NCT04771546|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
48338354|NCT02574819|DRUG|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
48338355|NCT02574819|DRUG|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
48496267|NCT04808466|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
48654883|NCT03952351|RADIATION|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
48338356|NCT03030014|BEHAVIORAL|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
48338357|NCT03030014|OTHER|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
48496268|NCT02452996|DRUG|GNbAC1|Single dose of IMP, IV infusion
48131174|NCT05460793|DEVICE|Minimally invasive endoscopy-guided surgery|The devices allowed into the trial, are minimally invasive neuronavigation integrated endoscopy-guided devices that are CE approved and admissible by the steering committee. Currently, only the Artemis Neuro Evacuation Device (Penumbra Inc, Alameda, California, USA) is available and CE approved.
48496269|NCT02875158|PROCEDURE|Cyclophotocoagulation protocol|"* Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
48338358|NCT00712933|DRUG|belimumab|"Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
48338359|NCT00457756|DIETARY_SUPPLEMENT|BiosLife Complete|
48338360|NCT00457756|DIETARY_SUPPLEMENT|Placebo|
48496270|NCT02875158|PROCEDURE|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
48496271|NCT02875158|PROCEDURE|Modified cyclophotocoagulation|2000 mW for 2 seconds.
48131177|NCT06597734|DRUG|Azacitidine (AZA)|Given by SC or IV
48131178|NCT06597734|DRUG|Decitabine|Given by IV
48496272|NCT04047914|DEVICE|Antimicrobial Photodynamic therapy|"Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2"
48496273|NCT04047914|DRUG|Mupirocin ointment|Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
48496274|NCT04853992|DRUG|LEO 152020|LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.
48338361|NCT03391076|DIAGNOSTIC_TEST|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
48338362|NCT00676156|DRUG|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
48496275|NCT04853992|DRUG|LEO 152020 placebo|LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.
48496276|NCT00959361|BEHAVIORAL|pharmaceutical care|consultation with the pharmacists and usual care
48496277|NCT04996563|OTHER|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
48496278|NCT05010044|BEHAVIORAL|mindfulness-based cognitive therapy (MBCT)|Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.
48496279|NCT05010044|OTHER|Antipsoriatic treatment|The routine drug therapy for psoriasis.
48496280|NCT05748613|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|Brief computerized treatment for anxiety sensitivity
48338363|NCT00676156|DRUG|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
48338364|NCT00676156|DRUG|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
48496281|NCT05748613|BEHAVIORAL|Health Education Control|Brief computerized presentation on healthy behaviors
48496282|NCT05769933|DEVICE|Simultaneous EEG-fMRI at 7 Tesla|Scalp electroencephalography (EEG) and functional magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
48496283|NCT05769933|DEVICE|Structural MRI at 7 Tesla|Structural magnetic resonance imaging (MRI) at 7 Tesla. These will be completely non-invasive techniques with no ionizing radiation and no injected contrasts.
48496284|NCT01196078|DRUG|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
48496285|NCT01196078|DRUG|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
48496286|NCT00003748|DRUG|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
48496287|NCT01602965|PROCEDURE|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
48338365|NCT04835571|OTHER|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~* blood pressure \<140/90 mmHg~* Tot cholesterol \<5 mmol/l~* LDL \<1,8 mmol/l~* Waist circumference: men \<94 cm, women \<80 cm~* BMI \<25 kg/m2~* HbA1c without diabetes mellitus \<42 mmol/mol, HbA1c with diabetes mellitus \<52 mmol/mol~* Antithrombotic treatment (or anticoagulants, if indicated)~* Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~* Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~* Smoking cessation~* Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
48131179|NCT06597734|DRUG|Olutasidenib|Given by PO
48131180|NCT06597734|DRUG|Cedazuridine|Given by PO
48338366|NCT00112684|DRUG|alvocidib|Given IV
48338367|NCT00112684|OTHER|pharmacological study|Correlative studies
48131181|NCT03737409|OTHER|Ambulatory Oxygen Therapy|Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
48338368|NCT00112684|OTHER|laboratory biomarker analysis|Correlative studies
48338369|NCT00814307|DRUG|CP-690,550|5mg CP-690,550 BID PO for 6 months
48338370|NCT00814307|DRUG|CP-690,550|10 mg CP-690,550 BID PO for 6 months
48338371|NCT00814307|DRUG|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
48338372|NCT00814307|DRUG|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
48338373|NCT04429152|DRUG|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
48338374|NCT00517205|PROCEDURE|Non-contrast helical computerized tomogram (NCHCT)|
48338375|NCT04107116|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
48338376|NCT04107116|OTHER|Usual Care|Usual care as provided by local oncologists
48496288|NCT01602965|PROCEDURE|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
48496289|NCT00839592|OTHER|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
48131182|NCT03737409|OTHER|Sham Ambulatory Oxygen Therapy|Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
48496290|NCT02637921|OTHER|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
48496291|NCT02637921|OTHER|Ambulatory|Participants hava a standardized activity level throughout the intervention
48131184|NCT00580866|DEVICE|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
48338377|NCT03990701|COMBINATION_PRODUCT|11C-Metomidate PET/CT Scan|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
48338378|NCT04883918|BIOLOGICAL|ASC930|4 intravenous doses of ASC930
48338379|NCT06450457|DEVICE|Polar H10 heart rate monitor|"Heart rate will be monitored utilizing a Polar H10 heart rate monitor, with the goal of reaching moderate to high intensity for 30 minutes during the one hour long therapy intervention"
48338380|NCT06450457|DEVICE|Therastride Treadmill System|Participants will be asked to walk on the Therastride Treadmill for 30 minutes.This treadmill can unweight patients so that the task of walking becomes easier. The treadmill's body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study.
48654884|NCT04812483|DRUG|Eltrombopag (Revolade®)|Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
48654885|NCT04812483|DRUG|standard therapy (without eltrombopag): HD-DXM|standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
48338381|NCT06450457|DEVICE|VECTOR Bioness|Participants will be asked to walk using the VECTOR Bioness on a track outside the gym with a harness attached to an overhead sling system. This system can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study. This system allows for overground walking on a small indoor track as opposed to walking on a treadmill.
48338382|NCT01444872|DRUG|TRV120027|IV infusion
48338383|NCT01444872|DRUG|Normal Saline|IV infusion
48496292|NCT02637921|OTHER|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
48496293|NCT02637921|OTHER|Bed Rest|Participants remain on supine bed rest throughout the intervention
48496294|NCT02637921|OTHER|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
48496295|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
48496296|NCT04031781|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
48338384|NCT03661255|BEHAVIORAL|PC CARES|PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
48496297|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with Listerine|
47979262|NCT00814528|DRUG|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
47979263|NCT00814528|DRUG|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
47979264|NCT03252834|DIAGNOSTIC_TEST|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
48496298|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with CHX|
48496299|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with serum|
48496300|NCT06187493|DRUG|lisinopril, enalapril|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
48496301|NCT06187493|DRUG|dapagliflozin, empagliflozin|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
48496302|NCT04915482|DRUG|Combined use of TPO-RAs with low-dose anti-CD20 antibody|Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
48496303|NCT04915482|DRUG|The best available therapy|The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
48496304|NCT04684004|OTHER|To report number of HF events and deaths|In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
48496305|NCT00415766|DRUG|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
48496306|NCT00415766|DRUG|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
48496307|NCT00415766|DRUG|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
48496308|NCT03712982|BEHAVIORAL|Attention to Variability - Patient Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
48496309|NCT03712982|BEHAVIORAL|Attention to Variability - Partner Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
47979265|NCT02466360|BEHAVIORAL|Back Belief questionnaire|
47979266|NCT02466360|BEHAVIORAL|QUEBEC scale|
47979267|NCT02466360|BEHAVIORAL|Fear Avoidance beliefs questionnaire|
47979268|NCT02466360|BEHAVIORAL|Visual analog scale|
47979269|NCT02466360|BEHAVIORAL|individual interviews|
47979270|NCT02466360|BEHAVIORAL|Focus groups|
47979271|NCT00936585|OTHER|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
48338385|NCT01712503|DEVICE|Phacoemulsfication cataract surgery and intra-ocular lens implant|
48338386|NCT01364857|GENETIC|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
48496310|NCT03712982|BEHAVIORAL|Attention to Variability - Patient & Partner|Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
48496311|NCT03712982|OTHER|Infertility Stories - Reading|Reading Stories About Others' Infertility Experiences
48496312|NCT03108092|OTHER|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
47979272|NCT04973826|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
47979273|NCT03989453|OTHER|Chi Kung|The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
47979274|NCT00290914|DRUG|Vilazodone|
47979275|NCT01635101|DRUG|IV Acetaminophen|IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
47979276|NCT01635101|DRUG|IV Control|IV Control q6h; 4 doses, in 24 hours
47979277|NCT04366440|BEHAVIORAL|Order set review and modification with facilitation|The antimicrobial stewardship program will receive facilitation training to aid in reviewing and changing order sets of clean or clean-contaminated procedures to eliminate unnecessary post-operative antibiotics.
47979278|NCT04366440|OTHER|Order set review and modification|The antimicrobial stewardship program will work to eliminate unnecessary post-operative antibiotics by reviewing and changing order sets of clean or clean-contaminated procedures.
47979279|NCT00629681|DRUG|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
47979280|NCT01023230|DRUG|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
48131185|NCT05171777|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
48338387|NCT02136550|BEHAVIORAL|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
48496313|NCT03108092|OTHER|Control|Standard care in the department where the trial is conducted
48496314|NCT06445634|OTHER|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
48496315|NCT00749736|DIETARY_SUPPLEMENT|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
48496316|NCT00749736|DIETARY_SUPPLEMENT|doxercalciferol|1 mcg of doxercalciferol per day
47979281|NCT01023230|DRUG|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
47979282|NCT06501482|DRUG|Postoperative reintroduction of FOLFIRI based chemotherapy|Postoperative reintroduction of FOLFIRI: irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion over 46 h biweekly. For a total of 12 cycles of perioperative chemotherapy including the preoperative chemotherapy
47979283|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo strength training classes
47979284|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo tai chi classes
47979285|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo stretching and relaxation classes
47979286|NCT01635413|OTHER|Questionnaire Administration|Ancillary studies
47979287|NCT04519710|BIOLOGICAL|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
47979288|NCT03847454|COMBINATION_PRODUCT|REACH|The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
47979289|NCT03847454|OTHER|Standard of care|Standard of care for rehabilitation treatment for musculoskeletal patients.
47979290|NCT00763477|BIOLOGICAL|ghrelin|subcutaneous injection
47979291|NCT03222050|OTHER|Distraction technique|
47979292|NCT00418314|DEVICE|Control|Empiric programming or one-time optimization using a non-IEGM method.
48496317|NCT00749736|DIETARY_SUPPLEMENT|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
48496318|NCT03158974|DRUG|East Indian Sandalwood Oil Cream|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
48496319|NCT02813057|PROCEDURE|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
48496320|NCT02813057|PROCEDURE|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
48496321|NCT00270257|DRUG|Buprenorphine/Naloxone|Oral tablet
48496322|NCT00704093|DEVICE|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
48496323|NCT02362555|OTHER|no intervention was used in this observational study|
47979293|NCT00418314|DEVICE|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
47979294|NCT02041286|DEVICE|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
48131186|NCT05848713|DRUG|Heparin|"Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement."
48496324|NCT04403711|OTHER|local anesthetic and dexmedetomidine|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
48496325|NCT04403711|OTHER|local anesthetic and placebo|in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
48654886|NCT05878795|BEHAVIORAL|WET-SP|WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 45 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.
48654887|NCT05878795|BEHAVIORAL|TAU|TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
48654888|NCT06640179|OTHER|Standard medical care|Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
48131188|NCT05867927|DEVICE|Robotic-assisted surgery (da Vinci)|Robotic-assisted surgery (da Vinci)
48131189|NCT05867927|DEVICE|Non-da Vinci Surgery|Non-da Vinci Surgery
48654889|NCT06640179|BEHAVIORAL|Monitoring Contacts|Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.
48496326|NCT00306943|BIOLOGICAL|Influsplit SSW®|
48496327|NCT05000086|DRUG|99Tc methylene diphosphonate|22mg qd，Once a day for 7 consecutive days
48496328|NCT06019520|DRUG|N-Acetylcysteine|Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
48496329|NCT06019520|DRUG|Chemotherapy|Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
47979295|NCT02401815|DRUG|PLX9486|PLX9486 will be administered per dose and schedule specified in the arm.
47979296|NCT02401815|DRUG|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
48496330|NCT01739621|DRUG|Proellex 12 mg|
47979297|NCT02401815|DRUG|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
48496331|NCT01739621|DRUG|Proellex 24 mg|
48496332|NCT04969510|DRUG|10 mg PRAX-114|Once daily oral treatment
48496333|NCT04969510|DRUG|20 mg PRAX-114|Once daily oral treatment
48496334|NCT04969510|DRUG|40 mg PRAX-114|Once daily oral treatment
48496335|NCT04969510|DRUG|60 mg PRAX-114|Once daily oral treatment
48496336|NCT04969510|DRUG|Placebo|Once daily oral treatment
48496337|NCT00725751|BIOLOGICAL|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
48654890|NCT06640179|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.
48131190|NCT04615416|BEHAVIORAL|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
48496338|NCT00725751|DRUG|Ribavirin|Ribavirin administered according to European labeling.
48131192|NCT06511908|DRUG|(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)|Arm 1 and 2 Experimental Intervention
48131193|NCT06511908|DRUG|Placebo|Arm 1 and 2 Control Intervention
48131194|NCT05793541|BEHAVIORAL|Phone call|A phone call from a trained study clinician that uses a standardized phone script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the call. This intervention occurs at High Risk only.
48131195|NCT05793541|BEHAVIORAL|Text messaging|A text message conversation initiated by a trained study clinician that uses a standardized text messaging script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the text messaging interaction. This intervention occurs at High Risk only.
48131196|NCT05793541|BEHAVIORAL|Automated interactive smartphone-based tool|An automated interactive, smartphone-based tool that will (a) (at High Risk only) guide the participant through a risk assessment and (b) (at High and Medium/Low Risk) present recommendation to use and a review of the safety plan.
48131197|NCT05793541|BEHAVIORAL|Non-interactive pop-up messages|Automated non-interactive, static pop-up messages that recommend use of the safety plan or its components (Medium/Low Risk only).
48496339|NCT03465826|BEHAVIORAL|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
48496340|NCT03465826|BEHAVIORAL|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
48338388|NCT04924010|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format \[Connolly KS et al\] AND an evidence-based CBT manual specifically designed to treat chronic pain \[Murphy JL et al\].
48338389|NCT04924010|BEHAVIORAL|Education and Mindfulness|To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
48338390|NCT00728663|BIOLOGICAL|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
48496341|NCT00664131|OTHER|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
48496342|NCT00010192|BIOLOGICAL|rituximab|Given IV
48496343|NCT00010192|BIOLOGICAL|aldesleukin|Given SC
48338391|NCT00728663|DRUG|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
48338392|NCT05068388|DRUG|Z-Endoxifen|Z-Endoxifen
48338393|NCT05068388|DRUG|Placebo|Placebo
48496344|NCT00010192|OTHER|laboratory biomarker analysis|Correlative studies
48496345|NCT00010192|OTHER|pharmacological study|Correlative studies
48496346|NCT01752647|PROCEDURE|Low dose computed tomography|Low dose computed tomography scan
48496347|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
48496348|NCT01024686|BIOLOGICAL|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
47979298|NCT05456464|OTHER|Reiki|Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
48496349|NCT01024686|BIOLOGICAL|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
48496350|NCT01727466|BEHAVIORAL|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
48496351|NCT03880435|DEVICE|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
48496352|NCT05012163|BEHAVIORAL|Reminder|Letter, short message service (SMS) text, phone, and/or email
48496353|NCT05012163|BEHAVIORAL|Financial incentive|Letter, SMS, phone, and/or email
48496354|NCT05012163|BEHAVIORAL|Lottery|Letter, SMS, phone, and/or email
48654891|NCT06640179|BEHAVIORAL|Diet|An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.
48496355|NCT03657212|DRUG|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
48496356|NCT04383236|OTHER|Probiotics|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
48496357|NCT04383236|DRUG|Oracure oral gel|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
48496358|NCT02963441|DEVICE|LumineticsCore (formerly IDX-DR)|Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
48496359|NCT00397306|DEVICE|Bioimpedance Analysis|
48496360|NCT01321619|DRUG|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
48654892|NCT06640179|BEHAVIORAL|Physical Activity|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.
47979299|NCT05245370|BEHAVIORAL|Control video|Control group 1 will see a control video consisting of basic information about the different types of psychotherapy that are covered by insurance in Germany and the process of applying for psychotherapy with the insurance. The control video is matched in duration (10 minutes), set-up and the overall topic (psychotherapy) to the intervention video testimonials.
47979300|NCT05245370|BEHAVIORAL|Rationale video|The active control group 2 will see a short rationale and the control video. The rationale is a 2:45 minute-long animated video (designed via the visual communication platform powtoon, https://powtoon.com/) explaining some of the underlying mechanisms of depression.
47979301|NCT05245370|BEHAVIORAL|Clinician testimonial|This group will see the rationale video first, followed by testimonial of a professional clinician/psychotherapist.
48338394|NCT00639262|DRUG|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
48338395|NCT00639262|DRUG|Temozolomide|For Cohort 2 - Gliomas only.
48338396|NCT00639262|RADIATION|Radiotherapy|Radiation Therapy (XRT)
48496361|NCT01321619|DRUG|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
48496362|NCT01804218|DRUG|Nadolol|
48496363|NCT01804218|DRUG|Placebo|
48496364|NCT03485183|DEVICE|White/Pink Noise|White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.
48496365|NCT03485183|OTHER|Control Group|Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
47979302|NCT05245370|BEHAVIORAL|Patient testimonial|This group will see the rationale video first, followed by testimonial of a patient who is being treated for depression with psychotherapy.
47979303|NCT02840370|DEVICE|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
48338397|NCT01933204|OTHER|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
48338398|NCT01933204|DRUG|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
48338399|NCT01632072|DIETARY_SUPPLEMENT|Nutritional support|Nutritional support and counseling
48496366|NCT05648461|RADIATION|Five fraction of post operative radiotherapy|Target volume will include tumor bed \& ipsilateral level I-III levels.
48496367|NCT03483168|BEHAVIORAL|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
48496368|NCT03483168|BEHAVIORAL|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
48496369|NCT00260169|BEHAVIORAL|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
48654893|NCT00020007|DRUG|isolated perfusion|
48654894|NCT00020007|DRUG|paclitaxel|
48654895|NCT00020007|PROCEDURE|hyperthermia treatment|
48654896|NCT06642090|BEHAVIORAL|Educational intervention for patients undergoing hemodialysis in Morocco|This is the first educational intervention in Morocco to improve the knowledge, self-care, and biological characteristics of patients undergoing hemodialysis.
48654897|NCT04305756|DRUG|Enoxaparin|Low molecular weight heparin
48654898|NCT02771327|DEVICE|CPAP plus Gas|
48654899|NCT02771327|DEVICE|ventimask plus gas|
48654900|NCT01055340|DRUG|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
47979304|NCT02840370|DEVICE|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
47979305|NCT02148692|PROCEDURE|Higher PEEP|
47979306|NCT02148692|PROCEDURE|Lower PEEP|
48338400|NCT03970824|BIOLOGICAL|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
48338401|NCT03970824|BIOLOGICAL|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
48496370|NCT00260169|BEHAVIORAL|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
48654901|NCT01055340|DRUG|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
48654902|NCT01055340|DRUG|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
47979307|NCT00859768|OTHER|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
48338402|NCT03970824|BIOLOGICAL|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
48654903|NCT06641024|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
48654904|NCT04796805|OTHER|Topical essential oil application|We applied black pepper essential oil to the participants in experimental group before the catheter insertion procedure
48654905|NCT06637059|OTHER|observational study|observation alone
48654906|NCT05406401|BIOLOGICAL|Zilovertamab Vedotin|IV infusion
48654907|NCT05406401|DRUG|Cyclophosphamide|IV infusion
48654908|NCT05406401|DRUG|Doxorubicin|IV infusion
48654909|NCT05406401|BIOLOGICAL|Rituximab|IV infusion
48654910|NCT05406401|BIOLOGICAL|Rituximab Biosimilar|IV infusion
48654911|NCT05406401|DRUG|Prednisone|IV or oral administration (per local guidelines)
48654912|NCT05406401|DRUG|Prednisolone|IV or oral administration (per local guidelines)
48654913|NCT01787747|DRUG|AVP-786 Dose 1|
48654914|NCT01787747|DRUG|AVP-786 Dose 2|
48654915|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 1|
48654916|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 2|
48654917|NCT01787747|DRUG|AVP-786 Dose 2/Q Dose 2|
48654918|NCT01787747|DRUG|AVP-923|
48338403|NCT01176240|DRUG|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
48654919|NCT00228956|DRUG|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
48654920|NCT00087672|DRUG|CC-5013|10 mg orally (2 capsules) daily
48654921|NCT05153317|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules or tablets for oral administration.
48654922|NCT05153317|DRUG|IVA|Granules or tablets for oral administration.
48496371|NCT05324826|DEVICE|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
47979308|NCT03012256|OTHER|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
47979309|NCT04954274|DRUG|Cyclic peptide Fertiline|"Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide."
48496372|NCT04191798|BEHAVIORAL|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
48131203|NCT06648837|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy, additional tubes of blood drawn during normal clinical vist.
48338404|NCT01176240|OTHER|Placebo|Placebo
48654923|NCT06429072|BEHAVIORAL|Mindfulness training|• I-MASS begins with one introductory telephone call by a mindfulness coach within 1 week of the patient scheduling surgery to introduce the participant to the Pattern Health app, discuss the benefits of combining mindfulness and acupuncture, discuss how to access the Healthwise educational content, and lead a brief (\~10 min) mindfulness exercise, as desired. Thereafter, participants will complete 4 self-directed mindfulness modules through the Pattern Health app (1 prior to surgery, 3 following surgery). Each mindfulness module is anticipated to last one week and includes a short (4-5 min) introductory video, daily sessions comprised of a 6-8 min guided mediation, and interactive suggestions for how to apply mindfulness within a daily routine (\~10-12 min total per daily session).
48338405|NCT00873145|PROCEDURE|HMRS|Modular prosthetic replacement of the humerus and elbow.
48338406|NCT00773851|PROCEDURE|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
48338407|NCT00773851|PROCEDURE|mesh fixation by staples|mesh fixation by staples
48338408|NCT01587274|DRUG|Naproxen|Naproxen 500mg twice/ day x 10 days
48338409|NCT01587274|DRUG|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
48338410|NCT01587274|DRUG|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
48338411|NCT00054444|DRUG|Topotecan Hydrochloride Liposomes|Given IV
48338412|NCT00054444|RADIATION|3-Dimensional Conformal Radiation Therapy|
48338413|NCT00054444|DRUG|Cisplatin|Given IV
48496373|NCT04191798|BEHAVIORAL|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
48496374|NCT04841018|DRUG|High dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.5mg/kg of intravenous dexamethasone
48496375|NCT04841018|DRUG|Low dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.15mg/kg of intravenous dexamethasone
48496376|NCT02470390|DRUG|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
48496377|NCT01781000|BEHAVIORAL|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
48496378|NCT01781000|BEHAVIORAL|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
48496379|NCT01781000|BEHAVIORAL|Treatment as usual|standard treatment protocol of schizophrenia ward
48496380|NCT05423444|BEHAVIORAL|TF-CBT|evidence-based psychotherapy for trauma in youth
48496381|NCT05423444|BEHAVIORAL|TAU|treatment as usual
47979310|NCT04242303|PROCEDURE|Total knee replacement|"Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts."
47979311|NCT05409573|OTHER|double monitoring of EtO2|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)"
48131204|NCT06648837|OTHER|Collection of relevant information|Collect relevant information to ensure potential participant meets all inclusion/exclusion criteria.
48496382|NCT02775708|DEVICE|Pillcam endoscopy system|
48131206|NCT02922088|DEVICE|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
48654924|NCT06429072|OTHER|Acupuncture|This arm also includes up to 8 total acupuncture treatments (1 prior to surgery and up to 7 treatments in the 12 weeks after surgery). Auricular acupuncture will be the preferred form of acupuncture used. This technique involves inserting tiny needles in specific areas of the outer ear to target points believed to influence pain. If participants are unable to tolerate auricular acupuncture, they will have the option to receive peripheral acupuncture.
48654925|NCT06429072|BEHAVIORAL|Enhanced education|• The program consists of education prior to and after surgery for all participants. All of the educational material is delivered via the Pattern Health App. All educational content is from the Healthwise.net Duke Health Library (https://www.healthwise.net/dukehealth/Content) and is carefully selected with input by surgeons to be delivered during the appropriate phase of recovery. Education is in the form of short reading materials or videos, all designed to help safely and effectively recover from surgery. Educational topics include learning how to lift and sit when experiencing pain, proper precautions following surgery, how to ease back into daily activities following surgery, and ways to self-manage pain.
48654926|NCT05501522|BIOLOGICAL|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
48654927|NCT05501522|OTHER|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
48654928|NCT06549816|DRUG|sigvotatug vedotin|Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.
47979312|NCT04810845|DEVICE|Application of Class II A device SmartCardia|Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
47979313|NCT02239757|PROCEDURE|Left radial approach|Primary PCI performed through left radial approach.
47979314|NCT02239757|PROCEDURE|Right radial approach|Primary PCI performed through right radial approach.
48496383|NCT01157780|DRUG|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
48496384|NCT01390285|DEVICE|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
48496385|NCT01390285|DEVICE|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
48496386|NCT03277638|DRUG|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
48496387|NCT03277638|DRUG|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
48496388|NCT03277638|DRUG|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
47979315|NCT04474704|DEVICE|Cheetah® non-invasive cardiac monitoring system|Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))
48338414|NCT02639923|PROCEDURE|Drawing of 7ml peripheral blood|puncture peripheral vein
48338415|NCT02703142|PROCEDURE|Patients after esophagectomy|postoperative endoscopic evaluation
48496389|NCT03277638|PROCEDURE|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
48496390|NCT02791893|DEVICE|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
48496391|NCT02791893|DEVICE|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
48496392|NCT00251225|DRUG|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
48496393|NCT00251225|DRUG|Docetaxel|60 mg/m\^2 administered IV on day 0
48496394|NCT00856973|DRUG|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
48654929|NCT04124419|DEVICE|Treatment with Evolve System|EMS and RF Treatment
47979316|NCT04474704|OTHER|Standard of care|24 hours of postpartum magnesium sulfate
47979317|NCT04734080|DRUG|Dronabinol 5mg Cap|Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.
47979318|NCT04734080|OTHER|Placebo oral tablet|Non-active placebo
47979319|NCT05678894|OTHER|Scanner and EOS imaging|Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
47979320|NCT00179634|BEHAVIORAL|Visualization relaxation|
47979321|NCT00179634|BEHAVIORAL|Visual Milieu Enhancement (Fine art photograph)|
48131207|NCT06242366|BEHAVIORAL|Intervention group|"Intervention 2 phases Phases 1) In-hospital period (4 times and 30-60 mins/times) intervention includes Stroke education, Rehabilitation, environmental management, and complication prevention. Intervention participants will receive a booklet (choose between hard copy or electronic copy) self-care for stroke patients, Rehabilitation clip, and Self-care record form.~Phases 2) after hospital discharge 5 times (first times within 24 hours after hospital discharge) and (second-fifth time: 1 time/weekly)15-30 mins/times by Line Application for repeat and following education, rehabilitation complication prevention and finding limit to self-care management."
48496395|NCT00856973|DRUG|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
48496396|NCT00856973|DRUG|Placebo|1 tablet per day for 12 weeks
48131208|NCT06429137|DRUG|BI 3731579|BI 3731579
48496397|NCT01378455|OTHER|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
48654930|NCT00410657|BIOLOGICAL|alemtuzumab|
48654931|NCT00410657|DRUG|methylprednisolone|
48654932|NCT00410657|DRUG|prednisone|
48654933|NCT00410657|OTHER|flow cytometry|
47979322|NCT06121687|PROCEDURE|Shaeer-I|Ligation of the internal pudendal vein under the Gluteus Maximus muscle as it courses above the scar-spinous ligament.
47979323|NCT06121687|PROCEDURE|PPI|Penile prosthesis implantation (PPI) will be performed
47979324|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
47979325|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
48131209|NCT06429137|DRUG|Matching placebo to BI 3731579|Matching placebo to BI 3731579
48496398|NCT01378455|OTHER|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
48496399|NCT01388166|PROCEDURE|Education|Education
48496400|NCT01261286|DRUG|verapamil|
48496401|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
48496402|NCT02038465|DEVICE|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
48496403|NCT00719849|BIOLOGICAL|anti-thymocyte globulin|30mg/Kg Days -6 to -4
48654934|NCT00410657|OTHER|immunologic technique|
48654935|NCT00410657|OTHER|pharmacological study|
48654936|NCT01138306|GENETIC|gene expression analysis|
48654937|NCT01138306|GENETIC|mutation analysis|
47979326|NCT04894903|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring \& preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
47979327|NCT01708681|DIETARY_SUPPLEMENT|Lean seafood|
47979328|NCT01708681|DIETARY_SUPPLEMENT|Meat, egg, milk|
47979329|NCT03578601|OTHER|Thyroid surgery|Patient undergoing thyroid surgery
47979330|NCT00349804|OTHER|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
47979331|NCT00248014|DEVICE|Mandibular Advancement Via A Functional Appliance|Functional appliance
47979332|NCT01852110|DRUG|MK-7622|MK-7622 capsule
47979333|NCT01852110|DRUG|Placebo|Matching placebo to MK-7622 capsule
48131210|NCT06515002|GENETIC|BI 3720931|BI 3720931
48131211|NCT06515002|DRUG|Placebo|Placebo
48496404|NCT00719849|DRUG|cyclophosphamide|50 mg/Kg Day -6
48654938|NCT01138306|OTHER|flow cytometry|
48654939|NCT01138306|OTHER|laboratory biomarker analysis|
48654940|NCT06499350|DRUG|FC084CSA+Tislelizumab combination (dose escalation)|Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy
48654941|NCT06499350|DRUG|RP2D of FC084CSA+Tislelizumab combination (dose expansion)|RP2D of FC084CSA+fixed dose Tislelizumab combination therapy
48654942|NCT04078373|BEHAVIORAL|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
48654943|NCT04078373|BEHAVIORAL|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
48654944|NCT04586751|OTHER|Pecs block|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
48654945|NCT04586751|OTHER|no Pecs block|no regional block will be performed in this arm
48338416|NCT05850013|DEVICE|Lifelight Junior|Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios
48338417|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the active comparator on the randomly assigned side of split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 28 days.
48338418|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the placebo comparator on the randomly assigned side of split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 28 dayd.
48338419|NCT01643304|BEHAVIORAL|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
48338420|NCT00077922|DRUG|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
48496405|NCT00719849|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
47979334|NCT01852110|DRUG|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
47979335|NCT01539057|DRUG|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
47979336|NCT01539057|DRUG|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
47979337|NCT04488900|DRUG|CKD-508 Capsule|Investigational drug
48131212|NCT06515002|DEVICE|Inhaler|Inhaler for application of BI 3720931 and placebo
47979338|NCT04488900|DRUG|Placebo Capsule|Placebo
48131213|NCT06659627|BEHAVIORAL|Aerobic exercise therapy|Participants will follow an aerobic exercise therapy program for 16 weeks.
48496406|NCT00719849|DRUG|fludarabine phosphate|40mg/m2 Days -6 to -2
48496407|NCT00719849|DRUG|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
47979339|NCT04488900|DRUG|CKD-508 Tablet|Investigational drug
48131214|NCT06659627|BEHAVIORAL|Cognitive behavioural therapy|Participants will follow an cognitive behavioural therapy program for 12-16 weeks.
47979340|NCT04488900|DRUG|Placebo Tablet|Placebo
47979341|NCT01829334|OTHER|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
47979342|NCT01829334|OTHER|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
47979343|NCT01829334|OTHER|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
47979344|NCT01829334|OTHER|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
48131215|NCT06659627|OTHER|Usual care|Participants do not follow a program, but continue with care as usual
48496408|NCT00719849|PROCEDURE|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
48496409|NCT00719849|RADIATION|total body irradiation|200 cGy Day -1
48496410|NCT02546336|DEVICE|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
48131219|NCT05141513|RADIATION|High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)|After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery.
48654946|NCT05516173|DIAGNOSTIC_TEST|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
47979345|NCT03968484|BIOLOGICAL|platelet transfusion|Transfusion of platelets
48338421|NCT02057367|DRUG|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
48131224|NCT06647511|DEVICE|Nokia-Withings BPM Connect Blood Pressure Monitor|At-home blood pressure (BP) measurements will be weekly via a blood pressure cuff (e.g., Nokia-Withings BPM (Beats per Minute) Connect), with measurements being manually entered into the study specific smartphone app.
48131225|NCT06647511|DEVICE|Smartwatch Devices|Passive continuous collection of digital data (e.g., daily heart rate trends, activity levels, sleep measurements) for exploratory outcomes will occur via Apple Watches and Fitbit Versa 3s, which are synced to a smartphone application.
48338422|NCT02057367|DRUG|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
48338423|NCT02923050|BEHAVIORAL|Simple Suppers|Theory-based 10-week family meals program
48338424|NCT01478178|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
48338425|NCT00083876|DRUG|Thalidomide|
47979346|NCT00939250|BEHAVIORAL|Diabetes and depression intervention|Disease self management for diabetes and depression
48496411|NCT06204211|DIAGNOSTIC_TEST|ophthalmologic examinations|All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
48338426|NCT04957303|DEVICE|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
48338427|NCT02937688|DEVICE|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
48338428|NCT05462405|PROCEDURE|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
48338429|NCT00003408|BIOLOGICAL|aldesleukin|
48496412|NCT02440568|DRUG|Cytarabine|Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
48496413|NCT02440568|DRUG|Idarubicin|Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
48496414|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m\^2
48496415|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m\^2
48496416|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m\^2
48654947|NCT00273780|BEHAVIORAL|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
48654948|NCT00273780|DEVICE|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
47979347|NCT00939250|BEHAVIORAL|Diabetes intervention|Disease self management for diabetes
48496417|NCT02440568|DRUG|Omacetaxine mepesuccinate|Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m\^2
48496418|NCT02906930|DRUG|semaglutide|Oral administration once daily.
48496419|NCT02906930|DRUG|placebo|Oral administration once daily.
48131230|NCT04149119|DEVICE|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
48496420|NCT00545675|DRUG|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
48338430|NCT00003408|BIOLOGICAL|recombinant interferon alfa|
48338431|NCT00003408|BIOLOGICAL|sargramostim|
48338432|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, two days treatment
48496421|NCT00545675|DRUG|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
47979348|NCT02243332|DEVICE|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
47979349|NCT00667004|DRUG|ecabet ophthalmic solution|sterile ophthalmic solution
47979350|NCT00667004|DRUG|placebo|sterile ophthalmic solution
47979351|NCT02069301|BEHAVIORAL|Integrated Depression/Microfinance Group|LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
48338433|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, two days treatment
48338434|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, two days treatment
48338435|NCT00700063|DRUG|Vehicle gel|two days treatment
48338436|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, three days treatment
48496422|NCT03752463|DRUG|DAOI-A group|DAOI with A dose
48496423|NCT03752463|DRUG|DAOI-B group|DAOI with B dose
48496424|NCT03752463|DRUG|DAOI-C group|DAOI with C dose
48496425|NCT03752463|DRUG|Placebo oral capsule|Placebo
48496426|NCT03008486|DEVICE|Real soft splint (6 cm)|
48496427|NCT03008486|DEVICE|Placebo soft splint (1 cm)|
48496428|NCT02598258|OTHER|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
48496429|NCT04408599|DRUG|NC410|NC410 is an experimental antibody drug that may make the immune response more active against cancer
48654949|NCT04573738|PROCEDURE|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
48654950|NCT04573738|PROCEDURE|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
48338437|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, three days treatment
48338438|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, three days treatment
48338439|NCT00700063|DRUG|Vehicle gel|three days treatment
48338440|NCT02569021|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes as a washout period~3. Biphasic pulse stimulation mode (assessment at 0.5hr)~4. Biphasic pulse stimulation mode (assessment at 1hr)~5. Biphasic pulse stimulation mode (assessment at 2hr)~6. Biphasic pulse stimulation mode (assessment at 3hr)"
48338441|NCT02569021|OTHER|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
48338442|NCT02569021|OTHER|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
48338443|NCT02569021|DEVICE|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
48338444|NCT02569021|DEVICE|Trigno wireless system|The Trigno system measure muscle contractions.
48338445|NCT02569021|OTHER|GaitRite walking assessment.|GaitRite records a patients gait pattern.
48338446|NCT04631614|OTHER|Warm up|Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
48131232|NCT03165734|DRUG|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
48131233|NCT03165734|DRUG|Physician's Choice medications|Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
48338447|NCT04631614|OTHER|Passive calf muscle stretching|With the participant lying in the supine position, the physiotherapist will passively perform the ankle dorsiflexion movement to stretch the participant's calf to the limit tolerated by the participant. This procedure will be performed in two repetitions with 30 seconds of held in the stretching position and 30 seconds of rest between repetitions.
48338448|NCT04631614|OTHER|Ankle joint mobilization - weight-bearing mobilization with movement (WB-MWM) technique|To perform the WB-MWM technique, the participant will be instructed to take a weight-bearing position with the tibia in a vertical position. The physiotherapist will be stay in front participant's ankle and will use the hands to stabilize the participant's foot as close as possible to the anterior region of the talus. A rigid belt will be placed on the participant's tibia and around physiotherapist´s hip. Then, the physiotherapist will project his hip backwards to produce a nonpainful anterior tibia glide. The participant will be asked to perform a forward lunge as far as possible without raising heel off the table and without reproducing knee symptoms. After achieving the maximum forward lunge, the participant will be instructed to hold this position for 5 seconds and then return to the starting position. This procedure will be performed in two sets of 10 repetitions with two minutes of rest between sets.
48338449|NCT04631614|OTHER|Clam exercise|The participant will side lying with trunk straight and both hips and knees at 45º and 90º of flexion, respectively. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the abduction and lateral rotation of the hip (keeping the heels in contact) against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
48338450|NCT04631614|OTHER|Hip abduction exercise in side lying|The participant will side lying with trunk straight, both hips in a neutral position and both knee in extension. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the hip abduction against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
48496430|NCT05034341|OTHER|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
48496431|NCT05034341|OTHER|Standard Pre-Surgical Clinical Care|"* Education related to preoperative activity and home-based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
48496432|NCT01383798|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
48496433|NCT01383798|DIETARY_SUPPLEMENT|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
48654951|NCT03163667|DRUG|Placebo|oral tablets
48654952|NCT03163667|DRUG|CB-839|oral tablets
48654953|NCT03163667|DRUG|everolimus|oral tablets
47979352|NCT02069301|OTHER|Treatment as Usual|National Guideline for antidepressant care
48338451|NCT04631614|OTHER|Knee extension exercise in a sitting position|The participant will be seated at the treatment table with the trunk straight and both knees in 90º of flexion. The external resistance will be positioned above the participant's ankle. The individual will be instructed to perform the knee extension at a protective angle (90º-45º of flexion), progressing to full extension (90º-0º of flexion) as long as the full knee extension does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
48338452|NCT04631614|OTHER|Squat exercise|The participant will be stand with the trunk straight, knees in extension and feet hip-width apart. Dumbbells will be used as external resistance.The individual will be instructed to perform the squat movement at a protective angle (0º-45º of knee flexion), progressing to a deep squat (90º of knee flexion) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
48496434|NCT03694366|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
48496435|NCT03945669|PROCEDURE|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
48131235|NCT02054351|DRUG|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
48131236|NCT03664635|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
48131237|NCT06598423|DEVICE|Specialized soft contact lens 1|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 2 in material, comfort, and lens geometry. They differ only in their spectral profile.
48496436|NCT03945669|PROCEDURE|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
48496437|NCT01301586|DRUG|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
48131238|NCT06598423|DEVICE|Specialized soft contact lens 2|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 1 in material, comfort, and lens geometry. They differ only in their spectral profile.
48131239|NCT03488719|DRUG|Metoprolol Succinate 25 MG|A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
48131240|NCT03488719|DRUG|Metoprolol Succinate 50 MG|A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
48131241|NCT03488719|DRUG|Metoprolol Succinate 100 MG|A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
48496438|NCT01301586|DRUG|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
48496439|NCT02693093|DRUG|NI-03|
48496440|NCT02693093|DRUG|Placebo|
48496441|NCT06301061|DEVICE|Equistasi®|Four devices will be attached to the skin according the indication of the investigators for 6 hours/day every day except Thursday and Sunday
48496442|NCT06301061|DEVICE|Sham|Four devices similar to the active one but not able to deliver the microvibration will be applied to the patients
47979353|NCT02069301|OTHER|Livelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
48131248|NCT01888744|DRUG|GnRH agonist|
48131249|NCT01888744|DRUG|GnRH antagonist|
48131250|NCT01888744|DRUG|hP-hMG|
48131251|NCT01888744|DRUG|Human chorionic gonadotropin|induction of final oocyte maturation
48131252|NCT01888744|DRUG|Progesterone|
48131253|NCT02717611|DRUG|ACP-196 (acalabrutinib)|ACP-196 100 mg to be administered orally (PO) twice a day BID.
48131254|NCT05766384|DRUG|Hyperpolarized Xe129|Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
47979354|NCT00147199|DRUG|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
47979355|NCT00147199|DRUG|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
48496443|NCT06301061|DRUG|Gabapentin; Pregabalin; Duloxetine; Amitriptyline|Patients will be treated with drugs (gabapentinoids, Serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, opioids) according to guidelines.
47979356|NCT01957553|DEVICE|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
47979357|NCT01957553|DEVICE|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
47979358|NCT06452654|DRUG|Comirnaty Injectable Product|Vaccination
47979359|NCT06452654|DRUG|Sodium Chloride 0.9% Inj|Vaccination
47979360|NCT03070782|DRUG|ISIS 681257|ISIS 681257 solution for SC injection.
48496444|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
48496445|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
48496446|NCT03525743|DEVICE|NICOM (Non invasive cardiac output monitor)|Non invasive hemodynamic device utilizing bioreactance
48496447|NCT00940797|DRUG|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
48496448|NCT00940797|DRUG|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
47979361|NCT03070782|DRUG|Placebo|Sterile normal saline (0.9% NaCl)
47979362|NCT00425451|DRUG|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
47979363|NCT06292065|DIAGNOSTIC_TEST|Point-of-care gastric ultrasound|Using ultrasound to visualise the gastric antrum in supine position and right lateral decubitus.
47979364|NCT05392998|DEVICE|Cataract surgery with Vivity intraocular lens implantation|Cataract surgery with Vivity intraocular lens implantation
47979365|NCT01045512|DRUG|fluvastatin|40-80mg once daily
47979366|NCT01906203|DEVICE|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
47979367|NCT05010031|RADIATION|Palliative radiotherapy|An initial cohort of 12 evaluable patients will be treated with 4Gyx2, with adaptive dosing planned for expansion cohorts pending the number of failures observed after 6 month observation of the initial cohort.
47979368|NCT05118906|DRUG|BP1.4979 active drug|2 tablets 15 mg of BP1.4979 per day
47979369|NCT05118906|DRUG|Placebo|2 tablets of placebo per day
47979370|NCT00650624|DRUG|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
48131261|NCT06670963|DRUG|Iron|Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)
48131262|NCT06670963|DRUG|EPO|Epoetin alfa 50 units/kg IV 3 times weekly
48131263|NCT06670963|DRUG|0.9 % NaCl|Volume of 0.9% NaCl identical as volume of medications used in experimental arm
48496449|NCT04680234|PROCEDURE|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
48496450|NCT04680234|DEVICE|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
48496451|NCT02330315|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
48496452|NCT02330315|DEVICE|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
48496453|NCT02838511|OTHER|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
47979371|NCT00650624|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
47979372|NCT00650624|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
47979373|NCT00650624|DRUG|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
47979374|NCT01457521|DRUG|Ibuprofen|Ibuprofen
47979375|NCT00923598|DRUG|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
48496454|NCT02838511|OTHER|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
48496455|NCT04660890|DRUG|ALXN2050|ALXN2050 will be administered orally twice daily as powder-in-capsule.
48496456|NCT04660890|DRUG|ALXN2050-matching Placebo|ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
48496457|NCT04660890|DRUG|Moxifloxacin|Moxifloxacin will be administered as a single oral dose.
47979376|NCT03413566|OTHER|Clinical diagnosis|A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
47979377|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
47979378|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
47979379|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
47979380|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
47979381|NCT00099853|DRUG|Vildagliptin|Vildagliptin 50 mg tablets
47979382|NCT00099853|DRUG|pioglitazone|pioglitazone 45 mg qd
47979383|NCT00099853|DRUG|Placebo|Vildagliptin matching placebo
48338453|NCT04631614|OTHER|Forward lunge exercise|The participant will be stand with one lower limb in a long stride forwards of the other limb, trunk straight and both knee in extension. Dumbbells will be used as external resistance. From this position, the participant will be instructed to bend both knees to lower your body at a protective angle (0º-45º of knee flexion), progressing to a greater knee flexion (90º) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
48338454|NCT03374436|BEHAVIORAL|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
48338455|NCT03374436|BEHAVIORAL|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
48338456|NCT03374436|BEHAVIORAL|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
48338457|NCT05718661|BEHAVIORAL|Watching video with virtual glasses|Using Mobile Virtual Glasses; In the preoperative period, after the patient is taken to the surgical service, a virtual reality video will be watched with mobile virtual glasses at the specified time (before going to the operating room on the day of surgery). Measurements will be made before and after the application. Necessary hygiene will be provided before the use of glasses, and the researcher will ensure hand cleaning before entering the patient's room.
47979384|NCT04624568|DEVICE|PAPILOCARE|"Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.~The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.~Smear and HPV test will be perform by all patients at 6 and 12 months."
47979385|NCT03457129|DRUG|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
48496458|NCT04660890|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo will be administered as a single oral dose.
48496459|NCT04725448|DRUG|Toripalimab|240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration
48496460|NCT04725448|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration
48496461|NCT04725448|DRUG|Nab-paclitaxel|260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles
48496462|NCT04725448|DRUG|Carboplatin|AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles
48496463|NCT01414595|GENETIC|DNA analysis|
48496464|NCT01414595|GENETIC|DNA methylation analysis|
48496465|NCT01414595|GENETIC|RNA analysis|
48496466|NCT01414595|GENETIC|gene expression analysis|
48496467|NCT01414595|GENETIC|polymorphism analysis|
48496468|NCT01414595|OTHER|laboratory biomarker analysis|
48496469|NCT01414595|OTHER|medical chart review|
48496470|NCT05433727|DIAGNOSTIC_TEST|videodermoscopy, lesional capillaroscopy|videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.
48496471|NCT03179163|DRUG|Captopril Pill|ACEi+SH
48496472|NCT03179163|DRUG|Enalapril Pill|ACEi
48496473|NCT03179163|DRUG|Hydrochlorothiazide|diuretic
48496474|NCT02933021|OTHER|Blood sample taken|
48496475|NCT02933021|OTHER|Answering a lifestyle questionnaire|
47979386|NCT06323278|BEHAVIORAL|Cognitive training|The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.
47979387|NCT06378463|OTHER|Cognitive remediation + active tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive active brain stimulation."
48496476|NCT02933021|OTHER|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
48338458|NCT05718661|BEHAVIORAL|watching video without virtual glasses|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded.
48338459|NCT01665768|DRUG|Everolimus|The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
48338460|NCT01665768|BIOLOGICAL|Rituximab|375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
48654954|NCT05745285|OTHER|LLS Program|The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
48338461|NCT05806112|BEHAVIORAL|Resiliency Training|"The Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) has been shown to be effective in improving resilience and reducing distress among individuals across different populations and settings. The SMART-3RP enhances resilience by 1) teaching tools to elicit the relaxation response (RR) to offset negative effects of chronic stress; 2) improving stress management and awareness; and 3) promoting growth enhancement and agency to effect positive change. It blends stress coping principles from mind-body, cognitive-behavioral, and positive psychology theory to teach skills to advance each of these resiliency processes. The training will be delivered in six 50-minute virtual group sessions with 2 optional booster sessions available for those who desire additional sessions to further consolidate the core resiliency skills."
48654955|NCT06437366|BEHAVIORAL|Nurse-Led Heart Math Training Program|"he nurse-led HeartMath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment:~Heart-Focused Breathing Techniques: Patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence.~Emotional Regulation Skills: The training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress."
48654956|NCT06644131|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate
48654957|NCT06644131|DIETARY_SUPPLEMENT|Sugar Pill (Placebo)|Placebo - sugar pill
48338462|NCT05806112|BEHAVIORAL|Task Sharing|"Task Sharing is a process involving health care workers in partnership with others in which workers retain many of their primary tasks, but some tasks are completed collaboratively or by other workers or volunteers in a shared effort. Study coaches will work with the group home directors and RCWs to identify shared tasks that may be conducted by peers or resident volunteers by task co-assignment with supervision and support. Task co-assignments will be discussed in routine house meetings occurring on a weekly basis and incorporated into a jointly developed house plan. The house plan will engage staff and residents to identify shared activities to reduce the burden on RCWs through task co-assignment and team-based efforts aimed at tasks that create unnecessary burden and stress for RCWs, yet do not require RCWs to complete them."
48654958|NCT01556334|DRUG|Azithromycin|Azithromycin 1g po
48496477|NCT05717530|PROCEDURE|wound site local anesthesic infiltration|: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
48654959|NCT01556334|DRUG|Erythromycin|Erythromycin IV then PO
48654960|NCT04656340|OTHER|non-medication, non-interventional therapies|non-medication, non-interventional therapies
48654961|NCT06642805|PROCEDURE|duodenal atresia|surgery for duodenal atresia
48654962|NCT02168699|OTHER|Ultrasound examination of the axilla|
48654963|NCT06643806|BEHAVIORAL|CHAI dyad study|In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
48654964|NCT04813120|BEHAVIORAL|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.
48131270|NCT05178420|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
48131273|NCT05985200|DRUG|BI 3032950|BI 3032950
48131274|NCT05985200|DRUG|Placebo matching BI 3032950|Placebo matching BI 3032950
48654965|NCT04813120|BEHAVIORAL|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.
47979388|NCT06378463|OTHER|Cognitive remediation + sham tDCS|"The cognitive remediation program Computerised Interactive Remediation of Cognition - a Training for Schizophrenia (CIRCuiTS) improves cognitive and metacognitive skills and strategies and is specifically aimed at the generalization of newly learnt skills to daily life. This method also offers the possibility to personalize the training program based on individual goals and cognitive functioning of the service user.~Transcranial Direct Current Stimulation is used to promote neural plasticity, which applies a small electrical current over the cortex. This can alter the excitability of neurons, such that it increases or decreases spontaneous network activity. When applied to fronto-parietal neural networks simultaneously with their engagement in cognitive tasks of CIRCuiTS, it is expected that plasticity of these networks will be modulated, resulting in improvements in cognitive functioning.~In this condition, participants will receive sham brain stimulation."
47979389|NCT03579160|DRUG|0.25% timolol gel with full-thickness skin grafts|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
48131275|NCT04448652|DRUG|NSAID|no other intervention than described in the groups.
48338463|NCT05806112|BEHAVIORAL|Workplace Improvement Learning Collaborative|The Workplace Improvement Learning Collaborative (WILC) consists of identifying major sources of RCW burnout across the system and then instituting an organizational (agency-wide) measure to address the identified sources of burnout by restructuring tasks (e.g., reducing administrative burdens, increasing workflow efficiencies) through a virtual earning collaborative with group home leaders. Learning collaboratives commonly use a structured framework within which teams learn about research and best practices, apply quality-improvement methods, and exchange their experiences in making improvements with the widespread use of such collaboratives. Program Directors will participate in a learning collaborative facilitated by trained and certified study coaches to identify and collaboratively develop and implement effective strategies to address root causes of RCW burnout across group homes and program directors assigned to the WILC intervention.
48338464|NCT04128527|DEVICE|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
48338465|NCT05433636|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
48654966|NCT04813120|BEHAVIORAL|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.
48131277|NCT06221215|PROCEDURE|trauma|The main purpose of this study is to observe whether the early hormone changes and trends in the two groups of patients with or without trauma.
48131278|NCT06078696|DRUG|Siplizumab|Premedication with diphenhydramine 50 mg PO is to be given 1 hour prior to siplizumab infusion. Premedication with hydrocortisone succinate 100 mg IV infused over 30 minutes and acetaminophen 650 mg PO are to be given at least 30 minutes prior to siplizumab infusion. Siplizumab 4.8 mg/kg total is given on Day -14 and 0.6mg/kg is given on days -6, -1, 0, and +1. It will be given as an IV infusion over 1 hour.
48131279|NCT06078696|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
48131280|NCT06078696|PROCEDURE|Total Body Irradiation|Radiation dose is 2Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
48131281|NCT06078696|PROCEDURE|Stem Cell Infusion|Standard institutional procedures should be followed for the processing and administration of stem cell products for infusion. The infused graft under no circumstances is to be irradiated. No in-line leukocyte filter should be used and no medications or fluids should be given piggyback through the catheter lumen used for infusion of stem cells. Vital signs should be monitored before beginning the infusion and periodically during administration and in accordance with institutional guidelines. Pre-medications prior to the graft infusion will be according to the institutions standard practice. Benadryl, epinephrine, hydrocortisone, and oxygen be available at the bedside, as well as an emergency medical code cart available in the vicinity of the patient, for emergency use in case of an infusion reaction.
48338466|NCT05433636|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
48338467|NCT05433636|BEHAVIORAL|Mindfulness of Discomfort|Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
48338468|NCT05433636|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
48338469|NCT05433636|BEHAVIORAL|Integrative Health Recording|Patients will listen to a 5-minute, audio-recorded description of integrative health.
48338472|NCT00997555|PROCEDURE|bronchoscopy|Scheduled bronchoscopy.
47979390|NCT03579160|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
47979391|NCT03932721|DRUG|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
47979392|NCT03140384|BIOLOGICAL|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
48654967|NCT04813120|BEHAVIORAL|Traditional MT using a mirror box|During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
47979393|NCT03283592|OTHER|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
47979394|NCT03283592|OTHER|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
47979395|NCT03723759|DRUG|Faster Aspart 200 U/mL|A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
47979396|NCT03723759|DRUG|Faster aspart 100 U/mL|A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
47979397|NCT03171792|OTHER|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
47979398|NCT01386554|DRUG|Repository Corticotropin Injection|Acthar given SC for 6 months
48131282|NCT06078696|DRUG|Cyclophosphamide 50mg|Cyclophosphamide will be given on days +3 and +4 at a dose of 50 mg/kg. Hydration prior to cyclophosphamide should be given according to standard institutional practice. Day +3 dose should occur between 60 and 72 hours after graft infusion and day +4 post-transplant should occur approximately 24 hours after prior dose. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume or as per institutional standard practice. Cyclophosphamide will be dosed according to adjusted ideal body weight (AIBW) in patients weighing \> 125% ideal body weight (IBW).
48131283|NCT06078696|DRUG|Mesna|Mesna is to be given starting 1 hour prior to cyclophosphamide at the same dose (50 mg/kg) as a continuous infusion over 24 hours.
48131284|NCT06078696|DRUG|Sirolimus Oral Tablet|Sirolimus will be given orally with a loading dose of 12 mg, then followed by 4 mg orally daily. Dosage will be adjusted to a therapeutic target of 10 - 15ng/ml in first 3 months post transplant and 3-10 after 3 months. Sirolimus should be started on day +5. It will be continued until at least day 180. Sirolimus can be tapered or continued according to the treating physician discretion and the presence of absence of GVHD and/or degree of donor chimerism. Sirolimus should be continued if donor chimerism is less than 50% to prevent graft loss.
48131285|NCT06078696|DRUG|Rituximab or Biosimilar|Rituximab (375 mg/m2/dose) will be administered on Days -14 and -6. In those subjects receiving ongoing renal replacement therapy, rituximab should be administered several hours after hemodialysis. The first rituximab solution for infusion should be administered intravenously at an initial rate of 50 milligrams/hour (mg/hr). The rate may be escalated by 50mg/hr every 30 minutes to a maximum of 400 mg/hr. Subsequent infusions may be started at 100 milligrams/hour (mg/hr) and titrated by 100 mg/hr every 30 minutes to a maximum of 400mg/hr if the subject tolerated the first infusion.
48654968|NCT02457546|BIOLOGICAL|EVICEL Fibrin Sealant|
48654969|NCT02457546|DEVICE|Hydrogel sealant|
48654970|NCT01251055|DRUG|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
48654971|NCT01251055|DRUG|Placebo|starch
48654972|NCT04692779|OTHER|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
48654973|NCT06638684|OTHER|Exercise|Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
47979399|NCT01386554|DRUG|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week)."
47979400|NCT01705821|DEVICE|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
47979401|NCT01705821|PROCEDURE|Removal of pituitary tumor using modified curette|
47979402|NCT03341949|BIOLOGICAL|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
47979403|NCT00560976|DRUG|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
47979404|NCT05608889|BEHAVIORAL|Total Worker Health Mindfulness Enhanced Program|"The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support."
47979405|NCT04590365|DEVICE|Carrageenan nasal and throat spray|Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)
47979406|NCT04590365|DEVICE|Saline nasal and throat spray|Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
48131288|NCT06252402|BIOLOGICAL|CMV/HIV-CAR T Cells|Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.
47979407|NCT05945043|OTHER|Surface parasternal eletromyogram|The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
47979408|NCT05945043|OTHER|Surface diaphragm electromyogram|The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal
47979409|NCT05945043|OTHER|Parasternal muscle ultrasound|The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal
47979410|NCT05945043|OTHER|Breathlessness assessment|The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
47979411|NCT01490957|OTHER|Database|Database
47979412|NCT02656121|DRUG|Vitamin D|6000 IU of vitamin D3
47979413|NCT02656121|DRUG|Ovulatory Agent|only Clomophine Citrate
47979414|NCT00503802|PROCEDURE|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
47979415|NCT00503802|PROCEDURE|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
47979416|NCT04085068|OTHER|cranioscaral treatment|dural release
47979417|NCT04850131|PROCEDURE|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
47979418|NCT02064868|DRUG|Serelaxin|30 µg/kg/day IV infusion
48496478|NCT05717530|PROCEDURE|Erector spina plane block|Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
48496479|NCT05520320|DEVICE|Hypothermic oxygenated machine perfusion (any device)|After static cold storage, all grafts included in this study are subjected to \>1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
47979419|NCT02064868|DRUG|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
47979420|NCT05533281|DRUG|tropisetron|One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
47979421|NCT05533281|DRUG|metoclopramide|One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
47979422|NCT05533281|DRUG|dexamethasone|One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
47979423|NCT05533281|OTHER|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
47979424|NCT01624454|OTHER|Laxabon|4 l PEG solution split dose cleansing
47979425|NCT01624454|OTHER|CitraFleet|Small volume osmotic bowelcleansing
47979426|NCT00001105|DRUG|F105 Monoclonal Antibody (Human)|
47979427|NCT04101825|DEVICE|Auralya|Hyaluronic Acid-Dermal Filler
47979428|NCT04542772|OTHER|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
47979429|NCT04542772|OTHER|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
48496480|NCT05451186|OTHER|Eye patch and headphones|Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
48496481|NCT02538848|DRUG|HTD4010|injectable solution
48131289|NCT06662968|OTHER|Lollipop group|In the Lollipop group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were given lollipops for sucking without chewing after waking up.Throughout the entire sucking process, we continuously monitor vital signs.
48338473|NCT00947934|DEVICE|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
48338474|NCT03326661|PROCEDURE|Aspiration|Needle aspiration of pus from the peritonsilar abscess
48338475|NCT03326661|PROCEDURE|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
48496482|NCT05275803|DIETARY_SUPPLEMENT|Probiotics|The participant would receive non-surgical periodontal treatment, after which the participant uses probiotics (BioGaia Prodentis, L. reuteri DSM 17938+L. reuteri ATCC 5289, 0.8g, qn) for another 30 days.
48338476|NCT03326661|DRUG|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
48496483|NCT05275803|DIETARY_SUPPLEMENT|Control|The participant does not use probiotics after non-surgical periodontal treatment.
48131290|NCT06662968|OTHER|Control group|In the Control group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were received routine nursing treatment.
48131291|NCT04724759|DRUG|Dexmedetomidine / Ketamine / Lidocaine|Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
48131292|NCT06612840|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
48496484|NCT00172536|BEHAVIORAL|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
48496485|NCT00172536|OTHER|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
48338477|NCT04362813|DRUG|Canakinumab|Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
48338478|NCT04362813|DRUG|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
48338479|NCT03374813|DEVICE|MimetikOss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
48338480|NCT03374813|DEVICE|Bio-Oss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
48338481|NCT00790530|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
48338482|NCT00790530|OTHER|Usual Care|Usual Care
48496486|NCT05656521|DRUG|101-PGC-005|'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
48496487|NCT05656521|DRUG|Dexamethasone|Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
48496488|NCT04111406|DRUG|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
48496489|NCT04111406|DRUG|Protocol based|"Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage"
48496490|NCT05617937|OTHER|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
48496491|NCT00132093|DRUG|Eplerenone|
48496492|NCT01394952|DRUG|Dulaglutide|Administered subcutaneously
48496493|NCT01394952|DRUG|Placebo|Administered subcutaneously
48496494|NCT01430793|DRUG|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
48496495|NCT01430793|DRUG|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
48496496|NCT01430793|DRUG|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
48496497|NCT01430793|DRUG|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
48496498|NCT01678053|DRUG|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
48496499|NCT01678053|DRUG|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
48496500|NCT01059539|DRUG|Cariprazine|Cariprazine was supplied in capsules.
48338483|NCT03947255|DRUG|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
48338484|NCT01674738|DRUG|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
48338485|NCT01674738|DRUG|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
48338486|NCT01674738|DRUG|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
47979430|NCT06314542|OTHER|relaxing eligibility criteria|Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data
47979431|NCT03886350|OTHER|blood and sputum samples|Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
48338487|NCT05428553|PROCEDURE|Endoscopic resection: CSP/p-CSP|Patients in the experimental arm will be assigned to receive CSP/p-CSP.
47979432|NCT00891254|DEVICE|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
47979433|NCT03241342|DRUG|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
47979434|NCT03241342|DRUG|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
48496501|NCT01697566|DRUG|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
48496502|NCT01697566|OTHER|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
48496503|NCT01697566|PROCEDURE|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
48338488|NCT05428553|PROCEDURE|Endoscopic resection: EMR/EPMR|Patients in the historical control arm have already finished EMR/EPMR
48338489|NCT06167278|OTHER|Indirect bonding with two different digital bracket bonding transfer tray|"To achieve more precise and predictable result is the common aim in contemporary treatment. Digital indirect bonding (IDB) is used for this purpose in orthodontic treatment. The aim of this study is to compare the transfer accuracy of two different IDB trays.~Digital IDB was performed on a total of 30 patients, using one of the two designs: shell and bar trays; with 15 patients in each group. Trays were designed with the Appliance Designer software (3Shape A/S, Copenhagen, Denmark) as shell and bar types."
48338490|NCT01711541|DRUG|Carboplatin|Given IV
48338491|NCT01711541|DRUG|Cisplatin|Given IV
48496504|NCT01697566|BEHAVIORAL|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
48496505|NCT01697566|BEHAVIORAL|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
48654974|NCT06639945|DEVICE|transcranial MR-guided focused ultrasound|MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.
48654975|NCT06362629|BEHAVIORAL|Artificial Intelligence assistant decision-making system (AIADMS) App|Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
48654976|NCT01257750|DRUG|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
48496506|NCT01330771|DRUG|hMG-HP/r-FSH|
48131310|NCT06645665|BIOLOGICAL|Bivalent RSV Vaccine (IN006)|Formulation for injection
48131311|NCT06645665|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48338492|NCT01711541|DRUG|Fluorouracil|Given IV
48338493|NCT01711541|DRUG|Hydroxyurea|Given PO
48338494|NCT01711541|OTHER|Laboratory Biomarker Analysis|Correlative studies
48338495|NCT01711541|DRUG|Paclitaxel|Given IV
48338496|NCT01711541|OTHER|Placebo Administration|Given PO
48338497|NCT01711541|RADIATION|Radiation Therapy|Undergo radiation therapy
48338498|NCT01711541|DRUG|Veliparib|Given PO
48496507|NCT05001932|PROCEDURE|Cataract surgery|Randomized Clinical Trial
48131313|NCT05552976|DRUG|Mezigdomide|Specified dose on specified days
48131314|NCT05552976|DRUG|Carfilzomib|Specified dose on specified days
48131315|NCT05552976|DRUG|Dexamethasone|Specified dose on specified days
48131316|NCT05167318|OTHER|frequent standardized oral care|Standardized oral care will be provided every 3-4 hours
48338499|NCT02583997|PROCEDURE|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
48338500|NCT02583997|PROCEDURE|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
48338501|NCT05009238|OTHER|lumbar stabilization exercises|selected exercises will taught to participant and practiced 3 times per week for 6 weeks
48338502|NCT05170672|BIOLOGICAL|Abatacept|
48338503|NCT04717895|DIAGNOSTIC_TEST|Rocking environment forward (B) followed by a translation environment|Start by the virtual reality session by viewing a rocking environment followed by a translation environment
48338504|NCT04717895|DIAGNOSTIC_TEST|Translation environment followed by a rocking environment|Start by the virtual reality session by viewing a translation environment followed by a rocking environment
48338505|NCT04104061|OTHER|iron profile|blood test
48338506|NCT00149383|DRUG|Rosiglitazone|
48338507|NCT00149383|DRUG|Placebo|
48496508|NCT06411587|DIAGNOSTIC_TEST|Ultrasound imaging and functional assessment|Participants in this study will undergo two types of assessments: capturing muscle images using ultrasound and evaluating their function through clinical scales.
48496509|NCT00466830|OTHER|questionnaire administration|
48496510|NCT00466830|PROCEDURE|management of therapy complications|
48496511|NCT00466830|PROCEDURE|psychosocial assessment and care|
48496512|NCT00466830|PROCEDURE|quality-of-life assessment|
48496513|NCT01023191|PROCEDURE|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
48338508|NCT03481569|OTHER|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
48338509|NCT05152667|DEVICE|levonorgestrel-releasing intrauterine device (LNG-IUS)|Intervention is administered proceeding the ICSI
48338510|NCT01754285|DRUG|LF-PB and Placebo|
48496514|NCT01023191|PROCEDURE|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
48496515|NCT02119286|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
48496516|NCT02119286|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
48338511|NCT01754285|DRUG|Placebo|
48338512|NCT01754285|DRUG|LF-PB|
48496517|NCT02119286|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
48496518|NCT02119286|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
48654977|NCT06569485|DRUG|Trilaciclib+R-CHOP|This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
48654978|NCT04577703|DRUG|CT053PTSA|CT053PTSA will be administered daily in fasting state
48654979|NCT00944645|DRUG|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
48654980|NCT00944645|DRUG|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
48654981|NCT02607163|DRUG|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
48654982|NCT02607163|DRUG|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
48654983|NCT03891446|DRUG|Bimatoprost SR|Intraocular implant
48496519|NCT03967496|PROCEDURE|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
48338513|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
48338514|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
48496520|NCT03967496|PROCEDURE|Access of Surgery|Type of surgical access
48496521|NCT03967496|OTHER|Comorbidities|A patient may have more than one comorbidity
48496522|NCT03967496|DRUG|Preoperative Medication|Preoperative medications
48496523|NCT03967496|DIAGNOSTIC_TEST|Routine blood test|Preoperative and Intraoperative Investigations
48496524|NCT06219590|PROCEDURE|Acetylcholine Iontophoresis|Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
48654984|NCT03891446|OTHER|Standard of Care|Standard of care treatment based on investigator's judgement.
47979435|NCT01569178|PROCEDURE|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
48496525|NCT06219590|PROCEDURE|Shame Acetylcholine Iontophoresis|Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
48496526|NCT01562340|OTHER|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
48496527|NCT01562340|OTHER|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
48496528|NCT00953641|DRUG|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
48654985|NCT06561087|DRUG|Nivolumab|Given by injections
48654986|NCT03787147|DEVICE|Google Cardboard|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
48654987|NCT03787147|DEVICE|Oculus|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
47979436|NCT05025761|OTHER|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
47979437|NCT00136656|DRUG|antibiotic|cephalosporine by oral route : cefixime
47979438|NCT00136656|DRUG|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
47979439|NCT05303636|DRUG|LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet|LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
47979440|NCT00822250|OTHER|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
47979441|NCT02853591|PROCEDURE|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
48338515|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
48496529|NCT00953641|DRUG|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
47979442|NCT02763189|OTHER|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
47979443|NCT02763189|OTHER|Self-study|All subjects will receive self-study
47979444|NCT01324336|DRUG|6-Mercaptopurine|75 mg/m2/dose/day
47979445|NCT01948050|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|
47979446|NCT00691821|OTHER|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
48496530|NCT04498403|DRUG|Crisaborole 2%|Crisaborole 2% ointment
48496531|NCT05152628|DRUG|Tacrolimus granules|Oral
48496532|NCT03933436|OTHER|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
48496533|NCT03933436|OTHER|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
48496534|NCT03934320|OTHER|FAMCAT|The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
48654988|NCT03787147|DRUG|Lidocaine Hydrochloride|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
48496535|NCT04442490|DRUG|SAGE-217|SAGE-217 oral capsules.
48496536|NCT04442490|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
48496537|NCT00299936|DRUG|Ribavirin, PEG-Intron|
48654989|NCT03787147|DRUG|Bupivacaine|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
47979447|NCT00691821|DEVICE|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
47979448|NCT03283228|DIAGNOSTIC_TEST|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
47979449|NCT01401270|BEHAVIORAL|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
48496538|NCT04645810|PROCEDURE|High-Dose-Rate Brachytherapy|High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
48496539|NCT04314414|OTHER|PRC brief motivational interview intervention|The intervention will involve the following elements: establishing rapport, asking permission to discuss drugs, discussing the pros and cons associated with drug use, uncovering the gaps between current and desired quality of life and determining readiness to change. The intervention will last approximately 20 minutes and take place at the time of the clinical visit while participants are waiting to be seen by a clinician or are awaiting laboratory testing.
48496540|NCT04314414|OTHER|Phone contact|The PRC will remain in at least weekly contact by phone with each participant.
48496541|NCT00523965|DRUG|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
48654990|NCT06499181|DRUG|Liposomal bupivacaine|The primary objective is to examine differences in post-operative opioid consumption between the two groups.
48654991|NCT06499181|DRUG|Bupivacain|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
48131329|NCT06046859|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
48338516|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
48338517|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
48338518|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
48338519|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
48338520|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
48338521|NCT03261570|DRUG|Pyridostigmine|60mg by mouth
48338522|NCT03261570|DRUG|Digoxin|0.5 (500mcg) by mouth
48338523|NCT03261570|DRUG|Placebo|Lactulose 50mg by mouth
48496542|NCT00523965|DRUG|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg
48496543|NCT00523965|DRUG|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
48496544|NCT00523965|DRUG|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
48496545|NCT01523457|DRUG|Folfirinox|"* Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
48496546|NCT01682616|DRUG|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
48654992|NCT06499181|DRUG|Epinephrin|Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
48131330|NCT06046859|DRUG|Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
48496547|NCT01682616|DRUG|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
48496548|NCT01141244|DRUG|temsirolimus|Given IV
47979450|NCT05725109|OTHER|Hepatitis C Treatment Alerts in CHORUS™|Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.
47979451|NCT05725109|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
47979452|NCT04537767|DRUG|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
47979453|NCT04537767|DRUG|Placebo|Placebo
47979454|NCT04655274|DIAGNOSTIC_TEST|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
47979455|NCT02781922|GENETIC|Autologous cardiac stem cells (JRM-001)|3x 10\^5 cells/kg, single treatment
47979456|NCT06379477|PROCEDURE|Refractive surgeries|after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options
47979457|NCT03111901|DRUG|Pembrolizumab|Pembrolizumab solution
47979458|NCT03111901|DRUG|Interleukin-2|Interleukin-2 solution
47979459|NCT01988792|DIETARY_SUPPLEMENT|Human milk fortifiers|
47979460|NCT01711970|DRUG|Paclitaxel|
47979461|NCT04465539|DRUG|Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]|Hydroxyethyl starch dose is 500 cc in 6 hours
47979462|NCT04465539|DRUG|Hydrocortisone|Hydrocortisone dose is 200-300 mg /day intravenously
47979463|NCT04465539|DRUG|Placebo|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
47979464|NCT05825846|DEVICE|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (\~2 min) involves the participant physically walking down a \~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
48338524|NCT06196619|DIAGNOSTIC_TEST|SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level|Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
48338525|NCT03846167|DRUG|Imaging Drug FluorThanatrace (FTT)|\[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
48496549|NCT01141244|DRUG|temozolomide|Given orally
48496550|NCT01141244|DRUG|irinotecan hydrochloride|Given IV
48654993|NCT06633991|PROCEDURE|verbal instructions|verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
47979465|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 11
47979466|NCT05497674|DRUG|Rifampin|QD for 10 days
47979467|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 6
47979468|NCT05497674|DRUG|Probenecid|twice a day, for 5 days
47979469|NCT03331419|BEHAVIORAL|Exercise test|30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
47979470|NCT03649464|DRUG|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
48496551|NCT01141244|OTHER|laboratory biomarker analysis|Correlative studies
48496552|NCT00167687|DRUG|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
48496553|NCT01584843|DRUG|GSK1358820|IM injection of Botulinum Toxin Type A
48496554|NCT06185335|GENETIC|ANB-010, dose 1|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.
48496555|NCT06185335|GENETIC|ANB-010, dose 2|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 2.
48496556|NCT06185335|GENETIC|ANB-010, dose 3|Adeno-associated viral vector carrying the FVIII gene single infusion at dose 3.
48496557|NCT00005809|PROCEDURE|computed tomography|
48496558|NCT00005809|PROCEDURE|diagnostic colonoscopy|
48496559|NCT04096508|BEHAVIORAL|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
48496560|NCT00324766|DRUG|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
48338526|NCT05022472|BEHAVIORAL|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration \[2-dose series and importance of vaccine completion\]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
48338527|NCT05022472|BEHAVIORAL|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
48338528|NCT05022472|BEHAVIORAL|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
48338529|NCT05022472|BIOLOGICAL|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
48338530|NCT00113711|BEHAVIORAL|smoking cessation|
48338531|NCT00113711|BEHAVIORAL|reducing diet|
48338532|NCT01002898|DRUG|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
48338533|NCT02560493|BEHAVIORAL|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
48496561|NCT00324766|DRUG|placebo,|24 h, infusion
48496562|NCT02712060|OTHER|No intervention|
48496563|NCT00568815|DRUG|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
48496564|NCT05192694|PROCEDURE|Computed tomography|Positron Emission Tomography
48496565|NCT03996161|OTHER|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
48496566|NCT04551833|DRUG|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
48496567|NCT05067530|DRUG|Palbociclib|CDK4/6 inhibitor
48496568|NCT05067530|DRUG|Paclitaxel|Chemotherapy
47979471|NCT05711849|BIOLOGICAL|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.|Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).
47979472|NCT05711849|PROCEDURE|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).|These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
47979473|NCT05196165|OTHER|No Intervention|No investigational product (IP) will be administered in this study
48496569|NCT05067530|DRUG|Carboplatin|Chemotherapy
48338534|NCT02969538|OTHER|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
48338535|NCT02969538|OTHER|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
48496570|NCT00386763|DRUG|Artemether-lumefantrine|
48496571|NCT04249544|DRUG|Pramipexole|1mg of pramipexole
48496572|NCT04249544|DRUG|Placebo|1mg equivalent of placebo
48496573|NCT03370016|PROCEDURE|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
48496574|NCT04023643|OTHER|Ventilation Weaning|Use of different weaning strategies
48496575|NCT00201955|DRUG|Rebamipide|
48654994|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 12|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
48654995|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 3|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
48654996|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 6|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
48654997|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 24|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
48131344|NCT06033833|DRUG|Amlitelimab|Injection Solution: by subcutaneous injection (SCI)
48131345|NCT06033833|DRUG|Placebo|Injection Solution: by subcutaneous injection (SCI)
48496576|NCT05715983|PROCEDURE|Bascom II procedure|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide was injected in all orifices to visualize all tracts and sinuses. The proposal area of incision is marked nearby sinus tract openings and the skin with lateralization on one side of the cleft. A vertical-orientated incision of the skin and subcutaneous fat around the primary and secondary orifices is made using a scalpel or a monopolar electrocautery. The sinus tract is excised in en-block till unchanged subcutaneous tissue. The wound is irrigated with antiseptic solution. If postoperative wound is larger than 5 cm then a silicone draining tube is placed through the contraperature in the upper corner. The wound is closed by interrupted sutures Vicryl/Polysorb 2/0 3/0 layer by layer. Aseptic dressing is applied to the closed wound.
48654998|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 21|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
48338536|NCT06153069|DRUG|Short-course regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
48338537|NCT06153069|DRUG|Standard regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
48338538|NCT05337150|BEHAVIORAL|Lifestyle Modification Intervention|For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
48338539|NCT05337150|BEHAVIORAL|Balanced Calorie Deficit Eating Plan|Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
48654999|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 18|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
48655000|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 15|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
47979474|NCT01275391|BEHAVIORAL|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
47979475|NCT01948453|DIETARY_SUPPLEMENT|Garlic|Garlic tablet in adjunct to medical treatment
47979476|NCT05253170|RADIATION|Hypofractionation|Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
47979477|NCT05253170|RADIATION|Conventional Fractionation|Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
47979478|NCT02596191|OTHER|Clinical evaluation|
47979479|NCT02596191|OTHER|electrophysiological record|
47979480|NCT02596191|OTHER|Muscle MRI|
47979481|NCT02596191|OTHER|blood samples analysis|
47979482|NCT03362476|BEHAVIORAL|Computer-based alcohol reduction intervention|Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
47979483|NCT03362476|BEHAVIORAL|Brief clinician-delivered MET|Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
47979484|NCT03362476|BEHAVIORAL|Standard of care|Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
47979485|NCT06145776|OTHER|tDCS + tredmill training (Standart trehab training)|Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.
47979486|NCT06145776|OTHER|Cognitite-motor Dual Task Training (DT training)|The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
47979487|NCT03902197|BIOLOGICAL|CD19 hsCAR-T|CD19 hsCAR-T will be administered by I.V. infusion
47979488|NCT01580618|DRUG|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
47979489|NCT01580618|DRUG|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
48131348|NCT03409159|DEVICE|LAAC|Left atrial appendage closure
48131352|NCT06593938|DRUG|HRS-5965 capsule|HRS-5965 capsule for 24 weeks
48131353|NCT06593938|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
48338540|NCT05337150|BEHAVIORAL|Ad Libitum Whole Food Plant-Based Eating Plan|Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
48496577|NCT05715983|PROCEDURE|SiLaC|Buttocks are strapped apart with wide adhesive tape. The area is prepared using antiseptic solution twice. Solution of brilliant green with 3% hydrogen peroxide is injected in all orifices to visualize all tracts and sinuses. All visible orifices are excised with a scalpel or dermo punch. After that hairs are removed from the sinus by Volkmann curette. A metallic stylet is used to determine the length and direction of the different tracts. Then laser destruction of the sinus is performed with FiberLase VT laser, wavelength 1460 or 1520 nm, the laser energy 10-12 Watts. The fiber delivers energy homogeneously in a continuous way. Hemostasis by electrocautery. The wound is washed with povidone-iodine solution. Aseptic dressing is applied.
48496578|NCT04842565|DRUG|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
48496579|NCT04842565|DEVICE|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
48338541|NCT00116987|DEVICE|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
48338542|NCT00116987|DEVICE|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
48338543|NCT00821860|OTHER|talc|Talc pleurodesis
48338544|NCT00821860|PROCEDURE|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
48338545|NCT00821860|PROCEDURE|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
48338546|NCT05452317|OTHER|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
48338547|NCT05452317|OTHER|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
48338548|NCT03006081|DRUG|Intravitreal Aflibercept injection|Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
48338549|NCT00696098|OTHER|sodium butyrate|1 enema (60 ml) once daily containing 100mM
47979490|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 13|HBM9161 680 mg qw by q2w from week 13
48496580|NCT02116426|BIOLOGICAL|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
48496581|NCT02116426|BIOLOGICAL|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
48496582|NCT02116426|BIOLOGICAL|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
47979491|NCT05015127|DRUG|Placebo|Placebo
48496583|NCT04293094|DRUG|AMG 650|AMG 650 administered orally as a tablet.
47979492|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 7|HBM9161 680 mg qw by q2w from week 7
47979493|NCT05015127|DRUG|Placebo|Placebo qw by HBM9161 680mg qw from week 12
47979494|NCT05370222|BEHAVIORAL|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
48338550|NCT00696098|OTHER|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
48338551|NCT03753204|DRUG|Furosemide 40 mg|Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
48338552|NCT05941676|DIAGNOSTIC_TEST|Tumour immunoprofile evaluation|Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
48496584|NCT04112173|BEHAVIORAL|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
48496585|NCT01713049|DRUG|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
48496586|NCT04425538|DRUG|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
48496587|NCT02317614|BEHAVIORAL|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
47979495|NCT05615974|DRUG|LM101|Administered intravenously
48338553|NCT02480504|OTHER|dietary intervention intermittent energy restriction|Randomized clinical trial
48338554|NCT02480504|OTHER|continuous energy restriction|
48338555|NCT06294041|BEHAVIORAL|Sleep Restriction Therapy (SRT)|SRT is a manualised, adaptive, behavioural insomnia intervention that is a key active ingredient within multi-component CBT-I. Our SRT protocol involves standardising and (where required) limiting a patient's time in bed with the aim of increasing homeostatic sleep pressure, over-riding cognitive and physiological arousal, and strengthening circadian control of sleep. Those randomised to the SRT arm will receive two online sessions supported by two telephone calls over a 4-week intervention phase. The intervention will be delivered by trained research nurses
48496588|NCT04280705|OTHER|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
48496589|NCT04280705|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
48496590|NCT02098096|OTHER|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~1. Familiarization~2. Acclimatization~3. Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
48496591|NCT02098096|OTHER|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
48496592|NCT03349008|DRUG|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
48496593|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
48496594|NCT03349008|DRUG|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
48496595|NCT03349008|DRUG|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
48496596|NCT03349008|DRUG|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
48496597|NCT02585934|DRUG|RVT-101|once daily, oral, 35 mg tablets
48496598|NCT02585934|DRUG|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
48496599|NCT01909830|DRUG|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
48655001|NCT02248493|DRUG|Paracetamol|
48496600|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Ropivacaine|
48496601|NCT02939833|PROCEDURE|Scalp Nerve Blocks With Saline|
48655002|NCT02248493|DRUG|Placebo (for paracetamol)|
48655003|NCT02248493|DRUG|Ketoprofen|
47979496|NCT05615974|DRUG|Toripalimab|Administered intravenously
47979497|NCT05615974|DRUG|Rituximab|Administered intravenously
47979498|NCT05615974|DRUG|Envafolimab|Administered intravenously
47979499|NCT03258151|GENETIC|detection of genotype|detection of genotype by next generation sequencing
47979500|NCT03117712|DIAGNOSTIC_TEST|Delirium Scores|"* Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5"
48496602|NCT03688438|DEVICE|Closed-Incision Negative-Pressure Therapy|A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
48496603|NCT01367665|DRUG|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
48496604|NCT01176708|DRUG|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
47979501|NCT03117712|DIAGNOSTIC_TEST|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB"
48496605|NCT01176708|OTHER|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
48655004|NCT02248493|DRUG|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
48655005|NCT02248493|DRUG|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
48655006|NCT06087536|DRUG|OMN6|"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"
48655007|NCT06087536|DRUG|Placebo|3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
48655008|NCT05819801|OTHER|Non-fasting|Instructing patients to eat before their local-only procedure
48655009|NCT05819801|OTHER|Fasting|Instructing patients to fast before their local-only procedure
48338556|NCT06294041|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Patients in the SHE condition will be instructed to implement the SHE advice over a 4-week period. One week after randomisation to SHE, the RA will telephone patients to check they understand the SHE advice and answer any questions they may have. SHE has successfully been used as a control condition in other trials evaluating SRT and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to SRT.
48338557|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
48338558|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
48496606|NCT01176708|OTHER|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
47979502|NCT03117712|DIAGNOSTIC_TEST|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation"
47979503|NCT02099357|DIETARY_SUPPLEMENT|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
48496607|NCT03791710|PROCEDURE|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
48131358|NCT06654323|BEHAVIORAL|Intensive Behavioral Lifestyle Modification|Participants in all arms will receive visits with their child's primary care provider (4 visits, 1 hour total), on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), and community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total). The difference between arms will be in the frequency and duration of personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional: 16 sessions (60 minutes per session), 12 sessions (60 minutes per session), 9 sessions (60 minutes per session), 8 sessions (45 minutes per session), or 6 sessions (30 minutes per session).
48131359|NCT06597058|DRUG|MAR|Once-daily tablet
48131360|NCT03805243|DEVICE|test of sensors for somnonaute device|test of sensors
48131361|NCT03805243|DEVICE|test of sensors for uronaute device|test of sensors
48496608|NCT03791710|DRUG|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
48496609|NCT03791710|PROCEDURE|split thickness skin grafting|depridment and split thickness skin grafting
48496610|NCT04436887|PROCEDURE|positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia|Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies \>20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
48496611|NCT00242619|DRUG|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
48131362|NCT03805243|DEVICE|test of sensors for toconaute device|test of sensors
48131363|NCT03805243|DEVICE|test of sensors for neuronaute device|test of sensors
47979504|NCT02099357|DIETARY_SUPPLEMENT|Placebo|
48131364|NCT03805243|DEVICE|test of sensors for cardioskin device|test of sensors
48131365|NCT01896843|DRUG|STX107|
48131366|NCT03886246|DRUG|Spesolimab|Solution for infusion
47979505|NCT02099357|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
48131367|NCT03886246|DRUG|Spesolimab|Solution for injection
48131368|NCT04777383|DRUG|Acetylcholine|Iontophoretic administration of 5 different concentrations of acetylcholine
48131369|NCT04777383|DRUG|Norepinephrine|Iontophoretic administration of 5 different concentrations of norepinephrine
47979506|NCT04590261|OTHER|Blood sampling|Peripheral Blood sampling, 25 mL
47979507|NCT04590261|OTHER|Nasal Brushing|Nasal Brushing, facultative
47979508|NCT06080607|BEHAVIORAL|Patient Reported Outcome (PRO)|Quality of Life evaluation
47979509|NCT02315781|DEVICE|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
47979510|NCT02315781|DEVICE|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
47979511|NCT04501666|DRUG|Nemolizumab 30 mg|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
47979512|NCT04501666|DRUG|Placebo|Participants received matching placebo as SC injection.
47979513|NCT00002079|DRUG|Butyldeoxynojirimycin|
47979514|NCT00002079|DRUG|Zidovudine|
48131370|NCT04777383|DRUG|Phenylephrine|Iontophoretic administration of 5 different concentrations of phenylephrine
48338559|NCT02171819|OTHER|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
48338560|NCT03989856|DEVICE|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
48496612|NCT03018210|PROCEDURE|Surgical repair of the rotator cuff|
48655010|NCT04025320|OTHER|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
48338561|NCT03989856|DEVICE|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
48338562|NCT06508775|BIOLOGICAL|MB-CART19.1|Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
48338563|NCT06508775|BIOLOGICAL|MB-CART20.1|Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
48338564|NCT06508775|BIOLOGICAL|MB-CART2019.1|Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.
47979515|NCT01883843|DEVICE|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
48131371|NCT04777383|DRUG|Atropine|Iontophoretic administration of 5 different concentrations of atropine
48131372|NCT04777383|DRUG|Neostigmine|Iontophoretic administration of 5 different concentrations of neostigmine
48131373|NCT04777383|DRUG|Sterile water|Iontophoretic administration of sterile water
48131374|NCT04874519|BEHAVIORAL|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
48496613|NCT03493386|DRUG|Daprodustat 2 mg tablet|Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
48338565|NCT06507605|BIOLOGICAL|R21|R21 is a portion of Pf circumsporozoite protein fused with hepatitis B surface antigen in the form of non-infectious virus-like particles (VLPs) produced in yeast cells (Hansenula) by recombinant DNA technology.
48338566|NCT06507605|BIOLOGICAL|Pfs230D1-CRM197|Recombinant Pfs230 domain 1 (Pfs230D1; a subdomain of a surface antigen of gametocytes, gametes, and zygotes, in the mosquito stage of Pf conjugated to CRM197 and adjuvanted with 50μg of Matrix-M.
48496614|NCT03493386|DRUG|Daprodustat 4 mg tablet|Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
48496615|NCT03107026|DRUG|dasotraline 4mg|dasotraline 4mg tablet once daily
48496616|NCT03107026|DRUG|dasotraline 6mg|dasotraline 6mg tablet once daily
48496617|NCT03107026|DRUG|Placebo|Placebo tablet once daily
48496618|NCT04398264|OTHER|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
48496619|NCT04068844|BEHAVIORAL|Exercise training|Exercise training, either whole body or isolated single leg
48496620|NCT05953974|OTHER|Clinical score of Granillo and al.|Compare the performance of the clinical prediction score of confirmed autoimmune encephalitis according to the type of antibody isolated from the CSF.
48496621|NCT01090921|DRUG|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
48496622|NCT03030820|PROCEDURE|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
48496623|NCT04575766|DRUG|FT-7051|"Dose levels: Dose Level -1 through Dose Level 7, assigned per the protocol using a BOIN design. Additional dose levels may be explored as applicable.~Capsules available in strengths of 10mg, 25mg, and 100 mg that are orally administered per the protocol frequency and dose level."
48496624|NCT04091711|DEVICE|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
48496625|NCT03870867|OTHER|No intervention|No intervention
48338567|NCT06507605|BIOLOGICAL|Pfs230D1-EPA|Recombinant Pfs230D1 conjugated to a recombinant Pseudomonas aeruginosa ExoProtein A (EPA)
48338568|NCT06507605|OTHER|Matrix-M|Vaccine adjuvant that contains purified saponin (from Quillaja saponaria Molina) and cholesterol and phosphatidyl choline. Matrix-M will be used at a 50μg dose for vaccinations.
48496626|NCT06169501|BEHAVIORAL|App-based Mindfulness Intervention|Participants in the trial will engage in a 30-day app-based mindfulness program called Unwinding Anxiety that they can complete over a maximum of 60 days. During this time, they will practice short daily mindfulness lessons and respond to a set of brief questions regarding their anxiety levels. Ultimately, we want to assess whether this intervention helps these caregivers feel less stressed and anxious.
48655011|NCT04025320|OTHER|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
48338569|NCT02017457|BIOLOGICAL|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~* Patients with a sibling donor will receive:~* 5x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6~* Patients with an unrelated donor will receive:~* 1x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6"
48496627|NCT01501864|BEHAVIORAL|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
48338570|NCT02017457|DRUG|Azacytidine|"* Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped."
48338571|NCT01459770|OTHER|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
48338572|NCT01459770|OTHER|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
48338573|NCT01869803|DRUG|gemtuzumab ozogamicin|Given IV
48338574|NCT01869803|OTHER|laboratory biomarker analysis|Correlative studies
48338575|NCT06508853|OTHER|Qualitative research (no intervention)|Interviews are being conducted with support workers and managers.
48338576|NCT05820646|OTHER|Boswellia Sacra|"1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days"
48338577|NCT06233214|DEVICE|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
48338578|NCT02622438|OTHER|Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.|
48338579|NCT00419458|PROCEDURE|inspiratory muscle strength training|
48338580|NCT02152449|DIETARY_SUPPLEMENT|Oral nutritional supplementation|
48338581|NCT03025152|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
48338582|NCT03025152|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
48338583|NCT03381625|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
48338584|NCT03381625|DRUG|Placebo|Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
48338585|NCT03313804|DRUG|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
48338586|NCT03313804|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
48338587|NCT02443805|BIOLOGICAL|300 IR|300 IR tablet of HDM Allergen Extracts
48338588|NCT02443805|BIOLOGICAL|Placebo|Placebo tablet
48655012|NCT06580990|PROCEDURE|specific neck exercises with the Spinetrack|This group will receive an telerehabilitation exercise programme for the deep neck musculature using the spinetrack
48496628|NCT00192244|BIOLOGICAL|CAIV-T, Liquid|
48496629|NCT04536532|DRUG|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
48496630|NCT04536532|DRUG|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
48496631|NCT04536532|DRUG|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
48496632|NCT04536532|DRUG|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
48131382|NCT06601218|DRUG|Oral cannabis low THC|4 months daily dosing with oral cannabis low THC
47979516|NCT01883843|DEVICE|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
48338589|NCT01947647|BEHAVIORAL|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
48338590|NCT01947647|BEHAVIORAL|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
48338591|NCT03184116|BEHAVIORAL|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning \& Rehabilitation
48338592|NCT02019498|BEHAVIORAL|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
48338593|NCT02019498|OTHER|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
48338594|NCT03713983|OTHER|Observational study|Observational study
48338595|NCT03170258|DEVICE|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
48338596|NCT00926666|DRUG|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
48338597|NCT04644484|BIOLOGICAL|SYN023|The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
48338598|NCT04644484|BIOLOGICAL|Human Rabies Immune Globulin (HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
48338599|NCT04644484|BIOLOGICAL|Rabies Vaccine|Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
48338600|NCT03056729|DRUG|BIIB076|Administered as single intravenous (IV) infusion
48338601|NCT03056729|DRUG|Placebo|Administered as single IV infusion
48338602|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenate
48338603|NCT00212212|DIETARY_SUPPLEMENT|selenium|400 µg selenium as selenate
48338604|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenomethionine
47979517|NCT05609240|DRUG|Cefuroxime|See arm/group description
47979518|NCT01083394|DEVICE|PTA|PTA using a conventional balloon
47979519|NCT01083394|DEVICE|PTA with PEB|PTA using a paclitaxel eluting balloon
47979520|NCT01083394|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
48338605|NCT00212212|DIETARY_SUPPLEMENT|placebo|placebo tablet
48338606|NCT00897091|GENETIC|comparative genomic hybridization|
48338607|NCT00897091|GENETIC|microarray analysis|
48338608|NCT00897091|GENETIC|reverse transcriptase-polymerase chain reaction|
48338609|NCT00897091|OTHER|diagnostic laboratory biomarker analysis|
48338610|NCT05343585|DEVICE|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
48338611|NCT00349037|BIOLOGICAL|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
48496633|NCT06073210|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
48131383|NCT06601218|DRUG|Placebo Comparator|4 months of daily dosing with oral placebo
48655013|NCT06580990|PROCEDURE|specific neck exercises|This group will receive a telerehabilitation programme with exercise for the deep neck musculature
47979521|NCT00429273|DRUG|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
47979522|NCT00429273|DRUG|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
48131384|NCT06601218|DRUG|Oral cannabis high THC|4 months of daily dosing with oral cannabis with high THC
48131385|NCT06601218|DRUG|Oral cannabis THC/CBD|4 months of daily dosing with oral cannabis with THC and CBD
48496634|NCT06073210|BEHAVIORAL|Action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a action observation intervention (observing movements without actually doing them).
48338612|NCT05525312|PROCEDURE|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
48338613|NCT05525312|PROCEDURE|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
48338614|NCT04467164|DEVICE|exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
48338615|NCT04467164|DEVICE|Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)|Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
48338616|NCT06022172|DIAGNOSTIC_TEST|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.|"Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used."
48338617|NCT00407550|DRUG|gemcitabine HCL|1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.
47979523|NCT04334629|DRUG|Ibuprofen|Lipid ibuprofen 200 mg
47979524|NCT05691452|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
47979525|NCT00523354|DRUG|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
47979526|NCT01733602|DEVICE|transcranial direct current stimulation|
47979527|NCT03905746|OTHER|blood sample at Day 0|"40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)"
47979528|NCT03905746|OTHER|blood sample at Day 2 and Day 7|20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
48131387|NCT04217694|BEHAVIORAL|Cogstate Assessment Battery|Complete CogState testing
48131388|NCT04217694|DRUG|Memantine|Given PO
48338618|NCT00407550|DRUG|pemetrexed disodium|500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
48338619|NCT00407550|DRUG|gemcitabine HCL|1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
48496635|NCT06073210|BEHAVIORAL|Sham action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a sham action observation intervention (observing space planets).
48496636|NCT02368574|PROCEDURE|Class II hysterectomy|Class II hysterectomy
48496637|NCT00002639|DRUG|chemotherapy|
48655014|NCT06344247|DRUG|RAS inhibitors：Losartan®️/Valsartan®️|Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.
48655015|NCT06344247|DRUG|dapagliflozin：Forxiga®️|Forxiga®️ : titrated to the target dose (10 mg qd).
48655016|NCT06344247|DRUG|simagliptin：Forxiga®️|Semaglutide®️ : titrated to the target dose (1 mg qw).
48655017|NCT00959049|BIOLOGICAL|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
48655018|NCT00959049|BIOLOGICAL|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
48131389|NCT04217694|DRUG|Memantine Hydrochloride|Given PO
48496638|NCT00002639|DRUG|suramin|
48496639|NCT04259983|OTHER|Maximal exercise test|The maximal exercise test will be performed on an electronically braked bicycle ergometer.
48496640|NCT04259983|OTHER|Endothelial dysfunction assessment|Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
48655019|NCT03249649|BEHAVIORAL|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
48655020|NCT06643013|DRUG|XBD173|4 weeks treatment
48338620|NCT01158066|PROCEDURE|CT Cardiac|the patient will undergo cardiac CT
48496641|NCT04259983|OTHER|Arterial stiffness assessment|Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
48496642|NCT04205019|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
48496643|NCT03346486|OTHER|Control diet|Regular diet
48496644|NCT03346486|OTHER|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
48496645|NCT05043844|DEVICE|abdominal binder|Wearing an abdominal binder postoperatively
48496646|NCT01449097|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
48496647|NCT01449097|PROCEDURE|The femoral nerve block|US-guided femoral nerve block with ropivacaine
47979529|NCT03905746|OTHER|stool sample at Day 0|stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
48496648|NCT01449097|PROCEDURE|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
48338621|NCT04961827|BEHAVIORAL|Self-efficacy based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
48338622|NCT04961827|BEHAVIORAL|Knowledge based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
48338623|NCT05390307|DRUG|Liraglutide / Semaglutide|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
48496649|NCT01342107|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
48496650|NCT01342107|DEVICE|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
48496651|NCT01342107|DEVICE|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
48496652|NCT04738474|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"Develops personal resilience resources through 1:1 sessions with a PRISM coach."
48496653|NCT04738474|OTHER|Usual Care|No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.
48496654|NCT02770885|DRUG|Dulaglutide|Treatment with dulaglutide for 3 weeks.
48496655|NCT02770885|DRUG|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
48496656|NCT05382169|OTHER|Determine the presence of mast cell activation syndrome|"Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) :~* At least two clinical signs compatible with MAS before the first consultation (V1)~* Improvement of symptoms on antihistamines within 2 months of initiation of treatment~* Significant increase in tryptase during crisis~Mast cell activation syndrome will be possible if :~* At least two clinical signs consistent with MAS before the first consultation (V1)~* Improvement of symptoms with antihistamines within 2 months of initiation of treatment~* No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely."
48496657|NCT02517437|DRUG|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
48496658|NCT02517437|DRUG|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
48496659|NCT00967044|DRUG|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
48496660|NCT00967044|DRUG|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
47979530|NCT03240250|PROCEDURE|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
48496661|NCT00469157|DRUG|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
48496662|NCT06109337|DIAGNOSTIC_TEST|drow blood|Participants will be taken peripheral blood about 5 ml
48496663|NCT01406392|DRUG|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
48496664|NCT01406392|DRUG|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
48338624|NCT05390307|DRUG|Dapagliflozin|Dapagliflozin 5-10 mg once daily for 6 months.
48338625|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin|Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
48338626|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
48338627|NCT05390307|OTHER|Usual care|Usual standard care
48338628|NCT01428440|RADIATION|18FML10|apoptosis imaging radio ligand
48496665|NCT00540683|DEVICE|Diffuse Optical Spectroscopy|Muscle properties
48496666|NCT00561561|BEHAVIORAL|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
48496667|NCT06514690|OTHER|Sedation|Different degrees of intravenous sedation according to the Ramsay scale
48496668|NCT00099710|DIETARY_SUPPLEMENT|Curcumin C3 Complex|
48496669|NCT03131674|OTHER|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
48655021|NCT05781503|BEHAVIORAL|Identity Capital Intervention (Coach + Co-designed Leadership Guide)|Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.
48338629|NCT04985240|DIETARY_SUPPLEMENT|Lettuce with no biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
48338630|NCT04985240|DIETARY_SUPPLEMENT|Intervention Molibdenum group|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
48338631|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
48338632|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
48338633|NCT06180876|DRUG|remimazolam|continuous infusion
48338634|NCT06180876|DRUG|propofol|continuous infusion
48338635|NCT06158282|OTHER|Voluntary apnoea|Walking apneas at high lung volume with cycles of 15-10s (apnea - breathing) during 6 minutes
48496670|NCT03994497|OTHER|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
48496671|NCT00003875|DRUG|busulfan|Given PO or IV
48655022|NCT05781503|OTHER|Monthly Rent Subsidies|All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
48655023|NCT05644301|DRUG|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
48655024|NCT05644301|DRUG|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
48655025|NCT05644301|DRUG|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
48496672|NCT00003875|DRUG|etoposide|Given IV
48496673|NCT00003875|BIOLOGICAL|aldesleukin|Given SC
48655026|NCT05509660|BEHAVIORAL|PUMA+|Transdiagnostic CBT
48131399|NCT06095440|OTHER|Hepatorenal Syndrome outcome in Patients at Methodist Health systems|1.2.1. To perform a retrospective analysis of patients with HRS with the aim of comparing various treatment modalities such as vasoconstrictors, albumin, CRRT, Molecular Adsorbent Recirculating System (MARS), and TIPS.
48131400|NCT00514306|DRUG|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
48496674|NCT00003875|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
48496675|NCT00369317|DRUG|asparaginase|Given IM
48496676|NCT00369317|DRUG|daunorubicin hydrochloride|Given IV
48496677|NCT00369317|DRUG|cytarabine|Given IV or IT
48496678|NCT00369317|DRUG|thioguanine|Given orally
48496679|NCT00369317|DRUG|etoposide|Given IV
48496680|NCT00369317|OTHER|laboratory biomarker analysis|Correlative studies
48496681|NCT00805753|DRUG|ACTH|comparison of different dosages of drug
48496682|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
48496683|NCT02414438|OTHER|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
48496684|NCT02245022|DRUG|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
48496685|NCT02245022|DRUG|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
48655027|NCT05509660|BEHAVIORAL|PUMA|Transdiagnostic CBT
48655028|NCT04844606|DRUG|Mirikizumab|Administered SC
48496686|NCT03041324|BIOLOGICAL|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
48338636|NCT00004300|DRUG|bromocriptine|
48338637|NCT00004300|DRUG|sertraline hydrochloride|
48338638|NCT05729269|DIAGNOSTIC_TEST|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
48338639|NCT06383689|OTHER|Seizure placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG
48655029|NCT04844606|DRUG|Mirikizumab|Administered IV
48655030|NCT06564857|DRUG|Remifentanil|Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction
48496687|NCT05335733|DIAGNOSTIC_TEST|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
48496688|NCT05916261|BIOLOGICAL|Personalized neoantigen tumor vaccine|neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
48338640|NCT06383689|OTHER|Well-being placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG
48338641|NCT05270083|DIAGNOSTIC_TEST|NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)|Participants will receive an intravenous (IV) dose of 300 MBq of Neuraceq™ in a volume of 10 mL or less. A 30 minute duration PET image will be acquired starting immediately after Neuraceq™ injection. A second 20-minute duration PET image will be acquired starting 90 minutes after Neuraceq™ injection.
48338642|NCT05446974|OTHER|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
48338643|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.3mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
48338644|NCT06430645|DRUG|Esketamine|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). Esketamine hydrochloride (0.6mg/kg total body weight) single intravenous injection after stable plasma concentration of propofol deep sedation.
48338645|NCT06430645|DRUG|Saline|Sufentanil(0.1ug/kg) and flurbiprofen axetil(50mg) are administered before induction. Propofol (10 mg/ml) is infused via target-controlled infusions (TCIs). The same volume of 0.9% saline instead of esketamine will be given to the control group after stable plasma concentration of propofol deep sedation.
48338646|NCT05939271|PROCEDURE|lower extremity amputation|"persons are defined as having a lower extremity amputation when an operation with removal of an extremity below the hips took place.~To identify those people with diabetes who underwent amputation, the following DBC's claims were extracted from the system: 038590; amputation upper leg, 038690; amputation lower leg, 038691; exarticulation of the lower leg, 038790; amputation of the tarsus, 038791; amputation or exarticulation of a toe, 038793; exarticulation of the foot, 038794; Chopart exarticulation, Lisfranc, respectively trans metatarsal amputation. Amputations were categorized into minor (038790, 038791, 038793, 038794) and major (038590, 038690,038691) amputations"
48338647|NCT02134067|DRUG|TAS-119|
48338648|NCT02134067|DRUG|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
48338649|NCT05018637|DRUG|WJ-MSC|"Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.~Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
48496689|NCT02422771|OTHER|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
48496690|NCT03884543|PROCEDURE|Individualized high PEEP strategy|Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
48655031|NCT06564857|DRUG|Rocuronium|Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction
48655032|NCT05395754|DEVICE|App Intervention|Use of the PCheck app, an app encouraging STI prevention behaviors.
48655033|NCT05605197|DRUG|U87 CAR-T|Subjects will be pretreated with cyclophosphamide 250\~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\~6 patients.
48655034|NCT06342609|DRUG|Colchicine 0.5 MG|0.5mg per day of Colchicine orally administered
48655035|NCT03286361|DEVICE|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
48338650|NCT05018637|DRUG|Teriparatide|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
48338651|NCT02251067|DRUG|VPI-2690B low dose|Comparison of different doses of study drug
48338652|NCT02251067|DRUG|VPI-2690B medium dose|Comparison of different doses of study drug
48338653|NCT02251067|DRUG|Placebo to match VPI-2690B|
48338654|NCT02251067|DRUG|VPI-2690B high dose|Comparison of different doses of study drug
47979531|NCT03240250|PROCEDURE|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
48655036|NCT00963638|DIETARY_SUPPLEMENT|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
48655037|NCT00963638|DIETARY_SUPPLEMENT|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
48655038|NCT04089111|OTHER|Minute volume target of 100%|Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
47979532|NCT03221400|DRUG|PEN-866 Sodium|PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
48338655|NCT03115125|OTHER|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
48338656|NCT01386892|OTHER|No intervention|There is no intervention for this study
48338657|NCT01454024|DEVICE|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
48338658|NCT01454024|DEVICE|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
48338659|NCT04000022|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
48338660|NCT06042192|DRUG|TK-254RX|Two TK-254RX per day to predetermined application site
48338661|NCT02143960|DEVICE|VelaShape III|Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
48496691|NCT01905748|OTHER|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
48655039|NCT04089111|OTHER|Minute volume target to reach PaCO2 less than 45% (high tidal volume)|Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
48655040|NCT04073420|DEVICE|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
48338662|NCT02143960|DEVICE|CoolSculpt|Noninvasive Cryolipolysis
48338663|NCT03685110|DEVICE|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
48338664|NCT05323487|DRUG|Bumetanide Injection|Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
48338665|NCT00049504|DRUG|cyclophosphamide|Given IV
48338666|NCT00049504|DRUG|fludarabine phosphate|Given IV
47979533|NCT03221400|DRUG|fluorouracil|Fluorouracil 2400 mg/m2 IV
47979534|NCT03221400|DRUG|Folinic acid|Folinic acid 400 mg/m2 IV
47979535|NCT03221400|DRUG|Niraparib|Niraparib
47979536|NCT04430114|DEVICE|branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms|"Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts."
47979537|NCT05626257|OTHER|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
48655041|NCT04073420|DEVICE|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
48131405|NCT04866641|DRUG|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
48131406|NCT05906550|DIAGNOSTIC_TEST|Vascular access monitoring|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
48338667|NCT00049504|DRUG|tacrolimus|Given IV or orally
48338668|NCT00049504|DRUG|mycophenolate mofetil|Given orally
48338669|NCT00049504|GENETIC|polymerase chain reaction|Correlative studies
48338670|NCT00049504|GENETIC|fluorescence in situ hybridization|Correlative studies
48338671|NCT00049504|GENETIC|polymorphism analysis|Correlative studies
48338672|NCT00049504|GENETIC|gene expression analysis|Correlative studies
48338673|NCT00049504|RADIATION|total-body irradiation|Undergo total-body irradiation
48655042|NCT00023595|PROCEDURE|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
48655043|NCT00023595|DRUG|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
48655044|NCT00023595|PROCEDURE|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
48655045|NCT06569992|OTHER|VIS, TIES|The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
48655046|NCT06630689|OTHER|Dry Full Body Massage|Applying massage after phototherapy
48655047|NCT06630689|OTHER|Oil Full Body Massage|Oil Full Body Massage
48655048|NCT01469156|DRUG|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
48655049|NCT05402332|DRUG|AVTX-801|D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)
48338674|NCT00049504|PROCEDURE|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
48338675|NCT00049504|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
48338676|NCT01522560|OTHER|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
48338677|NCT01522560|OTHER|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
48338678|NCT02219217|DRUG|Dolutegravir, Elvitegravir and Cobicistat|
48338679|NCT06422572|OTHER|No Intervention|No Intervention
48338680|NCT05704842|BEHAVIORAL|Exercise|Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
48338681|NCT02732184|DRUG|Co-ArgI-PEG modified human arginase I|
48338682|NCT02842541|DRUG|EBI-031|
48338683|NCT03600870|DRUG|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
48338684|NCT00822562|OTHER|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
48338685|NCT00822562|PROCEDURE|surgery|only surgery
48338686|NCT02366793|OTHER|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
48338687|NCT02366793|OTHER|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
48338688|NCT03345992|DRUG|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
47979538|NCT05240456|DRUG|Beta3-Agonists, Adrenergic|The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
47979539|NCT05240456|DRUG|Anticholinergic drug, Solifenacin|Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
48338689|NCT03345992|DRUG|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
48338690|NCT00105183|BIOLOGICAL|Placebo|placebo infusion, single
48338691|NCT00105183|BIOLOGICAL|EZ-2053|single IV infusion, 9 mg/kg
48338692|NCT00105183|BIOLOGICAL|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
48338693|NCT02690168|BEHAVIORAL|Fasting|72 hour fasting
48338694|NCT01628042|DRUG|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
48338695|NCT04797312|DRUG|Opioid Free Anaesthesia protocol|"The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated."
48338696|NCT04797312|DRUG|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
48338697|NCT00308243|DRUG|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
48338698|NCT01570205|DRUG|XG-102|single intravenous infusion
48338699|NCT02996955|BEHAVIORAL|social support|behaviour change intervention
48496692|NCT05912907|OTHER|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
48496693|NCT04819399|DRUG|Catumaxomab|"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose"
48496694|NCT03321630|DRUG|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
47979540|NCT00740701|DEVICE|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
47979541|NCT01714635|DEVICE|Tecnis Multifocal Intraocular Lens|
47979542|NCT01714635|DEVICE|Monofocal Intraocular Lens|
48131407|NCT05906550|DIAGNOSTIC_TEST|Vascular access blood flow measurement|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min.
48131408|NCT06664151|BIOLOGICAL|Fluzone Trivalent|Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.
48496695|NCT03321630|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
48496696|NCT03053219|DRUG|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
48496697|NCT01551108|BEHAVIORAL|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
48131412|NCT05842603|BEHAVIORAL|Cardiac Lifestyle Program|12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
48496698|NCT01551108|BEHAVIORAL|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
48655050|NCT05402332|DRUG|Placebo|placebo equivalent
47979543|NCT02804620|BEHAVIORAL|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
47979544|NCT01974349|DRUG|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
47979545|NCT01953588|DRUG|fulvestrant|Fulvestrant 500 mg IM
47979546|NCT01953588|DRUG|anastrozole|Anastrozole 1 mg oral tablet
47979547|NCT02397759|OTHER|Blood draw and cerebrospinal fluid draw|
47979548|NCT03922425|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
47979549|NCT02891850|DRUG|Riociguat (Adempas, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
47979550|NCT02891850|DRUG|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
47979551|NCT02891850|DRUG|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
47979552|NCT06506760|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
47979553|NCT06506760|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~Two hours of kinesiotherapy (120 minutes, including gait training). Thirty minutes of ergotherapy. Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
47979554|NCT01443754|PROCEDURE|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~* use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~* minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
47979555|NCT01443754|PROCEDURE|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
48131413|NCT05408091|DRUG|TRL345, a human monoclonal antibody|Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
48131421|NCT05484661|DIETARY_SUPPLEMENT|BCAA|Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (\~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
48131422|NCT04565977|OTHER|Observational|Retrospective chart review
48131423|NCT02278666|PROCEDURE|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
48338700|NCT02996955|BEHAVIORAL|treatment of illness perceptions|educational interview
48338701|NCT02996955|DEVICE|Activ8|wearing a move monitor
48496699|NCT00472862|BEHAVIORAL|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
48496700|NCT02935166|OTHER|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
48338702|NCT02996955|OTHER|activity advice|walking or cycling 5 days a week during at least half an hour
48338703|NCT01391455|PROCEDURE|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
48338704|NCT03607071|DRUG|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
48496701|NCT05576766|PROCEDURE|Routine care|"1. Routine information provided before surgery.~2. No nutritional therapy.~3. No aerobic exercise.~4. No pelvic floor muscle training.~5. No psychiatrist intervention.~6. Bowel preparation with oral cathartic agent.~7. Fasting for over 8 hours; no oral carbohydrate solution (OCS) loading before surgery.~8. Hypothermia prevention not emphasized.~9. General anesthesia; regional block not emphasized.~10. Routine blood pressure management.~11. Mobilization from postoperative day 1.~12. Start oral feeding from postoperative day 1.~13. Patient-controlled analgesia with opioids.~14. Thromboembolism prophylaxis with low-molecular-weight heparin (LMWH).~15. Routine pelvic drainage tube removal (usually at postoperative day 4).~16. Routine urinary catheterization removal (usually at postoperative day 14)."
48655051|NCT06637748|PROCEDURE|Echocardiography|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening)"
48655052|NCT06637748|PROCEDURE|Electrocardiography|"Standard 12-lead ECG recording~• Parameters assessed:~* Heart rate and rhythm~* P-wave morphology~* PR interval~* QRS complex duration and morphology~* ST-segment changes~* T-wave abnormalities~* QT interval"
48655053|NCT02768246|DEVICE|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
48655054|NCT02768246|DEVICE|Face Mask|Classic face mask
48655055|NCT02107989|DEVICE|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
48131424|NCT02278666|DEVICE|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
48131425|NCT02278666|DEVICE|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
48338705|NCT04707378|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
48338706|NCT02098005|OTHER|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
48338707|NCT02098005|OTHER|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
48496702|NCT05576766|PROCEDURE|ERAS management pathway|"1. Patient consultation and education before surgery.~2. Nutritional intervention for patients whose BMI\<18.5 or BMI\>24 kg/m2.~3. Aerobic exercise for 2 weeks before surgery.~4. Pelvic floor muscle training for 2 weeks before surgery.~5. Psychiatrist intervention for patients with severe depression and anxiety.~6. No bowel preparation before surgery.~7. Provide oral carbohydrate solution 2 hours before surgery.~8. Hypothermia prevention.~9. General anesthesia combined with regional block.~10. Goal-directed fluid infusion and targeted blood pressure management.~11. Early mobilization.~12. Early oral feeding.~13. Multimodal analgesia, including opioids and non-steroid anti-inflammatory drugs.~14. Thromboembolism prophylaxis with low-molecular-weight heparin; rivaroxaban for high-risk patients.~15. Early pelvic drainage tube removal (at postoperative day 2) unless contraindicated.~16. Early urinary catheterization removal (at postoperative day 7) unless contraindicated."
48496703|NCT02951468|PROCEDURE|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed \[14\]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
48496704|NCT05194878|DRUG|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
48496705|NCT05194878|PROCEDURE|Colectomy|Radical colectomy
48338708|NCT05651841|DRUG|Tezepelumab|"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
48338709|NCT05651841|OTHER|placebo|"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
48496706|NCT05194878|DRUG|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
48496707|NCT00967291|DRUG|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
48496708|NCT00967291|DRUG|mitomycin C|8 mg/mq on day 1 every 28 days
48338710|NCT04131985|PROCEDURE|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
48338711|NCT01757587|DRUG|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
48338712|NCT01757587|DRUG|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
48338713|NCT05151224|DIAGNOSTIC_TEST|microRNA 21|"Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment."
48338714|NCT03584438|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
48338715|NCT03584438|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
47979556|NCT00676351|PROCEDURE|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
48338716|NCT01844427|DRUG|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
48338717|NCT01844427|DRUG|Placebo|
48338718|NCT02143323|DRUG|Augmentin tablet|
48338719|NCT03366818|DEVICE|thrombectomy|mechanical thrombectomy
48338720|NCT01016678|DRUG|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
48338721|NCT01016678|DRUG|Placebo|Dummy pill comparator
48338722|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (low dose)|Participants are administered 25 µg of vilanterol + fluticasone furoate
48338723|NCT06066606|DRUG|Vilanterol and Fluticasone Furoate (high dose)|Participants are administered 100 µg of vilanterol + fluticasone furoate
48496709|NCT03272464|DRUG|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
48496710|NCT03272464|DRUG|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
48338724|NCT06066606|DRUG|Placebo|Participants are administered placebo
48338725|NCT02914197|OTHER|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
48338726|NCT01257672|DRUG|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
48338727|NCT01257672|DRUG|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
48338728|NCT01257672|DRUG|placebo|placebo
48338729|NCT06360536|BEHAVIORAL|Resistance Training|A home-based resistance training condition that is delivered through a web-based platform.
48338730|NCT00653094|DEVICE|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
48338731|NCT02687932|DRUG|LCZ696|
48338732|NCT02687932|DRUG|Valsartan|
48496711|NCT03272464|DRUG|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
48338733|NCT04408170|DIAGNOSTIC_TEST|Point-of-care test for SARS-CoV-2|Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2
48338734|NCT03981185|DEVICE|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
48338735|NCT03828500|BEHAVIORAL|Assistant-encouraged fasting up to ASA/CAS guideline limits|Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
48338736|NCT01735097|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (200 mg, soft capsule)
48338737|NCT01735097|DIETARY_SUPPLEMENT|Nigella sativa|Nigella sativa (200 mg, soft capsule)
48338738|NCT01735097|DIETARY_SUPPLEMENT|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
48338739|NCT02204410|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|
48338740|NCT02204410|DRUG|ADHD Medication|
48655056|NCT02107989|DEVICE|MEG|MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
48496712|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
48655057|NCT06161181|DEVICE|Decision Support System|"TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary."
47979557|NCT01083576|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
47979558|NCT01083576|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
47979559|NCT06385223|DEVICE|Beam F3 targeted accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
47979560|NCT06385223|DEVICE|Individualized connectome-guided accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
47979561|NCT02921854|OTHER|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
47979562|NCT01996982|DEVICE|CCS Device|Core Cooling System Device
47979563|NCT02322567|OTHER|medical records|review of medical records
47979564|NCT03731988|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
47979565|NCT03731988|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
47979566|NCT03731988|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
47979567|NCT03731988|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
47979568|NCT03731988|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
47979569|NCT02949102|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
47979570|NCT02949102|DIETARY_SUPPLEMENT|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
47979571|NCT03030872|DEVICE|Investigational software|The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
47979572|NCT04022044|BEHAVIORAL|Observational group|
47979573|NCT00585728|PROCEDURE|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
47979574|NCT01348945|OTHER|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
47979575|NCT06060288|DIAGNOSTIC_TEST|Diagnosis by mobile phone imaging|"The photographs will be taken with a smartphone iPhone 14 Pro in a one-year period. Imaging will follow the recommendations regarding intraoral photography in oral mucosal screening set by (Lin et al., 2021).~Personal data and a brief description of the present illness concerning the main complaint will be informed by the patients and recorded in a diagnosis chart of the Oral medicine department Cairo University. Complete intraoral physical examination will be performed by the main investigator under supervision of the main supervisor and the co-supervisor using dental equipment with artificial light."
47979576|NCT02159014|BEHAVIORAL|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
47979577|NCT02159014|BEHAVIORAL|Online, video prompted, individual aerobic dance|Supported online activity intervention
47979578|NCT02159014|BEHAVIORAL|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
47979579|NCT02159014|BEHAVIORAL|Self-paced online aerobic dance activity|Self paced physical activity
48655058|NCT03982173|DRUG|Tremelimumab|tremelimumab 75mg
48655059|NCT03982173|DRUG|Durvalumab|Durvalumab 1500mg
48655060|NCT05149872|OTHER|Muscle relaxation|Rocuronium will be used to induce partial paralysis
48655061|NCT05149872|OTHER|Reversal|Sugamamdex will be used to reverse muscle relaxation
48655062|NCT03850067|DRUG|CC-90011|CC-90011
48655063|NCT03850067|DRUG|Cisplatin|Cisplatin
48655064|NCT03850067|DRUG|Carboplatin|Carboplatin
48655065|NCT03850067|DRUG|Etoposide|Etoposide
47979580|NCT02159014|BEHAVIORAL|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
48655066|NCT03850067|DRUG|Nivolumab|Nivolumab
48131429|NCT06360354|DRUG|AMG 193|Administered Orally
48655067|NCT06230341|OTHER|Health Services Research|MSPs benefit from a learning system. The learning system combines an individualised support programme provided by a regional support structure for quality and safety in health care (QualiREL Santé) and the provision of a web platform. Based on the 4 dimensions of the Shortell model, the support programme includes initial training (6 months) and personalised methodological support (18 months) for each MSP. A web platform is provided to MSPs to enable them to implement the full approach of the Risk Management Support Programme. It provides support for reporting, analysis and management of PSIs.
48131430|NCT06360354|DRUG|Gemcitabine|Administered IV
48131431|NCT06360354|DRUG|Nab-paclitaxel|Administered IV
48131432|NCT06360354|DRUG|Modified FOLFIRINOX|Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
48338741|NCT04016987|BEHAVIORAL|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
48338742|NCT03010904|OTHER|Dietary intervention|
48131433|NCT03373448|DEVICE|Labrida BioClean|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
48131434|NCT03373448|OTHER|Titanium curettes|Peri-implant pockets will be debrided using titanium curettes.
48338743|NCT00219388|DRUG|Levosimendan|
48338744|NCT03780413|BEHAVIORAL|PR-ESSENCE treatment|
48338745|NCT03780413|BEHAVIORAL|Control (TAU)|
48338746|NCT01024101|DRUG|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
48655068|NCT03811119|DEVICE|MANTA vascular closure device|Collagen based vascular closure device
48655069|NCT03811119|DEVICE|Suture based vascular closure device|Suture based vascular closure device (ProGlide)
48655070|NCT06636838|BEHAVIORAL|Spanish-Speaking Provider|Spanish speaking patients will be seen by our Spanish-speaking provider
48655071|NCT04349098|DRUG|Selinexor|Participants will receive 20 mg of selinexor.
48655072|NCT04349098|OTHER|Placebo|Participants will receive 20 mg of placebo matched to selinexor.
48655073|NCT06464510|DRUG|Early Vasopressin|Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
48655074|NCT06464510|DRUG|Norepinephrine and Vasopressin for Rescue|Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
48131435|NCT03134300|DIAGNOSTIC_TEST|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
48655075|NCT06638749|DRUG|Tranexamic Acid|Administration of tranexamic acid
48655076|NCT06638749|DRUG|Normal Saline|Administration of normal saline
48131437|NCT00715884|DEVICE|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
48131438|NCT00715884|DEVICE|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
48131439|NCT03514836|BIOLOGICAL|DCVac/PCa|"Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy.~DCVac/Pca consists of activated autologous dendritic cells. This is an experimental therapy."
48131440|NCT03514836|DRUG|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
48338747|NCT01782924|DRUG|KHK4827|
48338748|NCT00740363|DRUG|sitagliptin|Once daily sitagliptin. If GFR\>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
48338749|NCT00740363|DRUG|placebo|No active sitagliptin treatment for 4 weeks
48338750|NCT04950660|DRUG|Caffeine Tablet|Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
48338751|NCT04950660|DRUG|Placebo|Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
48338752|NCT05793684|DRUG|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
48338753|NCT05793684|DRUG|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
48338754|NCT05793684|DRUG|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
48338755|NCT00973180|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
48338756|NCT05482555|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
48338757|NCT05482555|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
48338758|NCT06436560|OTHER|STRIVE Peer Support Intervention|A virtual group-based peer support intervention led by trans peers who have had genital gender-affirming surgery.
48655077|NCT06267430|BEHAVIORAL|Kleuter Extra training program|The intervention was described in the included arm/group explanation.
48655078|NCT06335706|BEHAVIORAL|Fit of underpants worn|Tight or loose-fitted underpants
48655079|NCT05468918|DEVICE|Phonak Audeo previous generation hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
48655080|NCT05468918|DEVICE|Phonak Audeo Lumity hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
48496713|NCT01633411|DEVICE|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
48496714|NCT01633411|DEVICE|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
48496715|NCT02416414|DEVICE|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
48496716|NCT02416414|DEVICE|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
48496717|NCT00426712|BIOLOGICAL|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
48496718|NCT00426712|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
48496719|NCT00754403|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
48496720|NCT00754403|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
48496721|NCT00993486|BIOLOGICAL|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
48496722|NCT00988065|DRUG|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
48496723|NCT00988065|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
48496724|NCT00988065|DRUG|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
48496725|NCT00988065|DRUG|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
48655081|NCT05220202|BEHAVIORAL|Behavioral Intervention Group (MOTIVATE)|Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
48655082|NCT05584566|DEVICE|OSSIX Breeze|barrier membrane
48655083|NCT05584566|DEVICE|Jason membrane|barrier membrane
48655084|NCT06540014|OTHER|No intervention|No intervention is made, groups are formed just due to the races.
47979581|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
47979582|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
47979583|NCT00615095|OTHER|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
47979584|NCT02086994|DRUG|misoprostol|given after the delivery of the anterior shoulder of the baby.
47979585|NCT02086994|DRUG|carbetocin|given after delivery of anterior shoulder
47979586|NCT05778123|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.
48338759|NCT01285752|DRUG|AK106-001616|
48496726|NCT06402370|DIAGNOSTIC_TEST|PET scan|\[18F\]Vizamyl
48496727|NCT03281863|DIAGNOSTIC_TEST|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
48496728|NCT01126411|PROCEDURE|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
48496729|NCT05892939|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
48496730|NCT05892939|DRUG|intranasal Placebo|Administration of intranasal Placebo
48496731|NCT05043623|DEVICE|Rhinoswab Junior|Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages
48496732|NCT05043623|DEVICE|Combined nose and throat swab|Combined nose and throat swab (standard of care)
48496733|NCT05043623|DEVICE|Saliva swab|Saliva swab
48496734|NCT05043623|DIAGNOSTIC_TEST|Abbott Panbio™ COVID-19 antigen self-test kit|COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
48496735|NCT00852969|DRUG|Niacin|1000 mg tablets once per day
48496736|NCT00852969|DRUG|Active Placebo|100 mg Niacin tablets once per day
48496737|NCT05873010|DIAGNOSTIC_TEST|Manual Compression and Stretching|Manual Compression and Stretching for The Myofascial Trigger Points
48496738|NCT03596151|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
48496739|NCT03457467|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
48496740|NCT03457467|RADIATION|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
48496741|NCT06478264|DRUG|Etoposide|100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles
48131445|NCT06665009|DEVICE|Manually Opened and Device-Opened Ampoules|this study is to evaluate the ampoule peeling device in terms of safety, ease of use, time efficiency, difficulty of operation, and user satisfaction among nurses when opening ampoule bottles of different capacities
48496742|NCT06478264|DRUG|Cisplatin|25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles
48496743|NCT06478264|DRUG|Carboplatin|Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;
48496744|NCT06478264|DRUG|Adebrelimab|1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.
48496745|NCT06478264|RADIATION|radiotherapy|Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.
48496746|NCT01191983|DRUG|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
48496747|NCT05215769|BEHAVIORAL|Health Education|Participate in a video intervention
48496748|NCT05215769|OTHER|Questionnaire Administration|Complete questionnaires
48338760|NCT01285752|DRUG|AK106-001616|
48338761|NCT01285752|DRUG|Active comparator|
48338762|NCT06149754|DEVICE|BraiN20(R) monitoring of N20 somatosensory evoked potential|N20 monitoring will be carried out using the BraiN20 medical device and appropriate electrodes. The device measures one N20 wave per 33 seconds. Scalp electrodes will be located on band and wrist electrodes on a globe. The device provides an automatic reading of N20 and outcome prediction and do not require a specific training.
48338763|NCT04767295|DRUG|Camrelizumab, Albumin Paclitaxel, Carboplatin|Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
48496749|NCT02593682|DRUG|suvorexant|
48496750|NCT02593682|DRUG|placebo|
48496751|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
48496752|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
48496753|NCT00309049|DRUG|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
48496754|NCT03269331|BEHAVIORAL|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
48496755|NCT03080753|DEVICE|Sphinkeeper|Intersphincteric implants in the anal sphincter
48131454|NCT06207604|PROCEDURE|Open sinus lifting without bone grafting and simultaneous implant placement|no bone graft will be used after open sinus lifting
48131455|NCT06207604|PROCEDURE|Open sinus lifting with bone grafting and simultaneous implant placement|bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
48496756|NCT00009009|DRUG|immunosuppressive regimen designed to complement HAART|
48496757|NCT05344430|PROCEDURE|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
47979587|NCT02384408|PROCEDURE|Endometrial Biopsy|Histological assessment
47979588|NCT02384408|DEVICE|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
48338764|NCT05739240|PROCEDURE|Osteosynthesis|Osteosynthesis of distal radius fractures
48338765|NCT02197897|DRUG|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
48338766|NCT00274066|DRUG|Tiotropium + placebo|
48338767|NCT00274066|DRUG|Tiotropium + ipratropium|
48338768|NCT00274066|DRUG|Tiotropium + fenoterol|
48338769|NCT01351311|OTHER|Exercise|Resistance Training exercise with swiss ball
48338770|NCT01351311|OTHER|Drug treatment|Drug treatment
48338771|NCT02082028|DEVICE|BGStar|
48338772|NCT02082028|DEVICE|glucose meter|
48338773|NCT06332612|DRUG|Metformin Hydrochloride|Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.
48496758|NCT04317209|DRUG|SHR0410|administered intravenously
48496759|NCT04317209|DRUG|Placebo|administered intravenously
48496760|NCT00367549|DIETARY_SUPPLEMENT|Energy-containing soft drink|Commercial energy/sports drink
48496761|NCT02041156|OTHER|aerobic and resistance training|
48496762|NCT02041156|OTHER|aerobic combined with balance training|
48131456|NCT05368350|DEVICE|high-definition transcranial direct current stimulation (HD-tDCS)|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with (1) Pre-SMA stimulation arm -- anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns or (2) LIFG stimulation arm -- at electrode F7 (International 10/10 System for electroencephalography electrode placement) and electrodes T7, FP1, AF3, and FC5 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
48131457|NCT03278873|BIOLOGICAL|either AAV - CNGB3 or AAV - CNGA3|Comparison of different dosages of either AAV - CNGB3 or AAV - CNGA3
48131458|NCT05064631|DRUG|Bacterial Lysate|Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system.
48496763|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 severe cases.
48338774|NCT06332612|DRUG|betamethasone dipropionate|Group 1will recieve topical cream betamethasone thrice daily
48338775|NCT06332612|DRUG|Pentoxifylline|Group 1 will receive Pentoxifylline tablet 400 mg twice daily
48338776|NCT02194517|DEVICE|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
48338777|NCT06165861|OTHER|Experimental (with VR-G)|Watching video with using VR-G before undergoing open heart surgery
48338778|NCT00228189|BIOLOGICAL|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
48338779|NCT00292578|PROCEDURE|NAET Testing Modalities|
48496764|NCT04432103|BIOLOGICAL|Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients|Administration of Convalescent Plasma to COVID-19 obtained from donors with prior documented SARS-CoV 2 infection with IgG antibodies to hospitalized COVID-19 critical cases.
48338780|NCT00915538|DRUG|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
48338781|NCT00915538|DEVICE|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
48338782|NCT05881512|DEVICE|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
48338783|NCT01614041|DRUG|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
48338784|NCT01614041|DRUG|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
48338785|NCT05671237|OTHER|bilateral infraorbital+infratrochlear block|we will perform bilateral infraorbital+infratrochlear nerve block
48496765|NCT05621408|BEHAVIORAL|Attention Training Technique|Attention Training Technique is a six weeks psychological intervention provided by trained professionals
48655085|NCT06230640|DIAGNOSTIC_TEST|In vitro medical diagnostic device TEG6s® Platelet Mapping|"Preoperative period:~* Pre-operative blood sampling, according to the usual practices of the unit before surgery~* Collection of the patient's usual demographic characteristics~per operative period :~* After anesthetic induction:a TEG6S platelet mapping® sampled from the arterial catheter routinely placed after anesthetic induction~* During the CPB, 30 min before aortic declamping: performing TEG 6S platelet mapping® (heparinized tube)~* 5 min after heparin antagonization by protamine, after the weaning of the bypass, and before any transfusion: performing a TEG 6S citrate® (citrated tube)~Post-operative period (resuscitation):~• postoperative bleeding at 2 hours and during the first 12 hours."
48655086|NCT02220400|DRUG|Ketamine|
48655087|NCT04154163|DIAGNOSTIC_TEST|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
48655088|NCT04154163|DIAGNOSTIC_TEST|Venous blood sampling|Venous blood
48655089|NCT06193681|OTHER|Pedi@ctivity Exercise Mobile Application Exercise Program|The first group of the study received a mobile application (Pedi@ctivity) based exercise program. With the Pedi@ctivity exercise mobile application, the selected exercises and exercise program will be offered personalized to each adolescent for 12 weeks. After 12 weeks, the effectiveness of the Pedi@ctivity mobile application-based exercise program on the evaluation parameters will be investigated.
48655090|NCT06193681|OTHER|Supervised Exercise Group|In the physiotherapist-supervised personalized exercise program, the exercises selected through the Pedi@ctivity exercise mobile application will be applied to adolescents under the supervision of a physiotherapist (2 sessions face-to-face, 1 session online/synchronous).
48655091|NCT06570720|BEHAVIORAL|Alcohol-focused Support of Survivors in Sororities Training (ASSIST)|A web-based intervention that includes sorority and individual values, personalized normative feedback (adapted to address sexual assault, support, and acceptability of encouraging peer drinking), psychoeducation on sexual assault and alcohol, and skills training in behaviors to support sexual assault survivors without heavy drinking.
48655092|NCT05080478|DRUG|Clopidogrel, Ticagrelor|P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
48655093|NCT00666042|DRUG|Vigamox - administration in spray form|Vigamox will be administered in a spray form
48655094|NCT00666042|DRUG|Vigamox eye drops|Vigamox eye drops
48338786|NCT05829395|OTHER|metaverse- based education|"The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course.~Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test."
48338787|NCT02792049|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
48338788|NCT02792049|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
48338789|NCT04787926|DEVICE|Locking Solution|The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
48338790|NCT05460689|OTHER|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
48338791|NCT05460689|OTHER|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
48338792|NCT00901862|DEVICE|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
48338793|NCT00901862|DEVICE|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
48338794|NCT04307953|DRUG|AZD0530 Difumarate|AZD0530 for the duration of the trial
48338795|NCT04307953|DRUG|Matching placebo|Matching placebo during 6 month RCT, AZD0530 thereafter
48338796|NCT03438513|BEHAVIORAL|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
48338797|NCT03438513|BEHAVIORAL|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
48338798|NCT03438513|BEHAVIORAL|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
48338799|NCT03438513|BEHAVIORAL|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
48338800|NCT00662389|DEVICE|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
48338801|NCT04125875|DIAGNOSTIC_TEST|Electrogastrogram(EGG)|Heart Rate Variability
48338802|NCT04125875|DIAGNOSTIC_TEST|Heart Rate Variability(HRV)|Heart Rate Variability
48338803|NCT04959604|PROCEDURE|ICG-marking endoscopically|Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.
48338804|NCT01666860|PROCEDURE|Anterior Lumbar Interbody Fusion procedure|
48338805|NCT04229108|DEVICE|Medopad|Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
48338806|NCT03483831|BEHAVIORAL|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
48338807|NCT02715596|DIETARY_SUPPLEMENT|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
48338808|NCT02715596|OTHER|Placebo|placebo in 15 cc emulsion stick-pack
48338809|NCT00993304|DRUG|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
48338810|NCT00993304|DRUG|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
48338811|NCT00215592|DRUG|Zonegran|
48338812|NCT02585076|OTHER|Standard of care|As prescribed by treated physician
48496766|NCT02878486|DEVICE|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
48655095|NCT05454982|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
48131460|NCT05254067|DEVICE|Codman Enterprise 2 Vascular Reconstruction Device|a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
48131461|NCT05643456|PROCEDURE|surgery|"69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group 30 patients had two muscles surgery; bilateral lateral rectus recession.~The 2nd group 39 patients had three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking."
48496767|NCT02878486|BEHAVIORAL|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
48338813|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
47979589|NCT02384408|PROCEDURE|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
48338814|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
48338815|NCT01220713|PROCEDURE|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
47979590|NCT04316754|OTHER|music|"During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group."
48338816|NCT05355181|OTHER|Scar mobilization techniques|"Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges."
48338817|NCT05355181|OTHER|Core stabilization exercises|Core stabilization exercises
48338818|NCT00838695|DRUG|Phenylephrine|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
47979591|NCT01294657|BEHAVIORAL|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
47979592|NCT01294657|BEHAVIORAL|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
47979593|NCT03272074|OTHER|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
48496768|NCT02878486|DEVICE|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
47979594|NCT03589443|DRUG|Multiplexed heptapeptides|Heptapeptides QRH and KSP
47979595|NCT00894049|DRUG|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
47979596|NCT01037647|OTHER|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
47979597|NCT03537898|OTHER|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
47979598|NCT03537898|OTHER|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
47979599|NCT04599712|DRUG|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram \[mg\] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
48131463|NCT06476119|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy according to local/ national guidelines
47979600|NCT05711173|BIOLOGICAL|Additional blood sampling|The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)
47979601|NCT04920370|DRUG|ALXN1720 SC|ALXN1720 will be administered via SC route.
47979602|NCT04920370|DRUG|ALXN1720 IV|ALXN1720 will be administered via IV route.
48131464|NCT06476119|OTHER|No adjuvant chemotherapy|no adjuvant chemotherapy
48131465|NCT04110743|DEVICE|EXPLORER PET/CT|Intervention: PET/CT using different protocols
48496769|NCT05597956|PROCEDURE|white defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
48496770|NCT05597956|PROCEDURE|yellow defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
48338819|NCT03747536|DRUG|Ipratropium bromide|ipratropium bromide via metered dose spray (21 micrograms per spray)
48338820|NCT03747536|OTHER|Placebo|normal saline delivered via metered dose spray
47979603|NCT04920370|DRUG|rHuPH20|rHuPH20 will be administered via SC route.
47979604|NCT04920370|DRUG|Placebo SC|Placebo will be administered via SC route.
47979605|NCT04920370|DRUG|Placebo IV|Placebo will be administered via IV route.
47979606|NCT01511315|DRUG|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
48496771|NCT05597956|PROCEDURE|brown defects|"With the previously cleaned tooth, the enamel will be prepared with a product that makes it more porous, thus eliminating the decalcified areas of the deepest part of the lesion. After completely removing the water from the surface, the resin will be applied infiltrating between the canaliculi of the enamel. When polymerized, it will form a framework that will seal the surface, thus improving surface resistance and aesthetics by modifying the refractive indices of the affected enamel, mimicking it with the remaining healthy enamel."
48655096|NCT06642493|BIOLOGICAL|Fresh frozen plasma|"Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion."
48131478|NCT06664021|DRUG|Tislelizumab combined with S-1|Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles.
48131479|NCT05094128|DRUG|Upadacitinib|Tablet; Oral
48131480|NCT06605391|BEHAVIORAL|Caregiving While Black-LIVE|Caregiving while Black-LIVE is a psychoeducation program that aims to intensify the development of caregiver mastery by integrating the online learning assets of the fully asynchronous Caregiving while Black program with synchronous, group-based opportunities for interactivity and active learning. The Caregiving while Black course includes topics of navigating the healthcare system, managing home life, and caregiver self-care. Once enrolled in the course, participants will be provided instructions for accessing the weekly sessions and course online, and supplemental course materials will be mailed to them. The Canvas platform enables the research team to monitor each individual's movement in the cohort through the asynchronous part of the course. Nudges and reminders to view these materials are sent twice a week via text or email with participant's consent. Synchronous sessions are conducted on a videoconferencing platform.
48131481|NCT04494113|PROCEDURE|Biopsy|Undergo biopsy
48131482|NCT04494113|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
48338821|NCT02532569|BIOLOGICAL|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
48338822|NCT05065268|DEVICE|Immersive Virtual-Reality Stimulation|IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
48338823|NCT00546507|DRUG|TDS-943 (topical diclofenac sodium 4% spray)|
48338824|NCT00546507|DRUG|celecoxib|
48338825|NCT00546507|OTHER|placebo|
48338826|NCT00631618|DRUG|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
48338827|NCT01146951|DRUG|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
48338828|NCT01146951|DRUG|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
48338829|NCT05152368|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48338830|NCT02788591|DRUG|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
48338831|NCT02788591|DRUG|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
48338832|NCT04023136|PROCEDURE|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
48338833|NCT02736396|OTHER|fMRI|Functional MRI scan to be performed
48338834|NCT02736396|OTHER|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
48131483|NCT04494113|PROCEDURE|Resection|Undergo surgical resection
48131484|NCT04494113|DRUG|Triapine|Given IV
48338835|NCT06094114|DEVICE|pacemaker follow-up|Performance of an exercise test in patients previously implanted with Micra AV
48338836|NCT00810810|BIOLOGICAL|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
48338837|NCT00810810|BIOLOGICAL|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
48338838|NCT00810810|BIOLOGICAL|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
48338839|NCT01181440|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
48338840|NCT01181440|OTHER|Conventional care|Weekly application of conventional care
48338841|NCT06418568|DEVICE|Ultra-pulsed Shockwave Therapy Device by Shenzhen Lifotronic Technology Co., Ltd.|The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration. The shockwave therapy parameters are tailored based on patient tolerance. Each patient undergoes 3 treatment sessions spaced 3 weeks apart, followed by a 4-week follow-up period. Facial skin is assessed using the VISIA system before each treatment and at the 4-week follow-up, evaluating the Melasma Area Severity Index (MASI). Patient and researcher satisfaction levels are rated on a scale of 1 to 5. Adverse reactions, including short-term effects like pain and swelling, and potential long-term effects such as allergic reactions and hyperpigmentation, are monitored after each treatment session.
48338842|NCT00371813|DRUG|Varenicline tartrate|
48131487|NCT00556478|DRUG|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
48131488|NCT00556478|DRUG|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
48496772|NCT05387538|PROCEDURE|One-layer Duct-to-mucosa Pancreaticojejunostomy|To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used
48655097|NCT00830531|DRUG|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
48655098|NCT00830531|DRUG|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
48655099|NCT06186284|DIAGNOSTIC_TEST|nerve conduction study|sensory and motor nerve conduction study of both median nerves and ulnar nerves
48655100|NCT06186284|DIAGNOSTIC_TEST|ultrasonography wrists|assess the cross-sectional area of the median nerves and the ulnar nerves
48655101|NCT06186284|DIAGNOSTIC_TEST|Boston carpal tunnel questionnaire|assess the severity of symptoms and the functional impact related to carpal tunnel syndrome
48655102|NCT06186284|DIAGNOSTIC_TEST|clinical provocative tests for carpal tunnel syndrome|Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
48655103|NCT03829501|DRUG|KY1044|A human anti-ICOS monoclonal antibody
48655104|NCT03829501|DRUG|KY1044 and atezolizumab|A human anti-ICOS monoclonal antibody in combination with anti-PD-L1 monoclonal antibody (atezolizumab)
48655105|NCT01660373|DRUG|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
48655106|NCT01660373|DRUG|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
48655107|NCT00044785|DRUG|triacetyluridine|
48655108|NCT00044785|DRUG|fluorouracil|
48131489|NCT05214222|DRUG|Anlotinib/Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Anlotinib: once a day, 1 capsule each time (10mg for body weight \<60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~* Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
48338843|NCT00371813|DRUG|Placebo|
48338844|NCT00603850|DEVICE|ForeseeHome|human factor
48655109|NCT00044785|DRUG|leucovorin|
48338845|NCT05564208|DRUG|elafibranor|Oral Tablet
48338846|NCT05564208|DRUG|elafibranor|Oral Tablet
48655110|NCT00044785|DRUG|camptosar|
48655111|NCT05078229|BEHAVIORAL|FOCUS|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.
48655112|NCT05078229|BEHAVIORAL|Healthy Living|There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
48655113|NCT05278715|DRUG|Carboplatin|Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
48655114|NCT05278715|DRUG|Vincristine|Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
48655115|NCT05278715|DRUG|Recombinant human endostatin|Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
48655116|NCT02873052|DEVICE|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
48655117|NCT06638502|DRUG|HRX215 capsules|HRX215 capsules 250 mg orally twice daily
48655118|NCT06638502|DRUG|Placebo capsules|placebo capsules matching appearance of HRX215
48655119|NCT00237159|DRUG|Zoledronic acid|
48655120|NCT03539614|DRUG|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
48131490|NCT05214222|DRUG|Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
48496773|NCT05387538|PROCEDURE|Two-layer Duct-to-mucosa Pancreaticojejunostomy|The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
48338847|NCT03797508|DIAGNOSTIC_TEST|ultrasound|To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
48131492|NCT05640115|DEVICE|Ureteral Stent|A ureteral stent is a soft, hollow tube that is placed temporarily into the ureter. The stent allows the urine to drain. The stent has a coil on each end that keeps it from moving. The top end coils in the kidney and the lower end coils inside the bladder.
48131493|NCT05640115|DEVICE|Percutaneous Nephrostomy Tube Placement|A percutaneous nephrostomy is the placement of a small, flexible rubber tube (catheter) through your skin into your kidney to drain your urine. It is inserted through your back or flank.
48338848|NCT00419367|DRUG|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
48338849|NCT01819441|DRUG|Azelnidipine|8mg or 16mg
48338850|NCT01819441|DRUG|Perindopril|4mg or 8mg
48338851|NCT01819441|DRUG|hydrochlorothiazide|12.5mg or 25mg
48338852|NCT06179706|DIAGNOSTIC_TEST|11C-choline PET/CT|In our study we evaluated the efficacy of high-dose RT guided by 11C-Choline PET/CT on bone metastases in prostate cancer patients with a limited number of metastases.
48338853|NCT05168176|DRUG|Dotilavir sodium tablet|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
48338854|NCT05168176|DRUG|Dotilavir sodium tablet(Tivicay@)|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
48338855|NCT03154177|BEHAVIORAL|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
48338856|NCT03154177|PROCEDURE|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
48338857|NCT05641155|DEVICE|Focused Multipolar Stimulation (FMS) strategy|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters.
48338858|NCT05008133|BEHAVIORAL|Bicycle exercise|Stepwise increased exercise for 5 minutes at 0, 50, 100 and 150 Watts. One series lying flat in prone position, after 15 minutes of rest, series repeated at 70 degrees head up tilt.
48338859|NCT04055467|DRUG|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
48338860|NCT04055467|BEHAVIORAL|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
48338861|NCT00002004|DRUG|CD4 Antigens|
48338862|NCT01714713|DRUG|EVP-6124|Arm 1, 2
48496774|NCT06238596|PROCEDURE|rehabilitation|The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
48496775|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
48496776|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
48338863|NCT02798562|DEVICE|Native and dynamic contrast-enhanced CT|
48338864|NCT02957110|BEHAVIORAL|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
48338865|NCT00647946|DRUG|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
48338866|NCT00647946|DRUG|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
48338867|NCT00179569|BEHAVIORAL|Relaxation response|8 weeks of relaxation response training
48338868|NCT02187341|DIETARY_SUPPLEMENT|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
48338869|NCT02187341|DIETARY_SUPPLEMENT|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
48496777|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
48496778|NCT01120041|BEHAVIORAL|health education|Traditional health education given during the prenatal phase and the postpartum phase
48496779|NCT00291980|BIOLOGICAL|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
48496780|NCT00291980|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
48496781|NCT03000218|DRUG|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
48496782|NCT03000218|DRUG|Metformin|Day 29 to 56: Metformin 500mg bid
48496783|NCT03000218|DRUG|Placebo|Day 1 to 56: Placebo bid
48496784|NCT00997568|DEVICE|PET-511BTM|Transesophageal Transducer
48496785|NCT03512860|DRUG|E4/DRSP|Administered as specified in the treatment arm.
48496786|NCT03512860|DRUG|VAL|Administered as specified in the treatment arm.
48496787|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
48496788|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
48496789|NCT04161846|BEHAVIORAL|Virtual Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.
48496790|NCT04161846|BEHAVIORAL|In Person Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
48496791|NCT03738020|DEVICE|HA IDF (YVOIRE classic)|Treatment with HA IDF
48496792|NCT03738020|DEVICE|Restylane|Treatment with Restylane
48496793|NCT01510548|BIOLOGICAL|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
48655121|NCT03539614|DRUG|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
48655122|NCT04627974|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
48655123|NCT00002809|BIOLOGICAL|anti-thymocyte globulin|
48496794|NCT01944176|DRUG|simvastatin, placebo|
48496795|NCT04310813|DIAGNOSTIC_TEST|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
48496796|NCT00144911|DRUG|Salmeterol|
48655124|NCT00002809|BIOLOGICAL|filgrastim|
48655125|NCT00002809|BIOLOGICAL|sargramostim|
48496797|NCT00144911|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
48496798|NCT02590250|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
48496799|NCT01561430|DRUG|LY2886721|
48655126|NCT00002809|BIOLOGICAL|therapeutic immune globulin|
48655127|NCT00002809|DRUG|cyclophosphamide|
48655128|NCT00002809|DRUG|methotrexate|
48655129|NCT00002809|DRUG|tacrolimus|
48655130|NCT00002809|PROCEDURE|allogeneic bone marrow transplantation|
48655131|NCT00002809|RADIATION|radiation therapy|
48655132|NCT06094855|OTHER|20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest|2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
48496800|NCT01561430|DRUG|Placebo|
48496801|NCT05552079|OTHER|No intervention|Patients will be asked to show their consultation slip to confirm they attend to clinic on the day. The will also be asked to show their HKID card to comfirm they are aged 40 or above. The purpose of the study will be explained. If patient agrees to proceed, he/she will be given a self-administered questionniare. An interviewer-administered questionnaire will be provided for subjects who have poor sightedness or are illiterate. Since only anonymous data and no identifiable information will be collected, participants cannot be identified from the questionnaire. Therefore, inform consent will not be obtained.
48496802|NCT01251029|DRUG|N-acetylcysteine|1200 mg orally; 600mg i.v.
48496803|NCT01251029|DRUG|Siran (N-acetylcysteine)|
48655133|NCT06095102|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
48655134|NCT06095102|DRUG|Placebo|Placebo will be administered orally.
48655135|NCT02070211|DIETARY_SUPPLEMENT|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
48655136|NCT02070211|OTHER|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
48655137|NCT02070211|DIETARY_SUPPLEMENT|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
48338870|NCT04516655|DRUG|chidamide combined with rituximab and high-dose methotrexate|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
48655138|NCT06300632|OTHER|geriatric locomotive syndrome|Elderly individuals will be included in the study. Before each elderly person starts the study, they will be informed about the content of the study and they will read and sign the consent form stating that they participate in the study voluntarily. Socio-demographic data (age, body mass index, and family history, fall history, ) of all individuals participating in the study will be recorded.Within the scope of the evaluation, locomotive syndrome evaluation will be made through a survey. Fear of movement will be evaluated with the Tampa kinesiophobia scale, your physical activity level with the physical activity scale for the elderly, your physical performance with the short physical performance battery, your fatigue level with the fatigue severity scale, and your cognitive functions with the Montreal Cognitive Assessment Scale.
48338871|NCT03616262|DRUG|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
48338872|NCT03616262|DRUG|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
48496804|NCT05153421|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
48496805|NCT05367479|DRUG|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
48655139|NCT05698498|OTHER|Guaranteed Income|Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.
48496806|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
48338873|NCT03848715|BIOLOGICAL|Endotoxin|Endotoxin
48496807|NCT01831765|DRUG|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
48338874|NCT03848715|BIOLOGICAL|Placebo|Placebo
48338875|NCT04181957|DRUG|Placebo oral tablet|Participants take one dose of placebo (lactose) tablet.
48338876|NCT04181957|DRUG|Lisdexamfetamine Dimesylate|Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
48338877|NCT05305001|GENETIC|Invitae Multi-Cancer Panel ®|Participants will have genetic testing.
48338878|NCT01592006|DRUG|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
48496808|NCT01831765|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
48496809|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
48496810|NCT05965115|DIAGNOSTIC_TEST|Sample of Blood|All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.
48496811|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
48496812|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
48496813|NCT03127644|DRUG|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
48496814|NCT03370874|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
48496815|NCT03370874|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to diabetic foot ulcer
47979607|NCT04435860|OTHER|Truncal flexion-extension muscle power|Patient performs a maximum truncal flexion laying supine on the bed with cap of muscle tester placed on sternum,
47979608|NCT04435860|OTHER|Truncal extension muscle power|Patient performs a maximum truncal extension laying prone on the bed while the cap of manual muscle tester placed on vertebrae at the level of midline between superior angles of scapulae.
47979609|NCT04435860|OTHER|Cervical flexion muscle power|Patient performs a maximum cervical flexion sitting while the cap of manual muscle tester placed on the middle of the forehead.
48496816|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
48496817|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
48131496|NCT05309616|DRUG|Taltz|Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
48496818|NCT04057469|DRUG|Tulobuterol Hydrochloride|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
48496819|NCT04057469|DRUG|Placebo transdermal patch|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
48496820|NCT02243839|DRUG|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
48338879|NCT01592006|DRUG|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
48338880|NCT01592006|DRUG|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
48655140|NCT05698498|OTHER|Public Benefits Information Session|All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
48655141|NCT06121856|DEVICE|VerioVue Enhancements BGMS|Blood glucose monitoring system
48655142|NCT03809351|DRUG|[F-18]AV-1451-PET|All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
48655143|NCT02371187|DRUG|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
48655144|NCT02371187|DRUG|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
48655145|NCT04649905|PROCEDURE|Surgical Treatment|Surgical standard-of-care treatment for knee OCD
47979610|NCT04435860|OTHER|Cervical extension muscle power|Patient performs a maximum cervical extension sitting while the cap of manual muscle tester placed on protuberantia occipitalis.
47979611|NCT04435860|OTHER|Cervical lateral flexion muscle powers|Patient performs a maximum cervical lateral flexions on right and left sitting while the cap of manual muscle tester placed on relevant pterion.
47979612|NCT04435860|OTHER|Shoulder flexion muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior aspect of acromion and anterior elbow.
47979613|NCT04435860|OTHER|Shoulder extension muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior aspect of acromion and posterior elbow.
47979614|NCT04435860|OTHER|Shoulder internal rotation muscle power|Patient performs a maximum shoulder internal rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior elbow and wrist.
48496821|NCT02243839|PROCEDURE|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
48496822|NCT02631967|PROCEDURE|Kono anastomosis|Kono anastomosis
48496823|NCT02631967|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
48496824|NCT04320654|OTHER|exercise|The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
48496825|NCT03155321|OTHER|It's an observational study - no intervention is planned|No intervention is planned
48496826|NCT03674086|DEVICE|eAdjust 0.2 hearing aid smartphone application (or app)|The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
48496827|NCT01555008|DRUG|LX4211|Subjects will receive LX4211 once daily for 7 days
48496828|NCT01555008|DRUG|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
48496829|NCT02286596|DEVICE|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
48496830|NCT02286596|DEVICE|dextran sulfate adsorption|Lipid apheresis for 3 hours
48496831|NCT00235196|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
48496832|NCT02931006|OTHER|water|
48496833|NCT02931006|OTHER|bovine milk|
48496834|NCT03204708|DEVICE|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
48496835|NCT03204708|DRUG|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
48496836|NCT05802251|DIAGNOSTIC_TEST|Ultrasonographic parameters|cervical length. placental thickness. distance placental edge from internal os of the cervix
48496837|NCT05824247|DEVICE|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
48496838|NCT02352545|DRUG|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
48496839|NCT01041183|DRUG|intravenous ramosetron|0.3 mg IV ramosetron (group I)
48655146|NCT04649905|PROCEDURE|Nonoperative Treatment|Nonoperative standard-of-care treatment for knee OCD
48496840|NCT01041183|DRUG|oral ramosetron|0.1 mg oral ramosetron (group II)
48496841|NCT01041183|DRUG|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
48496842|NCT04796753|OTHER|Basketball Injury Defense|To establish a specific evaluation protocol for youth basketball players.
47914275|NCT04506099|DEVICE|TINS Active protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect, verified with contraction of the rectus abdominis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
47979615|NCT04435860|OTHER|Shoulder external rotation muscle power|Patient performs a maximum shoulder external rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior elbow and wrist.
47979616|NCT04435860|OTHER|Shoulder abduction muscle power|Patient performs a maximum shoulder abduction of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line lateral aspect of acromion and lateral epicondyle.
47979617|NCT04435860|OTHER|Hip flexion muscle power|Patient performs a maximum hip flexion laying supine on the bed while the cap of manual muscle tester placed on middle of the anterior thigh.
48338881|NCT02768103|BEHAVIORAL|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
48338882|NCT04618406|DEVICE|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
48496843|NCT05934240|OTHER|Manual therapy group|Manual therapy will be applied to the diaphragm and thoracic region.
48496844|NCT05934240|OTHER|Sham-manual therapy|Sham-manual therapy will be applied to the diaphragm and thoracic region.
48496845|NCT00274820|DIETARY_SUPPLEMENT|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
48496846|NCT00274820|DRUG|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
48338883|NCT04618406|OTHER|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
48338884|NCT03374761|OTHER|Families First Home Visiting Program|10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
48496847|NCT00274820|DRUG|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
48496848|NCT00274820|DRUG|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience \< grade 1 thalidomide-attributed toxicity using CTC criteria.
48496849|NCT01879748|DRUG|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
47979618|NCT04435860|OTHER|Hip extension muscle power|Patient performs a maximum hip extension laying prone on the bed while the cap of manual muscle tester placed on middle of the posterior thigh.
47979619|NCT04435860|OTHER|Hip abduction muscle power|Patient performs a maximum hip abduction laying supine on the bed while the cap of manual muscle tester placed on middle of the lateral thigh.
47979620|NCT04435860|OTHER|Hip internal rotation muscle power|Patient performs a maximum hip internal rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between lateral condyle of femur and lateral malleolus.
47979621|NCT04435860|OTHER|Hip external rotation muscle power|Patient performs a maximum hip external rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between medial condyle of femur and medial malleolus.
47979622|NCT04435860|OTHER|Bath Ankylosing Spondylitis Functional Index (BASFI)|"This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being easy and 10 impossible) is used to answer the questions on the test. The final score varies between 0 and 10."
48496850|NCT01879748|DRUG|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)"
48496851|NCT04425135|DRUG|Camrelizumab|200mg,D1,ivgtt, Q3w.
48496852|NCT04425135|DRUG|Apatinib|250mg,Qd,Q3W.
48496853|NCT04425135|DRUG|Pemetrixed|500 mg/m2,D1,ivgtt, Q3w.
48338885|NCT05246488|DIAGNOSTIC_TEST|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
48338886|NCT05287269|DIAGNOSTIC_TEST|Ocular Coherence Tomography|OCT images were recorded as a fast macular radial line scan with captured on either Heidelberg Spectralis (Heidelberg Engineering GmbH, Germany) or Topcon DRI Triton (Topcon Medical Systems inc. USA).
48338887|NCT02288039|OTHER|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
48338888|NCT01085656|DRUG|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
48496854|NCT04425135|DRUG|Carboplatin|AUC=5\~6,D1,ivgtt, Q3w.
48496855|NCT04525235|COMBINATION_PRODUCT|phenotyping cocktail|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
48655147|NCT05101551|DRUG|Talazoparib|"Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19"
48496856|NCT04525235|DRUG|rifampicin|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
48496857|NCT02908282|DEVICE|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
48496858|NCT02908282|DEVICE|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
48496859|NCT02923674|BEHAVIORAL|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
48496860|NCT02923674|BEHAVIORAL|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
48338889|NCT00632996|OTHER|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
48338890|NCT02137707|DRUG|Gilenya|All patients will receive Gilenya
48496861|NCT02923674|BEHAVIORAL|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).
48496862|NCT00041249|DRUG|brostallicin|
48496863|NCT02180126|OTHER|Follow-up|Follow-up of of patients with borderline positive ANCA test results
48496864|NCT00453557|DRUG|rhGH|
48496865|NCT03073785|DRUG|Capecitabine|Given PO
48496866|NCT03073785|DRUG|Fluorouracil|Given IV
48496867|NCT03073785|OTHER|Laboratory Biomarker Analysis|Correlative studies
48496868|NCT03073785|OTHER|Pharmacological Study|Correlative studies
47979623|NCT04435860|OTHER|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
48496869|NCT03073785|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
48496870|NCT03073785|DRUG|Zoledronic Acid|Given IV
48496871|NCT03601650|BEHAVIORAL|Mindful eating|Attending to the sensory properties of food as it is eaten
47979624|NCT04435860|OTHER|The Health assessment questionnaire (HAQ)|The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
47979625|NCT04435860|OTHER|Bath Ankylosing Spondylitis Metrology Index (BASMI)|Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
47979626|NCT05803057|DEVICE|TMS stimulation treatment|Using the TMS treatment coli to stimulation with high frequency
47979627|NCT05803057|DEVICE|TMS stimulation sham-treatment|Using the TMS sham-treatment coli to stimulation with high frequency
47979628|NCT02465801|DRUG|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
47979629|NCT02465801|DRUG|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
47979630|NCT02465801|DRUG|GCSF|GCSF 5 mcg/kg/day
47979631|NCT03916328|DRUG|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
47979632|NCT03916328|DRUG|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
47979633|NCT03916328|OTHER|DMPA|Two thirds of the women will be on DMPA for contraception.
47979634|NCT06040112|DEVICE|Atelocollagen|Tendoregen (Atelocollagen) injection
47979635|NCT04161560|DRUG|Cetuximab-IRDye800|does of Cetuximab-IRDye800
47979636|NCT00399854|DEVICE|Dhermia® - Industra Mecânica Fina Ltda|
48131536|NCT06566742|DRUG|Olutasidenib|Given by PO
48496872|NCT03601650|BEHAVIORAL|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
48496873|NCT03967951|OTHER|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
48496874|NCT01715064|BEHAVIORAL|Exercise|1 hour of moderate-intensity exercise
48496875|NCT03400943|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
48496876|NCT03400943|DRUG|Placebo|Matching placebo was administered to group B1 and B2.
48496877|NCT00813566|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
48496878|NCT00813566|DRUG|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
48496879|NCT00813566|DRUG|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
48496880|NCT00813566|DRUG|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
47979637|NCT01824901|DRUG|docetaxel|Given IV
47979638|NCT01824901|DRUG|AZD4547|Given PO
48131543|NCT00044564|DRUG|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
48496881|NCT00671138|BIOLOGICAL|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
48496882|NCT00671138|OTHER|Sham inoculation|A diluted amount of McIlhenny \& Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
48496883|NCT04203875|DRUG|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
48496884|NCT01377675|OTHER|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
48496885|NCT05932992|OTHER|Mother education on how to perform MUAC assessment|Mothers will be trained to perform MUAC weekly on their children
48496886|NCT01104909|PROCEDURE|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
48496887|NCT01104909|DEVICE|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
47979639|NCT04544254|PROCEDURE|Bilateral transversus thoracis muscle plane block|The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
47979640|NCT04544254|PROCEDURE|Control|A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
47979641|NCT03532334|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
48655148|NCT05101551|DRUG|Topotecan|"Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5"
47979642|NCT04823650|DEVICE|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
48496888|NCT03039660|BEHAVIORAL|RefreshMD|Online Sleep Improvement Course
48496889|NCT03039660|BEHAVIORAL|Bond Between Us|Online Educational Course
48655149|NCT05101551|DRUG|Gemcitabine|"Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1"
48655150|NCT05247398|OTHER|Dynamic Stability Exercise Program|The thumb CMC DS intervention involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults.
48655151|NCT06134401|DEVICE|saline|nebulised
48655152|NCT06643559|OTHER|cognitive rehabilitation|Cognitive rehabilitation started to one group at the beginning of the antiseizure medicine. Participants underwent computer-based cognitive rehabilitation for 3 sessions per week, with each session lasting an average of 60 minutes. Before the sessions, all participants were given detailed information about the programme and its use. The rehabilitation process was carried out in three areas of cognitive functions: memory, executive functions, and language skills.
48655153|NCT01673919|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
48655154|NCT06637007|DRUG|Chidamide Tablets combined with AK112|Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
48655155|NCT03499743|DRUG|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
48655156|NCT03499743|DRUG|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
48655157|NCT03499743|DRUG|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
48131544|NCT00736463|DRUG|Simvastatin|One arm of randomized crossover
48131545|NCT00736463|DRUG|Atorvastatin 80 mg|Second arm of randomized crossover
48655158|NCT00567229|BIOLOGICAL|rituximab|
48496890|NCT03453801|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
48655159|NCT00567229|DRUG|lenalidomide|
48655160|NCT00567229|GENETIC|microarray analysis|
48496891|NCT03453801|BIOLOGICAL|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
48496892|NCT05094492|COMBINATION_PRODUCT|Curodont Repair Fluoride Plus|P11-4 self assembling peptide combined with fluoride
48496893|NCT05094492|OTHER|Bifluorid 10 fluoride varnish|5% Sodium Fluoride varnish (equal to 22,600 ppm fluoride)
48496894|NCT05157867|OTHER|Amylase trypsin inhibitors|Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.
48655161|NCT00567229|OTHER|flow cytometry|
48655162|NCT00567229|OTHER|laboratory biomarker analysis|
48655163|NCT06640777|DRUG|LEAF-4L6715|LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).
48655164|NCT06640777|DRUG|Supportive Care|Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
48655165|NCT05983809|DEVICE|Technological rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
48655166|NCT05815498|BIOLOGICAL|mRNA-1283.222|Sterile liquid for injection
48655167|NCT05815498|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
48655168|NCT05815498|BIOLOGICAL|mRNA-1283.815|Sterile liquid for injection
48655169|NCT05815498|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
48655170|NCT05544760|OTHER|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
48655171|NCT02805348|DRUG|Bixalomer|Oral
48655172|NCT02002858|DRUG|Nicotine Patch|
48655173|NCT02002858|BEHAVIORAL|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
48655174|NCT02002858|BEHAVIORAL|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
48655175|NCT06645119|DIETARY_SUPPLEMENT|Whey Protein Supplement|Examining the independent effect of post-exercise dietary protein ingestion on bone metabolic markers.
48655176|NCT06640127|PROCEDURE|Sinus lifting and implant placement with osteotomes|Osteotomes with increasing diameters were used for sinus membrane elevation and implant insertion
48496895|NCT05157867|OTHER|Placebo|Intraduodenal administration of placebo (physiological saline).
48496896|NCT02686645|BIOLOGICAL|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
48496897|NCT02686645|DRUG|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
48496898|NCT02686645|DRUG|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
48496899|NCT02686645|DRUG|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
48496900|NCT06345989|DEVICE|Alginate impression|Alginate impression
48655177|NCT06640127|PROCEDURE|Sinus lifting and implant placement with specifically designed drills|Sequential drills were used for sinus membrane elevation and implant insertion
48655178|NCT05917288|BIOLOGICAL|Belimumab|Belimumab will be administered
48655179|NCT05917288|DRUG|Standard of care|Standard of care will be administered
48496901|NCT06345989|DEVICE|Intraoral scan|Intraoral scan with Trios 3Shape Scanner
48655180|NCT06645392|DEVICE|visual transparent bladed trocar of|visual transparent bladed trocar of diameter 10 mm and Ternamian bladeless trocar of diameter 10 mm
48655181|NCT06645392|DEVICE|Ternamian bladeless trocar|Ternamian bladeless trocar of diameter 10 mm
48655182|NCT01687062|OTHER|FeSO4|
48655183|NCT01687062|OTHER|reduction of phytate|
48655184|NCT01687062|OTHER|NaFeEDTA|
48655185|NCT06564727|PROCEDURE|Uniportal VATS approach|Uniportal VATS resection for simple pulmonary aspergilloma
48655186|NCT06564727|PROCEDURE|VATS approach|VATS resection for complex pulmonary aspergilloma
48655187|NCT06333652|DRUG|Ravulizumab|Intravenous infusion 100 mg/ml
48655188|NCT04105283|BIOLOGICAL|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
48655189|NCT06631534|DRUG|Dexmedetomidine|Dexmedetomidine 1ug/kg bolus administered over 10 minutes followed by a continuous infusion of 0.5ug/kg/hr
48655190|NCT06631534|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline (placebo)
48655191|NCT06408233|OTHER|Performance Coaching|Performance coaching will consist of working with clinic staff to understand and guide current quality measurement practices as well as improving quality measurement and implementing new measures and management practices.
48655192|NCT06643143|DRUG|IkT-001Pro|IkT-001Pro
48496902|NCT03063879|DRUG|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
48496903|NCT00996775|BEHAVIORAL|brief alcohol intervention|this intervention consists of brief assessment and feedback
48496904|NCT00996775|BEHAVIORAL|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
48496905|NCT05097313|DIETARY_SUPPLEMENT|Yeast β-glucan fiber|The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.
48496906|NCT05097313|OTHER|Placebo|oral consumption of 200 mg (one capsule) or 400 mg (two capsules) of soy protein powder for 84 days.
48496907|NCT04149106|DRUG|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
48496908|NCT04149106|DRUG|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
48496909|NCT01431911|DRUG|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
48496910|NCT01431911|DRUG|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
48655193|NCT06643143|DRUG|Placebo|Placebo
48655194|NCT05685602|PROCEDURE|Biopsy|Undergo a tumor biopsy
48496911|NCT00188487|DEVICE|magnetic resonance imaging (MRI) of the thorax|
48496912|NCT01113944|BEHAVIORAL|Program 1|
48496913|NCT01113944|BEHAVIORAL|Program 2|
48496914|NCT06032962|PROCEDURE|salpingectomy|surgical removal of the fallopian tubes
48496915|NCT02646930|PROCEDURE|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
48496916|NCT03255655|DEVICE|Intense Therapeutic Ultrasound Treatment - ITU|
48496917|NCT03829696|DRUG|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
48655195|NCT05685602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48655196|NCT05685602|PROCEDURE|Computed Tomography|Undergo a CT scan
48655197|NCT05685602|BIOLOGICAL|Emavusertib|Given PO
48655198|NCT05685602|DRUG|Gemcitabine Hydrochloride|Given IV
48655199|NCT05685602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48655200|NCT05685602|DRUG|Nab-paclitaxel|Given IV
48655201|NCT05685602|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
48655202|NCT05685602|PROCEDURE|X-Ray Imaging|Undergo an x-ray
48655203|NCT05912634|PROCEDURE|Conservative TAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
48655204|NCT05912634|PROCEDURE|Extensive TAAD- R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
48655205|NCT05724771|DRUG|Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
48655206|NCT06454240|DRUG|lunsekimig|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
48655207|NCT06454240|DRUG|placebo|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
48655208|NCT01356940|DRUG|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
48131553|NCT04073953|DRUG|RPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
48131554|NCT04073953|DRUG|SPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
48131555|NCT04073953|DRUG|Placebo|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
48131556|NCT02958800|OTHER|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
48131557|NCT02620306|DRUG|Fimsartan 60mg~120mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
48496918|NCT03829696|DRUG|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
48496919|NCT03829696|DRUG|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
48496920|NCT03829696|DIAGNOSTIC_TEST|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
48496921|NCT01164345|DRUG|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
48496922|NCT02017548|BEHAVIORAL|Life-extension default advance directive|
48496923|NCT02017548|BEHAVIORAL|Comfort default advance directive|
48496924|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m\^2 for normal hepatic function.
48496925|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)
48496926|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
48496927|NCT02459496|BEHAVIORAL|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
48655209|NCT01356940|DRUG|placebo|identical placebo tablet administered bid for four weeks
48655210|NCT05832047|DRUG|Plasma solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
48655211|NCT05832047|DRUG|Lactated Ringer solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
47979643|NCT04823650|DEVICE|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
47979644|NCT05037591|DRUG|Sea grapes extract 1.68 g/70kg BW|Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
47979645|NCT05037591|DRUG|Placebo|placebo lactose powder (1.68 g/70kg BW day-1).
47979646|NCT05157854|BEHAVIORAL|Active in My Home (AiMH)|"AiMH starts with two workshops for staff to introduce them to the intervention and the contributions expected from them. Their task is to participate in a couple of the sessions, inspire the course participant to stick to strategies developed during the sessions and support activity in general between the occupational therapy sessions.~AiMH consists of eight sessions, five individual ones and three in a group. Each session has a theme, such as: activity and health, and is built up with short lessons, using one's senses such as smell or touch, testing a simple activity, and setting goals for an activity one wants to test between sessions. The participants are given around 25 USD to try out that activity."
47979647|NCT06397014|PROCEDURE|D-type stoma lateral hernia repair|underwent D-type stoma lateral hernia repair
47979648|NCT05747781|BEHAVIORAL|Pilot Phase: standardized behavioral task|"Pilot Phase:~* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.~* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.~* Ability to drive (UFOV and DVFAT psychophysical tests)."
48496928|NCT05656586|OTHER|observational-- no intervention|observational
48496929|NCT03823014|DEVICE|Elator|Measurement for device, use of device
48496930|NCT00446836|DRUG|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
48338891|NCT06423170|DRUG|Camrelizumab plus GEMOX|"1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses."
48131558|NCT02620306|DRUG|Fimsartan 60mg~120mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
48338892|NCT05854797|OTHER|Normal Walking|"Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
48338893|NCT05854797|OTHER|Brisk Walking|"Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
48338894|NCT00175071|BEHAVIORAL|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
48338895|NCT02120560|PROCEDURE|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
48338896|NCT03895918|OTHER|Educational Activity|Undergo parenting skills intervention
48338897|NCT03895918|PROCEDURE|Patient Monitoring|Undergo medication adherence monitoring
48338898|NCT03895918|OTHER|Questionnaire Administration|Ancillary studies
48338899|NCT01952288|DRUG|simvastatin|simvastatin 40 mg/day for 12 months
48338900|NCT01952288|DRUG|Placebo Oral Tablet|placebo comparator
48338901|NCT04555408|DEVICE|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
48338902|NCT04555408|DEVICE|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
48338903|NCT04555408|DEVICE|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
48338904|NCT00055848|GENETIC|cytogenetic analysis|
48338905|NCT00055848|GENETIC|gene mapping|
48496931|NCT04230694|DEVICE|Dexcom Generation 6 CGM (Dexcom Gen6) device|Standing orders for blood sugars less than 100 will allow for administration of glucose replacement in the intervention group based on Dexcom Gen6 readings.
48496932|NCT05180552|DEVICE|HEALiX is an alternative restraint patient safety device|The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
48496933|NCT05180552|DEVICE|soft wrist restraints|Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
48655212|NCT05832047|DRUG|8-hour aggressive hydration|If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling
48655213|NCT03511846|DRUG|Oral capsaicin|Subjects will drink a solution with capsaicin
48655214|NCT03511846|DRUG|Topical capsaicin|Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
48655215|NCT03511846|DRUG|Intranasal capsaicin|Capsaicin cream will be applied to the nostril
48655216|NCT03511846|OTHER|Cold Water Irrigation|Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
48655217|NCT03511846|OTHER|Medical Air|Subjects will be exposed to medical air
48655218|NCT03511846|DRUG|Low Flow Oxygen|Subjects will be exposed to oxygen gas between 1-9 L/min
48655219|NCT03511846|DRUG|High Flow Oxygen|Subjects will be exposed to oxygen gas between 10-25 L/min
48655220|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
48655221|NCT06637514|OTHER|Placebo|Placebo Tablet: BID
48338906|NCT00055848|GENETIC|microarray analysis|
48338907|NCT00220857|DRUG|Rabeprazole|
48338908|NCT01405378|DEVICE|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
48338909|NCT04907162|DIAGNOSTIC_TEST|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
48338910|NCT04907162|DIAGNOSTIC_TEST|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
48338911|NCT04907162|DIAGNOSTIC_TEST|Brief Pain Inventory|Validated questionnaire for pain.
48496934|NCT00986063|GENETIC|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
48496935|NCT00986063|OTHER|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
48496936|NCT02571192|DRUG|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
48496937|NCT02571192|RADIATION|5.95 μCi RAD|
48338912|NCT04907162|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
48338913|NCT04907162|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
48338914|NCT04907162|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
48496938|NCT03964064|RADIATION|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
48496939|NCT03964064|RADIATION|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
48338915|NCT04907162|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
48338916|NCT04907162|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
48338917|NCT04907162|DIAGNOSTIC_TEST|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
48338918|NCT04907162|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
48496940|NCT05948514|OTHER|The complications related to central venous access device|The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
48496941|NCT06048432|OTHER|Conventional Physiotherapy + telephysiotherapty|Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
48496942|NCT02898753|DRUG|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
48496943|NCT02898753|DRUG|RhGAA|Active comparator
48496944|NCT00196625|DRUG|Amprenavir (drug)|
48496945|NCT00196625|DRUG|ABT-378/r (drug)|
48496946|NCT00196625|DRUG|Ritonavir (drug)|
48496947|NCT00543608|DRUG|iclaprim|
48655222|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
48655223|NCT04933708|BEHAVIORAL|Labor Podcast|"Listening to podcasts.~Topics include:~Labor Anesthesia, Induction of Labor, Second Stage of Labor, Reasons for Cesarean Section, Postpartum Recovery, Complications of Labor and Birth"
48655224|NCT04977349|OTHER|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
48496948|NCT00543608|DRUG|vancomycin|
48496949|NCT01102062|DIETARY_SUPPLEMENT|orange juice|
48496950|NCT04732273|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
48496951|NCT04732273|OTHER|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
48496952|NCT02086630|BEHAVIORAL|Heart to Heart|
48496953|NCT01483053|DRUG|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
48496954|NCT01483053|DRUG|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
48655225|NCT04977349|OTHER|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
48131559|NCT02620306|DRUG|Losartan 50mg~100mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
48131560|NCT02620306|DRUG|Losartan 50mg~100mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
48131561|NCT04813133|OTHER|Synchronized Lifestyle Modification Program|Synchronization of dietary intake with circadian rhythm of the body.
48131562|NCT04813133|OTHER|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
48338919|NCT04907162|DIAGNOSTIC_TEST|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
48338920|NCT00642967|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
48338921|NCT02178072|DRUG|5-Azacitadine|
48338922|NCT01109069|DRUG|PCI-32765|Dose based on parent protocol
48338923|NCT02070341|DRUG|Polyethylene Glycol|
48496955|NCT03801265|PROCEDURE|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
48496956|NCT03801265|PROCEDURE|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
48655226|NCT06094803|BEHAVIORAL|Mindfulness-based Zentangle Program|"Session 1 focuses on Self-awareness and Self-kindness through the Zentangle method. It covers the introduction, basic techniques, and eight steps of Zentangle. Participants practice mindfulness and learn grid and round patterns. Drawing mindfully and interactive sharing are encouraged for engagement and reflection.~Session 2 emphasizes Acceptance and Non-judgmental Attitude. It builds on the previous session, exploring advanced techniques in the Zentangle method. Participants practice mindfulness, learn organic and texturing patterns, create their own artwork, and engage in interactive sharing for reflection."
48655227|NCT06639685|DIAGNOSTIC_TEST|MRI|MR Fingerprinting and ASL
48496957|NCT03801265|DRUG|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
48496958|NCT02835781|OTHER|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
48496959|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
48496960|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
48655228|NCT04728230|DRUG|Carboplatin|Given IV
48655229|NCT04728230|BIOLOGICAL|Durvalumab|Given IV
48655230|NCT04728230|DRUG|Etoposide|Given IV
48655231|NCT04728230|DRUG|Olaparib|Given PO
48655232|NCT04728230|RADIATION|Radiation Therapy|Undergo consolidative thoracic radiation therapy
48655233|NCT06361173|OTHER|BMT4me|Caregivers will pilot test a Spanish version of the BMT4me app at a single time point.
48655234|NCT06639659|PROCEDURE|Sphenopalatine Ganglion Block|patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
48655235|NCT06639659|DRUG|Dexmedetomidine|patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
48131563|NCT04813133|OTHER|Physiotherapy|Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
48496961|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
48131565|NCT06452212|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
48496962|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
48131568|NCT06662630|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in mechanically ventilated patients.
48338924|NCT02070341|DRUG|Picosalax|
48338925|NCT02156752|BEHAVIORAL|ACT|Treatment is based on Acceptance and Commitment Therapy
48338926|NCT02156752|BEHAVIORAL|SR|Treatment is based on Self-Regulation theory.
48338927|NCT02156752|BEHAVIORAL|WLO|Treatment is based on cooking tips and demonstrations.
48338928|NCT04709718|PROCEDURE|hepatectomy|liver resection taking over the liver hemangioma
48338929|NCT06516458|DIAGNOSTIC_TEST|Camera Based Kinematic Analysis|Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
48131572|NCT06590441|DEVICE|Myopia control spectacles|Myopia control spectacles fitted with temperature sensors
48131573|NCT06587919|DEVICE|Neurofeedback|EEG-based neurofeedback, administered with the Neuroguide software.
48131574|NCT06080425|BEHAVIORAL|Medical Nutrition Therapy|Counselling
48131575|NCT04959669|OTHER|DeSSBack|The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
48131576|NCT04549155|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
48496963|NCT03311100|OTHER|immunohistochemistry assay|biomarkers expression
48496964|NCT04285593|OTHER|Bulgarian squats|The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
48496965|NCT04590066|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
48131580|NCT06598553|BEHAVIORAL|Projet Jeune Leader Comprehensive Sexual Education|PJL provides trained educators to deliver a 22 week comprehensive sexual education (CSE) curriculum in participating middle schools. All adolescents enrolled in the school receive the CSE program.
48496966|NCT03858595|DEVICE|Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis."
48496967|NCT02896582|DRUG|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
48338930|NCT03182621|BEHAVIORAL|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
48496968|NCT02896582|DRUG|Dexamethasone|40 mg D1 to D4 in GA-DHAP
48496969|NCT02896582|DRUG|Aracytine|2g/m² D1 \& D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
48496970|NCT02896582|DRUG|Cisplatinum|100 mg/m² D1 in GA-DHAP
48496971|NCT02896582|DRUG|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
48496972|NCT02896582|DRUG|Melphalan|140 mg/m² D-2 in GA-BEAM
48496973|NCT02896582|DRUG|Carmustine|300 mg/m² D-7 in GA-BEAM
48496974|NCT04105426|DIETARY_SUPPLEMENT|Antioxidants|one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
48496975|NCT04105426|DIETARY_SUPPLEMENT|Placebo|one placebo tablet three times per day for 3 months.
48496976|NCT02373748|DEVICE|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
48131588|NCT03981588|OTHER|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
48131589|NCT06597279|BEHAVIORAL|Web-based dialysis decision support tool|"The intervention in this study is the Kidney Care Roadmap, a web-based dialysis decision support tool designed to assist patients with advanced chronic kidney disease and their caregivers."
48496977|NCT03065218|DRUG|99mTc sestamibi|The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.
48131591|NCT02848560|DRUG|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
48131592|NCT06541522|DEVICE|EIT|Two PEEP titrations monitored by EIT will be performed, each with the electrode belt positioned at a different chest height (2nd intercostal space or 5th intercostal space). The order will be drawn at random.
48131593|NCT06079164|DRUG|KITE-197|A single infusion of CAR-transduced autologous T cells administered intravenously
48338931|NCT03182621|BEHAVIORAL|SPARK|traditional YMCA program
48338932|NCT06369038|BEHAVIORAL|observation of level of dental anxiety in children|analysis of children's drawings using CD:H index
48338933|NCT00028418|DRUG|Clofarabine|
48338934|NCT01923571|OTHER|intraoperative BGC measure|
48338935|NCT04327050|PROCEDURE|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
48496978|NCT06149715|DEVICE|Bottle Filter|The household is given a Sawyer Squeeze Water Filtration System.
48496979|NCT06149715|DEVICE|Bucket Filter|The household is given a Sawyer International Bucket System, which is a Squeeze Water Filtration System that is integrated with a hose and bucket.
48496980|NCT06149715|DEVICE|Tap Filter|The household is given a Sawyer Tap Water Filtration System.
48496981|NCT00266357|DRUG|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
48496982|NCT00266357|DRUG|Placebo / Duration of Treatment: 2 days for screening period|
48496983|NCT02717858|DRUG|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
48496984|NCT02717858|DRUG|placebo|Injected s.c./subcutaneously (under the skin) once daily.
48496985|NCT04573517|PROCEDURE|Amniotomy|Artificial rupture of amniotic membranes
48655236|NCT06639659|OTHER|General Anesthesia (control group)|patients will be operated under general anesthesia including routine protocol for these cases
48131594|NCT06079164|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered intravenously
48131595|NCT06079164|DRUG|Fludarabine|Lymphodepleting chemotherapy administered intravenously
48131596|NCT05039554|BEHAVIORAL|Acceptance and commitment therapy|Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).
48131597|NCT05039554|OTHER|Valera Smartphone Application|For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
48131598|NCT05039554|OTHER|Treatment as Usual|TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
48131599|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
48131600|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
48131601|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
48496986|NCT04573517|DEVICE|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
48496987|NCT05233930|PROCEDURE|TKR with augmented reality-based navigation system|Surgery
48496988|NCT05233930|PROCEDURE|TKR with traditional mechanically aligned technique|As per local practice and standard guidelines.
48496989|NCT05178381|DEVICE|Continuous theta burst transcranial magnetic stimulation|Participants will receive cTBS (50Hz stimulation at 80% AMT for 40 seconds). Stimulation will be applied to either the target area (frontal pole or IFG) or control area (vertex). Targeting of each region will be achieved using a frameless neuronavigation system with a Polaris Spectra infrared camera that enables stimulation to be centered on specific coordinates in Montreal Neurological Institute space. We will use coordinates \[x,y,z\] = \[35,50,15\] for frontal pole and \[x,y,z\] = \[56,16,22\] for right IFG based on the location of our activations in the young pilot group (Figure 4). The vertex control site is defined as the Cz position of a 10-20 EEG system. After receiving TMS, participants will stare at a white wall for 1 minute before performing the Horizon Task for 45 minutes.
48496990|NCT03775720|BEHAVIORAL|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
48496991|NCT04418843|PROCEDURE|Standard Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
48496992|NCT04418843|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
48338936|NCT01976169|DRUG|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
48338937|NCT05063617|DEVICE|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
48338938|NCT03907592|DIETARY_SUPPLEMENT|L-carnitine supplementation|Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
48338939|NCT03907592|DIETARY_SUPPLEMENT|Leucine supplementation|Supplementation of 4000 mg L-leucine per day throughout the study period.
48496993|NCT01868893|DRUG|Obinutuzumab|
48496994|NCT01868893|DRUG|Chlorambucil|
48496995|NCT00281671|DRUG|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
48496996|NCT00281671|DRUG|Placebo|0.9% sodium chloride infusion
48496997|NCT01167257|DRUG|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
48496998|NCT01167257|DRUG|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
48496999|NCT03183492|BIOLOGICAL|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
48338940|NCT03907592|PROCEDURE|Resistance training|Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
48497000|NCT01196676|DRUG|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
48131622|NCT06589024|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets processing speed, attention and executive function for about 36 minutes per session, 5 sessions per week for a total of 36 sessions.
48131623|NCT06589024|OTHER|Sleep Hygiene Education|Access to sleep hygiene education materials
48338941|NCT03320889|OTHER|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
48338942|NCT02653313|DRUG|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
47979649|NCT05747781|BEHAVIORAL|Validation Phase: standardized behavioral task|"Validation Phase:~* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.~* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.~* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test)."
47979650|NCT04208698|DRUG|CIN-102 Dose 1|Deuterated domperidone (deudomperidone)
47979651|NCT04208698|DRUG|CIN-102 Dose 2|Deuterated domperidone (deudomperidone)
48131624|NCT05364697|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
48497001|NCT01196676|DRUG|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
48497002|NCT02178280|OTHER|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
48497003|NCT03837743|DRUG|DUR-928 Topical Solution|Topical solution containing active drug
48497004|NCT03837743|DRUG|Vehicle Topical Solution|Topical solution containing no active drug
48497005|NCT03589586|OTHER|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
47979652|NCT04208698|DRUG|Placebo for CIN-102|Placebo
47979653|NCT05627154|DRUG|Citalopram|Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
47979654|NCT05627154|BEHAVIORAL|Behavioural Activation|A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.
47979655|NCT05627154|DRUG|Placebo|A lactose-based tablet.
48131629|NCT03972046|DRUG|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
48131630|NCT03972046|DRUG|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
48338943|NCT04263415|DRUG|Semaglutide|semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
48338944|NCT04263415|OTHER|Placebo|once-weekly injection with placebo pen for 16 weeks
48497006|NCT00413686|DRUG|AZD7762|intravenous infusion
48497007|NCT00413686|DRUG|Gemcitabine|weekly intravenous infusion
48497008|NCT02838810|DRUG|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
48497009|NCT02838810|DRUG|Nucleoside analogues|Nucleoside analogues
48497010|NCT01753466|DIETARY_SUPPLEMENT|Hydration|
48497011|NCT01305395|DRUG|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
48497012|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
48338945|NCT04897646|OTHER|SFRMS/SPLF CPAP-telemonitoring diagnosis/therapeutic algorithm.|"In 2020, a working group from the Société Française de Recherche et de Médecine du Sommeil (SFRMS) and the Société de Pneumologie de Langue Française (SPLF) have proposed a CPAP-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea.~The algorithm is exhasutively described in the following published article: Prigent, A., Gentina, T., Launois, S., et al. \[Telemonitoring in continuous positive airway pressure-treated patients with obstructive sleep apnoea syndrome: An algorithm proposal\]. Rev. Mal. Respir., 2020, 37: 550-560."
48338946|NCT06330974|OTHER|No intervention|No intervention
48497013|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
47979656|NCT03244345|BEHAVIORAL|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
47979657|NCT00900497|BIOLOGICAL|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
47979658|NCT06277921|PROCEDURE|Elective Surgery for gastric cancer|Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach
48338947|NCT02152150|OTHER|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
48338948|NCT02152150|OTHER|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
48338949|NCT04827810|DRUG|Gamitrinib|This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
48338950|NCT03774368|OTHER|Emergency contraception website|Existing website with factual information about emergency contraception
48338951|NCT03774368|OTHER|Emergency contraception video|Existing video with factual information about emergency contraception
48338952|NCT04262791|DEVICE|Wrist Actigraphy Device|Wrist Actigraphy Device
48338953|NCT04262791|DEVICE|Sleep Headband|Sleep Headband
48497014|NCT01305395|DRUG|Sirolimus|Will start sirolimus after they develop CAV by angiogram
48497015|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
48497016|NCT02274844|BEHAVIORAL|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
48497017|NCT05200546|DIAGNOSTIC_TEST|molecular assays to screen for eXDR|"VRE detection will be performed using VIASURE Vancomycin resistance Real Time PCR Detection Kit.~BD MAX Check-Points CPO will be used to detect carbapenemase-producing organisms."
47979659|NCT00182377|DRUG|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
48131631|NCT03972046|DRUG|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
48338954|NCT02708615|OTHER|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
48338955|NCT04334772|DEVICE|Muscle belly Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.
48338956|NCT04334772|DEVICE|Tendon Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.
48131632|NCT05094011|BIOLOGICAL|Aadipose-Derived Mesenchymal Stem Cells|Stereotactic intrastriatal implantation of 3×10\^7 per hemisphere (total 6×10\^7 cells) or 1×10\^8 per hemisphere (total 2×10\^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
48131633|NCT06605924|OTHER|Tobacco-free|Ad contains baseline language + language that product is tobacco-free
48338957|NCT04334772|OTHER|Stretching exercises|5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
48338958|NCT03554850|DEVICE|Trevo® Retriever|Stent retriever procedure
48338959|NCT02959697|DRUG|Subcut. + Subconj. Xylocaine|Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
47979660|NCT02308085|OTHER|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
47979661|NCT04156425|DRUG|Escitalopram+golimumab|Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
48338960|NCT02959697|DRUG|Subcut. + Sham Subconj. Injection|Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
48655237|NCT06068361|DIAGNOSTIC_TEST|EEG|32-electrode EEG (resting state, passive auditory and active visual task)
48655238|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Active Treatment questionnaire|Electronic questionnaire to be administered to patients in active treatment.
48655239|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Survivors questionnaire|Electronic questionnaire to be administered to cancer survivors.
48655240|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Palliative Care questionnaire|Electronic questionnaire to be administered to patients in palliative care.
48655241|NCT06533059|DRUG|ALTA2618|Oral ALTA2618 tablets will be administered at protocol-defined dose
48655242|NCT05087342|DRUG|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
48655243|NCT05087342|DRUG|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
48655244|NCT06385353|OTHER|Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome|"Post-thrombotic syndrome will be assessed by the Villalta score until 6 months of follow-up.~Data collected from colour doppler ultrasound will be used to calculate the Venous Volumetric Index to quantify deep vein thrombosis burden until 6 months of follow-up."
48655245|NCT05183984|DRUG|Chemotherapy|Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
48655246|NCT05183984|DRUG|Bevacizumab-Awwb|"MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months."
48655247|NCT05183984|DRUG|Niraparib|niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
48655248|NCT06645106|DEVICE|Rapid Point of Care (POC) Syphilis testing|Participants will undergo the point of care (POC) FDA cleared syphilis health check (SHC) POC test by a research staff using 50 microliters or 1-3 drops of whole blood via finger stick. The analyzer is handheld, and all testing equipment is temperature stable and does not need refrigeration. The SHC-Syphilis results will be available within 10 minutes of receipt given the published turnaround time to results of 15 minutes per package insert and will be recorded as a research note in the electronic medical record (EMR) while the provider assigned to the patient and the Houston Health Department will be notified of results and further treatment will be done if results are positive.
47979662|NCT04156425|DIETARY_SUPPLEMENT|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
47979663|NCT04156425|DRUG|Escitalopram|Escitalopram will be administered at 10-20 mg/d during the acute phase.
48131634|NCT06605924|OTHER|Discrete|Ad contains baseline language + language that product is discrete
48131635|NCT06605924|OTHER|Convenient|Ad contains baseline language + language that product is convenient
48131636|NCT01503970|DEVICE|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
48131637|NCT05824559|DRUG|ME-344|ME-344 will be administered intravenously (IV)
48131638|NCT05824559|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV)
48338961|NCT02959697|PROCEDURE|Blepharoptosis Repair|Patients will undergo blepharoptosis repair using an anterior approach.
48338962|NCT05545878|DEVICE|Super enhanced single vision lens 01 for spectacles|This is a spectacle lens designed to have a small amount of positive power towards the bottom of the lens as this is the area that is in line with the eye when downwards for near tasks such as looking at a digital device.
48338963|NCT03012542|DIETARY_SUPPLEMENT|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
48338964|NCT03012542|DIETARY_SUPPLEMENT|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
48338965|NCT03261141|COMBINATION_PRODUCT|(PV-RQOL),(APA) ,Acoustic analysis|"1. severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
47979664|NCT04305483|PROCEDURE|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
48338966|NCT03905824|BIOLOGICAL|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
48338967|NCT03905824|PROCEDURE|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
48338968|NCT02366247|DRUG|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
48338969|NCT02366247|DRUG|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
48338970|NCT02366247|DRUG|Adefovir|10 mg, once daily, taken orally for 48 weeks
48338971|NCT04038385|BEHAVIORAL|Multilevel Behavioral Intervention|Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
48497018|NCT02866045|PROCEDURE|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
48497019|NCT02866045|PROCEDURE|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
48497020|NCT05555563|OTHER|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
48497021|NCT02838654|PROCEDURE|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
48497022|NCT00000386|BEHAVIORAL|Exposure and Response Prevention|
48497023|NCT00000386|BEHAVIORAL|Family Treatment Program|
48497024|NCT00000386|BEHAVIORAL|Relaxation Training|
48497025|NCT00000386|BEHAVIORAL|Behavior therapy|
48497026|NCT00000386|BEHAVIORAL|Family Counseling|
48655249|NCT06638944|BEHAVIORAL|In-person sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions in the clinic and 3 days of home practice per week using the i-Phagia sEMG system. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
48655250|NCT06638944|BEHAVIORAL|Remote sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions completed remotely (via telehealth) and 3 days of home practice per week. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients also use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
48655251|NCT06638944|BEHAVIORAL|Standard-of-care treatment|Participants in this intervention will complete the same standardized behavioral swallowing rehabilitation protocol and in the same frequency as the sEMG biofeedback intervention groups but WITHOUT a device. That is, they will complete the protocol for 12 weeks with weekly (once per week) treatment sessions completed in-person and 3 days of home practice per week. For this intervention group, patients use a visual analog scale and a timer as feedback tools, as frequently done in clinical practice where sEMG devices are not widely available.
48655252|NCT05884528|BIOLOGICAL|CC BoNT/A|Complex-containing BotulinumtoxinA (BoNT/A) formulations
48655253|NCT05884528|BIOLOGICAL|CF BoNT/A|Complex-free BotulinumtoxinA (BoNT/A) formulation
48655254|NCT05884528|BIOLOGICAL|CF to CC BoNT/A|Switch from complex-free to complex-containing BoNT/A formulations
48655255|NCT05884528|BIOLOGICAL|CC to CF BoNT/A|Switch from complex-containing to complex-free BoNT/A formulations
48655256|NCT05529602|OTHER|conventional physical therapy|"core stability exercises~A total of 3 sessions per week were given for 15-20 minutes"
48655257|NCT05529602|OTHER|relaxation exercise|"the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes"
48655258|NCT04654052|DRUG|Clopidogrel|Clopidogrel during 11 months
48655259|NCT04654052|DRUG|Previous treatment|non-intervention
48655260|NCT00693511|BEHAVIORAL|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
48497027|NCT00168597|DRUG|Vitamin A|
48497028|NCT03830827|DRUG|Vortioxetine|8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
48497029|NCT00259272|DRUG|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
48655261|NCT00693511|BEHAVIORAL|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
48655262|NCT05902754|DIETARY_SUPPLEMENT|Generally Recognized as Safe - Sulforaphane|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.
48497030|NCT05600790|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
47979665|NCT04305483|PROCEDURE|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
47979666|NCT04445324|BEHAVIORAL|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
47979667|NCT04445324|OTHER|Control Group (pharmacotherapy and/or psychotherapy, n=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
47979668|NCT00306605|BEHAVIORAL|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
47979669|NCT04049968|DEVICE|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
47979670|NCT04049968|OTHER|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
47979671|NCT05736744|DRUG|MgSO4|The patients will be pretreated with magnesium sulphate infusion (30 mg kg-1, total volume 100 ml, infusion rate 5 ml min-1) 20 min. before induction of anesthesia.
48655263|NCT05902754|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
48655264|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-1Gy|1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
47979672|NCT05736744|DRUG|Rocuronium Bromide|Rocuronium will be administered for intubation at a dose of 0.45-0.6 mg/kg IV and Maintenance at a dose of 0.1-0.2 mg/kg IV on fixed interval
47979673|NCT05736744|DRUG|Cis-Atracurium|Cis-Atracurium will be administered at 0.1-0.15 mg/kg IV bolus for intubation and maintenance at a dose of 0.03 mg/kg iv on fixed intervals.
47979674|NCT04817371|DEVICE|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
47979675|NCT04817371|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
47979676|NCT04817371|DEVICE|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
47979677|NCT04817371|DEVICE|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
47979678|NCT01320085|DRUG|MEK162|
47979679|NCT00742001|BIOLOGICAL|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
47979680|NCT03867981|BEHAVIORAL|Internet-based weight loss program|12-month, Internet-based weight loss/maintenance program.
47979681|NCT03867981|BEHAVIORAL|Brief phone coaching|Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
47979682|NCT03867981|BEHAVIORAL|Extended phone coaching|Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
47979683|NCT03041402|OTHER|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
48131639|NCT05662124|OTHER|Remote monitoring|"Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week."
48131640|NCT03241706|DRUG|Low Fructose|IV fructose (1.3 mg/kg/min)
48131641|NCT03241706|DRUG|Saline|Saline given as a comparison to fructose.
48131642|NCT03241706|DRUG|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
48131643|NCT03241706|DRUG|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
48131644|NCT03241706|DRUG|Glucagon|IV glucagon (0.65 ng/kg/min).
48131645|NCT03241706|DRUG|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
48131646|NCT03241706|DRUG|High Fructose|IV-fructose (6.5 mg/kg/min)
48497031|NCT04253496|OTHER|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
48338972|NCT03168555|DRUG|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
48497032|NCT01698827|OTHER|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
48497033|NCT02889055|DEVICE|patient requiring the MIRUS (mechanical ventilation)|
48497034|NCT02763371|OTHER|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
48497035|NCT02763371|OTHER|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
48497036|NCT05737342|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
48497037|NCT05737342|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
48655265|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-2-3Gy|ILDR will be administered as single fractions within 10 days. The total dose of radiotherapy will be 2-3 Gy in 2-3 fractions. ILDR design is as above.
47979684|NCT03041402|OTHER|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
47979685|NCT03041402|OTHER|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
47979686|NCT00335673|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
47979687|NCT04775602|DRUG|18F-PSMA|18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)
47979688|NCT06434844|PROCEDURE|Auricular acupunctures|After disinfection of the external ear with 75% alcohol wipes, 018x 13 filiform needles (Mocm International Limited) will be used to perform the auricular acupunctures at the relaxation point, tranquilizer point and master cerebral point at the left and right external ears.
47979689|NCT06434844|PROCEDURE|Sham acupunctures|The auricular acupoints of finger, shoulder and tonsil will be targeted instead. These points are also located at the external ear and comparable to those in the intervention group. The external ear will be disinfected with 75% alcohol wipes. Auricular acupunctures with 018x 13 filiform needles (Mocm International Limited) will be carried out at the finger point, shoulder point and tonsil point of the left and right external ears.
47979690|NCT06417476|RADIATION|Short-course radiotherapy|The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose
47979691|NCT06417476|DRUG|Irinotecan|150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
47979692|NCT06417476|DRUG|Oxaliplatin|85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
47979693|NCT06417476|DRUG|Calcium Formate|400 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
47979694|NCT06417476|DRUG|Fluorouracil|2400 mg/m² iv drip over 48 hours on day 1-2, repeated every 14 days.
47979695|NCT06417476|RADIATION|Long-course chemoradiation|The total dosage was 50Gy consisted of 25 fractions of 2 Gy to clinical target volume without a boost dose
47979696|NCT06417476|DRUG|Capecitabine|825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
47979697|NCT06302504|BEHAVIORAL|Nature-based mindfulness program|only one arm is included in this study
47979698|NCT04219631|DEVICE|expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.|women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
47979699|NCT02536040|DRUG|38% diammine silver fluoride|treatment of cavity with study agent
47979700|NCT02536040|OTHER|Water|Fluoride free, distilled water
48131650|NCT06667700|DRUG|Molnupiravir|Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
48338973|NCT04790539|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
48131651|NCT06667700|DRUG|Placebo|Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
48338974|NCT02747407|BIOLOGICAL|Hepatitis A Vaccine|
48338975|NCT02747407|OTHER|Laboratory Biomarker Analysis|Correlative studies
48338976|NCT02747407|BIOLOGICAL|Tetanus Toxoid Vaccine|
48338977|NCT02747407|BIOLOGICAL|Trivalent Influenza Vaccine|
48338978|NCT00527969|DRUG|HT1001 extract of Panax quinquefolius L|
48338979|NCT02841592|OTHER|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
48338980|NCT02841592|OTHER|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
48338981|NCT03835013|DRUG|Saline 0.9%|Intravenous infusion of 0.9% saline
48497038|NCT01928706|OTHER|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
48497039|NCT01928706|OTHER|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
48655266|NCT06076135|DRUG|PD-1/PD-L1 Inhibitors|The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
48655267|NCT01840072|OTHER|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
48497040|NCT04775186|PROCEDURE|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
48655268|NCT06478524|BEHAVIORAL|Live music|Patients will have baseline data collection in the first week, followed by live music sessions and data collection during dialysis in the second week. The live music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
47979701|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
47979702|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
47979703|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle capillary sampling|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
47979704|NCT04411875|DRUG|Amlodipine 10 mg|The subjects randomly received single oral administration of amlodipine 10 mg.
48131652|NCT06609187|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
48655269|NCT06478524|BEHAVIORAL|Pre-recorded music|Patients will have baseline data collection in the first week, followed by pre-recorded music sessions and data collection during dialysis in the second week. The pre-recorded music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
48655270|NCT06519981|DRUG|HRS-9231or matching placebo|HRS-9231 injection or matching placebo will be administered through IV injection.
48655271|NCT01822379|PROCEDURE|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
48655272|NCT01799135|OTHER|DCE-MRI scan|
48655273|NCT01799135|RADIATION|Stereotactic Body Radiation Therapy|
48655274|NCT01799135|OTHER|4D-CT scan|
47979705|NCT04411875|DRUG|Levamlodipine 5 mg|The subjects randomly received single oral administration of levamlodipine 5 mg.
47979706|NCT03903731|DEVICE|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
47979707|NCT00097110|DRUG|Vitamin C and E|
47979708|NCT01610544|DRUG|3'-deoxy-3'-18F fluorothymidine (FLT)|
47979709|NCT01610544|OTHER|PET/CT scan|
47979710|NCT04142853|OTHER|Training intervention + Dance intervention|Training intervention + Dance intervention
48131653|NCT05513365|DRUG|Goserelin 10.8 mg|Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
48131654|NCT05513365|DRUG|Bicalutamide 50 mg|Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
48338982|NCT03835013|DRUG|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
48655275|NCT04946370|DRUG|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
48655276|NCT04946370|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
48655277|NCT04946370|DRUG|Androgen receptor pathway inhibitor|Patients will receive an oral androgen receptor pathway inhibitor (ARPI). Examples include enzalutamide and apalutamide. Dosing will be the standard dosing, as described by the package insert.
48655278|NCT04946370|DIAGNOSTIC_TEST|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
47979711|NCT00142584|DRUG|Nebivolol (NEB)|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
48131655|NCT05513365|DRUG|Dutasteride 0.5 mg|Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
48338983|NCT03835013|DRUG|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
48338984|NCT03835013|DRUG|Exenatide|Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
48497041|NCT00960115|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram \[mcg\]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
48655279|NCT01527955|OTHER|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
48655280|NCT04585035|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
48655281|NCT04585035|DRUG|D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other|Standard treatment of solid tumor, NSCLC or CRC
47979712|NCT00142584|DRUG|Metoprolol (MET)|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
47979713|NCT02355353|OTHER|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
47979714|NCT02159495|DRUG|cyclophosphamide|Given IV
47979715|NCT02159495|BIOLOGICAL|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
47979716|NCT02159495|OTHER|laboratory biomarker analysis|Correlative studies
47979717|NCT02159495|BIOLOGICAL|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
47979718|NCT02159495|DRUG|Fludarabine Phosphate|Given IV
47979719|NCT06125353|DIETARY_SUPPLEMENT|Melatonin|Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
47979720|NCT01012960|DRUG|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
47979721|NCT04806854|DRUG|LUM-201|Administered orally once daily
48131656|NCT06658847|OTHER|Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. The investigational night cream will be used daily in the evening/at night.
48497042|NCT00960115|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg/m\^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
48497043|NCT00960115|BIOLOGICAL|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
48655282|NCT06638086|DRUG|Acetaminophen Suppositories|Per rectal suppositories
48655283|NCT06638086|DRUG|Acetaminophen Injection|Intra-venous injection
48655284|NCT06644352|PROCEDURE|different thoracic surgical approaches|Right Versus Left Thoracic Surgical Approaches
48655285|NCT04005326|PROCEDURE|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
47979722|NCT00173082|PROCEDURE|Glucose tolerance test|
47979723|NCT01732250|DRUG|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
47979724|NCT01732250|DRUG|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
47979725|NCT03119194|DRUG|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
48131657|NCT06658847|OTHER|No Night Cream Usage|Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. No night cream will be used.
48497044|NCT00960115|OTHER|Saline|A single dose of saline (sodium chloride, 9 grams per liter \[g/L\]) will be administered intravenously, 3 days prior to the start of placebo.
48338985|NCT03471104|OTHER|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
48338986|NCT01913171|OTHER|Exercise|
48497045|NCT01772758|DRUG|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
48655286|NCT04005326|PROCEDURE|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
47979726|NCT05908474|DIETARY_SUPPLEMENT|Enriched fibre water|Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
47979727|NCT06036459|OTHER|uterine peristalsis|Transabdominal us followed by Transvaginal ultrasonography scans (Sono Ace R5 ) of uterine peristalsis will performed on the day of embryo transfer while the patient lying relaxed in lithotomy position. The probe will be introduced into the vagina as gently as possible to avoid stimulating the cervix. After scanning the mid-sagittal plane of the uterus, the probe will be fixed as steady as possible while a 3 min video of uterine peristalsis will be recorded simultaneously. The records will be analyzed at 4X regular speed using a Video player application by two independent experienced observers. The uterine peristaltic wave frequency will be the mean of the results from each observer.
47979728|NCT00727181|DEVICE|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
47979729|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
47979730|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
48655287|NCT04005326|PROCEDURE|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
47979731|NCT05550402|DRUG|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
47979732|NCT05550402|DRUG|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
47979733|NCT05550402|DRUG|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
47979734|NCT05550402|OTHER|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
47979735|NCT00658593|DRUG|capecitabine|
47979736|NCT00658593|DRUG|gemcitabine hydrochloride|
47979737|NCT00658593|PROCEDURE|quality-of-life assessment|
47979738|NCT05512611|DIAGNOSTIC_TEST|Finger photoplethysmography|Finger photoplethysmography in tested hand, noninvasive blood pressure and heart rate during blood donation.
47979739|NCT01426880|DRUG|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
47979740|NCT01426880|DRUG|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
47979741|NCT01431833|DRUG|TR-701 FA|Oral single dose 200 mg
47979742|NCT03336853|DEVICE|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
48497046|NCT01772758|DRUG|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
48497047|NCT01772758|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
48131662|NCT03598244|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48131663|NCT03598244|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
48131664|NCT03598244|DRUG|Savolitinib|Given PO
48131665|NCT03598244|PROCEDURE|X-Ray Imaging|Undergo X-ray imaging
48131666|NCT06655480|DRUG|[ARNI + SGLTi + AMR]|Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Eplerenone 25-50 mg tablet
48131667|NCT06655480|DRUG|[SGLTi + previously taken RAAS blocker]|Empagliflozin 10mg tablet, previously taken RAAS inhibitor
48655288|NCT04857281|DEVICE|nVNS (gammaCore)|The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
48655289|NCT06642181|DRUG|Guanfacine pharmacotherapy|It is a pharmacotherapy
48131670|NCT06596564|BEHAVIORAL|choice architecture|Display the sugar content of the drink on the platform.
48131671|NCT06596564|BEHAVIORAL|choice architecture|Showing the various harms that can come from long-term excessive consumption of sugary beverages on the platform.
48131672|NCT06596564|BEHAVIORAL|choice architecture|The platform shows the information that the majority of their peers have chosen mineral water.
48131673|NCT06610994|DEVICE|local vibration apply|Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. Vibrasens© is a mechanical vibrator that produces transcutaneous vibration stimulations used in sensory-motor rehabilitation. Vibrasens©; It is a non-invasive, therapeutic device. Vibrasens© includes 1 pilot unit, 1 manual vibrator VB200, 4 flat skin contactors for tendon application, 4 round skin contactors for skin application, 1 power supply, 1 user manual and 1 protocol guide. LV application will be applied to the most swollen part of the spastic medial gastrocnemius muscles in the treatment group for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.
48655290|NCT06642181|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|It is a mindfulness intervention
47979743|NCT03336853|OTHER|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
48131674|NCT04885166|OTHER|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
48655291|NCT06643299|DIETARY_SUPPLEMENT|Probiotic Agent|BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
48655292|NCT06643299|OTHER|Placebo|Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
48131675|NCT04885166|BEHAVIORAL|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
48338987|NCT01906476|BEHAVIORAL|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
47979744|NCT01892228|BEHAVIORAL|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
48131676|NCT06652750|OTHER|Routine Management|Conducting routine in-office follow-up for CIED paitents
48131677|NCT06652750|DEVICE|5G Cloud Follow-up|This study employed a 5G-cloud follow-up platform, a research tool that allows a device specialist to test, and program CIEDs in real-time from a remote location via an internet connection or mobile wireless network. Consistent with of the 5G remote support terminal externally connected to the programmer, a PAD was installed with a 5G-cloud follow-up app. The onsite medical staff began the cloud follow-up session by contacting the remote device specialist via video call. The connection to the CIED was made by the medical staff through the use of a standard programmer. He was in charge of turning on the programmer and applying the programmer wand to the patient's device. After an initial introduction, communication was established and continued via the wand connection. The remote device specialist logged into the 5G-cloud follow-up app with two-step verification. The remote device specialist then had complete control of the programmer to check and reprogram the device as needed.
48338988|NCT01906476|BEHAVIORAL|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
48338989|NCT03345368|DEVICE|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
48338990|NCT03345368|DEVICE|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
48338991|NCT03345368|OTHER|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
48338992|NCT03087708|DRUG|Naloxegol|Given PO
48338993|NCT03087708|OTHER|Placebo|Given PO
48655293|NCT06639373|OTHER|Specialized clinical service access|A new model of addiction care that will offer comprehensive and coordinated service delivery
47979745|NCT03807466|BEHAVIORAL|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
47979746|NCT03807466|BEHAVIORAL|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
47979747|NCT05008497|OTHER|Questionnaire|Questionnaire
47979748|NCT05673512|COMBINATION_PRODUCT|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
47979749|NCT05673512|COMBINATION_PRODUCT|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
47979750|NCT02252094|DEVICE|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
47979751|NCT02252094|OTHER|Ultra-protective ventilation|Ventilation with \</= 3ml/kg predicted body weight
47979752|NCT02252094|OTHER|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
48338994|NCT03087708|OTHER|Laboratory Biomarker Analysis|Correlative studies
48338995|NCT03087708|OTHER|Quality-of-Life Assessment|Ancillary studies
48338996|NCT05235100|DRUG|Apatinib Mesylate|Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
48338997|NCT05531968|BIOLOGICAL|BMI2006|IM
48338998|NCT05531968|BIOLOGICAL|BOTOX®|IM
48338999|NCT01207284|OTHER|Physical Therapy|strengthening passive and active stretching balance training gait training
48339000|NCT04344704|OTHER|Single chamber DAI device with floating atrial dipole|DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods
48655294|NCT00205985|DEVICE|Scaphoid screw|Conservative treatment versus application of scaphoid screw
48655295|NCT05564052|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
48655296|NCT05564052|DRUG|Lenalidomide|Lenalidomide capsules will be administered orally.
47979753|NCT01030939|DRUG|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
47979754|NCT02965547|DEVICE|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
47979755|NCT02965547|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
48339001|NCT04390997|PROCEDURE|Non-surgical Periodontal Treatment|Non-surgical periodontal treatment includes scaling and root planning by using curettes and ultrasonic devices only in the periodontitis group.
48497048|NCT02774135|OTHER|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
48497049|NCT01454271|PROCEDURE|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
48655297|NCT05564052|DRUG|Rituximab|Rituximab will be administered IV.
48655298|NCT05564052|DRUG|Bortezomib|Bortezomib will be administered either intravenously or subcutaneously.
48339002|NCT05068999|DEVICE|shear wave elastography|"Shear wave elastography (SWE) is an emerging technology that provides information about the inherent elasticity of tissues by producing an acoustic radiofrequency force impulse, sometimes called an acoustic wind, which generates transversely-oriented shear waves that propagate through the surrounding tissue and provide biomechanical information about tissue quality. Although SWE has the potential to revolutionize bone and joint imaging, its clinical application has been hindered by technical and artifactual challenges. Many of the stumbling blocks encountered during musculoskeletal SWE imaging are readily recognizable and can be overcome, but progressive advances in technology and a better understanding of image acquisition are required before SWE can reliably be used in musculoskeletal imaging."
48339003|NCT03180242|BIOLOGICAL|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
48339004|NCT03180242|BIOLOGICAL|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
48339005|NCT03180242|BIOLOGICAL|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
48339006|NCT06283225|DEVICE|Pia-App|The dysmenorrhoea app (Pia-App) is evidence-based and helps patients to implement continuous multimodal (pain) treatment that is integrated into everyday life. Symptoms, events, influencing factors and examinations can be recorded in a specialised diary. Diary evaluations and learning modules on dysmenorrhoea and other relevant topics promote understanding of the condition and self-efficacy. An intelligent evaluation suggests suitable evidence-based and appropriate exercises. In the learning modules, patients can learn about the menstrual cycle, menstrual pain and self-management methods in a structured way. For example, there are structured courses on physiotherapy, yoga, stress reduction and relaxation methods such as progressive muscle relaxation and autogenic training.
48339007|NCT00430898|DRUG|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
48339008|NCT01911208|BEHAVIORAL|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
48655299|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young men|"Participants in this intervention will be healthy young men. The information of nutritional supplements is below.~Hydrolyzed collagen: 30 grams unflavored hydrolysed collagen (HC) (Myprotein, Cheshire, UK) 30.5 grams unflavored maltodextrin (Myprotein, Cheshire, UK) 50 milligrams vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK) 3 grams non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
48655300|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young women|Participants in this intervention will be healthy young women. The same nutritional supplements in Arm 1 wil be used in Arm 2.
48655301|NCT04046991|DEVICE|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
48655302|NCT04046991|BEHAVIORAL|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
48655303|NCT06500130|DEVICE|Body Surface Gastric Mapping|All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.
48655304|NCT06643221|BEHAVIORAL|Exercise|After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)
48655305|NCT06643221|DRUG|Isoproterenol|To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)
48655306|NCT06643221|DRUG|Placebo|Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
47979756|NCT02965547|PROCEDURE|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
48339009|NCT01911208|BEHAVIORAL|Control|Non-intervention control.
48655307|NCT06643221|DRUG|Bisoprolol Fumarate Tablet 10 mg|Healthy participants will consume a 10mg Bisoprolol Fumerate tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
48655308|NCT06643221|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|Healthy participants will consume a 80mg Nadolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
47979757|NCT01868750|DIETARY_SUPPLEMENT|Calcitriol|1.0ug twice daily for 7 days before surgery
47979758|NCT01868750|DIETARY_SUPPLEMENT|Control Pill|placebo pill taken twice daily for 7 days before surgery
48339010|NCT05163834|BIOLOGICAL|Efgartigimod|intravenous infusion of efgartigimod
47979759|NCT05816512|DRUG|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
47979760|NCT05816512|DRUG|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
47979761|NCT02011737|DRUG|naftopidil 75mg|
47979762|NCT04158440|DRUG|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
47979763|NCT04158440|DRUG|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
47979764|NCT04470674|DRUG|Durvalumab|Durvalumab 1500 mg
47979765|NCT04470674|DRUG|Carboplatin|carboplatin AUC 5
47979766|NCT04470674|DRUG|Pemetrexed|pemetrexed 500 mg/m2
47979767|NCT00279240|DRUG|Metformin|
48497050|NCT00902720|OTHER|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
48497051|NCT03743792|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
48497052|NCT03743792|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
48497053|NCT03039179|DEVICE|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
48497054|NCT03008876|DRUG|Acetaminophen|infants receive acetaminophen for treatment of their PDA
47979768|NCT01092104|DRUG|TBR-652|TBR-652 25 mg
47979769|NCT01092104|DRUG|TBR-652 Matching Placebo|Matching Placebo
47979770|NCT01092104|DRUG|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
47979771|NCT01092104|DRUG|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
47979772|NCT01092104|DRUG|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
47979773|NCT01092104|DRUG|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
47979774|NCT03062683|OTHER|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
47979775|NCT04604821|BEHAVIORAL|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
47979776|NCT04604821|BEHAVIORAL|Parent Education|Parents receive information on child developmental milestones.
47979777|NCT04271891|DEVICE|WBPC|The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks.
48131678|NCT06652360|DEVICE|Chemical Debridement|The chemical debridement is a dehydrating agent in a gel shape that will dry out the woundbed and biofilm.
48497055|NCT03008876|DRUG|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
48497056|NCT01777620|BIOLOGICAL|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
48497057|NCT01777620|DRUG|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
48655309|NCT06643221|DRUG|Carvedilol 50 mg|Healthy participants will consume a 50mg Carvedilol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
48655310|NCT06643221|DRUG|Roflumilast 500 Mcg Oral Tablet|Healthy participants will consume a 500mcg Roflumilast tablet and a 10mg Bisoprolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
47979778|NCT04271891|DEVICE|Without WBPC|Not treat with WBPC
47979779|NCT05554705|BEHAVIORAL|Intensive Lifestyle intervention|12 week therapeutic lifestyle change program
47979780|NCT00707824|DRUG|nalbuphine|nalbuphine 5 mg epidural
47979781|NCT00707824|DRUG|nalbuphine|nalbuphine 10 mg epidural
47979782|NCT00707824|OTHER|NSS|NSS
47979783|NCT05738005|OTHER|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|Amyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
48339011|NCT05163834|OTHER|Placebo|intravenous infusion of placebo
48339012|NCT05163834|BIOLOGICAL|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
48497058|NCT05340348|OTHER|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
48497059|NCT01540773|DRUG|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
48497060|NCT01540773|DRUG|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
48339013|NCT04010162|OTHER|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
47979784|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
47979785|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
48339014|NCT01855841|DRUG|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
48655311|NCT03735901|DRUG|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
48339015|NCT01855841|DRUG|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
48339016|NCT03714061|OTHER|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
48339017|NCT03714061|OTHER|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
48497061|NCT05876663|OTHER|Kinesio Taping|Kinesio Taping will be applied for 6 weeks and it will be changed with new one after every two days
48655312|NCT03735901|DRUG|Matching placebo|"Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
48655313|NCT01225224|DRUG|peficitinib|oral
48655314|NCT01225224|DRUG|Placebo|oral
47979786|NCT03182101|BEHAVIORAL|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
47979787|NCT00759811|DRUG|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
48131679|NCT06652360|DEVICE|Curettage debridement|The use of a currette will clean the wound bed. Debridement by mechanically removing the necrotic tissue and biofilm. This is performed confrom the standard of care standards.
47979788|NCT00759811|DRUG|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
47979789|NCT03314402|DRUG|Jaktinib Dihydrochloride Monohydrate|Active Substance
48131680|NCT04198922|DRUG|Acalabrutinib|Given PO
48339018|NCT05013294|OTHER|Intervention|Text messages through a basic phone or smart phone
48339019|NCT02680119|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
48339020|NCT02680119|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
48339021|NCT02060968|DEVICE|Promus PREMIER|
48339022|NCT04799704|DIAGNOSTIC_TEST|swabbing of conjunctiva|Each eye will be sampled with a single, sterile, nylon, flocked swab
48339023|NCT04816045|PROCEDURE|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
47979790|NCT03314402|DRUG|placebo|Placebo
47979791|NCT04384328|OTHER|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
48655315|NCT06638931|DRUG|Nivolumab|"The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol.~After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death."
48655316|NCT06643793|DRUG|Irinotecan liposome (ll) + 5-FU/LV + bevacizumab|"1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w."
48655317|NCT06570460|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 6 months
48655318|NCT06570460|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 6 months
48655319|NCT06637774|DEVICE|Aspirometer|a triaxial accelerometer and a contact microphone affixed with tape to patient neck, a data accrual infrastructure, algorithms that decode swallow physiology noninvasively
47979792|NCT01252108|DRUG|SQ109|300 mg SQ109 daily for 14 days
47979793|NCT06372860|BEHAVIORAL|Diabetes Prevention Program|"The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences.~Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences."
48131681|NCT04198922|OTHER|Questionnaire Administration|Ancillary studies
48131682|NCT06286800|DEVICE|Transcranial direct current stimulation (tDCS) with OT|Weak direct current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the ptDCS montage. The current will be increased and decreased ramp-like at the beginning and end of the 20-minute stimulation to lessen the itchy/numb skin sensation and decrease the likelihood of an innocuous phosphene-like visual phenomenon. The stimulation will be delivered during the first 20 minutes of occupational therapy targeted to the more affected upper extremity.
48131683|NCT06286800|DEVICE|Sham tDCS with OT|Same procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions. \[69\] This short length of stimulation is documented to elicit sensations comparable to those of real stimulation. With this procedure, subjects were unable to differentiate between tDCS and sham stimulation in our and other previous studies.
48339024|NCT04816045|PROCEDURE|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
48339025|NCT02069249|BEHAVIORAL|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
48339026|NCT02069249|BEHAVIORAL|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
48655320|NCT06637774|DEVICE|Videofluoroscopic X-ray|MBS is a fluoroscopic diagnostic test to evaluate swallowing physiology. Its images are judged by humans trained to do so.
48655321|NCT06641596|DIETARY_SUPPLEMENT|Placebo|2 capsules of Placebo, once daily after breakfast for 12 weeks
48655322|NCT06641596|DIETARY_SUPPLEMENT|Cr-400|1 capsule of Cr-400 + 1 capsule of Placebo, once a day after breakfast for 12 weeks
48655323|NCT06641596|DIETARY_SUPPLEMENT|Cr-800|2 capsules of Cr-400, once a day after breakfast for 12 weeks
48655324|NCT06641596|DIETARY_SUPPLEMENT|PE-500|1 capsule of PE + 1 capsule of Placebo, once a day after breakfast for 12 weeks
48497062|NCT05876663|OTHER|Conventional physiotherapy protocol|"Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks."
48497063|NCT00376311|DRUG|oral salmon calcitonin|
48497064|NCT03989622|OTHER|evaluation of the visual field on the ground|evaluation of the visual field on the ground
48497065|NCT01375153|DRUG|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
48497066|NCT01375153|DRUG|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
48497067|NCT02782793|PROCEDURE|Endoscopic Mucosal Resection|
48497068|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction with lateral extra articular tenodesis|Anatomical single bundle ACLR with modified Lemiere technique
48497069|NCT05962580|PROCEDURE|Isolated anterior cruciate ligament reconstruction only|arthroscopic anatomical single bundle ACL Reconstruction
48497070|NCT00121472|DEVICE|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
48497071|NCT03166423|DRUG|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
48497072|NCT03166423|DEVICE|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
48497073|NCT06074081|OTHER|motor relearning program|MRP is a therapy to regain particular motor function and neglecting accessory movements by engaging cognitive behavior .
48497074|NCT06074081|OTHER|mirror therapy|Mirror therapy enhance functional activities in patient with hemiplegic stroke. For betterment of result high quality methodological studies and larger sample size is required.
48497075|NCT03849287|DRUG|CKD-333, formula I|Test drug
48497076|NCT03849287|DRUG|CKD-333, formula II|Test drug
48497077|NCT03849287|DRUG|CKD-330, D090|Reference Drug
48497078|NCT00088621|DRUG|Lurasidone 80mg tablet|
48497079|NCT04648332|DRUG|Bupivacaine Hydrochloride|compartment psoas block
48497080|NCT00117208|DRUG|mannitol|400mg BD for 12 weeks
48497081|NCT00117208|DRUG|mannitol + pulmozyme|combination
48497082|NCT00117208|DRUG|Dornase alpha|2.5mg daily for 2 weeks
48497083|NCT01986010|BIOLOGICAL|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
48497084|NCT01986010|BIOLOGICAL|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
48497085|NCT01986010|BIOLOGICAL|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
48497086|NCT01986010|BIOLOGICAL|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
48497087|NCT01986010|BIOLOGICAL|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
48497088|NCT01986010|BIOLOGICAL|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
48497089|NCT01986010|OTHER|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
48497090|NCT01986010|BIOLOGICAL|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
48339027|NCT03960658|DRUG|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
48655325|NCT06641596|DIETARY_SUPPLEMENT|PE-1000|2 capsules of PE-500, once a day after breakfast for 12 weeks
48655326|NCT06058949|BEHAVIORAL|Health Protection and Promotion|An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
48655327|NCT06058949|BEHAVIORAL|General Health Program|Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
48655328|NCT06571227|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
48655329|NCT06043011|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
48655330|NCT03732794|DEVICE|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
47979794|NCT06372860|BEHAVIORAL|Breastfeeding|"Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC).~Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants."
47979795|NCT06372860|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
47979796|NCT04883502|BIOLOGICAL|Blood sample collection|A blood sample will be collected at enrollment.
47979797|NCT04883502|BIOLOGICAL|Other biological sample collection|"The following biological samples will be collected during the first surgery:~* 1 blood sample~* 3 fragments of induced membrane~* 1 fragment of periosteum"
47979798|NCT04883502|DIAGNOSTIC_TEST|Surgical waste collection|The pieces of polymethylmethacrylate surgical cement will be collected during the second surgery.
48339028|NCT03063398|DIAGNOSTIC_TEST|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
48339029|NCT01589263|DRUG|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
48655331|NCT01783808|OTHER|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
48655332|NCT06264596|DRUG|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
48655333|NCT06264596|PROCEDURE|Normal Saline irrigation fluid|The control group will have two 3-L normal saline solution bags prepared with no additive
48655334|NCT06256120|DIAGNOSTIC_TEST|Restrictive|3 mL/kg/hour Ringer Lactate will be given peroperatively to the restrictive group (Group R).
48655335|NCT06256120|DIAGNOSTIC_TEST|Liberal|7 ml/kg/hour Ringer Lactate will be given peroperatively to the liberal group (Group L).
48655336|NCT06367101|OTHER|AR training with gait and HRV feedback|Use projection-based AR system to train gait and HRV. To give gait and HRV feedback for subjects after AR training.
48655337|NCT05498870|DRUG|Adductor Canal Block (ACB) Only|Patients will receive an ACB with lidocaine skin wheal
48655338|NCT05498870|DRUG|Adductor Canal Block (ACB) + iPACK Block|Patients will receive an ACB with iPACK block
48339030|NCT01589263|DRUG|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
48339031|NCT00441480|DIETARY_SUPPLEMENT|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
48655339|NCT04605146|BEHAVIORAL|Tele-monitoring|"The tele-monitoring will consist in filling in a specific questionnaire once a week in the first 6 months, every 2 weeks until 12 months, and on-demand (in case of upcoming toxicity, at any time). These questionnaires will be reviewed by a coordinating nurse. According to the result of the questionnaire, the coordinating nurse will adapt patients' management, either by giving them a phone call, or inviting them to directly contact their medical department, or even plan an emergency hospitalization if necessary. The coordinating nurse will closely work with the investigator to adapt patients' management.~Quality of life questionnaire (FACT-G) will also be filled in at inclusion, M3 and M12."
48655340|NCT03590548|DIAGNOSTIC_TEST|gausher disease|lab investigation and radio logical
48655341|NCT06641037|DRUG|LY3866288|Administered orally
47979799|NCT04883502|DIAGNOSTIC_TEST|Radiological examination and functional exploration|A radiological examination and a functional exploration will be performed 6 weeks, 3 months and 6 months after the first surgery
47979800|NCT02152839|BEHAVIORAL|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
47979801|NCT04147221|DRUG|Imipenem-relebactam|After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
48497091|NCT01986010|OTHER|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
48339032|NCT00441480|DIETARY_SUPPLEMENT|placebo|4 gr of corn oil
48339033|NCT01267344|DRUG|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
48339034|NCT01267344|DRUG|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
48339035|NCT04161612|OTHER|Demographic characteristics, duration of spinal cord injury, spinal cord injurylevel, etiology, number of intermittent bladder catheterization (IC), number of night time|Observational clinical study
48339036|NCT02894255|DEVICE|Coronary artery bypass grafting|
47979802|NCT00273442|DRUG|timolol maleate|
48339037|NCT02894255|PROCEDURE|Percutaneous coronary intervention|
48655342|NCT06510231|OTHER|Inspiratory Muscle Training|Inspiratory muscle training (IMT) targets the inspiratory muscles and is used to improve inspiratory muscle strength.
48655343|NCT03924284|DIAGNOSTIC_TEST|PB2 gene RT-PCR; NS gene RT-PCR|PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
48655344|NCT05525520|DRUG|EP547|Once daily
48655345|NCT05525520|DRUG|Placebo|Once daily
48655346|NCT06638255|OTHER|Sequence A involves administering Low PEEP for 12 hours, followed by High PEEP for 12 hours.|"Patients will first receive the Low PEEP protocol for 12 hours, followed by the High PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies.~Description: Patients will first receive the High or LOW PEEP protocol for 12 hours, followed by the Low or HIGH PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies."
47979803|NCT00273442|DRUG|dorzolamide/timolol maleate fixed combination|
47979804|NCT04304807|DRUG|Melatonin 20 mg|Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
47979805|NCT04304807|DRUG|Traditional antibiotic treatment|Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
47979806|NCT05398211|BEHAVIORAL|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
47979807|NCT05398211|BEHAVIORAL|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
48497092|NCT00532038|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
48497093|NCT00589329|DRUG|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
48497094|NCT00589329|DRUG|placebo|IV and pill placebo
48497095|NCT04173624|DIAGNOSTIC_TEST|Endosonography|Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
48339038|NCT01673269|OTHER|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
48339039|NCT00904176|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
47979808|NCT05956860|PROCEDURE|abdominopelvic vascular intervention through the radial artery access|"According to the pathological changes and needs of the subjects (any abdominal and pelvic arterial intervention that can be performed through the radial artery access, including but not limited to:~1. hepatic intervention, such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc.;~2. Other visceral intervention, such as spleen, kidney, mesentery, etc.;~3. Pelvic intervention, such as uterine artery embolism, prostatic artery embolism, etc.;~4. Others, such as preoperative embolization of bone tumors (lumbar, sacral vertebra), etc."
48339040|NCT00904176|DRUG|Warfarin|Tablets, Oral, 25 mg, Single Dose
48339041|NCT00904176|DRUG|Digoxin|Tablets, Oral, 0.25, Single Dose
47979809|NCT04907656|BEHAVIORAL|dCBT|As per arm of the same name
48339042|NCT00124813|DRUG|thalidomide|
48339043|NCT00124813|DRUG|idarubicin|oral idarubicin
48339044|NCT03402282|PROCEDURE|embolization|upper rectal artery embolization with coils
48339045|NCT03402282|PROCEDURE|surgical repair|surgical repair through the classic technique (Milligan and Morgan technique)
48339046|NCT02949557|PROCEDURE|Decortication + bone grafts|
48655347|NCT06638255|OTHER|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.
48497096|NCT04173624|DIAGNOSTIC_TEST|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
48497097|NCT02175576|DEVICE|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
48655348|NCT06641336|DEVICE|RehAtt|Each patient received the RehAtt intervention.
48655349|NCT05110261|DRUG|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
48655350|NCT05110261|DRUG|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
48655351|NCT04519567|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
48655352|NCT04519567|BIOLOGICAL|Placebo|Placebo Comparator
48655353|NCT03211546|PROCEDURE|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
48655354|NCT03211546|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
47979810|NCT04334551|DRUG|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
48131687|NCT06241560|DRUG|BI 1015550|BI 1015550
48339047|NCT00212758|DRUG|Nutropin AQ|Nutropin AQ
48339048|NCT02693691|DEVICE|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
48339049|NCT02089503|OTHER|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
48339050|NCT05228756|OTHER|Accelerometer|Participants will complete 16 exercise sessions at home wearing an accelerometer
48339051|NCT05948319|DIAGNOSTIC_TEST|Doppler ultrasonography|Doppler study was performed in all cases. perinatal outcomes were evaluated.
48339052|NCT00439725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
48339053|NCT00439725|DRUG|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
48339054|NCT02695576|PROCEDURE|Lumbar Fusion Surgery|Interbody fusion with fixation
48339055|NCT02695576|OTHER|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
48339056|NCT02695576|OTHER|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
48339057|NCT04383613|OTHER|Prone positioning|The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for \>24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
48339058|NCT02524067|BEHAVIORAL|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
48339059|NCT01591811|RADIATION|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
48339060|NCT01591811|RADIATION|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
48339061|NCT04825249|PROCEDURE|traditional suture bridge technique|(A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
48339062|NCT04825249|PROCEDURE|modified suture bridge technique|(A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
48497098|NCT02175576|DEVICE|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
48497099|NCT01716624|DRUG|Oxybutynin|standard oral therapy
48497100|NCT01716624|DRUG|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
48497101|NCT04589416|OTHER|Dental adhesive materials.|It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
48655355|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
48131688|NCT06241560|DRUG|Pirfenidone|Pirfenidone
48497102|NCT05154435|DRUG|mostcare hemodynamic monitor|mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
48131690|NCT06649708|DRUG|HX044|Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
48131691|NCT00525954|DRUG|A-002|
48497103|NCT02528513|DRUG|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
48497104|NCT02528513|DRUG|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
48339063|NCT00259350|DRUG|Skin disinfection|
48339064|NCT01749800|DEVICE|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
48339065|NCT01749800|DEVICE|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
48655356|NCT00035984|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
48131694|NCT00137800|DRUG|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
48131695|NCT06213233|DRUG|Placebo|Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
48131696|NCT06213233|DRUG|Cannabidiol|Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).
48131697|NCT05153070|DRUG|Cyclosporin|• Ciclosporin: 3.5mg/kg, twice a day, oral, between Day 1 and Day 60
48131698|NCT05153070|DRUG|ILT101|• ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.
48131699|NCT05153070|DRUG|Placebo|• Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
48339066|NCT01749800|DEVICE|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
48339067|NCT04633031|DEVICE|Boston|
48339068|NCT04633031|DEVICE|Cheneau|
48339069|NCT03429764|PROCEDURE|CISS|continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
48339070|NCT03429764|PROCEDURE|VIMS|internal mattress suture will be placed with minimum two intact contact points at the surgical site
48339071|NCT01719679|BEHAVIORAL|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
48655357|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
48655358|NCT00035984|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
48655359|NCT00386581|DRUG|atomoxetine|
48655360|NCT00386581|DRUG|placebo|
48655361|NCT06231264|DEVICE|transcutaneous electrical acustimulation at treatment sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
48655362|NCT06231264|DEVICE|transcutaneous electrical acustimulation at sham sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
48131700|NCT00004559|BEHAVIORAL|dietary polyunsaturated fatty acid|
48131701|NCT05216770|OTHER|Brain imaging|Brain images will be conducted with function MRI, magnetoencephalography (MEG), and electroencephalography (EEG) to identify disorder-specific neural markers
48131702|NCT05216770|DRUG|Laryngeal sensory block with topical bupivacaine|Laryngeal sensory block with bupivacaine will be used to modulate sensory feedback from vocal fold mucosa and examine the impact of sensory feedback on abnormal neural activity in LD and VT
48497105|NCT02528513|DRUG|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
48131706|NCT00352599|DRUG|Lovastatin|
48339072|NCT00505804|DRUG|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
48339073|NCT00505804|DRUG|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
48339074|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
48339075|NCT00901589|DIETARY_SUPPLEMENT|thistle oil|four capsules a day
48339076|NCT00901589|DIETARY_SUPPLEMENT|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
48339077|NCT00901589|DIETARY_SUPPLEMENT|Thistle oil|Four capsules daily
48339078|NCT02324738|DRUG|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
47979811|NCT01731392|DIETARY_SUPPLEMENT|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
47979812|NCT01731392|DIETARY_SUPPLEMENT|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
48131707|NCT00352599|DRUG|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
48131708|NCT00352599|DRUG|placebo pill|
48131709|NCT05888805|OTHER|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
48131710|NCT03440996|OTHER|Clinpro™ 5000|Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
48339079|NCT02324738|OTHER|Wash-out period|
48339080|NCT02324738|DRUG|Mefloquine|2 tablets of Mefloquine single dose
48339081|NCT02533661|OTHER|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
48339082|NCT06067750|DIAGNOSTIC_TEST|Narcotrend compared to Cerebral Function Analysing Monitor (CFAM)|All patients will receive Narcotrend and CFAM monitoring in this observational study
48339083|NCT00383877|DRUG|insulin detemir|
48339084|NCT00383877|DRUG|insulin NPH|
48339085|NCT03633994|DRUG|Heparin|Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
48339086|NCT03633994|DRUG|Normal saline|Normal saline bladder instillation
48655363|NCT06638203|OTHER|The 2-hour Exemplary Leadership Course (ELC)|"This two-hour course, based on the Five Exemplary Leadership Model, aims to refresh participants' theoretical understanding of leadership while providing insights into effective leader-follower interactions through practical scenarios. The session will begin with an exploration of the nature of leadership, including its philosophical and historical context. The significance of leadership in nursing will be emphasized, highlighting its impact on education, clinical practice, and the profession overall. Participants will examine the key roles of nurse leaders, focusing on modeling the way, inspiring a shared vision, challenging the process, enabling others to act, and encouraging the heart. Content Outline:~1. The Nature and Definition of Leadership (5 minutes)~2. Leadership and Its Importance in Nursing (15 minutes)~3. Transformational Leadership and Its Components (40 minutes)~4. Positive Leader-Follower Interactions (15 minutes)~5. Case Study Discussions (45 minutes)"
48339087|NCT02253472|DEVICE|Deep Brain Stimulation|
48339088|NCT04594018|DRUG|Finlândia Association + finasteride placebo|Finlândia association hair lotion + finasteride placebo
48339089|NCT04594018|DRUG|Minoxidil + finasteride|Minoxidil hair lotion + Finasteride 1 mg
47979813|NCT01731392|DIETARY_SUPPLEMENT|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
47979814|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
47979815|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
47979816|NCT05147116|OTHER|Sleeping in a tent|Participants will spend 10 consecutive nights of sleeping in a tent
47979817|NCT03766555|PROCEDURE|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
48339090|NCT03215667|DEVICE|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
48339091|NCT04516733|OTHER|supportive care|visit with supportiv unit and neuropsychologue every 3 months
47979818|NCT03766555|PROCEDURE|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
47979819|NCT01179854|DRUG|Remegal|Drug/ placebo
47979820|NCT05573607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
48655364|NCT06638203|OTHER|The NurseLead in Progress Game|Developed collaboratively by the author and a company, this unpublished game focuses on role-playing leader-follower interactions to navigate scenarios effectively. Designed for five students per session, the game consists of five sections, lasting approximately one hour, with each section corresponding to one of the Five Practices of Exemplary Leadership. In each section, one student takes on the role of leader while the other four act as followers. The main objective is to guide a newly appointed charge nurse in making sound decisions when facing challenges to achieve key goals. Following the game, a debriefing session will allow participants to analyze responses with experts. Performance will not be formally evaluated, as the game serves as a learning experience, enabling students to lead and engage as followers. This activity aims to activate the experiential learning phase of Kolb's Learning Model.
48655365|NCT02763566|DRUG|Abemaciclib|Administered orally
48655366|NCT02763566|DRUG|Anastrozole|Administered orally
48655367|NCT02763566|DRUG|Letrozole|Administered orally
48655368|NCT02763566|DRUG|Placebo|Administered orally
48655369|NCT02763566|DRUG|Fulvestrant|Administered intramuscularly
48655370|NCT06463730|BEHAVIORAL|Serious games|Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board
48655371|NCT00219726|DRUG|Imatinib mesylate|
48655372|NCT04874194|DRUG|Omacetaxine Mepesuccinate|Given SC
48655373|NCT04874194|DRUG|Venetoclax|Given PO
48655374|NCT01631500|BEHAVIORAL|Conventional treatment|Conventional treatment
47979821|NCT05573607|DIETARY_SUPPLEMENT|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
47979822|NCT00711711|OTHER|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
47979823|NCT00711711|OTHER|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
48655375|NCT01631500|OTHER|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
48655376|NCT01631500|OTHER|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
48655377|NCT06008795|DRUG|Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone|Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone
48655378|NCT06008795|PROCEDURE|Placebo Pteryogpalatine Fossa Injection|Each placebo PPF-injection will consist of 5ml normal saline
47979824|NCT03992859|PROCEDURE|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
47979825|NCT04840615|BIOLOGICAL|LMB-100|LMB-100 administered into lesion on days 1 and 4 during cycle 1.
47979826|NCT04840615|DRUG|ipilimumab|Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
48339092|NCT06340672|OTHER|Augmented Reality Enhanced Preoperative Counseling|For patients undergoing AR enhanced preoperative counseling, headset-based AR holograms of standardized patient anatomy through AnatomyX as well as patient specific anatomy through SurgicalAR will be projected to assist the surgeon in educating the patient throughout preoperative counseling.
48655379|NCT03073967|DRUG|Pritelivir|100 mg oral tablets
48655380|NCT03073967|DRUG|Investigator's choice|Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
48655381|NCT04485104|DRUG|GWP42003-P|Oral Solution
48655382|NCT03840889|OTHER|Data collection|"he different modes of active data collection:~* Data collection by telephone~* Data collection by mail~* Collection from discharge database summaries (PMSI)"
48655383|NCT05392751|DRUG|EA-2353|EA-2353 Ophthalmic Suspension
48655384|NCT05715021|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
47979827|NCT04840615|DRUG|Diphenhydramine|Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
47979828|NCT04840615|DRUG|Famotidine|Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
48339093|NCT06340672|OTHER|Standard preoperative counseling|Control patients will undergo standard preoperative counseling.
48655385|NCT06275867|OTHER|Free high-quality care|Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.
48655386|NCT06275867|OTHER|Close distance|The network of contracted providers is located close to where participants live.
48655387|NCT06275867|OTHER|Far distance|The network of contracted providers is located far to where participants live.
48655388|NCT06049160|DRUG|Misoprostol|All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
48655389|NCT05620134|DRUG|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
48655390|NCT05620134|DRUG|Pembrolizumab|Immune checkpoint inhibitor
48655391|NCT05620134|DRUG|Lenvatinib Pill|Multi-kinase inhibitor
48655392|NCT06637319|DEVICE|Ultrasound|Ultrasound scan of blood vessels where front of neck access vertical incision would take place in a cant intubate cant oxygenate scenario
48655393|NCT05411900|DRUG|BoNT-A|"A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
48655394|NCT05411900|DRUG|Placebo|"Placebo will consist of equal volume of saline solution (0.9%). Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness."
48655395|NCT05821205|BEHAVIORAL|Narrative Persuasion|Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.
48655396|NCT05821205|BEHAVIORAL|Reciprocity|Researchers will track clicking on the gift card as a measure of engagement
48655397|NCT05821205|BEHAVIORAL|Personalized Feedback|Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.
48655398|NCT05821205|BEHAVIORAL|Commitment|Providers will receive a commitment message and be asked to reply as a measure of engagement.
48655399|NCT02975115|OTHER|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
48655400|NCT06057090|BEHAVIORAL|Therapy Dog|Certified, volunteer therapy dogs and their handlers will be present in the room during procedures in the experimental arm to see if their presence reduces anxiety and improves behavior in pediatric dental patients.
48655401|NCT03329131|DEVICE|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
48655402|NCT05528939|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
48655403|NCT05528939|OTHER|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
48655404|NCT05634811|BIOLOGICAL|VLA15|6-valent OspA-based Lyme disease vaccine
47979829|NCT04840615|DRUG|Acetaminophen|Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
47979830|NCT04840615|DRUG|Dexamethasone|Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.
47979831|NCT04840615|PROCEDURE|Biopsy|As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \& 4 Day 1, and Cycle 4 Day 21 (±7 days).
48655405|NCT05634811|OTHER|Normal Saline|0.9% sodium chloride solution for injection
47979832|NCT04840615|DIAGNOSTIC_TEST|FDG-PET|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
47979833|NCT04840615|DIAGNOSTIC_TEST|CT CAP|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
48497106|NCT02528513|DRUG|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
48497107|NCT02528513|PROCEDURE|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
48655406|NCT06645405|BEHAVIORAL|AI algorithm|Artificial intelligence algorithms in the automated reconstruction of intracranial large vessel occlusion (LVO)
48655407|NCT06498258|OTHER|Positive Psychotherapy Balance Model Based Psychoeducation|In this study, it can be said that adopting a loving, connected and balanced state of mind in the face of the difficulties experienced and responsibilities undertaken by caregivers will increase the joy, meaning and self-sufficiency in life and as a result, it can positively contribute to their level of well-being. All these results are important for caregivers to be able to recognise their own resources, to maintain their life balance, to develop a positive perspective towards themselves, to make subjective evaluations and to recognise their strengths.
48655408|NCT05245058|DRUG|SPH5030 tablets|SPH5030 tablets orally once or twice daily.
47979834|NCT04840615|DIAGNOSTIC_TEST|MRI|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
48655409|NCT06477601|OTHER|Assigning cooling agent type cigarettes|This study is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol cigarettes but allows cooling agent cigarettes.
48655410|NCT06477601|OTHER|Assigning traditional tobacco type cigarettes|This comparison group is intended to help understand what people who smoke menthol cigarettes would do in a scenario where the Food and Drug Administration bans menthol and cooling agent cigarettes.
47979835|NCT04840615|DIAGNOSTIC_TEST|ECG|At screening, Cycle 1 Day 1, Cycles 2, 3, \& 4 Day 1 and Follow-Up Visit (4-6 weeks after end of treatment).
48655411|NCT06477601|OTHER|Assigning menthol type cigarettes|This comparison group is for where the Food and Drug Administration does not ban menthol cigarettes.
47979836|NCT04840615|DIAGNOSTIC_TEST|Echocardiogram|At screening.
47979837|NCT00823394|BEHAVIORAL|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
47979838|NCT00823394|OTHER|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
47979839|NCT00823394|BEHAVIORAL|Self-help Materials|Information on how to lower risk for developing cancer.
47979840|NCT03855280|DRUG|APVO101|Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
47979841|NCT02205814|DRUG|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
48497108|NCT02528513|PROCEDURE|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
48497109|NCT02528513|DRUG|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
48497110|NCT02203214|DEVICE|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
48339094|NCT03322085|PROCEDURE|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
48339095|NCT00141934|DRUG|AD 452|
48339096|NCT05184127|DRUG|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
48497111|NCT05465239|DEVICE|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
48497112|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 120 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
48497113|NCT06236243|DIETARY_SUPPLEMENT|Korean Red Ginseng Extract Powder 500 mg/tablet|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
48497114|NCT06236243|DIETARY_SUPPLEMENT|Placebo|Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
48497115|NCT04265339|OTHER|Smoking cessation|Participants are required to quit smoking
48497116|NCT00121134|DRUG|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
48497117|NCT00121134|DRUG|Cyclophosphamide|Once a day for 6 months
48655412|NCT05130281|BEHAVIORAL|Maya mobile app|The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.
48655413|NCT05130281|BEHAVIORAL|Social Support|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.
48655414|NCT05130281|BEHAVIORAL|Gain Framed|Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.
48655415|NCT05130281|BEHAVIORAL|Loss Framed|Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
48655416|NCT02776735|DRUG|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
48655417|NCT03503331|DRUG|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
47979842|NCT02205814|DRUG|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
47979843|NCT02205814|DRUG|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
47979844|NCT02205814|DRUG|Placebo comparator|Single intra-articular injection of placebo
47979845|NCT04233151|DRUG|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
47979846|NCT04233151|DRUG|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
47979847|NCT04233151|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
48497118|NCT00121134|DRUG|Methotrexate|Twice daily for the first two days of every week for 6 months
48497119|NCT00121134|DRUG|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
48497120|NCT03279497|BEHAVIORAL|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
48497121|NCT03279497|BEHAVIORAL|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
48497122|NCT00895947|DRUG|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
48497123|NCT00895947|OTHER|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
48497124|NCT03233230|DRUG|M2591 25 mg QD|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
48497125|NCT03233230|DRUG|M2951 75 mg QD|Participants received 75 mg of M2951 orally QD for 12 weeks.
48497126|NCT03233230|DRUG|M2951 50 mg BID|Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
48497127|NCT03233230|DRUG|Placebo|Participants received placebo matched to M2951 orally for 12 weeks.
48339097|NCT05184127|COMBINATION_PRODUCT|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
47979848|NCT01352689|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
48339098|NCT00805012|DRUG|docetaxel+CDDP|docetaxel+CDDP
48339099|NCT00805012|DRUG|docetaxel+S-1|docetaxel+S-1
47979849|NCT01352689|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
48339100|NCT02376478|DRUG|TNF-alpha inhibitors|therapy for at least 6 months
48339101|NCT02376478|DRUG|Alternative/no medication|therapy for at least 6 months or no therapy
48339102|NCT02376478|OTHER|Alternative/no medication|phototherapy for at least 6 months
48339103|NCT02376478|DRUG|Purine/folic acid analogues|therapy for at least 6 months
48339104|NCT01703104|DRUG|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
48339105|NCT01703104|DIETARY_SUPPLEMENT|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
48339106|NCT03498092|DRUG|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
48339107|NCT03498092|DRUG|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
48339108|NCT03498092|DRUG|General anesthesia|Normal saline in a volume of 0.5 ml/kg
48339109|NCT00092482|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
48339110|NCT01528995|DEVICE|Medtronic Interstim II-3058|impulse generator
48339111|NCT01528995|PROCEDURE|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
48655418|NCT04704648|PROCEDURE|Surgical|"The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency."
48655419|NCT06640621|DRUG|Different concentration of ropivacaine for single brachial plexus block|40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
47979850|NCT02317068|DEVICE|HBR|
47979851|NCT02317068|DEVICE|DD|
48497128|NCT03360591|DEVICE|Physiologically-guided strategy|"The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches \>2.5mm, with a % coronary stenosis\>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR \>0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values \>0.80 that show a discrepancy with positive (\<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy"
47979852|NCT05693246|DRUG|Glycopyrrolate|At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.
47979853|NCT05693246|OTHER|normal saline|At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
47979854|NCT04637789|BEHAVIORAL|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
48339112|NCT04092010|BEHAVIORAL|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
48339113|NCT04092010|BEHAVIORAL|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
48339114|NCT04092010|BEHAVIORAL|Usual care|Normal services provided children and their mothers in Head Start
48339115|NCT00121680|DRUG|E7080|Oral.
48339116|NCT05204758|DRUG|TCM Formula|three packages of TCM preparations with each meal three times a day
48339117|NCT05204758|DRUG|Placebo|three packages of placebo preparations with each meal three times a day
48339118|NCT04735536|DRUG|CT1812|Active Treatment- CT1812 at a dose of 300mg
48339119|NCT04735536|OTHER|Placebo|Placebo Comparator
48339120|NCT01119963|DRUG|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
48339121|NCT01119963|DRUG|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
48339122|NCT02844673|DRUG|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
48339123|NCT02844673|DEVICE|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
48339124|NCT04745312|DEVICE|Visible light|Ambient room lighting will be supplemented with additional light from a task lamp.
48339125|NCT04734977|DEVICE|High-intensity laser therapy (HILT)|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of four weeks, and one session per day for a total of 20 sessions. A 3-phase treatment program was performed in each session.
48339126|NCT04734977|DEVICE|Sham high-intensity laser therapy (Sham HILT)|Sham High intensity laser therapy was applied in five sessions a week for four weeks, with a total of 20 sessions a day, with no current flowing through the device using a HIRO 3 device (ASA Laser, Arcugnano, Italy).
48497129|NCT00670163|BEHAVIORAL|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
48655420|NCT05549622|OTHER|Low-soluble fiber diet|12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
48655421|NCT05549622|OTHER|High-soluble fiber diet|12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
48655422|NCT06638892|BEHAVIORAL|Using PrEP, Doing it for Ourselves (UPDOs)|An e-Health intervention that considers women's lived experiences and uses three components: beauty salons and stylists as opinion leaders (trusted gatekeepers who share health information in the community), theory driven edutainment videos and blogs, and a secure online platform for accessing pre-exposure prophylaxis (PrEP).
48655423|NCT06638892|OTHER|Standard of Care|CDC standard of care, e.g., CDC videos and website.
48655424|NCT06636916|PROCEDURE|Short Intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
48655425|NCT06636916|PROCEDURE|Long intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
48655426|NCT04280588|DRUG|Fingolimod 0.5 mg|Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
48655427|NCT03282916|DRUG|Valacyclovir|Valacyclovir hydrochloride 500mg caplet
48655428|NCT03282916|DRUG|Placebo|Placebo sugar pill 500mg caplet
48655429|NCT06519526|DRUG|SHR-0302|SHR-0302 will be administered orally as tablets.
48655430|NCT06519526|DRUG|SHR-2554|SHR-2554 will be administered orally as tablets.
47979855|NCT04637789|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
48655431|NCT01893086|PROCEDURE|LH alone|LH, laparoscopic hysterectomy
47979856|NCT00580606|DRUG|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
47979857|NCT00580606|DRUG|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
48339127|NCT04734977|OTHER|Therapeutic Exercise|"As therapeutic exercise program; active cervical ROM, cervical isometric and progressive (self-exercise with Thera-Band) strengthening muscles; trapezius, scalene, rhomboid, levator scapular, pectoral, suboccipital muscles stretching exercises, scapular stabilization exercises.It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes.~Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
48339128|NCT03343782|COMBINATION_PRODUCT|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
48339129|NCT00640146|DRUG|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
48497130|NCT00670163|BEHAVIORAL|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
48497131|NCT00670163|BEHAVIORAL|Standard Care|Standard care will consist of usual care for STIs.
48655432|NCT01893086|PROCEDURE|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
48655433|NCT05396014|BEHAVIORAL|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
48339130|NCT00640146|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
48655434|NCT05396014|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
47979858|NCT01431560|DEVICE|fixation of the ankle fracture (Solco )|fixation with metallic implant
47979859|NCT01431560|DEVICE|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
47979860|NCT00459108|DRUG|dasatinib|Given orally
47979861|NCT03728660|DEVICE|Virtual bioptic magnification with large field of view|The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
47979862|NCT03728660|DEVICE|Full field magnification with small field of view|Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
48339131|NCT01715272|DEVICE|TF037|
48339132|NCT01715272|DRUG|Fleet enema|
48339133|NCT06360497|OTHER|mindfulness meditation intervention and loving-kindness and compassion meditation intervention|Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.
48339134|NCT02264015|DRUG|Cilobradine, low, film-coated tablets|
48339135|NCT02264015|DRUG|Cilobradine, high, film-coated tablets|
48339136|NCT02264015|DRUG|Placebo, film-coated tablets|
48131711|NCT03440996|OTHER|Clinpro™ Tooth Crème|Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
48131712|NCT03440996|OTHER|MI-Paste Plus|MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
48131713|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
48131714|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
48339137|NCT02264015|DRUG|Moxifloxacin, film-coated tablets|
48339138|NCT00422123|DRUG|Quetiapine fumarate (Seroquel) SR|
48497132|NCT00628537|DEVICE|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
48497133|NCT00746018|DEVICE|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
48497134|NCT02261844|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
48497135|NCT02261844|DRUG|Placebo|Placebo 1 pill daily X 10 days
48497136|NCT00230074|DRUG|TCH346|
48655435|NCT05396014|BEHAVIORAL|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
48339139|NCT05620069|OTHER|Music listening|Participants are asked to select one of four music playlists and listen to it for appr. 30 minutes at bedtime during the intervention period.
48497137|NCT04620135|DRUG|Netarsudil ophthalmic solution 0.02%|Topical sterile ophthalmic solution Other Name: Rhopressa®
48497138|NCT04620135|DRUG|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|Other Name: Glanatec®
48497139|NCT02912845|DRUG|KamRAB - HRIG|wound infiltration or IM injection
48497140|NCT02148679|OTHER|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
48497141|NCT02148679|OTHER|Usual care|Standardized advice to restrict dietary sodium intake to \< 2000 mg/day
48131715|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
48131716|NCT01206972|DRUG|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
48339140|NCT01157455|PROCEDURE|Everolimus Drug Eluting Stent|Implantation
48339141|NCT01157455|DRUG|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
48339142|NCT01157455|DRUG|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.~75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
48339143|NCT01157455|DRUG|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
48497142|NCT04098900|DIAGNOSTIC_TEST|Click Sexual Health Test|The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
48497143|NCT03764761|DEVICE|AAC Technology - Standard of Care|Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
48497144|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
48655436|NCT05396014|DRUG|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
48655437|NCT05472870|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
48655438|NCT06569446|OTHER|There is no intervention. This a qualitative study to explore barriers to rectal irrigation|"This will involve semi-structured, open-ended questions about hypothesized barriers to rectal irrigation where the interviewer will ask a pre-determined number of questions and the participants will answer which will further initiate discussion allowing new themes to emerge. After the entire list of barriers is discussed, participants will be asked if they have any new barriers to add which have not been discussed. All new barriers identified will be added to the hypothesized barriers list for the next focused group sessions. Focused group sessions will continue until no new barriers are found in two consecutive sessions (thematic saturation).~9.2 Phase - 2 includes Cognitive Interviews This will involve semi-structured, open-ended questions about barriers to rectal irrigation identified during focused group sessions where the interviewer will ask pre-determined number of questions for individual participants to answer."
48655439|NCT03533582|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48655440|NCT03533582|DRUG|Carboplatin|Given IV
48655441|NCT03533582|DRUG|Cisplatin|Given IV
48655442|NCT03533582|DRUG|Doxorubicin|Given IV
48655443|NCT03533582|DRUG|Etoposide|Given IV
48655444|NCT03533582|DRUG|Fluorouracil|Given IV
48655445|NCT03533582|DRUG|Gemcitabine|Given IV
48655446|NCT03533582|DRUG|Irinotecan|Given IV
48655447|NCT03533582|DRUG|Oxaliplatin|Given IV
48655448|NCT03533582|OTHER|Patient Observation|Undergo watchful waiting
48655449|NCT03533582|PROCEDURE|Resection|Undergo surgical resection
48655450|NCT03533582|DRUG|Sorafenib|Given PO
48655451|NCT03533582|DRUG|Vincristine Sulfate|Given IV
48655452|NCT03014258|BIOLOGICAL|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
48655453|NCT06641167|PROCEDURE|Shoulder surgery|shoulder surgery by arthroscopic approach under locoregional anesthesia combining an interscalene block and a superficial cervical plexus block
48655454|NCT06639204|DEVICE|Electrical stimulation|A removable appliance will be used to accelerate orthodontic tooth movement by emitting electrical stimulation.
48655455|NCT06639204|PROCEDURE|Orthodontic treatment without acceleration|No additional appliances will be used. Only the traditional fixed appliances (braces).
48655456|NCT01218321|BIOLOGICAL|antiepileptic treatment|White blood cells from peripheral blood samples
48655457|NCT05616026|BEHAVIORAL|Intervention|6 months of diabetes management support via SMS texts including reminders for medication adherence, appointments, and diabetes self-care activities as well as education, and support
48655458|NCT05616026|BEHAVIORAL|Attention Control|6 months of texts for general health promotion
48655459|NCT05492045|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
48655460|NCT05492045|DRUG|Other|Standard treatment of NSCLC.
48655461|NCT03984578|DRUG|CAPEOX|Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
48655462|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 and Day 22
48655463|NCT03984578|DRUG|Capecitabine/ 5-FU|Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
48497145|NCT03764761|DEVICE|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
48655464|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 of each cycle
48655465|NCT03984578|DRUG|CAPEOX/Pembrolizumab|"* Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle.~* IV Oxaliplatin: 130mg/m2 on Day 1 of a 3-week cycle.~* Pembrolizumab: IV infusion of 200mg on Day 1 of a 3-week cycle."
48655466|NCT03984578|DRUG|Pembrolizumab alone|IV infusion of 200mg 21 days from the last CAPEOX/Pembrolizumab combination dose.
48655467|NCT03984578|PROCEDURE|Surgical resection|Performed after all medical intervention.
48655468|NCT02683993|DEVICE|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
48655469|NCT00213525|OTHER|Questionnary for environmental factors research|Questionnary for environmental factors research
48131726|NCT03516032|BEHAVIORAL|exercises|
48131727|NCT06091995|BEHAVIORAL|impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.
48655470|NCT04557124|BEHAVIORAL|USS|social cognitive training
48497146|NCT01166906|DEVICE|pain blocking|pain blocking
48497147|NCT00418301|OTHER|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
48497148|NCT00003708|DRUG|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
48497149|NCT04186923|OTHER|F-SPOKE|This project includes communicative, emotional, and also organizational support with outreach across different sectors and phases (F-SPOKE - family-centered, cross-sector and cross-phase organizational, communicative, and emotional support).
48131732|NCT06575725|BIOLOGICAL|Balstilimab|Given IV
48131733|NCT06575725|PROCEDURE|Biopsy|Undergo biopsy
48131734|NCT06575725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48131735|NCT06575725|BIOLOGICAL|Botensilimab|Given IV
48131736|NCT06575725|PROCEDURE|Computed Tomography|Undergo CT
48131737|NCT06575725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48131738|NCT06575725|DRUG|Regorafenib|Given PO
48131739|NCT04852783|DEVICE|Contour Neurovascular System|Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
48497150|NCT03545035|DRUG|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
48497151|NCT04964518|DRUG|APG 2575 ramp up arm|APG2575 ramp up + Azacitidine
48497152|NCT02926820|BEHAVIORAL|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
48497153|NCT06217861|BIOLOGICAL|VGM-R02b|Administered as specified in the treatment arm.
48131744|NCT06445959|DRUG|Olutasidenib|Given by PO
48131745|NCT06445959|DRUG|Venetoclax|Given by PO
48131746|NCT06445959|DRUG|Decitabine|Given by IV
48497154|NCT04635293|PROCEDURE|preoperative infusion of levosimendan|the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
48497155|NCT04635293|PROCEDURE|no preoperative infusion of levosimendan|the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
48497156|NCT01725321|OTHER|Narrow band imaging|Colonoscopy with new narrow band imaging
48131750|NCT02704416|PROCEDURE|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
48339144|NCT03121807|OTHER|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
48339145|NCT03121807|DRUG|Oxaliplatin|
48339146|NCT03121807|DRUG|5Fluorouracil|
48339147|NCT03121807|DRUG|Leucovorin|
48497157|NCT02068664|BEHAVIORAL|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
48497158|NCT00254228|DEVICE|Electrotactile sensory substitution|
48497159|NCT01782235|DRUG|Tocilizumab|
48497160|NCT01782235|DRUG|Placebo|
48497161|NCT03867461|PROCEDURE|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
48497162|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
48497163|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
48497164|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
48497165|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
48497166|NCT00231218|DRUG|dietary supplement--echinacea, propolis, and vitamin c|
48655471|NCT04557124|BEHAVIORAL|MovingForward|problem solving training
48655472|NCT03797937|OTHER|Magnetic resonance imaging (MRI)|MRI scanner
48655473|NCT05878067|DRUG|ABBV-444|Lubricant Eye drops
48655474|NCT05167708|PROCEDURE|Micro-osteoperforation|flapless small punctures in the bone at direction of tooth movement to accelerate the movement.
48497167|NCT00276822|OTHER|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
48655475|NCT04816721|DRUG|EDP-938|Oral suspension
48655476|NCT04816721|DRUG|Placebo|Placebo oral suspension to match EDP-938
48339148|NCT06114030|PROCEDURE|Deep margin elevation with composite resin and Lithium disilicate glass-ceramic crowns|Restoration of the deep margin by composite restorations such as: Filtek Supreme XTE, Tetric EvoCeram, Estelite Sigma Qquick followed by Lithium disilicate glass-ceramic CAD/CAM crowns (IPS e.max CAD).
48339149|NCT00318370|DRUG|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
48339150|NCT00318370|DRUG|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
48339151|NCT00762268|DRUG|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
48339152|NCT00762268|DRUG|Placebo|
48497168|NCT04809935|DRUG|98% dehydrated alcohol|"* coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
48497169|NCT04809935|DEVICE|19G EUSRA needle, Taewoong Medical, Korea|"* 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
48497170|NCT02248038|PROCEDURE|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
48131751|NCT05609929|DRUG|Multiple administration of omeprazole Single administration of AB-106|Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
48131752|NCT04503681|OTHER|Enhanced compassion video|"Added five additional sentences to the standard introduction video. Those five sentences were compassion-focused statements. The compassionate statements added to the enhanced compassion video were based on the results of a recent systematic review of clinician compassionate behaviors, which found incorporating statements of support, acknowledgement, patient's perspective, emotion naming, and validation increased patient perception of compassion."
48131753|NCT04503681|OTHER|Standard introduction video|Standard introduction video sent to a new patient via email introducing the new patient to the cancer center prior to the initial consultation.
48497171|NCT02248038|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
48497172|NCT04031638|OTHER|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
48131756|NCT05173987|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
48131757|NCT05173987|DRUG|carboplatin|IV infusion
48131758|NCT05173987|DRUG|paclitaxel|IV infusion
48497173|NCT02808949|DRUG|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
48131759|NCT05173987|DRUG|docetaxel|IV infusion
48131760|NCT05173987|DRUG|cisplatin|IV infusion
48131761|NCT01970553|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
48131762|NCT01970553|DRUG|Gemcitabine|1000 mg vial, powder for injectable solution
48131763|NCT03766191|BEHAVIORAL|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
48131764|NCT03766191|OTHER|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
48339153|NCT00541736|DRUG|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
48339154|NCT03068936|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
48339155|NCT03068936|DRUG|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
48339156|NCT00436267|DRUG|fluorouracil|
48339157|NCT00436267|RADIATION|selective external radiation therapy|
48339158|NCT00436267|RADIATION|tomotherapy|
48339159|NCT00436267|RADIATION|yttrium Y 90 glass microspheres|
48339160|NCT00436267|RADIATION|yttrium Y 90 resin microspheres|
48339161|NCT01283867|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
48497174|NCT02536326|DEVICE|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
48497175|NCT03530176|RADIATION|18Fluoride-Sodium Fluoride radio-isotope|The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
48497176|NCT04099173|BEHAVIORAL|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
48497177|NCT03792724|DRUG|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
48655477|NCT06464640|DEVICE|"Online Interactive Podcast Program Living with Type 1 Diabetes to Grown-Up"|The podcast content was designed based on the results of previous research.Subjects will be randomly assigned to either the experimental group (N=44) or the comparison group (N=44). Comparative analyses will focus on variations in disease control, emotional disturbance,confidence in self-management, self-care behaviors, diabetes knowledge,interpersonal disturbance, and family conflict at baseline, and post-interventions of immediate, 3-month, and 6-month periods.
48497178|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48655478|NCT06464640|DEVICE|E-book|Participants in the active control group will use Ebook.According to the research results from the project leader\&#39;s app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled \&#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&#34;
48655479|NCT04981912|DRUG|HDMP + rituximab as a means of debulking prior to initiating venetoclax.|"* Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up."
48655480|NCT05151731|DRUG|Vamikibart|Vamikibart will be administered by IVT injection as specified in each treatment arm.
48497179|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48497180|NCT06138236|DRUG|Collagen hydrolyzed peptides|infiltration near the heal spur of 2ml of Arthrys
48497181|NCT00003093|BIOLOGICAL|filgrastim|
48497182|NCT00003093|BIOLOGICAL|sargramostim|
48497183|NCT00003093|DRUG|carboplatin|
48497184|NCT00003093|DRUG|cyclophosphamide|
48497185|NCT00003093|DRUG|doxorubicin hydrochloride|
48497186|NCT00003093|DRUG|etoposide|
47979863|NCT01920789|RADIATION|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (\<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
48339162|NCT04285710|DEVICE|Phototherapy|The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
48497187|NCT00003093|PROCEDURE|conventional surgery|
48655481|NCT05151731|DRUG|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
48339163|NCT04285710|PROCEDURE|Debridement Surgery and Wound Dressing|All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
48497188|NCT00003093|PROCEDURE|neoadjuvant therapy|
48497189|NCT01324674|OTHER|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
48655482|NCT05151731|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
48655483|NCT06267911|OTHER|Cognitive stimulation and psychological support (RGS-ICU)|The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
48655484|NCT06002477|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
48655485|NCT06002477|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
48655486|NCT04118920|DRUG|Topical insulin (4 units)|N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
47979864|NCT01920789|RADIATION|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
48497190|NCT01324674|OTHER|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
48655487|NCT04118920|DRUG|Topical insulin (20 units)|N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
48655488|NCT04118920|DRUG|Artificial tears|N=3, 40 microliters per drop
48655489|NCT05398848|BIOLOGICAL|Recombinant two-component COVID-19 vaccine (CHO cell)|Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
47979865|NCT02801292|DRUG|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
47979866|NCT03912766|DIAGNOSTIC_TEST|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
48339164|NCT05400538|OTHER|Biorepair Toothpaste + Mousse|Domiciliary application of the products twice a day.
48339165|NCT05400538|OTHER|Biorepair Toothpaste|Domiciliary application of the product twice a day.
48497191|NCT02328222|DRUG|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
48497192|NCT05484037|OTHER|CANATEXTS|Canadian Asthma Text Messaging (CANATEXTS) is a TH intervention facilitating access to an electronic AAP (eAAP) via a mobile device.
48497193|NCT04136691|OTHER|simulation training|Burn patient scenario was performed with the intervention group.
48497194|NCT02264470|OTHER|Not relevant|Not relevant
47979867|NCT01503151|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
47979868|NCT01503151|BEHAVIORAL|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
47979869|NCT01503151|BEHAVIORAL|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
47979870|NCT01503151|BEHAVIORAL|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
47979871|NCT02496533|PROCEDURE|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
47979872|NCT01464489|DRUG|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
48655490|NCT05398848|BIOLOGICAL|Placebo|"Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter"
47979873|NCT01464489|DRUG|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
47979874|NCT02309879|DRUG|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
48339166|NCT01967472|DRUG|amodiaquine-artesunate (AQAS) fixed-dose|
48497195|NCT04081766|BEHAVIORAL|SUGAR Handshake|"An interactive patient counselling session delivered by a pharmacist which mainly focuses on medication-related instructions towards preventing hypoglycaemia in addition to recommendations about hypoglycemia early recognition, causes, and treatment. The SUGAR Handshake is individualised according to shared decision making and each participant's characteristics.~Components of the SUGAR Handshake intervention will be covered under five main domains:~1. Signs and symptoms of hypoglycemia.~2. Understanding the underlying causes of hypoglycaemia such as misuse of anti-diabetic medications.~3. Good glycaemic control and self-monitoring, which mainly includes instructions on handling the anti-diabetic medications.~4. Acknowledgement by the patient~5. Recap and summary~The pictogram contains the main recommendations for easy recall by the participant. Moreover, the intervention will be reinforced by a phone call at week 6 of the inclusion visit."
48655491|NCT06640556|BEHAVIORAL|watching animation show|The intervention group will watch the animation titled 'A Green Future with the Hand of a Midwife' on days 7, 21, and 30 to mothers who have just given birth, and the scale will be evaluated on three separate days in total.
48339167|NCT01967472|DRUG|Artemether-lumefantrine combination (AL) dispersable|
48339168|NCT05263349|OTHER|Typical Dreams Questionnaire|"Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003)."
48655492|NCT06640647|DRUG|HDM1005 injection or placebo|HDM1005 injection or placebo isubcutaneous injection once
48655493|NCT06643117|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
48655494|NCT06643117|BIOLOGICAL|FYB206|Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)
48655495|NCT06643117|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
48655496|NCT04950439|OTHER|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
48655497|NCT02614248|OTHER|Organic, Unrefined Coconut Oil|
48655498|NCT02614248|OTHER|Medline Remedy Phytoplex Z-Guard Skin Protectant|
48655499|NCT04845347|DEVICE|Bright Light Therapy|Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.
48655500|NCT04845347|DEVICE|Dim Light Therapy|Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
48655501|NCT03123679|RADIATION|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"1. Patient referred to radiotherapy treatment are evaluated with a baseline PFT \[Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)\].~2. RT simulation at the radiotherapy department and treatment planning.~3. Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.~4. Radiotherapy."
47979875|NCT02309879|DRUG|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
47979876|NCT02309879|DRUG|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
48339169|NCT05263349|OTHER|HAD Questionnaire|"The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21)."
48339170|NCT05263349|OTHER|Dream Booklet|The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary
47979877|NCT02309879|DRUG|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
48339171|NCT01349296|DRUG|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
48339172|NCT00161811|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
48339173|NCT00161811|BIOLOGICAL|Egg cell-derived Influenza Vaccine|
48339174|NCT04853199|DRUG|Quercetin|Each patient should receive one tablet twice a day 30 minutes before the meal
48497196|NCT01169428|BEHAVIORAL|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
48655502|NCT02760342|DRUG|peficitinib|Oral
48339175|NCT04853199|DRUG|Placebo|Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
48339176|NCT05194111|DRUG|Sacubitril-valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
48339177|NCT05194111|DRUG|Valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
48339178|NCT06171815|BEHAVIORAL|Scenario-based simulation|Scenario-based simulation prepared for Respiratory Activity and Diabetes Management topics in the course curriculum
48339179|NCT01320969|BEHAVIORAL|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
48339180|NCT02608125|DRUG|PRN1371|
48339181|NCT06120959|OTHER|Stabilization exercise|The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
48655503|NCT02760342|DRUG|Metformin|Oral
48655504|NCT03231735|DEVICE|Mid frequency ventilation|Mechanical ventilator used at rates \> 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
48497197|NCT01169428|BEHAVIORAL|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors \[e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information \& education\]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
48497198|NCT02674906|DRUG|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
48131766|NCT05882877|DRUG|Rocatinlimab|Subcutaneous (SC) injection
48131767|NCT05882877|OTHER|Placebo|SC injection
47979878|NCT05576714|OTHER|delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis|We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
48497199|NCT02674906|DRUG|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
47979879|NCT02727023|OTHER|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
48131768|NCT04069416|PROCEDURE|living donor liver transplantation|liver graft from a living donor
48131769|NCT04446481|DEVICE|Neurofeedback|Neurofeedback will be tested in both groups of Vets
48497200|NCT02212002|DRUG|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
48497201|NCT00150943|DEVICE|Renal artery stent|
48497202|NCT05029401|DRUG|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
48497203|NCT05029401|DRUG|Placebo|Matching placebo to the IMP (DMX-1002)
48497204|NCT01930318|DRUG|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
47979880|NCT00492661|DRUG|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
48497205|NCT01325727|OTHER|Brief computerized feedback|Brief computerized feedback
48497206|NCT01325727|OTHER|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
48497207|NCT05583838|DRUG|rhTPO|initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
48497208|NCT05583838|DRUG|Eltrombopag|initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
47979881|NCT02018328|DIETARY_SUPPLEMENT|Curcumin|
47979882|NCT01160250|DRUG|vismodegib (GDC-0449)|Oral repeating dose
47979883|NCT03562481|DRUG|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
47979884|NCT03562481|DRUG|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
48497209|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 .|
48497210|NCT01632761|DRUG|omega-3 fatty acids (fish oil)|
48497211|NCT01632761|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
48497212|NCT01632761|DIETARY_SUPPLEMENT|Fish oil placebo|
48497213|NCT01201941|OTHER|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
48497214|NCT01558180|BEHAVIORAL|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
48131780|NCT04029090|DRUG|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
48131781|NCT04029090|DRUG|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
48131782|NCT04029090|DRUG|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
48131783|NCT02540824|DRUG|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
48131786|NCT04876846|DEVICE|GEN 3 Monitoring of Fetus|"Measurement of tissue light scatter in the body in body during late term pregnancy and evaluation of signal integrity"
48655505|NCT03231735|DEVICE|Standard frequency ventilation|Mechanical ventilator used at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
48655506|NCT04584008|DRUG|FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.|According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
47979885|NCT02373202|DRUG|Sarilumab|Pharmaceutical form:solution
47979886|NCT02373202|DRUG|Sulfasalazine|Pharmaceutical form: Tablet Route of administration: Oral
47979887|NCT02373202|DRUG|Leflunomide|Pharmaceutical form: Tablet Route of administration: Oral
48497215|NCT01558180|BEHAVIORAL|Usual Care|educational handouts on pediatric insomnia
48655507|NCT04584008|DRUG|Other Therapy|Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
48655508|NCT03421353|DRUG|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
48655509|NCT03421353|DRUG|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
48655510|NCT03421353|DRUG|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
47979888|NCT02373202|DRUG|Bucillamine|Pharmaceutical form: Tablet Route of administration: Oral
47979889|NCT02373202|DRUG|Tacrolimus|Pharmaceutical form: Capsule Route of administration: Oral
47979890|NCT02373202|DRUG|Mizoribine|Pharmaceutical form: Tablet Route of administration: Oral
47979891|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
47979892|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
47979893|NCT01616524|BIOLOGICAL|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
48655511|NCT03421353|DRUG|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
48655512|NCT03421353|DRUG|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
47979894|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
47979895|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
47979896|NCT01616524|DRUG|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
47979897|NCT01616524|DRUG|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
47979898|NCT03481036|DRUG|Direct Acting Antivirals|Sofosbuvir and Daclatasvir
48655513|NCT03421353|DRUG|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
48655514|NCT03421353|DRUG|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
48655515|NCT04148209|DRUG|PF-07081532|Participants will receive single ascending doses PF-07081532
48655516|NCT04148209|DRUG|Placebo|Participants will receive placebo
48655517|NCT03274466|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
47979899|NCT03481036|DRUG|DAAs in Cirrhotics Genotype 2/3|Sofosbuvir and Daclatasvir with weight based ribavirin
47979900|NCT03481036|DRUG|DAAs in Cirrhotics Genotye 1,4,5,6|Sofosbuvir and Ledipasvir with weight based ribavirin
47979901|NCT03489720|BEHAVIORAL|Prescribed Exercise Program|"Brief cardiovascular exercise training (\>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing"
48655518|NCT03274466|DEVICE|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
48497216|NCT03294486|DRUG|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~* Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~* Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~  5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
48497217|NCT00742924|DRUG|cisplatin|Given IV
48655519|NCT01889446|DIETARY_SUPPLEMENT|Calcium propionate|
48655520|NCT02615613|OTHER|Low Acceptability Meal|
48655521|NCT02615613|OTHER|High acceptability meal|
48655522|NCT06317909|OTHER|allergen challenge|Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.
48655523|NCT05644132|DEVICE|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
47979902|NCT03489720|BEHAVIORAL|Usual Exercise Program|Usual exercise activity for 8 weeks
47979903|NCT02733588|DRUG|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
47979904|NCT03408756|DRUG|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
47979905|NCT00038857|PROCEDURE|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
48497218|NCT00742924|DRUG|dexrazoxane hydrochloride|Given IV
48497219|NCT00742924|DRUG|doxorubicin hydrochloride|Given IV
48497220|NCT00742924|DRUG|etoposide|Given IV
48497221|NCT00742924|DRUG|ifosfamide|Given IV
48497222|NCT00742924|DRUG|leucovorin calcium|Given IV or orally
48655524|NCT06638359|BEHAVIORAL|moderate exercise|moderate exercise for 47 minutes
48655525|NCT06638359|BEHAVIORAL|interval exercise|interval exercise for 28 minutes
48655526|NCT06638359|BEHAVIORAL|Control (placebo) group|without exercise
48655527|NCT06596525|OTHER|Conventional physical therapy|"Conventional physical therapy program will include:~1. Stretching exercises (forearm pronators, ulnar deviators, shoulder internal rotators, hip flexors and adductors, and hamstring muscle groups)~2. Strengthening exercises (ankle dorsiflexors, knee extensors, and hip flexor muscle groups)~3. Posture exercises~4. Balance and proprioception exercises~5. Walking training, obstacle crossing training, stair climbing and descending exercises"
48655528|NCT06596525|OTHER|Barefoot Whole Body Vibration Training (WBVTb)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will be barefoot. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
47979906|NCT00038857|DRUG|Melphalan|140 mg/m\^2 on day -8
47979907|NCT00038857|DRUG|Thiotepa|10 mg/kg on day -7
48497223|NCT00742924|DRUG|methotrexate|Given IV
48497224|NCT00742924|DRUG|zoledronic acid|Given IV
48497225|NCT00742924|PROCEDURE|adjuvant therapy|
48497226|NCT00742924|PROCEDURE|neoadjuvant therapy|
48497227|NCT00742924|PROCEDURE|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
48497228|NCT00742924|BIOLOGICAL|filgrastim|Given SC
48497229|NCT00742924|DRUG|Mesna|Given IV
48497230|NCT00259168|DRUG|Nateglinide|
47979908|NCT00038857|DRUG|Fludarabine|160 mg/m\^2 over 4 days on days -6, -5, -4, -3
47979909|NCT00038857|DRUG|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
48497231|NCT03939325|RADIATION|ESWL|The impact of different frequencies on pattern of disintegration of renal stones
48497232|NCT02287207|DEVICE|transcranial direct current stimulation (tDCS)|
48497233|NCT01025544|BIOLOGICAL|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
48497234|NCT01025544|BIOLOGICAL|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
48497235|NCT05117983|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
48497236|NCT04995692|BEHAVIORAL|Telehealth Education for Asthma Connecting Hospital and Home|TEACHH aims to provide educational support to families managing childhood asthma throughout the transition from hospital to home, and includes several core components: 1) Health literacy-informed inpatient teaching for child and caregiver including pictorial materials, hands-on demonstration, and use of teach-back/show-back techniques; 2) Facilitated identification of rescue and controller medications using color- and shape-coded medication labels and a pictorial asthma action plan; and 3) A pair of virtual follow-up visits after discharge to reinforce inpatient teaching and support families during the shift from acute exacerbation to preventive care management. Virtual visits will be completed using the Zoom platform on smartphones or other compatible devices, 2-4 days after discharge (first visit) and 3 weeks after discharge (second visit). All intervention activities will be completed within 1 month of discharge.
48655529|NCT06596525|OTHER|Shod Whole Body Vibration Training (WBVTs)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will wear everyday sports shoes. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
48339182|NCT06120959|OTHER|Pelvic floor exercise|The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
48339183|NCT02104141|DEVICE|ROIA Interbody Cage with VerteBRIDGE plating|
47979910|NCT05752279|DRUG|Plasma-Lyte 148|Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis
48339184|NCT04827615|BEHAVIORAL|Ambuja Cement Foundation's Non Communicable Disease Program|"Government level: Strengthening linkages with Govt; Ensuring availability \& affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care \& medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community \& service provider~Community level: Screening of hypertension \& diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization \& active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices"
48339185|NCT01917552|DRUG|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
48339186|NCT04090580|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
48339187|NCT06142968|DIAGNOSTIC_TEST|laboratory tests|Laboratory tests inform of Complete blood count , liver function tests , kidney function tests abdominal ultrasound
48339188|NCT03364491|DRUG|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
48497237|NCT04995692|BEHAVIORAL|Standard Care (SC) Comparison Group|Patients in the SC group will receive standard impatient management, including pre-recorded asthma education videos shown prior to discharge and the hospital action plan. PCP follow-up with be scheduled within a week of discharge. All SC measures will also be provided to subjects randomized to TEACHH.
48497238|NCT02935205|DRUG|Enzalutamide|Given PO
48497239|NCT02935205|DRUG|Indomethacin|Given PO
48497240|NCT04241991|RADIATION|Active laser|Participants will receive laser irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the irradiation on eight points distributed over the muscle belly, using a gallium arsenide aluminum (Ga-As-Al) laser (λ: 808 nm) equipment. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
47979911|NCT05752279|DRUG|0.9% sodium chloride|0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis
47979912|NCT03763591|BEHAVIORAL|Trauma Systems Therapy for Refugees Group Intervention|Psychological skills group for youth of refugee and immigrant backgrounds.
47979913|NCT00398060|BEHAVIORAL|Cognitive-behavioral life-style counseling|
47979914|NCT00381095|DRUG|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
47979915|NCT00381095|DRUG|Placebo|Placebo
47979916|NCT00874965|DEVICE|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
48339189|NCT03364491|DRUG|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
48339190|NCT01517906|BEHAVIORAL|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
48339191|NCT01517906|BEHAVIORAL|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
48655530|NCT06596525|OTHER|Sham Whole Body Vibration Training (WBVTsh)|"During Sham WBVT; the same exercises that the intervention groups will receive on the vibration platform will be performed on the platform for the same duration (3 days per week for 15 minutes each session, over a period of 4 weeks) without the platform being activated."
48655531|NCT04215458|OTHER|sample collection (swap or tape strip)|collection of swap or tape strip to determine yeast colonization in skin
47979917|NCT00874965|DEVICE|Sham stimulation|30 min; 5 times / week
47979918|NCT05953246|BEHAVIORAL|Neutral labels|Participants view neutral labels (QR codes with and without neutral text) for menu items
47979919|NCT05953246|BEHAVIORAL|Numeric text-only sustainability labels|Participants view labels with numeric text depicting the greenhouse gas emissions associated with production of the menu item
47979920|NCT05953246|BEHAVIORAL|Endorsement text-only sustainability labels|Participants view labels using text to endorse menu items as having low environmental impact
48339192|NCT01461824|DRUG|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
48339193|NCT01989572|OTHER|Laboratory Biomarker Analysis|Correlative studies
48339194|NCT01989572|OTHER|Placebo|Given GM-CSF placebo SC
48339195|NCT01989572|OTHER|Placebo|Given peptide placebo SC
48339196|NCT01989572|BIOLOGICAL|Sargramostim|Given SC
48655532|NCT04139304|DRUG|Cyclophosphamide|Given IV
48655533|NCT04139304|BIOLOGICAL|Daratumumab|Given IV
48655534|NCT04139304|DRUG|Doxorubicin|Given IV
48655535|NCT04139304|DRUG|Doxorubicin Hydrochloride|Given IV
48655536|NCT04139304|DRUG|Etoposide|Given IV
48655537|NCT04139304|DRUG|Prednisone|Given PO
48655538|NCT04139304|DRUG|Vincristine|Given IV
48655539|NCT04139304|DRUG|Vincristine Sulfate|Given IV
48655540|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMRT
47979921|NCT05953246|BEHAVIORAL|Endorsement icon-only sustainability labels|Participants view labels using icons to endorse menu items as having low environmental impact
47979922|NCT05953246|BEHAVIORAL|Endorsement text-plus-icon sustainability labels|Participants view labels using text and icons to endorse menu items as having low environmental impact
48497241|NCT04241991|RADIATION|Placebo laser|Participants will receive placebo irradiation on the rectus femoris muscle of both legs immediately before the test (trial 1) and training (trial 2) sessions. A researcher blinded to the treatment conditions will apply the placebo irradiation on eight points distributed over the muscle belly. The points will placed at 25, 35, 50 and 75% of the total distance between the anterior superior iliac spine and superior border of the patella, bilaterally, with 2 cm of distance between each point.
48497242|NCT04856124|DRUG|Intranasal esketamine|Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
48655541|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMPT
48655542|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
48655543|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
48655544|NCT01629498|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48655545|NCT01629498|RADIATION|Photon Beam Radiation Therapy|Undergo image-guided IMRT
48655546|NCT01629498|RADIATION|Proton Beam Radiation Therapy|Undergo image-guided IMPT
48655547|NCT01629498|OTHER|Questionnaire Administration|Ancillary studies
47914276|NCT04506099|DEVICE|Sham protocol|Electrical stimulation will be applied to the T6-T11 levels of intercostal nerves, as close to the level directly below the level of injury as possible until contraction is seen in the rectus abdominis. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. Electrodes 2 inch by 4 inch will be placed according to anatomic landmarks with the negative electrode applied to the lateral ribcage and the positive electrode applied to the ventral aspect. The intensity level will be set to 1mA . If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable.
47979923|NCT02036463|DRUG|Prednisone|
47979924|NCT02036463|DRUG|Placebo|
47979925|NCT01782144|OTHER|NutriSystem portion-controlled pre-packaged meals|
48497243|NCT01536158|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
48339197|NCT01989572|BIOLOGICAL|Tyrosinase Peptide|Given SC
48339198|NCT03432767|DEVICE|Non-invasive hemoglobin monitor|
48497244|NCT01536158|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
48497245|NCT00256984|PROCEDURE|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
48497246|NCT01989962|OTHER|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
48497247|NCT05925075|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
48655548|NCT06554821|DRUG|Rosuvastatin|Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
48655549|NCT06554821|DRUG|Ticagrelor|Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.
48655550|NCT00088946|DIETARY_SUPPLEMENT|Polyphenon E|4-200mg capsules PO daily for 12 months
48655551|NCT00088946|DRUG|erlotinib hydrochloride|100 mg PO daily for 12 months
48655552|NCT00088946|OTHER|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
48655553|NCT00088946|OTHER|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
48655554|NCT06583720|PROCEDURE|Oral hygiene at home|Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.
48339199|NCT01804257|OTHER|Digital Health Feedback System|The digital health offering passively collects and records medication-taking behavior and other habits of daily living
48497248|NCT00714493|BIOLOGICAL|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
47979926|NCT04608526|DIAGNOSTIC_TEST|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
48497249|NCT01659866|DRUG|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
47979927|NCT00345345|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
48497250|NCT01659866|DRUG|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
47979928|NCT04464512|DRUG|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
47979929|NCT05050604|DRUG|Choline Alfoscerate 400mg|Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
48497251|NCT01659866|DRUG|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
48497252|NCT01659866|DRUG|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
48339200|NCT01158638|BEHAVIORAL|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
48339201|NCT04798846|PROCEDURE|dorsal plating|Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
48497253|NCT01659866|DRUG|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
48497254|NCT01659866|DRUG|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
48339202|NCT05165706|BEHAVIORAL|Dietary Intervention Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
48339203|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
48497255|NCT01659866|DRUG|aztreonam|500 mg intramuscularly 2 hours before the procedure
48497256|NCT01659866|DRUG|imipenem|500 mg intramuscularly 2 hours before the procedure
48497257|NCT01659866|DRUG|ceftriaxone|2000 mg intravenously 1 hour before the procedure
48497258|NCT01659866|DRUG|gentamicin|2 mg/kg intravenously 1 hour before the procedure
48497259|NCT01659866|DRUG|amikacin|5 mg/kg intravenously 1 hour before the procedure
48497260|NCT01659866|DRUG|aztreonam|2000 mg intravenously 1 hour before the procedure
48497261|NCT01659866|DRUG|imipenem|1000 mg intravenously 1 hour before the procedure
48497262|NCT03476863|PROCEDURE|Alveolar Recruitment Maneuver|Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.
48497263|NCT03476863|PROCEDURE|Conventional mechanical ventilation|Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
48131797|NCT04291027|OTHER|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
48497264|NCT01108211|DEVICE|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
48497265|NCT02567318|DEVICE|MRI-scan|Magnetic resonance imaging scan of the brain
48655555|NCT06583720|PROCEDURE|aPDT|A weekly aPDT session will be performed for a period of 30 days, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®). 2 ml (quantity measured with a pipette) will be applied to the middle third and dorsum of the tongue for 2 minutes for incubation (pre-irradiation time). The excess will be removed with a suction device in order to keep the surface moist with the PS itself. Six points will be irradiated with a distance of 1 cm between them, considering the light scattering halo; the LED will be positioned at a distance from the tongue so as to form a 2 cm halo at each point. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J.
48655556|NCT06583720|DIETARY_SUPPLEMENT|Probiotics|Probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®) (OralBiotic; Master Products, Fort Lauderdale, Florida, United States) will be used. Each patient will receive 60 lozenges, which should be allowed to dissolve slowly and completely in the mouth. Patients are instructed to use the lozenges twice a day for a period of 30 days.
48339204|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Fat Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
48655557|NCT05526157|DRUG|Finerenone (Kerendia, BAY 948862)|Retrospective analysis using secondary data collection from various sources
48339205|NCT02791360|OTHER|Brain MRI|
48655558|NCT05526157|DRUG|Sodium-glucose cotransporter 2 inhibitors (SGLT2i)|Retrospective analysis using secondary data collection from various sources
48655559|NCT05526157|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Retrospective analysis using secondary data collection from various sources
47979930|NCT05050604|DRUG|Placebo of Choline Alfoscerate 400mg|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
48339206|NCT04503512|PROCEDURE|removal of fat pad|Removal removal of fat pad
47979931|NCT05486104|DRUG|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
47979932|NCT05486104|DRUG|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
47979933|NCT02707510|OTHER|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
48339207|NCT04503512|PROCEDURE|non removal of fat pad|non removal of fat pad
48655560|NCT05526157|DRUG|Steroidal mineral corticoid receptor antagonists (sMRA)|Retrospective analysis using secondary data collection from various sources
48655561|NCT05526157|DRUG|Non-steroidal mineral corticoid receptor antagonists (nsMRA)|Retrospective analysis using secondary data collection from various sources
47914277|NCT03669783|DRUG|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
47914278|NCT03669783|DRUG|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
47914279|NCT03669783|DRUG|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
48131798|NCT04291027|OTHER|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
48131799|NCT04111471|DIETARY_SUPPLEMENT|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
48131800|NCT04111471|DIETARY_SUPPLEMENT|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
48131801|NCT05697705|OTHER|ChAdOx1 nCOV-19 vaccine (Vaxzeria)|Used as 2nd booster, 1st booster, or primary series
48131802|NCT05697705|OTHER|BNT162b2 (Pfizer)|Used as 2nd booster, 1st booster, or primary series.
48131803|NCT05697705|OTHER|Ad26.COV2.S (Janssen)|Used as 2nd booster, 1st booster, or primary series.
48131804|NCT05697705|OTHER|CoronaVac (Sinovac)|Used as 2nd booster, 1st booster, or primary series.
48339208|NCT02448017|DEVICE|The Herbst appliance|Orthodontic functional appliance
48339209|NCT02448017|DEVICE|Twin block appliance|Orthodontic functional appliance
48339210|NCT00081328|DRUG|Metformin|capsule, 1000 mg bid
48339211|NCT00081328|DRUG|Rosiglitazone|capsule, 4 mg bid
48497266|NCT03984123|DEVICE|Brachial cuff, in order to achieve ischemic stimuli|Standard treatment with no brachial cuff inflation
48497267|NCT03583632|OTHER|visual acuity testing|testing of visual ycuity by ETDRS charts
48497268|NCT03583632|DEVICE|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
48655562|NCT06554587|DIAGNOSTIC_TEST|Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)|Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
48655563|NCT05002309|BEHAVIORAL|Cognitive-Behavioural Therapy|"20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials."
48497269|NCT04607330|OTHER|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
48497270|NCT02373033|OTHER|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
48131807|NCT02844439|DRUG|Tesevatinib|
48131808|NCT01693822|DRUG|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
48131809|NCT03948438|PROCEDURE|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
48131810|NCT01611493|DEVICE|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
48131811|NCT01611493|DEVICE|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
48497271|NCT02373033|OTHER|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
48497272|NCT02373033|OTHER|Apple juice|Received apple juice containing no folate or folic acid.
48497273|NCT03758404|BIOLOGICAL|adeno-associated virus vector AAV- CNGA3|Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene
48497274|NCT00574912|DRUG|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
48497275|NCT00574912|DRUG|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
48497276|NCT00574912|DRUG|Insulin Glargine 1.0 u/kg body wt SC|
47979934|NCT01602874|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
47979935|NCT01602874|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
47979936|NCT01602874|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
47979937|NCT01602874|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
47979938|NCT04256070|BEHAVIORAL|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
47979939|NCT05922150|RADIATION|low level laser therapy|LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
48339212|NCT00081328|BEHAVIORAL|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
48339213|NCT02452749|DIETARY_SUPPLEMENT|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
48339214|NCT01646853|RADIATION|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
48339215|NCT01646853|DRUG|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
48339216|NCT04836546|DEVICE|Blood glucose meter|First phase: SMBG for 6 months
48339217|NCT04836546|DEVICE|Eversense CGM System|Second phase: CGM for 6 months
48339218|NCT05857007|DEVICE|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
48339219|NCT05754801|DRUG|Yunzhi Essence|Yunzhi Essence capsule
48339220|NCT05754801|OTHER|Placebo|Placebo capsules
48339221|NCT03024385|BEHAVIORAL|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
48339222|NCT00014001|DRUG|perphenazine|
48339223|NCT00014001|DRUG|olanzapine|
48339224|NCT00014001|DRUG|quetiapine|
48339225|NCT00014001|DRUG|risperidone|
48339226|NCT00014001|DRUG|ziprasidone|
48655564|NCT05002309|DRUG|Antidepressant medication|The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
47979940|NCT05922150|DRUG|ozone gel|ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
47979941|NCT05557461|DEVICE|End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility|"(0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test."
48339227|NCT00014001|DRUG|clozapine|
48339228|NCT00014001|DRUG|fluphenazine decanoate|
48339229|NCT00178061|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
48339230|NCT03515213|DRUG|Fenofibrate|145mg of fenofibrate
48339231|NCT03515213|DRUG|Placebo|Placebo
48339232|NCT04737980|DRUG|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
48339233|NCT04737980|DRUG|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
48339234|NCT04737980|DRUG|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
48339235|NCT04737980|DRUG|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
48339236|NCT02280486|DRUG|Saxagliptin|5 mg/d
48339237|NCT02280486|DRUG|Glimepiride|1mg/d, up titrated 1mg if FPG \>6.1 mmol/L (110mg/dL) till 6 mg
48339238|NCT00723671|PROCEDURE|MRI|
48339239|NCT02746770|OTHER|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
48339240|NCT00217009|PROCEDURE|Narrowband Ultraviolet B (TL-01UVB) Therapy|
48339241|NCT00217009|PROCEDURE|Topical Psoralen plus ultraviolet A (PUVA)|
48339242|NCT02915640|OTHER|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
48339243|NCT04134299|DIETARY_SUPPLEMENT|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
48339244|NCT05952960|OTHER|Placebo|Open Label Placebo + Rationale
48339245|NCT00805922|OTHER|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
48339246|NCT02894489|DEVICE|corneal lenses|wear corneal lenses on daily basis
48339247|NCT02894489|DEVICE|large diameter lenses|
48339248|NCT01157546|PROCEDURE|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
48339249|NCT01157546|PROCEDURE|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
48339250|NCT00587834|DEVICE|Gintuit|Application of Gintuit at Day 0 to the gingival bed
48339251|NCT00587834|OTHER|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
48497277|NCT00574912|DRUG|Insulin Glargine 1.5 u/kg body wt SC|
48497278|NCT00574912|DRUG|Insulin Glargine 2.0 u/kg body wt SC|
48497279|NCT03816566|DEVICE|patch|A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
48497280|NCT03972267|PROCEDURE|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
48131812|NCT04839185|DRUG|Ferumoxytol infusion|"Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject."
48131813|NCT04839185|PROCEDURE|MRI scan|The MRI scanning procedure will last for approximately 60 minutes.
48131814|NCT05911243|PROCEDURE|Acupressure Therapy|Undergo auricular acupressure
48131815|NCT05911243|OTHER|Best Practice|Receive usual care
48131816|NCT05911243|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48339252|NCT06054438|OTHER|Chinese medicine nutritional supplement Cs4|Cs4 will be provided by Chinese Pharm, produced by GMP standard manufacturing. The intervention will be given according to the product instruction. Each capsule is 0.4g. According to the product sheet, adults should take 3-4 capsules daily as a way to nourish and strengthen the lungs and kidneys. In our study, the participants are people with long-COVID symptoms. Therefore, in order to achieve maximum efficacy, we will follow the directions and let participants take the maximum amount allowed by the product which is 4 capsules daily. Participants will take one capsule (each 400mg) 4 times a day, for a total of 1.6g. Treatment will last 12 weeks.
48339253|NCT00228410|DRUG|Tigecycline|
48339254|NCT00228410|DRUG|vancomycin with aztreonam|
48497281|NCT03972267|DEVICE|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
48497282|NCT01930955|DRUG|Amoxicillin|β-lactam antibiotics
48497283|NCT02483143|DRUG|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
48497284|NCT02483143|DRUG|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
48497285|NCT02483143|DRUG|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
48497286|NCT03106831|DRUG|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
48497287|NCT03106831|DRUG|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
48131817|NCT05911243|OTHER|Questionnaire Administration|Ancillary studies
48131818|NCT06406400|DRUG|AZD4041|"Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7."
48131819|NCT06406400|DRUG|Itraconazole|Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.
48131820|NCT06406400|DRUG|Buprenorphine|Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.
48131821|NCT06406400|DRUG|Buprenorphine / Naloxone|Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7
48339255|NCT02121314|DRUG|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
48339256|NCT05863702|BEHAVIORAL|Penny|The chatbot will assist patients who have not been see for cancer follow-up care, with scheduling follow-up appointments, labs, scans, specialty appointments, and monitor compliance with the appointments made.
48339257|NCT01586650|OTHER|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
48497288|NCT05109806|BEHAVIORAL|problem prevention therapy with CHD|The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
48497289|NCT02570516|PROCEDURE|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
48497290|NCT02494609|DRUG|sotagliflozin|400 mg sotagliflozin
48497291|NCT02494609|DRUG|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
48497292|NCT02494609|DRUG|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
48497293|NCT00485628|DRUG|Atomoxetine Hydrochloride|
48131822|NCT06406400|DRUG|Hydromorphone|Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.
48131823|NCT06406400|DRUG|Placebo|"Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7."
47979942|NCT04413409|PROCEDURE|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
47979943|NCT00995826|DRUG|CS-8958|Inhaled CS-8958
47979944|NCT00995826|OTHER|Placebo|Inhaled placebo
48497294|NCT06332287|DRUG|combination of Trilaciclib and Pemetrexed|This was a single-arm, exploratory study of the combination of Trilaciclib and Pemetrexed in patients with non-small cell lung cancer with leptomeningeal metastasis. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every six cycles to assess tumor response.
48497295|NCT06431165|DRUG|Lidocaine IV|After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.
48131828|NCT00674752|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
47979945|NCT05489055|DRUG|Iopamidol|A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
47979946|NCT04582708|DEVICE|NERv's Inline Device|NERv's Inline Device is comprised of multiple sensors. It attaches in line to existing catheters or peritoneal drains that are currently approved for medical use. This allows the device to measure the pH and electrical conductivity of effluent fluids that are drained through peritoneal drains.
47979947|NCT03012906|OTHER|the prevalence of ischemic events|
47979948|NCT03455920|OTHER|Clinical nurse (supernurse) evaluation|The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
47979949|NCT03455920|OTHER|Pulmonologist evaluation|The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
48131829|NCT00674752|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
48131830|NCT00674752|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
48131831|NCT06244771|DRUG|FMC-376|Oral Capsule
48131832|NCT05907603|DRUG|RD13-02 cell infusion|CAR-T cells
48497296|NCT04260438|DRUG|CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|single oral administration under fed condition
48497297|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|single oral administration under fed condition
48497298|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 2 Tab. 1T|single oral administration under fed condition
48497299|NCT00786994|DRUG|Oleogel-S10 100 mg/g|topical use once or twice daily
48497300|NCT00786994|DRUG|Placebo (petroleum jelly)|topical use once or twice daily
48497301|NCT05134246|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
48497302|NCT05134246|PROCEDURE|Carotid artery stenting (CAS)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
48339258|NCT01586650|OTHER|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
48339259|NCT03125993|BEHAVIORAL|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week brisk walking.
48339260|NCT04989881|DEVICE|da Vinci Simulator|Single training session
48339261|NCT04989881|DEVICE|Laparascopic training box|Single training session
48339262|NCT02988219|DRUG|Bupivacaine-fentanyl|Local anesthetic
47914280|NCT03669783|DRUG|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
47979950|NCT05035550|BEHAVIORAL|Non-Deceptive Placebo|"The placebos were ordered through Amazon from Zeebo® (Zeebo, Zeebo Effect, LLC, South Burlington, Vermont, USA). The placebos in this study were blue and white capsules containing Microcrystalline cellulose (an inert fiber). Ingredients include ones that are typically used to make pills including silica, gelatin, titanium dioxide, red #3 food coloring, and blue #1 food coloring. Placebo capsules were free of any active ingredients. These bottles were not branded specifically for the experiment, including the brand name (Zeebo Relief), description of the contents, directions, and a disclaimer. The investigators chose to not include a custom label for transparency and in order to increase non-deceptive placebo effects. Participants were instructed to take two pills a day, one in the morning and one in the evening."
47979951|NCT04208620|DRUG|Placebo|Placebo administered subcutaneously
47979952|NCT04208620|DRUG|Cotadutide|Cotadutide administered subcutaneously
47979953|NCT03601689|PROCEDURE|rectal resection|total mesorectal excision
47979954|NCT05375643|BEHAVIORAL|SURGE|Video with or without person to person guidance to support decision making around genetic testing
47979955|NCT04220684|DRUG|Cytarabine Hydrochloride|Given IV
48497303|NCT03201250|DRUG|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
48497304|NCT01776697|DRUG|pelubiprofen (30mg) tablet IR|
48497305|NCT01776697|DRUG|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
48497306|NCT00727766|DRUG|Clofarabine|
48497307|NCT00482651|RADIATION|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
48497308|NCT00482651|PROCEDURE|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
48497309|NCT00482651|PROCEDURE|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
48497310|NCT00482651|PROCEDURE|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
48497311|NCT04467268|BEHAVIORAL|Sleep extension|The sleep extension programme was designed around four alternative assumptions: 1) that among this group of habitual short sleepers, extending time in bed (TIB) would represent a significant behavioral change to established night-time and daytime routines; 2) that for practical purposes (accommodating personal, family and work schedules) extended time in bed is best anchored against typical rise-times; 3) that sleep onset may represent a particular challenge for those advancing habitual bed-times by over 1 hour each night; and 4) that in consenting to the trial, participants were motivated to make and sustain behavioral change.
47979956|NCT04220684|DRUG|Fludarabine|Given IV
48497312|NCT00423683|DRUG|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
48497313|NCT00423683|DEVICE|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
47979957|NCT04220684|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
47979958|NCT04803357|DEVICE|Continuous glucose monitor|We are offering you an opportunity to wear a medical device that monitors your blood sugars (glucose). This device is called a continuous glucose monitor (CGM). The CGM measures glucose levels through a tiny plastic filament that is inserted under the skin in your abdomen by a skin prick. Typically, you cannot feel this device once it is inserted.
47979959|NCT03247855|PROCEDURE|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
48339263|NCT02988219|DEVICE|Holter ECG monitor|3-chanel, CM5 leads
48339264|NCT02988219|PROCEDURE|Open kidney cancer surgery|Lateral position
48497314|NCT01429116|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
48497315|NCT04188301|DRUG|IVM w/ ALB|Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)
48655565|NCT06637566|OTHER|Brandt Daroff exercises along with Cawthorne Cooksey exercises|"Brandt Daroff exercises along with Cawthorne Cooksey exercises. The Cawthorne Cooksey exercises include eye and head movements, coordination of eye and head movements (visual-vestibular interaction), postural control exercises, and progressively more difficult balance tasks (eyes open, eyes closed, large base support, uneven base support, while walking, in high visual or noisy environments). Exercises should be done three times a day, with 5 repetitions of each. The exercises will be performed in three sessions per week with 60 minutes each session for eight weeks. The cawthorne Cooksey exercises includes the following:~A: Eye and head movement~B: Head and body movement, sitting down:~C: Standing up exercises:"
47979960|NCT01935271|DIETARY_SUPPLEMENT|Muscle Armor Supplement|
47979961|NCT01935271|DIETARY_SUPPLEMENT|Placebo|
47979962|NCT05699395|DIAGNOSTIC_TEST|Non interventional|No intervention
48497316|NCT04188301|DRUG|Single dose of IDA|Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
48339265|NCT02988219|PROCEDURE|General anesthesia|
48339266|NCT02988219|PROCEDURE|Epidural Anaesthesia|
48339267|NCT00649168|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
48339268|NCT00649168|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
48339269|NCT05721196|BEHAVIORAL|Culturally adapted Psychoeducation (CaPE)|This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.
48339270|NCT05721196|DRUG|Treatment as Usual (TaU)|This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
48339271|NCT00005018|DRUG|Hydroxyurea|
48497317|NCT04188301|DRUG|Three daily doses of IDA|Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)
48497318|NCT06483139|PROCEDURE|Plasma exchange|Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
47979963|NCT00147810|PROCEDURE|Telephone outreach to enhance asthma care|
48339272|NCT00005018|DRUG|Abacavir sulfate|
48497319|NCT06483139|DRUG|Daratumumab|Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
48497320|NCT02846272|PROCEDURE|Observation|Observation of MRI changes in subjects
47914281|NCT03669783|DRUG|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
47914282|NCT06083064|DIAGNOSTIC_TEST|Abdominal imaging|Abdominal ultrasound and/or abdominal CT
48339273|NCT00005018|DRUG|Efavirenz|
48339274|NCT00005018|DRUG|Didanosine|
48339275|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
48339276|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
48339277|NCT01452724|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
48339278|NCT01452724|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
47914283|NCT06083064|OTHER|Score based selective abdominal imaging|Abdominal imaging is done selectively based on Adult Appendicitis Score
48339279|NCT01452724|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
48339280|NCT01452724|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
48339281|NCT03528824|OTHER|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
48339282|NCT03528824|DRUG|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
48339283|NCT02416778|DRUG|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
48339284|NCT01437267|BIOLOGICAL|Vi-CRM197 vaccine|
48339285|NCT01437267|BIOLOGICAL|Pneumococcal conjugate vaccine|
48339286|NCT01437267|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
48339287|NCT05308667|OTHER|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
47914284|NCT06083064|OTHER|Score based selective observation combined with selective abdominal imaging|Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
48497321|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
48655566|NCT06637566|OTHER|Brandt Daroff exercises|brandt daroff exercises without cawthorne Cooksey exercises. To begin the Brandt-daroff exercise, the patient will sit and swivel the head 45 degrees to one side (left), then instantly lie down on the other shoulder (right). The patient should be instructed to maintain this posture for 30 seconds or until the vertigo subsides. The patient then gradually returns to the starting position, maintaining the left ear rotation until sat upright. Following the same 30 second time limits, the patient turns his head in the opposite way (right) and rests down on the opposite shoulder (left). These exercises will be instructed to perform at home for 3 sets (morning, afternoon and evening) with 5 repetitions approximately for 30 minutes in each session for five weeks
48655567|NCT00130390|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
48655568|NCT00130390|OTHER|Placebo|One placebo tablet twice daily for 28 days
48655569|NCT06569316|PROCEDURE|Biospecimen Collection|Undergo blood or saliva and leftover tissue sample collection
48655570|NCT06569316|OTHER|Communication Intervention|Receive care plan recommendations
48655571|NCT06569316|OTHER|Genetic Testing|Undergo genetic testing
48655572|NCT06569316|OTHER|Survey Administration|Ancillary studies
48655573|NCT03079778|PROCEDURE|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
48655574|NCT03079778|RADIATION|TACE plus RT|radiobiologically guided radiation
48655575|NCT06642129|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
48655576|NCT00400140|DEVICE|Hyperopic lens|+3 D glasses
48655577|NCT06641700|DIAGNOSTIC_TEST|diagnosed with gastric cancer|Pathological biopsy confirmed the diagnosis of gastric cancer.
48655578|NCT04621188|DRUG|Lorlatinib|100 mg once daily
48655579|NCT04758988|OTHER|DermLoop Learn|DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
48655580|NCT06015438|BEHAVIORAL|Home Exercise Program|Participants will perform a minimum of one exercise from each of the targeted muscle groups at a frequency of every other day, for a total of 3-4 days a week of exercise with a rest day. The entire strengthening exercise routine should take approximately 25-30 minutes to perform, including rest periods. Each muscle grouping of exercises is designed to progress from minimal muscle effort required to moderate to maximal effort. Participants will use a video to perform the exercises as well as a handout with specific instructions.
48655581|NCT06015438|BEHAVIORAL|Short Exercise Program|Participants in this group will attend one in-person visit expected to last about 60 minutes. The clinic visit will consist of standard of care procedures and tests for individuals with mild-to-severe HS .
48655582|NCT03880019|PROCEDURE|Computed Tomography|Undergo CT
48655583|NCT03880019|PROCEDURE|Core Biopsy|Undergo tumor biopsy
48655584|NCT03880019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48655585|NCT03880019|DRUG|Olaparib|Given PO
48655586|NCT03880019|DRUG|Temozolomide|Given PO
48655587|NCT06220669|DRUG|LY3541860|Administered IV
48655588|NCT06220669|DRUG|Placebo|Administered IV
48655589|NCT06637046|DIAGNOSTIC_TEST|Diagnostic procedures|A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.
48655590|NCT06637046|DIAGNOSTIC_TEST|Lidocaine HCl|This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
48655591|NCT05976633|OTHER|Whole white rice (control)|One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.
48655592|NCT05976633|OTHER|Whole brown rice|One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.
48655593|NCT05976633|OTHER|Whole wild rice|One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.
48655594|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Stovetop|One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
47914285|NCT00674713|OTHER|Acupuncture|
47914286|NCT00674713|DRUG|Ondansetron|
48131846|NCT02641912|OTHER|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
48497322|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
48497323|NCT05707143|OTHER|home based stabilization exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
48497324|NCT05707143|OTHER|kegel exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
48497325|NCT03743740|OTHER|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
48497326|NCT01175031|OTHER|Manipulation of Positive Airway Pressure (PAP)|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
48497327|NCT05549908|BIOLOGICAL|rabies vaccine|The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
48497328|NCT01440036|PROCEDURE|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
48497329|NCT03720327|BEHAVIORAL|Get FIT|The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
48497330|NCT03720327|BEHAVIORAL|Get FIT+|The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
48655595|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Microwaved|One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
48655596|NCT05535569|DRUG|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
48655597|NCT00844220|PROCEDURE|CT/MR|CT/MRI-directed clinical management strategy
48655598|NCT00844220|PROCEDURE|Catheterization|Standard clinical management directed by conventional coronary angiography
48655599|NCT05166499|DIETARY_SUPPLEMENT|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
48655600|NCT05166499|DIETARY_SUPPLEMENT|Balanced Amino Acids|Balanced Amino Acids
48655601|NCT05897775|DEVICE|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
48655602|NCT06636708|COMBINATION_PRODUCT|Nanodropper and Proparacaine HCl 0.5%|The Nanodropper is an eyedrop bottle adaptor that creates smaller eyedrops by coupling to an existing eyedrop bottle. This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.
48655603|NCT06636708|COMBINATION_PRODUCT|Standard Eye Drop Bottle with Proparacaine HCl 0.5%|This intervention involves administration of proparacaine HCl 0.5% using a standard eye drop bottle.
48655604|NCT01751425|DRUG|Dasatinib|Given PO
48655605|NCT01751425|DRUG|Imatinib Mesylate|Given PO
48655606|NCT01751425|DRUG|Nilotinib|Given PO
48655607|NCT01751425|DRUG|Ruxolitinib|Given PO
47914287|NCT00674713|DRUG|Physiological saline solution|
47914288|NCT00674713|OTHER|Sham acupuncture|
47914289|NCT00674713|DRUG|Ondansetron|
47914290|NCT00674713|OTHER|Acupuncture at P6 point|
48131847|NCT02641912|OTHER|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
48131848|NCT02406092|DRUG|Rituximab|Rituximab SC 1400 mg
48655608|NCT06298058|DRUG|SIBP-A13 formulation for injection|"SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks."
48655609|NCT06469021|OTHER|Conservative Approach|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the individuals. In a one session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises and 10 minutes of balance training will be applied. The exercises will start from an easy level and the level of difficulty will be gradually increased. The assessments will be evaluated in three stages: at the beginning of treatment, at the third month of treatment and at the end of treatment (sixth month).
48655610|NCT06469021|OTHER|Rehabilitative Game Therapy|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the patients and will be applied to the patients with a conventional approach. In a one-session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises, and 10 minutes of balance training will be applied in the clinical setting. Home exercises will be performing with the SmartPose system differently from the control group. The SmartPose system is a special software system that enables the user to perform movements with a tablet or phone without the need for any sensors.
47979964|NCT00667368|DRUG|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
47979965|NCT01014650|DRUG|GLYX-13|single IV or SC dose
48339288|NCT05308667|OTHER|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
47979966|NCT01014650|DRUG|IV normal saline|Single IV dose of normal saline
48339289|NCT05256316|OTHER|Previously admitted COVID-19 patients in intensive care units|Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
48339290|NCT05725200|DRUG|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
48339291|NCT05725200|DRUG|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
47914291|NCT00674713|DRUG|Physiological saline solution|
47979967|NCT05195970|OTHER|Walnuts|Participants consume 2 ounces of walnuts daily for 21 days
47979968|NCT03447132|DRUG|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
47979969|NCT03447132|DRUG|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
47979970|NCT03447132|DRUG|Goserelin 3.6 MG|Only for pre or peri menopausal patient
47979971|NCT03447132|DRUG|Placebos|Placebo
47979972|NCT02037698|DEVICE|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
47979973|NCT04337125|OTHER|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
47979974|NCT06507592|DIAGNOSTIC_TEST|Saliva samples collection|The first sample of saliva was be taken before the start of the treatment and considered as the control sample (T0); the second sample was be taken one month after the start of the treatment (T1) and the third one after three months (T2).
47979975|NCT00856284|DRUG|Alogliptin|Alogliptin tablets
47979976|NCT00856284|DRUG|Metformin|Metformin tablets
47979977|NCT00856284|DRUG|Glipizide|Glipizide tablets
47914292|NCT00674713|OTHER|Sham acupuncture|
47979978|NCT03520803|OTHER|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
47979979|NCT00715078|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
47979980|NCT01648205|DRUG|Placebo|Matching Placebo will be given for first month.
47979981|NCT01648205|DRUG|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
47979982|NCT01252017|DRUG|nilotinib|nilotinib (200mg/tab) 1 tab everyday
48339292|NCT05725200|DRUG|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
47914293|NCT06208475|OTHER|Resistance exercise|Resistance exercises in the following order: squat, bench press, deadlift. Each exercise consisted of 3 sets with 7 repetitions, using a load of 70% 1RM with 120sec of rest between sets.
47979983|NCT02214524|DEVICE|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
47979984|NCT00295841|DRUG|clofarabine|
47979985|NCT00295841|DRUG|cytarabine|
47979986|NCT02601508|DRUG|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
47979987|NCT02601508|DRUG|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine \& Glycopyrrolate
47979988|NCT02050529|DRUG|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
47979989|NCT02050529|DRUG|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
47979990|NCT04856774|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined."
47979991|NCT00296374|DRUG|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
47979992|NCT00296374|DRUG|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
47979993|NCT00296374|DRUG|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
47979994|NCT03259204|DEVICE|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
47979995|NCT04160091|DRUG|FX006|Single intra-articular injection
48497331|NCT02735850|DRUG|L19-IL2|L19-IL2 added to SBRT
48497332|NCT02735850|RADIATION|SBRT|
48339293|NCT05725200|DRUG|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339294|NCT05725200|DRUG|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
48339295|NCT05725200|DRUG|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339296|NCT05725200|DRUG|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
48339297|NCT05725200|DRUG|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339298|NCT05725200|DRUG|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339299|NCT05725200|DRUG|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48497333|NCT02735850|OTHER|No intervention|
48655611|NCT05505500|BEHAVIORAL|Interview|Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
48339300|NCT05725200|DRUG|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
47979996|NCT04160091|DRUG|Normal Saline|Single intra-articular injection
47979997|NCT02559245|OTHER|Descurainia Sophia|
47979998|NCT02559245|OTHER|Ficus carica|
48339301|NCT05725200|DRUG|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48131849|NCT02406092|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
48131850|NCT02406092|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice.
48339302|NCT05725200|DRUG|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339303|NCT05725200|DRUG|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339304|NCT05725200|DRUG|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339305|NCT05725200|DRUG|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339306|NCT05725200|DRUG|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
48339307|NCT02319408|RADIATION|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
48339308|NCT04282876|DRUG|Degarelix|Patients receiving Degarelix
48339309|NCT04933409|PROCEDURE|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
48339310|NCT04933409|PROCEDURE|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
48339311|NCT04814407|DIAGNOSTIC_TEST|Blood-derived DNA methylation detection|Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
48339312|NCT01248364|DRUG|BI 10773|BI 10773 tablets once daily high dose
48339313|NCT04269837|OTHER|Counseling|Receive sexual health counseling
48339314|NCT04269837|OTHER|Quality-of-Life Assessment|Ancillary studies
48339315|NCT04269837|OTHER|Questionnaire Administration|Ancillary studies
48497334|NCT02296021|DRUG|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
48655612|NCT06636695|DEVICE|Cellular Matrix|Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.
48655613|NCT06636695|DEVICE|Orthovisc|Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1
47979999|NCT05552950|BIOLOGICAL|BioBlock® antiviral nasal spray|SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
47980000|NCT04661657|OTHER|Transthoracic echocardiogram (TTE)|Subjects will undergo TTE imaging.
47980001|NCT04661657|OTHER|Cardiovascular Magnetic Resonance (CMR) Imaging|Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
48131851|NCT02406092|DRUG|Vincristine|Vincristine will be administered as per standard local practice.
48131852|NCT02406092|DRUG|Prednisone|Prednisone will be administered as per standard local practice.
48497335|NCT02296021|DRUG|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
47980002|NCT01050972|BEHAVIORAL|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
47980003|NCT04768231|DRUG|Rifampin|The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.
47980004|NCT06460857|OTHER|Manual Diaphragmatic Release Technique|Manual Diaphragmatic Breathing Technique, 2 sets with a 5 min rest interval between sets will be given, patient will lie supine in a relaxed position, Therapist will stand behind the patients head with the therapist forearm aligned towards patient shoulders, the hypothenar and the last three fingers of therapist hand will make contact bilaterally with underside of 7th, 8th, 9th, and 10th ribs costal cartilages, Patient is instructed to inhale deeply, therapist will pull the contact sites towards head and slightly in a lateral direction, during expiration therapist increases the contact depth beneath costal margins and maintain the resistance, therapist will continue to increase the depth of contact in the coming deep breath. Initially patient will be asked to take 5 deep breath/ set in the first week then it will progress to 10 deep breaths in the second,third and fourth week.
47980005|NCT06460857|OTHER|Chest Wall Expansion Exercises|Four different types of chest exercises will be given to second group for 2-3 days/week for 4 weeks along with generalized body stretching
47980006|NCT00132587|DEVICE|cement Palacos R40 and LV40|
47980007|NCT06494839|PROCEDURE|Bipolar electrocautery tonsillectomy technique|The BED tonsillectomy procedures were done under general anesthesia, and the patient's position was the same as in the other method. The bipolar machine was adjusted to 30 watts, and a mucosal incision was cauterized with a single straight or stepped bipolar forceps. After carefully cauterizing the tissue, the palatine tonsil was located and removed from the superior to the inferior pole. Most of the identifiable vessels supplying the tonsil were cauterized before being separated from the tonsil. Point coagulation was used to maintain hemostasis. By using point coagulation, hemostasis was maintained. To avoid bias stemming from competence, consultants performed all of these tonsillectomies.
47980008|NCT06494839|PROCEDURE|Cold steel dissection technique|The cold steel blunt dissection tonsillectomy was carried out under general anesthesia while the patient was in the Rose position and had an endotracheal intubation. The tonsil was retracted medially with a tonsil holding forceps, and in the upper pole, the mucosal incision was made. To protect the tonsillar pillars, a delicate dissection was performed, and the suction tip was used to stop the hemorrhage. The tonsillar fossa was packed with swabs. The other palatine tonsil was then similarly removed. Hemostasis was secured by silk ligation and bipolar electrocautery.
47980009|NCT01867268|DRUG|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
47980010|NCT01867268|OTHER|prone positioning|prone positioning the patient for 10 days following the surgery
47980011|NCT01867268|OTHER|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
47980012|NCT02000973|DRUG|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
47980013|NCT02000973|DRUG|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
47980014|NCT02000973|DRUG|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
47980015|NCT02000973|DRUG|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
47980016|NCT05281939|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
47980017|NCT04405947|PROCEDURE|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
47980018|NCT01708733|DRUG|KSY|Chinese herbal formula
47980019|NCT01545284|DRUG|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
48131853|NCT02406092|DRUG|Fludarabine|Fludarabine will be administered as per standard local practice.
48497336|NCT02296021|DRUG|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
48131855|NCT05747014|DEVICE|Novapak Nasal Sinus Packing and Stent|Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.
48655614|NCT03162211|OTHER|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
48497337|NCT02296021|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
48497338|NCT02296021|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
48497339|NCT06162130|DIAGNOSTIC_TEST|Eccentric quadriceps exercises|The activation of the vastus medialis, vastus lateralis, and rectus femoris muscles will be measured using surface electromyography (sEMG) during four distinct quadriceps eccentric exercises: Reverse Nordic, Pistol squat, Suspension-based Bulgarian split squat, and Bulgarian split squat. Participants will be instructed to perform three successful repetitions for each exercise. A 30-second break will be provided between each repetition, and there will be a minimum of 10 minutes of rest between each of the four exercises. Due to the belief that fatigue could impact exercise performance, the modified Borg scale will be used to ensure that fatigue does not occur before each exercise. Exercise recording will commence when scores reported using the modified Borg scale are 1 or lower.
48497340|NCT00432302|DRUG|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
47980020|NCT05871294|DEVICE|Acoustic stimulation|The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.
48497341|NCT05237518|DEVICE|EarlySense Noomi system|The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
48497342|NCT03306524|DEVICE|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
48497343|NCT03306524|DEVICE|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
48497344|NCT03306524|DEVICE|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
48497345|NCT03306524|DEVICE|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
48497346|NCT03306524|DEVICE|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
48497347|NCT03306524|DEVICE|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
48497348|NCT03306524|DEVICE|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
48497349|NCT03306524|DEVICE|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
48497350|NCT03306524|DEVICE|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
48497351|NCT03306524|DEVICE|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
48497352|NCT03982979|DEVICE|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
48497353|NCT04340349|DRUG|Hydroxychloroquine Sulfate|A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
48497354|NCT04340349|DRUG|Bromhexine 8 MG|TMPRSS2 blocker
48655615|NCT00238329|BIOLOGICAL|PEG-interferon alfa-2b|
48655616|NCT00238329|DRUG|thalidomide|
48655617|NCT05826626|DEVICE|MindLenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
47980021|NCT05871294|DEVICE|Repetitive transcranial magnetic stimulation|The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)
47980022|NCT05000177|OTHER|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
48655618|NCT05826626|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
48655619|NCT05883709|DRUG|Tafasitamab Injection|The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
48131862|NCT06373835|DRUG|Emodepside|5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin
48131863|NCT01723267|OTHER|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
48131864|NCT01723267|OTHER|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
48131865|NCT05928390|DRUG|Pasireotide Diaspartate|Injectable ampoules
48131866|NCT06119711|OTHER|No intervention|No intervention
48655620|NCT06634069|DRUG|Sodium Lactate|0.5M HSL (containing 504mM of sodium and lactate)
48655621|NCT06634069|DRUG|3% NaCl|active compartor 3% NaCl
48339316|NCT06178757|DRUG|TAPB|As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.
48655622|NCT03712761|DIETARY_SUPPLEMENT|Enriched Protein®|This product contains high quality bovine milk proteins enriched with additional leucine.
47980023|NCT05000177|OTHER|30-minute rest|Rest for 30 minutes
48131867|NCT03351075|OTHER|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~* Start immediately after surgery, sessions are individual and take 30 minutes~* Intensive phase (4 months): 1-2x/week~* Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
48131868|NCT03351075|OTHER|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
48339317|NCT06178757|DRUG|EOIB|As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
48497355|NCT04695145|BEHAVIORAL|Aerobic exercise in group|"Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~* Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~* Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~* Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~* Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~* Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~* Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
48497356|NCT04695145|BEHAVIORAL|Group sessions with leisure activities|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
48655623|NCT06641934|OTHER|No intervention; Observational study|No intervention
48655624|NCT06589934|DIAGNOSTIC_TEST|Precise Image|Image reconstruction software
48655625|NCT05840913|DRUG|Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge|Local anesthetic injection for intra- operative pain control
47980024|NCT00166114|DRUG|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
47980025|NCT00166114|DRUG|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
47980026|NCT00616954|DRUG|ATG-F|ATG-f
47980027|NCT03733795|OTHER|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
48131869|NCT03351075|OTHER|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~* Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~* 3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
47980028|NCT06362811|PROCEDURE|Sacral Erector Spinae Plane Block|Ultrasound-guided bilateral injection of 1ml/kg 0.25% bupivacaine into the plane underneath the erector spinae muscles over sacral crests. The needle is inserted with in-plane technique from cranial to caudal direction over S3-4.
48131870|NCT05878288|DRUG|Cemiplimab|Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
48497357|NCT00703573|DRUG|S-777469 400 mg|S-777469 400 mg BID
48339318|NCT01569087|BIOLOGICAL|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
48339319|NCT01569087|BIOLOGICAL|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
48339320|NCT04556448|OTHER|Aligners|Clear aligners
48339321|NCT04556448|OTHER|Clear braces|Clear braces
48339322|NCT00929045|DRUG|Growth Hormone Replacement|
48339323|NCT02314598|OTHER|No treatment|
48339324|NCT02434913|DEVICE|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
47980029|NCT04056689|DRUG|DNL151|Oral repeating dose
48339325|NCT01578538|PROCEDURE|inguinal hernia repair|strangulated hernias will be repaired surgically
48339326|NCT01391338|DRUG|ASP3652|Oral
48497358|NCT00703573|DRUG|S-777469 800 mg|S-777469 800 mg BID
47980030|NCT04056689|DRUG|Placebo|Oral repeating dose
47980031|NCT00512993|DRUG|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
47980032|NCT00967798|DRUG|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
48497359|NCT00703573|DRUG|Placebo|Placebo BID
48131873|NCT06033105|DEVICE|ELISA|Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
48131874|NCT05721105|OTHER|Quality of life assessment using questionnaires|Several quality of life questionnaires will be submitted to the patients and their parents. The questionnaires will be adapted to the age of the patients.
48339327|NCT01391338|DRUG|Placebo|Oral
48339328|NCT02715492|DRUG|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
48497360|NCT04781101|OTHER|conventional therapy|Conventional therapy sessions that were planned by a physiotherapist for the children were conducted by a physiotherapist experienced in paediatrics. The therapy sessions mainly focused on functions such as the regulation of muscle tone, correction of posture, elimination of stiffness, muscle strengthening, balance/coordination training and mobilisation (Figure 2). The sessions were planned to last 40 minutes.
48497361|NCT04781101|OTHER|RoboGait®|The RoboGait®-assisted gait system was used for the robot-assisted gait training. In addition to conventional therapy, 16 robot-assisted gait training sessions were conducted, each lasting 25 minutes for 2 days a week (400 minutes in total). Gait speed was 1.5 km/h in all sessions. Considering conditions such as joint limitations and spasticity, gait training was performed with patients bearing 45% to 75% of their weight.
47980033|NCT01614054|OTHER|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
47980034|NCT04876625|DEVICE|myTAP oral appliance plus mouth shield|myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.
47980035|NCT04876625|DEVICE|myTAP oral appliance alone for first 4 weeks|myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
47980036|NCT03037411|DEVICE|Peripheral stenting|stent implantation during the index procedure
47980037|NCT03704207|OTHER|nNO testing|Collection of already performed clinical data and nNO testing
48339329|NCT02715492|PROCEDURE|TACE|Trans arterial chemoembolization
48339330|NCT02438046|PROCEDURE|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
48339331|NCT05606380|DRUG|HLX60|HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
48339332|NCT01181310|DRUG|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
48339333|NCT01181310|DRUG|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
48339334|NCT01181310|DRUG|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
48339335|NCT01181310|DRUG|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
48339336|NCT01181310|DRUG|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
48339337|NCT00004604|BIOLOGICAL|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
48339338|NCT00134017|DRUG|Busulfan|Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)
48339339|NCT00134017|DRUG|Cyclophosphamide|Days -3, -2, +3, +4: 50 mg/kg IV daily
48339340|NCT03499769|PROCEDURE|natural orifice|laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
48339341|NCT04714944|DIETARY_SUPPLEMENT|Placebo|Supplementation period 12 weeks
48339342|NCT04714944|DIETARY_SUPPLEMENT|Whole fiber product|Supplementation period 12 weeks
48339343|NCT00517413|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
48339344|NCT05825313|BEHAVIORAL|Podcast Using|Students in the experimental group listened to podcast episodes any time they desired following the course every week during the semester from February 2021 to June 2021.
48339345|NCT01960426|OTHER|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
48497362|NCT05328336|DRUG|Tislelizumab Nab paclitaxel|"Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will"
48497363|NCT03599830|OTHER|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
48497364|NCT00002679|BIOLOGICAL|filgrastim|
48497365|NCT00002679|DRUG|cyclophosphamide|
48497366|NCT00002679|DRUG|doxorubicin hydrochloride|
48339346|NCT01960426|OTHER|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
48339347|NCT00250367|DRUG|risperidone|
48339348|NCT04411706|DRUG|Sintilimab Combined With Apatinib and Capecitabine|"Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;"
47980038|NCT03377036|DIAGNOSTIC_TEST|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
47980039|NCT03377036|DIAGNOSTIC_TEST|2D-FFDM|2D full-field digital mammography
47980040|NCT03916198|DRUG|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
47980041|NCT03916198|DRUG|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
48339349|NCT03079557|DRUG|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
48339350|NCT00550277|DRUG|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
48339351|NCT03152396|OTHER|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
48339352|NCT02420795|DRUG|Akt/ERK Inhibitor ONC201|Given PO
48497367|NCT00002679|DRUG|paclitaxel|
48497368|NCT00002679|DRUG|tamoxifen citrate|
48497369|NCT00002679|RADIATION|radiation therapy|
48497370|NCT04677881|OTHER|Intervention group|intervention group: bread with sourdough control group: bread with yeast
48497371|NCT06456736|OTHER|None, non-interventional study|Not applicable, non-interventional study
48497372|NCT01386151|DRUG|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
48497373|NCT01386151|DRUG|Saline placebo|Normal (0.9%) saline will be used as a placebo.
48497374|NCT04373044|DRUG|Baricitinib|Given PO
47980042|NCT03967964|DRUG|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
47980043|NCT03967964|DRUG|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
47980044|NCT03967964|DRUG|Testosterone|Vaginal ring with 35 mg testosterone.
47980045|NCT03967964|DRUG|Testosterone Topical Gel|Gel containing 1% testosterone.
47980046|NCT03967964|DRUG|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
47980047|NCT05211791|PROCEDURE|erector spinae block|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
48339353|NCT02420795|OTHER|Laboratory Biomarker Analysis|Correlative studies
48339354|NCT02420795|OTHER|Pharmacological Study|Correlative studies
48339355|NCT02536157|DEVICE|Thermoplastic splinting|
48497375|NCT04373044|DRUG|Hydroxychloroquine|Given PO
48497376|NCT04373044|DRUG|Placebo Administration|Given Po
48497377|NCT00578669|DRUG|Fluoxetine|20mg once daily for 16 weeks
48497378|NCT00578669|DRUG|Dextrose|Once daily for 16 weeks
48497379|NCT02273791|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
48497380|NCT02273791|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
48497381|NCT04809883|DIAGNOSTIC_TEST|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
48339356|NCT06203483|DRUG|Adductor canal block|A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.
47980048|NCT05211791|PROCEDURE|paravertebral block anesthesia|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
47980049|NCT05211791|PROCEDURE|Thoracic epidural anesthesia|insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
47980050|NCT03495076|OTHER|Saline injection|In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
48339357|NCT06203483|DRUG|PENG block|The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
48339358|NCT05223036|PROCEDURE|Biopsy|Undergo biopsy
48497382|NCT03576183|BIOLOGICAL|VLA1701|VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
48497383|NCT03576183|BIOLOGICAL|Placebo|buffer component of VLA1701
48497384|NCT03576183|OTHER|Challenge Strain|LSN03-016011/A
47980051|NCT03495076|OTHER|Sham injection|In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
47980052|NCT00634166|DRUG|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
47980053|NCT00634166|DRUG|Topical Antimicrobial/Antifungal Medications|'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
47980054|NCT00937625|BIOLOGICAL|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
47980055|NCT01090960|DRUG|GDC-0068|Oral repeating dose
48339359|NCT05223036|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48339360|NCT05223036|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
48339361|NCT05223036|BIOLOGICAL|Obeticholic Acid|Given PO
48339362|NCT05223036|DRUG|Placebo Administration|Given PO
48339363|NCT05223036|OTHER|Questionnaire Administration|Ancillary studies
48339364|NCT06216106|PROCEDURE|Prepectoral breast reconstruction with polyurethane implants|Breast reconstruction in the prepectoral plane without elevate the pectoralis major muscle. We choose this type of reconstruction only in patients with mastectomy flap thickness of plus then 0.5 cm. We usally use silicone implants covered by an external layer of polyurethane so not to put directly in contact the silicone with the subcutaneus tissue.
48497385|NCT03252912|BIOLOGICAL|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
48497386|NCT04260867|OTHER|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
48497387|NCT04260867|OTHER|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
48497388|NCT04814030|DRUG|PD-1 inhibitor|Transarterial hepatic chemoembolization and FOLFOX-based infusion
48497389|NCT03785392|PROCEDURE|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
48339365|NCT00638417|BEHAVIORAL|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
48497390|NCT03785392|PROCEDURE|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
48497391|NCT01081535|DRUG|ketorolac, fentanyl|intravenous PCA
48497392|NCT02894281|DEVICE|pupillary light reflex|measure with infra-red cameras
48497393|NCT05668338|DEVICE|Implantable or non-implantable MED-EL hearing solution|Receipt of an implantable or non-implantable MED-EL hearing solution
48497394|NCT05717192|DEVICE|InterVapor®-System|"The InterVapor System uses heated water vapor to ablate the airways and parenchyma within targeted regions of the lung. Lung remodeling occurs after an initial localized inflammatory response and a subsequent healing and repair. The remodeling of the tissue results in reductions in tissue and air volume in the targeted regions of the lung. The remodeled lung tissue does not re-inflate as a result of collateral ventilation.~The lung volume reduction of diseased hyper-inflated lung segments after InterVapor treatment is expected to increase elastic recoil by reducing the most compliant segments of the lung, decompressing segments of healthier lung allowing for alveolar recruitment, and improving the mechanical efficiency of the respiratory muscles. These mechanical changes are anticipated to improve pulmonary function, exercise capacity and quality of life."
48497395|NCT05967052|DRUG|Pregabalin|Pregabalin pharmacotherapy
48497396|NCT05967052|BEHAVIORAL|Independent walking training|Independent walking training
47980056|NCT04797793|DRUG|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
48497397|NCT05967052|DRUG|Placebo|Placebo
48339366|NCT00638417|BEHAVIORAL|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (\>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
48339367|NCT02517268|PROCEDURE|Pancreaticoduodenectomy|
48339368|NCT06082375|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 in the form of cholecalciferol.
48339369|NCT06082375|DIETARY_SUPPLEMENT|Placebo|Vegetable oil.
48339370|NCT03245502|BIOLOGICAL|Blood transfusion|The transfusion of erythrocyte suspension
48339371|NCT04545034|OTHER|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
47980057|NCT04797793|DRUG|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
47980058|NCT04797793|DRUG|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
48339372|NCT04238611|DEVICE|Microneedle|Lactate microneedle applied on the skin of participant
48339373|NCT04238611|DIAGNOSTIC_TEST|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
48339374|NCT04238611|OTHER|Exercise regimen|Standardised aerobic exercise regimen
48339375|NCT03114423|OTHER|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
48339376|NCT03114423|OTHER|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
48339377|NCT01745913|DEVICE|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
48339378|NCT01745913|DRUG|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
48339379|NCT01745913|DRUG|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
48497398|NCT05967052|BEHAVIORAL|Gradual movement therapy in the ward|Gradual movement therapy in the ward
48497399|NCT05967052|BEHAVIORAL|Telerehabilitation|Telerehabilitation
48497400|NCT05967052|BEHAVIORAL|Psychotherapy|Psychotherapy
48497401|NCT04730089|DEVICE|Electrical impedance tomography|A bolus of 10ml 10% NaCl was injected during a respiratory pause (≥10s) through the central venous catheter.The results of arterial blood gas analysis and the data of EIT were collected before the first prone session (time baseline), the end of prone positioning (time P).
48497402|NCT00612430|DRUG|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG \& 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data \& order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
48497403|NCT03050060|DRUG|Atezolizumab|Given IV
47980059|NCT01773382|BEHAVIORAL|weight reduction|"1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~3. Daily body weight measurement.~4. Record food diary"
48497404|NCT03050060|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48497405|NCT03050060|OTHER|Laboratory Biomarker Analysis|Correlative studies
48131881|NCT06000956|DRUG|Jitongning tablets|The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
48131882|NCT06000956|DRUG|a simulated agent of Jitongning tablets|The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
48339380|NCT01745913|DRUG|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
48339381|NCT01745913|PROCEDURE|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of \> 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
48339382|NCT01745913|PROCEDURE|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
48339383|NCT02449772|OTHER|No intervention|No intervention
48339384|NCT00979719|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
47980060|NCT03096210|OTHER|Titanium-Prepared Platelet Rich Fibrin|Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
48131886|NCT04505371|BEHAVIORAL|Wellness Intervention for Smokers with HIV|"WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study."
48339385|NCT00979719|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. \& Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
48339386|NCT02033850|BEHAVIORAL|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
47980061|NCT03096210|OTHER|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
47980062|NCT04019002|DRUG|Hyperpolarized 13C Pyruvate|Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
48131887|NCT05858879|OTHER|Notification of patients and clinicians|"Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care."
48339387|NCT04864600|OTHER|Candle C|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
48339388|NCT04864600|OTHER|Candle 1|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
48339389|NCT00053638|DRUG|efavirenz|
48339390|NCT00053638|DRUG|tenofovir|
47980063|NCT02336711|RADIATION|dose escalation|molecular imaging based radiotherapy dose escalation
48339391|NCT00053638|DRUG|abacavir/lamivudine|
48339392|NCT02023918|DRUG|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
48339393|NCT04735809|DIETARY_SUPPLEMENT|Whole Cell Algae Fermentate|Contains at minimum 50% Beta Glucan
48339394|NCT04735809|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
47980064|NCT06030791|DIAGNOSTIC_TEST|MRI|MRI of operated knee
48339395|NCT06059092|BEHAVIORAL|Adapt Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to coping strategies, locus of control, coping metacognition, positive psychology strategies. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
48339396|NCT06059092|BEHAVIORAL|Engage Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to goal setting, planning, strengths identification, motivation; goal pursuit metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
47980065|NCT06501768|DRUG|Genistein|Escalation genistein dosing, followed by wash-out period
47980066|NCT05242848|BEHAVIORAL|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
48497406|NCT03050060|DRUG|Nelfinavir Mesylate|Given PO
48497407|NCT03050060|BIOLOGICAL|Nivolumab|Given IV
47980067|NCT06001424|OTHER|physical therapy|Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization
48339397|NCT06059092|BEHAVIORAL|Interact Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to social cognition, assertive communication and conflict resolution, proactive prosocial behaviors, interactional metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
48339398|NCT06059092|BEHAVIORAL|Control Group|Sessions will be devoted to serious game training cognitive and executive functions through individual and group activities based on board games.
48339399|NCT03347617|DRUG|Ferumoxytol|Given IV
48339400|NCT03347617|OTHER|Laboratory Biomarker Analysis|Correlative studies
48339401|NCT03347617|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
48497408|NCT03050060|BIOLOGICAL|Pembrolizumab|Given IV
48497409|NCT04990596|BIOLOGICAL|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
48497410|NCT02119819|DRUG|LY2944876|Administered SC
48497411|NCT02119819|DRUG|Exenatide extended-release|Administered SC
48497412|NCT02119819|DRUG|Placebo|Administered SC
48497413|NCT02119819|DRUG|Metformin|Oral
47980068|NCT06001424|OTHER|life kinetic exercises|A multimodal training that combines coordinative, cognitive and visual tasks.
47980069|NCT04063709|DIAGNOSTIC_TEST|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
48339402|NCT03347617|BIOLOGICAL|Pembrolizumab|Given IV
48339403|NCT03161171|OTHER|This is an observational study|This is an observational study
48339404|NCT00190645|DRUG|Duloxetine|
48339405|NCT04480541|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet
48497414|NCT00975403|DEVICE|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
48497415|NCT00975403|DEVICE|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
48497416|NCT02650479|DRUG|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
48497417|NCT02650479|DRUG|Placebo|6 hour IV infusion.
48497418|NCT02650479|DRUG|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
48497419|NCT02650479|DRUG|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
48497420|NCT00298779|DRUG|omeprazole and bortezomib|
48497421|NCT02496936|OTHER|SFA|High saturated fatty acid/SFA oil source
48497422|NCT02496936|OTHER|MUFA|High monounsaturated fatty acid/MUFA oil source
48497423|NCT02496936|OTHER|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
48497424|NCT02496936|OTHER|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
48339406|NCT04480541|OTHER|Wearable activity sensor|Caregivers and patients will receive a Fitbit wearable activity sensor
48339407|NCT04480541|OTHER|Survey administration|Caregivers and patients will be asked to complete health-related quality of life surveys
48339408|NCT00616291|BIOLOGICAL|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
48339409|NCT00660075|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
48339410|NCT00660075|DRUG|Placebo|Placebo for 6 weeks
48339411|NCT00182507|DRUG|Olanzapine|
48339412|NCT03855241|BEHAVIORAL|Informational Sheet|The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
47980070|NCT02891083|DRUG|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
48655626|NCT05269797|BEHAVIORAL|Nurse-led health coaching re: heart failure self-care management|A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
47980071|NCT02891083|RADIATION|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
48497425|NCT02496936|OTHER|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
48497426|NCT02683265|DRUG|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
48497427|NCT02683265|DRUG|Placebo|Placebo capsules
48497428|NCT03456154|DRUG|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
48655627|NCT04799535|PROCEDURE|Ultrasound|Undergo breast ultrasound
47980072|NCT02891083|OTHER|Control group (Surgery alone)|
47980073|NCT06504602|DEVICE|Active Virtual Reality|Active virtual reality group will play a game through a virtual environment.
47980074|NCT06504602|DEVICE|Passive Virtual Reality|Passive virtual reality group will watch a movie through a virtual environment.
48497429|NCT03456154|DEVICE|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
48131894|NCT05455697|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48131895|NCT05455697|DRUG|Cyclophosphamide|Given IV
48131896|NCT05455697|DRUG|Doxorubicin|Given IV
48131897|NCT05455697|DRUG|Prednisone|Given PO
48131898|NCT05455697|BIOLOGICAL|Retifanlimab|Given IV
48339413|NCT03855241|BEHAVIORAL|DisposeRx Drug Disposal kit|DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
48339414|NCT06076772|DRUG|Palbociclib|The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
48339415|NCT02880462|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
48339416|NCT02880462|OTHER|placebo|Placebo is made of starch
48497430|NCT02321735|BEHAVIORAL|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
48497431|NCT05100979|OTHER|The Art of Medicine Series|The Art of Medicine Series is a smartphone-based educational tool focused on teaching communication strategies to clinicians and patients.
48497432|NCT02317718|OTHER|monitor reproductive outcome|
48497433|NCT01478165|DRUG|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
48339417|NCT06149689|COMBINATION_PRODUCT|mFOLFIRINOX plus radiotherapy|Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
48131899|NCT05455697|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
48131900|NCT05455697|BIOLOGICAL|Tafasitamab|Given IV
48497434|NCT01478165|DRUG|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
47980075|NCT04154020|PROCEDURE|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
48131901|NCT05455697|DRUG|Vincristine|Given vincristine
48131902|NCT05455697|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48131903|NCT05455697|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48131904|NCT05455697|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
48131905|NCT05455697|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
47980076|NCT01810354|DRUG|Cefazolin|
47980077|NCT04334720|OTHER|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
48131906|NCT05455697|PROCEDURE|Computed Tomography|Undergo FDG-CT
48131907|NCT05455697|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48131908|NCT05455697|DRUG|Polatuzumab Vedotin|Given IV
48497435|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
48497436|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
48131909|NCT01492049|BEHAVIORAL|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
48339418|NCT03384004|DEVICE|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
48497437|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
48131910|NCT01492049|BEHAVIORAL|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
48131911|NCT01492049|BEHAVIORAL|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
48497438|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
48339419|NCT03384004|DEVICE|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
48497439|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
48497440|NCT03603379|DRUG|C225-ILs-dox|C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
47980078|NCT01832376|PROCEDURE|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
48497441|NCT05913089|DRUG|TQB2450 injection + Chemotherapy|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."
48655628|NCT06643845|PROCEDURE|arthroplasty|In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.
48655629|NCT06643845|OTHER|Medical and non-medical treatments|In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis
48655630|NCT01946880|DRUG|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
48131913|NCT02871206|BIOLOGICAL|Fluad|
48131914|NCT02871206|BIOLOGICAL|Fluzone|
48655631|NCT01946880|DRUG|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
48131915|NCT04687033|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down-regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
48339420|NCT02938507|DRUG|Formulation 1 solabegron|
48339421|NCT02938507|DRUG|Formulation 2 solabegron|
48339422|NCT01978600|DRUG|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
48339423|NCT01978600|DRUG|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
48497442|NCT05913089|DRUG|TQB2450 injection + Anlotinib Hydrochloride Capsule|"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
48131916|NCT03807908|OTHER|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
48339424|NCT00109005|DRUG|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
48339425|NCT04285853|DRUG|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
48339426|NCT04285853|DRUG|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
48339427|NCT05131529|OTHER|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
48339428|NCT05131529|OTHER|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
48339429|NCT05131529|OTHER|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
48339430|NCT06115057|DIETARY_SUPPLEMENT|Fiber|"Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption."
47980079|NCT01344161|DIETARY_SUPPLEMENT|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
47980080|NCT01344161|DIETARY_SUPPLEMENT|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
47980081|NCT01896531|DRUG|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
47980082|NCT01896531|DRUG|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
47980083|NCT01896531|DRUG|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
47980084|NCT01896531|DRUG|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
47980085|NCT01896531|DRUG|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
47980086|NCT03465202|DRUG|Capecitabine|
47980087|NCT03339960|OTHER|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
47980088|NCT06175260|DIAGNOSTIC_TEST|oral carnitine challenge test|Urine samples will be collected to quantify trimethylamine N-oxide (TMAO) levels at four time points: before, and 24, 48, and 72 hours after the oral administration of 1500 mg of L-carnitine.
47980089|NCT03755492|OTHER|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
47980090|NCT01654731|DRUG|Bezafibrate|
47980091|NCT01654731|DRUG|placebo|
47980092|NCT00053053|DIETARY_SUPPLEMENT|Juven|
47980093|NCT00053053|DIETARY_SUPPLEMENT|Non-Juven Supplement|
47980094|NCT03566394|DRUG|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
47980095|NCT04039815|DRUG|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
47980096|NCT04039815|DRUG|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
47980097|NCT04298892|OTHER|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
47980098|NCT06363851|DRUG|Kylo-11|Administered SC.
47980099|NCT06363851|DRUG|Placebo|Administered SC.
47980100|NCT03031977|OTHER|visceral mobilization|
47980101|NCT00230568|DRUG|Aricept|
47980102|NCT01661439|DRUG|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
48655632|NCT01946880|DRUG|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
48655633|NCT02832531|DRUG|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
48497443|NCT00801580|DRUG|doxorubicin liposomal|"* Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine"
48497444|NCT02408068|DRUG|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
47980103|NCT05151484|DRUG|Teriparatide|Participants will receive 20 μg teriparatide per day via subcutaneous injections. Participants, and if needed a caregiver, will be trained in the subcutaneous administration of teriparatide according to the manufacturer's guidelines. The investigators will measure serum calcium, BSAP and TRAP-5b levels via blood draws at quarterly monitoring visits. If BSAP or TRAP-5b do not increase compared to baseline or decrease after any quarter, participants will be contacted and correct administration will be reviewed. Serum calcium is measured for safety to avoid hypo- and hypercalcemia. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
47980104|NCT05151484|DRUG|Alendronate|Participants will receive 70 mg alendronate p.o. once per week. Participants will be carefully instructed to follow the manufacturer's recommendations for administration. Compliance will be assessed by measurement of the bone turnover markers BSAP and TRAP-5b from blood drawn at quarterly monitoring visits. These markers have been shown to be useful for assessment of turnover changes with treatment. If these markers do not decrease compared to baseline or rise after any quarter, participants will be contacted and correct administration will be reviewed. Participants will also be given a daily dose of Vitamin D of 800 IUs to prevent development of Vitamin D deficiency.
47980105|NCT05964244|DEVICE|Vela Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
47980106|NCT05964244|DEVICE|Nivairo Standard Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
47980107|NCT03725696|DIAGNOSTIC_TEST|Semen Analysis|Sperm counts will be determined by semen analysis.
47980108|NCT03725696|DIAGNOSTIC_TEST|Hormonal panel|Blood test for LH, FSH, testosterone, and estradiol
47980109|NCT03725696|PROCEDURE|RYGB Gastric Bypass|Roux-en-Y Gastric Bypass
47980110|NCT03725696|DIAGNOSTIC_TEST|IIEF Survey|International Index of Erectile Function is a validated 5-question survey examining sexual health in men
47980111|NCT00731289|DRUG|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
47980112|NCT00731289|DRUG|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
47980113|NCT04857242|DIAGNOSTIC_TEST|Apnea test, alveolar recruitment|Alveolar recruitment following the phase of apnea testing
47980114|NCT00280462|DRUG|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
47980115|NCT00280462|DRUG|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
48655634|NCT02832531|DRUG|Aspirin|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
48655635|NCT05176665|DRUG|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
48497445|NCT02408068|DRUG|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
47980116|NCT00280462|DRUG|Placebo|Placebo
47980117|NCT06039826|DRUG|LY3437943|Administered SC.
47980118|NCT06039826|DRUG|Ethinyl Estradiol|Administered orally
47980119|NCT06039826|DRUG|Drospirenone|Administered orally
48131917|NCT03807908|OTHER|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
48497446|NCT02408068|DRUG|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
48655636|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer relaxing acupressure
48655637|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer sham acupressure
48655638|NCT06442891|OTHER|Internet-Based Intervention|Receive access to acupressure mobile app
48655639|NCT06442891|OTHER|Interview|Ancillary studies
48497447|NCT02408068|DRUG|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
48497448|NCT03956810|OTHER|On-demand transportation|On-demand scheduling via telephone, web portal, or the broker's mobile application.
48497449|NCT03956810|OTHER|Usual transportation|Usual transportation scheduling via call-center.
48497450|NCT05244395|OTHER|Duchenne Muscular Dystrophy Gait Assessment Scale|a special gait assessment scale for Duchenne Muscular Dystrophy patients
48131918|NCT03694691|DIAGNOSTIC_TEST|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
48497451|NCT03821870|DIAGNOSTIC_TEST|Inditreat|Tumoroid formation and drug sensitivity analysis
48497452|NCT03821870|DRUG|Experimental drug|Second line treatment based on drug sensitivity analysis
48497453|NCT01072955|BIOLOGICAL|Bovine Heparin|5.000UI/mL bottle with 5mL
48131922|NCT05912738|OTHER|Interventional therapy|Interventional therapy for postherpetic neuralgia includes nerve blocks, pulsed radiofrequency therapy, etc
48497454|NCT01072955|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
48497455|NCT04127214|OTHER|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
48497456|NCT06289153|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
48131923|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
48131924|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
48655640|NCT06442891|OTHER|Medical Device Usage and Evaluation|Receive an AcuWand
47980120|NCT02911753|OTHER|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
48131925|NCT01741363|OTHER|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
48131926|NCT01741363|OTHER|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
48131927|NCT01741363|OTHER|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
48131928|NCT01741363|OTHER|FIT only|HPSA+FIT compared with FIT alone.
48497457|NCT06289153|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
48497458|NCT04989712|OTHER|Exposure|Participants randomised to one of the three exposures
48497459|NCT03757975|PROCEDURE|urethral length measure|measure of urethral length, distribution of questionnaires before and after operation
48497460|NCT04029896|BIOLOGICAL|HB-adMSCs|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
48497461|NCT05250466|PROCEDURE|Radiofrequency technology|The vulva and vagina were routinely disinfected with iodophor, the negative plate was placed on the patient's waist and abdomen, and the vulva module was selected for treatment for 10 minutes per side, for a total of 20 minutes. Parameters: power 10-20W, temperature 38-42C°, once every 10 days, 5 times in total
48497462|NCT05250466|PROCEDURE|Electrical stimulation|Routine vulvovaginal disinfection with iodophor, vaginal probes are placed in channel A, electrode pads are placed in channels B\\C\\D respectively, the frequency of electrical stimulation (the most comfortable amount) is adjusted, 10 times is a course of treatment, and mild lesions are treated for 1-2 courses of treatment , 2 to 3 courses of treatment for moderate to severe lesions.
48497463|NCT04644874|DIAGNOSTIC_TEST|Geriatric 8|The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.
48655641|NCT06442891|OTHER|Questionnaire Administration|Ancillary studies
48655642|NCT06640283|DIAGNOSTIC_TEST|ctDNA test|ctDNA involves the collection of peripheral blood samples for the analysis of circulating tumor DNA (ctDNA). The samples are processed using next-generation sequencing (NGS) and/or digital polymerase chain reaction (PCR) techniques to detect specific genetic alterations related to the tumor. The objective is to assess the presence and quantity of ctDNA, providing information on tumor burden and treatment response.
48497464|NCT04644874|DIAGNOSTIC_TEST|modified Geriatric 8|The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.
48655643|NCT06640283|DRUG|Pembrolizumab|Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.
48497465|NCT04644874|DIAGNOSTIC_TEST|30 second chair stand test|Repetitions within 30 seconds
48497466|NCT04644874|DIAGNOSTIC_TEST|Handgrip Strength Test|Measured in kilograms
48655644|NCT05912400|DIAGNOSTIC_TEST|Blood draw|• An additional 10 mL of blood will then be drawn for mitochondrial testing purposes.
48497467|NCT03564444|BIOLOGICAL|Bivalent influenza vaccine|A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
48655645|NCT05912400|OTHER|FACIT-F and Pain Scales|• Questionnaires regarding pain and fatigue will be provided for the subject to review and answer.
48655646|NCT05811949|DRUG|Dimethyl Fumarate 240 MG [Tecfidera]|DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
48655647|NCT06487936|DEVICE|TransLoc 3D SI Joint Fusion System|Satisfaction survey will be administered to collect real world evidence on patients that previously received the TransLoc 3D System commercially.
48655648|NCT06640296|DRUG|Liposomal Amphotericin B (LAmB)|collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
48655649|NCT00000884|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
48655650|NCT00000884|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
48655651|NCT00000884|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
48655652|NCT04275518|DRUG|APG-115|APG-115 orally once daily from Days 1 to 7 every 28 days.
48339431|NCT03954379|DRUG|Standard of Care (ACB, SA, peri-op pain management)|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2"
48339432|NCT03954379|DRUG|IPACK and multi-modal analgesic regimen|"INTERVENTION BEFORE SURGERY~1. Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~2. iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~1. IV dexmedetomidine~2. IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~1. injection of freezing medication through the tube in the thigh x 2~2. IV dexamethasone 8 mg 1 day after surgery"
48339433|NCT03954379|PROCEDURE|Periarticular Local Anesthetic Infiltration|INTERVENTION DURING SURGERY
48339434|NCT03954379|DRUG|IV Dexamethasone 8mg at the end of surgery as standard of care|INTERVENTION DURING SURGERY
48339435|NCT03067844|DRUG|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
48655653|NCT04275518|DRUG|Azacitidine|75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
48655654|NCT04275518|DRUG|Cytarabine|1g/m\^2 IV QD on Days 3-7 (28-day cycle)
48339436|NCT00606177|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
48339437|NCT00606177|DRUG|placebo|oral, 0mg(4tablets)/day
48497468|NCT03564444|OTHER|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
48497469|NCT03002662|OTHER|colonoscopy|
48497470|NCT03956121|OTHER|injection of magnesium sulfate|The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
48497471|NCT02953951|OTHER|blood transfusion|blood transfusion different sources
48497472|NCT05122936|COMBINATION_PRODUCT|XRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
48497473|NCT03744871|OTHER|N95 Respirator|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
48497474|NCT01323751|DRUG|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
48655655|NCT06569511|DIAGNOSTIC_TEST|N-terminal pro-B-type natriuretic peptide (NT-proBNP)|In patients diagnosed with Acute coronary syndrome, blood samples for serum NT-proBNP value were taken during transfer to the coronary intensive care unit
48655656|NCT06569511|DIAGNOSTIC_TEST|high sensitive cardiac troponin T (hs-cTnT)|In patients diagnosed with Acute coronary syndrome, serum high-sensitive cardiac troponin T (hs-cTnT) levels were measured on admission to the Emergency Department.
48655657|NCT03043573|BEHAVIORAL|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
48655658|NCT03043573|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
48339438|NCT00052936|BIOLOGICAL|filgrastim|
48339439|NCT00052936|BIOLOGICAL|rituximab|
48339440|NCT00052936|DRUG|CHOP regimen|
48339441|NCT00052936|DRUG|cyclophosphamide|
48131941|NCT05169580|DRUG|FTX-6058 oral capsule(s)|Participants will receive FTX-6058
48497475|NCT06452875|PROCEDURE|Primary Needle Knike Fistulotomy|"After verifying the eligibility of the papillary morphology (excluding flat or diverticular papillae according to Viana's classification), access to the bile duct will be initiated using the primary needle knife fistulotomy technique. After the first contact of the needle knife with the papilla, the endoscopist will have a total of 8 minutes, after which he can change to other cannulation techniques (eg standard cannulation methods through the papillary orifice) or even stop the procedure.~During ERCP all patients will be submitted to PEP prophylaxis with indomethacin. Also as a prophylactic PEP measure a pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct. For the purpose of this study, a dedicated form (attached) will be created with the various variables to be analyzed."
48497476|NCT01674153|PROCEDURE|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
48131944|NCT04565028|BEHAVIORAL|Contingency Management (CM)|Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
48131945|NCT05046613|OTHER|Rimegepant|75mg
48131946|NCT05046613|OTHER|Not taking Rimegepant|No rimegepant
48131947|NCT06231368|BIOLOGICAL|CNCT19 CAR-T cell therapy|CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.
48131948|NCT06409897|OTHER|Sequencial increasing of head of the bed elevation and alveolar recruitment maneuver followed by a PEEP titration with 10° of head of the elevation|Patients will be sequentially positioned at 0, 10, 20, 30, and 40 degrees of head-of-bed elevation. An alveolar recruitment maneuver will be performed. For patients with body mass index ≤ 30 kg/m\^2, the maneuver will be conducted in pressure control mode, pressure control = 15 cmH2O, respiratory rate = 20 breaths per minute, and the PEEP will be increased in steps of 5 up to 30 cmH2O. For patients with body mass index \> 30, the PEEP will be increased up to 35. Then, a PEEP titration will be performed, tidal volume = 5 mL/Kg, respiratory rate = 25 breaths per minute, and the PEEP will be decreased from 24 down to 4 cmH2O in steps of 2 cmH2O with 30 seconds in each PEEP level. The PEEP titration software of Enlight 2100 will be used to determine the ideal PEEP, defined as the PEEP level with a collapse less than 5%. The alveolar recruitment maneuver will be performed again to reopen the lungs. Then, data will be collected, as with the 0 and 40-degree steps, with ideal PEEP.
48131949|NCT06518551|DRUG|Elotuzumab|Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.
48131950|NCT06518551|DRUG|Iberdomide|A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.
48339442|NCT00052936|DRUG|doxorubicin hydrochloride|
48339443|NCT00052936|DRUG|prednisone|
48497477|NCT04499365|DRUG|68Ga-DOTA/NOTA-FAPI-04|Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
48655659|NCT02457793|DRUG|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
48655660|NCT02457793|DRUG|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
48655661|NCT06637501|DRUG|Sonrotoclax|Administered orally
48655662|NCT06637501|DRUG|Zanubrutinib|Administered orally
48655663|NCT06638372|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
48339444|NCT00052936|DRUG|vincristine sulfate|
48339445|NCT00052936|RADIATION|radiation therapy|36Gy on BULK and extranodal involvement
48339446|NCT02448914|DRUG|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
48339447|NCT02448914|DRUG|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
48497478|NCT04499365|DIAGNOSTIC_TEST|PET/CT scan|PET/CT scan
48497479|NCT05672823|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
48655664|NCT06637943|DIAGNOSTIC_TEST|POC viscoelastic test|applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample
48131951|NCT06518551|DRUG|Dexamethasone|Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.
48131953|NCT06471322|DEVICE|Continuous Glucose Monitoring (CGM)|Patients will wear a continuous glucose monitor upon discharge from the hospital for six months
48131954|NCT06471322|OTHER|Standard of Care|Standard of Care - retrospective review
48131955|NCT05897294|DRUG|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
48131957|NCT05242562|DRUG|Plenvu|a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
48131958|NCT05242562|DRUG|Moviprep|a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
48339448|NCT04663542|PROCEDURE|immobilization duration|brace immobilization duration after open surgery for Achilles tendon rupture
48339449|NCT04194515|DRUG|YH1|YH1 treatment for one month
48339450|NCT04194515|DRUG|metformin|metformin treatment for one month
48339451|NCT03027388|DRUG|LB-100|LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
48339452|NCT00154193|DRUG|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
48339453|NCT02623387|PROCEDURE|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
48339454|NCT03241589|OTHER|Direct to patient facing mobile apps introduction|VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
48339455|NCT06068504|OTHER|Arm-cranking exercise|Arm-cranking exercise
48339456|NCT06068504|OTHER|Heating|Immersion of the foot in warm water
48339457|NCT03163173|DRUG|GC4419|30 mg (\~100 μCi) dose of \[14C\]GC4419
48497480|NCT02593435|GENETIC|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
48497481|NCT00000408|PROCEDURE|Patient education evaluation|
48497482|NCT03917017|DEVICE|Radiomics and Watson artificial intelligence|"The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease."
47980121|NCT02911753|OTHER|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
47980122|NCT02911753|OTHER|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
48339458|NCT01708538|DRUG|CXL|corneal crosslinking
48497483|NCT02860221|DRUG|Tranexamic acid (TXA)|IV and topical administration
48497484|NCT02860221|DRUG|Epinephrine|
48655665|NCT06637943|DIAGNOSTIC_TEST|standard central laboratory test|applying central laboratory test to arterial blood sample
47980123|NCT03309150|DRUG|M6620|Participant will either receive M6620 intravenously as a monotherapy on Day 1, 8 and 15 OR as a combination therapy on Day 2 and 9 of the study.
48339459|NCT04613271|DRUG|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
48339460|NCT04613271|DRUG|Azithromycin|Azithromycin 500 mg once a day for 5 days.
47980124|NCT03309150|DRUG|Carboplatin|Participant will receive carboplatin intravenous infusion as a combination therapy on Day 1 of the study.
48497485|NCT02745886|DRUG|metformin 0.85 twice daily for 6 months|
48497486|NCT02745886|BEHAVIORAL|Calorie restriction|
48497487|NCT01264536|DIETARY_SUPPLEMENT|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
48497488|NCT01264536|DIETARY_SUPPLEMENT|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
48497489|NCT04619719|DEVICE|Hyperbaric Oxygen Therapy (HBOT)|Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
48497490|NCT04300140|DRUG|Batiraxcept|Batiraxcept is experimental drug
48497491|NCT04300140|DRUG|Cabozantinib (Cabo)|Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
48497492|NCT04300140|DRUG|Nivolumab|Nivolumab is standard of care in the first line treatment of ccRCC
48497493|NCT03809988|DRUG|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
48497494|NCT03809988|DRUG|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
48497495|NCT03776721|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs.
48497496|NCT03776721|PROCEDURE|Fat graft|30mL harvested lipoaspirate is injected at the affected axillary site.
48655666|NCT05399212|DRUG|FPT-20|FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.
48655667|NCT05277532|BEHAVIORAL|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
48655668|NCT05802134|DIETARY_SUPPLEMENT|Fruit and vegetable supplement|Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
47980125|NCT03309150|DRUG|Paclitaxel|Participant will receive paclitaxel intravenous infusion as a combination therapy on Day 1, 8 and 15 of the study.
48339461|NCT03948269|BEHAVIORAL|group behavioral cognitive therapy|First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
48339462|NCT01005199|DRUG|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
48655669|NCT05802134|BEHAVIORAL|Dietary and chronic disease management education|Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
48339463|NCT01005199|DRUG|sorafenib tosylate|Sorafenib 2 x 400 mg daily
48655670|NCT05453539|DRUG|DSPE-DOTA-Gd Liposomal Injection|Single dose, intravenous infusion
48655671|NCT06154525|OTHER|RO water|Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
48339464|NCT01374191|DRUG|onabotulinum toxin type-A|1 injection of Btx-A
48339465|NCT01374191|OTHER|placebo|1 injection of saline solution
48655672|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo Preg-Mom|LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
48497497|NCT03776721|PROCEDURE|Sham graf (Saline injection)|30mL saline is injected at the affected axillary site.
47980126|NCT02458820|PROCEDURE|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
47980127|NCT03553134|DIAGNOSTIC_TEST|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
47980128|NCT03553134|DIAGNOSTIC_TEST|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
47980129|NCT01759667|OTHER|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
47980130|NCT03063554|PROCEDURE|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
47980131|NCT03063554|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
47980132|NCT03006991|OTHER|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
47980133|NCT04052893|PROCEDURE|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
48497498|NCT03776721|BIOLOGICAL|Stem cell injection|4mL stem cell suspension injected at the affected axillary site.
48339466|NCT01374191|DRUG|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
48339467|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
48497499|NCT03776721|PROCEDURE|Saline injection|4mL saline injected at the affected axillary site.
48339468|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
48339469|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
48497500|NCT04366427|COMBINATION_PRODUCT|L-HBO|as previously described.
48497501|NCT04366427|COMBINATION_PRODUCT|HBO|as previously described.
48497502|NCT04366427|COMBINATION_PRODUCT|30% O2|as previously described
48497503|NCT04366427|COMBINATION_PRODUCT|50% O2|as previously described
48497504|NCT00807677|DRUG|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
48339470|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
48339471|NCT02613988|DEVICE|3 Tesla magnetic resonance imaging|High resolution structural imaging (contrast-enhanced T1-weighted image, T2-weighted image, Fluid-attenuated inversion recovery)
48339472|NCT02613988|DEVICE|Chemical exchange saturation transfer MRI|Amide proton transfer-weighted image
48339473|NCT02613988|DEVICE|Diffusion weighted MRI|diffusion-weighted image with b value 0, 1000, and 3000
48339474|NCT02613988|DEVICE|Dynamic susceptibility contrast MRI|dual echo EPI sequence
48497505|NCT02874209|OTHER|sodium MRI|
48497506|NCT03886987|DEVICE|Blue Non Sterile Powder Free Nitrile Examination Gloves|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
48497507|NCT02655744|RADIATION|Standard treatment protocol with combined chemoradiation|
48655673|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo KIDS|LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
48655674|NCT03662451|PROCEDURE|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
48339475|NCT05201482|DEVICE|SightPlus|SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
48339476|NCT06396377|DEVICE|Reborn doll (Therapeutic object - OT)|If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
48339477|NCT01501669|DRUG|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
48339478|NCT03370198|BIOLOGICAL|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
48339479|NCT03186261|DRUG|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
48339480|NCT03186261|DRUG|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
48339481|NCT04820153|DEVICE|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
48339482|NCT04820153|BEHAVIORAL|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
48339483|NCT02238782|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
48339484|NCT02238782|OTHER|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
48339485|NCT00002941|DRUG|carmustine|
48497508|NCT04896814|PROCEDURE|Transcutaneous tibial nerve stimulation|The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
48497509|NCT04896814|PROCEDURE|Placebo|The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
48497510|NCT01846013|BEHAVIORAL|Stand|Stand at least half of the workday at work.
48655675|NCT03158246|DRUG|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
48339486|NCT00002941|DRUG|cyclophosphamide|
48497511|NCT01846013|BEHAVIORAL|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
48497512|NCT01846013|BEHAVIORAL|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
48655676|NCT03158246|DRUG|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
48655677|NCT03158246|DIETARY_SUPPLEMENT|calcium|600mg/d calcium for oral daily
48339487|NCT00002941|DRUG|etoposide|
48655678|NCT03158246|DIETARY_SUPPLEMENT|vitamin D|925IU/d vitamin D for oral daily
48655679|NCT04441138|DRUG|Durvalumab|Adjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
48655680|NCT00273585|DEVICE|Personally-tailored educational software program|
48497513|NCT03111914|DIAGNOSTIC_TEST|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
48497514|NCT00574925|DRUG|Esomeprazole|
48339488|NCT00002941|DRUG|mesna|
48339489|NCT00002941|PROCEDURE|peripheral blood stem cell transplantation|
48339490|NCT01896661|DRUG|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
48339491|NCT01896661|DRUG|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
47980134|NCT04052893|PROCEDURE|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
47980135|NCT03144388|PROCEDURE|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
48339492|NCT00410904|DRUG|cediranib maleate|
48339493|NCT00410904|DRUG|pemetrexed disodium|
48497515|NCT05739344|BEHAVIORAL|Cognitive behavioral approach based resilience development program for schizophrenic individuals|The intervention will be administered as sessions of 2 hours once a week.
48497516|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 90 days)|90 days
48497517|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 180 days)|180 days
48497518|NCT03271450|DRUG|Dabigatran: extended treatment (e.g at least 270 days)|270 days
48497519|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 90 days)|90 days
47980136|NCT03144388|PROCEDURE|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
47980137|NCT05432414|DRUG|pomalidomide|Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
47980138|NCT05432414|DRUG|Bortezomib|Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
47980139|NCT05432414|DRUG|Dexamethasone|Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
48497520|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 180 days)|180 days
48131969|NCT06309576|BEHAVIORAL|Fasting-refeeding cycle|Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance with a standard diet, 2 days of fasting (only water), and 2 days of ad-libitum refeeding using a liquid diet provided in hydration bladders to avoid portion control.
48131970|NCT06248229|DRUG|Dyanavel XR|"Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
48339494|NCT05883345|DIAGNOSTIC_TEST|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin levels|Endoscopic biopsy
48339495|NCT00750217|DRUG|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.~Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
48339496|NCT03290794|DRUG|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
48339497|NCT06337162|DRUG|INCB099280|400 mg Tablet
48339498|NCT02650895|BIOLOGICAL|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
48497521|NCT03271450|DRUG|Apixaban: extended treatment (e.g at least 270 days)|270 days
48497522|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
48497523|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
48497524|NCT03271450|DRUG|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
48339499|NCT02650895|DRUG|Saline|0.9% sodium chloride
48339500|NCT03759028|DRUG|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
48339501|NCT03759028|DRUG|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
48339502|NCT03759028|DRUG|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
48497525|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 90 days)|90 days
48497526|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 180 days)|180 days
48497527|NCT03271450|DRUG|Edoxaban: extended treatment (e.g at least 270 days)|270 days
48497528|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 90 days)|90 days
48497529|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 180 days)|180 days
48497530|NCT03271450|DRUG|Warfarin: extended treatment (e.g at least 270 days)|270 days
48497531|NCT05961865|DIAGNOSTIC_TEST|Markers of inflammation and fibrosis|"Will be analyzed the following inflammation markers:~Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids."
48497532|NCT06361979|DRUG|SHR-A1811|SHR-A1811: intravenous
48497533|NCT06361979|DRUG|Bevacizumab|Bevacizumab:intravenous
48131971|NCT06248229|DRUG|Placebo|"Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment."
48131972|NCT05027581|DRUG|Bone marrow mesenchymal stem cells|The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
48131973|NCT05027581|DRUG|hyaluronic acid|(60 mg/3 mL hyaluronic acid \[HA\])
48131974|NCT05150106|OTHER|Clinical assessments of laryngeal function|Participants will undergo acoustic, aerodynamic, respiratory kinematic, nasoendoscopic, and laryngeal EMG recordings, as well as real-time MRI of the upper airway for comprehensive characterization of shared and distinct features of laryngeal dystonia and voice tremor.
48131975|NCT06428409|BIOLOGICAL|Sacituzumab tirumotecan|Given by IV infusion every 2 weeks (Day 1 and Day 15 of every 4-week cycle)
48131976|NCT06428409|DRUG|Fluorouracil (5-FU)|5-FU is administered by IV infusion over 46 to 48 hours every 2 weeks
48131977|NCT06428409|DRUG|Leucovorin (LV) or levoleucovorin|LV or levoleucovorin is administered by IV infusion every 2 weeks
48131978|NCT06428409|DRUG|Rescue medication|Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
48131979|NCT06428409|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents and antiemetic agents.
48131980|NCT05990452|DRUG|9MW2921|All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
48339503|NCT04720339|GENETIC|Molecular monitoring by quantification of cell-free DNA|"Molecular monitoring by quantification of cell-free DNA (absolute value and variation from baseline) of two house-keeping genes (RPP30, TMEM11) by droplet digital PCR, during based-immunotherapy treatments of NSCLC patients.~Cell-free DNA will be extracted from 4 ml of plasma before treatments by immunotherapy, obtained from blood Streck® tubes.~Quantification of house-keeping genes (or mutated genes if some are previously routinely identified in tumor tissue) by ddPCR."
48339504|NCT03177746|DRUG|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment."
48497534|NCT04295135|BEHAVIORAL|Chronic Pain OneSheet|The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. OneSheet works by aggregating and structuring information that is already collected, that PCPs often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of OneSheet is to make the information that is important in clinical decision making more readily available, and to reduce the amount of time that PCPs need to spend locating this information.
48131982|NCT05482945|OTHER|Noble gas Argon|Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
48131983|NCT04216342|BIOLOGICAL|Fx-5A peptide complex|subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min\*), 1h (+/- 10min\*), 2h (+/- 10min\*), 4h (+/- 15min\*), 8h (+/- 30min\*), 12h (+/- 30min\*), and 24h (+/- 30min\*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
48497535|NCT02319395|GENETIC|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
48497536|NCT00662948|DRUG|Rituximab|375 mg/m2 every 8 weeks during 24 months
48497537|NCT00662948|DRUG|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
48497538|NCT02000661|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
48497539|NCT05746065|DRUG|PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.
48131989|NCT04637763|GENETIC|CB-010|CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
48131990|NCT04637763|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
48131991|NCT04637763|DRUG|Fludarabine|Chemotherapy for lymphodepletion
48339505|NCT01268904|DRUG|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
48339506|NCT05223699|BIOLOGICAL|MGTA-117|MGTA-117 will be administered as an IV infusion
48339507|NCT00224783|BIOLOGICAL|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
48339508|NCT00224783|BIOLOGICAL|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
48339509|NCT05189704|DRUG|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
48339510|NCT05189704|DRUG|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
48339511|NCT04054739|DEVICE|Robot-assisted gait training|intervention with robot-assisted gait training
48339512|NCT04054739|DEVICE|Treadmill gait training|intervention with treadmill gait training
48339513|NCT03602989|DEVICE|AI-enabled Diabetic Retinopathy Screening Software|Color fundus images of both eyes are captured on site before being uploaded to and analyzed by the cloud-based Artificial Intelligence software
47980140|NCT06204718|OTHER|Standard pelvic floor exercises|Pelvic floor muscle exercises will be given as 2 separate exercises including fast and slow contractions. For fast contractions, participants will be asked to contract their pelvic floor muscles strongly, hold them contracted for 5 seconds, and then relax them. For slow contractions, participants will be asked to gradually contract the pelvic floor muscles, hold them at maximum contraction for 5 seconds, and relax them gradually. Participants will be asked to perform 10 slow contractions after every 10 fast contractions. The aim is to train strength, coordination, endurance, and symmetry of pelvic floor muscles, motor learning and control, dynamic lumbopelvic stability, pelvic floor, and abdominal co-contraction. Every day, 10 fast, and 10 slow contractions with a total of 20 repetitions will be applied without changing the number by modifying the exercises every week. It will be applied for a total of 12 weeks.
47980141|NCT06204718|OTHER|Involuntary reflexive pelvic floor exercises|Reflexive exercises (jump, squat jump, etc.) with 20 repetitions per day will be applied to the participants for 12 weeks with modifications every week.
47980142|NCT00949897|DEVICE|Biofoam|Device
47980143|NCT00949897|OTHER|Iliac Crest Allograft with locked plate|
47980144|NCT05063669|BEHAVIORAL|Cognitive Occupational Therapy|In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
47980145|NCT03687489|DEVICE|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
47980146|NCT05982392|DRUG|Tramadol|Tramadol 100mg will be given 60 minutes before start of procedure.
47980147|NCT05982392|DRUG|Naproxen Sodium|Naproxen sodium 550mg will be given 60 minutes before start of procedure.
47980148|NCT05982392|DRUG|Placebo|Placebo will be given 60 minutes before start of procedure.
47980149|NCT06037434|DRUG|Captopril Tablets|0.3mg/kg, tid
47980150|NCT06037434|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
47980151|NCT06037434|DRUG|Spironolactone Tablets|2-4mg/kg, bid
47980152|NCT06037434|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
47980153|NCT06037434|DRUG|Potassium citrate powder|0.06g/kg, tid
48497540|NCT01717586|DRUG|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
48497541|NCT01717586|DRUG|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
47980154|NCT04356131|OTHER|progressive relaxation exercises and massage|Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
48497542|NCT04068636|PROCEDURE|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
48339514|NCT04956081|DEVICE|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
48339515|NCT03669406|PROCEDURE|Autograft fat|autograft fat
48339516|NCT05766423|BEHAVIORAL|The PATTERN Intervention|"The intervention components include:~1. An adherence assessment that requests patients to self-report via MyChart about their medication use. The assessment provides a link between the health center and the patient ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team when a medication adherence related problem is identified by the adherence assessment. The alert will also include the type of problem the patient is experiencing (cognitive, psychological, medical, regiment, social and/or economic). Once they receive these alerts, the care team can then activate appropriate staff and/or resources to respond."
48497543|NCT02953470|BEHAVIORAL|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
48497544|NCT02953470|BEHAVIORAL|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
48339517|NCT00290524|BEHAVIORAL|Oral alimentation started 12 hours after colorectal surgery|
47980155|NCT01183897|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
48339518|NCT01842646|DRUG|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
48497545|NCT02991677|BEHAVIORAL|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
48339519|NCT02474914|DRUG|Octreotide|Octreotide will be given after PD
48339520|NCT02474914|DRUG|Placebo|Octreotide will NOT be given after PD
48655681|NCT05683977|DRUG|durvalumab|Visits will be completed at W0 (durvalumab in combination with chemotherapy initiation) and at regular visits approximately every 6 weeks during the induction period (durvalumab + PE) (W6 and W12), then every two months during the maintenance period (durvalumab alone) for the first year and every three months up to the end of follow-up or the final visit at M36.
48655682|NCT05996471|BIOLOGICAL|VH3810109|VH3810109 will be administered.
47980156|NCT00439842|BEHAVIORAL|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
47980157|NCT03687853|DEVICE|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
48497546|NCT02991677|OTHER|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
48339521|NCT01939093|DRUG|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
48339522|NCT01939093|DIETARY_SUPPLEMENT|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
48339523|NCT01939093|DRUG|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
48131998|NCT04111458|DRUG|BI 1701963|Tablet
48339524|NCT03723785|DRUG|Insulin icodec|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
48339525|NCT05059704|OTHER|Circuit Class Training|Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
47980158|NCT05491954|DEVICE|Dexcom G6|Continuous glucose monitoring
47980159|NCT02299609|OTHER|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
47980160|NCT00164554|BEHAVIORAL|Parent-child Interaction Therapy (PCIT)|
47980161|NCT00967525|PROCEDURE|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
47980162|NCT05130177|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
48339526|NCT05059704|OTHER|Individual Task specific training|Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
48131999|NCT04111458|DRUG|Trametinib|Tablet
48132000|NCT06246253|PROCEDURE|Virtual implant placement following safe angle concept|Virtual implant placement following safe angle concept in anterior maxillary teeth.
48132001|NCT06246253|PROCEDURE|actual implant placement following safe angle concept|actual implant placement following safe angle concept in anterior maxillary teeth
48497547|NCT02991677|BEHAVIORAL|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
48497548|NCT05364060|OTHER|Questionnaires|Different questionnaires detailed in the objectives part
48339527|NCT06055049|OTHER|Intervention (Kinesio Taping) group|It is the group to which Kinesio Taping applied.
48339528|NCT01670812|DRUG|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
47980163|NCT05130177|DRUG|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
48497549|NCT00006438|DEVICE|Shoes with Rocker Soles|
48497550|NCT00221611|DRUG|Administration of intrathecal baclofen|
48497551|NCT06309927|PROCEDURE|Operative hysteroscopy (by tissue removal device)|Surgical evacuation of the uterine cavity using the Truclear Mini-Elite hysteroscopic tissue removal device
48497552|NCT06309927|PROCEDURE|Suction curettage|Surgical evacuation of the uterine cavity with electrical vacuum suction curette
48655683|NCT05996471|DRUG|Cabotegravir|Cabotegravir will be administered.
48655684|NCT05996471|DRUG|Standard of care (SOC)|Pre-baseline SOC antiretroviral therapy (ART) will be administered.
48655685|NCT05996471|BIOLOGICAL|rHuPH20|rHuPH20 will be administered.
48655686|NCT03942653|DRUG|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
48655687|NCT03942653|DRUG|Pembrolizumab|Pembrolizumab, IV, Q3W
48497553|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
48132007|NCT06520514|DRUG|Spesolimab|Spesolimab
48497554|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
48132009|NCT04995627|DIETARY_SUPPLEMENT|Salt (NaCl)|12 grams of salt (NaCl) per day
48132010|NCT04995627|OTHER|Placebo|Placebo
48132011|NCT05962606|DRUG|AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
48132012|NCT05962606|DRUG|Placebo|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
48497555|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
48497556|NCT01550276|OTHER|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
48497557|NCT02541162|BEHAVIORAL|Oral information and interviews|interviews about sexuality and self experience during the disease
48497558|NCT05031689|BIOLOGICAL|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract|Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
48497559|NCT05031689|BIOLOGICAL|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract|Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
48497560|NCT02620150|DRUG|Escitalopram|10 week trial
48497561|NCT02620150|OTHER|Placebo|10 week trial
48497562|NCT00759135|DRUG|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
48132021|NCT05955040|DRUG|Nifedipine|Standard of care for treatment of elevated blood pressure during pregnancy
48132022|NCT05955040|DRUG|Labetalol|Standard of care for treatment of elevated blood pressure during pregnancy
48339529|NCT06249022|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
48339530|NCT06249022|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
48497563|NCT00759135|DRUG|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
48497564|NCT00759135|DRUG|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
48497565|NCT00054600|DRUG|Methoxsalen|
48497566|NCT00054600|PROCEDURE|Extracorporeal Photopheresis|
48497567|NCT02472223|DRUG|Betadine 5%|"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
48497568|NCT02472223|DRUG|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
48497569|NCT05900557|DIAGNOSTIC_TEST|ECoG monitoring|Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
48497570|NCT06171607|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
48497571|NCT06171607|DRUG|Perflutren Lipid Microspheres|Given IV
48497572|NCT06171607|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
48497573|NCT05211661|DIAGNOSTIC_TEST|Respiratory Muscle Testing|Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
48655688|NCT04883203|DRUG|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
48655689|NCT04883203|DRUG|Physiological Irrigating Solution|ARM 2 : placebo
48655690|NCT01589640|OTHER|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
48655691|NCT01589640|OTHER|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
48497574|NCT05927272|PROCEDURE|SKIN SAMPLES|"At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh~Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq)."
48497575|NCT05927272|PROCEDURE|BLOOD SAMPLES|Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
48497576|NCT05927272|DEVICE|narrowband UVB|narrowband UVB (Nb-UVB) 2 times a week
48497577|NCT05927272|DRUG|Systemic Steroids|Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
48132030|NCT05613985|OTHER|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) \[If, during the study, PEDIS is \< 2, the ulcer will be covered with nonadherent paraffin gauze\].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
48132031|NCT05613985|DEVICE|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
48132032|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized clinician-led self-management telehealth sessions
48132033|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized goal setting for daily steps and activity and dietary goals
48132034|NCT05075759|BEHAVIORAL|Behavioral Intervention|Remote sessions with a health coach
48132035|NCT05075759|OTHER|Survey Administration|Ancillary studies
48132036|NCT02135679|RADIATION|Radiotherapy|
48132037|NCT05869123|RADIATION|Online adaptive radiotherapy|PTV with 5 margins covers CTV
48497578|NCT00751907|DRUG|atorvastatin|40mg daily for 4 months
48497579|NCT00751907|DRUG|Placebo|Matching placebo daily for 4 months
48497580|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein + MIX)|Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
48132041|NCT05324878|OTHER|Training|Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
48132042|NCT06497010|DRUG|Biological: PD-1|Intravenous (IV) infusion
48655692|NCT01589640|OTHER|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
48655693|NCT03872115|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
48655694|NCT05634174|DRUG|Mirabegron|Single dose, 100mg oral mirabegron
48655695|NCT04109482|BIOLOGICAL|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1 will be administered."
48655696|NCT04109482|DRUG|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~* A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
48132043|NCT06497010|DRUG|Biological: InnoPCV|Intramuscular (IM) injection
48132044|NCT03983668|DRUG|CMP-001|Immunostimulatory therapeutic agent
48655697|NCT04109482|DRUG|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
48132045|NCT03983668|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy
48132046|NCT02669173|DRUG|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
48132047|NCT02669173|DRUG|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
48132048|NCT02972034|DRUG|MK-8353|PO capsule
48132049|NCT02972034|BIOLOGICAL|Pembrolizumab|IV infusion
48132050|NCT01961557|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
48132051|NCT03093428|DRUG|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
48497581|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein)|Protein supplement as needed
48497582|NCT02984618|PROCEDURE|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
48497583|NCT02984618|PROCEDURE|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
48339531|NCT06249022|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
48339532|NCT00044993|BIOLOGICAL|Ad5CMV-p53 gene|
48132052|NCT03093428|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor. Pembrolizumab binds to human PD-1 and blocks the interaction between PD1 and its ligands.
48132053|NCT05941715|DRUG|Aflibercept 40 MG/ML|treat-and-extend
48132054|NCT05941715|DRUG|Faricimab 120 MG/ML|treat-and-extend
48497584|NCT01983709|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
48497585|NCT03543241|DIAGNOSTIC_TEST|MyoStrain|Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
47980164|NCT05295043|DRUG|(CDK)4/6 inhibitor|CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
48339533|NCT00044993|DRUG|docetaxel|
48339534|NCT00044993|DRUG|doxorubicin hydrochloride|
47980165|NCT05877833|OTHER|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
48339535|NCT00044993|PROCEDURE|conventional surgery|
48339536|NCT00044993|PROCEDURE|neoadjuvant therapy|
48339537|NCT01511991|DRUG|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
48339538|NCT05960136|PROCEDURE|Sinus lift in patients with positive COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
48339539|NCT05960136|PROCEDURE|Sinus lift with negative COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
48339540|NCT01603212|DRUG|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
48339541|NCT01603212|DRUG|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
48339542|NCT01603212|DRUG|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
48339543|NCT01719016|PROCEDURE|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~1. N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~2. Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~1. Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~2. Adenosine - stress agent during catheterization, 140 ug/Kg/min"
47980166|NCT03931291|DRUG|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
47980167|NCT00869895|DRUG|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
48497586|NCT01340105|PROCEDURE|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
48497587|NCT01340105|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
48497588|NCT02502773|DRUG|Hydroxethyl starch|
48497589|NCT00482183|DRUG|Pioglitazone|
48132061|NCT04626037|BEHAVIORAL|WECS Relational Toolkit|The Cuddle and Calm Book, The Mommy Baby Book, mother and child mutual narrative, the Bottle of Emotions, and the WECS for emotional connection, make up the WECS Relational Health toolkit.
48339544|NCT03945448|DRUG|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
48339545|NCT03945448|DRUG|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
48339546|NCT04005807|DRUG|BPN-14967|BPN-14967 oral capsules
48339547|NCT04005807|DRUG|Placebo|Oral capsules
48339548|NCT00033982|DRUG|Posaconazole|
48339549|NCT03530618|DEVICE|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
48339550|NCT03530618|DEVICE|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
48339551|NCT05380960|DEVICE|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
48339552|NCT00066508|DRUG|bortezomib|
48497590|NCT05975736|BEHAVIORAL|Search only for masses|Participants search the simulated mammogram for simulated masses.
48655698|NCT06639334|OTHER|Fasttrack pathway for THA/HE prosthesis reduction|"The purpose of this study is to design a fast-track pathway for patients referred to the University Hospital of Southern Denmark, Esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time.~The intervention is changed logistic and work pathways at the hospital that should reduce time to reduction significantly. For detailed description we refer to the uploaded protocol."
48132062|NCT06215547|DEVICE|Enterra HDE|"Instructions for use Implanting physicians should have experience in the surgical and/or implantation techniques for the Enterra II system, operational and functional characteristics of the Enterra II system, 12 English 37800 2014-03 and experience in the continued management of patients by stimulation parameter adjustment. Physicians may contact Medtronic before prescribing or implanting an Enterra II system for the first time, and request a referral to a physician experienced in the use of the Enterra II system. Implanting physicians should be thoroughly familiar with all product labeling.~Cautions:~* When using sharp instruments near the neurostimulator, be extremely careful to avoid nicking or damaging the case, the insulation, or the connector block. Damaging the neurostimulator may require surgical replacement.~* Do not use saline or other ionic fluids at connections, which could result in a short circuit"
48497591|NCT05975736|BEHAVIORAL|Search only for calcifications|Participants search the simulated mammogram for simulated calcifications.
48497592|NCT05975736|BEHAVIORAL|Search for both together|Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.
48497593|NCT05975736|BEHAVIORAL|Search for one after the other|Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).
48497594|NCT02751970|PROCEDURE|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
48497595|NCT02751970|PROCEDURE|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
48132068|NCT04094519|DRUG|enzalutamide|oral
48132069|NCT04094519|DRUG|enzalutamide Placebo|oral
48497596|NCT02751970|PROCEDURE|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
47980168|NCT05652946|DEVICE|Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics|Participants to receive at least 5 sessions with advanced rehabilitation technology including at least one, or multiple, of the following devices: Amadeo, Diego, Myro, Arm Motus EMU, Pelma Motus, Tigo, Balo, EKSO NR. Sessions are 45 (+/- 5) minutes
47980169|NCT05652946|OTHER|Standard inpatient rehabilitation therapy|Standard inpatient rehabilitation therapy without advanced rehabilitation technology
48339553|NCT04356209|OTHER|e-PRO Intervention|"Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade \> 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~* general pain~* anxiety~* sadness~* texture of the treated breast~* Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm"
48339554|NCT04356209|DRUG|Pravastatin|All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
48339555|NCT02130752|DEVICE|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
48339556|NCT02130752|DEVICE|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
48339557|NCT03770780|DRUG|SAGE-718|SAGE-718 in combination with Ketamine
48497597|NCT02751970|PROCEDURE|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
48497598|NCT02751970|PROCEDURE|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
48655699|NCT06639334|OTHER|Standard pathway for THA/HE prosthesis reduction|Standard treatment for a dislocated THA/HA at our institution is education in general anesthesia at the operating theater. For detailed description we refer to the uploaded protocol.
48655700|NCT06637072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
48655701|NCT06240754|DRUG|Enasidenib|Provided by BMS.
48655702|NCT04365855|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
48655703|NCT04365855|OTHER|Blood draw|Clinical blood tests with a focus on liver function parameters and diabetes
47980170|NCT05615272|BIOLOGICAL|Bio-PRF|Intervention group
47980171|NCT05615272|DRUG|Alveogyl|Control group
47980172|NCT02154490|DRUG|Docetaxel|Given IV
47980173|NCT02154490|BIOLOGICAL|Durvalumab|Given IV
47980174|NCT02154490|DRUG|Erlotinib Hydrochloride|Given PO
47980175|NCT02154490|DRUG|FGFR Inhibitor AZD4547|Given PO
47980176|NCT02154490|BIOLOGICAL|Ipilimumab|Given IV
47980177|NCT02154490|OTHER|Laboratory Biomarker Analysis|Correlative studies
47980178|NCT02154490|BIOLOGICAL|Nivolumab|Given IV
47980179|NCT02154490|DRUG|Palbociclib|Given PO
47980180|NCT02154490|OTHER|Pharmacological Study|Correlative studies
47980181|NCT02154490|BIOLOGICAL|Rilotumumab|Given IV
47980182|NCT02154490|DRUG|Talazoparib|Given PO
47980183|NCT02154490|DRUG|Taselisib|Given PO
47980184|NCT02154490|BIOLOGICAL|Tremelimumab|Given IV
47980185|NCT01322360|DRUG|Morphine Sulfate|
47980186|NCT00115687|DRUG|placebo|
47980187|NCT00115687|DRUG|2 mg nicotine polacrilex|
48132070|NCT04094519|DRUG|digoxin|oral
48132071|NCT04094519|DRUG|rosuvastatin|oral
48132072|NCT05774704|DRUG|Low curcumin group|One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
48339558|NCT03770780|DRUG|Placebo|Placebo in combination with Ketamine
48132073|NCT05774704|DRUG|High curcumin group|One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
48497599|NCT02641197|DEVICE|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
48497600|NCT01781819|PROCEDURE|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
48497601|NCT04227236|OTHER|E-based virtual facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using an e-based virtual trainer on a computer. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
48497602|NCT04227236|OTHER|In-person facilitator training for Making Proud Choices|Participants complete the Making Proud Choices (MPC) facilitator training using the standard in-person training method. Making Proud Choices! (MPC) is an evidence-based pregnancy and HIV/STI risk-reduction program for youth. The facilitator training prepares educators to effectively deliver the MPC curriculum.
48497603|NCT04426279|OTHER|questionnaire assesment|15-minute face-to-face questionnaire
47980188|NCT01117831|OTHER|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
47980189|NCT05647954|DRUG|HX008 + TACE|HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).
47980190|NCT05647954|DRUG|Temozolomide + TACE|"Temozolomide Subjects receive Temozolomide 200 mg/sqm intravenous (IV),day1-5, every 3 weeks (Q3W)~Procedure: TACE :~cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions)."
47980191|NCT05647954|DRUG|Pembrolizumab|Subjects receive Pembrolizumab 2 mg/kg intravenous (IV),day1, every 3 weeks (Q3W)
47980192|NCT03629067|DRUG|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
47980193|NCT03629067|DRUG|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
47980194|NCT04998461|BIOLOGICAL|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
48132079|NCT05708365|OTHER|Standard-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
48132080|NCT05708365|OTHER|Ultra-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
48497604|NCT02944383|DRUG|Gemcabene|Gemcabene tablets administered orally once daily, for 12 weeks.
48497605|NCT02944383|DRUG|Placebo|Placebo tablets administered orally once daily, for 12 weeks.
48497606|NCT03847103|OTHER|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
48497607|NCT03847103|OTHER|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
48655704|NCT04365855|PROCEDURE|Liver biopsy|If indicated per MRE results a biopsy will be taken of the liver.
47980195|NCT02645110|DEVICE|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
47980196|NCT02645110|DEVICE|Tap water|Washing hand with water alone in comparison to hand washing with soap
47980197|NCT06285981|DEVICE|Chimaera Long Nail|The CHIMAERATM, is an internal fixation system intended intended for insertion into the medullary canal of a femur in individuals suffering from stable and unstable pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur alone or when these fractures occur in combination with shaft fractures extending distally to a point approximately 10cm proximal to the intercondylar notch.
47980198|NCT02801240|OTHER|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
48497608|NCT03847103|OTHER|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
48132086|NCT00564421|DRUG|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
48132087|NCT00564421|OTHER|placebo nasal spray|2 sprays in each nostril, dosed twice a day
48132088|NCT00564421|DRUG|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
48132089|NCT00564421|DRUG|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
48132090|NCT00564421|DRUG|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
48497609|NCT03525418|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|Allogeneic bone marrow-derived mesenchymal stem cell
48655705|NCT04365855|PROCEDURE|Fibro Scan|If indicated per MRE results a fibroscan will be performed of the liver.
48655706|NCT00195728|DRUG|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
48655707|NCT02063438|PROCEDURE|Pericostal suture technique|
48655708|NCT02063438|PROCEDURE|Intracostal suture technique|
48655709|NCT06645314|BIOLOGICAL|Group A|3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
48497610|NCT04672486|BEHAVIORAL|POD Adventures|"Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems."
48497611|NCT04178070|BIOLOGICAL|GB224 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
48132102|NCT05792956|BEHAVIORAL|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
48497612|NCT04178070|BIOLOGICAL|GB224 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
48497613|NCT04178070|BIOLOGICAL|GB224 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
48655710|NCT06645314|BIOLOGICAL|Group B|3.0 × 10 \^ 10 BST06 cells, intravenous infusion, at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
48655711|NCT06040827|DEVICE|Total Knee Arthroplasty|The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
48655712|NCT05838248|OTHER|antibiotic duration|Duration of antibiotic treatment post appendectomy
48655713|NCT06561126|BEHAVIORAL|Participatory, Learning and Action Based Intervention|The total number of participants exposed to the intervention (adapted from the DMagic trial in Bangladesh) will be determined based on random selection from the community. A PLA-based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
48132109|NCT05859113|DEVICE|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
48132110|NCT05859113|DEVICE|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
48132111|NCT01064999|DRUG|Oxaliplatin|CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
48132112|NCT01064999|DRUG|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
48132113|NCT01064999|RADIATION|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
48132114|NCT01064999|PROCEDURE|Surgery|Lower anterior resection or abdominoperineal resection
48339559|NCT03091699|DRUG|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
48339560|NCT03091699|BEHAVIORAL|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
48132115|NCT06314932|OTHER|MD high in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).
48132116|NCT06314932|OTHER|MD low in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
48132117|NCT02359448|DRUG|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
48132118|NCT05249153|DRUG|low dose of dexmedetomidine with sufentanil|low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
48132119|NCT05249153|DRUG|high dose of dexmedetomidine with sufentanil|high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
48339561|NCT00633048|DRUG|NSA-789|
48132120|NCT06566339|DEVICE|Robotically Aligned Eye Imaging System|Robotically Aligned Eye Imaging System is a non-contact, micrometer scale imaging technique that provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D. The study team will develop hardware systems and software algorithms necessary for acquiring ocular anterior segment images for those seeking eye care in emergency department settings.
48132121|NCT05779631|DIAGNOSTIC_TEST|mpMRI plus a same-day cystoscopic bladder biopsy|mpMRI plus a same-day cystoscopic bladder biopsy
48132122|NCT05779631|PROCEDURE|TURBT|Transurethral resection of the bladder tumor
48132125|NCT00557284|DRUG|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
48132126|NCT00557284|DRUG|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
48132127|NCT01146522|DRUG|LCQ908|
48132128|NCT01146522|DRUG|Placebo|
48132129|NCT05220111|PROCEDURE|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
48339562|NCT00633048|DRUG|placebo|
48339563|NCT00118469|BEHAVIORAL|Psychoeducation|
48339564|NCT00118469|BEHAVIORAL|Cognitive behavior therapy|
48339565|NCT06397976|DEVICE|ANTERION investigational|Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)
48132130|NCT01894308|DRUG|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
48132131|NCT01894308|DEVICE|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
48497614|NCT04178070|BIOLOGICAL|GB224 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
48497615|NCT04178070|BIOLOGICAL|GB224 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
48497616|NCT04178070|BIOLOGICAL|GB224 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
48132135|NCT06049797|DRUG|Fezolinetant|Oral
48132136|NCT06049797|DRUG|Paroxetine|Oral
48132137|NCT06049797|DRUG|Citalopram|Oral
48132138|NCT06049797|DRUG|Escitalopram|Oral
48132139|NCT06049797|DRUG|Desvenlafaxine|Oral
48132140|NCT06049797|DRUG|Venlafaxine|Oral
48132141|NCT06049797|DRUG|Gabapentin|Oral
48132142|NCT06049797|DRUG|Clonidine|Oral
48132143|NCT06049797|DRUG|Pregabalin|Oral
48339566|NCT03356808|BIOLOGICAL|Lung cancer-specific T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
48339567|NCT06398444|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.
48339568|NCT00255996|DRUG|linezolid|
48132144|NCT06049797|DRUG|Oxybutynin|Oral
48132145|NCT06049797|DRUG|Any other SSRI/SNRI not already specified|Oral
48132146|NCT06049797|DRUG|Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above|Oral
48497617|NCT04178070|OTHER|Placebo, 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
48132148|NCT06275464|COMBINATION_PRODUCT|BT-600|NaviCap device containing liquid formulation of Tofacitinib
48132149|NCT06275464|COMBINATION_PRODUCT|BT-600 Placebo|NaviCap device containing placebo formulation
48339569|NCT03322397|BEHAVIORAL|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
48339570|NCT03322397|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
48132150|NCT02460549|BEHAVIORAL|therapeutic education program|
48132151|NCT04975217|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
48132152|NCT04975217|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
48132153|NCT04975217|OTHER|Questionnaire Administration|Ancillary studies
48132154|NCT04975217|PROCEDURE|Resection|Undergo standard of care resection
48132155|NCT04975217|PROCEDURE|Therapeutic Colonoscopy|Undergo colonoscopy
48132156|NCT00181311|PROCEDURE|hysterectomy|
48339571|NCT03322397|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
48339572|NCT03385525|DRUG|BIIB074|Administered as specified in the treatment arm
48339573|NCT03385525|DRUG|Valproic Acid|Administered as specified in the treatment arm
48339574|NCT01515488|OTHER|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
48339575|NCT01515488|OTHER|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
48497618|NCT04178070|OTHER|Placebo, 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
48497619|NCT04178070|OTHER|Placebo, 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
47980199|NCT01901198|BIOLOGICAL|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
47980200|NCT01901198|BIOLOGICAL|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
47980201|NCT00147888|PROCEDURE|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
47980202|NCT00159536|DRUG|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
47980203|NCT00159536|DRUG|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
47980204|NCT05759650|OTHER|Execution of different motor tasks typical of daily life and work|Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.
48132157|NCT02304614|OTHER|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
48132158|NCT02304614|OTHER|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
48132159|NCT02304614|OTHER|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
48132160|NCT02304614|OTHER|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
48132161|NCT05397262|OTHER|Hyperthermia|Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
48132162|NCT05397262|RADIATION|Radiotherapy|50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
48132163|NCT05397262|DRUG|Chemotherapy 5-Fluorouracil|600 mg/m\^2 civ 120h; d 1-5, 29-33
48132164|NCT05397262|DRUG|Chemotherapy Cisplatin|20 mg/m\^2; d1-5, 29-33
48497620|NCT04178070|OTHER|Placebo, 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
48497621|NCT04178070|OTHER|Placebo, 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
48132165|NCT00629096|PROCEDURE|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
48132166|NCT06086067|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
48497622|NCT04178070|OTHER|Placebo, 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
48497623|NCT05518084|OTHER|Liponovo tissue product|Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
48655714|NCT06303427|OTHER|Modified constraint-induced movement therapy|"The unaffected arm will be restricted by using an upper extremity sling that will strap to the child's trunk with a distal end fastened to prevent the movement of the unaffected limb.~The modified constraint-induced movement therapy will include these exercises.~1. Playing with ball.~2. Playing with modeling clay.~3. Playing with LEGOS (building towers or different shapes from the toy bricks).~4. Tearing a paper towel from a roll.~5. Holding and eating biscuits.~6. Eating with a spoon.~7. Drinking from a glass.~8. Combing hair.~9. Brushing teeth.~10. Making bubbles using a bubble blower.~11. Pulling a toy.~12. Placing a hat or piece of cloth on the head.~13. Applying lotion to the trained caregiver."
48655715|NCT06303427|OTHER|Electrical stimulation|The participants in this group will first receive a 20-minute session of electrical stimulation (on time of 10 s, off time of 30 s, pulse rate of 35 Hz, the pulse width of 300 µs).
48132169|NCT03572257|DRUG|Quetiapine|Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
48132170|NCT03572257|OTHER|Placebo|Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
48497624|NCT05102292|DRUG|HLX208|HLX208 450mg bid po
48497625|NCT02881138|DRUG|RC48-ADC|
48497626|NCT03605511|DIAGNOSTIC_TEST|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
48132174|NCT01290003|DRUG|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
48132175|NCT04644679|DIAGNOSTIC_TEST|7-day electrocardiographic monitoring|7-day external electrocardiographic monitoring
48132176|NCT04644679|DIAGNOSTIC_TEST|48-hr electrocardiographic monitoring|48-hr external electrocardiographic monitoring
48132177|NCT03555175|OTHER|Eccentric exercise|The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
48339576|NCT05480761|BIOLOGICAL|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
48339577|NCT00816855|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
48339578|NCT01213290|DEVICE|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
48339579|NCT01213290|DEVICE|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
48339580|NCT00499460|DIETARY_SUPPLEMENT|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
48655716|NCT05971173|DRUG|Juven|Nutritional supplements
48655717|NCT05971173|DRUG|Centrum Silver 50+|Over the counter nutritional supplement
48132178|NCT03555175|OTHER|Proprioception|The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
48132179|NCT03555175|OTHER|Control group|Any exercise
48497627|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
48132181|NCT05730829|OTHER|pain informed movement|group classes twice weekly for 8 weeks of neuromuscular exercise in combination with mind-body techniques such as breath regulation, muscle tension regulation, relaxation, mindfulness, awareness of pain related thoughts and emotions.
48132182|NCT05730829|OTHER|standard neuromuscular exercise|group classes twice weekly for 8 weeks of neuromuscular exercise.
48339581|NCT00499460|DRUG|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
48339582|NCT03355768|DRUG|Romidepsin|Intravenous administration on a 28 day cycle
48339583|NCT03355768|DRUG|Pralatrexate|Intravenous administration on a 28 day cycle
48497628|NCT06008366|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
48132183|NCT05730829|OTHER|Pain Neuroscience Education (PNE)|The pain neuroscience education (PNE) will be delivered in videos addressing concepts such as the purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
48132184|NCT05730829|OTHER|Standard osteoarthritis (OA) education|The standard osteoarthritis (OA) education will address the following topics, OA prevalence, risk factors, symptoms, diagnosis, treatment, role of exercise, surgery, self-management
48132185|NCT06642571|DRUG|NNC0519-0130 B|NNC0519-0130 B will be administered subcutaneously.
48132186|NCT06642571|DRUG|NNC0519-0130 C|NNC0519-0130 C will be administered subcutaneously.
48132187|NCT03575624|BEHAVIORAL|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
48132188|NCT04852315|DIETARY_SUPPLEMENT|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
48132189|NCT04852315|DIETARY_SUPPLEMENT|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
48497629|NCT00667030|BEHAVIORAL|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
48132191|NCT03607175|DRUG|Triamcinolone-impregnated CMC foam|same information as included in the arm/group descriptions
48132192|NCT03607175|DEVICE|Propel Stent|same information as included in the arm/group descriptions
48132193|NCT03363529|DEVICE|Dynamic light|Dynamic lighting is light that changes in intensity and spectral distribution during the day
48132194|NCT03363529|DEVICE|Standard|Standard lighting is non-dynamical light corresponding to standard hospital lighting.
48497630|NCT04784910|DRUG|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
48497631|NCT04784910|DRUG|Lansoprazole 15 mg|Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
48497632|NCT04784910|DRUG|DWP14012 20mg placebo|DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
48497633|NCT04784910|DRUG|Lansoprazole 15 mg placebo|Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
48497634|NCT05953753|BEHAVIORAL|Food system and demand generation|The project is focused on improving egg consumption through enhanced availability, accessibility, and improved demand. To achieve this goal, the project intervention mix will work through three pathways: access, enabling environment, and demand. The access pathway aims to sustain availability and consumption of eggs by school children (age 6-9 years) from BoP households through interventions targeted at the Poultry Association of Nigeria (PAN) and state lead egg aggregators for the HGSFP. The enabling environment pathway focuses on the broader institutional, governance, and political factors to support accessibility, availability, improved consumption, and increased consumer demand for eggs. The demand pathway will be addressed by mass media and interpersonal communication to increase the willingness and motivation of parents/caregivers in BoP households to support and sustain egg consumption by pre-school children in Kaduna State.
48497635|NCT05770921|DEVICE|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
48497636|NCT01389583|DRUG|AUY922|70 mg/m2 60-min i.v. infusion weekly
48497637|NCT01962480|PROCEDURE|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson \& Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
48497638|NCT04221139|BEHAVIORAL|Virtual Reality games|Participants will play the following four virtual reality games for 15 minutes each: Beat Saber, Holopoint, Hot Squat, and Relax Walk.
48132204|NCT00418652|DEVICE|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
48132205|NCT00418652|DEVICE|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
48132206|NCT00418652|DEVICE|TMS over the vertex|10Hz TMS for over vertex.
48132207|NCT06091020|BIOLOGICAL|IncobotulinumtoxinA|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
48132208|NCT06091020|BIOLOGICAL|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
48497639|NCT00040053|DRUG|Ondansetron|
48132210|NCT05919680|DRUG|NST-6179 Part A|Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks
48132211|NCT05919680|DRUG|NST-6179 Part B|Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks
48132212|NCT05919680|OTHER|Matched Placebo|Matched placebo for administration in Part A or Part B
48132213|NCT06327815|DRUG|Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets|10 mg Dapagliflozin/1000 mg Metformin HCl extended-release
48132214|NCT06327815|DRUG|Dapagliflozin tablets and Metformin HCl extended-release tablets|Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg
48132215|NCT04421365|DEVICE|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
48497640|NCT00561704|DRUG|losartan|losartan, 100mg daily,
48655718|NCT06571604|DIAGNOSTIC_TEST|Dislocation|One episode of total hip dislocation diagnozied on Xray within 2 years of surgery
48655719|NCT06571604|DIAGNOSTIC_TEST|No dislocation|No experience of dislocation within two years post-surgery
48497641|NCT03272061|OTHER|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
48339584|NCT01901978|BEHAVIORAL|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
48339585|NCT02104323|DRUG|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
48497642|NCT05614557|DEVICE|Stratacel|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
48497643|NCT05614557|DEVICE|Stratamed|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
48132236|NCT06637358|BEHAVIORAL|Extended Scheduled Gradual Reduction (SGR)|The extended SGR program will allow participants additional time to reduce smokeless tobacco use until they reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
48132237|NCT06637358|BEHAVIORAL|Quit Coach|Weekly check-ins and support will be given to this group via the quit coach interactions. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
48132238|NCT04357158|DEVICE|AeonoseTM|All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with \>2 weeks in between).
48132239|NCT06411041|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT) and yoga|The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.
48132240|NCT04174079|DRUG|chemotherapy|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
48497644|NCT02586142|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
48497645|NCT02586142|OTHER|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
48497646|NCT01974336|DRUG|ursodeoxycholic acid|
48497647|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
48497648|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
48339586|NCT05812768|DEVICE|Suture-Tight Suture Delivery System|Implantation of the Suture-Tight Suture in the deployment of multiple nitinol sutures to provide augmented fixation and sealing between endovascular aortic graft and the native artery.
48339587|NCT05156333|DIETARY_SUPPLEMENT|Respecta|"Respecta® complex (mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).~Daily oral administration of two capsules of the Giellepi Spa class IIa medical device Respecta or placebo, to be taken with a glass of water preferably between meals, starting from the 30th week of pregnancy until the 37th week after having vagino-rectal swab screening performed."
48339588|NCT05800834|DRUG|Morphine Sulfate|"For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing."
48339589|NCT05800834|DRUG|Lidocaine Hcl 2% Jelly|The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
48339590|NCT01002404|PROCEDURE|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
48339591|NCT03048409|OTHER|Enteral Formula|Enteral feeding with a peptide-based formula.
48339592|NCT02269384|PROCEDURE|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
48339593|NCT02269384|BEHAVIORAL|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
48339594|NCT02269384|BEHAVIORAL|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
48339595|NCT02269384|PROCEDURE|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
48497649|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
48497650|NCT03476525|DRUG|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
48655720|NCT06639646|DIETARY_SUPPLEMENT|Probiotics supplements|"A Dietary intervention group receiving health education message about healthy diet and probiotics supplements ( spores of poly antibiotic resistant Lactobacilli 5 billion in form of capsules registrated by the Egyption drug auyjority EDA and sold in Egyption markets under brand name Lactèol Forte ® capsules by Rameda® company.~The probiotic supplement is recommended to be given twice daily for 12 wks duration."
48339596|NCT03496441|OTHER|Fecal sample collection for analysis|Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
47980205|NCT04867850|OTHER|Usual Care|Individual clinicians will receive an automated weekly email detailing a weekly roster of their upcoming repeat-patient visits (Index Visit) with patients at high risk of 6-month mortality as determined by a validated machine learning prognostic algorithm. Clinicians will receive a HIPAA compliant text message on the morning of the appointment reminding them to consider a serious illness conversation with patients on the list.
47980206|NCT04867850|OTHER|Clinician Nudge|Clinicians will receive the usual care weekly email and text message described above under Usual Care. In addition, embedded in the weekly email, clinicians will receive performance feedback information detailing their documented SICs relative to those documented by peers.
48132246|NCT00570388|DRUG|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
48132247|NCT06193343|BEHAVIORAL|Adaptive Daily Step Promotion|"Participants will wear a Fitbit monitor on their non-dominant wrist during a 10 to 14 day run-in screening to capture daily steps reported by the Fitbit but no daily step goals will be sent to the participant. The Fitbit monitor will be worn during all waking hours except water activities, and compliance will be considered as a day with ≥1,000 steps. Next, participants will undergo a 16-week intervention wearing the Fitbit monitor on their wrist and receive a text message each morning with a personalized, adaptive daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day. Goals will not exceed 10,000 daily steps."
48132248|NCT01600482|DEVICE|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
48132249|NCT05948774|DRUG|MT200605 for Injection|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
48132250|NCT05948774|DRUG|MT200605 Placebo|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
48132251|NCT00326196|DEVICE|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
48132252|NCT00326196|PROCEDURE|Coronary artery bypass graft (CABG)|coronary bypass
48132253|NCT04155905|PROCEDURE|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\\0 sutures
48132254|NCT04155905|PROCEDURE|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
48497651|NCT02379286|OTHER|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
48497652|NCT06194032|DRUG|Baxdrostat|Participants will receive baxdrostat as two separate doses.
48339597|NCT01082341|BIOLOGICAL|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
48339598|NCT02321683|DEVICE|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
48339599|NCT00355134|DRUG|Fingolimod|Fingolimod capsules for oral administration
47980207|NCT04867850|OTHER|Patient Nudge|Ahead of the Index Visit, high risk patients as identified by the prognostic algorithm will receive a nudge via personal text message and email consisting of a normalizing message prompting patients with a personalized link to a short electronic questionnaire on SIC topics.
48497653|NCT06194032|DRUG|Placebo|Participants will receive baxdrostat matching placebo.
47980208|NCT04684355|OTHER|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
48655721|NCT06639646|DIETARY_SUPPLEMENT|Health diet|A Control group receiving health education about healthy diet. At the end of the 12 wk. period, the same measurements are repeated
48655722|NCT06642740|OTHER|Platelet count|divide into two groups based on platelet count
48497654|NCT06194032|DRUG|Moxifloxacin|Participants will receive a single dose moxifloxacin
48497655|NCT02958423|DEVICE|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
48339600|NCT00355134|DRUG|Placebo|Matching placebo capsules for oral administration.
48339601|NCT03321370|DIAGNOSTIC_TEST|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
48339602|NCT04103242|OTHER|16s rRNA gene sequencing|High-throughput sequencing of the microbial 16s rRNA subunit to define the abundance of microbial phyla and genera
47980209|NCT06459908|OTHER|Robot Glove Hand Training|Robot Assisted group will perform hand exercises with the help of robotic glove assistance for 3 times per day/ 4 times per week, 45 minutes per session for 6 consecutive weeks. Total Number of Sessions will be 72 Hours.
48132259|NCT05437770|OTHER|BFR (Blood-Flow Restricted exercise)|The BFR group performs unilateral training with the knee-OA diagnosed leg first. BFR exercise is performed with a pneumatic cuff placed at the top of the thigh on the leg being trained. The cuff will be inflated to 60-80 % of the total arterial occlusion pressure (AOP). The participant will afterwards perform training of the knee extensors in a leg press exercise machine and a leg extension exercise machine with a load corresponding to 30 % of the maximal load (1RM = Repetition Maximum).
48132260|NCT05437770|OTHER|Standard rehabilitation|The GLA:D programme involves a circuit training program with four stations. Each station involves two to six exercises where the participants perform 10-15 repetitions over 2-3 sets, which depends on the participants pain- and functional level. Following the 8 weeks GLA:D programme, participants will continue 4 weeks of team group training performing similar neuromuscular lower limb exercises as for the first 8 weeks.
48132261|NCT00156507|BEHAVIORAL|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
48132262|NCT05352308|BEHAVIORAL|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
48132263|NCT04946682|DIAGNOSTIC_TEST|Types of etiological diagnostic methods|In Group of mNGS, all patients will be tested by meta next generation sequncing on admission, while patients in Group of PCR will be tested by polymerase chain reaction in accordance with the method in the guidelines.
48132264|NCT02988193|DEVICE|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
48132265|NCT06307743|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
48132266|NCT03406169|DRUG|Sildenafil 25 MG Oral Tablet|twice a day dosing
48132267|NCT03406169|DRUG|Pentoxifylline|400mg twice a day
48339603|NCT06276842|DRUG|Inferior Alveolar Nerve Block|Administration of a local anesthetic agent around the inferior alveolar nerve to achieve anesthesia in the mandibular region.
47980210|NCT06459908|OTHER|Conventional Hand Rehabilitation Exercises|Conventional therapy group will perform hand exercises without the help of robotic gloves 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Total number of sessions will be 72.
48339604|NCT06276842|DRUG|Buccal Infiltration|Administration of a local anesthetic agent into the tissue adjacent to the tooth being treated to achieve localized anesthesia.
48339605|NCT06276842|COMBINATION_PRODUCT|Inferior Alveolar Nerve Block and Buccal Infiltration|Utilization of both the Inferior Alveolar Nerve Block and Buccal Infiltration techniques simultaneously for anesthesia in the mandibular region.
48339606|NCT03609489|DRUG|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
48339607|NCT03609489|DRUG|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
48339608|NCT05167188|OTHER|no intervention|no intervention
48497656|NCT02958423|DEVICE|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
47980211|NCT00563511|PROCEDURE|adherence intervention|
47980212|NCT00563511|PROCEDURE|intervention without adherence advice|
47980213|NCT00563511|PROCEDURE|control|
47980214|NCT01437046|DRUG|Doxazosin|Doxazosin 16mg/day
47980215|NCT01437046|DRUG|Placebo|
48132268|NCT03406169|OTHER|Placebo|placebo twice a day
48497657|NCT02958423|DEVICE|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
47980216|NCT00804830|DRUG|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
47980217|NCT02635555|DRUG|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
48132269|NCT00012805|PROCEDURE|Telephone Monitoring|
48132270|NCT04759833|DRUG|Prucalopride|Prucalopride oral solution or oral tablets.
48497658|NCT02958423|DEVICE|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
48497659|NCT01367652|DRUG|Letrozole|2.5 mg tablet
48497660|NCT01367652|DRUG|Letrozole|2.5 mg Tablet
48132271|NCT04759833|OTHER|Placebo|Prucalopride-matching placebo oral solution or oral tablets.
48497661|NCT02488330|DRUG|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
48132273|NCT04214756|PROCEDURE|Acute Pancreatitis|All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
48132274|NCT06545942|DRUG|MOMA-313|MOMA-313 administered orally
48132275|NCT06545942|DRUG|Olaparib|Olaparib administered orally
48132276|NCT01602913|DRUG|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
48132277|NCT01602913|DRUG|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
48132278|NCT01602913|DRUG|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
48497662|NCT02488330|DRUG|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
48132280|NCT05485532|DEVICE|Telemonitoring System using Cosinuss° Two and/or Garmin Vivoactive 4|Development and validation of a telemonitoring system using smart devices
47980218|NCT02987920|DRUG|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
47980219|NCT02987920|DRUG|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
47980220|NCT02987920|DRUG|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
47980221|NCT02987920|DRUG|Oxycodone|Multimodal analgesic regimen to Group A and Group B
47980222|NCT02987920|DRUG|Celecoxib|Multimodal analgesic regimen to Group A and Group B
47980223|NCT02987920|DRUG|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
47980224|NCT02987920|DRUG|Ketorolac|Multimodal analgesic regimen to Group A and Group B
47980225|NCT02987920|DRUG|Gabapentin|Multimodal analgesic regimen to Group A and Group B
47980226|NCT02987920|DRUG|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
48132281|NCT06500559|PROCEDURE|PRP injection|PRP (0.7 ml = 70 unit) will be injected submucosal disto-buccal and disto-palatal to the maxillary canine like the local anesthesia injection in group I experimental sides
48132282|NCT06500559|PROCEDURE|Combined decortication and PRP injection|Experimental sides will receive PRP injection after performing decortication. After administration of local anesthesia, two-line flap will be performed from the mesial surface of the maxillary second premolar to the distal surface of the maxillary canine Mucoperiosteal flap will be reflected in the buccal side. Two millimeters of marginal crestal bone will be held intact and using a high-speed drill and a round carbide bur (1mm diameter) under copious saline irrigation, the cortical wall will be penetrated to reach marrow spaces. Multiple perforations (10 holes for standardization) in the cortical bone will be created. The surgical site will then rinsed, and the flap will be repositioned and sutured.
48497663|NCT02488330|DRUG|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
48497664|NCT02357563|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
48132285|NCT01902914|PROCEDURE|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
48132286|NCT01501617|BIOLOGICAL|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
48132287|NCT01501617|DEVICE|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
48132288|NCT03471559|DRUG|Cannabidiol|single or multiple dosing
47980227|NCT02726646|DRUG|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
47980228|NCT02726646|PROCEDURE|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
47980229|NCT02726646|DRUG|Placebo|The application of 1 mg of microspheres placebo
47980230|NCT01113801|DRUG|LY2382770|Subcutaneous injection given monthly for 12 months
47980231|NCT01113801|DRUG|Placebo|Subcutaneous injection given monthly for 12 months
47980232|NCT01655550|OTHER|Withhold oral contrast|The intervention is to withhold oral contrast
47980233|NCT04070950|OTHER|Questionnaires|Two self-questionnaires
47980234|NCT00139399|PROCEDURE|Coronary artery bypass graft (CABG) surgery|Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
47980235|NCT00268957|DRUG|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
47980236|NCT00268957|DRUG|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
47980237|NCT00001576|DRUG|Melphalan|
47980238|NCT00001576|DRUG|Floxuridine|
47980239|NCT00001576|DRUG|Leucovorin|
47980240|NCT06474585|DEVICE|Plantar orthosis|Plantar orthosis taken in sitting position Plantar orthosis taken in standing position
47980241|NCT00150982|DRUG|Mechanism of action of alefacept|
47980242|NCT02837094|DRUG|C19-A3 GNP|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
48132293|NCT05677269|PROCEDURE|Laparoscopic excision of endometriosis, including colorectal endometriosis|Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
48339609|NCT05452824|OTHER|Tai Chi Prehabilitation|The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.
48339610|NCT05452824|OTHER|Usual care|Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
48339611|NCT02074904|DRUG|Topiramate|
48339612|NCT02074904|DRUG|Placebo|
48339613|NCT01562145|PROCEDURE|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
48339614|NCT05200728|DRUG|SIM1910-09|"Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
48339615|NCT05200728|DRUG|Placebo|"Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
48339616|NCT02066545|DRUG|CLS001 Topical Gel|
48339617|NCT02066545|DRUG|CLS001 Topical Gel Vehicle|
47980243|NCT02031666|DRUG|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
47980244|NCT02031666|DRUG|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
47980245|NCT00760578|DRUG|Placebo|Once daily, oral
48339618|NCT04059471|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|Full dose and 500IU/dose
48339619|NCT06033690|BEHAVIORAL|multidisciplinary guide|use of the food guide for education, clarification of doubts
48339620|NCT02822157|DRUG|Olaparib|
47980246|NCT00760578|DRUG|Pioglitazone|Once daily, oral
47980247|NCT00760578|DRUG|MSDC-0160 90 mg|Once daily, oral
47980248|NCT00760578|DRUG|MSDC-0160 220 mg|Once daily, oral
47980249|NCT04742296|DEVICE|low level laser therapy|We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
48339621|NCT02822157|DRUG|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
48497665|NCT02357563|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
47980250|NCT02279173|DRUG|Romiplostim|Romiplostim subcutaneous weekly injection
47980251|NCT04769544|DEVICE|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
47980252|NCT00326989|PROCEDURE|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
47980253|NCT01863212|PROCEDURE|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
47980254|NCT01863212|BEHAVIORAL|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
47980255|NCT01863212|OTHER|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
47980256|NCT06462807|BEHAVIORAL|ARC|ARC is an evidence-based intervention that uses three strategies (ARC principles, ARC component tools, and ARC mental models) to create organizational social contexts (OSCs) that support the implementation of interventions to improve patient outcomes.
47980257|NCT04946838|DEVICE|DS5 electrical stimulator|TENS
47980258|NCT00002714|BIOLOGICAL|bleomycin sulfate|
47980259|NCT00002714|DRUG|Stanford V regimen|
47980260|NCT00002714|DRUG|doxorubicin hydrochloride|
47980261|NCT00002714|DRUG|etoposide|
47980262|NCT00002714|DRUG|mechlorethamine hydrochloride|
47980263|NCT00002714|DRUG|prednisone|
47980264|NCT00002714|DRUG|vinblastine sulfate|
47980265|NCT00002714|DRUG|vincristine sulfate|
47980266|NCT00002714|RADIATION|radiation therapy|
48655723|NCT06642948|OTHER|Motor rehabilitation based on ai visual recognition|Patients in the intervention group will engage in a home-based exercise program in addition to standard rehabilitation guidance. Initially, patients will be provided with exercise materials developed by the intervention team, one-on-one guidance via the AI rehabilitation platform, and a detailed explanation of the exercise intervention program (including its components, foundational knowledge, and benefits).The aerobic warm-up routine includes activities such as marching in place, full-body stretches, jumping jacks, side steps with arm circles, and squats with alternating punches. For the elderly, the warm-up routine is similar but also incorporates chest expansion exercises, abduction exercises, overhead reaches, lateral movements, hip extension exercises, calf raises, and additional full-body stretches.Functional training should be done 3 to 5 times per week at an intensity of RPE 3 to 4, with each session lasting 15 to 30 minutes.
48132294|NCT05677269|PROCEDURE|In vitro fertilisation or intracytoplasmic sperm injection|IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
48655724|NCT06559462|OTHER|Focus Group|Open-ended group discussion of potential nudges to elicit constructive feedback on nudge development.
48655725|NCT06559462|OTHER|Discrete Choice|Survey involving choice between two potential nudges to elicit feedback on which nudge version is considered superior.
48655726|NCT05713110|DRUG|tazemetostat|"Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days"
48655727|NCT05713110|DRUG|HMPL-689|"Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days"
48655728|NCT05949320|OTHER|e-Motivational Interviewing|"This study evaluates a 90-day mobile phone-based intervention using the e-Motivational Interviewing app for individuals with chronic conditions like hypertension and diabetes. The app provides short conversations with health messages and reflective questions on lifestyle choices, such as physical activity and diet. The intervention incorporates change talk from Motivational Interviewing and principles from Basic Psychological Needs Theory (BPNT) to encourage positive behavior change. Users interact via multiple-choice questions, promoting self-assessment and reflection. The goal is to facilitate sustained lifestyle changes and improved health outcomes."
48655729|NCT06644326|DRUG|100mg IkT-148009 Wet|100mg wet tablet formulation
48655730|NCT06644326|DRUG|200 mg Itraconazole|2 100mg capsules
48655731|NCT06644326|DRUG|100mg IkT-148009 Dry|100mg dry tablet formulation
48655732|NCT06644326|DRUG|50mg IkT-148009 Wet|50mg wet tablet formulation
48655733|NCT05207839|DIETARY_SUPPLEMENT|Milk powder|one sachet per day dissolved in 200 ml of water
48655734|NCT05054439|DRUG|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
48655735|NCT05054439|DRUG|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
48655736|NCT04279067|DEVICE|BCI-FES dorsiflexion therapy|"BCI technology enables direct brain control of external devices such as assistive devices and prostheses by translating brain waves into control signals. When BCI systems are integrated with functional electrical stimulation (FES) systems, they can be used to deliver a novel physical therapy to improve movement after stroke. The automated software will analyze the data to generate and calibrate a BCI decoder. In the online phase, the subjects will perform 20-25 BCI-FES runs. In each run, subjects will follow 10 alternating epochs of 10-s long idling/dorsiflexion textual cues, and respond by either idling or attempting dorsiflexion to elicit BCI-FES mediated contractions of the TA muscle."
48655737|NCT04279067|BEHAVIORAL|Physiotherapy one hour|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
48497666|NCT04316507|PROCEDURE|Genetic Counselling and Testing|Oncologist-initiated brief genetic counselling and testing
48497667|NCT04393090|OTHER|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
48497668|NCT03929783|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CEM
48497669|NCT02737982|PROCEDURE|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
48497670|NCT04671186|DIETARY_SUPPLEMENT|Culturelle (Lactobacillus rhamnosus strain GG)|Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily
48497671|NCT04671186|OTHER|Placebo|Placebo group will take 1 capsule of placebo orally once daily
47980267|NCT03999372|BIOLOGICAL|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
47980268|NCT03999372|OTHER|ICSI|Normal ICSI procedure
47980269|NCT05687591|DEVICE|Amplatzer Amulet Left Atrial Appendage Occlusion Device|The Amplatzer Amulet LAAO is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constucted from a nitinol mesh and consists of a lobe and a disc connected by a central waist. Polyester patches are sewn into both the lobe and disc to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires that permit visibility during fluoroscopy.
47980270|NCT04648072|PROCEDURE|Adductor Canal Block|As previously described.
47980271|NCT04648072|PROCEDURE|Periarticular Injection|As previously described.
47980272|NCT06404216|OTHER|Nordic walking group training|"16 60-minute NW group sessions, twice weekly. Sessions will be led by a qualified healthcare professional and a graduating student.~A social worker (SP) will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period.~Communication throughout the study will be conducted via a WhatsApp forum, to motivate and sustain regular walking during and after the training period. Following 2 months of guidance the group will be launched independently, while keeping remote contact. Same frequency and schedule will be encouraged."
47980273|NCT04756492|DRUG|sandimmun|follow up for treatment response
48132298|NCT04347733|DRUG|Triamcinolone Acetonide 40mg/mL|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
48132299|NCT04347733|DRUG|Hyaluronidase Injection|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
48132300|NCT03172871|DRUG|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
48132301|NCT03172871|DRUG|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
48132302|NCT04541797|DRUG|Empagliflozin 10 MG|Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
48497672|NCT01732484|PROCEDURE|intraocular lens implantation|
48497673|NCT03861481|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
48655738|NCT04279067|BEHAVIORAL|Physiotherapy two hours|This will consist of a standardized regimen of activities typical of conventional post-stroke gait therapy, including passive/active range of motion exercises (to reduce/prevent excessive plantarflexor contractures), lower-extremity muscle strengthening, and a progression from treadmill to overground walking exercises. A total of 12 sessions will be performed at 3x/week.
48655739|NCT04809064|PROCEDURE|Arthroscopic Bankart repair procedure|Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
48655740|NCT04809064|PROCEDURE|Open Bankart|Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
48655741|NCT04809064|PROCEDURE|Latarjet|Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
48655742|NCT04809064|OTHER|Post-Operative Rehabilitation|Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
48655743|NCT00404911|BEHAVIORAL|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
48655744|NCT00404911|BEHAVIORAL|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
48655745|NCT04050839|OTHER|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
48655746|NCT04050839|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
48655747|NCT05656040|BIOLOGICAL|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
48655748|NCT05656040|DRUG|Placebo|Normal saline administered subcutaneously
48655749|NCT03969030|OTHER|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~1. ART Refill~2. SMS notifications~3. Support"
48655750|NCT06238973|OTHER|Group Low|In order to maintain arterial blood pressure within the range of 50-57 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
48655751|NCT06238973|OTHER|Group Middle|In order to maintain arterial blood pressure within the range of 58-65 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
48655752|NCT03511287|OTHER|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
48655753|NCT04209543|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily
47980274|NCT03551054|BEHAVIORAL|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
47980275|NCT03551054|BEHAVIORAL|Health Education|
47980276|NCT05004753|DIETARY_SUPPLEMENT|Artemisinin|a herbal supplement
47980277|NCT05004753|DRUG|Dexamethasone|corticosteroids
47980278|NCT06087276|DRUG|60 mg ulixacaltamide|Once daily oral treatment with titration
47980279|NCT06087276|DRUG|Placebo|Once daily oral treatment
48132303|NCT04541797|DRUG|Placebo|Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
48132304|NCT04541797|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|Imaging: All patients will have stress CMR examinations at recruitment.
48497674|NCT03861481|OTHER|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
48132306|NCT01804387|DRUG|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
48132307|NCT01804387|DRUG|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
48497675|NCT01712737|OTHER|Dietary intervention|
48132309|NCT06074679|PROCEDURE|Open cholecystectomy|The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
48497676|NCT06305130|OTHER|No intervention|No intervention
48497677|NCT03750435|PROCEDURE|AF ablation or left-sided AT ablation|According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
48497678|NCT04276844|DIAGNOSTIC_TEST|Ultrasonography using the two-dimensional (2D) mode|Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
48497679|NCT04276844|DIAGNOSTIC_TEST|Respiratory Functional Explorations|Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
48497680|NCT01647672|DRUG|Abraxane|Abraxane for neoadjuvant chemotherapy
48132315|NCT05597943|BEHAVIORAL|Malama App|The Malama smartphone application is a gestational diabetes management app that syncs directly with commercially-available glucometers via Bluetooth, enabling both automatic blood glucose logging and providing interactive diet management/diet education tools. We aim to perform a pilot study assessing the impact of the Malama smartphone application on perinatal and postpartum outcomes in patients with GDM.
48497681|NCT00231647|DRUG|topiramate|
48497682|NCT03216018|BEHAVIORAL|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
48497683|NCT03852173|BEHAVIORAL|Wasserschulen|"Schools receive following materials and trainings:~* one training sessions for teachers (at the beginning of the intervention)~* refillable water bottles for each school student~* drying rack for water bottles for each classroom~* educational material for each class and for school events~* informational material for parents"
48497684|NCT04646941|OTHER|regular treatment|The patients with or without OSA received regular hypoglycemic drugs.
48497685|NCT05504590|DEVICE|Tuohy needle group|Ultrasound-guided caudal epidural block with Touhy needle
48497686|NCT05504590|DEVICE|Quincke needle group|Ultrasound-guided caudal epidural block with Quincke needle
48497687|NCT05405972|BEHAVIORAL|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
48497688|NCT06253026|OTHER|Search and rescue mission|Air search and rescue missions lasting 15 consecutive days
47980280|NCT06101979|DEVICE|Fortiva Tissue Matrix|Acellular Dermal Matrix used in hernia surgery
47980281|NCT02516215|OTHER|No intervention|
47980282|NCT04520737|BEHAVIORAL|Physical Prehabilitation|The prehabilitation program consists of the following interventions: in-hospital high-moderate intensive exercise training, nutritional assessment and high-protein supplementation, smoking cessation, psychological support and Comprehensive Geriatric Assessment.
47980283|NCT04378218|BEHAVIORAL|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
47980284|NCT03032094|PROCEDURE|connective tissue graft|palatal connective tissue graft to attain root coverage
47980285|NCT04755803|PROCEDURE|Penoplasty|"Modified penoplasty technique:~1. Degloved the penile skin and excise the inner prepuce.~2. Advanced penoscrotal skin to cover penile shaft~3. Fixed the penis base and reconstructed the penoscrotal angle"
48132318|NCT01163981|OTHER|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
48132319|NCT02203500|DRUG|Lacidipine|
48132320|NCT02203500|DRUG|Telmisartan|
48497689|NCT01560481|DRUG|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
48497690|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
48497691|NCT01560481|DRUG|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
48132324|NCT06453616|BEHAVIORAL|Hello bundle|"Hello Bundle comprises : posters, email reminders, morning huddles, hello jar, hello board and a led example.~Participants will have to fill out a questionnaire before and after the intervention.~The main components of the questionnaire include respondent's characteristics, visitation policies, team-family interactions, family-centeredness (VAS), and practices at the end of life. ICU-conflicts (VAS), symptoms of burnout, and a VAS to rank the ethical climate, satisfaction with work, and intent to leave the job. Symptoms of burnout will be measured using the validated version of the 22-item Maslach Burnout Inventory (MBI, Human Services version)"
48132325|NCT05112549|DRUG|Nivolumab [Opdivo]|Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
48497692|NCT01560481|DRUG|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
48497693|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
48497694|NCT01560481|DRUG|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
48339622|NCT01324427|BEHAVIORAL|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
48339623|NCT04397926|DRUG|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
48339624|NCT01288586|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
48339625|NCT00136838|BEHAVIORAL|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
48339626|NCT03189407|DIETARY_SUPPLEMENT|Moringa oleifera tea|
48339627|NCT04042012|OTHER|Eccentric exercise|soleus eccentric exercise
48497695|NCT01560481|DRUG|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
48497696|NCT02390609|DRUG|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
48497697|NCT02390609|DRUG|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
48497698|NCT02390609|DRUG|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
48655754|NCT04209543|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily
48655755|NCT04209543|DRUG|Progesterone oral tablet|Progesterone oral tablet will be administered orally once daily
48132329|NCT03876457|DEVICE|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
48132330|NCT03876457|OTHER|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
48497699|NCT02390609|DRUG|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
48497700|NCT02390609|DRUG|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
48497701|NCT02390609|DRUG|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
48497702|NCT05969613|PROCEDURE|Regional block|regional block with 0.25% Bupivacaine at a dose of 2ml/kg with adrenaline
48497703|NCT05969613|PROCEDURE|Wound infiltration|Infiltration of surgical site with 0.25% Bupivacaine at 0.5ml/kg dose
48132336|NCT05329766|DRUG|Domvanalimab|Administered as specified in the treatment arm
48132337|NCT05329766|DRUG|Quemliclustat|Administered as specified in the treatment arm
48132338|NCT05329766|DRUG|Zimberelimab|Administered as specified in the treatment arm
48132339|NCT05329766|DRUG|Fluorouracil|Administered as specified in the treatment arm
48132340|NCT05329766|DRUG|Leucovorin|Administered as specified in the treatment arm
48655756|NCT05368935|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
48655757|NCT00761137|DRUG|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
48132341|NCT05329766|DRUG|Oxaliplatin|Administered as specified in the treatment arm
48132342|NCT06639997|DRUG|AZD5148|Participants will receive AZD5148 as IM injection or IV bolus
48132343|NCT06639997|DRUG|Placebo|Participants will receive matching doses of placebo as an IM injection or IV bolus
48132344|NCT06058585|DRUG|Finerenone|Finerenone 10mg or 20mg tablets, oral, once daily
48132345|NCT06058585|DRUG|Placebo Finerenone|Finerenone matched placebo tablets, oral, once daily
48132346|NCT06161987|BEHAVIORAL|Early comprehensive rehabilitation|Patients randomized to the rehabilitation intervention group will be offered comprehensive rehabilitation plan containing 18 sessions of a structured outpatient-based exercise program over 6 weeks (3 times per week).
48132347|NCT06642584|DRUG|Semaglutide B|Semaglutide B will be administered subcutaneously.
48655758|NCT00761137|DRUG|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
48132348|NCT06642584|DRUG|Semaglutide J|Semaglutide J will be administered as oral tablets.
48132349|NCT06642584|DRUG|Semaglutide L|Semaglutide L will be administered as oral tablets.
48132350|NCT06642584|DRUG|Semaglutide M|Semaglutide M will be administered as oral tablets.
48132351|NCT06642584|DRUG|Semaglutide N|Semaglutide N will be administered as oral tablets.
48132352|NCT06312020|DRUG|HZN-1116|Subcutaneous Administration
48655759|NCT00761137|DRUG|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
48132353|NCT06312020|DRUG|Placebo|Subcutaneous Administration
48497704|NCT05969613|PROCEDURE|Caudal block|Infiltration of caudal epidural space with 0.25% Bupivacaine at 1ml/kg dose
48655760|NCT00761137|DRUG|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
48655761|NCT05829044|DEVICE|Pupillometry|Pupillometer measurement of pupil size in response to different light stimuli
48655762|NCT05829044|DEVICE|Light box exposure|Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
48655763|NCT06638125|DEVICE|3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping|All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.
48655764|NCT06638125|DEVICE|3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping|The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
48655765|NCT00159445|DRUG|gemcitabine, capecitabine|
48132362|NCT01046136|DRUG|guaifenesin (Mucinex)|bid 7 days
48132363|NCT01046136|DRUG|placebo|bid 7 days
48132364|NCT03958019|OTHER|RESTORE II Program|Detailed in arm description
48497705|NCT04190719|OTHER|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~* Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~* An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~* Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
48132366|NCT02250937|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
48132367|NCT02250937|DRUG|Busulfan|Given IV
48132368|NCT02250937|DRUG|Cladribine|Given IV
48132369|NCT02250937|DRUG|Fludarabine Phosphate|Given IV
48132370|NCT02250937|OTHER|Laboratory Biomarker Analysis|Correlative studies
48132371|NCT02250937|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
48132372|NCT02250937|OTHER|Pharmacological Study|Correlative studies
48132373|NCT02250937|DRUG|Venetoclax|Given PO
48132374|NCT06513507|DIETARY_SUPPLEMENT|Cannabigerol (CBG)|The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
48497706|NCT06276036|OTHER|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
48497707|NCT04509882|DRUG|bear bile pill|Bear bile pill (15 pills) taken orally three times a day after meals with water.
48497708|NCT04509882|DRUG|placebo|Placebo(15 pills) taken orally three times a day after meals with water.
48339628|NCT04042012|OTHER|PNE|the application of galvanic current
48655766|NCT06643754|DRUG|SHR-3276|"Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy."
48655767|NCT03684980|DRUG|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
48655768|NCT03684980|DRUG|Rituximab|Patients will be treated with rituximab 500 mg/m\^2.
48655769|NCT03684980|DRUG|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
48339629|NCT04042012|OTHER|Combined|soleus eccentric exercise and PNE
48339630|NCT05286268|DIAGNOSTIC_TEST|Ischemia Modified Albumin|"Blood sampling at admission for measurement of IMA and suPAR levels and at day 10 from symptom onset (peak of symptoms) for IMA level. Samples will be collected in blood collection tubes containing K2EDTA as anticoagulant and serum separation gel tubes for SuPAR and IMA assays respectively. The samples will be centrifuged (at 3000 x g for 10 minutes) within the first 3 hours of sampling. Then, both plasma and serum samples will be placed in Eppendorf tubes and stored at -80oC. IMA levels will be determined according to the principles of the ACB assay, using the commercially available Ischemia Modified Albumin Assay Kit method (Abbexa LTD, Cambridge, UK), on the Architect c8000 automatic analytical system (Abbott, USA). SuPAR levels will be determined by the suPARnostic TurbiLatex quantitative turbidimetric immunoassay (ViroGates A/S, Denmark), also on the Architect c8000 automatic analytical system."
48655770|NCT03684980|DRUG|Glucarpidase|Glucarpidase 2000 units. Arm E 1000 units.
48655771|NCT05143411|OTHER|PRE-test|we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
48655772|NCT03471845|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
48655773|NCT03246412|DIAGNOSTIC_TEST|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
48655774|NCT06638476|OTHER|Perturbation Induced Step training|A sudden lateral displacement of the treadmill.
48655775|NCT06638476|OTHER|Voluntary step training|Voluntary steps emphasizing speed, movement of center of mass and taking larger steps.
48655776|NCT02507934|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
48655777|NCT02507934|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
48655778|NCT05580042|DRUG|AC-1101|For each patient, once daily (QD)
48132379|NCT05691842|OTHER|HIIT intervention|Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
48132380|NCT05691842|OTHER|Dual task intervention|Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
48132381|NCT05074810|DRUG|avutometinib and sotorasib|The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
48132382|NCT05074810|DRUG|avutometinib and sotorasib and defactinib|The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
48132383|NCT06477588|BEHAVIORAL|Health Navigation|Participants meet with Health Navigator twice in-person and receive 7 check-ins from the Health Navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services
48132384|NCT06477588|BEHAVIORAL|Health Navigation, Employment Navigation plus Contingency Management Intervention|Participants meet with health navigator twice in-person and receive 7 check-ins from the health navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services. Participants meeting with the employment navigator twice in-person and receive 10 check-ins from the employment navigator over 12 months. The employment navigator provides participants with referrals to employment and career development opportunities in the community and up to $200 for employment and career development support (e.g., transportation to interview, GED preparation course). Participants also receive up to $140 for HIV/STI care, treatment, and prevention milestones as part of the contingency management interview over a period of 12 months.
48497709|NCT06179927|OTHER|QT voice|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes made via tablet. In the scenario, the depictions will be presented in color. They, guided by QT Robot's narrator voice, will have to choose from two or three alternatives the one that represents the appropriate mental state by selecting it on the tablet. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
48497710|NCT06179927|OTHER|Image stimuli|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the control group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes on paper. They, guided by the narrator's voice of the operator will have to choose from two or three alternatives the one that represents the appropriate mental state by indicating it on the paper. Consequently, feedback will be provided by the operator to return information to the subject on the accuracy of the response.
48132387|NCT01010945|DRUG|erlotinib|administered orally
48132388|NCT01010945|DRUG|gemcitabine|administered intravenously
48132389|NCT01010945|DRUG|nab-paclitaxel|administered intravenously
48132390|NCT03944694|DIAGNOSTIC_TEST|Delirium assessment.|Full blood count analysis.
48497711|NCT00527306|DIETARY_SUPPLEMENT|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
48497712|NCT04995705|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components."
48497713|NCT04144478|OTHER|Web based education|Web based education
48655779|NCT03295942|DRUG|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
48132395|NCT06292936|BEHAVIORAL|Acceptance-Based Behavioral Intervention|"Intervention will evaluate acceptance-based behavioral treatment (ABT) for individuals who are experiencing weight regain after bariatric surgery. ABT builds acceptance and mindfulness skills that increase the capacity to experience uncomfortable internal states (e.g., food cravings, hunger, negative affect). Online treatments include video modules demonstrating session content as well as interactive features. These interventions are particularly desirable, reduced participant burden, and are cost effective.~ABT provides patients unique skills that directly target causes of dietary non-adherence. ABT provides patients specialized skills to directly target causes of dietary nonadherence (rather that solely repeating behavioral strategies they received during preoperative medical weight management required by their third party payers and bariatric surgery programs)."
48132396|NCT00054210|DRUG|carboplatin|
48655780|NCT06641739|DEVICE|laser assisted SPPF|A full-thickness flaps were elevated. In the test sites after the SPPF access will be performed, root surface debridement will be meticulously performed, followed by intra-marrow penetrations (IMPs), on the defect walls using a 0.25 mm wide half round bur, mounted on a slow-speed handpiece. Following this, low-level laser biostimulation of the defect will be effected with an 940 nm diode laser at 3 W power, with an uninitiated 0.6mm optical fiber tip. The defects will be irradiated for 20 seconds in a continuous noncontact mode and then retracted for 8 seconds. This will be repeated for 3 times so that the defects were effectively lased for about 60 seconds.
48655781|NCT06641739|PROCEDURE|Platelet Rich Plasma|In the second group, following the SPPF, the defect will grafted with particulated PRF, which will be overlaid with a PRF membrane, without any adjunctive defect management measures. PRF will be prepared by collecting Intra-venous blood (from the antecubital vein) in a 10-ml sterile glass tube without anticoagulant and immediately centrifuged in a centrifugation machine at 3000 rpm for 10 minutes. It will result in the separation of blood into a structured fibrin matrix in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma (platelet poor plasma) at the top. PPP will be discarded. PRF will be easily separated from the red corpuscles base using sterile tweezers and scissors.
48132397|NCT00054210|DRUG|paclitaxel|
48132398|NCT00054210|DRUG|paclitaxel poliglumex|
48132399|NCT01754051|DEVICE|PC 400 coils|
48132400|NCT06112600|PROCEDURE|VR|Virtual reality glasses were used as a distraction method for children during vaccination.
48132401|NCT06112600|PROCEDURE|Kaleidoscope|Kaleidoscope toys were used as a distraction method for children during vaccination.
48132402|NCT06221137|PROCEDURE|conventional circumferential supracrestal fiberotomy|"The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)"
48132403|NCT06221137|PROCEDURE|laser circumferential supracrestal fiberotomy|"* The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed."
48132404|NCT05909670|BEHAVIORAL|Family Advice and Support Text and Telephone (FASTT) program|The Family Advice Support Text and Telephone (FASTT) service is a telehealth model that provides on-demand, evidence-based advice and support to reduce child behavior problems, address concerns about child development, and help manage stress for caregivers of children with DD. By using text and telephone, which are widely available without disparities in access by race, ethnicity, or socioeconomic status, FASTT overcomes barriers associated with videoconferencing which requires dependable Internet and familiarity with technology use. FASTT allows support to be delivered at times and locations that are convenient for the caregiver.
48132405|NCT00787969|BIOLOGICAL|rituximab|Give IV
48132406|NCT00787969|DRUG|cladribine|Give IV
48132407|NCT00787969|DRUG|temsirolimus|Give IV
48132408|NCT00787969|BIOLOGICAL|Filgrastim|Give SC
48132409|NCT00787969|BIOLOGICAL|Pegfilgrastim|
48497714|NCT03717714|DIETARY_SUPPLEMENT|Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
48132411|NCT03367338|OTHER|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
48339631|NCT03380026|DRUG|Triamcinolone|Apply up to three times daily on select lesions.
48132412|NCT06025318|DRUG|PanCytoVir™|PanCytoVir™ 100 mg/mL oral suspension
48132413|NCT05166057|OTHER|Synchronized online telerehabilitation exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient by videoconference.
48497715|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 750 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
48497716|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
48132414|NCT05166057|OTHER|Videobased telerehabilitation exercise program|A video containing breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be given to the patient and will be asked to exercise regularly.
48339632|NCT03380026|DRUG|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
48339633|NCT00836303|BEHAVIORAL|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
48339634|NCT00415545|BEHAVIORAL|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
48497717|NCT02881840|DRUG|14C-APD421|
48497718|NCT03654469|OTHER|questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany
48497719|NCT02603393|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
48497720|NCT02603393|DRUG|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
48497721|NCT02603393|DRUG|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
48497722|NCT05068089|PROCEDURE|Nissen fundoplication|Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
48497723|NCT05068089|BIOLOGICAL|Enteral nutrition|Type and switch of enteral nutrition formula (tube, PEG, PEJ)
48497724|NCT05473962|DIAGNOSTIC_TEST|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
48497725|NCT02768714|DRUG|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
48339635|NCT00415545|BEHAVIORAL|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
48132415|NCT05166057|OTHER|Hospital based outpatient exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient in the hospital..
48132416|NCT01854385|DRUG|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
48132417|NCT01532648|DRUG|Budesonide MMX®|Oral tablet taken daily in the morning after breakfast.
48497726|NCT02768714|DRUG|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
48132418|NCT01532648|DRUG|Placebo|Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
48132419|NCT01532648|DRUG|5-ASA|"Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g"
48132420|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol - duration 3 weeks|Standard metabolic integrated rehabilitation protocol
48132421|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol + respiratory exercises - duration 3 weeks|Standard metabolic integrated rehabilitation protocol + respiratory exercises (12 sessions \[5 sessions/week for 3 weeks\])
48132422|NCT03069859|DRUG|TXA (1g)|1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
48132423|NCT03069859|DRUG|Placebo (0.9% saline)|0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
48132424|NCT03955575|DRUG|Liraglutide 6 MG/ML|Liraglutide as injections.
48132425|NCT03955575|DRUG|Colesevelam|3 x 625 miligram 2 times a day.
48132426|NCT04402112|DRUG|Pitavastatin|1mg, 2mg, or 4mg, Once a day, at least 8 weeks
48132427|NCT04752072|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
48132428|NCT04752072|BEHAVIORAL|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
48132429|NCT05403359|DRUG|Steroids|"Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28."
48132430|NCT05033522|BIOLOGICAL|AlloStim® immunotherapy|3 cycles of intradermal and intravenous administrations
48132431|NCT05033522|DRUG|FOLFOX regimen|Comparative arm: Physician Choice of FOLFOX4 chemotherapy
48132432|NCT05033522|DRUG|Sorafenib|Comparative arm: Physician Choice of Sorafenib
48132433|NCT05033522|DRUG|Lenvatinib|Comparative Arm: Physician's Choice of Levantinib
48132434|NCT03513692|DEVICE|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
48339636|NCT02870257|OTHER|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
48655782|NCT04250051|DRUG|Cytarabine|Given IV
48132435|NCT05320289|DEVICE|AblaCare System|"The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue."
48655783|NCT04250051|BIOLOGICAL|Filgrastim|Given SC
48132436|NCT02929420|DRUG|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
48132437|NCT02929420|DRUG|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
48132438|NCT06287944|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
48339637|NCT02870257|OTHER|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
48339638|NCT00524043|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
48339639|NCT00524043|DRUG|Placebo|Once daily for 6 weeks
48339640|NCT00524043|DRUG|Paliperidone ER|6 mg tablet once daily for 6 weeks
48339641|NCT06104722|OTHER|High-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
48339642|NCT06104722|OTHER|Low-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
48132439|NCT06287944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48132440|NCT06287944|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48339643|NCT01656811|DRUG|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
48339644|NCT01656811|DRUG|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
48339645|NCT01656811|DRUG|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
48132441|NCT06287944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48132442|NCT06287944|PROCEDURE|Computed Tomography|Undergo CT
48132443|NCT06287944|BIOLOGICAL|Daratumumab|Given IV
48132444|NCT06287944|PROCEDURE|Echocardiography|Undergo echocardiography
48132445|NCT06287944|DRUG|Fludarabine|Given IV
48132446|NCT06287944|PROCEDURE|Hematopoietic Cell Transplantation|Undergo SCT
48132447|NCT06287944|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
48132448|NCT06287944|DRUG|Melphalan|Given IV
48339646|NCT01656811|DRUG|Placebo|Placebo 2 actuations QID
48132449|NCT06287944|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48339647|NCT05539872|DRUG|I004|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
48339648|NCT05539872|DRUG|NovoLog|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
48339649|NCT02951455|BEHAVIORAL|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
48339650|NCT02951455|BEHAVIORAL|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
48339651|NCT02951455|BEHAVIORAL|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
48339652|NCT02951455|BEHAVIORAL|PF|Whether the intervention is delivered by a peer facilitator.
48339653|NCT02951455|BEHAVIORAL|LC|Whether the intervention is delivered by a licensed clinician.
48339654|NCT00833807|DRUG|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
48339655|NCT00748865|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
48339656|NCT00748865|OTHER|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
48497727|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
48132450|NCT06287944|PROCEDURE|Radionuclide Imaging|Undergo nuclear scan
48132451|NCT06287944|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT scan
48132452|NCT06287944|DRUG|Sirolimus|Given sirolimus
48132453|NCT06287944|DRUG|Tacrolimus|Given tacrolimus
48132454|NCT06287944|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
48132455|NCT00909961|DRUG|Zoledronic acid|
48132456|NCT06581133|DEVICE|Alarm system|Generic alarm system programmed to sound during the night to try to induce arousals from sleep.
48132457|NCT03322995|DRUG|First-line Chemotherapy|The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
48132458|NCT03322995|DRUG|Second-line Chemotherapy|Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
48132459|NCT03322995|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
48132460|NCT02925988|DEVICE|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
48132461|NCT04920253|DEVICE|Study Device Debridement|debritom+ water jet debridement
48132462|NCT04920253|DEVICE|SOC Debridement|Sharp Scalpel
48132463|NCT04319549|OTHER|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
47980286|NCT01486251|DRUG|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade \> 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
48497728|NCT00039026|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
48497729|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
47980289|NCT00066950|DRUG|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
48132464|NCT04319549|OTHER|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
47980290|NCT00066950|DEVICE|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
47980291|NCT05744154|BEHAVIORAL|Audit & feedback with educational outreach and facilitation|As in arm descriptions
47980292|NCT05744154|BEHAVIORAL|Simple audit & feedback (usual practice)|As in arm descriptions
47980293|NCT00642941|DRUG|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
47980294|NCT01617174|BEHAVIORAL|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
47980295|NCT03676595|OTHER|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
47980296|NCT03676595|OTHER|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
47980297|NCT06069245|DIETARY_SUPPLEMENT|MitoQ|80mg of MitoQ taken in one dose on one occasion.
47980298|NCT06069245|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
47980299|NCT03131050|DRUG|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
47980300|NCT03131050|DRUG|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
47980301|NCT03131050|DRUG|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
47980302|NCT02093832|OTHER|There are no specific Intervention|are no specific Intervention
47980303|NCT01709890|DEVICE|YO2(R) catheter|
48132465|NCT01921075|OTHER|normal dietary behavior|normal dietary behavior during examination days
48339657|NCT00646438|DRUG|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
48339658|NCT04434105|DRUG|platlet rich plasma (PRP)|Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.
47980304|NCT06359067|OTHER|Treated by bispecific antibodies, teclistamab or elranatamab in usual care|Treated by bispecific antibodies, teclistamab or elranatamab in usual care
47980305|NCT06359067|OTHER|Not treated by bispecific antibodies in usual care|Not treated by bispecific antibodies in usual care
47980306|NCT03634449|DEVICE|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
48132466|NCT01921075|OTHER|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
48132467|NCT05138133|DRUG|Anifrolumab|Anifrolumab intravenous infusion (IV)
48132468|NCT05138133|DRUG|Placebo|Placebo intravenous infusion (IV)
48132469|NCT03791996|PROCEDURE|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
48132470|NCT05866536|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
48655784|NCT04250051|DRUG|Fludarabine|Given IV
48655785|NCT04250051|DRUG|Fludarabine Phosphate|Given IV
48655786|NCT04250051|DRUG|Ivosidenib|Given PO
48655787|NCT06127303|DRUG|Toripalimab|Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
48655788|NCT06127303|OTHER|Cryoablation|The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
48655789|NCT00936650|DRUG|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
48655790|NCT00936650|DRUG|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
48655791|NCT02097225|DRUG|Dabrafenib|Given PO
48655792|NCT02097225|OTHER|Laboratory Biomarker Analysis|Correlative studies
48655793|NCT02097225|DRUG|Onalespib|Given IV
48655794|NCT02097225|OTHER|Pharmacological Study|Correlative studies
48655795|NCT02097225|DRUG|Trametinib|Given PO
48655796|NCT05521269|DRUG|ANX1502|ANX1502 is a prodrug of ANX1439.
47980307|NCT03634449|DEVICE|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
47980308|NCT06370832|OTHER|IMT and exercise training group|Participants will perform supervised exercise training per usual care and will be provided with a personalized prescription for an IMT program during the pre-transplant phase. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session) 5 days per week in their home environment or in-person visits. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
47980309|NCT04425174|PROCEDURE|Quadratous lumborum block|Quadratus Lumborum (QL) block is a new technique for analgesia of the abdominal wall muscles. Its mechanism depends on the injection of the local anesthetic agent between the abdominal wall muscles into the thoracolumbar fascia surrounding the Quadratus Lumborum muscle by ultrasound (US) guided technique.
48132471|NCT05866536|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
48339659|NCT04434105|DRUG|Triamcinolone Acetonide|40 mg triamcinolone acetonide
48339660|NCT04434105|DRUG|Saline|Saline
48339661|NCT06103019|OTHER|conventional complete denture|conventional complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
48497730|NCT00039026|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
48497731|NCT00429195|BEHAVIORAL|Dietary Fatty Acid Modification|
48655797|NCT05521269|DRUG|Placebo|Placebo comparator.
48655798|NCT04603560|BEHAVIORAL|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
48655799|NCT04603560|BEHAVIORAL|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
48655800|NCT05781308|DRUG|Paclitaxel|Paclitaxel 200 mg/m² every 3 weeks
48655801|NCT05781308|DRUG|Bevacizumab|Bevacizumab 15 mg/kg every 3 weeks
48655802|NCT05781308|DRUG|Atezolizumab|1200 mg every 3 weeks
48655803|NCT06641609|DRUG|Dose-Escalation (Phase Ia) CFT8919 capsule|Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.
48655804|NCT06641609|DRUG|Dose-Expansion (Phase Ib) CFT8919 capsule|Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.
48655805|NCT06641609|DRUG|Cohort-Expansion (Phase Ic) CFT8919 capsule|Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.
48655806|NCT04787809|BEHAVIORAL|Living Well|Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
48655807|NCT04171895|OTHER|Questionnaires|Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
48655808|NCT04171895|OTHER|Communication training Part 1 (no longer recruiting)|1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.
48655809|NCT04171895|OTHER|Enhanced usual care|"Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants."
48339662|NCT06103019|OTHER|3D complete denture|3D complete denture. The succession of complete denture insertion was randomized to reduce the impact of the order of the complete denture on patient satisfaction outcomes. Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months and vice versa.
48339663|NCT01270724|DRUG|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
48339664|NCT02945995|PROCEDURE|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
48339665|NCT01917890|DIETARY_SUPPLEMENT|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
48655810|NCT04171895|OTHER|Communication training Part II|Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
48655811|NCT06638775|OTHER|Fesia Grasp|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
48655812|NCT06638775|OTHER|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
48339666|NCT01917890|DIETARY_SUPPLEMENT|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
48339667|NCT04957680|BEHAVIORAL|CCBT|computer-based treatment program for depressed adolescents
48655813|NCT06644443|BIOLOGICAL|BCMA-GPRC5D CAR-T cells|patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg
48655814|NCT01738412|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
48655815|NCT03331354|BEHAVIORAL|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
48655816|NCT03331354|OTHER|Basic vocational services|self-help manual
48655817|NCT06639464|DRUG|Semaglutide|This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.
48655818|NCT06639464|OTHER|Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
48339668|NCT02068950|BEHAVIORAL|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
48339669|NCT02677623|DRUG|Pyridium|
48339670|NCT02677623|DRUG|Sodium Fluorescein|
48339671|NCT02677623|DRUG|Mannitol|
48339672|NCT02677623|OTHER|Normal Saline|
48339673|NCT00095719|DRUG|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
48339674|NCT00095719|DRUG|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
48339675|NCT04826029|OTHER|Standard strategy|In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.
48132472|NCT02488148|BEHAVIORAL|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
48655819|NCT06377748|OTHER|Facilitated tucking position|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will administer intramuscular vaccine injection into the vastus lateralis region of the left leg of the infant in the facilitated tucking position according to routine practice.
48655820|NCT06377748|DEVICE|ShotBlocker|Immediately prior to the vaccination procedure, the nurse will place the protruding surface of the ShotBlocker on the neonate's vaccination procedure site (left leg vastus lateralis muscle). The nurse will continue to hold the ShotBlocker at the injection site by pressing against the skin for 20 seconds. At the end of the time, she will grasp the tissue with the ShotBlocker and inject the vaccine through the opening in the center. After the procedure is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin.
47980310|NCT04425174|PROCEDURE|Epidural anesthesia|Epidural analgesia is a gold standard analgesic technique for the majority of abdominal surgeries, yet it has some limitations in some surgeries as colorectal surgeries due to delayed ambulation due to muscular weakness and postural hypotension.
47980311|NCT03944954|DEVICE|Placebo TMS Sham|Individuals will receive placebo dose and sham TMS.
47980312|NCT03944954|DRUG|Marinol 10Mg Capsule TMS Sham|Individuals will receive 10mg dose and sham TMS.
48132473|NCT02488148|BEHAVIORAL|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
48132474|NCT04653506|DRUG|Paracetamol 1000 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
48132475|NCT04653506|DRUG|Ibuprofen 400 mg|Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia, by envelope contains paracetamol 1000 mg or ibuprofen 400 mg
48497732|NCT04069871|DEVICE|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
48497733|NCT04069871|DEVICE|Sham TENS|Patients in the control group will receive sham TENS.
47980313|NCT03944954|DRUG|Marinol 30Mg Capsule TMS Sham|Individuals will receive 30mg dose and sham TMS.
47980314|NCT03944954|DEVICE|Placebo TMS Real|Individuals will receive placebo and real TMS.
47980315|NCT03944954|OTHER|Marinol 10Mg Capsule TMS Real|Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
47980316|NCT03944954|OTHER|Marinol 30Mg Capsule TMS Real|Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
47980317|NCT01141907|BEHAVIORAL|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
47980318|NCT01141907|OTHER|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
48132476|NCT00635869|BEHAVIORAL|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
48132477|NCT00635869|BEHAVIORAL|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
48655821|NCT06377748|COMBINATION_PRODUCT|Combined facilitated tucking and ShotBlocker|Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will place the ShotBlocker on the procedure site and apply pressure to the skin for 20 seconds. At the end of the time, the nurse will grasp the tissue with the ShotBlocker and inject the vaccine through the central opening. After the injection is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin. The newborn will continue to take facilitated tucking position until 1 minute after the ShotBlocker is removed.
48655822|NCT05781685|DRUG|Testosterone|Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
48655823|NCT05781685|OTHER|Placebo Syrup|Oil-based sublingual product.
48655824|NCT04516213|OTHER|Enteral Formula With (PHGG)|Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
48655825|NCT04021745|BEHAVIORAL|App-based mindful eating|This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
48655826|NCT03755336|OTHER|Administered Slip Perturbations|Slips will be administered in early, middle or late phases of stance during overground walking.
48655827|NCT02538809|OTHER|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
48655828|NCT06211517|OTHER|Semi-structured interviews with visual mediations|Semi-structured interviews with visual mediations / An hour-long interview
48655829|NCT06211517|OTHER|Semi-structured interviews|Semi-structured interviews
48655830|NCT06644690|BEHAVIORAL|CO-OP with Creative Dance|The CO-OP with Creative Dance intervention integrates the Cognitive Orientation to daily Occupational Performance (CO-OP) approach with structured creative dance sessions. The CO-OP approach focuses on improving cognitive and functional performance through goal-setting, problem-solving, and the use of metacognitive strategies. Creative dance sessions involve simple, rhythmic movements aimed at enhancing motor coordination, memory, and attention. This intervention is administered three times per week for 60 minutes over 8 weeks. The sessions alternate between CO-OP activities and creative dance exercises.
47980319|NCT05977582|BEHAVIORAL|Spanish version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
48132478|NCT00635869|BEHAVIORAL|Placebo|didactic education sessions on physical assessment
48497734|NCT05213143|DRUG|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
48132480|NCT03838978|DEVICE|Calypso Knee System (Implantable Shock Absorber)|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
48132481|NCT03150875|DRUG|IBI308|Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
48655831|NCT06644690|BEHAVIORAL|CO-OP Only|The CO-OP Only intervention involves the Cognitive Orientation to daily Occupational Performance (CO-OP) approach, which is designed to improve cognitive and functional performance through structured goal-setting, problem-solving, and metacognitive strategies. Participants engage in activities focused on improving their ability to perform daily tasks by using cognitive tools to develop and execute solutions. The intervention is administered three times per week for 60 minutes over an 8-week period. No additional physical or dance activities are included in this arm.
48132482|NCT03150875|DRUG|Docetaxel|As 2nd line treatment to subjects with squamous NSCLC
48497735|NCT01423656|DRUG|LEO 29102|
48497736|NCT01423656|DRUG|Placebo|Placebo Comparator: LEO 29102 vehicle
48497737|NCT01688076|PROCEDURE|Botulinum Toxin A|Forehead will be injected with Botox.
48497738|NCT04532359|DEVICE|Implant placement|Implant placement
48497739|NCT03557424|DRUG|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
48497740|NCT03557424|DRUG|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
48497741|NCT03557424|DRUG|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
48497742|NCT00698893|BIOLOGICAL|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
48497743|NCT02802631|DRUG|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
48497744|NCT02802631|OTHER|Placebo|Placebo - Normal Saline
48497745|NCT04361903|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
48497746|NCT03059004|BEHAVIORAL|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
48497747|NCT03059004|BEHAVIORAL|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
48497748|NCT03059004|BEHAVIORAL|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
48497749|NCT03059004|BEHAVIORAL|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
47980320|NCT05977582|BEHAVIORAL|Psychoeducationa Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
47980321|NCT03731780|OTHER|Personalized Treatment|Targeting individual caries risk factors
48497750|NCT03550105|DEVICE|Gentle Jogger|Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
48497751|NCT04047524|OTHER|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
48497752|NCT03312595|DEVICE|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
48497753|NCT02903992|RADIATION|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
47980322|NCT03731780|OTHER|Chlorhexidine and Remineralization|chlorhexidine mouth wash and remineralizing agent
47980323|NCT03731780|OTHER|Control|Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
47980324|NCT04687878|DRUG|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
48497754|NCT03208361|DRUG|Penicillin V|
48497755|NCT03208361|DRUG|Amoxicillin|
48497756|NCT06162104|OTHER|No intervention|No intervention
48497757|NCT03402555|OTHER|Stool pattern|Collection of stool images
48497758|NCT03024658|OTHER|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
47980325|NCT04687878|DRUG|Normal saline|twice a day, intranasally, every day for 12 weeks
47980326|NCT01329731|DRUG|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
47980327|NCT01329731|DRUG|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
47980328|NCT02887521|OTHER|education|pulmonary rehabilitation participant manual
47980329|NCT02887521|PROCEDURE|rehabilitation|pulmonary rehabilitation
47980330|NCT02887521|DEVICE|pedometer|receive a pedometer
47980331|NCT02887521|OTHER|education|receive a pamphlet with exercises plus the standard course of care
47980332|NCT02887521|PROCEDURE|surgery|patients undergo surgery
47980333|NCT04104412|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2\*10\^7
48339676|NCT04826029|OTHER|Follow-up strategy|In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
48655832|NCT04556006|OTHER|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, Framingham Risk Score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
48655833|NCT06639724|COMBINATION_PRODUCT|Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)|Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
48655834|NCT00000397|BEHAVIORAL|Behavioral insomnia therapy|
48655835|NCT04943757|DRUG|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
48655836|NCT04943757|DRUG|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
48655837|NCT02284893|DRUG|Saxagliptin|administered orally once daily
48655838|NCT02284893|DRUG|Dapagliflozin|administered orally once daily
48655839|NCT02284893|DRUG|Sitagliptin|administered orally once daily
48655840|NCT02284893|DRUG|Placebo matching with Saxagliptin|administered orally once daily
47980334|NCT04702334|DRUG|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
48655841|NCT02284893|DRUG|Placebo matching with Dapagliflozin|administered orally once daily
48655842|NCT02284893|DRUG|Placebo matching with Sitagliptin|administered orally once daily
48655843|NCT04678258|PROCEDURE|HR electroanatomic mapping and MVG catheter ablation|High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation
47980335|NCT04702334|DRUG|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
47980336|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
48339677|NCT04801641|DRUG|Placebo|Six placebo capsules taken orally twice daily
48339678|NCT04801641|DRUG|Nabilone|Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)
48339679|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
48339680|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
48497759|NCT00540293|DRUG|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
47980337|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
47980338|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
47980339|NCT00632242|DRUG|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
47980340|NCT00632242|DRUG|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
47980341|NCT01116154|DRUG|lenalidomide|Given orally
47980342|NCT01116154|DRUG|vorinostat|Given orally
47980343|NCT01116154|OTHER|laboratory biomarker analysis|Correlative studies
47980344|NCT01320761|DRUG|ATX-101-BA-free|ATX-101-BA-free
47980345|NCT01320761|DRUG|ATX-101-BA|ATX-101-BA
47980346|NCT00812890|DEVICE|semi-quantitative pregnancy test|
47980347|NCT03041545|DEVICE|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
47980348|NCT05244330|OTHER||
47980349|NCT04931108|DRUG|Nitrendipine/Atenolol|Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.
47980350|NCT04931108|DRUG|Nitrendipine|Nitrendipine 5mg, oral tablet, one pill daily.
47980351|NCT04931108|DRUG|Atenolol|Atenolol 25mg, oral tablet, one pill daily.
47980352|NCT00227435|DRUG|val-mCyd|
47980353|NCT05508191|DEVICE|Fractional CO₂ Laser|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
47980354|NCT05508191|DEVICE|Microneedle|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
47980355|NCT00905398|DRUG|Nilotinib|400mg, Oral, Bid, Daily for three years
48655844|NCT04678258|PROCEDURE|Conventional bipolar mapping and linear catheter ablation|Bipolar mapping and conventional anatomic linear catheter ablation
48339681|NCT04469257|BEHAVIORAL|Sunbathing|the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
48339682|NCT03870906|BEHAVIORAL|Occupational-specific health talk|Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
48339683|NCT03870906|BEHAVIORAL|WhatsApp interaction|Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
48339684|NCT03870906|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
48339685|NCT03870906|BIOLOGICAL|Text message|Participants will receive regular text messages with similar frequency to those in the intervention group.
48339686|NCT03681834|OTHER|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
48339687|NCT04914819|BEHAVIORAL|Online Behavioral Weight Loss Program|Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.
48339688|NCT04914819|BEHAVIORAL|Virtual weigh-in|Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
48339689|NCT05373316|RADIATION|Ultrahypofractionated MR-guided radiotherapy boost|External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to 50Gy to the intraprostatic tumor as visible on multiparametric MRI.
48339690|NCT04439812|OTHER|Observation|The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
48339691|NCT03274245|BEHAVIORAL|Intervention Package|"* Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional."
48497760|NCT01121666|DRUG|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
47980356|NCT03842124|OTHER|Force gauge|The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
48655845|NCT00847730|DEVICE|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
48655846|NCT04526925|DEVICE|Respiratory filter in-line placed with the standard mouthpiece|The respiratory filter is a device that removes solid/large particles from gas
47980357|NCT03862820|DIAGNOSTIC_TEST|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
48497761|NCT04477772|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
48497762|NCT04477772|BIOLOGICAL|Drug：JS001, Intravenous infusion|Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
48655847|NCT04526925|OTHER|Standard mouthpiece|The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
48655848|NCT05359562|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.
48339692|NCT03274245|OTHER|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
48339693|NCT03969836|DEVICE|NeurOS system|NeurOS system pads will be placed on patients' head for monitoring.
48339694|NCT03892434|DRUG|Intravitreal bevacizumab and dexamethasone implant Injection|Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
48339695|NCT03892434|DEVICE|Intravitreal dexamethasone implant|Dexamethasone implant insertion using approved kit
48339696|NCT00888212|PROCEDURE|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
48339697|NCT01802268|DRUG|Conversion from Tacrolimus to Sirolimus|
48339698|NCT01802268|DRUG|Maintenance on tacrolimus|
48339699|NCT03725449|OTHER|Best Practice|Receive standard of care
48339700|NCT03725449|BEHAVIORAL|mySmartCheck|Receive access to mySmartcheck program
48339701|NCT03725449|OTHER|Survey Administration|Ancillary studies
48655849|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.|At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).
47980358|NCT02985554|DRUG|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
48132483|NCT06458179|PROCEDURE|Ultrasound-guided proximal greater occipital nerve radiofrequency ablation|In the prone position with the head slightly flexed and the US probe was placed in the neck transversely and then was located the bifid spinous process of C2 and the probe was lateralized (toward the affected side). At this level, the GON is located above the obliquus capitis inferior muscle and deeper than the semispinalis capitis muscle. The in-plane approach from medial to lateral was employed to treat the nerve with a 21 G 5-mm active tip radiofrequency needle. Sensory stimulation was administered at 50 Hz for 1 ms to induce paresthesia, pain, or irritation. A motor stimulus was applied at 2 Hz for 1 ms and up to 2 volts to see if fasciculation was absent. Then 1 mL of 2% lidocaine was administered through the RF cannulas to alleviate procedure related pain. Conventional RFA was conducted for 60 seconds at a temperature of 60 degrees. Following the procedure, 2 mg of dexamethasone was administered per lesion site.
48132484|NCT00982072|DRUG|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
48132485|NCT00982072|DRUG|prednisolone|Prednisolone 1mg/kg maximum 60mg od
48132486|NCT06300229|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
48339702|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
48339703|NCT01225276|DRUG|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
48655850|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.|Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
48339704|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
48339705|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
47980359|NCT05605314|OTHER|Cyclosporine|eye drop
47980360|NCT02341053|OTHER|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
48132487|NCT06300229|DRUG|sodium chloride|Subcutaneous injection with NaCl once
48132488|NCT06430866|DRUG|ABP 234|Administered by intravenous (IV) injection.
48132489|NCT06430866|DRUG|Pembrolizumab|Administered by IV injection.
48339706|NCT03254862|PROCEDURE|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
48339707|NCT03254862|PROCEDURE|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
48339708|NCT06260072|DRUG|magnesium and riboflavin supplement|Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)
48339709|NCT01385319|DEVICE|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
48339710|NCT01385319|DEVICE|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
48339711|NCT01821404|DRUG|Atorvastatin|Capsules including 80 mg of atorvastatin
48339712|NCT01821404|DRUG|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
48339713|NCT03258944|OTHER|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
48339714|NCT01375738|PROCEDURE|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\~40cm from the new gastric-jejunal junction.
48339715|NCT01375738|PROCEDURE|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
48339716|NCT02106572|DRUG|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
48339717|NCT02106572|DRUG|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
48339718|NCT02556411|DRUG|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
48339719|NCT02556411|DRUG|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
48339720|NCT00910728|DRUG|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
48339721|NCT02024945|DRUG|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
48339722|NCT01846689|DRUG|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
48339723|NCT01369446|DEVICE|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
48339724|NCT04673344|DEVICE|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
48497763|NCT04905030|BEHAVIORAL|Information T1|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in non-scientific, non-statistical terms and is emotionally charged: the consequences of cervical cancers are portrayed by testimonies of cancer survivors from Sweden.
48497764|NCT04905030|BEHAVIORAL|Information T2|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in scientific terms and incidence and mortality statistics are reported. The information is not emotionally charged but rather aseptic.
47980361|NCT00111592|PROCEDURE|current usual care|current usual care
48339725|NCT05097170|PROCEDURE|NIRS during ventricular tachycardia ablation|"NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia."
48339726|NCT04876963|DEVICE|Holter-monitor|7-day holtermonitoring of each patient
48339727|NCT01041001|BIOLOGICAL|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
48339728|NCT01041001|PROCEDURE|Microfracture treatment|
48339729|NCT00002268|DRUG|Sevirumab|
48339730|NCT05410977|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
48339731|NCT05410977|OTHER|Electronic Health Record Review|Medical records reviewed
48339732|NCT04263493|OTHER|Rehabilitation (physiotheraphy)|Time of loading, range of motion exercises, strength training
48339733|NCT01953367|DRUG|Vantobra (tobramycin)|Inhalation
48339734|NCT01953367|DRUG|TOBI (tobramycin)|Inhalation
47980362|NCT00111592|PROCEDURE|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
47980363|NCT02136524|DRUG|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
47980364|NCT02136524|DRUG|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
47980365|NCT03402386|DRUG|MT-6548|Oral tablet
47980366|NCT03982823|PROCEDURE|Hand-Sewn Sleeve Gastrectomy|After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.
48339735|NCT01952704|BEHAVIORAL|Aerobic exercise|
48339736|NCT01952704|BEHAVIORAL|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
48339737|NCT04030468|OTHER|Educational intervention addressed to general practitioners|"* feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course"
48339738|NCT04030468|OTHER|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
48339739|NCT04518722|RADIATION|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
48339740|NCT04518722|RADIATION|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
48339741|NCT04518722|OTHER|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
48339742|NCT03368352|DIETARY_SUPPLEMENT|Melatonin|Dietary supplement melatonin
48339743|NCT03368352|OTHER|Hypoxia|Sleep in a hypoxic tent simulating high altitude
48339744|NCT02883920|OTHER|Allergy and respiratory functional tests|
48339745|NCT05616845|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
48339746|NCT02685111|DRUG|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
47980367|NCT03982823|PROCEDURE|Stapled Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
47980368|NCT03555201|OTHER|Manual therapy|protocol of soft tissues techniques
48339747|NCT02685111|DRUG|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
48339748|NCT04125992|PROCEDURE|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
48339749|NCT04125992|PROCEDURE|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
48339750|NCT04409626|OTHER|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
48339751|NCT00509652|PROCEDURE|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
48339752|NCT00509652|PROCEDURE|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
48339753|NCT03476967|PROCEDURE|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
48339754|NCT05821036|BEHAVIORAL|Activitiy Management|"Activity Management training will be applied for 5 weeks, 2 sessions per week, and the 1st and 10th sessions will be pre and post-training evaluation, a total of 10 individual, internet-based sessions.~Week 1:Awareness training and ergonomics training including spine anatomy, correct posture use, ergonomic strategies were planned to increase awareness about FMS. Week 2:Focusing on the challenging activities stated by the individuals, it is aimed to change the behavior by arranging the activity resting cycle in daily life. In addition, the management, adaptation and modification of the activities will be provided within the scope of time management training. Week 3: Joint and energy conservation principles training will be given and it is aimed to create body mechanics and proper posture suitable for activities.Week 4: Relaxation training will be provided as a method of coping with pain.Week 5: Re-evaluation/review of the targets set to reduce pain during activities will be provided."
48339755|NCT01333462|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
48339756|NCT01333462|OTHER|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
48339757|NCT06238011|DRUG|Dexmedetomidine|Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
48339758|NCT06238011|DRUG|Normal saline|Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
47980369|NCT03555201|OTHER|Regular treatment control.|Regular treatment control.
47980370|NCT05261360|DRUG|SF-MSC-EX|Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
47980371|NCT05261360|DRUG|SF-MSC|Intra-articular administration of synovial fluid-derived mesenchymal stem cells
47980372|NCT04398498|DIAGNOSTIC_TEST|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
48132490|NCT04310449|PROCEDURE|Connective tissue graft and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
47980373|NCT00717340|DRUG|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
48339759|NCT05610969|OTHER|Music|patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff
47980374|NCT00754624|DRUG|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
47980375|NCT04958005|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
47980376|NCT06469983|DEVICE|ErigoBasic or ErigoPro®|Static bed with integrated robotic stepper (ErigoBasic) and optionally integrated with Functional Electrical Stimulation (FES ErigoPro®). The Erigo is a robot designed to be used for early functional mobilisation of patients with neurological manifestations or who are bedridden, even in intensive care. It is a tilt table equipped with an integrated passive stepper controlled by microprocessors that generate physiological leg movements: the patient's thighs are secured by straps to the movement mechanisms and the feet are secured to plates equipped with shock absorbers, while the upper body is held in place by a sling integrated into the table. Erigo provides active functions: gradual elevation in orthostatism up to 90°, controlled and independent mobilisation of the lower limbs, and functional stimulation.
47980377|NCT06469983|BEHAVIORAL|Traditional Verticalization|gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
47980378|NCT00390858|DRUG|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
47980379|NCT05381116|DEVICE|Avation System|Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
47980380|NCT05381116|DEVICE|Sham Avation System|Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
47980381|NCT00053040|BIOLOGICAL|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
47980382|NCT00053040|PROCEDURE|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
48132491|NCT04310449|PROCEDURE|Dual zone concept and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
48132492|NCT02963571|PROCEDURE|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
48497765|NCT04905030|BEHAVIORAL|Information C|A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.
48497766|NCT04016961|OTHER|AAT - Dog|therapy dog added to inpatient PT and OT session
48497767|NCT04016961|OTHER|TAU - No Dog|PT and OT as usual without the addition of therapy dog
48497768|NCT02078336|DRUG|Midazolam Mylan|
47980383|NCT04371991|DIAGNOSTIC_TEST|blood test|blood test (serum samples) for biochemical examination
48497769|NCT02078336|DRUG|Lorazepam Mylan|
48497770|NCT02078336|DRUG|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
48132497|NCT05671484|OTHER|Transversalis Fascial Plane Block|Patients will receive ultrasound-guided transversalis fascial plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
48132498|NCT05671484|OTHER|Quadratus Lumborum Plane Block|Patients will receive ultrasound-guided quadratus lumborum plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
48132500|NCT06581406|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
48497771|NCT01118286|DRUG|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
48497772|NCT00152724|DEVICE|pressure strain system, iontophoresis|
47980384|NCT03433768|GENETIC|Real time PCR|We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
48132501|NCT06581406|BIOLOGICAL|Ipilimumab|Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
48132502|NCT06581406|BIOLOGICAL|Nivolumab|Nivolumab: Anti-PD-1 Monoclonal antibody
48339760|NCT05610969|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
48339761|NCT04884945|PROCEDURE|Open Pyeloplasty (OP)|Open approach for the surgical correction of UPJ obstruction
48339762|NCT04884945|DEVICE|Robotic-Assisted Laparoscopic Pyeloplasty (RALP)|Robotic approach with the da Vinci Surgical System for the surgical correction of UPJ obstruction
48339763|NCT01318668|BIOLOGICAL|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
48339764|NCT06501040|OTHER|Web-based Educational Intervention|View web-based educational video
48339765|NCT06501040|OTHER|Questionnaire Administration|Pre video baseline survey and a post video educational survey
48339766|NCT01160263|DRUG|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
48339767|NCT06339606|OTHER|Biospecimen collection|Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.
48339768|NCT03638713|BEHAVIORAL|colonoscopy first|Received water exchange colonoscopy followed by EGD
48339769|NCT03638713|BEHAVIORAL|EGD first|Received EGD followed by water exchange colonoscopy
48339770|NCT02925312|OTHER|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
48339771|NCT00260195|BEHAVIORAL|School-based cognitive behavioral support group|
48497773|NCT00152724|DRUG|scopolamin|
48497774|NCT00152724|DRUG|emla|
48497775|NCT00152724|DRUG|capsaicin|
48497776|NCT00152724|DRUG|aspirin|
48497777|NCT00152724|DRUG|clopidogrel|
47980385|NCT02229747|DRUG|Meloxicam|
48339772|NCT04812860|DRUG|HR18042|Tablet, Dosing frequency: once daily, Route of administration: oral
48339773|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
47980386|NCT02229747|DRUG|Diclofenac|
48132503|NCT02482701|DEVICE|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
48497778|NCT00152724|DRUG|celecoxib|
48497779|NCT00152724|DRUG|indomethacin|
48339774|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
48339775|NCT04812860|DRUG|Tramadol hydrochloride ER|Tablet,Dosing frequency: once daily, Route of administration: oral
48339776|NCT04812860|DRUG|Placebo|Tablet,Dosing frequency: once daily, Route of administration: oral
48339777|NCT03818711|BEHAVIORAL|Communication & Coping Intervention|Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.
48497780|NCT00152724|DRUG|acetylcholine|
48497781|NCT00152724|DRUG|sodium nitroprusside|
48497782|NCT00152724|DRUG|brethyllium|
48497783|NCT00152724|DEVICE|general and local heating|
48497784|NCT03906396|DEVICE|Xbox 360 Kinect|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
48339778|NCT03818711|BEHAVIORAL|Education & Check Ins|Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
48339779|NCT00329784|BIOLOGICAL|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
48339780|NCT02305290|PROCEDURE|Endoscopic Mucosal Resection|
48497785|NCT05302830|BEHAVIORAL|Snackability app|This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).
48497786|NCT05302830|BEHAVIORAL|Control group|The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
48497787|NCT04475783|COMBINATION_PRODUCT|Percutaneous Transluminal Angioplasty (PTA)|PTA with an drug-coated balloon catheter (DCB) in the femoropopliteal artery
48497788|NCT06015243|DRUG|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
48655851|NCT05395312|OTHER|Online blended stepped-care mental well-being platform|"Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~* Topic-based personal growth articles, exercises, and chatbots~* Webinars and talks on varied mental health related topics~* Virtual support community~Level 3 (mild to moderate)~* Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~* Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy"
48132506|NCT05837533|OTHER|Communication model|During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
48132507|NCT05562427|BEHAVIORAL|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
48497789|NCT05763108|DIAGNOSTIC_TEST|genetic test|COL1A1 or COL5A1 genetic test
48497790|NCT05763108|OTHER|Beighton joint laxity test|Based on Beighton scale.
48132510|NCT06527404|DRUG|Rocatinlimab|SC Injection
48132511|NCT06527404|DRUG|Placebo|SC Injection
48497791|NCT02788682|GENETIC|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
48497792|NCT01212354|RADIATION|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
48497793|NCT04690517|PROCEDURE|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
48497794|NCT00093600|DRUG|cytarabine|
48132516|NCT06058377|PROCEDURE|Biospecimen Collection|Undergo optional collection of tissue and/or blood
48132517|NCT06058377|DRUG|Cyclophosphamide|Given IV
48132518|NCT06058377|DRUG|Doxorubicin|Given IV
48132519|NCT06058377|BIOLOGICAL|Durvalumab|Given IV
48132520|NCT06058377|OTHER|Genetic Testing|Undergo MammaPrint testing
48132521|NCT06058377|PROCEDURE|Mammography|Undergo mammography
48132522|NCT06058377|DRUG|Paclitaxel|Given IV
48132523|NCT06058377|OTHER|Quality-of-Life Assessment|Ancillary studies
48132526|NCT05990933|DRUG|Adrenaline|Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
48339781|NCT04731922|DRUG|TAK-510|TAK-510 solution.
48339782|NCT04731922|DRUG|TAK-510 Placebo|TAK-510 placebo-matching solution.
48339783|NCT03419845|DEVICE|Step Right Buddy|The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
48339784|NCT06298760|COMBINATION_PRODUCT|Knee Massage With Black Cumin Oil Group:|The patients received a knee massage with black cumin oil once a week for approximately 30 minutes for 6 weeks.
48655852|NCT03424733|DRUG|Plegridy|Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
48655853|NCT03424733|DRUG|Prednisone|Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
48132527|NCT06057974|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention."
48339785|NCT06298760|COMBINATION_PRODUCT|Foot Reflexology Group With Black Cumin Oil|The patients underwent foot reflexology with black cumin oil once a week for approximately 40 minutes for 6 weeks.
48339786|NCT06298760|COMBINATION_PRODUCT|placebo group|Applications were made with vaseline
48339787|NCT06260800|OTHER|Validation CEQ|In initial assessment, EQ-5D-5L and HADS questionnaires were completed. After sessions 1 and 2, CEQ and WAI-S were filled. Finally, EQ-5D-5L was completed before the fourth session.
48339788|NCT03582852|PROCEDURE|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
48497795|NCT00093600|DRUG|daunorubicin hydrochloride|
48497796|NCT00093600|DRUG|midostaurin|
48497797|NCT05227300|DRUG|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
48497798|NCT05227300|DRUG|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
48655854|NCT03424733|DRUG|Tylenol Pill|Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
48655855|NCT06629103|DIETARY_SUPPLEMENT|life's Omega 1035DS|A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
47980387|NCT02229747|DRUG|Nimesulide|
47980388|NCT00892853|PROCEDURE|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
48497799|NCT00605761|DRUG|SB656933|50 mg treatment
48497800|NCT00605761|DRUG|SB656933|150 mg treatment
48497801|NCT02789397|DRUG|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
48497802|NCT02789397|DRUG|Placebos|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
48132528|NCT06507345|OTHER|Opioid Analgesia (OA) [Multimodal analgesia including opioid drugs]|In line with current standard care, discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs given at regularly scheduled intervals) and opioid tablets 'as needed' for breakthrough pain (i.e., pain that erupts while patients are already taking analgesics). Non-pharmacological pain interventions (i.e., icepacks, music, meditation.) may be recommended by some surgeons as part of standard practice. Given the pragmatic nature of the trial, the specific around-the-clock analgesia and rescue opioid regimens and other non-pharmacological interventions will be determined by the patient's surgeon discretion considering the breast procedure undertaken, co-morbidities, and patient preference.
48132529|NCT06507345|OTHER|Opioid-Free Analgesia (OFA) [Multimodal analgesia not including opioid drugs]|Discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs). In case of breakthrough pain, rescue analgesia may be provided by (1) using evidence-based non-pharmacological pain interventions (i.e., icepacks, music, and meditation), (2) adding non-opioid drugs not included in the initial regimen, or (3) switching drugs targeting individual variances in analgesia response. The specific around-the-clock and rescue OFA regimens will be determined by the patient's surgeon considering the type of procedure, co-morbidities, and patient preference.
48497803|NCT03993730|DEVICE|ICD|Insertion of ICD in patients with LVEF \<45% and LGE on CMR.
48497804|NCT03993730|DEVICE|ILR|Insertion of ILR in patients with LVEF \<45% and LGE on CMR.
48132532|NCT05317390|DIAGNOSTIC_TEST|DystoniaNet-based diagnosis of isolated dystonia|DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
48132533|NCT05564377|DRUG|Alpelisib|Given PO
48132534|NCT05564377|DRUG|Binimetinib|Given PO
48132535|NCT05564377|PROCEDURE|Biopsy|Undergo biopsy
48339789|NCT06398951|DEVICE|Two nare high flow nasal cannula|Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.
48132536|NCT05564377|PROCEDURE|Biospecimen Collection|Undergo blood collection
48132537|NCT05564377|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48132538|NCT05564377|PROCEDURE|Bone Scan|Undergo bone scan
48132539|NCT05564377|PROCEDURE|Computed Tomography|Undergo CT
48132540|NCT05564377|PROCEDURE|Echocardiography|Undergo ECHO
48132541|NCT05564377|DRUG|Fluorouracil|Given IV
48132542|NCT05564377|DRUG|Fulvestrant|Given IM
48339790|NCT00005969|DRUG|Chemotherapy|
48339791|NCT00005969|DRUG|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
48339792|NCT04029623|OTHER|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
48497805|NCT03862066|OTHER|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
48497806|NCT03862066|OTHER|Tissue collection|Left over tissue will be collected at the time of surgery
47980389|NCT03569540|DRUG|Glibenclamide|Placebo-controlled; Double blind test
47980390|NCT03569540|OTHER|Placebo|Amylum
48132543|NCT05564377|DRUG|Ipatasertib|Given PO
48132544|NCT05564377|DRUG|Leucovorin|Given IV
48132545|NCT05564377|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48132546|NCT05564377|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48132547|NCT05564377|PROCEDURE|Mutation Carrier Screening|Undergo tumor mutational screening
48132548|NCT05564377|DRUG|Neratinib Maleate|Given PO
48132549|NCT05564377|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO
48132550|NCT05564377|DRUG|Olaparib|Given PO
48497807|NCT03420664|DEVICE|Orthosis VACOped|Orthosis for lower limb immobilisation
48497808|NCT03420664|DEVICE|Below knee cast|Below knee cast for lower limb immobilisation
48497809|NCT05385159|DRUG|AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION|Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay
48497810|NCT05385159|DRUG|Placebo|Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
48132551|NCT05564377|DRUG|Oxaliplatin|Given IV
48132552|NCT05564377|DRUG|Paclitaxel|Given PO or IV
48132553|NCT05564377|DRUG|Palbociclib|Given PO
48132554|NCT05564377|BIOLOGICAL|Panitumumab|Given IV
48132555|NCT05564377|PROCEDURE|Positron Emission Tomography|Undergo PET
48132556|NCT05564377|DRUG|Selumetinib Sulfate|Given PO
48655856|NCT06629103|DIETARY_SUPPLEMENT|Fish Oil|Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.
48655857|NCT06629103|OTHER|Placebo|The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.
48655858|NCT06629103|DIETARY_SUPPLEMENT|life's Omega O3020DS|A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
48655859|NCT01198691|DEVICE|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
48655860|NCT01198691|DEVICE|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
48655861|NCT01400412|DRUG|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
48655862|NCT01400412|DRUG|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
47980391|NCT01091493|DRUG|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
47980392|NCT02313181|OTHER|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
47980393|NCT02313181|OTHER|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
47980394|NCT01366521|BIOLOGICAL|Mepolizumab|Monoclonal antibody
47980395|NCT02248155|DRUG|Pramipexole|
47980396|NCT04488289|OTHER|Lifestyle|Cardiovascular risk and lifestyle
47980397|NCT01454622|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
47980398|NCT01454622|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
47980399|NCT05944809|DRUG|rhTPO|"Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV\>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)"
47980400|NCT06495047|DRUG|Long-acting bronchodilator therapy (LABD)|Long-acting inhaler therapy
47980401|NCT06495047|DRUG|Short-acting bronchodilator therapy (SABD)|Short-acting inhaler therapy
47980402|NCT02732704|DEVICE|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
47980403|NCT01569490|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
47980404|NCT01569490|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
47980405|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
47980406|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
47980407|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
47980408|NCT01080352|DRUG|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
47980409|NCT04333823|DRUG|Dapagliflozin 5mg|Dapagliflozin tablet
47980410|NCT04333823|DRUG|Placebo|Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
47980411|NCT00604539|DRUG|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
48655863|NCT01400412|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
48655864|NCT01400412|DRUG|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
48655865|NCT01400412|DRUG|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
48655866|NCT01400412|DRUG|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
48655867|NCT01400412|DRUG|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
48655868|NCT04163081|BEHAVIORAL|Quit Card Intervention (QCI)|"The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist."
48655869|NCT06639087|DRUG|AZD5462|Participants will receive AZD5462 on top of dapagliflozin once daily.
48655870|NCT06639087|DRUG|Dapagliflozin|Participants will receive dapagliflozin once daily with AZD5462 or placebo.
47980412|NCT00604539|DRUG|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
48132557|NCT05564377|DRUG|Sotorasib|Given PO
48655871|NCT06639087|OTHER|Placebo|Participants will receive placebo on top of dapagliflozin once daily.
48497811|NCT01167322|DRUG|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
48339793|NCT04029623|OTHER|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
48339794|NCT04972266|DEVICE|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
48339795|NCT00127699|PROCEDURE|Alcohol swab of umbilical cord|
48339796|NCT02936336|OTHER|exercise|circuit exercise, aerobic dance and Tai Chi exercise
48655872|NCT06641544|DRUG|Inetetamab|Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
48655873|NCT03533569|PROCEDURE|Intra-articular corticosteroid injection|Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
48655874|NCT05823259|OTHER|Hybrid Telehealth Program: Respiratory Muscle Training and Patient Education|"A testing session will be held where subjects will undergo respiratory muscle testing using the Pro2Fit device to measure PIMax and PEmax. During this session, subjects will be instructed in a respiratory muscle training home program utilizing a provided device call the Breather. They will be instructed to perform this program consisting of breathing exercises for 2 sets of 10 repetitions, twice a day at a difficulty level of 5-7 on the Visual Analogue Scale (VAS) scale for 8 weeks. Subjects will be shown how to follow a training program every day utilizing the free companion application to the device Breather Coach. If subjects have issues with using technology, they will be provided a physical log to record when they complete sessions. Ten to fifteen-minute Zoom sessions with the study coordinator will be held once a week to check in on how the program is progressing, compliance, and if the resistance can be increased."
47980413|NCT00426855|DRUG|Bendamustine|starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w
48339797|NCT01376388|DRUG|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
48339798|NCT02327312|DEVICE|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
48339799|NCT02327312|PROCEDURE|Laser|Laser Trabeculoplasty
47980414|NCT00426855|DRUG|Bortezomib|weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w
47980415|NCT05459324|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
47980416|NCT01779102|BIOLOGICAL|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
47980417|NCT01779102|BIOLOGICAL|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
47980418|NCT01779102|BIOLOGICAL|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
47980419|NCT03158064|DRUG|Durvalumab|1500 mg by IV
47980420|NCT03158064|DRUG|Tremelimumab|"75 mg by IV~\*300mg"
47980421|NCT02431234|OTHER|serum RANKL|
48497812|NCT04428515|DEVICE|Photoacoustic Imaging System|Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
47980422|NCT02999854|BIOLOGICAL|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
47980423|NCT02999854|DRUG|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
47980424|NCT02999854|PROCEDURE|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
47980425|NCT02999854|PROCEDURE|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
48497813|NCT00267449|DEVICE|SoftScan Optical Breast Imaging System|
48497814|NCT05850988|OTHER|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
48497815|NCT05850988|OTHER|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
48339800|NCT02327312|DEVICE|Laser Trabeculoplasty|
48339801|NCT00543868|DRUG|MK0782|
48339802|NCT04024241|DEVICE|Flow Cytometer|high dose
48339803|NCT04024241|DRUG|Mitoxantrone|high dose
48132562|NCT01370928|DEVICE|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
48132563|NCT01370928|DEVICE|Standard colonoscope|Screening colonoscopy
48497816|NCT05445674|COMBINATION_PRODUCT|Plasma Exchange Procedure|Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
48497817|NCT05445674|OTHER|Sham Plasma Exchange Procedure|For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
48497818|NCT02275130|PROCEDURE|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
48497819|NCT02275130|DEVICE|Radiesse Voice (Calcium Hydroxyapatite)|
48655875|NCT05823259|OTHER|Standard Physical Therapy Care|A group of patients who receive standard physical therapy care for chronic constipation at the University of Miami that consists of biofeedback therapy, manual therapy, therapeutic exercise, and patient education.
48655876|NCT02668757|BEHAVIORAL|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
48132565|NCT06132529|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI) Scan|Imaging of the brain
48132566|NCT06132529|OTHER|Speech Sample|Recorded reading aloud of pre-written words and sentences
48132567|NCT06132529|OTHER|Electronic Daily Headache Diary|Headache diary to provide information about headaches experience that day.
48497820|NCT02925507|OTHER|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
48497821|NCT06156189|DIETARY_SUPPLEMENT|Enteral Feeding|Feeding via Nasogastric tube in intubated and ventilated patients
48497822|NCT06112392|DIAGNOSTIC_TEST|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）|Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
48497823|NCT06112392|DIAGNOSTIC_TEST|Treatment （Oral standard anti-Parkinson's drugs）|Treatment （Oral standard anti-Parkinson's drugs）
48497824|NCT01204450|DRUG|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
48497825|NCT01204450|DRUG|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
48655877|NCT04077320|BEHAVIORAL|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
48655878|NCT04077320|BEHAVIORAL|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
48655879|NCT05245175|OTHER|Sodium chloride particles|Patients are exposed to sodium chloride particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
48655880|NCT05245175|OTHER|Lactose particles|Patients are exposed to lactose particles alone for 4 hours in the Fraunhofer Allergen Challenge Chamber.
48132577|NCT03769415|DEVICE|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
48132578|NCT04530630|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.
48132579|NCT06548607|DRUG|RD06-04 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
48339804|NCT04024241|DRUG|Cytarabine|high dose
48497826|NCT00107705|BIOLOGICAL|Tree MATA MPL|
48497827|NCT01600690|OTHER|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
48655881|NCT05245175|OTHER|Clean air|Patients are exposed to clean air for 4 hours in the Fraunhofer Allergen Challenge Chamber.
48655882|NCT05245175|OTHER|Sodium chloride particles with house dust mite|Patients are exposed to sodium chloride particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
48132582|NCT05776888|OTHER|Ofatumumab|There is no treatment allocation. For both cohorts, only patients that have received Ofatumumab treatment for at least 3 months prior to inclusion in the study will be enrolled.
48132583|NCT00412646|DRUG|TMC125|
48132584|NCT05112601|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and/or blood samples
48132585|NCT05112601|PROCEDURE|Computed Tomography|Undergo CT
48132586|NCT05112601|BIOLOGICAL|Ipilimumab|Given IV
48132587|NCT05112601|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48339805|NCT01609725|DEVICE|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
48132588|NCT05112601|BIOLOGICAL|Nivolumab|Given IV
48339806|NCT01609725|DEVICE|Oral prophylaxis|One session of supraginigval calculus removal
48655883|NCT05245175|OTHER|Lactose particles with house dust mite|Patients are exposed to lactose particles coupled with D. pteronyssinus for 4 hours in the Fraunhofer Allergen Challenge Chamber.
48655884|NCT05788991|DRUG|Dequalinium Chloride|Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days
48655885|NCT05788991|DRUG|Metronidazole Oral|Metronidazole oral tablets (500 mg) taken twice a day for 7 days
47980426|NCT02024633|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
47980427|NCT02024633|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
48132589|NCT05055063|DRUG|Belantamab mafodotin|by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
48132590|NCT04543903|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
48339807|NCT03549819|DRUG|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
48497828|NCT03830918|BIOLOGICAL|Atezolizumab|Given IV
48497829|NCT03830918|DRUG|Niraparib|Given PO
48655886|NCT01275300|DRUG|Aspirin|
48497830|NCT03830918|OTHER|Quality-of-Life Assessment|Ancillary studies
48655887|NCT01275300|DRUG|Placebo|
48655888|NCT01275300|DRUG|Niacin|
47980428|NCT03898141|OTHER|Placebo (PL)|"Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain."
48497831|NCT03830918|OTHER|Questionnaire Administration|Ancillary studies
48497832|NCT03830918|DRUG|Temozolomide|Given PO
48497833|NCT04579016|OTHER|PAIGE2 lifestyle intervention|Education session during pregnancy. provision of fitness tracker, referral to commercial weight management organization, text and phone support
48497834|NCT04579016|OTHER|Standard care|Care routinely provided to all pregnant women diagnosed with GDM
48497835|NCT05303337|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and W52
48497836|NCT05303337|OTHER|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
48497837|NCT05691686|OTHER|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
48498117|NCT04331561|BEHAVIORAL|sensory re-weighting|Participants will be supported in quiet standing by a safety harness and crisscrossing strap system. A cervical collar will be used to maintain consistent alignment between the head and trunk. A virtual reality headset is used to create a virtual environment in which visual stimuli will be presented. Three different body positions will be used during training: earth-vertical and clockwise and counterclockwise tilted 16º in the frontal plane. Sensory re-weighting will be driven by priming upregulation of somatosensory cues. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity.
48367388|NCT04225026|DRUG|GC4419 (avasopasem manganese)|90 mg, by 60-minute IV infusion, prior to each fraction of RT
48367389|NCT05109949|DRUG|Dapagliflozin 10Mg Tab|Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
47980587|NCT06248892|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
47980588|NCT00505531|DRUG|Tramadol Extended Release Oral Capsule|Tramadol ER- up to either 200 mg or 300 mg based on randomization
47980589|NCT00505531|DRUG|Benadryl|Placebo group will take up to 25 mg of Benadryl
47980590|NCT03684395|DRUG|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
47980591|NCT03684395|DRUG|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
47980592|NCT05699798|OTHER|Conservative Treatment (CT)|Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
47980593|NCT05699798|OTHER|Instrument-assisted Soft Tissue Mobilization (IASTM)|"IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
47980594|NCT05699798|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|"ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
47980595|NCT00638768|OTHER|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
47980596|NCT03176251|OTHER|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
47980597|NCT00481000|BEHAVIORAL|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
47980598|NCT05544357|OTHER|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
47980599|NCT05544357|OTHER|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
47980600|NCT01676389|OTHER|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
47980601|NCT01676389|OTHER|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
47980602|NCT01945957|DRUG|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
47980603|NCT04224311|BIOLOGICAL|Menactra|0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
47980604|NCT03796429|DRUG|GS+Toripalimab|"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."
47980605|NCT01031732|PROCEDURE|MIS-2 THA|MIS two-incision THA
47980606|NCT01031732|PROCEDURE|MIS-WJ|MIS-Watson Jones THA
47980607|NCT01031732|PROCEDURE|MIS-AL THA|Transgluteal approach
47980608|NCT01031732|PROCEDURE|MIS-PL THA|Posterolateral approach
47980609|NCT02196558|DRUG|E6011|
48132690|NCT06454682|DRUG|RJK002 Intrathecal injection|Eligible subjects will receive a single intrathecal administration of investigational product with dose 6E13 vg/person, 1.2E14 vg/person, and 2.4E14 vg/person sequentially.
48498118|NCT03663634|OTHER|Cytochalasin B use in ICSI handling medium|A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
48498119|NCT03840616|DRUG|Oteseconazole (VT-1161) 150mg capsule|600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
48132693|NCT04967664|DRUG|Qutenza (capsaicin) 8% topical system|High concentration capsaicin
48132694|NCT04967664|DRUG|capsaicin 0.04% topical system|Low-dose capsaicin control
48132695|NCT02839395|OTHER|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
48132696|NCT02839395|OTHER|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
48132697|NCT02839395|OTHER|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
48132698|NCT00640159|DRUG|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
48132699|NCT05346094|OTHER|No intervention|No intervention
48132700|NCT00643188|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
48132701|NCT00643188|OTHER|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
48498120|NCT03840616|DRUG|Fluconazole 150mg capsule|150mg administered every 72 hours in 3 sequential doses starting on Day 1.
48498121|NCT03840616|DRUG|Placebo|Administered once weekly starting on Day 14.
48498122|NCT00912483|BIOLOGICAL|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
48132705|NCT04657887|BIOLOGICAL|Voncento®|Solution for injection
48498123|NCT00912483|BIOLOGICAL|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
48132707|NCT06639074|PROCEDURE|Biopsy|Undergo biopsy
48132708|NCT06639074|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48132709|NCT06639074|PROCEDURE|Computed Tomography|Undergo CT
48132710|NCT06639074|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
48132711|NCT06639074|PROCEDURE|Leukapheresis|Undergo leukapheresis
48132712|NCT06639074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48132713|NCT06639074|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
48132714|NCT06639074|DRUG|Placebo Administration|Given ID
48132715|NCT06639074|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Given IM
48655983|NCT06639776|DIAGNOSTIC_TEST|Questionnaire|"All erection prosthesis placements in post-phalloplasty transgender and gender non-conforming individuals at Ghent University Hospital from start of the gender clinic until June 2023 will be evaluated. All patients that are at least 6 months after erection prosthesis placement and currently have a functioning prosthesis in place are eligible and will be contacted. Upon inclusion and informed consent, the patient's medical files will be used to gather all necessary underlying medical information that is relevant to this study. will receive an email asking them to complete a questionnaire for themselves. At the end of this questionnaire the patient will be asked if they have a sexual partner and if this partner is willing to participate as well. After affirmation, the partner will be contacted in the same way.~Patients will receive a series of questionnaires reviewing recent sexual activity, sexual preference, satisfaction with the erectile prosthesis and quality partner relationship."
48132716|NCT04218383|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC and cathode placed over the right primary motor cortex.
48132717|NCT00802126|DRUG|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
48498124|NCT06174870|OTHER|Inspiratory muscle training|Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
48498125|NCT00888823|RADIATION|Stereotactic Radiotherapy|Stereotactic Radiotherapy
48498126|NCT01381250|BEHAVIORAL|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
48498127|NCT00202423|DRUG|Sativex|
48498128|NCT00562575|DRUG|SLx-4090|
48498129|NCT00562575|DRUG|Placebo|
48498130|NCT05203718|BEHAVIORAL|Food Response Training (FRT)|All patients will complete the 12-week FRT intervention consisting of one in-person session (during the baseline visit) and three weekly sessions at home, one delivered via video conference (WebEx) and two self-guided. Food Response Training (FRT) is a computer-based attention bias modification intervention. The intervention will be delivered on a computer or smart device (e.g. iPhone). Patients will use the FoodTrainer application available for Android and iPhone (https://www.exeter.ac.uk/foodt/about/).
48132725|NCT06397118|BEHAVIORAL|Maternal Nutrition Education|Community Health Worker delivered Maternal Nutrition Education
48132726|NCT06397118|BEHAVIORAL|Standard Care|Standard care in the sickle cell disease (SCD) clinic
48498131|NCT02334592|RADIATION|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
48132729|NCT05090371|DRUG|Ofatumumab|3 loading doses followed by administration every 4 weeks as per label
48132730|NCT05090371|DRUG|Disease modifying treatment (DMT)|Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
48132731|NCT05467943|DRUG|Tazemetostat|All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
48132734|NCT05555628|OTHER|Mandibular Exercise|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
48132735|NCT05555628|OTHER|Mandibular Exercise and Postural Exercise Group|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
48132736|NCT05555628|OTHER|Occlusal Splint Group|Patients will use occlusal splints for 6 weeks. The occlusal splints will be used only sleep time.
48367390|NCT05109949|DRUG|Empagliflozin 25 MG|Daily morning dose per oral of Empagliflozine 25 mg for 7 days
48132737|NCT05284240|DEVICE|Auryon Laser System|"The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy."
48132738|NCT05737602|BEHAVIORAL|3RP-VHL|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.
48498132|NCT00681512|DIETARY_SUPPLEMENT|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
48132740|NCT06357533|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
48132741|NCT06357533|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
48132742|NCT06357533|DRUG|Pembrolizumab|Pembrolizumab IV (intravenous)
48655984|NCT03287492|OTHER|Informational Intervention|Receive QPS
47980610|NCT03107936|BEHAVIORAL|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
48655985|NCT03287492|OTHER|Informational Intervention|Receive GIS
47980611|NCT03355521|OTHER|Nordic Walking|Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
47980612|NCT03355521|OTHER|Free Walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
47980613|NCT04253145|DRUG|PM 01183|Lyophilisate for solution for infusion
47980614|NCT04253145|DRUG|Atezolizumab|Concentrate for solution for infusion
47980615|NCT05445986|PROCEDURE|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
47980616|NCT05445986|PROCEDURE|gap filling|to use biomaterials to fill the jumping gap
47980617|NCT05445986|PROCEDURE|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
47980618|NCT01554384|PROCEDURE|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
47980619|NCT01554384|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
47980620|NCT05484518|BEHAVIORAL|Method of Levels Therapy|"Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell \& Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions"
47980621|NCT05877781|DIETARY_SUPPLEMENT|Palmitoylethanolamide|8-week treatment 3x400 mg per day
47980622|NCT04082312|OTHER|No intervention|No intervention
47980623|NCT00303277|DRUG|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
47980624|NCT00303277|DRUG|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
47980625|NCT05792891|OTHER|Collecting biological material from frail patients, with or without COVID-19|The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.
47980626|NCT04340401|DRUG|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
48132743|NCT01745965|DRUG|T-DM1|
48132744|NCT01745965|DRUG|Trastuzumab|
48132745|NCT06444607|PROCEDURE|Venepuncture|Blood draw in the context of routine patient care, when a venipuncture is already scheduled.
48132746|NCT06444607|PROCEDURE|Venepuncture|Volunteering for blood draw.
48132747|NCT03936660|OTHER|Intense Education Intervention|Clinics provided with existing clinical care guidelines as well as a multifaceted educational intervention to support development of an integrated, multi-disciplinary care pathway for patients with T2DM and CVD.
48655986|NCT03287492|OTHER|Questionnaire Administration|Ancillary studies
48367391|NCT05109949|OTHER|Placebo|Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
48367392|NCT03395613|DEVICE|NPWT|Negative pressure wound thearpy on closed surgical wounds
47980627|NCT04340401|DRUG|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
47980628|NCT04340401|DRUG|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
48132751|NCT01578941|OTHER|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (\>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
48367393|NCT05666466|DIAGNOSTIC_TEST|extratympanic electrocochleograhy|electrophysiological test
48367394|NCT02944058|PROCEDURE|Multiloc nail|Intervention is surgery with Multiloc nail
47980629|NCT04340401|RADIATION|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
47980630|NCT04340401|PROCEDURE|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
47980631|NCT05641207|DEVICE|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients be assigned two sessions of RheOx bronchial rheoplasty procedures~* Treatment 1 is for the treatment of right lung~* Treatment 2 is scheduled one month apart for left lung"
47980632|NCT01601626|DRUG|Standard-dose Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
47980633|NCT01601626|DRUG|Double-dose Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
47980634|NCT01601626|DRUG|Raltegravir|One 400 mg tablet orally twice daily from entry to Week 72.
47980635|NCT01601626|DRUG|Isoniazid|300 mg orally once daily from entry through Week 24.
47980636|NCT01601626|DRUG|Pyridoxine|25 mg orally once daily from entry to Week 24.
47980637|NCT01601626|DRUG|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
47980638|NCT01601626|DRUG|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
47980639|NCT01601626|DRUG|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
47980640|NCT01601626|DRUG|Rifampin|Weight-based dose; for weight \< 45 kg: 450 mg orally once daily; for weight \> 45 kg: 600 mg orally once daily, from entry to week 24.
47980641|NCT05201560|DRUG|Butorphanol Tartrate Injection|Patients of this group will receive Butorphanol Tartrate Injection
47980642|NCT05201560|DRUG|Fentanyl|Patients of this group will receive Fentanyl
47980643|NCT03664557|DEVICE|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
47980644|NCT03655691|BIOLOGICAL|Vehicle|Vehicle Formulation
47980645|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
47980646|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
47980647|NCT02706470|DRUG|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
47980648|NCT02706470|DRUG|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
47980649|NCT05048940|BIOLOGICAL|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
47980650|NCT05048940|BIOLOGICAL|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
47980651|NCT06506227|BEHAVIORAL|Low risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine
47980652|NCT06506227|BEHAVIORAL|Medium risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces
47980653|NCT06506227|GENETIC|High risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation
47980654|NCT06506227|BEHAVIORAL|Control group COBB 10-20°|Specific Exercise Therapy
47980655|NCT06506227|BEHAVIORAL|Control group COBB 20-45°|Orthopedic Braces + Specific Exercise Therapy
47980656|NCT06506227|BEHAVIORAL|Control group COBB >45°|Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery
47980657|NCT06506227|OTHER|Experimental group (AIS group)|Molecular marker exploration and validation
47980658|NCT06506227|OTHER|Control group (healthy control)|Molecular marker exploration and validation
47980659|NCT06506227|OTHER|Controlled follow-up before and after AIS|Construction and validation of AIS risk prediction model completed
47980660|NCT01176084|BEHAVIORAL|low carbohydrate diet|
47980661|NCT01176084|BEHAVIORAL|low carbohydrate diet and exercise|
47980662|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
48132752|NCT06640881|RADIATION|ablative single-dose PBI|ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
48367395|NCT02944058|PROCEDURE|Philos plate|Intervention is surgery with Philos plate
48655987|NCT03757715|DRUG|Bupivacaine|20 mL of 1.3% bupivacaine
48655988|NCT03757715|DRUG|Dexamethasone|2 mg dexamethasone
47980663|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
48367396|NCT00888992|BEHAVIORAL|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
48655989|NCT06498687|DRUG|CYR-064|Theophylline Nasal Spray
47980664|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
47980665|NCT02526745|BIOLOGICAL|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
47980666|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
47980667|NCT02526745|BIOLOGICAL|placebo|
47980668|NCT00260494|OTHER|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
47980669|NCT00260494|OTHER|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
47980670|NCT00589563|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
47980671|NCT00589563|DRUG|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
47980672|NCT00589563|DRUG|etoposide|60mg/kg on day -4 from stem cell transplant
47980673|NCT00589563|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
47980674|NCT00589563|DRUG|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
47980675|NCT00589563|DRUG|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
47980676|NCT00589563|DRUG|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients \<40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
47980677|NCT00589563|DRUG|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
47980678|NCT00589563|PROCEDURE|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
47980679|NCT00589563|PROCEDURE|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
47980680|NCT00589563|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
47980681|NCT00589563|PROCEDURE|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
47980682|NCT00589563|RADIATION|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
47980683|NCT00166673|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|
47980684|NCT03859349|DIAGNOSTIC_TEST|Selective Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
47980685|NCT03859349|DIAGNOSTIC_TEST|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
47980686|NCT01506167|DRUG|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
47980687|NCT01506167|DRUG|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
47980688|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
47980689|NCT01506167|DRUG|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
47980690|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
47980691|NCT01506167|DRUG|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
47980692|NCT06463327|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
47980693|NCT01010386|PROCEDURE|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
47980694|NCT01010386|PROCEDURE|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
47980695|NCT03668912|BEHAVIORAL|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
47980696|NCT00818233|DEVICE|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
47980697|NCT00540514|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
47980698|NCT00540514|DRUG|Paclitaxel|Administered by intravenous infusion.
47980699|NCT00540514|DRUG|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
47980700|NCT05843981|DEVICE|Implant placement TS III|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.
48498133|NCT06160297|PROCEDURE|Modified Otago Exercise|"The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~* Knee extension while sitting on a chair~* Knee flexion while standing with support from a chair~* Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~* Standing on tiptoe with support from a chair~* Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~* Mini squats~* Toe walking~* Walking on heels~* Tandem stance~* Tandem walking~* Walking backwards (10 steps)~* Standing on one leg~* Assisted side walking~* Side walking without support~* Sit and stand on the chair~* Figure eight walking"
48655990|NCT06340867|DEVICE|CEREC primescan intra-oral scanner|intra-oral scanner
48655991|NCT00000709|DRUG|Zidovudine|
48655992|NCT04661358|DRUG|Fenofibrate|Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
47980701|NCT05843981|DEVICE|Implant placement ks|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
47980702|NCT00594984|DRUG|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
47980703|NCT00594984|DRUG|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
47980704|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
47980705|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
47980706|NCT00594984|DRUG|Brivanib Placebo|Oral, tablet, QD, until progression
47980707|NCT04862364|OTHER|Endo Patients with Endometriosis Health Profile -30 (EHP-30) Test|The appointment of the patients consists of patients who were surgically diagnosed with Endometriosis in our clinic.
47980708|NCT02319746|BEHAVIORAL|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
47980709|NCT02319746|BEHAVIORAL|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
47980710|NCT05908370|PROCEDURE|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
47980711|NCT01186679|PROCEDURE|laminectomy|surgical laminectomy with glial scar resection
47980712|NCT01186679|PROCEDURE|Intrathecal|direct into the CSF through lumbar puncture
47980713|NCT03171129|DEVICE|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
47980714|NCT03171129|DEVICE|High flow Nasal Canula|Oxygen will be administered via nasal canula
47980715|NCT04023786|PROCEDURE|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
47980716|NCT01058109|OTHER|calcium-rich diet|dietary calcium intake of 1500 mg/d
47980717|NCT01058109|OTHER|Calcium rich diet|dietary intake of 1500 mg/d from food
47980718|NCT03211689|OTHER|Exercise Program|Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
47980719|NCT03223246|OTHER|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
47980720|NCT04588948|DRUG|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
47980721|NCT01438957|DRUG|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
47980722|NCT01438957|DRUG|Placebo|
47980723|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
47980724|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
47980725|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
47980726|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
47980727|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
47980728|NCT04359433|BEHAVIORAL|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~* 8 anerobic movements in 20 seconds is a set~* Rest for 10 seconds before another set~* Finish 4 sets every time, it shall take you 4 minutes~* Do 4 sets 2 to 3 times a week"
47980729|NCT04059094|DRUG|BI 1265162|Inhalation solution
47980730|NCT04059094|DRUG|Placebo|Inhalation solution
47980731|NCT00477971|BIOLOGICAL|filgrastim|No administration information given
47980732|NCT00477971|DRUG|dexamethasone|Given orally
47980733|NCT00477971|DRUG|melphalan|Given IV or orally
47980734|NCT00477971|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
47980735|NCT05424042|BEHAVIORAL|In-Person Caloric Restriction|20% CR delivered in-person by dietitian/coach
47980736|NCT05424042|BEHAVIORAL|Remote Caloric Restriction|20% reduction in caloric intake, meeting schedule, and physical activity goal delivered remotely.
47980737|NCT05424042|BEHAVIORAL|Time-restricted|8-hour TRE with ad libitum caloric intake. This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake.
47980738|NCT02597075|OTHER|standard therapy + physical activity program|
47980739|NCT02597075|OTHER|standard therapy|
48498134|NCT06160297|PROCEDURE|Neuromuscular Exercise|"* Proprioceptive stabilization of the knee with ball~* Bridging with ball~* Stepping forward, sideways and backwards by holding on to a fixed support while standing~* Doing the same movements with the support leg on a different surface~* Hip abduction-adduction with resistance band~* Knee flexion-extension with resistance band~* Climbing and descending steps by taking steps~* Balancing on the step~* Standing up from the chair"
47980740|NCT04183595|DRUG|(N1, N3-bis(2- mercaptoethyl)isophthalamide)|600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
47980741|NCT04183595|OTHER|Excipients microcrystalline cellulose, silica and magnesium stearate|6 Capsules will be administered every 24 hours for 14 days.
47980742|NCT05515757|BEHAVIORAL|Mobile-app based contingency management|We are adapting an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with stimulant use disorders requiring prolonged hospitalization. Participants will be enrolled into an 8-week mobile-app based contingency management intervention.
47980743|NCT01120301|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
47980744|NCT02180152|BEHAVIORAL|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
47980745|NCT05565651|OTHER|Fecal microbiota analysis|Data analysis
47980746|NCT01093807|DRUG|Placebo|once daily for 10 weeks
47980747|NCT01093807|DRUG|Lercanidipine|10 mg once daily for 10 weeks
47980748|NCT01093807|DRUG|Lercanidipine|20 mg once daily for 10 weeks
47980749|NCT01093807|DRUG|Enalapril|10 mg once daily for 10 weeks
47980750|NCT01093807|DRUG|Enalapril|20 mg once daily for 10 weeks
47980751|NCT01093807|DRUG|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
47980752|NCT01093807|DRUG|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
47980753|NCT01093807|DRUG|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
47980754|NCT01093807|DRUG|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
47980755|NCT01411228|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
47980756|NCT03559257|DRUG|Galcanezumab|Administered SC.
47980757|NCT03559257|DRUG|Placebo|Administered SC.
47980758|NCT01134783|BEHAVIORAL|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
47980759|NCT04672928|DRUG|paclitaxel|80mg/m\^2,iv,Q4W
47980760|NCT04672928|DRUG|IBI318|300mg,iv,Q4W
47980761|NCT00003479|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
47980762|NCT02961751|DRUG|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
47980763|NCT04461730|DEVICE|deep brain stimulation|Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
47980764|NCT05073991|PROCEDURE|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
47980765|NCT05073991|PROCEDURE|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
47980766|NCT05073991|PROCEDURE|TEVAR|Patients underwent TEVAR.
47980767|NCT05073991|PROCEDURE|EVAR|Patients underwent EVAR.
47980768|NCT05070598|DRUG|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
47980769|NCT05209438|DEVICE|Cereset Research|Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
47980770|NCT04973124|DRUG|Dexmedetomidine|These participants will receive intraoperative dexmedetomidine.
47980771|NCT04973124|DRUG|Placebo|These participants will not receive intraoperative dexmedetomidine.
47980772|NCT06395454|DIAGNOSTIC_TEST|Shorten antibiotics duration based on procalcitonin test levels|procalcitonin test will be taken on day 1 of recruitment as baseline, test done on day 5 will decide whether antibiotics will be withheld, followed by day 7 to determine rate of reinfection.
47980773|NCT02423577|DRUG|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
47980774|NCT02423577|DRUG|Placebo|Placebo dry powder administered by nasal inhalation
47980775|NCT05887726|DRUG|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
47980776|NCT05887726|DRUG|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
47980777|NCT05887726|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
47980778|NCT05887726|DRUG|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
47980779|NCT05887726|DRUG|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
47980780|NCT05887726|DRUG|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
48498135|NCT06453135|DRUG|Eculizumab|On the Day 0, participants received a single dose of eculizumab before the transplant surgery: 900 mg (blood type antibody titer ≥ 1:64 and/or body weight ≥ 60 kg) or 600 mg (blood type antibody titer \< 1:64 and body weight \< 60 kg). Plasmapheresis was not planned. When participants developed AMR, they may receive additional dose of eculizumab.
48498136|NCT03666559|DRUG|Azacitidine|Chemotherapy
48340230|NCT04432571|BEHAVIORAL|E-Nav/IP-NAV|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) has unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement by providing in person navigation and counseling to a cash incentive for on-time clinic attendance and/or viral load suppression (MOH guidelines). Trained peer navigators will provide psychosocial support, case management, assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers
48655993|NCT04661358|OTHER|Placebo|Participants begin with a dose of either 160mg or 54mg placebo, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
48655994|NCT06639230|DEVICE|laser therapy|Laser-treated group (test group): This group consisted of ten patients treated using diode lasers. The diode laser was operated in continuous wave mode with an output power of 3 W in contact mode to excise the pyogenic granuloma. The tip was moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.
48655995|NCT06639230|DRUG|Sclerotherapy|Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
48655996|NCT04503616|DRUG|Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention|Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
48655997|NCT02248233|DRUG|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
48655998|NCT02248233|DRUG|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
48655999|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
48656000|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
47914532|NCT01221935|OTHER|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
47980781|NCT04003922|OTHER|Adalimumab treatment|Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
47980782|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
47980783|NCT01536847|OTHER|Dietary Intervention|300 mL of liquid food product
47980784|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
47980785|NCT06166498|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
47980786|NCT06166498|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
47980787|NCT04489823|DEVICE|AVP III|Transcatheter closure of a paravalvular leak using AVP III
47980788|NCT05901168|OTHER|Active Video Games Intervention|Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
48656001|NCT01189760|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
47980789|NCT05901168|OTHER|Traditional Exercise Intervention|"Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes."
47980790|NCT00003204|DRUG|cyclophosphamide|Given IV
47980791|NCT00003204|DRUG|fludarabine phosphate|Given IV
48656002|NCT06563570|OTHER|yoga (online)|8-week online yoga practices, 2 days a week
47914533|NCT02310867|DRUG|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
47914534|NCT02310867|PROCEDURE|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
47914535|NCT00363701|DRUG|esomeprazole|
47980792|NCT00003204|DRUG|vincristine sulfate|Given IV
47980793|NCT00003204|DRUG|prednisone|Given PO
47980794|NCT00003204|BIOLOGICAL|rituximab|Given IV
47980795|NCT00003204|OTHER|laboratory biomarker analysis|Correlative studies
47980796|NCT02518750|DRUG|Dexamethasone|Given orally (PO).
48656003|NCT06641583|BEHAVIORAL|LEGO|"The LEGO Therapy intervention in this clinical trial is designed to enhance social skills in children with high-functioning Autism Spectrum Disorder (ASD). The intervention involves the following components:~Group Sessions: The therapy will be conducted in small groups of three children of the same age (10-14 years) with a diagnosis of high-functioning ASD. The sessions are designed to foster collaboration and social interaction between the participants.~Duration: The intervention will last for 3 months, consisting of 12 sessions, with each session lasting 90 minutes. Sessions will take place once a week at the IRCCS Fondazione Stella Maris.~Supervision: The groups will be supervised by trained professionals specializing in neurodevelopmental disorders, ensuring that the therapy is structured and supportive of each child\&amp;amp;amp;#39;s individual needs.~Therapy Structure: During the sessions, children will engage in LEGO-based tasks, where they collaborate to build LEGO models."
48498137|NCT01097941|BIOLOGICAL|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
48132757|NCT03783416|DRUG|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
48132758|NCT06249165|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
48132759|NCT06254183|DRUG|Gabapentin|"Gabapentin is a drug that is commonly used to treat neuropathic pain, epilepsy, and other neurological disorders. According to some studies, gabapentin may affect the Wnt signaling pathway.~In this study Gabapentin will be given by a dose of 1200 mg 1 hour before a laparoscopic sleeve gastrectomy(LSG) to decrease postoperative pain and opioid consumption. As acute kidney injury is a common condition following LSG , and as gabapentin has a positive effect on decreasing AKI induced in animal studies, we assess the effect of gabapentin on the AKI status following LSG"
48656004|NCT06641583|OTHER|Controllo|This group will also consist of children aged 10-14 diagnosed with high-functioning ASD. However, these children will not receive LEGO therapy. Instead, they will continue their usual treatments in their local settings without participating in the LEGO therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of LEGO therapy.
48656005|NCT05309226|OTHER|Cannabis use in pregnancy or cannabis exposure in utero|Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
48656006|NCT03939065|DEVICE|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
48656007|NCT03939065|DEVICE|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
48132760|NCT06254183|DRUG|Placebo|A placebo is a sham medical treatment that appears to be a real medical intervention but has no therapeutic effect. It is often used in clinical trials to compare the effects of a new treatment to those of a placebo. Common examples of placebos include inert tablets (like sugar pills), inert injections (like saline), and even sham surgery or other procedures. Placebos are typically made of inactive substances such as starch or sugar and are designed to be indistinguishable from the actual treatment
48132761|NCT06144749|DRUG|HBI-002|Oral liquid carbon monoxide drug product.
48340231|NCT05177289|DEVICE|Theradome® LH80 pro|The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.
48498138|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
48498139|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
48340232|NCT05177289|DEVICE|Scalp cooling|Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.
48340233|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Test Arm|Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
47980797|NCT02518750|DRUG|Panobinostat|Given PO.
47980798|NCT02518750|DRUG|Liposomal vincristine|For intravenous (IV) use only.
48340234|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Control Arm|Single vision, impact-resistant spectacle lenses
48340235|NCT05241938|PROCEDURE|PSLT|PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
48340236|NCT05241938|DRUG|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
48656008|NCT06187909|PROCEDURE|PECS II BLOCK|The linear probe will be placed transversely between the clavicle medially and above . After identifying the pectoralis major and minor muscles , the probe will be angled caudally to look for the pulsating pectoral branch of the thoraco-acromial artery. The block needle will be inserted in an in-plane approach to the artery's location and 10 mL of 0.25% bupivacaine will be administered. Then probe will be moved laterally and caudally towards the anterior axillary fold until the serratus muscle appears beneath the pectoralis minor muscle attaching to the underlying ribs. The third and fourth ribs will be detected. The needle will target the plane between pectoralis minor and serratus muscles at the level of the third rib, followed by negative aspiration into the fascial plane then injection of 20 ml bupivacaine.
48498140|NCT01595386|DRUG|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
48498141|NCT01595386|DRUG|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
48656009|NCT06187909|PROCEDURE|MTP BLOCK|The block will be performed with the patient in a sitting position ,High frequency linear probe will be placed in a vertical orientation 3 cm lateral to the midline at T2 level in parasagittal plane. We will identify the midpoint between the transverse process and parietal pleura, and the distance from this point to the skin will be measured which will be the measured depth of insertion and will be marked in the block needle. The block needle will be inserted out of plane to the probe and advanced till the marked depth till the point is confirmed, 10 ml of 0.25% bupivacaine will be injected. Similar two injections will be made at T4, T6 levels sonographic identification and level determination by counting from the second rib.
48656010|NCT04876456|DRUG|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
48656011|NCT05559359|DRUG|Lebrikizumab|Administered SC
48498142|NCT03514849|PROCEDURE|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
48656012|NCT05559359|DRUG|Placebo|Placebo given SC
48656013|NCT05559359|DRUG|Topical corticosteroid|Topical corticosteroid
48656014|NCT06639139|BEHAVIORAL|CogFun RG occupational therapy|21 weekly, online group sessions (4-6 participants in each group), lasting 90 minutes. Sessions are structured, comprising opening, collaborative learning, and summary. Session topics include learning about ADHD as a biological disorder of executive functioning, understanding the impact of ADHD on daily life, discovering strategies for coping with ADHD through exploration of life experiences, and preparing for future self management
48656015|NCT06100731|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
48656016|NCT04034927|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48656017|NCT04034927|PROCEDURE|Computed Tomography|Undergo CT
48656018|NCT04034927|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47980799|NCT02518750|DRUG|Mitoxantrone|Given IV.
47980800|NCT02518750|DRUG|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
48340237|NCT01159821|DRUG|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
48340238|NCT04498468|DRUG|Sustained Release Dexamethasone, 0.4 mg|dexamethasone 0.4mg lacrimal insert
47980801|NCT02518750|DRUG|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
48340239|NCT04498468|OTHER|E-Caprolactone-L-Lactide copolymer (PCL) punctal plug|Control eye will receive a tear duct plug without the dexamethasone (EXTENDED WEAR SYNTHETIC ABSORBABLE PUNCTAL PLUG made of E-Caprolactone-L-Lactide copolymer (PCL). Absorbs in 60 to 180 days. Size 0.5mm which is comparable to the study treatment)
48656019|NCT04034927|DRUG|Olaparib|Given PO
48656020|NCT04034927|BIOLOGICAL|Tremelimumab|Given IV
48656021|NCT05962736|DEVICE|Mirror therapy|The patients received a total of 24 sessions of treatment for 8 weeks, 3 sessions a week, starting from the postoperative 1st day after thorakaotomy. Each treatment session lasts between 60 and 90 minutes.
48656022|NCT06564402|BEHAVIORAL|Positive Mental Rehearsal|After exposure trial, participants are asked about the positive aspects of their exposure experience (e.g., thoughts, feelings), based on which an imagination script is formulated and recounted
48656023|NCT06564402|BEHAVIORAL|Mental Rehearsal|After exposure, participants are asked about what happened during the exposure experience and whether their central concerns/expected outcome actually occurred during exposure
48656024|NCT06564402|BEHAVIORAL|Exposure|All participants complete exposure exercises (i.e., talking on the phone and talking with a stranger) before positive mental rehearsal is executed
48340240|NCT00012207|BIOLOGICAL|aldesleukin|
48340241|NCT00012207|BIOLOGICAL|therapeutic autologous lymphocytes|
48498143|NCT03514849|PROCEDURE|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
48340242|NCT00012207|DRUG|cyclophosphamide|
48340243|NCT00012207|DRUG|prednisone|
48340244|NCT00012207|DRUG|vincristine sulfate|
48340245|NCT00012207|PROCEDURE|adjuvant therapy|
48340246|NCT01016808|DRUG|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
48340247|NCT01016808|DRUG|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
48340248|NCT01016808|DRUG|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
48132778|NCT06638099|BEHAVIORAL|CGM Toolkit Prescriber Training|A CGM prescription toolkit was created for prescribing clinicians and staff that includes written guidance on CGM eligibility criteria, instructions for screening patients for eligibility using EHR records and during healthcare visits, recommended provider documentation templates to address all required eligibility criteria for insurance coverage of CGM device and supplies (e.g., Medicare, Medicaid), sample scripts for communicating with patients about the purpose and use of CGM, and patient-level frequently asked questions (FAQs), including free resources available to learn more about CGM benefits, where/how to acquire CGM, and determining out-of-pocket costs. The toolkit will be introduced during a 20 minute initial training session and reinforced during a 10 minute booster training approximately one month after initial training
48656025|NCT06071715|DEVICE|ACTIVE cryoneurolysis|Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium Initial treatment: Cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with an active probe separated by a 30-60 second defrost (Epimed). For active treatment, the gas will be deployed to the probe tip where a drop in temperature will result in cryoneurolysis.
48656026|NCT06071715|DEVICE|SHAM cryoneurolysis|SHAM cryoneurolysis of the major nerves of the thigh (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 1 cycle of 5.5-minute argon activation followed by a 30-60 second defrost period with helium (Varian) or 2 cycles of 2-minute gas activation with a sham probe separated by a 30-60 second defrost (Epimed). However, for sham treatment, the gas is NOT deployed to the probe tip and therefore there is NO drop in temperature with NO resulting cryoneurolysis.
48656027|NCT06644378|DRUG|[14C]-LY3866288|Administered orally.
48656028|NCT06644378|DRUG|LY3866288|Administered orally.
48656029|NCT06644378|DRUG|[14C]-LY3866288|Administered IV.
48132779|NCT06122818|OTHER|Immobile patients receiving home health care|Demographic characteristics, duration of immobility, sarcopenia presence, thigh circumference , Hand grip strength , bioelectrical impedance analysis
48656030|NCT05032352|DRUG|Adjuvant|Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
48132780|NCT06381531|DIAGNOSTIC_TEST|Imaging with CT and MRI|Quantitative and anthropometric analysis of brain and skull strutcure of imaging (CT/ MRI) undertaken as part of diagnosis or treatment for patients with brain tumor
48132781|NCT00754065|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
48132782|NCT00754065|DRUG|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
48498144|NCT03514849|DRUG|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
48340249|NCT04059991|BIOLOGICAL|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
47980802|NCT02518750|DRUG|Intrathecal Triples|Given IT as ITMHA.
48498145|NCT05298319|DEVICE|high flow nasal cannula|The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
48498146|NCT02516553|DRUG|BI 894999|film-coated tablets
48498147|NCT00297726|BEHAVIORAL|Self-Management Program|
48498148|NCT03746431|DRUG|[111In]-FPI-1547 Injection|\[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
48656031|NCT05032352|OTHER|Observation|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
48656032|NCT04630769|DRUG|IP FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
48656033|NCT04630769|DRUG|Enoblituzumab|Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
48340250|NCT01559701|DRUG|PF-00345439|5-80 mg twice-a-day for 12 months
48656034|NCT04630769|DRUG|IL-2|IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
48132791|NCT04148482|OTHER|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
48498149|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection multi-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
48132793|NCT01284920|DRUG|MDV3100|oral
48498150|NCT03746431|BIOLOGICAL|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
48498151|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection single-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
48498152|NCT02216318|OTHER|blue light|
48498153|NCT00429156|DEVICE|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
48656035|NCT05020769|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
48656036|NCT05020769|DRUG|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
48656037|NCT04197232|OTHER|clinical evaluation|- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
48656038|NCT06328569|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
48656039|NCT06328569|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
47980803|NCT02518750|DRUG|High-dose methotrexate|Given intrathecally (IT) or IV.
48498154|NCT00429156|DEVICE|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
48498155|NCT00742066|DRUG|Irbesartan|Single dose 600mg orally
48498156|NCT00742066|DRUG|Felodipine|single dose 10mg Felodipine ER
48498157|NCT00742066|DRUG|Placebo|Single dose tablet orally
48132801|NCT04420078|PROCEDURE|Catheter Ablation|Ventricular fibrillation substrate
48498158|NCT03983083|BEHAVIORAL|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
48513283|NCT06634017|BIOLOGICAL|Platelet rich fibrin|Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
48132802|NCT05307835|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 4 x 300 mcg per peptide given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses;
48132803|NCT05307835|BIOLOGICAL|GM-CSF|4 x 40 mcg (total dose 160 mcg) given on days 1, 4, 8, 15, 22, 52, and 82 for a total of 7 doses
48132804|NCT03613740|DRUG|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
48132805|NCT03613740|DRUG|Placebo|Intervention will be administered 30 minutes before breakfast.
48132807|NCT04919811|DRUG|Taletrectinib|400mg or 600mg QD
48656040|NCT04709393|OTHER|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
48132811|NCT05265689|BEHAVIORAL|Bike Club|"Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City."
48340251|NCT04119401|PROCEDURE|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
48340252|NCT04119401|PROCEDURE|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
48340253|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
48513284|NCT03466255|OTHER|Ultrasound|Contrast-enhanced ultrasound (CEUS)
48656041|NCT02072057|DRUG|Ruxolitinib|
48656042|NCT06422247|DRUG|Systemic therapy|Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
47980804|NCT02518750|DRUG|6-Mercaptopurine|Given PO at consistent time each day.
47980805|NCT02518750|DRUG|High-dose cytarabine|Given IT or IV.
47980806|NCT02518750|DRUG|Nelarabine|Given IV
47980807|NCT02518750|DRUG|Cyclophosphamide|Given IV.
47980808|NCT02518750|DRUG|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
47980809|NCT02518750|DRUG|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
47980810|NCT02425046|BEHAVIORAL|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
47980811|NCT02425046|BEHAVIORAL|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
47980812|NCT03837106|OTHER|Rehabilitation program|3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
47980813|NCT00924456|BEHAVIORAL|Transcendental Meditation program|a natural effortless mental technique
47980814|NCT02563275|OTHER|motion analysis system|
47980815|NCT02563275|OTHER|parabolic flight|
47980816|NCT03542968|PROCEDURE|magnetic resonance imaging|Acquisition 4D Flow magnetic resonance Imaging-8 minutes
47980817|NCT02955485|OTHER|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
47980818|NCT06356155|DRUG|Enfortumab vedotin|1.25 mg/kg IV
47980819|NCT06356155|DRUG|Pembrolizumab|200 mg IV
47980820|NCT00653250|DRUG|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
47980821|NCT00653250|PROCEDURE|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
47980822|NCT00653250|PROCEDURE|therapeutic conventional surgery|surgery to remove the lung tumor
47980823|NCT02485574|PROCEDURE|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
47980824|NCT05431452|OTHER|Pain management|Nonpharmacological pain management during blood collection in preterm infants
47980825|NCT02269345|OTHER|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
47980826|NCT02269345|OTHER|Standard Treatment|Standard Treatment alone.
48132812|NCT05265689|BEHAVIORAL|Bike Club Plus|Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
48656043|NCT05919498|OTHER|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
48498159|NCT03827746|OTHER|Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale|"Tampa Kinesiophobia Scale: The TSK is a 17-item self report checklist using a 4-point Likert scale that was developed as a measure of fear of movement or (re)injury.~Berg-Balance Test: 14-item scale designed to measure balance of the older adult in a clinical setting.~International Physical Activity Questionnaire-Short Form: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.~Falls Efficacy Scale: A 16- item self-administered questionnaire designed to assess fear of falling in mainly older population"
48132814|NCT04761939|COMBINATION_PRODUCT|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~* Ridaforolimus drug - CAS Registry Number: 572924-54-0"
48498160|NCT03199430|DIETARY_SUPPLEMENT|Epigallocatechin gallate|
48498161|NCT03199430|DIETARY_SUPPLEMENT|Placebo|1450mg Corn Flour
48340254|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
48340255|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
48340256|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
48340257|NCT04965285|BEHAVIORAL|quality assesment|"For each time-out procedure observed, the investigators will record compliance for each element of the time-out. Elements that are clearly verbalized by the member of the operating room team performing the time-out were considered compliant.~As each step of the time-out is verbalized by a team member, the operating room team members are expected to respond. The observations will be conducted by trained study staff using a standardized Checklist/ Proforma to assess surgical team compliance with the time-out protocol and to record general observations of the operating room environment. Any non-routine events that occurred during the time-out process will be recorded.~In each phase, the Checklist coordinator must be permitted to confirm that the team has completed its tasks before it proceeds onward."
48340258|NCT05830526|OTHER|Escape Room|"The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
48340259|NCT02336048|DRUG|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
48340260|NCT02336048|DRUG|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
48340261|NCT02336048|DRUG|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
48498162|NCT02038907|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
48656044|NCT05919498|OTHER|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
48498163|NCT02038907|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
48656045|NCT01179555|BEHAVIORAL|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
48656046|NCT01179555|BEHAVIORAL|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
48656047|NCT04874480|DRUG|Decitabine|Given IV
48656048|NCT04874480|DRUG|Tegavivint|Given IV
48656049|NCT06352970|OTHER|TB infection|Outcomes will be compared with regard to result of interferon-gamma release assay test for TB infection
48656050|NCT04011241|DRUG|BI 1323495|Tablet
47980827|NCT06466122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48656051|NCT04011241|DRUG|Itraconazole|Oral solution
48656052|NCT06309628|DIAGNOSTIC_TEST|Breathe sample|Patients will provide two breathe sample into the Breathe device to see if their VOC patterns can be used to diagnose lung transplant rejection.
48656053|NCT02684162|BIOLOGICAL|Donor Lymphocytes|Given IV
48656054|NCT02684162|DRUG|Guadecitabine|Given SC
48656055|NCT02684162|OTHER|Laboratory Biomarker Analysis|Correlative studies
48656056|NCT04595201|DEVICE|NIPT|Non-invasive pregnancy testing
48498164|NCT00422981|DRUG|AL-108|5 mg QD
48498165|NCT00422981|DRUG|AL-108|15 mg BID
48498166|NCT00422981|DRUG|Placebo|Placebo
48498167|NCT01753947|OTHER|Deliberate Practice|
48498168|NCT02393443|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
48498169|NCT02393443|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
48498170|NCT04791878|DRUG|Mesenchymal stem cells|Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
48498171|NCT05567263|PROCEDURE|Bulk-fill resin composite, (3M, ESPE)|Teeth will be restored with Bulk-fill resin composite, (3M, ESPE)
48498172|NCT05567263|PROCEDURE|Surefil one™ Self-Adhesive Composite Hybrid|teeth will be restored with Surefil one™ Self-Adhesive Composite Hybrid
48132826|NCT03220074|DRUG|Oral Tablet|study drug given and monitored for efficacy and tolerability
48498173|NCT02385253|BEHAVIORAL|Educational training program|"The educational training program (intervention) consists of four sequential phases:~1. Knowledge Acquisition~2. Skills Assessment~3. Deliberate Practice~4. Clinical Proficiency"
48498174|NCT04838548|DRUG|MRG003|Administered intravenously
48132829|NCT06416072|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
48132830|NCT06337838|DRUG|Desmopressin Injectable Solution|Intravenous desmopressin, 20 mcg, single dose administration.
48498175|NCT02490267|OTHER|Quality of Life questionnaire|
48498176|NCT03609723|PROCEDURE|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
48498177|NCT00856219|DIETARY_SUPPLEMENT|Enteral Continuous|Continuous Tube Feeding for 72 hours
48498178|NCT00856219|DIETARY_SUPPLEMENT|Enteral Intermittent|Intermittent Tube Feedings
48498179|NCT00856219|DIETARY_SUPPLEMENT|Parenteral Continuous|Parenteral Continuously for 72 hours
48656057|NCT05810467|OTHER|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
48656058|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 25mg|To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
48656059|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 50mg|To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
48656060|NCT06054542|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the DESQ
48132831|NCT06337838|DRUG|Tranexamic Acid Injectable Product|Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.
48132832|NCT06337838|OTHER|Placebo|Intravenous 0.9% saline solution
48132833|NCT04801823|OTHER|Home introduction|Cautious, graded introduction of individual tree nuts
48132834|NCT04801823|OTHER|Multi Nut oral food challenge|In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
48498180|NCT03054558|OTHER|Pelvic ultrasound both two dimensional and three dimentional|
48498181|NCT00110526|GENETIC|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
48498182|NCT02517086|OTHER|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
48498183|NCT02517086|OTHER|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
48498184|NCT02517086|OTHER|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
48498185|NCT02737748|DRUG|TWB-103 Group|Each subject received TWB-103+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
48498186|NCT02737748|DRUG|Placebo Group|Each subject received Placebo+Tegaderm for up to 10 days or to the day of 100% re-epithelialization, whichever comes first, followed by Tegaderm alone application from Day 10 to 14 if failing to achieve 100% re-epithelialization by Day 10.
48132842|NCT05798065|PROCEDURE|Inpatient gastrointestinal endoscopy|all inpatient endoscopy procedures (gastroscopy, colonoscopy, ERCP, sigmoidoscopy) during 2016-2022.
48498187|NCT04271553|OTHER|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
48498188|NCT00700323|DIETARY_SUPPLEMENT|PS-Omega3 conjugate supplementation|
48498189|NCT00700323|DIETARY_SUPPLEMENT|placebo|
48498190|NCT00292487|DRUG|Iopamidol 370 mgI/mL|
48656061|NCT04889989|DEVICE|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
48498191|NCT03300544|DRUG|Capecitabine|Given PO
48498192|NCT03300544|DRUG|Fluorouracil|Given IV
48498193|NCT03300544|DRUG|Leucovorin|Given IV
48132849|NCT06071702|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
48498194|NCT03300544|DRUG|Oxaliplatin|Given IV
48498195|NCT03300544|RADIATION|Radiation Therapy|Undergo chemoradiation
48498196|NCT03300544|BIOLOGICAL|Talimogene Laherparepvec|Given intralesionally
48498197|NCT00698880|PROCEDURE|Right hepatic vein embolization|Embolization of the right hepatic vein
48498198|NCT00266396|BEHAVIORAL|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
48498199|NCT00266396|BEHAVIORAL|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
48498200|NCT00110136|DRUG|St. John's Wort|St. John's Wort 300mg tablet three times per day
48498201|NCT03889366|DRUG|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
48498202|NCT03757351|DRUG|DNL747|Repeating oral dose
48498203|NCT03757351|DRUG|Placebo|Repeating oral dose
48498204|NCT02648295|PROCEDURE|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
48656062|NCT03409198|DRUG|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
48656063|NCT03409198|DRUG|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
48656064|NCT03409198|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
48656065|NCT03409198|DRUG|Cyclophosphamide|Chemotherapy
48132855|NCT05836103|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
48132856|NCT02157116|DRUG|cisplatin|
48132857|NCT02157116|DRUG|Docetaxel|
48132858|NCT02157116|DRUG|Pegfilgrastim|
48656066|NCT05517447|OTHER|Observational cohort study|Observational cohort study
48132859|NCT04905004|PROCEDURE|Canine retraction|Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
48132860|NCT05819242|DIAGNOSTIC_TEST|Angulus|Smartphone app
48656067|NCT05517447|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
48656068|NCT02599831|DEVICE|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
48656069|NCT02599831|DEVICE|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
48656070|NCT02599831|DEVICE|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
48656071|NCT03408262|BIOLOGICAL|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
48132861|NCT03689920|DEVICE|Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
48132862|NCT05685511|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
48132863|NCT05685511|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
48498205|NCT00792363|DRUG|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
48132865|NCT06562907|DRUG|GS-4571|Administered orally
48656072|NCT03408262|BIOLOGICAL|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
48132866|NCT06562907|DRUG|Placebo|Administered orally
48132867|NCT06562907|DRUG|Omeprazole|Administered orally
48132868|NCT04566861|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy|Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.
48132869|NCT01596296|DEVICE|Transcervical foley catheter|16 French foley catheter insertion
48132870|NCT01596296|DRUG|Dinoprostone 10mg|Dinoprostone vaginal insertion
48132871|NCT03387254|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
48132872|NCT03387254|DEVICE|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
48498206|NCT00792363|DRUG|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
48132874|NCT01957332|PROCEDURE|Molecular imaging|On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
48132875|NCT01957332|PROCEDURE|Molecular imaging|All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.
48340262|NCT02336048|OTHER|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
48498207|NCT04125849|PROCEDURE|Thoraco-laparoscopic esophagectomy|Thoraco-laparoscopic esophagectomy surgery
48498208|NCT04125849|PROCEDURE|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
48498209|NCT00938249|DIETARY_SUPPLEMENT|Monascus Garlic Fermented Extract|
48498210|NCT00938249|DIETARY_SUPPLEMENT|Placebo|
48498211|NCT01406483|OTHER|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
48656073|NCT03408262|BIOLOGICAL|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
48656074|NCT05860985|DEVICE|ZEISS disposable|a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
48656075|NCT00370084|DRUG|Itopride|oral, three times daily
48656076|NCT00370084|OTHER|Placebo|oral, three times daily
48656077|NCT02394574|OTHER|Clean Cookstove|Ethanol
48656078|NCT02394574|OTHER|Traditional Cookstove|Firewood / Kerosene
48656079|NCT06046378|OTHER|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application."
48656080|NCT06046378|OTHER|Control Group|After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
48132882|NCT03485287|DRUG|Midomafetamine HCl|Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
48132883|NCT03485287|BEHAVIORAL|Manualized therapy|Non-directive therapy
48132884|NCT04745156|DEVICE|RNS System Implantation|Following resection consistent with SoC, if there is evidence of residual tumor which cannot be resected due to invasion of hand-M1 but which is small enough to be covered by two four-electrode strips, these strips will be placed on the functional cortex of interest and secured to the dura. The location of the leads will be registered into the navigation software (either Medtronic Stealth or Brainlab). The dura will then be closed as watertight as possible, and the RNS System will be incorporated into the craniotomy on closure Prior to closure, four bone screws will be placed and registered to the intraoperative navigation system as internal fiducials to be retrieved for future procedures.
48132885|NCT03274076|DRUG|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
48132886|NCT03274076|DRUG|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
48132887|NCT06642402|DIAGNOSTIC_TEST|Kidney biopsy|Patient refered to kidney biopsy independent of the presented study
48132888|NCT06642402|DIAGNOSTIC_TEST|Urinary extracellular vesicle testing|Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease
48132889|NCT06642402|DIAGNOSTIC_TEST|Autoimmunity in plasma|Expected autoimmunity in plasma isolated from blood samples
48132890|NCT04620200|DRUG|Nivolumab|3mg/kg
48132891|NCT04620200|DRUG|Ipilimumab|1mg/kg
48132892|NCT05568082|DRUG|AMG 510|Oral tablet
48132893|NCT05568082|DRUG|Itraconazole|Oral capsule
48132894|NCT02720445|DRUG|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
48132895|NCT02720445|DRUG|Placebo Patch|Matching placebo patches worn during waking hours.
48498212|NCT03469336|DRUG|PF-06763809|Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%
48498213|NCT03469336|OTHER|Vehicle|Vehicle matching PF-06763809.
48498214|NCT03469336|DRUG|Calcipotriene/calcipotriol|Calcipotriene/calcipotriol 50 ug/mL solution
48498215|NCT03469336|DRUG|Betamethasone|Betamethasone 1 mg/g solution
48498216|NCT02908737|DEVICE|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
48656081|NCT06624345|PROCEDURE|Inspiratory muscle training|Patients in the IMT group received the intervention using a threshold loading device set at a pressure range of 5-39 cmH₂O. They were instructed to perform six sets of five breaths, totaling 30 breaths, twice daily for six weeks. Additionally, the aerobic exercise regimen included upper limb exercises (raising arms without resistance), a lower limb stepping warm-up, and a walking routine consisting of 5 minutes of slow walking, 2 minutes of brisk walking, and another 5 minutes of slow walking, for a total of 30 minutes per day.
48656082|NCT06624345|PROCEDURE|Control Group|Subjects received routine care.
48498217|NCT04354116|DEVICE|Rapid maxillary expansion|Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.
48498218|NCT04354116|DEVICE|Maxillary Protraction|Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).
48498219|NCT02331368|PROCEDURE|Autologous Stem Cell Transplant|
48498220|NCT02331368|DRUG|Melphalan|140-200 mg/m\^2
48132905|NCT05923606|DEVICE|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
48132906|NCT05923606|DEVICE|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
48498221|NCT02331368|DRUG|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
48498222|NCT02331368|DRUG|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
48132909|NCT05598957|DIAGNOSTIC_TEST|Vitamin D Binding protein|Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
48498223|NCT01830491|DRUG|Clopidogrel|
48498224|NCT01830491|DRUG|aspirin 100mg|
48132912|NCT06134089|BEHAVIORAL|Perceived Effectiveness Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below is more likely to make you want to get screened for colorectal cancer?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
48132913|NCT06134089|BEHAVIORAL|Perceived Shareability Prompt|"Participants will assess pairs of messages with the prompt, Which of the messages below would you be more likely to share with your friends or family?~Participants will also be able to provide their own idea for a message rather than selecting a message from the pairs presented."
48132914|NCT06550804|BEHAVIORAL|A-TEAM|Participants randomized to the intervention arm will receive the proposed intervention, which involves an electronic adherence device called Wisepill and triaged text alerts to the user, the social support, and the case manager for same day, two day, and seven day device non-openings.
48340263|NCT02336048|DRUG|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
48340264|NCT04125381|OTHER|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
48340265|NCT04853277|BEHAVIORAL|Education|Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
48656083|NCT04794504|DRUG|Botox 100 UNT Injection|Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients
48656084|NCT04794504|OTHER|0.9% Saline Injection|As a placebo control to the 100 UNT Botox injection, 0.9% saline will be injected intramuscularly into the masseter and temporalis muscles bilaterally
48498225|NCT03253523|PROCEDURE|Occipital neurolysis|Surgical occipital nerve decompression
48340266|NCT06280053|DEVICE|HealiAid Collagen Wound Dressing|HealiAid is an absorbable collagen wound dressing. It is fabricated by fibrous collagen matrix, in which the collagen is purified from bovine Achilles tendons. HealiAid can be applied easily by covering directly to the clean wound sites.
48340267|NCT02353403|OTHER|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
48656085|NCT06568172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or plasma
48340268|NCT02353403|OTHER|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
48340269|NCT05940350|BEHAVIORAL|Telerehabilitation Stroke Coaching of Program (TeleSCoP) group|"The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months."
48340270|NCT00088114|DRUG|STA-4783/paclitaxel|
48498226|NCT03163004|BEHAVIORAL|Implementation of standing desks|Three standing desks will be introduced to the classroom
48340271|NCT05801172|PROCEDURE|ketoprofen for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy
48498227|NCT03048253|BIOLOGICAL|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
48498228|NCT05323331|OTHER|Circuit Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
48498229|NCT05323331|OTHER|Aerobic Training Exercise Program|The participants allocated to this group will perform Circuit Training Exercise Program
48498230|NCT04229459|DRUG|Cisplatin|Cisplatin 100mg/m2 IV on day 1 of induction chemotherapy, 75mg/m2 IV on day 1 and 29 of chemoradiation
48498231|NCT04229459|DRUG|5-FU|5-FU 1000mg/m2/d IV on days 1-5 of induction chemotherapy, 1000mg/m2/d IV on days 1-4 and days 29-32 of chemoradiation
48498232|NCT04229459|RADIATION|Radiation therapy|1.8 Gy/fraction, 5 days a week for a total of 28 days
48498233|NCT04229459|DRUG|Cetuximab|Cetuximab 400mg/m2 IV on day 1 followed by 250mg/m2 IV weekly on induction chemotherapy, 250mg/m2 IV weekly on chemoradiation, 500mg/m2 IV on day 1 of each treatment cycle, every two weeks during immunotherapy
48498234|NCT04229459|DRUG|Nivolumab|Nivolumab 3mg/kg IV on day 1 of each treatment cycle, every two weeks during immunotherapy
48656086|NCT06568172|BIOLOGICAL|Cemiplimab|Given IV
48656087|NCT06568172|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
48656088|NCT06568172|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
48656089|NCT06568172|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48656090|NCT06568172|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48656091|NCT06568172|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
47980828|NCT06466122|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
47980829|NCT06466122|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
47980830|NCT06466122|PROCEDURE|Computed Tomography|Undergo CT
47980831|NCT06466122|DRUG|Pirtobrutinib|Given PO
47980832|NCT06466122|DRUG|Venetoclax|Given PO
47980833|NCT04208984|DEVICE|Study|After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.
48656092|NCT06568172|OTHER|Questionnaire Administration|Ancillary studies
48656093|NCT06568172|PROCEDURE|Surgical Procedure|Undergo surgery per SOC
48656094|NCT06568172|PROCEDURE|Surgical Procedure|Undergo response-adaptive surgery
48132916|NCT05916144|BEHAVIORAL|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
48132917|NCT05989841|BEHAVIORAL|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
48132918|NCT05989841|BEHAVIORAL|Relaxation Control|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
48132919|NCT05873686|DRUG|NXP900|NXP900 is an orally administered SRC/YES1 kinase inhibitor
48132920|NCT01727518|OTHER|As the LEAD study is an observational cohort study, there is no intervention to report.|As the LEAD study is an observational cohort study, there is no intervention to report.
48132921|NCT03640403|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
48132922|NCT03640403|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
48340272|NCT05801172|PROCEDURE|ketoprofen plus infiltration anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in intracervical administration at the start of the procedure
48340273|NCT05801172|PROCEDURE|ketoprofen plus paracervical block anesthesia with lidocaine for pain relief in office hysteroscopy|ketoprofen ketoprofen 100 mg intravenously 30 minutes pre-procedure for pain relief in office hysteroscopy plus 20 ml 1% lidocaine in paracervical block at the start of the procedure
48340274|NCT05187546|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
48340275|NCT00005675|DRUG|Oral bovine type I collagen|500 mcg of CI daily for 15 months
48340276|NCT00005675|DRUG|Placebo|CI placebo daily for 15 months
48340277|NCT05610241|DEVICE|Compression Therapy System Prototype|A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.
48340278|NCT05610241|DEVICE|Standard Compression|Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
48132923|NCT06274879|DRUG|Gemcitabin, Cisplatin and Durvalumab|CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.
48132924|NCT06274879|PROCEDURE|Biliary Radiofrequency Ablation|Biliary Radiofrequency Ablation is applied at baseline, 6 and 12 weeks
48132925|NCT06274879|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography with stenting|ERCP with stenting are applied at baseline and as clinically indicated
48132926|NCT06451952|OTHER|Virtual darkness|Chronotheraphy
48498235|NCT03276065|DEVICE|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
48132932|NCT06352632|DRUG|Standard-dose intravenous tenecteplase|Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation
48132933|NCT06352632|DRUG|Low-dose intravenous tenecteplase|Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation
48132934|NCT06352632|OTHER|No intravenous tenecteplase|No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)
48132935|NCT06352632|OTHER|Conservative Blood Pressure Control|No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
48340279|NCT04615780|OTHER|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
48132936|NCT06352632|OTHER|Moderate Blood Pressure Control|SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
48132937|NCT06352632|OTHER|Intensive Blood Pressure Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
48132938|NCT06352632|OTHER|Placebo|100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.
48132939|NCT06352632|DRUG|NoNO-42|NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration
48132940|NCT06352632|OTHER|No deferoxamine mesylate and no colchicine|No deferoxamine mesylate and no colchicine
48132941|NCT06352632|DRUG|Deferoxamine mesylate only|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
48340280|NCT04615780|OTHER|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
48656095|NCT06232954|DEVICE|Mossie-Go containing treated transfluthrin disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with repellent discs impregnated with transfluthrin and a carrier oil. These discs sit above a fan that is powered by a small motor charged by solar energy. The device is expected to both prevent bites and cause some mortality to mosquitoes when switched on for 8-12 hours overnight for up to 1 calendar month. The discs then need to be replaced.
48656096|NCT06232954|DEVICE|Mossie-Go containing untreated blank disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with a blank untreated disc. These discs sit above a fan that is powered by a small motor charged by solar energy. The device containing the untreated disc is not expected to prevent mosquito bites. The discs will still be replaced monthly for blinding purposes.
48656097|NCT06642883|DIETARY_SUPPLEMENT|Prolife|randomized in a 1:1 ratio to treatment :1 vial/day for 60 days.
48656098|NCT06642883|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 vial/day for 60 days.
48656099|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of short term study (7 days) of stevia leave powder 1000 mg/day in diabetic subjects
48132942|NCT06352632|DRUG|Colchicine only|0.5mg of oral colchicine daily for 30 days
48132943|NCT06352632|DRUG|Both deferoxamine mesylate and colchicine|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days
48132944|NCT03554083|DRUG|Atezolizumab|Given IV
48132945|NCT03554083|DRUG|Cobimetinib|Given PO
48132946|NCT03554083|BIOLOGICAL|Tiragolumab|Given IV
48132947|NCT03554083|DRUG|Vemurafenib|Given PO
48498236|NCT03276065|OTHER|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
48498237|NCT05384639|DEVICE|Dual-task Group|Participant will cycle and perform cognitive training simultaneously.
48132950|NCT06300879|PROCEDURE|Performing totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique|"Surgical Operation:~1. Gastric Resection Range:Proximal gastrectomy, preserving 2/3 of the distal stomach.~2. Lymph Node Dissection Range:D1+ to D2 lymph node dissection.~3. Anastomosis Method: esophagogastrostomy by fissure technique.~4. Anastomosis Risk Management Plan:For a rupture with a maximum diameter less than or equal to 5mm, repair with 4-0/3-0 absorbable sutures and proceed with the anastomosis.For a rupture with a maximum diameter greater than 5mm or failed anastomosis, resect that part of the remaining stomach, change to proximal gastrectomy, and perform double-channel anastomosis.~5. Surgical Approach:Totally laparoscopic proximal gastrectomy."
48132951|NCT06148740|OTHER|Manuka Health Pro Vitality Daily Restorative Face Serum with Propolis & Vitamin C|Skin serum containing propolis, vitamin C, and manuka honey.
48132952|NCT05056493|OTHER|Caremap app|The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
48132953|NCT06532097|BEHAVIORAL|Physical and behavioral smartwatch-based activation|We used smartwatches to provide an interactive tool for delivering a mixed intervention of physical and behavioral activation, with the former addressing physical activity level and the latter pleasant activities including and beyond physical activity (e.g., social, relaxing activities). Moreover, given the relationship with physical activity level, we additionally incorporated digital insomnia exercises that have also shown large effects in the amelioration of depression.
48340281|NCT06227806|PROCEDURE|Tibial Tubercle Transfer|Patients will receive the TTT surgery followed by a home exercise program.
48340282|NCT06227806|PROCEDURE|Home Exercise Program|Patients will receive an extensive home exercise program.
48340283|NCT05721755|DRUG|Carboplatin|Given IV
48340284|NCT05721755|DRUG|Cisplatin|Given IV
48340285|NCT05721755|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
48132956|NCT06121492|DRUG|Branched-chain amino acid|In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
48340286|NCT05721755|DRUG|Fluorouracil|Given IV
48340287|NCT05721755|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48340288|NCT05721755|DRUG|Paclitaxel|Given IV
48656100|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of long term study (60 days) of stevia leave powder 1000 mg/day in diabetic subjects
48656101|NCT03757949|OTHER|Laboratory Biomarker Analysis|Correlative studies
48656102|NCT03757949|DIETARY_SUPPLEMENT|Nutritional Intervention|Receive SIM PO
48132957|NCT06121492|DRUG|Placebo|In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
48132958|NCT05624138|DRUG|Placebo tablets|12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
48340289|NCT05721755|BIOLOGICAL|Pembrolizumab|Given IV
48340290|NCT05721755|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48340291|NCT05721755|OTHER|Quality-of-Life Assessment|Ancillary studies
48340292|NCT05721755|RADIATION|Radiation Therapy|Undergo radiation therapy
48340293|NCT06338007|DEVICE|Hand Dynamometer|Hand grip strength will be measured using a hand dynamometer. Research has demonstrated that hand grip strength is correlated with muscle strength in the upper extremities, as well as overall body and pulmonary muscle strength.
48498238|NCT05384639|DEVICE|Cycling Group|Participant will cycle only.
48498239|NCT05384639|DEVICE|Cognitive Group|Participant will perform cognitive training only.
48498240|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)
48132959|NCT05624138|DRUG|Ketotifen Oral Tablet|ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
48132960|NCT04207736|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
48132961|NCT04207736|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
48340294|NCT06338007|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry is a physiological test that measures the ability to inhale and exhale air relative to time. Spirometry is a diagnostic test of several common respiratory disperses such as asthma and chronic obstructive pulmonary disease (COPD). It is also instrumental in monitoring the progression of various respiratory disorders. The main results of spirometry are forced vital capacity (FVC), forced expiratory volume exhaled in the first second (FEV1), and the FEV1/FVC ratio. Pulmonary Function Test analysis values (FEV1, FVC and FEV1 /FVC) will be used.
48340295|NCT06338007|OTHER|Modified Frailty Index|The modified frailty index is a valuable preoperative risk assessment tool that can be used to assess the risk of both morbidity and mortality in patients undergoing surgery. It is calculated based on 11 parameters.
48340296|NCT01680939|DRUG|Morphine|0.2-0.5 mg/kg PO q4h
48340297|NCT01680939|DRUG|Ibuprofen|10mg/kg PO q6hrs
48340298|NCT02905110|DRUG|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
48340299|NCT02905110|DRUG|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
48340300|NCT02905110|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
48498241|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])
48498242|NCT04561375|DRUG|Sufentanil|30 µg tablet of sublingual sufentanil
48498243|NCT04561375|DRUG|Fentanyl|50 µg fentanyl
48498244|NCT02565173|DRUG|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
48340301|NCT05474755|DRUG|GP681 40mg|2X20mg tablets taken orally
48340302|NCT05474755|DRUG|Placebo|Placebo tablets matching GP681 40mg
48340303|NCT03489850|DRUG|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
48340304|NCT03489850|OTHER|Placebo|Placebo is matched to ibudilast active medication.
48340305|NCT01761994|DRUG|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
48656103|NCT03757949|OTHER|Placebo Administration|Given PO
48656104|NCT03757949|OTHER|Quality-of-Life Assessment|Ancillary studies
48656105|NCT03757949|OTHER|Questionnaire Administration|Ancillary studies
48656106|NCT06638632|BEHAVIORAL|Decision aid|Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
48656107|NCT05414799|OTHER|figure eight vision exercise|figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
48656108|NCT05414799|OTHER|chin nodding|chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
48656109|NCT05414799|OTHER|neck stretching|"trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides."
48656110|NCT01048853|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping with sentinel lymph node biopsy
48656111|NCT01048853|OTHER|Quality-of-Life Assessment|Ancillary studies
48498245|NCT02565173|DRUG|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
48132963|NCT05717140|BIOLOGICAL|Aerosol Sargramostim|Given via inhalation with nebulizer
48132964|NCT05717140|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48132965|NCT05717140|PROCEDURE|Computed Tomography|Undergo CT
48656112|NCT01048853|PROCEDURE|Salpingo-Oophorectomy|Undergo hysterectomy with or without salpingo-oophorectomy
48132966|NCT05717140|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48132967|NCT05717140|OTHER|Medical Device Usage and Evaluation|Use Aerogen Solo nebulization device
48132968|NCT05717140|BIOLOGICAL|Nivolumab|Given IV
48132969|NCT05023434|PROCEDURE|Intraoperative Brain Simulation - Alternate Stimulation Parameters|Additional stimulation parameters outside of standard of care during intraoperative brain stimulation to aid in motor mapping.
48340306|NCT00218361|DRUG|Hydromorphone|
48656113|NCT01048853|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo lymphatic mapping with sentinel lymph node biopsy
48656114|NCT01048853|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy with or without salpingo-oophorectomy
48656115|NCT05687578|DIAGNOSTIC_TEST|Measurements Only|This is an observational study only using biospecimen and imaging-based measurements only
48498246|NCT02565173|DRUG|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
48498247|NCT02565173|DRUG|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
48132972|NCT04621435|DRUG|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
48132973|NCT04621435|PROCEDURE|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes
48132974|NCT04621435|DRUG|Copper-64 labeled (64Cu-) FAP-2286|The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
48132975|NCT05977335|DIAGNOSTIC_TEST|Autonomic Function Testing|Autonomic Function Testing (AFT) includes Valsalva Manoever, Deep Breathing Test, and Head-up Tilt Table Testing.
48340307|NCT05591651|DRUG|Treatment of damaged nipple skin: Preparation with hyaluronic acid|The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
48340308|NCT05591651|DRUG|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid|The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
48340309|NCT03185312|DIAGNOSTIC_TEST|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
48340310|NCT04906824|DEVICE|great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing|VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
48340311|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
48340312|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
48340313|NCT01227720|DRUG|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
48498248|NCT02565173|DRUG|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
48498249|NCT01767961|PROCEDURE|diagnostic imaging|Undergo MBS
48498250|NCT01767961|OTHER|questionnaire administration|Correlative studies
48498251|NCT01767961|PROCEDURE|quality-of-life assessment|Correlative studies
48656116|NCT06247787|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
48656117|NCT06247787|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48656118|NCT06247787|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48656119|NCT06247787|DRUG|Cytarabine|Receive IV and IT
48656120|NCT06247787|PROCEDURE|Echocardiography|Undergo ECHO
48656121|NCT06247787|DRUG|Fludarabine|Receive IV
48656122|NCT06247787|DRUG|Hydrocortisone Sodium Succinate|Receive IT
48656123|NCT06247787|BIOLOGICAL|Imetelstat|Receive IV
48656124|NCT06247787|DRUG|Leucovorin Calcium|Receive IV or PO
48656125|NCT06247787|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48656126|NCT06247787|DRUG|Methotrexate|Receive IT
48656127|NCT06545903|DEVICE|LMA Supreme|The device is inserted and the manikin ventilated
48656128|NCT06545903|DEVICE|SLIPA|The device is inserted and the manikin ventilated
48656129|NCT06545903|DEVICE|I-gel|The device is inserted and the manikin ventilated
48656130|NCT06545903|DEVICE|AuraGain|The device is inserted and the manikin ventilated
48656131|NCT01506726|DRUG|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
48656132|NCT01506726|DRUG|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
48656133|NCT03404960|DRUG|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.
48656134|NCT03404960|DRUG|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
48656135|NCT02913846|OTHER|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
48656136|NCT02913846|OTHER|Muscular assessment|An assessment of muscular force will be performed once a week.
48656137|NCT02913846|OTHER|Pre-albumine dosage|Dosage performed once a month.
47980834|NCT04208984|OTHER|Music Video|After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
48498252|NCT00845806|OTHER|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
48498253|NCT02667015|BEHAVIORAL|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
48132978|NCT05610787|DEVICE|EXCOR Active Driving System for Pediatric VAD|The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
48132979|NCT05911451|PROCEDURE|Arteriovenous fistula creation|It is recommended to create the arteriovenous fistula 3 to 6 months before the expected start of hemodialysis treatment using locoregional anesthesia. It is recommended to use minimal venous and arterial diameters of 2mm for radiocephalic fistulas and 3mm for brachiocephalic and brachiobasilic fistulas. It is recommended to avoid creating an arteriovenous fistula at the same side as a pacemaker, central venous catheter, or arterial stenosis. It is recommended to use the following order of preference for arteriovenous fistula creation: radiocephalic fistula as first choice, brachiocephalic fistula as second choice, and brachiobasilic fistula as third choice.
48132980|NCT05911451|PROCEDURE|Arteriovenous graft placement|It is recommended to implant the arteriovenous graft 2 weeks before the expected start of hemodialysis treatment under antibiotic prophylaxis. Implantation of an early-cannulation graft is recommended for patients who require more urgent start of hemodialysis to avoid the use of a temporary central venous catheter. It is recommended to use minimal arterial and venous diameters of 3mm and 4mm, respectively. It is recommended to avoid placing an arteriovenous graft at the same side as a pacemaker, central venous catheter, or arterial stenosis.
48340314|NCT01227720|DRUG|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
48498254|NCT00077545|DRUG|triapine|Given IV
48498255|NCT00077545|DRUG|cisplatin|Given IV
48656138|NCT04285567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
47980835|NCT05600491|DRUG|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
47980836|NCT00374790|DRUG|Ferrous sulfate|
47980837|NCT01221883|DRUG|Diazepam|Single dose 10mg Diazepam tablet
47980838|NCT05567692|DIAGNOSTIC_TEST|OGTT|Oral Glucose Tolerance Test
47980839|NCT05567692|OTHER|HbA1c|HbA1c measurement
47980840|NCT05567692|OTHER|Questionnaire|Follow-up questionnaire
47980841|NCT01529255|DRUG|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
47980842|NCT01529255|DRUG|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
47980843|NCT01534871|BEHAVIORAL|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
48498256|NCT03206580|OTHER|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
48656139|NCT04285567|DRUG|Venetoclax|Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
48656140|NCT04285567|DRUG|Fludarabine|Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
48656141|NCT04285567|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
48656142|NCT04285567|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
48656143|NCT04285567|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
47980844|NCT04362787|DEVICE|High pressure non invasive ventilation in acute hypercapnic respiratory failure|Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
47980845|NCT00144963|DRUG|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
48656144|NCT01107496|DRUG|IR Viloxazine|"One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1.~Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6."
47980846|NCT00144963|DRUG|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
48132981|NCT05911451|PROCEDURE|Central venous catheter placement|It is recommended to place a tunneled central venous catheter just before the start of hemodialysis treatment under local anesthesia, with conscious sedation if preferred by the patient. The catheter should preferably be placed in the right internal jugular vein with ultrasound-guided puncture and fluoroscopy control under sterile conditions. According to usual practice at the trial center, catheters may be implanted by surgeons, interventional radiologists, or nephrologists.
48498257|NCT03206580|OTHER|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
48132983|NCT04217330|BEHAVIORAL|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
48132984|NCT04217330|BEHAVIORAL|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
48132985|NCT05403476|DRUG|FE 999049|FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
48132986|NCT05403476|DRUG|Placebo|Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
48132987|NCT02168998|BEHAVIORAL|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
48132988|NCT05822752|DRUG|Budigalimab|Intravenous (IV) Infusion
48132989|NCT05822752|DRUG|Livmoniplimab|Intravenous (IV) Infusion
48132990|NCT05822752|DRUG|Lenvatinib|Oral: Capsule
48132991|NCT05822752|DRUG|Sorafenib|Oral: Tablet
48132992|NCT01540318|PROCEDURE|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
48132993|NCT01285999|DEVICE|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent Drug-eluting Stent (DES) implantation
48132994|NCT01285999|DEVICE|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent Drug-eluting Stent (DES) implantation
47980847|NCT05738161|DRUG|Magrolimab|Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
47980848|NCT05738161|DRUG|Cisplatin|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
47980849|NCT05738161|DRUG|Gemcitabine|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
47980850|NCT05195125|PROCEDURE|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
47980851|NCT04022772|OTHER|Best Practice|Receive standard of care
48513285|NCT04666389|DRUG|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
48513286|NCT06104943|OTHER|Heredity for cardiovascular disease|First degree relatives with a diagnosis of Cardiovascular disease.
48513287|NCT06104943|OTHER|Heredity for pancreatitis|First degree relatives with a diagnosis of pancreatitis.
48656145|NCT01107496|DRUG|Placebo|Placebo capsules administered orally 3 times a day
47980852|NCT04022772|OTHER|Medical Chart Review|Ancillary studies
48656146|NCT04148911|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.
47980853|NCT04022772|OTHER|Quality-of-Life Assessment|Ancillary studies
47980854|NCT04022772|OTHER|Questionnaire Administration|Ancillary studies
47980855|NCT04022772|PROCEDURE|Supportive Care|Participate in PACK Health program
47980856|NCT02338284|OTHER|ultrasound of globe|"* A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.~* A value \> 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
47980857|NCT00913003|DRUG|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
47980858|NCT00913003|DRUG|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
48133004|NCT06360133|DRUG|VVN001 Ophthalmic Solution, 5%|VVN001 Ophthalmic Solution, 5%
48133005|NCT06360133|DRUG|VVN001 Ophthalmic Solution, Vehicle|VVN001 Ophthalmic Solution, Vehicle
48133006|NCT05949684|BIOLOGICAL|Luspatercept|Specified dose on specified days
48133007|NCT05949684|BIOLOGICAL|Epoetin Alfa|Specified dose on specified days
48133008|NCT03702777|DRUG|ASP8302|Oral Capsule
48133009|NCT03702777|DRUG|Placebo|Oral Capsule
48133012|NCT03779984|DEVICE|Red Rubber Catheter|Experimental group will be intubated with red rubber catheter guidance
48133013|NCT03779984|DEVICE|Standard nasal tracheal Intubation|Control group will be intubated with standard nasal tracheal tube without guidance
48133014|NCT06581965|OTHER|Short duration prophylaxis|"Only during hospitalization: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guideline Antitrombotisch beleid. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use (same type as used for control group)."
48656147|NCT04148911|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
48340315|NCT01007513|PROCEDURE|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
48498258|NCT02870387|OTHER|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
48656148|NCT03697447|PROCEDURE|Endermotherapy|Endermotherapy massage (mechanic massage) of burn scar
48656149|NCT02531191|DRUG|peficitinib|oral
48656150|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 25 mg
48656151|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 50 mg
48656152|NCT06539195|DRUG|DZD8586|Daily dose of DZD8586 at 75 mg
48656153|NCT00403052|DRUG|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
48656154|NCT04318938|DRUG|Brigatinib|Treatment with Brigatinib
47980859|NCT00511667|DRUG|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
47980860|NCT00511667|DRUG|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
47980861|NCT05513495|OTHER|The effect of drip versus intermittent feeding on splanchnic oxygenation|After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
47980862|NCT01288248|DEVICE|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
47980863|NCT01288248|DEVICE|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
47980864|NCT06474052|DRUG|Gelofusine 4%|Gelofusine 4% 10 ml/kg is administered following anaesthesia induction in 30 minutes.
47980865|NCT03758274|BEHAVIORAL|CBT by Phone to Promote Treatment|Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
47980866|NCT03758274|OTHER|Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment|The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
47980867|NCT04058145|DRUG|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
47980868|NCT04058145|DRUG|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
47980869|NCT04245787|DRUG|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
47980870|NCT02103764|DRUG|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
48340316|NCT01007513|PROCEDURE|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
48340317|NCT01922739|DRUG|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
48513288|NCT06104943|OTHER|Heredity for type 2 diabetes|First degree relatives with a diagnosis of type 2 diabetes.
48656155|NCT04318938|DRUG|Tyrosine kinase inhibitor|Treatment with any TKI
48656156|NCT06293781|DEVICE|Web-based ACT|ACT program delivered online
48656157|NCT06293781|BEHAVIORAL|Treatment as usual|Treatment as usual for major depressive disorder
48656158|NCT06643169|BEHAVIORAL|home-based fall prevention program with multifactorial|"* Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment"
48656159|NCT01334879|DRUG|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
48656160|NCT06476509|DRUG|LV232 40mg|oral
48656161|NCT06476509|DRUG|Escitalopram 20 mg|oral
48656162|NCT06642727|BEHAVIORAL|laughter yoga|Laughter yoga reduces stress levels through sessions lasting approximately 40 minutes without any invasive or pharmacological interventions. It regulates breathing, relaxes muscles, stimulates circulation, increases pain thresholds, strengthens immunity, lightens the mind, enhances social relationships, promotes mental balance, and boosts self-esteem, hope, energy, and quality of life. The content of a session includes deep breathing exercises, warm-up exercises, childlike games, and laughter exercises.
48656163|NCT05177536|DRUG|Iberdomide|Iberdomide is a novel potent cereblon E3 ligase modulator
48656164|NCT02019849|DEVICE|Plasmafit® Total Hip Arthroplasty|
48656165|NCT03610698|BEHAVIORAL|LEAF Positive Emotion Intervention|5-week online intervention teaching 8 positive emotions skills for caregivers
48656166|NCT03610698|OTHER|Emotion Reporting Control Condition|Daily reporting of emotions for participants assigned to the control condition.
48656167|NCT06640738|DRUG|arm 2|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
48656168|NCT06640738|DRUG|arm 1|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
48656169|NCT06644365|OTHER|Acupresure mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.This practice will continue for three menstrual cycles.
48656170|NCT06644365|OTHER|Basic mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.Participants in this group will also be sent a reminder message similar to the intervention group. This practice will continue for three menstrual cycles.
48656171|NCT05064085|DRUG|Cemiplimab|Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
48656172|NCT05064085|DRUG|Capecitabine|Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
48656173|NCT06271616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48656174|NCT06271616|PROCEDURE|Echocardiography|Undergo echocardiography
48656175|NCT06271616|DRUG|Ibrutinib|Given PO
48656176|NCT05214118|BEHAVIORAL|technology-based program|Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
48656177|NCT03728478|DRUG|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
48656178|NCT03728478|DRUG|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
48656179|NCT03728478|DRUG|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
48656180|NCT06294990|DRUG|Testosterone gel|Two years treatment with testosterone
48498259|NCT02870387|OTHER|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
48498260|NCT00616629|DRUG|AZD1305|Intravenous infusion
48656181|NCT06294990|OTHER|Placebo|Two years treatment with placebo
48656182|NCT04281940|DEVICE|Transcatheter implantation of chordal repair system|Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
48656183|NCT06583655|RADIATION|SLND(clinical low risk)|treated with whole breast irradiation(WBI)alone 50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx or no PMRT
48656184|NCT06583655|RADIATION|SLND(clinical high risk, genomic low risk)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
48656185|NCT06583655|RADIATION|SLND alone ,clinical high risk and genomic high risk group|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node Irradiation+ axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
48656186|NCT06583655|RADIATION|Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
48656187|NCT04717466|BIOLOGICAL|Secukinumab|300mg subcutaneous injection
48498261|NCT03972202|DIAGNOSTIC_TEST|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
48498262|NCT03972202|DEVICE|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
48513289|NCT06104943|OTHER|Heredity for hypertriglyceridemia|First degree relatives with hypertriglyceridemia
48656188|NCT06052358|DEVICE|LAAC with Watchman FLX device|LAAC with Watchman FLX device
48656189|NCT01915212|BIOLOGICAL|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
48656190|NCT01915212|OTHER|Placebo|Sodium Chloride 0.9%
48656191|NCT06637293|DEVICE|DeepECG plateform diagnosis & recommendations|EchoNeXT\& ECG-AI algorithm
47980871|NCT02103764|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
48133015|NCT06581965|OTHER|Higher intensity and longer duration prophylaxis|"The use of any thrombocyte aggregation inhibitors should be discontinued 5 days prior to surgery. Day 0-2: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.~Day 3: Apixaban 5mg b.i.d., continued until 6 weeks after surgery, conditional on the fact that no active bleeding of the surgical wound can be observed. In case of active bleeding, the prophylactic dose of thrombosis prophylaxis is continued. Thereafter, in case no active bleeding has been observed for 24 hours, the 5mg b.i.d. apixaban treatment will be started.~The 5mg b.i.d. apixaban dose will be adjusted to 2.5mg b.i.d. in case of an impaired kidney function (defined as eGFR 10-30ml/min)."
48133016|NCT06581965|OTHER|Control|4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
48498263|NCT03972202|BEHAVIORAL|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
47980872|NCT03210376|DRUG|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
48340318|NCT01922739|DRUG|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
48340319|NCT02671760|DRUG|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
48498264|NCT03277482|DRUG|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
48656192|NCT06642714|PROCEDURE|weaning by early non-invasive ventilation and progressive high flow oxygen therapy|"Step 1 Clinical stability was confirmed:~(1)Without organ failure;(2)Without sepsis;(3)Stable heart rate and blood pressure without use of vascular active drugs.~Step2 Reduce the support parameters of the ventilator gradually. Step3 SBT when the ventilator mode is pressure support ventilation(PSV),P+PEEP≤16cmH2O for 2 hours.~Step4~①Success of SBT: titrate based HFOT time-------connected with tracheostomy tube ,flow rate and FiO2 able to maintain oxygen saturation as assessed by pulse oximetry monitoring of at least 95%.HFOT was interrupted in cases of sighs or symptoms of distress such as oxygen desaturation, RR\>30bpm, HR\>130bpm,SBP\>180mmHg or \<90mmHg.The time was based HFOT time. When any of these conditions were present the patient was connected again to the ventilator with the same parameters before titration. The duration of SBT was increased progressively over the following day according to patient tolerance. Then gradually extending HFOT time daily according patient condition. Wh"
47980873|NCT03210376|DRUG|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
47980874|NCT03210376|DRUG|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
47980875|NCT03210376|DRUG|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
47980876|NCT03210376|BEHAVIORAL|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
47980877|NCT02642614|DRUG|BI 1026706|
47980878|NCT02642614|DRUG|Placebo|
47980879|NCT02642614|DRUG|Placebo|For blinding purposes
48498265|NCT03277482|DRUG|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
48498266|NCT03277482|RADIATION|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
48340320|NCT02671760|DRUG|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
47980880|NCT06217289|OTHER|Observation|Observation and knowledgement on behavior of healthcare professional workers during hpreparation of oral solid pharmaceutical drug
47980881|NCT02533154|DRUG|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
47980882|NCT02533154|DRUG|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
47980883|NCT02533154|OTHER|Bacterial culture|bacterial cultures obtained with conjunctival swabs
47980884|NCT03156673|BIOLOGICAL|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
47980885|NCT03912116|OTHER|CLARIX FLO|100mg CLARIX FLO
47980886|NCT03912116|OTHER|Saline|Saline
47980887|NCT05067829|DEVICE|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
47980888|NCT01725620|DRUG|LBEC0101 (Etanercept 25mg)|
47980889|NCT01725620|DRUG|Enbrel (Etanercept 25mg)|
47980890|NCT05891314|PROCEDURE|Botox Injectable Product|one group will have botox injection in the internal sphincter
47980891|NCT05891314|PROCEDURE|Internal sphincterotomy|this group will have internal sphincterotomy
47980892|NCT04666051|BIOLOGICAL|Application of fibrin glue sealant|
47980893|NCT00754819|DRUG|Colchicine|1mg once daily
47980894|NCT00754819|DRUG|Placebo|1 capsule daily
48340321|NCT02671760|DRUG|Placebo|Placebo
48340322|NCT05944029|DIETARY_SUPPLEMENT|Pomegranate seed powder|10 g powder / day
48340323|NCT01143714|DRUG|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
48340324|NCT01143714|OTHER|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
48498267|NCT05185401|OTHER|Observational study|Retrospective data-analysis
48133019|NCT05421832|DEVICE|Digital Speech Application|A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
48133020|NCT02398786|OTHER|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
48133021|NCT05900895|DRUG|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
48133022|NCT05900895|DRUG|17b-estradiol|17b-estradiol will be taken orally three times per day.
48498268|NCT00365131|DRUG|Cerezyme (imiglucerase for injection)|
48498269|NCT04275882|DIAGNOSTIC_TEST|Electrocardiogram|There will be no new intervention performed for the patients.
48498270|NCT02392351|DEVICE|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
48498271|NCT02392351|DEVICE|Renal Angiography|Percutaneous renal angiography
48498272|NCT01462773|DRUG|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
48133028|NCT00442104|DRUG|Ganaxolone|
48133029|NCT04065399|DRUG|revumenib|revumenib orally
48133030|NCT04065399|DRUG|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
48133031|NCT06292689|DRUG|Cardunolizumab|"1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment."
48133032|NCT04872478|DRUG|MRX-2843|MRX-2843 capsules
48133033|NCT01087346|BEHAVIORAL|Reading Information|Reading information about risk factors for obesity among children
48498273|NCT01462773|DRUG|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
48498274|NCT00814918|DRUG|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
48498275|NCT00814918|DRUG|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
48498276|NCT00548171|BIOLOGICAL|Boostrix™|Intramuscular injection, 1 dose
47980895|NCT04711408|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted displa|"For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins."
48498277|NCT02351271|DEVICE|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
48133038|NCT03835559|PROCEDURE|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
48498278|NCT02351271|DEVICE|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
48656193|NCT06606847|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
47980896|NCT04189211|DRUG|BAT8001|IV infusions.
47980897|NCT02360956|DRUG|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
48133039|NCT03835559|PROCEDURE|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
48133040|NCT05769777|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
48133041|NCT04407975|OTHER|Betamethasone|A single injection will be administered to the patient at least 24 hours before undergoing C-section. This injection will be prepared in the hospital's pharmacy to contain betamethasone
48340325|NCT00003000|DRUG|fentanyl citrate|
48656194|NCT06606847|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
48656195|NCT06099665|BEHAVIORAL|Automated alert|Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.
48340326|NCT00003000|DRUG|morphine sulfate|
48133042|NCT04407975|OTHER|Placebo|A single injection will be administered to the patient. This injection will be prepared in the hospital's pharmacy to contain normal saline.
48656196|NCT03073577|DRUG|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
48133043|NCT02919787|DRUG|5-FU|Neoadjuvant treatment
48133044|NCT02919787|DRUG|Oxaliplatine|Neoadjuvant treatment
48133045|NCT02919787|DRUG|Irinotecan|Neoadjuvant treatment
48133046|NCT02919787|PROCEDURE|Pancreatic surgery|All patients
48133047|NCT02919787|DRUG|5-FU|Adjuvant treatment
48133048|NCT02919787|DRUG|Oxaliplatine|Adjuvant treatment
48133049|NCT02919787|DRUG|Irinotecan|Adjuvant treatment
47980898|NCT02360956|DRUG|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
47980899|NCT03630627|DRUG|SB26|SB26 administered intravenously
47980900|NCT03630627|DRUG|Placebo|Placebo administered intravenously
47980901|NCT04282993|DEVICE|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
48656197|NCT04578041|DEVICE|TRPMS (Transcranial Rotating Permanent Magnet Stimulation)|"TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2"
47980902|NCT04282993|OTHER|Standard of care monitoring|Periodical medical examinations
47980903|NCT05894629|BEHAVIORAL|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
47980904|NCT05894629|BEHAVIORAL|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
47980905|NCT01378078|DEVICE|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
48133050|NCT01351545|DRUG|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
48498279|NCT03011736|OTHER|Laboratory Biomarker Analysis|Correlative studies
48133052|NCT05220501|DIAGNOSTIC_TEST|Micro-US Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
48498280|NCT03011736|PROCEDURE|Parathyroidectomy|Undergo parathyroidectomy
48513290|NCT01798316|DRUG|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
47980906|NCT01378078|DEVICE|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
47980907|NCT00616200|OTHER|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
47980908|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units of Vitamin D3 weekly
47980909|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 units weekly
47980910|NCT03886376|OTHER|Deep Massage|The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
48133053|NCT05220501|DIAGNOSTIC_TEST|MRI Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MRI targets will be identified and sampled.
48513291|NCT01798316|DRUG|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
48513292|NCT03259412|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil Capsule
48367397|NCT00888992|BEHAVIORAL|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
48367398|NCT04370041|DEVICE|Dokimos Plus aortic valve|Dokimos Plus aortic valve
48513293|NCT03259412|DIETARY_SUPPLEMENT|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
48133056|NCT06517771|OTHER|Online aerobic exercise|Before starting the online aerobic exercises, for general warm-up, two minutes of walking, one minute of marching, and ten repetitions of bilateral reciprocal shoulder flexion-extension, shoulder horizontal abduction-adduction, and unilateral shoulder flexion and circling exercises were performed. For the upper extremity, full elbow extension with shoulder retraction in full shoulder flexion (Exercise V), elbows 90 degrees flexion with shoulder retraction in 90 degrees abduction (Exercise U), and full elbow flexion with shoulder extension of about 30 degrees (Exercise W) were performed. Standing hip abduction-extension, elevation on tiptoe, standing-sitting from a chair with hands on shoulders, squatting, tandem walking, and standing on one leg exercises were performed in the lower extremities. Gastrocnemius, hamstring, and shoulder posterior and inferior capsule stretching exercises were conducted as cooling exercises.
48133057|NCT06309134|BEHAVIORAL|Healthy Families Bright Futures Program|Seven weekly online group sessions with separate sessions for teens and caregivers. Sessions focus on increasing knowledge and acceptance of LGBTQ+ identities, alcohol use and dating violence social norms correction, bystander intervention, assertive communication skills, social emotional skills, family problem solving, and parenting behaviors.
48133058|NCT05027958|DRUG|Tuberculin Purified Protein Derivative|PPD administered through the airways to elicit the development of alveolar inflammation challenge dose of 0.5 TU
48133059|NCT02808403|OTHER|No intervention|No intervention; observation of routine medical care
48133060|NCT05081804|DIETARY_SUPPLEMENT|Carbohydrate Preoperative Drink|Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
48498281|NCT06258603|OTHER|oral care bundle|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, an oral care bundle containing an oral care combination was applied to the experimental group. According to this bundle application, patients were received tooth brushing (with chlorhexidine solution) and ice water application twice a day and moisturizing attempts 4 times a day.~In the 3rd stage, saliva pH, dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
48498282|NCT06258603|OTHER|clinical oral care|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, routine oral care protocol used in intensive care unit was applied to patients by the patients' primary nurse. According to this application, patients were received oral care using tongue depressor with wrapped in gauze and chlorhexidine solution 4 times a day.~In the 3rd stage, saliva pH (power of hydrogen), dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
48498283|NCT05437367|OTHER|Scapular Stabilization exercises|Therapeutic exercises
48498284|NCT05437367|OTHER|Postural correction exercises|Therapeutic exercises
48498285|NCT05807516|OTHER|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
48133066|NCT01614405|DRUG|TDF/FTC/LPV/r|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
48133067|NCT01614405|DRUG|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
48498286|NCT05872893|DRUG|Ondansetron|Patients will receive age-adjusted doses of ondansetron 5mg/m2
48133069|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 1|single infusion of rapcabtagene autoleucel
48133070|NCT06581198|BIOLOGICAL|rapcabtagene autoleucel Regimen 2|single infusion of rapcabtagene autoleucel
47980911|NCT03886376|OTHER|Superficial Massage|The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
48133071|NCT06581198|OTHER|Standard of Care|The treatment regimen must be in line with KDIGO guidelines for treatment of class III/IV LN.
48133072|NCT03643224|DEVICE|Radiofrequency Ablation|A procedure will be performed using a radiofrequency ablation catheter.
48498287|NCT05872893|DRUG|Dexamethasone|Patients will receive dexamethasone 4mg/m2
48498288|NCT03106649|DEVICE|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
48656198|NCT04578041|OTHER|Aerobic Exercise Program|Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
48656199|NCT04578041|OTHER|Computerized CT (Cognitive Training)|"Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session."
47980912|NCT01373372|DRUG|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
47980913|NCT03042533|DEVICE|Conventional Compression|Method of Nail fitting
47980914|NCT03042533|DEVICE|Standard Backslapping|Method of Nail fitting
48133079|NCT04825379|DEVICE|bioactive composite|Cention N
48133080|NCT04825379|DEVICE|posterior composite|G-ænial Posterior
47980915|NCT03042533|DEVICE|Dynamic Locking with Backslapping|Method of Nail fitting
47980916|NCT05062681|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
47980917|NCT05062681|DRUG|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
48340327|NCT04869111|BEHAVIORAL|Brain Health Training|"1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.~3. Brain-Healthy Habits - daily reminders of habits you can track~4. BrainHQ - participants will gain temporary access to the exercise-based cognitive training of BrainHQ after completing their 3rd BrainHealth Index"
48340328|NCT00003110|BIOLOGICAL|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
47980918|NCT04350788|OTHER|Survivorship Care Plan|Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
47980919|NCT04350788|OTHER|Enhanced Survivorship Care Plan|In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
47980920|NCT06255314|PROCEDURE|ventral hernia repair|"Laparoscopic transabdominal retromuscular repair is a minimally invasive approach to the open Rives Stoppa retromuscular sublay repair for ventral hernia.~In ventral hernia repair, it relies on initiation of dissection in one retrorectus space and then crossover to the contralateral retrorectus space The sublay mesh technique is an open surgical procedure for ventral and incisional hernias"
47980921|NCT01144923|OTHER|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
47980922|NCT01144923|PROCEDURE|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
47980923|NCT01144923|OTHER|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
47980924|NCT02500888|RADIATION|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
47980925|NCT00446290|DRUG|Docetaxel, Capecitabine and Oxaliplatin|
48498289|NCT03106649|DEVICE|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
47980926|NCT04734444|DEVICE|SonoClear ACF|The SonoClear ACF is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
47980927|NCT03236740|DRUG|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
47980928|NCT03236740|DRUG|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
47980929|NCT03804879|DRUG|Nidufexor|50 mg (two 25 mg) LMB763 capsules for oral administration
47980930|NCT03804879|OTHER|Placebo|Placebo capsules for oral administration
47980931|NCT03804879|DRUG|Standard of Care (SoC)|Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
48498290|NCT04180163|DRUG|Lanadelumab|Lanadelumab solution, SC
48498291|NCT05561530|DRUG|ALG-125755|single or multiple doses of ALG-125755
47980932|NCT03681392|DIETARY_SUPPLEMENT|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
47980933|NCT02398851|BEHAVIORAL|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
48133083|NCT05902845|DRUG|RD13-02 cell infusion|CAR-T cells
48133084|NCT06490939|DRUG|Efepoetin Alfa|Single-intravenous administration
48498292|NCT05561530|DRUG|Placebo|single or multiple doses of placebo
48498293|NCT04915014|PROCEDURE|sleeve gastrectomy with transit bipartition (SG +TB)|In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.
48340329|NCT02818270|DRUG|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
48340330|NCT02818270|DRUG|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
48498294|NCT04915014|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.
48498295|NCT00355810|DIETARY_SUPPLEMENT|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
48498296|NCT00355810|DIETARY_SUPPLEMENT|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
48498297|NCT00914914|DRUG|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
48513294|NCT04420273|BEHAVIORAL|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
48656200|NCT06581237|OTHER|Eat2Win App|Voluntary use of the app will occur throughout the sport season.
48340331|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg IV infusion.
48340332|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
48340333|NCT03647176|OTHER|Cold snare polypectomy|cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
48340334|NCT06242093|DEVICE|whole body vibrator|• WBVT and Conservative treatment Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform
48340335|NCT06242093|OTHER|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks"
48340336|NCT05646719|DRUG|Phentolamine Opthalmic Solution 0.75%|phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
48340337|NCT05646719|OTHER|Placebo|Vehicle for Phentolamine Ophthalmic Solution
48340338|NCT05646719|DRUG|Low dose pilocarpine|Pilocarpine hydrochloride ophthalmic solution 0.4%
48340339|NCT05646719|OTHER|Low dose pilocarpine vehicle|Vehicle for low dose pilocarpine
48340340|NCT00470678|DRUG|ranibizumab|
48340341|NCT04313101|OTHER|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~* Euthyroid ( Normal TSH, FT3 and FT4)~* Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~* Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~* Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
48656201|NCT03298737|BEHAVIORAL|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
48656202|NCT06439706|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling kit
48656203|NCT06439706|BEHAVIORAL|Group Education|Small-group education led by bilingual health educator
48656204|NCT06141733|OTHER|NIRS group|Standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
47980934|NCT02398851|BEHAVIORAL|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
48340342|NCT04833790|BEHAVIORAL|Free distribution of ORS|Provides will receive 3 months supply of ORS at the beginning of the study to dispense to their patients. They will be asked to dispense the ORS at the market rate and not to give it away to other providers.
48133096|NCT04989816|DRUG|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
48133097|NCT06241573|DRUG|Spesolimab|Spesolimab
48133098|NCT06207578|PROCEDURE|implant placement using crestal sinus approach|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision. After flap reflection, the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm
48133099|NCT06207578|PROCEDURE|Implant placement using osseodensification|The implant motor will be adjusted on reverse mode with 800 to 1200 rpm. According to the desired implant dimension, Densah bur diameter will be used and then implant placement.
48340343|NCT04833790|BEHAVIORAL|Standardized patient with ORS preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests ORS to treat their child's diarrhea.
48498298|NCT04568473|OTHER|PRG Barrier Coat (By SHOFU Inc., Japan)|PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
48133101|NCT06492148|OTHER|Myofascial Release|The myofascial release technique is a widely used manual therapy method characterized by low-load, prolonged mechanical forces applied to manipulate the myofascial complex, aiming to restore optimal length, alleviate pain, and improve function.
48133102|NCT06492148|OTHER|Sham-Myofascial Release|The hands of the researcher applying the technique will be placed in the same areas as the myofascial release technique, with only the palms in light contact for the same duration. However, no intervention will be made to create any pressure or open the tissue barrier.
48133103|NCT05791162|OTHER|Blood collection|Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)
48656205|NCT03490240|BEHAVIORAL|BIPAMS|"The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention."
48133104|NCT05791162|OTHER|Urine sample|Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
48340344|NCT04833790|BEHAVIORAL|Standardized patient with Antibiotic preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who requests Antibiotics to treat their child's diarrhea.
47980935|NCT02606604|DEVICE|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
47980936|NCT03144362|PROCEDURE|Bilateral Sliding Techniques|Bilateral Sliding Techniques
47980937|NCT03144362|PROCEDURE|Unilateral Sliding Techniques|Unilateral Sliding Techniques
47980938|NCT00864045|DRUG|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
47980939|NCT00864045|DRUG|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
47980940|NCT04350840|BEHAVIORAL|feedback|feedback of optical diagnosis performance per 3 month
47980941|NCT00533845|DRUG|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
47980942|NCT03198949|DRUG|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
47980943|NCT00894569|DRUG|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
47980944|NCT00894569|DRUG|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
47980945|NCT04803097|DIAGNOSTIC_TEST||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
47980946|NCT02927080|DRUG|ACE-083|Recombinant fusion protein.
47980947|NCT02927080|DRUG|ACE-083 or placebo|Recombinant fusion protein or normal saline.
47980948|NCT02387853|DRUG|LEO 90100|
47980949|NCT00225160|DRUG|acetyl L-carnitine|
47980950|NCT03404791|DRUG|TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
47980951|NCT00022451|DRUG|tipifarnib|
48133105|NCT06489353|BEHAVIORAL|Video-watching|Participants will watch age-appropriate and engaging videos.
48133106|NCT06489353|BEHAVIORAL|Blowing Pinwheels|Participants will blow pinwheels during the venipuncture procedure
48498299|NCT04568473|OTHER|EMBRACE™ Varnish by (Pulpdent Corporation, USA)|5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
48133108|NCT06125197|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
48133109|NCT06125197|BIOLOGICAL|KEYTRUDA®|pembrolizumab, a monoclonal antibody binding PD-1
48498300|NCT05634850|DEVICE|Kinder|Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.
48498301|NCT02131597|DRUG|Guadecitabine|Given SC
48498302|NCT01076686|DRUG|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
48498303|NCT06434077|BIOLOGICAL|GcMAF injections (100 ng)|The GcMAF 100 ng (Gc protein macrophage-activating factor) will be injected subcutaneously.
48498304|NCT06434077|OTHER|placebo|the placebo solution will be injected subcutaneously 100 ng.
48498305|NCT03326609|DRUG|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
48498306|NCT01642459|OTHER|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
48498307|NCT01642459|OTHER|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
48133116|NCT03593642|DRUG|Continuous infusion of ropivacain in ESP catheter|administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
48340345|NCT04833790|BEHAVIORAL|Standardized patient with no preference|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea.
48656206|NCT03490240|BEHAVIORAL|WELLMS|The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
48656207|NCT03483701|BEHAVIORAL|Cognitive Remediation Therapy|The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
48656208|NCT06637202|RADIATION|postoperative radiotherapy|50 Gy in 25 fractions
48656209|NCT06645223|DRUG|No Interventions|no interventions
48656210|NCT02082379|BEHAVIORAL|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
47980952|NCT00837304|DEVICE|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
47980953|NCT00837304|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
48133117|NCT03593642|DRUG|Continuous infusion of Iso Saline in ESP catheter|administration of Iso Saline in ESP catheter to be the control group
48498308|NCT00000723|DRUG|Methotrexate|
48498309|NCT00000723|DRUG|Leucovorin calcium|
48498310|NCT00000723|DRUG|Zidovudine|
48498311|NCT00000723|DRUG|Dexamethasone|
48340346|NCT04833790|BEHAVIORAL|Standardized patient with no preference + no financial incentive|Providers will receive a visit from an anonymous standardize patient posing a caretaker for a child with diarrhea who does not request anything specific to treat their child's diarrhea. In addition they will inform the provider that they are not going to purchase anything from the provider because they have an uncle with a drug shop where they can get a discount.
48498312|NCT02440113|DEVICE|Nellix|Nellix Implantation
48498313|NCT03344861|DRUG|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
47980954|NCT01057654|DRUG|Pravastatin|Pravastatin 40 mg
48133122|NCT05717127|BEHAVIORAL|Time restricted feeding|Restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
48133123|NCT05717127|BEHAVIORAL|Standard lifestyle|Standard lifestyle recommendations
48498314|NCT03344861|DEVICE|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
48498315|NCT05209217|DRUG|Ketamine|Intranasal administration of their customary prescribed dose
48498316|NCT05680935|DIAGNOSTIC_TEST|blood microRNA|all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
48133126|NCT05490732|BIOLOGICAL|Blood sampling|"Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture"
48133127|NCT00361205|DEVICE|Electronic Monitoring cap|
48340347|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
48498317|NCT05680935|DIAGNOSTIC_TEST|plaque and intima microRNA|The resulting surgical material will be sent for microRNA isolation.
48498318|NCT05680935|DIAGNOSTIC_TEST|histological examination of the plaque|The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
48498319|NCT05680935|DIAGNOSTIC_TEST|blood level trimethyl N-oxide|all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
48498320|NCT00207675|DRUG|infliximab|
48498321|NCT00653952|DRUG|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
48656211|NCT06418308|DRUG|Dexmedetomidine|5 mcg of dexmedetomidine
48340348|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
48498322|NCT00653952|DRUG|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
48498323|NCT04452253|DIETARY_SUPPLEMENT|PS128|PS128 belongs to Lactobacillus plantarum subsp. plantarumand. Probiotic capsules contain 10 billion CFU (colony forming units) of PS128
48498324|NCT04452253|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 10 billion CFU (colony forming units) of PS23
48498325|NCT04452253|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 10 billion of PS23 cells.
48656212|NCT06418308|DRUG|Epinephrine|200 mcg of epinephrine
48656213|NCT06418308|DRUG|Standardized Spinal Mixture|Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
47980955|NCT01057654|DRUG|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
48498326|NCT04452253|OTHER|Placebo|The placebo capsule contains microcrystalline cellulose.
48498327|NCT04547530|DIETARY_SUPPLEMENT|Vitamin D|as above
48498328|NCT04547530|DIETARY_SUPPLEMENT|Placebo|as above
48498329|NCT03195153|DRUG|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
48498330|NCT03195153|DRUG|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
48340349|NCT06267807|DIAGNOSTIC_TEST|Dynamic contrast-enhanced lymphangiography|The subject is placed supine on a detachable MR imaging table, outside the scanning room. Both inguinal regions are prepared under sterile conditions. Using Ultrasound guidance, the thoracic duct outlet at the left venous angle is identified. Under US guidance, a small 25 gauge needle is placed at the corticomedullar junction of an inguinal lymph node on each side. The needle position is confirmed and checked that there is no extravasation at saline injection under US visualization. The subject is then transferred to the MR imaging machine. First, pre-contrast imaging is performed, this takes around 20 minutes.
48340350|NCT01997281|DIETARY_SUPPLEMENT|dietary fiber-enriched cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~* one serving of steamed egg is added for dinner and breakfast"
48498331|NCT03195153|DRUG|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
48498332|NCT05841927|DIETARY_SUPPLEMENT|Docosahexaenoic acid supplement|Docosahexaenoic acid supplement
48498333|NCT05841927|DIETARY_SUPPLEMENT|ASD placebo|ASD placebo
48498334|NCT05051761|DRUG|Jaktinib|Administered orally.
48498335|NCT05051761|DRUG|placebo|Administered orally.
48498336|NCT02338193|DRUG|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
48498337|NCT02338193|DRUG|DAPA|10 mg dapagliflozin QD for 20-24 weeks
48498338|NCT02338193|DRUG|MET XR|1000 mg Metformin XR BID for 20-24 weeks
48498339|NCT03694600|DIAGNOSTIC_TEST|Multi-analyte blood Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
48498340|NCT03145636|DEVICE|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
48498341|NCT03145636|OTHER|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
48498342|NCT03145636|OTHER|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
48498343|NCT05646420|OTHER|Blood sampling|A blood sample of 15 ml will be collected for each patient.
48498344|NCT03720379|DEVICE|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
48656214|NCT02603497|DRUG|ASP015K|oral
48656215|NCT00240266|DRUG|Rosuvastatin|
48498345|NCT03720379|DEVICE|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
48498346|NCT02866526|OTHER|Patient questionnaire|quantitative and qualitative data collection will be proposed.
48498347|NCT04001101|COMBINATION_PRODUCT|RT and Anti-PD-1|limited metastatic site radiation
48498348|NCT04001101|DRUG|Anti-PD-1|anti-PD-1 therapy alone
48133136|NCT05570617|BEHAVIORAL|Transition Coach Intervention|The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
48133137|NCT05570617|BEHAVIORAL|Standard of Care- Youth Transition Roadmap|All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
48133138|NCT05561231|PROCEDURE|Intubation with C blade|Intubation with C blade of CMAC videolaryngoscope
48133139|NCT05561231|PROCEDURE|Intubation with D blade|Intubation with D blade of CMAC videolaryngoscope
48133140|NCT05746429|BEHAVIORAL|Cognitive Behavior Therapy|Receive mobile CBT
48133141|NCT05746429|DEVICE|Transcranial Direct Current Stimulation|Undergo active tDCS
48133142|NCT05746429|OTHER|Interview|Attend virtual meetings and focus groups
48133143|NCT05746429|DRUG|Placebo Administration|Undergo sham tDCS
48133144|NCT05746429|OTHER|Questionnaire Administration|Ancillary studies
48498349|NCT01090830|DRUG|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
48498350|NCT05992818|DIAGNOSTIC_TEST|comparing DRS-R-98 (The Delirium Rating Scale--Revised-98) and 3D-CAM (3-minute diagnostic assessment for CAM-Confusion Assessment Method-defined delirium) tests to assess postoperative delirium|determine the test that is more effective and practical in the assessment of POD
48498351|NCT05650190|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
48133148|NCT04535856|DRUG|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)"
48133149|NCT04535856|OTHER|Placebo|Control group (placebo)
48133150|NCT06479889|BEHAVIORAL|Guardians receiving counseling + lock|Guardians of patients admitted to the Pediatric Hospital Medicine behavioral health team will be provided a brief lethal means educational session and offered up to 3 secure storage devices of their choosing (lock box and or cable locks)
48133151|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (2 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
48133152|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (4 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
48133153|NCT06259032|OTHER|Mechanical alignment|Goal alignment in TKA with mechanical alignment, resection bone in perpendicular to mechanical axis of femur and tibia.
48656216|NCT06637930|OTHER|Edentulous Alveolar Ridge In Mandible|"implant retained mandibular overdenture using telescopic attachment system. all the patients received 2 implants at the canine region bilaterally using sterelithographic guide , then healing period for 3 months for proper osseointegration , then digital intraoral scanning was performed to detect implant position using scannable bodies , abutments which act as primary crowns were designed on cad software then milled using premilled titanium abutments.the study grouping was performed then virtual model was done for the designing of the frameworks then milled according to the grouping of the study. Try in of the frameworks was done and overdentures were inserted.~* Retention force test was done using digital force gauge.~* Probing depth using Teflon coated periodontal probe.~* Marginal bone level and bone density were measured using digital periapical x-ray"
48133154|NCT06259032|OTHER|Functional alignment|Goal alignment in TKA with functional alignment, resection of bone base on native joint line obliquity.
48498352|NCT05650190|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
48498353|NCT06311162|BEHAVIORAL|Life-Style app|The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
48656217|NCT06643455|BEHAVIORAL|Behavioral Dietary Intervention|Participate in the MIND program
48656218|NCT06643455|OTHER|Best Practice|Participate in SOC
47980956|NCT02406976|OTHER|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
47980957|NCT02406976|BEHAVIORAL|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
47980958|NCT02406976|OTHER|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
48498354|NCT06311162|OTHER|Sham Comparator|The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
48340351|NCT01997281|OTHER|conventional cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast"
48340352|NCT03867110|DRUG|Placebo|
48340353|NCT03867110|DRUG|Ezetimibe 10 mg|
48656219|NCT06643455|OTHER|Electronic Medical Record|Ancillary studies
48340354|NCT03867110|DRUG|Atorvastatin 10 mg|
48340355|NCT03867110|DRUG|Atorvastatin 20 mg|
48656220|NCT06643455|OTHER|Questionnaire Administration|Ancillary studies
48656221|NCT06642649|PROCEDURE|General Anesthesia (control group)|Only General Anestesia
48656222|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined|General anesthesia + spinal anesthesia with local anesthetic and morfine
48656223|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined|General anesthesia + spinal anesthesia with local anesthetic, morfine and fentanyl
48656224|NCT06352463|OTHER|Denken + Doen = Durven|DDD is an evidence based cognitive behavioural therapy (CBT)-treatment protocol for children with anxiety. This research will use the modular version of DDD, which means that the therapist will decide which modules she will use based on the specific symptoms and needs of the child. DDD consists of four parts. First, there will be psycho education in which the child learns about how anxiety can arise, when anxiety is normal, and how thoughts, emotions, and behaviour are linked. Second, the child will learn coping strategies for dealing with anxiety. Third, there will be cognitive restructuring by which that the child will learn skills to deal with anxious and negative thoughts, through challenging and experimenting. Finally, there will be exposure. In the exposure sessions, the child will face their fears step by step.
47980959|NCT05833295|PROCEDURE|Downhill walking|Change in the H/M ratio after a downhill walk.
47980960|NCT05833295|PROCEDURE|Walking on flat ground|Change in the H/M ratio after a Walking on flat ground
48340356|NCT03867110|DRUG|Atorvastatin 40 mg|
48340357|NCT03867110|DRUG|Atorvastatin 80 mg|
48340358|NCT02951897|PROCEDURE|lobectomy|
48340359|NCT02951897|PROCEDURE|segmentecomy|
48340360|NCT02951897|DRUG|chemotherapy（pemetrexed+CISPLATIN）|
48498355|NCT05036356|OTHER|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
48498356|NCT02304627|DRUG|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
48133158|NCT06548594|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
48340361|NCT02951897|PROCEDURE|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
48367399|NCT04594616|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
48367400|NCT02549261|DRUG|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
48367401|NCT02549261|DRUG|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
48498357|NCT01656538|DRUG|Paclitaxel|
48498358|NCT01656538|DRUG|Reolysin|
48656225|NCT06352463|OTHER|Supportive Parenting for Anxious Childhood Emotions|Parents will follow the SPACE program. SPACE is a theory driven, evidence-based treatment program of 12 sessions. In a structured way, parents are trained to change their own behaviour as a reaction to the symptoms of their child. First, they are trained to recognise family accommodation and slowly reduce this. Second, this program focuses on the increase in supportive reactions from parents. They are taught to accept the child's feelings, fears, and problems and to trust in the ability of the child to cope with and tolerate anxiety-related problems. These two goals are attained via a sequence of steps in the SPACE manual. Furthermore, SPACE includes additional modules that can be implemented if needed. These provide tools for conquering communal challenges that can arise during the treatment process, including dealing with extremely disruptive behaviour of children and improving parental collaboration.
48656226|NCT06188741|DRUG|Selumetinib|Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
48498359|NCT00506129|DRUG|Fludarabine|25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
48498360|NCT00506129|DRUG|Melphalan|70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
48498361|NCT00506129|PROCEDURE|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
48498362|NCT00506129|DRUG|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
48498363|NCT01209130|DRUG|DCDT2980S|Intravenous repeating dose
48498364|NCT01209130|DRUG|rituximab|Intravenous repeating dose
48498365|NCT01335386|DRUG|KLYX|
48656227|NCT02392169|DRUG|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
48656228|NCT05118308|PROCEDURE|Transjugular hepatic venous pressure gradient measurement with liver biopsy|This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
48656229|NCT05118308|PROCEDURE|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy|A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
48656230|NCT05841667|DRUG|Remimazolam besylate|"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."
48656231|NCT03153410|DRUG|Cyclophosphamide|"200 mg/m\^2, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
48498366|NCT01335386|DRUG|Glycerine|
48498367|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
48498368|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
48656232|NCT03153410|DRUG|GVAX Pancreas Vaccine (GVAX)|"5x10\^8 cells, six intradermal (ID) injections~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
48498369|NCT01557738|DIETARY_SUPPLEMENT|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
48498370|NCT01557738|DIETARY_SUPPLEMENT|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
48498371|NCT00441506|DRUG|daily interruption of sedatives|
48340362|NCT02951897|OTHER|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
48656233|NCT03153410|DRUG|Pembrolizumab|"200 mg, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
48656234|NCT03153410|DRUG|IMC-CS4|"75 mg (dose level 1) or 100 mg (dose level 2), intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
48656235|NCT06217081|DEVICE|3M Topical Tissue Adhesive|Application of investigational topical tissue adhesive to trauma laceration or surgical incision.
48656236|NCT06217081|DEVICE|Histoacryl® Blue Topical Skin Adhesive|Application of control topical tissue adhesive to trauma laceration or surgical incision.
48656237|NCT03423979|DEVICE|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
47914536|NCT02470000|DEVICE|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
47980961|NCT05151146|DRUG|ANJ900|Metformin hydrochloride delayed-release tablets
47980962|NCT05151146|DRUG|Metformin IR|metformin hydrochloride
48498372|NCT04414462|OTHER|exergaming training|"* HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
48340363|NCT00968708|DRUG|Alogliptin|Alogliptin tablets
48340364|NCT00968708|DRUG|Placebo|Alogliptin placebo matching tablets
48656238|NCT03423979|DRUG|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
48656239|NCT04470037|DRUG|DAAOI-P|DAAOI-P 250-1500mg
48656240|NCT04470037|DRUG|Placebo|starch pill
48340365|NCT02031198|DRUG|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
48498373|NCT04414462|OTHER|training - Group II|"* Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
48656241|NCT06413914|BEHAVIORAL|Cognitive behavioral Therapy|"Cognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns.~A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment.~."
48133165|NCT05693935|DRUG|TV-44749 - Dose level 1|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
48133166|NCT05693935|DRUG|TV-44749 - Dose level 2|In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
48133167|NCT05693935|DRUG|TV-44749 - Dose level 3|In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
48133168|NCT05693935|DRUG|Placebo|In Period 1, 2 monthly injections (Period 1 only)
48340366|NCT01769638|DRUG|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
48656242|NCT06373068|OTHER|Resuscitation orders|Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
48656243|NCT03999424|BIOLOGICAL|autologous human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
48656244|NCT06249919|BIOLOGICAL|NS101|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
48656245|NCT06249919|BIOLOGICAL|Placebo|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
48656246|NCT03740113|BEHAVIORAL|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
48656247|NCT00997763|DEVICE|XIENCE V|everolimus-eluting stent
48656248|NCT00997763|DEVICE|CYPHER|sirolimus-eluting stent
48656249|NCT06373120|DEVICE|CorVad|The CorVad percutaneous ventricular assist system device is a microaxial rotary blood pump that expels blood from the left ventricle into the ascending aorta, thus unloading the left ventricle. The CorVad system device can be introduced through a femoral percutaneous approach (14Fr) and can deliver an output of up to 4-6 L/min.
48656250|NCT06373120|DEVICE|VA-ECMO|Veno-arterial extracorporeal Membrane Oxygenation (VA-ECMO) is a device originally created to replace heart and lung function. Venous deoxygenated blood is mechanically suctioned from a large central vein through a venous cannula by a centrifugal pump. It is then oxygenated, warmed, and restored into systemic circulation through an arterial cannula.
48656251|NCT05581121|OTHER|Standard treatment: Control arm|Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
48656252|NCT05581121|PROCEDURE|Experimental arm|Pre-therapeutic para-aortic lymphadenectomy followed by tailored chemo-radiotherapy and brachytherapy.
48656253|NCT05022654|DRUG|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
48656254|NCT05022654|DRUG|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
48656255|NCT05093621|DRUG|Furosemide|Standard of care diuretic
48656256|NCT05093621|DRUG|Torsemide|Standard of care diuretic
48656257|NCT05020457|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
48656258|NCT05020457|DRUG|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
48656259|NCT05020457|DRUG|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
48656260|NCT05268367|BEHAVIORAL|Written Exposure Therapy|A brief exposure-based psychotherapy for posttraumatic stress disorder
48656261|NCT06639867|DEVICE|VR-based home physiotherapy|VR-based home physiotherapy
48656262|NCT06639867|OTHER|Standard physiotherapy care|Standard physiotherapy care as prescribed by the treating physiotherapist
48656263|NCT01923038|PROCEDURE|First arm: patients ventilated with zero end expiratory pressure|
48656264|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure|
48656265|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
48656266|NCT06637397|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
48498374|NCT05148390|DEVICE|Cutimed® Gelling Fiber|application of dressing
48498375|NCT05320406|RADIATION|Radiation therapy|Undergo radiation therapy
48133173|NCT03328364|DRUG|enzalutamide|oral
48340367|NCT01769638|DRUG|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
48656267|NCT06637397|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
48656268|NCT04083378|PROCEDURE|Ablation Therapy|Undergo standard of care ablation
48656269|NCT04083378|PROCEDURE|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
48656270|NCT04083378|OTHER|Quality-of-Life Assessment|Ancillary studies
48656271|NCT04083378|OTHER|Questionnaire Administration|Ancillary studies
48656272|NCT06639035|OTHER|External oblique intercostal plane block|The external oblique intercostal plane block is applied to the patients at the end of the surgery.
48656273|NCT06639035|OTHER|intavenous tramadol|Intravenous tramadol will be administered with patient-controlled analgesia
48498376|NCT05320406|DRUG|Leuprolide|Given IM or SC
48498377|NCT05320406|DRUG|Relugolix|Given PO
48656274|NCT04155632|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
48656275|NCT04155632|DEVICE|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
48656276|NCT03100461|OTHER|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
48656277|NCT03100461|OTHER|Health Education|Standard of care approach that will provide basic information on CRC screening.
48656278|NCT05805189|PROCEDURE|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
48656279|NCT06637813|OTHER|Blood sampling for evaluation of biomarkers|Non-routine diagnostic test evaluations
48656280|NCT05575440|PROCEDURE|Computed Tomography|Undergo a PET/CT scan
48656281|NCT05575440|RADIATION|Fluorine F 18 Tetrafluoroborate|Given IV
48133174|NCT03328364|DRUG|docetaxel|intravenous infusion
48340368|NCT04165005|BEHAVIORAL|decentering|examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
48340369|NCT04165005|BEHAVIORAL|guided imagery|relaxing guided imagery including breathing exercises.
48340370|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
48340371|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
48340372|NCT01432457|DRUG|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
48340373|NCT00702260|DRUG|Ramipril|10 mg capsule
48340374|NCT05038787|DRUG|LY3473329|Administered orally.
48340375|NCT05038787|DRUG|Placebo|Administered orally.
48498378|NCT03333590|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
48656282|NCT05575440|PROCEDURE|Positron Emission Tomography|Undergo a PET/CT scan
48656283|NCT05575440|OTHER|Survey Administration|Ancillary studies
48656284|NCT04715581|DIETARY_SUPPLEMENT|Preoperative nutritional optimization|"1. Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~2. Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin \<130 g/L for men and \<120 g/L for women) will be given oral iron therapy.~3. The duration of nutritional optimization: The day admitted to the hospital to the surgery to one day prior to the surgery."
48656285|NCT04715581|BEHAVIORAL|Preoperative exercise training|"1. The respiratory training will be performed for at least 2-3 times per day. Respiratory training include thoracic breathing exercise and cough training.~2. Aerobic exercise will be performed for at least 1-2 times per day. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~4. The duration of exercise training: The day admitted to the hospital to the surgery to one day prior to the surgery."
48656286|NCT04715581|BEHAVIORAL|Postoperative exercise training|"1. Muscle strength training in the bedside and walking in the ward.~2. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Exercise training is performed under the supervision of physiotherpists durign hospital stay, and is reminded by regular telephone calls and phone messages after hospital discharge."
48656287|NCT03653819|OTHER|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
48340376|NCT05333003|DRUG|Semaglutide|The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week
48656288|NCT03653819|OTHER|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
48656289|NCT05996185|DRUG|Mogamulizumab|Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
48656290|NCT05996185|DRUG|DA-EPOCH Protocol|EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma.
48656291|NCT01653314|DRUG|Megavec|
48656292|NCT01653314|DRUG|Glivec|
48656293|NCT03751982|DEVICE|Transcranial Electrical Neuromodulation (TES)|TES phase-aligned with slow waves or not
48340377|NCT05333003|OTHER|Placebo|Placebo will be provided to participants
47914537|NCT02470000|DEVICE|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
47914538|NCT02470000|OTHER|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
47914539|NCT01802073|DRUG|Oral Vancomycin|
48340378|NCT00905268|DRUG|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
48340379|NCT00905268|DRUG|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
48340380|NCT04152746|OTHER|Periostin level|The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
48656294|NCT00756509|DRUG|Nilotinib|800 mg/d orally
48340381|NCT00254163|DRUG|Fludarabine|
48498379|NCT04199013|DRUG|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
48340382|NCT00254163|DRUG|Cyclophosphamide|
48340383|NCT00254163|DRUG|Rituximab|
48340384|NCT00254163|DRUG|Pentostatin|
48340385|NCT04283357|OTHER|Exercise|Short Foot Exercises
48340386|NCT04283357|DEVICE|Virtual Reality|Exercise with virtual reality
48340387|NCT03889964|OTHER|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
48340388|NCT05951543|OTHER|plyometric exercises|Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
48656295|NCT05044897|DRUG|SI-B001|administration weekly by intravenous infusion（QW）.
48656296|NCT06564480|DEVICE|MI-R1 lower limb walking machine assisted training device|The training is conducted under partial weight support training conditions, performing passive movements on the lower limbs through motor drive, improving the joint activity of the patient's hip and knee joints, and achieving sitting, standing, and walking functions.
48498380|NCT04199013|DRUG|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
48133175|NCT05738434|DRUG|Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib|camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135\~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
48133176|NCT05738434|DRUG|Camrelizumab+Chemotherapy→Camrelizumab|camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
48133177|NCT03878979|DRUG|Nivolumab 480mg and surgical resection|One dose of Nivolumab 480mg given four weeks prior to surgical resection.
48498381|NCT00732550|PROCEDURE|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
48133179|NCT05832151|DRUG|CIN-102 Dose 1 or 2|2 capsules twice daily for 12 weeks
48133180|NCT05832151|DRUG|Placebo|2 capsules twice daily for 12 weeks
48498382|NCT00732550|PROCEDURE|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
48340389|NCT05951543|OTHER|dynamic balance group control group|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
48340390|NCT02134041|OTHER|traumatic brain injury|mild TBI, GCS \>/=13 after traumatic brain injury
48340391|NCT03460613|OTHER|FODMAP diet|Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
48340392|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
48498383|NCT03889067|BIOLOGICAL|Salmonella Typhi challenge|The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
48498384|NCT05255874|OTHER|Aromatherapy|Patients in the study group will rest for 5 minutes before and after the urodynamics procedure. All patients will be asked to fill in the 'Spielberger State Anxiety Scale' before and after the urodynamic procedure. Before and after the procedure, blood pressure, heart rate, respiratory rate, peripheral oxygen saturation will be measured. Blood will be drawn for serum cortisol level. In addition to the routine treatment and care practices of the unit, aromatherapy will be applied to the patients included in the study group. Aromatherapy application will be applied to all patients by the same researcher. Aromatherapy application will be started 5 minutes before the urodynamic procedure after the patient is taken to the urodynamic room, and lavender essential oil (3 drops in 300 cc water for 5 cubic meters of room) will be used with a diffuser until the end of the procedure.
48498385|NCT02623348|BEHAVIORAL|pedometer|pedometer-based physical activity recommendations
48498386|NCT05971654|DRUG|azithromycin|azithromycin.:500 mg PO once for 5 days every month
48133183|NCT05716113|DRUG|RD13-02 cell infusion|CAR-T cells
48133184|NCT04636138|OTHER|Exercise|Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
48340393|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
48340394|NCT04069624|OTHER|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
48498387|NCT05172466|DEVICE|BeCare application|Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
48656297|NCT06564480|OTHER|Walking rehabilitation training under the guidance of therapists|Each patient undergoes training under the guidance of a rehabilitation therapist
48656298|NCT06405412|OTHER|MUST malnutrition score|MUST malnutrition score
48656299|NCT02249949|DRUG|efatutazone|Given PO
48133185|NCT05971979|OTHER|No intervention|No intervention
48340395|NCT06055972|OTHER|Educational Letter Post CT Examination|"Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination which will include the following:~1. Their calcium score, brief educational content explaining what the calcium score means and how the presence of coronary calcifications is associated with an increased risk of a cardiac event.~2. Guidance on what actions could be taken to decrease the risk of a heart event, including blood cholesterol management, smoking cessation, weight loss, dieting, exercise, and blood pressure control.~3. For patients with CAC\>0, the letter will encourage the patient to pursue a shared decision- making discussion with his/her primary care physician or cardiologist regarding risk reduction strategies.~4. Links to American Heart Association (AHA) and phone number for study research coordinator."
48340396|NCT05199883|OTHER|TI.VA algorithm: decision support system|TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
48340397|NCT01661946|DRUG|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
48133194|NCT03812874|DRUG|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency:~Phase I: one dose per day for 4 consecutive weeks (20 doses). Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
48133195|NCT03812874|DRUG|Placebo|"water for injection~Phase II (A)Daily Dose Regimen one dose per day for 12 consecutive weeks (60 doses). (B) Daily for first week, followed by weekly treatment Regimen One dose per day for 5 consecutive days in Week 1 (5 doses), and one dose per week till for 11 weeks (11 doses).~Duration: 12 weeks (Phase II)"
48340398|NCT01661946|DRUG|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
48340399|NCT00865046|OTHER|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
48498388|NCT00674557|DRUG|SOD1 inhibitor ATN-224|
48340400|NCT00865046|OTHER|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
48498389|NCT00674557|DRUG|exemestane|
48498390|NCT00674557|GENETIC|protein expression analysis|
48498391|NCT00674557|GENETIC|proteomic profiling|
48498392|NCT00674557|OTHER|laboratory biomarker analysis|
48498393|NCT00674557|OTHER|pharmacological study|
48498394|NCT05846867|DRUG|AK119|AK119 IV every 2 weeks.intravenous infusion
48498395|NCT05846867|DRUG|AK112|AK112 IV every 2 weeks.intravenous infusion
48498396|NCT05846867|DRUG|Oxaliplatin|Oxaliplatin: 85mg/m2, intravenous infusion
48498397|NCT05846867|DRUG|Irinotecan|Irinotecan 180mg/m2, intravenous infusion
48498398|NCT05846867|DRUG|Calcium folinate|Calcium folinate: 400mg/m2, intravenous infusion
47914540|NCT02664948|PROCEDURE|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
47914541|NCT00409669|DEVICE|Barraquer tonometer|barraquer tonometer
47914542|NCT00615901|DRUG|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
47980963|NCT00632411|DRUG|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
47980964|NCT00632411|BEHAVIORAL|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
48498399|NCT05846867|DRUG|Fluorouracil|Fluorouracil 400mg/m2, intravenous injection
48340401|NCT00607919|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
48133198|NCT05198674|DEVICE|Renal Denervation (Symplicity Spyral™)|Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
48340402|NCT00607919|DRUG|Placebo|oral, daily, for 16 weeks
48340403|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 5 mg
48340404|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
48133199|NCT01880567|DRUG|Ibrutinib|Given PO
48133200|NCT01880567|OTHER|Laboratory Biomarker Analysis|Correlative studies
48133201|NCT01880567|BIOLOGICAL|Rituximab|Given IV
48498400|NCT04351048|PROCEDURE|Stepwise Excavation|"* stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~* after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall."
48498401|NCT04351048|PROCEDURE|One Step Excavation|\*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
48133204|NCT02015013|BIOLOGICAL|Filgrastim|10 microgram/kg daily for 5 days, Subcutaneous injection.
48133205|NCT02015013|DRUG|Plerixafor|IV injection 0.24 mg/kg as a single dose, 11 hours prior to apheresis
48133206|NCT03703440|OTHER|Active arm|≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
48133207|NCT03703440|OTHER|Control arm|Usual diabetes care, every 3-month for 12 months
48498402|NCT01096030|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
48498403|NCT02845765|DEVICE|Dynamic Vessel Analyzer (DVA)|
48340405|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 10 mg
48340406|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
48340407|NCT02255760|DRUG|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
48340408|NCT02255760|DRUG|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
48340409|NCT02255760|DRUG|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
48498404|NCT02845765|DRUG|Phosphodiesterase type 5 Inhibitor (PDE5I)|
48498405|NCT02573090|PROCEDURE|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
48498406|NCT02573090|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
48498407|NCT02044406|DRUG|BI 1181181|single dose (low to high dose)
48656300|NCT06252584|DRUG|Vaccines, Peptide|Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
48656301|NCT06303518|OTHER|High normal ETCO2: ETCO2 50 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'High Normal ETCO2' (50 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
48656302|NCT06303518|OTHER|Normal ETCO2: ETCO2 40 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Normal ETCO2' (40 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
48656303|NCT06303518|OTHER|Low Normal ETCO2: ETCO2 30 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Low Normal ETCO2' (30 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
48656304|NCT06459804|PROCEDURE|Electro Dry Needling|"Standard Physiotherapy:~It will include Hot pack (10 min), Stretching of levator scapulae (3 times with 30 seconds hold), Scapular stabilization exercises (10 times with 5 seconds hold).~Scapular Stabilization exercises will be comprised of four exercise programs. The participants will sit on the knees in 90° flexion position, and a Swiss ball will be propped up between the stomach and chest."
48656305|NCT06459804|PROCEDURE|Dry Needling|Dry Needling
48656306|NCT04606472|DRUG|SI-B003|Administration by intravenous infusion.
48656307|NCT03285360|COMBINATION_PRODUCT|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
48656308|NCT03285360|COMBINATION_PRODUCT|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
48656309|NCT02779231|OTHER|Bi-directional texting|
47980965|NCT01059825|DRUG|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
47980966|NCT01059825|DRUG|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
48498408|NCT02044406|DRUG|BI 1181181, R|powder for oral solution
48498409|NCT02044406|DRUG|BI 1181181, T2|tablet, fasted
47980967|NCT01059825|DRUG|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
48340410|NCT02255760|DRUG|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
48340411|NCT02255760|OTHER|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
48340412|NCT01960504|DEVICE|Percutaneous Coronary Intervention (DREAMS) stenting|
48340413|NCT05373082|OTHER|questionnaire completion|Questionnaire to be completed by patients
48498410|NCT02044406|DRUG|Placebo to BI 1181181|Placebo to BI 1181181
47980968|NCT01059825|DRUG|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
47980969|NCT01059825|DRUG|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
47980970|NCT01059825|DRUG|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
47980971|NCT01059825|DRUG|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
47980972|NCT03577353|BEHAVIORAL|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
47980973|NCT03577353|BEHAVIORAL|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
47980974|NCT04667650|OTHER|Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.
47980975|NCT04698902|DEVICE|Intracoronary lithotripsy|Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.
47980976|NCT04236011|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
47980977|NCT05253053|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
47980978|NCT05253053|DRUG|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
47980979|NCT05253053|DRUG|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
47980980|NCT00293254|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
47980981|NCT00293254|DRUG|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
47980982|NCT05668455|DRUG|Hydrocortisone|1 drops 4 times a day
48498411|NCT02044406|DRUG|BI 1181181, T1|tablet, fed
47980983|NCT05668455|DRUG|Dexamethasone|1 drops 4 times a day
47980984|NCT05668455|OTHER|Povidone|1 drops 4 times a day
48340414|NCT03597503|DRUG|SPN-810|Flexible dose
48498412|NCT03884452|DRUG|Atorvastatin|Tablets taken orally once daily in the morning
48498413|NCT03884452|DRUG|Simvastatin|Tablets taken orally once daily in the morning or evening
47980985|NCT05861856|OTHER|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
47980986|NCT05861856|OTHER|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
47980987|NCT05937191|DRUG|Leflunomide|Leflunomide+Glucocorticoids treatment Group
47980988|NCT05937191|DRUG|Steroid Drug|Steroid Treatment
48133212|NCT05095740|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation used to regulate the contribution of the laryngeal motor cortex to voice production and laryngeal motor muscle activation.
48133213|NCT05095740|DEVICE|sham rTMS|Repetitive transcranial magnetic stimulation used to a cortical area not associated with change in outcomes at an intensity substantially lower than that of the established threshold.
48133214|NCT06555575|DRUG|Ubiquinone 200 Mg Oral Capsule|By mouth three times daily for three months
48133215|NCT06555575|DRUG|Ubiquinol 100 MG Oral Capsule|By mouth three times daily for three months
48133216|NCT04329221|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
48133217|NCT04329221|DRUG|Vaseline|Placebo
48133218|NCT04329221|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
48498414|NCT03884452|DRUG|Ezetimibe|Tablet taken orally once daily in the morning or evening
48340415|NCT03597503|DRUG|Placebo|Placebo
48340416|NCT00004916|DRUG|ifosfamide|
48340417|NCT00004916|DRUG|paclitaxel|
48498415|NCT03884452|DRUG|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
48340418|NCT00004916|DRUG|teniposide|
48340419|NCT00004916|PROCEDURE|peripheral blood stem cell transplantation|
48340420|NCT04641910|OTHER|No intervention|No intervention
48340421|NCT01394367|OTHER|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
47914543|NCT05969847|RADIATION|split-course hypofraction radiotherapy|After reaching a cumulative radiotherapy dose of 25Gy in the entire pelvic cavity (PTV1), the treatment field was subsequently narrowed to solely focus on the primary tumor (PTV2), with a total dose of 35Gy administered. All patients will undergo fractionated radiotherapy, following a regimen of 7Gy per fraction, delivered every 3 weeks for five cycles.
47914544|NCT05969847|DRUG|CAPOX|Drug: Oxaliplatin,130mg/m2，ivgtt，d1,for 6 cycles. Drug: Capecitabine,1000mg/m2，po，bid，d1-14, for 6 cycles.
48340422|NCT02976545|DEVICE|fMRI (functional Magnetic Resonance Imaging)|fMRI examination
48340423|NCT02976545|BEHAVIORAL|psychiatric evaluation|psychiatric evaluation
48340424|NCT05571904|PROCEDURE|thick STSG; thin STSG|"For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients."
48656310|NCT06316570|DRUG|Early Dual Antiplatelet Therapy|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;~Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
48656311|NCT06316570|DRUG|Placebo|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
48656312|NCT04806399|OTHER|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
48656313|NCT04923672|BEHAVIORAL|Moderate continuous exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
48656314|NCT04923672|BEHAVIORAL|High intensity interval exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
48656315|NCT06546618|BEHAVIORAL|pictorial warning and no flavor|LCC Package with pictorial warning and no flavor
48656316|NCT06546618|BEHAVIORAL|pictorial warning and 'sweet' flavor|LCC Package with pictorial warning and 'sweet' flavor
47980989|NCT03551860|PROCEDURE|TQL|"For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
48133220|NCT06432790|BEHAVIORAL|CHAMPION|The CHAMPION program is an intensive health behavior and lifestyle treatment (IHBLT), formed through the integration of the Healthy Weight Clinic IHBLT and with MGB's pediatric Asthma Population Health Management Program. It consists of 30 hours of contact time with the CHAMPION team (physician, dietician, community health worker), consistent with the USPSTF and AAP recommendations, monthly individual clinic visits with the team (in person or virtual, per randomization), health coaching calls with a community health worker and/or registered dietician, monthly group sessions (in the first six months), and educational materials for families that reinforce healthy lifestyle behaviors and provide self-management education. In this study, all participants will participate in CHAMPION, but one arm will receive the experimental form (delivery via telehealth) and the other arm will receive the active comparator (delivery via telehealth).
48498416|NCT05154630|DRUG|TQB2858 injection|TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
48340425|NCT06436820|PROCEDURE|Lumbar puncture|Lumbar puncture procedure performed within a clinical setting
48340426|NCT03874416|OTHER|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
48340427|NCT03874416|OTHER|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
48340428|NCT03678818|OTHER|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
48656317|NCT06546618|BEHAVIORAL|text-only warning and no flavor|LCC Package with text-only warning and no flavor
47980990|NCT03551860|PROCEDURE|FIB|"The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
48498417|NCT00630890|RADIATION|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
48656318|NCT06546618|BEHAVIORAL|text-only warning and 'sweet' flavor|LCC Package with text-only warning and 'sweet' flavor
48656319|NCT03584490|OTHER|Computerized Talking Touchscreen|"The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand."
48133225|NCT05626374|BEHAVIORAL|Basic Case Management|Usual case management support during 12-week training program
48340429|NCT00707538|DRUG|BMS747158|2 IV injection of \~11 mCi (total) F-18 labeled compound
48340430|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
48340431|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
48656320|NCT03584490|OTHER|Phone Administration of Questionnaires|This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
48656321|NCT05001737|DRUG|Emapalumab|Emapalumab iv infusion
48656322|NCT04855799|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
48340432|NCT01200160|DRUG|Niacin|
48340433|NCT00425074|DRUG|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
48340434|NCT00425074|DRUG|ASA|normal release acetylsalicylic acid
48340435|NCT00425074|DRUG|SR-ASA|slow release acetylsalicylic acid 150 mg
47980991|NCT02584335|DRUG|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
47980992|NCT02584335|DRUG|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
47980993|NCT04696445|DRUG|Morphine & Oxycodone|Morphine and Oxycodone are used in daily practice as part of standard care. Morphine and Oxycodone will be acquired through the clinical pharmacy of St Antonius and administered according to the standard postoperative pain protocol.
48656323|NCT06637891|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 2 weeks, 3 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
47980994|NCT02598076|BEHAVIORAL|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
47980995|NCT02598076|BEHAVIORAL|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
47980996|NCT01716351|BEHAVIORAL|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
47980997|NCT02329561|DRUG|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
47980998|NCT02329561|BEHAVIORAL|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
47980999|NCT02329561|DRUG|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
47981000|NCT03852355|DRUG|Radiofrequency|), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
48340436|NCT00766064|DRUG|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
48340437|NCT04432467|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous adipose tissue-derived mesenchymal stem cells
48340438|NCT04432467|OTHER|standard treatment|standard treatment according to clinical protocols
48340439|NCT06350006|DRUG|SHR-A1904; Adebrelimab|SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
48498418|NCT01207648|DRUG|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
48498419|NCT05284396|RADIATION|IFRT vs NFRT|involved field irradiation versus nodal field irradiation
48498420|NCT00954330|PROCEDURE|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
48656324|NCT04809805|DRUG|BAY2666605|One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
48656325|NCT03982316|BEHAVIORAL|Telehealth Behavioral Migraine Management|1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
48340440|NCT06350006|DRUG|SHR-A1904; CAPOX; Adebrelimab|SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
48340441|NCT04834050|PROCEDURE|Quadriceps femoris isometric home-based exercise|All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.
48340442|NCT01520688|DRUG|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
48340443|NCT01520688|DRUG|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
48340444|NCT01520688|DRUG|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
48340445|NCT01520688|DRUG|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
47981001|NCT03852355|DRUG|Steroids|received systemic steroids oral prednisolone tablet, 10 mg/day
47981002|NCT00438698|OTHER|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
47981003|NCT00438698|OTHER|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
48340446|NCT01520688|DRUG|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
48340447|NCT01520688|DRUG|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
48340448|NCT05154578|BIOLOGICAL|GBS-NN/NN2 Vaccine|0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
48656326|NCT06637163|DRUG|Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy|Benmelstobart: 1200 mg, i.v.gtt , d1, 22; Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week(If the number of patients achieving pCR in this group is ≥ 18 with the first 30 patients enrolled, the subsequent 20 patients will receive a reduced dose of 36 Gy in 20 fractions, 5 days per week.)
48656327|NCT06637163|DRUG|Paclitaxel + Carboplatin + Radiotherapy|Paclitaxel 50mg/m2, i.v.gtt , d1, 8, 15, 22, 29; Carboplatin AUC 2 mg/mL per minute, i.v.gtt , d1, 8, 15, 22, 29; Radiotherapy 41.4 Gy in 23 fractions, 5 days per week
48656328|NCT05517434|BIOLOGICAL|Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation|Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).
48656329|NCT05517434|OTHER|Saline (Placebo Comparator for BMA)|Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).
48656330|NCT05517434|BIOLOGICAL|Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations|Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
47981004|NCT00785395|DRUG|Oxytocin infusion|Up-down dosing determination
48340449|NCT05154578|BIOLOGICAL|Placebo|0.5 mL normal saline given by intramuscular injection
47914545|NCT05969847|DRUG|Envafolimab|Envafolimab is administered by subcutaneous injection. The recommended dose is 300 mg per 3 weeks (Q3W) for 6 cycles.
47914546|NCT05969847|PROCEDURE|Local excision|Local full-thickness resection is employed for patients with clinical complete response (cCR) or near-clinical complete response (ncCR) following TNT.
47914547|NCT06081933|DRUG|intranasal dexmedetomidine|Patients will receive 1.5 micro g/kg intranasal dexmedetomidine diluted with saline + infusion saline
48340450|NCT01285336|GENETIC||
48340451|NCT01774292|PROCEDURE|Endotracheal intubation with injection of liquid in the cuff|
48340452|NCT03459157|DRUG|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
48340453|NCT03959956|DIAGNOSTIC_TEST|Recording lung sound by a Smartscope|Lung sound will be recorded from four chest points by an electronic stethoscope called Smartscope which can also classify the recorded lung sound.
48340454|NCT01570062|DEVICE|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
48340455|NCT01570062|DEVICE|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
48656331|NCT05517434|OTHER|Saline (Placebo Comparator for LAM + LP-PRP)|Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
48656332|NCT05026710|DEVICE|Silicone (Coloplast Imajin Hydro) ureteral stent|During the end of the standard of care ureteroscopy the silicone stent will be placed.
48340456|NCT05968625|DEVICE|Thermoformed retainers|conventional thermoformed retainers fabricated on stone models.
48656333|NCT05026710|DEVICE|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)|During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
48656334|NCT06252415|BIOLOGICAL|foetal amniotic fluid sample|At the inclusion visit, during the foetal samples taken for the CMA/ES as part of the care.
48656335|NCT06252415|BIOLOGICAL|blood samples|2 x 5ml blood EDTA tubes for both parents
48656336|NCT06252415|OTHER|semi-structured online interviews|25 included couples will be invited to take part in 2 semi-structured online interviews (by telephone or videoconference)
48656337|NCT06607770|DRUG|Karelizumab+Apatinib|Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
48656338|NCT06602817|OTHER|Exposure: prone position|Exposure: surgery in prone position
48656339|NCT06602817|OTHER|Exposure: Supine position|Exposure: Surgery in supine position
48340457|NCT05968625|DEVICE|3D-printed retainers|3D-printed retainers fabricated directly by DLP printer.
48340458|NCT01962857|BEHAVIORAL|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
48340459|NCT01431469|DIETARY_SUPPLEMENT|Cow's milk|Powdered Whole Cow's Milk
48340460|NCT01431469|DIETARY_SUPPLEMENT|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
48340461|NCT03432572|DRUG|Pyridium|a urine discoloration agent
48498421|NCT00954330|DEVICE|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
48498422|NCT05268263|DEVICE|Artificial Intelligence Algorithm|The enrolled population will include patients with a history of lung pathologies. Artificial intelligence-based models are developed for classification of wheezes, crackles and normal lung sounds. These AI models will be tested and assessed on local lung sounds clinical data.
48498423|NCT03327636|DEVICE|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
48498424|NCT02677714|RADIATION|99mTc-rhAnnexin V-128|Kit for the preparation of 99mTc-rhAnnexin V-128
48498425|NCT03970928|DEVICE|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
48656340|NCT00336206|DRUG|Alemtuzumab|
48656341|NCT06644664|BEHAVIORAL|Health Education|Receive control MMS messages
48656342|NCT06644664|OTHER|Interview|Ancillary studies
48656343|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive AR MMS messages
48656344|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive RR MMS messages
48656345|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resources
48656346|NCT06644664|OTHER|Survey Administration|Ancillary studies
48656347|NCT06644664|OTHER|Text Message-Based Navigation Intervention|Receive check-in text message
48656348|NCT05882370|DRUG|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
48656349|NCT05882370|PROCEDURE|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
47981005|NCT04478474|DRUG|Ganciclovir|Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
47981006|NCT02468323|DRUG|Placebo|Patients will receive regular spinal anesthesia
48340462|NCT03432572|DRUG|Riboflavin|a urine discoloration agent
48340463|NCT03432572|DRUG|Thiamine|active placebo not known to cause urine discoloration
48340464|NCT00228033|DRUG|Elemental calcium (as carbonate)|
48340465|NCT00445341|DRUG|Flavopiridol|Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
48340466|NCT06207071|DIETARY_SUPPLEMENT|DHA|DHA supplementation
48340467|NCT02783209|PROCEDURE|Cataract surgery|
48340468|NCT03009149|OTHER|Aerobic exercise|Aerobic exercise will perform 3 days per week
48498426|NCT03482349|PROCEDURE|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
48656350|NCT06472856|PROCEDURE|Acupuncture|Acupuncture will be given using single use sterile stainless steel 34 gauge (Japanese size: 0.20 X 30 mm) filoform needles. Skin will be swabbed with an alcohol prep pad before acupuncture is administered. Needles will be inserted 0.5 to 1.0 centimetres deep into the skin and gently manipulated to create the deqi sensation. No electrical stimulation will be used.
48656351|NCT05845749|DRUG|Vosoritide Injection [Voxzogo]|Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
48656352|NCT03934619|DEVICE|Dolores One|Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
48656353|NCT03896581|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
48656354|NCT03896581|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
48656355|NCT01761149|DRUG|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
48656356|NCT06639048|BEHAVIORAL|Questionnaire|Questionnaire including demographic characteristics, social media usage habits, body weight, height, effects of social media on eating behavior scale and eating disorder fear questionnaire.
48656357|NCT06114628|DRUG|GSK3036656|Oral daily dosage of 20mg.
48656358|NCT06114628|DRUG|BTZ-043|Oral daily dosage of 1000mg.
48656359|NCT06114628|DRUG|Bedaquiline (B)|Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
48656360|NCT06114628|DRUG|Delamanid (D)|Oral daily dosage of 300mg.
48656361|NCT06114628|DRUG|Pretomanid (Pa)|Oral daily dosage of 200mg.
48656362|NCT06114628|DRUG|Moxifloxacin (M)|Oral daily dosage of 400mg.
48656363|NCT06114628|DRUG|Linezolid (L)|Oral daily dosage of 600mg for the first 8 weeks.
48656364|NCT06114628|DRUG|Pyrazinamide (Z)|Oral daily dosage of 1200mg-2000mg depending on weight.
48340469|NCT05167968|OTHER|No intervention (Observational cohort)|"For each patient, evaluation and adhesion to diuretics at inclusion are recorded:~* Self-questioning of medication adherence: Girerd questionnaire~* Assessment of the Medication Possession Ratio~* Social and demographic data~* Comorbidities~* PH characteristics"
48340470|NCT05054231|OTHER|Blood sample collection|Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
48498427|NCT06191393|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID/Flu Test|The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
48498428|NCT04053686|BEHAVIORAL|Breaks|3-min breaks every half hour at work
48656365|NCT06114628|DRUG|Rifampicin (R)|Oral daily dosage of 450mg-750mg depending on weight.
48656366|NCT06114628|DRUG|Isoniazid (H)|Oral daily dosage of 225mg-375mg depending on weight.
48656367|NCT06114628|DRUG|Ethambutol (E)|Oral daily dosage of 825mg-1375mg depending on weight.
48656368|NCT05536115|DEVICE|Alveogyl|"The patients will be treated by Alveogyl. Global treatment protocol (curettage, cleaning, local anaesthesia etc.) of the dry socket is at the discretion of the Investigator.~Alveogyl is used as an alveolar dressing. Placement of Alveogyl (about 0.2 g of paste) into the dental socket is done according to its instruction for use by a dental professional only."
48340471|NCT05688293|PROCEDURE|Connective tissue graft|non-surgical periodontal treatment and connective tissue graft
48340472|NCT05688293|PROCEDURE|Free gingival graft|will receive non-surgical periodontal treatment and partially de-epithelized free gingival graft
48340473|NCT05688293|PROCEDURE|Non surgical|non-surgical periodontal treatment only
48340474|NCT04251624|BEHAVIORAL|Goal Management Therapy|A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
48340475|NCT04251624|BEHAVIORAL|Psychosocial Education|A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
48340476|NCT03948451|DRUG|[14C]AZD5718 Oral Suspension|200 mg dose of \[14C\]AZD5718 Oral Suspension
48340477|NCT00152945|DRUG|Intravenous Intralipid|intravenous infusion
48133226|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool|Usual case management support during 12-week training program plus daily self-reports of distress using Distress Thermometer tool
48340478|NCT00152945|DRUG|Intravenous leucine, glycerol|intravenous infusion
48340479|NCT05531513|BEHAVIORAL|Virtual Reality (VR) Meditation|"The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~* Week 1 - Mindfulness of the Environment~* Week 2 - Embodied Mindfulness~* Week 3 - Embodied and Embedded Compassion~* Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
48340480|NCT05531513|BEHAVIORAL|Psychoeducational Pamphlet|"The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
48340481|NCT02072746|DIETARY_SUPPLEMENT|Zinc|
48340482|NCT02072746|DIETARY_SUPPLEMENT|Placebo|
48340483|NCT00995267|BEHAVIORAL|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories \& pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
48340484|NCT04366713|DRUG|Neratinib|Administered orally once daily as a single daily dose of 240 mg
48340485|NCT04366713|DRUG|Capecitabine|Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
48340486|NCT04366713|DRUG|Loperamide|Administered orally for prophylaxis for 28 days and then as needed
48340487|NCT01009736|DIETARY_SUPPLEMENT|tomato-soy juice|
48340488|NCT01009736|OTHER|laboratory biomarker analysis|
48340489|NCT01009736|OTHER|pharmacological study|
48340490|NCT01009736|PROCEDURE|therapeutic conventional surgery|
48340491|NCT03191812|OTHER|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
48340492|NCT04019210|PROCEDURE|MODIFIED TRABECULECTOMY|Rectangular scleral flap
47981007|NCT02468323|DRUG|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
48133227|NCT05626374|BEHAVIORAL|Basic Case Management plus rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus rapid access referral process for healthcare crisis services
48133228|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool and rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus daily distress self-reports plus rapid access referral process for healthcare crisis services
48340493|NCT02771457|DRUG|Infliximab at weeks 0,2, and 6|
48340494|NCT02771457|DRUG|Infliximab at weeks 0,4, and 8|
48340495|NCT02771457|DRUG|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
47914548|NCT06081933|DRUG|intravenous dexmedetomidine|patients will receive 0.1- 0.4 micro g/kg intravenous infusion dexmedetomidine + intranasal saline.
47981008|NCT02468323|DRUG|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
48340496|NCT04295707|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
48340497|NCT04295707|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
48340498|NCT01113840|BEHAVIORAL|Exercise|Exercise classes three times per week in a controlled, supervised environment.
48340499|NCT01113840|BEHAVIORAL|Control|Control group continues daily life as prior to randomization.
48340500|NCT02370550|DRUG|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
48340501|NCT02370550|DRUG|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
48340502|NCT02370550|DRUG|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
48340503|NCT02370550|DRUG|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
48340504|NCT02884128|DRUG|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
48340505|NCT02884128|DRUG|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
48340506|NCT02884128|DRUG|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
48340507|NCT05135429|OTHER|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
48340508|NCT05560152|DRUG|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
48340509|NCT02726048|DEVICE|Simplus/Eson|Released product Simplus and Eson masks
48340510|NCT01001572|DRUG|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
48340511|NCT01001572|DRUG|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
48656369|NCT06507644|PROCEDURE|light curettage|Before the treatment, the treated area will be degreased with 0.2% aqueous chlorhexidine. Next, a light curettage will be performed on the face with a sterile curette.
48133229|NCT05889910|PROCEDURE|Health education workshop|"The intervention will consist of 5 initial sessions, plus a reinforcement session at 6 months. The sessions will last 2 hours and will preferably be distributed one day a week.~The objective of the intervention is to reduce the fear of falling and falls in people over 65 years of age who live in the community. To this end, nursing interventions will be included to improve the knowledge, skills and attitudes of the participants regarding the improvement of their functional capacity, the prevention of falls and their preventive measures, as well as the improvement in the management of anxiety and coping with the fear of falling and falls.~The activities carried out during the intervention have been extracted from standardized nursing interventions through the Nursing Interventions Classification (NIC).~The following interventions and activities will be addressed: 1665, 5612, 6490, 6486, 4700, 5820 and 5230."
48133230|NCT00002235|DRUG|Indinavir sulfate|
48133231|NCT00002235|DRUG|Nelfinavir mesylate|
48133232|NCT00002235|DRUG|Efavirenz|
47981009|NCT03827304|DEVICE|Virtual Reality Distraction from Burn Pain|Patients wore a VR headset while undergoing a burns dressing change
48340512|NCT01001572|DRUG|Placebo|1 capsule or tablet taken orally once daily
48340513|NCT05362461|DIAGNOSTIC_TEST|Near Infrared Transillumination|Caries imaging detection technology.
48340514|NCT02126813|PROCEDURE|increased interventional threshold for urinary bladder catheterization (800 ml)|
48340515|NCT02126813|PROCEDURE|Current used interventional threshold for urinary bladder catheterization (500 ml)|
48340516|NCT02126813|DEVICE|Intermittent bladder catheter|
48340517|NCT02725268|DRUG|Paclitaxel|Paclitaxel intravenous solution.
48340518|NCT02725268|DRUG|Sapanisertib|Sapanisertib capsules.
48340519|NCT02725268|DRUG|MLN1117|MLN1117 capsules.
48340520|NCT05198427|OTHER|review of medical patient file|"The outcome measure is the evolution of HPV related lesions between :~* favourable evolution including partial or total regression~* unfavourable evolution including non-evolution or aggravation or recurrence."
48340521|NCT06337903|BEHAVIORAL|Self-compassion intervention (the Mindful Self-Compassion course)|An online 8-week mindful self-compassion course with weekly sessions.
48340522|NCT03770676|DIETARY_SUPPLEMENT|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
48340523|NCT05462340|DRUG|[18F]ASEM|\[18F\]ASEM demonstrated excellent imaging properties, as was recently confirmed by others. \[18F\]ASEM is the 1st validated α7 human PET radiotracer to examine α7-nAChR characteristics in the living brain of SCZ patients. Previous α7 studies in the SCZ literature were done using brains harvested post-mortem, and under variable storage conditions. The proposed studies will also determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
48498429|NCT02044796|DRUG|Cladribine|Given IV
48498430|NCT02044796|DRUG|Cytarabine|Given IV
48498431|NCT02044796|BIOLOGICAL|Filgrastim|Given SC
48498432|NCT02044796|OTHER|Laboratory Biomarker Analysis|Correlative studies
48498433|NCT02044796|DRUG|Mitoxantrone Hydrochloride|Given IV
48498434|NCT00103818|DRUG|gaboxadol|Duration of Treatment: 3 months
47981010|NCT04704167|OTHER|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
47981011|NCT04762797|OTHER|Non|This is a retrospective study, without intervention.
48340524|NCT05462340|DRUG|[18F]AZAN|The most widely used PET radioligand for human imaging of α4β2-nAChR is 2-\[18F\]FA. Because 2-\[18F\]FA exhibits very slow brain kinetics, the investigators developed \[18F\]AZAN, a highly α4β2 specific tracer with optimal brain kinetics. Therefore, the proposed studies will utilize \[18F\]AZAN to determine α4β2-nAChR \[18F\]AZAN binding characteristics in the same subjects who complete α7-nAChR PET studies with \[18F\]ASEM, which will be highly significant for understanding these receptors in SCZ.
48340525|NCT00111111|DRUG|Etanercept|
48656370|NCT06507644|OTHER|Pre irradiation of 1 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 1 hour.
48340526|NCT01686100|PROCEDURE|No touch technique|The vein graft is harvested with its surronding tissues.
48340527|NCT01686100|PROCEDURE|Conventional technique|The vein graft is stripped from its surrounding tissues.
48340528|NCT03955055|DEVICE|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
48340529|NCT04963881|DIAGNOSTIC_TEST|Antibody testing|Blood samples were taken and analyzed for APS antibodies
48340530|NCT01131845|DRUG|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
48340531|NCT00527072|BIOLOGICAL|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
48498435|NCT00103818|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
48656371|NCT06507644|OTHER|Pre irradiation of 3 hour|A thin layer of the photosensitizing medication, approximately 1 mm thick, will be applied to the participant's facial lesion sites. Then an occlusive dressing will be used to enhance MAL penetration, which will be covered with aluminum foil to prevent ambient light from influencing the protoporphyrin production process. For the PDT technique, the dressing will remain on the face for 3 hour.
48656372|NCT06507644|OTHER|topical application of 8% methyl aminolevulinate photosensitizer MAL|Participants will be treated with 8% topical MAL photosensitizer
48656373|NCT06507644|OTHER|topical application of 16% methyl aminolevulinate photosensitizer (MAL)|Participants will be treated with 16% topical MAL photosensitizer
48656374|NCT06507644|DEVICE|Visible light source|Skin illumination will be performed using a visible light source (LED) with a wavelength of 643 nm
48656375|NCT06020079|OTHER|laughter yoga|"According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~1. Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~2. Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~3. Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~4. Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation"
48656376|NCT02729519|PROCEDURE|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
48656377|NCT03037749|DRUG|Alcohol beverage|Alcohol beverage measured to have participant achieve a BAC of 0.08%
48656378|NCT03037749|DRUG|Placebo beverage|Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
48656379|NCT05826054|DIETARY_SUPPLEMENT|Montbretin A|The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).
48656380|NCT06160167|DRUG|IMiD treatment|Participants with MM treated with IMiDs
48656381|NCT06160167|DRUG|No IMiD treatment|Participants with MM not treated with IMiDs
48656382|NCT06160167|DRUG|Systemic therapy|Participants with MM treated with systemic therapy
48656383|NCT04742023|DEVICE|Continuous Glucose Monitor Application|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.
48656384|NCT04742023|DIAGNOSTIC_TEST|Finger Stick Glucose Measurement|Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
48656385|NCT04742023|DRUG|Insulin|Insulin will be administered.
48656386|NCT04742023|DEVICE|Continuous Glucose Monitor Placebo Applied|The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
48340532|NCT01692834|DRUG|Sandimmune® Injection|
48340533|NCT01692834|DRUG|NeuroSTAT®|
48340534|NCT03862495|DIAGNOSTIC_TEST|C. trachomatis and N. gonorrhoeae|In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
48498436|NCT01681602|OTHER|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
48498437|NCT05783518|DRUG|desflurane|Intraoperative anesthesia maintenance
48498438|NCT05783518|DRUG|propofol|Intraoperative anesthesia maintenance
48498439|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
47981012|NCT00901446|DEVICE|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
47981013|NCT01317082|DEVICE|Acupressure|P 6 Pressure Point
47981014|NCT02814513|DEVICE|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
47981015|NCT02814513|DEVICE|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
47981016|NCT02814513|DEVICE|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
47981017|NCT02814513|DEVICE|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
47981018|NCT02814513|DEVICE|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
47981019|NCT03876197|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells|Autologous adipose-derived mesenchymal stem/stromal cells
47981020|NCT03876197|OTHER|Placebo|Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
48340535|NCT03862495|DRUG|Azithromycin|Azithromycin 1g administered as a single oral dose
48340536|NCT03862495|OTHER|Partner notification and treatment|Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
48340537|NCT05193851|DRUG|ricolinostat|"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."
48340538|NCT02560480|DEVICE|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
48340539|NCT03931395|DIETARY_SUPPLEMENT|Honey|Will give patients and families included in the honey standard of care group 40 packets of hospital approved honey to implement in the tonsillectomy post-operative care of the child
48340540|NCT03931395|OTHER|Standard of Care|Patients will receive standard post operative medications per surgeon
48340541|NCT04703049|OTHER|Blood Viscosity Testing|we calculated WBV using the formula \[(0.12 × hematocrit) + (0.17 × (total protein - 2.07)\]. We defined CIN as the absolute (≥0.5 mg/dl) or relative increase (≥25%) in serum creatinine 48-72 h after exposure to a contrast agent compared with baseline serum creatinine values.
48340542|NCT06374589|DEVICE|Closed-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
48340543|NCT06374589|DEVICE|Conventional|Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
48656387|NCT04975646|BEHAVIORAL|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
48656388|NCT01522872|DRUG|TH-302|
48498440|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
48656389|NCT01522872|DRUG|TH-302 and Dexamethasone|
48656390|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
48656391|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
48656392|NCT03812848|OTHER|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
48656393|NCT06639893|PROCEDURE|Telescopic overdenture|Telescopic overdenture with two dental implants in intraforaminal area for mandible.
48656394|NCT05250934|DEVICE|Robotic rehabilitation|The upper limb rehabilitation will be carried out with the planar rehabilitation robot Icone (a CE Class IIA medical device manufactured by Heaxel). The proposed exercises require the patient to move a cursor on the screen using the end-effector of the robot to reach specific points (planar reaching exercises). When the patient is able to perform these exercises independently, the robot assists the movement by minimizing the interaction force applied to the hand and limiting itself to acquiring the kinematic and dynamic parameters of the exercise, which are useful in determining the state of motor skills. Icone assist the subject by applying a force to his hand that helps him complete the task in the phases where the patient plans the movement correctly but is unable to complete it. As a result, the system will enable you to perform planar elbow and shoulder movements in active, passive, or active-assisted modes, with visual and acoustic feedback.
47981021|NCT06221540|BEHAVIORAL|"Myth busting information leaflet"|A written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated, focusing on themes pertinent to the myth-busting information
48340544|NCT02330445|DRUG|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
48340545|NCT00293241|DEVICE|Managed Ventricular Pacing programmed ON/OFF|Device programming
48656395|NCT04954898|DEVICE|Study Lens: TECNIS Multifocal Toric 1-piece lens, Model ZMT|Surgeons will perform standardized, small-incision, cataract surgery and implant the study lenses using a JJSV-validated insertion system qualified for use with TECNIS Multifocal Toric 1-Piece IOL.
48656396|NCT05774041|DEVICE|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
48340546|NCT02953613|DEVICE|NIRS/IVUS|Cardiac catheterization using infraredx
48340547|NCT03684941|DEVICE|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
48340548|NCT03684941|DEVICE|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
48340549|NCT02477306|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
48340550|NCT02477306|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
48340551|NCT05265962|DRUG|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
48340552|NCT02778945|DRUG|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
48498441|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
48656397|NCT03038672|BIOLOGICAL|Nivolumab|Given IV
47981022|NCT03991715|BEHAVIORAL|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
47981023|NCT00000210|DRUG|Buprenorphine|
47981024|NCT03314428|BEHAVIORAL|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
47981025|NCT02853578|DRUG|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
47981026|NCT03824912|DRUG|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
47981027|NCT03824912|DRUG|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
47981028|NCT03824912|DRUG|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
47981029|NCT02396433|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle.
47981030|NCT02396433|DRUG|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
47981031|NCT02396433|DRUG|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
47981032|NCT00649701|BEHAVIORAL|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
47981033|NCT00649701|BEHAVIORAL|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
47981034|NCT00649701|BEHAVIORAL|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
47981035|NCT00649701|BEHAVIORAL|Both Videos|Morning After and Talking About HIV videos
47981036|NCT03263494|DEVICE|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
47981037|NCT05403125|DEVICE|silver diamine fluoride, 38%|Topical application to all surfaces of the teeth
47981038|NCT05403125|DEVICE|Sodium fluoride gel, 5000 PPM|Gel applied after application of silver diamine fluoride and dispensed for home use
47981039|NCT00617565|DRUG|biphasic insulin aspart|
47981040|NCT00617565|DRUG|biphasic human insulin|
48656398|NCT03038672|DRUG|Varlilumab|Given IV
48656399|NCT00280202|PROCEDURE|Biopsy of the major carinal area|Biopsy performed intraoperatively
48656400|NCT00280202|PROCEDURE|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
47981041|NCT02510859|OTHER|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
48340553|NCT02778945|DRUG|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
48340554|NCT00353990|DRUG|Insulin Aspart|
48340555|NCT02565953|DEVICE|Paclitaxel-releasing PTA balloon catheter|
48340556|NCT02565953|DEVICE|PTA balloon catheter|
48340557|NCT04511988|OTHER|Diagnostic Test|blood sample (20 ml) and biopsy
48656401|NCT00280202|PROCEDURE|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
48656402|NCT00280202|PROCEDURE|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
48340558|NCT02766907|DEVICE|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
48656403|NCT00280202|PROCEDURE|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
48340559|NCT01783470|DRUG|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
48656404|NCT00280202|PROCEDURE|Analysis of lymph nodes|Tissues banked for future analysis
48340560|NCT04504461|OTHER|Analysis of feasibility and costs|Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
48340561|NCT00004014|DRUG|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
48340562|NCT05911113|OTHER|sensory re-education training|the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
48340563|NCT05911113|OTHER|traditional treatment|the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
48340564|NCT01510223|DIETARY_SUPPLEMENT|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
48340565|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
48340566|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
48340567|NCT01510223|DIETARY_SUPPLEMENT|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
48340568|NCT00758407|DRUG|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
48656405|NCT06638710|DRUG|oral administration of midazolam or placebo|If the patient is opposed to a treatment (resistance to care ≥3 on the Pittsburgh scale), the nurse administers an oral dose of midazolam or placebo to the patient according to the random allocation.
48340569|NCT00758407|DRUG|Placebo|dosage according to an individual titration schedule
48340570|NCT00821782|DRUG|Levofloxacin; Azithromycin|
48340571|NCT04648228|BEHAVIORAL|ACT+MBRP|Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.
48340572|NCT04648228|BEHAVIORAL|Education control|Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.
48340573|NCT03402269|OTHER|Clavicle fracture injury- observation|The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
48656406|NCT06153108|DEVICE|PAMSys pendant PAMSys wrist sensors|The PAMSysTM sensor consists of a 3-axis accelerometer, battery, and built-in memory for recording long-term data. Accelerometer data is recorded at a sampling frequency of 50 Hz
48656407|NCT06188806|OTHER|ADDUKTOR CANAL BLOCK|All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.
48656408|NCT06188806|OTHER|CONTROL GROUP|No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.
48656409|NCT05497934|DRUG|Glycerol|In this study, 99.5% pure glycerol will be used as an optical clearing agent. The glycerol will be applied topically to the tympanic membrane.
47981042|NCT01549093|DRUG|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2\*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
47981043|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
47981044|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
47981045|NCT00002925|DRUG|ara-C|
48498442|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
48133234|NCT06376045|DRUG|Rocatinlimab|Rocatinlimab will be administered by SC injection.
48340574|NCT02077491|OTHER|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
48340575|NCT04995614|DRUG|Radium-223|Prospective observational cohort study investigating patient-reported outcomes
48340576|NCT04443036|DRUG|Albumin-Bound Paclitaxel|"* 125mg/m2 IV d1、8，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity"
48340577|NCT04443036|DRUG|Toripalimab|"* 240 mg，IV d1，Q3W~* until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months"
48340578|NCT00169039|DRUG|Clozapine|
48340579|NCT00169039|DRUG|Chlorpromazine|
48656410|NCT05987423|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
48656411|NCT05987423|DRUG|Placebo|Placebo will be administered by SC injection
48656412|NCT05299424|DRUG|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
47981046|NCT00002925|DRUG|Daunorubicin|
47981047|NCT00002925|DRUG|Etoposide|
47981048|NCT00002925|DRUG|PSC-833|
47981049|NCT00002925|BIOLOGICAL|Aldesleukin|
47981050|NCT00258245|DIETARY_SUPPLEMENT|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11
47981051|NCT00258245|DRUG|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
48133235|NCT06376045|DRUG|Placebo|Placebo will be administered by SC injection.
48133236|NCT00371345|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
48340580|NCT00017628|DRUG|cyclophosphamide|
47981052|NCT00258245|DRUG|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
47981053|NCT00258245|DRUG|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
47981054|NCT00258245|DRUG|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
47981055|NCT00258245|DRUG|Aspirin|Aspirin - 325 mg by mouth (PO) every day
47981056|NCT00459784|PROCEDURE|Dementia Training Program|
47981057|NCT05590754|DEVICE|Hyper-buoyancy Floatation (HBF)|Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment
48133237|NCT00371345|DRUG|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
48133238|NCT02926794|BEHAVIORAL|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
48133239|NCT02926794|BEHAVIORAL|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
48340581|NCT00017628|DRUG|filgrastim|
48340582|NCT00017628|DRUG|methylprednisolone|
48340583|NCT00017628|PROCEDURE|Autologous Stem Cell Transplantation|
48340584|NCT03504267|OTHER|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
48340585|NCT00235664|PROCEDURE|Collection of stool and endotracheal aspirate samples|collection of samples
48340586|NCT05110599|DRUG|Bryophyllum 50% chewable tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
48340587|NCT05110599|OTHER|Placebo|Lactose with adaption in appearance and tast
48367402|NCT02549261|DRUG|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
48656413|NCT05299424|DRUG|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
47981058|NCT05590754|DEVICE|Axial Load after 4h of HBF|Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.
48133240|NCT02926794|BEHAVIORAL|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
48133241|NCT02926794|BEHAVIORAL|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
48656414|NCT05299424|DRUG|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48133242|NCT06486012|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device home-use with a marker substance
48133243|NCT06486012|OTHER|Standard oral hygiene|Standard oral hygiene performed at home
48133244|NCT03454113|DEVICE|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
48133245|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 60mj|
48133246|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 120mj|
48656415|NCT05299424|DRUG|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48133247|NCT02358005|PROCEDURE|non extracorporeal shock wave therapy|
48133248|NCT06352905|OTHER|Whole body vibration (WBV)|WBV is a platform that vibrates while a person stands or sits and performs exercises. The WBV session will consist of 5 sets of 60 seconds set at 6 Hertz (frequency), 3 mm (amplitude) while performing mid-squats. There will be a 1 minute rest in between each set. These parameters were chosen as commonly used parameters in previous studies of WBV in people with PD.
48133249|NCT06352905|OTHER|Control|Mid-squats performed on level ground 5 repetitions of 60 seconds with 1 minute rest in between each set.
48340588|NCT05370079|BIOLOGICAL|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
48133250|NCT04566250|COMBINATION_PRODUCT|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
48133251|NCT06029244|DEVICE|EyeControl-Pro|Based on artificial intelligence (AI)-powered eye-tracking technology, the EyeControl-Pro wearable device and smart platform enable 24/7 customizable communication and monitoring between ventilated patients who cannot speak, their families, and medical teams
48133252|NCT06029244|OTHER|Control|No intervention
48340589|NCT03442504|DIAGNOSTIC_TEST|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~* The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~* The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
48498443|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
48498444|NCT02870218|DRUG|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
48656416|NCT05299424|DRUG|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656417|NCT05299424|DRUG|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48340590|NCT04586075|DIAGNOSTIC_TEST|Trio Whole Genome Sequencing and Participant-Specific Research|"The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses"
48340591|NCT03228394|DRUG|Ganaxolone|Ganaxolone IV
48340592|NCT03228394|DRUG|Placebo|Placebo IV
48340593|NCT00876486|DRUG|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
48656418|NCT05299424|DRUG|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656419|NCT05299424|DRUG|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656420|NCT05299424|DRUG|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656421|NCT05299424|DRUG|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656422|NCT05299424|DRUG|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656423|NCT05299424|DRUG|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656424|NCT05299424|DRUG|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656425|NCT05299424|DRUG|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
48656426|NCT05299424|DRUG|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
48656427|NCT06640036|OTHER|Rapeseed oil|During 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals.
48656428|NCT06640036|OTHER|Butter|During 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals.
48656429|NCT06640036|OTHER|Coconut oil|During 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals.
48656430|NCT05752487|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|Participants will undergo catheter ablation with the PF /RF ablation system consisting of the TRUPULSE Generator (delivers RF or PF energy through the study catheter) and the THERMOCOOL SMARTTOUCH SF (STSF) Catheter (indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a Generator, for cardiac ablation).
48656431|NCT06361836|BIOLOGICAL|SBT777101|Experimental treatment
48340594|NCT00876486|DRUG|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
47914549|NCT02527603|PROCEDURE|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
47914550|NCT02527603|PROCEDURE|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
48498445|NCT02870218|DRUG|Nicotine discrimination thresholds|Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
48498446|NCT03401125|OTHER|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
48498447|NCT02902783|OTHER|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
48656432|NCT05665608|DEVICE|Implantable cardioverter-defibrillator (ICD)|"A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing.~The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs."
48656433|NCT05665608|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure"
48133254|NCT03203525|BIOLOGICAL|Bevacizumab|Given IV
48133255|NCT03203525|DRUG|Fluorouracil|Given via pump
48498448|NCT01476618|OTHER|No Intervention|No Intervention
48656434|NCT02499926|DIETARY_SUPPLEMENT|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
48133256|NCT03203525|DRUG|Leucovorin|Given via pump
48133257|NCT03203525|DRUG|Oxaliplatin|Given via pump
48498449|NCT00611273|DEVICE|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
48656435|NCT05549362|OTHER|Dial Health Research Study|To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
48498450|NCT01853631|GENETIC|Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells|"Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2"
48498451|NCT01853631|GENETIC|Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells|The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
48498452|NCT04392583|DEVICE|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
48498453|NCT00782821|DRUG|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
48656436|NCT06638008|DRUG|perineural injection|perineural intervention of placental growth factor in one group and PRP in other group
48656437|NCT03599076|OTHER|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
48656438|NCT06615050|DRUG|Tacrolimus (Tac)|Tablet or intravenously (IV)
48656439|NCT06615050|DRUG|Methotrexate (MTX)|Intravenously (IV)
48656440|NCT06615050|DRUG|Ruxolitinib (Rux)|Tablet
47981059|NCT00264329|OTHER|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
48340595|NCT02307318|DEVICE|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
48340596|NCT04445350|OTHER|External Focus Of Attention|Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.
48340597|NCT04445350|OTHER|Internal Focus Of Attention|In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
48340598|NCT02338167|PROCEDURE|Blood sampling|A blood sample will be taken during a routine blood draw
48340599|NCT05616039|PROCEDURE|Standard Liver Surgery|Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours
48340600|NCT05616039|DIAGNOSTIC_TEST|Indocyanine Fluorescent Image Guided Surgery (I-FIGS)|Use of I-FIGS in accurate identification of tumours and their margins
48340601|NCT02283957|DRUG|CNTX-4975|
48340602|NCT02283957|OTHER|Placebo|
48340603|NCT04537754|DEVICE|bleaching device|activated bleaching
48340604|NCT00000314|DRUG|M-CPP|
48340605|NCT02854670|DRUG|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
48340606|NCT00596804|DRUG|veltuzumab|once weekly intravenous dosing for 4 weeks
48340607|NCT04679389|DRUG|Placebo|administered orally or enterally
48340608|NCT04679389|DRUG|Acetazolamide|administered orally or enterally
48340609|NCT00519168|PROCEDURE|Urine sample|Standard of care
48340610|NCT00519168|DEVICE|Electrode sleep recorder|Standard of care
48340611|NCT00519168|PROCEDURE|phlebotomy|Standard of care
48340612|NCT03949543|OTHER|Large Lunch Intervention|Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.
48340613|NCT03949543|OTHER|Large Dinner Intervention|Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
48340614|NCT02904525|DEVICE|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
48498454|NCT00782821|DRUG|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
48498455|NCT00782821|DRUG|Rituxan|Given via IV per group assignment.
48498456|NCT02011386|DRUG|Treatment|
48498457|NCT04871763|OTHER|Retainers' Cleansing with Geldis®|Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
48498458|NCT04871763|OTHER|Retainers' Cleansing with tablets|Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
48498459|NCT04871763|OTHER|Retainers' cleansing with water|Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
48498460|NCT01673438|DRUG|aldoxorubicin|
48656441|NCT06615050|DRUG|Cyclophosphamide|Intravenously (IV)
48656442|NCT06615050|DRUG|Mycophenolate mofetil (MMF)|Tablet or intravenously (IV)
48656443|NCT04683653|RADIATION|Hypofractionated Radiation|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less often. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
48656444|NCT04683653|OTHER|Clinical Follow-Up and Assessments|"At each visit, the subject will be evaluated for any signs of their endometrial cancer or symptoms returning (clinical disease recurrence) and any negative side effects associated with their prior radiation treatment. Study participants will also be asked to fill out a survey regarding bowel/urinary habits and quality of life questionnaires (known as the EPIC questionnaire) during these visits. The data collected during these clinical follow up visits will be used to determine how effective hypofractionated/shortened whole radiation therapy is for treating endometrial cancer."
48656445|NCT06637631|DRUG|SAR441566|Pharmaceutical form: Tablet Route of administration: Oral
48656446|NCT06637631|DRUG|SAR441566 matching Placebo|Pharmaceutical form: Tablet Route of administration: Oral
48656447|NCT04023110|DRUG|Carvedilol|Individually dosed carvedilol
48656448|NCT06077214|DRUG|Treatment with liposomal bupivacaine|Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.
48340615|NCT04936204|DEVICE|ConnettivinaBio Plus cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
48656449|NCT06077214|DRUG|Treatment with standard bupivacaine|Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
48656450|NCT06209619|PROCEDURE|Biopsy|Undergo biopsy
48656451|NCT06209619|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48656452|NCT06209619|PROCEDURE|Computed Tomography|Undergo PET/CT
48656453|NCT06209619|DRUG|Golcadomide|Given PO
48656454|NCT06209619|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48133258|NCT03203525|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48340616|NCT04936204|DEVICE|ConnettivinaBio cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
48340617|NCT06047990|DEVICE|Cryobiopsy catheter|Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
48340618|NCT01240304|DRUG|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
47981060|NCT03815331|DRUG|Xiaflex®|medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
47981061|NCT03815331|DRUG|Aveed|Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
47981062|NCT02957422|DIETARY_SUPPLEMENT|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
47981063|NCT02957422|DIETARY_SUPPLEMENT|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
47981064|NCT01489592|DRUG|curcuma longa|oral administration of 6 grams of curcumin
47981065|NCT02590653|DRUG|Atorvastatin|Lipid-lowering therapy
48340619|NCT01240304|RADIATION|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
48340620|NCT01240304|PROCEDURE|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
48340621|NCT04822441|OTHER|data collection|Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
48498461|NCT01439750|DRUG|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
48498462|NCT01439750|DRUG|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
48498463|NCT01439750|DRUG|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
48656455|NCT06209619|BIOLOGICAL|Rituximab|Given IV
48656456|NCT04581083|DIAGNOSTIC_TEST|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
47981066|NCT00523003|DIETARY_SUPPLEMENT|high protein|2.2 g protein/kg of LBM per day
47981067|NCT00523003|DIETARY_SUPPLEMENT|standard protein|1.1 g protein/kg LBM/day standard protein diet
47981068|NCT01204164|DRUG|TG02 citrate|TG02 citrate capsules given orally.
47981069|NCT01204164|DRUG|Carfilzomib|Carfilzomib per PI
47981070|NCT01204164|DRUG|Dexamethasone|Dexamethasone (Oral or IV)
47981071|NCT03187262|DRUG|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
47981072|NCT00141076|BEHAVIORAL|low vs high glycemic index diet|
47981073|NCT02622581|OTHER|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
47981074|NCT02130973|DRUG|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
48133259|NCT03203525|DRUG|Temsirolimus|Given IV
48133260|NCT03203525|PROCEDURE|Tumor Treating Fields Therapy|Use NovoTTF-100L(P) system
48133262|NCT06358755|DEVICE|Defocus Incorporated Multiple Segments lenses|Defocus Incorporated Multiple Segments lenses that provide optical defocus for myopia control will be given to this group of participants.
48133263|NCT06358755|DEVICE|single vision spectacle lenses|Single vision spectacle lenses will be given to this group of participants.
48133264|NCT06358755|DRUG|Low dose atropine|0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
48656457|NCT04581083|DIAGNOSTIC_TEST|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
48656458|NCT04581083|DIAGNOSTIC_TEST|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
48656459|NCT04581083|DIAGNOSTIC_TEST|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
48656460|NCT04659343|OTHER|Measurement of concentration of active metabolite in cancer treatment.|Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib, ipilimumab and nivolumab.
48656461|NCT05960604|DIAGNOSTIC_TEST|Passive leg raising|"All patients who met the inclusion criteria will be placed head down flat and feet up at a 45° angle for 30 seconds.~Hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected before, during and after the test until the end of the surgery.~The total duration of the intervention (passive leg raising) is 30 seconds. The total duration of hemodynamic parameters recording is expected to be 60-600 minutes."
48498464|NCT05979363|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
48498465|NCT05979363|DRUG|VRD-based regimen|Bortezomib, Lenalidomide and Dexamethasone
48498466|NCT02972918|DRUG|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
48498467|NCT05692050|DRUG|Epcoritamab|Subcutaneous Injection
48498468|NCT03898518|OTHER|12-week jump rope exercise program|Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
48498469|NCT01432379|BIOLOGICAL|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
48498470|NCT05712421|DRUG|North Star|North Star
48498471|NCT05712421|DRUG|Levothyroxine|Levothyroxine
48498472|NCT04851652|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
48498473|NCT00106340|DRUG|vildagliptin|
47981075|NCT02130973|DRUG|Experimental Cyclic Regimen|Experimental Cyclic Regimen
47981076|NCT05340868|DRUG|Semaglutide Pill|Oral semaglutide treatment
47981077|NCT04287491|OTHER|Oculus Go Virtual Reality System|The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
47981078|NCT05486858|OTHER|MSK ultrasonograpy|MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.
47981079|NCT05486858|OTHER|sitting Functional and Lateral Reach Test|Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
48340622|NCT03269136|DRUG|PF-06863135 monotherapy IV or SC|PF-06863135 will be administered intravenously or subcutaneously.
48340623|NCT03269136|DRUG|PF-06863135 + dexamethasone|PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
48340624|NCT03269136|DRUG|PF-06863135 + lenalidomide|PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
48340625|NCT03269136|DRUG|PF-06863135 + pomalidomide|PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
48498474|NCT00106340|DRUG|glimepiride|
48656462|NCT06089317|DRUG|TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
48656463|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
47981080|NCT02504008|DRUG|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
47981081|NCT02504008|DRUG|Placebo|Once weekly for 6 weeks
47981082|NCT02113605|OTHER|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
48340626|NCT04884529|BEHAVIORAL|Chair-yoga program|8-week chair yoga program with gentle postures, breathing techniques, and mindfulness.
48340627|NCT02473224|BIOLOGICAL|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
48340628|NCT02473224|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
48340629|NCT05950555|OTHER|Saline|We used 0.9% isotonic sodium chloride.
48498475|NCT00106340|DRUG|Metformin|
48498476|NCT00106340|DRUG|Vildagliptin matching placebo|
48498477|NCT00106340|DRUG|Glimepiride matching placebo|
48498478|NCT02603718|OTHER|Rehabilitation treatment|
48498479|NCT00500136|PROCEDURE|mortality salience|
48498480|NCT00148824|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (vaccine)|
48498481|NCT00148824|BIOLOGICAL|23-valent pneumococcal conjugate vaccine (vaccine)|
48498482|NCT05526261|PROCEDURE|Hemithyroidectoy|Hemithyroidectomy it is a surgical procedure where half of the thyroid gland is operated.
48498483|NCT01016886|DRUG|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
48498484|NCT02537366|DRUG|Dexmedetomidine|
48498485|NCT02537366|DRUG|Placebo|
48340630|NCT05950555|OTHER|Dexmedetomidine|We used the vial containing 200 mcg/2 ml i.v. concentrated infusion solution in 100 ml of 0.9% isotonic sodium chloride.
48340631|NCT05950555|OTHER|Ketamine|We used 500 mg/10 ml solution for injection in 0.9% isotonic sodium chloride.
48498486|NCT05145881|DIETARY_SUPPLEMENT|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
48498487|NCT05145881|DIETARY_SUPPLEMENT|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
48498488|NCT02163486|DEVICE|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
48498489|NCT02163486|DEVICE|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
48498490|NCT00309894|BIOLOGICAL|sargramostim|
48498491|NCT00309894|DRUG|ketoconazole|
48498492|NCT00309894|DRUG|therapeutic hydrocortisone|
48498493|NCT00894101|DRUG|[F-18] FLT|10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
48498494|NCT02545348|PROCEDURE|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
48498495|NCT02390349|OTHER|Placebo|
48498496|NCT02390349|DIETARY_SUPPLEMENT|Curamin|
48656464|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
47981083|NCT05954026|DEVICE|ExVent|ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
48133265|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
48656465|NCT06089317|DRUG|Placebo TCM ultrasonic atomization treatment (PA)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
48133266|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
48340632|NCT00198367|DRUG|Cisplatin-Gemzar|
48498497|NCT02390349|DIETARY_SUPPLEMENT|CuraMed|
48656466|NCT06089317|DRUG|Artificial Tears (AT)|The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
48498498|NCT00758680|DRUG|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
48498499|NCT00758680|DRUG|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
47981084|NCT03587012|OTHER|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
47981085|NCT03587012|OTHER|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
48340633|NCT00198367|DRUG|Cisplatin-Navelbine-Radiotherapy|
47981086|NCT03279328|DRUG|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
47981087|NCT03279328|OTHER|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
48133267|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
48133268|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
48340634|NCT00198367|DRUG|Carboplatin-Taxol-Radiotherapy|
48340635|NCT03251872|DRUG|Olaparib|Olaparib tablets
48340636|NCT04514588|DIETARY_SUPPLEMENT|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
48340637|NCT02556970|PROCEDURE|Single port VATS|Performing video-assisted thorascopic surgery through a single port
48340638|NCT02556970|DRUG|Paracetamol|1g intraoperatively
48340639|NCT02556970|DRUG|Diclofenac|75mg intraoperatively
48340640|NCT02556970|DEVICE|Camera (5mm diameter 30 degree videothoracoscope)|
48340641|NCT02556970|DEVICE|Forceps grasper|
48340642|NCT02556970|DRUG|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
48498500|NCT02361294|OTHER|Blood samples|
48498501|NCT02563106|DRUG|SYN-004|
48498502|NCT02563106|DRUG|Placebo|
48498503|NCT00095316|DRUG|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
48340643|NCT01927887|DRUG|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
48367403|NCT02549261|RADIATION|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
48498504|NCT00095316|OTHER|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
48498505|NCT03994718|OTHER|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
48498506|NCT03994718|OTHER|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
48498507|NCT03994718|OTHER|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
48498508|NCT04227353|BEHAVIORAL|HEAL ABC|Participants will be assigned their first booklet based on the one they perceive to be the easiest for setting an incremental goal and achieving it. After the participant achieves successful behaviour change, he or she can move more confidently to the next booklet. Support will be provided every two weeks over the phone for 12 weeks. During the follow-up period, participants will use the follow-up booklet which helps them to continue with changes they have made and encourage them to set new goals.
48656467|NCT00396370|BIOLOGICAL|BCG strain Connaught|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.
48656468|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10\^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
48133269|NCT03532100|DEVICE|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
48133270|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
48133271|NCT02180724|DRUG|Acalabrutinib (ACP-196)|
48498509|NCT05255796|PROCEDURE|one-piece|Patients underwent phacoemulsification cataract surgery with one-piece IOL implantation.
47981088|NCT03279328|DRUG|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
47981089|NCT02263794|PROCEDURE|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
48133273|NCT04088630|DRUG|Fingolimod 0.5 mg|A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
48656469|NCT00396370|BIOLOGICAL|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
48656470|NCT00396370|OTHER|Placebo|0.1 mL of sterile Sauton medium for intradermal administration.
48656471|NCT00396370|OTHER|Placebo|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
47981090|NCT02263794|PROCEDURE|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
47981091|NCT05520931|OTHER|Questionnaire and register-based data assessment|Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.
47981092|NCT06230081|DRUG|Ropivacain 5 mg/ml + Clonidine|Drug used in the block
48133274|NCT04088630|DRUG|Placebo|A single oral placebo pill within 24 hours of symptom onset
48133275|NCT04088630|OTHER|Standard of care|Standard of care protocol for the treatment of spontaneous ICH
48133276|NCT05142215|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.
48656472|NCT03374956|DRUG|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
48656473|NCT03374956|DRUG|Liraglutide|dose of 3 mg subcutaneous daily
48656474|NCT03374956|DRUG|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
48656475|NCT03374956|DRUG|Phentermine|15-37.5 mg oral daily
47981093|NCT04841031|BEHAVIORAL|NET Treatment|Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.
47981094|NCT04841031|OTHER|Alternative Intervention|Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
48133277|NCT05142215|PROCEDURE|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.
48133278|NCT06579157|OTHER|Pressure-Sensing Mattresses|using ballistocardiography (BCG) for monitoring respiration and heart rate in neonates
48133279|NCT06509243|BIOLOGICAL|tablets Acarizax|sublingual immunotherapy to house dust mites
48133280|NCT06509243|BIOLOGICAL|dupilumab|dupilumab - biologic therapy for atopic dermatitis
48133281|NCT06509243|DRUG|cyclosporine|cyclosporine used in atopic dermatitis
48133282|NCT03817970|DRUG|Granisetron|An antiemetic regimen containing granisetron 2 mg oral or IV.
48133283|NCT03817970|DRUG|Ondansetron|An antiemetic regimen containing ondansetron 8 mg oral or IV.
48656476|NCT06640010|OTHER|Non-Interventional Study|Non-interventional study
48656477|NCT06638034|DRUG|68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
48656478|NCT05424276|DRUG|IkT-148009|Oral administration gelatin capsule
48656479|NCT05424276|DRUG|Placebo|Oral administration gelatin capsule
48133284|NCT03817970|DRUG|Palonosetron|An antiemetic regimen containing palonosetron 0.25 mg IV.
48498510|NCT05255796|PROCEDURE|plate-haptic|Patients underwent phacoemulsification cataract surgery with plate-haptic IOL implantation.
48498511|NCT04992429|PROCEDURE|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
48133287|NCT03908606|PROCEDURE|Scaling and root planing|Supra and subgingival scaling and root planing.
48133288|NCT05564468|OTHER|Best Practice|Receive standard of care
48498512|NCT02894437|OTHER|qualitative interviews|semi-structured interviews as a conceptual frame work
48498513|NCT04582461|DEVICE|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
48498514|NCT00587015|DRUG|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60...μg/kg until toxicity supervenes.
47981095|NCT03666715|DRUG|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
47981096|NCT03666715|DRUG|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
47981097|NCT04203953|OTHER|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
47981098|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed QD
47981099|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed BID
47981100|NCT01190878|DRUG|DuraSite Vehicle|Vehicle dosed BID
48498515|NCT03468335|DRUG|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~* Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~* 5-FU 2400 mg/m2 as 46 hour infusion~* Folinic acid 400 mg/m2 as 0.5 hour infusion~* all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
48498516|NCT02001831|DIETARY_SUPPLEMENT|Supplement|
48498517|NCT02001831|DIETARY_SUPPLEMENT|Placebo|
48498518|NCT00654966|DRUG|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
48498519|NCT00654966|DRUG|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
48498520|NCT04557020|DRUG|PD-1 antibody|neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy
48498521|NCT04557020|DRUG|Gemcitabine|neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles
48498522|NCT04557020|DRUG|Cisplatin|neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
48498523|NCT04557020|RADIATION|IMRT|70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
48498524|NCT03292536|DRUG|Merestinib|"\*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
48498525|NCT03164421|DRUG|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
48498526|NCT03164421|DRUG|L-carnitine|L-carnitine in clomiphene resistant pcos women
48498527|NCT00653679|OTHER|exercise|1 hour of endurance or resistance exercise
48498528|NCT05354570|RADIATION|Intensity-Modulated Pleural Radiation Therapy (IMPRINT)|Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
48498529|NCT06432049|OTHER|restoration for endodontically treated molar|prefabricated stainless steel crown or endocrown
47981101|NCT01190878|DRUG|Xibrom™|0.09% bromfenac dosed BID
47981102|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
47981103|NCT01359657|BIOLOGICAL|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
47981104|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
47981105|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
47981106|NCT01359657|BIOLOGICAL|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
48133289|NCT05564468|OTHER|Internet-Based Intervention|Receive Peacefully's end-of-life planning program
48133290|NCT05564468|OTHER|Questionnaire Administration|Ancillary studies
48367404|NCT05215600|DEVICE|Anaverse Shoulder System|Reverse Shoulder Arthroplasty
48498530|NCT03623386|OTHER|PD neurofeedback|PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
48498531|NCT03623386|OTHER|PD control|PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
48498532|NCT03216070|DRUG|Dasatinib 50 MG|50mg of dasatinib orally daily
48498533|NCT00238706|DEVICE|Radiofrequency ablation|
48656480|NCT05328622|BEHAVIORAL|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
48656481|NCT06570746|DRUG|Sedative|Sedation is applied before the procedure
48656482|NCT04391569|DRUG|Ganaxolone|Ganaxolone will be administered.
48656483|NCT04391569|DRUG|Placebo|Placebo will be administered.
48498534|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
48656484|NCT06643273|OTHER|Robotic rehabilitation|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
48656485|NCT06643273|OTHER|Conventional rehabilitation|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
48656486|NCT05198245|DRUG|Rimegepant|Rimegepant 75mg
48656487|NCT05198245|DRUG|Various|Various
48656488|NCT05198245|OTHER|No intervention|No intervention
48656489|NCT03183947|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
48656490|NCT03183947|BEHAVIORAL|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)
48340644|NCT01927887|DEVICE|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
48498535|NCT03986827|BEHAVIORAL|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
48656491|NCT03183947|OTHER|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
48656492|NCT03183947|OTHER|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
48656493|NCT03183947|OTHER|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview
47981107|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
48498536|NCT01957176|DRUG|Eltrombopag (ELT)|Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
48498537|NCT05496660|OTHER|NHE+KT|the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
48498538|NCT05496660|OTHER|NHE|the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
47981108|NCT03108833|DRUG|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
47981109|NCT03108833|DRUG|Alteplase|The drug is used for intravenous thrombolysis therapy
47981110|NCT05277714|OTHER|Sham|The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.
48498539|NCT05447000|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
48133292|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
48133293|NCT05583227|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
48133294|NCT05583227|OTHER|Placebo|Placebo subcutaneous injection
48498540|NCT05447000|BEHAVIORAL|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
48498541|NCT05447000|OTHER|No Intervention|No Intervention
48498542|NCT06317090|PROCEDURE|guided bone regeneration|a non-resorbable membrane was used as a space maintainer, filled with a particulated bone graft.
48498543|NCT06404892|PROCEDURE|Single-lung ventilation|Patients undergoing thoracic surgery and intraoperative single-lung ventilation.
48498544|NCT06344936|DRUG|HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules|Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
48498545|NCT04289597|DIAGNOSTIC_TEST|Distance between hyoid bone-skin (DSHB)|Distance between hyoid bone-skin
47981111|NCT05277714|OTHER|NF|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
48498546|NCT04289597|DIAGNOSTIC_TEST|Vocal cord anterior commissura-skin distance (DSAC)|Vocal cord anterior commissura-skin distance
48498547|NCT04289597|DIAGNOSTIC_TEST|minimum distance of the trachea to the skin at the level of suprasternal notch|Distance of the trachea to the skin at the level of suprasternal notch
48498548|NCT04289597|DIAGNOSTIC_TEST|Thyroid isthmus-skin distance (DSI)|Thyroid isthmus-skin distance
48498549|NCT04289597|DIAGNOSTIC_TEST|Skin-epiglottic distance (DSE)|Skin-epiglottic distance
47981112|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
47981113|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
47981114|NCT01092754|DRUG|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
48498550|NCT02828241|DRUG|DFD-04 Ointment|
48498551|NCT02828241|OTHER|Placebo Ointment|
48133307|NCT05335928|DRUG|Abatacept plus|"Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC"
48133308|NCT05335928|DRUG|Placebo|Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
48498552|NCT04183075|DIETARY_SUPPLEMENT|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
48498553|NCT04183075|DIETARY_SUPPLEMENT|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
48498554|NCT00927693|OTHER|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
48133311|NCT05920356|DRUG|Sotorasib|Oral administration
48133312|NCT05920356|DRUG|Pembrolizumab|Intravenous administration
48133313|NCT06114069|PROCEDURE|implant supported maxillary fixed prosthesis|Maxillary fixed prosthesis according to all on four or all on six concept
48367405|NCT00280059|DRUG|Pregabalin|dose 150-600 mg/day given BID
48367406|NCT00280059|DRUG|Lamotrigine|dose 100-500 mg/day given BID
48498555|NCT03802253|BEHAVIORAL|Time Restricted Feeding(TRF)|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later, Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.
48498556|NCT03802253|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
48498557|NCT00063219|DRUG|MAC-321|
48498558|NCT03131492|DIAGNOSTIC_TEST|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
48498559|NCT00663767|DRUG|Placebo; oral|dose 1, dose 2
48498560|NCT00663767|DRUG|Placebo; oral|dose 1
48498561|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
48498562|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
48498563|NCT00663767|DRUG|Celecoxib, COX-2 inhibitor; oral|dose 1
48498564|NCT00663767|DRUG|Placebo; oral|dose 2
48498565|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
48498566|NCT06160570|RADIATION|Intensive Modulated Radiation Therapy|Radiotherapy technique: IMRT
48133314|NCT06490718|DRUG|USG ESPB|"After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle."
48133315|NCT06490718|DRUG|Intravenous Infusion|"Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure."
48340645|NCT05265793|DRUG|Camrelizumab Combined With Apatinib|After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
48498567|NCT06160570|RADIATION|3-Dimension Conformal Radiation Therapy|Radiotherapy technique: 3DCRT
48498568|NCT05808192|DRUG|Immunosuppressive|compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
48133316|NCT05030493|DRUG|mFOLFOX6 + panitumumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
48133317|NCT05030493|DRUG|mFOLFOX6 + bevacizumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
48133318|NCT04926597|DIETARY_SUPPLEMENT|nutritional supplement|daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).
48340646|NCT04890561|DRUG|Lemborexant|Lemborexant oral tablets.
48340647|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
48513295|NCT04420273|BEHAVIORAL|Active control:Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
48340648|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
48656494|NCT06642194|BEHAVIORAL|Education on sunnah of sleeping|The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping (early bedtime and early wake up time; perform ablution (wudoo) before going to bed and supplicate; dusting and cleaning the bed before sleeping; sleep position; turning off light before sleep; cover mouth when yawning and reciting some verses such as Ayat Kursi, Al-Ikhlas, Al-Falq and An-Nas); 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The surat brings every Muslim the closeness to Allah, the calmness of the soul, and the cure for many physical and psychological diseases. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
48656495|NCT05835323|DEVICE|Robotic-assisted mini-PCNL|Eligible participants will be enrolled to undergo robotic-assisted PCNL using the MONARCH Platform, Urology for the removal of kidney stones. The MONARCH Platform, Urology is a novel flexible robotic device that enables the clinician to obtain both transurethral and percutaneous access to a participant's kidney under continuous visualization for therapeutic application (for example, stone removal).
48656496|NCT05824728|DRUG|AGB101|low-dose levetiracetam, 220 mg, extended release tablet
48656497|NCT05557721|PROCEDURE|Topical lidocaine|Patients will receive topical anesthesia with tetracaine hydrochloride 1% three times, 5 minutes apart. Then, lidocaine gel 2% will be applied on the surface of the eye and refilled as needed for 10 minutes, as well as manipulated for a good coverage.
48656498|NCT05557721|PROCEDURE|MP-TLT|"Micro pulse transscleral laser treatment will be performed with the Iridex CycloG6 laser with the revised P3 probe, according to the recent consensus recommendations.~In brief, this includes MP-TLT with 2500 mW, 31.3% duty cycle, four 20 second sweeps per hemisphere, avoiding the 3 and 9 o'clock meridians and sectors with scleral thinning."
48656499|NCT05021835|DRUG|Ziltivekimab B|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
48656500|NCT05021835|DRUG|Ziltivekimab C|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
48656501|NCT05021835|DRUG|Placebo (Ziltivekimab B)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
48656502|NCT05021835|DRUG|Placebo (Ziltivekimab C)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
48656503|NCT05708859|DRUG|Tirzepatide|Tirzepatide 15mg Subcutaneous Solution
48656504|NCT05708859|DRUG|Placebo|Volume matched Subcutaneous Solution
48656505|NCT01139515|DRUG|Eletriptan commercial tablet|20 mg tablet, single dose
48656506|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
48656507|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
48656508|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
48656509|NCT05989997|DRUG|68Ga-NOTA-SNA002|68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
48340649|NCT03587922|DEVICE|Fantom|Treatment of den ovo coronary lesions
48340650|NCT01244204|DIETARY_SUPPLEMENT|Vitamin D|Daily dose of 800IU of vitamin D
48340651|NCT01244204|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules
48340652|NCT04119388|OTHER|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
48340653|NCT01094808|DRUG|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
48340654|NCT01094808|DRUG|Placebo|Placebo capsules
48340655|NCT01094808|OTHER|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
48340656|NCT00281567|DRUG|Tiotropium|
48340657|NCT00281567|DEVICE|Respimat SMI|
48340658|NCT00281567|DEVICE|HandiHaler|
48498569|NCT01517230|BEHAVIORAL|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
48656510|NCT05006040|DEVICE|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
48656511|NCT04886531|DRUG|Neratinib|120mg for 7 days; 160mg for 7 days ; 240mg for 7 days. 240 mg (up to a maximum of 24 weeks) orally daily\*.
48340659|NCT02318745|BEHAVIORAL|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
48340660|NCT02318745|BEHAVIORAL|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
48340661|NCT01300585|OTHER|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
48340662|NCT03508544|PROCEDURE|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
48498570|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
48498571|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
48498572|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
48656512|NCT04886531|DRUG|Letrozole (L) or Anastrozole (A)|L: (2.5 mg) OR A: (1 mg) orally daily (up to a maximum of 24 weeks)\*
48656513|NCT04886531|DRUG|Trastuzumab|All Arms 8mg/kg loading dose followed by 6mg/kg every 3 weeks administered every 3 weeks by IV starting wk 4. Trastuzumab biosimilars may be used per institutional guidelines.
48656514|NCT05325008|DRUG|Immunosuppression reduction/modification + intravenous immunoglobulin|Participants will receive intravenous immunoglobulin along with immunosuppression reduction/modification.
48656515|NCT05325008|OTHER|Immunosuppression reduction/modification|Participants will receive immunosuppression reduction/modification.
48656516|NCT03962647|DIETARY_SUPPLEMENT|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
48656517|NCT03962647|DRUG|Letrozole|2.5 mg taken once daily by mouth
48656518|NCT02945722|DRUG|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
48656519|NCT02945722|OTHER|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
48340663|NCT03508544|PROCEDURE|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
48340664|NCT03508544|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
48340665|NCT02522078|DRUG|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
48340666|NCT02522078|DRUG|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
48340667|NCT01070238|DIETARY_SUPPLEMENT|Isomaltulose|
48340668|NCT05176860|DEVICE|CBCT Imaging|Two research CBCT images will be acquired per subject.
48340669|NCT05070325|OTHER|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
48340670|NCT05070325|OTHER|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
48498573|NCT02280668|OTHER|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
48498574|NCT02280668|OTHER|the eccentric muscle damage exercise|
48498575|NCT00515541|DRUG|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
48656520|NCT03404713|BEHAVIORAL|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
48656521|NCT03404713|BEHAVIORAL|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
48656522|NCT01462747|DEVICE|KULIST|Twice daily dosing for 8 weeks
48656523|NCT02618941|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
48656524|NCT05018507|OTHER|Data collection only|No intervention, just data collection from system machines
48656525|NCT04272034|DRUG|INCB099318|INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
48340671|NCT05070325|OTHER|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
48340672|NCT03984812|DRUG|GSK3732394|It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
48340673|NCT03984812|DRUG|Placebo|Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
48340674|NCT02393222|OTHER|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
48340675|NCT01000025|DRUG|PF-00299804|PF-804 45 mg PO, daily
48340676|NCT01000025|DRUG|Placebo|Placebo 45 mg PO, daily
48340677|NCT03705260|OTHER|Usual Care|Usual care from Primary Care Physician and dietitian.
48340678|NCT03705260|BEHAVIORAL|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
48498576|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
48498577|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
48498578|NCT03012984|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
48498579|NCT03012984|DRUG|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
48498580|NCT02633488|DRUG|Placebos|A 12 week single blind placebos
48498581|NCT02633488|DRUG|metformin|A 12 week single blind metformin
48498582|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 1|Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
48656526|NCT05200481|DRUG|Brigatinib 180 MG|Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
48656527|NCT05200481|DRUG|Carboplatin|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
48133319|NCT04926597|OTHER|individualized nutritional guidelines|nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.
48133320|NCT04926597|OTHER|general nutritional information|general information about health food behavior upon hospital discharge
48498583|NCT00686075|OTHER|Placebo, Cohort 1|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
48133322|NCT04300764|BEHAVIORAL|Gamification Intervention|Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
48498584|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 2|Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
48656528|NCT05200481|DRUG|Pemetrexed|Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
48340679|NCT03705260|OTHER|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
48340680|NCT01197092|DIETARY_SUPPLEMENT|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
48340681|NCT01197092|DIETARY_SUPPLEMENT|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
48340682|NCT01197092|DEVICE|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
48340683|NCT01197092|BEHAVIORAL|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
48656529|NCT05132491|OTHER|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
48133327|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with double-cone coil|Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil
48133328|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with sham coil|Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
48340684|NCT04611061|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
48340685|NCT04611061|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
48498585|NCT00686075|OTHER|Placebo, Cohort 2|Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
48498586|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
48498587|NCT00686075|OTHER|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.
48498588|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
48133338|NCT06029842|OTHER|Collaborative approach of clinical pharmacist with physicians in a medical center|For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
48133339|NCT06247241|DRUG|VMB-100|VMB-100 is administered as intrasphincteric injection in the urethra sphincter
48498589|NCT00686075|OTHER|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.
48340686|NCT04564703|DRUG|Iberdomide|IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
48340687|NCT04605185|DRUG|Donafenib Tosilate Tablets|100mg Qd/150mg Qd/100mg Bid, po
48340688|NCT04605185|BIOLOGICAL|Toripalimab Injection|240 mg, iv drip,q3w
48656530|NCT06439810|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
48498590|NCT00686075|BIOLOGICAL|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
48498591|NCT00686075|OTHER|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
48133343|NCT04263714|BEHAVIORAL|Exercise|Aerobic exercise and resistance exercise
48340689|NCT04862741|DRUG|NX-13 250mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
48340690|NCT04862741|DRUG|NX-13 500mg IR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
48340691|NCT04862741|DRUG|NX-13 500mg MR|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
48656531|NCT06230913|DEVICE|Kinesiotape|To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
48340692|NCT04862741|DRUG|Placebo|Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
48340693|NCT00195481|DRUG|Rapamune|
48340694|NCT03199742|BEHAVIORAL|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
48340695|NCT03199742|BEHAVIORAL|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
48340696|NCT03423563|DEVICE|Flexible fiberoptic bronchoscopy|Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
48340697|NCT03423563|DEVICE|Fexible intubation video endoscopy|Fexible intubation video endoscopy
48340698|NCT03489070|COMBINATION_PRODUCT|Traumastem®|Intraoperative application as secondary hemostatic treatment
48340699|NCT03489070|COMBINATION_PRODUCT|Surgicel®|Intraoperative application as secondary hemostatic treatment
48656532|NCT06230913|DEVICE|Pressure garment|The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
48656533|NCT05022316|OTHER|CDS Tool Access|Clinics receiving the intervention will have access to EHR-based CDS tools designed to support social risk-informed care. Prior to tool activation in participating community health centers (CHCs), clinic staff members will be oriented to the CDS tools by an EHR trainer (either on-site or remotely).
48656534|NCT04591080|DEVICE|GUMMETAL Orthodontic Wire|Orthodontic archwire made of TiNbTaZr alloy.
48133344|NCT04887337|PROCEDURE|Arthroscopic stabilization|Early arthroscopic stabilization with Bankart repair
48133345|NCT04887337|OTHER|Rehabilitation including a period of immobilization followed by physical therapy|Rehabilitation including a period of immobilization followed by physical therapy
48340700|NCT00715013|DRUG|Patupilone|Patupilone
48340701|NCT02232724|DEVICE|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
48340702|NCT02575989|OTHER|1: control group|Classic - current management of trauma patients by French medical teams
48340703|NCT02575989|OTHER|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~* Continuous monitoring of body temperature~* Ambulance warming (target : 30°C)~* Patient warming with dedicated blanket~* Infusion fluid warming (and temperature control)"
48340704|NCT03561168|DIAGNOSTIC_TEST|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
48340705|NCT03024710|BEHAVIORAL|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
48340706|NCT01886755|DIETARY_SUPPLEMENT|ORS rehydration solution|
48340707|NCT01886755|DIETARY_SUPPLEMENT|placebo|
48340708|NCT04600453|OTHER|Physical Exercise|The intervention will consist of a multicomponent exercise training programme24, which will be composed of supervised progressive resistance exercise training, balance-training and walking for 4 consecutive days. During the training period, patients will be trained in 20 min sessions twice a day. The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM combined with balance and gait retraining exercises that progressed in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
48340709|NCT01634113|DRUG|tiotropium-bromide|IMP
48340710|NCT01634113|DRUG|tiotropium-bromide|IMP
48340711|NCT01634113|DRUG|placebo|placebo matching tiotropium
48340712|NCT01386567|DRUG|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
48340713|NCT01386567|DRUG|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
48340714|NCT01376895|BEHAVIORAL|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
48340715|NCT01376895|BEHAVIORAL|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
48340716|NCT04501757|BIOLOGICAL|Naxitamab/GM-CSF|naxitamab/GM-CSF for 5 Cycles
48340717|NCT02687607|DEVICE|WEB Aneurysm Embolization System|
48340718|NCT02657434|DRUG|Atezolizumab|Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
48340719|NCT02657434|DRUG|Carboplatin|Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
48340720|NCT02657434|DRUG|Cisplatin|Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
48340721|NCT02657434|DRUG|Pemetrexed|Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
48340722|NCT06506292|DRUG|Adebrelimab|Adebrelimab:1200 mg, iv, d1
48340723|NCT06506292|DRUG|XELOX|oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14
48340724|NCT02221960|BIOLOGICAL|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
48340725|NCT02221960|BIOLOGICAL|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
48340726|NCT03219801|BIOLOGICAL|mesenchymal stem cells|SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
48340727|NCT02114489|DRUG|ibandronate|Unique perfusion of ibandronate 3 mg IV
48340728|NCT02114489|DRUG|Placebo|
48340729|NCT04192760|PROCEDURE|Stenting|Comparison of two technical approaches in the interventional treatment on de-novo non-left main coronary lesions
48340730|NCT05419947|DRUG|VERDYE powder for solution for injection 25 mg|Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
48340731|NCT05381389|DRUG|Bupivacaine Hydrochloride in-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an in-plane approach to the brachial plexues
48340732|NCT05381389|DRUG|Bupivacaine Hydrochloride out of-plane approach for the interscalene block|20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an out of-plane approach to the brachial plexues
48133346|NCT06026943|DEVICE|DaRT seeds insertion|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
48656535|NCT04591080|DEVICE|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
48340733|NCT01149772|BEHAVIORAL|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
48340734|NCT02320214|DEVICE|Miami w/ frag Personal lubricant|
48340735|NCT03853304|OTHER|+ Folic acid|Salt fortified with folic acid
48340736|NCT03853304|OTHER|+ Vitamin B12|Salt fortified with vitamin B12
48340737|NCT03853304|OTHER|DFS|Salt fortified with iron and iodine
48340738|NCT04260841|DEVICE|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
48340739|NCT02108834|PROCEDURE|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
48340740|NCT02108834|PROCEDURE|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
48340741|NCT02382757|DRUG|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
48340742|NCT04085042|DEVICE|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
48340743|NCT02154334|DRUG|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
48340744|NCT02154334|DRUG|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
48340745|NCT02154334|DRUG|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
48340746|NCT06307977|BEHAVIORAL|Couples Health Project|A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention
48340747|NCT03571503|PROCEDURE|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
48367407|NCT01733394|DRUG|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
48367408|NCT01733394|DRUG|lamotrigine|
48656536|NCT06634498|OTHER|real rTMS on the dlPFC|During real rTM session, participants will perform the regulation of craving (ROC). In the rest phase, participants need to relax and rest. In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
48656537|NCT06634498|OTHER|Sham (No Treatment)|During the sham rTMS session, participants will perform the regulation of craving (ROC). In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
48656538|NCT00516308|DEVICE|NightHawk|
48656539|NCT04632654|BEHAVIORAL|A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)|A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
48656540|NCT04931017|PROCEDURE|Biopsy|Undergo biopsy
48656541|NCT04931017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48133348|NCT02220452|OTHER|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
48498592|NCT03056157|BEHAVIORAL|Adaptive Disclosure for Moral Injury and Loss|AD-MIL is a manualized, 12-session individual psychotherapy designed to improve functioning and to reduce PTSD symptoms by facilitating Veterans doing corrective things in their life to heal and repair traumatic loss and moral injuries. The change agents are: (1) emotional-processing of traumatic loss and moral injuries and motivating a healing and action plan by writing therapeutic letters (e.g., to a lost unit member, to victims of personal transgressions, to people who transgressed); (2) skills training and behavioral contracting to improve functioning and targeting moral injury- and traumatic loss-related psychological and behavioral obstacles to positive and potentially habilitative engagements in occupational, relationship, and family roles; and (3) teaching self- and other-compassion and mindfulness. The goal is to redress the functional impact of moral emotions (anger, shame).
48340748|NCT03571503|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
48340749|NCT03571503|PROCEDURE|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
48340750|NCT03571503|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48340751|NCT03571503|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48340752|NCT03571503|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48498593|NCT03056157|BEHAVIORAL|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on day-to-day functional problems with no focus on trauma or re-visiting past experiences
48498594|NCT01323049|PROCEDURE|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
48498595|NCT01323049|PROCEDURE|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
48340753|NCT03571503|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48340754|NCT03571503|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
48133349|NCT02220452|OTHER|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
48133350|NCT05267769|DRUG|AP707|Preparation of Cannabis flowers (Cannabis flos)
48340755|NCT03571503|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
48367409|NCT03868085|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|DXA scan
48498596|NCT05882292|DRUG|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
48498597|NCT02445976|DRUG|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
48498598|NCT01321463|DRUG|PH-797804|6 mg oral tablet once daily for 12 weeks
48498599|NCT01321463|DRUG|Placebo|Placebo oral tablet once daily for 12 weeks
48498600|NCT02448264|DRUG|BCX7353|
48498601|NCT02448264|DRUG|Placebo to match BCX7353|
48498602|NCT02976324|DEVICE|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
48498603|NCT03781284|DIAGNOSTIC_TEST|[18F]-FDG PET/MRI|
48498604|NCT03781284|DIAGNOSTIC_TEST|Colonoscopy|
48498605|NCT03123432|DIETARY_SUPPLEMENT|immunomodulating nutrients enriched diet|
48498606|NCT03123432|DIETARY_SUPPLEMENT|standard diet|
48498607|NCT04842838|DEVICE|paclitaxel DCB|Drug-coated balloon is a new kind of coronary interventional device. The balloon coated with anti-cell proliferation drugs (paclitaxel, etc.) is sent to the stenosis site. The balloon is closely adhered to the vascular wall during the expansion, and the drug is rapidly and evenly coated on the disaffected vessels.In recent years, DCB has gradually become an alternative for the treatment of in-stent restenosis (ISR), small vessel disease (SVD) and bifurcation disease.
48498608|NCT04842838|DEVICE|DES|Provisional T technique is the preferred method for the treatment of bifurcation lesions with the existing stent.According to the 2018 European Guidelines on revascularization and the consensus group of the European Bifurcation Club (EBC), Provisional T technique is still the first choice for the treatment of Bifurcation, despite the problems related to side branches.
48498609|NCT05003934|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48498610|NCT05515692|PROCEDURE|Biospecimen Collection|Correlative studies
48656542|NCT04931017|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
48133353|NCT06246110|DRUG|EIK1001|EIK1001 is a Toll like receptor 7/8 (TLR 7/8) agonist
48133354|NCT06246110|DRUG|Pembrolizumab|PD-1 inhibitor
48133355|NCT06246110|DRUG|Paclitaxel|Chemotherapy
48133356|NCT06246110|DRUG|Pemetrexed|Chemotherapy
48133357|NCT06246110|DRUG|Carboplatin|Chemotherapy
48133358|NCT06422806|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48133359|NCT06422806|PROCEDURE|Diagnostic Imaging|Undergo standard imaging scans
48133360|NCT06422806|DRUG|Doxorubicin|Given IV
48133361|NCT06422806|PROCEDURE|Echocardiography|Undergo ECHO
48340756|NCT02663180|BEHAVIORAL|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
48340757|NCT02663180|BEHAVIORAL|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
48340758|NCT04908969|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
48340759|NCT03511300|BEHAVIORAL|Goal-Setting Instructions|"In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)"
48340760|NCT03511300|BEHAVIORAL|Standard Instructions|Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
48340761|NCT03101449|OTHER|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
48340762|NCT03101449|OTHER|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
48340763|NCT01482468|DRUG|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
48340764|NCT01482468|DRUG|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
48340765|NCT06438965|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT scans will be obtained from two muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patient with neuromuscular diseases.
48340766|NCT05721560|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
48340767|NCT01468038|DRUG|Trazodone|active trazodone and sentra pm-like placebo
48340768|NCT01468038|OTHER|Sentra PM|Active Sentra PM and trazodone-like placebo
48340769|NCT01468038|DRUG|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
48340770|NCT01468038|DRUG|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
48340771|NCT01529619|DRUG|Rivastigmine transdermal patch|
48340772|NCT04483297|DRUG|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.
48340773|NCT04483297|OTHER|Control|Local Autologous Bone + Posterior Fixation
48340774|NCT05059847|OTHER|Training|Training routine assigned by randomized chart
48340775|NCT03702140|DRUG|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
48340776|NCT05359679|BEHAVIORAL|Value Champion Training Program|Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
48340777|NCT05359679|OTHER|No Intervention|Usual clinical care - no value champion present at this clinical setting
48340778|NCT01398228|BEHAVIORAL|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
48656543|NCT04931017|DRUG|Extended Release Metformin Hydrochloride|Given PO
48656544|NCT04931017|OTHER|Questionnaire Administration|Ancillary studies
48656545|NCT06637020|DRUG|HDM1005 injection or placebo|Within each cohort, subjects are randomized in a 4:1 ratio to receive either HDM1005 injection or placebo subcutaneously.
48656546|NCT06628986|BEHAVIORAL|MBSR|20 minutes once a week for 8 weeks
48656547|NCT06628986|BEHAVIORAL|NLP|NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
48340779|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus carbohydrate|A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
48340780|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus niacin|A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
48340781|NCT05417659|OTHER|Placebo|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
48340782|NCT01810380|DRUG|Placebo|Once daily as tablets and capsules, orally
48340783|NCT01810380|DRUG|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
48340784|NCT01810380|DRUG|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
48340785|NCT02463760|OTHER|Medical imaging|
48656548|NCT06628986|BEHAVIORAL|control|control group, no practice,
48133362|NCT06422806|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48656549|NCT06093191|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
48656550|NCT06093191|DRUG|Ciprofloxacin 750 MG|Oral ciprofloxacin 750mg twice daily will be prescribed for 2 weeks.
48656551|NCT06093191|DRUG|Oral ciprofloxacin placebo|Oral ciprofloxacin placebo twice daily will be prescribed for 2 weeks.
48340786|NCT03193450|BEHAVIORAL|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
48340787|NCT03193450|BEHAVIORAL|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
48340788|NCT00464711|DRUG|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
48340789|NCT02456792|PROCEDURE|IVF|Women will undergo one IVF cycle
48498611|NCT05515692|PROCEDURE|Computed Tomography|Undergo radiotherapy simulation using CT
48498612|NCT05515692|COMBINATION_PRODUCT|Electron Beam Therapy|Undergo electron beam radiotherapy
48656552|NCT06093191|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
48656553|NCT05208762|DRUG|PF-08046054|Given into the vein (IV; intravenously)
48656554|NCT05208762|DRUG|pembrolizumab|200 mg once every 3 weeks given into the vein (IV; intravenously)
48656555|NCT05940272|BEHAVIORAL|Hematolo-GIST Training|Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
48656556|NCT05940272|BEHAVIORAL|Participants Appointment|Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
48656557|NCT06062472|DIETARY_SUPPLEMENT|Probiotics|Lactobacillus paracasei PS23 will be used in this study
48656558|NCT06062472|DIETARY_SUPPLEMENT|heat-treated of Lactobacillus paracasei HT-PS23|heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
48656559|NCT06062472|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use
48656560|NCT00143845|PROCEDURE|Reduced intensity conditioning|Busulfan and Fludarabine regimen
48656561|NCT00143845|PROCEDURE|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
48656562|NCT00143845|PROCEDURE|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
48656563|NCT05095922|DRUG|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
48656564|NCT05095922|DRUG|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
48656565|NCT05095922|DRUG|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
48656566|NCT03526172|PROCEDURE|High tibial osteotomy|Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
48656567|NCT03526172|DEVICE|Allograft wedge|Insertion of allograft wedge into the osteotomy gap during the HTO procedure
48656568|NCT03526172|DEVICE|Accelerometer|ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
48656569|NCT03526172|OTHER|Questionnaire|Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
48656570|NCT06638827|PROCEDURE|Thoracic Sympathectomy|"Bilateral thoracoscopic sympathectomy will be performed with general anesthesia, using single lung ventilation and monopolar cautery for transection of the sympathetic chain.~Persons with PFH who underwent the BTS were classified into three groups, depending the level of transaction of sympathetic chain:~1. transection at the level from the second to the forth thoracic sympathetic ganglion (T2- T4);~2. transection at the level from the third to the forth thoracic sympathetic ganglion (T3-T4)~3. transection at the level from the second to the third thoracic sympathetic ganglion (T2-T3).."
48656571|NCT04729439|BEHAVIORAL|Homework Organization and Planning Skills (HOPS) Intervention|A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
48656572|NCT04729439|DEVICE|Digital Health Application (Online Platform) for Encouraging Skills Practice|This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
48656573|NCT02116335|DRUG|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
48656574|NCT02116335|DRUG|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
48656575|NCT06558253|DRUG|Coenzyme I for Injection|Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
48656576|NCT06638983|OTHER|Non-extraction Orthodontic Treatment of Angle Class I Malocclusion|Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention
48656577|NCT02586194|DRUG|ASP015K|Oral
48656578|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
48498613|NCT05515692|PROCEDURE|High Frequency Ultrasound Imaging|Undergo HFUS
48340790|NCT02456792|PROCEDURE|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
48340791|NCT00471783|PROCEDURE|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
48340792|NCT00383708|DRUG|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
48340793|NCT00383708|DRUG|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
48340794|NCT05316493|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|dietary guidance, exercise guidance, lifestyle intervention
48340795|NCT05316493|DRUG|Megestrol Acetate 160 MG Oral Tablet|enrolled participants will take Megestrol Acetate 160mg daily
48340796|NCT05316493|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg|enrolled patients will be treated with LNG-IUS.
48340797|NCT04039789|BEHAVIORAL|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
48340798|NCT04039789|PROCEDURE|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
48498614|NCT05515692|OTHER|Questionnaire Administration|Ancillary studies
48498615|NCT05515692|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo radiotherapy simulation using clinical setup
48340799|NCT06089707|DRUG|Naloxone Nasal Spray|IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
48340800|NCT02542670|GENETIC|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
48498616|NCT05515692|PROCEDURE|Skin Biopsy|Undergo biopsy
48498617|NCT05716386|DIETARY_SUPPLEMENT|Low salt diet|Low salt diet less than 2 gram per day
48498618|NCT03321435|OTHER|placenta previa patient|women had placenta previa either major or minor degree
48498619|NCT03321435|OTHER|normal women|those women had not placenta previa
48498620|NCT00030043|DEVICE|Penetrating auditory brainstem implant|
48498621|NCT00943267|DRUG|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
48498622|NCT00943267|DRUG|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
48498623|NCT00943267|DRUG|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
48133363|NCT06422806|BIOLOGICAL|Pembrolizumab|Given IV
48133364|NCT02189772|DRUG|Metadoxine extended release|MG01CI
48133365|NCT02189772|DRUG|Placebo|Inactive drug
48340801|NCT00571519|DRUG|Rivoglitazone HCl|0.5 mg tablets administered orally, once daily
48340802|NCT00571519|DRUG|rivoglitazone HCl|1.0 mg tablets administered orally, once daily
48340803|NCT00571519|DRUG|rivoglitazone HCl|1.5 mg tablets administered orally, once daily
48340804|NCT00571519|DRUG|placebo|placebo tablets matching rivoglitazone tablets administered orally, once daily
48340805|NCT00571519|DRUG|pioglitazone HCl|15 mg capsules administered orally, once daily
48340806|NCT00571519|DRUG|pioglitazone HCl|30 mg capsules administered orally, once daily
48340807|NCT00571519|DRUG|pioglitazone HCl 45 mg|45 mg capsules administered orally, once daily
48340808|NCT00571519|DRUG|placebo|placebo capsules for pioglitazone administered orally, once daily
48340809|NCT00571519|DRUG|metformin|Oral tablets. Rescue medication.
48340810|NCT01871415|DRUG|aleglitazar|150 mcg orally daily
48340811|NCT01871415|DRUG|metformin|pre-existing background regimen and dose
48340812|NCT01871415|DRUG|placebo|matching aleglitazar placebo orally daily
48340813|NCT04378439|BEHAVIORAL|Peer Navigation|"First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention"
48367410|NCT04888507|DRUG|Pozelimab|Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
48367411|NCT04888507|DRUG|Cemdisiran|SC administration
48367412|NCT05579938|DIETARY_SUPPLEMENT|Enzyme-containing lozenge|A lozenge containing 3 active enzymes
48367413|NCT05579938|DIETARY_SUPPLEMENT|Placebo lozenge|Identical placebo lozenge
48367414|NCT04048434|DEVICE|Cytosorb|extracorporeal cytokine adsorption
48498624|NCT00943267|PROCEDURE|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
48498625|NCT00943267|PROCEDURE|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
48498626|NCT05860205|BEHAVIORAL|Multiple Component Mobile-Aid Pain Reduction Intervention|1.Posture training through the wearable device, UPRIGHT GO. The participant wears the device on their neck. The device provides biofeedback to poor posture with vibrations and tracks posture. 2. A daily core muscle training and stretching exercise program including trunk rotation, lumbar rotation, hip flexor stretch, side plank, glute bridge, suitcase carry, and palloff press. 3. Participants will practice stress reduction through breath focus which will help them to concentrate on deep breathing to help them ignore distracting thoughts and sensations. 4. Strategies to improve daily level of activity including wearing a Garmin device that tracks their daily physical activity and reminds them to walk and the use of the communication principle to assist participants in overcoming barriers to physical activity.
48340814|NCT04378439|BEHAVIORAL|mHealth|"In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP."
48340815|NCT05215678|OTHER|Acceptance of invitation to trial participation|Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
48133366|NCT04325217|DRUG|Nintedanib|Capsules
48340816|NCT05215678|OTHER|Declining invitation to trial participation|Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
48340817|NCT01039311|DEVICE|Optical Coherence Tomography|Obtain OCT images.
48340818|NCT02837809|RADIATION|Low dose CT|annual CT vs biennial CT
48340819|NCT01313039|DRUG|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
48340820|NCT04253470|OTHER|embryo transfer|Step of the assisted reproduction in which embryos are placed into the uterus in order to obtain a pregnancy
48340821|NCT06156891|PROCEDURE|Toxicities reduced treatment|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
48340822|NCT06156891|PROCEDURE|Conventional treatment|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
48340823|NCT00455936|DRUG|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
48340824|NCT00455936|PROCEDURE|chemotherapy|gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
48340825|NCT02235168|PROCEDURE|six minute walking test|
48340826|NCT02003118|DRUG|AKR 202|
48340827|NCT02003118|DRUG|Placebo|
48340828|NCT00493194|DRUG|sirolimus|
48340829|NCT00493194|DRUG|cyclosporine|
48340830|NCT00493194|DRUG|daclizumab|
48340831|NCT04260672|BEHAVIORAL|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
48340832|NCT02527564|DRUG|Suvorexant|
48340833|NCT02527564|DRUG|Placebo|
48340834|NCT01300767|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
48340835|NCT01300767|DEVICE|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
48340836|NCT01300767|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
48340837|NCT04285372|PROCEDURE|Side branch protection/ballooning|Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
48340838|NCT04285372|PROCEDURE|No side branch protection/ballooning|No intervention on the side branch
48340839|NCT03538275|OTHER|Monitoring test|Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
48340840|NCT04373018|PROCEDURE|Sodium hypochlorite|Sodium hypochlorite irrigant will be used during biomechanical preparation.
48340841|NCT04373018|PROCEDURE|Chlorhexidine|Chlorhexidine irrigant will be used during biomechanical preparation.
48340842|NCT04373018|PROCEDURE|Chlorhexidine + Hydrogen peroxide|Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
48367415|NCT04160494|DRUG|D2C7-IT (6920 ng/mL via convection-enhanced delivery)|dual-specific mAB
48367416|NCT04160494|DRUG|Atezolizumab (1200 mg every three weeks)|programmed cell death ligand 1 (PD-L1) blocking antibody
48367417|NCT04160494|DRUG|D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)|dual-specific mAB
48367418|NCT06412471|DRUG|SSGJ-707|bispecific antibody
48367419|NCT06412471|DRUG|carboplatin|chemotherapy
48367420|NCT06412471|DRUG|Pemetrexed|chemotherapy
48367421|NCT06412471|DRUG|paclitaxel|chemotherapy
47914551|NCT02527603|DRUG|Anti-Inflammatory Agents, Non-Steroidal|"All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain."
47981115|NCT05339087|DRUG|Riociguat Oral Tablet|Riociguat Oral Tablet (1 mg, 1.5 mg, 2.0 mg or 2.5 mg three times daily) Titration phase: dose will be individually adjusted in accordance with the in-label titration regimen. Dose adjustment will be performed every two weeks by phone taking the systemic blood pressure of the patient, the subjects and physicians' subjective estimation and occurrence of adverse reactions into account. At week 8 the maintenance dose will be established and continued for the rest of the study
48340843|NCT05833568|DEVICE|Active Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition."
48340844|NCT05833568|DEVICE|SHAM Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions."
47981116|NCT05339087|OTHER|Placebo|Sham titration and adjustment to maintenance dose will be performed according to individual tolerability as in the experimental arm.
48340845|NCT05121961|PROCEDURE|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
48656579|NCT01066910|BEHAVIORAL|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
48656580|NCT05371379|BIOLOGICAL|CM338 Injection|A humanized monoclonal antibody.
48656581|NCT06434727|OTHER|observational study|Observational Study
48656582|NCT01380080|DRUG|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
48656583|NCT01380080|DRUG|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
48656584|NCT01380080|DRUG|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
48656585|NCT01380080|DRUG|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
48656586|NCT01380080|DRUG|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
48656587|NCT01380080|DRUG|Isoniazid|INH 300 mg orally once daily
48656588|NCT06333561|PROCEDURE|Hepatic arterial infusion chemotherapy|Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
48656589|NCT06333561|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
48656590|NCT06333561|DRUG|Tislelizumab|200mg intravenously every 3 weeks
48656591|NCT06333561|DRUG|Toripalimab|240mg intravenously every 3 weeks
48656592|NCT06333561|DRUG|Sintilimab|200mg intravenously every 3 weeks
48656593|NCT06333561|DRUG|Camrelizumab|200mg intravenously every 3 weeks
48656594|NCT06500156|OTHER|Fluid challenge|Rapid infusion (\< 15 minutes) of a fluid bolus of crystalloids (200 to 500cc)
48656595|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
48656596|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
48656597|NCT06634771|DEVICE|10 Hz transcranial alternating current stimulation (tACS)|10 Hz bi-frontal tACS: Alternating current stimulation is delivered by an XCSITE 100 device (Pulvinar Neuro, Chapel Hill, NC), through three conductive carbon-rubber electrodes. Electrodes are placed over the apex of the head (Cz) and the prefrontal cortex bilaterally (F3 and F4). Stimulation is delivered during the second half of the HABIT Test session. Stimulation parameters: 2mA peak-to-peak 10Hz sine-wave flanked by 10 second linear envelope ramps in and out for a total duration of 30 min and 20 seconds.
48656598|NCT06634771|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham tACS: The procedure for sham stimulation will be identical, but it will last for 2 minutes instead of 30 minutes.
48656599|NCT01250327|DEVICE|Melody|insertion of a pulmonic valved stent
48656600|NCT01250327|DEVICE|bare stent|insertion of a bare metal stent
48656601|NCT01250327|PROCEDURE|Surgery|conventional surgery methode
48656602|NCT03266783|DRUG|Apixaban|Refer to Apixaban group
48656603|NCT03266783|DRUG|Rivaroxaban|Refer to Rivaroxaban group
48656604|NCT06632080|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.
48656605|NCT06632080|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
48340846|NCT05228197|DIAGNOSTIC_TEST|Biopsy & Imaging|H\&E stained prostate biopsy slides from standard of care treatment
48340847|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, early treatment
48340848|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, deferred treatment
48340849|NCT03926637|OTHER|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
48340850|NCT05826041|BEHAVIORAL|(INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.|The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
48340851|NCT05826041|BEHAVIORAL|Traditional Domestic Violence Support Group|The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
48340852|NCT03624439|DEVICE|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
48340853|NCT03624439|DEVICE|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
48340854|NCT04258007|DRUG|Reversal Neostigmine|Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
48340855|NCT04258007|DRUG|Reversal Sugammadex|Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
48340856|NCT02944136|BEHAVIORAL|enhanced usual care|usual care from health providers
48340857|NCT02944136|BEHAVIORAL|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
48340858|NCT04414527|BEHAVIORAL|Standard counselling|"The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~1. national nutrition and health care including IFA supplementation,~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
48498627|NCT05860205|OTHER|Osteopathic Manipulation Treatment|Osteopathic Manipulation Treatment (OMT) will be conducted by putting pressure on certain muscles in the back and performing OMT exercises on the patient. The physician will treat participants with OMT twice during month 1 and once during month 2 and 3.
48656606|NCT06637904|DIAGNOSTIC_TEST|TriVerity Test|Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.
48340859|NCT04414527|BEHAVIORAL|Health-Video|"The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~1. National nutrition and health care including IFA supplementation~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
48340860|NCT03975712|OTHER|Not applicable, no intervention|Not applicable, no intervention
48340861|NCT00671398|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
48340862|NCT00671398|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
48340863|NCT00671398|DRUG|Placebo|Ramelteon placebo-matching tablets, orally for one night only
48498628|NCT05860205|OTHER|Sham Osteopathic Manipulation|The sham osteopathic manipulation treatment (OMT) will be performed by the medical team. Hands will be placed on the patient as if the OMT is being performed. The physician will treat participants with sham OMT twice during month 1 and once during month 2 and 3.
48498629|NCT03533023|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
48133368|NCT05598359|DIETARY_SUPPLEMENT|TA-65|TA-65 is a purified small molecule extracted from Astragalus root
48133369|NCT05598359|OTHER|Placebo|Inactive formulation
48340864|NCT02928666|OTHER|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
48340865|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
48340866|NCT01379729|OTHER|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
48340867|NCT01857024|DRUG|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
48340868|NCT02944513|DEVICE|Quell|
48340869|NCT04785937|DIAGNOSTIC_TEST|Ultrasound and Magnetic Resonance|liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2\* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
48340870|NCT05158179|DEVICE|Sensation testing|Sensation testing tactile aesthesiometer.
48340871|NCT03905876|OTHER|Questionnaire|Questionnaire to evaluate psychological experience
48340872|NCT05544071|DEVICE|Transcranial Magnetic Stimulation (TMS)|Compare active coil with sham coil.
48340873|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams once daily
48340874|NCT01316939|DRUG|Placebo|Placebo
48340875|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams twice daily
48340876|NCT04379323|DIAGNOSTIC_TEST|YuWell YE900 Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
48367422|NCT06412471|DRUG|PD-1/L1|Immune checkpoint inhibitors
48367423|NCT06412471|DRUG|Paclitaxel-albumin|chemotherapy
48656607|NCT05737680|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg daily
48656608|NCT05737680|DRUG|Colchicine|Colchicine continued
48656609|NCT06640530|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
48340877|NCT05970068|PROCEDURE|implantation of hydrophobic tubes for edema fluid drainage|1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.
48340878|NCT05970068|DEVICE|Best Medical Treatment|Compressive therapy, Phisioterapy, venous intervention
48340879|NCT00129740|DRUG|Nilotinib|400 mg orally twice daily
48340880|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Participants will take 2 capsules per day of either LGG or placebo.
48340881|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG Placebo|Participants will take 2 capsules per day of LGG placebo
48340882|NCT00092404|BIOLOGICAL|measles, mumps, and rubella virus vaccine live|
48340883|NCT00092404|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
48340884|NCT02229253|DRUG|degarelix|
48498630|NCT03533023|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
48656610|NCT06640530|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
48133371|NCT05856084|BIOLOGICAL|Low dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
48133372|NCT05856084|BIOLOGICAL|High dose Recombinant Herpes Zoster Vaccine (CHO cells)|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
48133373|NCT05856084|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
48133374|NCT05856084|BIOLOGICAL|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
48340885|NCT05347771|DRUG|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
48656611|NCT04547556|DIAGNOSTIC_TEST|BioFire|"A molecular rapid syndromic testing platform, using the following panels:~* BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~* BioFire FilmArray Pneumonia Panel plus (PP)"
48340886|NCT05347771|DRUG|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
48656612|NCT06644586|OTHER|videolaryngoscopy|The patients intubated with video laryngoscopy
48656613|NCT06644586|OTHER|Direct Laryngoscopy|The patients intubated with direct laryngoscopy
48656614|NCT06634719|DEVICE|Juveena Hydrogel System|The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.
48340887|NCT03255304|BEHAVIORAL|health mindest|groups be confronted with health aspects of food items
48340888|NCT03255304|BEHAVIORAL|palatability mindset|groups be confronted with palatability aspects of food items
48340889|NCT02667392|PROCEDURE|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
48367424|NCT03935945|BEHAVIORAL|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
48133375|NCT02029443|DRUG|Acalabrutinib|Participants will receive acalabrutinib as stated in the arms' description.
48498631|NCT04674748|DRUG|INCB086550|Each Participant will be treated at the specified dose level with a minimum of 3 subjects at each dose level. After the RP2D of INCB086550 is identified, the dose level will be expanded to better characterize the safety and tolerability and PK.
48656615|NCT06642376|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise Applied to Intensive Care Nurses on Fatigue and Perceived Stress
48367425|NCT00036660|DRUG|SarCNU|
48340890|NCT02667392|PROCEDURE|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
48340891|NCT00882830|PROCEDURE|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
47981117|NCT04151667|DRUG|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
47981118|NCT04151667|DRUG|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
47981119|NCT04151667|DRUG|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance \< 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
47981120|NCT04151667|DRUG|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m\^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
47981121|NCT00829946|BEHAVIORAL|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of \~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
47981122|NCT03305822|DRUG|LY900014|Administered SC
47981123|NCT03305822|DRUG|Insulin Lispro|Administered SC
47981124|NCT05778825|DRUG|Oral Minoxidil|minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
47981125|NCT05778825|OTHER|Placebo|placebo for 4 months
47981126|NCT04246008|OTHER|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
47981127|NCT04246008|OTHER|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
47981128|NCT00799240|DRUG|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
47981129|NCT00799240|DRUG|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
47981130|NCT02231333|DRUG|S-adenosylmethionine (SAMe)|
47981131|NCT02231333|DRUG|pentoxiphylline (PTX)|
47981132|NCT04358380|OTHER|Liver injury|LFTs elevation or liver decompensation
47981133|NCT03675607|OTHER|Complementary feeding behaviours|Any kind of complementary feeding practice
47981134|NCT05928897|DRUG|Disitamab Vedotin combined with Sintilimab|Disitamab Vedotin combined with Sintilimab
47981135|NCT05733624|DRUG|SCAI-001 0.01% eyedrop|BID for 12weeks
47981136|NCT05733624|DRUG|SCAI-001 0.02% eyedrop|BID for 12weeks
47981137|NCT05733624|DRUG|Restasis 0.05% eyedrop|BID for 12weeks
47981138|NCT03330808|OTHER|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
48133378|NCT06509412|DEVICE|LANAP surgical protocol using ND:YAG 1064 laser|A free running pulsed, 1064 nm wavelength-specific ND:YAG laser (Light walker AT)\* with an attached 320 µm diameter optical glass fiber attached to a metallic hand piece with a flexible tip, which will be set at 3:4 -watt average power, 20 HZ, and a 100-600 µs pulse duration
48340892|NCT05818072|PROCEDURE|One biopsy|To do one biopsy at the proximal part of the longest columnar-lined esophagus.
48340893|NCT05818072|PROCEDURE|Three biopsy|To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
48340894|NCT05818072|PROCEDURE|Seattle protocol|To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
48133379|NCT06509412|DEVICE|LANAP surgical protocol using diode 940 laser|Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm was attached with a power average set at 0.5-1 watt, in continuous mode, and 20 HZ
48133380|NCT06509412|PROCEDURE|Scaling and root planing (SRP)|Scaling and root planing (SRP) using ultrasonic device (Woodpecker USD-P Led Ultrasonic Scaler Ende) at moderate setting and with appropriate tips and also hand curettes will be used for root planning.
48340895|NCT05818072|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with narrow-band imaging.
48340896|NCT02548741|DRUG|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy \& David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
48133381|NCT03836105|DRUG|cemiplimab|No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
48340897|NCT02548741|DRUG|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
48340898|NCT02548741|OTHER|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
48340899|NCT02548741|OTHER|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
48340900|NCT05381207|DRUG|Montelukast Oral Tablet|Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
48498632|NCT01451086|BIOLOGICAL|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
48498633|NCT01451086|BIOLOGICAL|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
48498634|NCT05236283|DIAGNOSTIC_TEST|Blood Culture|Blood Culture
48498635|NCT01041066|DRUG|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
48340901|NCT05406440|DRUG|MK-8189|MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
48340902|NCT05406440|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
48340903|NCT01352845|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
48340904|NCT01352845|OTHER|Placebo|0.5 mL dose, given at 0, 2 and 6 months
48367426|NCT04870294|DEVICE|Teeth treated with composite resin, control group|The teeth grouped in group R were treated with composite resin restoration without liner material.
48367427|NCT04870294|DEVICE|Teeth treated with lining, pulp wall with PBS DTA® cement and composite resin restoration|The teeth grouped in group D received PBS CIMMO DTA® as indirect capping material of the cavity, followed by restoration of composite resin.
48367428|NCT01230827|DRUG|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
48498636|NCT01041066|DRUG|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
48498637|NCT03086837|BEHAVIORAL|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
48498638|NCT02788786|DRUG|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
48498639|NCT02788786|DRUG|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
48498640|NCT02788786|DRUG|Salt and Water|salt and water mix oral rinse
48498641|NCT00787397|BEHAVIORAL|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
48656616|NCT06423664|BEHAVIORAL|Play and Learn Strategies (PALS) Program|Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.
48656617|NCT06253767|PROCEDURE|Endodontic Treatment|Conventional endodontic treatment will be performed equally on all participants.
48133382|NCT06293066|DIAGNOSTIC_TEST|Ultrasound|Usefulness of transvaginal ultrasound
48340905|NCT04216706|DRUG|tailored pharmaceutical treatment|Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
48340906|NCT01089218|DRUG|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
48340907|NCT01089218|DRUG|control|no intervention with the same procedure of FB
48340908|NCT03420313|DRUG|Buprenorphine/naloxone sublingual tablets|24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
48340909|NCT02076334|OTHER|Far Infrared Fabric|
48340910|NCT02076334|OTHER|Spandex|
48340911|NCT01931150|DRUG|Topical Dapsone 5% Gel|
48340912|NCT01931150|OTHER|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
48340913|NCT01931150|DRUG|oral antibiotics|
48340914|NCT02411513|DEVICE|CEFALY|
48340915|NCT00910013|DRUG|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
48340916|NCT02754661|DEVICE|COLON Capsule endoscopy|
48340917|NCT02754661|DEVICE|Computed Tomographic Colonography|
48340918|NCT02958085|DRUG|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
48340919|NCT02958085|DRUG|Placebo|Dosed either once daily or once weekly
48340920|NCT06101316|DRUG|CB06-036|CB06-036 Capsule
48340921|NCT02637648|DRUG|Sodium Oxybate|parallel Group administration
48340922|NCT02637648|DRUG|Placebo|parallel Group administration
48340923|NCT01112982|OTHER|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
48340924|NCT01112982|DRUG|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is \> 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
48340925|NCT01112982|DRUG|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
48340926|NCT05026645|PROCEDURE|Clinical interventions performed in acute settings (contaminated environment)|Any clinical intervention performed on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic).
48340927|NCT05026645|PROCEDURE|Protection (clinician and patient)|As interrelated competence of the clinical intervention, any protection procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with.
48367429|NCT01230827|DRUG|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
48367430|NCT01230827|DRUG|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
48367431|NCT00000912|DRUG|Indinavir sulfate|
48367432|NCT00000912|DRUG|Abacavir sulfate|
48367433|NCT00000912|DRUG|Amprenavir|
48498642|NCT05842421|DEVICE|optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography|each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
48498643|NCT01433549|DEVICE|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
48498644|NCT01433549|DEVICE|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
48498645|NCT02455050|DRUG|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.
48498646|NCT02455050|DRUG|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
48340928|NCT05026645|PROCEDURE|Decontamination (clinician and patient)|As interrelated competence of the clinical intervention and protection, any decontamination procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with. This crucial step is usually expected prior the patient's transfer into a clean zone like the emergency room or its equivalent.
48340929|NCT01115517|DRUG|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
48340930|NCT01115517|DRUG|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
48340931|NCT05849636|BEHAVIORAL|ALERTA CANNABIS|The intervention consists of preventive messages about the benefits of not consuming cannabis, reducing the positive attitudes and encouraging the negative attitudes towards cannabis use, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject cannabis use. This information is presented through different tailored messages. In addition, the participants will be able to choose avatars to accompany them during the intervention. The intervention consists of a short story about the cannabis use by adolescents.The stories take place in three different scenarios (at home, at school leaving, and in public places).
48340932|NCT02755025|OTHER|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
48340933|NCT01316380|DRUG|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
48340934|NCT01316380|DRUG|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
48340935|NCT01316380|DRUG|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
48340936|NCT05197309|DIETARY_SUPPLEMENT|Metabolic Diet|Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
48340937|NCT05965206|BEHAVIORAL|Follow-up phone interview|Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
48340938|NCT02518542|PROCEDURE|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
48340939|NCT02518542|PROCEDURE|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
48340940|NCT02518542|PROCEDURE|Endoscopic intervention C|Endoscopic balloon dilatation
48340941|NCT02518542|PROCEDURE|Laparoscopic Surgery|Laparoscopic Heller myotomy
48340942|NCT01232192|BEHAVIORAL|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~* Midwife training~* Pregnant women campaigning~* Early detection with self pH detection~* Treatment of bacterial vaginosis"
48340943|NCT00169806|OTHER|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
48498647|NCT02455050|DRUG|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
48498648|NCT00398996|DRUG|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
48498649|NCT02485171|DEVICE|SAFEWALKER|Medical device walking aids.
48498650|NCT00718913|DRUG|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
48498651|NCT00718913|DRUG|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
48498652|NCT00718913|DRUG|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
48498653|NCT00718913|RADIATION|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
48498654|NCT00718913|DRUG|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
48340944|NCT06031025|OTHER|Questionnaire, clinical examination|At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.
48656618|NCT06253767|DEVICE|Low Level Laser Therapy|Treatment Group (TG) will receive photobiomodulation for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall
48656619|NCT06253767|DEVICE|Simulation Low Level Laser therapy|A simulation of low-level laser therapy was performed on the control group starting from patient preparation (placement of glasses) and the reproduction of device sounds without activation.
48498655|NCT03524989|DEVICE|Hyperbaric Oxygen Therapy|40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
48498656|NCT03524989|DEVICE|SHAM treatment|40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
48340945|NCT03564236|DEVICE|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates\[2\] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).\[3\]
48340946|NCT03564236|OTHER|Standard care|Standard regular care of a COPD exacerbation
48340947|NCT06383819|DRUG|Longidaza®|dose 3000 IU intramuscularly once every 5 days, 15 injections
48340948|NCT06383819|DRUG|Placebo|intramuscularly once every 5 days, 15 injections
48340949|NCT05618327|DRUG|JS203 for Injection|"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."
48340950|NCT01526005|DRUG|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
48656620|NCT04347538|OTHER|Saline Nasal Irrigation|Saline nasal irrigation BID
47981139|NCT04945551|BEHAVIORAL|Aerobic exercise training|12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
48340951|NCT01526005|DRUG|Transdermal Placebo Patch|1 patch per day; 8 weeks total
48340952|NCT01769625|DRUG|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
48367434|NCT00000912|DRUG|Nelfinavir mesylate|
48367435|NCT00000912|DRUG|Efavirenz|
48367436|NCT00000912|DRUG|Levocarnitine|
48367437|NCT00000912|DRUG|Adefovir dipivoxil|
48498657|NCT04321330|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
48498658|NCT05157958|BIOLOGICAL|ALLO-ASC-SHEET|Weekly administration
48498659|NCT05157958|OTHER|Vehicle Control|Weekly administration
48656621|NCT04347538|OTHER|Saline with Baby Shampoo Nasal Irrigation|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
48656622|NCT03649503|OTHER|No intervention|
47981140|NCT03927131|BIOLOGICAL|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
48498660|NCT00271154|DEVICE|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
48498661|NCT02674321|DRUG|SD-809|
48498662|NCT06013410|DIAGNOSTIC_TEST|colonoscopy|colonoscopy
48498663|NCT03790150|OTHER|Evidence-based practices|Implementation of evidence-based practices
48498664|NCT02492880|DEVICE|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
47981141|NCT03927131|BIOLOGICAL|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
47981142|NCT03927131|BIOLOGICAL|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
47981143|NCT03927131|BIOLOGICAL|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
47981144|NCT03927131|BIOLOGICAL|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
48498665|NCT01303757|BEHAVIORAL|Dietary counselling|
48498666|NCT02836496|DRUG|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
48498667|NCT02836496|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
47981145|NCT03927131|BIOLOGICAL|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
48133392|NCT06263946|DEVICE|Essilor® Stellest® spectacle lenses|patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.
48133393|NCT06571695|PROCEDURE|Anatomic Long Head of Biceps Tensioning Technique|The standard mini-open subpectoral approach will be made. The myotendinous junction of the long head of the biceps tendon and its location within the intertubercular groove will be marked using electrocautery. The surgeon will then turn to the glenohumeral joint and perform the biceps tenotomy.The long head of the biceps tendon will be retrieved.The tendon is tagged with a running, locking number 2 fiberwire suture at the mid substance of the myotendinous junction using the previously made electrocautery marks to set the tension. The tendon is shortened. The sutures from the biceps are passed through the Arthrex cortical button.The pectoralis major tendon is retracted and 2 centimeters proximal to the distal insertion a unicortical bone tunnel is drilled in the bicipital groove with a 3.2 millimeter drill.The wound is irrigated and the biceps button is threaded into this tunnel and then flipped.The suture is tensioned, securing the biceps against the groove
48133394|NCT06571695|PROCEDURE|Traditional Long Head of Biceps Tensioning Technique|Diagnostic arthroscopic shoulder scope will occur to assess the long head of the biceps for tendinopathy. Tenotomy will occur at the junction of the supraglenoid tubercle with arthroscopic scissors. Subsequent tensioning and tenodesis will be based on surgeon's preference
48340953|NCT00423592|DRUG|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
48340954|NCT02331641|PROCEDURE|Hepatectomy|Removal of a part of the liver
48340955|NCT04273841|DIETARY_SUPPLEMENT|Military Energy Gum|Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
48340956|NCT04273841|DIETARY_SUPPLEMENT|Placebo Gum|Pellet form placebo gum
48340957|NCT06450223|DRUG|Perampanel 12 MG|1 tablet of Perampanel Tablets 12 mg
48340958|NCT06450223|DRUG|Fycompa 12 mg film-coated tablets|1 tablet of Perampanel Tablets 12 mg
48340959|NCT06147778|DEVICE|MuCopilot mobile application|MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
47981146|NCT02202408|DRUG|SKI2670|Oral, Single Dose
47981147|NCT02202408|DRUG|Placebo|Same shape as the experimental drug
47981148|NCT04688710|BEHAVIORAL|Self-Hypnosis (HYP)|"Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed ...) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels."
47981149|NCT04688710|BEHAVIORAL|Mindfulness Meditation (MM)|"Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing."
48340960|NCT02629536|DRUG|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
48340961|NCT06082349|PROCEDURE|Lymphaticovenous anastomosis|Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to a adjacent vein of similar size, thereby facilitating the ouflow of lymphatic fluid in patients suffering from secondary lymphedema
48340962|NCT06082349|PROCEDURE|Sham surgery|Sham surgery involves the process of surgery, including local anesthesia and incisions, but no LVA is made.
48340963|NCT00422357|DRUG|Urtica Dioica (Tea bag)|
48340964|NCT06263244|DRUG|Ziltivekimab|Monoclonal antibody targeting IL-6
48340965|NCT06263244|DRUG|Placebo|Placebo
48340966|NCT01916187|DRUG|Imetelstat|
48340967|NCT05241665|DEVICE|SpectraWAVE Imaging System|Coronary imaging
48340968|NCT05374291|DRUG|Dapagliflozin 10 mg/day (oral)|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
48340969|NCT05374291|DRUG|Placebo|Patients take 10 mg dapagliflozin or matching placebo once daily in the morning
48340970|NCT04727645|OTHER|Philips interventional MRI suite (Philips Healthcare, Best, the Netherlands)|iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.
48340971|NCT03032250|OTHER|Communication Intervention|Attend interventionist sessions
48340972|NCT03032250|OTHER|Watch video|Watch video on a DVD
48340973|NCT03032250|OTHER|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
48340974|NCT03032250|OTHER|Quality-of-Life Assessment|Ancillary studies
48340975|NCT03032250|OTHER|Survey Administration|Ancillary studies
48133395|NCT05180838|DEVICE|BioSticker|The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
48498668|NCT02836496|DRUG|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
48498669|NCT02836496|DRUG|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
48498670|NCT03683368|DEVICE|YpsoPump Orbit soft|Insulin infusion sets will be used for up to 7 days or until failure
48498671|NCT03683368|DEVICE|YpsoPump Orbit micro|Insulin infusion sets will be used for up to 7 days or until failure
48498672|NCT00246142|BIOLOGICAL|Botulinum toxin type A|
48498673|NCT03465124|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
48133402|NCT05711693|DEVICE|Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)|Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared
48340976|NCT03032250|OTHER|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
48340977|NCT03186872|BEHAVIORAL|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
48340978|NCT02285517|PROCEDURE|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
48498674|NCT03465124|OTHER|Manual Cataract Surgery|conventional cataract surgery as control
48498675|NCT05898321|DRUG|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
48498676|NCT05898321|DRUG|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
48498677|NCT01348412|DRUG|oxaliplatin|130 mg/m²Every 21 days
48498678|NCT01348412|DRUG|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
48133403|NCT05711693|PROCEDURE|Blood pressure and heart rate measurement|"To all patients:~- blood pressure and heart rate will be measured"
48133404|NCT05711693|DEVICE|carotid to femoral PWW measurement|"To all patients:~- carotid to femoral PWW will be measured by LDV and tonometry for comparison"
48133405|NCT05711693|PROCEDURE|Questionnaire completion|All patients will complete a questionnaire of acceptability
48133406|NCT03792061|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
48498679|NCT01348412|DRUG|other intravenous chemotherapy drugs|
48133407|NCT03699163|DIAGNOSTIC_TEST|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
48340979|NCT02285517|PROCEDURE|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
48340980|NCT03198104|DEVICE|MRI|
48498680|NCT02836938|OTHER|Collection of exhaled breath volatile organic compounds|
48498681|NCT03591523|DIAGNOSTIC_TEST|Quantitative MR angiography|Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
48340981|NCT02983513|BEHAVIORAL|Early Intervention|
48340982|NCT06153914|PROCEDURE|Sequential Adult Left Lateral Liver Transplantation|Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
48340983|NCT02463318|DRUG|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
48340984|NCT02463318|OTHER|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
48340985|NCT03563261|DIETARY_SUPPLEMENT|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
48340986|NCT03563261|DIETARY_SUPPLEMENT|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
48340987|NCT00797810|DRUG|Rituximab|
48340988|NCT00409916|DEVICE|BioZ Dx|
48340989|NCT06206707|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Capsule FMT
48340990|NCT06206707|PROCEDURE|Placebo|Placebo capsules
48340991|NCT01122888|DRUG|Cilengitide|Given IV
48340992|NCT01122888|OTHER|Clinical Observation|Patients undergo a 2-week rest period
48340993|NCT01122888|OTHER|Laboratory Biomarker Analysis|Correlative studies
48340994|NCT05240612|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
48340995|NCT05240612|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
48340996|NCT01089166|DRUG|Metformin|
48340997|NCT00114218|DRUG|Gemcitabine Hydrochloride|Given IV
48340998|NCT00114218|DRUG|Docetaxel|Given IV
48340999|NCT01052636|OTHER|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
48341000|NCT04486612|OTHER|spinal anesthesia|prospective observational study
48341001|NCT00635245|BIOLOGICAL|figitumumab|
48341002|NCT00635245|OTHER|imaging biomarker analysis|
48341003|NCT00635245|OTHER|laboratory biomarker analysis|
48341004|NCT00635245|OTHER|pharmacological study|
48341005|NCT00635245|PROCEDURE|conventional surgery|
48341006|NCT00635245|PROCEDURE|magnetic resonance spectroscopic imaging|
48341007|NCT00635245|PROCEDURE|neoadjuvant therapy|
48341008|NCT03816397|BIOLOGICAL|Adalimumab|Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8mL and 40mg/0.8mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.
48341009|NCT03816397|OTHER|Placebo|The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The placebo is designed to match the characteristics of the citrate-free adalimumab during injection.
48341010|NCT04019392|DEVICE|Game Ready® device|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
48341011|NCT04019392|OTHER|Wetted Ice Bag with Elastic Wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
48341012|NCT04113512|OTHER|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
48341013|NCT04941157|PROCEDURE|Cerebrospinal Fluid Drain Placement|Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study
48341014|NCT00259389|BEHAVIORAL|Directly observed therapy (DOT)|
48341015|NCT06454162|OTHER|Modified Ketogenic Diet|the patients will receive KD after nutritional counseling, patients will instructed to start by limiting carbohydrate intake to just 20 g/day for 4 weeks in order to establish ketosis. Then, patients increase their carbohydrate intake by 5 g each week until they reach their individual maximum (approximately 40 g) to maintain stable ketosis. All carbohydrates relevant for elevating blood glucose are limited to 40-50 g/ day. In addition, the glycemic index and glycemic load of carbohydrates have to be below 50 and 60, respectively. This ketogenic diet is equivalent to a traditional ketogenic diet, but with a liberalized macronutrient composition of 70-80% fats, 15-20% proteins and 5-10% carbohydrates (compared to a traditional ketogenic diet with 90% fat, 6% proteins and 4% carbohydrates)+ exercise program
48341016|NCT06454162|OTHER|exercise program|the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
48341017|NCT01958554|BEHAVIORAL|Intervention Group|
48341018|NCT00628225|BEHAVIORAL|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
48367438|NCT00000912|DRUG|Saquinavir|
48367439|NCT05831956|PROCEDURE|Laparoscopic colectomy|Patients who under went laparoscopic colectomy
48367440|NCT04235673|DIETARY_SUPPLEMENT|melatonin|orally administered drops
48367441|NCT04235673|DRUG|placebo|orally administered drops
48341019|NCT00628225|BEHAVIORAL|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
48341020|NCT01983878|DRUG|Ramucirumab|Administered IV
48341021|NCT05983042|GENETIC|Ibuprofen|Ibuprofen 400mg three times a day for three days
48341022|NCT01250743|DIETARY_SUPPLEMENT|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
48341023|NCT03997760|DRUG|TAK-755|Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
48341024|NCT03997760|OTHER|Placebo|Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
48341025|NCT01291849|DRUG|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
48341026|NCT00929136|BIOLOGICAL|USP endotoxin|Continuous intra-arterial infusion
48341027|NCT03454204|OTHER|Pharmacokinetic|Analysis of blood samples
48341028|NCT02537223|DRUG|BYL719|
48341029|NCT02537223|DRUG|Cisplatin|
48341030|NCT02537223|RADIATION|Intensity modulated radiation therapy (IMRT)|
48341031|NCT04657445|DIAGNOSTIC_TEST|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
48341032|NCT01807091|DRUG|Chemotherapy|Receive outpatient induction chemotherapy
48341033|NCT06452368|DEVICE|facemask|Fixation of miniplates by four screws in the maxilla and protraction by using facemask
48341034|NCT00187850|PROCEDURE|PP|Partial pulpotomy
48341035|NCT00187850|PROCEDURE|DPC|Direct pulp capping
48341036|NCT01852916|DEVICE|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
48341037|NCT01852916|DEVICE|NHFOV|Nasal High Frequency Oscillatory Ventilation
48341038|NCT03512119|DRUG|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
48341039|NCT03273231|DRUG|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
48656623|NCT06116123|DEVICE|Massage mattress with cube/block system|Patients with an odd number were assigned to group I, while those with an even number were allocated to group II. Patients in group I were provided with a pressure sore prevention bed featuring a support surface with vibration (massage) capabilities, a cube/block system creating a low-pressure area, and a ventilation system, routinely utilized in the unit. For group II patients, a viscoelastic pressure sore prevention mattress with an orthopedic support surface, routinely employed in the unit, was used.Within the first six hours after admission, patients in both groups underwent initial assessments using the Braden Scale to determine their pressure sore risk. Both groups were monitored for a maximum of four weeks, with daily pressure ulcer assessments conducted using the Pressure Ulcer Observation Form. Pressure sore area in both groups was calculated in square centimeters (cm2) using the Wound Measurement Ruler.
48656624|NCT06275958|DRUG|Doublet Chemotherapy, Standard Dose (100%)|Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
48656625|NCT06275958|DRUG|Doublet Chemotherapy, Dose-reduced (75%)|75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
48656626|NCT06275958|DRUG|Monotherapy, Standard Dose (100%)|- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
48656627|NCT06275958|DRUG|Monotherapy, Dose-reduced (75%)|"75% of:~- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)"
48656628|NCT04100993|OTHER|No intervention used|No intervention used
48656629|NCT05152485|DRUG|BIIB104 Reference Formulation|Administered as specified in the treatment arm
48656630|NCT05152485|DRUG|BIIB104 Test Formulation|Administered as specified in the treatment arm
48656631|NCT06639984|DRUG|Psyllium (0.7 g/year of age per day)|Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
48341040|NCT03273231|DRUG|Saline|0.9% saline solution
48341041|NCT01399840|DRUG|BMN 673|Oral capsule with multiple dosage forms given once daily
48341042|NCT04220567|OTHER|Experimental: Exercise and Patient-centred education|"An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).~Patient-centred Education will follow the principles of transformative learning \& incorporate patients' narratives. It will precede 9 of the 24 exercise sessions and be delivered by the same physiotherapist"
48656632|NCT06639984|DRUG|Psyllium (0.5 g/year of age per day)|Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
48656633|NCT06639984|DRUG|Placebo|Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \&amp; Lyle, Staley, London, UK)
48341043|NCT04220567|OTHER|Active Comparator: Exercise|An eight-week programme based on 24 sessions of exercise supervised by a physiotherapist. Exercise will be carried out three times a week. Once a week the exercise session is performed autonomously by patient at home (according to the physiotherapist's recommendations).
48341044|NCT01431651|DIETARY_SUPPLEMENT|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
48341045|NCT00003250|DRUG|fenretinide|
48133408|NCT04310020|DRUG|Atezolizumab|Given IV
48133409|NCT04310020|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48133410|NCT04310020|PROCEDURE|Computed Tomography|Undergo CT scan
48133411|NCT04310020|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48341046|NCT02512276|BEHAVIORAL|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
48341047|NCT04919772|OTHER|Assessment|The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
48341048|NCT03907969|DRUG|AZD7648|Core: AZD7648 will be administered orally
48656634|NCT06639984|OTHER|fructans|Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
47981150|NCT01444326|OTHER|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
47981151|NCT00292695|OTHER|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
47981152|NCT01945177|DEVICE|narrow band imaging|narrow band imaging
47981153|NCT01945177|DEVICE|white light endoscopy|white light endoscopy
47981154|NCT03114813|DRUG|Carvedilol|Non-selective beta-blocker as per routine clinical care
47981155|NCT03114813|OTHER|MRI scan|One hour non-invasive MRI scan
47981156|NCT03114813|PROCEDURE|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
47981157|NCT04772755|DEVICE|Buzzy® and Electronic Game|Buzzy® was applied according to manufacturers directions and an electronic game was played. The participant was observed for 20 minutes post vaccination.
47981158|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 30 ug/day|
47981159|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 10 ug/day|
48133412|NCT04310020|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
47981160|NCT03256214|PROCEDURE|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
47981161|NCT03256214|PROCEDURE|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
48341049|NCT03907969|DRUG|PLD|The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
48341050|NCT01659359|DEVICE|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
48341051|NCT01659359|DRUG|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
48341052|NCT00224003|DRUG|Sodium Ferric Gluconate Complex in Sucrose.|
47981162|NCT04218305|DIAGNOSTIC_TEST|Serum Level Of Fetuin A|
47981163|NCT01739478|OTHER|Packing of abscess cavity|
47981164|NCT01739478|OTHER|External dressing|Application of external dressing whilst abscess cavity heals
47981165|NCT03152851|PROCEDURE|Pressure stimulus group|
47981166|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
48133417|NCT05345197|DRUG|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
48133424|NCT04218084|DRUG|Voxelotor|Participants are randomized 1:1 to receive voxelotor or placebo.
48133425|NCT04218084|DRUG|Placebo|Matching placebo.
48498682|NCT03591523|DIAGNOSTIC_TEST|Duplex sonography|Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
48133426|NCT05690230|OTHER|Virtual reality|Patients will be provided with a wireless virtual reality headset that contains a guided meditation application. The application allows users to select their preferred music, visual setting, and a topic for meditation.
48498683|NCT05498402|DEVICE|i-gel ® device|Ventilations will be delivered through an i-gel ® device
47981167|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
47981168|NCT06208033|DRUG|SMET12|"1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
47981169|NCT05248191|BIOLOGICAL|Capsule fecal microbiota material (cap-FMT)|Cap-FMT consists of Lyophilized FMT administered at 5 x 10\^11 bacteria per capsule daily for five days, for a total dose of 2.5 x 10\^12 bacteria.
48133427|NCT05690230|OTHER|Environmental changes|A nature themed wall mural decal will be installed in the procedure room and the in-room computer will play music from Pandora. A selection of suggested stations will be provided, with the option for outside selections.
48341053|NCT03020212|DRUG|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
48341054|NCT06394076|DEVICE|Cross-linked sodium hyaluronate gel for injection containing lidocaine|Cross-linked sodium hyaluronate gel for injection containing lidocaine
48656635|NCT04516434|DEVICE|Neurometer Neurotron CPT|All participants will undergo CPT testing. A Neurotron catheter (12-French) with electrode will be inserted through the urethra into the bladder. The catheter balloon will be inflated and positioned at the urethrovesical junction to stimulate the urethra 10-14 mm from the bladder neck. For bladder stimulation, the catheter balloon will be deflated and the catheter will be advanced into the bladder. The device will deliver sine wave stimulus pulses at 5, 250, and 2,000 Hz. CPT will be established using an automated forced choice paradigm by the method of levels. Testing order of the bladder and urethra will be randomized between participants.
48656636|NCT04516434|PROCEDURE|Cystometry|After bladder stimulation or during intraurethral stimulation, cystometry will be performed to assess bladder sensation and storage. A dual-chamber 8-French catheter will be passed through the urethra into the bladder for retrograde filling. A second 8-French catheter will be placed in the vagina to measure intra-abdominal pressure. A stimulation electrode catheter will only be inserted in the intraurethral stimulation arm. EMG pads will then be placed at 3 and 9 o'clock on each side of the perineum. The bladder will then be filled with room-temperature sterile saline solution in a retrograde fashion using a pump. Bladder sensation and urgency will be assessed while filling.
48656637|NCT04516434|PROCEDURE|Pressure-flow study|A pressure flow study will be performed to evaluate voiding function after stimulation. The transurethral and intra-vaginal catheters are left in place after cystometry and the participant will be asked to void around them, into a commode. Bladder and abdominal pressures will be recorded, as well as urine flow over time.
47981170|NCT05248191|BIOLOGICAL|Colonoscopic fecal microbiota material (colo-FMT)|Colo-FMT consists of rehydrated Lyophilized FMT material administered as a single dose of 2.5 x 10\^12 bacteria as liquid.
48133428|NCT06415591|DEVICE|Percutaneous electrical nerve field stimulation|FDA-approved acupuncture-like therapy applied to the external ear targeting several cranial nerve branches including the auricular branch of the vagus nerve to improve pain, physical function, and reduce symptoms of opioid withdrawal.
48498684|NCT05498402|DEVICE|bag-valve-mask ventilation|Ventilations will be delivered using a bag-valve-mask
48341055|NCT06328660|DEVICE|Lens 1|Frequent replacement silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
48341056|NCT06328660|DEVICE|Lens 2|Daily disposable silicone hydrogel contact lens for 14 ± 3 days on a daily disposable wearing modality
48498685|NCT03249337|DRUG|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
47981171|NCT04045340|DEVICE|Philips QLAB Ultrasound Quantification Software|Offline processing of intraoperative transesophageal echocardiography would be performed with Global Longitudinal Strain on apical 4 chamber, apical 2 chamber and long axis views in order to analyze left ventricle and left atrium contractility and right ventricle free wall motion
47981172|NCT01641770|OTHER|Nutritional beverage 10003RF|2 sachets per day
48498686|NCT03293407|DRUG|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
48498687|NCT03293407|DEVICE|Breelib nebulizer|Used for inhalation of Ventavis
48498688|NCT00375830|PROCEDURE|Bone scan|Scan to diagnose a number of bone conditions including cancer or metastasis
48133430|NCT03168750|DEVICE|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
48133431|NCT05577624|DRUG|AMG 510|Oral tablet
48133432|NCT05577624|DRUG|Rifampin|Oral capsule
48133433|NCT06117085|DEVICE|CellFX® Percutaneous Electrode (PE) System|Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology
48341057|NCT05752240|DEVICE|Transcranial direct current stimulation|Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia
48341058|NCT00531895|DRUG|duloxetine|duloxetine 60 mg/d
48341059|NCT04563572|DEVICE|PPG Smartwatch|Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
48341060|NCT01999712|PROCEDURE|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
48656638|NCT04625660|DEVICE|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
48656639|NCT05972772|DRUG|Doxycyclin|100-mg film-coated tablets; Pfizer
48656640|NCT05972772|DRUG|Azithromycin|250-mg capsules; Pfizer
47981173|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
47981174|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
47981175|NCT03993340|DEVICE|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
47981176|NCT02999945|DIETARY_SUPPLEMENT|SGA-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
47981177|NCT02999945|DIETARY_SUPPLEMENT|IUGR-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
47981178|NCT02999945|OTHER|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
47981179|NCT02999945|OTHER|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
47981180|NCT00569699|DRUG|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25 m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
47981181|NCT03403595|DRUG|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
47981182|NCT03883620|BIOLOGICAL|Dengushield 1 mg/kg (Cohort 1) intravenous|Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
47981183|NCT03883620|BIOLOGICAL|Dengushield 3 mg/kg (Cohort 2) intravenous|Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
47981184|NCT03883620|BIOLOGICAL|Placebo 3 mg/kg (Cohort 2) intravenous|Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
47981185|NCT03883620|BIOLOGICAL|Dengushield 7 mg/kg (Cohort 3) intravenous|Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
47981186|NCT03883620|BIOLOGICAL|Placebo 7 mg/kg (Cohort 3) intravenous|Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
47981187|NCT03883620|BIOLOGICAL|Dengushield 12 mg/kg (Cohort 4) intravenous|Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
47981188|NCT03883620|BIOLOGICAL|Placebo 12 mg/kg (Cohort 4) intravenous|Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
47981189|NCT01304901|DRUG|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
47981190|NCT01304901|DRUG|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
47981191|NCT00372125|DRUG|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
48341061|NCT05779800|DEVICE|Flowble resin composite stent|Flowble resin composite is a filling material used in operative dentistry and characterized by being flow and easily adapting the surfaces.
48498689|NCT00375830|DRUG|99mTc-methyl diphosphonate|Radiolabel for bone scan procedures
48341062|NCT05779800|DEVICE|periodontal pack|Non eugenol containing dressing supplied in two tubes
47981192|NCT05460117|DEVICE|Radiofrecuency|he use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.
47981193|NCT03134287|PROCEDURE|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
47981194|NCT01972503|DRUG|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
47981195|NCT01972503|PROCEDURE|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
47981196|NCT05534750|DRUG|Tedizolid arm (SIVEXTRO®)|Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
47981197|NCT05534750|DRUG|Linezolid arm (ZYVOXID®)|Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
47981198|NCT05534750|DRUG|Standard quadruple therapy arm|"Patients will be taken :~ISONIAZIDE :~o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®)~RIFAMPICINE :~o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach)~ETHAMBUTOL :~o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol~PYRAZAMIDE :~o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide~Then, the early bactericidal activity will be measured and compared to the other arms."
47981199|NCT05543876|PROCEDURE|suturing procedure|Children presenting to the emergency department for suturing
47981200|NCT00102882|DRUG|fluticasone propionate/salmeterol|
47981201|NCT00102882|DRUG|salmeterol xinafoate|
47981202|NCT05451368|OTHER|Coronary artery calcification lesions|Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
47981203|NCT02454881|DRUG|Dexmedetomidine|
47981204|NCT02454881|DRUG|Oxycodone|
47981205|NCT06259227|OTHER|Cardiorespiratory fitness (CRF) training|The CRF training will take place on an arm cycle ergometer, or on an recumbent cross trainer. The duration and intensity of these 2 CRF gait training sessions will be determined by scientific exercise guidelines. A practical way of increasing vigorous-intensity exercise is high-intensity interval training (HIIT). The HIIT intervention consist of 2-3 trainings per week, with each exercise session including a 5-minute warm-up, 30-second interval periods (with a power output up to 90% of the peak power output (PPO)), and 30-second recovery periods. There are 5 minutes of 50% of PPO between interval periods. The number of interval periods increases during the intervention period, resulting in a maximum total training time of 35 minutes.
47981206|NCT03412487|PROCEDURE|laparoscopy|under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
48341063|NCT00557323|DRUG|Lanthanum carbonate|
48341064|NCT02099760|DEVICE|STD testing (GC/Ct/trich)|
48341065|NCT05823792|DIAGNOSTIC_TEST|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery|Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
48341066|NCT02327156|DRUG|dexmedetomidine|adding dexmedetomidine to the local anesthetic
48498690|NCT00375830|PROCEDURE|Positron Emission Tomography (PET) scan|Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
48498691|NCT00375830|DRUG|18F-Fludeoxyglucose (18F-FDG)|Radiolabel for positron emission tomography scan procedures
48498692|NCT00375830|PROCEDURE|Computed Tomography (CT) scan|Scan to detect \& analyze X-rays
48498693|NCT00375830|DRUG|18F-Sodium Fluoride (18F-NaF)|Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.
48133435|NCT06171711|BEHAVIORAL|Exposure Therapy|The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
48133436|NCT04736199|DRUG|Darolutamide (Nubeqa, BAY1841788)|Coated tablet, oral administration
48133437|NCT04736199|DRUG|Placebo|Coated tablet matching Darolutamide in appearance, oral administration
48133438|NCT04736199|OTHER|Androgen deprivation therapy (ADT)|Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
48498694|NCT00375830|PROCEDURE|Whole Body Magnetic Resonance Imaging (WB-MRI) scan|Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
47981207|NCT05353231|BEHAVIORAL|Attention Feedback Awareness and Control Training (A-FACT)|"A-FACT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control.~Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Following a fixation que, the auditory neutral or negative simulated thought stimulus is delivered, and 500ms prior to termination of the auditory stimulus, a visual stimulus is presented until participants categorize the visual stimulus as greater than or smaller than 5 objects. Latency to disengage attention from each thought stimuli, at the trial-level, is repeatedly measured, and after each negative thought stimulus, trial-level feedback on the latency to disengage is delivered back to participants through a visual scale representing their attentional bias. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial."
48002456|NCT06241027|OTHER|Myofascial release|Myofascial release therapy involved the application of a low load, long duration stretch along the line of maximal fascial restriction. Pressure will be applied directly on the skin toward the direction of restriction until resistance of the tissue barrier will felt, Once found , the collagenous barrier will engaged for 90-120 seconds without sliding over the skin or forcing the tissues until the fascia complex started to yield and a sensation of softening will achieved.This stage will be repeated up to 5 times for new barrier until the sensation of tissue restriction during stretching became weaker.
48133439|NCT05286788|DRUG|Binimetinib Oral Tablet [Mektovi]|Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
48133440|NCT05600114|DRUG|Cannabidiol oral solution|CBD 150 mg BID
48133441|NCT05600114|DRUG|Cannabidiol oral solution|CBD 300 mg BID
48133442|NCT05600114|DRUG|Placebo|Placebo BID
48498695|NCT00375830|DRUG|Gadopentetate dimeglumine|A gadolinium-based contrast agent for MRI
48498696|NCT00375830|DRUG|Gadofosveset|A gadolinium-based contrast agent for MRI
48498697|NCT00375830|DRUG|Gadobutrol|A gadolinium-based contrast agent for MRI
48498698|NCT00006395|DRUG|St. John's Wort|
48498699|NCT00134693|DRUG|Prednisolone|
48498700|NCT00134693|DRUG|SB-681323|
48498701|NCT00599521|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
48133450|NCT05357820|DRUG|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17
48133451|NCT05357820|DRUG|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
48133452|NCT01818180|DIETARY_SUPPLEMENT|URELL|
48133453|NCT01818180|OTHER|Placebo|
48341067|NCT03625492|BEHAVIORAL|Reducing Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
48498702|NCT00599521|DRUG|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
48498703|NCT06405217|DRUG|Recombinant Human Thyroid Stimulating Hormone|Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
48498704|NCT05791513|OTHER|Using the MAP-Knee Tool|Using the MAP-Knee Tool
48498705|NCT05791513|OTHER|Usual practice|The consultation between clinician and adolescent is conducted as per usual practice.
48341068|NCT03625492|BEHAVIORAL|Adopting the USDA Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
48341069|NCT06481020|DIETARY_SUPPLEMENT|Plant sterols 2g/day|PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks
48341070|NCT06481020|DIETARY_SUPPLEMENT|Placebo|Sachet containing the powdered excipients of the dietary supplement during 8 weeks
48341071|NCT02866604|PROCEDURE|Sterofundin|
48498706|NCT02833701|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
48498707|NCT02833701|BIOLOGICAL|Bevacizumab|Given intravenously (IV)
48498708|NCT02833701|OTHER|Laboratory Biomarker Analysis|Correlative studies
48498709|NCT02833701|OTHER|Quality-of-Life Assessment|Ancillary studies
48498710|NCT00021580|PROCEDURE|human cadaveric islet cell transplantation|
48498711|NCT03360084|PROCEDURE|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
48498712|NCT02515149|DEVICE|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
48498713|NCT00989820|DRUG|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
48498714|NCT00891917|DIETARY_SUPPLEMENT|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
48133455|NCT04935177|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
48133456|NCT04935177|PROCEDURE|PLEX|PLEX is performed according to the respective site's standard procedure for desensitization.
48133457|NCT04935177|DRUG|IVIg|IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
48133458|NCT04935177|DRUG|Anti-CD20 antibodies|Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.
48133459|NCT04935177|DRUG|Eculizumab|Eculizumab according to the respective site's standard procedure for desensitization.
48133460|NCT04935177|OTHER|Remain on wait list|Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
48498715|NCT00891917|DIETARY_SUPPLEMENT|syrup (placebo)|syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
48498716|NCT03528083|OTHER|Bronchiolitis quality improvement|Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
48498717|NCT03702361|DRUG|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
48498718|NCT01676415|DRUG|Prednisone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study"
48133465|NCT05995262|OTHER|Chart Review|Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
48133466|NCT04463654|DEVICE|Zero Self-Harm app|Safety plan app for smartphones
48498719|NCT01676415|DRUG|Topical mometasone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study."
48341072|NCT02866604|PROCEDURE|0.9% saline|
48341073|NCT05276427|OTHER|Non Clinical procedure|Non clinical procedure- Informed consent completion and interview session
48341074|NCT05379205|BEHAVIORAL|Prehabilitation program (4 week before the surgery)|This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.
48498720|NCT04673682|DRUG|D309|D309(Testosterone) 1 vial, Once, IM injection
48498721|NCT04673682|DRUG|CKD-845|CKD-845(Testosterone) 1 vial, Once, IM injection
48341075|NCT05379205|BEHAVIORAL|Postoperative program (12 week after the surgery)|"This intervention will include 3 complementary modules: (i) supervised physical exercise: aerobic and strength High Intensity Interval Training (HIIT), 3 times per week (ii) dietary behavior change: nutritional talk + an informative brochure + a video summary, a session per week and (iii) psychological support: psychoeducation, written and verbal emotional expression, promotion of coping strategies, progressive muscle relaxation training, problem-solving and social skills, and self-efficacy enhancing, among others. This psychological component will also include counseling regarding smoking and alcohol cessation and sleep hygiene.~NOTE: Both preoperative and postoperative programs will be administer to the participants assigned to the intervention group."
48498722|NCT04342468|OTHER|non-interventional|No intervention
48498723|NCT06178432|GENETIC|CRG003 injection|The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
48498724|NCT00521040|DRUG|Levocetirizine dihydrochloride|
48498725|NCT01521416|OTHER|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
48498726|NCT00715936|BEHAVIORAL|Control|
48498727|NCT00715936|BEHAVIORAL|ECD|
48498728|NCT00715936|BEHAVIORAL|Enhanced Nutrition|
48498729|NCT02915965|DRUG|DCX|docetaxel, cisplatin and capecitabine
48498730|NCT02915965|PROCEDURE|surgery|Ivor Lewis Esophagectomy
48498731|NCT01323465|DRUG|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
48498732|NCT01323465|DRUG|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
48498733|NCT01323465|DRUG|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
48133482|NCT03836040|DRUG|Erenumab Dose 1|Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
48341076|NCT05379205|OTHER|Usual Care|Usual care group will follow the usual institutional pre-surgery care: (i) medication management, (ii) assessment of the surgery-derived risks, (iii) smoking cessation and peri-operative blood management. A trained nutritionist will evaluate the nutritional status of all patients at the baseline providing oral protein/vitamin supplementation, when necessary. Patients allocated to the control group will receive basic expert' advice on lifestyle changes.
47981208|NCT05353231|BEHAVIORAL|Mindful Disengagement from Thoughts Training (MDTT)|MDTT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Participants will first learn and practice a focused attention on the breath meditation. Then, participants will practice pressing a button each time they notice an inhalation or exhalation during the focused attention meditation. Next, during the meditation, participants will be presented the auditory neutral or negative simulated thought stimuli and will train internal attentional control by repeatedly disengaging their attention from these stimuli and back to their breath MDTT will thus entail 80 trials (40 negative, 40 neutral, ITI ≈ 10sec) during the focused attention on the breath meditation.
48341077|NCT01956058|RADIATION|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
48341078|NCT03224104|DRUG|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
48341079|NCT03224104|RADIATION|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
48341080|NCT03224104|DRUG|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
48341081|NCT02578992|PROCEDURE|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
47981209|NCT05353231|BEHAVIORAL|Placebo-Control|The condition is designed as a placebo control for the Attention Feedback Awareness and Control Training (A-FACT) training condition. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Rather than the quantity categorization task with trial-level feedback, participants only engage in the quantity categorization task. The task is identical in all other ways to the A-FACT condition. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.
47981210|NCT05329272|OTHER|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
48133483|NCT03836040|DRUG|Erenumab Dose 2|Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
48133484|NCT03836040|DRUG|Erenumab Dose 3|Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
48133485|NCT03836040|OTHER|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
48133486|NCT06117891|DRUG|Atezolizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
48133487|NCT06117891|DRUG|Bevacizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
48133488|NCT06117891|DRUG|Durvalumab|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
48133489|NCT06117891|DRUG|Tremelimumab,|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
48656641|NCT04416958|DEVICE|cardiac implantable electronic device (CIED) implantation|CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
48498734|NCT01323465|DRUG|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
48341082|NCT02578992|DEVICE|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
48341083|NCT00813267|BIOLOGICAL|mesenchymal stem cell infusion|
48341084|NCT00813267|BIOLOGICAL|bone marrow mononuclear cell infusion|
48341085|NCT04598841|DIETARY_SUPPLEMENT|supplement nutritional supporting|Special medical formula for the purpose of formula food
48341086|NCT02987244|DRUG|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
48341087|NCT02987244|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
48341088|NCT02987244|DRUG|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
48341089|NCT02987244|DRUG|Vindesine|vindesine (4mg)was administered intravenously on d1;
48341090|NCT02987244|DRUG|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
48498735|NCT01323465|DRUG|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
48498736|NCT01323465|DRUG|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
48341091|NCT02987244|DRUG|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
48341092|NCT00655811|DRUG|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
48341093|NCT00655811|DRUG|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
48341094|NCT04520178|DRUG|5-Hydroxytryptophan 100 MG|100mg combined with 50mg carbidopa
48656642|NCT04743011|DRUG|Heparin sodium|Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
48656643|NCT04743011|DRUG|Placebo|Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
48498737|NCT06354010|GENETIC|Genotyping|Genotyping to determine if patients present mutations to the gene GJB2.
48656644|NCT06119204|OTHER|Oviva programme|Total diet replacement for insulin-treated patients
48656645|NCT06119204|OTHER|Usual care|NHS 12 week weight loss programme
48656646|NCT06639841|DEVICE|Virtual Reality Psychotherapy|"Participants in this VR-facilited psychotherapy group will receive their treatment via Oculus Quest 2 and HTC Vive Flow wireless, standalone headsets systems to provide a comfortable immersive environment. The more hardware-intensive experiences will be carried out on Oculus Rift S headsets powered by high-end laptops.~Sessions will last 30-60 minutes each, ranging from six to ten sessions within two to four weeks. The treatment will include reducing anxiety and improving emotion regulation through Cognitive-Behavioural techniques such as mindfulness, acceptance and commitement therapy, exposure therapy and 4-7-8 breathing. The same investigator will conduct all sessions to ensure uniformity. Additionally, subjects will undergo unsupervised VR at home with pre-programmed headsets to minimize investigator bias and maintain cosistancy of the relaxation and cognitive-behavioral strategies."
48133492|NCT06485141|BEHAVIORAL|Safe Storage Intervention|Firearm storage information and secure storage device.
48133493|NCT06485141|BEHAVIORAL|Safe Kids Medication|The Control participants will view a brief medication storage safety video produced by Safe Kids. A Frequently Asked Questions handout on medication safety created by Safe Kids will be available for parents as well.
48133494|NCT06356129|DRUG|Golcadomide|Specified dose on specified days
48133495|NCT06356129|DRUG|Placebo|Specified dose on specified days
48133496|NCT06356129|DRUG|Rituximab|Specified dose on specified days
48133497|NCT06356129|DRUG|Cyclophosphamide|Specified dose on specified days
48133498|NCT06356129|DRUG|Doxorubicin|Specified dose on specified days
48133499|NCT06356129|DRUG|Vincristine|Specified dose on specified days
48341095|NCT04520178|DRUG|5-Hydroxytryptophan|50mg combined with 50mg carbidopa
48341096|NCT04520178|DRUG|Carbidopa|50mg
48341097|NCT04520178|DRUG|Placebo|Placebo
48341098|NCT03362489|PROCEDURE|IVF / IVF-ICSI|"In the IVF arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department."
48341099|NCT03362489|PROCEDURE|IUI|"In the conversion to IUI arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department."
48341100|NCT06349343|BIOLOGICAL|CD19/BCMA Hi-TCR-T cell therapy|CD19/BCMA Hi-TCR-T cell will be infused intravenously at the dose of 1×10\^6 cells/kg.
48341101|NCT01789892|DRUG|methylprednisolone|Given IV
48498738|NCT06354010|OTHER|Audiological assessments|Audiological assessments
48498739|NCT03579966|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
48498740|NCT03137927|BIOLOGICAL|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
48498741|NCT03137927|OTHER|Placebo|Placebo
48498742|NCT00119067|BIOLOGICAL|Anthrax Vaccine Adsorbed|
48498743|NCT00119067|BIOLOGICAL|Saline injection|
48498744|NCT04166448|OTHER|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
48133500|NCT06356129|DRUG|Prednisone|Specified dose on specified days
48133501|NCT04890938|COMBINATION_PRODUCT|Sputum-guided management and comprehensive care management|Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils \>3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells \>10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.
48133502|NCT04890938|OTHER|Usual Care|As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
48498745|NCT04770467|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
48498746|NCT04770467|DRUG|Placebo|Placebo given by intravenous administration
48498747|NCT03246646|BEHAVIORAL|Coaching|Telephone coaching was provided in a series of telephone based sessions with CSO participants
48498748|NCT00000130|DRUG|Intravitreal Antibiotics|
48498749|NCT00000130|PROCEDURE|Initial Pars Plana Vitrectomy|
48133508|NCT04973163|DRUG|BI 1823911|BI 1823911
48133509|NCT04973163|DRUG|BI 1701963|BI 1701963
48133510|NCT04973163|DRUG|Midazolam|Midazolam - only administered in Part B (dose confirmation) of the Monotherapy Arm
48133511|NCT05803109|OTHER|AVIVA-PURE-CocoPull-Organic-made in USA|virgin cold pressed coconut oil with Peppermint essential oil
48498750|NCT03324932|DRUG|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
48498751|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily
48133514|NCT05829109|DRUG|Fecal Microbiota Transplant (FMT)|"The intervention consists of the following steps:~* Step 1: Vancomycin 125 mg orally every 6 hours and metronidazole 250 mg orally every 6 hours for 5 days.~* Step 2: Bowel preparation with 10 ounces of magnesium citrate.~* Step 3: Two FMT doses will be administered via enema one week apart using stool from donors with a durably healthy pouch."
48133515|NCT02357966|BIOLOGICAL|514G3 (2 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
48133516|NCT02357966|BIOLOGICAL|514G3 (10 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
48133517|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
48341102|NCT01789892|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT scan
48341103|NCT01789892|PROCEDURE|positron emission tomography|Undergo FDG PET/CT scan
48341104|NCT01789892|PROCEDURE|computed tomography|Undergo FDG PET/CT scan
48341105|NCT01442519|BIOLOGICAL|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
48341106|NCT01442519|DRUG|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
48341107|NCT03793283|DEVICE|CSII|Currently receiving CSII therapy during 6 or more months.
48498752|NCT01197755|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
48341108|NCT03793283|DRUG|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
48341109|NCT00429572|DRUG|Fludarabine|30 mg/m\^2 intravenously Daily for 5 Days
48341110|NCT00429572|DRUG|Melphalan|70 mg/m\^2 intravenously Daily for 2 Days
48498753|NCT01197755|DRUG|placebo|Placebo twice daily
48498754|NCT00883623|DRUG|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
48498755|NCT04492865|DEVICE|MSCT|"-Laboratory tests: All routine indicators of CBC are evaluated~* Nasopharyngeal and oropharyngeal swabs are obtained from each patient to confirm the positivity to Covid-19 by performing RT-PCR to detect the viral RNA.~* MSCT Chest images of all patients are evaluated by three radiologists with variable experiences in CT chest interpretation. The readers are blinded of the RT-PCR results and the CBC indices of the patients and they have access only to the epidemiological history, clinical symptoms, and signs. By consensus, the radiologists score the chest CT as positive or negative for COVID-19 viral pneumonia. When the chest CT is classified as positive, the main CT features are recorded as present or absent (ground-glass opacity, crazy paving, consolidation, nodules, air bronchogram, air trapping, halo sign, reversed halo sign, bronchial wall abnormalities, vascular enlargement, pleural effusion, and lymphadenopathy."
48498756|NCT00015340|DRUG|Buprenorphine/naloxone|
48498757|NCT01884818|OTHER|Manipulation vs. TNS thoracic pain|
48341111|NCT00429572|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
48341112|NCT04228107|DEVICE|Medication monitoring|This is an observational study of medication use patterns. The propeller health device has reminders for controller medication use and gives feedback regarding medication use to the participant, their guardian and their asthma provider
48341113|NCT00736593|DRUG|Nexagon™ or Nexagon™ vehicle|
48341114|NCT01674816|DEVICE|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
48341115|NCT01674816|DEVICE|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
48341116|NCT00297128|DRUG|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
47981211|NCT05940207|DEVICE|e-Bandages|A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
47981212|NCT02374554|DEVICE|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
48341117|NCT00297128|DRUG|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
48341118|NCT06221956|BEHAVIORAL|relevis|Participants will receive access to the digital health intervention relevis in addition to TAU.
48498758|NCT05476419|OTHER|Direct intra-oral scanning technique for the post space.|scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
47981213|NCT02374554|DEVICE|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
47981214|NCT03661632|DRUG|BMS-986310|Specified dose on specified days
47981215|NCT03661632|BIOLOGICAL|Nivolumab|Specified dose on specified days
47981216|NCT03325361|OTHER|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
47981217|NCT03506815|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
47981218|NCT02482623|BEHAVIORAL|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
47981219|NCT05053789|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
48656647|NCT06639841|BEHAVIORAL|Yoga|"The Yoga group members will be guided in a yoga class focused on managing performance anxiety. The interventions will consist of body exercises (Asanas), breath (Pranayama) and meditation to increase relaxation, consciousness and resilience; typical yoga postures like Surya Namaskar, Padahastasana, Virabhadrasana, Bhujangasana and Shavasana will be included in the session, as will breathing movements like Ujjayi (Victory Breath).~Each class will be 60-90 minutes long, and 6-10 classes will be taught in two to four weeks. The technique will be progressive, from the basic to more advanced postures as participants cultivate confidence and resilience. All classes will conclude with meditation to ease tension and cultivate mindfulness."
47981220|NCT05053789|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
47981221|NCT01541124|DRUG|Opioid|10 mg/pill, po, each 6h, during 6m
48002457|NCT00655564|DRUG|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
48341119|NCT03366597|DRUG|Sevoflurane|1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
48341120|NCT00800930|BIOLOGICAL|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
48498759|NCT04730882|DIETARY_SUPPLEMENT|Mixed Meal|the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
48498760|NCT02218125|BIOLOGICAL|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
48498761|NCT02218125|BIOLOGICAL|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
48498762|NCT04268316|DEVICE|Virtual Reality Behavioral Activation|"Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities."
48656648|NCT04538482|BEHAVIORAL|DASH Diet|Participant will receive foods following the DASH dietary pattern for 28 days.
48002458|NCT00805766|DRUG|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
48341121|NCT00800930|BIOLOGICAL|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
48341122|NCT01582867|DEVICE|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01"
48341123|NCT02163668|OTHER|Yoga Group|8 months of Yoga training
48341124|NCT04364906|OTHER|Regional anesthesia|The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
48341125|NCT02175303|BIOLOGICAL|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.
48341126|NCT00333424|BIOLOGICAL|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
48341127|NCT01340560|PROCEDURE|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
48341128|NCT01936272|DEVICE|Chhabra Shunt Placement|
48341129|NCT01936272|PROCEDURE|ETV/CPC|
48341130|NCT06373536|DIAGNOSTIC_TEST|Thermoacoustic imaging, MRI and Ultrasound imaging|This is a Thermoacoustic imaging exam that will last 10-15 minutes. Distinguishing; assessment of steatosis liver disease in obese and morbidly obese patients.
48341131|NCT00481988|DEVICE|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
48341132|NCT00481988|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
48341133|NCT00481988|DEVICE|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
48341134|NCT00481988|DEVICE|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
48341135|NCT04444492|DRUG|Ranibizumab Injection|initial three injections of Ranibizumab - afterwards pro re nata monthly
48341136|NCT04444492|DEVICE|Laser photocoagulation|Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
48341137|NCT00971542|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
48341138|NCT04855357|BEHAVIORAL|Resident counselling|One hour, one-on-one counseling for residents
48341139|NCT04855357|BEHAVIORAL|Staff Training|A two-hour training for PSH staff on how to provide referrals to smoking cessation programs using materials previously developed from UCSF's 'Rx for change' curriculum for service providers, directed toward empowering PSH staff to provide referrals to local cessation services using the ask, advise, and refer approach. The training will address nicotine addiction, tobacco use among PSH residents, pilot data, brief cessation counseling (ask, advise, and refer), and local resources for cessation. Because PSH resident-PSH staff encounters will take place as part of routine care, the study team will request permission from a random sample of staff and resident dyads (n=40) to record these interactions to assess fidelity.
48341140|NCT03373318|DRUG|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
48341141|NCT03373318|DRUG|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
48341142|NCT05515445|DRUG|Chiglitazar|Oral single dose 48 mg
48133518|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment|Sterile isotonic formulation buffered at pH 6.2 - 6.5 plus standard IV antibiotic treatment
48133519|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II|A single dose of 514G3 plus standard IV antibiotic therapy
48341143|NCT02447640|DRUG|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
48341144|NCT02447640|RADIATION|[18F]FPEB|radiotracer used for PET scanning
48341145|NCT00319683|DRUG|ADH300004|
48341146|NCT04479449|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
48341147|NCT04479449|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
48341148|NCT03077243|RADIATION|Intensity Modulated Radiotherapy (IMRT)|60- 70 Gy at 2 Gy/fx
48341149|NCT03077243|DRUG|Cisplatin (or alternative)|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses.
48341150|NCT03077243|PROCEDURE|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
48341151|NCT00615212|DRUG|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
48341152|NCT00615212|DRUG|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
48341153|NCT00615212|DRUG|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
48656649|NCT04538482|BEHAVIORAL|standard American diet|Participants will receive foods following the standard American diet for 28 days.
48656650|NCT04357470|OTHER|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
48341154|NCT00615212|DRUG|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
48341155|NCT01614795|BIOLOGICAL|Cixutumumab|Given IV
48341156|NCT01614795|OTHER|Laboratory Biomarker Analysis|Correlative studies
48341157|NCT01614795|DRUG|Temsirolimus|Given IV
48341158|NCT02795611|BEHAVIORAL|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
48341159|NCT02795611|BEHAVIORAL|regular occupational therapy|regular occupational therapy
48341160|NCT02795611|OTHER|intervention done outside our hospital|intervention done outside our hospital
48341161|NCT04450342|DEVICE|Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue. The REGENETEN Bioinductive Implant is a bioabsorbable implant device that provides a layer of collagen over injured tendons. The implant is designed to provide a layer of collagen between a flat tendon and the surrounding tissue. After hydration, the implant is an easy-to-handle, pliable, nonfriable, porous collagen sheet.
48341162|NCT04450342|PROCEDURE|Arthroscopic rotator cuff repair|The Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear without supplement.
48341163|NCT04450342|DEVICE|Arthroscopic rotator cuff repair for revision surgery|The Arthroscopic rotator cuff repair can also occur in recurrent tears. The REGENETEN Bioinductive Implant will be applied during the ARCR procedure.
48341164|NCT05126134|DIAGNOSTIC_TEST|KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)|completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
48341165|NCT04225390|DRUG|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
48656651|NCT06625372|DIETARY_SUPPLEMENT|SMOF lipid|The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
48656652|NCT06625372|DIETARY_SUPPLEMENT|INTRALIPIDS|The Intralipid will be given to the patient as fat component of total parenteral nutrition.
48656653|NCT05734066|DRUG|Lurbinectedin|Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
48341166|NCT02920450|DRUG|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
48341167|NCT02920450|DRUG|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
48341168|NCT02920450|DRUG|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
48341169|NCT04745468|DEVICE|CRP apheresis|Selective CRP apheresis by use of the PentraSorb-CRP adsorber
48341170|NCT05852730|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel
48341171|NCT05852730|DRUG|Other (e.g., promethazine, meclizine)|Subjects will self-administer other medications as available.
48341172|NCT04709913|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
48341173|NCT00044642|DRUG|Lorazepam|
48341174|NCT04250025|PROCEDURE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
48341175|NCT06261476|DIETARY_SUPPLEMENT|Ashwagandha (Withnia somnifera)|Ashwagandha is the active ingredient in Withania somnifera (a medicinal plant in Indian medicine). Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
48341176|NCT06526598|PROCEDURE|PMI-targeted pressure support setting and adjustment|During PSV, the pressure support is set and adjusted to a PMI target between 0 and 2 cmH2O.
48341177|NCT06526598|PROCEDURE|VT/RR-targeted pressure support setting and adjustment|During PSV, pressure support is set and adjusted according to a VT/RR target of VT between 6 and 8 ml/kg predicted body weight, RR between 20 and 35 breaths/min, and no signs of respiratory distress.
48498763|NCT04268316|BEHAVIORAL|Behavioral Activation in real-life|Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
48656654|NCT06564350|DEVICE|IMU (Inertial Measurement Unit) sensors|IMU sensors track an object's acceleration and angular velocity over time and do not emit any electromagnetic fields or radiation. They use tiny masses and springs to measure the acceleration, as well as Hall effect materials to measure the magnetic fields. The force sensor changes its electric resistor value based on the force applied to the sensor surface.
48656655|NCT06555601|DRUG|UCB3101|Study participants will receive UCB3101 as prespecified in each cohort.
48656656|NCT06555601|DRUG|Placebo|Study participants will receive placebo as prespecified in each cohort to maintain the blinding.
48656657|NCT06645080|OTHER|Focus group or interview participation|90 minute focus group or 60 minute interview participation
48133520|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment: Phase II|A single dose of placebo plus standard IV antibiotic therapy
48133521|NCT01583868|DEVICE|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
48341178|NCT04466813|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
48341179|NCT04466813|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
48341180|NCT06013319|DRUG|Esmolol|The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
48341181|NCT00427791|DRUG|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
48656658|NCT06645080|OTHER|Delphi survey participation|Participation in a modified two-round Delphi technique. Optional third round in the event of insufficient agreement in the second round.
48656659|NCT05613127|BIOLOGICAL|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
47981222|NCT01397123|OTHER|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
48341182|NCT00427791|RADIATION|Total Body Irradiation|3 Gy Daily for 4 Days
48341183|NCT00427791|DRUG|Rituximab|375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
48341184|NCT02558283|DEVICE|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
48341185|NCT02558283|DEVICE|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
48341186|NCT05210621|DRUG|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
47981223|NCT00618059|DRUG|Pilocarpine|
47981224|NCT03124433|DRUG|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
47981225|NCT01922206|BEHAVIORAL|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
47981226|NCT04034420|OTHER|Online training platform|Self-paced training and learning materials in relation to family services
47981227|NCT02600377|OTHER|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
47981228|NCT04037605|DRUG|Ketoconazole Pill (also known as nizoral)|Ketoconazole pill is taken 4 times per inpatient visit
47981229|NCT04037605|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per inpatient visit
47981230|NCT04037605|DRUG|Dexamethasone Pill|Dexamethasone pills is taken twice per inpatient visit
47981231|NCT04037605|DRUG|Dexamethasone injection|Dexamethasone IV injection is given twice per inpatient visit
47981232|NCT04037605|DRUG|Cosyntropin Injectable Product|Cosyntropin injection is given twice per inpatient visit
47981233|NCT04037605|DRUG|Recombinant Human Luteinizing Hormone (also known as luveris)|Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
47981234|NCT04037605|DRUG|Hydrocortisone Injection (also known as solu-cortef)|Hydrocortisone IV push is given twice per inpatient visit
47981235|NCT04037605|DRUG|Gonadorelin (also known as Lutrepulse)|Gonadorelin IV injection is given twice per inpatient visit
47981236|NCT04037605|DRUG|Corticorelin (also known as Acthrel)|Corticorelin IV injection is given twice per inpatient visit
47981237|NCT04037605|DRUG|Placebo oral tablet|Placebo for Ketoconazole are given 4 times per inpatient visit
47981238|NCT04037605|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
47981239|NCT04037605|DRUG|Saline solution for injection|Saline Solution (placebo) for ganirelix subcutaneous injection
47981240|NCT03763123|DRUG|Sevacizumab|Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
47981241|NCT03763123|DRUG|Paclitaxel|paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
47981242|NCT03763123|DRUG|Topotecan|topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
47981243|NCT00416078|BEHAVIORAL|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
47981244|NCT00416078|BEHAVIORAL|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
47981245|NCT01679977|DEVICE|Vibrational-proprioceptive Resistance Exercise Training|
48341187|NCT05316818|DRUG|FOLFOXIRI Protocol|Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
48341188|NCT00735761|DRUG|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
48341189|NCT00735761|DRUG|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
48341190|NCT00683813|BEHAVIORAL|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
48341191|NCT06109077|OTHER|Levator ani release|Patients will be treated with levator ani release exercises for pain (3 sets with 10 repetitions 3 times per week for 6 weeks).
48341192|NCT06109077|OTHER|Post isometric relaxion|Patients will be treated with Post isometric relaxation exercise and hold contractions for 10 seconds over 5 to 12 repetitions, 3 times per week for 6 weeks
48341193|NCT00080184|PROCEDURE|Low Energy Neurofeedback System|
48341194|NCT03628495|DEVICE|compression|compression will be delivered using compression garment
48341195|NCT03628495|DEVICE|occlusion|occlusion will be delivered using silicone gel sheeting
48341196|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
48341197|NCT00435149|PROCEDURE|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
48341198|NCT03030183|DRUG|Zilucoplan (RA101495)|0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
48341199|NCT00085345|DRUG|arsenic trioxide|
48341200|NCT00085345|DRUG|ascorbic acid|
47981246|NCT01679977|DEVICE|Neuromuscular Electrical Stimulation Training|
48341201|NCT00085345|DRUG|melphalan|
48341202|NCT00085345|PROCEDURE|chemosensitization/potentiation|
48656660|NCT05613127|BIOLOGICAL|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
48656661|NCT01911260|DIETARY_SUPPLEMENT|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
48341203|NCT00085345|PROCEDURE|chemotherapy|
48341204|NCT02438761|DRUG|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
48341205|NCT04759222|DIAGNOSTIC_TEST|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
48341206|NCT06097325|DIAGNOSTIC_TEST|Clance impostor phenomenon scale|"The CIPS will be used as diagnostic test in the online survey."
48341207|NCT06097325|DIAGNOSTIC_TEST|Maslach Burnout Inventory for Medical Professional|"The MBI-HSS-MP will be used as diagnostic test in the online survey."
48341208|NCT04795492|BEHAVIORAL|remote intervention|Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.
48498764|NCT03507023|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
48498765|NCT03507023|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
47981247|NCT01412346|OTHER|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
47981248|NCT00004224|DRUG|cyclophosphamide|
47981249|NCT00004224|DRUG|etoposide|
47981250|NCT00004224|DRUG|vincristine sulfate|
47981251|NCT00004224|PROCEDURE|adjuvant therapy|
47981252|NCT00004224|PROCEDURE|conventional surgery|
47981253|NCT00004224|RADIATION|radiation therapy|
48002459|NCT01791361|OTHER|Other|No intervention other than routine medical care
48002460|NCT05724849|DRUG|Venlafaxine|See arm/group description.
48002461|NCT05724849|DRUG|Placebo|See arm/group description.
48341209|NCT04795492|BEHAVIORAL|Routine outpatient follow-up|Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.
48341210|NCT03578380|PROCEDURE|Surgery|Lymphovenous anastomosis
48341211|NCT03578380|OTHER|Compression and drainage therapy|Treatment with compression stockings and manual drainage (massage therapy)
48341212|NCT00846469|PROCEDURE|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
48341213|NCT00846469|OTHER|Control section|Normal emergency room treatment for symptoms of chest pain.
48341214|NCT04134169|OTHER|Not applicable(observational study)|Not applicable(observational study)
48341215|NCT05913518|DEVICE|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
48341216|NCT05913518|DEVICE|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
48002462|NCT01802775|DRUG|edoxaban|
48341217|NCT04764968|DRUG|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
48341218|NCT02158455|PROCEDURE|NT SVG grafts|
48341219|NCT01187134|BEHAVIORAL|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
48341220|NCT00202345|DRUG|Iron sucrose|
48341221|NCT02152072|OTHER|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
48341222|NCT00550290|DRUG|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
48341223|NCT00550290|DRUG|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
48341224|NCT05166551|PROCEDURE|Acupressure|"This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine."
48341225|NCT05166551|PROCEDURE|Placebo Acupressure|Placebo Acupressure
48656662|NCT01911260|OTHER|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
48656663|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
48002463|NCT01802775|DRUG|Clopidogrel|75mg tablet
48002464|NCT01802775|DRUG|Aspirin|
48002465|NCT04603729|DRUG|Dexamethasone 2 MG/ML|Dexamethasone 8mg/day will be given intravenous for 5 days to group 1 participants
48002466|NCT04603729|DRUG|Methylprednisolone Injection|methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants
48341226|NCT04437680|DEVICE|Votiva device|A retrospective chart review of the medical records
48341227|NCT00578422|OTHER|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
48341228|NCT00578422|PROCEDURE|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
48341229|NCT04306757|DEVICE|Evone|Airway ventilation device
48341230|NCT04306757|DEVICE|Primus|Airway ventilation device
48656664|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
47981254|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.
47981255|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System with Sham handpiece|The same procedure is applied above but with a sham handpiece and parameter presentations masked.
48133522|NCT01583868|DEVICE|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
48133523|NCT01583868|DEVICE|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
48133524|NCT01583868|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
48498766|NCT05874583|DRUG|Combined route administration of Tranexamic acid|tranexamic acid in topical route administration
48133526|NCT05068102|DRUG|BI 765063|BI 765063
48498767|NCT05874583|DRUG|Intravenous route Tranexamic acid injection|Intra venous route administration
48656665|NCT06192108|DRUG|Orforglipron|Administered orally
48133527|NCT05068102|DRUG|Ezabenlimab|Ezabenlimab
48133528|NCT05068102|DRUG|[89Zr]Zr- BI 765063|\[89Zr\]Zr- BI 765063, specifically radiolabelled for immune-Positron Emission Tomography (PET)
48341231|NCT04140539|BIOLOGICAL|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
48341232|NCT01153672|DRUG|vorinostat|Given PO
48341233|NCT01153672|OTHER|laboratory biomarker analysis|Correlative studies
48341234|NCT01153672|PROCEDURE|biopsy|Optional correlative studies
48341235|NCT01153672|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
48341236|NCT01153672|PROCEDURE|positron emission tomography|Correlative studies
48341237|NCT01153672|DRUG|anastrozole|Given PO
48656666|NCT06192108|DRUG|Dapagliflozin|Administered orally
48656667|NCT04731597|DRUG|drug interaction|when two drugs are taken together
47981256|NCT00073554|DRUG|Alfimeprase|
47981257|NCT05047510|DRUG|Anti-GPC3-IRDye800CW|Drug Injection: Anti-GPC3-IRDye800CW
48133529|NCT05068102|DRUG|BI 770371|BI 770371
47981258|NCT00197041|BIOLOGICAL|RTS,S/AS02A|
47981259|NCT03178981|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
48341238|NCT01153672|DRUG|letrozole|Given PO
48133530|NCT05068102|DRUG|[89Zr]Zr- BI 770371|\[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
48341239|NCT01153672|DRUG|exemestane|Given PO
48341240|NCT01153672|GENETIC|gene expression analysis|Correlative studies
48341241|NCT01614340|BEHAVIORAL|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
48498768|NCT04358289|OTHER|Basic antimicrobial stewardship education|Commune health center: Revision of guidelines for antibiotic prescribing for respiratory infections in primary care, Training primary healthcare doctors in the application of the new guidelines
48498769|NCT04358289|OTHER|Participatory action research group in commune health center and community|"* Establish a participatory action research group~* Engagement with the group through participatory action research involving problem identification, planning change strategies, implementing strategies, and evaluation"
48133531|NCT05969899|DRUG|FOLFIRI+Bevacizumab|irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
48656668|NCT03583294|OTHER|MRI pelvic|Pelvic MRI
48656669|NCT03369808|BIOLOGICAL|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
48656670|NCT03369808|BIOLOGICAL|Phosphate Buffer Solution|0.5ml phosphate buffer solution
48656671|NCT03369808|BIOLOGICAL|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
48656672|NCT03369808|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
48656673|NCT03369808|BIOLOGICAL|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
48656674|NCT06638762|PROCEDURE|surgery|We recruited patients diagnosed with oral squamous cell carcinoma who had received surgical treatment, collected patient follow-up information and postoperative pathological images, enhanced and standardized pathological images, and extracted pathological features through visual transformation model.
48656675|NCT03633201|DEVICE|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
48341242|NCT05097157|DEVICE|Potenza|Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
48341243|NCT05505149|OTHER|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
48341244|NCT05255341|PROCEDURE|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
48341245|NCT04675697|DRUG|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
48341246|NCT06460831|DEVICE|Microcatheter|The microcatheter group undergoes alcohol ablation using a microcatheter.
48341247|NCT06460831|DEVICE|OTW|The OTW group undergoes alcohol ablation using an OTW balloon.
48341248|NCT01915095|DEVICE|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
48341249|NCT01915095|DEVICE|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
48341250|NCT01915095|OTHER|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
48341251|NCT01915095|OTHER|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
48341252|NCT04446299|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
48341253|NCT03043261|BEHAVIORAL|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
48341254|NCT02455388|DIETARY_SUPPLEMENT|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
47981260|NCT03181204|PROCEDURE|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
47981261|NCT03181204|PROCEDURE|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
47981262|NCT03181204|PROCEDURE|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
47981263|NCT01250262|OTHER|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
47981264|NCT01250262|OTHER|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
47981265|NCT01250262|OTHER|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
47981266|NCT05357274|DIAGNOSTIC_TEST|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
47981267|NCT05522101|DEVICE|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480\*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
47981268|NCT05522101|DEVICE|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340\*340, working time is not less than 8 hours.
47981269|NCT01830699|DRUG|Rilonacept|160 mg intra-bursal once
47981270|NCT01830699|DRUG|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
47981271|NCT01569711|PROCEDURE|Deep brain stimulation of nucleus accumbens|"* Day0 : surgical placement of electrodes~* M1 : stimulation of nucleus accumbens~* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
47981272|NCT00311610|DRUG|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
47981273|NCT04977908|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid Lispro insulin
48133532|NCT05108363|BEHAVIORAL|Lifestyle modification program|Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
48341255|NCT02455388|DIETARY_SUPPLEMENT|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
48133533|NCT05456334|DEVICE|Pulsed-dye laser|Comparance of pulsed-dye laser-mediated and conventional photodynamic therapy in a split-head design
48133534|NCT05456334|DEVICE|Fractional CO2-laser|Comparance of fractional CO2-laser-mediated or plain daylight photodynamic therapy in a split-head design
48133535|NCT05456334|DRUG|Metvix cream|Metvix-cream was used for photodynamic therapy in all experimental arms
48133536|NCT03220724|BIOLOGICAL|CH505TF|Administered by intramuscular (IM) injection in the thigh
48133537|NCT03220724|BIOLOGICAL|CH505w53|Administered by IM injection in the thigh
48133538|NCT03220724|BIOLOGICAL|CH505w78|Administered by IM injection in the thigh
48341256|NCT03790540|DEVICE|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
48133539|NCT03220724|BIOLOGICAL|CH505 M5|Administered by IM injection in the thigh
48133540|NCT03220724|BIOLOGICAL|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
48133541|NCT03220724|BIOLOGICAL|Placebo|Administered by IM injection in the thigh
48133542|NCT06104124|DRUG|Dazodalibep|IV infusion
48133543|NCT06104124|DRUG|Placebo|IV infusion
48341257|NCT03790540|DRUG|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
48341258|NCT05481970|DRUG|dexmedetomidine,ketamine,lidocaine,propofol|Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.
48341259|NCT05481970|DRUG|fentanyl,propofol|In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
48341260|NCT03472872|DRUG|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
48341261|NCT03472872|DRUG|Acetaminophen|1,000mg acetaminophen IVPB
48341262|NCT00004910|PROCEDURE|bowel obstruction management|
48341263|NCT00004910|PROCEDURE|quality-of-life assessment|
48341264|NCT04368104|DIAGNOSTIC_TEST|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
48341265|NCT04955509|OTHER|MRI|conventional MRI and diffusion MRI
48498770|NCT04358289|OTHER|Antimicrobial stewardship program in hospitals|"The intervention activities in hospitals will include: training a health-worker in each of the participating hospitals to act as a facilitator or activator; forming an antibiotic stewardship group; meeting regularly and following an action-research cycle that includes problem identification, planning change strategies, implementing strategies, and evaluating strategies"
47981274|NCT04977908|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Dexcom G6 CGM
48133544|NCT00156845|PROCEDURE|AI-700 contrast-enhanced echocardiography|
48133545|NCT05076110|DRUG|Oxycodone|5 mg tablets every 4 hours postoperatively as needed for pain control
48133546|NCT05076110|DRUG|Ibuprofen|800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day
48133547|NCT05076110|DRUG|Gabapentin|300 mg three times a day for 5 days then wean off by day 10 postoperatively
48133548|NCT05076110|DRUG|Acetaminophen|1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
48133549|NCT05076110|DRUG|Methocarbamol|500 mg three times a week for 2 weeks postoperatively
48133550|NCT05902936|PROCEDURE|Pulpotomy for mature permanent mandibular molars|Performing pulpotomy for mature teeth that involves removal of the coronal pulp tissue that is diseased or inflammed followed by placement of a biocompatible material with the intent of maintaining the vitality of the remaining radicular pulp tissue.
48133551|NCT05775159|DRUG|Volrustomig|CTLA-4/Anti-PD-1 Bispecific Antibody
48133552|NCT05775159|DRUG|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
48133553|NCT05775159|DRUG|Lenvatinib|Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
48133554|NCT05775159|DRUG|Rilvegostomig|anti- PD-1 and TIGIT bispecific antibody
48133555|NCT05775159|DRUG|Gemcitabine|1000 mg/m2, IV infusion
48133556|NCT05775159|DRUG|Cisplatin|25 mg/m2, IV infusion
48133557|NCT05798117|DRUG|YTB323|Single infusion of YTB323
48133558|NCT05568017|DRUG|peptide receptor radionuclide therapy with Y-90-DOTATOC|Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
48133559|NCT05325866|DRUG|Bemarituzumab|Intravenous (IV) infusion.
48133560|NCT06544499|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
48133561|NCT06544499|OTHER|Placebo IV|Intravenous infusion of placebo
47981275|NCT05675943|BIOLOGICAL|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
47981276|NCT03421821|DRUG|Ropivacaine|Subfascial injection OR extrafascial injection
48498771|NCT04358289|OTHER|Community education|Development of educational materials for the community and farmers; Disseminated of messages through posters, leaflets and local media channels
48341266|NCT06009068|OTHER|Surgimap soft ware|20 healthy subjects will be recruited in the study, the q angle will be measured using goniometer and surgimap soft ware, 3 examiners will measure the q angles for the same individuals to check the inter rater reliability, and the test will be repeated after 2 days by the same examiners to check the intra rater reliability
48341267|NCT00145197|BEHAVIORAL|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
48341268|NCT05367713|OTHER|patients having had an osteitis of the cranial flap after craniectomy|description of management and failure of cranial flap after craniectomy
48341269|NCT01851525|DEVICE|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
48341270|NCT04824222|DRUG|Human fecal microbiota, MBiotix HBI|The FMT will be administered orally in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
48341271|NCT04824222|DRUG|Placebo|Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)
48341272|NCT04824222|DRUG|SOC|The standard COVID 19 pharmacological treatment
48341273|NCT04935970|DIAGNOSTIC_TEST|diagnostic blood test|vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
48341274|NCT04935970|DIAGNOSTIC_TEST|neuropsychological test|neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
48656676|NCT03633201|DEVICE|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
48656677|NCT02163863|DEVICE|Femoropopliteal stenting|
48656678|NCT06108544|DRUG|TAK-279|Specified drug on specified days.
47981277|NCT01347008|DRUG|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
47981278|NCT01347008|DRUG|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
48133565|NCT01920932|DRUG|brentuximab vedotin|Given intravenously (IV).
48341275|NCT05557097|DIAGNOSTIC_TEST|Intrapartum sonography|Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
47981279|NCT01717807|OTHER|C11-Erlotinib PET/CT|
48002467|NCT03738371|OTHER|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
48133566|NCT01920932|DRUG|etoposide|Given IV.
48498772|NCT04176406|DEVICE|rTMS|excitatory 5Hz rTMS will be used
48498773|NCT04176406|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
48656679|NCT06108544|DRUG|Placebo|Specified drug on specified days.
48656680|NCT06108544|DRUG|Apremilast|Specified drug on specified days.
48656681|NCT03988205|BEHAVIORAL|Outpatient Care Model|Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
48656682|NCT03988205|DRUG|CPX-351|CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
48656683|NCT01557244|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
48656684|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
48656685|NCT01557244|DRUG|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
48656686|NCT01557244|DRUG|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
48656687|NCT01557244|DRUG|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
48656688|NCT01557244|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
48656689|NCT01557244|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
48656690|NCT05548296|DRUG|ACR-368|ACR-368 is an experimental drug
48656691|NCT05548296|DRUG|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
48341276|NCT03643016|OTHER|Surgical strategy based on a software|Surgical strategy décision based on a software
48133567|NCT01920932|DRUG|prednisone|Given orally (PO).
48341277|NCT03004976|BIOLOGICAL|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.
48341278|NCT03004976|OTHER|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
48341279|NCT01709708|DRUG|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
48341280|NCT01709708|DRUG|Saline|Saline
48341281|NCT03301233|DRUG|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
48341282|NCT03530202|DRUG|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
48341283|NCT03530202|DRUG|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
48341284|NCT05628402|OTHER|Semi-structured interview|The semi-structured interview will take place during a standard follow-up appointment with the therapist already treating the patient after the patient has agreed to participate in the study.
48341285|NCT05410899|OTHER|exercise|Women with urinary incontinence will done exercise including pelvic floor muscle and will taught pelvic floor muscle anatomy, physiology, disorders, treatment of disease
48656692|NCT05548296|DIAGNOSTIC_TEST|OncoSignature|Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue
47981280|NCT03485768|PROCEDURE|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
47981281|NCT03485768|PROCEDURE|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
47981282|NCT02738151|DRUG|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
48133568|NCT01920932|DRUG|doxorubicin|Given IV.
48133569|NCT01920932|DRUG|cyclophosphamide|Given IV.
48133570|NCT01920932|DRUG|Dacarbazine(R)|Given IV.
48133571|NCT01920932|DRUG|filgrastim|Given subcutaneously (SQ) as clinically indicated.
48133572|NCT01920932|OTHER|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
48133573|NCT01920932|RADIATION|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
48341289|NCT02971293|DRUG|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
48341290|NCT02971293|DRUG|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
48341291|NCT02971293|DRUG|Placebo|The subject will receive Placebo single dose DPI.
48341292|NCT01985165|DRUG|Imrecoxib|
48498774|NCT00006267|DRUG|rubitecan|
48498775|NCT03093389|DRUG|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
48341293|NCT05378776|DIETARY_SUPPLEMENT|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
48341294|NCT05378776|DIETARY_SUPPLEMENT|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
48498776|NCT03093389|DRUG|Placebo|Matching placebo capsules
47981283|NCT02738151|DRUG|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
48341295|NCT04360772|DIAGNOSTIC_TEST|mHLA-DR|"* Before treatment/ At inclusion/Day 0 : Collection of gender, date of birth, comorbidities, pathology implicating treatment by corticosteroids and other treatment administered at the time of inclusion.~* At Day 0, Month 1, Month 3, Month 6 : Blood sampling (3mL) to proceed to mHLA-DR measurement. At those time-points, results from lymphocytes immunophenotyping, C-reactive protein and numeration will be collected.~* At Month 24 : Collection from medical report of~* any infectious events that would have occured during the follow-up~* course of the disease with corticosteroids~* survival or death at 24 months of follow-up."
48498777|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
48133576|NCT06243575|DRUG|Multimodal Intraosseous Femoral Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
48133577|NCT06243575|DRUG|Multimodal Intraosseous Tibial Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
48133578|NCT04754022|OTHER|Restrictive Transfusion Strategy|Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.
48341296|NCT01213914|DEVICE|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:~* double lumen dialysis catheter should be placed in the internal jugular or femoral vein~* Anticoagulation will be determined by prescribing physician~* Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~* Blood flow rate will be set to ensure a filtration fraction of no more than 25%~* Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~* Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~* All antibiotics will be dose adjusted for renal replacement therapy"
48341297|NCT01213914|OTHER|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
48341298|NCT00634465|DEVICE|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
48341299|NCT01697904|PROCEDURE|Titration of oxygen during newborn resuscitation in delivery room|
48341300|NCT00093470|PROCEDURE|Clinical Observation|Undergo observation
47981284|NCT02738151|DRUG|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
48341301|NCT00093470|DRUG|Tipifarnib|Given PO
48498778|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
48498779|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
47981285|NCT04693325|PROCEDURE|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted \[NMP1\]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) \[PNMP3\] and consequently 6 hours (n=6) \[PNMP6\].
48133579|NCT04754022|OTHER|Liberal transfusion strategy|Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
48498780|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
48498781|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
48498782|NCT00440544|BIOLOGICAL|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
47981286|NCT02175589|OTHER|Colchicine Cessation|Colchicine Cessation
47981287|NCT02599272|OTHER|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
47981288|NCT02599272|OTHER|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
47981289|NCT02599272|OTHER|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
48133580|NCT05629052|PROCEDURE|Pulmonary endarterectomy|Surgical removal of a chronic clot from the pulmonary artery
48133581|NCT05629052|PROCEDURE|Balloon pulmonary angioplasty|Catheter-based intervention to dilate occluded pulmonary vessels through the insertion and inflation of a small balloon
48133582|NCT05629052|DRUG|Pulmonary hypertension (PH)-specific medication|Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
48498783|NCT06262230|BEHAVIORAL|Online Inclusive Companionship Intervention|After prior intervention, professionals will conduct a lecture for ordinary children, which includes basic knowledge of ASD and communication skills with ASD children. These ordinary children will be paired with ASD children then. The entire intervention including 12 sessions will last for 3 months. Researchers will prepare a series of themes that the ASD children could choose, and the ordinary children need to ask their paired ASD children what activities they want to choose before each session. Then, they will carry out this entertainment online together through Tencent WeMeet. A researcher will supervise online at the same time and record the communication through instant video. The Researcher will turn off the video and sound throughout the process and will not intervene in the conversation between the ASD children and ordinary children except for special circumstances.
48341302|NCT01611298|BIOLOGICAL|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
48341303|NCT01186094|DEVICE|Cypher|Sirolimus-eluting stent
48341304|NCT01186094|DEVICE|Endeavor Resolute|Zotarolimus-eluting Stent
47981290|NCT05368857|DRUG|Afamelanotide|Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
48341305|NCT05709314|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
48341306|NCT03528590|DEVICE|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
47981291|NCT03398681|DRUG|Ferric carboymaltose|Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
47981292|NCT03398681|DRUG|Placebo (Normal saline)|Normal saline (0.9% weight/volume (w/v) NaCl)
47981293|NCT03398681|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance including T2\* and T1-mapping sequences
47981294|NCT05714657|RADIATION|Shortened Course Adjuvant Radiotherapy Following TORS|Shortened Course Adjuvant Radiotherapy Following TORS
47981295|NCT04827927|PROCEDURE|Procedure: INTELLiVENT-ASV|With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.
47981296|NCT04827927|PROCEDURE|Procedure: Conventional ventilation|With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.
47981297|NCT04941001|DEVICE|ReferID|The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
48133584|NCT04794972|DRUG|GNC-039|Administration by intravenous infusion.
48498784|NCT02948153|OTHER|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
48498785|NCT00006243|BIOLOGICAL|tyrosinase peptide|Given SC
48341307|NCT03528590|DEVICE|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
48341308|NCT02737176|OTHER|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
47981298|NCT03562104|OTHER|videofluoroscopy|Swallowing description in Minimally consciousness Patient
48341309|NCT00390429|DRUG|docetaxel|Given IV
48341310|NCT00390429|DRUG|erlotinib hydrochloride|Given orally
47981299|NCT03562104|OTHER|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
48133592|NCT04784585|BEHAVIORAL|Enhanced Education|"The Enhanced Education intervention option seeks to: 1) enhance understanding of personal health-behavior links, 2) improve health literacy by checking the adequacy of participant understanding, and 3) remind participant of important elements of Behavioral Obesity Treatment (BOT) dietary goals."
48133593|NCT04784585|BEHAVIORAL|Self-Efficacy|"This intervention option is based on a previously established self-efficacy intervention for weight loss, which is a multi-component intervention for increasing self-efficacy. To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either prompt: 1) attainable intention setting related to dietary adherence (e.g., I will focus on eating mostly fruits/vegetables in my next meal/snack in order to take back control of my eating); 2) barrier identification for adhering to dietary goals along with a brief problem-solving exercise; 3) devising a small self-reward; OR 4) self-assessment of thoughts/behaviors that could interfere with dietary adherence in the next several hours with coping strategies (e.g., stimulus control, social support)."
48133594|NCT04784585|BEHAVIORAL|Motivation|"To provide variety in this intervention option and limit time spent in a single intervention, components are split into independent modules that either: 1) guide participants in identifying values related to weight control (e.g., longevity, quality of life, being a role model) and connect those values to their behavior in the current moment.; 2) use a collaborative non-judgmental approach to explore the consequences of letting barriers drive behavior (e.g., Take a moment to consider the effect on your longevity if you let your preference for sweets determine your behavior.); 3) prompt participants to identify reasons for change, thereby eliciting change talk; OR 4) engage participants in a brief self-assessment of motivation for dietary adherence (i.e., On a scale of 1-10, how important to you is it to stick to your dietary goals today)."
48133595|NCT04784585|BEHAVIORAL|Self-Regulation|"There are 4 independent modules that prompt self-monitoring and self-awareness efforts: 1) advise participants to record everything that they eat before they eat it, with attention to eating in the subsequent few hours; 2) use the traffic light model to enhance awareness of dietary intake. This module provides the traffic light categories of foods (i.e., green=healthiest choices, yellow=sometimes choices, and red=rare choices), and asks participants to check-off foods that they intend to eat vs. stay away from in the next few hours; 3) advise participants to track portion sizes carefully and provide a portion size guide that is available to them until the following EMA survey; OR 4) provide a tutorial on noticing hunger/satiety cues and slowing down rate of eating, with an experiential exercise for use during their next eating episode."
48341311|NCT05678478|OTHER|semi-directed interview concerning the experience of adolescents and their parents on Lyme borreliosis and on the tick.|"semi-structured interview on the experience of adolescents and their parents on Lyme borreliosis and the tick.~The interviews will be semi-directed in physical presence. Three interviews will be conducted.~The minor will be questioned first, then the parent(s). And finally, the whole family in one interview. All interviews will be audio recorded with parallel note taking in order to best transcribe the visual expressions. The interviews will be transcribed in writing and pseudonymised."
48002468|NCT02467101|OTHER|Corticosteroid/Saline|"Corticosteroid/Saline~Two groups were defined: group A and group B.~* Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~* Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head."
48341312|NCT01721629|PROCEDURE|Sudden wean of nasal CPAP|
48341313|NCT01721629|PROCEDURE|Gradual wean of nasal CPAP|
48341317|NCT00936793|DRUG|Darunavir|
48341318|NCT00936793|DRUG|Ritonavir|
48341319|NCT00936793|DRUG|Beclomethasone Dipropionate HFA|
48341322|NCT05543824|DRUG|Levobupivacaine|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
48002469|NCT05377021|BEHAVIORAL|Lifestyle change|"In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention."
48341323|NCT01943188|RADIATION|stereotactic body radiation therapy|Undergo SBRT
48341324|NCT01943188|DRUG|cyclophosphamide|Given PO
48341325|NCT01943188|BIOLOGICAL|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
48341326|NCT01943188|OTHER|laboratory biomarker analysis|Correlative studies
48341327|NCT05795257|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
48341328|NCT01820767|DRUG|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
48341329|NCT01820767|DRUG|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
48341330|NCT01820767|DRUG|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
48341331|NCT00001890|DRUG|Estrogen therapy|
48341332|NCT04199546|OTHER|Chewing and swallowing rehabilitation|A home based chewing and swallowing training program (CST) will be applied by an experienced physical therapist. The Functional Chewing Training will be used to improve chewing function which has five steps including positioning the child and food, sensory stimulation, chewing training and adjustment of food consistency to improve chewing function. To support hyolaryngeal elevation, laryngeal mobilization will be performed. Hyolaryngeal mobilization will be performed by moving hyolaryngeal complex in right, left and up directions manually.
48341333|NCT03700346|DEVICE|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
48341334|NCT04066699|PROCEDURE|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
48656693|NCT06038175|DEVICE|Video Head Impulse Testing|During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, \& LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of \>150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is \<0.8 in the presence of refixation saccades .
48341335|NCT02527902|DEVICE|Holter|measure of ANS in IgAN patients
48133596|NCT04784585|BEHAVIORAL|Generic Risk Alert (Active Comparator)|"Participants will be notified that the JITAI algorithm has determined heightened lapse risk in the following 2-3 hours (i.e., We have detected that your risk of lapsing from your weight loss diet is higher than usual and may require attention.)."
48133597|NCT04784585|BEHAVIORAL|Online Behavioral Obesity Treatment|The online BOT consists of: (a) 12 weekly multimedia lessons for training in behavioral weight loss skills; (b) online tools for self-monitoring weight, diet, and physical activity; and (c) weekly automated text-based feedback on progress to date. Participants are given a goal of losing 1-2lbs per week to achieve a total weight loss of ≥10% of initial body weight. Participants are prescribed a calorie goal of 1200-1800 kcal/day tailored on initial weight. Participants are given guidelines to follow a lowfat or Mediterranean diet to meet the prescribed calorie goal. Participants are given a physical activity goal tailored on initial activity level that gradually increases to 200 min/wk of activity, emphasizing brisk walking as the primary form of activity. They also receive a primer in self-monitoring weight, diet, and physical activity. Participants are instructed to self-monitor and follow the prescribed diet for the 6-month study period.
48133598|NCT04936386|BEHAVIORAL|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
48341336|NCT02420990|BEHAVIORAL|Medication Integration Protocol (MIP)|
47981300|NCT03785431|DEVICE|PCI with Phantom Bioresorbable Scaffold|Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
47981301|NCT03709771|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
47981302|NCT00895323|OTHER|enzyme-linked immunosorbent assay|
47981303|NCT00895323|OTHER|pharmacological study|
47981304|NCT00895323|PROCEDURE|whole-body scintigraphy|
47981305|NCT00895323|RADIATION|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
47981306|NCT00026351|BIOLOGICAL|rituximab|
47981307|NCT00026351|DRUG|pentostatin|
47981308|NCT00933309|DRUG|Exemestane|25 mg tablets orally once a day
47981309|NCT00933309|DRUG|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
47981310|NCT04925128|OTHER|Moderate Physical Activity + Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
48498786|NCT00006243|BIOLOGICAL|MART-1:27-35 peptide vaccine|Given SC
48498787|NCT00006243|BIOLOGICAL|gp100 antigen|Given SC
48498788|NCT00006243|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
48498789|NCT00006243|BIOLOGICAL|sargramostim|Given SC
48341337|NCT02420990|BEHAVIORAL|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
48341338|NCT04734769|OTHER|Collect retrospectively clinical data on reproductive outcomes|Collect retrospectively clinical data on reproductive outcomes
48498790|NCT00006243|OTHER|laboratory biomarker analysis|Correlative studies
48656694|NCT06038175|OTHER|Standard of care neurologic evaluation|A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
47981311|NCT04925128|OTHER|Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain"
47981312|NCT06408532|DRUG|IDegLira|The participants in this group will be switched to IDegLira once daily injection therapy.
47981313|NCT06408532|DRUG|Premixed insulin|The participants in this group will be have optimized premixed insulin regimen.
48656695|NCT06643988|BEHAVIORAL|MemFlex|MemFlex employs cognitive training exercises in self-led sessions to improve 1) switching between specific and general AMs, 2) access to positive AMs, and 3) vividness of positive AMs.
48133604|NCT05839067|BEHAVIORAL|Care-HF|Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
48133605|NCT03407144|BIOLOGICAL|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
48133606|NCT03407144|DRUG|doxorubicin|"25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
48133607|NCT03407144|DRUG|vinblastine|"6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
48133608|NCT03407144|DRUG|dacarbazine|"375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
48133609|NCT03407144|DRUG|cyclophosphamide|500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
48133610|NCT03407144|DRUG|vincristine|"1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
48133611|NCT03407144|DRUG|prednisone/prednisolone|"60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
48133612|NCT03407144|DRUG|bleomycin|10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
48133613|NCT03407144|DRUG|etoposide|125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
48656696|NCT00153933|DRUG|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
48656697|NCT00153933|DRUG|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
47981314|NCT02861794|PROCEDURE|Medacta International, GMK Sphere medially stabilized knee|Total Knee Replacement
47981315|NCT03619486|DEVICE|Low energy shock wave|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
47981316|NCT03619486|DEVICE|Placebo|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
47981317|NCT04933942|DRUG|Lomustine|Oral administration of Lomustine
47981318|NCT04933942|DRUG|Romiplostim|Subcutaneous administration of Romiplostim
48133614|NCT03407144|RADIATION|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
48133615|NCT02896335|DRUG|Palbociclib|Administered orally once per day on days 1-21 of 28-day cycles.
48133616|NCT02896335|DRUG|Pembrolizumab|Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.
48656698|NCT02346279|OTHER|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
48656699|NCT05887401|BEHAVIORAL|Core|The core intervention will include behavioral lessons, activity tracker, weekly adaptive physical activity goals, weekly tailored feedback summary.
48656700|NCT05887401|BEHAVIORAL|Simplified Nutrition Monitoring (Green)|Simplified diet monitoring using smartphone tracking of green foods using a traffic light approach.
48656701|NCT05887401|BEHAVIORAL|Behavioral: Simplified Nutrition Monitoring (Red)|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
48656702|NCT05887401|BEHAVIORAL|Nutrition Goals (Yes)|Participant will be assigned a personalized weekly nutrition goal related to nutrition monitoring condition.
48656703|NCT05887401|BEHAVIORAL|Nutrition Goals (No)|Participant will not be assigned a personalized weekly nutrition goal.
48498791|NCT01011179|BEHAVIORAL|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
47981319|NCT04339127|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
48341339|NCT02699125|DRUG|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
48341340|NCT02699125|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
48341341|NCT03994276|DIETARY_SUPPLEMENT|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
47981320|NCT05002855|OTHER|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
47981321|NCT05951504|DRUG|Methylprednisolone|Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
47981322|NCT00680667|BIOLOGICAL|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
47981323|NCT00004443|DRUG|NTBC|
47981324|NCT04776499|DRUG|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
47981325|NCT04406961|PROCEDURE|Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.|Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
47981326|NCT04406961|DEVICE|The antegrade sphincterotome developed by Dr. Dovbenko.|A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
47981327|NCT04406961|PROCEDURE|Endoscopic sphincterotomy.|Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
48498792|NCT01011179|BEHAVIORAL|Self-Management|"Adolescents' own best efforts at managing their JIA"
48341342|NCT02839811|PROCEDURE|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
48341343|NCT01352013|DIETARY_SUPPLEMENT|Omega-3 (oil)|5ml daily with breakfast for 56 days.
48341344|NCT01352013|DIETARY_SUPPLEMENT|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
48367442|NCT01454895|BEHAVIORAL|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
48133626|NCT00192218|BIOLOGICAL|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
48133627|NCT04618250|OTHER|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
48133630|NCT01223274|DEVICE|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
48133631|NCT01223274|DEVICE|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
48341345|NCT06119425|DIAGNOSTIC_TEST|blood-based CRC screening|For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.
48341346|NCT06169995|DRUG|Remimazolam Tosilate|bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
48341347|NCT05392049|OTHER|Bowen's therapy|Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.
48341348|NCT05392049|OTHER|Post isometric relaxation|post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
48341349|NCT05592041|DRUG|Banaba Leaf Extract|a herbal extract in the form of Bigel
48341350|NCT05419115|DRUG|SQIN-Furosemide|The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
48341351|NCT05419115|DEVICE|SQIN-Infusor|The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
48341352|NCT00545467|DRUG|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
48341353|NCT00322387|DRUG|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
48341354|NCT02394327|DEVICE|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
48341355|NCT02394327|DEVICE|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
48341356|NCT01229956|GENETIC|DNA methylation analysis|
48656704|NCT05887401|BEHAVIORAL|Supportive Text Messages (Yes)|Participant will receive up to 5 supportive text-messages from the study staff per week.
48133632|NCT05333367|OTHER|Samples collection|Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)
48341357|NCT01229956|GENETIC|gene expression analysis|
48341358|NCT01229956|GENETIC|microarray analysis|
48341359|NCT01229956|GENETIC|reverse transcriptase-polymerase chain reaction|
48341360|NCT01229956|OTHER|laboratory biomarker analysis|
48341361|NCT03472963|DRUG|Single dose of Genvoya® and a single 800 mg dose of Darunavir®|Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
48341362|NCT01106391|DEVICE|"Cordis AAA stent graft system INCRAFT TM"|
48341363|NCT02090465|DRUG|Ingenol Mebutate|No intervention: observation of routine use of Picato®
48341364|NCT06268509|DIAGNOSTIC_TEST|Nutritional panel laboratory examination|As stated in group description
48341365|NCT06268509|DIETARY_SUPPLEMENT|Pregnancy supplements (other than provided by Ministry of Health)|As stated in group description
48341366|NCT06268509|DIAGNOSTIC_TEST|Fetomaternal ultrasound|As stated in group description
48341367|NCT05765552|OTHER|Dual-Task Training|Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.
48341368|NCT05765552|OTHER|Control Group|Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
48341369|NCT00610207|DEVICE|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
48498793|NCT06306586|BEHAVIORAL|Digital Treatment for Adolescents With Eating Disorders|"The main aim of the digital treatment is to reduce symptoms of eating disorders and increase life-coping skills. The digital treatment aims to help adolescents with eating disorders to:~* Gain knowledge about the symptoms of eating disorders and the consequences it has on everyday life.~* Be motivated to carry out the treatment.~* Gain knowledge of and skills in regulating food and activity in a more balanced way.~* Gain knowledge of and skills in managing emotions.~* Get tools to develop a better self-esteem.~* Gain awareness of the function of the eating disorder.~* Gain skills in coping with social challenges.~* Get a more realistic image of their bodies and handle information from social media."
48341370|NCT01675206|DIETARY_SUPPLEMENT|Vitamin K2 supplementation|
48341371|NCT05459480|OTHER|the jigsaw technique in web-based distance education|The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
48341372|NCT01487707|BEHAVIORAL|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
48656705|NCT05887401|BEHAVIORAL|Supportive Text Messages (No)|Participant will not receive supportive text-messages.
48656706|NCT05887401|BEHAVIORAL|Lesson Delivery (Once)|All behavioral lessons will be made available to participant simultaneously.
48656707|NCT05887401|BEHAVIORAL|Lesson Delivery (Weekly)|A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
48656708|NCT02034565|DRUG|Apixaban|
48656709|NCT05473715|DRUG|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
48656710|NCT06157593|PROCEDURE|NAVA|weaning from mechanical ventilator using neurally adjusted ventilatory assist
48498794|NCT03254381|BEHAVIORAL|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
48498795|NCT03254381|BEHAVIORAL|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
48133636|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
48133637|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
48498796|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (After the Alteration)|Recombinant human interferon α-2b gel (after the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
48498797|NCT05806918|DRUG|Recombinant Human Interferon α-2b Gel (Before the Alteration)|Recombinant human interferon α-2b gel (before the alteration of the active ingredient manufacturer) will be applied to the lesions as a thin layer, at the frequency of four times a day, together with the therapy of valaciclovir hydrochloride.
48133640|NCT05636293|DRUG|Ritlecitinib|200mg Ritlecitinib
48133641|NCT05636293|DRUG|Placebo|Placebo
48133642|NCT05636293|OTHER|Gluten|10g of gluten
48498798|NCT04439695|BIOLOGICAL|Low dose|Low dose of KBP-V001
48133644|NCT06522061|DEVICE|Stream™ Platform|Stream™ Platform consists of 5 main components: Origin™, Delta™ Monitor, Stream™ Application, Accessory Calibration Syringe(s), and Stream™ Cart. Origin™ is an inline biosensor system that can be attached between an off-the-shelf drainage catheter and evacuator bag/bulb system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) for the early identification of postoperative complications. Origin™ requires daily calibration (via Accessory Calibration Syringe(s)) for optimal performance and accuracy of its sensors. The Stream Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor) that are supplied by FluidAI. Origin connects to Stream Application via Bluetooth. Mobile carts/mounts, denoted Stream™ Carts/Delta Mounts, will be used to house the Delta™ Monitor.
48133645|NCT05670821|DRUG|Spesolimab|Spesolimab
48133646|NCT05150093|PROCEDURE|Deep Brain Stimulation|Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
48133647|NCT05285982|DRUG|Nintedanib (Ofev®)|Nintedanib (Ofev®) soft capsules
48498799|NCT04439695|BIOLOGICAL|Intermediate dose|Intermediate dose of KBP-V001
48498800|NCT04439695|BIOLOGICAL|High dose|High dose of KBP-V001
48341373|NCT01487707|BEHAVIORAL|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
48341374|NCT01487707|BEHAVIORAL|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
48341375|NCT04509362|DEVICE|Advanced Hybrid Closed Loop System|Evaluation of the use of an 8-day structured protocol to initiate patients from MDI to the AHCL system, in achieving safe glycemic control
48498801|NCT04439695|BIOLOGICAL|Placebo|Buffered Saline Solution
48341376|NCT02343419|OTHER|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
48341377|NCT04511338|DEVICE|Dialyzer with Endexo|"Sequence AB:~Period 1 Circuit A (Five Visits: 1,2,3,4,5) Period 2 Circuit B (Five Visits: 9,10,11,12,13)~Sequence BA:~Period 1 Circuit B (Five Visits: 1,2,3,4,5) Period 2 Circuit A (Five Visits: 9,10,11,12,13)"
48341378|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine QIV 0.5mL|
48498802|NCT00097396|BIOLOGICAL|rF1V vaccine|
48498803|NCT05984875|OTHER|Collection of tumor samples, blood and vaginal and rectal swabs|The following biological samples will be collected at different time points, according to the specified cohort and after signing the inform consent form: tumor tissue (fresh and archival) or normal tissue (cohort E), ascites (when present), peripheral blood, rectal swab, vaginal swab.
48498804|NCT00201409|DRUG|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
48498805|NCT00201409|DRUG|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
48498806|NCT03858543|DRUG|Poly-L Lactic Acid|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
47981328|NCT04406961|DEVICE|The standard sphincterotome.|"The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary."
47981329|NCT04169321|DRUG|Single Arm|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
48341379|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine TIV 0.5mL|
48498807|NCT03858543|DEVICE|Fractional laser treatment|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
48656711|NCT05007132|BIOLOGICAL|Panitumumab 20 milligram/ML|Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
48656712|NCT05007132|BIOLOGICAL|Bevacizumab|Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
48656713|NCT05007132|DRUG|Trifluridine/Tipiracil Hydrochloride|Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
48656714|NCT03215160|BEHAVIORAL|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
47981330|NCT01064401|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
47981331|NCT01064401|DRUG|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
48341380|NCT02048358|DRUG|2B3-201|
48341381|NCT02048358|DRUG|Placebo|
48656715|NCT03794947|PROCEDURE|Remote Ischaemic Conditioning|Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
48656716|NCT03794947|PROCEDURE|Sham Intervention|The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
48656717|NCT01652157|BIOLOGICAL|ULTRESA|pancreatic enzyme replacement therapy
48656718|NCT01652157|BIOLOGICAL|PANCREAZE|pancreatic enzyme replacement therapy
48656719|NCT01652157|BIOLOGICAL|CREON|pancreatic enzyme replacement therapy
48656720|NCT01652157|BIOLOGICAL|ZENPEP|pancreatic enzyme replacement therapy
48656721|NCT01652157|BIOLOGICAL|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
48656722|NCT01652157|BIOLOGICAL|PERTZYE|pancreatic enzyme replacement therapy
48656723|NCT01652157|OTHER|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
48656724|NCT00642759|DRUG|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
48656725|NCT00642759|DRUG|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
48656726|NCT00642759|DRUG|Bevacizumab|IV infusion
48498808|NCT03373773|PROCEDURE|Foley catheter removal|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
48656727|NCT06643182|OTHER|Back Support|When the sandbag is to be left by the researcher together with the nurse caring for the patient, the patient will be placed in the left lateral position for a short time, a gel-filled orthopedic non-sweating viscose pillow will be placed in the patient's lumbar region and the patient will be placed in a supine position with the head supported.
47981332|NCT01064401|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a for intramuscular injection
47981333|NCT01064401|DRUG|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
47981334|NCT00022009|DRUG|gemcitabine hydrochloride|
48133652|NCT06443073|OTHER|Patient-reported outcomes for speech disorders: positive|The Communicative Participation Item Bank (CPIB) aims to assess communication participation in all kinds of communication disorders. The Voice Self-Efficacy Questionnaire (VSEQ) monitors self-efficacy in individuals with self-declared voice problems before and after interventions. The Vocal Fatigue Handicap Questionnaire (VFHQ) and the Vocal Fatigue Index (VFI) aim at reflecting vocal fatigue. Both have been adapted to reflect purely positive wording.
48656728|NCT01339091|DRUG|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
48341382|NCT02048358|DRUG|Methylprednisolone hemisuccinate|
48341383|NCT04632745|OTHER|Wrist Rehabilitation|participants will undergo immobilization for the first 6 weeks of treatment
48341384|NCT04208217|BEHAVIORAL|Modeling to Learn (MTL)|Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
47981335|NCT00005892|DRUG|cyclophosphamide|
47981336|NCT00005892|PROCEDURE|Allogeneic Bone Marrow Transplantation|
47981337|NCT03096379|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
48656729|NCT01339091|DRUG|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
48133655|NCT06207617|PROCEDURE|Immediate implant placement + customized healing abutment|Immediate implant placement in fresh extraction molar sites + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant. no grafting material included in this arm
48341385|NCT04208217|BEHAVIORAL|Usual quality improvement (QI)|Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
48341386|NCT05843305|DRUG|BPI-452080|Subjects will receive BPI-452080 until disease progression
47981338|NCT04719507|PROCEDURE|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
47981339|NCT04719507|PROCEDURE|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
47981340|NCT04719507|DRUG|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
47981341|NCT00278655|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
47981342|NCT03489447|OTHER|ICU care|exposure to ICU treatment with or without diagnosed sepsis
48341387|NCT04310865|DRUG|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
48341388|NCT04310865|DRUG|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
48656730|NCT06217302|DRUG|Sotagliflozin|Oral sotagliflozin (200 mg per day)
48656731|NCT06217302|DRUG|Placebo|Inactive tablets identical to sotagliflozin tablets
48656732|NCT05878093|DRUG|Dupilumab|solution for subcutaneous injection
48656733|NCT05878093|DRUG|Placebo|solution for subcutaneous injection
48656734|NCT05878093|DRUG|Budesonide|nasal spray (suspension)
48133656|NCT06207617|PROCEDURE|Immediate implant placement + xenogeneic bone graft material + customized healing abutment|Immediate implant placement in fresh extraction molar sites + xenogenic bone graft + customized healing abutment fabricated by adding flowable composite to the temporary cylindrical abutment mimicking the shape of the socket at the marginal gingiva, then it will be screwed to the implant.
48341389|NCT04310865|OTHER|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
48341390|NCT04655924|DEVICE|Clinical Decision Support System|Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
48341391|NCT00264095|PROCEDURE|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
48341392|NCT06427148|OTHER|"The biofeedback-assisted VR game Golden Breath"|"The biofeedback-assisted VR game Golden Breath that we presented in this study was designed to meet children's healthcare needs quickly and efficiently while reducing pain and fear during medical procedures in the pediatric population. Golden Breath u"
48341393|NCT05401903|OTHER|Chiropractic Maintenance Care|"Subjects will receive high-velocity, low amplitude (HVLA) chiropractic manipulations to areas of defined restriction in the upper cervical spine, thoracic spine, lumbar spine, and pelvis. The clinician will use motion palpation to determine spinal segments with joint restrictions. Subjects will schedule weekly chiropractic visits.~The clinician will not use passive care modalities. The exclusions of passive modalities include heat and cold therapies, electric stimulation, massage, acupuncture, and cupping therapies. Subjects will be encouraged to maintain normal exercise activity levels throughout the study. The clinician will provide instructions on homecare exercises as needed to promote range of motion of spinal segments between chiropractic visits. A single clinician will deliver the HVLA chiropractic manipulations to ensure consistency of chiropractic care throughout the study."
48656735|NCT05392283|DEVICE|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
48656736|NCT05457725|BEHAVIORAL|Contingent rtfMRI neurofeedback training|Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
48656737|NCT05457725|BEHAVIORAL|Non-contingent/sham rtfMRI neurofeedback training|Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
48656738|NCT06320782|BEHAVIORAL|Calorie restriction and balanced distribution of macronutrients|Progressive reduction of 500 to 1000 calories from the usual food intake or the recommendation of 20 calories/kg of current weight/day and distribution of macronutrients: 5% of carbohydrates, 2% of proteins and 3% of fats
48656739|NCT06320782|BEHAVIORAL|Calorie restriction and low-carbohydrate diet|Reduction in carbohydrate consumption and an increase in fat and protein intake, with the following proportions: 45% fat, 20% protein and 35% carbohydrate
48656740|NCT06320782|BEHAVIORAL|Calorie restriction and low-fat diet|Restriction of fat consumption and an increase in carbohydrate consumption, with the following proportions: 20% fat, 15% protein and 65% carbohydrate
48656741|NCT06320782|BEHAVIORAL|Collective nutritional guidance|Recommendations of the Food Guide for the Brazilian Population: limitation of the intake of foods with high energy density from fats and simple carbohydrates; substitution of saturated fats for unsaturated fats; exclusion of trans fat from the diet; increasing fruit and vegetable consumption to a daily minimum of 400g; increased consumption of high-fibre foods and limiting the consumption of sugars and salt.
48656742|NCT05039307|BEHAVIORAL|Educational and motivational strategy|The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.
48656743|NCT01481103|PROCEDURE|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
48656744|NCT05208437|BEHAVIORAL|Complete oral feeding intervention|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.
48656745|NCT05208437|BEHAVIORAL|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
47981343|NCT04980859|DRUG|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
48513296|NCT04873973|OTHER|Telemedical support|The nursing homes participating in the project will be equipped with telemedical equipment. This will allow teleconsultations to take place when needed. In addition, an early warning system will be introduced and, within the framework of the teleconsultation, a trained medical assistant can be sent to the care facility if necessary, who can carry out medical activities on site under a physician's delegated instructions. In addition, an electronic patient file will be introduced which can be accessed by the telemedicine physician and the general practitioner.
48133658|NCT02575365|DRUG|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
48341394|NCT03507881|DEVICE|fusion|Internal fixation
48656746|NCT06507956|OTHER|Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis|Eligible patients will be presented with the study during a routine care visit CF center, at the end of a physiotherapy, adapted physical activity or nurse session, in accordance with the schedule for the day's visit, with no changes induced by this study. After sufficient time for reflection, patients agreeing to participate will be given self-questionnaires. From this visit, a proposal to participate at V2 will be made only to the inactive/hight sedentary patients on the ONAPS-PAQ questionnaire, under elexacaftor-tezacaftor-ivacaftor (ETI). Volunteers will know their participation in either actimetry or a qualitative interview following a draw. At V2, 40 patients will be offered a 7-day longitudinal follow-up by actimetry, and between 10 to 15 patients will take part in an qualitative semi-structured interview identifying motivational barriers and levers for action. At V3, patients monitored by actimetry will be invited to return their actimeter by postage-paid mail.
48656747|NCT05044845|BEHAVIORAL|Interview|Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.
47981344|NCT01659775|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
47981345|NCT01659775|DRUG|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
47981346|NCT02653391|DRUG|Part A Elamipretide 1.0% Ophthalmic Solution|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
47981347|NCT02653391|DRUG|Part B Elamipretide 3.0% Ophthalmic Solution|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
48133664|NCT05753501|DRUG|ABBV-101|Oral:Tablet
48341395|NCT01155960|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
48341396|NCT04983199|DEVICE|Hexoskin Medical System|Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.
48341397|NCT05537493|OTHER|Telerehabilitation|It will be followed by exercising on whatsapp
48341398|NCT05537493|OTHER|Face to face|It will be followed by face to face
48341399|NCT01574261|DRUG|Placebo|Placebo for four months
48341400|NCT01574261|DRUG|Inositol|Inositol 4g/die for four months
48341401|NCT03953885|OTHER|Fire needle|"1. Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4\*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~2. The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
48656748|NCT06533735|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
48656749|NCT05941780|DIAGNOSTIC_TEST|Pain classification method|A current clinical algorithm will be used to determine the predominant type of pain in individuals with FMS. The classification to diagnose nociceptive, neuropathic and nociplastic pain will based on a recent method developed by Nijs et al. This method consists of seven steps in total. These steps question the following, respectively: duration of pain, pain distribution, presence of nociceptive pain, presence of neuropathic pain, phenomenon of hypersensitivity, presence of hypersensitization and presence of specific comorbidity. Besides, inter-rater and intra-rater reliability of pain classification algorithm will be determined by two independent researchers.
48656750|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of nano-crystalline putty hydroxyapatite.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
48656751|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and ALB- PRF as membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade without vertical releasing incision.~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of nano-crystalline putty hydroxyapatite..~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
48656752|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
48656753|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and ALB-PRF membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing"
48656754|NCT03761641|OTHER|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics \& eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face \&cushion between the skin \& eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, \& dilation velocity. Total pupil dilation testing time is \< 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position \& movement velocity during these tests. Total saccade-tracking testing takes \< 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
48656755|NCT01644591|OTHER|Quality-of-Life Assessment|Ancillary studies
48656756|NCT01644591|OTHER|Questionnaire Administration|Ancillary studies
48656757|NCT01644591|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48656758|NCT06446648|DRUG|ICG|Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
47981348|NCT02653391|DRUG|Part A Placebo|Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
47981349|NCT02653391|DRUG|Part B Placebo|Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
47981350|NCT01890850|OTHER|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
48002470|NCT02467556|DRUG|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
48133665|NCT05084638|DRUG|Ofatumumab|20mg subcutaneous injection
48498809|NCT05342701|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity."
48656759|NCT06289764|OTHER|Bergamot Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
48656760|NCT06289764|OTHER|Grapefruit Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
48656761|NCT06289764|OTHER|Sweet almond oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles
48656762|NCT04381806|DRUG|5-ALA|Patients enrolled in this study will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed. Patients are followed through day 56 for adverse event and efficacy measures.
48656763|NCT05603637|PROCEDURE|Catheter ablation using SmartTouch radiofrequency ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)
48656764|NCT05603637|PROCEDURE|Catheter ablation using Farawave pulsed-field ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
48133667|NCT06517914|DRUG|YH35995|Oral administration of YH35995
48133668|NCT06517914|DRUG|Placebo|Oral administration of Placebo
48656765|NCT05000788|BEHAVIORAL|Qigong|Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.
48656766|NCT05000788|BEHAVIORAL|Exercise|Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.
48656767|NCT04441515|DEVICE|Ipod with music|music of patient's preference provided 2 hours daily
48656768|NCT04441515|DEVICE|ipod with books to listen|2 hours of daily listening to books
48656769|NCT04441515|DEVICE|ipod only with usual care|participants given device only
48656770|NCT06639763|DIAGNOSTIC_TEST|Questionnaire|Questionnaire containing a combination of basic epidemiological questions, questions regarding recent sexual activity, questions regarding sexual preference and sexual activity, questions regarding the use of different types of erectile aids, questions regarding satisfaction with the use of these different erectile aid and questions regarding the satisfaction with sexual functioning and the partner relation. Al patients at least 6 months after primary genital gender-affirming surgery and who are sexually active are eligible.
48341402|NCT03953885|OTHER|Fire needle Placebo|"1. Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4\*40mm to prepare for operation.~2. The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
48341403|NCT03437629|PROCEDURE|Temporary cement based on Calcium Hydroxide|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
48341404|NCT03437629|PROCEDURE|MTA temporary cement|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
48341405|NCT04307901|DEVICE|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
48341406|NCT04771481|DRUG|Metoclopramide|Metoclopramide 10 mg + NSS 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
48341407|NCT04771481|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml intravenous slowly push in 5min before endoscopy 30-120 min
48341408|NCT05236660|DEVICE|Custom-made shoes: pressure-optimized|Pressure-optimized custom-made shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months.
48341409|NCT05236660|DEVICE|Custom-made indoor shoes: pressure optimized|Pressure-optimized custom-made indoor shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months. Specifically designed for indoor use.
48341410|NCT05236660|DEVICE|Foot temperature monitoring|Personalised at-home daily foot temperature monitoring at high-risk regions.
48498810|NCT05760586|DRUG|Tovorafenib|Oral RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL)
48133674|NCT05237466|BEHAVIORAL|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
48133675|NCT05237466|BEHAVIORAL|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
48498811|NCT00813631|OTHER|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
48498812|NCT03286010|BEHAVIORAL|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
48341411|NCT05236660|BEHAVIORAL|Education|Personalised patient education consisting of quantitative feedback on in-shoe pressures, temperature measurements and footwear use and, in addition, motivational interviewing where indicated and needed to improve device use.
48341412|NCT01152411|OTHER|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
48341413|NCT05458362|BEHAVIORAL|Brief Enhanced Anxiety Sensitivity Treatment (Group BEAST)|"Group BEAST consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.~Only the EMI group will receive EMI prompts and intervention."
48498813|NCT05452135|OTHER|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
48498814|NCT04021849|OTHER|Face-to-face Class|The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
48656771|NCT05130801|DIAGNOSTIC_TEST|pHLIP® ICG NIRF imaging|"Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).~In Phase I, we propose to investigate 4 different doses:~Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg~In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40."
48656772|NCT04633330|DRUG|AHCC®capsules|AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
48656773|NCT04633330|DRUG|Simulation of AHCC®capsules|TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
48656774|NCT02236910|OTHER|Lu-DOTA-TATE|
48498815|NCT04021849|OTHER|Asynchronous Virtual Class|Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
48498816|NCT02337023|RADIATION|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
48498817|NCT04481321|BIOLOGICAL|Biological/Vaccine|
48133687|NCT06038747|OTHER|Self-Monitoring|The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.
48133688|NCT06038747|OTHER|Individual Psychotherapy|Individual psychotherapy sessions
48656775|NCT06156384|DEVICE|FITBONE® Lengthening Nail|"The patient is installed on a standard orthopaedic table, intramedullary reaming is performed through a metal working tube. The osteotomy is performed percutaneously and then an osteotome according to the postage-stamp technique. Once the FITBONE lengthening nail is placed in the desired location, it should be connected to the subcutaneous receiver. The receiver should be placed close enough to the skin surface to ensure the energy transfer from the external transmitter.~After 5 to 10 days after surgery, the lengthening mechanism is operated by the patient, using the transmitter. An elongation of approximately 1 mm/day takes place. The attending physician determines the rhythm of lengthening in each case. When the desired elongation length is reached, the consolidation phase begins, which is necessary for bone regeneration. The FITBONE lengthening nail can be removed once the bone has consolidated, approximately one to one and a half years after implantation."
48341414|NCT05458362|BEHAVIORAL|Control group Anxiety Sensitivity Treatment|Control group Anxiety Sensitivity Treatment consists of a 1.5-hour-long intervention session, followed by a 2-week-long EMI. During the intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety and stress), discuss popular misconceptions they may have about anxiety symptoms, and complete exposure exercises (e.g., practicing facing feared physical sensations such as trembling or elevated heart rate). Homework exposure exercises will be completed by all participants. They will receive phone app reminders about completing homework.
48341415|NCT00611767|DRUG|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
48498818|NCT06316648|DIETARY_SUPPLEMENT|whey intake group|It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink.
48656776|NCT06639802|OTHER|Hand Arm Bimanual Intensive therapy including lower extremity (HABIT-ILE)|HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) and the customized functional goals that were previously discussed with the parents (e.g., drinking on one\&#39;s own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.). HABIT-ILE activities are presented as games and the whole environment is arranged in such a way that children perceive the therapy as fun. Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest.
47981351|NCT02315378|BEHAVIORAL|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
47981352|NCT02315378|BEHAVIORAL|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
48341416|NCT00611767|DRUG|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
48341417|NCT01003613|DRUG|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
48498819|NCT06316648|PROCEDURE|control group|The patients were left fasting after 00:00.
47981353|NCT02211521|BIOLOGICAL|PRP|3ml of PRP
47981354|NCT02211521|DRUG|Hyaluronic acid|3ml hyaluronic acid
47981355|NCT00558025|DRUG|Pramipexole Extended Release|
47981356|NCT00558025|DRUG|Pramipexole Immediate Release|
47981357|NCT00047814|DRUG|FK788|
48341418|NCT01003613|OTHER|Beriplast P|0.1 ml to attach graft
48341419|NCT00474006|DRUG|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
48341420|NCT03950960|DRUG|BMS-986256|Specified dose on specified days
48341421|NCT03950960|DRUG|Itraconazole|Specified dose on specified days
48498820|NCT03126617|BIOLOGICAL|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
48513297|NCT03596138|OTHER|Evaluate the reliability and reproductibility of the automated angular measurement by the Gazelab|Compare the results of the Gazelab to the alternate occlusion by prism bar (standard gold) examiners.
48513298|NCT02513030|PROCEDURE|Defibrillation testing during ICD replacement|
48656777|NCT06640790|OTHER|Case Group|Root canal treated were categorized based on the AAE case difficulty assessment form. Endodontic mishaps investigated included over-instrumentation, working length loss, underfilling, overfilling, apical transportation, instrument fracture, and perforation.
48656778|NCT06419504|OTHER|SAP block group|US-guided SAP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
48656779|NCT06419504|OTHER|PECS II block group|US-guided PECS II block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
48656780|NCT06419504|OTHER|ESP block group|US-guided ESP block is performed approximately 30 minutes before the surgery in patients undergoing breast cancer surgery in a separate regional anesthesia room with standard anesthesia monitoring.
48656781|NCT06419504|OTHER|Control group|No intervention
48656782|NCT02304159|DRUG|daclatasvir|
48656783|NCT02304159|DRUG|Sofosbuvir, Sovaldi|
48656784|NCT02304159|DRUG|Ribavirin|
48656785|NCT02422108|DRUG|Denosumab|
48656786|NCT06645249|DRUG|Amiodarone (Antiarrhythmic drug)|Comparing 2 regimes of amiodarone pre-electrical cardioversion witn ECG monitoring
48656787|NCT05121558|OTHER|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
48656788|NCT05121558|OTHER|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN) , how yoga may help with CIPN, and how different therapies may help with CIPN.
48656789|NCT05121558|OTHER|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive a voucher for sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
48656790|NCT05755958|DEVICE|HIFU treatment in rectal Endometriosis|HIFU treatment of rectal endometriosis
48656791|NCT05755958|DEVICE|SHAM HIFU procedure|SHAM HIFU procedure
48656792|NCT03074669|BEHAVIORAL|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
48656793|NCT06640101|OTHER|sham IMT|with 10% maximum inspiratory pressure (MIP) as the training intensity, IMT will be conducted while sitting on the chair.
48656794|NCT06640101|OTHER|target IMT (sitting on a chair)|IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on a chair
48656795|NCT06640101|OTHER|target IMT (sitting on an unstable surface)|IMT intensity identified as optimal based on the results of our ongoing study, IMT will be conducted while sitting on an unstable surface
48341422|NCT06034041|DRUG|Mediclore|After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.
48341423|NCT06034041|DRUG|Normal Saline|After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
48341424|NCT01397045|OTHER|VATS|Video-assisted lung segmentectomy
48341425|NCT01397045|PROCEDURE|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
48656796|NCT06640101|OTHER|Conventional treatment|The conventional treatment includes limb muscle strengthening exercises, Bobath approach, bridging exercise, balance training in standing, general gait training and activities of daily living training
48656797|NCT04169009|BIOLOGICAL|Zostavax|Intradermal injection of Zostavax
48656798|NCT04169009|BIOLOGICAL|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
48656799|NCT02730169|DRUG|BGS649|Capsules were taken weekly for a maximum of 24 weeks
48656800|NCT02730169|DRUG|Placebo|Capsules were taken weekly for a maximum of 24 weeks
48656801|NCT00661180|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
48656802|NCT05234177|OTHER|Observation|No intervention
48656803|NCT01275378|BEHAVIORAL|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
48656804|NCT01275378|BEHAVIORAL|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
48656805|NCT06153264|OTHER|neurodynamic mobilization exercise|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
48656806|NCT06153264|OTHER|strengthening exercises|upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks
48656807|NCT04938817|BIOLOGICAL|coformulation pembrolizumab/quavonlimab|Intravenous (IV) infusion
48656808|NCT04938817|DRUG|lenvatinib|Oral administration
48656809|NCT04938817|BIOLOGICAL|MK-4830|IV infusion
48656810|NCT04938817|BIOLOGICAL|coformulation favezelimab/pembrolizumab|IV infusion
48656811|NCT04938817|BIOLOGICAL|R-DXd|IV Infusion
48341426|NCT01564602|DEVICE|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
48341427|NCT02435394|BEHAVIORAL|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
48341428|NCT02435394|BEHAVIORAL|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
48498821|NCT05906108|BEHAVIORAL|Self-initiated learning|A WeChat Subscription will be created for delivering the intervention. The educational materials involving introduction to internet addiction, the impact of internet addiction and strategies in coping with IA will be posted to the account at the beginning of the intervention. The materials will be prepared in different format including text and video followed by 3 to 5 multiple choice questions (MCQs), and one post for one topic. Relevant materials can be found by typing the keywords in the account or searching under the content list. Participants will be required to follow the account to study the materials at their own pace and complete the MCQs. There will be no limited access to the materials and attempts for MCQs.
48656812|NCT04821310|DRUG|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
48656813|NCT04821310|DRUG|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
48341429|NCT02435394|BEHAVIORAL|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
48341430|NCT01329341|OTHER|Service Dogs|Service dogs will be trained to help Veterans with PTSD
48656814|NCT03993262|DRUG|Bortezomib|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
48341431|NCT01489228|DRUG|E1224|100 mg tablets
48656815|NCT03993262|DRUG|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
48656816|NCT06644872|OTHER|Bedrest|Investigation of the effect of short-term bed rest (3 hours) on heart function, measured by cardiac magnetic resonance, in healthy participants ( males and females)
48341432|NCT01489228|DRUG|Benznidazole|100mg tablets
48341433|NCT01489228|DRUG|Placebo|tablets
48341434|NCT01605201|BIOLOGICAL|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
48341435|NCT02820038|BEHAVIORAL|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
48341436|NCT02820038|BEHAVIORAL|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
48341437|NCT02820038|BEHAVIORAL|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
48656817|NCT06486064|DIETARY_SUPPLEMENT|heat-treated Limosilactobacillus fermentum|one capsule daily for 8 weeks
48656818|NCT06486064|DIETARY_SUPPLEMENT|Placebo|one capsule daily for 8 weeks
48656819|NCT06642025|BIOLOGICAL|CAR-T Cell Injection|"Conditioning chemotherapy: Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before intraperitoneal infusion.~On the day of administration, premedication with 500mg of acetaminophen orally and 20mg of promethazine intramuscularly or intravenously (or other non-steroidal anti-inflammatory drugs and antihistamines) should be given 30 minutes before intraperitoneal infusion.~The therapeutic dose of CAR-T cells is defined as intravenous injection of 1.0E6 CAR-T cells/kg as the initial standard dosage."
48341438|NCT06241820|PROCEDURE|Lumbar Sympathetic Ganglion Block|A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.
48341439|NCT00368472|DRUG|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
48341440|NCT03649516|DEVICE|iCKD APP|Use iCKD APP to upload home bio-information data
48341441|NCT03381911|OTHER|Embodied Conversational Agent|The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
48498822|NCT05906108|BEHAVIORAL|Personalized and interactive behavioural support|The intervention group will receive 3-month personalized and interactive behavioural support via WeChat, which including regular messages and real-time conversation. The regular messages will cover the generic information about abstinence support, health warnings, benefits of reducing internet time, knowledge reinforcement, goal setting, encouragement and reminders for self-initiated online learning. The messages will be personalised according to baseline demographic characteristics and internet addiction level, and continually adapted to any change in internet behaviours change reported by subjects during the conversations. A total of 19 messages with a tapering schedule. Personalized real-time conversation via WeChat will be available based on participants' demand.
48656820|NCT06460155|DEVICE|3 methods intervention|Stu All participants will undergo all three methods being studied: epidurogram (gold standard), CompuFlo CathCheck, and physical exam in PACU following epidural placement.
48656821|NCT02096354|DRUG|RRx-001|
48341442|NCT04949828|DRUG|CREON|Oral Capsules
48341443|NCT04306367|DRUG|Pembrolizumab|200 mg given intravenously.
48498823|NCT05906108|BEHAVIORAL|General health information|Participants in control group will receive WeChat messages on general health information (similar frequency as the intervention group) and reminders on follow-up surveys via WeChat. Various topics will be involved in the general health information such as healthy diet, sleep management, exercise and mood management.
48498824|NCT00049582|DRUG|decitabine|Given IV
48498825|NCT00049582|OTHER|laboratory biomarker analysis|Correlative studies
48341444|NCT04306367|DRUG|Olaparib|300 mg given orally.
48498826|NCT00049582|OTHER|pharmacological study|Correlative studies
48498827|NCT04859621|DRUG|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
48498828|NCT04859621|DRUG|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
48498829|NCT04859621|DRUG|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
48498830|NCT04859621|OTHER|standard antibiotic therapy|standard antibiotic therapy
48498831|NCT03301623|OTHER|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
48498832|NCT03301623|OTHER|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
48498833|NCT01910389|DRUG|Tadalafil|
48498834|NCT01910389|DRUG|Placebo for tadalafil|
48498835|NCT02502279|DEVICE|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
48656822|NCT02096354|DRUG|Regorafenib|
48656823|NCT02096354|DRUG|Irinotecan|To be dosed after RRx-001 or regorafenib
48341445|NCT05782374|DRUG|Ibrutinib|ibrutinib alone or in combination with R-CHOP or R-CHOP like
48341446|NCT01827241|OTHER|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
48656824|NCT04625205|BIOLOGICAL|NEO-PTC-01|Administered via intravenous infusion.
48656825|NCT04625205|DRUG|IL-2|Administered via intravenous infusion.
48656826|NCT04625205|DRUG|αPD-1 therapy|Administered via intravenous infusion.
48656827|NCT05259501|OTHER|RMIST|"RMIST will involve:~1. A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~2. A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting."
48656828|NCT02941055|OTHER|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
48656829|NCT02941055|OTHER|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
48498836|NCT02502279|DEVICE|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
48656830|NCT06642246|BEHAVIORAL|Intervention|During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.
48656831|NCT06029010|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
48656832|NCT05498090|DRUG|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
48341447|NCT02786836|DRUG|13C-Methacetin|"The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
48341448|NCT03955497|OTHER|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
48341449|NCT03955497|DRUG|Sodium Hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
48341450|NCT03955497|PROCEDURE|Extraction of abdominal fat|In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
48498837|NCT00485680|DRUG|Olanzapine Hydrochloride|
48498838|NCT00485680|DRUG|Lithium Carbonate|
48498839|NCT00040768|DRUG|bortezomib|Given IV
48498840|NCT05291065|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
48498841|NCT05291065|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
48498842|NCT05291065|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
48656833|NCT04589650|DRUG|Alpelisib|"Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 2 to 5 years old) will receive alpelisib granules at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2 in addition to the data from Group 4 as available.~Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily."
48656834|NCT04589650|DRUG|Placebo|Participants will receive matching placebo once daily up to week 16.
48341451|NCT00778713|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
48498843|NCT03915353|OTHER|No Intervention|No Intervention
48498844|NCT00872885|DRUG|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
48498845|NCT00872885|DRUG|Morphine|60 mg
48498846|NCT00872885|DRUG|Placebo|single dosage
48498847|NCT04325035|DRUG|Istaroxime|Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
48498848|NCT04325035|DRUG|Placebo|Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
48498849|NCT03596892|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
48498850|NCT03596892|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
48498851|NCT03596892|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
48133689|NCT03568994|DRUG|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
48133690|NCT03568994|DRUG|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
48133691|NCT03568994|DRUG|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
47981358|NCT05898555|DEVICE|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
48133692|NCT03568994|DRUG|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
48133693|NCT03568994|DRUG|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
48133694|NCT06433050|DRUG|Sotagliflozin|Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.
48498852|NCT02413216|BEHAVIORAL|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
48498853|NCT02413216|OTHER|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
48498854|NCT02931903|OTHER|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
48498855|NCT02931903|OTHER|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
48498856|NCT01264731|BIOLOGICAL|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
48498857|NCT01264731|DRUG|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
48498858|NCT04380766|PROCEDURE|Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer|Comparison between the pre-COVID and COVID groups of general, clinical, endoscopic and surgical outcomes
47981359|NCT03258489|DEVICE|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
47981360|NCT03258489|DEVICE|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
47981361|NCT03258489|DEVICE|TENS and IES Placebo|Same protocol without electrical output.
47981362|NCT02186912|DEVICE|Nobel Active, Nobel Procera IBO|
47981363|NCT00563251|DRUG|Azithromycin|
47981364|NCT00563251|DRUG|Placebo tablet|
48133704|NCT04798261|DEVICE|Indigo Aspiration System|Indigo Aspiration System
48341452|NCT00292812|DRUG|Nutritional supplementation (nucleotides)|
48341453|NCT03785470|OTHER|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
48498859|NCT02400242|DRUG|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
48498860|NCT02400242|DRUG|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
48133709|NCT05671510|DRUG|Gotistobart|Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
48133710|NCT05671510|DRUG|Docetaxel|Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
48498861|NCT02400242|DRUG|Dexamethasone|40 mg qd on days 1, 8, 15, 22
48498862|NCT02730351|DRUG|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
48498863|NCT02730351|DRUG|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
48133714|NCT04999007|OTHER|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
47981365|NCT01878058|OTHER|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
48498864|NCT02730351|DRUG|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
48498865|NCT02730351|DRUG|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
48498866|NCT03441724|DIAGNOSTIC_TEST|Mechanocardiography|Mechanocardiographic recording
48133718|NCT04700410|DEVICE|Pure-Vu System|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
48498867|NCT04581174|DIAGNOSTIC_TEST|24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values <5.5 will be evaluated|Patients with the 1st degree of hypertrophy according to Camacho, 2nd degree of hypertrophy according to Camacho, 3rd degree of hypertrophy according to Camacho, 4th degree of hypertrophy according to Camacho will undergo 24-hour monitoring of oropharyngeal pH by Restech, RYAN scores upright and supine, and pH values \<5.5 will be evaluated.
48341454|NCT04407624|OTHER|Intermittent Exercise|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. During the loading period, taking into consideration the heart rate, fatigue and shortness of breath, exercises such as walking, squat, limb movements with weights, stepping on the steps, walking on different floors are shown. Stretching exercises are done during the cooling period. Intermittent loading workouts will consist of 3-minute loads and 1-minute rest intervals. Participants are contacted every two weeks via communication methods such as e-mail, message and telephone conversation. Exercise diary is given to all patients and is taken from them at the end of the study.
48341455|NCT04407624|OTHER|Control|Exercise programs including warm-up, loading, cooling, and relaxation exercises are shown. The warm-up period is consist of light-paced walking, active movements of several large muscle groups. In loading period, moderate aerobic exercise is consist of brisk walking to reach 60-85% of the person's maximum heart rate. Stretching exercises are done during the cooling period.
48341456|NCT03512470|DEVICE|Sistema Prevena ™(TVAC)|The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
47981366|NCT01223989|OTHER|hypocaloric diet balanced + nutrition education + ruled physical activity|
48341457|NCT03512470|OTHER|Standard medication|standard medication in use (sterile gauze and TNT patch or medicated patches).
48341458|NCT05975372|DEVICE|Blossom tissue expander|Mentor spectrum adjustable saline breast implant for expansion is placed with the Blossom tissue expander above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
48341459|NCT05975372|DEVICE|Standard tissue expansion|Mentor spectrum adjustable saline breast implant for expansion is placed with (without the Blossom tissue expander) above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
48341460|NCT02314871|OTHER|Epidural analgesia|see Arm/group description
48341461|NCT02314871|DRUG|Piritramide|see Arm/group description
48656835|NCT04353492|BIOLOGICAL|Ofatumumab|Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
47981367|NCT04949126|BEHAVIORAL|questionnaire|questionnaires of precarity, dental anxiety, self medication, pain
47981368|NCT01709591|BEHAVIORAL|Prenatal education|
47981369|NCT06357598|DRUG|Tislelizumab|Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.
47981370|NCT06357598|DRUG|Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
47981371|NCT06357598|DRUG|Carboplatin or Cisplatin|"Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles."
48498868|NCT05528835|PROCEDURE|Frozen embryo transfer|All women in both groups will receive oral estradiol valerate 8 mg/ day from the second day of the menstrual cycle. Endometrial thickness will be assessed by vaginal ultrasonography at the tenth day of treatment. When endometrial thickness reached ≥ 7 mm all subjects, in addition to estrogen, they will receive progesterone vaginal suppositories 400 mg twice daily and 100 mg of progesterone intramuscularly daily. Frozen thawed embryo transfer will be at day 6 of progesterone. Estrogen and progesterone will be continued until 9-10 weeks of gestation
48498869|NCT05041881|DEVICE|Trifocal lens AT LISA TRI, Zeiss|lens is made of hydrophilic acrylic material with square edge technology and having diffractive optic design
48341462|NCT02314871|DRUG|Morphine|see Arm/group description
48341463|NCT04499846|OTHER|Therapeutic education|Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
48341464|NCT05369624|OTHER|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|"The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms"
48341465|NCT02283333|BEHAVIORAL|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
48341466|NCT02283333|BEHAVIORAL|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
48341467|NCT00329394|DRUG|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
48341468|NCT05030597|DRUG|68Ga-DOTA-FAPI|Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
48341469|NCT05030597|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 20-30 minutes after injection.
48341470|NCT04961476|DIETARY_SUPPLEMENT|1-MNA|1-MNA supplementation
48341471|NCT02259946|DRUG|BI 1744 CL|
48341472|NCT02259946|DRUG|Placebo|
48341473|NCT02259946|DRUG|Tiotropium bromide|
48498870|NCT05041881|DEVICE|Accommodating Tetraflex HD lens, Lenstec inc.|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
48498871|NCT05041881|DEVICE|Monofocal lens, Softec HD|lens is made of hydrophilic acrylic material with square edge technology and having monofocal optic design
48498872|NCT02882243|DEVICE|FLXfit Cage for fusion|Evaluating patient outcomes and radiographic outcomes
48341474|NCT05339204|PROCEDURE|allo-HSCT|allo-HSCT from any type of donor
48341475|NCT01378845|DRUG|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
48341476|NCT01378845|DRUG|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
48341477|NCT01179867|OTHER|Electronic Medication Reconciliation|"1. At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~2. At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~3. The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes"
48341478|NCT04445688|DRUG|AD036|Oral administration before bed
48498873|NCT05211414|BEHAVIORAL|Yoga Based Daily Excercise|Subjects will be trained to perform 30 minutes of moderate level yoga daily, with instruction on breathing, self-awareness, and ways to modify poses to avoid pain. Subjects will be instructed in use of the email links to access the 30-minute instructive video. Subjects will attend weekly Zoom classes to learn additional postures and techniques, which will be reflected in their 30 minutes video (i.e. a new video for each week). At these weekly remote yoga classes, they will be asked about difficulties encountered and given advice about their personal home practice.
48498874|NCT04015323|DEVICE|Interferential current|An electrotherapy current with different carrier frequencies
47981372|NCT06357598|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
48341479|NCT04445688|DRUG|Atomoxetine|Oral administration before bed
48341480|NCT04445688|DRUG|Placebo|Oral administration before bed
48341481|NCT04606368|DEVICE|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
48341482|NCT02252757|DEVICE|CoVa|
48498875|NCT04333108|DRUG|Masitinib|Masitinib 6 mg/kg/day
48498876|NCT04333108|OTHER|Placebo|Matching placebo
48133722|NCT06375278|DEVICE|Intra-Ear Canal Cooling Catheter|Mild therapeutic hypothermia will be applied via the catheter device installed inside the ear canal by an experienced surgeon during cochlear implantation (CI) surgery.
48133723|NCT02124668|DRUG|Enzalutamide|oral
48498877|NCT04333108|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
48498878|NCT05530343|DIAGNOSTIC_TEST|Seattle protocol|Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
48133726|NCT06523699|DRUG|Recombinant glycosylated human interleukin-7|Provided by RevImmune
48133727|NCT06523699|DRUG|Melphalan|Standard of care
48133728|NCT06523699|PROCEDURE|Autologous hematopoietic cell transplant|Standard of care
48498879|NCT05530343|DIAGNOSTIC_TEST|WATS3D brushings|Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
48498880|NCT01177059|GENETIC|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
48133731|NCT05996627|DRUG|Belumosudil|Given PO
48133732|NCT05996627|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48133733|NCT05996627|OTHER|Electronic Health Record Review|Ancillary study
48133734|NCT05996627|DRUG|Placebo Administration|Given PO
48498881|NCT03547700|DRUG|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
48498882|NCT03547700|DRUG|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
48498883|NCT06367491|OTHER|Registration in a database|All patients with bone metastasis enrolled at the centre will be entered into the database and followed until death or interruption of follow-up for any another cause
48341483|NCT05446922|OTHER|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
48498884|NCT02868918|DRUG|biodentine|tricalcium silicate cement used to replace the carious dentin
48498885|NCT02868918|DRUG|glass ionomer cement|high viscosity glass ionomer used as a base material
48498886|NCT02868918|DEVICE|DigoraH optium|digital Xray for follow up
48133741|NCT03027128|BIOLOGICAL|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
48133742|NCT04314401|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
48133743|NCT04314401|OTHER|Medical Chart Review|Medical charts are reviewed and data is collected
48498887|NCT04098939|DIAGNOSTIC_TEST|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
48133744|NCT06150417|DRUG|Androgen deprivation therapy (ADT)|Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.
48133745|NCT06150417|DRUG|Androgen receptor signaling inhibitor (ARSI)|Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.
48133746|NCT06150417|OTHER|Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)|"Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~* Prostate +/- pelvic nodal radiation~* Radical prostatectomy + pelvic lymph node dissection"
48498888|NCT05920512|DRUG|Sodium valproate extended-release tablets|Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
48498889|NCT03258073|OTHER|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
48133747|NCT06150417|RADIATION|Metastasis directed radiotherapy (MDRT)|In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.
48498890|NCT06152952|PROCEDURE|The rhomboid flap approach|"The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed"
48656836|NCT06639425|DIETARY_SUPPLEMENT|Lactobacillus paracasei LC19 supplementation|Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
48656837|NCT06639425|DIETARY_SUPPLEMENT|Placebo probiotic milk powder|Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
47981373|NCT00686660|BEHAVIORAL|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
47981374|NCT00686660|BEHAVIORAL|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
47981375|NCT00686660|BEHAVIORAL|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
47981376|NCT00686660|BEHAVIORAL|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
48498891|NCT00179816|DRUG|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
48498892|NCT01884311|BIOLOGICAL|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
48498893|NCT01969292|OTHER|Colometer|Real time software based image analysis tool.
47981377|NCT03149185|BEHAVIORAL|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
48002471|NCT02467556|BEHAVIORAL|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
48002472|NCT02467556|OTHER|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
48002473|NCT04939727|OTHER|OUD-CDS + Suicide Risk Model associated CDS|Access to OUD-CDS + Suicide Risk CDS
48498894|NCT01969292|OTHER|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
48498895|NCT05321511|DRUG|Triptorelin acetate (a-GnRH)|Adminsitration of triptoreline acetate 0.2 mg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
48341484|NCT04894357|OTHER|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
48341485|NCT00422669|DEVICE|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
48341486|NCT00422669|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
48341487|NCT02726334|DRUG|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
48498896|NCT05321511|DRUG|Ovitrelle® (hCG)|Adminsitration of coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
48498897|NCT05321511|DRUG|Decapeptyl 0.1 mg® (a-GnRH) and Ovitrelle® (hCG) used together|Adminsitration of triptoreline acetate 0.2 mg and coriogonadotropine alfa 250 mcg for final oocyte maturation in the second ovarian stimuation inthe Double stimulation protocol.
47981378|NCT03149185|BEHAVIORAL|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
47981379|NCT03446183|BEHAVIORAL|Smoking cessation workshops|All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
47981380|NCT02062918|DEVICE|Abdominal belt|
47981381|NCT03622307|DEVICE|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
47981382|NCT03958721|DRUG|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
47981383|NCT03958721|RADIATION|Radiotherapy|Once daily (Monday through Friday) for six weeks
47981384|NCT00939081|BEHAVIORAL|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
47981385|NCT00939081|BEHAVIORAL|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
47981386|NCT03097874|BEHAVIORAL|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
47981387|NCT03097874|BEHAVIORAL|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
47981388|NCT04223570|DEVICE|Portable Apple Smart Phone Protoporphyrin IX Spectrometer Camera|This is a portable device that uses a camera to non-invasively and efficiently measure the level of protoporphyrin IX in various areas skin. This camera will be used in all participants to measure the level of protoporphyrin IX in various areas of skin as detailed in the study description.
47981389|NCT06076161|DIETARY_SUPPLEMENT|Spirulina supplementation and calorie restriction in obese men|The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
47981390|NCT01084174|DRUG|Peanut powder|Delivered orally
47981391|NCT01084174|DRUG|Peanut extract|Delivered sublingually
47981392|NCT01084174|DRUG|Placebo extract|Delivered sublingually
47981393|NCT01084174|DRUG|Placebo powder|Delivered orally
47981394|NCT02701439|DEVICE|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention will be administered to both arms"
47981395|NCT01898728|DRUG|topical povidone-iodine after premedication with topical liquid eye drops|
47981396|NCT01898728|DRUG|topical povidone-iodine after premedication with topical gel|
47981397|NCT04914104|BEHAVIORAL|Mindfulness Training - Headspace App|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
47981398|NCT03209687|DRUG|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
47981399|NCT05678309|OTHER|Blood samples|"At inclusion :~* 52.5 ml of blood :~* 24 ml plasma~* 20 ml serum~* 6 ml DNA~* 2.5 ml RNA"
47981400|NCT05678309|OTHER|skin swab sample|At inclusion a skin swab sample will be collected
47981401|NCT05678309|OTHER|skin biopsy sample|At inclusion a skin biopsy sample will be collected
47981402|NCT05678309|OTHER|Questionnaires|At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
47981403|NCT04960150|DEVICE|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
47981404|NCT04960150|DEVICE|Plesterin|Plesterin
47981405|NCT06192186|DRUG|Adebrelimab combined with SOX regimen|Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
47981406|NCT06192186|DRUG|Placebo combined with SOX (S-1/oxaliplatin) regimen|Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
48498898|NCT02844400|DEVICE|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
48656838|NCT06642077|DRUG|LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml|A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
47981407|NCT01382056|OTHER|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
47981408|NCT01382056|OTHER|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
47981409|NCT01382056|OTHER|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
47981410|NCT04897360|BEHAVIORAL|Increased breathing|hyperventilation to lower ETCO2
47981411|NCT04897360|OTHER|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
47981412|NCT04850807|BEHAVIORAL|Music & Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences at times when behaviors are likely
47981413|NCT00162656|DRUG|half cyclophosphamide|
47981414|NCT00162656|DRUG|without COPADM3|
47981415|NCT00162656|DRUG|mini CYVE, without 3 maintenance courses|
47981416|NCT00162656|DRUG|LMB B|
48133761|NCT06132659|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with the real neurofeedback. Visit 4 will take place one month after visit 3 and will include a follow-up interview with a trainer assessor as well as questionnaires. Additionally, 2 weeks after visit 3 participants will also complete some questionnaires online.
48341488|NCT02726334|DRUG|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days."
48341489|NCT00069017|BIOLOGICAL|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
48341490|NCT00069017|OTHER|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D\&C Yellow #10.
48341491|NCT01499797|OTHER|The CareWell programme|"The CareWell programme contains the following components:~* multidisciplinary primary care teams~* working with proactive care plans integrating cure, care and welfare~* advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~* medication review~* case-management~* guidelines for consultation of in-hospital geriatric experts~* guidelines for transfers from primary care to home-based facilities and hospital and back~* practice guidelines for management of common geriatric conditions"
48341492|NCT05344612|RADIATION|CT Coronary Angiography|Upfront ct-coronary angiography
48341493|NCT02353689|DIETARY_SUPPLEMENT|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
48656839|NCT04344795|DRUG|TPST-1495 twice daily|TPST-1495 administered orally twice daily
48656840|NCT04344795|DRUG|TPST-1495 once daily or on intermittent schedule|TPST-1495 administered orally once daily or on intermittent schedule
47981417|NCT00162656|DRUG|LMB C|
47981418|NCT05819515|PROCEDURE|Tunneled coronally advanced flap|Describes the flap design for both treatment arms
47981419|NCT04006197|OTHER|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
47981420|NCT01692327|DIETARY_SUPPLEMENT|High fat meal|
47981421|NCT04700618|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
47981422|NCT05108831|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
47981423|NCT00469989|PROCEDURE|Infection with hookworm larvae|
47981424|NCT05221814|DIAGNOSTIC_TEST|gross pathologic photo based deep learning model|Whether apply gross pathologic photo based deep learning model to predict pathologic subtype
47981425|NCT02485301|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
47981426|NCT02485301|DRUG|Placebo|A single dose administrated intramuscular
47981427|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
47981428|NCT03138889|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
48002474|NCT02667483|DRUG|DS-5141b|DS-5141b, Subcutaneous injection
48498899|NCT02844400|OTHER|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
47981429|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
47981430|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
48133762|NCT06132659|OTHER|fMRI with Sham-NF|Participants will have 4 visits (some can be done virtually). The baseline visit will include an interview and questionnaires. Eligible participants will have a practice session at visit 2, and may do a mock scanner if the visit is in person. Visit 3 will take place within 5 days of the practice session and participants will be asked to complete questionnaires and have an fMRI with feedback that looks similar to real neurofeedback, but is computer generated. Visit 4 will take place 2 weeks after visit 3 and participants will complete more questionnaires.
48498900|NCT00896909|GENETIC|gene expression analysis|
48498901|NCT00896909|GENETIC|mutation analysis|
48498902|NCT00896909|GENETIC|polymerase chain reaction|
48498903|NCT00896909|OTHER|diagnostic laboratory biomarker analysis|
48498904|NCT00643136|DRUG|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
48656841|NCT04344795|DRUG|Pembrolizumab|Pembrolizumab dosed per label recommendations
48656842|NCT06638905|DRUG|Babor Ultimate ECM Repair Serum|The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
48498905|NCT00643136|DRUG|Placebo|Matching placebo capsules twice daily for 28 days
48498906|NCT05508464|RADIATION|Arm 2: SABR|SABR to all tumors 6 Gy x 5 over three weeks
48498907|NCT05508464|RADIATION|Arm 1: Standard of Care|Standard of care palliative radiotherapy
48656843|NCT06638905|DRUG|Babor Cure Cream|Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
48656844|NCT06055231|BEHAVIORAL|Vape device|Consume THC via vape defice
48656845|NCT06055231|BEHAVIORAL|Joint|Consume THC via joint
48656846|NCT06055231|DRUG|Marijuana via vape device|Given via vape device
48656847|NCT06055231|DRUG|Marijuana via joint|Given via joint
48656848|NCT05213234|BEHAVIORAL|Chronotherapy|Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
47981431|NCT03138889|DRUG|Cisplatin|Cisplatin will be dosed per the pharmacy manual
47981432|NCT03138889|DRUG|Carboplatin|Carboplatin will be dosed per the pharmacy manual
48498908|NCT01038440|DIETARY_SUPPLEMENT|Safflower Oil|One softgel consumed daily with food
48498909|NCT01038440|DIETARY_SUPPLEMENT|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
47981433|NCT03138889|DRUG|Nab paclitaxel|Nab-paclitaxel will be dosed per local practice and label
48498910|NCT01038440|DIETARY_SUPPLEMENT|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
48341494|NCT02353689|DIETARY_SUPPLEMENT|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
47981434|NCT03138889|DRUG|Paclitaxel|Paclitaxel will be dosed per local practice and label
47981435|NCT03138889|DRUG|Pemetrexed|Pemetrexed will be dosed per the pharmacy manual
47981436|NCT03138889|DRUG|Atezolizumab|Atezolizumab will be dosed per current label indication
47981437|NCT00556712|DRUG|erlotinib [Tarceva]|150mg po daily
47981438|NCT00556712|DRUG|Placebo|po daily
47981439|NCT04026867|OTHER|Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
47981440|NCT04026867|OTHER|Clinician Referral|"The Clinician Referral arm will serve as an active control and baseline standard of care."
48002475|NCT02371707|DRUG|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
48498911|NCT04566341|DEVICE|OCT - TCE|Participants will be asked to swallow the TCE. They may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE is past the pharynx. We will advance the TCE until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
48498912|NCT04740814|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study."
48498913|NCT05062902|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
48498914|NCT05062902|DRUG|Botulinum Neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
48656849|NCT05196776|DEVICE|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
48656850|NCT05196776|DEVICE|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
48656851|NCT05359237|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48656852|NCT05359237|DRUG|Vincristine|Given IV per standard of care
48656853|NCT05636176|DRUG|Ziltivekimab|Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
48656854|NCT05636176|DRUG|Placebo|Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
48656855|NCT06645197|DRUG|SNUG01|Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
48498915|NCT05101837|DEVICE|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
48498916|NCT05371860|OTHER|Omit breast radiation|Omit breast radiation for 3 years after surgery
48498917|NCT05937828|OTHER|data collection|description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
48498918|NCT00993837|PROCEDURE|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
48133772|NCT04909619|PROCEDURE|Ultrasound-guided bilateral suprazygomatic maxillary nerve block|The maxillary nerve, V2, is purely a sensory branch of the trigeminal nerve. V2 exits the skull through the foramen rotundum and courses through the pterygopalatine fossa, a small pyramid-shaped depression located posterior to the maxilla. As the maxillary nerve exits the pterygopalatine fossa, it divides into numerous branches that supply sensation to the posterior nasal cavity, palate, sinuses, and maxilla. It is within the pterygopalatine fossa that the maxillary nerve is targeted and anesthetized during the block. With the patient in the supine position after nasotracheal intubation, a needle is inserted perpendicularly between the upper border of the zygomatic arch and posterior orbital rim until it reaches the greater wing of the sphenoid, where the needle is then retracted by a few millimeters and redirected toward the nasolabial fold until it hits the pterygopalatine fossa.
48133773|NCT04909619|PROCEDURE|Local anesthetic infiltration of the palate|Local anesthetic infiltration of the palate during cleft palate repair is universally practiced. The benefits of local anesthetic infiltration are twofold: to provide anesthesia to the terminal branches of the nasopalatine and greater palatine nerves that are in the immediate area of the injection sites and to achieve hemostasis during closure when the medication is mixed with epinephrine. To administer local anesthetic infiltration of the palate, a 25 gauge needle is inserted next to the incision into the soft tissue. The tissue is first aspirated to determine safety of injection at that site. The medication is then injected parallel to the incision on both sides.
48498919|NCT06187558|PROCEDURE|Pelvic and abdominal organ suspension technique|The intervention involves a unique organ suspension technique tailored for minimally invasive gynecologic surgeries. A fragment of a Foley catheter (2 cm of a 1 Fr/Ch) is tied at the end of an absorbable 2-0 Polyglactin suture with a straight needle to create the suspension device. This suture is introduced into the pelvic cavity via an ancillary port. It's designed to penetrate organs such as the ovary, posterior peritoneum, vesico-uterine peritoneum, or bowel. Once the suture is retrieved by passing it through the abdominal wall and pulled so that the Foley segment faces the organ's surface, it's secured using a Kelly clamp. This setup eliminates the need for a knot and offers the surgeon the flexibility to adjust the suspension tension as required.
48498920|NCT04602910|DEVICE|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
48498921|NCT04735757|OTHER|Contrast-enhanced MRI|Contrast-enhanced MRI
48133777|NCT03374254|BIOLOGICAL|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
48133778|NCT03374254|DRUG|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
48133779|NCT03374254|DRUG|Oxaliplatin|85 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m\^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
48133780|NCT03374254|DRUG|Leucovorin|400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
48133781|NCT03374254|DRUG|5-Fluorouracil [5-FU]|2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
48133782|NCT03374254|DRUG|Irinotecan|180 mg/m\^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m\^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
48498922|NCT04735757|OTHER|Measurement of respiratory muscle force|Measurement of the maximum inspiratory and expiratory pressure.
48656856|NCT04893811|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
48133785|NCT04241640|DRUG|Nefopam 20 MG/ML|Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
48133786|NCT04241640|DRUG|Placebo|Placebo
48656857|NCT06640140|BEHAVIORAL|Supervised aerobic plus strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training.
48656858|NCT06055751|DEVICE|TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)|No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
48341495|NCT02353689|DIETARY_SUPPLEMENT|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
48498923|NCT04301908|DRUG|interferon|Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
48341496|NCT03253133|DRUG|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level"
48341497|NCT03253133|DRUG|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
48341498|NCT03253133|DRUG|Oxycodone|Oxycodone
48341499|NCT00044655|DRUG|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
48341500|NCT00044655|DRUG|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
48341501|NCT00044655|DRUG|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
48341502|NCT00044655|DRUG|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
48341503|NCT00044655|DRUG|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
48341504|NCT00741806|BIOLOGICAL|GHB04L1|single dose intranasal administration of GHB04L1
48341505|NCT00741806|OTHER|Placebo|SPGN buffer
48341506|NCT06117904|DRUG|MEBO ointment|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks
48341507|NCT06117904|DRUG|Symptomatic treatment only|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
48341508|NCT03370913|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
48341509|NCT02020291|DRUG|Foxy-5|
48341510|NCT05944913|DEVICE|Prevena|PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
48341511|NCT02260388|DRUG|Nortriptyline|
48341512|NCT02260388|DRUG|Duloxetine|
48341513|NCT02260388|DRUG|Pregabalin|
48341514|NCT02260388|DRUG|Mexiletine|
48341515|NCT04269941|OTHER|total or subtotal gastrectomy|resection of the gastric tumor
48341516|NCT06156449|OTHER|Thyme oil|The composition of NV-2016 Coded Thyme Essential oil (Origanum vulgare) (GC-201900528) was obtained with Nature\&Nurture (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751). Content of origanum vulgare oil used: 1.3% y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2 borneol, 1.2% β-Bisabolene Contains 3.2% tymol and 75.7% carvacrol.
48341517|NCT03871465|DRUG|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
48341518|NCT03871465|PROCEDURE|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
48341519|NCT03871465|DRUG|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
48341520|NCT04424004|OTHER|COVID-19 PCR and serology testing|"1. PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~2. Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
48341521|NCT05324956|OTHER|No intervention|Individuals will not receive any interventions
48341522|NCT00047853|DEVICE|Shock device|A participant could receive a shock or not receive as shock
48341523|NCT00047853|DEVICE|Acoustic startle|Acoustic startle for MEG only
48341524|NCT01531361|DRUG|Crizotinib|Given PO
48341525|NCT01531361|OTHER|Laboratory Biomarker Analysis|Correlative studies
48498924|NCT04141475|DIETARY_SUPPLEMENT|Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
48498925|NCT04141475|DIETARY_SUPPLEMENT|Placebo - Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
48341526|NCT01531361|OTHER|Pharmacological Study|Correlative studies
48341527|NCT01531361|DRUG|Sorafenib Tosylate|Given PO
48341528|NCT01531361|DRUG|Vemurafenib|Given PO
48341529|NCT02939313|DEVICE|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
48341530|NCT02939313|DEVICE|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
48341531|NCT02939313|DEVICE|sham|sham stimulation
48341532|NCT03793634|DRUG|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
48341533|NCT02944669|DEVICE|ReWalk Personal Device|
48341534|NCT02565277|BIOLOGICAL|Influenza Vaccine|
48341535|NCT02565277|DRUG|Placebo|
48341536|NCT00430547|DRUG|Carbimazole, radio-active iodine (I131)|
48341537|NCT02201667|DRUG|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
48498926|NCT02344719|DRUG|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
48498927|NCT02344719|PROCEDURE|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
48498928|NCT02344719|PROCEDURE|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
48656859|NCT06642909|DRUG|Zuberitamab 600mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
48341538|NCT02201667|DRUG|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
48341539|NCT02201667|DRUG|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
48341540|NCT02201667|PROCEDURE|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
48498929|NCT02344719|DRUG|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
48498930|NCT01428050|DRUG|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
48656860|NCT06642909|DRUG|Zuberitamab 1000mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
48656861|NCT06642909|DRUG|cyclosporine|Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
48656862|NCT06557161|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
48656863|NCT06557161|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
48656864|NCT06557161|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
48341541|NCT02593461|DEVICE|Daifert|
48498931|NCT01428050|DRUG|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
48498932|NCT02885597|DRUG|Juanbi pill|4g, twice a day, 3month, oral
48498933|NCT02885597|DRUG|Juanbi pill placebo|4g, twice a day, 3month, oral
48341542|NCT02593461|OTHER|Control Group|
48341543|NCT01794546|BEHAVIORAL|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
48341544|NCT02763241|DRUG|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
48341545|NCT02763241|DRUG|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
48341546|NCT03627000|OTHER|failure after reimplantation|description of cinical and microbiological failure
48341547|NCT03706040|BIOLOGICAL|Placebo|subcutaneous (SC) injection
48341548|NCT03706040|BIOLOGICAL|Risankizumab|subcutaneous (SC) injection
48341549|NCT00056550|BIOLOGICAL|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
48341550|NCT05884268|DRUG|Venlafaxine|Patients scheduled for elective LC will receive 150 mg venlafaxine before surgery
48341551|NCT05884268|DRUG|Placebo|Patients scheduled for elective LC will receive placebo venlafaxine before surgery
48498934|NCT02885597|DRUG|Methotrexate|5mg, once a week, 3 month, oral
48498935|NCT05189886|PROCEDURE|Double Balloon Valvuloplasty in TAVR|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
48498936|NCT06102083|DRUG|TDI01 suspension|"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."
48656865|NCT06608589|OTHER|CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers|COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.
48656866|NCT06160791|DRUG|Ruxolitinib|Administered Orally (PO)
48656867|NCT06160791|DRUG|Etoposide|Administered IV
48656868|NCT06160791|DRUG|Dexamethasone|Administered PO or IV
48656869|NCT06160791|PROCEDURE|Non-interventional Imaging|Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
48656870|NCT06160791|PROCEDURE|Research Biopsy|Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
48498937|NCT02821052|DRUG|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
48498938|NCT01948466|BEHAVIORAL|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
47981441|NCT04348929|OTHER|Self-administered questionnaires|Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
48133789|NCT04574466|BEHAVIORAL|Problem Management Plus|Problem Management Plus (PM+) is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
48133790|NCT05593107|DRUG|[68Ga]N188|68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
48498939|NCT05040438|BIOLOGICAL|Vax-NK/HCC|autologous NK cells expanded ex vivo.
48498940|NCT03163524|OTHER|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
48498941|NCT03163524|OTHER|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
48498942|NCT02929186|BEHAVIORAL|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
48656871|NCT06160791|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48656872|NCT05327647|DRUG|Bicalutamide|Induction intravesical BCG with bicalutamide 150 mg for 90 days
48656873|NCT05327647|BIOLOGICAL|Control Arm|Induction BCG
48656874|NCT02465112|DRUG|In111-Pentetréotide|
48656875|NCT02465112|OTHER|simple monitoring without active therapy|
47981442|NCT00983021|DRUG|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
47981443|NCT00983021|DRUG|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
47981444|NCT00983021|DRUG|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
47981445|NCT00983021|DRUG|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
47981446|NCT00110149|BIOLOGICAL|rituximab|
47981447|NCT00110149|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
47981448|NCT04199572|DRUG|Diclofenac and Paracetamol|analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
47981449|NCT03438175|BEHAVIORAL|Enhanced communication by brochure, website and posters|Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
48656876|NCT05588323|DRUG|Naldemedine|Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
48341552|NCT01136746|DRUG|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
48341553|NCT01136746|DRUG|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
47981450|NCT00989014|DRUG|CD07805/47|0.5% Topical Gel
47981451|NCT00989014|DRUG|CD07805/47|0.18% Topical Gel
47981452|NCT00989014|DRUG|CD07805/47|0.07% Topical Gel
47981453|NCT00989014|DRUG|CD07805/47 placebo|Vehicle Topical Gel
47981454|NCT02561650|DRUG|COV155|COV155 tablets
47981455|NCT01463878|DIETARY_SUPPLEMENT|Glycerna|Diabetes specific formula
47981456|NCT01463878|DIETARY_SUPPLEMENT|Jevity - Control Diet|Control Diet
47981457|NCT04007094|OTHER|ViviGen Cellular Bone Matrix|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
48341554|NCT01136746|DRUG|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
48341555|NCT02635529|PROCEDURE|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
48341556|NCT02635529|PROCEDURE|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
48341557|NCT03814681|OTHER|Colorectal Surgery|elective Colorectal Surgery
48341558|NCT04490304|OTHER|durability of posterior soft tissue repair|how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
48341559|NCT06067724|OTHER|Pelvic and trunk control exercises|Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic and trunk control exercises for 40 min included abdominal drawing in maneuver for contraction of transversus abdominis pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included; anterior, posterior, lateral pelvic tilting and pelvic rotation on a therapeutic ball. Pelvic stabilization exercises include bridging, half bridging, clamshell from supine and side lying, quadribed exercises, weight shifting on the affected limb from standing by forward and diagonal reach out, ball bridging and rhythmic stabilization exercises
47981458|NCT00426491|DRUG|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
47981459|NCT05087784|COMBINATION_PRODUCT|Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps|Patient-centered, technology-supported integrated survivorship- and care management
48341560|NCT06304857|DRUG|Dapagliflozin|10 mg tablet q.d
48498943|NCT02929186|BEHAVIORAL|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
47981460|NCT01288469|DRUG|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
47981461|NCT01288469|DRUG|Placebo (for alirocumab)|One SC injection in the abdomen only.
47981462|NCT01288469|DRUG|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
47981463|NCT01288469|DRUG|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
47981464|NCT04447261|DRUG|BI 1356225|BI 1356225
47981465|NCT04447261|DRUG|Placebo|Placebo
47981466|NCT03453944|DEVICE|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
47981467|NCT03453944|DEVICE|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
47981468|NCT06061965|BEHAVIORAL|Web-based resilience-building intervention|There are 6 modules on the website. Participants will be encouraged to verbalize their impressions of the website prototype.
47981469|NCT04140799|DEVICE|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
48341561|NCT06304857|DRUG|Placebo|tablet matching dapagliflozin 10 mg q.d
48341562|NCT03882723|DEVICE|Evaluated 4 masks used for NIV with mechanical ventilators|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
48341563|NCT02025049|DRUG|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
48341564|NCT02025049|DRUG|Placebo|mannitol-based DP-b99 look-alike
48341565|NCT04268303|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Sublingual film containing dexmedetomidine (BXCL501)
48498944|NCT00278252|DRUG|etoposide|
48498945|NCT00278252|PROCEDURE|conventional surgery|
48498946|NCT00707382|GENETIC|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
48498947|NCT00707382|OTHER|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
48133797|NCT03422549|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both CPAP and NHFOV support.
48133798|NCT06132113|DRUG|BI 764532|BI 764532
48133799|NCT06132113|DRUG|Carboplatin|Standard of care
48133800|NCT06132113|DRUG|Etoposide|Standard of care
48133801|NCT06132113|DRUG|Cisplatin|Standard of care
48133802|NCT04856085|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
48133803|NCT04856085|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
48133804|NCT04856085|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
48498948|NCT00707382|OTHER|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
48498949|NCT05103566|DEVICE|gammaCore|Participants will receive two 2-minute non-invasive stimulations to the cervical branch of the vagus nerve (nVNS) three times daily with gammaCore, an FDA cleared device for the acute treatment and prevention of migraine and cluster headache. Intervention will begin within 72 hours post-rupture and end at 10 days post-rupture or discharge, whichever occurs first. The dosing regimen is supported by preclinical models and clinical data.
48133806|NCT00071799|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
48341566|NCT04268303|DRUG|Placebo Film|Placebo Film for BXCL501
48341567|NCT04645576|DEVICE|Face correction with injectable fillers|Injection of hyaluronic acid-based fillers
48341568|NCT06449989|DIAGNOSTIC_TEST|Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI|"For molecular genetic research, archival formalin-fixed and paraffin-embedded tumor blocks will be used. Research method - HRM-PCR sequencing to determine mutation status of KRAS, NRAS and BRAF (RotorGene 6000, ABI Prism 3500) and fragmentation analysis to determine MSI (ABI Prism 3500) Subject to study: mutations in the KRAS, NRAS, BRAF genes, as well as MSI status and HER2neu expression (± amplification) Somatic mutations in the RAS family genes are planned to be studied in exons 2 (codons 12 and 13), exon 3 (codon 61) and exon 4 (codon 146). In the case of the BRAF gene - exon 15 (codons 597-601). Determination of microsatellite instability is planned using five markers: BAT25, BAT26, NR21, NR24, NR27, associated with structural and functional disorders of the DNA unpaired base repair system.~Assessment of HER2 gene status is planned by immunohistochemical (IHC) screening of HER2neu expression. IHC-screening of HER2-status will be performed using an antibody clone 4B5 (Ventana)."
48341569|NCT00741104|DRUG|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
48656877|NCT06069713|BEHAVIORAL|CBD advertisements|Participants will view the 5 images of CBD advertisements in their assigned panel and answer questions about their perceptions of the advertisement.
48656878|NCT04868357|BEHAVIORAL|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
48002476|NCT02371707|DRUG|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
48133807|NCT00071799|OTHER|Physician Choice|"Physician Choice was one of three options:~* Best supportive care (BSC) alone,~* Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~* Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care"
48498950|NCT01248689|OTHER|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
48498951|NCT01248689|OTHER|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
48498952|NCT01248689|OTHER|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
48498953|NCT00498901|DRUG|goserelin|
48341570|NCT03338036|DEVICE|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
48341571|NCT03338036|DEVICE|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
48498954|NCT00498901|DRUG|letrozole|
48498955|NCT00498901|DRUG|leuprolide acetate|
48498956|NCT00498901|PROCEDURE|conventional surgery|
48498957|NCT01288053|BIOLOGICAL|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
48133814|NCT06164704|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])
48133815|NCT06164704|DRUG|Placebo|Verekitug (UPB-101) matching placebo
48498958|NCT05737316|BEHAVIORAL|Combat PD|CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
48133817|NCT05396638|BEHAVIORAL|Contingency Management|Participants will be paid for abstinence at each study visit.
48133818|NCT06350097|DRUG|Osimertinib|"Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet ."
48133819|NCT06350097|DRUG|Datopotamab Deruxtecan|Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
48133820|NCT06131372|DRUG|Cagrilintide|Participants will receive Cagrilintide subcutaneously.
48133821|NCT06131372|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
48133822|NCT06131372|DRUG|Placebo|Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
48341572|NCT01054612|OTHER|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
48341573|NCT04537572|DIAGNOSTIC_TEST|comparison of sample collection methods|Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
47981470|NCT02543645|DRUG|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
47981471|NCT03153254|DEVICE|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
47981472|NCT03153254|DEVICE|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
47981473|NCT00951990|BEHAVIORAL|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
47981474|NCT00951990|BEHAVIORAL|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
47981475|NCT02018588|DIETARY_SUPPLEMENT|tryptophan|graded levels of tryptophan will be given to each subject
47981476|NCT02642952|OTHER|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
47981477|NCT04211051|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
47981478|NCT01094223|BEHAVIORAL|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
48133824|NCT05611346|BEHAVIORAL|Hypnosis|"The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording"
48341574|NCT01038089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
48341575|NCT00826384|PROCEDURE|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
48341576|NCT05007340|OTHER|Blood draws|Blood draws will be performed by personnel that are both qualified and authorized by their employer/institution to perform the procedures. The procedures will be performed with standards expected in the context of clinical care. 40 mL (2-3 tbsp) of blood will be drawn in order to collect DNA, RNA, serum and PBMCs. Blood tubes will be sent to the Bank as per the SOP for patient blood sampling and processing. The blood will be processed, centrifuged and stored by a trained laboratory technician.
47981479|NCT01094223|BEHAVIORAL|Health Education|Psychoeducation group focused on various topics pertaining to physical health
47981480|NCT01949051|DRUG|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
47981481|NCT01949051|DRUG|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
47981482|NCT01941901|DRUG|Calcium electroporation|Intratumoral injection, once only treatment.
47981483|NCT01941901|DRUG|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
47981484|NCT03061838|DRUG|MabThera®|1000 mg intravenously
47981485|NCT03061838|DRUG|Ritumax®|1000 mg intravenously
47981486|NCT00941473|DRUG|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
47981487|NCT03266107|DEVICE|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
48133825|NCT06518486|OTHER|Foot-ankle exercise|Foot-ankle exercise group will receive usual care provide by public health center and intervention through health education, leaflets, and videos about foot-ankle exercise. At the first meeting, participants will be taught how to do foot exercises and practice them in front of the instructor. Afterwards, participants will practice foot exercises independently without supervision for 12 weeks. One foot exercise session takes 10-15 minutes, while the physical activity target is for participants to fulfil a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do foot exercises for 2-3 sessions every day. The minimum duration of each session is 10 minutes, and two consecutive days without foot exercise are not allowed. Participants are asked to document all foot exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for a minimum of 5 minutes
48341577|NCT05007340|OTHER|Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid)|If the patient's medical care or their participation in a research project involves a biopsy or surgery to remove tissue, the tissue not required for diagnosis (excess tissue) or hospital archives will be included in the biobank. This may include healthy tissue as well as tissue affected by the patient's health condition. The Investigators will not conduct extra procedures in order to obtain samples for the sole purpose of this study and will only operate on what's available. These may include blood samples, skin, lung and muscle biopsies, and bronchoalveolar lavage, all of which will be obtained from the pathology department.
48341578|NCT05007340|OTHER|Clinical data collection|Participant's relevant medical information from medical records, general health questionnaires and clinical assessments. The data includes gender, date of birth, race/ethnicity, habits, height, weight, vital signs, medical history, family history, pregnancy history, imaging data pertinent to ILDs and SARDs, results of routine blood tests, environmental exposures, medication and treatment exposures and adherence, function and quality of life, patient's assessment of their own health, clinical symptoms.
48498959|NCT05737316|BEHAVIORAL|Usual Care|Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
48498960|NCT03237949|BEHAVIORAL|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
48498961|NCT03237949|BEHAVIORAL|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
48656879|NCT04868357|BEHAVIORAL|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
48656880|NCT05487391|DRUG|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
48656881|NCT05487391|DRUG|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
48656882|NCT05487391|DRUG|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
47981488|NCT05810623|DRUG|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
48133826|NCT06518486|OTHER|Walking exercise|Participants in the walking exercise group will receive usual care provide by public health center and intervention through health education and leaflets about walking exercise. Participants will practice walking exercises independently without supervision for 12 weeks. Participants walked at the same speed as they did every day. The physical activity target to be achieved is for participants to be able to engage in a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do walking exercises with a minimum duration of 10 minutes for each session. Two consecutive days without walking exercise are not allowed, and a minimum of 150 minutes/week is allowed. Participants are asked to document all walking exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for a minimum of 5 minutes.
48133827|NCT06518486|OTHER|Usual care and health education|Participants in the control group will receive the usual care provided by the community health center and intervention in the form of health education about DM in general.
48498962|NCT03525925|DRUG|Ibrutinib|Given PO
48498963|NCT03525925|OTHER|Laboratory Biomarker Analysis|Correlative studies
48498964|NCT03525925|BIOLOGICAL|Nivolumab|Given IV
48498965|NCT00006199|DRUG|R115777 (farnesyl transferase inhibitor)|
48498966|NCT00006199|DRUG|Topotecan|
48498967|NCT03340363|BEHAVIORAL|environmental change|"1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store."
48656883|NCT05487391|DRUG|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
48656884|NCT05487391|DRUG|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
48656885|NCT05487391|DRUG|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
48656886|NCT05487391|DRUG|Placebo|Placebo
48656887|NCT04905407|DRUG|Tamibarotene|Tamibarotene tablets will be administered per dose and schedule specified in the arm.
48656888|NCT04905407|DRUG|Venetoclax|Venetoclax tablets will be administered per dose and schedule specified in the arm.
47981489|NCT00233103|DRUG|Sertraline|Sertraline arm
47981490|NCT00233103|DRUG|Placebo|Placebo
47981491|NCT00592839|DRUG|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
47981492|NCT00592839|DRUG|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
47981493|NCT04334161|COMBINATION_PRODUCT|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
48498968|NCT03340363|BEHAVIORAL|messaging|Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
48498969|NCT00688376|DRUG|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
48498970|NCT00688376|DRUG|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
47981494|NCT04690751|DRUG|Cenobamate 200Mg Tab Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
47981495|NCT04690751|DRUG|Cenobamate Oral Suspension Fed|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
47981496|NCT04690751|DRUG|Cenobomate Oral Suspension Fasted|Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
48133833|NCT06334666|OTHER|Encourage using pedometer|MASLD patient used pedometer recording actively with encourage by care provider or investigator
48133834|NCT05319587|DRUG|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
48133835|NCT05319587|DRUG|Cytarabine|Administered during cycle 1 at a dose of 2.0 g/m2/day by 4 hours IV infusion for 5 consecutive days and this dose will remain constant for all cohorts, including the expansion phase.
48133836|NCT04192773|DRUG|IV Lidocaine|IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
48133837|NCT06699329|DRUG|Enlicitide Decanoate|multiple doses, oral tablet
48133838|NCT06699329|DRUG|Semaglutide|multiple doses, oral tablet
48498971|NCT04376762|DRUG|Fibrinogen|Fibrinogen Concentrate (Human) Injection \[Fibryga\] (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
48498972|NCT04376762|DRUG|Cryoprecipitate|Cryoprecipitate group (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).
48498973|NCT03911050|DIETARY_SUPPLEMENT|Apple consumption|Apple blends (600 g) One single dose
48498974|NCT03911050|DIETARY_SUPPLEMENT|Control group|Breakfast without any apple-related products
48498975|NCT02906566|DRUG|Retinol|Retinol in the form of vitamin A lotion
48498976|NCT02906566|DRUG|Placebo|Placebo of Retinol
48498977|NCT00229983|BEHAVIORAL|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
48498978|NCT03101982|DRUG|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
48498979|NCT00899990|OTHER|Laboratory Biomarker Analysis|Correlative studies
48498980|NCT05571865|DIETARY_SUPPLEMENT|Probiotic|Oral administration of a probiotic
48341579|NCT05007340|OTHER|Genetic data/DNA/RNA|Results of the DNA or RNA sequencing, conducted for the Biobank and will be made available to future research; possible single nucleotide polymorphism (SNP) assays (including single SNP, low-plex or microarray-based assays).
48341580|NCT05859906|OTHER|mechanical power measurement|"Mechanical power values of the patients;~* Before insufflation (baseline value),~* 0 min after insufflation,~* 15th min after insufflation,~* 30 minutes after insufflation,~* 45th minute after insufflation (if insufflation continues),~* 60th minute after insufflation (if insufflation continues),~* Intraoperative after insufflation It will be measured with the following formula in the specified periods. MP = 0.098 x minute ventilation x \[Peak inspiratory pressure - 0.5 x (Plateau pressure - Positive end-expiratory pressure)\]"
47981497|NCT04626297|DRUG|Lebrikizumab|Given SC
47981498|NCT04626297|DRUG|Placebo|Given SC
48498981|NCT05199519|DRUG|IBI345|IBI345 CAR-T cell injection by intravenous infusion
48498982|NCT04407611|BEHAVIORAL|Online modality|Return of BRCA results directly online or return of printed BRCA results if participant cannot access online or chooses not to
48498983|NCT04407611|BEHAVIORAL|Genetic counselor follow-up|Optional genetic counselor follow-up over the telephone
47981499|NCT01941641|DRUG|neoadjuvant FOLFOXIRI|
47981500|NCT01941641|DRUG|Capecitabine|
47981501|NCT00875251|DEVICE|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
47981502|NCT04080297|DRUG|oral capsule of Q-122|
47981503|NCT05859789|PROCEDURE|kegel exercise|"* Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
48513299|NCT03281395|PROCEDURE|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
48513300|NCT03281395|PROCEDURE|No rapid ventricular pacing|
48341581|NCT05287204|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
48498984|NCT03544710|OTHER|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
48498985|NCT05234593|DIETARY_SUPPLEMENT|EmpowerPlus Lightning Sticks|multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue
48498986|NCT00893737|DRUG|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
48498987|NCT01819974|OTHER|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
48656889|NCT04905407|DRUG|Azacitidine|Azacitidine injection will be administered per dose and schedule specified in the arm.
48656890|NCT06377319|DIAGNOSTIC_TEST|Cardiac Output Response to Stress (CORS) test|Cardiac Output Response to Stress (CORS) is a novel, non-invasive, easy-to-use test developed by the Newcastle and Coventry Universities. CORS test measures heart function (cardiac output) at rest and in response to short step-exercise using validated electrical signal processing bioreactance technology, similar to an ECG.
48341582|NCT05287204|DIAGNOSTIC_TEST|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
48341583|NCT05287204|DIAGNOSTIC_TEST|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
48341584|NCT05076097|DRUG|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
48341585|NCT01983618|PROCEDURE|Interscalene nerve block and catheter|
48341586|NCT01983618|PROCEDURE|Interscalene catheter|
48341587|NCT02226419|DIETARY_SUPPLEMENT|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
48341588|NCT00305734|DRUG|bortezomib|Given IV
48656891|NCT02764138|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
48656892|NCT02652052|OTHER|Standard of Care - Observation Only|Control Arm - Observation only
48656893|NCT02652052|DRUG|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
48656894|NCT02652052|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
48656895|NCT06636981|DRUG|Cohort2: ATRA+Toripalimab+TPC|Receive 200 mg D1 of Toripalimab via intravenous infusion for a course of 21 days; TPC regimen (monoclonal antibody 10mg/kg D1, 8 intravenous infusions, 1 course of treatment every 21 days; Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Utideron 40mg/m2 D1-5 intravenous infusions, 1 course of treatment every 21 days; Gemcitabine 1000mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days; Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days); Capecitabine 1000mg/m2, D1-14, oral, one course of treatment every 21 days); All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.
48656896|NCT06636981|DRUG|Cohort1: ATRA+Toripalimab+chemo|Receive 200 mg of Toripalimab via D1 intravenous infusion, with 21 days as one course of treatment; Albumin paclitaxel 100 mg/m2, D1, D8, intravenous infusion, one course of treatment for 21 days; All trans retinoic acid 20 mg bid, oral, D-3-D11, continuous administration for 14 days, cessation for 7 days, 21 days is one course of treatment.
48656897|NCT05765175|DEVICE|Varian Cardiac Radioablation (CRA)|Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
48656898|NCT05765175|PROCEDURE|Catheter Ablation (CA)|Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
48656899|NCT04634435|COMBINATION_PRODUCT|BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2|Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2
48656900|NCT03966313|DEVICE|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~* After anesthetic induction~* Before starting the device~* 2h, 6h and 48h after starting the device"
48656901|NCT04134936|DRUG|Tafasitamab|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
48656902|NCT04134936|DRUG|Tafasitamab plus lenalidomide|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
48656903|NCT04278924|DRUG|Placebo|TAK-079 placebo-matching SC injection.
48656904|NCT04278924|DRUG|TAK-079|TAK-079 SC injection.
48133859|NCT06424340|BIOLOGICAL|MB-dNPM1-TCR.1|T Cell Receptor (TCR) T cell therapy
48341589|NCT00305734|DRUG|gemcitabine hydrochloride|Given IV
48341590|NCT00305734|OTHER|laboratory biomarker analysis|Correlative studies
48341591|NCT03942146|BEHAVIORAL|Information on smoking cessation|Smoking cessation is recommended 6 weeks before and after surgery
48341592|NCT02731976|OTHER|Dietary intervention|
48341593|NCT02329145|PROCEDURE|renal denervation|
47981504|NCT05859789|OTHER|Mediterranean diet regimen for 12 weeks.|kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
47981505|NCT00471744|DRUG|Treatment with levetiracetam or sulthiame over a six-month period.|
48341594|NCT04242459|RADIATION|Adaptive Radiotherapy|Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
48341595|NCT00278551|BIOLOGICAL|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
48341596|NCT00253929|DRUG|Intra-arterial infusion of adenosine|
48498988|NCT02118090|DRUG|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
48513301|NCT04226521|PROCEDURE|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
48656905|NCT06293183|OTHER|Mobile app|Participants in the intervention group will be expected to watch the training video in the mobile application installed on their phones or tablets and then regularly enter all the food and liquid amounts they consume during the day into this application. In the mobile application data entry area, visuals that will be included in the application showing the amount and types of foods consumed by the participants during the day (1 soup bowl, 1 vegetable dish plate, 1 meat dish plate, 1 water glass, 1 tea glass, tablespoon, dessert spoon, teaspoon, ladle). etc.) will choose through. The mobile application will calculate the total amount of liquid consumed by the participants in 24 hours, and will give a yellow warning when the amount of liquid consumed is 2-2.5 liters, an orange warning when it is 2.5-3 liters, and a red warning when it is 3 liters and above. This will contribute to reducing the amount of fluid intake of participants between two dialysis sessions.
48656906|NCT06632873|DRUG|177Lu-TATE-RGD|accepted intravenous injection of 177Lu-TATE-RGD
48656907|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
48656908|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
48656909|NCT02458729|DRUG|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
48656910|NCT02458729|DRUG|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
48656911|NCT02458729|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
48656912|NCT06638450|PROCEDURE|Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA)|"DCEAS+BA will be conducted for 2 sessions per week for 8 weeks.~For DCEAS, 6 pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). For body acupuncture, the following acupoints are used: Shenmen (HT7). Neiguan (PC6), Zhongwan (CV12), Guanyuan (CV4), Zusanli (ST36), Sanyinjiao (SP6), and Taichong (LV3).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is conducted to evoke a needling sensation. After that, electrical stimulation is delivered on DCEAS, with continuous waves at 2 Hz through an electrical acupuncture stimulation instrument (Hwarto, SDZ-II). The stimulation lasts 30 minutes."
47981506|NCT00005622|DRUG|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
47981507|NCT00005622|RADIATION|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
47981508|NCT05044598|OTHER|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
48341597|NCT00253929|DRUG|intra-arterial infusion of caffeine|
48341598|NCT00253929|DRUG|intra-arterial infusion of acetylcholine|
48341599|NCT00253929|DRUG|intra-arterial infusion of sodium nitroprusside|
48513302|NCT04258462|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
48341600|NCT00253929|PROCEDURE|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
48341601|NCT04677049|DRUG|Niacin CRT|A controlled release technology (CRT) tablet of Niacin
48341602|NCT00399867|DRUG|Simvastatin|
48341603|NCT01368952|DEVICE|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
48341604|NCT02599857|DEVICE|CONCOR smartphone application|
48341605|NCT00502619|PROCEDURE|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
48341606|NCT00502619|OTHER|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
48341607|NCT01689324|BIOLOGICAL|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
48341608|NCT02451488|DRUG|GM-CSF|14 days in a dose of 125 µg/m\^2
48341609|NCT02451488|OTHER|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
48513303|NCT04258462|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48513304|NCT04258462|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
48341610|NCT04511936|DEVICE|i-Lumen AMD|Microcurrent stimulator
48341611|NCT04511936|DEVICE|i-Lumen AMD Sham|Sham microcurrent stimulator
48341612|NCT04602819|DEVICE|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
48498989|NCT02118090|DRUG|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
47981509|NCT05998785|DEVICE|TAPESTRY Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
47981510|NCT01051024|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
48341613|NCT04602819|DEVICE|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
48341614|NCT04602819|DEVICE|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
48341615|NCT04602819|DEVICE|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
48341616|NCT01170949|DRUG|Miltefosine|50 or 100 or 150mg per day
48341617|NCT01170949|DRUG|Placebo|Placebo
47981511|NCT01051024|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
47981512|NCT03484481|DIETARY_SUPPLEMENT|Oral Nutritional Support; Nutrena|Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
47981513|NCT03484481|DIETARY_SUPPLEMENT|Intradialytic Parenteral Nutrition; Kabiven central|Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
47981514|NCT03414424|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
47981515|NCT03414424|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
47981516|NCT03585504|DRUG|Etonogestrel contraceptive implant|Etonogestrel contraceptive implant
47981517|NCT02835508|DRUG|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
47981518|NCT02835508|DRUG|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
47981519|NCT02835508|DRUG|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
47981520|NCT04878588|OTHER|patients received high resolution impedance manometry|patients received the above two examination at the same time
47981521|NCT01114321|BEHAVIORAL|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
47981522|NCT04638023|DEVICE|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
47981523|NCT00003623|DIETARY_SUPPLEMENT|multivitamin|
47981524|NCT00003623|OTHER|Placebo|
47981525|NCT05790629|PROCEDURE|endo-sequence putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
47981526|NCT05790629|PROCEDURE|neo-MTA putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
47981527|NCT03404557|OTHER|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
47981528|NCT05122273|DEVICE|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
47981529|NCT04043091|PROCEDURE|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
47981530|NCT03927664|OTHER|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
48498990|NCT02928367|OTHER|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
48498991|NCT02928367|OTHER|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
48498992|NCT02928367|OTHER|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
48498993|NCT00296634|DRUG|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
48341618|NCT02353338|PROCEDURE|Surgical intervention|Surgical management of radial fracture
48341619|NCT02353338|PROCEDURE|Conservative management|Immobilized/cast for 6 weeks
48341620|NCT02353338|DEVICE|cast|
48341621|NCT04774952|DRUG|RMC-5552|RMC-5552 for IV administration
48341622|NCT00131170|PROCEDURE|paravertebral block|
48341623|NCT01688999|DRUG|Cabozantinib|60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
48341624|NCT00379886|DRUG|Propofol Thiopental|
48341625|NCT04246346|OTHER|An interactive chatbot for patient decision aid|A chatbot embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
48341626|NCT04246346|OTHER|Senior ophthalmologists|Senior ophthalmologists would communicate with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
48341627|NCT03309904|OTHER|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
48341628|NCT04163367|BEHAVIORAL|Safer Kids|A behaviorally based parent training program with the purpose to reduce or prevent child abuse.
48341629|NCT04163367|OTHER|Intervention as usual (IAU)|Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
48341630|NCT03254940|BEHAVIORAL|Charge|Text messaging-based study to determine effect of different components on weight loss.
48341631|NCT06245681|DRUG|gender affirming hormone therapy|both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
48341632|NCT01989871|BEHAVIORAL|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
48341633|NCT05229640|DEVICE|Fibroscan|Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.
48341634|NCT01408134|OTHER|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
48341635|NCT06239324|DRUG|Latanoprost|Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
48341636|NCT03599544|BEHAVIORAL|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
48656913|NCT06638450|PROCEDURE|Minimal Acupuncture Stimulation (MAS)|"MAS will be conducted for 2 sessions per week for 8 weeks.~The following 6 acupoints are used: bilateral Tongtian (BL07), bilateral Shousanli (LI10) and bilateral Fuyang (BL59). Electrical stimulation will be only performed on bilateral Tongtian (BL07)."
48656914|NCT01189851|DEVICE|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
48656915|NCT03452202|DEVICE|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
48656916|NCT03452202|DEVICE|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
48656917|NCT06645275|GENETIC|POCT test|Patients undergo POCT testing on the day of warfarin administration, and based on the POCT results, the initial and maintenance doses of warfarin are determined according to the IWPC algorithm.
48656918|NCT06641635|COMBINATION_PRODUCT|Moderated hypofractionated online adaptive radiotherapy|"Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy~Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
48656919|NCT06641635|COMBINATION_PRODUCT|Conventional radiotherapy|"Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy~Contral group: 45Gy/25F EBRT + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
48656920|NCT06396741|OTHER|The quadriceps muscle will be punctured with ultrasound control|With the subject in the supine position, the quadriceps muscle will be shown by ultrasound. Subsequently, a dry needling technique will be performed at the most hyperalgesic point using ultrasound control.
48656921|NCT06638216|OTHER|Geriatric Assessment|"Frailty is assessed using the G8 questionnaire.~Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected."
48341637|NCT03599544|BEHAVIORAL|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
48656922|NCT04912518|DRUG|Dexmedetomidine (DEX)|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
48656923|NCT04912518|DRUG|Placebo (Saline)|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
48656924|NCT00582296|BEHAVIORAL|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
48341638|NCT05338658|DRUG|Peptide Alarm Therapy (PAT)|PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
48341639|NCT00261794|BEHAVIORAL|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
48341640|NCT00261794|BEHAVIORAL|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
48341641|NCT04544124|BEHAVIORAL|Contingency management|Incentives will be provided for treatment attendance over a 12-week period.
48341642|NCT02549521|DIETARY_SUPPLEMENT|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
48341643|NCT02549521|DIETARY_SUPPLEMENT|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
48341644|NCT02025530|OTHER|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
48341645|NCT01102140|DRUG|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
48341646|NCT01102140|DRUG|Sugar Pill|Matching sugar pill
48341647|NCT03736668|DIAGNOSTIC_TEST|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
48341648|NCT04154397|DEVICE|cerebellar transcranial stimulation|Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
48341649|NCT05333640|DEVICE|Sirolimus Drug Coated Balloon|AVFs treated with SDCB
48341650|NCT05333640|DEVICE|Paclitaxel Drug Coated Balloon|AVFs treated with PDCB
48341651|NCT04569617|OTHER|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
48341652|NCT04569617|OTHER|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
48341653|NCT04569617|OTHER|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
48341654|NCT04569617|OTHER|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
48341655|NCT04442386|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
48341656|NCT05730127|OTHER|Conditioning stimulus|Pain stimulus on non-dominant side
48341657|NCT06236763|DEVICE|TOFscan foot|TOFscan will be applied on the foot and recovery from neuromuscular blockade will be observed over time. These will be compared with the control (TOFscan at the hand) on the same patient (gold standard monitor).
48341658|NCT01351389|BEHAVIORAL|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
48341659|NCT01351389|BEHAVIORAL|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
48341660|NCT05634876|BIOLOGICAL|UB-312 Injection|UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.
48498994|NCT00296634|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
48498995|NCT06170437|BEHAVIORAL|Smoke-free home resident intervention|Study staff delivered intervention on how to adopt a smoke free home using a pamphlet
48513305|NCT05453097|DIAGNOSTIC_TEST|Selvester QRS Score with Preoperative ECG|Selvester QRS score will be calculated with the preoperative ECG of the patients.
48133860|NCT06098118|BEHAVIORAL|MyMammogram decision aid|An online breast cancer screening decision aid that includes personalized risk assessment, information on benefits and risks of mammography screening, values clarification, outcome expectancies, and a summative document with participant responses.
48341661|NCT05634876|BIOLOGICAL|Placebo Injection|Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.
48341662|NCT03135639|OTHER|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
48341663|NCT03135639|OTHER|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
48341664|NCT00086294|DRUG|Intravenous Levodopa|
48341665|NCT00086294|DRUG|ACP-103|
48341666|NCT01927068|DEVICE|"Stellarex 0.035 Over-the-Wire (OTW) drug-coated angioplasty balloon (Stellarex DCB)"|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
48341669|NCT05540210|DEVICE|measurement of PSP|one or two blood samples
48341670|NCT01503892|DIETARY_SUPPLEMENT|Metanx|Metanx- one tablet twice daily for twelve months
48341671|NCT01503892|DRUG|Placebo|Placebo- one tablet twice daily for twelve months.
48341672|NCT04165304|DIETARY_SUPPLEMENT|sugar reduction|sugar reduction in the offered drinks
48341673|NCT04804904|DRUG|TQ-B3101|TQ-B3101 oral capsule
48498996|NCT06170437|BEHAVIORAL|Lay Health Worker coaching|Brief tobacco cessation coaching by lay health worker housing staff with residents within 2 weeks of the smoke-free home resident intervention, and on a monthly schedule as part of their routine encounters with residents (total 6 sessions).
48498997|NCT00317252|DRUG|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
48498998|NCT02524730|DEVICE|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
48498999|NCT01770392|DRUG|Nintedanib|single dose administration
48499000|NCT01770392|DRUG|Rifampicin|single dose once daily for 7 days
48656925|NCT00582296|BEHAVIORAL|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
48133861|NCT06240741|DRUG|[68Ga]Ga-DOTA-TATE|Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1).
48133862|NCT06240741|DRUG|68Ge/68Ga Generator|Radionuclide generator
48133863|NCT05940298|DRUG|Intravenous injection of [99mTc]Tc-DB8|One single intravenous injection of \[99mTc\]Tc-DB8, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
48133864|NCT06699472|DRUG|Chemotherapy|Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
48341674|NCT01607073|DRUG|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
48341675|NCT01506219|PROCEDURE|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
48341676|NCT03820908|DRUG|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
48499001|NCT01770392|DRUG|Nintedanib|single dose administration
48499002|NCT03682458|GENETIC|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
47981531|NCT03038334|DIETARY_SUPPLEMENT|Magnesium sulfate|Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
47981532|NCT01879150|DEVICE|Cyclaplex bone anchor|Device implantation
48341677|NCT03150199|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
48341678|NCT03150199|BEHAVIORAL|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
48341679|NCT05148117|DIAGNOSTIC_TEST|Suspected Sepsis Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
48341680|NCT05148117|DIAGNOSTIC_TEST|Control Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
48341681|NCT02396693|DEVICE|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) \< 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) \< 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
48341682|NCT02396693|DEVICE|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
48341683|NCT02396693|DEVICE|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
48341684|NCT02915289|PROCEDURE|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
48341685|NCT02915289|PROCEDURE|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
48341686|NCT03933280|DRUG|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
48341687|NCT03933280|DRUG|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
48341688|NCT03933280|DRUG|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
48341689|NCT03933280|DRUG|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
48341690|NCT02019745|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
48341691|NCT00111436|DRUG|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
48341692|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1|"25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator."
48499003|NCT04846036|DRUG|Sonlicromanol|Oral administration of sonlicromanol twice daily
48499004|NCT04846036|DRUG|Placebo|Oral administration of matching placebo twice daily
48499005|NCT01546376|RADIATION|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
48499006|NCT01546376|OTHER|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
48133865|NCT06699472|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
48656926|NCT00189137|DRUG|ifosfamide and doxorubicin vs gemcitabine and docetaxel|"Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection."
48341693|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2|"12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator."
48499007|NCT02513511|PROCEDURE|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
48341694|NCT04565236|BIOLOGICAL|Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3|"15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator."
48341695|NCT05702736|BEHAVIORAL|logotherapy-based intervention|Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
48341696|NCT02469727|BEHAVIORAL|Fitbit|Participants will use the FitBit device to track their physical activity
48341697|NCT02469727|BEHAVIORAL|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
48341698|NCT03123484|DRUG|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
48341699|NCT03123484|DRUG|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
48341700|NCT01455506|DRUG|Decitabine plus Fludarabine and Busulfan|"* Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient \>20% above ideal body weight~* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~* Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
48341701|NCT05702372|OTHER|Glucose as reference food|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48341702|NCT05702372|OTHER|Cracker made by wheat flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48341703|NCT05702372|OTHER|Cracker made by rye flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48341704|NCT05702372|OTHER|Cracker made by sunflower flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48341705|NCT05956262|DEVICE|AR-toothbrush machine|Student in AR group received a two-time repeated AR-based training for 30 minutes at two-week intervals. The AR-based training system (PVIX Oral, EPED) digitized the steps of the toothbrushing technique applying optical tracking technology to enable the participants to obtain immediate scoring after the completion of practice. The scoring depends on the level of removing simulated dental plaque. The AR system was equipped with an optical tracking unit, a 3D training head model, and a wireless toothbrush. The toothbrushing practice time for the upper and lower jaw is 3 minutes, respectively. A tooth-brushing song played while the students implemented.
48656927|NCT00443014|DEVICE|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
48656928|NCT04289493|OTHER|Language and functional communication therapy|17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
47981533|NCT05931159|OTHER|Abdominal Hypopressive Training|"Week 1 and 2 - Patient education , Hypopressive Maneuvers in Standing, Sitting and Supine 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week.~Week 3 and 4, Hypopressive breathing in with varying arm movements along with Week 1 and 2 protocols.~Week 5 to 8 - Hypopressive breathing in kneeling, Four-point kneeling and sitting, and supine positions with varying arm movements 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week."
47981534|NCT05931159|OTHER|Conventional Physical therapy for DrA|"Week 1 to 4, Draw-in maneuver in supine, Quadruped and Prone lying, Bent knee Fallouts and Curl ups. (8 to 12 repetitions x 3 sets, 2 days/week)~Week 5 to 8, Front and side planks added to week 1 to 4 exercises. (12 to 20 repetitions x e sets, 2 days/week)"
47981535|NCT02060149|DRUG|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
48341706|NCT05956262|BEHAVIORAL|Teach proper brushing skills|Students in the traditional group received a two-time repeated 10-minute lesson regarding proper toothbrushing skills in the classroom at two-week intervals. The students were taught by a well-trained dental hygienist using teaching aids (such as dental models, and toothbrushes).
48341707|NCT00338260|DRUG|MK0954, /Duration of Treatment : 5 Years|
48341708|NCT00338260|DRUG|Comparator : atenolol /Duration of Treatment : 5 Years|
48341709|NCT00178698|OTHER|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
48341710|NCT00178698|DRUG|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
48341711|NCT00178698|OTHER|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
48341712|NCT02311790|DIETARY_SUPPLEMENT|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
48341713|NCT02311790|DIETARY_SUPPLEMENT|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
48341714|NCT01210755|DRUG|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
48341715|NCT01210755|DRUG|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
47981536|NCT02060149|DRUG|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
48499008|NCT01796613|DEVICE|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
48656929|NCT06534775|OTHER|Questionnary|"The patients were included in a previous study (PABLOS) - These patients received locoregional anesthesia (LRA) by deep parasternal intercostal block (Deep-PIP) or bilateral superficial parasternal intercostal block (Superficial-PIP), compared with standard management (general anesthesia without LRA) for chronic postoperative pain after cardiac surgery by sternotomy.~In PABLOS 2.0 study, the evaluation focuses on the presence of chronic pain between 12 and 24 months postoperatively. There is no intervention in PABLOS 2.0 study but only a questionnary."
48656930|NCT05607576|OTHER|Uncovered CGM during radiologic procedures|Dexcom G6 CGM will not be covered during radiologic procedures.
48133868|NCT03582085|BIOLOGICAL|Bacillus Calmette Guerin Vaccine|Experimental
48341716|NCT04880681|DEVICE|Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator.|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
48341717|NCT04880681|DEVICE|Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000)|Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient.
48656931|NCT06643676|PROCEDURE|Targeted Endodontic Microsurgery Using 3d Printed surgical guide using the patient's CBCT data|Patients with apical periodontitis with intact cortex in madibular molars receiving Targeted Endodontic surgery or Guided Endodontic Microsurgery with surgical guide fabricated using the cbct data following failure of non surgical root canal treatment
48656932|NCT06643676|PROCEDURE|Conventional Endodontic Microsurgery with a free hand procedure using bur and CBCT analysis|A conventional endodontic microsurgery using arbitrary localisation technique using the cbct data and performing the surgery with a carbide bur.
48656933|NCT03113929|RADIATION|MRI|Research MRI
48656934|NCT05368883|OTHER|Exercise- One-Legged|The exercise program consisted of a 5-minute warm-up, followed by 10 minutes of cycling for each leg during the first 2 weeks, increasing to 15 minutes for each leg in the subsequent weeks (with a 5-10 minute rest period between switching legs), and concluded with a 5-minute cool-down period. During the exercise, the inactive leg was kept stationary and in contact with the ground . In the one-legged cycling exercise training, whether patients started with the dominant or non-dominant leg was determined randomly
48656935|NCT05368883|OTHER|Exercise-Two-Legged|The exercise program consisted of a 5-minute warm-up, followed by 20 minutes of cycling during the first 2 weeks, increasing to 30 minutes in the subsequent weeks, and concluded with a 5-minute cool-down period.
47981537|NCT02060149|DRUG|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
48341718|NCT04098263|BIOLOGICAL|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
48341719|NCT01498588|DRUG|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
48341720|NCT01498588|DRUG|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
48341721|NCT01498588|DRUG|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
48341722|NCT01498588|DRUG|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
47981538|NCT02060149|DRUG|No nebulization|No nebulization will be given to the patients.
47981539|NCT00791167|DRUG|Paliperidone ER|
47981540|NCT04918264|DRUG|Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
48133869|NCT03582085|BIOLOGICAL|Saline Injection|Placebo
48341723|NCT04758741|BEHAVIORAL|Acceptance and Commitment Therapy|Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence
48341724|NCT04758741|OTHER|placebo|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
48341725|NCT01526317|DRUG|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
48341726|NCT04930952|DRUG|Ethanol-amine Oleate Sclerotherapy Injection|Intralesional Sclerotherapy Injection
48341727|NCT01785498|BEHAVIORAL|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
48341728|NCT05527106|DIETARY_SUPPLEMENT|Citicoline|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 (362 mg of citicoline per day), every day, for 3 months.
48341729|NCT05527106|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 3 pills of Brudypio 1.5g (1050 mg of DHA per day), every day, for 3 months.
48341730|NCT05527106|DIETARY_SUPPLEMENT|Citicoline and Docosahexaenoic Acid (DHA)|Every subject randomized into this group have to take 2 sachets of Cebrolux 800 and 3 pills of Brudypio 1.5g per day, every day, for 3 months.
48341731|NCT05527106|DIETARY_SUPPLEMENT|Vitamin C|Every subject randomized into this group have to take 1 pills of Vitamin C (500 mg per day), every day, for 3 months.
48341732|NCT04846972|BEHAVIORAL|FASTRACS intervention|"Intervention (4 steps) :~* Penultimate to last chemotherapy : patient will receive tools of the intervention~* 1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~* 2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~* 5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
48341733|NCT02944734|DRUG|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
48341734|NCT02944734|DRUG|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
48341735|NCT02944734|DRUG|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
48341736|NCT02944734|DRUG|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
48341737|NCT04359121|OTHER|Questionnaires for specific phobia|Questionnaires will be used.
48341738|NCT04834752|OTHER|No intervention (Retrospective Cohort Observational)|History of PPI and H2RA prescription of the participants who were tested for COVID-19 will be reviewed.
48341739|NCT02866461|OTHER|No treatment|Observation
48341740|NCT03702855|DRUG|Tetrabenazine Tablets 25 mg|
48341741|NCT04685538|DRUG|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
48341742|NCT04685538|DRUG|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
48341743|NCT01107704|BEHAVIORAL|Family Support Intervention|Multifaceted family support intervention
48341744|NCT01412151|DRUG|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
48341745|NCT01576666|DRUG|LDE225|
48341746|NCT01576666|DRUG|BKM120|
48341747|NCT03304262|DEVICE|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
48341748|NCT00931294|BEHAVIORAL|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
48341749|NCT00931294|BEHAVIORAL|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
48341750|NCT05370846|OTHER|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
48341751|NCT01319513|OTHER|whey protein bolus|single dose of 25 g whey protein
48499009|NCT01796613|DEVICE|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
48341752|NCT01319513|OTHER|whey protein pulses|10 2.5 g pulses of whey protein
48341753|NCT01902693|OTHER|No intervention for this study|No intervention
48341754|NCT02792660|DEVICE|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
48341755|NCT00334204|DEVICE|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
48341756|NCT02455362|DRUG|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
47981541|NCT04918264|OTHER|Uracil dosage|For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.
48341757|NCT02455362|DRUG|Placebo|
48341758|NCT00049972|DRUG|paroxetine CR|
48341759|NCT06322017|PROCEDURE|Rhythm control by Pulmonary Vein Isolation (PVI) procedure|"The PVI procedure involves the creation of a circumferential lesion around the ostium of the four pulmonary veins.~The choice of the type of energy to insure the lesion will be left to the discretion of the investigator, according to the center's habits and the patient's anatomy found on the scanner."
48341760|NCT06322017|DRUG|Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)|"Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations."
48341761|NCT03655769|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
48341762|NCT03655769|DEVICE|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
48341763|NCT03250624|DRUG|CD5024 0.3% cream|Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
48341764|NCT03250624|DRUG|Placebo|Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
48341765|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)"
48341766|NCT01379560|DRUG|unoprostone isopropyl|"1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)"
48341767|NCT03662555|DEVICE|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
47981542|NCT04918264|BEHAVIORAL|Overall survival|For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil \<16 vs Uracil ≥16).
48133870|NCT04274530|BEHAVIORAL|Cognitive Behavioural Therapy|Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.
48341768|NCT01421069|DRUG|etanercept|"Subjects aged \<18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or \>62 kg will receive etanercept SC at a dose of 50 mg QW."
48341769|NCT05226143|OTHER|Gel Cream|Gel Cream
48341770|NCT02122055|DRUG|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
48341771|NCT02122055|PROCEDURE|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
48341772|NCT02122055|PROCEDURE|Screen of weaning|1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
47981543|NCT04528849|DRUG|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
47981544|NCT03336333|DRUG|Zanubrutinib|Administered as two 80-milligram (mg) capsules by mouth twice a day (160 mg twice a day)
47981545|NCT03336333|DRUG|Bendamustine|Administered intravenously (IV) at a dose of 90 mg/m\^2/day on the first 2 days of each cycle for 6 cycles.
47981546|NCT03336333|DRUG|Rituximab|Administered intravenously (IV) at a dose of 375 mg/m\^2 on day 0 of cycle 1, and at a dose of 500 mg/m\^2 on day 1 of cycles 2 to 6
47981547|NCT03336333|DRUG|Venetoclax|400 mg tablets administered orally once daily.
47981548|NCT01800240|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
47981549|NCT05273138|OTHER|Blood sampling and skin biopsy|Blood sampling and skin biopsy
48499010|NCT01700036|DRUG|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
48499011|NCT00706511|DEVICE|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
48656936|NCT02946697|BEHAVIORAL|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
48499012|NCT01489631|DRUG|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
48133871|NCT05620979|BEHAVIORAL|Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.|Providing financial navigation to blood cancer survivors.
48341773|NCT02122055|DRUG|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
48499013|NCT01489631|DRUG|marcaine|bupivacaine 0,125%
48499014|NCT01489631|DRUG|sufentanil|sufentanil 1mcg/ml
48133874|NCT03520660|DRUG|Epclusa|sofosbuvir/velapatasvir combination (Epclusa)
48341774|NCT02122055|DRUG|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
48341775|NCT02122055|DRUG|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
48341776|NCT05534152|OTHER|sumac|1% iranian brown sumac
48341777|NCT01372644|DRUG|SOM 230 / Pasireotide|
48341778|NCT05299138|BEHAVIORAL|Marriage and Relationship Enhancement Skills (MRES) Intervention|The Intervention group will be assigned a Case Manager and placed in the next available Marriage and Relationship Enhancement Skills (MRES) class that is convenient for their schedule. Intervention participants will attend classes weekly and meet with their Case Manager weekly, bi-weekly, or monthly, as needed. Study measures will be gathered from intervention participants at baseline, 10 weeks after baseline, and then 22 weeks after baseline. The following tools will be utilized at baseline and follow-up assessment: (1) REACH program eligibility screening (only conducted at baseline), (2) Information, Family Outcomes, Reporting, and Management (nFORM) system, (3) Family Environment Scale (FES), (4) Revised Dyadic Adjustment Scale (RDAS), and (5) Economic Self-Sufficiency Scale (ESS).
48341779|NCT04509401|DRUG|Vitamin B 6 with Magnesium|Patients of intervention group will receive high dose of vitamin B6 with magnesium. This group will receive high dose of vitamin B6 with magnesium orally for 12 weeks.
48341780|NCT04509401|DRUG|placebo of vitamin B6 and magnesium|Patients of control group will receive oral placebo tablet in the same manner, schedule for 12 weeks.
48341781|NCT04503850|DRUG|Mirabegron 50 MG|Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
48341782|NCT04503850|DRUG|Alpha Blockers|Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
48341783|NCT00241449|DRUG|Fulvestrant|intramuscular injection 250 mg
48341784|NCT00241449|DRUG|Tamoxifen|20 mg oral tablet
48341785|NCT03944304|DRUG|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
48341786|NCT01502670|DRUG|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
48341787|NCT04530968|OTHER|No intervention|No intervention
48499015|NCT01489631|DRUG|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
48656937|NCT03275987|BEHAVIORAL|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
48133875|NCT01371994|DRUG|solifenacin succinate|oral
48133876|NCT01371994|DRUG|Placebo|oral
48499016|NCT03641521|BEHAVIORAL|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
48341788|NCT05425303|DIAGNOSTIC_TEST|Exposure to risk for injury|Athletes will be examined in the preseason stage and will be monitored during the competitive season.
48341789|NCT05376956|DIAGNOSTIC_TEST|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
48341790|NCT05376956|DIAGNOSTIC_TEST|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
48656938|NCT03275987|BEHAVIORAL|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
48656939|NCT03275987|BEHAVIORAL|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
48656940|NCT05927298|OTHER|Non-interventional|Standard of care intervention
48656941|NCT01448642|DRUG|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
48656942|NCT01448642|DRUG|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
48499017|NCT05979649|BEHAVIORAL|behavioral corrective tasks|"After each personalized conversation, the interveners will, based on a clear understanding of the participants' completion status and personal experiences with the previous behavioral corrective tasks, assist in formulating future behavioral corrective tasks for the next two weeks. These tasks will be selected from our designated To Do List, requiring at least one task from each category: social support, coping strategies, and emotional intelligence."
48499018|NCT05979649|OTHER|Counselling on psychological knowledge|Counselling on psychological knowledge includes weekly personalized feeds, as well as the methods and techniques for coping with challenges provided by the interveners.during personalized conversations with the participants.
48499019|NCT05979649|OTHER|placebo-controlled study|"feel-good articles without professional psychological knowledge will be sent to the control group participants weekly."
48499020|NCT05979649|OTHER|Peer Interventionist Training|The training is a one-day course, encompassing a broad range of topics, including but not limited to counseling techniques and specialized medical psychology knowledge.
47981550|NCT05639374|BEHAVIORAL|BASICS_HealthyClassroom|First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
48499021|NCT04948060|OTHER|Enhanced lung cancer screening services|A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
48499022|NCT01250197|DRUG|AR-12286|Ophthalmic Solution
48499023|NCT06429579|PROCEDURE|Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy|Potts-shunt procedure is the surgery that connect the descending aorta and the left/main pulmonary artery by direct anastomosis, a Gore-tex tube or a Gore-tex tube with flap.
48499024|NCT06429579|DRUG|Only conventional drug therapy|Only conventional drug therapy (i.e., Prostacyclin analogues, PDE-5 inhibitors, and Endothelin receptor antagonists)
48499025|NCT04422353|OTHER|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
48499026|NCT04422353|OTHER|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
48341791|NCT06076005|OTHER|Advanced lung cancer patients' group|Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
48341792|NCT00084604|DRUG|irinotecan hydrochloride|Given IV
48656943|NCT06493253|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite
48341793|NCT00084604|BIOLOGICAL|bevacizumab|Given IV
48341794|NCT00084604|DRUG|cisplatin|Given IV
47981551|NCT01389544|DRUG|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
47981552|NCT01389544|DRUG|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
48499027|NCT04758975|DRUG|Venetoclax|VENETOCLAX: Ramp-up than 400 mg QD
48499028|NCT04758975|DRUG|Rituximab|RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
48499029|NCT04758975|DRUG|Ibrutinib|IBRUTINIB 420 mg QD
48499030|NCT04719520|BEHAVIORAL|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
48499031|NCT00191113|DRUG|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
47981553|NCT01389544|DRUG|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
48499032|NCT00191113|DRUG|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
48499033|NCT00191113|DRUG|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
48499034|NCT04167293|RADIATION|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
48499035|NCT04167293|DRUG|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
48133891|NCT06698367|OTHER|Standard rehabilitation|Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.
48341795|NCT00084604|PROCEDURE|computed tomography|Correlative studies
48341796|NCT00084604|OTHER|laboratory biomarker analysis|Correlative studies
48341797|NCT02323399|DRUG|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
48341798|NCT04382677|BEHAVIORAL|Promoting First Relationships ®|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 12 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
48133892|NCT06698367|OTHER|Unilateral high-intensity strength exercise|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an eccentric exercise for the pronosupinator muscles with a dumbbell with adjustable weights. The training will start with an intensity of 60% of 1RM, until reaching 80% 1RM.
48133893|NCT06698367|OTHER|Unilateral mobility exercises|Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an active mobility exercise for the pronation-supination muscles using a plastic rod.
48341799|NCT04382677|OTHER|Resource & Referral|This condition consists of 1) Resource \& Referral assistance provided over the phone, and 2) Local Services Resource Packet. Throughout the intervention period, the provider makes monthly phone calls to offer further support to families, answer questions, and provide additional resources. The provider has at least four interactions with each family served. In addition, families in this condition have the Resource and Referral Specialist's phone number and they can call if an additional need arises. The resource packet includes local information organized by type of need or resource. These packets are updated regularly as services change over time.
48341800|NCT04430790|DRUG|Doxapram|Loading dose and continuous doxapram infusion.
48341801|NCT04430790|DRUG|Placebo|Loading dose and continuous placebo infusion.
48341802|NCT00334698|DRUG|Cetirizine|
48341803|NCT00334698|DRUG|Pseudoephedrine|
48341804|NCT00334698|DRUG|Cetirizine with Pseudoephedrine|
48341805|NCT04488757|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
48341806|NCT04488757|OTHER|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
48341807|NCT05903378|OTHER|Relational touch practice|Relational touch practice during the first bedside session. Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
48341808|NCT01351857|OTHER|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
48341809|NCT04556201|DEVICE|SOLTIVE™ Premium SuperPulsed Laser Fiber System|SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
48341810|NCT01522768|DRUG|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
48341811|NCT04597515|PROCEDURE|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
48341812|NCT01646567|DRUG|SHP-141C|Topical Cream
48341813|NCT01646567|DRUG|Placebo to SHP-141C|Placebo Topical Cream
48341814|NCT01646567|DRUG|Betamethasone Valerate|Topical cream, 0.02%
48341815|NCT01646567|DRUG|Calcipotriol|Topical cream, 0.005%
48341816|NCT04437316|DEVICE|Use of Low level Laser after wisdom tooth removal|Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
48499036|NCT03140852|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
48499037|NCT00004089|BIOLOGICAL|filgrastim|
48499038|NCT00004089|DRUG|fluorouracil|
48499039|NCT00004089|DRUG|hydroxyurea|
48499040|NCT00004089|DRUG|paclitaxel|
47981554|NCT04969120|DRUG|Metoclopramide 10mg|this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
47981555|NCT04969120|DRUG|Placebo (0.9 sodium chloride)|this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
48341817|NCT00440141|DRUG|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
48341818|NCT00440141|DRUG|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
48341819|NCT05154565|BEHAVIORAL|Guided meditation|App-based guided meditation intervention through Headspace. This can be accessed through various mobile devices.
48341820|NCT03148795|DRUG|Talazoparib|1 mg daily
48341821|NCT02262676|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
48341822|NCT01135745|DEVICE|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
48499041|NCT00004089|PROCEDURE|conventional surgery|
48499042|NCT00004089|RADIATION|radiation therapy|
48499043|NCT00420459|DRUG|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
48499044|NCT02460367|DRUG|Docetaxel|
48499045|NCT02460367|BIOLOGICAL|Tergenpumatucel-L|
48341823|NCT00251277|DRUG|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
47981556|NCT03020680|DIETARY_SUPPLEMENT|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
47981557|NCT00075140|GENETIC|Mutation in the gene|
48656944|NCT06636942|DEVICE|Intermittent pneumatic compression|Following a soccer match, athletes will be enrolled in a recovery treatment: placebo intervention or intermittent pneumatic compression. Participants will be randomly assigned to each group. Neuromuscular tests (cmj) and perceptual questionnaires (hooper index) will be conducted.
48656945|NCT06616610|BEHAVIORAL|Intervention with the Mobility Platform|The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.
47981558|NCT00388271|DRUG|Alfuzosin (Xatral)|standard treatment plus alfuzosin
48341824|NCT05070741|BEHAVIORAL|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
48341825|NCT01090674|OTHER|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
48341826|NCT00087386|DRUG|tanespimycin|Given IV
48341827|NCT00087386|OTHER|laboratory biomarker analysis|Correlative studies
48656946|NCT06616610|BEHAVIORAL|Intervention with Traditional Therapy|The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
48656947|NCT05627921|DEVICE|Extracorporeal Shock Wave Therapy|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.
47981559|NCT00388271|DRUG|standard treatment|standard treatment
48341828|NCT04309357|DRUG|Alteplase|Alteplase in dose 0.9 mg/kg in acute ischemic patient with indications of thrombolytic therapy
48341829|NCT02244229|DRUG|Tamsulosin|
48341830|NCT02244229|DRUG|Finasteride|
48341831|NCT02244229|DRUG|Placebo|
48341832|NCT00587444|DRUG|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is\>480 seconds
48341833|NCT00587444|DRUG|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is \<600 seconds anytime during CPB
48341834|NCT00587444|DRUG|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
48341835|NCT02920229|DRUG|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
47981560|NCT02533427|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily
48499046|NCT02460367|DRUG|Indoximod|
47981561|NCT02533427|DRUG|VOX|100 mg tablet administered orally once daily
47981562|NCT02533427|DRUG|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
47981563|NCT00551733|DRUG|carboplatin|Given IV
47981564|NCT00551733|DRUG|paclitaxel|Given IV
47981565|NCT00551733|DRUG|paclitaxel poliglumex|Given IV
47981566|NCT04889469|PROCEDURE|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
47981567|NCT01120912|DRUG|Oshadi Oral Insulin|Oral insulin single administration
47981568|NCT03467841|DEVICE|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
47981569|NCT00210041|DRUG|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
47981570|NCT00210041|DRUG|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
47981571|NCT04566224|DEVICE|Macintosh size 2 blade|intubate with Macintosh size 2 blade
47981572|NCT04566224|DEVICE|Macintosh size 3 blade|intubate with Macintosh size 3 blade
47981573|NCT01487226|DRUG|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks \* 6 cycles
47981574|NCT01487226|DRUG|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks \* 6 cycles"
48499047|NCT03663439|PROCEDURE|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
48499048|NCT02149108|DRUG|Nintedanib (BIBF 1120)|
48499049|NCT02149108|DRUG|Placebo|
48341836|NCT01619813|DRUG|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
48341837|NCT01619813|DRUG|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
48499050|NCT02149108|DRUG|BSC|
48499051|NCT02149108|DRUG|BSC|
48499052|NCT06142123|OTHER|3-D Ankle Mobility Exercises(A)|"The techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~1. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the prone position according to the resistance of therapist.~2. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the prone position according to the resistance of therapist.~3. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the crook-lying position according to the resistance of therapist.~4. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the crook-lying position according to the resistance of therapist."
48499053|NCT06142123|OTHER|Eccentric Heel Drop Training(B)|": Group B will be treated with Eccentric Heel Drop Training. It will comprise of following exercises (14).~1. Eccentric loading exercises of calf muscles.~2. Conventional physiotherapy treatment including Ultrasound Plantar fascia stretching Calf muscle stretching Intrinsic muscles strengthening"
48499054|NCT01777360|DEVICE|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
48499055|NCT04384744|DRUG|growth hormone|growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
48499056|NCT02834650|OTHER|Cardiac MRI with contrast|Cardiac MRI
48341838|NCT03582969|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
48341839|NCT03582969|OTHER|Placebo|Placebo capsules
48499057|NCT02834650|OTHER|Cardiac MRI without contrast|Cardiac MRI
48499058|NCT02834650|OTHER|Blood Test|Hematocrit, Creatinine, Troponin, BNP
48499059|NCT02834650|OTHER|Heart Rate|Holter Monitor
48499060|NCT02834650|OTHER|Pulmonary Function Test|Pulmonary Function Test
48499061|NCT02834650|OTHER|Genetic Testing|Genetic Testing
48499062|NCT02834650|OTHER|Repeat MRI scan|Repeat MRI scan
48656948|NCT05627921|DRUG|Botilinum Toxin injection|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.
48656949|NCT06073067|RADIATION|GRID therapy|GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
48656950|NCT04908046|DRUG|HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .|"Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
48341840|NCT03382197|DEVICE|Nebulization|For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
48499063|NCT04030065|DRUG|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
48499064|NCT05748249|DRUG|Vertistop® D|Vitamin D supplementation
48341841|NCT03382197|DEVICE|Positive expiratory pressure valve|For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
48499065|NCT00144664|DRUG|MRA(Tocilizumab)|
48499066|NCT02065700|DRUG|Filgotinib|Administered as Oral Tablets
48499067|NCT05137470|OTHER|This is an observational study|This is an observational study
48499068|NCT04959318|OTHER|Professional nutrition counseling|Published multi-cohort genome-wide association studies provided genes and genetic variants that are credibly associated with aspects of metabolic syndrome (MetS), CVD, overweight/obesity, and vitamin D metabolism. Registered dietitian (RD) counseling will review potentially harmful and protective variants for risk of MetS with subjects and make evidence-based recommendations to improve diet quality and achieve weight loss goals. Each of the 6 weekly sessions covered a specific component of MetS. Counseling will take place once a week either in-person or via phone/virtual platform based on preference and availability of the subject. Counselors will review digital app data entries for food intake prior to this interaction for the first 2 weeks.
48656951|NCT05704088|DRUG|Dapagliflozin tablet|randomized control trial, study group will receive dapagliflozin tablets
48656952|NCT05704088|DRUG|placebo|randomized control trial, control group will receive placebo tablets
48656953|NCT06640426|BEHAVIORAL|Two Messaging Nudges|This intervention involves receiving one personalized email and one personalized text message, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
48499069|NCT04959318|OTHER|No professional nutrition counseling|Participants receive pamphlets with evidence-based general health, healthy nutrition, exercise and sleep content. They receive information on genetic variants related to MetS at end of study period.
48341842|NCT03382197|DEVICE|Nonivasive ventilation|For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
48341843|NCT03457636|DRUG|Doxycycline Anhydrous 40 MG|One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
48341844|NCT03457636|DRUG|Adapalene/Benzoyl Peroxide Gel 0.3-2.5%|Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
48341845|NCT02348294|OTHER|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
48341846|NCT00899600|DRUG|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
48341847|NCT00899600|OTHER|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
48341848|NCT00352066|DRUG|apricitabine|
48341849|NCT04749160|DEVICE|Connected device|Connected device is a smart watch (with accelerometer without location data).
48341850|NCT03486561|DRUG|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
48341851|NCT01463124|BEHAVIORAL|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
48341852|NCT01463124|BEHAVIORAL|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
48341853|NCT05619003|DEVICE|Biatain Silicone Sacral dressing|Biatain Silicone Sacral will be applied over the bony prominence of the sacral area
48341854|NCT04078074|DEVICE|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
48656954|NCT06640426|BEHAVIORAL|Five messaging nudges|This intervention involves patients receiving up to five personalized email and text messages, which include the provider's name, the patient's name, and a phone number to schedule an Annual Wellness Visit
48499070|NCT00140218|DRUG|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
48499071|NCT00566566|OTHER|sample without DNA|family history, anthropometric measurements and blood sampling
48499072|NCT02264288|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
48656955|NCT04212923|BEHAVIORAL|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
48656956|NCT00240019|DRUG|Addition of furosemide 20 mg oral bid to baseline regimen|
48656957|NCT03738228|DRUG|Atezolizumab|Given IV
48656958|NCT03738228|RADIATION|Brachytherapy|Undergo standard of care image guided brachytherapy
48656959|NCT03738228|DRUG|Cisplatin|Given IV
48656960|NCT03738228|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
48656961|NCT06541678|DRUG|Danuglipron|MR Tablet
48499073|NCT02264288|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
48499074|NCT02264288|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
48499075|NCT02264288|OTHER|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
48499076|NCT00001365|DRUG|dextromethorphan|
48499077|NCT02908035|DRUG|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
48656962|NCT06541678|DRUG|Cyclosporine|Capsule
48656963|NCT06541678|DRUG|Itraconazole|Oral solution
48656964|NCT05263167|DRUG|Sodium Aescinate|sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
48656965|NCT05263167|DRUG|Placebo|250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
48499078|NCT02908035|DRUG|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
47981575|NCT04891783|DEVICE|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
47981576|NCT03879122|DRUG|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
47981577|NCT03879122|DRUG|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
48341855|NCT04078074|DEVICE|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
48341856|NCT04078074|DEVICE|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
48341857|NCT01896414|DIETARY_SUPPLEMENT|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
48341858|NCT01896414|DIETARY_SUPPLEMENT|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
48656966|NCT06644339|DEVICE|Voice assistant|"Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease.~Follow-up and management of disease provided by specialists at participating institutions."
48656967|NCT06411938|OTHER|Self-collection of vaginal swabs|Women will collect vaginal swabs for HPV testing, then undergo standard of care screening for cervical cancer
48656968|NCT05198934|DRUG|Sotorasib|Sotorasib will be administered orally
48656969|NCT05198934|DRUG|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
48656970|NCT05198934|DRUG|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
48656971|NCT05198934|DRUG|Regorafenib|Regorafenib will be administered orally
48341859|NCT06350357|OTHER|punching closure|The hole clamping and the grooves hold the metal clips better
48341860|NCT06350357|OTHER|Conventional clipping|Metal lip closure is one of the most commonly used closure methods
48341861|NCT02733471|DRUG|Lidocaine|
48341862|NCT02733471|DRUG|Placebo|Placebo
48341863|NCT00763178|DRUG|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
48656972|NCT06569472|BIOLOGICAL|CD19-targetd CAR-T|Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
48656973|NCT06644066|PROCEDURE|Partial pressure of Oxygen Control method|During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
48341864|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area
48341865|NCT05015322|DRUG|bupivacaine and methylprednisolone|5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint
48341866|NCT05015322|DRUG|bupivacaine and methylprednisolone|suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
48367443|NCT01454895|BEHAVIORAL|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
48656974|NCT02376010|DRUG|rivaroxaban|
48656975|NCT02376010|DRUG|Warfarin|
48656976|NCT05966714|DEVICE|NIRS|cerebral oxygenation and electrical activity monitoring
48656977|NCT05966714|DEVICE|aEEG|amplitude-integrated electroencephalography
48656978|NCT05574270|DEVICE|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
48656979|NCT06498648|DRUG|Abemaciclib|Given PO
48656980|NCT06498648|PROCEDURE|Biopsy|Undergo tumor biopsy
48656981|NCT06498648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48656982|NCT06498648|DRUG|Docetaxel|Given IV
48499079|NCT05808218|OTHER|Community-Led Total Sanitation|"The community-led total sanitation intervention is implemented across an entire Traditional Authority and includes the following village-level activities:~1. Triggering:~   * Village transect walks and open defecation site mapping~  * Demonstrations of food contamination and medical expense calculations~2. Development of a Community-Action Plan and identification of natural leaders~3. Post-triggering: routine follow-up by selected natural leaders to track and monitor progress against the Community Action Plan~In addition to the activities above, the WASH for Everyone team will:~* Train a cadre of local masons on sanitation construction~* Support the District Health office in the implementation of existing sanitation and hygiene promotion at village markets and other public spaces"
48499080|NCT05808218|OTHER|Care Groups|"* Orientation and training of village-level Care Group members on CLTS, latrine construction, and hygiene promotion~* Routine house-to-house follow-up of Care Group members to provide peer-to-peer counselling and support on sanitation and hygiene behaviours."
48341867|NCT04363944|DEVICE|mRehab|mRehab (mobile Rehab) was created to better support in-home upper limb rehabilitation programs. It incorporates a task-oriented approach and immediate performance-based feedback. mRehab consists of 3D-printed household items (a mug, bowl, key, and doorknob) integrated with a smartphone and an app. The app guides participants through practice of activities of daily living (ADL), for example, sipping from a mug. It can also consistently measure time to complete an activity and quality of movement (smoothness/accuracy) during the performance of ADLs. In each session of exercise participants receive feedback on the number of repetitions they complete for each activity, the average time to complete the activity and the average smoothness to perform the activity. Participants were trained in use of mRehab in lab visits and then took mRehab home to use the system. mRehab recorded longitudinal data.
48341868|NCT03157843|DRUG|low-molecular-weight heparin|
48341869|NCT02302755|DRUG|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
48341870|NCT03039569|BEHAVIORAL|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
48133896|NCT06700252|OTHER|Vestibular Rehabilitation|This intervention used gaze stabilization, habituation, balance training and exertional training. Exercises utilized included visual tracking, gaze holding with head turns, saccades, visual accommodation exercises, visual convergence exercises, positional accommodation, rockerboard proprioception, single leg balance on the floor and on dynamic surfaces, tandem balance on the floor and on dynamic surfaces, double leg balance on dynamic surfaces, mirror feedback of functional activities, and physical exertion training with walking, biking or sport specific activities.
48133897|NCT06700252|OTHER|Traditional Protocol|This intervention symptom management and graduated return to physical activity involving a stepwise progression in which the participant proceeded to the next step if symptom-free at the current step for a 24-hour period. If any symptoms occurred at that step, the participant was returned to the previous step and tried to progress again after 24 hours of rest. The steps were as follows: 1) Patient to return to regular activities such as school 2) Light aerobic activity to increase the patient's heart rate achieved with 5 to 10 minutes on a stationary bike or walking but without weightlifting 3) Moderate activity which increased the heart rate with head or body movement that may have included sport specific exercise with minimal-moderate resistance 4) Heavy, non-contact activity in three planes of movement 5) Full contact practice 6) Competition
48133898|NCT06698354|DEVICE|Virtual Reality-Assisted Hypnotherapy|Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic low back pain.
48341871|NCT00510367|DRUG|5-Fluorouracil|500 mg/m\^2 By Vein Daily x 2 Days
48341872|NCT00510367|DRUG|Cyclophosphamide|500 mg/m\^2 By Vein On Day 1
47981578|NCT03879122|DRUG|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
47981579|NCT03879122|DRUG|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
47981580|NCT00099346|DRUG|MK0457, VX-680 (Aurora Kinase Inhibitor)|
47981581|NCT06337331|DRUG|Venetoclax|400mg/day PO Days -8 to -2
47981582|NCT06337331|DRUG|Decitabine|20mg/m2/day IV Days -7 to -3
47981583|NCT06337331|DRUG|Fludarabine|30mg/m2/day IV Days -7 to -3
47981584|NCT06337331|DRUG|Busulfan|3.2mg/kg/day IV Days -5 to -4
47981585|NCT06337331|RADIATION|Total Body Irradiation|200cGy Day -2
47981586|NCT04399577|BIOLOGICAL|Candida antigen|Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
47981587|NCT01096524|OTHER|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
47981588|NCT01096524|DEVICE|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
48341873|NCT00510367|DRUG|Doxorubicin|50 mg/m\^2 By Vein Over 72 Hours
48341874|NCT00014586|DRUG|bicalutamide|
48341875|NCT00014586|DRUG|goserelin acetate|
48341876|NCT00014586|PROCEDURE|orchiectomy|
48133899|NCT06698354|OTHER|Standard Physical Therapy|Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
48133900|NCT06698575|DRUG|ABI-1179|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
48341877|NCT02584023|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
48341878|NCT05141357|DRUG|HBI-8000 in combination with pembrolizumab|Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
48341879|NCT05837507|OTHER|Telerehabilitation solution (m-Rehab)|"Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.~All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist."
48341880|NCT05837507|OTHER|Usual management including NIV.|Usual management including NIV.
48341881|NCT05021380|OTHER|GROUP|Non-invasive diagnosis of dental pain, dental root canal treatment, salivary specimen collection from the first visit to next and the last during 4 weeks of dental care
48341882|NCT05455307|DEVICE|Allium ureteral stent|observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture
48341883|NCT01668134|RADIATION|Stereotactic radiation|
48341884|NCT00716989|BIOLOGICAL|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
48499081|NCT04941118|DRUG|Injection of dextrose, local anesthetic and saline to the myofascial trigger point|An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
47981589|NCT06423820|DRUG|Ondansetron lozenge|Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
48133901|NCT06698575|DRUG|ABI-1179 Placebo|Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)
48133902|NCT06699459|DRUG|Irinotecan Liposome|②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
48133903|NCT06699459|DRUG|Capecitabine|① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
48656983|NCT06498648|OTHER|Fluorothymidine F-18|Given IV
48656984|NCT06498648|DRUG|Gemcitabine|Given IV
48499082|NCT04941118|DRUG|Local anesthetic and saline injection to the myofascial trigger point|A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
48341885|NCT03590093|PROCEDURE|Periodontal surgery|After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
48341886|NCT03590093|PROCEDURE|EMD application|Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
48656985|NCT06498648|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48656986|NCT05788926|DRUG|TG6050|Oncolytic Vaccinia virus containing genes encoding the human interleukin 12 (IL-12) and an anti-CTLA4 antibody administered at different dose.
47981590|NCT04012775|BIOLOGICAL|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
47981591|NCT04012775|BIOLOGICAL|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
47981592|NCT05084274|BEHAVIORAL|Lifestyle program|If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
48133906|NCT06142409|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Lozenge containing multiple enzyme combination
48341887|NCT06052189|PROCEDURE|Ultrasound|Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
48656987|NCT05018481|DRUG|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
48656988|NCT05018481|DRUG|Placebo|A placebo will be given in capsule form to study participants
48656989|NCT06192550|DEVICE|Profound Matrix™ System|Study subjects will be treated with the Profound Matrix System
48656990|NCT05845255|DEVICE|mjn-SERAS|Using of wearable, non-invasive device for EEG recording and forecasting of epileptic seizures
48656991|NCT05975450|DRUG|Abatacept 125Mg/Ml Syringe|"Participants on qualifying belatacept regimen (with low dose tacrolimus, mmf and prednisone) will have their maintenance regimen changed from i.v. belatacept to s.c. abatacept, which will continue through week 52 (month 12) post-transplant:~Costimulation blockade:~- Abatacept 125 mg subcutaneous weekly"
47981593|NCT04387851|BEHAVIORAL|Placebo induction|The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
48133907|NCT06699667|DIAGNOSTIC_TEST|Computed tomography|
48499083|NCT06420544|BEHAVIORAL|JAPI: Cognitive, Emotional and Social Stimulation for Preschool Children|"Those children in the intervention group will play with the gaming platform Japi using a tablet device in a designated time given from schools' authorities. Early Year Educators will be present to help with the discipline and motivation of the students and Research Assistants will be there as well to provide technical support for the use of the equipment.~The intervention has 24 sessions, and the dosage will be two sessions of 15 minutes each per week for 12 weeks. Sessions number 1 to number 8 are focused on emotional regulation and inhibitory control. Sessions number 9 to 16 work on working memory and problem-solving. Sessions number 17 to 24 promote empathy and planification skills. Each session will have eight activities with increasing levels of difficulty."
48656992|NCT05399433|OTHER|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
48341888|NCT01068613|DRUG|QAX028|QAX028 60 mcg via inhalation device
48341889|NCT01068613|DRUG|QAX028|QAX028 20 mcg via inhalation device
48341890|NCT01068613|DRUG|Tiotropium|Tiotropium via inhalation device
48341891|NCT01068613|DRUG|Placebo|Placebo to QAX028 via inhalation device
48341892|NCT05351190|DEVICE|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
48341893|NCT05788029|PROCEDURE|laparoscopic pancreaticoduodenectomy|laparoscopic pancreaticoduodenectomy
48341894|NCT05788029|PROCEDURE|open pancreaticoduodenectomy|open pancreaticoduodenectomy
48656993|NCT04392622|DRUG|D-Limonene Gelcaps|Administered orally at 2 to 8 grams daily
48656994|NCT04392622|RADIATION|Intensity modulated radiotherapy (IMRT)|Standard of Care -All patients will receive standard radiation treatment of 66 to 70 Gy given in 33 to 35 fractions (2 to 2.12 Gy/fractions) over 6.5 to 7 weeks.
48656995|NCT04392622|DRUG|Cisplatin|Standard of Care -Cisplatin as 100 mg/m2 IV
48499084|NCT04326205|DEVICE|transcranial direct current stimulation, tDCS|"The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice."
48341895|NCT02744560|DIETARY_SUPPLEMENT|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
48656996|NCT04392622|OTHER|Xerostomia questionnaire|Xerostomia questionnaire consists of 4 items on dryness while eating/speaking and 4 on dryness at rest. Patients rate each symptom on an 11 point ordinal Likert scale from 0 to 10, with higher scores indicating greater xerostomia
48656997|NCT06455033|OTHER|Manual Diaphragm Release Technique|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, the therapist deepens their contact towards the inner costal margin while maintaining resistance. As the respiratory cycles continues, the therapist progressively increases the depth of their contact within the costal margin.
48656998|NCT06455033|OTHER|Breathing Exercise|"Sit up straight in a chair lengthen the distance between your navel and sternum. Keep your shoulders relax.~Keep the pelvis in neutral position (Sit on your sitting bones). Place your hands at either side of your lower ribs. Breath in slowly through your nose. As you inhale feel your ribs expanding outwards and upwards. During inhalation is generated expansion of the trunk in three directions front , sides and back.~Breath out from your nose. As you exhale feel your lower ribs moving inwards."
48341896|NCT06060704|DRUG|Envafolimab|150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
48341897|NCT06060704|DRUG|Trifluridine/Tipiracil|35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
48341898|NCT06060704|DRUG|Bevacizumab|ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
48341899|NCT02312011|DRUG|IONIS-DMPKRx|Drug
48341900|NCT02312011|DRUG|Placebo|Placebo
48341901|NCT03037307|OTHER|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
48341902|NCT03037307|OTHER|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
48341903|NCT03037307|OTHER|Negative Control|No adhesive
48341904|NCT05438706|DRUG|chidamide|Chidamide, an HDAC inhibitor
48341905|NCT05438706|DRUG|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
48341906|NCT05438706|DRUG|carboplatin|Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
48341907|NCT05438706|DRUG|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
48341908|NCT00809055|DRUG|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
48341909|NCT06396988|OTHER|Novamin application|Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
48341910|NCT06396988|OTHER|Parodontax application|Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
48341911|NCT00300716|DRUG|Memantine|
48341912|NCT06337994|DRUG|Memantine Hydrochloride|Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.
48341913|NCT01752075|DRUG|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
48341914|NCT00141401|DRUG|Pregabalin|
48341915|NCT02848313|DRUG|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
48341916|NCT01844791|DRUG|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
48341917|NCT01844791|DRUG|Platinum|Platinum is given as standard chemotherapy each cycle
48341918|NCT01844791|DRUG|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
48341919|NCT05718453|COMBINATION_PRODUCT|Laboratory Tests|Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
48341920|NCT00572728|PROCEDURE|CT|Undergo 18F-FLT PET/CT
48341921|NCT00572728|DRUG|18F-FLT|Undergo 18F-FLT PET/CT
48341922|NCT00572728|PROCEDURE|PET|Undergo 18F-FLT PET/CT
48341923|NCT02657876|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
48341924|NCT04964557|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
48499085|NCT04326205|DEVICE|functional electrical stimulation, FES|"The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice."
48133915|NCT06699992|DIAGNOSTIC_TEST|Blood biomarkers quantification|Blood biomarkers quantification
48133916|NCT06699394|DRUG|Teclistamab (Tec)|Teclistamab is administered subcutaneously with the usual step-up dosing: 0.06 mg/kg at day 1, 0.3 mg/kg at day 4, 1.5 mg/kg at day 8, and then 1.5 mg/kg weekly.
48133917|NCT06699186|OTHER|Sleep|A training programme was devised which involved the participants performing maximum squat repetitions with their own body weight as a workload, in order to induce delayed-onset muscle soreness in the quadriceps. Before the maximum squat repetition, all participants performed a warm-up programme including 5 minutes of walking. Participants were instructed to perform the maximum number of repetitions within the one minute allotted for each set of squats and, after a 10-second rest period, to continue the programme in the same cycle until exhaustion. In the initial 24-hour period following the intervention, participants were instructed to maintain their habitual sleep schedules. In consideration of the delayed-onset muscle soreness, which typically occurs between 24 to 48 hours following maximal squat intervention.The sleep group was instructed to engage in a minimum of six hours of sleep over the course of the 24-hour observation period.
48133918|NCT06699186|OTHER|Non-sleep|A similar delayed-onset muscle soreness inducing protocol was applied to the sleep group.Participants in the non-sleep group were subjected to sleep restriction. The participants were permitted to sleep for a maximum of four hours in total over the course of the 24-hour period in non-sleep group.
48341925|NCT04964557|DRUG|Placebo|Placebo solution
48133919|NCT06699706|OTHER|Continuous theta-burst stimulation|"cTBS targets two regions: the dorsolateral prefrontal cortex (dlPFC) and the M1 area. Before the first treatment, each participant's resting motor threshold (RMT) will be determined using a five-step procedure for the primary motor cortex. RMT is defined as the minimum intensity required to elicit a motor response greater than 50 µV in at least 5 out of 10 consecutive trials in the right first dorsal interosseous muscle.~Participants will then undergo daily cTBS treatment three times a day for 7 consecutive days. Each stimulation session lasts 40 seconds, consisting of triplets of 50 Hz theta-burst stimulation repeated at 5 Hz, delivering a total of 600 pulses. Stimulation of the dlPFC target will be immediately followed by stimulation of the M1 target. To achieve cumulative aftereffects, the protocol will be repeated three times per day (a total of 3600 pulses/day) with two 15-minute breaks between sessions, timed with a stopwatch."
48341926|NCT00002097|DRUG|Nystatin|
48341927|NCT02911051|DEVICE|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
48341928|NCT05076331|DIAGNOSTIC_TEST|PI-2620 tracer for Tau PET scan|Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
48341929|NCT00159614|DRUG|KW-3902IV|
48341930|NCT02351739|DRUG|pembrolizumab|
48499086|NCT04326205|OTHER|no stimulation|Both tDCS and FES will not be used in this section.
48656999|NCT05166811|DRUG|Magnesium Sulfate, Heptahydrate|A single dose of intravenous magnesium sulfate given over 20 minutes through a peripheral intravenous line. Two arms of the study will deliver intravenous magnesium, one at a dose of 50 mg/kg, and the other at a dose of 75 mg/kg.
48341931|NCT02351739|DRUG|ACP-196 in combination with pembrolizumab|
48341932|NCT05386849|DEVICE|FUSION closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
48499087|NCT00977379|RADIATION|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
48341933|NCT00259519|PROCEDURE|Induction of delivery|Induction of delivery
48499088|NCT00977379|DRUG|Capecitabine|825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
48499089|NCT00977379|DRUG|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
48499090|NCT05841303|DRUG|Vit C|Vit c is proven to be an anti-inflammatory and antioxidant agent. also play a great role in collagen biosynthesis (collagen type I), as it helps in fibroblasts proliferation. It reduces the potentiality of scaring via inhibiting cross-linking of collagen fibers and fibrosis. It acts as a cofactor in hydroxyproline synthesis to produce collagen type IV and improves endothelial cell vitality and function..
48513306|NCT05523583|OTHER|questionnaire|A trained interviewer (Clinical Research Associate : CRA) will administer a questionnaire soon after the diagnosis on the phone (within 15 calendar days after diagnosis). The participants are followed up during the first year following the diagnosis through 3 follow-up assessments (at 3, 6, and 12 months after the baseline assessment) and hospital record reviews. At each follow-up, a brief questionnaire will be administered by an interviewer (CRA) via telephone.
48657000|NCT05166811|DRUG|0.9% saline|A single dose of intravenous 0.9% sodium chloride given over 20 minutes through a peripheral intravenous line as the placebo arm of the study.
48657001|NCT04428580|OTHER|Online FBT Training|Therapists will receive online training in Family-Based Treatment (FBT)
48657002|NCT04428580|OTHER|Webinar FBT Training|Therapists will receive webinar training in Family-Based Treatment (FBT)
48341934|NCT01883219|DRUG|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
48657003|NCT06095050|DEVICE|Embolization|Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
47981594|NCT04387851|BEHAVIORAL|Control|Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
47981595|NCT04387851|BEHAVIORAL|Nocebo|The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
47981596|NCT00006337|DRUG|KW-6002|
47981597|NCT00006337|DRUG|IV Levodopa|
47981598|NCT01781403|DRUG|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
47981599|NCT00940251|DRUG|Mersina|capsule, 3g/day, 3 months
47981600|NCT03021265|DRUG|T80/A5/H12.5 FDC|Drug
47981601|NCT01574326|DRUG|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
47981602|NCT01574326|DRUG|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
47981603|NCT02168179|PROCEDURE|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
47981604|NCT02168179|OTHER|questionnaire administration|Ancillary studies
47981605|NCT05947812|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
47981606|NCT05947812|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
48513307|NCT02029196|OTHER|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
48657004|NCT06095050|OTHER|Physical Therapy|Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
48657005|NCT00002759|DRUG|cyclosporine|
48657006|NCT00002759|DRUG|irinotecan hydrochloride|
48657007|NCT00002759|DRUG|phenobarbital|
48657008|NCT02719509|PROCEDURE|Cardiac Ultrasound|
48657009|NCT06092892|PROCEDURE|Breast Surgery (BCS or mastectomy) with TAD/SNB|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
48657010|NCT06092892|RADIATION|Adjuvant Radiation Therapy|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
48657011|NCT06493084|DRUG|LAE102 injection|intravenous drip or subcutaneous injection
48657012|NCT06493084|OTHER|Saline|intravenous drip or subcutaneous injection
48657013|NCT04906512|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
48657014|NCT04906512|DEVICE|3M™ Tegaderm™ Transparent Film Dressing 1626W|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
48657015|NCT05717439|DIAGNOSTIC_TEST|CAPS-5-R|A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.
48657016|NCT05717439|DIAGNOSTIC_TEST|Senseye DT|Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
48657017|NCT06284122|DRUG|Mosunetuzumab|5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21
48657018|NCT06284122|DRUG|Lenalidomide|20 mg/day Day 1 to Day 21 from C2 to C12
48657019|NCT06284122|DRUG|Rituximab|when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20
48657020|NCT06284122|DRUG|Obinutuzumab|when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18
48657021|NCT06284122|DRUG|Cyclophosphamide|750 mg/m2 Day 1 from C1 to C6
48657022|NCT06284122|DRUG|Doxorubicin|50 mg/m2 Day 1 from C1 to C6
48657023|NCT06284122|DRUG|Vincristin|1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
48657024|NCT06284122|DRUG|Prednisone|100 mg/day Day 1 to Day 5 from C1 to C6
48657025|NCT06284122|DRUG|Rituximab|when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18
48657026|NCT06284122|DRUG|Obinutuzumab|when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20
48657027|NCT06284122|DRUG|Bendamustin|90 mg/m2 Day 1 and Day 2 from C1 to C6
47981607|NCT06182189|OTHER|Observation of patients with a benign prostatic hyperplasia condition|Observation of patients with a benign prostatic hyperplasia condition who have undergone surgery
48513308|NCT02029196|OTHER|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
47981608|NCT04809207|OTHER|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
48133920|NCT06699706|OTHER|sham continuous theta-burst stimulation|The treatment pattern for the sham continuous theta-burst stimulation was similar to that for real stimulation. The sham coil is identical in appearance to the active coil, but it only produces sounds and sensations similar to those of the active coil on the scalp without generating a current, preventing participants from identifying their group assignment.
48341935|NCT02485613|DRUG|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
48341936|NCT01048255|DRUG|VX-765|300mg Oral Tablet, 900mg TID
48341937|NCT03613818|BEHAVIORAL|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
48341938|NCT03080051|DRUG|[18F]MNI-952|Subjects will undergo PET imaging using \[18F\]MNI-952, a PET radioligand for imaging tau.
48341939|NCT03080051|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-952.
47981609|NCT04044716|DEVICE|Auricular acupressure|Trained nurses in auricular acupressure will place acupressure beads on 5 acupoints on each ear (cingulate gyrus, thalamus, omega-2, point zero, and Shen Men). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 5 days. Acupoints were selected based on recommendation of faculty acupuncturist.
47981610|NCT04044716|OTHER|Standard of care pain management|The participant post-operative pain will be managed following the standard protocol by the treating physician.
47981611|NCT01572545|DRUG|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
47981612|NCT01572545|DRUG|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
47981613|NCT05316753|PROCEDURE|Cardioversion with a pulsed biphasic waveform|Cardioversion with a pulsed biphasic waveform
47981614|NCT05316753|PROCEDURE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion with a biphasic truncated exponential waveform
47981615|NCT05040997|DIAGNOSTIC_TEST|Small airways assessment|Small airways assessment
47981616|NCT02204163|DRUG|Eutropin|
47981617|NCT02204163|DRUG|Genotropin|
48341940|NCT05798819|DRUG|GLS-010|IV infusion
48341941|NCT05798819|DRUG|Placebo|IV infusion
48341942|NCT05798819|DRUG|paclitaxel|IV infusion
48341943|NCT05798819|DRUG|cisplatin|IV infusion
48341944|NCT05798819|DRUG|carboplatin|IV infusion
48499091|NCT05841303|OTHER|injectable PRF|5 ml of peripheral blood from each patient , blood will be transferred to a glass coated plastic vacutainer tube without anticoagulant. Then this tube will immediately centrifuged at 700 rpm for 3 mins \[Centrifuge Machine 5000rpm.After centrifugation, two fluid layers will formed, upper being yellow fluid layer (i-PRF) while lower layer containing red blood cells. Yellow fluid layer containing i-PRF will be immediately aspirated using micro needle to be injected for management of gingival phenotype
47981618|NCT01649687|BIOLOGICAL|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10\^7 cells of allogeneic adipose-derived mesenchymal stem cells
47981619|NCT04159844|DEVICE|URGOBD001|Application with 50% overlapping
47981620|NCT04159844|DEVICE|URGOBD001 associated with wading|Application with 50% overlapping in association with wading
48341945|NCT05798819|DRUG|bevacizumab|IV infusion
48341946|NCT00889980|OTHER|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
48341947|NCT02437968|BEHAVIORAL|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
48341948|NCT06086457|RADIATION|Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 50Gy in 25 fractions to planning gross tumor volume (PGTV) with involved site included.
48341949|NCT06086457|DRUG|TP or PF regimen depended on investigator's choice.|A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
48341950|NCT06086457|BIOLOGICAL|PD-1 inhibitor|Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
48341951|NCT03513289|OTHER|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
48341952|NCT04673955|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
48341953|NCT04673955|DRUG|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
48341954|NCT03880006|BEHAVIORAL|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
48341955|NCT02959970|DRUG|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
48499092|NCT02125162|DRUG|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
48499093|NCT02733926|OTHER|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
48513309|NCT03660306|PROCEDURE|opioid anesthesia|opioid anesthesia means using sufentanil during surgery
47981621|NCT03232957|PROCEDURE|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
47981622|NCT03232957|PROCEDURE|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
47981623|NCT03232957|PROCEDURE|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
47981624|NCT03232957|DRUG|Morphine|intrathecal morphine
47981625|NCT03232957|DRUG|Bupivacaine|0.5 isobaric bupivacaine
47981626|NCT00793403|OTHER|As per routinary clinical care|As per routine clinical care
47981627|NCT05463575|DRUG|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
47981628|NCT05463575|OTHER|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
47981629|NCT02043249|OTHER|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
47981630|NCT05768880|BIOLOGICAL|SC-CAR4BRAIN|Courses of weekly intraventricular CNS administered SC-CAR4BRAIN infusions for 3 weeks, then 1 week off
47981631|NCT04880512|DRUG|SYHX 1901 tablets|SYHX 1901, oral tablets, in fasted state
47981632|NCT04880512|DRUG|Placebo|Matching placebo, oral tablets, in fasted state
47981633|NCT02845453|DRUG|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
48341956|NCT02217683|DRUG|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
48341957|NCT00044213|DRUG|EDTA|Participants will receive 40 infusions of standard chelation solution.
48341958|NCT00044213|DRUG|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
48341959|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin|
48341960|NCT00044213|DIETARY_SUPPLEMENT|High Dose Vitamin Placebo|
48341961|NCT01736709|BIOLOGICAL|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
48341962|NCT01802515|DRUG|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
48341963|NCT01802515|DRUG|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
48499094|NCT02297698|BIOLOGICAL|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
48499095|NCT02297698|DRUG|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
48341964|NCT01802515|DRUG|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
48341965|NCT04703062|BEHAVIORAL|Experimental group 1|It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
48341966|NCT04703062|BEHAVIORAL|Experimental group 2|Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
47981634|NCT02845453|OTHER|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
48341967|NCT01211119|OTHER|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
48341968|NCT00524667|DRUG|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until \>1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
48341969|NCT03788967|DRUG|TBPM-PI-HBr|TBPM-PI-HBr tablets administered orally.
48341970|NCT03788967|DRUG|Ertapenem|Antibiotic Therapy for cUTI.
48341971|NCT03788967|DRUG|Dummy Infusion|Dummy intravenous infusion.
47981635|NCT02467010|DRUG|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
47981636|NCT02467010|DRUG|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
47981637|NCT02467010|DRUG|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
47981638|NCT01636401|DRUG|aclidinium bromide 400 μg|
47981639|NCT01636401|DRUG|aclidinium bromide placebo|
48341972|NCT03788967|DRUG|Dummy tablets|Dummy tablets orally.
48341973|NCT03696004|DRUG|FEC-100|Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
48341974|NCT02508519|PROCEDURE|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
48341975|NCT04308954|DRUG|[18F]flumazenil|\[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
48341976|NCT05955872|DRUG|VX-147|Tablets for oral administration.
48341977|NCT03703960|OTHER|hypnotic analgesia|classic three-step hypnosis procedure (induction, trance and return to consciousness).
48341978|NCT03703960|OTHER|music|calm music conducive to relaxation
48499096|NCT02297698|DRUG|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
48499097|NCT00501501|PROCEDURE|Cesarean section|
48499098|NCT00501501|PROCEDURE|Vaginal delivery|
48499099|NCT04873765|BIOLOGICAL|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
47981640|NCT01239654|DEVICE|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
47981641|NCT02579044|DRUG|Everolimus and lonafarnib|
48499100|NCT04873765|BIOLOGICAL|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
48133924|NCT06700330|OTHER|no intervention, observational study|Only data will be taken of patient's file.
48499101|NCT06344663|OTHER|motivational interview|Before starting the interview, mothers will be informed about the interview intervals, duration, how many times it will be held, and that, unlike other interviews, the topic will be determined and the mother's opinions on this subject will be obtained. Each meeting will last approximately 15-30 minutes
48499102|NCT02322463|DRUG|Arab children|Treatment with Oxycodone
48499103|NCT03963024|DRUG|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0\* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
48499104|NCT03963024|PROCEDURE|SCT|Stem Cell Transplant
48133929|NCT06699082|OTHER|KinesioTaping and Keltonborn Mobilization|Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.
48341979|NCT02394223|PROCEDURE|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
48341980|NCT05953324|OTHER|Kiwifruit|2 kiwifruit for 6 weeks
48341981|NCT06118554|OTHER|Irrigation head position|Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.
48657028|NCT01790191|BEHAVIORAL|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
47981642|NCT04909320|BEHAVIORAL|AWARD advice|Ask about smoking history; Warn about the high risk; Advise to quit; Refer smokers to smoking cessation services (with a referral card); Do it again
48133930|NCT06699316|OTHER|Individualized prognostic counselling|Individualized prognostic counselling on life expectancy using the prognostic model 'OncologIQ Palliative'
47981643|NCT04909320|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking and remind them to call the Department of Health SC hotline 183 3183.
47981644|NCT04909320|OTHER|Referral card|The contents consist of brief information and highlights of existing SC services, contact methods, motivation information, and strong supporting messages or slogans.
47981645|NCT04909320|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
48133931|NCT06699030|DRUG|Functional fatty acids|Days 1-3: Oral Administration of functional fatty acids Days 4-6: Oral Administration of functional fatty acids
48133932|NCT06699030|OTHER|Placebo|Days 1-3: Placebo Days 4-6: Oral Administration of functional fatty acids
48133933|NCT06700044|DIETARY_SUPPLEMENT|GutMagnific|Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37
48133934|NCT06700044|DIETARY_SUPPLEMENT|Placebo|Participants will take one stick/placebo per day from gestational week 12 until partus.
48499105|NCT03963024|DRUG|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
48499106|NCT01284296|DRUG|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
48499107|NCT01284296|DEVICE|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
48341982|NCT00614991|DRUG|Raltegravir|400mg BID
48341983|NCT00614991|DRUG|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
48341984|NCT00614991|DRUG|Ritonavir|100 mg BID or QD
48341985|NCT00675662|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
48341986|NCT00675662|BEHAVIORAL|waiting list control|waiting list control
48341987|NCT03688945|PROCEDURE|Art Therapy|Attend art viewing sessions
48341988|NCT03688945|OTHER|Best Practice|Receive standard of care
48341989|NCT03688945|OTHER|Questionnaire Administration|Ancillary studies
48341990|NCT00003413|BIOLOGICAL|filgrastim|
48341991|NCT00003413|DRUG|carmustine|
48341992|NCT00003413|DRUG|cisplatin|
48341993|NCT00003413|DRUG|melphalan|
48341994|NCT00003413|DRUG|paclitaxel|
48499108|NCT04068415|OTHER|Constipation risk assessment scale|questionnaires
48499109|NCT03768726|DRUG|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
47981646|NCT04909320|BEHAVIORAL|Positive psychological support through 3-people group chat using instant messaging apps|Each IM chat group will consist of a trained SC counselor (HKU staff), a peer supporter (former smoker), and a participant (smoker). The 3-month group chat-based intervention will consist of regular messages and real-time support through group chat. Regular messages will generally include goal setting, health warnings, abstinence support, positive psychological exercises, and encouragement and will be delivered in a tapering style. During the real-time chatting, SC counsellors and peer supporters will provide real-time chat-based support, and peer supporters will share their quitting experience as appropriate.
48499110|NCT03768726|DRUG|Placebo|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
48133939|NCT06699862|BEHAVIORAL|High Intensity Interval Training|Throughout the 10-weeks intervention period, B2L-M HIIT sessions will be delivered during regular PE classes twice a week, by the schools' PE teachers. The HIIT sessions will be applied in the first 8-10 min of each PE class, including a brief warm-up involving a combination of aerobic and body weight muscle-strengthening exercises, and designed to be fun and engaging as well as vigorous in nature
48133940|NCT06699862|BEHAVIORAL|High Intensity Interval Training with Competition|Students will participate in a school competition to win points for their class for a 10-week period. In every HIIT session the heart rate will be tracked to measure the exercise intensity and also it will be used to win points for the competition. Every class will receive the same number of points as the sum of the minutes of exercise at a vigorous intensity (i.e., ≥85% max. heart rate) of each participant. This fact means that the physical fitness is irrelevant to the competition aspect, which will only consider the effort of the participants.
48133941|NCT06700291|PROCEDURE|Surgery|Patient undergoing Anesthesia and Surgery
48499111|NCT05589532|DEVICE|Prosthetic single-tooth prosthesis using PEEK|A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
48499112|NCT05819216|DEVICE|Treadmill|Gait training on treadmill training
48499113|NCT00587990|BIOLOGICAL|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10\^7 cells. The injections will be administered following completion of CABG surgery.
48341995|NCT00003413|PROCEDURE|peripheral blood stem cell transplantation|
48341996|NCT00003413|PROCEDURE|surgical procedure|
48341997|NCT03336060|DIAGNOSTIC_TEST|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
48341998|NCT04287413|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
48341999|NCT04287413|BEHAVIORAL|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
48342000|NCT00076856|DRUG|Temozolomide|
48342001|NCT01856855|RADIATION|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
48342002|NCT04777123|OTHER|sitting position|patients will be left seated for 2 minutes after subarachnoid injection
48342003|NCT03013959|DRUG|Pranoprofen|it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
48499114|NCT00587990|GENETIC|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
48499115|NCT00587990|BIOLOGICAL|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10\^8 cells. The injections will be administered following completion of CABG surgery.
48499116|NCT00002149|DRUG|Clavulanate potassium|
48499117|NCT00002149|DRUG|Pseudoephedrine hydrochloride|
48499118|NCT00002149|DRUG|Amoxicillin trihydrate|
48499119|NCT04128020|DRUG|Nivolumab|Nivolumab
48499120|NCT04128020|DRUG|Azacitidine|Azacitidine
48342004|NCT06180733|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
48342005|NCT04301193|DEVICE|Quantra Analyzer|Subjects blood will be manipulated in the lab and will be tested with the Quantra Analyzer
48342006|NCT04977024|BIOLOGICAL|COVID-19 Vaccine|Receive SOC mRNA SARS-CoV-2 vaccine IM
48342007|NCT04977024|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48342008|NCT04977024|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1|Given IM
48342009|NCT04518020|PROCEDURE|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
48342010|NCT00365768|DRUG|Glutamine|Administered orally twice daily for 21 days
48342011|NCT00365768|OTHER|Placebo|Administered orally twice daily for 21 days
48342012|NCT00001669|DRUG|rhIGF-1 (CEP-151)|
48342013|NCT00128752|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
48342014|NCT01609738|DEVICE|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
47981647|NCT04909320|BEHAVIORAL|E-messages via SMS|Regular e-messages via SMS at twice per month within 3 months (total 6).
47981648|NCT04069611|OTHER|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
48342015|NCT00641706|DRUG|vorinostat|Given orally
47981649|NCT04069611|OTHER|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
48342016|NCT00641706|PROCEDURE|therapeutic conventional surgery|Patient undergoes surgery
48342017|NCT00641706|DRUG|bortezomib|Given IV
48342018|NCT03656666|DRUG|Apremilast|Apremilast oral tablets
48342019|NCT03656666|DRUG|Placebo|Placebo oral tablets
48499121|NCT00988442|BEHAVIORAL|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
48499122|NCT00988442|BEHAVIORAL|Standard care|Usual ACTG site care.
48499123|NCT02312518|DEVICE|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
48499124|NCT02312518|OTHER|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
48499125|NCT00107510|BIOLOGICAL|pegfilgrastim|
48133950|NCT06699524|DRUG|in vitro （chemotherapy）|resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.
48133951|NCT06699524|DEVICE|Adjuvant TACE（Adjuvant Transarterial Chemoembolization）|Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.
48499126|NCT00107510|DRUG|carboplatin|
48499127|NCT00107510|DRUG|docetaxel|
48133954|NCT06700226|DEVICE|AblaView® Unipolar PFA System|Patients with symptomatic paroxysmal atrial fibrillation will be treated with the AblaView® Unipolar PFA System system to achieve electrical isolation of the pulmonary veins. The AblaView® Unipolar PFA Catheter is a regular PFA irrigated catheter. The tip of the catheter has 7 holes distributed around that deliver at the same time irrigation and near infrared light for the OCR system, which will be processed and interpreted by the Console.
48499128|NCT00107510|PROCEDURE|conventional surgery|
48133956|NCT06698848|DRUG|ketamin|Participants in this study will have been diagnosed with major depressive episode (MDE) and have not received any psychiatric treatment for at least 2 weeks (5 weeks if on fluoxetine).Patients will receive intravenous ketamine as the only study drug treatment for the 2 weeks of the study. Magnetic Resonance Imaging (MRI) will be used to measure effects of ketamine on brain structure, function and chemistry, in addition to a soft-nasal brushing procedure to obtain olfactory sensory neurons which will provide the ability to profile in vivo how neurons may react to KET treatment in depressed patients.
48499129|NCT05713968|OTHER|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
48499130|NCT05713968|OTHER|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
47981650|NCT04069611|PROCEDURE|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
48499131|NCT04752046|PROCEDURE|maxillary cancer resection|patient with maxillary cancer will resected and reconstructed
48499132|NCT01293838|DRUG|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~* 10 mg tablets: 28~* 20 mg tablets: 84~Total for 30 participants:~* 10 mg tablets: 840~* 20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~\*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~\*20 mg tablets: 1512"
48499133|NCT03402750|BEHAVIORAL|Meds to Beds|Medications will be delivered to patient bedside before discharge
48499134|NCT03402750|BEHAVIORAL|Electronic Prescription|Patient or surrogate can pick up medication from pharmacy
48499135|NCT06080100|DRUG|Xenon|inhalation of xenon in a sub-narcotic dosage
48499136|NCT06080100|OTHER|premedication hydroxyzine 25 mg|taking anxiolytic 30 minutes before surgery
48499137|NCT02498106|DIETARY_SUPPLEMENT|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins \[B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene\] and minerals \[Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese\]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid \[EPA\] and docosahexaenic acid \[DHA\])
48133966|NCT06671353|BEHAVIORAL|video decision aid|video decision aid for advance care planning
48342020|NCT00588523|DRUG|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
48499138|NCT02808156|OTHER|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
48499139|NCT02808156|OTHER|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
48499140|NCT03472417|DEVICE|Active partial rebreathing device|
48499141|NCT03472417|DEVICE|Dummy partial rebreathing device|
47981651|NCT02634684|DRUG|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
48499142|NCT01032018|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
48513310|NCT03660306|PROCEDURE|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
48513311|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 1: 50 ug
48513312|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
48513313|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
47981652|NCT02634684|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
48499143|NCT01032018|DRUG|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
48133968|NCT05919511|OTHER|Non-Interventional|This is an observational study
48499144|NCT01032018|OTHER|Standard care|Participants will receive standard of care from the current physicians
48133970|NCT04363866|DRUG|Hydroxychloroquine|Hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. These characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions
48133971|NCT04363866|DRUG|Placebo|A placebo is a pill that looks like the study drug but has no real medicine in it.
48133972|NCT06698718|PROCEDURE|Periodontal basic treatment|Accept periodontal basic treatment
48499145|NCT01049711|DRUG|erythropoietin|
48499146|NCT06273826|DIAGNOSTIC_TEST|"Colorectal Leakage App"|"The Colorectal Leakage App is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring."
48133975|NCT06699810|DEVICE|Continuous Glucose Monitoring|After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
48133976|NCT06699810|DRUG|Insulin|Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
48133977|NCT06698536|DEVICE|Aktiia G2C|Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).
48499147|NCT05827835|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
48499148|NCT05827835|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
48499149|NCT05437926|DEVICE|Arrhythmia Analysis Software (software) which runs on a mobile application (Huawei Phone) and uses input from a wearable device (smart watch or smart band).|Subjects with or without cardiac arrhythmias and of light skin tone (melanin index \<150) or dark skin tone (melanin index \>350). Subjects will be divided based on their heart rhythm in three groups: approximately 1/3 with normal sinus rhythm, 1/3 with atrial fibrillation and 1/3 with premature beats
48499150|NCT03107143|DEVICE|Q2 System|
48499151|NCT04299906|DEVICE|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft for treatment of Iliac Lesions
48499152|NCT02885181|DRUG|GS-9876|One tablet administered orally once daily
48499153|NCT02885181|DRUG|Filgotinib|Two tablets administered orally once daily
48133985|NCT06673511|PROCEDURE|Lymph node visualization|Resect the developing lymph nodes and the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
48133986|NCT06673511|PROCEDURE|No visualization of lymph nodes|Resect the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
48133987|NCT05017025|DRUG|Aurora A Kinase Inhibitor LY3295668|Given PO
48342021|NCT00971230|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
48133988|NCT05017025|DRUG|Osimertinib|Given PO
48133989|NCT05230264|OTHER|Elective AAA Repair|Elective AAA Repair - Observation of Stress Response
48499154|NCT02885181|DRUG|GS-9876 placebo|One tablet administered orally once daily
48133991|NCT06699745|BEHAVIORAL|Music intervention|In studies, white noise was used as a sedative in infants. It was not used in older children. In school-age children, white noise will be used to reduce fear, anxiety and pain during the endoscopy procedure.
48342022|NCT00971230|DRUG|Placebo|Placebo
47981653|NCT06458608|DEVICE|virtual reality glasses|virtual reality glasses
48133992|NCT06699745|BEHAVIORAL|white noise intervention|White noise will be played at a decibel level appropriate for the children in the group.
48342023|NCT03002285|BEHAVIORAL|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
48342024|NCT03002285|BEHAVIORAL|Control group|Group with typical development that performed the Fitts law in a computer task
48342025|NCT02257125|BEHAVIORAL|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
48342026|NCT02257125|BEHAVIORAL|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
48342027|NCT01256320|OTHER|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
48342028|NCT01256320|OTHER|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
48499155|NCT02885181|DRUG|Filgotinib placebo|Two tablets administered orally once daily
48499156|NCT02885181|DRUG|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
48499157|NCT01850186|DEVICE|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
48342029|NCT03065725|PROCEDURE|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
48499158|NCT01850186|DRUG|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
48342030|NCT06440265|OTHER|AM-PAC inpatient short form (low function)|"The Activity Measure for Post-Acute Care(AM-PAC) 6-clicks instruments have advantages in that they are simple and quick to complete, easy to use within usual care and has been validated in the entire hospital population. It has gained broad adoption in acute care hospital and, although it includes items for people at lower levels of function, there is a concern of a floor effect in ICU measurement. So, new AM-PAC items are developed to measure physical function at the lowest level and added 2 new items to AM-PAC inpatient mobility short form. It lowered the floor effect and increased statistical power, measurement breath, and sensitivity.~2 new items~* Turning head~* Following simple instructions"
48342031|NCT03796195|DRUG|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
48499159|NCT01908816|DRUG|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
48499160|NCT05693207|DEVICE|EMG|wearables EMG
48499161|NCT01584557|DRUG|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
48499162|NCT01584557|DRUG|placebo or sugar pill|sugar pill
48499163|NCT03409393|OTHER|The COPUS intervention|The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
48342032|NCT00899678|DRUG|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
48499164|NCT03409393|OTHER|Usual Care (OPUS treatment)|Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
48499165|NCT02816099|BIOLOGICAL|Prise de sang|
48342033|NCT00899678|DRUG|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg~\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg"
48499166|NCT04669847|OTHER|Trunk-oriented exercise program|The trunk-oriented exercise program was performed by a physiotherapist two days of the week for 8 weeks.Trunk-oriented exercises were specially adapted to the patient based on the patient's functional status and active participation in the exercises.
48499167|NCT04669847|OTHER|Conventional exercise program|Conventional exercise program was performed daily for 8 weeks, twice a day, on average 45 minutes, each exercise 5-10 repetitions. The program formed stretching exercises, and active or active-assisted strength exercises (upper extremity, lower extremity, abdominal muscles, back muscles).
48499168|NCT06402617|PROCEDURE|Pulmonary vein isolation|Standard clinical radio-frequency ablation isolation of pulmonary veins
48499169|NCT06402617|DIAGNOSTIC_TEST|RETRO-Mapping without adjunctive ablation|RETRO-Mapping performed using research equipment and software, but without any adjunctive ablation
48499170|NCT06402617|PROCEDURE|Adjunctive ablation guided by RETRO-Mapping|Radio-frequency ablation using a European conformity (CE)-marked ablation catheter of sites of focal activation identified by RETRO-Mapping
48499171|NCT02829294|DEVICE|E002 - cerumen removal aid|topical treatment
48499172|NCT01524679|DRUG|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
48499173|NCT00146887|PROCEDURE|coronary catheterization|
48499174|NCT02760992|DRUG|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
48499175|NCT02760992|DRUG|Oral Baclofen|10 mg tablet
48499176|NCT02279134|RADIATION|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
48499177|NCT02279134|RADIATION|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
48499178|NCT02279134|DRUG|Paclitaxel|135-150mg/m2 (D1 and D29)
48499179|NCT02279134|DRUG|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
48499180|NCT00822796|DEVICE|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
48499181|NCT00822796|DEVICE|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
48499182|NCT05982717|OTHER|No intervention|As this is an observational study, no intervention will be administered.
48499183|NCT06002841|BIOLOGICAL|intravenous treatment with EVs|intravenous treatment with extracellular vesicles
48499184|NCT06002841|BIOLOGICAL|intravenous treatment with placebo solution|intravenous treatment with placebo solution (without extracellular vesicles)
48499185|NCT00399256|DRUG|Acetylcysteine|
48133995|NCT06698913|PROCEDURE|Rotational Therapy|Sample1- Ventilator settings where adjusted with PEEP based on BMI, followed by a 2 cmH2O increase and 20 minutes in a lateral position at 30 degrees for lung recruitment for both sides. And at the end were subjected to an alveolar recruitment maneuver with pressure increases up to a plateau pressure of 45 cmH2O. Sample2- A recruitment maneuver followed by PEEP titration is performed, selecting the PEEP that is above the crossing point between the collapse and hyperdistension curves provided by EIT. And the the PEEP-ARDSNet will be selected according to the low PEEP-FIO2 table from the ARDSNet protocol. Observations are made at 4 and 24 hours, with PEEP at 24 hours adjusted to the level identified by EIT.
48499186|NCT00399256|DRUG|Zinc|
48499187|NCT04193306|DRUG|Alirocumab|Alirocumab 150 mg s.c. every 2 weeks
48499188|NCT04193306|OTHER|Placebo|Placebo s.c. every 2 weeks
48499189|NCT00388401|DRUG|Alvimopan|
48134000|NCT06699420|DRUG|Qishenyiqi dripping pills 1 bag, three times a day|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
48134001|NCT06699420|DRUG|Placebo 1 bag, three times a day|Placebo, 1 bag once, three times a day, 12 months
48499190|NCT06347601|OTHER|Without Intervention|Without Intervention
48499191|NCT01593514|BIOLOGICAL|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
48499192|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
48513314|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
48513315|NCT01415102|DRUG|Placebo|Inhaled
48657029|NCT01790191|BEHAVIORAL|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
47981654|NCT04542655|OTHER|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
47981655|NCT04542655|OTHER|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
47981656|NCT04542655|OTHER|Rest|The participants undergo ergometer cycling, treadmill running and rest.
47981657|NCT02966587|BIOLOGICAL|Durvalumab|Given IV
47981658|NCT02966587|OTHER|Laboratory Biomarker Analysis|Correlative studies
47981659|NCT04076319|BEHAVIORAL|CAPABLE: Community Aging in Place-Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
47981660|NCT02986789|DEVICE|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
47981661|NCT05721963|DIAGNOSTIC_TEST|No interventions.|No interventions.
47981662|NCT04766801|PROCEDURE|Laparoscopic adjustable gastric banding|Weight-loss surgery, with the use of gastric banding
48513316|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
47981663|NCT03032731|BEHAVIORAL|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
47981664|NCT03032731|OTHER|Control|Standard, publicly available NHS resources for healthy lifestyles.
47981665|NCT02309489|BEHAVIORAL|Partner involvement|Partner is involved in maternity care
47981666|NCT03079908|OTHER|da Vinci Skills Simulator®|Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
47981667|NCT03079908|OTHER|LapSim®|Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
47981668|NCT03079908|OTHER|Dry lab box laparoscopic training|No initial simulator training. Dry lab box laparoscopic Training only.
47981669|NCT02317185|DEVICE|genex bone graft with bone graft|
47981670|NCT02317185|OTHER|autogenous bone graft|
47981671|NCT03468257|BEHAVIORAL|Pavlovian Conditioning|Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
48513317|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
48134002|NCT06699212|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)
48657030|NCT01790191|BEHAVIORAL|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
48342034|NCT06396260|OTHER|Diffusion Kurtosis Imaging (DKI)|Non-invasive MRI sequence which extracts information of diffusion signals from complex brain tissue
47981672|NCT05745779|DIAGNOSTIC_TEST|HbA1c, Vitamin D, Vitamin B12|Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
47981673|NCT03773081|DEVICE|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
47981674|NCT00869531|OTHER|wholegrain|wholegrain wheat vs. refined wheat products
47981675|NCT00869531|OTHER|refined wheat|refined wheat products
47981676|NCT01503944|DRUG|18F-AV-133|185 MBq
47981677|NCT01503944|DRUG|18F-AV-45|185-370 MBq
47981678|NCT01598051|DRUG|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
47981679|NCT00607412|BEHAVIORAL|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
47981680|NCT00607412|BEHAVIORAL|12-step based supportive therapy|supportive psychotherapy based on 12-step model
47981681|NCT00524368|DRUG|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
47981682|NCT00524368|DRUG|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
47981683|NCT01721330|DRUG|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
47981684|NCT01721330|DRUG|Placebo|Placebo twice a day for 6 weeks
48134003|NCT06699212|BIOLOGICAL|Pembrolizumab|200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)
48134004|NCT06699212|DRUG|Carboplatin|AUC 5 mg/mL/min IV infusion, Q3W up to 6 cycles
48134005|NCT06699212|DRUG|Cisplatin|100 mg/m\^2 IV infusion, Q3W up to 6 cycles
48134006|NCT06699212|DRUG|5-fluorouracil|1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles
48134007|NCT06699212|DRUG|Paclitaxel|100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles
48342035|NCT06396260|OTHER|Resting State Magnetoencephalography|Non-invasive method of measuring resting state brain activity through magnetoencephalography (MEG)
48342036|NCT05985395|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
48342037|NCT03128307|DEVICE|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
48342038|NCT05932381|OTHER|Complete decongestive therapy|the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs
48342039|NCT05932381|OTHER|Medical treatment|the patients will receive routine medical treatment
48342040|NCT03554785|BEHAVIORAL|Clinician and Non-clinician staff training|"An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients."
48657031|NCT01969929|PROCEDURE|20G Vitrectomy|
47981685|NCT05548725|OTHER|Reguired field|Investigations to know relationship between acute kidney injury and mineral bone disease
47981686|NCT02759471|DEVICE|comfilcon A sphere lens (control)|contact lens
47981687|NCT02759471|DEVICE|comfilcon A asphere lens (test)|contact lens
47981688|NCT02715414|BEHAVIORAL|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
48134008|NCT06699212|DRUG|Docetaxel|75 mg/m\^2 IV Infusion, Q3W up to 6 cycles
48513318|NCT01415102|DRUG|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
48513319|NCT01415102|DRUG|Placebo|Inhaled
48657032|NCT01969929|PROCEDURE|23G vitrectomy|
48657033|NCT05599165|OTHER|signal processing on consonant recognition|Consonant recognition will be measured in noise without any signal processing.
47981689|NCT02715414|BEHAVIORAL|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
48342041|NCT01756638|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
48342042|NCT01756638|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
48342043|NCT01847690|DRUG|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
47981690|NCT02511184|DRUG|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
48134009|NCT06699238|OTHER|Home Exercise|Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.
48342044|NCT04904315|OTHER|Mindera Kit|The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
48342045|NCT03797690|PROCEDURE|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
48342046|NCT03797690|PROCEDURE|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
48342047|NCT03991936|DRUG|Placebos|Normal saline intralesional injection
48342048|NCT03991936|DRUG|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
48342049|NCT03991936|DRUG|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
48342050|NCT03991936|DRUG|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
47981691|NCT02511184|DRUG|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
47981692|NCT05328973|OTHER|ELEQUIL|patch placed on skin
47981693|NCT03234764|OTHER|Immunotherapy|
47981694|NCT01877499|OTHER|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~1. Treatment time (up to 4 hours per session);~2. Blood flow rate (up to 400 mL/min;~3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
47981695|NCT02697786|DEVICE|Transcranial doppler|Prolonged de airing to decrease the number of MES
47981696|NCT02886520|DEVICE|PVDF transobturator tape|
47981697|NCT02886520|DEVICE|Polypropylene transobturator tape|
47981698|NCT01627522|PROCEDURE|TURP|Transurthral resection of prostate
47981699|NCT02633644|DEVICE|Harmony System|Percutaneous neuromodulation of the aortic wall
47981700|NCT05485597|DEVICE|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
47981701|NCT01409564|DRUG|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
47981702|NCT01409564|DRUG|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
47981703|NCT01229059|DIETARY_SUPPLEMENT|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
48002477|NCT03033407|OTHER|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
48002478|NCT02201303|DRUG|Danirixin|Powdered form for in-vitro administration to blood sample
48342051|NCT03991936|DRUG|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
48002479|NCT02201303|OTHER|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
48134010|NCT06699238|OTHER|Aerobic exercise|The aerobic exercise group performed the following training: warm-up for 5 min, walking for 20 min at an intensity that would use 60-70% of the HR reserve, and cool down for 5 min. Additionally, they performed standard conventional exercises at home for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.The aerobic exercise group performed on a treadmill under the supervision of a physician.
48499193|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
48499194|NCT01593514|BIOLOGICAL|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
48499195|NCT01593514|BIOLOGICAL|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
48499196|NCT05623306|DEVICE|PMT Stereoencephalography (SEEG)|For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
48134020|NCT05430087|DRUG|Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.|All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
48134021|NCT01260896|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
48134022|NCT01260896|DRUG|Effexor® XR|150 mg Extended-Release Capsule
48134023|NCT06614270|DRUG|anti-CD19 CAR-NK cells|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) on day -5, -4, and -3. Doses of 2×10\^6/kg, 3×10\^6/kg, 4×10\^6/kg anti-CD19 CAR-NK cells will be infused in each group on Day 0, 7, and 14 using the \&#34;3 + 3\&#34; dose-escalation strategy.
48134024|NCT03656042|DRUG|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment"
48134025|NCT05321082|DRUG|BI 1015550|BI 1015550
48134026|NCT05321082|DRUG|Placebo|Placebo
48134029|NCT06698445|OTHER|Short film video|The short film training video will be prepared by researchers based on literature and appropriate for the level of children aged 7-12. The content will include topics such as preparation for KİAB, KİAB environment and the process after KİAB. Since the short film will be shot in a realistic manner, the scenario will include a doctor, a nurse, a child patient and a parent. The short film will be shot in the clinic where the data will be collected, at the appropriate time for the clinic. After the short film is shot, the editing process will be done and the final version will be given.
48342052|NCT02167724|OTHER|Bucco-dental examination|
48342053|NCT02167724|OTHER|Blood sample|
48342054|NCT02167724|OTHER|Clinical and social questionnaire|
48342055|NCT03245710|OTHER|Placebos|starch
48342056|NCT03245710|DIETARY_SUPPLEMENT|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
48002480|NCT01519856|DRUG|piribedil (Clarium)|oral tablets, 50 mg
48342057|NCT04021576|OTHER|preventative training program|complementary training of leg-, hip- and core-strength/stability
48342058|NCT04246541|DRUG|Ketorolac|Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.
48342059|NCT04246541|DRUG|Oxycodone-Acetaminophen|Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
48342060|NCT04111653|OTHER|Mud therapy|Application of sludge poultice
48342061|NCT05651984|DEVICE|Comparison between communication board and eye tracking|The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
48134030|NCT06698393|PROCEDURE|Suture 3.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 3.0 Diameter.
48342062|NCT01852630|DRUG|cefepime + Albumin|cefepime + Albumin will be given for 2 days
48342063|NCT01852630|DRUG|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
48342064|NCT04456595|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
48342065|NCT04456595|BIOLOGICAL|Placebo|Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
48342066|NCT02062372|DEVICE|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
48342067|NCT02062372|PROCEDURE|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
48342068|NCT00644124|DRUG|aflibercept|in combination with standard treatment R-CHOP
48342069|NCT04371185|DRUG|BAT2206|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
48342070|NCT04371185|DRUG|Stelara(US-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
48342071|NCT04371185|DRUG|Stelara(EU-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
48342072|NCT02044315|DEVICE|ICD programming|
48342073|NCT05526092|OTHER|Dietary intervention|Changes in metabolism, microbiota, vitality and comprehensive health after 6 week consumption of oat / rice.
48342074|NCT03621189|DEVICE|intermittent theta burst stimulation|stimulatory protocol
48342075|NCT00519610|OTHER|Chart Review|Patients' charts will be reviewed for relevant medical information.
48342076|NCT03249701|DEVICE|Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
48499197|NCT05623306|DEVICE|Vercise Genus™ Deep Brain Stimulation (DBS) System|For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
48499198|NCT01597466|DEVICE|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
48499199|NCT01597466|PROCEDURE|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
48499200|NCT01498731|BEHAVIORAL|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
48499201|NCT00926224|DEVICE|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
48499202|NCT05565092|DRUG|ALXN1820|ALXN1820 will be administered subcutaneously.
48499203|NCT06223243|OTHER|Stingless bee honey mouthrinse|Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.
48499204|NCT06223243|OTHER|normal saline mouthrinse|Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.
48499205|NCT06223243|OTHER|chlorhexidine mouthrinse|Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
48342077|NCT03249701|DEVICE|Electroacupuncture|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
48342078|NCT03249701|DEVICE|sham Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
48342079|NCT06166290|PROCEDURE|CO2 LASER Vaporisation|The CO2 LASER vaporization procedure is described as follows. Patient positioning will be done, and patient will be anesthetized. Local infiltration with 2% lidocaine, nerve block or general anesthesia will be given. The surgical field will be disinfected and draped. The perianal and anal area will be investigated for lesion. CO2 LASER from 20 cm distance in a continuous wave mode and 20 W power will be applied. After warts melts, necrotic tissue will be removed. After the operation was completed, residual debris will be wiped away with a piece of moist gauze. Bacitracin cream applied over the treated areas. Upon discharge acetaminophen 1-gram q8 and Ibuprofen 600 q8 for pain.
48499206|NCT00399880|BEHAVIORAL|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
48513320|NCT05119179|DRUG|Semaglutide|Glucagon-like Peptide 1 Receptor Agonist
48134031|NCT06698393|PROCEDURE|Suture 6.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 6.0 Diameter.
48134032|NCT06700278|BEHAVIORAL|acupressure|Acupoint massage was performed three times daily, with each acupoint massaged for three minutes at an optimal pressure level that induced sensations of soreness, numbness, distension, or mild pain. This was conducted five days a week for three weeks, in addition to regular rehabilitation therapy provided five days per week.
48499207|NCT05638958|DEVICE|Immediate post-extractive Implant placement|Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
48134034|NCT06698458|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|DaRT source will be inserted using endoscopy into the tumor. The sources release by recoil into the tumor short-lived alpha-emitting atoms
48499208|NCT06457165|DEVICE|Difficult Intubation|Noted for each patient.
48499209|NCT06457165|DEVICE|Not Difficult Intubation|Noted for each patient.
48134037|NCT06698822|DRUG|tofacitinib 2% cream|Given topical
48134038|NCT03177590|OTHER|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~1. an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~2. an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~3. Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
48134039|NCT06699446|OTHER|pre rehabilitation|preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and postoperative communication via telephone or app
48499210|NCT05832528|OTHER|Low-FODMAP diet|6-week Low-FODMAP diet in patients with functional dyspepsia
48499211|NCT02272634|DRUG|YPL-001 80 mg|twice daily \[BID\]
48499212|NCT02272634|DRUG|YPL-001 160 mg|twice daily \[BID\]
48499213|NCT02272634|DRUG|Placebo|twice daily \[BID\]
48657034|NCT06497088|DEVICE|Nasotrak System|"Device: The Nasotrak System~The Nasotrak Medical System is intended to aid, in conjunction with institutional protocols, qualified operators in the placement of the Nasotrak's 12 Fr feeding tube into the stomach of patients requiring enteral feeding after insertion and before every feed. The Nasotrak nasogastric tube(NGT) is designed for use with Nasotrak's handheld device (HHD) which is able to detect the tip of the NGT via piezoelectric sensor, which converts ultrasound waves to electronic signals, thus assisting to track its location as an indicator of placement in the stomach. Nasotrak's NGT is intended only to be used with Nasotrak's HHD.~The Nasotrak NGT is intended for the administration of nutrition, fluids and medications by the nasoenteric route for patients who have an intact gastrointestinal tract but are physically unable to manage nutritional intake through normal mastication and deglutition."
48499214|NCT03576482|OTHER|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
48499215|NCT02865421|DRUG|stem cells|adipose tissue derived stromal vascular fraction
48499216|NCT02865421|DRUG|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
48513321|NCT05158543|OTHER|conventional therapy|The conventional group will receive active and passive range of motion exercises, balance, and strength training for upper and lower limbs. One session per day, three sessions/week for total of 12 weeks.
48657035|NCT04331249|PROCEDURE|surgery or catheter based cardiac procedure (catheter ablation)|patients with implanted CIED (pacemaker, ICD or CRT) that undergo any surgery or any catheter based cardiac procedure (e.g. radiofrequency ablation)
48513322|NCT05158543|OTHER|Task oriented training (moderate intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Single session/day, 4 sessions/week for 12 weeks.
48657036|NCT00245479|DRUG|Primary nocturnal enuresis|Desmopressin
48657037|NCT05530733|PROCEDURE|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
48657038|NCT05530733|PROCEDURE|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
48657039|NCT02645799|DRUG|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
48657040|NCT02645799|DRUG|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
48499217|NCT01300910|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
48499218|NCT01300910|PROCEDURE|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
48134042|NCT06700083|DRUG|SHR-6934 injection|SHR-6934 injection
48134043|NCT06700083|DRUG|SHR-6934 placebo|SHR-6934 placebo
48134044|NCT06699199|DRUG|Silver diamine Fluoride 38%|"Intervention is the application of Silver diamine fluoride 38% to children Group in arm 1 (Arm 1): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth~SDF: (Silver diamine fluoride 38% is a material used for arresting caries lesions in primary and permanent teeth)~- SDF Product generic name and information (E-SDF: it is a 1-step Technique) - The 38% SDF solution comprised a blend of silver, fluoride, and ammonia at a total concentration of 38%."
48134045|NCT06699199|DRUG|Silver diamine fluoride- potassium iodide|"Intervention is the application of Silver diamine fluoride 38% + potassium iodide to children Group in arm 2 (Arm 2): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth, Followed by an second minute of potassium iodide solution application~- SDF Product generic name and information (Riva-star: it is a 2-step Technique) 30-35% SDF solution (1st step) comprised a blend of silver, fluoride, and ammonia applied in combination with a second application of potassium iodide solution (2nd step)"
48342080|NCT06166290|PROCEDURE|Electrosurgical Fulguration|The procedure is described as follows. Patient will be administered regional or general anesthesia, placed in prone jack-knife position. Prepping and draping will be done. The perianal and anal area will be investigated for lesion. The lesions will be excised, and the bases will be fulgurated. Electrosurgery device will be used in monopolar setting (30 Cut mode, 30 Coag mode). After procedure local analgesics total MERCAINE/EPI 0.25% 20 ml on both sides of the lesion. Bacitracin cream applied over the treated areas. Upon discharge 1000 mg of Tylenol every 8 hours along with 600 mg of ibuprofen every 8 hours.
48342081|NCT00398125|DRUG|GSK364735|
48342082|NCT03976518|DRUG|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
48342083|NCT01324128|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
48342084|NCT01324128|DRUG|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
48342085|NCT01324128|DRUG|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
48342086|NCT04445051|DEVICE|SpeediCath® Standard male or female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male or female.
48657041|NCT04412746|DRUG|MANAGEMENT OF COVID-19|"MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient."
48657042|NCT05309291|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode.
48342087|NCT04445051|DEVICE|New intermittent Variant 1 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 for male or female.
48342088|NCT04445051|DEVICE|New intermittent Variant 2 catheter for male or female|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 for male or female.
48342089|NCT05330624|BIOLOGICAL|plague vaccine(F1+rV)|plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
48657043|NCT05309291|DEVICE|FX 800 Dialyzer|Dialysis performed in HDF mode.
48657044|NCT06637579|OTHER|universal exercise unit therapy with task oriented strength training|Leg press, Sit to stand, Half knee rise, Lateral step up, Forward step up.
48657045|NCT06637579|OTHER|Task-oriented training for gross motor functioning|Standing transfer (hip abduction/adduction), Stair climbing (hip extension, calf raise), Walking and gait training, Reaching and grasping activities.
48342090|NCT01706991|DEVICE|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
48657046|NCT02918942|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
48657047|NCT05669027|DEVICE|Neurofeedback|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
48657048|NCT05669027|DEVICE|Sham (Placebo Control)|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
48499219|NCT00675753|GENETIC|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
47981704|NCT02297074|OTHER|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
48499220|NCT01857141|DRUG|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
48657049|NCT04869527|DEVICE|BIOTRONIK ICDs with DX Technology|The BIOTRONIK DX system offers a single chamber ICD that enables sensing of atrial signals through floating atrial dipoles, using a single ventricular lead. This technology enables enhanced arrhythmia diagnosis based on atrial and ventricular electrograms and, in addition, early diagnosis and automatic transmission of AF and heart failure (HF) diagnostic data. The DX technology provides several features in a single chamber device that are usually only found in dual chamber devices, including atrial diagnostics and SVT discrimination - early detection of SAF, increased diagnostics accuracy, dual-chamber discrimination. Nevertheless, the benefits of a single chamber device are preserved: reduced lead complications, reduced procedure complexity, elimination of costs for atrial lead. The DX system also integrates with BIOTRONIK Home Monitoring, allowing physicians to remotely follow their patients' clinical and device statuses with daily updates.
47981705|NCT02297074|OTHER|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
47981706|NCT02297074|OTHER|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
47981707|NCT02297074|OTHER|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
47981708|NCT02297074|OTHER|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
47981709|NCT02297074|OTHER|Glucose|50 g of glucose were administered as a reference
47981710|NCT05533021|OTHER|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
47981711|NCT01228331|DRUG|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
47981712|NCT01228331|DRUG|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
47981713|NCT01228331|DRUG|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
47981714|NCT01228331|DRUG|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
47981715|NCT01228331|DRUG|Daunorubicin hydrochloride|part of induction and reinduction therapy
48499221|NCT01857141|DRUG|normal saline|patients in the control groups received the equivalent volume of normal saline.
48499222|NCT00348452|DRUG|tramadol HCl ER; celecoxib|
48657050|NCT04258631|DRUG|Hydromorphone|Given IT
48657051|NCT04258631|PROCEDURE|Laparotomy|Undergo laparotomy
48657052|NCT04258631|DRUG|Liposomal Bupivacaine|Drug
47981716|NCT01228331|DRUG|Dexamethasone|part of reinduction therapy
48499223|NCT00525551|DRUG|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
48499224|NCT00525551|DRUG|Placebo (NaCl)|300 mL 0.9% NaCl
48513323|NCT05158543|OTHER|Task oriented training (high intensity)|In the moderate-intensity group, patients will perform 100 functional tasks with a total (1000) repetitions. Two sessions/day, 5 sessions/week for 12 weeks.
48499225|NCT05910476|DRUG|a high dose of statin/ezetimib|"In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.~A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation."
48499226|NCT01627353|PROCEDURE|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
48499227|NCT01627353|PROCEDURE|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
48134051|NCT06697301|DRUG|EIK1001|EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.
48657053|NCT04258631|OTHER|Questionnaire Administration|Ancillary studies
48134052|NCT06697301|DRUG|Pembrolizumab (KEYTRUDA® )|Pembrolizumab is a PD-1 inhibitor.
48499228|NCT04935424|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
48499229|NCT04162054|OTHER|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
48134055|NCT06627179|DRUG|Intravitreal Injection of Ultevursen|Up to 4 doses over a 24-month period
48134056|NCT06627179|OTHER|No intervention, will not receive any active study intervention|Sham-procedure (no experimental drug administered)
48499230|NCT05262998|PROCEDURE|Plate fixation|"Procedure: plate fixation~Plate fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. A standard surgical protocol was used, the approach was moved inferiorly, the fracture was reduced, sometimes with osteosutur and fixed with an antero-superior anatomical plate. 3.5mm Locked and cortical screws were used on both sides of the fracture. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
48513324|NCT04283604|DRUG|MPH|The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
48513325|NCT03244644|DRUG|RBX2660|RBX2660 is a rectally administered microbiota suspension
48513326|NCT03244644|DRUG|Placebo|Placebo is normal saline solution administered rectally
48657054|NCT05294146|DRUG|Clofazimine|"All participants will receive an (experimental) oral loading dose regimen of 300 mg clofazimine once daily (= 3 capsules of 100 mg) for 4 weeks. Afterwards, all participants will continue with a standard oral dose of 100 mg clofazimine once daily (= 1 capsule of 100 mg) until a total 4 months of treatment with CFZ.~Blood samples will be taken at Day 28 (+/- 2 days), Day 29 (Day 28 +1) and after 4 months of treatment to assess the pharmacokinetics of CFZ, both with the loading dose and the standard dose. In addition, the safety/tolerability of CFZ will monitored."
47981717|NCT01228331|DRUG|Doxorubicin hydrochloride|part of reinduction therapy
47981718|NCT01228331|DRUG|Etoposide phosphate|part of different chemotherapy blocks
47981719|NCT01228331|DRUG|Mercaptopurine|part of different chemotherapy blocks
47981720|NCT01228331|DRUG|Methotrexate|part of different chemotherapy blocks
48134071|NCT06308653|DRUG|Psilocybin 25 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.
48134072|NCT06308653|DRUG|Inactive Placebo|The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.
48134073|NCT06308653|DRUG|Psilocybin 5 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.
48134074|NCT06308653|BEHAVIORAL|Psychosocial Support|Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.
47981721|NCT01228331|DRUG|Methylprednisolone|part of different chemotherapy blocks
47981722|NCT01228331|DRUG|Pegaspargase|part of different chemotherapy blocks
47981723|NCT01228331|DRUG|Thioguanine|part of different chemotherapy blocks
47981724|NCT01228331|DRUG|Vincristine sulfate|part of intravenous chemotherapy
47981725|NCT01228331|RADIATION|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
48499231|NCT05262998|PROCEDURE|Intramedullary Screw|"Procedure: Intramedullary screw fixation~Intramedullary screw fixation was performed by the regular on-call team surgeons and adhered to standard principles of fracture fixation. Intramedullary screw fixation was performed by using a 1.6 or 2.8 mm-diameter threaded guide pin and a 85-100 mm long, 4.5 or 6.5 mm-diameter cannulated screw tapped in along the guide pin. Fluoroscopy was used during the procedure. Intradermal suture was used to close the skin.~Other: post-intervention All patients were discharged the day after the surgery. Interruption of work was given for 45 days. The same analgesics were administered in both groups for three weeks. Graduated exercises for the shoulder joint with pendular movements in a range of 15°-20° with the protection of a forearm sling were commenced from the postoperative second day. The sling was removed when X-ray films showed growth of callus or an indistinct fracture line."
48499232|NCT02014207|OTHER|dietary treatment|
48134077|NCT03213145|DRUG|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
48134078|NCT03213145|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
48134079|NCT03213145|DRUG|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
48134080|NCT01358669|DRUG|Denosumab|60mg denosumab by injection as a single dose
48134081|NCT01358669|OTHER|Placebo|Placebo by injection as a single dose
48499233|NCT00151138|DRUG|Atenolol (drug), Lisinopril (drug)|
48499234|NCT02767154|DEVICE|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
47981726|NCT05769881|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
48499235|NCT02767154|DEVICE|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
48134085|NCT06534957|OTHER|Online mindfulness-based stress reduction|The online MBSR intervention sessions will be available in a website created specifically for this purpose, where each pre-recorded session will be uploaded so that each patient can begin the intervention at the same time as their chemotherapy regimen. Each session will last approximately 1 hour, for a total of 6 sessions. The topics that will be covered in these sessions include: mindfulness overview, stress and suffering, emotional regulation, meditation, management of stressful situations, self-compassion and acceptance. Participants will watch 1 session per week following the order that will be indicated on the website; patients will be encouraged to watch the sessions during their chemotherapy infusions. During these sessions, patients will be instructed in mindfulness practice and will perform targeted exercises to promote complete consciousness, including mindful body awareness (body scan), gentle yoga exercises, and meditation.
47981727|NCT05769881|PROCEDURE|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
48499236|NCT06230718|OTHER|Motor Imagery (MI)|mental process where an individual visualizes or imagines themselves performing a movement without actually executing it physically. This cognitive process involves the mental rehearsal of motor actions, engaging similar neural pathways that are used when physically performing the action.
48499237|NCT06230718|OTHER|Action Observation (AO)|rehabilitation technique based on the principle of observing actions to improve motor function and learning. This approach is rooted in the concept of the mirror neuron system, a group of neurons that are activated both when a person performs an action and when they observe the same action performed by others.
48499238|NCT06230718|OTHER|Control condition- placebo|Recording with images of landscapes without the presence of any person or animal that could evoke MI or OA.
47981728|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
48499239|NCT04930419|DEVICE|Videolaryngoscopy group|Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
48499240|NCT04930419|DEVICE|Direct laryngoscopy group|Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
48499241|NCT05797818|DEVICE|Methylene Blue Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene Blue (0.01%) + 4 minutes of light treatment"
48499242|NCT05797818|DEVICE|Chlorhexidine Gluconate Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
48499243|NCT05797818|DEVICE|Methylene Blue + Chlorhexidine Gluconate|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
48134098|NCT01019213|OTHER|Septal pacing|Septal lead activated
48134099|NCT01019213|OTHER|His lead activated|His lead will be activated 80 ms before septal lead
48342091|NCT06284759|OTHER|post-discharge telenursing intervention|Tele-nursing based on Orem's Self-Care Theory was applied to patients with lower extremity fracture surgery. Phone/video calls 24-48 after discharge. hours, 7-10. day,18-21. day, 28-30th day and 40-45th day. day was made. Telephone or video conference interviews were held on the day and time convenient for the patient. After each meeting, the date and time of the next meeting was planned. The video conferencing method (zoom, skype, whatsapp, etc.) was presented to the patient's preference and the decision was made together. In phone/video conference calls, patients were informed about their current problems. Additionally, patients' questions were answered. Prior to tele-nursing monitoring, the researchers identified emergent or urgent situations; Patients were informed that they should consult their doctor if this occurs. The interview with each patient lasted an average of 30 minutes.
48342092|NCT00663689|DRUG|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
48342093|NCT01909219|DRUG|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
48342094|NCT05211245|DEVICE|therapeutic ultrasound|Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
48342095|NCT03979872|DIAGNOSTIC_TEST|MC1R Genetic Testing|\[See arm/group descriptions\]
48342096|NCT03979872|OTHER|Skin Cancer Education|\[See arm/group descriptions\]
48342097|NCT03979872|DEVICE|UV Photo|\[See arm/group descriptions\]
48342098|NCT02395289|BEHAVIORAL|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
48342099|NCT02395289|BEHAVIORAL|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
48342100|NCT05007262|DRUG|Tangningtongluo tablets|Four pills each time and three times a day after meals.
48499244|NCT05797818|DEVICE|Light Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~- 4 minutes of light treatment only"
48499245|NCT04460859|OTHER|Specific lung recruitment maneuvers|Specific lung recruitment maneuvers will be performed to measure the potential for lung recruitment at different levels of positive end-expiratory pressure (PEEP) provided by the mechanical ventilator. Electrical impedance tomography signals, synchronized signals of airway pressure and flow, esophageal pressure (if available), and volumetric capnography (if available) will be recorded continuously, during the time span of the protocol for offline analysis.
48499246|NCT03257514|DRUG|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
48499247|NCT03257514|DRUG|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
48499248|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
48342101|NCT05007262|DRUG|Calcium dobesilate capsules|1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.
48342102|NCT04114045|DIETARY_SUPPLEMENT|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
48342103|NCT04114045|DIETARY_SUPPLEMENT|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
48499249|NCT03599492|DIAGNOSTIC_TEST|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
48499250|NCT02255825|GENETIC|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
48499251|NCT02255825|PROCEDURE|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
48499252|NCT02255825|OTHER|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
48499253|NCT01989988|PROCEDURE|LMGB|
48499254|NCT01989988|PROCEDURE|LRYGB|
48499255|NCT01989988|PROCEDURE|SADJB|
48499256|NCT06462859|OTHER|Sensory Integration Therapy Group|The experimental group received sensory integration therapy in addition to the NDT program. The NDT program is customized for each child, featuring a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. Participants attended 45-minute NDT and sensory integration sessions three times a week for 8 weeks. Sensory integration therapy, visual perception activities (block design, shape recognition in pictures, puzzles, matching geometric shapes and letters, numbers and classification exercises), body awareness activities (showing body parts, drawing life-size drawings, turning left and right, recognizing body parts by touching ), tactile perception exercises (feeling and touching various textures and shapes) and visual-motor coordination training (eye tracking exercises, activities with moving objects and panel activities).
48342104|NCT04114045|OTHER|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
48342105|NCT04572685|DRUG|Paliperidone Palmitate|A long acting extended release injectable suspension intended for monthly intramuscular administration
48342106|NCT00369746|DRUG|citalopram|tablets, 60 mg maximum, daily, 12 weeks
48342107|NCT04142710|DEVICE|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
48342108|NCT03221712|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
48342109|NCT05164263|DRUG|Empagliflozin|Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
48499257|NCT06462859|OTHER|Neurodevelopmental Treatment Group|The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
48499258|NCT04779515|PROCEDURE|low-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
48342110|NCT00643799|DRUG|Celecoxib|200 mg oral capsule once daily for 6 months
48134105|NCT06669611|DRUG|Camrelizumab combined GP chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.Q3W 1 cycle, 4-6 cycles.
48134106|NCT06669611|DRUG|Camrelizumab combined TPC chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle. Q3W 1 cycle, 4-6 cycles.
48499259|NCT04779515|PROCEDURE|standard-pressure pneumoperitoneum|insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
48657055|NCT03632044|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
48342111|NCT00643799|DRUG|Naproxen|500 mg oral capsule twice daily for 6 months
48342112|NCT00643799|DRUG|Placebo|Matched oral placebo for 6 months
48342113|NCT02205164|DRUG|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
48342114|NCT02205164|DRUG|Palonosetron|Aloxi 0.25mg
48342115|NCT01150604|BEHAVIORAL|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
48342116|NCT00035568|DRUG|Glucovance (metformin HCl/glyburide)|
48342117|NCT00035568|DRUG|or Metformin HCl alone|
48342118|NCT00035568|DRUG|or Glyburide alone.|
48342119|NCT02734095|DEVICE|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
48342120|NCT06409767|OTHER|Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.|The calculation of NEWS requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. Each parameter used to calculate the NEWS will be collected least three times a day by the attending nurse.
48499260|NCT05263622|OTHER|Split-mouth administration for group B|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~* Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)"
48499261|NCT05263622|OTHER|Split-mouth administration for group A|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~* Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)"
48657056|NCT03632044|OTHER|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
48657057|NCT06626516|DRUG|Tebentafusp-Tebn|Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.
48657058|NCT06626516|DRUG|GM-CSF (Sargramostim)|Recombinant human GM-CSF (Sargramostim, Leukine®, Sanofi US) 1,500mg will be mixed with ethiodized oil (Ethiodol®). The GM-CSF/ethiodized oil mixture will be injected selectively into one of the hepatic lobes, followed by infusion of gelatin sponge particles to achieve the stasis of blood flow. This will repeat every 4 weeks.
48657059|NCT06626516|DRUG|BCNU|Patients will be treated with hepatic artery infusion of 300mg BCNU (1,3-bis \[2-chloroethyl\]-1-nitrosourea, Carmustine) dissolved in ethiodized oil followed by embolization with gelatin sponge particles \[TACE with BCNU 300mg\]; every 4 weeks +/- 7 days in the case of either bilobar or unilobar metastasis
48657060|NCT06192420|DRUG|Traumeel®|3g of gel three times daily for 7days (+1 day visit window)
48657061|NCT06192420|DRUG|Diclofenac sodium gel 1%|3g of gel three times daily for 7days (+1 day visit window)
48657062|NCT06192420|DRUG|Placebo|3g of gel three times daily for 7days (+1 day visit window)
47981729|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
47981730|NCT06205004|OTHER|Questionnaires|In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
47981731|NCT02749981|PROCEDURE|blood and tissue sampling|
47981732|NCT03435744|DRUG|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
47981733|NCT03435744|OTHER|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
47981734|NCT01907204|DRUG|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
47981735|NCT01907204|DRUG|Budesonide|Budesonide by metered dose inhaler
47981736|NCT01907204|DRUG|Budesonide|Budesonide by nebulization
47981737|NCT04471012|OTHER|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session."
47981738|NCT02050074|DRUG|Colesevelam|
47981739|NCT02050074|DRUG|Metformin|
47981740|NCT02050074|OTHER|Placebo|
47981741|NCT03643640|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
47981742|NCT03643640|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
47981743|NCT04811625|DRUG|PL-ASA|Pharmacologic profile of different aspirin formulations
47981744|NCT00210002|DRUG|Darbepoetin alfa (Aranesp®)|
47981745|NCT00210002|DRUG|Ferric saccharose(Venofer®)|
47981746|NCT05615389|DRUG|Medicinal Cannabis - C12T12|"Participants randomised to receive C12T12 Ruby Balanced Oil will commence with 0.008ml/kg/day (0.1 mg/kg/day THC) in two divided doses, and titrate up in four steps (increase by 0.008ml/kg/day every four days) over 16 days up to a maintenance dose of 0.04ml/kg/day (0.5mg/kg/day THC) in two divided doses, with a ceiling dose of 2ml/day (25mg/day THC) for participants weighing 50kg or more. The maintenance dose will then be continued from day 17 until day 42.~Down-titration will occur for 16 days after the end of study visit, in the reverse of the up-titration period."
47981747|NCT05615389|DRUG|Medicinal Cannabis - C20T5|Participants randomised to the C20T5 Ruby CBD Oil will receive a matched volume to the C12T12 arm during the up-titration, maintenance, and down-titration phases.
47981748|NCT05281991|DEVICE|Doppler ultrasonography|color flow Doppler ultrasonography
47981749|NCT05281991|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
47981750|NCT00060112|BIOLOGICAL|oblimersen sodium|Given IV
47981751|NCT00060112|DRUG|gemcitabine hydrochloride|Given IV
47981752|NCT00060112|OTHER|pharmacological study|Correlative studies
47981753|NCT00060112|OTHER|laboratory biomarker analysis|Correlative studies
47981754|NCT03059498|PROCEDURE|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
47981755|NCT03059498|PROCEDURE|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
47981756|NCT03059498|DRUG|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
47981757|NCT06023420|DRUG|4 Herbs Formula|4 herbs formula dose: 5g/day
48499262|NCT02066103|DRUG|Paclitaxel|
48499263|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
48342121|NCT02877316|OTHER|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
48342122|NCT02877316|OTHER|safety plan on paper|Standard treatment with safety plan on paper
48342123|NCT03039790|BIOLOGICAL|NoV Vaccine|NoV vaccine injection administered.
48342124|NCT01554189|DRUG|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
48342125|NCT01554189|DRUG|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
48499264|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
48342126|NCT00826488|DEVICE|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
48657063|NCT03757663|BEHAVIORAL|UV Counseling|Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
48499265|NCT01135186|DRUG|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
48499266|NCT06125132|PROCEDURE|Restoration with-tooth colored material|Restoration of abrasions with different composite resin materials
48657064|NCT02007460|BEHAVIORAL|Exercise|multidirectional unilateral hopping exercise
48657065|NCT03236883|DRUG|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
48657066|NCT03236883|OTHER|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.
48657067|NCT02422550|DEVICE|MRI or CT|Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
48657068|NCT05154734|DRUG|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
48657069|NCT02853292|BIOLOGICAL|urine collection|
48657070|NCT05157698|DRUG|Naltrexone and Bupropion Combination|Participants in this intervention will take active naltrexone and bupropion pills.
48657071|NCT05157698|BEHAVIORAL|Behavioral Weight Loss|Participants in this intervention will receive behavioral weight loss treatment.
48657072|NCT05157698|OTHER|Placebo|Participants in this intervention will take inactive (placebo) pills.
48657073|NCT00297791|PROCEDURE|surgery|randomized to open or laparoscopic technique
48657074|NCT06456164|DEVICE|Cook Cervical Ripening Balloon|The Cook Cervical Ripening Balloon is a double-balloon catheter designed to mechanically ripen the cervix prior to labor induction when the cervix is unfavorable for induction.
48657075|NCT06139354|BEHAVIORAL|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
48499267|NCT04769063|OTHER|Kinesio Tape|Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus
48499268|NCT02519738|DRUG|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
48134114|NCT06699433|BEHAVIORAL|Virtual standardized patients (VSPs)|Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases
48342127|NCT01944488|DRUG|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
48342128|NCT01954810|BIOLOGICAL|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
48134115|NCT06699433|BEHAVIORAL|Case teaching manuals|Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases
48134116|NCT06699433|BEHAVIORAL|Case teaching videos|Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases
48499269|NCT02519738|DRUG|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
48499270|NCT02519738|OTHER|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
48499271|NCT03102801|DRUG|Humulin S|Humulin S used to induce hypoglycaemia
48499272|NCT06460207|OTHER|fMRI neurofeedback|fMRI neurofeedback is a technique that allows individuals to observe real-time feedback of their brain activity as measured by fMRI scans. During a session, the participant lies inside an MRI scanner while their whole brain is scanned. This data is processed in real-time by a computer and then presented to the participant in the form of visual feedback. This feedback might be presented as a graph, a color-coded representation, or some other easily interpretable format. The participant is instructed to modulate their brain activity based on the feedback they receive. This can involve various mental strategies, such as focusing attention on specific thoughts, images, or sensations. Over repeated sessions, participants learn to consciously influence their brain activity based on the feedback they receive. Through trial and error, they discover which mental strategies are most effective for achieving their desired changes in brain activity.
48499273|NCT03222583|DRUG|Placebo|Matching placebo tablet for oral administration
48499274|NCT03222583|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
48499275|NCT00496353|DRUG|MK2461|MK2461 treatment, bid, 28-day
48499276|NCT02316665|DEVICE|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
48499277|NCT02316665|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
48499278|NCT00686530|PROCEDURE|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
48499279|NCT00686530|PROCEDURE|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
48499280|NCT00166907|BEHAVIORAL|Balance and Exercise|
48499281|NCT01844739|DRUG|NVN1000 4% Gel|Applied topically twice daily
48499282|NCT01844739|DRUG|Vehicle Gel|Applied topically twice daily
48499283|NCT03844217|DRUG|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
48499284|NCT03844217|DRUG|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
48499285|NCT03805646|OTHER|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
48499286|NCT06063265|BEHAVIORAL|Integrated Attention Training Program|Integrated Attention Training Program (IATP) specifically aims at training attentional control, which involves the coordination of complex behaviours, such as planning, reasoning, selection and information inhibition.
48657076|NCT01661595|DRUG|Sildenafil|50 mg/day for 4 weeks
48657077|NCT01661595|DRUG|tadalafil|10 mg/day for 4 weeks.
48499287|NCT00227786|BEHAVIORAL|smoking cessation intervention|
48499288|NCT00227786|OTHER|counseling intervention|
48499289|NCT03009916|DRUG|"cholestagel® (Colesevelam)"|3750mg
48499290|NCT03009916|DRUG|Placebos|3750mg
48499291|NCT02141425|DRUG|ASP015K|oral
48499292|NCT02141425|DRUG|Placebo|oral
48499293|NCT04006483|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
48499294|NCT04006483|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
48657078|NCT01661595|DRUG|Placebo|Placebo 1 capsule per day for four weeks.
48657079|NCT03272321|DRUG|Oxytocin|Syntocinon nasal spray
48657080|NCT03272321|DRUG|Placebo|Placebo nasal spray
48657081|NCT05085834|DRUG|Zinc Gluconate|Two 45 mg capsules once daily
48499295|NCT04006483|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
48657082|NCT05085834|DRUG|Placebo|Two placebo capsules once daily
48657083|NCT04388228|OTHER|Extended audit and feedback in GPs electronic health record|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback."
48657084|NCT02239237|DRUG|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
47981758|NCT03719976|OTHER|Group-based educational intervention|The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
47981759|NCT02111772|BIOLOGICAL|Rhinovirus|
47981760|NCT03645551|DIAGNOSTIC_TEST|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
47981761|NCT01721382|DRUG|Sitagliptin|
47981762|NCT03789045|DIAGNOSTIC_TEST|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
47981763|NCT05780567|DRUG|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
47981764|NCT05780567|DRUG|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
47981765|NCT03544502|DEVICE|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
47981766|NCT03544502|DEVICE|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
47981767|NCT03544502|DEVICE|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
47981768|NCT03544502|PROCEDURE|Ambient operating room noise|patients were exposed to the ambient operating room noise.
47981769|NCT01134978|BEHAVIORAL|Practice Order|"Blocked order - predictable~Random order - unpredictable"
47981770|NCT02584114|BEHAVIORAL|Peak app for memory training|
47981771|NCT02584114|BEHAVIORAL|Non-memory training group|
47981772|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)|"MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction."
48499296|NCT04091659|OTHER|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
48513327|NCT03244644|DRUG|Open label RBX2660 (only for confirmed CDI recurrence)|RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
48513328|NCT06233773|PROCEDURE|Kinesio Taping|Kinesio Taping
48134126|NCT06698783|DIETARY_SUPPLEMENT|Fortimel|In this study, patients will be provided with ONS preparation (4 kinds of ready-to-drink special medical food) free of charge during the treatment period. Doctors will provide patients with different flavor nutritional preparations on a weekly basis, 2 bottles per day for patients with 1 flavor per week, and 14 bottles per day for each of 4 flavors at the recommended dosage of 400 kcal per day 28 days
48657085|NCT04204915|PROCEDURE|Aortic valve replacement|Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
48657086|NCT05604703|DIAGNOSTIC_TEST|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
48513329|NCT06233773|PROCEDURE|Manual Lymph Drainage|Manual Lymph Drainage Group
48657087|NCT04709523|PROCEDURE|bovine-derived xenograft with i-PRF|Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
48657088|NCT04709523|PROCEDURE|bovine-derived xenograft alone|Bovine-derived xenograft was placed in the augmentation site.
48657089|NCT04660344|DRUG|Atezolizumab|Participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
48657090|NCT04660344|OTHER|Placebo|Participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
48657091|NCT05031897|DRUG|Fludarabine|Given IV
48657092|NCT05031897|RADIATION|Total-Body Irradiation|Undergo TBI
48657093|NCT05031897|PROCEDURE|Donor Lymphocyte Infusion|Undergo DLI
48657094|NCT05031897|DRUG|Cyclophosphamide|Given IV
48657095|NCT05031897|DRUG|Tacrolimus|Given IV
48657096|NCT05031897|DRUG|Mycophenolate Mofetil|Given IV
48657097|NCT05031897|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
48657098|NCT05031897|DRUG|Melphalan|Given IV
48657099|NCT05031897|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/ biopsy
48657100|NCT05031897|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
47981773|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)|"MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on."
47981774|NCT06327451|DRUG|Atorvastatin 20mg|Liptor is a capsule in the form of 20 mg, once daily.
47981775|NCT05949060|BEHAVIORAL|Compassion Intervention|The compassion intervention is a single-session 40-min intervention in which the participants practiced soothing rhythm breathing (i.e., they are directed to slow their breathing using a five-count inhale and five-count exhale). They will then be provided didactic instruction on compassion, and will then be guided through an experiential compassion practice adapted that encompasses cultivating feelings of compassion for a loved one and then for oneself.
47981776|NCT01943292|DRUG|Defactinib|
47981777|NCT01244906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
47981778|NCT00547092|DRUG|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
47981779|NCT00547092|DRUG|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
47981780|NCT04014842|DEVICE|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
47981781|NCT05620004|DRUG|Bifidobacterium Bifidum Oral Product|experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
48134127|NCT06699888|OTHER|cervicothoracic manipulation group|"The participant lay prone with the head firmly into the head piece Palpation of the upper cervico-thoracic segment observed the side of the restriction.~The participants head was rotated to the contralateral side of the restriction. The practitioner's hand contacted the forehead and the other hand's thumb contacted the spinous process of the restricted side.~A low amplitude, high velocity thrust towards the axilla was applied, on the spinous process in PA direction.~Experimental group also received following exercises Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks"
48513330|NCT06233773|OTHER|Control Group|Control Group
48657101|NCT05031897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48657102|NCT06594770|PROCEDURE|Atraumatic Restorative Treatment|"A sharp excavator will be used to remove soft demineralized carious tissue from the patient\&#39;s primary molar 2-The molar will then be restored with capsulated Glass Ionomer in accordance to ART procedure.~3-Each capsule will be mixed for ten seconds and used for restoring teeth isolated by cotton rolls.~4-After the cement is cured, excess material will be removed with an excavator and a carver.~5-The occlusion will be tested for interferences with carbon paper. A layer of varnish coat will be applied to the surface and light-cured for 20 seconds ."
47981782|NCT01550380|DRUG|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
48513331|NCT05326243|BIOLOGICAL|CD19-targeted chimeric antigen receptor T-cell|"Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis."
48513332|NCT06458647|OTHER|Video Streaming with Virtual Reality|In the study, patients in the intervention group will be watched videos of natural landscapes such as mountains, beaches and waterfalls with virtual reality goggles before the angiography procedure.
48134128|NCT06699888|OTHER|forward head correction exercises traditional group|Chin tuck Strengthening Shoulder Retractors. Stretching SCM Pectoralis Stretch 3 × 10 repetitions, 3 times a week for 2 weeks.
48134129|NCT03739658|OTHER|Education|Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
48499297|NCT04091659|OTHER|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
48499298|NCT04190810|BEHAVIORAL|Inhibition|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
48499299|NCT04190810|BEHAVIORAL|Classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
48499300|NCT04190810|BEHAVIORAL|Control|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
48134134|NCT06699758|OTHER|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.|CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.
48134135|NCT06698835|DIETARY_SUPPLEMENT|Turnip Consumption|Turnip Consumption and Qigong Exercise with educational Program about loss of weight
48499301|NCT05533827|OTHER|Kaleidoscope|Kaleidoscope
48499302|NCT05533827|OTHER|Music|Music
48134138|NCT06698692|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib Combined chemoradiotherapy
48499303|NCT05533827|OTHER|Virtual reality glasses|Virtual reality glasses
48499304|NCT04730349|BIOLOGICAL|Nivolumab|Specified dose on specified days
48499305|NCT04730349|BIOLOGICAL|NKTR-214|Specified dose on specified days
48499306|NCT00549289|DRUG|cyclosporine A|
48499307|NCT05882994|BEHAVIORAL|rom exercise|At the beginning of the study, participants will be asked to fill out data collection tools consisting of Personal Information Form, Piper Fatigue Scale, Pittsburgh Sleep Quality Index. Data will be collected with data collection tools in the 6th and 12th weeks. Evaluation will be done. At the end of the study, rom exercises will be applied to the patients in the control group.
48499308|NCT04526886|OTHER|Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy|Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
48499309|NCT01050608|DEVICE|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
48499310|NCT01050608|DRUG|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
48499311|NCT01050608|BEHAVIORAL|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
48342129|NCT02417675|OTHER|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
48499312|NCT01050608|BEHAVIORAL|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
48499313|NCT03043859|BEHAVIORAL|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
48499314|NCT06447311|OTHER|Hyaluronic acid gel|Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.
48499315|NCT05973266|BEHAVIORAL|Mobile Application-Based Bowel Preparation Training|The contents of the training in the mobile application where the patients receive bowel preparation training before the procedure are; short videos, images and slides about colonoscopy, bowel preparation drugs, liquid-clear diet and foods recommendations.A mobile application-based training will be provided to guide patients, where user (patient) usage activities are monitored by the researcher, sending notifications or reminders to the patient in accordance with the colonoscopy procedure date.
48499316|NCT00190190|PROCEDURE|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
48499317|NCT00190190|PROCEDURE|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
48499318|NCT05160233|BEHAVIORAL|Standard implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
48499319|NCT05160233|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
48499320|NCT05160233|BEHAVIORAL|Practice Facilitation|A trained facilitator provides support for implementation by delivering the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
48499321|NCT00796263|DRUG|HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily"
48499322|NCT02743910|OTHER|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
48513333|NCT02885766|DRUG|PF-114|
48499323|NCT02743910|OTHER|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
48499324|NCT05739214|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
48499325|NCT00373698|BEHAVIORAL|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
48499326|NCT00170794|DRUG|Everolimus (RAD001)|
48134146|NCT06698965|DRUG|Chemotherapy （Etoposide and Carboplatin）|"Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle."
48134147|NCT06698965|DRUG|Immunotherapy （Envafolimab）|Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
48134148|NCT06698965|DRUG|Trilaciclib|Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy
48499327|NCT03979781|DRUG|tailored antiplatelet selection|antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
48134150|NCT06357299|BEHAVIORAL|Small Bottle Size|Small sized bottle
48134151|NCT06357299|BEHAVIORAL|Standard Bottle Size|Standard sized bottle
48134152|NCT06357299|BEHAVIORAL|Clear Bottle|Clear bottle
48499328|NCT03979781|DRUG|standard of care|antiplatelet selection using standard of care
48134153|NCT06357299|BEHAVIORAL|Opaque Bottle|Opaque bottle
48499329|NCT01751932|DEVICE|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
48134155|NCT06699069|OTHER|Control or Euthyroid group|Fed on normal standard diet
48342130|NCT02417675|OTHER|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
48342131|NCT02417675|OTHER|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
48342132|NCT04389268|DIAGNOSTIC_TEST|Visual Event-Related Potentials|Auditory P300-evoked brain potential: an eventrelated potential of cognitive neurophysiological significance. It represents the brain response to certain sensory/cognitive stimuli by paying attention to the different stimulus among the stereotypical ones (the auditory oddball paradigm). It measures mainly the decision-making process (Polich and Kok, 1995).
48342133|NCT00856817|DRUG|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
48342134|NCT00856817|DRUG|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
48342135|NCT05051176|DIAGNOSTIC_TEST|2D usg and 3D/4D usg|IRD distance measured by a linear probe 2D usg. Pelvic floor muscle morphometry measured by 3D/4D usg
48134156|NCT06699069|OTHER|Hypothyroid group|Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
48342136|NCT04969627|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
48342137|NCT04969627|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
48499330|NCT01170013|BEHAVIORAL|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
48499331|NCT01170013|BEHAVIORAL|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
48499332|NCT00807248|DRUG|Escitalopram placebo|Once daily before bedtime for 8 weeks
48499333|NCT00807248|DRUG|Gaboxadol placebo|Once daily before bedtime for 8 weeks
48499334|NCT00807248|DRUG|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
48499335|NCT00807248|DRUG|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
48499336|NCT00807248|DRUG|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
48134157|NCT06699069|OTHER|Hypothyroid group received exercise|Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am
48499337|NCT05200000|BIOLOGICAL|SygeLIX-Coll-T|Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
48342138|NCT01204307|DRUG|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
48499338|NCT03554213|BIOLOGICAL|Typhoid Conjugate Vaccine|Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
48499339|NCT00775905|DRUG|amlodipine 10 mg tablet|
48499340|NCT05219123|OTHER|ERCP with no PD cannulation|ERCP with no PD cannulation
48499341|NCT05219123|OTHER|ERCP with single PD cannulation|ERCP with single PD cannulation
48499342|NCT00398255|BEHAVIORAL|self-management program|
48499343|NCT04493866|OTHER|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
48513334|NCT01591343|BIOLOGICAL|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
48134159|NCT06699381|DEVICE|use of spinal mouse|Spinal Mouse (SM) is an external non-invasive measurement device that evaluates the spinal angle and shape in the frontal and sagittal planes
48134160|NCT06699381|DIAGNOSTIC_TEST|Brunnstrom's Hemiplegia Recovery Staging|According to Brunnstrom's stages of recovery, the individual will be identified at which stage
48134161|NCT06699381|DIAGNOSTIC_TEST|The six minute walking test (6MWT)|It evaluates the functional capacity of the individual and it provides valuable information regarding all the systems during physical activity, including pulmonary and cardiovascular systems, blood circulation, neuromuscular units, body metabolism, and peripheral circulation
48134162|NCT06699381|DIAGNOSTIC_TEST|Functional Reach Test (FRT)|"Functional Reach Test (FRT) is a clinical outcome measure and assessment tool for ascertaining dynamic balance in in simple task.~In standing, measures the distance between the length of an outstretched arm in a maximal forward reach, while maintaining a fixed base of support.~This information is correlated with risk of falling A number of factors exert a major influence on this evaluation: Research revealed that movement strategy and reduced spinal flexibility both affect reach distance."
48342139|NCT01204307|DRUG|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
48342140|NCT06168890|DIAGNOSTIC_TEST|PET/CT with choline in the restaging phase of prostate cancer.|PET/CT with choline in the restaging phase of prostate cancer in patients suffering from prostate cancer with biochemical recovery of the disease during hormonal therapy.
48342141|NCT00650312|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
48342142|NCT00650312|DRUG|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
48342143|NCT04725201|DRUG|Intravenous unfractionated heparin|See experimental arm description for intervention description.
48342144|NCT04725201|DRUG|Sham|See sham comparator arm description for intervention description.
48499344|NCT03269318|DRUG|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
48657103|NCT06594770|PROCEDURE|Hall technique|"The procedure involves assessing the occlusion, contact points, and tooth shape. If contact points are present, orthodontic separators will be placed between the primary molars to create space for crown fitting, with the child seated upright to maintain airway safety. After 3 to 5 days, the separators will be removed, and loose plaque and debris will be cleared.~The correct crown size will be selected, ensuring it doesn't impinge on adjacent teeth, and will be filled with glass ionomer cement. The child will be instructed to bite down for two minutes to ensure proper seating. Excess cement will be removed, and contacts will be flossed. Any initial occlusal discrepancies are expected to resolve within weeks."
48657104|NCT03804255|OTHER|Survey Administration|Complete surveys
48657105|NCT06645093|OTHER|Fasting|Fasting implies 0 kilojoule. Water ad libitum is permitted.
48342145|NCT01071369|DRUG|Xylocaine|0.5% Xylocaine
48499345|NCT00901992|BEHAVIORAL|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
48499346|NCT00901992|BEHAVIORAL|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
48499347|NCT04326114|DEVICE|Inspiratory training device|Inspiratory training by a Power-breath device
48342146|NCT01071369|DRUG|Xylocaine and Celestone|non-particulate Celestone
48342147|NCT05912348|BEHAVIORAL|Low Physical Activity and Added Carbohydrate Group|Young men and women will transition into a low physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group. One of the control groups will undergo a low physical activity intervention.
48342148|NCT05912348|BEHAVIORAL|Low physical Activity Control|Young men and women will transition into a low physically active lifestyle for 10 days.
48342149|NCT05912348|BEHAVIORAL|High Physical Activity and Added Carbohydrate Group|Young men and women will transition into a high physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group.
48342150|NCT02125630|PROCEDURE|Surgery|Surgery to primary tumor
48342151|NCT02125630|DRUG|Systemic therapy|Systemic therapy based on tumor phenotype
48342152|NCT04939532|BEHAVIORAL|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
48499348|NCT04326114|DEVICE|Expiratory training device|Expiratory training a Winner-flow device
48499349|NCT01715792|OTHER|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
48499350|NCT01268501|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
48499351|NCT05665114|DRUG|QN-030a|NK cell therapy
48499352|NCT05665114|DRUG|Cyclophosphamid|Lympho-conditioning Agent
48499353|NCT05665114|DRUG|Fludarabine|Lympho-conditioning Agent
48499354|NCT05665114|DRUG|Cytarabine|Lympho-conditioning Agent
48499355|NCT05665114|DRUG|VP-16|Lympho-conditioning Agent
48499356|NCT04471337|DRUG|BAY1817080|BAY1817080 will be administered orally as tablet.
48342153|NCT04939532|BEHAVIORAL|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
47981783|NCT02604108|BEHAVIORAL|Physical Exercise|"The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
47981784|NCT02604108|BEHAVIORAL|Healthy Diet|"The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
48342154|NCT04356872|DRUG|Sintilimab|immune check point inhibitor, 200mg, iv, d1
48342155|NCT04356872|DRUG|Doxorubicin Hydrochloride|ADM, 60mg/m2, iv, d1
48342156|NCT04356872|DRUG|Ifosfamide|IFO, 1.8 g/m2/d, d1-5
48342157|NCT00053222|DRUG|arsenic trioxide|
48342158|NCT04752917|DEVICE|Noise Cancelling headphones|Use of headphones playing patients choice of music
47981785|NCT03132532|DRUG|Carboplatin|Chemotherapy
47981786|NCT03132532|DRUG|Cisplatin|Chemotherapy
47981787|NCT03132532|DRUG|Etoposide|Chemotherapy
47981788|NCT03132532|DRUG|Paclitaxel|Chemotherapy
47981789|NCT03132532|DRUG|Pemetrexed|Chemotherapy
47981790|NCT03132532|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
47981791|NCT03132532|OTHER|Quality-of-Life Assessment|Ancillary studies
48342159|NCT03838380|OTHER|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
48342160|NCT05051033|PROCEDURE|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
47981792|NCT03132532|OTHER|Questionnaire Administration|Ancillary studies
47981793|NCT05937347|BEHAVIORAL|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
48134163|NCT06699381|DIAGNOSTIC_TEST|Mini Balance Evaluation Systems Test (Mini-BESTest)|"This test measures dynamic balance, functional mobility, and gait. It is commonly used in populations who have or have had multiple sclerosis (MS), Parkinson disease (PD), strokes, spinal cord injury (SCI), or cancer.~The Mini-BESTest was developed in 2010 from the Balance Evaluation Systems Test (BESTest), then revised in 2013 to clarify inconsistencies in scoring. The scoring instructions were different in the published and online versions. The revision clarified that the Mini-BESTest should be scored out of 28 points. Explanations for how to score items 3, 6, and 14 were also given.~The Mini-BESTest consists of 14 items, including 4 of the 6 sections (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait) from the BESTest."
48134164|NCT06699381|DIAGNOSTIC_TEST|The five Times Sit to Stand Test (5x Sit-To-Stand Test)|It's used to asses functional lower limbs strength, transitional movements, balance, and fall risk in older adults.
48134165|NCT06699381|DIAGNOSTIC_TEST|The Postural Assessment Scale for Stroke (PASS)|The Postural Assessment Scale for Stroke (PASS) is an outcome measure specifically designed to assess and monitor postural control after stroke. It was developed in 1999 as an adaptation of the Fugl-Meyer Assessment balance subscale\[1\]. It contains 12 four-level items of varying difficulty for assessing ability to maintain or change a given lying, sitting or standing posture
48134166|NCT06699381|DIAGNOSTIC_TEST|Postural Symmetry Index and Weight Transfer Symmetry|It is a form of measurement in which two scales are used to calculate the weight transferred to the intact and stroke limb. The values obtained as a result of the test are calculated with formulas.
48134167|NCT06699381|DIAGNOSTIC_TEST|Measurement of the craniovertebral angle|Measurement of the craniovertebral angle; the patient is asked to find the most natural position by flexion and extension of the head in the standing position and a photograph is taken with a digital camera from a distance of 1.5 m to the shoulder level of the patient and this process is repeated 3 times. The images obtained are then digitally calculated with the help of an appropriate program.
48499357|NCT00003538|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
48499358|NCT00003538|PROCEDURE|allogeneic bone marrow transplantation|
48499359|NCT03177174|DRUG|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
48499360|NCT03177174|DRUG|Docetaxel|Docetaxel
48134173|NCT06700200|DEVICE|taVNS|transauricular vagus nerve stimulation
47981794|NCT05937347|BEHAVIORAL|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
47981795|NCT05937347|BEHAVIORAL|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
47981796|NCT05937347|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
48499361|NCT00228514|DRUG|Rosuvastatin|
48499362|NCT00228514|PROCEDURE|Positron emission tomography|
48499363|NCT05656651|BEHAVIORAL|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
48499364|NCT05951855|DRUG|Selinexor|Selinexor 60mg/day, weight≥70kg (40mg/day, weight\<70kg) orally on d1,4,8,11,
48499365|NCT05951855|DRUG|Chidamide|Chidamide 10mg/day, orally on day 1 to 28
48499366|NCT06442306|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) is a cognitive-based education intervention that aims to change pain beliefs in patients experiencing CMP. Researchers have found PNE beneficial in assisting patients to reframe their understanding, attitudes, thoughts, and beliefs regarding their pain experience. PNE directs patients to relate chronic pain to overly sensitive nerves rather than assumed tissue damage. Further, PNE encourages patients to perform daily activities, work, and function in society, all despite pain. This facilitates behavior changes that are key in amending a patient's biopsychosocial state. Multiple sources make a strong case for the incorporation of PNE in having positive effects on reducing physical disability and modulating fear and anxiety in patients with CMP. Researchers have established a positive influence of PNE toward decreased kinesiophobia and have demonstrated a relation between increased self-efficacy and increased functional ability.
47981797|NCT04874727|PROCEDURE|Mandible slacked and captured with Correct Plus™ Impression Material Superfast|In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
48499367|NCT06442306|OTHER|General Health Education|General Health Education included: 20 Benefits of Walking 30 Minutes a Day; Why You Should Quit: Smoking Cessation; Heat vs. Cold: How to Use it For Pain Control; Sleep Hygiene.
48499368|NCT00479778|DRUG|Bazedoxifene/conjugated estrogens|
48499369|NCT05498675|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
48499370|NCT05498675|DRUG|ACEI/ARB|"There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
48342161|NCT05051033|DEVICE|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
48342162|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
48342163|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
48342164|NCT02955771|DEVICE|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
48342165|NCT00486512|DRUG|0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
48342166|NCT00486512|DRUG|75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
48342167|NCT00486512|DRUG|placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
48342168|NCT00486512|DRUG|placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
48342169|NCT00486512|PROCEDURE|Colonoscopy|
48342170|NCT00770224|BIOLOGICAL|rituximab|
48342171|NCT00770224|BIOLOGICAL|tositumomab|
48342172|NCT00770224|DRUG|cyclophosphamide|
48342173|NCT00770224|DRUG|doxorubicin|
48342174|NCT00770224|DRUG|prednisone|
48342175|NCT00770224|DRUG|vincristine|
48342176|NCT00770224|RADIATION|tositumomab|
48342177|NCT04288297|PROCEDURE|distal minimally invasive chevron osteotomy|With an electric motor-driven machine the resection of the medial eminence as well as a V-shaped osteotomy was performed in hallux valgus patients. Intraoperative fluoroscopy was used to identify the ideal osteotomy site and to control the Intervention. Fixation of the metatarsal head was achieved with a screw or with a K wire. Residual bone ridges were reamed and bone debris washed out.
48134176|NCT06699368|PROCEDURE|The ultra-high-power ablation group|The ultra-high-power ablation group will use the QDOT ablation catheter with a power of 90W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g. The cold saline flow rate during ablation is 8ml/min, and the ablation device will adjust power and saline flow rate based on the electrode temperature at the tip of the QDOT ablation catheter. The target temperature is 60°C, and the cut-off temperature is 65°C, with an ablation endpoint of 4 seconds.
48342178|NCT03510910|DRUG|Acetaminophen|acetaminophen 600 mg to be taken every 8 hours (TID)
48342179|NCT03510910|DRUG|Percocet|"Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN"
48342180|NCT03105661|DRUG|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
48342181|NCT03105661|DRUG|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
48342182|NCT03105661|DRUG|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
48342183|NCT05396807|DEVICE|AI|The aim of using AI software to support physicians in choosing the most effective treatment.
48342184|NCT02939651|DRUG|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
48342185|NCT00252317|DRUG|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
48342186|NCT00252317|DRUG|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
48342187|NCT00966680|OTHER|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
48342188|NCT04843072|DEVICE|Evolut R/PRO bioprosthesis|To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses
48342189|NCT04843072|DEVICE|Edwards Sapien S3/Ultra bioprosthesis|Edwards Sapien S3/Ultra bioprosthesis
48342190|NCT02266004|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
48342191|NCT02266004|OTHER|locomotor training|An individualized dual-task walking program for approximately 30 minutes.
48499371|NCT03048188|OTHER|wound dressing|Manuka honey wound dressing
47981798|NCT03747328|DRUG|ABI-009|nanoparticle albumin bound sirolimus
48134177|NCT06699368|PROCEDURE|The high-power ablation group|The high-power ablation group will use the STSF ablation catheter with a power of 50W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g, and a cold saline flow rate of 15ml/min during ablation. The ablation endpoint for the posterior wall of the left atrium is an Ablation Index (AI) value of 360-410, for the anterior wall 450-480, and for the bottom and top of the left atrium 420-450.
48499372|NCT02651779|PROCEDURE|Open reduction and internal plate fixation|
48499373|NCT02651779|OTHER|Closed reduction and plasterimmobilisation|
48499374|NCT02323516|DRUG|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
48499375|NCT02323516|DRUG|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
48134182|NCT06697106|DRUG|Nonsteroidal anti-inflammatory drugs|Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
48134183|NCT06697106|DRUG|Placebo|Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.
48134184|NCT06696508|PROCEDURE|Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing during laparoscopic pyeloplasty|"After proper dissection of the PUJ, the anterior wall of the renal pelvis was incised.~The incision continued downwards and laterally towards the PUJ and the lateral aspect of the ureter.~In cases where crossing vessels were present, the pelvis with the PUJ and the uppermost part of the ureter were properly dissected from these vessels. This gave a wide room for pulling the pelvis upwards and gentle retraction of the crossing vessels allowing incision of the anterior wall of the pelvis and starting the spatulation of the PUJ. Spatulation could then continue to the upper ureter behind the properly dissected and retracted vessels.~After complete spatulation and before dismembering the PUJ, we made benefit of splinting the ureter in place; a Maryland grasper opened the lumen of the ureter and the first stitch was precisely placed from outside inwards at the proper angle of the ureteric spatulation using 5/0 Vicryl sutures.~The posterior wall of the PUJ and the pelvis was then dismembered"
48134185|NCT06696508|PROCEDURE|Classic Laparoscopic Dismembered Pyeloplasty|the PUJ was dismembered after proper dissection, the lateral aspect of the ureter was spatulated and the first stich was also placed in the spatulation angle from outside inwards. All these steps were done after the discontinuation of the ureter and the pelvis, losing the benefit of ureteric splinting and orientation
48134186|NCT06687148|OTHER|Manual manipulation|The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
48134187|NCT06687148|OTHER|Sham manipulation|The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
48499376|NCT00236366|DRUG|fentanyl|
48342192|NCT06507098|OTHER|Video-assisted training|Patients received a QR code and a link for access to a YouTube video recorded to this effect where the process of setting up the respiratory polygraph was explained. The contents of the video were the same as those in the face-to-face instructions. The visualization of the video was at home, and it could be viewed as many times as necessary.
48342193|NCT06507098|OTHER|Nurse training|A trained nurse with long experience in home sleep studies explained the setup of the respiratory polygraph. At the end of the intervention doubts about the procedure were addressed. Patients did not have access to the video.
48342194|NCT01234519|DRUG|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
47981799|NCT05525143|PROCEDURE|Pregnant women who have given birth vaginally or by cesarean section|Full-term pregnant women who have given birth vaginally or by cesarean section with PPH. Descriptive statistics and possible causal factors
47981800|NCT04876274|BEHAVIORAL|TMU-LOVE|Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
48342195|NCT01234519|DRUG|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
48367444|NCT01454895|BEHAVIORAL|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
47981801|NCT02050360|DRUG|Sildenafil 40 mg|
47981802|NCT02050360|DRUG|Sildenafil 80 mg|
47981803|NCT02050360|DRUG|Placebo|
47981804|NCT04384666|DRUG|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
48657106|NCT06541197|OTHER|Robotic rehabilitation combined with Functional Electrical Stimulation (FES) bicycle ergometry group|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks. For FES bicycle ergometry, a current-controlled six-channel stimulator (RT 300-SLSA; Restorative Therapies, Baltimore, MD, USA) will be used. The quadriceps, hamstring and tibialis anterior muscles will be stimulated bilaterally with six channels through 3 × 4 cm2 adhesive surface electrodes. Stimulation intensity will be adjusted according to palpable muscle contraction and sensory discomfort felt by patients with incomplete SCI. The pedaling cadence range will be set to 40-50 rotations per minute. FES bicycle ergometry will be performed in 30-minute sessions for 4 weeks for a total of 20 sessions before robotic rehabilitation.
48657107|NCT06541197|OTHER|Robotic rehabilitation|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks.
48657108|NCT00605189|DEVICE|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
48657109|NCT00605189|DEVICE|Powered Suction Pump|continuous gauze based negative pressure wound therapy
48657110|NCT00605189|DEVICE|MWT|moist wound therapy
47981805|NCT04384666|OTHER|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
48657111|NCT04621877|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
48657112|NCT04621877|BEHAVIORAL|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
48657113|NCT03671226|OTHER|Questionnaire Administration|Given questionnaire
48657114|NCT06640153|DIAGNOSTIC_TEST|mpMRI|Gastroesophageal junction or upper gastric adenocarcinoma patients undergo mpMRI at siewert classification, length of esophageal involvement, primary staging and restaging
48657115|NCT00112385|DRUG|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
48657116|NCT00112385|DRUG|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
48657117|NCT06241352|DRUG|statin addition to chemotherapy|Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels (with CA19-9 negative patients referenced against CEA or CA-125) rose more than 20% above baseline.
48657118|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy with use of Emdogain|Scaling of root with assisted use of the Videoscope and regrowth of attachment by the use of Emdogain.
48657119|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy without the use of Emdogain|Scaling of root with assisted use of the Videoscope.
48657120|NCT06212817|OTHER|Dietary intervention|Increase dietary fiber intake
48657121|NCT06498479|DRUG|HS-20093|HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.
48657122|NCT06498479|DRUG|Topotecan|Topotecan will be administered per drug label.
48657123|NCT04952571|DRUG|Camrelizumab and Bevacizumab|"Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion."
48657124|NCT06003712|BEHAVIORAL|Mindfulness|Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
48657125|NCT06642597|OTHER|Incremental PD|Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.
48657126|NCT06642597|OTHER|Full dose PD|Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
48657127|NCT02758821|OTHER|No CRP will be measured onsite|No CRP will be measured onsite
47981806|NCT00819221|DRUG|AZD2281|capsules, oral, bd, 2 months
47981807|NCT00819221|DRUG|liposomal doxorubicin|once every 4 weeks at 40mg/m2
47981808|NCT01414114|DRUG|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
47981809|NCT00525707|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
48499377|NCT03552094|OTHER|Blood donations of hemochromatosis or polycythemia patients|Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
48134190|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
48134191|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
48134192|NCT06690242|DRUG|Etelcalcetide Hydrochloride|the already-marketed therapeutic agents
48134193|NCT06690242|DRUG|Placebo|The measure does not contain the active ingredients
47981810|NCT03229161|BEHAVIORAL|IWT-group|
47981811|NCT04570150|DRUG|Sugammadex|Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
48499378|NCT03552094|OTHER|Blood donations of healthy donors|Blood samples are from blood donations of healthy donors.
48499379|NCT02705404|GENETIC|Multifocal Tissue Banking|
48134196|NCT06400537|BIOLOGICAL|A-319|A-319 will be infused intravenously.
48499380|NCT04296058|OTHER|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
48499381|NCT01195103|DRUG|Fospropofol disodium|10 mg/kg bolus
48499382|NCT01195103|DRUG|Fospropofol disodium|6.5 mg/kg bolus
48499383|NCT01195103|DRUG|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients \<60 kg; 1.5 mg for patients ≥60 kg to \<90 kg; or 2 mg for patients ≥90 kg
48657128|NCT02758821|OTHER|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.
48657129|NCT02758821|OTHER|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.
48657130|NCT06645444|OTHER|immediate implant placement with customized PEEK healing abutment|"* an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery."
48367445|NCT03077646|BEHAVIORAL|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
48657131|NCT05620940|DRUG|Vivitrol Injectable Product|Naltrexone Long-Acting Injection
48657132|NCT05620940|DRUG|IVL3004|Naltrexone Long-Acting Injection
48657133|NCT05620940|DRUG|IVL4002|Naltrexone Long-Acting Injection
47981812|NCT04570150|DRUG|Neostigmine|Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
47981813|NCT05604690|BIOLOGICAL|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
47981814|NCT05604690|COMBINATION_PRODUCT|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
48367446|NCT03077646|BEHAVIORAL|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
48657134|NCT05426083|OTHER|Physiological Assessment|Observational only
48657135|NCT06323421|BEHAVIORAL|Mindfulness|Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.
48657136|NCT02208167|BIOLOGICAL|HXTC infusion|
48657137|NCT01875601|BIOLOGICAL|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
48657138|NCT01875601|BIOLOGICAL|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
48657139|NCT05504434|DEVICE|Single-use gastroscope|Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
48657140|NCT03427619|DRUG|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
48657141|NCT03044054|DEVICE|ECHOPULSE|HIFU Under ultrasound guidance
48657142|NCT06474013|DEVICE|ExAblate 4000 Type 2.1|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.1 system, and this will be performed 3 times every 2 months.
48499384|NCT01195103|DRUG|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
48499385|NCT05332028|DRUG|bupivacaine|Block applications
48499386|NCT05332028|DEVICE|22 gauge 100 mm needle|Block applications
48499387|NCT05332028|DRUG|Propofol|Routine general anesthesia protocol
48499388|NCT05332028|DRUG|fentanyl|patient-controlled analgesia
48657143|NCT06094621|OTHER|Survey|For the patients who underwent a pre-operative virtual visit, data will be collected through semi-structured interviews conducted by trained research personnel. The interviews will be conducted in a one-on-one format, either in-person or via telephone, according to the participant's preference.
48657144|NCT05229705|BEHAVIORAL|Resistance exercise|Participants in this exercise group will receive progressive resistance training.
48657145|NCT03537508|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
48657146|NCT03537508|BIOLOGICAL|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
48657147|NCT03537508|BIOLOGICAL|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
48657148|NCT03537508|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
48657149|NCT03537508|BIOLOGICAL|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
48657150|NCT03537508|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
48657151|NCT03537508|BIOLOGICAL|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age, Subcutaneous
48657152|NCT03537508|BIOLOGICAL|Varicella vaccine|Varicella vaccine at 12 months of age
48657153|NCT03537508|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
48657154|NCT03616340|DRUG|Shoulder injection|intra articular or subacromial shoulder injection
48657155|NCT03616340|DRUG|knee injection|intra-articular knee injection
48657156|NCT02959346|PROCEDURE|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
48657157|NCT02959346|PROCEDURE|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
48657158|NCT05745246|BEHAVIORAL|e-health training program|"1. Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~2. A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~3. A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
48657159|NCT06347315|DIETARY_SUPPLEMENT|BrainXpert|sachet/stickpack of 25 g, has no preservatives, no flavors, no sweeteners, and no colorants.
48657160|NCT06347315|OTHER|Placebo|high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will also be provided in a powder format in a sachet/stickpack of 25 g.
48657161|NCT04938427|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
47981815|NCT05604690|OTHER|Placebo|Placebo will be administered via intranasal route.
48499389|NCT02588950|DRUG|U-500R|
48499390|NCT00295295|DEVICE|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
48499391|NCT00295295|OTHER|Standing|Standing 10 min/day
48499392|NCT00258050|DRUG|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
48499393|NCT00258050|DRUG|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
48499394|NCT02802449|DRUG|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
48499395|NCT02802449|DRUG|Placebo|
48499396|NCT06168786|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
48657162|NCT04938427|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
48657163|NCT03702270|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
48657164|NCT06641011|DEVICE|Immediate restoration (resin- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant
48657165|NCT06641011|DEVICE|Immediate restoration (GI- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant
48657166|NCT06641011|DEVICE|Immediate restoration (Resin based) after rinsing silver fluoride application|Rinsing silver fluoride off followed by resin-based fissure sealant
48342196|NCT05018169|BEHAVIORAL|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
48342197|NCT06338852|OTHER|Socio demographic and evaluation questionnaires|Socio demographic and evaluation questionnaires Used to measure the awareness of gynaecologists about role of physical therapy in genital prolapse
48342198|NCT03168841|DRUG|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
48342199|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
48342200|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
48342201|NCT01095666|DRUG|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
48342202|NCT01095666|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
48342203|NCT01095666|DRUG|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
48342204|NCT04901104|DRUG|Thymosin Alpha1|Drug interventions have been done in previous clinical studies
48342205|NCT01804647|OTHER|No study treatments administered - blood draws only|
48342206|NCT06244719|DEVICE|Vibrotactile Stimulation|Shirts contain embedded vibration motors that stimulate the impaired upper-extremity at 18 different locations. The gloves stimulates the fingertips.
48342207|NCT02685618|DRUG|Iloprost|
48342208|NCT02685618|DRUG|Saline|
48342209|NCT02685618|DEVICE|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
48342210|NCT02685618|DEVICE|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
48342211|NCT01026350|DIETARY_SUPPLEMENT|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
48342212|NCT00355329|PROCEDURE|Tongue Acupuncture (Procedure)|
48499397|NCT06168786|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
48657167|NCT06641011|DEVICE|Immediate restoration (GIC) after rinsing silver fluoride application|Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant
48342213|NCT03927911|DRUG|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
48342214|NCT03927911|DRUG|Standard of Care|Standard of Care
48342215|NCT03049072|RADIATION|Protons and Carbon Ions|
48342216|NCT05537961|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness instruction incorporated in classroom-based curriculum
48342217|NCT01674985|BIOLOGICAL|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
48342218|NCT01178723|DIETARY_SUPPLEMENT|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
48342219|NCT00784082|DRUG|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
48342220|NCT02957474|DRUG|GED-0301|
48342221|NCT02957474|DRUG|Omeprazole|
48342222|NCT05514925|DRUG|Bevacizumab Injection [Avastin]|Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
48342223|NCT05514925|PROCEDURE|Peripheral Retinal Cryoapplication|In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
48342224|NCT05936593|DEVICE|Condylar Stabilizing (CS) insert|During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
48342225|NCT05936593|DEVICE|Cruciate Retaining (CR) insert|During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
48342226|NCT00134407|PROCEDURE|Normal diet|
48342227|NCT00134407|PROCEDURE|Nutrition via jejunal needle-catheter|
48342228|NCT00735527|DRUG|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
48342229|NCT00735527|DRUG|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
48342230|NCT05750485|OTHER|Pupilometric evaluation|Pupilometric evaluation under procedural sedation with propofol
48499398|NCT06168786|RADIATION|SBRT|SBRT:8-10Gy×5F，qod， in 10 days
48499399|NCT05527574|OTHER|Resistance Exercise|Participants are enrolled in 30-40 minutes of resistance exercise training using elastic bands for 30-40 minutes/session three times per week over six months
48342231|NCT02365805|DRUG|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
48342232|NCT02365805|DRUG|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
48342233|NCT02365805|DRUG|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
48342234|NCT03363165|DRUG|VM202|"Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
48342235|NCT03363165|OTHER|Placebo|"Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
48342236|NCT03786406|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
48342237|NCT00606294|RADIATION|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
48342238|NCT00606294|DEVICE|18F-FMISO PET scan|
48342239|NCT00606294|DEVICE|MRI|
48499400|NCT03735069|PROCEDURE|IPT (Indirect pulp treatment)|Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
48342240|NCT00606294|DEVICE|FDG PET/CT scan|
48342241|NCT02866929|PROCEDURE|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
48342242|NCT02866929|DEVICE|Orthodontics|Self-ligation brackets in upper and lower teeth
48342243|NCT02866929|DRUG|Mucograft|Porcine naturally cross-linked collagen matrix
48342244|NCT03788616|DRUG|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
48342245|NCT03788616|DRUG|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
48499401|NCT03735069|PROCEDURE|Cvek/partial pulpotomy|Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
48499402|NCT03735069|PROCEDURE|Cervical pulpotomy|Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
48342246|NCT02672618|OTHER||The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
48342247|NCT00621010|DRUG|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
48499403|NCT01480843|DRUG|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
48499404|NCT00045292|DRUG|acyclovir|
48499405|NCT00045292|DRUG|acyclovir sodium|
48134205|NCT06603623|DRUG|BHV-2100|BHV-2100 75mg
48134206|NCT06603623|DRUG|BHV-2100|BHV-2100 150 mg
48134207|NCT06603623|DRUG|Placebo|matching placebo
48342248|NCT00618904|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
48342249|NCT00618904|DIETARY_SUPPLEMENT|Placebo|Placebo administered bid for 6 weeks.
48342250|NCT00645515|DRUG|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
48499406|NCT00045292|DRUG|valacyclovir|
48342251|NCT00645515|DRUG|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
48342252|NCT01934868|DRUG|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
48499407|NCT02302547|DRUG|triple therapy|Dosage treatment and usual prescription
48342253|NCT01934868|DRUG|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
48342254|NCT01505114|DRUG|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
48499408|NCT02302547|DRUG|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
48499409|NCT05935241|BEHAVIORAL|mPATH|The active mPATH intervention takes 6 months including (1) The physical activity education session , (2)mHealth learning and practice; (3)Personalized physical activity training, plan, and biweekly phone calls over 24 weeks (4) mHealth strategies to encourage physical activity and facilitate intervention adherence (5) (5) mPATH during 6-12 months: mPATH will be delivered mainly in 24 weeks before the 6-month data collection. During 6-12 months, the participants will have access to study mHealth strategies, and exercise videos. No additional physical activity training by staff will be supported.
48499410|NCT05935241|OTHER|Attention Control|A registered nurse from the study team will provide 6 monthly home visit (approximately 55-60 minutes each) to provide physical activity education, physical activity safety at home evaluation, feedback, and social activity (meaningful or enjoyable activities as identified by the participants, such as playing cards, doing arts and crafts, listening to music, talking about life history, etc.).
48499411|NCT02303041|DRUG|Buparlisib|Administered orally at starting dose of 80 mg/day
48499412|NCT02303041|DRUG|Sonidegib|Administered orally at starting dose of 200 mg/day
48499413|NCT02852720|DRUG|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
48499414|NCT02852720|PROCEDURE|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
48134208|NCT06226155|BEHAVIORAL|TENDAI4PrEP|An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
48134209|NCT06226155|OTHER|Enhanced treatment as usual|"Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC."
48342255|NCT01505114|DRUG|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
48342256|NCT01505114|DRUG|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
48499415|NCT02852720|PROCEDURE|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
48499416|NCT02852720|PROCEDURE|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
48499417|NCT02852720|DEVICE|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
48499418|NCT02724930|BEHAVIORAL|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
48499419|NCT01866059|DEVICE|Calcium silicate cement|Calcium silicate cement
48499420|NCT01866059|DEVICE|Glass Ionomer Cement|Glass Ionomer Cement
48499421|NCT01866059|DEVICE|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
48657168|NCT06641011|DEVICE|Resin based fissure sealant restoration one week after silver fluoride (AgF) application|Resin based fissure sealant restoration one week after silver fluoride (AgF) application
48657169|NCT06641011|DEVICE|GI- based fissure sealant restoration one week after silver fluoride (AgF) application|GI- based fissure sealant restoration one week after silver fluoride (AgF) application
48657170|NCT04897568|OTHER|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
48499422|NCT01372774|RADIATION|stereotactic radiosurgery|Undergo RT
48657171|NCT02989857|DRUG|AG-120|Tablet administered orally
48657172|NCT02989857|DRUG|Placebo|Tablet administered orally
48657173|NCT00867139|DRUG|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
48657174|NCT00867139|DRUG|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
48657175|NCT00867139|OTHER|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
48657176|NCT06303453|OTHER|Balance exercises|Balance exercises includes active movements (flexion, extension, abduction, adduction) of one upper extremity and lower extremity, trunk movements (bending forward and rotation), raising heel, raising toes and raising heel. Every move in each session will be hold for 30 seconds. The part B comprises of training i.e., holding positions in standing posture which include moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand and throwing the ball against the wall with foot.
48342257|NCT01505114|OTHER|Maraviroc placebo|Once daily from Week 0 through Week 48
48342258|NCT01505114|OTHER|Emtricitabine placebo|Once daily from Week 0 through Week 48
48342259|NCT01505114|OTHER|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
48342260|NCT04824105|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System will be used to deliver intermittent theta burst to ventromedial prefrontal cortex, and continuous theta burst to pre-supplementary motor area.
48342261|NCT06127511|OTHER|Food (peanut)|After the recruitment, the participants will follow a peanut-free diet for two weeks.
48342262|NCT05128695|OTHER|there is no intervention; the study is observational|there is no intervention; the study is observational
48342263|NCT03556865|OTHER|A self administered questionnaire|"The questionnaire is in English language, it contains binary questions related to KAP on different preventive measures in pediatric dentistry and consists of 38 items divided into 4 sections as follows:~I) Socio-demographic data: (7 items). It includes gender, total years in practice, nature of primary practice, school of graduation, scientific degree and specialty II) Assessment of Knowledge towards preventive measures in pediatric dentistry. (16 items) III) Assessment of Attitude towards preventive measures in pediatric dentistry. (10 items) IV) Assessment of Practice towards preventive measures in pediatric dentistry. (5items) One score is given for each response to items."
48342264|NCT05757024|DEVICE|high power laser therapy|m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
48342265|NCT02929368|DEVICE|PICC implantation under fluoroscopy|PICC Catheter implantation
48342266|NCT02929368|DEVICE|PICC Implantation under Sherlock System|PICC Catheter implantation
48342267|NCT04616092|DRUG|FEFINJECT|FEFINJECT injection
48342268|NCT02242760|DRUG|SB204 2%|Applied topically twice daily
48342269|NCT02242760|DRUG|SB204 4%|Applied topically daily
48342270|NCT02242760|DRUG|Vehicle Gel|Applied topically twice and once daily
48342271|NCT03520205|PROCEDURE|Quadratus Lumborum Block|Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia
48342272|NCT03520205|PROCEDURE|Continuous Epidural|Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
48342273|NCT04058158|DRUG|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
48342274|NCT04058158|DRUG|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
48134210|NCT01462799|BEHAVIORAL|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
48134211|NCT01462799|BEHAVIORAL|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
48342275|NCT03879629|DRUG|Carvedilol|oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
48342276|NCT02547519|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
48342277|NCT02547519|DRUG|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
48342278|NCT03945201|OTHER|Virtual walking trails|During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.
48342279|NCT03945201|OTHER|Standard of care|"Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes."
48342280|NCT03658317|DIAGNOSTIC_TEST|renal arterial resistive index|done by dupplex on renal arteries
48342281|NCT03658317|DIAGNOSTIC_TEST|uric acid level|serum sample for doing the test
48342282|NCT03658317|DIAGNOSTIC_TEST|serum urea and creatinine|serum samples for doing the test
48342283|NCT03658317|DIAGNOSTIC_TEST|24 hours urinary proteins|urine collected over 24 hours for doing the test
48342284|NCT03658317|DIAGNOSTIC_TEST|lipogram|serum sample for doing the test
48342285|NCT03658317|DIAGNOSTIC_TEST|HbA1c level|serum sample for doing the test
48342286|NCT03658317|DIAGNOSTIC_TEST|urine analysis|urine sample for doing the test
48342287|NCT03658317|DIAGNOSTIC_TEST|abdominal ultrasonography|done by the ultrasonography device
48342288|NCT01477073|DRUG|FSH-GEX™|
48342289|NCT01477073|DRUG|recombinant FSH|
48342290|NCT01477073|DRUG|urinary FSH|
48342291|NCT01477073|DRUG|Placebo|
48342292|NCT02746445|OTHER|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
48342293|NCT01116310|DRUG|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
48342294|NCT01116310|DRUG|Placebo|Bottles containing 60 capsules.
48342295|NCT02758912|DRUG|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
48342296|NCT06089655|DEVICE|CGMS|The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).
48342297|NCT06089655|BEHAVIORAL|AI diet application|The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
48499423|NCT01372774|RADIATION|whole-brain radiation therapy|Undergo radiotherapy (RT)
48499424|NCT01915706|PROCEDURE|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
48499425|NCT03479567|OTHER|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
48657177|NCT06303453|OTHER|Resisted exercises|"The resistance training protocol include shoulder flexion and extension with 1 kg weight, shoulder pulley with 2 kg weight, arm curls with 1 kg weight, wall push-ups, bridging, hip abduction and adduction against resistance band, knee extensions and flexion in sitting position with resistance applied by contralateral limb, knee adduction and abduction with resistance band, mini squats, strengthening exercise for toes flexor and extensor (22), resisted inversion and eversion and straight leg raise (SLR) with 1 kg ankle weight (10).~Every move in each session comprises of 2 sets of 3 reps each and 1 set will be added at 4th and 8th week."
48657178|NCT03774121|DEVICE|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve \& anterior femoral cutaneous nerve) guided by ultrasound visualization.
48657179|NCT03774121|OTHER|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
48657180|NCT03774121|DEVICE|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
48134212|NCT05834452|PROCEDURE|The Epley Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotated 90° towards the unaffected side around the yaw axis~4. Rotate a further 90° toward the unaffected side around the yaw axis~5. Rotates back to an upright position with a 135° backward rotation around the pitch axis."
48134213|NCT05834452|PROCEDURE|The 360 Degree Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotate a further 90° backward around the pitch axis (total 225°)~4. Rotate a further 90° backward around the pitch axis (total 315°)~5. Rotate back to an upright position with an additional 45° backward rota-tion around the pitch axis (total 360°)."
48134214|NCT05834452|DEVICE|Mechanical rotational chair|TRV chair
48134215|NCT00612209|DRUG|ARQ 197|Treatment with ARQ 197
48499426|NCT03479567|OTHER|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
48342298|NCT00845507|DRUG|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
48342299|NCT00845507|DRUG|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
48342300|NCT05226767|DIETARY_SUPPLEMENT|NLC-V|NLC-V
48342301|NCT03197350|DIAGNOSTIC_TEST|cMR|cardiac MRI done to complete the diagnosis
48342302|NCT03197350|BIOLOGICAL|biomarker|Biomarker correlation with cMR parameters Prognostic information
48342303|NCT04214041|OTHER|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
48499427|NCT03479567|OTHER|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
48499428|NCT03479567|DIAGNOSTIC_TEST|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
48499429|NCT03479567|OTHER|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
48499430|NCT06425497|OTHER|The dosage of dnDSA|Flow cytometric analysis using FlowPRA Screening Test and/or Luminex Single Antigen Beads class I and II- IgG (cut- positivity off = MFI\> 1000)
48499431|NCT06380868|PROCEDURE|Intravascular imaging-guided PCI|Intravascular imaging including intravascular ultrasound or optical coherence tomography.
48499432|NCT06380868|PROCEDURE|Angiography-guided PCI group|Deployment of a drug-eluting stent under angiography.
48499433|NCT02067468|DEVICE|HPV test|QIAGEN - The Digene HPV test®
48499434|NCT02067468|PROCEDURE|COLPOSCOPY|Colposcopy routine health services
48499435|NCT02067468|DEVICE|cytology|Cytology routine health services
48499436|NCT03584724|DRUG|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
48657181|NCT05497206|DEVICE|One of the following hip implants may be used within this arm of the study: G7 Acetabular System, Taperloc Complete System, Avenir and Avenir Complete Systems, and Echo Bi-Metric System|Total Hip Arthroplasty
48499437|NCT03584724|DRUG|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
48499438|NCT01327261|DRUG|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
48499439|NCT03908177|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
48342304|NCT04214041|OTHER|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
48342305|NCT00531908|DRUG|furosemide|furosemide
48342306|NCT04481945|DRUG|bioceramic sealer|pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
48342307|NCT04121572|DEVICE|Nasal cannula capnography|Capnography: a continuous wave form of the CO2 level with the digital reading of CO2 level at end of expiration
48342308|NCT01282567|OTHER|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
48342309|NCT00115544|DRUG|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
48342310|NCT04240912|DEVICE|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
48342311|NCT03490019|DRUG|Metformin|500, 850 or 1000 mg depending on body weight once daily for 24 weeks
48342312|NCT02525887|OTHER|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
48513335|NCT02452437|DRUG|Oxycodone|Controlled release oxycodone 40 mg twice daily
48513336|NCT02323828|DIETARY_SUPPLEMENT|High RS cookies|High RS cookies ingestion in healthy young adults
48513337|NCT02323828|DIETARY_SUPPLEMENT|Placebo|Placebo cookies ingestion in healthy young adults
48342313|NCT06287918|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
48513338|NCT00878176|PROCEDURE|First stage tined lead procedure|bilateral first stage tined lead placement
48134226|NCT05845814|BIOLOGICAL|Coformulated favezelimab/pembrolizumab|Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
48342314|NCT02556580|DRUG|Albumin 20%|Intervention: intravenious infusion Drug: albumin
48134227|NCT05845814|BIOLOGICAL|Coformulated vibostolimab/pembrolizumab|Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
48342315|NCT03125161|DRUG|HAI|HAI
48342316|NCT03125161|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
48342317|NCT03639987|DRUG|Aducanumab|Administered as specified in the treatment arm.
48342318|NCT03639987|DRUG|Placebo|Administered as specified in the treatment arm.
48342319|NCT00004772|DRUG|Immune globulin|
48342320|NCT05743257|BEHAVIORAL|Questionnaire|Each participant completes a questionnaire (online or paper version) about socio-demographic characteristics, health outcomes (general health, respiratory health, and weight status), physical activity and sedentary behaviors, perception of neighborhood characteristics, air quality, and noise exposure.
48134228|NCT05845814|COMBINATION_PRODUCT|EV|1.25 mg/kg IV infusion
48134229|NCT05845814|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
48134231|NCT01280513|DIETARY_SUPPLEMENT|High protein intake|30% of energy intake coming from proteins
48134232|NCT01280513|DIETARY_SUPPLEMENT|Low Protein intake|9% of energy intake coming from proteins
48134233|NCT06293261|DRUG|Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg|Experimental only, not included active and placebo comparator
48134234|NCT06587789|DRUG|Ribociclib|Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).
48657182|NCT05115773|PROCEDURE|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
48657183|NCT05115773|PROCEDURE|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
48657184|NCT03657485|DIETARY_SUPPLEMENT|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
48342321|NCT05743257|BEHAVIORAL|Food diary supply|Sample of participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops. For each food purchase, participants provided details of date, place of purchase and foods purchased (name, quantity and expense incurred). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary.
48342322|NCT05743257|BEHAVIORAL|Interviews (semi-structured)|Sample of participants was interviewed about their food provisioning practice and living conditions.
48499440|NCT03908177|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
48499441|NCT01674127|DRUG|Methyldopa|
48134237|NCT06698640|BEHAVIORAL|Automated SMS|Participants will receive automated SMS messages reminding them of their Well-Child Visits. These messages will be standardized and sent at intervals designed to prompt appointment attendance.
48134238|NCT06698640|BEHAVIORAL|Automated SMS + Scheduling Assistance|Participants will receive the same automated SMS messages as in Arm 2, but with the added component of proactive appointment scheduling assistance. This may include options for scheduling directly through the SMS platform or follow-up messages encouraging appointment setting.
48499442|NCT01674127|DRUG|Placebo|
48134240|NCT06306118|DEVICE|Multiple stereotactic Tumor Biopsies during a Brain Tumor Resection|For pre-resection biopsy cases (3 target per patient), the targets will be selected from metabolite hotspots on MR-spectroscopy imaging and/or amino acid tracer uptake hotspots on PET imaging. Depending on the tumor location and surgical procedure, all biopsies will be performed via one single or multiple entry points.
48499443|NCT06303037|DRUG|Remimazolam besylate and low-dose Esketamine|Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg
48499444|NCT06303037|DRUG|Remimazolam besylate and Medium dose Esketamine|Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
48499445|NCT02365558|DRUG|Evacetrapib|Administered orally
48499446|NCT02365558|DRUG|Omeprazole|Administered orally
48499447|NCT00042536|DRUG|Naltrexone HCL/ Yohimbine HCL|
48499448|NCT01687426|DRUG|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
48499449|NCT01687426|DRUG|Vehicle|1 drop in each eye daily four times a day for 14 days
48499450|NCT02195453|DRUG|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
48657185|NCT06639789|DIETARY_SUPPLEMENT|Vitamin B12 (B12)|The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).
48657186|NCT06639789|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested 3 days before and the same day of the tests (3 hours before).
48342323|NCT05743257|BEHAVIORAL|air and noise|Sample of participant were instructed to wear air and noise sensors to record their daily environmental exposure for 7 consecutive days, except for sleeping, bathing and performing activities in the water. Particulate matter concentrations, the temperature, and the relative humidity were measured - the nitrogen dioxide (NO2) and ozone (O3) concentrations were determined with data loggers that integrate reliable electrochemical gas sensors. Noise levels was measured using noise dosimeters. Sensors were accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
48342324|NCT03183960|BEHAVIORAL|Mentor|Traditional rehabilitation.
48342325|NCT05337345|DRUG|Cendakimab|Specified Dose on Specified Days
48342326|NCT01770756|BEHAVIORAL|Self-Care Training|
48342327|NCT02656862|OTHER|No intervention|
48342328|NCT00882167|OTHER|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
48342329|NCT00310063|PROCEDURE|acupressure therapy|Acupressure wristband
48342330|NCT00310063|PROCEDURE|sham intervention|Sham wristband
48499451|NCT02195453|DRUG|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
48657187|NCT06639191|DRUG|[177Lu]Lu-AKIR001|"Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq."
48657188|NCT06029647|OTHER|Mango|The participants will consume the treatment for 16 weeks, followed by a 4-week washout period.
48657189|NCT06029647|OTHER|vanilla wafers|vanilla wafers
48657190|NCT06564558|OTHER|Spinal Strengthening Exercises|Individuals in the experimental group will carry out 3 sets of 10 repetitions or what is tolerated within a Borg scale intensity of 4-5 with 70-80% of perceived exertion with appropriately picked elastic bands. The exercises include: Shoulder horizontal abduction; Shoulder elevation; Back Extensions over a plinth; Shoulder extension exercises; One arm and opposite leg lifts from quadruped; and finally bilateral arm lifts with upper thoracic extension from prone (superman exercise).
48499452|NCT04147923|DIETARY_SUPPLEMENT|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of \>1 x 10\^9 CFU. Participants will also consume a multivitamin.
48657191|NCT06564558|OTHER|Thoracic Spine Stretching|Participants will be instructed to do two exercises: Firstly, to lay supine with and hinge the thoracic spine over a roller placed in a way that would ensure the patient is forward lying and not completely supine. The participant will be instructed to maintain hinging until a stretch or pressure feeling is felt in the midback and hold this position for 3 sets of 30 seconds. Secondly, the patient was asked to be in a seated position, clasp the hands together and behind the head while arching backward over the chair and looking up. This exercise will be done for 3 sets of 20-30 repetitions with a slight hold time at the end of the movement. All interventions will be carried out for 45 minute sessions 3 times per week.
48657192|NCT06564558|OTHER|Thoracic Spine Mobilization|The patient will be seated with both hands clasped at shoulder level. An experienced and blinded therapist standing homolateral to the patient supports the clasped hands with one arm while placing the other hand was placed at different thoracic regions until the thoracolumbar junction. Specifically, the dorsal aspect of the index finger and pad of the thumb were used to create a fixation point at the junction. Following that, gentle extension-directed glides (postero-anterior) will be done by the therapist for 3 sets of 10 repetitions or until tolerated by the patient.
48657193|NCT06564558|OTHER|Sham Postural Correction|comprised an hour of social interaction with similar participants where a blinded therapist will provide educational tips for dealing with kyphosis along with educational reading material for each participant.
48342331|NCT03208075|OTHER|normal diet|Diet containing 1500mg of phosphorus
48342332|NCT03208075|OTHER|low-phosphorus diet|Diet containing 500mg of phosphorus
48342333|NCT03208075|OTHER|high-phosphorus diet|Diet containing 2300mg of phosphorus
48342334|NCT02645461|DRUG|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
48342335|NCT02645461|DRUG|Riluzole|Riluzole 50 mg twice daily
48342336|NCT02872324|OTHER|Procurement questionnaires|
48342337|NCT05490381|OTHER|Iodixanol|Given via injection
48342338|NCT05490381|PROCEDURE|Angiogram|Undergo diagnostic cerebral angiogram
48342339|NCT05490381|PROCEDURE|Arterial Embolization|Undergo tumor vessel embolization
48342340|NCT05490381|DRUG|Polyvinyl Alcohol|Given via catheter
48342341|NCT05490381|DRUG|Ethiodized Oil|Given via catheter
48342342|NCT05490381|PROCEDURE|Computed Tomography|Undergo head and neck CT scans
48342343|NCT05490381|OTHER|Chart Abstraction|Ancillary studies
48342344|NCT00288041|DRUG|carboplatin|Given IV
48342345|NCT00288041|DRUG|paclitaxel|Given IV
48342346|NCT00288041|DRUG|bortezomib|Given IV
48342347|NCT02211950|DRUG|BI 44847|
48342348|NCT02211950|DRUG|Acarbose|
48342349|NCT02211950|OTHER|Japanese diet|
48342350|NCT05421091|OTHER|Asciminib|Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
48342351|NCT01948349|OTHER|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
48342352|NCT01948349|OTHER|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
48342353|NCT03582436|PROCEDURE|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
48657194|NCT00005978|BIOLOGICAL|filgrastim|
47981816|NCT01373801|DEVICE|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
48657195|NCT00005978|DRUG|carboplatin|
48134241|NCT06597591|DEVICE|VR headset|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
48657196|NCT00005978|DRUG|etoposide|
48342354|NCT02200068|OTHER|SANOIA Website|
47981817|NCT01373801|DEVICE|Control|Standard packing gauze roll bandage.
47981818|NCT03080311|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
47981819|NCT00931762|DRUG|Panobinostat|Panobinostat oral capsules
47981820|NCT02468544|OTHER|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
47981821|NCT05856201|PROCEDURE|Laparoscopic cervicosacropexy|The first step consists of a supracervical hysterectomy with morcellation. Anterior and posterior dissection of the vesicovaginal and rectovaginal space. Placing a flexible blade or a Breisky blade in the vagina which is manipulated by the assistant in order to improve exposure of the tissue planes. The retroperitoneum will then be opened from sacral promontory to cervix with the incision just medial to the uterosacral ligament. A low-weight preshaped Y-shaped polypropylene mesh will be secured to the anterior and posterior vagina with four to six separated absorbable 2.0 polyglactin sutures and two nonabsorbable 2.0 prolene sutures can be placed at the level of the remaining cervix. The mesh will be attached to the sacral promontory using two or three nonabsorbable monofilament 2.0 prolene suture. The retroperitoneal space will be closed with continuous 2.0 polyglactin suture or barbed 2.0 absorbable suture material.
47981822|NCT05856201|PROCEDURE|Shull technique via V-NOTES|Using a cold-bladed scalpel, pericervical colpotomy and subsequent opening of the Douglas and vesico-uterine space is performed. The following step is forcipressure and section of uterosacral ligaments bilaterally with cold blade scissors and ligation in Polysorb 0. A v-PATH® wall retractor is placed, after insertion of three trocars. Total hysterectomy is then performed by standard V-NOTES technique. After transperitoneal visualization of the ureters bilaterally, the peritoneum is incised between the ureters and the uterosacral ligaments, which are thus bilaterally isolated, and three points in polydioxanone 2/0 are placed per side. The v-PATH wall retractor is then removed. Finally the suspension of the vaginal vault at the uterosacral ligaments is made according to Shull technique. Eventual fascial corrections of concomitant anterior or posterior defects will be associated if needed.
47981823|NCT06208891|PROCEDURE|Robotic myomectomy|Robotic assisted laparoscopic myomectomy
47981824|NCT04044612|OTHER|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
47981825|NCT03372811|DRUG|TC cream|A well-characterized botanical drug for topical treatment of psoriasis vulgaris
47981826|NCT03372811|DRUG|Vehicle|Vehicle
48499453|NCT04147923|DIETARY_SUPPLEMENT|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
48499454|NCT02606214|DRUG|TBA-354|
47981829|NCT04774107|DRUG|P1101 + Ribavirin|P1101 400 µg SC
47981830|NCT00002531|DRUG|asparaginase|
47981831|NCT00002531|DRUG|cyclophosphamide|
47981832|NCT00002531|DRUG|cytarabine|
47981833|NCT00002531|DRUG|daunorubicin hydrochloride|
47981834|NCT00002531|DRUG|dexamethasone|
47981835|NCT00002531|DRUG|doxorubicin hydrochloride|
47981836|NCT00002531|DRUG|etoposide|
47981837|NCT00002531|DRUG|ifosfamide|
47981838|NCT00002531|DRUG|leucovorin calcium|
47981839|NCT00002531|DRUG|mercaptopurine|
47981840|NCT00002531|DRUG|methotrexate|
47981841|NCT00002531|DRUG|mitoxantrone hydrochloride|
47981842|NCT00002531|DRUG|prednisolone|
48342355|NCT04104841|BEHAVIORAL|Behaviorally Enhancing Adolescents' Mood in Schools|8-session modified behavioral activation intervention
48342356|NCT04104841|BEHAVIORAL|Usual Care|Referral to school mental health provider, social worker, or community care.
48499455|NCT02606214|DRUG|TBA-354 Placebo|
48657197|NCT00005978|DRUG|melphalan|
48657198|NCT00005978|PROCEDURE|autologous bone marrow transplantation|
48657199|NCT00005978|PROCEDURE|peripheral blood stem cell transplantation|
48657200|NCT00005978|RADIATION|iobenguane I 131|
48657201|NCT00005978|RADIATION|radiation therapy|
48657202|NCT03604744|DRUG|LSD|LSD 0.1 mg per os, single dose
48657203|NCT03604744|DRUG|LSD|LSD 0.2 mg per os, single dose
48657204|NCT03604744|DRUG|Psilocybin|Psilocybin 15 mg per os, single dose
48657205|NCT03604744|DRUG|Psilocybin|Psilocybin 30 mg per os, single dose
48657206|NCT04904913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
48657207|NCT04904913|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
48657208|NCT04695665|OTHER|Cervical pain|Exercise program for cervical spine according to McGill's approach.
48657209|NCT04695665|OTHER|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
48657210|NCT04695665|OTHER|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
48342357|NCT04979962|DEVICE|EW10-EC02 (Endoscopy Support Program)|EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
48499456|NCT04141358|DIAGNOSTIC_TEST|Advanced ultrasound measurements|"Clinical interventions and procedures:~* Consent at 0 week~* Clinical data collection at 0 week~* Strain for native artery at 0 week~* Young's modulus for native artery at 0 week~* Intimal medial thickness for native artery at 0 week~* Ultrasound blood volume flow measurement at 0 week~* Vessel diameter at 0 week~* Blood pressure at 0 week~* BMI at 0 week~* Intra-operative blood volume flow measurement at AVF surgery time~* Strain for native artery at 6 weeks~* Young's modulus native artery at 6 weeks~* Intimal medial thickness native artery arteries at 6 weeks~* Ultrasound blood volume flow measurement at 6 weeks~* Vessel diameter at 6 weeks~* Blood pressure at 6 weeks~* BMI at 6 weeks"
48342358|NCT05001776|PROCEDURE|Endovenous laser ablation|Laser ablation of the great saphenous vein close to sapheno-femoral junction
48342359|NCT05001776|DRUG|Fondaparinux Sodium|Fondaparinux sodium for 7 days or 45 days
48499457|NCT06414720|DRUG|Dienogest 2 MG|The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
48499458|NCT04141124|OTHER|breathing exercise/HRV-biofeedback|5 min of relaxing breathing, coupled with biological feedback.
48134242|NCT06597591|DEVICE|Tablet|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a tablet. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
48499459|NCT04141124|OTHER|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
48657211|NCT06152172|DRUG|KYV-101|The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
48134243|NCT06522438|COMBINATION_PRODUCT|Hyaluronic Acid (HA) and Octenidine gel|A thermosensitive gel with Hyaluronic Acid (HA) and Octenidine (Pocket-X®, Geistlich, Wolhusen, Switzerland) will be applied in the periodontal pockets ≥5mm immediately after the subgingival PMPR, by means of a pre-filled syringe bearing a thin plastic tip and following manufacturer's instructions.
48342360|NCT01353183|PROCEDURE|colonoscopy or rectosigmoidoscopy|Usual procedure
48342361|NCT05406245|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
48342362|NCT05272657|OTHER|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
48499460|NCT04141124|OTHER|Control|5 minutes of reading fictitious biological medical results
48499461|NCT00428636|PROCEDURE|ileostomy|
48499462|NCT05075720|DIETARY_SUPPLEMENT|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
48657212|NCT06152172|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
48657213|NCT06152172|DRUG|Fludarabine|Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
48342363|NCT05272657|OTHER|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
48499463|NCT05075720|DIETARY_SUPPLEMENT|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
48499464|NCT05075720|DIETARY_SUPPLEMENT|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
48499465|NCT01214915|DRUG|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
48657214|NCT06592001|DEVICE|Atala™ lead|Subjects will receive the Atala™ lead being evaluated in the study.
48657215|NCT03852420|DEVICE|LUMINIZE RF Balloon Catheter|Ablation Therapy with the LUMINIZE RF Balloon Catheter
48499466|NCT00015769|DRUG|levetiracetam|
48657216|NCT06215716|DRUG|Efruxifermin|Administered by subcutaneous injection
48657217|NCT06215716|DRUG|Placebo|Administered by subcutaneous injection
48342364|NCT03959345|DRUG|Combination therapy group|Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
48342365|NCT03959345|DRUG|Standard therapy group|Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
48342366|NCT01804842|DRUG|Met DR|metformin delayed-release tablets
48342367|NCT06508970|BEHAVIORAL|Experimental RAM-based virtual reality glasses|"RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.~Video contents:~1. week; 1st sub-dimension (physiological domain)~2. weeks; 2nd sub-dimension (self-space) Three weeks; 3rd sub-dimension (Role function/function area) week 4; 4th sub-dimension (Independence and interdependence/autonomy)"
48342368|NCT06508970|OTHER|pre-post test|Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
48342369|NCT01000519|OTHER|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
48342370|NCT01000519|OTHER|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
48342371|NCT06156462|DEVICE|ResAppDx v.20|Software device measuring cough sounds to aid diagnosis of respiratory diseases
48342372|NCT06009861|DRUG|Tislelizumab|Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
48342373|NCT06009861|DRUG|Albumin-Bound Paclitaxel|Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
48499467|NCT05941455|DEVICE|Venus-Neo Surgical Aortic Valve|Implant of a Venus-Neo Surgical Aortic Valve
48134244|NCT06522438|PROCEDURE|Non-surgical periodontal treatment (NSPT)|Full mouth supragingival professional mechanical plaque removal (PMPR) and subgingival PMPR at sites with PPD ≥4mm will be performed with the aid of manual and power-driven instruments under local anaesthesia.
48499468|NCT01447420|DRUG|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
48499469|NCT01447420|DRUG|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
48499470|NCT01995305|GENETIC|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
48499471|NCT01995305|GENETIC|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
47981843|NCT00002531|DRUG|teniposide|
47981844|NCT00002531|DRUG|thioguanine|
47981845|NCT00002531|DRUG|vincristine sulfate|
47981846|NCT00002531|DRUG|vindesine|
48342374|NCT06009861|DRUG|Cisplatin|Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
48342375|NCT02911519|OTHER|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
48342376|NCT02911519|OTHER|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
48499472|NCT05912283|DEVICE|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
48499473|NCT05912283|DEVICE|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
48499474|NCT05912283|DEVICE|Control Latex Condom|Commercial natural rubber latex condom
48499475|NCT01205386|DEVICE|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
48499476|NCT05808673|BIOLOGICAL|Post-change CMAB807X|for subcutaneous injection only
48499477|NCT05808673|BIOLOGICAL|Pre-change CMAB807X|for subcutaneous injection only
47981847|NCT00002531|PROCEDURE|allogeneic bone marrow transplantation|
47981848|NCT00002531|PROCEDURE|peripheral blood stem cell transplantation|
47981849|NCT00002531|RADIATION|radiation therapy|
47981850|NCT02626520|DRUG|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
48657218|NCT05299320|DIAGNOSTIC_TEST|Neuromuscular fatigue and postural sway evaluation|Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.
48657219|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
48342377|NCT06161688|DRUG|Ensitrelvir|Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
48342378|NCT06161688|OTHER|Placebo|Matching placebo for Ensitrelvir
48342379|NCT00000345|DRUG|Lofexidine|
48342380|NCT00776698|DRUG|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
48342381|NCT00776698|DRUG|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
48342382|NCT00776698|DRUG|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
48342383|NCT04909294|RADIATION|Stereotactic Radiotherapy with Linac MRI|"38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI."
48342384|NCT05477017|DRUG|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
48342385|NCT03049943|DEVICE|low level laser|
48342386|NCT02803814|PROCEDURE|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
48342387|NCT02803814|PROCEDURE|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
48342388|NCT04480346|BEHAVIORAL|Challenging Horizons Program|Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
48342389|NCT04992377|DRUG|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
48342390|NCT01983449|DRUG|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
48342391|NCT05225506|BEHAVIORAL|Exercise|Exercise sessions will be one hour in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on movements specifically targeting common deficits seen in Parkinson's.
48342392|NCT00656578|DRUG|4975|Single dose, solution
48657220|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
47981851|NCT02626520|DRUG|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
47981852|NCT02626520|RADIATION|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
48342393|NCT00656578|DRUG|Placebo|Single dose, solution
48657221|NCT05377411|DEVICE|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
48342394|NCT00303576|DRUG|dapivirine (TMC120) vaginal gel|
48342395|NCT03346291|BEHAVIORAL|counseling|individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
48342396|NCT00294684|DRUG|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
48499478|NCT05808673|BIOLOGICAL|Xgeva®|for subcutaneous injection only
48499479|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 1500 mg
48657222|NCT05377411|BEHAVIORAL|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
48657223|NCT00610220|DEVICE|Fiberglass short arm cast|Cast will be applied for a 4-week period
48499480|NCT04505137|OTHER|GMA301 Placebo Injection|GMA301 Injection without GMA301 administered as a single intravenous dose
47981853|NCT02626520|PROCEDURE|Definitive resection|Definitive surgical resection of primary tumor
48657224|NCT00610220|DEVICE|Prefabricated wrist splint|Splint will be applied for a 4-week period
48499481|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 2000 mg
48134245|NCT06442748|DRUG|Levetiracetam|Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
48499482|NCT03511326|DRUG|Methyl Aminolaevulinate 16% Cream|Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
48499483|NCT01495156|DRUG|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
48499484|NCT01495156|DRUG|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
48499485|NCT02287909|DRUG|Clopidogrel|Swiching from ticagrelor to clopidogrel
48499486|NCT02287909|DRUG|Ticagrelor|Continue treatment with ticagrelor
48657225|NCT05407636|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
48657226|NCT05407636|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
48657227|NCT05407636|BIOLOGICAL|Aflibercept (EYLEA®)|"2.0 mg (0.05 mL solution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections~Other Names:~• Eylea (anti-VEGF agent)"
48657228|NCT06641557|DRUG|200mg of Ikt-148009|4 50mg capsules
48657229|NCT01383876|BEHAVIORAL|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
48499487|NCT02283294|DRUG|Apixaban|
48499488|NCT02283294|DRUG|Warfarin|
48499489|NCT04711616|BEHAVIORAL|physical therapy intervention|physical therapy interventions include thermal therapy, electrical therapy, manual therapy, and therapeutic exercise.
48657230|NCT01383876|BEHAVIORAL|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
48499490|NCT03744663|DRUG|Suboxone® SL|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
48499491|NCT03744663|DRUG|Sublocade®|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (\> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of \> 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
48499492|NCT00309725|DRUG|galantamine|
48657231|NCT00137449|DRUG|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
48657232|NCT05837481|BEHAVIORAL|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
48657233|NCT06027905|OTHER|E3 Remote Monitoring and Social Intervention|Patients are enrolled in a 12 week remote blood pressure monitoring program composed of a community health worker, nurse, pharmacist and social worker. Participants will receive a home cellular blood pressure cuff for remote monitoring and will receive tele-health calls from their community health worker to assist with blood pressure taking technique and adherence, medication adherence, education around diet and activity. Social work is available to provide institutional and community resources to patients with social needs. Patients will be screened pre intervention and post intervention for medication adherence and social determinants of health needs. The team nurse monitors and triages home blood pressures on the remote portal. The pharmacist assists with medication reconciliation, adherence, and titration of medications according to standards or care.
48342397|NCT00294684|DRUG|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
48342398|NCT02356328|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
48342399|NCT03626480|OTHER|No treatment|No treatment
48342400|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
48342401|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
48342402|NCT02422394|DRUG|Eltrombopag|
48342403|NCT02738580|DRUG|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
48342404|NCT02738580|DRUG|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
48342405|NCT04206670|DEVICE|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
48342406|NCT04206670|DEVICE|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
48342407|NCT00291187|DRUG|20 mg VEC-162|20 mg VEC-162
48342408|NCT00291187|DRUG|50 mg VEC-162|50 mg VEC-162
48342409|NCT00291187|DRUG|100 mg VEC-162|100 mg VEC-162
48657234|NCT06557863|BEHAVIORAL|WeCareToFeedDysphagia web tool|The web tool uses written and video content, care-partner testimonials, frequently asked questions, and resource links to provide accurate information (e.g., dysphagia diets), set realistic expectations, identify/support feeding goals (quality of life considerations), acknowledge/support care-partner feelings, and provide competencies/skills for oropharyngeal dysphagia (OD) management.
48657235|NCT06512259|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
47981854|NCT04400240|BEHAVIORAL|CALLS|The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
47981855|NCT03091634|DRUG|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
48342410|NCT00291187|DRUG|Placebo|Placebo
48342411|NCT06153199|BEHAVIORAL|Self-management videos|Short video modules on self-management of back pain without medication and ergonomic adjustments for limiting back pain in nursery and landscape work
48657236|NCT05633927|BIOLOGICAL|SARS-CoV-2 Vaccine|Analyse humoral and cellular response to SARS-CoV-2 Vaccine.
47981856|NCT03091634|DRUG|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
48342412|NCT06153199|BEHAVIORAL|Check lists for ergonomic options|Guidance on ergonomic choices appropriate for work tasks not currently being used that are the most difficult due to back pain, using a checklist
48342413|NCT06153199|BEHAVIORAL|Text reminders|Reminders to implement choices using graphics and gifs as well as motivational messages
48342414|NCT06153199|BEHAVIORAL|Video review|Participants will review videos of their movement during their most difficult work tasks to help problem solving to adjust ergonomic adjustments
48342415|NCT01651312|DRUG|14C-labeled YM178|oral solution (1.85 MBq)
48342416|NCT01048047|DRUG|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
48499493|NCT05282186|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
48499494|NCT05282186|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
48342417|NCT05094804|DRUG|OR2805|IgG1 monoclonal antibody that binds specifically to the CD163 protein.
48342418|NCT05094804|DRUG|Cemiplimab|IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
48342419|NCT05094804|DRUG|Docetaxel|An antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
48342420|NCT04904341|DRUG|Cerebrolysin|neuroprotection treatment
48342421|NCT01233180|OTHER|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
48342422|NCT01233180|DEVICE|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
48342423|NCT04134728|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
48342424|NCT04134728|BIOLOGICAL|Sarilumab|Sarilumab solution in PFS to be administered SC.
47981857|NCT04661540|DRUG|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
47981858|NCT04661540|DRUG|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
47981859|NCT05339594|DEVICE|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
47981860|NCT05339594|DEVICE|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
47981861|NCT02348827|BEHAVIORAL|Family psychoeducation|
47981862|NCT02348827|BEHAVIORAL|Social support group|
47981863|NCT04271605|BEHAVIORAL|diet and exercise suggestion|diet and exercise suggestion according to blood biochemistry data and bone mineral density
47981864|NCT03409406|BEHAVIORAL|Caregiver Intervention|This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
47981865|NCT03409406|BEHAVIORAL|ST Intervention|This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
47981866|NCT06087666|PROCEDURE|FICare|The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
47981867|NCT03552653|DIETARY_SUPPLEMENT|Vitafusion Extra Strength Vitamin D|Monitor Vitamin D blood levels
47981868|NCT03836612|OTHER|No intervention|Observation of routine clinical practice
47981869|NCT02328755|DRUG|peg-IFN-α|
48342425|NCT04134728|DRUG|Placebo to GSK3196165/ Sarilumab|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
48342426|NCT04134728|DRUG|csDMARDs|Stable dose of csDMARD(s) as SoC.
48342427|NCT01041404|DRUG|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
47981870|NCT02328755|PROCEDURE|Hematopoietic Cell Transplant (HCT)|
47981871|NCT02328755|DRUG|Tacrolimus|Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
47981872|NCT02328755|DRUG|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
48342428|NCT01041404|DRUG|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
48342429|NCT01041404|DRUG|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
48342430|NCT01041404|DRUG|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
48342431|NCT02637804|DEVICE|stenfilcon A|contact lens
48342432|NCT02637804|DEVICE|narafilcon A|contact lens
47981873|NCT05279898|DEVICE|EEG Monitoring|Perioperative monitoring, MMGA guided by EEG for intervention group
47981874|NCT05279898|DRUG|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.2% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision (total of 40mL) PIFB on postoperative day 1 (provided they are extubated or getting ready to be extubated) to help with mobilization (for intervention group)
47981875|NCT05279898|DRUG|Ketamine|Intraoperative infusion
47981876|NCT05279898|DRUG|Remifentanil|Intraoperative infusion
47981877|NCT05279898|DRUG|Dexmedetomidine|Intraoperative infusion
47981878|NCT05279898|DRUG|Rocuronium|Intraoperative intermittent bolus
47981879|NCT05279898|DRUG|Propofol|Intraoperative infusion
47981880|NCT00211445|PROCEDURE|Photodynamic Therapy with Verteporfin|
47981881|NCT00211445|DRUG|verteporfin|
48499495|NCT05854017|DIETARY_SUPPLEMENT|Theanine for stress relief formulation|Theanine for stress relief formulation tablet
47981882|NCT02524795|DIETARY_SUPPLEMENT|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
47981883|NCT05734625|DRUG|Bupivacaine HCl 0.5% Injectable Solution|Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
48499496|NCT05854017|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
48134266|NCT01767467|BIOLOGICAL|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
48134267|NCT01767467|DRUG|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
48499497|NCT01226771|DRUG|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
48499498|NCT01226771|DRUG|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
48134270|NCT06699251|BEHAVIORAL|Chat|Chat is a brief motivational interviewing intervention for partner clinic participants with an alcohol or cannabis use condition.
48342433|NCT02637804|DEVICE|delefilcon A|contact lens
48342434|NCT00196807|BEHAVIORAL|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
47981884|NCT05734625|DRUG|Methylprednisolone 40 MG Injection|Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
47981885|NCT00115050|DRUG|TMC114|
48134271|NCT06699251|BEHAVIORAL|Enhanced Usual Care|An informational brochure will be give to partner clinic participants with an alcohol or cannabis use condition.
48134272|NCT06624072|DRUG|Nerandomilast, Formulation 1|Reference treatment (R)
48134273|NCT06624072|DRUG|Nerandomilast, Formulation 2|when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
48342435|NCT04421612|BEHAVIORAL|Co-mestring (co-coping)|8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
48342436|NCT04992299|BEHAVIORAL|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
48342437|NCT04992299|BEHAVIORAL|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
48499499|NCT01226771|DRUG|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
48499500|NCT03777423|DEVICE|PEEK framework partial dentures|Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
48657237|NCT02553733|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
48657238|NCT02553733|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
47981886|NCT02700815|DRUG|Diclofenac|
47981887|NCT02700815|DRUG|Capsaicin|
47981888|NCT02700815|DRUG|Placebo|
47981890|NCT04358666|PROCEDURE|surgery and focal radiosurgery of the surgical bed|hypofractionned radiosurgery of the lesion
47981891|NCT05066594|DEVICE|Transoral incisionless fundoplication|The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.
47981892|NCT02353598|DRUG|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
47981893|NCT02353598|DRUG|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
47981894|NCT02353598|DRUG|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
47981895|NCT02353598|DRUG|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
47981896|NCT01050868|DEVICE|Accu-Chek Combo Kit mg DE/de|
47981897|NCT06144489|DIETARY_SUPPLEMENT|Tart Cherry|Tart cherry supplementation in two doses
47981898|NCT06144489|DIETARY_SUPPLEMENT|Placebo|Control group
48499501|NCT03777423|DEVICE|Cobalt- chromium framework partial dentures|It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
48134277|NCT06696105|DRUG|Resin infiltration|"Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization."
48134278|NCT06696105|DRUG|Vanish XT varnish (resin modified glass ionomer restoration)|Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
48134279|NCT06699576|DRUG|HS-20093|HS-20093: administered as an IV infusion
48134280|NCT06699576|DRUG|Anlotinib|Anlotinib: 12mg once daily (QD) orally
48134281|NCT06699576|DRUG|Epirubicin|Epirubicin: administered as an IV infusion
48134282|NCT06699576|DRUG|Adebrelimab|Adebrelimab: administered as an IV infusion
48134283|NCT04919499|DRUG|BI 765128|BI 765128
48134284|NCT04919499|OTHER|Sham comparator|Sham comparator
48134285|NCT00909025|DRUG|Claudiximab|"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks."
48134286|NCT06698978|OTHER|Simplified protocol (PS)/Conventional protocol (PC)|Complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months).
48134287|NCT06698978|OTHER|Conventional protocol (PC)/Simplified protocol (PS)|Complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS)in period 2 (3 months).
48499502|NCT05225532|OTHER|Radiofrequency ablation|Radiofrequency ablation of ganglionated plexi located in the left or right atrium
48134289|NCT06698809|DEVICE|Active tPBM|tPBM is a neuromodulatory treatment that uses red and/or near infrared light to penetrate the cortex and can alter both cerebral metabolism and blood flow. Subjects will receive treatment for approximately 12 minutes per treatment.
48657239|NCT03574363|DRUG|KBP-5074 0.25 mg tablet|Oral administration, QD, 84 days
48657240|NCT03574363|DRUG|KBP-5074 0.5 mg tablet|Oral administration, QD, 84 days
48134292|NCT06699732|BEHAVIORAL|Mindful Self Compassion Therapy|"Mindful Self-Compassion (MSC) therapy is an 8-week program blending mindfulness and self-compassion to improve emotional resilience and well-being.~Week 1: Introduction - Learn the basics of mindfulness, self-compassion, and reframing self-critical thoughts with kindness.~Week 2: Mindfulness - Practice observing thoughts and emotions without judgment to build self-awareness.~Week 3: Self-Kindness - Develop skills to treat yourself with warmth and care during difficult times.~Week 4: Common Humanity - Explore shared human experiences to reduce feelings of isolation.~Week 5: Working with Challenges - Learn strategies to respond compassionately to emotional pain.~Week 6: Growing Compassion - Deepen compassion for yourself and others through guided exercises.~Week 7: Resilience Building - Strengthen coping skills and foster emotional flexibility.Week 8: Embodying a Compassionate Life Week 8: Integration - Consolidate skills to maintain self-compassion in daily life."
48342438|NCT04992299|BEHAVIORAL|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
48657241|NCT03729609|DRUG|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
48657242|NCT06643442|DRUG|Empagliflozin Tablets|Empagliflozin 10mg p.o. once daily (commercially available tablet)
47981899|NCT01819077|PROCEDURE|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
48657243|NCT06640309|DRUG|Nicotinamide Tablet|Nicotinamide is anti-inflammatory and antioxidant.
48657244|NCT06640309|DRUG|conventional synthetic antirheumatic drugs|methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
48657245|NCT04323046|BIOLOGICAL|Nivolumab|Given IV
48657246|NCT04323046|OTHER|Quality-of-Life Assessment|Ancillary studies, given in person or online
48657247|NCT04323046|OTHER|Questionnaire Administration|Ancillary studies, given in person or online
48657248|NCT06161493|DRUG|ZEN003694|A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
47981900|NCT03033511|DRUG|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
47981901|NCT03033511|DRUG|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
48499503|NCT05778136|OTHER|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
48499504|NCT05739552|OTHER|Telerehabilitation program|Application of customised respiratory and/or motor rehabilitation exercises to be carried out directly at the patients' home after hospital discharge in order to evaluate its effects.
48499505|NCT01409161|DRUG|Arsenic Trioxide|Given IV
48499506|NCT01409161|DRUG|Gemtuzumab Ozogamicin|Given IV
48499507|NCT01409161|OTHER|Laboratory Biomarker Analysis|Correlative studies
48499508|NCT01409161|DRUG|Tretinoin|Given PO
48499509|NCT03677076|OTHER|Ancillary/Correlative|Collection of research blood and urine
48499510|NCT02166814|DRUG|Fimasartan and Rosuvastatin|
47981902|NCT03033511|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
48134293|NCT06698432|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
48499511|NCT02166814|DRUG|Fimasartan|
48499512|NCT02166814|DRUG|Rosuvastatin|
48499513|NCT04185051|DRUG|JNJ-67953964|Participants will receive JNJ-67953964 as oral capsules.
48499514|NCT04185051|DRUG|Placebo|Participants will receive matching placebo oral capsules.
48342439|NCT02855645|DRUG|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
48342440|NCT02855645|DRUG|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
48342441|NCT05719077|BEHAVIORAL|EDITH-HC|This study tests feasibility and acceptability of implementing a tool and training in a clinical practice and the preliminary efficacy of training materials to enhance hospice clinicians' knowledge of dementia-related caregiving issues at end of life and a tool for clinicians to use to address caregiving issues related to dementia at end of life.
48342442|NCT04757376|BIOLOGICAL|CT-P41|60 mg/mL single dose, Solution for injection in PFS
48342443|NCT04757376|BIOLOGICAL|US-licensed Prolia|60 mg/mL single dose, Solution for injection in PFS
48342444|NCT01787851|DRUG|Triheptanoin oil|
48342445|NCT00646581|DRUG|Placebo|Placebo
48342446|NCT00646581|DRUG|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
48342447|NCT00439504|DRUG|Lobeline|
48342448|NCT00302770|DRUG|quetiapine|
48342449|NCT05227768|DRUG|VV116 25mg Group|4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
48342450|NCT05227768|DRUG|VV116 200mg Group|6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
48342451|NCT05227768|DRUG|VV116 400mg Group|6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
48342452|NCT05227768|DRUG|VV116 800mg Group|6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
48657249|NCT06161493|DRUG|Niraparib|An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
47981903|NCT03033511|DRUG|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
47981904|NCT00741637|BIOLOGICAL|CholeraGarde®|"Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
47981905|NCT00741637|BIOLOGICAL|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
48342453|NCT05227768|DRUG|VV116 1200mg Group|6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
48342454|NCT03383068|DRUG|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
48342455|NCT03383068|DRUG|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
48342456|NCT03383068|DRUG|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
48342457|NCT03383068|DRUG|Metformin|metformin effective subjects,act as control group
48499515|NCT04242914|DRUG|Ketamine|Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
48499516|NCT04242914|DRUG|Midazolam|Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
48499517|NCT06033638|OTHER|Score assessment|PBS Score
48499518|NCT04016441|OTHER|Survey|Participants will complete a survey online
48499519|NCT00384644|DEVICE|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
48499520|NCT01599065|OTHER|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
48499521|NCT05107141|PROCEDURE|Ridge preservation|Ridge preservation in molar areas using a xenograft or an allograft in combination with a barrier collagen membrane
48499522|NCT05107141|DEVICE|bone graft plus a collagen membrane|
48499523|NCT01604590|RADIATION|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
48499524|NCT00788749|DRUG|Prednisolone|tablets 25 mg/day
48499525|NCT00788749|DRUG|Placebo|tablets once daily
48499526|NCT00788749|OTHER|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
48499527|NCT00788749|OTHER|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
48499528|NCT04856150|DRUG|Q-1802|Q-1802 will be administered intravenously.
48499529|NCT00581126|DRUG|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
48657250|NCT04714177|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
48657251|NCT04714177|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
48657252|NCT00233246|PROCEDURE|FFP Infusion|
47981906|NCT05502393|DRUG|JS107|JS107, i.v., q3w
48499530|NCT06351475|OTHER|Intra-operative albumin administration|Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
48499531|NCT06351475|OTHER|Control|Ringer lactate
48499532|NCT03487952|OTHER|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
48342458|NCT04393909|BEHAVIORAL|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
48342459|NCT04393909|BEHAVIORAL|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
48499533|NCT00003916|RADIATION|radiation therapy|
48499534|NCT00003916|RADIATION|stereotactic radiosurgery|
48499535|NCT03249974|DEVICE|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
48499536|NCT04781192|DRUG|Durvalumab|Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
47981907|NCT05502393|DRUG|Toripalimab|Toripalimab i.v., q3w
48499537|NCT04781192|DRUG|Regorafenib|Oral once per day, Days 1 - 21 every 28 days
48499538|NCT00002883|DRUG|cisplatin|
48499539|NCT00002883|DRUG|fluorouracil|
48499540|NCT00002883|PROCEDURE|adjuvant therapy|
48499541|NCT00002883|PROCEDURE|conventional surgery|
48499542|NCT00002883|PROCEDURE|neoadjuvant therapy|
48499543|NCT02737527|PROCEDURE|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
47981908|NCT01414075|DRUG|Roxadustat|Tiered, weight-based dosing per schedule specified in the arm.
47981909|NCT01414075|DRUG|Oral Iron|Administered per oral dose and schedule specified in the arm.
47981910|NCT01414075|DRUG|IV Iron|Administered per IV dose and schedule specified in the arm.
47981911|NCT03220516|PROCEDURE|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
48499544|NCT02737527|DEVICE|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
48499545|NCT02737527|DEVICE|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
48499546|NCT02737527|DEVICE|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
48499547|NCT02737527|DRUG|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
47981912|NCT03220516|PROCEDURE|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
47981913|NCT03220516|PROCEDURE|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
48499548|NCT02737527|PROCEDURE|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
48499549|NCT02737527|PROCEDURE|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
48134303|NCT06700317|DEVICE|HSS1|Surgery performed using HSS1
48134304|NCT06698419|DEVICE|RADA16 gel application into mastoid cavity|A single application of RADA16 gel will be applied along the surface of the mastoid cavity intraoperatively prior to insertion of gelatin sponge packing. Application will involve a thin layer of gel just enough to cover the entire surface of the cavity.
48499550|NCT03052868|OTHER|Cognitive Assessment|Cognitive testing session
48499551|NCT02752763|DRUG|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
48499552|NCT02752763|DRUG|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
48342460|NCT04393909|BEHAVIORAL|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
48342461|NCT04393909|BEHAVIORAL|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
48342462|NCT05130268|DRUG|Dronedarone|Dronedarone 400 mg twice daily in addition to usual care
48342463|NCT05813613|OTHER|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
48342464|NCT04447911|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg per os once daily for 30 days
48342465|NCT04447911|DRUG|Placebo|Placebo per os once daily for 30 days
48342466|NCT00220259|DRUG|Fluticasone or placebo|
48342467|NCT00333047|DRUG|Letrozole|
48499553|NCT05326321|OTHER|Study Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
48657253|NCT06614933|DEVICE|Biphasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a biphasic current, continuous at 25 Hz, for 1 hour, in-person.
48657254|NCT06614933|DEVICE|Monophasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a monophasic current, with a 50% duty cycle at 25 Hz, for 1-hour, in-person.
48499554|NCT06081426|OTHER|Non-ketogenic Diet|Consuming a non-ketogenic diet
48657255|NCT03290521|PROCEDURE|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
48657256|NCT03290521|PROCEDURE|No washing|no washing
48657257|NCT05127174|DRUG|Fedratinib Pill|Fedratinib is taken orally once per day, in 100 mg capsules. Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
48657258|NCT06099002|OTHER|Changed Medical research Council,Mini Mental Test, Quadriceps Femoris muscle strength measurement,2 min walking test, fall effectiveness scale,Fall risk self-assessment scale|"All individuals were given a respiratory function test to evaluate respiratory functions before and after training Modified Medical research Council to evaluate dyspnea, Mini Mental Test to evaluate cognitive status~, Berg Balance Test to evaluate balance, 2-minute walk test to evaluate walking speed. A hand dynamometer will be used to measure QuadricepsFemoris muscle strength, Fall efficiency scale Fall risk self-assessment scale will be used to evaluate falls."
48499555|NCT06081426|OTHER|Ketogenic Diet|Consuming a ketogenic diet
48499556|NCT06081426|OTHER|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
48499557|NCT01688570|DRUG|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
48499558|NCT01688570|DRUG|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
48499559|NCT01688570|DRUG|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
48499560|NCT04493320|DRUG|Carbidopa/levodopa|150-450mg carbidopa/levodopa 3 times daily
48499561|NCT04493320|DRUG|Placebo|Carbidopa/levodopa-matched placebo tablet 3 times daily
48499562|NCT00872482|DRUG|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
48499563|NCT05316883|DRUG|Clozapine|clinical doses adjusted to sideeffects and clinical effect
48499564|NCT00085930|BIOLOGICAL|EBV specific CTLs|CTLs: 2x10e7 cells/m2
48342468|NCT03690674|BEHAVIORAL|Lifestyle Enhancement for ADHD Program|The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
48342469|NCT02714608|DRUG|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
48499565|NCT01331226|BEHAVIORAL|telephone counseling 3 sessions|3 sessions of telephone counseling
48499566|NCT01331226|BEHAVIORAL|telephone counseling 1 session|1 session of telephone counseling
48499567|NCT01331226|BEHAVIORAL|written materials only|written materials only
48499568|NCT00831766|DRUG|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
48499569|NCT00831766|DRUG|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
48499570|NCT00831766|DRUG|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
48499571|NCT03123510|DIETARY_SUPPLEMENT|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
48499572|NCT03123510|DIETARY_SUPPLEMENT|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
48499573|NCT00600808|DRUG|BPLG-003|
48499574|NCT06281327|DRUG|Avatrombopag|"After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L."
48499575|NCT03170427|DEVICE|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
48499576|NCT03170427|DIAGNOSTIC_TEST|Sensory levels|Sensory levels are checked using ice test cold
48657259|NCT04767048|PROCEDURE|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
48499577|NCT03170427|DIAGNOSTIC_TEST|Motor block|motor block is measured by modified Bromage scale
48342470|NCT02714608|DRUG|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
48342471|NCT02714608|DRUG|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
48342472|NCT04062799|OTHER|no intervention|It is an observationa study. There is no intervention.
48342473|NCT00626769|DIETARY_SUPPLEMENT|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
48342474|NCT00626769|DIETARY_SUPPLEMENT|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
48499578|NCT03170427|DIAGNOSTIC_TEST|Sensory level|Sensory levels are checked using touch with alcohol puffs
48499579|NCT00895414|DRUG|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
48499580|NCT00895414|DRUG|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
48499581|NCT01671332|DRUG|Docetaxel|IV over 60 minutes, 75 mg/m2
48499582|NCT01671332|DRUG|Suramin|IV over 30 minutes
48499583|NCT01671332|DRUG|Docetaxel|IV over 60 minutes. 56 mg/m2
48499584|NCT03924206|DEVICE|Smoke evacuation system|The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
48657260|NCT04767048|PROCEDURE|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
48657261|NCT06016244|OTHER|Oxygen saturation threshold|Oxygen saturation threshold on which supplemental oxygen is decided
48657262|NCT01565759|DRUG|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
48499585|NCT02796118|DRUG|ASP2151|Oral
48499586|NCT02796118|DRUG|Placebo|Oral
48342475|NCT00003838|PROCEDURE|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
48342476|NCT00003838|DRUG|Methotrexate|IV MTX on days +1, +3, and +6 will be given
48342477|NCT00003838|DRUG|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade \> II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade \> II GVHD will have CSA discontinued regardless of chimerism results.
48342478|NCT00003838|DRUG|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
48499587|NCT03173144|OTHER|Primary exposure variable|"1. Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~2. Low intake of red and processed meat (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of dietary fibres (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
48499588|NCT03173144|OTHER|Other (exploratory) exposure variables|"* Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~* Pretreatment lifestyle-associated biomarkers~* Combinations of lifestyle factors and lifestyle-associated biomarkers~* Gene-environment interaction analyses~* Pretreatment levels of inflammatory molecules"
48499589|NCT04438226|PROCEDURE|Surgical approach|The surgical approach of hemiarthroplasty after femoral neck fracture
48499590|NCT00004180|DRUG|rosiglitazone maleate|
48499591|NCT02135653|RADIATION|Radiotherapy|
48499592|NCT02135653|OTHER|Eischens Yoga|
48342479|NCT00289861|DRUG|Risperidone|
48342480|NCT00289861|DRUG|placebo|
48342481|NCT01480232|DRUG|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
48342482|NCT01480232|DRUG|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
48342483|NCT01480232|DRUG|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
48342484|NCT01480232|DRUG|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
48342485|NCT01480232|BEHAVIORAL|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
48342486|NCT04721938|BEHAVIORAL|Systematic weight loss intervention|"Weight reduction through life style changes in diet and exercise by the following means:~* Counselling with a Nutritionist Nurse on diet and exercise~* Online Smartphone coaching program (Life-sum App)~* Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month"
48499593|NCT01830218|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
48134318|NCT06699498|DRUG|Benmelstobart|1200mg, D1, IV,q3w
48134319|NCT06699498|DRUG|Anlotinib|10mg，D1-14，po，q3w
48134320|NCT06699498|DRUG|Cisplatin|60mg/m2， D1， IV，q3w
48134321|NCT06699498|DRUG|Paclitaxel for Injection （Albumin Bound）|260mg/m2，IVgtt ，D1，q3w
48134322|NCT06699121|DRUG|LB-P8 low-dose|One capsule QD (1×10\^10 CFU/day) oral administration
48134323|NCT06699121|DRUG|LB-P8 high-dose|One capsule QD (1×10\^11 CFU/day) oral administration
48134324|NCT06699121|DRUG|Placebo|One capsule QD oral administration
48499594|NCT04713150|OTHER|No Intervention|No Intervention
48134326|NCT06699108|DRUG|VGR-R01|Subretinal injection of VGR-R01 (0.1 mL)
48134327|NCT06698744|BIOLOGICAL|UF-KURE-BCMA CAR T-cells|"Experimental anti-BCMA CAR T-cells manufactured with a proprietary ultrafast process. Patients will receive a single dose of CAR T-cells at one of three potential doses:~* Dose -1: 3x10\^6 cells~* Dose 1: 10x10\^6 cells~* Dose 2: 15x10\^6 cells"
48134328|NCT06698744|DRUG|Cyclophosphamide|Patients will receive 3 days of intravenous (IV) cyclophosphamide 500 mg/m\^2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
48134329|NCT06698744|DRUG|Fludarabine|Patients will receive 3 days of IV fludarabine 30 mg/m2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
48342487|NCT00134953|DRUG|Rivastigmine|
48342488|NCT05589740|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
48342489|NCT05589740|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
48342490|NCT00918346|DRUG|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
48342491|NCT05621018|DEVICE|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
48342492|NCT03682055|DRUG|VK-2019|EBNA1 inhibitor
48499595|NCT02045082|PROCEDURE|Corneal sampling|Slit lamp corneal sampling with a Swab
48499596|NCT05653310|DRUG|Tradipitant|Tradipitant Capsule
48499597|NCT05653310|DRUG|Placebo|Placebo Capsule
48134331|NCT06699095|DEVICE|Telerehabilitation|Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital. Balance rehabilitation program will be scheduled on the patients' need and ability to be performed three times a week with high levels of satisfaction and safety at home under remote control of the physical therapist.
48499598|NCT02893202|OTHER|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
48499599|NCT04651894|DEVICE|reactive hyperaemia index measurement|"reactive hyperaemia index with EndoPAT®~Pulse wave velocity measurement with Sphygmocor®"
48499600|NCT05009680|DRUG|GB1211|GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
48499601|NCT05009680|DRUG|Placebo|Placebo is administered orally twice a day
48499602|NCT03859765|BEHAVIORAL|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
48499603|NCT01181960|DRUG|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
48499604|NCT01181960|DRUG|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
48499605|NCT01181960|DRUG|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
48134340|NCT06698666|DRUG|Rosuvastatin 10 mg tablet.|"The dose of rosuvastatin was derived from literature describing the doses at which the agents' targeted actions are effective and safe. The 10- mg rosuvastatin dose reflects the lowest prescribed therapeutic dose A serum cholesterol level will be drawn from the whole participants and sent to the central laboratories of El-Demerdash hospital at baseline and at week 12.~At each visit, participants will be requested to return all unused investigational products. Adherence to medication will be assessed by a pill count."
48134341|NCT06698666|DRUG|Sertraline Pill|Both control and intervention group will receive the sertraline as a standard therapy
47981914|NCT02118051|DRUG|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.
47981915|NCT02118051|DRUG|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed
47981916|NCT02118051|DRUG|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
48499606|NCT01181960|DRUG|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
48134343|NCT06698952|OTHER|Intervention Group|The intervention group will engage with SPI-Bot, a conversational agent designed to deliver cognitive and behavioral strategies for managing psychological symptoms through fully automated interactions. SPI-Bot operates on a template-based platform with predefined dialogue options, utilizing natural language processing technology. The intervention spans eight weeks and includes key components such as psychoeducation, cognitive restructuring, relaxation training, activity scheduling, problem-solving skills training, and social skills training. Participants will complete one session per week over the eight-week period. Participants will receive weekly contact from the research team to report AIS symptoms, receive homework reminders, and address any intervention-related questions.
48134344|NCT06698952|OTHER|control group|Participants in the control group will interact with a different generative chatbot, engaging in casual conversations at a similar dosage to ensure balanced attention and interaction effects.
48499607|NCT04632160|DEVICE|IASD System II|The implant is placed across the interatrial septum using a percutaneous transcatheter approach.
48134347|NCT06698861|DRUG|PEG-MetHuG-CSF|Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2
48134348|NCT06698861|DRUG|Neulasta (Amgen)|Single dose of Neulasta will be given SC injection at 6 mg in Cohort 2b.
48499608|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement with probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
48499609|NCT03924089|DIETARY_SUPPLEMENT|Oral nutritional supplement without probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
48499610|NCT03924089|OTHER|Dietary recommendations|Dietary recommendations
48499611|NCT06199063|OTHER|Self-Streching Exercises|The participants in the SSE group; received 1 session SSE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
48499612|NCT06199063|OTHER|Post-Isometric Relaxation Exercises|The participants in the PIRE group; received 1 session PIRE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
47981917|NCT03386682|DEVICE|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
48499613|NCT06199063|OTHER|Reciprocal-Inhibiton Exercises|The participants in the RIE group; received 1 session RIE with 10 repetitions, about 30 min. The assessments were applied before and after the session.
48499614|NCT03407235|DEVICE|Computerized Laparoscopic Trainer|Gold standard laparoscopic trainer using simulated computerized equipment.
48499615|NCT03407235|DEVICE|Box trainer with eye patch|Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
48499616|NCT03220061|BEHAVIORAL|music therapy|
48499617|NCT03544619|OTHER|Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms
48657263|NCT02050399|OTHER|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
48499618|NCT00505089|DRUG|ACZ885|
48499619|NCT00505089|DRUG|ACZ885|
48499620|NCT00505089|DRUG|ACZ885|
48499621|NCT00505089|DRUG|ACZ885|
48499622|NCT02656511|DRUG|Dolutegravir|Dolutegravir 50 mg PO daily
48134357|NCT05928845|DIAGNOSTIC_TEST|Muscle thickness measurement|Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
48134358|NCT06698627|DEVICE|Daily Disposable Continence Device|The Poise® Impressa® is an over-the-counter intravaginal device for women over the age of 21 years with SUI. It is a disposable, one-time use tampon-like device that comprises a core, cover, and applicator. The device is inserted and removed like a vaginal tampon and comes in three sizes.
48134359|NCT06698627|DEVICE|Monthly Disposable Continence Device|The Revive® is another over the counter vaginal insert for the treatment of SUI. This is a self-deployable, double-loop pessary device.
48499623|NCT02656511|DRUG|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
48499624|NCT06057441|DEVICE|Auditory noise stimulation|Auditory white noise stimulation delivered at 78dB through earphones
48499625|NCT06057441|DEVICE|Visual noise stimulation|Visual white pixel noise stimulation, backgound pixel noise visible at computer screen
48499626|NCT02229123|DRUG|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
48499627|NCT00955526|DRUG|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
48499628|NCT00955526|DRUG|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
48499629|NCT00955526|DRUG|Placebo|Two placebo tablets once daily for 12 weeks
48342493|NCT03523949|BEHAVIORAL|PNE|The PNE will be delivered by a physiotherapist in a single, group-based session.
48342494|NCT04415190|OTHER|early palliative care|early palliative care
48499630|NCT03096743|DIAGNOSTIC_TEST|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
48342495|NCT05427175|RADIATION|Narrowband ultraviolet B|Patients will receive 8 sessions of NB-UVB per month for 3 successive months
48342496|NCT05427175|DRUG|Methotrexate|Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
48342497|NCT03639922|DRUG|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
48342498|NCT03639922|DRUG|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
48499631|NCT03096743|DIAGNOSTIC_TEST|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
48499632|NCT03096743|PROCEDURE|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
48499633|NCT03096743|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
48499634|NCT03096743|DIAGNOSTIC_TEST|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
48499635|NCT00671918|DRUG|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
48499636|NCT02095808|PROCEDURE|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
48499637|NCT00442039|DRUG|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing \< 20 kg
48499638|NCT00442039|DRUG|Lithium Carbonate|"The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability"
48134373|NCT06699017|OTHER|Continuous anterior chest compression|CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
48499639|NCT00442039|DRUG|Lithium Carbonate|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
48134375|NCT06698926|DRUG|ABBV-CLS-616|Oral Tablet
48134376|NCT06698926|DRUG|Placebo|Oral Tablet
48134377|NCT06698926|DRUG|Itraconazole|Oral Capsule
48134378|NCT06699550|OTHER|Haptonomy|The session transitioned to energy work and dream visualization. The researcher and the pregnant participant placed their left hands on each other's hearts. The goal was for the participants to feel the energy flowing between them, sense their hearts, open their third eye, and prepare their hands. This exercise aimed to enhance the pregnant participant's confidence in her own emotions and body by recognizing her feelings and physical sensations. Next, the researcher and the pregnant participant placed their right hands on the participant's forehead and their left hands over their hearts. This positioning facilitated the pregnant participant in visually sensing the presence of her baby. It was intended to promote communication between the mother and her baby at both a physical and spiritual level.
48134379|NCT06699550|OTHER|Mindfulness-Based Stress Reduction Program|Participants were introduced to each other and provided with information related to pregnancy. The Mindfulness-Based Stress Reduction Program (MBSR) was introduced. The participants shared their levels of well-being, stress, coping mechanisms for fear of childbirth, and their expectations from the MBSR program. Awareness of habitual behaviors was facilitated. Afterwards, breath-focused meditation and dried fruit meditation were practiced. Participants were encouraged to maintain awareness of activities performed at any time during the day. Lastly, body scan meditation was taught, and participants were instructed to repeat the practice throughout the week using audio recordings.
48134380|NCT06698523|BEHAVIORAL|Breathing exercise|bubble blower used as play toys to facilitate the breathing exercise
48134381|NCT06698523|BEHAVIORAL|Deep breathing|pin wheel used as a play toy for achievement of breathing exercise
48499640|NCT00442039|DRUG|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
48499641|NCT01267994|DRUG|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
48499642|NCT02093130|DIETARY_SUPPLEMENT|Pomegranate Juice|
48499643|NCT02093130|DIETARY_SUPPLEMENT|Placebo|
48134386|NCT06699264|OTHER|Blood Flow Restriction Training|Pressure cuff is applied to the leg during training for low-load strength training with simultaneous restiction of blood flow
48134387|NCT06699264|OTHER|Training without BFR|Strength training according to experimentral group without simultaneous restriction blood flow
48499644|NCT03652558|DEVICE|Ozone application with the Ozonytron XL device|An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
48499645|NCT00470067|DRUG|carboplatin|IV
48499646|NCT00470067|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
48499647|NCT00322504|PROCEDURE|Accupuncture|
48499648|NCT02901964|OTHER|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
48499649|NCT02901964|OTHER|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
47981918|NCT04067895|PROCEDURE|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
48134388|NCT06699303|OTHER|Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care|In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.
48499650|NCT03370809|RADIATION|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
48134390|NCT06696781|PROCEDURE|Pacemaker stimulation|We deactivate the pacemaker to establish baseline measurements of NOL, bispectral index (BIS), mean arterial pressure (MAP), and heart rate (HR), recorded every minute for 5 minutes. We then adjust the pacemaker to 90 bpm and 110 bpm in subsequent 5-minute phases to assess the physiological responses. After deactivating the pacemaker to analyze washout effects, we reactivate it at 110 bpm to observe any changes. A temporary disconnection of the NOL monitor for 1 minute tests system reliability, followed by continued monitoring at the same rate for an additional 5 minutes. Each measurement phase averages data from the last 10 seconds each minute to ensure accuracy and reduce artifacts.
48499651|NCT05933980|DRUG|Rego+Tori+Cele|combination of Toripalimab,regorafenib and celecoxib
48342499|NCT05341284|OTHER|Questionnaire Survey and Cervical Cancer Screening|"A brief questionnaire will be administered to all participants at enrollment and at the pre-scheduled follow-up visit at Month 36.~For the subject who are eligible for the screening (i.e. (1)≥ 18 years old; (2) had sexual debut prior to enrollment, (3) no contradiction to the screening, (4) voluntary to the screening) will be referred to the study site hospitals by offering the subjects a cervical cancer screening voucher, and the type-specific HPV test will be performed as primary screening approach at Month 0 and 36."
48342500|NCT02705222|PROCEDURE|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
48342501|NCT02705222|PROCEDURE|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
48342502|NCT02999191|DRUG|BI 1467335 (Treatment A)|
48342503|NCT02999191|DRUG|BI 1467335 (Treatment B)|
48342504|NCT02999191|DRUG|BI 1467335 (Treatment C)|
48499652|NCT06334965|OTHER|Simultaneous 18F-Choline PET-MRI|before first TARE administration (after work-up procedure) and one month after TARE administration
48499653|NCT04811586|PROCEDURE|coronary revascularization|to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
48499654|NCT03670693|DIAGNOSTIC_TEST|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
48499655|NCT03670693|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
48657264|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)|Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients
48499656|NCT03670693|DIAGNOSTIC_TEST|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
48657265|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV2-IgM (DiaSorin)|Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients
48657266|NCT05338736|DIAGNOSTIC_TEST|Human IFN-g ELISpot PLUS (ALP) (AUROGENE)|Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
48657267|NCT06350110|BIOLOGICAL|CD19- BCMA CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
48657268|NCT05881291|DRUG|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
47981919|NCT06043076|DEVICE|TMS|Active iTBS will be applied using a butterfly figure-of-eight C-B60 coil connected to MagPro R30 stimulator with add-on Theta Burst option (MagVenture A/S, Farum, Denmark).
47981920|NCT06043076|DEVICE|Sham|Sham iTBS will be applied using acoustic stimulation of a second coil behind the participant's head
48499657|NCT03670693|DIAGNOSTIC_TEST|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
48499658|NCT03670693|DIAGNOSTIC_TEST|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
48513339|NCT01653912|DRUG|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
48342505|NCT02190630|DEVICE|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
48342506|NCT00442182|DRUG|ITF2357|
48342507|NCT03654560|DEVICE|HemoStyp|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
48657269|NCT05881291|DRUG|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
48657270|NCT06449222|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
48657271|NCT06449222|DRUG|BNT327 Dose Level 1 (DL2)|IV infusion
48657272|NCT06449222|DRUG|Taxane A|IV infusion
48657273|NCT06449222|DRUG|Alkylating agent|IV infusion
48342508|NCT03654560|DEVICE|Surgicel|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
48342509|NCT00553761|DEVICE|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
48342510|NCT02275910|DRUG|E7090|
48657274|NCT06449222|DRUG|Antimetabolite|IV infusion
48657275|NCT06449222|DRUG|Taxane B|IV infusion
48513340|NCT01867203|OTHER|Genotyping|DNA extraction from blood
48657276|NCT02754297|DRUG|177Lu-Octreotate|"* The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
48342511|NCT00953225|DRUG|vitamin D3|4,000 IU daily for one year
48342512|NCT00953225|DRUG|Placebo daily for one year|Placebo
48342513|NCT00866060|DRUG|Memantine|20mg memantine
48342514|NCT00866060|DRUG|Donepezil|10mg donepezil
48657277|NCT06201845|OTHER|Exercise awareness training|Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
48657278|NCT06201845|OTHER|physical activity awareness training|In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
48657279|NCT01370551|DRUG|Estriol 0.03 mg, lyophylized lactobacillus|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
48499659|NCT06408883|DEVICE|Vibrabot capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
48499660|NCT05897385|DRUG|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
48499661|NCT05897385|DRUG|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
48499662|NCT01914627|DRUG|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
48499663|NCT01914627|DRUG|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
48657280|NCT02500108|DRUG|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
48657281|NCT02556047|DEVICE|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N\&S
48657282|NCT06482996|OTHER|Intraocular pressure (IOP) was measured|The Frail Scale was used to assess the frailty of the patients.Intraocular pressure (IOP) was measured before anesthesia, 5 minutes after induction of anesthesia and 1 hour postoperatively. IOP was measured using a Tono-pen tonometer (AccuPen). The normal range of IOP is 11-21 mmHg (mean 16 mmHg) and values above 24 mmHg are pathologic.
48657283|NCT02721732|OTHER|Laboratory Biomarker Analysis|Correlative studies
48657284|NCT02721732|BIOLOGICAL|Pembrolizumab|Given IV
48342515|NCT00866060|DRUG|Placebo donepezil|Placebo donepezil
48657285|NCT02721732|OTHER|Questionnaire Administration|Ancillary studies
48657286|NCT03457662|COMBINATION_PRODUCT|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
48342516|NCT00866060|DRUG|Placebo memantine|Placebo memantine
48657287|NCT03457662|COMBINATION_PRODUCT|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
48657288|NCT02738619|DRUG|Vitamin D3|1600 UI
48499664|NCT04561687|DRUG|Montelukast|Montelukast and nasal budesonide
47981921|NCT06439992|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
48657289|NCT02738619|DRUG|placebo|placebo
47981922|NCT06053463|DEVICE|Daily disposable multifocal soft contact lens|Daily disposable multifocal soft contact lens that will be worn for 1 month.
47981923|NCT00002667|OTHER|cytology specimen collection procedure|
47981924|NCT00002667|OTHER|immunoenzyme technique|
47981925|NCT00002667|PROCEDURE|study of high risk factors|
47981926|NCT04075565|BEHAVIORAL|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
48499665|NCT04561687|DRUG|Azelastine|Azelastine and nasal budesonide
48657290|NCT06642038|PROCEDURE|Transbronchial Endoscopic Thermal Vapor Ablation|Transbronchial Endoscopic Thermal Vapor Ablation
48657291|NCT05870124|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
47981927|NCT04075565|BEHAVIORAL|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
47981928|NCT03249766|OTHER|Observational|Observational study
48002481|NCT02479711|OTHER|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
48342517|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
48342518|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
48342519|NCT05823610|DIAGNOSTIC_TEST|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
48342520|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
48342521|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
48342522|NCT04039763|DEVICE|Dexcom G6|Realtime Continous Glucose Monitoring
48342523|NCT04039763|DEVICE|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
48499666|NCT04561687|DRUG|Budesonide|To all groups
48499667|NCT04561687|DRUG|Placebo|Placebo and nasal budesonide
48513341|NCT02018575|DIETARY_SUPPLEMENT|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
48513342|NCT02018575|DIETARY_SUPPLEMENT|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
48513343|NCT05391386|PROCEDURE|modified bonding technique|adding a layer of compomer adhesive at the molar/tube interface.
48657292|NCT05870124|OTHER|Conventional Medical Management|Conventional Medical Management is the best standard of care treatment for the patient
48657293|NCT06561243|DRUG|BTK inhibitor (Ibrutinib or Acalabrutinib)|Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)
48657294|NCT02078726|DRUG|Glucagon|glucagon (hormone produced by the body)
48342524|NCT00744640|DRUG|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
48499668|NCT04864470|BEHAVIORAL|Stroke Odysseys|"The participants will take part in a twelve-week performance programme that takes place online/in a community halls/arts centre. Sessions run for three hours and during these sessions, participants devise a dance and music performance work from their own stories. The culmination of the programme will be a public facing performance to an audience of carers, health care practitioners, friends, family and the wider community, done online through Zoom.~After the performance is completed, participants will be invited to a training programme where they learn to act as advocates for life after stroke - termed 'stroke ambassadors'. The training will be a four-day programme. The programme will take place once weekly and is led by a team of artists supported by a leadership coach, on Zoom.~Following training, ambassadors will support artists in recruitment, befriend the newly discharged stroke survivors and take part in small scale performance tours to challenge the perception of disability."
48499669|NCT02015429|DIETARY_SUPPLEMENT|Pasta meal with added fractions or control with no fractions|
48499670|NCT05344248|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
48499671|NCT05344248|BIOLOGICAL|JS005 placebo|Subcutaneous injection
48499672|NCT03577483|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
48499673|NCT05238818|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocyte Injection (GT202)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. T cells then are manufactured to express mbIL-12. After lymphodepletion, patients are infused with GT202 followed by IL-2.
47981929|NCT05490745|BEHAVIORAL|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
47981930|NCT05490745|OTHER|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
47981931|NCT03382938|DRUG|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
47981932|NCT03382938|DRUG|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
47981933|NCT03382938|DRUG|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
47981934|NCT03382938|OTHER|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
47981935|NCT02188212|DEVICE|NobelProcera Crown Shaded Zirconia|
48499674|NCT00406744|DRUG|Intravitreal injection of Bevacizumab|
48499675|NCT01377376|DRUG|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
48499676|NCT01377376|DRUG|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
48499677|NCT02727881|DRUG|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
47981936|NCT03966378|OTHER|Grape seeds extract|Grape seeds extract powder
47981937|NCT03966378|OTHER|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
47981938|NCT02529514|DRUG|Baclofen|25 mg for 7 days at 10 pm every day
47981939|NCT02529514|DRUG|Placebo|Placebo for 7 days at 10 pm every day
47981940|NCT05752201|BIOLOGICAL|Gamma Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
47981941|NCT05752201|BIOLOGICAL|Omicron Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
47981942|NCT05752201|BIOLOGICAL|Bivalent RBD-based ARVAC-CG vaccine|Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
47981943|NCT05752201|OTHER|Placebo (Alum)|Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
47981944|NCT00017498|DRUG|gemcitabine hydrochloride|
47981945|NCT01579175|OTHER|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
47981946|NCT02335294|DRUG|TRV130|Rescue: Ibuprofen, oxycodone
47981947|NCT02335294|DRUG|Morphine|Rescue: Ibuprofen, oxycodone
47981948|NCT02335294|DRUG|Placebo|Rescue: Ibuprofen, oxycodone
47981949|NCT05356494|OTHER|Postural drainage|(Group A will be treated with postural drainage)
47981950|NCT05356494|OTHER|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
47981951|NCT00902369|DRUG|AK106-001616|Part1: Dose escalation Part2: Dose expansion
47981952|NCT00902369|DRUG|Placebo|
47981953|NCT00902369|DRUG|Active comparator|
47981954|NCT01149824|DRUG|Salvinorin A|
47981955|NCT01149824|DRUG|Placebo|
48499678|NCT02727881|DRUG|Placebo Ophthalmic solution|Placebo Ophthalmic solution
48499679|NCT02727881|DRUG|ranibizumab|ranibizumab
48513344|NCT04573894|DIAGNOSTIC_TEST|Procalcitonin dosage|Plasma PCT levels measured by automated enzyme immunoassay (Kryptor).
48657295|NCT04411069|DRUG|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
48342525|NCT01505660|BEHAVIORAL|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at \~9 and 12 months after enrollment.
48342526|NCT03596970|DRUG|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
48342527|NCT03596970|DRUG|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
48342528|NCT03375970|OTHER|TCM|oral chinese herb, chinese topical ointment
48657296|NCT05677971|DRUG|Fazirsiran Injection|Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
47981956|NCT00844688|DRUG|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~1. Progression of disease.~2. The patient is unlikely to benefit from further treatment as~   Judged by the Investigator.~3. Intolerable toxicity of the drugs.~4. Withdrawal of consent for any reason."
47981957|NCT00844688|DRUG|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 \& 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
47981958|NCT02480842|OTHER|Alloplastic free ROM|
48657297|NCT05677971|OTHER|Placebo|Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
48342529|NCT03375970|OTHER|Western medicine|oral steroid, oral antihistamine, topical steroid
48342530|NCT00761358|DRUG|Z-338|Oral
48342531|NCT00761358|DRUG|Placebo|Oral
48657298|NCT06258382|OTHER|Questionnaires and functional test|Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
48657299|NCT05050279|DRUG|Delgocitinib capsule|oral capsule
47981959|NCT02480842|OTHER|Alloplastic limited ROM|
47981960|NCT02480842|OTHER|Oncoplastic free ROM|
48657300|NCT05050279|DRUG|Placebo capsule|oral capsule
47981961|NCT02480842|OTHER|Oncoplastic limited ROM|
47981962|NCT04071730|DIETARY_SUPPLEMENT|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
48342532|NCT02808013|DRUG|NDS-446|
48657301|NCT06443632|OTHER|Sleep Adjustment|(1) Establishing a sleep schedule with early bedtime and wake-up times; (2) Establishing a consistent bedtime routine based on the child's preferences, such as wearing a sleep sack, providing soothing touch before sleep, offering a pacifier, using white noise, or playing sleep-inducing music; (3) Setting a fixed afternoon radiotherapy time each day and familiarizing the child with the radiotherapy environment beforehand; (4) Engaging the child in stimulating activities like watching videos, playing with toys, snacking, or outdoor activities to keep them awake from morning until 2 PM before radiotherapy; (5) Ensuring the child reaches deep sleep; (6) Completing the radiotherapy plan.
48657302|NCT04144517|DRUG|Nemvaleukin Alfa|Nemvaleukin alfa IV infusion.
48657303|NCT04144517|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
47981963|NCT03498040|OTHER|Study of the occurrence of Carcinoid Heart Disease|"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, ...) biological parameters (urinary 5HIAA, NT-ProBNP ...) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
47981964|NCT03398395|PROCEDURE|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
47981965|NCT03398395|PROCEDURE|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
47981966|NCT00881712|RADIATION|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
47981967|NCT00881712|RADIATION|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
48342533|NCT02808013|DRUG|Placebo|
48342534|NCT05463172|OTHER|abdominal strengthening exercises|abdominal strengthening exercises
48342535|NCT05463172|OTHER|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
48342536|NCT01126684|DRUG|Atorvastatin|10 mg of atorvastatin once daily for six months
48342537|NCT01126684|DRUG|Placebo|placebo once daily for six months
48657304|NCT05548556|DRUG|Placebo|Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
48657305|NCT05548556|DRUG|RO7204239|Participants will receive SC RO7204239 Q4W
48657306|NCT06524739|BIOLOGICAL|IgPro20|IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration
48342538|NCT06110104|OTHER|routine physiotherapy program for knee osteoarthritis|The Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
48657307|NCT06524739|BIOLOGICAL|Placebo|2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.
48657308|NCT05516875|DRUG|JM-010|JM-010
48513345|NCT01959373|PROCEDURE|electroencephalograms (EEG)|
48342539|NCT06110104|OTHER|Retro-walking program|Retro-walking program is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
48513346|NCT01959373|PROCEDURE|electro-myography (EMG)|
48342540|NCT06110104|OTHER|whole body vibration training|whole body vibration is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
48342541|NCT02435862|DRUG|1.0mg Luminate®|
48513347|NCT05638061|OTHER|Soy protein|Soy foods or isolated soy protein
48657309|NCT04557423|BEHAVIORAL|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
48657310|NCT04557423|BEHAVIORAL|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
48657311|NCT04557423|BEHAVIORAL|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
48657312|NCT05312658|PROCEDURE|External aortic compression|External aortic compression by assistant in cesarean section.
48657313|NCT04203576|DEVICE|FIRE1 System|FIRE1 System
48657314|NCT04124757|OTHER|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
48657315|NCT05939544|DIETARY_SUPPLEMENT|Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient|Milk Fat Globule Membrane-enriched Powdered Ingredient
48657316|NCT05939544|DIETARY_SUPPLEMENT|Placebo Comparator: Control (Placebo) Powdered Ingredient|Placebo Comparator: Control (Placebo) Powdered Ingredient
48657317|NCT01405664|OTHER|Weight-Bearing as Tolerated|WBAT immediately after surgery
47981968|NCT00881712|RADIATION|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
48342542|NCT02435862|DRUG|2.0mg Luminate®|
48342543|NCT02435862|DRUG|3.0mg Luminate®|
48342544|NCT02435862|OTHER|Balanced Salt Solution for intravitreal injection in 0.10cc|
48657318|NCT00938626|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
48657319|NCT00938626|PROCEDURE|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
48657320|NCT00938626|PROCEDURE|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
48657321|NCT02888340|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
48657322|NCT00131885|DIETARY_SUPPLEMENT|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
48499680|NCT02328235|OTHER|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
47981969|NCT02257788|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCR5
48657323|NCT00131885|DIETARY_SUPPLEMENT|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
48657324|NCT00131885|DRUG|Levonorgestrel|Levonorgestrel in a single oral dose
48657325|NCT06486467|OTHER|Fluid challenge (cristalloids) OR passive leg raising|"Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition"
48657326|NCT06559007|DRUG|HRS-5041 dose level 1|Single dose of HRS-5041 orally administered
48657327|NCT06559007|DRUG|HRS-5041 dose level 2|Single dose of HRS-5041 orally administered
48657328|NCT02447692|OTHER|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
48657329|NCT02447692|OTHER|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
47981970|NCT01577823|DEVICE|Foley Catheter|
47981971|NCT05548829|BIOLOGICAL|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
47981972|NCT01584687|BIOLOGICAL|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
47981973|NCT00905554|PROCEDURE|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
47981974|NCT00905554|PROCEDURE|air insufflation|air insufflation during the insertion phase of colonoscopy
47981975|NCT05604222|DRUG|Mirabegron 50 MG|Medication to treat overactive bladder
47981976|NCT05604222|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
47981977|NCT00314665|DRUG|Thalidomide|
47981978|NCT02751996|DRUG|SB 9200|SB 9200
47981979|NCT02751996|DRUG|Placebo|
47981980|NCT02751996|DRUG|Tenofovir|
47981981|NCT04492839|DEVICE|Intestinal adsorbent|Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.
48499681|NCT04419792|OTHER|Assessment of physical performance variables|"Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test"
48499682|NCT03587389|BIOLOGICAL|Rotarix vaccine|In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
48499683|NCT04328857|DEVICE|pseudoelastic orthosis|The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
48499684|NCT03756467|BEHAVIORAL|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
47981982|NCT03867604|PROCEDURE|Sham injection|Injection to the subcutaneous layer at upper trapezium level
47981983|NCT03867604|PROCEDURE|Fascia injection|Injection to the fascia below upper trapezium muscle
47981984|NCT05756946|PROCEDURE|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
47981985|NCT05756946|PROCEDURE|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
47981986|NCT03232021|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
47981987|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
47981988|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
47981989|NCT00229060|DRUG|doripenem|
48342545|NCT05843591|BEHAVIORAL|aerobic exercise or Tai Chi Chuan interventions|8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
48499685|NCT04310969|DEVICE|MiBoFlo Thermoflo|Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.
48134399|NCT06693648|DRUG|AMZ001 Diclofenac gel|Diclofenac gel applied once daily
48134400|NCT06693648|DRUG|Placebo gel|Matching placebo gel applied once daily
48134401|NCT02238041|DEVICE|GlucoClear System|
48499686|NCT04310969|PROCEDURE|forceful expression of the meibomian glands|Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force
48342546|NCT01489267|OTHER|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
48342547|NCT03650036|DRUG|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
48342548|NCT03650036|DRUG|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
48342549|NCT04955496|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
48342550|NCT06185868|OTHER|No intervention measures|No intervention measures
48342551|NCT03174561|DIETARY_SUPPLEMENT|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
48342552|NCT03174561|OTHER|diet restriction|diet restriction for 28 days
48342553|NCT04401410|BIOLOGICAL|Dose Finding Phase (MTD)|Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
47981990|NCT00468572|BEHAVIORAL|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
47981991|NCT00468572|BEHAVIORAL|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
47981992|NCT02989194|DRUG|VIS410 low dose|Single intravenous fixed low dose of VIS410
48342554|NCT04401410|BIOLOGICAL|Partially HLA-matched SARS-CoVSTs|Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
48499687|NCT04310969|DEVICE|LipiFlow|LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
48499688|NCT02080013|OTHER|radiofrequency|ClosureFAST
47981993|NCT02989194|DRUG|VIS410 high dose|Single intravenous fixed high dose of VIS410
47981994|NCT02989194|DRUG|Placebo|Single intravenous infusion of placebo
47981995|NCT05625672|OTHER|Training|Hemovigilance module training
48499689|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
48134404|NCT04097535|OTHER|PET/MRI|Imaging scan
48499690|NCT01682863|DRUG|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
48499691|NCT01682863|DRUG|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
48342555|NCT04401410|OTHER|Routine care (no SARS-CoVSTs)|Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
48342556|NCT01496274|BIOLOGICAL|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
48342557|NCT02613091|DRUG|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
48342558|NCT02883426|BIOLOGICAL|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
48342559|NCT02883426|BIOLOGICAL|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
48342560|NCT02883426|BIOLOGICAL|Placebo|Administered by nasal spray
48342561|NCT04348435|BIOLOGICAL|HB-adMSCs|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
48342562|NCT04348435|OTHER|Placebos|Saline
48342563|NCT01784614|DRUG|LY2624803 - Solution|Administered orally as reconstituted solution
48342564|NCT01784614|DRUG|LY2624803 - Capsule|Administered orally as a capsule
48342565|NCT01784614|DRUG|Placebo - Solution|Administered orally as solution
48499692|NCT01682863|DRUG|Placebo|To mimic QAB149
48513348|NCT03834142|DEVICE|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
48342566|NCT01784614|DRUG|Placebo - Capsule|Administered orally as a capsule
47981996|NCT02461563|DRUG|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
47981997|NCT02461563|DRUG|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
48342567|NCT01963936|DEVICE|Supreme LMA|
48342568|NCT01963936|DEVICE|Facial mask|
48342569|NCT03487315|DIAGNOSTIC_TEST|immunoblot|immunoblot
48342570|NCT03472768|DIAGNOSTIC_TEST|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
48342571|NCT02794025|DRUG|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
48342572|NCT02794025|DRUG|natural saline|Control group also received natural saline via a micro pump,
48342573|NCT00251589|DRUG|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
48342574|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
48342575|NCT00251589|DRUG|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
48342576|NCT00251589|DRUG|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
48342577|NCT00251589|DRUG|erlotinib|erlotinib 150 mg once a day.
48342578|NCT00432185|DRUG|PEP005|0.25% PEP005 Gel
48342579|NCT00776334|DRUG|Fosinopril 40mg Tablets|
48342580|NCT05021172|OTHER|Best Practice|Receive usual care
48342581|NCT05021172|OTHER|Informational Intervention|Receive Passport to Health booklet
48342582|NCT05021172|OTHER|Questionnaire Administration|Complete ePrognosis
48342583|NCT05021172|OTHER|Survey Administration|Ancillary studies
48342584|NCT05437913|OTHER|Psychological intervention (self-compassion based)|4 weeks intervention for both primary caregivers and adolescents with T1D will be done online through videoconferencing and will be based on three validated protocols that use self-compassion (MSC and MSC Teens).
48499693|NCT03282630|PROCEDURE|Sphenopalatine ganglion acupuncture|"* active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
48499694|NCT02195089|DRUG|BLS_ILS_E710c 500mg|- 2 capsules per day for 20 days (week 1,2,4 \& 8)
47981998|NCT02461563|DRUG|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
48342585|NCT04368000|BEHAVIORAL|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
48342586|NCT04368000|BEHAVIORAL|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
48342587|NCT05668325|OTHER|Mini trampoline exercise group|In this study, patients performed a 30-45 minute mini-trampoline exercise program 3 times a week for eight weeks (two months) under the supervision of the investigator.
47981999|NCT02090660|OTHER|ICG Localization with Spy thoracoscope localization|
48342588|NCT05668325|OTHER|Control group|In this study, patients were visited at home once a week for eight weeks and their feet were checked.
48342589|NCT03964506|DRUG|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
48342590|NCT01186367|BEHAVIORAL|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
48342591|NCT01186367|BEHAVIORAL|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
48342592|NCT01186367|BEHAVIORAL|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
48342593|NCT01186367|OTHER|Cardiopulmonary exercise test (CPET)|
48342594|NCT01186367|OTHER|Blood draws|Complete blood count
48342595|NCT05109611|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
48342596|NCT05109611|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
48342597|NCT04107636|PROCEDURE|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (\<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
48342598|NCT04107636|PROCEDURE|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
48342599|NCT05911737|BEHAVIORAL|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
48499695|NCT02195089|DRUG|BLS_ILB_710c 1000mg|- 4 capsules per day for 20 days (week 1,2,4 \& 8)
48499696|NCT02195089|DRUG|BLS_ILS_E710c 1500mg|- 6 capsules per day for 8 weeks (week 1,2,4 \& 8)
48499697|NCT00822341|DRUG|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
48499698|NCT04311788|DEVICE|Prophylactic self gripping mesh|Prophylactic self gripping mesh, Propgrip by Medtronic.
48499699|NCT04311788|DEVICE|Slowly absorbable continuous monofilament suture|Fascial closure by continuous slowly absorbable 4:1 suture
48499700|NCT02562105|PROCEDURE|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
48499701|NCT03568279|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust for intubation.
48499702|NCT03568279|PROCEDURE|Control|The intubation was done without two-handed jaw thrust.
48499703|NCT02377518|RADIATION|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
48499704|NCT05782959|BIOLOGICAL|BCD-245|BCD-245 is administered as prolonged intravenous infusions during each cycle
48499705|NCT00346463|DRUG|Allopurinol|
48499706|NCT04600778|OTHER|placebo|placebo
48657330|NCT06638411|BEHAVIORAL|ADHD information workshop|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms. To control for the duration of the nocebo module (see the condition below), participants will also learn about sleep and its relevance for maintenance of good cognitive health. At the end, the workshop will involve a writing reflection activity about personal experiences with ADHD symptoms.
48342600|NCT01318525|DRUG|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
48342601|NCT01318525|DRUG|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
48342602|NCT01085604|OTHER|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
48499707|NCT04600778|DRUG|Cavosonstat 5 mg|Cavosonstat (low dose)
48499708|NCT04600778|DRUG|Cavosonstat 10 mg|Cavosonstat (medium dose)
48499709|NCT04600778|DRUG|Cavosonstat 25 mg|Cavosonstat (high dose)
48499710|NCT01470768|OTHER|Amino Acid-based Formula with high DHA and ARA|
48499711|NCT01470768|OTHER|Amino Acid-based Formula with lower DHA and ARA|
48499712|NCT01156142|DRUG|doxepin hydrochloride|Oral rinse
48499713|NCT01156142|OTHER|placebo|Oral rinse
48499714|NCT04934449|DEVICE|Occlusal splint|Using occlusal splints during sleep for 2 months
48499715|NCT06486961|DEVICE|BeatMove Application|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
48499716|NCT06486961|DEVICE|BeatMove Application without synchronized music|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
48499717|NCT06486961|DEVICE|BeatMove Application without music|The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
48499718|NCT05944380|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the PENG block
48499719|NCT05944380|DRUG|0,9% normal saline|20 mL 0.9% normal saline will be injected for the PENG block
48134407|NCT06601933|OTHER|Cognitive Training|"Participants (n=240) will be randomized to high dose crosswords, low dose crosswords, and health education at 1:1:1 ratio, stratified by site, age (\< 70 and 70 years), and MCI status (early MCI and late MCI). In the two crossword puzzles conditions, after initial training to use the web-based platform, the participant will be assigned to do 12 weeks of crossword puzzles four times per week or 12 weeks of crossword puzzles once per week at home. After these 12 weeks, booster sessions will be either four or one 30-minute session(s) completed over 1 week. These booster sessions will occur at weeks 20, 32, 42, 52, 64, and 78. In-person assessments will occur at 0, 12, 32, 52, 78 weeks with one crossword puzzle session, which will count toward the booster session.~Health education will involve reading chapters in a book on common illnesses and lifestyle, and a research staff member will review these chapters at the same assessment intervals as the crossword puzzles conditions."
48134408|NCT06621771|OTHER|Music intervention|Participants will engage in a step-by-step piano training consisting in playing piano pieces designed to involve all 5 digits of the paretic hand and increasing in complexity. They will be using a Musical Instrument Digital Interface (MIDI) piano program called Synthesia to display musical pieces on a computer screen that is adapted for people with no music reading abilities and will be playing on a touch sensitive piano keyboard. The supervised session will also be complemented with a unsupervised home program consisting of piano sequence exercises comprising short excerpts of the same musical pieces practiced during the supervised sessions and they will receive a roll-up flexible piano
48134409|NCT06621771|OTHER|Occupational Therapy|Participants will receive conventional occupational therapy treatment (e.g., mobility, ADL, IALD, information session), excluding treatments focusing specifically on arm and hand motor recovery.The supervised session will also be complemented with an unsupervised home program consisting of assignments related to occupational therapy exercises and/or IALD/ADLs.
48499720|NCT00570895|DIETARY_SUPPLEMENT|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
48134411|NCT06675357|RADIATION|FAPI|5 +/- 2 mCi of Ga-FAPI-46
47982000|NCT04035681|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
47982001|NCT04035681|OTHER|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
47982002|NCT02064894|DRUG|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
47982003|NCT02064894|DRUG|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
48134412|NCT06675357|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET scan
48134413|NCT06675357|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
48499721|NCT03533738|OTHER|Food sequence 1|Vegetables first then meat \& rice together
48342603|NCT03790072|BIOLOGICAL|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
48342604|NCT01251822|DRUG|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
48342605|NCT01251822|DRUG|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
48499722|NCT03533738|OTHER|Food sequence 2|Meat first then vegetables \& rice together
48499723|NCT03533738|OTHER|Food sequence 3|Vegetables first then meat followed by rice
47982004|NCT02064894|DRUG|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
48342606|NCT05462457|PROCEDURE|Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)|Intraoperative excision of TAD lymph nodes followed by ALND in the same surgical session or secondary surgical intervention
48342607|NCT04823546|OTHER|activity based therapy|Standing and reaching (2) Sit-to-stand (3) Stepping forward and backward onto blocks (4) Stepping sideways onto blocks (5) Forward step up onto blocks (6) Raising and lowering of heel (7) Standing with the base of support constrained with feet in parallel and tandem conditions Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise. (10) Walking on a treadmill; (11) Walking over various surfaces and obstacles;
48342608|NCT04823546|OTHER|Strength Training|Strength training included for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
48342609|NCT02394990|BEHAVIORAL|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
47982005|NCT01157936|DRUG|Allopurinol|daily dosage
47982006|NCT01157936|OTHER|placebo|daily dosage
47982007|NCT05030974|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccination
47982008|NCT05030974|BIOLOGICAL|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
48342610|NCT02394990|BEHAVIORAL|ABI|
48342611|NCT00841672|DRUG|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
48499724|NCT03533738|OTHER|Food sequence 4|Vegetables first followed by meat and rice together
48499725|NCT03533738|OTHER|Food sequence 5|Rice first followed by vegetables \& meat together
48499726|NCT02973230|OTHER|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
47982009|NCT02557646|BIOLOGICAL|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
47982010|NCT02557646|DRUG|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
47982011|NCT05992610|OTHER|Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy|"Chemotherapy based on carboplatin 6 AUC + paclitaxel 75 mg/m2.~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
47982012|NCT04763915|OTHER|Correlative Studies (Survey)|Administer surveys
47982013|NCT04763915|OTHER|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
47982014|NCT04763915|BEHAVIORAL|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
47982015|NCT04763915|BEHAVIORAL|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
47982016|NCT04763915|BEHAVIORAL|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
47982017|NCT04763915|OTHER|Access to Education Materials|Receive access to VUS educational materials
47982018|NCT00875212|DRUG|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
47982019|NCT00875212|DRUG|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
47982020|NCT00875212|DRUG|fluoride|use of a dentifrice containing fluoride (1500ppm) only
47982021|NCT00875212|DRUG|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
47982022|NCT04597827|OTHER|Metacognition tests|Test on episodic or semantic memory
47982023|NCT03393741|DRUG|Taxane|Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
48499727|NCT04642937|DRUG|Treatment with hP1A8|Treatment with hP1A8
48499728|NCT02130882|DRUG|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
48499729|NCT02130882|OTHER|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
47982024|NCT03393741|DRUG|Vinorelbine|Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
48499730|NCT04993014|DRUG|Pertuzumab|Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
48499731|NCT04993014|DRUG|Trastuzumab|Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
47982025|NCT03393741|DRUG|Ixabepilone|Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
48342612|NCT00841672|DRUG|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
48342613|NCT00800475|DRUG|Gemfibrozil Tablets|
48342614|NCT02998255|DRUG|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
48342615|NCT02998255|DRUG|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
48342616|NCT02007252|DRUG|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
48342617|NCT02007252|DRUG|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
48134415|NCT03559413|BIOLOGICAL|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
48134416|NCT01836445|BEHAVIORAL|Keep It Up!|
48342618|NCT04356924|BEHAVIORAL|Psychological treatment|The treatment is an adjusted (to the cognitively impaired individual) combination of CBT, ACT, validation strategies, and psychoeducation. One focus is to increase motivation to lifestyle changes, and to a larger degree live life in correspondence with internal goals.
48342619|NCT04356924|BEHAVIORAL|Cognitive training|Computer based training tasks implemented with adaptive intensity. The cognitive training method that will be used is mainly related to executive control (i.e., ability to coordinate thoughts and actions in accordance with internal goals).
48342620|NCT03062267|OTHER|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
48342621|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
48342622|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
48342623|NCT05027113|BEHAVIORAL|Mindfulness meditation|Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
48342624|NCT03073213|DRUG|Ixekizumab|Administered as subcutaneous (SC) injection
48342625|NCT01918683|RADIATION|TACE transarterial chemoembolization|
48342626|NCT01918683|RADIATION|stereotatic body radiotherapy (SBRT)|
48342627|NCT01964287|DRUG|GEMBRAX|
48342628|NCT01964287|DRUG|FOLFIRINOX|
48342629|NCT06269588|DEVICE|Nexpowder|Endoscopic hemostasis
48499732|NCT04993014|OTHER|Circulating tumor cells|Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.
48342630|NCT03983460|DRUG|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
48342631|NCT03983460|DRUG|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
48342632|NCT03983460|PROCEDURE|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion"
48499733|NCT00057421|DRUG|prednisolone|
48499734|NCT04181749|DRUG|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
48134417|NCT01836445|BEHAVIORAL|HIV Knowledge Control|
48499735|NCT02564081|OTHER|Static Stretching lower limb|
48499736|NCT02564081|OTHER|Static stretching Cervical|
48513349|NCT04796298|PROCEDURE|Ballistic Hamstring Stretching|Athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute.
48134419|NCT06669351|DRUG|ZX-7101A|Day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water
48134420|NCT00545311|DRUG|NVA237|
48134421|NCT00545311|DRUG|NVA237|
48134422|NCT00545311|DRUG|NVA237|
48134423|NCT00545311|DRUG|NVA237|
48134424|NCT00545311|DRUG|Placebo|
48134425|NCT04984889|DRUG|TAK-662|Lyophilized, sterile concentrate of human protein C
48342633|NCT03983460|PROCEDURE|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm"
48342634|NCT03983460|PROCEDURE|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
48342635|NCT02525406|OTHER|All surgeries performed from Jan 01, 2010 to Aug 31, 2020|
48342636|NCT02157168|BEHAVIORAL|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
48342637|NCT04713111|BEHAVIORAL|Lifestyle (Meditation)|Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace 2 or more times a week for a duration of 4 weeks.
48342638|NCT04713111|BEHAVIORAL|Lifestyle (Exercise)|Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks.
48342639|NCT03595449|DRUG|Lidocaine jelly|lidocaine 2% jelly applied during Mohs surgery
48342640|NCT03595449|DRUG|Surgilube|surgilube (placebo) applied during Mohs surgery
48342641|NCT01761136|BIOLOGICAL|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
48342642|NCT01761136|BIOLOGICAL|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
48342643|NCT04541095|OTHER|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
48342644|NCT04541095|OTHER|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
48342645|NCT02533401|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
48342646|NCT02533401|DRUG|Fludarabine|Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
48342647|NCT02533401|DRUG|Rituximab|Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
48342648|NCT06431412|OTHER|no intervention|no intervention
48342649|NCT04595409|DRUG|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
48342650|NCT04595409|DRUG|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
48342651|NCT04494477|BEHAVIORAL|The IN•clued program|The INclued program as previously described.
48499737|NCT00654758|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
48499738|NCT00171301|DRUG|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
48499739|NCT02447744|BEHAVIORAL|Mindfulness based intervention|The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
48499740|NCT04058249|DEVICE|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
48342652|NCT02820688|DRUG|Bupivacaine 0.25%|
48342653|NCT02820688|DRUG|Prilocaine 1%|
48342654|NCT02820688|PROCEDURE|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
48342655|NCT02820688|DRUG|Bupivacaine 0.167%|
48342656|NCT02820688|DRUG|Bupivacaine 0.125%|
48499741|NCT00421395|BIOLOGICAL|90Y-hLL2|weekly dosing for either 2 or 3 weeks
48499742|NCT04056286|DIETARY_SUPPLEMENT|Whey|45 g whey protein + 20 g maltodextrin
48499743|NCT04056286|DIETARY_SUPPLEMENT|3-OHB/whey|50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
48499744|NCT00045539|DRUG|leucovorin calcium|
48499745|NCT00045539|DRUG|methotrexate|
48499746|NCT00045539|DRUG|thiotepa|
48342657|NCT02820688|DRUG|Prilocaine 0.66%|
48342658|NCT02820688|DRUG|Prilocaine 0.5%|
48342659|NCT02820688|DEVICE|Ultrasound|All nerve blocks will be performed with ultrasound guidance
48342660|NCT04838041|DRUG|Asciminib 40 MG|40 mg by mouth (PO) when used with imatinib.
48657331|NCT06638411|BEHAVIORAL|ADHD information workshop with nocebo education|ADHD information workshop that will be delivered by a clinical psychology student in one 30-minute session to a group of participants. The workshop will present information about lesser-known or commonly misdiagnosed ADHD symptoms, together with a module on nocebo effects and their potential role in worsening symptoms. The nocebo module will describe the current understanding of the role of expectations in creating side effects and elaborate on how this applies to the field of mental health through a series of examples. It will also involve a writing reflection activity about personal experiences with ADHD symptoms, potential for nocebo effect when talking about ADHD symptoms, and ability to apply this information to personal experiences.
48657332|NCT06638411|BEHAVIORAL|Sleep workshop|An information workshop about sleep and dream experiences that will be delivered by a clinical psychologist in one 30-minute session to a group of participants. It will be matched on duration, type of content, and engagingness with the experimental sessions.
48342661|NCT04838041|DRUG|Asciminib 40 MG Twice Daily|40 mg twice daily when used with nilotinib.
48342662|NCT04838041|DRUG|Asciminib 80 MG daily|80 mg daily when used with dasatinib.
48342663|NCT04838041|DRUG|Imatinib|Maximum dose of 400 mg PO once daily.
48342664|NCT04838041|DRUG|Nilotinib|Maximum dose of 300 mg twice daily.
48342665|NCT04838041|DRUG|Dasatinib|Maximum dose of 100 mg PO once daily.
48499747|NCT05437640|BEHAVIORAL|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
48657333|NCT03923335|OTHER|DNA methylation detection|detecting the methylation status of colorectal cancer specimen
48657334|NCT03235804|DIETARY_SUPPLEMENT|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
48499748|NCT05437640|BEHAVIORAL|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
48342666|NCT04301011|BIOLOGICAL|TBio-6517|Engineered Oncolytic Vaccinia Virus
48342667|NCT04301011|BIOLOGICAL|Pembrolizumab|Immune checkpoint inhibitor.
48342668|NCT02676453|OTHER|Intervention|Dental hygienist support
48342669|NCT02491827|OTHER|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
48342670|NCT01577004|DIETARY_SUPPLEMENT|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
48342671|NCT00804986|DRUG|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
48342672|NCT00804986|DRUG|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
48499749|NCT04901598|OTHER|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
48499750|NCT04952636|PROCEDURE|arthroscopic Cuistow|peforming the Cuistow Procedure under arthroscopy
48657335|NCT00392574|DRUG|Prulifloxacin|Tablet
48499751|NCT04952636|PROCEDURE|open Cuistow|peforming the Cuistow Procedure with the traditional open process
48134431|NCT01170208|DEVICE|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
48134432|NCT06635538|DRUG|Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.
48499752|NCT04896749|OTHER|Nerve mobilization|"Moist pack all over cervical spine for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.~Median, ulnar and radial nerve stretch with 3 sets of 10 repetitions , with 3 sec hold at final stretched position.~Following nerve mobilizations are used in experimental group/group A:~Median Nerve: Glenohumeral abduction, wrist extension, supination, glenohumeral lateral rotation, elbow extension, neck lateral bending to opposite side. Radial Nerve: Glenohumeral depression, elbow extension, whole arm internal rotation, wrist flexion Ulnar Nerve: Wrist extension, forearm pronation elbow flexion, glenohumeral lateral rotation, glenohumeral depression, shoulder abduction each with 3 sets of 10 repetitions , with 3 sec hold at final stretched position."
48657336|NCT00392574|DRUG|Placebo|Tablet
48657337|NCT00425555|DRUG|Panobinostat|
48657338|NCT04474873|PROCEDURE|erector spinae block|we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
48657339|NCT06638190|OTHER|100% Orange juice|250 mL of commercial 100% orange juice containing 25 g of total sugars (glucose, fructose, saccharose).
48657340|NCT06638190|OTHER|50% Orange juice|250 mL of 50% diluted orange juice (100% orange juice) plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
48657341|NCT06638190|OTHER|0% Orange juice|250 mL of water plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
48657342|NCT06638190|OTHER|Glucose|250 mL of water with 25 g of glucose. To determine the glycemic index of the different drinks and to characterize the glucose and insuline response of the participants
48657343|NCT06638190|OTHER|100% Orange juice Rep|Repetition of the 100% orange juice intervention
48657344|NCT06638190|OTHER|0% Orange juice Rep|Repetition of the 0% orange juice intervention
48657345|NCT05270863|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
48134433|NCT06635538|DRUG|Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
48134434|NCT06635538|DIAGNOSTIC_TEST|Monitoring cycle|Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.
48134435|NCT02432898|DEVICE|3D OCT-1|Spectral Domain OCT Device
48134436|NCT02432898|DEVICE|3D OCT-2000|Spectral Domain OCT Device
48134437|NCT02432898|DEVICE|DRI OCT-1|Swept Source OCT Device
48134438|NCT02432898|DEVICE|NW-300|Fundus Camera
48134439|NCT02432898|DEVICE|CT-1P|Tonometry
48134440|NCT02432898|DEVICE|TRK-2P|Tonometry, Corneal Topography
48657346|NCT05270863|DRUG|Carbachol PF|A single drop in each eye at a visit.
48657347|NCT05270863|DRUG|Brimonidine tartrate|A single drop in each eye at a visit.
48657348|NCT06174220|DRUG|Tideglusib|Tideglusib 1g po daily
48134441|NCT02432898|DEVICE|SP-1P|Specular Microscopy
48134442|NCT02432898|DEVICE|SL-D701|Slit Lamp Imaging
48134443|NCT02432898|DEVICE|MC-4S|Visual Acuity Testing
48657349|NCT06174220|DRUG|Placebo|Matching placebo 1g po daily
48134445|NCT03355573|DRUG|Bimekizumab|Bimekizumab at a prespecified dose.
48342673|NCT01308294|BIOLOGICAL|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
48342674|NCT01308294|BIOLOGICAL|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
48342675|NCT01308294|BIOLOGICAL|"2 vaccine injections in distinct limbs"|
48657350|NCT05917145|DRUG|WSD0628|A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
48657351|NCT06138418|PROCEDURE|Neurotomy|Surgical treatment of spastic foot
48657352|NCT00406926|DRUG|Somatropin|
48657353|NCT06397040|DEVICE|provider monitoring and feedback to remote data|provider monitoring of remote data and feedback to changes in remote data
48657354|NCT06397040|DEVICE|participant monitoring of remote data|participant monitoring of remote data, based upon post-operative instructions
48657355|NCT04943679|DRUG|Anti-PD-1/PD-L1|Intravenous injection for up to 2 years
48657356|NCT04943679|DRUG|PEG-Interferon Alfa|3 µg/kg every week by subcutaneous injection for up to 2 years
48134446|NCT06174948|DEVICE|CUE1 non-invasive device|This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.
48657357|NCT04227379|BEHAVIORAL|Intervention 1- DD-TXT|Participants in this group were signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol consisted of the same daily educational content as the DSE arm augmented by the following: regular two-way check-in messages about diabetes self-management behaviors, an invitation to receive messages written by other Veterans living with diabetes on demand, and a menu of optional and customizable modules (e.g., medication reminders, blood sugar and blood pressure monitoring,: physical activity reminders, weight management, and goal setting) from which participants could select messaging that supported their diabetes self-management goals. Patients could customize the timing and frequency of their messages. DD-TXT participants also received a once monthly message asking whether the messages had been helpful.
48134447|NCT06174948|DEVICE|CUE1+ device active vs sham CUE1+ device|30-40 participants with idiopathic Parkinson's disease only will be randomly allocated to one of two interventions groups: one group will use the active CUE1+ device while the other group will use the CUE1+ at silent settings (e.g., sham device). All participants will use their device in the same way which is starting the usage from the morning, within an hour once they took their medications for Parkinson's (if any) and continue using the device for 8 hours, once a day, every day for 12 weeks
48499753|NCT04896749|OTHER|Conventional physical therapy|Moist pack for 10 minutes. TENS for 10 minutes at frequency of 60 Hz with 2 electrodes. Cervical traction for 10 minutes with 7 sec hold and 5 sec rest time. Cervical isometric exercises with 7 sec hold and 30 repetitions in each direction twice a day.
48342676|NCT05083949|DRUG|FDC 12.5mg empagliflozin/850mg metformin|empagliflozin/metformin
48499754|NCT02307266|BEHAVIORAL|Standard of care + supplementary education|
48499755|NCT02307266|BEHAVIORAL|Standard of care + additional visits|
48499756|NCT02307266|BEHAVIORAL|Standard of care|
48499757|NCT06295848|BEHAVIORAL|Exercise|An individual program will be organized for each patient according to the exercise test result. Since the patients have both arthritis and HTN, aerobic exercises will be given at moderate intensity (40-60% VO2 reserve) according to ACMS recommendations. Xrcise Runner Med treadmill and Xrcise Care 2.5.8.3 software will be used for aerobic exercises. Resistant exercises will be given under the supervision of a physiotherapist, calculating 1 repetitation maximum (1-RM) in the main muscle groups.Patients will perform isotonic exercises with 3 sets of 15 repetitions with a resistance of 60% of 1-RM. The education sessions will be conducted by a multidisciplinary team of health professionals (nurse, physiotherapist and dietician) under the leadership of a clinician experienced in CR. Education topics will consist of 60-minute sessions covering heart-healthy eating, setting health-related goal, exercise, diet, healthy weight loss, smoking cessation, and stress/coping.
48499758|NCT03310411|DRUG|Lasmiditan|Administered orally
48499759|NCT03310411|DRUG|Sumatriptan|Administered orally
48499760|NCT03310411|DRUG|Placebo for Lasmiditan|Administered orally
48499761|NCT03310411|DRUG|Placebo for Sumatriptan|Administered orally
48499762|NCT04162132|DEVICE|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
48499763|NCT01216696|DRUG|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
48499764|NCT05073952|PROCEDURE|Connective tissue graft|Implants will be placed with a flap and a connective tissue graft.
48499765|NCT05073952|PROCEDURE|Flapless|Implants will be placed with a flapless approach
48499766|NCT02080169|DRUG|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
48657358|NCT04227379|BEHAVIORAL|Comparison - DSE|"Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE was comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSE messages could not be customized. There was no interactive content for the DSE arm other than a once monthly message asking whether the messages had been helpful."
48657359|NCT06635850|DRUG|Mosliciguat|Dose level 1, 2, or 3 for inhalation
48499767|NCT02080169|DRUG|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
48342677|NCT05083949|DRUG|Empagliflozin|empagliflozin 10mg (R1)
48342678|NCT05083949|DRUG|Glifage®|Glifage® 850mg (R2)
48342679|NCT00400556|DRUG|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
48342680|NCT00671619|DRUG|ESBA105|eye drops
48342681|NCT03066297|PROCEDURE|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
48342682|NCT05169736|BEHAVIORAL|Cognitive Behavioural Therapy|Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
48342683|NCT05883839|OTHER|Student Group|"Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish."
48342684|NCT05906576|DRUG|Infliximab|Infliximab in the treatment of Crohn's disease in children
48342685|NCT04336111|PROCEDURE|retrolaminar block|will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
48342686|NCT02791867|DRUG|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
48499768|NCT02080169|DRUG|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
48499769|NCT00491140|GENETIC|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
48499770|NCT00992524|DRUG|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
48499771|NCT00992524|DRUG|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
48499772|NCT03903809|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
48499773|NCT03903809|DRUG|ESPO|Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
48499774|NCT02969681|DRUG|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
48499775|NCT02969681|DRUG|Chemotherapy|"* mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
48499776|NCT00658021|DRUG|Placebo|Subcutaneous injection, twice a day
48499777|NCT00658021|DRUG|Exenatide|Subcutaneous injection, 5 µg, twice a day
48499778|NCT00658021|DRUG|Exenatide|Subcutaneous injection,10 µg, twice a day
48657360|NCT06635850|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat or placebo delivery
48657361|NCT06635850|DRUG|Placebo|Matching placebo for inhalation
48657362|NCT05077072|OTHER|Best Practice|Receive SOC
48657363|NCT05077072|OTHER|Counseling|Participate in CHAT counseling intervention
48657364|NCT05077072|PROCEDURE|Electroencephalography|Undergo EEG
48657365|NCT05077072|BEHAVIORAL|Neurofeedback|Undergo NFB intervention
48657366|NCT05077072|OTHER|Questionnaire Administration|Ancillary studies
48342687|NCT05899829|DRUG|Camlipixant + Rifampin|Camlipixant will be administered alone as well as in co-administration with rifampin
48342688|NCT05899829|DRUG|Camlipixant + Rabeprazole|Camlipixant will be administered alone as well as in co-administration with rabeprazole
48342689|NCT03641794|DRUG|DN1406131|IDO1 and TDO2 inhibitor
48342690|NCT03641794|DRUG|Placebo|Placebo
48342691|NCT02801006|DEVICE|stenfilcon A|contact lens
48342692|NCT02801006|DEVICE|etafilcon A|contact lens
48342693|NCT03736551|BEHAVIORAL|5:2 diet|very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
48342694|NCT03736551|BEHAVIORAL|Renal Weight Management Programme|Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
48342695|NCT01779804|PROCEDURE|OFAR|OFAR
48342696|NCT00663338|DRUG|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
48342697|NCT01300949|DIAGNOSTIC_TEST|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
48499779|NCT02398630|RADIATION|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
48499780|NCT02398630|OTHER|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
48499781|NCT02398630|OTHER|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
48499782|NCT02398630|OTHER|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
48499783|NCT00613535|DEVICE|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
48499784|NCT00613535|DEVICE|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
48499785|NCT00613535|PROCEDURE|Lavage debridement|Remove loose chondral fragments
48342698|NCT01300949|DIAGNOSTIC_TEST|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
48342699|NCT04342416|BEHAVIORAL|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
48499786|NCT00613535|DEVICE|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
48499787|NCT00613535|DEVICE|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
48499788|NCT05199168|PROCEDURE|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
48657367|NCT01352455|PROCEDURE|Hemodialysis|5 days per week hemodialysis
48499789|NCT02507544|DRUG|TRX-818 capsules|
48134451|NCT05912218|BIOLOGICAL|MEI6570|Saline Control
48134452|NCT05891132|DRUG|10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
48134453|NCT05891132|DRUG|lidocaine prilocaine cream 15gm|Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
48342700|NCT05018468|DEVICE|Ventilation|Patients in group 1 undergo ventilation with an anatomical facial mask and 100% oxygen for three minutes. Patients in group 2 undergo ventilation with a nasal mask and 100% oxygen for three minutes. In both groups, ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
48657368|NCT03456076|DRUG|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
48499790|NCT01675661|DRUG|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
48134455|NCT06301867|DIAGNOSTIC_TEST|Plateau Pressure|Plateau pressure will be measured on all patients in the participating intensive care units prior to extubation.
48134456|NCT02099123|DRUG|Atorvastatin|Atorvastatin 20 mg tablet
48134457|NCT02099123|DRUG|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
48499791|NCT01675661|DRUG|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
48499792|NCT05950230|DIAGNOSTIC_TEST|Assess Periodontal Health Status|"For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:~* Plaque index (PI)(Silness and Löe, 1964).~* Sulcus bleeding index(BOP)(Perez et al., 2008).~* Probing depth (PD) (Polson et al., 1980).~* Clinical attachment level (CAL) (Glavind and Löe, 1967).~* Standardized Periapical Radiograph."
48134460|NCT04642287|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriene is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
48342701|NCT05660889|OTHER|Blood sampling.|Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
48342702|NCT00864344|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
48134461|NCT04642287|DRUG|Vaseline|Placebo
48134462|NCT04642287|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
48134463|NCT02131584|OTHER|Questionnaire Administration|Ancillary studies
48134464|NCT02131584|DRUG|Ruxolitinib Phosphate|Given PO
48499793|NCT05950230|OTHER|Collecte GCF samples by paperstrip|GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).
48499794|NCT04877886|DIAGNOSTIC_TEST|Ultrasound with IV contrast|To compare the efficiency over the ultrasound scan within contrast
48499795|NCT04877886|DIAGNOSTIC_TEST|CT with IV contrast|CT with IV contrast
48657369|NCT03456076|DRUG|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
48342703|NCT00864344|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
48342704|NCT00224692|DRUG|Low dose ketamine|
48342705|NCT00528008|OTHER|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
48342706|NCT00528008|OTHER|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
48342707|NCT02050451|DIETARY_SUPPLEMENT|Ensure Plus®|
48342708|NCT02050451|DIETARY_SUPPLEMENT|Multivitamin|
48657370|NCT03456076|DRUG|Vinorelbine|Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
48657371|NCT03456076|DRUG|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
48657372|NCT03456076|DRUG|Pemetrexed|"Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
48657373|NCT03456076|DRUG|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
48499796|NCT04877886|DIAGNOSTIC_TEST|Ultrasound without IV contrast|Ultrasound without IV contrast
48134465|NCT03552276|DRUG|SUNPG18_07 I (Tildrakizumab 200 mg)|injection
48134466|NCT03552276|DRUG|SUNPG18_07 II (Tildrakizumab 100 mg)|injection
48134467|NCT04004325|DRUG|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
48134468|NCT04004325|DRUG|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
48499797|NCT04877886|DIAGNOSTIC_TEST|CT without IV contrast|CT without IV contrast
47982026|NCT03393741|DRUG|Eribulin|Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
48342709|NCT01117025|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
47982027|NCT03393741|DRUG|Chemotherapy|Chemotherapy is used to treat various stages of breast cancer.
48134469|NCT04004325|OTHER|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
48134470|NCT05216796|BEHAVIORAL|Diet Intervention|Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
48134471|NCT05129722|DRUG|Low dose combination polydiuretic therapy|"Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg"
48134472|NCT05129722|DRUG|Comparator monotherapy empagliflozin|Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
48499798|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
48134474|NCT06601504|DRUG|HMPL-760 planned dose 1|HMPL-760 planned dose 1 daily (QD) orally
48499799|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
47982028|NCT02289079|DRUG|Bupivacaine|
47982029|NCT02289079|DRUG|liposomal bupivacaine|
47982030|NCT06430658|COMBINATION_PRODUCT|Tislelizumab (BGB-A317) with chemoradiotherapy|Different sequences and methods of treatment to convert surgery
47982031|NCT00703079|DRUG|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
47982032|NCT00703079|PROCEDURE|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
47982033|NCT00541489|DRUG|Naproxcinod|750 mg, bid
47982034|NCT00541489|DRUG|Naproxen|500 mg, bid
47982035|NCT00541489|DRUG|Placebo|bid
47982036|NCT06471894|RADIATION|Magnetic resonance imaging scanning|Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals
47982037|NCT06471894|DRUG|FMT Protocol|Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution
48134475|NCT06601504|DRUG|R-GemOx|R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
48134476|NCT06601504|DRUG|HMPL-760 placebo planned dose 1|HMPL-760 placebo planned dose 1 daily (QD) orally
48134477|NCT06601504|DRUG|HMPL-760 planned dose 2|HMPL-760 planned dose 2 daily (QD) orally
48499800|NCT02092896|DRUG|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
48499801|NCT02092896|DRUG|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
48134478|NCT06601504|DRUG|HMPL-760 placebo planned dose 2|HMPL-760 placebo planned dose 2 daily (QD) orally
48134479|NCT06590064|DEVICE|Non-invasive Blood Pressure Measurement|Non-invasive Blood Pressure Measurement in Both Upper and Lower Limbs
48499802|NCT05531318|OTHER|Qualitative Interview|Participants will be interviewed about their experiences of substance use, post-traumatic stress and the way they regulate their emotions.
47982038|NCT04489667|OTHER|+STEP Implementation|All patients receiving care at five RWHAP-funded clinics will receive the intervention (+STEP), in which patient-reported outcomes (PROs) on mental health and substance use disorder (SUD) will be integrated into routine care, targeted training will be provided for frontline clinicians on best practices for mental health and SUD treatment, and telemedicine for mental health and SUD will be offered to patients in need of expanded access to services.
47982039|NCT06320028|DEVICE|Non-Invasive Transcranial Focused Ultrasound|The ultrasound will be delivered for 10 minutes per treatment session targeting to the participant's amPFC.
47982040|NCT00143403|DRUG|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
48134481|NCT06668571|DRUG|Ketamine|The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
48134482|NCT06668571|DRUG|Normal Saline|The subjects will receive 1:1 single IV normal saline/placebo (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
48499803|NCT03838510|BEHAVIORAL|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
48499804|NCT06086418|DRUG|0.9 % Sodium Chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
48499805|NCT06086418|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
48499806|NCT06086418|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
48499807|NCT03123458|BIOLOGICAL|clonal fetal MSCs|
48499808|NCT05173675|BEHAVIORAL|Empathy in Action for life with diabetes.|"In Phase 1 (Months 1-6) participants receive (Program):~1. Empathetic communications: A dedicated partner (lightly-trained lay person) who communicates with them via phone with timing and frequency defined by the participant within certain parameters. Two letters mailed during the 6 months that compile anonymized learnings from all participants in the callers panel of 10-20 participants, written as a newsletter to share back with the participant.~2. Material Incentives: One choice of health tool (weight scale or pedometer) selected with the caller in week 1 and expected to be received in weeks 3-5. Two small recognition gifts (valued at US$25) chosen by the caller based on their understanding of the participants preferences, and sent at month 2.5 and 4.5.~3. Educational Materials: Printed DM management educational materials mailed right after enrollment and randomization, and expected to be received in weeks 1-2."
48499809|NCT05173675|BEHAVIORAL|Control Phase 2 Materials Only|"1. Material Incentives:~   a. Choice of health tool (weight scale or pedometer) and 2 health promoting gifts chosen by the caller at the end of their 6 month measurement visit.~   i. Health tool is mailed out within the 7th month ii. Health promoting gifts are mailed out in the 8th and 10th month~2. Educational Materials a. The same educational materials mailed to participants in the intervention arm Program will be mailed to control arm participants after they complete their 6 months visit"
48134495|NCT06677957|DRUG|Digoxin|Digoxin will be administered together with Rosuvastatin as a drug cocktail as specified for the respective period
48134496|NCT06677957|DRUG|Divarasib|Divarasib will be administered in combination with Digoxin and Rosuvastatin as specified for the respective period
48134497|NCT06677957|DRUG|Rosuvastatin|Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
48342710|NCT01117025|PROCEDURE|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
47982041|NCT00143403|DRUG|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
48134507|NCT04172532|PROCEDURE|Biopsy|Undergo tissue collection
48134508|NCT04172532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48134509|NCT04172532|PROCEDURE|Computed Tomography|Undergo CT
48134510|NCT04172532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48134511|NCT04172532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48134512|NCT04172532|DRUG|Peposertib|Given PO
48134513|NCT04172532|OTHER|Placebo Administration|Given PO
48134515|NCT06678269|DRUG|Abemaciclib|The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases
48134516|NCT02500147|DRUG|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
48134517|NCT02500147|DRUG|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
48134520|NCT03459846|DRUG|Durvalumab|Durvalumab 1500 mg IV q4w
48134521|NCT03459846|DRUG|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
48134522|NCT03459846|DRUG|Placebo|Matching placebo for oral tablet BID
48657374|NCT04150445|BEHAVIORAL|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
47982042|NCT02532933|DEVICE|DePuy Synthes Attune PS RP|
47982043|NCT02045368|DRUG|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
47982044|NCT03569553|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
47982045|NCT00237874|DRUG|Aripiprazole|
47982046|NCT00679146|DRUG|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
47982047|NCT00679146|DRUG|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
47982048|NCT02190357|DRUG|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
47982049|NCT01936688|DRUG|MK-3222 200 mg|MK-3222 200 mg administered SC.
47982050|NCT01936688|DRUG|MK-3222 100 mg|MK-3222 100 mg administered SC.
47982051|NCT01936688|DRUG|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
47982052|NCT01936688|DRUG|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
47982053|NCT01936688|DRUG|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
47982054|NCT00861432|OTHER|additive homeopathic treatment|These patients receive additive homeopathic treatment
47982055|NCT06334692|DIAGNOSTIC_TEST|"In-house ELISA, and ELISA kits from DBA Italy (Abbexa)."|"Nunc MaxiSorp ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm."
47982056|NCT02375568|OTHER|103024-F|mesenchymal stem cell isolation
47982057|NCT05780112|OTHER|breathing exercise|"* Place one hand on your chest and the other on your stomach.~* Slowly take a deep breath through the nose.~* During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~* Hold your breath and stretch your muscles in a second or two.~* Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~* Set the time you use when exhaling air to be twice the time you use when exhaling.~* As you exhale, focus on the inward movement of your abdominal hand."
47982058|NCT01690247|DRUG|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
47982059|NCT01690247|DRUG|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
47982060|NCT05249361|OTHER|no intervention|no intervention
47982061|NCT05369455|PROCEDURE|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
47982062|NCT05369455|PROCEDURE|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
47982063|NCT02514447|DRUG|Trilaciclib|
48134523|NCT04433091|DRUG|2-Hydroxybenzylamine|2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
47982064|NCT02514447|DRUG|Placebo|
47982065|NCT02514447|DRUG|Topotecan|
47982066|NCT04769024|DEVICE|LUMEEN Virtual Reality sessions|"It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~1. The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~2. The facilitator announces the immersion theme of the session~3. Participants are equipped with virtual reality head-mounted displays.~4. Participants watch the content.~5. The head-mounted displays are removed.~6. A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator."
48134524|NCT04433091|OTHER|Placebo|Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
48134525|NCT04448561|DRUG|ASP8082|oral
48134526|NCT04448561|DRUG|morphine|oral
48134527|NCT04448561|DRUG|Placebo|oral
48499810|NCT00902031|DRUG|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
48499811|NCT00902031|DRUG|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
48657375|NCT05293717|DRUG|Ruxolitinib|1.5% Ruxolitinib cream
48657376|NCT01661543|DIETARY_SUPPLEMENT|Beans|120g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
48499812|NCT03203564|DRUG|Modufolin (arfolitixorin)|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
48499813|NCT05676281|BEHAVIORAL|Healthy Together (Control)|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals"
48499814|NCT05676281|BEHAVIORAL|Healthy Together + Promotora Support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)"
48499815|NCT05676281|BEHAVIORAL|Healthy Together + Parenting Training|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
48657377|NCT01661543|DIETARY_SUPPLEMENT|Control (rice)|110g (3/4 c) of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group. This amount of rice equates to a similar volume as 120g of cooked beans or peas.
48134534|NCT06252649|DRUG|FOLFIRI Regimen|Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.
48134535|NCT06252649|DRUG|Sotorasib|Immediate-release solid dosage form administered PO.
48134536|NCT06252649|DRUG|Panitumumab|Administered IV Q2W.
48134537|NCT06252649|DRUG|Bevacizumab-awwb|Administered IV Q2W.
48657378|NCT01661543|DIETARY_SUPPLEMENT|Peas|120 grams of peas will be consumed 5 out of 7 days per week
48342711|NCT02324868|DEVICE|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
48342712|NCT02324868|DEVICE|Conventional IV catheter protection|No Shower patch will be provided during study period
48657379|NCT02852837|DRUG|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
48657380|NCT05509127|DRUG|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
47982067|NCT04769024|BEHAVIORAL|Control/non-digital stimulation sessions|It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes...). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
47982068|NCT00402766|DRUG|Cisplatin|Starting Dose: 60 mg/m\^2 by vein, Over 2 Hours
47982069|NCT00402766|DRUG|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
47982070|NCT00402766|DRUG|Pemetrexed|Starting Dose: 500 mg/m\^2 by vein, Over 40 Minutes
47982071|NCT00402766|DRUG|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
47982072|NCT04326348|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
48134539|NCT06067763|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
48342713|NCT03751969|DRUG|HSK3486|The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
48342714|NCT04410081|DRUG|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
48342715|NCT01237301|DEVICE|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
48342716|NCT01237301|DEVICE|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
48657381|NCT05509127|DRUG|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
48134540|NCT06067763|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
48134541|NCT06067763|OTHER|The Weight of the Nation|This 2012 documentary discusses the facts and myths about obesity and the impacts of obesity on individuals and the health care system in the United States.
48499816|NCT05676281|BEHAVIORAL|Healthy Togethers + Parenting Training + Promotora support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~* 8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
48499817|NCT01768013|DRUG|LEO 90105|Once daily for four weeks
48499818|NCT00539227|PROCEDURE|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
48499819|NCT00539227|BEHAVIORAL|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
48134546|NCT03795298|DEVICE|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
48134547|NCT03795298|DRUG|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
48134548|NCT06682728|DRUG|Sacituzumab Govitecan (SG)|Given IV
48134549|NCT06682728|DRUG|Nivolumab|Given IV
48499820|NCT03035344|OTHER|Metabolome study|Metabolome study in ALL patients compared to healthy controls
48134551|NCT06686797|DRUG|PF-08049820|Oral solution/suspension
48134552|NCT06686797|DRUG|Placebo|Oral solution/suspension
48134553|NCT06687226|DIETARY_SUPPLEMENT|Reconstitutable food powder|During the intervention week, participants will be asked take one dose of a reconstitutable food powder provided in a ziplock bag. This powder will be a mix of Gatorade Zero Powder (1 serving) and 1 serving of commercially available powders of either one or all of the following: camu camu, kelp or maqui. The powder mix in the bag will be added to water and drunk by the participant as soon as possible after having a bowel movement (baseline stool sample). Food powders are sourced from reputable companies and are safe for consumption (Gatorade is a wellrecognized brand and available in grocery stores nationally, Navitas Organics provides certified organic, third-party tested plant food powders with fairtrade certification).
48499821|NCT02514850|DRUG|Biochaperone Combo|Injection of BioChaperone Combo
48499822|NCT02514850|DRUG|Humalog Mix25|Injection of Humalog Mix25
48499823|NCT02514850|DRUG|Humalog|Injection of Humalog
48499824|NCT02514850|DRUG|Lantus|Injection of Lantus
48134558|NCT00179933|BEHAVIORAL|Newborn Individualized Assessment Program|
48342717|NCT04279652|OTHER|Combined exercise|Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
48134559|NCT06691035|DRUG|Elacestrant|"345 mg (or 86 mg tablets) orally daily during vaccination and continued after until progression.~Cycle Length 28 days (4 weeks)"
48134560|NCT06691035|BIOLOGICAL|DC1 native/mutated ESR1|"2.0-5.0 x 10 (20-50 million) cells (Injections in groin nodes (or accessible breast tumor if available) weekly with DC1 for eight consecutive weeks, alternating between native ESR1 DC1s and mutated ESR1 DC1s.~Mutated ESR1 DC1s on week 1 followed by native ESR1 DC1s on week 2, alternating during the initial vaccination series and the subsequent booster phase.~Pulsed DC1 will be administered after initial induction every four weeks x 3 doses."
48342718|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme1|15 to 20 minutes and 1 to 2 hours after first perfusion and before second perfusion/administration of paracetamol
48342719|NCT06135389|BIOLOGICAL|Titration of paracetamol and its metabolites - scheme 2|30 to 40' after first perfusion and before second perfusion/administration of paracetamol (residual concentration)
48342720|NCT05402722|DRUG|Eribulin|Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
48342721|NCT05402722|DRUG|anti-PD-1 antibody|Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
48342722|NCT05676827|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders Clinical Examination|Clinical examination made by experienced dentists (minimum 5 years of practice) and trained and calibrated in accordance with the protocol available on the DC/TMD.
48499825|NCT02514850|DRUG|Placebo|Injection of saline 0.9% solution
48499826|NCT05941689|DEVICE|AI-assisted colonoscopy|AI can not only detect suspicious lesions timely, and label them in the field of view of the colonoscopy, but also monitor withdrawal speed and calculate the clean withdrawal time automatically.
48499827|NCT02757365|DRUG|aspirin|
48499828|NCT02757365|DRUG|Levofloxacin|
48499829|NCT03542955|DEVICE|ActiPatch|A Pulsed Shortwave Therapy Device
48499830|NCT03542955|DRUG|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
48499831|NCT03239912|DEVICE|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
48657382|NCT06560892|DRUG|Bupivacaine injection|patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
48657383|NCT06560892|DRUG|Dexmedetomidine injection|Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
48657384|NCT04720001|DRUG|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
48657385|NCT04720001|DEVICE|PET|PET Scan for brain imaging
48657386|NCT03559530|DRUG|Antimicrobial|Antimicrobial therapy according to A. baumannii susceptibility profile
48657387|NCT00622206|DRUG|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
48342723|NCT05676827|DIAGNOSTIC_TEST|Blood test|Blood samples will be tested to investigate two polymorphisms of genes encoding proteins for serotonin receptors HTR2A - rs4941573 in intron 3 and dopamine DRD3 - rs6280 (Ser9Gly) and levels of serotonin, dopamine, C-reactive protein, cortisol, sodium, potassium, and calcium.
48342724|NCT02882165|OTHER|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
48342725|NCT04155125|DRUG|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
47982073|NCT03029377|OTHER|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
48342726|NCT04155125|DRUG|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
47982074|NCT01218204|DRUG|10mg atorvastatin|10mg
47982075|NCT01218204|DRUG|80mg atorvastatin|80mg
48342727|NCT03482336|OTHER|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
48342728|NCT01255293|PROCEDURE|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
48342729|NCT01255293|PROCEDURE|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
48342730|NCT02539524|OTHER|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
48342731|NCT02539524|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
48342732|NCT02180568|PROCEDURE|Lipiodol|Lipiodol-guided lung localization technique
47982076|NCT01218204|DRUG|GSK1292263 Placebo|Placebo
47982077|NCT01218204|DRUG|100mg GSK1292263|100mg
47982078|NCT01218204|DRUG|300mg GSK1292263|300mg
47982079|NCT01218204|DRUG|800mg GSK1292263|800mg
47982080|NCT01218204|DRUG|10mg ezetimibe|10mg
47982081|NCT01218204|OTHER|Washout|No interventions - washout period
47982082|NCT00901160|PROCEDURE|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
47982083|NCT01840501|DRUG|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
47982084|NCT01840501|DRUG|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
47982085|NCT01840501|DRUG|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
47982086|NCT01840501|DRUG|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
48342733|NCT02180568|PROCEDURE|Hookwire|Hookwire-guided lung localization technique
48342734|NCT02180568|DRUG|Lipiodol|
48657388|NCT06270056|DRUG|Misoprostol|Self-administered misoprostol by clients obtaining medication abortion via telemedicine
47982087|NCT04682067|BEHAVIORAL|Contingency Management|Escalating financial incentives contingent upon biochemical evidence of abstinence
47982088|NCT04682067|BEHAVIORAL|Usual Care smoking cessation|Usual care smoking cessation support
48342735|NCT05108441|OTHER|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
47982089|NCT03294057|BEHAVIORAL|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
48342736|NCT05400369|DRUG|Sitafloxacin|Oral administration, 50 mg tablets
48342737|NCT05400369|DRUG|Moxifloxacin Hydrochloride|Oral administration, 400 mg tablets
48342738|NCT01898962|PROCEDURE|Complete Surgical Removal|
48342739|NCT01898962|RADIATION|Stereotactic Radiosurgery|
48342740|NCT01898962|RADIATION|Ablative external beam radiation dose|
48499832|NCT03239912|OTHER|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
48657389|NCT06274957|OTHER|CONTROL|Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education
48657390|NCT06274957|DEVICE|PEP DEVICE|"Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~PEP training was applied using the Acapella device.~In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device."
48657391|NCT06274957|DEVICE|HFCWO DEVICE|"Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each.~HFCWO training was applıed using the WEST device"
48657392|NCT01600651|OTHER|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
48657393|NCT01600651|OTHER|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
47982090|NCT03294057|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
48342741|NCT01898962|PROCEDURE|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
48342742|NCT01898962|RADIATION|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
48342743|NCT03486249|OTHER|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
48342744|NCT01025232|DRUG|Ranibizumab|Intravitreal Injection of 2.0mg formulation
48499833|NCT04896411|OTHER|Alternative phrasing for no code|This intervention will use the alternative phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
48499834|NCT04896411|OTHER|Standard of care for no code|This intervention will use the standard of care phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
48499835|NCT02181426|DRUG|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
48499836|NCT00258700|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
48499837|NCT03525158|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
48499838|NCT05934955|DRUG|BI 1839100|BI 1839100
48499839|NCT05934955|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
48499840|NCT01436799|DRUG|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
48499841|NCT01436799|DRUG|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
48499842|NCT01436799|DRUG|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
48499843|NCT01436799|DRUG|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
48499844|NCT02605993|BIOLOGICAL|Ravulizumab|All treatments were given as IV infusions.
48499845|NCT03317886|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
48499846|NCT01345435|PROCEDURE|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
48342745|NCT04756349|OTHER|composite resin restoration|All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.
47982091|NCT03294057|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
47982092|NCT00734903|BEHAVIORAL|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
47982093|NCT00734903|BEHAVIORAL|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
47982094|NCT00708006|DRUG|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
47982095|NCT01748643|DRUG|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio \> 0.9.
47982096|NCT01748643|DRUG|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is \> 0.9.
47982097|NCT03590379|DRUG|CHF 5993 DPI|BDP/FF/GB DPI
48342746|NCT01113190|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
48342747|NCT01113190|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller \& Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
48342748|NCT01113190|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (\~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
48342749|NCT01113190|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
48342750|NCT02606396|PROCEDURE|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
48342751|NCT02606396|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
48342752|NCT02606396|PROCEDURE|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
48342753|NCT05778162|DIAGNOSTIC_TEST|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments \[CLIA\] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
48342754|NCT01332695|DRUG|ST101|tablets for oral administration
48342755|NCT01332695|DRUG|Placebo|placebo to match
48342756|NCT02579902|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
48342757|NCT02579902|DIETARY_SUPPLEMENT|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
48342758|NCT04213118|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg QD PO d1-14, 21 days per cycle.
48342759|NCT04213118|PROCEDURE|TACE|TACE first, followed by anlotinib within day4（+/-1days）
48342760|NCT03103776|OTHER|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
48342761|NCT02164604|DRUG|intravitreal injection of 0.03ml ranibizumab|
48342762|NCT01631292|DIETARY_SUPPLEMENT|600 IU Vitamin D3|Once daily
48342763|NCT01631292|DIETARY_SUPPLEMENT|2000 IU Vitamin D3|Once daily
48342764|NCT01631292|DIETARY_SUPPLEMENT|4000 IU Vitamin D3|Once daily
48342765|NCT02901080|DEVICE|Alpha Stim AID cranial electrotherapy stimulation|- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
48499847|NCT01345435|PROCEDURE|Telemonitoring & Telemedicine|The Telemonitoring \& Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
48499848|NCT01345435|OTHER|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
48499849|NCT05338606|DRUG|Bimatoprost Sustained Release Implant|Intraocular Implant
48342766|NCT02901080|BEHAVIORAL|Pregnancy test|- Pregnancy test x 1 (day 1)
48342767|NCT02901080|OTHER|Anxiety questionnaire|- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
48342768|NCT02901080|OTHER|Quality of life questionnaire|- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
48342769|NCT02901080|OTHER|Work and social questionnaire|- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
48342770|NCT02901080|OTHER|Sleep questionnaire|- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
48342771|NCT02901080|OTHER|Depression questionnaire|- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
48342772|NCT02901080|OTHER|Quality of life and financial questionnaire|- CSRI questionnaire x 3 (day 1, week 12 and week 24)
48342773|NCT00000440|DRUG|naltrexone (Revia)|
48342774|NCT00000440|DRUG|sertraline (Zoloft)|
48342775|NCT00151541|DRUG|Dapsone Topical Gel + adapalene gel 0.1%|
47982098|NCT03590379|DRUG|CHF5993 pMDI|BDP/FF/GB pMDI
47982099|NCT03590379|DRUG|CHF 1535 pMDI|BDP/FF pMDI
47982100|NCT03590379|DRUG|Placebo DPI|CHF 5993 DPI matched placebo
48342776|NCT00151541|DRUG|Dapsone Topical Gel + benzoyl peroxide gel 4%|
48342777|NCT00151541|DRUG|Dapsone Topical Gel + vehicle control|
48342778|NCT05522855|DEVICE|EEG Sensorband and mobile application|EEG headband to record brain signals. The Sensorband uses Bluetooth to link to the mobile application on a user's device. This raw EEG data is processed on a HIPPA compliant cloud based server and displays mental workload and brain energy data on the application. This can help the user with cognitive pacing to avoid overexertion. The control version will not display mental workload and brain energy data on the application.
48342779|NCT00653068|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
48342780|NCT00653068|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
48342781|NCT00653068|DRUG|Carboplatin|Given IV
48342782|NCT00653068|DRUG|Cisplatin|Given IV
48342783|NCT00653068|DRUG|Cyclophosphamide|Given IV
48342784|NCT00653068|DRUG|Etoposide|Given IV
48342785|NCT00653068|BIOLOGICAL|Filgrastim|Given IV or SC
48342786|NCT00653068|OTHER|Laboratory Biomarker Analysis|Correlative studies
48499850|NCT01907126|BEHAVIORAL|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
48499851|NCT01907126|BEHAVIORAL|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
48499852|NCT05590832|BEHAVIORAL|Activity of Whatsapp messages|Informative messages will be sent to the initiative group on Mondays, Wednesdays and Fridays for the first 10 weeks / three times a week (up to the 28th week), and reminder messages will be sent once a week on Wednesdays between the 29th-36th weeks.
48499853|NCT00440960|DRUG|propofol|
48499854|NCT00440960|DRUG|midazolam|
48499855|NCT00440960|DRUG|alfentanil|
48499856|NCT00440960|DRUG|lidocaine|
48499857|NCT02105974|DRUG|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
48499858|NCT02105974|DRUG|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
48499859|NCT00635063|DRUG|AD 923|
48499860|NCT00782574|DRUG|AZD2281|Tablets Oral BID
48342787|NCT00653068|DRUG|Leucovorin Calcium|Given IV or PO
48342788|NCT00653068|DRUG|Methotrexate|Given IV
48342789|NCT00653068|DRUG|Thiotepa|Given IV
48342790|NCT00653068|DRUG|Vincristine Sulfate|Given IV
48342791|NCT03156725|DRUG|Ferrous Sulfate|
48342792|NCT03156725|DIETARY_SUPPLEMENT|Aspiron|
48342793|NCT00272480|DRUG|Zidovudine/lamivudine|
48342794|NCT00272480|DRUG|Placebos|
48342795|NCT04773704|DIAGNOSTIC_TEST|FILMARRAY® Pneumonia Plus Panel technique|FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample
48342796|NCT00588757|DEVICE|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
48342797|NCT00588757|DEVICE|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
48342798|NCT00273299|DRUG|valsartan plus hydrochlorothiazide|
48342799|NCT00969488|OTHER|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
48342800|NCT04173403|DRUG|450mg AK102|AK102 Q4W
48342801|NCT04173403|DRUG|300mg AK102|AK102 Q4W
48342802|NCT04173403|DRUG|150mg AK102|AK102 Q2W
48342803|NCT04173403|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
48342804|NCT01975675|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
48342805|NCT01975675|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
48342806|NCT03803449|DRUG|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
48499861|NCT00782574|DRUG|Cisplatin|IV every 3 weeks
48342807|NCT03803449|DRUG|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
48342808|NCT03803449|DRUG|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
48342809|NCT04880772|OTHER|Prehabilitation|exercise \& multivitamin (nutritional/dietary advice)
48342810|NCT03257618|DRUG|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
48342811|NCT03257618|OTHER|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
48342812|NCT00810251|DEVICE|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
48342813|NCT01858597|DIAGNOSTIC_TEST|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
48342814|NCT00074867|DRUG|CP-547,632|
48342815|NCT03422055|DRUG|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
47982101|NCT03590379|DRUG|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
48342816|NCT04646226|DEVICE|AV graft|The purpose of the surgery is to connect a large vein in the arm to a nearby artery indirectly by inserting a graft material (graft surgery)
48342817|NCT04646226|PROCEDURE|surgical intervention for creation of a fistula|The purpose of the surgery is to connect a large vein in the arm to a nearby artery directly (fistula surgery)
48499862|NCT02889471|PROCEDURE|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
48134561|NCT06692296|BEHAVIORAL|Balance training over stabilometric platform|"The treatment using the stabilometric platform (a total of 20 sessions) generally includes an initial phase (approximately 5 minutes) of training and warm-up in monitor mode, during which the patient becomes familiar with the equipment. The patient then moves on to training library mode, which includes the following subcategories: (1) Stabilometric tracings in both static and dynamic phases (10 minutes); (2) Dexterity exercises in both static and dynamic phases (10 minutes); (3) Imbalance exercises in both static and dynamic phases (10 minutes).~The goal during this phase is to increase the patient's stability limits and provoke balance reactions through load shifts in all directions. The session concludes with 10 minutes of TecnoBody Exergames, which help to automate the functions learned within a more complex activity."
48134562|NCT06692296|BEHAVIORAL|Balance training by means of conventional rehabilitation|Conventional rehabilitation to improve balance includes an initial phase of tissue mobilization, particularly of the foot structures (approximately 5 minutes per foot), in order to prepare them for the subsequent activation phase. This is followed by a phase focused on activating the anti-gravity muscles and aligning the trunk within the chosen setting (10 minutes). The treatment continues with balance training, both static and dynamic, load transfers, and dual-task exercises using external references (15 minutes). The session concludes with functional exercises relevant to the patient's daily life context (10 minutes).
48134563|NCT06694155|DIETARY_SUPPLEMENT|Whey Protein Isolate Crossover|This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation.
48134564|NCT06694155|DIETARY_SUPPLEMENT|Placebo|1 week of Non-whey protein Placebo supplement
48134565|NCT06694441|OTHER|Light Exposure|The intervention in this study will involve 28 (+4) days of daily exposure to bright light (BL) for two 60-minute sessions (morning and afternoon). For the intervention, we will use Re-Timer® light glasses emitting light with an intensity of 230μW/cm2 (\~500lux) with a green blue 500nm dominant wavelength (between 480-520nm). Light with these characteristics has been shown effective in suppressing melatonin levels supporting their potential to exert effects on other biological non-visual functions associated with exposure to light relevant for this study. Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects.
48134566|NCT06694441|OTHER|Placebo|Participants randomized to the control group will wear for two 60-minute sessions (morning and afternoon) customized dim-red light (RL) control Re-Timer® light glasses (wavelength peak at 632nm, light intensity \< 3 lux).
48499863|NCT02889471|PROCEDURE|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
48499864|NCT05500196|DEVICE|Per Oral Endoscopy Myotomy (POEM)|POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
48342818|NCT00019214|BIOLOGICAL|MART-1 antigen|
48342819|NCT00019214|BIOLOGICAL|aldesleukin|
48342820|NCT00019214|BIOLOGICAL|gp100 antigen|
48342821|NCT02155504|DRUG|ASP3700|oral
48342822|NCT02155504|DRUG|itraconazole|oral
48342823|NCT02155504|DRUG|Placebo|oral
48342824|NCT00723853|BEHAVIORAL|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
48342825|NCT00723853|BEHAVIORAL|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
48342826|NCT00271791|DRUG|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
48342827|NCT00271791|DRUG|Prednisone|PO, Placebo, 17 days
48342828|NCT02425436|DRUG|Ginkgo Biloba Extract|
48342829|NCT02425436|OTHER|Placebo|
48342830|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
48342831|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
48342832|NCT00943410|RADIATION|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
48342833|NCT00943410|DRUG|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
48499865|NCT04602065|DRUG|IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)|IBI318, 300mg, Q2W, Intravenous influsion.
48499866|NCT03550573|DEVICE|CardioInsight™ Noninvasive 3D Mapping System|"The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit."
48499867|NCT00045903|BEHAVIORAL|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
48499868|NCT00045903|BEHAVIORAL|Stress Management Therapy (Cognitive Behavior Therapy)|
48342834|NCT04873843|BEHAVIORAL|Functional digital game training group|Functional digital game training group is divided in 16 participants. In one session, participants in the functional digital game training group completed 40 minutes of intervention using various functional digital game such as working memory, memory, and attention. (Total 10 session)
48342835|NCT04873843|BEHAVIORAL|Individual cognitive training|Functional digital game training group is divided in 16 participants. In one session, participants in the individual cognitive training group completed 40 minutes of intervention using various cognitive training such as working memory, memory, and attention. (Total 10 session)
48342836|NCT05384795|OTHER|Lung ultrasound|Lung atelectasis score
48499869|NCT06002737|DEVICE|Occlusion of blood vessels with a diameter greater than 5mm and less than or equal to 7mm using harmonic scalpel|Screening of lung or esophageal surgery patients who meet the inclusion criteria but do not meet the exclusion criteria, and evaluating the effectiveness and safety of ultrasound scalpel in the process of coagulation of blood vessels with a diameter greater than 5mm but not equal to 7mm.
48342837|NCT03799627|DRUG|Vadadustat|Vadadustat Tablets 150 mg
48342838|NCT03799627|DRUG|Epoetin Alfa|Epoetin Alfa
48342839|NCT03799627|DRUG|Vadadustat TIW|Oral Vadadustat
48342840|NCT01170468|DRUG|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
48499870|NCT01620619|OTHER|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
47982102|NCT00102102|DRUG|[18F]SPA-RQ|
47982103|NCT00661622|DRUG|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
47982104|NCT00661622|PROCEDURE|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
47982105|NCT05872646|DIAGNOSTIC_TEST|clinical assessment|clinical staging
47982106|NCT03935906|OTHER|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
47982107|NCT03935906|OTHER|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
48342841|NCT01170468|DRUG|Placebo|Placebo orally, daily for 2 years
48342842|NCT01781624|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
48342843|NCT02470429|DEVICE|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
48342844|NCT02470429|DEVICE|Hyabak 0.15% eye drops|Preservative-free
48342845|NCT02470429|DRUG|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
48342846|NCT00257868|DRUG|Rivastigmine prevention of delirium|
48342847|NCT01067313|DEVICE|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
48499871|NCT01620619|PROCEDURE|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
48499872|NCT02398773|PROCEDURE|Computed Tomography|Undergo PET/CT
48499873|NCT02398773|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
48499874|NCT02398773|OTHER|Laboratory Biomarker Analysis|Correlative studies
48499875|NCT02398773|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48499876|NCT05596721|DRUG|Azithromycin|Treat patient with azithromycin for 12w.
48342848|NCT01067313|DEVICE|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
48342849|NCT01426724|DRUG|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
48342850|NCT02533076|OTHER|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
48342851|NCT02533076|OTHER|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
47982108|NCT03557463|DIETARY_SUPPLEMENT|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
47982109|NCT02703584|DRUG|Buseralin|
47982110|NCT02703584|OTHER|Placebo|
47982111|NCT02703584|DRUG|pregnyl|
47982112|NCT01694641|OTHER|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
47982113|NCT00063973|DRUG|cilengitide|Given IV
47982114|NCT00063973|OTHER|laboratory biomarker analysis|Correlative studies
47982115|NCT04974710|DIAGNOSTIC_TEST|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
47982116|NCT00568074|DRUG|repaglinide|
47982117|NCT00568074|DRUG|Glurenorm®|
47982118|NCT00568074|DRUG|Glucobay®|
47982119|NCT02259582|DRUG|Pemetrexed|
47982120|NCT02259582|DRUG|Carboplatin|
48134569|NCT06223373|DEVICE|Blood Flow Restriction|In the BFR group, the tourniquet will be pressurized to 50% limb occlusion pressure (LOP), which is the pressure necessary for occluding 50% of arterial limb flow in the upper extremity.
48134570|NCT06223373|DEVICE|"sham Blood Flow Restriction"|In the sham BFR group, the tourniquet will be pressurized to 0% occlusion pressure, while maintaining enough pressure to keep the tourniquet in place.
48499877|NCT05596721|DRUG|ICS/LABA|Treat patient with ICS/LABA according to Global Initiative for Asthma (GINA) guideline.
48499878|NCT06314789|DIAGNOSTIC_TEST|doing lung ultrasonography|In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and LUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
47982121|NCT02259582|DRUG|demcizumab|
47982122|NCT03982927|OTHER|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
48499879|NCT00336245|DEVICE|Copper T Intrauterine Contraceptive Device|
47982123|NCT03502044|DEVICE|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
47982124|NCT03502044|DEVICE|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
47982125|NCT02192814|DRUG|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
47982126|NCT05376969|DRUG|DWP16001|DWP16001 Tablets
47982127|NCT04845789|OTHER|Non-interventional|Non-interventional. Interview would be conducted for data collection.
47982128|NCT05827523|DRUG|Cisplatin|Hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75mg/m2 after interval cytoreductive surgery
47982129|NCT05599607|DIETARY_SUPPLEMENT|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
47982130|NCT05599607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
47982131|NCT00286169|DRUG|Amrubicin Hydrochloride|
47982132|NCT02875483|OTHER|Expedited Scheduling|Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.
47982133|NCT02875483|OTHER|Standard Scheduling|Scheduling of tubal surgery occurs after completion of post-partum office visit
48657394|NCT00751985|OTHER|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
48657395|NCT00751985|OTHER|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
48657396|NCT00751985|OTHER|Control|The participant is being informed about their allocation to the control group.
48657397|NCT06267729|BIOLOGICAL|AZD0754|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion."
48342852|NCT02533076|DEVICE|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
48342853|NCT02533076|DEVICE|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
48342854|NCT03023605|BEHAVIORAL|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~1. Clinical Update Sessions for staff ED (20 physicians)~2. training sessions for residents that rotate in ED (60 physicians )~3. Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~4. Development of posters, with brief information~5. Dissemination by e-mail of scientific information~6. Direct reminder during the working day"
48342855|NCT05154071|OTHER|Collection of medical data|Collection of adverse events, of mortality, length of hospitalization
47982134|NCT04170114|OTHER|Comprehensive Respiratory Physiotherapy|"All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control."
47982135|NCT04290884|DRUG|Tranexamic Acid|The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
48342856|NCT05380908|OTHER|None of any intervention|The patients did not have any intervention.
48134571|NCT06685809|DRUG|FZ008-145 solution|Dose formulation- Oral solution
48134572|NCT06685809|DRUG|FZ008-145 Tablet|Dose formulation- Oral tablet
48342857|NCT00493155|DRUG|RG1530|Administered po at escalating doses (10 cohorts)
48342858|NCT02811172|OTHER|BEhavior of biomarkers during pregnanCy and lactatiOn|
48342859|NCT00444418|DRUG|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
48342860|NCT00444418|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
48342861|NCT00444418|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
48342862|NCT01151176|DRUG|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
48342863|NCT01151176|DRUG|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose \>141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; \> 400=16U"
48342864|NCT02215616|DRUG|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
48342865|NCT02215616|DRUG|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
48342866|NCT05885568|BIOLOGICAL|blood sampling|Blood sampling from healthy volunteers
48342867|NCT05885568|OTHER|drone transportation|drone transportation
48342868|NCT05885568|OTHER|car transportation|car transportation
48499880|NCT00336245|DRUG|Hormonal Contraception|
48499881|NCT02935153|BIOLOGICAL|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
47982136|NCT05957484|DEVICE|Investigational brainstem neuromodulation device|This study device is non-invasive meaning it stays outside of the body. It stimulates activity in the brain through a headset with metallic earpieces that fit into the participant's ear canals. The device will be loaded with certain neurostimulation pattern, and the earpieces will provide the stimulation at the prescribed pattern.
47982137|NCT00315198|DEVICE|Eye Patch|2 hours daily patching
47982138|NCT00315198|PROCEDURE|Near activities|near visual activities while patching
47982139|NCT00315198|PROCEDURE|Distance activities|distance visual activities while patching
47982140|NCT03329950|DRUG|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
47982141|NCT03329950|DRUG|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
47982142|NCT03329950|DRUG|pembrolizumab|pembrolizumab will be administered every 3 weeks.
47982143|NCT03329950|DRUG|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
48134573|NCT06685809|DRUG|Placebo|Dose formulation- Matching doses
48499882|NCT00554606|DRUG|Canakinumab|Canakinumab
48499883|NCT00006083|DRUG|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
48499884|NCT00006083|OTHER|placebo|placebo injected subcutaneously daily
48499885|NCT03046407|BIOLOGICAL|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
48499886|NCT05673330|OTHER|Spinal Mobilizations|"1. Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~2. Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
47982144|NCT00759954|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
48134574|NCT04934995|OTHER|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
48134575|NCT05009862|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|rivaroxaban 2.5 milligrams twice daily
48134576|NCT05009862|DRUG|Placebo|placebo
48134577|NCT05009862|DRUG|Aspirin 81Mg Ec Tab|aspirin 81 milligrams
48134578|NCT06696690|DEVICE|MNS|The MNS treatment group use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300 ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for one week.
47982145|NCT00759954|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
47982146|NCT06124586|PROCEDURE|percutaneous transluminal angioplasty|percutaneous transluminal angioplasty
47982147|NCT05983276|DRUG|Decitabine|Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
47982148|NCT05983276|DRUG|Carboplatin|Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.
47982149|NCT05983276|DRUG|Paclitaxel|"Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent."
47982150|NCT05983276|DRUG|Selinexor|Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
48134579|NCT06696690|DEVICE|Sham stimulation|The sham stimulation treatment group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
48499887|NCT05673330|OTHER|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
48342869|NCT00647907|DRUG|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
48134581|NCT06696599|PROCEDURE|Serum and corporal irisin|measure serum and corporal irisin
48134582|NCT06699784|BEHAVIORAL|Progressive lenses intervention|Progressive lenses intervention group will receive 1-month progressive lens correction in daily life.
48134583|NCT06699784|BEHAVIORAL|Single-vision lenses intervention|Single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month.
48499888|NCT03707665|DIAGNOSTIC_TEST|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
48499889|NCT01879865|OTHER|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
48134586|NCT06699485|DIETARY_SUPPLEMENT|Low carb diet|Low-carbohydrate diet contains (\<26% carbohydrates) or less than 130 g/d
48499890|NCT01879865|OTHER|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
48499891|NCT01459562|DRUG|NI-0501|
48499892|NCT01459562|DRUG|Placebo|
48499893|NCT05537194|DRUG|dihydropyridine calcium channel inhibitors use|administration of dihydropyridine calcium channel inhibitors
48342870|NCT03823430|DIAGNOSTIC_TEST|Pupillometry|Pupillar diameter variation measurement
48342871|NCT01856803|DRUG|anti thymoglobulin|
48342872|NCT05462912|DEVICE|custom foot orthotic|The goal of this study is to find out whether the use of software generated custom-made orthopedic foot orthoses improves pain in the long term.
47982151|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with multimodal feedback (VRET-M)|The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
48499894|NCT01593033|DIETARY_SUPPLEMENT|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
48342873|NCT06445569|DIETARY_SUPPLEMENT|KH-1|3 capsules and one stick packet consumed daily around the same time
48342874|NCT06445569|OTHER|Placebo|3 capsules and one stick packet consumed daily around the same time
48342875|NCT00059319|PROCEDURE|single aorta clamp with retrograde cardioplegia|
48342876|NCT00059319|PROCEDURE|multiple aorta clamps with antegrade cardioplegia|
48342877|NCT02683460|PROCEDURE|Patella resurfacing|
48499895|NCT01593033|DIETARY_SUPPLEMENT|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
48499896|NCT01593033|DRUG|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
48499897|NCT04516135|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
48499898|NCT04516135|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
47982152|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with bimodal feedback (VRET-B)|The VRET-B group will experience visual and auditive cues in the exposure sessions.
47982153|NCT05939986|BEHAVIORAL|Imagery exposure treatment (IET)|The IET group will experience its own subjective imagined environment without any external stimulation.
47982154|NCT02865187|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 600IU/day
47982155|NCT02865187|DRUG|Hormonal contraception|Hormonal contraceptives
47982156|NCT04472624|OTHER|Fasting|Acute fasting for 72 hours
48499899|NCT04516135|OTHER|Quality-of-Life Assessment|Ancillary studies
48499900|NCT04516135|OTHER|Questionnaire Administration|Ancillary studies
48499901|NCT04516135|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
48499902|NCT00863395|PROCEDURE|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
48342878|NCT02683460|PROCEDURE|Patella retention|
48499903|NCT01463735|DIETARY_SUPPLEMENT|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
48499904|NCT03282474|DRUG|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet \[Sovaldi\]
48134593|NCT06699875|OTHER|Trak exercise prescription protocol at home|Online exercise protocol using the TRAK software. The patient will undergo 4 weeks of an exercise prescription protocol based on shoulder mobility exercises.
48134594|NCT06699875|OTHER|Conventional rehabilitation plan at home|Treatment is based on therapeutic exercise following a conventional rehabilitation plan on paper. The patient will undergo 4 weeks of an exercise prescription protocol based on mobility exercises.
48134595|NCT06698770|OTHER|Anticipated long-term use of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.
48134596|NCT06698770|OTHER|Period re-evaluation of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.
48499905|NCT04226326|OTHER|Directly measure microvascular function using direct coronary flow measurements|The study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. Evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. The overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with CTO.
48499906|NCT05379231|OTHER|BiCROS fitting|Each participant will be fitted with the experimental CROS device on the unaidable ear and with a compatible hearing aid on the other ear.
48499907|NCT05379231|OTHER|Monaural hearing aid fitting|"Each participant will be fitted with a hearing aid on the better hearing ear and no device on the unaidable ear.~Monaural hearing aid fitting acts as control intervention."
48134600|NCT06699849|BIOLOGICAL|CSL889|CSL889 is a solution for infusion to be administered by the IV route.
48134601|NCT06699849|DRUG|Placebo|Volume and regimen matched to CSL899 will be administered.
48134602|NCT06700304|DEVICE|N1 Implant|The N1 Implant is a type of implantable brain-computer interface.
48134603|NCT06700304|DEVICE|R1 Robot|The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
48499908|NCT05379231|OTHER|Unaided condition|"No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention."
48499909|NCT04473911|DRUG|FLUDARABINE|predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles
48342879|NCT00962468|OTHER|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
48657398|NCT04046419|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants.~4. Second application of the scales to the participants.~5. Statistical analysis and scaling"
48342880|NCT04083794|OTHER|Laboratory based assessments|physical maneuvers to assess physiological responses in bone blood flow
48342881|NCT05243719|BIOLOGICAL|ADP101|Active dry powder formulation at various volumes.
48342882|NCT01498497|DRUG|EUR-1100|
48342883|NCT01498497|DRUG|Placebo|
48342884|NCT01620008|PROCEDURE|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
48342885|NCT01020968|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
48342886|NCT01020968|OTHER|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
47982157|NCT04472624|OTHER|Ketogenic diet|Intake of a ketogenic diet for 14 days
47982158|NCT02226406|OTHER|A: Chair - Leg Cycle ergometer|
47982159|NCT02226406|OTHER|B: Chair - Arm Cycle ergometer|
47982160|NCT02226406|OTHER|C: Walk in place|
48342887|NCT06043245|PROCEDURE|Duodenal Switch|Classic Duodenal Switch
48342888|NCT06043245|PROCEDURE|SADI-S|SADI-S with a 300cm common channel
48342889|NCT06043245|PROCEDURE|Minigastric Bypass|Classic minigastric bypass
47982161|NCT05679908|DRUG|TNX-1900|Patients will spray TNX-1900 once into each nostril.
47982162|NCT05679908|DRUG|Placebo Nasal Spray|Patients will spray placebo nasal spray once into each nostril.
48499910|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
48499911|NCT04473911|RADIATION|TBI|Total body irradiation (TBI) once per cycle.
48499912|NCT04473911|DRUG|Melphalan|Melphalan, infusion, determined dosage, once per cycle
48499913|NCT04473911|DRUG|Sirolimus|Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism
48499914|NCT04473911|DRUG|Mycophenolate mofetil|◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
48499915|NCT04473911|DRUG|RGI-2001|IV, predetermined dose, weekly to 6 total doses
48499916|NCT04473911|DRUG|CYCLOPHOSPHAMIDE|◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
48499917|NCT00950963|BEHAVIORAL|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
48134608|NCT06699537|DIETARY_SUPPLEMENT|probiotic product|During the study, subjects take one sachet of Lactobacillus rhamnosus LRa05 daily. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the intervention.
48134609|NCT06699537|DIETARY_SUPPLEMENT|Maltodextrin|During the study, subjects in the control group take one sachet of maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the 8-week trial.
48342890|NCT05579223|DRUG|Intrathecal Hydromorphone Mono Injection|Experimental Drug: Hydromorphone Hydrochloride Injection. Administration: subarachnoid space mono bolus inject, + 5% glucose injection diluted to 75 μg:1.5ml, Speed ≤ 0.5 ml/s
48134610|NCT06698549|DRUG|ALG-097558|Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)
48134611|NCT06699836|DRUG|350 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
48134612|NCT06699836|DRUG|700 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
48134613|NCT06700070|DRUG|PBA-0111|Intratumoral microdose injection by the CIVO device.
48499918|NCT00950963|OTHER|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
48499919|NCT02629354|DRUG|Ibuprofen|
48499920|NCT02629354|DRUG|Caffeine|
48499921|NCT02629354|DRUG|Ibuprofen|
48134618|NCT06698471|OTHER|Community worker training|Training community workers in Self Help Plus intervention, a 5 session self-help intervention based on Acceptance and Commitment Therapy
48342891|NCT05579223|DRUG|Intrathecal Placebo Mono Injection|Placebo: 5% glucose injection. Administration: subarachnoid space mono bolus inject, 1.5ml, Speed ≤ 0.5 ml/s
48342892|NCT05690906|DEVICE|ReSpace™|The experimental group subjects will be injected with ReSpace™ hydrogel.
48657399|NCT06186518|OTHER|PİKSEÇ|"In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process."
48134619|NCT06698471|OTHER|Referral to Health System|Referral to Health System of Senegal
48499922|NCT03393806|DRUG|GSK3772847|GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
48499923|NCT03393806|DRUG|Placebo|Commercially sourced sterile normal saline will be provided as Placebo
48134622|NCT06700161|OTHER|Obtaining CGF from patients|Periodontal clinical parameters and Annexin and Lipoxin parameters in CGF will be compared between the test and control groups
48134623|NCT06699628|DRUG|IRL757|IRL757 capsules
48134624|NCT06699654|OTHER|Placebo gel|A gel without active Spirulina components applied as a control intervention.
48134625|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Gel|A conventional Spirulina gel formulation applied as a periodontal therapy.
48134626|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Nanoparticles Gel|A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.
48342893|NCT05690906|DEVICE|gauze packing|The subjects of both groups will be given gauze packing
48342894|NCT05448508|DEVICE|Automatic lancet|An automatic lancet, which can reach a depth of 2.4 mm-3 mm, was used for safe piercing in babies.
48342895|NCT04501172|BEHAVIORAL|Questionnaire completion|"Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~1. participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~2. 20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire."
48499924|NCT02256527|OTHER|Observational|compare data
48499925|NCT01383213|OTHER|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
48499926|NCT01383213|OTHER|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
48499927|NCT02395952|DRUG|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
48499928|NCT02395952|DEVICE|Acuvue Oasys Bandage Contact Lens|
48499929|NCT02395952|DEVICE|Ambiodisk|
48499930|NCT02395952|DEVICE|Prokera|
48499931|NCT02759601|DRUG|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
48499932|NCT01568138|DEVICE|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
48499933|NCT00416702|DRUG|QAB149|
48499934|NCT00051987|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
48657400|NCT06186518|OTHER|Routine care|The pediatric unit's PIVC insertion process will be routinely performed in routine care.
48657401|NCT03338790|BIOLOGICAL|nivolumab|Specified dose on specified days
48499935|NCT04940260|DIAGNOSTIC_TEST|Renal function|measure eGFR at one year post partum
48342896|NCT01637090|DRUG|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
48342897|NCT04123431|DEVICE|Total Hip Replacement|Primary elective total hip replacement
48342898|NCT01498536|BEHAVIORAL|aerobic exercise|3 times per week for 12-weeks
48342899|NCT02844140|PROCEDURE|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
48342900|NCT06507137|OTHER|Fractal|Walking in a treadmill while synchronizing their steps with fractal external visual cues
48342901|NCT06507137|OTHER|Isochronous|Walking in a treadmill while synchronizing their steps with isochronous external visual cues
48342902|NCT06507137|OTHER|Control|Walking in a treadmill
48342903|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
48499936|NCT04940260|DIAGNOSTIC_TEST|proteinuria|measure urine protein creatinine ratio at one year postpartum
48657402|NCT03338790|DRUG|docetaxel|Specified dose on specified days
48657403|NCT03338790|DRUG|enzalutamide|Specified dose on specified days
47982163|NCT04367220|DIAGNOSTIC_TEST|Diagnostic testing performed as per routine care|
47982164|NCT02705495|OTHER|acupuncture|"Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture."
47982165|NCT02705495|DRUG|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
47982166|NCT06415292|DRUG|Winlevi (clascoterone) 1% cream|Split face. Blinded study treatment product to be applied to the randomized half face
47982167|NCT02683889|DRUG|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
47982168|NCT04911530|OTHER|no intervention|no intervention
47982169|NCT00722033|DRUG|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
48342904|NCT01698177|BIOLOGICAL|Influenza vaccine|Seasonal inactivated trivalent vaccine
48342905|NCT01894334|DRUG|Ulinastatin|
48342906|NCT01894334|DRUG|Tranexamic acid|
48342907|NCT01894334|DRUG|Edaravone|
48342908|NCT03232138|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
48342909|NCT03232138|DRUG|Placebo|Inactive ingredients
48342910|NCT01750840|DEVICE|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
48499937|NCT01831453|DRUG|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
48499938|NCT01831453|DRUG|placebo|soft gelatinous capsules filled with isopropylmyristate oil
48657404|NCT03338790|DRUG|rucaparib|Specified dose on specified days
48657405|NCT03338790|DRUG|prednisone|Specified dose on specified days
48657406|NCT06502028|DEVICE|Video laryngeal mask airway|The airway is secured with a video laryngeal mask airway.
48657407|NCT06502028|DEVICE|Endotracheal tube|The participant is intubated with an endotracheal tube via direct laryngoscopy.
47982170|NCT01285310|DRUG|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
47982171|NCT01285310|DRUG|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
47982172|NCT01285310|DRUG|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
48499939|NCT03378050|BEHAVIORAL|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
48134630|NCT06700187|OTHER|Interrupting sitting with walking breaks|Participants will engage in 27 minutes walking in different frequencies, including short breaks (walk 1 minute every 10 minutes), moderate breaks (walk 3 minutes every 30 minutes), and long breaks (walk 27 minutes in one time during the intervention).
48134631|NCT06698484|DRUG|CAR-T cells|2×10\^6 CAR T cells/kg
48499940|NCT03378050|OTHER|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
48499941|NCT03728634|DRUG|ION-682884|ION-682884 administered SC
48499942|NCT03728634|DRUG|Placebo|Placebo comparator calculated volume to match ION-682884 administered SC
48499943|NCT03728634|DIETARY_SUPPLEMENT|Vitamin A|Oral supplement
48342911|NCT01750840|DEVICE|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
48342912|NCT01750840|DEVICE|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
48342913|NCT05248646|DRUG|Sibeprenlimab 400 mg|Sibeprenlimab 400 mg s.c. q 4 weeks
48342914|NCT05248646|DRUG|Placebo|Placebo s.c. q 4 weeks
48342915|NCT01465451|PROCEDURE|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
48342916|NCT01465451|DRUG|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
48342917|NCT00001827|BIOLOGICAL|aldesleukin|
48342918|NCT00001827|BIOLOGICAL|incomplete Freund's adjuvant|
48342919|NCT00001827|BIOLOGICAL|p53 peptide vaccine|
48342920|NCT00001827|BIOLOGICAL|sargramostim|
47982173|NCT01124422|DRUG|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
47982174|NCT01124422|DRUG|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
48499944|NCT03107312|PROCEDURE|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
48499945|NCT01259115|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
47982175|NCT02908503|OTHER|Placebo Film|placebo vaginal films
47982176|NCT02250365|OTHER|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
47982177|NCT02250365|OTHER|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
48499946|NCT01259115|DRUG|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
48499947|NCT01259115|DRUG|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
47982178|NCT02240160|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
47982179|NCT01397474|OTHER|PPTFM|Peripheral Perfusion Targeted Fluid Management
48342921|NCT00001827|BIOLOGICAL|therapeutic autologous dendritic cells|
48342922|NCT00001827|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48342923|NCT04248686|BEHAVIORAL|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
48342924|NCT03538990|OTHER|DASH Eating Pattern|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
48342925|NCT00394693|GENETIC|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
48342926|NCT06311253|OTHER|Emoform Glic Toothpaste|Daily use of Emoform Glic toothpaste twice a day during home oral hygiene
48342927|NCT06311253|OTHER|Emoform Glic Mouthwash|Daily use of Emoform Glic mouthwash twice a day during home oral hygiene
48342928|NCT00768768|OTHER|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
48499948|NCT05107388|DEVICE|FreeStyle Libre Pro|Measurements of interstitial glucose variations with FreeStyle Libre Pro
48499949|NCT03397771|DRUG|Litoxetine|oral study medication provided in a dose titration manner
48499950|NCT03397771|DRUG|placebo|placebo medication provided in a dose titration manner
48499951|NCT03785366|DRUG|VeraCept|VeraCept Intrauterine Device (IUD)
48342929|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
48342930|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
48342931|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
48342932|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
48342933|NCT04701749|DEVICE|Percutaneous left atrial closure|Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.
48342934|NCT04701749|OTHER|No Percutaneous left atrial closure|No Percutaneous left atrial closure
48342935|NCT02959190|DRUG|Galcanezumab|Administered SC
48342936|NCT04599972|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
48499952|NCT03785366|DRUG|ParaGard|ParaGard intrauterine copper contraceptive
48499953|NCT04571151|DRUG|LEXETTE 0.05% Topical Foam|Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
48657408|NCT01404247|OTHER|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
48657409|NCT01404247|PROCEDURE|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
48499954|NCT04571151|DRUG|Sorilux 0.005 % Topical Foam|Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
48499955|NCT04571151|OTHER|Vehicle Foam|Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
48657410|NCT03890094|DRUG|Sufentanil|Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
48499956|NCT02255682|DRUG|Simvastatin|
48499957|NCT02255682|DIETARY_SUPPLEMENT|Q10|
48657411|NCT05725031|DRUG|Ephedrine|70 μg/kg as pretreatment
48134637|NCT06699680|DRUG|PRX019|Specified dose on specified days
48134638|NCT06699680|DRUG|Placebo|Placebo
48134639|NCT06698991|BIOLOGICAL|Plasma Exchange|"• Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours"
48657412|NCT05725031|DRUG|Rocuronium 0.6|0.6 mg/kg
48134640|NCT06698991|OTHER|Standard Medical Treatment|Standard Medical Treatment
48499958|NCT06201429|DEVICE|Mechanical Tissue Resuscitation (MTR™)|Mechanical Tissue Resuscitation (MTR™) to externally drain excess fluid volume from the site of surgery in patients who have undergone a surgical procedure (craniotomy/craniectomy) for which a portion of the skull has been removed resulting in exposure of the dura/brain and require drainage of fluid.
48499959|NCT01167959|PROCEDURE|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
48499960|NCT01167959|BEHAVIORAL|Prodimed dietary intervention|3 months of using the prodimed diet
48499961|NCT00521469|DEVICE|Pro Adjuster|
48657413|NCT05725031|DRUG|Rocuronium 0.8|0.8 mg/kg
48657414|NCT05725031|DRUG|Rocuronium 1.2|1.2 mg/kg
48657415|NCT05085366|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)
47982180|NCT00001008|DRUG|Methadone hydrochloride|
47982181|NCT00001008|DRUG|Zidovudine|
48499962|NCT04625725|DRUG|AZD7442|"* Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
48499963|NCT04625725|DRUG|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
48499964|NCT03792763|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
48657416|NCT05085366|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48657417|NCT06073119|DRUG|SAR441566|Tablet
48657418|NCT06073119|DRUG|Placebo|Tablet
48499965|NCT03792763|DRUG|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
48134644|NCT06698510|DRUG|Arpraziquantel 150mg dispersible tablet|Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
48499966|NCT04492020|DRUG|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
48499967|NCT04492020|DRUG|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
48499968|NCT03880786|DEVICE|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
48134648|NCT06699901|OTHER|Massive Transfusion Group|This group includes trauma patients who receive a massive transfusion, defined as the transfusion of at least 3 units of blood. Blood samples are collected at six specific timepoints following the administration of antibiotics to analyze plasma antibiotic concentrations. Existing clinical draws will be used whenever possible to minimize additional venipunctures, with a maximum of two dedicated research-only draws allowed if necessary. Data analysis will assess the impact of large blood transfusions on antibiotic pharmacokinetics over time, adjusting for factors such as kidney function.
48134649|NCT06699901|OTHER|Control Group|This group consists of trauma patients who receive minimal or no blood transfusions (up to 2 units of blood). Blood samples are also collected at six designated timepoints after antibiotic administration to measure plasma antibiotic concentrations. As with the massive transfusion group, clinical draws will be coordinated whenever possible to obtain research samples, with a maximum of two dedicated research-only draws if needed. Data analysis will compare antibiotic concentration trends in this group with those in the massive transfusion group to understand the effects of blood transfusion volume on antibiotic pharmacokinetics.
48134650|NCT03849482|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI
48134651|NCT03849482|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology|Ultrasound-Guided Fine Needle Aspiration Cytology
48134652|NCT03849482|DIAGNOSTIC_TEST|Clinical Evaluation|Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)
48134653|NCT03849482|DIAGNOSTIC_TEST|Final Histopathological Diagnosis|Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
48134654|NCT06699173|OTHER|Heat ped|The hot ped was used during ricig cystoscopy
48134655|NCT06700031|DEVICE|Inertial measurement unit|A sensor, an inertial measurement unit (IMU), will be attached to the thigh when the individual is on the postoperative ward and will be worn throughout the hospital stay. The IMU measures 7.9 x 3.2 x 0.8 cm and records body positions, movements, and gait parameters.
48134656|NCT06698874|OTHER|ds-MCE and EGD examinations|Sequentially performing ds-MCE and EGD examinations on enrolled participants.
48134657|NCT06699966|DRUG|Celecoxib|The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
48134658|NCT06699966|DRUG|Minocycline|Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
48134659|NCT06698757|BIOLOGICAL|Sintilimab|Subjects were enrolled and received Sintilimab at a dose of 200 mg, administered via intravenous infusion on the first day of each cycle, with each cycle lasting 3 weeks (Q3W)
48499969|NCT01340326|DRUG|high dose of valsartan|comparison of different dosages of drug
48499970|NCT01340326|DRUG|usual dose of valsartan|comparison of different dosages of drug
48657419|NCT06021613|BEHAVIORAL|Randomized instructions|"Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.~Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis."
48134663|NCT06698796|DRUG|Dazukibart|anti-interferon beta therapy
48134664|NCT06699719|BEHAVIORAL|Expressive writing|"Participants are asked to complete four 20-minute sessions of a writing task on consecutive days, which is sent to their email address via an online link. Participants are instructed for the next 20 minutes to please use the provided box to write their very deepest thoughts and feelings about a negative issue or personal problem that they are currently being affected by. In their writing, they are encouraged to let go and explore their emotions and thoughts regarding this issue or problem, and to not worry about spelling or grammar. They are asked to consider setting a timer or have a clock handy to make sure they write for 20 minutes. Instructions are accompanied by a text box, which allows participants to write freely for the allotted time."
48134665|NCT06700096|GENETIC|ANB-002|Adeno-associated viral vector carrying the FIX gene single infusion
48134666|NCT06700148|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
48134667|NCT06700148|BIOLOGICAL|MPSV4|1 dose of MPSV4 on Day0
48342937|NCT04599972|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
48342938|NCT06021847|OTHER|Ozonated water|ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
48499971|NCT01019928|DRUG|AZD1386|95 mg, oral solution, single dose
48342939|NCT06021847|OTHER|Chlorhexidine mouthwash|Commercial available chlorhexidine mouthwash in the market was used.
48342940|NCT00568620|PROCEDURE|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
48342941|NCT00568620|PROCEDURE|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
48342942|NCT04259060|DRUG|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
48342943|NCT04259060|DRUG|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
48342944|NCT03349593|DIAGNOSTIC_TEST|Echocardiography|Preoperative transthoracic echocardiography
48342945|NCT04146038|DRUG|Azacitidine|Given IV
48342946|NCT04146038|DRUG|Decitabine|Given IV
47982182|NCT02656979|DRUG|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
47982183|NCT04867538|OTHER|no intervention|No intervention
47982184|NCT02381249|DRUG|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
47982185|NCT02381249|DRUG|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
47982186|NCT02041611|PROCEDURE|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
47982187|NCT00203177|DRUG|rasagiline mesylate|0.5 rasagiline mesylate
47982188|NCT00203177|DRUG|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
47982189|NCT02990091|DRUG|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
47982190|NCT02990091|DIETARY_SUPPLEMENT|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
47982191|NCT02520401|OTHER|Probiotic - BioGaia|Use of a probiotic tablet
47982192|NCT02520401|OTHER|Placebo|Use of a placebo tablet
47982193|NCT02818322|DEVICE|telemedical monitoring ( T)|
47982194|NCT02818322|DEVICE|classic monitoring|
47982195|NCT04844632|BIOLOGICAL|Vaccine anti-Covid19|Vaccination with AstraZeneca or Pfizer-Biontech anti-Covid19 vaccine
47982196|NCT00512707|DRUG|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
47982197|NCT00512707|DRUG|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
48342947|NCT04146038|DRUG|Salsalate|Given PO
48342948|NCT04146038|DRUG|Venetoclax|Given PO
48342949|NCT01711658|RADIATION|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
47982198|NCT00512707|OTHER|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
47982199|NCT06125015|DIAGNOSTIC_TEST|Hearing Thresholds Assessments|Auditory Neuropathy Spectrum Disorder (ANSD) is a type of hearing disorder that affects the transmission of sound signals from the inner ear to the brain. In individuals with ANSD, the outer hair cells in the cochlea, which are responsible for amplifying sound, typically function properly. However, there is a disruption in the transmission of auditory information from the cochlea to the auditory nerve and then to the brain. It is characterized by a mismatch between the results of objective hearing tests, such as Auditory Brainstem Response (ABR), and subjective hearing experiences. In ABR tests, the responses of the auditory nerve to sounds may be abnormal, while the individual perceives their hearing to be better than suggested by the test results. In this study we showed ANSD patients with abnormal ABR results by using ABR, Otoacoustic Emissions, Tympanometry and behavioral test batteries.
48342950|NCT01711658|DRUG|Cisplatin|100 mg/m\^2 administered intravenously on days 8 and 29
48342951|NCT01711658|DRUG|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
48499972|NCT01019928|DRUG|Placebo to AZD1386|Placebo, oral solution, single dose
48499973|NCT01761370|PROCEDURE|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
48499974|NCT01761370|PROCEDURE|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
48499975|NCT00095797|DRUG|R(+)XK469|Given IV
48499976|NCT00095797|OTHER|pharmacological study|Correlative studies
48499977|NCT00095797|OTHER|laboratory biomarker analysis|Optional correlative studies
48499978|NCT02365870|DRUG|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
48342952|NCT01711658|DRUG|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
48342953|NCT04076618|DEVICE|Vest|Weighted Vest worn \> or = 8 hours per day
48134669|NCT06698341|PROCEDURE|Blood Draw|3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient
48499979|NCT02365870|DRUG|placebo|Participants will receive a placebo transdermal patch to be worn daily
48657420|NCT05419492|DRUG|ETX101|ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
48657421|NCT06399718|DRUG|BOTOX|Intramuscular Injections
47982200|NCT06224101|BEHAVIORAL|Simulation-based training|simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
48134671|NCT06699342|PROCEDURE|Pacemaker implantation with Left bundle branch area pacing (LBBAP)|"Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients.~The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice."
48499980|NCT01551225|DRUG|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
47982201|NCT02144389|DRUG|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally"
47982202|NCT02144389|DIETARY_SUPPLEMENT|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
47982203|NCT02144389|DIETARY_SUPPLEMENT|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
47982204|NCT04034381|OTHER|No intervention (descriptive survey only)|No intervention
47982205|NCT01635192|BIOLOGICAL|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
47982206|NCT01635192|BIOLOGICAL|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
47982207|NCT02655562|DRUG|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
47982208|NCT06291025|PROCEDURE|PEX-FREE|The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
47982209|NCT02064647|OTHER|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
47982210|NCT02064647|OTHER|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
47982211|NCT03857191|DIETARY_SUPPLEMENT|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
48342954|NCT04076618|BEHAVIORAL|Resistance Exercise Training|Structured exercise training 3 days a week
47982212|NCT00403442|DEVICE|Verteporfin Therapy/ Drug: Bevacizumab|
47982213|NCT04667767|OTHER|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
47982214|NCT04667767|OTHER|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
47982215|NCT00425360|BIOLOGICAL|sargramostim|
48342955|NCT04076618|BEHAVIORAL|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
48342956|NCT00466661|DRUG|Acamprosate|666 mg po TID
48499981|NCT03810755|OTHER|Personalized Supervised physical activity|personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
47982216|NCT00425360|BIOLOGICAL|telomerase peptide vaccine GV1001|
48342957|NCT00466661|DRUG|Placebo|2 tabs po TID
48499982|NCT00941148|DRUG|Insulin Glargin|
48499983|NCT00941148|DRUG|NPH insulin|
48499984|NCT00941148|DRUG|Insulin detemir|
48499985|NCT00941148|DRUG|metformin|metformin (2000 mg/day)
48499986|NCT02950818|BEHAVIORAL|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
48499987|NCT00620100|DRUG|Docetaxel|
48499988|NCT00668161|BEHAVIORAL|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
48657422|NCT06399718|DRUG|Placebo|Intramuscular Injections
48134672|NCT06699342|PROCEDURE|Atrioventricular node ablation (AVNA)|Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.
48499989|NCT04866732|BEHAVIORAL|Physical Activity Cardiac Health Program|The investigators anticipate that the physical activity program will include the following components: a) physical activity component - the investigators propose an incremental physical activity component whereby participants will gradually increase their physical activity ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to Cardiovascular disease risk factors prevention; c) daily diary, which will be used to document record about any barriers for completing various components of the intervention; d) problem-solving sessions whereby participants will meet once a week with the investigators to talk about the barriers and facilitators of their weekly activity and any adherence issues.
48134673|NCT06699342|DRUG|Pharmacologic therapy optimized for Atrial Fibrillation management|"Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.~Treatment is tailored based on patient tolerance and clinical efficacy."
48499990|NCT00769093|DRUG|Ferumoxytol|2 mg/kg
48499991|NCT00328016|BEHAVIORAL|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
48499992|NCT00328016|DEVICE|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
48499993|NCT00593047|DRUG|KB2115|tablet formulation given once daily for 12 weeks
48499994|NCT00000718|DRUG|Zidovudine|
48499995|NCT00000718|DRUG|Zalcitabine|
48499996|NCT04100785|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
48499997|NCT00237913|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
47982217|NCT00425360|DRUG|capecitabine|
47982218|NCT00425360|DRUG|gemcitabine hydrochloride|
47982219|NCT01074957|DEVICE|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
47982220|NCT01074957|DEVICE|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
48134682|NCT06698588|DIETARY_SUPPLEMENT|Omega 3 Fish Oil supplements|Wileys Easy Swallow Mini Softgel capsules, dose 3 caps/day, providing 945mg/day long-chain omega-3 (540mg EPA, 405mg DHA).
48342958|NCT01759355|PROCEDURE|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
48342959|NCT03821480|DRUG|Test drug|Fluconazole capsule 50 mg Manufacturer: West Ryde
48342960|NCT03821480|DRUG|Reference drug|Fluconazole capsule 50 mg Manufacturer: Amboise
48342961|NCT04012333|DRUG|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
48499998|NCT00237913|DRUG|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
48499999|NCT06291350|OTHER|Plaque sampling and stool collection|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
47982221|NCT01074957|OTHER|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
47982222|NCT03393546|BEHAVIORAL|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatments.
47982223|NCT02235012|DRUG|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
48500000|NCT06291350|OTHER|periodontal examination|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
48500001|NCT04359511|DRUG|Prednisone|prednisone 0.7 mg/kg/d (PO)
48500002|NCT04359511|DRUG|Hydrocortisone|hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
48500003|NCT03157648|OTHER|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
48500004|NCT00093873|DRUG|Anti-angiogenesis|Anti-angiogenesis
48500005|NCT00093873|DRUG|AMG 706|Anti-angiogenesis
48500006|NCT01297387|OTHER|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
48500007|NCT02936011|DEVICE|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
48500008|NCT04635826|DRUG|Adderall 10Mg Tablet|Participants will be administered Adderall
48500009|NCT04635826|DRUG|Placebo|Participants will be administered placebo
48500010|NCT04364659|BEHAVIORAL|Food-Specific Inhibitory Control Training (FoodT App)|FoodTrainer (FoodT) is a simple game that aims to train individuals to 'stop' to certain unhealthy foods. Repeatedly playing this game is hypothesised to help build associations between certain foods (such as chocolate) and stopping, putting the brakes on unhelpful eating behaviour.
48500011|NCT04495283|DRUG|Pregabalin|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
48342962|NCT05045105|OTHER|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication|Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
48342963|NCT05117268|PROCEDURE|SDF Application for caries arrest|Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
48342964|NCT05117268|PROCEDURE|Glass ionomer restoration|The lesions of control group glass ionomer restoration group will be treated according to following clinical protocol: (A) Isolation of treatment area using cotton rolls and saliva ejectors; (B) Carious lesion excavation using high speed handpiece; (C) High viscosity glass ionomer cement mixed following manufacturer's instructions; (D) Cavity will be slightly overfilled using a flat plastic instrument, the occlusal surface will be protected with Vaseline and gloved finger will be used to apply slight pressure for 30s. Postoperative instructions will be clearly explained to each patient caregiver.
48342965|NCT05117268|PROCEDURE|Hall technique|In Hall technique, correct size preformed metal crown will be selected and shall be placed without caries excavation. The crown will be filled with glass ionomer cement and seated with finger pressure. Local anesthesia was not used finger pressure was maintained on the crown until the glass ionomer cement was set.
48342966|NCT00490867|DRUG|Alpha lipoic acid|
48342967|NCT01341236|OTHER|different nutrional regimen|compare bolus versus intermittent nutrition
48342968|NCT01341236|OTHER|comparison of different feeding regimens|compare intermittent versus bolus nutrition
47982224|NCT02235012|DRUG|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
47982225|NCT01721616|DRUG|Azithromycin|
47982226|NCT01721616|DRUG|Cefazolin|
47982227|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using total-breath method
48342969|NCT00852423|DRUG|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
48342970|NCT00852423|DRUG|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
48500012|NCT04495283|DRUG|Acetaminophen|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
48500013|NCT04495283|OTHER|Placebo 1|Placebo for APAP
48500014|NCT04495283|OTHER|Placebo 2|Placebo for combination
47982228|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using standard method
47982229|NCT04155112|BEHAVIORAL|Physical activity|Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).
47982230|NCT04155112|BEHAVIORAL|Hypocaloric Mediterranean diet|Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.
47982231|NCT01986985|DEVICE|PET/MRI system|Compared to PET CT
47982232|NCT03102021|DRUG|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
47982233|NCT03102021|DRUG|saline|saline 10 ml for 3 days
47982234|NCT00223951|DRUG|R89674 (generic name not yet established)|
47982235|NCT01318304|OTHER|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
48134683|NCT06698588|DIETARY_SUPPLEMENT|Placebo|Placebo: high-oleic sunflower oil (which broadly matches the overall fatty acid composition of typical UK diet), matched with active treatment for appearance and taste.
48500015|NCT01741051|DEVICE|HEPA Filter|
48134685|NCT06700109|DEVICE|Neural Ice|This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.
48134686|NCT06700109|DRUG|Triamcinolone acetate|A single dose of Triamcinolone 40mg injected directly into the joint space.
48500016|NCT04271735|DIETARY_SUPPLEMENT|Niagen|Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.
48500017|NCT04271735|OTHER|Placebo|Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.
48500018|NCT05988853|OTHER|follow-up of patients|Follow-up of evidence of nosocomial infections of patients in music therapy
48500019|NCT06288503|OTHER|Hydrolysed Rice Protein Formula|Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.
48342971|NCT00852423|DRUG|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
48500020|NCT06288503|OTHER|Cow's Milk Based Extensively Hydrolysed Formula|Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.
48500021|NCT04677296|OTHER|VS002A|Amino acid based ORS/Medical food
48500022|NCT04677296|OTHER|WHO-ORS|WHO Oral rehydration solution, which is glucose based
48500023|NCT05903456|PROCEDURE|TACE（transcatheter arterial chemoembolization）|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
48500024|NCT05903456|DRUG|lenvatinib|Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
47982236|NCT05360511|DRUG|particulate xenograft + erythropoietin gel.|"1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect."
47982237|NCT05360511|COMBINATION_PRODUCT|particulate xenograft|"* All surgeries will be performed by the same operator as follows:~  1. Surgical sites will be anaesthetized using local anaesthesia.~ 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~ 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~ 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~ 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~* In Group B (control group):~Particulate xenograft will be applied to fill the whole defect."
47982238|NCT04202692|DEVICE|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
47982239|NCT04202692|DEVICE|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
47982240|NCT01026467|DRUG|cisplatin|Given IV
47982241|NCT01026467|DRUG|carboplatin|Given IV
47982242|NCT01026467|OTHER|questionnaire administration|
47982243|NCT05120297|DRUG|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
48342972|NCT00852423|DRUG|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
48342973|NCT02126241|OTHER|NICaS guided CRT optimization|"1. Baseline CO measurement by NICaS~2. AV delay optimization:~   1. AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~  2. The AV delay yielding the maximal CO, will be considered the optimal AV delay~  3. The device will be programmed using the optimal AV delay~3. VV delay optimization:~   1. After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~  2. The VV delay yielding the maximal CO, will be considered the optimal VV delay~  3. The device will be programmed using the optimal VV delay"
48342974|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of darifenacin
48342975|NCT01229280|DRUG|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
48342976|NCT04568811|BIOLOGICAL|Adenovirus Type-5 Vectored COVID-19 Vaccine|Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
48342977|NCT04140370|OTHER|There is no intervention|There is no intervention
48342978|NCT03651128|BIOLOGICAL|bb2121|bb2121
48342979|NCT03651128|DRUG|Daratumumab|Daratumumab
48342980|NCT03651128|DRUG|Pomalidomide|Pomalidomide
48342981|NCT03651128|DRUG|Dexamethasone|Dexamethasone
48657423|NCT06643195|PROCEDURE|anti-leukemic treatment|2.Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
48342982|NCT03651128|DRUG|Bortezomib|Bortezomib
48342983|NCT03651128|DRUG|Ixazomib|Ixazomib
48342984|NCT03651128|DRUG|Lenalidomide|Lenalidomide
48342985|NCT03651128|DRUG|Carfilzomib|Carfilzomib
48342986|NCT03651128|DRUG|Elotuzumab|Elotuzumab
48342987|NCT02779530|DRUG|Diclofenac|50 mg po, b.i.d for 6 days
48342988|NCT02779530|OTHER|Placebo|Placebo po, b.i.d. for 6 days
48500025|NCT05903456|DRUG|Icaritin soft capsules|Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
48500026|NCT01339481|DRUG|abatacept|Intravenous Infusion
48500027|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
48657424|NCT06643195|PROCEDURE|HSCT|1.patients proceeded to allogeneic HSCT as soon as possible..
47982244|NCT05120297|DRUG|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
48342989|NCT03051269|DRUG|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
48342990|NCT03051269|DEVICE|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
48342991|NCT06087094|DRUG|HRS-7450 ；Placebo|HRS-7450 or Placebo
48342992|NCT01673490|DRUG|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
48657425|NCT06571864|DRUG|Anti-CD38 Monoclonal Antibody|Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
48657426|NCT04743232|OTHER|Decision tool for clinicians|Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
48500028|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
48134694|NCT01744808|DRUG|EB-1020 IR|Immediate release
48342993|NCT03577951|PROCEDURE|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
48342994|NCT03577951|PROCEDURE|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
48342995|NCT05421546|DIETARY_SUPPLEMENT|Spermidine or Placebo|The supplement, Spermidine, is made mainly from wheatgerm and can be bought in health food shops. It is a powder that can be easily dissolved in water and taken as a drink. The 'placebo' is a sugar powder that can be similarly dissolved in water and taken as a drink.
48342996|NCT03154294|DRUG|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
48342997|NCT03154294|DRUG|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
48342998|NCT03154294|DRUG|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
48342999|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\]
48343000|NCT01297023|DIETARY_SUPPLEMENT|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 \[10µg/d\]
48343001|NCT01297023|DIETARY_SUPPLEMENT|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate \[1g calcium/d\] and vitamin d3 (10µg/d\]
48500029|NCT04175210|RADIATION|Radiation therapy - 3 weeks|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
48343002|NCT01297023|OTHER|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
48343003|NCT04963634|OTHER|Biobanking|For patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).
48343004|NCT05778357|OTHER|Group1|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
48343005|NCT00253799|DEVICE|Hylan GF-20|
48343006|NCT01937013|DRUG|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
48343007|NCT01937013|DRUG|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
48343008|NCT06391567|OTHER|There was no intervention in this study.|There was no intervention in this study.
48343009|NCT04949425|DRUG|Adavosertib|Patients will receive Adavosertib orally.
48343010|NCT02490839|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
48343011|NCT02490839|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
48343012|NCT03397550|OTHER|salt restriction education|Salt intake target：\<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
48343013|NCT04566757|BIOLOGICAL|Umbilical Cord Blood Plasma|Intravenous Infusion of Umbilical Cord Blood Plasma
48343014|NCT04177875|DRUG|Teripalimab|Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
48343015|NCT04176718|DRUG|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
48343016|NCT04176718|DRUG|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
48343017|NCT04176718|DRUG|Pomalidomide|predetermined dose, orally, daily per cycle
48343018|NCT04176718|DRUG|Dexamethasone|predetermined dose, orally, given 8 times per cycle
48343019|NCT05757479|PROCEDURE|Steroid-eluting stent implantation|The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.
48343020|NCT05757479|DRUG|Steroid nasal spray|1 spray into each nostril once a day.
48343021|NCT05757479|PROCEDURE|nasal saline rinses|The saltwater runs through nasal passages and drains out of the nostril.
48343022|NCT04741646|DRUG|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC and matching placebo will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
48500030|NCT04175210|RADIATION|Radiation therapy - 2 weeks|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
48657427|NCT05763641|PROCEDURE|Target Axillary Dissection|TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
48343023|NCT04741646|DRUG|Placebo|Placebo to match Ferric Citrate tablets
48343024|NCT04738604|OTHER|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
48343025|NCT04738604|OTHER|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
48343026|NCT00517218|DRUG|Genasense® (, oblimersen sodium G3139)|
48343027|NCT02891252|PROCEDURE|outpatient procedure|
48134695|NCT01744808|DRUG|EB-1020 SR1|sustained release
48134696|NCT01744808|DRUG|EB-1020 SR2|Sustained release
48343028|NCT05022641|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console (see Figure 1), as per device functionality requirements.
48343029|NCT00666380|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
48343030|NCT01695213|PROCEDURE|uncemented total hip arthroplasty|
48343031|NCT06157580|DRUG|Compound 21|differences in vasodilation to compound 21 in the skin between groups
48343032|NCT06157580|DRUG|Angiotensin II|differences in vasoconstriction to angiotensin II in the skin between groups
48343033|NCT05637957|DEVICE|active transcranial direct current stimulation|Device: 20 minutes of up to 2.0 mA active anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
48513350|NCT04796298|PROCEDURE|Hamstring Extender Exercise|Athletes were asked to applied 12 repetitions and 3 sets of hamstring extender exercise. Firstly athlete lies on his/her back. Then, athlete is asked to do 90 degrees of knee and hip flexion at the same time. Finally, the person is expected to perform slow repetitive knee extension to the point of maximal possible extension.
48513351|NCT04796298|PROCEDURE|Kinesiotape|Kinesio tape is applied on the hamstring muscle with a Y shape and %25 tension force.
48134697|NCT01744808|DRUG|EB-1020 SR3|Sustained release
48343034|NCT05637957|DEVICE|sham transcranial direct current stimulation|Device: 1 minute of 1.0 mA anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) and 19 minutes with unit turned off and electrodes remaining in place Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
48343035|NCT03749213|DRUG|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
48343036|NCT03882853|OTHER|Conservative exercise group|The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
48343037|NCT03882853|OTHER|Tree pose added exercise group|"The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed."
48343038|NCT02831283|DRUG|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
48343039|NCT02831283|DRUG|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
48343040|NCT02831283|PROCEDURE|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
48343041|NCT01685203|DRUG|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
48343042|NCT01685203|DRUG|ABT-267|Tablet
48343043|NCT01685203|DRUG|Ribavirin (RBV)|Tablet
48343044|NCT00688623|DRUG|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
48343045|NCT03430336|OTHER|CDSS provides drug-therapy relevant information|External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
48343046|NCT03430336|OTHER|Modification of medication|GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
48343047|NCT03430336|OTHER|Assessment of medication appropriateness|GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
48343048|NCT03430336|OTHER|Medication plan|GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
48343049|NCT03430336|OTHER|Guidance in medication process|GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
48343050|NCT05941910|DRUG|Q10|240mg of Q10 orally, every day
48343051|NCT06455384|BEHAVIORAL|Genetics Navigator|The Genetics Navigator will be used to support patients during the delivery of genetic services, including intake, education, pre- and post-test counselling, and physician-generated management recommendations
47982245|NCT05725811|OTHER|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
47982246|NCT00711854|DRUG|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
48343052|NCT06455384|BEHAVIORAL|Standard Care with Genetics Professionals|Standard care for the delivery of genetic services, including receiving genetic counselling and test results
47982247|NCT00711854|DRUG|Linezolid|Linezolid (600 mg IV or PO twice daily)
47982248|NCT00711854|DRUG|Rifampicin|Rifampicin (600 mg IV or PO once daily)
47982249|NCT05860803|DEVICE|LungTrainers|A training device that provides a variable resistance against which users breathe out. Users breathe through a plastic mouthpiece that is connected to an acrylic cylinder via rubber tubing. The mouthpiece has several small holes of various diameters and up to three stainless steel weights (half-weight increments) can be inserted into the acrylic tube. With each breath-out, the user exhales against the resistance provided by the weight inserts, and each inspiration (i.e., breath-in) is unresisted. During each resisted exhalation, the weight inserts are 'lifted' within the acrylic tube depending on the level of expiratory pressure generated by the participant.
48134698|NCT01744808|OTHER|Placebo|Placebo formulation
48343053|NCT05078671|DRUG|Olaparib|olaparib treatment
48343054|NCT05078671|DRUG|Cobicistat|Pharmacokinetic booster
48343055|NCT01755325|DRUG|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
48343056|NCT01755325|DRUG|placebo|
48343057|NCT02032186|DRUG|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
48343058|NCT04776889|DRUG|Rosuvastatin 20mg|Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
48343059|NCT04776889|PROCEDURE|surgical castration|bilateral subcapsular orchiectomy
48500031|NCT02766374|BEHAVIORAL|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
48500032|NCT02766374|BEHAVIORAL|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
48134699|NCT06699953|OTHER|Observational study in patients receiving fentanyl for surgery|"This observational study enrolls patients receiving fentanyl, a drug routinely administered during surgery under general anesthesia. The primary difference in our research protocol is the inclusion of a 5-minute interval between fentanyl administration and the induction of general anesthesia. Fentanyl will be given in two boluses of 2 mcg/kg (ideal body weight), spaced 2 minutes apart, totaling 4 mcg/kg. If the participant remains conscious, an additional 2 mcg/kg bolus will be administered after 2 minutes. Additionally, participants will complete a drug-liking questionnaire before the first bolus and every 30 seconds until anesthesia induction, rating how much they liked the drug on a 0-100 scale."
48343060|NCT04709874|OTHER|Paravertebral block|Paravertebral block using nerve stimulator guidance will be done at C7-T1
48343061|NCT04709874|OTHER|Suprascapular block|Paravertebral block using nerve stimulator guidance will be done
48134700|NCT06699147|DEVICE|Hyaluronic Acid (HA)|6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis
48343062|NCT05119972|DRUG|ZSP1603|ZSP1603 administered orally
48343063|NCT05119972|DRUG|Placebo|Placebo administered orally
48134701|NCT06699693|PROCEDURE|ultrasonography-guided PENG block|This study aimed to evaluate the effect of ultrasonography-guided PENG block prior to joint mobilization therapy on shoulder pain, function, and kinesiophobia in patients with AC resistant to conservative treatment, in comparison with a control group
48134702|NCT06699693|OTHER|Mobilization|The mobilization methods encompassed the scapula and clavicular joints, in addition to the glenohumeral (GH) joint, taking into consideration their biomechanical interactions. These exercises were supervised and administered by the physiotherapist during each session. Additionally, the patients were provided with a home exercise program that included exercises for posture, thera band, and finger ladder, with instructions to perform 10-15 repetitions twice a day independently \[
48134703|NCT06699511|BEHAVIORAL|Exercise|Exercise
48500033|NCT04674865|OTHER|Standardized Physical therapy protocol|Standardized Phase 1 protocol without for 7 days without ANB sessions.
48500034|NCT04674865|OTHER|Alternate nostrils breathing|Alternate nostrils breathing 2 sessions per day
48343064|NCT05001568|DEVICE|Immediate in-brace correction: Conventional Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
48343065|NCT05001568|DEVICE|Immediate in-brace correction: Optimized Brace|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic (supine position) and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
48343066|NCT05001568|DEVICE|Long-term bracing: Conventional Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
48343067|NCT05001568|DEVICE|Long-term bracing: Optimized Brace|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
48134706|NCT06618976|DRUG|Sotagliflozin|Sotagliflozin 400 mg, P.O. once daily for 1 month.
48134707|NCT06618976|DRUG|Empagliflozin|Empagliflozin 10 mg, P.O. once daily for 1 month.
48134708|NCT06353334|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
48134709|NCT06353334|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
48343068|NCT03968081|BEHAVIORAL|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
48343069|NCT00049140|DRUG|EF5|
48657428|NCT01549015|OTHER|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
48343070|NCT00049140|OTHER|bioluminescence|
48343071|NCT00049140|OTHER|flow cytometry|
48343072|NCT00049140|OTHER|immunohistochemistry staining method|
48343073|NCT00049140|PROCEDURE|biopsy|
48343074|NCT01043783|OTHER|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
48343075|NCT01499212|PROCEDURE|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
48343076|NCT02304419|DRUG|Galunisertib|Administered orally.
48343077|NCT04494529|DRUG|12 mg betamethasone + placebo|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
48343078|NCT04494529|DRUG|24 mg betamethasone|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone."
48343079|NCT01980225|PROCEDURE|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
48343080|NCT06252740|OTHER|No intervention|Comare the difference in batting mechanics, hip and thoracic spine mobility, and muscle stiffness in baseball players with and without a history of low back pain
48343081|NCT04275999|DRUG|ivermectin|Subjects will be given the ivermectin with an electronic monitoring device attached with a return appointment at month 3 for end of study visit. Subjects will be instructed to use the ivermectin once daily.
48343082|NCT04275999|BEHAVIORAL|digital interaction|Subjects will receive weekly digital interaction; an electronic survey asking about their use of the ivermectin which will have the electronic monitoring device attached. Subjects will be instructed to use the ivermectin once daily. They will have a 3 month return appointment for end of study visit.
48343083|NCT04275999|DEVICE|GPSkin|Subjects in the GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin with the electronic monitoring device once daily. They will be scheduled for a 3 month end of study visit.
48343084|NCT03683043|DRUG|Long GnRH agonist protocol|"8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
48343085|NCT03683043|PROCEDURE|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
48343086|NCT06300892|OTHER|No intervention|samples from the incision site and GI tract collected
48343087|NCT00981682|DRUG|SER120|once a day treatment of nocturia
48343088|NCT02287662|OTHER|Vancouver 3M Clinical Pathway|
48343089|NCT00442949|PROCEDURE|Catheterization immediate PCI|Catheterization immediate PCI
48500035|NCT06504420|DRUG|Sirolimus|Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen
48500036|NCT06504420|DRUG|Placebo|Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
48500037|NCT05030558|BEHAVIORAL|Web-assisted patient education intervention designed according to the common-sense model|Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.
48500038|NCT05030558|BEHAVIORAL|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.|The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
48500039|NCT03824496|DIAGNOSTIC_TEST|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
48500040|NCT00210990|DRUG|doripenem|
48657429|NCT01146821|DIETARY_SUPPLEMENT|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care
48657430|NCT01146821|DIETARY_SUPPLEMENT|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care.
48343090|NCT00442949|PROCEDURE|delayed PCI|delayed PCI
48343091|NCT00117728|DRUG|nevirapine|
48500041|NCT04259463|PROCEDURE|Third molars extraction|Third molars extractions with concious sedation or general anesthesia
48513352|NCT06447194|DRUG|Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail|Please refer to description for interventional group.
48657431|NCT06129903|OTHER|referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences.|The primary intervention in this study is referral to the Memorial Sloan-Kettering Cancer Center (MSK) Department of Psychiatry and Behavioral Sciences. This study will not dictate specific psychiatry interventions beyond providing the referral.
48657432|NCT06401044|DRUG|AMG 732|SC injection
48657433|NCT06401044|OTHER|Placebo|SC injection
48657434|NCT00720785|DRUG|Bortezomib|Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
48657435|NCT00720785|BIOLOGICAL|NK cells|NK Cell Infusion
48657436|NCT03970447|DRUG|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
48343092|NCT05326568|OTHER|Complementary treatment practice|Applying sesame oil to the patients assigned to the intervention group by applying 10 drops to the 10 cm circumference of the cannula for 10 minutes
48343093|NCT00107822|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
48343094|NCT00159380|DRUG|Aminoguanidine|500mg
47982250|NCT05860803|BEHAVIORAL|LungTrainers Pulmonary Rehabilitation regime|Series of different exercises using the LungTrainers device 3-5 days per week for approximately 10 weeks. Exercises complete in one long session (20-30 minutes) or be broken down into multiple shorter sessions (e.g., 3 x 10 minutes). A health coach will be assigned to guide participants through the LT-PR program.
47982251|NCT03970161|DEVICE|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
48343095|NCT00159380|DRUG|Placebos|2ml
48343096|NCT00280605|DRUG|Alfuzosin|
48500042|NCT01342536|BEHAVIORAL|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
48657437|NCT03970447|DRUG|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
47982252|NCT02301884|BIOLOGICAL|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
47982253|NCT06234007|DRUG|Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine|"Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;"
47982254|NCT00478569|DRUG|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
47982255|NCT01700725|OTHER|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
47982256|NCT01700725|DRUG|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
47982257|NCT00387439|BEHAVIORAL|standard medical treatment + anoperineal physiotherapy.|
47982258|NCT00387439|BEHAVIORAL|Standard medical treatment|
48500043|NCT05613296|DRUG|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
48343097|NCT01553591|DRUG|Eluxadoline|Oral tablets twice daily
48500044|NCT03591393|DIAGNOSTIC_TEST|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
48500045|NCT01529918|OTHER|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
48343098|NCT01553591|DRUG|Placebo|Oral tablets twice daily
48500046|NCT00520286|DRUG|Modafinil|200 mg or 400 mg /daily
48500047|NCT00520286|DRUG|Placebo|Placebo / daily
48343099|NCT00001753|PROCEDURE|Magnetic resonance imaging|
48343100|NCT03136913|DEVICE|Cytoplast® TXT-200|Non-resorbable membrane
48343101|NCT03136913|DEVICE|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
48343102|NCT03136913|PROCEDURE|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
48343103|NCT03136913|PROCEDURE|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
48343104|NCT05264480|PROCEDURE|Bone augmentation with minimally invasive corticotomy (piezotomy)|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated."
48500048|NCT04713553|BIOLOGICAL|BNT162b2|Intramuscular injection
48657438|NCT03970447|DRUG|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
48657439|NCT03970447|RADIATION|Radiation|60 Gy
48500049|NCT04713553|BIOLOGICAL|BNT162b2.B.1.351|Intramuscular injection
47982259|NCT03876912|DRUG|GnRH antagonist|18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
47982260|NCT06289608|OTHER|No intervention|No dental intervention was made. Only a clinical examination
48500050|NCT01783249|OTHER|Stationary Exercise cycling|Stationary exercise cycling
48500051|NCT03865368|OTHER|Whole Body Vibration Training|Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
48500052|NCT01070771|DEVICE|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
48500053|NCT00396435|DRUG|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
48500054|NCT05404607|OTHER|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
48657440|NCT03970447|DRUG|Paxalisib|Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
47982261|NCT03176329|OTHER|Nursing 1 : INTELLIVENT-ASV|
47982262|NCT03176329|OTHER|Nursing 2 : INTELLIVENT-ASV|
47982263|NCT03176329|OTHER|Nursing 1 : Conventional mode|
47982264|NCT03176329|OTHER|Nursing 2 : Conventional mode|
47982265|NCT00170053|DRUG|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
47982266|NCT05299125|DRUG|Amivantamab|Low fucose, fully human immunoglobulin gamma-1-based bispecific antibody directed against EGFR and MET tyrosine kinase receptors. It shows clinical activity against tumors with the primary activating EGFR mutations Exon 19del or Exon 21 L858R substitution, EGFR Exon 20ins mutations, the EGFR resistance mutations Threonine790Methionine (T790M) or Cysteine797Serine (C797S), and activation of the Mesenchymal Epithelial Transition (MET) pathway.
47982267|NCT05299125|DRUG|Lazertinib|It selectively inhibits both primary activating EGFR mutations (Exon 19del, Exon 21 L858R substitution) and the EGFR T790M resistance mutation, while having less activity versus wild-type EGFR.
47982268|NCT05299125|DRUG|Pemetrexed 500 mg|Inhibits enzymes involved in folate-dependent metabolism, thereby disrupting cellular replication.
47982269|NCT01994460|DRUG|Linezolid|
47982270|NCT01994460|DRUG|Ethambutol|
47982271|NCT04204954|OTHER|Tea Tree Oil Shampoo|Twice a day eyelid margin cleansing for three days.
47982272|NCT04204954|DRUG|Ciprofloxacin Ophthalmic Ointment 0.3%|Applied topically in the eyelid margin every four hours for three days.
47982273|NCT04204954|OTHER|Baby shampoo|Twice a day eyelid margin cleansing for three days.
47982274|NCT04204954|OTHER|Blephaclean|Twice a day eyelid margin cleansing for three days.
47982275|NCT00319644|DEVICE|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
47982276|NCT04920604|OTHER|Face-to-face anesthesia consultation|The anesthesia consultation is carried out in person in accordance with the usual management.
47982277|NCT04920604|OTHER|Remote anesthesia consultation|"Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation."
47982278|NCT00814398|PROCEDURE|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
47982279|NCT00814398|PROCEDURE|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
47982280|NCT01021540|DRUG|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
47982281|NCT05951062|BEHAVIORAL|behavior management for anti-hypertensive medication|five sessions of educational interview and home visiting to improve medication-related self-management skills
47982282|NCT05951062|OTHER|placebo group|treatment as usual
48500055|NCT05404607|OTHER|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
48500056|NCT05532124|BIOLOGICAL|LAENNEC (Human Placenta Hydrolysate)|Intravenous Injection
48500057|NCT05532124|OTHER|normal saline|Intravenous Injection
48500058|NCT04101500|DRUG|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
48500059|NCT04101500|DRUG|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
48500060|NCT04101500|DRUG|Placebo Tablets|Applied only to the control group.
48500061|NCT05779423|DRUG|Ipilimumab|Monoclonal antibody administered through intravenous infusion
48500062|NCT05779423|DRUG|Nivolumab|Monoclonal antibody administered through intravenous infusion
48500063|NCT05779423|PROCEDURE|Cryoablation|Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.
48500064|NCT03715361|DIAGNOSTIC_TEST|SL-ECG|additional SL-ECG measurement
48500065|NCT00019786|DRUG|isolated perfusion|
48500066|NCT00019786|DRUG|melphalan|
48500067|NCT00019786|PROCEDURE|conventional surgery|
48500068|NCT05439876|DRUG|Melatonin|Melatonin 2 mg daily for 4 weeks
48500069|NCT05439876|DRUG|Placebo|Placebo daily for 4 weeks
48500070|NCT05277623|DRUG|Mannitol|During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg
48500071|NCT05277623|OTHER|0.9% normal saline|the same amount of 0.9% normal saline
48500072|NCT01516307|BIOLOGICAL|OPT-822/OPT-821(30 μg/100 μg)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
48500073|NCT01516307|BIOLOGICAL|Phosphate Buffer Saline (PBS)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
48343105|NCT05264480|PROCEDURE|Bone augmentation without corticotomy|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated."
48343106|NCT01478061|DEVICE|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
48343107|NCT05248529|OTHER|Education booklet|Hip/Knee Replacement Adaptation Booklet explains preoperative preparation, post-operative care practices, how to walk with walker, what needs to be done at home after discharge
48657441|NCT03970447|DRUG|VAL-083|Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
48500074|NCT01516307|DRUG|Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
48134721|NCT03800914|OTHER|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
48134722|NCT03800914|OTHER|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
48500075|NCT01567748|PROCEDURE|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
48500076|NCT05285670|BEHAVIORAL|Digital counseling plus interactive two-way SMS dialogue|We will utilize a digital counseling tool on a tablet to provide initial reproductive life planning counseling while waiting for an HIV care provider. We will then use Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women following enrollment and for up to 2 years. Women will receive automated theoretically grounded SMS messages targeting the appropriate reproductive health needs and will have the capability to respond and spontaneously message a nurse based at the clinic. . Automated SMS will be delivered at times and in languages based on patient preferences, weekly the first 3 months, every other week in months 4-12, and monthly during the last year of the trial. If there is a change in the reproductive health needs, more frequent messaging will be re-initiated at the same frequency as enrollment.
48500077|NCT00311402|DRUG|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
48500078|NCT00311402|OTHER|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
48500079|NCT02266134|BEHAVIORAL|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
48500080|NCT02266134|BEHAVIORAL|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
48500081|NCT02785536|BEHAVIORAL|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
48500082|NCT02785536|BEHAVIORAL|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
48500083|NCT00030992|DRUG|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
48500084|NCT00030992|DRUG|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
48500085|NCT00030992|DRUG|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
48134733|NCT06698562|OTHER|Distraction with Virtual reality glassess|the injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. The patient and the physician wore protective goggles during the whole procedure to prevent possi
48134734|NCT06698562|OTHER|Distraction with Virtual reality glassess + LLLT|The injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
48343108|NCT05894772|BEHAVIORAL|Power over Pain Portal|Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
48343109|NCT02708472|DEVICE|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
48343110|NCT02715050|DEVICE|Active or Placebo Phototherapy (MR4)|
48343111|NCT01820494|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
48343112|NCT02192619|OTHER|observational|
48343114|NCT05759390|DIAGNOSTIC_TEST|Ultrasound elastography|Using an ultrasound scanner for chest ultrasound examinations. If patients has multiple sub pleural lung lesions, the largest and most approachable lesion to perform 2 Dimensions- shear wave elastography (2D-SWE) will be chosen.
48343115|NCT00367341|DRUG|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
48343116|NCT00367341|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
48343117|NCT00656760|OTHER|PET/CT|PET/CT is being performed on all patients in the study.
48500086|NCT02125253|DRUG|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
48500087|NCT02125253|DRUG|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
48500088|NCT02125253|DRUG|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
48343118|NCT01142544|OTHER|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
48657442|NCT03970447|DRUG|VT1021|"Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration."
48657443|NCT03970447|DRUG|Troriluzole|Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
48343119|NCT00074620|DRUG|PEG-hirudin|
48343120|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution high dose|Topical treatment for 24 weeks
48343121|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution low dose|Topical treatment for 24 weeks
48343122|NCT05636904|DRUG|active ingredient-free vehicle solution to DLQ01|Topical treatment for 24 weeks
48343123|NCT05636904|DRUG|Minoxidil 5% Topical Solution|Topical treatment for 24 weeks
48343124|NCT05264636|OTHER|Sucrose|Sucrose Beverage
48500089|NCT04319185|OTHER|Assistance to perform Peritoneal Dialysis (PD) at home|The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
48657444|NCT03970447|BIOLOGICAL|ADI-PEG 20|Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
48657445|NCT06629961|PROCEDURE|abutment placement|Placement of a subcrestal implant at more than 35 N and placement of a trans-epithelial abutment at 30 N
48134735|NCT06698562|OTHER|Tell Show Do Group + LLLT|The injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. During the whole procedure, the patient wore virtual glasses and the physician wore protective go
48134736|NCT06698562|OTHER|Tell Show Do Group|In this session, the injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
48134737|NCT06698380|OTHER|Conventional Physical Therapy|The subjects of the control group received the CPT based on their routine physical therapy neurological evaluation. The CPT was individualized based on the needs of the subjects. It included: normalization of muscle tone, strengthening of weak muscles, lengthening of tight muscles, training for transfers like supine to sit, sit to stand, balance training, and gait training. The upper extremity training for ADLs also were incorporated using mobilization, reaching, grasping and dexterity movements
48134738|NCT06698380|OTHER|Mirror Therapy|A mirror was positioned in front of the subjects to shield the involved upper extremity, reflecting the image of the uninvolved side. The involved upper extremity was placed in a relaxed posture beside the mirror, mirroring the same posture on the uninvolved side to enhance illusional movements. The MT for the experimental group included reaching, grasping, and dexterity movements of the unaffected upper limb, followed by imitation on the involved side. Subjects performed five activities: finger flexion and extension, finger opposition, counting with fingers, wrist flexion and extension, and forearm supination and pronation. Each activity was done 10 times, with mirror therapy lasting 15 minutes followed by 30 minutes of CPT treatment. Each session lasted 45 minutes, held three times per week over six weeks.
48343125|NCT05264636|OTHER|Steviol Glycosides|Steviol Glycoside Beverage
48343126|NCT00062205|DRUG|imatinib mesylate|
48343127|NCT05297799|DEVICE|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
48343128|NCT05786534|DIETARY_SUPPLEMENT|Green Seaweed|400 mg per day
48343129|NCT03648606|OTHER|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
48343130|NCT01578590|DIETARY_SUPPLEMENT|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
48343131|NCT04513405|DIAGNOSTIC_TEST|Blood sampling|"a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel."
48500090|NCT03473626|DRUG|Alicaforsen|Alicaforsen tablet
48657446|NCT06629961|PROCEDURE|Ti-base placement|Placement of a subcrestal implant at more than 35 N and placement of a Tibase placement at 30 N
48500091|NCT01425918|BEHAVIORAL|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
47982283|NCT02678260|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
48500092|NCT01425918|BEHAVIORAL|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
48657447|NCT05271383|DEVICE|Orthognathic surgery using Global D's implants.|Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
48657448|NCT06052553|DEVICE|TopSpin360|Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
48657449|NCT03048825|DRUG|Colchicine|Colchicine 0.5 mg once daily
48657450|NCT03048825|DRUG|Spironolactone|Spironolactone 25 mg once daily
47982284|NCT00165243|PROCEDURE|Tangential radiation|Radiation given over 6 1/2 weeks
47982285|NCT01103011|DRUG|ND0611|Continuous delivery of ND0611
48343132|NCT04513405|PROCEDURE|Shave Biopsy|in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
48343133|NCT05029336|BIOLOGICAL|Depletion of CD3/CD19 in an autologous stem cell transplant|The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
48343134|NCT04928157|DEVICE|Positive Airway Pressure (PAP)|A device used with a nose or face mask which delivers airflow/pressure into the airway, holding the airway open and keeping it from collapsing. Device will be used for 8 weeks.
48343135|NCT02284945|PROCEDURE|Open fixation|
48343136|NCT02284945|PROCEDURE|Keyhole surgery|
48343137|NCT01238952|DRUG|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
48343138|NCT00060151|DRUG|pazopanib hydrochloride|
48343139|NCT00965549|DRUG|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
48343140|NCT00965549|DRUG|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
48343141|NCT00965549|DRUG|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
48343142|NCT02778373|DIETARY_SUPPLEMENT|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
48343143|NCT02778373|DIETARY_SUPPLEMENT|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
48343144|NCT02778373|OTHER|Placebo: Water|
48343145|NCT01755338|DRUG|Methylprednisolone|Methylprednisolone 15mg/kg
48343146|NCT01755338|DRUG|Placebo|Placebo
48343147|NCT04583345|BEHAVIORAL|Questionnaires|Questionnaires: Physical therapists ask questions these assess quality of life, anxiety and depression, physical activity level.
47982286|NCT01103011|DRUG|ND0611|Solution of ND0611 delivered continuously
48343148|NCT03357770|DRUG|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL
48343149|NCT04967911|OTHER|Rhythmic stabilization exercises|"PNF techniques and Conventional Treatment:~Experimental group received rhythmical Stabilization Technique on shoulder joint on all shoulder movements up to 1 minute in supine position For stability of joint ,re-establish dynamic rotator cuff stability and to enhance MS strength and decrease pain.~Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps).."
48343150|NCT04967911|OTHER|conventional treatment|Conventional Treatment: heating pad for 15 minutes, TENS (Transcutaneous Electrical Nerve Stimulation) and after that shoulder stretching of upper trapezius muscle, pectorals and levator scapule and isometric exercises of rotator cuff muscles performed in supine .( 10 sec hold and 10 to 15 reps)..
48343151|NCT00432562|DRUG|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
48343152|NCT02177812|DRUG|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
48343153|NCT02177812|DRUG|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
47982287|NCT05629624|DIETARY_SUPPLEMENT|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
48500093|NCT06349252|PROCEDURE|Radical resection|Patients should undergo radical resection.
48513353|NCT06447194|OTHER|Placebo|100mL paraspinal normal saline injection intraoperatively, once.
48513354|NCT03104712|OTHER|Glucose #1|50g available carbohydrate
48343154|NCT03053401|PROCEDURE|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
47982288|NCT05629624|DIETARY_SUPPLEMENT|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
48134739|NCT06699589|BEHAVIORAL|Old SCHOOL Hip-Hop (Dementia Education)|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
48343155|NCT03053401|PROCEDURE|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
48343156|NCT03053401|DEVICE|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
48343157|NCT03053401|DEVICE|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
48343158|NCT03053401|DRUG|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
48657451|NCT03048825|DEVICE|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
48657452|NCT03048825|DRUG|Colchicine-Placebo|Matching Colchicine-placebo once daily
48657453|NCT03048825|DRUG|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
48657454|NCT05260242|OTHER|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
48657455|NCT06630130|DRUG|Trastuzumab deruxtecan|"* Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)"
48657456|NCT06630130|DRUG|Capecitabine|"* Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"
48657457|NCT06630130|DRUG|Rilvegostomig|"(Only Cohort B)~* Neoadjuvant; Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months)"
48657458|NCT04600973|BEHAVIORAL|Technical assistance or team-based coaching|Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
48657459|NCT02185768|DRUG|idarubicin|
48657460|NCT02185768|DEVICE|Dc- Beads 300-500µm|
48657461|NCT04873557|OTHER|Copper-based surfaces plus copper-enriched linen|We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
48657462|NCT05715320|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
47982289|NCT05629624|DIETARY_SUPPLEMENT|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ \<-2 and ≥-3 z-score, and/or MUAC \<12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case \& control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
48343159|NCT03053401|DRUG|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
48657463|NCT03746210|DIAGNOSTIC_TEST|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
48657464|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 100 and 150
48657465|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
48657466|NCT00420537|DRUG|Mycophenolate mofetil|mycophenolate with low doses
48657467|NCT00420537|DRUG|Everolimus|
48343160|NCT01961102|PROCEDURE|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
48343161|NCT01755104|DIETARY_SUPPLEMENT|Stablor|
47982290|NCT02484963|DRUG|Zolpidem|
47982291|NCT02484963|DRUG|placebo|
47982292|NCT02622542|DEVICE|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
48343162|NCT01755104|DIETARY_SUPPLEMENT|Placebo|
47982293|NCT02622542|OTHER|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
48343163|NCT00235053|DRUG|fluticasone/salmeterol DISKUS 250/50|
47982294|NCT03276884|OTHER|Experimental Infant Formula|amino acid-based infant formula powder
47982295|NCT03276884|OTHER|Control Infant Formula|amino acid-based infant formula powder
47982296|NCT03498690|BEHAVIORAL|Integrative|Stakeholder groups: a-b
48343164|NCT01453933|DRUG|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
48343165|NCT00285649|OTHER|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
48500094|NCT03259438|BEHAVIORAL|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
48657468|NCT06571916|BEHAVIORAL|Brief-SfSL|"Brief-SfSL is a single 90-minute intervention that that:~1. helps clients understand their suicide narrative, which explores the origin and meaning of their suicidal thoughts~2. builds specific skills to keep oneself safe from suicide even if suicidal thoughts are present~3. includes enhanced safety planning by identifying the barriers to enacting a safety plan and solutions to overcome them"
47982297|NCT03498690|BEHAVIORAL|Role specific|Stakeholder groups: a or b
47982298|NCT03498690|BEHAVIORAL|Consecutive|Stakeholder groups: a=\> b
47982299|NCT03516591|DRUG|AMV564 14-Day CIV|A 14-Day Continuous Intravenous Infusion regimen
47982300|NCT06504758|OTHER|Breathing Retraining Program|"* 1st to 5th week - Breathing Retraining 10 repetitions (Pursed Lip Breathing, Diaphragmatic Breathing)~* Two days / a week The total duration of 5 weeks."
47982301|NCT06504758|OTHER|Postural Exerises Program (Stretching and Strengthening Exercises)|"* TheraBand® or Free Weight~* 1st week - neck isometrics, chin tuck, SCM - upper trapezius - pectoral major stretching, scapular retraction without weight, rowing with yellow TheraBand®, wall squat / mini squat (5 repetitions - 15 second hold for stretching exercises, 10 repetitions for strengthening exercises)~* 2nd and 3rd week - same exercises (5 repetitions - 15 second hold for stretching exercises, 15 repetitions for strengthening exercises)~* 4th and 5th week - same exercises (10 repetitions - 15 second hold for stretching exercises, 20 repetitions for strengthening exercises)~* Two days / a week,The total duration of 5 weeks"
47982302|NCT04090840|BEHAVIORAL|Intermittent Fasting|Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
47982303|NCT05183373|OTHER|Evaluation of inflammation and clotting|Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
47982304|NCT03934931|OTHER|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
47982305|NCT03934931|OTHER|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
47982306|NCT03934931|OTHER|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
47982307|NCT03934931|OTHER|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
47982308|NCT03934931|OTHER|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
47982309|NCT03934931|OTHER|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
48343166|NCT00285649|OTHER|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
48343167|NCT00285649|OTHER|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
48343168|NCT06382961|DRUG|Dexmedetomidine injection|Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
48343169|NCT06382961|DRUG|Sufentanil injection|3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.
48343170|NCT01689766|DRUG|Technetium Tc 99m EC20|
48343171|NCT02802072|DEVICE|Enterprise stent implantation|Enterprise stent system (Johnson \& Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
48343172|NCT02802072|DRUG|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
48343173|NCT00906906|DEVICE|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
48343174|NCT02142855|BEHAVIORAL|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
48343175|NCT02142855|BEHAVIORAL|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
48343176|NCT06078891|BIOLOGICAL|BCG vaccine|Three intra-dermal vaccinations over a period of one year.
48343177|NCT01057862|DRUG|Naltrexone|Targeted dosage of 50mg PO daily
48657469|NCT04695366|OTHER|No intervention|No intervention
48500095|NCT03259438|BEHAVIORAL|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
48500096|NCT02134743|PROCEDURE|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
48500097|NCT02954263|DRUG|TD-1439|
48500098|NCT02954263|DRUG|Placebo|
48513355|NCT03104712|OTHER|Glucose #2|50g available carbohydrate
48657470|NCT06468137|BEHAVIORAL|Swedish I-ACE|Rehabilitative programme with focus on communication strategies and problem solving for people with hearing loss.
48657471|NCT06468137|BEHAVIORAL|Clinical visit|Visit in the clinic with focus on audiologic rehabilitation.
48657472|NCT06468137|OTHER|No follow-up|Participants choosing no follow-up.
48657473|NCT01955551|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
48657474|NCT01955551|BEHAVIORAL|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
48657475|NCT06475300|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
48657476|NCT06475300|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
48657477|NCT03092011|DRUG|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
48657478|NCT03092011|DRUG|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
48657479|NCT06568575|BEHAVIORAL|experiment of music|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by exercise program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes.
48657480|NCT06568575|BEHAVIORAL|experiment of exercise|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by music program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes. The music experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time, and a total experiment time of 1420 minutes. Examples of songs：Everytime We Touch- Cascada (115 bpm), Beat It - Michael Jackson (120 bpm), Viva La
48657481|NCT06268249|DRUG|Ulinastatin|Ulinastatin was pumped continuously during the operation
48657482|NCT06640205|PROCEDURE|pulpotomy|Removal of coronal pulp tissue and then placing pulpotomy agent
48657483|NCT01033669|DEVICE|CRC-749|There is no drug being used. This is a device.
48657484|NCT01033669|DEVICE|Diskus|There is no drug being used. This is a device.
48657485|NCT01033669|DEVICE|Twisthaler|There is no drug being used. This is a device.
48657486|NCT01033669|DEVICE|Miat Monohaler|There is no drug being used. This is a device.
48657487|NCT00087035|DRUG|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
48657488|NCT00087035|DRUG|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
48657489|NCT02987140|BEHAVIORAL|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
48657490|NCT04612192|DEVICE|Active luminette|receive an active light using glasses of 1500 lux (an average of 180 photons/s/cm2, with a maximum wavelenght at 468 nm), 30-minute long light therapy in the morning, in a time period defined by sleep log and chronotype questionnaire, on a 4-week period
48657491|NCT04612192|DEVICE|Placebo luminette|receive a placebo light using glasses (an average of n photons/s/cm2, single- band spectrum with a narrow peak at 660 nm under 50 lux), with the same modality as the experimental group
48657492|NCT00778401|DRUG|Gabapentin tablets 800 mg|
48657493|NCT02836249|DRUG|TAF|TAF 25 mg tablet administered orally once daily
48657494|NCT02836249|DRUG|TDF|TDF 300 mg tablet administered orally once daily
48657495|NCT02836249|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
48657496|NCT02836249|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
48343178|NCT01057862|OTHER|Placebo|Sugar pills daily PO
48513356|NCT03104712|OTHER|Glucose #3|50g available carbohydrate
48513357|NCT03104712|OTHER|Spaghetti|50g available carbohydrate
48513358|NCT03104712|OTHER|Rice|50g available carbohydrate
48343179|NCT02972281|BIOLOGICAL|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
48343180|NCT01870791|DRUG|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
48343181|NCT05116891|DRUG|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
48343182|NCT05116891|DRUG|mFOLFOX|mFOLFOX/CAN04
48343183|NCT05116891|DRUG|DTX|DTX/CAN04
48343184|NCT05116891|DRUG|G/C|G/C/CAN04
48343185|NCT05851092|DRUG|HRS-2189 Tablets|HRS-2189 Tablets
48343186|NCT03438760|BEHAVIORAL|Science + Phonological Awareness|The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
48343187|NCT03438760|BEHAVIORAL|Science + Grammar Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
48343188|NCT03438760|BEHAVIORAL|Science + Vocabulary Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
48343189|NCT00475371|DRUG|MKC253 Inhalation Powder|Inhalation powder
48343190|NCT02636738|DEVICE|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
48343191|NCT05524558|DEVICE|Pulmonary artery catheter|PAC already in place
48343192|NCT05524558|DEVICE|Esophagal pressure|Esophagal pressure already in place
48343193|NCT06037512|DIAGNOSTIC_TEST|subject|blood glucose measurement by subject
48343194|NCT06037512|DIAGNOSTIC_TEST|reference|blood glucose measurement with reference
48343195|NCT00001036|DRUG|Thymalfasin|
48343196|NCT00001036|DRUG|Interleukin-2, Polyethylene Glycolated|
48343197|NCT00001036|DRUG|Zidovudine|
48343198|NCT01407406|DRUG|BIIB023 - low dose IV Dose|
48343199|NCT01407406|DRUG|BIIB023 - high dose IV Dose|
48343200|NCT01956994|DIETARY_SUPPLEMENT|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
48343201|NCT01956994|DIETARY_SUPPLEMENT|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
48500099|NCT04771403|DEVICE|FMPD AP algorithm|The Fading Memory Proportional Derivative (FMPD) insulin infusion algorithm determines insulin delivery rates based on proportional error, defined as the difference between the current CGM level and the target CGM level, and the derivative error, defined as the rate of change of the CGM. The FMPD algorithm utilizes derivative and proportional glucose errors to determine delivery rates of insulin.
48343202|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
48343203|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
48513359|NCT03104712|OTHER|Spaghetti + Tomato Sauce|50g available carbohydrate
48513360|NCT03104712|OTHER|Rice + Tomato Sauce|50g available carbohydrate
48343204|NCT02296294|DRUG|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
48343205|NCT02296294|DEVICE|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
48343206|NCT00398138|BIOLOGICAL|WT-1 analog peptide vaccine|
48343207|NCT00398138|BIOLOGICAL|incomplete Freund's adjuvant|
48343208|NCT00398138|BIOLOGICAL|sargramostim|
48343209|NCT00398138|GENETIC|polymerase chain reaction|
48343210|NCT00398138|OTHER|flow cytometry|
48343211|NCT00398138|OTHER|immunoenzyme technique|
48343212|NCT04767776|DRUG|Rivaroxaban|rivaroxaban 40 mg/day (1 day).
48343213|NCT04767776|DRUG|Activated charcoal|Activated charcoal 2 hours after rivaroxaban administration (1 day).
48343214|NCT01821885|BEHAVIORAL|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
48343215|NCT01821885|BEHAVIORAL|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
48343216|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
48343217|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
48343218|NCT00162708|DRUG|CDDP, 5 Fu|
48343219|NCT02498327|OTHER|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
48343220|NCT02498327|OTHER|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
48343221|NCT00615459|DRUG|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
48343222|NCT00615459|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
48343223|NCT00615459|DRUG|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
48343224|NCT03891615|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage."
48343225|NCT03891615|DRUG|Osimertinib|Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
48343226|NCT04238689|BIOLOGICAL|TB31F|Monoclonal antibody
48343227|NCT01813968|PROCEDURE|Ischemic postconditioning|
48343228|NCT02948504|PROCEDURE|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
48343229|NCT01921452|DEVICE|Quantitative POC TSH Kit|A drop (approximately 30 microliter \[mcL\]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
48343230|NCT01921452|DEVICE|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
48343231|NCT01921452|DEVICE|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
48343232|NCT03383614|DRUG|LSF emodepside (BAY 44-4400) or matching placebo|Emodepside administered as an LSF oral solution (1mg/mL)
48343233|NCT03879460|DRUG|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
48343234|NCT02061904|RADIATION|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
47982310|NCT03792282|BEHAVIORAL|Time Restricted Feeding|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
47982311|NCT03792282|BEHAVIORAL|Usual care|Participants receive a general lifestyle counseling.
47982312|NCT03861715|DIAGNOSTIC_TEST|live birth rate|The blastulation rate and live birth rate according to the protocol of COS
47982313|NCT00865124|DRUG|Spironolactone|25 mg capsule daily for 6 months
47982314|NCT00865124|DRUG|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
48343235|NCT02061904|OTHER|Short Form Health Survey 12|questionnaire for general health monitoring
48343236|NCT02061904|OTHER|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
47982315|NCT00865124|OTHER|Placebo|Placebo capsule daily
48343237|NCT02061904|OTHER|VAS-pain|questionnaire for pain monitoring
48343238|NCT02061904|OTHER|Harris Hip Score|questionnaire for hip function monitoring
48343239|NCT05904938|DEVICE|Lenodiar Pediatric|Medical Device made of natural substance
48343240|NCT05904938|OTHER|Placebo|Product appearance similar to verum without clinical efficacy
48343241|NCT00348491|DRUG|Lumiracoxib|
47982316|NCT00539448|DRUG|insulin glargine|in combination with insulin Glulisine as bolus regimen
48134740|NCT06699589|BEHAVIORAL|My Plate (Nutrition Education)|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
48134741|NCT06699355|DRUG|Enlicitide Decanoate|Oral administration
48343242|NCT04616924|DRUG|RHB-204|RHB-204
48343243|NCT04616924|DRUG|Placebo|Matching placebo to RHB-204
48343244|NCT03480646|DRUG|CPI-1205|Administered orally
47982317|NCT00539448|DRUG|insulin glulisine|in combination with insulin Glargine as bolus regimen
47982318|NCT00184691|DRUG|somatropin|
47982319|NCT02268864|DRUG|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
48134742|NCT06699355|DRUG|Atorvastatin|Oral administration
48134743|NCT06699043|PROCEDURE|nanocrystalline hydroxyapatite in putty form|"decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space.~* Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa~* The intrabony defects in Group I will be received nanocrystalline hydroxyapatite in putty form as grafting material (NanoBone® SBX Putty)."
48343245|NCT03480646|DRUG|Enzalutamide|Administered orally
47982320|NCT02268864|DRUG|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
48343246|NCT03480646|DRUG|Abiraterone/Prednisone|Administered orally
48343247|NCT05258513|DIETARY_SUPPLEMENT|Placebo Supplementation|8 weeks of placebo supplementation
48343248|NCT05258513|DIETARY_SUPPLEMENT|GG sourced from Annatto|8-weeks of Geranylgeraniol supplementation
48343249|NCT04321278|DRUG|Hydroxychloroquine + azithromycin|Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
48343250|NCT04321278|DRUG|Hydroxychloroquine|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.
48343251|NCT01503619|OTHER|laboratory biomarker analysis|Correlative studies
48343252|NCT00688545|DRUG|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
48343253|NCT00688545|DRUG|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
48513361|NCT03104712|OTHER|Spaghetti + Pesto|50g available carbohydrate
47982321|NCT06136754|DRUG|Varnishes, Fluoride|Fluoride varnish containing 5.0% NaF
48002482|NCT02479711|OTHER|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
48002483|NCT00379496|PROCEDURE|Antidepressants|
48002484|NCT00379496|PROCEDURE|acupuncture|
48343254|NCT02596828|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
48343255|NCT02596828|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
48343256|NCT02596828|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
48343257|NCT02596828|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
48343258|NCT00923624|OTHER|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
48343259|NCT00923624|BEHAVIORAL|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
48343260|NCT05166603|OTHER|TeleGRACE|Patients receive a virtual home visit and care from the GRACE team
48343261|NCT02580591|DRUG|Empagliflozin|
48343262|NCT02580591|DRUG|Placebo|For blinding purposes
48343263|NCT05887089|OTHER|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
48343264|NCT04695418|DIETARY_SUPPLEMENT|Rice Germ|The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
48513362|NCT03104712|OTHER|Rice + Pesto|50g available carbohydrate
48343265|NCT04695418|COMBINATION_PRODUCT|Placebo|An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
48343266|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
48343267|NCT01704976|DEVICE|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
48343268|NCT00476398|PROCEDURE|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
48343269|NCT04142944|DEVICE|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
48343270|NCT04142944|DEVICE|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
48343271|NCT04011644|BEHAVIORAL|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
48343272|NCT04011644|BEHAVIORAL|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
48657497|NCT02249520|OTHER|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
48343273|NCT04011644|BEHAVIORAL|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
48367447|NCT03077646|BEHAVIORAL|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
48513363|NCT06467799|DRUG|Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1|Patients will first receive two cycles of FOLFOX-HAIC combined with tislelizumab as neoadjuvant therapy, with a 3-week interval between cycles. Two weeks after completing the neoadjuvant therapy, imaging assessments will be conducted to evaluate treatment efficacy and surgical feasibility. Surgical resection should be performed within two weeks following the imaging assessment. Four weeks post-resection, patients will undergo a follow-up evaluation to assess postoperative recovery and determine the presence of any residual tumor. If no residual or recurrent tumor is detected, adjuvant therapy with tislelizumab will commence (every three weeks, for a total of four cycles).
48657498|NCT02249520|OTHER|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
48657499|NCT02249520|OTHER|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
48002485|NCT05723016|OTHER|preimplantation genetic test for aneuploidies (PGT-a)|preimplantation genetic test for embryo aneuploidies after IVF
48002486|NCT05398978|OTHER|e-Registration and mHealth|Registration to the electronic database Counseling through voice calls for facility delivery Text messages to promote facility delivery
48002487|NCT01515683|BEHAVIORAL|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
48657500|NCT06431581|BEHAVIORAL|m-Health intervention (educational video, SMS and reminder phone call)|Pregnant women meeting the inclusion criteria and assigned to the intervention group will receive m-health intervention that includes a tailored educational video regarding perinatal care targeting positive birth outcomes and infant health, SMS messages, and reminder phone calls for follow-up
48657501|NCT05450978|DRUG|Lamotrigine|Anti-seizure concentrations
48657502|NCT05450978|DRUG|Levetiracetam|Anti-seizure concentrations
48343274|NCT00881699|BEHAVIORAL|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
48367448|NCT04045431|DEVICE|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.
48367449|NCT04045431|DEVICE|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
48657503|NCT00940121|DRUG|mirabegron|oral tablet
48657504|NCT00940121|DRUG|mirabegron|IV solution
48343275|NCT00881699|BEHAVIORAL|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
48343276|NCT01670708|BEHAVIORAL|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
48343277|NCT01670708|BEHAVIORAL|Probation as Usual|Probation officer supervises following standard protocols.
48343278|NCT04483752|OTHER|CHEST CT SCAN|Chest CTscan at 3 and 12 months
48343279|NCT04118062|BEHAVIORAL|Questionnaires|Questionnaires
48343280|NCT04118062|BEHAVIORAL|Semi-structured individual interviews|Semi-structured individual interviews
48343281|NCT04118062|OTHER|Focus Group|Focus Group
48343282|NCT04118062|OTHER|DELPHI Consensus Method|DELPHI Consensus Method
48343283|NCT05183646|DRUG|DMX-200|DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
48343284|NCT05183646|DRUG|Placebo|Patients will receive 120 mg capsules of Placebo twice daily
48343285|NCT03395041|DIAGNOSTIC_TEST|cardiac imaging tests|cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
48343286|NCT03825497|OTHER|Promotion of activity during and after hospitalization|1) a welcome folder encouraging physical activity; 2) encouragement to use a walk path established in the ward; 3) encouragement to use posters containing exercise suggestions;4) prescription of a walk-plan for in-hospital use; 5) encouragement to pick up clothes and beverages by oneself; 6) prescription of a walk-plan at discharge for at home use 7) follow-up on walk plan after discharge by municipality
48343287|NCT03519841|DEVICE|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
48343288|NCT00404638|DRUG|Desmopresin|
48343289|NCT00404638|BEHAVIORAL|Paula Method of Circular Muscle Exercise|
48343290|NCT04691531|DEVICE|The use of classical Gauge 22 needle|After induction of general anesthesia, patients will undergo caudal block by using classical Gauge 22 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
48343291|NCT04691531|DEVICE|The use of classical Gauge 27 needle|After induction of general anesthesia, patients will undergo caudal block by using Gauge 27 needle under ultrasound guidance using a linear probe 5.5-12 MHz.
48343292|NCT00817037|DRUG|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
48513364|NCT04594564|PROCEDURE|Total hip arthroplasty with Delta TT cup|Total hip arthroplasty using Delta TT cup and ceramic bearings
48513365|NCT03183596|DRUG|Bupivacaine|20-60cc of 0.25% Bupivacaine
48343293|NCT00817037|DRUG|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
48343294|NCT00817037|DRUG|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
48343295|NCT05218538|DIAGNOSTIC_TEST|Fibroscan (non interventional)|An elastography test that includes an ultrasound wave imaging of the liver to estimate liver fatness, in combination with a proprioty examination of the liver stiffness.
48343296|NCT00552344|BIOLOGICAL|Cimzia|"* Active substance: Certolizumab Pegol~* Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~* Concentration: 200 mg/ml~* Route of Administration: Subcutaneous use"
48343297|NCT00005640|PROCEDURE|Preoperative Endoscopy|
48343298|NCT00005640|RADIATION|Technetium Tc 99m Sulfur Colloid|
48343299|NCT00005640|PROCEDURE|Gamma Probe|
48343300|NCT00005640|PROCEDURE|Biopsy of Sentinel Lymph Nodes|
48343301|NCT05728762|DEVICE|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
48343302|NCT03224260|DRUG|BMS-986177|Oral Suspension
48343303|NCT03224260|OTHER|Matched Placebo|Oral Suspension
48343304|NCT04403698|DRUG|Alendronate Effervescent Oral Tablet|At the earliest three months but no later than four months after the last denosumab injection, subjects will be randomized to effervescent alendronate administered for either 24 or 48 weeks
48367450|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
48343305|NCT02891772|PROCEDURE|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
48343306|NCT01335490|OTHER|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
48500100|NCT04771403|DEVICE|MPC AP system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
48513366|NCT03183596|DRUG|Dexamethasone|2-4mg of Dexamethasone
48134744|NCT06699043|PROCEDURE|Demineralized Bone Matrix allograft putty|decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. • Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa • The intrabony defects in Group II will be received Demineralized Bone Matrix allograft putty as grafting material, in both groups will be use membrane to cover of the graft materials and finally will be sutured the flap.
48343307|NCT05556915|OTHER|Ultrasound-guided AVF cannulation method|For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.
48367451|NCT03278834|DEVICE|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
48367452|NCT03769753|DEVICE|IRE Device|For use in ablating soft tissue
48500101|NCT04771403|DEVICE|Dexcom G6 Continuous Glucose Monitoring (CGM) System|The Dexcom G6 CGM measures interstitial glucose through a sensor transmitter. This glucose value is reported to the MPC algorithm during this intervention.
48134746|NCT06698679|OTHER|No intervention|There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.
48343308|NCT05556915|OTHER|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
48367453|NCT00224757|PROCEDURE|Transoesophageal echocardiography|TEE
48134747|NCT06698887|DRUG|Idecabtagene vicleucel|As per CA089-1043 study protocol
48500102|NCT04054960|DEVICE|Active tPCS|Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.
48500103|NCT04054960|DEVICE|Sham tPCS|For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
48500104|NCT04054960|DRUG|Levodopa tablet|We will give 3 tablets of Levodopa-Carbidopa (100/25).
48500105|NCT02318238|OTHER|6 minutes walking test|
48500106|NCT02318238|OTHER|6 minutes step test|
48134752|NCT06698328|DEVICE|Transauricular Vagus Nerve Stimulation|"Mild non-invasive electrical stimulation to the vagus nerve using electrodes or stickers that adhere to the ear and the surrounding area."
48134753|NCT06698328|DEVICE|Sham Stimulation|"Sham non-invasive electrical stimulation using electrodes or stickers that adhere to the ear and the surrounding area."
48500107|NCT02318238|OTHER|4 meters gait speed|
48500108|NCT04363840|DRUG|Aspirin 81 mg|Aspirin 81 mg to be taken orally once daily for 14 days.
48500109|NCT04363840|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
48500110|NCT03560648|DEVICE|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
48500111|NCT05818618|DRUG|Clobetasol Topical Gel|Topic Clobetasol gel applied locally on OLP lesions.
48500112|NCT05818618|DRUG|Placebo|Placebo oral gel applied locally on OLP lesions.
48500113|NCT02043587|DRUG|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
48500114|NCT02043587|DRUG|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
48500115|NCT02043587|DRUG|PEG-asp|2,000 IU/m2 IV for ages \</= 50, age \> 50, 1000 IU/m2 IV Day 16, Courses 1A \& 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
48500116|NCT02043587|DRUG|CTX|750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
48500117|NCT02043587|DRUG|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A \& 2A; Maintenance: Monthly, days 1-5
48367454|NCT01873027|DEVICE|OFDI|"* OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
48500118|NCT02043587|DRUG|Liposomal AraC|25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
48500119|NCT02043587|DRUG|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B \& 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
48500120|NCT02043587|DRUG|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
48500121|NCT02043587|DRUG|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
48500122|NCT02043587|DRUG|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C \& 2C
48500123|NCT02043587|DRUG|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
48500124|NCT02043587|DRUG|Rituximab|375 mg/m2 IV once daily on days 1 \& 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C \& 2A
48500125|NCT02043587|DRUG|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
48500126|NCT01593696|BIOLOGICAL|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
48513367|NCT02681211|OTHER|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
48513368|NCT02681211|DRUG|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
48343309|NCT02360449|BEHAVIORAL|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
48343310|NCT01562197|DRUG|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
48657505|NCT06296225|DEVICE|Vibration|"Grip strenght measurement will always be done in the same way : for each series, 3 measurements of maximum strength will be taken for each side. Participants will receive verbal encouragement.~After initial both sides grip strength evaluation, all participant will first experiment the vibration situation using the device Vibramoov Physio (TechnoConcept, Manosque, France): the vibrations had a frequency of 100Hz, with an amplitude of 2mm, they will be applied to the anterior part of the forearm for 10 minutes, 3 times. At the end of each 10 minutes vibration session, handgrip strength will be assessed.~* Participants then have a one-hour rest period.~* Control situation: participants will have 4 series of grip strength measurements every 10 minutes.~At the end of the 2 hours, the patient will be discharged from the study protocol."
48657506|NCT04667572|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
48657507|NCT03470051|DIAGNOSTIC_TEST|QT Ultrasound|All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
48657508|NCT05598788|OTHER|Measurement of drug concentrations|Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
48657509|NCT04469686|COMBINATION_PRODUCT|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator|Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
48657510|NCT04469686|COMBINATION_PRODUCT|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator|Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator
48343311|NCT01562197|DRUG|Axitinib plus Lomustine|Lomustine 90mg/m²
48657511|NCT04469686|COMBINATION_PRODUCT|Twice daily placebo suppository administered with Sephure applicator|Twice daily placebo suppository administered with Sephure applicator
48500127|NCT05591586|BEHAVIORAL|Web based educational modules|This strategy will consist of 6 web-based modules, clinic-specific interpreter access information, and 4 booster modules, all delivered via the internet. The online modules will cover 6 topics: 1) the importance and fundamentals of good communication; 2) the importance of professional interpreter use and disparities for LEP populations; 3) how to use an interpreter effectively; 4) what to do when the encounter is not going well; and 5) special challenges and 6) solutions related to remote interpreter use. Modules will be interactive, with tailoring to the learner, and each will be \<15 minutes long. All modules will be available at once, but assigned providers will be prompted to view a new one each week. Every month for months 3-6 after randomization, a booster module will be released. The brief (\<10 min) boosters will review crucial points from initial modules and feature video vignettes. Providers will be reminded to view these weekly until they are complete.
48657512|NCT06548438|PROCEDURE|Transurethral resection of the bladder performed with PDD tecnique and Hexvix|For the execution of PDD cystoscopy in blue light, it is necessary to use the study drug (Hexvix) which, after intravesical instillation, causes an accumulation of porphyrins in the lesions of the bladder wall at the intracellular level. The intracellular porphyrins are photoactive fluorescent compounds that emit red light when excited with blue light. Consequently, the preneoplastic and neoplastic lesions will emit a red luminescence against a blue background, allowing for better visualisation and subsequent resection.
48657513|NCT02073201|OTHER|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
48657514|NCT02073201|OTHER|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
48657515|NCT02073201|OTHER|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
48657516|NCT06571097|DRUG|Levoﬂoxacin|0.5g/day for 2 weeks
48657517|NCT05817110|OTHER|Participant Cohort|Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.
48657518|NCT05286619|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
48657519|NCT05286619|DRUG|Cisplatin|Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
48657520|NCT05286619|DRUG|Carboplatin|Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
48657521|NCT05286619|DRUG|Gemcitabine|Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
48657522|NCT04293432|DRUG|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
48657523|NCT05385978|DRUG|APHD-012|Distal jejunal-release dextrose beads (Aphaia technology, AT)
48657524|NCT05385978|DRUG|APHD-012P|Distal jejunal-release placebo beads
48657525|NCT06501963|BIOLOGICAL|Live Attenuated Influenza Vaccine|The FDA-approved live attenuated seasonal influenza vaccine (LAIV) (FluMist®, AstraZeneca) is licensed in the US for people 2-49 years of age. The approved seasonal LAIV at the time of study enrollment will be obtained from the manufacturer. LAIV will be administered by a study nurse or health care provider at the Hope Clinic as a single 0.2 milliliter (mL) dose given as 0.1 mL spray in each nostril.
48657526|NCT05119335|DRUG|Oral NKT2152|Oral HIF2α inhibitor
48343312|NCT04803019|COMBINATION_PRODUCT|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
48367455|NCT01873027|DEVICE|IVUS|"* IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
48367456|NCT00582842|BEHAVIORAL|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
48657527|NCT05418426|DEVICE|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
48657528|NCT05418426|DEVICE|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
48657529|NCT05418426|DRUG|Oral Reference|estradiol 1mg/progesterone 100 mg
48657530|NCT06193239|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
48657531|NCT04573881|DEVICE|HistoSonics System|The HistoSonics System - intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
48657532|NCT06569914|BEHAVIORAL|Humanized care|(1) Humanized environmental care；(2) Humanized medical guidance；(3)Humanized psychological nursing；(4) Humanized and standardized management of IVGTT treatment process
48657533|NCT06445595|OTHER|patients with traumatic brain injury|Patients will be contacted by phone
48002488|NCT01515683|BEHAVIORAL|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
48657534|NCT03334955|PROCEDURE|Laparoscopic ovarian drilling|A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points, with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds.
48002489|NCT01515683|BEHAVIORAL|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
48343313|NCT04803019|DEVICE|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
48343314|NCT00033059|DRUG|Tolcapone|
48343315|NCT05106439|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
48343316|NCT05106439|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
48343317|NCT05106439|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
48343318|NCT02402881|BEHAVIORAL|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
48500128|NCT05591586|BEHAVIORAL|mobile video interpreting (mVI) access|This strategy will involve giving assigned providers access to mobile video interpreting (mVI) on a personal device, installation and support as needed, a tip sheet, and an extra charger, optional shock-resistant case, disposable antimicrobial sleeves, and a positioning stand to support use of their personal device for clinical care. mVI-assigned providers can opt for a study-issued smartphone in lieu of using their own. Access to mVI is achieved by downloading the application from the relevant location (e.g., Apple App Store), then entering an access code that links to a billing account. The study staff would then demonstrate use and answer questions. Technical support will be offered in-person following randomization; we will then email mVI-assigned providers weekly for the first month, then monthly, to offer additional support. A tip-sheet will be sent via email during the first week of the study that will include mVI instructions and best-practices.
48500129|NCT05578196|DRUG|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
48500130|NCT05578196|DRUG|physiological saline solution|physiological saline solution 20ml
48500131|NCT03844958|OTHER|Red Furu|"50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day"
48500132|NCT03844958|OTHER|Tofu|"50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day"
48657535|NCT05094609|BIOLOGICAL|Ad5-triCoV/Mac|Ad5-triCoV/Mac is a recombinant type 5 human adenovirus vector which has been engineered to express our trivalent SARS-CoV-2 transgene cassette under the control of an MCMV promoter, and is followed by an SV40 polyA signal. The adenovirus construct is E1 and E3 deleted.This trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
48657536|NCT05094609|BIOLOGICAL|ChAd-triCoV/Mac|ChAd-triCoV/Mac is an E1 and E3 deleted chimpanzee adenovirus serotype 68 where the trivalent SARS-CoV-2 transgene cassette is under the control of an HCMV promoter and is followed by an SV40 polyA signal. The trivalent transgene cassette consists of the S1 region of SARS-CoV-2 spike protein (aa 47-716), full-length SARS-CoV-2 nucleoprotein (N) fused to a highly conserved portion of the SARS-CoV-2 polymerase (RdRp or POL).
48343319|NCT02020928|DEVICE|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
48343320|NCT04249284|DRUG|BMS-986165|Specified dose on specified days
48343321|NCT04249284|DRUG|BMS-986165 prototype 1|Specified dose on specified days
48343322|NCT04249284|DRUG|BMS-986165 prototype 2|Specified dose on specified days
48343323|NCT00917137|PROCEDURE|TBNA + transbronchial lung biopsy + bronchial washing|
48343324|NCT04362189|BIOLOGICAL|HB-adMSC|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
48343325|NCT04362189|OTHER|Placebo|Saline
48343326|NCT01496404|PROCEDURE|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
48657537|NCT06551727|OTHER|Intervention group|"After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.~In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database."
48657538|NCT06551727|OTHER|Control group|After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
48657539|NCT03113344|DRUG|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
48657540|NCT04494698|DEVICE|Duotherm VibraCool Back Device|Active New multimodal pain device
48657541|NCT04494698|DEVICE|TENS 8-channel unit|LG Smart TENS unit
48343327|NCT01496404|PROCEDURE|Scalpel|Incising skin (epidermis and dermis) with scalpel.
48343328|NCT03905525|DRUG|CFZ533|Biological
48343329|NCT03905525|OTHER|Placebo|liquid placebo for injections
48343330|NCT06362395|RADIATION|Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)|Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
48343331|NCT01801189|DRUG|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
48343332|NCT01801189|DRUG|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
48343333|NCT04319640|BEHAVIORAL|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
48343334|NCT04319640|BEHAVIORAL|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
48343335|NCT00044525|DRUG|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
48343336|NCT00560794|BIOLOGICAL|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
48343337|NCT05267483|OTHER|No intervention|No intervention
48343338|NCT05467072|DEVICE|Annular closure|Lumbar discectomy patients treated with Annular Closure Device BARRICAID
48343339|NCT00798473|DRUG|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
48343340|NCT00798473|OTHER|IV saline infusion|
48343341|NCT03571113|OTHER|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
48343342|NCT05560295|PROCEDURE|Naser Al-Husban|uterine surgery
48343343|NCT03933124|DEVICE|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
48500133|NCT05489237|DRUG|IDRX-42|IDRX-42 will be administered at assigned doses and schedules once or twice daily in continuous cycles of 28 days each.
48657542|NCT06204809|DRUG|PGN-EDODM1 for infusion|Single dose of PGN-EDODM1 by intravenous (IV) infusion
48657543|NCT06204809|OTHER|Placebo|Administered by IV infusion
48657544|NCT02960893|DRUG|Troriluzole|Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
48343344|NCT05904314|BEHAVIORAL|Simulation training in electronic fetal monitor management|Simulation training in electronic fetal monitor management
48343345|NCT05060198|DRUG|Artemether-lumefantrine (AL)|AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
48343346|NCT05060198|DRUG|Dihydroartemisinin-piperaquine (DP)|DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
48657545|NCT02960893|DRUG|Placebo|Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
48657546|NCT02960893|DRUG|Troriluzole|Extension phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
48343347|NCT06269575|BEHAVIORAL|SAFE NUTRITION PROGRAM|"Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment"
48343348|NCT01458795|PROCEDURE|Endovenous laser ablation|
48343349|NCT02539914|OTHER|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
48343350|NCT02539914|OTHER|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
48343351|NCT04541732|OTHER|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
48500134|NCT05489237|DRUG|IDRX-42|IDRX-42 will be administered at RP1bD(s) once or twice daily in continuous cycles of 28 days each.
48500135|NCT03122067|DRUG|oxytocin treatment|intranasal administration of oxytocin
48500136|NCT03122067|DRUG|placebo treatment|intranasal administration of placebo
48500137|NCT04483635|DIETARY_SUPPLEMENT|Placebo|Weekly oral dose of placebo
48500138|NCT04483635|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral dose of Vitamin D
48500139|NCT02841813|OTHER|No intervention|No intervention
48500140|NCT02331329|DEVICE|NICOM cardiac output measurement|
48500141|NCT02331329|DEVICE|Cardiac MRT cardiac output measurement|
48500142|NCT04808401|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
48657547|NCT04593277|OTHER|Internet Mobile Technology|Use INSPIRE mobile application
48657548|NCT04593277|OTHER|Internet-Based Intervention|Access to a study-specific control website
48657549|NCT04593277|OTHER|Questionnaire Administration|Ancillary studies
48343352|NCT04541732|OTHER|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
48343353|NCT04541732|DRUG|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
48343354|NCT04541732|DRUG|Muscle Relaxant|Atracurium : 0.5mg/Kg.
48343355|NCT04541732|DRUG|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
48343356|NCT04045691|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
48343357|NCT04045691|DRUG|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
48343358|NCT03504462|PROCEDURE|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
48343359|NCT03046563|OTHER|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
48343360|NCT03046563|OTHER|Pressing the Sham points|Pressing the sham points for eight minutes
48343361|NCT05615038|PROCEDURE|Contact aspiration Thrombectomy|Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
48657550|NCT04593277|PROCEDURE|Supportive Care|Receive telehealth stepped care
48343362|NCT05615038|PROCEDURE|Stent retriever thrombectomy|Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
48343363|NCT01751360|DRUG|SYR-472|
48343364|NCT02688153|DEVICE|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR \& CABG.
48343365|NCT02688153|DEVICE|Stented aortic bioprostheses|In comparison to control valves available on the market.
48343366|NCT00871936|DRUG|SLx-4090|SLx-4090
48343367|NCT00871936|OTHER|Placebo|matching tablets
48343368|NCT00871936|DRUG|Metformin|
48657551|NCT04593277|OTHER|Informational Intervention|Receive printed SCP materials
47982322|NCT05265000|DEVICE|tSpinalStim|Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
47982323|NCT06347536|COMBINATION_PRODUCT|Supported rescue pack|1) a rescue pack (prednisolone and antibiotics for 5 days); 2) a written rescue pack management plan based on the Asthma-Lung UK plan; and 3) twice-weekly automated telephone symptom reminder calls for 90 days (with preferred language as needed). The reminder phone calls (to home telephone or mobile) will ask questions aligned to the written management plan
48343369|NCT04580888|PROCEDURE|early transthoracic echocardiography|In the intervention arm, echocardiography will be performed immediately and potentially repeated to confirm the need for additional fluid resuscitation up to 30 mL/kg in the presence of persisting hypovolemia, or not (e.g., severe ventricular dysfunction). A therapeutic algorithm will allow standardized impact on ongoing management according to the hemodynamic profile identified by early echocardiography. After the completion of initial fluid resuscitation up to 30 mL/kg if required, a new echocardiographic assessment will be systematically performed by the same operator to stop or not fluid resuscitation, and to potentially initiate another treatment according to both the hemodynamic profile and clinical context.
48343370|NCT04580888|PROCEDURE|standards of care|In the control arm, patients will be treated according to standards of care based on current SSC recommendations, including a fluid resuscitation of 30 mL/kg.
48343371|NCT05412667|DIETARY_SUPPLEMENT|TWK10|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
48343372|NCT05412667|OTHER|Placebo|"1. 4 days without training: drink 2 hours before bedtime.~2. 3 days of training: drink within 30 minutes after training (uniformly brewed in the laboratory).~3. To analyze the amino acid concentration in blood, drink it immediately before blood collection."
48343373|NCT00045591|DRUG|celecoxib|100 mg PO bid
48343374|NCT00045591|DRUG|Celecoxib|400 mg PO bid
48343375|NCT01843205|DRUG|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
48343376|NCT01843205|DRUG|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
48343377|NCT00903994|DRUG|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
48343378|NCT02845999|BIOLOGICAL|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10\^6 ; 8.10\^6 and 12.10\^6 cells/kg of recipient body weight
48343379|NCT02845999|BIOLOGICAL|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
48343380|NCT02845999|DRUG|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
48657552|NCT05767086|DRUG|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
48657553|NCT05767086|DRUG|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
48513369|NCT02681211|DRUG|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
48513370|NCT02681211|DRUG|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
48343381|NCT02845999|DRUG|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
48657554|NCT05767086|DRUG|Dydrogesterone|clinical pregnancy rates
48657555|NCT03308474|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
48657556|NCT06354049|OTHER|Reiki|Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.
48343382|NCT02845999|DRUG|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
48343383|NCT03940014|OTHER|Data collection from standard follow up|"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."
47982324|NCT05820555|BEHAVIORAL|Timed evening technology and digital media use (tablet use)|timing of children's evening tablet device use relative to bedtime
48343384|NCT01301417|DEVICE|ColonRing™|Creation of a circular Compression Anastomosis
48343385|NCT05428540|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Polyphenol-rich capsules containing 1,200 mg of a combination of plant extracts rich in polyphenols. Frequency: 3 capsules a day. Duration: 12 weeks.
48657557|NCT06644040|DRUG|TeriQ Patch|"Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch"
48657558|NCT06644040|DRUG|Teribone Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
48343386|NCT05428540|OTHER|Placebo|Placebo
48343387|NCT01620593|DRUG|Placebo|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
48343388|NCT01620593|DRUG|Metformin|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
48343389|NCT01804660|OTHER|No study treatments administered|
48343390|NCT01650441|DRUG|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
48343391|NCT01650441|RADIATION|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
48343392|NCT04635345|OTHER|External Vibrator - patient-administered.|Patient provided with external vibrator for self-use, as well as vaginal dilators.
48343393|NCT04635345|OTHER|Standard care|Dilators, lidocaine topical gel, referral to psychotherapy, group therapy or womens health physio if required, self-help resources.
48343394|NCT00630708|DRUG|Benazepril|20 mg per day
48343395|NCT00630708|DRUG|Losartan|100 mg per day
48343396|NCT00630708|DRUG|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
48343397|NCT01942408|PROCEDURE|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
48657559|NCT06644040|DRUG|Forteo Inj.|"Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection"
48657560|NCT04169243|BEHAVIORAL|New Nordic Diet|The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.
47982325|NCT05820555|BEHAVIORAL|no technology and digital media use (screen media use)|no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)
47982326|NCT05620563|DRUG|LY3857210|Administered orally
47982327|NCT05620563|DRUG|Placebo|Administered orally
47982328|NCT02894918|DRUG|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
48002490|NCT01515683|BEHAVIORAL|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
48343398|NCT04477525|PROCEDURE|Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block|The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score \>5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
48343399|NCT04477525|DRUG|Bupivacaine Injection|20 cc of 0.25% bupivacaine will be injected
48343400|NCT03247010|OTHER|Blood sampling|Blood samples are taken before each cycle of Radium 223
48343401|NCT00003551|DRUG|aminocamptothecin colloidal dispersion|
48343402|NCT05133206|OTHER|Advice on fasting before the procedure|Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
48343403|NCT01337518|DRUG|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
48343404|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 175mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
48343405|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 350mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
48657561|NCT04169243|OTHER|Control|The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
48657562|NCT01234376|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy
48657563|NCT03368144|DEVICE|ClearLumen II Peripheral Thrombectomy System|Patients will be treated with the ClearLumen Peripheral Stent Graft System
48657564|NCT05417906|OTHER|Standard care|Oral prednisolone for 5 days
48657565|NCT05417906|OTHER|Eosinophil-directed care|Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
48657566|NCT03030755|OTHER|Optical coherence tomography|
48657567|NCT05085847|OTHER|Mindfulness meditation training|Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (\> 5 years each) experiences.
48657568|NCT05085847|OTHER|Active control|Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
48657569|NCT04211948|PROCEDURE|robotic surgery|Pancreatectomy with robotic assisted system
48657570|NCT04211948|PROCEDURE|open surgery|Traditional open pancreatectomy
48657571|NCT06503016|DRUG|Phosphocreatine|Administration of Phosphocreatine
48657572|NCT06503016|DRUG|Placebo|Saline solution of NaCl 0.9%
48657573|NCT02315950|OTHER|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
48657574|NCT04347109|DIAGNOSTIC_TEST|Non invasive epicardial mapping|Non invasive mapping using Cardio Insight system is performed in all included patients.
48657575|NCT05380947|DRUG|BI 1810631 - trial formulation 1 (TF1)|BI 1810631 - trial formulation 1 (TF1)
48657576|NCT05380947|DRUG|BI 1810631 - new formulation (NF)|BI 1810631 - new formulation (NF)
48657577|NCT05380947|DRUG|Rabeprazole sodium|Rabeprazole sodium
48657578|NCT05686122|BEHAVIORAL|PainPac|Patient-focused behavioral pain intervention delivered via mobile application.
48657579|NCT00712283|DRUG|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
48657580|NCT04832698|OTHER|Survey Administration|Complete survey
48657581|NCT06015516|DRUG|Minoxidil Tablets|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
48657582|NCT06015516|DRUG|Minoxidil topical solution 20 mg/ml|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
48657583|NCT00646230|DRUG|fenretinide|
48657584|NCT00646230|OTHER|high performance liquid chromatography|
48657585|NCT00646230|OTHER|pharmacological study|
48657586|NCT06600971|OTHER|acupressure application|The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week.
48657587|NCT04841148|DRUG|HCQ|600 mg tablets twice daily D1-28 of each 28-day cycle
48657588|NCT04841148|DRUG|Avelumab|10 mg/kg, IV, D1 and D15 of each 28-day cycle
48657589|NCT04841148|DRUG|Palbociclib|125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
48657590|NCT04649099|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
48657591|NCT05214573|DRUG|Glucagon like peptide 1 receptor agonist|Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication
48657592|NCT05214573|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor
48657593|NCT05214573|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Patients in the data who filled a dipeptidyl peptidase-4 inhibitor
48657594|NCT05214573|DRUG|Sulfonylurea|Patients in the data who filled a sulfonylurea
48657595|NCT00091156|DRUG|gefitinib|
48657596|NCT00091156|PROCEDURE|adjuvant therapy|
48657597|NCT05883787|OTHER|Exploration of a database|extraction of data
48657598|NCT06643130|DRUG|JW0104+C2402|For 8 weeks(PO (Per Oral), QD)
48657599|NCT06643130|DRUG|JW0104+C2403|For 8 weeks(PO, QD)
48657600|NCT06643130|DRUG|C2402|For 8 weeks(PO, QD)
48657601|NCT01080235|OTHER|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
48657602|NCT01080235|OTHER|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
48343406|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Asthma in Children|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
48500143|NCT04549103|OTHER|Baduanjin exercise program|Baduanjin (BDJ), also known as Eight-Section Brocades, is one of the forms of traditional Chinese Qigong exercises, characterized by symmetrical physical posture, movements, mindfulness, and breathing. Its primary focus is on the release of 'Qi' or internal body energy with the intent of improving health outcomes. BDJ encompasses eight simple movements involving combinations of postures, meditation, slow relaxing movements, and breathing exercises. It is a low intensity exercise, which have been found to improve range of motion, strength and general health. The simplicity and low intensity level is ideal for older adults to practice at home using instructional videos.
48500144|NCT01018589|OTHER|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
48500145|NCT01284621|DRUG|BI 10773|medium dose, oral administration
48500146|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
48500147|NCT01284621|DRUG|BI 10773|medium dose oral administration
48500148|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
48500149|NCT01284621|DRUG|Ramipril|Low dose oral administration on day 1
48657603|NCT05430321|OTHER|Assessment of physiological parameters|FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form
48657604|NCT05430321|OTHER|Assessment of Stress|Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
48657605|NCT05430321|OTHER|Assessment of Comfort|Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
48500150|NCT01284621|DRUG|Ramipril|Medium dose oral administration on day 2-5
48500151|NCT02789618|OTHER|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
48500152|NCT02789618|OTHER|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
48500153|NCT02789618|OTHER|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
48500154|NCT00317707|DRUG|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
48657606|NCT02446509|BEHAVIORAL|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
48657607|NCT02446509|BEHAVIORAL|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
48657608|NCT01648933|RADIATION|Rubidium PET|Myocardial Perfusion Imaging
48500155|NCT00317707|DRUG|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
48500156|NCT01229163|DEVICE|Automated Contingency Management (ACM) software|
48500157|NCT01235195|DRUG|sertraline hydrochloride|50 mg capsule, single-dose
48500158|NCT01235195|DRUG|sertraline hydrochloride|50 mg tablet, single-dose
48500159|NCT01654133|DEVICE|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft|Repair of thoracoabdominal aortic aneurysms
48500160|NCT01654133|DEVICE|Endovascular repair of ascending/arch aortic aneurysm using branched stent graft|Repair of ascending/arch aortic aneurysms
48500161|NCT04293328|DEVICE|orthokeratology|Nightly wear of orthokeratology lenses to correct vision in the daytime
48500162|NCT04293328|DEVICE|Menicon Progent A+B|Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
48343407|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
48343408|NCT03503812|BEHAVIORAL|Intervention (1) for outdoor exposure reduction - Atrial Fibrillation|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity"
48500163|NCT04706286|DRUG|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
48657609|NCT06638515|OTHER|Walking apnea at Low Lung Volume|Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
48657610|NCT06638515|OTHER|Walking at normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
48657611|NCT06571526|BEHAVIORAL|External focus|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to focus on a random series of digits ranging from 0 to 9 displayed on monitors placed at the immediate and future destinations of the walkway. Each number was displayed for at least 2 seconds to allow participants to have sufficient time to read them.
48657612|NCT06571526|BEHAVIORAL|Control|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to walk to the end of the walkway at your natural pace.
48657613|NCT04084366|DRUG|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
47982329|NCT03398291|PROCEDURE|Synchronous resection of primary pancreatic cancer and liver oligometastasis|Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
47982330|NCT03398291|DRUG|Standard chemotherapy|Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
47982331|NCT00612924|DEVICE|Anaconda Stent Graft System|Endovascular device
47982332|NCT00612924|DEVICE|Anaconda ONE-LOK Stent Graft System|Endovascular device
47982333|NCT03600610|DEVICE|gadolinium-enhanced cardiac MRI|cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping
48500164|NCT04706286|DRUG|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
48134763|NCT06699407|DRUG|Qishenyiqi dripping pills|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
48134764|NCT06699407|DRUG|Placebo|Placebo, 1 bag once, three times a day, 12 months
48500165|NCT03418090|DRUG|129Xe MRI|Evaluation of pulmonary function
48500166|NCT03418090|DRUG|133XE scintigraphy|Evaluation of pulmonary function
48500167|NCT03633734|DRUG|Sequential Treatment|One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
48657614|NCT04084366|DRUG|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
47982334|NCT00491998|DRUG|V1512|6 doses of IMP at 2-hourly intervals
47982335|NCT00491998|DRUG|V1512|3-hourly dosing
47982336|NCT00491998|DRUG|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
47982337|NCT00751829|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
48500168|NCT01399879|OTHER|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
48500169|NCT02627248|DRUG|Huaier Granule|20g tid, orally
48343409|NCT03503812|BEHAVIORAL|Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners."
48343410|NCT01494025|BEHAVIORAL|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
48343411|NCT00663104|BEHAVIORAL|exercise|exercise: 3 joint sessions/week for 12 months
48500170|NCT02627248|DRUG|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
48500171|NCT02627248|DRUG|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
48500172|NCT02627248|DRUG|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
48500173|NCT00724048|DRUG|ACR16|ACR16 will be administered per dose and schedule specified in the arm description.
48500174|NCT00724048|OTHER|Placebo|Placebo matching to ACR16 will be administered per schedule specified in the arm description.
48500175|NCT02132637|DRUG|Insulin Peglispro|Administered SQ
48500176|NCT02132637|DRUG|Insulin Glargine|Administered SQ
48500177|NCT05362734|BEHAVIORAL|obstetric outcomes after fresh versus cryopreserved embryo transfer|measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate
48657615|NCT06645431|BEHAVIORAL|Water Intake|Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.
48657616|NCT04076709|PROCEDURE|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
48657617|NCT06641973|DEVICE|Robotic balance rehabilitation with hunova® robotic platform|The G-Hun will perform robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to the services provided in their clinical pathway.
48500178|NCT04063436|DEVICE|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
48500179|NCT01505153|BIOLOGICAL|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
48500180|NCT02718508|BEHAVIORAL|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
48500181|NCT00369655|BIOLOGICAL|ziv-aflibercept|
48500182|NCT01045213|OTHER|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
48500183|NCT02337959|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
48500184|NCT02351583|DEVICE|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
48500185|NCT02351583|DEVICE|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
48500186|NCT04658017|DEVICE|GARNET device|Use of new filter in conjunction with standard of care dialysis.
48500187|NCT04966273|DEVICE|Microcatheter|Only to be used if Biosensor Microcatheter does not perform accordingly
48500188|NCT06155318|DIAGNOSTIC_TEST|68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included|Patients meeting the inclusion criteria will undergo 68Ga-DOTATOC PET(PET/MRI or PET/CT) as part of their routine work-up, according to the referral clinicians' indication.PET/MRI will be performed on a 3.0T time of flight PET/MRI. Simultaneous PET/MRI will start approximately 60 minutes after the injection of 68Ga-DOTATOC.
48500189|NCT06137690|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
48500190|NCT02016703|OTHER|Erythritol drink|
48500191|NCT02016703|OTHER|Placebo drink|
48513371|NCT02681211|DRUG|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL"
48513372|NCT03483363|DRUG|topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)|Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
48500192|NCT03256331|DRUG|BEL-X-HG|"This study will be carried out in 2 parts:~1. A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~2. A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~* Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~* Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~* Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~* Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2."
48343412|NCT00663104|BEHAVIORAL|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
48343413|NCT00663104|BEHAVIORAL|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
48343414|NCT04006067|OTHER|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
48343415|NCT04831593|OTHER|Group El|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
48343416|NCT04831593|OTHER|Group Em|Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
48343417|NCT00810043|DEVICE|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
48343418|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
48500193|NCT06213935|DRUG|Norepinephrine|after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
48343419|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
48343420|NCT03379441|DRUG|Pembrolizumab Injectable Product|Pembrolizumab Injectable Product 200 mg Q3W Intravenous
48343421|NCT02977507|OTHER|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
48343422|NCT02977507|DRUG|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
48343423|NCT02977507|OTHER|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
48343424|NCT02977507|OTHER|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
48343425|NCT02977507|OTHER|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
48343426|NCT04085692|BEHAVIORAL|Low-Dose, High-Frequency Simulation-Based Training|"Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback"
48343427|NCT00381589|DRUG|ipratropium bromide 0.03% spray|
48343428|NCT00324740|DRUG|vorinostat|Given orally
48343429|NCT00324740|DRUG|isotretinoin|Given orally
48343430|NCT03534791|OTHER|Reminders|Personalized email which will aim for reminding of the translator about the PLSs on hold.
48343431|NCT00928512|DRUG|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
48343432|NCT00928512|DRUG|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
48500194|NCT06213935|DRUG|Midodrine|10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
48343433|NCT00675688|DRUG|Bazedoxifene/Conjugate Estrogens (CE)|
48343434|NCT00675688|DRUG|Raloxifene|
48343435|NCT00675688|DRUG|Placebo|
48343436|NCT03739710|DRUG|Docetaxel|Docetaxel will be administered.
48500195|NCT04516759|DRUG|AZD1656|50mg film-coated tablets (at daily dose of 100mg BID)
48500196|NCT04516759|OTHER|Placebo|Matched placebo tablets
48500197|NCT05535985|DEVICE|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
48343437|NCT03739710|DRUG|Feladilimab|Feladilimab will be administered.
48500198|NCT05535985|DEVICE|placebo acupuncture|placebo acupuncture
48343438|NCT03739710|DRUG|Ipilimumab|Ipilimumab will be administered.
48343439|NCT03739710|DRUG|GSK4428859A|GSK4428859A/EOS884448 will be administered.
48343440|NCT03739710|DRUG|Dostarlimab|Dostarlimab will be administered.
48343441|NCT03739710|DRUG|GSK6097608|GSK6097608 will be administered.
47982338|NCT00751829|DRUG|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
48134772|NCT06699563|BEHAVIORAL|Mobilization Motivation Card|On the morning of the surgery, the Mobilization Motivation Card and Pedometer will be introduced and the patient will be informed. On the morning of the first postoperative day, before the patient's first mobilization, pain assessment will be made with the Visual Analog Scale (VAS), and the Mobilization Motivation Card will be hung at the bedside during the day and will help increase the patient's participation in mobilization. Later, after a pedometer is attached to the patient's waist, the patient will be mobilized.
48134773|NCT06700122|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D
48500199|NCT01561508|DRUG|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
48500200|NCT01561508|DIETARY_SUPPLEMENT|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
48134776|NCT06269731|BEHAVIORAL|Hamilton depression Rating Scale|also known as the Ham-D is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. Although the scale was designed for completion after an unstructured clinical interview, The scale has been translated into a number of languages including French, German, Italian, Thai , Turkish and Arabic version by Mostafa Lotfy.
48500201|NCT02539862|OTHER|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
48500202|NCT02539862|OTHER|psychoeducation|the psychoeducation is delivered by a doctor
48500203|NCT02439931|BEHAVIORAL|Remote psychosocial intervention|
48500204|NCT04663295|DEVICE|MiniMed™ 670G system|Hybrid closed loop insulin pump with associated CGM and blood glucose meter
48500205|NCT04576299|OTHER|Group 1|Survey about social networks, notification of adverse events, multidisciplinary teams, the doctor-patient relationship, the role of the ethics and patient safety committees, protocol compliance and suspension of outpatient procedures
48500206|NCT03468075|DRUG|Ascorbate|Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
48500207|NCT03468075|DRUG|Gemcitabine|Administered on Days 1, 8 and 15, after the infusion of ascorbate
48500208|NCT00022542|DRUG|ixabepilone|Given IV
48500209|NCT03508505|DEVICE|Venoarterial extracorporeal oxygenation|Veno-arterial extracorporeal oxygenation (VA-ECMO) is inserted in the acute setting in case of cardiac low output after adult cardiac surgery in order to provide cardiopulmonary support to recovery or as bridge to transplantation.
48343442|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
48343443|NCT02114060|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
48343444|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
48343445|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
48343446|NCT02114060|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
48343447|NCT02114060|BIOLOGICAL|Placebo|0.9% Normal Saline (NaCl)
48343448|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
48500210|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of parenchymal lung change cause|Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.
48500211|NCT04721444|DIAGNOSTIC_TEST|Machine Learning Classification of recurrence and non-recurrence|Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
48500212|NCT01570803|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
48657618|NCT03725592|OTHER|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
48657619|NCT03725592|BEHAVIORAL|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
48657620|NCT06082843|DRUG|Placebo|Placebo matching Avenciguat (BI 685509)
47982339|NCT03238508|PROCEDURE|Deferred stenting|Previously described
47982340|NCT00051402|DRUG|Isoflavones|
47982341|NCT05244577|DRUG|Olanzapine Tablets|Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
47982342|NCT05244577|DRUG|Placebo|Placebo,Ondansetron,Dexamethasone,Fosaprepitant
47982343|NCT01326416|DIETARY_SUPPLEMENT|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
48500213|NCT01570803|DEVICE|Complete SE Stent|same to SMART CONTROL Stent
48343449|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
48343450|NCT02658968|DRUG|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
48343451|NCT01095939|DRUG|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
48343452|NCT01095939|DRUG|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
48343453|NCT06401252|BEHAVIORAL|Mindfulness-based intervention|"• The mindful mediators are asked to act as neutral observers who view the world as it is, without reactions, judgments, and evaluations. They quietly attend to, note, and let go of every internal external stimulus such as thought, feeing, sensation, sound, idea that enters awareness. They do not try to think about, push away, and do anything with these stimuli experienced and do not have to figure out the connections between each 19 stimuli. They simply let each stimulus come and go and wait for the next stimulus. They do not have to be concerned about distractions. Each time they are distracted, they note it as yet another passing stimulus (Ah, a distraction... how interesting)"
48343454|NCT02653352|BEHAVIORAL|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
48343455|NCT04430699|DRUG|Cisplatin|Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.
48343456|NCT04430699|DRUG|Pembrolizumab|Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.
48343457|NCT04430699|RADIATION|Radiation Therapy|Standard of care radiation therapy 1x daily up to 8 weeks.
48343458|NCT03167125|OTHER|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
48343459|NCT03167125|OTHER|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
48500214|NCT06169189|BEHAVIORAL|global warming-climate change based education|The experimental group will be given 8 weeks of global warming-climate change based training. No intervention will be applied to the control group.
47982344|NCT01326416|OTHER|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
47982345|NCT03103633|PROCEDURE|mean artery pressure|mean artery pressure declined with less than 20% of baseline
48500215|NCT01751763|DRUG|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
48500216|NCT00148642|DEVICE|silver salts coated endotracheal tube|intubation with silver coated tube
48500217|NCT00148642|DEVICE|uncoated endotracheal tube|intubation
47982346|NCT03103633|PROCEDURE|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
48500218|NCT05136300|BEHAVIORAL|Pulmonary rehabilitation|"Patients in the intervention group will receive physical therapy, scheduled pain monitoring and coaching by a social worker.~The intensity of the rehabilitation training program will be determined separately for each patient by a steepramp and 1-repetition test within 3 weeks post-operative. The intervention group will be trained and educated in 2 sessions of 2 hours per week, for a period of 3 months."
48500219|NCT03283319|BIOLOGICAL|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
48500220|NCT03283319|BIOLOGICAL|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
48657621|NCT06082843|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
48500221|NCT03283319|BIOLOGICAL|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
48500222|NCT03283319|BIOLOGICAL|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
48657622|NCT05261126|DRUG|Enlicitide Decanoate|Enlicitide Decanoate administered orally
48657623|NCT05261126|DRUG|Placebo|Placebo matching enlicitide decanoate administered orally
48657624|NCT06643572|DEVICE|Virtual reality simulator|This virtual reality simulator allows for the simulation of a lumbar transforaminal epidural steroid injection using the patient's 3D lumbar images.
48657625|NCT02831049|BEHAVIORAL|Retrieval-extinction|Retrieval-extinction
48657626|NCT02831049|BEHAVIORAL|Extinction|extinction
48657627|NCT02831049|BEHAVIORAL|Retrieval|Retrieval
48657628|NCT06119477|OTHER|Bioceramic Putty Apical Plugs|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, then dried, and filled with Ca(OH)2 dressing. Afterward, the incisor will be temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. The Bioceramic Putty will be inserted in the apical 4 mm of the canal using the modified cannula and adapted to the canal walls with a hand plugger. The correct placement and thickness of the apical plug will be verified with a periapical radiograph. Afterward, the remainder of the root canal will be filled with gutta-percha with sealer. Finally, a suitable immediate final restoration was made for each case individually.
48657629|NCT06119477|OTHER|Single Cone Gutta-percha with Bioceramic Sealer|Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried. A large sized gutta-percha cone (GC) will be inserted to the working length, The GC was ensured to make tag-back with the apical third of the immature canal and confirmed with a periapical radiograph. Then the immature canal will be gently filled with Bioceramic sealer and the GC will be placed again and another apical radiograph will be taken to confirm that the canal was properly filled. Finally, a suitable immediate final restoration was made for each case individually.
48657630|NCT06119477|OTHER|Combination of Bioceramic Putty and Sealer|"Under local anesthesia and rubber dam isolation, the canal orifice will be prepared gently. The working length and apex diameter value will be recorded as a reference. Afterward, shaping and debridement the root canals will be achieved by gentle instrumentation. The canal will be irrigated copiously with NaOCl, dried, filled with Ca(OH)2 dressing and temporarily restored. After 14 days the temporary filling and Ca(OH)2 will be removed. Afterward, canals will be irrigated with NaOCl and EDTA and dried.~The immature canal will be gently filled with Bioceramic sealer and then 3 to 5 small balls of BP (diameter of 1 mm) will be inserted into the canal orifice and gently plugged with hand pluggers. Afterward, an apical radiograph will be taken to confirm that the canal was properly filled without gaps and voids. Finally, a suitable immediate final restoration was made for each case individually."
48657631|NCT03900650|BEHAVIORAL|High provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
48657632|NCT03900650|BEHAVIORAL|Low provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
48657633|NCT03900650|BEHAVIORAL|Alcoholic beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
48657634|NCT03900650|BEHAVIORAL|Non-alcoholic beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
48657635|NCT04921865|DEVICE|DPS VA-LCP® Clavicle Plate 2.7 System; DPS VA-LCP® Clavicle Hook Plate 2.7 System|"The DPS VA-LCP® Clavicle Plate 2.7 System is indicated for the fixation of clavicle bone fragments. The system consists of three plate types: lateral, shaft, and medial, each available in different sizes and materials (titanium alloy and stainless steel). Each plate is available in left and right.~The DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 System is indicated or the fixation of lateral clavicle fractures and AC joint dislocations. The Clavicle Hook Plate system consists of three plate types: long, short and button plates."
48657636|NCT05963984|DRUG|Samuraciclib|Samuraciclib tablet by mouth once a day
48657637|NCT05963984|DRUG|Fulvestrant|Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
48500223|NCT03283319|BIOLOGICAL|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
48500224|NCT02540759|DIETARY_SUPPLEMENT|Buglossoides oil|
48500225|NCT02540759|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|
48500226|NCT03673527|DRUG|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
48500227|NCT04831073|PROCEDURE|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
48500228|NCT00005634|DRUG|vorinostat|
48343460|NCT05178290|BEHAVIORAL|CHILD back-to-ECE COVID-19 saliva testing|Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
48343461|NCT05178290|BEHAVIORAL|ECE personnel back-to-ECE COVID-19 saliva screening|ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
48343462|NCT05178290|BEHAVIORAL|SAGE garden programming|The SAGE garden programming includes installation of a garden; teacher training via Zoom and/or short videos, a binder and website support along with other accompanying materials and teacher technical support (email, text, phone); gardening supplies and gear (e.g., hats, watering cans, gloves); and delivers active songs, games, science experiments and other outdoor learning opportunities.
48343463|NCT05666206|PROCEDURE|fibrin sealant in hypospadias|fibrin sealant will be used over the suture line
48343464|NCT04761952|DRUG|azathioprine|daily orally
48343465|NCT04761952|DRUG|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
48500229|NCT00521534|DEVICE|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
48500230|NCT05533762|DEVICE|arch insole and sham insole|children wear insoles on feet
48500231|NCT01906450|DRUG|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
48500232|NCT01906450|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
48500233|NCT01157806|RADIATION|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
48500234|NCT04851938|DEVICE|transcutaneous electrical nerve stimulation device|The application of transcutaneous electrical nerve stimulation is a nonpharmacological method that midwives can apply and determining the effect on these factors will be a guide for the future applications.
48500235|NCT00144261|DRUG|nevirapine|
48134793|NCT06699602|DRUG|Cemiplimab|cemiplimab IV flat
48343466|NCT04761952|DRUG|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
48343467|NCT04839406|BEHAVIORAL|Structured support of caregivers at the ICU|Structured support of caregivers at the ICU provided by a trained group of 10-15 ICU nurses
48343468|NCT00004852|DRUG|Efavirenz|
48343469|NCT00004852|DRUG|Lamivudine|
48343470|NCT00004852|DRUG|Zidovudine|
48343471|NCT01190020|DRUG|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
48500236|NCT03653910|DEVICE|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
48500237|NCT03653910|DEVICE|Macintosh|Macintosh is a traditional laryngoscope for intubation
48134794|NCT06699602|DRUG|Fianlimab|fianilmab IV flat
48500238|NCT00085475|DRUG|imatinib mesylate|
48500239|NCT00085475|PROCEDURE|conventional surgery|
48500240|NCT00859586|DEVICE|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
48500241|NCT05068453|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|OH2：less than 8mL/time，Q2W，i.t.；
48500242|NCT05068453|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|HX-008：200mg/time，Q3W，i.v.；
48500243|NCT05068453|RADIATION|RT|3 times radiation，totally 24-30 Gy for each lession.
48500244|NCT02249130|DRUG|Tipranavir (TPV)|
48500245|NCT02249130|DRUG|Ritonavir (RTV)|
48500246|NCT02249130|DRUG|Delavirdine (DLV)|
48500247|NCT02249130|DRUG|Zidovudine (ZDV)|
48500248|NCT02249130|DRUG|Lamivudine (3TC)|
48500249|NCT02249130|DRUG|Stavudine (d4T)|
48500250|NCT03710993|DEVICE|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
47982347|NCT03103633|PROCEDURE|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
47982348|NCT03103633|OTHER|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
47982349|NCT04519684|DRUG|Mesenchymal stem cells|Allogeneic bone marrow derived mesenchymal stem cells
48134798|NCT06696521|BEHAVIORAL|Intervention A- Telephone|For intervention A: Once a patient is randomized to telephone (Intervention A), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
48134799|NCT06696521|BEHAVIORAL|Intervention B- Televideo|For intervention B: Once a patient is randomized to televideo (Intervention B), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
48134800|NCT04104672|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
48134801|NCT04104672|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
48134802|NCT04104672|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
48134803|NCT04104672|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
48657638|NCT04697823|OTHER|use of hyaluronan-enriched transfer medium|In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium
48657639|NCT02956148|RADIATION|Radioligand [18F]MNI-659|The effective radiation dose for the injection of \[18F\]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
48657640|NCT04482920|DIAGNOSTIC_TEST|p-aminohippurate clearance study|To measure kidney blood flow, small doses of a substance called p-aminohippurate (PAH) are used.
48657641|NCT04482920|DIAGNOSTIC_TEST|Iohexol infusion|To measure glomerular filtration rate (GFR)
48657642|NCT05375929|DRUG|Abrocitinib 100 mg|Orally administered, abrocitinib 100 mg tablets QD
48657643|NCT05375929|DRUG|Abrocitinib 200 mg|Orally administered, abrocitinib 200 mg tablets QD.
48657644|NCT05807945|DRUG|Ropivacaine 0.75% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
48657645|NCT05807945|DRUG|Ropivacaine 0.2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
48657646|NCT04965064|DRUG|Capecitabine and Neratinib.|Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
48657647|NCT05918770|DIAGNOSTIC_TEST|systematic screening and early treatment|in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
48657648|NCT03507725|BEHAVIORAL|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
48657649|NCT03507725|PROCEDURE|Prostate Biopsy|Prostate needle biopsy under local anesthesia
47982350|NCT04519684|OTHER|Placebo|Normal Saline
47982351|NCT00192842|DRUG|curcumin (+ gemcitabine)|
47982352|NCT05855460|DIAGNOSTIC_TEST|Skin biopsy|biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
47982353|NCT04203784|OTHER|Plasma concentration measurements|Plasma concentration measurements
47982354|NCT06083116|DRUG|Hydrochlorothiazide、Henagliflozin Proline|Hydrochlorothiazide and Henagliflozin Proline
47982355|NCT02664454|OTHER|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
48657650|NCT03507725|BEHAVIORAL|Questionnaires|Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
48343472|NCT01190020|DRUG|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
48343473|NCT03209011|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
48343474|NCT02756546|DRUG|Cyclophosphamide|
48343475|NCT02756546|DRUG|Hydroxychloroquine|
48343476|NCT02756546|DRUG|Hydrocortisone|
48343477|NCT04645004|DRUG|Aspirin 81Mg Non-enteric coated Tab|one tab daily
48343478|NCT04568876|DIETARY_SUPPLEMENT|Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Micronized and ultra-micronized Palmitoylethanolamide is on the market in Italy as a Food for Special Medical Purposes
48343479|NCT04568876|COMBINATION_PRODUCT|Standard Therapy|Standard therapy established for individual patients
48657651|NCT06066333|RADIATION|Ablative Radiotherapy|All participants will first undergo ablative RT
48657652|NCT06066333|DRUG|Pembrolizumab|After completion of ablative RT, all subjects may begin pembrolizumab treatment
47982356|NCT01919125|DRUG|IDX719|IDX719 supplied as 50 mg tablets.
47982357|NCT01230268|OTHER|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
48343480|NCT04526704|DRUG|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
48343481|NCT01340404|PROCEDURE|Stem cell transplantation|Stem cell transplantation
48343482|NCT01340404|PROCEDURE|Transfusion program|Transfusion program
48343483|NCT04506281|DRUG|neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
48343484|NCT00073034|DRUG|EAA-090|
48343485|NCT03237429|DIAGNOSTIC_TEST|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
48343486|NCT06119555|DIETARY_SUPPLEMENT|Cinnamon Capsules|The intervention consists of four cinnamon capsules (each 1.5 grams, totaling 3 grams) a day, with two with breakfast and two with dinner for 60 days
48657653|NCT06258564|BIOLOGICAL|vaccination against human papillomavirus infection (HPV vaccination)|Women with or without HPV vaccination before or after excision
48657654|NCT06439524|DRUG|40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate|if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
48500251|NCT02784353|BEHAVIORAL|Perioperative rehabilitation program|"Perioperative rehabilitation program~* preoperative rehabilitation : 2 weeks prior to operation~* postoperative rehabilitation : 3 months after operation"
47982358|NCT06372782|DEVICE|Restylane Skinboosters Vital Lidocaine|Each subject will receive treatment on Day 1 with Restylane Skinboosters Vital Lidocaine in one hand and Restylane Vital in the opposite hand, as randomly assigned.
47982359|NCT06372782|DEVICE|Restylane Vital|Each subject will receive treatment on Day 1 with Restylane Vital in one hand and the experimental device in the opposite hand, as randomly assigned
47982360|NCT05076526|BIOLOGICAL|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~* NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~* Sorbitol: 40mg/mL~* Molecular weight of 2MDa, sterilized in moist heat"
48500252|NCT02784353|BEHAVIORAL|Conventional|conventional perioperative management without rehabilitation program
48500253|NCT04447950|PROCEDURE|Type 2/posterior Quadratus Lumborum block|Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
48002491|NCT01331616|DRUG|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
48002492|NCT00439556|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
48500254|NCT04447950|PROCEDURE|Placebo block with Saline|Injection of saline into posterior boundary of Quadratus Lumborum muscle.
48657655|NCT06621277|OTHER|No intervention|No intervention
48657656|NCT06621277|OTHER|Tailored counseling programs (Phase 2)|Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)
48657657|NCT05724030|DEVICE|integrated pulmonary index|integarted pumobary index monitoring
48657658|NCT05724030|DEVICE|saturation|saturation monitorization
48657659|NCT06496477|DEVICE|Ayo wearable|Primary study device - the Ayo wearable which are glasses that emit either bright blue-spectrum white light or dim blue-spectrum white light or Mini motion logger AAM-32 - an actigraphy device work during the first and last week of the study on the participants wrist throughout most of the day, measuring activity. This will be used as an indicator of sleep.
48657660|NCT05213221|DRUG|Envafolimab|300mg, subcutaneous injection, q3w
48657661|NCT05213221|PROCEDURE|TACE|The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
48657662|NCT05213221|DRUG|Lenvatinib|8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
48657663|NCT05358223|OTHER|Music|A standard music determined by us for the 1st and 4th groups will be played during the process.
48657664|NCT05358223|DEVICE|TENS|TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
48657665|NCT03140969|DRUG|QR-110|RNA antisense oligonucleotide for intravitreal injection
48657666|NCT04280380|DIAGNOSTIC_TEST|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with \>500 copies/mL of plasma will be considered positive.
48657667|NCT00091975|DRUG|Zemplar Capsule|
48657668|NCT05694611|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
48343487|NCT00735098|OTHER|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
48657669|NCT05694611|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
48657670|NCT06126172|DIAGNOSTIC_TEST|Multiparametric magnetic resonance imaging (mpMRI)|Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
48657671|NCT05810597|DRUG|Tirzepatide|Administered SC
48657672|NCT05810597|DEVICE|Single Dose Pen|Used to administer tirzepatide SC
48657673|NCT05810597|DEVICE|Multi-use Prefilled Pen|Used to administer tirzepatide SC
48657674|NCT06637683|COMBINATION_PRODUCT|LiveSpo COLON|LiveSpo® COLON has a registration number: 10401/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
48657675|NCT06637683|OTHER|Routine treatment|The standard internal medicine treatment protocol of the hospital
48343488|NCT00735098|OTHER|strength training exercise|strength training exercise, 3 times per week for 8 weeks
48343489|NCT00735098|OTHER|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
48343490|NCT00735098|OTHER|Control group|8 week control group
48343491|NCT05620173|DEVICE|Vedea Amblyopia Therapy (VAT)|Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
48343492|NCT05620173|DEVICE|Occlusion therapy|Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
48657676|NCT04979143|PROCEDURE|Surgical Approach|The surgical laser used will be randomized. All lasers used during this trial are all FDA approved devices and used per routine clinical care.
48657677|NCT02087852|OTHER|salvia for germline DNA|
48657678|NCT02087852|BEHAVIORAL|the Kidney Cancer Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
48657679|NCT02087852|BEHAVIORAL|Family History Questionnaire (when applicable)|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
48657680|NCT02087852|OTHER|Blood draw|
48343493|NCT04459104|OTHER|Low glycemic load|Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
48343494|NCT04459104|OTHER|High glycemic load|Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
48343495|NCT00625014|DRUG|Haloperidol|Haloperidol 3 mg/day for 8 days
48343496|NCT03896906|DEVICE|High-flow nasal cannula|Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher \& Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
48343497|NCT03896906|DEVICE|simple mask|Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
48657681|NCT02087852|BEHAVIORAL|Epidemiologic Questionnaire|Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
48657682|NCT05613946|DRUG|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
48657683|NCT05613946|DRUG|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
48657684|NCT05613946|DRUG|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
48657685|NCT00205322|DRUG|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
48657686|NCT06644703|OTHER|Cryotherapy|The pulpotomy area was irrigated with 2 °C saline solution for 5 minutes in cryotherapy group.
48657687|NCT06643715|DEVICE|PANDA PLUS|Using the PANDA PLUS model to assist in image interpretation, radiologists are provided with the model's output classification-non-PDAC, PDAC, or normal-alongside the initial CT image assessment. The radiologists then integrate the information from both the PANDA PLUS output and the original image interpretation to formulate the final report.
48657688|NCT06067139|OTHER|SHUTi|"Each core includes a variety of interactive features, such as animations, vignettes, myth and reality buttons that reveal common misperceptions and facts about sleep, learn more buttons that provide in-depth information about a topic, and quizzes. All cores follow a similar structure with objectives, main content, homework, and review. Participants are free to revisit cores as many times as they like."
48657689|NCT06067139|OTHER|Patient Education|The PE website will present content in a simple, static form, without interactive components; and all content on the website will be provided at once, rather than in modules that unlock over time. The PE website will also not provide personalized or individually tailored treatment recommendations.
48343498|NCT04905810|DRUG|Azacitidine|Given IV
48343499|NCT04905810|DRUG|Decitabine|Given IV
48343500|NCT04905810|DRUG|Venetoclax|Given PO
48343501|NCT05132101|DRUG|Patients who received Palbociclib as first line therapy in MBC setting|Patients who received Palbociclib as first line therapy in MBC setting
48343502|NCT05229588|DRUG|Lurbinectedin 4 MG Injection [Zepzelca]|"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."
48343503|NCT05592158|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
48343504|NCT02515188|DRUG|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
48513373|NCT03483363|DRUG|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure.
48343505|NCT02515188|DRUG|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
48343506|NCT05703113|BEHAVIORAL|Web 2.0 tools|Education with Web 2.0 tools
48343507|NCT05193604|DRUG|TQB2858 injection|TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
48513374|NCT03483363|DRUG|intravenous (IV) prophylactic antibiotic|All arms with receive standard parenteral (IV) prophylactic antibiotic.
48343508|NCT05193604|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
48343509|NCT05193604|DRUG|Gemcitabine hydrochloride for injection|Chemotherapy medicine for metastatic pancreatic cancer
48343510|NCT05193604|DRUG|Paclitaxel for injection (albumin bound)|Chemotherapy medicine for metastatic pancreatic cancer
48343511|NCT01175590|DRUG|Besivance|Ocular administration to affected eye for 7 days
48343512|NCT01175590|DRUG|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
48343513|NCT05432895|DEVICE|Dynamic splint|Device treats plantar fasciitis and replacing boot immobilization which is quite benign
48343514|NCT03907813|DRUG|Exparel|liposomal bupivacaine wound infiltration
48343515|NCT03907813|OTHER|Saline infiltration|saline wound infiltration
48343516|NCT05587634|BEHAVIORAL|Virtual Peer Health Coaching|"Intervention arm: weekly sessions (\~30 min each session) of physical activity counseling with an assigned peer health coach over the course of 12 weeks. The focus of the initial 2 calls is on rapport development and trust building with a focus around PA with discussion of physical activity goals and motives, where possible. The remainder of the call sessions follow a standardized format of a 30-minute call to 1) review the previous week, 2) integrate motivational strategies, and 3) develop action and support plans for the next week. The final call format includes a summary and evaluation of the intervention, discussion of short- and long-term goals, and relapse prevention strategies. Sessions guided by a call tracking form.~These participants receive an adaptive physical activity local guide including information on local adaptive sports opportunities, which the control group also receives."
48343517|NCT05476380|DRUG|camrelizumab|Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
48343518|NCT01596192|OTHER|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
48343519|NCT01802541|DIETARY_SUPPLEMENT|diacylglycerol oil|
48343520|NCT01802541|DIETARY_SUPPLEMENT|triacylglycerol oil|
48343521|NCT00250068|DRUG|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
48343522|NCT05203003|OTHER|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
48343523|NCT05305976|OTHER|Telerehabilitation|The 8 week exercise program with telerehabilitation
48343524|NCT05316519|OTHER|Transcutaneous Vagus Nerve Stimulation|Visuomotor task training with transcutaneous stimulation targeting landmark that activates biomarker
48343525|NCT02868099|DRUG|Romiplostim|
48343526|NCT02868099|DRUG|Placebo|
48343527|NCT01024660|DRUG|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
48343528|NCT01024660|DRUG|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
48343529|NCT01024660|DRUG|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
48343530|NCT04115527|PROCEDURE|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
48343531|NCT04115527|PROCEDURE|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
48343532|NCT04205110|DIAGNOSTIC_TEST|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
48657690|NCT06643923|OTHER|Exercise|"F (Frequency): 3 days per week, with a total of 24 sessions. I (Intensity): Low to moderate intensity exercises with progression, ensuring no fatigue is induced.~T (Time): Each session will last 30 minutes, over a total period of 8 weeks.~T (Type):~Warm-up exercises Core stabilization exercises: Aimed at improving core stability. Cool-down exercises E (Enjoyment): Gamified exercises, with sessions conducted to music. A (Adherence): A follow-up system will be implemented, including reminder notes and regular sending of session links to ensure compliance."
48343533|NCT03119922|OTHER|No intervention|
48343534|NCT00961558|PROCEDURE|Varicocelectomy|Varicocelectomy
48343535|NCT04127461|DEVICE|Medtronic endoscope|The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
48343536|NCT02583711|DEVICE|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
48343537|NCT05722977|DRUG|Surufatinib + envafolimab|Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
48343538|NCT00530491|PROCEDURE|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
48343539|NCT05288855|DRUG|Voclosporin|calcineurin inhibitor
48343540|NCT05288855|DRUG|Placebo Oral Capsule|matching placebo capsule
48343541|NCT00554255|DRUG|SB751689|
48343542|NCT04220710|DIAGNOSTIC_TEST|DNA extraction and methylation detection|DNA extraction and methylation detection
48343543|NCT00130468|DRUG|Hyalgan (sodium hyaluronate)|
48343544|NCT05212376|OTHER|Foot massage|"Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days."
48343545|NCT04569760|DRUG|50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|Oral cannabinoid oil preparation dosed in 1ml increments
48343546|NCT04569760|DRUG|Placebo Oil|Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
48343547|NCT01006213|BEHAVIORAL|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
48343548|NCT00493467|DRUG|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
48343549|NCT00493467|DRUG|Rituximab|250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.
48343550|NCT05355818|DRUG|Delgocitinib|Cream for topical application
48343551|NCT05355818|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
48343552|NCT03182153|DEVICE|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
48343553|NCT02253628|OTHER|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
48343554|NCT02253628|OTHER|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
48343555|NCT02253628|OTHER|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
48343556|NCT02253628|OTHER|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
48343557|NCT05254587|DEVICE|IOLMASTER 700 TK|4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
48343558|NCT03341234|DRUG|Bupivacaine|30 ml %0,25 bupivacaine
48343559|NCT03341234|DRUG|Saline|2 ml saline subcutaneously
48002493|NCT00439556|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
48002494|NCT00439556|DRUG|Bortezomib|Given IV
48343560|NCT03341234|DEVICE|Ultrasound|Ultrasound guided block
48343561|NCT05299645|BEHAVIORAL|Interview|Pilot study with digital browsers
48343562|NCT00661167|DRUG|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
48343563|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
48343564|NCT03464890|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
48343565|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO - PLACEBO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
48343566|NCT03464890|OTHER|Untreated control area|Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
48500255|NCT05918731|BEHAVIORAL|Self Management|"A training book was given to this group, which was created for the study. The implementation process followed a five-step approach including sessions once a month for five consecutive months with a coach and follow-up phone calls after the end of the sessions.To inspire and engage patients, the sessions included a variety of educational techniques, including knowledge transfer, discussion, hands-on training, and homework. Additionally, coaches received training in motivational interviewing methods. The self-management program and all the process of data collection is described in detail on the supplementary file."
48500256|NCT02951091|OTHER|biomarker screening|immunohistochemistry and in situ hybridization
48002495|NCT00439556|DRUG|Carmustine|Given IV
48002496|NCT00439556|DRUG|Cytarabine|Given IV
48002497|NCT00439556|DRUG|Etoposide|Given IV
48343567|NCT01507571|OTHER|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~1. a tape-recorded session with the patient using the DT question protocol~2. Transcription of the interview, which is then edited~3. A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
48134804|NCT06697431|DRUG|Anakinra|"Patients who fulfill the eligibility criteria a will be randomized 1:1 to receive either~1. IVIG 2g/kg administered in 10-12 hours as per local standard of care (standard treatment) OR~2. Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day (investigational treatment)~Patients showing fever, between 36 hours and 72 hours from the end of first line treatment will be considered failures. Failures from the investigational treatment arm will receive a dose of IVIG and they will drop from the study.~Children who remained afebrile between the 36th and 72nd hour will be considered as responders, and they will proceed into the study.~Patients in the standard treatment arm will continue ancillary treatment and follow-up .~Patients in the investigational treatment arm will enter the tapering phase."
48343568|NCT01963780|DEVICE|OCS Lung Preservation|
48343569|NCT00116194|BEHAVIORAL|Physical Activity|
48500257|NCT06064019|DEVICE|Nevisense|The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
48500258|NCT02549235|OTHER|Ultrasound|Routine 2D/3D ultrasound assessment
48500259|NCT04153383|DRUG|Milrinone Injection|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
48500260|NCT02345629|PROCEDURE|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
48500261|NCT02345629|BEHAVIORAL|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
48500262|NCT02345629|PROCEDURE|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
48343570|NCT06233838|DEVICE|KHA80 hemoperfusion treatment|On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
48343571|NCT04742036|DRUG|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
48500263|NCT02345629|PROCEDURE|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
48500264|NCT05418530|OTHER|with pause- without pause|start with pause expiration
48343572|NCT04742036|DRUG|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
48343573|NCT04208880|BEHAVIORAL|TBH Brain Workout 1.0|TBH Brain Workout program with easy challenge activities.
48343574|NCT04208880|BEHAVIORAL|Brain Health Book Club|Each week a new chapter will be read that contains new information to enhance brain health.
48343575|NCT04208880|BEHAVIORAL|TBH Brain Workout 2.0|TBH Brain Workout program with moderately difficult challenge activities.
48500265|NCT05418530|OTHER|without pause-with pause|start without pause expiration
48657691|NCT06643923|BEHAVIORAL|Urotherapy|The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.
48134805|NCT06697431|DRUG|Intravenous Immunoglobulins, Human|see previous section
48657692|NCT06399094|OTHER|Lung sound recordings|The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.
48657693|NCT05848570|OTHER|Keeping it LITE|observational cohort only
48500266|NCT05894967|BEHAVIORAL|C1 - Standard Perceptual Learning (SPL)|Each trial starts with a fixation point (500ms) after which a Gabor (1° radius, at cut-off SF of 25% accuracy, estimated from Pre-Test CSF, at either 45° or 135°) appears for 128ms. The task is to indicate whether the Gabor was tilted left or right. Gabor contrast will be controlled by a 3/1 staircase (converging on approximately \~80% contrast threshold) across all training sessions.
48343576|NCT04208880|BEHAVIORAL|TBH Memory 1.0|TBH Memory program with easy challenge activities.
48343577|NCT04208880|BEHAVIORAL|TBH Memory 2.0|TBH Memory program with moderately difficult challenge activities
48500267|NCT05894967|BEHAVIORAL|C2 - Long Training (LT)|Will be the same as the SPL with the exception that each session in LT will be twice as long as in SPL.
48134808|NCT06697405|OTHER|Prolonged ≥ 120 minutes|No intervention, regular therapy
48134809|NCT06697132|PROCEDURE|laparoscopic dismembered pyeloplasty|Modified antegrade stenting in laparoscopic pediatric pyeloplasty
48134810|NCT05931406|BEHAVIORAL|Control|A normal working day from of 12h
48134811|NCT05931406|BEHAVIORAL|Sit-and-stand desk|a working day during which the participants have to get up at least 5 min/hour
48134812|NCT05931406|BEHAVIORAL|Cycloergometer|a working day during which they can use a cycloergometer installed under the desk
48500268|NCT05894967|BEHAVIORAL|C3 - Short Staircases (SS)|"Will be largely the same as SPL with the only difference being a change to the adaptive procedure. SS will use so-called short-staircases, which are initialized at 60% contrast with steps of .05 log units and employs a 3/1 staircase that after every 40 trials is reset (the short in short-staircases) back to 60% contrast."
48500269|NCT05894967|BEHAVIORAL|C4 - Mixed Difficulty (MD)|This condition will be identical to SPL with the exception that two staircases - one a 2/1 staircase producing difficulties centered around 60-70% accuracy, the other a 4/1 staircase producing difficulties centered around 85-95% accuracy - will be utilized to control the stimuli.
48500270|NCT05894967|BEHAVIORAL|C5 - Noise Training (NT)|The NT condition will be the same as SPL with the exception that contrast thresholds will be estimated in 5-different levels of external noise (10%, 15%, 20%, 25%, 30%).
48134816|NCT06631183|BEHAVIORAL|Self-help information based on principles of behavioral activation|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on behavioral activation and physical activity.
48134817|NCT06631183|BEHAVIORAL|Self-help information based on principles of cognitive restructuring|Participants will engage with the self-help tool e-couch (https://ecouch.com.au). In the first week, they will complete the depression information submodule from the depression program. Over the following four weeks, they will complete submodules on cognitive restructuring.
48657694|NCT04720807|DRUG|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
48134820|NCT06223633|DEVICE|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
48343578|NCT00703430|DRUG|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
48343579|NCT03704389|BEHAVIORAL|Clinical decision support|Clinical decision support nudges within the electronic health record
48343580|NCT03158090|PROCEDURE|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
48343581|NCT03158090|DRUG|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
48343582|NCT03158090|RADIATION|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
48343583|NCT01470365|PROCEDURE|quality-of-life assessment|Ancillary studies
48343584|NCT01470365|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48134821|NCT06692998|OTHER|Rehabilitation|Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
48343585|NCT01470365|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
48343586|NCT01581996|DRUG|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
48343587|NCT06187285|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
48343588|NCT06187285|DRUG|Sitagliptin 100mg|Patient will get Sitagliptin 100 mg
48343589|NCT03082807|DIETARY_SUPPLEMENT|NCDsport|Negative Calorie Diet supplemented with exercise
48343590|NCT03082807|DIETARY_SUPPLEMENT|LCDsport|Low-Calorie diet with exercise
48343591|NCT03039049|DRUG|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
48343592|NCT04994522|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
48343593|NCT00937001|PROCEDURE|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
48343594|NCT05572541|DIAGNOSTIC_TEST|Fonseca questionnaire|Fonseca questionnaire for the evaluation of temporomandibular dysfunction
48343595|NCT04836923|BEHAVIORAL|"LIver FrailTy intervention (LIFT)"|Novel physical therapy intervention to decrease frailty in pre-transplant patients
48343596|NCT04836923|BEHAVIORAL|"Realistic Effort Action Planning intervention (REAP)"|This intervention is an interactive behavioral interviewing process to engage patients in their care
48343597|NCT00443625|DRUG|SK3530|
48513375|NCT03750292|DEVICE|HEPAirX air filter|It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
48657695|NCT00951639|DIETARY_SUPPLEMENT|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
48657696|NCT00951639|PROCEDURE|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
48343598|NCT01770145|DRUG|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
48343599|NCT01770145|DRUG|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
48343600|NCT01770145|DRUG|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
48343601|NCT01611922|OTHER|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
48343602|NCT01611922|DEVICE|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
48343603|NCT05899894|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
48343604|NCT01507623|DEVICE|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation\* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~\*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
48343605|NCT03672669|GENETIC|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
48343606|NCT03672669|GENETIC|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
48343607|NCT05171855|DRUG|Lonapegsomatropin|Study participants are individually dosed with subcutaneous injection of Lonapegsomatropin once-weekly for 52 weeks
48343608|NCT02228772|DRUG|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
48343609|NCT02228772|DRUG|Vincristine|Standard chemotherapy dosage and duration
48343610|NCT02228772|DRUG|Cytarabine|Standard chemotherapy dosage and duration
48343611|NCT02228772|DRUG|Doxorubicin|Standard chemotherapy dosage and duration
48343612|NCT02228772|DRUG|Mercaptopurine|Standard chemotherapy dosage and duration
48343613|NCT02228772|DRUG|Cyclophosphamide|Standard chemotherapy dosage and duration
48343614|NCT02228772|DRUG|Methotrexate|Standard chemotherapy dosage and duration
48343615|NCT05132595|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
48657697|NCT00951639|DIETARY_SUPPLEMENT|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
48343616|NCT05132595|DRUG|Esketamine at high dose|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
48343617|NCT05132595|DRUG|Esketamine at low dose|After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
48343618|NCT05132595|DRUG|Ketorolac at high dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
48343619|NCT05132595|DRUG|Ketorolac at low dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
48343620|NCT05033678|DEVICE|Diagnostic algorithms|Assessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case.
48343621|NCT00301470|DEVICE|MR urography|undergoing both renal scintigraphy and MR within a month
48343622|NCT00469872|PROCEDURE|Context-focused compared to child-focused interventions|
48343623|NCT04287439|BEHAVIORAL|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
48343624|NCT04287439|BEHAVIORAL|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
48343625|NCT04287439|OTHER|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
48500271|NCT05894967|BEHAVIORAL|C6 - Training with Flankers (TWF)|TWF will be reasonably different from the standard SPL task. Here, on 50% of trials a target Gabor will be presented at either 45° or 135° (as in SPL) and will be flanked by two collinear Gabors. On the remaining 50% of trials, flankers will be present without a target. TWF is thus a yes/no detection task, which is necessary since the collinear flankers fully indicate the target orientation. In different 20-trial mini-blocks the flankers will appear either lambda, 1.5 lambda, or 2 lambda from the target (i.e., closer or further from the target) and target contrast will be controlled by a 3/1 staircase separately for each spacing.
48500272|NCT05894967|BEHAVIORAL|C7 - Parafoveal Training (PT)|The PT condition is the baseline for C8-C11 (all of which involve parafoveally presented targets). In PT, we utilize the same task as in SPL, however, in PT, in addition to central training, targets will also appear in one of two peripheral locations (5° eccentricity; angles = 135° and 270°). The location of targets will be randomized trial-wise so as to discourage eye-movements and independent 3/1 staircases will be run at each location. By training only 2 peripheral locations we can measure the extent to which training gives rise to location transfer (e.g., in transfer tasks examining performance at 8 different locations - 2 trained locations and 6 untrained locations). Furthermore, training at the central location facilitates comparisons between PT and SPL.
48343626|NCT02997774|OTHER|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
48134838|NCT06180070|DRUG|Ibuprofen/ Paracetamol tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
48134839|NCT06180070|DRUG|Nuromol® tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
48134840|NCT06622226|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally.
48134842|NCT05473663|DEVICE|Radiofrequency Ablation|Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
48134843|NCT05473663|DEVICE|Sham|Is performed identically to the active treatment but without the application of the RFA current
48134844|NCT06683157|DIAGNOSTIC_TEST|not drug|"Patients presenting with symptomatic ICVT will be examined by CCUS for both legs. Inclusion/exclusion criteria will be checked. No anticoagulation therapy is given. Compression stockings at the calf length will be prescribed for 30 days.~CCUS will be repeated on day 5±2, day 10±2, and day 30±4. If the ICVT has propagated into the trifurcation area, the popliteal vein, or into more proximal veins therapy will be implemented according to current guidelines for proximal DVT. If no propagation to proximal veins has occurred anticoagulation will be withheld further on."
48134847|NCT06681350|DEVICE|Ocular surface imaging|Telemedical examination of high-resolution, all-in-focus images of the cornea, sclera, conjunctiva, and lid margins for montioring of postoperative complications
48134848|NCT05464498|DEVICE|MD-Tissue Collagen Medical Device|"MD-Tissue (GUNA, Milan-Italy) Composition per 2 ml: collagen 100 micrograms Excipients: Ascorbic acid, Magnesium gluconate, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, NaCl, Water for injection.~Subjects will be treated with No. 6 peri-tendon injections (2 infiltrations per week for three weeks)."
48134849|NCT05464498|OTHER|eccentric strengthening protocol|Group B which, will implement only physiotherapy (eccentric strengthening protocol)
48343627|NCT02997774|OTHER|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
48134850|NCT06621186|OTHER|No intervention measures|No intervention measures
48343628|NCT03634176|DIAGNOSTIC_TEST|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
48500273|NCT05894967|BEHAVIORAL|C8 - Stimulus Variety (SV)|"The base task for SV is the PT condition. However, SV employ 20 trial mini-blocks of different SFs (.75, 1.5, 3, 6, 12, 24 cpd) and locations (45°, 135°, 225°, 315° - i.e., more locations than PT, but not the full set tested in the transfer battery) with separate staircases for each SF and location. Orientations will also be drawn from a larger set (22.5°, 45°, 67.5° - for which participants respond clockwise and 112.5°, 135°, 157.5° - for which participants respond counter-clockwise) and will vary on a trial-by-trial basis. This design holds-out 4 locations and 2 orientations to address transfer."
48343629|NCT06109129|DEVICE|EXOPULSE Mollii Suit|EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
48343630|NCT01830244|DRUG|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
48343631|NCT03633513|DIAGNOSTIC_TEST|LBT-3627|Immunomodulatory agent
48343632|NCT03633513|DIAGNOSTIC_TEST|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
48343633|NCT03999385|BEHAVIORAL|Mindful Self-Compassion (MSC)|The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
48343634|NCT04682106|DRUG|LY3493269|Administered orally.
48343635|NCT04682106|DRUG|Placebo|Administered orally.
48343636|NCT02758041|DEVICE|Sebacia Microparticles|
48343637|NCT04128618|DEVICE|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
48343638|NCT05882123|OTHER|cerebral microbleeds|Whether patients with acute ischemic stroke are complicated by cerebral microbleeds
48500274|NCT05894967|BEHAVIORAL|C8a - Complex Features (CF)|This is the same as C8, however we will use band-pass filtered stimuli similar to what has been done by a number of groups including Hussein et al.
48500275|NCT05894967|BEHAVIORAL|C9 - Exogenous Attention Training (ExAT)|Stimuli will be presented in a similar manner as in PT. However, in ExAT, a 100% valid cue, a small black dot - 48ms duration with an 96ms SOA prior to stimulus onset - will appear above the target location on each trial.
48500276|NCT05894967|BEHAVIORAL|C10 - Endogenous Attention Training (EnAT)|Stimuli will be presented in a similar manner as in PT. However, in EnAT, a 100% valid cue (letter UL, LR; standing for upper left and lower right, respectively) - 150ms duration with an 500ms SOA prior to stimulus onset - will appear at the fixation point.
48500277|NCT05894967|BEHAVIORAL|C11 - Multisensory Facilitation (MF)|MF utilizes the same basic task structure as in ExEAT, however, rather than a visual cue, an auditory cue will be used (50ms, 1000hz tone with sound location determined by convolving sound with generic head-related transfer function, kemar large ears.
48500278|NCT05894967|BEHAVIORAL|No Contact Control|"While not a training condition one type of experience that could be part of a condition is a no contact control (i.e., where participants do no training activities over the same rough time span as for the other training tasks)."
48500279|NCT05379049|BIOLOGICAL|Infliximab: Adalimumab; Etanercept;|Therapeutic drug monitoring, evaluation of clinical outcomes and laboratory analysis of biomarkers
48513376|NCT03750292|DEVICE|control air filter|A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
48513377|NCT00154518|PROCEDURE|Orthodontic treatment|
48657698|NCT05709327|OTHER|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
48657699|NCT05712681|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
48657700|NCT05712681|DRUG|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
48657701|NCT05320809|BIOLOGICAL|3D189|"3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient.~A maximum of 15 total injections of 3D189 will be administered as follows:~1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment.~2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment.~3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52)."
48134854|NCT06619847|DRUG|VX-993|Tablets for oral administration.
48134855|NCT06619847|DRUG|HB/APAP|Capsules for oral administration.
48134856|NCT06619847|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
48343639|NCT04880993|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
48343640|NCT04880993|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
48343641|NCT00028795|DRUG|temozolomide|
48343642|NCT00028795|PROCEDURE|adjuvant therapy|
48343643|NCT00028795|RADIATION|radiation therapy|
48343644|NCT00591175|BEHAVIORAL|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
48343645|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
48343646|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
48343647|NCT02795455|BEHAVIORAL|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
48500280|NCT04902092|BEHAVIORAL|High Intensity Interval Training|Exercise sessions will commence with an initial 3-week accustomization period whereby training load will increase incrementally from 2 x 45min sessions with effort peaking at 60% VO2 max (week 1) increasing to 3 x 45minute with effort peaking at 80% VO2max (week 3). Participants will transition to the full HIIT protocol for the remaining weeks. The HIIT component will comprise a work-rest ratio of ≥1:1minutes, with alternating exertion epochs at \>80% VO2max and \<60% VO2max. As VO2max is likely to increase as fitness improves toward the end of the 3-month program, adjustments to HIIT will be made by the exercise physiologist based on real-time heart rate monitoring, ensuring greater accuracy in participants achieving their heart rate targets.
48500281|NCT04902092|BEHAVIORAL|Strength and Resistance Training|Exercise sessions will comprise a combination of strength, coordination and mobility exercises. The strength component will consist of 2-3 sets of resistance exercises at ≤70% of a predicted 1 repetition maximum, targeting all body segments. Heart rate tracking will occur to ensure participants do not exceed 70% v02 (or exceed Lactate Threshold).
48343648|NCT02795455|BEHAVIORAL|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
48343649|NCT02795455|DIETARY_SUPPLEMENT|meal replacement shake|
48343650|NCT00010803|DRUG|Ginkgo biloba|120mg twice a day
48343651|NCT00010803|DRUG|Placebo|One pill twice daily
48343652|NCT05391620|OTHER|Cardiac rehabilitation with 3/7 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3/7 method 3 rep (15 sec of rest), 4 rep (15 sec), 5 rep (15 sec), 6 rep (15 sec), 7 rep. (total volume : 25 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned."
48343653|NCT05391620|OTHER|Cardiac rehabilitation with 3X9 method|"HIIT ( 2 min 80% wmax: 2 min 50% wmax) during 30 minutes 3X9 method 9 rep 1 minute of rest, 9 rep (1 min) and 9 rep (total volume : 27 repetitions) at 70 of 1 repetition Leg press, Dips Press, Leg curl, Traction and Leg extension.~1 minute between each machine is planned"
48343654|NCT04616794|BEHAVIORAL|Cognitive Engagement Group|Participants in this group will be encouraged to lead a cognitively stimulating lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase cognitively stimulating activities and by assisting participants outlining goals to progressively adopt a more cognitively active lifestyle.
48343655|NCT04616794|BEHAVIORAL|Physical Activity Group|Participants in this group will be encouraged to lead a physically active lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to increase physical activities and by assisting participants outlining goals to progressively adopt a more physically active lifestyle.
48343656|NCT04616794|BEHAVIORAL|Diet Group|Participants in this group will be encouraged to adopt a healthy diet, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and suggestions about the different options to change their diet and by assisting participants outlining goals to progressively adopt a Mediterranean-like diet.
48343657|NCT04616794|BEHAVIORAL|Multimodal group|Participants assigned to this group will select which domain they wish to tackle first. Interventions are as described for the single-domain interventions.
48343658|NCT03437993|OTHER|Recollect, the game|"Recollect is a working memory training game"
48343659|NCT03437993|OTHER|Tetris|App-based video game where shapes are rotated and placed to fit a grid
48343660|NCT02282891|DRUG|Propofol|Induction of general anesthesia using propofol 2mg/kg
48343661|NCT02282891|DRUG|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
48343662|NCT04509557|DRUG|[177Lu]Ludotadipep|Dose is sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi). If DLT is observed in 2 or less of 6 subjects at each level, advance to the next step. If DLT is observed in 3 or more participants, no further subject will participate in the study at the relevant dose. Appropriateness of the dose elevation is evaluated 8-9 weeks after drug administration.
48343663|NCT00618865|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
48343664|NCT01176890|DRUG|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
48343665|NCT01176890|OTHER|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
48343666|NCT01999348|DRUG|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
48134857|NCT06619847|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
48343667|NCT02380482|OTHER|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
48343668|NCT02380482|OTHER|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
48343669|NCT03256136|DRUG|Carboplatin|Chemotherapy
48343670|NCT03256136|DRUG|Nivolumab|will allow the body's immune system to work against tumor cells
48343671|NCT03256136|DRUG|pemetrexed|Chemo therapy
48343672|NCT03256136|DRUG|Ipilimumab|will allow the body's immune system to work against tumor cells
48343673|NCT04126460|DRUG|Toripalimab|Toripalimab is a type of PD-1 antibody
48343674|NCT02544204|BIOLOGICAL|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
48343675|NCT02544204|BIOLOGICAL|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
48343676|NCT04427228|RADIATION|Radiosurgery Single Treatment|Frameless single-fraction SRS. One large treatment done on each brain tumor. 20 Gy for GTVs (or resection cavity CTVs) \< 2 cm, and 18 Gy for GTVs (or resection cavity CTVs) between 2-3 cm in the single-fraction.
48343677|NCT04427228|RADIATION|Radiosurgery Three Treatments|Multi-fraction SRS. Three small doses done on each brain tumor. 27 Gy in 3 fractions in the multi-fraction group
48343678|NCT04753723|COMBINATION_PRODUCT|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
48343679|NCT01216904|DRUG|nicotine patch|7 mg patches to be worn for 16 hours per day
48500282|NCT05809167|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
48343680|NCT01216904|DRUG|placebo|placebo patch to be worn 16 hours per day
48343681|NCT01121952|OTHER|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
48343682|NCT05243004|OTHER|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~* underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~* ensures that the reason for hospitalization is understood~* answers the patient's questions."
48343683|NCT02562976|OTHER|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
48343684|NCT04681365|OTHER|Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR)|Staff will wear and evaluate the Bubble PAPR instead of usual PPE consisting of FFP3/N95 facemasks. This novel, non-CE marked prototype PPE is a Powered air Purifying Respirator and is used 'in house' (not approved for use outside of the Sponsor organisation)
48343685|NCT03385434|DEVICE|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
48343686|NCT03676205|BIOLOGICAL|PRP|Platelet-Rich Plasma
48343687|NCT03676205|OTHER|Traumeel|Homeophatic Treatment
48343688|NCT05412836|DEVICE|AqueousJoint|AqueousJoint is a liposomal boundary lubricant, which coats the cartilage surface and protects it from further damage and degradation.
48343689|NCT06417268|PROCEDURE|Caudal epidural analgesia|"patient will be placed in the left lateral position with flexed hips.After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture is performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, the needle is inserted immediately below the spinous process S4.~After perforating the membrane, the needle will be advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection, The confirmation of the correct position of the caudal needle before injection by performing the modified 'swoosh' test performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of saline. Bupivacaine 0.25% at a dose of 1 ml/kg will be injected, with care taken not to exceed the maximum recommended dose (2 mg/kg)."
48343690|NCT06417268|PROCEDURE|Ultrasound-guided Combined Pericapsular Nerve Group Block|"With supine position, the probe will be put in a transverse plane along the anterior inferior iliac spine (AIIS) to identify the iliopsoas muscle, femoral nerve, and femoral artery (FA).~Then the probe will be rotated counter clockwise to align with the pubic ramus to visualize the AIIS, iliopsoas prominence (IPE), FA, iliopsoas, and iliopsoas notch.~Under direct vision, a 22-gauge, 50-mm echo needle will be advanced in the lateral-medial plane between the psoas tendon and the pubic ramus until the needle tip touches the IPE. The needle will be withdrawn, and after negative aspiration, 1 ml/kg (Bupivacaine 0.25%) is injected"
48343691|NCT06417268|PROCEDURE|Ultrasound-guided Lateral Femoral Cutaneous Nerve Block|patient remains supine, and the transducer is parallel to the inguinal ligament. With the femoral artery and vein as guidance, the lateral part of the sartorius muscle and fascia lata is visualized. Approximately 3 cm inferior from this point, the branches of the lateral femoral cutaneous nerve are visualized in the hypoechoic fat-filled subfascial space between the sartorius muscle medially and the tensor fascia lata muscle laterally. A 22-gauge, 50-mm needle is inserted with in plane approach at a shallow angle to reach the area of the nerve and after negative aspiration, 0.1 ml/kg (Bupivacaine 0.25%) is injected.
48343692|NCT06417268|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
48500283|NCT03598335|DEVICE|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
48500284|NCT01194986|OTHER|[11C]AZ12807110|Radioligand
48500285|NCT01194986|DRUG|AZD5213|
48343693|NCT06417268|DRUG|Morphine|If a FLACC pain Score is ≥ 4/10, the patient in the PACU will receive morphine (intravenous, 0.03 mg/kg), and the maximum allowed dose is 0.1mg/kg every 4 hours.
48343694|NCT06417268|DRUG|Acetaminophen|P atients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
48343695|NCT06265467|PROCEDURE|Closed Sinus Elevation|using a unique design of osteotomes to crestally elevate the Schneiderian membrane of the maxillary sinus floor
48343696|NCT06265467|PROCEDURE|Open Sinus Elevation|using a unique design of sinus elevators to laterally elevate the Schneiderian membrane of the maxillary sinus floor
48343697|NCT06005272|OTHER|Questionnaire|Interviewer assisted completion of questionnaire.
48343698|NCT00422240|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
48343699|NCT00422240|DRUG|Adapalene Gel, 0.1%|0.1% of adapalene gel topically daily in the evening for 12 Weeks.
48343700|NCT00422240|DRUG|Benzoyl Peroxide Gel 2.5%|2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
48134860|NCT06615479|DRUG|BMS-986393|Specified dose on specified days
48343701|NCT00422240|DRUG|Gel Vehicle|Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
48343702|NCT01451567|BEHAVIORAL|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
48343703|NCT05660512|PROCEDURE|Intracept Procedure|Radiofrequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
48343704|NCT01448707|DRUG|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
48343705|NCT01448707|DRUG|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
48134861|NCT06615479|DRUG|Cyclophosphamide|Specified dose on specified days
48134862|NCT06615479|DRUG|Fludarabine|Specified dose on specified days
48343706|NCT01636453|DEVICE|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
48343707|NCT05074862|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
48134863|NCT06615479|DRUG|Daratumumab|Specified dose on specified days
48343708|NCT05074862|DIETARY_SUPPLEMENT|Maltodextrin and fat-based placebo|Dosis isocaloric to the KetoneAid Arm
48343709|NCT02475629|BIOLOGICAL|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
48343710|NCT02475629|DRUG|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
48343711|NCT03674541|DRUG|Pyridostigmine Bromide|Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose
48343712|NCT03674541|DRUG|Placebo|Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
48343713|NCT01591993|PROCEDURE|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
48343714|NCT01591993|PROCEDURE|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
48343715|NCT05243147|DEVICE|nasal stents|using nasal stents after septoplasty
48343716|NCT05243147|DEVICE|merocel|using merocel after septoplasty
48343717|NCT01039428|DIETARY_SUPPLEMENT|HS219|Chewing for 30 min three time a day far after meal
48343718|NCT01039428|DIETARY_SUPPLEMENT|Placebo|Chewing for 30 min three times a day far after meal
48343719|NCT01216345|DRUG|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
48343720|NCT01150760|DRUG|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
48134864|NCT06615479|DRUG|Pomalidomide|Specified dose on specified days
48343721|NCT04180917|OTHER|Survey|survey
48002498|NCT00439556|BIOLOGICAL|Filgrastim|Given SC
48002499|NCT00439556|DRUG|Melphalan|Given IV
48002500|NCT00439556|DRUG|Methotrexate|Given IV
48002501|NCT00439556|BIOLOGICAL|Rituximab|Given IV
48002502|NCT00439556|DRUG|Tacrolimus|Given IV and PO
48002503|NCT00703547|DRUG|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
48002504|NCT00703547|DRUG|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
48002505|NCT00703547|DRUG|Placebo|Placebo tablets and capsules will be provided to subjects.
48002506|NCT05678062|DIAGNOSTIC_TEST|Point-of-care ultrasound|An ultrasound examination (approximately 35-40 minutes in duration) will be performed. The ultrasound examination will consist of evaluation of lung- and cardiac ultrasound, as well as optic nerve sheath diameter.
48343722|NCT02814136|PROCEDURE|Ablation|
48343723|NCT01500863|DRUG|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
48343724|NCT01500863|DRUG|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
48343725|NCT01500863|DRUG|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
48500286|NCT03525652|BIOLOGICAL|Therapeutic vaccine|The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.
48134865|NCT06615479|DRUG|Dexamethasone|Specified dose on specified days
48500287|NCT03525652|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
48500288|NCT04366934|OTHER|Nasal swab|Nasal swab
48500289|NCT04366934|OTHER|Taste and olfactory function evaluation|Taste and olfactory function evaluation
48500290|NCT02784444|DRUG|MSDC-0602K|MSDC-0602K capsules
48134866|NCT06615479|DRUG|Carfilzomib|Specified dose on specified days
48134867|NCT06678243|BEHAVIORAL|Smiling instead of Smoking|"Participants randomized to the treatment condition will use the Smiling instead of Smoking (SiS) smartphone app. This app delivers and guides participants through two types of content to help them during their quit attempt: (1) positive psychology content (i.e., happiness habit-building exercises, happiness boost activity, and science-based information on the relevance of positive psychology activities) designed to help nondaily smokers maintain positive affect while they go through the process of smoking cessation; and (2) traditional behavioral smoking cessation content to guide their quit process based on US Clinical Practice Guidelines."
48343726|NCT01500863|DRUG|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
48343727|NCT01500863|DRUG|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
48343728|NCT01500863|DRUG|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
48343729|NCT03515239|PROCEDURE|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
48343730|NCT02495090|GENETIC|Exome sequencing|Plain DNA sequencing
48343731|NCT04107428|DRUG|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
48343732|NCT04107428|DRUG|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
48343733|NCT03771001|OTHER|Motivational Interviewing coaching and habit-building app|Coaches will use a manualized motivational interviewing approach and participants' wellness promoting changes will be supported via a habit building app that also delivers a micro-mindfulness program
48343734|NCT04755283|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
48500291|NCT02784444|DRUG|Placebo|Placebo capsules
48343735|NCT04755283|DRUG|Rivaroxaban|Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
48343736|NCT05784870|DRUG|Shengxuening Tablet|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
48500292|NCT04428216|OTHER|Group RIB|In group RIB, RIB block will be performed. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
48500293|NCT03361475|BEHAVIORAL|SME App|"The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~* Express gratitude to family members (sharing)~* Deliver positive messages regularly (mind)~* Record physical and other joyful activities (enjoyment)~* Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)"
48500294|NCT04428112|BEHAVIORAL|Building Better Caregivers Workshop|"Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times."
48500295|NCT04428112|BEHAVIORAL|Attention Control|Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
48500296|NCT00511095|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
48657702|NCT06570005|OTHER|Water Quality Assurance Fund|"* At the water system level: Written legal agreements between water systems, centralized laboratories, and the organization facilitating the Assurance Fund will provide water systems with regular water quality testing and provide laboratories a guarantee of payments if water systems fail to pay for testing services on time (for up to three concurrent unpaid invoices). Regular debrief meetings will be held with water operators and local government authorities to discuss test results and water treatment options, and to encourage water systems to share water quality information with their consumers. Technical guidance to improve water treatment will be provided, if requested by water system operators or local government authorities.~* At the community level: Community engagement, primarily at the onset, to inform the community about the water quality testing program and answer questions."
48657703|NCT06603493|OTHER|Assessment of sleep disorders|: Sleep disturbances will be assessed with the Pittsburgh Sleep Quality Index
48657704|NCT06603493|OTHER|Assessment of Central Sensitization|Central sensitization will be assessed with the Central Sensitization Inventory
48657705|NCT06603493|OTHER|Assessment of depression, anxiety and stress levels|Depression, anxiety and stress levels will be assessed using the Depression, Anxiety, Stress Scale (DASS-21)
48657706|NCT06565091|DEVICE|Measurements of physiological parameters of the anterior chamber|Acquisition by the investigational device
48657707|NCT06565091|DEVICE|Measurements of the Axial biometry|Acquisition by the investigational device
48657708|NCT05190666|BEHAVIORAL|PACE Weight Loss program|12 month phone-based behavioral weight loss program
48500297|NCT00106067|BEHAVIORAL|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
48500298|NCT05190809|PROCEDURE|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
48500299|NCT04008654|BEHAVIORAL|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
48500300|NCT04008654|BEHAVIORAL|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
48500301|NCT02379780|PROCEDURE|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71\*50 mm 22G\*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
48500302|NCT02379780|PROCEDURE|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71\*50 mm 22 G\* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
48500303|NCT01975727|DRUG|Placebo|Injection of placebo (saline 0.9%)
48500304|NCT01975727|DRUG|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
48500305|NCT01975727|DRUG|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
48500306|NCT01975727|DRUG|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
48500307|NCT03937336|BEHAVIORAL|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
48500308|NCT06049979|OTHER|Acute gastrointestinal injury|AGIUS score\>2
48500309|NCT00700830|DRUG|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
48500310|NCT01103726|DRUG|PF-02545920|1 and 5 mg tablets, 6 mg single dose
48343737|NCT05784870|DRUG|Ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
48343738|NCT03275805|OTHER|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration of bracing (for the treatment to normalization arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
48343739|NCT03275805|OTHER|12 week standard of care|The intervention for this arm will be standard treatment for this pathology.
48343740|NCT01475318|DRUG|mifepristone|200 mg mifepristone on day 1
48343741|NCT01475318|DRUG|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
48343742|NCT01475318|DRUG|Misoprostol|misoprostol 800mcg PV on day 3
48343743|NCT03577522|DEVICE|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
48500311|NCT01103726|DRUG|placebo|matching placebo tablets, single dose
48500312|NCT01103726|DRUG|PF-02545920|1 mg tablets, 3 mg single dose
48500313|NCT01103726|DRUG|PF-02545920|5 mg tablets, 15 mg single dose
48500314|NCT01103726|DRUG|Placebo|matching placebo tablets, single dose
48500315|NCT04471974|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
48657709|NCT05190666|BEHAVIORAL|Chronic Disease Self-Management|12 month phone-based chronic disease self-management program
48500316|NCT04471974|DRUG|Enzalutamide|Given PO
48500317|NCT04471974|BIOLOGICAL|Pembrolizumab|Given IV
48343744|NCT03577522|DEVICE|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
48343745|NCT04728815|BEHAVIORAL|TAU - Phase 1|4-8 weeks of TAU treatment
48343746|NCT04728815|BEHAVIORAL|CAMS - Phase 1|4-8 weeks of CAMS treatment
48343747|NCT04728815|BEHAVIORAL|DBT - Phase 1 and 2|up to 16 weeks of DBT treatment
48343748|NCT04728815|BEHAVIORAL|CAMS - Phase 2|Up to 8 weeks of CAMS treatment
48343749|NCT04728815|BEHAVIORAL|DBT - Phase 2|Up to 8 weeks of DBT treatment
48500318|NCT06116084|OTHER|Ericksonian Hypnosis|An Ericksonian hypnosis session given to patients during a scintigraphic or PET examination, in a conventional manner, i.e. the hypnotherapist (MERM) is close to the patient in the examination room at the time of the session and communicates with him/her without any special device dedicated to this purpose.
48343750|NCT02401113|DIETARY_SUPPLEMENT|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
48134868|NCT06678243|BEHAVIORAL|QuitGuide|"Participants randomized to the control condition will use the National Cancer Institute (NCI)'s QuitGuide (QG) smartphone app. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
48134869|NCT06075082|DEVICE|LEFT smartwatch app|The LEFT smartwatch app is an app on the Apple Watch which measures body sleep position and gently vibrates when the body is in the right lateral decubitus position. In this way, patients with nocturnal gastroesophageal reflux symptoms learn to avoid the right lateral sleep position as they will avoid the annoying vibrations. Measurements while using the smartwatch app will be compared to measurements at baseline.
48343751|NCT04737759|BEHAVIORAL|Taking Care of Us|A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
48343752|NCT04737759|OTHER|SUPPORT|SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
48343753|NCT02120469|DRUG|everolimus|Given PO
48343754|NCT02120469|DRUG|eribulin mesylate|Given IV
48343755|NCT02120469|OTHER|pharmacological study|Correlative studies
48343756|NCT02120469|OTHER|laboratory biomarker analysis|Optional correlative studies
48343757|NCT01871272|PROCEDURE|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
48343758|NCT03935490|PROCEDURE|emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)|"The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary."
48500319|NCT06116084|OTHER|Hypnosis|A hypnosis session given to patients during a scintigraphic or PET examination, in a remote manner, i.e. the hypnotherapist (MERM) is in the control room at the time of the session and communicates with the patient via a microphone and the patient has headphones.
48500320|NCT00699062|DRUG|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
48500321|NCT00699062|DRUG|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
48500322|NCT05612373|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
48500323|NCT00146497|DRUG|Budesonide-Surfactant|
48500324|NCT05920733|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
48500325|NCT04953936|DIETARY_SUPPLEMENT|HMB-enriched Nutritional Supplements|The participants will receive oral HMB-enriched nutritional supplements (65 g, once daily), which include soybean isolate protein, flaxseed oil powder, yam powder, whey protein, oligomeric isomaltose powder, cocoa powder, medium-chain fatty acid powder, calcium beta-hydroxy-beta-methylbutyrate, sunflower seed oil powder, L-glutamine, wheat germ powder, membrane isolated casein, wheat oligopeptide, konjac flour, vitamin E, vitamin D, stevioside, edible flavors.
48500326|NCT04953936|DIETARY_SUPPLEMENT|Placebo|Placebo (maltodextrin 65 g once daily) with the same package as the intervention.
48500327|NCT04953936|BEHAVIORAL|Caloric Restrition Diet|Caloric restriction diet with individualized nutritional guidance from professional dietitians by video regarding caloric restriction strategies
48500328|NCT00003920|BIOLOGICAL|filgrastim|
48657710|NCT06644924|COMBINATION_PRODUCT|Intervention: AS MDI|"Drug: Treatment A (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)~Drug: Treatment B (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)~Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)"
48657711|NCT06644924|COMBINATION_PRODUCT|Intervention: Ventolin Evohaler|"Drug: Treatment A (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)~Drug: Treatment B (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)~Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)"
48657712|NCT06644924|COMBINATION_PRODUCT|Intervention: Placebo matching AS MDI|"Drug: Treatment A (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)~Drug: Treatment B (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)~Treatment C (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)"
48657713|NCT02383823|DRUG|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
48657714|NCT02383823|OTHER|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
48500329|NCT00003920|DRUG|cyclosporine|
48500330|NCT00003920|PROCEDURE|peripheral blood stem cell transplantation|
48500331|NCT00003920|RADIATION|indium In 111 monoclonal antibody m170|
48343759|NCT04673240|DRUG|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
48343760|NCT06418152|BEHAVIORAL|Multi-modal treatment|Multi-modal treatment was designed to target PD-specific declines in the areas of cognitive function and gait and posture impairments. MMT consists of simultaneously training a motor and cognitive task.
48343761|NCT03636880|BEHAVIORAL|Brief treatment for Insomnia|This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
48343762|NCT03636880|BEHAVIORAL|Sleep Monitoring|This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
48343763|NCT03174769|OTHER|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
48343764|NCT03174769|OTHER|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
48343765|NCT00391248|DRUG|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
48343766|NCT01047436|DRUG|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
48343767|NCT01047436|DRUG|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
48343768|NCT01010776|DRUG|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
48343769|NCT05963555|DEVICE|NovoThor|Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
48343770|NCT05963555|DEVICE|VieLight|Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.
48343771|NCT05963555|DEVICE|ZeroBody|Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
48343772|NCT04059874|DRUG|donafenib tablets|donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
48500332|NCT00003920|RADIATION|yttrium Y 90 monoclonal antibody m170|
48343773|NCT02892175|PROCEDURE|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
48343774|NCT04534049|OTHER|Intensive Strength Training (IST)|
48343775|NCT04534049|OTHER|Strength Endurance Training (SET)|
48343776|NCT04534049|OTHER|Flexibility Training (FT)|
48500333|NCT02355483|DEVICE|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
48500334|NCT05396261|DEVICE|Film forming silicone gel (7-0940)|Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
48500335|NCT04714983|BIOLOGICAL|DNX-2440|DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
48657715|NCT01775345|PROCEDURE|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
48657716|NCT01775345|PROCEDURE|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
48500336|NCT03653117|DEVICE|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
48500337|NCT00541216|DRUG|Ephedrine|
48500338|NCT04880824|BEHAVIORAL|Prehabilitation- new form of care|The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
48500339|NCT02246439|DRUG|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
48002507|NCT02433236|DRUG|Fostamatinib Disodium tablet 100 mg|
48002508|NCT02433236|DRUG|Fostamatinib Disodium tablet 150 mg|
48500340|NCT02246439|DRUG|Placebo Oral Tablet|Placebo
48500341|NCT05921357|OTHER|Questionnaire|Questionnaire and examine
48513378|NCT04913012|COMBINATION_PRODUCT|Systematic aerobic training|Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
48343777|NCT05911945|PROCEDURE|Flexible Ureterorenoscopy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
48343778|NCT05911945|PROCEDURE|Mini Percutaneous Nephrolithotomy|A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
48343779|NCT02542813|DRUG|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
48343780|NCT02542813|DRUG|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
48343781|NCT02542813|DRUG|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
48343782|NCT02542813|DRUG|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
48343783|NCT02542813|DRUG|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
48343784|NCT02542813|DRUG|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
48343785|NCT03542149|DRUG|480 mg Piperaquine phosphate|480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
48500342|NCT04755933|BEHAVIORAL|Raising Confident Children Course|An online learning tool consisting of 8 different modular components, designed to reduce the transmission of anxiety from parents to children. The modular components include: a core starter about anxiety, the role of avoidance, using play to develop childrens confidence, using Emotion Coaching with children, managing difficult behaviour, the role of sleep, exercise and diet, reducing overprotection, modelling confident behaviour and managing difficult behaviour.
48343786|NCT03542149|DRUG|640 mg Piperaquine phosphate|640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
48343787|NCT03542149|DRUG|200 mg OZ 439|200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
48343788|NCT03542149|DRUG|400 mg OZ 439|400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
48343789|NCT03542149|DRUG|800 mg OZ 439|800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
48343790|NCT03542149|DRUG|960 mg PQP|960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
48343791|NCT03542149|DRUG|320 mg PQP|320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
48343792|NCT05118711|DIAGNOSTIC_TEST|Cardiorespiratory fitness|Cardiopulmonary exercise testing
48343793|NCT05118711|DIAGNOSTIC_TEST|Lung function|Body plethysmography
48343794|NCT05118711|DIAGNOSTIC_TEST|Muscular strength and balance tests|Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
48343795|NCT05118711|DIAGNOSTIC_TEST|Micro- and macrovascular endothelial function and cardiac function|Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
48500343|NCT05616962|DIETARY_SUPPLEMENT|Diosmiplex|diosmin glycoside in combination with alkaline granules known as alka4-complex
48657717|NCT01775345|PROCEDURE|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
48657718|NCT01775345|PROCEDURE|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
48657719|NCT06291987|DRUG|Ivosidenib|Ivosidenib will be given at assigned dose once daily.
48657720|NCT06291987|DRUG|Ruxolitinib|Ruxolitinib will be given at assigned dose twice daily.
47982361|NCT05076526|BIOLOGICAL|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~* 2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~* 3g of inert cell-selector gel~* 0.6mL of anticoagulant (sodium citrate 4%)"
47982362|NCT03445338|DRUG|K0706|Study
48343796|NCT05118711|DIAGNOSTIC_TEST|Blood sampling and analysis|Blood sampling by venepuncture
48343797|NCT05118711|DIAGNOSTIC_TEST|Physical activity|Physical activity surveillance using accelerometers
48343798|NCT05118711|DIAGNOSTIC_TEST|Questionnaires|Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
48343799|NCT05118711|DIAGNOSTIC_TEST|Body composition|Dual-energy x-ray absorptiometry (DXA)
48343800|NCT04063644|DEVICE|Vis Glyc Neo|1 drop in each eye, three times a day.
48343801|NCT04063644|DEVICE|Physiological saline solution|1 drop in each eye, three times a day.
48343802|NCT03716687|DEVICE|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
48343803|NCT02816476|DRUG|Daratumumab|
48343804|NCT03436147|OTHER|POP-Q|Pelvic Organ Prolapse Quantification
48343805|NCT05480241|DRUG|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
48343806|NCT05480241|DRUG|Placebo|Placebo + Omeprazole 20mg once daily on fasting
48343807|NCT05526781|DEVICE|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
48343808|NCT04493463|DRUG|Methylprednisolone 40 mg + Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
48343809|NCT04493463|DRUG|Ropivacaine + Saline|To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
48343810|NCT02776852|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: SR15-43-Y65-158)
48343811|NCT06269757|BEHAVIORAL|Individualized Exercise Program|"The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~* Running analysis;~* Training program review;~* Strength and flexibility assessment;~* Review of running video;~* Personalized final report."
48343812|NCT06269757|BEHAVIORAL|Standard Physical Therapy|Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
48343813|NCT03099798|OTHER|Questionnaires|"All patients will complete a number of questionnaires at different time points.~* SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~* 1 week, 1 month, 3, 6 and 12 months after treatment"
48343814|NCT03099798|DIAGNOSTIC_TEST|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
48343815|NCT05774613|DIETARY_SUPPLEMENT|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
48657721|NCT06644560|BEHAVIORAL|Prehabilitation Intervention|The intervention involves a 3-week prehabilitation program during the participant's preoperative window before cancer surgery. During the intervention, patients will be asked to consume 60 grams of walnuts daily, participate in two 60-minute individualized supervised physical activity training sessions per week, meet with a nutritionist for a 30-60 minute session, and conduct 30 minutes of independent walking per day. The participants will be given pre-portioned walnuts for daily consumption, a pedometer, and educational materials. The participants will track their completion of tasks with a daily log and the study coordinator will also track their attendance at scheduled nutrition and fitness sessions. In addition, the study coordinator will check-in with participants twice weekly and send text reminders about their required activities.
47982363|NCT03445338|DRUG|K0706|Study
47982364|NCT03445338|DRUG|K0706|Study
48343816|NCT01570452|PROCEDURE|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
48657722|NCT05879029|DRUG|Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
48343817|NCT03825445|DRUG|GnRHa (Fertipeptil 0.1mg)|Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
48343818|NCT03825445|DRUG|hCG (Pregnyl 5000IU)|hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
48343819|NCT06195046|DEVICE|Baroreflex Activation Therapy (BAT)|activation of BAROSTIM NEO system that affects autonomic modulation with BAT therapy.
48343820|NCT02509676|OTHER|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
48657723|NCT05879029|DRUG|Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.|Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
48657724|NCT03753516|PROCEDURE|Laparoscopic - Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.
48657725|NCT03753516|PROCEDURE|Vaginal- Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
48343821|NCT04472013|OTHER|Data collection from lumbar puncture|Cerebro spinal fluid (CSF) will be acquired by lumbar puncture and sent for routine analysis including CSF chemistry, cytology and microbiology. Targeted CSF proteomics using OLINK Proximity Extension Assay (PEA) technology to assess a potential CNS-contribution of the disease will be performed.
48343822|NCT04472013|OTHER|Data collection from blood draw|Plasma samples will be acquired for plasma cytokine proteomics using CyTOF (mass cytometry analysis) technology.
48343823|NCT04472013|OTHER|CNS magnetic resonance imaging (MRI) imaging|3Tesla magnetic resonance imaging (MRI) will be performed to document early/manifest encephalitic changes in COVID-19 patients.
48343824|NCT04472013|OTHER|Microscopy of defined brain regions on autopsy specimens|High dimensional, microglia-centric CODEX fluorescent microscopy of defined brain regions on autopsy specimens will be acquired from medulla oblongata, cortex, cerebellum, and olfactory bulb. A brain-specific CODEX panel for the assessment of the immune microenvironment was implemented, with inclusion of a wide array of myeloid/microglia markers, T-cell markers, and a few neuronal markers. All the antibodies have been validated and tested in formalin-fixed tissues of different zones of glioblastoma tumors including invading tumor periphery. The Panel will be modified to include the viral entry receptors, CD147, ACE2 and TMPRSS2. Presence of SARS-CoV-2 virus particles will be assessed by qPCR, andMultiplexed Ion Beam Imaging (MIBI) technology will be used to visualize tropism of virus to specific cellular brain compartments.
48657726|NCT00849992|DRUG|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
48657727|NCT00849992|PROCEDURE|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
48343825|NCT03926260|OTHER|ctDNA analysis|blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
48500344|NCT02861742|OTHER|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
48500345|NCT02861742|BEHAVIORAL|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
48500346|NCT02861742|BEHAVIORAL|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
48500347|NCT02861742|BEHAVIORAL|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
48500348|NCT02861742|BEHAVIORAL|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
48500349|NCT02861742|BEHAVIORAL|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
48500350|NCT03948139|DEVICE|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
48500351|NCT03948139|DEVICE|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
48657728|NCT03009292|DRUG|lenvatinib|once daily continuous dosing
48343826|NCT03217318|DEVICE|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
48343827|NCT01399255|BIOLOGICAL|Insulin lispro|Dosage form- Subcutaneous Injection
48500352|NCT02352779|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Given PO
48500353|NCT02352779|OTHER|Placebo|Given PO
48500354|NCT02352779|OTHER|Questionnaire Administration|Ancillary studies
48500355|NCT02352779|OTHER|Laboratory Biomarker Analysis|Correlative studies
48500356|NCT04780282|OTHER|Scapular Stabilization Group|Participants will apply the 5 exercises given.
48657729|NCT06340269|DEVICE|MEX-CD1 Dialysis|"MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit."
48657730|NCT04980209|DEVICE|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
48657731|NCT05379972|DRUG|Pembrolizumab|Pembrolizumab 200mg IV every 3 weeks starting C2D1
48343828|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold spreaded with photoinduced-imine-crosslink hydrogel|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
48343829|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
48500357|NCT02984085|DRUG|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
48500358|NCT05362838|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
48500359|NCT05362838|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
48500360|NCT02831608|BIOLOGICAL|Influenza vaccine|
48500361|NCT02831608|BIOLOGICAL|Placebo|
48343830|NCT02484950|BIOLOGICAL|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
48657732|NCT05379972|DRUG|Olaparib|Olaparib 200mg orally twice daily starting C1D1 concurrently with radiation. Starting C2D1, Olaparib 300mg orally twice with Pembrolizumab
48343831|NCT02484950|PROCEDURE|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
48657733|NCT05379972|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy Dose 25Gy in 5 fractions daily (M-F) for 5 days starting C1D1 with Olaparib
48657734|NCT02033941|DRUG|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
48657735|NCT02033941|DRUG|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
48657736|NCT00751231|DRUG|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
48343832|NCT06231914|DEVICE|StarWalker® PQX|Third-generation ASP-powered technology for ultra performance: Highest pico power \& energy, shortest pico pulse width, wide range of laser wavelengths, exceptional spot size capabilities, largest fluence spectrum for flat-top handpieces
48343833|NCT04504019|DEVICE|USCTR|Ultrasound guided CTR via a single \< 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®, also known as UltraGuideCTR
48343834|NCT04504019|PROCEDURE|mOCTR|Mini-open CTR via a single 1-3cm palmar incision
48343835|NCT01616069|DRUG|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
48657737|NCT00751231|DRUG|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
48657738|NCT06283212|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A)
48657739|NCT06571890|DEVICE|Narcotrend bispectral index anaesthesia monitor|A bispectral index anaesthesia monitor collects simplified EEG via forehead electrodes and displays an index of 0-100, where an index of 40-60 is considered optimal
48134872|NCT05144659|PROCEDURE|Double faced transverse preputial onlay island flap|A well-established one-stage repair of penile hypospadias called Double faced transverse preputial onlay island flap
48343836|NCT02566876|DRUG|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
48343837|NCT00618813|OTHER|radiation therapy|Undergo radiation therapy
48343838|NCT00618813|OTHER|therapeutic conventional surgery|Undergo surgery
48343839|NCT00618813|DRUG|etoposide|Given IV
48343840|NCT00618813|DRUG|ifosfamide|Given IV
48343841|NCT00618813|DRUG|doxorubicin hydrochloride|Given IV
48343842|NCT00618813|DRUG|cyclophosphamide|Given IV
48343843|NCT00618813|DRUG|vincristine sulfate|Given IV
48343844|NCT00618813|DRUG|topotecan hydrochloride|Given IV
48343845|NCT00618813|BIOLOGICAL|filgrastim|Given SC
48343846|NCT00756093|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
48343847|NCT00756093|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
48343848|NCT00756093|OTHER|Blink Tears|Blink Tears one drop each eye one time
48343849|NCT00756093|OTHER|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
48343850|NCT02017704|RADIATION|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
48343851|NCT02017704|DRUG|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
48343852|NCT02017704|RADIATION|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
48343853|NCT02017704|DRUG|FOLFOX6|"* Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
48343854|NCT02017704|PROCEDURE|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
48343855|NCT00852761|DRUG|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
48343856|NCT00852761|DRUG|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
48343857|NCT05915117|DIETARY_SUPPLEMENT|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
48343858|NCT05915117|DRUG|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
48343859|NCT00428376|DEVICE|Building Blocks|
48343860|NCT04148768|DEVICE|Inferential therapy|Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
48343861|NCT04148768|DEVICE|short wave diathermy|SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
48343862|NCT06309498|PROCEDURE|blood test|11 DOC levels will be measured in enrolled patients
48343863|NCT02172846|RADIATION|Proton beam radiation therapy (PBT)|
48343864|NCT02172846|DRUG|Paclitaxel|
48343865|NCT02172846|DRUG|Carboplatin|
48343866|NCT03054740|DRUG|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
48343867|NCT03054740|DRUG|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
48343868|NCT03665207|DRUG|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
48343869|NCT01590667|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
48343870|NCT01590667|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
48500362|NCT03112785|DEVICE|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
48500363|NCT06258798|RADIATION|Taking a dental X-ray|Dental X-rays taken in patients with indications confirmed by a written referral.
48343871|NCT02945839|DRUG|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
48343872|NCT02945839|BEHAVIORAL|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
48500364|NCT03543436|DRUG|Temocillin|Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .
48500365|NCT03543436|DRUG|meropenem or imipenem|Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
48500366|NCT02444923|DEVICE|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
48500367|NCT02444923|DEVICE|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
48657740|NCT06571890|DEVICE|Mdoloris Anaesthesia Nociception Monitor|A heart rate variability-based nociception monitor collects ECG-signal from electrodes on the patient's chest and displays an index of 0-100 where an index below 50 is considered nociceptive.
48343873|NCT02945839|BEHAVIORAL|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
48343874|NCT01188460|BEHAVIORAL|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
48500368|NCT06404658|PROCEDURE|Genicular nerve block|patients who receive Genicular nerve block with spinal anathesia .
48657741|NCT04945837|OTHER|self administered questionnaire|longitunidal descriptive study
48657742|NCT00004419|DRUG|insulin-like growth factor I|
48657743|NCT06210893|OTHER|The cricoid cartilage is located.|The cricoid cartilage is located.
48657744|NCT02788292|DRUG|Acetylcysteine|See arm description
48657745|NCT06090799|DRUG|SHR-3032|Single dose at varying dosage levels depending on treatment assignment
48657746|NCT06090799|DRUG|SHR-3032 Placebo|Single dose at varying dosage levels depending on treatment assignment
48657747|NCT03926247|BEHAVIORAL|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
48657748|NCT06643871|OTHER|Adapted physical activity program involving connected bikes|The treatment being studied involves a program (DYNAMO-PSY) of adapted physical activity with an enriched environment (connected bike, visualized and experienced routes in virtual reality) and is supervised, comprising (on average) two sessions per week, a total of 20 sessions to be completed over a maximum of 15 weeks. Each session will last 60 minutes and will be supervised by a case manager. They will be composed of a warm up, session on the bike (around 30 minutes of bicycling) and stretching. They will take place in an adequate room in the clinical research department of Saint Anne Hospital. The usual hygienic-dietetic care is not modified by the study and consists of the care proposed to patients of the GHU Paris Psychiatry and Neuroscience who have had a first psychotic episode and are treated primarily with medication: clinical and biological monitoring, dietary consultations, therapeutic education group concerning diet and lifestyle.
48657749|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
48657750|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
48134873|NCT05144659|PROCEDURE|Transverse inner preputial onlay island flap|A second well-established one-stage repair of penile hypospadias called Transverse inner preputial onlay island flap
48500369|NCT05875792|DEVICE|EvolvRehab - MoveWell|The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
48657751|NCT04904549|BIOLOGICAL|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
48657752|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
48343875|NCT01188460|BEHAVIORAL|Sleep diary|
48343876|NCT01841489|DRUG|Treatment A|1600 mg GS-9973 (Formulation 1)
48343877|NCT01841489|DRUG|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
48500370|NCT00810316|DRUG|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
48500371|NCT00810316|DRUG|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
48500372|NCT00810316|DRUG|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
48500373|NCT00127218|DRUG|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
48500374|NCT00127218|DRUG|niacin|long-acting niacin daily for 18 months
48500375|NCT00127218|DRUG|Placebo|matching placebo pill daily for 18 months
48500376|NCT04642651|DRUG|Dexmedetomidine|Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
48500377|NCT04642651|DRUG|Placebo|Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
48500378|NCT06400134|OTHER|Cognitive Function|The Standardized Mini Mental Test (SMMT) was used to evaluate the cognitive status of the geriatric individuals'. In the test, which has a total score of 30, those with a score of 24 or less are recommended to be evaluated for dementia.
48500379|NCT06400134|OTHER|Physical Performance|The Brief Physical Performance Battery (BPPB) was used to assess the physical performance of geriatric individuals. All three physical performance measures (balance, walking speed, getting up from the chair) were scored between 0-4 according to the duration of the activity, these scores were summed and the total score was determined between 0 (poor) and 12 (very good).
48657753|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
48657754|NCT03482232|DRUG|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
48500380|NCT06400134|OTHER|Grip Strength|Muscle strength was assessed with a hand grip dynamometer. In the geriatric individuals, less than 30 kg for men and less than 20 kg for women was considered as low hand grip strength.
48657755|NCT03482232|DRUG|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
48657756|NCT03482232|DRUG|paracetamol|paracetamol 1g for more than 3 days
48657757|NCT03482232|DRUG|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
48002509|NCT02012595|OTHER|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil
48500381|NCT06400134|OTHER|Walking speed|Walking speed was assessed with the 6-metre walk test. Speed was calculated by dividing each known distance by the time it took for each individual, on each trial, to walk from the start to the end points marked on the floor and then converting to m/s.
48500382|NCT06400134|OTHER|Mobility|The Time up Go test (TUG) was used for mobility. The risk of falling increases with increasing duration.
48134875|NCT06668623|OTHER|Reiki Group|Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second level training. No changes will be made to the standard treatment plan of the patients during the application.
48134876|NCT06668623|OTHER|Sham Reiki Group|In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.
48343878|NCT01841489|DRUG|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
48343879|NCT01841489|DRUG|Treatment D|1600 mg GS-9973 (Formulation 2)
48343880|NCT01841489|DRUG|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
48343881|NCT01841489|DRUG|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
48343882|NCT01841489|DRUG|Treatment G|1600 mg GS-9973 (Reference formulation)
48500383|NCT06400134|OTHER|Fraility|Frailty assessment was performed using the FRAIL scale.The scale was scored by giving 0 or 1 point according to the answer given. The higher the score, the greater the fraility.
48657758|NCT03482232|DRUG|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
48657759|NCT03482232|DIAGNOSTIC_TEST|Prostate cancer|Screening for prostate cancer in asymptomatic patients
48657760|NCT03482232|RADIATION|Lumbago|image tests in non-specific lumbago
48657761|NCT03482232|DRUG|Antimicrobial agent|antibiotics for pharyngitis (infants)
48002510|NCT03852797|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
48002511|NCT03852797|DRUG|Ketamine|Ketamine in solution, 10-4M to 10-7M
48002512|NCT03852797|DRUG|Propofol|Propofol in solution, 10-4M to 10-7M
48002513|NCT03852797|DRUG|Etomidate|Etomidate in solution, 10-4M to 10-7M
48343883|NCT01841489|DRUG|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
48343884|NCT01841489|DRUG|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
48343885|NCT01841489|DRUG|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
48343886|NCT02836080|BEHAVIORAL|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
48343887|NCT02836080|OTHER|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
48343888|NCT00493714|BEHAVIORAL|Questionnaire|Surveys lasting 30 minutes or more.
48343889|NCT03857607|GENETIC|Whole exome sequencing|Whole exome sequencing will be used to identify causative genes in ATP1A3 mutation negative patients, to confirm causality in ambiguous phenotypes and to identify modifier genes.
48343890|NCT00250497|BEHAVIORAL|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
48343891|NCT03498976|PROCEDURE|pulsed radiofrequency|Echoguided technic
48343892|NCT00029289|DRUG|Lutein (10 or 30 mg/day) capsules|
48343893|NCT04538261|DEVICE|Fetal Pillow insertion|Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
48343894|NCT00004125|DRUG|cyclophosphamide|
48343895|NCT00004125|DRUG|docetaxel|
48343896|NCT00004125|DRUG|doxorubicin hydrochloride|
48343897|NCT00004125|DRUG|paclitaxel|
48343898|NCT00004125|DRUG|tamoxifen citrate|
48343899|NCT00004125|RADIATION|radiation therapy|
48343900|NCT05642065|OTHER|Hip muscle activation home exercise program|Participants will perform a home exercise program consisting of five hip muscle activation exercises with the use of a resistance band. The program will be eight weeks in duration, and participants will perform the exercises twice weekly.
48343901|NCT01451866|OTHER|resistance training|hypertrophic resistance training
48343902|NCT01451866|OTHER|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
48343903|NCT02635685|OTHER|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
48343904|NCT02237898|BEHAVIORAL|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
48343905|NCT02237898|BEHAVIORAL|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.
48343906|NCT02237898|DEVICE|Sensordrone™ carbon-monoxide sensor|A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.
48500384|NCT04669691|BIOLOGICAL|H5N1 antigen combined with MF59 adjuvant|Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
48343907|NCT02237898|DEVICE|MoMba Live Long Smartphone application|The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.
48343908|NCT01853852|DRUG|GR181413A/AT1001 solution|Powder for reconstitution
48343909|NCT01853852|DRUG|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
48343910|NCT01853852|OTHER|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
48343911|NCT01853852|DRUG|Placebo capsule|Solution matched
48343912|NCT02564068|DRUG|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
48343913|NCT05844774|DEVICE|HPI (using HemoSphere) - guided algorithm|Treatment of hypotension guided by the hypotension prediction index. Patients will receive treatment following the predetermined HPI-algorithm when the HPI exceeds 85%.
48343914|NCT05844774|DEVICE|Treatment of hypotension following standard of care|Patients receive standard of care treatment for hypotension, with a goal-mean arterial pressure (MAP) of 65mmHg.
48343915|NCT00595868|DRUG|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
48343916|NCT00595868|DRUG|Placebo|same as Varenicline arm
48343917|NCT04623255|DRUG|OCTAPLAS|plasma exchange
48343918|NCT02428075|BEHAVIORAL|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
48343919|NCT03904576|DRUG|BI 1358894|Film-coated tablet
48343920|NCT03904576|DRUG|Placebo|Film-coated tablet
48343921|NCT04702204|DRUG|Denosumab 60 MG/ML|"Denosumab, another antiresorptive agent, is a fully human monoclonal IgG2 antibody that binds to the receptor activator of the nuclear factor-kB ligand (RANKL) with high specificity and affinity. Denosumab inhibits bone resorption by affecting the development, activation, and survival of osteoclasts.~Denosumab 60 mg subcutaneously was administered to the patients whose consent forms were obtained, once every 6 months."
48343922|NCT04672031|OTHER|Glycemic Targets|The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
48343923|NCT01235507|DRUG|methotrexate|stable dose as prescribed
48500385|NCT03240237|DEVICE|Optimizer SMART|Cardiac Contractility Modulation
48500386|NCT05940155|DIAGNOSTIC_TEST|RT PCR test of COVID 19|diagnostic test by naso-pharyngel swab to confirm the diagnosis of covid-19 at moderate and severe cases.
48500387|NCT04060316|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
48500388|NCT04060316|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
48500389|NCT01383135|DRUG|F18-FPPRGD2|Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV).
48500390|NCT00986713|DRUG|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
48500391|NCT04899388|PROCEDURE|Pericapsular Nerve Block|regional anaesthia
48500392|NCT04899388|PROCEDURE|Lumbar Erector Spinae Plane Block|regional anaesthia
48500393|NCT04899388|DRUG|Fentanyl|intavenous
48500394|NCT02013011|PROCEDURE|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
48500395|NCT05973292|OTHER|resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate|Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max
48500396|NCT05973292|OTHER|Non MDP containg resin cement|Adhesive resin cement not containing an MDP agent
48657762|NCT03482232|DRUG|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
48657763|NCT03482232|DRUG|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
48657764|NCT05660538|DRUG|VX-548|Tablets for oral administration.
48134877|NCT05039840|DRUG|SAR441344 IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
48134878|NCT05039840|DRUG|SAR441344 SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
48134879|NCT05039840|DRUG|Placebo IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
48343924|NCT01235507|DRUG|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
48134880|NCT05039840|DRUG|Placebo SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
48500397|NCT04211727|DIAGNOSTIC_TEST|Capillary finger prick blood sample|Patients will have a blood finger prick sample
48134881|NCT06362291|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
48134882|NCT06362291|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
48500398|NCT04320121|DIETARY_SUPPLEMENT|Nelutri™|Nelutri™ 2,000 mg/day for 12 weeks
48343925|NCT00718250|BIOLOGICAL|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
48500399|NCT04320121|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
48657765|NCT05660538|DRUG|Pregabalin|Capsules for oral administration.
48657766|NCT05660538|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
48657767|NCT05660538|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
48657768|NCT01143441|BIOLOGICAL|DAC-HYP|
48657769|NCT05518045|DRUG|LM-108|Administered intravenously
48343926|NCT00718250|BIOLOGICAL|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
48343927|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
48343928|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
48343929|NCT02716662|DIETARY_SUPPLEMENT|Axona|medical powder, supplement food
48343930|NCT02985489|DIETARY_SUPPLEMENT|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
48343931|NCT05483283|OTHER|Empowerment and Navigation|Empowerment and Navigation
48343932|NCT05483283|OTHER|SOC|SOC
48343933|NCT00331084|DRUG|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
48343934|NCT00331084|DRUG|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
48343935|NCT02620046|DRUG|Vedolizumab SC|Vedolizumab SC 108 mg injection
48500400|NCT00300508|DRUG|Anastrozole|
48500401|NCT00678197|OTHER|Access Intervention|
48500402|NCT00678197|OTHER|Bonus/Pay-for-Performance Intervention|
48500403|NCT05347381|DRUG|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
48500404|NCT04300010|DRUG|5% Topical Benzoyl Peroxide Gel|Gel treatment used to treat acne
48500405|NCT04300010|DEVICE|Blue Light Therapy|Blue light therapy treatment for acne
48500406|NCT03441932|PROCEDURE|Fiberoptic endoscopic evaluation of swallowing (FEES)|"Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree."
48500407|NCT05312320|OTHER|Information film|"* Sexual activity after MI does not increase risk of recurrence or death~* Sexual activity is associated with improved outcome after MI~* Resuming sexual activity as normal is recommended and completely safe"
48500408|NCT03260985|OTHER|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
48500409|NCT00213135|DRUG|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
48657770|NCT05518045|DRUG|Toripalimab|Administered intravenously
48657771|NCT06615219|OTHER|Intergroup contact training|The intervention program uses direct contact and four types of indirect contact as the intervention strategy and general framework, and is divided into three main steps, assessing and reflecting on aging stereotypes, carrying out indirect and direct contact, and evaluating the effectiveness of the intervention. The time period is 12 weeks, with the interventionists comprising the researcher and nursing students. The forms of the intervention include holding mini-lectures, organizing participation in voluntary activities, and nostalgia interviews.
48343936|NCT05290051|GENETIC|Optical Genome Mapping (Bionano®)|Search for chromosome abnormalities through alteration of the optical map of the genome compared to reference genome using the Bionano® 's pipeline.
48500410|NCT00213135|DRUG|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
48657772|NCT06615219|OTHER|Regular course training only|The specific process is to sign in the classroom, review the knowledge of the previous class by asking questions, introduce the content of the new class, the teacher explains the knowledge points according to the teaching objectives and teaching content, and finally assigns the post-class homework of the course content. At the end of the experiment, the control group was given compensatory intervention.
48657773|NCT05022719|DEVICE|PillCam Colon2 procedure with MB-MMX|Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.
48657774|NCT02251041|DRUG|Antithrombin-III|
48657775|NCT02251041|DRUG|Infliximab|
48657776|NCT02251041|DRUG|Apotransferrin|
48657777|NCT02251041|DRUG|Human recombinant erythropoietin|
48500411|NCT00213135|OTHER|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
48500412|NCT01857271|DRUG|Erlotinib Hydrochloride|Given PO
48657778|NCT02251041|DRUG|C1-Inhibitor|
48657779|NCT02251041|DRUG|Glutathione|
48500413|NCT01857271|PROCEDURE|Therapeutic Conventional Surgery|Undergo thoracotomy
48657780|NCT02251041|DRUG|Alfa-tocopherol|
48657781|NCT02251041|DRUG|Melatonin|
48657782|NCT02251041|DRUG|Epoprostenol|
48657783|NCT02251041|DRUG|Sodium chloride solution|
48343937|NCT05290051|GENETIC|Longread sequencing (Nanopore®)|Search for chromosome abnormalities from the sequencing data obtain from high molecular weight DNA molecules using dedicated analysis pipeline.
48343938|NCT00005883|DRUG|phenethyl isothiocyanate|
48343939|NCT01059890|DRUG|cefotaxime|
48343940|NCT01059890|DRUG|Metronidazole|
48343941|NCT01059890|DRUG|Ciprofloxacin|
48343942|NCT01059890|DRUG|Fosfocine|
48500414|NCT01857271|OTHER|Laboratory Biomarker Analysis|Correlative studies
48500415|NCT02340130|BIOLOGICAL|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
48500416|NCT02340130|BIOLOGICAL|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
48500417|NCT04013984|OTHER|Accupuncture|In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
48500418|NCT02212288|OTHER|Blood sample|Blood samples are for metabolic and genetic and biological investigation
48500419|NCT02212288|OTHER|Urine sample|Urine sample for biological investigation
48657784|NCT01512576|OTHER|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
48657785|NCT01512576|BEHAVIORAL|relaxation|1 treatment session of 30 minutes
48657786|NCT05982678|DRUG|Trastuzumab deruxtecan|T-DXd 5.4mg/kg on a three weekly (21 day) basis, with the goal of 16 cycles leading to a treatment period of year, including local treatment. The first 8 cycles of T-DXd are administered neo-adjuvant, and 8 cycles adjuvant, after completion of local treatment.
48657787|NCT04362644|DRUG|PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714|Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
48134883|NCT01467128|OTHER|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
48134884|NCT01467128|OTHER|No Intervention|Normal hospital pharmaceutical care
48343943|NCT01978392|BEHAVIORAL|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
48343944|NCT03006900|OTHER|Pilates|Pilates
48343945|NCT03006900|OTHER|Massage|Massage
48343946|NCT04409730|OTHER|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
48343947|NCT03632668|DRUG|AD-2071 10/20mg|AD-2071 10/20 mg tablet
48343948|NCT03632668|DRUG|AD-2072 80/5mg|AD-2072 80/5mg tablet
48343949|NCT03632668|DRUG|AD-2071 10/20mg + AD2072 80/5mg|AD-2071 10/20 mg + AD-2072 80/5mg tablet
48343950|NCT03869216|BEHAVIORAL|Educational Shared Decision-Making Intervention|The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
48343951|NCT00263315|DRUG|nebulised liposomal amphotericin B|
48343952|NCT00189436|DRUG|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
48343953|NCT00189436|DRUG|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
48343954|NCT03373344|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
48343955|NCT03373344|BEHAVIORAL|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
48343956|NCT04745390|RADIATION|Radiation therapy|Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
48343957|NCT04960462|PROCEDURE|nerve root sleeve reinforcement|treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
48343958|NCT02797769|DRUG|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
48343959|NCT02797769|DRUG|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
48343960|NCT03431792|DEVICE|Long Tail Balloon|s. description of experimental Arm
48343961|NCT04090697|DRUG|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
48343962|NCT05318040|DRUG|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
48343963|NCT05318040|DRUG|Placebo|Placebo will be provided as visually matching placebo capsules.
48500420|NCT01104792|DRUG|Cariprazine|Cariprazine was supplied in capsules.
48513379|NCT04913012|COMBINATION_PRODUCT|Systematic resistance training|Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
48134885|NCT06698497|BEHAVIORAL|Communication Campaign|A social media vaccine communications campaign is deployed once increasing amounts of SARS-CoV-2 RNA are identified in the New York State wastewater surveillance network. The social media campaigns on Facebook, Instagram, and NextDoor social media platforms will run for 11 weeks. The campaign disseminates information about the wastewater surveillance network and vaccination (not COVID-19 specific) to residents in intervention counties. These social media platforms not only allow for quick and cost-effective exposure, but also allow for participation and interaction with participants. The campaign ads include a call-to-action link to the New York State wastewater surveillance network webpage which has information and links regarding vaccines for respiratory transmitted pathogens (COVID-19, influenza, and RSV) and how to schedule an appointment.
48134886|NCT06511284|OTHER|High protein dose|High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition
48134887|NCT06511284|OTHER|Usual protein dose|Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition
48134888|NCT03542305|DRUG|Lorlatinib|Lorlatinib single oral dose
48134889|NCT02823574|BIOLOGICAL|Nivolumab|
48657788|NCT05664178|BEHAVIORAL|Tele-Resistance Training|Tele-Resistance training sessions will be supervised and guided by a certified exercise trainer via smartphone, tablet or laptop. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously. Participants will engage in brief warm up exercises lasting 2-3 minutes prior to each RT session and will rest at least 1 minute between sets of the same exercise to aid muscle recovery. Participants will perform at least 2 sets of 12 repetitions for each of 6 exercises. Including warm up, training sets, and rest, sessions will last approximately 30 minutes. RT will include six target exercises focusing on major muscle groups of the upper body, lower body, and core.
48134890|NCT02823574|BIOLOGICAL|Ipilimumab|
48134891|NCT02823574|OTHER|Placebo|
48513380|NCT04913012|COMBINATION_PRODUCT|Aerobic training booster sessions|Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).
48134893|NCT06303674|BEHAVIORAL|Physical activity with engaging cognitively|"This experimental condition will follow the following structure: involving 10 consecutive, 30 second-blocks of physical activity. This experimental condition will focus on aerobic metabolism. The total exercise time commitment is 10 minutes (30 seconds of working - 30 seconds of executing an engaging cognitive task, 1:1 work-to-rest ratio), plus 5 minutes of warm-ups and 5 minutes of cool-down activities. The cognitive task consists of solving various tangrams."
48134894|NCT06303674|BEHAVIORAL|Physical activity without engaging cognitively|This experimental condition will replicate the structure of the preceding one. Participants will engage in physical activity, guided by video observation and imitation. However, during the rest periods, they will refrain from engaging in cognitive tasks
48134895|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose|Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
48134896|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose|Medium dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
48134897|NCT05268302|BIOLOGICAL|Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose|High dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.
48134898|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
48134899|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
48657789|NCT05761756|BEHAVIORAL|Sleep Deprivation|24 hours sleep deprivation
48657790|NCT05761756|DRUG|Caffeine|Oral administration of caffeine
48134900|NCT03642366|OTHER|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
48513381|NCT04913012|COMBINATION_PRODUCT|Resistance training booster sessions|Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).
48513382|NCT01859910|PROCEDURE|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
48657791|NCT05761756|DRUG|Methylphenidate|Oral administration of methylphenidate
48657792|NCT05761756|DRUG|Carbon Dioxide|Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
48500421|NCT03092063|BEHAVIORAL|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
48500422|NCT03092063|BEHAVIORAL|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
48500423|NCT03092063|BEHAVIORAL|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
48500424|NCT03092063|BEHAVIORAL|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
48500425|NCT02632461|BEHAVIORAL|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
48500426|NCT02632461|BEHAVIORAL|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
48500427|NCT02632461|BEHAVIORAL|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
48500428|NCT01008982|DRUG|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
48500429|NCT03603548|DRUG|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
48500430|NCT03603548|DRUG|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
48500431|NCT02823418|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
48500432|NCT02823418|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
48657793|NCT01758120|DRUG|prednisone plus cyclophosphamide|"1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
48657794|NCT01758120|DRUG|Prednisone alone|"1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
48657795|NCT06497673|OTHER|sample collection|New collected samples, as well as surplus surgical and diagnostic samples.
48134901|NCT00766909|DRUG|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
48134902|NCT00766909|DRUG|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
48134903|NCT00766909|OTHER|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
48500433|NCT06052930|DEVICE|HTC Vive™ Pro|"A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session)."
48513383|NCT01859910|PROCEDURE|routine preparation for cataract|
48657796|NCT04512378|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
48657797|NCT05136560|DRUG|Dexamethasone|Intervention drugs would be administered for 1 or 2 days.
48513384|NCT03089710|OTHER|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
48513385|NCT00716794|DRUG|HE3235|HE3235 will be administered orally in 28 day cycles.
48513386|NCT02354625|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
48657798|NCT04142723|BIOLOGICAL|blood withdraw|venous blood sampling
48657799|NCT01450631|DEVICE|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
48134904|NCT03297138|PROCEDURE|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
48134905|NCT05508737|DRUG|Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)|Single arm: Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
48134906|NCT06635759|OTHER|Upper trapezius low-load endurance exercise|Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.
48500434|NCT05953090|DEVICE|7-0940|A non-hormonal and non-steroidal gel that supports vulvovaginal mucosal conditions and speeds up recovery post vaginal rejuvenation. It is a suitable alternative to vaginally administered estrogen and topical corticosteroids, that promotes a moist healing environment leading to faster re-epithelialization. The gel relieves symptoms such as itchiness, tenderness, dryness, burning sensation, painful intercourse (dyspareunia), painful urination (dysuria), rectal and defecating pain. It improves erythema, mucosal tissue thinning, erosions, fissures, ulcerations, scarring/adhesions and swelling. It is indicated for long-term use to maintain the health of the vaginal mucosa without the side effects of vaginally administered hormonal therapy and topical corticosteroids.
48134907|NCT06635759|OTHER|Upper trapezius stretching exercise|Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
48500435|NCT02418663|DRUG|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
48500436|NCT04504305|OTHER|NeuropAWAY|2 capsules thrice daily to be taken half an hour prior to meal.
48500437|NCT04504305|OTHER|Microcystalline cellulose|2 capsules thrice daily to be taken half an hour prior to meal.
48500438|NCT05543408|BEHAVIORAL|EXERCISE|individualized, progressive, exercise program
48500439|NCT04719962|PROCEDURE|Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease|"Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics."
48500440|NCT06506162|OTHER|Flavor|The study will compare sweet vs. cool flavors
48500441|NCT06506162|OTHER|Nicotine concentration|The study will compare low vs. high strength Oral Nicotine Products
48500442|NCT02648100|OTHER|biomarker study|
48500443|NCT00002608|DRUG|cisplatin|
48500444|NCT00002608|DRUG|doxorubicin hydrochloride|
48500445|NCT00002608|DRUG|tamoxifen citrate|
48500446|NCT00002608|PROCEDURE|conventional surgery|
48500447|NCT00002608|RADIATION|radiation therapy|
48500448|NCT06017310|DIAGNOSTIC_TEST|Evaluate the performance of IFN I/III|Evaluate the response in diagnosing non-respiratory viral infection.
48500449|NCT01682395|PROCEDURE|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
48500450|NCT01682395|PROCEDURE|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
48500451|NCT01682395|PROCEDURE|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
48500452|NCT01267721|PROCEDURE|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
48500453|NCT05206292|DIAGNOSTIC_TEST|Sulfitest|Urine strip to detect the presence of sulfites in urine. Immediate result.
48500454|NCT06151496|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
48500455|NCT06151496|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
48500456|NCT02107820|BEHAVIORAL|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
48134908|NCT02564705|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|
48134909|NCT02564705|PROCEDURE|Posterior Fusion|"* Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)"
48134910|NCT05657821|DIETARY_SUPPLEMENT|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
48134911|NCT06628908|DRUG|Suzetrigine|Tablets for oral administration.
48134912|NCT06628908|DRUG|Pregabalin|Capsules for oral administration.
47982365|NCT05728450|DEVICE|Light amplification by stimulated emission of radiation (LASER)|"* The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points"
48134913|NCT06628908|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
48134914|NCT06628908|DRUG|Placebo (matched to Pregabalin)|Placebo matched to Pregabalin for oral administration.
48343964|NCT03157336|OTHER|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.
48500457|NCT02107820|DEVICE|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
48500458|NCT04709770|DRUG|2-liters polyethylene glycol with citrate and simethicone|Low-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
48500459|NCT04709770|DRUG|4-liters polyethylene glycol with simethicone|High-volume polyethylene glycol-based bowel cleansing agent for colonoscopy.
48500460|NCT04709770|DIETARY_SUPPLEMENT|Low-residue diet|Diet before colonoscopy.
48500461|NCT01877226|DRUG|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
47982366|NCT01777256|DRUG|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
47982367|NCT01777256|DRUG|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
48500462|NCT02155543|DRUG|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
48134916|NCT03616015|BIOLOGICAL|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
48134917|NCT03616015|BIOLOGICAL|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
48134918|NCT03616015|BEHAVIORAL|Anxiety test|Test of Spielberger
48134919|NCT03616015|BEHAVIORAL|Stress test|Test of Cohen
48134920|NCT03677037|OTHER|Short-term MBT|Short-term mentalization-based therapy
48134921|NCT03677037|OTHER|Long-term MBT|Long-term mentalization-based therapy
48134922|NCT06336590|BEHAVIORAL|Morning Exercise|Exercise is changed from normal (6pm-11pm) exercise to morning (6am-11am) exercise.
48134923|NCT05141539|DEVICE|Rehabilitation assessment software|"In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability."
48134924|NCT05141539|DEVICE|VFSS and FOIS|In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
48500463|NCT02155543|DRUG|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
48500464|NCT02155543|DRUG|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
48134925|NCT06121375|DRUG|OCA|OCA will be administered.
48134926|NCT06121375|DRUG|Matching Placebo|Matching Placebo will be administered.
48134927|NCT03861234|DRUG|BI 836880|Solution for Intravitreal (IVT) injection
48134928|NCT05819398|DRUG|Spesolimab Formulation 1|Spesolimab Formulation 1
48134929|NCT05819398|DRUG|Spesolimab Formulation 2|Spesolimab Formulation 2
48343965|NCT06507358|BEHAVIORAL|Parent-Child Interaction group|The intervention for the Parent-Child Interaction group consists of a 6-week program involving weekly 40-minute sessions of therapeutic horticulture in a group setting, with 4-6 participants per group. The sessions focus on sensory-motor activities aimed at helping children engage in daily tasks and activities. Various sensory stimuli are provided through different materials used in gardening activities, including visual, auditory, gustatory, tactile, and olfactory stimuli. The program encourages mutual support and sharing among group members, showcases different outcomes, and emphasizes a sense of responsibility for home care. With a family-centered approach, parental involvement serves as a mediator to promote children's overall development and abilities. Participants are required to complete homework assignments and maintain activity records, including documentation of the 6 sessions through photos and written records.
48343966|NCT05041062|DRUG|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
48343967|NCT05041062|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
48343968|NCT00405236|DRUG|tiotropium|
48343969|NCT01292525|DRUG|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
48343970|NCT01292525|DRUG|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
48343971|NCT04986111|PROCEDURE|Linear skin closure with wound drain|"An oval incision is made around the ileostomy and the continuity of the intestinal tract is restored after adhesion division.~Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. A Jackson-Pratt drainage tube is placed in the subcutaneous tissue and vertical mattress suture is performed with a non-absorbable thread."
48500465|NCT02155543|DRUG|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
48500466|NCT00174954|PROCEDURE|MRI|Subjects underwent MRI to evaluate tophi.
48500467|NCT05988632|DRUG|Regular Human Insulin then Placebo|Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
48657800|NCT01450631|DEVICE|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
48657801|NCT05256537|OTHER|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
48500468|NCT05988632|DRUG|Placebo then Regular Human Insulin|Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
48500469|NCT06370130|DRUG|Esketamine 0.2mg/kg|"Patients received 0.2 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
48500470|NCT06370130|DRUG|Esketamine 0.3mg/kg|"Patients received 0.3 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points."
48500471|NCT04229927|DRUG|BPDO-1603|"Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug~Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug"
48500472|NCT06455007|DRUG|Propolis|Propolis 3x10 drops (7 days)
48500473|NCT03219619|DEVICE|Cap-EGD|Undergoing cap-assisted endoscopy
48500474|NCT03219619|DEVICE|Duo|Undergoing side-viewing duodenoscope
47982368|NCT01777256|DRUG|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
47982369|NCT01777256|DRUG|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
47982370|NCT01777256|DRUG|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
47982371|NCT03273374|DEVICE|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
47982372|NCT00190996|DRUG|Duloxetine Hydrochloride|
47982373|NCT00190996|DRUG|placebo|
47982374|NCT04240925|DEVICE|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
48134930|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 1|Placebo matching Spesolimab Formulation 1
48134931|NCT05819398|DRUG|Placebo matching Spesolimab Formulation 2|Placebo matching Spesolimab Formulation 2
48500475|NCT04987697|BEHAVIORAL|counseling|nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
48500476|NCT00991419|DRUG|[18F]AZD4694|\[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
48500477|NCT03577418|BEHAVIORAL|Clinician-facilitated educational intervention|People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.
48343972|NCT04986111|PROCEDURE|Purse-string skin closure with negative pressure wound therapy|"Recover the intestinal continuity after adhesion division by making a circular incision along the ileostomy Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. Negative pressure wound therapy is performed after suturing the subcutaneous tissue using absorbable thread."
48343973|NCT04748913|DEVICE|Radiographic examination|Standardized bitewing radiographs will be performed by the principal investigator
48343974|NCT04748913|DEVICE|Scanning with DIAGNOcam|The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device
48343975|NCT04748913|DEVICE|Scan with DIAGNOcam and Indocyanine|One the dye has been applied, a new series of images will be taken with Diagnocam
48343976|NCT04748913|DIAGNOSTIC_TEST|Visual-tactile exploration with separation|The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator
48343977|NCT05258526|OTHER|Home based exercise training|The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
48343978|NCT04689217|DRUG|intrathecal drug injection|"All patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~The patients will be divided equally into 3 groups according to the additive (fentanyl, nalbuphine or placebo), and all patients will receive the local anesthetic dose of 0.5% heavy bupivacaine according to weight and height"
48500478|NCT03577418|BEHAVIORAL|Enhanced usual care|In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
48500479|NCT06270212|DEVICE|STAIRWAY|Evaluation of STAIRWAY (new airway device) during sedation.
48500480|NCT06270212|DEVICE|NO DEVICE|Evaluation of NO DEVICE during sedation
47982375|NCT04240925|DEVICE|Standard NIMV|Will be treated by standard NIMV with no sigh
48500481|NCT03944174|PROCEDURE|Fixation of unstable pelvic fractures|Percutaneous fixation of both iliac bones through the sacrum using one screw
48500482|NCT01296282|DEVICE|Medronics CRT Optivol Impedance Measurement|Pacemaker
48500483|NCT01296282|DEVICE|External Thoracic Impedance Measurement|
48500484|NCT00601562|DRUG|Zidovudine|
48500485|NCT03563651|PROCEDURE|Biopsy|Undergo biopsy
48500486|NCT03563651|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and stool
48500487|NCT03563651|OTHER|Laboratory Biomarker Analysis|Correlative studies
48500488|NCT03563651|OTHER|Questionnaire Administration|Ancillary studies
47982376|NCT01737151|RADIATION|stereotactic body radiation therapy|Undergo SBRT
47982377|NCT01737151|RADIATION|four fraction split-course SBRT|four fraction split-course SBRT
47982378|NCT06043089|DIETARY_SUPPLEMENT|Beetroot juice supplementation or placebo|Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
47982379|NCT06085079|DRUG|Ixekizumab Prefilled Syringe|Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
47982380|NCT02654483|DRUG|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
47982381|NCT02654483|OTHER|Placebo|Matching tablets to VPD-737 tablets without active drug
47982382|NCT00005610|BIOLOGICAL|sargramostim|
47982383|NCT00168688|DIETARY_SUPPLEMENT|multi micronutrient supplement|
47982384|NCT00168688|DIETARY_SUPPLEMENT|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
48513387|NCT01141855|DRUG|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)"
48513388|NCT01141855|BEHAVIORAL|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
48343979|NCT01415908|DEVICE|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
48343980|NCT01415908|OTHER|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
48343981|NCT02826876|DRUG|Topical use|Topical use of Ropivacaine in laparoscopic surgery
48343982|NCT02826876|OTHER|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
48343983|NCT02826876|OTHER|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
48343984|NCT05633797|DEVICE|FibriCheck|During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
48343985|NCT05810298|OTHER|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
48343986|NCT05810298|OTHER|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
48343987|NCT05810298|BEHAVIORAL|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
48343988|NCT00396422|DRUG|RWJ-445380|
48343989|NCT00853190|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
48343990|NCT00853190|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
48343991|NCT05392166|DIAGNOSTIC_TEST|blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound|blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.
48343992|NCT01438359|DRUG|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
48343993|NCT01438359|DRUG|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
48343994|NCT01438359|DRUG|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
48513389|NCT05378594|DIAGNOSTIC_TEST|Nasal allergen challenge|graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
48513390|NCT04439617|BIOLOGICAL|blood examination|use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
48513391|NCT02794246|BIOLOGICAL|CART-19 cells|
48343995|NCT00895778|OTHER|Neuromuscular blockade with rocuronium and reversal with sugammadex|
48343996|NCT01863901|DEVICE|Treatment with Cryo-Touch III device|
48343997|NCT03456180|DEVICE|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
48343998|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth Supplement & Hair Nutra Boost Supplement|"Study Initiation (Week 0) to Week 8:~Each participant will take both the Hair Nutra Growth capsules and the Hair Nutra Boost capsules.~Participants should take 2 capsules of Hair Nutra Growth daily, one in the morning and one in the afternoon, with food or after a meal. The capsules should be taken with water.~Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
48343999|NCT06120933|DIETARY_SUPPLEMENT|Hair Nutra Growth|"From Week 9 to Week 12:~Participants should ONLY take the Hair Nutra Growth. Participants should take 1 capsule of Hair Nutra Boost daily with food or after a meal. These capsules should also be taken with water."
48500489|NCT02991326|OTHER|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~* Compression of the fourth ventricle;~* inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~* inhibition of the inferior head of the lateral pterygoid muscle;~* intra-oral inhibition of the masseter muscle;~* Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~* BLT of the accessory ligaments - pterygomandibular raphe;~* sphenopalatine ganglion technique;~* Craniosacral rebalancing;"
48500490|NCT02991326|OTHER|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
48500491|NCT03421730|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System|The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
48500492|NCT03421730|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
48500493|NCT00003577|DRUG|CMF regimen|
48500494|NCT00003577|DRUG|cyclophosphamide|
48500495|NCT00003577|DRUG|epirubicin hydrochloride|
48500496|NCT00003577|DRUG|fluorouracil|
48657802|NCT05280860|PROCEDURE|ultrasound-guided bilateral rectus sheath block|Bilateral RSB was guided by ultrasound before surgery after the completion of general anesthesia, First, the probe is placed transversely and perpendicular to reveal the anterior, hypoechoic, and posterior rectus sheath of the hyperechoic rectus abdominis. Moving the probe outward to reveal the sound images of the lateral margin of the rectus abdominis, external oblique, internal oblique, and transverse abdominis muscles. After the scanning, the needle was inserted from any segment of the probe under the guidance of real-time ultrasound; the tip reached between the rectus abdominis muscle and the posterior sheath of the rectus abdominis muscle. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct, If the needle tip was correctly positioned, 0.5 % ropivacaine 10 mL of local anesthetic was injected on each side. The same anesthesiologist was performed bilateral RSB under ultrasound guidance.
48657803|NCT04096677|PROCEDURE|hysteroscpy|
48657804|NCT03598829|DIAGNOSTIC_TEST|Tryptase, Serum test|Blood draw lab test which measures concentration of Tryptase in the sample. Tryptase is the one of the primary secretions of active mast cells and is used as a measure of inflammatory activity. Normal Reference Value: \&lt;11.5 ng/mL
48657805|NCT06645171|DIETARY_SUPPLEMENT|Fibre drink|One drink will be tested
48657806|NCT01160718|DRUG|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
48657807|NCT01160718|DRUG|selumetinib|AZD6244 75 mg p.o. bid
48657808|NCT02108808|DRUG|Ticagrelor|
48657809|NCT02108808|DRUG|Prasugrel or Clopidogrel|
48344000|NCT00748306|DRUG|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
48344001|NCT00748306|DRUG|Placebo|Matching Intervention Drug
48344002|NCT00643097|BIOLOGICAL|PEP-3 vaccine|Given intradermally
48344003|NCT00643097|BIOLOGICAL|sargramostim|Given intradermally
48344004|NCT00643097|DRUG|Temozolomide|Standard of care chemotherapy
48344005|NCT00788918|DRUG|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
48344006|NCT03466671|DRUG|TTA-121|A nove intranasal spray of oxytocin and placebo
48500497|NCT00003577|DRUG|methotrexate|
48500498|NCT00003577|PROCEDURE|adjuvant therapy|
48500499|NCT00003577|RADIATION|radiation therapy|
48500500|NCT03760003|DRUG|ABX464 25mg|ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
48500501|NCT03760003|DRUG|ABX464 50mg|ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
48500502|NCT03760003|DRUG|ABX464 100mg|ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
48500503|NCT03760003|DRUG|Placebo|Two capsules of placebo once daily for 16 weeks
48344007|NCT01786850|PROCEDURE|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
48344008|NCT04907812|DRUG|Tranexamic acid|Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery
48344009|NCT04907812|PROCEDURE|Surgery|This will include regional anaesthesia, tourniquet inflation to 250mmHg and perioperative antibiotics. At the conclusion of the procedure hemostasis will be achieved followed by standard closure technique. There will be three separate surgical groups that will undergo the outlined study protocol: 1) Distal radius fractures will be treated with open reduction from a volar approach only technique 2) Mild dupuytren's: a. Low: i. MCP joints \<50 contracture ii. PIP joints \<40 contracture b. 1-2 fingers involved 3) Severe dupuytren's a. High: i. MCP joints \>50 degree contracture ii. PIP Joints \>40 degrees contracture b. \>2 fingers involved
48344010|NCT03499340|BEHAVIORAL|text-only PWL|control condition (no image)
48344011|NCT03499340|BEHAVIORAL|low arousal graphic PWL|pictorial warning
48344012|NCT03499340|BEHAVIORAL|high arousal graphic PWL|pictorial warning
48344013|NCT03499340|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
48344014|NCT03499340|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
48344015|NCT00723268|DRUG|Prednisolone|5MG Prednisolone per day for 3 months
48344016|NCT00723268|DRUG|Colchicine|0.5 MG Colchicine per day for 3 months
48500504|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
48500505|NCT01909063|DIETARY_SUPPLEMENT|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
48657810|NCT04474847|DRUG|Abatacept|Participants randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
48657811|NCT04474847|DRUG|Placebo|Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
48657812|NCT05932914|PROCEDURE|Liver Biopsy|Standard transjugular liver biopsy under moderate sedation
48344017|NCT06039150|PROCEDURE|M-TAPA Block|M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.
48344018|NCT06039150|PROCEDURE|Local anesthetic infltration to port sites|Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
48344019|NCT00106249|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
48344020|NCT00106249|DEVICE|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
48500506|NCT01909063|DIETARY_SUPPLEMENT|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
48500507|NCT02167373|OTHER|Cogito Companion Intervention|
48500508|NCT02167373|DEVICE|mobile phone application|
48500509|NCT03946553|OTHER||No intervention
48500510|NCT01683838|DRUG|Fampridine-SR|25mg bid (twice daily)
48657813|NCT06609304|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel at 2.0×10\^6/Kg
48657814|NCT02420314|DRUG|Paclitaxel|"* Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
48500511|NCT01683838|DRUG|Placebo|Placebo
48500512|NCT00543946|DRUG|GAP-134|24-Hour IV infusion, SAD
48500513|NCT04620928|BEHAVIORAL|Concepts|Images and sounds that are characteristic of various common objects.
48500514|NCT01996332|DRUG|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
48134940|NCT05357911|DRUG|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
48134941|NCT04776239|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
48134942|NCT04776239|OTHER|Placebo|Placebo delivered via peripheral intravenous infusion
48500515|NCT03735316|DRUG|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
48500516|NCT03735316|PROCEDURE|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
48500517|NCT03735316|DRUG|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
48500518|NCT00987389|PROCEDURE|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
48344021|NCT00779363|DEVICE|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
48500519|NCT00987389|OTHER|No Plasma Exchange|No plasma exchange.
48500520|NCT00987389|DRUG|Glucocorticoids [Standard Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
48500521|NCT00987389|DRUG|Glucocorticoids [Reduced Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
47982385|NCT00168688|DIETARY_SUPPLEMENT|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
47982386|NCT05752903|DRUG|Dexmedetomidine-propofol|1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion
47982387|NCT05752903|DRUG|Ketamine-Propofol|1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
47982388|NCT06181201|PROCEDURE|Stool collection|"Stool collection is done with the Coll-off device (Zymo research, reference R1101-2-5) provided to the patient before and after the induction treatment and after the reference chemo-radiotherapy treatment (Cap50, Capecitabine). Collection must be carried out by the patient at home (collection using the Coll-off device and then transfer to a coproculture jar provided). The fresh sample is then picked up the same day by an approved transporter mandated by the promoter and will be stored at -20°C until the start of the analyses"
47982389|NCT02288559|OTHER|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
47982390|NCT02288559|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
47982391|NCT02402439|DRUG|Islet cells|Transplantation of islets into the gastrointestinal submucosa
47982392|NCT02402439|PROCEDURE|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
47982393|NCT04859023|DIAGNOSTIC_TEST|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
47982394|NCT04859023|DIAGNOSTIC_TEST|saliva sample (Self-sample)|Tested by RT-PCR.
47982395|NCT04859023|OTHER|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
47982396|NCT04859023|OTHER|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
47982397|NCT03067649|BEHAVIORAL|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
48500525|NCT00205244|BEHAVIORAL|Healing images, relaxation and distraction materials|
48500526|NCT01004094|BEHAVIORAL|simple goal setting|This group will set goals only
48500527|NCT01004094|BEHAVIORAL|goal setting plus action intentions|This group will set goals and form action intentions (plans)
48500528|NCT01004094|BEHAVIORAL|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
48500529|NCT01004094|BEHAVIORAL|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
48500530|NCT04467801|DRUG|Ipatasertib|Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
48500531|NCT02336035|PROCEDURE|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
48500532|NCT02185053|DRUG|CPC-201|
48134953|NCT04110301|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
48134954|NCT04110301|DRUG|Lenalidomide|Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
48500533|NCT00044668|DRUG|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
48500534|NCT05226546|DRUG|Platelet rich plasma (PRP)|PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
48657815|NCT02420314|DRUG|Carboplatin|"* Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
48500535|NCT05226546|OTHER|olfactory training|"The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training."
48500536|NCT04527445|PROCEDURE|Reduced radiation fluoroscopy|See previous information about each arm
48500537|NCT04527445|PROCEDURE|Conventional fluoroscopy|See previous information about each arm
48500538|NCT02740387|DRUG|OTO-104|
48657816|NCT02420314|DRUG|Ascorbic Acid|"* Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts"
48657817|NCT01587196|DRUG|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
48500539|NCT03881956|BEHAVIORAL|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
48134962|NCT06311266|DEVICE|Robotic endoscopic neurosurgical intervention|Robotic guidance device for intraoperative trajectory alignment in endoscopic neurosurgical procedures
48134963|NCT06015308|DRUG|Amlitelimab|Subcutaneous injection in abdomen, outer thigh, or upper arm
48344022|NCT02137304|DEVICE|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
48344023|NCT03948113|OTHER|Dialysis|
48500540|NCT02734654|PROCEDURE|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
48500541|NCT05975138|PROCEDURE|implant insertion|a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
48513392|NCT03762044|OTHER|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"* Health education / patient empowerment.~* Neurodynamic activities oriented to ADL.~* Proprioceptive neuromuscular facilitation exercises oriented to ADL.~* Self-adherent self-adhesive antiedema of low compression."
48134964|NCT06015308|DRUG|Placebo|Subcutaneous injection in abdomen, outer thigh, or upper arm
48134965|NCT06015308|BIOLOGICAL|Tdap vaccine|Intramuscular (IM) injection into the deltoid muscle of the upper arm
48134966|NCT06015308|BIOLOGICAL|PPS vaccine|Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
48344024|NCT00923962|DRUG|Glucagon like peptide-1|0,1 pmol/kg/min
48344025|NCT00923962|DRUG|Adenosine|20-40 microgram/minute
48344026|NCT00646750|DRUG|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
48344027|NCT06009198|DRUG|Iron folate tablets|Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
48344028|NCT00493441|DRUG|AVN944|150, 200, 250, 300, or 400 mg q12h
48344029|NCT00650897|DRUG|Escitalopram|10-20 mg once daily
48344030|NCT02027272|DRUG|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
48344031|NCT03561246|OTHER|Incline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
48134969|NCT05856552|BEHAVIORAL|CBT|Cognitive behavioral therapy delivered by community resource persons via home visits.
48134970|NCT05856552|BEHAVIORAL|Group Activities|Weekly hour-long group activities delivered by community resource persons in community spaces.
48500542|NCT03047798|DRUG|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
48500543|NCT03638778|DRUG|Semaglutide 3 mg|Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
48500544|NCT03638778|DRUG|Semaglutide 7 mg|Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
48500545|NCT03638778|DRUG|Semaglutide B 3 mg|Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
48344032|NCT03561246|OTHER|Decline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
48344033|NCT03561246|OTHER|Level Treadmill (Control)|Those with a Pp \<0.47 or \>0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
48344034|NCT05181748|BIOLOGICAL|Autologous platelet rich plasma|Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
48500546|NCT03638778|DRUG|Semaglutide B 7 mg|Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
48500547|NCT03638778|DRUG|Semaglutide C 3 mg|Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
48500548|NCT03638778|DRUG|Semaglutide C 7 mg|Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
48500549|NCT03638778|DRUG|Semaglutide D 3 mg|Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
48500550|NCT03638778|DRUG|Semaglutide D 7 mg|Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
48500551|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
48500552|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
48500553|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
48500554|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
48500555|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
48500556|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
48500557|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
47982398|NCT03067649|BEHAVIORAL|Information only control|Participants are provided with a pamphlet containing referral information
48134975|NCT05728645|DRUG|Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg|Intravenous Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg before induction of general anesthesia
48134976|NCT05728645|DRUG|Multiple Electrolytes injection of 5 ml/kg|Intravenous Multiple Electrolytes injection of 5ml/kg before induction of general anesthesia
48134977|NCT05432804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48134978|NCT05432804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48344035|NCT02611518|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
48344036|NCT02611518|DRUG|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
48344037|NCT02611518|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
48344038|NCT00838383|DRUG|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
48344039|NCT00838383|DRUG|sitaxsentan (Thelin)|Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
48500558|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
48500559|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
48500560|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
48500561|NCT01512706|BIOLOGICAL|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
47982399|NCT00426192|DRUG|i.v. mannitol|
47982400|NCT00426192|PROCEDURE|hemofiltration|
48134979|NCT05432804|DRUG|Selinexor|Given PO
48134980|NCT05432804|DRUG|Temozolomide|Given PO
48344040|NCT00838383|DRUG|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
48344041|NCT02533856|OTHER|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
48134981|NCT05529420|OTHER|measurement of the depth of neuromuscular blockade|time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
48344042|NCT01405027|PROCEDURE|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
48344043|NCT01405027|OTHER|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
48344044|NCT01261260|DRUG|Uridine|1 gram tablets BID for 7 days
48344045|NCT01023373|DRUG|Medical treatment|hypotensive drugs, statins and anti-platelets
48344046|NCT01023373|PROCEDURE|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
48344047|NCT01023373|DEVICE|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
48344048|NCT01023373|DEVICE|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
48344049|NCT04815733|PROCEDURE|Mandatory ventilation|Use PCV-VG
48344050|NCT04815733|PROCEDURE|pressure support ventilation|Use PSVpro
48500562|NCT01512706|BIOLOGICAL|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
48500563|NCT01512706|BIOLOGICAL|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
48500564|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
48500565|NCT01512706|BIOLOGICAL|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
48500566|NCT01154816|DRUG|Alisertib|Given orally
48500567|NCT01154816|OTHER|Laboratory Biomarker Analysis|Correlative studies
48500568|NCT01154816|OTHER|Pharmacological Study|Correlative studies
48500569|NCT04917653|DEVICE|Heart rhythm monitoring with wearable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel."
48657818|NCT04175184|OTHER|Mobilisation with Movement|"MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion."
48344051|NCT05078307|PROCEDURE|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
48344052|NCT03551184|BIOLOGICAL|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
48344053|NCT03551184|BIOLOGICAL|Placebo|Saline administered intravenously
48344054|NCT04443894|OTHER|PECS block|PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
48134982|NCT05184062|DRUG|600 mg AZD7442 IV|Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
48134983|NCT05184062|DRUG|600mg placebo IV|Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
48134984|NCT06598306|DRUG|Tarlatamab|Administered by SC injection.
48134985|NCT06593457|DRUG|IP|NX-5948 oral
48344055|NCT04443894|OTHER|local infiltration|local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
48344056|NCT00373906|DRUG|Bortezomib (Velcade)|
48344057|NCT02899260|DEVICE|Peanut Exercise Ball|A Peanut shaped exercise ball.
48344058|NCT03491904|DRUG|Fasinumab AI|Self-administered with auto injector
48344059|NCT03491904|DRUG|Fasinumab PFS|Prefilled syringe administered by study staff
48344060|NCT06248242|DRUG|Edaravone dexborneol|edaravone 10 mg and dexborneol 2.5 mg twice daily
48344061|NCT05668806|DEVICE|Cerviron|Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
48344062|NCT03783013|OTHER|High Lycopene Tomato Juice With Soy Germ Extract|Tomato juice made from high lycopene tomatoes with soy germ extract added
48344063|NCT03783013|OTHER|Low Lycopene Tomato Juice|Tomato juice made from low lycopene tomatoes with no soy germ extract added
48344064|NCT00836524|PROCEDURE|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
48344065|NCT02569333|OTHER|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
48344066|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
48344067|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
48344068|NCT01502761|DRUG|Magnesium Sulfate|Intra-arterial
48344069|NCT04713670|DRUG|(A) T-V14|vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
48344070|NCT04713670|DRUG|(B) T-V7|vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
48344071|NCT04713670|DRUG|(C) D-V14|vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
48344072|NCT04713670|DRUG|(D) HD-V14|vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
48344073|NCT04713670|DRUG|(E) BQ-V14|vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
48344074|NCT04713670|DRUG|(F) RH-V14|vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
48344075|NCT04713670|DRUG|(G) BQ-L14|lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
48344076|NCT04713670|DRUG|(H) T-L14|lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
48344077|NCT00796224|DRUG|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
48344078|NCT00796224|DRUG|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
48344079|NCT00453661|BEHAVIORAL|Questionnaire|"Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only."
48344080|NCT00453661|BEHAVIORAL|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
48344081|NCT01304472|DRUG|Prasugrel|Prasugrel 10mg per day
48344082|NCT01304472|DRUG|Clopidogrel|Clopidogrel 150mg per day
48344083|NCT02868164|DRUG|Fecal Microbiota Transplantation|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
48344084|NCT02868164|DRUG|Standard Treatment|Standard Treatment
48344085|NCT02868164|OTHER|Weight Reduction|routine exercise for weight reduction
48344086|NCT02713945|DRUG|Simvastatin|Experimental drug administrated orally
48344087|NCT02713945|DRUG|Placebo|Treatment for the control group
48134986|NCT06593457|DRUG|Matching Placebo|Fluconazole
48344088|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
48344089|NCT00643448|DRUG|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
48344090|NCT00643448|DRUG|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
48344091|NCT05839236|COMBINATION_PRODUCT|Atorvastatin Calcium Tablets|The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
48500570|NCT04917653|OTHER|Blood samples and biomarkers|"Several blood samples will be collected during the study protocol in pre-defined times before and after the cardioversion intervention.~Atrial peptides and cardiac troponins will be analyzed and kinetics estimated to predict the duration of early-onset AF period."
48500571|NCT00315731|BIOLOGICAL|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
48134989|NCT06665022|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode). For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
48134990|NCT06665022|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
48134991|NCT01558544|PROCEDURE|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
48344092|NCT04296604|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
48344093|NCT04720313|DRUG|NXC-201 (formerly HBI0101)|NXC-201 (formerly HBI0101) CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 (formerly HBI0101) CART is provided fresh without cryopreservation.
48344094|NCT02106104|DRUG|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
48344095|NCT02106104|DRUG|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
48500572|NCT03033966|DEVICE|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
48500573|NCT00005727|BEHAVIORAL|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
48500574|NCT04883619|OTHER|Placebo|Placebo will be administered intravenously.
48500575|NCT04883619|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
48500576|NCT04883619|DRUG|Standard-of-care treatment|Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
48657819|NCT04175184|OTHER|Sham Mobilisation with Movement|Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
48500577|NCT04443348|RADIATION|Radiation Therapy Boost|Participants randomized to the low-dose or high-dose RT boost group will be receiving treatment on Day 1-3 of Cycle 1 of pembrolizumab. Proton therapy may be used in the high dose RT group.
48344096|NCT03147573|DIAGNOSTIC_TEST|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
48344097|NCT03147573|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
48344098|NCT03147573|DIAGNOSTIC_TEST|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
48500578|NCT04443348|DRUG|Pembrolizumab|"Neoadjuvant Phase: Day 1 (once every 6 weeks) of Cycles 1-4 (by intravenous infusion) over about 30 minutes.~Adjuvant Phase: Pembrolizumab may be given post-surgery for up to 4 cycles (once every 6 weeks) by intravenous infusion over about 30 minutes. Pembrolizumab after surgery is optional and should be discussed with the study doctor."
48500579|NCT04443348|DRUG|Paclitaxel|Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes.
48500580|NCT04443348|DRUG|Carboplatin|"Carboplatin is optional for TNBC patients and should be discussed with the study doctor.~Starting Week 3 and administered once per week for 12 weeks (up to 12 doses) by intravenous infusion over about 30 minutes."
48500581|NCT04443348|DRUG|Cyclophosphamide|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion).
48500582|NCT04443348|DRUG|Doxorubicin|Starting Week 15 and administered every 2 weeks for 4 cycles (up to 4 doses) into your vein (by intravenous infusion). Doxorubicin will be administered after pembrolizumab.
48344099|NCT03147573|DIAGNOSTIC_TEST|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
48344100|NCT03507192|DEVICE|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
48500583|NCT04443348|DRUG|Capecitabine|"Capecitabine after surgery is optional for TNBC patients and should be discussed with the study doctor.~Starting 3-6 weeks after surgery, administered orally twice daily for 6 courses, each 3 weeks long (for a total of 18 weeks)."
48500584|NCT01864850|RADIATION|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
47982401|NCT04497506|BEHAVIORAL|Wise Intervention (Self-affirmation and Incremental theory of personality)|The intervention designed to promote prosocial behavior and reduce online risks is based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes two components: a self-affirmation activity and an ITP intervention. The SA component includes a list of values so that they could choose the two or three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component includes activities such as reading scientific information about social behavior and its role in people's well-being, the meaning and value of online risk behaviors through stories and videos of the experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change.
47982402|NCT04497506|BEHAVIORAL|Standard preventive intervention|It consists of an educational intervention that provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
47982403|NCT02076880|OTHER|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.~* usual breakfast of the patient (possibly limited in quantity)~* midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
47982404|NCT02076880|OTHER|No caloric restriction|No change in eating habits to patients in this arm
47982405|NCT04833504|BIOLOGICAL|CD19 CAR-T Expressing IL7 and CCL19|A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19
47982406|NCT00213798|PROCEDURE|Biopsy samples|
47982407|NCT05390879|OTHER|Meditation|After the circuit, a 6 minutes long meditation auto-guided video.
47982408|NCT05390879|OTHER|Control|After the circuit, a 6 minutes long emotionally neutral video.
47982409|NCT00105482|DRUG|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
47982410|NCT00105482|DRUG|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
47982411|NCT00105482|BEHAVIORAL|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
47982412|NCT02859207|DRUG|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
47982413|NCT02625259|DRUG|TAK-117|TAK-117 capsules
47982414|NCT02625259|DRUG|Lansoprazole|Lansoprazole capsules
47982415|NCT02625259|DRUG|TAK-117|TAK-117 tablets
47982416|NCT01110954|DRUG|PD L 506|Two different doses will be compared
47982417|NCT04955522|DIAGNOSTIC_TEST|radiomics|Differential diagnosis of spinal myeloma and metastases by radiomics
47982418|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
48500585|NCT01864850|RADIATION|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
48344101|NCT01392768|DRUG|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
48344102|NCT01392768|DRUG|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
47982419|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
47982420|NCT00680043|DRUG|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
47982421|NCT00806754|DRUG|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
47982422|NCT00806754|DRUG|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
47982423|NCT05518643|PROCEDURE|ERAS protocol|ERAS protocol as described above
47982424|NCT05049876|OTHER|urine sample taken during consultations|urine sample taken during consultations
48344103|NCT01599572|OTHER|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
48500586|NCT02040779|DRUG|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
48513393|NCT03762044|OTHER|Complete Decongestive Therapy (CDT)|"* Skin care.~* Kinesitherapy~* Manual lymphatic drainage (MLD)~* Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
48513394|NCT03149276|OTHER|Interpreter services|
48500587|NCT02040779|DRUG|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
48344104|NCT00946023|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
48344105|NCT00946023|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
48344106|NCT00946023|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
48344107|NCT00946023|DRUG|Tacrolimus|Start on Day 5 through Day 180
48500588|NCT02040779|DRUG|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
48657820|NCT02998866|PROCEDURE|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI \[means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
48657821|NCT03913130|DRUG|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
47982425|NCT01778881|OTHER|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
47982426|NCT01778881|OTHER|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
47982427|NCT01778881|OTHER|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
47982428|NCT01778881|OTHER|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
48344108|NCT00946023|DRUG|Mycophenolate Mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
48344109|NCT00946023|DRUG|Rituximab|Day 30 and every week after for 8 total doses: 375 mg/m\^2 IV
48344110|NCT00946023|BIOLOGICAL|Allogeneic Bone Marrow Transplant (BMT)|Day 0: Donor bone marrow infusion
47982429|NCT00740844|DEVICE|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
47982430|NCT03770442|DEVICE|Cycling with FES|As described already
48344111|NCT04010812|OTHER|Questionnaire|RHDS- Readiness For Hospital Discharge Scale, Patient Self-Assessment Form
48344112|NCT00323427|BEHAVIORAL|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
47982431|NCT03770442|OTHER|Routine physiotherapy|As described already
47982432|NCT02600949|DRUG|Imiquimod|Applied topically
48344113|NCT00323427|DEVICE|hearing aid services|Standard VA audiological hearing aid dispensing services
48344114|NCT02621372|OTHER|platelet count|Correlation of esophageal varices with platelet count
48344115|NCT01455233|DRUG|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
48344116|NCT01455233|DRUG|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
48344117|NCT04739241|DRUG|premixed insulin therapy|Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).
47982433|NCT02600949|BIOLOGICAL|Pembrolizumab|Given IV
47982434|NCT02600949|BIOLOGICAL|Sotigalimab|Given IV
47982435|NCT02600949|BIOLOGICAL|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
47982436|NCT02600949|PROCEDURE|Computed Tomography|Undergo CT
47982437|NCT02600949|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48344118|NCT04739241|DRUG|basal bolus insulin therapy|Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals
48344119|NCT05255705|OTHER|Observation only|Observation only
48344120|NCT03907449|DIAGNOSTIC_TEST|Preview Rapid Strep A test|Rapid assay for the detection of type A streptococcal infection of the throat.
48344121|NCT00111891|DRUG|niacin (+) laropiprant|
48344122|NCT00111891|DRUG|Comparator: placebo (unspecified)|
48657822|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Neutral-Relaxing)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of neutral everyday objects (e.g., tools, dirt) and their use (construction, gardening).
48657823|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Drug)|Audio instruction for participant to allow themselves to experience their feelings followed by 3-min passive viewing of images of drug paraphernalia (e.g., syringe, tourniquet, heroin) and preparation.
48657824|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Non-Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping an everyday object (e.g., box of crayons) and taking out its contents.
48657825|NCT06440577|BEHAVIORAL|Audio-visual stimuli (Food)|Audio instruction for participant to focus their attention on the experimenter followed by 3-min audio-guided viewing of the experimenter opening/unwrapping a snack (e.g., chocolate bar, bag of chips) and taking out its contents.
47982438|NCT01051050|BEHAVIORAL|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
47982439|NCT01051050|BEHAVIORAL|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
47982440|NCT02371551|OTHER|Blood/urine sampling|Routine chemistry profile
47982441|NCT02371551|OTHER|Conventional routine CT examination|Standard diagnostic examination
47982442|NCT02371551|OTHER|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
47982443|NCT02371551|OTHER|Functional MRI|Study-specific diagnostic examination
47982444|NCT00003596|DRUG|cisplatin|
47982445|NCT00003596|DRUG|fluorouracil|
47982446|NCT00003596|DRUG|mitomycin C|
47982447|NCT00003596|RADIATION|radiation therapy|
47982448|NCT03912285|DRUG|Amlodipine10mg|Amlodipine 10mg will be administered orally twice a day for 9 days
47982449|NCT03912285|DRUG|Losartan potassium 100mg|Losartan 100mg will be administered orally once a day for 9 days
47982450|NCT03912285|DRUG|Amlodipine plus Losartan|"Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan"
47982451|NCT02337257|DRUG|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
47982452|NCT02337257|DRUG|Placebo|subjects will receive placebo one pill per day for 16 weeks
47982453|NCT03010163|OTHER|Health Fair|Testing includes weight, height, waist and blood pressure testing. In the event that the participants are unable to meet in person for health measurements, the staff will accept self-reported measurements over the phone.
48344123|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
48344124|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
48344125|NCT00693693|DRUG|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
48344126|NCT03423862|OTHER|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
47982454|NCT03010163|OTHER|Pedometer|The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
47982455|NCT03010163|OTHER|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
47982456|NCT03010163|OTHER|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
47982457|NCT06186011|PROCEDURE|Wire-guided surgery|If assigned to the WGS, the marking will be performed by the radiologist on the day prior to the intervention.
47982458|NCT06186011|PROCEDURE|Radioactive seed localization|If assigned to the RSL, the marking will be performed by the radiologist on the day prior to the intervention. The handling and traceability will be done by the nuclear medicine physician.
47982459|NCT06186011|PROCEDURE|Intraoperative ultrasound localization|If the patient is assigned to the Intraoperative ultrasound localization (IOUS), no further procedures will be necessary until surgery. Subsenquently, the primary surgery will be performed.
47982460|NCT01302587|DRUG|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
48500589|NCT00769990|DIETARY_SUPPLEMENT|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
48500590|NCT00769990|RADIATION|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
48500591|NCT03375203|DRUG|Placebo|Matching placebo will be administered once daily based upon dosing group.
48344127|NCT02244008|OTHER|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
48344128|NCT02244008|OTHER|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
48344129|NCT03591913|DRUG|Misoprostol|Oral tablets
48344130|NCT03619850|DRUG|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
48500592|NCT03375203|DRUG|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
47982461|NCT00596570|PROCEDURE|PCI|Percutaneous coronary interventiom
47982462|NCT02707250|DRUG|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
47982463|NCT02707250|DRUG|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
47982464|NCT02707250|DRUG|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
48134995|NCT02409680|DRUG|Low dose aspirin|Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
48344131|NCT03619850|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
48500593|NCT03375203|DRUG|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
48500594|NCT03375203|DRUG|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
48500595|NCT03375203|DRUG|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2\*5mg capsule) oral capsule once daily based upon the local labeling information.
48500596|NCT05755776|DRUG|TMF|switch ETV to TMF
47982465|NCT02707250|DRUG|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
47982466|NCT04279951|OTHER|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
47982467|NCT04279951|DIETARY_SUPPLEMENT|Omega-3|1 gram of omega-3 per day for 20 weeks
48344132|NCT05825989|BEHAVIORAL|Healthy Beat Acupunch Regimen|The Healthy Beat Acupunch (HBA) regimen, developed by Chen et al. (2017), is based on the Meridian Theory or Jing-Luo Theory. The HBA regimen focuses on body movement with hands swinging, resulting in the natural swinging of fists that hit on acupoints. There are three phases: phase 1 is activating qi and blood; phase 2 is punching meridians; phase 3 is relaxing body and mind.
48344133|NCT01203124|DRUG|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
48344134|NCT01203124|DRUG|Placebo|Placebo
48344135|NCT00351806|DRUG|Erigeron breviscapus injection|
48500597|NCT06303479|OTHER|Non-Instrumental breathing exercise group|Before starting the exercises, participants will be told about diaphragmatic breathing exercises, maximum inspiratory holding technique and thoracic expansion exercises through the Zoom program by telerehabilitation method, and people will be checked by the physiotherapist who manages the program during the practice. The program will last for 8 weeks and will be planned to be implemented 5 days a week in total, including 2 days of telerehabilitation, 3 days of home program. The participant will be asked to start the exercises in a reclining position with his back to the chair. He will be asked to place his right hand on his upper abdomen and his left hand on the upper side of his chest. In each session, the exercises will be performed with 1 set of 10 repetitions for each of the diaphragmatic breathing and thoracic expansion exercises and will progress with progression.
48500598|NCT06303479|OTHER|Instrumental breathing exercise group|The volume-oriented spirometer works with pressure and its indicator changes during breathing. When the participants breathe, the pressure in the tube decreases and the piston of the spirometer rises. The inhaled breath volume is seen at the top of the piston. In our study, participants will be told about the exercises through the Zoom program using the telerehabilitation method, and people will be checked by the responsible physiotherapist who manages the program during the application. The program will last for 8 weeks, 2 days of telerehabilitation, 3 days of home program will be planned to be implemented 5 days a week in total. Participants will be instructed to breathe up to their total lung capacity and maintain continuous inspiration for at least 3 seconds. The exercises will start with 1 set of 15 repetitions and the program will progress with progression.
48500599|NCT02005263|PROCEDURE|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
47982468|NCT04279951|DIETARY_SUPPLEMENT|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
48344136|NCT00351806|DRUG|hua tuo zai zao wan (a herbal medicine pill)|
48344137|NCT00351806|DRUG|Compound stroke herbal medicine (8 herbal)|
47982469|NCT00345254|PROCEDURE|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
48134996|NCT02409680|DRUG|Placebo|Placebo
48134997|NCT04865172|OTHER|Remote collection of passive and active data for 28 consecutive days|Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.
48500600|NCT02822495|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
48500601|NCT03534843|PROCEDURE|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
48500602|NCT03534843|OTHER|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
48135001|NCT01231438|DRUG|Renvela|800mg t.i.d. over 2 weeks
48135002|NCT01231438|DRUG|Etalpha|0.25ug o.d. for 2 weeks
48500603|NCT04128280|PROCEDURE|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
48500604|NCT04128280|PROCEDURE|TUIB|a surgery: transurethral incision of bladder neck
47982470|NCT03999450|BEHAVIORAL|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
48500605|NCT03173638|PROCEDURE|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
48135006|NCT04365556|BEHAVIORAL|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
47982471|NCT03999450|BEHAVIORAL|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
48135007|NCT02823028|DRUG|NRT|8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
48135008|NCT02823028|BEHAVIORAL|Web Guide|"A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules."
48135009|NCT02823028|BEHAVIORAL|Tweet2Quit|"A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group."
48500606|NCT06110624|OTHER|Survey|A survey study will be conducted to evaluate if GHCPs have the Intention to Use (IU) MuSt-PC in daily practice.
47982472|NCT00047840|DRUG|ZD6474|
47982473|NCT00047840|DRUG|Placebo|
47982474|NCT00047840|DRUG|Docetaxel|
48500607|NCT05214703|OTHER|cold therapy application|cold therapy
47982475|NCT01148758|DRUG|RO5323441|cohorts receiving multiple doses iv
47982476|NCT01922089|DRUG|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
48500608|NCT00006216|BIOLOGICAL|PA-1-STK ovarian carcinoma vaccine|
48500609|NCT00006216|DRUG|ganciclovir|
48500610|NCT03151408|DRUG|Pracinostat|60 mg capsule
47982477|NCT00330564|DRUG|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
47982478|NCT00500851|DEVICE|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
47982479|NCT00500851|DEVICE|Endoscopy|Endoscopic placement of jejunal feeding tubes
47982480|NCT01580189|DIETARY_SUPPLEMENT|Whey protein|18g protein, immediately after training, 9 weeks
47982481|NCT01580189|DIETARY_SUPPLEMENT|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
47982482|NCT01580189|DIETARY_SUPPLEMENT|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
48500611|NCT03151408|DRUG|Placebos|capsule
48135013|NCT06673368|DRUG|NRCT-101SR, NRCT-202XR|NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone
48500612|NCT03151408|DRUG|Azacitidine|SC or IV injection
48500613|NCT05070000|DIAGNOSTIC_TEST|Radiologic examination|Patients underwent US, CT or CT after US
48500614|NCT02402114|DRUG|Hydrocortisone|120 mg Hydrocortisone given orally one time.
48500615|NCT06548308|DIAGNOSTIC_TEST|Corneal Incision|Astigmatism will be assessed by objective and subjective refraction by using the Autorefrectometer and retinoscop.Autorefrectometer uses to acsess the refracive state of eye by which we measure the astigmatim in patients eyes .Then after ctaract surgry in the next followup we will again use autorefrectometer to take readings and these both will be compared on visits among patients undergoing two procedures.
48513395|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
48500616|NCT06548308|OTHER|Toric Intraocular|Two cataract surgery techniques will be used .1 : Toric IOL lenses designed with a unique shape to help provide clear vision at all distances for individuals with astigmatism compared to give better results specially in astigmatic patients.2: Corneal Inscion is which eye surgeon makes a very small opening on the eye, next to the outer corner. to remove the catract during surgry .
48500617|NCT04263402|DRUG|Methylprednisolone|Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
48500618|NCT04263402|DRUG|Methylprednisolone|Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).
48135017|NCT05440058|DEVICE|Bispectral Index (BIS) monitoring system|Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
48135018|NCT02252822|BEHAVIORAL|Overcoming Bulimia Online Programme|
48135019|NCT02698475|DRUG|Ustekinumab 0.75 mg/kg|Participants weighing less than (\<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
48135020|NCT02698475|DRUG|Ustekinumab 45 mg|Participants weighing greater than or equal to (\>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
48500619|NCT03726853|DRUG|CKD-497 200mg|CKD-497 200mg
48500620|NCT03726853|DRUG|CKD-497 300mg|CKD-497 300mg
48500621|NCT03726853|DRUG|CKD-497 placebo|Placebo of CKD-497
48500622|NCT03726853|DRUG|Comparator|Comparator
48500623|NCT03726853|DRUG|Comparator placebo|Comparator placebo
48657826|NCT06468553|BEHAVIORAL|Prediabetes Care Program|Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months
47982483|NCT02793102|OTHER|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
47982484|NCT02793102|OTHER|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
47982485|NCT02793102|OTHER|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
47982486|NCT03275051|OTHER|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
47982487|NCT01109654|DRUG|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
47982488|NCT03612297|DIAGNOSTIC_TEST|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
47982489|NCT04700982|OTHER|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and \> 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
48135021|NCT02698475|DRUG|Ustekinumab 90 mg|Participants weighing \>100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
48500624|NCT00273390|DRUG|Remicade (infliximab)|
48500625|NCT05900128|BEHAVIORAL|workshop|Patients will receive workshops and they will encourage to practice physical activity
48500626|NCT05900128|OTHER|no workshop|patients won't receive educative workshops
48500627|NCT00227110|DRUG|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
48500628|NCT00227110|DRUG|Placebo|Placebo is given to match pioglitazone.
48500629|NCT00561418|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
48500630|NCT00561418|OTHER|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
48500631|NCT03544489|BEHAVIORAL|E-ICD Intervention|Home walking 3 days/week x 12 weeks
48513396|NCT02309138|DIAGNOSTIC_TEST|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
48657827|NCT05383898|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
48657828|NCT03336606|DRUG|MEDI0562|Surgical resection of tumor
48657829|NCT03708315|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride
48657830|NCT03708315|DRUG|Placebos|Placebo
48657831|NCT00780585|DRUG|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
48657832|NCT04614337|DRUG|LUM-201|Administered orally once daily
48135022|NCT02937493|BEHAVIORAL|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
48135023|NCT02897206|DRUG|Imipenem|A wide-spectre antibiotic from the carbapenem group
48135024|NCT02897206|DRUG|Placebo|An imipenem-matching placebo
48135025|NCT03275961|BEHAVIORAL|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
48135026|NCT06196749|PROCEDURE|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique|This study employs a modified ultrasound-guided dynamic needle tip positioning technique for distal radial arterial cannulation. The technique uses an ultrasound probe with two wires to create an acoustic shadow, improving needle tip visibility. Real-time dynamic tracking assists in precise needle placement within the distal radial artery through the nose-horn region. This method is used for coronary angiography and potential percutaneous coronary interventions, aiming to increase success rates and reduce complications like hematoma, nerve injury, and arterial spasm, thus enhancing safety and efficiency.
47982490|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
48135027|NCT06196749|PROCEDURE|Palpation guided puncture|Perform distal radial arterial cannulation under palpation guidance
48135028|NCT03632876|DIETARY_SUPPLEMENT|retinyl palmitate|The intervention is a daily vitamin A supplement.
48135029|NCT01171976|DRUG|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
48135030|NCT04407884|DEVICE|Soovu Labs Inc. Pain Relief System|Longnitual follow-up
48344138|NCT02853149|BEHAVIORAL|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
48500632|NCT04000763|DEVICE|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
48500633|NCT01857843|DEVICE|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
48657833|NCT04614337|DRUG|rhGH Norditropin® pen (34 µg/kg)|Administered subcutaneously (s.c., under the skin) once daily.
47982491|NCT02345850|PROCEDURE|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
48135031|NCT05516745|DEVICE|AioCare spirometer|In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
48135032|NCT05516745|OTHER|telerehabiliation of the respiratory system|A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
48135033|NCT00224432|DRUG|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
48135034|NCT01105234|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
48135035|NCT05359536|BEHAVIORAL|Training Early Childhood educators in PA|The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
48135036|NCT03035084|DRUG|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
48657834|NCT05651490|BEHAVIORAL|Problem Solving Treatment for Diabetes|"In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~1. Clarifying and defining the problem~2. Setting a realistic goal~3. Brainstorming multiple solutions~4. Generating pros and cons for each solution~5. Evaluating and choosing a preferred solution~6. Developing a specific action plan to implement the solution~7. Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants."
48657835|NCT05651490|BEHAVIORAL|Attention Control Group|During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
48657836|NCT06641076|DRUG|Sonelokimab|Randomized treatment, parallel-group
48657837|NCT06641076|DRUG|Placebo|Randomized treatment, parallel-group
48344139|NCT02853149|BEHAVIORAL|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
47982492|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
47982493|NCT02345850|DRUG|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
47982494|NCT02345850|DRUG|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
47982495|NCT02345850|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
47982496|NCT00254813|DRUG|Quetiapine|
48135037|NCT03035084|DRUG|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
48135038|NCT03035084|DRUG|Placebo oral capsule|Placebo oral capsule
48344140|NCT02853149|BEHAVIORAL|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
48513397|NCT06365411|DIAGNOSTIC_TEST|Biomarker discovery and validation - with focus on genomic biomarkers|Biomarker discovery and validation - with focus on genomic biomarkers
48657838|NCT06572397|DRUG|H-1337 1.0%|ophthalmic solution
48657839|NCT04774666|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening|Oral fluid-based HIV test
48657840|NCT05495126|DIAGNOSTIC_TEST|Standard Limbic Access pathway|Relevant information for clinical referral (e.g. demographics) and basic clinical information (e.g. PHQ-9 \& Gad-7 scores) are collected during the self-referral process which is then attached to the referral notes in order to facilitate the clinical assessment conducted by the clinician.
48135039|NCT00387075|PROCEDURE|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
48344141|NCT03655080|RADIATION|Radiation therapy|Using the View Ray System
48344142|NCT03655080|DRUG|nab-Paclitaxel|"* Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes"
48344143|NCT05469100|DRUG|Selpercatinib|Administered orally
47982497|NCT05513079|BEHAVIORAL|Positive Psychotherapy Based Counseling|The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
48135040|NCT00387075|DRUG|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
48135041|NCT02191891|DRUG|BI 836845|Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
48344144|NCT01333098|DRUG|Mifepristone|300mg per day, by mouth, for 21-28 days
48344145|NCT03521401|BEHAVIORAL|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
47982498|NCT03442907|PROCEDURE|24 hour blood pressure measurement, fluids, vasopressors|Targeting individual blood blood pressure values during surgical procedures
47982499|NCT03442907|PROCEDURE|Standard of Care|Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
47982500|NCT04122092|DIAGNOSTIC_TEST|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
47982501|NCT00770289|OTHER|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
47982502|NCT03017950|DRUG|CKD-330|
47982503|NCT03017950|DRUG|D086|
47982504|NCT03017950|DRUG|CKD-330 + D086|
47982505|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
47982506|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
47982507|NCT02300584|OTHER|iPad|a tablet computer with an internet connection
47982508|NCT04311424|DRUG|14C Tirzepatide|Administered SC.
47982509|NCT02601950|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
47982510|NCT00285597|DRUG|Ursodeoxycholic Acid|
48344146|NCT00878813|PROCEDURE|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
47982511|NCT05630612|DRUG|Sparsentan|6 weeks of treatment with sparsentan or irbesartan. This will be administered in a double-blind fashion.
47982512|NCT06117150|DEVICE|Drug-eluting Coronary Spur Stent System|All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.
47982513|NCT01659463|OTHER|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
47982514|NCT01659463|BEHAVIORAL|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
47982515|NCT01607086|DRUG|Cherry lamotrigine ODT|25mg, taken orally on one study visit
47982516|NCT01607086|DRUG|Cherry Placebo|Taken orally on one study visit
47982517|NCT01558830|DRUG|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
47982518|NCT01558830|DRUG|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
47982519|NCT05107687|BEHAVIORAL|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
47982520|NCT01806948|DRUG|Ramosetron|
47982521|NCT04926350|BEHAVIORAL|Resistance Exercise|8 total resistance exercises that target all major muscle groups
47982522|NCT04040478|DEVICE|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
47982523|NCT02200445|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
48135042|NCT02191891|DRUG|afatinib|Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
48344147|NCT00878813|PROCEDURE|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
48344148|NCT05298228|DRUG|Remimazolam bolus does administration|The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
48344149|NCT03395327|OTHER|quality of life questionnaire|QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)
48500634|NCT01857843|DEVICE|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
48344150|NCT00322751|DRUG|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
48135043|NCT02513667|DRUG|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
48135044|NCT02513667|RADIATION|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
48344151|NCT00510107|DRUG|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
48344152|NCT00510107|DRUG|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
48500635|NCT01857843|DRUG|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
47982524|NCT04415255|OTHER|EABPI plus IABPI|If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, \~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
47982525|NCT04415255|OTHER|IABPI-alone|If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
47982526|NCT01157949|DRUG|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
47982527|NCT03641651|OTHER|Rehabilitation technology|"* Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~* With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~* A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~* The training can take place in an outpatient or inpatient setting.~* Training will be organized in individual one-to-one or group session"
47982528|NCT02165020|DEVICE|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
47982529|NCT04278079|PROCEDURE|Pars Plana Vitrectomy with Internal Limiting Membrane peel|Pars plana vitrectomy with staining and peeling of internal limiting membrane
47982530|NCT00217139|DRUG|Celgosivir|
47982531|NCT05908695|DRUG|GV-971|Administered PO
47982532|NCT05908695|DRUG|Placebo|Administered PO
47982533|NCT01563003|OTHER|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
48135045|NCT03413085|DEVICE|soft contact lens|"Group A~Group B"
48135046|NCT02276599|PROCEDURE|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
48135047|NCT05794659|BIOLOGICAL|AST-201|i.d. (3-week interval, 3 cycles in total)
48135048|NCT05794659|DRUG|Paclitaxel|3-week interval, 6 cycles in total
48135049|NCT05794659|DRUG|Carboplatin|3-week interval, 6 cycles in total
48135050|NCT05794659|DRUG|Placebo|i.d. (3-week interval, 3 cycles in total)
48135051|NCT05794659|DRUG|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
48344153|NCT00252876|DRUG|tesaglitazar|
48344154|NCT00454480|BIOLOGICAL|alemtuzumab|
48344155|NCT00454480|DRUG|arsenic trioxide|
48344156|NCT00454480|DRUG|azacitidine|
48344157|NCT00454480|DRUG|busulfan|
48344158|NCT00454480|DRUG|clofarabine|
48344159|NCT00454480|DRUG|cytarabine|
48344160|NCT00454480|DRUG|daunorubicin hydrochloride|
48344161|NCT00454480|DRUG|fludarabine phosphate|
48344162|NCT00454480|DRUG|gemtuzumab ozogamicin|
48344163|NCT00454480|DRUG|melphalan|
48344164|NCT00454480|DRUG|tipifarnib|
48344165|NCT00454480|GENETIC|DNA methylation analysis|
48344166|NCT00454480|GENETIC|cytogenetic analysis|
48344167|NCT00454480|GENETIC|gene expression analysis|
48344168|NCT00454480|GENETIC|mutation analysis|
48344169|NCT00454480|OTHER|diagnostic laboratory biomarker analysis|
48135052|NCT02595346|DRUG|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
48344170|NCT00454480|OTHER|immunologic technique|
48344171|NCT00454480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48344172|NCT00454480|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
48344173|NCT00937508|BEHAVIORAL|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
48344174|NCT00937508|DRUG|varenicline|varenicline (an approved medication for smoking cessation)
48344175|NCT00937508|DRUG|placebo|sugar pill without any active medication
48344176|NCT05914740|PROCEDURE|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
48344177|NCT04247789|OTHER|Self-reported questionairres|the fatigue will be determined through self reported questionnairres
48344178|NCT00427375|PROCEDURE|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
48344179|NCT00427375|PROCEDURE|total mesorectal excision|standard surgery
48344180|NCT03150810|DRUG|Pamiparib|60 mg (20 mg capsules) administered orally twice a day
48344181|NCT03150810|DRUG|Temozolomide|Doses of up to 120 mg (as 20 mg capsules) administered orally once daily (QD) as specified in the treatment arm
48344182|NCT00619606|DEVICE|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
48344183|NCT00619606|DEVICE|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
48344184|NCT00619606|DEVICE|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
48344185|NCT00619606|DEVICE|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
48344186|NCT04955301|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
47982534|NCT01563003|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
47982535|NCT06228560|BIOLOGICAL|LP-003|Liquid in vial
47982536|NCT06228560|BIOLOGICAL|Placebo|Liquid in vial
48344187|NCT01209806|DRUG|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
48344188|NCT03294772|OTHER|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
48344189|NCT03294772|OTHER|liquid soap|DCCs received liquid soap and a program educational.
48344190|NCT04006704|DRUG|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
48500636|NCT01857843|DRUG|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~1. Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~2. Pravastatin 20mg (mevalotin®, BMS)"
47982537|NCT06228560|BIOLOGICAL|Omalizumab|Liquid in vial
47982538|NCT05394909|DRUG|Tocilizumab 162Mg/0.9Ml Autoinjector|Patients will receive high-dose pulse intravenous methylprednisolone (500 mg ) for 3 consecutive days (Day 0-1-2) and subsequently will be treated weekly with Tocilizumab 162 mg s.c. for 52-weeks and then following according to SOC
47982539|NCT06374706|BEHAVIORAL|Morning Walk training for stroke|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Symmetrical Walking on the Ground.
48135053|NCT02595346|DRUG|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
48135054|NCT04639869|DRUG|Phenyramydol HCl 400 mg Film Tablet|Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
48135055|NCT04639869|DRUG|Cabral 400 mg Film Tablet|Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
48344191|NCT04843943|DRUG|Sintilimab|Sintilimab: 200mg IV Q3W D1
48344192|NCT04843943|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar: 15mg/kg, IV, Q3W, D1
48344193|NCT04144049|DRUG|MT921|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
48344194|NCT04144049|DRUG|Placebo|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
48344195|NCT05328414|DRUG|Prednisolone|intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
48344196|NCT01501734|DEVICE|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
48344197|NCT01574417|DIETARY_SUPPLEMENT|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
47982540|NCT06374706|BEHAVIORAL|Morning Walk training for healthy|Assessing the Feasibility of the End-Effector Rehabilitation Robot, Morning Walk Training and investigate the Immediate Post-Adaptation Effect of Morning Walk Training for Asymmetrical Walking on the Ground.
48344198|NCT01574417|DIETARY_SUPPLEMENT|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
48344199|NCT03623022|DRUG|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
48344200|NCT03623022|DRUG|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
48344201|NCT05445336|BEHAVIORAL|PREVENT Program|PREVENT (Person-centred Routine Fracture PreEVENTion) is a scalable model for delivering routine assessments and interventions on diet and supplements, multifactorial fall and fracture prevention strategies, and medications to long term care teams to treat residents at high risk of fracture.
48500637|NCT04312529|OTHER|Isokinetic test + EMG|Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
48344202|NCT06144567|DRUG|Upadacitinib|As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
47982541|NCT03357159|DRUG|Cyclophosphamide|In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.
48135056|NCT03524755|OTHER|Exercise|
48344203|NCT01849562|DRUG|Sovaprevir|Nonstructural protein 3/4A protease inhibitor.
48344204|NCT01849562|DRUG|ACH-3102|Nonstructural protein 5A inhibitor.
48500638|NCT05341349|BIOLOGICAL|Ipilimumab|Given IV
48500639|NCT05341349|BIOLOGICAL|Nivolumab|Given IV
48500640|NCT05341349|BIOLOGICAL|Pembrolizumab|Given IV
48500641|NCT05341349|RADIATION|Stereotactic Radiosurgery|Undergo SRS
47982542|NCT03357159|DRUG|anti-human T-lymphocyte immunoglobulin (ATLG)|15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation
47982543|NCT01164956|DRUG|methylphenidate|
47982544|NCT01164956|OTHER|Placebo|
48344205|NCT01849562|DRUG|Ribavirin|
48344206|NCT01849562|DRUG|Placebo|
48344207|NCT04682249|DRUG|Systemic Chemotherapy|Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
48500642|NCT05341349|PROCEDURE|Tumor Treating Fields Therapy|Undergo TTFields
48500643|NCT02736877|PROCEDURE|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
47982545|NCT06017440|BEHAVIORAL|EXERCISE|Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
48135057|NCT01974843|DRUG|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
48135058|NCT01974843|DRUG|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
48135059|NCT02182479|DRUG|Berodual® via Respimat®, high dose|
48135060|NCT02182479|DRUG|Berodual® via Respimat®, low dose|
48344208|NCT04682249|DRUG|Sintilimab|Sintilimab
48344209|NCT04682249|DRUG|Apatinib|Apatinib
48344210|NCT04254445|OTHER|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
48500644|NCT02736877|PROCEDURE|Conventional Microscope|corneal transplantation guided by Conventional Microscope
48500645|NCT03011138|PROCEDURE|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
48135061|NCT02182479|DRUG|Berodual® via MDI, high dose|
48500646|NCT00224926|PROCEDURE|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
48500647|NCT00173550|PROCEDURE|Hysterectomy and Bilateral salpingo-oophorectomy|
48500648|NCT04689555|PROCEDURE|Novel method without manual compression|Novel method for femoral artery hemostasis without manual compression. After sheath removal, four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
48500649|NCT04689555|PROCEDURE|Standard method with manual compression.|Standard method for femoral artery hemostasis with manual compression.After sheath removal, manual compression was continued for at least 10 minutes or until hemostasis. After that four or five sterile gauzes were overlaid layer by layer and then bandaged without the procedure of manual compression.
48657841|NCT05495126|DIAGNOSTIC_TEST|Limbic Access with AI pathway|"The same information as in the Limbic Access pathway is collected. However, additional information (i.e. disorder specific questionnaires) are collected for the most likely problem descriptors based on the ML-model predictions.~All information is attached to the referral in order to facilitate the clinical assessment conducted by the clinician."
48657842|NCT04437745|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
47982546|NCT06017440|BEHAVIORAL|CONTROL|Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
47982547|NCT06481514|OTHER|Interpretation of the CTG using FRI score|At each of the components of the score will be assigned a score of 1 if the variable evaluated is considered normal, 0 if classified as abnormal. To encourage a simplified clinical interpretation of the different scores obtained (score from 1 to 8) they will be classified into 3 risk categories: Score 5-8: green zone, Score 3-4: zone yellow, Score 1-2: red zone. An FRI of 1-2 (red zone) is to be considered as anomalous
47982548|NCT06481514|OTHER|Classic interpretation of the CTG|evaluate the CTG of group B patients according to the usual internal management protocols
48344211|NCT01197794|DRUG|AZD1981|AZD1981 twice daily
48344212|NCT01197794|DRUG|AZD1981|AZD1981 once daily
48344213|NCT01197794|DRUG|Placebo|Placebo to match AZD1981
48344214|NCT01993667|DRUG|Low Dose Acetazolamide|Administration of low dose acetazolamide
48344215|NCT01993667|DRUG|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
48344216|NCT01311739|DRUG|Cyanocobalamin|
48344217|NCT05247983|PROCEDURE|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"|"patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
48344218|NCT03582267|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
48344219|NCT04520867|OTHER|STRENGTH|Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
48344220|NCT03572153|BEHAVIORAL|Self-Administered Hypnosis|Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
48344221|NCT03572153|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
48344222|NCT04159701|DRUG|LY3454738|Administered IV
48344223|NCT04159701|DRUG|Placebo|Administered IV
48344224|NCT04276779|OTHER|Alcohol administration|Participants in the alcoholic beverage group will be provided a dose of 95% alcohol (0.99g/kg for males and 0.90 g/kg for females body weight) distributed in two equally spaced beverages (mixed with orange juice 1:5 ratio). This dose will produce a breath alcohol content ranging between .08-.10.
48500650|NCT03052127|DRUG|Light-activated AU-011|Study treatment
48500651|NCT03052127|DEVICE|Laser Activation|Study treatment
47982549|NCT02212392|DRUG|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
48135062|NCT02182479|DRUG|Placebo Respimat®|
48135063|NCT02182479|DRUG|Placebo MDI|
48500652|NCT05291039|DRUG|Infliximab|group 1 (n=20): patients will receive IFX
48657843|NCT03886636|OTHER|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
48657844|NCT03886636|OTHER|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
48135064|NCT00872872|DRUG|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
48344225|NCT04276779|OTHER|Placebo administration|Individuals in the placebo condition will receive orange juice with 4 ml of alcohol layered on top of the juice. Ethanol will be sprayed on the rims of the glasses.
48135065|NCT01441284|DRUG|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
48500653|NCT05291039|DRUG|Adalimumab|group 2 (n=20): patients will receive ADA
47982550|NCT04219332|DRUG|Subserosa injection of indocyanine green|After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.
48500654|NCT01058460|PROCEDURE|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
47982551|NCT04219332|DRUG|submucosal injection of indocyanine green|One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
47982552|NCT01890551|OTHER|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
48500655|NCT04914221|DRUG|JLP-2002|administration of JLP-2002
48657845|NCT03886636|OTHER|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
48657846|NCT01817777|DRUG|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
48657847|NCT01817777|DRUG|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
47982553|NCT05420129|DEVICE|MAD Therapy|Participants will be treated with a Mandibular Advancement Device therapy
47982554|NCT05420129|DEVICE|CPAP Therapy|Participants will be treated with a Continuous Positive Airway Pressure therapy
47982555|NCT03336047|BEHAVIORAL|personal activity intelligence|"Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms)."
47982556|NCT03336047|BEHAVIORAL|10,000 steps daily|Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
47982557|NCT00198965|BEHAVIORAL|dietary education|
47982558|NCT00198965|BEHAVIORAL|dietary education and provided full fat snack foods|
47982559|NCT00198965|BEHAVIORAL|dietary education and provided fat free snack foods|
48657848|NCT00834197|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
48657849|NCT00834197|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
48135066|NCT01441284|DRUG|placebo|placebo
48135067|NCT05380089|OTHER|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
48500656|NCT04914221|DRUG|Comparator|administration of comparator
48500657|NCT01234922|DRUG|lisinopril|Given orally
48500658|NCT01234922|DRUG|losartan potassium|Given orally
48657850|NCT05803772|DRUG|APHD-012|Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
48657851|NCT05803772|DRUG|APH-012P|Distal jejunal-release placebo beads
48657852|NCT03420820|BIOLOGICAL|Bacterial Culture Swab|Culture swabs will be obtained before application of PI and after injection.
48657853|NCT06644053|BEHAVIORAL|Quantified analysis of walking during a crossing task through different horizontal openings|Functional test that reproduce a task of daily living
48657854|NCT05052684|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
48657855|NCT06567925|BEHAVIORAL|Customized Sleep Coaching|Demonstrate the feasibility of a gradual sleep extension strategy using customized sleep coaching.
48657856|NCT06567925|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy
48657857|NCT02447406|DRUG|AZD6094|
48657858|NCT02447406|DRUG|docetaxel|
48135068|NCT00309751|DRUG|Pitavastatin|Pitavastatin 4 mg QD
48135069|NCT00309751|DRUG|Atorvastatin|Atorvastatin 20 mg
48135070|NCT00056654|DRUG|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
48135071|NCT00232375|DRUG|Insulin|
48135072|NCT03903614|BEHAVIORAL|SML|SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
48135073|NCT03903614|BEHAVIORAL|CON|CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
48500659|NCT01234922|OTHER|laboratory biomarker analysis|Correlative studies
48500660|NCT01234922|DRUG|benazepril hydrochloride|Given orally
48344226|NCT04276779|BEHAVIORAL|Positive mood induction|Participants will be randomized to either positive mood induction procedure. Both conditions involve listening to music that reliably induces positive mood, while simultaneously reading self-referent statements that also induce either positive mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
48344227|NCT04276779|BEHAVIORAL|Negative mood induction|Participants will be randomized to either negative mood induction procedure. Both conditions involve listening to music that reliably induces sad mood, while simultaneously reading self-referent statements that also induce either sad mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
48344228|NCT03049930|DRUG|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
47982560|NCT01286181|BEHAVIORAL|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
47982561|NCT03249298|DRUG|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
47982562|NCT03249298|DRUG|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
48135074|NCT04326140|DEVICE|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
48135075|NCT04326140|DEVICE|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
48135076|NCT04326140|DEVICE|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
48135077|NCT02498145|OTHER|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
48135078|NCT02498145|OTHER|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
48135079|NCT00982644|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
48135080|NCT00982644|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
48344229|NCT03049930|DRUG|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
48344230|NCT01024062|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
48344231|NCT01493934|DRUG|injection of 6-DIG|Unique injection dose of 92.5 MBq
48344232|NCT04117594|DIAGNOSTIC_TEST|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
48344233|NCT06395740|OTHER|Enteral nutrtion|enteral nutrition via nasogastric tube.
48344234|NCT06395740|OTHER|TPN|of NPO strategy except for medications to be given via nasogastric tube till 14 days from day of stroke with fulfilment of nutrition requirement by parenteral route
48344235|NCT04634019|BEHAVIORAL|Financially incentivized knowledge assessments|We will conduct quarterly provider knowledge assessments at selected health facilities and will pay facilities a financial bonus if providers perform well on these tests. For the intervention, 12 clinical vignettes were created. These vignettes cover typical patient cases such as malaria, diarrhea and respiratory infections, and assess providers' ability to correctly diagnose and treat hypothetical questions. All medical staff members will be informed hat every 3 month there will be a knowledge assessment based on these vignettes and that the results will determine the total bonus payment made to the facility.
48344236|NCT03975530|BEHAVIORAL|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
48500661|NCT01234922|DRUG|ramipril|Given orally
47982563|NCT05319145|BEHAVIORAL|Intervention group|1) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).
47982564|NCT05319145|OTHER|Control group|General recommendations (written and videos) will be offered.
47982565|NCT04328584|PROCEDURE|surgical navigation system|Navigation system providing surgeons with an additional view of the chest wall lesion
47982566|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
48344237|NCT03975530|BEHAVIORAL|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
48344238|NCT04446767|RADIATION|polarized light|bioptron light therapy sessions, about 12 minutes on the foot ulcer 3 sessions per week for about 8 weeks
48344239|NCT04446767|OTHER|Medical Care|Appropriate day-care and principles of local ulcer therapy, washing and bandaging, use of anti exudative, anti-inflammatory and disinfection solutions will be administered to this group, topical antibiotics will be administered based on bio-gram and antibiogram results
48344240|NCT00232414|DRUG|Quetiapine|
48344241|NCT06075368|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
48657859|NCT05374798|DEVICE|Heart Rate Variability-Biofeedback (HRV-B) via Smartwatch Device Intervention|"Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed. HRV-B will guide participants in an evidence-based paced breathing technique (about 6 breaths per minutes) using visualization on thier mobile device of thier real-time respiratory and cardiac parameters.~During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed."
48344242|NCT05231421|BEHAVIORAL|Focus Group|Each focus group will consist of 5-10 participants. They will first introduce to each other and be asked to keep information shared during the session private. The moderator will initiate some questions for the group to discuss. Prompt and follow-up questions will be asked. There is no right or wrong answer for each question and no sensitive questions will be asked. The conversations during the focus group discussion will be recorded. The group will be debriefed about the purpose of the study and have a chance to ask any questions about the study if they have. The focus group discussion for each session will last about 60-90 minutes.
47982567|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
47982568|NCT01949350|DIETARY_SUPPLEMENT|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
47982569|NCT05527392|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over approximately a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Section 1- Insurance Plan Basics; Section 2- Your Plan in Relation to Policy; Section 3- Navigating Your Plan and Overcoming Obstacles; Section 4- Managing Care Costs; 5-Understanding Your Medical Bills.
47982570|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
47982571|NCT02240199|DRUG|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
47982572|NCT02240199|DRUG|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
47982573|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
48344243|NCT04363463|OTHER|prone position|Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.
48135081|NCT01089335|PROCEDURE|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
47982574|NCT05948254|PROCEDURE|Triple function scan body|The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
48135082|NCT03212638|DRUG|Baricitinib suspension|Administered orally
48135083|NCT03212638|DRUG|Baricitinib tablet|Administered orally
48135084|NCT04613713|OTHER|Somatocognitive physiotherapy|"The main intervention areas include:~1. education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~2. bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~3. techniques to cope with emotions and thoughts related to bodily experiences and to PVD~4. structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
48135085|NCT04613713|OTHER|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
48657860|NCT06325410|PROCEDURE|resection of colorectal cancer|resection of bowel segment and re-anastmosis or stoma formation
48657861|NCT06013852|DIAGNOSTIC_TEST|"processing the radiography with the Boneview software"|all X-Rays will be analysed with and without the software
48657862|NCT06637124|DEVICE|Blood Flow Restriction Therapy Device|"Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group)."
47982575|NCT04941235|DEVICE|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
47982576|NCT05058443|DRUG|Denosumab 60 mg/ml [Prolia]|denosumab subcutaneously every 6 months (Q6M)
48135086|NCT05500170|DIETARY_SUPPLEMENT|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
48135087|NCT05500170|DIETARY_SUPPLEMENT|Placebo|The placebo pill will contain micro cellulose powder.
48135088|NCT00125905|BEHAVIORAL|Advice|
48135089|NCT00125905|BEHAVIORAL|Motivational Interviewing|
48135090|NCT00125905|DRUG|Nicotine Gum and Patch|
47982577|NCT05058443|DRUG|Placebo|placebo subcutaneously every 6 months (Q6M)
47982578|NCT01866501|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
47982579|NCT01866501|DEVICE|EZ-IO|
47982580|NCT05789979|DEVICE|The resident-handling device|Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
47982581|NCT00422175|DRUG|BAF 312|
48135091|NCT00125905|DRUG|Bupropion|
48135092|NCT05106842|OTHER|Hydrotherapy|Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.
48135093|NCT05106842|OTHER|Land-based Therapy|Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
48135094|NCT00710294|DEVICE|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
48344244|NCT04171063|DEVICE|Thoracic compressor|The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
48135095|NCT04010136|OTHER|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
47982582|NCT03791840|DIAGNOSTIC_TEST|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
48657863|NCT06637124|DEVICE|45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.|Patients assigned to group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
47982583|NCT01907880|DRUG|Pamidronate|90mg IV once every 4 weeks for 3 cycles
47982584|NCT01907880|DRUG|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
48344245|NCT01027572|DEVICE|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
48500662|NCT01299259|BEHAVIORAL|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
48657864|NCT03189719|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
48657865|NCT03189719|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
48657866|NCT03189719|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
48657867|NCT03189719|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
48657868|NCT06381791|DRUG|Epidiolex|150mg of Epidiolex
48657869|NCT06381791|DRUG|Placebo oral solution|150mg of Placebo oral solution
48657870|NCT05172297|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
48657871|NCT05395338|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
48657872|NCT04627103|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.
48657873|NCT05314387|DEVICE|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
48657874|NCT05314387|DEVICE|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
48657875|NCT04822883|DRUG|RL-007|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
48657876|NCT04822883|DRUG|RL-007 Matching Placebo|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
48657877|NCT05175664|OTHER|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
48657878|NCT05175664|OTHER|Short-term study|No intervention. Investigations: blood samples and pupillometry.
48657879|NCT05175664|OTHER|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
48657880|NCT01844596|BEHAVIORAL|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
48657881|NCT01844596|BEHAVIORAL|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
48657882|NCT05546866|DRUG|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
48657883|NCT06644300|DRUG|BM230|SC injection
48657884|NCT06644300|DRUG|BM230|SC injection
47982585|NCT01907880|DRUG|placebo|
47982586|NCT01407640|PROCEDURE|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
48135096|NCT01571557|DRUG|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
48135097|NCT04751799|DEVICE|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
48657885|NCT06360237|DRUG|Olezarsen|Olezarsen 80 mg administered once monthly by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
48657886|NCT04275284|BIOLOGICAL|PCV10|0.5 ml injection
48135098|NCT04751799|DEVICE|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
48135099|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
48657887|NCT04275284|BIOLOGICAL|PCV13|0.5 ml injection
48344246|NCT05468580|PROCEDURE|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
47982587|NCT05778747|OTHER|Heart to Heart Yoga|The Heart to Heart Yoga intervention is a therapeutic and standardized form of yoga intervention that is adapted from MediYoga designed to fit the needs of patients with HF and family caregivers who have physical limitations and depressive symptoms and to fit cultural and social norms in Kentucky. The intervention will use a gradual, physical/ psychological yoga adaptation approach, and it will be delivered two times per week (40 -60 minutes per session) via videoconference technology for 12 weeks (total 24 sessions). Real-time, face-to-face, video conferencing technology is used.
47982588|NCT01657279|OTHER|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome \[i.e. from low (\<10%) to high (\>50%) expected risk death at 30 days\].
47982589|NCT03504150|BEHAVIORAL|SPHERE|Comprehensive Internet-based CBT program with no human support
47982590|NCT03504150|BEHAVIORAL|PRISM|Brief Internet-based CBT program with no human support
48135100|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and collagen membrane (CM)|Interdental guided creeping technique (IGCT) and collagen membrane (CM)
48135101|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)|The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
48344247|NCT05468580|PROCEDURE|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
48344248|NCT06305091|DIAGNOSTIC_TEST|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
48344249|NCT04057040|DRUG|PTG-300|Active
48344250|NCT04057040|DRUG|Placebo|Placebo
48344251|NCT01204424|DEVICE|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
48500663|NCT01557361|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
47982591|NCT01327885|DRUG|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
48500664|NCT01557361|OTHER|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~1. Serum potassium ≥6.0 mmol/L, or~2. Serum bicarbonate ≤ 10 mmol/L, or~3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or~4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
48500665|NCT06040775|DEVICE|Theta Burst Transcranial magnetic Stimulation using real MCF-B65 coil|"Site of stimulation will be predetermined at Dorsolateral prefrontal cortex of non-dominant side using the BeamF3 method.1 burst will be - 3 pulses at 50 Hz, burst will be set at 5Hz i.e. interburst interval 200ms .~At100% of resting motor threshold of dominant side - 5 trains (each 40sec on and 20 sec off) will be given at each session with a pause of 1 minute in between 2 trains Standard therapy with Applied Behavior Analysis and sensory integration would continue"
48500666|NCT06040775|DEVICE|Sham magnetic stimulation using sham MCF-B65 coil|"Similar set parameters using a sham coil which simulates sound and tactile effect of real coil but no electromagnetic induction is produced.~Standard therapy with Applied Behavior Analysis and sensory integration would continue"
48513398|NCT03180645|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
47982592|NCT01327885|DRUG|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
47982593|NCT02354079|GENETIC|hypobetalipoproteinemia genetic and genotypic screening|
48135102|NCT05750966|DRUG|cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)|The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
48135103|NCT04433637|DIETARY_SUPPLEMENT|Cake + fruit juice|Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
48135104|NCT04433637|OTHER|Video group|Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
48135105|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
48135106|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
48135107|NCT01968967|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
48135108|NCT01968967|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
48135109|NCT04634682|DIETARY_SUPPLEMENT|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
48135110|NCT03452254|DEVICE|Active Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session."
48135111|NCT03452254|DEVICE|Sham Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour."
48135112|NCT03452254|OTHER|Modified Constraint Induced Movement Therapy|"Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~1. Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~2. Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve."
48135113|NCT04314375|DRUG|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
48135114|NCT04314375|DRUG|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
48135115|NCT04314375|DRUG|Placebo|Matching placebo once daily.
48135116|NCT02631369|DEVICE|Heidelberg Spectralis OCT device|
48135117|NCT04587505|PROCEDURE|Epidural anesthesia with light general anesthesia|Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ ml and fentanyl 8.3 μg/ml. Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.
48135118|NCT04587505|DRUG|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
48135119|NCT04587505|PROCEDURE|General anesthesia|Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1. Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.
48135120|NCT04587505|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
48135121|NCT03768466|DRUG|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
48135122|NCT03568175|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
48135123|NCT06031116|PROCEDURE|depigmentation|gingival depigmentation
48135124|NCT02961868|OTHER|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
48344252|NCT01204424|DEVICE|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.~The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
48135125|NCT02961868|GENETIC|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
48135126|NCT02961868|OTHER|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
48135127|NCT02961868|OTHER|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
48344253|NCT04289194|DRUG|HCR040 (Phase 1)|(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
48344254|NCT04289194|DRUG|Placebo (Phase 2)|(Phase 2) Intravenous administration of vehicle solution
48344255|NCT04289194|DRUG|HCR040 (Phase 2)|(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
48657888|NCT00572819|DRUG|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
48657889|NCT00572819|DRUG|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
48500667|NCT05016193|DEVICE|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
48135128|NCT05835934|DRUG|[14C]HSK21542|A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
48135129|NCT05452525|DRUG|CKD-379 I|1 tablet administration under fed condition
48135130|NCT05452525|DRUG|CKD-379 II|1 tablet administration under fed condition
48135131|NCT05452525|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
48135132|NCT05387044|RADIATION|SBRT|Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
48135133|NCT01593020|DRUG|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
48344256|NCT02482740|DRUG|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
48344257|NCT02482740|DRUG|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
48344258|NCT02103595|DEVICE|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
48344259|NCT02103595|DEVICE|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
48344260|NCT02353676|DRUG|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
48500668|NCT05016193|BEHAVIORAL|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
48500669|NCT05016895|DRUG|Single-dose azithromycin|Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
48500670|NCT02183207|PROCEDURE|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
48500671|NCT03275714|DEVICE|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
48513399|NCT03180645|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
48513400|NCT03180645|OTHER|No treatment|No treatment
48344261|NCT02353676|OTHER|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
48513401|NCT03939663|DRUG|misoprostol|misoprostol 2 tablets
48657890|NCT06194838|DEVICE|Ossur Power Knee|Newest version of the commercially-available powered knee developed by Ossur.
48135134|NCT01593020|DRUG|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
48135135|NCT01593020|DRUG|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
48657891|NCT06194838|DEVICE|Reboocon Intuy Knee|Commercially-available powered knee developed by Reboocon.
48135136|NCT01593020|DRUG|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
48135137|NCT01593020|DRUG|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
48135138|NCT01593020|DRUG|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
48135139|NCT01606813|OTHER|Usual Care|Standard care
48657892|NCT06644105|DRUG|cefditoren pivoxil tablets|took cefditoren pivoxil tablets 200mg after
48657893|NCT06096363|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.
48657894|NCT06406621|PROCEDURE|Laser hair depilation|"Laser hair depilation treatment with Nd:YAG laser every 4-6 weeks to obtain a total of 5 treatments. Similar to the control group, they will also receive the best recommended standard care including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments."
48657895|NCT00219414|DEVICE|Adacolumn Apheresis System|
48657896|NCT03602508|DRUG|mirabegron|oral
48657897|NCT03602508|DRUG|solifenacin|oral
48657898|NCT03602508|DRUG|darifenacin|oral
48657899|NCT03602508|DRUG|imidafenacin|oral
48135140|NCT01606813|BEHAVIORAL|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
48135141|NCT01606813|BEHAVIORAL|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
48135142|NCT01606813|BEHAVIORAL|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
48135143|NCT00817154|BEHAVIORAL|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
48135144|NCT01972776|DRUG|QBM076|Supplied in 25 mg and 75 mg capsules
48135145|NCT01972776|DRUG|Placebo|Matching placebo capsules
48135146|NCT00666419|OTHER|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
48135147|NCT00885313|DRUG|DHA250|DHA 250 mg/kg/d
48135148|NCT00885313|DRUG|DHA500|DHA 500 mg/kg/d
48135149|NCT00885313|DRUG|PLACEBO|placebo
48135150|NCT00885313|BEHAVIORAL|Lifestyle intervention|lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
48135151|NCT00744913|DRUG|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
48135152|NCT00744913|OTHER|Counselling|Women in this arm of the study will receive standard counseling only.
48135153|NCT03777566|DIAGNOSTIC_TEST|sonohysterography|sonohysterography with measuring the uterine cavity volume
48657900|NCT03602508|DRUG|tolterodine|oral
48344262|NCT04125303|BEHAVIORAL|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
48513402|NCT03939663|DRUG|Placebo|starch pills manufactured to mimic misoprostol 200 mg tablets
48657901|NCT03602508|DRUG|oxybutynin|oral
48135154|NCT04178213|DEVICE|Implantation of ADAPT 3D ALR|The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
48135155|NCT03923452|BEHAVIORAL|Mindfulness-based Stress Reduction|"Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day."
48135156|NCT02147093|DEVICE|Test (multi-focal)|contact lens was to be worn a daily wear.
48135157|NCT02147093|DEVICE|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
48135158|NCT02315456|PROCEDURE|capsulorhexis|
48344263|NCT04838795|BIOLOGICAL|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine|To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) as compared to the general unvaccinated population in South Africa
48344264|NCT05581355|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
48513403|NCT01967914|OTHER|PVI|Measurement of PVI (plethysmography variability index)
48513404|NCT03500380|DRUG|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
48657902|NCT03602508|DRUG|trospium|oral
48135159|NCT04910438|OTHER|STIs screening and care|"* Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).~* Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM."
48135160|NCT05568381|DEVICE|digital CBT-I|Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.
48135161|NCT05568381|OTHER|Online Sleep Health Education package|Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
48657903|NCT03602508|DRUG|fesoterodine|oral
48657904|NCT03602508|DRUG|propiverine|oral
48657905|NCT05929313|DEVICE|OrbusNeich Scoreflex TRIO|To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
48135162|NCT03689946|DRUG|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
48135163|NCT03689946|DIAGNOSTIC_TEST|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
48135164|NCT03689946|DIAGNOSTIC_TEST|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
48135165|NCT03689946|DRUG|Omnipaque|contrast agent for CCTA
48135166|NCT03689946|DRUG|Metoprolol|beta blocker to optimize heart rate during CCTA
48135167|NCT03689946|DRUG|Nitroglycerin|premedication for CCTA
48135168|NCT01611545|GENETIC|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
48135169|NCT05185245|PROCEDURE|Liver Transplantation|Liver Transplantation for Non-Resectable Colorectal Liver Metastasis
48135170|NCT03565484|DRUG|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
48135171|NCT03565484|DRUG|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
48135172|NCT03565484|DRUG|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
48135173|NCT00491894|DRUG|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
48135174|NCT03852069|DIETARY_SUPPLEMENT|Inulin|Patient receive inulin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of inulin-rich vegetables
48135175|NCT03852069|DIETARY_SUPPLEMENT|Placebo|Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of vegetables poor in inulin
48657906|NCT05929313|DEVICE|OrbusNeich Scoreflex NC|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
48135176|NCT04502381|DRUG|Inhaled amp B deoxycholate+intravenous liposomal amp B|"Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization."
48135177|NCT04502381|DRUG|Intravenous liposomal amphotericin B alone|Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
48135178|NCT05211232|DRUG|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
48135179|NCT05211232|DRUG|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
48135180|NCT05121636|DEVICE|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
48135181|NCT06179667|BEHAVIORAL|Mobile Application|"It is aimed to develop the mobile application to address the problems and training needs of informal caregivers regarding the caregiving process. In this context, in order to determine the needs of caregivers, face-to-face in-depth interviews will be held with caregivers using the Semi-Structured Questionnaire for Qualitative Interviews at the University of Health Sciences GTRH Geriatrics Department. The content of the mobile application will be created according to the topics determined as a result of qualitative research. Technical development of the application will be carried out by the web application designer."
48513405|NCT03500380|DRUG|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
48513406|NCT03500380|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle.
48135182|NCT03661463|DRUG|Aspirin|Drug
48135183|NCT02437422|BIOLOGICAL|SANGUINATE|Single two-hour infusion of SANGUINATE
48135184|NCT03107169|OTHER|FMT|Patients in the FMT group received FMT-FURM
48135185|NCT03107169|DRUG|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
48657907|NCT04666740|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
48657908|NCT04666740|DRUG|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
48135186|NCT00177177|DRUG|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
48135187|NCT05282966|DIAGNOSTIC_TEST|QSant-TM Urine Test|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
48135188|NCT01937494|DRUG|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
48135189|NCT05719519|PROCEDURE|Initial periodontal therapy and 3D intraoral scanning|Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
48135190|NCT05811936|BEHAVIORAL|Survivorship Needs Assessment Planning (SNAP) tool|"SNAP includes 2 educational survivorship modules for caregivers and survivors. There are 3 main elements: needs assessment, a tailored care plan and a mobile support app. SNAP uses pre-specified categories of needs, resources, and messaging behind the scenes to automate the identification, rating and management of high priority needs. Generated tailored care plans include referrals, messages and educational materials mapped to prioritized dyad-reported concerns addressing survivorship domains (diagnosis, treatment, follow-up care). Care plans and referrals are reviewed with an Advanced Practice Provider. Barriers to uptake are addressed, goal-oriented action planning is refined with brief mobile app training. Dyads receive a personalized binder with care plan, referrals, and an action plan. Dyads receive e-monitoring for 6 weeks to check in and identify barriers with algorithm-driven messaging to reinforce progress, provide further resources and encouragement."
48135191|NCT02605850|OTHER|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
48135192|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
48135193|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
48135194|NCT00389194|DRUG|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
48500672|NCT06340763|DEVICE|JETi Hydrodynamic Thrombectomy System|The JETi Hydrodynamic Thrombectomy System is a hydro-mechanical aspiration system intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter, JETi Pump Set, and JETi Saline Drive Unit (SDU), accessory cart, suction tubing, and non-sterile canister set. The JETi System is designed to simultaneously deliver a stream of high-pressure saline via a displacement pump to the distal tip of the JETi Catheter, while aspirating thrombotic material macerated by the saline stream.
47982594|NCT05199298|OTHER|"Mandala Activity-Based Breastfeeding Program"|Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
47982595|NCT02566226|DRUG|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
47982596|NCT02566226|DRUG|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
48135195|NCT02524769|DRUG|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
48500673|NCT03400085|OTHER|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
48500674|NCT03002571|DRUG|IDP-124 Lotion|IDP-124 Lotion, twice-daily application
48657909|NCT03631511|PROCEDURE|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
48657910|NCT06638788|OTHER|Knee extension|Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.
48657911|NCT00323622|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
48657912|NCT00323622|BIOLOGICAL|Engerix™-B|IM injection in the deltoid muscle
47982597|NCT03348956|DIAGNOSTIC_TEST|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
47982598|NCT02499250|DEVICE|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
48135196|NCT02505191|DRUG|St. John's wort prolonged-release tablet 500 mg|
48135197|NCT02505191|DRUG|St. John's wort film coated tablets 250 mg|
48500675|NCT03002571|DRUG|IDP-124 Vehicle Lotion|IDP-124 Vehicle Lotion, twice-daily application
48500676|NCT06287749|BIOLOGICAL|Blood sample/Liquid Biopsy|ctDNA analysis
48500677|NCT02325518|DRUG|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
48500678|NCT02325518|DRUG|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
48657913|NCT00323622|BIOLOGICAL|Hiberix®|IM injection in the deltoid muscle
48344265|NCT04594304|BEHAVIORAL|Behavioral: Usual care plus eToolkit|A baseline e-survey will be sent to participants prior to their scheduled appointment to collect baseline alcohol/tobacco use levels as well as a series of questions evaluating precursors to behaviour change. If randomized into the intervention group, patients will be sent a link to a tailored toolkit based on their behaviours, motivation to change and other pertinent factors. Patients who identify as non-smokers and meet the low-risk drinking guideline, will complete a third screening survey for physical activity. The cumulative patient profile (CPP) status for the patient for alcohol/smoking will be automatically updated post-baseline survey, and the PCP will receive a notification via EMR about the status update. For patients identifying with risky behaviours, the PCP will receive a prompt to update the CPP for the patient and will receive a link, embedded in the EMR, to a PCP-facing toolkit that facilitates evidence-based intervention.
48344266|NCT03699904|DRUG|Valaciclovir|Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
48344267|NCT03699904|DRUG|Placebo capsules (containing Avicel blend)|Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
48344268|NCT02382965|DEVICE|transcranial focused ultrasound|
48344269|NCT04176536|DRUG|BI 764198|Capsules
48344270|NCT03961893|DEVICE|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
48344271|NCT03961893|DEVICE|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
48344272|NCT01248585|DRUG|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
48344273|NCT01248585|DRUG|Placebo|2 placebo tablets taken once daily for 5 days
48344274|NCT04236219|DRUG|ALLN-346|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
48344275|NCT04236219|DRUG|Placebo|Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
48135198|NCT02246946|DEVICE|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
48135199|NCT02246946|OTHER|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
48135200|NCT02246946|PROCEDURE|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
48344276|NCT04306302|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
48344277|NCT04306302|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo.
48344278|NCT02607462|BIOLOGICAL|PRP|
48344279|NCT02607462|OTHER|Placebo|
48135201|NCT04595461|OTHER|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
48344280|NCT01459887|DRUG|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
48344281|NCT01459887|DRUG|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
48344282|NCT00481221|PROCEDURE|Observation of results from laboratory tests|Laboratory data summary only
48344283|NCT03815760|DEVICE|Blood Flow Restriction|Subjects will perform sidelying external rotation exercise
48344284|NCT03565991|DRUG|Avelumab|IV treatment
48344285|NCT03565991|DRUG|Talazoparib|Oral treatment
48344286|NCT01791790|DEVICE|Stimulation|
48500679|NCT02325518|DRUG|Subject's habitual PGA monotherapy|
48500680|NCT02208635|OTHER|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (\~30 µg Zn/g).
48500681|NCT02208635|OTHER|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of \~60 µg Zn/g).
48135202|NCT04595461|OTHER|Control|Standard patient education with verbal and written education
48135203|NCT02877641|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
48135204|NCT02877641|OTHER|Laboratory Biomarker Analysis|Correlative studies
48135205|NCT02877641|DIETARY_SUPPLEMENT|Multivitamin|Given PO
48135206|NCT02877641|OTHER|Placebo|Given PO
48135207|NCT02877641|OTHER|Questionnaire Administration|Ancillary studies
48344287|NCT01791790|DEVICE|SHAM|no stimulation
48344288|NCT04033380|DEVICE|Resin blocs (Grandio Blocs, VOCO)|composite-base bloc (Grandio Blocs, VOCO)
48344289|NCT04033380|DEVICE|Ceramic (Suprinity, VITA)|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
48344290|NCT03938025|PROCEDURE|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
48344291|NCT03647748|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
48344292|NCT06321276|DEVICE|extracorporeal shockwave therapy|Extracorporeal shock wave therapy (ESWT) is a non-invasive procedure that uses single-pulse acoustic waves generated outside the body and focused on a specific area of the body. Shock waves promote axonal regeneration of peripheral nerves through various molecular reactions. Although the anti-nociceptive mechanisms of ESWT have not yet been elucidated, ESWT may produce analgesia through biochemical changes in the nerve fiber itself and reduce inflammation of soft tissues.
48344293|NCT00003760|DRUG|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
48344294|NCT05267938|DRUG|Topical Anesthetic|The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
48500682|NCT02208635|OTHER|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (\~15 µg Zn/g maize).
48135208|NCT03676569|BIOLOGICAL|ADRC transplantation in autoimmune refractory epilepsy|
48135209|NCT05489913|OTHER|cardiac rehabilitation support program|First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
48135210|NCT01310348|DEVICE|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
48135211|NCT01310348|DEVICE|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
48135212|NCT04468412|DIAGNOSTIC_TEST|Carotid Artery Reactivity Testing|The carotid artery reactivity (CAR) test assesses macrovascular endothelial function by measuring the carotid artery diameter in response to sympathetic stimulation. Participants are in the supine position with the neck extended for assessment of the carotid artery. Left carotid artery diameter is recorded continuously during baseline (30 seconds) and during immersion of the right hand up to the wrist in icy water (4°C) for 3 minutes. CAR can either represent a dilatory response (normal endothelial function) or a constrictive response (endothelial dysfunction) of the carotid artery.
48135213|NCT05340231|DRUG|TACE protocol|"Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6"
48135214|NCT05340231|DRUG|Neoadjuvant Chemotherapy|mFOLFOX6, Q2W
48344295|NCT05267938|DRUG|Local anesthetic|After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
48135215|NCT01178372|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
48135216|NCT01178372|DRUG|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
48344296|NCT03491969|DRUG|Alpha-Lipoic Acid(α-LA)|200 mg, po, tid
48344297|NCT03491969|DRUG|Placebos|200 mg, po, tid
48344298|NCT05474989|DRUG|LSD|Moderate to high dose LSD
48344299|NCT05474989|DRUG|Active placebo|Low dose LSD
48344300|NCT06148350|OTHER|Stroke Rehabilitation|Both the groups received interventions three days/week for 30-60 minutes for four weeks
48344301|NCT02741310|DRUG|Placebo|Administered by intravenous infusion
48135217|NCT01149759|DRUG|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
48344302|NCT02741310|DRUG|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
48344303|NCT02741310|DRUG|Erenumab|Administered by intravenous infusion
48344304|NCT05768893|DEVICE|Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm|Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
48344305|NCT05768893|DEVICE|Er:YAG Laser 2940nm|Warts with this intervention treated only with the Er:YAG laser.
48500683|NCT05942053|DRUG|Placebo|Placebo match vitamin K2 capsules once per day.
48135218|NCT02005159|OTHER|Microbiological studies|
48344306|NCT05934136|BEHAVIORAL|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
48344307|NCT05934136|BEHAVIORAL|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
48344308|NCT06508788|DEVICE|CO2 laser|Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels
48344309|NCT00225212|DRUG|Rituximab 375 mg/m2|
48344310|NCT00890669|OTHER|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~* treadmill training with additional body load (A1),~* control condition (conventional physical therapy group) (B). and~* treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
48344311|NCT03757260|DEVICE|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
48500684|NCT05942053|DRUG|Vitamin K 2|Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
48657914|NCT00323622|BIOLOGICAL|Prevnar™|IM injection in the deltoid muscle
48135219|NCT03056183|BEHAVIORAL|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
48135220|NCT03343184|PROCEDURE|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
48135221|NCT03343184|PROCEDURE|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
48500685|NCT01513382|PROCEDURE|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
48500686|NCT04399044|PROCEDURE|Prophylactic muscle flap|"A muscle flap refers to taking an expendable muscle with its vascular supply and moving it to a new area. In this case, the investigators will take a muscle from the leg or abdomen that is redundant (other muscles perform the same function) and moving it to cover vascular grafts to provide healthy tissue to prevent infection."
48500687|NCT01476592|DIETARY_SUPPLEMENT|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
48657915|NCT00323622|DRUG|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
48657916|NCT00323622|DRUG|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
48657917|NCT06634875|DRUG|isunakinra|Isunakinra is a potent IL1R1 inhibitor
48657918|NCT04232553|DRUG|Mirikizumab|Administered IV
48657919|NCT04232553|DRUG|Mirikizumab|Administered SC
47982599|NCT02499250|DRUG|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
47982600|NCT03992742|BEHAVIORAL|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
48500688|NCT04051463|DRUG|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
48500689|NCT04051463|DRUG|Placebo|Placebo eye drops instilled once daily
48500690|NCT05325307|OTHER|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
48500691|NCT05325307|OTHER|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
48657920|NCT06414031|DRUG|Tranexamic Acid|Intravenous administration
48657921|NCT06414031|DRUG|Placebo|Intravenous administration
48657922|NCT06122597|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
48657923|NCT04648085|DEVICE|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
48657924|NCT05920252|BEHAVIORAL|Vira|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
48657925|NCT05920252|BEHAVIORAL|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
48657926|NCT00583583|DEVICE|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
48344312|NCT03757260|DEVICE|Placebo of photodynamic therapy|The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
48657927|NCT02572648|OTHER|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes."
48657928|NCT02572648|OTHER|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
48657929|NCT05681481|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
48657930|NCT05681481|DRUG|Prednisone|Oral Prednisone
47982601|NCT03992742|BEHAVIORAL|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
47982602|NCT03992742|BEHAVIORAL|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- \& 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
47982603|NCT03992742|BEHAVIORAL|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
47982604|NCT03992742|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
47982605|NCT03992742|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
47982606|NCT03992742|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
47982607|NCT03992742|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
47982608|NCT01110707|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).
47982609|NCT01110707|DRUG|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
48135222|NCT03343184|PROCEDURE|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
48135223|NCT03343184|PROCEDURE|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
48344313|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Prophylaxis|a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
48344314|NCT04377789|DIETARY_SUPPLEMENT|Quercetin Treatment|a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
48344315|NCT01055457|DEVICE|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
48344316|NCT01055457|DEVICE|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
48657931|NCT06312059|OTHER|Advance Infant Formula Powder|Sole source infant nutrition for the control arm.
48657932|NCT06312059|OTHER|"Kendamil Cow milk test product"|Sole source infant nutrition for the cow milk test arm.
48135224|NCT01596972|DEVICE|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
48135225|NCT03956628|BEHAVIORAL|stay safe program|Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
48135226|NCT05174520|OTHER|Routine Physical Therapy|Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
48344317|NCT05522296|DRUG|Mpox Vaccine|Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
48657933|NCT06312059|OTHER|"Kendamil goat milk test product"|Sole source infant nutrition for the goat milk test arm.
47982610|NCT04498611|DIAGNOSTIC_TEST|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
48135227|NCT05174520|OTHER|Muscle Energy Technique|Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
48135228|NCT01141803|DIETARY_SUPPLEMENT|Apples|550g of apples/day
48135229|NCT01141803|DIETARY_SUPPLEMENT|Apple pomace|22g apple pomace/day
48135230|NCT06232681|BEHAVIORAL|Progressive relaxation exercise|The intervention group will take one month progressive relaxation exercise starting from the hospitalisation to the clinic
47982611|NCT00271050|OTHER|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
47982612|NCT03666845|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
47982613|NCT04425733|DRUG|MK-5475|MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
47982614|NCT04425733|DRUG|Placebo|MK-5475-matching placebo administered QD via inhalation
47982615|NCT02899910|BEHAVIORAL|Health education|Education on lifestyle changes for treatment of metabolic syndrome
47982616|NCT02899910|BEHAVIORAL|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
47982617|NCT01465087|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
47982618|NCT04508868|BEHAVIORAL|Brief Behavioral Activation with Mental Imagery|"Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary."
47982619|NCT04508868|BEHAVIORAL|Minimal Attention Control Intervention|Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
47982620|NCT01904682|DRUG|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
47982621|NCT00329654|PROCEDURE|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
47982622|NCT06261554|DIETARY_SUPPLEMENT|Dietary Supplement: Low dose OIT|Following the building-up phase (up to 14 months), patients will receive a daily low dose of sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread for 3 months (12 +/- 3 weeks).
47982623|NCT03813979|DRUG|Dolutegravir|Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
47982624|NCT02068833|PROCEDURE|Gastrectomy|
47982625|NCT02068833|PROCEDURE|BPD-DS|
48135231|NCT00547066|BIOLOGICAL|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
48135232|NCT02134106|DRUG|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
48344318|NCT00067626|DIETARY_SUPPLEMENT|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
48344319|NCT03417505|DEVICE|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
48344320|NCT03417505|DEVICE|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
48344321|NCT04746781|BEHAVIORAL|Mobile 360° Video intervention|Using 360° Videos to educate participants about the effect of diabetes.
48344322|NCT04746781|BEHAVIORAL|Motivation and Problem Solving (MAPS)|Using Motivation and Problem Solving to help people enroll in the Diabetes Prevention Program.
48657934|NCT06001749|DRUG|Psilocybin|A tryptamine derivative, capsule, taken orally.
48657935|NCT05161195|DRUG|Ribociclib|Participants continue ribociclib as was administered in their parent study
48657936|NCT05161195|DRUG|Letrozole|Participants continue ribociclib in combination with letrozole as was administered in their parent study
48657937|NCT05161195|DRUG|Anastrozole|Participants continue ribociclib in combination with anastrozole as was administered in their parent study
48135233|NCT02134106|DRUG|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
48135234|NCT05914896|DRUG|HighOsmo|This group received a priming solution with high osmolality
48135235|NCT02195232|DRUG|Isoquercetin|
48135236|NCT05299034|DIAGNOSTIC_TEST|Multiparametric imaging|MR perfusion or multiparametric CT including NCCT, CTA and CTP
48135237|NCT05299034|DIAGNOSTIC_TEST|Non contrast CT+CT angiography|NCCT+CTA
48135238|NCT04756271|BIOLOGICAL|SARS-Cov-2 neutralizing antibody titer|Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
48135239|NCT06509763|DEVICE|ECGI system during LBBP implant|ECGI system to create non-invasive ventricular maps during the screwing steps of the LBBP electrode
48135240|NCT05066022|BIOLOGICAL|CT0590 CAR T Cells|Dose-escalated CAR T cells infusion
48135241|NCT00895609|DRUG|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
48135242|NCT05473416|OTHER|McKenzie back extension exercise|McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.
48135243|NCT05473416|OTHER|Pilates pelvic tilt exercise|Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.
48135244|NCT05473416|OTHER|Baseline treatment|Postural guidelines + proper lifting technique + stretch break Rest
48135245|NCT05913349|BEHAVIORAL|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
48135246|NCT03345095|DRUG|Marizomib|Intravenous administration of Marizomib
48135247|NCT03345095|DRUG|Temozolomide|Oral Administration of Temozolomide
48135248|NCT03345095|RADIATION|radiotherapy|60 Gy in 30 fractions over 6 weeks
48135249|NCT01943669|DEVICE|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
48135250|NCT00111683|DRUG|MK0457|
48135251|NCT02426255|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
48135252|NCT04383184|PROCEDURE|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
48344323|NCT04746781|BEHAVIORAL|Risk notification/education|Sending participants (all of whom meet the diagnostic criteria for prediabetes) educational information about the condition.
48344324|NCT02062476|DIETARY_SUPPLEMENT|Lactobacillus GG|
48344325|NCT06343454|OTHER|Digital Interocclusal Record In Different Head Positions|Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
48500692|NCT04220931|DRUG|botulinum toxin injection|injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
47982626|NCT00975481|DRUG|dimebon|Oral tablet; 20 mg dimebon, single dose
47982627|NCT00975481|DRUG|dimebon|Oral tablet; 40 mg dimebon, single dose
47982628|NCT00975481|DRUG|dimebon|Oral tablet; 60 mg dimebon, single dose
47982629|NCT00975481|DRUG|placebo|Oral tablet or capsule; placebo, single dose
47982630|NCT00975481|DRUG|alprazolam|Oral capsule; 1 mg alprazolam, single dose
47982631|NCT00975481|DRUG|alprazolam|Oral capsule; 3 mg alprazolam, single dose
47982632|NCT06146426|DIETARY_SUPPLEMENT|Early diet resumption|Resuming oral diet at pace started from 2 hours after extubation from ventilator.
47982633|NCT03460483|OTHER|Genetic Counseling|Undergo genetic counseling
47982634|NCT03460483|OTHER|Genetic Testing|Undergo genetic testing
47982635|NCT03460483|OTHER|Laboratory Biomarker Analysis|Correlative studies
47982636|NCT03460483|PROCEDURE|Mutation Carrier Screening|Undergo tumor screening via next-generation sequencing
47982637|NCT00232817|DRUG|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
47982638|NCT05105061|DRUG|Ketamine (Ketalar)|0.5 mg/kg of body weight
47982639|NCT05105061|DRUG|Placebo|IM injection of matching placebo
47982640|NCT05296759|DRUG|botulinum toxin A|botulinum toxin A injection
47982641|NCT05296759|DRUG|Gabapentin|Gabapentin oral intake
47982642|NCT05296759|DRUG|Duloxetine|Duloxetine oral drug intake
47982643|NCT05072561|DIAGNOSTIC_TEST|Sentinel lymph node scintigraphy|"During the surgery, right after the identification of the primary, 18-37 MBq of 99mTc-Nanocolloids in two ml will be injected at four peritumoral locations. After a brief waiting time (5-10'), the thoracic surgeon will perform the clinical intervention, including the lobectomy (the injection sites will be resected alongside the tumour) and lymphadenectomy, according to the best clinical practice. All the excised lymph nodes will be ex vivo counted using a gamma probe: those with a detectable activity (at least 10% of the hottest lymph node) will be considered as SLN. Thereafter, the mediastinum will be scanned using the gamma probe and a handheld gamma-camera (the latter will not be employed in case of robotic-assisted surgery); any further source of radioactivity will be investigated and, should further lymph nodes be identified, these will be also resected and classified in SLN or non-SLN, based on ex vivo activity."
48135253|NCT00968695|DRUG|Albumin|The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
48657938|NCT05161195|DRUG|Goserelin|Participants continue ribociclib in combination with goserelin as was administered in their parent study
48657939|NCT05161195|DRUG|Tamoxifen|Participants continue ribociclib in combination with tamoxifen as was administered in their parent study
48657940|NCT05161195|DRUG|Fulvestrant|All participants continue ribociclib in combination with fulvestrant as was administered in their parent study
48344326|NCT01632176|BEHAVIORAL|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
48500693|NCT05417035|DRUG|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
48135254|NCT02788994|DEVICE|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~* stable fracture synthesis for fast rehabilitation and early mobilization~* an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
48135255|NCT02788994|DEVICE|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
48657941|NCT06645483|OTHER|ChatGPT-assisted instruction|"ChatGPT will interactively support students by answering questions, initiating discussions, and providing customized learning materials in line with the course objectives. It will be supervised by the instructor to ensure guidance and prevent misinformation.~Duration: ChatGPT-assisted learning for the first two weeks, followed by traditional teaching for the next two weeks."
47982644|NCT05118828|BEHAVIORAL|Guided internet-based cognitive behavioural therapy|AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
47982645|NCT05118828|BEHAVIORAL|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
48135256|NCT01065649|DRUG|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
48135257|NCT01065649|DRUG|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
48135258|NCT00140491|DEVICE|Vision Restoration Therapy (NOVAVISION)|
48135259|NCT05892562|OTHER|No intervention|As this study is purely observational, no intervention is involved.
48135260|NCT00894894|DRUG|MP-470|escalating daily doses of amuvatinib
48135261|NCT00894894|DRUG|amuvatinib (MP-470)|escalating doses of daily amuvatinib
48135262|NCT01911767|DRUG|Dimethyl fumarate|Administered as specified in treatment arm.
48344327|NCT01128166|DEVICE|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
48344328|NCT05987475|PROCEDURE|Breast reconstruction|Breast reconstruction and breast augmentation based on the indications as listed out in the instructions for use of the medical device under investigation
48344329|NCT04331028|DEVICE|Shockwave therapy|A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
48344330|NCT05783492|DRUG|Intranasal ketamine|10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
48344331|NCT05693103|DEVICE|High-Intensity Focused Electromagnetic therapy|"The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation."
47982646|NCT00971854|PROCEDURE|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
48135263|NCT01911767|DRUG|Peginterferon beta-1a|Administered as specified in treatment arm.
48657942|NCT06645483|OTHER|Traditional lecture-based instruction|"Students will learn through a traditional teaching format, where the instructor delivers the course content through lectures and presentations.~Duration: Traditional teaching for the first two weeks, followed by ChatGPT-assisted learning for the next two weeks."
48135264|NCT03665532|BEHAVIORAL|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
48344332|NCT00776490|DRUG|Glimepiride 1mg Tablets|
48344333|NCT05549414|DEVICE|Proton Radiation|Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
48344334|NCT04913571|DRUG|Eribulin|Eribulin
48344335|NCT04913571|DRUG|Tislelizumab|Tislelizumab
48344336|NCT05369533|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
48344337|NCT05369533|DRUG|Sinemet Pill|Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
48344338|NCT05369533|DRUG|Placebo|Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
48657943|NCT01172782|DRUG|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
48344339|NCT02790684|DRUG|DS-8500a|
48500694|NCT04644822|DIAGNOSTIC_TEST|[18F] PSMA-1007 Injection|a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.
48657944|NCT05918029|DRUG|Potassium Citrate Extended Release Oral Tablet|Oral potassium citrate extended-release tablet
48657945|NCT05918029|OTHER|Placebo|Placebo capsule identical to active ingredient
48657946|NCT05918029|DRUG|Potassium Citrate and Citric Acid Oral Solution|Oral potassium citrate and citric acid
48657947|NCT01245608|DRUG|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
48657948|NCT06308237|OTHER|RESISTED EXERCISES|"Patients will perform Chest plank for 30 seconds with 4 repetitions.~Then the Participants will perform these exercises for 1 minute each with 4 repetitions:~Wide grip lateral pull down , Lying triceps press, Sit up squats, Barbell curl each.~And will perform Thigh adduction for1 minute with 2 repititions."
47982647|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
47982648|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
48135265|NCT02931396|DEVICE|FES|
48135266|NCT01988402|DRUG|allopurinol|
48135267|NCT01988402|DRUG|Placebo (sugar pill)|
48135268|NCT03476798|DRUG|Rucaparib|Rucaparib 600mg PO BID daily
48135269|NCT03476798|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV on day 1 of each cycle
48135270|NCT04278755|DRUG|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
48135271|NCT02681900|BEHAVIORAL|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
48135272|NCT02681900|BEHAVIORAL|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
48135273|NCT01835639|DIETARY_SUPPLEMENT|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
48500695|NCT06264401|OTHER|Alendronate|control group received (Alendronate) 70 mg 1 tab every week.
48135274|NCT01391767|DEVICE|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
48135275|NCT02082652|DRUG|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
48344340|NCT04247321|DEVICE|Licox® Brain Tissue Oxygen Monitoring System|Invasive brain tissue oxygenation monitoring
48344341|NCT04247321|DEVICE|Near-infrared spectroscopy (NIRS)|Non-invasive approach to monitoring brain tissue oxygenation which uses two wavelengths of near infrared light and takes measurements of the ratio of oxyhemoglobin to total hemoglobin
48344342|NCT00959894|DRUG|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
48344343|NCT00959894|DRUG|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
48344344|NCT02212080|DRUG|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
48344345|NCT02212080|DRUG|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
48344346|NCT02931747|DIETARY_SUPPLEMENT|Placebo|Subjects are received Placebo once daily for 16 weeks.
48344347|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
48657949|NCT06308237|OTHER|BALANCE EXERCISES|"Static and dynamic balance exercises will include:~Patients will perform Arm abduction holding a half-kg dumbbell, Opposite arm and leg in a quadruped position, Walking in a tandem stance(forward and backward), Turning and bending to the sides in a standing position, Pass through obstacles in a spiral, for 2 minutes each.~Then they will perform throwing a medicine ball to investigator and back while trying to maintain balance, Tandem stance, Walking backwards, Two-leg bridge as well as single (2 repetitions), Leg bridge (raising the other leg), walking on the heel, performing rhythmic movements while stepping on a circular environment and balance board exercises, for 1 minute each.~And will Walk up and down the stairs for 3 minutes."
48344348|NCT02931747|DIETARY_SUPPLEMENT|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
48344349|NCT00829660|DRUG|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
48344350|NCT00829660|DRUG|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
48344351|NCT01543113|OTHER|sequencing|sequencing
48657950|NCT04003038|PROCEDURE|Negative Pressure Wound Therapy|Receive wound care with NPWT
48657951|NCT04003038|PROCEDURE|Wound Care Management|Receive wound care with a standard dressing (bandage)
48657952|NCT00934180|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
48657953|NCT00934180|DRUG|Zofran®|1 x 8 mg ODT
48657954|NCT05617196|BEHAVIORAL|Virtual PREHAB|The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.
48657955|NCT05617196|BEHAVIORAL|Standard care|In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
48657956|NCT05098821|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
48657957|NCT04089358|OTHER|Educational Intervention|Receive educational materials
48657958|NCT04089358|DEVICE|FitBit|Wear a Fitbit
48657959|NCT04089358|OTHER|Goal Setting|Set goals
48135276|NCT05940740|OTHER|Colorectal-Mobile application|The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
48135277|NCT01737749|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
48135278|NCT03222934|DEVICE|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
48135279|NCT02663804|DEVICE|Total Knee Arthroplasty|
48344352|NCT03787095|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
48135280|NCT05861570|DRUG|normal saline|Ultrasound guided injection using 3ml normal saline
48135281|NCT05861570|DRUG|(Sodium Hyaluronate (Hyruan One , LG)|Ultrasound guided injection using 3ml of Sodium Hyaluronate
48135282|NCT05861570|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
48135283|NCT05861570|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 4ml of 40mg triamcinolone acetonide
48135284|NCT02958696|DRUG|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
48344353|NCT03787095|BIOLOGICAL|Placebo|Diluent for REGN2810, administered as an IV infusion
48344354|NCT04673812|DRUG|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
48135285|NCT01584752|PROCEDURE|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
48344355|NCT00821899|BIOLOGICAL|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
48344356|NCT01042054|OTHER|Standard optimised recovery protocol.|"* Epidural analgesia for the first 48 hours postoperatively.~* Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
48344357|NCT01042054|OTHER|Wound catheter plus patient-controlled analgesia.|"* Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~* Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~* Sham epidural catheter applied to the patient's back for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
48344358|NCT04123171|DIAGNOSTIC_TEST|Neuroimaging studies|Complementary exams are not invasive and will be performed in enrolled individuals who sign a comprehensive informed consent form
48344359|NCT02072694|OTHER|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
48500696|NCT06264401|OTHER|treatment exercises|the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program, each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 minutes.
48500697|NCT03512132|BIOLOGICAL|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
48657960|NCT04089358|OTHER|Health Promotion and Education|Receive text message about goal setting
48657961|NCT04089358|OTHER|Media Intervention|Follow Instagram group
48657962|NCT04089358|BEHAVIORAL|Telephone-Based Intervention|Receive phone call about goal setting
48657963|NCT06461507|OTHER|Janda's Approach|For Tightened Structures Stretching applied toIliopsoas and Erector spinal muscles (5 repetitions of stretching with 30-s hold for each muscle). For Strengthening of Weakened Structures; Glute bridge and Abdominal crunch(10 repetitions of each).
48657964|NCT06023264|PROCEDURE|Dry needling|It is a minimally invasive treatment modality. Its effectiveness has been confirmed in numerous studies. It consists of applying an antiseptic in the puncture area and inserting the needle in the required aseptic conditions. During puncture, the patient's physical response is observed at all times, in order to control the local spasmodic responses in each muscle. After applying the technique, we assessed jaw pain, mouth opening, and the appearance of headaches. The adverse effects of the technique are the following: pain after puncture (1.7%), local bleeding at the puncture site (6.1%) and syncopal responses (0.7%).
48657965|NCT06061185|DEVICE|Multimodal CT|Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
48657966|NCT05798520|DRUG|BIIB091|Administered as specified in the treatment arm.
48657967|NCT05798520|DRUG|DRF|Administered as specified in the treatment arm.
48657968|NCT05798520|DRUG|Placebo|Administered as specified in the treatment arm.
48657969|NCT06098573|BEHAVIORAL|High Alert|Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app \[CIAS\]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
47982649|NCT04767204|BEHAVIORAL|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
47982650|NCT05230810|DRUG|Alpelisib|Orally twice a day
47982651|NCT05230810|DRUG|Tucatinib|Orally once a day
48135286|NCT05980507|DRUG|ICI201|ICI201 CAR-T cell injection
48135287|NCT03372694|BEHAVIORAL|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
48500698|NCT03512132|BIOLOGICAL|Urine sample|Urine sample on an empty stomach
48500699|NCT03996148|DRUG|Remifentanil, Propofol, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
48344360|NCT02072694|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
48344361|NCT02033655|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
48344362|NCT02033655|BEHAVIORAL|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
48344363|NCT02320240|DRUG|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48344364|NCT02320240|DRUG|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48344365|NCT02320240|DRUG|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48135288|NCT03372694|DRUG|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
48344366|NCT02320240|DRUG|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48344367|NCT02320240|DRUG|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48344368|NCT02320240|DRUG|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48344369|NCT02320240|DRUG|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48344370|NCT02320240|DRUG|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48344371|NCT02320240|DRUG|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
48500700|NCT03996148|DRUG|Remifentanil, Dexmedetomidine, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
48500701|NCT03996148|DRUG|Remifentanil and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
48135289|NCT03372694|OTHER|Rehabilitation Education|General health education
48135290|NCT03372694|DRUG|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
48344372|NCT01052831|DRUG|Naltrexone|50-100 mg qd for 8 weeks
48500702|NCT01754337|OTHER|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
48500703|NCT03077555|DRUG|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
48500704|NCT03077555|DRUG|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
48500705|NCT02553031|DEVICE|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
48500706|NCT01229709|BEHAVIORAL|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
48500707|NCT00619112|DRUG|temozolomide|single arm study
48135291|NCT02912247|DRUG|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
48135292|NCT02912247|DRUG|adalimumab|adalimumab, 40mg,subcutaneous injection,once
48344373|NCT01052831|DRUG|Placebo|50-100 mg qd for 8 weeks
48344374|NCT01402024|DRUG|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
48344375|NCT01402024|DRUG|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
48344376|NCT01174836|OTHER|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
48135293|NCT03763682|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
48135294|NCT04251169|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as 30 minutes IV infusion every 3 weeks beginning in Cycle 1
48135295|NCT04251169|DRUG|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour IV infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
48135296|NCT03098589|DRUG|Revlimid|Revlimid
48344377|NCT06145204|OTHER|questionnaire|anamnesis, OMSPQ, DN4, Brief Pain Inventory-short form, lymph-ICF-LL
48500708|NCT02497651|DIETARY_SUPPLEMENT|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
48500709|NCT02497651|OTHER|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
48657970|NCT06098573|BEHAVIORAL|Information condition|Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.
48344378|NCT02697058|BIOLOGICAL|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
48344379|NCT02697058|DRUG|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
48344380|NCT05148559|BEHAVIORAL|Reminder Sent Via Preferred Method of Communication|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
48344381|NCT05148559|BEHAVIORAL|Reminder Sent Via Mailed Letter|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
48344382|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
48500710|NCT02819050|DEVICE|NCPAP|Nasal Continuous Positive Airway Pressure
47982652|NCT05230810|DRUG|Fulvestrant|"500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"
47982653|NCT01432353|DRUG|DFRF4539A|multiple ascending doses
47982654|NCT06295263|OTHER|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups
48135297|NCT00321152|OTHER|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
48135298|NCT00061906|DRUG|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
48135299|NCT00034489|DRUG|pemetrexed|
48135300|NCT00034489|DRUG|gemcitabine|
48135301|NCT04682418|DEVICE|xvision Spine sytem|pedicle screw placement will be performed using the XVS navigation system
48135302|NCT03484949|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
48135303|NCT03307694|DIAGNOSTIC_TEST|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
48135304|NCT03307694|DIAGNOSTIC_TEST|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
48500711|NCT02747550|PROCEDURE|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
48500712|NCT02747550|PROCEDURE|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
48657971|NCT06098573|BEHAVIORAL|No contact|Participants in the passive control will receive no contact until the three and six-month follow-ups.
48657972|NCT04316143|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat
48657973|NCT06638151|DRUG|aspirin + clopidogrel|Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).
48657974|NCT06638151|DRUG|Aspirin|Aspirin 81 mg once daily alone
47982655|NCT05890040|OTHER|questionnaire|assessment of anxiety
47982656|NCT01621620|DRUG|Yohimbine|
48344383|NCT03954704|DRUG|mFOLFOX6 Regimen|Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
48344384|NCT03954704|DRUG|Dalutrafusp alfa|Administered intravenously
48344385|NCT00320190|DRUG|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
47982657|NCT05346341|PROCEDURE|Minimally invasive techniques|"All patient will be treated under general anaesthesia An appropriate gland-preserving minimally-invasive surgical procedure will be performed for all patients according to the nature and extent of the disease for either submandibular or parotid ducts.~Minimally invasive techniques for ductal salivary gland pathologies include:~1. Sialolithotomy through a simple cutdown~2. Sialendoscopy~3. Transoral microscopic-assisted sialolithotomy."
47982658|NCT00432107|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
48135305|NCT03307694|DIAGNOSTIC_TEST|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
48135306|NCT03109080|DRUG|Olaparib|five levels of dose, per os administration, twice daily each day
48135307|NCT03109080|RADIATION|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
48135308|NCT04089930|DIAGNOSTIC_TEST|Immunogenicity|anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
48135309|NCT05980559|DRUG|Xeomin|50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
48135310|NCT06359548|PROCEDURE|Peeled ILM Reposition|"The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required."
48135311|NCT06359548|PROCEDURE|ILM Peeling|The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.
48135312|NCT00325767|DRUG|nebulized albuterol (2.5 mg/3ml/dose)|
48135313|NCT00325767|DRUG|nebulized levalbuterol (1.25 mg/3ml/dose)|
48135314|NCT00325767|DRUG|nebulized placebo (3ml/dose)|
48135315|NCT04747418|PROCEDURE|Diagnostic Hysteroscopy|Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
48135316|NCT04747418|PROCEDURE|Trans-vaginal ultrasound|Trans vaginal ultrasound performed immediately following the diagnostic hysteroscopy ( as sonohysterography)
48135317|NCT02674841|OTHER|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
48344386|NCT00320190|DRUG|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
48135318|NCT02674841|OTHER|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
48135319|NCT02674841|OTHER|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
48135320|NCT04394897|COMBINATION_PRODUCT|Remifentanil-Propofol admixture|
48135321|NCT00644566|OTHER|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
48135322|NCT03759249|OTHER|Sleep medical treatment|"The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion."
48344387|NCT04888728|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
48344388|NCT04888728|DRUG|Nebivolol|Nebivolol
48344389|NCT04888728|DRUG|Paroxetine|Paroxetine
48344390|NCT02359136|PROCEDURE|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
48344391|NCT02359136|PROCEDURE|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
48657975|NCT05317481|BEHAVIORAL|BE-SMART-DR|Therapy that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk
48657976|NCT05317481|BEHAVIORAL|psychoeducational control comparator condition (CC)|Structured sessions, matched for BE-SMART-DR session number and time, that will emphasize established strategies to manage health and well being
48657977|NCT05380700|DEVICE|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
48657978|NCT06516198|OTHER|Auricular Acupressure|Seeds will be placed during the clinic visit by the acupuncturist or the research associate according to the group the patient was assigned to. The care partner will observe the placement. A photograph of the seed placement will be taken and given to the care partner and to the patient after the relevant points are labeled by number or letter. The method of pressing is demonstrated for 1 one of the seeds, the care partner practices pressing on 2 other seeds, and the patient practices pressing on the remaining 2 seeds. Pressing consists of applying pressure, gradually increasing the pressure until the patient expresses discomfort, and maintaining that pressure until 2 minutes have passed. After pressing has been performed for each seed, the seeds are removed in clinic prior to clinic discharge.
48657979|NCT05409794|BIOLOGICAL|Blood sample|Blood sample for the determination of plasma lithium levels
48657980|NCT02845414|DRUG|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
48657981|NCT04705766|OTHER|Urine Collection|A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.
48657982|NCT05870072|OTHER|Dual task training|In addition to balance exercises, random name-word generation, counting the days of the week forward and backward, counting the months of the year forward and backward, subtracting 3 by 3 numbers from 300 to 900 starting from a random number, adding 7 from 1 to 100 and adding 100 Cognitive tasks such as counting tasks by subtracting 7 will be given. While testing dual-task performance, subjects will be asked to perform both tasks without prioritizing and do their best, and will be warned not to stop thinking. In dual-task training, the additional task to be assigned to the motor task will initially be of low complexity and novelty, and will progress to a high degree of complexity and novelty in the training process.
48135323|NCT00837954|DEVICE|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
48135324|NCT00837954|DEVICE|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
48344392|NCT02359136|PROCEDURE|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
48344393|NCT04319770|DEVICE|enamel matrix derivative (EMD)|periodontal regenerative surgery with enamel matrix derivative (EMD) (control)
48344394|NCT04319770|DEVICE|hyaluronic acid (HA)|periodontal regenerative surgery with hyaluronic acid (HA) (test)
48344395|NCT03924427|DRUG|BMS-986165|Oral tablet administration
48344396|NCT05298163|DRUG|Calcitriol capsules|Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
48344397|NCT05298163|DRUG|Placebo|One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
48344398|NCT04841213|PROCEDURE|Dental implantation|Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
48344399|NCT02984891|PROCEDURE|Optical Coherence Tomography (OCT)|Procedure will be performed using the OCT Dragonfly catheter is a hydrophilic-coated catheter that uses infrared light with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, and maximum tissue penetration with OCT is approximately 1.5 mm-3 mm.
48344400|NCT02984891|PROCEDURE|Intravascular Ultrasound (IVUS)|Procedure will be performed using the IVUS Kodama catheter is a hydrophilic-coated catheter that used high-fidelity ultrasound transmission to capture high-definition images of coronary artery anatomy. It uses ultrasound waves with a frequency of 40 or 60 MHz, as opposed to 20 MHz in conventional IVUS, to improve resolution while optimizing tissue penetration. It provides axial resolution of \< 40 microns and tissue penetration of 10 mm.
48344401|NCT04105322|OTHER|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
48344402|NCT00148525|BEHAVIORAL|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
48135325|NCT00837954|PROCEDURE|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
48344403|NCT00148525|BEHAVIORAL|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
48344404|NCT03030391|OTHER|PET|
48344405|NCT03030391|OTHER|MRI|
48344406|NCT02451189|DIETARY_SUPPLEMENT|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
48135326|NCT02730624|DRUG|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
48344407|NCT02451189|DIETARY_SUPPLEMENT|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
48344408|NCT02451189|DIETARY_SUPPLEMENT|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
48344409|NCT03272971|DEVICE|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
48344410|NCT04938089|OTHER|Maintenance|Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking \> 9 cigarettes per day.
48344411|NCT05841641|DEVICE|Laser Bandage|The Diode Laser will create a biological bandage at a wavelength of 810 nm, set at 5W in continuous-wave mode, applied via a 400-µm optical fibre.
48344412|NCT05841641|PROCEDURE|Hemostatic agent with surgical stent|Following graft harvesting, the donor site was secured with a hemostatic agent and protected with a palatal stent
48344413|NCT00978133|PROCEDURE|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
48344414|NCT00978133|PROCEDURE|Skin closure with skin staples|Skin closure with skin staples
48344415|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
48344416|NCT02157584|DRUG|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
48344417|NCT02681640|OTHER|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
48344418|NCT02681640|DEVICE|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
48344419|NCT02979561|DRUG|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
48344420|NCT02979561|DRUG|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
48344421|NCT02177214|PROCEDURE|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
48344422|NCT01002495|BIOLOGICAL|VM202|Endocardial injections on Day 0.
48344423|NCT05928104|OTHER|Medication review|Pharmacist-led medication review in primary care using a co-designed document
48344424|NCT01914939|DRUG|Oxytocin|
48344425|NCT01914939|BEHAVIORAL|Social Skills focused CBT|
48344426|NCT01914939|BEHAVIORAL|Stress management/relaxation training|
48344427|NCT01914939|DRUG|placebo drug|
48344428|NCT03066310|DIAGNOSTIC_TEST|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
48344429|NCT00026975|PROCEDURE|Hyperbaric Oxygen|
48344430|NCT05157776|DRUG|PD-1 and chemotherapy|Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
48344431|NCT01555736|DRUG|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
48344432|NCT02143141|DRUG|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
48344433|NCT02143141|DRUG|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
48344434|NCT05153564|DRUG|Semaglutide 1.34 mg/mL|Semaglutide will be administered at a dose of 0.25, 0.50 or 1.0 mg as indicated on scale drum once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
48344435|NCT05153564|DRUG|Semaglutide 3.0 mg/mL|Semaglutide will be administered at a dose of 2.0 mg corresponding to the increment of 67 (pen injector units) as indicated on scale drum. once weekly by subcutaneous (s.c.) (under the skin) injections in the abdomen for 14 weeks.
48344436|NCT05153564|DRUG|NNC0480-0389 10 mg/mL|NNC0480-0389 will be administered at a dose of 0.23, 0.45 or 0.90 mL once weekly by s.c. (under the skin) injections for 14 weeks.
48344437|NCT05153564|DRUG|NNC0480-0389 30 mg/mL|NNC0480-0389 will be administered at a dose of 0.60 mL once weekly by s.c. (under the skin) injections for 14 weeks.
48344438|NCT05153564|DRUG|Microgynon®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
48344439|NCT04031157|DEVICE|Predictix Antidepressant|Predictix Antidepressant guided treatment
48344440|NCT01105949|DEVICE|Marketed nasal strip|Marketed nasal strip
48344441|NCT01105949|DEVICE|NexGen AB 2R11|Nasal strip prototype
48344442|NCT01105949|DEVICE|NexGen JB Organic PET/PE|Nasal strip
48344443|NCT04836091|BEHAVIORAL|Waitlist|From day 31 to day 60 (ie., during month 2) of the trial, participants in the waitlist arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
48344444|NCT04836091|BEHAVIORAL|Intervention|From day 1 to day 60 (ie., entire 2 month duration) of the trial, participants in the intervention arm will be granted access and instructed to use the OurPlan program as directed. The OurPlan program includes 4 modules covering topics of communication, HIV/STI prevention, HIV/STI statistics, and stigma / discrimination. Each module contains content, questions, and an activity for the participant and couple to complete. OurPlan also includes a resource locator using GPS-capabilities to allow participants to find sexual health resources, as well as a calendar and reminder system. One goal of OurPlan is to help both partners of the couple create and use a risk-reduction plan of evidence-based prevention strategies over time. Answers provided during the assessments will help determine whether participants/couples created a risk-reduction plan and used evidence-based strategies over time, including changes in their own and partner-related attitudes toward these strategies.
48344445|NCT02092168|DRUG|BIA 9-1067|
48344446|NCT02082665|DRUG|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
48344447|NCT02082665|DRUG|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
48344448|NCT02082665|DRUG|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
48344449|NCT02446860|DRUG|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
48344450|NCT01116804|PROCEDURE|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
48344451|NCT01116804|PROCEDURE|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
48344452|NCT01116804|PROCEDURE|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
48657983|NCT05870072|OTHER|Kinesthetic motor imagery training|Kinesthetic motor imagery training will be planned according to the PETTLEP model. In our study, a single standard motor imagery frame will be created for the subjects. Before starting the motor imagery sessions, individuals will be given an introductory motor imagery session. How to visualize from first-person and third-person perspectives will be explained practically. Motor imagery training will be done in a quiet environment with the door and window closed in order to minimize the external factors that will distract the individual and prevent him from focusing, and the individual will be asked to sit in the motor imagery training sessions. a comfortable chair in the position they feel most comfortable in. Individuals will have their eyes closed throughout the entire motor imagery training. At the beginning of the session, approximately 5 minutes of relaxation exercise will be performed to maximize attention during motor imagery.
48344453|NCT01116804|PROCEDURE|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
48344454|NCT02996500|DRUG|PF-06650833|Investigational
48344455|NCT02996500|DRUG|Placebo|Placebo
48344456|NCT02996500|DRUG|Tofacitinib|Investigational
48344457|NCT02903368|DRUG|Apalutamide|
48344458|NCT02903368|DRUG|Leuprolide|
48344459|NCT02903368|DRUG|Prednisone|
48344460|NCT02903368|DRUG|Abiraterone Acetate|
48344461|NCT04587895|BEHAVIORAL|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
48344462|NCT04587895|BEHAVIORAL|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
48344463|NCT04587895|BEHAVIORAL|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
48344464|NCT02000219|BIOLOGICAL|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
48135327|NCT06152900|DEVICE|Accufit|"Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation.~Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle."
48135328|NCT04381949|PROCEDURE|positive pressure extubation|"Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure"
48135329|NCT00221559|PROCEDURE|Blood sampling for determination of serum Zn|
48135330|NCT00149591|PROCEDURE|coronary balloon-angioplasty with stenting|
48135331|NCT03709849|DRUG|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
48344465|NCT02758925|DRUG|Rituximab|375mg/m2 IV day 1
48135332|NCT03709849|DRUG|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
48135333|NCT03615612|OTHER|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
48135334|NCT00640588|DRUG|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
48135335|NCT00640588|DRUG|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
48135336|NCT01663454|BEHAVIORAL|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
48135337|NCT03699410|RADIATION|Neoadjuvant radiotherapy|Radiotherapy with total dose of at least 50 Gy on the tumor (cT) and the involved nodes (cN+) and with standard fractionation (1.8 Gy/fraction), 5 days/week.
48135338|NCT03699410|DRUG|Neoadjuvant chemotherapy|Oral Capecitabine, at the standard dose of 825 mg/m2 twice daily, concomitant to radiotherapy.
48135339|NCT03699410|PROCEDURE|Radical surgery|The time point of surgery is usually dependent on surgeon's and institutional habits and lies within 6 to 12 weeks after the end of nCRT. Surgeons participating in this study will be asked to operate patients on the 10th week after the end of nCRT.
48135340|NCT02371395|OTHER|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
48135341|NCT02652585|DRUG|Naltrexone|
48135342|NCT02652585|DRUG|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
48135343|NCT03282045|DRUG|Lysobact Complete Sprey|Inhaling spray
48135344|NCT03282045|DRUG|Tantum Verde® Spray|Inhaling spray
48135345|NCT03282045|DRUG|Pharyngal® Oromucosal Spray|Inhaling spray
48135346|NCT03282045|DRUG|Placebo|Inhaling spray
48135347|NCT06510881|PROCEDURE|Rhinoplasty with or without cleft alveolus repair|"* Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years ."
48135348|NCT05485818|DRUG|Low Dose|12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
48344466|NCT02758925|DRUG|Bendamustine|90mg/m2 IV day 1-2
48344467|NCT02758925|DRUG|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
48344468|NCT05698004|OTHER|prone positioning|The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU.
48344469|NCT00048490|DEVICE|transcranial magnetic stimulation (TMS)|
48344470|NCT00110591|DRUG|PRO 140|Monoclonal antibody to CCR5
48344471|NCT03813199|DRUG|ABX464 50mg|ABX464 is a new anti-inflammatory drug
48135349|NCT05485818|DRUG|Middle Dose|12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
48344472|NCT03813199|DRUG|Matching Placebo|placebo matching with ABX464
48135350|NCT05485818|DRUG|High Dose|12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
48135351|NCT05485818|OTHER|Placebo|15 subjects will be randomly assigned to the placebo for 7 days
48135352|NCT02022657|DRUG|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
48135353|NCT01630902|DRUG|Torrent's Felodipine Extended-Release Tablets|
48344473|NCT03813199|DRUG|ABX464 100mg|ABX464 is a new anti-inflammatory drug
48344474|NCT03813199|DRUG|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
48344475|NCT03199144|DRUG|Chemotherapy|3 cycles of Gemzar-Abraxane
48344476|NCT03199144|RADIATION|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
48344477|NCT03199144|PROCEDURE|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
48344478|NCT01305941|DRUG|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
48344479|NCT01305941|DRUG|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
48344480|NCT01305941|DRUG|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
48344481|NCT01761942|DIETARY_SUPPLEMENT|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
48344482|NCT06048380|DRUG|Ripasudil|"Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil."
48344483|NCT06048380|OTHER|Placebo|Saline eye drops
48344484|NCT04572698|DRUG|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
48344485|NCT04572698|DRUG|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
48344486|NCT04563104|DIAGNOSTIC_TEST|Lung Ultrasound|We will evaluate the role of lung ultrasound on the duration of antibiotics, we hypothesize that ultrasound imaging may have a role, will be correlated with, procalcitonin (PCT). The created database will help in establishing conclusion and recommendations that will help to improve the antibiotics duration and decrease the resistance.
48344487|NCT04629976|DRUG|NCO-48 Fumarate 4 mg|2 x 2mg NCO-48 Fumarate over 28 days of therapy
48344488|NCT04629976|DRUG|NCO-48 Fumarate 20 mg|2 x 10 mg NCO-48 Fumarate over 28 days of therapy
48135354|NCT05943132|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC-CBO is a year-long semi-structured, manualized video-feedback caregiver intervention that targets key components in caregiver-child interactions known to improve caregiving quality and child outcomes. These components include emotional and cognitive components shown to improve socio-emotional and cognitive developmental outcomes in children.
48135355|NCT05943132|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes general support for children in homework and nutrition.
48344489|NCT04629976|DRUG|Tenofovir Alafenamide 25 mg|25 mg over 28 days of therapy
48344490|NCT03749668|OTHER|non applicable|no intervention in this observational study
48135356|NCT01772212|DRUG|Terbinafine 250 mg|Test product
48135357|NCT01772212|DRUG|Terbinafine 250 mg|Reference product
48135358|NCT06509165|PROCEDURE|Modified coronally advanced flap technique|Subepithelial connective tissue graft was applied to the relevant areas with a modified coronally placed flap technique to cover the gingival recession.
48135359|NCT06509165|PROCEDURE|Tunnel technique|Subepithelial connective tissue graft was applied to the relevant areas with the tunnel technique to cover the gingival recession.
48344491|NCT06350149|OTHER|Sugar Sweetened Beverages (SSB)|The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.
48344492|NCT06350149|OTHER|Hi GI|The Glycemic Index of the high-GI meals will be at least 75
48344493|NCT06350149|OTHER|Lo GI|The Glycemic Index of the low- -GI meals will not be higher than 55.
48344494|NCT02002624|DEVICE|PSI|
48344495|NCT02002624|DEVICE|Conventional instrumentation|
48344496|NCT02590640|DEVICE|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
48344497|NCT02590640|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
48344498|NCT01060124|DRUG|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
48344499|NCT01464814|DIETARY_SUPPLEMENT|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
48344500|NCT01464814|DIETARY_SUPPLEMENT|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
48344501|NCT03713424|DRUG|Clavulanic Acid|Beta lactamase inhibitor for smoking cessation
48344502|NCT03713424|DRUG|Placebo oral capsule|placebo
48344503|NCT00395616|DRUG|Botox (drug)|
48344504|NCT04630210|DRUG|Letrozole|Letrozole 2.5 mg/day oral until surgery
48344505|NCT04630210|DRUG|Atezolizumab|Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
48344506|NCT03562624|DRUG|BAY98-7443|"Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5"
48344507|NCT03562624|DRUG|Levonogestrel (Skyla, BAY86-5028)|Comparative LNG dose
48657984|NCT05870072|OTHER|Balance exercises|Balance exercises will begin with approximately 5 minutes of warm-up exercises and will end with approximately 5 minutes of cool-down exercises at the end of each session. Balance exercises; Static standing on flat ground for 30 seconds with feet together, standing in tandem position for 30 seconds, standing on one leg for 30 seconds, and toes for 30 seconds, one foot airborne backwards, one foot airborne knee flexion slightly squat, one foot airborne knee extension slightly squat, going on the toes, turning with the heel, and multi-directional stretching exercises with eyes open and closed on one leg on the balance board. Each exercise will be performed with 10 repetitions for both lower extremities. Exercises will be applied once a day, 3 days a week for 6 weeks. The exercise program will be accompanied by a physiotherapist and groups of 6-10 people with similar suitability will be formed for the session hours.
48657985|NCT03537794|DIAGNOSTIC_TEST|PET scans|PET scans and PHNO scans
48344508|NCT02772224|DEVICE|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
48344509|NCT02772224|DEVICE|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
48344510|NCT04306666|OTHER|Regional anesthesia|Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
48344511|NCT02970539|DRUG|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
48344512|NCT02970539|DRUG|Ramucirumab|Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
48344513|NCT00221663|DEVICE|surgery techniques (sternotomy for aortic valve replacement)|
48344514|NCT06228443|DRUG|Leflunomide 20 mg Film-coated Tablet|Leflunomide 20 mg Film-coated Tablet (Test Drug)
48500713|NCT03898089|OTHER|Core Stability Exercise|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration \<150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.
48135360|NCT04779853|DIAGNOSTIC_TEST|Blood samples for pertussis antibody testing|Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.
48135361|NCT01943305|BIOLOGICAL|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
48135362|NCT01943305|BIOLOGICAL|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
48135363|NCT00031720|DIETARY_SUPPLEMENT|soy protein|Given orally
48135364|NCT00031720|DIETARY_SUPPLEMENT|isoflavones|Given orally
48657986|NCT05595668|BEHAVIORAL|Prism Adaptation - 15-degree prism goggles|Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.
48657987|NCT05595668|OTHER|Prism Adaptation - 5-degree prism goggles|5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.
48657988|NCT05366751|DRUG|SAGE-324|SAGE-324 oral tablets
48657989|NCT03661099|DIAGNOSTIC_TEST|colonoscopy|endoscopists' performance outcome
48344515|NCT06228443|DRUG|ARAVA® 20 mg Film-coated Tablet|ARAVA® 20 mg Tablets (Reference Drug)
48344516|NCT03403855|DEVICE|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
48657990|NCT04430010|BEHAVIORAL|BEST in CLASS|BEST in CLASS is a Tier-2 evidence based program (EBP) that has demonstrated effectiveness at reducing children's Disruptive Behavior Problems (DBPs) and risk for Emotional and Behavioral Disorders (EBDs)
48344517|NCT03403855|DEVICE|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
48344518|NCT03961295|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
48344519|NCT02804373|DRUG|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
48344520|NCT02804373|DRUG|Placebo|Placebo daily during 28 days
48135365|NCT00031720|DRUG|Tamoxifen|
48135366|NCT00031720|OTHER|Placebo|Oral
48135367|NCT01617369|DEVICE|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
48135368|NCT02659124|DEVICE|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
48344521|NCT02804373|DRUG|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
48344522|NCT02804373|DRUG|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
48344523|NCT01154907|DRUG|Praziquantel|One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
48344524|NCT00854061|DRUG|T-Pred|sterile ophthalmic solution
48344525|NCT00854061|DRUG|Pred Forte|sterile ophthalmic solution
48344526|NCT03962634|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
48344527|NCT03962634|DRUG|Articaine Injection|Local anesthetic
48344528|NCT03058263|DRUG|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
48344529|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 milligrams (mg) orally, twice daily (BID) up to Week 48
48344530|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 25 mg orally, once daily (QD) up to Week 48
48344531|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48
48344532|NCT02975349|DRUG|Placebo|Placebo were administered for 24 weeks
48344533|NCT02975349|DRUG|Tecfidera|Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (48 weeks).
48344534|NCT02975349|DRUG|Evobrutinib|Following Placebo for 24 weeks, participants received Evobrutinib 25 milligram (mg) orally, once daily (QD) from Week 24 to 48 weeks.
48344535|NCT05287724|DRUG|N-acetyl cysteine|1,500 mg twice daily for seven days
48344536|NCT05287724|DRUG|Placebo|Placebo taken twice daily for seven days
48344537|NCT00641459|OTHER|Observational BPSD treatment study|Observational BPSD treatment study
48344538|NCT03928444|PROCEDURE|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~* Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~* Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
48344539|NCT03928444|PROCEDURE|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
48344540|NCT04567420|DRUG|Palbociclib|4 week cycles
48344541|NCT04567420|DRUG|Fulvestrant|4 week cycles
48344542|NCT04567420|DRUG|Adjuvant Therapy|Standard of Care
48500714|NCT03898089|OTHER|Core Stability Exercise plus Myofascial Release Technique Group|In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
48500715|NCT00699374|DRUG|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
48500716|NCT00699374|DRUG|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
48657991|NCT06391268|BEHAVIORAL|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
48657992|NCT02956564|PROCEDURE|intrauterine intervention|choose different surgeries according to different causes
48657993|NCT03454347|DIETARY_SUPPLEMENT|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
48657994|NCT03454347|OTHER|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
48657995|NCT04558736|DRUG|Anti-Thymocyte Globulin (Rabbit)|Given intravenously (IV)
48657996|NCT04558736|DRUG|Fludarabine|Given intravenously (IV)
48657997|NCT04558736|DRUG|Cyclophosphamide|Given intravenously (IV)
48657998|NCT04558736|DRUG|Mesna|Given intravenously (IV)
48657999|NCT04558736|DRUG|G-CSF|Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated
48344543|NCT06183736|DRUG|CVL237 tablets|CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
48344544|NCT01766245|DRUG|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
48135369|NCT02659124|PROCEDURE|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
48344545|NCT03398824|DRUG|metformin HCl|Receive metformin HCl
48344546|NCT03580525|DRUG|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
48344547|NCT03580525|DRUG|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
48344548|NCT03580525|DRUG|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
48344549|NCT03580525|DRUG|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
48344550|NCT03580525|DRUG|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
48344551|NCT01427660|BEHAVIORAL|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
48658000|NCT04558736|RADIATION|Total Lymphoid Irradiation (TLI)|TLI will be given at 800 cGy total dose in 4 fractions.
48658001|NCT04558736|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
48658002|NCT04558736|BIOLOGICAL|HPC, A Infusion|Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
48658003|NCT04558736|BIOLOGICAL|CD45RA-depleted DLI|CD45RA-depleted DLI will be given at least ONE week after engraftment
48344552|NCT01427660|BEHAVIORAL|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
48500717|NCT02129244|OTHER|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~1. Assuring effective, efficient clinical care and self-management support~2. Promoting clinical care consistent with scientific evidence and patient preferences~3. Organizing data to facilitate efficient, effective care~4. Empowering and preparing patients to manage their health and health-care needs~5. Mobilizing community resources to meet the needs of patients"
48500718|NCT03483246|DRUG|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum."
48658004|NCT06365502|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.
48658005|NCT06365502|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
48658006|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
48344553|NCT06115824|DRUG|Orelabrutinib|Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d
48344554|NCT00963313|DRUG|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
48344555|NCT00533299|DRUG|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
48344556|NCT00533299|DRUG|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
48344557|NCT00633893|DRUG|Apixaban|Tablets, Oral, twice daily, 12 months
48135370|NCT02909959|DRUG|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
48135371|NCT02909959|DRUG|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
48344558|NCT00633893|DRUG|Placebo|Tablets, Oral, twice daily, 12 months
48344559|NCT04921410|DEVICE|Biofeedback Knee Sleeve|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. A 'bad' knee motion will provide a haptic output to the wearer (biofeedback) so that they can take note of what the previous motion was that caused the device to signal a warning.
48658007|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
48344560|NCT04921410|DEVICE|Sham Biofeedback|The biofeedback knee sleeve is a device that is artificially-intelligent and utilizes determined cut-off values of knee motion and forces to determine whether a motion is 'good' or 'bad'. This intervention will provide sham biofeedback during training sessions.
48658008|NCT05641116|OTHER|physical activity program|24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).
48344561|NCT00534560|DRUG|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
48344562|NCT00534560|DRUG|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
48344563|NCT00534560|DRUG|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
48500719|NCT03483246|DRUG|Sham-transplantation Placebo|"The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum."
48500720|NCT02469259|DRUG|Oxytocin|
48500721|NCT02469259|OTHER|Placebo|
48500722|NCT05965453|DEVICE|the Castor single branch stent graft|Participants who received thoracic endovascular aortic repair by meant of the Castor single branch stent graft from June 2018 to June 2022 were enrolled in our study.
48500723|NCT04287335|DIAGNOSTIC_TEST|Multitarget stool FIT-DNA test - ColoClear|Multitarget stool FIT-DNA test
48500724|NCT04287335|DIAGNOSTIC_TEST|FIT|fecal immunochemical test
48500725|NCT04287335|PROCEDURE|Colonoscopy|diagnostic colonoscopy
48658009|NCT05641116|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
48658010|NCT05524246|DRUG|Pravastatin|Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
48658011|NCT06115954|OTHER|Self-Management Supported Telerehabilitation|Supporting the exercises with an internet-based environment and self-management training for Children and Adolescents with Juvenile Idiopathic Arthritis
48658012|NCT02592863|DRUG|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
48658013|NCT02592863|DRUG|Placebo|Patients will take placebo 3 times per day for 12 weeks
47982659|NCT03914781|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
48344564|NCT06043934|OTHER|Neural Mobilization with Intermittent Cervical Traction|This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
48344565|NCT06043934|OTHER|Neural Mobilization|"This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session)."
48344566|NCT00479167|DRUG|Bortezomib and Tositumomab I-131|
48344567|NCT04016090|DIETARY_SUPPLEMENT|Folic Acid|Folic acid (5 mg)
48344568|NCT04016090|OTHER|Placebo|Placebo capsule
48344569|NCT05739331|DEVICE|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
48344570|NCT02315417|DRUG|gevokizumab|
48344571|NCT02315417|DRUG|Placebo|
48344572|NCT02315417|DRUG|gevokizumab open-label|
48344573|NCT00704392|DRUG|XL647|Tablets supplied at 50-mg strength administered orally daily
48500726|NCT06008743|BEHAVIORAL|Belt Accelerations|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.
48500727|NCT06008743|BEHAVIORAL|Belt accelerations combined with an exoskeleton|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.
48500728|NCT06008743|BEHAVIORAL|Variable Stiffness treadmill|Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.
47982660|NCT00534989|PROCEDURE|FDG PET|FDG PET
47982661|NCT04987957|OTHER|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
48344574|NCT00704392|DRUG|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
48344575|NCT02768389|DRUG|Bevacizumab|Subjects receive Bevacizumab as standard of care
48344576|NCT02768389|BEHAVIORAL|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).
48344577|NCT05753202|DEVICE|transcranial current direct stimulation|Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
48344578|NCT01905904|DRUG|sevorane|Sevorane 4% Sevorane 7%
48344579|NCT04116190|BEHAVIORAL|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
48500729|NCT03341819|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
48135372|NCT01212744|DRUG|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
48344580|NCT04116190|BEHAVIORAL|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
48344581|NCT00815776|DEVICE|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
48500730|NCT03341819|PROCEDURE|Urinary Catheterization|Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
48344582|NCT00815776|DEVICE|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
48658014|NCT06152926|OTHER|Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions|"People diagnosed with a urological cancer receiving Immune checkpoint inhibitor treatment at a single centre trust will be invited to either face to face or online video-conference individual interviews (Microsoft teams) according to participant preference.~Consenting participants will be interviewed via semi-structured interview methods round a topic guide and audio-recorded. Inductive thematic analysis will be conducted to explore participant experiences and perceptions of physical activity and exercise."
48658015|NCT02927964|DRUG|Ibrutinib|Given PO
48658016|NCT02927964|RADIATION|Radiation Therapy|Undergo radiation therapy
48658017|NCT02927964|DRUG|TLR9 Agonist SD-101|Given IT
48658018|NCT04748237|DIAGNOSTIC_TEST|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days.
48658019|NCT01096251|BEHAVIORAL|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
48658020|NCT02496000|DRUG|ORMD-0801|Oral Insulin
48658021|NCT02496000|DRUG|Placebo Comparator|Placebo
48344583|NCT00815776|OTHER|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
48500731|NCT04380129|OTHER|Music therapy-conversation sessions|"The intervention will be performed four times per patient at a frequency once weekly. An effort shall be made to ensure that each treatment is exactly seven days from the previous one within ± one day. Each session is expected to last approximately seventy minutes (75'). The musical hearing will include Helen Bonny's short program Caring short version, which is proposed by the author of this Music therapy model as the most suitable for patients with chronic and severe pain. The program is as follows:~* Haydn - Cello Konzert in C, Adagio with duration 9:42~* Dvorak - Serenade in E-Dur, Larghetto with duration 6:49~* Warlock - Capriol Suite, Pieds en I'air with duration 2:21"
48500732|NCT04380129|OTHER|Discussion sessions|Discussion sessions without the application of music therapy
48500733|NCT02397408|DRUG|Carbon C 11 Choline|Given intravenously (IV) prior to imaging
48500734|NCT02397408|DRUG|Fluorine F 18 Choline|Given intravenously (IV) prior to imaging
48500735|NCT02397408|PROCEDURE|Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)|Undergo whole-body PET/MR imaging
48500736|NCT03899441|OTHER|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
48500737|NCT03218059|PROCEDURE|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
48658022|NCT04223271|DIAGNOSTIC_TEST|Indicor|Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.
48658023|NCT05364502|DEVICE|Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter|The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm
48500738|NCT00935610|DIETARY_SUPPLEMENT|Immunocal|20 grams per day of Immunocal for 135 days.
48500739|NCT00935610|DIETARY_SUPPLEMENT|Casein|20 grams per day for 135 days
48500740|NCT00604123|DRUG|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
48344584|NCT04864327|BEHAVIORAL|Brief smoking cessation advise|The tobacco cessation protocol consisted of performing a routine assessment (asking) of cigarette use; providing advice on the importance of quitting; performing an assessment of the tobacco user's readiness to quit; assisting in setting a quit date; and making arrangements for follow-up visits. This protocol is popularly known as the 5A's strategy (The first 3A's should be delivered to all smokers regardless of their willingness to quit). Tobacco users were identified by staff nurses. Clinicians provided brief advice on quitting, and the researcher assessed the patient's dependence and readiness to quit. Patients who were not ready to quit were motivated to consider quitting, whereas those who were ready to quit were referred to practitioners who could assist them and follow them in the tobacco cessation clinic
48344585|NCT00829062|DEVICE|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
48344586|NCT02363855|DRUG|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
48344587|NCT06430814|OTHER|No intervention|No intervention
48344588|NCT01394211|DRUG|anastrozole|Given PO
48344589|NCT01394211|DRUG|pazopanib hydrochloride|Given PO
48344590|NCT01394211|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
48344591|NCT00381719|DRUG|AGN 203818|3 mg Capsule twice daily for 4 weeks
48344592|NCT00381719|DRUG|AGN 203818|20 mg Capsule twice daily for 4 weeks
48344593|NCT00381719|DRUG|AGN 203818|60 mg Capsule twice daily for 4 weeks
48344594|NCT00381719|DRUG|placebo capsule|Capsule twice daily for 4 weeks
48344595|NCT03534713|DRUG|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
48344596|NCT03534713|DRUG|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
48344597|NCT03534713|DRUG|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
48344598|NCT03534713|RADIATION|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
48344599|NCT03119441|DEVICE|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
48344600|NCT03119441|DEVICE|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
48344601|NCT01319045|DRUG|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
48344602|NCT06039657|OTHER|SEAS training|Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way
48344603|NCT06039657|OTHER|Standard Care|Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
48344604|NCT03801798|DRUG|GC1102|NAs antivirals+GC1102 180,000 IU
48344605|NCT03801798|OTHER|GC1102 Placebo|NAs antivirals+GC1102 Placebo
48344606|NCT01924195|DRUG|Anlotinib|Anlotinib QD po.
48344607|NCT01924195|DRUG|Placebo capsule|Placebo QD po.
48344608|NCT04115345|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
48344609|NCT04803890|PROCEDURE|"No-Touch Radiofrequency Ablation"|"No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode"
48344610|NCT00132158|DRUG|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
48344611|NCT05076994|OTHER|Exercise therapy|A series of home exercise videos to improve patient adherence to exercise prescription
48658024|NCT05303233|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
48500741|NCT00604123|DRUG|Placebo|Placebo nasal spray twice daily for 2 weeks.
47982662|NCT04761289|OTHER|Multimodal Exercise and Functional Rehabilitation Program|"1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment."
47982663|NCT05745350|DRUG|Pembrolizumab, Plinabulin plus Etoposide and Platinum|Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
48344612|NCT05076994|OTHER|Standard Care|An exercise prescription and verbal instructions in clinic
48344613|NCT05843617|DIETARY_SUPPLEMENT|Liposomal Vitamin C|1000 mg of ascorbic acid in liposomal formulation
48658025|NCT05303233|PROCEDURE|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
48658026|NCT01313676|DRUG|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
48658027|NCT01313676|DRUG|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
47982664|NCT03012425|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
47982665|NCT03012425|PROCEDURE|Acupuncture|
47982666|NCT03012425|BEHAVIORAL|questionnaires|
48500742|NCT05788614|DEVICE|Reverse shoulder arthroplasty|Reverse shoulder arthroplasty
48344614|NCT05843617|DIETARY_SUPPLEMENT|Traditional Vitamin C|1000 mg of ascorbic acid in traditional formulation
47982667|NCT03012425|OTHER|Diurnal Cortisol|saliva test
47982668|NCT01659515|DRUG|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
47982669|NCT00699621|BIOLOGICAL|platelets|Four units of fresh platelets will be infused immediately
48344615|NCT06438744|PROCEDURE|Thread embedding acupuncture (TEA) + standard therapy|"* TEA : one-time TEA using 30 gauge TEA needle with 30 mm polydioxanone thread at CV3 through CV4, SP6 and ST36 bilaterally~* Standard therapy : 2 mg dienogest daily for 8 weeks after TEA"
48344616|NCT01313468|BEHAVIORAL|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
48344617|NCT01313468|BEHAVIORAL|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
48344618|NCT01313468|BEHAVIORAL|Moderate continuous Training|47 minutes of Moderate continuous Training
48500743|NCT02029573|DRUG|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
48500744|NCT02029573|DRUG|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
48658028|NCT01313676|DRUG|vilanterol|25mcg given once daily via novel dry powder inhaler
48344619|NCT06229808|DEVICE|Multifunctional Birthing ball|"In order to reduce low back pain in labor, massages will be applied to the experimental group in the first stage of labor for 30 minutes each at the end of the latent, active and transition phases (cervical dilatation 3-4 cm, 5-7 cm, 8-10 cm), respectively.~Perineal heating application is planned to be performed at least twice until the delivery occurs as 20 minutes of application and 20 minutes of tissue rest periods when the second stage of labor begins (the duration of this stage may reach 2 hours in primiparous women)."
48344620|NCT01666990|DRUG|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
48344621|NCT01666990|DRUG|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
48344622|NCT01651234|DRUG|GCC-4401|"* Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg GCC-4401C~ * Cohort 2: 5.0-mg GCC-4401C~ * Cohort 3: 10-mg GCC-4401C~ * Cohort 4: 20-mg GCC-4401C~ * Cohort 5: 40-mg GCC-4401C~ * Cohort 6: 80-mg GCC-4401C"
48344623|NCT01651234|DRUG|GCC-4401C|"* Capsule, identical in appearance to GCC-4401C, for oral use~* single dose~* dosage~  * Cohort 1: 2.5-mg matching placebo~ * Cohort 2: 5.0-mg matching placebo~ * Cohort 3: 10-mg matching placebo~ * Cohort 4: 20-mg matching placebo~ * Cohort 5: 40-mg matching placebo~ * Cohort 6: 80-mg matching placebo"
48344624|NCT01873807|DRUG|IDA|Idarubicin: 15mg/m2/d: -8-\>-6d
48344625|NCT01873807|RADIATION|TBI|TBI: 4.5 Gy/d, -5d, -4d
48344626|NCT01873807|DRUG|CTX|CY:60mg/kg/d, -3d, -2d
48344627|NCT01873807|DRUG|VP-16|VP-16: 15mg/kg, -2d, -1d
48344628|NCT05410808|OTHER|Questionnaires and physical examination|Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
48344629|NCT05410808|OTHER|Questionnaire|Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
48344630|NCT01638169|DEVICE|adding a heel|walking with and without heels on the gaitrite system
48344631|NCT02714023|PROCEDURE|Normal Saline|Intra-operative irrigation with normal saline
48344632|NCT02714023|PROCEDURE|Sterile Water|Intra-operative irrigation with sterile water
48344633|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
48344634|NCT03766113|OTHER|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
48344635|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
48344636|NCT00767299|DRUG|arzoxifene|20 mg, QD, PO,24 weeks
48344637|NCT00767299|DRUG|Placebo|QD, PO, 24 weeks
48658029|NCT01313676|OTHER|Placebo|placebo comparator once daily via novel dry powder inhaler
48658030|NCT02304185|BIOLOGICAL|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
48658031|NCT02304185|BIOLOGICAL|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
47982670|NCT01970111|DRUG|KPS-0373, High dose|
48344638|NCT01723176|PROCEDURE|Echocardiography|
48344639|NCT01339208|OTHER|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
48344640|NCT03389269|OTHER|Meal test|240 min mixed meal test with aspiration using AspireAssist.
47982671|NCT01970111|DRUG|KPS-0373, Low dose|
47982672|NCT01711177|DRUG|placebo|Placebo
47982673|NCT01711177|DRUG|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
48344641|NCT03140124|BEHAVIORAL|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
48344642|NCT03140124|BEHAVIORAL|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
48344643|NCT02398721|OTHER|Fine Needle Aspiration Cytology|
48658032|NCT02304185|BIOLOGICAL|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
48658033|NCT02304185|BIOLOGICAL|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
47982674|NCT05700045|DRUG|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
48658034|NCT02304185|DRUG|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
48135373|NCT02008669|PROCEDURE|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
48135374|NCT02008669|OTHER|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
48135375|NCT02008669|OTHER|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~* Fatigue (EMIF-SEP)~* Dysphagia (DYMUS)~* Food intake (semi-structured questionnaire)~* Depression (BDI-II)~* Daily energy expenditure (NAP)~* Visual analog scale to study quality of sleep"
48135376|NCT04434651|PROCEDURE|SPGB|Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
48135377|NCT03024021|DEVICE|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia \[36.5 C\]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
48135378|NCT02522598|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
48135379|NCT02522598|DRUG|Placebo|water for injection
48344644|NCT00067444|DRUG|Paroxetine CR|
48344645|NCT05861557|DRUG|Toripalimab|240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
48344646|NCT05861557|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Subjects were treated with SBRT radiotherapy (8Gy\*5Fx), after 1 cycle of immunotherapy
48344647|NCT01861613|BIOLOGICAL|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
48344648|NCT04151446|DEVICE|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
48344649|NCT04523467|DRUG|Anti-angiogenic Targeted Drugs|A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
48344650|NCT04523467|DRUG|Ginsenoside Rg3|An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
48344651|NCT04523467|PROCEDURE|TACE|A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
48344652|NCT05597904|GENETIC|Genetic predisposition|Assessment of genetic predisposition to various celiac disease phenotypes. No intervention.
48344653|NCT01100294|BIOLOGICAL|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose."
48135380|NCT03577106|DEVICE|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
48135381|NCT02138123|PROCEDURE|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
48135382|NCT02138123|PROCEDURE|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
48135383|NCT04724265|BIOLOGICAL|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
48135384|NCT03526406|DIETARY_SUPPLEMENT|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
48344654|NCT00565357|DEVICE|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
48344655|NCT00565357|OTHER|Control|Standard care in the neonatal intensive care unit
48344656|NCT04716049|OTHER|Powerade©, CHP, CJ, FR, CWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL during the game~Carbohydrate and protein (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the game.~Tart cherry concentrate (CJ): players will drink 30 mL of CJ within 30 minutes after the end of the game.~Foam roller (FR): players will follow FR protocol using a polyvinylchloride pipe roller. They will begin with the FR at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth at a cadence of 1 second superior and 1 second inferior for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.~Cold Water Immersion (CWI): will be the last strategy used. Players will immerse their lower body to the level of hips for 10 minutes in cold water (13-14°C)."
48500745|NCT02029573|RADIATION|Radiotherapy|60 Gy in 30 fractions
48500746|NCT03783273|DIETARY_SUPPLEMENT|Vitamin D3|Single dose vitamin D3
48500747|NCT03783273|COMBINATION_PRODUCT|Whey protein-complex|Whey protein complex-bound vitamin D3
48500748|NCT03783273|OTHER|Water|500 mL water
48500749|NCT03783273|OTHER|Milk|500 mL milk
48500750|NCT03783273|OTHER|Juice|500 mL juice
48658035|NCT06643611|BEHAVIORAL|Continuous Glucose Monitor|Patient will be provided a continuous glucose monitor. Pharmacist will provide information regarding how to best manage type 2 diabetes.
47982675|NCT04245696|DEVICE|Dermal Handpiece / SubQ Handpiece|Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
48500751|NCT00062543|PROCEDURE|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
48500752|NCT00062543|DEVICE|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
48500753|NCT02374489|DRUG|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
48500754|NCT01799525|PROCEDURE|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
48500755|NCT03858634|DRUG|KPL-716|A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.
48500756|NCT03858634|DRUG|Placebo|Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
48500757|NCT00985712|DRUG|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
48500758|NCT00985712|DRUG|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
48500759|NCT00985712|DEVICE|HumaPen Memoir|subcutaneously, daily for 24 weeks
48658036|NCT06643611|BEHAVIORAL|Usual Care|Routine physician office visits and hemoglobinA1c every 3 for those with HbA1c outside goal and every 6 months for those with HbA1c within goal. Medication regimens managed by physicians, nurse practitioners, and physician assistants. Patients are sent reminders on the phone prior to their visits or when they are due for a visit or any physical examination.
48658037|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - fast|Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
48658038|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - slow|Continuous passive motion device (CPM) of ankle 0.25HZ (15rpm) for 10 repetitions
48658039|NCT03779620|DEVICE|Ultrasound treatment of Calcified aortic valve|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
48658040|NCT06325631|PROCEDURE|Intra-articular injection to lumbar facet joint|to treat low back pain caused by facet joint syndrome
48500760|NCT00985712|DEVICE|HumaPen Luxura|subcutaneously, daily for 24 weeks
48658041|NCT04831229|OTHER|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
48500761|NCT04298060|DRUG|DAS181|SD (4.5mg/day), HD (9mg/day)
48500762|NCT04298060|DRUG|Placebo|Placebo 0mg/day
48500763|NCT04333238|OTHER|New progress note template|Residents assigned to document with new progress note template
48500764|NCT04333238|OTHER|Standard progress note template|Residents assigned to document with standard progress note template
48500765|NCT04122066|DRUG|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
48500766|NCT01206049|DRUG|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
48500767|NCT01206049|DRUG|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
48500768|NCT01206049|DRUG|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
48500769|NCT01206049|DRUG|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
48500770|NCT01206049|DRUG|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
48500771|NCT02006693|DEVICE|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
48500772|NCT02006693|PROCEDURE|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
48500773|NCT05395455|PROCEDURE|Non-surgical periodontal treatment|Treatment of patients with periodontitis was performed scaling and root planing by using manual and ultrasonic instruments.
48500774|NCT00534807|DRUG|Vinflunine|
48500775|NCT00534807|DRUG|Rifampin|
48500776|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + Regenfast + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
48500777|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
47982676|NCT05792371|PROCEDURE|induced membrane technique|Masquelet technique, also called an induced membrane technique (IMT), was first introduced to treat critical size bone defect up to 25 cm in 1986 by Pr. Alain Charles Masquelet et al. IMT is a two-stage surgical operation that recently provides a more popular option for the treatment of critical size bone defect as well as fracture nonunion. Basically, first stage of IMT comprises the implantation of a polymethylmethacrylate (PMMA) cement spacer loaded with antibiotics into defect site. During 6 to 8 weeks, this spacer induces the formation and maturation of a thin layer called induced membrane surrounding it via a foreign body immune response. In stage II, the spacer is carefully removed while keeping induced membrane at the fracture site, autologous bone graft is then performed to provoke bone healing.
47982677|NCT05792371|PROCEDURE|Bone graft (Stage II of IMT)|Bone graft is only performed in this group to provoke bone healing, as same as demonstrated in the stage II of IMT.
47982678|NCT04410224|DRUG|ASN004|ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
47982679|NCT01503281|OTHER|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
47982680|NCT03929575|DIETARY_SUPPLEMENT|Placebo of calcium|Ingestion of 250 mg of calcium
47982681|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola|Ingestion of 250 mg of Rhodiola
48135385|NCT03526406|DIETARY_SUPPLEMENT|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
48135386|NCT06238934|BIOLOGICAL|Bone marrow aspirate matrix|Bone marrow aspirate \* Hyaluronic acid
48135387|NCT06238934|BIOLOGICAL|Bone marrow aspirate|Bone marrow aspirate
48135388|NCT06238934|DEVICE|Hyaluronic acid|Hyaluronic acid
48344657|NCT04716049|OTHER|Powerade©, CHP, STR, ICWI|"Combination of recovery strategies including dietary, neuromuscular and physiological as follows:~Powerade©: players will drink 500 mL of Powerade© during the game~Carbohydrate and protein intake (CHP): players will drink 250 mL of water with CHP within 30 minutes after the end of the competition.~Stretching (STR): players will perform 10-min of static stretching, involving 2 unilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.~Intermittent Cold-Water Immersion (ICWI): will be the last strategy used. It will consist of five 2 min intermittent immersions of the lower limb (up to the iliac crest) in a cold-water bath (13-14ºC), separated by 2 min rest in ambient air. Ice will be added to the bath at regular intervals to maintain water temperature at 13-14ºC. Players will be instructed to stand in the bath, with as little movement as possible."
48500778|NCT06394700|BEHAVIORAL|written exposure therapy|Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
48500779|NCT06394700|BEHAVIORAL|Written Exposure Therapy plus Mindfulness-Based App (WET + MBA)|"WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation."
48658042|NCT04831229|OTHER|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
48658043|NCT05745961|RADIATION|TSPO PET scan (11C-PBR28)|PET scan
47982682|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola and Cordyceps|Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
47982683|NCT05822531|BEHAVIORAL|Maternal CVH Intervention|All participants will be enrolled into the intervention arm of this pilot study.
47982684|NCT02245490|DRUG|Tamsulosin HCl controlled release capsules|
47982685|NCT02245490|DRUG|Matching placebo capsule|
47982686|NCT03905187|BEHAVIORAL|Modified CR|Stress management involved modified cardiac rehabilitation
47982687|NCT03905187|BEHAVIORAL|Traditional CR|Traditional cardiac rehabilitation
47982688|NCT03905187|BEHAVIORAL|Education|Education
48135389|NCT01258036|RADIATION|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
48658044|NCT06071221|BEHAVIORAL|Living Healthy educational program + peer coaching|The Living Healthy intervention is an 8-session health education program with cognitive behavioral training (CBT) techniques. For those in the interventional arm, the Living Healthy intervention program will be delivered by trained peer coaches by telephone or Zoom over 3 months. In this study, trained peer coaches are trained home health aides themselves. Informed by social cognitive theory (SCT), peer coaches train participants on cognitive behavior techniques and empower participants to adopt positive health behaviors through personalized goal setting, motivational interviewing, and peer modeling. Each content-based session incorporates principles of CBT, teaching participants to recognize and modify negative thinking and modifying outcome expectations through self-monitoring, reflection, and practice.
48658045|NCT06071221|BEHAVIORAL|Living Healthy educational program|Participants assigned to receive health education alone will be asked to read health education (online; covering aspects of the Living Healthy program) which corresponds to a weekly topic about health. They will be called by a research assistant each week to prompt them to do this and answer any questions they might have about the materials.
48135390|NCT01258036|BIOLOGICAL|Sampling|Urine and blood samples
48135391|NCT01258036|RADIATION|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
48344658|NCT01444183|BEHAVIORAL|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
48344659|NCT01444183|BEHAVIORAL|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
48344660|NCT05824767|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
48344661|NCT06507332|DRUG|Letrozole 2.5mg|to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
48344662|NCT00373880|DRUG|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
48344663|NCT00373880|DRUG|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
48344664|NCT02972593|BIOLOGICAL|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb \>7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
48344665|NCT00837239|DRUG|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
48344666|NCT00837239|DRUG|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
48344667|NCT00837239|DRUG|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
48344668|NCT02443155|DRUG|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
48344669|NCT02443155|DRUG|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
48344670|NCT02443155|DRUG|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
48344671|NCT02182999|DEVICE|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
48344672|NCT02182999|DRUG|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
48500780|NCT06394700|BEHAVIORAL|Minimal Contact Control (MCC)|MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
48500781|NCT01418963|DRUG|RO5285119|single and multiple ascending oral doses
48500782|NCT01418963|DRUG|placebo|single and multiple oral doses
48500783|NCT00054808|DRUG|gallium nitrate|
48500784|NCT05561543|DIETARY_SUPPLEMENT|Peppermint oil|Peppermint oil
48500785|NCT05561543|OTHER|Placebo|Placebo
48500786|NCT02748967|DRUG|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
48500787|NCT02748967|DRUG|Placebo|Participant will receive single dose of Placebo on Day 1.
48658046|NCT04922216|BEHAVIORAL|Core|Behavioral weight loss core includes behavioral lessons, activity tracker, daily self-weighing, weekly tailored feedback summary.
47982689|NCT06030557|DRUG|Truvada|Participants will receive either Truvada or Descovy (based on prescription guidelines).
47982690|NCT02436889|DRUG|Mirabegron|
48658047|NCT04922216|BEHAVIORAL|Standard Diet Monitoring|Standard monitoring using smartphone tracking of all calorie intake.
47982691|NCT02436889|DRUG|Tolterodine Tartrate|
47982692|NCT02821481|DIETARY_SUPPLEMENT|Beta-alanine|
47982693|NCT02821481|DIETARY_SUPPLEMENT|Placebo|
47982694|NCT02821481|BEHAVIORAL|Muscular endurance exercise|
47982695|NCT01252940|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
47982696|NCT01252940|DRUG|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
47982697|NCT01252940|DRUG|RTV|Ritonavir (RTV) was administered according to prescribing information.
48344673|NCT02182999|DRUG|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
48344674|NCT00561340|DIETARY_SUPPLEMENT|Pediasure|50% will be randomized to pediasure with nutritional counseling
48344675|NCT00561340|BEHAVIORAL|Nutritional counseling|50% randomized to nutritional counseling only
48344676|NCT02372110|DRUG|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
48344677|NCT02372110|DRUG|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
48344678|NCT00366418|DRUG|Rituximab|
48344679|NCT04816370|DIAGNOSTIC_TEST|FSFI|2 group and 2 subgroup
48344680|NCT03460470|DRUG|Sildenafil|PDE5 Inhibitor
48344681|NCT03460470|DRUG|Placebo oral capsule|Placebo for Sildenafil
48344682|NCT02668172|DRUG|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
48344683|NCT02668172|DRUG|Pegvisomant|only in combination with pasireotide LAR
48344684|NCT05309369|BEHAVIORAL|Preferred Music|Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
48344685|NCT05309369|BEHAVIORAL|Nature Sounds|Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
48344686|NCT00068484|DRUG|topotecan hydrochloride|Given IV
48344687|NCT00068484|DRUG|bortezomib|Given IV
48500788|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-coated balloon|"SeQuent Please (BBraun) + tailored antithrombotic regimen:~1. Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT and lifelong OAC~3. ACS patients without OAC: 1-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 1-month SAPT and lifelong OAC"
47982698|NCT01252940|DRUG|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
47982699|NCT02889484|PROCEDURE|Lumbar disc hernia surgery|
47982700|NCT00704158|DRUG|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
47982701|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
47982702|NCT03017651|DIETARY_SUPPLEMENT|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
47982703|NCT06184815|BEHAVIORAL|Educational programme 12|Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment
47982704|NCT06184815|BEHAVIORAL|Standard education and treatment|Outpatient management and education in the office and consultation referral to nutrition and psychology
47982705|NCT05467436|DRUG|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
47982706|NCT06401616|DRUG|OAC will be discontinued for the duration of the trial|Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
47982707|NCT00789451|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
47982708|NCT05519423|BEHAVIORAL|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
47982709|NCT01308346|DEVICE|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
48344688|NCT00068484|OTHER|pharmacological study|Correlative studies
48344689|NCT00068484|OTHER|laboratory biomarker analysis|Correlative studies
48344690|NCT05433974|BIOLOGICAL|Blood sample collection|Blood sample collection : 2 X 6 mL
48344691|NCT03458403|PROCEDURE|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
48344692|NCT05263726|BEHAVIORAL|DSMP through a Mobile Applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
48344693|NCT00832689|DRUG|Irinotecan and Gemcitabine|
48344694|NCT06100107|OTHER|Mirror Therapy exercise|Mirror Therapy for the upper limb involves the use of a mirror to create a reflected image of the unaffected arm, making it appear as if both arms are moving symmetrically. During the therapy, the patient places their affected arm behind the mirror and their unaffected arm in front. While focusing on the mirror reflection, the patient performs various movements with the unaffected arm, giving the illusion that the affected arm is moving normally.
48344695|NCT05810389|COMBINATION_PRODUCT|Fluoride|Application methods of delivery of topical fluoride
48344696|NCT01674946|OTHER|saline|intraduodenal perfusion
48344697|NCT01674946|OTHER|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
48658048|NCT04922216|BEHAVIORAL|Simplified Diet Monitoring|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
48658049|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Daily)|Physical activity goals that adapt once each day using the participants' data derived from activity tracker.
48344698|NCT01674946|OTHER|oleanolic acid|intraduodenal perfusion
48344699|NCT01674946|DIETARY_SUPPLEMENT|oleic acid|intraduodenal perfusion
48500789|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-eluting stent|"Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic), Xience Pro S (Abbott) or Promus Elite (Boston Scientific) or any other DES can also be used provided that it has a CE mark for 1-month DAPT, combined with tailored antithrombotic regimen:~1. Stable patients without OAC: 1-month DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and life-long OAC~3. ACS patients without OAC: 3-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and lifelong OAC"
48500790|NCT04008628|DRUG|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
48658050|NCT04922216|BEHAVIORAL|Adaptive Activity Goals (Weekly)|Physical activity goals that adapt once each week using the participants' data derived from activity tracker.
48344700|NCT04775394|OTHER|Bronchoscopy|Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy
48344701|NCT05136040|DRUG|Bupivacaine|Two Different Low-Doses Of Isobaric Bupivacaine ( Group İzobarik bupivakain (5 mg) + fentanil and Group İzobarik bupivakain (7 mg)+ fentanyl ) were administered to the subarachnoid space
48344702|NCT06382740|PROCEDURE|Liver transplantation|Liver transplantation
48344703|NCT01996436|DRUG|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
48344704|NCT01996436|DRUG|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
48344705|NCT01996436|DRUG|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
48500791|NCT00813527|DRUG|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
48500792|NCT00813527|DRUG|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
48500793|NCT01189487|DRUG|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
48500794|NCT02728843|DRUG|Deferiprone|600 mg tablets
48500795|NCT02728843|DRUG|Placebo|Tablets that match the deferiprone tablets in appearance
47982710|NCT01308346|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
47982711|NCT05118074|DIAGNOSTIC_TEST|Creatinine, eGFR|Compare diagnostic tests to reference methods
47982712|NCT05109039|DIETARY_SUPPLEMENT|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
47982713|NCT05109039|DIETARY_SUPPLEMENT|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
48344706|NCT00171002|DRUG|valsartan/amlodipine|
48344707|NCT02680561|DRUG|Fluticasone Propionate MDPI|
48344708|NCT02680561|DRUG|Fluticasone Propionate/Salmeterol MDPI|
48344709|NCT02680561|DRUG|Fluticasone propionate/salmeterol|
48344710|NCT02429349|PROCEDURE|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
48500796|NCT06494345|BIOLOGICAL|Genolair, solution for subcutaneous administration, 150 mg|Genolair (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
48658051|NCT04922216|BEHAVIORAL|Message Decision Points (Fixed)|Message timing is fixed and evaluated at specific times each day to determine message eligibility.
48658052|NCT04922216|BEHAVIORAL|Message Decision Points (Adaptive)|Message timing is adaptive and derived from individual user data to determine message eligibility.
48658053|NCT04922216|BEHAVIORAL|Message Decision Rules (Standard)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
47982714|NCT01640145|DIETARY_SUPPLEMENT|Protein|Whey protein intake
47982715|NCT01640145|OTHER|Exercise|Unilateral low intensity exercise
47982716|NCT03787953|DRUG|Anti-PD-1/PD-L1 antibodies|The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
47982717|NCT03906903|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
48344711|NCT00549653|DRUG|GW856553|
48344712|NCT05146934|RADIATION|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
48344713|NCT05068427|DRUG|Chidamide|20mg or 30mg orally twice per week(BIW)
48344714|NCT05068427|DRUG|Envafolimab|400mg subcutaneous infusions every 4 weeks
48344715|NCT04826120|PROCEDURE|PCEA Infusion|Patients of this group Had PCEA during the second stage of labor
48344716|NCT04826120|PROCEDURE|Continuous epidural infusion|Patients of this group Had continuous epidural infusion during the second stage of labor
48344717|NCT01624467|BIOLOGICAL|Necitumumab|800 mg necitumumab, administered once per week IV
48344718|NCT02839473|DEVICE|Castalie water spray|
48344719|NCT02839473|DEVICE|Hydrogel Hydrosorb®|
47982718|NCT03906903|BEHAVIORAL|Cognitive Stimulation|Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
48344725|NCT03108300|DRUG|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
47982719|NCT00543348|PROCEDURE|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
48344726|NCT03108300|DRUG|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
48344727|NCT05845411|BEHAVIORAL|Mindful Eating|Nutritional advice through expository content, group discussion, and exchange of experiences on self-knowledge, food awareness, and relationship with food and the body.
48344728|NCT05845411|OTHER|Standard dietary treatment|Hypocaloric dietary prescription and nutritional education.
48344729|NCT03556982|BIOLOGICAL|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
48344730|NCT01156363|PROCEDURE|Dialysis|regular haemodialysis or peritoneal dialysis
48344731|NCT01156363|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
48344732|NCT00558233|BEHAVIORAL|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
48344733|NCT00558233|BEHAVIORAL|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
48344734|NCT01391468|DIETARY_SUPPLEMENT|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
48344735|NCT01391468|DIETARY_SUPPLEMENT|Cornstarch|placebo will be given in 6 months
48344736|NCT04631367|BEHAVIORAL|Kukaa Salama: mHealth intervention|Kukaa Salama is a 8-week social group program of COVID-19 prevention messaging, which includes sending informational SMS once per week and holding secure group discussions on COVID-19 prevention. Weekly SMS messages will focus on COVID-19 knowledge, including information about transmission, hand washing, respiratory hygiene (coughing and sneezing in ways that won't spread germs), face masks, and physical distancing. Participants can also respond to the SMS with any questions about COVID-19, and the study team will respond with further information and/or additional resources. Weekly group chats will be administered using the customized WelTel platform, and will focus on discussions of how participants can apply and practice the information on COVID-19 prevention in their daily lives. Each group chat will be composed of 15-20 participants, and will be facilitated by a research assistant in Kampala as well as a peer navigator.
48344737|NCT04631367|DEVICE|Face Mask + Soap|Participants will be offered the opportunity to pick up a parcel that contains a face mask, bar of soap, and a small parcel of food from the partner agency YARID.
48344738|NCT06068647|DIAGNOSTIC_TEST|Lung ultrasound, computed tomographic scan and patch-based cardio-respiratory evaluations|"Ultrasonographic findings will be obtained with machines supplied with clinical Units. Additionally, US scans as acquired with open research platform will also be gathered. For both scanners, ultrasonographic scans will be performed and videos will be recorded and stored in each landmark. Metal cutaneous landmarks will be positioned and left during computed tomographic (CT) scans, indicating the areas of ultrasonographic assessment.~Finally, on the same day of enrolment, a wearable system for measuring physiological signals, will be applied. Within the scope of this study, sensors will be applied to the upper chest. The following information will be collected by each sensor: electrocardiography, respiratory effort, respiratory flow, activity, position, and sound pressure level."
48344739|NCT02903966|DRUG|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
48344740|NCT02903966|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
48344741|NCT06153394|DRUG|Redesca (enoxaparin sodium for injection)|Redesca is low molecular weight heparin and a biosimilar biologic drug (biosimilar) to Lovenox. Indications have been granted on the basis of similarity between Redesca and the reference biologic drug Lovenox. As such, Redesca (enoxaparin sodium) is indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield.
48500797|NCT06494345|BIOLOGICAL|Genolair, lyophilisate for the preparation of solution for subcutaneous administration|Genolair (omalizumab), lyophilisate for the preparation of solution for subcutaneous administration, 150 mg for single subcutaneous administration
48658054|NCT04922216|BEHAVIORAL|Message Decision Rules (Adaptive)|Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
48658055|NCT04922216|BEHAVIORAL|Message Choice (No)|Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
48658056|NCT04922216|BEHAVIORAL|Message Choice (Yes)|Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
48658057|NCT03904134|OTHER|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
48658058|NCT05259098|DRUG|Sufentanil Sublingual Tablet System|Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
47982720|NCT00543348|PROCEDURE|Balloon angioplasty|HIGH PRESSURE BALLOON
47982721|NCT05248412|OTHER|COVID-19 outbreaks|The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
47982722|NCT02315170|DEVICE|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
48500798|NCT06494345|BIOLOGICAL|Xolair®, solution for subcutaneous administration, 150 mg|Xolair® (omalizumab), solution for subcutaneous administration, 150 mg for single subcutaneous administration
48500799|NCT05939583|OTHER|Shock Wave Therapy|Receiving Shock wave therapy + US, TENS, IR and exercises.
48500800|NCT05939583|OTHER|US, TENS, IR and exercises.|Receiving US, TENS, IR and exercises only.
48500801|NCT02036359|DRUG|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
48500802|NCT02036359|DRUG|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
48500803|NCT05630690|DEVICE|IPL with smart diagnostic handpiece|treatment with IPL following diagnostic with SMART system
48500804|NCT02771886|BEHAVIORAL|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
48658059|NCT05259098|DRUG|Intravenous Patient-Controlled Analgesia with morfine|Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
47982723|NCT02315170|DEVICE|standard lid speculum|standard wire lid speculum
47982724|NCT01486914|DRUG|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
47982725|NCT00848367|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
47982726|NCT06187727|DRUG|Henagliflozin|After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
47982727|NCT02446990|DRUG|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
48344742|NCT06153394|DRUG|Fragmin (dalteparin)|Fragmin is a low molecular weight heparin indicated for thromboprophylaxis in patients undergoing high risk abdominal and colorectal surgeries. Doses are provided as self-administered subcutaneous injections using a pre-filled syringe with a protective shield. Our institution uses this drug for standard of care thromboprophylaxis (30 days) in this patient population.
48344743|NCT03156413|DEVICE|F&P nasal mask|Investigative Nasal Mask to be used for OSA therapy
48344744|NCT01973972|BEHAVIORAL|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
48344745|NCT01973972|BEHAVIORAL|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
48344746|NCT01291706|DEVICE|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
48344747|NCT05342142|BEHAVIORAL|Aerobic and ResistanceExercise|Exercise program consisting of 12 weeks of aerobic and resistance exercises
48658060|NCT03763370|DRUG|Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)|"Drug: Belantamab mafodotin~•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.~Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles~Drug: Dexamethasone~•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles"
48658061|NCT03763370|DRUG|Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)|"Drug: Belantamab mafodotin:~* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once~* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment~Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information~Drug: Dexamethasone~•Dexamethasone will be administered at every cycle, based on the full prescribing information"
47982728|NCT02446990|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
47982729|NCT04857515|DEVICE|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
48344748|NCT06451276|DEVICE|Nasoalveolar molding in unilateral cleft lip and palate|compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate
48344749|NCT06348758|OTHER|questionnaire|E-Questionnaire will be sent to the students
48344750|NCT01628393|DRUG|Ozanimod|Oral capsule taken once a day
48344751|NCT01628393|DRUG|Placebo|Oral capsule taken once a day
48344752|NCT00952601|DIETARY_SUPPLEMENT|Modified Atkins diet|Low carbohydrate diet
48344753|NCT03807778|DRUG|Mobocertinib|Mobocertinib capsule.
48344754|NCT00437203|DRUG|PF-00477736|"* Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
48344755|NCT00437203|DRUG|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
48344756|NCT04113278|GENETIC|FGL2 immunohisyochemistry|Correlation between FLG2 expression and progression free survival and overall surviv
48344757|NCT02813863|DRUG|SP2086|
48344758|NCT02813863|DRUG|Metformin|
48344759|NCT04517110|DRUG|Pregabalin 300 mg|Pregabalin 300 mg, capsule
48344760|NCT04517110|DRUG|Pregabalin 75 mg|Pregabalin 75 mg twice daily, capsules
48344761|NCT04517110|DRUG|Pregabalin 300 mg Placebo|Placebo, matching Pregabalin 300 mg capsule
48658062|NCT06313593|DRUG|INCB160058|Oral; Tablet
48658063|NCT05946044|BEHAVIORAL|Diet and Exercise|Group and individual weight loss and weight maintenance sessions combined with exercise throughout the 48 months.
48658064|NCT04233021|DRUG|Osimertinib|Osimertinib 80 mg/d
48658065|NCT00811837|DRUG|Midazolam|Intravenous infusion
48658066|NCT00811837|DRUG|Remifentanil|Intravenous infusion
48658067|NCT00086515|DRUG|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
48658068|NCT00086515|DRUG|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
48658069|NCT00086515|DRUG|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
48658070|NCT00086515|DRUG|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
47982730|NCT03921554|DRUG|Baricitinib|Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
48344762|NCT04517110|DRUG|Pregabalin 75 mg Placebo|Placebo, matching Pregabalin 75 mg capsules
48344763|NCT04517110|OTHER|Usual Care|Usual Care
48344764|NCT04078191|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
48344765|NCT02001506|DRUG|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
48658071|NCT02722785|BEHAVIORAL|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum \[1-RM\] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
48658072|NCT01980147|BEHAVIORAL|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
48658073|NCT05119582|DEVICE|TOOsonix System ONE-M|Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
48658074|NCT06616155|PROCEDURE|Biopsy|Undergo tissue biopsy
48344766|NCT02342613|BIOLOGICAL|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
48344767|NCT01160861|DRUG|MEMP1972A|Repeating ascending dose
48344768|NCT01160861|DRUG|placebo|Repeating ascending dose
48344769|NCT04068038|OTHER|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
48344770|NCT04333992|DRUG|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
48344771|NCT04333992|DRUG|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
48135392|NCT00168415|BIOLOGICAL|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
48135393|NCT03528213|DRUG|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
48135394|NCT03528213|DRUG|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
48344772|NCT02456571|DEVICE|CTC biomarker expression prevalence|
48658075|NCT06616155|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47982731|NCT05534997|OTHER|intensive combined rehabilitation therapy|graded exercise therapy and cognitive behavioral therapy
48658076|NCT06616155|PROCEDURE|Bone Scan|Undergo bone scan
48658077|NCT06616155|PROCEDURE|Computed Tomography|Undergo CT
47982732|NCT05276544|BEHAVIORAL|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
47982733|NCT05421234|OTHER|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
47982734|NCT05558163|PROCEDURE|transverse scrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
47982735|NCT05558163|PROCEDURE|penoscrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
47982736|NCT03012412|BEHAVIORAL|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
48135395|NCT03528213|DRUG|Normal saline|normal saline at physician discretion
48135396|NCT01324310|DRUG|Romidepsin|Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
48135397|NCT01324310|DRUG|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
48135398|NCT01401231|BEHAVIORAL|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
48344773|NCT03781388|DRUG|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
48344774|NCT02551913|BEHAVIORAL|Control|the adolescents will not receive any specific intervention
48344775|NCT02551913|BEHAVIORAL|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
48344776|NCT05663476|OTHER|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
48135399|NCT01401231|OTHER|Usual care|Continued usual care (could include referral for medication or psychotherapy)
48344777|NCT01269177|DEVICE|Non invasive ventilation|"Indications for the use of NIV are at least one of the following:~* Respiratory Rate ≥ 30 bpm~* PaO2/FiO2 \< 200~* pH \< 7.35 and PaCO2 \> 45 mmH~Contraindications for the use of NIV are at least one of the following:~* Coma~* Hemodynamic instability / shock~* Lack of compliance~Indications for endotracheal intubation (ETI) are at least one of the following:~* Respiratory or cardiac arrest~* Coma~* Hemodynamic instability"
48344778|NCT03372447|DRUG|Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg|Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
48658078|NCT06616155|DRUG|Enzalutamide|Given PO
48135400|NCT03813524|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
48135401|NCT00259142|DRUG|Chloroquine, sulphadoxine-pyrimethamine|
48135402|NCT03132688|DRUG|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
48658079|NCT06616155|DRUG|Ruxolitinib|Given PO
48658080|NCT00829465|DRUG|Licartin|Licartin
48135403|NCT04304937|OTHER|patient reported outcome measure|2 questionnaires are tested against each other
48658081|NCT00829465|PROCEDURE|Transcatheter arterial chemoembolization|TACE
48135404|NCT03342820|PROCEDURE|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
48135405|NCT06108635|PROCEDURE|McKenzie Exercises|"These can be performed in sitting and the protocol includes,~1. Retraction and extension~2. Retraction and extension with rotation~3. Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds."
48658082|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
48135406|NCT06108635|PROCEDURE|Maitland mobilization|The grade I and II Maitland mobilizations are given in week 1 and then progressed to grade III and IV in week 2
48135407|NCT06108635|PROCEDURE|Heat Therapy|Moist heat therapy with hot pack.
48658083|NCT05410223|DRUG|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
48344779|NCT01882192|BEHAVIORAL|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
48135408|NCT04713124|BEHAVIORAL|R2C-M|R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.
48344780|NCT01769482|DRUG|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
47982737|NCT02105792|DRUG|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
47982738|NCT03277105|DRUG|Dara SC|Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
47982739|NCT03277105|DRUG|Dara IV|Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
47982740|NCT02242409|DRUG|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
47982741|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
47982742|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
48135409|NCT04713124|OTHER|Self-help booklet|A booklet of information and self-help strategies for methamphetamine use problems.
48658084|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
47982743|NCT05336955|OTHER|Intake and quarterly assessment:|The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
48135410|NCT03618758|DRUG|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
48135411|NCT03618758|DRUG|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
48135412|NCT04898569|DRUG|Ferinject|Ferric carboxymaltose injection
48135413|NCT04898569|DRUG|Normal Saline Flush|placebo
48135414|NCT04939909|DRUG|Botulinum toxin type A|Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
48344781|NCT01769482|DRUG|placebo|
48344782|NCT00185172|OTHER|placebo|Placebo oral tablets for 2 weeks
48344783|NCT00185172|DRUG|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
48135415|NCT06466512|BEHAVIORAL|Midwifery-embodied care|The midwife will provide ANC, delivery and PNC. The Community Healthcare Provider, Health Assistants will act as auxillary staff. Local transports will be integrated into the system. Coordination committee will see through that the interventions are carried out properly.
48135416|NCT00582972|DRUG|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
48135417|NCT04072328|DRUG|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
48135418|NCT04072328|DRUG|Midazolam|midazolam with propofol
48135419|NCT00005974|DRUG|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
48344784|NCT00185172|DRUG|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
48344785|NCT02305550|DEVICE|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
48135420|NCT00144040|BEHAVIORAL|Physician & patient education on appropriate antibiotic use|
48135421|NCT00144040|PROCEDURE|Rapid C-reactive protein testing to guide antibiotic treatment|
48344786|NCT06056401|BEHAVIORAL|record Hemodynamic variables, respiratory variables and arterial blood gas at specific times|Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .
48344787|NCT02100202|OTHER|Placebo|
48500807|NCT04462211|PROCEDURE|Implementation of management pharmacological protocol of constipation|"first 48 hours:~* polyethylene glycol 3350 (about 17 grams) 1 every 8 hours enterally.~* Patients who have vomiting and / or gastric residue greater than 500 mL (in a timely measurement every 6 hours) will also be given domperidone 10 mg every 8 hours intravenously.~* Patients who have excessive abdominal distension will be administered in addition, levosulpiride 25 mg every 8 hours intravenously.~  48 hour evaluation:~* Patients who do not have bowel movements will be administered lactulose or sodium phosphate enema.~* For patients who do not have a bowel movement, administration of neostigmine intravenously or of naloxone enterally will be evaluated.~* Every patient who uses one or more prokinetics will have an electrocardiogram.~* Any patient who has bowel movements during management, doses of polyethylene glycol 3350 will be adjusted according to the daily goal of bowel movements, the days of treatment of the prokinetics will be adjusted, for a maximum of 5 consecutive days."
48500808|NCT04462211|PROCEDURE|Implementation of bundle of prevention and non-pharmacological management|"Bundle of prevention:~* Start early enteral nutrition.~* Optimize and / or decrease opioid doses.~* Start early mobilization.~Non-pharmacological management bundle~* Select laxative and/or prokinetic/s to manage constipation.~* Optimize and / or decrease doses of opioids and sedatives.~* Start early mobilization.~* Pharmacological reconciliation."
48658085|NCT05410223|DRUG|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
48658086|NCT03770286|DEVICE|5% Fluoride Varnish|Topical varnish
48658087|NCT03770286|DEVICE|38% Silver diamine fluoride|Topical varnish
48500809|NCT01405716|BEHAVIORAL|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
48500810|NCT01405716|BEHAVIORAL|Health Education|8-week health education program
48135422|NCT01051271|DRUG|midazolam|midazolam 1.5 mg
48500811|NCT02330536|DEVICE|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or twenty L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
48658088|NCT03770286|DEVICE|Super Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
48658089|NCT02287779|DRUG|SHP626|
48658090|NCT02287779|DRUG|Placebo|
48135423|NCT06190132|DRUG|Omega 3 fatty acid, gabapentin|To study the effect of omega 3 fatty acids on uremic pruritus in prevalent hemodialysis patients versus the effect of gabapentin
48135424|NCT00734578|DRUG|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
48135425|NCT00734578|DRUG|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
48135426|NCT00734578|DRUG|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
48135427|NCT04263051|DRUG|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
48135428|NCT04263051|DRUG|standard chemotherapy|Second line chemotherapy at the choice of the investigator
48135429|NCT04376567|PROCEDURE|One stage approach|Upper extremity brachial basilic arteriovenous fistula will be created either using one stage or two stage approach.
48135430|NCT01793779|PROCEDURE|cold water immersion|
48135431|NCT01793779|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
48135432|NCT01793779|DIETARY_SUPPLEMENT|Placebo|
48135433|NCT02841449|BEHAVIORAL|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
48135434|NCT02841449|BEHAVIORAL|Rehydrated|Participants rehydrate after the heat tent procedure
48344788|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
48344789|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
48135435|NCT03293875|BEHAVIORAL|Encuentro|a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV
48344790|NCT02100202|DIETARY_SUPPLEMENT|MaQxan (Tagetes erecta flower extract)|
48344791|NCT03230357|DEVICE|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
47982744|NCT05336955|OTHER|Consultation & coping skills coaching:|Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
48344792|NCT02793206|DEVICE|Imaging|
48344793|NCT04603274|PROCEDURE|8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome|All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
48500812|NCT04158388|OTHER|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
48500813|NCT04158388|OTHER|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
48500814|NCT04158388|OTHER|Manual therapy|That group received moderate pressure digital manual therapy.
48658091|NCT05573308|DEVICE|Clear Aligners with Dental Monitoring|Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.
48658092|NCT05573308|DEVICE|Clear Aligners|Removabale orthodontics appliances
48658093|NCT04430738|DRUG|tucatinib|For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
47982745|NCT05336955|OTHER|24-hour urgent crisis response and intervention:|START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
48135436|NCT02022670|DRUG|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
48135437|NCT02022670|DRUG|Sodium Nitrite|80 mg/d or 160 mg/d
48135438|NCT02727205|DRUG|Rotigotine Transdermal System|
48135439|NCT05773092|DRUG|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
48135440|NCT04717570|DEVICE|Foldax TRIA Mitral Valve|Mitral Valve Replacement
48344794|NCT05376189|DIETARY_SUPPLEMENT|400 IU|An Oral Vitamin D3 400 IU will be given once daily for a total of 8 weeks
48344795|NCT05376189|DIETARY_SUPPLEMENT|5000 IU|An Oral Vitamin D3 5000 IU will be given once daily for a total of 8 weeks
48344796|NCT05376189|DIETARY_SUPPLEMENT|10000 IU|An Oral Vitamin D3 10000 IU will be given once daily for a total of 8 weeks
48344797|NCT05376189|DRUG|Fixed Drug Combination|Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
48344798|NCT04931550|DEVICE|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
48344799|NCT00382655|PROCEDURE|Education and referral|
48344800|NCT02171039|DRUG|Dabigatran|
48658094|NCT04430738|DRUG|trastuzumab|Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.
48658095|NCT04430738|DRUG|oxaliplatin|85 mg/m\^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m\^2 given every 3 weeks.
48658096|NCT04430738|DRUG|leucovorin|200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
48658097|NCT04430738|DRUG|fluorouracil|400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
48658098|NCT04430738|DRUG|capecitabine|1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
48344801|NCT02171039|DRUG|Atorvastatin|
48344802|NCT02278224|BEHAVIORAL|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
48344803|NCT02278224|BEHAVIORAL|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
48344804|NCT02159768|DEVICE|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
48344805|NCT04787263|BIOLOGICAL|CD19-CAR_Lenti T cell|Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10\^6 CAR+ cells/kg.
48344806|NCT00498641|PROCEDURE|computer program and patching|
48002514|NCT01667640|RADIATION|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
48135441|NCT03789071|DIAGNOSTIC_TEST|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
48135442|NCT00940069|DRUG|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
48135443|NCT02436174|DEVICE|novel device|novel device being used to measure shivering
48135444|NCT02593149|DEVICE|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
48344807|NCT01782885|PROCEDURE|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
48500815|NCT04158388|OTHER|Placebo therapy|That group was treated with a US (in off mode) without conductive gel.
48135445|NCT02920034|DEVICE|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
48135446|NCT02920034|DEVICE|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
48135447|NCT02920034|DEVICE|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
48135448|NCT05543044|BEHAVIORAL|Peer mentor intervention|Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
48135449|NCT00076648|DRUG|Poly SFH-P Injection|
48135450|NCT05144984|DRUG|NNC0480-0389|A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
48135451|NCT05144984|DRUG|Semaglutide|A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
48135452|NCT05144984|DRUG|Placebo (NNC080-0389)|A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
48500816|NCT00401986|DEVICE|Bronchial thermoplasty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY (NCT00214539).
48135453|NCT05144984|DRUG|Placebo (semaglutide)|A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
48135454|NCT05555901|DRUG|Fruquintinib+ chemotherapy|"Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
48135455|NCT05555901|DRUG|Bevacizumab+ chemotherapy|"Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
48135456|NCT03483649|DRUG|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
48135457|NCT03483649|DRUG|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
48135458|NCT03483649|DRUG|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
48135459|NCT03483649|DRUG|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
48135460|NCT03054415|PROCEDURE|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
48135461|NCT04738656|DIETARY_SUPPLEMENT|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
48135462|NCT03443700|DEVICE|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
48344808|NCT01782885|DRUG|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
48344809|NCT01660997|DRUG|MLN9708|
48344810|NCT01660997|DRUG|Dexamethasone|
48344811|NCT03038516|DRUG|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
48344812|NCT03038516|DEVICE|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
48500817|NCT03761264|DRUG|Odontopaste®|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
48658099|NCT04430738|DRUG|pembrolizumab|400 mg given by IV on day 1 of cycle 1, then every 6 weeks.
48135463|NCT03443700|PROCEDURE|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
48135464|NCT04914403|BIOLOGICAL|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
48135465|NCT00325000|BEHAVIORAL|Interpersonal Psychotherapy|
48344813|NCT03169114|DRUG|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
48344814|NCT03169114|PROCEDURE|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
48344815|NCT02262013|BEHAVIORAL|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
48344816|NCT02262013|BEHAVIORAL|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
48344817|NCT00725829|DRUG|simvastatin|Simvastatin 40mg/d
48344818|NCT00725829|DRUG|ezetimibe|ezetimibe 10mg/d
48344819|NCT00725829|DRUG|placebo|placebo
47982746|NCT05336955|OTHER|Service linkages, referrals, outreach, & training:|START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
47982747|NCT03917108|DEVICE|retraction cord|retraction cord ( Ultra dent sizes #0, #00, #000 ) is placed in the gingival sulcus using blunt instrument and using cotton roll isolation.
47982748|NCT03917108|DEVICE|subgingival clamp|subgingival clamp (KSK clamps W8A, #44, #42, #43) or (Brinker clamps B5, B6) is placed to retract the gingiva with rubber dam isolation
47982749|NCT00050843|DRUG|thalidomide|
47982750|NCT02967497|DRUG|YQ1|Oral administered powder
47982751|NCT03512509|OTHER|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
47982752|NCT03512509|OTHER|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
47982753|NCT03051035|DRUG|KO-947|Intravenous administration
48135466|NCT00325000|DRUG|sertraline or amitriptyline|
48135467|NCT05374694|DIAGNOSTIC_TEST|Physiological invasive coronary evaluation|Performance of FFR, IMR and acetylcholine test (Only patients in groups 3 and 4 will undergo the acetylcholine test)
48344820|NCT01581905|PROCEDURE|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
48344821|NCT01581905|PROCEDURE|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
48344822|NCT06508398|DIAGNOSTIC_TEST|Microbiological Diagnostic Testing|"This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:~Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.~Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.~Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.~Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.~This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs."
48344823|NCT02863861|DRUG|Dexmedetomidine-ketamine|
48344824|NCT02863861|DRUG|propofol-ketamine|
47982754|NCT03272490|PROCEDURE|Medartis|Surgery using the medartis implant
47982755|NCT03272490|PROCEDURE|Synthes|Surgery using the Synthes implant
47982756|NCT00782145|OTHER|educational intervention|
47982757|NCT00782145|OTHER|informational intervention|
47982758|NCT00782145|OTHER|internet-based intervention|
47982759|NCT00782145|OTHER|questionnaire administration|
47982760|NCT00782145|OTHER|study of socioeconomic and demographic variables|
47982761|NCT00782145|OTHER|survey administration|
47982762|NCT00782145|PROCEDURE|psychosocial assessment and care|
47982763|NCT00782145|PROCEDURE|quality-of-life assessment|
47982764|NCT00782145|PROCEDURE|standard follow-up care|
47982765|NCT05891509|PROCEDURE|Minimally Invasive Hematoma Evacuation|Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
47982766|NCT05891509|OTHER|Best Medical Therapy|Best medical therapy
48344825|NCT00949845|DRUG|Endotoxin|
48344826|NCT03537183|OTHER|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
48344827|NCT00896350|DRUG|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
48135468|NCT05440812|BEHAVIORAL|Storytelling and Training to Advance Individual Recovery Skills (STAIRS)|STAIRS is a 8-week program, in which 8 different themes are addressed. Coverage of each theme starts with a group meeting guided by a professional and expert by experience. In these meetings different exercises are done (e.g., filling out an actual and desired week-schedule, role-playing a difficult situation), information is given and experiences are shared. Between meetings, participants can choose from a range of homework exercises to practice their desired skills in a tailored way. In addition, participants can share experiences with the other group members and exchange reactions using a private online community.
48135469|NCT00731341|PROCEDURE|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
48135470|NCT00538759|DEVICE|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
48135471|NCT00538759|OTHER|Sham Control|
48135472|NCT02616926|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
48135473|NCT02616926|PROCEDURE|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
48135474|NCT02616926|PROCEDURE|RFA|RFA will be performed 1 week after TACE.
48135475|NCT00808405|DRUG|acyclovir|400mg taken orally three times daily for 5 days
48135476|NCT00808405|DRUG|matching placebo|matching placebo taken orally three times daily for 5 days.
48135477|NCT05179187|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
48135478|NCT02993211|DEVICE|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
48135479|NCT02993211|DEVICE|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
48135480|NCT06116929|OTHER|Morphological and functional magnetic resonance imaging (MRI)|"Patients will undergo 3 morphological and functional MRI scans (during rest and activity) on the 3T MRI scanner at St Philibert Hospital (Lille, France) at 0 (M0), 6 (M6) and 12 (M12) months.~The controls will perform a single functional MRI on the 3T MRI."
48135481|NCT06116929|OTHER|Neuropsychological assessment|"3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once."
48135482|NCT03284359|BEHAVIORAL|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
48135483|NCT03188341|OTHER|vascular surgery procedure|"* an elective open vascular surgery procedure~* ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
48135484|NCT02531841|DRUG|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~* Rituximab 375 mg/m²/d i.v. (d0)~* Dexamethasone 40 mg/d i.v. (d1-3)~* Etoposide 100 mg/m²/d i.v. (d1-3)~* Ifosfamide 1500 mg/m²/d i.v. (d1-3)~* Carboplatin 300 mg/m² i.v. (d1)"
48135485|NCT02531841|DRUG|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~* Rituximab 375 mg/m²/d i.v. (d0,5)~* Methotrexate 3.5 g/m² i.v. (d1)~* Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~* Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~* Carmustine\* 400 mg/m² i.v. (d-6)~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)~  \* if carmustine is not available at the investigation site, busulfan can be administered instead:~* Busulfan 3,2 mg/kg/d (d-8-(-7))~* Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~* Autologous Stem Cell Transplantation (d0)"
48344828|NCT04745247|PROCEDURE|RSS|"Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours~Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS"
48344829|NCT05639829|BEHAVIORAL|Time-restricted eating|Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
48344830|NCT02230839|BEHAVIORAL|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
48344831|NCT02230839|BEHAVIORAL|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (\<30% of calories from fat) diet will be used as part of the weight loss intervention.
48344832|NCT00260572|BEHAVIORAL|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
48344833|NCT00260572|BEHAVIORAL|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
48344834|NCT00260572|BEHAVIORAL|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
47982767|NCT04673331|OTHER|exercise capacity|3minute step test and 1minute sit to stand test used assessment of exercise capacity.
48135486|NCT01359150|DRUG|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
48135487|NCT01359150|DRUG|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
48135488|NCT05913791|DIETARY_SUPPLEMENT|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
48135489|NCT05913791|OTHER|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
48135490|NCT02412033|DRUG|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
48344835|NCT00260572|BEHAVIORAL|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
48344836|NCT03456414|OTHER|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
48344837|NCT03622216|DRUG|Bradanicline|Three different doses over the course of the study
48658100|NCT03327129|PROCEDURE|fMRI|An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
48135491|NCT02412033|DRUG|Placebo|This group will receive placebo
48135492|NCT06175299|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System with Social Functions|The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
48135493|NCT02383043|DRUG|Cocaine|
48135494|NCT02383043|DRUG|Sustained Release d-Amphetamine|
48135495|NCT00562614|DRUG|SLx-2101|
48135496|NCT03600844|BEHAVIORAL|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
48135497|NCT02660294|BIOLOGICAL|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
48135498|NCT05869331|PROCEDURE|Early mobilization|Patients randomized to nonoperative treatment have already received treatment using early mobilization in the original trial, and all fractures have been confirmed healed. Mobilization consisted of 5 repetitions of full finger extension followed by maximum finger flexion, and 5 such sets of 5 were required per day for the first 6 weeks. Buddy taping or resting splint was offered if the patient experienced difficulty, and mobilization was performed by all patients in this treatment arm.
48135499|NCT05869331|PROCEDURE|Operative treatment|Patients randomized to operative treatment have already received treatment using open reduction and internal fixation (ORIF) with cortical screws in the original trial, and all fractures have been confirmed healed. Surgery was performed under general anaesthesia through a dorsal incision centered over the fractured metacarpal. Reduction was performed under visual inspection and fixation performed using 2 or more cortical screws (Synthes Compact Hand 2.0) as first option. At the surgeons preference fixation using plate and screw fixation was also allowed. Postoperatively patients were put in a plaster cast for two weeks and then hand therapy was initiated.
48344838|NCT03622216|DRUG|Placebo|Matching placebo for Bradanicline
48344839|NCT04036513|PROCEDURE|MINST|"For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes."
48500818|NCT03761264|DRUG|Pulpdent|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
48500819|NCT03761264|DRUG|Amoxicillin|Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
48500820|NCT00942435|DRUG|YM150|oral
48500821|NCT00942435|PROCEDURE|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
48500822|NCT04140305|DRUG|RPC-1063|Oral capsule
47982768|NCT04216017|DRUG|kenalog|Cortisone injection into shoulder
48135500|NCT01964781|DRUG|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
48344840|NCT04036513|PROCEDURE|Conventional SRP|Scaling and root planing with conventional instruments.
48344841|NCT05889169|OTHER|Neurorehabilitation|Four to eight weeks motor rehabilitation (500 minutes per week across 6 day per week)
48344842|NCT00415753|BEHAVIORAL|No antibiotics if se-procalcitonin is below stated limit|
48500823|NCT06499857|DRUG|Semaglutide|3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
48500824|NCT06499857|DRUG|Placebo|3ml pen-injector containing placebo solution for subcutaneous use.
48658101|NCT05913687|DIAGNOSTIC_TEST|AIDP|Machine learning algorithm of imaging data
48658102|NCT04595292|OTHER|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
48658103|NCT06625710|DRUG|GV1001|Lyophilized peptide from hTERT
48658104|NCT06625710|DRUG|Placebo|0.9 % Normal Saline
48344843|NCT05565794|DRUG|Pemigatinib|Intake of up to 3 tablets of pemigatinib (4,5 mg each) daily per oral for 14 days in a 21-day cycle (maximum of 18 cycles in total)
48135501|NCT01964781|DRUG|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
48135502|NCT01964781|DRUG|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
48135503|NCT01964781|DRUG|tranexamic acid plus saline|
48135504|NCT01964781|DRUG|saline|
48135505|NCT06079242|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
48135506|NCT06514391|PROCEDURE|compressive single piece dental implant|4 inter-foraminal single piece compressive dental implants were placed in the mandible via flapless protocol by the aid of stereolithographic surgical guide
48135507|NCT06515457|DIETARY_SUPPLEMENT|Eye Empower|Participants will take three capsules of the Eye Empower supplement daily for three weeks.
48135508|NCT05152849|DRUG|AXA1125|AXA1125 administered BID with or without food
48135509|NCT05152849|DRUG|Placebo|Matching Placebo administered BID with or without food
48135510|NCT04068272|DRUG|Bosentan|Eyedrop
48135511|NCT04068272|DRUG|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
48135512|NCT03738384|DEVICE|Knee Connect + Visual Feedback System|A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
48135513|NCT01132560|GENETIC|RNA analysis|
48135514|NCT01132560|GENETIC|gene expression analysis|
48135515|NCT01132560|GENETIC|reverse transcriptase-polymerase chain reaction|
48135516|NCT01132560|OTHER|laboratory biomarker analysis|
48135517|NCT03624335|PROCEDURE|ECC|Early clamping of the umbilical cord
48135518|NCT03624335|PROCEDURE|DCC|Delayed clamping of the umbilical cord
48344844|NCT06234085|OTHER|VCA feedback report available|Access to feedback report described in the intervention
48344845|NCT01848795|DEVICE|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
48344846|NCT01848795|DEVICE|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
47982769|NCT04216017|DRUG|Lidocaine|Lidocaine injection into shoulder
47982770|NCT03072615|DIAGNOSTIC_TEST|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
48135519|NCT03624335|PROCEDURE|Blood Test 6hours|Blood Test 6hours
48135520|NCT03624335|PROCEDURE|Blood Test 24hours|Blood Test 24hours
48135521|NCT03624335|PROCEDURE|Blood Test 48hours|Blood Test 48hours
48135522|NCT03624335|PROCEDURE|Blood Test 28days|Blood Test 28days
48135523|NCT03875313|DRUG|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
48135524|NCT03875313|DRUG|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
48135525|NCT01785446|DRUG|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
48135526|NCT01785446|DRUG|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
48135527|NCT03428633|DRUG|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
48135528|NCT03428633|DRUG|Morphine|Morphine intraoperatively and postoperatively
48135529|NCT03421249|OTHER|Exercises|Muscle strengthening exercises of the hip and knee muscles
48135530|NCT03421249|OTHER|Electromagnetic field therapy|Electromagnetic field therapy with Magnetron®
48135531|NCT01262963|DRUG|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
48135532|NCT00528320|DEVICE|Ovatio CRT|
48135533|NCT01438034|DRUG|kisspeptin 112-121|0.24 nmol/kg
48135534|NCT01438034|DRUG|GnRH|75 ng/kg
48135535|NCT05343494|BEHAVIORAL|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
48135536|NCT03148600|BEHAVIORAL|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
48135537|NCT03148600|OTHER|Standard arm|Standard medical and nursing care
48344847|NCT01845519|BEHAVIORAL|Tailored Email|Participants will receive tailored emails.
48344848|NCT01845519|BEHAVIORAL|Targeted Email|Participants will receive targeted emails.
48500825|NCT05669183|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.
48658105|NCT05944692|DEVICE|Tripolar electroencephalography|We will record physiological signals with the tripolar electroencephalography
48658106|NCT04087642|DIAGNOSTIC_TEST|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
48658107|NCT04087642|DIAGNOSTIC_TEST|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
48658108|NCT04756453|DEVICE|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
48658109|NCT01991873|DRUG|Maintenance Chemotherapy|
48658110|NCT01991873|DRUG|Panitumumab (Within maintenance phase)|
48658111|NCT01991873|DRUG|mFOLFOX6 (Within re-induction phase)|
48658112|NCT01991873|DRUG|Panitumumab (Within re-induction phase)|
48658113|NCT06602128|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise on Anxiety, Pain and Life Findings in Patients Undergoing Coronary Angiography
48658114|NCT02825667|OTHER|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
48658115|NCT05508789|DRUG|Donanemab|Administered IV
48658116|NCT05508789|DRUG|Placebo|Administered IV
48658117|NCT06412146|BEHAVIORAL|Peer Support Group|Participation in an Online Peer Support Group
48658118|NCT05442216|DRUG|Tagraxofusp (Cycles 1-2)|12 mcg/kg intravenously Days 1-5
48658119|NCT05442216|DRUG|Azacitidine|75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
48658120|NCT05442216|DRUG|Tagraxofusp (Cycles 3-12)|12 mcg/kg intravenously Days 1-3
48500826|NCT02018783|PROCEDURE|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
48500827|NCT02018783|PROCEDURE|Sensodyne|Digital application for 60 seconds.
48500828|NCT02018783|PROCEDURE|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
48500829|NCT02018783|PROCEDURE|Cocorico|Digital application for 60 seconds
48500830|NCT02290301|DRUG|gemigliptin|
48500831|NCT04682730|BEHAVIORAL|Deliberative Loop|"The investigators will give background information to the stakeholders before they engage in the Deliberative session.~Stakeholders from a given clinic will come together for a Deliberative session (i.e., facilitated conversation), enabling them to hear the full range of perspectives held by their fellow colleagues and to share their own perspective regarding how best to implement the guideline in small-group discussions.~Following the Deliberative session, each stakeholder will have the opportunity to record their opinions regarding possible implementation interventions. The investigators will share these opinions with the clinic's decision-makers to help guide their decision-making about which implementation interventions to deploy. If a stakeholder happens to be absent the day of their clinic's Deliberative session, they will still have the opportunity to complete the survey."
48658121|NCT06395935|OTHER|Wecare (website)|support feedback of qutionaire \& supply educational contents
48658122|NCT02659241|DRUG|Adavosertib|Given PO
48658123|NCT02659241|OTHER|Laboratory Biomarker Analysis|Correlative studies
48658124|NCT06608303|DRUG|Topical Human Granulocyte Macrophage Stimulating Factor Gel|Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of haematopoietic precursor cells to granulocyte macrophages and promotes their peripheral translocation, as well as enhances phagocytosis and secretion of granulocytes and macrophages \[11\]. Since macrophages are key players in regulating the inflammatory response of wounds and promoting wound repair, rhGM-CSF is thought to potentially play a positive role in the treatment of acute and chronic wounds.
48658125|NCT06608303|DRUG|Saline (NaCl 0,9 %) (placebo)|placebo
48658126|NCT04877041|BEHAVIORAL|Intradialytic Cycling|This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.
48658127|NCT01771354|BIOLOGICAL|Engerix B Vaccine|
48658128|NCT01771354|BIOLOGICAL|Placebo|
48658129|NCT01597700|DRUG|10mg Ezetimibe|1 tablet taken by mouth
48658130|NCT01597700|DRUG|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
48658131|NCT06572293|BEHAVIORAL|Nurse-led intervention|Nurse-led intervention involves patient education, collecting Patient Reported Outcomes (PRO) and evaluating them by specialists nurses, as well as navigating patients to services that can assist with their symptoms. During three-five planned appointments, the nurse will talk with you about adjusting to life after complete the radiotherapy of nasopharyngeal carcinoma, including symptoms of relapse and how to deal with them.In the first year, PROs will be collected every six months on recurrences and late effects, and thereafter every 12 months. PRO will be administered to patients for three years after the nurse appointments are finalized.
48658132|NCT04535297|OTHER|exposure|Exposure to social distancing due to COVID-19
48658133|NCT03318627|DEVICE|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
48658134|NCT04543591|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
48344849|NCT05984511|PROCEDURE|I-125 Seeds Brachytherapy in PVTT|Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.
48344850|NCT05984511|PROCEDURE|Transcatheter arterial chemoembolization|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
48344851|NCT05984511|DRUG|Atezolizumab plus Bevacizumab|Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
48344852|NCT05128604|DEVICE|Gastroenterostomy|Endoscopic ultrasound guided gastroenterostomy
48344853|NCT02139267|BIOLOGICAL|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
48344854|NCT04655846|BEHAVIORAL|Nursing intervention outcome: Breastfeeding Counseling (5244)|"Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~1. Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~2. Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~3. Educational Session: Explain the extraction and conservation of breast milk.~4. Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding."
48344855|NCT04655846|BEHAVIORAL|Nursing education about maternal care and usual education in maternity preparation course|Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
48344856|NCT05411224|OTHER|Custom made orthosis|In patients with Morton Neuroma, stride length, stance phase percentage, swing phase percentage, cadence and speed parameters, and fore, mid and hind foot pressure distribution will be recorded with the Zebris FDM-THM-S treadmill system in the analysis of barefoot walking after the physical examination evaluation of the cases.While the treadmil is in a static state, pressure distribution measurement will be taken by baropedography, and personalized insoles will be produced according to the baropedographic pressure map. Patients will be delivered to the patient for indoor and outdoor use for 4 weeks. After a 4-week usage period, measurements related to pressure and walking parameters will be repeated.
48344857|NCT05711719|DRUG|Vericiguat|Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms
48344858|NCT05711719|DRUG|Placebo|Administered the same way
48344859|NCT02966236|DRUG|Tranexamic Acid|
48344860|NCT02966236|DRUG|Placebos|
48658135|NCT04543591|OTHER|Placebo|Matching placebo
48658136|NCT04543591|OTHER|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
48658137|NCT06493526|DRUG|Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.|Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
48658138|NCT05488522|BIOLOGICAL|SBRT + atezolizumab and bevacizumab|"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
48658139|NCT02033408|DRUG|AB (antibiotics)|"1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
48658140|NCT02033408|DRUG|CS (corticosteroids) Only|"1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
48658141|NCT00526799|DRUG|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
48344861|NCT02071329|DRUG|Vaccine FP-01.1|
48344862|NCT02071329|DRUG|Placebo|
48344863|NCT02071329|OTHER|Virus Challenge|
48344864|NCT03218189|OTHER|Country characteristics|Observational study of country characteristics
48344865|NCT02866318|DEVICE|Echocardiography|
48344866|NCT01666353|RADIATION|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
48344867|NCT05057468|DRUG|Cyclosporine|2.5-5 mg orally for 3 months
48344868|NCT05057468|DRUG|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks
48344869|NCT00691977|RADIATION|Radiation Therapy followed by prostatectomy|Radiation Therapy
48500832|NCT05301153|DIAGNOSTIC_TEST|real time PCR , ELISA|Real-time RT PCR will be performed on complementary DNA produced from 250 ng total RNA using the following primers Interleukin 37, F: 59-CAGTGAGGTCAGCGATTAGGAA-39 R: 59-TTAGTGAGCAGGTTTGGTGTTTT-39 b-actin, F: 59-CACCATTGGCAATGAGCGGTTC-39 R 59-AGGTCTTTGCGGATGTCCACGT-39. Detection of autoantibodies to muscle specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4) serum levels by ELISA
48500833|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
48500834|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
48500835|NCT00289536|BIOLOGICAL|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
48344870|NCT01921283|DEVICE|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
48344871|NCT01921283|DRUG|no- BIS sensor attachment|
48658142|NCT00526799|DRUG|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
48344872|NCT03694067|OTHER|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
48658143|NCT06288828|BEHAVIORAL|Aerobic exercise|"Participants in the intervention group will engage in 150 minutes of moderate aerobic exercise weekly for 16 weeks, primarily brisk walking or jogging. They will follow a personalized nutritional plan: 1.2 grams of protein per kilogram of ideal body weight daily and 35 kilocalories per kilogram of ideal body weight daily.~For the initial four weeks, they will visit the hospital weekly for guidance. Healthcare professionals will help adjust exercise intensity based on heart rate (60-80% of max) and perceived exertion (RPE 12-15), monitoring vital signs and adverse events.~After, they will transition to a home exercise program for eight weeks, recording exercise details in a logbook. Weekly follow-up calls will ensure adherence and monitor adverse events."
48658144|NCT06288828|BEHAVIORAL|Nutrition consultant|"Participants will be provided with a personalized nutritional plan by a nutritionist, which will involve consuming 1.2 grams of protein per kilogram of ideal body weight daily, while also maintaining a calorie intake of 35 kilocalories per kilogram of ideal body weight per day. To assess adherence and make necessary adjustments, participants will complete a 3-day food record at the beginning of the study, at week 8, and at the end of the study at week 16.~If participants encounter difficulty in adhering to the recommended nutritional intake, the nutritionist will offer additional guidance to help them meet the requirements. The primary objective of this nutritional plan is to ensure that participants receive adequate nutrition to support their exercise regimen and maintain their body weight throughout the study period."
48658145|NCT00839501|DIETARY_SUPPLEMENT|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
48658146|NCT00839501|DRUG|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
48344873|NCT03238079|BIOLOGICAL|10% IGIV|300-900 mg/kg
48344874|NCT02454894|DRUG|lidocaine|surface anesthesia with lidocaine
48344875|NCT02454894|PROCEDURE|postoperative management|lying without the pillow for half an hour after lumbar puncture
48344876|NCT03869164|DEVICE|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
48344877|NCT05326074|OTHER|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
48344878|NCT02500472|DIETARY_SUPPLEMENT|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
48344879|NCT01301404|DIETARY_SUPPLEMENT|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
48344880|NCT06075498|PROCEDURE|transversus abdominis plane block,|2 different plan blocks; 1. transversus plane block 2. quadratus lumborum plane block
47982771|NCT03520231|DRUG|Denosumab|RANK Ligand Inhibitor
47982772|NCT03520231|OTHER|Denosumab Placebo|Placebo
48344881|NCT02762760|BIOLOGICAL|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
48344882|NCT02762760|BIOLOGICAL|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
48344883|NCT02940028|BEHAVIORAL|Expressive writing|Brief expressive writing intervention
48500836|NCT03916510|BIOLOGICAL|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
48500837|NCT03916510|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
48500838|NCT03916510|RADIATION|Radiotherapy|50 Gy/25#
48500839|NCT03862755|DRUG|Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)|Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
48500840|NCT05009914|PROCEDURE|cardiac denervation|Excision of Marshall ligament and Waterstone fat pad during CABG.
48500841|NCT03082287|DEVICE|Fecal Calprotectin Level|Measurement of calprotectin in feces
48344884|NCT02940028|BEHAVIORAL|Control writing|Brief fact-based writing exercise.
48500842|NCT06404164|PROCEDURE|Wedge resection under watershed analysis method|"* Compare the preoperative 3D reconstruction model, and use electrocautery to directionally separate and expose the target artery;~  * Auxiliary devices (unlimited) to block the target artery, but should not be severed; ③ Peripheral intravenous injection of ICG, electrocautery to mark the border of counter-staining; ④ Evaluate the actual incisal margin according to the preoperative planning, and use the cutting stapler to wedge resection of the pulmonary nodule"
48658147|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Therapeutic|"Photobiomodulation (PBM) is a non-invasive treatment option that uses nonionizing light sources such as laser diodes and light-emitting diodes in the visible and near-infrared spectrum.~Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'therapeutic setting' of 35mW/cm2 = 42J/cm2"
48344885|NCT02094625|DRUG|N-Acetylcysteine|"NAC will be administered intravenously over \~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC."
48344886|NCT02623491|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
48344887|NCT02623491|DRUG|Placebo|Participants will receive matching placebo.
48344888|NCT02520713|GENETIC|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
48344889|NCT03753386|OTHER|Oxygen therapy simulation|"The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~* rest (9 minutes);~* drinking water (1 minute);~* rest (1 minute);~* coughing (1 minute);~* rest (1 minute);~* reading aloud (1 minute);~* rest (1 minute);~* breathing by the mouth (1 minute);~* rest (1 minute);~* exercising (running) (3 minutes) and~* rest (10 minutes)~Recordings will be retrieved after each test."
48658148|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Control|"Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'non-therapeutic setting' of 0mW/cm2 = 0J/cm2"
48135538|NCT02738307|OTHER|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
48344890|NCT01775800|OTHER|Treatment modification|
48344891|NCT00493610|DRUG|N-acetylcysteine(Mucomyst)|
48344892|NCT03491280|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
48344893|NCT01427114|DRUG|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
48500843|NCT05869461|BEHAVIORAL|KP Specific Wellness Sessions|The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.
48500844|NCT05869461|BEHAVIORAL|Peer Navigation|Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
48500845|NCT05607979|DRUG|Lavior Diabetic Wound Gel|Daily application of hydrogel treatment for 60 days.
48500846|NCT05607979|DRUG|Smith & Nephew Solosite Gel Hydrogel Wound Dressing|Daily application of hydrogel treatment for 60 days.
48500847|NCT01666197|DRUG|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
48500848|NCT01666197|DRUG|placebo|placebo
48500849|NCT03802955|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment.
48658149|NCT02154230|DIETARY_SUPPLEMENT|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
48344894|NCT05656118|DEVICE|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
48344895|NCT03383055|BIOLOGICAL|CMV-MVA Triplex Vaccine|"* CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56"
47982773|NCT03520231|DRUG|Gemcitabine|Antineoplastic Agent
48135539|NCT04452383|DRUG|Ketamine + propofol|effect of adding ketamine to propofol for patients undergoing DISE surgery
48135540|NCT04452383|DRUG|propofol|effect of IV propofol alone for patients undergoing DISE surgery
48344896|NCT05255627|OTHER|Control|"Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using written educational material prepared in line with the literature."
48344897|NCT05255627|OTHER|Mobile application group (Experimental Group)|"A mobile application program was installed on the phones of the experimental group students for their benefit. Prevention, Care and Treatment of Pressure Injury was explained by 1 researcher who is responsible for the Nursing Fundamentals course, using a mobile application program prepared in line with the literature."
48344898|NCT05151562|BEHAVIORAL|Virtual Music Therapy|Each study participant will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be delivered by a board-certified music therapist (using Zoom as a primary platform). These individualized therapeutic encounters will use music that is personally meaningful and familiar to the participant and the participant's loved ones to facilitate reminiscence. Decision-making processes made by the music therapist will reflect a flexible session structure and series of intervention choices contingent on each participant's cultural identity, expressive and receptive communication, fine and gross motor ability, affect, orientation to time and place, and personal preferences on any given day.
48344899|NCT03228849|PROCEDURE|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
48344900|NCT03228849|PROCEDURE|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
48658150|NCT02154230|DIETARY_SUPPLEMENT|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
48658151|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose A|Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
48658152|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose B|Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
47982774|NCT03520231|DRUG|Carboplatin|Antineoplastic Agent
47982775|NCT03520231|DRUG|Cisplatin|Antineoplastic Agent
47982776|NCT03520231|DIETARY_SUPPLEMENT|Calcium|Calcium Supplement
47982777|NCT03520231|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D Supplement
47982778|NCT01203150|OTHER|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
47982779|NCT03326791|DRUG|Acetylsalicylic acid|Trombyl 160 mg once daily
47982780|NCT03326791|DRUG|Placebo Oral Tablet|Placebo one tablet daily
47982781|NCT01042327|DEVICE|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
47982782|NCT01042327|DEVICE|Fresenius FX100 dialyzer|
47982783|NCT06474364|DRUG|Long-acting Cabotegravir injection|Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.
47982784|NCT06474364|OTHER|SEARCH-YOUTH|It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.
47982785|NCT01121887|BEHAVIORAL|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
47982786|NCT01121887|BEHAVIORAL|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
47982787|NCT00514540|DRUG|Docetaxel|75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.
48135541|NCT01823224|DRUG|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
48135542|NCT01823224|DRUG|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
48135543|NCT05765331|DEVICE|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
48344901|NCT00862498|OTHER|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
48344902|NCT04996524|DRUG|epidural analgesia|Patients recieving epidural analgesia instead of systemic analgesia for acute pain in the intensive care unit
48344903|NCT05810376|BEHAVIORAL|Digital-based physical activity intervention|The digital behavioral program comprises goal planning, motivational messages and video calls, social support, and routine follow-up of weekly goals.
48500850|NCT02177656|BEHAVIORAL|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
48500851|NCT05357755|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as delayed release tablets.
48500852|NCT05357755|DRUG|Placebo|Matching placebo will be administered orally as delayed release tablets.
48500853|NCT00999427|DRUG|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
48500854|NCT03705130|DEVICE|Single Vision Contact Lens|Spherical Contact Lens worn on non-dispensing basis
48658153|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose C|Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
48658154|NCT06194656|OTHER|HER3 Monoclonal antibodies-Dose D|The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
48658155|NCT06194656|OTHER|Placebo|SIBP-03 solvent without HER3 antibody, intravenous infusion (IV), once every one weeks, 21 days as a cycle.
48658156|NCT06194656|COMBINATION_PRODUCT|Cetuximab injection|Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
48658157|NCT06211296|DEVICE|Shortcut|Splitting bioprosthetic aortic valve leaflets
48658158|NCT03578315|DEVICE|HGM|To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study
48658159|NCT05038839|DRUG|Cabozantinib|Given PO
48658160|NCT05038839|DRUG|Pamiparib|Given PO
48658161|NCT04331522|DIAGNOSTIC_TEST|Oral provocation test|Titrated provocation with allergen
48344904|NCT05810376|OTHER|Patient education and exercise|Patient education will include information on osteoarthritis, prognosis, pain management, importance of physical activity and exercise. The exercise program will include warm up, stretching and strengthening.
48344905|NCT00544466|DRUG|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
48344906|NCT00544466|DRUG|melphalan|140 mg/m2 day -2 prior to transplant
48344907|NCT00544466|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
48658162|NCT06351371|PROCEDURE|Biopsy|Undergo tumor biopsy
48344908|NCT00544466|RADIATION|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
47982788|NCT00514540|DRUG|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
47982789|NCT00514540|DRUG|Etoposide|120 mg/m\^2 daily for 3 days of 21 day cycle.
48344909|NCT02225925|RADIATION|Brachytherapy|
48344910|NCT03642028|DRUG|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
48344911|NCT03642028|OTHER|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
48344912|NCT04781049|PROCEDURE|Trans-Perineal Laser Ablation of Prostate|"TPLA treatment will be performed using the EchoLaser EVO system (Elesta SpA - Calenzano, FI, Italy). EchoLaser EVO consists of four echolasers, a multi-source laser system with a wavelength of 1064nm and Echolaser Smart Interface (ESI), a treatment planning device for safely inserting introductor needles and optical fibers into prostate tissue. EchoLaser therapy is a micro-invasive percutaneous procedure that uses laser light transmitted through applicators (optical fibers) for a few minutes, causing a heating of the affected tissue to its irreversible damage in situ, without the need to remove it. EchoLaser therapy, through flat-tip fibers, produces an ellipsoidal clotting area (area where the tissue has irreversible damage). EchoLaser therapy will be performed under ultrasound guidance."
48344913|NCT04781049|PROCEDURE|Trans-Urethral Resection of Prostate|TURP is the gold standard for the treatment of benign prostatic obstruction. It will be performed by using a bipolar energy resectoscope. The procedure will be carried out with patient in a lithotomic position.
48344914|NCT05460390|OTHER|Therapeutic drug monitoring (TDM)|Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
48344915|NCT00232050|DRUG|Omalizumab|
48344916|NCT04827719|DRUG|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
48344917|NCT00122070|DRUG|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
48344918|NCT03616249|OTHER|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
48344919|NCT03616249|OTHER|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
48344920|NCT04884906|BIOLOGICAL|Camrelizumab|200mg/m2, iv, d1, Q3W, a total of 6 cycles
48344921|NCT04884906|RADIATION|radiotherapy|1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.
48344922|NCT04884906|DRUG|Albumin Paclitaxel|260mg/m2, iv, d1, Q3W, a total of 6 cycles
48344923|NCT04884906|DRUG|Cisplatin|80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
48344924|NCT02482649|BEHAVIORAL|EAA/T|bi-weekly for 12weeks
48658163|NCT06351371|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48658164|NCT06351371|PROCEDURE|Computed Tomography|Undergo CT
47982790|NCT00514540|DRUG|Cisplatin|25 mg/m\^2 for 3 days of 21 day cycle.
48135544|NCT02847520|BEHAVIORAL|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
48135545|NCT00447837|DRUG|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
48344925|NCT02482649|DRUG|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
48344926|NCT02482649|DRUG|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
48344927|NCT01690819|PROCEDURE|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
48344928|NCT01690819|PROCEDURE|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
48344929|NCT04470011|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
48658165|NCT06351371|DRUG|Erdafitinib|Given orally
48658166|NCT06351371|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48658167|NCT05704803|DIAGNOSTIC_TEST|Diagnostic Test: IN Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
48658168|NCT02177162|OTHER|Education to physiotherapists|
48658169|NCT03462602|PROCEDURE|NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
48135546|NCT02561195|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
48135547|NCT02561195|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
48344930|NCT04470011|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
48344931|NCT01406158|DRUG|Solifenacin Succinate Formulation A|oral suspension
48344932|NCT01406158|DRUG|Solifenacin Succinate Formulation B|oral suspension
48344933|NCT01406158|DRUG|Solifenacin Succinate|oral tablet
48344934|NCT04391153|PROCEDURE|ERCP with tissue sampling|Patients with biliary strictures undergo ERCP o EUS. Tissue specimens obtained via either of brush cytology, forceps biopsy or fine needle aspiration during ERCP or endosonography (EUS) were examined by routine cytology or histology methods. In addition, FISH inlcuding fluorescence-based polynucleotide probes targeting chromosomes 3, 7, 17 and locus 9p21 was performed. Gold standard for final diagnosis is the histology from surgical resection. In patients without surgery, a follow up of 12 months will be considered adequate to exclude or confirm malignant etiology.
48344935|NCT01769612|OTHER|No Intervention|
48344936|NCT06074718|OTHER|pricking therapy and wheat grain moxibustion|pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
48344937|NCT00584779|DRUG|Gabapentin|CLcr:14-5 mL/min
48344938|NCT00584779|DRUG|Gabapentin|CLcr: 29-15 mL/min
48344939|NCT00584779|DRUG|Gabapentin|Hemodialysis
48344940|NCT00584779|DRUG|Gabapentin|CLcr: 29-30 mL/min
48344941|NCT02719457|OTHER|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
48344942|NCT02719457|OTHER|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
48344943|NCT01228149|DRUG|Trabeculectomy with preoperative Diamox/DexaEDO treatment|Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
48344944|NCT01228149|DRUG|Trabeculectomy with preoperative Cosopt S treatment|Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
48344945|NCT00952952|DRUG|Mesalamine|
48500855|NCT03705130|DEVICE|Multifocal Contact Lens 1|Multifocal Contact Lens worn on non-dispensing basis
48500856|NCT03705130|DEVICE|Multifocal Contact Lens 2|Multifocal Contact Lens worn on non-dispensing basis
48500857|NCT04317859|BEHAVIORAL|Behavioural Activation|Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
48500858|NCT00701961|DRUG|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
48658170|NCT03462602|PROCEDURE|non-NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
47982791|NCT01399138|DIETARY_SUPPLEMENT|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
47982792|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
47982793|NCT01575496|DEVICE|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
47982794|NCT01176669|DRUG|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
47982795|NCT01101347|DEVICE|Aneurysm-Embolization System|
47982796|NCT03414723|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
47982797|NCT03414723|DRUG|Ramipril|"Pharmaceutical form: tablets~Route of administration: oral"
47982798|NCT00748033|DEVICE|Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12|The subjects were first catheterized with this reference catheter.
47982799|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 5 seconds|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds
48344946|NCT02724280|DEVICE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
48344947|NCT02724280|DEVICE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
48344948|NCT06050577|DRUG|oral Semaglutide/Rybelsus|Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
47982800|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 24 hours|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
47982801|NCT00953446|PROCEDURE|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
47982802|NCT03267186|DRUG|Ibrutinib|Given PO
47982803|NCT03267186|OTHER|Laboratory Biomarker Analysis|Correlative studies
47982804|NCT03566927|COMBINATION_PRODUCT|FLEX Scoring Catheter with Lutonix DCB|Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
47982805|NCT00001995|DRUG|Rifabutin|
47982806|NCT01442233|PROCEDURE|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
48344949|NCT06050577|DRUG|Placebo|Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
47982807|NCT01442233|PROCEDURE|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
48344950|NCT00032006|RADIATION|brachytherapy|
48344951|NCT00032006|RADIATION|radiation therapy|
48344952|NCT04553978|DRUG|WD-1603|WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
48500859|NCT00764686|OTHER|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
48500860|NCT00764686|OTHER|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
48500861|NCT00376038|DRUG|GSK189075 oral tablets|
48500862|NCT00376038|DRUG|metformin tablets|
48344953|NCT05240963|PROCEDURE|Temporal PEEK implant|Temporal PEEK implant to reconstruct temporal fossa after temporalis muscle transfer
48344954|NCT03325010|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
48344955|NCT03325010|DRUG|Placebo oral capsule|non-active dosage form
48344956|NCT02180490|DRUG|UHAC 62 XX tablet|
48344957|NCT02180490|DRUG|UHAC 62 XX capsule|
48344958|NCT04904536|DRUG|Atorvastatin|40mg atorvastatin + standard care daily for 12 months.Atorvastatin 40mg has TGA approval for general marketing for the treatment of hypercholesterolaemia and cardiovascular prevention under a number of manufacturer names.The study medication selected will be the atorvastatin 40mg (Apotex) which is scored, and allows down-titration to 20mg should a participant develop symptoms.The study medication will be packaged, labelled and dispensed directly to particpants by the Syntro Health pharmacy in Australia. A comparable atorvastatin 40mg is being sourced in Chile, and will be dispensed from the pharmacy of the Clínica Alemana de Santiago. Similarly, a comparable atorvastatin 40mg is being sourced in Hong Kong, and will be dispensed from the site's pharmacy.
48344959|NCT04904536|OTHER|Standard Care|Standard care for neurological symptoms as a result of COVID-19 infection.
48344960|NCT03396640|PROCEDURE|Unicondylar Knee Arthroplasty|"Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not."
48344961|NCT03396640|PROCEDURE|Total Knee Arthroplasty|Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
48344962|NCT04063865|DRUG|Tacrolimus|Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
48344963|NCT04063865|DRUG|Everolimus|Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
48344964|NCT02352649|DRUG|Neovasculgen|
48344965|NCT00236613|DRUG|topiramate|
48344966|NCT06123741|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .
48344967|NCT06123741|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
48344968|NCT02963766|DRUG|Dulaglutide|Administered SC
48344969|NCT02963766|DRUG|Placebo|Administered SC
48344970|NCT00610077|DRUG|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
48344971|NCT00610077|DRUG|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
48344972|NCT02971007|DRUG|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
48344973|NCT02971007|DRUG|Fluconazole|
48500863|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
48500864|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
48500865|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
48344974|NCT04872504|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen record the incidence of intraoperative hypotension
48344975|NCT05385926|RADIATION|Radiotherapy|Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
48500866|NCT00535665|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
48658171|NCT06632171|BEHAVIORAL|Cognitive Behavioral Therapy- Based and Motivational Interviewing-Supported Psychoeducation|The aim of this study is to examine the effects of cognitive-behavioral-based and motivational interview-supported psychoeducation on emotional eating and psychological resilience in obese individuals. The study will be conducted in a randomized controlled experimental design. The sample of the study will consist of 102 obese individuals in total, 51 in the experimental group and 51 in the control group, who meet the inclusion criteria. A cognitive-behavioral and motivational interview-supported psychoeducation program will be applied to the experimental group. All patients will be evaluated at three time points: pretest (baseline), posttest (8 weeks), and follow-up test (3 months after the posttest). No intervention will be applied to the control group.
48658172|NCT05078112|DEVICE|Sleep sensor technology|Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
47982808|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
48344976|NCT04912661|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
48344977|NCT03771989|BIOLOGICAL|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
48344978|NCT03771989|OTHER|Saline|The placebo is an injection with saline
48344979|NCT04695236|DEVICE|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
48344980|NCT04695236|OTHER|Standard Treatment|Standard Treatment for Ischemic Strokre
48344981|NCT06071780|OTHER|organic product - Virgin Coconut Oil|A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
48500867|NCT00000259|DRUG|15 % Nitrous oxide|
48500868|NCT00000259|DRUG|0.3 % Sevoflurane|
48500869|NCT00000259|DRUG|30% Nitrous oxide|
48500870|NCT00000259|DRUG|0.6% Sevoflurane|
48500871|NCT00000259|OTHER|Placebo|
48135548|NCT05573724|DRUG|AZD5305|"In Part A, the participants will receive a single dose of AZD5305 on Day 1 and Day 7.~In Part B, the participants will receive AZD5305 once daily."
48135549|NCT05573724|DRUG|Itraconazole|In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
48135550|NCT00900341|GENETIC|DNA analysis|
48135551|NCT00900341|GENETIC|gene expression analysis|
48135552|NCT00900341|GENETIC|protein expression analysis|
48135553|NCT00900341|GENETIC|reverse transcriptase-polymerase chain reaction|
48135554|NCT00900341|GENETIC|western blotting|
48344982|NCT06361420|PROCEDURE|Driving pressure-guided positive end expiratory pressure|The positive end expiratory pressure setting rules are as follows: a 10-cycle experimental ventilation will be carried out at each level of positive end expiratory pressure after intubation, and the driving pressure of the last cycle will be recorded. The positive end expiratory pressure value corresponding to the lowest driving pressure is recognised as the optimal ventilation parameter. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
48344983|NCT06361420|PROCEDURE|Optimal oxygenation-guided positive end expiratory pressure|Positive end expiratory pressure will be maintained at the level facilitating optimal oxygenation during the off-pump period. Partial pressure of carbon dioxide monitoring is employed to determine the tidal volume and respiratory rate. Inspiration/expiration pattern is adjusted based on the preoperative small airway condition. This parameter is subject to modification upon cessation of ventilation, ICU admission, and every morning throughout the ventilation period. During cardiopulmonary bypass, mechanical ventilation is maintained using the low-level parameters.
48500872|NCT01036139|DRUG|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
48500873|NCT04049110|DRUG|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
48500874|NCT04049110|DRUG|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
48500875|NCT06423443|BEHAVIORAL|Digital Cognitive Behavioral Therapy|digital cognitive behavioral therapy app
48500876|NCT06423443|BEHAVIORAL|Health Education|traditional on-line health education app
48500877|NCT06423443|DRUG|TAU|treatment as usual
48658173|NCT01751880|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
48658174|NCT03599713|DRUG|Retifanlimab|INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
48658175|NCT06564246|DRUG|Vonoprazan 20 mg versus Pantoprazole 40 mg|Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
48135555|NCT00900341|OTHER|immunohistochemistry staining method|
48658176|NCT06114368|PROCEDURE|Surgery for the treatment of Acute Achilles tendon rupture|Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
48135556|NCT00900341|OTHER|laboratory biomarker analysis|
48135557|NCT04174339|DRUG|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
48135558|NCT04174339|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
48135559|NCT04174339|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
48135560|NCT00821301|DRUG|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
48135561|NCT00797212|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
48135562|NCT05868304|DEVICE|BFR|Exercises may involve warm up on a stationary bike for 5 minutes, application of a BFR cuff (a cuff that often uses air to inflate around a limb) on the selected extremity, and exercise sets (e.g. banded squats, step ups, Romanian dead lifts). We will record metrics on an iPad. Testing will be done with ForceDecks and ForceFrames (system for measuring muscle strength and imbalance).
48135563|NCT05868304|OTHER|Stanard strengthening program.|"The exercise program will be completed 3 times per week Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
48135564|NCT01419210|OTHER|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
48135565|NCT01419210|OTHER|Educational Presentations|Attend a two-hour presentation each week for four weeks
48135566|NCT01419210|OTHER|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
48135567|NCT01419210|OTHER|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
48135568|NCT00293410|DRUG|clofarabine|
48658177|NCT04083027|DEVICE|MRI|Breast MRI
48658178|NCT04970966|DEVICE|PuraSinus|A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
48344984|NCT06361420|PROCEDURE|Ventilation strategy|A Pressure regulated volume control mode is used in the patients before extubation. The ventilation target are: (1) a pulse oximetry ≥ 90% or a partial pressure of arterial oxygen ≥ 60mm Hg; (2) a partial pressure of arterial carbon dioxide: 35 \~ 50 mm Hg and (3) a pondus hydrogenii (pH) value \> 7.20. The ventilation parameters are: (1) tidal volume: 6 \~ 8 mL/Kg predictive body weight; (2) respiratory rate 10 \~ 15 cycles per minute; (3) inspiratory/expiratory ratio: 1:1.5 (1:2.5 - 1:3 in the patients with chronic obstructive pulmonary disease); positive end expiratory pressure: 0 \~ 8 cm centimeter water column. On-pump ventilation parameters are: (1) tidal volume: 4 mL/Kg predictive body weight; (2) respiratory rate: 4 circles per minute; (3) positive end-expiratory pressure: 4 cm centimeter water column; (4) inspiratory oxygen fraction: 21%.
48344985|NCT06361420|PROCEDURE|Management of hypoxemia|Management of hypoxemia will be initiated immediately through the following steps: (1) carefully checking anaesthesia apparatus malfunction, airway normality, and monitoring accuracy; (2) improving cardiac function, correcting fluid overload, and alleviating systemic inflammation; (3) performing alveolar recruitment manoeuvres as described above; (4) increasing the tidal volume and positive end expiratory pressure within the upper limits; (5) increasing the respiratory rate while addressing concurrent hypercapnia; (6) titrating the fraction of inspiratory oxygen until the pulse oximetry reaches or exceeds 90%; and (7) considering the use of extracorporeal membrane oxygenation if any following situations occurred 14: (a) a partial pressure of arterial oxygen \< 50 mm Hg for more than 3 hours; (b) a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio \< 80 mm Hg for more than 6 hours; or (c) a critical respiratory acidosis for more than 6 hours.
48344986|NCT03360942|DEVICE|SCC DBS|Deep Brain Stimulator
48344987|NCT01126294|DIETARY_SUPPLEMENT|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
48344988|NCT01126294|DIETARY_SUPPLEMENT|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
47982809|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
48344989|NCT01126294|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
48344990|NCT06434025|DRUG|Iron Carboxymaltose|Iron Carboxymaltose 500 mg. 2 vials administered IV.
48344991|NCT06434025|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg Tab, PO, onde a day.
48658179|NCT04970966|DEVICE|Bioresorbable Nasal Dressing|PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
48658180|NCT04197583|DEVICE|Boston Scientific Ureteral Stents, Urinary Diversion Stent|A BSC Ureteral Stent is an implantable device that is used to restore flow of urine from the kidney to the bladder in obstructed ureters. A BSC Urinary Diversion Stent is an implantable device that is used to restore flow of urine from the kidney.
48658181|NCT06014801|DRUG|Dialysate fluid, Filtration replacement fluid|Dose of continuous hemodialysis and/or hemofiltration
48658182|NCT04540471|OTHER|music|MT group receives additional music therapy
48658183|NCT04540471|OTHER|comprehensive in-patient education program|comprehensive in-patient education program
48658184|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
48658185|NCT06563934|DRUG|Lenvatinib + PD-1 monoclonal antibody|"Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks."
48658186|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules placebo|Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
48658187|NCT04012450|PROCEDURE|Epidural anesthesia|Performing an epidural anesthesia
48500878|NCT00933348|DRUG|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
48658188|NCT04012450|PROCEDURE|spina-epidural anesthesia|Performing a spina-epidural anesthesia
47982810|NCT02107027|DEVICE|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
48135569|NCT00293410|DRUG|cyclophosphamide|
48135570|NCT01057433|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
48135571|NCT01057433|DRUG|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
48658189|NCT01616147|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
48658190|NCT01616147|BEHAVIORAL|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
48658191|NCT05576337|OTHER|16 weeks of strength training protocol|16 weeks of strength training protocol
48658192|NCT03924895|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
48135572|NCT04060212|OTHER|Tuna fish|Six meals of tunafish (\~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
48135573|NCT04060212|DIETARY_SUPPLEMENT|prebiotic|Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
48135574|NCT01647932|DRUG|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
48135575|NCT01647932|DRUG|Placebo|Placebo according to clearance of creatinine; \>50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.
48135576|NCT01160354|DRUG|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
48135577|NCT01160354|DRUG|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
48135578|NCT03293914|BEHAVIORAL|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
48135579|NCT00000958|BIOLOGICAL|MTP-PE/MF59|
48135580|NCT00000958|BIOLOGICAL|Env 2-3|
48135581|NCT04593238|DRUG|Double Antibiotic paste|Metronidazole and Ciprofloxacin
48135582|NCT04593238|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
48135583|NCT05619705|BEHAVIORAL|Healthy for Two-Health Coaching (H42)|The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
48135584|NCT05619705|BEHAVIORAL|Maintain Healthy in Pregnancy and Postpartum(mHIPP)|A brief video on maternal warning signs that is available in English or Spanish.
48135585|NCT05444075|OTHER|a method for communication|"the Arabic alphabet (arranged in the traditional order) printed on double-sided cardboard, with one copy facing the person and one facing the doctor.~The code will be in the case of a positive selection (the desired line or letter) by looking up or one blink, but in the case of a negative selection (not the desired line or letter), it will be by looking down or two blinks.~The person will choose the letters of each word and then choose the end of the word and after selecting all the words of the sentence choose the end of the sentence.~After the strategy has been taught to the subject, he or she will be asked to communicate with the physician using this way."
48135586|NCT03414645|BIOLOGICAL|CAM-101 10%|fibrinogen-depleted human platelet lysate
48135587|NCT03414645|BIOLOGICAL|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
48344992|NCT06434025|DRUG|Placebo of Iron Carboxymaltose|Solution Sodium Chloride 0,9% 100 ml, IV, once.
48344993|NCT06434025|DRUG|Placebo of Dapagliflozin|Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
48658193|NCT03924895|PROCEDURE|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
48658194|NCT03924895|DRUG|Enfortumab Vedotin|Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
48658195|NCT00001465|DEVICE|Toshibia Aquilion One CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
48658196|NCT04057157|DEVICE|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
48658197|NCT06643637|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
48658198|NCT06643637|DRUG|Placebo|Capsule with no active ingredients
48658199|NCT06630156|BIOLOGICAL|Revascularization of Immature Young Permenant Teeth|"An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C"
48658200|NCT02892279|OTHER|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
48135588|NCT03414645|BIOLOGICAL|CAM-101 30%|fibrinogen-depleted human platelet lysate
48135589|NCT03746613|DEVICE|HEARO|Robotic system for otological procedures
48135590|NCT05950867|DIAGNOSTIC_TEST|ECG + echocardiography|Electrocardiogram and echocardiography
48500879|NCT00933348|DRUG|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
48500880|NCT02687529|DEVICE|CST001|
48344994|NCT05551260|OTHER|Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition|"Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests"
48344995|NCT04976478|DRUG|Nimotuzumab|Patients receive Nimotuzumab: 200mg, intravenous infusion, weekly for 6 weeks.
48344996|NCT04976478|RADIATION|EBRT combined with brachytherapy|"IMRT/VMAT are adopted. A total dose of 45-50.4 Gy, 1.8\~2.0Gy/f, 25\~ 28F in pelvic and/or extension filed. For patients with metastasis in pelvic lymph node and abdominal para-aortic lymph node, the dose of radiation in local lesion will be increased to 60\~66Gy. For patients at stage IIIB, concurrent radiation will be given in parametrial extension or in the late course the dose will be increased to 60Gy.~Brachytherapy: Three dimensional high dose rate brachytherapy is used with HR-CTV D90 cumulative dose of 80\~85Gy (EQD2); If the tumor diameter is ≥4cm, HR-CTV D90 cumulative dose is ≥87Gy (EQD2). Brachytherapy combined with external beam radiotherapy will be completed within 8 weeks."
48344997|NCT01481766|DIETARY_SUPPLEMENT|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
48344998|NCT01481766|DIETARY_SUPPLEMENT|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
48135591|NCT05950867|OTHER|Answering questionnaires|Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).
48135592|NCT06425250|OTHER|Management, progression and risk factors for failure of BJI caused by Campylobacter spp.|Description of demographic data (sex, age), comorbidities (ASA and Charlson scores), orthopedic and septic history, and surgical and medical management (antibiotic therapy)
48135593|NCT06425250|OTHER|Description of the evolution and risk factors for failure of osteoarticular infections caused by Campylobacter spp.|"Failure of treatment: defined according to a composite criterion bringing together~* persistence of the infection under treatment, and/or~* recurrence of the infection after stopping antibiotic therapy, and/or~* need for surgical revision for septic reasons more than 5 days after initial treatment, and/or~* superinfection, and/or~* definitive explantation of the material, and/or~* decision for suppressive antibiotic therapy, and/or~* amputation, and/or~* death linked to infection"
48344999|NCT01481766|BEHAVIORAL|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
48345000|NCT01210976|DRUG|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
48500881|NCT06279559|BEHAVIORAL|Music-therapy|10 sessions of online music therapy held by expert music therapists
48500882|NCT02475330|DIETARY_SUPPLEMENT|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
48500883|NCT00673244|DRUG|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
48500884|NCT06059443|BEHAVIORAL|mLab App Plus|Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
48500885|NCT06284603|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session includes exposure of 60 minutes to 100% oxygen at 2.5 atmosphere absolute (ATA), with 5-minute air breaks every 20 minutes
48500886|NCT04832893|DIAGNOSTIC_TEST|steady intensity aerobic test of 30 minutes long|the use of different type of masks during an aerobic exercise
48500887|NCT06186934|DRUG|the standard-dose group (4 g/day)|Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
48658201|NCT05977439|DEVICE|fMRI-EEG-TMS|Participants will undergo a magnetic resonance imaging (MRI) scan with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
48658202|NCT05977439|DEVICE|fNIRS-EEG-TMS|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and single-pulse transcranial magnetic stimulation (TMS) while completing cognitive flexibility (CF) and emotion recognition (CR) tasks.
48135594|NCT04612868|DEVICE|AEYE Software Device|"Eligible participants will undergo the following procedures:~* Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~* Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~* All study subjects will have their pupils dilated using dilation drops."
48135595|NCT04797468|DRUG|HLX23|administered IV.
48500888|NCT04164914|DIETARY_SUPPLEMENT|Prebiotic|Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
48500889|NCT04468516|DEVICE|KKT|Vibroacoustic sound waves applied focally.
48500890|NCT04468516|DEVICE|sham KKT|sham KKT
48500891|NCT03709823|DRUG|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
48500892|NCT03709823|DRUG|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
48500893|NCT03709823|BEHAVIORAL|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
48500894|NCT02636543|OTHER|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
48135596|NCT03085433|DEVICE|Microfluidic Sperm Sorting|Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
48135597|NCT03085433|PROCEDURE|in vitro fertilization|ivf/icsi
48135598|NCT05323032|DEVICE|Multifocal electroretinogram (mf-ERG) by electroretinogram device|Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
48135599|NCT00488566|DRUG|GSK drug|GSK drug
48135600|NCT00488566|OTHER|Placebo|Placebo
48135601|NCT00488566|OTHER|Lamictal|Positive control
48135602|NCT04650191|OTHER|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
48135603|NCT03738709|BEHAVIORAL|Falls prevention and education giving a demonstration of the usage of technical assistance.|"* Ecological trail to work on balance and walking.~* Technical assistance presentation and try-outs within the therapeutic apartment.~* Discussion on the perceived feelings over the exercises and the technical assistance submitted.~* Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
48345001|NCT01210976|DRUG|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
48345002|NCT01000818|DRUG|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
48345003|NCT01000818|DRUG|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
48345004|NCT01000818|DRUG|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
48345005|NCT02505802|DRUG|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
48345006|NCT05402904|DIAGNOSTIC_TEST|nerve conduction study|Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.
48345007|NCT06437548|DEVICE|Percutaneous spinal cord stimulation|The parameters of percutaneous cervical spinal cord stimulation leads will be adjusted for optimal upper extremity motor function.
48345008|NCT00938197|DRUG|Fimasartan|Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
48500895|NCT02636543|OTHER|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
48135604|NCT03021512|PROCEDURE|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
48135605|NCT03021512|PROCEDURE|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
48135606|NCT03000257|DRUG|Venetoclax|Tablet taken orally
48135607|NCT03000257|DRUG|Rovalpituzumab Tesirine|Intravenous infusion
48135608|NCT03000257|DRUG|ABBV-181|Intravenous infusion
48135609|NCT03863587|BIOLOGICAL|HLX12|healthy volunters receive HLX12 (8mg/kg) once
48345009|NCT00938197|DRUG|Amlodipine|Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
48345010|NCT02198560|DEVICE|RS-3000 Lite|
48345011|NCT03554304|DRUG|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
48345012|NCT03554304|DRUG|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
48345013|NCT03554304|DRUG|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
48135610|NCT03863587|BIOLOGICAL|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
48500896|NCT03401359|GENETIC|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only \~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
48500897|NCT03376230|OTHER|Collect of blood, urines, and intestinal biopsies|
48500898|NCT06490445|DRUG|Medical Cannabis|Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.
48135611|NCT04140643|DEVICE|Ozonated water delivering device effects on the oral health of pregnant women|Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
48135612|NCT04140643|BEHAVIORAL|Oral hygiene instructions|Oral Hygiene instructions
48345014|NCT04944927|OTHER|Recording of clinical parameters and electrocardiogram parameters|Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
48345015|NCT04691557|OTHER|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
48345016|NCT04691557|OTHER|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
48500899|NCT06490445|DRUG|Placebo|Placebo administered using Fixed-dose Syqe Inhaler.
48345017|NCT01603706|PROCEDURE|Echo guided implantation group|Lead placement according echo strain imaging result
48345018|NCT04773847|PROCEDURE|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.|Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.
48345019|NCT01780324|DRUG|Lidocaine|Intervention - intraurethral lidocaine
48345020|NCT04892680|BEHAVIORAL|Online Diabetes Self-Management Education and Support (DSMES) Program|Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.
48345021|NCT06417008|DRUG|HS-20117|Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)
48345022|NCT06417008|DRUG|Aumolertinib|110 mg orally once daily.
48345023|NCT03989089|DRUG|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
48500900|NCT04433338|OTHER|14-day Low Calorie Diet|"Participants will be asked to:~* Use 4 (women) or 5 (men) Modifast meal replacements per day.~* Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~* Daily consume 100 grams of lean meat/fish/meat analogues.~* Daily consume two spoons of liquid oil~* Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks."
48345024|NCT00871676|BEHAVIORAL|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
48345025|NCT00871676|BEHAVIORAL|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
48345026|NCT04258293|DIAGNOSTIC_TEST|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
48345027|NCT05784103|DEVICE|Clarifi Modulum|During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.
48345028|NCT05784103|DEVICE|Perimed PeriFlux 5000|Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.
48345029|NCT05784103|DEVICE|Apple Watch Oxygen Sensor|The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.
48345030|NCT05784103|DEVICE|Innovo iP 900AP|The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
48345031|NCT03723408|DEVICE|ClearLine IV (formerly, AirPurge)|Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
48345032|NCT03234270|DEVICE|Core temperature measurements|Core temperature measurements with coretemp pill
48345033|NCT01707095|OTHER|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
48345034|NCT01707095|OTHER|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
48500901|NCT04062656|DRUG|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
48500902|NCT04062656|DRUG|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
48500903|NCT04062656|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
48500904|NCT04062656|DRUG|Docetaxel|Docetaxel 50mg/m² IV over 1 h
48135613|NCT04788524|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
48500905|NCT04062656|DRUG|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
48500906|NCT04062656|DRUG|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
48500907|NCT00562237|BIOLOGICAL|S205 placebo|2 i.m. injections per subject (0.5 mL each)
48500908|NCT00562237|BIOLOGICAL|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
48135614|NCT02146469|BIOLOGICAL|2 doses with an 3 months interval|varicella vaccination
48500909|NCT00562237|BIOLOGICAL|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
48345035|NCT04625088|OTHER|Standardized liquid test meal|During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
48135615|NCT02146469|BIOLOGICAL|A second dose with an 1 year interval|varicella vaccine
48345036|NCT04625088|DRUG|Atropine + Standardized liquid test meal|During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
48345037|NCT02597192|OTHER|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
48500910|NCT00562237|BIOLOGICAL|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
48500911|NCT00562237|BIOLOGICAL|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
48500912|NCT00562237|BIOLOGICAL|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
48500913|NCT00562237|BIOLOGICAL|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
48500914|NCT02620644|DEVICE|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
48500915|NCT00642681|DRUG|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
48345038|NCT02597192|OTHER|oral hygiene products without Bacillus|products without Bacillus
48345039|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 50μg group|50μg/person
48500916|NCT01752686|DRUG|carboplatin|carboplatin as adjuvant chemotherapy
48500917|NCT00264368|DRUG|intravenous (IV) ganciclovir|
48500918|NCT00684892|DEVICE|Chartis System|Assessment of airway flow and pressure
48135616|NCT02146469|BIOLOGICAL|A second dose with an 3 year interval|varicella vaccine
48135617|NCT02146469|BIOLOGICAL|A second dose with an 5 year interval|varicella vaccine
48135618|NCT02146469|BIOLOGICAL|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
48135619|NCT02146469|BIOLOGICAL|1 dose MMR|MMR
48135620|NCT00785200|OTHER|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
48135621|NCT00785200|OTHER|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
48135622|NCT02381470|DRUG|Faropenem|Faropenem 600mg
48135623|NCT02381470|DRUG|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
48135624|NCT02381470|DRUG|Cefadroxil|Cefadroxil 1g
48135625|NCT02381470|DRUG|Rifampicin|Rifampicin 10mg/kg
48345040|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 100μg group|100μg/person
48345041|NCT05352867|OTHER|Placebo|0.5ml/person
48345042|NCT00868361|DRUG|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
48345043|NCT00826709|DEVICE|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
48345044|NCT00719524|DRUG|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
48345045|NCT00125892|DRUG|duloxetine|
48345046|NCT06066853|DRUG|MDMA|MDMA-assisted psychotherapy
48345047|NCT04820036|DIAGNOSTIC_TEST|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
48345048|NCT04820036|BEHAVIORAL|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
48500919|NCT05509816|DRUG|Midazolam|Administered orally.
48500920|NCT05509816|DRUG|Imlunestrant|Administered orally.
48500921|NCT05134753|BIOLOGICAL|Advanced PRF|Advanced PRF will be placed for patients undergoing sinus augmentation
48500922|NCT05134753|BIOLOGICAL|Control|PRF will be placed for patients undergoing sinus augmentation
48500923|NCT04158700|DRUG|LY3200882|LY3200882 administered orally
48500924|NCT04158700|DRUG|Pembrolizumab|Pembrolizumab administered IV
48500925|NCT04729309|DRUG|[12C] RO7049389|Participants will receive oral \[12C\] RO7049389.
48500926|NCT04729309|DRUG|[13C] RO7049389|Participants will receive IV \[13C\] RO7049389.
48500927|NCT04729309|DRUG|[14C] RO7049389|Participants will receive an oral suspension of \[14C\] RO7049389.
48500928|NCT02387515|OTHER|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
48135626|NCT01697891|DEVICE|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
48135627|NCT04139005|BEHAVIORAL|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
48135628|NCT04139005|BEHAVIORAL|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
48345049|NCT04820036|DIAGNOSTIC_TEST|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
48135629|NCT04139005|BEHAVIORAL|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
48135630|NCT03500549|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
48135631|NCT03500549|DRUG|Soliris|Complement (C5) Inhibitor
48135632|NCT04068506|DRUG|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
48135633|NCT01630824|OTHER|Structured education program|structured education program after kidney transplantation
48135634|NCT05254912|DRUG|6% Bemotrizinol in sunscreen formulation|6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation (SU E 101413 85)
48135635|NCT05254912|DRUG|6% Bemotrizinol in petrolatum|6% Bemotrizinol (BEMT) as a dispersion in petrolatum (SU-E-101413-82)
48135636|NCT05254912|OTHER|Vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91)
48135637|NCT00062660|DRUG|Tipranavir|Tipranavir 250 mg soft elastic capsules
48135638|NCT02874534|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
48500929|NCT03303183|DEVICE|Standard Impression technique|Silicone impression technique
48500930|NCT03303183|DEVICE|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
48135639|NCT02874534|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
48135640|NCT00690131|BEHAVIORAL|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
48135641|NCT05127967|OTHER|Skin biopsy|A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
48135642|NCT04359069|OTHER|Urinary catheter removal on postoperative day 1|Urinary catheter will be removed on day 1 (experimental) instead of day 3 (standard of care).
48135643|NCT04359069|OTHER|Urinary catheter removal on postoperative day 3|Urinary catheter will be removed on day 3 (standard of care)
48345050|NCT04820036|DIAGNOSTIC_TEST|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
48345051|NCT04820036|DIAGNOSTIC_TEST|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
48345052|NCT00626834|DRUG|Vigabatrin|Dose 1 BID
48345053|NCT00626834|DRUG|Vigabatrin|Dose 2 BID
48500931|NCT06244849|BIOLOGICAL|Blood samples|A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine
48500932|NCT06244849|BIOLOGICAL|Stool simple|A fresh stool sample will be collected and conserved at room temperature until shipment
48500933|NCT06244849|BIOLOGICAL|Ileocolonic biopsies|An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed
48135644|NCT03820050|DEVICE|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
48135645|NCT00664690|DRUG|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
48135646|NCT00664690|DRUG|placebo|placebo given preop and BID postop
48135647|NCT02307396|DRUG|Olanzapine|
48135648|NCT02307396|DRUG|Amisulpride|
48135649|NCT02307396|DRUG|Risperidone|
48345054|NCT00626834|DRUG|Vigabatrin|Dose 3 BID
48345055|NCT00626834|DRUG|Matching placebo|Matching placebo BID
48345056|NCT00136357|BEHAVIORAL|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
48345057|NCT04250740|OTHER|Coffee with butter-1|250 mL brewed black coffee with hazelnut flavouring and 50 g water
48345058|NCT04250740|OTHER|Coffee with butter-II|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I
48345059|NCT04250740|OTHER|Coffee with butter-III|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
48345060|NCT00858676|DRUG|acarbose|50mg acarbose 3 times a day PO. duration: one year
48500934|NCT00151112|PROCEDURE|Positioning and plexus anesthesia|positioning during plexus anesthesia
48500935|NCT06085118|OTHER|Pepticate® Syneo®|Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
48500936|NCT05363514|DRUG|Low Dose Naltrexone|Participant takes Low Dose Naltrexone 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
48500937|NCT05363514|DRUG|Microcrystalline cellulose|Participant takes microcrystalline cellulose 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
48345061|NCT02030860|DRUG|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
48135650|NCT02307396|DRUG|Haloperidol|
48135651|NCT02307396|DRUG|Quetiapine|
48135652|NCT02307396|DRUG|Perphenazine|
48135653|NCT02307396|DRUG|Sulpiride|
48135654|NCT02307396|DRUG|bromperidol|
48135655|NCT02307396|DRUG|Zuclopenthixol|
48135656|NCT02307396|DRUG|Thioridazine|
48135657|NCT02307396|DRUG|Paliperidone|
48135658|NCT02307396|DRUG|Ziprasidone|
48135659|NCT02307396|DRUG|Benperidol|
48135660|NCT02307396|DRUG|Fluspirilene|
48135661|NCT02307396|DRUG|Pimozide|
48135662|NCT02307396|DRUG|Perazine|
48135663|NCT02307396|DRUG|Fluphenazine|
48135664|NCT02307396|DRUG|Flupentixole|
48135665|NCT02307396|DRUG|Sertindole|
48135666|NCT04242212|BEHAVIORAL|Misoprostol sourced from clinics|One cohort of women using misoprostol sourced from clinics
48135667|NCT04242212|BEHAVIORAL|Misoprostol sourced from PMVs|One cohort of women using misoprostol sourced from PMVs
48135668|NCT06104423|DRUG|Nebivolol 5 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
48500938|NCT00837473|DEVICE|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
48135669|NCT06104423|DRUG|Ramipril 2.5/5/10 mg|1 tablet of study medication to be administered orally according to instructions of Investigator.
48135670|NCT06517641|DRUG|Haploidentical donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive a haploidentical donor bone marrow transplant."
48135671|NCT06517641|DRUG|Unrelated donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive an unrelated donor bone marrow transplant."
48135672|NCT02890524|DEVICE|night guard|60 days before and after intervention with the night guard
48135673|NCT02890524|DEVICE|placebo night guard|60 days before and after intervention with the placebo night guard
48345062|NCT02030860|DRUG|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
48345063|NCT02030860|DRUG|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
48500939|NCT03084367|DIAGNOSTIC_TEST|iFR pullback|iFR pullback assessment post angiographically successful PCI
48500940|NCT03476733|OTHER|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
48658203|NCT05977439|DEVICE|fNIRS-EEG-rTMS Interleaved with CBT|Participants brain activity will be measured using functional near-infrared spectroscopy (fNIRS) with combined electroencephalography (EEG), and repetitive transcranial magnetic stimulation (rTMS). rTMS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist 6 session a day for 5-6 days. Each rTMS session will be separated by 30 minutes of Cognitive Behavioral Therapy (CBT). rTMS treatment will be delivered at an individualized left DLPFC target based on each participant's individualized scans from prior neuroimaging sessions.
48658204|NCT06459778|DEVICE|Piezo-ICSI|Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.
48658205|NCT01085903|DRUG|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
48135674|NCT02994407|DRUG|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
48135675|NCT04551651|DEVICE|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
48135676|NCT04551651|DEVICE|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
48135677|NCT00367874|DRUG|Buprenorphine|
48135678|NCT00367874|DRUG|Valproate|
48135679|NCT04924296|DRUG|SHR-1314|SHR-1314 s.c. + Steroids
48135680|NCT04924296|DRUG|Placebo|Placebo s.c. + Steroids
48135681|NCT04295642|DRUG|CVL-751|Oral tablet
48135682|NCT06455059|DRUG|Vosoritide|Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
48135683|NCT06455059|DRUG|Placebo|Subcutaneous injection of recommended dose of placebo
48135684|NCT04044781|DRUG|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
48135685|NCT04478487|DIETARY_SUPPLEMENT|Medolac human milk based human milk fortifier (MHMHMF)|MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
48135686|NCT05499663|BEHAVIORAL|POSTHOC app|The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
48135687|NCT01862016|PROCEDURE|APRV|Pressure ventilation mode allowing early spontaneous breathing
48135688|NCT01862016|BIOLOGICAL|arterial blood gas measurement each morning|
48135689|NCT01447706|DRUG|MM-121|MM-121 (SAR256212) (IV)
48135690|NCT01447706|DRUG|Paclitaxel|Standard dosing Paclitaxel (IV)
48135691|NCT04580459|BEHAVIORAL|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
48135692|NCT04580459|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
48135693|NCT01332175|DEVICE|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
48135694|NCT01332175|DEVICE|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
48135695|NCT01332175|PROCEDURE|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
48135696|NCT02160119|OTHER|MRI-based techniques|fMRI, DTI
48135697|NCT02160119|OTHER|EEG|ERP
48135698|NCT03597087|PROCEDURE|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
48135699|NCT03597087|DRUG|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
48135700|NCT04694937|DEVICE|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
48345064|NCT04929691|DEVICE|CPAP helmet|helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation
48345065|NCT04929691|OTHER|Standard of care non-helmet based CPAP ventilation|Standard of care ventilation without helmet-based CPAP
48135701|NCT00081913|GENETIC|Cell Therapy - Autologous CD34 Positive Cells|
48135702|NCT01818869|DRUG|AZD8848|Multiple doses inhaled IMP via a nebulizer
48345066|NCT02076243|DRUG|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
48345067|NCT04672070|OTHER|Selective Caries Removal|"Selective caries are removed only for secure sealing with a direct restoration, without removing deep caries next to the pulp.~If the pulp is exposed, pulpotomy will be performed instead and the tooth will be excluded from further analysis."
48345068|NCT04672070|OTHER|Pulpotomy|"Complete caries removal and excision of the coronal pulp to the level of the root canal orifices will be performed. After haemostasis, sealing with Biodentine® and restoration.~If the pulp is not exposed after complete caries removal, the tooth will be restored without further excavation and pulp exposure. If the pulp is assessed intra-operatively to be non-vital or not amenable to pulpotomy, root canal treatment will be performed instead. In both cases, the tooth will be excluded from further analyses."
48500941|NCT05394649|DEVICE|Intravascular Lithotripsy|"A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable."
48500942|NCT05394649|DEVICE|Rotational Atherectomy|Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
48135703|NCT01818869|DRUG|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
48135704|NCT04003324|BEHAVIORAL|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
48135705|NCT01449760|OTHER|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
48135706|NCT01449760|OTHER|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
48135707|NCT01530334|DRUG|Gefitinib 250mg|Gefitinib 250mg once daily
48135708|NCT02261805|DRUG|Ganetespib|
48135709|NCT02261805|DRUG|Doxorubicin|
48135710|NCT00505336|DRUG|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
48345069|NCT05369793|DRUG|Alpha lipoic acid|Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
48345070|NCT05369793|DRUG|Roflumilast|Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
48345071|NCT06224868|OTHER|insufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
48135711|NCT00505336|OTHER|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
48345072|NCT06224868|OTHER|desufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
48345073|NCT04106180|DRUG|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
48345074|NCT04106180|DRUG|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
48345075|NCT04106180|RADIATION|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
48345076|NCT02918539|DRUG|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
48345077|NCT04552626|BEHAVIORAL|Prolonged sitting (social breaks)|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
48345078|NCT04552626|BEHAVIORAL|Prolonged sitting with step-up exercise break|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
48345079|NCT04552626|BEHAVIORAL|Prolonged sitting with simple resistance activity breaks|Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
48345080|NCT02341404|DRUG|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
48345081|NCT00916396|DRUG|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
48345082|NCT00916396|DRUG|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
48135712|NCT00505336|DRUG|Atorvastatin|oral Atorvastatin 40mg
48135713|NCT03491540|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
48345083|NCT01201967|OTHER|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
48345084|NCT01201967|OTHER|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
48345085|NCT04746157|OTHER|Nurse intervention|Patients will undergo an individualized patient care plan conducted by a lead nurse. According to their results on the Stroke Riskometer and their cardiovascular risk factors, the nurse will prepare a phone call for the next two weeks with information and support adapted to each patient and their necessities. Phone calls will be repeated monthly until the sixth month, then, one more the ninth month and one last previous to the end of the treatment. Patients will be able to contact the reference nurse whenever they would need to.
48135714|NCT03491540|DRUG|Oral Gentamycin|"Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials"
48658206|NCT01085903|DRUG|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
48135715|NCT03491540|DRUG|Oral Ornidazole|"Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
48135716|NCT03491540|DRUG|Oral Placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
48135717|NCT03491540|DRUG|Oral Placebo Ornidazole|"Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1"
48135718|NCT06454929|PROCEDURE|operative|open reduction : fixation by k-wires or screws
48135719|NCT06454929|PROCEDURE|non-operative|close reduction : by cast Immobilization
48135720|NCT00104741|DRUG|flutamide|
48135721|NCT00104741|DRUG|triptorelin|
48135722|NCT00104741|RADIATION|radiation therapy|
48135723|NCT01692769|DRUG|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
48135724|NCT01692769|DRUG|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
48345086|NCT00940849|DIETARY_SUPPLEMENT|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
48345087|NCT00940849|DIETARY_SUPPLEMENT|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
48345088|NCT02327078|DRUG|Nivolumab|specified dose and dosing schedule
48658207|NCT01085903|BEHAVIORAL|Baseline|Observations made at baseline before any intervention
48345089|NCT02327078|DRUG|Epacadostat|oral twice daily continuous at the protocol-defined dose
48345090|NCT02327078|DRUG|Chemotherapy|Specified dose on specified days
48345091|NCT00497159|OTHER|Placebo|Placebo TID x 90 days
48345092|NCT00497159|DRUG|Dimebon|Dimebon 20 mg TID x 90 days
48135725|NCT02013115|DRUG|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
48500943|NCT05338216|BEHAVIORAL|Traditional EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day."
48500944|NCT05338216|BEHAVIORAL|Micro-Interaction EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day."
48500945|NCT00510289|DRUG|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
48500946|NCT03557879|GENETIC|Exome sequencing|DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
48500947|NCT05483725|BIOLOGICAL|Booster dose of mRNA vaccine|Administration of SARS-CoV-2 mRNA vaccine.
48500948|NCT03205891|DRUG|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
48345093|NCT06107790|DRUG|HS022|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
48345094|NCT06107790|DRUG|Trastuzumab|"8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg"
48345095|NCT06107790|DRUG|Vinorelbine Bitartrate|"Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion.~3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first."
48345096|NCT00767793|DRUG|Placebo|One drop in each eye every 12 hours for seven days
48345097|NCT00767793|DRUG|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
48345098|NCT00767793|DRUG|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
48345099|NCT00767793|DRUG|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
48345100|NCT04260529|DRUG|CyPep-1|Intratumoral injection
48500949|NCT03205891|DRUG|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
48500950|NCT03205891|DEVICE|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
48500951|NCT06389643|PROCEDURE|Four-point scleral fixation of Akreos AO60 IOL|Intrascleral tunnels were marked at a distance of 2 mm from the corneal limbus, 6 mm apart (4 in number) after retrobulbar anesthesia. Next corneal incisions were performed. An artificial lens was then implanted into the anterior chamber. The 6-0 polypropylene suture was introduced into the anterior chamber through openings in the cornea. The next stage was to perform a sclerotomy using a 30G needle. Then the needle was passed through the hole in the haptic and 6-0 polypropylene suture was inserted into the needle hole and guided outside. The other end of the suture, passed through the opening in the haptic, was placed in the lumen of the needle and carried out through another sclerotomy and then externalised. This maneuver was repeated with another haptics as well. Correct position of the IOL in the eye was achieved by pulling on the ends of the monofilament. The ends of sutures were trimmed and cauterized. The melted tips of the sutures were then fixed subconjunctivally.
48658208|NCT01085903|BEHAVIORAL|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
48658209|NCT01085903|BEHAVIORAL|Post CPS|20 minutes following the CPS condition.
48135726|NCT04243915|OTHER|Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program|The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
48345101|NCT04260529|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
48345102|NCT03900663|DEVICE|Anthropometric measures|Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
48345103|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
48345104|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
48500952|NCT06389643|PROCEDURE|Sutureless scleral fixation of AcrySof MA60AC IOL with Yamane technique|The surgery was performed under retrobulbar anesthesia. The first step of the procedure was to mark the locations of the intrascleral tunnels (2 mm from the corneal limbus) and locate them at a distance of 180° from each other to prevent the lens from tilting in the eyeball. Openings in the cornea were done. Three-piece IOL was implanted into the anterior chamber. The first sclerotomy was performed through the conjunctiva using a 30G needle 2 mm from the limbus. One of the haptics was inserted into the needle lumen and then brought out. Same procedure was performed with another haptic at a distance of 180°. The next step was to perform cautery of the tips of the haptics, obtaining a 0.3 mm collar that prevents the risk of the haptic coming out of the tunnel and displacing the lens inside the eyeball. The tips of the haptics were finally gently inserted into the scleral canals and covered with conjunctiva.
48500953|NCT03131544|DEVICE|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
48658210|NCT01085903|BEHAVIORAL|Follow up|Follow up testing occurred at 3 months
48658211|NCT06564987|DRUG|4% Articaine with 1:200,000 epinephrine|Inferior Alveolar Nerve Block with 4% articaine
48658212|NCT06564987|DRUG|2% lidocaine with 1:100,000 epinephrine|Inferior Alveolar Nerve Block with 2% lidocaine
48658213|NCT06558604|DRUG|Obinutuzumab|1000 mg/40mL
48658214|NCT06558604|DRUG|Glofitamab|10mg/mL
48135727|NCT04243915|OTHER|Sham PNMES (introducing the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
48135728|NCT04243915|OTHER|TENS plus motor control exercise program|Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
48135729|NCT04243915|OTHER|Sham PNMES (without inserting the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
48135730|NCT04376775|OTHER|Transplant patient|Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.
48135731|NCT01681654|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
48135732|NCT01681654|BEHAVIORAL|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
48345105|NCT01425320|DRUG|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
48345106|NCT01425320|DRUG|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
48345107|NCT02293590|DRUG|Certolizumab Pegol|
48345108|NCT05822960|DEVICE|far-infrared radiation|far-infrared radiation on foot acupoints (Yinlingquan and Sanyinjiao acupoints) during dialysis
48345109|NCT01231828|DRUG|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
48345110|NCT01231828|DRUG|Lactulose|Lactulose (30-60 ml per day)
48345111|NCT02619006|OTHER|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
48345112|NCT05424952|OTHER|Conversational AI Service (Chatbot)|WhatsApp or Messenger Chatbot for COVID-19 vaccines
48345113|NCT04883697|OTHER|vitrectomy with ILM peeling and ILM flap technique|outcomes after vitrectomy with ILM peeling and ILM flap technique for macukar hole repair are assessed
48345114|NCT02091193|DIETARY_SUPPLEMENT|Krill Oil (Supplement A)|
48345115|NCT02091193|DIETARY_SUPPLEMENT|Placebo (Supplement B)|
48345116|NCT01364142|PROCEDURE|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
48345117|NCT01636167|DEVICE|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
48345118|NCT04432181|OTHER|ophthalmic examination|ophthalmic examination including; best corrected visual acuity, alternating prism cover test, retinoscopy, fundus examination, ocular vergence evaluation
48658215|NCT06558604|DRUG|Venetoclax Oral Product|10mg, 50mg and 100mg tablets
48658216|NCT06558604|DRUG|Zanubrutinib Oral Capsule|80mg capsules
48658217|NCT04605276|OTHER|No intervention|No intervention
48658218|NCT00601445|BEHAVIORAL|Amount of sleep and wake|4 groups with different patterns of sleep and wake
48658219|NCT04716725|DRUG|68Ga-PSMA-11|Given IV
48135733|NCT02798900|OTHER|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
48135734|NCT02798900|DEVICE|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
48135735|NCT05782699|DEVICE|BP monitoring during tilt testing|BP measure at various times during tilt testing
48135736|NCT03440086|DEVICE|abdominal Jackson-Pratt drain|One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
48135737|NCT01852006|DEVICE|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
48135738|NCT05179265|DRUG|recombinant human serum albumin|10 g/bottle (20%, 50 mL)
48135739|NCT05179265|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
48135740|NCT01732120|PROCEDURE|Off-clamp partial nephrectomy|
48135741|NCT04389385|BIOLOGICAL|COVID-19 Specific T Cell derived exosomes (CSTC-Exo)|The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
48135742|NCT06161259|DRUG|Leritrelvir(Ray1216)|Participants receive Leritrelvir orally.
48135743|NCT00274417|DRUG|dutasteride|
48135744|NCT01096472|DRUG|LAS41003|Once daily
48135745|NCT01096472|DRUG|LAS189961|Once daily
48135746|NCT01096472|DRUG|LAS189962|Once daily
48135747|NCT04789759|DEVICE|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
48135748|NCT04789759|PROCEDURE|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
48135749|NCT00010088|DRUG|fluorouracil|
48135750|NCT00010088|DRUG|gemcitabine hydrochloride|
48135751|NCT00010088|DRUG|leucovorin calcium|
48345119|NCT01063946|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
48345120|NCT04400227|OTHER|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
48658220|NCT04716725|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET
48135752|NCT00010088|PROCEDURE|conventional surgery|
48135753|NCT00010088|RADIATION|radiation therapy|
48135754|NCT00979459|DRUG|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
48135755|NCT00979459|DRUG|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
48135756|NCT05078775|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food.
48135757|NCT00869934|OTHER|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
48135758|NCT00869934|OTHER|Behavior Therapy|Sleep restriction and stimulus control
48135759|NCT00869934|OTHER|Cognitive Therapy|Cognitive restructuring therapy
48135760|NCT00512252|DRUG|AMD3100|
48135761|NCT00512252|DRUG|Mitoxantrone|
48135762|NCT00512252|DRUG|Etoposide|
48135763|NCT00512252|DRUG|Cytarabine|
48135764|NCT06285409|DRUG|Carbetocin|Carbetocin first bolus 10-8 M (equivalent to 100 mcg) will be added to the muscle bath to create ex-vivo environment similar to Cesarean delivery, and after 20 minutes the baths will be washed three time with physiological salt solution (PSS).
48135765|NCT06285409|DRUG|Oxytocin|Oxytocin 10-5M will be added to all strips for 2 hours to induce desensitization.
48135766|NCT06285409|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-5 M to 10-5 M
48135767|NCT06285409|DRUG|Oxytocin|Increasing concentrations of oxytocin from 10-10 M to 10-5 M
48135768|NCT06285409|DRUG|Ergonovine|Increasing concentrations of ergometrine from 10-10 M to 10-5 M
48135769|NCT06285409|DRUG|Carboprost|Increasing concentrations of carboprost from 10-10 M to 10-5 M
48135770|NCT03535272|DRUG|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
48135771|NCT03535272|DRUG|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
48135772|NCT05728684|BIOLOGICAL|CM310|CM310 Injection
48135773|NCT03637036|OTHER|Communication intervention|The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
48135774|NCT00877305|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
48135775|NCT00877305|OTHER|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
48135776|NCT03478969|DEVICE|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
48135777|NCT03478969|DEVICE|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
48135778|NCT03478969|OTHER|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
48135779|NCT05523869|DRUG|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
48135780|NCT05523869|PROCEDURE|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
48135781|NCT03709706|DRUG|Lete-cel|lete-cel will be administered to eligible participants.
48135782|NCT03709706|DRUG|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
48135783|NCT01185600|BIOLOGICAL|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
48345121|NCT01718366|DRUG|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
48345122|NCT02466204|DRUG|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
48345123|NCT02466204|DRUG|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
48345124|NCT01922986|DEVICE|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
48345125|NCT01922986|DEVICE|sham rTMS|20 minutes of sham rTMS stimulation
48345126|NCT01922986|BEHAVIORAL|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
48658221|NCT01524744|DRUG|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
48135784|NCT01185600|BIOLOGICAL|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
48135785|NCT00222924|BEHAVIORAL|weight loss/ exercise|
48135786|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
48135787|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
48135788|NCT03898505|OTHER|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
48135789|NCT02741505|DEVICE|Actigraph|Participants will be asked to wear an actigraph
48135790|NCT03658109|DRUG|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
48135791|NCT03658109|PROCEDURE|QL block|Patients will undergo a posterior QL block pre-operatively
48135792|NCT03658109|DRUG|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
48135793|NCT03658109|PROCEDURE|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
48135794|NCT00283205|BEHAVIORAL|Yoga|
48135795|NCT00188305|BEHAVIORAL|General health counselling and risk information|General health counselling and risk information
48135796|NCT00421759|DEVICE|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
48135797|NCT00336505|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
48135798|NCT00336505|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
48135799|NCT01323790|DRUG|NKTR-118|12.5 mg oral tablet once daily
48135800|NCT01323790|DRUG|NKTR-118|25 mg oral tablet once daily
48135801|NCT01323790|DRUG|Placebo|Placebo to NKTR-118
48135802|NCT05496374|DRUG|Placebo|Placebo-matching capsules will be administered orally.
48135803|NCT05496374|DRUG|SPR720 500 mg|SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
48135804|NCT05496374|DRUG|SPR720 1000 mg|SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
48135805|NCT01137916|DRUG|Imatinib|800 mg
48135806|NCT00898352|PROCEDURE|regional lymph node dissection|
48135807|NCT00898352|RADIATION|radiation therapy|
48345127|NCT02201472|DEVICE|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
48345128|NCT03297944|DRUG|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
48345129|NCT03297944|DRUG|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
48345130|NCT03297944|DRUG|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
48345131|NCT03297944|DRUG|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
48345132|NCT03297944|DRUG|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
48345133|NCT03297944|DRUG|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
48345134|NCT05194605|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
48658222|NCT01524744|DRUG|Adcortyl|triamcinolone acetonide 0.1% in orabase
48345135|NCT03598660|GENETIC|Sorcin gene expression|Sorcin gene expression Will be measured by real time PCR
48658223|NCT05142293|OTHER|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
48658224|NCT06132789|BIOLOGICAL|Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried|This vaccine（1.0ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
48345136|NCT03598660|OTHER|Annexin A3 serum mesurement|serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
48345137|NCT03964493|DRUG|TNP-2092|TNP-2092 100mg/vial
48345138|NCT03964493|DRUG|Vancomycin|Vancomycin 1g/vial
48345139|NCT04341311|DRUG|Marizomib|- Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
48345140|NCT04341311|DRUG|Panobinostat|- Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
48345141|NCT03477669|DIETARY_SUPPLEMENT|chamomile/probiotic arm|Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
48345142|NCT03477669|DIETARY_SUPPLEMENT|Placebo of chamomile/probiotic arm|Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
48345143|NCT02005510|BEHAVIORAL|Mailed in-home high-risk HPV testing kit|
48345144|NCT02005510|OTHER|Usual care|
48345145|NCT04926792|DEVICE|Leadless Pacemaker|Leadless pacemaker implantation
48345146|NCT03710694|DEVICE|DAV132|"DAV132:~* Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~* Route: Oral~* Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America."
48345147|NCT01686347|DRUG|ropivacaine|
48345148|NCT04103203|DIAGNOSTIC_TEST|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
48345149|NCT04741295|DRUG|Low molecular weight heparin|Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
48345150|NCT04429074|PROCEDURE|Minimally invasive distal pancreatectomy|Minimally invasive distal pancreatectomy
48345151|NCT01878240|PROCEDURE|EVAR without coils embolization/ Coils embolization during EVAR|
48345152|NCT01619488|DEVICE|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
48345153|NCT06332183|GENETIC|Presence of polymorphisms|Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
48345154|NCT01644981|OTHER|blood sampling|blood sampling
48345155|NCT04884997|DRUG|toripalimab|toripalimab 3mg/kg, Q2w;
48345156|NCT04884997|DRUG|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
48345157|NCT06092086|DRUG|Loratinib|Continuous daily PO dosing of lorlatinib 100mg QD.
48345158|NCT00171613|DRUG|Octreotide|
48345159|NCT02995473|DRUG|NP000888|270 µg/g topical (BID) for 24 weeks
48345160|NCT02995473|DRUG|Vehicle|Topical (BID) for 24 weeks
48345161|NCT03260283|DRUG|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
48345162|NCT03260283|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
48345163|NCT03260283|DRUG|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
48345164|NCT00668850|DRUG|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
48345165|NCT00668850|DRUG|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
48345166|NCT02910089|BEHAVIORAL|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
48345167|NCT04718402|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
48345168|NCT01041391|PROCEDURE|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
48345169|NCT05589623|OTHER|Copenhagen adduction exercise|The CAE is a progressive eccentric training program that enhances hip adduction. The fact that exercises are done with a partner and do not require special equipment makes them more useful in a team setting. The MPCA program, adapted from the original CAE, included six progressive levels for eight weeks, beginning with an assisted isometric adduction hold (level 1) and progressing incrementally to a complete CAE as the original exercise (level 6). The progression in levels will depend on a pain score ≤ 4/10 numeric rating scale (NRS) in the adductor squeeze test and post-session DOMS score ≤ 4/10 NRS.
48345170|NCT05589623|OTHER|Usual rehabilitation program|The usual rehabilitation program will include leg swings extension/flexion, leg swings abduction/adduction, standing hip circles, isometric standing hip adduction using elastic bands, stretching exercises, balance training on a wobble board, and single leg coordination exercises. Difficulty and volume are progressing incrementally.
48345171|NCT04974957|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion"
48345172|NCT05047016|OTHER|Virtual investigational product|The virtual investigational product is a predefined text (e.g. AB123F). By entering the code into the application, the virtual 'administration' of the IP is conducted.
48135808|NCT00944593|DIETARY_SUPPLEMENT|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
48135809|NCT00944593|DIETARY_SUPPLEMENT|Normal Saline|200ml Normal Saline 0.9%
48135810|NCT05768282|DRUG|Oral prednisolone (30mg/day) for 28 days|Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
48135811|NCT05371951|DEVICE|Erchonia HLS|84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
48135812|NCT00210106|DEVICE|Ablathermy|
48135813|NCT05981352|PROCEDURE|mineral trioxide aggregate pulpotomy|"* After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline.~* Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
48345173|NCT00760045|DRUG|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
48345174|NCT00760045|DRUG|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
48345175|NCT00878306|DRUG|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
48345176|NCT00878306|DRUG|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
48345177|NCT00878306|DRUG|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
48345178|NCT00878306|DRUG|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
48345179|NCT03077711|DRUG|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
48500954|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
48500955|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
48135814|NCT05981352|PROCEDURE|Dehydrated amniotic membrane pulpotomy|"* After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute.~* Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber."
48135815|NCT05981352|PROCEDURE|Hyaluronic acid pulpotomy|"* After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .~* The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol ."
48135816|NCT06379516|OTHER|Moisturising Cream (5%)|This intervention is a moisturiging cream of concentration 5% for topical application to the respective test sites.
48345180|NCT03077711|DRUG|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
48345181|NCT00043004|BIOLOGICAL|bevacizumab|
48345182|NCT00043004|DRUG|FOLFOX regimen|
48345183|NCT00043004|DRUG|fluorouracil|
48345184|NCT00043004|DRUG|leucovorin calcium|
48345185|NCT00043004|DRUG|oxaliplatin|
48345186|NCT00043004|PROCEDURE|conventional surgery|
48345187|NCT00043004|PROCEDURE|radiofrequency ablation|
48135817|NCT06379516|OTHER|Moisturising Cream (10%)|This intervention is a moisturiging cream of concentration 10% for topical application to the respective test sites.
48135818|NCT06379516|OTHER|Coconut Oil|This intervention is a 100% pure coconut oil product (Parachute Pure Coconut Oil) for topical application to the respective test sites.
48135819|NCT05999682|OTHER|apigenin|Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
48135820|NCT05999682|OTHER|sterilized water|Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
48345188|NCT02150460|PROCEDURE|One-site peribulbar injection|injection into the inferior medial orbital compartment
48500956|NCT04542616|DEVICE|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
48500957|NCT03044717|OTHER|Nutrition survey|Survey will be done prior to the initiation of the education
48135821|NCT03809949|DRUG|Fentanyl Opioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
48135822|NCT03809949|DRUG|Saline Nonopioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
48345189|NCT02150460|PROCEDURE|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
48135823|NCT06522919|BIOLOGICAL|Autologous Dendritic Cell (DC) Vaccine|Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
48135824|NCT02821299|OTHER|Laryngeal transplantation|Laryngeal transplantation
48345190|NCT00991367|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
48500958|NCT03044717|OTHER|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
47982811|NCT02107027|DEVICE|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
48135825|NCT01331499|DEVICE|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
48135826|NCT01331499|PROCEDURE|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
48135827|NCT04051333|DEVICE|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
48135828|NCT03347396|DRUG|BIVV009|Sutimlimab was administered as intravenous (IV) infusion.
48135829|NCT04015505|BEHAVIORAL|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
48135830|NCT02553889|DRUG|ISIS 416858|subcutaneous injection
48135831|NCT02553889|DRUG|Placebo|subcutaneous injection
48135832|NCT05815628|DIAGNOSTIC_TEST|DISQVER|NGS based infection diagnosis
48135833|NCT00495144|DRUG|TH-302|
48135834|NCT02408887|PROCEDURE|Total Thyroidectomy (TT)|Total removal of thyroid
48135835|NCT02408887|PROCEDURE|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
48135836|NCT02821936|PROCEDURE|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
48135837|NCT01119651|DRUG|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
48135838|NCT02574611|DRUG|Neostigmine|
48135839|NCT02574611|DRUG|Glycopyrrolate|
48135840|NCT02574611|OTHER|Saline (Placebo)|
48135841|NCT02574611|DEVICE|High Resolution Colonic Manometry|
47982812|NCT04685915|DRUG|Ibrutinib|Capsule, taken by mouth once daily
47982813|NCT04685915|DRUG|Copanlisib|Intravenous Infusion
47982814|NCT04685915|DRUG|Acalabrutinib|Capsule, taken by mouth twice daily
47982815|NCT01053728|DRUG|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
48135842|NCT00753545|DRUG|AZD2281|Tablets Oral BID
48135843|NCT00753545|DRUG|matching placebo|matching placebo bid
48135844|NCT04845386|DEVICE|TOF Cuff on arm|The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
48135845|NCT04845386|DEVICE|TOF Cuff on lower leg|The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
48135846|NCT04845386|DEVICE|TOF Scan on toe|The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
48345191|NCT00991367|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
48345192|NCT01131078|DRUG|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
48345193|NCT01131078|DRUG|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
48345194|NCT01131078|DRUG|Irinotecan|Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
48345195|NCT04927351|BEHAVIORAL|Electronic Medical Record Based Discharge Medication Order Set|New medication discharge order set including recommended opioid quantities, adjunct pain medication
48345196|NCT00118404|BEHAVIORAL|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
48345197|NCT00118404|DRUG|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
48500959|NCT03044717|OTHER|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
48345198|NCT00118404|OTHER|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
47982816|NCT01053728|DRUG|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
47982817|NCT05748977|DRUG|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
48345199|NCT00118404|BEHAVIORAL|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
48345200|NCT01287767|BEHAVIORAL|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
48345201|NCT06097741|DEVICE|MRI sequences|Ultra short / zero TE sequence on MRI being tested on healthy patients and improved by manually fine tuning the sequence
47982818|NCT01717404|DRUG|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
47982819|NCT06057168|DRUG|Elucirem|Intravenous administration
47982820|NCT06057168|DRUG|Dotarem|Intravenous administration
47982821|NCT06456151|DIAGNOSTIC_TEST|Invasive candidiasis test|The combination of acute phase marker monitoring and the T2Candida assay will be assessed.
47982822|NCT06456151|OTHER|Urine sample collection for future research|Patients will be asked to provide a urine sample for future research (urine biobank).
48500960|NCT03388489|BEHAVIORAL|Mind-Body Walking|walking, breathing, and mindfulness
47982825|NCT03479606|BEHAVIORAL|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
47982826|NCT04691284|OTHER|Blood, urine and stool sampling|Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
47982827|NCT02677142|BEHAVIORAL|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
47982828|NCT02677142|BEHAVIORAL|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
47982829|NCT02031926|DEVICE|Positive expiratory pressure|
47982830|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
47982831|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
47982832|NCT02697695|OTHER|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
47982833|NCT05442320|DEVICE|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
47982834|NCT01808053|DEVICE|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
47982835|NCT01845350|OTHER|M2 macrophage introduction|"* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages"
48345202|NCT04339725|OTHER|DNA extraction|Extraction fecal DNA and compare disease group to normal group
48345203|NCT03839056|DEVICE|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
47982836|NCT04924647|DRUG|lenalidomide and dexamethasone|lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
47982837|NCT05817188|OTHER|No intervention|No intervention was applied
47982838|NCT04083170|DRUG|Fludarabine|Given IV
47982839|NCT04083170|DRUG|Cyclophosphamide|Given IV
47982840|NCT04083170|DRUG|Thiotepa|Given IV
47982841|NCT04083170|RADIATION|Total-Body Irradiation|Undergo TBI
47982842|NCT04083170|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
47982843|NCT04083170|BIOLOGICAL|Dilanubicel|Given IV
47982844|NCT05528679|DRUG|610 100mg|100mg administered subcutaneously Q4W
47982845|NCT05528679|DRUG|610 300mg|300mg administered subcutaneously Q4W
47982846|NCT05528679|DRUG|placebo|administered subcutaneously Q4W
47982847|NCT04533347|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
47982848|NCT04533347|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
48135847|NCT04845386|DEVICE|TOF Scan on adductor pollicis|The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
48345204|NCT03839056|DEVICE|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
48345205|NCT03839056|DEVICE|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
48345206|NCT01936597|OTHER|Therapeutic and preventive strategies|Single set (control Arm)
48345207|NCT01936597|OTHER|Therapeutic and preventive strategies|Controller
48345208|NCT01936597|OTHER|Therapeutic and preventive strategies|Audio
48345209|NCT06267716|PROCEDURE|PENG block|preoperative ultrasound-guided pericapsular nerve group block
48345210|NCT06267716|PROCEDURE|IPB|preoperative ultrasound-guided iliopsoas plane block
48345211|NCT01375439|OTHER|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
48345212|NCT00187044|BIOLOGICAL|PolyEnv1 vaccine|administered subcutaneously as 10\*7 pfu in 0.8 mL
48345213|NCT00367705|DIETARY_SUPPLEMENT|VSL#3®|1-2 sachets/day per os, 6 months
48345214|NCT00367705|DIETARY_SUPPLEMENT|Placebo|1-2 sachets/day per os, 6 months
48345215|NCT05695404|PROCEDURE|Segmentectomy|Lung resection
48345216|NCT03531606|DRUG|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
48345217|NCT03531606|DRUG|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
48345218|NCT03216668|DRUG|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
48345219|NCT03216668|DRUG|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
48345220|NCT03527186|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
48345221|NCT04889690|DRUG|Danicopan|
48345222|NCT04889690|DRUG|Placebo|
48345223|NCT00126672|DRUG|Rapamycin|
48345224|NCT05919953|DEVICE|Virtual reality|Immersive virtual reality neck exercises targeting relaxation, mobility, control, and speed of movement, using the Pico G2 4K headset.
48135848|NCT04845386|DEVICE|TOF Scan on corrugator supercilii|The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
48135849|NCT03795688|OTHER|Pregnancy|Peripartum transition from pregnant to postpartum state
48345225|NCT05919953|BEHAVIORAL|Therapeutic education|"Several brochures will be given to participants. These brochures will cover the general principles of pain, the persistence of pain, tips for managing chronic non-specific pain, and the use of immersive virtual reality in the rehabilitation of chronic non-specific neck pain.~The information provided in the brochures will be discussed with the physiotherapist during the teleconsultations in order to individualize the therapeutic education."
48345226|NCT03012360|DRUG|ceftriaxone|2 g iv every 24h
48345227|NCT03012360|DRUG|ciprofloxacin|400 mg iv every 8h
48500961|NCT03880916|DRUG|Duloxetine|"1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
48135850|NCT05018156|BEHAVIORAL|Default Genetics Referral Process|Patients and their oncology providers will be notified of their eligibility for a cancer genetics referral, with an option to opt out if they are not interested in proceeding. Everyone else will be automatically referred to their local hospital's cancer genetics program for contact and scheduling. Standard genetic counseling, testing, and results disclosure will take place, including usual methods of payment and insurance coverage for testing.
48135851|NCT01440933|DRUG|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
48135852|NCT01440933|DRUG|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
48135853|NCT02424474|DEVICE|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
48135854|NCT02424474|BIOLOGICAL|Regular serum screening|
48135855|NCT01753167|DRUG|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
48135856|NCT01753167|DRUG|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
48135857|NCT01753167|DRUG|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
48135858|NCT01397006|DRUG|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
48135859|NCT00051584|DRUG|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
48135860|NCT00051584|DRUG|Gemzar (Gemcitabine)|
48135861|NCT00892541|DRUG|ER OROS paliperidone|
48135862|NCT00146172|DRUG|neratinib|HKI-272
48135863|NCT03022968|DRUG|[18F]T807 PET|Imaging with \[18F\]T807 PET
48135864|NCT03488550|BIOLOGICAL|ANX007|Single ascending dose
48135865|NCT01752699|DRUG|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
48135866|NCT01752699|DRUG|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
48135867|NCT01094106|DRUG|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
48135868|NCT01094106|DRUG|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
48135869|NCT04860505|DRUG|Doxycycline|Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
48135870|NCT04860505|DRUG|Biktarvy|Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
48345228|NCT03012360|DRUG|imipenem|1 g iv every 8h
48345229|NCT03012360|DRUG|linezolid|600 mg iv every 12h
48345230|NCT03012360|DRUG|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
48345231|NCT05832060|DEVICE|Active tDCS|Active tDCS will be delivered over TPC for a stimulation session. The anodal electrode will be placed on the left TPC, T7/TP7 position according to the 10-20 International EEG 10-20 System for electrode placement. The cathodal electrode will be placed on the right TPC, T8/TP8 position. Intensity will be set at 1 mA, the duration of stimulation will be 20 min.
48345232|NCT05832060|DEVICE|Active tRNS|Active tRNS will be delivered to bilateral TPC for a stimulation session. The electrodes will be placed on the left and right TPC, respectively T7/TP7 and T8/TP8 position, at 0.75 mA (100-500 Hz) for 20 min.
48345233|NCT05832060|DEVICE|Sham tRNS or tDCS|Sham tRNS or tDCS will be delivered over bilateral TPC for a stimulation session. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down without the participants awareness.
48345234|NCT05394207|DIETARY_SUPPLEMENT|L. casei DG® (Lactobacillus paracasei CNCM I-1572)|L. casei DG® (Lactobacillus paracasei CNCM I-1572) containing 8 billion of live cells daily + Vitamin D 4.000 U.I. daily.
48345235|NCT05394207|OTHER|placebo|The comparator product is an identical matching placebo daily + Vitamin D 4.000 U.I. daily.
48345236|NCT00002146|DRUG|Magnesium sulfate|
48345237|NCT00002146|DRUG|Foscarnet sodium|
48500962|NCT03880916|DRUG|Placebo|Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
48135871|NCT03288688|OTHER|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
48135872|NCT02940249|DIETARY_SUPPLEMENT|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
48135873|NCT02940249|DIETARY_SUPPLEMENT|Placebo|
48500963|NCT00620555|DRUG|gabapentin|Orally administered gabapentin
48135874|NCT06182475|BEHAVIORAL|EPPComm Provider Training|A curriculum will be developed to educate patients about LDKT and promote the search of potential living donors while supporting patients' values and cultural preferences. The curriculum will consist of two components: didactic education and skills-based communication. The didactic component provides evidence of the impact of patient-provider communication and LDKT process outcomes for Black and Caucasian patients. The skills-based component will build communication confidence leading discussions about LDKT. It provides instructions for the key communication skills needed to confidently assuage patients' concerns about LDKT/live donation and motivates patients to search for living donor. The following will be covered: providing LDKT information/answering questions, highlighting LDKT benefits, refuting live donation misinformation, and encouraging patients to seek living donors.
48135875|NCT06162702|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
48135876|NCT00131274|DRUG|Imatinib Mesylate (Gleevec)|
48135877|NCT05319041|DRUG|Wei's Qi Ju Gan Lu Formula|"The formulation, Wei's Qi Ju Gan Lu Formula, is initiated by the senior TCM collaborator, Prof Wei QP, is formulated to treat the dry eye patients with liver-kidney yin deficiency. The treatment regulation aims to nourish the Liver and Kidney, enrich yin deficiency, in order to promote tears production, hence treatment of Dry Eye."
48135878|NCT05319041|DRUG|Placebo|0.5g maltodextrin without any herbs medicine
48135879|NCT02330588|BEHAVIORAL|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
48135880|NCT02330588|BEHAVIORAL|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
47982849|NCT06387745|DEVICE|Hepatoscope|The Hepatoscope is a non-invasive external ultrasound imaging device, intended for general purpose pulse echo ultrasound imaging, and soft tissue elasticity imaging of the human body. In addition, the Hepatoscope provides measurements of shear wave speed and tissue stiffness, ultrasound beam attenuation and estimates of speed of sound, in internal structures of the body.
47982850|NCT00260403|PROCEDURE|Photodynamic therapy versus Transpupillary thermotherapy|
47982851|NCT03595033|DEVICE|iPad app-based intervention|The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
47982852|NCT03630003|DEVICE|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
48135881|NCT02330588|BEHAVIORAL|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
48135882|NCT02807857|PROCEDURE|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
48135883|NCT03697603|DRUG|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
48135884|NCT03697603|DRUG|Placebo|Tablets, Oral, once daily, 14 weeks
48135885|NCT01917994|BEHAVIORAL|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
48135886|NCT01917994|BEHAVIORAL|Appointment Reminders|
48135887|NCT03205566|DRUG|Raltegravir 400Mg Tab|bd for 7 days
48135888|NCT03205566|DRUG|Lamivudine 150Mg Tablet|+ Raltegravir 400Mg tablet bd for 7 days
48135889|NCT04786275|DRUG|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
48135890|NCT04786275|OTHER|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
48135891|NCT00279981|DEVICE|Diagnostic|
48135892|NCT02265354|BEHAVIORAL|Collective-Intelligence computer tailored health communication|
48135893|NCT02265354|BEHAVIORAL|Rule-based computer tailored health communication|
48135894|NCT01190852|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
48500964|NCT05039138|OTHER|NEUROMUSCULAR TRAINING EXERCISE|patients will receive neuromuscular training exercises in group II
48500965|NCT05039138|OTHER|traditional training exerises|traditional strength training exercises in group I
48500966|NCT00422578|DRUG|tadalafil|
48500967|NCT00090363|DRUG|ZD4054 15 mg|15 mg oral tablet once daily
47982853|NCT03630003|OTHER|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
48500968|NCT00090363|DRUG|Placebo|
48500969|NCT00090363|DRUG|ZD4054 10 mg|10mg oral tablet once daily
47982854|NCT06020365|OTHER|sequential fecal microbiota transplant combined with small intestinal fluid transplant|for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
48500970|NCT05907629|OTHER|MRI|Additional MRI to the CAPTIVA study at baseline and 12 months follow-up
48345238|NCT04066010|OTHER|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
48345239|NCT05064540|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
48345240|NCT05064540|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
48345241|NCT04880460|DIETARY_SUPPLEMENT|Magnesium Glycinate tablet 200mg|Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs
47982855|NCT05585528|PROCEDURE|Functional or surgical management in 1st intention|Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
48345242|NCT04880460|DIETARY_SUPPLEMENT|Placebo tablet 200mg|Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs
47982856|NCT04520932|PROCEDURE|Radiofrequency ablation|RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
47982857|NCT03487029|OTHER|Short duration|exercise Short duration high intensity training
47982858|NCT03487029|OTHER|Long duration|exercise Long duration high intensity training
47982859|NCT02890706|DEVICE|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
47982860|NCT02902965|DRUG|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
47982861|NCT02902965|DRUG|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
47982862|NCT02902965|DRUG|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter."
48135895|NCT01190852|DRUG|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
48135896|NCT01190852|DRUG|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
48345243|NCT04921657|DRUG|Rosuvastatin 10mg|
48345244|NCT03418376|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
48500971|NCT04140435|DEVICE|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
48500972|NCT00195637|DRUG|Immune Globulin|
48500973|NCT05076695|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)
48135897|NCT02852252|DRUG|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
48135898|NCT02852252|DRUG|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
48135899|NCT02438007|DRUG|Galeterone|2550 mg galeterone tablets once daily PO
48135900|NCT02438007|DRUG|Enzalutamide|160 mg enzalutamide capsules once daily PO
48135901|NCT00804219|BIOLOGICAL|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
48135902|NCT06191016|DEVICE|Vagal nerve stimulation|Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications
47982863|NCT00714454|OTHER|APS Topical Lotion|
47982864|NCT00714454|OTHER|Placebo|
47982865|NCT00820131|PROCEDURE|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
47982866|NCT00820131|PROCEDURE|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
48135903|NCT06191016|DEVICE|Sham vagal nerve stimulation|control will receive sham stimulation to vagal nerve along with prescribed medications
48135904|NCT05605925|DRUG|Artemether/lumefantrine|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
48135905|NCT05605925|DRUG|Ivermectin|IVN 600 mcg/kg/day for 3 days
48135906|NCT02684435|DRUG|Perflutren lipid microsphere|Dosing per approved package label
48135907|NCT01932632|OTHER|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
47982867|NCT01572454|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
48135908|NCT03711084|DIETARY_SUPPLEMENT|Natural high potency sweetener from leaf extract|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
48135909|NCT03711084|DIETARY_SUPPLEMENT|Glucose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
48345245|NCT03418376|OTHER|Exercise intervention|The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax\*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
48345246|NCT04281108|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
47982868|NCT01572454|DRUG|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
48345247|NCT04281108|DRUG|Placebo oral tablet|Placebo orally disintegrating tablet.
48345248|NCT04281108|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus.
48345249|NCT02732223|DIETARY_SUPPLEMENT|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
48345250|NCT02732223|DIETARY_SUPPLEMENT|Control treatment|placebo supplements
48500974|NCT05076695|DRUG|trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
47982869|NCT03898050|PROCEDURE|transcutaneous cardiac pacing|transcutaneous cardiac pacing
47982870|NCT01806324|DRUG|HL040XC|single dose
47982871|NCT01806324|DRUG|Losartan + Atorvastatin|Single dose
47982872|NCT01506427|RADIATION|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
47982873|NCT02277301|BEHAVIORAL|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
48135910|NCT03711084|DIETARY_SUPPLEMENT|Sucrose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
48135911|NCT03711084|DIETARY_SUPPLEMENT|Maltodextrin|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
48345251|NCT00707486|DEVICE|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
48500975|NCT05076695|DRUG|pyrotinib|Pyrotinib 400mg, PO daily, continuously
48500976|NCT05076695|DRUG|fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
48500977|NCT01400919|DEVICE|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
48500978|NCT02261350|DIETARY_SUPPLEMENT|Food fortification|
47982874|NCT04080817|DEVICE|Neolexon|Application (Neolexon) on Tablet. Same frequency \& intensity as in the other interventions
47982875|NCT04080817|OTHER|Speech therapy|standard logopedic speech therapy. Same frequency \& intensity as in the other interventions
47982876|NCT04080817|OTHER|Self training|Same frequency \& intensity as in the other interventions
47982877|NCT04111484|OTHER|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
47982878|NCT04111484|OTHER|Saline|Placebo
47982879|NCT00847704|DEVICE|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
48345252|NCT00707486|DEVICE|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
48345253|NCT05004389|DIAGNOSTIC_TEST|MRI|white matter integrity and brain structural connectivity metrics
48345254|NCT05004389|DIAGNOSTIC_TEST|blood draw|post-stroke serum/plasma levels of BDNF, VEGF, IL-6, IL-10, CRP, TNFalpha, MMPs, IGF-1, cGP
48345255|NCT05004389|OTHER|Clinical assessments|measures of strength, balance, and mobility
48345256|NCT02253940|DRUG|BILR 355 - Treatment A (current tablet formulation)|
48345257|NCT02253940|DRUG|BILR 355 - Treatment B (new tablet formulation)|
48345258|NCT02253940|DRUG|BILR 355 - Treatment C (new capsule formulation)|
48345259|NCT02253940|DRUG|BILR 355 - Treatment D (current tablet formulation)|
48345260|NCT02253940|DRUG|BILR 355 - Treatment E (new capsule formulation)|
48345261|NCT02253940|DRUG|Ritonavir|
47982880|NCT03779204|BEHAVIORAL|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
47982881|NCT03779204|BEHAVIORAL|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
47982882|NCT06518135|OTHER|SLNB group|After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
47982883|NCT02405845|RADIATION|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
47982884|NCT06135987|DEVICE|TLC-NOSF dressings (D'URGOSTART PLUS® BORDER, URGOSTART PLUS® PAD and URGOSTART INTERFACE®)|Clinical evaluation of the dressing in the local treatment of chronic wounds (DFU and VLU)
47982885|NCT02189746|OTHER|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
48135912|NCT03711084|DIETARY_SUPPLEMENT|Water|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
48135913|NCT05986994|OTHER|Metabolic acidosis|Metabolic acidosis at birth with umbilical cord arterial pH at birth \< 7.12
48345262|NCT05528328|DEVICE|CACIPLIQ20®|CACIPLIQ20®
48345263|NCT05528328|DRUG|Placebo (saline solution)|Placebo (saline solution) administered in identic al vials
48345264|NCT03134469|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
48135914|NCT05986994|DIAGNOSTIC_TEST|microRNA|Evaluation of microRNA levels
48135915|NCT05986994|OTHER|Hypothermia|Therapeutic induced hypothermia refers to a lowering of the central body temperature for therapeutic purposes
48345265|NCT03134469|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement
48345266|NCT05825586|DEVICE|Distilled waters based eye drops|Distilled Waters (DW)-based eyedrops
48345267|NCT04746989|DRUG|Probenecid|Probenecid claim is used as the exposure group.
48345268|NCT04746989|DRUG|Allopurinol|Allopurinol claim is used as the reference group.
48345269|NCT04259034|OTHER|diagnosis of periodontitis in oral lichen planus patients|diagnosis of periodontitis in oral lichen planus patients
48345270|NCT04259034|OTHER|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus|diagnosis of periodontitis in systemically healthy individuals without oral lichen planus
48345271|NCT05944445|DRUG|Linezolid 600 mg|Linezolid 600mg injection
48345272|NCT03930667|PROCEDURE|clips|
48345273|NCT03930667|PROCEDURE|knotting|
48345274|NCT03889990|DEVICE|IQOS|"Smoke IQOS"
48500979|NCT02261350|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|
48500980|NCT02320760|BEHAVIORAL|Physical activity on prescription|
48500981|NCT00727870|DEVICE|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
48345275|NCT04251741|DIAGNOSTIC_TEST|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
48345276|NCT04251741|OTHER|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
48345277|NCT06419790|DEVICE|EIT electrode belt, spirometry|Placing electrode belt for EIT monitoring and measuring tidal volume with spirometer
48345278|NCT06039280|DRUG|N Acetylcysteine|NAC started at 12 hr prior to procedure - (150 mg/kg/hr for 1 hr followed by 12.5 mg/Kg/hr for 4 hr, then continuous infusion of 6.25 mg/h for 48 after the procedure.
48345279|NCT06039280|DRUG|Dexamethasone|Dexamethasone 20 mg in 5 ml NS 1 hour prior to procedure and 8 mg in 5 ml NS at day 2, day 3. Placebo 5 ml NS 1 hr prior to procedure.
48345280|NCT06039280|OTHER|Placebo|The placebo will be administered in the same way as the drug in the experimental group.
48345281|NCT04479007|DEVICE|Probe based optical techniques|During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
48345282|NCT06231004|PROCEDURE|glucocorticosteroid and surgery|Take glucocorticosteroid at once in the morning and use the following course of treatment: 6 tablets/day for 7 days-- 5 tablets/day for 2 days-- 4 tablets/day for 2 days-- 3 tablets/day for 2 days-- 2 tablets/day for 2 days-- 1 tablets/day for 2 days--surgery
48345283|NCT05386875|DIAGNOSTIC_TEST|rK28|"rK28 RDT (Index): The Leishmania Ab Rapid Test is a rapid immunochromatographic test that uses the recombinant antigen rK28 to detect antibodies against Leishmania species in human serum, plasma, or whole blood samples intended for primary VL diagnosis. It is a Research Use Only product commercialized by CTK Biotech, Inc. (USA).~IT-Leish rK39 RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by Bio-Rad (France). This is currently the recommended RDT for VL diagnosis in Kenya.~Kalazar Detect rK39, RDT: Rapid immunochromatographic test for detection of antibodies against Leishmania species in human serum, plasma, or whole blood samples of utility in the VL diagnosis algorithm. It is a CE marked product commercialized by InBios (United States)."
48345284|NCT06198504|PROCEDURE|Protocol using end-tidal oxygen monitoring during preoxygenation before intubation|"According to previous studies a target of EtO2 ≥ 90% is proposed to trigger RSI and intubation. If this target is judged impossible to achieve and/or there is an imperative need to interrupt the pre-oxygenation phase, the operator is free to continue the procedure according to current recommendations.~Before the start of the inclusions, a training session on the use of the module will be organized with a reminder of the recommendations.~During the procedure, preoxygenation modalities and duration, achieved EtO2 level, conduction of the induction and intubation, minimum SpO2 and occurrence of complications will be recorded.~The procedure will stop ten minutes after completion of the orotracheal intubation procedure (defined as inflation of the balloon,clinical and capnography control)."
48345285|NCT02795065|DRUG|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
48345286|NCT02795065|DRUG|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
48345287|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
48345288|NCT01413867|PROCEDURE|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
48345289|NCT00137293|DRUG|GAP-486 (ZP-123)|
48345290|NCT00137293|DRUG|0.9% Sodium Chloride, USP|
48500982|NCT00727870|DEVICE|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
48500983|NCT00727870|DEVICE|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
48500984|NCT03134118|DRUG|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
48500985|NCT05149157|OTHER|Symptomatic malaria|This observational study will be recruiting patients who have symptomatic malaria (confirmed by presence of asexual stage parasitaemia of any Plasmodium species on blood film)
48500986|NCT06080256|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
48500987|NCT06080256|DRUG|Atorvastatin|Atorvastatin 20-40mg
47982886|NCT02189746|OTHER|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
48345291|NCT04261283|OTHER|Experimental|"The Circuit Training will be consisting of:~1. Habituation Exercises~2. Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~3. Exercises to improve Saccade Latency.~4. Adaptation Exercises~5. Substitution Exercises~6. Postural Control Exercises~7. General Conditioning Activities~8. Cawthorne-Cooksey Exercises~9. Ocular Motor Exercises~10. Gait Exercises~11. Treatment to Decrease Sensitivity to Motion in the Environment"
48345292|NCT04261283|OTHER|Active Comparator|Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
48345293|NCT00992914|PROCEDURE|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
48345294|NCT00992914|PROCEDURE|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
48345295|NCT02913833|OTHER|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
48345296|NCT01720693|PROCEDURE|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
48658225|NCT05665452|PROCEDURE|Patellar mobilization, retinacula release, deep friction message, stretch and strength|"All exercises will be performed for 30 to 45 minutes per session, 3 times per week for 4 weeks (12 sessions). Group (1): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise).~Group (2): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise). manual therapy consists from iliotibial band release, deep friction message for lateral retinacula and medial patella mobilization."
48658226|NCT05023018|DRUG|NEO100|NEO100 is a purified form of perillyl alcohol.
48345297|NCT02869685|RADIATION|radiotherapy|radiotherapy
48345298|NCT01080625|DRUG|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
48345299|NCT01080625|DRUG|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
48345300|NCT01080625|DRUG|placebo control|10ml of normal saline is administered at the time of reperfusion
48345301|NCT00995813|BIOLOGICAL|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
48135916|NCT04199338|OTHER|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
48135917|NCT06440226|BEHAVIORAL|Eye Movement Technique|Participants were instructed to move their eyes as much as possible with their eyes closed just before falling asleep. This technique aimed to mimic the Rapid Eye Movement (REM) sleep phase, which is often associated with more vivid and memorable dreams.
48345302|NCT06183268|RADIATION|Spot Delete|"The treatments plans will utilize the scripted spot delete method to remove spots from the skin rind. To ensure all relevant skin spots are removed, the SkinSpots structure will be a 0.5 cm rind extending inward from the skin contour within 5 cm of the CTV. Spots will be removed from this structure and optimization will continue. Optimization objectives will be utilized to spare the skin rind structure during treatment planning, in addition to deleting spots."
48345303|NCT03395860|DRUG|ATG|group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
48135918|NCT06440226|BEHAVIORAL|Memory Recall of Previous Night's Thoughts|Another intervention involved asking participants to recall and think about their thoughts or events from the previous night before going to sleep. This method engaged cognitive processes related to memory and reflection, potentially setting the stage for increased awareness during sleep.
48345304|NCT00054418|DIETARY_SUPPLEMENT|calcium carbonate|calcium 600 mg daily administered orally for one year
48345305|NCT00054418|DIETARY_SUPPLEMENT|vitamin D|vitamin D 400 U daily administered orally for one year
48345306|NCT00054418|DRUG|risedronate sodium|risedronate 35 mg weekly administered orally
48345307|NCT00054418|OTHER|placebo|placebo tablet weekly administered orally for one year
48345308|NCT03299452|DRUG|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
48345309|NCT03299452|DRUG|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
48345310|NCT03299452|DRUG|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
48345311|NCT05880160|OTHER|Phased withdrawal of heart failure medications|As per arm/group description
48345312|NCT00533169|DRUG|ZD6474|Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
48345313|NCT00533169|DRUG|Retinoic Acid|Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
48345314|NCT05467605|DIETARY_SUPPLEMENT|probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),|therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
48500988|NCT00662623|BEHAVIORAL|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
48500989|NCT00662623|BEHAVIORAL|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
48658227|NCT04877366|DIETARY_SUPPLEMENT|Dietary Supplement: Sprinkled Format REDUCOSE.|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
48658228|NCT04877366|OTHER|Reference control|A placebo matching to the test product will be used as control
48658229|NCT04877366|OTHER|Active comparator|Acarbose 100 mg tablet (provided in open-label format)
47982887|NCT02189746|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
48345315|NCT05467605|OTHER|maltose dissolved in distilled water|the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
47982888|NCT02189746|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
47982889|NCT00002245|DRUG|Abacavir sulfate|
47982890|NCT00002245|DRUG|Amprenavir|
48135919|NCT06440226|BEHAVIORAL|Recall of Previous Lucid Dreams|Participants were also asked to recall their lucid dreams from previous nights. This intervention seemed to activate memory and awareness related to dreaming, which significantly increased the likelihood of experiencing lucid dreams the following night.
48345316|NCT04064372|BEHAVIORAL|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
48500990|NCT02494180|DRUG|fentanyl|arm A receiving iv fentanyl
48500991|NCT02494180|DRUG|pethidine|arm B receiving iv pethidine
48658230|NCT05136495|OTHER|caffeinated coffee - decaffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
48500992|NCT02494180|DRUG|Diazepam|arm B receiving iv diazepam
48500993|NCT02494180|DRUG|Midazolam|arm A receiving iv midazolam
48500994|NCT04759053|PROCEDURE|FNB|Fine needle aspiration from the nodules
48658231|NCT04740567|BEHAVIORAL|Cognitive Training|The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (\>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.
48658232|NCT04740567|BEHAVIORAL|Goal Management Training|"Goal management training will (1) teach patients compensatory strategies such as stop techniques \[e.g., to stop and think about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies."
47982891|NCT00002245|DRUG|Lamivudine|
47982892|NCT01564797|BEHAVIORAL|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
48135920|NCT05228184|DRUG|Tirosint®-SOL|Dosage will be according to the USPI and Standard of Care.
48500995|NCT04759053|PROCEDURE|Core biopsy|Core biopsy from thyroid nodules
48500996|NCT00922272|DRUG|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
48500997|NCT00922272|DRUG|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
48500998|NCT05837013|PROCEDURE|Spinal anesthesia (with nerve block)|Spinal Anesthesia and Nerve Block: No premedication will be applied. Spinal anesthesia will be administered to the patients in this group in the sitting position with a 27G Quincke needle (15 mg hyperbaric 0.5% bupivacaine) to be entered through the L2-L3 or L3-L4 interval. If hypotension develops, it will be corrected with a crystalloid infusion and ephedrine. These patients will be administered intravenous sedation with increasing doses of midazolam to provide adequate sedation. According to Hadzic, II and IH nerve block will be performed by applying 10 mL of 0.75% ropivacaine 2 cm above and 2 cm medial to the anterior superior iliac spine.
48135921|NCT05228184|DRUG|Levothyroxine Sodium|Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
48345317|NCT04064372|BEHAVIORAL|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
48135922|NCT02349516|DRUG|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
48135923|NCT03828968|DIAGNOSTIC_TEST|bladder scan|Measurement of vesical volume by bladder scan
48135924|NCT04078607|BEHAVIORAL|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
48345318|NCT00444834|DRUG|Carvedilol|50 mg
48345319|NCT03449706|DRUG|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
48135925|NCT04078607|BEHAVIORAL|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
48345320|NCT00880100|DRUG|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
48345321|NCT01279967|DRUG|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
48345322|NCT03202368|DRUG|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
48345323|NCT02702167|DEVICE|High-frequency rTMS|10 Hz active stimulation, once daily
48345324|NCT02702167|DEVICE|Low-frequency rTMS|1 Hz active stimulation, once daily
48345325|NCT02702167|DEVICE|Sham rTMS|Sham stimulation, once daily
48345326|NCT05838794|OTHER|Mckenzie exercise for neck|The McKenzie protocol will be used to manage extension, rotation, and lateral flexion dysfunctions in patients with non-specific neck pain. An experienced physical therapist will perform the protocol 3 times a week for 6 weeks, tailoring exercises to each patient's individual needs based on limited and painful directions of movement. Exercises include retraction, extension, rotation, lateral flexion, and overpressure techniques. Patients will receive education on posture and body mechanics, and exercises will be progressed over time as the patient improves.
48345327|NCT05838794|OTHER|Stabilization exercise|Cervical and scapulothoracic stabilization exercises will be performed by an experienced physical therapist 3 times a week for 6 weeks, with each session including a warm-up, stabilization exercises, and cool-down and stretching exercises. Postural education will be provided using mirrors to find a neutral balanced position, and the cervical bracing technique with deep neck flexor activation will be used to stabilize the cervical spine. Upper extremity range of motion exercises and cervical dynamic isometric exercises with elastic resistive bands will also be performed. Scapulothoracic stabilization exercises will include specific exercises for muscles affecting scapular orientation related to neck pain, using latex bands with mild or medium tension.
48345328|NCT02745041|DRUG|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm \[FIBTEM ≤ A5 10mm\]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
48500999|NCT05837013|PROCEDURE|General anesthesia (GA)|General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
48658233|NCT06531018|DRUG|Eltrombopag 25 MG|Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
48135926|NCT03408041|OTHER|Medical file data extraction|Medical file data extraction
48135927|NCT01160588|DRUG|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
48135928|NCT03130894|OTHER|Plasma TMAO concentration|Plasma TMAO concentration
48135929|NCT00139165|DRUG|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
48135930|NCT00139165|PROCEDURE|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
48135931|NCT00527267|DRUG|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
48135932|NCT00527267|DRUG|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
48135933|NCT00507767|DRUG|dasatinib|Given PO or via PEG tube
48135934|NCT00507767|PROCEDURE|pharmacological study|Correlative studies
48135935|NCT00507767|PROCEDURE|laboratory biomarker analysis|Correlative studies
48135936|NCT04954885|PROCEDURE|Biospecimen Collection|Undergo stool sample
48345329|NCT02745041|OTHER|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm \[FIBTEM A5 ≤ 10mm\]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
48658234|NCT06531018|DRUG|Prednisolone|Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
47982893|NCT03251768|DRUG|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
48345330|NCT03966352|OTHER|Questionnaire|Enrolled subjects will complete a questionnaire to ascertain information on treatment considerations, obstacles, motivations, and outcomes encountered on their pathway to fatherhood.
48345331|NCT01730001|PROCEDURE|Early Intubation|
48345332|NCT01730001|PROCEDURE|Late intubation|
48345333|NCT03238352|DEVICE|Potassium oxalate|Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
47982894|NCT03251768|DRUG|GCSF|GCSF 5 mcg/kg/day
47982895|NCT06364540|DRUG|Ketamine|Nebulized ketamine administered at 0.75 mg/kg via BAN
47982896|NCT06364540|DRUG|Fentanyl|Nebulized fentanyl administered at 3 mcg/kg via BAN
47982897|NCT04566211|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
47982898|NCT04566211|DRUG|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
48345334|NCT03238352|DRUG|Sodium fluoride|Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
48345335|NCT03238352|OTHER|Placebo|Oral rinse containing 0% KOX and 0 ppm fluoride
48501000|NCT02011113|DRUG|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
48501001|NCT02011113|DRUG|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
48658235|NCT05849467|DRUG|89 Zr-Df-crefmirlimab|"an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours)."
48658236|NCT04035486|DRUG|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
48658237|NCT04035486|DRUG|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
48658238|NCT04035486|DRUG|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
48658239|NCT06526429|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
48658240|NCT03686657|DRUG|Metformin|1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
48658241|NCT03686657|DRUG|Val, Cel and Met XR Low|500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
48658242|NCT03686657|DRUG|Val, Cel and Met XR High|1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
47982899|NCT02441777|DEVICE|Polarization-Sensitive OFDI|OCT Imaging of the eye
47982900|NCT05601258|OTHER|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
47982901|NCT01763216|OTHER|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
48135937|NCT04954885|OTHER|Physical Performance Testing|Undergo short physical performance battery
48345336|NCT06507215|DIAGNOSTIC_TEST|Protein analysis|The investigator enrolled 149 healthy volunteers and collected peripheral blood samples for protein analysis. While 18 of these individuals with protein levels in the range of 40%-64% were predicted to be carriers by the monocyte assay, subsequent DYSF sequencing analysis in 14 of 18 detected missense variants in only four. Analysis of DNA methylation patterns at the DYSF locus showed no changes in methylation levels at CpG islands and shores between samples.
48345337|NCT00925067|PROCEDURE|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
48345338|NCT00925067|DEVICE|lightweight TiMesh|
48345339|NCT00925067|DEVICE|lightweight VyproII|
48345340|NCT00925067|DEVICE|Heavyweight Marlex|
48345341|NCT02773472|DEVICE|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
48345342|NCT02773472|DRUG|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
48345343|NCT01529450|DRUG|LDE225|800-mg (4 200-mg capsules/day) capsule
48345344|NCT04471168|DEVICE|Cryo-Auriculotherapy|3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
48345345|NCT04471168|DEVICE|Sham comparator|3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.
48345346|NCT03307018|PROCEDURE|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
48345347|NCT01600105|DRUG|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
48345348|NCT05295940|DRUG|LY3841136|Administered SC.
48501002|NCT04655430|OTHER|3-second SDF application|Dosage: 3-second 38% SDF solution application
48501003|NCT04655430|OTHER|5-second SDF application|Dosage: 5-second 38% SDF solution application
48501004|NCT04655430|OTHER|10-second SDF application|Dosage: 10-second 38% SDF solution application
48501005|NCT04655430|OTHER|15-second SDF application|Dosage: 15-second 38% SDF solution application
48501006|NCT04655430|OTHER|30-second SDF application|Dosage: 30-second 38% SDF solution application
48345349|NCT05295940|DRUG|Placebo|Administered SC.
48658243|NCT05488795|BEHAVIORAL|Team-Based Home Blood Pressure Monitoring|Implementation of best practices for hypertension control using a practice wide team-based home blood pressure monitoring intervention
47982902|NCT01763216|OTHER|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
47982903|NCT03066271|OTHER|Exercise +|Usual care
47982904|NCT03066271|OTHER|Control +|Usual care
47982905|NCT03218553|DRUG|Dexamethasone|Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
47982906|NCT03218553|DRUG|Placebos|placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
47982907|NCT05402592|DIETARY_SUPPLEMENT|Carbonhydrate rich drink|It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
47982908|NCT05402592|OTHER|Water|A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
48501007|NCT04655430|OTHER|45-second SDF application|Dosage: 45-second 38% SDF solution application
48501008|NCT04655430|OTHER|60-second SDF application|Dosage: 60-second 38% SDF solution application
48501009|NCT04655430|OTHER|120-second SDF application|Dosage: 120-second 38% SDF solution application
48501010|NCT04655430|OTHER|180-second SDF application|Dosage: 180-second 38% SDF solution application
47982909|NCT02256228|DRUG|Ropivacaine|Active Group
47982910|NCT02256228|DRUG|Saline|Placebo Comparator
47982911|NCT01964703|DRUG|Rubus occidentalis extract|
47982912|NCT01170455|DEVICE|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
47982913|NCT01170455|DEVICE|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
48345350|NCT01061645|DRUG|MOC31-PE|Immunotoxines
48501011|NCT02171494|DRUG|IVAX Warfarin|
48501012|NCT02171494|DRUG|BMS Coumadin|
48501013|NCT03636412|OTHER|Ambulation|An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
48501014|NCT06483568|BEHAVIORAL|Pathways to Happiness Intervention|Four weeks of activities including a gratitude journal, random acts of kindness, self-compassionate letter, and capitalizing on positive events activities.
48501015|NCT06483568|BEHAVIORAL|Personal Organization Activities|"Four weeks of activities including a completed tasks journal, weekly task burst, productivity letter, and talking to others about task activities."
48345351|NCT06263725|OTHER|Restricted dietary protein|Participants will be allocated to 5 week isocaloric restricted protein intake
48345352|NCT06263725|OTHER|Habitual diet|Participants will be follow their habitual, high protein intake
48345353|NCT02637167|DRUG|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
48501016|NCT04763564|DRUG|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
48658244|NCT05974800|BEHAVIORAL|Emergency department caregivers interview|The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
48658245|NCT00656695|DRUG|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
48658246|NCT00656695|DRUG|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
48135938|NCT04954885|OTHER|Physical Performance Testing|Perform 6-minute walk test
48135939|NCT04954885|OTHER|Questionnaire Administration|Complete questionnaires
48135940|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 200mg
48135941|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 300mg
48135942|NCT02646618|BEHAVIORAL|Get Social|Online-delivered weight loss intervention
48135943|NCT02646618|BEHAVIORAL|Traditional|Group-delivered weight loss intervention
48135944|NCT02646618|DEVICE|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
48135945|NCT02575924|DRUG|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
48135946|NCT02575924|DRUG|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
48135947|NCT03307044|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
48135948|NCT03307044|OTHER|Questionnaire Administration|Ancillary studies
48135949|NCT01023698|PROCEDURE|laser photocoagulation|Laser photocoagulation
48135950|NCT00569634|PROCEDURE|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always \< 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
48135951|NCT00001968|DRUG|Amprenavir|
48345354|NCT02637167|DRUG|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
48345355|NCT05265390|OTHER|Adolescents watching an informational video|In the information video; The materials used during the PCR test, how long the process will take, how the sample will be taken, why healthcare professionals wear personal protective equipment, and what adolescents should do are included.
47982914|NCT03590587|DRUG|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
48658247|NCT05510934|BEHAVIORAL|Shared-care model|A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
47982915|NCT03590587|DEVICE|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
48135952|NCT00001968|DRUG|Ritonavir|
48135953|NCT00001968|DRUG|Abacavir|
48135954|NCT00001968|DRUG|Lamivudine|
48345356|NCT01011088|OTHER||Not any artificial interventions were given
48345357|NCT00475072|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
48345358|NCT00475072|DRUG|ribavirin|1000/1200mg po daily for 48 weeks
48345359|NCT03225560|OTHER|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
48501017|NCT04763564|DRUG|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
47982916|NCT02505230|BEHAVIORAL|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
47982917|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
48135955|NCT00369902|PROCEDURE|acupuncture|
48135956|NCT04125901|OTHER|Pain Neuroscience Education and Exercise|The incorporation of the exercise in this group will be gradual, in order to decrease the education component and increase the exercise component (up to 45/60 minutes). The 1st session will be only PNE and will last approximately 45 minutes. In the 2nd session, there will be 30 minutes of PNE and the remaining 15 minutes of exercise. In the following 4th and 6th sessions, 15 minutes of each session will be used to clarify doubts and emphasize PNE concepts and strategies. The 8th session will include exercises only. In WhatsApp sessions, in addition to the video with the exercises, participants will receive activities about the PNE.
48135957|NCT04125901|OTHER|Exercise|The exercise group will perform exercises in all sessions (45 minutes of exercise in face-to-face sessions). In WhatsApp sessions, participants will receive a video with exercises to perform at home.
48135958|NCT01333800|DRUG|Beclomethasone|200 to 400 mcg per day for 6 months
48135959|NCT01333800|DRUG|Ciclesonide|80 to 160 mcg per day for 6 months
48135960|NCT00990600|OTHER|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
48135961|NCT04870775|BEHAVIORAL|Mindfulness Training Program|Mindfulness training program to reduce psychotropathological symptoms in hospital workers
48135962|NCT05701059|PROCEDURE|Cervical arthroplasty|A joint replacement procedure administered by inserting an artificial disc between the vertebrae to replace a natural spinal disc after it has been removed.
48135963|NCT05701059|DEVICE|Semi-Constrained Nuvasive Simplify|This weight-bearing implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile zirconia toughened alumina (ZTA) ceramic core will be administered by cervical arthroplasty into the specified single-level cervical region.
48135964|NCT05701059|DEVICE|Unconstrained Biomet Zimmer Mobi-C|This unconstrained, three-piece implant will be administered by cervical arthroplasty into the specified single-level cervical region.
48135965|NCT06341946|DEVICE|Endoscopic third ventriculostomy|role of endoscopic third ventriculostomy in management of malfunctioning ventriculoperitoneal shunt
48135966|NCT00683800|DRUG|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
48345360|NCT05310760|DRUG|Vit C|Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)
48345361|NCT02176980|BEHAVIORAL|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
48658248|NCT01752179|PROCEDURE|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~1. stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~2. puts the base of tape over the contralateral of sacrum with no tension.~3. attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~4. attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
48135967|NCT00683800|DRUG|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
48135968|NCT01669356|OTHER|Parenteral supplement with enteral nutrition for patients after esophagectomy|
48135969|NCT01669356|OTHER|Enteral Nutrition alone for patients after esophagectomy|
48135970|NCT04366024|OTHER|other|clinical diagnosis
48135971|NCT01218009|DRUG|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
48135972|NCT01218009|DRUG|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
48135973|NCT02310581|DRUG|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
48135974|NCT02310581|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
48135975|NCT05785728|DRUG|DB-1202|Administered I.V.
48345362|NCT02176980|BEHAVIORAL|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
48135976|NCT01229904|BEHAVIORAL|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
48345363|NCT05628129|OTHER|smartphone application service and phone reminder|smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients
48135977|NCT02199626|DEVICE|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
48345364|NCT06225804|DRUG|ABSK112|In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
48345365|NCT04572893|DRUG|danicamtiv|Myosin activator
48135978|NCT00237120|DRUG|Imatinib|
48135979|NCT00392899|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
48345366|NCT06181227|DRUG|AVD-104|An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
48345367|NCT02071641|DRUG|Sunitinib|
48345368|NCT03967847|DRUG|Ketorolac|Oral Ketorolac
48345369|NCT01063504|DRUG|teriparatide|
48345370|NCT01462968|DEVICE|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
48345371|NCT04329325|BIOLOGICAL|Blinatumomab|Please see detailed summary.
48345372|NCT04329325|DRUG|dasatinib|Please see detailed summary.
48345373|NCT04329325|DRUG|dexamethasone|Please see detailed summary.
48135980|NCT03258866|DRUG|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
48345374|NCT04329325|DRUG|methotrexate|Please see detailed summary.
48345375|NCT06444594|DRUG|TRPM8 Agonist|menthol gel 4-10%
48345376|NCT06444594|DRUG|TRPV1 Agonist|camphor gel 5-20%
48345377|NCT06444594|DRUG|TRPV4 Agonist|capsaicin gel 0.05-1%%
48345378|NCT06444594|DRUG|TRPM8, TRPV4, TRPV1 Agonists|menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
48345379|NCT06444594|OTHER|Vehicle gel|Inactive vehicle gel
47982918|NCT01594125|DRUG|Nintedanib low dose|twice daily oral dosing
47982919|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
48345380|NCT04737967|DRUG|Venlafaxine|Patients will receive will receive Venlafaxine extended release (37.5 mg) tablets once daily(Zimmerman et al., 2016)
48345381|NCT04737967|DRUG|Memantine|Patients will receive memantine (10 mg) once daily (Morel et al., 2016)
48345382|NCT03081572|DIAGNOSTIC_TEST|Platelet aggregation|Platelet aggregation
48345383|NCT01966653|DRUG|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
48345384|NCT01966653|DRUG|fosfomycin|fosfomycin 3g po single dose
48345385|NCT01877031|DEVICE|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
48345386|NCT01877031|DEVICE|Ultrasound|Standard of Care - Ultrasound guided intervention
48501018|NCT02551432|DRUG|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
47982920|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
47982921|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
47982922|NCT02630433|PROCEDURE|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
48345387|NCT04261777|DRUG|Ferrotran® (Ferumoxtran-10)|"Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care."
48345388|NCT04055025|OTHER|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
48501019|NCT06159777|DRUG|Polyethylene Glycol 3350|\*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
47982923|NCT02630433|PROCEDURE|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
48501020|NCT02569112|DEVICE|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
48501021|NCT02569112|DEVICE|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
47982924|NCT03829150|DRUG|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
47982925|NCT03829150|DRUG|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
47982926|NCT03829150|DRUG|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
47982927|NCT03829150|DRUG|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
47982928|NCT06346496|OTHER|Douyin Xinqing AI dialog bot|"Douyin Xinqing is an AI dialog bot. Users can start chatting with the Douyin companion bot by clicking on the Direct Message on the homepage of their accounts on Douyin app.~After a user sends any message to the Douyin companion bot, it first asks the user about his or her mood and guides him or her to start chatting around his or her emotions. According to the situation described by the user, the companion bot expresses empathy, asks questions to guide the user to talk, and provides suggestions at the appropriate time. Users can also record their emotions every day and look back regularly to observe changes in their inner feelings. In addition, the Douyin companion bot can also identify crisis situations such as suicide and severe mental illness and, if necessary, guide users to call the hotline to obtain professional psychological assistance."
47982929|NCT06346496|OTHER|Douyin Xinqing AI dialog bot for delayed intervention|Only the users in the waiting group had the task of waiting for the first four weeks, and they completed the three questionnaires at exactly the same point in time as those in the intervention group. Only after the first four weeks of intervention did the waiting group begin to receive the 28-day conversational intervention, and no additional questionnaires were interspersed in between.
47982930|NCT05893407|DIAGNOSTIC_TEST|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
47982931|NCT04993456|PROCEDURE|Caridac surgery|Cardiac surgery
47982932|NCT03552146|DRUG|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
47982933|NCT03552146|DRUG|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
47982934|NCT02007018|DEVICE|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
48135981|NCT03258866|DRUG|Rituximab|given with a single dose of 375mg/m2
48501022|NCT05644600|DRUG|Nintedanib|The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
48501023|NCT05644600|DRUG|AZD5055|The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
48501024|NCT00357084|DRUG|methotrexate|
48345389|NCT04055025|OTHER|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
48501025|NCT00357084|DRUG|methylprednisolone|
48501026|NCT00357084|DRUG|prednisone|
48135982|NCT02810600|OTHER|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
48501027|NCT03365752|DRUG|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
48501028|NCT03365752|DRUG|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
48501029|NCT03365752|DRUG|General Anesthetics|General anesthetics will be administered intravenously
48501030|NCT01133886|DRUG|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
48135983|NCT02408913|BIOLOGICAL|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
48135984|NCT02408913|BIOLOGICAL|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
48135985|NCT04456413|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
48658249|NCT04112992|PROCEDURE|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
48135986|NCT04456413|OTHER|Best Supportive Care|Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
48135987|NCT02441569|BEHAVIORAL|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
48345390|NCT00853619|OTHER|Service based decision support intervention|Delivering CDS via services
48345391|NCT00003549|DRUG|CMF regimen|
48345392|NCT00003549|DRUG|cyclophosphamide|
48345393|NCT00003549|DRUG|fluorouracil|
48345394|NCT00003549|DRUG|methotrexate|
48345395|NCT03552289|DEVICE|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
48345396|NCT03552289|DEVICE|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
48345397|NCT01083225|BEHAVIORAL|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
48345398|NCT01083225|BEHAVIORAL|Treatment as usual|Treatment as usual, consultations
48345399|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
48345400|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
48345401|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
48345402|NCT02428933|DRUG|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
48345403|NCT02392468|DRUG|Placebo matching BI 409306 25 mg|Film-coated tablet
48345404|NCT02392468|DRUG|Placebo matching BI 409306 50 mg|Film-coated tablet
48345405|NCT02392468|DRUG|BI 409306 25 mg|Film-coated tablet
48345406|NCT02392468|DRUG|BI 409306 50 mg|Film-coated tablet
48345407|NCT05378048|DRUG|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
48345408|NCT05378048|DRUG|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
48501031|NCT04500418|DRUG|Cenicriviroc (CVC)|Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).
48501032|NCT04500418|DRUG|Placebo|Optically identical pills without CVC.
48658250|NCT00265122|DRUG|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
48658251|NCT00265122|DRUG|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
48658252|NCT00265122|DRUG|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
48345409|NCT05658419|PROCEDURE|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
48345410|NCT03859804|PROCEDURE|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
48345411|NCT03859804|PROCEDURE|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
48345412|NCT02151799|PROCEDURE|Abdominoplasty and liposuction|
48345413|NCT04746313|BIOLOGICAL|blood test|"* to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin"
48345414|NCT06229210|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
48345418|NCT03529890|DRUG|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
48345419|NCT03529890|RADIATION|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
48345420|NCT03529890|PROCEDURE|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
48501033|NCT00918840|BIOLOGICAL|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
48501034|NCT00918840|BIOLOGICAL|Placebo|Dextrose/glucose solution
48501035|NCT00918840|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
48501036|NCT04405843|DRUG|Ivermectin Oral Product|Ivermectin oral suspension, 6 mg/mL
48135988|NCT02441569|BEHAVIORAL|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
48135989|NCT01912300|BEHAVIORAL|experimental condition: Passvice Video game; Avtive Video game; Exercise|
48135990|NCT04633148|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion for 3 days
48135991|NCT04633148|DRUG|Fludarabine (Non-IMP)|Intravenous infusion for 3 days
48135992|NCT04633148|DRUG|UniCAR02-T-pPSMA|Intravenous Infusion for 21 days
48135993|NCT04633148|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
48135994|NCT00076115|DRUG|Risperidone|
48135995|NCT00694889|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
48345421|NCT05145673|OTHER|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
48345422|NCT05145673|OTHER|Cinnamon (OGTT plus aqueous cinnamon extract)|The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
48135996|NCT00694889|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
48345423|NCT01492166|DRUG|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
48345424|NCT02511275|PROCEDURE|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
48345425|NCT00780104|DRUG|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
48345426|NCT00780104|DRUG|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
48345427|NCT01425645|OTHER|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
48135997|NCT03948295|DIETARY_SUPPLEMENT|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
48135998|NCT02436694|DRUG|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
48135999|NCT02436694|DRUG|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
48345428|NCT00552994|DEVICE|Cypher Select plus|Drug eluting stent
48345429|NCT00552994|DEVICE|Xience V stent|Drug eluting stent
48345430|NCT02027064|DRUG|Interferon-alpha|
48345431|NCT02052323|DRUG|Artesunate/mefloquine (AS/MQ)|"* artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~* mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~* primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
48345432|NCT02980549|OTHER|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
48345433|NCT02108223|DRUG|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
48658253|NCT00265122|DRUG|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
48136000|NCT02631668|DRUG|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
48136001|NCT02631668|DRUG|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
48136002|NCT02631668|DRUG|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
48136003|NCT04508777|BEHAVIORAL|Saliva-based testing|Participants will take part in a voluntary COVID-19 screening program that includes bi-weekly saliva-based testing.
48136004|NCT05600387|DRUG|Empagliflozin 10 MG|subjects in Empagliflozin group take 10mg Empagliflozin per day
48136005|NCT03041090|DEVICE|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
48136006|NCT00220649|DRUG|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
48136007|NCT02767674|DRUG|Rituximab|375 mg/m2 IVD day0
48136008|NCT02767674|DRUG|Gemcitabine|Gemcitabine 1 g/m2 IVD day 1
48345434|NCT02108223|DRUG|r-LH supplementation|recombinant luteinizing hormone
48345435|NCT02108223|DRUG|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
48136009|NCT02767674|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IVD day1
48136010|NCT02767674|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IVD d1
48345436|NCT02757404|DRUG|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
48345437|NCT02757404|DRUG|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
48658254|NCT06637189|DRUG|Ganirelix|Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
47982935|NCT02007018|OTHER|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending \> 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
47982936|NCT00106392|DRUG|Tacrolimus|oral
47982937|NCT00106392|DRUG|Placebo|oral
47982938|NCT00820157|PROCEDURE|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
47982939|NCT00820157|PROCEDURE|TACE|TACE alone or TACE followed by downstage resection for MNHCC
47982940|NCT03684954|OTHER|Prf|Take 10 cc blood from patient and gain prf
47982941|NCT02944474|DRUG|Lucerastat|Capsule for oral administration containing lucerastat
47982942|NCT02944474|DRUG|Placebo|Placebo capsules matching lucerastat capsules
47982943|NCT00252954|DRUG|Levetiracetam|Tablets 2000-3000 mg per day
47982944|NCT01379547|BEHAVIORAL|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
47982945|NCT01379547|BEHAVIORAL|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
47982946|NCT01378351|OTHER|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
47982947|NCT04326907|PROCEDURE|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
47982948|NCT02447549|RADIATION|WBRT|One RT plan with whole bladder treated to standard dose.
47982949|NCT02447549|RADIATION|SART|Three plans (small, medium \& large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
47982950|NCT02447549|RADIATION|DART|Three plans (small, medium \& large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
47982951|NCT00996216|DRUG|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
47982952|NCT00996216|DRUG|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
47982953|NCT02924779|OTHER|No intervention|Retrospective observational study
47982954|NCT02821182|RADIATION|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated \>48h and \<96h."
48136011|NCT02767674|DRUG|Epirubicin Injectable Product|Epirubicin 35 mg/m2 IVD d1
48136012|NCT02767674|DRUG|Vindesine|Vindesine 2 mg IVP d1
48136013|NCT02767674|DRUG|Prednisone|Prednisone 40mg/m2 PO d1-5
48136014|NCT03113409|DRUG|Buprenorphine|Buprenorphine will be administered daily
48136015|NCT03113409|DRUG|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
48136016|NCT03113409|DRUG|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
48136017|NCT02490956|BIOLOGICAL|Verorab® (PVRV; Purified Vero Cell Vaccine)|"* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
48345438|NCT02757404|DRUG|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
48345439|NCT00424034|DRUG|GSK1325760A|
48345440|NCT00502398|PROCEDURE|Blood test|
48345441|NCT05601050|OTHER|There is no intervention|There is no intervention
48501037|NCT04405843|DRUG|Placebo|Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient
48501038|NCT04445363|DRUG|Jaktinib hydrochloride cream|Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks
48501039|NCT04445363|DRUG|Placebo|Dose extension: Placebo
47982955|NCT04425707|DRUG|Ivermectin|use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt
48136018|NCT06207981|DRUG|induction chemotherapy (mDCF)|"Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)"
48345442|NCT03612544|OTHER|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
47982956|NCT04766125|BEHAVIORAL|Adverse event information|All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon
47982957|NCT04822064|DRUG|Intranasal dexmedetomidine and ketamine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
48136019|NCT06207981|DRUG|Concomitant chemotherapy (Capecitabin + Mitomycin-C)|Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given
48658255|NCT06637189|DRUG|Medroxyprogesterone Acetate 10 MG|Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
48345443|NCT03612544|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
48136020|NCT06207981|RADIATION|radiotherapy|"Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes"
48136021|NCT04070963|OTHER|HbA1C|To take additional blood test of HbA1C once patient consented to the study
48136022|NCT03937765|PROCEDURE|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
48136023|NCT03875066|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
48345444|NCT00432640|PROCEDURE|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
48345445|NCT00432640|PROCEDURE|Surgical staging|Surgical staging
48658256|NCT00480727|PROCEDURE|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
48658257|NCT00480727|PROCEDURE|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
47982958|NCT04822064|DRUG|Oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
47982959|NCT01220622|DRUG|Nimodipine|Administration of nimodipine 30mg tid for 6 months
47982960|NCT01220622|DRUG|Placebo|Administration of placebo 30mg tid for 6 months
47982961|NCT00939328|BIOLOGICAL|rituximab|
47982962|NCT00939328|DRUG|bendamustine hydrochloride|
47982963|NCT02988505|OTHER|Standard care|
47982964|NCT06339723|BEHAVIORAL|Pecha Kucha|Pecha Kucha Method training was given
47982965|NCT01876342|PROCEDURE|open repair|2-0 sutures
47982966|NCT01876342|PROCEDURE|endoscopic TEP repair|mesh
47982967|NCT00296894|DRUG|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
47982968|NCT00296894|DRUG|Placebo|Placebo
47982969|NCT06037291|DIETARY_SUPPLEMENT|Coriander Seed Oil|The study foresees the intake of 1 capsule per day during 56 days
47982970|NCT06037291|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
47982971|NCT03626922|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
47982972|NCT03626922|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
48345446|NCT04314609|DEVICE|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
47982973|NCT03626922|DRUG|Oxaliplatin|"Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion."
48136024|NCT03875066|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
48345447|NCT03058302|BEHAVIORAL|CETA (Common Elements Treatment Approach)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
47982974|NCT03626922|DRUG|Dexamethasone|Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.
47982975|NCT03626922|DIETARY_SUPPLEMENT|Folic Acid|Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.
47982976|NCT03626922|DIETARY_SUPPLEMENT|Vitamin B-12|1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
47982977|NCT01702454|BIOLOGICAL|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
47982978|NCT01057550|PROCEDURE|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
47982979|NCT01057550|PROCEDURE|TVT|Standard TVT as described by Ulmsten 1996
47982980|NCT01057550|PROCEDURE|Pelvicol|retropubic mid urethral sling made from Pelvicol
47982981|NCT01259323|BIOLOGICAL|REGN668|Dose 1: REGN668 or placebo
47982982|NCT01259323|BIOLOGICAL|REGN668|Dose 2: REGN668 or placebo
47982983|NCT01259323|BIOLOGICAL|REGN668|Dose 3: REGN668 or placebo
47982984|NCT01269060|PROCEDURE|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
48501040|NCT03058588|GENETIC|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
47982985|NCT04742933|OTHER|There is no intervention in this observational trial|There is no intervention in this observational trial
47982986|NCT06040554|OTHER|Elastic Band Resistance Exercises|8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
47982987|NCT03824327|PROCEDURE|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
47982988|NCT03824327|DRUG|Papaverine Hydrochloride|Given IV
47982989|NCT03824327|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
47982990|NCT00627003|DRUG|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
47982991|NCT00627003|OTHER|Placebo|Placebo oral tablets administered daily for 5 weeks
47982992|NCT02589951|OTHER|admission to non-psychiatric service|
47982993|NCT05187793|DRUG|Olokizumab|Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
47982994|NCT05187793|DRUG|Standard therapy|"Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV"
47982995|NCT01516424|DRUG|Blonanserin|Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
47982996|NCT01516424|DRUG|Risperidone|Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
47982997|NCT04576832|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT) web-course|Pre-recorded weekly sessions for 4 weeks. Each session will consist of approximately 2 hours of video content per week and weekly mindfulness exercises. This video will include MBAT program lectures, pre-recorded testimony from military leaders, and teaching materials. The course will also include 15-min daily mindfulness practice drills.
48658258|NCT06223269|DRUG|Skin Xenotransplant|"realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area."
48658259|NCT06223269|PROCEDURE|Autograft(ing)|Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
47982998|NCT02012998|BIOLOGICAL|HBVAXPRO 5µg|0.5mL intramuscular injection
47982999|NCT05111158|DIAGNOSTIC_TEST|mfERG|mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
47983000|NCT02275650|RADIATION|nbUVB|2 SED nbUVB exposure will be given every other week
48658260|NCT05003856|OTHER|Quality-of-Life Assessment|Ancillary studies
48658261|NCT05003856|PROCEDURE|Radiofrequency Ablation|Undergo RFA
48501041|NCT04778553|DIAGNOSTIC_TEST|iMOST X-1 Hematology Analyzer|The X-1 is a point of care automated hematology analyzer
47983001|NCT01414907|BEHAVIORAL|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
47983002|NCT00138476|DRUG|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
48501042|NCT04451681|OTHER|Cardiopulmonary exercise test|Data such as oxygen consumption, cardiac parameters and speed of the patient are analyzed numerically on the treadmill in the KPET; Objective performance values such as maximum oxygen use (VO2max), maximum heart rate, respiratory capacity, and maximum rate will be obtained.
48345448|NCT01722357|BEHAVIORAL|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
48345449|NCT01722357|BEHAVIORAL|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
48345450|NCT04809025|DEVICE|endoscopy|gastroscope
48345451|NCT04809025|PROCEDURE|Surgery|radical gastrectomy
48345452|NCT04672902|PROCEDURE|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
48345453|NCT03278444|OTHER|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
48345454|NCT03278444|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
48345455|NCT03278444|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
48345456|NCT02373566|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
48345457|NCT02868255|PROCEDURE|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
48345458|NCT05942170|DRUG|ICG/ blue dye|The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
48501043|NCT04458792|OTHER|Paraffin tissue samples|Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue
48501044|NCT04458792|OTHER|blood sample|MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
48501045|NCT05912439|BEHAVIORAL|SidekickHealth|Usage of mobile application called SidekickHealth.
47983003|NCT00138476|BIOLOGICAL|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
47983004|NCT01606345|DRUG|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
47983005|NCT02611778|BIOLOGICAL|ranibizumab|
47983006|NCT05855850|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H4-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
47983007|NCT05855850|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H7-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
48345459|NCT01885949|DRUG|Tivozanib|Oral
48345460|NCT01885949|DRUG|Enzalutamide|oral
48345461|NCT02225236|BEHAVIORAL|Classroom Intervention|
48501046|NCT02895607|PROCEDURE|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
48658262|NCT05581511|OTHER|Evaluation of the natural history of cutaneous neurofibromas|Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
48345462|NCT02572804|DEVICE|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
48345463|NCT02572804|DEVICE|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
48345464|NCT02985684|DEVICE|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
48345465|NCT04573192|DRUG|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
48658263|NCT05773469|OTHER|Exercise|Ski traverse of Greenland polar Icecap
48658264|NCT05773469|OTHER|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
47983008|NCT00696176|DRUG|STAT 3 DECOY|single administration to a head and neck tumor
47983009|NCT00132145|BEHAVIORAL|Vascular Management Program|
47983010|NCT00132145|BEHAVIORAL|Clinical Care Coordinators|
47983011|NCT00132145|BEHAVIORAL|Web-based Vascular Tracker for Patient and Physician|
47983012|NCT00132145|BEHAVIORAL|Automated Telephone Reminder System|
47983013|NCT02567942|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation
47983014|NCT02567942|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
47983015|NCT05235074|BIOLOGICAL|OH2 injection|OH2: Oncolytic Type 2 Herpes Simplex Virus
47983016|NCT05340608|OTHER|Smart, non-invasive shirt - Physiological parameters|Observation Group One and Control Group - Participants in these groups will be asked to wear a smart, non-invasive shirt while watching two different five-minute videos. One video will show relaxing images and will emit relaxing music (relaxing video). The second video will present impressive human body deformities accompanied by anxious music (disturbing video). Both videos will be presented with the participant in a sitting position. The duration of the entire session will be approximately 15 minutes. For the whole duration of the session, the smart shirt will collect data on participants' physiological parameters (electrocardiogram, heart rate, heart rate variability, respiration rate, minute ventilation, and body movement). Collected data will be used to develop an ad-hoc algorithm to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
48345466|NCT04573192|DRUG|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
48345467|NCT01826448|DRUG|PLX3397|
48345468|NCT01826448|DRUG|vemurafenib|
48501047|NCT00296231|OTHER|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
47983017|NCT05340608|OTHER|Smart, non-invasive shirt - Relation with challenging behaviors|Observation Group Two - Each participant in this group will be asked to wear the smart, non-invasive shirt for seven consecutive days during waking hours, performing his usual daily activities. During the same seven days, the caregivers who care for the participant will be asked to accurately report the participant's status in a behavioral diary. Each evening, the data collected by the smart shirt will be uploaded to an online cloud along with the behavioral diary of the day. Collected data will be used to develop an ad-hoc algorithm able to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
48136025|NCT05011955|BEHAVIORAL|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
48501048|NCT02427035|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
48501049|NCT02427035|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
48136026|NCT05011955|BEHAVIORAL|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
48136027|NCT05011955|OTHER|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
48136028|NCT02325466|DRUG|Aspirin|Aspirin 81mg
48136029|NCT02325466|DRUG|Ticagrelor|ticagrelor 90 mg
48136030|NCT02325466|DRUG|Aspirin Placebo|
48136031|NCT02325466|DRUG|Ticagrelor Placebo|
48136032|NCT01589341|OTHER|laboratory biomarker analysis|Correlative studies
48345469|NCT05856279|PROCEDURE|mulligan SNAG and mulligan lion position|manual therapy techniques for lumbar spine
48345470|NCT02748525|OTHER|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
48345471|NCT02748525|BIOLOGICAL|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
48345472|NCT04414488|PROCEDURE|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml\*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
48345473|NCT04223206|DIETARY_SUPPLEMENT|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
48345474|NCT02361489|DEVICE|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
48345475|NCT03362203|OTHER|Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
48501050|NCT06506214|OTHER|Questionnaires|"Responses to questionnaires:~* Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Medical Adherence Self-Report Inventory (MASRI)~* Morisky Medication Adherence Scale (MMAS4)~* Visual analog scale (VAS) on the perception of disease control~* Belief on Medicine Questionnaire (BMQ)~* Care patient Feedback measure~* Hospital Anxiety and Depression Scale (HAD)~* Dermatology Life Quality Index (DLQI)"
48501051|NCT02202070|DRUG|onabotulinumtoxinA|
48501052|NCT03560986|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
48136033|NCT01948024|DRUG|SAPHRIS|10 mg BID sublingual tablet
48136034|NCT01948024|DRUG|Asenapine|10 mg BID sublingual tablet
48136035|NCT05028933|DRUG|EPCAM CAR-T|Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
48136036|NCT00023400|DRUG|Nelfinavir|
48501053|NCT03560986|DRUG|Placebo|Glass vials with matching placebo.
48501054|NCT03665441|DRUG|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
48501055|NCT03665441|DRUG|Gemcitabine plus Abraxane|gemcitabine, Abraxane
48136037|NCT00023400|DRUG|Rifabutin|
48136038|NCT04436016|DRUG|Ivabradine|Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.
48136039|NCT04436016|DRUG|Placebo|Mannitol will be encapsulated for adequate blinding.
48501056|NCT03665441|DRUG|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
48501057|NCT00732576|DIETARY_SUPPLEMENT|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
48345476|NCT03362203|OTHER|Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
48345477|NCT06346704|OTHER|Digital HealthTechnology|Subject will wear the Syde® for 1 month every 6 months
48136040|NCT02915432|BIOLOGICAL|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
48136041|NCT02915432|BIOLOGICAL|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
48136042|NCT02915432|BIOLOGICAL|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
48345478|NCT04741087|DRUG|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
48345479|NCT04741087|DRUG|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
48345480|NCT02382289|PROCEDURE|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
48345481|NCT01909986|DRUG|[14C]ONO-4053|Single dose \[14C\]ONO-4053
48345482|NCT00920946|DRUG|Dimebon|20 mg Dimebon orally TID
48345483|NCT00920946|OTHER|Placebo|Orally TID
48658265|NCT06044571|OTHER|Prescriptive|Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
48658266|NCT06044571|BEHAVIORAL|Behavioral|Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
48345484|NCT00938093|BEHAVIORAL|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
48658267|NCT03558126|DEVICE|silicone tube|
47983018|NCT05340608|OTHER|Smart, non-invasive shirt - Proof of Concept|Proof of Concept - The participant with autism spectrum disorder enrolled in the proof-of-concept phase of this study will wear the smart, non-invasive shirt for seven days during all hours of attendance at the special school. At the end of the seven days, the healthcare professional and teacher who interacted with the developed system at the special school will participate in a focus group to analyze their experiences and opinions related to the system use.
47983019|NCT04078061|BEHAVIORAL|MABA|Adaptive, modular, behavioral intervention.
48345485|NCT00938093|BEHAVIORAL|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
47983020|NCT04078061|BEHAVIORAL|EIBI|Early Intensive Behavioral Intervention
48345486|NCT00345514|BEHAVIORAL|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
48345487|NCT00345514|BEHAVIORAL|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
48345488|NCT02095990|DRUG|Hydroquinone|
48345489|NCT02095990|DRUG|Placebo|
48345490|NCT00755391|BEHAVIORAL|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
48345491|NCT00755391|BEHAVIORAL|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
48345492|NCT03885609|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
48345493|NCT03885609|DEVICE|powered toothbrush|regular powered toothbrush with no RF
48345494|NCT04894227|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell）|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48345495|NCT03975049|RADIATION|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
48345496|NCT03975049|DRUG|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
48345497|NCT03975049|DRUG|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
48345498|NCT04930172|DEVICE|Steerable introducers|endografts via total transfemoral approach for visceral vessels cannulation
48658268|NCT00375232|DRUG|Administration of montelukast or placebo|
48136043|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
48136044|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
48345499|NCT03044080|DRUG|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
48345500|NCT03044080|DRUG|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
48345501|NCT05724381|DIAGNOSTIC_TEST|auramine phenol staining|The samples will be divided into 2 parts. The 1st part will be subjected to a direct wet saline smear, iodine smear, and concentration techniques. The 2nd part will be used to perform thin smears of the fecal concentrates and air-dried on 2 different slides. The first slide will be stained with Kinyoun's acid-fast stain and examined with the conventional light microscope and the second will be stained with auramine-phenol stain and examined with the fluorescent microscope.
48345502|NCT06239285|DEVICE|Brief Violence Intervention VR (BVI-VR)|BVI-VR is being developed as a hospital-based brief gun violence intervention program founded on the principles of positive psychology, motivational goal setting (via gameplay), psychoeducation, cognitive-behavioral therapy, and dialectical behavioral therapy. All steps of the BVI-VR emphasize being in control of making positive choices, and how to locate and leverage opportunities within their communities to improve their well-being. BVI-VR empowers patients to be the driver of their well-being
48345503|NCT06239285|OTHER|Treatment as Usual (TAU)|group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area. These include organizations that provide mental health counseling, mentorship services, career development programs, organized community activities and sports, educational support, financial support, substance abuse programs, and resource assistance (e.g., food, housing, etc.).
48345504|NCT02404584|GENETIC|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
48345505|NCT02404584|BIOLOGICAL|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.\*~\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
48501058|NCT00732576|DIETARY_SUPPLEMENT|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
48501059|NCT00732576|DIETARY_SUPPLEMENT|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
48501060|NCT04466241|DRUG|Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|2 tablets morning and evening from Day 1 to Day 10
48658269|NCT05371327|BEHAVIORAL|Public deliberation|Public deliberation is a method for engaging the public in collective decision-making. Its goal is to facilitate debate and discussion that: 1) fosters the formation of reasonable and informed opinions, 2) permits participants to revise their perspectives and positions in light of new information and dialogue with others, and 3) encourages participants to consider not only their own preferences but also the greater goal of a policy or resolution that is justifiable for all persons affected by the issue under debate.
48658270|NCT05651711|DRUG|Rocatinlimab|Rocatinlimab will be administered through a subcutaneous (SC) injection.
48501061|NCT04466241|DRUG|Telmisartan 40Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
48501062|NCT04466241|DRUG|Atorvastatin 20 Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
48501063|NCT02755077|PROCEDURE|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
48501064|NCT05227911|PROCEDURE|Abdominal Surgery|Abdominal surgery (laparotomy or laparoscopy) ,which includes proper inspection of the abdominal cavity.
48501065|NCT01760525|DRUG|CGM097|Patients treated with CGM097
48501066|NCT03516110|OTHER|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
48501067|NCT05749250|DEVICE|Acoustic cavitation of ultrasound enhancing agents|Cavitation therapy
48658271|NCT05651711|OTHER|Placebo|The matching placebo will be administered through a SC injection.
48658272|NCT02866747|RADIATION|Hypofractionated stereotactic radiation therapy|
48658273|NCT02866747|DRUG|Durvalumab|
48136045|NCT06407804|OTHER|Thrower's Ten Exercise Program|No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 2 sets for 10 repetitions with 1 minute rest between sets.
48136046|NCT06407804|OTHER|Routine physical therapy.|"In this, the exercises will be performed in 2 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min Per Session)"
48136047|NCT04806100|DEVICE|Malleo-Lok|The Malleo-Lok is a novel, low-profile carbon fiber device with two laterally positioned struts aligned in the sagittal plane.
48501068|NCT03261986|RADIATION|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
48501069|NCT03261986|PROCEDURE|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
48345506|NCT04882358|DEVICE|ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
47983021|NCT05230225|BEHAVIORAL|Physician Notification Letter|Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
48136048|NCT06030817|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
48136049|NCT04441775|OTHER|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
48345507|NCT04882358|DRUG|SGLT2 inhibitor|treatment with a standard dose of SGLT-2 inhibitor
48345508|NCT02030249|BEHAVIORAL|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
48345509|NCT02030249|BEHAVIORAL|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
48345510|NCT02030249|BEHAVIORAL|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
48345511|NCT00949806|DRUG|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
48345512|NCT03795636|OTHER|Garlic extract|A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water
48345513|NCT03795636|OTHER|NaOCl (COLTENE®)|Sodium hypochlorite
48345514|NCT04044313|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
48345515|NCT04044313|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48345516|NCT04044313|DRUG|Toripalimab|240mg intravenously every 3 weeks
48345517|NCT04031924|OTHER|Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity|All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
48345518|NCT02707601|DRUG|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
47983022|NCT05248022|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
47983023|NCT05248022|DRUG|Programmed Cell Death Protein 1 Inhibitor|Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
47983024|NCT05575011|DRUG|BIIB115|Administered as specified in the treatment arm
47983025|NCT05575011|DRUG|BIIB115-Matching Placebo|Administered as specified in the treatment arm
47983026|NCT02352714|DRUG|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
47983027|NCT02352714|DRUG|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
47983028|NCT01334814|DEVICE|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
47983029|NCT00192829|PROCEDURE|Blood sample withdrawal|
47983030|NCT00036504|DRUG|Insulin Lispro low mixture|
47983031|NCT02260050|DRUG|WAL 801 CL dry syrup new formulation|
47983032|NCT02260050|DRUG|WAL 801 CL dry syrup conventional formulation|
48345519|NCT02707601|DRUG|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
48345520|NCT02707601|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
48266807|NCT04773405|DRUG|a 1: 1 mixture of 2% lidocaine with 5ug/ml epinephrine and 0.5% levobupivacaine|"This study adopts a Modified Narayana rule (MNR), a sequential up-and-down pharmacodynamics method (UDM) to estimate the minimum effective local anesthetic volume of 90% (MELAV90) of cases of the aforementioned local anaesthetic (LA) mixture, in order to produce the surgical anaesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries. Based on the principal investigator's clinical experience, the initial volume of 21ml will be used. Depending on the success or failure of the SeTB, which is defined as the readiness for surgery at 30 minutes after the block, the volume for the next patient will be adjusted up or down by 3ml (1ml for each trunk of brachial plexus located above the clavicle). The upper dose limit of the study to minimize the potential for local anaesthetic systemic toxicity will be 30ml and the lower dose limit will be 12ml, which will be of no clinical importance."
48501070|NCT01840865|DEVICE|brain stimulation|oscillating direct current brain stimulation
48501071|NCT01840865|DEVICE|no stimulation|sham Stimulation
48345521|NCT03015623|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
48345522|NCT03015623|DEVICE|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
48345523|NCT02756845|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10\^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10\^8 PFU/mL (or up to 4.0 mL of 10\^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
48501072|NCT06324851|DRUG|Drospirenone / Estetrol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Drospirenone/Estetrol at any time of the menstrual cycle
48501073|NCT06324851|DRUG|Nomegestrol Acetate / Estradiol|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol at any time of the menstrual cycle
48501074|NCT06324851|DRUG|Ethinylestradiol / Dienogest|Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
48501075|NCT05608980|DRUG|0.01% hypochlorous acid|once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
48501076|NCT05608980|DRUG|Placebo|once daily eyelid wipes for 2 weeks
48501077|NCT05280730|OTHER|No intervention|There is no intervention
48501078|NCT02140411|DRUG|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
48501079|NCT06388759|DRUG|TQ05105 Tablets|TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor
48501080|NCT02808689|BEHAVIORAL|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
48501081|NCT02808689|OTHER|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
48658274|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 30/30|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 30 second on and 30 second off, for 1 hour, in-person.
47983033|NCT05439512|PROCEDURE|transantral orbital floor reconstruction by titanium mesh|reconstruction of orbital floor fracture by patient specific titanium mesh
47983034|NCT04676646|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
47983035|NCT04676646|DRUG|Placebo|Placebo comparator
47983036|NCT04676646|OTHER|Spironolactone|"Background intervention.~During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained."
47983037|NCT04617444|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
47983038|NCT04617444|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
47983039|NCT05560984|COMBINATION_PRODUCT|cervical internal os plasty|A long Allis forceps will be passed through the uterine incision and used to grasp the anterior lip of the cervix, pulling the cervix upwards into the uterine cavity. An assistant sometimes needs to elevate the cervix upwards from the vaginal aspect. The anterior lip of the cervix will be sutured to the anterior wall of the lower uterine segment using two or three simple interrupted absorbable stitches (Vicryl or Vicryl rapid no. 0). This aids to compress the bleeding sites of the placental bed and support the very thin lower uterine segment. If the placenta was implanted posteriorly and the bleeding areas will be mainly from the posterior wall of the uterus, the same procedure could be repeated using the posterior lip of the cervix. A Hegar dilator (size 12) will be inserted in a retrograde manner from the abdominal aspect toensure patency of the cervical canal .
47983040|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
47983041|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
47983042|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
47983043|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
47983044|NCT04496544|OTHER|Retrospective data collection|No intervention; retrospective data collection
47983045|NCT02511366|OTHER|Ileal infusion of casein|Intraileal infusion of casein
47983046|NCT02511366|OTHER|Ileal infusion of tap water|Intraileal infusion of tap water
48345524|NCT03472040|DRUG|BCX7353|BCX7353 mg oral capsules administered once daily
47983047|NCT01397032|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
47983048|NCT01397032|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
48136050|NCT05935969|PROCEDURE|ERCP(Endoscopic retrograde choangiopancreatography), ETGBD(endoscopic transpapillary gallbladder drainage)|For transpapillary gallbladder drainage, biliary cannulation was performed with a duodenoscope (JF-260V or TJF-260V; Olympus Optical). After successful deep cannulation of the CBD, we checked the cholangiogram, performed endoscopic sphincterotomy, and removed the CBD stone using a memory basket and/or retrieval balloon. Cholangiography was then performed again to locate the cystic duct orifice, and a guide wire (Jagwire; Boston Scientific, Marlborough, Massachusetts, USA or Visiglide; Olympus, Tokyo, Japan) was inserted into the gallbladder with different types of catheters (standard catheter, pull-sphincterotome, or rotating sphincterotome) under fluoroscopic guidance. After placement of the guide wire into the gallbladder, contrast dye was injected to confirm good entry into the gallbladder. Once the gallbladder was selected and the guidewire was coiled in the GB, a 7Fr 12-15cm double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Winston-Salem, NC) was inserted into the GB.
48136051|NCT01023542|DRUG|delayed, low-dose CNI|immunosuppression
48136052|NCT01023542|DRUG|BU-CNI|Immunosuppression
48136053|NCT01023542|DRUG|BU-Everolimus|Immunosuppression
48658275|NCT06381102|DEVICE|transcutaneous auricular vagus nerve stimulation 10/10|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a 10 second on and 10 second off, for 1 hour, in-person.
48658276|NCT03440411|DRUG|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
48658277|NCT03440411|DRUG|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
48658278|NCT03440411|DRUG|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
47983049|NCT02747901|OTHER|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
47983050|NCT02747901|OTHER|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
47983051|NCT06405061|DRUG|Adebrelimab|Adebrelimab: 1200 mg, IV, q3w
48136054|NCT03960957|BIOLOGICAL|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
48136055|NCT03960957|OTHER|Placebo|Treatment of glabellar facial lines with placebo
48136056|NCT03039296|PROCEDURE|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
48136057|NCT01333449|DRUG|Decitabine|20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
48658279|NCT05383482|DRUG|Afuresertib|Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD
47983052|NCT02528656|DEVICE|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
47983053|NCT02528656|DEVICE|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
47983054|NCT06506604|DEVICE|CLEVER|"CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes."
47983055|NCT05543525|OTHER|Echocardiography|Transthoracic echocardiography
47983056|NCT05543525|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing
48658280|NCT05383482|DRUG|Nab paclitaxel|Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W
48136058|NCT04334005|DIETARY_SUPPLEMENT|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
48136059|NCT02021396|PROCEDURE|Embolization|this arm of the study was interventional (splenic artery embolization)
48345525|NCT01791465|DRUG|extended-release exenatide|Single arm study - 2mg Bydureon every 7 days x 16 weeks
48345526|NCT06152692|DEVICE|SHAM Continuous positive airway pressure|Placebo treatment
48345527|NCT06152692|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group
48345528|NCT03304652|DRUG|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
48345529|NCT03304652|OTHER|Natural Sleep|Natural Sleep without medication
48345530|NCT04818489|DRUG|Colchicine 0.5 MG|colchicine 0.5 mg (2 tablets: 1 mg) twice per day as a loading dose, followed by one tablet 0.5 twice per day for three weeks in addition to the standard protocol
48658281|NCT05383482|DRUG|Docetaxel|Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W
48658282|NCT05383482|DRUG|Sintilimab|Sintilimab 200 mg Q3W
48658283|NCT03407950|BEHAVIORAL|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
48345531|NCT04818489|OTHER|the standard protocol only|the local standard protocol for COVID19
48345532|NCT01763112|DEVICE|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
48136060|NCT00084435|DRUG|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
48345533|NCT05137275|BIOLOGICAL|Anti-5T4 CAR-raNK Cells|In the 3+3 dose escalation study, the minimum initial dose is 3.0×10\^9 cells and then escalate to 6.0× 10\^9 and 9.0× 10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
48345534|NCT06336681|DEVICE|PrO2Fit Device|The flow-resistive protocol using the device requires participants to maximally inhale as hard as they can and as long as they can against a small leak (2mm diameter hole) until task failure. This records maximum inspiratory pressure (MIP) and sustained maximal inspiratory pressure (SMIP) values which will be recorded and the best is chosen for the software template by the participant to continue their training session (previously described in arm/group description). The use of the device occurs three times a week, and used for 6-8 weeks.
48345535|NCT03630016|DIAGNOSTIC_TEST|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
48345536|NCT06318260|DRUG|Dobutrex|Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.
48345537|NCT01171313|DRUG|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
48345538|NCT01171313|DRUG|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
48345539|NCT01171313|DRUG|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
48345540|NCT01171313|DRUG|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
48658284|NCT03407950|BEHAVIORAL|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
48658285|NCT03077061|PROCEDURE|Open flap debridement|Open flap debridement using saline as irrigation
48658286|NCT03077061|DEVICE|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
48658287|NCT06462456|DEVICE|Verofilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
47983057|NCT03137472|DEVICE|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
48658288|NCT06462456|DEVICE|Verofilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
47983058|NCT03541824|BEHAVIORAL|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
48658289|NCT04993196|DIAGNOSTIC_TEST|T1rho imaging|Magnetic Resonance Imaging using T1rho
47983059|NCT01751867|DRUG|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
47983060|NCT01751867|DRUG|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
47983061|NCT06369376|DIAGNOSTIC_TEST|New nerve conduction protocol|We opted for three different recording sites, each mimicking distinct parts of the pectoral muscle, allowing for a comprehensive assessment of nerve conduction across various regions.
47983062|NCT05066373|DRUG|EDP1815 capsule A|EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
47983063|NCT05066373|DRUG|EDP1815 capsule B|EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
48136061|NCT00084435|DRUG|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
48136062|NCT00084435|RADIATION|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
47983064|NCT05066373|DRUG|EDP1815 tablet|EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
47983065|NCT01893710|PROCEDURE|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
48136063|NCT02470169|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
48136064|NCT02470169|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
48266808|NCT04031456|BIOLOGICAL|Autologous Platelet Rich Plasma|Autologous PRP intra ovarian infusion
48658290|NCT02578251|DRUG|Paracetamol|
48345541|NCT04350372|DEVICE|MitraClip Procedure|MitraClip procedure with MitraClip NT System
48345542|NCT00168168|DRUG|G-CSF/Filgrastim|
48345543|NCT04322240|DRUG|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
48345544|NCT00397553|DRUG|Insulin glulisine|
48345545|NCT01835314|DRUG|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
48345546|NCT01782404|DEVICE|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
48345547|NCT04707924|DEVICE|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
48345548|NCT02055170|DRUG|finasteride 5mg oral daily|
48345549|NCT02273414|DRUG|BIIL 284 BS - rising dose|
48345550|NCT02273414|DRUG|Placebo|
47983066|NCT02936245|OTHER|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
48345551|NCT04679714|DEVICE|Transcatheter mitral valve repair (PLAR Implant and Delivery System)|The PLAR Implant is placed on the mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture
48345552|NCT05516940|OTHER||
48345553|NCT01665976|DRUG|RO4917838|film coated tablet, single dose
48345554|NCT01665976|DRUG|RO4917838|oral suspension, single dose
48345555|NCT01665976|DRUG|RO4927838|hard gelatin capsule, single dose
48345556|NCT04207008|OTHER|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
48345557|NCT00074542|DRUG|Epanova™ (Omega-3 Free Fatty Acids)|
48345558|NCT00024674|DRUG|SS1(dsFv)-PE38|
48345559|NCT06009575|DIETARY_SUPPLEMENT|Iron Supplement Tablets|The intervention group received IST and local culture-based nutrition education
48345560|NCT03358004|DRUG|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
48345561|NCT03358004|DRUG|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
48501082|NCT02808689|OTHER|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
48501083|NCT05416697|DRUG|CBD oil|The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
48501084|NCT05416697|DRUG|Placebo|The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
48501085|NCT04626583|BIOLOGICAL|Allogeneic MSC|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
48501086|NCT06021535|OTHER|No intervention|No intervention
48501087|NCT01359969|DRUG|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
48501088|NCT00935688|OTHER|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
48345562|NCT02530099|PROCEDURE|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
48345563|NCT02530099|PROCEDURE|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
48345564|NCT02667236|DRUG|A-101 Solution|Active Drug
48345565|NCT02667236|OTHER|Vehicle Solution|Placebo
48345566|NCT04842877|DRUG|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
48345567|NCT06066190|OTHER|Web-Based Training on ERAS Protocols Applied in Gynecological and Obstetric Surgery|Web-Based Training will be given to Midwives and Nurses on ERAS Protocols Applied in Gynecological and Obstetric Surgery. The training will last 6 weeks and they will be asked to watch a training video every week.
48345568|NCT01209572|DEVICE|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
48345569|NCT01209572|DEVICE|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
48345570|NCT01799161|BIOLOGICAL|gp96-Ig Vaccine|
48345571|NCT01799161|DRUG|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
48345572|NCT01799161|OTHER|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
48345573|NCT01799161|PROCEDURE|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response \[frequency of CD4+, FoxP3 (Treg), et al\] in treated patients.
48501089|NCT01717716|DIETARY_SUPPLEMENT|water with Sucralose|
48501090|NCT01717716|DIETARY_SUPPLEMENT|water with HFCS|
48501091|NCT01717716|DIETARY_SUPPLEMENT|water with glucose|
48136065|NCT02470169|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
48136066|NCT02470169|DEVICE|shepherd catheter|
48345574|NCT04644055|DIAGNOSTIC_TEST|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
48345575|NCT00988377|OTHER|dietary intervention|whey protein 10-40 g
48345576|NCT00988377|OTHER|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
48345577|NCT05907772|OTHER|No intervention|No intervention
48345578|NCT06204289|BEHAVIORAL|Nurse-led Supportive Care Programme|Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
47983067|NCT05871827|PROCEDURE|Intraoperative Fluoroscopic Computer Navigation|Computer technology used during surgery
48345579|NCT03478462|DRUG|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
48345580|NCT02546310|DRUG|HTL0009936|
48345581|NCT02546310|DRUG|HTL0009936 matching placebo|
48345582|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
48345583|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
48345584|NCT06367972|PROCEDURE|Local Consolidation Therapy|Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.
48345585|NCT06367972|PROCEDURE|Next-line Systemic Therapy|The specific next-line systemic therapy will be determined by your doctor.
48658291|NCT02578251|DRUG|Pethidine|
48658292|NCT06418061|DRUG|IBI3005|Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
48658293|NCT05754996|DRUG|Nifuroxazide|Nifuroxazide dosing : 200 mg capsule four times daily
47983068|NCT02121288|DRUG|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
48136067|NCT02470169|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
48136068|NCT00038636|DRUG|Lopinavir/ritonavir|
48345586|NCT02557334|DIETARY_SUPPLEMENT|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
48345587|NCT02557334|DIETARY_SUPPLEMENT|High Dose Strawberry Powder|40 g freeze dried strawberry powder
48658294|NCT05754996|DRUG|Lactulose|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools
48345588|NCT02557334|DIETARY_SUPPLEMENT|Placebo Powder|40 g color and taste matched placebo powder
48345589|NCT04614467|BIOLOGICAL|CLBS16|GCSF-mobilized autologous CD34+ cells
48345590|NCT04614467|BIOLOGICAL|Placebo|isotonic solution (no CD34+ cells)
48345591|NCT02550093|PROCEDURE|Intervention 1|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 1 (Day 1).
48345592|NCT02550093|BEHAVIORAL|Washout Period|The wash-out period will be between intervention 1 and intervention 2. 13 days in length.
48658295|NCT05754996|DRUG|Rifaximin 550Mg Tab|Rifaximin 550 MG twice daily
48658296|NCT01260779|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
48658297|NCT04898179|OTHER|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
48136069|NCT00038636|DRUG|Ritonavir|
48136070|NCT02509858|DRUG|thyroxine|treatment with 50μg of thyroxine once daily for two months.
48136071|NCT02509858|DRUG|Placebo|treatment with 50μg of placebo, once daily, for two months.
48136072|NCT02509858|OTHER|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
48658298|NCT04898179|OTHER|Control group|Usual care
48136073|NCT01596413|DRUG|Sancuso|granisetron transdermal system
48136074|NCT01596413|DRUG|IV granisetron|IV
48136075|NCT06137898|BIOLOGICAL|biological check-up|Blood sampling
48136076|NCT06041165|DRUG|JS401|Single dose of JS401 by subcutaneous (sc) injections
48136077|NCT06041165|DRUG|Placebo|Calculated volume to match active treatment
48345593|NCT02550093|PROCEDURE|Intervention 2|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing on intervention 2 (Day 14).
48345594|NCT00516958|DRUG|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
48345595|NCT00516958|DRUG|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
48501092|NCT01717716|DIETARY_SUPPLEMENT|water with sucrose|
48136078|NCT02290158|OTHER|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
48136079|NCT01989052|DRUG|CTO|
48136080|NCT01989052|DRUG|Lomustine|
48136081|NCT05522023|PROCEDURE|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
48136082|NCT05522023|PROCEDURE|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
48136083|NCT04332094|DRUG|Tocilizumab|162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
48136084|NCT04332094|DRUG|Hydroxychloroquine|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
48136085|NCT04332094|DRUG|Azithromycin|500 mg / day v.o. for 3 days
48136086|NCT06308406|DRUG|Bevacizumab； HRS-1167|Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
48136087|NCT04142255|BIOLOGICAL|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
48136088|NCT03385031|OTHER|CBCT imaging|CBCT imaging at first and last fraction of radiotherapy treatment
48136089|NCT00401479|DRUG|Placebo|
48345596|NCT00516958|DRUG|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
48345597|NCT00784706|OTHER|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
48345598|NCT00784706|OTHER|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
48136090|NCT00401479|DRUG|Solabegron (GW427353)|
48136091|NCT02813954|DEVICE|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
48136092|NCT04275167|DEVICE|Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope|Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
48136093|NCT01786876|DRUG|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
48345599|NCT00784706|OTHER|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
48345600|NCT06032572|PROCEDURE|VRS100 robotic-assisted PCI|The VRS100 is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
48345601|NCT06032572|PROCEDURE|Manual PCI|Use the traditional technique of manually advancing intracoronary guidewires, balloons, and stents at the patient's tableside.
48136094|NCT04644887|OTHER|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA \< 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) \>2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
48136095|NCT04644887|OTHER|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (\~2%), normal fat cheese (\~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
48345602|NCT00616772|DRUG|ABT-335|Capsule
48136096|NCT06477679|PROCEDURE|• Furlow with buccinators myomucosal flap|• Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily
48136097|NCT06477679|PROCEDURE|• Two flap palatoplasty as von langenbeck technique|• Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back
48136098|NCT06116968|DRUG|Aficamten|5-20mg
48136099|NCT01419808|PROCEDURE|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
48136100|NCT01419808|PROCEDURE|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
48345603|NCT00616772|DRUG|Placebo|Capsule
48345604|NCT00616772|OTHER|Atorvastatin|Capsule
48136101|NCT00866619|BIOLOGICAL|Malaria Vaccine 257049|administered intramuscularly into the left deltoid.
48136102|NCT00866619|BIOLOGICAL|Meningococcal C Conjugate Vaccine|administered intramuscularly into the left deltoid.
48136103|NCT00866619|BIOLOGICAL|Cell-culture rabies vaccine|administered intramuscularly into the left deltoid.
48136104|NCT00866619|BIOLOGICAL|TritanrixHepB/Hib|administered intramuscularly into the left deltoid.
48136105|NCT00866619|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK)|administered orally.
48136106|NCT04047407|DEVICE|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
48136107|NCT01484743|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
48136108|NCT04603508|DRUG|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
48136109|NCT04603508|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
48136110|NCT04603508|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
48136111|NCT04603508|OTHER|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
48136112|NCT04603508|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
48345605|NCT00549406|PROCEDURE|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
48345606|NCT00549406|PROCEDURE|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
48345607|NCT00549406|PROCEDURE|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
48345608|NCT02480803|DRUG|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
48658299|NCT05143814|DEVICE|3D Printed Mask Adapter Designed from Facial 3D scans for Fit testing.|Given the high level of fit test failures, without the provision of improved fits of masks, patient care will be highly curtailed for frontline staff at risk of SARS-CoV-2. Therefore, a reusable bespoke mask adapter used with a soft FFP3 disposable mask might be an economical solution to address the passing of fit testing. Currently, this is a major challenge in delivery of healthcare and urgent action is needed.
48136113|NCT04603508|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
48136114|NCT05407272|OTHER|Health Education Manual|A health education manual based on a shared model
48136115|NCT05407272|OTHER|manual|routine care
48136116|NCT02861820|DEVICE|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
48136117|NCT03872063|OTHER|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
48136118|NCT03872063|OTHER|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
48136119|NCT01788605|DRUG|ramosetron|
48136120|NCT00405184|DRUG|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
48136121|NCT00405184|DRUG|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
48136122|NCT01765374|DEVICE|ESAOTE MyLab60|US evaluation at different time points
48136123|NCT01765374|DRUG|Rituximab|
48345609|NCT02480803|DEVICE|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
48136124|NCT05208034|DRUG|Methotrexate|Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
48136125|NCT01982994|BEHAVIORAL|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
48266809|NCT04031456|BIOLOGICAL|Placebo-Platelet Free Plasma|Autologous PFP intra ovarian infusion
48501093|NCT05490290|OTHER|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
48658300|NCT06524960|DRUG|Denosumab|Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.
48266810|NCT02020044|OTHER|Endothelial Keratoplasty|
48345610|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
48345611|NCT02544698|BIOLOGICAL|One dose of PCV13a vaccine|
48136126|NCT01343797|OTHER|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
48136127|NCT06322368|OTHER|Myofunctional and respiratory training program|The patients will receive exercises included in a myofunctional approach and a respiratory training focused on inspiratory and expiratory muscles using a device.
48136128|NCT06322368|OTHER|Range of motion and thermal and mechanical stimulation exercising|The patients will receive the standard treatment of speech and language therapy including range of motion exercises (open and close the mouth) and thermal and mechanical stimulation in the orofacial region.
48136129|NCT06140875|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
48136130|NCT01083732|DRUG|dabigatran etexilate|Experimental dose chosen based on age and weight
48136131|NCT01555138|DRUG|Indacaterol|Indacaterol is delivered via a SDDPI.
48136132|NCT01555138|DRUG|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
48136133|NCT04180683|OTHER|Battery of screening tests with semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
48136134|NCT04180683|OTHER|Battery of screening tests without semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
48136135|NCT00663819|DEVICE|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
48136136|NCT00663819|PROCEDURE|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
48136137|NCT06510140|BEHAVIORAL|Detection of the Post-operative delirium (POD)|Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).
48136138|NCT02403375|DEVICE|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
48136139|NCT01014299|OTHER|Recruitment maneuver|"Assigned interventions:~* No intervention after tracheal intubation (control group)~* Alveolar recruitment maneuver (RM group) immediately after intubation"
48136140|NCT03090711|DEVICE|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
48136141|NCT03090711|DEVICE|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
48136142|NCT03090711|DEVICE|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
48136143|NCT03090711|DEVICE|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
48136144|NCT05474404|DIAGNOSTIC_TEST|Cervical smear test|collection of cervical cells using spatula
48136145|NCT03444415|OTHER|Motivational interviewing in groups|Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
48136146|NCT03444415|OTHER|Usual care|Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
48136147|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety normal nebulizer and mask+ distraction|Children in group 2 will receive their inhaler treatment with a normal nebulizer and mask, while at the same time one of the distraction techniques of their choice (drawing a picture, reading a story or watching an age-appropriate cartoon) will be applied.
48266811|NCT05398198|DRUG|GSK3923868|GSK3923868 dose and administration as per study intervention.
48345612|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
48345613|NCT02544698|BIOLOGICAL|three doses of PCV13a vaccine|
48345614|NCT03288441|DRUG|Hold|Hold antithrombotic therapy
48658301|NCT06524960|OTHER|Placebo|Placebo is 1 mL of normal saline drawn up in a commercially available syringe.
48345615|NCT03288441|DRUG|Prophylactic dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
48345616|NCT03288441|DRUG|Change antithrombotic Drug|Change in type of antithrombotic therapy
48345617|NCT03288441|BIOLOGICAL|Change platelet transfusion threshold|Increase or reduce platelet transfusion threshold
48136148|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety a toy nebulizer and a toy mask|Children in Group 3 will receive their inhaler treatment using a toy nebulizer and a toy mask.
48345618|NCT03288441|DRUG|Full dose antithrombotics|Continue full dose antithrombotic therapy
48345619|NCT03288441|DEVICE|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
47983069|NCT02121288|DRUG|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
48345620|NCT03288441|DRUG|Intermediate dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
48345621|NCT04459078|DRUG|Camrelizumab|Intravenous administration of (200mg/3weeks)
48345622|NCT04459078|DRUG|Albumin Paclitacxel|intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles)
48345623|NCT04459078|DRUG|Apatinib|Patients will be given oral of Apatinib (250mg Qd po for 5 days, take rest for 2 days every week)
48345624|NCT00995605|DRUG|AMAP102|AMAP102 or Placebo
48345625|NCT05475444|DEVICE|Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels|antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction.
48345626|NCT05475444|DEVICE|Ciprofloxacin paste and solution|Conventional antibacterial paste and solution were compared to nanoparticles smart gels to treat endodontics bacterial infection
48658302|NCT00798408|DIETARY_SUPPLEMENT|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
48658303|NCT00798408|DIETARY_SUPPLEMENT|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
48658304|NCT05916937|DRUG|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
48658305|NCT05916937|DRUG|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
48658306|NCT05305651|DRUG|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
48658307|NCT06241846|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
48658308|NCT03174067|DRUG|Buprenorphine|The participant receives buprenorphine
48658309|NCT03174067|DRUG|Clonidine|The participant receives clonidine
48658310|NCT00003455|DRUG|antineoplaston A10|
48658311|NCT00003455|DRUG|antineoplaston AS2-1|
47983070|NCT03358290|DRUG|JTE-051|Active drug tablets containing JTE-051
47983071|NCT03358290|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
47983072|NCT03316131|DRUG|Verinurad|Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
47983073|NCT03316131|DRUG|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
48136149|NCT01942915|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
48136150|NCT04955951|DEVICE|polarized light|A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
48136151|NCT04955951|DRUG|Topical corticosteroid ointment|corticosteroid 1 %.
48136152|NCT04528498|OTHER|Preimplantation Genetic Testing|Embryo biopsies will undergo preimplantation genetic testing for aneuploidies as per standard of care, and polygenic disease risk (PGT-P) will be computed for these samples.
48345627|NCT02377908|OTHER|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
48345628|NCT03026205|DRUG|ARMS-I|
48345629|NCT02058641|DRUG|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
48345630|NCT05488925|DRUG|Vitamin E|Evion, 400 mg
48345631|NCT05488925|DRUG|Diclofenac Sodium|Voltral SR100, 100 mg
48345632|NCT05488925|DRUG|Piroxicam|Feldene, 20 mg
48345633|NCT05488925|DRUG|Tramadol|Tramal, 50 mg
48345634|NCT00651768|DRUG|budesonide/formoterol|
48345635|NCT00651768|DRUG|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg \& budesonide HFA pMDI 4 X 160mcg
48658312|NCT00003455|PROCEDURE|alternative product therapy|
48658313|NCT00003455|PROCEDURE|biological therapy|
48658314|NCT00003455|PROCEDURE|biologically based therapies|
48658315|NCT00003455|PROCEDURE|cancer prevention intervention|
48658316|NCT00003455|PROCEDURE|complementary and alternative therapy|
48658317|NCT00003455|PROCEDURE|differentiation therapy|
48658318|NCT04458857|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
48658319|NCT04458857|DRUG|Placebo|Matching placebo
48658320|NCT05497024|BEHAVIORAL|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
48658321|NCT05497024|BEHAVIORAL|Surveys|Participants may answer questions that are sensitive in nature.
48658322|NCT02247128|DRUG|Aspirin + clopidogrel|
48345636|NCT02880735|DEVICE|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
48658323|NCT02247128|DRUG|Aspirin monotherapy|
48345637|NCT03638336|DEVICE|ILY robotic flexible ureteroscopy|fragmentation of nephrolithiasis
48501094|NCT03495349|OTHER|safety and effectiveness of the usual treatments of diabetic foot infections|clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
48501095|NCT05960812|PROCEDURE|skillful neglect Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear conservative treatment which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
48501096|NCT05960812|PROCEDURE|arthroscopic repair Of upper subscapularis tear in Lafosse type 1 and type 2 with long head biceps tenotomy .|"The following technique will be utilized for confirm isolated or combined upper subscapularis border partial tear repair which is considered the standard technique.~* Semisetting position under GA.~* Standard shoulder arthroscopy with standard portals for RC repair.~* Inspection of articular surface of rotator cuff and biceps tendon.~* Bursectomy, visualization of all rotators.~* Mobilization is done for associated rotator tears by shaver and radiofrequency device.~* Both preoperative Statistics randomization that is used to determine which case will be repaired and intraoperative loss of tension of the elongated aspect of the tendon are used to confirm diagnosis and treatment of upper subscapularis border tear.~* Skillful neglect to the tear.~* Rotator repair technique by RC anchors~* Biceps Tenotomy will be done in all cases by cutting of LHBT."
48501097|NCT04270136|PROCEDURE|total mastectomy|breast cancer non conserving surgery
48501098|NCT00125840|DRUG|clofarabine (IV formulation)|
48501099|NCT03806712|OTHER|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
47983074|NCT03316131|DRUG|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
47983075|NCT03316131|OTHER|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
48345638|NCT02793804|DEVICE|Oraquick (made in Thailand)|
48345639|NCT01938560|OTHER|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
48658324|NCT02247128|DRUG|OAC + clopicogrel|
48658325|NCT02247128|DRUG|OAC monotherapy|
48658326|NCT01533987|DIETARY_SUPPLEMENT|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
48658327|NCT03439449|DEVICE|CLEOS software program|Computer-assisted history taking program
48658328|NCT03439449|PROCEDURE|Physician taken history|Conventional history taking by physicians
48658329|NCT06639828|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.
48658330|NCT06550388|BEHAVIORAL|Nutritional Education|In addition to the traditional course of CBT-I, the PI will provide education and materials regarding the Mediterranean Diet. Patient will be provided with the Mayo Clinic booklet on Mediterranean Diet and asked to increase their daily intake in two categories assessed by the Mini-EAT.
48658331|NCT06550388|BEHAVIORAL|Physical Activity|In addition to the traditional course of CBT-I, the PI will recommend patient to increase physical activity minutes per week. The increase in physical activity will be based on patient's current level of physical activity.
48658332|NCT01374854|BIOLOGICAL|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10\^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
48345640|NCT05326204|OTHER|Home blood glucose monitoring|Self monitoring of capillary blood glucose
48501100|NCT03659292|OTHER|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
48501101|NCT03659292|OTHER|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
48501102|NCT03659292|OTHER|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
48658333|NCT01374854|DRUG|traditional therapy|exogenous insulin injection daily
48658334|NCT05301764|COMBINATION_PRODUCT|LVGN6051 and Anlotinib|"LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week."
48658335|NCT04463355|BEHAVIORAL|Video discharge instructions|Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
48658336|NCT06563804|DRUG|S227928|For administration via intravenous (IV) infusion
48658337|NCT06563804|DRUG|Venetoclax|For oral administration
47983076|NCT03084874|BEHAVIORAL|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
47983077|NCT01321268|DIETARY_SUPPLEMENT|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
47983078|NCT01321268|DIETARY_SUPPLEMENT|Viatmin E|oral, twice daily in morning and evening for 6 months
47983079|NCT04521075|BIOLOGICAL|Fecal Microbial Transplantation by capsules|"Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion."
47983080|NCT05219084|DRUG|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
48658338|NCT04623593|PROCEDURE|ACDF|Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.
47983081|NCT05219084|DRUG|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
47983082|NCT05219084|DRUG|Combined group|hip denervation and intra-articular hydration were conducted together
47983083|NCT05219084|DRUG|Control group|Normal; saline was injected subcutaneously
47983084|NCT01105195|OTHER|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
47983085|NCT01105195|OTHER|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
47983086|NCT05039151|BIOLOGICAL|interstitial fluid sampling|The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
47983087|NCT05039151|BIOLOGICAL|blood sampling|A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
48501103|NCT03659292|OTHER|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
48501104|NCT05944601|BEHAVIORAL|Virtual and computer-based cognitive remediation training|Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
48658339|NCT04623593|PROCEDURE|ACDA|The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
47983088|NCT01899794|PROCEDURE|TVT-O/Oxytrol|
47983089|NCT01899794|DEVICE|TVT-O|
47983090|NCT01899794|DRUG|Oxytrol|
47983091|NCT01737515|OTHER|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
47983092|NCT02938871|DIETARY_SUPPLEMENT|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
47983093|NCT02938871|DIETARY_SUPPLEMENT|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
48136153|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
47983094|NCT05872672|BEHAVIORAL|Sleep Program|Participants will complete the Headspace Health Sleep Program, which is an 18 day program based on CBTi, and includes the following intervention components: 1) a sleep diary to monitor sleep and associated factors; 2) cognitive interventions to address maladaptive thoughts related to sleep; 3) behavioral interventions to address maladaptive behaviors related to sleep (e.g., sleep hygiene, stimulus control, and sleep restriction); 4) de-arousal techniques (e.g., mindfulness, breathing, and muscle relaxation exercises).
47983095|NCT05872672|OTHER|Waitlist|Participants will continue their regular sleep routines for an 18 day period and will not be assigned to an intervention.
47983096|NCT05571098|BEHAVIORAL|individualized colorectal cancer education|"Subjects taught within the scope of individualized colorectal cancer education:~* Common symptoms and management related to disease and treatment,~* Importance of nutrition in the treatment process."
47983097|NCT05571098|BEHAVIORAL|psycho-oncological counseling|"Topics discussed within the scope of psycho-oncological counseling:~* Psychological state (anxiety, depression, etc.),~* Coping strategies about the process,~* Presence of fear about the disease and/or treatment,~* Lifestyle changes/problems,~* Changes in body image,~* Family/friendship/work-related concerns,~* Additional issues, comments he wishes to convey"
47983098|NCT05571098|BEHAVIORAL|telephone support hotline service|Within the scope of the NNP, a telephone support hotline service was provided to the participants, where they could consult at any time about the subject they wanted.
47983099|NCT02527460|DRUG|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
47983100|NCT05461794|DRUG|Sitravatinib|administered orally
47983101|NCT05461794|DRUG|Tislelizumab|administered intravenously
47983102|NCT05461794|DRUG|Docetaxel|administered intravenously
47983103|NCT05461794|DRUG|Irinotecan|administered intravenously
47983104|NCT00267046|DRUG|Palifermin|180 mcg/kg 3 days prior to chemotherapy
47983105|NCT00267046|DRUG|Placebo|Single dose 3 days prior to chemotherapy
47983106|NCT00267046|DRUG|Adriamycin (Doxorubicin)|30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).
47983107|NCT00267046|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.
47983108|NCT00267046|DRUG|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
47983109|NCT00267046|DRUG|Cisplatin|120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
47983110|NCT04646889|DRUG|AR882 Single Dose|A single dose of AR882
47983111|NCT04646889|DRUG|AR882 Multiple Dose|AR882 taken once daily for 14 days
47983112|NCT06336850|PROCEDURE|Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement|The endoscopic ultrasound (EUS)-guided 25G fine needle aspirate (FNA) needle procedure is a straightforward minimally invasive technique for direct portal pressure measurements.
47983113|NCT03527966|BIOLOGICAL|5cc Vivigen and local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
47983114|NCT03527966|BIOLOGICAL|Small kit rhBMP-2 with local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
47983115|NCT02610179|DIETARY_SUPPLEMENT|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
47983116|NCT02610179|DIETARY_SUPPLEMENT|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
48266812|NCT05398198|DRUG|Placebo|Placebo matching GSK3923868 will be administered.
47983117|NCT02366845|BIOLOGICAL|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
47983118|NCT02366845|DIAGNOSTIC_TEST|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
47983119|NCT02366845|DIAGNOSTIC_TEST|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
47983120|NCT01533233|PROCEDURE|thoracoscopic lobectomy and mediastinal lymph node dissection|
48345641|NCT01249157|DEVICE|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
47983121|NCT06420843|DIETARY_SUPPLEMENT|FOODMAP|Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
47983122|NCT04516590|OTHER||There was no intervention in this observational study
48345642|NCT05326906|DRUG|PD-1/PD-L1 inhibitors|PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
48501105|NCT06182176|DRUG|Sulphadoxine-pyrimethamine and Amodiaquine|The intervention drugs are standard drugs approved by the World Health Organisation for the preventive treatment of malaria (sulphadoxine-pyrimethamine and amodiaquine), schistosomiasis (praziquantel) and soil-transmitted helminths (albendazole).
48501106|NCT06126068|DRUG|Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia|Loading dose magnesium sulfate versus the Pritchard regimen
47983123|NCT05989126|DRUG|aflibercept 8 mg PFS|Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
48136154|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
48345643|NCT00374036|DRUG|ECC|capecitabine
48501107|NCT05604456|PROCEDURE|secondary ear reconstruction based on Nagata method|Secondary auricular reconstructions based on Nagata method were conducted on patients who sought for secondary revision.
48345644|NCT00374036|DRUG|FOLFIRI|Irinotecan
48345645|NCT05182541|OTHER|Guided self help|Introduce the knowledge about twins pregnancy, and reduce the pregnant stress, and relief the anxiety and depressor.
48345646|NCT05182541|OTHER|Problem solving therapy|Based on the steps of problem-solving therapy, nurses guide mothers with mild psychological problems to solve the existing problems through wechat and telephone, 10-15 min each time for 4 weeks
48345647|NCT05182541|OTHER|Face to face PST course|Face to face interviews with nurses with psychological counselors, combined with auxiliary tools, identify patients' problems, set goals for patients, provide different solutions, and let patients choose appropriate ways according to their preferences. Once a week, 1 hour for the first time and 45 min for the rest for 5 weeks.
48658340|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
48501108|NCT00154271|DRUG|Valsartan, Valsartan HCT|
48266813|NCT02639663|DEVICE|dental device|"Leboride~1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
48266814|NCT00289263|DRUG|Paclitaxel|
48266815|NCT05112887|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
48266816|NCT05977647|DRUG|Tamsulosin Oral Capsule|Patient will be enrolled in one of study arm through randomization.
48501109|NCT06032650|OTHER|Calisthenics exercise and High intensity interval training|"1. The calisthenics exercise focuses on big muscles and can be combined with breathing exercises and applied rhythmically,10-15 for each exercise,1-3 sets,3 days/week for 8 weeks. It will be progressed gradually by increasing the number of sets, repetitions and by using elastic bands and weighted vest progression.~2. High intensity interval training will be on treadmill for eight weeks, three times/week based on the following program:-Warming up period for 5 min at intensity corresponding to 65-75% of heart rate maximum (HRmax).Training phase for 30 min divided into four sets of 4-min length each at intensity equals 85- 90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.Cooling down period for 5 min of at 50-60% of the HRmax"
48501110|NCT03876418|DIAGNOSTIC_TEST|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
48501111|NCT03354767|PROCEDURE|Aortic and aortic valve surgery|
48658341|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
47983124|NCT00888251|OTHER|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
48136155|NCT01186224|DRUG|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
48136156|NCT01749319|DRUG|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
48136157|NCT01749319|DRUG|Intervenous baclofen|
48136158|NCT01353274|DRUG|Micamlo|Telmisartan plus Amlodipine T40/A5
48345648|NCT05182541|OTHER|Professional psychological intervention|The mental health physicians and (or) psychological counselors strengthened the intervention and carried out specialized nursing
48345649|NCT03001414|BIOLOGICAL|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
48345650|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
48345651|NCT03001414|BIOLOGICAL|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
48658342|NCT04254627|DRUG|Etanercept|Etanercept 50 mg weekly injection
47983125|NCT01502423|BIOLOGICAL|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
47983126|NCT06131307|PROCEDURE|Education|Paternalistic leadership training will be given to clinical manager nurses.
48345652|NCT05409092|DIETARY_SUPPLEMENT|Astaxanthin|8 mg/day in one capsule for 4 weeks
48345653|NCT05409092|DIETARY_SUPPLEMENT|Placebo|8 mg/day in one capsule for 4 weeks
48345654|NCT00415623|DRUG|Amlodipine|Amlodipine 5mg/ day
48345655|NCT00415623|DRUG|Amlodipine|Amlodipine 10mg/ day
48345656|NCT05855213|DEVICE|High Velocity Nasal Insufflation|A relatively new respiratory support modality which delivers very high velocity flows. This improves ventilatory efficiency via washing out carbon dioxide occupying the anatomical dead space of the upper airways.
48345657|NCT05855213|DEVICE|Non-invasive positive pressure ventilation|An established non-invasive ventilation method via delivery of an expiratory positive airway pressure and inspiratory positive airway pressure.
48501112|NCT05268068|DRUG|Risankizumab|Intravenous (IV) Infusion
48501113|NCT05268068|DRUG|Risankizumab|Subcutaneous (SC) Injection
48501114|NCT04131777|DEVICE|Radiofrequency (RF) catheter|A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
47983127|NCT05945693|DIETARY_SUPPLEMENT|Placebo|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.
48136159|NCT02185794|DRUG|Voxilaprevir|Voxilaprevir tablets administered orally once daily
48345658|NCT04095793|DRUG|ampreloxetine|Oral tablet, QD
48345659|NCT01072240|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
48501115|NCT02476240|BEHAVIORAL|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
48658343|NCT04254627|DRUG|Mifepristone|Mifepristone 300 mg pill
48658344|NCT04017208|DRUG|ASP2713|Administered intravenously
48658345|NCT04017208|DRUG|placebo|Administered intravenously
48658346|NCT00200746|DRUG|Arginine|Amino Acid Arginine
48345660|NCT02031627|DEVICE|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
48658347|NCT06565286|PROCEDURE|inner preputial graft versus transverse preputial island flap in two-stage repair of proximal penile hypospadias|compare outcomes of inner preputial graft versus transverse preputial island flap when used to substitute the urethral plate in two-stage repair of primary proximal penile hypospadias .
48658348|NCT04891198|DRUG|Envafolimab|Subcutaneous injection
48345661|NCT02031627|DEVICE|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM \& PM (2 hours)
48345662|NCT02031627|DEVICE|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM \& PM (4 hours)
48345663|NCT05105529|BEHAVIORAL|Exercise|Cycling at 60% of VO2max on a cycle ergometer for 30 minutes
48345664|NCT05105529|OTHER|Ozone|Breathing 170ppb ozone
48501116|NCT00952211|DEVICE|CPAP|CPAP at therapeutic pressure during nighttime
48501117|NCT00952211|DEVICE|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
48658349|NCT03960177|DRUG|Glucarpidase|Given IV
48658350|NCT03960177|OTHER|Quality-of-Life Assessment|Ancillary studies
48658351|NCT06272578|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
48658352|NCT05053685|DIAGNOSTIC_TEST|Measurement of Urine and plasma metanephrines|Measurement of Urine and plasma metanephrines
48345665|NCT05105529|OTHER|Filtere Air|Breathing filtered air
48345666|NCT01680991|DRUG|Obinutuzumab|Multiple doses of obinutuzumab.
48345667|NCT02832817|DEVICE|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
48345668|NCT00671970|DRUG|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs \& 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
48345669|NCT05447260|DRUG|Ruxolitinib|Dosage based on platelet count
48345670|NCT04570982|BIOLOGICAL|Convalescent Plasma|The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
48501118|NCT05410132|OTHER|Internet-delivered Mindfulness Based Training (iMBT)|"The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice."
48501119|NCT06123923|OTHER|no intervention|no intervention, just retrospective observation
48658353|NCT05748210|OTHER|Symptom management mobile health application with personalised support|"Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
48345671|NCT05388734|OTHER|alternative medicine education consultation|The intervention will consist in a 1h30 individual consultation with a GP physician. Patients will be able to ask any questions they have regarding treatments for their breast cancer delivered outside of the hospital. Topics such as benefit-risk ratios, placebo effects and expectancies from CAM will be discussed with the patients. This consultation will promote a shared-decision model to help patients better discuss these matters with their healthcare providers.
48345672|NCT03365336|DRUG|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
48345673|NCT03365336|DRUG|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
47983128|NCT05945693|DIETARY_SUPPLEMENT|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.
47983129|NCT05945693|DIETARY_SUPPLEMENT|Aerobic exercise|The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.
47983130|NCT05422014|BEHAVIORAL|Life Care Specialist (LCS)|"Life Care Specialist (LCS) will :~* Provide patients with individualized risk assessment for opioid misuse.~* Act as patient's Pain Coach. Providing targeted education and behavior-based pain treatment options.~* Train and provide CWC evidence based non-pharmaceutical pain management techniques, using the Community Resiliency Model.~* Use the Opioid Risk Tool (ORT) as the method to identity the risk of substance misuse.~* Provide education, support and resources, as well as local, state, and national resources to enhance the whole health aspect of the position. These resources include but are not limited to: written documents that outline the key concepts of the pain management techniques taught by the LCS and a list of hotlines and websites.~* LCS, when applicable, will provide education for caretakers on the risk of opioid use and the non -pharmaceutical pain management protocol.~* Provide follow up for all patients in intervention group."
47983131|NCT00372112|DRUG|GW642444|GW642444H
47983132|NCT00372112|OTHER|Placebo|Placebo administered twice daily
47983133|NCT06264167|DIAGNOSTIC_TEST|High-resolution bilateral groin ultrasound surveillance|Participants in the Interventional Treatment (serial ultrasounds) group will undergo surgical excision of the primary tumor, either via radical wide local excision or radical vulvectomy. Post-vulvar surgery, follow-up appointments occur bi-monthly for 12 months, involving a clinical examination and groin ultrasound. Senior imaging specialists review bilateral ultrasound scans for positive lymph nodes or suspicious findings, promptly sending reports to the primary care physician and trial manager if detected within 3 business days. Subsequently, participants consult their primary care physician for options. Depending on clinical judgment, they may be referred for LND or continue with bi-monthly ultrasounds based on preference and clinician guidance.
47983134|NCT03867929|OTHER|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
47983135|NCT06363968|DEVICE|RETeval|as previous
47983136|NCT00672789|BEHAVIORAL|Blood smear education|education at baseline and three month follow-up
48345674|NCT03611036|OTHER|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
48345675|NCT03611036|OTHER|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
48501120|NCT01161407|DIETARY_SUPPLEMENT|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
48136160|NCT02185794|DRUG|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
48136161|NCT02185794|DRUG|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
48136162|NCT02198300|PROCEDURE|Coronary angioplasty with stent implantation|
48136163|NCT02198300|DRUG|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
48136164|NCT00476736|DRUG|Effect on small airways (N-Acetylcystein)|
48136165|NCT02150616|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
48658354|NCT05748210|OTHER|Wait-list Symptom management mobile health application with personalised support|To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
48658355|NCT05902442|DEVICE|3DxSPLINT|Routine immobilization procedure with a patient-specific 3D printed splint instead of the use of a conventional forearm splint after one week of conventional immobilization.
48136166|NCT02150616|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
48658356|NCT01117246|DEVICE|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
48345676|NCT04970433|PROCEDURE|Electroacupuncture (EA)|Acupuncture at Hegu (LI4), Neiguan (PC6), Zusanli (ST36), Sanyinjiao (SP6) and Sishencong (EX-HN1). Electrical stimulation with a pair of electrodes connecting on LI4/PC6 and ST36/SP6.
48345677|NCT04970433|PROCEDURE|Laser acupuncture (LA)|The laser applies to each point for 40 seconds, which delivers 3 J of energy at each of the acupoints as those in electroacupuncture group.
48501121|NCT01161407|DIETARY_SUPPLEMENT|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
48501122|NCT02636426|DRUG|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
48501123|NCT00818688|PROCEDURE|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
48658357|NCT06445777|BEHAVIORAL|Mental Health Prevention and Promotion|The Inner Lion Programme is made up of 12 interactive workshops which are based on four key pillars: building confidence by identifying strengths and personal qualities; improving emotional intelligence and self-awareness; establishing adaptive coping strategies and channels of support; and boosting resilience. Professionally created by Child Psychologist Stijn de Leeuw together with an advisory team of psychologists from the Netherlands and South Africa, the programme follows a carefully structured and curated prevention and promotion mental health curriculum with games, crafting activities, psycho-educational stories, dance, movement, and breathing exercises. Workshops are led by local role models (a male-female duo) with lived experience trained to be mental health coaches.
48136167|NCT02150616|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
48136168|NCT02150616|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
48345678|NCT04970433|PROCEDURE|Sham laser acupuncture (SLA)|The laser device without any laser output applies on the acupoints the same as those in the LA group.
48345679|NCT00006968|BIOLOGICAL|filgrastim|
48136169|NCT00211549|DRUG|IDEA-033|
48136170|NCT01357694|BEHAVIORAL|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
48345680|NCT00006968|DRUG|cyclosporine|
47983137|NCT00672789|OTHER|standard education|standard education
48136171|NCT01375699|DRUG|Doxorubicin|As prescribed by treating provider.
48136172|NCT01375699|DRUG|Sildenafil|Given PO, by mouth
48136173|NCT02148705|DRUG|NexoBrid|
48136174|NCT02148705|PROCEDURE|Standard of Care (SOC)|
48136175|NCT02148705|DRUG|Gel Vehicle|
48136176|NCT00507494|DRUG|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
48136177|NCT05596331|OTHER|eye-tracker|Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
48136178|NCT06395571|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula fed at age appropriate quantities for 24 weeks
48136179|NCT06395571|DIETARY_SUPPLEMENT|Cow's milk-based infant formula|Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks
48345681|NCT00006968|DRUG|pentostatin|
48345682|NCT00006968|PROCEDURE|allogeneic bone marrow transplantation|
48345683|NCT00006968|PROCEDURE|peripheral blood stem cell transplantation|
48345684|NCT05664555|DRUG|Fluorescein Sodium|Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
48501124|NCT05551819|DIETARY_SUPPLEMENT|MDF then RUTF/RUSF|Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
48501125|NCT05551819|DIETARY_SUPPLEMENT|RUTF/RUSF then MDF|Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
48345685|NCT03526341|DEVICE|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
48345686|NCT00987636|DRUG|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
48345687|NCT00987636|DRUG|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: \<9 kg= 1mg/kg BW 9 - \<16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW \>23 - 34 kg= 0.95 mg/kg BW \>34 kg = 0.8 mg/kg BW
48136180|NCT00856700|DRUG|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
48136181|NCT05088421|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days."
48136182|NCT05088421|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
48136183|NCT01009424|DRUG|R7103|escalating inhaled dose
48136184|NCT04071106|DRUG|Turmeric Extract|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
48345688|NCT00987636|DRUG|Treosulfan|12 g/m² d-5 to d-3
48345689|NCT00287846|DRUG|imatinib mesylate|
48345690|NCT04128605|PROCEDURE|Suprascapular nerve block (SSNB)|"SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve."
48345691|NCT04128605|PROCEDURE|Intraarticular shoulder steroid injection (IAS)|"IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space"
48345692|NCT01695460|DRUG|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
48345693|NCT01695460|DRUG|Placebo|
48345694|NCT05693649|BEHAVIORAL|No Direct Patient Outreach|Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.
47983138|NCT04519151|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
48345695|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Colonoscopy Only|Patient will receive direct outreach including an order to schedule and complete colonoscopy.
47983139|NCT04519151|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
48136185|NCT04071106|DRUG|Turmeric Extract in Olive oil|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
48345696|NCT05693649|BEHAVIORAL|Direct Patient Outreach: Sequential Choice|Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.
48345697|NCT05693649|BEHAVIORAL|Visit-Based Nudge/Text|Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
48136186|NCT04071106|DRUG|Petrolatum|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
48136187|NCT04071106|DEVICE|NB-UVB|Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
48136188|NCT04071106|DRUG|calcipotriol/ Betamethasone|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
48136189|NCT05193799|DEVICE|Investigational devices must be used 8 hours per day|During 3 consecutive days
48136190|NCT01809275|DRUG|QBECO|
48136191|NCT01809275|DRUG|Placebo|
48136192|NCT01006772|OTHER|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
48136193|NCT00009932|DRUG|cisplatin|
48136194|NCT00009932|DRUG|fenretinide|
48136195|NCT00009932|DRUG|paclitaxel|
47983140|NCT04138420|DRUG|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
48345698|NCT05693649|BEHAVIORAL|No Nudge/Text|Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.
48345699|NCT01193049|DRUG|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
48345700|NCT01193049|DRUG|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
48345701|NCT03286881|OTHER|Brief individual psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
48345702|NCT03286881|OTHER|Brief group psychotherapy|"Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care."
48136196|NCT05758506|DEVICE|Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)|We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
48345703|NCT03286881|OTHER|Combined intervention|Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.
48345704|NCT03286881|OTHER|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
48345705|NCT03286881|OTHER|Usual treatment|Medication provided by a general practitioner.
48345706|NCT01793090|DRUG|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
48345707|NCT01793090|OTHER|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
48345708|NCT02947490|OTHER|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
48345709|NCT02947490|OTHER|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
48345710|NCT02947490|OTHER|Standard BP management|GP to measure BP and manage BP control
48345711|NCT02947490|OTHER|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
48345712|NCT03581799|OTHER|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
48345713|NCT02390960|DRUG|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
48345714|NCT02390960|DRUG|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
48345715|NCT02390960|DEVICE|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
48345716|NCT05728749|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
48345717|NCT05369780|DIETARY_SUPPLEMENT|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
48345718|NCT01712776|DEVICE|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
48501126|NCT04029753|BEHAVIORAL|Walk out from operating room|After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
48501127|NCT02592083|DRUG|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
48658358|NCT05215145|BEHAVIORAL|Baby Navigator Bundle|The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
48658359|NCT05215145|BEHAVIORAL|Baby Navigator Bundle + Individual-ESI|Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
48658360|NCT05427929|DEVICE|NVR 4mm Edi catheter|Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
48658361|NCT03562156|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
48501128|NCT02592083|DRUG|Palbociclib|
48136197|NCT00686465|OTHER|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
48136198|NCT05532501|DRUG|Oral Oxytocin|Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
48136199|NCT05532501|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
48136200|NCT05532501|DRUG|Oral placebo|Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
48136201|NCT05532501|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
48136202|NCT01235936|DRUG|AKB-6548|Different dose levels
48266817|NCT04164303|OTHER|Physical Therapist management|Physical Therapist management included joint manipulation, mobilization with movement, strengthening exercises, and grip proprioception training.
48345719|NCT01712776|DEVICE|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
48345720|NCT01766765|PROCEDURE|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
48345721|NCT01766765|OTHER|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
48345722|NCT00952770|PROCEDURE|transradial coronary intervention|percutaneous coronary intervention with transradial approach
48345723|NCT04419662|DRUG|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
48345724|NCT04419662|OTHER|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
48345725|NCT03661372|OTHER|Robot|Use of a telesimulation robot using contextual interview format.
48345726|NCT03661372|OTHER|Face-to-face|Use of face-to-face patient interview using contextual interview format.
48658362|NCT03562156|DRUG|Placebo|matching placebo capsule
48658363|NCT05570253|DRUG|Eribulin|Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
48658364|NCT05570253|DRUG|SDX-7320|SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
48658365|NCT05570253|OTHER|Placebo|Placebo
48658366|NCT03267849|OTHER|wearing swimming goggles or having laser suturelysis|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
48658367|NCT05082909|DRUG|Probenecid|Addition of 500mg QDS to oral penicillin.
48658368|NCT06081920|BIOLOGICAL|IBI363|IBI363 monotherapy
48658369|NCT06424262|DEVICE|CI622D|A dexamethasone-eluting Slim Straight electrode
48658370|NCT06424262|DEVICE|CI622|A standard Slim Straight electrode
48658371|NCT00492050|DRUG|Bortezomib|1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.
48658372|NCT00492050|DRUG|Rituximab|375 mg/m\^2 IV on Day 8 and 22.
48658373|NCT00492050|DRUG|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
48658374|NCT05818254|BEHAVIORAL|HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention|The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current pregnancy intention and contraceptive use, (2) patient and provider collaboratively arrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed conversation, and (3) create a warm handoff with a patient-specific SLE risk assessment and guideline-aligned recommendations.
48658375|NCT05818254|BEHAVIORAL|Routine Care|Providers will continue to provide reproductive healthcare in their current manner.
48658376|NCT03131193|OTHER|Physician|Study primary health centers will be staffed with an additional physician
48658377|NCT03131193|OTHER|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
48658378|NCT03131193|BEHAVIORAL|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
48658379|NCT03577470|DRUG|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
48658380|NCT05974787|BEHAVIORAL|Emergency department cancer patients interview|The interview focuses on several parts of the (pre-)admission process: The first part is regarding the barriers and facilitators encountered during the (pre-)admission process. The second part will focus on the timeline that led to an emergency department (ED) visit. It will be established when and which symptoms were first detected. The third part is regarding the number and type of health care workers that were contacted before visiting the ED. The fourth part will be about the actions and considerations taken before the ED visit.
48266818|NCT03488160|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
48266819|NCT03247621|BEHAVIORAL|Whatsapp|
48266820|NCT03247621|BEHAVIORAL|Article|
48266821|NCT03247621|BEHAVIORAL|No Phone|
48266822|NCT00743808|OTHER|quality improvement|3-phase quality improvement intervention
48658381|NCT03286699|BEHAVIORAL|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
48658382|NCT03286699|BEHAVIORAL|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
48136203|NCT05911867|OTHER|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
48658383|NCT06293053|DRUG|Dupilumab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous"
48658384|NCT06643156|DRUG|GP681 10mg/20mg/40mg|0.5/1/2×20mg power for oral suspension taken orally
48658385|NCT05438121|DEVICE|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
48658386|NCT06625437|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and commitment therapy is a psychotherapy focused at increasing psychological flexibility and an individual\&#39;s engagement in valued activities rather than focusing solely or primarily on reducing psychiatric symptoms
48658387|NCT06571617|PROCEDURE|Mini PCNL (mini percutaneous nephrolithotomy)|half of the cases will be treated using mini PCNL
48658388|NCT06571617|PROCEDURE|RIRS (retrograde intrarenal surgery/ flexible URS)|THE OTHER HALF WILL BE TRAETED USING Flexible URS
48658389|NCT05848817|DEVICE|Contoura LASIK|Subjects receiving Phorcides Planned Contoura LASIK
47983141|NCT03070574|DRUG|mesalamine 2400 MG (5-ASA)|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
48136204|NCT05911867|OTHER|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
48345727|NCT00505518|DRUG|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
48345728|NCT00505518|BEHAVIORAL|Collaborative psychiatric and primary medical care|Regular care visits from health workers
48345729|NCT00964249|DRUG|GW642444|Long acting Beta 2 agonist
48345730|NCT00964249|DRUG|Placebo|Matching placebo
48345731|NCT05935475|PROCEDURE|Anatomical landmark guided dialysis catheter insertion|.: Before insertion, the catheter depth was calculated from the insertion point to the catheter tip point (midway the vertical line from the clavicular head of sternocleidomastoid to inter nipple line.
48345732|NCT05935475|PROCEDURE|ECG guided dialysis catheter insertion|after inserting the dialysis catheter into right IJV, the guidewire will be then withdrawn until the tip to be exactly positioned at the entry of the Superior Vena Cava in the right atrium. This will be ECG guided: the p wave appears as biphasic wave in the RA then the catheter will be withdrawn at 0.5 cm intervals until the P-wave returned to a normal configuration. (At that point, the catheter will be secured at the skin with suture and dressed with a transparent dressing
48345733|NCT06047860|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
48345734|NCT06047860|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor within one week of radiotherapy
48345735|NCT06047860|DRUG|Granulocyte-macrophage colony-stimulating factor subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
48345736|NCT06047860|DRUG|Interleukin 2 subcutaneous injection|IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
48345737|NCT06047860|DRUG|Endostatin|Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
48345738|NCT02491216|OTHER|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
48345739|NCT03395067|BEHAVIORAL|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
48345740|NCT06136455|DRUG|Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
48345741|NCT06136455|DRUG|Listerine Total Care Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
48501129|NCT04784754|DRUG|Melatonin|Melatonin capsules will be prepared using hypromellose capsules containing 3 mg or 30 mg of the active component and identical excipient (Microcrystalline Cellulose) used in the placebo preparation. Melatonin will be administered orally three times a day for 14 days.
48501130|NCT04784754|DRUG|Placebo|Placebo capsules will be prepared using hypromellose capsules, filled using microcrystalline cellulose. This is the same excipient used in the preparation of the interventional drug. Placebo will be administered orally three times a day for 14 days in the same regimen used for the intervention.
48501131|NCT02552212|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
48658390|NCT06518655|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Detection of volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
48658391|NCT05834738|DRUG|Atrasentan|Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo
48658392|NCT05834738|DRUG|Atrasentan|Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet
48658393|NCT05834738|DRUG|Placebo|Placebo
47983142|NCT03070574|DRUG|mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
47983143|NCT03070574|OTHER|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
47983144|NCT03785665|DEVICE|MDI|Capsule MD1 (Motility dummy 1)
48136205|NCT05911867|OTHER|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
48136206|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
48136207|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
48658394|NCT05935085|DRUG|ANB032|BTLA agonist antibody
48658395|NCT05935085|DRUG|Placebo|Placebo
48658396|NCT03563079|OTHER|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
48658397|NCT03563079|OTHER|Manual Myofascial Release|Myofascial Release Technique
48658398|NCT03921567|DRUG|Lidocaine Hydrochloride|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
48345742|NCT06136455|OTHER|Listerine Cool Mint Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
47983145|NCT06149507|DRUG|Acetaminophen|Prescribe the drug to the child
47983146|NCT06149507|DRUG|Ibuprofen|Prescribe the drug to the child
47983147|NCT01722071|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
48136208|NCT00887224|DRUG|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
48345743|NCT06136455|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
48345744|NCT05100004|DEVICE|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
48345745|NCT05100004|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
48658399|NCT03921567|DRUG|Lidocaine Hydrochloride and Ketamine|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
48658400|NCT03921567|DRUG|Placebo|will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
48658401|NCT05967169|DEVICE|Nasal Septal Strap implantation|Correction of NSD with Nasal Septal Strap implant
48658402|NCT02337556|OTHER|Peptamen Bariatric|Commercially available enteral diet
48658403|NCT02337556|OTHER|Replete|Commercially available enteral diet
47983148|NCT01722071|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
47983149|NCT05911776|DRUG|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
47983150|NCT05911776|DRUG|Intravenous Dexmedetomidine|patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
47983151|NCT00529542|DRUG|Lipitor|40mg caplets per day for six weeks
48345746|NCT06433024|DIAGNOSTIC_TEST|PPG Diagnostic|The study investigates venous competence through three distinct exercises using photoplethysmography (PPG) technology to record blood flow in the leg veins of 20 subjects, split into two groups: those with chronic venous disease (CVD) and those without. The null hypothesis is that there will be no significant difference in venous filling times (VFT) and PPG trace variations between subjects with CVD and those without under different physical conditions. The alternative hypothesis suggests that individuals with CVD will show distinct PPG patterns, particularly shorter VFT and varied pressure changes, indicative of venous reflux or obstruction. This hypothesis is chosen based on prior evidence suggesting observable differences in venous function between affected and non-affected individuals.
48345747|NCT03743298|DRUG|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
48345748|NCT03777397|OTHER|Questionnaire|Questionnaire on the level of awareness of this risk among health sector employees, and more specifically the Lyon Civilian Hospices, and on participation in breast cancer screening for HCL employees, particularly among night shift staff.
48345749|NCT02837861|DRUG|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
48345750|NCT02837861|OTHER|Routine Nutritional Support|Enteral nutrition as tolerated.
48345751|NCT01329068|BEHAVIORAL|individual consult|regular individual consultations
48345752|NCT01329068|BEHAVIORAL|group medical consult|group medical consult
48501132|NCT02552212|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
48501133|NCT03669939|OTHER|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
48501134|NCT03669939|OTHER|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
48501135|NCT05668078|DIAGNOSTIC_TEST|Rapid Antigen Testing (RAT) for COVID-19|COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
48658404|NCT02887794|OTHER|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
48658405|NCT02686944|BIOLOGICAL|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
48658406|NCT05810480|DIAGNOSTIC_TEST|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
48658407|NCT06643585|DRUG|Trastuzumab-Deruxtecan|Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
48658408|NCT06643585|OTHER|Physicians Choice (PhC).|Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)
47983152|NCT00529542|DRUG|Placebo|1 placebo caplet per day for six weeks.
48136209|NCT00042965|DRUG|capecitabine|
48136210|NCT00042965|DRUG|gemcitabine hydrochloride|
48136211|NCT02895659|PROCEDURE|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
48345753|NCT02927184|DRUG|VK2809|
48345754|NCT02927184|DRUG|Placebo|
48345755|NCT03208049|BEHAVIORAL|Sleep Restriction Therapy|Sleep Restriction Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Sleep Restriction therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
48501136|NCT04889144|OTHER|Communication Intervention|Participate in PLAN intervention
48501137|NCT04889144|OTHER|Best Practice|Receive usual care
48501138|NCT04889144|OTHER|Questionnaire Administration|Ancillary studies
48501139|NCT02378350|DEVICE|Hemodialysis treatment (no specific device is defined)|
48501140|NCT02378350|DRUG|Peritoneal Dialysis treatment (no specific drug is defined)|
48501141|NCT00000717|DRUG|Primaquine|
48501142|NCT00000717|DRUG|Clindamycin|
48345756|NCT03208049|BEHAVIORAL|Cognitive Therapy|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
48345757|NCT03073382|OTHER|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
48658409|NCT05868811|BEHAVIORAL|Music Together|The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.
48658410|NCT05868811|BEHAVIORAL|Play Group|The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
47983153|NCT01952431|DEVICE|Total Lung Capacity (TLC) testing|Comparison of TLC results
48345758|NCT03766542|DEVICE|Bi-level positive airway pressure with ventilatory support|Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
48345759|NCT03766542|DEVICE|continuous positive airway pressure without ventilatory support|Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
48345760|NCT05401604|DIETARY_SUPPLEMENT|Moderate probiotic beer consumption|Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
48345761|NCT05401604|DIETARY_SUPPLEMENT|Moderate normal beer consumption|Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
48345762|NCT03367611|DIAGNOSTIC_TEST|Immunochemical faecal occult blood test (iFOBT)|All participants in the study will collect a single faecal sample for haemoglobin measurement.
48501143|NCT04661683|OTHER|Combustible Hookah Smoke|Exposure to combustible hookah smoke for a duration of 60 minutes.
48501144|NCT04661683|OTHER|Electronic Hookah Aerosol|Exposure to electronic hookah aerosol for a duration of 60 minutes.
48501145|NCT04661683|OTHER|Clean Room Air|Exposure to room air for a duration of 60 minutes.
48658411|NCT06163404|DEVICE|Implantation of Spirair Nasal Device using the Spirair delivery system.|The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.
48658412|NCT06244823|DRUG|Fremanezumab Prefilled Syringe|MRI will be scanned prior to the first administration of Fremanezumab, within 0-14 days, prior to Fremanezumab injection. The second MRI will be acquired at 12 ± 1 weeks after the first Fremanezumab injection.Images will be acquired during interictal periods, defined as at least 24 hours from last migraine attack. All the scans will be acquired during the same session, starting with the T1-weighted scan, followed by the diffusion-weighted scan and ending with the rs-fMRI scan. Total acquisition time for a single subject is approximately 28 minutes, divided in the following periods of time: six minutes for the T1-weighted scan, 12 minutes for the diffusion-weighted scan and 10 minutes for the rs-fMRI scan. If we consider patient preparation, obtainment of documents and informed consent form, the whole process will take about 50-70 minutes.
48658413|NCT05020808|DIETARY_SUPPLEMENT|NEAA|Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
48658414|NCT05020808|DIETARY_SUPPLEMENT|PPI|Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
48658415|NCT04618276|OTHER|Photodynamic Therapy|PDT with two different photosensitizers
48658416|NCT05553236|DIAGNOSTIC_TEST|Targeted next-generation sequencing|During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
48658417|NCT04166747|OTHER|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
48658418|NCT06638853|BEHAVIORAL|Distress Tolerance Skills Training|"These lessons are adapted from DBT Skills in Schools: Skills Training for Emotional Problem Solving for Adolescents (DBT STEPS-A) by Mazza et al. and include elements of mindfulness training, psychoeducation about emotions, and techniques/skills for managing extreme emotions."
48658419|NCT04756531|DRUG|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
48658420|NCT04756531|DRUG|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
48658421|NCT04756531|DRUG|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
48658422|NCT04756531|DRUG|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
48658423|NCT04756531|DRUG|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
48658424|NCT04756531|DRUG|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
48658425|NCT02929732|OTHER|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
48658426|NCT06048029|PROCEDURE|laparscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
47983154|NCT04322253|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
48345763|NCT00809510|DRUG|ABT-089|20 mg ABT-089 taken once-daily for 6 months
48345764|NCT01678313|DRUG|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
48345765|NCT01678313|DRUG|Doxazosin 4 mg every day (QD)|Control group
48345766|NCT02340572|DRUG|PRS-080#022-DP|hepcidin antagonist
48345767|NCT02340572|DRUG|PRS-080-Placebo#001|Placebo treatment
48345768|NCT01233570|DRUG|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
48345769|NCT02561104|PROCEDURE|Laser-assisted cataract surgery.|
48345770|NCT02561104|PROCEDURE|Traditional manual phacoemulsification|
48345771|NCT01120821|DRUG|Gleevec|400 mg once daily for 12 months
48345772|NCT03425851|OTHER|Diapers|Receive 600 diapers.
48345773|NCT03425851|OTHER|Resources of diaper banks|Caregivers will receive resources of diaper banks.
48345774|NCT05001581|PROCEDURE|Arthroscopic partial repair of massive rotator cuff tear|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons
48345775|NCT05001581|PROCEDURE|Arthroscopic partial repair of rotator cuff with biceps augmentation|Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
48345776|NCT04771104|DIETARY_SUPPLEMENT|Amino Acid Challenge (AAC)|The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.
48345777|NCT00047593|DRUG|IOP Lowering Medications|
48345778|NCT02531503|OTHER|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
48345779|NCT03444467|DRUG|NNC9204-1513|"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
48345780|NCT03444467|DRUG|Glucagon|Participants will receive single dose of 1 mg glucagon s.c. injection.
48345781|NCT03444467|DRUG|Placebo|Participants will receive single dose of placebo (for double dummy injections).
48345782|NCT04462978|OTHER|Non IgE-mediated food allergy|
48345783|NCT00617617|DIETARY_SUPPLEMENT|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
48345784|NCT00617617|OTHER|Placebo|Control Group - Control Group participants will receive an identical placebo.
48345785|NCT00071214|BIOLOGICAL|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
48345786|NCT00431223|BEHAVIORAL|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
48345787|NCT02457299|PROCEDURE|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
48345788|NCT02457299|PROCEDURE|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
48345789|NCT03162094|DRUG|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
48345790|NCT03162094|DRUG|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
48345791|NCT03162094|DRUG|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
48345792|NCT00369278|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
48345793|NCT00488059|DRUG|enfuvirtide [Fuzeon]|90 mg SC twice daily
48345794|NCT00488059|DRUG|Optimized background ARV|As prescribed
48345795|NCT00488059|DRUG|Integrase inhibitor|As prescribed
48345796|NCT00488059|DRUG|enfuvirtide [Fuzeon]|180 mg SC once daily
48345797|NCT00654420|DRUG|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
48345798|NCT00654420|DRUG|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
48345799|NCT01328769|DRUG|Febuxostat|
48345800|NCT01328769|DRUG|Placebo|
48345801|NCT04540783|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
48345802|NCT00296166|PROCEDURE|Catheter ablation|
48345803|NCT00296166|PROCEDURE|Thoracoscopic epicardial ablation|
48345804|NCT00674375|OTHER|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
48345805|NCT05187572|BEHAVIORAL|Group intervention|This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
48345806|NCT03348813|BEHAVIORAL|HIV/STI Prevention Intervention|The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
48501146|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|400 IU daily (low dose)
47983155|NCT02132325|BEHAVIORAL|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
48136212|NCT03433794|BEHAVIORAL|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
48345807|NCT03348813|BEHAVIORAL|General Health Control Intervention|"The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care."
48136213|NCT03433794|BEHAVIORAL|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
48136214|NCT03433794|BEHAVIORAL|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
48136215|NCT03980418|PROCEDURE|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
48345808|NCT02673528|PROCEDURE|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
48345809|NCT01401101|OTHER|PCM|Care Manager (CM) intervention
48345810|NCT01401101|OTHER|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
48345811|NCT00484367|BEHAVIORAL|Adolescent group therapy|Adolescent group therapy
48345812|NCT00484367|BEHAVIORAL|Transitional family therapy|Transitional family therapy
48345813|NCT03649139|DRUG|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
48345814|NCT03649139|DRUG|Placebo drops|sublingual placebo drops
48345815|NCT05990166|OTHER|Mineral-enriched powder|Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate
48345816|NCT05990166|OTHER|Placebo powder|Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
48345817|NCT05302102|OTHER|Unilateral plyometric training|The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
48345818|NCT05302102|OTHER|Bilateral plyometric training|The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
48345819|NCT05302102|OTHER|Standard physical therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
48136216|NCT02071316|DRUG|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
48136217|NCT02071316|DRUG|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
48136218|NCT02376309|BEHAVIORAL|Inactivity|Inactivity
48345820|NCT01153568|DIETARY_SUPPLEMENT|Vitamin D 3|Patients will bew given a single capsule to take once daily
48345821|NCT01153568|OTHER|placebo|placebo tablets
48345822|NCT02603406|DRUG|erythropoietin|
48345823|NCT01465373|DRUG|Endometrin|100 mg per vagina TID
48345824|NCT01465373|DRUG|Progesterone in Oil|50 mg IM injection daily
48345825|NCT01976624|DRUG|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
48501147|NCT00681590|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D)|2000 IU daily (high dose)
48136219|NCT02376309|DRUG|ND|1 nandrolone decanoate injection
48136220|NCT02376309|DIETARY_SUPPLEMENT|Leu|Leucine supplements
48136221|NCT05075421|PROCEDURE|Gastrectomy|Any type of gastrectomy for gastric cancer
48345826|NCT05778929|DIAGNOSTIC_TEST|Radiomics Model|"A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status."
48345827|NCT03624790|BIOLOGICAL|rRSV A/Maryland/001/11|10\^5 PFU; delivered intranasally
48345828|NCT02347462|DEVICE|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
48345829|NCT02347462|OTHER|Standard care|Standard care according to the hospital severe asthma protocol
48345830|NCT03547349|DEVICE|Digital Incentive Spirometer|This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
48345831|NCT03547349|DEVICE|Jamboxx Respiratory Therapy Device|THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
48345832|NCT01759628|DRUG|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
48345833|NCT04341584|DRUG|Anakinra|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
48345834|NCT03822546|OTHER|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
48345835|NCT03822546|OTHER|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
48345836|NCT03822546|OTHER|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
48345837|NCT03822546|OTHER|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
48345838|NCT03822546|OTHER|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
48345839|NCT03822546|OTHER|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
48345840|NCT05560919|DRUG|Dihydroxycholecalciferols|Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
48345841|NCT05560919|OTHER|dimethyl sulfoxide|Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.
48345842|NCT05560919|OTHER|serum|Injection of serum in the periodontal ligament for lower anterior segment teeth.
48345843|NCT04347616|BIOLOGICAL|UCB-NK cells|Natural killer cells generated from CD34+ hematopoietic progenitor cells derived from an allogeneic umbilical cord blood
47983156|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
48345844|NCT04347616|DRUG|IL-2|In vivo cytokine support
48345845|NCT03587467|OTHER|collect fecal specimens|collect fresh fecal specimens of participants
48345846|NCT05991895|DRUG|Iruplinalkib|Iruplinalkib is administered orally with approximately fixed dosing times each day. The recommended dosage is once daily, on an empty stomach or with food, at 60 mg per dose for the first 1 to 7 days. If tolerated, the dosage is increased to 180 mg per dose starting from the 8th day.
48345847|NCT00605358|BEHAVIORAL|Open Door intervention|"Open Door intervention subjects will:~1. receive an evaluation~2. receive a referral to a local mental health provider~3. identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
48345848|NCT01597440|DRUG|N-carbamylglutamate|"Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
48345849|NCT01597440|OTHER|Standard of Care|Standard of Care
48345850|NCT06096389|OTHER|100 Drop Jumps|100 drop jumps from 60 cm height. Divided into 5 sets of 20 reps
48345851|NCT06096389|DIETARY_SUPPLEMENT|Whey supplementation|Consume whey protein isolate based on subjects' daily protein intake
48345852|NCT06096389|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Consume carbohydrate (isocaloric to whey)
48345853|NCT06096389|DIETARY_SUPPLEMENT|House cricket supplementation|Consume defatted house cricket powder based on subjects' daily protein intake
48345854|NCT05829811|DEVICE|Lifestyle APP and Artificial Intelligence solutions validation|The lifestyle APP will take into account all the psychological aspect linked to the disease, including the social isolation. Lifestyle APP is not a measurement technology but it is a preventive measures against diabetes evolution that provide insights and advices daily, by the collection of structured data of parameters, essential to feed the AI for Risk analysis module. The involvement of Physicians expert in this discipline will evaluate the effectiveness of the psychosocial education.
48345855|NCT02090673|DRUG|Exenatide|
48345856|NCT03104959|DIETARY_SUPPLEMENT|N-acetyl cysteine|
48345857|NCT03104959|OTHER|placebo|
48345858|NCT04882904|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
48345859|NCT05609383|OTHER|assessment|An exit evaluation was initiated immediately upon recovery from anesthesia
48345860|NCT00588380|DRUG|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
48345861|NCT01756833|DRUG|Doxycycline|100 mg po bid
48345862|NCT01756833|DRUG|Placebo|capsule identical to the doxycycline capsule
48345863|NCT04705168|DIAGNOSTIC_TEST|Nevisense electrical impedance spectroscopy|Each participants will undergo Nevisense electrical impedance spectroscopy in order to characterize the electrical impedance spectroscopy scores of nevi in patients with ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter
48345864|NCT01224106|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
48345865|NCT01224106|DRUG|Placebo|Participants received Placebo SC injection Q4W.
48345866|NCT01977807|DEVICE|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
48501148|NCT01043835|PROCEDURE|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
48658427|NCT06042491|BEHAVIORAL|Prehabilitation intervention|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions \>= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
48658428|NCT04523025|DIAGNOSTIC_TEST|NLR-ratio|The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation
48658429|NCT00179686|DRUG|CC-5013|
48658430|NCT03979001|OTHER|complete ophthalmological examination|"collection:~* ophthalmological history and current treatments~* occular tension measurement~* measurement of visual acuity (Snellen chart)~* Axial length measurement~* Photograph of the posterior segment of the eye~* 3x3 and 6x6 macular and papillary OCT angiography"
48658431|NCT00738660|DRUG|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
48345867|NCT02338856|DRUG|MB12066 200mg|100mg bid (multiple dose, day 8)
48345868|NCT02338856|DRUG|Placebo|100mg bid (multiple dose, day 8)
48345869|NCT00005015|DRUG|Fluoxetine|
48345870|NCT05165108|DEVICE|Vagal Nerve Stimulator|A handheld device which consists of a battery powered portable stimulator with a digital control user interface that controls signal amplitude and two steel contact electrodes will deliver the nVNS electrical stimulation to the cervical Vagus nerve. The device has been approved by the U.S. Food and Drug Administration (FDA) for non-invasive Vagus nerve stimulator therapy for adjunctive use for the prevention and treatment of migraine and cluster headaches in adult patients.
48501149|NCT01043835|PROCEDURE|Open gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
48501150|NCT04305587|DRUG|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
48501151|NCT04305587|OTHER|Placebo|Placebo once daily for up to 42 days.
48501152|NCT04305587|DRUG|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
48501153|NCT06368115|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
48501154|NCT00010621|PROCEDURE|Acupuncture|
48501155|NCT00010621|PROCEDURE|chiropractic therapy|
48345871|NCT04559997|OTHER|Exercise+FU|6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
48345872|NCT04559997|OTHER|Active Comparator group Exercise|After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
48345873|NCT04144062|OTHER|CAD/CAM crowns|CAD/CAM crowns
48501156|NCT00010621|PROCEDURE|bodywork therapy|
48501157|NCT05451992|DIETARY_SUPPLEMENT|Placebo|The group will have to consume a jar every day (approx. 75 ml) which contain (water, malt-dextrins, 0.1% starch, 0.1% guar gum, flavorings and colorants)
48345874|NCT02480062|OTHER|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
48345875|NCT02480062|OTHER|Usual Care|Usual care at the community health centers
48345876|NCT04053218|COMBINATION_PRODUCT|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
48345877|NCT04053218|DIETARY_SUPPLEMENT|Placebo|Olive oil placebo
48345878|NCT01184339|DEVICE|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
48345879|NCT05759104|DRUG|Infliximab|Drug
48345880|NCT05759104|PROCEDURE|Stomy|Surgery
48345881|NCT00108277|BEHAVIORAL|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
48136222|NCT06047535|DRUG|Naxitamab|"Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles."
48345882|NCT00108277|BEHAVIORAL|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
48345883|NCT02663947|DEVICE|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
48345884|NCT02270489|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
48345885|NCT02270489|BIOLOGICAL|AFFITOPE® PD03A + Adjuvant|s.c. injection
48501158|NCT05451992|DIETARY_SUPPLEMENT|SuperFood|The group will have to consume a jar of superfood (vegetable smoothie) every day. The jar will be filled with approx. 75 ml which corresponds to about 75 g. The superfood formulated by the University of Bolzano on the basis of the results and evidence acquired in collaboration with the Istituto Superiore di Sanità. Composition: pomegranate, walnuts, moringa, broccoli, according to the proportions indicated in Annex 2. This mixture has been analyzed by an external laboratory and authorized for human use
48501159|NCT03771248|DEVICE|peek telescopic partial denture|removable partial denture
48658432|NCT06116175|PROCEDURE|60 degree thermal radiofequency of tennis elbow|under strict aseptic technique ultrasound guided TRF of lateral epicondylitis advanced for 5 mm active tip canula
48658433|NCT04501718|DRUG|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
48658434|NCT03162627|DRUG|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
48658435|NCT03162627|DRUG|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
48658436|NCT01657188|DEVICE|Cheyne-Stokes respiration by adaptive servoventilation|
48658437|NCT06206720|DRUG|Deuremidevir Hydrobromide for Suspension|"15 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg TID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension 3 times every day, total 15 times."
48345886|NCT02270489|BIOLOGICAL|Adjuvant without active component|s.c. injection
48658438|NCT06206720|DRUG|Placebo|"15 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg TID group: 5 subjects will receive placebo 3 times every day, total 15 times."
48345887|NCT00797706|DRUG|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
48345888|NCT06325540|PROCEDURE|indirect pulp capping with theracal pt|indirect pulp capping using the theracal pt material
48345889|NCT06325540|PROCEDURE|indirect pulp capping with therabase|indirect pulp capping using the therabase material
48345890|NCT06325540|PROCEDURE|indirect pulp capping with biodentine|indirect pulp capping using the biodentine material
48345891|NCT04829461|DEVICE|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
48345892|NCT04829461|DEVICE|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
48345893|NCT03672552|OTHER|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
48136223|NCT05769244|OTHER|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
48136224|NCT01780649|PROCEDURE|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
48136225|NCT01780649|PROCEDURE|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
48345894|NCT00336661|DEVICE|PerioWave|
48501160|NCT03470168|DEVICE|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
48501161|NCT03470168|DEVICE|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
48501162|NCT02208986|DRUG|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
48501163|NCT03413293|DIAGNOSTIC_TEST|Diagnosis of bacterial infections|Cultures
48501164|NCT04435535|PROCEDURE|PEP|Positive expiratory pressure 10 cmH2O 15 min
48501165|NCT03330210|PROCEDURE|3D printing|Manufacturing and use of a model printed in 3D
48501166|NCT03981419|BIOLOGICAL|GRF6021|for IV infusion
48501167|NCT03981419|OTHER|Placebo|for IV infusion
48136226|NCT03314324|DRUG|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
48136227|NCT03314324|DRUG|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
48136228|NCT00609869|DRUG|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
48501168|NCT03570671|DIAGNOSTIC_TEST|Spasm positive|"Investigators define the positive criteria for VSA on MDCTA as follows:~1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT."
48501169|NCT03570671|DIAGNOSTIC_TEST|Spasm negative|Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
48501170|NCT00149812|BEHAVIORAL|Family Functioning Intervention|
48501171|NCT01874067|DEVICE|Arthritis glove|Isotoner three-quarter finger arthritis glove
48501172|NCT00969540|DEVICE|Active Mattress Cover|Active Mattress Cover
48501173|NCT00969540|DEVICE|Placebo Mattress Cover|Placebo Mattress Cover
48501174|NCT04024839|OTHER|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
48658439|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
48658440|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
48658441|NCT03951480|OTHER|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity \< 2, manipulations will not be continued. The patient being considered as not very symptomatic.
48136229|NCT00609869|DRUG|Rituximab|Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
48136230|NCT02304757|DRUG|99Tc-MDP|99Tc-MDP, H20000218
48501175|NCT04024839|OTHER|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
48658442|NCT03951480|DRUG|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
48136231|NCT02304757|DRUG|Fosamax|H20080172
48136232|NCT05722912|DRUG|Ruxolitinib|Ruxolitinib Cream
48136233|NCT03462485|OTHER|Golf|Eight weeks of twice-daily golf training
48658443|NCT03782493|BEHAVIORAL|the Enhanced Milieu Teaching-Sentence Focus|Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
48658444|NCT06643520|DEVICE|19-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 19 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
48501176|NCT03449680|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
48501177|NCT03449680|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
48501178|NCT02087995|DEVICE|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
48501179|NCT02924636|BEHAVIORAL|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
48136234|NCT01022125|DRUG|TMC435|
48136235|NCT04105816|DEVICE|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
48136236|NCT04105816|DIAGNOSTIC_TEST|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
48136237|NCT02788019|DRUG|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
48345895|NCT06257134|OTHER|No systematic monitoring of symptoms|No systematic monitoring of symptoms will be carried out, and patients will receive the usual care. Data collection will be carried out with the assistance of a clinical research nurse up to 12 months, then under the direction of local healthcare teams at 18 months.
48345896|NCT06257134|OTHER|Systematic monitoring of symptoms|"once a month, individual patient scores will be sent to dialysis staff. Any score of 3 (severe symptoms) or 4 (overwhelming) on a scale of 0 to 4, on the IPOS-Renal instrument, will be permanently reported to the referrer to trigger the patient's usual symptom management.~Patients will complete 3 further HRQoL questionnaires at baseline, M6, M12 and M18: EQ-5D-5L, KDQoL-36, SONG Fatigue.~A clinical research nurse will be present in half of the participating dialysis units to help patients and dialysis teams to include and follow up patients, up to 12 months. Between 12 and 18 months, data will be collected in real life, under the guidance of local healthcare teams.~In the other half of the dialysis units, data will be collected under the direction of the local healthcare teams, who will have to organize themselves to ensure data collection. These units will also be asked to conduct semi-structured interviews as part of the qualitative phase."
48345897|NCT05375825|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery: minimally invasive (VATS/robotic) or open (thoracotomy)
48658445|NCT06643520|DEVICE|22-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely.~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 22 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
47983157|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
47983158|NCT04464915|OTHER|Isopropyl alcohol swab|Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
48658446|NCT05744063|DRUG|Emapalumab-Lzsg 5 MG/ML [Gamifant]|iv
47983159|NCT06140303|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
48345898|NCT05375825|DRUG|LMB-100|1000 mcg/mL (DL1) post-operative dose as a single 90-minute normothermic intrathoracic perfusion using a closed circuit and roller pump with a heat exchanger following maximal cytoreductive surgery
48658447|NCT06569251|DRUG|Dexamethasone 12 mg QD|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. shortened scheme
47983160|NCT06140303|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen dressing~* Local offloading~* Foam~* Multi-layer compression dressing~* Off-loading device such as a controlled ankle motion (CAM) boot"
47983161|NCT04406727|BIOLOGICAL|UB-421|UB-421 in combination with their ARV
47983162|NCT04406727|OTHER|Antiretroviral (ARV)|Antiretroviral (ARV)
47983163|NCT00004182|DRUG|irinotecan hydrochloride|
47983164|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
47983165|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
47983166|NCT02630550|DEVICE|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
47983167|NCT02630550|DEVICE|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
47983168|NCT03696511|DEVICE|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
47983169|NCT05517928|DRUG|Omeprazole|40 MG oral capsules daily
47983170|NCT05517928|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given as Culturelle Digestive Probiotic in the form of oral capsules daily
47983171|NCT05517928|DRUG|Placebo|Oral capsules daily that look exactly like the study drug, but contains to active ingredient
47983172|NCT03902067|BIOLOGICAL|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml.
47983173|NCT03902067|BIOLOGICAL|Control Group|Routine treatment without catheter infusion
47983174|NCT01898611|DRUG|Ghrelin|Ghrelin
48136238|NCT05302076|DEVICE|Low-intensity electrical current (LIEC)|Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
48345899|NCT05375825|DIAGNOSTIC_TEST|Immunohistochemical Assay for Mesothelin|Performed at screening to determine mesothelin expression; separate testing of tumor mesothelin expression will be assessed retrospectively in resected tumor tissues. The device is not diagnostic; protocol assessment of mesothelin expression status will only be used to help to increase the possibility that all persons enrolling on the study might derive benefit from therapy.
48501180|NCT04819048|DEVICE|Low-Level Laser Therapy+acupuncture|"The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol."
48501181|NCT04819048|DEVICE|Low-Level Laser Therapy|The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
48501182|NCT03936426|DRUG|Cu-64 SARTATE and Cu-67 SARTATE|Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
48501183|NCT05141331|DEVICE|piezoelectric|Comparing Piezoelectric split-crest technique versus expansion using Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
48501184|NCT03506906|DIAGNOSTIC_TEST|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
48658448|NCT06569251|DRUG|Dexamethasone 6 mg BID|Administration of dexamethasone to the mother as an inducer of fetal lung maturity. standard Scheme
48658449|NCT00583531|DRUG|AST-120|Oral, 2 grams TID in sachets for 4 weeks
48658450|NCT03238547|DIAGNOSTIC_TEST|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
48658451|NCT03238547|DIAGNOSTIC_TEST|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
48658452|NCT01969058|DRUG|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
48345900|NCT03667794|DIAGNOSTIC_TEST|body plethysmography|measurement of conventional lung function parameters
48345901|NCT03667794|DIAGNOSTIC_TEST|impulse oscillometry|measurement of central and peripheral airway resistance
48345902|NCT03667794|DIAGNOSTIC_TEST|multiple breath washout|measurement of ventilation heterogeneity
47914552|NCT05126251|DRUG|Tangningtongluo tablet|Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
47983175|NCT01898611|DRUG|Placebo|Saline will be used as a placebo
48501185|NCT03506906|DIAGNOSTIC_TEST|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
48501186|NCT03712215|OTHER|Rehabilitation|diaphragmatic electrical stimulation
48658453|NCT06639243|DEVICE|QYM Technique|"The intervention in this study involves the application of the Quick Yielding Modified (QYM) technique for the treatment of complex aortic arch diseases. This procedure consists of two main components:~1. Thoracic Endovascular Aortic Repair (TEVAR): This minimally invasive procedure utilizes a covered stent graft to exclude the diseased segment of the thoracic aorta, providing immediate protection against rupture and controlling blood flow.~2. In Situ Fenestration and Revascularization of Supra-Aortic Branches: Following TEVAR, the QYM technique includes creating fenestrations in the stent graft to allow for the revascularization of the supra-aortic branches (such as the brachiocephalic, left common carotid, and left subclavian arteries). This is achieved through direct puncture and reconstruction of the branch vessels, ensuring adequate blood flow to these critical arteries while preserving their function.~The combination of these techniques aims to achieve effective treatment out"
48658454|NCT05145569|DRUG|Carboplatin AUC 5 and paclitaxel|Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
48658455|NCT05145569|DRUG|HCW9218|HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
48658456|NCT02759133|DEVICE|Metal wire|Localization technique for breast surgery using metal wire
48345903|NCT03625804|GENETIC|PNS+AO+Training|Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
48345904|NCT03625804|GENETIC|PNS+AOsham+Training|PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
48345905|NCT03625804|GENETIC|PNSsham+AOsham+Training|The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
48345906|NCT05110404|OTHER|The high-volume HIIT|patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
48345907|NCT05110404|OTHER|The low-volume HIIT|Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
48345908|NCT06168474|OTHER|Simplified layered consent form|The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.
48345909|NCT06168474|OTHER|Full-length consent form|The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
48345910|NCT01124513|PROCEDURE|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
48345911|NCT02881671|GENETIC|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
48345912|NCT01481506|PROCEDURE|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
48345913|NCT06391476|OTHER|Study of the evolution of a cohort of children born between 22 and 25 weeks gestational age|"* Study of mortality in a cohort of children born between 22 and 25 weeks gestational age~* Study of neonatal morbidity~* Description of postnatal growth~* Description of nutrition and breastfeeding at discharge~* Study of the neurological, respiratory and growth outcome at 2 years."
48345914|NCT02912962|BEHAVIORAL|Self-Regulation Intervention adapted from the Alert Program ®|
48345915|NCT00107172|PROCEDURE|surgery|
48345916|NCT00107172|RADIATION|brachytherapy|
48345917|NCT05228080|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|Peripheral blood samples will be drawn from each patient at study entry (before reperfusion therapy) and at 12,24 hours after reperfusion therapy.Serum will be immediately separated by centrifugation at 3000 rpm for 15 minutes and stored at -80°C. Endocan,ICAM-1,VCAM-1,MMP-9 levels will be determined in duplicate by commercially available enzyme-linked immunosorbent assay (ELISA).
48345918|NCT02019758|DRUG|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
48345919|NCT02019758|DRUG|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
48345920|NCT02019758|DRUG|Placebo slurry|Slurry of sucralose - 4 mL twice daily
48345921|NCT02019758|DRUG|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
48345922|NCT00702936|DRUG|TELMISARTAN|80 mg daily
48345923|NCT00702936|DRUG|RAMIPRIL|5 mg daily
48345924|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
48345925|NCT00420342|DRUG|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
48345926|NCT00420342|DRUG|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
48345927|NCT01786434|DRUG|Routine medication arm|50 micrograms of fentanyl given before the procedure
48345928|NCT01786434|DRUG|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
48345929|NCT00744692|BIOLOGICAL|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
48345930|NCT00744692|DRUG|Reduced Intensity Conditioning|
48345931|NCT03644381|OTHER|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
48345932|NCT02289833|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
48345933|NCT01895634|DEVICE|Rev-01|Treatment arm patients have used Rev-01 at least once
48345934|NCT06321640|GENETIC|Cohort A: primarily operable disease, candidate to adjuvant|This cohort includes any patient with nonmetastatic disease, candidate to surgery as primary treatment, for whom adjuvant therapy with targeted or immune therapy is recommended based on prior information obtained on the diagnostic biopsy. This cohort represents a control group, for whom high-throughput DNA/RNA sequencing is considered feasible in the vast majority of cases, and will not be considered in the computation of the primary endpoint
48658457|NCT02759133|DEVICE|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
47983176|NCT00757744|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
48345935|NCT06321640|GENETIC|Cohort B: locally advanced disease|Patients in this cohort are eligible if diagnosed with or highly suspected of locally advanced (nonmetastatic) neoplasm and candidate to a diagnostic/confirmatory biopsy and subsequent treatment with targeted therapy, immune therapy or radiotherapy, where the treatment is administered with potentially curative intent. Patients in this cohort may be considered for enrolment prior to a formal diagnosis, so the study should be offered on the basis of a high suspicion of invasive cancer upon radiological evidence.
48658458|NCT03508674|DEVICE|Levita Magnetic Surgical System|use of surgical tool
48658459|NCT06298708|BIOLOGICAL|Mevac-A vaccine|"Mevac-A: A freeze-dried live-attenuated hepatitis A vaccine.~Dose and administration: a freeze-dried live-attenuated vaccine, subcutaneous injection of 0.5 ml will be administered for 1 time."
48501187|NCT00372411|DEVICE|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
48501188|NCT00372411|OTHER|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
48501189|NCT00372411|OTHER|Usual Care|The usual chronic stroke care as delivered at each participating medical center
48501190|NCT00150891|PROCEDURE|Kidney transplantation|
48501191|NCT00150891|DRUG|cyclosporine A|
48501192|NCT00150891|DRUG|tacrolimus|
48501193|NCT00150891|DRUG|azathioprine|
48501194|NCT00150891|DRUG|mycophenolate mofetil|
48501195|NCT03781037|BEHAVIORAL|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
48501196|NCT06035263|OTHER|FUNCTIONAL REEDUCATION AND ENVIRONMENTAL ADAPTATION PROGRAMME|the prescription of reeducation in activities of daily living and the prescription of assistive devices and environmental adaptations, for one month from the first baseline assessment at the time of hospital discharge.
48501197|NCT06035263|OTHER|Health education programme:|"instructions and recommendations for maintaining an active and healthy life will be given as part of a health education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow, as well as the importance of nutrition and hydration in a healthy lifestyle.~They will receive the dossier of instructions and recommendations of the health education programme, as in the experimental group."
48501198|NCT04171206|OTHER|Free From Abuse|Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
48501199|NCT04171206|OTHER|Technology and crime|Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
48501200|NCT00478426|DRUG|Sunitinib Malate|Given PO
48501201|NCT03213730|OTHER|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
48501202|NCT03213730|OTHER|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
47983177|NCT00757744|BEHAVIORAL|Drug counseling|individual drug counseling
48345936|NCT06321640|GENETIC|Cohort C: metastatic disease|In this cohort, patients are eligible if diagnosed with invasive cancer with radiologically proven metastatic localization and candidate to treatment with targeted or immune therapy.
48501203|NCT03659097|PROCEDURE|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
48501204|NCT03771937|OTHER|Education and telephone follow-up intervention|A telephone follow up and a pre-discharge education
47983178|NCT00330616|DRUG|323U66 SR|
47983179|NCT02176876|DRUG|GS-5745|GS-5745 400 mg administered intravenously
47983180|NCT02176876|DRUG|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
48345937|NCT06321640|GENETIC|Cohort D: Progressive disease|In this cohort, patients are eligible if a tumor biopsy is considered indicated by the referring physician upon disease progression to prior treatment in the metastatic setting or for hematological neoplasms. Definition of progression is based on the investigator's judgement and does not strictly require RECIST 1.1 definition, although all relevant radiological data will be collected whenever possible. Tumor biopsy must be collected no more than 6 months after the documented date of progression.
47983181|NCT03181568|DEVICE|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
48501205|NCT00045669|DRUG|imatinib mesylate|
48501206|NCT04202809|DRUG|Durvalumab|Durvalumab is given earlier as registered, during chemotherapy and radiotherapy in treatment Arm A
47983182|NCT03181568|PROCEDURE|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
47983183|NCT01096264|OTHER|SSI and SphygmoCor® evaluations|"* SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~* SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
48136239|NCT05302076|DEVICE|Traditional fixed orthodontic appliance|"The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction."
48136240|NCT04373694|PROCEDURE|vaginoscopy|vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)
48136241|NCT04373694|PROCEDURE|standard hysteroscopy|speculum, paracervical block before hysteroscopy morcellation
48136242|NCT00463229|OTHER|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
48136243|NCT03001206|DEVICE|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
48136244|NCT00312806|DRUG|Pantoprazole|Pantoprazole 40 mg o.d.
48345938|NCT06321640|GENETIC|Cohort E: Hematological neoplasms|Any patient that is expected to be treated with targeted agents. Special consideration will be given to patients affected by chronic lymphoid leukemia and follicular lymphoma treated with BTKi, PI3Ki, BCL-2i +/- monoclonal antibodies. Any patient that is expected to be treated with immunotherapy. Special consideration will be given to patients affected by Hodgkin lymphoma and Diffuse Large B-cell lymphoma treated with ICIs, Tafasitamab/Lenalidomide, immunoconjugates.
48345939|NCT06321640|GENETIC|Cohort F: Toxicity|In this cohort, patients are enrolled upon experiencing an adverse event of grade 3/4 as per CTCAE v 5.0 that, in the opinion of the investigator, is unequivocally caused by a targeted or immune therapeutic. The event may occur at any time after the last dose of the drug. Events may be of any nature but particular attention will be given to those events for which pathophysiology is currently poorly understood (severe myocardial or neurologic Immune-related events or DS-8201-induced pneumonitis)
48345940|NCT06450808|DIETARY_SUPPLEMENT|Dried Microalgae biomass|The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.
48345941|NCT01113788|DEVICE|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
48345942|NCT01474889|DEVICE|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
48345943|NCT00608881|DRUG|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
48345944|NCT00608881|OTHER|placebo|an inactive substance
48345945|NCT01384188|DRUG|ONO-5334|150 mg for 5 days administered in the morning or in the evening
48345946|NCT01384188|DRUG|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
48345947|NCT01525745|RADIATION|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
48345948|NCT01525745|RADIATION|External Beam Radiation Therapy|10 consecutive days of standard radiation
47983184|NCT05202509|DRUG|Obicetrapib|10mg obicetrapib tablet
47983185|NCT05202509|DRUG|Placebo|Placebo tablet to resemble obicetrapib
47983186|NCT02969304|DRUG|dimethyl fumarate|"Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
47983187|NCT00061880|DRUG|forodesine hydrochloride|
48136245|NCT03901781|COMBINATION_PRODUCT|ST266 via Intranasal Delivery|ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
48345949|NCT01994278|DEVICE|Peri Clean|
48345950|NCT01779895|DIETARY_SUPPLEMENT|Lactobacillus paracasei probiotic strain|
48501207|NCT03860662|DIAGNOSTIC_TEST|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
47983188|NCT01434069|DRUG|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
47983189|NCT01434069|DRUG|FOLFIRI Infusion|Standard therapy of FOLFIRI
47983190|NCT00001054|DRUG|Valacyclovir hydrochloride|
48501208|NCT03860662|DRUG|Botox|botox
47983191|NCT02793141|OTHER|No intervention|No intervention will be administered
47983192|NCT00536601|DRUG|etoposide|Given IV
47983193|NCT00536601|DRUG|cyclophosphamide|Given IV
47983194|NCT00536601|DRUG|carmustine|Given IV
47983195|NCT00536601|DRUG|melphalan|Given IV
47983196|NCT00536601|DRUG|busulfan|Given IV
47983197|NCT00536601|DRUG|carboplatin|Given IV
47983198|NCT00536601|DRUG|thiotepa|Given IV
47983199|NCT00536601|RADIATION|total-body irradiation|Undergo TBI
47983200|NCT00536601|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo ASCT
48136249|NCT03733275|DRUG|Lidocaine|for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
48136250|NCT05562102|BIOLOGICAL|Typbar-TCV, Bharat Biotech|Typhoid conjugate vaccine
48136251|NCT00562094|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
48345951|NCT01779895|DIETARY_SUPPLEMENT|Placebo|maltodextrin
48345952|NCT00033449|DRUG|gefitinib|Given orally
48345953|NCT00033449|RADIATION|radiation therapy|Undergo radiation therapy
48345954|NCT00033449|DRUG|cisplatin|Given IV
48345955|NCT00033449|OTHER|laboratory biomarker analysis|Correlative studies
48345956|NCT01600391|BEHAVIORAL|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
48345957|NCT01600391|BEHAVIORAL|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
48345958|NCT01600391|BEHAVIORAL|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
48345959|NCT02412527|OTHER|Patch III heart rate sensor|
48345960|NCT05915104|DRUG|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
48345961|NCT05915104|DRUG|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
48345962|NCT00236405|DRUG|epoetin alfa|
48345963|NCT04734626|DIAGNOSTIC_TEST|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
48345964|NCT00922519|OTHER|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 6 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
48345965|NCT05459766|BEHAVIORAL|Action observation and motor imagery|Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.
48345966|NCT05459766|BEHAVIORAL|Usual care|Participants will be educated about the postoperative rehabilitation program
48345967|NCT00645203|DRUG|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
48345968|NCT03423615|BEHAVIORAL|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
48345969|NCT01712490|DRUG|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
48136252|NCT06251336|OTHER|UroialTM Plus|Nutraceutical
48136253|NCT06251336|OTHER|Placebo|Placebo sachet
48136254|NCT01860079|PROCEDURE|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
48345970|NCT01712490|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
48345971|NCT01712490|DRUG|bleomycin|Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
48345972|NCT01712490|DRUG|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
48345973|NCT01712490|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
48345974|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm A)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
48345975|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm B)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
48345976|NCT03739736|OTHER|Standard of care (arm C)|"The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm."
48501209|NCT03860662|DRUG|Baclofen|baclofen
47983201|NCT00536601|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
47983202|NCT02826031|DRUG|Sodium Hyaluronate Injection|
47983203|NCT02826031|DRUG|DICL-SR|
48345977|NCT03778580|DIETARY_SUPPLEMENT|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
48345978|NCT03778580|DRUG|placebo|placebo
48345979|NCT05796349|DIAGNOSTIC_TEST|multifrequency EIT-based for detecting intracranial abnormalities|For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
48345980|NCT04449991|PROCEDURE|Repeat kidney biopsy|Intensification of immunosuppression if NIH AI \> 3
48345981|NCT01283893|PROCEDURE|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
48345982|NCT05317260|DRUG|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
48345983|NCT05479006|DEVICE|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
48345984|NCT00244777|DRUG|Hypo-osmolar ORS|
48345985|NCT01673425|DRUG|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
48345986|NCT04104204|DRUG|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
48345987|NCT04104204|DRUG|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
48345988|NCT02003768|DRUG|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
48345989|NCT02003768|DRUG|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
48345990|NCT02725736|DRUG|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
48345991|NCT02725736|DRUG|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
48345992|NCT03304093|DRUG|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
48345993|NCT04399057|DIAGNOSTIC_TEST|shear Wave Elastosonography|both the left cavernous body and the right cavernous body are ideally divided longitudinally into three sections: proximal, middle and distal. subsequently for each section of the corpora cavernosa the stiffness of the tissue is calculated by means of a specific Region Of Interest (ROI). the result is expressed in Kilopascals and in a color scale. when registering the stiffness the patient is asked to hold their breath.
48345994|NCT00004194|DRUG|fludarabine phosphate|
48345995|NCT04140682|DEVICE|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
48345996|NCT04140682|DEVICE|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
48345997|NCT04290403|DEVICE|Pull Ups|Participants will be asked to wear pull-ups continence products for the duration of four weeks
48345998|NCT04290403|DEVICE|Styled Briefs with tapes|Participants will be asked to wear styled briefs with tapes for the duration of four weeks
48345999|NCT04786730|DRUG|Centanafadine|Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
48346000|NCT05498025|OTHER|Deterra activated charcoal pouch|drug disposal pouch
48346001|NCT02628704|DRUG|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
48346002|NCT02628704|DRUG|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
48346003|NCT02628704|DRUG|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
48346004|NCT02628704|DRUG|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
48346005|NCT06025084|DRUG|Egg Shell nanoparticles|Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
48346006|NCT02224937|DRUG|Melatonin|
48346007|NCT02224937|DRUG|Placebo|
48346008|NCT01553760|PROCEDURE|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
48346009|NCT01553760|PROCEDURE|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
48346010|NCT04143425|DIAGNOSTIC_TEST|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
48346011|NCT04143425|DIAGNOSTIC_TEST|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
48346012|NCT04143425|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
48346013|NCT00247273|DRUG|risedronate|tablet, 5 mg risedronate, once a day for 2 years
48346014|NCT00247273|DRUG|risedronate|oral, 150 mg risedronate, once a month for 2 years
48501210|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
48501211|NCT00265395|DRUG|Combination of pegylated interferon alfa-2b and ribavirin|"1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
48501212|NCT04269538|DRUG|PF-06480605|PF-06480605 150 mg and 450 mg SC dosing
48501213|NCT04269538|DRUG|Placebo|Placebo SC dosing
48501214|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
48501215|NCT03023176|BIOLOGICAL|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
48501216|NCT06283576|DIAGNOSTIC_TEST|Liquid biopsy|"Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth"
47983204|NCT04506489|OTHER|Psychological investigation|Psychological tests, psychological interviews.
48136255|NCT00765544|DEVICE|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
48346015|NCT05423704|OTHER|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
48346016|NCT02381067|OTHER|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
48346017|NCT01892241|DRUG|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
48346018|NCT01892241|DRUG|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
48346019|NCT00163163|PROCEDURE|Echographic measurements|
48346020|NCT00163163|PROCEDURE|Blood samples|
48346021|NCT03903913|DRUG|S-1226|The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
48346022|NCT05258981|DIAGNOSTIC_TEST|MRI|Brain MRI
48346023|NCT02740712|DRUG|Caffeine|200 mg (4 x 50mg) Tablet
48346024|NCT02740712|DRUG|Warfarin|10 mg (2 x 5mg) Tablet
48501217|NCT00883909|DRUG|dutasteride|A follow-up study in adult male subjects who have received investigational product
48501218|NCT00019864|BIOLOGICAL|filgrastim|
48501219|NCT00019864|DRUG|cisplatin|
48501220|NCT00019864|DRUG|dexrazoxane hydrochloride|
48501221|NCT00019864|DRUG|doxorubicin hydrochloride|
48501222|NCT00019864|DRUG|leucovorin calcium|
48501223|NCT00019864|DRUG|methotrexate|
48501224|NCT00019864|PROCEDURE|adjuvant therapy|
48501225|NCT00019864|PROCEDURE|conventional surgery|
47983205|NCT03773705|PROCEDURE|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
48346025|NCT02740712|DRUG|Omeprazole|40 mg Tablet
48346026|NCT02740712|DRUG|Midazolam|5 mg/mL
48346027|NCT02740712|DRUG|digoxin|.25 mg Tablet
48346028|NCT02740712|DRUG|Vitamin K|10 mg Tablet
48346029|NCT02740712|DRUG|Rucaparib|200 \& 300 mg tablet
48346030|NCT05270967|DIAGNOSTIC_TEST|F-18 FDG PET/CT imaging|Oncological imaging
48346031|NCT05270967|BIOLOGICAL|Pfizer/biontech mRNA vaccine|COVID-19 vaccine
48346032|NCT05160662|PROCEDURE|New guidlines|New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
48346033|NCT05573568|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen
48501226|NCT00019864|PROCEDURE|neoadjuvant therapy|
48501227|NCT05483595|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 10ml
48501228|NCT06421883|DIETARY_SUPPLEMENT|Lactobacillus containing probiotic|"Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months."
48501229|NCT04810286|PROCEDURE|3d-Printing Myofunctional Appliance|To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.
48501230|NCT06406218|BEHAVIORAL|Phase I Cardiac Rehabilitation Exercise Training|"A) In the morning, take a supine position and perform straight leg raises with each leg individually, lifting to a height of 30° and holding for 3-5 seconds. Raise both arms to the side of the head to a 90° angle and hold for 5-10 seconds. Inhale deeply when exerting force and exhale slowly when lowering. Alternate between leg lifts and arm raises, performing 5 sets per session. Adjust intensity based on individual condition and may be repeated. In the afternoon, sit beside the bed for 5 minutes. B) After transitioning to secondary care according to the patient's condition, stand beside the bed for 5 minutes in the morning; in the afternoon, march in place beside the bed for 5 minutes. C) Walk beside the bed for 10 minutes per session, twice a day. D) Move around and doing activities under supervision inside the ward, 10 minutes per session, twice a day.~Spend approximately one day at each level, gradually progressing the exercise to the patient's tolerance level."
48501231|NCT00773734|DRUG|Apremilast 10mg|
48501232|NCT00773734|DRUG|Apremilast 20mg|
48501233|NCT00773734|DRUG|Apremilast 30 mg|
48501234|NCT00773734|DRUG|Placebo|
48501235|NCT00773734|DRUG|Apremilast 30mg|
48501236|NCT00773734|DRUG|Apremilast 20mg|
48501237|NCT01212588|DRUG|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
48346034|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
48501238|NCT01212588|DRUG|Placebo|3 tablets once daily for seven days
48501239|NCT02314091|PROCEDURE|onlay mesh hernioplasty|
48658460|NCT06298708|BIOLOGICAL|Havrix 720 Junior|"Havrix 720 Junior: An inactivated hepatitis A vaccine, 720 ELISA units per 0.5 ml of formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain).~Dose and administration: a pre-filled syringe, intramuscular injection of 0.5 ml will be administered for 2 times with 6-month interval."
48658461|NCT06601179|DEVICE|HIFU|high-intensity focused ultrasound treatment of benign prostatic hyperplasia
48136256|NCT00765544|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
48136257|NCT05119543|OTHER|outdoor time|This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
48136258|NCT02138994|DEVICE|Next Science Wound Gel|
48136259|NCT02138994|DRUG|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months"
48136260|NCT05784259|BEHAVIORAL|Transdiagnostic single-session treatment|Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
48346035|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles);~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
48501240|NCT02562339|BEHAVIORAL|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
48501241|NCT00556777|PROCEDURE|axillary lymph node dissection|
48136261|NCT03214172|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
48136262|NCT00087022|BIOLOGICAL|girentuximab|Given IV
48136263|NCT00087022|OTHER|placebo|Given IV
48136264|NCT01337141|OTHER|Control|7 face-to-face visits.
48136265|NCT01337141|DEVICE|Telecare system|5 telematic visits and 2 face-to-face visits.
48501242|NCT00556777|PROCEDURE|conventional surgery|
48501243|NCT00556777|PROCEDURE|sentinel lymph node biopsy|
48501244|NCT00556777|RADIATION|intraoperative radiation therapy|
48501245|NCT00867997|OTHER|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
48501246|NCT00867997|OTHER|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
48501247|NCT00867997|OTHER|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
48136266|NCT05795088|DEVICE|Continuous theta burst stimulation|Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
48136267|NCT00131209|DIETARY_SUPPLEMENT|fortified spread (RUTF)|
48136268|NCT00131209|DIETARY_SUPPLEMENT|maize and soy flour|
48136269|NCT05623436|BEHAVIORAL|Nursing students will be trained through virtual reality.|Nursing students will be trained through virtual reality.
48501248|NCT04885465|BEHAVIORAL|web-based psychoeducational support|Caregivers in the experimental group will have access to psycho-educational support through a web-based plattform during 3 months.
48501249|NCT04735861|DRUG|Sintilimab|Sintilimab 200mg iv. q3w, up to 2 years.
48501250|NCT04735861|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
48658462|NCT06570616|DEVICE|CPAP (fixed mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
48136270|NCT00104949|BIOLOGICAL|trastuzumab|
48136271|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management and Dietary Fiber|Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
48136272|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management|Routine nutrition management for 12 weeks.
48136273|NCT03389919|BIOLOGICAL|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
48136274|NCT02610608|OTHER|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
48658463|NCT06570616|DEVICE|APAP (automatic mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
48658464|NCT02734004|DRUG|Olaparib|Olaparib
48501251|NCT06406270|OTHER|Fava|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
48658465|NCT02734004|DRUG|MEDI4736|MEDI4736
48136275|NCT03916341|OTHER|EC with nicotine|Use an EC with nicotine for up to 30 minutes
48136276|NCT03916341|OTHER|EC without nicotine|Use an EC without nicotine for up to 30 minutes
48136277|NCT03916341|OTHER|control|sham control
48136278|NCT03916341|OTHER|TC with nicotine (own brand)|smoke a TC
48346036|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study."
48346037|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm B)|"Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis."
48346038|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
48658466|NCT02734004|DRUG|Bevacizumab|Bevacizumab
48658467|NCT00830336|DRUG|Azithromycin|Oral Suspension
48658468|NCT00830336|DRUG|Zithromax®|Oral Suspension
48658469|NCT05524012|DIAGNOSTIC_TEST|Blood sample|longitudinal blood samples for CTC monitoring
48658470|NCT05524012|DEVICE|MRI scan|longitudinal MRI scans (non-contrast enhanced)
48658471|NCT05024162|DIAGNOSTIC_TEST|MRT Accuracy|Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
48658472|NCT05024162|DIAGNOSTIC_TEST|MRT Stability|MRT's predicted GG at second MRI-P.
48658473|NCT04240509|DRUG|Emtricitabine / Tenofovir|Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
48658474|NCT06477029|DEVICE|tFUS|tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
48658475|NCT06477029|DEVICE|Sham tFUS|Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
48658476|NCT00303407|DRUG|nadroparin|
48658477|NCT05462262|DRUG|Intensive lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
48658478|NCT05462262|DRUG|Moderate-intensity lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
48136279|NCT03916341|OTHER|research TC with very low level nicotine|smoke a research TC with very low level nicotine
48136280|NCT00976651|DRUG|human menopausal gonadotropin|200 IU per day in the late follicular phase
48136281|NCT00005820|DRUG|nitrocamptothecin|
48658479|NCT05937802|DIETARY_SUPPLEMENT|Osmotin|Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
48136283|NCT01505166|BIOLOGICAL|Vigil™ Vaccine|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
48136284|NCT01505166|DRUG|Placebo|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
48136285|NCT02042703|DEVICE|anterior segment OCT|
48346039|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
48346040|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
48346041|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm B)|"4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion."
48346042|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
48346043|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm B)|"Arm B (Experimental arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
48346044|NCT00678236|OTHER|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
48346045|NCT00678236|OTHER|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
48346046|NCT02323308|OTHER|blood sampling|
48346047|NCT02152540|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
48346048|NCT02152540|DEVICE|Sham rTMS|Placebo Device that simulates active rTMS treatment
48346049|NCT05286567|DRUG|RGRN-305|Heat shock protein 90 inhibitor
48346050|NCT05286567|DRUG|Placebo|Placebo (blinded)
48346051|NCT03116841|DRUG|Vonoprazan|Vonoprazan 20 mg
48346052|NCT02163772|PROCEDURE|Intracordal hyaluronate injection|
48346053|NCT02262338|DRUG|AGT-182|Recombinant HIRMAb-IDS
48346054|NCT04819867|DRUG|Propolis|propolis is an extract derived from bee hives
48346055|NCT04819867|DRUG|Gluma Desensitizer|Gluma is a desensitizer agent
48346056|NCT04440462|OTHER|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
48346057|NCT04440462|OTHER|Sterile water|2 ml of sterile water
48346058|NCT05826002|BEHAVIORAL|Digital self-guided psychological intervention for insomnia|A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
48346059|NCT03615989|BEHAVIORAL|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
48346060|NCT03615989|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
48346061|NCT03615989|DIETARY_SUPPLEMENT|Skim Milk|500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
48346062|NCT01824836|DRUG|anastrozole|Given PO
48346063|NCT01824836|OTHER|questionnaire administration|Ancillary studies
48658480|NCT06303310|OTHER|Gaze Stability Exercises|Group A ( Gaze Stability Exercise+ Routine Physical Therapy) Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.(16)
48346064|NCT01824836|OTHER|laboratory biomarker analysis|Correlative studies
48658481|NCT06303310|OTHER|Optokinetic Exercises|Group B (Optokinetic Exercises+Routine Physical Therapy) Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks
48136286|NCT05424666|PROCEDURE|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
48346065|NCT01824836|OTHER|pharmacogenomic studies|Correlative studies
48658482|NCT06303310|OTHER|Routine Physical Therapy|Routine Physical Therapy
48136287|NCT03003286|BEHAVIORAL|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
48136288|NCT03003286|BEHAVIORAL|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
48136289|NCT01183767|DRUG|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
48658483|NCT00409656|DRUG|Basiliximab|
48658484|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave once a week
47983206|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml)|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
47983207|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
47983208|NCT01096225|BIOLOGICAL|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
47983209|NCT01413191|BIOLOGICAL|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
47983210|NCT01413191|OTHER|Laboratory biomarker analysis|Correlative studies
47983211|NCT06454110|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. All subjects will be administered 17 mg/kg of NM8074 intravenously weekly for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.
47983212|NCT04489212|OTHER|Medical Chart Review|Review of medical chart
47983213|NCT04489212|OTHER|Patient Observation|Undergo observation
47983214|NCT04489212|OTHER|Quality-of-Life Assessment|Ancillary studies
48136290|NCT01183767|DRUG|Placebo|
48346066|NCT02603172|DRUG|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
48346067|NCT00774969|DRUG|Metronidazole|Metronidazole 10% ointment three times a day 7 days
47983215|NCT04489212|OTHER|Questionnaire Administration|Ancillary studies
47983216|NCT02932033|PROCEDURE|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
47983217|NCT02932033|PROCEDURE|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
47983218|NCT03007381|DRUG|Ketorolac Tromethamine|Intravenous analgesic
48346068|NCT03802240|DRUG|Sintilimab|200mg IV Q3W
48346069|NCT03802240|DRUG|IBI305|15mg/kg IV Q3W
48346070|NCT03802240|DRUG|Pemetrexed|500mg/m2 IV Q3W
48346071|NCT03802240|DRUG|Cisplatin|75mg/m2 IV Q3W
48346072|NCT03802240|DRUG|Placebo1|Placebo1 IV Q3W
48346073|NCT03802240|DRUG|Placebo2|Placebo2 IV Q3W
48346074|NCT03003130|DEVICE|Restylane Defyne|Intradermal injection
48346075|NCT03003130|DEVICE|Restylane|Intradermal injection
48658485|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave twice a week
48658486|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave once a week
48658487|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave twice a week
48346076|NCT04212936|PROCEDURE|Intraabdominal pressure|Limited intraabdominal pressure during laparoscopic cholecystectomy between 8 and 10 mmHg.
48346077|NCT02867384|DRUG|Obinutuzumab|B cell depletion
48346078|NCT02867384|DRUG|Placebo|Placebo
47983219|NCT03007381|DRUG|Normal Saline|Sham comparator
48136291|NCT04040296|OTHER|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
48136292|NCT01608568|DEVICE|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
48136293|NCT02563119|PROCEDURE|Gastric Bypass or Sleeve gastrectomy|
48136294|NCT03382470|OTHER|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
48136295|NCT06064669|DRUG|Metformin pretreatment before ovarian stimulation|The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
48346079|NCT06370949|DRUG|Bupivacain|Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
48136296|NCT06064669|DRUG|Placebo pretreatment before ovarian stimulation|The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
48136297|NCT06064669|DRUG|Metformin pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
48136298|NCT06064669|DRUG|Placebo pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
48136299|NCT03903692|DEVICE|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
48346080|NCT06370949|DRUG|bupivacain+dexmedetomidine|Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
48658488|NCT06563739|PROCEDURE|Focused low energy shock wave|Receive focused low energy shock wave once a week
48658489|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave once a week
47914553|NCT05126251|BEHAVIORAL|lifestyle intervention|Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
47914554|NCT01110148|OTHER|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
47983220|NCT01793675|PROCEDURE|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
48136300|NCT03903692|DEVICE|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
48136301|NCT04318834|OTHER|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
48136302|NCT03398876|DRUG|Oromucosal Nicotine Spray (ONS)|Participants will receive oral dose of oromucosal nicotine spray (ONS).
48136303|NCT03398876|DRUG|Nicotine Gum|Participants will chew nicotine gum for 30 minutes.
48136304|NCT03398876|OTHER|Cigarette|Participants will smoke one cigarette as 10 puffs for 3 minutes.
48136305|NCT02013700|BIOLOGICAL|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
48136306|NCT02013700|BIOLOGICAL|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
48346081|NCT03022513|OTHER|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
48346082|NCT01301755|PROCEDURE|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
48346083|NCT02109744|DRUG|Decitabine|
48346084|NCT02499575|DRUG|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
48346085|NCT02499575|DRUG|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
48346086|NCT05292573|DRUG|Metformin|During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
48346087|NCT05480501|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
48346088|NCT06032988|DIETARY_SUPPLEMENT|LactoLevure|Participants will receive LactoLevure\^R probiotic dietary supplement or matching placebo once a day.
48346089|NCT02283840|DRUG|BIA 2-093|
48658490|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave twice a week
48658491|NCT06563739|PROCEDURE|Non-exposed group|Traditional rehabilitation assessment and training guidance
48658492|NCT05878704|DRUG|GBT021601|Oral
48658493|NCT04956016|DEVICE|classic rTMS using the 8-shaped coil|20 rTMS sessions are planned (5 sessions per week)
48658494|NCT04956016|DEVICE|deep rTMS using the H1-shaped coil|20 rTMS sessions are planned (5 sessions per week)
48346090|NCT00135525|DRUG|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
48136307|NCT02079649|DRUG|AL-53817 Ophthalmic Solution, 0.1%|
48136308|NCT02079649|DRUG|AL-78843 Ophthalmic Solution, 0.03%|
48136309|NCT02079649|DRUG|Dexamethasone Ophthalmic Suspension, 0.1%|
48136310|NCT02079649|DRUG|AL-53817 Vehicle|Inactive ingredients used for masking purposes
48136311|NCT02724501|BEHAVIORAL|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
48346091|NCT00135525|DRUG|Placebo|Placebo
48346092|NCT01098032|DEVICE|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate \>300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
48346093|NCT01098032|DRUG|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
48136312|NCT02724501|PROCEDURE|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
48658495|NCT06565182|OTHER|Exercise|The intervention consists of two different types of moderate intensity exercise: Continuous aerobic and resistance exercise.
48136313|NCT06081608|DIAGNOSTIC_TEST|kidney function test|blood sample for kidney function test
48136314|NCT01760382|DEVICE|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
48136315|NCT03551379|DEVICE|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
48658496|NCT00645658|DRUG|Testim, 1% testosterone gel|Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.
48658497|NCT06272890|BEHAVIORAL|motivational interviewing|motivational interviewing
48658498|NCT02499237|DRUG|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
48658499|NCT02499237|DRUG|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
48658500|NCT02321514|DEVICE|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
48658501|NCT05961735|OTHER|PECS II Block|The Pecs II block is applied to the patients after induction of anesthesia .
48658502|NCT05961735|OTHER|Combined Serratus Anterior Plane Block|Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
47983221|NCT06473766|DIAGNOSTIC_TEST|RF data extraction|"To will be acquired:~10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.~The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural."
47983222|NCT00289315|BEHAVIORAL|Primary (Environmental) Weight Gain Prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
47983223|NCT00289315|BEHAVIORAL|Secondary (Behavioral) Weight Gain Prevention|School-based environmental program to promote healthy eating and physical activity in the overweight students.
47983224|NCT00289315|BEHAVIORAL|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
48136316|NCT01750684|DRUG|AC105|
48136317|NCT01750684|OTHER|Placebo|
48136318|NCT03489369|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
48136319|NCT05459350|DIAGNOSTIC_TEST|Safe Discharge Classification|Safe Discharge Classification
48136320|NCT02736851|OTHER|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
48136321|NCT02369484|DRUG|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
48136322|NCT04623489|BEHAVIORAL|¡Vivir Mi Vida! Lifestyle Intervention|
48346094|NCT01711580|OTHER|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
48346095|NCT01711580|OTHER|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head \& Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
48346096|NCT01711580|OTHER|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
48346097|NCT01711580|OTHER|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
48346098|NCT01711580|OTHER|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
48346099|NCT01711580|OTHER|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
48346100|NCT01711580|OTHER|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
48346101|NCT01711580|OTHER|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
48346102|NCT00230295|PROCEDURE|IMR LAG|
48346103|NCT01056419|PROCEDURE|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
48346104|NCT01056419|DRUG|Propylthiouracil|150-600 mg in two-three divided doses
48346105|NCT05181241|DRUG|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
48346106|NCT04823741|GENETIC|PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA|All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
48346107|NCT06392178|DEVICE|SugarVita|Serious digital game (application) that can be played on mobile phone, tablet or personal computer. Self-developed game.
48346108|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
48346109|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
48346110|NCT01641081|DRUG|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
48346111|NCT01641081|DRUG|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
48346112|NCT01641081|DRUG|Placebo|Placebo in the Pressair for 14 days
48346113|NCT00039091|BIOLOGICAL|ipilimumab|Given IV
48501252|NCT06406270|OTHER|Buckwheat|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
48501253|NCT04413331|OTHER|Data collection|Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse
48501254|NCT04413331|OTHER|Biological samples and data collection|Biological samples at M0, M6, M12, M24 and at each relapse until M60
47983225|NCT05152901|DRUG|EpiPen ®.|A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
48136323|NCT00767741|DEVICE|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
48136324|NCT04338451|OTHER|Music during the first part of ESWL|Music listening during first part of ESWL
48136325|NCT04338451|OTHER|Music during the second part of ESWL|Music listening during second part of ESWL
48346114|NCT01283178|RADIATION|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
48346115|NCT01283178|DRUG|cisplatin|Given IV
48346116|NCT01283178|RADIATION|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
48346117|NCT01283178|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
48346118|NCT01283178|PROCEDURE|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
48346119|NCT01283178|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
48346120|NCT02406339|DEVICE|NMES|Neuromuscular Electrical Stimulation
48136326|NCT01102699|DRUG|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
48346121|NCT02406339|DEVICE|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
48346122|NCT00289614|DRUG|Iopamidol 370 mgI/dL|
48346123|NCT02762708|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
48136327|NCT02903875|OTHER|Patient therapeutic education (PTE) programme|
48136328|NCT03202992|DRUG|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
48136329|NCT04233905|BEHAVIORAL|Psychometric questionnaire study|Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
48136330|NCT01892176|DIETARY_SUPPLEMENT|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
48136331|NCT02189174|DRUG|CLR457|
48136332|NCT02018900|DIETARY_SUPPLEMENT|Ecologic 825/scFOS|
48136333|NCT02018900|DIETARY_SUPPLEMENT|Placebo|
48136334|NCT00143130|DRUG|Pregabalin|Pregabalin
48136335|NCT01730456|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
48136336|NCT01218841|DIETARY_SUPPLEMENT|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
48136337|NCT01218841|DIETARY_SUPPLEMENT|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
48136338|NCT04439500|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
48136339|NCT04439500|BEHAVIORAL|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
48136340|NCT01292863|OTHER|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
48346124|NCT02762708|BEHAVIORAL|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
48346125|NCT02762708|DRUG|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
48658503|NCT02671292|BEHAVIORAL|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
48136341|NCT01292863|OTHER|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
48136342|NCT03745170|DRUG|Sintilimab|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
48136343|NCT03745170|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
48136344|NCT03745170|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
48346126|NCT02762708|DRUG|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
48136345|NCT03745170|DRUG|placebo|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
48136346|NCT01006538|DEVICE|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
48136347|NCT01006538|DRUG|Ranibizumab|intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
48346127|NCT05166486|OTHER|Calisthenic exercise|"Exercises involving major muscle groups will be given. Before starting the calisthenic exercises, they will be asked to perform 10 repetitive warm-ups and breathing exercises. The intensity of the calisthenic exercises will be adjusted on a weekly basis.~Calisthenic exercises are repeated 10-15 times in the first and second weeks; third and fourth weeks 15-20 repetitive; In the five, six, seven and eight weeks, it will be done with 25-30 repetitions.~Patients will be asked to keep an exercise diary and weekly follow-ups will be made over the phone.~Within eight weeks, each patient will come for control twice a month and will be asked to perform the exercises individually under the supervision of a physiotherapist. Patients will be asked to do the exercises three times a week for 8 weeks."
48346128|NCT04225312|DRUG|Personalized extended interval dosing of natalizumab|Personalized extended interval dosing of natalizumab with a schedule from every 6 weeks, which will be further extended if the trough level exceeds 10 ug/ml.
48346129|NCT04225312|DRUG|Standard interval dosing|Standard interval dosing in control group and historic group
48346130|NCT04346277|BIOLOGICAL|IC14, a monoclonal antibody against CD14|IC14 is a recombinant chimeric anti-human monoclonal antibody directed against human CD14. It recognizes both membrane-bound CD14 and soluble CD14.
48346131|NCT00801710|DEVICE|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
48346132|NCT00510770|DEVICE|CPAP application|
48346133|NCT03771781|DRUG|Empagliflozin Tablets|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
48346134|NCT03771781|DRUG|Empagliflozin Tab 25 MG|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
48346135|NCT01900405|DRUG|Dexmedetomidine|
48346136|NCT02253394|DRUG|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
48346137|NCT02253394|DRUG|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
48346138|NCT03914651|DRUG|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
48658504|NCT02671292|OTHER|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
48658505|NCT03947463|PROCEDURE|PECS block|After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
48658506|NCT01285232|DRUG|Anakinra|150 mg sc once daily during four weeks
48136348|NCT00523419|DRUG|Pemetrexed|500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
48136349|NCT01644032|OTHER|Teleconsultation|Teleconsultation between paramedics and an EMS physician
48346139|NCT03914651|DRUG|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
48346140|NCT04973085|DEVICE|Cold circulated water|Cold water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
48501255|NCT06456983|DEVICE|maintenance electroconvulsive therapy (mECT)|see Arms
47914555|NCT01110148|OTHER|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
47914556|NCT04765267|DIETARY_SUPPLEMENT|Zinc sulphate heptahydrate|Dietary supplements
47914557|NCT00234754|PROCEDURE|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
47914558|NCT06053125|PROCEDURE|Adipose Tissue Biopsy|Fat sample collected from abdomen before exercise, immediately after exercise, and 3 hours after exercise
47914559|NCT06053125|BEHAVIORAL|Exercise|30 minutes of exercise on a cycle ergometer exercise machine
47914560|NCT00748904|DRUG|Rifaximin|400 mg orally
47914561|NCT00748904|DRUG|Lactulose|20 grams titrate to 2-3 bowel movements in one day
47914562|NCT04834089|BIOLOGICAL|AntiSARS-CoV-2 Serum|Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1.
47914563|NCT04834089|OTHER|Placebo|Saline solution Administration Route: Intravenous
47914564|NCT03742752|OTHER|Enteral nutrition|administration of enteral nutrition
47914565|NCT03742752|OTHER|Parenteral nutrition|administration of parenteral nutrition
48346141|NCT04973085|DEVICE|Body-temperature circulated water|Body-temperature water was circulated through an adhesive wrap applied to the front of the neck, overlying the carotid arteries, for 120 minutes. MR thermometry was used to measure core brain temperature in 1-minute intervals throughout the intervention. On a different day, subjects crossed over and repeated the intervention in the other study arm (i.e., cold went to body-temperature, and vice-versa).
48346142|NCT00096551|DRUG|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
48346143|NCT00096551|DRUG|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
48346144|NCT00096551|DRUG|Recombinant Fowlpox-GM-CSF|
48501256|NCT03559400|DRUG|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
48501257|NCT03559400|DRUG|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
48501258|NCT05311748|DIAGNOSTIC_TEST|Ultrasound and doppler|Penile echocolour doppler ultrasound
48501259|NCT03878771|BIOLOGICAL|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
48501260|NCT03878771|DRUG|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
48658507|NCT06421350|DEVICE|Spinal Cord Stimulation Device|The closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
47983226|NCT05152901|DRUG|Epinephrine (0.3mg) inhaled|Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
47983227|NCT05152901|DRUG|Epinephrine (1.3mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
47983228|NCT05152901|DRUG|Epinephrine (4mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
47983229|NCT02457910|OTHER|Biomarker Analysis|Correlative studies
48346145|NCT01611662|DRUG|gemcitabine hydrochloride|Given IV
48346146|NCT01611662|DRUG|cisplatin|Given IV
48501261|NCT02906761|DRUG|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
48501262|NCT02906761|DRUG|Placebo|Placebo (2 tablets) twice daily for 6 months
48346147|NCT01611662|PROCEDURE|therapeutic conventional surgery|Undergo radical cystectomy
48346148|NCT01611662|OTHER|laboratory biomarker analysis|Correlative studies
48346149|NCT02031757|OTHER|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
48346150|NCT02031757|OTHER|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
48346151|NCT00041704|DRUG|Anidulafungin, VER002|
48501263|NCT01350583|DRUG|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
48501264|NCT00067899|DRUG|Vitamin E with and without Vitamin C|
48501265|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
48501266|NCT01600430|DIETARY_SUPPLEMENT|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
48658508|NCT06039761|PROCEDURE|Digestive or gynecological surgery by laparoscopy|Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
48658509|NCT05648812|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
48658510|NCT05648812|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
48658511|NCT02014467|DRUG|Denosumab|Injection
48658512|NCT02014467|DRUG|Placebo|Injection
48658513|NCT02014467|DIETARY_SUPPLEMENT|Elemental Calcium|Oral, at least 600 mg
48658514|NCT02014467|DIETARY_SUPPLEMENT|Vitamin D|Oral, at least 400 IU
47983230|NCT02457910|DRUG|Enzalutamide|Given PO
47983231|NCT02457910|OTHER|Pharmacological Study|Correlative studies
47983232|NCT02457910|DRUG|Taselisib|Given PO
48346152|NCT05932394|BEHAVIORAL|Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery|"Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered."
48346153|NCT05932394|BEHAVIORAL|the usual unit treatment|CAM-ICU scale is administered to the Control group. No visual material is used.
48346154|NCT00439894|PROCEDURE|Blood draw|blood draw at baseline, week 12 and week 24
48346155|NCT00839436|DRUG|CYT107|
48346156|NCT02456454|DRUG|Risperidone|Liquid risperidone
48346157|NCT02456454|DRUG|Valproic Acid|Liquid valproic acid
48346158|NCT02456454|DRUG|Placebo|
48346159|NCT04685369|OTHER|Medical Data extraction|Medical Data extraction
48346160|NCT01894867|DIETARY_SUPPLEMENT|magnesium|supply magnesium oxide for 6 weeks
48346161|NCT01894867|DIETARY_SUPPLEMENT|Placebo|
48346162|NCT02011672|OTHER|nutrient-enriched milk|
48346163|NCT02011672|OTHER|regular milk|
48346164|NCT06315686|DRUG|pemetrexed|The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
48346165|NCT06031181|PROCEDURE|Sublobar Resection|Sublobar Resection includes segmentectomy and wedge resection
48346166|NCT00881140|DRUG|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
48346167|NCT05265104|DRUG|SDF with stainless steel crown|Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown
48346168|NCT05265104|DEVICE|Diode laser application with stainless steel crown|Diode laser will be applied to the carious lesions primary molars to eradicate the bacteria and then the tooth will be sealed with stainless steel crown
48346169|NCT05265104|OTHER|stainless steel crown only|the primary molars with carious lesions will be sealed with stainless steel crowns following the concept of hall technique
48346170|NCT03125655|DIAGNOSTIC_TEST|Inflammatory markers|
48346171|NCT05241288|COMBINATION_PRODUCT|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)"
48346172|NCT00757367|DRUG|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
48136350|NCT01970410|DRUG|teriflunomide|14 mg oral teriflunomide daily
48346173|NCT02389218|DEVICE|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
48136351|NCT03170050|DEVICE|YYD701-2|HA Filler
48346174|NCT02389218|DRUG|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
48346175|NCT02332798|DRUG|PF-04958242|Administered as specified in the treatment arm
48346176|NCT02332798|DRUG|Placebo|Administered as specified in the treatment arm
48346177|NCT05920070|PROCEDURE|therapeutic mammoplasty|therapeutic oncoplastic surgeries in cases of breast cancer
48346178|NCT03764462|DRUG|AD-101 45mg|Raloxifene 45mg tablet
48346179|NCT03764462|DRUG|Raloxifene 60mg|Raloxifene 60mg tablet
48346180|NCT06240624|OTHER|No intervention|No intervention will be given.
48658515|NCT01765413|BIOLOGICAL|Varicella-zoster virus|
47983233|NCT03165279|PROCEDURE|Zenith Alpha Abdominal stentgraft|
47983234|NCT02442362|DRUG|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
47983235|NCT02442362|DRUG|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
48136352|NCT03170050|DEVICE|Restylane Perlane Lidocaine|HA Filler
48346181|NCT06095206|DRUG|GenSci094|On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
48346182|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion Subjects will receive conditioning therapy by ludarabine and Cyclophosphamide before cell infusion.
48346183|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
48346184|NCT01462045|BEHAVIORAL|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
48346185|NCT06291545|DEVICE|Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
48346186|NCT06291545|DEVICE|ScoreFlex NC Coronary Dilatation Catheter|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
48346187|NCT02621645|PROCEDURE|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
48346188|NCT02621645|PROCEDURE|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
48346189|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
48346190|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
48346191|NCT02621645|DEVICE|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
48346192|NCT05635279|OTHER||
48346193|NCT00565006|DRUG|MK0859|
48346194|NCT00957190|DRUG|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
48658516|NCT01765413|BIOLOGICAL|Yellow Fever Vaccine|
48658517|NCT01765413|BIOLOGICAL|Placebo|
47983236|NCT06199531|GENETIC|GS-100|A single intracerebroventricular (ICV) dose of the study treatment will be administered to patients with confirmed mutations in the NGLY1 gene.
47983237|NCT04464343|OTHER|no intervention|This is an observation study, with no intervention
48658518|NCT03790189|BIOLOGICAL|Subchondral and intra-articular injection of BMC|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
48136353|NCT04422405|PROCEDURE|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
48501267|NCT01600430|DIETARY_SUPPLEMENT|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
48501268|NCT03433898|DRUG|BI 754091|Solution for infusion
48501269|NCT03433898|DRUG|BI 754111|Solution for infusion
48501270|NCT00971776|DEVICE|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
48501271|NCT03190213|DRUG|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
48501272|NCT00627315|PROCEDURE|Gastric bypass|NOTE: Surgery will not be paid by the study
48501273|NCT00627315|PROCEDURE|Gastric banding|NOTE: Surgery will not be paid by the study
48501274|NCT01796938|DRUG|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
48501275|NCT03897985|DEVICE|Narcotrend TM|Measurement of anesthesia depth
48501276|NCT00898235|GENETIC|clonality analysis|analyze clonality
48501277|NCT00898235|GENETIC|polymerase chain reaction|analyze polymerase chain reaction
48501278|NCT00898235|GENETIC|protein analysis|analyze protein
48501279|NCT00898235|OTHER|biologic sample preservation procedure|preserve biologic samples
48501280|NCT00898235|OTHER|laboratory biomarker analysis|analyze laboratory biomarkers
48346195|NCT00662727|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
48346196|NCT00662727|DEVICE|Placebo|Placebo
48501281|NCT00898235|PROCEDURE|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
48501282|NCT00898235|PROCEDURE|quality-of-life assessment|assess quality of life at each follow-up for life
48501283|NCT04710316|DIAGNOSTIC_TEST|SARS-CoV-2 screening by molecular biology|SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome
48501284|NCT04710316|DIAGNOSTIC_TEST|Serological screening|Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies).
48501285|NCT02912650|DRUG|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
48501286|NCT02912650|DRUG|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
48501287|NCT02912650|DRUG|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
48658519|NCT06583343|DRUG|OnabotulinumtoxinA|Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.
48658520|NCT06583343|OTHER|Conventional Physical Therapy|Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions
48136354|NCT03520036|DRUG|MT-7117 low dose|MT-7117 low dose QD, oral, 16 weeks
48346197|NCT02307604|GENETIC|Tumour markers testing|
48501288|NCT02912650|DRUG|Placebo|2 caplets of Placebo
48501289|NCT06367608|DEVICE|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's dystonia . The ExAblate uses ultrasound to heat a small spot in the brain called globus pallidus internus(GPi). Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
48501290|NCT00886223|PROCEDURE|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
48501291|NCT00072592|DRUG|Rituximab|
48658521|NCT05660642|DRUG|BPL-003|Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)
48658522|NCT06295354|OTHER|No intervention, we just study 'aging'|No intervention, we just study 'aging'
47914566|NCT01454141|OTHER|Cognitive Control Training|Three sessions of CCT.
47914567|NCT01454141|OTHER|Peripheral Vision Task|Three sessions of PVT.
48136355|NCT03520036|DRUG|MT-7117 high dose|MT-7117 high dose QD, oral, 16 weeks
48136356|NCT03520036|DRUG|Placebo|Placebo QD, oral, 16 weeks
48346198|NCT01199497|DRUG|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
48346199|NCT01199497|DRUG|Group 2|placebo
48346200|NCT01537523|PROCEDURE|community-care program|community nurse care, physiotherapy
48346201|NCT02090218|DEVICE|I-Gel|I-Gel supraglottic airway device
48346202|NCT02090218|DEVICE|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
48346203|NCT03121456|OTHER|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
48346204|NCT03121456|OTHER|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
48501292|NCT06000943|OTHER|Low vs Intermediate vs High surgical risk stratified according with SAPT/DAPT/OAC and OAC+SAPT|"All patients undergoing TAVR will be stratified according with surgical risk level and all combination of antithrombotic therapy at discharge~Low risk (SAPT vs DAPT and OAC vs OAC+SAPT) Intermediate risk (SAPT vs DAPT and OAC vs OAC+SAPT) High risk (SAPT vs DAPT and OAC vs OAC+SAPT)"
48501293|NCT00175188|DEVICE|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
48501294|NCT04810130|OTHER|Soccer Kicking|Subjects assigned to the soccer kicking arm will complete 10 soccer kicks in 10 minutes.
48501295|NCT04810130|OTHER|Soccer Heading (Frontal)|Subjects assigned to the soccer heading (frontal) arm will complete 10 frontal soccer headers (ball headed directly back to launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
48136357|NCT00293397|DEVICE|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
48136358|NCT04886466|PROCEDURE|core stability in a sitting position and while walking in one place|The intervention consisted of checking how the active tension of the multisection and transverse abdominal muscles affects the pattern of the trunk movement (in the sitting position) and the work of the lower limbs and the speed of movement while walking in a place.
48136359|NCT03194659|DIETARY_SUPPLEMENT|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
48136360|NCT03856619|DRUG|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
48136361|NCT01214759|DRUG|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
48136362|NCT01214759|DRUG|Raltegravir|Raltegravir 400mg twice a day
48136363|NCT04630899|OTHER|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
48136364|NCT04630899|OTHER|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
48136365|NCT01515241|DRUG|CER-001|Weekly injection
48136366|NCT03396107|DRUG|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
48136367|NCT03396107|DRUG|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
48346205|NCT00625040|OTHER|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
48346206|NCT00466024|BEHAVIORAL|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
48346207|NCT00466024|BEHAVIORAL|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
48346208|NCT02408484|BIOLOGICAL|Octafibrin|Plasma-derived Fibrinogen concentrate
48346209|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once on Day 1 and Day 9, respectively
48501296|NCT04810130|OTHER|Soccer Heading (Oblique)|Subjects assigned to the soccer heading (oblique) arm will complete 10 oblique soccer headers (ball headed 90° to the right from ball launch direction) in 10 minutes. Soccer balls will be projected at 10-17.5 m/s from approximately 10-15 m with a JUGS ball launcher.
47983238|NCT02968251|BEHAVIORAL|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
47983239|NCT00045500|DRUG|7-hydroxystaurosporine|
47983240|NCT00045500|DRUG|prednisone|
47983241|NCT04758754|OTHER|Training|8-weeks iso-volume active (SLKE) or passive static stretching training (PST) involving lower limb muscles
48136368|NCT04617574|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
48136369|NCT04617574|DEVICE|Endo GIA Reloads with Tri-Staple Technology|Surgery with Endo GIA Reloads with Tri-Staple Technology
48346210|NCT05063968|DRUG|Placebo|Tablet is administered orally once on Day 1 and Day 9, respectively
48346211|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered fasted orally once on Day 1
48346212|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered after a high-fat meal orally once on Day 9
48346213|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once daily for 14 Days continuously
48346214|NCT05063968|DRUG|Placebo|Tablet is administered orally once daily for 14 Days continuously
48346215|NCT01496144|PROCEDURE|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
48346216|NCT01496144|PROCEDURE|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
48346217|NCT00182013|DRUG|Risperidone|Open treatment with Risperidone
48136370|NCT01748864|DRUG|Etarfolatide (EC20)|
48136371|NCT00002294|DRUG|Fluconazole|
48136372|NCT05871385|DEVICE|rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises
48136373|NCT05871385|DEVICE|placebo rTMS group|Twenty five randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
48136374|NCT00968903|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
48501297|NCT05739279|DIAGNOSTIC_TEST|STAR-Sonographic Thigh Adjustment Ratio|With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
48346218|NCT00182013|DRUG|Olanzapine|Open treatment with Olanzapine
48658523|NCT06305429|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 6 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. They will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
48346219|NCT00182013|DRUG|Quetiapine|Open treatment with Quetiapine
47983242|NCT01189214|DRUG|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
47983243|NCT01333059|DRUG|Midazolam|
47983244|NCT01333059|DRUG|Normal saline|
48501298|NCT05739279|DIAGNOSTIC_TEST|Hand Grip Strength|Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
48501299|NCT05739279|DIAGNOSTIC_TEST|Chair Stand Test|For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
48501300|NCT05739279|DIAGNOSTIC_TEST|6 Meter Gait Speed|For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
48501301|NCT03107247|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
47983245|NCT01333059|DRUG|Fentanyl|
47983246|NCT04197089|DRUG|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
48346220|NCT02450500|BEHAVIORAL|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
48501302|NCT04009512|DEVICE|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
48501303|NCT03193073|DIAGNOSTIC_TEST|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
48501304|NCT03193073|DIAGNOSTIC_TEST|serum fibroblast growth factor-23|serum levels of FGF-23
48346221|NCT04732572|BEHAVIORAL|Sleep and healthy lifestyle education|Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
48501305|NCT03193073|DIAGNOSTIC_TEST|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
48346222|NCT04732572|OTHER|Other supportive care|Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
48346223|NCT04732572|PROCEDURE|Adenotonsillectomy|Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
48346224|NCT03555968|DRUG|THC 0|THC dose = 0mg
48346225|NCT03555968|DRUG|THC 5|THC dose = 5mg
48346226|NCT03555968|DRUG|THC 10|THC dose = 10mg
48346227|NCT03555968|OTHER|BAC 0|Blood alcohol concentration = .000%
48346228|NCT03555968|OTHER|BAC .025|Blood alcohol concentration = .025%
48346229|NCT03555968|OTHER|BAC .049|Blood alcohol concentration = .049%
48501306|NCT00850434|DEVICE|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
48501307|NCT00850434|DEVICE|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
48501308|NCT05251519|OTHER|Kinesio Taping|Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
48501309|NCT05251519|OTHER|Conventional Rehabilitation|Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
48501310|NCT02985190|DRUG|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
48501311|NCT04732624|DRUG|Oral Rehydration Solution|Feasibility study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
48658524|NCT04416724|PROCEDURE|Phacoemulsification|Lens removal by Phacoemulsification
48658525|NCT04416724|DEVICE|Selective Laser Trabeculoplasty|Laser application in trabecular meshwork
48501312|NCT04732624|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
48346230|NCT02283541|BEHAVIORAL|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
48346231|NCT06393413|DRUG|Jiedu Yizhi Formula|Observation after 24 weeks of drug treatment
48501313|NCT02863783|DEVICE|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
48658526|NCT05919563|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
48658527|NCT06331949|OTHER|video assisted training|Ebelik bakımının yanı sıra NST konusunda eğitim içerikleri, eğitim videoları ve broşür destekli eğitimler verilecek. NST cihazı takılacak ve standart olarak işlem başladıktan 5 dakika sonra NST kaydı sırasında cihazdan gelen fetal kalp sesinin şiddeti artırılarak fetal kalp sesinin devam etmesi sağlanacaktır. Transfer edilecek hamile kadın yaklaşık 2 dakika kadar dinlenecektir.
48658528|NCT00864279|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
48658529|NCT00864279|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
48346232|NCT06393413|DRUG|Donepezil Hydrochloride Tablets|Donepezil Hydrochloride Tablets
48346233|NCT02244619|DRUG|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
48501314|NCT04569396|DIAGNOSTIC_TEST|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
48501315|NCT04569396|DIAGNOSTIC_TEST|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
48501316|NCT04569396|OTHER|BMI measurement|BMI was measured among the study subjects before and after the surgery.
48501317|NCT04569396|DIAGNOSTIC_TEST|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
48501318|NCT04569396|DIAGNOSTIC_TEST|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
48501319|NCT01646138|BIOLOGICAL|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
47983247|NCT02550145|DRUG|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
48501320|NCT04559737|OTHER|Case Management|"Population management platforms capable of automatically risk stratifying patients (eg, automatically identifying poor users) may be another cost-effective technology-based tool by enabling a management by exception (MBE) follow-up intervention. This intervention concentrates provider effort on patients most at need by allowing providers to passively observe successful users and actively intervene only in CPAP strugglers. Therefore, in addition to Usual Care we will implement this population management process by identifying CPAP strugglers only and further follow-up encounters will be triggered for these select patients for troubleshooting. Additionally, throughout the 1-year period, Q1 window of \<70% nights \>4 hours will trigger a phone call and at the discretion of the sleep provider convert to video or in-person encounter for troubleshooting. CPAP Follow-Up Questionnaire will also be delivered to patient at 3 months and 1 year."
48501321|NCT06008782|DEVICE|HEARS-SLP device|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
48501322|NCT06008782|BEHAVIORAL|HEARS-SLP program|Tailored aural rehabilitation for participant and communication partner
48501323|NCT00810576|DRUG|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
48501324|NCT00810576|DRUG|Bortezomib|Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
48501325|NCT03340207|DEVICE|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
48501326|NCT04013321|DEVICE|SleepScore Max coaching feature|The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.
48501327|NCT04013321|BEHAVIORAL|Online CBTi|Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
48501328|NCT04657796|DEVICE|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
48501329|NCT00299026|DEVICE|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
48501330|NCT03782909|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of;~1. Feedback via an app based food diary~2. Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
48658530|NCT03167060|DEVICE|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
48658531|NCT03167060|DEVICE|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
48658532|NCT00374179|DRUG|CT-322|IV solution, weekly or bi-weekly
48658533|NCT04647357|DRUG|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
48658534|NCT06591741|DIETARY_SUPPLEMENT|Oral PCA|PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years
48346234|NCT02244619|DRUG|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
48346235|NCT00392951|DRUG|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
48658535|NCT05013138|BEHAVIORAL|Training for ACEs and study procedures|"The providers will lead a resilience-based conversation discussion regarding the impact of caregiver ACEs, after receiving training for ACEs and study procedures.~The first training component will provide an overview of ACEs using the ACE Interface Training. The second training component will address the implementation of the caregiver ACEs screening in the clinic."
48346236|NCT02947334|BIOLOGICAL|Bococizumab|Bococizumab PFS
48346237|NCT02947334|DRUG|Placebo|Placebo
48346238|NCT01335594|PROCEDURE|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
48346239|NCT05905861|PROCEDURE|Skin incision with scalpel.|"A Pfannenstiel skin incision will be performed using a scalpel, extending through the subcutaneous tissue and rectus sheath. After separation of rectus muscles, peritoneum will be visualized and opened. Optimal hemostasis will be achieved by applying pressure to skin blood vessels and ligating any subcutaneous bleeding.~Group A: skin incision with a scalpel."
48346240|NCT05905861|PROCEDURE|Skin incision with a diathermy.|"A Pfannenstiel skin incision will be made using a scalpel. Subsequently, a diathermy pen electrode will be employed for the dissection of deeper tissues.~Optimal hemostasis will be achieved by using the same blade pen electrode, set to coagulation mode.~Group B: skin incision with diathermy."
48346241|NCT02724111|DRUG|sufficient dose of rocuronium|
48346242|NCT02724111|DRUG|sugammadex 10 min after position change|
48346243|NCT03207724|DRUG|Xilonix plus Onivyde and 5FU|Xilonix by IV
48346244|NCT02737605|DRUG|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
48346245|NCT02737605|DRUG|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
48346246|NCT02737605|DRUG|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
48346247|NCT02737605|DRUG|Oral Placebo|Participants will receive matching placebo orally.
48501331|NCT06017479|DRUG|Fosfomycin 3000 MG|Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
48501332|NCT06017479|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
48501333|NCT05353010|DRUG|Tacrolimus|Tacrolimus 5mg (1 mg \* 5 capsules)
48501334|NCT05353010|DRUG|IN-A001(Tegoprazan)|IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
48346248|NCT02737605|DRUG|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
48346249|NCT02737605|DRUG|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
48501335|NCT05353010|DRUG|IN-A001(Tegoprazan) + Tacrolimus|IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
48346250|NCT03074318|DRUG|Avelumab|Given IV
48346251|NCT03074318|DRUG|Trabectedin|Given IV
48346252|NCT00369044|DRUG|prednisone|
48346253|NCT03828565|PROCEDURE|ScvO2 Perioperative continue monitoring|"ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective\> 8g / dL), SaO2 (objective\> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV\> 13%, norepinephrine if PPV\<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (\> 65%), a measurement of arterial lactate is performed. If lactatemia is\> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is \<2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary."
48346254|NCT02224274|DRUG|Clopidogrel|
48346255|NCT02224274|DRUG|Ticagrelor|
48346256|NCT03756870|PROCEDURE|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
48346257|NCT02433691|OTHER|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
48501336|NCT03775759|PROCEDURE|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
48501337|NCT03775759|OTHER|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
48501338|NCT03275116|DRUG|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
48501339|NCT03275116|DRUG|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
48501340|NCT00132028|DRUG|vorinostat|Given orally
48501341|NCT00132028|OTHER|laboratory biomarker analysis|Correlative studies
48346258|NCT02433691|OTHER|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
48346259|NCT02433691|OTHER|stretching and toning|anaerobic stretching and toning followed by memory training.
48346260|NCT06234072|DRUG|Astragalus + Gemcitabine|Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
48346261|NCT06234072|DRUG|Gemcitabine alone|Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
48346262|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48346263|NCT03812783|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
48501342|NCT02744118|OTHER|5A's Model|"The adapted 5A's model will include the following elements:~1. Ask the patient about their marijuana use~2. Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~3. Assess factors affecting choice of behavior and behavior change~4. Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~5. Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
48501343|NCT02744118|OTHER|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~1. Balance~2. Boundaries~3. Communication"
48136375|NCT05247437|BEHAVIORAL|Digital Intensive Lifestyle Intervention|The FitD consists of 8 digital lessons on how to improve dietary and exercise habits using self-monitoring, goal-setting, cognitive restructuring, and other behavioral and cognitive strategies. The FitD app offers a virtual coach that guides the participant to complete the treatment.
48136376|NCT05247437|BEHAVIORAL|Digital Self-Help Control Condition|The digital self-help control condition consists of educational materials related to diet and exercise. The materials are open for access all at once. There is no guidance by a virtual coach or digital lessons.
48346264|NCT03812783|DRUG|Sorafenib|administration of Sorafenib
48136377|NCT01662505|DRUG|Volasertib|Patient to receive volasertib
48136378|NCT00262015|BIOLOGICAL|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
48136379|NCT03477968|DIAGNOSTIC_TEST|DDimer test|Measuring the level of DDimer in blood sample
48136380|NCT05660434|OTHER|Aroma Inhaler with Bergamot essential oil|The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
48136381|NCT05603182|DRUG|PRA052|PRA052
48136382|NCT05603182|OTHER|Placebo|Placebo
48136383|NCT03614663|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
48136384|NCT03614663|OTHER|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
48136385|NCT01016457|DEVICE|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
48658536|NCT05013138|BEHAVIORAL|Training on study procedures|Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination.
48136386|NCT00686595|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV infusion.
48136387|NCT05298358|BIOLOGICAL|RIC alloBMT w PTCy in refractory SSc|"The preparative regimen:~* Thymoglobulin 0.5 mg/kg IV day -9~* Thymoglobulin 2 mg/kg IV Days -8, -7~* Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~* Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~* Total body irradiation (TBI) 400cGy~* Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~* Cy 50 mg/kg IV Days 3, 4~* Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~* Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~* Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~* Mesna- 10 mg/kg/ IV Day 3, 4~* Patients will receive infection prophylaxis and treatment according to institutional guidelines."
48136388|NCT03042741|BIOLOGICAL|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
48136389|NCT03042741|BIOLOGICAL|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
48136390|NCT02262299|DRUG|Pirfenidone|Receive tablets with pirfenidone
48346265|NCT03812783|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48346266|NCT03812783|DRUG|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
48346267|NCT01041040|DRUG|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
48346268|NCT01144091|DRUG|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
48501344|NCT03309995|DEVICE|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
48658537|NCT03466151|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
48658538|NCT03466151|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
47983248|NCT02550145|OTHER|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
48136391|NCT02262299|DRUG|Placebo|Recieve tablets with placebo
48136392|NCT04163042|BEHAVIORAL|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
48136393|NCT03781349|DEVICE|MENS|
48136394|NCT03781349|DEVICE|TENS|
48136395|NCT02336958|DRUG|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
48136396|NCT02336958|DRUG|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
48136397|NCT02336958|DRUG|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
48136398|NCT02336958|DRUG|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
48136399|NCT03664011|DRUG|BI 730357 mixed with [C-14]BI 730357 BS|Oral Solution
48346269|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
48346270|NCT01144091|DRUG|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
48346271|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
48346272|NCT03512275|DRUG|Bermekimab Monoclonal Antibody 400 mg|subcutaneous injection
48501345|NCT03309995|DEVICE|Placebo lozenges|Placebo lozenges
48501346|NCT04889287|DRUG|Elinzanetant (BAY3427080)|Once daily over 12 days
48501347|NCT04889287|DRUG|Rosuvastatin|Single doses on Day 1, Day 8, and Day 13
48501348|NCT02592135|OTHER|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
48501349|NCT04061031|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
48346273|NCT03573804|OTHER|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
48136400|NCT05206240|OTHER|Radial extracorporeal shock wave therapy and conventional physical therapy|"The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks."
48136401|NCT01581216|OTHER|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
48136402|NCT01581216|OTHER|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
48136403|NCT01581216|OTHER|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
48136404|NCT03317652|OTHER|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
48136405|NCT03317652|OTHER|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
48346274|NCT03870672|DEVICE|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
48346275|NCT03870672|DEVICE|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
48346276|NCT03870672|DEVICE|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
48346277|NCT03870672|DEVICE|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
48346278|NCT04431804|OTHER|silver nanoparticle|fungicidal effect of silver nanoparticles on aspergillus isolates
48346279|NCT01229410|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
48501350|NCT04061031|BEHAVIORAL|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
48501351|NCT00294463|DRUG|Tibolone|
48501352|NCT00294463|DRUG|Estradiol|
48501353|NCT00294463|DRUG|Estradiol + Medroxy Progesterone Acetate|
48501354|NCT06634342|DIAGNOSTIC_TEST|HCV RNA Rapid testing|Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
48501355|NCT01709838|DRUG|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
48501356|NCT05486793|BEHAVIORAL|Written Exposure Therapy (WET)|5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend \~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.
48501357|NCT05486793|BEHAVIORAL|Emotion Focused Supportive Therapy (EFST)|5 individual sessions where patients choose what problems to discuss in each session. Therapists validate and clarify patients' emotions and engage in problem solving during sessions.
48136406|NCT03317652|DRUG|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
48346280|NCT01229410|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
48346281|NCT02318069|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 5 arms
48346282|NCT05106036|OTHER|Clinical Support Decision Tool|Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
48346283|NCT02389530|DRUG|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
48346284|NCT06247449|DIAGNOSTIC_TEST|Brain imaging|Brain Magnetic resonance (or computed tomography if magnetic resonance is contraindicated)
48346285|NCT06247449|DIAGNOSTIC_TEST|Analysis of circulating tumor DNA|One single blood draw for analysis of circulating tumor DNA
48346286|NCT06247449|BEHAVIORAL|Testing Morbidities Index|Questionnaire regarding the participant's perception of brain imaging.
48346287|NCT04463238|COMBINATION_PRODUCT|Guided cartilage regeneration membrane|On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
48346288|NCT04463238|PROCEDURE|Microfracture|Operate in accordance with the clinical microfracture surgery method.
48346289|NCT04228445|DRUG|3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
48346290|NCT04228445|DRUG|Saline spray|Placebo
48346291|NCT00553618|DRUG|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
48346292|NCT02805062|PROCEDURE|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
48346293|NCT02805062|PROCEDURE|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
48501358|NCT04470687|DEVICE|contrast enhanced ultrafast ultrasound imaging|"Ultrasound contrast medium: SonoVue 8µL/mL (Bracco International BV) Ultrasound scanner: Aixplorer® device marketed by SuperSonic Imagine©, CE Doppler UltraFast™Doppler, contrast ultrasound (CEUS), color Doppler and ultra-sensitive energy Doppler, high-performance directional energy Doppler, Elastography ShearWave™ UF-Doppler (UltraFast-Doppler) and microbubble injection (SonoVue) Apparatus for performing the UF Doppler sequence: Aixplorer, manufacturer : Supersonic Imagine, Aix-en-Provence, France, CE Marking.~3D RCA dedicated vascular probe with dedicated Doppler sequences"
47983249|NCT02129725|DRUG|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
48136407|NCT01078909|BIOLOGICAL|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
48136408|NCT00354237|OTHER|Conventional antidiabetic treatment|No intensive treatment
48346294|NCT03401476|DRUG|Morphine Sulfate|Morphine Sulfate Tablets
48346295|NCT03868475|PROCEDURE|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
48346296|NCT03868475|PROCEDURE|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
48346297|NCT03494023|DIAGNOSTIC_TEST|Endoscopic ultrasound|Measurement of the common bile duct diameter
48346298|NCT02348840|DEVICE|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
48346299|NCT05058118|DRUG|FL058|50mg、250mg、500mg、1000mg、1500mg、2000mg
48346300|NCT05058118|DRUG|Placebo|empty bottle
48346301|NCT04099836|DRUG|Atezolizumab|1200 mg IV every 3 weeks
48346302|NCT04099836|DRUG|Bevacizumab|15 mg/kg IV every 3 weeks
48346303|NCT04460365|DIETARY_SUPPLEMENT|10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin|"This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood."
48346304|NCT04460365|OTHER|Placebo|Softgel capsule containing sunflower oil (no active ingredients)
48346305|NCT03718273|DRUG|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
48346306|NCT03718273|DRUG|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance \<60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
48346307|NCT03064269|BIOLOGICAL|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
48346308|NCT00408291|PROCEDURE|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
48136409|NCT00354237|OTHER|Intensive insulin treatment|Intensive insulin treatment
48346309|NCT03137056|DEVICE|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
48346310|NCT03137056|DEVICE|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
48346311|NCT03137056|DEVICE|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
48501359|NCT01119508|DRUG|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
48136410|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in semi-sitting position|Patients will be placed in semi-sitting position. To achieve the semi-sitting position, the patient is placed in supine position. The operating table is then separated and flexed to elevate the torso (angle of 30°). The head, which is fixed in a head clamp, is slightly flexed to bring the floor of the sella right in front of the surgeon and gently rotated toward the operating team.
48346312|NCT05154357|OTHER|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
48501360|NCT01119508|DRUG|Temozolomide|Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
48501361|NCT05259995|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
48501362|NCT03666650|DRUG|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
48501363|NCT00798148|DRUG|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
48501364|NCT00021827|DRUG|Parathyroid hormone-related protein or ''PTHrP''|
48501365|NCT05204836|DRUG|Zoledronic Acid Injection|5 mg / 100 mL intravenous infusion
47983250|NCT02129725|DRUG|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
48136411|NCT04584866|PROCEDURE|Endonasal endoscopic pituitary surgery in supine position|Patients will be operated in the standard supine neutral position
48136412|NCT06487702|DRUG|fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium|"Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w"
48136413|NCT03670121|DEVICE|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
48136414|NCT01970007|DEVICE|Zilver Vena Venous Self-Expanding Stent|stenting
48136415|NCT01672333|DRUG|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
48136416|NCT05381519|BIOLOGICAL|DXP604|1800mg，IVgtt
48136417|NCT02339259|OTHER|Observation|
48136418|NCT04773431|DRUG|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
48136419|NCT05001659|OTHER|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
48136420|NCT01758549|OTHER|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
48136421|NCT01758549|OTHER|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
48136422|NCT04589975|PROCEDURE|laparoscopic surgery|
48136423|NCT01856569|OTHER|no intervention|in real life of drug,dosage,frequency and duration
48136424|NCT00836498|BIOLOGICAL|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
48136425|NCT00836498|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
48136426|NCT00836498|BIOLOGICAL|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
48136427|NCT05620472|DRUG|Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1|One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
48658539|NCT06094296|DRUG|BMS-986315|Specified dose on specified days
47983251|NCT04602455|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
47983252|NCT00531050|DRUG|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
47983253|NCT00531050|DRUG|Placebo|Single dose indacaterol matching placebo via Concept 1 device
47983254|NCT00531050|DRUG|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
47983255|NCT00128778|DRUG|Pegylated liposomal doxorubicin|
48136428|NCT00309166|BIOLOGICAL|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
48136429|NCT00309166|BIOLOGICAL|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
48136430|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
48136431|NCT00743574|DRUG|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
48136432|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
48136433|NCT00743574|DIETARY_SUPPLEMENT|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
48136434|NCT05705323|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (iCBT)|This CBT is specifically adapted for individuals experiencing tinnitus
48136435|NCT05705323|BEHAVIORAL|Internet-delivered mindfulness-based tinnitus stress reduction (iMBTSR)|This is a mindfulness-based intervention specifically adapted for individuals experiencing tinnitus
48501366|NCT05204836|DRUG|Placebo|100 mL intravenous infusion
48501367|NCT06165250|DRUG|BR1018A|One tablet administered alone
48658540|NCT06094296|DRUG|Nivolumab|Specified dose on specified days
48136436|NCT02842957|BEHAVIORAL|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
48501368|NCT06165250|DRUG|BR1018A-1|One tablet administered alone
48501369|NCT06165250|DRUG|BR1018B|One tablet administered alone
48658541|NCT06094296|DRUG|Pemetrexed|Specified dose on specified days
48658542|NCT06094296|DRUG|Cisplatin|Specified dose on specified days
48658543|NCT06094296|DRUG|Carboplatin|Specified dose on specified days
48658544|NCT06094296|DRUG|Paclitaxel|Specified dose on specified days
48658545|NCT03524157|DRUG|PRO-087|The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
48658546|NCT03524157|DRUG|Systane Ultra|The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
48501370|NCT06165250|DRUG|BR1018B-1|One tablet administered alone
48501371|NCT06165250|DRUG|BR1018C|One tablet administered alone
48658547|NCT03524157|DRUG|Xyel Ofteno|The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
48658548|NCT02686775|BEHAVIORAL|Patient coach|
48658549|NCT02686775|BEHAVIORAL|Standard care|
48136437|NCT01253213|DRUG|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
48658550|NCT05996120|PROCEDURE|Hypothermic Cardiopulmonary Bypass|Mild hypothermia (between 32 - 35 °C) during cardiopulmonary bypass
48658551|NCT05996120|PROCEDURE|Normothermic Cardiopulmonary Bypass|Normothermia (active maintenance of temperature between 36.5 °C to 37.5°C; no active cooling below 36.5 °C) during cardiopulmonary bypass
48658552|NCT04770285|DEVICE|CT-152 - Digital Therapeutic|CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.
48136438|NCT06515873|DEVICE|Virtual Reality Headset|The virtual reality headset, which will display one of the 3 available scenarios, will be placed on the patient head during a surgery under spinal anesthesia.
48136439|NCT02961075|OTHER|local surface anesthesia|Airway anesthesia for Bronchoscopy
48136440|NCT02961075|DEVICE|Laryngeal tube|
48136441|NCT03220334|DRUG|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
48136442|NCT03220334|DRUG|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
48136443|NCT04006834|OTHER|No intervention involved|No intervention involved
48136444|NCT02103166|DRUG|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
48136445|NCT02103166|DRUG|Physiological serum|100 ml of physiological serum (0.9% NaCl).
48136446|NCT01778842|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
48136447|NCT01778842|DRUG|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
48136448|NCT03065049|BEHAVIORAL|Peer-Facilitated Counseling|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
48136449|NCT03065049|BEHAVIORAL|Fitbit activity tracker|Participants will be given a Fitbit activity tracker to monitor physical activity.
48136450|NCT01872494|OTHER|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
48136451|NCT01872494|OTHER|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
48136452|NCT01872494|DRUG|0.33% ropivacaine 250ml|
48136453|NCT01872494|DRUG|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
48136454|NCT04061759|OTHER|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
48136456|NCT04148560|OTHER|Tests of the validity of the RFPM and SmartIntake app.|Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
48136457|NCT00449774|DRUG|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
48136458|NCT00449774|DRUG|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
48136459|NCT00000852|PROCEDURE|Allogeneic lymphocyte transfer|
48136460|NCT05925699|OTHER|Collection of clinical, radiological, and biological data from patients' medical records|Collection of clinical, radiological, and biological data from patients' medical records
48136461|NCT04185181|OTHER|virtual reality|wii video game based exercise
48136462|NCT04185181|OTHER|proprioceptive neuromuscular facilitation|PNF with breathing
48346313|NCT05154357|OTHER|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
48501372|NCT06165250|DRUG|BR1018C-1|One tablet administered alone
48501373|NCT02067273|DEVICE|Transcranial Magnetic Stimulation (TMS)|
48501374|NCT04447339|PROCEDURE|Nipple Sparing Mastectomy|Prophylactic open NSM procedures
48501375|NCT06308614|DRUG|20 mg estetrol monohydrate|Active treatment
48501376|NCT06308614|OTHER|Placebo|Matching Placebo to E4
48658553|NCT04770285|DEVICE|Sham|Sham mobile app was used by the participants as per the schedule specified in the respective arm.
48658554|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
48658555|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
48658556|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
48658557|NCT03773419|BEHAVIORAL|Texting Intervention (T-WRITE)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
48136463|NCT04185181|OTHER|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
48658558|NCT03773419|BEHAVIORAL|HandWriting Intervention (ORLA+WTG)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
48658559|NCT05547984|DEVICE|Dual Mobility Cup|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the Dual Mobility cup
47983256|NCT06469866|DEVICE|low-pressure pneumoperitoneum|low-pressure pneumoperitoneum (LPP) with deep NMB.
47983257|NCT06469866|DEVICE|standard-pressure pneumoperitoneum|standard-pressure pneumoperitoneum (SPP) with moderate NMB.
47983258|NCT00815945|DRUG|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
47983259|NCT00815945|DRUG|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
47983260|NCT03454581|PROCEDURE|Photobiomodulation|PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
47983261|NCT03454581|PROCEDURE|Manual Therapy (MT)|Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
47983262|NCT01286012|DRUG|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
47983263|NCT01286012|DRUG|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
47983264|NCT01286012|DRUG|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
47983265|NCT01286012|DRUG|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
47983266|NCT01957644|DRUG|Azacitidine|
47983267|NCT01957644|DRUG|Volasertib|
47983268|NCT02993068|OTHER|Educational Intervention|Watch genetic testing online educational video
47983269|NCT02993068|OTHER|Genetic Counseling|Receive post-telephone genetic counseling
47983270|NCT02993068|OTHER|Genetic Counseling|Receive pre-telephone genetic counseling
47983271|NCT02993068|OTHER|Laboratory Biomarker Analysis|Correlative studies
47983272|NCT02993068|OTHER|Questionnaire Administration|Ancillary studies
47983273|NCT02880189|DEVICE|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
47983274|NCT02880189|PROCEDURE|Endoscopic Ultrasound Guided Core Liver Biopsy|
47983275|NCT01961323|DRUG|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP\<140 and DBP \<90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
47983276|NCT00050596|DRUG|MDX-010 / MDX-010 + Docetaxel|
47983277|NCT01504945|OTHER|RBC transfusion|1 bag of packed red blood cells
47983278|NCT01504945|OTHER|Normal saline infusion|500 mL of normal saline infusion
47983279|NCT04006249|DIAGNOSTIC_TEST|dental probes|Measurement of the depth of the periodontal pockets and clinical loss
47983280|NCT05546567|DIETARY_SUPPLEMENT|Nicotinamide Riboside|1200mg x1 Nicotinamide Riboside
47983281|NCT01516320|PROCEDURE|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
47983282|NCT01516320|PROCEDURE|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
47983283|NCT01516320|PROCEDURE|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
47983284|NCT06498947|OTHER|This study was observational with no intervention.|This study was observational with no intervention.
47983285|NCT01772706|PROCEDURE|low level laser therapy|
47983286|NCT01772706|PROCEDURE|placebo (laser low level energy nonfunctional)|
47983287|NCT05226325|DRUG|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
47983288|NCT01938599|DRUG|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
47983289|NCT01938599|DRUG|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
47983290|NCT00763308|BEHAVIORAL|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
47983291|NCT00518986|DRUG|armodafinil|200 mg/day
47983292|NCT00518986|DRUG|placebo|placebo
47983293|NCT05378815|PROCEDURE|PRP injection|3 weekly intra-articular injections of 5mL PRP under ultrasound guidance
47983294|NCT05378815|PROCEDURE|Placebo injection|3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
48136464|NCT00789542|DEVICE|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
48346314|NCT06405685|DRUG|Nimotuzumab|Nimotuzumab 400 mg will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
48346315|NCT06405685|DRUG|AG|Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
48136465|NCT00789542|OTHER|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
48136466|NCT04023175|OTHER|Telemedicine preoperative counseling|The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.
48346316|NCT04520308|DRUG|Dupilumab Only Product|SC injections of 300 mg dupilumab every 2 weeks for 24 weeks following a loading dose of 600 mg on day 1
48346317|NCT01489761|DEVICE|percutaneous coronary intervention|drug eluting stent implantation
48346318|NCT01226589|PROCEDURE|MRS|
48346319|NCT01355497|DRUG|GTx-024|subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.
48346320|NCT01355497|DRUG|placebo|subject will receive matching placebo for the duration of the trial
48501377|NCT04644835|DEVICE|Low Energy Shock Wave Treatment|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
47983295|NCT03226392|DRUG|QAW039|QAW039 once daily
48346321|NCT00877760|DRUG|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
48346322|NCT00877760|DRUG|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
48346323|NCT04328441|DRUG|BCG Vaccine|Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
48346324|NCT04328441|DRUG|Placebo|Intracutaneously 0.1ml NaCl 0,9%
48346325|NCT04546867|DIAGNOSTIC_TEST|Sonographic based visualization of a pancreatic stent|As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
48346326|NCT00863941|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
48346327|NCT00863941|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
48346328|NCT03903276|OTHER|rehabilitation|Tens
48346329|NCT04313504|DRUG|Niraparib|Niraparib \& Dostarlimab combination
48346330|NCT04313504|DRUG|Dostarlimab|Niraparib \& Dostarlimab combination
48346331|NCT01611311|DRUG|BI 409306|Film-coated tablet
48346332|NCT01611311|DRUG|Placebo|Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
48346333|NCT04738240|DIAGNOSTIC_TEST|Intra-operative endoscopy|Intra-operative endoscopy to assess rectal anastomosis
47983296|NCT03226392|DRUG|Placebo|Placebo once daily
47983297|NCT02601131|BIOLOGICAL|Platelet transfusion|
47983298|NCT06378567|DIETARY_SUPPLEMENT|Dietary supplement liquid shot beverage products|Participants will use their product as instructed for 3 of the 4 study weeks
47983299|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
48346334|NCT04851327|BEHAVIORAL|High Energy preload|Tests the extent to which participants reduce their intake at a meal following ingestion of a high energy preload drink
48346335|NCT04851327|BEHAVIORAL|Low energy preload|Tests the amount participants eat at a meal following ingestion of a low energy preload drink
48346336|NCT04851327|BEHAVIORAL|Test meal|Test meal to follow low or high energy preload
47983300|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237 mL
47983301|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
47983302|NCT00622960|OTHER|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
47983303|NCT00622960|OTHER|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
48136467|NCT04023175|OTHER|In office preoperative counseling|This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
48346337|NCT03195686|DEVICE|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
48346338|NCT02769013|OTHER|Pre-treatment follow up|No active intervention; medical support provided if needed
48346339|NCT02769013|OTHER|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
48346340|NCT02769013|OTHER|Post treatment follow up|No active intervention; medical support provided if needed.
48346341|NCT02769013|OTHER|Olfactometer experiment|No active intervention; medical support provided if needed.
48346342|NCT05872698|DRUG|Carvedilol|Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.
48346343|NCT05872698|DRUG|Placebo|Placebo
48346344|NCT00092391|BIOLOGICAL|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
48346345|NCT00092391|BIOLOGICAL|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
48346346|NCT04319445|BEHAVIORAL|Mindfulness session(s)|The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
48346347|NCT02688725|DEVICE|post mastectomy ultrasound|post mastectomy ultrasound
48346348|NCT01386229|DRUG|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
48346349|NCT01386229|DRUG|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
48346350|NCT04974268|OTHER|Specific supervised exercise and weight loss program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
48346351|NCT04617106|PROCEDURE|Radial artery cannulation|cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
48346352|NCT04324086|DEVICE|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
48346353|NCT04324086|DEVICE|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
48346354|NCT04324086|DEVICE|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
48346355|NCT06133985|OTHER|Costovertebral mobilizations + Conventional PT|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness."
48346356|NCT06133985|OTHER|Conventional treatment|diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
48346357|NCT01201304|BEHAVIORAL|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
48346358|NCT01201304|BEHAVIORAL|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
48346359|NCT01201304|BEHAVIORAL|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
48346360|NCT01201304|BEHAVIORAL|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
48346361|NCT00591162|DRUG|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
48346362|NCT00591162|RADIATION|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
48346363|NCT00591162|PROCEDURE|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
48346364|NCT05999812|DRUG|all trans Retinoic Acid|ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days
48346365|NCT05999812|DRUG|Atezolizumab|Atezolizumab IV D1, 840 mg every 14 days
48346366|NCT05999812|DRUG|Bevacizumab|Bevacizumab IV D1, 10 mg/kg every 14 days
48346367|NCT00873704|OTHER|supplemental postoperative oxygen|
48346368|NCT00724646|OTHER|Survey|3 individual surveys
48346369|NCT00724646|OTHER|Focus group|Focus group discussions facilitated by a psychologist
47983304|NCT06293807|DRUG|Xylocaine 2 % with 1:100,000 epinephrine|Local anesthetic used during dental procedures
47983305|NCT06293807|DRUG|Bupivicaine 0.5% with 1:200,000 epinephrine|Local anesthetic used during dental procedures
48346370|NCT00879047|DRUG|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
48346371|NCT00879047|DRUG|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
48658560|NCT05547984|DEVICE|Standard Acetabular component|Total hip arthroplasty (THA) is a successful and established therapy for coxarthrosis, rheumatic arthritis, hip fractures and femoral head necrosis. The acetabular implant for this arm is the standard device with polyethylene + vitamin E inlay and metal head
47983306|NCT06293807|OTHER|Placebo|0.9% Normal Saline solution used in place of local anesthetic
48346372|NCT06240793|PROCEDURE|unilateral transforaminal epidural steroid block|unilateral transforaminal epidural steroid block
48346373|NCT06240793|PROCEDURE|bilateral transforaminal epidural steroid block|bilateral transforaminal epidural steroid block
48501378|NCT04644835|DEVICE|Sham Treatment|The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
48501379|NCT04047186|DRUG|Nivolumab Injection|Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
48658561|NCT04199390|PROCEDURE|total hip arthroplasty|each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
48658562|NCT06473675|PROCEDURE|Hysterectomy with adnexal surgery|Robotic-assisted and laparoscopic hysterectomy with adnexal surgery for benign disease.
48136468|NCT02105259|BEHAVIORAL|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
48136469|NCT02105259|OTHER|Waiting list|Waiting list, where participants wait for delayed treatment
48136470|NCT03991416|BEHAVIORAL|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
48136471|NCT03991416|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
48501380|NCT02281292|BIOLOGICAL|LKA651 ophthalmic solution|
48136473|NCT00973999|DRUG|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
48136474|NCT02266654|OTHER|IV fluids|Normal Saline 0.9%
48136475|NCT02266654|OTHER|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
48136476|NCT03926702|DRUG|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
48136477|NCT01000805|DRUG|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
48136478|NCT01000805|DRUG|Placebo|Participants received placebo QD, po for 8 weeks.
48136479|NCT04230941|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
48136480|NCT02479672|DEVICE|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
48136481|NCT02479672|PROCEDURE|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
48136482|NCT02479672|DEVICE|VividTrac®|
48136483|NCT03712150|DEVICE|tdcs|application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
48136484|NCT03066609|DRUG|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
48136485|NCT03066609|DRUG|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
48136486|NCT03066609|DRUG|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
48136487|NCT03665792|DEVICE|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
48136488|NCT02363049|PROCEDURE|Colectomy|
48136489|NCT02363049|DRUG|Chemotherapy|
48136490|NCT04305197|DRUG|ICP-022|Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
48136491|NCT04305197|DRUG|ICP-022|Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
48136492|NCT04305197|DRUG|ICP-022|Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
48136493|NCT04305197|DRUG|Placebos|Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
48136494|NCT00758550|DEVICE|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
48136495|NCT00758550|DEVICE|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
48136496|NCT01462175|DRUG|RO5503781|
48136497|NCT03707899|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
48136498|NCT03707899|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
48136499|NCT01303796|DRUG|Sapacitabine|Oral sapacitabine capsules
48136500|NCT01303796|DRUG|Decitabine|Decitabine intravenous
48136501|NCT04516057|DRUG|Nabilone|After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
48136502|NCT04516057|OTHER|Placebo|After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.
48136503|NCT01256242|DEVICE|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
48136504|NCT01256242|PROCEDURE|Standard Suture Repair|standard suture repair
48136505|NCT00954668|PROCEDURE|immediate angiography and revascularization|immediate angiography \< 2 hours after randomization
48136506|NCT00954668|PROCEDURE|early invasive angiography|early invasive angiography 12-72 h after randomization
48501381|NCT02281292|BIOLOGICAL|Ranibizumab ophthalmic solution|
48136507|NCT00140725|DRUG|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
48136508|NCT00140725|DRUG|Lamivudine|
48136509|NCT01736449|DRUG|Bevacizumab|
48501382|NCT02281292|BIOLOGICAL|Sham injection|Mock injection administered as an empty hub without needle
48136510|NCT02325349|DRUG|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
48136511|NCT04899011|OTHER|Questionnaire|"Questionnaire about taste and salivary disturbance before surgery, 10 days, 4 months and 1 year after surgery.~Questionnaires include characteristics of taste disturbance, and specific impact on quality of life."
48136512|NCT03324724|BEHAVIORAL|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
48136513|NCT02765594|DRUG|Hydroxychloroquine Sulfate|200mg bid
48501383|NCT02517463|DRUG|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
48501384|NCT02089035|DIETARY_SUPPLEMENT|MUFA-rich dairy products (UHT milk, cheese and butter)|
48501385|NCT02089035|DIETARY_SUPPLEMENT|Conventional dairy products (UHT milk, cheese, butter)|
48501386|NCT01123967|OTHER|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
48501387|NCT01123967|OTHER|telephone counseling (TC)|free telephone counseling
48501388|NCT01123967|OTHER|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
48501389|NCT01123967|OTHER|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
48136514|NCT02765594|DRUG|Valsartan|160mg qd
48136515|NCT01203293|BEHAVIORAL|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
48501390|NCT06372327|BEHAVIORAL|Daily Exercise Snacks|Participants will be encouraged to break up prolonged sitting at work with brief, high-intensity exercise snacks of varying length / total number depending on condition assignment.
48501391|NCT00004553|PROCEDURE|Electromyography|
48501392|NCT04485039|DRUG|Tecovirimat|oral antiviral
48501393|NCT04485039|DRUG|sevelamer carbonate oral tablet|phosphate binder
48501394|NCT04485039|DRUG|sucroferric oxyhydroxide chewable tablet|phosphate binder
48501395|NCT04485039|DRUG|calcium acetate oral tablet|phosphate binder
48501396|NCT04485039|DRUG|Lanthanum Carbonate Chewable Tablet|phosphate binder
48501397|NCT01330459|DRUG|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
48501398|NCT01330459|DRUG|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
48501399|NCT01330459|DRUG|Ibuprofen|800 mg oral ibuprofen
48136516|NCT01203293|BEHAVIORAL|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
48136517|NCT05829512|OTHER|Validity and reliability study|Face-to-face questionnaire study
48501400|NCT01330459|DRUG|Lorazepam|2 mg oral lorazepam
47983307|NCT00662610|DRUG|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
47983308|NCT00662610|DRUG|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
48136518|NCT02816398|DEVICE|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
48136519|NCT02350400|DEVICE|DEBIRI|DEBIRI TACE
48136520|NCT02189759|OTHER|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
48501401|NCT01330459|DRUG|Lidocaine|20 ml 1% buffered lidocaine, injected
48501402|NCT05914935|DRUG|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
48501403|NCT00187382|DRUG|Multiple vs. single courses of antenatalcorticosteroids|
48501404|NCT04600102|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
48501405|NCT01058772|OTHER|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score \< 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
48501406|NCT05267743|DRUG|Tegoprazan 50mg QD|Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
48501407|NCT05267743|DRUG|Lansoprazole 30mg QD|Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.
48501408|NCT03080415|DRUG|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
48501409|NCT03279211|OTHER|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
48501410|NCT03279211|OTHER|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
48501411|NCT03279211|OTHER|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
48501412|NCT04342260|OTHER|Active Monitoring|The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
48501413|NCT04342260|OTHER|Passive Monitoring|Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
48346374|NCT04922710|BEHAVIORAL|Home-based aerobic exercise|Guidelines for exercise programming (ACSM, 2018) will be followed including a warmup and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, three times a week, for 12 weeks. Participants who are unable to do a 60-minute session would instead complete it in two 30-minute sessions. The prescribed intensity will be based on estimated heart rate reserve, calculated using resting heart rate and age-adjusted heart rate maximum (220-age in years). Participants will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
48346375|NCT06189066|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
48346376|NCT01831804|DRUG|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
48501414|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)|Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
48501415|NCT06314880|BIOLOGICAL|Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)|Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
48501416|NCT06314880|BIOLOGICAL|Placebo control|Placebo control. 20 people/group.
48501417|NCT05240170|DEVICE|RIRS|The standard RIRS will be performed using a disposable flexible ureteroscope. Holmium: YAG laser will be used for stone dusting and fragmentation. If indicated, JJ ureteral stent will be placed at the end of the procedure.
48501418|NCT05240170|DEVICE|SWL|Patients who underwent SWL at our institution in the past five years. According to (a) the type of renal anomaly (rotation, position, or rotation/position anomaly), (b) the size of the stone (±5 mm), (c) location of the stone (lower polar or non-lower polar), and (d) density of the stone (\>800 HU or ≤800 HU), matched cases will be selected for comparison.
48501419|NCT04317183|DRUG|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
48501420|NCT04317183|DRUG|Miconazole Topical Gel|topical anti fungal agent
48501421|NCT04317183|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
48501422|NCT04317183|DRUG|Oracure gel|Topical analgesic gel
48501423|NCT06415877|OTHER|Episio Training|episio repair training
48501424|NCT04332887|BEHAVIORAL|Multidimensional Exercise Program|Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
48501425|NCT03730818|OTHER|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
48501426|NCT03730818|OTHER|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
48346377|NCT01831804|DRUG|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
48346378|NCT02552667|DRUG|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
48346379|NCT02552667|DRUG|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
48346380|NCT05720962|PROCEDURE|uninterrupted accompanying support|"When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm."
48346381|NCT04629586|OTHER|No intervention|Observational research study
48346382|NCT00539318|PROCEDURE|Blood drawing|Once when enroll in study
48346383|NCT01962389|DEVICE|Winsor Laser Catheter|
48501427|NCT00164151|DRUG|HalfLytely|
48658563|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) or matching placebo will be reconstituted with 1 mL of water for injection. Further dilution with 1 mL sodium chloride (NaCl) 0.9% will be performed for preparation of the dose of 8 mg selatogrel.
48346384|NCT00628342|DRUG|Esomeprazole|20mg Oral tablet once daily
48346385|NCT00628342|DRUG|Esomeprazole|40mg Oral tablet once daily
48346386|NCT00628342|DRUG|Placebo|Oral once daily
48346387|NCT03932890|DEVICE|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
48501428|NCT00164151|DRUG|Visicol|
48501429|NCT03063840|DEVICE|Microwave ablation|Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
48501430|NCT04067427|OTHER|Mental training|App-based mental training
48501431|NCT03056586|DEVICE|vaginal pessary|A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
48501432|NCT04709835|DRUG|AT-527|Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
48501433|NCT04709835|DRUG|Placebo|The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
48658564|NCT03384966|DRUG|Placebo|Matching placebo for subcutaneous administration.
48658565|NCT03384966|DRUG|Selatogrel|Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.
48136521|NCT02189759|OTHER|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
48346388|NCT03932890|DEVICE|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
48346389|NCT05068076|DRUG|Perfluorobutane|Perfluorobutane enhanced ultrasound will be done prior to ablation of HCC and after 2hours post ablation and comparison will be done with 1 month post procedure CT/MRI
48346390|NCT01729676|DRUG|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
48346391|NCT03185923|DRUG|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
48346392|NCT03185923|DRUG|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
48346393|NCT02597985|OTHER|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
48346394|NCT02597985|OTHER|Usual Care|
48346395|NCT01155791|DRUG|Docetaxel|IV 75 mg/m2
48346396|NCT01155791|DRUG|Biosyn|IV dosage varies
48346397|NCT01155791|DRUG|Prednisone|5mg, orally
48346398|NCT00433667|DRUG|RWJ-333369|
48346399|NCT02377271|DRUG|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
48346400|NCT02377271|DRUG|placebo|treatment by bosentan or placebo is randomized
48346401|NCT00859573|DRUG|Modafinil|400 mg/day
48346402|NCT00859573|DRUG|Placebo|inactive substance
48346403|NCT05345938|DRUG|Mitoxantrone Hydrochloride Liposome|Intravenous injection (IV), on day 1 of each 28-day cycle (q4w)
48346404|NCT05799547|OTHER|cold group|Application will be made in the form of 10 minutes of application to the cesarean section incision, 20 minutes of break and 10 minutes of application.
48346405|NCT03398252|DRUG|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
48346406|NCT03398252|DRUG|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
48346407|NCT06506851|OTHER|AR-based Training with Microsoft HoloLens 2®|Practical nurses in this group receive AR-based training using Microsoft HoloLens 2®. This training method incorporates augmented reality technology to provide immersive and interactive learning experiences, enhancing their proficiency in device utilization.
48346408|NCT06506851|OTHER|Traditional Guideline-based Self-Learning|Practical nurses in this group follow traditional guideline-based self-learning methods without augmented reality technology. They rely on conventional educational materials and guidelines for learning device utilization skills.
48346409|NCT05103995|OTHER|no intervention|no intervention, just observation
48346410|NCT04324268|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
48346411|NCT04324268|OTHER|Placebo|Placebo
48346412|NCT01963962|DRUG|Copper IUD|
48346413|NCT01963962|DRUG|Levonorgestrel IUD|
48346414|NCT04705350|DRUG|Zampilimab|Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
48346415|NCT04705350|DRUG|Placebo|Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
48136522|NCT02189759|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
48136523|NCT02189759|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
48136524|NCT02927249|OTHER|Placebo|Given PO
48136525|NCT02927249|DRUG|Aspirin|Given PO
48136526|NCT00822120|BIOLOGICAL|bleomycin sulfate|
48136527|NCT00822120|BIOLOGICAL|filgrastim|
48136528|NCT00822120|DRUG|ABVD regimen|
48136529|NCT00822120|DRUG|BEACOPP regimen|
48136530|NCT00822120|DRUG|cyclophosphamide|
48136531|NCT00822120|DRUG|dacarbazine|
48346416|NCT03860168|OTHER|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
48346417|NCT02392676|DRUG|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
48346418|NCT02392676|DRUG|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
48136532|NCT00822120|DRUG|doxorubicin hydrochloride|
48136533|NCT00822120|DRUG|etoposide|
48346419|NCT03942549|DEVICE|Retropubic midurethral sling|Midurethral sling
48346420|NCT04828850|PROCEDURE|Endobronchial ultrasound transbronchial needle aspiration lymph node staging|EBUS-TBNA in clinical N0 NSCLC patients
48346421|NCT00174928|DRUG|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
48346422|NCT00174928|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
48346423|NCT04124406|DEVICE|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
48136534|NCT00822120|DRUG|prednisone|
48346424|NCT03246711|BEHAVIORAL|Fasting|Totally or partially fasting the holy month of ramadan for muslims
48346425|NCT04693806|OTHER|Continuous CO2 Level|Embryos will be cultured in a single, continuous CO2 setting
48346426|NCT04229069|DIETARY_SUPPLEMENT|alkaline salt mixture|blood and tissue alkalinisation
48346427|NCT04229069|DIETARY_SUPPLEMENT|placebo|no blood and tissue alkalinisation
48346428|NCT04101370|DRUG|Bosentan 125 mg|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
48136535|NCT00822120|DRUG|procarbazine hydrochloride|
48136536|NCT00822120|DRUG|vinblastine sulfate|
48136537|NCT00822120|DRUG|vincristine sulfate|
48346429|NCT04101370|DRUG|Tracleer 125Mg Tablet|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
48346430|NCT04348188|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program with 12-month follow-up compared to the same unsupervised intervention
48346431|NCT05682768|PROCEDURE|Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures|Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
48346432|NCT04528004|DRUG|Nicotinamide riboside|Nicotinamide riboside 250mg capsules
48136538|NCT02915315|DIETARY_SUPPLEMENT|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
48346433|NCT04528004|OTHER|Placebo|Matching placebo 250mg capsules
48346434|NCT03890497|BIOLOGICAL|IPV|The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
48346435|NCT06455423|PROCEDURE|Thoracic Manipulation|Thoracic manipulation will be administered at hypomobile or stiff segments.
48346436|NCT06455423|PROCEDURE|Chin tuck in exercises|Chin tuck in exercises
48346437|NCT06455423|PROCEDURE|Thoracic Extension Exercise|Thoracic Extension Exercise
48346438|NCT06455423|PROCEDURE|Scapular Retraction Exercises|Scapular Retraction Exercises
48346439|NCT06455423|DEVICE|Hot Pack|Hot Pack
48346440|NCT06455423|DEVICE|TENS|Trans Cutaneous Electric Nerve Stimulation (TENS)
48346441|NCT06455423|PROCEDURE|ELDOA|ELDOA exercises
48346442|NCT01997138|DRUG|Anakinra 100 mg in 2 ml saline IA|
48346443|NCT01899768|DRUG|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
48346444|NCT01899768|DRUG|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
48346445|NCT02920879|PROCEDURE|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
48346446|NCT02876484|DRUG|Colesevelam|
48346447|NCT02876484|DRUG|Chenodeoxycholic Acid|
48346448|NCT02876484|OTHER|Water|
48346449|NCT02813590|OTHER|Ascitic fluid puncture|
48346450|NCT02813590|OTHER|Skin swaps from puncture side|
48346451|NCT02813590|OTHER|Stool samples|
48346452|NCT06104891|DIETARY_SUPPLEMENT|Recharge Placebo Control 1|Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.
48346453|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 1|Participants will use their Radicle Recharge Active Study Product 1 as directed for a period of 5 hours.
48346454|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 2|Participants will use their Radicle Recharge Active Study Product 2 as directed for a period of 5 hours.
47983309|NCT01522989|DRUG|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
48346455|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 3|Participants will use their Radicle Recharge Active Study Product 3 as directed for a period of 5 hours.
48346456|NCT03366974|DRUG|Midazolam|Midazolam 5 mg PO, Midazolam 1 mg IV
48346457|NCT03366974|DRUG|Clarithromycin|Clarithromycin 500 mg bid
48346458|NCT03366974|DIETARY_SUPPLEMENT|Grapefruit juice|Grapefruit juice 500 mL
48501434|NCT04461561|GENETIC|end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
48501435|NCT02009514|OTHER|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
48346459|NCT01455155|OTHER|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
48501436|NCT02451332|BIOLOGICAL|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
48501437|NCT02410980|DRUG|Tretinoin cream 0.1%|Assessment of the skin change
48346460|NCT01455155|OTHER|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
48346461|NCT04485468|OTHER|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
48346462|NCT00433927|DRUG|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
48346463|NCT00433927|DRUG|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
48346464|NCT00433927|DRUG|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
48346465|NCT00433927|DRUG|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
48346466|NCT00433927|DRUG|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
48346467|NCT04127240|OTHER|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
48346468|NCT00120510|DRUG|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
48346469|NCT00120510|DRUG|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
48346470|NCT03275519|OTHER|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
48346471|NCT03275519|OTHER|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
48346472|NCT04917731|DRUG|Botulinum toxin type A|Botox injected at digital artery
48501438|NCT05899751|DRUG|High-dose methotrexate|High-dose methotrexate
48346473|NCT02497053|DRUG|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
48346474|NCT02497053|DRUG|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
48501439|NCT05899751|DRUG|Glucarpidase|Glucarpidase
48501440|NCT04722822|BEHAVIORAL|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Providers within intervention practices will receive training which includes both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
48501441|NCT04722822|BEHAVIORAL|(Control) Recommending HPV vaccine for patients 11-12 years of age|Providers within control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
48346475|NCT04705428|OTHER|FLUORINE VARNISH|"Participants in all groups will receive written oral hygiene and oral prophylaxis instructions. All groups will receive the application of fluorine varnish every 3 months.~The application of fluoride in the three groups will be done as follows:~-Drying of the teeth, placement of the fluorine varnish on the teeth by quadrants. The varnish will be left to dry for a few seconds according to the manufacturer's instructions. Children in all groups will be asked to avoid brushing and flossing for one day after applying fluoride. They will be instructed to avoid hard food and hot drinks for 4 hours. Children and parents will be instructed on how to care for their teeth at home: brush teeth with conventional toothpaste containing 1000 ppm sodium fluoride, for 3 minutes without rinsing.~In the following reviews (3 and 6 months) the effectiveness of the treatments will be evaluated by visual examination, tactile examination, fluorescence and photography."
48346476|NCT05561634|RADIATION|Radiotherapy|Irradiation of the tumoral bed.
48346477|NCT05561634|OTHER|Observation|Patients will be followed up in consultation every 3 months.
48346478|NCT05561634|DRUG|Vismodegib|Sonic Hedgehog inhibitors (SHHi) = Vismodegib et Sonidegib,
48346479|NCT02826655|DEVICE|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
48346480|NCT02932319|DEVICE|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
48346481|NCT02932319|OTHER|expectative|expectative until the next day befor starting the induction
48346482|NCT00909818|RADIATION|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
48346483|NCT00909818|RADIATION|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
48346484|NCT01639300|BIOLOGICAL|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
48346485|NCT01639300|BIOLOGICAL|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
48346486|NCT00673218|DRUG|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
48346487|NCT00673218|DRUG|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
48346488|NCT06435962|DEVICE|sonography|measurement of optic nerve in RRMS by sonography and visual evoked potential( VEP) as correlation of axonal affection in RRMS patient
48346489|NCT00005065|DRUG|paclitaxel|Given IV
48346490|NCT00005065|DRUG|carboplatin|Given IV
48346491|NCT00005065|DRUG|motexafin gadolinium|Given IV
48346492|NCT00005065|PROCEDURE|conventional surgery|Undergo complete surgical resection
48346493|NCT00005065|RADIATION|radiation therapy|Undergo radiation therapy
48346494|NCT02849184|DRUG|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
48346495|NCT02849184|OTHER|Placebo|Placebo once daily before bedtime.
48346496|NCT06266871|DRUG|SOX+Tislelizumab+LDRT|"All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
48346497|NCT03022604|DIETARY_SUPPLEMENT|C4/Generation 4|12 grams of C4/Generation 4
48346498|NCT03022604|DIETARY_SUPPLEMENT|C450X|12 grams of C450X
48346499|NCT03022604|DIETARY_SUPPLEMENT|Placebo|12 grams of flavored dextrose
48346500|NCT04601844|DRUG|Pozelimab|Single dose administered subcutaneously
48346501|NCT04601844|DRUG|Cemdisiran|Single dose administered SC
48346502|NCT04827940|OTHER|Progressive relaxation exercise with music|"The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music."
48346503|NCT02617329|OTHER|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
48346504|NCT02617329|OTHER|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
48346505|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
48346506|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
48346507|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
48346508|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
48346509|NCT02111629|DRUG|Fluconazole and Secnidazole|
48346510|NCT02400060|BEHAVIORAL|Telephone-Based Intervention|Receive text messaging
48346511|NCT02400060|OTHER|Survey Administration|Ancillary studies
48346512|NCT02400060|OTHER|Laboratory Biomarker Analysis|Correlative studies
48346513|NCT05093569|DEVICE|K'watch|Patients
48346514|NCT02135549|DIETARY_SUPPLEMENT|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
48346515|NCT02135549|DRUG|Placebo Oral Tablet|Placebo comparator
48346516|NCT06145217|DRUG|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg|To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.
48346517|NCT05055037|OTHER|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
48346518|NCT01191957|DRUG|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
48346519|NCT01191957|DRUG|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
48346520|NCT02650440|PROCEDURE|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
48346521|NCT02650440|PROCEDURE|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
48346522|NCT06016335|DIAGNOSTIC_TEST|CT scan|Participants receive a CT scan of the head as part of their regular care. A larger part of the head will be scanned than for standard care.
48346523|NCT06016335|DIAGNOSTIC_TEST|MRI scan|Participants receive an MRI scan, specifically for the purpose of the study.
48346524|NCT06016335|OTHER|Synthetic CT scan|Synthetic CT scans will be generated from MRI scans, using the trained machine learning algorithm.
48346525|NCT01309373|OTHER|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
48346526|NCT03336203|DRUG|Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet|treatment either with allopurinol or febuxostat
48346527|NCT06167772|DIETARY_SUPPLEMENT|BCAA|"branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days"
48346528|NCT06167772|OTHER|Standard nutrition|Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70
48346529|NCT06167772|OTHER|Standard physiotherapy|A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
48501442|NCT01673243|OTHER|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
48501443|NCT06053918|OTHER|additional follow-up extension at home|additional interview when leaving the sector, and the extension of follow-up of the patient at home
48346530|NCT05519124|DEVICE|BTL-785-7|Treatment with the BTL-785-7 applicator to the BTL-785F system.
48346531|NCT02397967|OTHER|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
48346532|NCT06004440|DEVICE|Ion Endoluminal System|Subjects will under a planned procedure with the Ion Endoluminal System
48501444|NCT02114476|DEVICE|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
47983310|NCT01522989|DRUG|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
48346533|NCT02276794|OTHER|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
48501445|NCT02114476|DEVICE|Placebo|
48501446|NCT05635383|OTHER|PERIPHERAL NERVE BLOCK|Observation of rebound pain after peripheral nerve block application
48501447|NCT03180463|DRUG|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2\*10\^7 cells,
48501448|NCT03180463|PROCEDURE|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
48501449|NCT04352387|BEHAVIORAL|Montessori Method for Dementia|The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.
48501450|NCT04352387|BEHAVIORAL|Usual care|Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
48501451|NCT01334983|BEHAVIORAL|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
48501452|NCT05318274|RADIATION|Hypofractionated radiotherapy|Ultra hypofractionated 26 Gy in 5 fractions applied once with daily port film.
48501453|NCT04341857|DRUG|PD-1 Monoclonal Antibody(Sintilimab)|Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
48501454|NCT02988024|DRUG|LY03005|LY03005
48501455|NCT02988024|DRUG|Pristiq|
48501456|NCT03874286|DIAGNOSTIC_TEST|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsies are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
48136539|NCT03919721|BEHAVIORAL|Applied Behavioral Analysis|Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
48658566|NCT03058887|OTHER|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
48136540|NCT05194696|BEHAVIORAL|Questionnaire|Patients have to answer a questionnaire about their caffeine consumption habits during lifetime
48346534|NCT02276794|OTHER|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
48346535|NCT02532413|DRUG|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
48346536|NCT02532413|DRUG|Entecavir|Entecavir can inhibit the replication of HBV.
48346537|NCT06086782|OTHER|autogenic inhibition|Group 1 will receive AI-MET with conventional treatment. AI include stretching of the affected muscle and performing isometric contraction with 50% of the total patient's effort in the same muscle that will being stretched and position hold for 10 seconds, with 5 seconds of rest after every repetition. This procedure will repeat 5 times.
48346538|NCT06086782|OTHER|reciprocal inhibition|Group 2 receive RI-MET with conventional treatment. The RI also include stretching of the affected muscle but contrary to AI, isometric contraction of the antagonist muscles with the 50% of total patient's effort will follow. This position holds for 10 seconds, while agonist's muscle will still in the stretched position, with 5 seconds of rest after every repetition. This procedure will repeat 5 times too.
48346539|NCT02650167|BIOLOGICAL|Colostrum feeding|
48346540|NCT02650167|BIOLOGICAL|formula for preterm infants|
48346541|NCT04545411|DRUG|Dapagliflozin 10 MG [Farxiga]|4-Week, double-blind, once daily oral 10mg dapagliflozin
48501457|NCT01344278|BEHAVIORAL|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
48501458|NCT02936180|BIOLOGICAL|HD-TIV|
48501459|NCT02936180|BIOLOGICAL|SD-QIV|
48136541|NCT06260670|DEVICE|Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter|"Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps.~Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL)."
48136542|NCT04197622|DRUG|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
48136543|NCT01645124|DRUG|Hydroxyurea|
48136544|NCT01645124|PROCEDURE|Phlebotomy|
48346542|NCT04545411|DRUG|REMD-477|4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.
48346543|NCT04545411|DRUG|Placebo|4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
48346544|NCT03685929|PROCEDURE|Punch skin biopsy|Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
48346545|NCT00802724|BEHAVIORAL|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
48346546|NCT00802724|BEHAVIORAL|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
48346547|NCT05936372|BEHAVIORAL|Acute intense aerobic exercise|The acute intense aerobic exercise bout (iE) will consist of a 13-minute 20-meter shuttle run. During this exercise bout two speeds, based on a percentage of the estimated maximal oxygen consumption (VO2max), will be combined: a fast-paced speed (fast: 85% of VO2max) and a slow-paced speed (slow: 60% VO2max). A total of 3 series of 3 min of the fast-paced speed will be carried interspersed with 2 series of 2 min of the slow-paced speed. Prior to the iE start, a warm-up protocol consisting of 2 min slow and 1 min fast will be done with the objective to familiarize participants with the iE speeds. A 5-minute rest period will be guaranteed before starting the iE. Transition time between iE and the rotational visuomotor adaptation task (rVMA) will be 4 min.
48346548|NCT02792283|BIOLOGICAL|whole blood collection|
48346549|NCT05923151|PROCEDURE|The cranial-caudal mixed medial approach|"Expose the fusion fascia of Transverse colon mesocolon and stomach, and cut the gastrocolic ligament. The mesentery of Transverse colon was dissociated from the medial side to the lateral side along the gastroepiploic vessels to expose the branches of Henle's trunk and the right colon vessels. The dorsal mesentery of the small intestine is cut along the yellow white line, and free cephalically along the Toldt space to separate the posterior space of the Ascending colon and the anterior space of the pancreas and duodenum behind the Transverse colon. The right colon blood vessels were dissected along SMV from the projection of ileocolic blood vessels, and the blood vessels were cut off by high ligation, and the lymph nodes at the root of Mesentery were cleared. Through a small incision in the middle of the abdomen, the right colon and mesentery were completely removed to complete digestive tract reconstruction."
47983311|NCT01522989|DRUG|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
47983312|NCT05417061|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
47983313|NCT06101745|DRUG|Nizaracianine Triflutate|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0, 2.5 or 5.0mg depending on trial phase.
47983314|NCT06101745|DRUG|Placebo Comparator|In Phase 3A only, 50 subjects will be randomly allocated to receive sugar placebo
47983315|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.1 μg|solution for intradermal injection, 0.1 µg / 0.1 mL
47983316|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.2 μg|solution for intradermal injection, 0.2 µg / 0.1 mL
47983317|NCT05398562|DIAGNOSTIC_TEST|Placebo|solution for intradermal injection
48136545|NCT04415775|OTHER|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
48136546|NCT04415775|OTHER|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
48136547|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
48136548|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
48136549|NCT05786872|DEVICE|dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
48136550|NCT00733174|DRUG|Rosiglitazone|tablet
48136551|NCT00733174|DRUG|Placebo|
48136552|NCT02220959|OTHER|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
48136553|NCT04809376|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
48136554|NCT04809376|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
48136555|NCT04809376|DRUG|Pentosan Polysulfate Sodium Fixed Dose|Subcutaneous Injection, 100/150/180 mg if \<65kg/ ≥ 65 kg and ≤ 90kg/ \>90 kg IBW
48136556|NCT04809376|DRUG|Pentosan Polysulfate Sodium once weekly|Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
48136557|NCT05254392|DEVICE|Digital BP monitor (Chidalex®)|Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
48136558|NCT03315065|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, \< 1 hour
48136559|NCT06502132|OTHER|Patient Education Group|Patients whose surgery has been postponed will be educated by the researcher through a booklet regarding the waiting process. The education includes information such as anxiety management, pain management, and re-surgery planning. The booklet consists of 22 pages and a copy is given to each patient in this group. The education lasts between 15-20 minutes and the patients' questions are answered. It is applied in a single session.
48136560|NCT06502132|OTHER|Therapeutic Touch Group|Therapeutic touch application is applied as a single session and lasts approximately 20-25 minutes. The therapeutic touch that emerges from the artistic aspect of nursing is an energybased practice that does not involve physical contact. Therapeutic touch is a conscious and compassionate effort to direct the flow of one's universal life energy to healing by influencing this energy.
48136561|NCT00714207|BEHAVIORAL|NOT program|Students in this arm of the study received the reformatted NOT intervention
48346550|NCT01977157|DEVICE|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
48346551|NCT05874336|DRUG|Aramchol|Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
48346552|NCT05942677|PROCEDURE|proportion of colorectal lesions|Evaluation of the proportion of colorectal lesions detected by a computer-aided detection system (CADe) compared with experienced endoscopists.
48346553|NCT00806650|GENETIC|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
48346554|NCT00806650|GENETIC|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
48346555|NCT00806650|DIAGNOSTIC_TEST|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
48501460|NCT04696809|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
48136562|NCT00714207|BEHAVIORAL|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
48136563|NCT00714207|BEHAVIORAL|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
48136564|NCT00714207|BEHAVIORAL|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
48136565|NCT05758584|OTHER|Intervention|Vibrating tourniquet
48136566|NCT05758584|OTHER|Distraction card|Distraction card
48136567|NCT05340452|DRUG|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
48136568|NCT05340452|DRUG|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
48136569|NCT04172207|OTHER|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
48501461|NCT02714517|OTHER|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
48501462|NCT02714517|OTHER|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
48501463|NCT00673153|DRUG|gemtuzumab ozogamicin|Given IV
48501464|NCT00673153|DRUG|vorinostat|Given orally
48501465|NCT00673153|OTHER|laboratory biomarker analysis|Correlative studies
48501466|NCT00002393|DRUG|Indinavir sulfate|
48136570|NCT01356524|DRUG|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
48346556|NCT00806650|OTHER|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
48346557|NCT00806650|OTHER|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
48346558|NCT06404229|DIAGNOSTIC_TEST|CardioPulmonary Exercise Testing|CardioPulmonary Exercise Testing using an arm ergometer prior to surgery
47983318|NCT06157814|OTHER|STOMA Care web-based application|The STOMA Care App, with program software developed in collaboration with the Information Technology Department at Mount Sinai, is organized in a web-based app accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modelling competencies 4) mental health, support group, and ostomy supplier resources.
47983319|NCT06157814|OTHER|Usual Care|Patients and caregivers NOT given access to the web-based application.
47983320|NCT00989794|DEVICE|GelrinC|Applied once during surgery
47983321|NCT00479661|DRUG|Dexmedetomidine|Continuous infusion
47983322|NCT00479661|DRUG|Propofol|Continuous infusion
47983323|NCT01980992|DRUG|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
47983324|NCT02356744|OTHER|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
47983325|NCT06377254|BEHAVIORAL|Decreased Physical Activity|Physical activity levels will be decreased
47983326|NCT06377254|BEHAVIORAL|Increased Physical activity|Physical activity levels will be increased
48346559|NCT00379873|DEVICE|ProAdjuster|
48346560|NCT02030093|BEHAVIORAL|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
47983327|NCT01857388|BEHAVIORAL|ParentCorps|
47983328|NCT03855098|OTHER|Biomarkers of Fruit and Vegetable Intake|"Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption."
47983329|NCT00035620|DRUG|pegfilgrastim|pegfilgrastim
47983330|NCT00035620|DRUG|filgrastim|filgrastim
47983331|NCT04081311|DEVICE|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
47983332|NCT02025244|PROCEDURE|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
48136571|NCT00893555|DRUG|voriconazole|TDM (through level of 2-5mg/L).
48136572|NCT00893555|DRUG|voriconazole (dosing according to the SPC)|No serum concentrations are determined
48136573|NCT05528549|OTHER|Exercise|The investigators are looking at how blood flow and blood pressure are regulated in individuals with Down syndrome, who have a reduced ability to do work. This study will compare individuals with Down syndrome to a control group without Down syndrome.
48346561|NCT04516824|PROCEDURE|Orthopaedic Surgical Procedures|Intramedullary nails, Dynamic Compression Plate, Dynamic Hip Screw, Manipulation Under Anaesthesia POP, Ilizarov, Cannulated Screw Fixators, Bipolar Hemiarthroplasty, Locking Compression Plate, AO External fixators, Tension Band Wiring Patella, Pelvis and Acetabulum Fixations, Elbow Reconstructions, K wiring, Disc Excision, Spine Fracture i-e TPSF, Posterior Cervical Decompression and LMS, Dura repair, AD cage,Bilateral Total Hip Replacement, Unilateral Total Hip Replacement, Bilateral Total Knee Replacement, Unilateral Total Knee Replacement, Knee Arthroscopy for Mensicectomy, Arthroscopic Anterior Cruciate Ligament reconstruction,Removal of Implant, Amputations, VAC dressings,Wound wash, Arthrotomy for Septic Arthritis, Biopsy
48501467|NCT00002393|DRUG|Efavirenz|
48501468|NCT03696030|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given HER2-CAR T cells via intraventricular administration
48346562|NCT03669744|OTHER|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
48346563|NCT02347254|DEVICE|Transcranial ExAblate|Transcranial ExAblate MRgFUS
48346564|NCT03971292|GENETIC|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
48501469|NCT01906892|OTHER|Group drumming (participatory)|Active participation in group drumming workshops
48501470|NCT01906892|OTHER|Group drumming (live)|Listening to live performances of group drumming
48501471|NCT01906892|OTHER|Group drumming (recorded)|Listening to recorded performances of group drumming
48501472|NCT01906892|OTHER|Comparative activity|Taking part in a literary-based activity
48501473|NCT00555386|DIETARY_SUPPLEMENT|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
48501474|NCT03881020|DRUG|Silver diamine Fluoride 38%|In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
48501475|NCT03881020|PROCEDURE|Conventional atraumatic restorative treatment|In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
48501476|NCT00084032|BEHAVIORAL|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
48501477|NCT00084032|DRUG|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
48501478|NCT02781870|PROCEDURE|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
48501479|NCT02781870|PROCEDURE|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
48501480|NCT04048044|DEVICE|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
48501481|NCT01123135|DRUG|Vaginal ERT|1gm of estrogen vaginal cream \[EVC\] at bed time 3 times a week
48501482|NCT01123135|DRUG|Placebo|Placebo
48501483|NCT03509805|DIAGNOSTIC_TEST|polysomnography|
48501484|NCT01462812|DRUG|Sumatriptan|Sumatriptan 20mg
48501485|NCT01462812|DRUG|Placebo|Matching placebo
48501486|NCT03934411|DRUG|Tramadol|The subjects will orally ingest 100 mg tramadol retard actavis
48501487|NCT03934411|OTHER|Placebo|The subjects will orally ingest 100 mg calcium powder
48501488|NCT00566007|PROCEDURE|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
48501489|NCT00566007|DRUG|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
48501490|NCT00566007|DRUG|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
48346565|NCT04816786|OTHER|no intervention will be administered, this is a retrospective observational study.|no intervention will be administered, this is a retrospective observational study.
48346566|NCT02094729|DRUG|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
48501491|NCT06299020|BEHAVIORAL|intermittent fasting|fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.
48501492|NCT05876988|DEVICE|Chinese acupuncture|"Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment."
48136574|NCT04250636|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
48136575|NCT04250636|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
48346567|NCT02094729|DRUG|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
48501493|NCT06438809|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|MSC suspension single does injection.
48501494|NCT01001988|OTHER|Blood sample|Blood sample for immunogenicity assessment
48501495|NCT01001988|BIOLOGICAL|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
48501496|NCT04541316|DEVICE|ProFlor inguinal hernia device|Inguinal hernia repair
48501497|NCT01517373|DRUG|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
48501498|NCT01517373|DRUG|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
48501499|NCT01517373|DRUG|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
48346568|NCT02094729|DRUG|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
48346569|NCT02094729|DRUG|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
48346570|NCT01657227|BEHAVIORAL|Intervention to patients|"Multifaceted intervention consisting of:~* Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~* Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~* Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
48136576|NCT02840929|PROCEDURE|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
48136577|NCT02840929|DRUG|Esomeprazole|
48346571|NCT01657227|BEHAVIORAL|Intervention to professionals|"Multifaceted intervention consisting of:~* Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~* Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~* Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
48346572|NCT01657227|OTHER|Usual care|Usual care for T2DM received in primary health care
48346573|NCT01431521|DRUG|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
48346574|NCT01431521|DRUG|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
48346575|NCT01431521|DRUG|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
48346576|NCT01431521|DRUG|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
48346577|NCT03908086|OTHER|Risk factors in RA cohort|
48346578|NCT03908086|OTHER|Risk factors in general population|
48346579|NCT04189640|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
48346580|NCT00063388|BIOLOGICAL|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
47983333|NCT02025244|PROCEDURE|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
47983334|NCT04977583|BEHAVIORAL|Unmet Need Screening|"Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization."
48136578|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Scheduled|VSTs will be infused into stem cell transplant recipients on schedule.
48136579|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Treatment|VSTs will be infused into stem cell transplant recipients only if viremia is detected.
48136580|NCT03918252|DRUG|Nivolumab Injection|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
48346581|NCT00053014|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48346582|NCT00053014|DRUG|cyclosporine|
48346583|NCT00053014|DRUG|fludarabine|
48346584|NCT00053014|DRUG|mycophenolate mofetil|
48346585|NCT00053014|PROCEDURE|peripheral blood stem cell transplantation|
48346586|NCT00053014|RADIATION|radiation therapy|
48346587|NCT02245880|DEVICE|Glidescope|videolaryngoscope
48346588|NCT02245880|DEVICE|ILMA|handling of the device till the optimal ventilation achieved
48346589|NCT03898388|PROCEDURE|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
48346590|NCT04151719|DRUG|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
48346591|NCT00251017|PROCEDURE|Vancomycin|Two hour creatinine clearance before and after vancomycin
48346592|NCT00251017|PROCEDURE|DNA are extracted from the whole blood of subjects|
48501500|NCT01517373|DRUG|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
48501501|NCT01517373|DRUG|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
48501502|NCT04105140|DRUG|Oxytocin|intranasal administration of oxytocin (24 IU)
48501503|NCT04105140|DRUG|Placebo|intranasal administration of placebo (24 IU)
48501504|NCT02430285|PROCEDURE|Endoscopic Ultrasound|Endoscopic Ultrasound
48346593|NCT01452191|BEHAVIORAL|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
48346594|NCT01452191|BEHAVIORAL|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
48346595|NCT02239367|BEHAVIORAL|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
48346596|NCT03426761|DRUG|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
48346597|NCT03426761|DRUG|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
48346598|NCT04639505|DIAGNOSTIC_TEST|ELISA|ELISA kit detecting the serum AMH level
48346599|NCT04639505|DIAGNOSTIC_TEST|Chemiluminescence|CLIA method detecting the serum AMH level
48346600|NCT03243955|DEVICE|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
48346601|NCT03243955|DEVICE|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
48346602|NCT04123444|DRUG|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
48346603|NCT04123444|DRUG|Isotonic saline|Continuously infusion for 72 hours.
48346604|NCT03606655|DRUG|Kava|Kava: 75 mg three times daily (3 capsules)
48346605|NCT05153863|DEVICE|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
48501505|NCT02430285|DEVICE|Olympus 180 series echoendoscope|
48501506|NCT05434429|OTHER|mobile application|Participants in the intervention group are able to access the intervention materials 5 days after enrollment. Two main self-guided intervention modules are available. Short-term self-guided intervention module include mainly audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation. Moreover, there based on breath relaxation exercises, craving management, and motivation to change. Long-term self-guided intervention module include CBT-based interventions, meditations, mindfulness, and journaling.
48346606|NCT02490904|DRUG|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
48346607|NCT02490904|DRUG|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
48501507|NCT02664714|OTHER|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
48501508|NCT05484219|DEVICE|Functional navigation|Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
48501509|NCT02064114|PROCEDURE|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
48501510|NCT02064114|PROCEDURE|control group|Followed for a period of 3,6 and 12 months after the procedure.
48501511|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 1|Free mobile mental health application that focuses on meditation
48501512|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 2|Free mobile mental health application that assists with coping with COVID-19
48501513|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 3|Free mobile mental health application that focuses on positive psychology.
48501514|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 4|Free mobile application that addresses mental health issues through mood tracking
48346608|NCT02123394|OTHER|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
48346609|NCT02123394|OTHER|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
48346610|NCT00024206|DRUG|orantinib|Given orally
48346611|NCT00024206|OTHER|laboratory biomarker analysis|Correlative studies
48346612|NCT00024206|OTHER|pharmacological study|Correlative studies
48346613|NCT01192100|BEHAVIORAL|Breakfast Skipping|Participants will continue to skip breakfast each morning.
48346614|NCT01192100|BEHAVIORAL|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
48346615|NCT01192100|BEHAVIORAL|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
48346616|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
48346617|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 3mcg
48346618|NCT00902057|DRUG|desmopressin|single desmopressin subcutaneous injection, 15mcg
48346619|NCT00902057|DRUG|placebo|saline subcutaneous
48346620|NCT04308408|BEHAVIORAL|Guideline Daily Amounts|All food items displayed the corresponding GDA label in the lower left corner of the front of the package.
48346621|NCT04308408|BEHAVIORAL|Multiple Traffic Light|All food items displayed the corresponding MTL label in the lower left corner of the front of the package.
48501515|NCT03463382|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block will be administered under general anesthesia before the surgery
48501516|NCT03463382|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block will be administered under general anesthesia before the surgery
48501517|NCT03463382|DRUG|Bupivacaine (Block Drug)|0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
48501518|NCT06172244|OTHER|Applying with whole body vibration device|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.
48501519|NCT03967535|DEVICE|MRI Brain Imaging|Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
48501520|NCT03967535|BEHAVIORAL|Mental Health Assessment and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
48501521|NCT02436967|OTHER|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
48501522|NCT05357118|BEHAVIORAL|Suppress Stigma, Support Services|Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
48501523|NCT03630250|BIOLOGICAL|N. lactamica|Genetically modified N. lactamica
48501524|NCT02815358|OTHER|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
48501525|NCT02815358|OTHER|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
48501526|NCT06206200|OTHER|Cognitive dual task training (intervention group)|Simultaneously performing cognitive tasks and motor rehabilitative exercises.
48501527|NCT06206200|OTHER|Standard of care physiotherapy (control group)|The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
48501528|NCT04485832|DEVICE|Telehealth care|Patients in the intervention group daily answer 6 questions, which are focused on the recognition of AECOPD, using the electronic healthcare platform Evita by Swisscom, which has been and continuously is developed by the study team and Swisscom. The study team daily analyses all patients online and reacts according to a pre-specified action plan.
48346622|NCT04308408|BEHAVIORAL|Warning Labels|"Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL."
48501529|NCT04485832|DIAGNOSTIC_TEST|Weekly CAT measurement|
48501530|NCT05354635|OTHER|Antibiotics Dosing|Dosing concerns the main antibiotics used in the unit: b-lactams, linezolid, vancomycin and aminosides
48501531|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
48501532|NCT01356264|BEHAVIORAL|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
48501533|NCT01442428|DRUG|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
48501534|NCT01442428|DRUG|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
48501535|NCT01442428|DRUG|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
48346623|NCT04308408|BEHAVIORAL|Video|Participants viewed a short (less than 1 min) video explaining how to interpret the label.
48501536|NCT01442428|DRUG|Placebo|Atorvastatin placebo
48501537|NCT04689867|BEHAVIORAL|Cognitive Behavioral Suicide Prevention for psychosis CBSPp)|Cognitive and behavioral approach to suicide prevention among individuals with psychosis
48658567|NCT03058887|OTHER|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
48658568|NCT00538447|OTHER|Database|data base for CML
48658569|NCT05065216|DRUG|Recombinant human tissue kallikrein|Treatment is completed by week 3 (Day 21). After dosing is complete, participants will be followed up by the investigator at approximately 30 and 90 days after their first dose.
48658570|NCT05345158|PROCEDURE|Robotic Retroperitoneal Lymph Node Dissection (RPLND)|Robotic RPLND performed using the DaVinci robotic surgical system.
48658571|NCT00725855|DRUG|MEM 3454|1 mg dose
48658572|NCT00725855|DRUG|MEM 3454|5 mg dose
48346624|NCT05557136|DEVICE|Multistranded stainless steel fixed retainer|Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
48136581|NCT03918252|DRUG|Ipilimumab Injection|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
48136582|NCT05949567|OTHER|urodynamic exam in sitting and lying position|Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)
48136583|NCT03927651|DRUG|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
48136584|NCT01299194|DRUG|ATORVASTATIN|80mg once daily for 3 months
48136585|NCT05461235|DRUG|Pembrolizumab|2mg/kg or 200mg,iv,q3w
48501538|NCT04005235|DEVICE|Thorasys Tremoflo C-100 Airwave Oscillometry System (FOT)|Ultrasonography will be used to confirm hemidiaphragm dysfunction after brachial plexus nerve block. In subjects with U/S confirmed hemidiaphragm dysfunction, FOT measurements will be taken before and after nerve block and post-operatively after upper extremity surgery.
48346625|NCT05557136|DEVICE|Polyether-Ether-Ketone (PEEK) fixed retainer|Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
48346626|NCT00366938|DRUG|Lumiracoxib|
48346627|NCT00706758|BEHAVIORAL|IBS school|Structured patient group education
48346628|NCT00706758|BEHAVIORAL|IBS-guidebook|Written information - IBS-guidebook
48346629|NCT01519349|BIOLOGICAL|rAAV1.CMV.huFollistatin344|"* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
48346630|NCT01100762|DEVICE|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
48346631|NCT01100762|DEVICE|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
48346632|NCT01100762|DEVICE|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
48501539|NCT03368456|BEHAVIORAL|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs and a forthcoming module on tobacco prevention and cessation.
48346633|NCT05108961|PROCEDURE|Acupuncture|one session with precise acupunture points
48346634|NCT05108961|BEHAVIORAL|A digital stress scale|The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
48346635|NCT05108961|BEHAVIORAL|a relaxation questionnaire|The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
48346636|NCT05108961|DIAGNOSTIC_TEST|Bispectral Index|BIS is based on an EEG analysis algorithm
48346637|NCT04859504|DEVICE|transcranial alternating current stimulation (NE Starstim)|dual-channel theta-tACS over right DLPFC and cerebellum simultaneously
48346638|NCT03838601|DRUG|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
48346639|NCT02483065|OTHER|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
48501540|NCT03368456|BEHAVIORAL|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
48501541|NCT03788304|DEVICE|non-invasive ventilation|conventional NIV
48501542|NCT03788304|DEVICE|high flow nasal cannula|HFNC ventilation
48501543|NCT00678886|BIOLOGICAL|otelixizumab infusion plus physician determined standard of care|infusion
48136586|NCT05461235|DRUG|Nivolumab|3mg/kg or 240mg,iv,q2w
48136587|NCT05461235|DRUG|Sintilimab|200mg,iv,q3w
48136588|NCT05461235|DRUG|Toripalimab|3mg/kg or 240mg,iv,q2w
48136589|NCT05461235|DRUG|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
48136590|NCT05461235|DRUG|Tislelizumab|200mg,iv,q3w
48136591|NCT05461235|BIOLOGICAL|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.
48136592|NCT05073224|DIAGNOSTIC_TEST|Active Straight Leg Raise Test|The ASLR test is a well-established clinical test that assesses stability of the lumbar spine/pelvis, posterior pelvic pain severity, and ability to activate the abdominal muscles. It is performed in supine. Participants are instructed to raise one leg, with the knee straight, to a heel height of 20 cm. The leg is held at the top for 5 seconds, then slowly lowered to the ground. The participant is asked to report perceived difficulty to raise the leg on a 0 to 5 scale (0=not at all difficult; 5=unable to lift leg) and pain on a 0 to 10 scale (0=no pain; 10=worst possible pain). If difficulty or pain are rated at a 1 or higher, the test is repeated with the researcher providing external compression of the pelvis. If perceived difficulty or reported pain are lower with compression, the test is considered positive for lumbopelvic instability. The test is then repeated on the opposite limb.
48136593|NCT05073224|OTHER|Active Straight Leg Raise Fatigue Task|The protocol is similar to the ASLR test, except that the participant is instructed to maintain the elevated leg off the ground for as long as possible. A biofeedback air cuff will be placed under the participant's lumbopelvic region to assess movement of the spine/pelvis. The cuff will be inflated to 40 mm Hg, and the participant instructed to keep the needle as close to 40 mm Hg as possible throughout the test; no information will be provided on how to affect cuff pressure, but visual feedback of cuff pressure will be provided throughout the task. Ratings of perceived exertion (RPE) and pain will be obtained from participants every 30-60 seconds. Task failure will be defined as a heel height ≤10 cm or a change in cuff pressure ≥20 mm Hg. Both limbs will be tested, but in different sessions. The order of limb testing (dominant vs non-dominant) will be randomized and counter-balanced. Limb dominance will be self-reported.
48136594|NCT05073224|OTHER|Lower Extremity Strength Testing|"A straight leg raise maximal voluntary contraction (MVC) of each lower extremity an MVC of the hip extensors of the grounded limb will be performed in supine before and within 2 minutes of completing the ASLR fatigue task. The straight leg raise MVC will be performed with a custom-made load cell instrumented strength testing device, which consists of a rigid platform on which the participant will lie. At the foot of the device is a tower that houses 2 load cells connected to a lightly padded push plate.~The hip extension MVC will be performed on a force plate. Before the ASLR fatigue task, a minimum of 3 MVC trials will be performed for each muscle group, with a minimum of 1 minute rest between trials; the highest peak force will be considered the MVC. Only 1 MVC trial per muscle group will be performed following the ASLR Fatigue Task."
48136595|NCT05073224|DIAGNOSTIC_TEST|Ultrasound imaging of abdominal wall|Real time ultrasound will be used to assess inter-recti distance above and below the umbilicus. Participants will be assessed with B Mode images in supine at rest, in supine while lifting their head, and in supine while performing a straight leg raise. The Principle Investigator has training and experience in musculoskeletal ultrasound.
48136596|NCT00526994|OTHER|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
48136597|NCT00526994|BEHAVIORAL|universal education|receives referral information
48136598|NCT06463041|OTHER|Experimental, comparator and control|How does implementing a GetUp Assist device in addition to a daily low-intensity functional or traditional training program affect Norwegian female office workers' physical health after 12 weeks?
48136599|NCT05454059|PROCEDURE|Non-surgical periodontal treatment|Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
48346640|NCT00654368|BIOLOGICAL|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
48346641|NCT00654368|DRUG|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
48346642|NCT00874224|PROCEDURE|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
48346643|NCT00874224|PROCEDURE|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
48346644|NCT00644813|OTHER|Scapular with glenoid neck fractures|
48346645|NCT00639496|DRUG|n-acetylcysteine|600 mg x 3, for 12 months
48346646|NCT00639496|DRUG|placebo|Placebo
48501544|NCT00678886|BIOLOGICAL|placebo infusion plus physician determined standard of care|infusion
48501545|NCT03888950|DIAGNOSTIC_TEST|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
48501546|NCT02099682|DRUG|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
48501547|NCT06399848|OTHER|Skip one day of peritoneal dialysis treatment|Skip one day of peritoneal dialysis treatment
48501548|NCT00416884|DRUG|Campath|30 mg on day -8 over 5-6 hours
48501549|NCT00416884|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 on day -4 through day -2
48501550|NCT00416884|RADIATION|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
48136600|NCT05454059|DIAGNOSTIC_TEST|ELISA Test|C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
48346647|NCT00655304|DEVICE|Prometheus (R) liver support dialysis|6-8 hours of dialysis
48346648|NCT00655304|DEVICE|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
48346649|NCT02189304|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
48346650|NCT02189304|DRUG|PT009|PT009 administered as 2 inhalations
48346651|NCT02189304|DRUG|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
48346652|NCT05462899|OTHER|Purpose in life, goals, and expectations|There is no intervention. This is a cross-sectional study.
48346653|NCT00108836|DRUG|XBD173|
48346654|NCT04480749|DIAGNOSTIC_TEST|Access to Facility based Syphilis Testing|List of facilities where syphilis testing can be accessed
48346655|NCT04480749|DIAGNOSTIC_TEST|Syphilis Self-Test|Rapid Treponemal Test kit
48501551|NCT00416884|OTHER|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
48501552|NCT05783830|DRUG|ACD856|IV injection 100 mcg
48501553|NCT00060138|BIOLOGICAL|monoclonal antibody CAL|
48501554|NCT00060138|DRUG|zoledronic acid|
48658573|NCT00725855|DRUG|MEM 3454|15 mg dose
48658574|NCT00725855|DRUG|MEM 3454|50 mg dose
48346656|NCT01456520|DRUG|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
48346657|NCT01456520|DRUG|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
48346658|NCT05934890|BIOLOGICAL|Walvax PCV13-TT|"PCV13-TT is supplied as 0.5 mL prefill syringe (PFS), with 0.5 mL suspension for intramuscular injection. After shaking, the vaccine is a homogenous, white suspension. Each dose (0.5 mL) of PCV13-TT contains pneumococcal polysaccharide serotypes 1, 3 4, 5, 6A 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F which are conjugated to TT carrier protein individually.~The vaccine is formulated in phosphate-buffered saline containing 4.25 mg/dose sodium chloride (NaCl), 44.35 μg/dose sodium dihydrogen phosphate (NaH2PO4), 19.0 μg/dose disodium hydrogen phosphate (Na2HPO4), and contains 0.5 mg/dose of aluminum phosphate as an adjuvant; no preservatives added."
48346659|NCT05934890|BIOLOGICAL|Pfizer PCV13|PCV13 is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes. Each 0.5 mL dose of PCV13 is formulated to contain approximately 2.2 μg of each of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F polysaccharides, 4.4 μg of 6B polysaccharides, 34 μg 26 CRM197 carrier protein, 100 μg polysorbate 80, 295 μg succinate buffer and 125 μg aluminum as aluminum phosphate adjuvant.
48346660|NCT01713257|DIETARY_SUPPLEMENT|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
48346661|NCT01713257|DIETARY_SUPPLEMENT|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
48346662|NCT05687253|DRUG|BX1000|IV BX1000
48346663|NCT05687253|DRUG|Rocuronium Bromide|IV Rocuronium
48346664|NCT03420157|OTHER|Focus Group|Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
48346665|NCT00995189|DEVICE|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
48346666|NCT00995189|DEVICE|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
48346667|NCT00995189|DEVICE|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
48346668|NCT06063525|OTHER|Structural anatomy|images acquired with 3T MRI system with 32 channel head coil
48346669|NCT04584944|RADIATION|Dual energy X-ray absorptiometry|"Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).~Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups."
48501555|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC+NOL|Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
48346670|NCT02897154|DIAGNOSTIC_TEST|In-vitro|
48346671|NCT04333875|DEVICE|TAVR or SAVR|Patients with critical aortic stenosis as defined by an AVA \<0.6 cm2 or a transvalvular mean gradient of \>60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR.
48346672|NCT00022893|DRUG|Iodine-131 Anti-B1 Antibody|
48346673|NCT01058057|DRUG|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
48346674|NCT00430027|DRUG|Capecitabine|Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
48346675|NCT00430027|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4
48658575|NCT00725855|DRUG|Placebo for MEM 3454|Placebo dose
48346676|NCT00430027|DRUG|Cetuximab|Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
48346677|NCT04432168|PROCEDURE|Fetoscopic Laser Surgery|Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
48346678|NCT04432168|OTHER|Standard Treatment|"In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease.~* Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week.~* IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia.~* PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia.~* Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation."
48346679|NCT02126527|DRUG|auranofin|Given PO
48346680|NCT02126527|DRUG|sirolimus|Given PO
48346681|NCT02126527|OTHER|laboratory biomarker analysis|Correlative studies
48346682|NCT02126527|OTHER|pharmacological study|Correlative studies
48346683|NCT03529175|DRUG|Abraxane (nab-paclitaxel)|
48346684|NCT03529175|DRUG|Gemcitabine|
48346685|NCT05551910|DRUG|Esketamine|The patients in the test group were given esmketamine (50mg / 2ml \* branch, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 0.15-0.5mg/kg H was pumped intravenously. Two minutes after the administration, the pain was scored with the cpot pain observation scale. The target cpot was \< 3 points. The dose of esketamine was adjusted according to the cpot score.
48346686|NCT05551910|DRUG|Remifentanil|Patients in the control group were given remifentanil (1mg / branch, Yichang humanwell Pharmaceutical Co., Ltd.) 0.05-2ug/kg Minutes after administration, the analgesic score was measured with cpot pain observation scale. The target cpot was less than 3 points, and the dose of remifentanil was adjusted according to the cpot score.
48346687|NCT05551910|DRUG|propofol|propofol
48501556|NCT03776838|DRUG|Intravenous Fentanyl guided by SoC|Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
48346688|NCT04324476|DRUG|Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine|Drug: Bevacizumab 5mg/kg, iv, 30min, d1, 2w; Drug: Oxaliplatin 85mg/㎡, iv, 120min, d1, 4W; Drug: Irinotecan 150mg/㎡, iv, 90min, d15, 4w; Drug: Capecitabine 1000mg/㎡, bid, d2-8, 2w.
48346689|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
48501557|NCT06483321|DIETARY_SUPPLEMENT|Creatine Supplementation|"Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate~Normocaloric diet based solely on foods of plant sources with creatine supplementatio (0.1 g/kg/day)"
48501558|NCT06483321|DIETARY_SUPPLEMENT|Placebo|Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
48501559|NCT03632863|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~1. Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~2. Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~3. Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
48501560|NCT03632863|BEHAVIORAL|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
48501561|NCT04472091|DEVICE|Genicular artery embolization (GAE)|Participants will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ).
48136601|NCT05454059|OTHER|Periodontal Examination|All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
48136602|NCT05454059|OTHER|Saliva Sample Collection|Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
48136603|NCT05454059|DIAGNOSTIC_TEST|HbA1c Level|Measurement of HbA1c levels from blood tests
48136604|NCT05054270|OTHER|Chest examination with Ultrasound device|Chest examination with Ultrasound device
48136605|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
48346690|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
48346691|NCT05143918|OTHER|assessment of quality of life using questionnaire|assessment of quality of life in hypothyroid patients using SF 36 questionnaire
48346692|NCT02781415|PROCEDURE|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
48346693|NCT02781415|DRUG|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
48346694|NCT04336007|DEVICE|Resistive Diathermy (INDIBA® Activ Ct9)|Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
48501562|NCT02897583|PROCEDURE|YAG vitreolysis|
48136606|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
48136607|NCT00452452|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
48136608|NCT01928459|DRUG|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
48346695|NCT04336007|DEVICE|Resistive Diathermy OFF (INDIBA® Activ Ct9)|Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
48346696|NCT04336007|OTHER|Control|This group will warm-up as they usually do in competitions, for later time trial measuring.
48346697|NCT02049229|DEVICE|percutaneous coronary intervention|Optimax-stent implantation
48346698|NCT02049229|DEVICE|percutaneous coronary intervention|Synergy stent implantation
48136609|NCT01928459|DRUG|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
48136610|NCT02260154|DRUG|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
48136611|NCT01747707|DRUG|Docetaxel|
48346699|NCT02195947|DRUG|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
48136612|NCT01747707|DRUG|Cisplatin|
48346700|NCT01925482|DRUG|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
48346701|NCT01925482|DRUG|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
48346702|NCT01925482|DRUG|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
48346703|NCT01925482|DRUG|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
48346704|NCT01925482|DRUG|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
48346705|NCT01925482|DRUG|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
48346706|NCT02394262|RADIATION|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
48346707|NCT02394262|OTHER|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
48346708|NCT00215189|BEHAVIORAL|In SHAPE (Pilot Health Promotion Intervention)|
48346709|NCT06002997|OTHER|Pregnancy and/or delivery complications|Analysis of post-delivery reports for pregnancy and/or delivery complications.
48346710|NCT06002997|OTHER|Periodontal disease|Measuring clinical periodontal parameters for assessing presence of periodontal disease.
47983335|NCT04977583|BEHAVIORAL|Unmet Need Referral - Resource Sheet|Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
47983336|NCT04977583|BEHAVIORAL|Unmet Need Referral Assistance|Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
47983337|NCT02573727|DRUG|Nor adrenaline + albumin|
47983338|NCT02573727|DRUG|Terlipressin + albumin|
48136613|NCT01747707|DRUG|S-1|
48136614|NCT01158248|BIOLOGICAL|panitumumab|
48136615|NCT01158248|DRUG|cisplatin|
48346711|NCT02089867|OTHER|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
48346712|NCT02089867|DRUG|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
48501563|NCT00080314|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
48501564|NCT00080314|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
48136616|NCT01158248|RADIATION|brachytherapy|
48136617|NCT01158248|RADIATION|external beam radiation therapy|
48136618|NCT02227706|BIOLOGICAL|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
48136619|NCT02227706|DEVICE|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
48136620|NCT03504904|BEHAVIORAL|Internet-Delivered ACT and CFT|An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
48136621|NCT03674515|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
48346713|NCT02089867|DIETARY_SUPPLEMENT|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
48346714|NCT01678560|DEVICE|Monitoring every 3 months by face-to-face visits|These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
48346715|NCT01678560|DEVICE|Frequent remote monitoring|These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
48346716|NCT03536273|OTHER|Pilates Group Exercises|For 12 weeks, 3 repetitions per week
48346717|NCT02797470|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
48346718|NCT02797470|DRUG|Carmustine|300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
48346719|NCT02797470|DRUG|Cytarabine|100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
48346720|NCT02797470|DRUG|Etoposide|VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
48346721|NCT02797470|OTHER|Laboratory Biomarker Analysis|Correlative studies
48501565|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
48346722|NCT02797470|BIOLOGICAL|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
48346723|NCT02797470|DRUG|Melphalan|140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
48346724|NCT02797470|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
48346725|NCT01117181|DRUG|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
48346726|NCT01117181|DRUG|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
48136622|NCT03674515|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
48346727|NCT01117181|OTHER|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~* Review and adjustment of the patient and caregiver supportive care plans~* Emotional support and opportunity to ventilate feelings~* Counseling regarding specific caregiving skills~* Assistance with problem solving of specific issues that the caregiver brings to the sessions~* Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
48346728|NCT05104086|DEVICE|ultrasound elastography|strain ratio and resistivity index
48346729|NCT03822780|DRUG|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg\*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg\*d to 10mg/kg\*d, p.o., bid ; the maximum daily dose is 400mg.
48136623|NCT05838781|DIAGNOSTIC_TEST|Risk prediction model|A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
48136624|NCT05838781|DIAGNOSTIC_TEST|14-days continuous ECG monitoring|14-days continuous ECG monitoring with an ECG patch.
48346730|NCT03647462|DEVICE|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
48346731|NCT01957085|OTHER|observation only|This is an observational only, nonintervention study. There will be no patient contact. This was a de-identified point prevalence study of hepatitis C infection in hospitalized patients in an inner city hospital.
48346732|NCT03510728|BEHAVIORAL|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
48346733|NCT03510728|BEHAVIORAL|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
48346734|NCT03510728|BEHAVIORAL|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
48346735|NCT01823757|OTHER|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
48346736|NCT02484040|RADIATION|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
48346737|NCT02484040|DRUG|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
48501566|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
48501567|NCT06049810|DRUG|IBI112/placebo|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
48136625|NCT05483088|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
48346738|NCT02940860|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
48346739|NCT02940860|DRUG|Iron sucrose|Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
48346740|NCT04376424|DIAGNOSTIC_TEST|Hand Held Ultrasound|Guideline directed medical therapy for heart failure with the addition of hand held ultrasound
48346741|NCT03402360|OTHER|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
48346742|NCT03402360|OTHER|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
48346743|NCT00662285|DIETARY_SUPPLEMENT|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
47983339|NCT00799604|DRUG|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (\<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
48136626|NCT00474799|DRUG|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
48136627|NCT02377700|DEVICE|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
48346744|NCT02796079|BIOLOGICAL|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
48346745|NCT02796079|BIOLOGICAL|saline|saline injections
48346746|NCT00926991|OTHER|No intervention|No intervention; observation only
48346748|NCT03692195|DEVICE|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
48346749|NCT03692195|OTHER|No Device|The WHOOP Strap 2.0 is not worn on the wrist for a seven day period.
48346750|NCT00388375|PROCEDURE|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
48346751|NCT02336880|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|
48346752|NCT04403841|OTHER|patient education and self-management intervention in a low-resource setting on diabetes knowledge and levels of blood glucose control|The intervention consisted group education on type 2 diabetes, including, in addition to usual diabetes care: information on diet, exercise, drug therapy, and adherence
47983340|NCT04481750|DRUG|MT-1186|Solution or suspension
47983341|NCT04481750|DRUG|MT-1186-matching placebo|Solution or suspension
47983342|NCT05789446|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
47983343|NCT01680523|PROCEDURE|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
47983344|NCT01680523|RADIATION|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
47983345|NCT01680523|RADIATION|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
47983346|NCT04466254|DRUG|CPGJ602|Q2W/QW iv
48136628|NCT02246075|DRUG|EVP-6124|
48136629|NCT01800305|DRUG|Pegylated rhEPO|
48136630|NCT01800305|DRUG|EPIAO®|
48136631|NCT05860504|DIAGNOSTIC_TEST|Echocardiography|All patients in the study will be examined with echocardiography
48136632|NCT05860504|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
48136633|NCT05860504|DIAGNOSTIC_TEST|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
48136634|NCT02103556|OTHER|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
48136635|NCT02103556|DIETARY_SUPPLEMENT|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
48346753|NCT04403841|OTHER|Usual diabetes care alone|Usual diabetes care was consistent with the ADA guidelines (15) and comprised standard dietary and exercise advice in addition to antidiabetes treatment
48346754|NCT04224987|DRUG|Azithromycin|"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
48136636|NCT02103556|DIETARY_SUPPLEMENT|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
47983347|NCT04466254|DRUG|cetuximab|QW iv
48136637|NCT03074032|DRUG|ONC1-0013B|ONC1-0013B per os daily
48136638|NCT04480385|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
48136639|NCT04639999|OTHER|Echocardiography|LV vortex flow in Echocardiography
48346755|NCT04224987|OTHER|Placebo|"Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
48346756|NCT02668055|BIOLOGICAL|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
47983348|NCT03484884|DIAGNOSTIC_TEST|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
47983349|NCT02742324|DRUG|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
48136640|NCT04105387|PROCEDURE|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
48136641|NCT01576796|RADIATION|Radiotherapy|"No additional dose (patients negative F-miso)~* Radiation therapy is conducted under standard conditions of conformal radiotherapy:~* The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
48136642|NCT03473717|DEVICE|classic method|"* Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~* Insert the hysterometer to measure the uterus depth.~* Locate the uterine depth on the inserter tube."
48346757|NCT00003304|DRUG|temozolomide|
48346758|NCT02723019|BEHAVIORAL|Volunteer Peer Mentor+Behavioral Health Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
48501568|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
48501569|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
47983350|NCT02742324|DRUG|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
48136643|NCT03473717|DEVICE|direct method|"* Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~* Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity"
48136644|NCT01808352|DRUG|FTC/TDF|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
48136645|NCT03353636|DIETARY_SUPPLEMENT|Magnesium|150mg elemental magnesium
48136646|NCT03353636|DIETARY_SUPPLEMENT|Placebo|Rice flour
48136647|NCT02656147|BIOLOGICAL|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
48136648|NCT03507972|RADIATION|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
48136649|NCT03507972|RADIATION|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
48136650|NCT02845466|BIOLOGICAL|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
47983351|NCT05744544|PROCEDURE|External Oblique Block|Patients will be followed after EOIB which are routinely performed in our clinic.
48136651|NCT02845466|DEVICE|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
48136652|NCT02845466|DEVICE|Placebo Dressing|Inactive wound dressing.
48136653|NCT03802994|DRUG|23 valent pneumococcal polysaccharide vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
48136654|NCT03802994|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
48346759|NCT05379192|OTHER|Group 1, Group 2, Group 3, Group 4|The total amount of antiemetic,the time of first antiemetic use and VAS scores at 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24th hours postoperatively will also be recorded according to circadian rhythm
48346760|NCT05305625|PROCEDURE|remote ischemic postcondioning|remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
48346761|NCT05305625|DRUG|standard therapy|received standardized treatment
48346762|NCT01833806|DEVICE|ExAblate MRgFUS|Focused Ultrasound Ablation
48501570|NCT06049810|DRUG|IBI112|Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection
48501571|NCT03848637|DRUG|CKD-375|Test drug
48501572|NCT03848637|DRUG|D387|Reference drug
47983352|NCT05744544|PROCEDURE|m-TAPA block|m-TAPA block
47983353|NCT01321515|DRUG|famciclovir|500 mg tablet
47983354|NCT02415881|DRUG|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
47983355|NCT02415881|DEVICE|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
47983356|NCT02415881|DEVICE|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
47983357|NCT04304391|PROCEDURE|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
48346763|NCT05539924|DRUG|Pregabalin 150mg gabapentin 400mg|oral administration
48346764|NCT04897594|DRUG|TERN-201|Investigational drug
47983358|NCT05162131|DRUG|Bentracimab (PB2452) 100 mg or Placebo|"Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
47983359|NCT05162131|DRUG|Bentracimab (PB2452) 300 mg or Placebo|"Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
47983360|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo|"Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion"
47983361|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
47983362|NCT05162131|DRUG|Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
48136655|NCT03802994|OTHER|Peripheral blood sample|Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.
48136656|NCT01240707|OTHER|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
48346765|NCT04897594|OTHER|Placebo|Matching placebo
48346766|NCT01442090|DRUG|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
48346767|NCT01442090|DRUG|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
48346768|NCT04410913|DRUG|Psilocybin plus Visual Healing Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist who will guide and accompany participants before, during, and after the psychedelic session. In addition, participants will have the chance to view nature-themed videos before and after the psychedelic sessions. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
48346769|NCT04410913|DRUG|Psilocybin plus Standard Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist will guide and accompany participants before, during, and after the psychedelic session. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
48501573|NCT02826837|DRUG|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
48136657|NCT06523478|PROCEDURE|Intratonsillar immunotherapy (ITIT)|During injection, the operator needs to gently shake the injection bottle about 20 times, the drug must be mixed to ensure the consistency of allergen concentration, and carefully check the patient's name and concentration on the bottle. Allergy extracts should not be injected intravenously, so the syringe will be aspirated to avoid inadvertent intravascular injection. Before each injection, after inserting the needle into the selected tonsil, before injecting the dose, the investigator will slightly pull the plunger of the syringe. If blood returns from the syringe, the syringe, and its contents will be discarded. The other tonsil will be selected and a new syringe will be prepared.
48136658|NCT06523478|PROCEDURE|Subcutaneous immunotherapy (SCIT)|Injection requires shaking bottle 20x to mix drug for consistency. Verify patient name \& concentration. Use 1 ml skin test syringe for deep subcutaneous injection at 45° angle, 1 cm into outer upper arm. Lift skin folds for deeper injection, avoid subcutaneous, muscular or intravascular. Inject slowly, 1 min for 1 ml. Avoid shallow injections which may cause local side effects. Alternate between left \& right arm for 5 min after injection for compression.
48136659|NCT01903109|DRUG|Cevimeline|
48136660|NCT02551224|OTHER|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
48501574|NCT00708773|DRUG|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
48136661|NCT02804256|OTHER|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
48346770|NCT01828567|BEHAVIORAL|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
48501575|NCT00799448|DRUG|repaglinide|
48501576|NCT00799448|DRUG|biphasic human insulin 30|
48136662|NCT00306475|DRUG|divalproex sodium ER|divalproex sodium ER1000 mg
48136663|NCT00306475|DRUG|placebo|placebo identical in appearance to active comparator
48346771|NCT02763267|OTHER|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant \[4-14 weeks gestation\] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at 6-12 weeks postpartum)
48346772|NCT03408288|OTHER|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
48501577|NCT00799448|DRUG|insulin NPH|
48501578|NCT00331240|DRUG|travoprost/timolol fixed combination|
48136664|NCT00345046|DRUG|Pred Forte|Four drops daily decreasing to once daily over four weeks.
48136665|NCT00345046|DRUG|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
48136666|NCT00345046|DRUG|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
48501579|NCT00331240|DRUG|placebo (artificial tears)|
48501580|NCT00770081|DRUG|vildagliptin|50mg qd
47983363|NCT05162131|DRUG|Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
48346773|NCT03408288|OTHER|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
48346774|NCT03408288|OTHER|Color description|Describe color of reference sample
48346775|NCT02736929|BEHAVIORAL|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
48136667|NCT00475241|BEHAVIORAL|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
48136668|NCT00475241|BEHAVIORAL|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
48346776|NCT03884127|DRUG|Ezetimibe 10mg|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
48346777|NCT03884127|DRUG|Orlistat 120 MG|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
48346778|NCT00417833|DRUG|Intravitreal Bevacizumab|
48346779|NCT00052832|DIETARY_SUPPLEMENT|doxercalciferol|
48501581|NCT00770081|DRUG|sitagliptin|25mg qd
48501582|NCT04008849|OTHER|Safety and efficacy assessments|Long term safety and clinical outcomes
48501583|NCT06216223|PROCEDURE|treatment of anal diseases in inflammatory bowel patients|treatment of anal diseases in inflammatory bowel patients
48501584|NCT06216223|DEVICE|Laser|laser
48501585|NCT06216223|PROCEDURE|traditional surgery|traditional surgery
48501586|NCT02923986|DRUG|BP1001 (varying dose)|BP1001 (varying dose)
48501587|NCT02923986|DRUG|BP1001 (fixed dose)|BP1001 (fixed dose)
48501588|NCT02923986|DRUG|Dasatinib|Dasatinib
48501589|NCT01844466|PROCEDURE|Physiotherapy and speech therapy|
48501590|NCT05131243|PROCEDURE|Chemotherapy time|6 months of chemotherapy
48501591|NCT05131243|PROCEDURE|Chemotherapy time|3 months of chemotherapy
48501592|NCT03339167|DIETARY_SUPPLEMENT|Metabolic availability of lysine in millet|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
48501593|NCT00462124|DEVICE|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
48501594|NCT03437226|DRUG|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
48501595|NCT03437226|DRUG|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
48658576|NCT06569719|OTHER|Complex decongestive therapy|Includes manual lymphatic drainage (MLD), compression therapy (which consists of compression bandages, compression sleeves, or other types of compression garments), skin care, and lymph-reducing exercises
48136669|NCT05926674|OTHER|Myofascial Release|Myofascial release is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.
48136670|NCT05926674|OTHER|Light Touch Contact|The sham treatment of light touch will be applied to the lumbar spine and this form of contact is not therapeutic. It is only meant to only mimic a manual therapy technique.
48136671|NCT03477305|BEHAVIORAL|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
48346780|NCT01787045|OTHER|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
48346781|NCT01787045|OTHER|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
48136672|NCT02419300|DEVICE|ultrasoungraphy|pelvic ultrasonography and Doppler
48136673|NCT05521906|BEHAVIORAL|Promoting Resilient Youth with Strong Hearts and Minds (PRYSHM)|The intervention focuses on psycho-education (provision of accurate information about LGBTQIA2S+ people, education about the effects of alcohol), fostering positive identity development for LGBTQIA2S+ youth (e.g., fostering pride in identity, exposure to positive adult role models), teaching of alcohol use and sexual refusal skills, correction of inaccurate social norms about alcohol use and dating violence, teaching assertive communication skills, teaching emotion coping skills, mindfulness and grounding skills, and teaching bystander intervention skills related to dating/sexual violence and alcohol use..
48136674|NCT01500200|DRUG|ALKS 5461|Two active tablets, given daily
48136675|NCT01500200|DRUG|Placebo|Two placebo tablets, given daily
48136676|NCT05063006|OTHER|Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.|Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.
48346782|NCT04687436|DEVICE|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
48346783|NCT05427864|DIAGNOSTIC_TEST|Multiparametric Prostate MRI|Comparison of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer
48346784|NCT01725295|OTHER|NST|A form of physical therapy
48136677|NCT05063006|OTHER|Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.|During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
48136678|NCT02613403|DRUG|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
48136679|NCT02613403|DRUG|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
48346785|NCT01725295|OTHER|Hydrotherapy|
48346786|NCT03674307|OTHER|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
48346787|NCT03674307|OTHER|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
48346788|NCT03422016|DIAGNOSTIC_TEST|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
48346789|NCT04019236|OTHER|visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care|Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
48346790|NCT03035422|DRUG|Sequential Packaging (SET)|"Sequential chemotherapy:~* Thiotepa 5 mg / kg / day for 1 day (D-13)~* Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~* Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~* Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~* Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~* Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
47983364|NCT05162131|DRUG|Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
47983365|NCT03750812|BEHAVIORAL|Aerobic Exercise|Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes
47983366|NCT03750812|BEHAVIORAL|Watching television|Sitting and watching television for 30 minutes
48136680|NCT05777304|DEVICE|wearable device|IMU sensors and EMG sensors
48136681|NCT04455204|DIAGNOSTIC_TEST|Serum asymmetteric dimethyl arginine|Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
48346791|NCT03035422|DRUG|Transfusion graft|Graft of peripheral stem cells is preferred at D0
48346792|NCT03035422|DRUG|Prevention of GVHD|"* Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~* Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~* Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
48136682|NCT04455204|DIAGNOSTIC_TEST|serum lipid profiles|serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
48136683|NCT04455204|DIAGNOSTIC_TEST|Serum vaspin|vaspin concentrations will be assayed using commercially available ELISA kits
48136684|NCT04455204|DIAGNOSTIC_TEST|Serum resistin|resistin concentrations will be assayed using commercially available ELISA kits
48346793|NCT03035422|DRUG|Care supports|According to the protocols of each center
48136685|NCT06046196|DRUG|Sarpogrelate SR|Sarpogrelate SR 300mg, once a daily, for 24weeks
48346794|NCT03035422|DRUG|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II"
48346795|NCT02885272|PROCEDURE|Computed Tomography|Undergo PET/CT scans
48346796|NCT02885272|RADIATION|Fludeoxyglucose F-18|Given IV
48346797|NCT02885272|PROCEDURE|Magnetic Resonance Imaging|Undergo standard of care MRI
48136686|NCT06046196|DRUG|Sarpogrelate|Sarpogrelate 100mg, 3 times a day, for 24weeks
47983367|NCT02651727|DRUG|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
47983368|NCT02651727|DRUG|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
47983369|NCT02651727|DRUG|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
47983370|NCT00461682|DRUG|SB-705498|
47983371|NCT01151644|BIOLOGICAL|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
47983372|NCT04326231|DEVICE|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
47983373|NCT06108791|DRUG|FIO2=0.8|the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air
47983374|NCT06108791|DRUG|FIO2=0.33|the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air
47983375|NCT04075058|RADIATION|Hypofractionated Radiation therapy|
47983376|NCT04065906|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
47983377|NCT04065906|DRUG|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
48136687|NCT05348603|OTHER|Traditional Letter|Patients receive a traditional letter.
48136688|NCT05348603|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
48136689|NCT05348603|OTHER|Chatbot|Patients are contacted by a chatbot via the portal.
48346798|NCT02885272|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
47983378|NCT05989789|DEVICE|Radioactive Seed Implantation|In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
48136690|NCT05348603|OTHER|Banner|Patients are exposed to a banner ad via the portal.
48136691|NCT01025167|DIETARY_SUPPLEMENT|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
48136692|NCT01025167|DIETARY_SUPPLEMENT|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
48136693|NCT06270862|BEHAVIORAL|Resilience training|Receive mini course on what is resilience and how to use different exercises to be more resilient in life.
48136694|NCT06270862|BEHAVIORAL|cognitive training|Play games that trains attention, memory and planning using the services provided by CogniFit.
48136695|NCT06270862|BEHAVIORAL|physical exercise|Engage in age-appropriate physical exercises.
48136696|NCT06270862|BEHAVIORAL|social interaction|Engage in social discussion with peers in the group.
48136697|NCT06270862|BEHAVIORAL|workshop series|Watch a series of workshops targeting the older adult population.
48136698|NCT04810390|DRUG|Bilastine|Ophthalmic solution 0.6%
48136699|NCT04810390|DRUG|Placebo|Ophthalmic solution
48136700|NCT01961466|OTHER|psychological and social self-administered questionnaires|
48346799|NCT03931889|DIETARY_SUPPLEMENT|Vitamin D3|Cap. Cholecalciferol 40,000 IU
48346800|NCT00820313|BEHAVIORAL|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
48346801|NCT05570357|DIETARY_SUPPLEMENT|Berberine+Cinnamon (TDS)|The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract
48346802|NCT05570357|OTHER|Placebo (TDS)|Placebo contains Maltodexterin
48346803|NCT03139435|PROCEDURE|Biopsy|Undergo skin biopsy
48346804|NCT03139435|OTHER|Questionnaire Administration|Ancillary studies
48346805|NCT03139435|DIAGNOSTIC_TEST|Ultrasound Tomography|Undergo peripheral nerve ultrasound
48346806|NCT05791006|BEHAVIORAL|Neuropsychological tests|"Neuropsychological assessment with:~* NADL-F~* Frontal Assessment Battery (FAB)~* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)~* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients~* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients"
48346807|NCT02280096|DRUG|4-aminopyridine|Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
47983379|NCT02668133|DIETARY_SUPPLEMENT|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
47983380|NCT02668133|DIETARY_SUPPLEMENT|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing
47983381|NCT02668133|DIETARY_SUPPLEMENT|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
47983382|NCT02668133|DIETARY_SUPPLEMENT|1 mg isotopically enriched 68Zn|administered intravenously
48346808|NCT02280096|DRUG|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
48346809|NCT00576368|DRUG|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
48346810|NCT01069809|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
48346811|NCT01069809|BIOLOGICAL|Placebo|Inactive Placebo Injection
48658577|NCT06638528|OTHER|Walking apnea at High Lung Volume|Walking apnea at High Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
47983383|NCT00433849|DRUG|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
47983384|NCT00433849|DRUG|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
47983385|NCT02105428|BEHAVIORAL|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
47983386|NCT03579589|DRUG|Sugammadex vs Neostigmine|Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
47983387|NCT03618992|OTHER|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
47983388|NCT05079295|PROCEDURE|CSDH evacuation|Burr hole for chronic subdural hematomas
47983389|NCT02430584|OTHER|Observational - no intervention|
47983390|NCT02289690|DRUG|Veliparib|Capsules administered orally twice a day according to the dosing schedule.
47983391|NCT02289690|DRUG|Carboplatin|Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
48346812|NCT00757081|DRUG|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
48346813|NCT00193128|DRUG|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
48346814|NCT00193128|DRUG|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
48346815|NCT00193128|DRUG|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
48346816|NCT00193128|RADIATION|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
48346817|NCT02479386|OTHER|No intervention|No intervention was administered in this study.
48136701|NCT03607591|OTHER|rTMS|rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
48136702|NCT04263610|DRUG|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
48136703|NCT04263610|DRUG|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (\>=) 30% at Week 8, no dose increase will be done and if PASI is less than (\<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
48136704|NCT04263610|DRUG|Tildrakizumab|Participants who achieve PASI less than (\<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg \[(as per the Summary of Product Characteristics (SmPC)\] at Weeks 16, 20 and 32 up to Week 40.
48136705|NCT02095366|DRUG|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
48136706|NCT02095366|DRUG|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
48136707|NCT02095366|DRUG|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
48346818|NCT02035241|DIETARY_SUPPLEMENT|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
48346819|NCT02035241|DIETARY_SUPPLEMENT|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
48346820|NCT02035241|DIETARY_SUPPLEMENT|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
48346821|NCT02035241|DIETARY_SUPPLEMENT|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
48346822|NCT02035241|DIETARY_SUPPLEMENT|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
48346823|NCT02035241|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
47983392|NCT02289690|DRUG|Etoposide|Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
47983393|NCT02289690|DRUG|Placebo|Placebo to veliparib administered orally twice a day according to the dosing schedule.
47983394|NCT05232240|DIAGNOSTIC_TEST|blood pressure variability measured by ambulatory 24-hour blood pressure monitoring|The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.
47983395|NCT04468204|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
47983396|NCT04468204|DEVICE|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
47983397|NCT03535103|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
47983398|NCT03535103|DRUG|LM001|A single Subcutaneous injection, 225IU
47983399|NCT05283057|DRUG|Empagliflozin 25 MG|single dose of the SGLT inhibitor Empagliflozin was given
47983400|NCT05283057|DRUG|placebo|single dose of placebo that is similar to Empagliflozin in physical appearance
47983401|NCT06010940|DIETARY_SUPPLEMENT|Dietary supplement|nasogastric tube and oral care
47983402|NCT06010940|OTHER|Physical therapy|Designed physical therapy program consisting of neuromuscular electrical stimulation in addition to exercises for oropharyngeal muscles.
47983403|NCT04890223|BEHAVIORAL|Brief MI intervention|Brief MI intervention
47983404|NCT04890223|BEHAVIORAL|Placebo intervention|Generic health advice consultations and self-help smoking cessation booklets
47983405|NCT04307693|DRUG|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
47983406|NCT04307693|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
47983407|NCT01488539|BEHAVIORAL|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
47983408|NCT01488539|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
48346824|NCT06041191|DIAGNOSTIC_TEST|Assessment|The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.
48346825|NCT00729560|DRUG|Flutamide|250 mg twice daily for 4 weeks
48346826|NCT00729560|DRUG|Placebo|Placebo twice daily for 4 weeks
48346827|NCT03345173|DRUG|CI-581-a|Two infusions in the context of naltrexone induction protocol.
48346828|NCT03345173|DRUG|CI-581-b|Two infusions in the context of naltrexone induction protocol.
48346829|NCT02049788|BEHAVIORAL|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
48346830|NCT02049788|BEHAVIORAL|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
48346831|NCT01084473|DRUG|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
48346832|NCT01084473|DRUG|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
47983409|NCT01693926|BEHAVIORAL|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
47983410|NCT01693926|BEHAVIORAL|placebo|
48346833|NCT01084473|DRUG|Placebo|0.9 % NaCl will be infused.
48346834|NCT02705755|DRUG|TD-9855|Administered orally.
48346835|NCT02705755|DRUG|Placebo|Administered orally.
48346836|NCT01125904|DRUG|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
48346837|NCT00850265|DEVICE|Volumatic spacer|A spacer is a plastic device to inhaler medication
48658578|NCT06638528|OTHER|Walking normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
48346838|NCT05823649|DIETARY_SUPPLEMENT|Early feeding/intervention group|The patients will be given orally 5 to 10 ml of warm water as first feeding. If there will be no problem of swallowing and other clinical complication, they will be further provided 20 ml of water after 10 minutes. If further patients do not suffer from nausea, vomiting and other discomfort, 100 ml clear fluid or less than it will be provided as based on the protocol followed by the study. We will use oral rehydration solution (ORS) as clear fluid.
48346839|NCT04528394|RADIATION|Photon|Photon combined with Carbon ion in Arm 1
48346840|NCT04528394|RADIATION|Proton|Proton combined with Carbon ion in Arm 2
48136708|NCT02095366|DRUG|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~* at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~* at 10 minutes and if NPRS\>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~* at 20 minutes and if NPRS\>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
48136709|NCT06466616|OTHER|Real stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks stretching of plantar fascia, gastrocnemius and hamstring muscle.
48136710|NCT06466616|OTHER|Placebo stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks placebo stretching of plantar fascia, gastrocnemius and hamstring muscle.
48136711|NCT01401790|DEVICE|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~* Automatic download of blood glucose levels~* Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~* Changes in treatment plan by the diabetes professionals~* E mail exchanges between families and health care professionals~* Reinforcement of teaching program"
47983411|NCT00137423|DRUG|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
47983412|NCT02014896|OTHER|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
48136712|NCT01401790|OTHER|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
48136713|NCT01193205|BEHAVIORAL|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
48136714|NCT06264583|OTHER|HDV screening|1. Analyze the rate of HDV-testing and evaluate the prevalence of HDV-infection by testing.
48136715|NCT00219791|DRUG|glucarpidase (50 Units/kg)|
48136716|NCT03180541|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
48136717|NCT00333372|DRUG|Z-338|
48136718|NCT05377918|OTHER|Diary|spiritual diary group and diary gruop will write a diary
48136719|NCT00374959|DRUG|ceftriaxone|
48346841|NCT04528394|RADIATION|Carbon ion|Same dose and fractionation will be used in both arms.
48346842|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
48136720|NCT00374959|DEVICE|Endotracheal tube for aspiration of subglottic secretions.|
48136721|NCT02992652|DRUG|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
48136722|NCT05381090|DIAGNOSTIC_TEST|Venous blood collection|Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
48136723|NCT02720432|OTHER|CIMT|Constraint-induced movement therapy
48136724|NCT02720432|OTHER|HABIT|hand-arm bimanual intensive training
48136725|NCT02720432|OTHER|baby-massage|instructions for baby-massage
48346843|NCT01908855|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
48346844|NCT06350877|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.
48346845|NCT05764811|DRUG|Canagliflozin 100mg|100 mg daily for a month
48346846|NCT00776191|DRUG|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
48346847|NCT00776191|DRUG|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
48346848|NCT01116349|PROCEDURE|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
48136726|NCT05851495|PROCEDURE|physiotherapist-led groups, home-based follow up groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises
48346849|NCT01116349|DEVICE|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
48346850|NCT00383266|DRUG|Pemetrexed|
48346851|NCT00383266|DRUG|Carboplatin|
47983413|NCT04669483|OTHER|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
47983414|NCT02452398|DEVICE|Treatment group|The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
47983415|NCT02452398|OTHER|No intervention|Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
47983416|NCT01737788|PROCEDURE|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
47983417|NCT00968994|DEVICE|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
47983418|NCT00968994|DEVICE|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
47983419|NCT04484792|OTHER|green tea mouthwash|green tea bags in 100 ml warm water for 5 min
47983420|NCT04484792|OTHER|green tea mouthwash|, in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
47983421|NCT04484792|OTHER|placebo|Plain water
47983422|NCT01938378|BIOLOGICAL|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
47983423|NCT06293170|OTHER|DETECT|DETECT periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a Richmond Agitation Sedation Scale (RASS) score of - 4 or - 5 or Glasgow Coma Scale (GCS) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. Both findings are considered early indicators of impending ILBF. In case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. The email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ILBF examination.
47983424|NCT06293170|OTHER|Conventional care|Conventional care
47983425|NCT03690115|DRUG|Ponatinib 30 MG|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
47983426|NCT02345382|DRUG|Atuveciclib, BAY1143572|The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
47983427|NCT04041804|PROCEDURE|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
47983428|NCT06147310|PROCEDURE|Study Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
48346852|NCT02762045|BIOLOGICAL|Ad5-gag|Ad5-gag is used as vaccine in all arms.
48346853|NCT02762045|BIOLOGICAL|Placebo|Preservation Solution is used as control in all arms.
48346854|NCT05528562|OTHER|PrEP Rapid Access|'Rapid PrEP Access' is a low-threshold intervention designed to provide on-site access to HIV self-testing at the Victory Program for persons who use opioids.
48346855|NCT05528562|OTHER|HIV self-testing|After enrollment the research assistant (RA) will provide the participant with a HIV self-test and provide instructions on how to obtain a proper sample for the test. It uses an oral fluid test and yields results within 20 minutes.
48346856|NCT05528562|OTHER|Dried blood spot testing|HIV Dried blood spot (DBS) testing provides an accurate method of measuring the HIV viral load in comparison to plasma viral load.
48346857|NCT00805038|BEHAVIORAL|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
48346858|NCT00805038|BEHAVIORAL|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
48346859|NCT05016440|DRUG|Lisinopril|10mg Lisinopril daily for 6-8 weeks postpartum
48346860|NCT02437721|OTHER|infant formula containing folic acid|
48346861|NCT02437721|OTHER|infant formula containing MTHF|
48346862|NCT05260125|DRUG|Ultrasound-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. A linear probe with a frequency of 7-8 MHz on the SonoScape A8 ultrasound device will be used for suprascapular block under ultrasound guidance. the ultrasound probe was placed in the coronal plane over the suprascapular fossa. Suprascapular fossa was scanned from medial to lateral side to identify suprascapular nerve. After identification, solution of suprascapular nerve block will be injected into the area around the nerve under the scanning with in-plane technique with a 22 gauge 90 mm spinal needle."
48658579|NCT03405350|PROCEDURE|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
47983429|NCT06147310|PROCEDURE|Control Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
47983430|NCT01668550|DRUG|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
47983431|NCT02392741|OTHER|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
47983432|NCT01024803|DEVICE|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
47983433|NCT01325389|DIETARY_SUPPLEMENT|Myo-Mel|
47983434|NCT01325389|DIETARY_SUPPLEMENT|Placebo|
47983435|NCT03655197|DRUG|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
47983436|NCT03598192|PROCEDURE|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
47983437|NCT03598192|PROCEDURE|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
47983438|NCT03598192|DRUG|Ropivacaine|Ropivacaine has been treated the both group
47983439|NCT03598192|DRUG|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
47983440|NCT00165347|DRUG|PTK787/ZK222584|
47983441|NCT03578289|BEHAVIORAL|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
47983442|NCT04123054|DEVICE|Mobile App|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
47983443|NCT04123054|DEVICE|Mobile App + Basal-Bolus Optimization Algorithm|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
47983444|NCT00815009|BEHAVIORAL|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
47983445|NCT00815009|BEHAVIORAL|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
47983446|NCT00815009|BEHAVIORAL|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
47983447|NCT06164223|DEVICE|VR Baby Pump|VRBaby-Pump application is a video application specially prepared with virtual reality glasses and a milking pump placed inside a toy doll. In the video content, the mother is breastfeeding her baby on an armchair in the baby room prepared for a newborn baby.
47983448|NCT06371118|DEVICE|Directly mailed self-sampling kit to collect a vaginal sample|"The HPV self-sampling test will be sent by post directly to the woman's address. If the woman does not return the sample within 20 days, she will be sent a SMS reminder.~The returned samples will be analysed. If high-risk HPV is present, women will be invited to be screened for cervical cancer in a clinical setting by their family doctors.~Self-samples in which high-risk HPV is present will also be subjected to HPV DNA methylation test. If an abnormal HPV DNA methylation is detected and the woman has not attended the screening in a clinical setting yet, she will be informed by her family doctor that a new test has indicated the need to attend a medical appointment."
47983449|NCT06371118|DEVICE|Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure|"Women will initially receive an invitation letter in their home addresses to receive the self-sampling kit, as well as a pre-paid envelope to return the answer to this invitation. If the woman does not return the answer within 10 days, she will be sent a SMS reminder. Only those who respond affirmatively to the question will receive the self-sampling kit.~The steps that follow will be the same as in intervention 1."
47983450|NCT06371118|DIAGNOSTIC_TEST|Standard of care - screening in a clinical setting|Corresponds to the standard of care. An invitation to attend the conventional cervical cancer screening (clinician-collected cervical sample for HPV test and reflex cytology) will be sent by post to the woman's address.
47983451|NCT00860964|DRUG|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
47983452|NCT00860964|DRUG|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
48658580|NCT03405350|PROCEDURE|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
48658581|NCT03405350|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
48658582|NCT03405350|PROCEDURE|Terrain Therapy|walking, outdoors physical activities,
48658583|NCT03405350|PROCEDURE|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
48346863|NCT05260125|DRUG|Anatomical Landmark-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. The suprascapular notch projection will be determined using the anatomical landmark technique defined by Dangoisse et al., and then suprascapular nerve block will be applied with a 22 gauge 90 mm spinal needle to the patients"
48346864|NCT03688893|DEVICE|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
48346865|NCT00863317|DRUG|montelukast sodium|4mg granules daily for 14 days
48136727|NCT01584466|DRUG|Paliperidone|"The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary."
48136728|NCT05703698|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
48136729|NCT00716170|BIOLOGICAL|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
48346866|NCT00863317|OTHER|sucrose|table sugar as placebo daily for 14 days
48346867|NCT04255368|OTHER|Water-soluble choline|600 mg choline as choline bitartrate
48346868|NCT04255368|OTHER|Fat-soluble choline|600 mg choline as phosphatidylcholine
48346869|NCT04255368|OTHER|No choline control|No choline
48346870|NCT00365742|DRUG|simvastatin|
48346871|NCT00365742|DRUG|red yeast rice|
48346872|NCT00365742|DRUG|pharmaceutical grade fish oil|
48346873|NCT00365742|BEHAVIORAL|therapeutic lifestyle changes|
48346874|NCT00225667|DRUG|Irbesartan|
48346875|NCT03320486|DRUG|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
48346876|NCT03320486|DRUG|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
48346877|NCT00559013|DEVICE|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
48346878|NCT02924272|DRUG|Ixazomib|Ixazomib Capsules
48346879|NCT00592072|DIETARY_SUPPLEMENT|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
48346880|NCT00592072|OTHER|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
48658584|NCT03405350|PROCEDURE|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
48346881|NCT05265936|PROCEDURE|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
48136730|NCT00091988|BEHAVIORAL|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
48136731|NCT00091988|BEHAVIORAL|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
48136732|NCT01567605|DRUG|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
48136733|NCT01567605|OTHER|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
48136734|NCT02108574|DEVICE|Placebo Filter|
48346882|NCT05265936|PROCEDURE|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
48346883|NCT02002065|BIOLOGICAL|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
48346884|NCT02002065|BIOLOGICAL|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
48346885|NCT01519336|DRUG|danoprevir|100 mg q12h
47983453|NCT04337606|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
48136735|NCT02108574|DEVICE|Rhinix Nasal Filter|
48136736|NCT01091168|DRUG|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
48346886|NCT01519336|DRUG|darunavir|600 mg q12h
48346887|NCT01519336|DRUG|ritonavir|100 mg q12h
48346888|NCT04386473|DEVICE|pacemaker|electrode is implanted in left bundle branch in LBBP; electrode is implanted in right ventricular outflow tract septal in RVOP
48346889|NCT03369210|DRUG|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
47983454|NCT04337606|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
47983455|NCT04337606|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
47983456|NCT00168727|DRUG|ibritumomab tiuxetan (Zevalin®)|
47983457|NCT05217433|OTHER|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
47983458|NCT05217433|OTHER|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
47983459|NCT01373437|DEVICE|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
47983460|NCT00075049|BIOLOGICAL|RTS,S with AS02A/AS01B adjuvant|
47983461|NCT02389010|BIOLOGICAL|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
47983462|NCT02389010|OTHER|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
47983463|NCT04534023|DRUG|Idebenone|trial group
47983464|NCT04534023|DRUG|Placebo|control group
48136737|NCT01091168|DRUG|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
48346890|NCT04352881|OTHER|Questionary patient|Assessing pain reduction using a 4-step questionary
48346891|NCT01604434|PROCEDURE|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
48346892|NCT01604434|PROCEDURE|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
48346893|NCT03535090|DRUG|Methylprednisolone|
48658585|NCT03405350|PROCEDURE|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
48658586|NCT03405350|PROCEDURE|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
48346894|NCT02315105|PROCEDURE|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
48346895|NCT00655239|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
48346896|NCT00655239|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
48346897|NCT01819194|DEVICE|senofilcon A|
48346898|NCT06302608|GENETIC|NGGT001|Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration
48346899|NCT06005038|BEHAVIORAL|pSOPT|computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
48346900|NCT06005038|BEHAVIORAL|MLA|computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
48346901|NCT03394118|DRUG|Osimertinib|A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
48346902|NCT00509938|DRUG|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
48346903|NCT05984628|PROCEDURE|human umbilical cord mesenchymal stem cells|After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.
48346904|NCT05984628|PROCEDURE|blank solvent|After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.
48346905|NCT04934293|PROCEDURE|Virtual reality|Before proton therapy, virtual reality sessions will be performed.
48346906|NCT02864706|DRUG|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
48346907|NCT02864706|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
48346908|NCT02864706|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
48346909|NCT02864706|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
48346910|NCT00256646|DRUG|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
48346911|NCT04282369|DEVICE|HHHFNC|noninvasive ventilation modality
48346912|NCT04282369|DEVICE|NCPAP|noninvasive ventilation modality
48346913|NCT04282369|DEVICE|NIPPV|noninvasive ventilation modality
48346914|NCT04282369|DEVICE|NHFO|noninvasive ventilation modality
48346915|NCT04841850|OTHER|Clinical and biological characteristics|"* Age at beginning of IOT~* Sex~* Atopic and non atopic Comorbidities~* Sensitization to aero-allergens~* Sensitization to trophallergens~* Stage of severity of the elicited reaction~* Hazelnut Specific IgE + Cor a 1,8,9,14 before IOT and during follow up~* Hazelnut skin prick test before IOT and during follow up~* Adverse effects of IOT and their stage (in hospital and at home)~* Use of adrenaline auto-injector (in hospital and at home)~* Maintenance dose"
48136738|NCT05400161|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. Investigators will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
48136739|NCT05400161|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. Investigators will organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily and provides feedback to participants. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed and counts of sessions viewed and comments posted. Participants randomized to the intervention will also have the option to take part in a preliminary virtual session through a secure video platform (e.g. BlueJeans) and will receive weekly engagement text messages. Women in the intervention group will be enrolled in the online depression treatment program, MoodGym.
48346916|NCT02485067|DRUG|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
48346917|NCT02485067|DRUG|Placebo(For THVD-201)|
48136740|NCT01100151|DRUG|RDC-1036 (ALKS 37)|Capsules for oral administration
48136741|NCT01100151|DRUG|Placebo|Capsules for oral administration
48136742|NCT00485693|DRUG|Bupivacaine HCl|150 mg Bupivacaine HCl
48136743|NCT00485693|DRUG|SKY0402|600 mg SKY0402 (study drug)
48136744|NCT05746234|BEHAVIORAL|Emotion Regulation Course|"Each module contains a) the session outline, b) review of previous session's homework, c) theoretical background and module's rationale, d) skills activities, and e) homework assignment.~Each group will attend five 1.5-hour sessions with their allocated instructor. Participants in both groups will receive the same training modules in the same chronological order. For consistency across modalities, participants will receive an instructor's manual containing the core material for facilitating the ER4ALL training, and a companion students' workbook with supporting information and activities."
48346918|NCT02485067|DRUG|Detrusitol 2mg tablet|Tolterodine 2mg
48346919|NCT02485067|DRUG|Placebo(For Detrusitol 2mg tablet)|
48346920|NCT00776373|DRUG|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
47983465|NCT02299479|DEVICE|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
47983466|NCT02299479|DEVICE|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
47983467|NCT00467259|DRUG|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
47983468|NCT00467259|DRUG|Placebo patch|placebo patch, changed twice a week for 52 weeks
48346921|NCT02509611|OTHER|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
48346922|NCT04594668|DRUG|Senicapoc|The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
48501596|NCT03963986|DEVICE|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
47983469|NCT00729989|PROCEDURE|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
47983470|NCT02532790|DRUG|Prednisone|1.5mg/kg/d
47983471|NCT02532790|DRUG|ACEI|0.2-0.3mg/kg/d
47983472|NCT03306680|RADIATION|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
47983473|NCT02562794|BEHAVIORAL|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
47983474|NCT00758212|BIOLOGICAL|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
47983475|NCT03441854|DEVICE|HFNC group|Application of HFNC oxygen delivery after extubation.
47983476|NCT03199586|DRUG|NP-G2-044|capsule
47983477|NCT00290368|PROCEDURE|Skin Prick Test|
47983478|NCT00290368|PROCEDURE|Nasal allergen challenge|
47983479|NCT00290368|PROCEDURE|Nasal filter paper placement|
47983480|NCT00290368|PROCEDURE|Nasal lavage|
48136745|NCT01837602|BIOLOGICAL|cMet RNA CAR T cells|
48346923|NCT04935372|OTHER|Observational|"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."
48346924|NCT00383006|BEHAVIORAL|Skills for affect regulation (behavior)|
48346925|NCT02280525|DRUG|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
48346926|NCT02280525|DRUG|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
48346927|NCT02280525|DRUG|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
48346928|NCT02280525|DRUG|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
48346929|NCT02280525|PROCEDURE|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
48346930|NCT02280525|DRUG|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
48346931|NCT01467089|OTHER|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
48501597|NCT03918694|DIETARY_SUPPLEMENT|Vitamin C|Daily use of Vit C tablets
47983481|NCT00290368|PROCEDURE|Nasal scrape|
47983482|NCT00290368|PROCEDURE|Nasal symptoms score|
48136746|NCT03387540|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
47983483|NCT04053192|PROCEDURE|BAV|BAV
47983484|NCT04053192|PROCEDURE|BAV + TAVR|BAV + TAVR
47983485|NCT04053192|PROCEDURE|SAVR|Surgical aortic valve replacement (SAVR)
47983486|NCT04193657|OTHER|Daily and weekly triggered symptom monitoring|Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
47983487|NCT05205421|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
47983488|NCT02533830|BIOLOGICAL|sugarless gum|"One Stick of Sugarless Gum (Samara for food \& Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
47983489|NCT02533830|OTHER|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
47983490|NCT02744391|DRUG|Levodopa|
47983491|NCT01816633|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
47983492|NCT00002144|DRUG|Foscarnet sodium|
47983493|NCT04020679|BEHAVIORAL|Goals of Care Initiative|Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
47983494|NCT03252301|DEVICE|PMD 200|finger sensor which estimate objectively the pain level
47983495|NCT02059460|DRUG|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
47983496|NCT02059460|DRUG|placebo|
47983497|NCT04988711|DIAGNOSTIC_TEST|Hb Oxymeter|Measurement of Hb Oximeter
47983498|NCT06219057|BEHAVIORAL|The Wise Adolescent|The program encompasses 20 individual weekly sessions manualized. Its main objective is to help adolescents to create affiliative feelings towards themselves and to develop a more compassionate inner voice. Sessions are organized across 6 main domains: (1) placing ourselves in the challenges of life: evolutionary roots of our mind, how social circumstances and life experiences shape us; the 3-affect regulation systems; (2) understanding difficulties: compassion focused therapy case formulation; (3) understanding compassion: the three flows of compassion, its three pillars (caring commitment, wisdom, strength and courage); (4) compassionate mind training: cultivating the compassion skills (compassionate attention, imagery, reasoning, and behavior); (5) working with difficulties: fears, blocks and resistances to compassion; multiple selves; shame and self-criticism; (6) sustaining a compassionate mind: reviewing the gains and relapse prevention.
48136747|NCT03934567|DRUG|Abexinostat|Abexinostat tablets
48346932|NCT00744731|DRUG|placebo|placebo for 1 week
48346933|NCT00744731|DRUG|carisbamate|400 mg/day to 1,200 mg per day
48501598|NCT03918694|DIETARY_SUPPLEMENT|Placebo|Daily use of placebo tablets
48501599|NCT05743205|BEHAVIORAL|voluntary consultative wellness session|Professional wellness counseling sessions provided to health care professionals through voluntary enrollment. Consultative sessions will conducted throughout the course of 1 year and number of subsequent sessions will be determined by the participant.
48501600|NCT01563835|DRUG|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
48501601|NCT01563835|DRUG|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
48346934|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
48136748|NCT05080036|OTHER|Medio-lateral imbalance|Thrust on the pelvis in the medio-lateral direction in order to create a balance perturbation
48346935|NCT02635867|PROCEDURE|Indirect Pulp capping-Calcium hydroxide - Dycal|Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
48346936|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-based dentin bonding agent|Use of a dental restorative protocol using resin-based dentin bonding system only
48346937|NCT02635867|PROCEDURE|Direct Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
48346938|NCT02635867|PROCEDURE|Direct Pulp capping-Calcium hydroxide - Dycal|\\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
48346939|NCT05284656|DRUG|combination of Pentoxifylline 400 MG and Folic Acid|drugs used to delay progression of chronic kidney disease
48346940|NCT05284656|DRUG|folic acid|drugs used to delay progression of chronic kidney disease
48346941|NCT05284656|DRUG|Pentoxifylline 400 MG|drugs used to delay progression of chronic kidney disease
48346942|NCT03978572|BEHAVIORAL|Resistance Training|Exercise intervention designed to improve muscular strength and power
48346943|NCT03978572|BEHAVIORAL|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
48346944|NCT03978572|BEHAVIORAL|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
48346945|NCT01899001|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
48346946|NCT01899001|BEHAVIORAL|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
47983499|NCT06160154|OTHER|no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization
47983500|NCT00876772|DRUG|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
47983501|NCT02157298|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
47983502|NCT02157298|DRUG|Placebo tablet|Placebo tablet. Oral dose
47983503|NCT00937157|DRUG|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
47983504|NCT00775151|DRUG|amlodipine 10 mg tablet|
48346947|NCT00572312|DRUG|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
48346948|NCT00223652|BEHAVIORAL|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
47983505|NCT03251066|OTHER|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
48136749|NCT05561491|BIOLOGICAL|ONCOS-102|Oncolytic virus
48136750|NCT05561491|BIOLOGICAL|Balstilimab|Anti PD-1
48658587|NCT03405350|PROCEDURE|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
47983506|NCT01128257|DRUG|alendronate|As prescribed by physician
47983507|NCT01128257|DRUG|ibandronate [Bonviva/Boniva]|As prescribed by physician
48136751|NCT05095974|DEVICE|ultrasonography|Ultrasound assessment will performed with parturient in the supine position using Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz). A C60x 5-2 MHz convex transducer will used for lung ultrasound (Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz).The Echo Comet Score (ECS) will obtained by the 28-rib interspaces technique dividing the chest wall in 12 areas on the left side (from the second to the fourth intercostal space) and 16 (from the second to the fifth intercostal space) on the right anterior and lateral hemithorax.
47983508|NCT04480437|DEVICE|mp-BUS data collection|Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
47983509|NCT05251909|BIOLOGICAL|Benralizumab|Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
47983510|NCT05251909|BIOLOGICAL|Placebo|Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
47983511|NCT04937829|DRUG|BI 1569912|BI 1569912
47983512|NCT04937829|DRUG|Placebo|Placebo
48136752|NCT05095974|DEVICE|echocardiography|MHz cardiac transducer for echocardiography with two-dimensional, M-mode, color-flow, continuous, pulsed wave and tissue Doppler imaging.
48346949|NCT05735236|DEVICE|BFR Cuff|The BFR cuff will be applied to the proximal thigh of the surgical leg while the patient completes specified physical therapy exercises.80% occlusion pressure will be determined by PT's in clinic through the use of a Delphi unit. Subjects will then be able to use the Saga Fitness app to adjust this pressure if it differs from the automatic calibrated pressure.
48136753|NCT05095974|DEVICE|thoracic electrical bioimpedence|EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.
48346950|NCT01091142|DRUG|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
48346951|NCT01091142|DRUG|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
48346952|NCT00668772|DRUG|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
48658588|NCT03405350|PROCEDURE|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
48658589|NCT03405350|PROCEDURE|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
48658590|NCT04111354|DEVICE|Pacemaker implantation|Pacemaker implantation
47983513|NCT05104164|OTHER|Self-myofascial release|At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
48136754|NCT03473249|DRUG|Contrast-Enhanced Ultrasound using Lumason|Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
48136755|NCT01641900|DRUG|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
48136756|NCT01641900|DRUG|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
48136757|NCT04359017|DRUG|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
48136758|NCT02520674|OTHER|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
48136759|NCT00003654|DRUG|patent blue V dye|
48136760|NCT00003654|PROCEDURE|lymphangiography|
48136761|NCT00003654|PROCEDURE|radionuclide imaging|
48136762|NCT00003654|PROCEDURE|sentinel lymph node biopsy|
48346953|NCT00668772|DRUG|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
48346954|NCT00668772|DRUG|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
48346955|NCT00668772|DRUG|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
48346956|NCT00668772|DRUG|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
48346957|NCT01556789|BIOLOGICAL|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
48346958|NCT05589012|BIOLOGICAL|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
48346959|NCT05589012|BIOLOGICAL|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
48658591|NCT01355627|PROCEDURE|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
48658592|NCT01355627|PROCEDURE|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
48136763|NCT00003654|RADIATION|technetium Tc 99m sulfur colloid|
48136764|NCT04224415|DRUG|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
48136765|NCT05153681|OTHER|Peloid Therapy|Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
48136766|NCT00083590|DRUG|Huperzine A|
48136767|NCT02144597|DIETARY_SUPPLEMENT|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
48136768|NCT02144597|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Participant went through Roux-en-Y gastric bypass (RYGB) surgery
48136769|NCT02144597|OTHER|Control diet|
48136770|NCT04082507|DIAGNOSTIC_TEST|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
48136771|NCT02894099|OTHER|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
48136772|NCT02894099|OTHER|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
48136773|NCT02894099|OTHER|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
48346960|NCT05589012|BIOLOGICAL|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
48346961|NCT05632913|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
48346962|NCT04430868|BEHAVIORAL|lifestyle redesign program|In this group, it starts with health education, the participants then change their opinions and experience health activities, and it ends with discussion and sharing their experience.
48346963|NCT06165016|DEVICE|Far red light therapy|All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
48658593|NCT05463419|BIOLOGICAL|PIKA COVID-19 vaccine|"SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant."
48658594|NCT05463419|BIOLOGICAL|Inactivated Covid-19 vaccine|Inactivated SARS-CoV-2 virus
48658595|NCT00356187|DRUG|Propranolol|
48658596|NCT05454514|DEVICE|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
48658597|NCT05454514|DEVICE|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
47983514|NCT04405986|PROCEDURE|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
48346964|NCT06165016|DEVICE|Sham light therapy|All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
48136774|NCT02894099|OTHER|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
48136775|NCT02334215|DRUG|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
48136776|NCT02334215|BEHAVIORAL|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
48346965|NCT02027974|DEVICE|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
48346966|NCT02027974|DEVICE|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
48136777|NCT02334215|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
48136778|NCT02428556|OTHER|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
48136779|NCT02428556|OTHER|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
48136780|NCT02428556|OTHER|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
48136781|NCT02428556|OTHER|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
48346967|NCT01701856|DRUG|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
48346968|NCT06249880|OTHER|Observation|This project seeks to recruit 20 male and 20 female typically developing individuals, between the ages of 3 and 25 years of age. Non-invasive measurements of movement patterns (motion analysis and force plate data) will be collected during bipedal gait.
48346969|NCT06087731|DRUG|Tocilizumab|Tocilizumab (8mg/kg) every 4 wekks
48346970|NCT00453323|DRUG|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
48346971|NCT00453323|DRUG|Capecitabine|capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
48136782|NCT02428556|OTHER|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
48136783|NCT02873533|OTHER|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
48136784|NCT05473806|DRUG|Pioglitazone 15 Mg Oral Tablet|24weeks dose
48136785|NCT05473806|DRUG|Evogliptin 5mg|24weeks dose
48346972|NCT05228704|BEHAVIORAL|activities in the Botanical Garden or in urban|activities in the Taipei Botanical Garden or in Urban
48346973|NCT04885127|OTHER|Palliative Care + Digital Symptom Monitoring|Previously described in Arm description
48346974|NCT00508469|DRUG|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
48346975|NCT00508469|DRUG|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
48346976|NCT00508469|DRUG|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
48346977|NCT00508469|DEVICE|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
48346978|NCT04073641|OTHER|No intervention|No intervention
48346979|NCT06099028|OTHER|no intervention|no intervention
48136786|NCT04826406|DRUG|Camrelizumab combined Apatinib regimen|Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
48136787|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 50 mg
48136788|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 300 mg
48136789|NCT01025128|DRUG|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
48136790|NCT05338567|DIAGNOSTIC_TEST|Small intestine length measurement method|Accuracy of digital 3D reconstruction for predicting small bowel length
48136791|NCT04802681|DEVICE|FFR-measurement with different pressure guidewires|Measuring FFR with different pressure guidewires
48136792|NCT03454256|DEVICE|Virtual Reality|Virtual Reality Rehabilitation System
48136793|NCT06318559|PROCEDURE|3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy|"The operation is performed using the Da Vinci HD robotic system which allows the use of laparoscopic instruments, with greater mobility and the possibility of easier and more precise control of movements in three dimensions. Furthermore, the system allows the surgeon a three-dimensional view of the operating field. The surgery is performed under general anesthesia. Six or more trocars are positioned, into which the instruments operated by the robot or directly by the surgical assistants are inserted.~Then a radical prostatectomy is performed."
48136794|NCT02433587|DRUG|Aspirin|Patients will take Aspirin 81 mg
48136795|NCT02433587|DRUG|Clopidogrel|Patients will take Clopidogrel 75 mg
48136796|NCT05964907|DEVICE|Light Source B: Visible Light solar simulator (VL + UVA1)|Patients will be radiated with light source B (Visible light solar simulator)
48136797|NCT05964907|DEVICE|Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)|Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
48136798|NCT01212913|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
48346980|NCT00102804|DRUG|Pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV) administration, every (q) 21 days, until disease progression
48136799|NCT01212913|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
48136800|NCT01212913|DRUG|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
48136801|NCT01773993|DRUG|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
48136802|NCT01450163|DRUG|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
48136803|NCT01450163|DRUG|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
48136804|NCT01310166|DRUG|Fingolimod|
48136805|NCT03254472|DIAGNOSTIC_TEST|Measured concentrations of biomarkers|
48136806|NCT04784390|DEVICE|Binocular video games|Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
48346981|NCT00102804|DRUG|Placebo|IV administration, q 21 days
48346982|NCT00102804|OTHER|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
48346983|NCT03949127|OTHER|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
48658598|NCT05454514|OTHER|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
48658599|NCT06569407|OTHER|Online Educational Intervention|An educational program for EBP based on the online learning model was planned to be developed based on the literature and expert opinions. In the program, in line with the literature, the introduction to the EBP, the importance of EBP, EBP steps, clinical research question design in line with PICO, and introduction of EBP databases. It is planned to include topics such as literature search strategies, types of research, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflection of EBP on patient care and clinical decision-making processes, and it is planned to determine the final version of the education content with expert opinions. The program will include recorded videos, slides and documents for each module. The content of the program will be integrated into the Koç University Online Programs Platform by the experts working at Koç University Educational Technologies Unit.
48136807|NCT04784390|DEVICE|Patching of the sound eye|Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
48136808|NCT04405310|BIOLOGICAL|Convalescent Plasma of patients with COVID-19|Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
48136809|NCT04405310|OTHER|placebo (hartmann plus albumine)|use of albumin 20% in 250cc of Hartmann solution
48136810|NCT03551600|PROCEDURE|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
48136811|NCT04157894|OTHER|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
48136812|NCT04157894|OTHER|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
48136813|NCT04157894|OTHER|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
48136814|NCT00428805|BEHAVIORAL|classroom curriculum|"classroom curriculum for 3 \& 4 year old children includes activities to increase intake of fruits, vegetables, \& whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
48136815|NCT00428805|BEHAVIORAL|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
48346984|NCT04692818|DIAGNOSTIC_TEST|GE Logiq E10 clinical ultrasound scanner|2D B-mode, Doppler, and shear wave elastography images of the lesion
48346985|NCT04692818|DIAGNOSTIC_TEST|Verasonics research scanner|3D B-mode imaging, microvessel imaging, and shear wave elastography
48346986|NCT04677023|OTHER|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
48136816|NCT00428805|BEHAVIORAL|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
48136817|NCT00428805|BEHAVIORAL|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
47983515|NCT04405986|PROCEDURE|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
47983516|NCT01453114|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
48136818|NCT00428805|BEHAVIORAL|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
48136819|NCT00428805|BEHAVIORAL|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
48136820|NCT00428805|BEHAVIORAL|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
48136821|NCT05137600|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
48136822|NCT05137600|DRUG|Midazolam|Midazolam is a sensitive CYP3A index substrate
48136823|NCT05137600|DRUG|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
48136824|NCT00294736|DRUG|Tarceva|Dose Escalation: 150-350+ mg/day
48136825|NCT03185936|PROCEDURE|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
48346987|NCT04677023|OTHER|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
47983517|NCT01506479|BEHAVIORAL|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
47983518|NCT01506479|BEHAVIORAL|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
47983519|NCT01506479|BEHAVIORAL|No Intervention|No-exercise control (i.e., usual care);
47983520|NCT02107482|DEVICE|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
47983521|NCT02107482|DEVICE|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
47983522|NCT00548925|DRUG|ABT-894|6 mg BID tablets, 8 weeks of treatment
47983523|NCT00548925|DRUG|placebo|BID tablets, 8 weeks of treatment
47983524|NCT05971407|DEVICE|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
47983525|NCT05971407|DEVICE|Sham Remote Ischaemic Preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
47983526|NCT01901237|BEHAVIORAL|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
47983527|NCT04054388|BEHAVIORAL|LINE re-education|
48136826|NCT03938337|DRUG|Cohort 1 Not Previously Treated|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
48136827|NCT03938337|DRUG|Cohort 2 Treated Previously|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
48136828|NCT03615352|PROCEDURE|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
48136829|NCT03615352|PROCEDURE|ovarian cyst aspiration and coagulation|laparoscopic ovarian cyst aspiration and coagulation in endometrioma
48136830|NCT01828671|OTHER|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
48136831|NCT01828671|OTHER|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
48136832|NCT01828671|OTHER|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
48136833|NCT01828671|OTHER|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
48136834|NCT01828671|OTHER|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
48136835|NCT03067974|DRUG|Ketamine Hcl 100Mg/Ml Inj|10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation
48136836|NCT04865718|DIAGNOSTIC_TEST|ICGA imaging|subjects undergoing intraoperative ICGA imaging
48136837|NCT01296815|DRUG|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
48501602|NCT05962203|DIAGNOSTIC_TEST|Multi-factorial geriatric assessment, monitoring & management systems|Multi-factorial geriatric assessment, monitoring \& management systems, e.g. community-based and home-based exercise programs, polypharmacy
48501603|NCT01912027|PROCEDURE|Open Latarjet technique|
48346988|NCT01868594|DRUG|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
48346989|NCT01868594|DRUG|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
48346990|NCT04655690|DRUG|NNC0471-0119|Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
48346991|NCT04655690|DRUG|Fast-acting insulin aspart|Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
48501604|NCT01912027|PROCEDURE|Arthroscopic Latarjet techniques|
48501605|NCT00469144|DRUG|Busulfan|"Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
47983528|NCT01850550|BEHAVIORAL|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
47983529|NCT01710254|DRUG|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
47983530|NCT01710254|DRUG|Gadobenate dimeglumine|Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
47983531|NCT00613249|DRUG|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
47983532|NCT00613249|DRUG|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
48136838|NCT00552253|DRUG|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
48501606|NCT00469144|DRUG|Fludarabine|40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
48501607|NCT02826772|DRUG|GT0918|anti-tumor activity
48136839|NCT03944200|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
48658600|NCT06569407|OTHER|Educational Booklet|An educational booklet for EBP was planned to be developed based on the literature and expert opinions. The learning objectives and content of the educational booklet to be developed will be created by considering Bloom\&#39;s taxonomy. In line with the literature, it is planned to include topics such as introduction to EBP, importance of EBP, evidence-based practice steps, clinical research question design in line with PICO, introduction of evidence-based databases, literature search strategies, research types, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflections of EBP on patient care and clinical decision-making processes, and finalization of the booklet topics with expert opinions.
48346992|NCT06357962|OTHER|Semi-permanent acupuncture|These are sessions that last approximately one hour. The selection of points will be based on the energy diagnosis made during the first visit. In some cases, a point may be changed depending on progress. During the session, an interrogation will be conducted to assess symptoms and signs of the condition, and to evaluate if there have been any adverse reactions to the previous session. At the end of the visit, semi-permanent acupuncture will be applied to the selected points.
48346993|NCT06357962|OTHER|Sham of semi-permanent acupuncture|A simulated semi-permanent acupuncture session will be conducted, consisting of specific placebo materials without needles and without stimulation for a few minutes. These points will not correspond to any acupuncture point and will be located on the hands, feet, and back. Stickers without pins will be applied, but never in critical points related to contraction stimulation or cervical ripening.
48346994|NCT04212546|OTHER|Synbiotic test drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g inulin + Lactobacillus casei431 \[\>106cfu/mL\] per day for 21 days with their habitual diet.
48346995|NCT04212546|OTHER|Control drink|In a healthy male population, participants consumed a synbiotic test drink containing 200 mL milk + 16 g maltodextrin per day for 21 days with their habitual diet.
48346996|NCT05538429|PROCEDURE|erector spinal plane combined with serratus anterior plane block|The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
48346997|NCT01966276|DRUG|Methyl-P plus Nutrient Formula|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P (5mg)~ * Four tablets of CFS Nutrient Formula~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P (10mg)~ * Four tablets of CFS Nutrient Formula"
48346998|NCT01966276|DRUG|Methyl-P plus Nutrient matched placebos|"* Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo"
48346999|NCT01744041|BEHAVIORAL|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
48347000|NCT01744041|OTHER|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
48501608|NCT02930967|BIOLOGICAL|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
48658601|NCT03917615|OTHER|pelvic floor contraction|Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
48658602|NCT05601869|DEVICE|RECOVER Prosthetic Ankle-Feet System|The RECOVER prosthetic ankle-feet system includes a single prosthetic ankle joint that can be easily attached to 3D printed feet. The feet are designed to fit specifically within different footwear.
48658603|NCT03974061|BEHAVIORAL|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
47983533|NCT00613249|DRUG|HEC-based Placebo Gel|intravaginal gel, dosed daily
48658604|NCT03974061|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
48658605|NCT06564194|BIOLOGICAL|JCXH-108|IM injection
47983534|NCT00745147|DRUG|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
47983535|NCT00745147|DRUG|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
48136840|NCT03944200|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
48658606|NCT06564194|OTHER|Placebo|IM injection
47983536|NCT02528643|DRUG|Enzalutamide|Oral capsule
47983537|NCT02528643|DRUG|Placebo|Oral capsule
47983538|NCT05451160|DEVICE|steep pulse therapy system|The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation
47983539|NCT05451160|DEVICE|RF Ablation System|RF Ablation System
47983540|NCT01484873|DRUG|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
47983541|NCT04756843|DEVICE|Quad-helix|Fixed orthodontic appliance
48136841|NCT03946956|BEHAVIORAL|Prebooking|Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
48136842|NCT03946956|BEHAVIORAL|Pictured invitation|Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
48136843|NCT05467813|OTHER|mirror therapy|The mirror therapy (MT) will be done with participants seated at a table. The affected upper-extremity (UE) will be placed behind the mirror and the unaffected UE in front of the mirror. Participants will be asked to do the same movements using both the unaffected and affected UE as possible. Each participant will practice two different MT protocols: unilateral mirror therapy (UMT) and bilateral mirror therapy (BMT). During UMT, the affected hand is static, while during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements, fine motor movements, and object manipulation.
48136844|NCT05467813|OTHER|augmented reality (AR)|The training program provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. To ensure safety, the investigators will place a handrail in front of the participant for support. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg), activities of daily living training (i.e., reaching), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
48136845|NCT05467813|OTHER|control therapy|The control intervention will include practice of upper limb activities, balance activities, activities of daily living, and cognitive enhancement tasks. The protocols of the conventional therapy will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their prioritized goals. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
48136846|NCT02280031|DRUG|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
48136847|NCT02280031|DRUG|Placebo|Capsule containing placebo pill with lactose
48136848|NCT02457806|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
48136849|NCT02457806|DRUG|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
48658607|NCT03743519|DIETARY_SUPPLEMENT|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
48658608|NCT03743519|DIETARY_SUPPLEMENT|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
48658609|NCT06135064|DEVICE|Diadem|The device delivers low-intensity ultrasonic waves into specified brain targets.
47983542|NCT02520050|BEHAVIORAL|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
47983543|NCT02520050|BEHAVIORAL|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
47983544|NCT02520050|BEHAVIORAL|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
47983545|NCT05184920|OTHER|P1012919 nicotine pouch|P1012919, a nicotine pouch with 12 mg of nicotine
47983546|NCT05184920|OTHER|P1012915 nicotine pouch|P1012915, a nicotine pouch with 8 mg of nicotine
47983547|NCT05184920|OTHER|P1012914 nicotine pouch|P1012914, a nicotine pouch with 4 mg of nicotine
47983548|NCT05184920|OTHER|P1013315 nicotine pouch|P1013315, a nicotine pouch with 8 mg of nicotine
47983549|NCT05184920|OTHER|P1013119 nicotine pouch|P1013119, a nicotine pouch with 12 mg of nicotine
47983550|NCT05184920|OTHER|P1013218 nicotine pouch|P1013218, a nicotine pouch with 10 mg of nicotine
47983551|NCT05184920|OTHER|P1012818 nicotine pouch|P1012818, a nicotine pouch with 10 mg of nicotine
47983552|NCT05184920|OTHER|P1312915 nicotine pouch|P1312915, a nicotine pouch with 8 mg of nicotine
47983553|NCT05184920|OTHER|P1312914 nicotine pouch|P1312914, a nicotine pouch with 4 mg of nicotine
48136850|NCT04767815|DRUG|Diet A group|Fasting + DWN12088 200 mg
47983554|NCT05184920|OTHER|P1313015 nicotine pouch|P1313015, a nicotine pouch with 8 mg of nicotine
48136851|NCT04767815|DRUG|Diet B group|30 minutes after a high-fat meal + DWN12088 200 mg
48136852|NCT04767815|DRUG|Diet C group|2 hours after a high-fat meal + DWN12088 200 mg
48136853|NCT04012970|OTHER|Manual spinal mobilisations|
48136854|NCT03197649|PROCEDURE|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
48658610|NCT04278781|DRUG|AG-120|AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
47983555|NCT05184920|OTHER|P1313314 nicotine pouch|P1313314, a nicotine pouch with 4 mg of nicotine
47983556|NCT05184920|OTHER|P1312815 nicotine pouch|P1312815, a nicotine pouch with 8 mg of nicotine
47983557|NCT03959566|DRUG|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
47983558|NCT03959566|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
47983559|NCT03959566|DRUG|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
48136855|NCT00023920|BIOLOGICAL|bevacizumab|Given IV
48136856|NCT00023920|DRUG|idarubicin|Given IV
48136857|NCT00023920|DRUG|cytarabine|Given SC
48136858|NCT00073372|DRUG|Abciximab|
48136859|NCT05309200|DRUG|OCE-205|The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
48136860|NCT05309200|DRUG|Placebo|Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
47983560|NCT05039645|BEHAVIORAL|Patient specific, clinician determined Intervention|Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of \>2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
47983561|NCT06123104|DEVICE|Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)|Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
47983562|NCT05766644|OTHER|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q\&A session. Topics are on general disease information, nutrition, and exercise.
47983563|NCT01432886|DRUG|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
47983564|NCT06391151|OTHER|exposure: OSA resulting from chronic tonsillitis|exposure: OSA resulting from chronic tonsillitis
47983565|NCT06377228|BIOLOGICAL|TAK-007|TAK-007 IV infusion.
47983566|NCT06377228|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide as per standard of care.
47983567|NCT02643082|DRUG|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
47983568|NCT02643082|DRUG|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
47983569|NCT01912651|DRUG|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
47983570|NCT01821521|DRUG|AGSPT_L20|
47983571|NCT01821521|DRUG|Pantoloc 40mg|
47983572|NCT00000854|DRUG|Nandrolone decanoate|
47983573|NCT00931814|OTHER|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
47983574|NCT01719523|DRUG|EPI-743|
47983575|NCT02872467|DRUG|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
47983576|NCT02872467|OTHER|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
47983577|NCT05986162|DRUG|Itolizumab|Patients to be treated with Itolizumab.
47983578|NCT03171623|DRUG|globalagliatin hydrochloride|orally administration, single dose
47983579|NCT03171623|DRUG|placebo|orally administration, single dose
48136861|NCT03827200|DRUG|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
48136862|NCT03234959|DEVICE|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
48136863|NCT03234959|OTHER|Infant Massage|Infants will received IM by their parents
48136864|NCT02959385|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
47983580|NCT02324374|DEVICE|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
47983581|NCT02324374|DEVICE|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
47983582|NCT01741701|DRUG|Oxaloacetate (OAA)|
47983583|NCT01741701|DRUG|Placebo|
48136865|NCT02959385|PROCEDURE|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
48136866|NCT02803749|DRUG|Buspirone|
48136867|NCT02803749|DRUG|Placebo|
48136868|NCT03582566|BEHAVIORAL|Phonological Awareness|Earobics training
48136869|NCT03582566|BEHAVIORAL|Working Memory|Cogmed training
48136870|NCT03582566|BEHAVIORAL|Phonological Awareness + Working Memory|Earobics + Cogmed training
48136871|NCT03582566|BEHAVIORAL|Active Control|Spashmath
47983584|NCT02255981|OTHER|Acupuncture and massage|"Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself."
47983585|NCT02694874|DRUG|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
47983586|NCT02694874|DRUG|Placebo|This is the placebo control
47983587|NCT05741567|PROCEDURE|correction of anterior prolapse|percentage of failed prolapse correction
47983588|NCT01881776|PROCEDURE|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
47983589|NCT03686371|PROCEDURE|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
47983590|NCT01493206|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
47983591|NCT06087107|OTHER|High Intensity Spinal Decompression Exercises|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
47983592|NCT06087107|OTHER|Eldoa|The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
47983593|NCT03227029|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L|10\^6 plaque-forming units (PFU); administered as nose drops
47983594|NCT03227029|BIOLOGICAL|RSV 276|10\^5 PFU; administered as nose drops
47983595|NCT03227029|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
47983596|NCT04212104|OTHER|watch a mukbang|watch the dim sum mukbang
47983597|NCT04212104|OTHER|watch a non-food video|watch the Big Bang Theory video
47983598|NCT05415085|PROCEDURE|Culprit-first PCI|PCI to the culprit artery prior to the demonstration of the whole coronary tree.
47983599|NCT06208228|DEVICE|Kinesiotaping|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
47983600|NCT02845245|OTHER|3D printed plastic model prototype|
47983601|NCT02845245|OTHER|3D CT scan|
47983602|NCT02845245|OTHER|Plain film radiographs|
47983603|NCT00549523|DRUG|Placebo|Capsules containing 0 mg bid (placebo)
47983604|NCT00549523|DRUG|Low Dose|Capsules containing 400 mg bid of L. frutescens.
47983605|NCT00549523|DRUG|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
47983606|NCT00549523|DRUG|High Dose|Capsules containing 1200 mg bid of L. frutescens.
47983607|NCT00788151|BIOLOGICAL|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
47983608|NCT00788151|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL, SC
47983609|NCT02554812|DRUG|Avelumab|Anti-PD-L1 antibody
47983610|NCT02554812|DRUG|Utomilumab|Anti-4-1BB antibody
47983611|NCT02554812|DRUG|PF-04518600|OX40 Agonist
47983612|NCT02554812|DRUG|PD 0360324|Anti-M-CSF
47983613|NCT02554812|DRUG|CMP-001|TLR9 agonist
47983614|NCT02818686|DRUG|TD-1473|
47983615|NCT02818686|DRUG|Placebo|
47983616|NCT04358133|DRUG|Chlorhydrate de morphine|The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol
47983617|NCT04358133|DRUG|NaCl 0,9%,|The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
47983618|NCT01131923|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
47983619|NCT00262808|BIOLOGICAL|sargramostim|
47983620|NCT00262808|DRUG|fluorouracil|
47983621|NCT00262808|DRUG|leucovorin calcium|
47983622|NCT00262808|DRUG|oxaliplatin|
47983623|NCT00262808|PROCEDURE|adjuvant therapy|
48136872|NCT01560494|OTHER|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
48136873|NCT02501694|OTHER|Auscultation|Electronic stethoscope
47983624|NCT00262808|PROCEDURE|conventional surgery|
47983625|NCT00262808|PROCEDURE|neoadjuvant therapy|
47983626|NCT05163353|DEVICE|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
47983627|NCT03758144|DRUG|Rifaximin 200 MG|patients with type 2 diabetes and gut dysbiosis will be given rifaximin
47983628|NCT01942291|DRUG|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
47983629|NCT00827424|BEHAVIORAL|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
47983630|NCT03151460|DRUG|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
47983631|NCT03202797|OTHER|audiometric tests|tone and speech audiometry
48136874|NCT02254759|DRUG|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
48347001|NCT03642275|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
48347002|NCT01816373|DEVICE|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
48347003|NCT00848289|BEHAVIORAL|Interviews|Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
48347004|NCT00741260|DRUG|Neratinib|Neratinib orally once daily continually
48347005|NCT00741260|DRUG|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
48347006|NCT03640520|OTHER|FACETS: Pediatric Resuscitation|Family-centered \& Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
48347007|NCT03640520|OTHER|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
48347008|NCT05278936|OTHER|The cataract surgery and the anterior vitrectomy|Surgical
47983632|NCT03202797|OTHER|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
47983633|NCT03202797|OTHER|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
47983634|NCT02622516|OTHER|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
47983635|NCT02622516|OTHER|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
47983636|NCT00427466|DRUG|Pemetrexed|
48136875|NCT02254759|DRUG|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
48136876|NCT02254759|DRUG|RO5186582|RO5186582 120 mg film-coated release tablet.
48136877|NCT05842265|OTHER|Self acupressure|patients will do self acupressure
48136878|NCT01012063|DRUG|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
48347009|NCT03850210|DEVICE|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
48347010|NCT03850210|DEVICE|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
48501609|NCT03009630|PROCEDURE|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
47983637|NCT04432662|DRUG|Darbepoetin Alfa|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
47983638|NCT03886012|DEVICE|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
48136879|NCT01012063|DRUG|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
48136880|NCT04433780|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
48136881|NCT02502526|DEVICE|Centurion® Vision System, 45° Balanced Tip|
48136882|NCT02502526|DEVICE|Centurion® Vision System, 45° MFK Tip|
48136883|NCT02502526|DEVICE|lnfiniti® Vision System, 45° MFK Tip|
48136884|NCT02502526|DEVICE|INTREPID® Ultra infusion sleeve|
48136885|NCT02502526|DEVICE|Ultra infusion sleeve|
48136886|NCT06341959|PROCEDURE|Oral screening|The participants in the intervention group will receive an oral examination. Subsequently, information about any identified problem will be given. Lastly, participants will receive a referral letter for their dentist and a report for the general practitioner. If the participants don't have a regular dentist, they will also be given a list with contact information of dentists in the area.
48136887|NCT04196309|DRUG|low molecular weight heparin|LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
48136888|NCT04114019|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
48347011|NCT03986567|BEHAVIORAL|gamification for partner notification among youngsters|"Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification"
48347012|NCT03190967|DRUG|T-DM1|T-DM1 3.6 mg/kg intravenous (IV) every 21 days
48658611|NCT06398197|BEHAVIORAL|Nourish Intervention then No Intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 8 weeks, participants crossover into the No Intervention group.
48347013|NCT03190967|DRUG|TMZ|Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
47983639|NCT03886012|DEVICE|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
47983640|NCT01671189|OTHER|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
47983641|NCT05759923|DRUG|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
47983642|NCT05482763|DRUG|Terbinafine Topical Gel|Topical application of terbinafine
47983643|NCT05482763|DRUG|Itraconazole 200 mg|systemic itraconazole pulse therapy
47983644|NCT05482763|DRUG|Terbinafine 250 mg|systemic terbinafine
47983645|NCT05482763|DRUG|Ciclopirox Topical Gel|Topical application of ciclopirox
47983646|NCT05482763|DRUG|Amorolfine 50 MG/ML|Topical application of amorolfine
47983647|NCT03643094|DIETARY_SUPPLEMENT|Golden Black Seed|1 capsule per day for 8 weeks.
47983648|NCT00926276|PROCEDURE|Fundoplication|Fundoplication
47983649|NCT00135720|DRUG|Enbrel (Etanercept)|
48136889|NCT05645068|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography
48136890|NCT05645068|OTHER|multidisciplinary care program|multidisciplinary care program including sports activity
48136891|NCT00127582|PROCEDURE|Electrophysiological study|
48136892|NCT00127582|DEVICE|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
48136893|NCT02098837|DRUG|Dolutegravir|Dolutegravir 50mg once daily
48136894|NCT02568215|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
48136895|NCT02568215|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
48136896|NCT04165772|DRUG|TSR-042 or Dostarlimab|Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
48136897|NCT04165772|DRUG|capecitabine or 5-FU|Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
48136898|NCT04165772|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
48136899|NCT03336892|BEHAVIORAL|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
48347014|NCT05723874|DRUG|BI 425809|BI 425809
48347015|NCT05723874|DRUG|bosentan|bosentan
48347016|NCT04847141|BIOLOGICAL|C19-IG 20%|Anti-COVID-19 Immune Globulin (Human) 20%
48347017|NCT04847141|DRUG|0.9% Sodium chloride|C19-IG 20% matching placebo
48347018|NCT03972605|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
48136900|NCT06106100|PROCEDURE|Antireflux mucosal ablation|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
48136901|NCT06106100|PROCEDURE|Sham procedure|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
48347019|NCT05104788|DRUG|Icotinib|Oral
48347020|NCT05104788|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
48347021|NCT05104788|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
48347022|NCT05104788|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
48347023|NCT00314041|BIOLOGICAL|Meningococcal C|
48347024|NCT00314041|BIOLOGICAL|DTP/Hib|
48347025|NCT00197340|DRUG|Epidural ropivacaine|
48347026|NCT01510028|BIOLOGICAL|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
48347027|NCT02733146|OTHER|cardiac arrest|
48347028|NCT02625467|PROCEDURE|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
48347029|NCT02625467|PROCEDURE|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
48347030|NCT02625467|DRUG|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
48347031|NCT03557736|BEHAVIORAL|Training mode|type of exercise training completed for 12 weeks
48347032|NCT04453605|OTHER|standard treatments|patients were treated according to the good clinical practice recommended by the international guidelines, and followed a six-month or an yearly calendar of follow-up visits
48347033|NCT03111589|BIOLOGICAL|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
48136902|NCT00158483|DRUG|Acyclovir (ACV)|
48347034|NCT03111589|DIAGNOSTIC_TEST|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
48347035|NCT05049018|OTHER|Traditional Physical Therapy Program|"This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities."
48347036|NCT05049018|DEVICE|ArmeoSpring Virtual Reality Device (Upper Extremity Training Device with Virtual Reality Technology)|ArmeoSpring virtual Reality Equipment is a functional upper extremity rehabilitation device that provides specific therapy with augmented feedback. The ArmeoSpring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3 D workspace that allows functional therapy exercises in a virtual reality environment.
48347037|NCT04426292|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
48347038|NCT03515616|DIAGNOSTIC_TEST|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
48347039|NCT04055844|DRUG|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
48347040|NCT04055844|DRUG|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to \>100 x 10\^9/L.
48347041|NCT04055844|DRUG|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
48347042|NCT02047968|BEHAVIORAL|wake therapy|
48347043|NCT04914195|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
48347044|NCT02774291|BIOLOGICAL|Aldesleukin|Given IV
48347045|NCT02774291|BIOLOGICAL|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
48347046|NCT02774291|DRUG|Cyclophosphamide|Given IV
48347047|NCT02774291|BIOLOGICAL|Filgrastim|Given SC
48347048|NCT02774291|DRUG|Fludarabine Phosphate|Given IVPB
48347049|NCT02774291|OTHER|Laboratory Biomarker Analysis|Correlative studies
48347050|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
47983650|NCT01929850|PROCEDURE|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
48136903|NCT02590094|DRUG|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
48136904|NCT01561300|OTHER|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
48136905|NCT01561300|OTHER|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
48136906|NCT03879538|DRUG|Nitrous Oxide|A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
48136907|NCT03879538|DRUG|Oxygen|A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
48347051|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
48347052|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
48347053|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
48347054|NCT04144179|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
47983651|NCT01929850|BEHAVIORAL|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
47983652|NCT05544331|BEHAVIORAL|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
47983653|NCT05544331|BEHAVIORAL|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
48136908|NCT03636854|OTHER|Concentric exercises|Resistance concentric straight leg raise and knee extension will be done.
48136909|NCT03636854|OTHER|Eccentric exercises|Resistance eccentric straight leg raise and knee extension will be done.
48347055|NCT02776306|OTHER|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
48347056|NCT01952613|DEVICE|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
48347057|NCT00351390|OTHER|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
48136910|NCT02797132|DRUG|LUM/IVA|
48136911|NCT01155206|DRUG|glucagon|glucagon 3ng/kg/min
48136912|NCT04276506|OTHER|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
48136913|NCT04276506|OTHER|information group|A visual information booklet which is prepared by the researchers will be used
48347058|NCT00351390|OTHER|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP \<1000 pg/mL
48347059|NCT06278155|OTHER|Social relation training with social robot|"The protocol is divided in two sections: basic and advanced social relations.~The basic social relationssection consists of 4 stages:~Stage 1 focuses on spontaneous eye contact between the child and the robot Strage 2 introduces the goal of spontaneously looking at a peer Stage 3 focuses on respecting the turn between children Stage 4 aims to encourage peer cooperation Nao social robot helps children to develop specific social skills.~The advanced social relation section consists of 5 stages:~Stage 1: The goal is to initiate physical interaction with a peer during a game Stage 2 is focused on mand (verbal requests) directed to peers Stage 3: The goal is to respond spontaneously to questions or statements from peers In the Stage 4 the child should to play with peers for at least 5 minutes Stage 5: the goal is to conduct at least 4 verbal exchanges on a given topic with peers At each stage, Nao provides verbal prompts to guide the child toward the appropriate response"
48136914|NCT04237909|BIOLOGICAL|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
48136915|NCT05017454|DRUG|the optimized sodium valproate-loaded nanospanlastic dispersion|participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
48136916|NCT05017454|DRUG|mometasone furoate lotion|participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
48136917|NCT05185167|DRUG|Anesthetics, General Desflurane Maintenance|Comparison of dna damage of desflurane maintenance with propofol maintenance according to comet analysis
48347060|NCT06278155|OTHER|Traditional social relations training|Traditional social relations training is the same as the experimental one, however in this context the entire protocol is conducted without the aid of social robot NAO.
48347062|NCT02335034|BEHAVIORAL|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
48347063|NCT02335034|BEHAVIORAL|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
48347064|NCT00486889|BIOLOGICAL|alglucosidase alfa|Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion
48347065|NCT02037204|OTHER|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
48347066|NCT03418220|OTHER|blood and aqueous humor sampling|The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
48347067|NCT00944580|BIOLOGICAL|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
47983654|NCT03045328|DRUG|Ibrutinib|Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
47983655|NCT03045328|DRUG|Venetoclax|Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
47983656|NCT05188950|DEVICE|depression screening test App|The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
47983657|NCT05816551|OTHER|Controlled hyperthermia|Individuals will be exposed to a control trial (no hyperthermia) and a controlled hyperthermia trial.
47983658|NCT03807063|BIOLOGICAL|Rivogenlecleucel|Given IV
47983659|NCT03807063|DRUG|Rimiducid|Given IV
47983660|NCT01347450|DIETARY_SUPPLEMENT|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
47983661|NCT01347450|DIETARY_SUPPLEMENT|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
47983662|NCT03447756|DRUG|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
47983663|NCT03447756|DRUG|Placebo oral capsule|placebo to match
47983664|NCT00353561|DRUG|Boric|Gelatin capsules filled with 600 mg of boric acid
47983665|NCT00353561|DRUG|Fluconazole|150 mg oral fluconazole gives once in 14 days
47983666|NCT02496273|BIOLOGICAL|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
48136918|NCT05185167|DRUG|Anesthetics, General Propofol Maintenance|Comparison of dna damage of propofol maintenance with desflurane maintenance according to comet analysis
48347068|NCT02665468|BEHAVIORAL|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
48501610|NCT03009630|DEVICE|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
48501611|NCT03614897|BEHAVIORAL|Education|Education on guidelines for care of individuals at risk of falling
48658612|NCT06398197|BEHAVIORAL|No Intervention then Nourish Intervention|Participants will receive no intervention for 8 weeks. After 8 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
48658613|NCT06436781|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
48658614|NCT06436781|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
48658615|NCT01353729|DRUG|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
48658616|NCT01353729|DRUG|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
47983667|NCT02415127|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
47983668|NCT02415127|DRUG|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
48002515|NCT01667640|RADIATION|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
48136919|NCT03018067|DRUG|RDX227675|
48136920|NCT03018067|DRUG|Placebo|
48136921|NCT02195856|DIETARY_SUPPLEMENT|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
48136922|NCT02195856|DIETARY_SUPPLEMENT|Placebo|
48136923|NCT06457516|COMBINATION_PRODUCT|Mirror Therapy|A mirror is used to create a reflective illusion of an affected limb in order to trick the brain into thinking movement has occurred without pain, or to create positive visual feedback of a limb movement. It involves placing the affected limb behind a mirror.
48136924|NCT06457516|OTHER|Music Therapy|Music therapy, an allied health profession, the clinical and evidence-based use of music interventions to accomplish individualized goals
48136925|NCT03877354|OTHER|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
48136926|NCT03877354|OTHER|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
48136927|NCT03408028|OTHER|Medical File consultation|Medical File consultation
48136928|NCT04256148|BIOLOGICAL|ALXN1830|Administered via intravenous (IV) infusion
48136929|NCT04256148|OTHER|Placebo|Matching placebo (sterile liquid diluent) administered via IV infusion
48136930|NCT05292521|OTHER|Best Practice|Receive usual care
48136931|NCT05292521|OTHER|Informational Intervention|Receive QOL fact sheet
48658617|NCT01353729|DRUG|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
48136932|NCT05292521|OTHER|Questionnaire Administration|Ancillary studies
48658618|NCT01353729|DRUG|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
48658619|NCT05561374|DRUG|Low-dose OKN-007, BID|Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
48658620|NCT05561374|DRUG|Low-dose OKN-007, TID|Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
48658621|NCT05561374|DRUG|Mid-dose OKN-007, TID|Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
48658622|NCT05561374|DRUG|High-dose OKN-007, TID|Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
48347069|NCT02665468|BEHAVIORAL|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
48136933|NCT00284752|DRUG|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
48347070|NCT00698776|DRUG|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
48347071|NCT00698776|BIOLOGICAL|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
48347072|NCT02388672|DIETARY_SUPPLEMENT|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
48347073|NCT02388672|DIETARY_SUPPLEMENT|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
48347074|NCT02388672|DIETARY_SUPPLEMENT|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
48347075|NCT02388672|DIETARY_SUPPLEMENT|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
48347076|NCT01261494|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
48136934|NCT01782105|BEHAVIORAL|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
48136935|NCT01782105|BEHAVIORAL|Control group|Evaluation of nutritional and physcial activity habits
48347077|NCT01261494|DRUG|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
48002516|NCT02040610|RADIATION|Hypofractionated Proton Therapy|
48002517|NCT05203471|OTHER|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
48136936|NCT00004361|DRUG|calcium gluconate|
48136937|NCT00004361|DRUG|sodium citrate|
48136938|NCT01263496|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
48136939|NCT01263496|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
48347078|NCT05046236|OTHER|Interactive POWER rehabilitation|Interactive POWER rehabilitation training for twice a week, total 12 weeks, that consisted of 6 types of equipment for strength training.
48347079|NCT05046236|OTHER|Conventical physical training|Conventional physical training models in current clinical use for twice a week, total 12 weeks, that consisted of strength training, balance training, stretching, gait training, and etc.
48347080|NCT02785666|DRUG|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
48347081|NCT02785666|BEHAVIORAL|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
48347082|NCT03454724|DEVICE|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
48347083|NCT03454724|DEVICE|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
48347084|NCT06432491|BEHAVIORAL|Drinking cold water|Volunteers in the intervention group will be asked to drink up 500 ml 4℃ water within 10 minutes four times per day throughout the study.
48347085|NCT05617794|DEVICE|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
48347086|NCT05617794|DEVICE|Control Spectacle Lens|Control Spectacles
48347087|NCT06262672|OTHER|Evaluation form|This form is a form of demographic information, questions that question the habits of COVİD-19 era, and evaluation scales.
48002518|NCT03044197|DEVICE|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
48002519|NCT03044197|DEVICE|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
48347088|NCT05859867|OTHER|Promotion of Healthy Nutrition and Physical Activity|Through scheduled and specific activities, enrolled subjects receive information for the promotion of the Mediterranean diet and Mediterranean lifestyle habits, according to the pyramid of the Mediterranean diet. In addition, subjects receive general recommendations about the promotion of regular recreational motor activity, the pyramid of physical activity for pediatric age, and free games appropriate to age. These activities are conducted by professionals in the food (nutritionists) and sports sectors and are aimed in the preparation of simple recipes repeatable at home, and in motor play activities to encourage physical activity. Information regarding clinical, and socio-demographic parameters and family habits will be collected through validated questionnaires.
48136940|NCT01263496|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
48136941|NCT01263496|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
48136942|NCT01263496|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
48347089|NCT05469880|OTHER|moisturizing cream and 5% benzoyl peroxide gel|"Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months"
48347090|NCT05469880|OTHER|anti-acne face cream and 5% benzoyl peroxide gel|"Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months"
47983669|NCT03965910|OTHER|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
48002520|NCT00581776|DRUG|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
48136943|NCT02298842|DEVICE|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
48136944|NCT02298842|DEVICE|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
48136945|NCT01389921|OTHER|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
48136946|NCT01847534|OTHER|Supplemental PN|
48347091|NCT00636155|DRUG|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
48136947|NCT01847534|OTHER|Standard Care|
48136948|NCT00964236|DRUG|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
48136949|NCT00790699|DEVICE|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
48136950|NCT00790699|OTHER|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
48347092|NCT00636155|DRUG|Rituximab|375 mg/m2 on day 2
48347093|NCT00636155|DRUG|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
48347094|NCT00636155|DRUG|Fludarabine|25 mg/m2 on days 2, 3, and 4
48658623|NCT04300894|DEVICE|Mamma Mia|"Users of the Mamma Mia program progress through the intervention in a sequence of modules.~Every day that a module should be completed, you will receive a notification with a reminder to access the program. By clicking on the reminder, you can access that particular day's session content. Modules involve a variety of information and activities; for example, there are guided mindfulness practices, information on breastfeeding, instructional videos on how to interpret your baby's cries, and discussions on how to have effective discussions with your partner or healthcare provider about your needs."
48658624|NCT04300894|OTHER|Mamma Mia Plus|Participants will use the Mamma Mia program, plus receive contact (phone calls or emails or texts) from study staff every few months.
48347095|NCT01436357|BIOLOGICAL|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.
48347096|NCT01436357|BIOLOGICAL|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.
48347097|NCT01436357|OTHER|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
48658625|NCT00476645|DRUG|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
48658626|NCT00750399|DRUG|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
48658627|NCT00750399|DRUG|ranibizumab|intravitreal ranibizumab 0.5 mg
47914568|NCT02267798|OTHER|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
48347098|NCT01737138|PROCEDURE|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
48136951|NCT06387810|DRUG|irinotecan liposome II combined with 5-FU/LV and oxaliplatin|"irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.~Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs."
48347099|NCT01737138|DRUG|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
48347100|NCT04246424|BEHAVIORAL|Fibit + Coaching|This intervention is a combination of the coaching and fitbit interventions
48136952|NCT06270524|PROCEDURE|Blood sampling|Blood sampling will be taken for further analysis
48136953|NCT01736475|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
48347101|NCT04246424|BEHAVIORAL|Coaching|"Coaching Participants who are assigned coaching group will receive telephone coaching. Coaches follow a guide developed by Kelly Glazer Baron, Jennifer Duffecy, Kathryn Reid, and Lauren Caccamo. The first session is an approximately 30 minute engagement session, with the purpose of getting to know the participant to increase likelihood for participation. The end goal is to have participants express Desire, Ability, Reason, Need, Can (DARN-C) to make changes in sleep). The remainder calls (week 2-6) are follow-up calls lasting about 5 minutes. The goal of these calls is to keep participants motivated and address any issues with the Fitbit hard or software.~Participants will also receive weekly email lessons to their personal email address for 1-6 weeks."
48136954|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
48136955|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
48347102|NCT04246424|BEHAVIORAL|Fitbit|Fitbit Participants in the fitbit group will receive a Fitbit Charge 3 black, and asked to wear it for 1-6 weeks. Participants will monitor their sleep through the sleep section in the Fitbit app on the smartphone. Participants will be provided login information so that researchers can access this data and asked to keep Bluetooth on. After week 6, participants can choose to continue to wear the device for the duration of the study (12 weeks). Though wear at weeks 7-12 is not required, researchers will still use any data that was collected from the fitbit during that time. At the completion of their participation, researchers retain the login information and the device is switched to a personal login of the participants choice.
48347103|NCT02465489|DRUG|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
48347104|NCT02465489|DRUG|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
48347105|NCT01876472|BEHAVIORAL|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
48347106|NCT00050336|DRUG|Lonafarnib (SARASAR)|
48347107|NCT00000768|DRUG|Glutamic acid hydrochloride|
48002521|NCT00581776|DRUG|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
48136956|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|On-demand treatment
48347108|NCT00000768|DRUG|Ganciclovir|
48347109|NCT00083304|DRUG|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
48347110|NCT00083304|RADIATION|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
48002522|NCT00581776|DRUG|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
48136957|NCT02179359|DRUG|Reduced Toxicity Ablative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Stem Cell Infusion Day 0"
48136958|NCT02179359|DRUG|Reduced Intensity Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Fludarabine~* Total Body Irradiation (TBI)~* Stem Cell Infusion Day 0"
48136959|NCT02179359|DRUG|Myeloablative Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Busulfan~* Stem Cell Infusion Day 0"
48136960|NCT03071354|DIETARY_SUPPLEMENT|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
47983670|NCT05342259|PROCEDURE|Caudal nerve block /neuroaxial|"Technique of the caudal block The patient was placed in lateral decubitus position for blind caudal epidural block. A line was drawn to connect the bilateral posterior superior iliac crests and used as one side of an equilateral triangle; then the location of the sacral hiatus was approximated by palpating the sacral cornua as 2 bony prominences, the sacral hiatus was identified as a dimple in between. A needle was inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone was contacted.~A subjective feeling of loss of resistance suggests piercing the sacral ligament.The whoosh test, performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of air, Palpating for subcutaneous bulging on rapid injection of 5 mL air or saline had a positive predictive value of 83% and a negative predictive value of 44%."
47983671|NCT05342259|PROCEDURE|Dorsal penile nerve block|"Technique of Dorsal penile nerve block:~Under aseptic technique and under ultrasound guidance. A 'hockey-stick' probe was used, covered by transparent sterile dressing. The probe was placed vertically over the pubic symphysis and the base of the penile shaft. With adjustment of the probe, a sagittal view of the penile shaft was produced. Scarpa's fascia was seen as a hyperechoic line superficial to the penile shaft. Under real-time guidance, the needle was inserted and advanced until its tip laid deep to Scarpa's fascia (i.e., within the subpubic space), where local anesthetic was deposited. The local anesthetic solution injected was 0.5% bupivacaine in a recommended volume. (2 ml up to 3 years and an additional 1 ml for each3 years up to maximum 6 ml)."
47983672|NCT05342259|PROCEDURE|Combined caudal and dorsal penile nerve block|Combined techniques of caudal and dorsal penile nerve block
47983673|NCT00705081|DRUG|ezetimibe|10 mg once daily
47983674|NCT00705081|DRUG|statin|
47983675|NCT02295150|DRUG|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
47983676|NCT00330941|DRUG|lidocaine|
47983677|NCT06495164|DRUG|Palbociclib|CDK4/6 inhibitor
47983678|NCT06495164|DRUG|Aromatase inhibitor|Aromatase inhibitor
47983679|NCT06495164|DRUG|Ribociclib|CDK4/6 inhibitor
47983680|NCT06495164|DRUG|Abemaciclib|CDK4/6 inhibitor
47983681|NCT01550640|DRUG|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
47983682|NCT03970954|DRUG|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
47983683|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
47983684|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
47983685|NCT02417974|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
47983686|NCT02614950|OTHER|Treatment interruption|
47983687|NCT06409884|DEVICE|T-cell activation test using intracellular markers|A blood sample will be taken which is needed for the T-cell activation test (TAT). The TAT will than be performed by trained laboratory personnel.
47983688|NCT05802667|DIAGNOSTIC_TEST|Tryptase|Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
47983689|NCT06257810|DIAGNOSTIC_TEST|VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG|"For patients managed in an intervention site, a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well.~The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria."
48658628|NCT06109324|OTHER|Robotic Rehabilitation of the upper limb|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
48658629|NCT06109324|OTHER|Conventional Rehabilitation of the upper limb|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
47983690|NCT06257810|OTHER|Standard of care practices|"For patients managed in a control site, the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed."
48658630|NCT06564129|DEVICE|electroencephalography|Fifty-nine EEG electrodes conforming to international standard points were placed using a saline electrode EEG cap (Gelfree, Prysmian, China), and an accompanying portable multimodal EEG acquisition system (Neurohub, Prysmian, China) was used. EEG data were collected using collect software (Brycon, China).
48658631|NCT04055012|DRUG|Metformin|500mg tabs of Metformin Extended Release
48658632|NCT04055012|DRUG|Placebo|Placebo Tabs
48658633|NCT05995626|DRUG|Hyaluronidase|hyaluronidase injection is used during fluid administration under the skin to help achieve hydration, to increase the dispersion and absorption of other injected drugs, or during some types of urography (imaging of the urinary tract) to help improve resorption of drugs used during the procedure.
48002523|NCT00581776|DRUG|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
48347111|NCT00083304|OTHER|Supplemental Oxygen|"4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
48347112|NCT05578313|DRUG|Medical Cannabis|Patients will be observed throughout their treatment with medical cannabis, prescribed to them by for clinically treating their disease (treatment is not an intervention of the study).
48347113|NCT04510155|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 1 day
48347114|NCT00852098|PROCEDURE|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
48347115|NCT00852098|PROCEDURE|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
48347116|NCT00257322|DRUG|GM-CSF|250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
48347117|NCT02410590|DRUG|Rocuronium|
48347118|NCT02410590|DRUG|Sugammadex|
48347119|NCT02410590|DRUG|Cisatracurium|
48347120|NCT02410590|DRUG|Neostigmine/Atropine|
48347121|NCT02410590|DRUG|Succinylcholine|
48347122|NCT06283134|BIOLOGICAL|BioTTT001 hepatic artery infusion|"BioTTT001 monotherapy period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, administered every 2 weeks, for a total of two doses after enrollment.~BioTTT001 in combination with toripalimab and regorafenib period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, D2 and D16, 4 weeks per cycle， and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase."
48347123|NCT06283134|DRUG|toripalimab|BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.
48347124|NCT06283134|DRUG|regorafenib|BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
47983691|NCT04101981|PROCEDURE|oocytes retrieval|The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
47983692|NCT05241067|DRUG|Normal Saline|Placebo (Dose: equal volume saline) + Standard of care
48347125|NCT00546936|DRUG|ranibizumab|0.5mg ranibizumab
47983693|NCT05241067|DRUG|Centhaquine|Centhaquine (Dose: 0.01 mg/kg) + Standard of care
48347126|NCT00546936|DRUG|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
48347127|NCT00757640|PROCEDURE|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
48347128|NCT01456728|DIETARY_SUPPLEMENT|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
48347129|NCT01456728|DIETARY_SUPPLEMENT|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
48347130|NCT02525952|PROCEDURE|Hepatectomy|Surgical removal of all lesions
48347131|NCT02525952|PROCEDURE|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
47983694|NCT04573816|OTHER|Use of an internet plateform|Use of an internet platform for remote monitoring of patients.
47983695|NCT03326258|DRUG|Glembatumumab Vedotin|Given IV
47983696|NCT03326258|BIOLOGICAL|Ipilimumab|Given IV
47983697|NCT03326258|OTHER|Laboratory Biomarker Analysis|Correlative studies
47983698|NCT03326258|BIOLOGICAL|Nivolumab|Given IV
48347132|NCT01560104|DRUG|Veliparib|
48347133|NCT01560104|DRUG|Carboplatin|
48347134|NCT01560104|DRUG|paclitaxel|
47983699|NCT03326258|OTHER|Pharmacological Study|Correlative studies
47983700|NCT00098085|BIOLOGICAL|HSPPC-96|
47983701|NCT02632955|DRUG|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
48347135|NCT01560104|DRUG|placebo|
48347136|NCT00763607|GENETIC|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
48347137|NCT06279975|DIAGNOSTIC_TEST|non-invasive device-supported, automated pupillometry|non-invasive device-supported, automated pupillometry with a precise quantitative measurement of the pupils within the range of micrometers
48347138|NCT06124352|DIAGNOSTIC_TEST|Gross Motor Function Measurement - 66 (GMFM- 66)|GMFM-66 was performed for participants established on self-independent motion, with importance on allocations, and motion. The emphasis is to detect the grade that greatest reveals the current skills and disabilities of the child regarding motor functions. The new Gross Motor Ability Estimator (GMAE) scoring method for test-retest reliability data showed a high level of stability of the GMFM-66 over time (ICC=0.9932) that did not differ since the original GMFM 88-item test-retest reliability
48658634|NCT05995626|DEVICE|co2 laser|CO2 lasers use an aiming beam to see where the treatment beam will impact the focus tissue. The focus tissue will then be cleanly incised. They have greater precision for laser surgery and have more flexibility in tip sizes and protocols.
48347139|NCT06124352|DIAGNOSTIC_TEST|Bruininks- Oseretsky Motor Proficiency|The BOT-2 are scale used to evaluate fine and gross motion skill development. It's used to classify children with movement control limitation. The test is appropriate for those aged 4 to 21 years. The interrater reliability ranging from 0.92 to 0.99 and construct validity. r = 0.78 (0.56 - 0.86) (test grades / chronological age)
48347140|NCT06124352|DIAGNOSTIC_TEST|the Peabody Developmental Motor Scale - Second Edition (PDMS-2|The PDMS-2 is a consistent test that evaluates a child's movement skills. It is norm-referenced and consists of three composites: Fine Motor (FM), Gross Motor (GM), and Total movement composites (TM). GM composite incorporates 151 points from four sub-tests: reflexes, stationary, locomotion, and object manipulation. A 3-point scale scored for each item, with 2 being the highest score. Definite criterion for score of 2 is given when the child achieves the item, 1 is given when the behavior is emerging but not fully met, and 0 is given when the child cannot achieve the point. The highest raw scores of the sub-tests range from 16 to 198. The test-retest reliability of PDMS-2 was found to be r = 0.85 \[24, 25\].
48347141|NCT03846089|PROCEDURE|Graft reperfusion|antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
48347142|NCT01255189|DEVICE|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
48347143|NCT01255189|DEVICE|invos 5100|near infrared spectroscopy: invos 5100
48347144|NCT03200795|OTHER|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula (\[Heart rate reserve x training percentage\] + resting heart rate)(Nuhu \& Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu \& Maharaj, 2017)."
48347145|NCT03200795|OTHER|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
48347146|NCT03527303|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
47983702|NCT02632955|PROCEDURE|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
47983703|NCT01988805|OTHER|Blood Draw|
48136961|NCT03071354|DIETARY_SUPPLEMENT|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
48136962|NCT01616472|DRUG|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
48136963|NCT05419466|DIETARY_SUPPLEMENT|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm|dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
48136964|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit # 1
48136965|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit #1
47983704|NCT06316141|OTHER|Aqua Jogging|This group performed aqua jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
48136966|NCT00077935|DRUG|Civamide|Cream 0.075%, TID for 52 weeks
48136967|NCT04210258|DEVICE|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
48136968|NCT04210258|DEVICE|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
48347147|NCT03377569|OTHER|Sleep, PD and DBS|Sleep, PD and DBS
48347148|NCT03797157|DIETARY_SUPPLEMENT|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
48347149|NCT03797157|DIETARY_SUPPLEMENT|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
48347150|NCT02216292|OTHER|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
48347151|NCT02216292|OTHER|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
48347152|NCT01715090|DEVICE|Web-based insulin titration|
48136969|NCT03559205|OTHER|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~* Pre-clinic preparation.~* Clinic dashboard.~* Summary action plan.~* Personal goal setting.~* Follow-up and monitoring."
48136970|NCT00372775|DRUG|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
48136971|NCT05635357|DRUG|Anastrozole|Anastrozole claim is used as the exposure group.
48136972|NCT05635357|DRUG|Exemestane/Letrozole|Exemestane/Letrozole claim is used as the reference group.
48136973|NCT06038942|BEHAVIORAL|Formal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The formal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught formal mindfulness practices (e.g., sitting meditation, body scan, thought meditation, loving-kindness meditation) during the group sessions and will be asked to commit to practicing the strategies independently throughout the project period."
48136974|NCT06038942|BEHAVIORAL|Informal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The informal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught how to integrate informal mindfulness into their daily routine and will be guided through a series of demonstrations within the group sessions. Participants will be asked to commit to practicing informal mindfulness independently throughout the project period."
47983705|NCT06316141|OTHER|Land based Jogging|This group performs land jogging for 60 minutes consisting of 10 minutes warming up, 40 minutes aqua jogging or land jogging and 10 minutes cooling down.
48136975|NCT02159352|DRUG|Daclatasvir|
48136976|NCT02159352|DRUG|Darunavir|
48136977|NCT02159352|DRUG|Ritonavir|
48347153|NCT02100410|DEVICE|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
48136978|NCT02159352|DRUG|Lopinavir/Ritonavir|
47983706|NCT01752907|OTHER|General Education DVD|A general chemotherapy side effects education DVD
47983707|NCT01752907|OTHER|Bone Pain Education DVD|
47983708|NCT05450783|OTHER|Biocollection|serum
47983709|NCT04541056|BEHAVIORAL|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
48002524|NCT00581776|DRUG|Vincristine|1 mg administered by IV on day 3 of each cycle.
48136979|NCT04769141|COMBINATION_PRODUCT|CURATE.AI|"CURATE.AI is one example of an artificial intelligence guided dosing decision tool. It is customized to each individual and can be applicable across many different conditions, as it is disease agnostic.~This platform has already demonstrated initial success in cancer and transplant populations but yet to be applied to chronic disease patients."
48136980|NCT06027970|DRUG|Terlipressin|After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
48136981|NCT06027970|OTHER|0.9% normal saline (NS)|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
48136982|NCT00649272|DRUG|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
48136983|NCT00649272|DRUG|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
48347154|NCT02100410|DEVICE|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
48347155|NCT02100410|DEVICE|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
48002525|NCT00581776|DRUG|Dexamethasone|40 mg orally on days 1-4 of each cycle.
48347156|NCT02100410|DEVICE|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
48347157|NCT02100410|DEVICE|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
48347158|NCT02100410|DEVICE|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
48347159|NCT00948428|DRUG|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
48347160|NCT00948428|DRUG|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
48347161|NCT00948428|DRUG|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
48347162|NCT04197206|OTHER|costotransverse block|patient controlled analgesia devices with tramadol
48658635|NCT05852431|DRUG|Pegozafermin|Subcutaneous injection
48658636|NCT05852431|DRUG|Placebo|Subcutaneous injection
48136984|NCT04003259|BEHAVIORAL|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
48136985|NCT00661336|DRUG|buthionine sulfoximine|
48136986|NCT00661336|DRUG|melphalan|
48136987|NCT00661336|GENETIC|microarray analysis|
48347163|NCT03327246|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
48136988|NCT00661336|OTHER|high performance liquid chromatography|
48136989|NCT00661336|OTHER|laboratory biomarker analysis|
48136990|NCT00661336|OTHER|pharmacological study|
48347164|NCT03834480|OTHER|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
48347165|NCT00031135|DRUG|Choline Chloride|
48347166|NCT05896410|DEVICE|splint (orthosis)|3D printed splint (orthosis) help prevent the joint from shifting during pinch activities. This reduces improper joint loading and helps reduce pain and the progression of degenerative change in patients with OA.
48347167|NCT00289393|BEHAVIORAL|Perceived outcome by both patient and physician|
48347168|NCT02422563|PROCEDURE|hysterectomy|radical hysterectomy
48347169|NCT02422563|RADIATION|Radiation|
48347170|NCT02422563|DRUG|Cisplatin|
48347171|NCT02422563|DRUG|Paclitaxel|
48347172|NCT02422563|DRUG|Carboplatin|
47983710|NCT04541056|BEHAVIORAL|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
47983711|NCT01573572|DRUG|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
47983712|NCT02385045|DEVICE|i-scan|i-scan function is located on the head of the Pentax endoscopes
48136991|NCT00661336|PROCEDURE|biopsy|
48347173|NCT02422563|DRUG|Ifosfamide|
47983713|NCT02385045|DEVICE|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
47983714|NCT06078761|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL) Program|Evidence-based lifestyle medicine program for cancer survivors
48136992|NCT02301806|OTHER|dieting|
48136993|NCT02301806|DRUG|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
48136994|NCT02301806|DRUG|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
48136995|NCT02172560|DRUG|Tiotropium|
48136996|NCT04926519|OTHER|Type of periodontal treatment|Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
48136997|NCT06415994|DRUG|Buprenorphine or Methadone Treatment|Pregnant mothers must be taking Buprenorphine or Methadone
48347174|NCT01840436|DEVICE|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
48347175|NCT01840436|DEVICE|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
48347176|NCT06022224|BIOLOGICAL|hAd5-S-Fusion+N-ETSD|Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10\^11 viral particles/mL.
48347177|NCT06022224|BIOLOGICAL|Placebo (0.9% (w/v) saline)|Clear and colorless liquid.
48347178|NCT04072536|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
48658637|NCT04349969|DRUG|AK117|All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
48658638|NCT04349969|DRUG|AK117+AK104|All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
48136998|NCT06415994|DIAGNOSTIC_TEST|Fetal and Placental MRI|"Two MRIs :~* Second Trimester~* Third Trimester"
48136999|NCT06415994|BEHAVIORAL|Child Developmental Assessment|At 1 year of life child will receive a developmental assessment
48137000|NCT06415994|BEHAVIORAL|Questionnaires|Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development
48658639|NCT03777605|DRUG|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
47983715|NCT03015012|GENETIC|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
47983716|NCT03015012|OTHER|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
47983717|NCT00396591|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
47983718|NCT03352206|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
47983719|NCT03352206|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
47983720|NCT01913912|DRUG|LDX.|"In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
47983721|NCT01913912|DRUG|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
47983722|NCT01913912|DEVICE|computer task (Go/No-Go task)|
47983723|NCT01913912|DEVICE|EEG|event-related potentials (ERP) and heart rate measurements
47983724|NCT01913912|DEVICE|pupil size measurements (by using eye tracking)|
47983725|NCT03415750|DRUG|Everolimus|Conversion from Mycophenolate mofetil to Everolimus
47983726|NCT03415750|DRUG|Mycophenolate mofetil|Patients will remain in Tacrolimus + Mycophenolate mofetil
47983727|NCT03415750|DRUG|Tacrolimus|
47983728|NCT02432404|DRUG|NuvaRing|
48137001|NCT06415994|OTHER|Blood and Placental Samples|"At each MRI visit a blood sample will be collected for substances, DNA, RNA, epigenetics, and placental biomarkers.~At delivery: A sample of placenta will be collected for RNA, DNA, and epigenetic analysis."
48137002|NCT02347332|DRUG|Vinflunine|
47983729|NCT00042172|DRUG|Donepezil|
47983730|NCT00042172|DRUG|Ginkgo Biloba Extract|
47983731|NCT01280916|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
47983732|NCT01138631|DEVICE|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
48137003|NCT02347332|DRUG|Methotrexate|
48137004|NCT03567616|DRUG|Venetoclax|Tablet; oral
48137005|NCT03567616|DRUG|Pomalidomide|Capsule; oral
48137006|NCT03567616|DRUG|Dexamethasone|Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
48658640|NCT04398225|DRUG|Centanafadine|Extended release capsule
48658641|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection (prefilled syringe)|MG-K10 Humanized Monoclonal Antibody Injection
48347179|NCT04072536|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
48347180|NCT03607149|DRUG|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
48347181|NCT00683501|DRUG|DNB-001|four dosages of DNB-001, one placebo dosage
48347182|NCT03252262|OTHER|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
48347183|NCT03692312|DRUG|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
48347184|NCT03692312|DRUG|Placebo|Matching placebo formulation
48347185|NCT00141310|DRUG|Sildenafil citrate|
48347186|NCT02314286|DRUG|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
48347187|NCT02314286|DRUG|Placebo|
48347188|NCT03782844|DEVICE|Simple CPAP+Conventional fixed CPAP|Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.
48347189|NCT03782844|DEVICE|Simple CPAP + Auto CPAP|Patients used simple CPAP and Auto CPAP during overnight polysomnography.
48347190|NCT02506491|OTHER|Pilates exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
48347191|NCT02506491|OTHER|Muscular exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
48347192|NCT02506491|OTHER|Control Group|No exercise
48501612|NCT03895671|DRUG|Ponatinib|"Induction phase (first three cycles)~- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day"
48501613|NCT03895671|DRUG|Azacitidine|"Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;"
48501614|NCT00730223|DRUG|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
48347193|NCT04731688|BEHAVIORAL|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
48002526|NCT04050111|BIOLOGICAL|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
48347194|NCT02327728|PROCEDURE|Botulinum toxin A injection (5 sites: 12.5U)|
48347195|NCT02327728|PROCEDURE|Botulinum toxin A injection (4 sites: 10U)|
48347196|NCT02327728|DRUG|Botulinum toxin A 12.5U|
48347197|NCT02327728|DRUG|Botulinum toxin A 10U|
48347198|NCT02855086|BIOLOGICAL|Cetuximab|Administered intravenously (IV)
48347199|NCT02855086|DRUG|Cetuximab-IRDye 800CW|Administered intravenously (IV)
48347200|NCT02855086|PROCEDURE|Tumor resection|Standard of care treatment
48347201|NCT02738346|DRUG|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
48347202|NCT02738346|DRUG|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
48347203|NCT02738346|DRUG|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
48347204|NCT02738346|DEVICE|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
48347205|NCT00096304|DRUG|docetaxel|
48347206|NCT00096304|DRUG|epirubicin hydrochloride|
48347207|NCT02481791|DRUG|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
48501615|NCT02053935|DRUG|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
48501616|NCT04791514|DRUG|Treprostinil Palmitil|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
48347208|NCT02481791|DRUG|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
48347209|NCT02481791|DRUG|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
48347210|NCT02789072|OTHER|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
48347211|NCT06262204|PROCEDURE|Hallux Valgus Treatment with Shark Screw®|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
48347212|NCT06262204|PROCEDURE|Hallux Valgus Treatment with metal screw|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
48347213|NCT05906914|DRUG|cladribine + homoharringtonine + cytarabine|CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
48347214|NCT02748278|PROCEDURE|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
48347215|NCT02748278|PROCEDURE|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
48347216|NCT03288727|OTHER|interviews with a psychologist|an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
48347217|NCT00236210|BEHAVIORAL|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
48347218|NCT00236210|BEHAVIORAL|VIP program|Risk assessment, lifestyle counselling, exercise program
48347219|NCT00846352|PROCEDURE|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
48347220|NCT05868460|DEVICE|High intensity laser|patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.
48347221|NCT05868460|OTHER|traditional physical therapy exercise program|passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
48347222|NCT05868460|DEVICE|placebo High intensity laser|patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
48347223|NCT01055470|DRUG|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
48501617|NCT02286310|OTHER|Kinetic Chain Exercises|Exercises include kinetic chain segments.
48501618|NCT02286310|OTHER|Traditional Exercises|Stretching, strengthening exercises.
48501619|NCT00185445|DRUG|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
48137007|NCT00255372|DRUG|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
48137008|NCT00255372|DRUG|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
48501620|NCT04181073|DEVICE|Jet Nebuliser|Jet Nebuliser
48501621|NCT04181073|DEVICE|Vibrating Mesh Nebuliser|Aerogen Device
48658642|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection（Penicillin bottle）|MG-K10 humanized monoclonal antibody injection (single injection)
48658643|NCT04614532|DIAGNOSTIC_TEST|cognitive assessment|"global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery"
48137009|NCT01229384|DEVICE|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
48137010|NCT01229384|DEVICE|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
48347224|NCT01055470|DRUG|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
48347225|NCT04889755|BEHAVIORAL|SibACCESS|The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
48347226|NCT04576260|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
48347227|NCT03278925|PROCEDURE|Biopsy|Undergo biopsy
48347228|NCT03278925|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48347229|NCT03278925|PROCEDURE|Computed Tomography|Undergo CT
48347230|NCT03278925|DRUG|Defined Green Tea Catechin Extract|Given PO
48347231|NCT03278925|OTHER|Laboratory Biomarker Analysis|Correlative studies
48347232|NCT03278925|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48347233|NCT03278925|OTHER|Pharmacological Study|Correlative studies
48501622|NCT04638530|OTHER|Education on breaking bad news to family members remotely|Participants will receive a combination of surveys, pre- and post-tests, lectures and didactics to increase their awareness of techniques to communicate difficult topics with patients remotely as well as skill building exercises.
48501623|NCT03779737|BEHAVIORAL|Muscular Resistance training|
48501624|NCT03779737|BEHAVIORAL|Cardiorespiratory training|
48347234|NCT03278925|OTHER|Questionnaire Administration|Ancillary studies
48347235|NCT03278925|PROCEDURE|Ultrasound|Undergo ultrasound
48347236|NCT06377436|BEHAVIORAL|Experimental training|Through The Dividat Senso intelligent platform, subjects will be subjected to locomotion, cognitive and sensory domain-specific exercise programs. The exercises will be of increasing difficulty. Cognitive exercises will in fact be carried out by interacting with the DIVIDAT device consisting of a monitor and a pressure-sensitive platform through weight shifts, multidirectional steps and jumps.
48501625|NCT03779737|BEHAVIORAL|Habitual training|
48501626|NCT00185666|PROCEDURE|Stereotactic radiosurgery|
48501627|NCT00912912|DRUG|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
48501628|NCT03822832|DRUG|BI 655130|Solution for infusion
48501629|NCT03822832|DRUG|Placebo|Solution for infusion
48347237|NCT04383964|DEVICE|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
48501630|NCT06190418|OTHER|Loaded sit to stand strengthening exercise|This Group will be given with the wieghted vest equal to that of 1RM for each child and Sit-to-Stand Strengthening Excerise will be given 3 times per week for 6 weeks
48501631|NCT06190418|OTHER|Unloaded sit to stand strengthening exercise|This Group will be given with the Sit-to-Stand Strengthening Excerise without any external load for 3 times per week for 6 weeks
48501632|NCT02293889|DIETARY_SUPPLEMENT|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (\>50nmol/L) by 3 months.
48501633|NCT02293889|BEHAVIORAL|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
48501634|NCT02293889|OTHER|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
48347238|NCT02502955|PROCEDURE|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
48347239|NCT01160224|DRUG|GW766944|Drug: GW766944 (Active Drug Treatment)
48347240|NCT01160224|OTHER|Placebo|This is placebo to match.
48347241|NCT04835441|DRUG|ALPN-101|Blinded ALPN-101 will be administered
48347242|NCT04835441|DRUG|Placebo|Blinded placebo matching ALPN-101 will be administered.
48347243|NCT01637857|DIETARY_SUPPLEMENT|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
48347244|NCT01637857|DIETARY_SUPPLEMENT|oligoantigenic diet|oligoantigenic diet associated to life style counseling
48347245|NCT03484689|BEHAVIORAL|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
48347246|NCT04722380|PROCEDURE|periodontal regenerative surgery|Procedure/Surgery: open flap debridement Open flap for removal of diseased periodontal tissues and necrotic cementum , using xenogenic bone graft with or without Nigella Sativa oil extract
48501635|NCT04325763|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48501636|NCT04325763|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
48501637|NCT04325763|DRUG|TQB2450(blank)|Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
48501638|NCT04325763|DRUG|Anlotinib(blank)|Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
48501639|NCT01691924|DRUG|PBF-509|
48501640|NCT01691924|DRUG|Placebo|
48501641|NCT05213338|DEVICE|Wear-documentation microchip|Microchip embedded in the appliance
48501642|NCT04617054|DRUG|AB-106|600mg QD for each subjects.
48501643|NCT03415061|DRUG|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
48347247|NCT00481689|DRUG|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
48347248|NCT04774913|PROCEDURE|Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)|CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks
48137011|NCT03259269|OTHER|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
48137012|NCT05917236|PROCEDURE|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
48137013|NCT04690738|DIAGNOSTIC_TEST|Fecal Elastase Concentration|Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
48137014|NCT02186106|DRUG|Cholecalciferol|
48137015|NCT02873559|DRUG|testosterone|Testosterone supplemented in 5 months
48137016|NCT02873559|OTHER|Progressive muscle training|Progressive muscle training during 4 months
48137017|NCT06510764|OTHER|intradermal needles|Disposable intradermal needles will be used for acupoint stimulation and Tai Chong, Taixi, Sanyinjiao, Hegu as well as Yanglingquan are chosed for acupuncture point. Acupuncture point pressure will last for 10 minutes each time, three times per day, and the intradermal needles will be changed every 2 days.
47983733|NCT04889716|DRUG|mosunetuzumab|1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
47983734|NCT04889716|DRUG|glofitamab|2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
47983735|NCT04889716|DRUG|obinutuzumab|1000 mg IV on Cycle 1 Day 1.
47983736|NCT01831544|DEVICE|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
48137018|NCT06510764|DRUG|Ziyinxiehuo Granules of tradional Chinese Medicine|Ziyinxiehuo Granules of tradional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
48137019|NCT03502369|PROCEDURE|Anterior Quadratus lamborum block|Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
48137020|NCT03941665|DEVICE|Gelronate|Gel for topical use
48137021|NCT03941665|OTHER|Aloevera|Gel for topical use
48137022|NCT03315299|DRUG|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
48137023|NCT00278135|DIETARY_SUPPLEMENT|DHA (nutritional supplement) or placebo|oral 900mg/day
48137024|NCT05325541|DEVICE|Visual Biofeedback Therapy|Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
48137025|NCT05325541|BEHAVIORAL|Conventional Balance exercise|Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
48137026|NCT02928250|DIETARY_SUPPLEMENT|Carnosine|Patients in intervention group received carnosine capsules orally daily
48137027|NCT02928250|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
48137028|NCT04025255|DIETARY_SUPPLEMENT|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
48137029|NCT04025255|DIETARY_SUPPLEMENT|Placebo|Matched placebo
48137030|NCT02063659|DRUG|Telotristat etiprate|Telotristat etiprate tablets
48137031|NCT02063659|DRUG|Placebo|Placebo-matching telotristat etiprate tablets
48137032|NCT06006962|OTHER|Aging Well through Interactions and Scientific Education - Action Plan|20-week program designed to provide education and individualized planning with a goal of improving brain health.
48137033|NCT00442637|DRUG|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
48137034|NCT00442637|OTHER|observation|observation after induction treatment
47983737|NCT02792933|PROCEDURE|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
48002527|NCT05595629|BEHAVIORAL|App-based remote blood pressure monitoring|Fully synched bluetooth-enabled remote blood pressure monitoring using a smartphone application. The digital health company, Twistle, has modified an existing postpartum hypertension pathway in their app according to our hospital's management algorithm.
48137035|NCT02977832|DIETARY_SUPPLEMENT|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
48137036|NCT02977832|DRUG|Alfuzosin|10Mg Oral Tablet, Extended Release
48137037|NCT06510751|OTHER|CGRP level|CGRP and substance P levels will be analysed by ELISA method in CSF and blood materials.
48501644|NCT03415061|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
48501645|NCT02658825|DRUG|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
48501646|NCT02658825|DRUG|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
48137038|NCT02188836|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
48137039|NCT02188836|DEVICE|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
48137040|NCT06430424|BIOLOGICAL|Relapsed glioblastoma|Paired tumor samples diagnosis/relapse
48137041|NCT01341132|PROCEDURE|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
48137042|NCT05168306|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
48137043|NCT02142751|DRUG|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
48137044|NCT02142751|DRUG|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
48137045|NCT02142751|DRUG|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
48137046|NCT01664741|DRUG|Nicotine patch - transdermal|21 mg patch
48137047|NCT01664741|DRUG|placebo|
48137048|NCT02579915|BEHAVIORAL|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
48137049|NCT02579915|BEHAVIORAL|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
48137050|NCT02766296|BEHAVIORAL|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
48137051|NCT02766296|BEHAVIORAL|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
48137052|NCT00000492|DRUG|propranolol|
48137053|NCT02861456|OTHER|Standard Model of Care|
48347249|NCT04576416|OTHER|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( \>10 years of experience) through a web-based review system developed by our group."
48501647|NCT02658825|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
48137054|NCT02861456|OTHER|Alternative Model of Care|
48137055|NCT04942184|BEHAVIORAL|Memory strategies in Arm 1|Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.
48137056|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 1|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
48137057|NCT04942184|OTHER|Tablet in Arm 1|A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
48137058|NCT04942184|BEHAVIORAL|Memory strategies in Arm 2|Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.
48137059|NCT04942184|DEVICE|Electroencephalogram (EEG) headset in Arm 2|A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.
48137060|NCT04942184|OTHER|Tablet in Arm 2|A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.
48137061|NCT01476241|PROCEDURE|PEG tube placement|Percutaneous endoscopic gastrostomy
48137062|NCT01458600|DRUG|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
48137063|NCT01458600|DRUG|Methimazole|T Methimazole 5 mg 3x2 for 18 months
48137064|NCT01458600|DRUG|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
48501648|NCT02658825|DRUG|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
48501649|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
48501650|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
48501651|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
48501652|NCT02658825|DRUG|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
48501653|NCT04305951|PROCEDURE|Comprehensive acupuncture therapy (CAT)|"CAT will be conducted for 2 sessions per week for 12 consecutive weeks.~The following 14 body acupoints with only manual stimulation will be used: HT7 (Shenmen), LI4 (Hegu), TH5 (Waiguan), ST36 (Zusanli), ST40 (Fenglong) and SP6 (Sanyinjiao) in two sides, and CV12 (Zhongwan) and CV4 (Guanyuan) in midline. Electrical stimulation will be conducted on the following frontal acupoints: GV20 (Baihui), EX-HN3 (Yintang), GB15 (Toulinqi), GB8 (Shuaigu), EX-HN5 (Taiyang), and ST8 (Touwei) on two sides, and left and right EX-HN1 (Sishencong).~Disposable acupuncture needles (0.25 mm in diameter and 25-40 mm in length) will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation is additionally delivered on the 6 pairs of the frontal acupoints. Each session of treatment will last 30 minutes."
47983738|NCT02792933|PROCEDURE|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
48347250|NCT06328855|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48347251|NCT06328855|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48347252|NCT06328855|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48347253|NCT00732706|PROCEDURE|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
48347254|NCT00732706|PROCEDURE|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
48501654|NCT04305951|PROCEDURE|Comfy Acupressure for the Elderly (CAE)|"CAE intervention will be conducted for 3 times per week for 12 consecutive weeks.~CAE consists of 12 steps which need about 15 minutes to complete and mainly concentrates on the acupoints on face, head, neck, and shoulder. The detailed CAE Operation Guide will be provided for the provider and the video demonstration is accessible at https://www.youtube.com/watch?v=pAqNIZPKmnM."
48501655|NCT01837524|BEHAVIORAL|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
48501656|NCT01837524|BEHAVIORAL|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
48501657|NCT06171724|DIETARY_SUPPLEMENT|Shoden 240 mg|Participants will receive a single dose of 240 mg Shoden at pharmacokinetics visit 1 or 2 depending on their sequence group. Forty-eight hours later, participants will receive a 35-day supply of Shoden at a dose of 240 mg per day.
47983739|NCT06493721|PROCEDURE|Clear Aligner Treatment|Clear aligner therapy to treat incisors crowding
48137065|NCT01458600|DRUG|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
48137066|NCT01458600|DRUG|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
48347255|NCT01652222|OTHER|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
48347256|NCT01652222|OTHER|Socio-educational training only|4 socio-educative training sessions during 8 weeks
48347257|NCT01336257|OTHER|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
47983740|NCT06493721|PROCEDURE|Low level laser|Apply clear aligner therapy with low level laser application on incisors
47983741|NCT04396431|BEHAVIORAL|education|"The intervention group was offered a six-hour training program based on the transtheoretical model in order to promote sun protection behavior and to reinforce self-efficacy. The program was prepared by the researchers in consideration of the SunSmart Program implemented in Australia, the SunWise School Program developed by the United States Environmental Protection Agency. The program included various educational tools such as a sun protection story, activity book, PowerPoint presentations, cartoons, and puzzles.~Refresher training was conducted 15 days, 1 month, and 2 months after the initial training. Sun protection behavior and self-efficacy of the children were evaluated at the beginning of the study and six months after the program. As gifts to support their sun protection behavior, the children were given an FDA-approved sunscreen with 50+ SPF, a white cotton short-sleeved T-shirt as protective clothing, sunglasses with 100% UV protection, and a wide-brimmed hat."
47983742|NCT06128395|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
47983743|NCT02093754|PROCEDURE|MRI and biopsy|
48347258|NCT04407286|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3 capsules
48347259|NCT03007628|DEVICE|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
48347260|NCT03007628|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
48347261|NCT03007628|OTHER|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
48347262|NCT00862524|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
48347263|NCT00862524|DRUG|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
48347264|NCT01037751|BEHAVIORAL|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
48347265|NCT01037751|BEHAVIORAL|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
48347266|NCT04655768|DEVICE|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
48347267|NCT01908049|DIETARY_SUPPLEMENT|Probiotic.|
48347268|NCT01908049|DIETARY_SUPPLEMENT|Placebo|
48347269|NCT01838304|DEVICE|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
48501658|NCT06171724|DIETARY_SUPPLEMENT|Shoden 480 mg|Participants will receive a single dose of 480 mg Shoden at pharmacokinetics visit 1 or 2 depending on their sequence group. Forty-eight hours later, participants will receive a 35-day supply of Shoden at a dose of 480 mg per day.
48501659|NCT01724580|DRUG|Baricitinib|Administered orally
47983744|NCT01020851|BEHAVIORAL|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
48347270|NCT01838304|DEVICE|Monitoring|Manual recording of drug doses determined by CRNA
48347271|NCT05354973|DEVICE|Consilium CareTM|This is an observational study using the Consilium CareTM smartphone ePRO application.
48347272|NCT00948285|PROCEDURE|MRI|magnetic resonance imaging (MRI)
48347273|NCT01126567|OTHER|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
48347274|NCT02740894|DRUG|Gefitinib|
47983745|NCT01020851|BEHAVIORAL|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
47983746|NCT04012385|BEHAVIORAL|lifestyle counseling|Nutritional plan and Physical activity goals
47983747|NCT06095427|BIOLOGICAL|LY06006 (Denosumab Biosimilar)|single dose of 60 mg LY006006 s.c.
47983748|NCT06095427|BIOLOGICAL|US-Prolia (Denosumab)|single dose of 60 mg US-Prolia s.c.
47983749|NCT06095427|BIOLOGICAL|EU-Prolia|single dose of 60 mg EU-Prolia s.c.
48002528|NCT05595629|BEHAVIORAL|text-message based remote blood pressure monitoring|Participants will receive automatic blood pressure cuffs and instructions as to how to upload their measurements to the Electronic Medical Record.
48347275|NCT05367362|DRUG|Minocyclin|200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
48347276|NCT03374891|OTHER|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
48347277|NCT02233582|DRUG|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
48347278|NCT02233582|DRUG|Sugar pill|
48347279|NCT02630485|BEHAVIORAL|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
48347280|NCT02630485|DIETARY_SUPPLEMENT|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
48347281|NCT02630485|DRUG|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
48347282|NCT03624829|OTHER|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
48347283|NCT03860844|DRUG|Isatuximab|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
48347284|NCT03860844|DRUG|Dexamethasone or equivalent|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
48347285|NCT03860844|DRUG|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347286|NCT03860844|DRUG|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347287|NCT03860844|DRUG|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347288|NCT03860844|DRUG|Daunorubicin (nonliposomal)|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
48347289|NCT03860844|DRUG|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347290|NCT03860844|DRUG|Filgrastim or equivalent|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347291|NCT03860844|DRUG|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347292|NCT03860844|DRUG|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347293|NCT03860844|DRUG|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347294|NCT03860844|DRUG|Pegaspargase (PEG) Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
48347295|NCT03860844|DRUG|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
48347296|NCT03860844|DRUG|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
48347297|NCT03860844|DRUG|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
48347298|NCT03860844|DRUG|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
48347299|NCT03860844|DRUG|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: PO
48347300|NCT03860844|DRUG|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
48347301|NCT04748822|OTHER|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
48347302|NCT02283346|RADIATION|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
48347303|NCT00333931|DRUG|Phenytoin|
48347304|NCT00333931|BEHAVIORAL|Cognitive Behavioral Therapy|
48347305|NCT01253967|PROCEDURE|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
48347306|NCT01253967|OTHER|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
48347307|NCT02387073|OTHER|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
48347308|NCT04110444|DRUG|Sildenafil|oral sildenafil t.d.s for high-risk pregnancies
48347309|NCT03855761|BEHAVIORAL|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
48347310|NCT03855761|BEHAVIORAL|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
48347311|NCT04649190|DEVICE|TAVI|Coronary access for PCI after TAVI
48347312|NCT03748420|OTHER|Adherence Intervention|The adherence enhanced intervention consists of clinical decision support related to cardiovascular risk factors enhanced with external medication adherence information and is delivered at the point of care to the healthcare provider and patient.
48347313|NCT02982642|DRUG|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
48347314|NCT02982642|DRUG|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
48347315|NCT00712270|DRUG|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
48347316|NCT00712270|DRUG|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
48347317|NCT04358913|DEVICE|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
48347318|NCT00045357|BIOLOGICAL|therapeutic autologous lymphocytes|
48347319|NCT00518336|PROCEDURE|Blood sampling|Blood sampling at Visit 3, 5 and 7.
48347320|NCT00518336|PROCEDURE|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
48347321|NCT00518336|BIOLOGICAL|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
48347322|NCT01505244|BEHAVIORAL|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
48347323|NCT00622570|DRUG|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
48347324|NCT00622570|DRUG|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
48347325|NCT00410345|DRUG|Mifepristone|
48347326|NCT03502941|DIETARY_SUPPLEMENT|6.3 g of EAAs mixture and whey protein isolate|A single dose of the mixture of EAAs/whey
48347327|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of EAAs mixture and whey protein isolate|A double dose of the mixture of EAAs/whey
48347328|NCT03502941|DIETARY_SUPPLEMENT|12.6 g of whey protein isolate|Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
48347329|NCT02858713|DRUG|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
48347330|NCT02858713|DEVICE|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
48347331|NCT05562700|OTHER|On-line questionnaire|"It is a self-administered questionnaire (20 minutes) with several subparts:~* Socio-demographic questions: age, height, weight, smoking status, etc.~* Care: date of accident, initial treatment, duration of symptoms, complications, return to work, return to sport, recovery of skills, etc.~* Functional results"
48347332|NCT00479934|DRUG|imatinib mesylate|6 month treatment with 400mg/day (per os)
48347333|NCT02752425|DEVICE|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
48347334|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
48347335|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
48347336|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
48347337|NCT01964027|DRUG|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
48347338|NCT03077789|PROCEDURE|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
48347339|NCT03874104|DIETARY_SUPPLEMENT|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
48347340|NCT05081089|DRUG|Artemether-lumefantrine|Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.
48347341|NCT05081089|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
48347342|NCT05081089|DRUG|Sulphadoxine-pyrimethamine with amodiaquine|Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
48347343|NCT05081089|DRUG|Tafenoquine|100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
48347344|NCT04185662|DIETARY_SUPPLEMENT|sucralose|daily intake different dose of artificial sweeteners sucralose or placebo
48347346|NCT05795400|DRUG|Dapagliflozin 10mg Tab|10 mg tablets given once daily, per oral use
48137067|NCT03964740|OTHER|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
48347347|NCT05795400|DRUG|Placebo|tablet of placebo drug dosed once daily
48347348|NCT01654393|OTHER|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
48347349|NCT01237223|DRUG|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
48347350|NCT01237223|DRUG|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
48347351|NCT01237223|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
48347352|NCT01237223|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
48347353|NCT01237223|DRUG|Placebo of Aliskiren|Aliskiren placebo tablet
48347354|NCT01237223|DRUG|Placebo of Amlodipine|Amlodipine placebo capsule
48347355|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
48347356|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
48137068|NCT00724399|BEHAVIORAL|Survey on womens health Issues.|Cardiovascular health.
48347357|NCT04669509|DIAGNOSTIC_TEST|Liver function tests|Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, hemoglobin, platelet count), coagulation parameters (prothrombin time, activated partial thromboplastin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. It will also be recorded whether mortality develops on day 7 and day 28.
48347358|NCT06263790|DEVICE|Intubating laryngeal mask|Intubation through a laryngeal mask
48347359|NCT06263790|DEVICE|Direct laryngoscopy|Intubation by using a direct laryngoscope
48347360|NCT04548479|DEVICE|PEP bottle|PEP bottle: it will be performed with a bottle of distilled water and a plastic tube, where the patient breathes against a resistance during expiration.
48347361|NCT04974190|DEVICE|Nasal Spray Device|A Nasal Spray apparatus containing a liquid
48347362|NCT06183554|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary aldosteronism will receive a CXCR4 PET imaging.
48347363|NCT01706120|DRUG|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
48347364|NCT01706120|DRUG|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
48347365|NCT01706120|DRUG|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
48347366|NCT04011306|DEVICE|Lumina24 BLU|Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns
48347367|NCT03594461|DRUG|Aflibercept Injection|Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
48347368|NCT00020449|BIOLOGICAL|recombinant interleukin-12|
48347369|NCT00020449|DRUG|paclitaxel|
48347370|NCT00020449|DRUG|pegylated liposomal doxorubicin hydrochloride|
48347371|NCT02978170|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
48347372|NCT03955120|BEHAVIORAL|Dayzz mobile sleep training|"1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
48347373|NCT03955120|OTHER|Treatment as usual|Standard medical care for specific sleep condition
48347374|NCT00492518|DRUG|Acetylcysteine|
48347375|NCT00492518|DRUG|Theophylline|
48347376|NCT00492518|DRUG|Placebo|
48347377|NCT04062370|DRUG|Ranibizumab|Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
48347378|NCT04062370|DEVICE|laser photocoagulation|After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
48347379|NCT01899040|DEVICE|neuromodulation for episodic migraine headache|
48347380|NCT03205189|OTHER|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
48347381|NCT01603979|BIOLOGICAL|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
48347382|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular nerve only|"PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg.~Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg"
48347383|NCT04954391|PROCEDURE|Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves|Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg
48347384|NCT05462691|PROCEDURE|tuberosity suture|to suture or not suture the tuberosities in reverse shoulder arthroplasty because of a proximal humeral fracture
48347385|NCT04561284|DIETARY_SUPPLEMENT|Indigestible fiber (classified)|Participants will be asked to ingest 12 grams of indigestible fiber powder per day for a period of 8 weeks. Three times daily, they will take 4 grams of powder with their meal.
48347386|NCT04561284|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to ingest 6 grams of placebo powder per day for a period of 8 weeks. Three times daily, they will take 2 grams of powder with their meal.
48347387|NCT00023205|BEHAVIORAL|11th grade reading level arthritis materials|
48347388|NCT00023205|BEHAVIORAL|Interactive in-person arthritis education|
48347389|NCT04723004|COMBINATION_PRODUCT|Toripalimab combined with Bevacizumab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
48347390|NCT04723004|DRUG|Sorafenib|"Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol."
48347391|NCT00739960|DRUG|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
48347392|NCT04443868|DRUG|Nitric Oxide-Releasing Drug|Nasal Spray + Nasal Irrigation
48347393|NCT04915872|PROCEDURE|Blood sampling (T0, inclusion)|Blood sample (5 ml) at 30 minutes after the loading dose of 4g/0.5g over 30 minutes for therapeutic drug monitoring at peak concentration (Cmax)
48347394|NCT04915872|PROCEDURE|other samplings (T1)|"- T1 : Day of the first surgical revision, under PTZ administered by continuous infusion : Blood sample (5 ml) for therapeutic drug monitoring at steady state concentration (Css).~Urinary sample and collection of urinary volume between T0 and T1 (Urinary Clearance) NPT fluid sample and collection of NPT volume between T0 and T1 (Peritoneal Clearance) Peritoneal sampling for therapeutic drug monitoring at the site of infection (CPt)"
48347395|NCT02029391|OTHER|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
48347396|NCT02029391|OTHER|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
48347397|NCT00565240|DRUG|Marvelon|oral contraceptive
48501660|NCT03958253|OTHER|Toolbox for Lung Cancer Screening|"-Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~* Patient education materials~* Primary care practice educational materials~* Pack-years/eligibility calculator~* Local referral process guide~* Smoking cessation materials and support~* Shared decision-making guide~* LDCT best practice guidelines"
48501661|NCT01593943|BEHAVIORAL|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
48501662|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 11)|lenalidomide 25 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
48501663|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 21)|lenalidomide 15 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
47983750|NCT05299515|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately four weekly core sessions (approximately 30 minutes-1 hour) with two additional sessions to reinforce core content, and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to assist in their retention and persistence in methadone treatment and incorporating value-driven, substance-free, rewarding activities into their daily life."
48501664|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 31)|lenalidomide 10 mg/day D1-D14 and gemcitabine 1000 mg/m2 D1, D8
48501665|NCT05105412|DRUG|Lenalidomide and Gemcitabine (Dose level 41)|lenalidomide 10 mg/day D1-D14 and gemcitabine 800 mg/m2 D1, D8
48501666|NCT01194518|BEHAVIORAL|Lifestyle Intervention Program|
48501667|NCT03215186|OTHER|observational study|
48501668|NCT05783544|DIAGNOSTIC_TEST|Interleukin-1B|Level of serum interleukin-1B will be detected
48501669|NCT05783544|DIAGNOSTIC_TEST|Interleukin-4|Level of serum interleukin-4 will be detected
48501670|NCT05783544|DIAGNOSTIC_TEST|Interleukin-6|Level of serum interleukin-4 will be detected
48501671|NCT05783544|DIAGNOSTIC_TEST|tumor necrosis factor - a|Level of serum tumor necrosis factor - a will be detected
48501672|NCT05783544|DIAGNOSTIC_TEST|interferon- gamma|Level of serum interferon- gamma will be detected
48501673|NCT02336724|DRUG|Famitinib|
48501674|NCT05288712|OTHER|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
48501675|NCT05288712|OTHER|Conventional training protocol|Conventional training protocol
48501676|NCT02235090|OTHER|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
48501677|NCT03582748|PROCEDURE|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
47983751|NCT00006344|RADIATION|radiation therapy|
47983752|NCT06036667|PROCEDURE|"28Fr coaxial smart drain chest tube"|"To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies."
47983753|NCT01858090|DRUG|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
47983754|NCT01858090|DRUG|Group Fentanyl|
48347398|NCT00565240|DRUG|Nuvaring|contraceptive vaginal ring
48347399|NCT00565240|DRUG|Letrozole|Aromatase Inhibitors
48347400|NCT01525420|BEHAVIORAL|Acceptance Therapy (ACT)|ACT
48347401|NCT01525420|OTHER|Cognitive Behavioral Therapy (CBT)|CBT
48347402|NCT02541500|DRUG|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
47983755|NCT01858090|DRUG|Group sufentanil|
47983756|NCT01858090|DRUG|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.
48347403|NCT02373306|PROCEDURE|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
48501678|NCT03582748|PROCEDURE|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
48501679|NCT05000879|BEHAVIORAL|MMB for Moms|12-week program that emphasizes mindfulness and cognitive behavioral skills
48501680|NCT02102516|DRUG|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing \>=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
48501681|NCT01696851|OTHER|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
48658644|NCT04614532|OTHER|Cold Pressor Test|"consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test."
48347404|NCT00287755|DRUG|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
48347405|NCT02950441|DIETARY_SUPPLEMENT|Nicotinamide Riboside|
48347406|NCT02950441|OTHER|Placebo|
48347407|NCT01163695|BEHAVIORAL|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families-and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
48347408|NCT01677676|BIOLOGICAL|FP-01.1|IM injection
48347409|NCT01677676|BIOLOGICAL|FP-01.1-Adjuvant|IM injection
48347410|NCT05320536|DRUG|Guilingji Capsule|This medicine is capsule medicine, take method is oral.
47983757|NCT01858090|DRUG|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
47983758|NCT01858090|DRUG|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
48347411|NCT05320536|DRUG|Placebo|This medicine is capsule medicine（Placebo）, take method is oral.
48347412|NCT03904004|PROCEDURE|Peroral endoscopic myotomy|Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
48347413|NCT03904004|PROCEDURE|Neumatic dilatation|Inflation of a ballon of specific diameter in the gastro-oesophageal junction
48347414|NCT03904004|PROCEDURE|Botulinum toxin injection|Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
47983759|NCT01858090|DRUG|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
47983760|NCT01858090|DRUG|Diphenhydramine|for severe pruritus
47983761|NCT01858090|DRUG|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
47983762|NCT01858090|DRUG|Diclofenac sodium|as additional analgesic among cases in which VAS\>3(Postoperatively)
48347415|NCT03904004|PROCEDURE|Laparoscopic Heller Myotomy|Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
48347416|NCT01789255|DRUG|vorinostat|Given PO
48347417|NCT01789255|DRUG|tacrolimus|Given IV or PO
47983763|NCT01499667|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
48347418|NCT01789255|DRUG|cyclosporine|Given IV or PO
47983764|NCT01499667|DRUG|Placebo|Matching placebo in capsules for oral administration once daily.
47983765|NCT06125587|DRUG|Chiglitazar|Chiglitazar is a novel PPAR agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization.
48347419|NCT01789255|DRUG|methotrexate|Given IV
48658645|NCT04614532|OTHER|digital sensor of Nociception Level Index|placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
48658646|NCT06308315|OTHER|Rhythmic balance visual auditory exercise + Routine physical therapy|"5 minute warm-up activities.~Bal-A-Vis-X training includes:~1. Ball Rectangle; A and B hold one ball in each hand, simultaneously bounce right balls to patient left hand; while balls bounce, clap left balls on right hand; catch patient ball with left hand; continue pattern. Bounces must be simultaneous. (10 minutes)~2. Ball rectangle in which one hand has to toss a ball to a partner and the other hand catch an incoming bag from the partner and 2 ball drop/pass/catch, two-foot jumping forward, tandem walking on ground. (10 minutes)~Routine Physical therapy treatment includes:~Range of Motion exercises, Stretching, Strength, balance training for 15 minutes~5 minute cool-down activities."
48658647|NCT06308315|OTHER|Strength Training + Routine Physical Therapy|"The expert managed sessions based on:~5 minute warm-up activities. 5 minute cool-down activities. Strength training includes 5 tasks for 20 minutes~1. core strengthening,~2. upper and lower limbs strength in both static positions as well as with dynamic movements~3. standing long jump,~4. knee push-ups,~5. sit-ups~Routine Physical therapy treatment will be given for 15 minutes.~It includes:~Range of Motion exercises, Stretching, Strength, balance training."
47983766|NCT06125587|DRUG|Metformin|Metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome.
48347420|NCT01789255|OTHER|laboratory biomarker analysis|Correlative studies
48347421|NCT01789255|OTHER|pharmacological study|Correlative studies
48347422|NCT05195424|DIAGNOSTIC_TEST|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
48347423|NCT04285177|PROCEDURE|Strabismus surgery|Resection or recession of the medial or lateral rectus muscle, or inferior oblique myectomy
48347424|NCT01998113|DRUG|Glyburide vs Insulin trials|Affecting groups 1 and 2
48347425|NCT01998113|DRUG|Metformin vs Insulin trials|Affecting groups 3 and 4
48347426|NCT01998113|DRUG|Metformin vs Glyburide trials|Affecting groups 5 and 6
48347427|NCT01733524|BEHAVIORAL|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
48658648|NCT05888922|DRUG|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
48658649|NCT05888922|DRUG|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
48658650|NCT05888922|DRUG|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
48658651|NCT05888922|DRUG|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
48658652|NCT01678742|DIETARY_SUPPLEMENT|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
48658653|NCT01678742|DIETARY_SUPPLEMENT|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
48658654|NCT00723632|BIOLOGICAL|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
48658655|NCT00723632|DRUG|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants \<65 kg, 1000 mg/day for participants \>65 to \<85 kg, and 1200 mg/day for participants \>=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
48658656|NCT01128517|BEHAVIORAL|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.~* Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 \& 2006).~* First session --\> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~* Second session --\>breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~* Third session --\> previous sessions recall. protein based and iron rich food encouragement.~* The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
48658657|NCT01128517|BEHAVIORAL|Education|Maternal education on complementary food
47983767|NCT05999136|OTHER|Pulses diet|Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
47983768|NCT05999136|OTHER|Plant proteins diet|Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
47983769|NCT05999136|OTHER|Habitual diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
48347428|NCT01733524|BEHAVIORAL|Picture of a fish|Participants will receive a picture of a betta fish.
48347429|NCT03858569|PROCEDURE|active management of third stage of labor|Active management of the third stage of the labor will be done administering oxytocin and cord traction.
48501682|NCT04570462|OTHER|Hypothermia Via Cooling Machine- Arctic Sun 5000|"Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature.~Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming.~The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject."
48501683|NCT04243083|DRUG|TLL018 tablet, placebo|Oral QD
48501684|NCT00224380|BEHAVIORAL|Using Medications Effectively|
48501685|NCT01664130|RADIATION|stereotactic body radiation therapy|Undergo SBRT
48501686|NCT01664130|PROCEDURE|quality-of-life assessment|Ancillary studies
48501687|NCT01664130|OTHER|laboratory biomarker analysis|Correlative studies
48501688|NCT02952898|DRUG|GDC 695|GDC 695 is a topical gel.
48501689|NCT02952898|DRUG|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
48501690|NCT02952898|DRUG|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
48501691|NCT00460538|DIETARY_SUPPLEMENT|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
48501692|NCT00460538|DIETARY_SUPPLEMENT|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
48658658|NCT03596554|OTHER|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
48658659|NCT04662450|BEHAVIORAL|ABM affective pain stimuli|Patients undergo ABM training to shift attention away from affective pain stimuli
48658660|NCT04662450|BEHAVIORAL|ABM sensory pain stimuli|Patients undergo ABM training to shift attention away from sensory pain stimuli
48347430|NCT04063228|OTHER|Simple Skill Group|will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
48658661|NCT04662450|BEHAVIORAL|Placebo|Patients undergo ABM training to receive affective/neutral and sensory/neutral word pairs
48658662|NCT06558578|DIAGNOSTIC_TEST|Helicobacter pylori antigen in stool|"H pylori antigen in stool: for all patients suffering from migraine and control group.~Upper GIT endoscopy: for children with positive H Pylori antigen in stool."
48658663|NCT03699865|OTHER|Nicotine content|Study-supplied cigarettes will contain either intermediate or very low nicotine content
48658664|NCT06112275|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).
48658665|NCT04306926|DRUG|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
48501693|NCT04244123|COMBINATION_PRODUCT|integrated information and nurse led telephone clinic|combining web-based information from easypod connect with nurse led telephone clinic
48501694|NCT01589965|BEHAVIORAL|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
48501695|NCT03410251|PROCEDURE|Socket preservation|"Teeth were extracted atraumatically and without flap release in patients who have received prophylactic antibiotherapy and local anaesthesia. After checking the integrity of the buccal and palatal bone plate, biomaterial (Bio-Oss®) was introduced into the socket. A connective tissue graft harvested from the palate was inserted and sutured in buccal and palatal pouches in order to cover the socket.~chlorhexidine spray (0.12%) twice a day and Ibuprofen 600 mg three times/ day were prescribed whereas antibiotics were continued for 5 days. Tooth brushing was banned at the extraction site for 10 days and sutures were removed 10 days after surgery."
48501696|NCT00811356|DRUG|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
48501697|NCT04384653|DRUG|Furosemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution for subcutaneous administration (80 mg)
48501698|NCT04384653|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10 mg/mL), 80 mg by intravenous administration
48658666|NCT04306926|RADIATION|SBRT|Give according to the location of the lesion and clinical condition.
48347431|NCT04063228|OTHER|Complex Skill Group|The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
48347432|NCT05148689|DRUG|Oxymetazoline hydrochloride Cream, 1%|Cream
48347433|NCT05148689|DRUG|Rhofade™ (oxymetazoline) cream, 1%|cream
48347434|NCT05148689|DRUG|Placebo|cream
48347435|NCT00887068|DRUG|Azacitidine|32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
48658667|NCT00932607|DRUG|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
48347436|NCT02054936|DRUG|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
48347437|NCT02054936|DRUG|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
47983770|NCT05625009|PROCEDURE|Procedure/Surgery: Transversus Abdominis Plane Block (TAPB)|Patients received TAPB postoperatively
48347438|NCT00000703|DRUG|Bleomycin sulfate|
48347439|NCT00000703|DRUG|Vincristine sulfate|
48347440|NCT00000703|DRUG|Doxorubicin hydrochloride|
48347441|NCT00000703|DRUG|Cyclophosphamide|
48347442|NCT00000703|DRUG|Allopurinol|
48347443|NCT00000703|DRUG|Methotrexate|
48347444|NCT00000703|DRUG|Cytarabine|
48347445|NCT00000703|DRUG|Leucovorin calcium|
48347446|NCT00000703|DRUG|Zidovudine|
48347447|NCT00000703|DRUG|Dexamethasone|
48347448|NCT03239262|PROCEDURE|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure\>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
48347449|NCT03239262|PROCEDURE|No intervention|No intervention was performed in patients without ganglionated plexi.
48347450|NCT02865928|DRUG|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
48658668|NCT01916473|OTHER|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
48658669|NCT01916473|OTHER|Continuous wound infusion|Continuous wound infusion via catheter
48347451|NCT02865928|DRUG|Normal Saline|Same injection technique as intervention arm with normal saline
48347452|NCT03170908|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
48347453|NCT06198218|OTHER|Scapular mobilization|Group A: will be treated with manual scapular mobilization in upward rotation and downward rotation, adduction and abduction of scapula.Sets of 10 repetitions were applied with a rest interval of 30 seconds between set for 20 minutes, activity based scapular mobilization(Codman pendulum exercises, scapular pushups, band wall apart ,wall ball circles and advance study wall pushups) along with conventional physical therapy program(heating,EMS,stretching for tight muscles , strengthening exercises and graduated active exercises) for 25 min
48347454|NCT06198218|OTHER|Conventional physical therapy program|Group B:will receive conventional physical therapy program including (heating to improve circulation and release muscle tension,EMS,stretching for stiff muscle,weight bearing, strengthening exercises \& graduated active exercises)for 20 min along with activity based scapular mobilization (Codman pendulum exercises,band wall apart,wall ball circles, scapular pushups and advance study wall pushups)for 20 min with 5 min resting interval.
48347455|NCT02321397|DRUG|Oxycodone|
48347456|NCT02321397|DRUG|Naloxone|Prolonged Release Tablets
47983771|NCT05625009|PROCEDURE|Procedure/Surgery: Erector Spinae Plane Block (ESPB)|Patients received ESPB postoperatively
48347457|NCT06177015|DRUG|Darolutamide continuous|standard of care
48347458|NCT06177015|DRUG|Darolutamide intermittent|experimental group
48347459|NCT00529412|OTHER|Seprafilm|two sheets per body
48347460|NCT05615155|OTHER|Platelets Rich Fibrin (i-PRF / C-PRF)|one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
47983772|NCT00914524|DRUG|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
47983773|NCT04162015|DRUG|Nivolumab|nivolumab 360 mg
47983774|NCT04162015|DRUG|Pemetrexed|500 mg/m\^2
47983775|NCT04162015|DRUG|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
47983776|NCT01096121|DRUG|Enalapril|"* during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day"
47983777|NCT01096121|DRUG|Placebo|Glucose
47983778|NCT03845907|DEVICE|Gen 1B|Diagnostic Ultrasound and Optoacoustic Imaging
48658670|NCT04363892|OTHER|Optical and infrared imaging|Acquiring images (photographs) of the skin
47983779|NCT03845907|DEVICE|Gen 1|Diagnostic Ultrasound and Optoacoustic Imaging
48137069|NCT02091752|DRUG|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
48137070|NCT03588832|DIAGNOSTIC_TEST|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
48137071|NCT02859844|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|
48137072|NCT02170259|OTHER|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
48347461|NCT04571736|OTHER|access to the internet information platform|This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
47983780|NCT01961388|DRUG|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
48347462|NCT03024229|DEVICE|LifePort® perfusion machine|Renal perfusion on LifePort® machine
48347463|NCT01619527|DRUG|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
48347464|NCT01619527|DRUG|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
48347465|NCT01259921|BEHAVIORAL|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
48347466|NCT03570190|OTHER|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~* Determination of the status quo~* Dedicated reflection and training followed by implementation of tailored changes~* Determination of the effect"
48347467|NCT05210413|DRUG|Spartalizumab in Pediatric cohort|Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
48347468|NCT05210413|DRUG|Low-dose Pazopanib in Pediatric Cohort|Oral pazopanib treatment at a fixed dose of 225mg/m²/day
48347469|NCT05210413|DRUG|Spartalizumab in Adult cohort|Infusion of 400 mg of spartalizumab on Day1 of each cycle.
48347470|NCT05210413|DRUG|Low-dose Pazopanib in Adult Cohort|Oral pazopanib treatment with a fixed dose of 400 mg/day
48347471|NCT05097976|DRUG|Methylprednisolone|21 x 4mg tablets beginning on POD 1
48347472|NCT05097976|DRUG|Placebo|21 sugar tablets beginning on POD 1 with standard management
48347473|NCT05840523|OTHER|Proprioceptive Neuromuscular Facilitation exercises|The PNF group performed flexion-abduction-internal rotation and extension-abduction-internal rotation patterns as 15 repetitions, 2 sets. The metronome was used to fix the construction speed of the exercises (50bpm). PNF exercises were performed with EB at a metronome speed of 50bpm at a ratio of 1:2 sec. In other words, while transition from the antagonist to agonist pattern in 3 clicks, there was return from agonist to antagonist in 6 clicks.
48347474|NCT05840523|OTHER|The Range Of Motion exercises|The ROM group performed hip flexion abduction, neutral abduction and extension abduction exercises with an EB at 50bpm metronome speed in 3 sets of 10 repetitions. In both groups, 30 seconds of rest was given between exercises.
48501699|NCT04384653|DEVICE|Medfusion 3500 (v6) precision infusion pump|Furosemide Injection Solution for subcutaneous administration (80 mg)
47983781|NCT01961388|DRUG|Metformin|Oral, dosage of Metformin as per the directions of treating physician
47983782|NCT00597545|PROCEDURE|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
47983783|NCT00597545|DEVICE|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
47983784|NCT05548231|DRUG|LY3437943|Administered SC
47983785|NCT05548231|DRUG|Placebo|Administered SC
47983786|NCT02140229|DEVICE|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
48501700|NCT02968836|DIETARY_SUPPLEMENT|Blend of amino acids|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
48658671|NCT03018873|OTHER|remote ischemic preconditioning （RIPC）|once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
48658672|NCT00265499|PROCEDURE|Skeletonization of the internal thoracic artery|
48658673|NCT01980264|DEVICE|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
48347475|NCT05024890|OTHER|Splash WASH in Schools programme (Project WISE)|"The Project WISE intervention includes:~WASH infrastructure~* Water storage tanks and water filtration systems~* Durable plastic drinking water and handwashing stations~* New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~* Training of focal teachers to organise student 'hygiene club'~* Annual soap drive and soap restocking~* Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~* Toilets have water tap, bucket and waste bin~* Emergency menstrual hygiene products available at school~* Training of focal teachers to organise student 'gender club'~* Education on puberty and menstruation for all pupils above 10 and parent resource guide"
48347476|NCT05980676|BEHAVIORAL|Personalized Two-Week Email-Based Program|Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The Coached group will be able to reply to the emails to give feedback, ask questions, and receive additional support.
48347477|NCT03850171|OTHER|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
48347478|NCT02187224|DRUG|Progesterone|
48347479|NCT02187224|DRUG|Placebo (for Progesterone)|
48347480|NCT04379960|OTHER|Peptides|Peptides will be added to PBMCs in in vitro cell culture.
48347481|NCT00246376|BEHAVIORAL|Diet|ATP-III diet
48347482|NCT00246376|BEHAVIORAL|Exercise|Supervised exercise in study gym
48501701|NCT02968836|DIETARY_SUPPLEMENT|Maltodextrin only|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
48347483|NCT00246376|DRUG|Niacin|Niaspan, titrated up to 2 grams per day
48347484|NCT00246376|DRUG|Fenofibrate|Tricor, 120 mg per day
48347485|NCT00246376|OTHER|Placebos|Placebos for Niaspan and Tricor
48347486|NCT03677544|OTHER|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
48347487|NCT05645276|DRUG|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
48347488|NCT03152188|DRUG|FMT|Fifteen FMT Openbiome capsules administered at the same time
48501702|NCT04319016|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
48137073|NCT02170259|OTHER|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
48137074|NCT02170259|OTHER|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
48137075|NCT02534285|DEVICE|hearing protection|Attenuation of hearing during surgery
48347489|NCT03152188|OTHER|Placebo|Fifteen placebo capsules administered at the same time
48501703|NCT03151811|DRUG|Melflufen|Intravenous infusion
47983787|NCT02140229|OTHER|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
48347490|NCT03375762|OTHER|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
48347491|NCT03375762|OTHER|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score \>0 and RACE motor item\>0
48347492|NCT00126425|DRUG|123I-mIBG (meta-iodobenzylguanidine)|Single dose
48501704|NCT03151811|DRUG|Pomalidomide|Oral capsules
47983788|NCT02140229|OTHER|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
48501705|NCT03151811|DRUG|Dexamethasone|Oral tablets
48501706|NCT00191971|DRUG|Gemcitabine|
48501707|NCT02454660|BEHAVIORAL|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
48501708|NCT05682859|DRUG|Roflumilast 500 Mcg Oral Tablet|Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.
48501709|NCT05682859|DRUG|Placebo|Placebo tablets
48501710|NCT00778024|DRUG|fluoxetine HCL 40 mg capsules|
48501711|NCT05328934|DEVICE|SoftHand Pro|Performance assessments utilizing the SoftHand Pro over an 8-week period.
48501712|NCT05328934|DEVICE|Ossur i-Limb|Performance assessments utilizing the i-Limb over an 8-week period.
47983789|NCT01967121|DEVICE|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
47983790|NCT01967121|OTHER|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
47983791|NCT05931354|OTHER|HPV test and Pap Smear|HPV test and Pap Smear
47983792|NCT02549183|DEVICE|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
47983793|NCT01075945|DRUG|Dihydroartemisinin- piperaquine|three tablets per day
47983794|NCT01075945|DRUG|artemether- lumefantrine|twenty tablet in eight doses
48137076|NCT03232398|DRUG|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
48137077|NCT03232398|DRUG|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
48137078|NCT02386098|DRUG|BMS-955176|HIV Maturation Inhibitor
48347493|NCT04783376|DRUG|: Insulin, lispro and regular insulin|"* A: the participant will have a mealtime bolus dose of fast-acting insulin 10 minutes before the meal representing 100% of the dose calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio~* B: the bolus insulin dose for the meal will be calculated according to the carbohydrate content of the meal and the individual insulin to carbohydrate ratio and additional 30% of the calculated dose will added to cover the fat and protein content of the meal. This total dose will be divided into 2 portions. A premeal portion (60%) will be given 10 minutes before the meal and (40%) will be given 30 minutes after the premeal dose. Both doses will be given as fast-acting insulin.~* C: the same as intervention B but the 40% of the total dose will be given as regular insulin."
47983795|NCT01406431|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
47983796|NCT01406431|DRUG|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
47983797|NCT01662258|DEVICE|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
47983798|NCT00363922|BEHAVIORAL|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
47983799|NCT00363922|BEHAVIORAL|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
47983800|NCT00363922|BEHAVIORAL|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
48137079|NCT02386098|DRUG|Atazanavir (ATV)|Atazanavir
48347494|NCT04500223|OTHER|Cervical Cranioflexion exercise plus cardiopulmonary exercise|Intervention:Cervical Cranioflexion exercise plus cardiopulmonary exercise
48347495|NCT04500223|OTHER|Cervical stretch exercise plus cardiopulmonary rehabilitation|control:Cervical stretch exercise plus cardiopulmonary rehabilitation
48137080|NCT02386098|DRUG|Ritonavir (RTV)|Ritonavir
48137081|NCT02386098|DRUG|Dolutegravir (DTG)|Dolutegravir
48137082|NCT02386098|DRUG|Tenofovir (TDF)|Tenofovir
48137083|NCT00309036|BIOLOGICAL|Recombinant grass pollen|
48137084|NCT01940107|OTHER|evaluations|Only evaluations
48137085|NCT01940107|PROCEDURE|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
48137086|NCT04187066|BEHAVIORAL|mindset induction|induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
48137087|NCT06396338|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
47983801|NCT05947370|DRUG|Berberine Chloride|Traditional Chinese medicine
47983802|NCT05947370|DRUG|Placebo|Placebo control
47983803|NCT02093845|DEVICE|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
47983804|NCT02093845|DEVICE|SYNERGY stent|Percutaneous coronary intervention involving use of stent
47983805|NCT05314855|DEVICE|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
47983806|NCT01503268|DEVICE|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
47983807|NCT01503268|PROCEDURE|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
47983808|NCT01503268|PROCEDURE|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
47983809|NCT01017614|DRUG|Monofer|"* administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~* administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
47983810|NCT01017614|DRUG|Iron Sulphate|200 mg daily
47983811|NCT05696678|DRUG|Intrathecal Morphine|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
48137088|NCT03169933|RADIATION|Combined, intensified and modulated adjuvant radiotherapy|
48137089|NCT05118178|DIAGNOSTIC_TEST|echocardiography, computed tomography|echocardiography - including GLS and MWI computed tomography - with calcium score index
48137090|NCT00571649|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
48137091|NCT00571649|DRUG|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
48347496|NCT03127462|BEHAVIORAL|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
48347497|NCT05759481|DRUG|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
48347498|NCT05759481|OTHER|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
48347499|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
48347500|NCT01148576|DRUG|entecavir|entecavir 0.5 mg qd for 12 months
48347501|NCT01148576|DRUG|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
48347502|NCT01148576|DRUG|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
48347503|NCT02288442|OTHER|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
48347504|NCT01807611|RADIATION|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
48347505|NCT01807611|DRUG|Fludarabine|Given IV.
48347506|NCT01807611|DRUG|Cyclophosphamide|Given IV.
48347507|NCT01807611|DRUG|Thiotepa|Given IV.
48501713|NCT03122080|DEVICE|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
48501714|NCT03122080|DEVICE|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
48501715|NCT03122080|OTHER|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
48347508|NCT01807611|DRUG|Melphalan|Given IV.
48347509|NCT01807611|BIOLOGICAL|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
47914569|NCT02267798|DEVICE|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
48347510|NCT01807611|BIOLOGICAL|TC-NK Infusion|Participants receive infusions of TC-NK.
48347511|NCT01807611|BIOLOGICAL|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
48347512|NCT01807611|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
48347513|NCT01807611|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
48347514|NCT01807611|DRUG|Mycophenolate mofetil|Given intravenously or orally.
48137092|NCT00571649|DRUG|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
48137093|NCT00571649|DRUG|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
48137094|NCT01719874|BIOLOGICAL|TCN-032|
48137095|NCT01719874|BIOLOGICAL|Placebo (saline)|
48137096|NCT03842605|OTHER|Strength training|
48137097|NCT04245995|DIAGNOSTIC_TEST|Feature Extraction Technology|The study´s aim was evaluation of the clinical applicability of the Feature Extraction Technology (FET) during a simulated blood loss scenario in comparison to visual estimation.
48137098|NCT05443945|DEVICE|Nasal Spray|3 sprays in each nostril 3 times per day
48137099|NCT01180231|DRUG|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
48137100|NCT01180231|OTHER|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
48501716|NCT01080664|DRUG|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
48137101|NCT01841671|BIOLOGICAL|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
48137102|NCT01841671|BIOLOGICAL|bOPV|As indicated
48137103|NCT01841671|BIOLOGICAL|mOPV type 2|Administered at 28 weeks of age to all study participants
48137104|NCT01841671|BIOLOGICAL|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
48501717|NCT01080664|DRUG|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
48501718|NCT05858502|BIOLOGICAL|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
48347515|NCT02043509|BEHAVIORAL|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
48347516|NCT01561040|DIETARY_SUPPLEMENT|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
48347517|NCT02078089|DRUG|Morphine|Morphine will be given to patients as part of their standard care
48347518|NCT02078089|DRUG|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
48347519|NCT00460525|BIOLOGICAL|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
48347520|NCT00460525|BIOLOGICAL|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
48347521|NCT02277236|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
48347522|NCT02277236|RADIATION|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
48347523|NCT01698073|BEHAVIORAL|mCOL|
48347524|NCT01698073|OTHER|AS+|
48347525|NCT04304404|BEHAVIORAL|Breast Cancer Risk Reduction Program (BrCaRRP)|Women in the intervention group will complete the pre-tests electronically, and a 12-week intervention program will be implemented. The first meeting will be face-to-face individual training. In this training session, the risk of developing breast cancer will be calculated with each participant using breast cancer risk assessment tools. Modifiable and non-modifiable factors that increase breast cancer risk will be explained. With the participant, it will be decided which of the modifiable risk factors will be improved. Guidance will be given on topics such as genetic counseling, breast cancer screenings, increasing physical activity, healthy nutrition, weight control, smoking and alcohol use. The interventions will continue with phone calls and the 12-week program will be completed.
48347526|NCT00005577|DRUG|gemcitabine hydrochloride|
48347527|NCT03300427|DRUG|sacubitril/valsatran|sacubitril/valsatran 100 or 200 mg BID
48347528|NCT03300427|DRUG|valsartan|Valsartan 80 or 160 mg BID
48347529|NCT03300427|DRUG|placebo to valsartan|placebo to valsartan 80 or 160 BID
48347530|NCT03300427|DRUG|placebo to sacubitril/valsartan|placebo to sacubitril/valsartan 100 or 200 mg BID
48347531|NCT04762264|DEVICE|ProFlor inguinal hernia device|Device follow up after inguinal hernia repair with ProFlor
48347532|NCT04046276|BEHAVIORAL|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
48347533|NCT04046276|OTHER|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
48501719|NCT05858502|OTHER|Saliva sample collection|Saliva sample collection between inclusion and 3 months
48501720|NCT05858502|OTHER|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
48501721|NCT05858502|OTHER|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
48501722|NCT06189547|OTHER|different prior cancer history type|different types of prior cancer history
48137105|NCT00273052|DRUG|Carvedilol Phosphate modified release formulation|
48137106|NCT00273052|DRUG|metoprolol succinate|
48501723|NCT06403124|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation by reconstruction plate and screws
48501724|NCT00446901|DIETARY_SUPPLEMENT|Selenium|Selenized yeast, 300 ug/day
48501725|NCT05990153|OTHER|Myofascial Release (MR)|Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
48501726|NCT05990153|DRUG|clinical practice drug treatment|drug treatment according to the medical indications of clinical practice
48137107|NCT03704519|DRUG|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
48137108|NCT03704519|DRUG|Enzalutamide|4 x 40 mg capsules, once orally
48347534|NCT04046276|BEHAVIORAL|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
48347535|NCT04046601|DEVICE|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
48347536|NCT04640753|PROCEDURE|Endoscopic procedure for achalasia|POEM procedure will have a high technical feasibility, with effective clinical resolution of symptoms both in the short and long term.
48347537|NCT00954824|BIOLOGICAL|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
48347538|NCT03185468|GENETIC|4SCAR-PSMA|PSMA-specific 4th Generation CART
48347539|NCT03185468|GENETIC|4SCAR-FRa|FRa-specific 4th Generation CART
48347540|NCT00520650|DRUG|Aripiprazole|
48347541|NCT05882604|DRUG|Mesna Injection|1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
48137109|NCT03704519|OTHER|Placebo|4 placebo tablets, once orally
48137110|NCT05093062|OTHER|Tian Jiu Therapy|
48658674|NCT05163639|PROCEDURE|Non-invasive pairing of cortical and spinal stimulation|Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
48658675|NCT05163639|PROCEDURE|Intraoperative pairing of cortical and spinal stimulation|The surgeon will position spinal cord electrodes on the epidural surface one level rostral (typically C4/C5) to the site of myelopathy. Spinal and cortical thresholds will be determined. Investigator will then test the immediate effects of paired stimulation by stimulating the cortex at 120% of threshold and the spinal cord at 90% of threshold at various latencies relative to the time of synchronous convergence. The control intervention will include cortical only (120%) spinal only (90%) and non-convergent latency pairing stimulation.
48501727|NCT05990153|OTHER|Manual therapy (MT)|The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
48347542|NCT05882604|DRUG|Arthrocentesis with ringer solution|Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
48137113|NCT03204032|DRUG|Tegafur|Tegafur 40-60mg po bid(d1-d14);
48347543|NCT02283372|DRUG|nab-Paclitaxel|
48501728|NCT05990153|OTHER|Therapeutic exercise (TE)|The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
48501729|NCT02566356|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
48501730|NCT02566356|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
48501731|NCT00357123|DRUG|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
48137114|NCT03204032|DRUG|Temozolomide|200mg po qd(d10-d14)
48137115|NCT03204032|DRUG|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
48137116|NCT03088800|DRUG|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
48347544|NCT02283372|DRUG|Gemcitabine|
48347545|NCT02283372|RADIATION|Intensity modulated radiation|
48501732|NCT05773833|BEHAVIORAL|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
48347546|NCT02244658|DRUG|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
47914570|NCT03060980|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
47914571|NCT03060980|DRUG|Empagliflozin (oral)|10 mg/day and 25 mg/day
47914572|NCT03060980|DRUG|Glimepiride (oral)|1-6 mg/day
48137117|NCT03088800|DRUG|APAP|Oral APAP at 15mg/kg dose
48347547|NCT04998292|DEVICE|Piezo-surgery with low level laser therapy|Low level laser therapy
48347548|NCT04998292|DEVICE|Piezo-surgery only|Piezo-surgery only
48347549|NCT03122652|DRUG|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
48347550|NCT03122652|DRUG|Placebo Oral Tablet|1 tablet once a day
48347551|NCT00004695|DRUG|PEG-interleukin-2|
48501733|NCT05869903|DRUG|Orforglipron|Administered orally.
48501734|NCT05869903|DRUG|Placebo|Administered orally.
48347552|NCT05575089|DEVICE|Inspiratory muscle training - Powerbreath|"The device Powerbreath is an inspiratory muscle training used to train respiratory muscles. Currently, it is one of the most used devices for the TMI, a linear load model with continuous application of inspiratory pressure throughout inspiration, in which the inspiratory regulating valve remains open while allowing an unrestricted expiration that generates resistance through a spring or of an electronic valve system, ability to offer greater load during training."
48347553|NCT05575089|OTHER|Aerobic exercise in cycle ergometer|10 face-to-face non consecutive sessions with 30 minutes in a cycle ergometer(divided into three steps: heat 5 minutes; 20 minutes with a comfortable and supportable speed or load ( individually prescribed) and 5 minutes recovery
48347554|NCT05575089|OTHER|Deep breathing exercises|Diaphragmatic exercises ( deep inspirations) associated to raise upper limbs ( 3 times - 10 repetitions each)
48347555|NCT04192318|BEHAVIORAL|Bridging the Gap|Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.
48501735|NCT04607161|OTHER|no intervention|no intervention
48501736|NCT05278728|DRUG|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
48501737|NCT05278728|DRUG|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
48347556|NCT04192318|OTHER|Communities that Care (CTC)|In CTC programs stakeholders elect evidence-based prevention strategies that are most appropriate for their community. These evidence-based strategies target their community's specific needs, such as reducing risk factors while supporting and increasing protective factors.
48347557|NCT04192318|OTHER|Treatment as usual|Treat and release
48501738|NCT05726903|DRUG|Depo-subQ Provera Injectable Product|SC Injection at Home
48501739|NCT04084093|DEVICE|Surfactant Gel|This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
48501740|NCT03768518|DIAGNOSTIC_TEST|68Ga-exendin-4 PET/CT|68Ga-exendin-4 PET/CT
48501741|NCT03815734|PROCEDURE|motor imagery|motor imagery during the postoperative immobilization period
48501742|NCT03753763|DRUG|Safinamide Methanesulfonate|100 mg (free base)
48501743|NCT03753763|DRUG|Safinamide Methanesulfonate matching placebo|100 mg placebo
48501744|NCT03256279|DEVICE|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
48501745|NCT03256279|DEVICE|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
47983812|NCT05696678|DRUG|Ropivacaine 0.2%|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
47983813|NCT00006488|DRUG|recombinant-methionyl human glial cell line-derived neurotrophic factor|
48501746|NCT02485119|DRUG|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
48501747|NCT00800007|DRUG|ANZ-521|3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
48501748|NCT00800007|DRUG|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
48347558|NCT05478538|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
48347559|NCT01492816|BEHAVIORAL|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
48501749|NCT00182468|OTHER|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
47983814|NCT00001929|DRUG|Eliprodil|
47983815|NCT05368974|DRUG|Direct Acting Antivirals|Direct-acting antiviral exposure during documented pregnancy
48137118|NCT03524131|OTHER|risk-framed leaflet|2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
48137119|NCT03524131|OTHER|benefits-framed leaflet|2-sided leaflet, emphasizing benefits of attending an NHS Health Check
48137120|NCT03524131|OTHER|current national leaflet|4-sided leaflet
48501750|NCT00635232|DRUG|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
48137121|NCT00204685|DRUG|dornase alfa|
48501751|NCT00635232|DRUG|placebo|placebo capsules once daily for 12 weeks
48501752|NCT00635232|DRUG|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
48501753|NCT00635232|DRUG|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
48501754|NCT00635232|DRUG|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
48501755|NCT05159167|OTHER|Baduanjin, a type of Qigong|Baduanjin is very popular in China. There is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders.
48347560|NCT02774668|OTHER|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ."
48347561|NCT02774668|OTHER|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
48347562|NCT02977533|DRUG|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48347563|NCT02977533|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48347564|NCT02977533|DRUG|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
48347565|NCT02128919|DEVICE|tDCS|Transcranial Direct Current Stimulation
48347566|NCT00081744|DRUG|Tigecycline|
48347567|NCT03352869|DRUG|Exenatide|Use Exenatide for 3 months to treat PCOS
48347568|NCT03352869|DRUG|Metformin|Use Metformin for 3 months to treat PCOS
48137122|NCT01420497|DRUG|intra-articular infiltration|intra articular infiltration
48347569|NCT03749850|DRUG|LTLD|"Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol."
48347570|NCT03749850|PROCEDURE|MR-HIFU induced hyperthermia|"Patients will receive up to six cycles at three-weeks intervals of:~- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol."
48347571|NCT03749850|DRUG|Cyclophosphamide|"Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol."
48347572|NCT05837000|DRUG|Dexmedetomidine|Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally
48347573|NCT05837000|DRUG|Ketamine|Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally
48347574|NCT05837000|DRUG|Magnesium sulphate|Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.
48347575|NCT06424041|OTHER|Fecal Microbiome Transplantation|Healthy donor fecal microbiome transplantation, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
48347576|NCT06424041|OTHER|Sham Fecal Microbiome Transplantation|Capsules containing preservative solution only, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
48347577|NCT00728728|DRUG|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
48137123|NCT01420497|DRUG|epidural infiltration|epidural infiltration
48347578|NCT00728728|DIETARY_SUPPLEMENT|Placebo|Placebo
48347579|NCT05770739|BEHAVIORAL|Perioperative accelerated rehabilitation surgical measures|To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
48347580|NCT05770739|BEHAVIORAL|Traditional treatment|To provide traditional perioperative treatment for children with cholangiectasia
48347581|NCT05418725|DEVICE|PVI and Linear lesion using PEF|PVI and Linear lesion using PEF
48347582|NCT05418725|DEVICE|PVI and Linear lesion using CFRF|PVI and Linear lesion using CFRF
48347583|NCT00003761|BIOLOGICAL|rV-DF3/MUC1|"- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU"
48347584|NCT03327363|DEVICE|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
48347585|NCT02310360|RADIATION|Fallypride|
48347586|NCT03518034|DRUG|AndroGel®|testosterone administered topically
48347587|NCT03518034|DRUG|Placebo|placebo administered topically
48347588|NCT00744991|DRUG|Enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
48347589|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
48347590|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
48347591|NCT00728195|DRUG|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
48347592|NCT00728195|DRUG|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
48347593|NCT00728195|DRUG|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
48347594|NCT01462591|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
48347595|NCT02047708|DRUG|Zibotentan|Selective endothelin-A antagonist
48347596|NCT04552067|DRUG|Lovenox|patients given curative dose of Lovenox
48347597|NCT04552067|DRUG|Enoxaparin|patients given curative dose of Enoxa
48347598|NCT01372813|DRUG|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
48137124|NCT03750682|OTHER|Physical Activity (PA) Intervention|The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.
48137125|NCT03750682|OTHER|Healthy Aging Education (HE) Intervention|"The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects."
48137126|NCT04163237|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
48137127|NCT04163237|DRUG|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
48137128|NCT02739100|DRUG|Triferic|
48137129|NCT02945059|PROCEDURE|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
48137130|NCT03926624|DRUG|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
48137131|NCT03926624|DRUG|Cytarabine|cytosine arabinoside (ara-C)
48137132|NCT03926624|DRUG|Azacitidine|Azacitidine
48347599|NCT01473355|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
48347600|NCT05346861|DRUG|Trastuzumab plus chemotherapy|Trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy Experimental: Pyrotinib +Trastuzumab + chemotherapy
48347601|NCT05346861|DRUG|Trastuzumab in combination with pyrotinib plus chemotherapy|Pyrotinib: 400 mg po QD, Q3W Chemotherapy regimen is chosen from the following: Vinorelbine, Gemcitabine, taxanes or Eribulin monotherapy
48347602|NCT00174889|DRUG|Pregnenolone|
48347603|NCT01546090|DRUG|Alprazolam|preoperative administration of an orally 0.50 mg single dose
48347604|NCT01546090|DRUG|placebo|placebo capsules were filled with starch
48347605|NCT02550119|DRUG|Aprepitant|Given PO
48347606|NCT02550119|DRUG|Dexamethasone|Given PO or IV
48347607|NCT02550119|DRUG|Dolasetron Mesylate|Given PO or IV
48347608|NCT02550119|DRUG|Placebo|Given PO
48658676|NCT05163639|PROCEDURE|Non-invasive repeated pairing of cortical and spinal stimulation (SCAP)|Thresholds will be determined as above. Immediately prior to repetitive pairing, a set of 12 TMS pulses will be delivered at 120% threshold to measure the baseline cortical MEP. Likewise, a set of 12 TSCS pulses will be delivered at 120% of threshold to establish the baseline spinal MEP. For each session, baseline maximal pinch dynamometry will be determined. Immediately after the SCAP protocol is completed, response to TMS, TSCS, and maximal pinch dynamometry will be measured again every 10 minutes over the subsequent hour. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
48002529|NCT05564663|BEHAVIORAL|PTSD Coach App + Brief Support|PTSD Coach App + Brief Support will include downloading the PTSD Coach App for personal use and four, brief (\<20 minutes), weekly, individual support sessions. The sessions will focus on the instruction and encouragement of App use and activities (i.e., assessments, self-management strategies, and psychoeducational readings).
48347609|NCT03810053|BEHAVIORAL|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
48347610|NCT04903886|OTHER|observational|observational
48347611|NCT03745404|DRUG|Lidocaine 5% medicated Plaster|
47983816|NCT00853801|BEHAVIORAL|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
48137133|NCT03926624|DRUG|Decitabine|Decitabine
48137134|NCT03926624|DRUG|Mitoxantrone|Mitoxantrone
48137135|NCT03926624|DRUG|Etoposide|Etoposide
48137136|NCT03926624|DRUG|Fludarabine|Fludarabine
48137137|NCT03926624|DRUG|Idarubicin|Idarubicin
48137138|NCT03926624|DRUG|Venetoclax|Venetoclax
48137139|NCT03926624|DRUG|Cladribine|Cladribine
48137140|NCT05274321|DEVICE|Nanodropper|Device used for administering eye drops
48137141|NCT05274321|DEVICE|Standard Eye Dropper|Standard Eye Dropper used for administering eye drops
48137142|NCT01357512|DEVICE|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
48347612|NCT03745404|DRUG|Placebo Plaster|
48347613|NCT01070706|DRUG|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
48347614|NCT04642378|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
48347615|NCT04642378|DRUG|routine insulin treatment regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
48347616|NCT06417398|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
48347617|NCT02897076|DRUG|betamethasone 24 mg|
48347618|NCT02897076|DRUG|12mg betamethasone +placebo|
48347619|NCT01424319|DRUG|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
47914573|NCT03482596|BEHAVIORAL|Reducing/breaking prolonged sitting|"The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour."
47914574|NCT02199600|DEVICE|GMK Sphere Knee Replacement|
48137143|NCT03987646|PROCEDURE|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
48137144|NCT04643574|BIOLOGICAL|NeoTIL|Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
48347620|NCT01424319|DRUG|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
47914575|NCT04845711|OTHER|Control group|patients will receive general anesthesia only.
47914576|NCT04845711|PROCEDURE|Erector spinae plane block group|patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)
48137145|NCT04643574|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
48137146|NCT04643574|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
48137147|NCT04643574|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
48137148|NCT04643574|RADIATION|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
48137149|NCT00343408|DRUG|cediranib maleate|
48137150|NCT00343408|DRUG|cisplatin|
48137151|NCT00343408|DRUG|fluorouracil|
48137152|NCT00343408|DRUG|gemcitabine hydrochloride|
48137153|NCT00343408|DRUG|leucovorin calcium|
48137154|NCT00343408|DRUG|oxaliplatin|
48347621|NCT01424319|DRUG|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
48347622|NCT01858506|PROCEDURE|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
48347623|NCT01858506|PROCEDURE|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
48347624|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
48347625|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
48347626|NCT00255008|BIOLOGICAL|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
48347627|NCT00255008|DRUG|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
48347628|NCT01863706|DRUG|Misoprostol|400µg oral misoprostol
48347629|NCT01863706|DRUG|Oxytocin|20 IU Oxytocin
48347630|NCT04570228|DEVICE|Pulmonary artery denervation|The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
48347631|NCT04570228|DEVICE|Sham procedure|A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
48347632|NCT05765214|BEHAVIORAL|Intervention Group (IG)|"In general, the education will cover:~(i) Colorectal cancer - knowledge, perceptions, self-care, and social norms (CRC-KPSS): Knowledge; Perceptions (perceived susceptibility, perceived severity, perceived benefits, perceived barriers); Self-care; and Social norms; and information on colorectal cancer screening (ii) Healthy nutrition colorectal for cancer risk reduction and complementary to diabetes guideline (increasing consumption of fiber, fruits, vegetables, whole grains, and calcium; reducing red and processed meat, fat, added sugars and alcohol)"
48347633|NCT04100291|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
48347634|NCT04100291|OTHER|Placebo|Placebo by daily enema with placebo mixture
48347635|NCT01245231|GENETIC|protein expression analysis|
48347636|NCT01245231|GENETIC|western blotting|
48347637|NCT01245231|OTHER|flow cytometry|
48347638|NCT01245231|OTHER|laboratory biomarker analysis|
48137155|NCT04399772|BEHAVIORAL|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
48347639|NCT01245231|OTHER|medical chart review|
48347640|NCT05526625|OTHER|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC \& IJV.
48347641|NCT03842501|DIETARY_SUPPLEMENT|Release Supplement|Calorie reduced diet plus Release supplement
48347642|NCT03842501|DIETARY_SUPPLEMENT|Placebo|Calorie reduced diet plus Placebo
48347643|NCT03648411|GENETIC|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
47983817|NCT05091099|DRUG|Alendronate|On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
47983818|NCT04049123|DRUG|LY900014|Administered SC
47983819|NCT04049123|DRUG|Insulin Lispro|Administered SC
47983820|NCT03077750|DRUG|VBP-245 Topical Gel|Topical application BID
48347644|NCT00722098|BIOLOGICAL|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
48347645|NCT00722098|BIOLOGICAL|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
48347646|NCT03229304|OTHER||
48347647|NCT02825940|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
48347648|NCT02825940|DRUG|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m\^2 on Days 1 and 8.
48347649|NCT02825940|DRUG|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m\^2 on Day 1.
48347650|NCT02602704|DRUG|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
48347651|NCT02602704|DRUG|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks
47983821|NCT03077750|DRUG|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
48002530|NCT05564663|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will consist of one brief session (with brochure) of PTSD and AUD psychoeducation and referral information for mental health clinics that provide PTSD services, with encouragement to schedule an appointment at one of the listed clinics to discuss PTSD-related symptoms.
48347652|NCT02282930|DRUG|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
48347653|NCT06015841|BIOLOGICAL|Placebo|The placebo is a solution matching the study vaccine formulation.
48347654|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose A|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
48347655|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose B (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
48501756|NCT03562559|OTHER|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
48501757|NCT05789693|BEHAVIORAL|Physical activity changes|Previously an initial measure (qualitative and qualitative) will be made to know the little active adolescents. At the end of the physical activity program a retention measure will be carried out to know the scope and persistence of the variables analyzed. The intervention will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where there will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all.
48347656|NCT06015841|BIOLOGICAL|ACI-7104.056 at Dose C (optional)|The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
48347657|NCT04951180|OTHER|Demographic data and MRI images extraction|The data were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.
48347658|NCT01880203|PROCEDURE|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
48347659|NCT05193929|DEVICE|OptiPulse™|TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait
48347660|NCT05193929|DEVICE|Standard of Care offloading device|CAM boot
48347661|NCT05655728|DRUG|Metformin|The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose \[maximum: 1500 mg/day\]).
48347662|NCT05655728|OTHER|Placebo|The participants will receive treatment of placebo.
48347663|NCT02702284|BEHAVIORAL|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
47983822|NCT01450839|DRUG|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
47983823|NCT01450839|DRUG|Placebo|Matching Placebo tablets and tape
47983824|NCT04334408|DRUG|Fremanezumab|Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
48137156|NCT04399772|BEHAVIORAL|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
48137157|NCT01905800|DEVICE|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
48137158|NCT05501652|DEVICE|ALV1System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
48137159|NCT04000750|OTHER|Time Restricted Eating|Diet will be tracked and reported every day to a qualified dietitian.
48347664|NCT02702284|BEHAVIORAL|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
48347665|NCT02668692|DRUG|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
48347666|NCT02668692|DRUG|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
48347667|NCT00446797|DRUG|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
48347668|NCT00446797|DRUG|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
48347669|NCT01086449|BIOLOGICAL|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
48658677|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)|Intraoperative: Spinal and cortical thresholds will be determined. Immediately prior to repetitive pairing, a set of 12 baseline cortical pulses and 12 baseline spinal pulses will be delivered at 120% threshold. SCAP protocol will be applied, both of which have been successful at inducing lasting effects in the rat. After pairing, cortical stimulation at 120% of threshold and spinal cord stimulation at 120% threshold will be repeated every 10 minutes for the duration of surgery. In a subset of patients repeated pairing will be conducted with a latency that investigator does not expect will induce SCAP, or with electrodes placed over the ventral epidural surface. The control intervention will include repeated pairing at a non-convergent latency, as well as pairing of cortical stimulation with ventral epidural stimulation.
48658678|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region|As per the intervention 'Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)' targeted at or below myelopathic region.
47983825|NCT04334408|DRUG|Placebo|Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
48137160|NCT04000750|OTHER|Normal Feeding|Diet will be tracked and reported every day to a qualified dietitian.
48137161|NCT04000750|OTHER|Resistance Training|8 weeks of supervised and programmed whole body resistance training, performed 4x per week
48137162|NCT04000750|DIETARY_SUPPLEMENT|Whey Protein|Consumed on all exercise days.
48347670|NCT03080532|OTHER|dietary habits|
48347671|NCT05588713|PROCEDURE|Brief assessment protocol|The intervention constitutes of a brief assessment protocol for assessing ADHD.
47983826|NCT00150722|DRUG|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
48347672|NCT05588713|PROCEDURE|Comprehensive assessment protocol|The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.
48347673|NCT04533516|OTHER|Manual therapy technics|Manual therapy technics
47983827|NCT03051607|DRUG|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
48347674|NCT04533516|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training
48347675|NCT00389805|DRUG|bortezomib|
48347676|NCT00389805|DRUG|pemetrexed disodium|
48347677|NCT00389805|GENETIC|gene expression analysis|
48347678|NCT00389805|GENETIC|mutation analysis|
48347679|NCT00389805|GENETIC|protein expression analysis|
48347680|NCT00389805|GENETIC|reverse transcriptase-polymerase chain reaction|
48347681|NCT00389805|OTHER|flow cytometry|
48347682|NCT00389805|OTHER|immunoenzyme technique|
48347683|NCT00389805|OTHER|immunohistochemistry staining method|
48347684|NCT00504192|DRUG|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
48347685|NCT03138291|DEVICE|Somnodent|Each pregnant women will be treat with a Somnodent
47983828|NCT03491241|DIETARY_SUPPLEMENT|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
47983829|NCT02066233|DEVICE|EG Scan II (transnasal endoscopy)|
48137163|NCT06132594|PROCEDURE|Conventional arthrocentesis followed by I-PRF injection|An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.
48347686|NCT04861636|BEHAVIORAL|HealthTRAC|Behavioral weight management intervention targeting emotion regulation skill building. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
48347687|NCT04861636|BEHAVIORAL|SBWC|Behavioral intervention focused on behavioral weight control. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
48347688|NCT05596474|DIETARY_SUPPLEMENT|Beet-root juice|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
48347689|NCT05596474|RADIATION|red-light therapy|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
48658679|NCT02215473|DRUG|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
48658680|NCT02215473|PROCEDURE|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
48658681|NCT05495568|BIOLOGICAL|CT-P17|CT-P17 40mg will be subcutaneous administered
47983830|NCT02066233|PROCEDURE|Standard Endoscopy|
47983831|NCT06477458|OTHER|Single inspiratory phase computed tomography.|Utilizing deep learning technology in conjunction with single inspiratory phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
47983832|NCT06477458|OTHER|Respiratory dual-phase computed tomography.|Utilizing deep learning technology in conjunction with respiratory dual-phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
47983833|NCT03662685|OTHER|Goeckerman Therapy|The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.
47983834|NCT03662685|DRUG|Crude Coal Tar Only|A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.
47983835|NCT03662685|DEVICE|Phototherapy Only|Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
47983836|NCT02392247|DEVICE|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
47983837|NCT01910610|BIOLOGICAL|FOLFIRI-cetuximab|
47983838|NCT01910610|BIOLOGICAL|mFOLFOX6-bevacizumab|
48658682|NCT05495568|BIOLOGICAL|EU-approved Humira|subcutaneous administration
48658683|NCT04480866|DEVICE|Colli-Pee® (FV5000 and Small Volumes)|"Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order."
48658684|NCT01232140|OTHER|CRP-guided antibiotic treatment|If CRP\> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
47983839|NCT01910610|BIOLOGICAL|OPTIMOX-bevacizumab|
47983840|NCT01910610|BIOLOGICAL|irinotecan-based chemo + bevacizumab|
47983841|NCT01910610|BIOLOGICAL|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
47983842|NCT01910610|BIOLOGICAL|XELOX + bevacizumab|
47983843|NCT04962633|OTHER|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
48347690|NCT05596474|DIETARY_SUPPLEMENT|Placebo|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
48347691|NCT05596474|RADIATION|sham light|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
48347692|NCT06147336|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, fixated within the inter-atrial septum.
48347693|NCT05892536|PROCEDURE|dental regenerative endodontics|regenerative procedures performed in necrotic mature permanent teeth
48347694|NCT00419835|DRUG|enalapril|
48347695|NCT00419835|DRUG|losartan|
48347696|NCT03634293|DRUG|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
48347697|NCT03634293|DRUG|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
48347698|NCT01425307|DRUG|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
48347699|NCT05307523|DEVICE|Enriched Play Environment with Partial Body Weight Support Harness|A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
48347700|NCT05307523|OTHER|Enriched Play Environment without Partial Body Weight Support Harness|Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
48347701|NCT02237365|DRUG|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
48347702|NCT02237365|DRUG|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
48347703|NCT02237365|DRUG|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
48347704|NCT00373464|DRUG|etoricoxib|
48347705|NCT00354952|DRUG|Macrolides (azithromycin or clarithromycin)|
48501758|NCT05775952|BIOLOGICAL|HRV-39|We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
47914577|NCT04845711|PROCEDURE|Quadratus lumborum block group|patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
48347706|NCT01780207|DEVICE|PFO Closure|
48347707|NCT01006694|OTHER|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
48347708|NCT01006694|DRUG|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
48347709|NCT05509491|BEHAVIORAL|A postural awareness program with exercises|A program about postural awareness, bad posture, good posture and their effects on daily life
48347710|NCT00666536|DRUG|valsartan and amlodipine|
48347711|NCT00666536|DRUG|valsartan and amlodipine|
48347712|NCT00432354|DRUG|atorvastatin|
48347713|NCT00521118|OTHER|Laboratory Biomarker Analysis|Correlative studies
48347714|NCT00521118|PROCEDURE|Therapeutic Conventional Surgery|Undergo second curettage
48347715|NCT06175754|PROCEDURE|Laser ablation|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser
48347716|NCT06175754|PROCEDURE|Laser with Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy
48347717|NCT06175754|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
48501759|NCT05358470|OTHER|Exercise therapy and adapted physical activity-based program|Exercise therapy and adapted physical activity program based on racket sports
48501760|NCT00000535|BEHAVIORAL|diet, reducing|
48501761|NCT00000535|BEHAVIORAL|diet, sodium-restricted|
47914578|NCT04181125|OTHER|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
48347718|NCT04437810|BIOLOGICAL|Albumin|- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
48347719|NCT04437810|OTHER|Standard Medical Treatment|standard medical therapy
48347720|NCT02606344|OTHER|Mico-finance based intervention|
48347721|NCT04662645|OTHER|Palliative Therapy|Undergo embedded palliative care
48347722|NCT04662645|OTHER|Questionnaire Administration|Ancillary studies
48347723|NCT00030160|BEHAVIORAL|Strength Training|
48501762|NCT01034254|BIOLOGICAL|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
48347724|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
48347725|NCT01681836|DRUG|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
48347726|NCT02918721|DEVICE|Restylane Lidocaine|Intradermal injection
48347727|NCT02918721|DEVICE|Restylane|Intradermal injection
48347728|NCT06071923|DEVICE|Fibroscan|Scan the liver for metabolic fatty changes
48347729|NCT02915692|DEVICE|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
48347730|NCT02915692|DEVICE|Comparator Silver Coated Catheter|Foley catheter coated with silver
48347731|NCT01039038|RADIATION|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
48347732|NCT05056636|DIAGNOSTIC_TEST|Plasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.|"Screening Visit 1:~1. Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr)~2. Female patient will first screened by lyso-GB3 (Cutoff: \> 5ng/ml)~Screening Visit 2:~If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: \> 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing."
48347733|NCT04282460|BEHAVIORAL|Baduanjin practice|Use the Baduanjin training system to practice the whole set of Baduanjin at least once a day and at least 5 days each week for 3 months.
48347734|NCT04282460|BEHAVIORAL|Regular physical exercise|Take physical exercise for at least half an hour every day in addition to regular physical activities at school.
48347735|NCT05831514|OTHER|Mobile Application Supported Education Program (G-MUEP)|Parents who meet the inclusion criteria will use the Mobile Application Supported Education Program (G-MUEP).
48347736|NCT04964804|PROCEDURE|real-time ultrasound-CT fusion imaging|selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging
48347737|NCT04964804|PROCEDURE|ultrasound alone|selective lumbar nerve root block puncture under the guidance of ultrasound alone
48347738|NCT01838655|DRUG|Nitisinone|Oral dose of 2mg daily for 12 months.
48347739|NCT01194414|DRUG|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
48347740|NCT01194414|DRUG|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
48658685|NCT03085953|BEHAVIORAL|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
48658686|NCT03085953|OTHER|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
48347741|NCT01194414|DRUG|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
48347742|NCT01194414|DRUG|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
48347743|NCT01194414|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
48347744|NCT06398665|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting motor threshold (MT)
48347745|NCT03645915|OTHER|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
48347746|NCT03019172|COMBINATION_PRODUCT|Lactobacillus reuteri|Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5\*10\^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
48347747|NCT03019172|DIETARY_SUPPLEMENT|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
48658687|NCT03985527|DEVICE|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
48658688|NCT03761706|BEHAVIORAL|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
48347748|NCT05590104|PROCEDURE|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
48347749|NCT03592394|DEVICE|Immersive Virtual Reality (Gear VR)|Immersing the user in a total visual environment.
48347750|NCT04017624|OTHER|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
48347751|NCT04017624|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
48347752|NCT01234311|DRUG|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
48347753|NCT01234311|DRUG|Placebo|
48347754|NCT04629365|OTHER|Ketogenic Diet|KD group consumed less than 50g/day of carbohydrates
48347755|NCT04629365|OTHER|Normal Diet|ND group consumed 55% of the caloric intake from carbohydrates
48347756|NCT02823236|DRUG|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
48347757|NCT02823236|DRUG|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
48347758|NCT02823236|DRUG|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
48347759|NCT01226472|BIOLOGICAL|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
48347760|NCT04290260|OTHER|Use of breast bra|Patients will use a breast from admission to hospital discharge
48347761|NCT04290260|OTHER|Usual care (not use of bra)|
48347762|NCT04270565|BEHAVIORAL|In-Field Gait-Training|The intervention will deliver a series of vibrations on the participants' wrists through the Garmin when the sensors indicate that their contact time in milliseconds exceeds a threshold. The runners will be asked to reduce the amount of time their foot is in contact with the ground by picking their feet up more quickly. Participants will also receive a series of exercises based on noted impairments at baseline. The feedback during running will be completed twice per week for four weeks.
48501763|NCT01034254|BIOLOGICAL|saline placebo|Vaccination of pregnant women with saline placebo.
48658689|NCT03761706|OTHER|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
48658690|NCT01817400|OTHER|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
48347763|NCT04270565|BEHAVIORAL|Home Exercise|Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.
48347764|NCT01240967|DRUG|TC-5214|Oral tablets, single dose
48347765|NCT06343129|BEHAVIORAL|Dietary education program|"Jumpstart educational program:~https://www.rochesterlifestylemedicine.com/about-community-jumpstart/"
48347766|NCT01855490|DRUG|Exenatide|
48347767|NCT04878289|BEHAVIORAL|TOTAL with Motivational Telemedicine Sessions|Teaching Obesity Treatment Options to Adult Learners Educational Video with 3, 30 minute motivational sessions at 1 week, 6 months, and 12 months after viewing video
48347768|NCT02253160|DEVICE|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
48347769|NCT02253160|DEVICE|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
48347770|NCT02253160|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
48501764|NCT02150135|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
48658691|NCT01817400|DIETARY_SUPPLEMENT|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
48137164|NCT06132594|PROCEDURE|3d surgical guided Arthrocentesis followed by I-PRF injection|Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
48137165|NCT01223924|OTHER|placebo|placebo
48137166|NCT01223924|DRUG|M2ES|M2ES IV 7.5mg-90mg
48137167|NCT01759862|DRUG|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
48137168|NCT01759862|OTHER|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
48137169|NCT01759862|DRUG|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
48137170|NCT05923190|DRUG|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
48137171|NCT05923190|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
48658692|NCT01817400|DRUG|Aspirin|
48658693|NCT01817400|DRUG|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
48137172|NCT05486494|OTHER|Treatment (non- surgical/surgical)|Treatment Outcome based on different aspects
48501765|NCT00000474|BEHAVIORAL|behavior therapy|
48658694|NCT05406713|DRUG|Pembrolizumab|400 mg intravenously
48658695|NCT06602011|COMBINATION_PRODUCT|TACE, Lenvatinib, combined with Tislelizumab group|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.
48658696|NCT06527274|DEVICE|Experimental: Myopic defocus soft lens design (MDSL)|An optical device designed to provide a myopic defocus to control myopia progression
48137173|NCT03725020|OTHER|Fluoride varnish|The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
48137174|NCT05609149|PROCEDURE|total mesorectal excision|patients must underwent total mesorectal excision
48658697|NCT06527274|DEVICE|Active Comparator: Single vision soft lens design (SVSL|An optical device designed to correct refractive error like myopia
48137175|NCT05240300|BIOLOGICAL|BX005-A|phage gel
48137176|NCT05240300|OTHER|Placebo|vehicle gel
48137177|NCT03961451|DEVICE|Podometer|Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
48347771|NCT02940197|BEHAVIORAL|MediterrAsian diet|no other description
48347772|NCT00004056|BIOLOGICAL|filgrastim|
48347773|NCT00004056|DRUG|asparaginase|
48347774|NCT00004056|DRUG|cytarabine|
48347775|NCT00004056|DRUG|daunorubicin hydrochloride|
48347776|NCT00004056|DRUG|melphalan|
48347777|NCT00004056|DRUG|thioguanine|
48347778|NCT00004056|PROCEDURE|peripheral blood stem cell transplantation|
48347779|NCT03342404|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
48347780|NCT03342404|OTHER|Placebo|Placebo, Subcutaneous, every 21 days
48347781|NCT03342404|OTHER|Best Supportive Care (BSC)|Best Supportive Care (BSC)
48347782|NCT00284336|DRUG|Caelyx|
48347783|NCT00284336|DRUG|endoxan|
48137178|NCT04437043|OTHER|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
48501766|NCT03828513|DEVICE|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
48658698|NCT02875418|DEVICE|EUM|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
48658699|NCT02875418|DEVICE|Tocodynamometry|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
48658700|NCT06456892|DRUG|Pucotenlimab|Pucotenlimab Combined with Standard Chemotherapy Regimen
47914579|NCT04181125|OTHER|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
48137179|NCT00244673|BIOLOGICAL|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
48137180|NCT01981603|OTHER|navigator|
48347784|NCT02774044|DRUG|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
48347785|NCT02774044|DRUG|Survanta|
48347786|NCT00299416|DRUG|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
48347787|NCT00299416|PROCEDURE|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
48347788|NCT03365440|DEVICE|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
48347789|NCT05094570|DRUG|Dupilumab Prefilled Syringe|Dupilumab 300 mg
48347790|NCT02615262|DRUG|Dexamethasone|
48347791|NCT02615262|DRUG|Placebo|0.9% Sodium Chloride
48347792|NCT02802956|OTHER|Daily Life Promotion Program|Daily Life Promotion Program
48347793|NCT02802956|OTHER|general rehabilitation treatment|general rehabilitation treatment
48347794|NCT04944758|DEVICE|Light therapy|Light therapy
48658701|NCT02133079|BIOLOGICAL|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
48658702|NCT05299580|DRUG|dabrafenib|Dabrafenib 150 mg bid
48658703|NCT05299580|DRUG|Trametinib|Trametinib 2mg qd
48137181|NCT05305508|DRUG|Calcium Dobesilate|The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
48347795|NCT03415672|BIOLOGICAL|HBVaxPro|Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
48347796|NCT03415672|BIOLOGICAL|HBAI20|Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
48347797|NCT03424044|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
48347798|NCT03424044|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
48658704|NCT06307457|DRUG|Palbociclib in combination with AI|Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI as first-line treatment, in Denmark.
48658705|NCT04070703|BEHAVIORAL|The Go for Exercise & Healthy Aging Project|Exercise and Cognition
48658706|NCT04861701|BEHAVIORAL|Static stretching exercise|The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
48137182|NCT05305508|DRUG|Mannitol|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
48347799|NCT03424044|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
48347800|NCT03424044|DRUG|XeriSol glucagon|XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
48347801|NCT04889612|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
48347802|NCT04889612|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
48347803|NCT02727504|DEVICE|Electrocardiogram|ECG at inclusion and M12
48347804|NCT02727504|DEVICE|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
48347805|NCT02727504|DEVICE|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
48501767|NCT03828513|DEVICE|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2\> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
48501768|NCT03816852|BIOLOGICAL|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
48501769|NCT03069950|DRUG|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
48501770|NCT03069950|DRUG|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
48658707|NCT02081703|DRUG|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
48658708|NCT02081703|DRUG|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
48658709|NCT02081703|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
48658710|NCT02081703|DRUG|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
48658711|NCT06368206|DEVICE|Investigational device Aktiia G2C|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
48658712|NCT06368206|DEVICE|Marketed device used as reference for blood pressure monitoring: double auscultation cuff|Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
48658713|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
48658714|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
48658715|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
48658716|NCT06368206|DEVICE|Marketed device used as reference for pulse rate monitoring: pulse finger oximeter|Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.
48658717|NCT01215331|DRUG|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
48137183|NCT02944123|DRUG|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
48501771|NCT03069950|DRUG|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
47914580|NCT01629225|DRUG|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
47914581|NCT05349006|DRUG|Azathioprine|Dose related to weigh (100 mg for \<50 kg, 150 mg 50-100 kg, 200 mg for \>100 kg) = 2 to 4 50mg oral caps, daily, during all the study period
47914582|NCT05349006|OTHER|Placebo|Dose related to weigh (100 mg for \<50 kg, 150 mg 50-100 kg, 200 mg for \>100 kg) = 2 to 4 50mg oral caps, daily, during all the study period
48347806|NCT02727504|BIOLOGICAL|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
48347807|NCT02727504|DEVICE|Cardiac MRI|Cardiac MRI at inclusion
48347808|NCT02727504|DEVICE|Cardiac scanner|Cardiac scanner at inclusion
48347809|NCT02727504|OTHER|6-minutes walking test|6-minutes walking test at inclusion and M12
48347810|NCT02727504|OTHER|Duke Activity Score|Duke Activity Score at inclusion and M12
48347811|NCT01641224|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
48347812|NCT01641224|DEVICE|Atractylodes|Atractylodes (\~10-15g)
48347813|NCT01641224|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
48347814|NCT01641224|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
48347815|NCT01641224|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
48347816|NCT01641224|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
48347817|NCT01641224|DRUG|Radix curcumae|Radix curcumae (\~10g)
48347818|NCT01641224|DRUG|Fingered citron|Fingered citron (\~10g)
48347819|NCT01641224|DRUG|Tuckahoe|Tuckahoe (15g)
48501772|NCT03069950|DRUG|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
48347820|NCT01641224|DRUG|Placebo|Placebo is blindly given to patients.
48347821|NCT00469040|DRUG|GW642444M for 14 days|M salt
48501773|NCT03069950|DRUG|DEXAMETHASONE|flat dose of 25 mg on Day 1
48658718|NCT01215331|DRUG|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
48501774|NCT03069950|DRUG|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
48501775|NCT04322110|OTHER|PronoKal Method|Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support
48501776|NCT04322110|OTHER|Low calorie diet|Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
48501777|NCT01502410|DRUG|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
48658719|NCT03220633|DRUG|ATB-346|
48658720|NCT03220633|DRUG|Placebo|
48347822|NCT04720560|DIAGNOSTIC_TEST|regulatory B cell by flow cytometry|"4-Evaluation of the Frequency of regulatory B cells (Bregs) by Flow Cytometry Using flow cytometry, circulating Bregs will be detected using FITC-conjugated-CD38, PE-conjugated-CD24 (Bioscience, USA), and PerCP-conjugated CD19 (BD Bioscience, USA). Briefly, 100 µl of blood sample will be incubated with 10 µL of CD24, CD38 and CD19 for 20 minutes at 4 °C in the dark. Following incubation, RBCs will be lysed and washed. Cells will be fixed and permeabilized then stained with APC-conjugated IL-10 (BD Bioscience, San Jose, CA, USA) and analysis will be done by FACS Calibur flow cytometry with CellQuest software (Becton Dickinson Biosciences, San Jose, CA, USA).~An isotype-matched negative control will be used for each sample. Forward and side scatter histograms will be used to define the lymphocytes population. CD19+ IL-10+ B cells will be gated, then the expression of CD38 and CD24 on the CD19+B cells will be detected. Bregs will be identified as CD19+ IL-10+CD24+hiCD38+hi cells."
48347823|NCT00783549|DRUG|an undetermined dose of GSK1292263|GSK investigational product or placebo
48347824|NCT00783549|DRUG|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
48501778|NCT01502410|OTHER|pharmacological study|Optional correlative studies
48501779|NCT01502410|OTHER|laboratory biomarker analysis|Optional correlative studies
48501780|NCT02051400|DEVICE|the McGrath® MAC video laryngoscope|
47914583|NCT06087627|DRUG|Dupilumab SAR231893 (REGN668)|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
48347825|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
48347826|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposures.
48347827|NCT00783549|DRUG|ascending dose of GSK1292263|An ascending dose based on target exposure
48347828|NCT04710992|PROCEDURE|Isolated needling procedure|The needle will be inserted into the common extensor tendon of the epicondyle (dominant elbow) for 90 seconds without galvanic current.
48347829|NCT04710992|PROCEDURE|Low intensity percutaneous electrolysis|Once the needle is located in the common extensor tendon of the epicondyle (dominant elbow), a single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.
48347830|NCT04710992|PROCEDURE|High intensity percutaneous electrolysis|The needle will be inserted in the target position during the same time as in the other groups (90 seconds). During the first stage of intervention the needle will be imbedded without galvanic current and when the end of the application time approaches (approximately 75 seconds) three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
48347831|NCT01789710|DRUG|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
48347832|NCT01789710|DRUG|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
48501781|NCT02051400|DEVICE|the GlidesScope® Ranger video laryngoscope|
48501782|NCT02051400|DEVICE|the Macintosh laryngoscope|
48501783|NCT02662660|DRUG|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
48501784|NCT02662660|DRUG|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
48347833|NCT01789710|BEHAVIORAL|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
48501785|NCT02662660|DRUG|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
48347834|NCT04856215|DRUG|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The Investigational Medicinal Product (IMP) consist of 1) 111Indium- and 2) 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody.~The anti-CD66 is a murine IgG1 monoclonal antibody originally developed as an in vivo leucocyte and bone marrow imaging agent (Boßlet 1985, Thomsen 1991). BW 250/183 anti-CD66 is a murine IgG1 kappa monoclonal antibody, originally produced as an anti-CEA antibody.~The batch of antibodies required for treatment will be radiolabelled by Royal Free Hospital radiology team with Indium 111 and Y90 for patient."
48658721|NCT03388827|DEVICE|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
48658722|NCT03388827|DRUG|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
48658723|NCT06335212|DEVICE|Single vision and multifocal contact lenses|Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia.
48658724|NCT05493657|DRUG|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
48658725|NCT05493657|DRUG|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
48658726|NCT05401799|DEVICE|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
48658727|NCT05401799|PROCEDURE|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
48347835|NCT01905306|PROCEDURE|computer guided implant planning|
48347836|NCT01905306|PROCEDURE|free hand implants placement|
47983844|NCT04962633|OTHER|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
47983845|NCT05641233|RADIATION|Stereotactic radiotherapy|Preoperative radiotherapy delivered in a single fraction of 12 Gy focussed on 4cm pancreas at the intended (i.e. future) anastomotic site.
48618207|NCT01911091|BEHAVIORAL|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
48658728|NCT06172023|DRUG|Silver Nanoparticles Irrigant|Nanosilver irrigant solution
48658729|NCT06172023|DRUG|Chitosan Nanoparticles Irrigant|Chitosan nanoparticles irrigant solution
48658730|NCT05750784|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
48137184|NCT02944123|DRUG|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
48137185|NCT02944123|DRUG|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
48137186|NCT02230046|DRUG|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
48347837|NCT03826693|DRUG|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
48347838|NCT03826693|DRUG|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
48347839|NCT06070727|OTHER|Obturator|Evaluation of patient satisfaction and oral healthy related quality of life of Polyetherketoneketone(PEKK) and metal framework for management of maxillectomy cases.
48347840|NCT06331273|PROCEDURE|"Liver transplantation with No-touch technique"|"The core principle of no-touch tumor surgery revolves around avoiding direct contact with the tumor or surrounding tissues as much as possible to minimize the release of cancer cells into the bloodstream or nearby tissues."
48347841|NCT01432938|BIOLOGICAL|dulaglutide|Administered subcutaneously
48347842|NCT01432938|DRUG|Warfarin|Administered orally
48347843|NCT00262327|DRUG|Antangiogenesis|
48347844|NCT00262327|GENETIC|endostatin gene|
48347845|NCT04888182|DIETARY_SUPPLEMENT|intervention|a protein intake of ≥25 E%. An oral nutritional supplement (containing 1570 kJ/100 g and 92 g protein/100 g. Atpro 200) was used as supplement to the patients' habitual diet.
48347846|NCT00058188|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
48347847|NCT00058188|DRUG|calcium gluconate|Given orally
48347848|NCT00058188|DRUG|zoledronic acid|Given IV
48347849|NCT04135664|PROCEDURE|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
48501786|NCT04129359|BEHAVIORAL|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
48501787|NCT04129359|OTHER|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
48658731|NCT03253237|DEVICE|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
48347850|NCT04135664|COMBINATION_PRODUCT|chemoradiation|concurrent chemotherapy and radiotherapy
48347851|NCT04135664|OTHER|active surveillance|No further adjuvant therapy
47914584|NCT01252732|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
48347852|NCT02306941|BEHAVIORAL|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
48347853|NCT03408886|DRUG|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
47983846|NCT05040841|BEHAVIORAL|M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result|"Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1."
48347854|NCT03408886|DRUG|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
48347855|NCT03408886|BIOLOGICAL|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
48347856|NCT02289521|DEVICE|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~* Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~* Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
48347857|NCT04870255|DEVICE|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
48347858|NCT04870255|DEVICE|Dorsomedial Prefrontal Cortex (DMPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
48347859|NCT04870255|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
48347860|NCT04868162|DRUG|MRG003|Administered intravenously
48658732|NCT04171960|DIAGNOSTIC_TEST|Blood draw|Venous whole blood collection within 12 hours and 12-24 hours following injury.
48658733|NCT04171960|OTHER|Outcome assessments|Administered at baseline.
48347861|NCT03588104|DEVICE|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
48347862|NCT03588104|OTHER|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
47914585|NCT01252732|DRUG|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
48501788|NCT06000774|OTHER|Therapeutic Ketogenic Diet|therapeutic ketogenic diet
48501789|NCT02711735|BIOLOGICAL|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
48658734|NCT05446207|OTHER|Routine Physiotherapy and Task-oriented Training|The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.
48347863|NCT00576147|DEVICE|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
48347864|NCT02490241|DRUG|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
48347865|NCT01681290|DRUG|CBX129801|
48347866|NCT00864123|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
48347867|NCT00864123|DRUG|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
48501790|NCT02711735|BIOLOGICAL|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
48658735|NCT05446207|OTHER|Music Therapy and Task oriented Training with Routine Physiotherapy|Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
48658736|NCT06053372|DEVICE|Apple Watch|Wearable monitor for heart rate and arrhythmia detection
48658737|NCT01489137|DRUG|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
48658738|NCT06540976|BEHAVIORAL|Cognitive testing|Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.
47983847|NCT05040841|BEHAVIORAL|M2/PRM: Immediate outreach to subject after a missed pharmacy refill|The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
48501791|NCT04457336|DRUG|Tildacerfont/Placebo|Tablet, administered daily
48658739|NCT04870515|OTHER|Best Practice|Receive standard lifestyle recommendations
48658740|NCT04870515|OTHER|Dietary Intervention|Receive dietary instructions
48658741|NCT04870515|OTHER|Exercise Intervention|Complete aerobic and strength/resistance exercises
48658742|NCT04870515|OTHER|Quality-of-Life Assessment|Ancillary studies
48347868|NCT00864123|DRUG|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
48347869|NCT05609136|OTHER|Bobath+Scapular Stabilization Exercises|Scapular stabilization exercises will be given to patients in addition to Bobath therapy. It will be applied with the patient in a sitting position, with the shoulder at 90 degrees and the elbow extended. The patient will be given exercises with isometric contraction while the shoulder is in protraction and retraction by the physiotherapist. Isometric contraction will last for 5 seconds and each exercise will be repeated 2x15 times. There will be a 1-minute rest period between sets. The exercises will be performed in 2 different positions, in the flexion position and in the diagonal position.
48501792|NCT01794026|PROCEDURE|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
48501793|NCT03856112|DRUG|Dexamethasone|Given PO
48501794|NCT03856112|DRUG|Ixazomib|Given PO
48658743|NCT04870515|OTHER|Questionnaire Administration|Ancillary studies
48658744|NCT02502552|OTHER|blood specimen|blood specimen
48658745|NCT05145010|DRUG|Infigratinib|Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
48658746|NCT05145010|DRUG|Infigratinib|Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
48658747|NCT05479370|BIOLOGICAL|Flublok Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
48658748|NCT05479370|BIOLOGICAL|Fluarix Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
48658749|NCT05479370|BIOLOGICAL|Flucelvax Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
48501795|NCT03856112|DRUG|Ixazomib Citrate|Given PO
48501796|NCT03856112|DRUG|Venetoclax|Given PO
48501797|NCT05522985|DRUG|Triprilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
48501798|NCT02777073|DRUG|Victoza|Single dose of Liraglutide
48501799|NCT02777073|DRUG|Placebo|Single dose of generic placebo
48501800|NCT02777073|DRUG|Dapagliflozin 10mg Tab|single dose of 10 mg dapagliflozin
48658750|NCT06616415|DRUG|Belumosudil|Pharmaceutical form: Tablet Route of administration: Oral
48658751|NCT02245659|DEVICE|CPAP|Continuous Positive Airway Pressure
48658752|NCT02245659|OTHER|Nasal dilator strip|Nasal dilator strip to be worn nightly
48658753|NCT06611306|RADIATION|DE-iPTV|Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
48658754|NCT06213480|DIETARY_SUPPLEMENT|Synbiotic Group|"WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
48658755|NCT06213480|OTHER|Placebo Group|Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
48658756|NCT03592264|DRUG|OBI-3424|liquid formulation for Intravenous infusion
48658757|NCT03926013|DRUG|JNJ-63898081|JNJ-63898081 will be administered.
48658758|NCT03664544|DRUG|MCI-186|30 mg MCI-186 will be administered intravenously over 60 minutes.
48137187|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
48137188|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
48347870|NCT02809118|DRUG|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
48347871|NCT02809118|DRUG|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
48347872|NCT02809118|OTHER|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
48501801|NCT02792608|BEHAVIORAL|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
48501802|NCT04201886|OTHER|serum calprotectin|serum calcium binding leucocyte protein
48501803|NCT00351533|DRUG|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
48501804|NCT02689050|DEVICE|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
48501805|NCT00714896|BEHAVIORAL|Stepped-Care|"* stage-based expert system written intervention at baseline and 3 months~* in-person stage appropriate counseling at baseline and 3 months~* telephone counseling sessions at weeks 2,4 and 8,~* as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~* optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
48501806|NCT00714896|BEHAVIORAL|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
48658759|NCT05408780|DRUG|AC-OLE-01-VA|formulation of tricaprilin or matching placebo
48347873|NCT03597789|BEHAVIORAL|Helping the Noncompliant Child (HNC)|HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
48347874|NCT01347073|DRUG|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
48347875|NCT01167088|DRUG|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
48347876|NCT01167088|DRUG|Placebo|Placebo
48347877|NCT03779906|DRUG|Isovue|Isovue will be given to all subjects per the standard of clinical care.
48658760|NCT05653206|PROCEDURE|Nonsurgical treatment|Cervical collar, Halo ring, Halo vest, cervical braces, skeletal skull traction, MAP, steroids, observation or bedrest
48347878|NCT03938636|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
48347879|NCT00227968|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
48347880|NCT00227968|BEHAVIORAL|Clinical Status and Symptom Response Therapy (CSSRT)|
48658761|NCT05653206|PROCEDURE|Surgical treatment|Anterior discectomy and instrumented fusion (single level), Anterior discectomy and instrumented fusion (multi-level), Posterior decompression-laminectomy, Posterior decompression-laminoplasty, Posterior decompression and instrumented fusion, Combined anterior and posterior decompression and instrumented fusion
48658762|NCT03847584|OTHER|Survey|The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
48658763|NCT02174237|DRUG|LNP1892|Tablets of two strengths (5 and 25 mg)
48658764|NCT02174237|DRUG|Placebo|Matching placebo
48658765|NCT05652569|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) on metastatic biopsy lesions
48347881|NCT03878160|OTHER|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use a semi-structured interview guide. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
48347882|NCT06020768|OTHER|the bed-head was raised to an angle of 0, 20, 30 and 45 degrees|With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
48347883|NCT04130100|BIOLOGICAL|Low Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
48347884|NCT04130100|BIOLOGICAL|High Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
48347885|NCT04130100|DRUG|Sodium Hyaluronate|Sodium Hyaluronate injection
48347886|NCT03931980|PROCEDURE|Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection|we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
48347887|NCT02236650|BEHAVIORAL|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
48347888|NCT02236650|OTHER|Treatment as Usual|Treatment as Usual for 4 weeks
48347889|NCT00593775|PROCEDURE|assisted hatching|assisted hatching with laser
48347890|NCT02966899|DIETARY_SUPPLEMENT|Omega-3 fatty acids|
48347891|NCT01720472|GENETIC|Biomarker studies|
48347892|NCT01712191|DEVICE|NUsurface Meniscus Implant|
48501807|NCT02450955|OTHER|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
48501808|NCT02450955|OTHER|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
48501809|NCT06476951|BEHAVIORAL|Parent-Child Physical Activity Program|The program includes online education, parent-child games, parent-child dancing, and other parent-child physical activity activities.
48501810|NCT01796912|OTHER|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
48501811|NCT01796912|OTHER|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
48501812|NCT01051219|DRUG|Losartan|50 milligrams to be taken orally, daily
47983848|NCT05040841|BEHAVIORAL|M3/EAM: Immediate outreach to subject after EAM-identified missed doses|The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
48347893|NCT06188260|DRUG|Systane COMPLETE Lubricant Eye Drops|Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
48501813|NCT05824416|DEVICE|Experimental: ALBA|"Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension."
48347894|NCT00002981|PROCEDURE|positron emission tomography|
48347895|NCT00002981|RADIATION|fludeoxyglucose F 18|
48347896|NCT00002981|RADIATION|methionine C 11|
48347897|NCT01572636|DRUG|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
48347898|NCT02974660|DRUG|Protamine sulfate|
48347899|NCT02974660|DRUG|0.9% NaCl|
48347900|NCT00000767|BIOLOGICAL|TBC-3B Vaccine|
48347901|NCT00000767|BIOLOGICAL|Smallpox Vaccine|
48347902|NCT01386190|OTHER|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
48347903|NCT04958525|PROCEDURE|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
48347904|NCT04958525|PROCEDURE|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
48137189|NCT03388736|BEHAVIORAL|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
48137190|NCT05558072|GENETIC|Toll-like receptor 4|Toll-like receptor 4
48137191|NCT00963092|GENETIC|DNA analysis|
48137192|NCT00963092|GENETIC|RNA analysis|
48137193|NCT00963092|GENETIC|microarray analysis|
48137194|NCT00963092|GENETIC|protein analysis|
48137195|NCT00963092|OTHER|cytology specimen collection procedure|
48137196|NCT00963092|OTHER|laboratory biomarker analysis|
48137197|NCT00963092|OTHER|questionnaire administration|
48137198|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|2 capsules - 200 mg total CoQ10
48137199|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP1)|2 softgels - 200 mg total CoQ10
48137200|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP2)|2 softgels - 200 mg total CoQ10
48347905|NCT02853786|BEHAVIORAL|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
48347906|NCT02853786|OTHER|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
48347907|NCT02861118|OTHER|No Intervention|
48347908|NCT01438775|DRUG|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
48347909|NCT00195624|BIOLOGICAL|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
48347910|NCT00195624|DRUG|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
48137201|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP3)|2 softgels - 200 mg total CoQ10
48137202|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP4)|2 capsules - 200 mg total CoQ10
48137203|NCT02080585|BEHAVIORAL|Physical Activity advice.|Subjects receive advice regarding physical activities.
48137204|NCT05769816|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
48137205|NCT05769816|DRUG|NAs|Once/day, 1 capsule/time, oral
48347911|NCT03623906|PROCEDURE|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
48347912|NCT03623906|PROCEDURE|Air insufflation colonoscopy|Room air insufflation colonoscopy
48347913|NCT02587104|OTHER|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
48347914|NCT01942304|PROCEDURE|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
48347915|NCT01942304|PROCEDURE|Anorganic bovine bone mineral in direct sinus augmentation|
48347916|NCT04420208|PROCEDURE|Modified Pap test|Adding a non-painful step after the most uncomfortable phase of Pap smear
47983849|NCT05040841|BEHAVIORAL|S1/Text: Weekly check-in texts|"Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent."
48137206|NCT00605306|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
48137207|NCT00605306|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
48137208|NCT02423642|PROCEDURE|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
48137209|NCT02423642|PROCEDURE|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
48137210|NCT05510700|DEVICE|Acupuncture|All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.
48137211|NCT05510700|DEVICE|Sham acupuncture|"The placebo needles selected for this study are flat-tipped needles without a tip that cannot be pierced into the skin. Also, an external patch device will hold the needles in place and these needles are visually pierced into the skin. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needles being pulled out."
48137212|NCT01602185|DRUG|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
48137213|NCT01602185|DRUG|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
48347917|NCT04527666|DRUG|Anticoagulation Agents|Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.
48347918|NCT04745689|DRUG|Durvalumab|"IV infusions through induction phase.~IV infusions through maintenance phase until PD or other discontinuation criteria."
48347919|NCT04745689|DRUG|AZD2811|IV infusions through maintenance phase until PD or other discontinuation criteria.
48347920|NCT04745689|DRUG|Carboplatin|IV infusions through induction phase if chosen by Investigator.
48137214|NCT01602185|DRUG|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
48137215|NCT05622097|OTHER|0.9% Saline warmed to 37 degrees Celsius|0.9% Saline warmed to 37 degrees Celsius
48347921|NCT04745689|DRUG|Cisplatin|IV infusions through induction phase if chosen by Investigator.
48347922|NCT04745689|DRUG|Etoposide|IV infusions through induction phase.
48347923|NCT04459923|PROCEDURE|ultrasound-guided erector spinae plane block catheter|for postoperative pain management ultrasound-guided erector spine plane block catheter placement
48347924|NCT04459923|PROCEDURE|thoracic epidural catheter|for postoperative pain management thoracic epidural catheter placement
48137216|NCT05622097|OTHER|0.9% Saline warmed to 24 degrees Celsius|0.9% Saline warmed to 24 degrees Celsius
48347925|NCT01236768|DRUG|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
48137217|NCT01673399|DRUG|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
48347926|NCT01236768|DRUG|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
47983850|NCT05040841|BEHAVIORAL|S2/Peer: Enhanced peer group support|"Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks."
48347927|NCT03127852|DEVICE|Medly|
48347928|NCT06139198|BEHAVIORAL|Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans|SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
48347929|NCT02040298|DRUG|Clemastine|4mg tablet twice daily
47983851|NCT02031731|DRUG|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
48347930|NCT02040298|DRUG|Placebo|Placebo tablet twice daily
47983852|NCT02031731|DRUG|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
48347931|NCT01365091|DRUG|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
48347932|NCT01365091|DRUG|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
48347933|NCT01365091|DRUG|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
48501814|NCT05824416|BEHAVIORAL|Conventional Therapy|The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
47983853|NCT02031731|DRUG|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
48347934|NCT01365091|DRUG|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
48501815|NCT04903951|DEVICE|Adaptive Servoventilation (ASV) therapy|Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
48501816|NCT04903951|OTHER|Best medical treatment|Best medical treatment for stroke, including rehabilitation
47983854|NCT00607529|OTHER|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
47983855|NCT06038084|DRUG|Bronpass Tab.|Twice a day
47983856|NCT06038084|DRUG|Placebo of Erdos capsule|Three times a day (It is for the masking.)
48137218|NCT01673399|DRUG|placebo|
48501817|NCT05509738|BEHAVIORAL|SMS Text Messaging|"The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses."
48137219|NCT03760653|OTHER|Physical Exercise and probiotic group|The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of \~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
48347935|NCT01365091|DRUG|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
48347936|NCT03023319|DRUG|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
48347937|NCT03023319|DRUG|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
48347938|NCT01866813|BEHAVIORAL|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
48347939|NCT01736163|DRUG|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
48347940|NCT01736163|DRUG|131I|28 mCi or ≥ 1.036 GBq.
48658766|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
47983857|NCT06038084|DRUG|Erdos capsule|Three times a day
47983858|NCT06038084|DRUG|Placebo of Bronpass Tab.|Twice a day (It is for the masking.)
47983859|NCT00938379|DRUG|20% deet insect repellent|skin-applied repellent lotion
48137220|NCT03760653|DIETARY_SUPPLEMENT|Probiotic group|Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
48347941|NCT01736163|OTHER|Thyroid Hormone Withdrawal|Stop taking hormone therapy
48347942|NCT01537289|DEVICE|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
48347943|NCT01537289|DEVICE|chest tube (28-French)|inserting chest tube to decompress pneumothorax
48347944|NCT00442130|BIOLOGICAL|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
48501818|NCT02335918|DRUG|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
48501819|NCT02716727|DEVICE|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
48501820|NCT02716727|DEVICE|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
48501821|NCT04020757|DEVICE|variation in dialysis bicarbonate|35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
47983860|NCT00938379|DRUG|placebo control|Identical base formulation of lotion but without any deet active
48501822|NCT04020757|DIETARY_SUPPLEMENT|Zone Perfect bar|16g protein supplement given during first 30 mins of dialysis on last testing day
48501823|NCT05169450|DRUG|Diterpene ginkgolides meglumine injection|Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
48501824|NCT05169450|DRUG|Ginaton|Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.
47983861|NCT05319522|BEHAVIORAL|Acute Exercise|Participants with and without SCI will complete an arm ergometer, high-intensity interval exercise bout. The exercise bout will be performed at a relative intensity based on previously determined peak power output during an arm ergometer graded exercise test.
47983862|NCT00970333|DRUG|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
48347945|NCT00442130|PROCEDURE|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
48347946|NCT04539262|DRUG|Remdesivir (RDV)|Administered as an aerosolized solution
48347947|NCT04539262|DRUG|Placebo|Administered as an aerosolized solution
48347948|NCT00833612|DEVICE|Counterpulsation with IAB|IABC pre-reperfusion PCI
48347949|NCT03945656|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
48347950|NCT03945656|DRUG|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
48137221|NCT03760653|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
48137222|NCT00405990|BEHAVIORAL|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
48137223|NCT00405990|BEHAVIORAL|VCT|HIV VCT for PMTCT
48137224|NCT03528603|OTHER|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal
48137225|NCT03528603|OTHER|Oleocanthal-low Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal
48347951|NCT01764022|DRUG|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
48347952|NCT01764022|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
48347953|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
48347954|NCT02218762|DRUG|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
48347955|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
48347956|NCT02218762|DRUG|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
48347957|NCT05023460|DEVICE|Paresthesia-free (burst) ONS|Stimulation intensity target of 60% of paresthesia threshold.
48347958|NCT05023460|DEVICE|Placebo|ONS system deactivated
48501825|NCT00638027|DRUG|placebo|matched tablets bid
48501826|NCT00638027|DRUG|memantine|10 mg bid
48501827|NCT02834676|DRUG|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
47983863|NCT04921254|DRUG|BSG005 or placebo|"SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level."
48347959|NCT02384785|DEVICE|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
48347960|NCT00681291|DEVICE|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
48347961|NCT00681291|DEVICE|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
48347962|NCT03166657|PROCEDURE|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
48347963|NCT01086904|BIOLOGICAL|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
48347964|NCT00474773|DRUG|Celecoxib|
48347965|NCT02708004|DRUG|Aprocitentan|Formulated in capsules in 2 different strengths; 2 capsules per day
48347966|NCT02708004|OTHER|Placebo|Matching active drug
48347967|NCT05495191|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
48347968|NCT04985513|PROCEDURE|Ventilation during cardiopulmonary bypass|Ventilation was performed using an inhaled oxygen fraction of 20% and a tidal volume of 5ml/kg at the time of cardiopulmonary bypass.
48347969|NCT05685394|DRUG|Dapagliflozin|Dapagliflozin 10mg P.O. daily
48347970|NCT02907281|OTHER|Observational|Observational
48347971|NCT05104749|DRUG|Homeopathic Medication|Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.
48347972|NCT05104749|OTHER|Placebo|Inert lactose pellets
48347973|NCT04493944|BEHAVIORAL|Culinary workshop|A 3-hour culinary workshop will be led by a chef. The aim of this workshop will be to develop participants' culinary skills related to the preparation and consumption of recipes based on seaweeds, through various practical activities in the kitchen (starter, main course, dessert). An evaluation questionnaire will be completed at the end of the workshop.
48347974|NCT00152789|PROCEDURE|Oxygen measurement - Eppendorf machine|
48347975|NCT03193944|DRUG|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
48347976|NCT03193944|DRUG|Placebo vitamin D3|vitamin D as a placebo
48347977|NCT00269295|BIOLOGICAL|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.
48347978|NCT00269295|DRUG|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
48347979|NCT00657930|DRUG|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
48347980|NCT04369872|PROCEDURE|Microwave ablation|Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
48347981|NCT04898868|PROCEDURE|cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.
48347982|NCT04898868|PROCEDURE|Umbilical cord miking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
48347983|NCT03731910|DIAGNOSTIC_TEST|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
48347984|NCT04247529|OTHER|Exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
48658767|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
47983864|NCT02213016|DEVICE|Transcranial Magnetic Stimulation|
47983865|NCT02213016|DEVICE|Sham Transcranial Magnetic Stimulation|
48137226|NCT00738400|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
48137227|NCT00738400|DRUG|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
48347985|NCT04247529|OTHER|No exposure to conflicting health information|At 2 time points across a \~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
48347986|NCT03868670|DEVICE|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
48347987|NCT02462122|DRUG|IDP-118 Lotion|Lotion
48347988|NCT02462122|DRUG|IDP-118 Vehicle Lotion|Lotion
48501828|NCT00888056|PROCEDURE|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
48347989|NCT01929018|BEHAVIORAL|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
48347990|NCT01929018|BEHAVIORAL|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
48347991|NCT01929018|BEHAVIORAL|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
48347992|NCT05431738|DEVICE|Gastroesophageal stent placement|A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
48501829|NCT06055530|DIAGNOSTIC_TEST|Artificial Intelligence Digital Pathology|School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
48501830|NCT02388360|DRUG|topical prostaglandin analogs|
48347993|NCT01011595|PROCEDURE|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
48137228|NCT03170882|DRUG|Ixazomib|Ixazomib capsules
48347994|NCT01011595|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
48501831|NCT05478512|DRUG|VenObi+Ven or VenObi+VenZan|"Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression"
48501832|NCT00000114|DRUG|Vitamin E|
48501833|NCT00000114|DRUG|Vitamin A|
48501834|NCT00749021|DRUG|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
48137229|NCT03170882|DRUG|Pomalidomide|Pomalidomide capsules
48137230|NCT03170882|DRUG|Dexamethasone|Dexamethasone tablets
48137231|NCT05782894|DRUG|Remimazolam besylate|0\~2.0mg/kg/h
48137232|NCT05782894|DRUG|Propofol|0.3\~4.0mg/kg/h
48137233|NCT05782894|DRUG|Remifentanil|1.5\~12μg/kg/h
48137234|NCT02562937|BEHAVIORAL|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
48347995|NCT01011595|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
48137235|NCT05554549|OTHER|Dietary pattern observed|Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
48347996|NCT00215813|DRUG|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
48347997|NCT01028040|DRUG|AZD3043|Intravenous, single dose
48137236|NCT01105988|OTHER|Radiologic exams|FLT PET scan x 2 MRI scan x 2
48347998|NCT01028040|DRUG|AZD3043|Infusion, single dose
48347999|NCT02256345|DRUG|KNO3|Active Comparator
48348000|NCT02256345|DRUG|KCl|Placebo Comparator
48348001|NCT03797885|OTHER|No treatment given|No treatment is administered to the participants for this study
48348002|NCT03130504|DRUG|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
48348003|NCT06212388|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
48348004|NCT06212388|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
48348005|NCT06212388|DRUG|Pembrolizumab|Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
48348006|NCT01751204|DIETARY_SUPPLEMENT|Calcium tablet|
48348007|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (250mg)|
48348008|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (125mg)|
48348009|NCT03426449|PROCEDURE|posterolateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
48137237|NCT01898299|DEVICE|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
48137238|NCT01898299|DEVICE|Sham tDCS|Sham (inactive) tDCS treatment
48348010|NCT03426449|PROCEDURE|lateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
48348011|NCT01547962|DEVICE|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
48348012|NCT01547962|OTHER|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
48348013|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
48348014|NCT03966664|DIAGNOSTIC_TEST|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
48501835|NCT00749021|DRUG|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
48501836|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
48348015|NCT03966664|DIAGNOSTIC_TEST|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
48137239|NCT03627637|DIETARY_SUPPLEMENT|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
48137240|NCT02757469|DRUG|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
48137241|NCT01825720|DRUG|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
48348016|NCT05031806|DRUG|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
48348017|NCT05031806|DRUG|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
48348018|NCT05031806|DRUG|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
48137242|NCT01825720|DRUG|normal saline group|same rate of normal saline
48137243|NCT02628626|DRUG|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
48348019|NCT05031806|DRUG|Vehicle (eye drop formulation without aCT1)|"36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.~During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2)."
48348020|NCT01976585|DRUG|rhuFlt3L/CDX-301|"rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7."
48501837|NCT00749021|DRUG|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
48658768|NCT02041273|DRUG|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
48137244|NCT02628626|DRUG|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
48658769|NCT06541951|OTHER|Services as usual|During this phase of the stepped wedge design, agencies offering prenatal and postnatal care will follow their standard procedures
48658770|NCT06541951|OTHER|Scale-up implementation approach|An implementation approach for scaling up bundled equity-focused maternal health safety guidelines in community care settings county-wide, co-developed with partners. It may involve implementation approaches such as training, facilitation, learning collaboratives, coalitions, and other activities.
48658771|NCT04408612|DIAGNOSTIC_TEST|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
48137245|NCT02628626|OTHER|Placebo|Placebo will be identical in appearance to the active drug.
48137246|NCT03739866|DRUG|Lenacapavir|Administered subcutaneously in the abdomen
48137247|NCT03739866|DRUG|Placebo|Administered subcutaneously in the abdomen
48137248|NCT03739866|DRUG|B/F/TAF|50/200/25 mg tablets administered orally once daily
48658772|NCT01379690|OTHER|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
48658773|NCT03510689|DIAGNOSTIC_TEST|echocardiography|Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
48137249|NCT03739866|DRUG|TAF|Tablets administered orally
48137250|NCT01121965|PROCEDURE|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
48137251|NCT04790331|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
48348021|NCT01976585|DRUG|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
48501838|NCT01046786|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
48348022|NCT03687476|DRUG|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
48501839|NCT01046786|DRUG|Methylprednisolone|30 mg/kg methylprednisolone
48501840|NCT01046786|DRUG|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
48501841|NCT04497948|DRUG|Acalabrutinib|Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor
48501842|NCT05001217|DRUG|Conventional medication|Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
48501843|NCT05001217|DRUG|Chinese herbal medicine treatment|"1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction"
48501844|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal|Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken
48501845|NCT05168683|DRUG|Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state|Selected dosing of Part One treatments in fasted and/or fed states
48501846|NCT06450795|BEHAVIORAL|Participants in both groups will then receive PTKE treatment for 8 weeks, 3 days a week for 30-45 minutes, under the supervision of specialist physiotherapists.|HIFEM treatment for 6 weeks, 2 days a week for 28 minutes. The evaluations will be repeated at the end of the treatment.
48501847|NCT01478386|OTHER|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
48501848|NCT01478386|DEVICE|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
48501849|NCT01478386|DEVICE|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
48501850|NCT05367583|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation
48501851|NCT00416650|DRUG|erlotinib hydrochloride|All patients will receive 150 mg orally daily
48501852|NCT02119923|BEHAVIORAL|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
48501853|NCT02119923|BEHAVIORAL|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers \& Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
48658774|NCT03510689|OTHER|Cardiopulmonary Exercise Testing|A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
48348023|NCT04692233|BEHAVIORAL|Qigong Baduanjin|Qigong Baduanjin will comprise eight standardized movements. It is practiced as a combination of body movements, breath control, and mindful meditation, which is designed to improve qi function.
48348024|NCT04692233|BEHAVIORAL|Light flexibility exercise|Each session will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, back, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
48137252|NCT04790331|DRUG|Diltiazem|"Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina."
48348025|NCT01964729|DEVICE|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
48348026|NCT01964729|DEVICE|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
48501854|NCT04990700|PROCEDURE|Partial rib resection|1 cm partial rib resection during thoracotomy opening
48501855|NCT05508841|OTHER|tDCS and Cognitive Training|Participants will receive mild stimulation or no stimulation along with cognitive training
48658775|NCT03510689|OTHER|Blood Collection|We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
48501856|NCT03467139|OTHER|Abdominal breathing exercise|Deep Breathing Exercise
48501857|NCT06490614|DRUG|Dexmedetomidine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
48618208|NCT01474343|GENETIC|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
48501858|NCT06490614|DRUG|Nalbuphine in superficial cervical plexus block|While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, 10 mg of Nalbuphine (nalufin 20mg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
48501859|NCT02974179|BIOLOGICAL|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
48501860|NCT03371459|DRUG|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
48348027|NCT00132522|DRUG|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
48501861|NCT03371459|DRUG|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
48501862|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
48501863|NCT02465294|BEHAVIORAL|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
48137253|NCT04790331|DRUG|Placebo|Placebo oral tablet
48137254|NCT02432274|DRUG|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
48501864|NCT02465294|OTHER|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
48501865|NCT02465294|OTHER|Blood Test|All subjects will have blood tests performed.
48501866|NCT02465294|DIETARY_SUPPLEMENT|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
48501867|NCT04493086|DIAGNOSTIC_TEST|FFRCT-angio|According to invasive coronary angiography (CAG) images, image databases of critical lesions, diffuse lesions, left main trunk lesions, ostium lesions and bifurcation lesions were established. In order to ensure that the position of the pressure guide wire sensor is consistent with that of FFRCT-angio, a professional with unknown FFR results is used to mark the position of the pressure wire sensor on the CAG image. The clinical information and characteristics of coronary artery lesions were collected, and the baseline data of patients were completed. The accuracy and diagnostic performance of FFRCT-angio in the diagnosis of functional stenosis (FFR \< 0.8) were evaluated with FFR value measured by pressure guide wire as reference standard.
47983866|NCT03055351|BEHAVIORAL|Stop&Go Intervention|Stop\&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
47983867|NCT01740986|DRUG|SA09012 Low dose|Tablet, b.i.d
47983868|NCT01740986|DRUG|SA09012 High dose|Tablet, b.i.d
47983869|NCT01740986|DRUG|Placebo|Tablet, b.i.d
48137255|NCT02432274|DRUG|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
48137256|NCT02432274|DRUG|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
48137257|NCT02432274|DRUG|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
48137258|NCT02432274|DRUG|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
48137259|NCT02432274|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
48501868|NCT01152151|DEVICE|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
48501869|NCT01152151|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
48501870|NCT01152151|DEVICE|Reminder letters|up to four reminder letters in september - december 2010
48501871|NCT03074123|DIAGNOSTIC_TEST|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
48501872|NCT01890135|DRUG|Zibotentan (ZD4054)|10 mg
48501873|NCT01890135|DRUG|placebo|randomized double blind
47983870|NCT03578991|DEVICE|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
48137260|NCT02432274|DRUG|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
48137261|NCT02432274|DRUG|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
48348028|NCT06347965|BEHAVIORAL|Low load blood flow restriction training|Low load blood flow restriction training will be conducted on the subjects three times a week. Each training session includes upper and lower limb training, with 4 groups trained and repeated 30, 15, 15, and 15 times for each group. Train for a total of 12 weeks.The resistance strength will remain at 30% RM for weeks 1-12.
48348029|NCT06347965|BEHAVIORAL|Progressive resistance training group|The subjects will undergo progressive resistance training three days a week, three groups per day, with each group repeating 10 times. Training includes upper and lower limbs. The resistance load increases over time, with a resistance load of 30% RM for weeks 1-4, 50% RM for weeks 5-8, and 70% RM for weeks 9-12.
48348030|NCT03875833|DEVICE|Collagen Nerve Wrap Conduit|The collagen nerve wrap conduit will be placed on all exposed radial and ulnar nerves at the time of free flap harvest.
48348031|NCT06254846|OTHER|Urine sample, 1st stream|Use of the Colli-Pee® device for collecting the first urine stream
48348032|NCT06254846|OTHER|Cervico-vaginal swab|"Use of a gold standard reference method = HPV PCR using the Anyplex® II HPV HR kit (Seegene) carried out on a cervico-vaginal swab in ThinPrep® medium (liquid medium medium into which the cervico-vaginal swab is discharged)."
48348033|NCT06242106|DEVICE|Glucometer|A glucometer, which is a portable device used to measure blood glucose levels, was used in this study to collect data. It is a dependable and widely used tool for assessing glycemic control in people with diabetes, including gestational diabetes
48348034|NCT05208450|OTHER|Practice support And Community Engagement (PACE)|A practical and sustainable implementation strategy, referred to as Practice Facilitation And social deTerminants of health support utilizing CHWs (PATCH), to support the implementation and evaluation of three multi-level evidence-based interventions: \[nurse case management (NCM) + remote blood pressure monitoring (RBPM) + social determinants of health (SDOH) support\] delivered as an integrated community-clinic linkage model \[Practice support And Community Engagement (PACE)\]
48501874|NCT04270318|OTHER|CH Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
48658776|NCT06154590|DRUG|Method(s)1 Attribution|"Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
48501875|NCT04270318|OTHER|CH pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
48137262|NCT02432274|DRUG|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
48137263|NCT00238485|DRUG|Licarbazepine|
48501876|NCT04270318|OTHER|MTA Pulpotomy, physiologic saline|Pulp chamber was cleansed with physiologic saline for 30 s.
48501877|NCT04270318|OTHER|MTA pulpotomy, NaOCl|Pulp chamber was cleansed with 5 % NaOCl for 30 s.
48501878|NCT00690976|BEHAVIORAL|Proyecto SOL|Group intervention
48658777|NCT06154590|DRUG|Method(s)2 Attribution,|"Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
48137264|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
48658778|NCT03376386|RADIATION|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
48137265|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
48137266|NCT05746741|BEHAVIORAL|Telehealth solution|Video conferencing
48137267|NCT05515146|DIAGNOSTIC_TEST|near infra red fluorescence lymphatic imaging|ICG (0.2 ml from 25mg of ICG diluted by 5.0 ml of aqua ad injectabilia) was injected intradermally at the basis of the tattooed cutaneous area and at one point chosen so that the tracer had to flow under this area directly towards the root of the limb
48501879|NCT00690976|BEHAVIORAL|HCT|Offer of HIV counseling and testing
48501880|NCT05151666|OTHER|Sunny Health & Fitness Magnetic Mini Exercise Pedal Cycle - SF-B020026 Gray|The intervention will be that the patient cycles in a sitting position within the first 2 hours of hemodialysis treatment for 15-60 minutes/as tolerated, either intermittent/continuous duration. - Graded duration will increase every 2 weeks. This will be supervised by a dialysis nurse as per the schedule of study assessments.
48618209|NCT05502731|DRUG|Filgotinib|Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.
48618210|NCT05502731|DRUG|Adalimumab|Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.
48137268|NCT05957510|DRUG|Serplulimab|serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
48658779|NCT03255395|DEVICE|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
48137269|NCT05957510|DRUG|SOC|the treatment recommended by the investigator
48348035|NCT03458988|DEVICE|Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)|Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
48501881|NCT03043976|DEVICE|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
48658780|NCT00618787|DEVICE|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
48658781|NCT00618787|DEVICE|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
48658782|NCT00890760|BIOLOGICAL|AdCh63 ME-TRAP|5 x 10\*10 vp IM
48658783|NCT00890760|BIOLOGICAL|MVA ME-TRAP|2 x 10\*8 pfu ID
48658784|NCT00890760|OTHER|Sporozoite challenge|Infected mosquito bite
47983871|NCT03578991|OTHER|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
48348036|NCT05844657|OTHER|Case report form|Sociodemographic information (age, gender, height, body mass index, marital status, occupation, education level, contact information), frequency of smoking and alcohol use, frequency of caffeine consumption, frequency of salt consumption, dominant side, background, family history, medical and audiological information were recorded.
47983872|NCT01199523|DRUG|Placebo|oral
47983873|NCT01199523|DRUG|mirabegron|oral
48137270|NCT02683174|DEVICE|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
48137271|NCT02683174|BIOLOGICAL|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
48137272|NCT00415688|BEHAVIORAL|Low carbohydrate, ketogenic diet|
47983874|NCT01199523|DRUG|moxifloxacin|oral
47983875|NCT05713721|DEVICE|Transcranial magnetic stimulation (TMS)|TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
47983876|NCT05713721|OTHER|Video-based clinical examination|A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
47983877|NCT05713721|OTHER|24 hours drug withdrawal of dopaminergic medication|Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
48137273|NCT00415688|BEHAVIORAL|Low glycemic index, reduced calorie diet|
48137274|NCT02893969|BEHAVIORAL|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
48501882|NCT04824157|OTHER|Non|Follow up
48137275|NCT02893969|BEHAVIORAL|Rest|Complete physical rest until asymptomatic.
48501883|NCT03482700|BEHAVIORAL|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
48501884|NCT03482700|BEHAVIORAL|Control Arm|Usual standard of care
48501885|NCT02511821|OTHER|Computer-Assisted Intervention|Complete online surveys
48501886|NCT02511821|DEVICE|Vivofit watch|Wear Vivofit watch
48658785|NCT00890760|BIOLOGICAL|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10\*10 vp MVA ME-TRAP 2 x 10\*8 pfu
48658786|NCT05287373|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
48658787|NCT05287373|OTHER|conventional medical management|Conventional medical management
48658788|NCT06547632|DEVICE|ClearPetra Ureteral access sheath|Patients will be randomly assigned (1:1) to vacuum-assisted (ClearPetra) or traditional approach group for retrograde intrarenal surgery according to standard of care.
48658789|NCT04304248|DRUG|Albumin-bound paclitaxel, Carboplatin, Toripalimab|Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment
48658790|NCT02168556|BEHAVIORAL|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
48137276|NCT02546531|BIOLOGICAL|Defactinib|
48137277|NCT02546531|BIOLOGICAL|Pembrolizumab|
48137278|NCT02546531|DRUG|Gemcitabine|
48137279|NCT03142490|OTHER|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
48137280|NCT03142490|OTHER|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
48658791|NCT02168556|BEHAVIORAL|Video|Subject watches an informational video prior to undergoing urodynamic testing.
48658792|NCT02168556|OTHER|Standard of care|Standard of care
48658793|NCT03367104|DEVICE|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
48348037|NCT05844657|OTHER|Tinnitus disability scale|Tinnitus disability scale was used to evaluate the tinnitus severity of Meniere's patients. It consists of 25 items in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Tinnitus level or severity is determined by calculating the total score of the answers given.
48137281|NCT02328144|DRUG|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
48137282|NCT02328144|DRUG|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
48137283|NCT05335044|DRUG|CKD-331|QD, PO
48137284|NCT05335044|DRUG|EX5619|QD, PO
48137285|NCT03705663|BEHAVIORAL|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
48137286|NCT04775810|DEVICE|The device is an algorithm designed to enhance speech intelligibility of speech-in-noise signals|Normal-hearing and hearing-impaired subjects will listen to speech-in-noise audio files that are either unprocessed or processed in order to increase speech intelligibility.
48348038|NCT05844657|OTHER|A feeling of fullness and/or pressure in the ear|The feeling of fullness or pressure in the ear was evaluated verbally by receiving yes/no responses from the participants.
48348039|NCT05844657|OTHER|Dizziness intensity and frequency|In order to determine the frequency and severity of dizziness, the participants were asked to mark the appropriate score between 1-10 points.
48348040|NCT05844657|OTHER|Dizziness disability inventory|The dizziness disability inventory was used to determine the disability level of the individuals participating in our study. It consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'.
48348041|NCT05844657|OTHER|Vertigo symptom scale-short form|The short form of the vertigo symptom scale was used to determine the frequency and duration of vertigo in the individuals participating in our study. The vertigo symptom scale consisting of 8 questions consists of vertigo (VSS-V), and the vertigo symptom scale consisting of 7 questions consists of two subsections consisting of a total of 15 questions: anxiety (VSS-A). Each item; Never (0), Very rarely (1 point), Often (2 points), Often - every week (3 points), Very often - On average, at least twice a week (4 points). The total score ranges from 0 to 60.
48501887|NCT02511821|OTHER|Quality-of-Life Assessment|Ancillary studies
48501888|NCT02511821|OTHER|Questionnaire Administration|Ancillary studies
48501889|NCT00182247|PROCEDURE|venogram|
48501890|NCT01759732|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -4
48501891|NCT01759732|DRUG|Cyclophosphamide|60 mg/kg IV on day-3 and -2
48501892|NCT01759732|BIOLOGICAL|anti-thymocyte globulin|
48501893|NCT01759732|BIOLOGICAL|filgrastim|
48501894|NCT01759732|RADIATION|Total body irradiation|200 cGy per day on D-5 \& -4
48501895|NCT01759732|PROCEDURE|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
48501896|NCT03713619|DRUG|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
48501897|NCT03713619|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
48501898|NCT06322173|DIAGNOSTIC_TEST|NGS Analysis|An analytical pipeline with NGS technology developed in the GENRES study will be used for the identification of infecting microorganisms and the drug resistance they carry. For this purpose, a sequencing method will be identified and adopted that can obtain gene sequences of approximately 75 bp in length and on the Illumina MiSeq platform. Furthermore, IT software and bioinformatics analyzes with specific quality control parameters (pre- and post-alignment of reads) will be identified and adopted in order to develop an IVD system that includes a complete package of sequencing kits and software.
48501899|NCT05220189|DIAGNOSTIC_TEST|EarlyTect® Bladder Cancer test|A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.
48501900|NCT04380363|DEVICE|Honda Walk Assist (HWA) device|Use of HWA for 2 months in the home setting
48501901|NCT04380363|OTHER|SRALab fitness center membership|Membership to Shirley Ryan AbilityLab fitness center for 2 months
48501902|NCT06149663|DRUG|LP352|LP352 will be administered as a liquid either orally or through a G-tube or PEG tube.
48501903|NCT05568901|BEHAVIORAL|Lethal means counseling|"Lethal means counseling is a type of safety education that advises securement or removal of potentially hazardous household items such as medications, knives, and firearms. Counseling provided by study team was derived from the Suicide Prevention Resource Center's Counseling on Access to Lethal Means training module and the Store It Safe campaign from the Ohio Chapter of the American Academy of Pediatrics (AAP). Guidance focused on securement of dangerous items in the household, such as medications and firearms, with locking devices-or more preferably removing these items from the home, even if temporarily."
48618211|NCT04639440|OTHER|Adipose tissue|Adipose tissue sampling
48658794|NCT04555759|OTHER|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
48658795|NCT02714751|BEHAVIORAL|Daily asynchronies information|
48137287|NCT00012259|DRUG|troxacitabine|
48137288|NCT06348225|OTHER|Exercise or heat treatment|Interventions will be each of the four arms described previously, administered \~1 week apart in a randomized, counter-balanced fashion.
48137289|NCT00864006|DRUG|Divalproex Sodium|
48137290|NCT00864006|DRUG|Depakote DR Tablets|
48137291|NCT01072045|DRUG|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
48137292|NCT01072045|DRUG|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
48137293|NCT01493882|DRUG|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
48137294|NCT01493882|DRUG|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
48137295|NCT01493882|DRUG|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
48348042|NCT05844657|OTHER|Hearing Impairment Scale|The Adult Hearing Impairment Scale was used to determine the effect of the current hearing impairment levels of the individuals participating in our study on their daily living activities. The scale consists of 25 questions in total. The questions are scored between 0-2-4. It is calculated as 'Yes (4 points)', 'Sometimes (2 points)', 'No (0 points)'. Participants mark the most appropriate expression for them.
48348043|NCT05844657|OTHER|Cervical Range of Motion (CROM 3) device|"Cervical Range of Motion (CROM) device was used to evaluate the sense of proprioception and range of motion (ROM) in the cervical region muscles. A total of six positions were performed: right cervical rotation, left cervical rotation, right cervical lateral flexion, left cervical lateral flexion, cervical extension and cervical flexion."
48348044|NCT05844657|OTHER|Temporomandibular joint range of motion assessment|In our study, the temporamandibular joint range of motion (ROM) was evaluated with a ruler specific to each participant in four positions, including mandibular depression, protraction, and right and left lateral deviation.
48348045|NCT05844657|OTHER|Posture evaluation with New York posture analysis|The New York Posture Evaluation method was used to obtain information about the general posture correctness of the participants. Posture changes that may occur in 13 different parts of the body, 7 from the side and 6 from the back, including the head, neck, shoulder, back, waist, hip and ankle, were examined in the anatomical position of the individuals. As a result of the observation, the posture of the individual was scored according to whether it was severely bad (1 point), moderately bad (3 points), and straight (5 points). The total score obtained varies between 13-65.
48348046|NCT05844657|OTHER|Evaluation of the anterior tilt angle of the head|Anterior tilt angles of the head of the participants were evaluated with photographs taken from the lateral (lateral) side. The anterior tilt angle was calculated as the angle between the line drawn between the C7 cervical spinous process and the tragus and the straight line drawn vertically from C7.
48501904|NCT05568901|BEHAVIORAL|Provision of Cable-style gun locks|Caregivers were provided 2 (two) SnapSafe Cable Padlock (Item No. 75281), advised on how to use these devices to store firearms safely (including instructions from within the package of the provided gun locks) and were advised to store keys away from the firearm in a location that children would not have access
48501905|NCT05485701|DIAGNOSTIC_TEST|Screening tools for common mental disorders|A number of screening tools will be administered which will establish the likelihood of depression, anxiety, PTSD, somatisation and suicidality.
48501906|NCT01789723|DRUG|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
48348047|NCT05844657|OTHER|Evaluation of postural balance with the Freemed pressure platform|Postural sway and lower extremity weight transfer were evaluated with the Freemed baropodometric pressure platform (Rome, Italy) system, which has been shown to be valid and reliable.
48348048|NCT05844657|OTHER|Static balance assessment with tandem stance test|In our study, the tandem stance test was used for static evaluation. A total of four assessments were made on the participants, first with their right foot in front, eyes open and eyes closed, then left foot in front with eyes open and eyes closed.
48348049|NCT05844657|OTHER|Dynamic balance assessment with tandem gait test|In our study, the tandem gait test was used for dynamic evaluation. A straight line was created with a white tape attached to the floor, almost 2 feet away from the 10-foot-long wall. The participant was asked to walk along the line created by taping the heel of the forward foot to touch the toe of the back foot, at a comfortable pace in daily life and with eyes open.
48348050|NCT05844657|OTHER|Headache, Temporomandibular pain and Craniocervical pain presence and severity assessment|Headache, temporomandibular pain and craniocervical pain were asked to mark the person from the photographs taken from the front, back and side in the form of a human figure. Pain severity was evaluated with the numerical rating scale (NRS).
48348051|NCT05844657|OTHER|Pain sensitivity assessment in the head, neck, shoulder girdle and upper back region|In our study, muscle tenderness was evaluated by manual pressure algometry and palpation. Muscle tenderness was assessed in the upper and lower regions of the masseter, temporalis, sternocleidomastoid, and upper trapezius muscles on both right and left sides.
48501907|NCT01789723|DRUG|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
48501908|NCT01290562|RADIATION|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
48501909|NCT01568060|OTHER|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
48501910|NCT00866736|DRUG|dasatinib|100mg QD
48501911|NCT03036254|DEVICE|HBOT intervention|"HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure.~HBOT intervention arm - 3 months of HBOT treatment, 9 months observation~all participants receive HBOT treatment for 3 months at year 2"
48501912|NCT03036254|DEVICE|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
48501913|NCT01081834|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
48137296|NCT01493882|DRUG|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
48501914|NCT01081834|DRUG|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
48501915|NCT01081834|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
48501916|NCT03149445|DRUG|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
48501917|NCT03149445|DRUG|Placebos|Study medication will be administered for 91 days.
48501918|NCT04304040|DRUG|Orelabrutinib|BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
48501919|NCT04304040|DRUG|Recombinant humanized monoclonal antibody MIL62 injection|Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
48137297|NCT05825274|DEVICE|Cathodal tDCS|We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
48348052|NCT05844657|OTHER|International physical activity questionnaire-measurement of physical activity level with short|The short form of the international physical activity questionnaire was used to determine the physical activity level of the individuals participating in our study. The short form of the international physical activity questionnaire evaluates the last week and consists of a total of 4 sections and 7 questions. Duration of physical activity that requires intense physical effort, such as heavy lifting, soccer, or fast cycling; times of doing moderate physical activities that cause breathing slightly more often than usual; The total duration of walks at work, home, for sports, exercise and hobby, and the total sitting time spent in a day at work, at home or while resting are calculated.
48348053|NCT05844657|OTHER|Evaluation of sleep quality with the Pittsburgh sleep quality index|The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate the sleep quality and disturbance of the individuals participating in our study in the last month. It consists of a total of 24 questions. The participant responds to each item according to the frequency between 0-3 points. The total score (0-21 points) from these components indicates whether the sleep quality is good or not.
48348054|NCT05844657|OTHER|Evaluation of fatigue with the fatigue severity scale|The Fatigue severity scale was used to evaluate the fatigue status of the individuals participating in our study. The scale uses a scoring system ranging from 1-7, which starts as I do not agree (1 point) and increases gradually towards I agree (7 point). It consists of 9 items in total and people mark the option that suits them.
48348055|NCT05844657|OTHER|Evaluation of anxiety-depression status with hospital anxiety and depression scale|The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the anxiety and depression status of the individuals participating in our study. For each item, the participant answers with a four-point (0-3 points) response option. Therefore, the possible score probabilities in line with the answers given are minimum '0' and maximum '21'. The cut-off point for the anxiety subscale is 10 points, while the cut-off point for the depression subscale is 7 points.
48348056|NCT05844657|OTHER|Evaluation of quality of life with short form-12 (SF-12)|The Short form SF-12 Questionnaire was used to evaluate the quality of life of the individuals participating in our study. The summary score of the physical and mental components varies between 0-100, and the higher the score in the components, the better the quality of life.
48348057|NCT05844657|OTHER|the International Fall Efficiency Scale|The International Fall Activity Scale (UDES) was used to evaluate both the attack and the general fear of falling of the individuals participating in our study. It consists of 16 questions in total. The answer to each question is marked on a scale between 1 and 4 points. Expressions such as I never worry (1 point), I worry a little (2 point), I am very worried (3 point), I am very worried (4 point) are used as the level of anxiety increases as the score increases. The total score obtained ranges from 16 (no worries) to 64 (extremely worried).
48348058|NCT05844657|OTHER|assessment of muscle performance|In our study, the strength of cervical flexors, anterior and oblique trunk flexors, cervical extensor muscles, back extensor muscles, trapezius muscle, and rhomboid major-minor muscles were evaluated. In addition, the endurance of the deep cervical flexor muscles, cervical flexors and cervical extensor muscles were also evaluated.
48348059|NCT05352321|DRUG|Gemcitabine|for induction chemotherapy
48348060|NCT05352321|DRUG|Cisplatin|for induction and concurrent chemotherapy
48658796|NCT06526273|BEHAVIORAL|PILI 'Āina|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks).
48348061|NCT05352321|RADIATION|regular intensity-modulated radiotherapy|in active comparator arm
48348062|NCT05352321|PROCEDURE|surgery|in experimental arm
48348063|NCT05352321|RADIATION|Target-reduction intensity-modulated radiotherapy|in experimental arm
48348064|NCT02373891|DRUG|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
48348065|NCT02373891|DRUG|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
48348066|NCT02728206|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
48348067|NCT00441012|BIOLOGICAL|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 \& 12 months of age. Duration of treatment is 11 months.
48348068|NCT00441012|BIOLOGICAL|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP \[OMPC\] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
48348069|NCT04412772|DRUG|Tocilizumab|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.
48501920|NCT03580083|GENETIC|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
47983878|NCT05713721|OTHER|Evaluation of deep brain stimulation|Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)
48137298|NCT04121715|DEVICE|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
47983879|NCT02136186|DEVICE|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
48137299|NCT04121715|DRUG|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
48137300|NCT00293761|DRUG|Travoprost, Investigational|One drop in study eye once daily for 13 days
48501921|NCT03328195|DEVICE|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
48501922|NCT03328195|DEVICE|Sham|Twenty minutes, six days per week for 12 weeks with sham device
48501923|NCT03328195|DEVICE|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
48348070|NCT04412772|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
48348071|NCT00964639|DRUG|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
48348072|NCT00964639|DRUG|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
48501924|NCT01709253|RADIATION|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
48501925|NCT05584592|OTHER|Intergrate early palliatuve care + Conventional chemotherapy|Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
48501926|NCT05584592|OTHER|Conventional chemotherapy|patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.
48501927|NCT03190330|DRUG|Ibrutinib 420 mg|Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
48501928|NCT03190330|DRUG|Ibrutinib 560 mg|Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
48501929|NCT01604135|DEVICE|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
48501930|NCT04120571|OTHER|Sleep Audiological Intervention Device (SleepAID)|subtle sound stimulation in phase with the slow oscillations
48501931|NCT04120571|OTHER|sham control|no noise
48501932|NCT05830149|OTHER|Cryoinsufflation|In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
48501933|NCT05830149|OTHER|Deroofing|Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
48501934|NCT03590912|DRUG|Mometasone 50 Mcg/Inh Nasal Spray|One spray in each nostril once daily for one month
48348073|NCT00558740|OTHER|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
48501935|NCT03590912|DRUG|Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%)|Children in this group will be treated with antiboitics (syp cefpodoxime) at 10 mg/kg/day in two divided dose for a week, plus antihistamine and nasal decongestants. Oral levocetirizine (Syrup levocet 2.5 mg/5ml) 1.25 mg once daily for age up to six years, 2.5 mg once daily for elder children for a month, plus oxymetazoline (Nasivion) 0.025%, 4 drops twice daily for two weeks
48501936|NCT03590912|DRUG|Steroid Drug (prednisolone)|This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
48348074|NCT05597241|DRUG|apimostinel|N-methyl-D-aspartate (NMDA) receptor modulator
48348075|NCT05597241|DRUG|Placebo|Placebo
48348076|NCT02128204|DEVICE|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
48348077|NCT02128204|DEVICE|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
48348078|NCT05129683|OTHER|Anodal tDCS cerebellar stimulation group|Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
48348079|NCT05129683|OTHER|Anodal tDCS cerebral (M1) stimulation group|single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
48348080|NCT05129683|OTHER|sham group|single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
48348081|NCT03099304|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
48348082|NCT03099304|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
48348083|NCT01531686|PROCEDURE|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
48348084|NCT06287658|BEHAVIORAL|Training on Kegel exercise and Ba Duan Jin applications online|Kegel exercises and Ba Duan Jin applications online
48348085|NCT06287658|BEHAVIORAL|training on Kegel exercises and Ba Duan Jin applications after the research is completed|Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
48501937|NCT00563576|DRUG|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
48137301|NCT00293761|DRUG|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
48137302|NCT00958321|PROCEDURE|computed tomography|
48137303|NCT00958321|RADIATION|3-dimensional conformal radiation therapy|
48137304|NCT00958321|RADIATION|fludeoxyglucose F 18|
48137305|NCT00958321|RADIATION|radiation therapy treatment planning/simulation|
48137306|NCT05618041|BIOLOGICAL|CAR-T Autologous T cell injection|Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
48137307|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
48137308|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
48137309|NCT06143007|DRUG|BB3008 tablet|BB3008 tablets will be administered orally once daily (QD).
48137310|NCT00162253|DRUG|BMS 587101|
48137311|NCT00491296|DEVICE|SYNERGO|
48137312|NCT00491296|DEVICE|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
48137313|NCT05716425|DRUG|STI-1558|STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
48137314|NCT05716425|DRUG|STI-1558 placebo|STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
48137315|NCT01988649|DRUG|Intranasal Oxytocin|Administration of intranasal Oxytocin
48137316|NCT01988649|DRUG|Placebo (saline)|Administration of normal saline intranasally.
48137317|NCT03280511|DRUG|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
48501938|NCT00563576|DRUG|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
48501939|NCT01687478|DRUG|Olanzapine|Administered Orally
48501940|NCT01687478|DRUG|Fluoxetine|Administered Orally
48501941|NCT01687478|DRUG|Placebo|Administered Orally
48501942|NCT01236586|DRUG|RO4929097|
48137318|NCT06159959|DRUG|Carbetocin|To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
48137319|NCT06175871|OTHER|OTAGO exercises|Exercices for improvement postural control and mobility and decrease falls risks
48137320|NCT06175871|OTHER|Conventional therapy|Exercice and education from physical therapy practice conventional from Hospital.
48137321|NCT02108704|DRUG|Helicobacter pylori eradication therapy|
48137322|NCT02108704|DRUG|Placebo|
48137323|NCT01613417|DRUG|gadoteridol|ProHance 0.1 mmol/kg
48137324|NCT01613417|DRUG|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
48137325|NCT03340415|OTHER|Accelerated Rehabilitation plan|early weight bearing after surgery
48137326|NCT02813525|OTHER|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
48137327|NCT03212885|DEVICE|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
48137328|NCT01320800|BEHAVIORAL|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
48137329|NCT01320800|BEHAVIORAL|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
48501943|NCT01236586|DRUG|Dexamethasone|
48348086|NCT06127472|OTHER|Training in detection and diagnosis of ASD|To improve detection and diagnosis of ASD the participating mental health institutes will be trained by the research group on how to detect and diagnose autism in older adults. The basis of the ASD training involves two separate training sessions. Part one focuses on recognition and detection of ASD, specifically in older adults, and will be offered to the entire teams of the participating centres. The second part of the training focuses on the diagnosis of ASD and as such is offered primarily to diagnosticians. Follow up will consist of monthly recurring options for online consultation during the entire project to discuss clinical cases by experts in ASD in older adults from PersonaCura, clinical centre of excellence for personality and developmental disorders in older adults (dr. A. Videler and R. Wilting).
47983880|NCT03896776|BEHAVIORAL|Keep It Up! 3.0|KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
47983881|NCT00044356|GENETIC|Allovectin-7®|
48137330|NCT05224986|BEHAVIORAL|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
48137331|NCT01766206|BIOLOGICAL|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
48137332|NCT04124887|DRUG|Sodium Fluoride|Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
48137333|NCT04124887|DRUG|Tricalcium Phosphate|Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
48137334|NCT04124887|DRUG|Xylitol-coated calcium and phosphate|Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
48137335|NCT04124887|DRUG|Casein phosphopeptide amorphous calcium phosphate|Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
48137336|NCT02795884|DRUG|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
48137337|NCT02795884|DRUG|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
48137338|NCT03087318|BEHAVIORAL|Physical activity|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months."
48348087|NCT06127472|OTHER|PE program|An adapted PE program for older adults with a recent diagnosis of ASD. The PE program consists of seven, two-hour group meetings on a weekly basis.
48501944|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
48501945|NCT01172119|DEVICE|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
48658797|NCT06526273|OTHER|Control|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker based on previously tested materials and protocols. At 3 months, participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers' markets, cultural events, and physical activity events.
48501946|NCT01172119|DEVICE|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
48501947|NCT00858143|OTHER|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
48501948|NCT03634475|DRUG|PP-001|Drug - no placebo
48501949|NCT00277173|BEHAVIORAL|Adoption of Crew Resource Management approach|
48501950|NCT06391255|OTHER|scintigraphy|oesophageal and gastric emptying
48348088|NCT02822352|OTHER|Chromoendoscopy|High definition virtual chromoendoscopy
48348089|NCT01235338|DRUG|LDX + Venlafaxine XR|"* Day 1-5 LDX 30mg~* Day 6-10 LDX 50mg~* Day 11-15 LDX 70mg~* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~* Day 31-34 Venlafaxine XR 150mg daily~* Day 35-38 Venlafaxine XR 75mg daily."
48501951|NCT00896480|BIOLOGICAL|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
48501952|NCT03283761|DRUG|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
48501953|NCT03283761|DRUG|Oxaliplatin 85 mg/m^2|Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
48137339|NCT03438409|OTHER|Robotic gait training|Robotic gait training
48501954|NCT03283761|DRUG|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
48501955|NCT03283761|DRUG|Leucovorin 400 mg/m^2|Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
48658798|NCT01254214|BEHAVIORAL|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
48137340|NCT01829646|OTHER|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
48137341|NCT01829646|OTHER|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
48137342|NCT01829646|OTHER|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
48137343|NCT01201772|DRUG|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
48137344|NCT01583166|DRUG|Bupivacaine|10ml 0.5% bupivacaine
48137345|NCT01583166|DRUG|Saline|10ml 0.9% sodium chloride
48137346|NCT01583166|DRUG|Epinephrine|1:200,000 epinephrine
48137347|NCT05972252|DEVICE|Cerebrovascular Interventional Procedural Control System|The Cerebrovascular Interventional Procedural Control System is intended for use in the remote delivery and manipulation of guidewires and rapid deliver stent catheters, and remote manipulation of guide catheters during cerebrovascular intervention procedures.
48348090|NCT01235338|DRUG|Venlafaxine XR + LDX|"* Day 1-5 Venlafaxine XR 75mg~* Day 6-10 Venlafaxine XR 150mg~* Day 11-15 Venlafaxine XR 225mg~* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~* Day 21-25 Venlafaxine XR and LDX 50mg daily~* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~* Day 31-34 Venlafaxine XR 150mg~* Day 35-38 Venlafaxine XR 75mg."
48348091|NCT01867580|DEVICE|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
48348092|NCT01867580|DEVICE|V.A.C.Ulta without instillation|NPWT only
48501956|NCT00486941|BEHAVIORAL|Exercise and diet - based on DPS and DPP|
48501957|NCT02444117|OTHER|functional rehabilitation of social communication|
48501958|NCT05643053|OTHER|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
48501959|NCT05643053|OTHER|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
48501960|NCT05643053|OTHER|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
48501961|NCT05643053|OTHER|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
48501962|NCT05109338|DEVICE|Ben-Guard Garment|Wearable device designed to secure CVCs and gastrointestinal feeding tubes. The Ben-Guard Catheter Securement Device was designed specifically to better secure and conceal CVC tubing, protecting the patient by keeping tubing closer to the body.
48501963|NCT04917289|DRUG|Chemotherapy|Started chemotherapy or change the current adjuvant therapy
48501964|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
48501965|NCT01104467|DRUG|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
48501966|NCT01104467|OTHER|Placebo|1 bolus injection of placebo IV
48501967|NCT02619435|DRUG|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
48501968|NCT00851318|DRUG|Certolizumab pegol|Subcutaneous (SC) injection
48501969|NCT00851318|DRUG|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
48501970|NCT02029586|DRUG|MB12066 200mg|oral administration, 100mg bid
48501971|NCT02029586|DRUG|Placebo|oral administration, 100mg bid
48501972|NCT00106964|BIOLOGICAL|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
48501973|NCT00106964|BIOLOGICAL|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
48501974|NCT00106964|BIOLOGICAL|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
48501975|NCT03474497|DRUG|IL-2|• A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
48348093|NCT02805894|DRUG|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
48501976|NCT03474497|DRUG|Pembrolizumab|Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
48501977|NCT03474497|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
48137348|NCT03589768|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.
48348094|NCT02805894|DRUG|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
48348095|NCT03382327|PROCEDURE|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
48348096|NCT04847739|PROCEDURE|Seton Placement|This treatment consists of inserting a seton (a soft flexible tube or nonabsorbable string) into the subject's perianal fistula. The seton will be removed by a study doctor at study visits as applicable.
48348097|NCT04847739|DRUG|AVB-114|AVB-114 consists of stem cells taken from a subject's fat tissue seeded into a bioabsorbable plug. AVB-114 will be inserted into the subject's fistula by a study doctor on Day 0.
48348098|NCT00832091|DRUG|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
48348099|NCT00832091|DRUG|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
48348100|NCT00760890|DIETARY_SUPPLEMENT|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
48348101|NCT00760890|DIETARY_SUPPLEMENT|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
48348102|NCT06398093|BEHAVIORAL|Self-Compassion Tool Kit|Participants will mediate, journal their reactions, exercise, and apply sleep hygiene measures over the course of four weeks.
48348103|NCT04516941|DRUG|Edoxaban Tablets|Treatment
48348104|NCT04516941|DRUG|Colchicine Tablets|Treatment
48348105|NCT06353867|OTHER|Group Exercise|The children with special needs included in the study were included in group exercises for 45 minutes 2 days a week in groups of 10 children each. Group exercises were planned as balance and coordination exercises including warm-up and cool-down periods. In the warm-up and cool-down periods, counting in place and balance exercises were performed. The exercises included tasks such as side walking, tandem walking, walking on a balance board, walking in a figure 8, walking over obstacles, throwing a ball to the person next to him/her while passing through cones, and throwing a ball by jumping while passing through cones.The exercises were made more difficult by following a progressive method every 2 weeks. The exercises were performed in 3 sets of 5 repetitions under the supervision of a physiotherapist.
48348106|NCT05748236|DRUG|Lamotrigine tablet|Lamotrigine: Starting dose 25mg once daily for 2 weeks, then 50 mg once daily for next 2 weeks . Then dose will be increased until seizure control or side effects develop (Maximum 500 mg/day).
48348107|NCT05748236|DRUG|Carbamazepine-Containing Product in Oral Dose Form|Starting dose 100mg twice daily for 2 weeks, then 200 mg twice daily for next 2 weeks. Then dose will be increased until seizure control or side effects develop (Maximum 1600 mg/day).
48501978|NCT02242916|RADIATION|Photon therapy versus proton therapy|
48501979|NCT02242916|RADIATION|Photon therapy versus C-ion therapy|
48501980|NCT05913778|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner in coronary artery and in others organ arteries.
48501981|NCT02971735|OTHER|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
48137349|NCT03589768|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide|A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
48137350|NCT02158806|DRUG|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
48137351|NCT02158806|DRUG|Placebo|Matching placebo capsule containing inert bulking agent
48501982|NCT02378792|DEVICE|Vagus Nerve Stimulation|Vagus Nerve Stimulator
48501983|NCT00140426|DRUG|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
48501984|NCT00140426|DRUG|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
48501985|NCT06470815|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
48501986|NCT04638335|BIOLOGICAL|Blood test|blood test for Anti-HAV antibodies
48658799|NCT01254214|BEHAVIORAL|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
48137352|NCT01171638|DEVICE|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
48137353|NCT01241526|OTHER|Disease Management|"* Individual, group and phone education sessions~* Telephone supporter follow-up~* LTOT monitoring"
48137354|NCT01241526|OTHER|Usual site management|"* Usual education as per site protocol~* Usual follow-up as per site protocol~* LTOT monitoring"
48348108|NCT02124928|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
48501987|NCT05029830|COMBINATION_PRODUCT|investigations like MRI..|• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
48501988|NCT04100720|DEVICE|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
48501989|NCT02553083|DRUG|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
48501990|NCT02553083|DRUG|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
48501991|NCT02553083|DRUG|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
48501992|NCT02553083|DRUG|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
48348109|NCT06356415|DRUG|Bupivacaine injection|Group one will receive infraclavicular block using bupivacaine
48501993|NCT02553083|DRUG|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
48501994|NCT02553083|DRUG|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
48501995|NCT03033082|OTHER|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
48501996|NCT01879930|DRUG|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
48137355|NCT03848975|OTHER|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
48137356|NCT03848975|OTHER|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
48348110|NCT06356415|DRUG|Bupivacaine+ Dexamethasone+ Dexmedetomidine|Group two will receive infraclavicular block using dexamethasone and dexmedetomidine added to the bupivacaine
48348111|NCT00130494|DRUG|Zoledronic acid|
48348112|NCT02451865|DRUG|Binimetinib|Given PO
48348113|NCT02451865|DRUG|Docetaxel|Given IV
48348114|NCT02451865|OTHER|Laboratory Biomarker Analysis|Correlative studies
48501997|NCT01879930|DRUG|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
48501998|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
48501999|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
48502000|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
48502001|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
48502002|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
48502003|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
48502004|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
48502005|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
48348115|NCT01307228|OTHER|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
48502006|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
48502007|NCT02036775|DRUG|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
48502008|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
48502009|NCT02036775|DRUG|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
48137357|NCT03647358|DEVICE|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
48502010|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
48502011|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
48502012|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
48502013|NCT02036775|DRUG|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
48348116|NCT05708729|DEVICE|MCS surgery for CPSP|The investigational devices that will be used for the MCS surgeries are the following: the Vanta with AdaptiveStim Technology Primary cell neurostimulator or the Intellis Implantable Neurostimulator with AdaptiveStim Technology from Medtronic, Inc. (MN, USA). These implantable neurostimulators are intended to generate electrical pulses and to deliver stimulation trough one or more leads as part of a neurostimulation system for pain therapy in adults.
48502014|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
48348117|NCT05708729|DEVICE|Vc-DBS surgery for CPSP|For the deep brain stimulation procedure, we will use Vercise stimulators from Boston Scientific together with the Cartesia Directional Leads or the Percept PC stimulator from Medtronic.
48502015|NCT02036775|DRUG|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
47983882|NCT04062331|DEVICE|Transcranial Magnetic Stimulation (TMS)|"By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months."
48137358|NCT03647358|DRUG|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose.
48137359|NCT01554267|DEVICE|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
48137360|NCT00780806|BIOLOGICAL|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
48348118|NCT05242809|BEHAVIORAL|Group-based PFMT group|The intervention group receives PFMT supervision in groups of about 6-8 women
48502016|NCT03408535|OTHER|Eriksholm Guide to Better Hearing|Online rehabilitation program.
48348119|NCT01111721|BEHAVIORAL|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
48348120|NCT01111721|BEHAVIORAL|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
48348121|NCT02056756|DRUG|Carfilzomib|
48348122|NCT02227290|DRUG|Naftin Cream|
48658800|NCT06484881|DIETARY_SUPPLEMENT|Daniel Alain Probiotic Treatment for Androgenetic Alopecia|Probiotic
48658801|NCT06484881|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
48348123|NCT02227290|DRUG|Placebo Cream|
48348124|NCT05408052|PROCEDURE|Dural Puncture Epidural (DPE)|"Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
48502017|NCT04334694|DEVICE|Atrial flow regulator (Occlutech® AFR device)|Atrial septostomy followed by implantation of AFR.
48502018|NCT00509366|DRUG|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
48502019|NCT00509366|DRUG|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
48502020|NCT00509366|DRUG|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
48502021|NCT00509366|DRUG|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
47983883|NCT04062331|DRUG|Placebos|Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
48137361|NCT00780806|PROCEDURE|Blood draw|Blood draw
48137362|NCT04352517|OTHER|Online Survey|Online survey completion through google app.
48502022|NCT03167723|DEVICE|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
48618212|NCT02177994|DRUG|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
48618213|NCT02750293|DRUG|Cholecalciferol|Vitamin D preparation
48618214|NCT02750293|DRUG|Placebo|placebo
48137363|NCT02513043|DRUG|medical abortion|medical abortion
48137364|NCT05435859|BEHAVIORAL|Speech Tasks|Listen to 25-minutes of speech sounds in English.
48137365|NCT03403036|DRUG|Brodalumab|Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
48137366|NCT03862469|PROCEDURE|Individualized laboratory test|Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.
48137367|NCT06342700|DRUG|Rilzabrutinib crystalline form|Pharmaceutical form:Film coated tablet Route of administration:Oral
48137368|NCT06342700|DRUG|Rilzabrutinib amorphous form|Pharmaceutical form:Film coated tablet Route of administration:Oral
48137369|NCT01499849|DRUG|Rolapitant|(4 X 50 mg capsules) 200 mg PO
48348125|NCT05408052|PROCEDURE|Standart Epidural|"The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
48348126|NCT03152110|OTHER|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
48348127|NCT05303025|OTHER|Survey|Survey to acquire baseline demographic information as well as information regarding professional experience, working environment and attitudes towards artificial intelligence.
48348128|NCT05303025|OTHER|Semi-structured group discussion|Semi-structured group discussion.
48348129|NCT01318928|DRUG|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
48348130|NCT02558452|DRUG|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
48348131|NCT02159989|DRUG|Sapanisertib|Given PO
48137370|NCT01499849|DRUG|Granisetron|10 mcg/kg IV
48137371|NCT01499849|DRUG|dexamethasone|20 mg PO and 8 mg PO
48348132|NCT02159989|BIOLOGICAL|Ziv-Aflibercept|Given IV
48348133|NCT04551560|OTHER|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
48348134|NCT02977039|OTHER|NDPR diet|nutrient rich plant based diert
48348135|NCT02977039|OTHER|USDA healthy eating diet|DASH diet
48348136|NCT05478057|DEVICE|"MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system"|we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
48348137|NCT00655122|DRUG|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
48618215|NCT06281249|DEVICE|Ultrasound placement device|Device to assist in placement of epidural procedure
48137372|NCT01499849|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
48137373|NCT00344916|DRUG|Ng-monomethyl-L-arginine (drug)|
48137374|NCT03418610|DRUG|Azelaic Acid foam 15%|mild to moderate rosacea
48137375|NCT03773471|BEHAVIORAL|Mobile Health App|ArthritisPower App
48137376|NCT04477707|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
48137377|NCT00794300|DEVICE|second magnetic resonance imaging scan|
48137378|NCT00666705|DRUG|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
48137379|NCT00666705|DRUG|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
48137380|NCT00666705|DRUG|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
48137381|NCT00666705|DRUG|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
48137382|NCT03986359|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
48137383|NCT06271850|OTHER|Ergonomics breastfeeding training|The ergonomics training includes the most ergonomically appropriate methods to breastfeed and ergonomic guidelines, including how to cuddle and breastfeed the baby correctly.
48137384|NCT06271850|OTHER|Pilates exercises|Pilates exercises, 3 times per week, for 8 weeks, in the form of neck extensor stretching, neck extensor and rotation stretching, pectoral muscle stretching, strengthening of deep neck flexors and scapular retractor, and core strengthening exercises ( pelvic bridging, plank, cat and camel, curl up, single leg abdominal press and double leg abdominal press).
48137385|NCT00003087|DRUG|cisplatin|
48137386|NCT00003087|DRUG|paclitaxel|
48137387|NCT00003087|PROCEDURE|surgical procedure|
48348138|NCT00655122|DRUG|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
48137388|NCT00003087|RADIATION|radiation therapy|
48348139|NCT00713284|DRUG|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
48348140|NCT00260091|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
48348141|NCT00260091|PROCEDURE|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
48348142|NCT00169767|OTHER|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
48348143|NCT02623699|DRUG|Tofersen|Administered as specified in the treatment arm.
48348144|NCT02623699|DRUG|Placebo|Administered as specified in the treatment arm.
48348145|NCT00922038|BEHAVIORAL|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
48658802|NCT02921867|OTHER|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
48658803|NCT04892277|BIOLOGICAL|Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|Given IV
48658804|NCT04892277|DRUG|Bendamustine|Given IV
48658805|NCT04892277|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48658806|NCT04892277|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48658807|NCT04892277|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48658808|NCT04892277|PROCEDURE|Computed Tomography|Undergo CT
48658809|NCT04892277|DRUG|Cyclophosphamide|Given IV
48658810|NCT04892277|DRUG|Fludarabine|Given IV
48348146|NCT02108522|BIOLOGICAL|Multivirus Specific T cells|
48348147|NCT04819191|BEHAVIORAL|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
48348148|NCT02371018|DIETARY_SUPPLEMENT|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
48348149|NCT03486184|DIAGNOSTIC_TEST|Cystatin-C|"* Laboratory values will be obtained, including level of preoperative serum creatinine, complete blood count, coagulation profile and Cystatin-C (5 ml. venous sample).~* Serum creatinine and hemoglobin will be measured after operation, and thereafter at least once a day as a part of routine clinical care. Postoperative serum Cystatin-C will measured only once."
48348150|NCT02789189|DRUG|nedaplatin and gemcitabine|
48348151|NCT03832816|DRUG|Placebo|Placebo vapor (distilled water)
48137389|NCT01585623|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
48137390|NCT01585623|DRUG|omeprazol|"Pharmaceutical form:capsule~Route of administration: oral"
48658811|NCT04892277|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48658812|NCT04892277|PROCEDURE|Positron Emission Tomography|Undergo CT/PET
48658813|NCT05175157|OTHER|Gut Fellings questionnaire|Answer the Gut Fellings questionnaire
48348152|NCT03832816|DRUG|Vaporized THC alone|Acute exposure to vaporized THC
48348153|NCT03832816|DRUG|Vaporized CBD alone|Acute exposure to vaporized CBD
48348154|NCT03832816|DRUG|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
48658814|NCT06160245|OTHER|exercise therapy|core stabilization exercises
48658815|NCT04039464|DRUG|Mono-Therapy with Sildenafil|The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
48658816|NCT04039464|DRUG|Duo-Therapy with Sildenafil + Bosentan|The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
48658817|NCT05697380|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted.
48658818|NCT06101485|DEVICE|Telerehabilitation|Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)
48658819|NCT06500507|DRUG|QLS4131 Injection|Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
48658820|NCT06197724|DEVICE|Magnetocardiography|Magnetocardiography
48658821|NCT01342315|DRUG|33525|Daily dosing
48658822|NCT01342315|DRUG|Placebo|Daily dosing
48658823|NCT06569823|BIOLOGICAL|Z-1018|Formulation for injection
48658824|NCT06569823|BIOLOGICAL|Shingrix|Formulation for injection
47983884|NCT05192551|OTHER|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
47983885|NCT05688189|DEVICE|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
47983886|NCT00003514|DRUG|antineoplaston A10|
48137391|NCT01585623|DRUG|metoprolol|"Pharmaceutical form:tablet~Route of administration: oral"
48137392|NCT01585623|DRUG|midazolam|"Pharmaceutical form:solution~Route of administration: oral"
48137393|NCT04715269|DRUG|Alprazolam|Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency
48137394|NCT04715269|OTHER|Placebo|Empty capsule
48137395|NCT03041233|OTHER|Observation / Data Collection|"The following data will be reviewed / collected:~Baseline Visit: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~Ablation Procedure: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6- and 12-month follow-up (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
48137396|NCT06100159|DEVICE|Tympanostomy tube insertion|Ventilation tube insertion in the tympanic membrane
48137397|NCT05328466|DEVICE|The engineer-built system, video-game based Kinect sensor|The games were developed by the researcher team.
48137398|NCT04561089|DIAGNOSTIC_TEST|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
48137399|NCT01667198|PROCEDURE|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
48137400|NCT01667198|BEHAVIORAL|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
48137401|NCT05359796|BIOLOGICAL|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
48137402|NCT05359796|BIOLOGICAL|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
48137403|NCT05359796|GENETIC|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
48137404|NCT05359796|DIETARY_SUPPLEMENT|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
47983887|NCT00003514|DRUG|antineoplaston AS2-1|
47983888|NCT00003514|PROCEDURE|alternative product therapy|
47983889|NCT00003514|PROCEDURE|biological therapy|
47983890|NCT00003514|PROCEDURE|biologically based therapies|
47983891|NCT00003514|PROCEDURE|cancer prevention intervention|
47983892|NCT00003514|PROCEDURE|complementary and alternative therapy|
47983893|NCT00003514|PROCEDURE|differentiation therapy|
47983894|NCT00075179|DRUG|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
47983895|NCT00075179|PROCEDURE|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
47983896|NCT02408640|BEHAVIORAL|Cannabishjalpen.se|
47983897|NCT04341454|DRUG|DWP14012 X mg|DWP14012 X mg, tablet, orally, once daily for 2 weeks
47983898|NCT04341454|DRUG|DWP14012 X mg placebo|DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
47983899|NCT04341454|DRUG|DWP14012 Y mg|DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
47983900|NCT04341454|DRUG|DWP14012 Y mg placebo|DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
48137405|NCT05359796|GENETIC|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
48137406|NCT05359796|BIOLOGICAL|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
48137407|NCT05359796|BIOLOGICAL|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
48137408|NCT01052974|DRUG|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
48137409|NCT01702259|DEVICE|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
48137410|NCT01702259|DEVICE|Placebo device|Inactive Erchonia GLS.
48348155|NCT03170492|OTHER|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
48137411|NCT03651934|DIETARY_SUPPLEMENT|Normal iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
48137412|NCT03651934|DIETARY_SUPPLEMENT|Weak iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
48348156|NCT03170492|OTHER|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
48348157|NCT00492895|DRUG|Discontinuation of Azathioprin|Discontinuation of Azathioprin
48348158|NCT02608294|DEVICE|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
48348159|NCT02608294|DEVICE|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
48348160|NCT05654662|DRUG|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million \[ppm\] Fluoride ion \[F\])
48348161|NCT05654662|DRUG|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
48348162|NCT01012804|GENETIC|western blotting|
48348163|NCT01012804|OTHER|immunohistochemistry staining method|
48348164|NCT01012804|OTHER|laboratory biomarker analysis|
48348165|NCT01983683|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
48348166|NCT01983683|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
48348167|NCT01983683|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
48348168|NCT01983683|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
48348169|NCT01805674|DIETARY_SUPPLEMENT|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
48137413|NCT03651934|DIETARY_SUPPLEMENT|Normal selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
48348170|NCT04506879|PROCEDURE|Popliteal Sciatic nerve block|Patients schedule for lower limb surgery under regional anesthesia will receive ultrasound guided subparaneural popliteal sciatic nerve block. After identification of the common peroneal nerve and tibial nerve, local anesthetic agents will be injected close to each nerve below the point of divergence at the popliteal fossa. The spread of the drug and the sensory and motor function of that limb will be assessed regularly till it is ready for surgery.
48348171|NCT03973749|OTHER|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
48502023|NCT02761005|DRUG|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
48502024|NCT02853370|DRUG|Bendamustine and Rituximab|
48502025|NCT00326963|DRUG|Background ARVs|As prescribed
48502026|NCT00326963|DRUG|PI|As prescribed
48502027|NCT00326963|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
48502028|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
48658825|NCT03070665|DRUG|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
48658826|NCT04419987|GENETIC|draw blood|search for new genetic variations (when the diagnostic exploration will have been non informative) by sequencing exons.
48658827|NCT06223152|OTHER|parental support|parental support
48658828|NCT03333187|PROCEDURE|Allogeneic stem cell transplantation|
47983901|NCT00258882|BIOLOGICAL|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
48348172|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
48658829|NCT03333187|DRUG|Ruxolitinib continuous therapy|
48658830|NCT02602145|OTHER|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.
48658831|NCT02494492|OTHER|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
48348173|NCT03743376|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
48502029|NCT01877746|DRUG|Combination of prednisone and azathioprine|"* Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~* Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
48502030|NCT01877746|OTHER|No intervention|No intervention, only standard medical therapy
48502031|NCT06437483|PROCEDURE|Sustained Natural Apophyseal Glides|"SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions."
48502032|NCT06437483|PROCEDURE|Kinesiotaping|"Kinesiotaping (KT):~Subject will be in comfortable sitting position. Neck of the subject will be thoroughly cleaned with alcohol and sterile gauze pads before the application of Kinesiotape.The layers of KT will be applied in the form of two strips i.e. Y strip and I strip. and applied over the neck in a position of cervical flexion and contralateral rotation and, pasted up and over either ridge of the spine covering the cervical muscles.It extends from T1-T2 to either side of C1-C2.The second layer is I-strip:The overlaying I-strip will be placed perpendicular to the Y-strip, It will be stretched from the both ends, and the middle portion of the tape will be applied first after which tension is released and ends are applied without tension."
48502033|NCT06437483|PROCEDURE|Conventional Treatment|Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
48502034|NCT00405444|DRUG|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
48502035|NCT00405444|DRUG|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
48658832|NCT01957384|DEVICE|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
48658833|NCT01957384|DEVICE|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
48658834|NCT01957384|DEVICE|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~* Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~* Dansac: Nova 1 \& Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~* Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~* ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~* B. Braun: Flexima Active \& Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
48658835|NCT05456087|DRUG|incobotulinumtoxin A|Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
48502036|NCT04731337|DEVICE|Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and lower canine teeth.
48502037|NCT02861079|DEVICE|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
48502038|NCT02861079|DRUG|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
48137414|NCT03651934|DIETARY_SUPPLEMENT|Weak selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
48502039|NCT03857750|DRUG|Rocuronium|0.6 mg/kg
48502040|NCT02628743|DRUG|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
48137415|NCT03930940|DEVICE|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
48137416|NCT03930940|OTHER|Regular treatment|Regular treatment is based on associated guidelines for ICH.
48502041|NCT00465465|BIOLOGICAL|MVA 85A|i.d. injection
48502042|NCT01142479|DRUG|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
48658836|NCT05586776|DRUG|4% Chlorhexidine Gluconate|Used for daily showering/bathing for 30 days after hospital discharge.
48658837|NCT05586776|DRUG|2% Mupirocin|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
48348174|NCT05137210|OTHER|Male Counseling and Facility Navigation|At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.
48348175|NCT05137210|OTHER|Home-Based ART Initiation and Facility Navigation|"At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit."
48658838|NCT05586776|DRUG|Soap Without Antiseptic Properties (Placebo)|Used for daily showering/bathing for 30 days after hospital discharge.
48137417|NCT00609050|BEHAVIORAL|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
48137418|NCT00609050|BEHAVIORAL|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
48137419|NCT00609050|BEHAVIORAL|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
48502043|NCT04938323|DRUG|BCG Vaccine|.1 mL of reconstituted BCG vaccine given intradermally at baseline.
48502044|NCT04938323|DRUG|Placebo|.1 mL of diluent (saline) given intradermally at baseline
48502045|NCT02909283|PROCEDURE|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
48502046|NCT02578030|DRUG|SHP465 12.5mg|
48502047|NCT02578030|DRUG|SHP465 25mg|
48502048|NCT02933255|BIOLOGICAL|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.
48502049|NCT02933255|DRUG|Nivolumab|Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.
48502050|NCT02933255|PROCEDURE|Prostatectomy|Participants in the neoadjuvant cohort will undergo a radical prostatectomy in week 9. (If surgery is scheduled earlier than 9 weeks after initial dosing, the 6 and 8 week dosing may be skipped, and surgery may be done as early as week 5.)
48502051|NCT02933255|PROCEDURE|Biopsy|A baseline biopsy is performed for participants in the neoadjuvant cohort that do not have a previous collection of biopsy material.
48502052|NCT02933255|DRUG|Tylenol|Participants who experience aches or fever after vaccination may take Tylenol as directed.
48658839|NCT05586776|DRUG|Placebo Nasal Ointment|Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
48658840|NCT05204485|PROCEDURE|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
48348176|NCT05137210|OTHER|Stepped Intervention|"Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm."
48348177|NCT05625815|DEVICE|Prototypes (816-v1 001) to (816-v1 050)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48502053|NCT06309654|BEHAVIORAL|12-week home-based circuit training (HBCT)|Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks. The first session was conducted at USM Hospital and participants were instructed how to perform the prescribed exercises in a correct form. In each session, participants performed seven exercises (two aerobic- and five resistance-based) in a circuit fashion, using bodyweight movements and adjustable dumbbells for varied weights, activating all the major muscle groups. In weeks 1-6, participants executed 15 repetitions for 2 rounds with 1 min passive rest between exercises and rounds. In weeks 7-12, participants executed 30 repetitions for 4 rounds with the same rest as prescribed in weeks 1-6. Each round lasted 10-15 min and the total session duration was 20-60 min, aiming to help participants adapt gradually to increasing training volume.
48502054|NCT06309654|BEHAVIORAL|Standard of care (CONT)|"Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise)."
48658841|NCT05204485|PROCEDURE|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
48502055|NCT00252239|DRUG|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
48502056|NCT00252239|DRUG|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
47983902|NCT05061810|BEHAVIORAL|Smartphone application self-management programme|The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
48502057|NCT03460392|DRUG|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
48502058|NCT01788618|OTHER|Cognitive exams|"Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
48658842|NCT06482034|DRUG|N-acetyl cysteine|N-acetyl cysteine sachets
48658843|NCT06482034|DRUG|Zinc sulfate|zinc sulfate capsules
48658844|NCT06482034|DRUG|saline mouth wash|saline mouth wash
48658845|NCT06112379|DRUG|Dato-DXd|Experimental drug IV infusion
48658846|NCT06112379|DRUG|Durvalumab|Experimental drug IV Infusion
48658847|NCT06112379|DRUG|Pembrolizumab|IV Infusion Active comparator
47983903|NCT05176353|OTHER|VAP diagnostic stewardship bundle|Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
48502059|NCT01788618|OTHER|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
48658848|NCT06112379|DRUG|Doxorubicin|IV infusion Experimental/Active Comparator
48658849|NCT06112379|DRUG|Epirubicin|IV Infusion Experimental/Active Comparator
48348178|NCT05625815|DEVICE|Prototype (816-v1 051) to (816-v1 100)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48348179|NCT05625815|DEVICE|Prototypes (816-v1 101) to (816-v1 150)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48348180|NCT05625815|DEVICE|Prototypes (816-v1 151) to (816-v1 200)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48348181|NCT00533351|DRUG|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
48348182|NCT00533351|DRUG|placebo|placebo 50 mg capsules three-times daily for 2 weeks
48502060|NCT01788618|OTHER|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
48502061|NCT01788618|OTHER|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
48502062|NCT02041910|BIOLOGICAL|Stem Cells|MSCs injection intratesticular
48502063|NCT02041910|BIOLOGICAL|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
48502064|NCT02468570|OTHER|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
48502065|NCT00471952|DRUG|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
48502066|NCT00471952|DRUG|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
48502067|NCT00471952|DRUG|Placebo + Placebo|One migraine attack will be treated with double placebo
48502068|NCT02702661|PROCEDURE|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
48658850|NCT06112379|DRUG|Cyclophosphamide|IV infusion Experimental/Active Comparator
48658851|NCT06112379|DRUG|Paclitaxel|IV infusion Experimental/Active Comparator
48658852|NCT06112379|DRUG|Carboplatin|IV infusion Experimental/Active Comparator
48658853|NCT06112379|DRUG|Capecitabine|Tablet Oral route of administration Experimental/Active Comparator
48658854|NCT06112379|DRUG|Olaparib|Tablet Oral route of administration Experimental/Active Comparator
48658855|NCT02381587|OTHER|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
48658856|NCT06327425|DEVICE|Magnetocardiography|Magnetocardiography
48658857|NCT05006248|DEVICE|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
48502069|NCT02702661|PROCEDURE|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
48502070|NCT02702661|DRUG|Levobupivacaine|Levobupivacaine 0.125% - 40ml
48348184|NCT05726955|OTHER|Exercise training program|an exercise training program applied with conservative treatment and a stretching platform (ETSP) 3 days a week for 6 weeks
48348185|NCT03329664|BIOLOGICAL|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
48348186|NCT03329664|OTHER|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
48348187|NCT04624672|DRUG|Semaglutide (1 Mg Dose)|Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
48348188|NCT04624672|DRUG|Placebo|Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
48348189|NCT06281314|DEVICE|Vespa software|The Vespa2.0 project refers to the production of tasks useful for neuropsychological rehabilitation, aimed at subjects suffering from Alzheimer's Dementia, Parkinson's and Multiple Sclerosis. It is a neuropsychological rehabilitation project using Virtual Reality (VR).
48348190|NCT02568852|PROCEDURE|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
48348191|NCT02568852|PROCEDURE|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
48348192|NCT02415595|DRUG|BMS-955176|HIV Maturation Inhibitor
48348193|NCT02415595|DRUG|EFV|EFV
48348194|NCT02415595|DRUG|TDF/FTC|TDF/FTC
48348195|NCT04432376|DRUG|miconazole 2% oil|Drug treatment of otomycosis for 14 days
48348196|NCT04432376|DRUG|vehicle oil|Placebo treatment of otomycosis for 14 days
48348197|NCT03011775|DRUG|Pioglitazone 15 mg Tablet|Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
48348198|NCT03011775|DRUG|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
48658858|NCT05006248|DEVICE|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
48658859|NCT05006248|DEVICE|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
48348199|NCT03011775|DRUG|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
48348200|NCT03011775|DRUG|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
48348201|NCT03011775|DRUG|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
48348202|NCT03011775|DRUG|Ramipril 5 MG|1 tablet per a day
48348203|NCT02382614|DEVICE|Spiration Valve System|
48348204|NCT01518309|DRUG|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
48502071|NCT03263975|OTHER|Gatorade or Enterade|Commercially available oral rehydration therapies
48502072|NCT02879734|OTHER|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
48502073|NCT00654290|DRUG|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
48502074|NCT00654290|DRUG|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
48502075|NCT00654290|DRUG|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
48348205|NCT00149890|DRUG|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
48348206|NCT00149890|DRUG|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
48348207|NCT00149890|DRUG|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
48348208|NCT00895908|BEHAVIORAL|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
48348209|NCT00895908|BEHAVIORAL|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
48348210|NCT01336595|DEVICE|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
48348211|NCT01336595|DEVICE|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
48348212|NCT05681897|PROCEDURE|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
48348213|NCT01529827|DRUG|fludarabine phosphate|Given IV
48348214|NCT01529827|DRUG|melphalan|Given IV
48348215|NCT01529827|RADIATION|total-body irradiation|Undergo TBI
48348216|NCT01529827|DRUG|tacrolimus|Given IV or PO
48348217|NCT01529827|DRUG|mycophenolate mofetil|Given IV or PO
48348218|NCT01529827|DRUG|methotrexate|Given IV
48348219|NCT01529827|OTHER|laboratory biomarker analysis|Correlative studies
48348220|NCT01529827|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
48502076|NCT04330716|BEHAVIORAL|Standard Genetic Counseling|Standard of care genetic counseling
48502077|NCT04330716|BEHAVIORAL|Educational Video|Video tutorial about genetic testing
48502078|NCT04864405|OTHER|Morning administration of endocrine therapy|Endocrine therapy administered within one hour of patient wake up time
48348221|NCT01529827|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
48348222|NCT00402285|DIETARY_SUPPLEMENT|lycopene supplement|
48658860|NCT06088667|OTHER|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
48137422|NCT04880018|DEVICE|Capsular Tension Ring|Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd
48348223|NCT00402285|DIETARY_SUPPLEMENT|fish oil supplement|
48348224|NCT00402285|OTHER|Placebo|placebos for lycopene and fish oil.
48658861|NCT00741728|OTHER|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
48658862|NCT05231915|GENETIC|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
48348225|NCT04454749|DIAGNOSTIC_TEST|Blood test|Mesurement of E2, P4, LH, FSH hormones
48348226|NCT04454749|DIAGNOSTIC_TEST|Ultrasound|Follicular measurement and endometrium measurement
48348227|NCT03353441|DIETARY_SUPPLEMENT|Microencapsulated Sublingual Glycine (MSG)|Glycine (MSG) tablet
48658863|NCT05721079|DEVICE|ECP (Extracorporeal Photopheresis System)|Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
48137423|NCT03736980|DRUG|Placebo|100% lactose
48137424|NCT03736980|DRUG|Psilocybine|Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
48137425|NCT03451695|DRUG|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
48137426|NCT03451695|DRUG|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
48137427|NCT01588093|DRUG|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
48137428|NCT01588093|DRUG|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
48137429|NCT01217866|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
48137430|NCT02878616|DRUG|LFG316|LFG316 single dose
48137431|NCT02878616|DRUG|IVIG|IVIG single dose
48137432|NCT05985408|DEVICE|left ventricular septal pacing|For left bundle branch pacing (LBBP) failure cases, use left ventricular septal pacing instead of LBBP; others were same as traditional CRT.
48137433|NCT05985408|DEVICE|right ventricular apical pacing|For left bundle branch pacing (LBBP) failure cases, use right ventricular apical pacing instead of LBBP; others were same as traditional CRT.
48348228|NCT03353441|DIETARY_SUPPLEMENT|Placebo|Lactose tablet manufactured to mimic Glycine (MSG) tablet
48348229|NCT02062970|BIOLOGICAL|blood draw|
48348230|NCT00982748|BEHAVIORAL|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
48348231|NCT03563586|OTHER|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
48348232|NCT03563586|OTHER|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
48348233|NCT00063986|PROCEDURE|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
48348234|NCT04971993|DEVICE|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
48348235|NCT00139633|DRUG|carboplatin, 5FU, Taxol and radiation|
48502079|NCT04864405|OTHER|Evening administration of endocrine therapy|Endocrine therapy administered within one hour of the patient bed time
48502080|NCT05896930|DRUG|Meropenem 6g IV over 6 hours|Meropenem 6g intravenously over 6 hours once daily on days 1-14.
48502081|NCT05896930|DRUG|Ertapenem 1g IM|Ertapenem 1g intramuscularly once daily on days 1-14.
48348236|NCT04124224|OTHER|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
48348237|NCT00858975|PROCEDURE|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
48502082|NCT05896930|DRUG|Meropenem 3g IV|Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
48502083|NCT05896930|DRUG|Ertapenem 1g IV|Ertapenem 1g intravenously once daily on days 1-14.
48348238|NCT04925830|BEHAVIORAL|Heart rate variability biofeedback; haemoncephalography biofeedback|Ten 25-minute weekly heart rate variability biofeedback and 30 minute haemoencephalogrphy biofeedback sessions
48502084|NCT05896930|DRUG|Amoxicillin/CA twice daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
48502085|NCT05896930|DRUG|Rifampicin 35 mg/kg|Rifampicin 35 mg/kg once daily on days 1-14.
48502086|NCT05896930|DRUG|Meropenem 6g IV over 60 minutes|Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
48502087|NCT05896930|DRUG|Rifafour e-275|Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
48502088|NCT05896930|DRUG|Meropenem 4g IV|Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
48502089|NCT05896930|DRUG|Amoxicillin/CA once daily|Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
48502090|NCT04283500|DRUG|Buprenorphine Naloxone|Participants will receive the BUP SL 32mg in divided doses rather than all at once. If after the initial 8mg dose a participant experiences over-sedation or another adverse event that would preclude further dosing, such as an allergic reaction, the subsequent dose will not be administered and the patient will be withdrawn from the study. The participant will be reassessed for other possible etiologies for these symptoms.
48348239|NCT01723202|DRUG|dabrafenib|150 mg orally twice daily given orally
48348240|NCT01723202|DRUG|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
48348241|NCT01723202|OTHER|Correlative Studies|"1. Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~2. BRAF mutation studies in circulating plasma DNA (all study patients)~3. Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~4. Assess predictors of response (Archival tumor block/unstained slides in all study patients)~5. Pharmacokinetic studies (First 10 pts enrolled on each arm)~6. Pharmacogenomics studies (All study patients)"
48502091|NCT01239134|BIOLOGICAL|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
48502092|NCT02455037|OTHER|Neck Strengthening|Targeted neck strengthening exercises
48502093|NCT06299917|OTHER|WORK-ON|The intervention includes three parts: 1) a coordinating occupational therapist, 2) four group sessions and 3) Individual consultations based on the agreed upon goals.
48502094|NCT06483841|BEHAVIORAL|Parents as Partners|The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their participation in the study is finished and if positive outcomes are found.
48502095|NCT05231538|OTHER|Neurodevelopmental therapy|NDT is a hands-on, 'problem solving approach'. It is used in the management and treatment of children who have disorders of function, movement or postural control because of damage in their central nervous system.
48502096|NCT05231538|OTHER|Routine physical therapy|stretching, passive range of motion, and active range of motion).
48348242|NCT02823613|DIETARY_SUPPLEMENT|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
48137434|NCT00862030|PROCEDURE|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
48137435|NCT05996315|OTHER|Hematoma block|A patient who presents to the emergency department with a suspected distal end radius fracture , will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give hematoma block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
48137436|NCT05996315|OTHER|Supracondylar radial nerve block|A patient who presents to the emergency department with a suspected distal end radius fracture will be assessed with a baseline NRS score1 and given analgesics if needed. Further they will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give supracondylar radial nerve block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
48137437|NCT00223756|OTHER|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
48137438|NCT05183126|DRUG|Paclitaxel|Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
48137439|NCT05183126|DRUG|Paclitaxel|"Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time."
48137440|NCT01401218|OTHER|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
48137441|NCT04658667|BIOLOGICAL|IHV01|IHV01 consists of the Full-Length Single Chain (FLSC) gp120-CD4 chimera subunit HIV-1 vaccine formulated in aluminum phosphate adjuvant. It is encoded by a synthetic gene, which contains a human codon-optimized HIV (BaL) gp120 sequence followed by human CD4D1D2, with a flexible 20-amino acid linker.
48137442|NCT04658667|BIOLOGICAL|A244|A244 consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE. The A244 gp120 envelope has an 11 amino N-terminal deletion, similar to the A244 protein used in AIDSVAX B/E. The aluminum hydroxide fluid gel (AHFG) adjuvant that is mixed with A244 consists of Rehydragel HPA that is diluted with sterile water for injection to a concentration of 5 + /- 1mg/mL.
48137443|NCT04658667|BIOLOGICAL|ALFQ|ALFQ (Army Liposomal Formulation) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA) with the addition of QS-21.
48137444|NCT04658667|OTHER|Placebo|Normal saline (Sodium Chloride for injection USP, 0.9%) will be used as placebo.
48137445|NCT05150873|OTHER|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
48137446|NCT00036140|DRUG|Investigational drug|
48348243|NCT02823613|DIETARY_SUPPLEMENT|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
48348244|NCT02387450|DRUG|Sildenafil|100 mg per day
48348245|NCT02387450|DRUG|Placebo|Placebo with same presentation as the active drug
48348246|NCT06214923|DEVICE|RelieVRx|Participants will use RelieVRx daily for 20min/day for 3 weeks
48348247|NCT06214923|DEVICE|Sham-VR|"Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks"
48348248|NCT06214923|OTHER|No-VR (natural history control)|Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)
48137447|NCT01465152|DRUG|metformin|Adminstered orally during the three main meals for 24 weeks
48137448|NCT01465152|DRUG|repaglinide|Administered orally before the three main meals for 24 weeks
48137449|NCT03773549|OTHER|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
48137450|NCT04161716|DEVICE|NIRS recording|Patient has a NIRS module during their urodynamic exam.
48348249|NCT00675311|BEHAVIORAL|DM-Standard|Device/t+ Medical Diabetes Management System
48348250|NCT00675311|BEHAVIORAL|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
48348251|NCT02583360|DIAGNOSTIC_TEST|Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy|Addition of research HRM along with diagnostic VFSS with parental choice of therapy
48348252|NCT01105468|DEVICE|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
48348253|NCT01105468|DEVICE|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
48137451|NCT06452173|DIAGNOSTIC_TEST|Plasma|Plasma levels of metabolites and some proteins will be further determined
48137452|NCT06452173|DIAGNOSTIC_TEST|carotid high-resolution magnetic resonance imaging|Define plaque composition and morphological characteristics
48137453|NCT04136990|PROCEDURE|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
48658864|NCT01715116|DEVICE|Enhanced ICD programming|"* VT monitor: \> 166/min~* fVT: \> 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~* VF: \> 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~* SVT/VT discrimination is turned on, high rate time out is OFF~* SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~* SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~* T wave-oversensing and lead noise discrimination is turned on in all devices."
48348254|NCT01675856|OTHER|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
48348255|NCT01675856|OTHER|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
48137454|NCT04136990|PROCEDURE|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
48137455|NCT01928875|DEVICE|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
48137456|NCT01928875|DEVICE|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
48137457|NCT06071052|PROCEDURE|TACE and HAIC Combined With Regorafenib|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer who failed the second line treatment regimens
48502097|NCT06351436|BEHAVIORAL|Mindfulness|The mindfulness-based intervention will last for three months, with 6-8 weekly sessions lasting 1.5 hours each. Participants will attend the sessions in a group format, and the sessions will be administered by registered social worker who are specialized in counseling. The intervention is delivered using an immersive virtual reality cave system. The intervention content is designed by a registered clinical psychologist accredited for delivering mindfulness-based intervention and nurses who are experienced in mindfulness training. To ensure protocol adherence, the social workers administering the intervention will receive close supervision from the clinical psychologist. Weekly meetings will be held to discuss and resolve any difficulties or challenges encountered by the social workers.
48137458|NCT02233556|DRUG|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~1. Mismatch negativity(MMN)~2. P50"
48137459|NCT03066921|DIETARY_SUPPLEMENT|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
48137460|NCT03066921|DIETARY_SUPPLEMENT|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
48658865|NCT05925400|DEVICE|Virtual Reality during Embryo Transfer|Patients randomized to the study group, will be provided with the VR headset. The VR exposure will take place 10-15 minutes before the Embryo Transfer (ET) and a 10 min immersion after the ET
48658866|NCT04956887|BEHAVIORAL|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
48137461|NCT01128595|DRUG|FF/GW642444M|
48137462|NCT01128595|DRUG|GW642444M|
48137463|NCT01128595|DRUG|Fluticasone Furoate|
48348256|NCT03634228|DRUG|Cytarabine|Given SC
48348257|NCT03634228|DRUG|Milademetan Tosylate|Given PO
48348258|NCT03634228|DRUG|Venetoclax|Given PO
48137464|NCT01128595|DRUG|Placebo|
48137465|NCT01235520|DRUG|Placebo|Oral doses, once a day for 52 weeks
48137466|NCT01235520|DRUG|RO4917838|Oral dose level 1, once a day for 52 weeks
48137467|NCT01235520|DRUG|RO4917838|Oral dose level 2, once a day for 52 weeks
48137468|NCT00729209|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
48137469|NCT00729209|DRUG|Placebo; oral|matching placebo
48137470|NCT01263132|DRUG|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
48348259|NCT04671095|DEVICE|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
48348260|NCT02329860|DRUG|Apatinib|
48348261|NCT02329860|DRUG|Placebo|
48348262|NCT00307814|DRUG|Epoetin Alfa|
48348263|NCT04737954|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
48348264|NCT04737954|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
48348265|NCT04591873|OTHER|telemedicine|Using telemedicine system to communicate
48348266|NCT04591873|OTHER|traditional communication tools|Use telephone or direct verbal communication
48348267|NCT00000281|BEHAVIORAL|Amantadine|
48348268|NCT02295436|DRUG|minodronic acid|comparison of different doses, ages and medication conditions
47983904|NCT03954951|OTHER|Multimodality behavioral strategy|"* On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~* Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province."
48348269|NCT06396130|DEVICE|Photobiomodulation by low level diode laser|Diode laser exposure (Lite Medics 1.00-Watt serial number 148 Ver. SwvM. 150VS108VT.100) will be carried out using a continuous mode with 10 Hz frequency, 980 nm wavelength, and max power 15 WCW. The tip will be applied both at the buccal and the lingual side for 30 s each.
48658867|NCT04956887|OTHER|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
47983905|NCT02379806|DRUG|Enoxaparin|
47983906|NCT02379806|DRUG|Placebo|
48658868|NCT03301584|OTHER|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
48348270|NCT06396130|OTHER|Mock Laser Application|Placebo for control group
48348271|NCT04481880|DIAGNOSTIC_TEST|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
47983907|NCT05971810|DIETARY_SUPPLEMENT|immunonutrition supplement of ORAL IMPACT™|For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
47983908|NCT05971810|OTHER|oral chlorhexidine decontamination|For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
47983909|NCT02724475|PROCEDURE|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
48137471|NCT01263132|DRUG|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
48348272|NCT05980611|DIAGNOSTIC_TEST|IL B,IL 3 in nasal swap and serum|Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).
48348273|NCT05821374|DRUG|Deucravacitinib|6 mg tablet
48348274|NCT04987424|DIAGNOSTIC_TEST|Development and validation of Lymphedema levels diagnostic|A single intervention was carried out in which the patients were summoned for an interview and anthropometric measurements of the upper limbs, thus calculating the arm volume for a lymphedema primary diagnosis .
48348275|NCT01387074|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
48348276|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
48348277|NCT00183261|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
48502098|NCT05119348|OTHER|STOPCOV|Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.
48502099|NCT06315595|OTHER|Non-Interventional Study|Non-interventional study
48502100|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|"1. Cohort A: PBC treatment group: (1) PBC patients with poor response to UDCA after treatment: 30 patients continued to take UDCA（13-15mg/kg）, 30 patients took UDCA（13-15mg/kg）+SASP (0.5g orally three times a day), 30 patients took SASP (0.5g orally three times a day) for 12 months, and 12 months of follow-up observation.~(2) Newly treated PBC patients: 30 patients took UDCA（13-15mg/kg） and 30 patients took UDCA（13-15mg/kg）+SASP (0.5g orally three times a day) for 12 months and were followed up for 12 months.~2. Cohort B-D: 60 cases were collected from each group, 30 cases continued the current treatment(people with hepatitis B cirrhosis and hepatitis C cirrhosis continue to take antivirals), and 30 patients were taking sulfasalazine for 12 months of follow-up observation.~After 12 months of treatment, at the time of enrollment and the 1st/2nd/3rd/6th/9th/12 months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected。"
48658869|NCT03301584|OTHER|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
48658870|NCT06565312|DIETARY_SUPPLEMENT|Flora Power Probiotic Vaginal Suppository|The suppository contains Microcrystalline Cellulose, Ascorbic Acid, Vitamin C, Gelatin Capsule, Vaginal Probiotic Blend (Lactobacillus fermentum LF61, Lactobacillus acidophilus LA85, Lactobacillus plantarum Lp90), Magnesium Stearate, and Silicon Dioxide.
48658871|NCT06095011|DEVICE|UpRight Go|The UpRight Go posture trainer is a commercially available biofeedback sensor that externally attaches to the wearer via a necklace or silicon adhesive. It vibrates when it senses that the wearer is slouching and connects to a smartphone application which sets daily goals, tracks usage, and provides assistance and support. It complies with International Electrotechnical Commission (IEC) standards.
48137472|NCT00980213|DRUG|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
48137473|NCT06067776|BIOLOGICAL|Cetuximab|Given IV
48137474|NCT06067776|DRUG|Osimertinib|Given PO
48137475|NCT06067776|DRUG|Tucatinib|Given PO
48137476|NCT02447666|DRUG|Azacitidine|
48137477|NCT04948736|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|"Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks).~Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol.~Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink."
48137478|NCT04948736|OTHER|Conventional medial care|"Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein-rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
48348278|NCT06201403|DIAGNOSTIC_TEST|Determination of biomechanical properties of muscles|All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
48348279|NCT02945943|OTHER|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
48348280|NCT02945943|OTHER|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
48502101|NCT06075108|OTHER|P-KIDs CARE|The P-KIDs CARE intervention will include two components: 1) the World Health Organization (WHO) Basic Emergency Care Course for training on patient assessment and stabilization, and 2) a decision support tool which integrates adaptation of two evidence-based tools: a) the Pediatric Resuscitation and Trauma Outcome model for mortality risk assessment, and 3) the Field Triage Decision Scheme to assist with timely referral decisions. WHO Basic Emergency Care Course includes modules delivered via PowerPoint with hands-on training components. The decision support tool will be online with checkboxes that healthcare providers can cross as they fill it out in real time. The team will adapt the tool for use in Northern Tanzania, with particular attention to local contextual and cultural factors.
48502102|NCT04555720|BEHAVIORAL|Interdisciplinary Visit|If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
48502103|NCT01062867|DRUG|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
48502104|NCT01615237|BEHAVIORAL|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
47983910|NCT02724475|PROCEDURE|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
47983911|NCT04159025|DEVICE|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
47983912|NCT06119360|PROCEDURE|Face-to-face approach|A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement
47983913|NCT06119360|PROCEDURE|Conventional approach|Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
48137479|NCT05964023|DEVICE|pBFS rTMS|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
48137480|NCT05964023|DEVICE|5-cm rTMS|"Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be localized by 5-cm rule."
48137481|NCT06387550|PROCEDURE|Eccentric Training|Warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
48137482|NCT01883193|DIETARY_SUPPLEMENT|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
48137483|NCT01087437|DIETARY_SUPPLEMENT|gastrolith calcium|
48137484|NCT02734355|DRUG|Telmisartan 80 mg and amlodipine 5 mg|
48137485|NCT02734355|DRUG|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
48348281|NCT03684525|PROCEDURE|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
48348282|NCT03998241|OTHER|No intervention was provided|No intervention given
48348283|NCT02587975|DRUG|Evogliptin|10 mg
48137486|NCT01015872|DEVICE|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
48137487|NCT01673594|DRUG|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
48137488|NCT01673594|DRUG|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
48137489|NCT05965700|DRUG|NVG-291|A once daily injection
48137490|NCT03295409|BEHAVIORAL|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
48137491|NCT03075683|BEHAVIORAL|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
48137492|NCT03075683|BEHAVIORAL|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
48137493|NCT02113267|DRUG|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
48348284|NCT03714789|OTHER|Blood and spent dialysate collection|A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
48348285|NCT01833390|DRUG|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
48502105|NCT01615237|BEHAVIORAL|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
48348286|NCT01464294|DEVICE|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
47914586|NCT01705509|DRUG|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
47983914|NCT03557151|OTHER|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
47983915|NCT03557151|BEHAVIORAL|Transdisciplinary Care-In Person & Telehealth|TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
48137494|NCT02113267|DRUG|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
48348287|NCT01464294|DEVICE|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
48348288|NCT00564200|DRUG|Bortezomib|"PREACONDICIONAMIENTO:~* 2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~* 1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~- Day -2: Velcade~POSTRANSPLANTATION:~* 2 cycles of 21 days : Velcade days 1, 8 and 15~* 5 cycles of 56 days : Velcade days 1, 8 and 15"
48348289|NCT00564200|DRUG|dexamethasone|"PREACONDICIONAMIENTO:~- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
48348290|NCT00564200|DRUG|Fludarabine|"ACONDICIONAMIENTO:~- Days -9 al -5: Fludarabine"
48348291|NCT00564200|DRUG|Melphalan|"ACONDICIONAMIENTO:~- Days -4 and -3: Melphalan."
48348292|NCT05254925|DRUG|Sunscreen oil with 6% Bemotrizinol|Sunscreen oil with 6% BEMT (PARSOL® Shield) and 10% ethanol as penetration enhancer
48348293|NCT05254925|OTHER|Sunscreen oil vehicle|Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (BEMT replaced by Isopropylmyristate)
48618216|NCT04562909|DEVICE|Neurocom balance master device|With the Modified Sensory Balance Interaction Clinical Test, the static balance will be examined by measuring the torso oscillation velocities while the eyes are open and the eyes closed on the stable rigid and unstable foam floors, and the dynamic balance will be examined with the sit-stand test, which is the basic motor activity in daily life, and the parameters will be measured on the same device.
48348294|NCT05254925|DRUG|Dispersion of 6% BEMT in petrolatum|Dispersion of 6% BEMT (PARSOL® Shield) in petrolatum
47914587|NCT01794143|DRUG|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
48137495|NCT02988713|DEVICE|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
48137496|NCT01971112|DIETARY_SUPPLEMENT|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
48137497|NCT02111096|DRUG|LY2409021|Administered orally
48137498|NCT02111096|DRUG|Sitagliptin|Administered orally
48137499|NCT02111096|DRUG|Placebo|Administered orally
48137500|NCT02111096|DRUG|Metformin|Administered orally
48137501|NCT02111096|DRUG|Sulfonylurea|Administered orally
48137502|NCT02879942|OTHER|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
48137503|NCT02879942|OTHER|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
48137504|NCT04256395|OTHER|mobile internet survey on self-test|1. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
48348295|NCT05254925|OTHER|Petrolatum vehicle|Petrolatum vehicle
48348296|NCT05315024|DRUG|Fluarix Tetra|Fluarix Tetra
48502106|NCT01615237|BEHAVIORAL|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
47983916|NCT02786251|OTHER|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
48137505|NCT03723031|DRUG|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
48137506|NCT01833455|DRUG|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
48502107|NCT02564146|DRUG|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
48618217|NCT01148485|OTHER|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
48618218|NCT03704688|DRUG|Trametinib 0.5 mg|0.5mg PO q daily
47983917|NCT02786251|OTHER|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (\~26-28°C).
48002531|NCT03951246|OTHER|Cognitive and Motor Training|"In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo .....~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again."
48137507|NCT01833455|DRUG|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
48137508|NCT02191670|DRUG|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
48137509|NCT01291212|DRUG|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
48348297|NCT05315024|DRUG|Imiquimod cream|Imiquimod cream
48137510|NCT01291212|DRUG|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
48137511|NCT04246866|BIOLOGICAL|GEM103|GEM103
48137512|NCT04148170|PROCEDURE|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
48137513|NCT02879136|DRUG|Methylphenidate|Patient will be randomized to Methylphenidate
48137514|NCT02879136|OTHER|Physical Therapy|All Patients will have standard of care PT used for PD patients
48137515|NCT02879136|DRUG|Atomoxetine|Patient will be randomized to Atomoxetine
48348298|NCT02644694|DRUG|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
48348299|NCT01946568|DRUG|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.
48348300|NCT01378091|DRUG|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
48348301|NCT01378091|DRUG|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
48348302|NCT01378091|DRUG|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
48348303|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
48348304|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
48348305|NCT00407641|DRUG|Tinzaparin administration|Patients will receive tinzaparin during the HD session
48348306|NCT00407641|DRUG|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
48348307|NCT03073200|DRUG|Ixekizumab|Administered SC
48348308|NCT03073200|DRUG|Placebo|Administered SC
48502108|NCT02564146|DRUG|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
48348309|NCT03073200|DRUG|Etanercept|Administered SC
48348310|NCT03016039|DIETARY_SUPPLEMENT|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
48348311|NCT03250130|BEHAVIORAL|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
48348312|NCT03051217|OTHER|Placebo|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W"
48502109|NCT05006768|DRUG|Barcimiant|1 tablet contains 4 mg Barcitinib
48502110|NCT05006768|DRUG|Olumiant (first dose)|1 tablet contains 4 mg Barcitinib
48502111|NCT05006768|DRUG|Olumiant (second dose)|1 tablet contains 4 mg Barcitinib
48348313|NCT03051217|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
48502112|NCT00792935|DRUG|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
48502113|NCT00792935|DRUG|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
48502114|NCT00792935|DRUG|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
48502115|NCT05379907|OTHER|SIGNATERA™ ctDNA testing|Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.
48502116|NCT00315237|DRUG|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
48618219|NCT03704688|DRUG|Trametinib 1 MG|1.0 mg PO q daily
48618220|NCT03704688|DRUG|Trametinib 1.5 MG|1.5mg PO q daily
48618221|NCT03704688|DRUG|Trametinib 2 mg|2 mg PO q daily
47914588|NCT01794143|DRUG|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
48348314|NCT01679704|DIETARY_SUPPLEMENT|Food products|
48348315|NCT02374073|OTHER|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
48348316|NCT02374073|OTHER|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
48348317|NCT01407289|DRUG|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
48137516|NCT02134171|OTHER|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
47983918|NCT05927090|PROCEDURE|Conservative Root- Sparing Aortic Valve Resuspension with or without Hemiarch Repair|Cardiac arrest will be performed by administering a potassium-rich antegrade cardioplegia solution delivered directly into the coronary ostium or in the case of aortic regurgitation after insertion of the coronary sinus cannula.The aorta will be resected up to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion can be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget above every commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients demonstrating normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferable.
48348318|NCT04524091|OTHER|Positive end expiratory pressure|Initially, the patients will be ventilated using pressure support ventilation with an inspiratory pressure adjusted to achieve 6 - 8 ml/kg of PBW with a minimal esophageal pressure swing of 5 cmH2O and a PEEP of 5 cmH2O. After 5 minutes, we will measure five IPSexp and five IPSinsp in random order and considering a resting period between each occlusion in order to avoid learning effect and disconfort. The IR will be calculated using the average of the measured IPSexp and the average of the IPSinsp. Besides, we will register the average of esophageal pressure and transpulmonary pressure swings continuously. The same procedure will be carried out with 10 and 15 cmH2O of PEEP. Inspiratory pressure will be kept constant throughout the protocol.
48348319|NCT00831857|OTHER|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
48348320|NCT03638518|OTHER|Acupuncture|Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
48348321|NCT03638518|OTHER|Physiotherapy|Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
48658872|NCT04164927|OTHER|Manual Lymphatic Drainage|"1. Lymphatic correction method was used via the KinesioTaping® to patients group.~2. Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~3. Control group received only physiotherapy treatment."
48658873|NCT04164927|OTHER|Kinesio Taping|Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
48348322|NCT00054756|DRUG|TRH (Thyrotropin Releasing Hormone)|
48348323|NCT01339780|RADIATION|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
48348324|NCT01003340|BEHAVIORAL|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
48348325|NCT04724213|OTHER|Testing of reliability / validity of new questionnaire|Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
48348326|NCT01045551|DRUG|Apremilast|20mg taken orally twice per day for 12 weeks
48618222|NCT03704688|DRUG|Ponatinib 15 MG|15mg PO q daily
48618223|NCT03704688|DRUG|Ponatinib 30 MG|30mg PO q daily
47914589|NCT01794143|DRUG|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
47914590|NCT01794143|DRUG|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
47914591|NCT00856518|DEVICE|EMST|Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
47914592|NCT00856518|DEVICE|Sham|The same device just like the EMST but does not provide a load on the target muscle group
47914593|NCT02506803|DRUG|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
47914594|NCT06327880|DRUG|PF-07054894 or placebo|multiple oral doses of PF-07054894 for 14 days
47914595|NCT00982059|OTHER|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
47914596|NCT00207285|BEHAVIORAL|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
47914597|NCT00207285|PROCEDURE|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
48137517|NCT04255316|PROCEDURE|Modified method of eversion carotid endarterectomy|Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
48137518|NCT04255316|PROCEDURE|Standard method of eversion carotid endarterectomy|standard eversion technic
48137519|NCT05656066|BEHAVIORAL|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
48137520|NCT05656066|BEHAVIORAL|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
48137521|NCT01727570|DIETARY_SUPPLEMENT|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
48137522|NCT02170337|DRUG|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
48137523|NCT02170337|DRUG|Placebo|Contains no active drug
48658874|NCT04164927|OTHER|Control|Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
48137524|NCT02305511|DEVICE|Peripheral venous catheterization|Cannulation using standard method
48137525|NCT02305511|DEVICE|Jamshidi|intraosseous access using the Jamshidi device
48137526|NCT02305511|DEVICE|BIG|intraosseous access using the BIG device
48348327|NCT00626340|DRUG|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
48348328|NCT00626340|DRUG|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
48348329|NCT00626340|DRUG|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
48348330|NCT00626340|DRUG|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
48348331|NCT00262353|DEVICE|Dialysis with different artificial devices|
48348332|NCT05177224|OTHER|Ultrasound acquisitions to define liner position during movements|"Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~* Walking~* Knee-bending~* Standing up~* Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate."
48348333|NCT04311437|PROCEDURE|Self-acupressure therapy|The self-acupressure therapy is as follows: Patients are in sitting position, applied firm pressure (3-5 kg of pressure) with the fingertips in a circular motion at a speed of two circles per second for a duration of one min per acupoint. A 1-2-s rest is applied after each ten circles. The complete process lasts for about 5 min.
48502117|NCT04164225|BEHAVIORAL|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
48137527|NCT02305511|DEVICE|Cook|intraosseous access using the Cook device
48137528|NCT02305511|DEVICE|EZIO|intraosseous access using the EZIO device
48137529|NCT04346914|BIOLOGICAL|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide|ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w
48137530|NCT03569774|PROCEDURE|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
48137531|NCT03569774|PROCEDURE|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
48137532|NCT03813472|DEVICE|Hydration Sensor|This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
48348334|NCT04311437|PROCEDURE|Combined Valsalva and Toynbee maneuvers|Valsalva maneuver: blowing against a closed mouth and nostrils, increasing the middle ear pressure. Toynbee maneuver: swallowing while the mouth and nostrils are closed, decreasing the middle ear pressure.
48348335|NCT03228992|DRUG|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
48348336|NCT03228992|OTHER|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
48137533|NCT05879276|DRUG|Empagliflozin 10 MG|Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.
48137534|NCT03455985|OTHER|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
48137535|NCT03455985|OTHER|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
48137536|NCT05116709|DRUG|BAT6005 injection|Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
48137537|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
48137538|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
48137539|NCT02311621|BIOLOGICAL|Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
48137540|NCT00548444|BIOLOGICAL|MVA85A|Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
48137541|NCT00548444|OTHER|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
48137542|NCT04301206|BEHAVIORAL|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
48137543|NCT01413659|BIOLOGICAL|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
48502118|NCT04164225|BEHAVIORAL|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
48137544|NCT00093353|DRUG|cefixime|
48137545|NCT00093353|DRUG|irinotecan hydrochloride|
48348337|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
48348338|NCT03216980|DIETARY_SUPPLEMENT|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
48348339|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
48348340|NCT03216980|DIETARY_SUPPLEMENT|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
48502119|NCT01345916|DRUG|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
48502120|NCT01345916|DRUG|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
48502121|NCT01345916|DRUG|BDP DPI 2 months|BDP DPI 2 months
47914598|NCT06044701|OTHER|Hologram Distraction Technique|Hologram fan application during blood collection process
48137546|NCT00093353|DRUG|temozolomide|
48137547|NCT01960738|OTHER|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
48502122|NCT01485744|DRUG|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
48502123|NCT06300320|DRUG|TQ05105 tablets|Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
48137548|NCT06389266|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of rTMS with functional magnetic resonance imaging allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.
48137549|NCT05657210|GENETIC|Mutation|
48137550|NCT00000215|DRUG|Pergolide|
48137551|NCT04813224|BEHAVIORAL|TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT|Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
48348341|NCT00959699|DRUG|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
48348342|NCT00959699|DRUG|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
48348343|NCT00959699|DRUG|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
48348344|NCT00959699|DRUG|Boceprevir|Boceprevir (800 mg, orally, three times per day)
48348345|NCT01822249|DRUG|EPI-743|
48348346|NCT01822249|DRUG|Placebo|
48348347|NCT05116683|DRUG|ATX-101|Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
48348348|NCT03027869|DEVICE|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
48348349|NCT02023541|RADIATION|Proton beam therapy|
48137552|NCT04487249|OTHER|Vision Therapy|20 consecutive weeks of office-based vision therapy with home therapy that aim to improve the participant's vergence skills, accommodative skills, and sensory fusion.
48137553|NCT04388865|BEHAVIORAL|Control|Subjects will engage with their providers as is standard of care.
48137554|NCT04388865|BEHAVIORAL|Text-based Clinical Hovering|Subjects will receive remote monitoring via text messaging of clinical symptoms and medication adherence reminders with feedback to social support.
48348350|NCT01948518|DRUG|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
48348351|NCT03411434|DRUG|Methylphenidate Oral Tablet|cf arm group description
48348352|NCT01951872|BEHAVIORAL|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
48348353|NCT03562520|BEHAVIORAL|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
48348354|NCT00000895|DRUG|Nelfinavir mesylate|
48658875|NCT05497687|OTHER|Resistance exercise|The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
48137555|NCT06074744|OTHER|SSNB + IPACK|already included in arm/group description
48137556|NCT06074744|OTHER|FNB + IPACK|already included in arm/group description
48137557|NCT05689606|BEHAVIORAL|Exercise|Exercise includes acute high-intensity interval training.
48137558|NCT02089529|DRUG|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
48137559|NCT02089529|DRUG|Placebo|Placebo with no information, positive information and neutral information
48137560|NCT04236700|OTHER|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
48137561|NCT00679406|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting \>1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
48137562|NCT02722434|OTHER|Laboratory Biomarker Analysis|Correlative studies
48137563|NCT02722434|OTHER|MC5-A Scrambler Therapy|Undergo Scrambler therapy
48502124|NCT02828306|OTHER|Patient Specific Implant|Implantation of Patient Specific Implant
48137564|NCT02722434|OTHER|Questionnaire Administration|Ancillary studies
48502125|NCT04159935|DEVICE|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
48502126|NCT03716414|PROCEDURE|SLN mapping|"Intra-operative SLN mapping with indocyanine green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible."
48658876|NCT05769062|PROCEDURE|Single digit pelvic exam|The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
48658877|NCT01442610|DRUG|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
48658878|NCT01442610|DRUG|Placebo|Placebo 1tablet once daily for 8 weeks
48137565|NCT02722434|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
48137566|NCT00989118|PROCEDURE|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
48137567|NCT05856682|PROCEDURE|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.
48137568|NCT01887275|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
48348355|NCT00000895|DRUG|Nevirapine|
48348356|NCT00000895|DRUG|Azithromycin|
48348357|NCT06384300|OTHER|Financial Incentives|In the financial incentive group, participants will receive reimbursement for transportation, accommodation, and food costs, along with RMB 200 (about 30 US dollar) to compensate for potential income loss due to endoscopy, provided they undergo the endoscopy.
48502127|NCT00835965|DRUG|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
48348358|NCT06384300|OTHER|Motivational Intervention|For the motivational intervention group, researchers will provide detailed information about the social norms surrounding endoscopy screening, including the prevalence of screening participation, the potential risks of gastric cancer, and the health benefits of screening.
48348359|NCT06384300|OTHER|Mixed Intervention|Participants in the mixed intervention group will receive both financial incentives and motivational intervention.
48348360|NCT01525524|DEVICE|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
48348361|NCT03221660|DEVICE|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
48348362|NCT03445611|DRUG|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
48348363|NCT03445611|DRUG|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
48348364|NCT05549089|DEVICE|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
48348365|NCT05549089|DEVICE|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
48348366|NCT05549089|DEVICE|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
48348367|NCT03021928|OTHER|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 72 (+/- 24) hours, 132 (+/- 12) hours, 228 (+/- 12) hours, and 324 (+/- 12) hours.
48348368|NCT05017168|DRUG|CT-P63|CT-P63 will be administered
48348369|NCT05017168|DRUG|Placebo|Placebo-matching CT-P63
47983919|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Aortic Root Replacement (ARR)|Patients who experienced dilatation of the sinuses of Valsalva \> 4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will receive replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure associated to AAR
47983920|NCT05927090|PROCEDURE|Extensive Ascending Aorta Replacement (AAR) with Total Arch Replacement (TARP)|Total arch replacement procedures (TARP) will performed with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
47983921|NCT05927090|PROCEDURE|Extensive Root and Ascending Aorta Replacement with Total Arch Replacement|This extensive procedure will include complete replacement of the anterior thoracic aorta extending to part or all of the aortic arch. It will be performed with the previously reported techniques
47983922|NCT04607850|BIOLOGICAL|ChAdOx1-HPV|Trial vaccine
47983923|NCT04607850|BIOLOGICAL|MVA-HPV|Trial vaccine
47983924|NCT04607850|BIOLOGICAL|Placebo|Saline placebo vaccine
47914599|NCT06044701|OTHER|Bubble Machine Distraction Technique|Bubble machine application during blood collection
47983925|NCT03061331|DRUG|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
47983926|NCT03061331|DRUG|Placebo|No Active Drug
47983927|NCT01432860|BEHAVIORAL|In-person counseling|The design is a 3 \[in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care\] X 7 \[baseline, 4, 8, 12, 16, 20, and 24 month follow-up\] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
47983928|NCT01432860|BEHAVIORAL|Workbook|Participants will read a workbook and perform skills training exercises.
47983929|NCT01432860|BEHAVIORAL|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
48137569|NCT01887275|DRUG|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
48348370|NCT00360672|DRUG|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
48348371|NCT04488549|OTHER|Survey|International E-survey
48348372|NCT03144830|DEVICE|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
48348373|NCT01934608|BEHAVIORAL|Refill synch|
48348374|NCT06384625|OTHER|AIRWISE|AIRWISE (Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education) utilizes personal air cleaners (PACs) to filter indoor air, while enhanced aspects focus on improving compliance to PAC use. Key components include low-cost sensors (PurpleAir, Inc, USA) that change color according to air quality index (AQI) and behavioral recommendations that correspond to varying AQI levels.
48348375|NCT04878276|DEVICE|Dimet 5|The application is carried out according to the enclosed instructions for use.
48348376|NCT00633360|DRUG|Drospirenone and ethinyl estradiol|Once daily by mouth
48348377|NCT00633360|DRUG|Placebo|Once daily by mouth
48348378|NCT05533164|DRUG|Rituximab|1000mg rituximab in 250ml NaCl 0.9% intravenously
48348379|NCT05533164|DRUG|Placebo|Placebo in 250ml NaCl 0.9% intravenously
48348380|NCT01945788|DRUG|Teriparatide (rDNA origin)|
48348381|NCT02278380|OTHER|Low GI Standard Breakfast|Low GI Standard Breakfast
48348382|NCT02278380|OTHER|Medium GI Standard Breakfast|Medium GI Standard Breakfast
48348383|NCT02278380|OTHER|Enfamama A+|Nutritional pregnant milk supplement
48348384|NCT02278380|OTHER|Glucerna Triple Care|Nutritional product for diabetics
48348385|NCT02278380|OTHER|Dumex Precima|Pregnant and lactation women milk powder
48348386|NCT02278380|OTHER|Diasip|Nutritional drinks for diabetics
48348387|NCT02278380|OTHER|Test product|Test product not patented yet
48348388|NCT03993119|DRUG|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
48348389|NCT01171742|PROCEDURE|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
48348390|NCT06400693|OTHER|Endotracheal Intubation|Preparation of all necessary equipment for endotracheal intubation
48348391|NCT06400693|OTHER|Supraglottic Airway|Preparation of all necessary equipment for laryngeal mask
48137570|NCT06239519|BEHAVIORAL|Usual Practice + JoyPop|Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
48137571|NCT03609099|DRUG|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
48348392|NCT02252588|DRUG|Chlorhexidine|Oral Rinse
48348393|NCT02252588|OTHER|Placebo|Oral Rinse
48348394|NCT04673461|DRUG|STA363 containing 90 mg (60 mg/mL) lactic acid|STA363 (90 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
48348395|NCT04673461|DRUG|STA363 containing 180 mg (120 mg/mL) lactic acid|STA363 (180 mg) will be injected into maximally two pain-generating degenerated intervertebral discs
48502128|NCT00835965|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
47983930|NCT02733367|DRUG|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
48348396|NCT04673461|DRUG|Placebo|Placebo will be injected into maximally two pain-generating degenerated intervertebral discs
48348397|NCT05434936|PROCEDURE|Oophorectomy|Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
48348398|NCT01901367|DIETARY_SUPPLEMENT|nutritional intervention|Receive nutritional intervention
48348399|NCT01901367|BEHAVIORAL|exercise intervention|Receive exercise intervention
48348400|NCT01901367|OTHER|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
48348401|NCT01901367|BEHAVIORAL|counseling intervention|Receive phone counseling with a trained health coach
48348402|NCT01901367|OTHER|quality-of-life assessment|Ancillary studies
48348403|NCT01901367|OTHER|laboratory biomarker analysis|Correlative studies
48348404|NCT01901367|OTHER|questionnaire administration|Ancillary studies
48348405|NCT03993301|OTHER|Probiotic A formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
48348406|NCT03993301|OTHER|Probiotic B formula|Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
48348407|NCT03993301|OTHER|Regular formula|Feeding baby two meals a day with regular formula at least.
48348408|NCT05793424|OTHER|Cerebrospinal fluid (CSF) sample and additional blood samples|Lumbar puncture (Spinal Tap) and additional blood samples
48348409|NCT00628134|DRUG|calfactant|single inhaled dose by nebulizer
48348410|NCT00628134|DRUG|isotonic saline|single inhaled dose by nebulizer
48348411|NCT04694157|DEVICE|cardiac shock wave therapy|Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
48348412|NCT02279160|DRUG|APD811|
48348413|NCT02279160|DRUG|Placebo|Placebo
48348414|NCT00321360|DRUG|Propofol|
48502129|NCT00835965|DRUG|Placebo Dexamethasone|
48502130|NCT00159627|DRUG|KW-3902IV|
48502131|NCT03594058|DRUG|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
48348415|NCT00321360|DEVICE|Patient maintained sedation|
48348416|NCT01428986|DRUG|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
48348417|NCT00835276|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
48348418|NCT00835276|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
48348419|NCT00003804|BIOLOGICAL|dactinomycin|
48502132|NCT03594058|DRUG|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
47983931|NCT06315439|PROCEDURE|Endoscopic ultrasound fine needle biopsy|"EUS FNA/B for solid pancreatic lesions. After the FNA/FNB, the needle was removed from the EUS endoscope and the specimen obtained after the first needle pass was expelled and placed directly in a dedicated scaffold (Cytomatrix, UCS Diagnostics).~a drop of ethanol was put on it and the liquid was drained away thanks to the porous structure of the matrix. This step was followed by the deposition of a drop of acridine-orange for 20 and a rapid washing with buffered saline. After that, the Cytomatrix was put on a dedicated microscopic slide and covered with a second slide before the introduction in the slot of the machine.~The FCM VivaScope® 2500 (2500M-G4; VivaScope, Munich, Germany) was used for immediate imaging."
47983932|NCT03867305|DEVICE|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
47983933|NCT03520374|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography use for the evaluation of gastric contents
47983934|NCT01430156|DRUG|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
47983935|NCT01430156|DRUG|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
47983936|NCT03174236|DRUG|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
47983937|NCT03174236|DRUG|Benzyl penicillin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
47983938|NCT03174236|DRUG|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
47983939|NCT03174236|OTHER|Placebo|Suspension manufactured to match metronidazole
47983940|NCT03174236|DRUG|Gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
47983941|NCT02070692|DRUG|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
47983942|NCT02070692|DRUG|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
47983943|NCT03590236|OTHER|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
47983944|NCT03590236|OTHER|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
47983945|NCT01036035|DRUG|Tolterodine|Comparison of different dosages of drug
47983946|NCT01036035|DRUG|Pilocarpine|Comparison of different dosages of drug
47983947|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
47983948|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
47983949|NCT01036035|DRUG|placebo capsule|Comparison of different dosages of drug
47983950|NCT00758082|DEVICE|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
47983951|NCT00758082|DEVICE|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
48137572|NCT03609099|DRUG|Placebo|once a day oral treatment during 3 days.
48348420|NCT00003804|DRUG|vincristine sulfate|
48348421|NCT00003804|PROCEDURE|conventional surgery|
48348422|NCT03625960|DRUG|Cantharidin|A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
48348423|NCT03625960|DRUG|Trichloroacetic Acid|Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
48348424|NCT01716949|RADIATION|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
48348425|NCT01716949|PROCEDURE|Hyperthermia|10 sessions, therapeutic time 60 min
48348426|NCT01716949|DRUG|5-Fluorouracil|250 mg/m\^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
48348427|NCT01716949|DRUG|Capecitabine|1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
48348428|NCT01716949|DRUG|Oxaliplatin|50 mg/m\^2/d as 2-hour bolus infusion on d2, 9, 23, 30
48348429|NCT04476615|DIETARY_SUPPLEMENT|Fasting-Mimicking Diet (ProLon®)|Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
48502133|NCT03594058|DRUG|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
48348430|NCT04476615|DIETARY_SUPPLEMENT|Placebo bars|"Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total)."
48502134|NCT02679235|DRUG|POST Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
48137573|NCT04056754|DRUG|Abiraterone Acetate|Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
48137574|NCT04056754|DRUG|Placebo|Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
48137575|NCT04056754|DRUG|Prednisone|Subjects administered 5mg prednisone twice daily in 28-day cycle.
48137576|NCT06509828|BIOLOGICAL|AVB-114|AVB-114 is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.
48348431|NCT06237673|DIAGNOSTIC_TEST|CT|CT-directed clinical management strategy
48348432|NCT06237673|DIAGNOSTIC_TEST|invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
48137577|NCT05662436|OTHER|Open Sky School program|Teachers lead students in 2 hours of outdoor activities per week for 12 weeks, as detailed in the arm description
48137578|NCT05106049|DIAGNOSTIC_TEST|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
48502135|NCT05419609|PROCEDURE|Limited facelift|A limited procedure under local anesthesia that addresses signs of aging in the lower face and neck
48502136|NCT05419609|PROCEDURE|Full facelift|A full face and neck lift that addresses signs of aging in the face and neck
48502137|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline."
48502138|NCT05419609|OTHER|"FACE-Q | Aesthetics - Recovery Early Symptoms"|"Completed by patients. The FACE-Q \| Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure."
47983952|NCT06505629|BEHAVIORAL|the online Paired Emotion Reading Intervention (PERI)|In the PERI, all children will receive three books about emotion knowledge. The paired reading groups will read and discuss these books over the next six weeks. Before starting the reading sessions, the paired groups will meet online via video to get to know each other and set reading goals. During the reading process, participants will check in daily with their reading progress. From the second week to the fifth week, participants will engage in weekly online discussions about the reading content. These discussions, led by the urban children, will follow a semi-structured discussion guide. The discussions aim to deepen the children's understanding of the book content and facilitate the application of emotion-related knowledge and emotion regulation strategies in their daily lives. The discussion sessions will be recorded and uploaded for regular review by the researchers.
47983953|NCT06505629|BEHAVIORAL|the online Paired General Reading Intervention (PGRI)|Apart from the differences in the reading materials and discussion topics, all other aspects are identical to the PERI group. In the online PGRI, children will read three books of their choice, and discussions will center around general reading experiences and feelings.
47983954|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
47983955|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
47983956|NCT02781051|BEHAVIORAL|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
48137579|NCT00078156|BEHAVIORAL|Behavior Therapy|
48137580|NCT03124472|PROCEDURE|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
48348433|NCT03148184|DIAGNOSTIC_TEST|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
48348434|NCT00233181|BEHAVIORAL|Home-based adherence monitoring|
48348435|NCT00638690|DRUG|Placebo|Four tablets once daily until disease progression
48348436|NCT00638690|DRUG|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
48348437|NCT00638690|DRUG|Prednisone/prednisolone|5 mg twice daily until disease progression
48348438|NCT04609215|OTHER|ALECSAT|"Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months."
48348439|NCT05306262|PROCEDURE|Hypnosis session|Comfort hypnosis: accompaniment of a pleasant memory.
48348440|NCT05306262|OTHER|Catalepsy|Catalepsy of the hand.
48348441|NCT02762123|DRUG|BMS-986142 200mg|
48348442|NCT02762123|DRUG|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
48348443|NCT02762123|DRUG|BMS-986142 350mg|
48348444|NCT03858686|DRUG|FP-025 capsules|FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
48348445|NCT03858686|DRUG|Placebo FP-025 capsules|Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
48348446|NCT01251315|DRUG|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
48348447|NCT01251315|DRUG|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
48348448|NCT01251315|DRUG|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
48348449|NCT01251315|DRUG|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
48348450|NCT01251315|DRUG|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
48348451|NCT01251315|DRUG|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
48348452|NCT00481377|PROCEDURE|ablation|
48348453|NCT05155410|DIETARY_SUPPLEMENT|Exogenous Ketone Monoester|Participants will consume 15g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
48348454|NCT05155410|DIETARY_SUPPLEMENT|Placebo|Participants will consume an equivalent volume (30ml) of the active intervention supplement 15 minutes prior to each meal for 14 days. All meals will be provided throughout the 14-day placebo supplementation period.
48658879|NCT06440837|BEHAVIORAL|IMB stress self-management health education|The health education intervention program contains eight module topics: stress-related knowledge, the thinking and mentality under stress, social support, take care of your suffering, manage your difficult emotions, acceptance, embrace a better life, ending. One topic or session is delivered by weeks, each session lasting 30-40 minutes.
48348455|NCT04928313|DRUG|Glatiramer Acetate|Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.
48658880|NCT04900298|DEVICE|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
48658881|NCT00843960|BEHAVIORAL|behavioral adaptation and symptom management|behavioral adaptation and symptom management
48658882|NCT01649869|OTHER|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
48658883|NCT01649869|DRUG|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
48658884|NCT05575466|DIAGNOSTIC_TEST|Blood samples|Hemostatic biomarkers
48658885|NCT05575466|DIAGNOSTIC_TEST|Questionnaires|Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
48658886|NCT05787249|BEHAVIORAL|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
48658887|NCT05787249|BEHAVIORAL|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
48658888|NCT06560021|OTHER|Biopsy strategy|Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia
48658889|NCT01702298|DRUG|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
47983957|NCT02781051|DEVICE|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
47983958|NCT02781051|BEHAVIORAL|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
47983959|NCT02781051|OTHER|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
47983960|NCT03757689|DRUG|Pembrolizumab|Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
47983961|NCT03757689|PROCEDURE|Wide Excision and Sentinel Lymph Node (SLN) Biopsy|Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
47983962|NCT05489809|PROCEDURE|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
47983963|NCT05489809|PROCEDURE|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
47983964|NCT00054314|DRUG|ortataxel|
47983965|NCT02581449|DIETARY_SUPPLEMENT|omega-3|dietary supplement
47983966|NCT02581449|OTHER|empty soft gelatin capsules|empty softgels of matched size, shape and color
47983967|NCT01108705|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
47983968|NCT01108705|DRUG|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
47983969|NCT05631886|BIOLOGICAL|TP53-EphA-2-CAR-DC|5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.
47983970|NCT05631886|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
47983971|NCT05631886|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
47983972|NCT05631886|DRUG|anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
47983973|NCT05631886|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
48348456|NCT00540527|DRUG|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
48348457|NCT00540527|DRUG|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
48348458|NCT01577628|DRUG|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
48348459|NCT03436745|DRUG|Zolpidem|In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
48348460|NCT00679380|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
48348461|NCT00679380|DRUG|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
48348462|NCT00679380|DRUG|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
48348463|NCT00679380|DRUG|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
48348464|NCT00679380|DRUG|Placebo|Placebo
48348465|NCT04175431|PROCEDURE|Positron Emission Tomography|Undergo fluciclovine PET/CT
48348466|NCT04175431|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
48348467|NCT04175431|RADIATION|Radiation Therapy|Undergo radiation therapy
48348468|NCT04175431|DRUG|Abiraterone Acetate|Given PO
48348469|NCT04175431|DRUG|Prednisone|Given PO
48348470|NCT04175431|PROCEDURE|Computed Tomography|Undergo fluciclovine PET/CT
48348471|NCT04175431|DRUG|Abiraterone|Given PO
48348472|NCT04175431|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
48348473|NCT00002413|DRUG|Emivirine|
48658890|NCT01702298|DRUG|Metformin|Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
48658891|NCT04941885|DRUG|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
47983974|NCT01330589|DRUG|Placebo|Non-active placebo for 7 days: PO/TID
47983975|NCT01330589|DRUG|St. Johns Wort|For 7 days: 300mg PO/TID
47983976|NCT05205733|OTHER|Mail-in semen analysis kit|Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
48658892|NCT00689884|DRUG|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
48658893|NCT05229744|DEVICE|sequence MRI 3D FLAIR|"Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):~- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product"
48658894|NCT00163293|DRUG|Ciclesonide|Ciclesonide metered-dose inhaler
48658895|NCT00163293|DRUG|Placebo|Ciclesonide placebo-matching metered-dose inhaler
48658896|NCT05227326|DRUG|PCNA Inhibitor AOH1996|Given PO
47983977|NCT01454947|BEHAVIORAL|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
47983978|NCT01454947|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
48348474|NCT04587973|PROCEDURE|Group Dexmedetomidine|Ropivacaine plus dexmedetomidine group
48348475|NCT04587973|PROCEDURE|Group Ropivacaine|Plain ropivacaine group
48348476|NCT04587973|PROCEDURE|Group Control|Control group
48348477|NCT04001660|PROCEDURE|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
48348478|NCT03102463|DIETARY_SUPPLEMENT|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
48348479|NCT03102463|DIETARY_SUPPLEMENT|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
48348480|NCT03102463|DIETARY_SUPPLEMENT|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
48348481|NCT03102463|OTHER|Lipid Load|100mL oral lipid load
48658897|NCT03539679|OTHER|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
48348482|NCT05333536|OTHER|Experimental: Experimental group exercises|Experimental performs Strengthening exercises of core.10 reps , 3 sets of each.Prone plank(10 sec hold)(18) ,Side plank (8 sec hold),Bridging (8 sec hold)(19),Bird dog (10 reps ,3 sets),Leg drop (10 reps, 3 sets)(15),Dying bug with their regular swimming practice. First 2 weeks simple strengthening exercises.Next 4 weeks stability ball exercises. Dying bug without stability ball. And strengthening exercises of Upper Limb and Lower Limb with theraband ,10 reps each.Upper Limb: Latissimus dorsi,Serratus anterior, Upper trapezius.Lower limb : Flexors of hip, Extensors of hip,Plantar flexors.
48348483|NCT05333536|OTHER|No Intervention: Control group|control only participates in their yearly swimming trainings.
48348484|NCT06120192|BEHAVIORAL|Piano|Receives the piano training
48658898|NCT03758846|BEHAVIORAL|Cognitive-motor exergaming|Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
48658899|NCT03758846|BEHAVIORAL|Conventional balance Training|Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
48658900|NCT03758846|BEHAVIORAL|Dance Therapy for Stroke|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
48658901|NCT03758846|BEHAVIORAL|Dance Therapy for Older adults|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists."
48658902|NCT03758846|BEHAVIORAL|Home education for Older adults|Participants will receive a one-hour education on conventional physical exercises.
48348485|NCT03121482|DEVICE|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
48348486|NCT03121482|DEVICE|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
48348487|NCT01466062|DRUG|Palivizumab|
48348488|NCT00205946|DRUG|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
48348489|NCT00205946|DRUG|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
48658903|NCT01828060|DIETARY_SUPPLEMENT|Jobelyn™|Sorghum bicolor leaf sheath extract
48658904|NCT01828060|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
48348490|NCT00314054|DRUG|HCV-796|HCV-796 1000mg single dose
48348491|NCT00117572|DRUG|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
48658905|NCT05071326|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
47983979|NCT01454947|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
47983980|NCT06061653|COMBINATION_PRODUCT|IPT plus HD-tDCS|psychotherapy plus device
47983981|NCT06061653|COMBINATION_PRODUCT|IPT plus sham HD-tDCS|psychotherapy plus sham device
47983982|NCT02943720|DRUG|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
47983983|NCT02943720|DRUG|placebo|placebo
47983984|NCT06479798|DIAGNOSTIC_TEST|Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)|Endo bronchial ultrasound enables visualization of parabronchial structures throughout a bronchoscopic procedure. EBUS-TBNA, which is considered a less invasive diagnostic tool for nodal staging compared to mediastinoscopy, allows real-time, direct sampling of hilar \& MLNs under sonograghic guidance with concurrent cytological and histopathological examination
48658906|NCT04925284|DRUG|XB002|IV administration of XB002
48658907|NCT04925284|DRUG|Nivolumab|IV administration of Nivolumab
48658908|NCT05856396|BIOLOGICAL|Triaxis® (Pertussis-containing vaccine)|"Triaxis® (Pertussis-containing vaccine) will be administered:~* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation~* in Pregnant women between 16 and 29 weeks of gestation."
48658909|NCT05856396|BIOLOGICAL|Vaxelis® (Pertussis-containing vaccine)|Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
47983985|NCT00531817|DRUG|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
47983986|NCT00531817|DRUG|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
48348492|NCT00117572|DRUG|cisplatin|75 mg/m2 on day 1
48348493|NCT00117572|DRUG|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
48348494|NCT00117572|DRUG|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
48348495|NCT00117572|PROCEDURE|chemotherapy|See protocol for details
48348496|NCT00117572|PROCEDURE|radiotherapy|See protocol for details
48137581|NCT03124472|PROCEDURE|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers"
48137582|NCT06294249|DEVICE|Laser-induced Incision|On the treatment side, an incision was made on the crest of the alveolar soft tissue using the laser.
48137583|NCT06294249|PROCEDURE|Punch Incision|On the control side, a punch incision was made on the crest of the alveolar soft tissue using using a punch.
48348497|NCT05312268|DRUG|Rasburicase|Rasburicase 1.5 mg/day for 3 consecutive days at scheduled times.
48348498|NCT04396327|DRUG|SM-1|diphenhydramine, zolpidem and lorazepam
48348499|NCT04396327|DRUG|Active Comparator|diphenhydramine and lorazepam
48348500|NCT06000761|PROCEDURE|Standardized oral Care|One sponge-tipped swab, saturated with sterile water or human milk, will used clean the oral cavity with 15 seconds each area. Surfaces include all 4 quadrants of the gum surface and upper posterior part of the oropharynx. A second swab, with sterile water or milk will be used on the ventral and posterior surfaces of the tongue. A third swab, saturated with sterile water or human milk, will be used to clean the outer surface of any dwelling oral tubes (endotracheal tube, NAVA or feeding tube). Lips will be cleaned with a sterile gauze saturated with sterile water or human milk. Oral cavity will be suctioned as needed with an oral suction devise to remove secretions.
48348501|NCT00993980|PROCEDURE|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
48348502|NCT00993980|PROCEDURE|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
48348503|NCT05493436|DIAGNOSTIC_TEST|MII pH-meter|using multichannel impedance pH-meter
48502139|NCT05419609|OTHER|"FACE-Q | Aesthetics - Satisfaction with Outcome"|"Completed by patients. The FACE-Q \| Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure."
48502140|NCT05419609|OTHER|"FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck"|"Completed by patients. The FACE-Q \| Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure."
48502141|NCT02052050|OTHER|core stability|
48502142|NCT05919316|DEVICE|Rhinophototherapy|Intranasal rhinophotometer to be used at home for 4.5 minutes three times daily for 14 days
48502143|NCT05919316|DRUG|Nasonex Nasal Spray|50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
48502144|NCT06345365|DRUG|mitoxantrone liposome, Ara-Cytarabine and azacitidine|Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7
48502145|NCT06345365|DRUG|Daunorubicin,Ara-Cytarabine, azacitidine|Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
48502146|NCT01687244|DRUG|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
48502147|NCT00525798|DRUG|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
48502148|NCT00525798|DRUG|SMC021 Placebo|SMC021 - Placebo, once daily
48658910|NCT06424002|BIOLOGICAL|Mosquirixs|RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.
47983987|NCT00531817|DRUG|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
47983988|NCT05070533|BEHAVIORAL|Individual treatment|Participants will receive 7 home visits to implement the program.
47983989|NCT05070533|BEHAVIORAL|Groupal treatment|Subjects will participate in groups of about 8 - 12 to implement the program.
47983990|NCT02388945|OTHER|APD|PDGO APD machines used in the PD patients for 8 weeks
47983991|NCT02388945|OTHER|CAPD|CAPD used in the PD Patients for 8 weeks
48137584|NCT06294249|PROCEDURE|Implant Placement|Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
47983992|NCT03835585|DEVICE|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
47983993|NCT03835585|OTHER|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
48348504|NCT06046586|BEHAVIORAL|Support and information|Emotional and technical support. Information about the long-term effects of cancer.
48348505|NCT06046586|BEHAVIORAL|Behavioral activation|Behavioral activation with existential themes and emphasis on values and relationships.
48348506|NCT06046586|BEHAVIORAL|Systematic exposure with mindfulness training|Systematic exposure with mindfulness training with a focus on anxiety about health and/or death, body image, and cancer-related trauma.
48502149|NCT04297033|DRUG|Lovastatin|lovastatin 40mg/d 12m
48137585|NCT00291694|DRUG|celecoxib|Celecoxib 400 mg BID
48137586|NCT00291694|OTHER|placebo|placebo
48348507|NCT06046586|BEHAVIORAL|Promotion of health behaviors|An overview of self-management techniques in terms of physical exercise, dietary advice, and strategies for improved sleep.
48348508|NCT03216395|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
48348509|NCT03216395|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
48348510|NCT03216395|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 8 pulses
48348511|NCT03216395|DRUG|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer \<20 mls
48348512|NCT01154322|DEVICE|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
48348513|NCT05142176|OTHER|Erector spinae catheters insertion|Ultrasound-Guided ESPB The ESPB will be performed with the child in a right lateral decubitus position under aseptic precautions by a high frequency (6-13 MHz) linear ultrasound transducer
48348514|NCT05142176|DRUG|Postoperative pain management|IV acetaminophen 15 mg/kg every 8 hours as a component of multimodal analgesia.
48348515|NCT01013090|DRUG|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
48502150|NCT04297033|DRUG|Placebo|placebo
48502151|NCT00044967|GENETIC|microsatellite instability analysis|
48658911|NCT06424002|DRUG|artemether-lumefantrine|A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
47983994|NCT03835585|BEHAVIORAL|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
47983995|NCT03835585|BEHAVIORAL|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
47983996|NCT00277888|PROCEDURE|Femoral route for hemodialysis|
48348516|NCT01013090|DRUG|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
48502152|NCT05407324|DRUG|Dazucorilant 300 mg|300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
48502153|NCT05407324|DRUG|Dazucorilant 150 mg|Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
47983997|NCT00277888|PROCEDURE|Jugular route for hemodialysis|
47983998|NCT05470426|OTHER|COVID-19 Omicron Recurrence|COVID-19 Omicron Recurrence
47983999|NCT04246294|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
48137587|NCT01553487|OTHER|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
48137588|NCT02094534|BIOLOGICAL|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
48002532|NCT03272919|OTHER|Arm 1: Investigational INF|INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
48137589|NCT02094534|OTHER|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
48137590|NCT04231279|DRUG|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
48137591|NCT03400579|DEVICE|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
48137592|NCT00759798|DRUG|Fludarabine|25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
48137593|NCT00759798|DRUG|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
48137594|NCT00759798|DRUG|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
48502154|NCT05407324|OTHER|Placebo|Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.
48502155|NCT04530708|RADIATION|Thoracic radiotherapy|36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
48502156|NCT04441710|OTHER|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
48502157|NCT01835054|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
48502158|NCT01835054|GENETIC|DNA collection|Observational Study using Imaging and Biomarkers
48502159|NCT01835054|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
48502160|NCT01835054|OTHER|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
48502161|NCT01835054|OTHER|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
48502162|NCT01835054|OTHER|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
48502163|NCT01835054|OTHER|Holter ECG|Observational Study using Imaging and Biomarkers
48658912|NCT05473520|DRUG|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
48348517|NCT05746000|BEHAVIORAL|Intervention Group (IG)|Three individual diet counselling that includes sugar calculation (sugar exchange) (60 minutes per session) at baseline, week-4 and week-8.
48348518|NCT05746000|BEHAVIORAL|Control Group (CG)|Three individual diet counselling (60 minutes per session) at baseline, week-4 and week-8.
48348519|NCT03996889|DEVICE|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~* Number of GORE VIABAHN® stent used (length and diameter of each)~* Embolization of collaterals and other related actions~* Operative complications~* Intraoperative fibrinolysis~* Collar cover\> 2 cm~* Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~* Arteriography in profile, kink"
48348520|NCT00017927|DRUG|Pegvisomant|
48348521|NCT01815905|OTHER|Mobile program for occupational and speech therapy|
48348522|NCT01815905|OTHER|Traditional rehabilitation therapy|
48348523|NCT01545414|BEHAVIORAL|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
48348524|NCT01545414|BEHAVIORAL|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
48348525|NCT03774706|DRUG|Misoprostol|two tablets misoprostol 400 μg sublingual
48348526|NCT03774706|DRUG|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
48348527|NCT03774706|DRUG|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
48348528|NCT00844415|DRUG|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
48348529|NCT03741140|DIAGNOSTIC_TEST|Motivation tests|Motivation tests will characterize elementary deficits of motivation
48348530|NCT04480515|OTHER|in-hospital mortality rate|In-hospital mortality rate during pandemic of 2020 will be compared with the in-hospital mortality rate of the last year's same time period
48348531|NCT04168151|OTHER|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
48348532|NCT04485936|DEVICE|Epitomee Device|medical Device designed to enhance the feeling of early satiation and prolonged satiety
48348533|NCT02740036|DEVICE|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
48348534|NCT00175422|BEHAVIORAL|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
48348535|NCT03774836|DRUG|Tramadol|IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
48658913|NCT05473520|DRUG|Placebo|Placebo + standard anti-tuberculous treatment
48348536|NCT03774836|DRUG|Morphine|Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
48348537|NCT03774836|OTHER|Placebo|Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
48348538|NCT00579462|OTHER|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
48002533|NCT03272919|OTHER|Arm 2: standardized muscle stretching and strength|subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
48348539|NCT05909462|DRUG|2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine|ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
48348540|NCT00411840|PROCEDURE|intraarterial and intramuscular injection of BMCs|
48348541|NCT01801124|DRUG|EXPAREL|single dose 266 mg of undiluted EXPAREL
48658914|NCT03952559|DRUG|Baricitinib|Administered orally
48658915|NCT03952559|DRUG|Placebo|Administered orally
48658916|NCT03952559|DRUG|Topical corticosteroid|Administered as standard-of-care
48137595|NCT04864782|DRUG|QL1604|Intravenous Infusion
48348542|NCT00777257|BIOLOGICAL|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
48348543|NCT00777257|BIOLOGICAL|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
48348544|NCT00777257|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
48348545|NCT01518140|DEVICE|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
48348546|NCT01518140|BEHAVIORAL|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
48348547|NCT06004193|BEHAVIORAL|Exercise|At least 150 minutes of exercise in a week
48348548|NCT01877811|DRUG|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
48348549|NCT02282488|OTHER|Low protein formula|
48348550|NCT02282488|OTHER|High protein formula|
48348551|NCT05479136|DRUG|PET imaging with 18F fluciclovine|PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
48502164|NCT01468818|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
48658917|NCT00823797|DRUG|Bendamustine Hydrochloride|Given IV
48658918|NCT00823797|OTHER|Quality-of-Life Assessment|Ancillary studies
48137596|NCT04864782|DRUG|Paclitaxel injection|Intravenous Infusion
48137597|NCT04864782|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
48137598|NCT01688765|OTHER|Observational|
48137599|NCT05671445|BIOLOGICAL|CM326|CM326 injection
48137600|NCT00406887|DRUG|Difluprednate Ophthalmic Emulsion|
48137601|NCT02300467|DRUG|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
48137602|NCT06052722|OTHER|Correlation assessment|The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
48137603|NCT01898754|OTHER|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
48137604|NCT04671875|DRUG|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
48137605|NCT03622710|OTHER|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
48348552|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Experimental Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~5. Session duration: 25 minutes"
48137606|NCT00621673|DRUG|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
48137607|NCT01809457|OTHER|educational poster|educational poster for dental trauma
48137608|NCT03700554|DEVICE|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
48348553|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Control Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes"
48137609|NCT03700554|PROCEDURE|Chest tube|Chest tube insertion
48137610|NCT02972424|DRUG|Teriparatide Prefilled Syringe|TPTD 20 mcg
48137611|NCT02972424|DRUG|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
48137612|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
48137613|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
48348554|NCT01046968|DIETARY_SUPPLEMENT|Lepticore|300 mg twice daily
48348555|NCT05458869|PROCEDURE|HPV Self-Collection|Use HPV self-collection kit
48348556|NCT05458869|OTHER|Interview|Attend interview
48348557|NCT05458869|OTHER|Survey Administration|Complete surveys
48137614|NCT00606216|PROCEDURE|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
48137615|NCT02695134|OTHER|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
48137616|NCT06406426|DRUG|Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin|Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
48137617|NCT00843050|DRUG|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
48137618|NCT02701296|DRUG|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
48137619|NCT02701296|DRUG|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
48137620|NCT02440438|BIOLOGICAL|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
48137621|NCT02449785|DEVICE|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
48137622|NCT02449785|DEVICE|CT measurements of lung morphological changes in cystic fibrosis|
48137623|NCT00598390|DRUG|[11C]MePPEP|
48137624|NCT03978728|DEVICE|Extra-corporeal membrane oxygenation|Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
48348558|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
48348559|NCT00678249|PROCEDURE|PTA|Percutaneous Transluminal Angioplasty
48348560|NCT00678249|DEVICE|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
48348561|NCT01576224|DEVICE|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
48502165|NCT01468818|DRUG|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
48348562|NCT05180604|BEHAVIORAL|experience learning programs of eHealth care|The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
48348563|NCT06149741|PROCEDURE|Defunctioning left-sided loop colostomy|Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
48348564|NCT06482255|OTHER|manual therapy and therapeutic exercise|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise"
48348565|NCT06482255|OTHER|manual therapy and therapeutic exercise and virtual reality|"* Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise~* virtual reality"
48348566|NCT01074840|OTHER|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
48348567|NCT02521168|DRUG|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
48348568|NCT02521168|DRUG|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
48348569|NCT04023344|DRUG|Humalog Mix25|Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
48348570|NCT04023344|DRUG|Insulin Lispro Biphasic 25|"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
48348571|NCT00479349|DRUG|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
48348572|NCT01759693|PROCEDURE|Blood sampling|Blood sampling
48348573|NCT02371694|OTHER|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
48348574|NCT05249465|BEHAVIORAL|Core behavioral weight loss intervention|"All participants will receive a 6-month core behavioral obesity treatment consisting of goal setting, behavioral lessons, action plans, and tailored feedback - all of which will be delivered remotely."
48658919|NCT00780598|DRUG|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~* 120 mg for 6 months once daily, OR~* 240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
48348575|NCT05249465|BEHAVIORAL|Self-monitoring diet|Participants randomized to receive this component will be instructed to self-monitor their dietary intake daily via the Fitbit mobile app. Participants will receive a daily calorie goal.
48658920|NCT05234216|OTHER|Informed consent|the investigator will verify the inclusion criteria, the patient's understanding of the protocol and will obtain oral informed consent
48348576|NCT05249465|BEHAVIORAL|Self-monitoring weight|Participants randomized to receive this component will be instructed to self-monitor their body weight daily via a wireless e-scale (e.g., the Fitbit Aria Scale).
48348577|NCT05249465|BEHAVIORAL|Self-monitoring steps|Participants randomized to receive this component will be instructed to self-monitor their step count daily via a wrist-worn Fitbit activity monitor. A daily step goal will be given that will adapt based on progress.
48348578|NCT01188811|DRUG|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
48348579|NCT01188811|DRUG|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
48348580|NCT03965546|COMBINATION_PRODUCT|Sorafenib combined with ET140202-T cell|"1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
48348581|NCT03965546|COMBINATION_PRODUCT|TAE combined with ET140202-T cell|"1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
48348582|NCT03965546|BIOLOGICAL|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
48348583|NCT06437639|DRUG|Mexidol|Neurocytoprotector
48658921|NCT05234216|PROCEDURE|Surgery|The patient will undergo surgery in accordance with standard care
48658922|NCT05234216|BEHAVIORAL|Comfort scale|The patient will be evaluated, in the post-operative care unit, with a comfort scale
48658923|NCT05234216|BEHAVIORAL|Pain|The patient will be evaluated, in the post-operative care unit, with a pain scale
48658924|NCT05234216|OTHER|Questionnaires|Evaluation of the Experience of Local/General Anesthesia
48658925|NCT06449118|BEHAVIORAL|Mindfulness Stress Reduction Program|Mindfulness based-Stress Reduction Program an 8-week program
48658926|NCT06296498|PROCEDURE|Leukocyte Platelet-rich fibrin|Leukocyte-PRF (L-PRF) contains neutrophils and macrophages that facilitate bacteria and necrotic tissue elimination via phagocytosis
48658927|NCT06296498|OTHER|Standard of care OFD|Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
48002534|NCT04865237|BIOLOGICAL|SARS-CoV-2 Virus|SARS-CoV-2, intranasally, (1x10\^1 TCID50, 1x10\^2 TCID50 and 1x10\^3 TCID50 or higher, as necessary)
48137625|NCT00312208|DRUG|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
48137626|NCT00312208|DRUG|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
48137627|NCT01488656|DIETARY_SUPPLEMENT|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
48137628|NCT01488656|DIETARY_SUPPLEMENT|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
48137629|NCT03398798|DEVICE|".014"|".014 CuNiTi orthodontic arch wire"
48348584|NCT01365013|BEHAVIORAL|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
48348585|NCT01365013|BEHAVIORAL|Control group|Standard advice for lifestyle change
48348586|NCT02778425|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
48348587|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
48348588|NCT02778425|PROCEDURE|beta blockers|A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
48348589|NCT02778425|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
48348590|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
48348591|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
48137630|NCT03398798|DEVICE|".016"|".016 CuNiTi orthodontic arch wire"
48348592|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy+PSE|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
48348593|NCT05535270|DIAGNOSTIC_TEST|Oxford Depression Questionnaire (ODQ)|"The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of emotional blunting: not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections ."
48348594|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
48348595|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
48137631|NCT03398798|DEVICE|Twin brackets|Ormco Insignia Metal Twin brackets
48137632|NCT03398798|DEVICE|Self-ligating brackets|Ormco Insignia SL brackets
48137633|NCT03131128|BEHAVIORAL|Mindfulness-based Intervention|"1. Keeping mindful when selecting food.~2. Be aware of hunger and satiety by the body clues.~3. Understanding how stress affect diet and life, and learn how to cope with stress in life.~4. Learning to identify overeating caused by mood, social stress and specific food."
48002535|NCT04865237|DRUG|Remdesivir|VEKLURY™
48002536|NCT00607763|DRUG|Micafungin (Mycamine)|IV
48348596|NCT00596349|BEHAVIORAL|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
48348597|NCT02507050|DRUG|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
48348598|NCT05385913|OTHER|Multivitamin-no intervention|No intervention. All participants will be given a multi-vitamin to take for the duration of the study
48348599|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with investigational device
48348600|NCT05316350|DEVICE|Electrocardiogram recording|ECG recording with reference device
48137634|NCT03131128|BEHAVIORAL|Health Education Intervention|"1. Identifying improper diet patterns and attitudes~2. Understanding the impact of irrational cognition and attitudes on dietary behavior~3. Training coping skills for stresses in real life and preventing the recurrence of bulimia."
48137635|NCT01064466|DRUG|ETOPOSIDE - Usual|Etoposide Injection
48137636|NCT01064466|DRUG|ETOPOSIDE - Study|Etoposide Capsule
48348601|NCT04152668|PROCEDURE|Titanium curette.|Implant debridement.
48348602|NCT04152668|PROCEDURE|Ultrasonic|Implant debridement.
48137637|NCT05845970|OTHER|Pamprin Botanicals|Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.
48137638|NCT05845970|COMBINATION_PRODUCT|Pamprin Botanicals + Pamprin Menstrual Pain Relief|Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).
48137639|NCT00898521|DRUG|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
48137640|NCT02909205|OTHER|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
48137641|NCT02909205|OTHER|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
48348603|NCT04152668|PROCEDURE|Air-polishing|Implant debridement and polishing.
48348604|NCT00446641|DRUG|Cilostazol|cilostazol 100mg twice a day for 4 weeks
48348605|NCT00446641|DRUG|placebo|placebo 1 tablet twice a day matching for cilostazol
48348606|NCT05477251|PROCEDURE|microwave ablation|MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
48348607|NCT05477251|PROCEDURE|lobectomy|lobectomy for GGOs located in hilar regions
48348608|NCT01366534|BIOLOGICAL|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
48348609|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
48348610|NCT01366534|BIOLOGICAL|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
48348611|NCT01366534|OTHER|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
48348612|NCT05135091|BIOLOGICAL|NRTX-1001|Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
48348613|NCT05135091|PROCEDURE|Sham Comparator|Sham Comparator.
48348614|NCT00085644|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
48348615|NCT00085644|BIOLOGICAL|placebo|Placebo every other week, subcutaneous
48348616|NCT04461145|BEHAVIORAL|command|The participant was asked to walk along the walkway while backward counting numbers with increment of seven starting from a randomly given number.
48137642|NCT04153838|OTHER|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
48137643|NCT00592891|DRUG|Hyperbaric oxygen therapy|Total body pressurized oxygen
48348617|NCT00320294|DRUG|irinotecan|
48348618|NCT00320294|DRUG|cisplatin|
48348619|NCT04134377|OTHER|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
47984000|NCT04270123|OTHER|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
48137644|NCT00227175|BEHAVIORAL|Semi-structured, open ended interview|
48137645|NCT05413200|DRUG|Isotretinoin|oral isotretinoin with a standard dose regime for 90 days
48137646|NCT04696016|PROCEDURE|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
48137647|NCT04696016|PROCEDURE|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
48137648|NCT02509715|PROCEDURE|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
48137649|NCT03926026|DRUG|Fluticasone Propionate|NCX 4251 Ophthalmic Suspension, 0.1%
48137650|NCT03926026|DRUG|Placebo|NCX 4251 Ophthalmic Suspension, 0%
48137651|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
48137652|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
48137653|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
48137654|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
48137655|NCT03106259|DRUG|FURESTEM-RA Inj.|Non-interventional observational study
48137656|NCT04454476|DRUG|Trametinib treatment|1 mg taken by mouth once a day for 14 days
48137657|NCT04454476|PROCEDURE|Endoscopy|A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.
47984001|NCT04593563|DRUG|Psilocybin|Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
47984002|NCT02046356|PROCEDURE|MESS-RFA|
48137658|NCT04681794|OTHER|exercise-based intervention|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
48137659|NCT00849485|DRUG|Levetiracetam|750 mg Tablet
48137660|NCT00849485|DRUG|Keppra®|750 mg Tablet
48137661|NCT02794363|BIOLOGICAL|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
48137662|NCT03646266|DRUG|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
48137663|NCT00317395|DRUG|Otamixaban (XRP0673)|intravenous administration
48348620|NCT02138162|DRUG|enzalutamide|oral
48348621|NCT06507228|DIAGNOSTIC_TEST|NWL PEBBLE STT|At home testing for OSA with AcuPebble.
48348622|NCT02698852|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
48348623|NCT03061227|DRUG|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
47984003|NCT02335489|DEVICE|Implantation with the commercially available Axium neurostimulator|
47984004|NCT05721989|DRUG|Ziltivekimab B|Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
47984005|NCT05721989|DRUG|Ziltivekimab D|Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.
47984006|NCT05721989|DRUG|Ziltivekimab C|Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
48137664|NCT00317395|DRUG|unfractionated heparin|intravenous administration
48137665|NCT00317395|DRUG|eptifibatide|intravenous administration
48348624|NCT03061227|DRUG|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
48137666|NCT03281603|DEVICE|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
48348625|NCT01525108|BEHAVIORAL|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
48348626|NCT01525108|OTHER|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
48502166|NCT01468818|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
48502167|NCT00849186|DRUG|sunitinib malate|oral
48502168|NCT00849186|PROCEDURE|neoadjuvant therapy|IV
48137667|NCT05162339|OTHER|No intervention was made|No intervention was made
48502169|NCT00849186|PROCEDURE|therapeutic conventional surgery|Surgery
48137668|NCT04000399|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
48137669|NCT05276999|OTHER|Healthcare provider education|Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
48137670|NCT05276999|OTHER|Community Awareness campaign|A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
48348627|NCT04697108|OTHER|Shoulder reproduction teste assisted by laser pointer|In the step (1) of Familiarization in which the SRTLP was applied through a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability
48348628|NCT03893851|BEHAVIORAL|Interactions Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
48348629|NCT00985140|RADIATION|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
48348630|NCT02116738|PROCEDURE|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
48348631|NCT02821988|DEVICE|External fetal monitor for Nonstress test|
48348632|NCT02821988|DEVICE|Ultrasonography for Biophysical profile|
48348633|NCT00246285|DRUG|risperidone|
47984007|NCT05514691|DIAGNOSTIC_TEST|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
47984008|NCT05514691|DIAGNOSTIC_TEST|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
47984009|NCT01001611|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
47984010|NCT01001611|DRUG|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
47984011|NCT03338855|DRUG|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
47984012|NCT04975360|DIETARY_SUPPLEMENT|Caffeine|The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.
47984013|NCT04975360|OTHER|Placebo|Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
47984014|NCT03807869|PROCEDURE|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
47984015|NCT00743327|DRUG|Pioglitazone|45mg capsule, once daily for 1 year
47984016|NCT05724069|DRUG|Velusetrag|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
47984017|NCT05724069|DRUG|Placebo|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
47984018|NCT03187093|DRUG|Vortioxetine|10-20 mg once daily for 8 weeks
47984019|NCT03187093|DRUG|Escitalopram|10-20 mg once daily for 8 weeks
47984020|NCT01072812|DRUG|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
47984021|NCT04678154|DRUG|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
48137671|NCT05011292|BEHAVIORAL|Educational Video about SCB|3-4 minutes video about SCB.
48348634|NCT03914872|BIOLOGICAL|Neoantigen DNA Vaccine|The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.
48348635|NCT03914872|DEVICE|Integrated electroporation device|"* Ichor Medical Systems~* All study injections will be given intramuscularly using an integrated electroporation device"
48502170|NCT00027248|DRUG|MBI 226|
48502171|NCT04776837|BEHAVIORAL|Observational Cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
47984022|NCT04678154|DRUG|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
48137672|NCT05011292|BEHAVIORAL|Survey on child feeding and related knowledge and practices|Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
48137673|NCT05011292|BEHAVIORAL|Educational Video other than SCB|Educational video about a topic other than infant SCB consumption.
48137674|NCT00195403|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
48137675|NCT01215747|DRUG|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
48348636|NCT04330989|BEHAVIORAL|iNSC and Adherence supporter training|"Integrated next step counseling: iNSC is a structured, patient-centered approach informed by motivational interviewing techniques, which aims to foster an environment for joint-problem solving in order that the participant may identify their individual needs to increase or sustain sexual health through biomedical and non-biomedical approaches. iNSC frames the counselling sessions as a non-judgmental discussion to explore the facilitators and challenges to sexual health and medication adherence.~Adherence supporter training: Participants will be asked to identify a partner, family member, or friend to whom they are willing to disclose their HIV status (for HIV-positive women) or their intent to initiate PrEP (for HIV-negative women). Participants may also select a clinic-based peer to serve this adherence supporter role. Trainings will emphasize basic HIV knowledge, importance of antiretroviral adherence, potential drug side effects, and practical strategies for supporting adherence."
47984023|NCT04838756|OTHER|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
48348637|NCT06329713|PROCEDURE|Group I: 30 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 7,5 ml of the same solution once in every 30 minutes, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programmed so that 8 ml of the same solution with a lock-time of 15 minuts may be administered
48348638|NCT06329713|PROCEDURE|Group II: 60 Min Interval Time|10 ml of a solution containing 0,1% of bupivacaine and 2 mcg/ml fentanyl through the epidural cathether, maintained by programmed intermittant epidural (PIE) boluses of 15 ml of the same solution once in every hour, starting 1 hour after the loading dose. patient controlled epidural analgesia (PCEA) will be programme
48348639|NCT01605890|DRUG|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
48348640|NCT04869189|DEVICE|JJVC Marketed Contact Lens|Acuvue Oasys® 1-Day
48348641|NCT00623766|DRUG|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
48137676|NCT01215747|DRUG|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
48348642|NCT00623766|DRUG|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
48348643|NCT00623766|DRUG|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
48348644|NCT00623766|DRUG|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
48348645|NCT00623766|DRUG|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
48348646|NCT00623766|DRUG|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
48502172|NCT05200897|DEVICE|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
47984024|NCT04838756|OTHER|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
47984025|NCT00052208|DRUG|gefitinib|Given PO
47984026|NCT00052208|RADIATION|radiation therapy|Undergo radiation therapy
48137677|NCT00978588|DRUG|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
48137678|NCT00003593|DRUG|asparaginase|Given IV
48137679|NCT00003593|DRUG|cytarabine|Given IT
48137680|NCT00003593|DRUG|daunorubicin hydrochloride|Given IV
48137681|NCT00003593|DRUG|methotrexate|Given IV
48137682|NCT00003593|DRUG|therapeutic hydrocortisone|Given IT
48137683|NCT00003593|DRUG|thioguanine|Given IV
48137684|NCT02605174|DRUG|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
48137685|NCT02605174|DRUG|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
48348647|NCT00623766|DRUG|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
48348648|NCT00623766|DRUG|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
48502173|NCT02424110|PROCEDURE|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
48502174|NCT02424110|PROCEDURE|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
48502175|NCT02424110|DEVICE|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
48502176|NCT02424110|DEVICE|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
48502177|NCT04034563|PROCEDURE|1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy|"3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval."
48137686|NCT02605174|DRUG|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
48137687|NCT02605174|DRUG|Placebo|Two placebo tablets to match lasmiditan doses.
48137688|NCT01184885|DRUG|Hyper-CVAD|"* Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are \< 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
48137689|NCT01184885|DRUG|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
48137690|NCT04334317|DRUG|TAK-071|TAK-071 tablet.
48137691|NCT04334317|DRUG|Placebo|TAK-071 placebo-matching tablet.
48137692|NCT01969916|DRUG|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
48348649|NCT00623766|DRUG|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
48348650|NCT00623766|DRUG|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
48137693|NCT06100198|OTHER|nutrition and exercise program|Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
48137694|NCT03905642|DRUG|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
48137695|NCT01888991|OTHER|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
48348651|NCT02252068|BEHAVIORAL|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
48348652|NCT02252068|BEHAVIORAL|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
48137696|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
48348653|NCT03726541|OTHER|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
48348654|NCT00721357|BEHAVIORAL|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
48348655|NCT00721357|OTHER|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
48348656|NCT01930669|OTHER|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
47984027|NCT00052208|OTHER|laboratory biomarker analysis|Correlative studies
47984028|NCT00380978|PROCEDURE|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
48137697|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
48137698|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
48137699|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
48137700|NCT00692120|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule once daily for 12 months
48137701|NCT04806841|BEHAVIORAL|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
48137702|NCT04806841|OTHER|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
48137703|NCT05599815|DRUG|ADX-629|ADX-629 (250 milligrams) administered twice daily
48137704|NCT03056066|DEVICE|Plethysmograph|A full Body Plethysmography examination
48348657|NCT04226144|DEVICE|Breath Stacking Group|Lung recruitment technique using manual bag resuscitation with oronasal mask interface
48348658|NCT04226144|DEVICE|Breath stacking and EMT|Lung recruitment technique with one way valve with counter resistance during all expiratory phase
48348659|NCT02098928|BEHAVIORAL|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
48348660|NCT02098928|DEVICE|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
48348661|NCT02045225|BEHAVIORAL|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
48348662|NCT06376435|DRUG|Herombopag Olamine Tablets|Herombopag Olamine；combined rhTPO;combined IL-11
48348663|NCT04557007|DRUG|Pembrolizumab|Drug trough-level will be measured in patients on Pembrolizumab with or without additional chemotherapy in routine care.
48348664|NCT03029767|OTHER|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
48137705|NCT03069391|BEHAVIORAL|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
48137706|NCT03069391|DEVICE|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
48348665|NCT03029767|OTHER|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
48348666|NCT03029767|OTHER|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
48348667|NCT00002675|BIOLOGICAL|filgrastim|
48348668|NCT00002675|DRUG|carboplatin|
48348669|NCT00002675|DRUG|cisplatin|
48348670|NCT00002675|DRUG|cyclophosphamide|
48348671|NCT00002675|DRUG|etoposide|
48348672|NCT00002675|DRUG|mesna|
48348673|NCT00002675|DRUG|vincristine sulfate|
48348674|NCT01089751|DRUG|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
48348675|NCT01089751|DRUG|placebo|Placebo once daily on an empty stomach for 14 weeks.
48348676|NCT05816954|DIAGNOSTIC_TEST|Chest Computed Tomography Scan per normal clinical practice|Normal Clinical practice
48348677|NCT00583830|BIOLOGICAL|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
48348678|NCT00583830|BIOLOGICAL|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
47984029|NCT00380978|PROCEDURE|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
47984030|NCT06407544|PROCEDURE|peripheral nerve block|peripheral nerve block guided by ultra sound through Ultrasound-guided quadratus lumborum block versus FICB or fascia iliaca block
47984031|NCT06407544|DRUG|PCA device as rescue medication with IV morphine 1mg if VAS more than 4|PCA device as rescue medication with IV morphine 1mg if VAS more than 4 with a 10 min lock-out time
48137707|NCT03069391|DEVICE|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
48137708|NCT05820763|DRUG|Selinexor|Selinexor is administered by mouth on Days 1, 8, 15, and 22 at a dose of 60 mg during the four cycles of consolidation. Selinexor is then decreased to 40 mg and administered by mouth on Days 1, 8, 15, and 22 for up to 8 cycles of maintenance therapy.
48348679|NCT00583830|DRUG|Paclitaxel|200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
48348680|NCT00583830|DRUG|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
48348681|NCT05554744|PROCEDURE|EUS-guided fine-needle injection|Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
48348682|NCT06189625|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
48348683|NCT06189625|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended."
48348684|NCT03885674|OTHER|Video Call Reminder Condition|Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
48502178|NCT03239743|DEVICE|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
48502179|NCT03239743|DRUG|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
48137709|NCT05820763|DRUG|Lenalidomide|"Lenalidomide is administered by mouth daily on Days 1 to 21 at a dose of 10 mg during the first three cycles of consolidation, and then titrated up to 15 mg on Days 1 to 21 for the fourth cycle of consolidation. Lenalidomide 15 mg by mouth daily on Days 1 to 21 can be continued for up to 8 cycles of maintenance therapy.~For patients with baseline renal dysfunction, the starting dose of lenalidomide will be 2.5 mg or 5 mg by mouth daily on Days 1 to 21. Patients may titrate up per physician discretion."
48137710|NCT05820763|DRUG|Dexamethasone|Dexamethasone is administered by mouth on Days 1, 8, 15, and 22 at a dose of 20 mg during all four cycles of consolidation only.
48137711|NCT02334917|PROCEDURE|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
48348685|NCT03885674|OTHER|Automated Text Message Reminder Condition|Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
48348686|NCT02550860|DRUG|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
48137712|NCT03838549|PROCEDURE|Prophylactic mastectomy with immediate breast reconstruction|It is an endoscopic approach for prophylactic mastectomy using an axillary single port
48137713|NCT06510361|DRUG|Epcoritamab|Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.
48137714|NCT04696900|PROCEDURE|Exercise training|exercise training in an approved rehabilitation program
48348687|NCT02550860|DRUG|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
48348688|NCT01085162|DRUG|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
48137715|NCT01687751|DRUG|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
48348689|NCT00372294|DRUG|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
48348690|NCT00372294|DRUG|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
48348691|NCT06287931|DRUG|Ursodoxycholic acid group|Ursodoxycholic acid, 250mg po tid x 6 months
48348692|NCT06287931|DRUG|Bifidobacterium group|Bifidobacteria, 210 mg po tid x 6 months
48348693|NCT01985204|DIETARY_SUPPLEMENT|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
48348694|NCT01985204|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet without iodine
48658928|NCT00804232|BEHAVIORAL|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
48348695|NCT03583112|DRUG|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
48658929|NCT01928056|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
48658930|NCT05229666|OTHER|Cognitive Challenge|Cognitive challenge delivered via computer.
48658931|NCT03025035|DRUG|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
48137716|NCT01687751|DRUG|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
48137717|NCT02717819|DIETARY_SUPPLEMENT|Protein|Daily intake of supplement
48137718|NCT02717819|DIETARY_SUPPLEMENT|Placebo|Daily intake of supplement
48137719|NCT02717819|OTHER|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
48348696|NCT03583112|DRUG|Placebo Tablet|oral one placebo tablet before MRI scan.
48348697|NCT05135468|DRUG|CU-40102 Spray|topical application, 1\~4 sprays each time, once daily
48348698|NCT03344562|DEVICE|CES|Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
48348699|NCT03344562|DEVICE|CES|Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
48348700|NCT02269982|DEVICE|AR-v7 assays|
48348701|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera|An ultra-high sensitivity camera attached to the side arm of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
48658932|NCT03025035|DRUG|Olaparib|Olaparib administered orally twice a day
48658933|NCT02558868|DRUG|Irinotecan|
48658934|NCT02558868|DRUG|Oxaliplatin|
48658935|NCT00461890|DRUG|Injectable Naltrexone|
48658936|NCT04531579|DRUG|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
48348702|NCT04556929|DIAGNOSTIC_TEST|Intra-operative imaging of 5-ALA fluorescence using in-built operative microscope camera|In-built camera of the operative microscope will be used to take images of the anterior, posterior, lateral and inferior walls of the resection cavity on completion of tumour resection.
48348703|NCT04556929|DIAGNOSTIC_TEST|Biopsies|Following image capture, biopsies (approx 5x5x5mm size) will be taken from regions of the anterior, posterior, lateral and inferior walls of the resection cavity corresponding to the imaged areas.
47984032|NCT00003492|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48348704|NCT02967640|DRUG|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
48348705|NCT02967640|DRUG|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
48348706|NCT04272762|PROCEDURE|Cryoablation|Pulmonary vein isolation with cryoablation
48348707|NCT04272762|PROCEDURE|Placebo|Placebo procedure
48348708|NCT01461798|DIETARY_SUPPLEMENT|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
48348709|NCT01461798|DIETARY_SUPPLEMENT|Placebo Yogurt|Yogurt without the active principle
48348710|NCT01461798|DIETARY_SUPPLEMENT|yogurt|yogurt without plant stanols
48348711|NCT04691011|OTHER|Muscular MRI|MRI (1.5T)
48658937|NCT04531579|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
48658938|NCT04255381|DEVICE|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)
48658939|NCT05386472|DRUG|nirmatrelvir|Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
48658940|NCT05386472|DRUG|ritonavir|Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
47984033|NCT03363204|DEVICE|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
47984034|NCT00356369|BIOLOGICAL|meningococcal ACWY (vaccine)|One intramuscular dose.
47984035|NCT00356369|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
47984036|NCT05584176|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
47984037|NCT05584176|DEVICE|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
48348712|NCT04691011|OTHER|Electrophysiological exam|MUNIX
48348713|NCT04691011|OTHER|Brain MRI|MRI (7T)
48502180|NCT01195792|DRUG|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
48502181|NCT01195792|DRUG|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
48658941|NCT01532739|BEHAVIORAL|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
48658942|NCT04219020|OTHER|Co-created intervention|
48348714|NCT04691011|OTHER|Spinal cord MRI|7T and 3T MRI
48348715|NCT01352767|DEVICE|InsuPad|Heating pad
48348716|NCT05300958|DRUG|Deferoxamine Plus Chemotherapy|Deferoxamine：50mg/kg+500ml normal saline (NS)
48348717|NCT05998824|BEHAVIORAL|SCD-specific COVID-19 vaccination information (SCVI) video|SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
48348718|NCT03733106|DIAGNOSTIC_TEST|digital breast tomosynthesis|pseudo three dimension mammography
48348719|NCT03733106|DIAGNOSTIC_TEST|standard two dimension digital mammogram|standard two dimension mammogram
48348720|NCT06001892|BEHAVIORAL|Tennessee Youth Prepared for Success|both 5 day classroom interventions.
48348721|NCT05553262|BEHAVIORAL|Behavioral support|Behavioral support as described under 'Arm description'.
48348722|NCT04743401|OTHER|Tele-exergaming Tablet|"The Tele-Exergame platform virtually supervises exercise tasks and coaches patients to perform evidence-based foot and ankle exercises that have been designed to improve balance, cognition, and lower extremity vascular health.~The exergame program uses a game-based approach, similar to playing a video game, which helps to increase patient motivation and engagement in the cognitively demanding exercise program."
48502182|NCT00030979|DRUG|Donepezil|
48502183|NCT02458287|BIOLOGICAL|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
48502184|NCT02458287|BIOLOGICAL|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
47984038|NCT00407823|PROCEDURE|Central venous oxygen saturation continuous monitoring|
48137720|NCT02717819|DIETARY_SUPPLEMENT|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
48348723|NCT03780985|PROCEDURE|Intrauterine device insertion|Post-placental insertion of intrauterine device during Cesarean section
48348724|NCT03780985|PROCEDURE|Cesarean section|to delivery of the fetus
48348725|NCT03780985|PROCEDURE|Suture|to fix the intrauterine device
48658943|NCT05974176|BEHAVIORAL|Trauma Focused CBT (TF-CBT)|TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.
48658944|NCT05974176|BEHAVIORAL|Trauma Systems therapy (TST)|Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
48658945|NCT03770611|DIETARY_SUPPLEMENT|Probiotic|The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
47984039|NCT04665284|DRUG|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
47984040|NCT04665284|DRUG|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
47984041|NCT00265954|BEHAVIORAL|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
47984042|NCT03348020|PROCEDURE|Blood Donation|Subjects will donate blood within \~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
47984043|NCT05789147|DEVICE|Active tVNS|It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).
47984044|NCT05789147|DEVICE|Sham tVNS|Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
48348726|NCT00029341|BEHAVIORAL|Treatment Interruption|
48502185|NCT02458287|BIOLOGICAL|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
48502186|NCT02458287|BIOLOGICAL|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
48658946|NCT03770611|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic fiber is Agave inulin
48658947|NCT03770611|DIETARY_SUPPLEMENT|Symbiotic|The supplement is a combination of the probiotic product + the prebiotic fiber
47984045|NCT05990543|DRUG|Nelmastobart and Capecitabine|"Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period"
47984046|NCT05502328|DIETARY_SUPPLEMENT|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
47984047|NCT02548494|DRUG|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
47984048|NCT02548494|DRUG|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
47984049|NCT02548494|OTHER|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
48137721|NCT01691716|DRUG|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
48137722|NCT01691716|BEHAVIORAL|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
48348727|NCT00648492|DRUG|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
48348728|NCT00648492|DRUG|Glucophage® XR 500 mg|500mg, single dose fed
48348729|NCT03309241|DRUG|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
48348730|NCT03309241|OTHER|Placebo|Placebo Single Dose
48502187|NCT04206982|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
48502188|NCT04206982|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
47984050|NCT02548494|OTHER|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
47984051|NCT00968656|RADIATION|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
47984052|NCT00968656|OTHER|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
48348731|NCT02996110|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
48348732|NCT02996110|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
48348733|NCT02996110|BIOLOGICAL|Relatlimab|Specified Dose on Specified Days
48348734|NCT02996110|DRUG|BMS-986205|Specified Dose on Specified Days
48502189|NCT04206982|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus.
48348735|NCT02996110|DRUG|BMS-813160|Specified Dose on Specified Days
48348736|NCT05440344|DRUG|Imlunestrant|Administered orally.
48658948|NCT03770611|DIETARY_SUPPLEMENT|Placebo|The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
48658949|NCT00506766|BEHAVIORAL|Bladder Health Class consisting of 6 weekly group sessions|1 time
48658950|NCT00506766|BEHAVIORAL|Practice PFMT and BT|As needed for 4 years
48658951|NCT00506766|BEHAVIORAL|Clinic examination for pelvic muscle function|1/year for 4 years
48658952|NCT00506766|BEHAVIORAL|Record keeping in 3-day voiding diary|Every 6 months for 4 years
48348737|NCT02907411|OTHER|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
48658953|NCT06507618|DRUG|Tamoxifen, Letrozole, Anastrozole, or Exemestane|Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.
48658954|NCT03464201|DRUG|Enzalutamide 40 MG|Enzalutamide 160 mg p.o. every day
48658955|NCT04237584|DRUG|Enzalutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
48658956|NCT04237584|DRUG|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
48658957|NCT04237584|DRUG|Lead-in Enzalutamide followed by Placebo/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
48658958|NCT04237584|DRUG|Darolutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
47984053|NCT00968656|OTHER|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
48348738|NCT01017666|DRUG|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
48348739|NCT01017666|DRUG|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
48348740|NCT04431141|DRUG|Teneligliptin|Teneligliptin alone
48348741|NCT04431141|DRUG|Empagliflozin|Empagliflozin alone
48348742|NCT04431141|DRUG|Teneligliptin and Empagliflozin|Teneligliptin and empagliflozin
48348743|NCT03887052|DEVICE|ASSURE™ Wearable Cardioverter Defibrillator (WCD)|WCD with shock alarms and shock functionality disabled
48348744|NCT03409575|OTHER|5 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 5 minutes of NMES will be made in 4 sets. Fifteen contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
48658959|NCT04237584|DRUG|Lead-in Darolutamide followed by Radium-223/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
48658960|NCT04237584|DRUG|Lead-in Darolutamide followed by Placebo/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
48658961|NCT04605666|BIOLOGICAL|CD19-CAR-T2 Cells|CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
48658962|NCT03096431|BEHAVIORAL|Physical Activity|"* Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
48658963|NCT03096431|BEHAVIORAL|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
48658964|NCT04921267|BEHAVIORAL|training|training with filtered speech
48348745|NCT03409575|OTHER|10 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 10 minutes of NMES will be made in 2 sets. Thirty contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
48137723|NCT02374736|DRUG|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
48348746|NCT00209092|DRUG|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1."
48348747|NCT00209092|DRUG|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
48348748|NCT02579863|BIOLOGICAL|Pembrolizumab|IV infusion
48348749|NCT02579863|DRUG|Lenalidomide|oral capsules
48348750|NCT02579863|DRUG|Dexamethasone|oral tablets
48348751|NCT01986517|BEHAVIORAL|No feedback|Therapists will receive no feedback.
48348752|NCT01986517|BEHAVIORAL|Feedback after every fourth session|
48348753|NCT04245657|OTHER|Tissue Dielectric Constant Measurement|Sub-tissue fluid proportion will be evaluated via Moisture Meter D (Delfin Technologies, Kuopio, Finland) on both upper extremity (right and left) in predefined reference points on volar side (6 cm distal and 8 cm proximal points from cubital crease, 10 cm inferior side point from axilla and dorsal point of web space in the hand) by using four different probes which can assess 0.5 mm, 1.5 mm, 2.5 mm and 5.0 mm depth. Values taken by 2.5 mm depth probe will be used to calculate the ratio (affected side TDC value/Unaffected side TDC value) to stage lymphedema severity along with the International Society of Lymphology staging system. This device mainly aims to assess the dielectric constant of tissues which is related to the amount of tissue water. In the case of pre-lymphedema or lymphedema, one can assess objectively regarding sub-tissue fluid changes via this device. Triplicate measurements will be taken for each reference point.
48348754|NCT04245657|OTHER|Muscle strength measurement|Participants' muscle strength of shoulder flexion, abduction, and elbow flexion will be assessed via Handheld digital dynamometer (Lafayette Manual Muscle Tester, Model 01165, LaFayette Instruments, NY, USA). Both upper extremities will be assessed three times and the average value will be recorded.
48348755|NCT04245657|OTHER|Hand-Grip Strength Measurement|Handgrip strength will be assessed with LaFayette Professional Hand Dynamometer, Model 5030L1, LaFayette Instruments, NY, USA). The standard position which can be achieved by 90-degree elbow flexion, shoulder abducted, and hand mid-prone positioned; 90-degree shoulder abduction and 90-degree shoulder abduction positions will be used to assess hang-grip strength. Three measurements will be requested and the maximum value of them will be recorded. 1 minute resting period will be provided between the positions at which handgrip is assessed.
47984054|NCT00968656|OTHER|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
48137724|NCT02620449|OTHER|Diet|Participants will be fed a low-additive diet as the primary intervention
48137725|NCT01836159|OTHER|iPad Intervention|"Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~1. Popping a stationary balloon~2. Popping a moving balloon~3. Popping a pair of stationary balloons~4. Popping a pair of moving balloons~5. Stretching a balloon to pop~6. Balloon/Text distraction test"
48348756|NCT04245657|OTHER|Pain Threshold Measurement|The sensitive pain threshold and normal pain threshold will be evaluated by a digital algometer (Wagner FDIX, Greenwich, USA) on reference points as follows: C5-C6 zygapophyseal joints' lateral points, upper trapezius (proximal, middle and distal lateral points, length measured by a tape from C7 Processus spinosus to acromion and this length will be divided equally into three parts for proximal, middle and distal lateral point), deltoid muscle (crista deltoidea), dorsum of the webspace.
48348757|NCT04245657|OTHER|International Physical Activity Questionnaire-Short Form (IPAQ-SF)|This scale was intended to be filled to assess participants' physical activity levels within the last seven days. Then, MET calculations will be done via a basic Excel Spreadsheet which is pre-defined MET values formulated inside. Scale data then obtained according to the participants' answers and recorded.
48137726|NCT01836159|OTHER|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
47984055|NCT00968656|DRUG|F-18-ISO|Patients receive F-18-ISO-1 i.v.
47984056|NCT05767892|DRUG|YK-209A tablet|YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
48137727|NCT02163148|BEHAVIORAL|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
47984057|NCT05767892|DRUG|Pemetrexed+carboplatin/Cisplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
47984058|NCT05483179|DIAGNOSTIC_TEST|CPET|Cardiopulmonary exercise test
48137728|NCT03244800|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously once daily for 49 days.
48137729|NCT03244800|DRUG|Placebo|Placebo will be administered subcutaneously once daily for 49 days.
48137730|NCT00780494|DRUG|bevacizumab|Intravenous 15 mg/kg
48137731|NCT00780494|DRUG|carboplatin|AUC 6, Intravenously Day 1 every 21 days
48137732|NCT00780494|DRUG|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
48137733|NCT04037020|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
48137734|NCT04890899|PROCEDURE|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
48137735|NCT03259568|DEVICE|Repetitive TMS|1-10 Hertz rTMS will be administered
48137736|NCT00002095|DRUG|Ganciclovir|
48137737|NCT03758391|OTHER|Flipped Classroom education|Fellows will receive GI/Bilirubin education in a flipped classroom format.
48137738|NCT01122914|DRUG|Anakinra|
48137739|NCT01335867|DRUG|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
48137740|NCT01335867|DRUG|Placebo|Placebo pills
48137741|NCT03476772|DRUG|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
48137742|NCT06268782|BEHAVIORAL|Rehabilitate your core|The intervention was an online exercise program \&#34;Rehabilitate your core,\&#34; designed for postpartum women by a company called Nordic Fit Mama. Its primary goal is to fortify the core and pelvic floor muscles to enhance the recovery process after childbirth, while also emphasizing overall well-being. The program is accessible through a website and is intended to be completed independently over a span of 6 weeks. Each week focuses on a specific theme, encompassing six to seven subtopics. The regimen follows a progressive structure, starting with the identification of pelvic floor and core muscles and gradually advancing to exercises aimed at strengthening them. The exercises, which last around 10 minutes each, are tailored to integrate seamlessly into daily life. Comprising 25 instructional exercise videos and 13 guidance videos, the program only necessitates access to a device for logging into the platform.
48137743|NCT02131922|PROCEDURE|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
47984059|NCT03715218|OTHER|Mothers Touch Program|Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
47984060|NCT03715218|OTHER|Usual Care Program|Usual care group had advice, support and educational program delivered by midwife, or physicians.
48137744|NCT02131922|PROCEDURE|Dental Hygienization Treatment|
48137745|NCT02131922|DRUG|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
48137746|NCT02029469|DEVICE|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
48137747|NCT00145587|PROCEDURE|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
48348758|NCT04245657|OTHER|Fatigue Impact Scale|"This scale has 9 items that can be answered as Strongly Disagree through Strongly Agree by numbered as 1 and 7, respectively. Then total points will be calculated and divided into 9 to achieve the Fatigue Impact Scale score. The higher points will be indicated more perceived fatigue, while lower points indicate less."
47984061|NCT00064207|DRUG|gemcitabine hydrochloride|
47984062|NCT00064207|PROCEDURE|adjuvant therapy|
47984063|NCT00064207|RADIATION|radiation therapy|
48137748|NCT00145587|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
48137749|NCT00145587|DRUG|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
48348759|NCT04245657|OTHER|Disabilities of Arm, Shoulder and Hand Scale (DASH)|"DASH has 30 items related to upper extremity function. Participants will be requested to grade some expressions related to the function within a 5-point Likert scale as follows: No difficulty: 1, Mild Difficulty:2, Moderate Difficulty: 3, Severe Difficulty: 4 and Unable to perform: 5). The symptom score of the DASH will be calculated as dividing filled items total score to filled items' number and minus one from this data then multiplying with 25. The higher points indicate a deteriorated shoulder and hand function while lower points indicate a better upper extremity function."
48348760|NCT04245657|OTHER|Exercise Benefits/ Barriers Scale|Exercise Benefits/Barriers Scale has 43 items each can be graded within a four-point Likert type scale. Barrier items are reverse coded. 43 items are all related to exercise and exercise beliefs in both in the aspect of health and general. Strongly disagree, disagree, agree, strongly agree will be scored as 1,2,3,4 or vice versa whether the item should de reversely coded, respectively. Total scores ranged between 29 and 172. The barrier scale score is ranged between 14 and 56. The benefits scale is also ranged between 29 and 116. The higher the score of Barriers scale, the greater the perception of barriers to exercise.
48348761|NCT04245657|OTHER|Beck Depression Scale|Beck Depression Scale has 21 items each can be scored within 0 to 3. All items are related to the depressive mood of a participant. The higher the score of the Beck Depression Scale, the higher the depression level.
48137750|NCT05364385|DRUG|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
48137751|NCT05364385|DRUG|Infants in the control group (S/P group) receive placebo (Normal saline 1mL)|Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
48137752|NCT02599025|DEVICE|Innowalk cycling system|Innowalk is a unique, motorized medical device
48137753|NCT02599025|DEVICE|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
48137754|NCT05474313|BEHAVIORAL|PrEP-3D package|A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
48137755|NCT05474313|BEHAVIORAL|Standard of Care|Participants are given local standard of care navigation for initiation of PrEP
48137756|NCT04147637|COMBINATION_PRODUCT|FreeStyle Libre with MiaoMiao|Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
48137757|NCT04147637|DEVICE|FreeStyle Libre alone|Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
48137758|NCT01473485|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
48137759|NCT06151340|OTHER|Data collection|Data collection
48137760|NCT00326183|BIOLOGICAL|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
48348762|NCT00926185|DRUG|Lifitegrast|Ophthalmic Solution
47984064|NCT01166178|DRUG|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
48137761|NCT00326183|BIOLOGICAL|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
48137762|NCT02226159|DRUG|Lidocaine|
48137763|NCT02226159|DRUG|Lidocaine with Dexamethasone|
48348763|NCT00926185|DRUG|Placebo|Ophthalmic Solution
48348764|NCT04343391|BEHAVIORAL|Brief transdiagnostic cognitive-behavioral therapy|Time-limited transdiagnostic evidence-based psychological treatment
48137764|NCT01141257|DRUG|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
48348765|NCT04343391|DRUG|Pharmacological treatment|Treatment as usual in PC
48502190|NCT01997216|DEVICE|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
48658965|NCT02971163|BEHAVIORAL|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
48658966|NCT06545552|DIETARY_SUPPLEMENT|An oral formulation of green tea extract, bamboo shoot extract and selenium-enriched yeast|Hard shell capsule containing 280mg of the oral formulation
48658967|NCT06545552|DIETARY_SUPPLEMENT|Placebo|Hard shell capsule containing maltodextrine
48658968|NCT04933422|DRUG|CM93|oral capsule of CM93 administered once daily
48658969|NCT00977444|DRUG|kondrium|intraarticular injections once month
48658970|NCT00977444|DRUG|kondrium f|intraarticular injections once month
47984065|NCT01166178|DRUG|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
47984066|NCT01166178|DIETARY_SUPPLEMENT|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
47984067|NCT03021421|PROCEDURE|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
48137765|NCT03389789|OTHER|Oral glucose solution + maternal holding|Infant will receive both the oral glucose solution and the contact with the mother
48137766|NCT03389789|OTHER|Breastfeeding|Infants will be breastfed
48137767|NCT03389789|OTHER|Oral glucose solution|Infant will receive only oral glucose solution without contact with the mother
48137768|NCT03389789|OTHER|Oral expressed breastmilk|Infant will receive only oral expressed breast milk without contact with the mother
48137769|NCT03435367|DEVICE|Virtual Reality Program|VR with head mounted display (HMD) and headphones.
48137770|NCT03435367|DEVICE|iPad Tablet|iPad with headphones
48137771|NCT06509607|OTHER|Concentric Lower Limb Training Program|A specially designed 30-minute concentric lower limb training program (squats, lunges and leg extensions) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the coach, 2 days per week for 8 weeks.
48137772|NCT06509607|OTHER|Eccentric Lower Limb Training Program|A specially designed 30-minute eccentric lower limb training program (wall sit, sitting straddle single leg and full squat) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the same coach, 2 days per week for 6 weeks.
48137773|NCT05499767|BEHAVIORAL|HEPPI|Homebound Elderly People Psychotherapeutic Intervention
48137774|NCT01544907|DEVICE|Conventional PTA|Use of conventional balloon for angioplasty only
47984068|NCT03021421|PROCEDURE|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
47984069|NCT03274401|DEVICE|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
47984070|NCT03274401|DEVICE|5 day ECG patch|Selection of device for monitoring clinicians' choice
47984071|NCT05821868|DEVICE|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
48137775|NCT01544907|DEVICE|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
47984072|NCT05821868|DEVICE|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
48137776|NCT03529994|OTHER|Enrollment|All infants enrolled will have work of breathing assessed.
48137777|NCT00154609|DRUG|Gu-Sui-Bu (Davallia Divaricata)|
48137778|NCT04653688|DEVICE|The FeetMe® Evaluation|The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
47984073|NCT04002531|OTHER|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
48658971|NCT00977444|DRUG|methyl prednisolone (corticosteroid)|intraarticular injections once month
47984074|NCT04002531|OTHER|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
48137779|NCT04653688|DEVICE|the PKG® Watch,|The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,
48137780|NCT04653688|RADIATION|MRI|"* an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis"
48137781|NCT04653688|RADIATION|DaTSCAN|"* quantify nigrostriatal dopaminergic depletion~* correlate its impact on the type and severity of gait disorders in Parkinson's disease."
48658972|NCT05019079|OTHER|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
48348766|NCT05605704|DRUG|atherolive|In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
48348767|NCT01086267|DRUG|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
48348768|NCT01086267|DRUG|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
48658973|NCT05135754|DEVICE|Heylo|Test of the supporting product (test product) for a 12 weeks period. No additional intervention will be conducted. A few follow up nurse calls to assess few endpoints together with subject. All remaining endpoints are captured via surveys send to the subjects every 14 days.
48348769|NCT01086267|DRUG|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
48502191|NCT01997216|DEVICE|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
48502192|NCT05305612|OTHER|early anticoagulation|Anticoagulation prior to transseptal puncture
48658974|NCT00522379|DRUG|Rotigotine|2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
48658975|NCT00522379|DRUG|Rotigotine|4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
48137782|NCT01237067|DRUG|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
48348770|NCT00682760|DRUG|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
48348771|NCT01160042|DRUG|Metformin|Metformin Tablets 1000 mg
48348772|NCT01160042|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
48502193|NCT05305612|OTHER|late anticoagulation|Anticoagulation after transseptal puncture
48348773|NCT02022891|BEHAVIORAL|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
48348774|NCT02177786|DRUG|Selonsertib|Tablets administered orally once daily
48348775|NCT02177786|DRUG|Placebo to match selonsertib|Tablets administered orally once daily
48348776|NCT02111070|BIOLOGICAL|IL-YANG FLU Vaccine|0.5mL
48348777|NCT04725604|DEVICE|pH probe|"Patients who agree to take part will have a pH probe inserted into their injured limb. The pH probe will be attached to a pH monitor which will record pH data for up to a maximum of 72 hours (24 hours per probe). The surgical team will not have access to the pH data. During the time they are considered at risk for ACS, patients will be monitored in the routine way (using regular clinical assessment and pressure monitoring). If ACS is diagnosed in the routine way, then treatment (fasciotomy) will be offered as appropriate."
48658976|NCT00522379|OTHER|Placebo|Placebo transdermal patch applied daily
48658977|NCT00522379|DRUG|Rotigotine|6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
48658978|NCT00522379|DRUG|Rotigotine|8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
48658979|NCT05585294|BEHAVIORAL|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
48348778|NCT01117805|BEHAVIORAL|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
48348779|NCT00790218|DRUG|CF102|CF102 capsules twice daily by mouth
48348780|NCT03988894|DEVICE|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
48348781|NCT00002968|BIOLOGICAL|edrecolomab|Given IV
48348782|NCT00002968|OTHER|laboratory biomarker analysis|Correlative studies
48348783|NCT01381809|DRUG|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
48502194|NCT06167863|DIAGNOSTIC_TEST|radiomics|extracted image features from CT or MRI
48502195|NCT00362544|DRUG|Ambisome|
48502196|NCT03261960|DRUG|BLI4700|Oral bowel preparation
48502197|NCT03261960|DRUG|Magnesium bowel preparation|Oral bowel preparation
48348784|NCT01381809|DRUG|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
48348785|NCT05122013|BEHAVIORAL|A comprehensive remote multidisciplinary intervention for weight regain after sleeve gastrectomy|A remote 3-months multidisciplinary intervention for weight regain after sleeve gastrectomy including bi-monthly remote consultations with a registered dietitian, physical activity consultant and sleep consultant, combined with weekly text messages meant to enhance happiness and subjective wellbeing.
48348786|NCT05122013|BEHAVIORAL|Control group|Standard nutritional care: One frontal meeting with the study's registered dietitian at the clinic, including nutritional and behavioral assessment and recommendations, followed by guidance to to continue follow up in order to support healthy lifestyle.
48348787|NCT03011528|DRUG|VDC-IE x2|"Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
48348788|NCT03011528|DRUG|VDC-IE|"Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
48348789|NCT03011528|DRUG|TEMIRI|"Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d"
48348790|NCT03011528|DRUG|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10\^6 CD34/kg"
48348791|NCT03011528|DRUG|Maintenance|"\* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously"
48348792|NCT03011528|PROCEDURE|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
48348793|NCT03011528|RADIATION|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
48502198|NCT02743338|BEHAVIORAL|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
48502199|NCT02743338|BEHAVIORAL|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
48502200|NCT02743338|BEHAVIORAL|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
48658980|NCT06570564|DEVICE|The arm crank ergometer|Before starting the program, patients will perform an adaptation session for familiarization with the ergometer and also to identify the training load. For this, patients will perform 10 bouts of two minutes of exercising with a minimum load and two minute passive intervals between bouts. Patients will be instructed to maintain 50 revolutions per minute (RPM) during the exercise. Subsequently, to determine the training load for each session, patients will perform a progressive test where the load will be increased by 10 watts every minute of the test, following the protocol of two minutes of exercise with two minutes of interval
48348794|NCT03334656|BIOLOGICAL|biological dressing|to test a biological dressing on the wound healing of the split-thickness skin graft donor site
48348795|NCT03334656|OTHER|Paraffin gauze dressing|standard intervention : Paraffin gauze dressing on the wound healing
48348796|NCT02966106|DEVICE|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
48348797|NCT02966106|OTHER|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
48348798|NCT02014545|DRUG|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
48348799|NCT02014545|OTHER|Placebo|Only standard treatment of whole brain radiation therapy is done.
48348800|NCT06220188|DRUG|[177Lu]Lu-PSMA I&T|2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
48348801|NCT03991468|DIAGNOSTIC_TEST|Whole Slide Imaging|Scanning of a glass slide to create a digital image that can be viewed on a monitor
48348802|NCT03991468|DIAGNOSTIC_TEST|Light Microscopy|Use of traditional light microscopy per institutional standard practice
48348803|NCT05953272|OTHER|EMG Biofeedback therapy and Bobath therapy|"EMG Biofeedback therapy will be used to up-train the ankle dorsiflexors in stroke patients. It will be given for 15 minutes. Patient will practice 2 blocks of Tibialis Anterior muscle contraction trials (holding for 10 seconds per trial with 10 seconds of rest, 20 trials per block with 1 minute 40 seconds of rest in between the blocks) with the heel contacts the floor for a total of 40 trials.~In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
48348804|NCT05953272|OTHER|Bobath therapy|"In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
48348805|NCT00118040|DRUG|Genistein|Given orally
48348806|NCT00118040|OTHER|Laboratory Biomarker Analysis|Correlative studies
48502201|NCT03207867|DRUG|NIR178|"NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days."
48502202|NCT03207867|DRUG|PDR001|PDR001 is a human monoclonal antibody (MAb) administered on Day 1 of each cycle. PDR001 400 mg was administered via intravenous (i.v.) infusion over 30 minutes every 4 weeks (Q4W).
48348807|NCT00118040|OTHER|Pharmacological Study|Correlative studies
48502203|NCT04066595|DRUG|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
48502204|NCT04146116|DRUG|intranasal povidone-iodine|povidone-iodine USP, 10% w/w antiseptic
48502205|NCT03183336|PROCEDURE|ridge split interpositional block graft|
48502206|NCT03183336|PROCEDURE|decortication Onlay block graft|
48502207|NCT02352818|OTHER|no study intervention|
48502208|NCT04913948|OTHER|No intervention|No intervention
48137783|NCT01237067|DRUG|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
48348808|NCT00118040|OTHER|Placebo Administration|Given orally
48348809|NCT00118040|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
48348810|NCT05769907|BEHAVIORAL|Intervention Group|The study will consist of one session per week for 8 weeks, during which the participant will receive MI for 30-45 minutes. All participants will receive the MI intervention according to their readiness to lose weight measured by means the P-weight and S-weight at the beginning of each session.
48348811|NCT04929847|OTHER|Self-prepared emollient|The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.
48348812|NCT01951911|DRUG|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
48348813|NCT01951911|DRUG|Placebo|
48348814|NCT04737161|BIOLOGICAL|T regulatory cells|T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
48348815|NCT02415504|BEHAVIORAL|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
48348816|NCT02415504|BEHAVIORAL|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
48502209|NCT03516396|BEHAVIORAL|Training Plus|Training plus enhanced community development activities
48502210|NCT03516396|BEHAVIORAL|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
48502211|NCT03516396|BEHAVIORAL|No Inputs then Community development and training|No inputs for 24 months then add community development and training
48502212|NCT02951975|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
48502213|NCT05578456|DRUG|Prednisone and Aspirin|prednisone 10 mg and aspirin 75-100mg per day per os
48502214|NCT05578456|DRUG|Placebo|placebo 2 starch tablets per day per os
48502215|NCT03194841|OTHER|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
48502216|NCT05191017|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
48502217|NCT05191017|DRUG|Enzalutamide|Enzalutamide
48502218|NCT02107365|DRUG|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
48502219|NCT02107365|DRUG|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
48502220|NCT02107365|DRUG|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( \<75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
48137784|NCT02919748|OTHER|Choral Singing|Weekly sessions at 1 hour of choral singing.
48348817|NCT00834925|DRUG|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
48348818|NCT03887975|PROCEDURE|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
48348819|NCT03887975|PROCEDURE|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
48348820|NCT00291746|DRUG|Esomeprazole|
48348821|NCT00291746|PROCEDURE|Bravo technique|
48348822|NCT00944957|DRUG|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
48348823|NCT00944957|DRUG|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
48502221|NCT02107365|DRUG|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
48502222|NCT02552056|OTHER|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
48502223|NCT01006226|DRUG|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
47984075|NCT04002531|PROCEDURE|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
48348824|NCT00944957|DRUG|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
48348825|NCT00944957|DRUG|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
48348826|NCT01208818|DRUG|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
48348827|NCT01208818|DRUG|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
48348828|NCT01208818|DEVICE|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
47984076|NCT04002531|PROCEDURE|Echocardiogram|A non-invasive sonogram of the heart
47984077|NCT04002531|PROCEDURE|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
47984078|NCT04002531|PROCEDURE|Urine collection|Urine will be collection to evaluate renal function (kidney health)
48348829|NCT01208818|DEVICE|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient \> 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
48137785|NCT02919748|OTHER|Health Education Program|Weekly session at 1 hour of health education talk and group activities
48348830|NCT03321890|DRUG|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
48348831|NCT03321890|DRUG|prednisone|oral, 20mg / day,after breakfast
48348832|NCT03321890|DRUG|Cyclophosphamide|oral, 50mg / day,after lunch
48348833|NCT03321890|DRUG|etoposide|oral, 50mg / day,after dinner
48348834|NCT03321890|DRUG|Methotrexate|oral, 10mg / times, once a week,after breakfast
48502224|NCT03913819|DRUG|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
48502225|NCT03913819|DRUG|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
48502226|NCT03913819|DRUG|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
48502227|NCT03913819|PROCEDURE|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
47984079|NCT04002531|PROCEDURE|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
47984080|NCT04002531|OTHER|Brief Pain Inventory questionnaire|A questionnaire about daily pain
47984081|NCT04002531|OTHER|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
47984082|NCT00619801|DRUG|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
47984083|NCT00619801|DRUG|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
48137786|NCT01534546|DRUG|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
48137787|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
48348835|NCT04259346|DRUG|Ixekizumab|Administered SC.
48348836|NCT03050307|DRUG|TAK-438|TAK-438 tablets
48348837|NCT03050307|DRUG|Lansoprazole|Lansoprazole capsules
48348838|NCT03050307|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
48348839|NCT03050307|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
48348840|NCT03050307|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
48348841|NCT00464620|DRUG|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
48348842|NCT01679340|DRUG|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
48502228|NCT04645264|DEVICE|Foley Catheter|The patient is catheterized during surgery.
47984084|NCT02985307|BEHAVIORAL|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
48348843|NCT01679340|DRUG|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
48348844|NCT01679340|DRUG|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
48348845|NCT04146129|DRUG|CDX-0159|Single dose of one of four dosages of CDX-0159
48348846|NCT04146129|DRUG|Normal saline|Single infusion of normal saline
48348847|NCT02929381|DEVICE|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
48348848|NCT02929381|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
48348849|NCT04506385|DIETARY_SUPPLEMENT|probiotics|In the first phase: 10 subjects have added in the diet a daily dose of 1 billion of freeze-dried LDD01 probiotics (A arm), 12 individuals are supplemented with a daily dose of 1 billion of the DLBL mix (B arm). In the second phase: 10 individuals are supplemented with a daily low dose of probiotics blend (C arm) and 10 individuals are supplemented with a daily high dose of probiotics blend (D arm).
48348850|NCT01191424|DRUG|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
47984085|NCT02985307|BEHAVIORAL|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
48348851|NCT01191424|DRUG|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
48348852|NCT02764086|RADIATION|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
48348853|NCT02766972|PROCEDURE|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
48348854|NCT02691468|DEVICE|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
48348855|NCT02691468|DEVICE|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
48502229|NCT03275818|DRUG|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
48502230|NCT04865393|DRUG|SPR206|SPR206 100 mg single-dose IV infused over 1 hour
48502231|NCT02884401|DEVICE|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
47984086|NCT04178499|DIAGNOSTIC_TEST|cytokine analysis|analysis of intraocular cytokines
47984087|NCT02311010|DRUG|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
47984088|NCT01364662|DRUG|SPN-810|administered orally
47984089|NCT01364662|DRUG|Placebo|administered orally
47984090|NCT03874520|OTHER|Video triage|The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
47984091|NCT01829516|DRUG|Oxytocin|Intranasal oxytocin
47984092|NCT01829516|DRUG|Placebo|Intranasal placebo
47984093|NCT06167044|OTHER|thoracic mobilization|Thoracic mobilization will be performed for the thoracic spine mobilization group, thoracic mobilization therapy will be performed for five minutes.
47984094|NCT05894421|DRUG|TQB2223 injection+ Penpulimab Injection|TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
47984095|NCT02659631|DRUG|PF-06671008|Dose Escalation Phase - Part 1
48348856|NCT02469584|PROCEDURE|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
48348857|NCT03912324|PROCEDURE|Unipolar voltage subtraction map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury~3. Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~4. the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~5. Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~6. Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~7. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~8. Evaluate time to complete isolation after additional ablation~9. Evaluation of Procedure and Ablation time, and perfusion saline dose~10. Rhythm follow-up after the procedure in accordance with the study design."
47984096|NCT02659631|DRUG|PF-06671008|Dose Expansion Phase - Part 2
48348858|NCT03912324|PROCEDURE|CT myocardial thickness map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~4. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~5. Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~6. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~7. Evaluate time to complete isolation after additional ablation~8. Evaluation of Procedure time, Ablation time, and perfusion saline dose~9. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
48348859|NCT03912324|PROCEDURE|Empirical PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~4. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~5. Evaluate time to complete isolation after additional ablation~6. Evaluation of Procedure time, Ablation time, and perfusion saline dose~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
48348860|NCT01595308|DIETARY_SUPPLEMENT|Pomegranate juice|Pomegranate juice
48348861|NCT00141622|DRUG|Slow sodium|
48348862|NCT05298410|OTHER|Limitless|Participants will be instructed to take Limitless for 30 days.
48348863|NCT02467660|BEHAVIORAL|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
48348864|NCT02467660|BEHAVIORAL|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
48348865|NCT04162912|BEHAVIORAL|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
48348866|NCT02758561|BEHAVIORAL|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
48348867|NCT02267902|DRUG|DA-1229|
48348868|NCT01492738|PROCEDURE|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
48348869|NCT05291741|DIETARY_SUPPLEMENT|VLCD|Advice regarding VLCD
48348870|NCT05291741|DIETARY_SUPPLEMENT|Standard care|Standard dietary advice for weight loss before bariatric surgery
48348871|NCT00809575|OTHER|questionnaire administration|
48348872|NCT00809575|OTHER|fatigue assessment and management|
48348873|NCT00809575|OTHER|observation|
48348874|NCT00809575|OTHER|quality-of-life assessment|
48348875|NCT04838639|DRUG|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
48348876|NCT04838639|DRUG|Placebo|Two subjects per cohort will take a matched placebo.
48348877|NCT05875012|OTHER|action observation physical training|Action observation training 3 sessions per week for 3 successive months
48348878|NCT05875012|OTHER|Traditional physical therapy training|Traditional physical therapy training 3 sessions per week for 3 successive months
48348879|NCT00732238|OTHER|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
48348880|NCT00732238|OTHER|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
48348881|NCT06244524|OTHER|High indoor CO2 exposure|The participants will stay and sleep for eight hours in a closed bedroom.
47984099|NCT00042770|OTHER|talc|Given intrapleurally
48348882|NCT05274009|OTHER|No cooling (control)|Participants are exposed to 35°C, 60% relative humidity for 8 hours.
48348883|NCT05274009|OTHER|Recommended cooling|Participants are exposed to 35°C, 60% relative humidity for 3 hours, are then moved to an air-conditioned room for 2 hours (\~23°C, \~50% relative humidity), and then return to the heat for a final 3 hours.
48348884|NCT05274009|OTHER|Hybrid cooling|Participants are exposed to 35°C, 60% relative humidity for 2 hours, are moved to an air-conditioned room for 1 hour (\~23°C, \~50% relative humidity), return to the heat for 2 hours, move back to the air-conditioned room for 1 hour, and then return to the heat for a final 2 hours
48348885|NCT06263400|BEHAVIORAL|psychoeducation and follow-up study|In the study, we hypothesized that the caregiver psychoeducation program (consisting of six sessions over a 3-week period) would improve depressive symptoms in depressed patients, increase recovery levels, reduce the caregiver's burden, and reduce emotional expression levels in the family.
48348886|NCT03428295|DEVICE|Dose Safety AP system|Device will be used to automatically dose insulin
48348887|NCT00537771|DRUG|Anastrozole|1 mg once daily oral dose
48348888|NCT00537771|DRUG|Tamoxifen|20 mg once daily oral dose
48348889|NCT05455840|DEVICE|Da Vinci SP surgical platform|using Da Vinci SP platform in thymothymectomy or extended thymectomy
48348890|NCT02656524|DRUG|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
48137788|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
48137789|NCT00219466|OTHER|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
48348891|NCT04707027|DRUG|Aflibercept Injection (2 mg/0.05 ml)|Intravitreal aflibercept injections (treat and extend regimen)
48348892|NCT04707027|OTHER|Defer treatment|Follow up with fundus photo and OCT every 4 weeks
47984100|NCT00042770|PROCEDURE|dyspnea management|No talc
47984101|NCT04670081|DRUG|Psilocybin|25 mg, p.o.
48137790|NCT00219466|OTHER|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
48137791|NCT06381700|OTHER|MySmile app|"The MySmile app contains several features:~A) Knowledge Hub~1. Do You Know section: This section consists of seven (7) topics where users can learn about oral health knowledge.~2. Quiz time section: In this section, school children can play games and challenge themselves.~B) Track yourself Brushing diary Diet diary~C) Get help~1. Ask an expert~2. Find your dentist~3. Friendly reminders"
48137792|NCT06381700|OTHER|Control|"This will receive the usual School Dental Service.~School Dental Service provide students who need dental treatment and will be called to be given treatment. Among the treatments given include:~* Dental filling~* Full mouth scaling~* Dental extraction~* Preventive treatment, such as topical fluoride application~All treatment is free of charge except for dentures, crown/bridge work and orthodontics. Treatment for school children is based on normative needs assessment as determined by the dentist. A child is defined as orally fit when all required treatment in the SDS has been completed and appropriate oral hygiene status is maintained."
48137793|NCT01624493|DRUG|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
48348893|NCT00608491|DRUG|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
48348894|NCT00608491|DEVICE|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
48348895|NCT03068052|BEHAVIORAL|No incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
48502232|NCT02748811|OTHER|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
48348896|NCT03068052|BEHAVIORAL|Incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
48348897|NCT03455634|DEVICE|Twin Block|functional appliances for the stimulation of the mandibular growth
48502233|NCT01672216|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
47984102|NCT04670081|DRUG|Psilocybin|5 mg, p.o.
47984103|NCT04670081|DRUG|Nicotinamide|100 mg, p.o.
48348898|NCT03455634|DEVICE|Sander bite jumping appliance|functional appliances for the stimulation of the mandibular growth
48502234|NCT01672216|DEVICE|EMG-biofeedback alone|
48502235|NCT01422629|DEVICE|Ultrasonic ablation device|High Intensity focused ultrasound treatment
48502236|NCT03330821|DRUG|Cytarabine|Given IV
48502237|NCT03330821|DRUG|Idarubicin|Given IV
48502238|NCT03330821|OTHER|Laboratory Biomarker Analysis|Correlative studies
48502239|NCT03330821|DRUG|Pevonedistat|Given IV
48502240|NCT03330821|OTHER|Pharmacological Study|Correlative studies
48502241|NCT06400277|OTHER|Edentulous maxilla final impression for complete denture|Final impressions of edentulous maxilla separated in two groups. In physical impression group stock and individual trays and physical impression materials used.
48502242|NCT05217719|DRUG|recombinant human thrombopoietin|The dose of rhTPO is 15,000 U per day. The subcutaneous injection will be terminated when PCs are increased to normal. The duration of rhTPO will be 7 days.
48658981|NCT06570564|DEVICE|bicycle ergometer|bicycle ergometer program will consist of a bicycling exercise 3 days per week. Exercise intensity was set at 70% of maximal load with 30 minutes per session. The exercise protocol also incorporated warm-up and cool-down sessions that involved stretches of the major lower limb muscle groups (total exercise time, 40-60 minutes)
48658982|NCT06570564|DEVICE|treadmill|Supervised treadmill exercise as routine physiotherapy program
48658983|NCT01809431|BEHAVIORAL|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
48658984|NCT03282994|DEVICE|Dermal Cooling System|Cryotherapy
48658985|NCT00835549|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
48658986|NCT00835549|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
48658987|NCT01519479|OTHER|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
48658988|NCT01519479|OTHER|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
48658989|NCT06077279|BEHAVIORAL|Horticultural Therapy Program|Horticultural Therapy Program Is selected plant therapy
48658990|NCT03459222|BIOLOGICAL|Relatlimab|Specified dose on specified days
48658991|NCT03459222|BIOLOGICAL|Nivolumab|Specified dose on specified days
48658992|NCT03459222|DRUG|BMS-986205|Specified dose on specified days
48658993|NCT03459222|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48658994|NCT02474173|OTHER|Laboratory Biomarker Analysis|Correlative studies
48658995|NCT02474173|DRUG|Onalespib|Given IV
48658996|NCT02474173|DRUG|Paclitaxel|Given IV
48658997|NCT02474173|OTHER|Pharmacological Study|Correlative studies
48658998|NCT04846946|BEHAVIORAL|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
48658999|NCT03622606|DIAGNOSTIC_TEST|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
48659000|NCT04160832|GENETIC|Multi-Cancer Cancer Panel|Eligible patients will receive genetic testing to determine germline cancer predisposition.
47984104|NCT03654651|DRUG|Peanut|Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.
48348899|NCT05653336|DEVICE|PerQseal® Closure Device System|Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
48348900|NCT03865849|DEVICE|Cooled radiofrequent treatment|In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
48348901|NCT03865849|DEVICE|Conventional radiofrequent treatment|In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
48348902|NCT01751789|BEHAVIORAL|Linkage|
48348903|NCT01751789|OTHER|Treatment as Usual|
48348904|NCT01432704|DRUG|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
48348905|NCT05648123|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
48348906|NCT06206772|DIAGNOSTIC_TEST|Resting state HD-EEG recording|All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.
48348907|NCT01222897|DRUG|Valacyclovir hydrochloride|
48348908|NCT04067011|DRUG|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
48348909|NCT04067011|DRUG|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
48348910|NCT04067011|BIOLOGICAL|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
48659001|NCT00685295|DRUG|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
48659002|NCT00685295|DRUG|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
48659003|NCT00685295|DRUG|Oxycodone|Oxycodone 5/325 mg tablet
48348911|NCT06379880|DEVICE|CONTINUUM+ CONNECT remote monitoring|"CONTINUUM+ CONNECT is a web platform, accessible via the internet, which contains the digital medical device (DMN) Continuum+ alert module. This is a medical software intended for the interpretation of clinical constants, symptoms, adverse events and pain, generating alerts with a view to improving the monitoring of patients undergoing anticancer treatment. The Continuum+ Alert Module version 1.0.0 dated 30 April 2021 is CE-marked and will be used in accordance with the manufacturer's instructions for use by patients in the experimental group."
48348912|NCT00338429|BEHAVIORAL|FHP Sleep Program|Cognitive-Behavioral Intervention
48502243|NCT05217719|DRUG|normal saline|Patients in the control group will receive the same amount of saline as a placebo, which is injected subcutaneously. The duration of saline will be 7 days.
48502244|NCT06422910|OTHER|Telerehabilitation|"Home exercises will be delivered through a video mobile application. In this application, exercises for knee osteoarthritis will be presented according to their types (stretching, strengthening, etc.). Videos deemed appropriate by the physiotherapist will be added to the exercise prescription and sent to the patients via message. Patients will have the opportunity to remotely access their own exercise prescription with visual, auditory and written commands.~Translated with DeepL.com (free version)"
48502245|NCT04645966|BIOLOGICAL|MenABCWY|Neisseria meningitis groups A, B, C W, and Y vaccine
48502246|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (60-µg Dose)|Trumenba (half dose) - Meningococcal Group B vaccine
48502247|NCT04645966|BIOLOGICAL|Bivalent rLP2086 (120-µg Dose)|Trumenba - Meningococcal Group B vaccine
48502248|NCT04645966|BIOLOGICAL|Bexsero|Bexsero - Meningococcal Group B vaccine
48502249|NCT04645966|DRUG|Prophylactic Liquid Paracetamol (PLP)|PLP administration during primary vaccinations 1 and 2
48502250|NCT04645966|BIOLOGICAL|Nimenrix|Nimenrix - Meningococcal Group A, C, W and Y vaccine
48502251|NCT04645966|OTHER|Placebo|Normal Saline
48502252|NCT04645966|DRUG|Scheduled Liquid Paracetamol (SLP)|SLP administration after primary vaccinations 1 and 2.
48502253|NCT04645966|DRUG|Therapeutic Liquid Paracetamol (TLP)|TLP administration after primary vaccinations 1 and 2
48502254|NCT05231330|DRUG|silvernanoparticles|silvernanoparticles in fluoride varnish
47984105|NCT03654651|DRUG|High carbohydrate snack|Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).
47984106|NCT06376110|DRUG|Topical Antioxidant Serum|An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
48348913|NCT02219672|DRUG|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
48348914|NCT02219672|DRUG|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
48502255|NCT05231330|DRUG|SDF|silver diamine fluoride
48502256|NCT04237337|OTHER|Exposure to MS drugs|Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
48502257|NCT01898650|OTHER|MR scan|
48502258|NCT02373189|DEVICE|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
48502259|NCT02875015|DRUG|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
48502260|NCT02875015|DRUG|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
48659004|NCT00679614|DRUG|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
48659005|NCT00679614|DRUG|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
48659006|NCT00679614|DRUG|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
48659007|NCT06570369|DRUG|SP-624|Oral dose, once daily for 2 weeks
48659008|NCT06570369|DRUG|Placebo|Oral dose, once daily for 2 weeks
48659009|NCT03884257|DEVICE|Passeo-18 Lux treatment group|Percutaneous endovascular angioplasty with the Passeo-18 lux
48659010|NCT03884257|DEVICE|IN.PACT Admiral treatment group|Percutaneous endovascular angioplasty with the IN.PACT Admiral
48659011|NCT06630767|PROCEDURE|ERAS|Enhanced recovery after surgery (ERAS) programs are a combination of evidenced-based perioperative care approaches that work synergistically to improve recovery after surgery. The core elements of ERAS protocols are preoperative advice, optimization of diet, systematic analgesic and anesthetic regimes, and early mobilization.
48659012|NCT06630767|PROCEDURE|Conventional|Conventional care for patients subjected for laparoscopic common bile duct exploration
48659013|NCT06250673|DIETARY_SUPPLEMENT|Diet experiment|For the isotretinoin users
48659014|NCT05368519|DEVICE|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
48659015|NCT00928772|DEVICE|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
48348915|NCT04071808|DIAGNOSTIC_TEST|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
48502261|NCT02875015|PROCEDURE|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
48659016|NCT00928772|DRUG|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
48659017|NCT00928772|OTHER|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
48348916|NCT02664389|GENETIC|Genetic analysis|Sequencing of 200 selected genes in the different study populations
48348917|NCT00985738|DRUG|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
48659018|NCT05470166|DRUG|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
48659019|NCT05470166|OTHER|saline IV|saline infusion same volume as lidocaine
48659020|NCT04827914|BEHAVIORAL|Enhanced Care|Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.
48659021|NCT04827914|BEHAVIORAL|Basic Care|Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
48659022|NCT05329831|BEHAVIORAL|Structured training using telehealth|The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
48659023|NCT05196620|OTHER|Endoanal Ultrasound (EAUS)|Endoanal Ultrasound pre- and postpartum
48659024|NCT03130049|PROCEDURE|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
48659025|NCT01821755|BEHAVIORAL|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
48659026|NCT02527512|DRUG|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
48659027|NCT02527512|OTHER|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
48659028|NCT05527769|PROCEDURE|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
48659029|NCT01809769|BIOLOGICAL|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
48137794|NCT01624493|DRUG|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
48137795|NCT01624493|DRUG|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
48348918|NCT00985738|OTHER|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
48348919|NCT05069389|OTHER|Data collection|"Some data will be collected for all patients included :~* specific treatment administered in COVID unit~* dosages of treatment~* inclusion in clinical trials~Evolution of French recommendations and the publication of scientific articles"
48659030|NCT01809769|BIOLOGICAL|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
48659031|NCT01809769|BIOLOGICAL|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
48348920|NCT05758974|PROCEDURE|dental treatment|Extraction, pulp therapy or both
48659032|NCT00270556|DRUG|tenofovir disoproxil fumarate|
48348921|NCT00505544|BEHAVIORAL|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
48348922|NCT00505544|DEVICE|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
48659033|NCT00270556|DRUG|Abacavir|
48659034|NCT06564324|DRUG|Taletrectinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met."
48348923|NCT01135394|DRUG|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
48137796|NCT01624493|DRUG|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
47984107|NCT06376110|DEVICE|AviClear Laser|The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
48137797|NCT01624493|DRUG|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
48137798|NCT02282254|OTHER|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
48137799|NCT04378205|PROCEDURE|0.014-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
48137800|NCT04378205|PROCEDURE|0.016-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
48137801|NCT04383067|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
48137802|NCT04383067|DRUG|Proleukin|high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
48137803|NCT01724996|OTHER|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
48137804|NCT00192959|DRUG|Xenon vs propofol|
48137805|NCT02525822|DRUG|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
48137806|NCT02525822|DRUG|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
48137807|NCT02525822|DRUG|Vehicle Cream|Comparator Product: Vehicle Cream
48137808|NCT02525822|DRUG|Vehicle Lotion|Comparator Product: Vehicle Lotion
48137809|NCT05305391|OTHER|Dietary intervention|The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
48137810|NCT01267643|DRUG|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
48137811|NCT05110794|DRUG|LY3502970|Administered Orally.
48137812|NCT00587886|BEHAVIORAL|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
48137813|NCT00587886|BEHAVIORAL|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
48137814|NCT00372476|DRUG|Imatinib and Vinorelbine|
48502262|NCT05657392|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.
48502263|NCT05657392|OTHER|32 electrode electroencephalography (EEG)|32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
48502264|NCT02512653|BIOLOGICAL|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
48502265|NCT02459548|OTHER|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
48502266|NCT02459548|OTHER|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
48502267|NCT03052296|DEVICE|Passeo-18 Lux DCB|The endovascular procedure is conducted as per the local standard practice and device instruction for use
48502268|NCT01682486|DEVICE|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
47984108|NCT00415103|DRUG|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
48659035|NCT06564324|DRUG|Crizotinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met. Crossover from control group (crizotinib) to taletrectinib is also permitted, at the Investigator's discretion with the Sponsor's approval, for qualifying participants who have experienced objective progression confirmed by the BIRC."
48659036|NCT06477692|DRUG|ENI using IMRT with or without chemotherapy|This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
48659037|NCT06477692|RADIATION|INRT|INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
48348924|NCT02782247|DEVICE|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal \< 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis \>11.5kPa. It cannot be used in patients with ascites."
48502269|NCT01682486|PROCEDURE|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
48502270|NCT05939635|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|"Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
48659038|NCT06477692|RADIATION|ENI|ENI using IMRT with or without chemotherapy
48659039|NCT03097640|OTHER|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
48502271|NCT05939635|PROCEDURE|Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block|"Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis."
48502272|NCT05939635|DRUG|IV morphine patient-controlled analgesia (PCA)|Morphine will be administered via PCA device for the first 24 hours after surgery
48502273|NCT04111393|PROCEDURE|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
48502274|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
48618224|NCT05722301|DRUG|Testosterone Therapy|The testosterone pellet implantation will be performed 2 weeks before surgery. The dose is determined by baseline levels of sex hormone binding globulin (SHBG) in the following manner: If SHBG \> 60nmol/L implant 5 Testosterone Compounded 200mg (total 1000mgs testosterone). If SHBG 41-59 nmol/L implant 4 Testosterone Compounded 200mg (total 800mgs testosterone). If SHBG \<40 nmol/L implant 3 Testosterone Compounded 200mg (total 600mgs testosterone).
48618225|NCT05722301|OTHER|No Testosterone Therapy|For the sham procedure no pellets will be implanted.
48618226|NCT06403371|OTHER|Fluoride varnsh|Fluoride varnish was applied to the teeth surfaces before aligner therapy
48137815|NCT00695188|DRUG|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
48137816|NCT00695188|DRUG|methotrexate|25 mg oral administration
48137817|NCT05532072|DRUG|Rapamycin|Rapamycin plus Methylprednisolone
48137818|NCT05532072|DRUG|Methylprednisolone|Methylprednisolone Alone
48348925|NCT02782247|DEVICE|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
48348926|NCT01855204|RADIATION|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
48348927|NCT05642793|DRUG|proactive Anti-VEGF (conbercept) use|preventive intravitreal injection of conbercept 2 weeks after vitrectomy, and repeat at 5 weeks and 8 weeks if either of the following is present: intravitreal VEGF concentration at 2 weeks postop is higher than 100 pg/ml, or clinical presentation of DME, VH or NVG.
48348928|NCT05642793|DRUG|passive Anti-VEGF (conbercept) use|No intravitreal injection of conbercept is used until the patient present with postoperative DME, VH, NVG
48348929|NCT03105375|DRUG|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
48348930|NCT03105375|DRUG|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
48348931|NCT03105375|DRUG|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
48348932|NCT04457661|DIETARY_SUPPLEMENT|Bacillus coagulans TCI711|Using Bacillus coagulans TCI711 for one month and implementing alcohol testing at weeks 0, 1, and 4.
48348933|NCT03823898|BEHAVIORAL|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
48348934|NCT03823898|BEHAVIORAL|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
48348935|NCT03823898|BEHAVIORAL|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
48502275|NCT00103610|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
48348936|NCT01875068|BEHAVIORAL|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
48502276|NCT00169481|BIOLOGICAL|Pneumococcal (vaccine)|
48137819|NCT05162560|OTHER|patients with acute diverticulitis|registry and hospital charts of patients with acute diverticulitis
48348937|NCT01875068|BEHAVIORAL|versus NPs and PAs who are not required to discuss patient referrals (control group).|
48348938|NCT02474628|DIETARY_SUPPLEMENT|sodium bicarbonate|
47984109|NCT00415103|DRUG|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
48137820|NCT03491566|OTHER|Clinic Pilates Group|"Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises."
48137821|NCT03491566|OTHER|Aerobic Exercise Group|Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
48137822|NCT00082836|BIOLOGICAL|rituximab|
48137823|NCT00082836|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48137824|NCT03695549|PROCEDURE|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
48137825|NCT03695549|PROCEDURE|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
48137826|NCT00853255|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
48137827|NCT02429115|OTHER|Mentoring|Six months of peer-mentoring.
48659040|NCT06471010|OTHER|Blended Dynamic Interpersonal Therapy (B-DIT)|The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.
48659041|NCT06100120|PROCEDURE|Implant placement|Placement of osteointegrated implants
48659042|NCT00391716|DRUG|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
48659043|NCT00391716|BEHAVIORAL|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
48659044|NCT00391716|DRUG|placebo|lactose capsule compounded to mimic gabapentin capsules
48659045|NCT00391716|DRUG|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
48659046|NCT04236154|OTHER|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
48659047|NCT04236154|OTHER|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
48137828|NCT04486820|OTHER|Analysis Immunohistochemical|Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
48137829|NCT05900466|DRUG|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
48137830|NCT05900466|DRUG|Placebo|Matching tablets once daily in the morning for 8 weeks
48137831|NCT03878966|DEVICE|Inserting polymer free drug eluting stent in the coronary arteries|• Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
48137832|NCT02441374|DEVICE|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
48659048|NCT04236154|OTHER|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
48659049|NCT05185622|DRUG|Vamorolone|Oral administration of vamorolone for 12 weeks.
48659050|NCT04805593|DEVICE|WaveLight EX500 excimer laser system|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the Wavefront Optimized (WFO) Ablation profile of the WaveLight EX500 excimer laser system will be used for bilateral LASIK treatment of hyperopia with and without astigmatism.
48659051|NCT04805593|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system.
48137833|NCT02441374|OTHER|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
48137834|NCT04248868|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
48137835|NCT04248868|DRUG|r-tPA|Pulse spray and infusion
48137836|NCT05072002|OTHER|no intervention / observational study|no intervention / observational study
48137837|NCT00002232|BIOLOGICAL|APL 400-003|
48137838|NCT02615132|BEHAVIORAL|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
48137839|NCT01035372|DIETARY_SUPPLEMENT|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
48348939|NCT02474628|DIETARY_SUPPLEMENT|calcium carbonate|
48348940|NCT03775603|DEVICE|TOFscan|comparison of TOFscan over TOF-Watch SX
48348941|NCT01770886|DRUG|UE2343|Oral capsule
48137840|NCT03506945|BEHAVIORAL|mPEP|Behavioral Activation Therapy
48137841|NCT03506945|BEHAVIORAL|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
48348942|NCT01770886|DRUG|Placebo|Oral capsule
48348943|NCT04567953|OTHER|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
48348944|NCT02364661|BEHAVIORAL|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
48502277|NCT01283594|DRUG|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
48137842|NCT01769716|PROCEDURE|Umbilical cord blood transplantation|
48137843|NCT00337610|DRUG|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
48137844|NCT00337610|DRUG|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
48137845|NCT03020498|BIOLOGICAL|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
48137846|NCT03020498|BIOLOGICAL|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
48137847|NCT03831698|DRUG|Omega-3 fatty acid ethyl esters (2 gram)|Omega-3 fatty acid ethyl esters (2 gram)
48137848|NCT03865875|BEHAVIORAL|Exercise Program|Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.
48137849|NCT03865875|BEHAVIORAL|Nutrition Program|Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
48137850|NCT04983615|DRUG|fentanyl-based sedation|fentanyl-based sedation instead of midazolam-based sedation in ventilated patients
48137851|NCT04983615|DRUG|midazolam-based sedation|midazolam-based sedation
48137852|NCT01827982|DRUG|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
48137853|NCT01827982|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
48137854|NCT01827982|DRUG|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
48137855|NCT01827982|DRUG|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
48502278|NCT01283594|DRUG|Placebo|White-coated, modified-oval placebo tablets.
48137856|NCT01827982|DRUG|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
48137857|NCT01827982|DRUG|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
48137858|NCT01827982|DRUG|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
48137859|NCT01827982|DRUG|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
48137860|NCT01827982|DRUG|Placebo|Matching placebo will be given as a single oral dose.
48137861|NCT00880074|DRUG|Fluorothymidine F-18|Undergo fluorine F-18 fluorothymidine PET
48137862|NCT00880074|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48137863|NCT00880074|PROCEDURE|Positron Emission Tomography|Undergo fluorine F-18 fluorothymidine PET
48137864|NCT02405702|OTHER|restrospective study|
48137865|NCT03314636|DRUG|Carfilzomib|See in arm description
48137866|NCT03314636|DRUG|Lenalidomide|See in arm description
48137867|NCT03314636|DEVICE|PET-CT|See in arm description
48502279|NCT01283594|DRUG|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
48137868|NCT03314636|DRUG|Dexamethasone|See in arm description
48137869|NCT05500352|OTHER|Hyperglycemia with slow decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
48502280|NCT01283594|DRUG|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
48502281|NCT01283594|DRUG|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
48502282|NCT01283594|DRUG|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
48502283|NCT02594085|OTHER|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
48502284|NCT02594085|OTHER|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
48502285|NCT02594085|OTHER|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
48502286|NCT02594085|OTHER|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
48502287|NCT02594085|OTHER|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
48502288|NCT02594085|OTHER|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
48502289|NCT04675814|OTHER|Adapted Physical Activity (APA)|Adapted Physical Activity (APA)
48502290|NCT02969265|DRUG|Amlodipine|Amlodipine Capsules
48502291|NCT02969265|DRUG|TCV-116CCB|TCV-116CCB Tablets
48502292|NCT02969265|DRUG|Amlodipine Placebo|Amlodipine placebo-matching capsules
48502293|NCT02969265|DRUG|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
48348945|NCT01524926|DRUG|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
48137870|NCT05500352|OTHER|Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
48137871|NCT05500352|OTHER|Rebound hyperglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)
48137872|NCT05500352|OTHER|Rebound euglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).
48137873|NCT05500352|OTHER|Hypoglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)
48137874|NCT05500352|OTHER|Hypoglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
48137875|NCT05500352|OTHER|Hypoglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
48137876|NCT05500352|OTHER|Hyperglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
48137877|NCT05500352|OTHER|Hyperglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
48137878|NCT01957163|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
48348946|NCT01718119|DRUG|r-hCG|r-hCG(250mcg) injection subcutaneously
48348947|NCT02620124|DRUG|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
48348948|NCT02620124|DRUG|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
48348949|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device|
48348950|NCT02077036|DEVICE|Kinetic Oscillation Stimulation Device in placebo mode|
48659052|NCT05035108|BIOLOGICAL|hiHep bioartificial liver therapy|HiHep cell bioartificial liver treatment was performed 24-48 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 6-9h.
48659053|NCT06419881|BEHAVIORAL|Tele-drama therapy|A 12-week tele-drama therapy group intervention integrating Playback Theater and Life Review Therapy
48659054|NCT06419881|OTHER|Usual Care|This arm continued to receive the routine activities provided by Uniper Care
48659055|NCT00693147|PROCEDURE|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
48659056|NCT06062485|DRUG|Surufatinib+Toripalimab+AG|"This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）"
48659057|NCT05128903|DRUG|[18F]DPA714|"Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy"
48659058|NCT05634200|PROCEDURE|Bronchoscopy|During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
48659059|NCT03110562|DRUG|Selinexor|oral 100 mg dose
48659060|NCT03110562|DRUG|Bortezomib|subcutaneous dose of 1.3 mg/m2
48348951|NCT03447067|PROCEDURE|computer guided surgical|has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
48348952|NCT03447067|PROCEDURE|Conventional surgery|Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
48659061|NCT03110562|DRUG|Dexamethasone|oral dose of 20mg
48659062|NCT06267846|DRUG|NBI-1070770|Suspension for oral administration
48659063|NCT06267846|DRUG|Placebo|Suspension for oral administration
48348953|NCT03447067|DEVICE|CBCT|For measuring the bone removeal
48348954|NCT03447067|DEVICE|CBCT|for identifed the nerve
48137879|NCT01957163|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
48137880|NCT01957163|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
48348955|NCT04416269|DRUG|Oral Anti-diabetes Drugs alone|OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
48348956|NCT04416269|DRUG|Basal bolus insulin|Basal insulin with glargine or detemir will be used as per the hospital formulary.
48348957|NCT04416269|DRUG|Supplemental insulin|Supplemental (correction) lispro or aspart insulin following the supplemental/sliding scale standard of care protocol for BG \>140 mg/dl.
48348958|NCT04416269|DEVICE|Continuous glucose monitoring (CGM)|"A subset of participants (50 per study arm) will be randomized to take part in an optional study where a CGM device will be placed for the duration of the study. CGM reports will be reviewed at the end of the study to assess parameters of glycemic control and hypoglycemia, and not used for insulin dose adjustment.~The Dexcom CGM is a small sensor that inserts just under the skin to continuously monitor glucose levels. Results are transmitted to the wearer's smartphone every five minutes."
48348959|NCT05299151|OTHER|Vestibular exercises|The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.
48348960|NCT05299151|OTHER|Standard neurorehabilitation exercises|A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
48502294|NCT03121378|OTHER|Blood sample 1|Blood taken before prosthesis implantation
48659064|NCT02314195|DRUG|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
48659065|NCT02314195|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
48137881|NCT01957163|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
48137882|NCT00916409|DEVICE|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
48348961|NCT01755260|OTHER|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
48348962|NCT05094882|PROCEDURE|pulmonary lobectomy|resection of lung lobe
48348963|NCT00928304|DRUG|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
48348964|NCT05888532|DRUG|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
48348965|NCT05888532|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
48348966|NCT05756205|DEVICE|Immersive Virtual Reality (IVR)|"The intervention will consist of an Immersive Virtual Reality (IVR) application with virtual reality goggles Oculus GO, to reduce anxiety during pregnancy. This application lasts 14 minutes by the use of mindfulness techniques based on breathing, mindfulness and passive muscle relaxation. It consists of three modules that can be chosen completely or separately.~The aspects that conform this intervention will be: information about, the most common perinatal mental health problems, exercises based on attention to breathing (mindfulness-relaxation), 6 weeks of duration, for 14 minutes a day, knowledge from involved personnel of the number of times the woman has connected and the time she has done the exercise, satisfaction questions to pregnant women after pregnancy, alerts to notify the principal investigator if there is a problem with e-health, and, finally, an email address to contact the principal investigator."
48348967|NCT01522118|DEVICE|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
48348968|NCT00498368|DRUG|Intravenous Rituximab|"Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182"
48348969|NCT00498368|DRUG|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
48348970|NCT00498368|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
48348971|NCT00164567|BEHAVIORAL|Onsite IPV specialist|
48348972|NCT00164567|BEHAVIORAL|Empowerment focused intervention|
48348973|NCT00551967|PROCEDURE|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
48348974|NCT01974440|DRUG|Bendamustine|90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
48348975|NCT01974440|DRUG|Rituximab|375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
48348976|NCT01974440|DRUG|Cyclophosphamide|750 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
48348977|NCT01974440|DRUG|Doxorubicin|50 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
48659066|NCT02314195|OTHER|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
48659067|NCT03076151|DRUG|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
48659068|NCT03439488|DRUG|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
48659069|NCT03439488|DRUG|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
48348978|NCT01974440|DRUG|Vincristine|1.4 mg/m\^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
48348979|NCT01974440|DRUG|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
48348980|NCT01974440|DRUG|PCI-32765 (Ibrutinib)|560 mg (4\*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
48348981|NCT01974440|DRUG|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
48348982|NCT02692560|BEHAVIORAL|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
48348983|NCT02692560|OTHER|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
48502295|NCT03121378|OTHER|Blood sample 2|Blood taken after prosthesis implantation
48659070|NCT00037882|DRUG|PEG-Intron|Once weekly injection.
48659071|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.
48348984|NCT02333136|DEVICE|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
48348985|NCT03820206|DRUG|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
48348986|NCT03820206|PROCEDURE|Cesarean section|Lower segement transverse cesarean section
48348987|NCT04179760|BIOLOGICAL|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
48348988|NCT04179760|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
48348989|NCT02287805|OTHER|qualitative survey|
48348990|NCT02287805|OTHER|quantitative survey|
48348991|NCT00564603|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
48659072|NCT05769036|DEVICE|Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing|The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
48659073|NCT05770973|OTHER|Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany|Compression dressing after ptosis surgery
48348992|NCT00564603|OTHER|0.9% Saline|Saline, in same volume of 2mL
48348993|NCT05474768|OTHER|no intervention|no intervention
48348994|NCT01665898|PROCEDURE|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
48348995|NCT01665898|PROCEDURE|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
48348996|NCT01818765|PROCEDURE|Trans-ventricular-septal placement of LV pacing lead|
48348997|NCT01818765|OTHER|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
48348998|NCT01818765|OTHER|Acute response assessment|Cardiac output monitoring
48659074|NCT03810807|DRUG|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
48659075|NCT03810807|DRUG|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
48659076|NCT05516121|DRUG|VLT-015|100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
48659077|NCT00895505|DRUG|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
48348999|NCT03518463|COMBINATION_PRODUCT|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
48349000|NCT06508697|DIAGNOSTIC_TEST|invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement|A consecutive series of patients who underwent Coronary computed tomography angiography (CTA) within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement were candidates for this study at Fujita Health University Hospital, Bantane Hospital, and Nagoya First Red Cross Hospital
48349001|NCT02515773|DRUG|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
48349002|NCT02515773|BEHAVIORAL|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
48349003|NCT01886495|OTHER|nutrition intervention|
48349004|NCT01542294|DRUG|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
48349005|NCT01542294|DRUG|Oxaliplatin|130mg/m2 d1 repeated every 21 days
48502296|NCT04590638|OTHER|tumescent with adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution containing adrenaline to see the bleeding control of donor site.
48659078|NCT00895505|DRUG|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
48659079|NCT06006286|DRUG|Atezolizumab|Given by IV (vein)
48659080|NCT06006286|DRUG|Bevacizumab|Given by IV (vein)
47984110|NCT00415103|DRUG|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
48349006|NCT03923504|OTHER|Physical Activity Intervention (PAI)|Those who opt-in to attend in-person study visits and to undergo COVID testing will also complete an MRI exam and CPET testing. Participants unwilling to have COVID testing done will only complete an MRI exam and home-based testing. All testing will take place either within 6 weeks of initiating systemic treatments or within 8 weeks of completing radiation then at 3 \& 6 months. Patients may participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training,15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down. Participants will have the ability to participate in training sessions facilitated via online channels at home.
48349007|NCT03923504|OTHER|Healthy Living Control|Patients randomized to the control arm will either attend online sessions via secure video conferencing (e.g. Zoom) or telephone or to come to a centralized meeting location (if safety allows) to participate in organized health workshops. Session attendance will be required 2 times/month (over the 6 months). Make up sessions will be offered for those participants who have to miss a group session. Each session lasts 60 minutes and matches the number of visits made by the PAI group as much as possible.
48349008|NCT04708340|DRUG|Rejuveinix (RJX) Active Comparator|Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.
48349009|NCT04708340|DRUG|Placebo Comparator|0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
48349010|NCT06367049|DIAGNOSTIC_TEST|Methylation-specific PCR|"Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly."
48349011|NCT01092949|DEVICE|MRI|MRI, 45 minutes
48659081|NCT06006286|DRUG|ADI-PEG 20|Given by Injection (inj)
48659082|NCT02979990|OTHER|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
48659083|NCT02979990|OTHER|Control Video|The control group will have access to a video about the IVF process
48349012|NCT01381224|OTHER|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
48659084|NCT00141011|DRUG|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
48659085|NCT00141011|DRUG|Placebo|0.6 mL/kg/hr
47984111|NCT05286307|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
47984112|NCT01338493|PROCEDURE|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
47984113|NCT03349112|BEHAVIORAL|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
47984114|NCT03349112|BEHAVIORAL|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
48659086|NCT04344873|OTHER|Placebo|Placebo injection at day one and day fourteen.
48659087|NCT04344873|DRUG|Abatacept 10 mg/kg|Abatacept injection at day twenty eight and day forty two.
48659088|NCT01422382|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
48659089|NCT01422382|DRUG|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
47984115|NCT05125978|DRUG|Canadá|Canadá association 1 tablet twice a day
47984116|NCT05125978|OTHER|Canadá placebo|Placebo of Canadá association 1 tablet twice a day
47984117|NCT05125978|DRUG|Dipyrone|Dipyrone 1 tablet twice a day
47984118|NCT05125978|OTHER|Dipyrone placebo|Placebo of dipyrone 1 tablet twice a day
47984119|NCT05125978|DRUG|Tramadol hydrochloride|Tramadol 1 coated tablet twice a day
48659090|NCT01782274|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
48659091|NCT01782274|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
48659092|NCT05514288|PROCEDURE|Endobariatric procedure|Endoscopic sleeve gastroplasty or transoral outlet reduction
48659093|NCT06637215|PROCEDURE|laparoscopic colorectal day surgery|laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
48659094|NCT06637215|PROCEDURE|traditional laparoscopic colorectal surgery|traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
48659095|NCT03520114|DEVICE|RP sling placement|A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
48659096|NCT03520114|DEVICE|SIS placement|The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally. The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of Sodium Chloride (NaCl). Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
48659097|NCT03141437|OTHER|Best Practice|Receive standard of care
48349013|NCT02663245|OTHER|Intervention 1|"* Diabetes specific consultation~* Basic training in clinical guidelines~* Platform of communication for professionals~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
48502297|NCT04590638|OTHER|tumescent without adrenaline|skin graft donor site of patients enrolled in this group will be injected subcutaneously with tumescent solution not containing adrenaline to see the bleeding control of donor site.
48137883|NCT00916409|DRUG|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
48659098|NCT03141437|OTHER|Educational Intervention|Receive educational materials
48659099|NCT03141437|OTHER|Internet-Based Intervention|Use decision-making website
48659100|NCT03141437|OTHER|Questionnaire Administration|Ancillary studies
48659101|NCT05970367|OTHER|Intensive rehabilitation programme|"Intensive rehabilitation using advanced technology, based on the patient's goals.~Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management."
48659102|NCT03683433|DRUG|Azacitidine|Given SC or IV
48659103|NCT03683433|DRUG|Enasidenib Mesylate|Given PO
48659104|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
48659105|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
48659106|NCT06463366|DEVICE|3D-MRE,MRI-PDFF|3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)
48659107|NCT00302822|DRUG|enfuvirtide|from week 0 to 24
48659108|NCT00302822|DRUG|emtricitabine/tenofovir|1 pill/day
47984120|NCT05125978|OTHER|Tramadol hydrochloride placebo|Placebo of tramadol 1 coated tablet twice a day
48659109|NCT00302822|DRUG|lopinavir or efavirenz|investigator choice
48659110|NCT06564064|DEVICE|abdominal binder|study group will be abdominal binders and control group will be control group , 12 hrs and one week later VAS and QOR 40 will assess patient,s wellbeing
48349014|NCT02663245|OTHER|Intervention 2|"* 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~* Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~* Basic training in clinical guidelines.~* Platform of communication for professionals.~* Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
48349015|NCT03987867|BIOLOGICAL|CIK cell|CIK cell injection
48502298|NCT04504123|DRUG|Doxycycline Hyclate|Doxycycline Hyclate capsules, USP 50 mg
48502299|NCT04504123|DRUG|Placebo|Placebo
48502300|NCT00104143|DRUG|A4I Antagonist|
48502301|NCT00400816|DRUG|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days \[i.e., 7 days on/7 days off\]
48659111|NCT02331303|OTHER|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
48659112|NCT02071589|DRUG|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
48659113|NCT02071589|DRUG|Nifedipine oral solution|6 mL of Nife Par solution
48659114|NCT04701242|DRUG|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
48659115|NCT00283166|BEHAVIORAL|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
48659116|NCT03531580|DEVICE|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
48349016|NCT03987867|BIOLOGICAL|Sintilimab Injection|IBI308 injection
48349017|NCT03987867|DRUG|Pemetrexed|Pemetrexed injection
48502302|NCT02376543|DEVICE|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
48502303|NCT02376543|DEVICE|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
48502304|NCT05490485|DRUG|Camrelizumab|Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
48502305|NCT03718312|PROCEDURE|clamping with pre-conditioning (PCl)|"PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice."
48349018|NCT03987867|DRUG|Liposome paclitaxel|Liposome paclitaxel injection
48349019|NCT03987867|DRUG|Carboplatin|Carboplatin injection
48349020|NCT03600220|OTHER|acupuncture|antihypertension drug, acupuncture twice a week for 3 months
48502306|NCT02098239|DRUG|G17DT|
48502307|NCT05890495|DRUG|Lidocaine topical|4% aqueous solution
48502308|NCT05890495|DEVICE|Tampon|Tampon with plastic applicator provided
48502309|NCT06632522|DRUG|radiotherapy combined with Camrelizumab and Apatinib|Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
48349021|NCT00658866|PROCEDURE|Microdialysis|PK measurements with microdialysis
48349022|NCT05987514|DIAGNOSTIC_TEST|multimodal ultrasound|contrast-enhanced ultrasound and shear wave elastography on liver target lesion
48137884|NCT03306498|DRUG|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
48137885|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48349023|NCT02654041|DRUG|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
48349024|NCT02736474|DRUG|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
48349025|NCT02736474|DRUG|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
48349026|NCT02736474|DRUG|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
48349027|NCT02736474|DRUG|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
48137886|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48349028|NCT00329459|DRUG|sumatriptan succinate/naproxen sodium|
48349029|NCT00329459|DRUG|placebo|placebo to match
48349030|NCT03906591|PROCEDURE|allogenic bone ring|allogenic bone ring with simultaneous dental implant placement
48349031|NCT03906591|PROCEDURE|autogenous bone ring|autogenous bone ring with simultaneous dental implant placement
48349032|NCT00108615|DRUG|Metformin|
48349033|NCT00108615|DRUG|Pioglitazone|
48349034|NCT00108615|DRUG|Metformin|
48349035|NCT00108615|DRUG|Pioglitazone|
48349036|NCT00108615|RADIATION|CT scans|To measure changes in adipose tissue volumes
48137887|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48349037|NCT00108615|PROCEDURE|Oral glucose tolerance test|To detect a change in glucose tolerance
48349038|NCT04246268|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.
48349039|NCT02384928|PROCEDURE|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
48349040|NCT02384928|DEVICE|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
48137888|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48137889|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48137890|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48137891|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
48349041|NCT02384928|DRUG|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
48349042|NCT02384928|PROCEDURE|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
48502310|NCT05865730|OTHER|Live Bacterial Product - Akkermansia muciniphila|Oral administration of Oncobax-AK to patients deficient in Akkermansia by stool metagenomic analysis.
48502311|NCT06407986|DIAGNOSTIC_TEST|pulmonary function test|Whether the estimated value of FEV1 and FVC is greater than 80%.
48502312|NCT03759119|BEHAVIORAL|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
48502313|NCT03759119|BEHAVIORAL|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~* Complete educational session with primary investigator.~* Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
48502314|NCT03090607|DEVICE|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
48502315|NCT03090607|DRUG|Saline|Endoscopic injection of saline
48502316|NCT02109419|OTHER|HHT-G|Helping Hands Technology global cognitive function assessment
48502317|NCT02109419|OTHER|HHT-D|Helping Hands Technology depression assessment
48137892|NCT03973515|DRUG|glucokinase activator|PB-201 is a kind of dual and partial GKA
48137893|NCT03973515|DRUG|Placebo|Placebo oral tablet
48137894|NCT03510052|BEHAVIORAL|Diet Modification Pilot Program (DPM)|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
48137895|NCT03224806|OTHER|Wholegrain bread|156.8g wholegrain bread
48137896|NCT03224806|OTHER|White bread|122.6g white bread
48137897|NCT03224806|OTHER|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
48502318|NCT02109419|OTHER|Geriatric Depression Scale (DGS)|Geriatric Depression Scale (DGS)
48502319|NCT02109419|OTHER|MMSE|Mini Mental State Exam
48137898|NCT03224806|OTHER|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
48502320|NCT05988684|DRUG|Metformin|Patients randomized to metformin group will be instructed to take 500 mg metformin daily for 1 week before titrating up to twice a day
48137899|NCT01487460|DRUG|TAP311|
48137900|NCT02018549|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
48349043|NCT02384928|BEHAVIORAL|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
48502321|NCT01337258|DRUG|Dutasteride|dutasteride 0.5mg daily.
48659117|NCT04803565|DEVICE|Custom-made shoe insole|Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
48659118|NCT04803565|DEVICE|Sham conventional Insole|Subjects will receive a conventional insole without any specific property (sham insole)
48137901|NCT05445349|DEVICE|Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy|The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
48137902|NCT01627314|BIOLOGICAL|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
48349044|NCT04564690|DIETARY_SUPPLEMENT|QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)|Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks
48349045|NCT04564690|DIETARY_SUPPLEMENT|Regular hen eggs|Consumption of three regular hen eggs per day for three weeks
48349046|NCT02385591|BEHAVIORAL|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
48349047|NCT02385591|BEHAVIORAL|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
48502322|NCT01337258|DRUG|Placebo|Men taking placebo daily
48502323|NCT02472327|BEHAVIORAL|Pre-operative support|
48502324|NCT02068235|DRUG|Ponesimod 5mg i.v.|
48502325|NCT02068235|DRUG|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
48502326|NCT02068235|DRUG|Ponesimod 10 mg tablet|
48137903|NCT01627314|BIOLOGICAL|Untreated CB|Cord Blood
48349048|NCT05580185|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
48349049|NCT02614261|DRUG|Galcanezumab|Administered SC
48502327|NCT00837772|DEVICE|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
48502328|NCT00837772|DEVICE|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
48502329|NCT00081536|DRUG|Aroplatin (Liposomal NDDP) in combination with capecitabine|
48502330|NCT02495259|DEVICE|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
48502331|NCT02495259|DEVICE|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
48618227|NCT06403371|OTHER|Normal saline|Normal saline was applied to the teeth surfaces before aligner therapy
48659119|NCT02790736|DRUG|propranolol|active treatment
48659120|NCT02790736|DRUG|Placebo|inactive pill
48349050|NCT02614261|DRUG|Placebo|Administered SC
48349051|NCT05848336|BEHAVIORAL|Gluten Free Casein Free Diet|Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
48349052|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4|
48659121|NCT02956473|DEVICE|Supine MRI|
48659122|NCT02956473|OTHER|Neoadjuvant Therapy (NAT)|
48659123|NCT02956473|DEVICE|Ultrasound|
48659124|NCT02956473|DEVICE|Mammography|
48659125|NCT02956473|PROCEDURE|Standard of Care|
48659126|NCT02956473|DEVICE|Standard MRI|
48659127|NCT05734196|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
48659128|NCT02729415|PROCEDURE|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
48349053|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, before cooking|
48349054|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4, after cooking|
48502332|NCT02495259|DEVICE|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
48502333|NCT02495259|DEVICE|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
48502334|NCT02495259|DEVICE|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
48502335|NCT05707754|DRUG|Bupivacaine|Topically applied to sphenopalatine ganglion
48502336|NCT05707754|DEVICE|angiocatheter|Introduced into nose to reach sphenopalatine ganglion nerve
48618228|NCT02412943|OTHER|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
48659129|NCT02729415|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
48349055|NCT02353325|DIETARY_SUPPLEMENT|non-encapsulated FeSO4 + ascorbic acid|
48349056|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, before cooking|
48349057|NCT02353325|DIETARY_SUPPLEMENT|encapsulated FeSO4 + ascorbic acid, after cooking|
48659130|NCT02729415|OTHER|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
48659131|NCT04416711|BEHAVIORAL|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
48659132|NCT04416711|BEHAVIORAL|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
48659133|NCT04416711|OTHER|Services As Usual|These participants will receive services as usual
48659134|NCT06045078|OTHER|Elequil Lavender-peppermint Aromatabs|100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical
48349058|NCT00349024|DRUG|polyvinylpyrrolidone-sodium hyaluronate gel|
48349059|NCT06141499|BEHAVIORAL|Provider educational materials|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
48349060|NCT06141499|BEHAVIORAL|Patient letters|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process. Letters will describe kidney waitlist status, living donor transplantation, Hepatitis C positive kidney transplants, and high Kidney Donor Profile Index (KDPI) transplants.
48349061|NCT01069094|DRUG|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
48349062|NCT01069094|DRUG|Progenta|25 mg, administered as a once daily oral dose for 90 days.
48349063|NCT01069094|DRUG|Progenta|50 mg, administered as a once daily oral dose for 90 days.
48659135|NCT06045078|OTHER|Elequil Almond-Oil Aromatabs|100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
48349064|NCT01069094|DRUG|Lucron Depot|3.75 mg IM monthly
48349065|NCT01069094|DRUG|Placebo|Administered as a once daily oral dose for 90 days.
48349066|NCT00741767|DRUG|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
48349067|NCT00128362|PROCEDURE|Radio-guided sentinel node biopsy|
48659136|NCT04815174|OTHER|Standard of Care|(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.
48659137|NCT04172220|DRUG|Midazolam|1-2 mg of Midazolam as premedication.
48349068|NCT00128362|PROCEDURE|Axillary sampling|
48349069|NCT03505957|DEVICE|SafeBreak Vascular|SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
48349070|NCT05553652|DIETARY_SUPPLEMENT|ASTARTE™ oral capsules|1 Capsule daily for 6 months
48349071|NCT05553652|DIETARY_SUPPLEMENT|Placebo oral capsules|1 Capsule daily for 6 months
48349072|NCT04450004|BIOLOGICAL|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
48349073|NCT05168423|DRUG|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
48137904|NCT04881305|DIAGNOSTIC_TEST|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
48349074|NCT03272880|BEHAVIORAL|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
48502337|NCT02435095|DRUG|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
48659138|NCT04172220|PROCEDURE|PECS|"Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle."
47984121|NCT00532584|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
47984122|NCT03835494|OTHER|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
47984123|NCT04963933|DEVICE|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
48349075|NCT01149525|DRUG|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
48349076|NCT01149525|DRUG|Placebo|oral solution, twice per day (morning/evening), during 3 months
48502338|NCT02435095|DRUG|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
48502339|NCT06424015|OTHER|Intralipid and heparin|Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
48502340|NCT06424015|OTHER|Saline|Saline will be infused
48502341|NCT03285100|DIAGNOSTIC_TEST|Venipuncture|"* Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~* At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
48659139|NCT04172220|PROCEDURE|Opioid-free general anesthesia|"Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
48659140|NCT04172220|PROCEDURE|General anesthesia|"Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
47984124|NCT00126841|PROCEDURE|CT and MR fusion|
48349077|NCT06353204|BEHAVIORAL|Halt-intervention|The Halt-intervention is a Dutch extrajudicial, or diversion, measure for minors (aged 12-17) who committed a minor offence. The intervention can consist of conversations with the Halt-employee, working or learning assignments to learn from the mistakes made or to work on certain skills, such as social skills, and/or apologizing to the victim.
48659141|NCT04172220|PROCEDURE|Postoperative analgesia|Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS\>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
48659142|NCT06379100|DEVICE|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
48659143|NCT04789941|DRUG|Cis Platinum + Irinotecan|Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
48659144|NCT06236646|OTHER|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
48502342|NCT03835676|DRUG|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~* Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~* CMR will be performed at 6 monthly intervals for 2 years.~* Peak power output at 6,12, 18 and 24 month~* Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
48659145|NCT06236646|OTHER|Control (CON)|The CON group did not have any intervention but usual care.
48659146|NCT05630456|OTHER|Receving feedback|Receving regular feedback from a health provider
48502343|NCT04471025|PROCEDURE|USG guided infraclavicular block|USG guided infraclavicular block was applied to patients either by conventional two-person technique or by one person Jedi technique according to the allocated group. On Group I single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm. On Group II, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic.
48502344|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill|Pomegranate extract pill
48502345|NCT00719030|DIETARY_SUPPLEMENT|Pomegranate pill placebo|Pomegranate pill placebo
48659147|NCT05630456|OTHER|No regular feedback|No regular feedback from a health provider
48659148|NCT02299999|DRUG|AZD2014|Target: m-TOR
48659149|NCT02299999|DRUG|AZD4547|Target: EGFR
48659150|NCT02299999|DRUG|AZD5363|Target: AKT
48659151|NCT02299999|DRUG|AZD8931|Target: HER2, EGFR
48659152|NCT02299999|DRUG|Selumetinib|Target: MEK
48659153|NCT02299999|DRUG|Vandetanib|Target: VEGF, EGFR
48659154|NCT02299999|DRUG|Bicalutamide|target: Androgen receptor
48659155|NCT02299999|DRUG|Olaparib|Target: PARP
48659156|NCT02299999|DRUG|Anthracyclines|DNA intercalation
48659157|NCT02299999|DRUG|Taxanes|Target: mitotic tubulin and microtubules
48659158|NCT02299999|DRUG|cyclophosphamide|Alkylating agents
48659159|NCT02299999|DRUG|DNA intercalators|DNA intercalators
48659160|NCT02299999|DRUG|Methotrexate|DNA intercalators
48659161|NCT02299999|DRUG|vinca alkaloids|Target: mitotic tubulin and microtubules
48659162|NCT02299999|DRUG|Platinum based chemotherapies|Platinum based chemotherapies
48659163|NCT02299999|DRUG|Bevacizumab|Target: VEGF
48659164|NCT02299999|DRUG|Mitomycin C|Alkylating agents
48659165|NCT02299999|DRUG|Eribulin|Microtubule modulator
48659166|NCT02299999|DRUG|MEDI4736|Target: PD-L1
48659167|NCT04414943|DRUG|S-ketamine|For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
48659168|NCT04414943|DRUG|Placebo|For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
48659169|NCT03826472|OTHER|Almond Butter|Natural almond butter
48659170|NCT01230411|OTHER|saline placebo|250 cc of placebo administered IV
48659171|NCT01230411|DRUG|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
48659172|NCT04986150|OTHER|Resistance exercise|Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)
48659173|NCT05728242|DIAGNOSTIC_TEST|Gastric ultrasound|Preoperative gastric antrum examination to detect gastric content (empty, liquid, or solid) and measure gastric volume
48659174|NCT05640557|OTHER|Physical Exercises|An original, noninvasive exercise program
48659175|NCT06545617|DRUG|BAT8006 for Injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
48659176|NCT03340779|DRUG|Norepinephrine|After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
48659177|NCT04528186|DIAGNOSTIC_TEST|Maternal thyroid volume|Maternal thyroid volume measurement
48659178|NCT02311504|DEVICE|OCT examination|
48659179|NCT05848297|DEVICE|Transcranial Doppler ultrasonography (TCD)|Portable, bedside, non-invasive diagnostic tool used for real-time assessment of cerebral hemodynamics
48659180|NCT03709017|DRUG|Ponatinib|Iclusig 45mg, 15mg
47984125|NCT01577329|BEHAVIORAL|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
47984126|NCT06392503|DIAGNOSTIC_TEST|different diagnostic models|the patients were screened by different diagnostic models
47984127|NCT00844051|BIOLOGICAL|School-based influenza vaccination program|School-based influenza vaccination program
48659181|NCT02649309|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
47984128|NCT02550366|DRUG|MRI Contrast|MRI Contrast
48659182|NCT02649309|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
48659183|NCT02649309|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
48659184|NCT02649309|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
48659185|NCT06563167|DIAGNOSTIC_TEST|CXR|CXRs will be performed at 3 different time points - (i) within 1 hour after TTLB, (ii) at 4 hours (± 1 hour) after TTLB and (iii) at 18 hours (± 2 hours) after TTLB.
48659186|NCT06298734|BEHAVIORAL|Exercise Program|A high-intensity interval training, aerobic exercise program virtually supervised, home-based, and appointment-based program under direct one-on-one supervision by a trained oncology exercise specialist. Sessions will be conducted via the Zoom platform. Participants will be provided with home stationary bike, heart rate monitor, blood pressure monitor. For participants who do not have a smart device, a Wi-Fi enabled tablet will be provided.
48659187|NCT06298734|BEHAVIORAL|Diet Program|A virtual dietary consultation program supervised by trained research staff. Appointments will be conducted via the Zoom platform. Participants will receive an education handout at the baseline visit.
48659188|NCT03204812|BIOLOGICAL|Durvalumab|Given IV
48659189|NCT03204812|BIOLOGICAL|Tremelimumab|Given IV
48659190|NCT06176586|OTHER|Mat Pilates Exercises|The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
48659191|NCT06022887|BEHAVIORAL|TRE|daily ad libitum food intake, 8-h 12pm - 8pm, 8 wks active weight loss phase;
48659192|NCT06022887|BEHAVIORAL|MBSR|Completed 30 sessions of a Mindfulness-Based Stress Reduction (MBSR) interventions for 8 weeks
48659193|NCT05755269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48659194|NCT05755269|PROCEDURE|Genotyping|Undergo genotyping
48659195|NCT05755269|OTHER|Survey Administration|Complete surveys
48659196|NCT03519880|DEVICE|Custom Mask Interface|Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
48659197|NCT02881554|PROCEDURE|Computed Tomography|Undergo SC SPECT/CT
48659198|NCT02881554|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
48659199|NCT02881554|DRUG|Technetium Tc-99m Sulfur Colloid|Given IV
48659200|NCT02886962|BIOLOGICAL|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
48659201|NCT02886962|DRUG|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week"
48659202|NCT06051357|DRUG|HRS-5965 tablets|HRS-5965 tablets for 12 weeks
48659203|NCT03303729|DIETARY_SUPPLEMENT|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
48659204|NCT03303729|DIETARY_SUPPLEMENT|Cluster Dextrin|75 grams of Cluster Dextrin
48659205|NCT03303729|DIETARY_SUPPLEMENT|Placebo|75 grams of Glucose
48502346|NCT02955823|DRUG|Rituximab-Dexamethasone-Lenalidomide|"1. st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~2. nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~   * if \<PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~  * if \<PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
48502347|NCT03422939|OTHER|there was no intervention, only separate analyses|We only conducted separate analyses to see if responses differed according to level of experience.
48502348|NCT02113189|OTHER|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
48659206|NCT05705167|DRUG|Plitidepsin|IV infusion over 60-minutes
48659207|NCT06402487|DIETARY_SUPPLEMENT|Propionic acid 1000 mg capsule|Patients will be assigned to propionic acid or placebo as add on MS treatment.
48659208|NCT06402487|DIETARY_SUPPLEMENT|Placebo|Patients will be assigned to propionic acid or placebo as add on MS treatment.
48137905|NCT03082313|BEHAVIORAL|Movement Intervention|At each visit, the caregiver will be reminded of the infant's movement rate from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will be based upon the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
48137906|NCT05351294|OTHER|Questionnaires|"All patients in Arm 2 will be seen and treated by one of three ROs with an interest in participating in this study, who will be trained by the PI to perform these visits reproducibly and with rigor. These will all be regular ROs, who like most ROs administer a mix of curative and PRT in their clinical practice; like most cancer centers, there are no ROs who formally subspecialize in PRT at our institution. Notably, patients in Arm 1 (control arm) will always have standard-of-care RO referral available for consideration of PRT if needed for symptom relief. However, patients in Arm 1 will be seen by other ROs without any specific training for this study. Any courses of PRT administered in either arm are at the discretion of the treating RO in terms of the timing, dose, fractionation, and treatment technique."
48137907|NCT05351294|COMBINATION_PRODUCT|Early Radiation Oncology Involvement Alongside Standard Oncologic Care|Early Radiation Oncology Involvement Alongside Standard Oncologic Care
48502349|NCT02113189|OTHER|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
48502350|NCT02113189|OTHER|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
48659209|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
48659210|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
48659211|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
48659212|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
48659213|NCT05364073|DRUG|Furmonertinib|Furmonertinib tablet
48659214|NCT03722407|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
48659215|NCT06570252|DEVICE|activated Light Source (aPDT)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~Activation of SW4000 Light Source (Class 1 Laser Device) that generates red light consisting of 2 channels of 700 mW, 664 nm light (continuous wave) used to activate the disinfecting formulation.~Duration of illumination 2 minutes"
48659216|NCT06570252|DEVICE|non activated Light Source (Control)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~No activation of SW4000 Light Source~Waiting for 2 minutes"
48659217|NCT06565325|BEHAVIORAL|Exercise + Audible Cues|Combined Terminal Knee Extension Exercise with Audible Cues
48659218|NCT06565325|BEHAVIORAL|Exercise|Terminal Knee Extension Exercise
48659219|NCT02891356|DEVICE|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
48659220|NCT05131256|BEHAVIORAL|Neurofunctional characterization of emotional regulation (fMRI)|Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
48659221|NCT05507047|DRUG|Enamel Matrix Protein|Enamel matrix derivated is used with transcrestal sinus lifting treatment
48349078|NCT00608244|DRUG|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
48349079|NCT00608244|DRUG|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
48349080|NCT01589692|PROCEDURE|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
48349081|NCT01589692|PROCEDURE|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
48349082|NCT01589692|PROCEDURE|Percutaneous Pinning|Pinning with any number of Kirschner wires
48349083|NCT01589692|PROCEDURE|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
48349084|NCT03017833|OTHER|Laboratory Biomarker Analysis|Correlative studies
48502351|NCT00948727|BEHAVIORAL|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
48502352|NCT00948727|DRUG|Cyclosporine (CsA)|Cyclosporine (CsA)
48502353|NCT03957070|DEVICE|Liver Incyte|Ultrasound elasticity imaging
48502354|NCT00927394|DRUG|Aliskiren|Aliskiren 150 mg tablet
48502355|NCT00927394|DRUG|Valsartan|Valsartan 160 mg capsules
48659222|NCT04723719|BEHAVIORAL|SIESTA|SIESTA is a CBT sleep training for adolescents with ADHD with a focus on sleep hygiene, motivational interviewing and planning and organization.
48502356|NCT00927394|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
48502357|NCT00927394|DRUG|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
48502358|NCT01902368|OTHER|gluten free diet|
48502359|NCT00124761|PROCEDURE|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
48659223|NCT04723719|OTHER|Treatment as usual for ADHD|Participants continue their treatment as usual for ADHD.
48659224|NCT01836757|DRUG|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
48659225|NCT01836757|DRUG|Placebo|
48659226|NCT05640427|DRUG|Dexmedetomidine|Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
48502360|NCT00124761|RADIATION|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
48659227|NCT05640427|DRUG|normal saline|The same capacity of 0.9% normal saline was used in group C
48659228|NCT03815344|DRUG|Standard|20 units diluted in 100mL of Normal Saline injected laparoscopic needle
48349085|NCT03017833|DRUG|Metformin|Given PO
48659229|NCT03815344|DRUG|Standard-vaginal misoprostol|20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
48659230|NCT05197842|DRUG|BDB-001 injection|Intravenously administered
48659231|NCT05197842|DRUG|Cyclophosphamide|Intravenously administered
48659232|NCT05197842|DRUG|Glucocorticoids|Orally administered
48349086|NCT03017833|OTHER|Pharmacological Study|Ancillary studies
48349087|NCT03017833|DRUG|Sapanisertib|Given PO
48349088|NCT02240524|PROCEDURE|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
48349089|NCT02240524|PROCEDURE|Systemic chemotherapy|
48349090|NCT02240524|PROCEDURE|HIPEC|
48349091|NCT03976193|BEHAVIORAL|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
48349092|NCT03976193|BEHAVIORAL|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
48659233|NCT00511199|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
48659234|NCT00511199|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
48659235|NCT01356147|DRUG|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
48659236|NCT01356147|DRUG|Placebo|No therapy will be given to placebo arm
48659237|NCT02415114|DIETARY_SUPPLEMENT|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
48659238|NCT05611164|DEVICE|Software assisted selection of individual spermatozoa for intracytoplasmic sperm injection|Half of the oocytes will be injected with a sperm selected with SiD's assistance
48659239|NCT02959463|OTHER|Laboratory Biomarker Analysis|Correlative studies
48659240|NCT02959463|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
48659241|NCT02959463|BIOLOGICAL|Pembrolizumab|Given IV
48659242|NCT02959463|RADIATION|Radiation Therapy|Undergo hemithoracic radiation therapy
48659243|NCT06511349|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
48659244|NCT05175729|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
48659245|NCT06567392|DRUG|[14C] HRS-5965|Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
47984129|NCT01980914|DEVICE|iPro2 glucose sensor attachment|At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
47984130|NCT01575665|DEVICE|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
48349093|NCT04574674|BEHAVIORAL|Flexibility exercise programme|Static passive flexibility exercises.
48502361|NCT06422312|DEVICE|Cystoscopy with RedPine flexible disposable cystoscope|Use of a disposable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents.
48659246|NCT06061757|DEVICE|Imaging guidance with TEE and ICE for Left atrial appendage closure|The occluder size for both LAAC devices will be selected based on the maximal diameter of the LAA orifice following the manufacturer guidelines and using the maximal length of the LAA measured on Echocardiogram. Intraprocedural measurements of the LAA width and depth were acquired on both ICE and TEE per protocol. Both ICE and TEE will be used to assess for any procedural complications prior to insertion of the device delivery sheath.
48659247|NCT06007690|DRUG|Bel-sar|Bel-sar via suprachoroidal administration followed by laser application.
48659248|NCT06007690|DEVICE|Suprachoroidal Microinjector|Suprachoroidal injection device
48659249|NCT06007690|DEVICE|Infrared Laser|Laser application
48659250|NCT06007690|DEVICE|Sham Infrared Laser|Sham laser application
48659251|NCT06007690|DEVICE|Sham Microinjector|Sham injection device
48659252|NCT04319809|DEVICE|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
48659253|NCT01146197|DRUG|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
48659254|NCT05893732|DEVICE|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
48659255|NCT05893732|DEVICE|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
48349094|NCT04574674|BEHAVIORAL|Resistance exercise programme|Body weight and resistance bands exercises.
48349095|NCT05734014|BEHAVIORAL|Healthy Relationship|The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
48349096|NCT01397513|DRUG|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
48349097|NCT01285414|DRUG|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide \& Radiation Therapy
48349098|NCT01285414|DRUG|Temozolomide & Radiation Therapy|Temozolomide \& Radiation Therapy
48349099|NCT05829564|OTHER|virtual reality|The individuals participating in the study will experience virtual reality.
48349100|NCT05829564|OTHER|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
48349101|NCT05829564|OTHER|exercise|The individuals participating in the study will performed neck-specific exercises.
48349102|NCT04358991|DRUG|Ceftazidime-avibactam|collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
48349103|NCT03414268|OTHER|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
48502362|NCT06422312|DEVICE|Cystoscopy with standard of care flexible reusable scope|Use of a reusable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents
48502363|NCT02105558|DRUG|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
48502364|NCT02105558|DRUG|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
48618229|NCT04336683|DEVICE|Interstitial and intracavitary brachytherapy|Standard of care in interstitial or intracavitary brachytherapy is to insert the brachytherapy needle and applicator with no standard real-time image guidance. Interstitial brachytherapy is done under general anesthesia. Trans-abdominal and trans-rectal standard 2D ultrasound is used in some cases, but is typically not consistent and therefore its value is limited. Pre-procedure imaging in the form of MRI is used to help guide needles insertion as well as the clinical exam. Post-procedure CT is done for radiation planning
48349104|NCT03414268|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
48349105|NCT03458234|DEVICE|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
48349106|NCT03885076|PROCEDURE|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
48349107|NCT00384449|DRUG|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
48349108|NCT05399836|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants.
48349109|NCT01548209|DRUG|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
48349110|NCT01548209|DRUG|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
48349111|NCT05233423|DEVICE|compressed cold therapy bandage|Compressed cold therapy bandage was applied by wrapping the operated knee of the patients. The patients in the intervention group received 9 cold applications with 30 mmHg pressure for 20 minutes and 40 minutes of rest.
48349112|NCT00893763|PROCEDURE|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
48349113|NCT00893763|PROCEDURE|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
48349114|NCT05418140|OTHER|Ultrasound diagnosis of adenomyosis|The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).
48349115|NCT00411970|DEVICE|20- and 23 gauge vitreoretinal surgery systems|
48349116|NCT01173822|OTHER|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
48349117|NCT02834494|PROCEDURE|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
48349118|NCT02834494|BIOLOGICAL|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
48349119|NCT00467948|DRUG|cefazolin|
48349120|NCT02443051|BEHAVIORAL|Attention Bias Modification|Computer delivered modification in 80% of trials
48502365|NCT04431726|DRUG|Emicizumab|"Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.~At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.~During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first."
48502366|NCT00794755|DIETARY_SUPPLEMENT|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
48618230|NCT01034553|DRUG|Aurora A kinase inhibitor MLN8237|Given orally
48618231|NCT01034553|DRUG|bortezomib|Given IV
48659256|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
48659257|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
48659258|NCT06592079|PROCEDURE|Immediate implant and connective tissue graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
48349121|NCT00036231|DRUG|RG1068 (Synthetic Human Secretin)|
48349122|NCT06137989|PROCEDURE|Fill-Up Class ӀӀ restoration|Bulk-fill technique
48349123|NCT06137989|PROCEDURE|QuiXfil Class ӀӀ restoration|Bulk-fill technique
48349124|NCT06137989|PROCEDURE|Tetric N-Ceram Bulk Fill Class ӀӀ restoration|Bulk-fill technique
48349125|NCT00357786|DRUG|Replagal agalsidase alfa|
48349126|NCT00357786|DRUG|Replagal|
48349127|NCT02647372|PROCEDURE|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
48349128|NCT02647372|PROCEDURE|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
48349129|NCT02100813|DRUG|LEO 43204|
48349130|NCT02100813|DRUG|Placebo|
48659259|NCT06592079|PROCEDURE|Immediate implant with connective tissue graft and bone graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Xenograft will placed to fill the jumping gap.Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
48659260|NCT05560399|DRUG|Iberdomide|Route of administration: oral pill. Schedule: Taken Once daily on days 1-21. Dose: will be tested at 1 mg, 1.3 mg, and 1.6mg. 1mg dose may be reduced to 0.75mg if not tolerated.
48659261|NCT05560399|DRUG|Elotuzumab|Route of administration: IV Dose: 10 mg/kg for cycles 1 and 2. 20 mg/kg for cycle 3 and beyond. Schedule: Days 1, 8, 15, and 22 for cycles 1 and 2. Then taken on Day 1 (every 28 days) of each cycle thereafter.
48349131|NCT03167827|OTHER|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
48349132|NCT03167827|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
48349133|NCT03167827|OTHER|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
48349134|NCT00911222|OTHER|non-interventional|non-interventional
48659262|NCT05560399|DRUG|Dexamethasone|"Route of administration: Oral pill or IV Dose: 36 mg within 24 hrs of day 1 of each cycle and day 8, 15, and 22 of cycle 1 and 2.~40 mg on days 8, 15, 22 of cycle 3 and all subsequent cycles. (20 mg for \> 75 years old).~Schedule: On days that Elotuzumab is administered, Dexamethasone to be taken 28mg orally (for ≤75 years old) or 8mg orally (for \> 75 years old) between 3 and 24 hours before Elotuzumab plus 8 mg IV between 45 and 90 minutes before Elotuzumab for all patients.~On days that Elotuzumab is not administered but a dose of Dexamethasone is scheduled (Days 8, 15, and 22 of cycle 3 and all subsequent cycles), 40 mg orally for ≤75 years older and 20 mg for"
48659263|NCT06589999|DIAGNOSTIC_TEST|MP2RAGE sequence|Addition of MRI sequence MP2RAGE
48349135|NCT05651074|DRUG|Vicagrel and omeprazole|18 mg vicagrel capsules and 40 mg omeprazole magnesium enteric-coated tablets
48349136|NCT00155467|PROCEDURE|CT|
48349137|NCT00979472|DRUG|Solifenacin|oral
48349138|NCT04007367|DRUG|SAGE-217|SAGE-217 capsule
48349139|NCT04007367|DRUG|Placebo|SAGE-217 matching placebo capsule
48349140|NCT06076239|OTHER|ESWT Group|EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).
48349141|NCT06076239|OTHER|Control Group|Both EG and CG were given conventional treatment.Conventional treatment is consist of Ultrasound therapy (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes (45)) around the glenohumeral joint of the cases in both groups participating in the study; TENS applied at an intensity that the patient can tolerate, covering the painful area (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
48349142|NCT02203942|OTHER|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
48502367|NCT00794755|DIETARY_SUPPLEMENT|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
48659264|NCT05905302|OTHER|Forced and Voluntary Exercise|Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).
48659265|NCT04639791|OTHER|No intervention|Observation only, no intervention
48502368|NCT03127683|OTHER|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
48659266|NCT02102945|PROCEDURE|Computed tomography perfusion|Computed tomography perfusion of the head
48349143|NCT05455255|OTHER|Experimental|FL was applied by Jonathan Bergmann and Aaron Sams in 2007 for high school students who had to be absent from chemistry class. Bergmann and Sams published all the learning activities they used during the lesson as videos. Bergmann and Sams (2012) stated that in this model, which they developed over time, it is not compulsory for the trainer to explain the entire course content in the videos, and the important thing is to allocate time to active learning methods during the course. In the FL model, the summary of the course content is presented to the individuals outside the classroom with tools such as video and power point presentations. In the lesson, activities are carried out for the active participation of the student. The student performs the course content outside of the classroom, and the homework and learning the course in the classroom.
48349144|NCT03441555|DRUG|Venetoclax|tablet, oral
48659267|NCT00925574|DRUG|CNTO 1959; Placebo|
48659268|NCT03796104|OTHER|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
48659269|NCT06634524|DRUG|Dexmeditomidine|Patients who will receive IV infusion of (0.2 µg/kg/hr dexmeditomidine).
48659270|NCT06634524|DRUG|Normal saline|Patients who will receive IV infusion of normal saline, at the same rate of dexmedetomidine infusion.
48137908|NCT04396210|OTHER|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
48137909|NCT06082115|OTHER|Selected Physical and Occupational Therapy Program|"The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands."
48137910|NCT06082115|OTHER|Mirror Therapy|The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
48349145|NCT03441555|DRUG|Alvocidib|Intravenous
48659271|NCT03563001|DRUG|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
48349146|NCT00620737|BIOLOGICAL|Autologous Human Fibroblasts (Isolagen TherapyTM)|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
48349147|NCT00620737|BIOLOGICAL|Placebo|"1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits"
48349148|NCT04312789|DRUG|Avatrombopag|Given PO
48349149|NCT05125991|PROCEDURE|Prepectoral reconstruction|Prepectoral breast reconstruction
48659272|NCT02987738|DRUG|Dapagliflozin|two administrations in the evening and 12 hours later
48659273|NCT02987738|DRUG|Placebo Oral Tablet|two administrations in the evening and 12 hours later
48349150|NCT05125991|PROCEDURE|Submuscolar reconstruction|Submuscolar breast reconstruction
48349151|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
48349152|NCT00613340|PROCEDURE|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
48349153|NCT01147367|BEHAVIORAL|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
48349154|NCT03596255|DIAGNOSTIC_TEST|Estimated level of DA|the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS
48659274|NCT03862950|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
48659275|NCT03862950|DRUG|Metformin|Active medication
48659276|NCT06645327|OTHER|a change in operating room table position, which will mimic an IV fluid bolus|"Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained"
48659277|NCT06216288|OTHER|Repeated back extension exercise (McKenzie)|repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
48659278|NCT06216288|DEVICE|Mechanical traction|The traction was applied using a 3D ActiveTrac table. This motorized split table applied static traction to the lumbar spine with the participant in a prone position. The intensity of the force of traction was 40% to 60% of the participant's body weight applied for 15 minutes. The intervention was done 3 times per week for 6 weeks.
48137911|NCT06082115|OTHER|Task-Oriented Training|The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
47984131|NCT03703765|DEVICE|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
48137912|NCT04363112|BEHAVIORAL|Mini Kid II|Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
48137913|NCT02961634|DEVICE|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
48659279|NCT06517043|BEHAVIORAL|Balance Training|Complex balance task involving static and dynamic weight shifting and coordinated stepping
48659280|NCT06517043|DEVICE|Spinal Active tsDCS|Active tsDCS over lumbar regions
48659281|NCT06517043|DEVICE|Spinal Sham tsDCS|Sham tsDCS over lumbar regions
48659282|NCT02135133|DRUG|Idelalisib|150 mg BID Oral Daily
48659283|NCT02135133|DRUG|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
48659284|NCT06554639|DRUG|MK-5684|Administered via oral tablet per dosing regimen.
48659285|NCT06554639|DRUG|Prednisone|Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.
48659286|NCT06554639|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.
48659287|NCT06554639|DRUG|Diltiazem hydrocholoride|Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
48659288|NCT04199026|DRUG|Doxorubicin|Given via microdevice
48659289|NCT04199026|DRUG|Doxorubicin Hydrochloride|Given via microdevice
48659290|NCT04199026|DEVICE|Drug Delivery Microdevice|Undergo percutaneous implantation of drug delivery microdevice
48659291|NCT04199026|DRUG|Everolimus|Given via microdevice
48659292|NCT04199026|BIOLOGICAL|Ganitumab|Given via microdevice
48349155|NCT03596255|DIAGNOSTIC_TEST|MDAS|The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
48349156|NCT00250029|DRUG|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion \& the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 \& the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
48659293|NCT04199026|DRUG|Ifosfamide|Given via microdevice
48659294|NCT04199026|DRUG|Irinotecan|Given via microdevice
48659295|NCT04199026|DRUG|Pazopanib|Given via microdevice
48659296|NCT04199026|DRUG|Polyethylene Glycol|Given via microdevice
48137914|NCT02961634|DRUG|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
48137915|NCT01292213|PROCEDURE|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
48349157|NCT02136316|DRUG|ASP7962|Oral
48349158|NCT02136316|DRUG|Placebo|Oral
48349159|NCT03144089|DEVICE|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.
48349160|NCT03144089|DEVICE|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
48502369|NCT03127683|OTHER|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
48349161|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
48137916|NCT01292213|PROCEDURE|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
48502370|NCT03127683|OTHER|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
48502371|NCT03127683|OTHER|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
48502372|NCT03127683|DEVICE|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
48659297|NCT04199026|DRUG|Temozolomide|Given via microdevice
48659298|NCT04199026|DRUG|Temsirolimus|Given via microdevice
48659299|NCT04199026|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
48659300|NCT04199026|DRUG|Vincristine|Given via microdevice
48659301|NCT05103332|DRUG|Olmesartan|Olmesartan administered orally
48659302|NCT05103332|DRUG|Amlodipine|Amlodipine administered orally
48659303|NCT05103332|DRUG|Indapamide|Indapamide administered orally
48659304|NCT05103332|DRUG|Placebo|Placebo administered by subcutaneous (SC) injection
48659305|NCT05103332|DRUG|Zilebesiran|Zilebesiran administered by SC injection
48659306|NCT03506360|DRUG|Dexamethasone|Given PO
48659307|NCT03506360|DRUG|Ixazomib Citrate|Given PO
48659308|NCT03506360|OTHER|Laboratory Biomarker Analysis|Correlative studies
48659309|NCT03506360|BIOLOGICAL|Pembrolizumab|Given IV
48659310|NCT04967456|DIAGNOSTIC_TEST|Measurement of pulpal blood flow of traumatised tooth|"Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)"
48659311|NCT06126315|DRUG|Acetyl-l-carnitine|Acetyl-l-carnitine
48659312|NCT06126315|DRUG|Placebo|placebo
48659313|NCT04981392|BEHAVIORAL|Primary care text message outreach to unvaccinated patients and resources to support PCPs|"Patients: Eligible patients will receive a series of text messages from their PCP or primary care clinic recommending a study website as a trusted source of information about the COVID-19 vaccines and information on how and where to schedule a vaccination.~Providers: PCPs will receive resources to support their conversations with patients about the COVID-19 vaccines (factsheets, prescription pads, electronic smartphrase)."
48659314|NCT06205069|DEVICE|Tissue flossing|While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
48659315|NCT00814255|DRUG|Adalimumab|Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
48659316|NCT00814255|DRUG|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
48659317|NCT00814255|DRUG|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
48349162|NCT02401776|DIETARY_SUPPLEMENT|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
48349163|NCT02401776|DIETARY_SUPPLEMENT|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
48659318|NCT01964261|DEVICE|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
48659319|NCT02923167|DEVICE|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
48659320|NCT00005038|BIOLOGICAL|aldesleukin|
48659321|NCT00005038|DRUG|histamine dihydrochloride|
48659322|NCT00003680|DRUG|CMF regimen|
48659323|NCT00003680|DRUG|cyclophosphamide|
48659324|NCT00003680|DRUG|fluorouracil|
48659325|NCT00003680|DRUG|methotrexate|
48137917|NCT01292213|PROCEDURE|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
48349164|NCT02401776|DIETARY_SUPPLEMENT|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
48349165|NCT01250301|OTHER|De-nicotinised cigarettes + standard treatment|"Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline)."
48659326|NCT00003680|DRUG|tamoxifen citrate|
48659327|NCT00003680|DRUG|thiotepa|
48659328|NCT00003680|PROCEDURE|peripheral blood stem cell transplantation|
48659329|NCT00003680|RADIATION|radiation therapy|
48659330|NCT06400082|DRUG|Insulin|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
48659331|NCT06400082|DRUG|Povidone-Iodine|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
48349166|NCT01250301|OTHER|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
48659332|NCT06633393|OTHER|Feedback on Predicted High Myopia Risk at Age 18 Using the Myopia Prediction System|At baseline and six months, participants will be provided with the results of their predicted risk of high myopia at age 18 based on the myopia prediction system.
48659333|NCT06633393|OTHER|Feedback on Ophthalmic Examinations|At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
48137918|NCT01292213|PROCEDURE|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
48349167|NCT01040728|DRUG|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
48349168|NCT01040728|DRUG|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
48349169|NCT01040728|DRUG|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
48659334|NCT01955863|PROCEDURE|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
48137919|NCT01292213|PROCEDURE|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
48137920|NCT01292213|OTHER|Data collection|Questionnaire completion.
48349170|NCT01040728|DRUG|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
48659335|NCT01955863|PROCEDURE|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
48659336|NCT01955863|PROCEDURE|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
48659337|NCT04190472|DIAGNOSTIC_TEST|IOP HPV test|Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
48659338|NCT00541424|PROCEDURE|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
48659339|NCT04205786|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
48659340|NCT04205786|OTHER|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA"
48659341|NCT04205786|OTHER|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
48659342|NCT04205786|OTHER|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
48659343|NCT04205786|OTHER|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
48659344|NCT04205786|OTHER|Demographics Questionnaire|Demographics Questionnaire
48659345|NCT04788693|OTHER|Physical rehabilitation of gait with motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. In this intervention, in addition to physical exercise to correct gait, mental exercises will be included in which the patient visualizes himself performing the exercises that he will then develop with the body.
48659346|NCT04788693|OTHER|Physical rehabilitation of gait without motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. Motor imagery exercises are not included in this program.
48659347|NCT04138355|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
48659348|NCT03312114|DRUG|Avelumab|Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
48659349|NCT02689557|OTHER|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
48659350|NCT05560113|OTHER|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
48349171|NCT01040728|DRUG|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
48349172|NCT03131011|OTHER|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
48659351|NCT05560113|OTHER|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
48659352|NCT02410187|RADIATION|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
48659353|NCT02410187|DRUG|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
48349173|NCT01318421|DRUG|ELND002|
48349174|NCT03140657|DRUG|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
48349175|NCT03140657|DRUG|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
48349176|NCT00789724|DRUG|Anakinra|100 mg daily subcutaneous injection for 14 days
48349177|NCT00789724|DRUG|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
48502373|NCT00616798|DRUG|RO4917838|10mg po daily
48502374|NCT00616798|DRUG|RO4917838|30mg po daily
48502375|NCT00616798|DRUG|RO4917838|60mg po daily
48502376|NCT00616798|DRUG|Placebo|po daily
48502377|NCT00616798|DRUG|Standard antipsychotic therapy|As prescribed
48618232|NCT01583088|DEVICE|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
48659354|NCT02410187|RADIATION|palliative RT|fraction size of RT = \< 3 Gy
48659355|NCT00889330|DRUG|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
48659356|NCT00889330|DRUG|Placebo|Vehicle without active, one drop in each eye at each of two visits.
48659357|NCT00875446|DRUG|PLACEBO|Placebo
48659358|NCT00875446|DRUG|GSK1223249|I.V Infusion
48659359|NCT01728896|OTHER|Patient-controlled oral refeeding|
48659360|NCT05025865|DRUG|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
48659361|NCT05025865|DRUG|Placebo|A placebo will be given in capsule form to study participants.
48659362|NCT06004037|DRUG|Delpazolid|"Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total."
48659363|NCT05105620|DIAGNOSTIC_TEST|Fluorescein Angiography|Fluorescein Angiography for pateints with diabetes using fundus camera (TRC-NW8F retinal camera; Topcon Corporation, Tokyo, Japan).
48659364|NCT05105620|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography for pateints with diabetes using • Topcon DRI OCT Triton device (ver.10.13; Topcon Corporation, Tokyo, Japan).
48659365|NCT03988218|BEHAVIORAL|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
48659366|NCT05727501|OTHER|Post isometric relaxation|post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
48659367|NCT05727501|OTHER|Post facilitation stretching|post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
47984132|NCT05072574|OTHER|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
47984133|NCT04028206|DIETARY_SUPPLEMENT|Hydroxymethylbutyrate|Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
48137921|NCT05157113|DRUG|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
48659368|NCT06642415|PROCEDURE|Surgery under loupes|surgery performed under loupes
48659369|NCT06642415|PROCEDURE|surgery performed under microscope|surgery performed under microscope
48659370|NCT06569979|OTHER|Survey|"The survey was developed using the Google Forms platform. The first part of the questionnaire consisted of descriptive information such as age, gender, duration of academic experience. In addition to this informations, the questionnaire also included information related the status of use ICF in any fields.~In the other part of the questionnaire, a total of 59 questions (16 related to body functions, 3 related to body structures, 30 related to activity and participation, 10 related to environmental factors) were asked to the academicians whether these categories are present in the amputee rehabilitation course content. Academicians were asked to answer yes or no to each question."
48659371|NCT01520441|DRUG|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
48659372|NCT06222684|OTHER|Music therapy|Women applying for mammography screening will receive music therapy for 5 minutes before the procedure, during the mammography scan and for 5 minutes after the procedure.
48659373|NCT04980157|BEHAVIORAL|CARES-HCV|CARES-HCV is an educational intervention to promote both hepatitis c screening and colorectal cancer screening among diverse baby boomers in the area.
48659374|NCT02626884|DRUG|Ibrutinib|
48659375|NCT04943848|BIOLOGICAL|rHSC-DIPGVax|Off-the-shelf, neoantigen heat shock protein vaccine
48659376|NCT04943848|DRUG|Balstilimab|BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
48659377|NCT04943848|DRUG|Zalifrelimab|ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
48659378|NCT04966169|DEVICE|GentleWave System|The GentleWave hydrodynamic cavitation system is a 510k FDA-approved multisonic energy system that is used in complex root canal procedures.
48659379|NCT06511401|OTHER|Pharmacogenomic (PGx) results.|These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
48659380|NCT05508126|DIAGNOSTIC_TEST|DECT examination|DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
47984134|NCT04028206|DEVICE|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
48002537|NCT01067768|OTHER|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter"
48659381|NCT05508126|DIAGNOSTIC_TEST|mpMRI examination|The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
48349178|NCT03966092|PROCEDURE|Quadratus lumborum block|"* Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~* 20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
48349179|NCT00324272|DRUG|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
48502378|NCT05947110|OTHER|Plyometric-based hydro-kinesio therapy|The plyometric-based hydro-kinesio therapy was conducted for 45 minutes, twice weekly, for 8 successive weeks. The training was geared toward the lower body and was conducted under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
48502379|NCT05947110|OTHER|Standard exercise therapy|The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for 8 successive weeks.
48502380|NCT01527812|PROCEDURE|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
48502381|NCT00906386|DRUG|Varenicline|oral, 1 mg twice daily, 12 weeks
48502382|NCT00906386|DRUG|placebo|oral, 1 mg twice daily, 12 weeks
48502383|NCT04499092|BEHAVIORAL|Neuropsychological treatment|Neuropsychological treatment
48502384|NCT04795830|COMBINATION_PRODUCT|Bioceramic root repair material as pulp dressing in pulpotomy in primary molars|BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.
48502385|NCT04795830|COMBINATION_PRODUCT|Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)|MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
48502386|NCT00003224|BIOLOGICAL|QS21|vaccine adjuvant
48502387|NCT00003224|BIOLOGICAL|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
48502388|NCT00003224|BIOLOGICAL|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
48502389|NCT00003224|BIOLOGICAL|p946/tet-p|This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)
48502390|NCT00003224|BIOLOGICAL|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
48502391|NCT02564211|DRUG|Ipragliflozin|one 50 mg tablet QD
48002538|NCT05112666|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.
48002539|NCT05112666|DRUG|other DOACs|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
48002540|NCT05112666|DRUG|LMWH|Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
48502392|NCT02564211|DRUG|Sitagliptin|one 50 mg tablet QD
48502393|NCT05495958|DRUG|Topical Vitamin D eye drop|25 Microgram/cc or 1000 IU
48502394|NCT05495958|DRUG|Topical placebo eye drop|The same-shape packed drop without vitamin D
48502395|NCT02192320|DRUG|Atorvastatin|20 mg (every evening orally) for 5 weeks
48659382|NCT01483560|DRUG|Metformin|3 years treatment duration
48659383|NCT01483560|DRUG|Placebo|3 years duration
48502396|NCT02192320|DRUG|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
48618233|NCT01583088|DEVICE|sham phrenic nerve stimulation|sham phenic nerve stimulation
48618234|NCT05594082|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
48659384|NCT01890031|OTHER|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
48659385|NCT01890031|OTHER|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
48659386|NCT06637098|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
48002541|NCT01072695|DRUG|GS-9256|75 mg BID x 28 days
48002542|NCT01072695|DRUG|GS-9190|40 mg BID x 28 days
48618235|NCT04146883|DRUG|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
48659387|NCT06637098|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48659388|NCT06637098|BEHAVIORAL|Gastrostomy feeding|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
48659389|NCT06355297|BEHAVIORAL|Education about pelvic floor|The three educational sessions will last 60 minutes, as follows: session1, anatomy of pelvic floor; session2, function and dysfunction of pelvic floor; session3, risk factor for pelvic floor dysfunctions.
48659390|NCT00271180|DEVICE|Device|
48349180|NCT04120480|DIAGNOSTIC_TEST|Pharmacogenomic test|The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
48349181|NCT01326390|DEVICE|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
48349182|NCT01326390|PROCEDURE|DSA arteriogram- hepatic arteries|Standard of care
48659391|NCT04110132|PROCEDURE|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
48659392|NCT04110132|PROCEDURE|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
48659393|NCT01190527|RADIATION|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
48659394|NCT06624995|OTHER|chatbot education|elderly patients interacted with Chatbot to discuss general postoperative complication related inquiries
48002543|NCT01072695|DRUG|Ribavirin|1000-1200 mg/day given BID
48659395|NCT06039514|DEVICE|GGTCA-AD mobile app|The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
48659396|NCT06039514|DEVICE|GGNeutra mobile app|"the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen."
48659397|NCT00732888|DRUG|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
48137922|NCT05157113|DRUG|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
48137923|NCT03376659|DRUG|Durvalumab|750mg IV q2 weeks
48137924|NCT03376659|BIOLOGICAL|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
48137925|NCT03376659|DRUG|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
48137926|NCT03376659|DRUG|Bevacizumab|5mg/kg IV q2weeks
48502397|NCT02878941|PROCEDURE|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
48502398|NCT04932057|OTHER|Action observation Training|Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.
48659398|NCT00732888|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
48137927|NCT02589457|DRUG|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
48137928|NCT02589457|DRUG|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
48349183|NCT01326390|PROCEDURE|CO2 aortogram|Standard of care
48349184|NCT05732597|PROCEDURE|Coronary angiography|A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
48349185|NCT04027036|BIOLOGICAL|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
48502399|NCT04932057|OTHER|Action Practice|Participants perform an upper extremity functionality test a couple of times.
48659399|NCT03369223|BIOLOGICAL|BMS-986249|Specified dose on specified days
48659400|NCT03369223|BIOLOGICAL|Nivolumab|Specified dose on specified days
48659401|NCT03369223|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48137929|NCT03876184|OTHER|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
48349186|NCT00927576|BEHAVIORAL|Digit span testing|Testing of short-term verbal memory with digit span
48002544|NCT01072695|DRUG|Peginterferon alfa-2a|180 ug q week
48349187|NCT00927576|BEHAVIORAL|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
48349188|NCT00927576|BEHAVIORAL|Finger tapping|Testing motor speed with a finger tapping test.
48349189|NCT00927576|BEHAVIORAL|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
48659402|NCT03659825|DIETARY_SUPPLEMENT|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
48659403|NCT03659825|DIETARY_SUPPLEMENT|Taste Matched Placebo|Placebo that tastes similar to active intervention
48502400|NCT04932057|OTHER|Observation|Participants will watch a slide show of landscape
48502401|NCT01894035|DRUG|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
48502402|NCT01171118|DRUG|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
48502403|NCT01171118|DRUG|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
48502404|NCT01171118|DRUG|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
48659404|NCT03659825|OTHER|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
48659405|NCT06063876|PROCEDURE|Induction of experimental peri-implant mucositis|Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
48659406|NCT06063876|PROCEDURE|Resolution of experimental peri-implant mucositis|Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
48659407|NCT06028464|DRUG|BI 1810631|BI 1810631
48137930|NCT03876184|OTHER|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
48137931|NCT06470386|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
48137932|NCT06470386|DRUG|Carvedilol|taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.
48137933|NCT04580433|BEHAVIORAL|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
48137934|NCT00678925|DIETARY_SUPPLEMENT|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
48137935|NCT00678925|DIETARY_SUPPLEMENT|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
48349190|NCT00927576|BEHAVIORAL|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
48502405|NCT03322735|DRUG|Fludarabine|25-30mg/m2/day IV for 3 days
48502406|NCT03322735|DRUG|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
48502407|NCT03322735|BIOLOGICAL|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
48502408|NCT00152737|PROCEDURE|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
48502409|NCT00152737|PROCEDURE|Ankle and arm pressure values|one test before and one test after surgery
48502410|NCT02549027|DRUG|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
48502411|NCT02549027|DRUG|MK-6096|Oral MK-6096 tablets (5 mg strength)
48502412|NCT02549027|DRUG|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
48659408|NCT06028464|DRUG|Carbamazepine|Carbamazepine
48349191|NCT00927576|BEHAVIORAL|Verbal fluency|Evaluating how many words are produced in 90s.
48502413|NCT00630929|DRUG|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
48502414|NCT00630929|DRUG|Placebo|Matched placebo orally for 6 weeks
48502415|NCT00630929|DRUG|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
48502416|NCT05958888|BEHAVIORAL|Text only sodium label|"Warning: High in sodium. is shown in a black square label on the can of soup."
48502417|NCT05958888|BEHAVIORAL|Icon sodium label|"Warning: High in sodium. is shown beneath a yellow triangle icon with an exclamation mark all in a black square label on the can of soup."
48502418|NCT05958888|BEHAVIORAL|Pictorial sodium label|"Warning: High in sodium. is shown beneath an image of a spilled salt shaker, all in a black square label on the can of soup."
48659409|NCT02798757|DRUG|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
48659410|NCT06597656|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
48659411|NCT06597656|PROCEDURE|Plasmapheresis|Therapeutic plasma exchange procedure
48659412|NCT04501822|DIAGNOSTIC_TEST|Evaluation of clinical, instrumental and laboratory diagnostics tests|During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
48659413|NCT04527432|OTHER|Survey|Survey at baseline, 6 and 12 months
48659414|NCT04527432|DIAGNOSTIC_TEST|SARS-CoV-2 antibody test|SARS-CoV-2 antibody test results and testing again at 6 and 12 months
48659415|NCT05126303|DRUG|RMC-035|Concentrate for Solution for Infusion
48137936|NCT05811273|OTHER|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
48137937|NCT05811273|OTHER|Control group|general exercises
48137938|NCT05362942|DRUG|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
48659416|NCT05126303|DRUG|Placebo|Concentrate for Solution for Infusion
48659417|NCT05903235|BEHAVIORAL|Virtual Reality-based Mirror Therapy (VR+MT)|In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.
48137939|NCT02680262|BEHAVIORAL|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
48137940|NCT02680262|BEHAVIORAL|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
48137941|NCT02680262|BEHAVIORAL|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
48349192|NCT00927576|BEHAVIORAL|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
48349193|NCT00927576|BEHAVIORAL|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
48349194|NCT00927576|BEHAVIORAL|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
48349195|NCT00927576|BEHAVIORAL|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
48659418|NCT05903235|BEHAVIORAL|Mixed Reality-based Mirror Therapy (MR+MT)|In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.
48659419|NCT05903235|BEHAVIORAL|Traditional Mirror Therapy (MT)|In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.
48349196|NCT02930811|DRUG|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
48349197|NCT02930811|DRUG|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
48502419|NCT05958888|BEHAVIORAL|Barcode label|Barcode is shown in white square label on the can of soup
48502420|NCT05369832|DRUG|Ozanimod|Specified dose on specified days
48502421|NCT04280276|DIAGNOSTIC_TEST|TruGraf test|To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
48502422|NCT03761563|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
48502423|NCT03292159|DEVICE|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
48502424|NCT03292159|DEVICE|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
48502425|NCT06031987|DEVICE|CareSens N (iSENS)|Control group is asked to perform SMBG (4 times or more per day).
48502426|NCT06031987|DEVICE|Freestyle Libre (Abbott)|CGM group is asked to scan CGM (4 times or more per day).
48502427|NCT00229320|BEHAVIORAL|Group therapy|
48502428|NCT03684967|DRUG|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
48137942|NCT04996225|OTHER|Aerobics exercises, Balance exercises|Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
48137943|NCT02027259|BEHAVIORAL|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
48137944|NCT03656198|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
48137945|NCT03656198|DRUG|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
48659420|NCT06312930|DEVICE|Transcranial pulse stimulation|A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency)
48137946|NCT06147466|DEVICE|Dexcom Continuous Glucose Monitoring|A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely
48349198|NCT02264652|DEVICE|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
48349199|NCT05118568|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
48659421|NCT06456346|DRUG|Bomedemstat|Oral capsule
48659422|NCT06456346|DRUG|Hydroxyurea|Oral capsule
48659423|NCT06456346|DRUG|Bomedemstat placebo|Oral capsule placebo
48137947|NCT02340013|DRUG|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
48659424|NCT06456346|DRUG|Hydroxyurea placebo|Oral capsule placebo
48137948|NCT02173288|DRUG|Standard medical therapy|
48137949|NCT02173288|DRUG|Tolvaptan|
48137950|NCT02173288|DRUG|Midodrine|
48137951|NCT04863339|DRUG|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
48137952|NCT04863339|DRUG|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
48137953|NCT02463994|DRUG|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
48137954|NCT02463994|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
48137955|NCT00775866|PROCEDURE|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
48137956|NCT05139784|OTHER|Biosampling|Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
48137957|NCT00649857|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
48137958|NCT00649857|DRUG|Zyrtec® 10 mg|10mg, single dose fed
48137959|NCT04263740|PROCEDURE|Kinesio Taping|Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
48659425|NCT04354857|OTHER|olfactory and gustatory tests|"Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste"
48659426|NCT00938574|DRUG|Atu027|
48659427|NCT01833078|DRUG|ghrelin|ghrelin administration subcutaneously for 7 days
48659428|NCT02048540|BIOLOGICAL|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
48659429|NCT02048540|DRUG|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
48659430|NCT02048540|PROCEDURE|Gastrectomy|
48349200|NCT05090098|OTHER|None intervention|None intervention
48349201|NCT04574869|DRUG|RLS-0071 10 mg/kg|Single dose IV infusion of 10 mg/kg RLS-0071
48349202|NCT04574869|DRUG|RLS-0071 40 mg/kg|Single dose IV infusion of 40 mg/kg RLS-0071
48349203|NCT04574869|DRUG|Placebo|The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
48349204|NCT04574869|DRUG|RLS-0071 10 mg/kg|Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
48349205|NCT04574869|DRUG|RLS-0071 40 mg/kg|Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
48349206|NCT00034892|DRUG|Olanzapine, risperidone|
48349207|NCT04432324|BIOLOGICAL|Intravenous Immune Globulin|IVIG Intravenous infusion
48659431|NCT03277599|DRUG|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
48659432|NCT03277599|DRUG|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
48137960|NCT04263740|PROCEDURE|Traditional Physical therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
48349208|NCT04432324|DRUG|Standard Medical Treatment|SMT
48137961|NCT00692913|DRUG|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
48137962|NCT00692913|DIETARY_SUPPLEMENT|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
48137963|NCT00692913|OTHER|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
48137964|NCT04874259|PROCEDURE|Living donor liver transplantation|Living donor liver transplantation
48137965|NCT04720612|BIOLOGICAL|Omalizumab|Single subcutaneous dose of 375mg of omalizumab and standard of care.
48502429|NCT00886405|DRUG|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
48502430|NCT05104190|OTHER|Stabilization of teeth during debonding using fingure pressure and elastic wafer|To control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. In second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. In order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. With the help of VAS, pain score was measured after debonding. A single operator performed complete procedure of debonding and pain recording.
48502431|NCT01069276|OTHER|No intervention in this study|No intervention in this study
48502432|NCT06260709|DRUG|NNC6019-0001|Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
48659433|NCT03277599|DRUG|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
48349209|NCT05280236|DRUG|Propofol TIVA|Patients will receive propofol-based TIVA with propofol and remifentanil TCI (target controlled infusion)
48349210|NCT05280236|DRUG|Remimazolam TIVA|Patients will receive remimazolam-based TIVA with remimazolam infusion and remifentanil TCI
48659434|NCT05193708|DEVICE|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
48659435|NCT05193708|DEVICE|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
48659436|NCT02295865|DRUG|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
48659437|NCT02295865|DRUG|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
48659438|NCT02295865|DRUG|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
48349211|NCT02147691|DRUG|Azelaic acid 15%|Applied to the face each AM and PM
48349212|NCT02147691|DRUG|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
48502433|NCT00244530|DRUG|Nifedipine|
48502434|NCT04405167|DRUG|Tasquinimod|Tasquinimod will be supplied as oral capsules.
48502435|NCT04405167|DRUG|IRd chemotherapy|IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone
48502436|NCT01830205|DRUG|Daclatasvir|
48502437|NCT05375526|DEVICE|Magtrace|"In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle."
48659439|NCT02295865|DRUG|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
48659440|NCT00734032|DRUG|SB480848 40mg EC Tablet|1 tablet once a day
48659441|NCT00734032|DRUG|SB480848 80mg EC Tablet|1 tablet once a day
48659442|NCT00734032|DRUG|SB480848 160mg EC Tablet|1 tablet once a day
48659443|NCT00734032|DRUG|SB480848 Placebo Tablet|1 tablet once a day
48659444|NCT04023045|DEVICE|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
48659445|NCT04023045|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
48659446|NCT04139291|OTHER|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
48137966|NCT04720612|OTHER|Placebo|Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.
48502438|NCT05623072|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
48659447|NCT03132987|OTHER|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
48659448|NCT02015130|OTHER|Individual treatment|See detailed description
48659449|NCT06500585|OTHER|Mill's Manipulation|"Mill's Manipulation: The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5 min.~Stretching of Wrist Extensors: 15 sec hold, 10 stretches/session/day. Wrist extensors Isometric: resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
48659450|NCT06500585|OTHER|Mill's Manipulation and Muscle Energy Technique|"Mill's Manipulation:The therapist should apply a high-velocity low-amplitude thrust accompanied by a single application . Patients will be treated 3 times a week for 2 consecutive weeks.~Muscle Energy Technique: Extensor carpi radialis stretch for 30 sec repeated 5 times during a single treatment session. Patients will be treated 3 times a week for 2 consecutive weeks.~Conventional Therapy:~Ultrasound therapy: Frequency: 1Mhz Pulse ultrasound: 1:4 Intensity: 1.5 W/cm2 Duration: 5min.~Stretching of Wrist Extensors, 15 sec hold, 10 stretches/session/day. Wrist Extensors Isometric, resistance 5 to 10 seconds, 15 contractions/ session/day.~Patients will be treated 3 times a week for 2 consecutive weeks."
48659451|NCT05704647|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV (vein)
48137967|NCT00747006|DRUG|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
48137968|NCT00747006|DRUG|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
48349213|NCT02324712|DEVICE|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
48349214|NCT02324712|DEVICE|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
48502439|NCT05623072|DEVICE|Sham tDCS|20 min, vmPFC Sham tDCS
48502440|NCT03667209|OTHER|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
48659452|NCT05704647|DRUG|Nivolumab|Given by IV (vein)
48659453|NCT05704647|DRUG|Relatlimab|Given by IV (vein)
48659454|NCT05983133|DRUG|SGN-EGFRd2|Given into the vein (IV; intravenously)
48659455|NCT03190954|DRUG|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
48659456|NCT03190954|DRUG|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
48137969|NCT01861015|DRUG|Epinephrine|
48137970|NCT01861015|DRUG|Vasopressin|
48349215|NCT02111707|DRUG|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
48349216|NCT05580237|PROCEDURE|Simultaneous right and left heart catheterization|Pressure recordings across the aortic valve with simultaneous flow measurements by right heart catheterization, during rest and during supine exercise.
48618236|NCT01258049|DRUG|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
48618237|NCT01258049|DRUG|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
48137971|NCT03085407|PROCEDURE|early cholecystectomy|cholecystectomy was done within 48 after admission
48137972|NCT03085407|PROCEDURE|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
48137973|NCT05898126|PROCEDURE|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
48618238|NCT00265434|DRUG|Pulmozyme|
48618239|NCT03726476|BEHAVIORAL|Patient centered pre-op education|To implement a patient centered education intervention to evaluate post-op narcotic use.
48502441|NCT03667209|OTHER|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
48349217|NCT02828995|OTHER|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~1. The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~2. The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~3. Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
48349218|NCT05982444|PROCEDURE|water vapor thermal therapy (Rezum) for prostate|all patients underwent rezum therapy for bph are evaluated for its effectiveness for long period
48349219|NCT04709094|DRUG|Danicopan|Danicopan was dosed as 2 x 100 milligram (mg) tablets.
48349220|NCT04709094|DRUG|Warfarin|Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).
48349221|NCT04709094|DRUG|Bupropion|Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.
48349222|NCT04709094|DRUG|Ethinyl Estradiol/Norethindrone|EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
48349223|NCT02081911|PROCEDURE|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
48349224|NCT02081911|PROCEDURE|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
48349225|NCT02081911|PROCEDURE|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
48349226|NCT02257112|DEVICE|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
48349227|NCT01902836|BIOLOGICAL|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
48349228|NCT01902836|BIOLOGICAL|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
48349229|NCT06435494|OTHER|Systematic use of patient reported outcome measures in clinical work with the patients|Se description of the arms
48502442|NCT05851625|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
48502443|NCT05851625|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
48502444|NCT00077857|DRUG|capecitabine (Xeloda®)|825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
48502445|NCT00077857|DRUG|docetaxel (Taxotere®)|75 mg/m\^2 intravenous on day 1 of each 3 week cycle
48502446|NCT03214796|DRUG|Human albumin|Infusion of human albumin
48502447|NCT05179538|BEHAVIORAL|Cued picture-naming therapy|The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
48659457|NCT03190954|DRUG|[11C]NNC-112|\[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
48659458|NCT01392157|DEVICE|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
48659459|NCT01392157|DEVICE|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
47984135|NCT04028206|BEHAVIORAL|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
48137974|NCT05898126|PROCEDURE|Usual care|Standard of care
48349230|NCT00649610|DRUG|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
48349231|NCT00649610|DRUG|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
48349232|NCT04946760|OTHER|Sham Manipulation|The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
48349233|NCT03021590|DRUG|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
48659460|NCT01392157|DEVICE|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
48659461|NCT01392157|DEVICE|LNG-IUS|100 women will receive an LNG-IUS
48349234|NCT03021590|DRUG|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
48659462|NCT04632862|DRUG|DWP16001|DWP16001 A mg
48659463|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
48659464|NCT00280488|BEHAVIORAL|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
48349235|NCT05838820|DIAGNOSTIC_TEST|Nine-Hole Peg Test|The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.
48502448|NCT00483483|BEHAVIORAL|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
48502449|NCT00483483|BEHAVIORAL|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
48659465|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
48659466|NCT04054180|OTHER|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
48502450|NCT01178216|BIOLOGICAL|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
48502451|NCT02075177|DRUG|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
48502452|NCT02075177|DRUG|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
48502453|NCT00721630|DRUG|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
48502454|NCT05272748|OTHER|Conventional Exercise + Core Stabilization Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.
48618240|NCT03726476|BEHAVIORAL|routine preop education|To implement routine patient education intervention to evaluate post-op narcotic use.
48659467|NCT01847014|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
48659468|NCT04692506|OTHER|Probiotic|The study product is probiotic
48659469|NCT03208790|DRUG|Nigella sativa buccal tablets 10mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
48659470|NCT03208790|DRUG|Nigella sativa buccal tablets 5mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
48349236|NCT05838820|DIAGNOSTIC_TEST|Jebsen-Taylor Hand Function Test|is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
48659471|NCT03208790|DRUG|Placebo buccal tablets|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
48659472|NCT05548114|PROCEDURE|EUS-guided gastrojejunostomy|AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
48659473|NCT05548114|PROCEDURE|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic (preferred) or open technique, as clinically appropriate.
48659474|NCT05337189|DIAGNOSTIC_TEST|Urine DNA methylation analysis|Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
48659475|NCT05337189|PROCEDURE|medical imaging and/or cystoscopy and/or pathological examination|Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
48349237|NCT05537506|DEVICE|Bracket slot 0.018|That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
48349238|NCT05537506|DEVICE|Bracket slot 0.022|Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
48659476|NCT06610903|DRUG|Hemay005|In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over
47984136|NCT06398535|DEVICE|magenetic resonance and ultrasound|examination of patient using magentic resonace coil for imaging of knee and comapring the results obtaines by ultrasound examination using the ulatrsound tarsnsducer .
47984137|NCT00002067|DRUG|Megestrol acetate|
48137975|NCT05302882|BEHAVIORAL|Myofascial release|The physiotherapist placed both palms on the two right and left ribs at the T12 level and applied continuous stretching to the superior for 2 minutes. After this application, the physiotherapist placed one hand on the sacrum with the other hand on T12 with his hands crossed, and applied rhythmically 2 seconds of stretching and 2 seconds of relaxation for a total of 2 minutes. Then, myofascial release was terminated by applying deep compression to the paraspinal muscles with palms for 2 minutes on the right and 2 minutes on the left side, respectively.
48137976|NCT05302882|BEHAVIORAL|Classical massage|Classical massage was applied to the lumbar region for 9 minutes. Classical massage was applied with the patient in the prone position. A small amount of solid vaseline was taken and a gentle stroke was applied for 1 minute to spread it sufficiently to the lumbar region. Then, superficial stroking was applied to the right paraspinal region for 1 minute from distal to proximal by the physiotherapist. After the same procedure was performed on the right paraspinal region for 1 minute. Then, both hands were placed on the right and left paraspinal region and friction was applied for 2 minutes. Afterwards, the patient's right paraspinal region was kneeding for 1 minute and then the same procedure was applied to the left paraspinal region for 1 minute. As the last procedure, the fingertips of both hands were placed on the right and left paraspinal region and the classical massage was completed by performing 2 minutes of deep euphlorage from the L5-S1 level to the T12 level.
48137977|NCT06430021|BIOLOGICAL|blood sample|8 mL blood sample in EDTA tube
48137978|NCT03653364|DRUG|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
48137979|NCT06195813|DIETARY_SUPPLEMENT|Asparagus capsule|Asparagus capsule is categorized as dietary supplement.
48137980|NCT06195813|OTHER|Placebo capsule|Placebo capsule is categorized as other.
48137981|NCT04694066|BEHAVIORAL|Qigong|Qigong Baduanjin, comprising eight standardized movements, will be adopted in the study. It is practiced as a combination of body movements, breath control, and mindful meditation.
48137982|NCT04694066|BEHAVIORAL|Light flexibility exercise|The supervised sessions will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
48349239|NCT00877734|DRUG|baclofen|10 mg Baclofen administered tid for 11 weeks
48349240|NCT00877734|DRUG|placebo|Placebo administered tid for 11 weeks
48349241|NCT00877734|BEHAVIORAL|BRENDA counseling|
48349242|NCT06113172|OTHER|Hip flexion|during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
48349243|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
48349244|NCT01159457|BIOLOGICAL|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
48659477|NCT06137248|DIETARY_SUPPLEMENT|Energy drink|Participants on this arm will consume an energy drink once daily in addition to their normal diet for 4 weeks.
48659478|NCT05861843|DIAGNOSTIC_TEST|Virtual Reality-based cue exposure paradigm|Virtual Reality (VR) cue exposure to alcohol-associated cues using head-mounted displays (HMD)
48659479|NCT05731245|DRUG|Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
47984138|NCT00726804|DRUG|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
48349245|NCT06059833|DIAGNOSTIC_TEST|Magnesium|The aim of the study is to evaluate serum Mg level in type 2 DM patients.
48349246|NCT01770119|BIOLOGICAL|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
48349247|NCT01709604|PROCEDURE|CVVH|Ultrafiltration at 35ml/h/Kg
48618241|NCT03641365|DEVICE|Test group|Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
48618242|NCT03641365|DEVICE|Control group|Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
48659480|NCT05301127|DEVICE|spinal-epidural device|received combined spinal-epidural-general anesthesia.
48659481|NCT06196905|DRUG|MT-2990|i.v. infusion
47984139|NCT03394807|DRUG|Levobupivacaine|Levobupivacaine injection to Transversus abdominis plane and rectus sheath
47984140|NCT03394807|DRUG|Placebo|Saline injection to Transversus abdominis plane and rectus sheath
47984141|NCT01320462|DRUG|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
47984142|NCT01320462|OTHER|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
47984143|NCT02697175|DEVICE|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
47984144|NCT02697175|OTHER|No Live Video-Colposcopy|The TV will be shut off during colposcopy
47984145|NCT05294445|PROCEDURE|Ablation of atrial fibrillation (AF)|Cryo-AF-ablation of pulmonary vein (pulmonary vein isolation = PVI)
47984146|NCT03259854|DEVICE|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
48349248|NCT01709604|PROCEDURE|Standardized therapy regimens|"Standardized therapy regimens included the followings:~1. Remove all contaminated clothing~2. Gastric lavage~3. Receive activated charcoal as quickly as possible~4. Hemoperfusion with activated charcoal(160g)~5. Immunosuppression with methylprednisolone~6. Antioxidants (glutathione,1.2 gram iv twice a day)~7. Supportive care"
48659482|NCT05326295|DIAGNOSTIC_TEST|CTC detection|CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
48349249|NCT05977803|RADIATION|MRI with CEST sequence, IVIM and ASL sequence|"Three sequences will be added as part of the protocol (for an additional duration of about 10 minutes) :~* The CEST sequence~* The ASL infusion sequence~* The IVIM sequence"
48349250|NCT03696628|OTHER|Electrocardiogram|heart testing
48349251|NCT03696628|OTHER|physical examination|done by the investigator
48349252|NCT03696628|OTHER|echocardiography|heart testing
48502455|NCT05272748|OTHER|Conventional Exercise|Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
48502456|NCT04040608|OTHER|Influence of screen sizes on responses to visual analog scales of stress|"An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes)."
47984147|NCT03259854|DEVICE|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
47984148|NCT06066645|DRUG|Travoprost Intraocular Implant|anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite
47984149|NCT06066645|OTHER|Sham procedure|Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite
47984150|NCT06066645|DEVICE|iStent infinite|Successful iStent infinite surgery
47984151|NCT05350150|DEVICE|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
47984152|NCT04436185|BEHAVIORAL|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
47984153|NCT00998660|DEVICE|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
47984154|NCT05980650|OTHER|Reiki implication|Reiki will be implicate by researcher by putting hands on patient
47984155|NCT05967611|DIAGNOSTIC_TEST|Trendelenburg hip abduction test|The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
48349253|NCT03696628|BIOLOGICAL|blood test|A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
48349254|NCT03745989|DRUG|MK-8353|Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.
48349255|NCT03745989|DRUG|Selumetinib|Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.
48502457|NCT02149290|DEVICE|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
48502458|NCT05325073|DRUG|Erythropoietin|Erythropoietin
48502459|NCT00995280|DEVICE|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
48502460|NCT00995280|DEVICE|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
48502461|NCT00599963|DRUG|paricalcitol|paricalcitol 1 mg/day
48502462|NCT00936897|DRUG|Ibandronate|Ibandronate 150mg PO QM (tablet)
48502463|NCT00936897|DRUG|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
48659483|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
48659484|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Full-electric stimulation fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
47984156|NCT05406258|DEVICE|Modified Self-Catheterization Mirror|Following training, participants will have a modified mirror available for self-catheterization, as well as a standard, hospital-provided mirror. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
48137983|NCT03132298|OTHER|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
48659485|NCT05360784|DRUG|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
48137984|NCT03132298|OTHER|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
48137985|NCT00779194|DRUG|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
48137986|NCT03057600|DRUG|Paclitaxel|standard weekly paclitaxel in 28-day cycles
48137987|NCT03057600|DRUG|CB-839|CB-839 administered as oral tablets twice daily (BID)
48137988|NCT01513616|OTHER|Pulmonary rehabilitation|8-week program, 3 supervised session per week
48659486|NCT05360784|DRUG|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)|Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
48659487|NCT05789290|DEVICE|Hilotherm cryocompression device|An electronic device that is capable of circulating warm or cooled water at a user-selected temperature between 10-30℃. Water is circulated from a central unit, through a tube, to a cuff wrapped around the intended therapy area (the knee). A treatment lasts for 30-minutes, at which point the device is turned off and the cuff is removed from the limb of the user.
48137989|NCT01513616|OTHER|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
48137990|NCT06459284|OTHER|retrospective data analysis|Surgical video-documentation including continous iOCT will ne reviewed for Instrument tissue interactions at the grasp site of the starting point of Membrane peeling
48137991|NCT03737487|PROCEDURE|Multidisciplinary fall risk and geriatric comprehensive assessment|"* Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~* Calculation of BMI~* A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~* A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~* A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~* A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~* A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
48137992|NCT03955926|DIETARY_SUPPLEMENT|preoperative oral carbohydrate loading|Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
48137993|NCT01543893|BEHAVIORAL|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
48137994|NCT01543893|BEHAVIORAL|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
48137995|NCT03488043|PROCEDURE|Needle lung biopsy|Needle lung biopsy
48502464|NCT03358186|PROCEDURE|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
48502465|NCT00700297|DRUG|Colchicine|100 mg Colchicine per day for 4 months
48502466|NCT00700297|DRUG|Placebo|One tablet placebo per day for 4 months
48502467|NCT03555331|BEHAVIORAL|Child Safety Control Intervention|In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
48659488|NCT05322005|PROCEDURE|partial meniscectomy|Arthroscopic procedure
48659489|NCT05322005|DEVICE|Condrotide® (polynucleotides gel: class III medical device)|Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
48659490|NCT01282398|DRUG|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
48659491|NCT01282398|DRUG|placebo|the control group wiil take placebo pills for at least two years.
48659492|NCT05591365|OTHER|Structured In-Patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
48659493|NCT05591365|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
48659494|NCT00003053|DRUG|cisplatin|
48659495|NCT00003053|DRUG|etoposide|
48659496|NCT00003053|PROCEDURE|adjuvant therapy|
48137996|NCT03496558|OTHER|Variability of the lipid profile in pregnant women|"The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed."
48659497|NCT05745844|OTHER|activity sessions|77 activity sessions ; muscle strengthening, testing or unloading
48659498|NCT04452916|OTHER|Buchinger fasting|Caloric intake of \< 250 kcal/d for 5 days
48659499|NCT05720104|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
48659500|NCT05720104|OTHER|Standard oral hygiene instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
48137997|NCT03871439|DRUG|PF-05221304 Formulation A|50mg
48137998|NCT03871439|DRUG|PF-05221304 Formulation B|50mg
48137999|NCT01360918|DEVICE|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
48138000|NCT01360918|OTHER|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
48138001|NCT02966652|DRUG|DITEST|Lipid formulation of native oral testosterone.
48138002|NCT02966652|DRUG|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
48138003|NCT02025504|DEVICE|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
48138004|NCT00086359|DRUG|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
48138005|NCT00086359|DRUG|Lamivudine/zidovudine|one pill twice daily
48502468|NCT03555331|BEHAVIORAL|Responsive Parenting Intervention|During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
48138006|NCT00086359|DRUG|Lopinavir/ritonavir|four pills twice daily
48659501|NCT05414045|PROCEDURE|Autologous testicular tissue transplantation of prepubertal frozen testicular tissue|"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells (SSCs).~If patient has a childwish on adult age and in case no spermatozoa are found in the ejaculate or after performing a testicular biopsy (TESE), we will perform autologous testicular tissue transplantation with the primary objective being to restore spermatogenesis and fertility."
48659502|NCT06443814|BEHAVIORAL|Health Education|This was a didactic classroom-based control which educates the patient on adapting a healthier lifestyle through proper diet, exercise, and moderating substance usage according to current AHA guidelines. This intervention does not include a stress management component.
48659503|NCT06443814|BEHAVIORAL|Transcendental Meditation|TM was taught in a standardized and validated format as a simple, natural mental technique practiced for 20 minutes twice a day (morning and evening) to give rest and relaxation to mind and body. TM was taught by a certified instructor and a 7-step process taking place over 4 consecutive days after which the meditator can practice at home twice a day.
48659504|NCT01577407|DRUG|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
48659505|NCT03519945|DRUG|Mirikizumab|Administered SC.
48659506|NCT05044481|PROCEDURE|third molar surgical removal|ambulatory surgical intervention of the maxilla and / or mandible for third molar removal
48659507|NCT03181984|DRUG|Hemoporfin|Hemoporfin mediated photodynamic therapy
48659508|NCT06609096|BEHAVIORAL|Sexual counseling based on the PLISSIT model|Four sessions of sexual counseling based on the PLISSIT model will be provided. The intervention consisted of four consecutive sessions, with one session per week. Each session is 30 minutes on average.
48659509|NCT06609096|BEHAVIORAL|Sexual counseling based on the BETTER model|A total of four sessions of sexual counseling based on the BETTER model will be provided. The intervention consists of four consecutive sessions, one session per week. Each session is 30 minutes on average.
48138007|NCT04929600|DRUG|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
48138008|NCT04929600|DRUG|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
48138009|NCT01307800|DRUG|LY2140023|Administered orally
48138010|NCT01307800|DRUG|Placebo|Administered orally
48138011|NCT00065000|BEHAVIORAL|Water, Cafeteria and Staff Health Promotion|
48138012|NCT02718196|BEHAVIORAL|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
48138013|NCT03865004|DRUG|Paracetamol+Morphine|1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
48138014|NCT03865004|DRUG|Dexketoprofen plus Morphine|Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
48138015|NCT03865004|DRUG|Placebo plus Morphine|100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
48138016|NCT03905278|BEHAVIORAL|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
48138017|NCT00006350|BIOLOGICAL|daclizumab|
48138018|NCT00006350|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48138019|NCT00006350|DRUG|mycophenolate mofetil|
48138020|NCT00006350|DRUG|tacrolimus|
48138021|NCT00006350|PROCEDURE|peripheral blood stem cell transplantation|
48138022|NCT04760678|OTHER|Observational study|No intervention (observational study in human participants)
48138023|NCT03397459|DIAGNOSTIC_TEST|Spine teleradiography EOS|
48138024|NCT00808834|DEVICE|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
48138025|NCT00808834|DEVICE|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
48502469|NCT03049605|DEVICE|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
48502470|NCT03049605|DEVICE|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
48138026|NCT05389618|OTHER|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
48138027|NCT03127605|DRUG|Inotuzumab Ozogamicin|
48138028|NCT01824225|DRUG|Aflibercept|
48138029|NCT01354782|DRUG|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
48138030|NCT05040152|BEHAVIORAL|Dietary Counseling and Surveillance|Receive dietary recommendations
48138031|NCT05040152|OTHER|Exercise Intervention|Complete home exercises
48138032|NCT05040152|OTHER|Informational Intervention|Receive education brochures
48502471|NCT03049605|DRUG|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
48502472|NCT03703869|DRUG|Insulin glargine (U300)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
48659510|NCT01458457|OTHER|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
48659511|NCT01458457|OTHER|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
48138033|NCT05040152|OTHER|Questionnaire Administration|Ancillary studies
48138034|NCT05040152|BEHAVIORAL|Telephone-Based Intervention|Receive telephone-based weight loss intervention
48138035|NCT02070809|PROCEDURE|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
48138036|NCT02070809|PROCEDURE|split-thickness skin graft method|This method is traditional split-thickness skin graft
48138037|NCT01113736|BIOLOGICAL|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
48138038|NCT03272412|DIAGNOSTIC_TEST|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
48138039|NCT01351376|DEVICE|Low Level Laser Therapy|Placebo LLL combined with CDT
48138040|NCT01351376|DEVICE|Low Level Laser|Active LLL combined with CDT
48138041|NCT00054938|DRUG|pravastatin|
48138042|NCT00054938|DRUG|aspirin|
48138043|NCT00054938|DRUG|ramipril|
48138044|NCT00054938|DRUG|Vitamins: B6, B12, and folate|
48138045|NCT00054938|BEHAVIORAL|heart health educational program|
48502473|NCT02509299|OTHER|Physiotherapy program 1|The standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises.
48138046|NCT02043041|OTHER|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
48502474|NCT02509299|OTHER|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally, they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included neuromuscular stimulation therapy on quadriceps accompanied by lower limbs exercises
47984157|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
48502475|NCT02509299|DRUG|Standard medical treatment|"The standard medical treatment consists on:~* Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~* Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
48502476|NCT02076373|DRUG|recombinant human Erythropoietin|i.v. administration
48502477|NCT02076373|DRUG|Placebo|i.v. administration
48659512|NCT06614582|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|"The ssNPA device is a flexible, medical-grade silicone, nasal tube that is self-inserted into the airway through one nostril and worn during the night. It can also be used during the day. The device works by supporting collapsed airway muscles and keeping the airway open.~In addition to wearing the device, study team members will call monthly and collect certain data, and medical information and participants will be asked to have a sleep study at the 12-month visit."
47984158|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
47984159|NCT06503419|OTHER|non-intervention|non-intervention
47984160|NCT03857243|DEVICE|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
47984161|NCT03444519|DRUG|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
47984162|NCT01059786|DRUG|Pentostatin|28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
48138047|NCT04758949|DRUG|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
48138048|NCT04758949|DRUG|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
48659513|NCT01161966|DRUG|Zonisamide|Zonisamide capsules 100 mg
48138049|NCT04758949|DRUG|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
48138050|NCT01959958|OTHER|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
48138051|NCT03779672|DRUG|Memantine Hydrochloride 10 mg|"* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps"
48138052|NCT00746759|DEVICE|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
48502478|NCT05410782|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
48659514|NCT01161966|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
48659515|NCT01978301|DRUG|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
48659516|NCT01978301|DRUG|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
48659517|NCT00809588|BIOLOGICAL|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
48138053|NCT02446106|DIETARY_SUPPLEMENT|Soup with MSG|0.5% MSG + 0.48% salt
48138054|NCT02446106|DIETARY_SUPPLEMENT|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
47984163|NCT01059786|DRUG|Rituximab|Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
47984164|NCT01059786|DRUG|Bendamustine|1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
47984165|NCT01059786|DRUG|Acetaminophen|Treatment of infusion-related symptoms with acetaminophen is recommended.
47984166|NCT01059786|DRUG|Diphenhydramine|Treatment of infusion-related symptoms with diphenhydramine is recommended.
48138055|NCT04069455|OTHER|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
48659518|NCT06247683|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
48659519|NCT03452345|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
48659520|NCT03452345|DRUG|Placebo|Placebo (Normal saline)
48659521|NCT04116489|OTHER|Forest walk|Participants will be provided with an educational program about the forest and take a guided forest walk.
48659522|NCT04116489|OTHER|Wildlife rehabilitation|Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
47984167|NCT01059786|DRUG|Epinephrine|Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
47984168|NCT01059786|DRUG|Antihistamines|Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
47984169|NCT01059786|DRUG|Corticosteroids|Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
48138056|NCT02715518|DEVICE|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~1. FFR-guided strategy arm~2. Angiography-guided strategy arm"
48502479|NCT06455098|DEVICE|OMNYPULSE™ Catheter with the TRUPULSE Generator|OMNYPULSE™ Catheter and TRUPULSE™ Generator will be used for PF ablation.
48502480|NCT03995186|BEHAVIORAL|Behavioural activation|4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.
48659523|NCT04116489|OTHER|Wildlife sanctuary observation|Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
48659524|NCT04116489|OTHER|Bird feeding and watching|Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
48659525|NCT05914129|OTHER|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
48659526|NCT05914129|OTHER|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
48659527|NCT05914129|OTHER|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
48659528|NCT03403179|OTHER|Functional Remediation|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
48659529|NCT02170519|DRUG|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
48659530|NCT00525863|DRUG|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to \~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
48659531|NCT03970031|DRUG|MSDC-0602K|MSDC-0602K tablet
48659532|NCT03970031|DRUG|Placebo|Matching tablet
48659533|NCT00835354|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
48659534|NCT00835354|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
48659535|NCT02758730|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
48659536|NCT02758730|BIOLOGICAL|Adjuvant without active component|s.c. injection
48659537|NCT00839930|DRUG|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
48659538|NCT00839930|DRUG|Pletal®|1 x 50 mg, single-dose tablet
48659539|NCT00381641|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48659540|NCT00381641|OTHER|Pharmacogenomic Study|Optional correlative studies
48659541|NCT00381641|DRUG|Sunitinib|Given PO
48502481|NCT03995186|BEHAVIORAL|Activity monitoring|4-week programme where participants simply monitor their general daily activities in a diary.
48502482|NCT05502081|DRUG|Casirivimab and Imdevimab Drug Combination|antiviral Monoclonal Antibodies
48502483|NCT05502081|DRUG|Remdesivir|antiviral drug
48502484|NCT05502081|DRUG|Favipiravir|antiviral drug
48502485|NCT04675619|DRUG|Oral pirfenidone|Treatment
48502486|NCT04675619|DRUG|Standard care|Treatment
48659542|NCT00381641|DRUG|Sunitinib Malate|Given PO
48659543|NCT02871440|DRUG|Omega 3|
48659544|NCT02871440|DRUG|Optive Advanced|
48659545|NCT02871440|DRUG|Optive|
48659546|NCT06643104|PROCEDURE|Tuina|X-ray mapping guides three days of tailored exercises, including 3D therapy, breathing techniques, and spinal manipulation.
47984170|NCT01059786|DRUG|Bronchodilators|Additional treatment with bronchodilators may be indicated.
48502487|NCT05493137|OTHER|No intervention will be provided|No intervention will be provided, this is an observational study
48502488|NCT02653430|PROCEDURE|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
48659547|NCT04198012|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
48659548|NCT01283984|DRUG|AZD2115|Single dose, oral inhalation (nebuliser solution)
47984171|NCT01059786|OTHER|Intravenous (IV) Saline|Additional treatment with intravenous (IV) saline may be indicated.
47984172|NCT05156320|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
48659549|NCT01283984|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
48138057|NCT03601715|OTHER|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
48502489|NCT03097510|BEHAVIORAL|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
48502490|NCT00475150|DRUG|cediranib maleate|Given orally
48502491|NCT00475150|OTHER|laboratory biomarker analysis|Correlative studies
48659550|NCT05712109|OTHER|Follow-up after Anterior cruciate ligament reconstruction|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8.months after the surgery
48659551|NCT00668642|DRUG|Dutasteride|0.5 mg capsule given orally on daily basis
48659552|NCT00668642|DRUG|Placebo|Identical placebo
48659553|NCT02852707|BEHAVIORAL|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
48659554|NCT02852707|BEHAVIORAL|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
48659555|NCT02852707|BEHAVIORAL|Not exposed|People not engaged in regular sports competition/exercise training.
48659556|NCT05719246|BEHAVIORAL|Yoga|The yoga video set that the participants will follow is a brief, at-home, 6-week twice per week Standardized Yoga \& Meditation Program for Stress Reduction (SYMPro-SR) program. The videos feature Sydney Topfer guiding the participants through different yoga poses.
48659557|NCT01322152|DRUG|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
48659558|NCT05583955|DRUG|NOE-105|Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
48659559|NCT05583955|DRUG|Placebo|Escalating dose levels of matching Placebo will be given
47984173|NCT05156320|DRUG|Placebo|Placebo will be administered every 4 weeks by intravenous (IV) infusion.
47984174|NCT01107041|BEHAVIORAL|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
47984175|NCT03933189|OTHER|Physical Therapy|Physical therapy modalities to treat chronic pain
48138058|NCT03601715|OTHER|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
48349256|NCT02561676|OTHER|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
48502492|NCT00045188|DRUG|imatinib mesylate|Given PO
48502493|NCT00045188|OTHER|laboratory biomarker analysis|Optional correlative studies
48659560|NCT03559556|OTHER|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
48659561|NCT04182334|OTHER|Slow Tempo Music|For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.
47984176|NCT04671550|DIAGNOSTIC_TEST|questionnaire|"Questionnaire on Driving performances and Visual Field"
47984177|NCT06228547|OTHER|Questionnaire|Standardized questionnaire specifically made for the study. The interview lasts approximately 15 minutes. The form gathers baseline characteristics of the patients such as socio-demographic information, symptoms, lifestyle factors and gynecological history. The questionnaire focuses also on the manner in which the diagnosis was revealed to the patient and their experience of this disclosure. Lastly, the questionnaire includes items issued from French practice guidelines concerning etiological investigations, fertility assessment, osteoporotic and cardiovascular complications, HRT use, and residual symptoms
48502494|NCT04339283|DIETARY_SUPPLEMENT|Standardized Hibiscus sabdariffa tea|Daily consumption of Standardized Hibiscus sabdariffa tea
48502495|NCT02857751|BEHAVIORAL|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
48659562|NCT04182334|OTHER|Attention Control|Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
48659563|NCT00785720|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
48659564|NCT06625528|BIOLOGICAL|open flap debridement|does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
47984178|NCT05434182|PROCEDURE|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
47984179|NCT05434182|PROCEDURE|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
47984180|NCT01248442|DRUG|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
47984181|NCT01248442|DRUG|Placebo|Matching Placebo
48659565|NCT02943161|DIETARY_SUPPLEMENT|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
48138059|NCT03601715|OTHER|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
48138060|NCT02263105|DRUG|CDDP|
48138061|NCT02263105|DRUG|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
47984182|NCT03971890|OTHER|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
47984183|NCT03971890|OTHER|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
48138062|NCT03683576|DRUG|GB001|film-coated oral tablet
48138063|NCT03683576|DRUG|Placebo|film-coated oral tablet
48138064|NCT05558124|DRUG|Vyxeos|Fixed dose of Vyxeos (44 mg/m2 daunorubicin and 100 mg/m2 cytarabine) (Day 1, 3, and 5) in combination with various dose schedules of Gemtuzumab Ozogamicin (GO)
48138065|NCT05558124|DRUG|Gemtuzumab Ozogamicin|"Participants will be treated at the following dose levels:~Dose Level 1 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 Dose Level 2 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1 and 4 Dose Level 3 - Gemtuzumab Ozogamicin will administered 3mg/m2 on Day 1, 4, 7"
48138066|NCT00981552|RADIATION|IMRT planning|
48138067|NCT00981552|RADIATION|4-Field Radiation Planning|
48138068|NCT02067819|DEVICE|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
48138069|NCT02067819|DEVICE|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
48138070|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
48138071|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
48138072|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
48138073|NCT00637858|DIETARY_SUPPLEMENT|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
48138074|NCT00637858|OTHER|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
48138075|NCT02073500|OTHER|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
48138076|NCT03830151|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
48138077|NCT03830151|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
48138078|NCT02867956|DRUG|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
48138079|NCT02867956|DRUG|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
48502496|NCT05331196|DIAGNOSTIC_TEST|Preoperative cardiopulmonary exercise tetsing|Patients underwent a cardiopulmonary exercise test prior to surgery.
48138080|NCT00384514|DEVICE|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
48138081|NCT04975087|OTHER|Patients group|Patients will complete the mentioned questionnaires.
48659566|NCT06570655|DRUG|Huperzine A injection|intramuscular
48659567|NCT06570655|DRUG|Huperzine A injection|intravenous bolus
48659568|NCT04429919|DRUG|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
48659569|NCT04429919|DRUG|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
48659570|NCT06644820|DIAGNOSTIC_TEST|radiology|"Chest x ray posteroanterior view and lateral view.~CT. chest without contrast:~To assess the underlying lung pathology e.g. multiple bullae, interstitial lung disease (ILD) , cavitating lesions or nodules."
47984184|NCT05455788|DRUG|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
48138082|NCT02329704|PROCEDURE|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
48138083|NCT02329704|PROCEDURE|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references."
48349257|NCT02561676|OTHER|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
48349258|NCT05740267|PROCEDURE|Natural Orifice Specimen Extraction|After bowel resection, all bowel anastomoses are created via side-to-side intracorporeal anastomosis, either isoperistaltic or antiperistaltic. The surgical steps of NOSE with the transrectal method are illustrated in Figure 1. First, the rectosigmoid colonic lumen is blocked with a bowel clamp. After rectal irrigation with povidone-iodine water, a transanal endoscopic microsurgery (TEM) scope or Alexis wound protector is inserted through the anus, reaching the upper rectum. Enterotomy is performed at the upper rectum, and a suction device is used to clean any fecal spillage. The TEM scope is pushed forward beyond the rectal opening, and the specimen is extracted with the TEM scope. The rectal opening is closed with a barbed suture, and an air leak test is performed to identify anastomotic leakage.
48349259|NCT03878043|OTHER|Follow-up Care|Follow up care provided upon readmission to patients who were diagnosed with a TSDH upon initial visit.
48349260|NCT03270618|DEVICE|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
48138084|NCT02329704|PROCEDURE|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
48349261|NCT00659906|BEHAVIORAL|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
48349262|NCT00659906|BEHAVIORAL|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
48349263|NCT05578560|PROCEDURE|Prehabituation|chemical labyrinthectomy with intratympanically installed gentamicin
48659571|NCT01156350|DRUG|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained \< 2.5 x 104 CD3+ cells/kg
48349264|NCT05578560|PROCEDURE|3D optokinetic stimulation in virtual reality space|3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.
48349265|NCT05578560|PROCEDURE|Vestibular training|vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
48659572|NCT05765474|BEHAVIORAL|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
48138085|NCT02329704|PROCEDURE|24 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
48138086|NCT02329704|PROCEDURE|48 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
48138087|NCT02329704|PROCEDURE|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
48138088|NCT02329704|BIOLOGICAL|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
48138089|NCT03951259|DRUG|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
48138090|NCT03951259|DRUG|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
48659573|NCT05765474|BEHAVIORAL|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
48659574|NCT00448513|DIETARY_SUPPLEMENT|catechin extracts|comparison with placebo
48138091|NCT00000418|PROCEDURE|Psychosocial intervention|
48659575|NCT05897320|DRUG|Eptinezumab|Solution for infusion
48659576|NCT05897320|DRUG|Placebo|Solution for infusion
48659577|NCT05657847|DEVICE|Photon-counting detector-CT|CT scan
48659578|NCT01445275|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
48659579|NCT01445275|OTHER|Medical Chart Review|Ancillary study
48659580|NCT01445275|OTHER|Study of Socioeconomic and Demographic Variables|Ancillary studies
48659581|NCT04695990|DRUG|Wenyang Huoxue Decoction|Wenyang Huoxue granules
48659582|NCT04695990|DRUG|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
48138092|NCT04703907|OTHER|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
48659583|NCT05849766|DRUG|Dapagliflozin Farxiga®|Dapagliflozin 10 mg once daily
48659584|NCT05849766|DRUG|Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®|Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
48659585|NCT06588608|DEVICE|auricular nerve stimulation (aVNS)|The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
48659586|NCT06588608|DEVICE|sham aVNS|The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
48349266|NCT02034864|OTHER|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
48349267|NCT02034864|OTHER|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
48349268|NCT04831268|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
48659587|NCT00224549|DRUG|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
48659588|NCT02354573|DRUG|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
48659589|NCT02085863|DRUG|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
48659590|NCT02085863|DRUG|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
48659591|NCT00421564|DRUG|DBT-Danggui Buxue Tang|
47984185|NCT06466109|BEHAVIORAL|social robot intervention|"In the first course, the patient and their parents interact with the social robot PARO for 30 minutes.~In the second course, the parent interacts with PARO individually for 10 minutes, then the parent and patient interact with PARO together for 10 minutes. At last, the patient interacts with PARO for 10 minutes.~In the third course, the parent interacts with PARO individually for 10 minutes, then the parent and patient interact with PARO together for 10 minutes. At last, the patient interacts with PARO for 10 minutes.~In the last course, the parent interacts with PARO individually for 10 minutes, and then the patient interacts with it. At last, they interact with PARO together for 10 minutes."
47984186|NCT01822340|DRUG|HM10560A|Once weekly HM10560A
47984187|NCT01822340|DRUG|Genotropin|Once daily Genotropin
47984188|NCT06264128|DEVICE|TPAP|"TPAP is a form of CPAP therapy where the therapy pressure is reduced from the beginning of inhalation through mid or later exhalation. The CPAP therapy pressure is only present at the end of the expiratory phase."
47984189|NCT06264128|DEVICE|CPAP|CPAP is a standard formal at home therapy for obstructive sleep apnea where a device attached via a facemask applies a constant pressure to a patient's lungs during sleep. It is the reference standard in this study.
47984190|NCT05974033|COMBINATION_PRODUCT|Stenting plus medical therapy|Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
47984191|NCT05974033|DRUG|Medical therapy alone|Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
48349269|NCT04831268|OTHER|Lentils and lupins mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from lentils and lupins mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
48502497|NCT01630967|DRUG|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
48659592|NCT04619602|DRUG|GSNO|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
48659593|NCT04512690|DEVICE|Epidural electrical stimulation (EES) of the cervical spinal cord|All participants enrolled in this group will undergo a surgical procedure to implant a system which provides epidural electrical stimulation (EES) of the cervical spinal cord. Researchers will quantify the ability of EES to recruit arm and hand muscles and produce distinct kinematic movements. The implant will be removed after less than 30 days.
48659594|NCT06010979|PROCEDURE|conventional intrumentation assisted knee arthroplasty|conventional intrumentation assisted knee arthroplasty
48659595|NCT06010979|PROCEDURE|computer navigation assisted knee arthroplasty|computer navigation assisted knee arthroplasty
48659596|NCT06010979|PROCEDURE|robotic system assisted knee arthroplasty|robotic system assisted knee arthroplasty
47984192|NCT02175498|DRUG|Homoeopathic medicines|4 pills once a week of the indicated Similimum
47984193|NCT00508625|DRUG|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
47984194|NCT00508625|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
47984195|NCT00508625|DRUG|Carboplatin|Standard platinum based chemotherapy
47984196|NCT00508625|DRUG|Paclitaxel|Standard taxane chemotherapy
47984197|NCT04231539|DRUG|Nicotine|Vape different flavor nicotine products
48138093|NCT00130182|DRUG|denufosol tetrasodium (INS37217)|
48138094|NCT06456359|DRUG|Signifor|Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).
48138095|NCT01399450|DRUG|paliperidone|paliperidone augmenting on ongoing medication
48659597|NCT06010979|PROCEDURE|patient-spercific assisted knee arthroplasty|patient-spercific assisted knee arthroplasty
48659598|NCT06442800|BEHAVIORAL|Liver Cancer|Participants will view messages about the risk of liver cancer from alcohol consumption.
48138096|NCT03537326|DRUG|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
48659599|NCT06442800|BEHAVIORAL|Throat and Mouth Cancer|Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.
48659600|NCT06442800|BEHAVIORAL|Colorectal Cancer|Participants will view messages about the risk of colorectal cancer from alcohol consumption.
48659601|NCT06442800|BEHAVIORAL|Multiple Cancers|Participants will view messages about the risk of multiple cancers from alcohol consumption.
48659602|NCT06442800|BEHAVIORAL|Liver Disease|Participants will view messages about the risk of liver disease from alcohol consumption.
48659603|NCT06442800|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
48659604|NCT06442800|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
48659605|NCT06442800|BEHAVIORAL|Drinking Guidelines|Participants will view messages about guidelines for alcohol consumption.
48659606|NCT06442800|BEHAVIORAL|Current Warning|Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.
48659607|NCT06442800|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
48659608|NCT00950521|PROCEDURE|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
47984198|NCT04231539|DEVICE|Vaporizer Device|Take puffs from vaporizer filled with different flavors
48138097|NCT04969666|DRUG|IPED2015|Active treatment
48138098|NCT04969666|DRUG|Placebo|Placebo
48138099|NCT04873206|OTHER|routine stain by H&E.|formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.
48138100|NCT00776009|DRUG|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
48138101|NCT00776009|DRUG|Placebo|Placebo Comparator
48138102|NCT01233934|DRUG|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
48659609|NCT00950521|DRUG|convention therapy|antiplatelet
48138103|NCT01233934|DRUG|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
48659610|NCT00836706|DRUG|clarithromycin|500 mg Tablet
48659611|NCT00836706|DRUG|BIAXIN®|500 mg Tablet
48138104|NCT01489774|DRUG|Placebo|single and multiple dose
48138105|NCT01489774|DRUG|CJ-12406|single and multiple dose
48659612|NCT05642338|DIAGNOSTIC_TEST|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
48659613|NCT00265798|DRUG|Sorafenib Tosylate|
48659614|NCT06594705|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
48659615|NCT02551185|DRUG|ACY-241|
48659616|NCT04344912|OTHER|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
48659617|NCT02209987|DRUG|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
48659618|NCT02209987|DRUG|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
48659619|NCT06521268|OTHER|Inspiratory muscle training|Inspiratory muscle training
48659620|NCT06521268|OTHER|Decongestive treatment|Decongestive treatment
47984199|NCT05013567|DRUG|Ibuprofen gel|Ibuprofen gel 5% topically four times a day
47984200|NCT05013567|OTHER|Placebo|Placebo gel topically four times a day
47984201|NCT00707707|DRUG|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
47984202|NCT00707707|DRUG|Paclitaxel|Intravenous infusion over 1 hour
48138106|NCT06267300|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
48138107|NCT05416476|DRUG|Anisodine Hydrobromide|Anisodine Hydrobromide 1 mg oral tablet, twice times a day
48138108|NCT05416476|DRUG|Anisodine Hydrobromide placebo|Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
48138109|NCT02401932|OTHER|Hemophagocytosis|Best supportive care and immunosuppressive treatments
48138110|NCT02628106|DRUG|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
48138111|NCT00268723|DRUG|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
48138112|NCT00268723|DRUG|Placebo|Placebo MDI QID
48138113|NCT01030237|OTHER|FID 114657|1 drop both eyes four times a day for 6 weeks
48138114|NCT01030237|OTHER|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
48138115|NCT05186688|BEHAVIORAL|Braining|"Braining is a clinical invention that helps patients in psychiatry to start and execute physical exercise (PE) regularly in psychiatric care. The core components are basic moderate to vigorous aerobic group training session and motivational work led by the psychiatric staff. Braining is used as add-on treatment to regular psychiatric care and is included in the patient care plan."
48138116|NCT00773500|OTHER|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
48659621|NCT05997901|OTHER|Varenicline healthbot|The intervention is a healthbot that will provide information, reminders, answers to questions, and support to participants using varenicline for smoking cessation.
48138117|NCT02644122|DRUG|SF1126|
48659622|NCT03560388|OTHER|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
48659623|NCT06308224|OTHER|Modified-Otago Exercises|"Walking for 15 minutes before or after the strengthening and balance exercises of Modified-Otago.~Strengthening exercises for 10 minutes: Knee extensor, Knee flexor, Hip adductor, Ankle plantar flexors (calf raises), and Ankle dorsiflexion (toe raises).~Balance exercises 20 minutes: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel-toe stand), Tandem walk (heel-toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backward, sit to stand and Stair walking."
48138118|NCT04090632|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
48502498|NCT02187692|BEHAVIORAL|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
48349270|NCT04831268|OTHER|Trahanas with tomato sauce mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
48349271|NCT04831268|OTHER|Halva with currants mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
48659624|NCT06308224|OTHER|Tai-Chi Exercises|"Warm-up exercises for 10 minutes.~Tai Chi Qigong Exercises for 30 minutes: Commencing form and regulating breathing, Expanding your chest, Painting a rainbow, Circling arms to separate the clouds, Fixed step invert brachial, Row a boat in the middle of the lake, Shoulder the ball, Turning the body to look at the moon, Twisting waist and pushing palms, Horse step and cloud hands, Drag the sea and watch the sky, Undulating waves, Dove spreading wings, Extend arms and punch, Wild goose flying, Flywheel turning, Bounce ball while stepping, Pressing palms in calmness.~Cool-down exercises for 5 minutes."
48659625|NCT03884673|DRUG|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
48659626|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
48659627|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
48659628|NCT06221449|PROCEDURE|Positive end expiratory pressure|"The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O."
47984203|NCT04519125|DRUG|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
48659629|NCT01202084|DRUG|Formoterol/Fluticasone|
48659630|NCT01202084|DRUG|Foraseq®|
48659631|NCT01202084|DRUG|Fluticasone|
48659632|NCT04907955|PROCEDURE|phacoemulsification with implantation of presbyopia correcting IOL|cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
48659633|NCT06177184|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
48659634|NCT06549348|RADIATION|Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance|Fenestrated Endovascular Aortic Repair (FEVAR) procedure done with either LumiGuide or conventional fluoroscopy guidance
48349272|NCT04684160|DEVICE|Fixed-bearing TKA|
48349273|NCT04684160|DEVICE|Mobile-bearing TKA|
48349274|NCT02545972|DRUG|tacrolimus extended release|daily dosing of tacrolimus
48349275|NCT05849545|DEVICE|Garston tool|GT group protocol included the use application of IASTM along with the application of ice therapy at the end of the session. Using the Graston instrument, 20 strokes per minute proximal to distal and 20 strokes per minute distal to proximal for a period of 3 minutes were given over the painful area. Baseline values were recorded for demographics evaluation and episodes of pain onsets. The assessment of patients was done at the initial and last visit before the completion of the treatment program. Three treatment sessions per week were given to each patient for a total of four weeks.
47984204|NCT04519125|OTHER|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
48138119|NCT04365205|PROCEDURE|Endobronchial biopsy|Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
48138120|NCT02765126|BIOLOGICAL|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
48138121|NCT02765126|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
48138122|NCT05120336|DEVICE|transcutaneous vagus nerve stimulation|Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
48138123|NCT05120336|DEVICE|sham stimulation|Sham procedure for active transcutaneous vagus nerve stimulation
48138124|NCT02205515|DRUG|Everolimus|Everolimus is a novel derivative of rapamycin.
48659635|NCT05206929|OTHER|Self Managed Care|Self Managed Care
48659636|NCT02958345|BIOLOGICAL|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
48659637|NCT02958345|OTHER|Placebo|Injection of 0.65 mL of sterile normal saline
48659638|NCT05812690|OTHER|This is a non intervention - observation only study|This is non intervention study
48659639|NCT05114174|OTHER|mami-educ|The intervention corresponds to sending 3 messages a week through Telegram, with nutritional information, for 12 consecutive weeks (a different nutritional topic each week). The messages address the three domains of learning, cognitive, affective, and psychomotor for each topic.
48659640|NCT06114745|DRUG|SHR-1707 injection|Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion
48659641|NCT06114745|DRUG|Placebo|Placebo will be administered through IV infusion
47984205|NCT04843423|DRUG|Cariprazine|"At the screening visit, those who are eligible will enter an open-label trial with cariprazine in doses ranging from 1.5mg to 3 mg. The study will begin with a single week of cariprazine 1.5 mg oral tablets. After the first week the participants' dosage may be increased up to a maximum of 3 mg daily. This dose will remain fixed after 4 weeks of treatment until week 8, at which time the medication will be discontinued.~Because the drug is not yet available to market in Canada, participants will be dispensed the drug in appropriately labelled 7-day tablet containers with the appropriate dose, including 3 additional tablets to account for scheduling conflicts. Participants will be instructed to return the tablet containers at each Study Visit in order to assess drug compliance. They will then be newly dispensed the appropriate quantity according to their next scheduled study visit."
47984206|NCT00299455|DRUG|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
47984207|NCT00299455|DRUG|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
48138125|NCT01540305|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
48138126|NCT01540305|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
48138127|NCT01475266|DRUG|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
48138128|NCT01475266|DRUG|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
48138129|NCT04130932|OTHER|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
48138130|NCT03492021|OTHER|Diet Intervention_AP-CPT|Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
48138131|NCT03492021|OTHER|Diet Intervention_PP-PPT|Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
48138132|NCT05259800|OTHER|Peppermint oil vapors|Subjects will be exposed to vapor of peppermint oil
48138133|NCT05259800|OTHER|Mineral Oil|Subjects will be exposed to vapor of placebo (mineral oil)
48502499|NCT02576912|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
48502500|NCT02576912|DRUG|Active Pregnenolone|A dose given sublingually.
48659642|NCT04824911|DRUG|Clopidogrel|300mg loading and 75mg/day from day 2
48659643|NCT04824911|DRUG|Aspirin|Aspirin(100-300mg/day)
48659644|NCT04824911|DRUG|Atorvastatin|Atorvastatin 40-80mg/day
47984208|NCT03009435|OTHER|prophylactic manual rotation|
47984209|NCT04635215|DEVICE|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
48659645|NCT04824911|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day.
48659646|NCT01292031|DRUG|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
48659647|NCT01292031|DRUG|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
48659648|NCT06060535|BEHAVIORAL|Suicide Attempt Risk Model Care Pathway|The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
48659649|NCT01855984|DIETARY_SUPPLEMENT|Oral mixed tocotrienols|200mg per day
48138134|NCT06231316|DRUG|Norepinephrine Injection|Norepinephrine is both a neurotransmitter and a hormone. It is essential vasopressor for rapid blood pressure support, crucial in maintaining hemodynamic stability
48138135|NCT06157554|OTHER|Breathing Exercises|During the exercise sessions, participants will be seated in a chair. In the first five and last five minutes of the session, they will be instructed to focus on their breathing and the sensations produced in the body while sitting comfortably in a relaxed position with all joints in the chairs with their eyes closed. After the initial 5 minutes of relaxed breathing, participants will be instructed to perform diaphragmatic and costal breathing for 10 minutes. After 5 minutes of diaphragmatic breathing, the patient will be rested for 1 minute and then 5 minutes of costal breathing will be performed. While doing coastal breathing, patients will be asked to place their hands on their costas, take a deep breath and inflate the bottom of their hands; then they will be asked to exhale the breath they take in a longer (1:2) time.
48138136|NCT06157554|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
48138137|NCT03058757|DRUG|intravesical mitomycin-C 40mg/20ml instillation|"neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~* one day before surgery~* four hours before surgery"
48138138|NCT05485116|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
48138139|NCT01473069|DRUG|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
48138140|NCT01473069|DRUG|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
48138141|NCT04205799|DRUG|Cabozantinib|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
48138142|NCT01034306|DRUG|CF101|orally q12h
48138143|NCT01034306|DRUG|Placebo control|orally q12 hours
48659650|NCT01855984|DIETARY_SUPPLEMENT|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
48138144|NCT04226456|DRUG|N-acetyl cysteine|Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
48138145|NCT00091689|DRUG|852A|
48138146|NCT02221505|DRUG|LOP628|
48138147|NCT03176056|DIETARY_SUPPLEMENT|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
48659651|NCT05713292|DRUG|Pirfenidone Oral Product|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
48659652|NCT05713292|DRUG|Pirfenidone placebo|Pirfenidone placebo
48659653|NCT05962775|PROCEDURE|Ethanol Sclerotherapy for Endometrioma|2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
48659654|NCT00672035|BIOLOGICAL|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
48138148|NCT03176056|DIETARY_SUPPLEMENT|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI \> 24 and 30 kcal/day for underweight subjects with a BMI \<18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
48138149|NCT01238874|DEVICE|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
48138150|NCT05035329|OTHER|Outcome measurements|Outcome measurements were applied.
48138151|NCT03067857|BIOLOGICAL|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
48138152|NCT04178421|OTHER|Computerized training program|Eye-gaze fixation computer based training program
48138153|NCT04178421|OTHER|Placebo|Pac-Man, Zookeeper, Tetris
48138154|NCT00918333|DRUG|panobinostat|Given PO
48138155|NCT00918333|DRUG|everolimus|Given PO
48138156|NCT00918333|OTHER|laboratory biomarker analysis|Correlative studies
48138157|NCT00918333|OTHER|pharmacological study|Correlative studies
48349276|NCT05849545|PROCEDURE|Neuromuscular Re-education|General stretching and strengthening exercises for the neck muscles. The protocol of treatment for the NMR group included the use of the Neuromuscular re-education soft tissue mobilization technique (NMR) followed by active movements of the patient.
48659655|NCT03601026|BEHAVIORAL|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
48659656|NCT00559039|OTHER|questionnaire administration|
48659657|NCT00559039|PROCEDURE|evaluation of cancer risk factors|
48659658|NCT05951101|DEVICE|Zenith LAA Occlusion System|LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
48659659|NCT01416337|DRUG|GSK1120212|2 mg single dose tablet on Day 1 of study
48659660|NCT01416337|DRUG|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
48659661|NCT02310321|DRUG|Gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
48659662|NCT02310321|DRUG|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.
48659663|NCT02310321|DRUG|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5."
47984210|NCT00719251|DEVICE|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
47984211|NCT00719251|DEVICE|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
48349277|NCT05546749|DEVICE|RelieVRx|The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
47984212|NCT00719251|OTHER|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
47984213|NCT04919850|DIETARY_SUPPLEMENT|Saccharomyces boulardii and SOD|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
47984214|NCT04919850|COMBINATION_PRODUCT|Placebo|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
47984215|NCT02237859|DRUG|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
47984216|NCT02237859|DIETARY_SUPPLEMENT|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
48349278|NCT05546749|DEVICE|Sham VR|The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
48349279|NCT03557229|DRUG|Melatonin 5 mg|Oral: 50 mg once daily for 5 days
48349280|NCT03557229|DRUG|Vitamin C 1 GM Oral Tablet|Oral: 1 GM every 6 hours for 5 days
48349281|NCT03557229|DRUG|Vitamin E 400 UNT|Oral: 400 UNT every 8 hours for 5 days
48349282|NCT03557229|DRUG|N-acetylcysteine|Oral: 1200 mg every 12 hours for 5 days
48502501|NCT02576912|DRUG|Placebo|A placebo dose given sublingually.
48659664|NCT02444247|OTHER|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
48659665|NCT02444247|OTHER|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
48659666|NCT02444247|OTHER|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
48659667|NCT02444247|OTHER|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
48659668|NCT02699411|DEVICE|Dry needling|dry needling Travell and Simons
48659669|NCT02699411|OTHER|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
47984217|NCT00774150|BEHAVIORAL|Cognitive Behavioral Therapy|16 sessions of CBT
47984218|NCT00774150|BEHAVIORAL|Client Centered Therapy|16 sessions of CCT
47984219|NCT01979484|DRUG|PPI-668 capsule|
47984220|NCT01979484|DRUG|PPI-668 tablet|
47984221|NCT03727490|OTHER|Repair|The subscapularis will be repaired.
47984222|NCT03727490|OTHER|Standard Treatment|No repair will be performed
47984223|NCT03793231|COMBINATION_PRODUCT|fungalAi platform technology|Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
48502502|NCT02576912|DRUG|Placebo|Placebo dose given intravenously.
48502503|NCT02065856|BIOLOGICAL|AVANZ Salsola|AVANZ Salsola
48659670|NCT03828604|BEHAVIORAL|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
48659671|NCT03828604|BEHAVIORAL|Placebo Trier Social Stress Task|Active control version of the TSST
48659672|NCT04077502|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
48659673|NCT04868422|DEVICE|Telemonitoring via wireless internet-based system|
48659674|NCT05442697|DEVICE|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
48659675|NCT05442697|DEVICE|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
48349283|NCT06434090|DRUG|Liposomal irinotecan|Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.
48502504|NCT01798355|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
48659676|NCT06530459|DRUG|Menopausal hormone therapy|Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily Ingest Micronized Progesterone 200mg daily for 12 days each month
48349284|NCT06434090|DRUG|Bevacizumab|bevacizumab will be given biweekly at a dose of 5mg/m2
48502505|NCT01798355|BEHAVIORAL|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
48659677|NCT06530459|BEHAVIORAL|Exercise training|Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week.
48349285|NCT05394012|BIOLOGICAL|RQ3013|Two doses of 30 μg/0.15 mL at an interval of 28 days, or two doses of 60 μg/0.3 mL at an interval of 28 days
48349286|NCT05394012|BIOLOGICAL|Comirnaty|Two doses of 30 μg/0.3 mL at an interval of 28 days
48349287|NCT04018105|OTHER|Oral glucose tolerance test (OGTT) with or without metformin|Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
48349288|NCT03850704|DRUG|Selinexor|
48349289|NCT00179998|DRUG|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
48349290|NCT00179998|DRUG|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
48349291|NCT02403960|DIETARY_SUPPLEMENT|probiotic|the patients used probiotic tablets in addition to scaling and root planning
48349292|NCT02403960|DIETARY_SUPPLEMENT|placebo|the patients used placebo tablets in addition to scaling and root planning
48349293|NCT00421590|DRUG|SMC021|
48618243|NCT05529433|PROCEDURE|Atraumatic Restorative Treatment (ART)|Atraumatic Restorative Treatment is highly accepted by the patients as there is no need for local anesthesia. It is a minimal invasive technique which preserves sound tooth structure as caries removal will be done by a sharp spoon excavator. It requires less time during caries removal. There is a chemical bond between the tooth and the glass ionomer adhesive material. So, there is no need for cutting sound tooth structure for retention of the restoration.
48618244|NCT05529433|PROCEDURE|Smart Burs|Smart Bur is a polymer bur which removes only soft infected dentin as the cutting edges become dull in contact with the hard affected dentin.Caries removal will be done by Smart Bur mounted on a low speed hand-piece leaving the affected dentin intact. It requires less time for caries removal.
48659678|NCT06530459|COMBINATION_PRODUCT|Menopausal hormone therapy + exercise training|"1. Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily and Ingest Micronized Progesterone 200mg daily for 12 days each month~2. Exercises would focus on upper and lower body strength generally. It is anticipated that patients ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week."
48349294|NCT03929406|DEVICE|Brain Tissue Imprint|"Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~* The guide tube with the first stylet is set up to the target~* Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~* Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal."
48349295|NCT03064165|DRUG|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
48349296|NCT03064165|PROCEDURE|Sham block|Injection as for obturator nerve block, but with placebo
48349297|NCT03064165|PROCEDURE|Obturator nerve block|Postoperative obturator nerve block
48659679|NCT03231553|OTHER|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
48349298|NCT03064165|DRUG|Sodium Chloride 9mg/mL|Placebo
48659680|NCT05826665|OTHER|Persistent AF ablation assisted with the STAR Apollo Mapping System|This exploratory hypothesis generating data set will be collected during standard AF ablation procedures using FDA cleared technologies as described in their Instructions for Use (IFU). No randomization or experimental protocols will be used during this study, and all follow up will be performed as per the center's standard of care(SOC).
48349299|NCT01207674|OTHER|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
48349300|NCT05689749|DEVICE|Superb Microvascular Imaging (SMI) (Toshiba)|To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
48349301|NCT02219737|DRUG|Carboplatin|Given IVPB
48349302|NCT02219737|DRUG|Etoposide|Given IVPB
48349303|NCT02219737|DRUG|Ibrutinib|Given PO
48659681|NCT05534646|DRUG|Apalutamide|Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
48349304|NCT02219737|DRUG|Ifosfamide|Given IV
48349305|NCT02219737|OTHER|Laboratory Biomarker Analysis|Correlative studies
48349306|NCT02219737|OTHER|Pharmacological Study|Correlative studies
48349307|NCT02219737|BIOLOGICAL|Rituximab|Given IV
48349308|NCT06323499|PROCEDURE|Induction of atypical atrial flutter|Electrophysiological study with induction of atypical atrial flutter. When the induction was successful, ablation of arrhythmia was performed similar to the control group.
48349309|NCT00441727|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
48502506|NCT05935111|BEHAVIORAL|Physical Activity Self-efficacy (PAS) intervention|The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
48659682|NCT05534646|DRUG|Carotuximab|"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."
48659683|NCT03874559|DIAGNOSTIC_TEST|Blood Draw|Serum samples will be obtained from each patient enrolled
48659684|NCT01150357|DRUG|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
48659685|NCT01150357|DRUG|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
48659686|NCT01150357|DRUG|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
48659687|NCT05543317|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
48659688|NCT05231980|DIETARY_SUPPLEMENT|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
48659689|NCT05231980|DRUG|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
47984224|NCT05264155|BEHAVIORAL|GameBus (mHealth app)|Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
47984225|NCT05356247|BEHAVIORAL|Lausanne Trialogue Play Brief|The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
47984226|NCT00366145|BIOLOGICAL|Prochymal®|2 infusions of 2 million cells/kg per week for 4 weeks
47984227|NCT00366145|DRUG|Placebo|2 infusions per week for 4 weeks
47984228|NCT00366145|DRUG|Standard of Care for GVHD|Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
47984229|NCT02296268|BEHAVIORAL|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
47984230|NCT05237583|BEHAVIORAL|Prehabilitation|All participants will be offered a multimodal prehabilitation program. This program will include an individualized and supervised aerobic and resistance exercise training program, nutritional optimization, and psychological support. The program will last 6 months or until liver transplantation, whichever comes first.
47984231|NCT01549392|DEVICE|DECT|DECT at tumor progression and 3 months later
47984232|NCT01549392|DEVICE|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
47984233|NCT06120231|DIAGNOSTIC_TEST|Pulse width modulation|Will be stimulating the pedicle screws utilizing three different pulse-width settings, 0.4 milliseconds, 0.2 milliseconds, and 0.05 milliseconds.
47984234|NCT00951808|BIOLOGICAL|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
48502507|NCT01333774|DRUG|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
48659690|NCT05231980|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
47984235|NCT00951808|BEHAVIORAL|Standard care|Participants will receive standard care for ACS while in the hospital.
47984236|NCT00421538|DRUG|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
47984237|NCT00421538|DRUG|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
47984238|NCT01800864|OTHER|obesity|
47984239|NCT03472027|BIOLOGICAL|BCD-145|Anti-CTLA-4 monoclonal antibody, IV infusion
47984240|NCT05083104|DIAGNOSTIC_TEST|laboratory investigations on coagulation profiles|CBC ,PT ,aPTT ,Protein C .Protein S ,ATIII and vWF
47984241|NCT03582072|BEHAVIORAL|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.\*
47984242|NCT01804374|DRUG|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
47984243|NCT01804374|DRUG|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
48349310|NCT00441727|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
48349311|NCT00441727|DRUG|Placebo|Placebo once daily
48349312|NCT05264740|BEHAVIORAL|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
48349313|NCT05264740|BEHAVIORAL|Educational materials|The control group will receive educational material only.
48502508|NCT05400408|DIAGNOSTIC_TEST|VOX|Breath Biopsy Analysis
48138158|NCT05134103|BEHAVIORAL|Mindbeacon Therapist Guided, Internet Cognitive Behavioral Therapy for Depression|"The treatment consists of 11 depression modules delivered approximately once per week (at therapists' discretion) over a period of 12 weeks. Additionally, the therapist typically tailors treatment to client's individual needs by including supplementary modules for a variety of issues such as generalized anxiety, panic, social anxiety, post-traumatic stress, insomnia, pain, and relationships etc. Clients can complete the readings, exercises, and worksheets at any convenient time, using their web-enabled smartphone, tablet, or computer. Access to the modules and all messaging is provided through the secure platform. Messaging is asynchronous meaning participants can message their therapist as often as they choose and expect a response within 1-2 business days. After 12 weeks of active treatment, they will have unguided access (without therapist support) to the treatment materials that were covered for an additional 40 weeks."
48138159|NCT05134103|OTHER|Waitlist Control Group|Participants assigned to this arm will wait for 12 weeks before receiving active treatment condition
48138160|NCT00895245|DRUG|fosaprepitant dimeglumine|Given IV
48138161|NCT00895245|DRUG|cisplatin|Given IV
48138162|NCT00895245|DRUG|palonosetron hydrochloride|Given IV
48138163|NCT00895245|DRUG|dexamethasone|Given IV and orally
48659691|NCT06042816|PROCEDURE|Free-opioid anesthesia|Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
47984244|NCT03437525|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
47984245|NCT03255486|BIOLOGICAL|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
47984246|NCT01863225|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
47984247|NCT01863225|DRUG|Rosuvastatin|20 mg daily, 28-42 days
47984248|NCT01863225|DRUG|Atorvastatin|40 mg daily, 28-42 days
48138164|NCT00895245|OTHER|Functional Living Index-Emesis Questionnaire|Ancillary studies
48138165|NCT00895245|BEHAVIORAL|Emesis Diary|Ancillary studies
48138166|NCT00895245|RADIATION|Radiotherapy|Undergo radiotherapy
48138167|NCT04762914|OTHER|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
48138168|NCT04350619|OTHER|Genetic screening. No therapeutic intervention|Genetic screening using NGS technique. No therapeutic intervention
48138169|NCT04714346|OTHER|no interventions|there is no intervention
48138170|NCT06167434|DEVICE|Future Cardia™ Insertable Cardiac Monitoring (ICM) System|The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.
47984249|NCT01863225|DRUG|Rosuvastatin|40 mg daily, 28-42 days
47984250|NCT01863225|DRUG|Atorvastatin|80 mg daily, 28-42 days
48138171|NCT00687869|BEHAVIORAL|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
48138172|NCT00687869|BEHAVIORAL|Case management|Usual stroke aftercare plus patient-information-notes
48138173|NCT02168309|DRUG|Labetalol|Titrate up for blood pressure control
48138174|NCT02168309|DRUG|Nifedipine|Titrate up to achieve blood pressure control
48138175|NCT04614805|BEHAVIORAL|Mobilizing clinical leaders|Clinical leaders and clinical personnel will regularly receive feedback regarding performance of their own hospital as well as other providers in the regional health trust of North Norway.
48138176|NCT04913103|DRUG|Polatuzumab vedotin|treatment by a study drug polatuzumab-vedotin, i.v.
48138177|NCT04913103|DRUG|Bendamustine Hydrochloride|treatment by a study drug bendamustin i.v.
48138178|NCT04913103|DRUG|Rituximab|treatment by a study drug rituximab, i.v.
48138179|NCT06387966|DRUG|flunotinib|Day one will be used for drug administration, and Day two\~Day seven will be used for experimental data collection.
48138180|NCT06387966|DRUG|flunotinib placebo|Day one will be used for drug administration, and Day two\~Day seven will be used for experimental data collection.
48138181|NCT02565966|OTHER|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
48138182|NCT02093169|DRUG|Part A: Lu AF35700|One 30 mg single dose for one day; orally
48349314|NCT00330239|DRUG|Paroxetine CR|
48138183|NCT02093169|DRUG|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
48349315|NCT00275041|BIOLOGICAL|cetuximab|
48349316|NCT00275041|DRUG|irinotecan hydrochloride|
48659692|NCT06042816|PROCEDURE|opioid anesthesia|Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
48659693|NCT06460532|OTHER|Baseline treatment|Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
48659694|NCT01481610|DRUG|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
48659695|NCT01481610|DRUG|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
47984251|NCT04579692|DEVICE|ExAblate Transcranial treatment|Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
47984252|NCT01052051|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU/daily
47984253|NCT01052051|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 1500mg / daily
47984254|NCT03906045|DRUG|BGF-MDI|Budesonide, Glycopyrronium and Formoterol Fumarate.
47984255|NCT01361464|DRUG|Tipifarnib|Given PO
47984256|NCT01361464|OTHER|Laboratory Biomarker Analysis|Correlative studies
47984257|NCT02526472|PROCEDURE|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
47984258|NCT02526472|PROCEDURE|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
47984259|NCT00243789|DRUG|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
47984260|NCT06464081|OTHER|Sleep quality assessment|1. Pediatric Sleep Questionnaire.
48138184|NCT05673551|OTHER|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
48349317|NCT02174809|BEHAVIORAL|Use of 5As to discuss gestational weight gain|
48659696|NCT00285194|DRUG|Allogeneic Islets of Langerhans|
48138185|NCT00177619|DRUG|Alendronate|
48138186|NCT04539015|DEVICE|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
48349318|NCT02174809|BEHAVIORAL|Usual care|
48349319|NCT05726643|OTHER|resistive training|"5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times."
48349320|NCT05726643|OTHER|kinesiotaping|Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.
48349321|NCT00135993|DRUG|Rotigotine|
48659697|NCT00285194|DRUG|hOKT3γ1 (Ala-Ala)|
48659698|NCT05727332|BEHAVIORAL|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
48659699|NCT06090552|BEHAVIORAL|Letter, AD, PREPARE|Letter, AD, PREPARE
48659700|NCT06090552|BEHAVIORAL|Letter, AD, PREPARE, reminders|Letter, AD, PREPARE, reminders
48659701|NCT06090552|BEHAVIORAL|Letter, AD, PREPARE, reminders, healthcare navigator|Letter, AD, PREPARE, reminders, healthcare navigator
48659702|NCT01573429|OTHER|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
48659703|NCT06421649|RADIATION|Proton Beam Therapy|All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
47984261|NCT06464081|OTHER|Anthropometry|2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate The measures 2.3 and 2.4 will be realized via the Quick Tongue-Tie assessment tool
48349322|NCT02852291|BEHAVIORAL|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
48349323|NCT02852291|BEHAVIORAL|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
48349324|NCT05578326|DRUG|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
48349325|NCT05578326|DRUG|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
48659704|NCT03593759|DRUG|Prednisone or Prednisolone|Oral prednisone/prednisolone tablet
48659705|NCT03593759|DRUG|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
47984262|NCT06464081|OTHER|Tongue strength assessment|3. Tongue pressure while swallowing. 4. Tongue peak pressure during tongue elevation. 5. Tongue peak pressure during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device.
47984263|NCT06464081|OTHER|Tongue endurance assessment|6. The tongue endurance during tongue elevation. 7. The tongue endurance during tongue protrusion. These measures will be realized via the IOPI (Iowa Oral Performance Instrument) device and a timer.
47984264|NCT06464081|OTHER|Orofacial praxis assessment|8. Motricité Bucco-Linguo-Faciale (MBLF) test.
47984265|NCT04896008|DRUG|Sotatercept|Sotatercept is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
47984266|NCT04896008|OTHER|Placebo|Placebo
47984267|NCT03692364|DEVICE|Ceramic-on-ceramic uncemented hip arthroplasty|
47984268|NCT03692364|DEVICE|Metal-on-polyethylene uncemented total hip arthroplasty|
47984269|NCT01372280|DRUG|Reminyl|Galantamine Hydrobromide Tablets 4 mg
47984270|NCT06522048|OTHER|Observational studies do not require intervention|This is an observational retrospective study and does not require any intervention.
47984271|NCT02589574|OTHER|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
48138187|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a therapeutic intensity|"The active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax) for 4 months.~In the active treatment group, the inspiratory and expiratory threshold (intensity) will be adjusted to the perceived exertion (measured with a Borg scale)."
48349326|NCT01402323|OTHER|time point of tooth extraction|
48349327|NCT01634100|DRUG|Probenecid|Probenecid
48349328|NCT01634100|DRUG|Rifampicin|Rifampicin
48659706|NCT05089916|DRUG|Osimertinib|Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.
48659707|NCT05089916|RADIATION|Radiotherapy|"Radiotherapy: according to standard of care~The target population will comprise 3 parallel cohorts, for cohort 1 and 3 a minimum of 10 subjects is planned to be enrolled:~1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases~2. Irradiation of brain metastases (initial lesion size \< 3 cm)~3. Irradiation of lung lesions (primary tumor or metastases, lesion size \< 5 cm)"
48659708|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging with physical grid using conventional processing|X-ray imaging with physical grid using conventional processing
48659709|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using conventional processing|X-ray imaging without physical grid using conventional processing
48659710|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using experimental SimGrid offline processing|X-ray imaging without physical grid using experimental SimGrid offline processing
48659711|NCT02343185|OTHER|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
48659712|NCT02343185|OTHER|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
48659713|NCT05576012|BIOLOGICAL|SOL-116|Participants will receive SC injection in a double-blind manner
48659714|NCT05576012|BIOLOGICAL|Placebo|Participants will receive SC injection in a double-blind manner
48659715|NCT02137343|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
48659716|NCT02137343|DRUG|Placebo|Placebo
47984272|NCT05567289|PROCEDURE|Blood sample collection|"Enrolled patients will undergo sequential blood collection beginning prior to conditioning, then on the day of transplant (day 0), followed by days 7, 14, 21, 28, 56 (2 months) and 90 (3 months) post-transplant.~Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.~The study will also collect an additional blood sample at the onset of treatment for aGvHD for those who receive systemic corticosteroids (PO or IV steroid equivalent to ≥0.5mg/kg prednisolone)."
48349329|NCT01634100|DRUG|Empagliflozin|BI Drug
48349330|NCT01634100|DRUG|Empagliflozin|BI Drug
48349331|NCT01634100|DRUG|Rifampicin|Rifampicin
48349332|NCT01634100|DRUG|Probenecid|Probenecid
48349333|NCT01634100|DRUG|Empagliflozin (BI 10773)|BI Drug
48659717|NCT02137343|DRUG|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
48659718|NCT02137343|DRUG|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
48659719|NCT02712203|BIOLOGICAL|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
48659720|NCT06251115|DRUG|QY-1-T|QY-1-T is a TCR-T drug targeting HBV-related HCC
48138188|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a non-therapeutic intensity|The sham-control group will receive the same training protocol as the active treatment group but with a low (10% of PImax and PEmax) and stable non-therapeutic intensity.
47984273|NCT05567289|PROCEDURE|Bone marrow aspirate|Bone marrow aspirates taken within this period as part of routine care will also be collected, these are typically performed around day 100 and whenever there is suspicion of disease recurrence.
47984274|NCT03648060|DEVICE|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
48138189|NCT04638738|DEVICE|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
48138190|NCT00764582|DRUG|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
48138191|NCT00764582|DRUG|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
48138192|NCT04510324|OTHER|Red meat patties group|"1. Baseline Visit: day -7 before randomization~* Clinical history~* Refrain from seafood, eggs, fish or meat, for 7-day (washout) prior to Day 1. 2. Day 1 Randomization~* Randomization to 1 of 2 interventions: plant-based or meat burgers~* 6 days-worth of burgers will be delivered to the participant's house 3. Day 1-6:~* The participant will be asked to eat a specific randomized diet for 6 days 5. Days 7~* Physical exam (weight, BP, HR)~* Food questionnaire~* Blood draw: Circulating TMAO, Total, LDL, and HDL cholesterol, Creatinine, High-sensitivity c-reactive protein~* Urine Collection - TMAO 6. Day 7-14: Washout 7. Day 14: Patties delivery 8. Day 14-20: Assigned diet for 6 days 9. Days 20: Same as day 7"
48138193|NCT04510324|OTHER|Plant-based patties group|Same as above
48138194|NCT00570999|DRUG|Palifermin|60 mg/kg/day
48349334|NCT05525286|DRUG|SOT102|SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
48349335|NCT00598806|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
48349336|NCT00598806|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
47984275|NCT05773287|BEHAVIORAL|Targeted Health Coaching Group|Participants in the THC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will partake in 6 virtual or in-person health coaching sessions lasting approximately 30-60 minutes in duration. These sessions will take place approximately every other week during the 3-month intervention period.
47984276|NCT05773287|BEHAVIORAL|Standard Care Group|Participants in the SC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will be provided with a single virtual or in-person education session, lasting approximately 30 minutes, at the beginning of the 3-month intervention period.
47984277|NCT01190709|PROCEDURE|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
47984278|NCT01190709|PROCEDURE|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
47984279|NCT06321965|OTHER|evaluation of muscle function|Myogrip (≥ 6 years): precise dynamometric measurement of gripping force, measuring force in Newton up to 90kg with 0.01kg resolution. It's evaluated at D0, M6, M12, M18, and M24 Myopinch (≥ 6 years) : measure thumb-index force up to 15 kg with a resolution of 0.001 kg using a precision sensor equipped with two steel distance blades. It's evaluated at D0, M6, M12, M18, and M24
47984280|NCT06321965|OTHER|First-line cognitive assessment|"Vineland-II (All patients) : is a scale for assessing adaptive behaviors. will be carried out during the telephone call at M1/V2.~All tests are evaluated at D0, and M18 :~Bayley-4 language part (\< 42 months) PVSE (≥ 4 years) CELF-5 (≥ 5 years) Conners-3 (≥ 6 years) AQ (≥ 4 years), EQ (≥ 11 years)~M-CHAT-R (\< 4 years) :~SRS-2 (≥ 2 years)"
48138195|NCT00570999|OTHER|Placebo|1,2 mL once daily
48138196|NCT06002035|DIETARY_SUPPLEMENT|Binom Vitamin D drops|Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added
48138197|NCT01827839|BIOLOGICAL|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
48138198|NCT00989742|DRUG|Doxycycline|50mg od
48349337|NCT00598806|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
48138199|NCT00989742|DRUG|Placebo|50mg od
48349338|NCT03122249|BEHAVIORAL|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
48349339|NCT02128958|DRUG|CF102|orally q12h
48349340|NCT02128958|DRUG|Placebo|orally q12 hours
48502509|NCT05700370|DIAGNOSTIC_TEST|MyProstateScore|MyProstateScore is a urine-based biomarker test used to predict the risk of clinically significant prostate cancer
48349341|NCT05725161|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
48659721|NCT05336695|DIAGNOSTIC_TEST|PET/MR Imaging|PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
48659722|NCT05336695|DRUG|64Cu-FBP8|Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
48659723|NCT02160431|BEHAVIORAL|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
48659724|NCT06399224|DEVICE|Local Plantar vibrator|A vibrating device that applies 80 hz vibration waves applied on the sole of the foot
47984281|NCT06321965|OTHER|second-line cognitive assessment|"In the event of positive cognitive screening at D0 or M18, a second-line cognitive assessment will be carried out at a subsequent visit. A list of tests is proposed below, but will be adapted according to the tests available at each center.~* EVALO BB (0-2 years) or EVALO (2-6 years) or full CELF-5 (5-18 years) following positive screening in the communication domain of first-line tests (Vineland II communication domain, Bayley 4, CELF-5 pragmatic profile)~* FEE and DSM-5 diagnostic criteria for ADHD (from age 6 only) following positive screening in the attention and executive functions domain of first-line tests (Conners 3, BRIEF)~* M-CHAT-R/F (\< 4 years) or SCQ (≥ 4 years) and ADOS-2 (≥ 12 years) following a positive screening in the area of social cognition and autistic traits on first-line tests (Vineland II, M-CHAT-R, SRS-2, EQ, AQ)."
47984282|NCT06321965|OTHER|Cardiac evaluation|"All tests are evaluated at D0, M12, and M24 :~Electrocardiogram (ECG) : This examination will be carried out in accordance with the 12 leads recording the following parameters: verification of sinus rhythm, P wave, PR interval, QRS complex (interval), ST segment, T wave, QT complex, heart rate.~Cardiac ultrasound: Non-invasive ultrasound will focus on the following parameters measured from 2-dimensional images, to look for cardiomyopathy and/or structural abnormality:~* end-diastolic/end-systolic diameter/left ventricular ejection fraction~* Septal wall thickness / left ventricular posterior wall~* Fractional shortening 24-hour Holter-ECG : This examination consists of a continuous test recording the heart rhythm for 24 hours."
47984283|NCT06321965|RADIATION|MRI|"Cerebral MRI : Performed at D0, only for patients with ASI type 1 ≥ 6 years, or younger patients for whom the investigator considers that the examination can be performed without sedation or general anesthesia. It will include sequences:~* 3D T1, gradient echo, 1.1 mm voxel, sagittal acquisition~* axial T2, spin-echo, slice thickness 4 mm~* 3D FLAIR, spin-echo, 1 mm voxel, sagittal acquisition Muscular MRI: performed at V1/J0, and V6/M24. The examination will include water-fat imaging (Dixon) in full-body, 3D mode, with proton density weighting and millimeter resolution."
47984284|NCT06321965|OTHER|Assessment of activity and muscle fatigue|"Syde® : evaluated at D0, M6, M12, M24. Patients aged 2 and over will receive the Syde® wearable device to collect their daily activities.~Muscular endurance tests (≥ 6 years) : evaluated at D0, M12, M24 ( only one of 3 tests based on motor function level) oESNHPT : In this test, patients are asked to walk a 10-meter path. oESBBT : In this test, patients have to move 10 blocks over a partition. oESWT: In this test, patients must repeatedly place and remove 9 sticks in 9 holes.~PedsQL Fatigue (≥ 2 years): evaluated at D0, M12, M24. Scale designed to measure fatigue in patients with acute and chronic conditions, as well as in healthy school and community populations.~Fatigue rating scale (≥ 6 years): evaluated at D0, M12, M24. The fatigue assessment scale has 11 numerical points ranging from 0 to 10. The patient is asked to give a rating that best reflects his or her perception of fatigue at that particular moment."
47984285|NCT06321965|OTHER|Assessment of bulbar function|"DDD-pNMD (≥ 2 years) : evaluated at D0, M6, M12, M18, and M24, is a list of 9 questions used by doctors to screen for dysphagia and dysarthria.~NdSSS (All Patients) : evaluated at D0, M6, M12, M18, and M24, is an 8-level scale for assessing swallowing.~TOMASS-c : (≥ 4 years of age, in patients able to eat solids safely, after assessment of the risk of a false route by the speech therapist): this is a score designed to assess mastication when eating a cracker. Age-dependent standards exist for different types of cracker.~- Fluid intake test (\> 110 cm, in patients able to drink a liquid safely, after assessment of the risk of a false route by the speech therapist): swallowing limit."
47984286|NCT06321965|OTHER|Evaluation of body composition and metabolism|"Food survey : The dietary survey questionnaire will be sent to parents at D0 and M18. Parents will be asked to complete it for 3 days before the M6 and M24.~Bioelectrical impedancemetry: Evaluated at M6 and M24. Renal ultrasound: Evaluated at M6, is a non-invasive examination that analyzes the appearance of the kidney and urinary tract.~Dual-energy X-ray absorptiometry (DXA) : Evaluated at M6, it measures body composition using spectral imaging, including fat mass, lean mass and bone mineral density.~Fibroscan : Evaluated at M6 and M24. This examination uses pulse elastography to measure liver elasticity, which provides information on the presence of hepatic fibrosis, and sound attenuation, which provides information on the presence of liver fat overload.~Indirect calorimetry : Evaluated at M6. This device enables precise measurement of Resting Energy Expenditure , Respiratory Quotient and metabolic substrate oxidation."
48349342|NCT05725161|BEHAVIORAL|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
48349343|NCT00290303|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
48349344|NCT06446895|DIAGNOSTIC_TEST|Coronariography|Patients were classified as MICAD or MINOCA by the presence or absence of an epicardial vessel with ≥50% stenosis after performing a coronariography.
48349345|NCT03175250|BEHAVIORAL|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
48502510|NCT02480868|DEVICE|ARTEBONE|4,3 g Bone Void Filler
48659725|NCT06399224|OTHER|Otago exercise|Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down
48659726|NCT01464606|DRUG|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
48659727|NCT01464606|DRUG|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
48659728|NCT01464606|DRUG|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
48659729|NCT01464606|DRUG|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
48659730|NCT01464606|DRUG|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
48659731|NCT00189475|DRUG|Montelukast|
48659732|NCT00189475|DRUG|Placebo|
48138200|NCT05099419|DEVICE|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
48138201|NCT01747304|DEVICE|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
48138202|NCT03941106|DEVICE|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
47984287|NCT06321965|OTHER|Questionnaires|"SMAIS : The questionnaire has been developed specifically for ASI. At D0, M6, M12, M18 and M24.~HUI2 : specializes in preference-based measures of health-related quality of life. At D0, M6, M12, M18 and M24.~Peds QL : is a modular instrument designed to measure health-related quality of life and disease-specific symptoms. At D0, M6, M12, M18 and M24.~Neuromuscular module : 17 disease-related items. It is evaluated at D0, M6, M12, M18 and M24.~Family impact module : It measures parents' reported physical, emotional, social and cognitive functioning, communication and concerns. At D0, M12, and M24.~ASI cost questionnaire: At visit 1 (D0): This questionnaire, completed by the parents, includes information on occupation, parents' working hours and any reduction in them due to the child's pathology, the number of working days missed by the parents or school days missed by the child, and disability-related costs."
47984288|NCT06321965|BIOLOGICAL|Biocollection|"A blood bio collection (optional) will be offered to patients at D0, M6 , M12, M18, M24.~Patients receiving intrathecal injections will also be offered the opportunity to participate in a CSF (cerebrospinal fluid) biocollection (optional)."
47984289|NCT06321965|OTHER|Skinfold measurement|The tricipital point should be marked on the posterior aspect of the arm, on the midline of the tricipital muscle, midway between the acromion and the radius. At D0, M6, M12, M18 and M24
47984290|NCT04411589|DEVICE|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
47984291|NCT04411589|DEVICE|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
47984292|NCT03258190|DRUG|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
47984293|NCT03992820|DEVICE|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
47984294|NCT03992820|COMBINATION_PRODUCT|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
47984295|NCT00332033|DRUG|Pirfenidone|
47984296|NCT04493281|DRUG|MT-1186|Oral suspension
47984297|NCT04493281|DRUG|MCI-186|Intravenous formulation
47984298|NCT01988857|BIOLOGICAL|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
47984299|NCT03443440|OTHER|Neurocognitive Testing|neurocognitive testing, computerized
47984300|NCT04053959|DRUG|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
47984301|NCT04053959|DRUG|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
47984302|NCT00221754|DRUG|Pravastatin (drug)|
48002545|NCT03662438|OTHER|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
48138203|NCT02824198|BIOLOGICAL|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
48138204|NCT02824198|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
48138205|NCT06153745|DEVICE|Tecnis Eyhance ICB00 intraocular lens (Johnson&Johnson Vision, Santa Ana, California USA)|pediatric cataract surgery
48349346|NCT03175250|BEHAVIORAL|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
48349347|NCT03175250|BEHAVIORAL|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
48349348|NCT03405974|DRUG|Aspirin|Aspirin (acetylsalicylic acid)
48138206|NCT00502294|DRUG|Visilizumab (HuM291; Nuvion®)|
48138207|NCT01020266|PROCEDURE|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
48349349|NCT03405974|DRUG|Placebo|Placebo
48349350|NCT03675594|DEVICE|CAD/CAM titanium denture base|metallic denture base made of titanium
48349351|NCT03675594|DEVICE|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
48349352|NCT04724772|DRUG|Tranexamic acid injection|Injection of tranexamic acid preoperatively
47984303|NCT06124612|DIAGNOSTIC_TEST|Thrombotic assessment|"GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)"
47984304|NCT03359447|DRUG|Weekly Ferrous Sulfate|Drops
47984305|NCT03359447|DRUG|Daily Ferrous Sulfate|Drops
48502511|NCT04460508|DRUG|Pegylated rhG-CSF|Pegylated rhG-CSF:6mg
48502512|NCT04460508|DRUG|rhG-CSF|rhG-CSF:5ug/kg/d
47984308|NCT02867189|OTHER|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
47984309|NCT00791466|DIETARY_SUPPLEMENT|Placebo|Daily placebo supplementation from enrolment \<14 wk of gestation until delivery
47984310|NCT00791466|DIETARY_SUPPLEMENT|Iodine|Daily supplementation with 200 µg iodine from enrolment \<14 wk of gestation until delivery
47984311|NCT03184415|DRUG|DWC20155|tablet
47984312|NCT03184415|DRUG|DWC20156|tablet
47984313|NCT03184415|DRUG|placebo of DWC20155|tablet
47984314|NCT03184415|DRUG|placebo of DWC20156|tablet
47984315|NCT06455371|OTHER|Decision support tool|Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.
47984316|NCT03108027|DRUG|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
47984317|NCT03108027|DRUG|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
47984318|NCT03108027|DRUG|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
48349353|NCT02257060|PROCEDURE|Endocardial Ablation|
48349354|NCT00176878|PROCEDURE|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10\^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10\^9/kg.
47984319|NCT03218033|BEHAVIORAL|Social Media|
47984320|NCT03913793|OTHER|Exercise based-cardiac rehabilitation (EB-CR) program|The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
47984321|NCT04573907|DRUG|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
47984322|NCT04573907|DRUG|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
47984323|NCT02670954|DRUG|Dexmedetomidine, tramadol and flurbiprofen|
47984324|NCT02670954|DRUG|tramadol and flurbiprofen|
47984325|NCT03635957|BIOLOGICAL|Pegloticase|pegloticase administered intravenously (IV)
48138208|NCT01020266|PROCEDURE|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
48349355|NCT00176878|DRUG|Fludarabine monophosphate|fludarabine 175 mg/m\^2 (total) on Days -6 through -3.
48349356|NCT00176878|PROCEDURE|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
48349357|NCT00176878|DRUG|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
48349358|NCT00176878|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
48502513|NCT01140503|DRUG|Apremilast|Apremilast 20mg PO BID
48502514|NCT00788320|DRUG|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
48502515|NCT00788320|DRUG|Placebo|Placebo three times a week for 8 weeks
48659733|NCT00633685|DRUG|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
48659734|NCT00633685|DRUG|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
48659735|NCT05246566|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
48659736|NCT00913822|DRUG|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
48659737|NCT00913822|DRUG|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
48659738|NCT05405270|DRUG|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
48349359|NCT05203328|DEVICE|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
48349360|NCT05203328|DEVICE|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
48349361|NCT04372979|DRUG|Transfusion of SARS-CoV-2 Convalescent Plasma.|2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
48502516|NCT01774552|DEVICE|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
48502517|NCT05082792|DIAGNOSTIC_TEST|doppler ultrasound|"Doppler ultrasound evaluation of AVF:~* pre-operative evaluation: venous system (patency of central veins and deep venous system, patency of superficial veins, the latter diameter, depth form skin surface, distance from nearby artery, any sizable adjacent tributaries), and arterial system including morphological evaluation (course, diameter, wall alterations, any stenoocclusive disorders) and functional evaluation (flow volume and ability to dilate)~* post-operative evaluation: anastomotic site (type of anastomosis, patency, diameter, PSV and any other morphologic alterations), inflow afferent artery (diameter, PSV and flow volume), outflow efferent vein (patency, diameter, color flow, spectral waveform)~* the first post-operative sonographic evaluation will be done after removal of stiches from the wound and periodic monitoring every one week up until completion of 6 weeks"
47984326|NCT03635957|DRUG|Methotrexate (MTX)|oral MTX
48349362|NCT04372979|DRUG|Transfusion of standard Plasma.|2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
48349363|NCT02840734|OTHER|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
48349364|NCT02482792|OTHER|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
48349365|NCT02482792|OTHER|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
48349366|NCT04131244|PROCEDURE|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
48349367|NCT06188728|DIETARY_SUPPLEMENT|effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner|comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers
48349368|NCT06188728|BEHAVIORAL|Effect of life style modification (Diet, Behavior and physical activity)|To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers
47984327|NCT03635957|DRUG|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
47984328|NCT03635957|DRUG|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
48349369|NCT06188728|COMBINATION_PRODUCT|Combined effect of 10 gm Psyllium husk fiber and lifestyle modification|To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers
48349370|NCT06188728|OTHER|Control|No intervention
48349371|NCT05232292|BIOLOGICAL|Ultrix Quadri|vaccination by Ultrix Quadri against flu
48349372|NCT04732780|OTHER|No intervention|No intervention
48349373|NCT03998891|OTHER|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
48349374|NCT05315973|DEVICE|Testing sensor vs glucometer|Will test accuracy of this sensor; there will be no intervention.
48659739|NCT05405270|DIAGNOSTIC_TEST|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
48659740|NCT05405270|OTHER|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
48659741|NCT05405270|DIAGNOSTIC_TEST|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
48659742|NCT00216190|DRUG|Dexmedetomidine HCL Injection|
48659743|NCT00216190|DRUG|Midazolam Injection|
47984329|NCT03635957|DIETARY_SUPPLEMENT|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
47984330|NCT01147029|DRUG|angiogenesis inhibitor GSAO|
47984331|NCT01147029|OTHER|laboratory biomarker analysis|
48659744|NCT02697448|DRUG|propofol|Participant receives propofol as anesthetic for cardiac ablation.
48659745|NCT02697448|DRUG|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
48659746|NCT05857241|DIETARY_SUPPLEMENT|Fasting mimicking diet (FMD)|"D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period."
48138209|NCT02401711|BEHAVIORAL|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
48138210|NCT02401711|BEHAVIORAL|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
48659747|NCT02290912|BEHAVIORAL|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
48659748|NCT00899301|OTHER|biologic sample preservation procedure|Tissue, urine and blood collection.
48659749|NCT05923723|OTHER|FIBNUTRITION|"The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant)."
48659750|NCT05923723|OTHER|Placebo|The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
47984332|NCT01147029|OTHER|pharmacological study|
47984333|NCT01147029|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
47984334|NCT00006903|DRUG|Fulvestrant|Given intramuscularly
47984335|NCT00934154|DRUG|Thalidomide|100 mg/day continuously for 12 months
47984336|NCT00934154|DRUG|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
47984337|NCT05132829|DRUG|Azithromycin 1 gram IV|Perioperative addition of azithromycin at the time of physical exam indicated cerclage placement.
48138211|NCT02401711|BEHAVIORAL|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
48659751|NCT06183970|DEVICE|AssistI patients|The AsistI software package rehabilitation involves tailored upper limb exercises under an individual program. The regimen consists of 10-12 sessions, each lasting 30 minutes. Patients execute 10 exercises sequentially with their unaffected and affected limbs, involving tasks like touching mouth, forehead, and trunk parts with hand's brush, and amplitude movements in upper limb joints. AsistI assesses exercise accuracy, prevents unfavorable patterns, and logs target achievement, considering speed, accuracy, and repetitions.
48659752|NCT06183970|DEVICE|Habilect patients|The Habilect rehab program involves 10-12 sessions using software and hardware. Patients perform upper limb exercises for 30 minutes individually, focusing on specific movements. They repeat 10 exercises, first with the healthy limb, then the affected one. Tasks include touching mouth, forehead, and trunk, along with joint movements like shoulder flexion. Habilect assesses exercise accuracy, preventing wrong moves, and tracks progress, considering speed, accuracy, repetitions.
47984338|NCT05132829|DRUG|Cefazolin and indomethacin|Perioperative standard of care with cefazolin and indomethacin
47984339|NCT00180414|DEVICE|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
47984340|NCT01516814|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
47984341|NCT01516814|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
47984342|NCT01516814|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
47984343|NCT03344432|DIAGNOSTIC_TEST|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
47984344|NCT03344432|DIAGNOSTIC_TEST|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
47984345|NCT01265732|DRUG|PF-04191834|single dose, 100mg, dispersion
47984346|NCT01265732|DRUG|PF-04191834|single dose, 100mg, suspension
47984347|NCT01265732|DRUG|PF-04191834|single dose, 300mg, suspension
47984348|NCT01914744|DRUG|Entecavir|entecavir 0.5 mg/day PO
47984349|NCT01914744|DRUG|Lamivudine|lamivudine 100 mg/day PO
47984350|NCT03186833|OTHER|no intervention|no intervention
47984351|NCT02389088|DRUG|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
47984352|NCT05332340|DRUG|BZ371A|Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
48502518|NCT02739945|PROCEDURE|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
48502519|NCT02149329|DRUG|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
48502520|NCT03619681|DRUG|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
48502521|NCT05658978|OTHER|Neuromuscular training|Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
48502522|NCT05658978|OTHER|Control group|The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
48502523|NCT01581866|DRUG|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
48502524|NCT00093119|DRUG|ABI-007|
48502525|NCT05284487|DEVICE|Jalosome® soothing gel|Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.
48502526|NCT05284487|DEVICE|Placebo|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
48502527|NCT03767335|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle
48502528|NCT03767335|DRUG|Trastuzumab|Trastuzumab solution for infusion administered weekly via IV
48502529|NCT03767335|DRUG|Fulvestrant|Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
48502530|NCT01377987|DRUG|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
48659753|NCT05706740|OTHER|Physician survey on antithrombotic medication during end-of-life care in cancer patients|"Participating healthcare professionals will be asked to complete the survey electronically within seven days. The survey will consist of general questions (i.e., Have you ever considered deprescribing antithrombotic medicine?), a discrete choice experiment (DCE), and questions involving actual decision-making in patients.~For the DCE, participants will be presented a sequence of choice sets with (hypothetical) scenarios that vary along several characteristics (attributes; e.g., bleeding risk, thrombotic risk). Attributes will be further specified by varying choice levels (attribute levels; e.g., low or high bleeding risk). Participants will be asked to select the healthcare intervention with the highest benefit for the patient according to their opinion.~Finally, participants will be asked to describe actual decisions they made in max. three consecutive patients with active cancer, who were considered to receive end-of-life care."
48138212|NCT04661306|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
48138213|NCT05657470|DRUG|Tenecteplase|intra-arterial tenecteplase
48138214|NCT03293238|PROCEDURE|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
48138215|NCT03293238|PROCEDURE|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
48502531|NCT01377987|DRUG|Placebo|4 mg/kg, once daily before bed, for 7 days
48502532|NCT01830894|DEVICE|MRI|3 MRI on different times during the study for each arm.
48502533|NCT00711438|BEHAVIORAL|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
48502534|NCT00711438|BEHAVIORAL|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
48502535|NCT05545358|OTHER|Questionnaires|Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)
48502536|NCT05545358|DEVICE|Brain and Spinal Cord functional Magnetic Resonance Imaging|Brain and Spinal Cord functional Magnetic Resonance Imaging
48502537|NCT05545358|OTHER|Proprioceptive training|Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
48502538|NCT04699851|BEHAVIORAL|Tailored recommendations|Tailored informations delivered by email about health prevention behavior in a pandemic based on the answers in the survey.
48659754|NCT03955978|DRUG|TSR-042|-TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
48659755|NCT03955978|RADIATION|Brachytherapy|-This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
48502539|NCT04699851|BEHAVIORAL|General recommendation|The control group will receive general recommendations by email about health prevention in a pandemic.
47984353|NCT05527145|PROCEDURE|Minimally invasive surgery|Surgery with decompression. Central decompression of the stenotic segment with undercutting of the lateral recesses.
48502540|NCT01190553|DRUG|Amantadine|Initiation: IV amantadine 200mg/500ml \* 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
47984354|NCT05527145|PROCEDURE|Percutaneous Spacer|percutaneous image guided outpatient procedure that enables interspinous spacer insertion and fusion
48502541|NCT04626453|BEHAVIORAL|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
47984355|NCT05608109|BEHAVIORAL|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
48502542|NCT04345601|BIOLOGICAL|Mesenchymal Stromal Cells|Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10\^8 MSCs.
47984356|NCT05608109|BEHAVIORAL|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
48502543|NCT04345601|OTHER|Supportive Care|Patients will receive supportive care per their treating physician
48659756|NCT03955978|PROCEDURE|Endometrial biopsy|-Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 4 of brachytherapy
48138216|NCT03293238|PROCEDURE|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
48659757|NCT03955978|PROCEDURE|Blood draw for immune response|-Prior to the start of any treatment, at the time of brachytherapy fractions 1 and 4 (corresponding to endometrial biopsy), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
47984357|NCT05548166|OTHER|Interview and scale development|Interview and scale development
47984358|NCT00513474|DRUG|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
47984359|NCT00513474|DRUG|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
47984360|NCT00513474|DRUG|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
47984361|NCT00513474|DRUG|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
48138217|NCT03293238|PROCEDURE|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
48138218|NCT04748341|OTHER|Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)|"The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed."
48659758|NCT05817357|DEVICE|Rensair Compact air purifier unit|Installation of Rensair Compact air purifier (Rensair Ltd.) in the homes of children/young people participating in this study
47984362|NCT00513474|DRUG|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
47984363|NCT00513474|DRUG|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
47984364|NCT00513474|DRUG|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
47984365|NCT00513474|DRUG|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
47984366|NCT00513474|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
47984367|NCT00513474|PROCEDURE|peripheral blood stem cell transplantation|
47984368|NCT00513474|RADIATION|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
48659759|NCT06634784|OTHER|Bone Conduction Implant (BCI)|Improvement in hearing using BCI.
47984369|NCT00513474|DRUG|fludarabine|Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
48659760|NCT01763762|BEHAVIORAL|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
48659761|NCT01763762|BEHAVIORAL|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
48659762|NCT01763762|BEHAVIORAL|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
48659763|NCT04417985|DEVICE|18F-FDG PET/CT, MRI|
48659764|NCT04855890|PROCEDURE|Ablation|The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.
48659765|NCT06037811|DRUG|Adalimumab|Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
48349375|NCT02968966|OTHER|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
47984370|NCT00513474|DRUG|allopurinol|Allopurinol per institutional guidelines
47984371|NCT06141590|DRUG|administration of UI068|Test
48502544|NCT04142892|DRUG|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
48502545|NCT05149677|BEHAVIORAL|Music therapy|Music therapy intervention + Standard of Care for labor pain
48502546|NCT01750489|DEVICE|non-invasive ventilation (NIV)|
48502547|NCT06195488|PROCEDURE|Gastric ultrasound|performing gastric ultrasound to determine gastric contents
48502548|NCT03240835|DRUG|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
48502549|NCT03240835|RADIATION|IMRT|intensity modulation radiation therapy
47984372|NCT06141590|DRUG|administration of UIC202205, UIC202206|Reference
48138219|NCT04748341|OTHER|Traditional Method|"The traditional method group learns through 2-step method.~1. didactic lectures on neonatal resuscitation were delivered.~2. Practice skill on mannequins"
48138220|NCT03387826|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
48138221|NCT03387826|DRUG|Prasugrel 5mg|Prasugrel 5 mg once daily
48138222|NCT03611088|OTHER|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
48349376|NCT01207804|DEVICE|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
48349377|NCT03631394|OTHER|beetroot and anthocyanin|Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
48349378|NCT03631394|OTHER|beetroot and placebo|Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
48349379|NCT02597686|BEHAVIORAL|SD-PB training|
47984373|NCT01626560|DRUG|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
47984374|NCT01626560|DRUG|Vancomycin|Vancomycin 1g q12h 10 - 14 days
47984375|NCT05875090|DIAGNOSTIC_TEST|Glaucoma Screening|Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
47984376|NCT01641692|DRUG|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
47984377|NCT01641692|PROCEDURE|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
48138223|NCT03642834|DRUG|ICP-105|25mg, 100mg capsule
48349380|NCT02444806|OTHER|Full polysomnography|Full sleep and respiratory monitoring with EEG
48502550|NCT02135835|DRUG|Shenfu Zhusheye|
48502551|NCT02135835|DRUG|5% glucose injection|
48502552|NCT02083718|BIOLOGICAL|PBSC|
48502553|NCT02083718|BIOLOGICAL|MSCs|
48502554|NCT02799368|DRUG|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
48502555|NCT02799368|DRUG|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
48502556|NCT01399567|BEHAVIORAL|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
48502557|NCT00070096|DRUG|ixabepilone|
48659766|NCT06037811|DRUG|Prednisone|Prednisone as per standard of care.
47984378|NCT01641692|DRUG|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
47984379|NCT01518166|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
48138224|NCT03771066|BEHAVIORAL|bisphenol A|Vanilla wafer cookie with bisphenol A administered
48138225|NCT03771066|BEHAVIORAL|Placebo|Vanilla wafer cookie with no bisphenol A
48138226|NCT03261466|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
47984380|NCT01518166|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
48349381|NCT02444806|OTHER|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
48349382|NCT05321589|OTHER|impression techniques for implant used for maxillary screw retained hybrid prosthesis|"conventional splinted open tray impression technique was done for maxillary implants to fabricate screw retained hybrid prosthesis and digital intra oral impression was done for the same patients after screwing scan bodies to the implants intra orally.~evaluation of accuracy and 3D deviation between the two techniques was done"
48349383|NCT04052412|DRUG|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
48502558|NCT04286711|DRUG|Albumin-paclitaxel, Apatinib, Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
48502559|NCT04067986|DRUG|Camrelizumab|"Camrelizumab One course will last 28 days.Intravenous injection at a dose of 200 mg, q2w~One course will last 28 days. Oral administration at a dose of 250 mg/d"
48349384|NCT01879475|DEVICE|032-11|Topical haemostat
48502560|NCT04067986|DRUG|Apatinib|Apatinib One course will last 28 days.Oral administration at a dose of 250 mg, qd
48349385|NCT01879475|DEVICE|Floseal (R)|Topical haemostat
48502561|NCT01021059|BIOLOGICAL|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
48502562|NCT02516943|OTHER|Control|The patient's ABGs were test according to a 4 - hour routine
48502563|NCT02516943|OTHER|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
48502564|NCT00785460|DRUG|Benfotiamine|
48502565|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.once a week，for a total of six times.
48502566|NCT06117878|DRUG|NK510|NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
48659767|NCT05229614|RADIATION|Carbon Ion Therapy|After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy\[RBE\], 8 Gy\[RBE\]/fraction, one fraction/day, for 3 days.
48659768|NCT05229614|DRUG|Immunotherapy (Pembrolizumab)|Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
48659769|NCT04218981|DRUG|Antipsychotic drugs|Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
48659770|NCT04218981|DRUG|Mood stabilizer|Choose lithium or valproate for bipolar disorder group
48659771|NCT04218981|DRUG|Paroxetine|Patients with major depressive disorder are treated with paroxetine
48659772|NCT00726583|DRUG|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
48659773|NCT04992130|BEHAVIORAL|Pre-season supplementary neurologic training program|A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
48659774|NCT05703763|DIAGNOSTIC_TEST|Applanation tonometry|"Applanation tonometry will be used to measure arterial stiffness in these segments, bilaterally:~* Superficial temporal artery to frontal temporal artery~* Common carotid artery to frontal temporal artery"
48349386|NCT02168660|DRUG|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
48502567|NCT01401556|OTHER|case management|
48502568|NCT01401556|OTHER|Multifaceted quality improvement intervention|
48659775|NCT05703763|DIAGNOSTIC_TEST|Standardized GCA assessment|Clinical assessment, blood test review, high-resolution temporal artery ultrasound using a 24mHz probe.
48659776|NCT01269775|OTHER|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
47984381|NCT01518166|DRUG|atorvastatin|One single dose of 40 mg. Tablet
47984382|NCT01518166|DRUG|lisinopril|One single dose of 20 mg. Tablet
47984383|NCT01518166|DRUG|griseofulvin|One single dose of 500 mg. Tablet
47984384|NCT01518166|DRUG|digoxin|One single dose of 1 mg. Tablet
48138227|NCT03261466|DRUG|Placebos|
48138228|NCT05364840|DRUG|STI-1558|Orally available protease inhibitor capsule
48138229|NCT05364840|DRUG|Placebo|Placebo product capsule
48138230|NCT06061900|OTHER|Group exercise program|Group fitness program
48138231|NCT02397707|DRUG|Voxilaprevir|100 mg tablet administered orally
48138232|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0 and receive placebo at week4,8,12
48138233|NCT06509334|DRUG|JYB1904|Participants will receive JYB1904 at week0,8 and receive placebo at week4,12
48502569|NCT00069511|DRUG|UT-231B|
48138234|NCT06509334|DRUG|Omalizumab|Participants will receive Omalizumab every 4 weeks for 12 weeks
48349387|NCT01660646|BEHAVIORAL|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
48659777|NCT05525390|BEHAVIORAL|Extended Reality-Enhanced Behavioral Activation|"Participants will choose at least four activities to complete in Oculus extended reality over the course of the week. These activities are chosen from the Oculus and may include video 360, social interactions, gaming, etc."
48659778|NCT05525390|BEHAVIORAL|Traditional Behavioral Activation|Participants will choose at least four pleasurable and/or mastery activities to complete over the course of the week in real life.
48659779|NCT06523166|PROCEDURE|Transesophageal echocardiography (TEE)|TEE will be performed using a 3D probe. TEE images will be acquired at the standard 0, 45, 90, and 135 degree views along with a 3D acquisition encompassing the entire LAA, device, left pulmonary vein and lateral mitral annular landmarks.
48659780|NCT06523166|PROCEDURE|Cardiac CTA|Cardiac CTA will be performed with ECG gating using systems with ≥ 64 detector rows and with temporal resolution that is at least 175 msec (rotation speed ≤ 350 msec for single source systems). Cardiac CTA images will be acquired for the entire cardiac cycle without ECG phase specific pulsing and with contrast appropriately timed for peak left atrial/arterial phase contrast enhancement. In addition, a targeted end systolic only delayed phase image set (45 seconds after the arterial phase scan and limited to the left atrium and appendage device) will be acquired.
47984385|NCT04954781|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
47984386|NCT04954781|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
47984387|NCT01500629|DEVICE|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
47984388|NCT01500629|DEVICE|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
47984389|NCT04734223|DIAGNOSTIC_TEST|Neuroimaging Findings in Patients With COVID-19|MR and BT Imaging
47984390|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
47984391|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
47984392|NCT05069454|BIOLOGICAL|COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine|To measure the effectiveness of COVID-19 vaccines against symptomatic laboratory-confirmed SARS-CoV-2 infection amongst hospital level health workers eligible for vaccination.
47984393|NCT01248377|PROCEDURE|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
47984394|NCT05036434|DRUG|Pembrolizumab / Lenvatinib|Pembrolizumab Plus Lenvatinib administration.
47984395|NCT02348541|DEVICE|CollaGUARD|
47984396|NCT05016973|DRUG|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
47984397|NCT05016973|DRUG|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
47984398|NCT06265740|OTHER|vaginal swab|Any pregnant woman attending the obstetrics department of Clermont-Ferrand University Hospital who requires a vaginal swab (VS) for her clinical situation (routine care) will be offered the study. If she accepts, the usual swab will be doubled and performed simultaneously in a single procedure using two swabs. The first swab will be sent to the laboratory and used for diagnosis. The second swab will be used for microbiota analysis.
47984399|NCT00412022|DRUG|tamoxifen|20 mg daily for 5 years
47984400|NCT00412022|DRUG|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
47984401|NCT00412022|DRUG|letrozole|2.5 mg daily for 5 years
47984402|NCT00412022|DRUG|zoledronic acid|4 mg every 6 months
47984403|NCT03963791|OTHER|Eggshell powder gel|Eggshell powder gel produced from chicken eggs.
47984404|NCT03963791|OTHER|CPP-ACP crème|A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
47984405|NCT05347550|OTHER|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
47984406|NCT06163261|OTHER|Physical activity|The intervention group will receive an individualized and person-centred prescription of physical activity and exercise.
48138235|NCT06360978|DRUG|Docetaxel|Our patients will receive docetaxel (15 mg per meter squared) once weekly concurrently with radiotherapy.
48138236|NCT00123409|BEHAVIORAL|Telephone disease management|Telephone based care management
48138237|NCT00123409|BEHAVIORAL|Usual Care|Usual care
48349388|NCT00122317|DRUG|eculizumab|
48349389|NCT02250391|DRUG|NPB-06|5 days continuous-infusion
48618245|NCT05529433|PROCEDURE|Chemo-Mechanical Caries Removal (CMCR)|Selecti-Solve gel is a dental gel which main active ingredient is Papain enzyme which selectively removes the caries without pain and has bacteriostatic, bactericidal and anti-inflammatory properties. The use of CMCR is recommended as an alternative treatment technique in anxious patients. The gel will be applied with a blunt spoon instrument and distributed well into the cavity according to manufacturer's instructions.
48349390|NCT02250391|DRUG|Placebo|5 days continuous-infusion
48349391|NCT02415829|DRUG|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
48349392|NCT06411106|DRUG|IMIQUIMOD cream 50mg/g|5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber
48138238|NCT05290090|DRUG|Rituximab, Lenalidomide, Zanubrutinib and RCHOP|"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
48138239|NCT01448941|PROCEDURE|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
48138240|NCT01448941|PROCEDURE|Primary arthrodesis|Primary arthrodesis
48138241|NCT01448941|PROCEDURE|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
48138242|NCT02824926|DRUG|Dapaconazole|
48138243|NCT02824926|DRUG|Ketoconazole|
48138244|NCT01410409|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
48138245|NCT01410409|DRUG|Paracetamol|1 g x 4/day
48138246|NCT01410409|DRUG|Burana|400 mg x 3/day for three weeks
48138247|NCT01410409|DRUG|Pantoprazol|20mg x 1/day for three weeks
48138248|NCT01410409|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
48138249|NCT01410409|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
47984407|NCT03395886|DRUG|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
48138250|NCT01410409|PROCEDURE|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
48138251|NCT01410409|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
48659781|NCT02526290|DEVICE|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
48138252|NCT03998098|DIAGNOSTIC_TEST|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
48659782|NCT05910346|BEHAVIORAL|education and counseling based on maternal role theory|Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.
48659783|NCT01204957|DIETARY_SUPPLEMENT|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
48138253|NCT03998098|DIAGNOSTIC_TEST|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
48659784|NCT01204957|DIETARY_SUPPLEMENT|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
48659785|NCT00363298|DRUG|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
48659786|NCT00363298|DRUG|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
47984408|NCT03395886|DRUG|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
47984409|NCT03499223|DRUG|Ranibizumab 0.5mg|3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
47984410|NCT03499223|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
47984411|NCT03499223|DRUG|Sham injection|3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
48138254|NCT03998098|DIAGNOSTIC_TEST|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
48138255|NCT03998098|DIAGNOSTIC_TEST|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
48138256|NCT00002281|DRUG|Filgrastim|
48138257|NCT00002281|DRUG|Epoetin alfa|
48138258|NCT00002281|DRUG|Zidovudine|
48138259|NCT01953679|DRUG|Ulipristal Acetate|
48138260|NCT01683188|DRUG|vemurafenib + HD IL-2|
48138261|NCT02224469|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
48138262|NCT02955199|BEHAVIORAL|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
48138263|NCT02955199|BEHAVIORAL|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
48138264|NCT05851014|DRUG|GB491 combined with Letrozole|Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
48138265|NCT05851014|DRUG|Placebo combined with Letrozole|Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
48659787|NCT04952714|DEVICE|Oxiris|Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
48659788|NCT03308357|DIAGNOSTIC_TEST|Drug assays to measure infliximab|See protocol
48349393|NCT05471024|PROCEDURE|Digitized Mounted Articulator Scan|Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.
48349394|NCT05471024|PROCEDURE|Average Positioning on Virtual Bonwill Triangle|"Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
48349395|NCT05471024|PROCEDURE|Digital Face Scan|"Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration."
48349396|NCT04574765|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for COVID-19
48349397|NCT04574765|OTHER|Questionnaire collection|Fill out questionnaires regarding exposures and travel history, occupation category, any symptoms in the past 21 days, any face-to-face care of a known COVID-19 positive patients in past 14 days or any children at home who are less than 12 years of age.
48349398|NCT04574765|OTHER|Optional blood completion|Provide blood samples to look for COVID-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks.
48349399|NCT04574765|OTHER|Optional questionnaire completion|Fill out an optional mental health questionnaire.
48349400|NCT00354484|DRUG|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
48349401|NCT00354484|DRUG|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
48138266|NCT03208465|DRUG|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
48138267|NCT03208465|DRUG|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
48138268|NCT05951972|OTHER|nutritional|participants will receive 2 pairs of food items to consume - pair A - Bananas and Apples, pair B - cucumbers and peanuts.
48138269|NCT03443999|DEVICE|Supraflex Family Sirolimus-eluting Coronary Stent System|Patient implanted with at least one Supraflex Family sirolimus-eluting stent as a part of planned clinical care
48138270|NCT00002866|BIOLOGICAL|filgrastim|
48138271|NCT00002866|DRUG|docetaxel|
48138272|NCT00002866|DRUG|epirubicin hydrochloride|
48138273|NCT02911961|DRUG|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
48349402|NCT03933306|DRUG|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
48349403|NCT03933306|DRUG|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
48349404|NCT03933306|OTHER|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
48349405|NCT03933306|OTHER|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure \> 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
48138274|NCT04668729|OTHER|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
48138275|NCT05456932|DRUG|Intravenous iron|Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.
48138276|NCT05456932|DRUG|Ferric maltol|Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)
48349406|NCT04447625|DRUG|Oral antibiotic administration|per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
48349407|NCT04447625|DRUG|Intrauterine antibiotic infusion|intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
48349408|NCT02839044|DIETARY_SUPPLEMENT|Menaquinone-7|
48502570|NCT03756506|DEVICE|Novel Microbicidal Liquid Polymer|The polymer is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
47984412|NCT00157950|BIOLOGICAL|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
48138277|NCT05456932|DRUG|Ferrous fumarate|Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)
48349409|NCT02839044|DIETARY_SUPPLEMENT|Placebo|
48349410|NCT00058006|DRUG|celecoxib|
48349411|NCT00058006|PROCEDURE|adjuvant therapy|
47984413|NCT00157950|BIOLOGICAL|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
47984414|NCT04461171|PROCEDURE|Enhanced Recovery After Surgery|Undergo an enhanced recovery after surgery program
47984415|NCT01891695|RADIATION|39.6 Gy radiation|
47984416|NCT05100524|OTHER|Motivational interview|The motivational interviewing technique is a client-focused, directive form of counseling to create behavior change. Its main goal is to discover and solve ambivalence. This method is especially useful for people who are reluctant or ambivalent to change.
47984417|NCT05100524|OTHER|Ongoing treatment|Patients with total knee replacement receive standard nurse care. Treatment is applied. He does his own exercises at home.
48138278|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
48349412|NCT00994760|DRUG|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
48349413|NCT02967562|OTHER|Inflation Breaths|
48349414|NCT02967562|OTHER|Sustained Inflation|
48349415|NCT04486391|DRUG|Tislelizumab|200 mg administered via intravenous (IV) infusion once every 3 weeks
48349416|NCT04486391|DRUG|Salvage Chemotherapy|Salvage chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE (dexamethasone, ifosfamide, carboplatin, etoposide), ICE (ifosfamide, carboplatin, etoposide), IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone), GVD (gemcitabine, vinorelbine, liposomal doxorubicin), and MINE (etoposide, ifosfamide, mesna, mitoxantrone)
47984418|NCT01409655|BEHAVIORAL|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
48138279|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
48138280|NCT01478594|DRUG|Tivozanib|Capsules for oral administration
48138281|NCT01478594|DRUG|Bevacizumab|Solution for intravenous infusion
48138282|NCT01478594|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
48138283|NCT03752216|DRUG|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
48138284|NCT02762201|PROCEDURE|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~* Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~* Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
48138285|NCT02762201|PROCEDURE|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
48138286|NCT00002236|DRUG|Indinavir sulfate|
48138287|NCT00002236|DRUG|Delavirdine mesylate|
48138288|NCT00002236|DRUG|Zidovudine|
48659789|NCT04641832|OTHER|Soccer heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
48138289|NCT05372224|DRUG|Cholecalciferol|4000 IU were administrated once a day for 3 months.
48138290|NCT04022421|DRUG|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
48138291|NCT00145145|BIOLOGICAL|MAGE-3.A1 peptide and CpG 7909|
48659790|NCT05671666|DIAGNOSTIC_TEST|Urea cycle flux study|Quantification of ureagenesis
48659791|NCT05356715|PROCEDURE|Ultrasound guided bilateral ESBP|Patients in group A will be positioned in the lateral position , ESPB will be done under complete aseptic conditions , using , linear ultrasound probe(Philips HD11XE Ultrasound System) , to locate the ESP at the level of the fifth dorsal vertebrae , 22 G spinal needle will be used to inject 20 ml of 0.25% of bupivacaine in the ESP bilaterally, block will done by an expert anesthesiologist , who will not be included in the data collection
48659792|NCT01312298|PROCEDURE|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
47984419|NCT06404606|COMBINATION_PRODUCT|Black cumin and turmeric with Quantum Acoustic Waves (QAW)|Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.
47984420|NCT03792867|DRUG|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
48502571|NCT00090610|DRUG|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
48659793|NCT01312298|PROCEDURE|Regional anesthesia|Patients will receive intrathecal anesthesia
48659794|NCT01598155|PROCEDURE|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
48002546|NCT03662438|DEVICE|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device \[Philips SimplyGo Mini\] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
48138292|NCT04535999|DRUG|Secukinumab Auto-Injector|300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
48138293|NCT03194516|OTHER|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
48138294|NCT04872296|DEVICE|Controlled Ankle Motion (CAM) boot|A CAM boot will be worn on the affected ankle to allow weight bearing
48138295|NCT04872296|PROCEDURE|Physical Therapy|Standard physical therapy protocol will be started at 6 weeks after surgery
48138296|NCT04812249|OTHER|Clinical assessment|Clinical assessment and follow up of oral feeding ability
48502572|NCT00090610|DRUG|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
48502573|NCT01844232|DRUG|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
48502574|NCT05445661|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
48502575|NCT05445661|OTHER|Normal Saline|Sham Comparator
47984421|NCT03711045|BEHAVIORAL|eye-tracking|"After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded."
48138297|NCT00890591|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
48138298|NCT03701906|DIETARY_SUPPLEMENT|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L.salivarius PS11603 and 1\*10E8 CFU of B.longum PS10402.
48138299|NCT03701906|DIETARY_SUPPLEMENT|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
48349417|NCT06391970|DEVICE|Cognitive screening|The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.
48349418|NCT03067051|DRUG|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
48349419|NCT03067051|DEVICE|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
48349420|NCT02300506|OTHER|No intervention|
48349421|NCT01161927|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
48349422|NCT01161927|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
48349423|NCT00674024|DRUG|Pazopanib|
48502576|NCT00802594|DRUG|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
48502577|NCT03153761|OTHER|CSD170201AA|A moist snuff product
48502578|NCT03153761|OTHER|CSD170201AB|A moist snuff product
48502579|NCT02086903|DRUG|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
48502580|NCT02086903|DRUG|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
48502581|NCT03886740|PROCEDURE|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
47984422|NCT03869866|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
47984423|NCT03474354|DEVICE|chemoembolization|correlation of necrosis with the deposition of beads
48138300|NCT04284085|OTHER|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
48138301|NCT00786864|OTHER|exercise programme|Specific low back pain exercise programme for children
48138302|NCT03975400|BEHAVIORAL|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
48138303|NCT00974805|DRUG|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
48138304|NCT03844685|DRUG|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
48138305|NCT03844685|DRUG|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
48138306|NCT05460910|OTHER|core stability exercises with treadmill|swiss ball use patient is lying in supine position with 15 repitations and 3 sets.
48138307|NCT05460910|OTHER|core stability exercise without treadmill|technique used to improve stability
48349424|NCT00674024|DRUG|Pazopanib (GW786034)(GW786034)|
48349425|NCT01099761|BIOLOGICAL|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
48349426|NCT01099761|BIOLOGICAL|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
48349427|NCT01099761|OTHER|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
48349428|NCT04699240|DRUG|clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
48349429|NCT04699240|DRUG|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
48349430|NCT03084432|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
48502582|NCT02584400|DRUG|Injection with the hypoxia tracer [18F]HX4,|The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
48138308|NCT01379651|OTHER|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
48349431|NCT03424616|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
48349432|NCT04472819|DRUG|SHR2285 tablet|single dose or multi-dose
48659795|NCT01598155|PROCEDURE|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing of coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~* Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
48659796|NCT02749916|OTHER|Methods of carotid wall imaging|
47984424|NCT01727973|DRUG|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
47984425|NCT03271112|OTHER|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
47984426|NCT00751244|BEHAVIORAL|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
48349433|NCT04472819|DRUG|Placebo|single dose or multi-dose
48349434|NCT04008667|OTHER|Acupoint application|Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
48502583|NCT04428333|DRUG|Feladilimab|Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
48502584|NCT04428333|DRUG|Pembrolizumab|Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
47984427|NCT00751244|BEHAVIORAL|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
48349435|NCT04008667|OTHER|Fake acupoint application|Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
48502585|NCT04428333|DRUG|Placebo|Sterile normal saline
48502586|NCT04428333|DRUG|Platinum based chemotherapy|Cisplatin/carboplatin
48502587|NCT04428333|DRUG|Fluorouracil (5FU)|5-fluorouracil
48502588|NCT02546401|DRUG|Insulin Aspart|Injection of Insulin Aspart before or after meals
48502589|NCT03449004|OTHER|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
48502590|NCT05944614|OTHER|Magnetic Resonance imaging (MRI) examination|3D CINE and 4 dimensional (4D) flow MRI sequence
48502591|NCT04960579|BIOLOGICAL|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
48502592|NCT04960579|DRUG|Rimiducid|Safety switch activator
48618246|NCT03813108|BIOLOGICAL|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.
48618247|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
48659797|NCT06595290|OTHER|High intensity care|This arm follows a structured algorithm for initiating and uptitrating all four pillars of HFrEF oral medications post-randomization (pre-discharge) and during at least 4 visits over 6 weeks post-discharge.
48659798|NCT06595290|OTHER|Usual care|Patients will be managed by their cardiologist according to their usual practice. Follow-up appointments will be scheduled as per the cardiologist\&#39;s instructions. Participants will return to the recruiting study site for clinical outcome assessment by study investigators at 90 and 180 days post-discharge.
48659799|NCT02593630|DEVICE|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
48659800|NCT01088906|DRUG|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
48138309|NCT02219659|DRUG|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
48138310|NCT02219659|DRUG|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
48138311|NCT02219659|DRUG|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
48138312|NCT01218594|DRUG|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
48138313|NCT03126604|DIAGNOSTIC_TEST|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
48138314|NCT00000170|DRUG|Atropine|Atropine
48138315|NCT00000170|DEVICE|Eye Patch|Patching
48138316|NCT00677209|BIOLOGICAL|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
48138317|NCT00764166|DRUG|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~* To D1 of every cycle in the dose of 70 mg/m²,~* Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
48138318|NCT00764166|DRUG|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
48659801|NCT02239003|DRUG|DAOIB|
48138319|NCT03805672|DRUG|Low Dose Enoxaparin|
48138320|NCT03805672|DRUG|High Dose Enoxaparin|
48349436|NCT05006391|OTHER|Tele-Coaching (Online) Community-Based Exercise|"PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training \~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes \~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout."
48659802|NCT02239003|DRUG|Placebo|
48659803|NCT02055339|DEVICE|Fisher & Paykel heated humidified high flow nasal cannula|
48659804|NCT02055339|DEVICE|InfantFlow/RAM nasal continuous positive airway pressure|
48659805|NCT01550510|DRUG|Ascorbic Acid|3x a week for 9 weeks
48659806|NCT01550510|DRUG|Irinotecan|350mg/m2 once a week every 3 weeks
48659807|NCT06363708|DRUG|Tislelizumab|Tislelizumab 200mg D1 ,Q3W
48659808|NCT06363708|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 ) D1,Q3W
48659809|NCT06363708|DRUG|Carboplatin|Carboplatin(AUC=5) D1,Q3W
48138321|NCT05331872|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cell infusion|Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
48138322|NCT02994667|DEVICE|Permanent Pacemaker Placement|
48138323|NCT05376982|DIAGNOSTIC_TEST|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
48138324|NCT05376982|DIAGNOSTIC_TEST|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
48138325|NCT00464893|DRUG|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
48502593|NCT01120704|DRUG|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes \>10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
48349437|NCT02756741|DRUG|ALBUMIN|Albumin in two different doses
48659810|NCT03170986|BEHAVIORAL|Multisectoral agriculture and Microfinance Intervention|
48659811|NCT02443857|DEVICE|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
48659812|NCT02443857|DEVICE|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
48659813|NCT02443857|DEVICE|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
48349438|NCT00854867|DRUG|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
48349439|NCT00854867|DRUG|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
48349440|NCT05501457|DEVICE|Muscle strengthening with neuromuscular electrical stimulation|The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.
48349441|NCT05821192|DRUG|Rituximab|375mg/m2 by IV infusion once every 3 weeks
48349442|NCT05821192|DRUG|Gemcitabine|1 g/m2 on Days 1 by IV infusion once every 3 weeks
48349443|NCT05821192|DRUG|Dexamethasone|40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
48618248|NCT03813108|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
48659814|NCT02443857|DEVICE|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
48659815|NCT02443857|DEVICE|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
48659816|NCT02443857|DEVICE|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
48659817|NCT03232567|BIOLOGICAL|NasoVAX|Single ascending dose study
48659818|NCT06571682|DEVICE|Target Controlled Infusion|TCI (Target Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
48659819|NCT06571682|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
48659820|NCT00249626|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
48659821|NCT05021848|OTHER|partnered multicomponent exercises program|aerobic,strength, flexibility and balance exercises and game
48138326|NCT00464893|DRUG|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
48138327|NCT04343898|OTHER|No intervention|Observational
48138328|NCT05850793|BEHAVIORAL|Sensorimotor Exercise|Balance, perturbation , aging and strengthing exercise will be performed for knee
48138329|NCT05850793|BEHAVIORAL|Conventional Exercise|Range of motion, strengthing and stretching exercise will be performed for knee
48138330|NCT05850793|BEHAVIORAL|Progressive Motor Imagery Exercise|Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
48138331|NCT01683409|DRUG|Baricitinib|Administered orally
48138332|NCT01683409|DRUG|Placebo|Administered orally
48349444|NCT05821192|DRUG|Cisplatin|75 mg/m2 on Days 1 by IV infusion once every 3 weeks
48349445|NCT05821192|DRUG|PD-1 monoclonal antibody|200mg on Days 2 by IV infusion once every 3 weeks
48349446|NCT03965806|BEHAVIORAL|SURVEY|SURVEY
48349447|NCT05774574|DIETARY_SUPPLEMENT|Cannabidiol (CBD) supplementation|Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally
48349448|NCT05774574|DIETARY_SUPPLEMENT|Placebo supplementation|Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
48618249|NCT03813108|BIOLOGICAL|CPS-immunization (A/L)|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.
48138333|NCT06051799|OTHER|Myofascial trigger points pressure release|Patient lying down in the supine position, Therapist do a first and second finger pincer grasp is performed on the myofascial trigger points located on the upper trapezius muscle and sternocleidomastoid muscle, this pressure will be increased as the therapist perceives a reduction in soft tissue resistance under the finger over a period of 90 seconds. Previous studies indicate no difference between 60 and 90 seconds of pressure. It will be performed on as many trigger points as we find in each muscle associated with the study.
48138334|NCT06051799|OTHER|Therapeutic exercise and postural hygiene|"Therapeutic exercise and postural hygiene: A progression of exercises with contraction of the deep neck flexor muscles will be included in the first session. Subjects will be taught to perform a slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed at least once a day during the treatment regimen.~Also Postural correction exercises carried out regularly throughout the day, especially when seated. Indications are given to avoid pelvic retroversion and maintain a natural lumbar lordosis while performing retraction and adduction of the scapulae and gently lengthening the spine."
48138335|NCT03158506|DRUG|HMS5552|\[14C\]-labelled HMS5552
48138336|NCT02124356|OTHER|Evaluation of functional performance|
48138337|NCT01453959|DRUG|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
48138338|NCT01453959|OTHER|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
48349449|NCT06204510|OTHER|complex decongestive therapy|This application consists of manual lymph drainage, skin care, compression bandage and exercises. This phase will continue for 3 weeks, 5 days a week.
48349450|NCT03595189|DRUG|Cilastatin|Dose escalation 3-hour single intravenous administration
48502594|NCT01120704|DRUG|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes \>10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
48659822|NCT05678465|PROCEDURE|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
48659823|NCT05678465|PROCEDURE|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
48659824|NCT05562388|DEVICE|Somnodent Classic|The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
48659825|NCT05548283|DRUG|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
48659826|NCT05548283|DRUG|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
48659827|NCT04636073|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
48659828|NCT03032029|DEVICE|Adaptive Servo-Ventilation|Adaptive Bi-Level positive airway pressure with a targeted minute ventilation and auto-adjusting expiratory pressure level.
48659829|NCT01969214|DEVICE|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
48659830|NCT00943137|DRUG|5-Fluorouracil|"Chemotherapy will be one of the following:~1. de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~2. FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~3. Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
48659831|NCT01554904|DEVICE|Facial-Flex|Oral exercise device
48659832|NCT03868696|PROCEDURE|MUA with sham ultrasound|Standard MUA with sham ultrasound
48659833|NCT03868696|PROCEDURE|MUA with active ultrasound|Standard MUA guided by ultrasound
48659834|NCT03552029|DRUG|Quizartinib|20 or 30 mg tablets for oral administration
48138339|NCT06412094|OTHER|Standard care|Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
48138340|NCT06412094|BEHAVIORAL|"Access to the AtopicApp mobile application"|"Access to the AtopicApp mobile application with 1 day after enrollment."
48138341|NCT06412094|BEHAVIORAL|Virtual oversight through the AtopicApp|Notification of doctor's virtual oversight through the AtopicApp mobile application.
48138342|NCT04923022|OTHER|Vegan Diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
48349451|NCT03595189|DRUG|Placebo|3-hour single intravenous administration
48138343|NCT04923022|OTHER|Therapeutic exercise|Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
48138344|NCT03412266|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
48138345|NCT01566890|DRUG|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
48138346|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
48138347|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
48138348|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
48138349|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
48138350|NCT05032716|OTHER|Balance exrcises|the group (20 children) received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance. Tools of traditional physical therapy exercises were; special tools were used for traditional physical therapy exercises include vestibular board, rolls of different sizes, blocks and wedges of different heights
48138351|NCT05032716|OTHER|Balance exrcises and Treadmill training|the group (20 children) received the same traditional physical therapy program as the same applied in group of balance exercises, in addition to treadmill training (30 min). The child walked on the treadmill (motorized treadmill, ENTRED, Enraf-Nonius) at 75% of over-ground speed and individually prescribed low-endurance walking at 0% incline for 20 min, three times a week for 8 successive weeks. The walking area of the treadmill is made from heavy steel with a minimum 8-inch thickness and is available with cushioning in case of accidental impacts. Before the walking session, each child underwent 5 min of active stretching exercises that include prolonged and progressive stretching of the hamstrings, quadriceps muscles, and Achilles tendon.
48138352|NCT02634307|DRUG|ALKS 8700|Administered as specified in the treatment arm.
48138353|NCT06509022|DIAGNOSTIC_TEST|PEPTEST test|Quantitative determination of gastric salivary amylase。
48138354|NCT00528216|DRUG|Capsaicin Dermal Liquid|
48659835|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
48502595|NCT01120704|BEHAVIORAL|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
48618250|NCT03813108|DRUG|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
48618251|NCT06452550|DIAGNOSTIC_TEST|Logistic regression (LR) prediction models|Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.
48618252|NCT01492959|DRUG|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
48618253|NCT04111315|DRUG|Metamizole Sodium|Novalgin® Oblong tablets 0,5 g 2-2-2
48618254|NCT04111315|DRUG|Ibuprofen 600 mg|Ibufen-L® tablets 500 mg 2-2-2
48618255|NCT04111315|BEHAVIORAL|Patient education|Leaflet and phone call
48618256|NCT04031170|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
48618257|NCT04031170|OTHER|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
48659836|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
48659837|NCT03636022|OTHER|VR System|Use of virtual reality to deliver exposure therapy
48618258|NCT00485823|DRUG|Olanzapine Hydrochloride|
48618259|NCT00485823|PROCEDURE|Weight Management Program|
48618260|NCT02039349|DRUG|PF-05190457|
48618261|NCT04626505|DRUG|Ziltivekimab|Administered subcutaneously (s.c., under skin) once every 4 weeks for 12 weeks
48618262|NCT04626505|DRUG|Placebo (ziltivekimab)|Administered s.c. once every 4 weeks for 12 weeks
48618263|NCT06462677|DIAGNOSTIC_TEST|Babesia NAT|Blood donors will be tested with Babesia NAT
48618264|NCT01136590|DRUG|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
48618265|NCT01136590|DRUG|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
48618266|NCT03687424|DEVICE|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
48659838|NCT03636022|OTHER|Control|Use of conventional delivery of exposure therapy
47984428|NCT00751244|OTHER|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
47984429|NCT04421729|BEHAVIORAL|Group sessions over 3 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
48138355|NCT01507506|RADIATION|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
48349452|NCT00666055|DRUG|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
48502596|NCT01120704|BEHAVIORAL|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
48502597|NCT01120704|BEHAVIORAL|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
48502598|NCT01120704|BEHAVIORAL|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 \& 23."
48659839|NCT02322840|DEVICE|Twelve TMVR Implant|Implantation of the Twelve TMVR System -Apical
48659840|NCT02322840|DEVICE|Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System|Implant of Intrepid valve -Transfemoral
48659841|NCT04987814|OTHER|HD-sEMG|high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.
48659842|NCT04987814|OTHER|- Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.
48659843|NCT04987814|OTHER|IPAQ Physical Activity Questionnaire.|physical activity assessment questionnaire/adapted version for seniors
48659844|NCT04991948|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
48659845|NCT04991948|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
48659846|NCT04991948|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
48659847|NCT05501899|DRUG|Levocarnitine|Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
48659848|NCT05918354|DEVICE|Skin Prick Automated Test|Detection of sensitisation to specific allergens via the skin prick automated test.
48659849|NCT05646082|DRUG|Dostarlimab in Combination Antiretroviral Therapy|Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
48659850|NCT01174563|DRUG|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
47984430|NCT04421729|BEHAVIORAL|Group sessions over 6 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
47984431|NCT00723892|BIOLOGICAL|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week
47984432|NCT00723892|DRUG|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
47984433|NCT00723892|BEHAVIORAL|Psychotherapy support program|Each site has implemented a psychotherapy support program.
47984434|NCT03707314|PROCEDURE|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
47984435|NCT03231865|DIAGNOSTIC_TEST|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
48618267|NCT03687424|DEVICE|low-flow nasal oxygenation (LFNO)|Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
48659851|NCT06040398|BEHAVIORAL|JUMPSTART exercise program|The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
48349453|NCT00493844|OTHER|Exercise testing|Exercise testing
48349454|NCT00493844|OTHER|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
48349455|NCT03734770|DRUG|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
48349456|NCT03734770|DRUG|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
48349457|NCT02454452|PROCEDURE|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
48502599|NCT01782300|BIOLOGICAL|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
48502600|NCT01782300|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
47984436|NCT02377466|DRUG|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
47984437|NCT02377466|DRUG|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
47984438|NCT04334291|COMBINATION_PRODUCT|Observational (registry)|Observational study.
47984439|NCT00271609|DRUG|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
47984440|NCT05741008|RADIATION|Target range|Compared with conventional radiotherapy, the target dose is unchanged and the CTV2 volume is reduced.
47984441|NCT01953133|BEHAVIORAL|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
47984442|NCT05328791|BEHAVIORAL|Dietary and mindfulness intervention|"Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program"
47984443|NCT01430091|DRUG|Prasugrel (clinical formulation)|Administered orally
47984444|NCT01430091|DRUG|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
47984445|NCT02402543|DRUG|Gabapentin|
47984446|NCT02402543|DRUG|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
48349458|NCT02454452|PROCEDURE|Saphenous vein stripping|Saphenous vein stripping
48349459|NCT02454452|PROCEDURE|CHIVA|conservative hemodynamic treatment venous insufficiency
48502601|NCT03639454|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
48502602|NCT03639454|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
47984447|NCT02402543|DRUG|Acetaminophen|
47984448|NCT02402543|DRUG|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
47984449|NCT02402543|DRUG|Placebo|
47984450|NCT05168410|OTHER|Alvarado Score|The Alvarado Score assesses patient symptoms to enable optimal triage and management of cases with suspected acute appendicitis.a
48502603|NCT05224310|PROCEDURE|PECS block, SAP block|performing either PECS block or SAP block
48502604|NCT06187090|DIETARY_SUPPLEMENT|Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form|Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
48502605|NCT05183386|PROCEDURE|dental socket regeneration|after a dental extraction the fresh socket is filled with graft materials and compared with the spontaneous healing (control)
48349460|NCT05983016|DEVICE|Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA|"All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA)."
48349461|NCT03021044|OTHER|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
48349462|NCT03021044|OTHER|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
48349463|NCT02112461|BEHAVIORAL|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
48349464|NCT02645136|OTHER|Pilates|Pilates exercises
48659852|NCT01927614|RADIATION|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
48659853|NCT04277130|BEHAVIORAL|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I \& II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
48349465|NCT02645136|OTHER|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
48349466|NCT02645136|OTHER|Control|
48502606|NCT03424018|DRUG|BMN 111|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
48502607|NCT02079779|OTHER|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
48659854|NCT03999476|DEVICE|ambu ascope|nasal route intubation by the device in fixed cancer tongue patients
48659855|NCT03999476|DEVICE|fibreroptic bronchoscope|nasal route intubation by the device in fixed cancer tongue patients
48349467|NCT00486590|PROCEDURE|Prolact-Plus Human Milk Fortifier|
48349468|NCT02296229|RADIATION|stereotactic body radiation therapy|Undergo SBRT
48349469|NCT02296229|OTHER|quality-of-life assessment|Ancillary studies
48502608|NCT02079779|OTHER|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
48502609|NCT05828576|DIAGNOSTIC_TEST|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
48502610|NCT04892017|DRUG|DCC-3116|Oral Tablet Formulation
48502611|NCT04892017|DRUG|Trametinib|Oral Tablet Formulation
48502612|NCT04892017|DRUG|Binimetinib|Oral Tablet Formulation
48502613|NCT04892017|DRUG|Sotorasib|Oral Tablet Formulation
48502614|NCT04340609|BIOLOGICAL|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
48502615|NCT00527553|DIETARY_SUPPLEMENT|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
48349470|NCT02296229|OTHER|laboratory biomarker analysis|Correlative studies
48349471|NCT02296229|DRUG|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
48349472|NCT00609167|DRUG|bortezomib|"First 33 patients: 1.3 mg/m\^2 IV Days 1, 4, 8 \& 11~Remaining 30 patients: 1.5 mg/m\^2 IV Days 1, 8, 15 \& 22"
48349473|NCT00609167|DRUG|cyclophosphamide|300mg/m\^2 PO days 1, 8, 15 \& 22
48502616|NCT00527553|DIETARY_SUPPLEMENT|lutein|daily lutein enriched egg
48138356|NCT01507506|RADIATION|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA\> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
48138357|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Low - Dose 435 mg/day)|Plant protein hydrolysate
48138358|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (Mid - Dose 870 mg/day)|Plant protein hydrolysate
48138359|NCT06440213|DIETARY_SUPPLEMENT|PeptiControl™ (High - Dose 2610 mg/day)|Plant protein hydrolysate
48138360|NCT06440213|DIETARY_SUPPLEMENT|Placebo Microcrystalline Cellulose|Placebo MCC micro-crystalline cellulose
48138361|NCT04596488|DRUG|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
48138362|NCT02113826|DRUG|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
48138363|NCT01141075|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
48138364|NCT05030415|DRUG|Ixekizumab Auto-Injector|160 mg week 0 followed by 80 mg every two weeks
48138365|NCT05967858|OTHER|observation|no intervention
48138366|NCT00110669|DRUG|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
48138367|NCT05390905|DRUG|HSK21542 Injection|1μg/kg/dose
48138368|NCT05390905|DRUG|Tramadol hydrochloride|50mg/dose
48138369|NCT05390905|DRUG|placebo|placebo
48138370|NCT05909449|OTHER|exercises|participants will be given a structured home exercise program
48138371|NCT00949117|DIETARY_SUPPLEMENT|Ensure|Given orally
48138372|NCT00949117|DIETARY_SUPPLEMENT|PediaSure|Given orally
48138373|NCT00949117|DRUG|cyproheptadine hydrochloride|Given orally
48138374|NCT02597699|DRUG|Remifentanil + Lidocaïne|
48138375|NCT02597699|DRUG|Sufentanil + Lidocaïne|
48138376|NCT06033352|DEVICE|KTP laser|Treatment with KTP 532 nm laser. Laser fluence depends on erythema intensity and ranges from 7.0 J/cm2 to 11 J/cm2 with a 4-11 mm spot size and 8-12 ms pulse duration.
48138377|NCT06033352|DRUG|Ivermectin 1% cream|Application of ivermectin 1% cream 1x/day. Interruption for 4 days in case of irritation/redness.
48138378|NCT05223959|BEHAVIORAL|Culturally adapted Psychoeducation|This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
48502617|NCT00527553|DIETARY_SUPPLEMENT|zeaxanthin|daily zeaxanthin enriched egg
48502618|NCT00527553|DIETARY_SUPPLEMENT|egg product from enriched eggs|daily egg product from lutein enriched eggs
48502619|NCT05637164|DRUG|norepinephrine bitartrate|The treatment group will receive a continuous infusion of norepinephrine at the beginning of anesthesia induction until 15 minutes after intubation. The dosage of norepinephrine was decided by the up-and-down sequential allocation method with an initial dose of 0.05 µg/kg/min and a 0.005 µg/kg/min gradient.
48138379|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
48138380|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
48138381|NCT02493166|OTHER|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
48138382|NCT02268708|PROCEDURE|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
48138383|NCT02167451|DRUG|Maraviroc|
48138384|NCT02588443|DRUG|RO70097890|
48138385|NCT02588443|DRUG|nab-paclitaxel|
48138386|NCT02588443|DRUG|gemcitabine|
48138387|NCT02555306|DRUG|0.5 mg of DE-122|DE-122 Injectable Solution
48138388|NCT02555306|DRUG|1.0 mg of DE-122|DE-122 Injectable Solution
48138389|NCT02555306|DRUG|2.0 mg of DE-122|DE-122 Injectable Solution
48138390|NCT02555306|DRUG|4.0 mg of DE-122|DE-122 Injectable Solution
48138391|NCT02115659|DRUG|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
48138392|NCT02115659|DRUG|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
48138393|NCT01005849|DIETARY_SUPPLEMENT|Protecflor|1 Capsule to be taken once a day during the entire study period
48138394|NCT01005849|DIETARY_SUPPLEMENT|Placebo|1 Capsule to be taken once a day during the entire study period
48138395|NCT01878305|DEVICE|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
48138396|NCT04440800|DEVICE|Wearable activity tracker - FitBit|Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
48659856|NCT01356368|DRUG|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
48659857|NCT03194347|DIAGNOSTIC_TEST|molecular genetic analyses|molecular genetic analyses
48349474|NCT00609167|DRUG|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
48349475|NCT02117791|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
48138397|NCT05298371|BEHAVIORAL|Corrected Sitting postures|Change after being in Corrected Sitting postures
48138398|NCT05298371|BEHAVIORAL|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
48138399|NCT05298371|BEHAVIORAL|Corrected Standing posture|Change after being in Corrected Standing posture
48138400|NCT05298371|BEHAVIORAL|Natural / relaxed standing postures|Change after being in relaxed standing postures
48659858|NCT05840250|OTHER|Continuous Glucose Monitoring and Education Support|Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
47984451|NCT01326689|DRUG|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
47984452|NCT01326689|DRUG|Placebo|
47984453|NCT04021004|OTHER|Survey Questionnaire|Survey Questionnaire
48138401|NCT04205669|DRUG|Benzyl Benzoate 25% Topical Application Lotion|Applied to skin for the treatment of scabies
48138402|NCT05270460|DRUG|PCS12852|PCS12852 oral tablet administered once daily
48138403|NCT05270460|DRUG|Placebo|Placebo comparator oral tablet administered once daily
48138404|NCT02892019|DRUG|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
48138405|NCT02892019|DRUG|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
48138406|NCT00236652|DRUG|levofloxacin|
48138407|NCT01354574|OTHER|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
48138408|NCT01354574|OTHER|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
48138409|NCT02736422|OTHER|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
48138410|NCT04165018|PROCEDURE|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
48349476|NCT05431036|DEVICE|transthoracic ultrasonography|"1. The lung ultrasound score (LUS) will be calculated according to the observed worst ultrasound pattern and Finally, the LUSs of all the parts will added to obtain the total LUS for each patient (maximum36 points)~2. The diaphragmatic ultrasound will performed for assessment of diaphragmatic thickness and motion."
48349477|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
48349478|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
48349479|NCT00427167|DRUG|AMA1-C1/Alhydrogel + CPG 7909|
48349480|NCT05263011|OTHER|Avocado|1 avocado as evening snack
48349481|NCT05263011|OTHER|low fat yogurt|1 serving of low fat yogurt matching calories of 1 avocado
48349482|NCT05263011|OTHER|low fat yogurt + fiber +fat|low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
48349483|NCT06213415|DRUG|Corticosteroid|Oral steroids plus intratympanic injection
48349484|NCT05894889|BIOLOGICAL|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
48659859|NCT03549325|BIOLOGICAL|Neisseria lactamica|Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
48659860|NCT00568009|DRUG|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
48659861|NCT05136755|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
47984454|NCT01586169|DRUG|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
47984455|NCT00215163|DRUG|Cognitive-behavioral therapy and paroxetine-CR|
48349485|NCT01528436|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
48349486|NCT01528436|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
48349487|NCT01528436|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
48349488|NCT04940741|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
48349489|NCT04940741|OTHER|Placebo|comparator without active ingredient
48349490|NCT03966872|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness.
48349491|NCT03966872|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
48349492|NCT04989595|DEVICE|MyIUS app|Data will be self-reported by participants through the MyIUS app.
48349493|NCT04769336|DEVICE|Central Lab based CBC|lab samples will be sent to the central lab for CBC analysis
48349494|NCT04769336|DEVICE|Point of Care CBC|lab samples will be analyzed at point of care
48349495|NCT04112745|OTHER|Static magnet|Static magnet with 2,000 Gauss
48349496|NCT04112745|OTHER|Placebo|Polyvinyl chloride resin material black jewelry
48349497|NCT01510561|DRUG|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
48349498|NCT01510561|DRUG|90Y-hPAM4|
48349499|NCT01510561|DRUG|90Y-hPAM4 + gemcitabine|
48349500|NCT02418728|OTHER|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
48349501|NCT00997828|DEVICE|everolimus-eluting stent|Xience V stent
48349502|NCT00997828|PROCEDURE|coronary artery bypass graft surgery|coronary artery bypass graft surgery
48349503|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
48349504|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
48349505|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
48349506|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
48349507|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
48349508|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
48349509|NCT03614702|BIOLOGICAL|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
48502620|NCT05938608|DRUG|Regimen 1 (Oral primaquine)|Primaquine 15 mg base orally once
48659862|NCT05136755|DRUG|Placebo Cap|Use of placebo as a comparator
48659863|NCT03802019|OTHER|LNC Cigarettes + Colored Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.
47984456|NCT03444714|DRUG|RiMO-301|"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"
47984457|NCT03641144|DEVICE|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
47984458|NCT03641144|DEVICE|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
47984459|NCT01654367|DRUG|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
47984460|NCT03683446|PROCEDURE|Laparoscopic rectal surgery|Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
48349510|NCT03614702|BIOLOGICAL|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
48349511|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
48349512|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
48502621|NCT05938608|DRUG|Regimen 2 (IV primaquine phosphate)|Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously
47984461|NCT03683446|PROCEDURE|Open rectal surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
48349513|NCT03614702|BIOLOGICAL|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
48349514|NCT03614702|BIOLOGICAL|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
48349515|NCT00251186|DRUG|Capecitabine and Cetuximab|
48349516|NCT00673816|DRUG|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
48349517|NCT05865756|OTHER|Acoustic cough features analysis|Acoustic cough features analysis
48349518|NCT00068822|DEVICE|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
48349519|NCT00068822|PROCEDURE|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
48502622|NCT05938608|DRUG|Regimen 3 (IV carboxyprimaquine)|Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously
48502623|NCT03335449|OTHER|Protective ventilation group|Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
48502624|NCT02918253|RADIATION|targeted focal HDR brachytherapy|
48502625|NCT02918253|RADIATION|Whole-gland HDR Brachytherapy|Control/Standard of Care
48502626|NCT02845141|PROCEDURE|Actifuse|bone tunnel filled with Actifuse
48502627|NCT02845141|PROCEDURE|bone graft|bone graft to fill bone tunnel
48659864|NCT03802019|OTHER|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
48659865|NCT03413800|DRUG|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
47984462|NCT00492687|DRUG|carboplatin|
48349520|NCT01430949|PROCEDURE|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
48502628|NCT04055038|DRUG|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
48502629|NCT04055038|DRUG|Conventional chemotherapy|Conventional chemotherapy
48502630|NCT01242995|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
48502631|NCT03868150|DRUG|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
48659866|NCT06557850|DRUG|Lu AG22515|Solution for infusion
47984463|NCT00492687|DRUG|tamoxifen citrate|
47984464|NCT00492687|DRUG|temozolomide|
47984465|NCT00492687|PROCEDURE|adjuvant therapy|
47984466|NCT00492687|RADIATION|radiation therapy|
47984467|NCT04864379|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
47984468|NCT04864379|OTHER|GM-CSF|GM-CSF: 40 mcg
47984469|NCT04864379|DRUG|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
47984470|NCT04864379|PROCEDURE|RFA|Radiofrequency ablation surgery
47984471|NCT00300586|DRUG|observation|observation, second line chemotherapy if progression
47984472|NCT00300586|DRUG|gemcitabine|1250 mg/m² D1, D8 q21 days
47984473|NCT00300586|DRUG|erlotinib|150 mg daily
48138411|NCT06304051|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48138412|NCT06304051|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, the investigators made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48349521|NCT02909582|PROCEDURE|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
48502632|NCT03868150|DEVICE|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
48502633|NCT05984979|OTHER|Standardized meal|The participants will receive a standardized meal for breakfast
48502634|NCT02912169|PROCEDURE|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
48502635|NCT02912169|BIOLOGICAL|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
48502636|NCT03786718|OTHER|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
48502637|NCT03466437|DEVICE|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
48502638|NCT03466437|DEVICE|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
48502639|NCT03466437|DEVICE|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
48502640|NCT01833819|DRUG|Dexmedetomidine and lidocaine|
48502641|NCT01833819|DRUG|Remifentanil|
48659867|NCT06336564|OTHER|Pelvic floor muscle training|"Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days."
47984474|NCT02596581|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
47984475|NCT01847157|DEVICE|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
47984476|NCT01847157|DRUG|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
47984477|NCT01847157|DRUG|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
48002547|NCT05167162|DIAGNOSTIC_TEST|State-Trait Anxiety Questionnaire|"The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always"
48138413|NCT05827185|BIOLOGICAL|Ergonomic modifications|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
48138414|NCT05827185|BIOLOGICAL|Physiotherapy|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
48138415|NCT05827185|BIOLOGICAL|Ergonomic modifications and Physiotherapy|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given."
48138416|NCT05827185|BIOLOGICAL|Patient education|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
48659868|NCT06336564|DEVICE|Microablative Radiofrequency|Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
48138417|NCT04108403|OTHER|Pain Inducing Massage|A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
48138418|NCT04108403|OTHER|Pain Free Massage|A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
48138419|NCT04108403|OTHER|Positive Expectation Instructional Set|Participants will be instructed that the massage is effective for some people with neck pain.
48138420|NCT04108403|OTHER|Negative Expectation Instructional Set|Participants will be instructed that the massage is ineffective for some people with neck pain.
48138421|NCT05734690|DRUG|SGLT2i, beta blocker, ARNI, MRA, MTD|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
48349522|NCT01269827|DRUG|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
48349523|NCT01269827|DRUG|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
48349524|NCT03718468|BIOLOGICAL|GC FLU Quadrivalent|A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
48349525|NCT03718468|BIOLOGICAL|Fluarix Tetra|A single dose administration of Fluarix Tetra will be through intramuscular injection.
48349526|NCT06371209|PROCEDURE|Modified Amputation|Modified amputation procedure
48349527|NCT06371209|PROCEDURE|Standard Amputation|Standard amputation procedure
48349528|NCT01831011|DRUG|mildronate injection|
48349529|NCT01831011|DRUG|cinepazide maleate injection|
48349530|NCT01831011|DRUG|aspirin|
48349531|NCT00302055|BEHAVIORAL|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
48502642|NCT00086827|DRUG|romidepsin|Given IV
48502643|NCT00086827|OTHER|laboratory biomarker analysis|Correlative studies
48502644|NCT01910974|PROCEDURE|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
48502645|NCT00196924|BIOLOGICAL|HPV-16/18 L1/AS04|
48502646|NCT01910779|PROCEDURE|100 joule as first biphasic shock energy|
48138422|NCT05734690|BEHAVIORAL|Education-First|For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
48349532|NCT00302055|BEHAVIORAL|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
48349533|NCT03669146|DEVICE|Glasses|Partial refractive correction in a pair of glasses.
48138423|NCT01115036|DRUG|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
48349534|NCT03607240|PROCEDURE|lung ultrasound-guided alveolar recruitment|Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.
48659869|NCT03682965|BIOLOGICAL|Intra-lymphatic allergenic extract|Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
48659870|NCT03682965|BIOLOGICAL|Intra-lymphatic placebo|The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
48659871|NCT03508583|OTHER|Participation|"The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires"
48659872|NCT06077357|OTHER|MMSE Test|Mini Mental State Examination (MMSE), is a brief mental test used to assess individuals' cognitive functions. This test evaluates basic cognitive abilities such as memory, attention, calculation, language, orientation, and problem-solving. MMSE is commonly used for monitoring and assessing mild cognitive impairments, dementia, and other neurological conditions. This test is typically scored out of 30, with higher scores indicating better cognitive function.
48138424|NCT06028308|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone mounted with earphones) during movement
48659873|NCT06077357|OTHER|PASE Test|"The PASE test stands for Physical Activity Scale for the Elderly. This scale is used to assess the physical activities undertaken by elderly individuals in their daily lives. The PASE test allows for the evaluation of both daily activities such as walking, climbing stairs, and household chores, as well as exercise routines. It is used to determine the level of physical activity in elderly individuals and support the process of healthy aging."
48659874|NCT06077357|OTHER|The PRISMA-7 Frailty Scale|The PRISMA-7 Frailty Scale is a tool used to assess the level of frailty in elderly individuals. This scale evaluates signs of frailty such as physical activity, fatigue, weight loss, and difficulties with vision and hearing. PRISMA-7 is employed in determining the risk of frailty in the elderly and aids in identifying appropriate treatment and support methods.
48138425|NCT04909333|DRUG|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
48138426|NCT04909333|DRUG|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
48349535|NCT03607240|PROCEDURE|conventional alveolar recruitment|Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
48349536|NCT02640755|DRUG|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
48349537|NCT02640755|DRUG|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
48349538|NCT02640755|DRUG|Fulvestrant|Hormonal Agent
48349539|NCT02640755|DRUG|Paclitaxel|Taxane
48349540|NCT02015104|BIOLOGICAL|BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
48349541|NCT02015104|BIOLOGICAL|PANVAC|A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).
48502647|NCT01910779|PROCEDURE|120 joule as first biphasic shock energy|
48659875|NCT06077357|OTHER|TAMPA Test|"The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area."
48659876|NCT06077357|OTHER|(JAMAR) Muscle Test|The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
48138427|NCT05467566|DEVICE|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
48002548|NCT05167162|DIAGNOSTIC_TEST|Rating of Perceived Exertion|"The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable"
48138428|NCT05467566|DEVICE|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
48138429|NCT03378791|DRUG|Iron bisglycinate Oral Tablet|
48138430|NCT03378791|DRUG|Ferrous Fumarate Oral Tablet|
48138431|NCT05674981|DIETARY_SUPPLEMENT|Probiotic group|Two-strain probiotic supplement includes Lactobacillus reuteri ADR-1 (alive) and Lactobacillus rhamnosus GM-020 ( alive).
48138432|NCT05674981|OTHER|Placebo group|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
48138433|NCT05659394|OTHER|Standard Wound Care Alone|gold standard compression therapy
48138434|NCT05659394|DEVICE|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
48138435|NCT06380309|BIOLOGICAL|IDOV-SAFE|Intravenous injection of oncolytic virus every 3 weeks until tumor progression
48138436|NCT06375759|PROCEDURE|Subarachnoid-Subarachnoid (S-S) Bypass|"The dura was widely exposed beyond the level of trauma, and then a midline dural opening was made under an operative microscope. When dura and arachnoid were adhered because of an expansion of arachnoiditis, they had to be released with great care to place the bypass tubes. During this procedure, S-S bypass was not usually needed to performed arachnoid lysis. This exposure had to reach the normal arachnoid mater free from arachnoiditis and adhesion, with normal CSF circulation.~After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long."
48138437|NCT06375759|PROCEDURE|Intradural Adhesion Lysis|Intradural spinal cord Adhesion Lysis
48138438|NCT00949364|DRUG|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
48138439|NCT04746404|BEHAVIORAL|Emotional Skills Development Program|Emotional Skills Development Program (positive psychology)
48138440|NCT06079736|DRUG|PGN-EDO51|IV infusion
48138441|NCT05575505|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
48138442|NCT04069806|DIETARY_SUPPLEMENT|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
48349542|NCT01700140|DRUG|SyB D-0701|Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
48349543|NCT01700140|DRUG|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
48349544|NCT02616536|OTHER|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
48349545|NCT00333970|BEHAVIORAL|cognitive remediation|individual cognitive training
48349546|NCT01816386|OTHER|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
48502648|NCT05475886|DRUG|Hydroxyethyl starch 130/0.4|An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
48659877|NCT06077357|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
48659878|NCT04831346|OTHER|Low level laser|940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.
48502649|NCT05540028|BIOLOGICAL|IVT PCV-25|25 valent pneumococcal conjugate vaccine
48502650|NCT05540028|BIOLOGICAL|PCV 20|20 valent pneumococcal conjugate vaccine
48138443|NCT02586467|BEHAVIORAL|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
48138444|NCT02586467|BEHAVIORAL|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
48138445|NCT02586467|BEHAVIORAL|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
48138446|NCT02586467|BEHAVIORAL|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
48138447|NCT02586467|BEHAVIORAL|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
48138448|NCT04464031|OTHER|electronic alert|The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
48138449|NCT00777049|DRUG|Panobinostat|Hard gelatine capsule - 5mg and 20mg
48138450|NCT03004625|DRUG|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
48138451|NCT03004625|DRUG|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
48138452|NCT03004625|DRUG|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
48138453|NCT01218659|DRUG|migalastat hydrochloride|150-mg capsule administered orally QOD
48138454|NCT01218659|BIOLOGICAL|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
48138455|NCT06326788|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus pushups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till 60-70% of their maximum heart rate is achieved and maintained."
48138456|NCT06326788|BEHAVIORAL|SUSTAINED SOLEUS PUSH-UPS|"Participants will start soles push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum 4-minute break time after every 90 mins intervention. In the meantime, their blood sample will be collected."
48349547|NCT01816386|OTHER|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
48349548|NCT02209259|OTHER|PROMIS Upper Extremity Function|
48349549|NCT02209259|OTHER|Pain intensity|
48349550|NCT02209259|OTHER|PROMIS depression|
48349551|NCT02209259|OTHER|Positive affect negative affect scale (PANAS)|
48659879|NCT04831346|DEVICE|Soft occlusive splint|"A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene."
48138457|NCT01278914|BIOLOGICAL|Dendritic Cells (DC) prostate|
48138458|NCT03650465|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
48349552|NCT02209259|OTHER|standard PCS|
48349553|NCT02209259|OTHER|positively-adjusted version of the PCS|
48349554|NCT01869452|BEHAVIORAL|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
48349555|NCT06313749|DEVICE|Minimally Invasive Micro Sclerostomy Device|During this clinical trial, the Minimally Invasive Micro Sclerostomy (MIMS®) procedure will be performed by investigators using the proprietary MIMS® device developed by Sanoculis Ltd.
48349556|NCT04868331|BEHAVIORAL|Exercise|Two trials of 7-min High Intensity Interval Training (HIIT) with 12 different exercises. Each exercise lasts for 30 seconds continuously with 10 seconds rest interval.
48349557|NCT00482365|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
48349558|NCT00482365|OTHER|medical chart review|review of patients' medical records at study entry and every 6 months
48659880|NCT06565676|DIETARY_SUPPLEMENT|Bread with whey protein powder added|Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.
48659881|NCT05994352|OTHER|virtual reality simulation|The effect of virtual reality simulation on therapeutic communication skill levels
48138459|NCT03807596|PROCEDURE|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
48138460|NCT03807596|PROCEDURE|Scaling & root planning alone|Patients received full-mouth supra- \& sub-gingival SRP with the use of ultrasonic device \& periodontal universal \& Gracey curettes under local anesthesia.
48138461|NCT04559633|OTHER|cognitive and behavioral therapy (CBT)|"The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work."
48349559|NCT00482365|OTHER|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
48349560|NCT00986804|DRUG|Decitabine|
48349561|NCT04409496|BEHAVIORAL|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
48349562|NCT04409496|BEHAVIORAL|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
48349563|NCT04409496|BEHAVIORAL|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
48349564|NCT02708966|DRUG|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
48349565|NCT02708966|DRUG|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
48349566|NCT02799628|BEHAVIORAL|intervention|intervention with recommendation and therapist introduction
48502651|NCT03183648|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
48502652|NCT01616108|DRUG|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
48659882|NCT05338073|DIAGNOSTIC_TEST|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
48659883|NCT02568319|DRUG|LIPO-202|
48659884|NCT02568319|DRUG|Placebo|
48659885|NCT03255473|DRUG|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
48659886|NCT03255473|DRUG|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
48138462|NCT04055818|DRUG|Nicotinamide|Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
48502653|NCT00658515|DRUG|Dalcetrapib (RO4607381)|600mg po daily
48659887|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor+Regorafenib|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
48138463|NCT01792557|DRUG|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
48138464|NCT01792557|PROCEDURE|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
48138465|NCT01792557|PROCEDURE|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
48138466|NCT01792557|PROCEDURE|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
48349567|NCT02799628|OTHER|placebo|low back pain education, and physical therapy 3 times per week
48349568|NCT00409396|PROCEDURE|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
48349569|NCT00409396|PROCEDURE|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
48349570|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
48349571|NCT00926263|BIOLOGICAL|CP-751,871|single dose, 1-hr IV infusion
48349572|NCT00926263|BIOLOGICAL|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
48349573|NCT04157751|DRUG|Empagliflozin|Film-coated tablet
48349574|NCT04157751|DRUG|Placebo to Empagliflozin|Film-coated tablet
48349575|NCT00389129|DRUG|acetylsalicylic acid|
48502654|NCT00658515|DRUG|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
48502655|NCT00658515|DRUG|Placebo|po daily
48502656|NCT02598687|DRUG|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
48502657|NCT02598687|OTHER|HX4 scan|HX 4 scan day 1 and day 8
48502658|NCT02598687|DRUG|Carboplatin|2mg/ml/min
48502659|NCT02598687|DRUG|Paclitaxel|50 mg/m2
48659888|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) ."
48138467|NCT00845364|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
48138468|NCT00845364|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
48138469|NCT05430555|BIOLOGICAL|Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR|Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
48138470|NCT00853580|DRUG|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
48138471|NCT00853580|DEVICE|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
48138472|NCT02611869|PROCEDURE|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
48138473|NCT02611869|PROCEDURE|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
48138474|NCT01355172|BIOLOGICAL|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
48138475|NCT02551237|RADIATION|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
48138476|NCT02551237|DRUG|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
48138477|NCT02551237|RADIATION|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
48138478|NCT01822756|DRUG|ruxolitinib|
48138479|NCT01822756|DRUG|gemcitabine|Other names: Gemzar®
48138480|NCT01822756|DRUG|nab-paclitaxel|Other names: Abraxane®
48349576|NCT01785290|DRUG|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
48659889|NCT06558773|DRUG|Regorafenib+Immune checkpoint inhibitor|"Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
48502660|NCT02598687|RADIATION|Radiotherapy|23 x 1.8 Gy
48659890|NCT02955290|OTHER|Laboratory Biomarker Analysis|Correlative studies
48659891|NCT02955290|BIOLOGICAL|Nivolumab|Given IV
48138481|NCT01822756|DRUG|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
48138482|NCT01787032|DRUG|BI 113608|tablet
48138483|NCT01787032|DRUG|BI 113608|tablet
48659892|NCT02955290|BIOLOGICAL|Pembrolizumab|Given IV
48138484|NCT01787032|DRUG|BI 113608|tablet
48138485|NCT01787032|DRUG|Ketoconazole|tablet
48138486|NCT01787032|DRUG|Voriconazole|tablet
48138487|NCT03154775|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
48138488|NCT00201045|OTHER|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
48138489|NCT06509581|DIETARY_SUPPLEMENT|vitamin E|Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
48138490|NCT06509581|OTHER|PLACEBO|placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
48138491|NCT05566444|DEVICE|Heat stimulus|Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
48138492|NCT03096470|PROCEDURE|anesthesia|no anesthesia
48138493|NCT00856687|DRUG|PF-03893787|Oral, two doses 12 hours apart
48138494|NCT00856687|DRUG|Placebo|Oral, two doses 12 hours apart
48138495|NCT00856687|DRUG|Montelukast|Oral, two doses 12 hours apart
48138496|NCT03629366|BEHAVIORAL|Supported Employment (SE)|Supported Employment
48138497|NCT03629366|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual
48138498|NCT04169776|DEVICE|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
48138499|NCT04727294|BEHAVIORAL|Questionnaire|Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
48659893|NCT02955290|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
48659894|NCT05280054|DRUG|AV-101|360 mg capsules
48659895|NCT05280054|DRUG|Probenecid|1000 mg oral
48659896|NCT05039281|BIOLOGICAL|Atezolizumab|Given IV
48659897|NCT05039281|DRUG|Cabozantinib|Given PO
48138500|NCT03029299|DEVICE|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
48138501|NCT01205633|PROCEDURE|venous angioplasty|catheter venous angioplasty via femoral vein approach
48659898|NCT02631785|OTHER|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
48138502|NCT02776982|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
48138503|NCT02776982|PROCEDURE|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
48138504|NCT02776982|PROCEDURE|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
48138505|NCT02776982|PROCEDURE|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
48349577|NCT01785290|DRUG|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~* aged ≥ 80 years~* weight ≤ 50 kg~* liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
48349578|NCT01785290|DRUG|Placebo|Sodium Chloride 0.9%
48349579|NCT00962481|DRUG|Bimosiamose|
48349580|NCT00962481|DRUG|Placebo|
48349581|NCT02705352|DRUG|5-Fluorouracil|Treatment medication
48502661|NCT02598687|PROCEDURE|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
48502662|NCT00912925|BIOLOGICAL|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
48659899|NCT06195007|BEHAVIORAL|Motivational Interview|"The motivational interview (MI) is a 10-15 minute patient-centered conversation which will focus on tobacco use. Multiple communication strategies can be employed during the MI, including open-ended questions, affirmative statements, reflective listening, use of a 'confidence ruler', and summarizing. The 'confidence ruler' technique in this patient population involves asking the patient On a scale of zero to ten, how confident are you that you can stop using tobacco?, and then requesting further information about why they selected a certain number. These communication strategies and techniques are designed to uncover and foster a patient's own internal motivations to change the target behavior."
48659900|NCT05545059|DRUG|Sacubitril/valsartan|In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
48659901|NCT05545059|DRUG|valsartan|In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
48659902|NCT04581395|OTHER|non-pretreated Succinylcholine|no pretreatment
48659903|NCT04581395|DRUG|succinylcholine 1 minute after rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
48659904|NCT04581395|DRUG|succinylcholine 2 minutes following rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
48659905|NCT03346837|DRUG|BMS-986205|BMS-986205
48659906|NCT03346837|DRUG|Itraconazole|Oral solution
48659907|NCT03346837|DRUG|Rifampin|Tablet
48659908|NCT05961527|DRUG|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
48659909|NCT05961527|BEHAVIORAL|Group Therapy|Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
48659910|NCT02244398|OTHER|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
48138506|NCT04881409|DEVICE|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
48138507|NCT04881409|DEVICE|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
48138508|NCT04950920|DRUG|Y-2 sublingual tablets|30mg Edaravone+6mg d-borneo OR， Bid
48138509|NCT04950920|DRUG|d-borneol|60 μg d-borneol OR， Bid
48138510|NCT03999788|PROCEDURE|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
48349582|NCT02705352|OTHER|Normal saline|Placebo
48349583|NCT01060722|DRUG|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
48349584|NCT01060722|DRUG|Placebo|Single subcutaneous dose of placebo material
48659911|NCT02244398|OTHER|FP services|VHTs in the control arm only provide family planning services
48138511|NCT03999788|PROCEDURE|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
48138512|NCT04624139|BEHAVIORAL|Internet-based cognitive behavioral therapy + physiotherapy|"Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
48138513|NCT04624139|BEHAVIORAL|Physiotherapy only|"A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
48138514|NCT04526639|BEHAVIORAL|Virtual Reality-based Interactive Cognitive Training Program|Three virtual reality-based games designed to train inhibitory control, working memory, and cognitive flexibility among children with TBI
48138515|NCT04526639|BEHAVIORAL|Placebo Virtual Reality Game|A virtual playground for control group to interact without training executive functions
48138516|NCT01201837|DRUG|Placebo|Weekly injection
48138517|NCT01201837|DRUG|CER-001|Weekly injection
48138518|NCT03989310|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
48138519|NCT03989310|DRUG|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
48138520|NCT03989310|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
48138521|NCT03989310|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
48138522|NCT03784469|OTHER|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
48138523|NCT03413826|BEHAVIORAL|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
48138524|NCT00451711|DRUG|Liposomal amphotericin B|
48138525|NCT02448069|DRUG|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
48138526|NCT02571868|DEVICE|Optimization CRT-D|
48138527|NCT01911559|DEVICE|standing-frame|
48349585|NCT01987752|DRUG|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
48349586|NCT05415865|COMBINATION_PRODUCT|Alkalinized Lidocaine|20 ml of Lidocaine Hydrochloride and 10 ml of Sodium hydrogen carbonate will be pulled up and mixed in a syringe on site, and 30 ml mixed solution in total will afterwards be installed in the bladder with a catheter.
48502663|NCT00912925|BIOLOGICAL|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
48502664|NCT05802732|DIAGNOSTIC_TEST|Stool Antigen test|Correlation between the result of endoscopic biopsy and stool antigen test
48659912|NCT02600650|DIETARY_SUPPLEMENT|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
48659913|NCT02600650|DIETARY_SUPPLEMENT|Placebo Comparator|Daily administration of Placebo Comparator
48138528|NCT03958773|DEVICE|Cardiovalve transfemoral Mitral valve system|Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
48138529|NCT02727634|OTHER|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
48138530|NCT03154736|OTHER|Interview|Individual interview and group interview Socio-economic questionnaire
48138531|NCT02124252|BEHAVIORAL|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
48138532|NCT02124252|BEHAVIORAL|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
48138533|NCT03072303|OTHER|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
48138534|NCT01784809|BEHAVIORAL|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. \*\*\*To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
48138535|NCT01784809|BEHAVIORAL|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
48138536|NCT01784809|BEHAVIORAL|Wellness Promotion|
48138537|NCT05535959|DRUG|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
48138538|NCT03120026|DIETARY_SUPPLEMENT|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
48138539|NCT03120026|DIETARY_SUPPLEMENT|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
48138540|NCT02562612|DRUG|SM-88|Daily SM-88 in multiple ascending doses over 6 months
48138541|NCT02797587|DRUG|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
48349587|NCT05415865|DRUG|Placebo Sodium Chloride 0.9% Inj|20 ml of Sodium Chloride 9 g/L and 10 ml of Sodium Chloride 9 g/L will be pulled up and mixed in a syringe on site, and 30 ml solution in total will afterwards be installed in the bladder with a catheter.
48349588|NCT04993755|DRUG|TPN-101, 400 mg/day|400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
48349589|NCT04993755|DRUG|Placebo|Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).
48349590|NCT01789749|OTHER|Snare Tip Soft Coagulation|
48349591|NCT01789749|OTHER|No Snare Tip Soft Coagulation|
48349592|NCT02142712|DRUG|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
48349593|NCT02142712|DRUG|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
48349594|NCT02142712|DRUG|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
47984478|NCT01847157|OTHER|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
48002549|NCT05167162|DIAGNOSTIC_TEST|Motor coordination tests|"The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns"
48659914|NCT05463341|BEHAVIORAL|Fentanyl Test Strips|A brief fentanyl test strip (FTS) education intervention will be given to participants at Project DAWN sites in the intervention arm after enrollment and collecting baseline data. It will be offered one-on-one with participants and will include the purpose, benefits, and limitations of FTS testing, and information on how to use FTS, interpret the results, what to do if the FTS is positive, and how to use FTS for different drug delivery methods. Participants will practice and demonstrate use of the FTS, and the short video on how to interpret the FTS will include an on-camera statement on the importance of testing for fentanyl. The video will be accessible to participants after study enrollment. Participants will be advised of the possibility of both false positive/negative results, and that the drugs may be mixed with other substances not detectable with FTS. Participants will be encouraged to practice other harm reduction strategies.
48659915|NCT06145646|DEVICE|Muscle warm-up|Passive heating of the vastus lateralis of the right quadriceps will be performed using a microwave device. The device will be set at a power of 150 W and a distance of 10-15 cm from the skin surface for 20 minutes with the purpose of increasing local muscle temperature to 40 ºC.
48659916|NCT04432623|DRUG|Benserazide Only Product|Investigational drug
48138542|NCT02797587|DRUG|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
48138543|NCT02797587|DRUG|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
48138544|NCT02797587|DRUG|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
48138545|NCT02797587|DRUG|Cytisine Placebo|Multi-daily dosing for 25 days.
48138546|NCT02797587|DRUG|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
48138547|NCT00002437|DRUG|Cidofovir|
48138548|NCT00002437|DRUG|Probenecid|
48138549|NCT01604824|DRUG|Alirocumab|SC injection in the abdomen
48138550|NCT01604824|DRUG|Placebo|SC injection in the abdomen
48138551|NCT05701579|PROCEDURE|"ACL decompression"|"The technique of ACL decompression by the means of longitudinal incisions and evacuation of extrafibrous mucoid tissue."
48138552|NCT01411566|BEHAVIORAL|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
48138553|NCT01411566|BEHAVIORAL|regular treatment|regular treatment
48349595|NCT02142712|DRUG|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
48349596|NCT02446028|DRUG|BIOD-531|
48502665|NCT01020955|DRUG|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
48502666|NCT01020955|DRUG|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
48659917|NCT05987813|DEVICE|TENS Unit|Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.
47984479|NCT01847157|DEVICE|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
47984480|NCT01029574|OTHER|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
47984481|NCT03615976|PROCEDURE|high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation|"Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~1. Scoring of patellofemoral disorders( Kujala) score~2. Knee Injury and Osteoarthritis Outcome Score (KOOS)"
47984482|NCT01220947|DRUG|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
47984483|NCT01220947|DRUG|Danoprevir|Danoprevir 50 mg BID
47984484|NCT01220947|DRUG|Danoprevir|Danoprevir 100 mg BID
47984485|NCT01220947|DRUG|Danoprevir|Danoprevir 200 mg BID
47984486|NCT01220947|DRUG|Pegasys|Pegasys 180 microgram sc qw
47984487|NCT01220947|DRUG|Ritonavir|Ritonavir 100 mg
47984488|NCT03853395|DIAGNOSTIC_TEST|Tests for drug levels and anti-drug antibodies|Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
47984489|NCT01835067|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
47984490|NCT01835067|DRUG|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
48138554|NCT05558683|OTHER|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
48138555|NCT02089295|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
48138556|NCT02089295|DRUG|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
48138557|NCT02089295|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
48349597|NCT02446028|DRUG|Humalog® Mix 75/25|
48349598|NCT05320640|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
48502667|NCT02048930|DEVICE|Budesonide Easyhaler|
48502668|NCT02048930|DEVICE|Budesonide dry powder inhaler|
48138558|NCT04473703|DRUG|renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor|Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
48138559|NCT03461666|BEHAVIORAL|Cognitive Behavior Therapy-Insomnia|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
48349599|NCT05320640|DRUG|Decitabine|Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.
48138560|NCT03461666|BEHAVIORAL|Focus of Attention|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
48349600|NCT05320640|DRUG|Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies）|Immune checkpoint inhibitors (ICIs) have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.
48138561|NCT03461666|BEHAVIORAL|Combined-CBT-I and FOA Group|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
48138562|NCT03461666|BEHAVIORAL|Sleep Hygiene|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
48138563|NCT01437410|PROCEDURE|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
48138564|NCT01961609|BIOLOGICAL|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
48138565|NCT04018300|DIETARY_SUPPLEMENT|Ferrous sulfate|65 mg Fe as ferrous sulfate
48138566|NCT04018300|DIETARY_SUPPLEMENT|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
48138567|NCT04018300|OTHER|Placebo|Contains maltodextrin.
48138568|NCT03335488|DRUG|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
48138569|NCT03335488|DRUG|NaPBA|"* NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose"
48349601|NCT00251849|DRUG|Rifalazil|
48349602|NCT04774224|DRUG|Baricitinib|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.
48349603|NCT04774224|DRUG|Placebo|Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
48349604|NCT03696849|OTHER|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
48349605|NCT06139939|PROCEDURE|Double layer technique|Double layer technique for alveolar ridge augmentation (first layer autograft followed by xenograft second layer).
48349606|NCT00511108|DRUG|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
48659918|NCT04434729|DEVICE|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
48659919|NCT06274177|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
47984491|NCT01835067|DRUG|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
47984492|NCT03707327|OTHER|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
47984493|NCT03707327|OTHER|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
47984494|NCT04539847|DEVICE|High-end hearing aid|hearing aid with premium level of technology
48138570|NCT02759575|DRUG|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
48138571|NCT02759575|RADIATION|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
48138572|NCT02759575|DRUG|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
48138573|NCT01232166|OTHER|Auscultation|
48138574|NCT01232166|OTHER|Observation of symmetric chest movements|
47984495|NCT04539847|DEVICE|Basic hearing aid|hearing aid with basic level of technology
47984496|NCT05327686|BIOLOGICAL|Avelumab|Given IV
47984497|NCT05327686|DRUG|Axitinib|Given PO
47984498|NCT05327686|DRUG|Cabozantinib|Given PO
47984499|NCT05327686|BIOLOGICAL|Ipilimumab|Given IV
47984500|NCT05327686|DRUG|Lenvatinib|Given PO
47984501|NCT05327686|BIOLOGICAL|Nivolumab|Given IV
47984502|NCT05327686|BIOLOGICAL|Pembrolizumab|Given IV
48138575|NCT01232166|OTHER|Tube depth|
48138576|NCT01232166|OTHER|All three|
48349607|NCT00511108|DRUG|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
48349608|NCT00511108|DRUG|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
48349609|NCT00511108|DRUG|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
48349610|NCT04935567|OTHER|Statistical model for the prediction of VNS efficacy|statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data
48349611|NCT04990102|DRUG|CPX-351|Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
48349612|NCT01505140|OTHER|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
48349613|NCT02812108|DEVICE|intracranial stent, flow diverter and coils|
48502669|NCT02913092|BEHAVIORAL|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
48659920|NCT05614869|DEVICE|Prevena Plus Incision Management System with Prevena Dressings|Negative pressure pump and dressings
48349614|NCT06004089|PROCEDURE|V NOTES Sacrocolpopexy|The procedure involved a single-port laparoscopic surgery through the vaginal route, aiming to restore pelvic floor function by suspending the vagina to the anterior longitudinal ligament. The surgical approach differs from conventional methods, as these procedures are conducted through abdominal or vaginal routes without the aid of laparoscopic cameras, However, in our approach, we uniquely combine the widely acknowledged gold standard sacrocolpopexy procedure using vaginal route with laparoscopic camera assistance. No experimental drugs or devices were employed; only the surgical approach was modified.
48138577|NCT00822900|DRUG|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
48349615|NCT00955344|BEHAVIORAL|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
48659921|NCT05997953|OTHER|Edinburgh Postnatal Depression Scale|Edinburgh Postnatal Depression Scale used as screening tool for postpartum depression
47984503|NCT05327686|RADIATION|Stereotactic Ablative Radiotherapy|42 Gy in 3 fractions
47984504|NCT01991067|BIOLOGICAL|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
47984505|NCT05060159|OTHER|Hemofiltration|Postdilutional Hemofiltration
47984506|NCT05443932|DRUG|Dapagliflozin|10mg Dapagliflozin daily for 8 weeks
48138578|NCT00822900|DRUG|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
48138579|NCT00703391|DRUG|AZD9668|30mg oral tablets twice daily (bid) for 14 days
48138580|NCT00703391|DRUG|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
48138581|NCT04031365|PROCEDURE|Acupuncture|Use of sterile, disposable needles in acupuncture
48138582|NCT04031365|BEHAVIORAL|Cognitive Behavioral Therapy|psychotherapy
48138583|NCT04495426|OTHER|Non-interventional study|There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
48138584|NCT04221659|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.
48349616|NCT00955344|BEHAVIORAL|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
48349617|NCT04555811|DRUG|FT596|FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to ≤Grade 1.
48349618|NCT04555811|DRUG|Rituximab|Rituximab 375 mg/m\^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion
48349619|NCT05336019|BEHAVIORAL|Diabetes self-management Coaching|A 12-week Diabetes self-management coaching program
48349620|NCT05336019|OTHER|Usual care|Assigned to 12 weeks of usual care which includes a physical examination, history taking,, medication refill, lab investigation, and health education
48659922|NCT03802396|DRUG|CN-105|"Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses."
47984507|NCT05443932|DRUG|Hydrochlorothiazide|50mg Hydrochlorothiazide daily for 8 weeks
47984508|NCT01614067|DRUG|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
47984509|NCT00005972|DRUG|gemcitabine hydrochloride|
47984510|NCT00005972|DRUG|irinotecan hydrochloride|
47984511|NCT01565785|BEHAVIORAL|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
48138585|NCT01532999|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
48138586|NCT01532999|BEHAVIORAL|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
48138587|NCT04164446|DRUG|Placebos|The placebo that will be used contains starch and glucose.
48138588|NCT04164446|DIETARY_SUPPLEMENT|Oil Palm Phenolics|One capsule contains 250 mg OPP or 1 g OPP
48138589|NCT03365232|DEVICE|non custom base attachment|non custom base attachment
48138590|NCT03365232|DEVICE|custom base attachment|custom base attachment
48349621|NCT06111404|PROCEDURE|central urinary bladder dissection|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
48349622|NCT06111404|PROCEDURE|Lateral urinary bladder dissection|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
48138591|NCT00900900|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
48138592|NCT00900900|DIETARY_SUPPLEMENT|pregnenolone|one-time 400mg oral dose of pregnenolone
48659923|NCT03802396|DRUG|Placebo|Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
48659924|NCT05896839|PROCEDURE|Biopsy|Undergo tumor biopsy
48659925|NCT05896839|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47984512|NCT04867681|BEHAVIORAL|Psycho-education programme|4 individual sessions (S1, S2, S3, S4) of one hour each spread over 2 weeks, i.e. 2 sessions per week. S1 explains the different clinical signs and discusses the prognosis of the disease, S2 deals with the question of drug treatments, their different forms and their mechanisms of action. S3 discusses the evolution of the disease and the organisation of the care pathway. Finally, S4 looks at the aspects of quality of life, lifestyle and the fight against addictive co-morbidities, and concludes with a review of the patient's motivation and involvement in the subjects covered.
47984513|NCT02577211|DIETARY_SUPPLEMENT|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
47984514|NCT02577211|DIETARY_SUPPLEMENT|Normocaloric enteral nutrition|25 kcal/kg of body weight
48138593|NCT00900900|DRUG|Placebo|one-time dose oral dose
48138594|NCT00779805|DRUG|Pseudoephedrine hydrochloride 120 mg ER tablets|
48138595|NCT04474496|OTHER|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
48138596|NCT01084941|BEHAVIORAL|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
48138597|NCT01084941|BEHAVIORAL|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
48138598|NCT02617693|BEHAVIORAL|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
48138599|NCT02617693|OTHER|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
47984515|NCT04675203|PROCEDURE|Tooth extraction|Tooth extraction
48502670|NCT04405830|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) refers to modalities of treatment that are used to replace the waste filtering functions of a normal kidney.
48138600|NCT04547660|BIOLOGICAL|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
48138601|NCT04547660|OTHER|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
47984516|NCT06046339|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
47984517|NCT00170716|DEVICE|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
48138602|NCT06466083|OTHER|no intervention|this is an observation study,no intervention
48138603|NCT06075030|DRUG|AND017|Oral administration of AND017 capsules three times per week
48349623|NCT06111404|DEVICE|Wolf laparoscopy tower|set of instruments used for laparoscopic surgery
48349624|NCT02462889|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection
48349625|NCT02462889|DRUG|Placebo|Sham injection
48502671|NCT02996214|DRUG|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
48502672|NCT02996214|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles.
48502673|NCT02996214|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
48659926|NCT05896839|PROCEDURE|Computed Tomography|Undergo CT scan
48659927|NCT05896839|BIOLOGICAL|Ipilimumab|Given IV
48659928|NCT05896839|PROCEDURE|Kidney Biopsy|Undergo kidney biopsy
48659929|NCT05896839|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48659930|NCT05896839|BIOLOGICAL|Nivolumab|Given IV
48659931|NCT05896839|DRUG|Prednisone|Given PO
48659932|NCT05896839|DRUG|Sirolimus|Given PO
48659933|NCT06567002|DRUG|MK-6552|Oral Administration
48659934|NCT04983030|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
48138604|NCT05538572|DRUG|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
47984518|NCT00170716|OTHER|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
48502674|NCT03597659|GENETIC|phenome-wide association study (PheWAS)|Phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of TSH levels identified by a previously published genome-wide association study (GWAS) which included North American and European participants. A phenome-wide scanning of 1,318 phenotypes will be performed, using a cohort of 37,154 North American individuals of European ancestry with electronic-health-record (EHR) data.
48502675|NCT02520063|DRUG|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
48502676|NCT02520063|DRUG|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
48502677|NCT02520063|DRUG|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
48502678|NCT06050889|OTHER|Positive Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention known to be effective for some people with shoulder pain. We expect this will make you less sensitive to the pressure applied to your shoulder and thigh and you will require more pressure than what was previously necessary to experience pain."
48502679|NCT06050889|OTHER|Negative Expectations Instructional Set|"Participants randomly assigned to this instructional set will be told, You will be completing an intervention which is not effective for some people with shoulder pain. We expect this will make you more sensitive to the pressure applied to your shoulder and thigh and you will require less pressure than what was previously necessary to experience pain."
48502680|NCT05241028|DRUG|Ensartinib|Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
48502681|NCT03318731|OTHER|Sugar Pill|Taken orally in capsule form
48502682|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, Low Dose|Taken orally in capsule form
48502683|NCT03318731|DIETARY_SUPPLEMENT|Fenugreek Extract, High Dose|Taken orally in capsule form
48502684|NCT03825341|DRUG|Hydroxyurea|Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
48502685|NCT03825341|DRUG|Hydroxyurea Oral Capsule|Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
48502686|NCT01054235|BEHAVIORAL|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
48502687|NCT02472535|OTHER|Run-In Period: Placebo|2 capsules, once a day for two weeks
48502688|NCT02472535|DRUG|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"
48502689|NCT02472535|DRUG|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"
47984519|NCT02298803|DEVICE|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
47984520|NCT03535870|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
47984521|NCT03535870|DRUG|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
47984522|NCT03535870|DRUG|Placebo|placebo dry powder administered via the LOMI inhaler device
48138605|NCT05437666|OTHER|Education and booklet|The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
48138606|NCT05437666|OTHER|Booklet|The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
48502690|NCT02472535|DRUG|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
48502691|NCT04933968|BIOLOGICAL|ALVR106|Infusion, visually identical to placebo
48502692|NCT04933968|BIOLOGICAL|Placebo|Infusion, visually identical to ALVR106
48502693|NCT04335786|DRUG|Valsartan (Diovan)|"At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.~Study drug dosages will be titrated to blood pressure with a maximum of 160mg b.i.d."
48502694|NCT04335786|DRUG|Placebo oral tablet|At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
48502695|NCT04044911|BEHAVIORAL|Task model (CogWatch)|
48138607|NCT00828126|PROCEDURE|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
48502696|NCT03839030|OTHER|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
48502697|NCT06084897|DRUG|TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.|"A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin."
47984523|NCT02632539|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
47984524|NCT02632539|PROCEDURE|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
48138608|NCT00933270|DEVICE|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
48138609|NCT00752414|DRUG|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
48138610|NCT00752414|DRUG|Placebo|same frequency as MP-376
48502698|NCT06084897|BIOLOGICAL|PD-1 inhibitor|Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab
48502699|NCT06084897|RADIATION|Consolidation Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66Gy/19f or 40Gy/20f for organ metastasis patients. Radiation treatment is planned after chemotherapy completed.
48659935|NCT04983030|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
48659936|NCT04983030|BIOLOGICAL|PGT121|PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
48659937|NCT04983030|BIOLOGICAL|PGDM1400|PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
48659938|NCT04983030|BIOLOGICAL|VRC07-523LS|VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
48659939|NCT06483113|DEVICE|Delefilcon A spherical soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia)
47984525|NCT00081380|DRUG|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
47984526|NCT00081380|DRUG|lithium (mood stabilizer)|
47984527|NCT00081380|DRUG|divalproex (mood stabilizer)|
47984528|NCT05277701|DRUG|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
47984529|NCT00811551|DEVICE|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
47984530|NCT04226274|DRUG|REN001|Once daily for 12 weeks
47984531|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
47984532|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
47984533|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
47984534|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
47984535|NCT00362115|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
47984536|NCT00362115|DRUG|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
47984537|NCT00362115|DRUG|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
47984538|NCT02057198|DRUG|Fidaxomicin|
47984539|NCT02057198|DRUG|Metronidazole|
47984540|NCT02057198|DRUG|Vancomycin|
47984541|NCT06336915|BEHAVIORAL|Physician-Nurse Dyad Rounding|Collaborative Approach to Improve Unit-Level Metrics
48138611|NCT05537012|DIAGNOSTIC_TEST|clinical and radiological staging, pathological types, grading and lymphovascular space invasion|70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.
48138612|NCT03163563|DEVICE|Easywarm|Warming blanket
48138613|NCT03163563|DEVICE|BairHugger|Patient warming mattress with continuous warm air.
48138614|NCT00070317|DRUG|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
48138615|NCT00070317|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping
48138616|NCT00070317|PROCEDURE|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
48138617|NCT00070317|DRUG|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
48659940|NCT06483113|DEVICE|Delefilcon A toric soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with astigmatism
48659941|NCT06483113|DEVICE|Delefilcon A multifocal soft contact lenses|Silicone hydrogel contact lenses prescribed for single use, daily disposable wear (less than 24 hours while awake) for the correction of ametropia (myopia or hyperopia) with presbyopia
48138618|NCT00070317|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
48138619|NCT00070317|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
48138620|NCT00070317|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
48138621|NCT00070317|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical hysterectomy
48138622|NCT03606551|DEVICE|EXD-959 Bracket System|EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
48138623|NCT06294834|OTHER|Part 1 of intervention A - Wheelchair skills training modules|"Clinicians will review a suite of training videos in a prescribed order that discuss motor learning principles, safe spotting, and how to complete 15 intermediate and advanced skills:~1. Opening/closing doors~2. getting over a gap~3. getting over a threshold~4. ascending a low curb~5. descending a low curb~6. ascending a high curb~7. descending a high curb~8. performing a stationary wheelie~9. descending a high curb in a wheelie position~10. descending a steep incline in a wheelie position and stopping~11. ascending stairs~12. descending stairs~13. completing a floor-to-chair transfer~14. car transfers~15. folding and unfolding wheelchair"
48138624|NCT06294834|OTHER|Part 2 of intervention A - Asynchronous feedback from a remote trainer|Participants will practice of wheelchair skills paired with remote feedback. Participants will be reminded to practice once per week. The participant will practice any number of the 15 skills for a self-selected duration. Following each practice session, the participant will upload video(s) of the skills practiced and a session log, indicating any difficulties they encountered. The remote trainer will then review the video-recordings and reply to the participant with feedback.
48138625|NCT06294834|OTHER|Intervention B: Education on wheelchair provision|Participants will be provided with access to web-based wheelchair provision education modules. When the content is viewed will be self-selected by participants. Participants will be asked to complete a feedback survey at the end of the modules. Participants will receive weekly reminders to complete the intervention until a feedback survey completed.
48659942|NCT00001854|DRUG|Ribavirin|
48659943|NCT01516372|DRUG|GEn 1200mg|1200 mg of Gen administered as a single dose
48659944|NCT01516372|DRUG|Gen 6000 mg|6000 mg of Gen administered as a single dose
48659945|NCT01516372|DRUG|GEn Placebo|Placebo to match GEn Tablets
48659946|NCT01516372|DRUG|Moxifloxacin Placebo|Placebo to match Moxifloxacin
48138626|NCT01179802|OTHER|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
48138627|NCT06509386|OTHER|Major Depressive Disorder without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
48138628|NCT06509386|OTHER|Major Depressive Disorder with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
48138629|NCT06509386|OTHER|Major Depressive Disorder without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
48138630|NCT06509386|OTHER|Major Depressive Disorder with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
48659947|NCT01516372|DRUG|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
48659948|NCT03741270|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
47984542|NCT05592782|BEHAVIORAL|Virtual Reality Based Mindfulness meditation|Participants will undergo a guided VR meditation using a commercial VR application. The meditation will last approximately 15 minutes. Prior to starting and on upon completion of each VR meditation session, participants' state pain, anxiety, depression, and stress will be assessed. For each participant enrolled, baseline and monthly assessments using the DASS-21 and PPI-SFI3a will be performed for three consecutive months.
47984543|NCT00680745|DRUG|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
47984544|NCT00680745|DRUG|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
47984545|NCT00680745|DRUG|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
47984546|NCT00680745|DRUG|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
47984547|NCT00680745|DRUG|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
47984548|NCT03877289|DRUG|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
47984549|NCT03877289|OTHER|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
48002550|NCT05167162|PROCEDURE|Physiotherapeutic intervention|Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
48659949|NCT05323344|OTHER|Neuro-physiotherapy|Neuro-Physiotherapy will be done in Intervention group I
48659950|NCT05323344|OTHER|Combination of metacognitive behavioral therapy and Neuro-physiotherapy|Combination of metacognitive behavioral therapy and Neuro-physiotherapy will be done in intervention group II
48659951|NCT06121752|PROCEDURE|Endoscopic submucosal dissection|Endoscopic resection is recommended for the management of small DNETs measuring ≤10 mm. Various endoscopic techniques have been utilized for the resection of DNETs including endoscopic mucosal resection (EMR), band ligation assisted EMR, endoscopic submucosal dissection (ESD). However, the published studies report a high rate of histologically incomplete resection even with ESD. More recently, device assisted endoscopic full thickness resection (EFTR) has emerged as a safe and effective resection modality in cases with upper and lower gastrointestinal (GI) mucosal as well as submucosal lesions. There is limited data on the outcomes of EFTR in cases with DNETs.
48659952|NCT06121752|DEVICE|EFTR|"Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed.~The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device.~After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning.~The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4)."
48659953|NCT00939185|DRUG|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
48659954|NCT05430438|OTHER|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
48659955|NCT05430438|OTHER|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
48659956|NCT05734885|OTHER|Back and Sacral massage massage application|Massage will be applied to the pregnant woman in the position preferred by the pregnant woman. Circular movements are applied to the sacrum with the thumb. Pressure is applied to both sides of the spinal cord with the thumb. The thumb is moved towards the hip of the pregnant woman at 1.5 cm intervals, starting from the lower part of the pelvis and the sacrum. The palm is placed in direct contact with the mother's sacrum and pressure is applıed. The massage is completed by making a bunch of flowers from the sacrum upwards, towards the shoulder and around it.
48659957|NCT04958096|DEVICE|Standard Therapeutic Deep Brain Stimulation|DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD
48138631|NCT06509386|OTHER|Schizophrenia without treatment or role fulfillment|Read vignette describing the condition and ask stigma questions.
48659958|NCT04958096|DEVICE|Cortical Stimulation for PFC|Patients enrolled in this study will have a second pair of leads placed in the prefrontal cortex (PFC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
48659959|NCT04958096|DEVICE|Cortical Stimulation for ACC|Patients enrolled in this study will have a second pair of leads placed in the anterior cingulate cortex (ACC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
47984550|NCT03877289|DRUG|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
47984551|NCT03566251|OTHER|Balance|Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
47984552|NCT03566251|OTHER|Functional mobility|Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
47984553|NCT03566251|OTHER|Core stability|Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
48138632|NCT06509386|OTHER|Schizophrenia with treatment but no role fulfillment|Read vignette describing the condition and ask stigma questions.
48138633|NCT06509386|OTHER|Schizophrenia without treatment but with role fulfillment|Read vignette describing the condition and ask stigma questions.
48138634|NCT06509386|OTHER|Schizophrenia with treatment and role fulfillment|Read vignette describing the condition and ask stigma questions.
48349626|NCT02622048|BEHAVIORAL|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
48349627|NCT01680146|DIETARY_SUPPLEMENT|PRO+FAT|
48349628|NCT01680146|DIETARY_SUPPLEMENT|PRO|
48659960|NCT01364831|BEHAVIORAL|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
48349629|NCT00262639|DRUG|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
48349630|NCT00262639|DRUG|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
48349631|NCT03934489|BEHAVIORAL|PERSIST|12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
48349632|NCT03934489|BEHAVIORAL|Facilitated Peer Support|12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
48349633|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly
48349634|NCT01379430|BIOLOGICAL|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal
48349635|NCT02619058|BIOLOGICAL|NKT cells|autologous natural killer T cell
48349636|NCT05981755|OTHER|Breathing tasks|Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.
48349637|NCT05981755|DEVICE|Brain mapping with stimulation|Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
48349638|NCT04350918|DEVICE|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
48349639|NCT04350918|DEVICE|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
48349640|NCT00113906|DRUG|melatonin|
48349641|NCT05205928|DRUG|Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy|The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
48349642|NCT00805818|DRUG|NNZ-2566|"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
48349643|NCT00805818|DRUG|Placebo|Sodium Chloride 0.9% Injection
48349644|NCT06024291|OTHER|8-week HIIT programme|See arm description
48502700|NCT06084897|RADIATION|Salvage Radiation|IMRT/VMAT technique. Patients receive radiotherapy once daily, 5 days a week for an average of 5 weeks. Radiotherapy is delivered to achieve a dosage of 49.22Gy/23f or 50Gy/25f to PGTV for lymphnode metastasis only patients and 40.66\~49.22Gy/19f \~23f or 40\~50Gy/20\~25f for organ metastasis patients. Radiation treatment is planned after disease progression when recommended by multidisciplinary team.
48502701|NCT00388076|DRUG|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
48502702|NCT00388076|DRUG|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
48502703|NCT00388076|DRUG|paclitaxel|in combination with pazopanib
48659961|NCT03416894|DEVICE|Deep Brain Stimulation|DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
48349645|NCT06024291|OTHER|Physical activity recommendation|See arm description
48349646|NCT03017040|DEVICE|CT scan|A CT scan of the wrist
48349647|NCT03017040|DEVICE|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
48349648|NCT06340776|OTHER|Acupressure|For the acupressure application, planning was made to adjust the temperature, light and silence of the environment and to pay attention to privacy. 5 points that positively affect gastrointestinal functions and pain were selected (SP6, ST36, PC6, HT7 AND LI4). The duration of the session was determined to be approximately 18-20 minutes, depending on the preparation and pressure time to be applied on the 5 selected points (a total of 10 points were applied since each point will also be applied to its counterpart in the other extremity). Acupressure application was applied to each point for 1.5 minutes (1.5\*10=15 minutes).
48349649|NCT01968304|OTHER|Iron status follow up|
48349650|NCT02324036|DEVICE|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
48349651|NCT02324036|BEHAVIORAL|Coached Care|Community health worker provides participation training to patient
48502704|NCT00388076|DRUG|carboplatin|in combination with pazopanib
48502705|NCT05532371|OTHER|Aerobic exercise training combined with lower limb strengthening|The participants performed aerobic exercise training and lower limb strengthening during this intervention.
48502706|NCT05532371|OTHER|Dual-task training combined with lower limb strengthening group (DG)|The participants performed dual-task training combined with lower limb strengthening during this intervention.
48502707|NCT05532371|OTHER|Aerobic exercise training combined with dual-task training and lower limb strengthening|The participants performed aerobic exercise training combined with dual-task training and lower limb strengthening during this intervention.
48659962|NCT05911165|OTHER|No surgical coaching|During the twelve-month study period, all participants will have access to an instructional video related to laparoscopic vaginal cuff suturing and the laparoscopic vaginal cuff trainer in order to practice laparoscopic suturing as desired. All participants will keep a log of voluntary practice time on the vaginal cuff trainer. These resources will constitute the control arm of the study
48659963|NCT05911165|OTHER|Surgical coaching|Surgical coaching sessions will include 30-60 minute meetings in which the coach-coachee pair reviews recorded laparoscopic suturing practice sessions to examine different aspects of surgical performance.
48659964|NCT05507333|DEVICE|Gedea pessary|Daily administration of the Gedea pessary during 6 days
48659965|NCT06564363|DIAGNOSTIC_TEST|IUrisure test|Postoperative patients are followed up every three months on average, and IUrisure test was performed at each follow-up visit.
48502708|NCT05532371|OTHER|Only lower limb strengthening group (CG)|The participants performed only lower limb strengthening group during this intervention.
48502709|NCT01413516|BEHAVIORAL|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
48502710|NCT01413516|DRUG|Placebo|Sugar pill without any active medication
48002551|NCT05167162|OTHER|Data Analysis|The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
48502711|NCT01413516|DRUG|Varenicline|Varenicline (an approved medication for smoking cessation)
48502712|NCT05385965|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants reduce pain interference so that they can engage with what gives them a sense of meaning, purpose, and peace.
48349652|NCT03794011|DEVICE|fetoscopy|The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
48502713|NCT02909946|BEHAVIORAL|Multi-modal Infection Control Program|"1. Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~2. Hand hygiene education to residents and families (resident-level intervention).~3. Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~4. Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~5. Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
48659966|NCT01676870|BEHAVIORAL|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
48659967|NCT01676870|BEHAVIORAL|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
48659968|NCT01676870|BEHAVIORAL|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
48349653|NCT04402385|DRUG|Aspirin 81 mg|Participants randomized to 81 mg of Aspirin daily
48349654|NCT04402385|DRUG|Placebo|Participants randomized to placebo daily
48659969|NCT06024538|PROCEDURE|Tumor samples|Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
48659970|NCT05985239|PROCEDURE|VI|Laparoscopic or robotic surgery with virtual ileostomy
48659971|NCT05985239|PROCEDURE|DI|Laparoscopic or robotic surgery with virtual ileostomy
48659972|NCT06035887|DIAGNOSTIC_TEST|Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)|RETEval Complete hand-held electroretinogram
48502714|NCT03832101|BEHAVIORAL|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
48659973|NCT06035887|DIAGNOSTIC_TEST|Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)|UTAS multifocal electroretinogram
48349655|NCT05522543|OTHER|Conventional treatment with Passive translatoric intervertebral glides|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets • Core stabilization exercise (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan (bridges, knee to chest, cat and camel stretch and prone press ups"
48502715|NCT06182761|DRUG|Sunvozertinib combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
47984554|NCT03566251|OTHER|Trunk position sense|Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
47984555|NCT00528385|DRUG|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
47984556|NCT03590145|DIAGNOSTIC_TEST|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
47984557|NCT05898815|DIAGNOSTIC_TEST|Medical record collection|Medical record collection
47984558|NCT02123745|DEVICE|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
47984559|NCT03342690|DRUG|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
48349656|NCT05522543|OTHER|Conventional treatment with manual segmental lumbar traction|"Patient education (Postural correction, lifting, sitting and sleeping positions) • Hot Pack 10 mins~• Manual lumbar Traction (L1-L5) for 15-20 sec x5 sets • Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets) • .Core stability exercises (Knee to chest, bridges, prone press ups, cat and camel stretches) • Home plan"
48659974|NCT06035887|DIAGNOSTIC_TEST|Spectral-Domain Optical Coherence Tomography (Standard of Care test)|Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)
48349657|NCT00275106|DRUG|asparaginase|
48659975|NCT06035887|DIAGNOSTIC_TEST|Macular Autofluorescence (Standard of Care test)|Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)
48659976|NCT06571877|OTHER|Dietary intervention with manipulation of the energy density|Dietary intervention with manipulation of the energy density either during breakfast or during lunch
47984560|NCT05423652|DEVICE|Lung point of care ultrasound|Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
47984561|NCT05423652|OTHER|PRESUNA software|PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
47984562|NCT02895906|DRUG|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
48349658|NCT00275106|DRUG|cyclophosphamide|
48349659|NCT00275106|DRUG|cytarabine|
48349660|NCT00275106|DRUG|daunorubicin hydrochloride|
48349661|NCT00275106|DRUG|dexamethasone|
48659977|NCT03132467|BIOLOGICAL|Durvalumab|Given IV
48349662|NCT00275106|DRUG|doxorubicin hydrochloride|
48349663|NCT00275106|DRUG|leucovorin calcium|
48349664|NCT00275106|DRUG|mercaptopurine|
48349665|NCT00275106|DRUG|methotrexate|
48659978|NCT03132467|BIOLOGICAL|Tremelimumab|Given IV
47984563|NCT02941965|PROCEDURE|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
48138635|NCT03690804|DEVICE|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
48138636|NCT05715632|DRUG|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical hand surgery for gastric cancer
48138637|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
48138638|NCT04111419|DRUG|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
48138639|NCT04111419|DRUG|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
48138640|NCT04995588|OTHER|Blood test|Unique blood draw of 45mL for all the participants
48138641|NCT00385606|DRUG|gemcitabine|
48138642|NCT00385606|DRUG|prolonged continuous infusion gemcitabine|
48138643|NCT00385606|DRUG|cisplatin|
48138644|NCT00385606|DRUG|rofecoxib|
48138645|NCT05901532|DRUG|Szechwan Lovage Rhizome, Biod Magnolia Bud, Taiwan Angelica Root, Wild Mint Herb, Baikal Skullcap Root, and Borneol|The bilateral nasal cavity was irrigated with a plastic bottle containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day for 2 months.
48349666|NCT00275106|DRUG|prednisolone|
48502716|NCT00986518|BIOLOGICAL|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
47984564|NCT02941965|PROCEDURE|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
48138646|NCT05901532|DRUG|edible caramel|The bilateral nasal cavity was irrigated with a plastic bottle containing edible caramel dissolved in 240 ml of warm normal saline once a day for 2 months.
48138647|NCT00739934|DRUG|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
48349667|NCT00275106|DRUG|thioguanine|
48349668|NCT00275106|DRUG|vincristine sulfate|
48349669|NCT00275106|PROCEDURE|radiation therapy|
48349670|NCT02332876|BEHAVIORAL|Exercise|
48502717|NCT00967655|BIOLOGICAL|panitumumab|
48502718|NCT00967655|DRUG|capecitabine|
48502719|NCT00967655|DRUG|irinotecan hydrochloride|
47984565|NCT03774511|OTHER|High-Intensity Interval Exercise & Moderate Intensity Interval Exercise|Different Interval intensities Exercise
47984566|NCT02834208|OTHER|MRI (Magnetic resonance imaging)|
47984567|NCT02834208|GENETIC|Polymorphism (SNP in DNA)|
48138648|NCT06098105|PROCEDURE|Ultrasound-guided transversus abdominis plane block|This group will receive ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
48138649|NCT06098105|PROCEDURE|Laparoscopic-assisted transversus abdominis plane block|Patients will receive laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
48138650|NCT06098105|PROCEDURE|Laparoscopic-assisted intraperitoneal instillation|This group will receive laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
48138651|NCT06098105|DRUG|Bupivacaine|bupivacaine
48138652|NCT03884413|OTHER|questionnaires|Longitudinal observational study. Collection of health data using self-administered questionnaires online.
48138653|NCT01052935|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
48349671|NCT02332876|BEHAVIORAL|Control|
48349672|NCT02465762|DEVICE|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
48349673|NCT00904111|DRUG|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
48349674|NCT00904111|DRUG|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
48349675|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
48502720|NCT00967655|PROCEDURE|neoadjuvant therapy|
47984568|NCT02834208|GENETIC|quantitative measures of mRNA|
47984569|NCT02834208|OTHER|Neuropsychological assessment|
48502721|NCT00967655|PROCEDURE|therapeutic conventional surgery|
48138654|NCT03500523|DIAGNOSTIC_TEST|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
48349676|NCT00242710|DRUG|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
48502722|NCT00967655|RADIATION|radiation therapy|
48502723|NCT05729516|BEHAVIORAL|Hope App immersive learning and telehealth platform|As part of the Hope App intervention, participants attend 10 skills sessions related to diabetes self-management. ITG participants will also receive monthly health coaching calls. After 6 months of active participation, participants enter a maintenance period, during which programming concludes but continued access to the program materials remains.
48659979|NCT06548828|BEHAVIORAL|NNS Restriction Intervention|"Discuss current scientific literature surrounding NNS consumption, obesity, and chronic disease and the emerging evidence that consumption in pregnancy/lactation may have unfavorable effects on infants' adiposity and health.~Provide detailed handouts, which will include a list of specific foods and beverages containing NNS to avoid during the study and summarize current scientific evidence on the metabolic and health effects of NNS.~Emphasize that sugar is not the best alternative to NNS, and that the participant should drink still water, sparkling water, flavored waters with no added sweeteners, or unsweetened tea instead.~Bi-weekly shipments of unsweetened beverages of participant's choice to replace usual consumption of NNS containing beverages.~Automated text messages will also be sent to mothers once per week with reminders that they should avoid NNS"
47984570|NCT05611034|DRUG|Oxaliplatin|Oxaliplatin infusion in single lung via IVLP technique
48138655|NCT03195803|BEHAVIORAL|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
48349677|NCT00242710|DRUG|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
48349678|NCT00242710|OTHER|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
48349679|NCT06251544|GENETIC|HTR2 T Cells|"Arm A -- Two dose levels will be evaluated:~Dose level One: 1.00E+06~Dose level Two: 1.00E+07"
48349680|NCT06251544|GENETIC|HTR2 T Cells|"Arm B -- Two dose levels will be evaluated:~Dose level Two: 1.00E+07~Dose Level Three: 1.00E+08"
48349681|NCT00085358|DRUG|carboplatin|Given intraperitoneally
48349682|NCT00085358|DRUG|paclitaxel|Given IV or intraperitoneally
48349683|NCT00085358|DRUG|docetaxel|Given IV
48349684|NCT00085358|BIOLOGICAL|bevacizumab|Given IV
48349685|NCT03903536|PROCEDURE|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
48349686|NCT03903536|PROCEDURE|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
48349687|NCT00125229|DRUG|Mannitol|
48502724|NCT01743950|DRUG|Bevacizumab|10mg/kg every 2weeks.
48502725|NCT01743950|RADIATION|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
48502726|NCT01531829|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
48502727|NCT01531829|DRUG|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
48502728|NCT00128050|DRUG|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
47984571|NCT02349581|PROCEDURE|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
47984572|NCT02349581|DRUG|Bupivacaine|
47984573|NCT00044395|DRUG|Ruboxistaurin mesylate|
47984574|NCT04827329|OTHER|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
47984575|NCT02560584|DRUG|Hexaminolevulinate hydrochloride|Instillation in bladder
47984576|NCT02560584|DEVICE|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
47984577|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
47984578|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
47984579|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
47984580|NCT00385879|BEHAVIORAL|Case management|
48349688|NCT00125229|DRUG|Hypertonic Saline|
48349689|NCT03712995|PROCEDURE|'Cutler-Beard modified with graft'|A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
48349690|NCT04996277|PROCEDURE|angiography|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
48502729|NCT00128050|DRUG|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
48502730|NCT00128050|OTHER|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
48502731|NCT04954027|BEHAVIORAL|Questionnaires|"5 visits are planned during the study :~* the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~* 4 telephone interviews for follow-up by investigator"
48138656|NCT03407976|DRUG|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
48659980|NCT06548828|BEHAVIORAL|Control Intervention|"Counsel about best practices for home safety and babyproofing.~Provide a detailed booklet to take home, which will provide information about home safety and baby proofing.~Educate about common causes of accidental infant and young child injuries or death.~Automated text messages will also be sent to mothers once per week with reminders about home safety, infant safety, and baby proofing."
48659981|NCT02306252|OTHER|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
48659982|NCT00853853|DEVICE|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
48659983|NCT00853853|PROCEDURE|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
48659984|NCT02329587|OTHER|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
47984581|NCT06494683|DRUG|Pueraria lobata radix|The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
47984582|NCT04358653|OTHER|fall prevention exercise program|The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
47984583|NCT04645641|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
47984584|NCT06201533|BEHAVIORAL|combined physical-cognitive exercise|A combined physical-cognitive exercise will be delivered in the form of exergame, where the participants move their body to interact with the game.
47984585|NCT01401868|DRUG|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
47984586|NCT03735433|DRUG|162mg aspirin dose|2 pills of 81mg aspirin
47984587|NCT05575167|DRUG|Zoledronate or Alendronate|infusion (for zoledronate) or oral digestion (for alendronate)
47984588|NCT05701150|OTHER|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
47984589|NCT05701150|OTHER|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
47984590|NCT00703989|DIETARY_SUPPLEMENT|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
47984591|NCT04502953|PROCEDURE|Vertical plication|Vertical plication of the rectovaginal septum was done
47984592|NCT04502953|PROCEDURE|Horizontal plication|Horizontal plication of the rectovaginal septum was done
47984593|NCT05965947|BEHAVIORAL|Medical Nutrition Therapy|One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
47984594|NCT04824885|DEVICE|Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)|usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months
47984595|NCT00056407|DRUG|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
47984596|NCT00056407|DRUG|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
47984597|NCT00911495|DRUG|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
47984598|NCT01698047|BEHAVIORAL|Resiliency Class|See Arm Description
47984599|NCT01698047|OTHER|Case Management|See Case Management description
48138657|NCT03407976|DRUG|Pembrolizumab|200 mg Q3 weeks IV
48138658|NCT05823818|DEVICE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
48138659|NCT04597866|BEHAVIORAL|Multimodal rehabilitation|A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
48138660|NCT01583920|RADIATION|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
48138661|NCT02894554|DRUG|Telbivudine|
48138662|NCT02894554|DRUG|Lamivudine|
47984600|NCT02302781|OTHER|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
48138663|NCT00229970|DRUG|montelukast sodium|7 mg or 14 mg single injection
48138664|NCT00229970|DRUG|Comparator: Placebo|Placebo single injection
48138665|NCT01082900|OTHER|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
48349691|NCT04996277|PROCEDURE|Thrombus suction|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
48349692|NCT04996277|PROCEDURE|Fibrinolytic therapy|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
48138666|NCT00875706|BEHAVIORAL|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
48138667|NCT03011047|PROCEDURE|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
48502732|NCT03866902|BEHAVIORAL|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
48502733|NCT03866902|OTHER|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
48502734|NCT04610372|RADIATION|Hypofractionated external beam radiotherapy|5500 cGy/20 fractions delivered 5 days per week over 4 weeks
48502735|NCT04610372|RADIATION|High dose rate brachytherapy|A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
48502736|NCT04610372|RADIATION|Permanent seed implant|Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
48138668|NCT03011047|PROCEDURE|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
48138669|NCT03770520|PROCEDURE|QFR-guided CABG|CABG surgery based on CAG and QFR
48502737|NCT04610372|RADIATION|Stereotactic body radiotherapy|External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
48502738|NCT02148289|DIETARY_SUPPLEMENT|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
47984601|NCT00869206|DRUG|zoledronic acid|Given IV
47984602|NCT04588792|DRUG|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
47984603|NCT04588792|DRUG|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
48138670|NCT03770520|PROCEDURE|Angio-guided CABG|CABG surgery based on heart team discussion of CAG
48138671|NCT02667366|BEHAVIORAL|Tel-PT|
48138672|NCT02667366|BEHAVIORAL|TAU and text messages|
48349693|NCT04996277|BEHAVIORAL|Medication stabilized the condition|All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
48349694|NCT03350802|DIAGNOSTIC_TEST|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
47984604|NCT03930043|DIAGNOSTIC_TEST|Metagenomic shotgun sequencing|preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
47984605|NCT05020990|DEVICE|Lens A (delefilcon A)|Daily disposable for one week
47984606|NCT05020990|DEVICE|Lens B (stenfilcon A)|Daily disposable for one week
47984607|NCT02703389|BEHAVIORAL|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
47984608|NCT02703389|BEHAVIORAL|Pamphlet|Contains same information as video.
47984609|NCT03251079|DEVICE|Continuous glucose monitoring system|Implanted continuous glucose monitoring system
48002552|NCT04289116|BEHAVIORAL|We Test|This design tests the added benefits of adjunct intervention components delivered prior to receipt of CHTC-Assertive Communication Training (ACT) videos viewed by the couple separately and individually delivered Motivational Interviewing-based Communication Skills Training (MI-CST). These target the development of communication skills necessary to participate fully in HIV prevention and sexual safety discussions inherent to CHTC.
48002553|NCT04289116|BEHAVIORAL|IHTC|Individual HIV Testing and Counseling
48349695|NCT01376505|BIOLOGICAL|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
48138673|NCT05040828|BEHAVIORAL|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
48138674|NCT05040828|BEHAVIORAL|Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.|10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
48502739|NCT02148289|DIETARY_SUPPLEMENT|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
48659985|NCT02329587|OTHER|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
48659986|NCT06512558|PROCEDURE|Additional MRI with gadolinium injection and 3D camera imaging|The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.
48659987|NCT05374603|DRUG|Savolitinib|Savolitinib combine with Durvalumab
48659988|NCT05374603|DRUG|Durvalumab|savolitinib plus durvalumab
48659989|NCT00433186|DRUG|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
48659990|NCT02399228|DRUG|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
48659991|NCT03815552|DEVICE|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
48659992|NCT00789711|DRUG|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
48659993|NCT00789711|DRUG|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
48659994|NCT00184392|PROCEDURE|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
48659995|NCT04174586|BIOLOGICAL|microtransplantation|HLA mismatched donor cord blood infusion
48659996|NCT06645184|DIETARY_SUPPLEMENT|Oral nutritional supplement|During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.
48659997|NCT06535373|OTHER|Blood flow restriction|Both groups will undergo a 6-week training intervention with training 2x a week, after which grip strength and other relevant outcomes will be measured and compared. Exercise sessions will be at least 48 hours apart. Participants will be allowed to continue with their normal exercise routine outside of the study.
48659998|NCT03462745|DEVICE|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
48659999|NCT04509388|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
48660000|NCT04932772|OTHER|Kinesiotaping|Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
48660001|NCT04932772|OTHER|Abdominal Exercises|Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
48660002|NCT04518228|DRUG|Bictegravir (BIC)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
47984610|NCT06469970|DRUG|Glucose 30% Intravenous Solution|"Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection.~The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients."
48349696|NCT01376505|BIOLOGICAL|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
48349697|NCT02396004|DEVICE|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
48349698|NCT00224497|DRUG|SB-742457|
48349699|NCT05997173|OTHER|Control|Investigation of scale of control
47984611|NCT05552768|PROCEDURE|Bone level-driven placement|The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.
48349700|NCT05997173|OTHER|Non erosive OLP|Investigation of cale of non erosive OLP patients
48349701|NCT05997173|OTHER|Erosive OLP|Investigation of cale of erosive OLP patients
48502740|NCT05310695|OTHER|NSAC - rapid|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.
48660003|NCT04518228|DRUG|Tenofovir alafenamide (TAF)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660004|NCT04518228|DRUG|Cabotegravir (CAB)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660005|NCT04518228|DRUG|Dolutegravir (DTG)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660006|NCT04518228|DRUG|Atazanavir/ritonavir (ATV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660007|NCT04518228|DRUG|Darunavir/ritonavir (DRV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660008|NCT04518228|DRUG|Lopinavir/ritonavir (LPV/r)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660009|NCT04518228|DRUG|Cobicistat|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660010|NCT04518228|DRUG|Ritonavir|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660011|NCT04518228|DRUG|First-Line TB Treatment|"Participants will be receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), or moxifloxacin (MFX).~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
48138675|NCT05040828|DRUG|No oral drug therapy throughout the pollen period|Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
48138676|NCT02491489|OTHER|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (\~50 degrees abduction, slight horizontal adduction, external rotation).
48138677|NCT01054287|OTHER|Multifactorial falls prevention program|
48138678|NCT01054287|OTHER|No falls prevention intervention|
48138679|NCT01534091|BEHAVIORAL|Pedometer with supervision|
48138680|NCT01534091|BEHAVIORAL|Pedometer without supervision|
48349702|NCT02772991|OTHER|troponin measurement|Cardiac catheterization (for patients with \>50% lesions) or discharge or in patients with intermediate risk.
48349703|NCT05179057|DRUG|Posoleucel|Administered as 2-4 milliliter infusion, visually identical to placebo
48349704|NCT05179057|DRUG|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel
48349705|NCT00472043|DRUG|PDT with Metvix 160 mg/g cream|
48349706|NCT00472043|DRUG|Placebo|
48349707|NCT06417190|DRUG|Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)|Single-arm, open-label
48349708|NCT04461613|OTHER|Original IPAQ followed by a revised one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
48349709|NCT04461613|OTHER|Revised IPAQ followed by an original one.|Comparing two questionnaires (a revised version and an original International Physical Activity Questionnaire short form) with an activity diary.
48349710|NCT05071911|PROCEDURE|TAD (Targeted Axillary Dissection)|Dual agent SLNB + resection of proven lymph nodes metastasis marked with clip at diagnosis
48349711|NCT03931590|DRUG|[14C]-Omaveloxolone|\[14C\]-Omaveloxolone 50 mg capsules
48349712|NCT02352090|DRUG|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
48349713|NCT02352090|DRUG|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
48349714|NCT02352090|DRUG|Dienogest|One tablet orally for 9 weeks, continuous use
48138681|NCT04009291|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
48349715|NCT00515099|DRUG|Antithymocyte globulin|Daily 4-day escalating dose
48660012|NCT04518228|DRUG|Second-Line TB Treatment|"Participants will be receiving second-line TB treatment with at least one of the following second-line TB treatment drugs:~* Levofloxacin (LFX) 750mg - 1000mg q.d.~* Clofazimine (CFZ) 100mg q.d.~* Linezolid (LZD) 300mg - 600mg q.d.~* Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~* Delamanid (DLM) 100mg b.i.d.~* Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study~Drugs will be administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants."
48660013|NCT04518228|DRUG|Doravirine (DOR)|Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
48660014|NCT01044069|BIOLOGICAL|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed \& frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, \& transduced with the 19-28z chimeric receptor \& expanded. All relapsed (either MRD+ or morphologic) \& refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo \& highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
48660015|NCT01542944|DRUG|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
47984612|NCT05552768|PROCEDURE|Biological width-driven placement guidelines|Biological width-driven placement guidelines
47984613|NCT05755685|DRUG|Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)|5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
47984614|NCT03026608|BEHAVIORAL|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
47984615|NCT02409992|BEHAVIORAL|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
47984616|NCT02409992|BEHAVIORAL|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
48660016|NCT02695277|DEVICE|AtriCure Bipolar System|
48660017|NCT02695277|DEVICE|Standard Endocardial Ablation with Catheter|
47984617|NCT03963362|DRUG|GLA5PR tablet 75 mg|GLARS-NF3 tablet
47984618|NCT03963362|DRUG|GLA5PR tablet 150 mg|GLARS-NF3 tablet
48349716|NCT00515099|DRUG|Placebo|Daily 4-day saline solution
48349717|NCT01711437|DEVICE|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
48349718|NCT01711437|DEVICE|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
48349719|NCT01711437|DEVICE|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
48349720|NCT01711437|DEVICE|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
48660018|NCT02695277|DEVICE|AtriClip® PRO LAA Exclusion System|
48660019|NCT02695277|DEVICE|Endocardial Ablation with Catheter|
48660020|NCT02695277|DEVICE|Repeated Endocardial ablation(s)|
47984619|NCT01196923|DEVICE|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
47984620|NCT04726423|OTHER|transcranial direct current stimulation|5 daily sessions of tDCS (2mA, 20 min) were recommended to all patients. Physical exercises were also done at the physiotherapy clinic. Physical exercises program was recommended to be continued at home after the week of physiotherapy visits.
47984621|NCT03043027|DRUG|liposomal bupivicaine|local anesthetic
47984622|NCT03043027|DRUG|Bupivacaine|local anesthetic
47984623|NCT03043027|DRUG|Saline Solution|saline injection
47984624|NCT04720846|OTHER|Matrix-based physical therapy|Matrix-based physical therapy will be physical therapy that is based on the matrix categorization of the patient (stiff vs. mobile hips, weak vs. strong hips) and involves instructions on the amount of time that should be spent doing stretching and strengthening therapy.
47984625|NCT04720846|OTHER|Standard-of-care physical therapy|Physical therapy that is being conducted as standard-of-care
47984626|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
48002554|NCT02611492|DRUG|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
48138682|NCT04009291|COMBINATION_PRODUCT|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
48349721|NCT00380406|DRUG|Leuprolide acetate|
48349722|NCT02791477|DEVICE|Attune FB PS knee arthroplasty|
48349723|NCT05126550|BIOLOGICAL|SARS-CoV-2 vaccine (Vero cell) inactivated|"Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)"
48660021|NCT00860769|BEHAVIORAL|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
48660022|NCT00860769|BEHAVIORAL|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
47984627|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
48502741|NCT05310695|OTHER|NSAC - ordinary|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.
48660023|NCT01480830|DEVICE|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
47984628|NCT05516706|OTHER|Dynamic stretching|Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
47984629|NCT05516706|OTHER|Plyometric push up|Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
47984630|NCT03952000|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
48660024|NCT02326584|DRUG|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
48349724|NCT04268706|DRUG|CD30.CAR-T|Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
48660025|NCT02326584|DRUG|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
48660026|NCT02326584|DRUG|Daunorubicin|60 mg/m2/day Days 1-3
48660027|NCT02326584|DRUG|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
48660028|NCT03227549|PROCEDURE|Direct Superior Approach|Total hip arthroplasty using direct superior approach
48660029|NCT03227549|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
48660030|NCT03227549|PROCEDURE|Posterior Approach|Total Hip Arthroplasty using posterior approach
48660031|NCT00643656|DRUG|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
48660032|NCT00643656|DRUG|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
48502742|NCT05310695|OTHER|NSAC - active control|The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
48502743|NCT05561647|OTHER|No Intervention|This is non-interventional study.
48660033|NCT06637969|BEHAVIORAL|mindfulness-based|The experimental group was also provided with a total of 30 minutes of mindfulness training once a day for seven consecutive days. The content included mindful breathing awareness for 8 minutes while resting and lying in bed, 10 minutes of mindfulness meditation, 12 minutes of mindfulness body scanning, and 10 minutes of mindful walking and breathing. The control group The group received routine care, and a pre-test was conducted before the implementation of the interventional measures (from 7 pm to 9 pm the day before the operation), and a post-test was conducted after the seven-day intervention (from 7 pm to 9 pm on the seventh day of the interventional treatment). Comparison between the experimental group and the control group group differences
48660034|NCT03750019|BEHAVIORAL|Satisfying rehearsal task|Participants rehearsed satisfying aspects of the lunchtime meal they just ate.
48660035|NCT03750019|BEHAVIORAL|Dissatisfying rehearsal task|Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.
48660036|NCT03750019|BEHAVIORAL|Neutral rehearsal|Participants rehearsed their journey to campus that day.
48660037|NCT05577741|BEHAVIORAL|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
47984631|NCT04694144|DEVICE|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
47984632|NCT02442869|BEHAVIORAL|Stage 1 Treatment as usual (TAU)|4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
47984633|NCT02442869|BEHAVIORAL|Stage 1 CAMS|4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
47984634|NCT02442869|BEHAVIORAL|Stage 2 CAMS|4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
47984635|NCT02442869|BEHAVIORAL|Stage 2 Dialectical Behavioral Therapy (DBT)|4-16 weeks of Dialectical Behavioral Therapy (DBT)
48138683|NCT03912909|DRUG|Empagliflozin Oral Tablet [Jardiance]|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
48138684|NCT03912909|DRUG|Placebo Oral Tablet|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
48138685|NCT02235298|DRUG|Dapagliflozin|5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
48502744|NCT01841476|DRUG|POL6326|
48660038|NCT05577741|BEHAVIORAL|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
48660039|NCT05577741|OTHER|Standard treatment|Standard of care treatment
48660040|NCT04656912|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
48660041|NCT03919162|DRUG|PQ912|PQ912 150 mg tablets
48660042|NCT03919162|OTHER|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
48660043|NCT01585025|DRUG|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
48349725|NCT04268706|DRUG|Fludarabine|Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
48660044|NCT03731429|DRUG|Lidocaine|prior to extubation
48138686|NCT02235298|DRUG|Metformin|500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
48138687|NCT02235298|DRUG|Placebo|Placebo pill taken once daily to mimic Dapagliflozin
48138688|NCT04275960|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
48138689|NCT02508441|DRUG|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
48138690|NCT00290537|DRUG|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
48138691|NCT00290537|DRUG|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
48138692|NCT00290537|DRUG|Paclitaxel|200 mg/m\^2 IV Over 3 Hours On Day 1
48138693|NCT05935046|BEHAVIORAL|Walk test and meal test|"The subjects will perform a treadmill walking test at increasing speed from 2 to 6km.h-1 in 5min increments.~During the second experimental visit, subjects will be required to consume a test meal containing 590kcal (12% protein, 35% fat, 53% carbohydrate) (Duhita et al 2017).~The composition of the test meal will be developed based on the food preferences and habits questionnaires completed during the inclusion visit. Foods indicated as preferred by participants will not be offered during these sessions to avoid any influence of their palatable nature on participants' consumption."
48138694|NCT05168397|OTHER|RV4857A|RV4857A formula CD2110 is a sunscreen product
48138695|NCT02745990|DRUG|Recombinant human erythropoietin|rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
47984636|NCT00000233|DRUG|Buprenorphine|
47984637|NCT04226378|DEVICE|Omnipod|Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.
48138696|NCT02745990|DRUG|Normal saline|Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
48660045|NCT03731429|DRUG|Saline Solution|Prior to extubation
48660046|NCT05770570|BEHAVIORAL|Counseling|In-person individual diet and physical activity (PA) counseling
47984638|NCT04226378|OTHER|MDI|Continued use of MDI therapy (traditional basal/bolus insulin regimen).
47984639|NCT05975515|PROCEDURE|Connective tissue graft /Bone graft/ Customized HA|Soft tissue management and augmentation
47984640|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in left side|
48138697|NCT01428206|OTHER|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
48138698|NCT01935063|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
48138699|NCT01935063|OTHER|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
48138700|NCT02461979|OTHER|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
48660047|NCT05770570|BEHAVIORAL|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
48660048|NCT05770570|BEHAVIORAL|Phone calls|Weekly telephone support
48660049|NCT05770570|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools
48660050|NCT05994287|DRUG|Aspirin|The patients received aspirin in a dose of 100 mg orally daily.
48660051|NCT05994287|DRUG|Ketorolac|The patients received ketorolac in a dose of 90 mg mg orally daily.
47984641|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in right side|
47984642|NCT04388267|DRUG|Fluid challenge|"All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min."
47984643|NCT05962970|DRUG|continuous adductor canal block (CACB) ropivacaine|The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h
48660052|NCT05994287|DRUG|Celecoxib|The patients received celecoxib in a dose of 400 mg orally daily.
48660053|NCT00480532|DRUG|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
48660054|NCT00480532|DRUG|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
48138701|NCT04932018|BEHAVIORAL|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
48138702|NCT04932018|BEHAVIORAL|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
48138703|NCT04415307|OTHER|Acupuncture|Acupuncture over acupoints.
48138704|NCT04415307|OTHER|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
48138705|NCT04415307|OTHER|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
48138706|NCT04415307|OTHER|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
48138707|NCT00087256|DRUG|Celecoxib|
48138708|NCT00087256|OTHER|placebo|
48138709|NCT01249209|DEVICE|lifestyle advice|
48138710|NCT04132154|PROCEDURE|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
48138711|NCT01439906|PROCEDURE|Surgical correction of the deformity|"Three different surgical techniques are used:~* lumbar fusion vs thoraco-lumbar fusion~* iliac fixation vs fixation to the sacrum~* posterior + interbody fusion vs posterior interbody fusion"
48138712|NCT00838461|DRUG|HSD-016|
48002555|NCT02611492|DRUG|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
48138713|NCT00838461|DRUG|placebo|
48138714|NCT06497920|DEVICE|Active rTMS to the motor cortex|Active bilateral repetitive transcranial magnetic stimulation to the motor cortex
48138715|NCT06497920|DEVICE|Sham rTMS to the motor cortex|Sham bilateral repetitive transcranial magnetic stimulation to the motor cortex
48138716|NCT03530631|DRUG|Adderall|Participants will be administered Adderall
48138717|NCT03530631|DRUG|Placebo|Participants will be administered placebo
48138718|NCT06033040|OTHER|MRI|Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor
48138719|NCT00186446|DRUG|bupropion and smoking cessation behavioral intervention|
48138720|NCT04497337|PROCEDURE|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
48138721|NCT03857321|DRUG|Insulin|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly \& Company)
48138722|NCT03857321|OTHER|Placebo|Matching placebo (sterile saline) to 20 IU Humulin® R U-100
48138723|NCT03857321|DEVICE|intranasal nebulizer-like device|Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
48138724|NCT02802566|DIETARY_SUPPLEMENT|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
48138725|NCT02802566|DIETARY_SUPPLEMENT|Standard prenatal vitamin|Standard prenatal vitamin
48138726|NCT04886674|DIETARY_SUPPLEMENT|bovine colostrum|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for \< 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
48138727|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
48660055|NCT00480532|DRUG|Oracea|40-mg tablet daily for 84 days
48660056|NCT00480532|DRUG|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
48138728|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
48138729|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
48138730|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
48502745|NCT00370812|PROCEDURE|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
48660057|NCT00480532|DRUG|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
48138731|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
48660058|NCT00480532|DRUG|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
47984644|NCT05962970|DRUG|sham continuous adductor canal block - ShACB NaCl|sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
47984645|NCT03182829|DIAGNOSTIC_TEST|DOAC Dipstick|"Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]"
48138732|NCT00016107|DRUG|estramustine phosphate sodium|Given orally
48138733|NCT00016107|DRUG|docetaxel|Given IV
48138734|NCT00016107|BIOLOGICAL|bevacizumab|Given IV
48138735|NCT00016107|OTHER|laboratory biomarker analysis|Correlative studies
48138736|NCT03897699|DEVICE|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
48138737|NCT03897699|BEHAVIORAL|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
48138738|NCT03897699|OTHER|Sham|Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
48138739|NCT05604755|DRUG|HQP1351( Olverembatinib dimesylate)|HQP1351 was initiated at a dose of 40mg every two days
48138740|NCT03247595|DIETARY_SUPPLEMENT|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
48138741|NCT03247595|OTHER|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
48138742|NCT03247595|OTHER|Dulcolax Tablets|4 Dulcolox Tablets
47984646|NCT02760667|DRUG|Cisplatinum|Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
47984647|NCT02760667|DRUG|Docetaxel|Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
47984648|NCT02760667|DRUG|Carboplatin|Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)
47984649|NCT02760667|PROCEDURE|Transoral Robotic Assisted Surgery|TORS will be performed for the patients who responded to the induction treatment (80% reduction)
47984650|NCT05366803|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
47984651|NCT05195463|OTHER|Exercise intervention|Women with diastasis recti abdominis will do core stabilization exercises for the transversus abdominis muscle with 10 repetitions 3 days a week for 8 weeks. The exercises include diaphragmatic breathing exercises, core stabilization exercises for the transversus abdominis muscle, and pelvic floor contractions
48138743|NCT02533232|DRUG|Minocycline|Minocycline 200mg per day
48660059|NCT00480532|DRUG|placebo daily|Placebo daily for the first 84 days of the study
48660060|NCT03374306|DRUG|Atropine (0.01%)|tropical application
48349726|NCT04268706|DRUG|Bendamustine|Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
48349727|NCT05740891|DRUG|BCMA CAR-T cells injection|Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
48349728|NCT02954861|OTHER|No intervention|No intervention
48349729|NCT03872336|DRUG|Experimental labetalol dose|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
48502746|NCT03996135|DEVICE|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
48502747|NCT02532725|PROCEDURE|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
48660061|NCT03374306|DRUG|Artificial tear|tropical application
48349730|NCT03872336|OTHER|Current standard of care|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
48502748|NCT02532725|PROCEDURE|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
48502749|NCT02532725|PROCEDURE|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
48502750|NCT02532725|PROCEDURE|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
48660062|NCT03275337|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
48660063|NCT05706350|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
48660064|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (2g per day)|Participants have to consume 4 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 2g daily
47984652|NCT05195463|OTHER|Exercise intervention by wearing abdominal corset|In this group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. Participants will be asked to wear their corsets while performing their exercises.
47984653|NCT05195463|OTHER|Corset intervention|Participants included in this group will be required to wear only this corset all day (except for the bathroom) for 8 weeks.
47984654|NCT00989339|DRUG|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
47984655|NCT05938543|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS"
47984656|NCT03297996|DIAGNOSTIC_TEST|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
47984657|NCT00849810|DRUG|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
47984658|NCT00849810|DRUG|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
47984659|NCT04496154|DIETARY_SUPPLEMENT|Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)|Triple Strength Omega-3 from Webber Naturals
47984660|NCT03316664|BEHAVIORAL|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
47984661|NCT03316664|BEHAVIORAL|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
47984662|NCT03316664|OTHER|COGPACK|Information already included in arm/group description.
47984663|NCT01150981|DRUG|Rosiglitazone|One 8mg capsule daily for 6 weeks.
47984664|NCT01150981|DRUG|Placebo|One capsule daily for 6 weeks.
47984665|NCT04646798|OTHER|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
47984666|NCT04646798|OTHER|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
47984667|NCT02150096|OTHER|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
47984668|NCT02150096|OTHER|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
47984669|NCT02150096|OTHER|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
47984670|NCT03586856|DEVICE|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
47984671|NCT03586856|DEVICE|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
47984672|NCT04407000|DRUG|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
47984673|NCT04407000|DRUG|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
47984674|NCT03938584|DIETARY_SUPPLEMENT|Vitamin C|Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
48002556|NCT02611492|DRUG|Aracytine (Ara C)|Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
48660065|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (3g per day)|Participants have to consume 6 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 3g daily
48660066|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (4g per day)|Participants have to consume 8 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 4g daily
48660067|NCT05706350|DIETARY_SUPPLEMENT|Control soft chews|Participants have to consume 6 control soft chews per day that does not contain plant stanols
48660068|NCT05860244|DRUG|Salbutamol|Salbutamol for 6 months
48660069|NCT05860244|DRUG|Placebo|Placebo Syrup for 6 months
48660070|NCT02951481|BEHAVIORAL|Systematic evaluation by an ID expert.|"Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."
48660071|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
47984675|NCT03938584|OTHER|Placebo|Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
47984676|NCT02029950|DRUG|Cytarabine|Given IV
47984677|NCT02029950|DRUG|Daunorubicin Hydrochloride|Given IV
47984678|NCT02029950|DRUG|Etoposide|Given IV
47984679|NCT02029950|DRUG|Idarubicin Hydrochloride|Given IV
47984680|NCT02029950|OTHER|Laboratory Biomarker Analysis|Correlative studies
47984681|NCT02029950|OTHER|Pharmacological Study|Correlative studies
47984682|NCT02029950|DRUG|Pomalidomide|Given PO
47984683|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
47984684|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
47984685|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
47984686|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
47984687|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
47984688|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
47984689|NCT01529346|DRUG|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
47984690|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
47984691|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
47984692|NCT01529346|OTHER|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
47984693|NCT01370174|OTHER|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
47984694|NCT00913042|OTHER|sample blood|"* Early culture~* Bacterial DNA tests in blood"
47984695|NCT00110825|BEHAVIORAL|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
47984696|NCT02921698|DEVICE|FRED®|Flow Re-Direction Endoluminal Device
47984697|NCT06420440|PROCEDURE|Hepatic arterial infusion chemotherapy|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)
47984698|NCT06420440|DRUG|Lenvatinib|Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).
47984699|NCT06420440|DRUG|Tislelizumab|Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)
47984700|NCT06420440|PROCEDURE|Liver resection|Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.
47984701|NCT06420440|DRUG|Tislelizumab|Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
47984702|NCT05599633|DIETARY_SUPPLEMENT|Sago starch drink|Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
47984703|NCT05599633|DIETARY_SUPPLEMENT|Corn starch drink|Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
47984704|NCT06188936|DEVICE|ExSeed®|"In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email."
47984705|NCT06188936|OTHER|Survey|Surveys will be completed on a hard copy or electronically.
47984706|NCT05571241|BEHAVIORAL|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
48349731|NCT03025516|DEVICE|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
48349732|NCT03025516|DEVICE|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
48349733|NCT02431793|BEHAVIORAL|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
48349734|NCT02431793|BEHAVIORAL|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
48349735|NCT04871386|BEHAVIORAL|Acceptance and commitment therapy (ACT) exercises|The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.
47984707|NCT04434794|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
47984708|NCT04434794|OTHER|standard treatment|standard treatment according to clinical protocols
47984709|NCT02228551|OTHER|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
47984710|NCT03778554|DRUG|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
47984711|NCT03778554|DRUG|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
47984712|NCT03778554|DRUG|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
47984713|NCT03778554|DRUG|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
47984714|NCT00002222|DRUG|Valganciclovir|
47984715|NCT02746874|PROCEDURE|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
47984716|NCT02746874|PROCEDURE|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
48349736|NCT04871386|BEHAVIORAL|Positive psychology (PP) exercises|The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
48502751|NCT00471289|DEVICE|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
48138744|NCT06511089|PROCEDURE|carotid artery stenting during EVT|"Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.~In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke)."
48138745|NCT06511089|OTHER|no carotid artery stenting during EVT|A deferred treatment approach: carotid revascularization within two weeks after stroke onset or best medical management only, depending on the functional recovery of the patient.
48138746|NCT00399828|DEVICE|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
48138747|NCT00336349|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
48138748|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
48138749|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
48138750|NCT00824408|DRUG|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
48138751|NCT04630509|PROCEDURE|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
48138752|NCT03874169|DEVICE|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
48138753|NCT04587219|BIOLOGICAL|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
48138754|NCT05113134|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder will undergo Transvaginal NOSE
48138755|NCT05841407|DIETARY_SUPPLEMENT|High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
48138756|NCT05841407|DIETARY_SUPPLEMENT|No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
48138757|NCT05001126|BEHAVIORAL|HIFT 1x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 1x/week represents a dose of one HIFT workout per week.
48138758|NCT05001126|BEHAVIORAL|HIFT 2x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 2x/week represents a dose of two HIFT workouts per week.
48138759|NCT05001126|BEHAVIORAL|HIFT 3x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 3x/week represents a dose of three HIFT workouts per week.
48349737|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
48349738|NCT00952419|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
48349739|NCT00952419|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
48660072|NCT04769869|DRUG|Placebo for AZD4604 for inhalation via DPI|"Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10."
48660073|NCT04769869|DRUG|AZD4604 for IV administration|Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
48660074|NCT04769869|DRUG|AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
47984717|NCT00368654|DRUG|Methotrexate|Initial dose 5 mg, then 15 mg per week
48138760|NCT01801800|PROCEDURE|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
48138761|NCT03590899|DEVICE|Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)|Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
48349740|NCT05533073|DRUG|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
48349741|NCT05533073|DRUG|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
48502752|NCT00471289|DEVICE|PTA|PTA
48138762|NCT01670799|DRUG|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
48138763|NCT04150042|DRUG|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
48138764|NCT04150042|DRUG|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
48138765|NCT04150042|DRUG|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
48349742|NCT05533073|DRUG|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
48349743|NCT04202432|DIAGNOSTIC_TEST|Mean systemic filling pressure|"Peri- and postoperative measurement of continuous cardiac output with thermodilution derived pulse contour calculated device (PiCCO).~Estimation of mean systemic filling pressure using a computerized algorithm and by creating venous return curves with inspiratory hold maneuvers, thereby extrapolating the VR-curve until mean systemic filling pressure is calculated."
48349744|NCT04514406|DEVICE|APERTO OTW DCB|Drug Coated Balloon Angioplasty
48502753|NCT06355791|DEVICE|Minuteman G5|The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy
47984718|NCT00368654|DRUG|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
47984719|NCT03443284|BEHAVIORAL|Health Partner|Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
47984720|NCT03443284|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
47984721|NCT05851781|DRUG|Lacosamide tablet|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
48002557|NCT02611492|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
48138766|NCT04150042|DRUG|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
48138767|NCT04150042|DRUG|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
48138768|NCT04150042|DEVICE|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
48138769|NCT04390516|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
48138770|NCT03421301|DIETARY_SUPPLEMENT|dietary portfolio|The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
48138771|NCT05088200|PROCEDURE|surgery|Our study is observational and we use secondary data
48349745|NCT01846208|DRUG|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
48349746|NCT01846208|DRUG|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
48502754|NCT01685411|DRUG|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
48502755|NCT01685411|DRUG|Keppra|Day -8 (prior to transplant): Per institutional guidelines
48502756|NCT01685411|DRUG|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
48002558|NCT02611492|DRUG|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
48002559|NCT02611492|DRUG|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
48502757|NCT01685411|DRUG|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
48002560|NCT02611492|DRUG|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
48138772|NCT02148575|BEHAVIORAL|Self-Management Group|
48138773|NCT02148575|BEHAVIORAL|Symptom Management Group|
48138774|NCT00715351|DRUG|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
48138775|NCT00715351|DRUG|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
48138776|NCT03568409|DEVICE|ABO-GLYC|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
48502758|NCT01685411|DRUG|Tacrolimus|All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
48138777|NCT03568409|OTHER|ABO-GLYC Placebo|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
48138778|NCT06497699|DRUG|Dexycu|single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
48138779|NCT03950206|OTHER|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung\&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
48138780|NCT02234141|DRUG|Placebo|Tablet administered orally once daily
47984722|NCT05851781|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
47984723|NCT01502189|OTHER|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
47984724|NCT05485298|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
47984725|NCT05039242|OTHER|Conventional Physical Therapy)|"Participants will receive a Hand exercise program including 8 different movements according to Flat 20 (flexion, extension, radial deviation of the fingers, dorsal flexion, palmar flexion, ulnar deviation of the fingers, and opposition and abduction of thumbs.~Repetitions include 5 times during each session, as given in the study. Balanced resistive hand exercise with use of physio hand ball squeezes including finger abduction and adduction exercises with MCP extended and gross grip.~Each contraction to be held for 3-5 seconds with a 20-second rest between contractions. Five repetitions of each resistive exercise will be done."
48002561|NCT02611492|DRUG|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
48138781|NCT02234141|DRUG|Selonsertib|Tablets administered orally once daily
48138782|NCT01502813|DRUG|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
48138783|NCT05739370|OTHER|Problem-Solving Therapy for Older Adults|"Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback."
48138784|NCT05503368|PROCEDURE|surgical treatment of vitiligo using NCES|NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension
48138785|NCT01433185|OTHER|Text message|Text messages sent to women before and after delivery
48138786|NCT03375424|BIOLOGICAL|vedolizumab|duration of disease and kind of therapy
48502759|NCT01685411|DRUG|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (\> or = 40 kg) or 15 mg/kg 3 times per day (\< 40 kg) for up to 30 days unless no engraftment.
48502760|NCT01685411|BIOLOGICAL|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
48502761|NCT01685411|BIOLOGICAL|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is \>2500 x 10\^9/L or per institutional guidelines.
48502762|NCT01685411|BIOLOGICAL|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
48502763|NCT02128061|DRUG|Lenalidomide|
48502764|NCT02128061|DRUG|Rituximab|
48502765|NCT06251492|RADIATION|Stereotactic body radiotherapy|8 Gray x 3 for 2 cycles
48502766|NCT06251492|DRUG|Adebrelimab|Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
48502767|NCT06633354|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-ALL Targeted CAR T-cells by intravenous infusion
48502768|NCT00076076|DRUG|Roflumilast|
48502769|NCT05360940|DIAGNOSTIC_TEST|H.pylori stool antigen rapid test and stool parasitological examination|200 stool samples ( 100 positive and 100 negative for H.pylori) after performance of H.pylori stool rapid antigen test then parasitological stool examination will be done
48502770|NCT05710692|DRUG|PRX-102 1 mg/kg every 2 weeks|PRX-102 1 mg/kg every 2 weeks
48502771|NCT05710692|DRUG|PRX-102 2 mg/kg every 4 weeks|PRX-102 2 mg/kg every 4 weeks
48502772|NCT00853463|BEHAVIORAL|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
48660075|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
47984726|NCT05039242|OTHER|Kinesiotaping with I shaped application|Participants will receive Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm with less than 50% stretch of the subjects on both hands, once a week for a total time period of 4 weeks with 4 KT applications in total (19). Kinesiotape will be worn by the subjects for 3 days. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs.
48138787|NCT04378894|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
48349747|NCT03567590|PROCEDURE|Pulsed Radiofrequency treatment|The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
48349748|NCT03567590|PROCEDURE|Nerve Block treatment|A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
48349749|NCT00669513|BEHAVIORAL|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
48349750|NCT05394181|OTHER|Notification|Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
48349751|NCT01044056|DRUG|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
48349752|NCT01044056|DRUG|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
48660076|NCT06185751|BIOLOGICAL|WS-CART-CS1|-Subject will be hospitalized for 7 days
48660077|NCT06185751|DRUG|Lymphodepleting chemotherapy|"* Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3"
48660078|NCT02852330|DEVICE|SA16 research software|Software for measurement of voltage tomography intraoperatively.
48660079|NCT02852330|DEVICE|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
48138788|NCT05726526|DEVICE|VIEWER virtual care platform|VIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
48138789|NCT03056313|BEHAVIORAL|Proactive support of labor|In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
48349753|NCT01044056|DRUG|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
48349754|NCT01898000|BEHAVIORAL|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
48349755|NCT01898000|BEHAVIORAL|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
48660080|NCT06263803|OTHER|Music listening, classic physical therapy|Participants will listen to the music pieces Pachabel Canon in D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes), free from external sounds (max 70 dB through headphones).
48660081|NCT06047470|BEHAVIORAL|Kangaroo Care|Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.
48660082|NCT06047470|BEHAVIORAL|No Kangaroo Care|Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
48660083|NCT00759395|DRUG|AZD2327|Tablet, Oral, Daily
48660084|NCT00759395|DRUG|Placebo|Tablet, Oral, Daily
48660085|NCT03409809|BEHAVIORAL|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
48660086|NCT03409809|BEHAVIORAL|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
47984727|NCT05039242|OTHER|Kinesiotaping with Fan-shaped Application|"Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects, once a week for a total time period of 4 weeks with 4 KT applications in total.~Kinesiotape will be worn by the subjects for 3 days. Less than 50% stretch with space correction technique. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs."
48002562|NCT02611492|DRUG|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
48138790|NCT03056313|BEHAVIORAL|support of labor as usual|In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
48138791|NCT04627896|DEVICE|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
48138792|NCT06195306|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48138793|NCT06195306|PROCEDURE|Mammography|Undergo mammography
48138794|NCT06195306|DRUG|Omega-3-Acid Ethyl Esters|Given PO
48349756|NCT01429155|GENETIC|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
48660087|NCT03409809|BEHAVIORAL|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
48660088|NCT01220583|DRUG|cisplatin|Given IV
48660089|NCT01220583|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
48660090|NCT01220583|RADIATION|intensity-modulated radiation therapy|Undergo radiotherapy
48660091|NCT02144532|DEVICE|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
48660092|NCT05703295|PROCEDURE|Biopsy|Sentinel lymph node biopsy
48660093|NCT06501196|DRUG|BH-30236|BH-30236 will be provided as either a 5 or 30 mg tablet. Patients will take BH-30236 orally depending on their dose level assignment.
48660094|NCT04017312|DEVICE|High Frequency Chest Wall Oscillation|High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
48349757|NCT06250504|DRUG|APRETUDE (cabotegravir) 600 mg\3 mL|choice of 2-monthly injectable long acting cabotegravir. The initial visit will be followed by planned visit for the first injection, one month visit for second injection, and then 2-monthly CAB LA injections with repeat HIV testing and pregnancy testing, and referral to peer navigators for adherence and retention support. We will conduct HIV testing, STI testing, Hep B, Hep C, and safety bloods (Full Blood Count, Creatinine, Liver Function Tests) at baseline, HIV testing two monthly, and annual safety bloods, alongside annual STI testing.
48660095|NCT04017312|DEVICE|Oscillating Positive Expiratory Pressure (OPEP)|Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
48660096|NCT05614089|DRUG|Insulin Glargine|"Formulation: Available as a clear liquid in a glass cartridge (1 cartridge =3ml=300 units).~Route: Reusable pen~Amount of each dose: varies depending on baseline basal insulin needs~Dose escalation scheme: Participants randomly assigned to glargine will start with a dose that is generally equal to 80% of their total basal human insulin dose prior to the switch (per ISPAD guidelines and the switching guide developed by Life for a Child with the guidance of Dr. Ragnar Hanas and two other ISPAD members familiar with less-resourced settings).~Frequency of dose: once per day (usually administered before bedtime)"
47984728|NCT05874856|DIAGNOSTIC_TEST|Heart rate variability, blood pressure and pulse wave velocity|Resting HRV in supine and standing position, blood pressure and pulse wave velocity in supine position at first and last week of inpatient treatment
47984729|NCT05874856|DIAGNOSTIC_TEST|Assessment of cognitive function, balance, strength and cardiorespiratory fitness|"THINC-it test for cognitive function; One-leg Standing test for balance assessment; 10-time chair rise test and hand grip test for strength assessment; Åstrand-Ryhming Test for cardiorespiratory fitness.~All assessments will be performed at first and last week of inpatient treatment."
48502773|NCT03173326|PROCEDURE|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
47984730|NCT05874856|BEHAVIORAL|Monitoring of physical activity and sleep|GENEActiv accelerometer will be worn on the wrist daily during 8-week inpatient treatment.
47984731|NCT05874856|BEHAVIORAL|Monitoring of self-rated exhaustion, mood and tension|Using the customized PsyMate app.
48002563|NCT04262895|DRUG|TTI-0102|TTI-0102 is a cysteamine precursor.
48138795|NCT06195306|OTHER|Questionnaire Administration|Ancillary studies
48138796|NCT06195306|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
48138797|NCT06195306|DRUG|Tamoxifen|Given PO
48138798|NCT04934033|OTHER|Neurological assessments|The participants will have a MRI, and language and cognitive assessments.
48138799|NCT05706246|DIAGNOSTIC_TEST|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
48138800|NCT04203966|DIAGNOSTIC_TEST|12-item General Health Questionnaire (GHQ-12)|Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
48138801|NCT04203966|DIAGNOSTIC_TEST|WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)|Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
48138802|NCT04715815|OTHER|No intervention (only interview)|Interview
48138803|NCT04649645|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
48138804|NCT04649645|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
48138805|NCT04649645|OTHER|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
48138806|NCT01375790|DEVICE|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
48138807|NCT01375790|OTHER|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
48138808|NCT01164488|DRUG|danoprevir|Repeated daily doses
48138809|NCT01164488|DRUG|ketoconazole|Repeated daily doses
48349758|NCT06250504|DRUG|DAPIRING (Dapivirine) 25mg Vaginal Ring|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
48502774|NCT03173326|PROCEDURE|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
48660097|NCT05614089|DRUG|NPH or premixed 70/30 (human insulin)|"Drug: NPH or Premixed 70/30 Formulation: Available as a liquid in a glass vial or glass cartridge (10ml=1000IU).~Route: Bangladesh = syringes or reusable pens; Tanzania = disposable pens~Subcutaneous injection using insulin syringe and needle Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician) Frequency of dose: once or twice per day (per usual care or treating clinician)~Duration of therapy: 12 months~Participants in both groups will receive the same frequency of blood glucose testing and same intensity of education and counseling (e.g. titration advice according to fasting glucose targets and strategies to avoid hypoglycemia). Participants in both groups will have equal access to test strips (sufficient to test up to 5 times per day during the active titration phase and after 3 times/day)."
48660098|NCT02427932|DRUG|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
47984732|NCT06122129|PROCEDURE|Flexible ureteroscope with ureteral access sheath|The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
47984733|NCT06122129|PROCEDURE|Flexible ureteroscope without ureteral access sheath|Ureteroscopy will be carried out without a ureteral access sheath
47984734|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
47984735|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
47984736|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
47984737|NCT01750242|DEVICE|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
47984738|NCT02143869|DEVICE|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
47984739|NCT04718467|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.
47984740|NCT04718467|BIOLOGICAL|Placebo|Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
48138810|NCT01164488|DRUG|ritonavir|Repeated daily doses
48002564|NCT04262895|DRUG|Placebo|Placebo
48138811|NCT04230434|BEHAVIORAL|Safety Plan Intervention|The SPI has 6 key steps: (1) identify personalized warning signs for an impending suicide crisis; (2) determine internal coping strategies that distract from suicidal thoughts and urges; (3) identify family and friends who are able to distract from suicidal thoughts and urges and social places that provide the opportunity for interaction; (4) identify individuals who can help provide support during a suicidal crisis; (5) list mental health professionals and urgent care services to contact during a suicidal crisis; and (6) lethal means counseling for making the environment safer (Stanley \& Brown, 2012)
48138812|NCT04463394|DRUG|Vasopressin|Vasopressin administered intravenously
48138813|NCT02201888|BEHAVIORAL|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
48138814|NCT02201888|OTHER|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
48502775|NCT02870179|DEVICE|Pulse Oximeter|Measurement of physiological parameters
48660099|NCT02427932|DRUG|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
48660100|NCT02427932|DRUG|Gentamicin|Prescribed to non-pregnant participants
47984741|NCT05890807|DIAGNOSTIC_TEST|Front view photography of the patient's oral cavity with the help of a smartphone in the diabetology department.|The diabetologist will take a photograph of the patient's oral cavity in the diabetology department.
48138815|NCT02201888|OTHER|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
48138816|NCT01214031|DEVICE|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
48138817|NCT04566172|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
48138818|NCT03989388|BEHAVIORAL|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
48138819|NCT03989388|BEHAVIORAL|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
48660101|NCT01827020|DRUG|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
47984742|NCT03445572|OTHER|Best Practice|Receive standard supportive care
47984743|NCT03445572|PROCEDURE|Meditation Therapy|Perform MSB
47984744|NCT03445572|PROCEDURE|Meditation Therapy|Perform IK meditation
47984745|NCT03445572|OTHER|Questionnaire Administration|Ancillary studies
47984746|NCT00376350|PROCEDURE|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
47984747|NCT00376350|PROCEDURE|Light Massage|light pressure massage of the low back.
47984748|NCT00376350|PROCEDURE|Pulsed Ultrasound|5 minutes pulsed ultrasound
47984749|NCT04018950|DRUG|ETX2514|intravenous infusion
47984750|NCT04018950|DRUG|14C-ETX2514|intravenous infusion
48138820|NCT03989388|BEHAVIORAL|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
48660102|NCT01827020|DRUG|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
47984751|NCT01622153|PROCEDURE|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
47984752|NCT01622153|PROCEDURE|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
47984753|NCT00815581|DEVICE|photorefraction,cycloautorefraction,cycloretinoscopy|
47984754|NCT02662946|PROCEDURE|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
47984755|NCT02662946|PROCEDURE|No angiography|Extension of resection based on subjective measures
47984756|NCT06133192|DRUG|Uvadex|Uvadex use for ECP
47984757|NCT06133192|DRUG|Steroids|steroids 2 mg/kg/d
47984758|NCT03752359|DIETARY_SUPPLEMENT|whey protein|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
47984759|NCT03752359|DIETARY_SUPPLEMENT|placebo|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
48138821|NCT06152718|OTHER|Karisma|Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen
48138822|NCT03515369|DRUG|Babaodan oral capsule|On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
48660103|NCT01827020|DRUG|Saline|12 mL saline (0.9% isotonic solution)
48660104|NCT03073512|OTHER|Ultrasound examination|Participants will undergo ultrasound examination at 32 weeks gestation
48660105|NCT05020587|BEHAVIORAL|Open pilot trial of a group therapy manual.|Open pilot trial of a group therapy manual.
48660106|NCT06015932|BEHAVIORAL|Cognitive Behavior Therapy|Participate in CBCSM group sessions
48660107|NCT06015932|OTHER|Questionnaire Administration|Complete questionnaires
48138823|NCT03515369|DRUG|Placebo oral capsule|On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
48138824|NCT03473041|PROCEDURE|Hybrid sling|sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
48138825|NCT03473041|PROCEDURE|TVT-O|midurethral transobturator vaginal tape
48138826|NCT03440645|OTHER|Family-oriented primary cardiovascular prevention|An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
48138827|NCT04598594|DRUG|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
48138828|NCT04598594|DRUG|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
48138829|NCT03451422|DRUG|Efavaleukin Alfa|Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
48138830|NCT03451422|DRUG|Placebo|The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
48138831|NCT03258398|DRUG|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
48138832|NCT03258398|DRUG|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
48138833|NCT04805736|PROCEDURE|Microwave Ablation|Image-guided microwave ablation 7-10 days prior to surgery
48138834|NCT04805736|DRUG|Camrelizumab|Camrelizumab 200 mg was given a few days after microwave ablation
48660108|NCT04514835|DRUG|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
48138835|NCT04805736|PROCEDURE|Breast Surgery|Standard of care breast conserving surgery or radical mastectmoy
48138836|NCT04707170|DEVICE|MRI with gadolinium injection|"Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study.~The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5."
48660109|NCT04600089|DRUG|Saline|Saline infusion
48660110|NCT04600089|DRUG|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
48660111|NCT01568879|OTHER|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
48660112|NCT01568879|OTHER|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
48138837|NCT04675684|BEHAVIORAL|Recovery-group|The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
48138838|NCT06476769|OTHER|blow bottle technique|There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
48138839|NCT06476769|OTHER|percussion|Group B: There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
48138840|NCT05750043|DRUG|bi-annual CDTI|"bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention"
48502776|NCT04594707|DRUG|PRM-151 (Zinpentraxin Alfa)|"Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo."
48660113|NCT05044468|DRUG|Lidocaine|Given via injection
48138841|NCT01170845|DRUG|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
48502777|NCT02637661|OTHER|earlobe crease positive|
48660114|NCT05044468|DRUG|Liposomal Bupivacaine|Given via injection
48660115|NCT05044468|OTHER|Questionnaire Administration|Ancillary studies
48138842|NCT03363945|BIOLOGICAL|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
48138843|NCT05252832|PROCEDURE|Superficial Cervical Plexus Block|Location of injection for block.
48138844|NCT05252832|PROCEDURE|Local Infiltrate|Local infiltration location.
48138845|NCT04818632|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
48138846|NCT04818632|DRUG|AZD9833|Part B: AZD9833 monotherapy dose expansion
48138847|NCT04818632|DRUG|AZD9833 with palbociclib|Part B: AZD9833 with palbociclib dose expansion
48502778|NCT02637661|OTHER|earlobe crease negative|
47984760|NCT02953327|BIOLOGICAL|Bacille Calmette-Guerin|Vaccine against tuberculosis
48138848|NCT04818632|DRUG|AZD9833 with everolimus|Part B: AZD9833 with everolimus dose expansion
48138849|NCT01436175|DRUG|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
47984761|NCT02953327|BIOLOGICAL|BCG solvent|Simple solvent
47984762|NCT04290689|DRUG|Botulinum Toxin-A injection|Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
47984763|NCT04290689|PROCEDURE|Serial casting stretching|Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
48138850|NCT01097811|DRUG|Erythromycin|250 mg orally q.i.d.
48138851|NCT01097811|DRUG|Neomycin|1 g orally q.i.d.
48138852|NCT02039999|OTHER|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
48138853|NCT02039999|OTHER|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
48138854|NCT02039999|OTHER|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
47984764|NCT03969394|DIAGNOSTIC_TEST|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
48138855|NCT03908164|BIOLOGICAL|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
48138856|NCT01849107|BIOLOGICAL|Plasma citrulline|
47984765|NCT01822405|DRUG|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
48138857|NCT05741450|DEVICE|Lens 1 (monthly replacement)|Monthly replacement spherical silicone hydrogel contact lens for 15 minutes
48138858|NCT05741450|DEVICE|Lens 2 (daily disposable)|Daily disposable spherical silicone hydrogel contact lens for 15 minutes
48660116|NCT06011733|OTHER|Placebo|Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
48660117|NCT06011733|DRUG|Bimekizumab|Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
47984766|NCT01822405|OTHER|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
47984767|NCT01926314|DEVICE|PHENIX Neuromuscular Stimulation Therapy System device|
48138859|NCT00040105|DRUG|Zarnestra (R115777)|"Starting Dose:~300 mg by mouth (PO) Twice daily"
48660118|NCT06564714|DRUG|Early baclofen Intervention|"Baclofen is initiated as soon as any sign of acute spasticity.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic."
48660119|NCT06564714|DRUG|Usual routine care|"Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response."
48138860|NCT00040105|DRUG|Gleevec (Imatinib mesylate)|"Starting Dose:~300 mg By Mouth (PO) daily"
48138861|NCT04373291|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
48138862|NCT04373291|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
48660120|NCT04049474|DEVICE|ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)|See BCI description.
48660121|NCT03755427|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
48660122|NCT03755427|BIOLOGICAL|Aluminum Hydroxide Adjuvant|The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
48660123|NCT03817229|BEHAVIORAL|Education microlearning sessions|mHealth education microlearning sessions
48660124|NCT03817229|BEHAVIORAL|Automated digital reminders|reminders from electronic monitors based on texts or lights/chimes
48660125|NCT03817229|BEHAVIORAL|Problem-solving mHealth module|mhealht problem solving module with 2 telehealth sessions with a therapist
48660126|NCT03817229|BEHAVIORAL|Individualized Adherence Feedback Report|Individual Adherence Feedback reports sent to parents weekly
47984768|NCT01926314|OTHER|usual home care without device|
47984769|NCT01095016|DRUG|Meptin swinghaler|"* Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days"
47984770|NCT01095016|DRUG|Berotec|"* Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days"
47984771|NCT00488345|DRUG|Tygacil|
48138863|NCT06509048|OTHER|STN-DBS Theta Gamma Stimulation|Standard STN-DBS stimulation with addiction of bilateral theta frequency stimulation of ventral contacts
48138864|NCT00667732|DRUG|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
48138865|NCT00667732|DRUG|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
48138866|NCT03417700|DIETARY_SUPPLEMENT|NW training|NW training
48138867|NCT03417700|DIETARY_SUPPLEMENT|Placebo|training with placebo
48138868|NCT03417700|DIETARY_SUPPLEMENT|HICT|Training and vitamin D
48138869|NCT01579799|DRUG|L-lysine|Dose finding study for L-lysine
48138870|NCT03225625|PROCEDURE|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
48138871|NCT03225625|PROCEDURE|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
48349759|NCT06250504|DRUG|tenofovir disoproxil and emtricitabine|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
48349760|NCT06250504|DRUG|Tenofovir Disoproxil, Lamuvidine and Dolutegravir|The initial visit is followed by a 7-day phone call, 3-monthly follow-up. Each follow-up will include repeat HIV testing (POCT x2 and dry blood spots for HIV ELISA) and pregnancy testing, syndromic management of STIs, and referral to peer navigators for adherence support and PrEP/ART and if applicable contraception refills. Safely bloods (full blood count, creatinine, liver function tests) will follow national guidelines. Currently we aim to do baseline and annual safety bloods, alongside annual STI testing
48349761|NCT02682576|PROCEDURE|Brachial artery ultrasound imaging|
48349762|NCT06272357|OTHER|Antiarrhythmic drugs|Antiarrhythmic drugs in pediatrics
48349763|NCT00004889|BIOLOGICAL|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
48349764|NCT02169960|BEHAVIORAL|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
48349765|NCT02169960|BEHAVIORAL|Breaking Free|Online based intervention for Drug and Alcohol Use
48349766|NCT02169960|BEHAVIORAL|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
47984772|NCT05126862|BEHAVIORAL|MindTrails|MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
47984773|NCT05922787|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
47984774|NCT02953054|DRUG|DMTS|DMTS applied before surgery and worn for 72 hours
47984775|NCT02953054|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
47984776|NCT02066740|DEVICE|EverFlex™ stent with Entrust™ delivery system|
47984777|NCT02953314|DRUG|TEZ|
47984778|NCT02953314|DRUG|TEZ/IVA|
47984779|NCT02953314|DRUG|IVA|
47984780|NCT05407467|DIETARY_SUPPLEMENT|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
47984781|NCT05291247|DEVICE|Peripheral lithotripsy system (Shockwave Medical)|The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.
47984782|NCT00965588|BIOLOGICAL|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
47984783|NCT00384995|DRUG|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
47984784|NCT00384995|DRUG|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
47984785|NCT00613938|DRUG|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
47984786|NCT00613938|DRUG|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
47984787|NCT00613938|DRUG|oxycodone|10mg capsule q4-6 hrs for 3 days
47984788|NCT00613938|DRUG|placebo|1 capsule q4-6 hrs for 3 days
47984789|NCT02890589|DEVICE|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
48138872|NCT03225625|PROCEDURE|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
48138873|NCT04417075|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
48138874|NCT04417075|BEHAVIORAL|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
48138875|NCT00210275|BEHAVIORAL|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
48138876|NCT05964426|OTHER|Turkey Health Literacy Scale (TSOY-32)|A survey will be conducted.
48138877|NCT04465721|BEHAVIORAL|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
48349767|NCT02169960|BEHAVIORAL|Resiliency Training|Op Volle Kracht (OVK)
48349768|NCT03442933|OTHER|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
48349769|NCT03442933|OTHER|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
48349770|NCT02095249|DRUG|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
48349771|NCT00134342|OTHER|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
48349772|NCT02565862|DRUG|Daclatasvir|
48349773|NCT02565862|DRUG|Metformin|
48502779|NCT04645836|BEHAVIORAL|New management mode|"New management mode intervention: Pharmaceutical care~* SMS text messages and Phone Calls~* Behavioural Educational leaflet~* Self-Administered Therapy A financial incentive for mobile use"
48502780|NCT06010537|DRUG|polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
48502781|NCT01030653|DRUG|Voriconazole low dose|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
48502782|NCT01030653|DRUG|Voriconazole high dose|Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
48502783|NCT02798432|PROCEDURE|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
48502784|NCT02798432|DEVICE|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
48502785|NCT04400032|BIOLOGICAL|Mesenchymal Stromal Cells|The Mesenchymal Stromal Cells will be administered intravenously
48502786|NCT06414317|PROCEDURE|Assessment of Distress|Undergo psychological distress screening
48349774|NCT00591396|DRUG|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
48660127|NCT06268847|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo."
48349775|NCT00976963|DRUG|TMP/SMX|Take one twice daily for 3 days for urinary tract infection
48349776|NCT00976963|DRUG|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediately
48349777|NCT04884386|DEVICE|robot-assisted gait training|RAGT, WALKBOT-G, is a walking training equipment that can reproduce natural motions by adjusting the leg length and adjusting the motion with the actuator of the ankle joint.
48349778|NCT04884386|BEHAVIORAL|conventional locomotion therapy|locomotion exercise, postural control training, balance training, electrotherapy
48349779|NCT01975376|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
48349780|NCT01975376|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
48502787|NCT06414317|OTHER|Consultation Visit|Attend consultations
48502788|NCT06414317|OTHER|Nutritional Assessment|Undergo malnutrition screening
48502789|NCT06414317|OTHER|Questionnaire Administration|Ancillary studies
48502790|NCT06414317|OTHER|Supportive Care|Receive access to bladder cancer ENST
48349781|NCT00510575|DEVICE|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
48502791|NCT06414317|OTHER|Supportive Care|Attend virtual support group meetings
48502792|NCT02994940|DRUG|Acetaminophen|already included in arm/group descriptions
48349782|NCT01387594|PROCEDURE|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
48349783|NCT01387594|DRUG|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
48349784|NCT00378534|DEVICE|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selection and delayed T cell depletion add back
48349785|NCT00378534|DRUG|Fludarabine|Therapeutic
48349786|NCT00378534|DRUG|Cyclosporine|Therapeutic
48349787|NCT00378534|DRUG|Cyclophosphamide|Therapeutic
48349788|NCT00378534|OTHER|FILGRASTIM (G-CSF)|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. Stem cell Donors will receive G-CSF for stem cell mobilization. The stem cell collection aspect of this protocol is not investigational.
48349789|NCT06259604|OTHER|PIOMI|Babies in this group will be administered PIOMI once a day, 30-45 minutes before feeding, for 14 days.
48349790|NCT06259604|OTHER|PIOMI+kangaroo care|Babies in this group will start using PIOMI once a day, 30-45 minutes before feeding, and kangaroo care for at least 30 minutes during the last 2 minutes of non-nutritive sucking phase of PIOMI, for 14 days.
48502793|NCT00176423|DRUG|galantamine|see arm/group description
48502794|NCT04800549|OTHER|Oral Mucositis|The data of the study were obtained by conducting six interviews with each child and the family. The first interview was conducted before starting to treatment on the first day of the treatment, the second interview was conducted on the 2nd day after the treatment and the following interviews were conducted on the 4th, 8th, 16th, and 21st days and in-mouth mucosa of the patient was evaluated by taking in-mouth pictures following interviewing with the child and the family. Oral care application was conducted four times a day with sodium bicarbonate solution and a lollipop made with black mulberry syrup (after meals and before going to the bed at night). Oral care was first conducted by the researcher, the oral care was then taught to the patient and patient's relatives and the application was evaluated. Figure 1 shows the study design.
48502795|NCT00780910|DRUG|MP-424|750 mg every 8 hours for 12 weeks
48502796|NCT00780910|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
48660128|NCT06268847|DIETARY_SUPPLEMENT|ACT01|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
48660129|NCT06268847|DIETARY_SUPPLEMENT|ACT02|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
48660130|NCT05053061|BEHAVIORAL|Application program for pulmonary rehabilitation|Exercise videos for pulmonary rehabilitation
48502797|NCT00780910|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
48660131|NCT05650866|DEVICE|Activation of pro-erectile nerves within the pelvic plexus|The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
48660132|NCT00105066|DRUG|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
48660133|NCT00105066|DRUG|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
48660134|NCT03886857|DEVICE|transcutaneous spinal cord stimulation|noninvasive electrical stimulation of the human lumbar spinal cord
48349791|NCT05010863|OTHER|Blood collection|The subject will be drawn a 5ml blood sample
48349792|NCT02792036|DRUG|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
48349793|NCT02792036|DRUG|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
48349794|NCT02792036|PROCEDURE|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
48502798|NCT03327792|DRUG|Mavoglurant|200 mg Mavoglurant
48502799|NCT03327792|DRUG|Placebo|Placebo
48660135|NCT06069570|BIOLOGICAL|KB-GDT-01|KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
48502800|NCT01147263|OTHER|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
48502801|NCT01310270|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
48502802|NCT01310270|DIETARY_SUPPLEMENT|Omega 3 Fatty Acid|4.4 gm/day for 1 month
48502803|NCT06399809|DRUG|Fisetin|Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.
48502804|NCT06399809|DRUG|Placebo|The placebo will be matched to the Fisetin intervention
48138878|NCT04465721|BEHAVIORAL|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
48138879|NCT05610566|DEVICE|the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System|The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a subannular implant (SAI), and their delivery systems and accessories. The TMV is a 28mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI), comprising a ring (made of polycarbonate urethane (PCU), nitinol, gold markers and polyester (Dacron) to be placed around the mitral valve apparatus to stabilize the position of the mitral valve implant.
48138880|NCT01334840|DIETARY_SUPPLEMENT|Bicarbonated mineral water|"Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
48138881|NCT01334840|DIETARY_SUPPLEMENT|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal"
48138882|NCT04092322|DEVICE|Actical accelerometers (Philips Respironics)|patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
48138883|NCT04092322|OTHER|PASE|Physical Activity Scale for Elderly
48138884|NCT01767688|DRUG|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
48138885|NCT04798534|BEHAVIORAL|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
48138886|NCT01212822|BIOLOGICAL|bevacizumab|Given IV
48138887|NCT01212822|DRUG|oxaliplatin|Given IV
48138888|NCT01212822|DRUG|leucovorin calcium|Given IV
48138889|NCT01212822|DRUG|fluorouracil|Given IV
48138890|NCT01212822|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
48502805|NCT01119183|BEHAVIORAL|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
48502806|NCT01119183|BEHAVIORAL|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
47984790|NCT02890589|DEVICE|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
47984791|NCT01182545|PROCEDURE|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
47984792|NCT01645696|DEVICE|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
48138891|NCT01212822|OTHER|laboratory biomarker analysis|Correlative studies
47984793|NCT01645696|DEVICE|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
47984794|NCT01645696|DEVICE|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
48138892|NCT03580551|BEHAVIORAL|Intervention Group|"Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status."
48349795|NCT02792036|PROCEDURE|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
48349796|NCT05513092|DIAGNOSTIC_TEST|placenta accreta index score|role of placenta accreta index score in prediction of conservative surgery for placenta placenta accreta spectrum
48349797|NCT02325804|BEHAVIORAL|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
48349798|NCT00000405|PROCEDURE|Exercise intervention|
48502807|NCT02032095|DRUG|GB-0998|
48502808|NCT05033093|DRUG|Root Canal Sealants|it is planned to conduct the research described below, on the effect of calcium silicate-based (iRoot SP), silicone-based (GuttaFlow Bioseal) and rezin-based (AH Plus) sealer on postoperative pain
47984795|NCT05160454|DEVICE|near infrared spectroscopy|evaluate cerebral blood flow with and without breatholding
48349799|NCT06465355|PROCEDURE|pharyngo-esophageal high-resolution manometry|The high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus. Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure. 3. Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed. There is a 30 second interval between swallows.
48349800|NCT02072733|OTHER|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
48502809|NCT02968849|BIOLOGICAL|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose \> 10\^6 cell culture infectious dose 50% (CCIDv50) and \< 1 × 10\^8 CCIDv50 (nominal dose of 10\^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
48502810|NCT02968849|BIOLOGICAL|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
48502811|NCT02968849|BIOLOGICAL|Placebo|Sodium Chloride for injection, 0.9% delivered IM
48502812|NCT00147953|DRUG|Rituximab|
48502813|NCT00147953|PROCEDURE|Total nodal irradiation|
48660136|NCT03446690|DRUG|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
48660137|NCT03446690|OTHER|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
48660138|NCT06528418|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
48660139|NCT06564935|DRUG|Heptaminol Hydrochloride|heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
48660140|NCT06564935|DRUG|Placebo|Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
48660141|NCT00005980|DRUG|pegylated liposomal doxorubicin hydrochloride|
47984796|NCT06263751|OTHER|Product prescription program- NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Rewards account every other week for F\&V shopping. The Rewards credit can be used either through the Schnucks App or in store.
48502814|NCT04549753|DEVICE|Transcranial direct current simulation|Four sessions of stimulation over C3 (patient with left-sided lesion) or C4 (patient with right-sided lesion) based on 10-20 system
48502815|NCT02312908|DRUG|Clonazepam|For experimental treatment of RBD
48502816|NCT02312908|DRUG|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
48502817|NCT04565925|DRUG|Sildenafil Citrate|Sildenafil 20mg TID for 4 weeks
48502818|NCT04565925|DRUG|Placebo|Placebo (Lactose) TID for 4 weeks
48502819|NCT05177718|DRUG|Natalizumab 300 MG in 15 ML Injection|Disease modifying agent
48502820|NCT04876365|OTHER|Non-Interventional|This is a Non-Interventional Study.
48502821|NCT00148005|PROCEDURE|Questionnaire and micturition and drinking diaries|
48502822|NCT00148005|PROCEDURE|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
48502823|NCT00148005|BEHAVIORAL|Adaptation of the drinking scheme|
48502824|NCT00148005|DRUG|Anticholinergic therapy|
48502825|NCT00148005|BEHAVIORAL|Micturition clock|
48502826|NCT03286335|RADIATION|Proton Radiation|Radiation treatment
48502827|NCT04360096|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
48502828|NCT04360096|DRUG|Placebo|Normal Saline Inhalation
48502829|NCT04360096|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
48502830|NCT00390559|DRUG|nicotine transdermal system|21 mg nicotine transdermal system
48502831|NCT00390559|DRUG|Nicotine transdermal system|Placebo nicotine patch
48502832|NCT00390559|OTHER|Nicotine containing cigarette|Nicotine containing cigarette
48502833|NCT00390559|OTHER|Placebo cigarette|Non nicotine containing cigarette
48502834|NCT06049459|DEVICE|Optical Correction|Optical correction (if needed)
48502835|NCT06049459|DEVICE|Therapeutic Dichoptic Virtual Reality Games|Virtual Reality Game play for amblyopia treatment
48502836|NCT02076490|OTHER|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
48502837|NCT02329938|PROCEDURE|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
48502838|NCT02329938|PROCEDURE|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
48138893|NCT03580551|BEHAVIORAL|Waitlist Control Group|"At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment."
48349801|NCT02725749|RADIATION|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
48660142|NCT04114955|BEHAVIORAL|Manas por Manas|Manas for Manas works at both the group- and individual-levels to increase self-care and reduce the negative health impacts of stigma, including: 1) a group-level, peer-led intervention, which first demonstrated efficacy with trans women in the US as 'Sheroes' and has been successfully adapted for Brazil, and 2) an individual-level peer navigation program.
48660143|NCT04239703|DIAGNOSTIC_TEST|MMDx|Portion of kidney transplant indication biopsy
48660144|NCT04239703|DIAGNOSTIC_TEST|Prospera|Transplant patient blood sample
48660145|NCT04239703|DIAGNOSTIC_TEST|HLA antibody|Transplant patient blood sample
48660146|NCT05425121|PROCEDURE|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
48660147|NCT05425121|DEVICE|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
48660148|NCT05014919|DRUG|Vortioxetine|Tablets
48660149|NCT05014919|DRUG|Placebo|Tablets
48660150|NCT02769104|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
48660151|NCT02769104|DRUG|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
48660152|NCT06230198|PROCEDURE|retrograde autologous priming (RAP)|sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
48660153|NCT06230198|PROCEDURE|Crystalloid priming|sites implement crystalloid priming use during cardiac surgery
48660154|NCT06570850|DRUG|Colistin Sodium Methanesulfonate|Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
47984797|NCT06263751|OTHER|Product prescription program- NutriConnect Delivery|Patient receives produce (F\&V) box (equivalent $20 value) delivered to home every other week. The items in the box will be pre-selected by Schnucks and the NutriConnect dieticians.
47984798|NCT01472081|BIOLOGICAL|Nivolumab|
48138894|NCT04815720|DRUG|pepinemab + pembrolizumab|The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
48349802|NCT02725749|OTHER|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
48502839|NCT04431583|PROCEDURE|Bariatric surgery- single surgeon service|
48502840|NCT04431583|PROCEDURE|Bariatric surgery- multiple surgeon + multidisciplinary team approach|
48502841|NCT04431583|PROCEDURE|Bariatric surgery: formalized streamlined multiple surgeon + multidisciplinary team approach|
48660155|NCT06570850|DRUG|Colistin Sodium Methanesulfonate plus Fosfomycin|Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
48660156|NCT03663543|DRUG|Conjugated Estrogen|Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
48660157|NCT03663543|DRUG|Normal saline|Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
47984799|NCT01472081|BIOLOGICAL|Pazopanib|
47984800|NCT01472081|DRUG|Sunitinib|
47984801|NCT01472081|BIOLOGICAL|Ipilimumab|
47984802|NCT03921086|DRUG|Antihypertensive medication according to the study's algorithm|"Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm."
48660158|NCT03190876|PROCEDURE|Variable drain usage|Influence of drain usage on seroma formation rate
48660159|NCT03899415|BIOLOGICAL|TCR redirected T cells|HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.
48502842|NCT03250559|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
48660160|NCT04258748|BEHAVIORAL|Motivational Interviewing (MI)|In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.
48660161|NCT04258748|BEHAVIORAL|Gaming and MI|In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.
48138895|NCT03512782|OTHER|CARDIOENF|The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
48138896|NCT02955563|OTHER|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
48138897|NCT02132520|DEVICE|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
48138898|NCT02132520|BEHAVIORAL|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
47984803|NCT00776347|DRUG|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
48138899|NCT02024217|RADIATION|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
48138900|NCT00914641|DRUG|Apixaban IR|immediate release tablet, 10 mg, single dose
48138901|NCT00914641|DRUG|Apixaban MR1|modified release tablet 1, 10 mg, single dose
48138902|NCT00914641|DRUG|Apixaban MR2|modified release tablet 2, 10 mg, single dose
48138903|NCT00914641|DRUG|Apixaban MR3|modified release tablet 3, 10 mg, single dose
48138904|NCT00829400|BEHAVIORAL|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
48138905|NCT00829400|BEHAVIORAL|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
48349803|NCT02725749|RADIATION|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
47984804|NCT00776347|DRUG|Donepezil|
48349804|NCT00700349|OTHER|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
48349805|NCT04453891|DEVICE|Monitoring physiological data with the Hexoskin smart shirt|Participants will be monitored using a validated biometric garment (Hexoskin smart shirt). Cardiorespiratory and activity data will be collected over a 28-day monitoring period. Participants will be invited to wear the shirt during the day and at night.
48349806|NCT05732493|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
47984805|NCT02614430|OTHER|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
48502843|NCT01830634|BEHAVIORAL|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
47984806|NCT02859675|OTHER|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
47984807|NCT02859675|BIOLOGICAL|blood sampling|sampling of 2 mL
47984808|NCT02859675|OTHER|Questionnaires|Stunkard, PrefQuest
48138906|NCT00712413|DRUG|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
48138907|NCT03592797|OTHER|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
48502844|NCT05157906|BEHAVIORAL|Education based|The interventional materials will be provided digitally for 12 weeks, with the monthly theme featured from the educational Grow Happy book and related tips and videos that will be released weekly.
48502845|NCT05157906|BEHAVIORAL|Control|At enrollment, subject will be provided with the Mother and Child booklet, which is the Indonesian standard of care for parenting guidance.
47984809|NCT02056704|DEVICE|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
47984810|NCT02843932|OTHER|functional brain MRI|functional imagery during motor-perception tasks
48138908|NCT03592797|OTHER|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
48138909|NCT02971215|DEVICE|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~+ Physical Therapy protocol."
48138910|NCT02971215|DEVICE|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
47984811|NCT00268996|DRUG|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
47984812|NCT00268996|DRUG|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
47984813|NCT00111618|DRUG|AS1404 (DMXAA)|
48138911|NCT05886972|BEHAVIORAL|Awareness about propofol injection induced pain|The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
48138912|NCT04852471|BEHAVIORAL|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
48138913|NCT04852471|BEHAVIORAL|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
48138914|NCT01402518|PROCEDURE|Per-oral enodscopic myotomy|
48138915|NCT04728191|OTHER|Physiotherapy|physiotherapeutical instructions and training as described.
48138916|NCT04728191|OTHER|standard care|Standard care as described.
47984814|NCT06299033|DRUG|hNPC01|hNPC01, human forebrain neural progenitor cell product, intracerebral injection
47984815|NCT00546845|DEVICE|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
48138917|NCT01319058|PROCEDURE|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
48138918|NCT00403494|OTHER|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
48138919|NCT00403494|DRUG|Sapropterin Dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
48138920|NCT01459952|DIETARY_SUPPLEMENT|Rose hip Liquid|Rose hip Liquid, 20 ml BID
48138921|NCT00539812|BEHAVIORAL|Standard Care|Standard 40 hour state mandated batterer intervention program
48138922|NCT00539812|BEHAVIORAL|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
47984816|NCT00546845|DEVICE|Use of self-expanding Expert stent|Nitinol stent
47984817|NCT04446377|DRUG|Apilimod Dimesylate Capsule|LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
47984818|NCT04446377|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, Size 0 capsules
47984819|NCT03724539|DEVICE|STRIPA intervention|"STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices."
48138923|NCT02596061|BEHAVIORAL|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
48502846|NCT03202524|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
48502847|NCT03202524|BIOLOGICAL|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
48502848|NCT00421980|DRUG|Etanercept|
48502849|NCT01333371|PROCEDURE|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
48502850|NCT03574948|DRUG|5-HTP|8 weeks active substance 5-HTP (2 x 100mg per day)
48502851|NCT03574948|DRUG|Placebo oral capsule|8 weeks placebo (2 x 1 caps per day)
48502852|NCT02827838|BIOLOGICAL|Durvalumab|Given IV
48502853|NCT02827838|OTHER|Laboratory Biomarker Analysis|Correlative studies
48502854|NCT02827838|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48502855|NCT02287818|DRUG|Placebo|Placebo twice daily from Day 1 to Week 12
48502856|NCT02287818|DRUG|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
48502857|NCT02287818|DRUG|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
48660162|NCT04258748|BEHAVIORAL|Conventional dental health education|It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
48660163|NCT03795142|BIOLOGICAL|BGB149|Single Ascending Dose
48502858|NCT03624608|DEVICE|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
48660164|NCT03795142|BIOLOGICAL|Placebo|Matching placebo
48660165|NCT03663023|PROCEDURE|Intestinal obstruction|
48660166|NCT02720458|OTHER|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
48660167|NCT02720458|BEHAVIORAL|Short-term simple self-help program|"The short-term simple self-help program consists in:~* Restriction of time in bed~* Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
47984820|NCT03724539|OTHER|Sham intervention|Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
48349807|NCT05732493|RADIATION|short-term radiotherapy|radiation: 25Gy/5Fx
47984821|NCT00269282|BEHAVIORAL|Self-Management Training|Asthma education and self-monitoring strategies
48349808|NCT05732493|DRUG|Oxaliplatin|130mg/m2 d1 q3w
48349809|NCT05732493|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
48502859|NCT03143426|PROCEDURE|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
48502860|NCT04063423|PROCEDURE|blood sample|Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
48660168|NCT02670408|PROCEDURE|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
48660169|NCT04461886|DRUG|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
48660170|NCT04431063|PROCEDURE|Distal Stump Suturing|in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
48660171|NCT04539288|OTHER||There is no intervention in this study.
48660172|NCT05328648|BEHAVIORAL|Community Score Card|In Community Score Card intervention, all communities associated with the targeted facilities will assess the primary barriers to quality family planning service delivery and develop indicators. The communities will then each complete the score card and generate ideas for quality improvement. Family planning providers in the target facilities will meet and determine the barriers to high quality family planning service delivery. Providers will decide on priority areas and make suggestions for improving service delivery. Study facilitators will bring these two groups together to share their respective score cards and jointly develop an action. Within the action plan, agreed upon responsibilities will be assigned and a timeline will be communicated.
48660173|NCT05328648|BEHAVIORAL|Citizen Report Card|Citizen Report Card (CRC): The data from the CRC questionnaire will be analyzed and translated into a report card. Extensive dissemination activities will ensure the CRC is widely shared with members of the community. The goal is to create a public record of service quality.
47984822|NCT00269282|BEHAVIORAL|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
47984823|NCT06505031|DRUG|TAK-861|Oral tablet.
47984824|NCT06505031|DRUG|Placebo|TAK-861-matching placebo tablet.
47984825|NCT06120816|DRUG|Nitric Oxide|Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
47984826|NCT03349749|DEVICE|LiDCOplus haemodynamic monitor|Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
47984827|NCT01390311|DRUG|Azacitidine|
47984828|NCT01390311|DRUG|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
47984829|NCT01390311|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|
48138924|NCT02596061|OTHER|Incentives|Patients receive incentives for completing smoking cessation activities.
48138925|NCT02117310|DRUG|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
48138926|NCT04895670|BEHAVIORAL|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
48502861|NCT00339092|BEHAVIORAL|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
48660174|NCT05019209|DRUG|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
48660175|NCT05019209|OTHER|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
48660176|NCT05512338|OTHER|Treatment|ACT-informed interventions combined with standard physiotherapy methods.
48660177|NCT05512338|OTHER|Active control group|Standard physiotherapy methods.
48660178|NCT02310269|DRUG|Pasireotide|
48660179|NCT00654602|DRUG|Rosuvastatin|
48660180|NCT00654602|BEHAVIORAL|Maintenance of specific diet|
48660181|NCT06489509|DEVICE|Positive End Expiratory Pressure 5 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
48660182|NCT06489509|DEVICE|Positive End Expiratory Pressure 10 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
48660183|NCT04252079|PROCEDURE|Endovascular Repair of Juxtarenal Aortic Aneurysm|"1. History taking and clinical examination.~2. Preoperative Imaging~   CTA is the cross-sectional imaging modality of choice.~3. Preoperative evaluation~   a-Renal evaluation~   b_ cardiac evaluation C-Pulmonary evaluation~4. Surgical techniques~   1. Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~  2. Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique."
48660184|NCT01437189|DRUG|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
48660185|NCT05338307|DIETARY_SUPPLEMENT|R-1,3-Butanediol|Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
48660186|NCT06301113|DIETARY_SUPPLEMENT|CBD infused candy|300 Nano mg CBD Candy cherry flavor
48660187|NCT06301113|DIETARY_SUPPLEMENT|Sugar free Candy|Raspberry flavored sugar free candy
48660188|NCT05537376|BEHAVIORAL|SUicide Prevention by Peers Offering Recovery Tactics|Following the completion of a comprehensive mental health evaluation by a licensed VA provider, which includes a suicide safety plan, if a Veteran is having active thoughts of suicide or made a suicide attempt in past three months, they may be eligible for SUPPORT. In SUPPORT, the Peer Specialist and Veteran co-create a personalized suicide-focused recovery plan (SUPPORT Plan) in flexible, 50-minute weekly encounters. The SUPPORT Plan includes modules that focus on valuing recovery, building a hope kit and daily plan, setting recovery goals, and looking ahead to enhance the Veteran's safety plan. Learning strategies are incorporated into each module to promote salience and recall of intervention material. The Peer Specialist works closely with the Veteran's treatment team and uses the most recent safety plan in the Veteran's chart to help complete the SUPPORT Plan as well as reinforce the usage of the Veteran's safety plan.
48660189|NCT06409260|OTHER|Acceleromyography (AMG)|Philips IntelliVue NMT Module
48660190|NCT06409260|OTHER|Electromyography (EMG)|Senzime TetraGraph
48660191|NCT02009787|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
48660192|NCT02009787|DRUG|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
48660193|NCT00867035|DRUG|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
48660194|NCT00867035|DRUG|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
48660195|NCT04337970|DRUG|Talazoparib|"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."
48660196|NCT04337970|DRUG|Axitinib|5 mg PO BID
48660197|NCT04331275|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
48660198|NCT00496119|RADIATION|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
48138927|NCT05031923|PROCEDURE|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
48138928|NCT05031923|PROCEDURE|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
48138929|NCT05136066|OTHER|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
48138930|NCT00004805|BEHAVIORAL|CPR instruction|
48138931|NCT01519557|DRUG|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
48138932|NCT01519557|DRUG|Placebo|Placebo
48138933|NCT05664672|OTHER|OTDN Product 1|Mint on!® 2 mg nicotine pouches
48138934|NCT05664672|OTHER|OTDN Product 2|Mint on!® 4 mg nicotine pouches
48138935|NCT05664672|OTHER|OTDN Product 3|Mint on!® 8 mg nicotine pouches
48660199|NCT00496119|RADIATION|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
48660200|NCT06626126|OTHER|ApoB-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets
48660201|NCT06626126|OTHER|LDL-C-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
48138936|NCT05664672|OTHER|No Tobacco|subjects completely stop all tobacco product usage for 7 days
48660202|NCT02615288|DIETARY_SUPPLEMENT|Vitamin D3|
48660203|NCT06639529|DIAGNOSTIC_TEST|Tests of the expression of CXCL3 in various tissues|1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.
48138937|NCT03479918|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
48138938|NCT03479918|DRUG|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
48138939|NCT03479918|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
47984830|NCT01979809|BEHAVIORAL|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
48138940|NCT03479918|DRUG|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
48138941|NCT01409837|DRUG|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
48138942|NCT05520359|DEVICE|Mobility Device|Use of mobility device during session.
48138943|NCT05520359|DEVICE|Spinal Stimulation|A stimulator will be used non-invasively stimulate the spine at the neck and/or lower back (cervical and/or lum
48138944|NCT03398980|RADIATION|survivors treated with CRT|Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
48660204|NCT03553836|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
48138945|NCT06133530|DIETARY_SUPPLEMENT|Human milk oligosaccharides|Prebiotic
48138946|NCT06133530|DIETARY_SUPPLEMENT|Maltose|Control
48138947|NCT04030585|DEVICE|Robot|Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
48660205|NCT03553836|OTHER|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
48138948|NCT04030585|OTHER|Home exercise|Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
48138949|NCT06017700|BEHAVIORAL|Interpersonal Psychotherapy Group|IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.
48138950|NCT06017700|BEHAVIORAL|Enhanced Usual Care|Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
48502862|NCT00339092|BEHAVIORAL|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
48660206|NCT06460376|OTHER|Wurn Technique|"Treatment:~Site-specific pressures for 30 seconds across the restrictive bands of adhered tissues and structures, working progressively deeper from the most superficial tissues Traction: focusing on these adhered areas, engage the uterine fundus and sidewalls and traction them to the left.~To assist and improve the mobility of the soft tissues, release the traction tension either suddenly or gradually, depending on the desired effect to decrease spasms and adhesions between the uterus and the bladder. The baseline treatment was moist heat.~Each therapy session was 30 minutes for 6 weeks and 2 sessions per week. 10 minutes for baseline treatment."
48138951|NCT05864196|RADIATION|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
48138952|NCT02085772|OTHER|Blood samples at 37-38 Weeks of amenorrhea|
48138953|NCT02085772|OTHER|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
48138954|NCT02085772|OTHER|Blood samples at the time of delivery|
48502863|NCT04728503|BEHAVIORAL|5-Minute Mindful Movement Video|5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.
48138955|NCT00252005|DRUG|Apixaban|
48502864|NCT04728503|BEHAVIORAL|Written Educative Materials|1 page written educative material about the benefits of mindfulness to serve as a control.
48660207|NCT06460376|OTHER|Mercier Therapy|"Treatment:~The patient lay face up on a massage or exam table. Feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles.~Manual poking, pressing, and massage actions do three things:~Reveals visceral adhesions. Find tender spots. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that make up fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Abdominal massage with pressing, deep strokes, and friction. The baseline treatment was moist heat. Each therapy session was 25 minutes for 6 weeks and 1 session per week. 10 minutes for baseline treatment"
48660208|NCT00270387|DRUG|Natrecor (nesiritide)|
47984831|NCT01477606|DRUG|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
47984832|NCT01477606|DRUG|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
47984833|NCT01477606|DRUG|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
47984834|NCT03686163|DRUG|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
48138956|NCT03958526|DEVICE|active tDCS|Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
48138957|NCT03958526|DEVICE|sham tDCS|Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
47984835|NCT03686163|DRUG|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
48618268|NCT01035788|BEHAVIORAL|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
48138958|NCT01556594|DRUG|Nasal Glucagon 1 mg|
48138959|NCT01556594|DRUG|Nasal Glucagon 2 mg|
48502865|NCT03546920|BEHAVIORAL|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
47984836|NCT01819402|DRUG|Pioglitazone vs Glimepiride|
47984837|NCT06215599|OTHER|Survey|The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
48502866|NCT01525264|BEHAVIORAL|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
48502867|NCT01525264|BEHAVIORAL|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
48502868|NCT01437943|DRUG|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
48502869|NCT01437943|DRUG|Placebo|Take 1 tablet (0 mg) daily for 180 days.
48502870|NCT01120509|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
48502871|NCT04487938|OTHER|No intervention utilised|No intervention utilised
48502872|NCT02216786|DRUG|AZD2014|Oral tablet
48502873|NCT02216786|DRUG|Everolimus|Oral tablet
48502874|NCT02216786|DRUG|Fulvestrant|Im injection
48502875|NCT01085734|DRUG|Avastin|1.25mg intravitreally
48502876|NCT01085734|DRUG|Osurdex|0.7mg intravitreally
48502877|NCT01085734|DRUG|Avastin|1.25mg intravitreally
48502878|NCT05491876|OTHER|Chest physiotherapy with breathing exercises and ACBT|Group A got chest physiotherapy with breathing exercises and ACBT
48660209|NCT04261985|BEHAVIORAL|healthy weight behaviors supported by web-based mobile phone application|Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content was created in English and Spanish.
48660210|NCT04183712|DRUG|gemcitabine and oxaliplatin.|GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
48660211|NCT04183712|DRUG|Afatinib|Target therapy Drug: afatinib
48660212|NCT00149357|OTHER|Thrombophilia Testing|TP testing in Group 1 and 3 only
48660213|NCT04255433|DRUG|Tirzepatide|Administered SC
48502879|NCT05491876|OTHER|Chest physiotherapy with breathing exercises|Group B got chest physiotherapy with breathing exercises.
48660214|NCT04255433|DRUG|Dulaglutide|Administered SC
48660215|NCT06242795|DRUG|7% Hypertonic Saline via nebulization|Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
48660216|NCT03723473|DEVICE|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
47984838|NCT03894579|BIOLOGICAL|Study Product: SNK01|SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
47984839|NCT05830292|DEVICE|Diffuse reflectance spectroscopy (DRS) probe|The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
48138960|NCT01556594|DRUG|SC Glucagon|
48138961|NCT01556594|DRUG|Nasal Glucagon 3 mg|
48502880|NCT04111055|DEVICE|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
48502881|NCT00485420|OTHER|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
48502882|NCT03986138|DRUG|gadopiclenol|Single intravenous bolus injection
48502883|NCT03986138|DRUG|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
48502884|NCT01022944|PROCEDURE|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
48502885|NCT01022944|PROCEDURE|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
48502886|NCT06495489|OTHER|Detection of preload responders by a PLR test|Detection of preload dependency by using PLR test and echocardiography
48502887|NCT04605003|DEVICE|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
48502888|NCT04605003|DEVICE|Conventional Autoclave machine|The gold standard device to clean all medical instruments
48502889|NCT03045991|BEHAVIORAL|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
48502890|NCT03045991|BEHAVIORAL|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
48138962|NCT01642719|BEHAVIORAL|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
48138963|NCT01642719|BEHAVIORAL|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
48138964|NCT03263611|DRUG|Placebo|single intradiscal injection
48138965|NCT03263611|DRUG|AMG0103|single intradiscal injection
48138966|NCT03068988|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
48138967|NCT03068988|PROCEDURE|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
48138968|NCT05155358|DIAGNOSTIC_TEST|Peripheral blood test|Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
48138969|NCT00369460|OTHER|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
48138970|NCT02285218|OTHER|serum blood sampling|
48138971|NCT00960206|DEVICE|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
48138972|NCT00960206|DEVICE|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
48138973|NCT00960206|DEVICE|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
48138974|NCT05361356|RADIATION|Spectral CT scanning|Volunteer accept spectral CT scanning
48138975|NCT04886349|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma injection for first CMC OA
48138976|NCT03292692|BEHAVIORAL|OurRelationship|Online intervention with coach support
48138977|NCT02587052|DRUG|Generic tacrolimus|Generic tacrolimus
48138978|NCT02587052|DRUG|Prograf|Prograf, the original tacrolimus
48138979|NCT02593760|OTHER|Placebo|Placebo will be administered PO QD for up to 48 weeks.
48502891|NCT03045991|BEHAVIORAL|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
48502892|NCT00283023|PROCEDURE|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
48502893|NCT04053920|BEHAVIORAL|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
48502894|NCT04053920|BEHAVIORAL|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
48138980|NCT02593760|DRUG|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
48138981|NCT02593760|DRUG|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
48138982|NCT01939249|DEVICE|Abbott Laboratories Xience|
48138983|NCT01939249|DEVICE|Biotronik Orsiro|
48138984|NCT02915783|DRUG|lenvatinib|4 mg and 10 mg capsules
48138985|NCT02915783|DRUG|everolimus|5 mg tablets
48138986|NCT05995795|DEVICE|ARTHROSCOY|arthroscopy
48138987|NCT02132039|OTHER|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
48138988|NCT02132039|OTHER|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
48138989|NCT00143806|DRUG|Transitioning patients from cyclosporine to alefacept|
48138990|NCT00745875|DRUG|ZD4054|10mg oral tablet, once daily
48138991|NCT00745875|DRUG|Pemetrexed|500mg2/m IV infusion
48138992|NCT00745875|DRUG|Placebo|10mg oral tablet, once daily
48138993|NCT01203943|DRUG|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
48138994|NCT01203943|OTHER|Placebo|Placebo
48138995|NCT01203943|DRUG|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
48138996|NCT01203943|DRUG|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
48138997|NCT06472713|DRUG|Mitoxantrone hydrochloride liposome injection|mitoxantrone hydrochloride liposome injection combined with PD-1 blockade once every 3 weeks for up to 8 cycles, following the uniform PD-1 blockade alone once every 3 weeks for two years, or until intolerable toxicity, subject withdrawal of informed consent, initiation of new antitumor therapy, loss of follow-up, or death, whichever occurs first.
48138998|NCT05715684|OTHER|Exercise Training|Virtually supervised exercise training for four weeks prior to cystectomy
48138999|NCT05715684|DIETARY_SUPPLEMENT|Nutritional Intervention|Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
48139000|NCT04349319|DEVICE|Digital preoperative planning|Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.
48139001|NCT01653652|DIETARY_SUPPLEMENT|Probiotic|
48139002|NCT01653652|DIETARY_SUPPLEMENT|Maltodextrin|
48139003|NCT04002349|DRUG|Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
48139004|NCT04002349|DRUG|Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
48139005|NCT04002349|DRUG|0.9% natural saline|Detailed in arm descriptions
48139006|NCT02734706|DIETARY_SUPPLEMENT|LRC™ capsule|Twice per day (BID), 9 weeks
48139007|NCT02734706|OTHER|Placebo capsule|Twice per day (BID), 9 weeks
48139008|NCT05038215|BEHAVIORAL|adherence promotion techniques|The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.
48139009|NCT05038215|PROCEDURE|Routine Care|The control group will receive routine care
48139010|NCT05912374|BEHAVIORAL|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
48139011|NCT05912374|BEHAVIORAL|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
48139012|NCT03003104|DRUG|DMT210 Topical Gel 5%|
48139013|NCT03003104|OTHER|Vehicle Control|
48139014|NCT01728324|DRUG|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
48660217|NCT04139408|DEVICE|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
48139015|NCT01728324|DRUG|Ribavirin: 24-week treatment|24 weeks of active treatment
48660218|NCT06588582|OTHER|Water Temperature Variation - WW|Participants are assigned to warm water temperature.
48139016|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
48139017|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
48139018|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
48502895|NCT04311372|BEHAVIORAL|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
48502896|NCT04311372|BEHAVIORAL|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
48502897|NCT03288701|DEVICE|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
48660219|NCT06588582|OTHER|Water Temperature Variation - CW|Participants are assigned to cold water temperature and are video recorded.
47984840|NCT00643682|OTHER|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
47984841|NCT06090279|DEVICE|OmniFlow Breathing Therapy BioFeeback System|FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab. Each game usage itself is expected to last 15-20 minutes.
48139019|NCT01728324|DRUG|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
48139020|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
48139021|NCT01728324|DRUG|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
48139022|NCT01728324|DRUG|Faldaprevir: 16-week treatment|16 weeks of active treatment
48139023|NCT01728324|DRUG|Ribavirin: 16-week treatment|16 weeks of active treatment
48139024|NCT01728324|DRUG|RBV: 24-week treatment|24 weeks of active treatment
48139025|NCT01728324|DRUG|BI 207127: 16-week treatment|16 weeks of active treatment
48139026|NCT04039646|COMBINATION_PRODUCT|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
48139027|NCT02118311|BIOLOGICAL|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
48139028|NCT02118311|DRUG|Fludarabine|Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
48139029|NCT02118311|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
48139030|NCT02118311|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
48618269|NCT01035788|BEHAVIORAL|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
48618270|NCT02969018|DRUG|PF-06700841|
48618271|NCT02969018|OTHER|Placebo|
48618272|NCT03518684|DRUG|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
48618273|NCT01668043|DRUG|Antibody UB-421|UB-421 is administered by intravenous infusion
48618274|NCT00204789|DRUG|Difluoromethylornithine|
48660220|NCT06449183|DIAGNOSTIC_TEST|VIDAS® TBI Test [GFAP and UCH-L1 assays]|The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.
48502898|NCT04558268|DRUG|Prednisone|"Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders."
48660221|NCT01052779|DRUG|Ferumoxytol|IV Ferumoxytol
48660222|NCT01052779|DRUG|Iron Sucrose|IV Iron Sucrose
48660223|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days
48660224|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
48660225|NCT06344416|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
48660226|NCT02314923|BIOLOGICAL|V920 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.
48660227|NCT02314923|OTHER|Placebo|0.9% Saline
48660228|NCT05713266|DEVICE|MouthLabTM|Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
48660229|NCT00427830|BIOLOGICAL|MVA85A|
48502899|NCT04558268|DRUG|Progesterone|"Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy."
48502900|NCT04558268|DIETARY_SUPPLEMENT|vit D|Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
48502901|NCT04558268|DIETARY_SUPPLEMENT|Iron Supplement|Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
48502902|NCT04558268|DIETARY_SUPPLEMENT|Folic Acid|"Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer."
48502903|NCT02266537|DRUG|Tamsulosin|
48502904|NCT02266537|DRUG|Alfuzosin|
48502905|NCT02266537|DRUG|Doxazosin|
48502906|NCT02266537|DRUG|Placebo|
48502907|NCT02521935|DEVICE|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination \& diagnosis \& initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
48660230|NCT04890509|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
47984842|NCT03267498|DRUG|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
48660231|NCT04890509|OTHER|SoC|The SoC will be administered based on local guidelines.
48660232|NCT05432609|DIAGNOSTIC_TEST|Weight bearing CT|Weight bearing CT in loaded and unloaded positions
48660233|NCT03772119|PROCEDURE|Surgical resection|Surgical resection of hemivertebra
48660234|NCT03960944|OTHER|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
48660235|NCT04104789|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
48502908|NCT02521935|DEVICE|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, \& tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
48502909|NCT02021357|BEHAVIORAL|hyperbolid combined with tongue exercises on the palate|
48502910|NCT02021357|OTHER|hyperbolid|
48660236|NCT04104789|DRUG|Articaine Injection|Local anesthetic
48660237|NCT00203606|DRUG|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
48660238|NCT06251310|DRUG|SW-682|SW-682 tablet administered orally
48502911|NCT02712333|BEHAVIORAL|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
48660239|NCT06251310|DRUG|Combination Therapy|Appropriate combination therapy
48660240|NCT06269315|OTHER|Cleaning product exposure|Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
48660241|NCT02266771|DEVICE|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
48660242|NCT02266771|DEVICE|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
48660243|NCT06464991|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
48660244|NCT06464991|DRUG|Daratumumab|"dosage form: Injection dose level:16mg/kg frequency: 28days/cycle for DPd regimen~* Cycle1-2：D1, D8, D15, D22；~* Cycle3-6：D1, D15；~* above Cycle7：D1"
48660245|NCT06464991|DRUG|Pomalidomide|dosage form:capsule. doseage form: capsule. dose level: 4mg/d. frequency: every cycle: D1-D21 for DPd regimen, D1-D14 for PVd regimen.
48660246|NCT06464991|DRUG|Bortezomib|dosage form: subcutaneous injection. dose level: 1.3mg/m2. frequency: 21days/cycle for PVd regimen cycle 1-8: D1,D4, D8, D11； above cycle 9: D1, D8.
48660247|NCT06464991|DRUG|Dexamethasone|dosage form: oral or intravenus injection. dose level:20mg/d. frequency: for DPd: every cycle, D1, D2, D8, D9, D15, D16, D22, D23； for PVd: Cycle1-8：D1, D2, D4, D5, D8, D9, D11, D12; above Cycle 9: D1, D2, D8, D9.
48660248|NCT05437419|DRUG|TCK-276|Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
48660249|NCT05437419|DRUG|TCK-276 Placebo|Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
48502912|NCT02712333|BEHAVIORAL|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
48660250|NCT00835172|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
48660251|NCT00835172|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
48660252|NCT05949957|BEHAVIORAL|LvL UP App|LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).
48660253|NCT05949957|BEHAVIORAL|HAPPY App|HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.
48660254|NCT05949957|BEHAVIORAL|Oura Ring And Oura App|Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
48660255|NCT03575598|DRUG|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
48660256|NCT03575598|BIOLOGICAL|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
48502913|NCT02658838|DRUG|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
48660257|NCT01542892|OTHER|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
48660258|NCT01542892|DIETARY_SUPPLEMENT|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
48660259|NCT04109300|GENETIC|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1\*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
48660260|NCT04109300|OTHER|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
48660261|NCT01979185|DRUG|Simvastatin|
48139031|NCT02483468|BEHAVIORAL|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
48139032|NCT02483468|DEVICE|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
48139033|NCT02483468|DEVICE|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
48660262|NCT01979185|DRUG|SSP-004184SS|
48139034|NCT06543797|DEVICE|wearable rTMS|Application of inhibitory low-frequency rTMS on unaffected primary motor cortex by wearable rTMS
48139035|NCT03987698|BIOLOGICAL|SHR-1210|SHR-1210 injection
48139036|NCT03987698|BIOLOGICAL|CIK cells|CIK cells injection
48660263|NCT04169763|DRUG|Cisplatin|Given IV
48660264|NCT04169763|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48139037|NCT02417285|DRUG|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
48660265|NCT04169763|DRUG|Nelfinavir|Given PO
48660266|NCT06570161|DEVICE|SEEUS95 Transparent mask|SEEUS95 developed transparent filtering mask
48660267|NCT06570161|DEVICE|CrystalGuard Mask|CrystalGuard transparent mask
48660268|NCT06570161|DEVICE|N95 face mask|Standard N95 style face mask
48660269|NCT02943473|DRUG|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
48660270|NCT04039347|DRUG|Liposomal Cyclosporine A 5 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
48660271|NCT04039347|DRUG|Liposomal Cyclosporine A 10 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
48660272|NCT00600496|DRUG|AZD6244|twice daily oral dose
48660273|NCT00600496|DRUG|Dacarbazine|intravenous infusion
48660274|NCT00600496|DRUG|Erlotinib|daily oral dose
48660275|NCT00600496|DRUG|Docetaxel|intravenous infusion
48660276|NCT00600496|DRUG|Temsirolimus|intravenous infusion
48660277|NCT06003504|OTHER|First aid training with blended learning approach|"The content of the first aid blended learning training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of 2 consecutive parts:~1. First aid theory is learned independently in a mobile application followed by an online test to ob-tain an admission ticket for the subsequent in-class training;~2. First aid skills are practiced during a 1-day in-class training facilitated by a certified first aid instructor of the Rwanda Red Cross.~Participants get at least 10 days to learn in the mobile application and obtain the admission ticket."
48660278|NCT06003504|OTHER|First aid training with face-to-face approach|"The content of the first aid face-to-face training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of a 3-days in-class training with lectures and practical exercises on first aid the-ory and skills, facilitated by a certified first aid instructor of the Rwanda Red Cross."
48660279|NCT06168773|DRUG|Haloperidol Injection|to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
48660280|NCT04838288|DRUG|Change from Prograf to Envarsus XR|Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
48660281|NCT06639958|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48660282|NCT06639958|BEHAVIORAL|Compliance Monitoring|Receive DST
48660283|NCT06639958|OTHER|Health Promotion and Education|Receive customized printed medication schedules
48660284|NCT06639958|OTHER|Informational Intervention|Receive Patient Supply Kit
48660285|NCT06639958|OTHER|Media Intervention|View MIPE program videos
48660286|NCT06639958|OTHER|Media Intervention|Review booster MIPE videos
48660287|NCT06639958|OTHER|Medical Device Usage and Evaluation|Use MEMS® with TrackCap™
48660288|NCT06639958|DRUG|Mercaptopurine|Given PO
48660289|NCT06639958|OTHER|Questionnaire Administration|Ancillary studies
48660290|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive automated customized electronic reminders via smartphone
48660291|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|Receive additional automated reminder
48660292|NCT06639958|BEHAVIORAL|Telephone-Based Intervention|"Receive electronic reminders with successive alerts (using the snooze function)"
48660293|NCT06639958|BEHAVIORAL|Training and Education|Undergo training for prompting and supervising 6MP
48660294|NCT04635774|DRUG|Insulin|40 IU via four activations of an intranasal spray
48660295|NCT04635774|DRUG|Saline|Four activations of an intranasal spray containing placebo (normal saline).
48660296|NCT05626712|BIOLOGICAL|CELZ-201 Administration|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
48660297|NCT05626712|OTHER|Control Group|Enhanced standard of care for Type 1 Diabetes treatment only.
48660298|NCT02756585|RADIATION|ct perfusion|computed tomography perfusion of the head
48502914|NCT02658838|DRUG|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
48502915|NCT02658838|DRUG|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
48502916|NCT02658838|DRUG|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
48660299|NCT02705963|DRUG|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
48660300|NCT02705963|DRUG|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
48660301|NCT02705963|DRUG|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
48660302|NCT01422577|DEVICE|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
48660303|NCT01422577|DEVICE|White light Endoscopy|White light Endoscopy
47984843|NCT03267498|DRUG|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
47984844|NCT03267498|RADIATION|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
47984845|NCT06092489|OTHER|graded motor imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
48139038|NCT02417285|DRUG|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
48139039|NCT05252468|DEVICE|TaffiX™|Personal nasal powder spray.
48139040|NCT02161354|DRUG|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
48139041|NCT02161354|DRUG|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
48139042|NCT02161354|DRUG|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
48502917|NCT03186781|BIOLOGICAL|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
48502918|NCT03186781|BIOLOGICAL|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
48502919|NCT03908762|DEVICE|iSage App with connected glucometer|Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
48502920|NCT03908762|BEHAVIORAL|Magnet|Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
48502921|NCT00625625|DRUG|isosulfan blue|
48502922|NCT00625625|GENETIC|polymerase chain reaction|
48502923|NCT00625625|OTHER|diagnostic laboratory biomarker analysis|
48502924|NCT00625625|OTHER|immunohistochemistry staining method|
48660304|NCT02706392|OTHER|Laboratory Biomarker Analysis|Correlative studies
48660305|NCT02706392|BIOLOGICAL|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
48660306|NCT00583154|DRUG|BLI-801|Dose 1
48660307|NCT00583154|DRUG|BLI-801|Dose 2
48660308|NCT00583154|DRUG|BLI-801|Dose 3
48660309|NCT00583154|DRUG|BLI-801|Dose 4
48660310|NCT04100018|BIOLOGICAL|Nivolumab|Specified dose on specified days
48660311|NCT04100018|DRUG|Prednisone|Specified dose on specified days
48660312|NCT04100018|DRUG|Docetaxel|Specified dose on specified days
48660313|NCT04100018|OTHER|Placebo|Specified dose on specified days
48660314|NCT01323374|DRUG|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
48660315|NCT01323374|DRUG|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
48660316|NCT01323374|DRUG|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
48660317|NCT01323374|DRUG|Placebo|Oral, placebo TID
48660318|NCT06438731|OTHER|BREAST MILK|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
48660319|NCT06438731|OTHER|KNITTED OCTOPUS|The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
48660320|NCT03888027|BEHAVIORAL|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
48660321|NCT06610890|DRUG|Hemay005|One 15mg tablet, four tablets at a time
48660322|NCT06610890|DRUG|Midazolam maleate|One 15mg tablet, one tablet at a time
48660323|NCT02516813|DRUG|M3814 100 mg|Participants received 100 mg of M3814 as capsule or tablet orally once daily.
48660324|NCT02516813|DRUG|M3814 200 mg|Participants received 200 mg of M3814 as capsule or tablet orally once daily.
48139043|NCT03963466|DRUG|tranexamic acid|Oral tranexamic acid group(menstrual period\>2days) 250mg bid（exclude menstrual period ）
48139044|NCT03963466|RADIATION|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
48660325|NCT02516813|DRUG|M3814 300 mg|Participants received 300 mg of M3814 as capsule or tablet orally once daily.
48660326|NCT02516813|DRUG|M3814 400 mg|Participants received 400 mg of M3814 as capsule or tablet orally once daily.
48660327|NCT02516813|DRUG|M3814 50 mg|Participants received 100 mg of M3814 as capsule orally once daily.
48660328|NCT02516813|RADIATION|Fractionated RT|Participants received fractionated palliative RT (3 Gray \[Gy\] \* 10 in Arm A and 2 Gy \* 33 to 35, 5 fractions per week \[F/W\]) in Arm B and received a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2 in ancillary CPoP part.
47914792|NCT01882608|OTHER|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
48139045|NCT03963466|RADIATION|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
48139046|NCT00268333|DRUG|fluorouracil|
48139047|NCT00268333|DRUG|leucovorin calcium|
48139048|NCT00268333|DRUG|oxaliplatin|
48139049|NCT00268333|PROCEDURE|neoadjuvant therapy|
48139050|NCT04235998|DIAGNOSTIC_TEST|Systematic lung ultrasound|"Patients will undergo a systematic lung ultrasound including review of:~* Sonographic characteristic of effusion~* Parietal, diaphragmatic and visceral pleura~* Pleural nodules~* Lung parenchyma~* Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment."
48139051|NCT02941549|OTHER|Placebo capsules|
48139052|NCT02941549|DRUG|Epeleuton|
48660329|NCT02516813|DRUG|Cisplatin|Participants received Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 mg/m\^2.
48139053|NCT04129099|BIOLOGICAL|GC022F|GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
48139054|NCT01595451|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
48139055|NCT02773732|DRUG|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
48139056|NCT02773732|DRUG|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
48139057|NCT02773732|DRUG|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
48139058|NCT02773732|DRUG|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
48139059|NCT00661206|DRUG|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
48139060|NCT00661206|DRUG|Placebo|Patients randomized in this group will receive placebo for 6 months.
48139061|NCT02434991|DEVICE|Barostat|"* During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~* A urine pregnancy test for females of childbearing years.~* Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~* At this point healthy controls have completed the study.~* Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~* Patients will be contacted to complete a phone survey 3 \& 6 months and 2 \& 4 years after treatment."
48139062|NCT03034278|OTHER|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
48139063|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
48139064|NCT05026970|DEVICE|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
48139065|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Kegel|Biofeedback+Kegel exercises
48502925|NCT00625625|PROCEDURE|diagnostic lymphadenectomy|
48502926|NCT00625625|PROCEDURE|therapeutic conventional surgery|
48502927|NCT00625625|PROCEDURE|therapeutic lymphadenectomy|
48502928|NCT04981730|BEHAVIORAL|Web-based intervention|The web-based intervention participants will follow the website's orientation, the curriculum of modules, and professional feedback to complete the intervention.
48502929|NCT00944619|DEVICE|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
48502930|NCT00944619|DEVICE|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
48502931|NCT02623283|OTHER|No intervention given|Participants will have a full dental examination but no operative intervention
48502932|NCT04937114|PROCEDURE|Barbed suture|Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
48349810|NCT05908929|PROCEDURE|SRP and concomitant insertion of PRF membrane|The pockets were treated with scaling and root planing (SRP) along with the simultaneous insertion of a Platelet Rich Fibrin (PRF) membrane. Blood samples were drawn without anticoagulants in 10 mL tubes, which were immediately centrifuged at 4000 rpm for 8 minutes. Upon centrifugation, the blood showed three distinct layers: the uppermost layer contained platelet poor plasma, the middle layer consisted of a fibrin clot, and the lowermost band appeared bright red due to the presence of red blood cells. The fibrin clot polymerized in a diffuse manner within the tube, which was then cut with sharp scissors and squeezed between two glass slides to obtain a thick membrane. The PRF membrane was carefully handled using a carrier and isolated with a periodontal pack dressing (Coe-Pak). All patients were followed up at one week and six weeks after the treatment.
48349811|NCT05908929|PROCEDURE|SRP|The pockets were treated using the conventional procedure of scaling and root planing (SRP) utilizing curettes and an ultrasonic device. All patients were followed up at one week and six weeks after the treatment.
48349812|NCT03148899|DRUG|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
48349813|NCT03148899|DRUG|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
48349814|NCT02853123|DRUG|Tiotropium|fixed dose combination once daily
48349815|NCT02853123|DRUG|Olodaterol|fixed dose combination once daily
48349816|NCT02853123|DRUG|Tiotropium|
48349817|NCT02743975|DRUG|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
48349818|NCT04298749|DRUG|GX-P1 or Placebo (dose level 1)|GX-P1 dose level 1 or placebo
48349819|NCT04298749|DRUG|GX-P1 or Placebo (dose level 2)|GX-P1 dose level 2 or placebo
48349820|NCT04298749|DRUG|GX-P1 or Placebo (dose level 3)|GX-P1 dose level 3 or placebo
48349821|NCT03277794|BEHAVIORAL|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
48349822|NCT03277794|BEHAVIORAL|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
48349823|NCT03192514|OTHER|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
48349824|NCT05211973|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
48349825|NCT05211973|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
48349826|NCT05211973|DEVICE|Chair Scale|a wheel-chair compatible scale to measure body weight
48349827|NCT05211973|DEVICE|Handheld Body Fat Percentage Device|a handheld device that measures body fat percentage
48660330|NCT04707209|DRUG|Sirolimus|"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~The interval between injections is roughly suggested to be between 3 to 8 weeks based on the drug deposit present in the eye. A total of 3-12 injections will be given per eye, over 6-24 months."
48660331|NCT04419519|DRUG|Venetoclax monotherapy|Venetoclax monotherapy
48349828|NCT05211973|DEVICE|Bioelectric Impedance Analysis Scale|a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)
48349829|NCT01921699|PROCEDURE|taking blood samples from healthy people|
48349830|NCT05784545|DIETARY_SUPPLEMENT|Blueberry powder supplement|The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
48349831|NCT05784545|DIETARY_SUPPLEMENT|Maltodextrin supplementation|The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
48349832|NCT01855867|DRUG|Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
48349833|NCT01518634|DRUG|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
48660332|NCT04419519|DRUG|Venetoclax with anti CD20 monoclonal antibody|Venetoclax with anti CD20 monoclonal antibody
48660333|NCT05576649|OTHER|Task difficulty adaptation according to Arvaneh et al. (2019)|The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
48660334|NCT05576649|OTHER|Random task difficulty|The task difficulty in the P300 speller training is chosen randomly.
48660335|NCT05576649|OTHER|Task difficulty adaptation according to iterative learning controller|The task difficulty in the P300 speller is determined by an iterative learning controller.
48660336|NCT06533553|DRUG|Dexpramipexole Dihydrochloride|Administration of dexpramipexole tablet
48349834|NCT01518634|DRUG|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
48349835|NCT05017987|DRUG|ATB-101, ATB-1011, ATB-1012|"1. Test drug~   - Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin"
48349836|NCT04692896|DRUG|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
48349837|NCT01864486|DEVICE|Intelligent Retinal Implant System|
48349838|NCT05793372|OTHER|Retrospective study of clinical features|Retrospective study of clinical features
48660337|NCT02853136|DRUG|Fluvoxamine|Fluvoxamine
48660338|NCT02853136|DRUG|BI 409306 - Powder for oral solution (PfOS)|BI 409306 - Powder for oral solution (PfOS)
48660339|NCT02853136|DRUG|BI 409306 - film coated tablet|BI 409306 - film coated tablet
48660340|NCT00556114|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography
48660341|NCT03193580|DEVICE|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
48660342|NCT03193580|DEVICE|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
48660343|NCT03193580|DEVICE|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
48660344|NCT06427980|DRUG|Chinese Herbal formula HuoXue LiShui|The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
48660345|NCT06427980|DRUG|Chinese Herbal formula Placebo|The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
48002565|NCT04733963|DRUG|Fruquintinib Plus Capecitabine|Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
48349839|NCT01408732|DRUG|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
48349840|NCT01408732|OTHER|Standard Treatment|Normal standard of care followed by Drug interevention
48349841|NCT02308904|OTHER|Blood Draw/Semen Exam|"Females:~1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~1. Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~2. Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
48618275|NCT04262219|BEHAVIORAL|iShare|The iShare intervention consists of a two-episode educational podcast series containing information about breast cancer patients' sexual problems, approaches for addressing sexual concerns, and information about discussing sexual concerns with patients, such as initiating a conversation about sexual health and asking questions to assess sexual concern. Both episodes feature expert guests and relevant discussions or case studies.
48618276|NCT01493817|OTHER|laboratory biomarker analysis|Correlative studies
48660346|NCT02439957|DRUG|Brincidofovir|
48660347|NCT02439957|DRUG|Valganciclovir|
48660348|NCT02676180|OTHER|Group|
48660349|NCT01655056|DRUG|YM150|oral
48660350|NCT01655056|DRUG|Placebo|oral
48660351|NCT06265415|DRUG|Labetalol|it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
48660352|NCT06265415|DRUG|Nitroglycerine|a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
48618277|NCT04252729|PROCEDURE|Psychotherapy|Psychotherapy sessions based on Psychoanalytic Psychosomatics
48660353|NCT06265415|DRUG|Nifedipine|dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
48660354|NCT05892900|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
48660355|NCT05892900|DEVICE|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
48660356|NCT01631266|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
48660357|NCT01631266|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
48139066|NCT03675321|DEVICE|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
48139067|NCT03675321|DEVICE|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
48139068|NCT00705159|DRUG|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
48139069|NCT00705159|DRUG|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
48139070|NCT00705159|DRUG|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
48139071|NCT00705159|DRUG|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
48139072|NCT02269852|BIOLOGICAL|trivalent seasonal influenza vaccine|"* Infants: 0.25 ml/ dose;~* Adults: 0.5 ml/ dose;~* Seniors: 0.5 ml/ dose;"
48139073|NCT04176952|DRUG|FOLFOX-A|"* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
48139074|NCT04176952|DRUG|AG|"* nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
48139075|NCT06509282|BEHAVIORAL|Concurrent training|"Protocol:~Duration: 6 weeks. Frequency: 3 times a week. Type: Concurrent. This consists of a combination of aerobic exercise and muscular resistance exercise.~Details of the type of exercise:~Aerobic exercise:~Participants will perform 5-10 intervals per session of walking or jogging at a moderate to high intensity, with a rating of 5 to 10 points on the modified Borg scale of 1-10 points. Each interval will consist of 1 minute of walking or jogging, followed by 2 minutes of inactive pause.~Muscular resistance exercise:~Participants will perform concentric and eccentric and/or isometric contractions for 1 minute at an intensity of 5-10 according to the OMNI-RES scale. The rest period will last 2 minutes, and each exercise will be repeated 3 times. Three exercises per session will be performed: squats, push-ups, and plank.~Pharmacological treatment:~Participants will be asked to maintain their lifestyle, including taking prescribed medication as usual."
48139076|NCT02808234|PROCEDURE|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
48349842|NCT02308904|OTHER|Retrospective data/Chart Review/Relevant Clinical Results|"1. 1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2\* MRI. 4. Ferritin levels.~2. NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~3. 1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~4. 1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~5. Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
48139077|NCT02808234|OTHER|Nucel|Allograft derived from human amnion and amniotic fluid
48139078|NCT01857999|DRUG|Losartan|
48660358|NCT06387953|DEVICE|Bridge Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Bridge therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
48660359|NCT06387953|DEVICE|Sham Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Sham therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
48660360|NCT01508767|OTHER|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
48660361|NCT01644331|DRUG|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
48660362|NCT01644331|DRUG|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
48660363|NCT04442269|DRUG|dupilumab|Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
48139079|NCT01857999|DRUG|Placebo|
48139080|NCT05089487|PROCEDURE|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
48139081|NCT00198185|PROCEDURE|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
48139082|NCT00943969|PROCEDURE|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
48139083|NCT03987074|DRUG|Semaglutide|Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
48139084|NCT03987074|DRUG|Firsocostat|Tablets administered orally once daily
48139085|NCT03987074|DRUG|Cilofexor|Tablets administered orally once daily
48660364|NCT04442269|DRUG|Placebo|Matching placebo
48660365|NCT05558579|OTHER|No sling use|Patients will not use standard of care sling
48660366|NCT06217263|DEVICE|Vibration device|Vibracool vibration device from Pain Care Labs will be used.
48660367|NCT06217263|OTHER|Vibration device&Cold application pack|Pain Care Labs' Vibracool vibration device and cold gel pack will be used.
47984846|NCT06092489|OTHER|traditional physiotherapy method|This protocol included stretching and strengthening exercises. Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening.
48139086|NCT03673566|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
48139087|NCT01825850|DRUG|Gemigliptin|
47984847|NCT04801160|PROCEDURE|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
47984848|NCT04801160|PROCEDURE|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
47984849|NCT01930747|DRUG|rocuronium|measure effect on laparoscopic workspace
47984850|NCT01930747|DRUG|Sevoflurane|1 MAC sevoflurane inhalation is given
47984851|NCT01930747|DRUG|remifentanyl|remifentanyl is given in infusion
47984852|NCT01166724|DRUG|Sirolimus|Tacrolimus to Sirolimus
47984853|NCT01166724|DRUG|Tacrolimus|dosage per trough level
47984854|NCT02894931|DIETARY_SUPPLEMENT|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
47984855|NCT02894931|DIETARY_SUPPLEMENT|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
47984856|NCT02894931|DIETARY_SUPPLEMENT|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
47984857|NCT02894931|DIETARY_SUPPLEMENT|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
47984858|NCT02894931|OTHER|Control- water|Chilled water flavored with lemon juice as control
47984859|NCT02097810|DRUG|Entrectinib|
47984860|NCT05383768|OTHER|preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C|"Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020)."
47984861|NCT00094627|DRUG|gaboxadol|Duration of Treatment - 6 weeks
47984862|NCT00094627|DRUG|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
47984863|NCT03584022|DEVICE|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
47984864|NCT03584022|PROCEDURE|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
47984865|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
47984866|NCT03989557|DEVICE|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
47984867|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
47984868|NCT05756374|BEHAVIORAL|OUT to IN|OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
48139088|NCT01825850|DRUG|Irbesartan|
48139089|NCT01634165|DRUG|LY2963016|Administered subcutaneously
48139090|NCT01634165|DRUG|Lantus|Administered subcutaneously
48139091|NCT01706666|DRUG|bortezomib|Given SC
48139092|NCT01706666|DRUG|cyclophosphamide|Given PO
48139093|NCT01706666|DRUG|lenalidomide|Given PO
48139094|NCT01706666|OTHER|laboratory biomarker analysis|Correlative studies
48139095|NCT01706666|DRUG|dexamethasone|Given PO
48139096|NCT01706666|PROCEDURE|quality-of-life assessment|Ancillary studies
48139097|NCT05688605|DRUG|MRG003+HX008|Administered intravenously
48139098|NCT03301870|DRUG|ATx201 Gel 2%|2% active gel
48139099|NCT03301870|DRUG|ATx201 Gel 4%|4% active gel
48139100|NCT03301870|DRUG|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
48139101|NCT03301870|DRUG|Negative Control|Water for Injection, USP
48139102|NCT03301870|DRUG|ATx201 Placebo|matching placebo gel
48139103|NCT00241618|DRUG|Pegylated interferon alpha 2|
48139104|NCT00241618|DRUG|Ribavirin|
48618278|NCT04685811|DRUG|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron|68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
48139105|NCT04243200|OTHER|Hypos can strike twice|"The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover."
48139106|NCT05987774|DEVICE|AI Modules for Improving Social Conversation|"The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers."
48139107|NCT04757194|DIAGNOSTIC_TEST|openTriage - Alitis algorithm|A machine learning algorithm (Gradient boosting) applied to structured data collected in the Alitis Clinical Decision Support system, patient demographics, and free-text notes.
48139108|NCT02725138|DIETARY_SUPPLEMENT|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
48139109|NCT02725138|OTHER|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
48139110|NCT04808024|PROCEDURE|SelfMyofascial Release|Myofascial auto-release consisted of rolling the roller on a group of knee flexors for 3.5 minutes between the sciatic tumor and the knee joint in both directions, omitting the popliteal fossa. Before and after the intervention, sEMG of the biceps and gluteal muscles will be performed.
48139111|NCT01227421|DRUG|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
48139112|NCT01227421|DRUG|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
48349843|NCT02308904|OTHER|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
48349844|NCT05089188|OTHER|Immunomarkers|immunohistochemical expression profile of ambiguous melanocytic proliferation.
48349845|NCT04235088|OTHER|Somatosensory intensive intervention|The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
48618279|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
47914793|NCT04549298|OTHER|No interventions|No interventions - observational study
47914794|NCT03820687|OTHER|Clinical Trial Educational Video|Bilingual, culturally tailored educational video, low literacy booklet, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trial participation.
47914795|NCT03820687|OTHER|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
47914796|NCT03820687|OTHER|Low literacy booklet|A bilingual low-literacy booklet with educational content about clinical trials.
48139113|NCT01227421|DRUG|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
48139114|NCT03221881|DRUG|Pegylated Liposomal Doxorubicin and docetaxel|
48139115|NCT05519852|BEHAVIORAL|Pilates training|the pilates group (20 patients) will be trained 30 minutes of pilates exercise (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
48139116|NCT06032689|COMBINATION_PRODUCT|Xtra-fill|the material was placed in bulk.
48139117|NCT06032689|COMBINATION_PRODUCT|x-base|The x-base liner was placed and then veneered with Xtra-fill.
48139118|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-tra|bulk placement of the restoration Admira fusion -xtra.
48139119|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-base|Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
48139120|NCT05400759|OTHER|IOP monitoring data|
48139121|NCT02980588|DEVICE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
48139122|NCT06272591|OTHER|Preliminary search in the patient's file|"Details of the information previously sought in the patient's file :~age profession gender/parity physiological or pathological pregnancy indication for induction of labour gestational age at time of induction"
48349846|NCT01656018|DRUG|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
48349847|NCT03733249|DRUG|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
48349848|NCT03733249|BIOLOGICAL|rivogenlecleucel|donor T-cells modified with iCasp safety switch
48349849|NCT03369704|DRUG|Omalizumab|Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
48349850|NCT03369704|DRUG|Placebo|Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
48349851|NCT02936362|OTHER|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
48349852|NCT02936362|OTHER|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
48349853|NCT03188302|OTHER|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
48349854|NCT03175952|DIAGNOSTIC_TEST|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
48349855|NCT01723124|PROCEDURE|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
47984869|NCT00528333|DRUG|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
47984870|NCT00528333|DRUG|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
48349856|NCT05983679|DIAGNOSTIC_TEST|Blood sample|Blood sample
47984871|NCT00528333|DRUG|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
47984872|NCT03194698|DEVICE|Intense Pulsed Light Treatment (IPL)|IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
48349857|NCT01585168|DRUG|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
48349858|NCT01585168|DRUG|Placebo|Identically appearing sugar pill, given orally
48349859|NCT02827487|DRUG|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
48349860|NCT02827487|DRUG|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
48349861|NCT02827487|DRUG|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
48349862|NCT02827487|DRUG|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
48349863|NCT02827487|PROCEDURE|IUD|IUD insertion
48349864|NCT01642004|BIOLOGICAL|Nivolumab|
48349865|NCT01642004|DRUG|Docetaxel|
48349866|NCT04060433|BEHAVIORAL|Family Therapy|Swedish version of the evidence based manualized Family Therapy
48349867|NCT02261402|OTHER|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
47984873|NCT03194698|PROCEDURE|Meibomian Gland Expression|Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
48349868|NCT00794469|OTHER|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
48349869|NCT06409507|GENETIC|FKBP12 expression|The expressions of FKBP12 were determined by immunohistochemistry (IHC) , and the immunoreactive score (IRS), calculated by multiplying the staining intensity grades by the proportion of positive cells, was used to assess the expression levels of FKBP12. IRS (0-7) represented low expression levels, and IRS (8-12) represented high expression levels.
48349870|NCT02949414|PROCEDURE|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
48349871|NCT03100006|DRUG|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
48349872|NCT03100006|DRUG|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
48349873|NCT05974891|OTHER|Pilot application|"Pilot application will be carried out with at least 10 students. A pre-test will be applied to the experimental group. After the scales are applied, the experiment will be applied to the experimental group with the Geriatric Medication Game simulation.~Students simulating the elderly patient role during this simulation will gain a better understanding of age-related health problems and how older adults feel when confronting them. After the application, debriefing, which is the last stage of the simulation training, will be done to evaluate the application. After the application and analysis session is completed, the post-test will be applied to the experimental group. A 3-week clinical practice will be planned for the students in the experimental groups in order to evaluate the continuation of the acquired skills and acquired awareness. In this application, students will be asked to care for the elderly patient and the pre-test will be repeated at the end of the application."
48349874|NCT03904862|DRUG|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
48349875|NCT04573491|GENETIC|Pharmacogenetic test|genotyping for genes that affect drug metabolism
48349876|NCT04573491|OTHER|Medication review|systematic and interdisciplinary method aiming to increase quality of medication treatment
48349877|NCT05699044|DIAGNOSTIC_TEST|Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)|"Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.~DPD-scintigraphy. (Echocardiography)"
48349878|NCT02425969|PROCEDURE|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
48349879|NCT02425969|DRUG|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
48139123|NCT06272591|OTHER|A posteriori research in the patient's file|Data on maternal and foetal morbidity and mortality following childbirth will be collected.
48349880|NCT04416191|OTHER|Limb immobilization|Participants will undergo a 2-week period of leg immobilization
48349881|NCT00638898|DRUG|busulfan|Given IV
48349882|NCT00638898|DRUG|melphalan|Given IV
48349883|NCT00638898|DRUG|topotecan hydrochloride|Given IV
48687846|NCT05780008|BEHAVIORAL|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
48349884|NCT00638898|OTHER|laboratory biomarker analysis|Correlative studies
48139124|NCT06272591|OTHER|First questionnaire : choice of induction method reason for choice|Given on arrival at the maternity unit to begin induction.
48139125|NCT06272591|OTHER|Second questionnaire : experience of induction|Given post-partum in the maternity unit.
48349885|NCT00638898|BIOLOGICAL|filgrastim|Given IV or subcutaneously
48349886|NCT00638898|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transplantation
48349887|NCT00638898|OTHER|pharmacological study|Correlative studies
48349888|NCT00638898|PROCEDURE|autologous bone marrow transplantation|Undergo transplantation
48349889|NCT04290767|DIAGNOSTIC_TEST|Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)|Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
48349890|NCT01992328|DRUG|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
48349891|NCT04051489|OTHER|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
48349892|NCT05382806|DRUG|Flumazenil|During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
48349893|NCT04739917|BIOLOGICAL|Vaccine PvCS N+C+R 150 mcg|Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
48139126|NCT00881296|DRUG|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
47984874|NCT02348606|DRUG|JZP-110|
48139127|NCT00881296|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
48139128|NCT05230966|DEVICE|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
48139129|NCT03608293|DIAGNOSTIC_TEST|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
48139130|NCT01562184|DEVICE|Sham tDCS device|Sham tDCS
48687847|NCT05859555|OTHER|Thematic quality circles - Deprescription|Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
47984875|NCT02348606|DRUG|Placebo oral tablet|
47984876|NCT02904512|DEVICE|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
47984877|NCT02904512|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
47984878|NCT02947529|DRUG|Tranexamic Acid|intravenous dose
47984879|NCT02947529|OTHER|Placebo|intravenous dose
47984880|NCT03234192|PROCEDURE|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
47984881|NCT03234192|PROCEDURE|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
47984882|NCT03234192|PROCEDURE|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
47984883|NCT03483883|DRUG|Avelumab|Avelumab IV 10 mg/kg every 2 weeks
47984884|NCT03483883|DRUG|Gemcitabine|Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
47984885|NCT04246060|DRUG|Cysteamine Bitartrate|ERT
47984886|NCT06332651|OTHER|Black beans|Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed
47984887|NCT06332651|OTHER|Milk|Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
48139131|NCT01562184|DEVICE|Soterix tDCS device|Active tDCS
48139132|NCT02432300|BEHAVIORAL|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
48139133|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
48139134|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
48349894|NCT04739917|OTHER|Placebo SSN Montanide ISA-51 1 mL|SSN Montanide ISA-51 1 mL
48687848|NCT05628285|DEVICE|Sentio 1|Sound processor
48687849|NCT05806346|DRUG|TXA administration|Tranexamic acid intravenous administration
48687850|NCT05806346|DRUG|Placebo administration|Placebo (normal saline) intravenous administration
47984888|NCT06332651|OTHER|Sorghum|Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
47984889|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
47984890|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
47984891|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
47984892|NCT05687422|PROCEDURE|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
47984893|NCT05687422|PROCEDURE|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
47984894|NCT01336920|DRUG|carfilzomib|Given IV
47984895|NCT02060604|DRUG|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
47984896|NCT02060604|DRUG|Ranibizumab|3 monthly ranibizumab, then as needed
47984897|NCT05633524|OTHER|blood sample analysis|All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
47984898|NCT03314753|OTHER|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
47984899|NCT04946539|DIAGNOSTIC_TEST|Ultrasonography|Enthesitis assessment via ultrasonography
47984900|NCT04843774|DRUG|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
47984901|NCT02905331|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
47984902|NCT02905331|DRUG|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
47984903|NCT03163615|DRUG|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
47984904|NCT03163615|DRUG|Placebo oral capsule|4 capsules, po, from admission up to 84 days
47984905|NCT04047433|GENETIC|screening for single nucleotide polymorphism|samples from both arms will be tested for a set of single nucleotide polymorphism
47984906|NCT04047433|GENETIC|whole exome sequencing|samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
47984907|NCT02371109|OTHER|selftaken versus clinically taken swabs|
47984908|NCT01453634|DRUG|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
47984909|NCT01453634|DRUG|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
48349895|NCT03338452|BEHAVIORAL|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
48349896|NCT00255606|DRUG|docetaxel|Given in 3- or 4- week courses
48349897|NCT00255606|DRUG|prednisone|Given in 3- or 4- week courses
48349898|NCT02039128|DIETARY_SUPPLEMENT|Krill oil or Fish oil|
48502933|NCT04034537|DIAGNOSTIC_TEST|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
48502934|NCT00002785|BIOLOGICAL|filgrastim|
47984910|NCT04961645|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.~Participants will be seated comfortably in a chair and asked to complete either a simple computer-based task or a simple behavioral task that will require them to walk around in a small room. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur. The entire visit will last about one and a half hours."
47984911|NCT02062034|DRUG|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
48349899|NCT02039128|DIETARY_SUPPLEMENT|Placebo|
48687851|NCT01336712|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
48502935|NCT00002785|DRUG|asparaginase|
48502936|NCT00002785|DRUG|cyclophosphamide|
48502937|NCT00002785|DRUG|cyclosporine|
48502938|NCT00002785|DRUG|cytarabine|
48502939|NCT00002785|DRUG|daunorubicin hydrochloride|
48502940|NCT00002785|DRUG|dexamethasone|
48502941|NCT00002785|DRUG|etoposide|
48687852|NCT01458743|DRUG|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
48502942|NCT00002785|DRUG|leucovorin calcium|
48502943|NCT00002785|DRUG|mercaptopurine|
48502944|NCT00002785|DRUG|mesna|
48502945|NCT00002785|DRUG|methotrexate|
48502946|NCT00002785|DRUG|methylprednisolone|
48502947|NCT00002785|DRUG|pegaspargase|
48502948|NCT00002785|DRUG|prednisone|
48687853|NCT01458743|DRUG|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
48502949|NCT00002785|DRUG|therapeutic hydrocortisone|
48687854|NCT02840188|OTHER|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
48687855|NCT04322435|OTHER|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
48687856|NCT04322435|OTHER|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
48687857|NCT01301287|DRUG|Chlorella|
48687858|NCT06231875|DEVICE|Press|Fabrication of clear aligners using press machine (Mini-star)
48687859|NCT03672812|DRUG|Liraglutide|liraglutide 3mg 6/6 hours
48687860|NCT06280638|OTHER|Virtual stent-guided incremental optimization strategy (VIOS)|"PCI is performed according to strategy recommended by Imaging-Heart Team based on VIOS protocol."
48687861|NCT06280638|OTHER|Standard angiographic strategy|PCI is performed based on international guidelines, local protocols and practice.
48687862|NCT05336929|OTHER|Roy adaptation model-based nursing education|
48687863|NCT04700085|DEVICE|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
48687864|NCT05273814|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
48687865|NCT05273814|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
48687866|NCT05273814|DRUG|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
48139135|NCT06009666|DIAGNOSTIC_TEST|Shear Wave Elastography and B Mode Ultrasonography|We evaluated the both upper extremities of the patient and control group with elastography and B mode ultrasonography. Shear wave elastography evaluates tissue deformation caused by acoustic radiation force. A highly focused ultrasound radiation is produced; The propagation speed of the shear wave depends on the stiffness of the tissue. It is a simple, inexpensive, bedside, widely available, non-invasive technique. B mode USG can be used to assess skin and subcutaneous tissue thickness and echogenicity. Skin and subcutaneous thickness were measured with b mode ultrasound. Skin and subcutaneous tissue stiffness was measured by shear wave ultrasonography
48139136|NCT06009666|DIAGNOSTIC_TEST|Quick Dash Questionnare|Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. In the questionnaire, the difficulties of the patients during their daily living activities are questioned with 11 questions. Each answer is scored from 1 to 5 on a Likert scale, from best to worst.
47984912|NCT02062034|DRUG|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
48139137|NCT06009666|DIAGNOSTIC_TEST|The Lymphedema Life Impact Scale|The Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 functional subgroups. Each question is scored from 1 to 5, with higher scores indicating increased seriousness.
48139138|NCT06009666|DIAGNOSTIC_TEST|Questioning lymphedema-related symptoms|Arm pain and feeling of tension, heaviness and stiffness in the arm were evaluated separately by numerical scale. This scale is a 10 cm ruler that writes no pain, no tension, no heaviness, no stiffness on one side, and unbearable pain, tension and heaviness on the other side. Patients were asked to rate their associated symptoms on this scale between 0 and 10.
48349900|NCT06501794|DEVICE|Quantitative measurement of eye movements|Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
47984913|NCT02062034|DRUG|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
47984914|NCT02266745|DRUG|PT-112 Injection|
47984915|NCT06421779|BEHAVIORAL|Virtual reality (VR)|Children watch underwater experience video by wearing the virtual reality glass during the skin prick test.
47984916|NCT03282942|OTHER|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~* Squatting~* Leg press~* Knee Extension~* Knee Flexion~* Supine Challenge~* High Pull~* Elbow flexion~* Extension of elbows~* Development~* Abdominal"
47984917|NCT03282942|OTHER|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
47984918|NCT04128384|DIAGNOSTIC_TEST|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR|For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
47984919|NCT01726153|BEHAVIORAL|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
47984920|NCT00770796|DRUG|Atorvastatin|80 mg die
47984921|NCT00770796|DRUG|Placebo|
47984922|NCT03228589|DIETARY_SUPPLEMENT|probiotic strain|8 weeks of treatment with probiotic strain
47984923|NCT03228589|DIETARY_SUPPLEMENT|Placebo|8 weeks of treatment
47984924|NCT01882621|DRUG|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
47984925|NCT01882621|DRUG|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
47984926|NCT01712854|DRUG|Budesonide|budesonide 80 mcg
47984927|NCT01712854|DRUG|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
47984928|NCT04602182|PROCEDURE|music therapy intervention|Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
47984929|NCT01031940|DEVICE|macintosh laryngoscope|intubate with the macintosh laryngoscope
47984930|NCT01031940|DEVICE|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
47984931|NCT01031940|DEVICE|Airtraq device|intubate with the Airtraq device
47984932|NCT00527007|OTHER|External cooling|External cooling
47984933|NCT03059654|PROCEDURE|tracheostomy|
47984934|NCT00608231|DRUG|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
47984935|NCT00608231|DRUG|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
47984936|NCT02042248|BIOLOGICAL|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
47984937|NCT01537744|DRUG|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~1. Each cycle will last 28 days.~2. Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~3. On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~4. Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
48660368|NCT02957240|BEHAVIORAL|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
47984938|NCT01494480|PROCEDURE|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
48002566|NCT04733963|DRUG|Bevacizumab Plus Capecitabine|Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
48002567|NCT01391481|DRUG|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
48002568|NCT01391481|DRUG|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
48002569|NCT02782416|OTHER|Examination of latent tuberculosis|
48502950|NCT00002785|DRUG|vincristine sulfate|
48502951|NCT00002785|PROCEDURE|allogeneic bone marrow transplantation|
48502952|NCT00002785|RADIATION|low-LET cobalt-60 gamma ray therapy|
48502953|NCT00002785|RADIATION|low-LET photon therapy|
48660369|NCT02957240|BEHAVIORAL|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
48660370|NCT05466383|BEHAVIORAL|Exercise|Exercise rehabilitation with Schroth method
48660371|NCT05466383|DEVICE|Brace|Wear an orthopedic brace
48660372|NCT05807594|BEHAVIORAL|HMZ 2.0 Intervention|The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will receive adaptation). The model-based predictive control system in the HMZ 2.0 digital platform will continually and automatically evaluate GWG, identify when a woman may exceed GWG guidelines, and recommend an adaptation. The registered dietitian will review the data and behavior strategies that are suggested (guided PA workouts, EI cooking demonstrations, customized grocery planning, portion size control, food scales, and meal replacements). Practical, easy-to-adopt examples will be provided (walking in 5-10 min increments throughout the day to increase PA kcal, reduce sitting by 5 min/hour; replace 8 oz of whole milk with skim milk to reduce EI kcal) to facilitate behavior change while adhering to safety standards. Each woman's unique preferences and past successes with strategies are also considered when personalizing the dosage.
48139139|NCT06009666|OTHER|Extremity circumference and volume measurement|For the diagnosis of lymphedema, a detailed physical examination and extremity circumference were measured. This measurement was taken from both wrists to arm height with 4 cm intervals. Those with a circumference difference greater than 2 cm and/or no 10% volume difference were considered preclinical (latent) and those with clinical lymphedema.
48139140|NCT04366193|DIAGNOSTIC_TEST|Oximetry|Validation of a high-resolution wireless oximeter for OSA diagnosis comparing with a well established and validated method (home sleep test).
48502954|NCT06408948|DRUG|[14C]SHR7280|Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
48139141|NCT03658252|BEHAVIORAL|Targeted education|Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
48139142|NCT03658252|BEHAVIORAL|Online disease specific forum|An invitation to join an online moderated disease specific social forum
48139143|NCT02792855|DEVICE|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
48139144|NCT02792855|DEVICE|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
48139145|NCT02052440|DRUG|Baclofen|Treatment arm: baclofen 10mg tid
48139146|NCT02052440|DRUG|Placebo|Sugar pill by mouth three times daily
48139147|NCT02733159|DRUG|pembrolizumab|anti PD-1
48349901|NCT02377076|DIETARY_SUPPLEMENT|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
48349902|NCT02377076|DIETARY_SUPPLEMENT|Control|Control (Whey protein, vitamin D, sugar and salt)
48349903|NCT01315340|PROCEDURE|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
48349904|NCT05354869|DEVICE|Urostym|electric pelvic floor muscle stimulator
48502955|NCT01723579|DRUG|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
48502956|NCT01723579|DRUG|Estradiol (E2)|Daily release of 1.5 mg
48502957|NCT05735041|BEHAVIORAL|Multi-domain cognitive digital therapy|Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
48502958|NCT05735041|BEHAVIORAL|Basic cognitive therapy|The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.
48618280|NCT01631188|PROCEDURE|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
48349905|NCT05354869|BEHAVIORAL|Standard care|patient education on home exercises and stretching
48349906|NCT02397772|DRUG|albendazole|Single dose of albendazole (400 mg)
48349907|NCT01231672|BIOLOGICAL|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
48349908|NCT02114398|OTHER|usual treatment|usual treatment
48349909|NCT02114398|OTHER|usual treatment + sophrology|usual treatment + sophrology
48349910|NCT00604357|DRUG|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
48618281|NCT01631188|DEVICE|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
48002570|NCT02815748|DRUG|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
48002571|NCT01926795|PROCEDURE|Short leg cast|
48002572|NCT01926795|PROCEDURE|No Immobilization|
48660373|NCT05807594|BEHAVIORAL|Attention Control Intervention|Consistent with guidelines for comparator groups, all women will receive prenatal care offered by recruitment sites with routine provider visits, counseling about prenatal behaviors (e.g., no smoking), and clinical oversight of health. Women randomized to the attention control group will complete the same measurement procedures as the intervention group.
48660374|NCT05537727|DEVICE|robotic-assisted surgery|Gynecology: robot-assisted and laparoscopic hysterectomy for benign or low risk malignant disease
48660375|NCT05537727|DEVICE|robotic-assisted surgery|Urology: robot-assisted and laparoscopic partial nephrectomy
48660376|NCT05537727|DEVICE|robotic-assisted surgery|General surgery: robot-assisted and laparoscopic right colectomy
48660377|NCT03747367|BEHAVIORAL|Insufficient Sleep|
48660378|NCT03350945|PROCEDURE|Device: tumor localization|At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
48660379|NCT01005290|DRUG|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
48660380|NCT01005290|DRUG|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
48660381|NCT06396559|BEHAVIORAL|pre test-post test|The mobile application will be installed on the mobile devices of student nurses and its effectiveness will be tested.
48660382|NCT05718739|DEVICE|AX6 6-axis logging accelerometer|The device is collecting longitudinal movement data.
48660383|NCT01690273|OTHER|mobility exercise|30 minutes, twice a week
48660384|NCT01690273|OTHER|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
48660385|NCT05309629|DRUG|QL1706|Intravenous infusions of QL1706 5mg/kg on Day 1 of every 21-day cycle.
48660386|NCT05309629|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle for 4-6 cycles.
48349911|NCT03330093|BEHAVIORAL|Sleep Health in Preschoolers|In-person, family-based behavioral intervention
48349912|NCT03330093|BEHAVIORAL|Health and Safety Intervention|In-person, family-based behavioral intervention
48349913|NCT02374359|OTHER|follow-up|
48502959|NCT04001127|OTHER|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
48502960|NCT03915028|OTHER|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~* Cure of Drink (in addition to 4 daily cares)~* Bath in running water: Bath~* Bath in running water: Pool at 32 ° C~* Bath with aerobain~* Immersion shower bath~* Shower of high pressure under immersion in swimming pool~* General penetrating shower~* General jet shower~* Local jet shower~* Local mud bath at the feet~* Single poultice~* Multiple poultice~* Compress~* Mobilization pool~* Massages under water"
48660387|NCT05309629|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle for 4-6 cycles.
48660388|NCT05007704|BEHAVIORAL|Global Experts Consensus opinion using Delphi Methodology|The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
48660389|NCT05697224|DIAGNOSTIC_TEST|urinary micro RNA detection|Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR_71a gene expression analysis MAPK-3 gene expression analysis
48660390|NCT01300637|DRUG|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
48660391|NCT01300637|DRUG|placebo|identical-appearing pill of placebo
48660392|NCT04763343|DRUG|Ketamine Hydrochloride|Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
48660393|NCT04763343|DRUG|Saline|Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
48002573|NCT05395962|DRUG|Carboplatin|treatment with bleomycin and carboplatin in association with electroporation
48349914|NCT03809156|DRUG|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
48349915|NCT04247828|DEVICE|Experimental AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with an adaptive and individualized keyboard to test communication performance.
48349916|NCT04247828|DEVICE|Generic AAC|Participant receives an AAC system comprising a single hybrid wearable sensor for head-mediated cursor control that is integrated with a generic QWERTY keyboard to test communication performance.
48349917|NCT03368079|DEVICE|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
48349918|NCT04037462|DRUG|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
48660394|NCT04763343|BEHAVIORAL|CAMS Therapy|CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
48660395|NCT05341843|DRUG|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
48660396|NCT05341843|DRUG|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
48660397|NCT04951193|BEHAVIORAL|Behavioral Activation Therapy app|Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
48660398|NCT04951193|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
48660399|NCT03332056|DRUG|Belladonna and Opium|
48660400|NCT03332056|OTHER|Placebo suppository|
48660401|NCT04322279|DIAGNOSTIC_TEST|Serology|SARS-CoV-2 serology
48660402|NCT04322279|GENETIC|Sequencing|Whole exome sequencing
48349919|NCT01969305|BEHAVIORAL|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
48502961|NCT01894594|DRUG|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: \*\~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: \*\~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~\* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
48660403|NCT04977232|DRUG|Escitalopram|Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.
48660404|NCT04977232|BEHAVIORAL|Game intervention|Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.
48660405|NCT06043154|OTHER|Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding|Clinical and biological measurements, blood and stool sample collection
48660406|NCT04354233|DEVICE|Physical activity intervention with connected devices|"Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team."
48660407|NCT06220084|BEHAVIORAL|Dance for PD®|The intervention consists of 16 60-min adapted to Greek culture DfPD® classes, which will be performed twice weekly for 8 weeks and instructed by a single researcher, who has the approval to use it for research reasons. The intervention will be delivered both live and online in separate periods for each participant.
48660408|NCT05569317|OTHER|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
48660409|NCT04899687|DRUG|Fluoxetine|Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
48349920|NCT01969305|BEHAVIORAL|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~1. Facts and Myth about HIV. HIV/STIs modes of transmission;~2. Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~3. Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
48349921|NCT02717676|PROCEDURE|Episiotomy|episiotomy will be done after crowning of the fetal head
48349922|NCT03973567|DRUG|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
48349923|NCT03973567|OTHER|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
48349924|NCT00909883|DRUG|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
48349925|NCT00909883|DRUG|Placebo|Placebo injection
48349926|NCT01961999|PROCEDURE|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output \<0,5ml/Kg/h for \> 6 hours"
48349927|NCT01961999|PROCEDURE|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (\<0,5ml/Kg/h \>12h), despite therapy refractory extravascular fluid overload azotemia \>40mmol/L or 240mg/dL metabolic acidosis (pH\<7,2) hyperkaliemia (k+\>6mmol/L)"
48502962|NCT04023162|BEHAVIORAL|Graded Activity|Active participation of participants, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
48660410|NCT04899687|DRUG|Dextromethorphan|Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
47914797|NCT03820687|OTHER|Navigator|Support will be provided by a patient navigator to empower cancer patients to make an informed decision about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes, and intentions to consider clinical trials as an appropriate treatment option for cancer.
48349928|NCT00554528|DEVICE|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
48502963|NCT04023162|BEHAVIORAL|Group-based Therapy Exercise|Aerobic exercise, Stretching exercise and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercise Muscle strength training exercise
48502964|NCT04023162|BEHAVIORAL|Back School|Basic information of Low Back Pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
48502965|NCT04619095|DIETARY_SUPPLEMENT|Psyllium|See the information already included in the arm descriptions.
48660411|NCT06415240|OTHER|Facilitated Tucking|Facilitated Tucking is a position to be adopted for pain relief in neonates.
48660412|NCT06415240|OTHER|Gentle Human Touch|while gentle human touch is caressing on head for pain relief.
48002574|NCT05395962|DRUG|Bleomycin|treatment with bleomycin in association with electroporation
48349929|NCT00554528|PROCEDURE|arthrodesis - cervical disk surgery|discectomy and arthrodesis
48349930|NCT06409104|DRUG|Propofol|will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion
48349931|NCT06409104|DRUG|Dexmedetomidine|will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
48349932|NCT03238040|OTHER|None, observational study|Observational study, no interventions
48349933|NCT01071291|DRUG|Niaspan|Niaspan™
48349934|NCT01071291|DRUG|Comparator: Placebo|Placebo
48349935|NCT06118190|DRUG|Lidocain|All participants treated with procaine and lidocaine injection for treatment.
48349936|NCT02943044|DEVICE|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
48349937|NCT04275492|DRUG|Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)|Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
48349938|NCT04275492|DRUG|Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)|Siforl® is produced by Boehringer Ingelheim International Gmbh
48349939|NCT03948594|DIETARY_SUPPLEMENT|resource|1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
48502966|NCT04619095|DIETARY_SUPPLEMENT|Placebo|See the information already included in the arm descriptions.
48502967|NCT02936453|PROCEDURE|Device implantation|"* Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~* Implantation of Activa RC neurostimulator"
48660413|NCT04765397|PROCEDURE|Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound|During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.
48139148|NCT01026805|DEVICE|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
48139149|NCT04755504|DIAGNOSTIC_TEST|EEG behind the ear|2 additional electrodes behind each ear will record EEG
48139150|NCT04003558|OTHER|No interventions|As this is a patient registry, there are no interventions.
48349940|NCT03948594|OTHER|plain water|250ml plain water
48660414|NCT02128776|OTHER|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
48660415|NCT02128776|OTHER|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
48660416|NCT02076711|DRUG|Metoprololsuccinate|
48660417|NCT02076711|DRUG|Placebo|Placebo
48139151|NCT03246750|DRUG|B-MAD chemotherapy|B-MAD chemotherapy
48139152|NCT03464955|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
48349941|NCT00290680|DRUG|bortezomib|
48349942|NCT00290680|DRUG|celecoxib|
48349943|NCT02749786|OTHER|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
48349944|NCT02419586|OTHER|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
48349945|NCT00650364|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
48349946|NCT00650364|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fasting
48349947|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
48349948|NCT01110486|DRUG|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
48660418|NCT06291779|DEVICE|Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio|"* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample."
48660419|NCT03404180|PROCEDURE|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
48660420|NCT03404180|DRUG|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
47984939|NCT03206853|PROCEDURE|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
47984940|NCT05944341|DRUG|articaine hydrochloride 4% with epinephrine 1:100 000|Local anesthetic agent
47984941|NCT05944341|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Local anesthetic agent
48139153|NCT03849066|OTHER|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
47984942|NCT05474742|OTHER|The Nori Health app|The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
47984943|NCT02101645|PROCEDURE|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
47984944|NCT02101645|PROCEDURE|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
47984945|NCT02461901|OTHER|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
47984946|NCT02461901|OTHER|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
48139154|NCT02311062|OTHER|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
48139155|NCT02311062|OTHER|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
48139156|NCT02311062|OTHER|Control|Only soccer training
48349949|NCT01110486|DRUG|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
48349950|NCT01110486|DRUG|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
48349951|NCT01110486|DRUG|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
48349952|NCT04668365|DRUG|Rituximab|375mg/m2, Intravenous administration on day 0 of each 3-week cycle.
48349953|NCT04668365|DRUG|Zanubrutinib|160mg twice daily continuous oral administration.
48349954|NCT04668365|DRUG|Cyclophosphamide|750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48502968|NCT00430820|PROCEDURE|per intervention|per intervention
48502969|NCT02393248|DRUG|Pemigatinib|
48502970|NCT02393248|DRUG|Gemcitabine|
48502971|NCT02393248|DRUG|Pembrolizumab|
48502972|NCT02393248|DRUG|Docetaxel|
48660421|NCT03404180|PROCEDURE|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
48660422|NCT03404180|PROCEDURE|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
48660423|NCT05984290|DEVICE|orthokeratology lens|Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
48660424|NCT04817956|DRUG|Atezolizumab|drugs used outside indication, based on biomarker
48349955|NCT04668365|DRUG|Epirubicin|70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48349956|NCT04668365|DRUG|Vincristine|1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48349957|NCT04668365|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48349958|NCT05905705|DIAGNOSTIC_TEST|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
48349959|NCT05905705|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
48349960|NCT04427410|DIAGNOSTIC_TEST|Salivary test|Salivary test for measured of oxytocin levels
48139157|NCT05655000|PROCEDURE|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
48349961|NCT02110472|DEVICE|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
48349962|NCT05364112|DEVICE|Compreflex|The Compreflex standard calf and foot (with basic liner) from Sigvaris (St. Gallen, Switzerland) is an easy-to-use interlacing Velcro wrap device with adjustable compression levels.
48349963|NCT00653406|DRUG|Risperidone long acting injectable|
48349964|NCT06415916|PROCEDURE|Cardiac ultrasound|Performed 5 times between 0 and 120 minutes
48349965|NCT06415916|PROCEDURE|Lung ultrasound|Performed 5 times between 0 and 120 minutes
48349966|NCT00213967|DEVICE|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
48349967|NCT03105869|DIAGNOSTIC_TEST|fluorocholine PET/CT|standard diagnostic PET/CT procedure
48349968|NCT05129111|DEVICE|PHYSICAL VIBRATION OF THE PAROTID GLANDS|The system will be placed bilaterally in the parotid glands and assessed the efficacy of the salivary secretion by sialometry before and after the stimulation
48139158|NCT00690404|DRUG|AZD2066|single oral dose
48139159|NCT01372085|DRUG|LY2584702 Reference Formulation|Administered orally
48349969|NCT01183481|DRUG|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
48349970|NCT01183481|RADIATION|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
48349971|NCT01183481|DRUG|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
48349972|NCT00164788|DRUG|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
48349973|NCT00164788|DRUG|Oral esomeprazole|40mg every 12 hours for 24 hours
48349974|NCT00669591|DRUG|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
48349975|NCT00914719|BEHAVIORAL|Information only|
48660425|NCT05316844|OTHER|There will be no interventions.|Measurements and performance tests were conducted to investigate predictors of work-related performance
48349976|NCT00914719|BEHAVIORAL|Sexual risk reduction intervention|
48660426|NCT00835367|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
48660427|NCT00835367|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
48139160|NCT01372085|DRUG|LY2584702 Test Formulation|Administered orally
48139161|NCT01372085|DRUG|Placebo|Administered orally
48139162|NCT06405906|OTHER|Fat-free diet|The low-fat diet will consist of instructions to avoid fatty foods.
48349977|NCT00914719|BEHAVIORAL|sexual risk reduction + alcohol risk reduction component|
48349978|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
48349979|NCT03199014|DEVICE|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
48349980|NCT01518673|PROCEDURE|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
48349981|NCT01614522|DRUG|ASLAN001|ASLAN001 500mg BID
48139163|NCT06405906|OTHER|Balanced WHO diet|The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025
48139164|NCT00001004|DRUG|Tumor Necrosis Factor|
48660428|NCT06059898|DEVICE|GBR surgery including membrane placement|After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
48139165|NCT00001004|DRUG|Interferon gamma-1b|
48139166|NCT04197791|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
48139167|NCT04197791|OTHER|Core Stabilization Exercises|Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
48139168|NCT01802424|BEHAVIORAL|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
48139169|NCT06324344|DEVICE|High-Dose TENS|high-dose TENS device delivers 1 hour of TENS therapy per session.
48139170|NCT06324344|DEVICE|Low-Dose TENS|low-dose TENS device delivers 6 minutes of TENS therapy per session.
48139171|NCT02293551|DRUG|Lispro|Administered SC
48139172|NCT06062641|DRUG|SR-GDP|Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
48139173|NCT03418545|DEVICE|JUVÉDERM VOLBELLA® XC injectable gel|JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.
48660429|NCT06059898|PROCEDURE|Biopsy|After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
48139174|NCT01752959|DRUG|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
48139175|NCT01752959|DRUG|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
48139176|NCT06157645|DEVICE|Prolene mesh|Application of mesh onlay post stoma closure
48139177|NCT00653172|DRUG|NXL103|600mg orally twice daily
48660430|NCT04354623|OTHER|A 6-minute walk test|Each subject will perform a 6-minute walk test during which gait assessment will be obtained from the APDM system (Portland, OR). In addition there will be four video cameras (on the front, back and sides) that will measure raw video data for our gait analysis. The camera does not record any facial data (in fact, 'deepfake' software in the system deletes all facial details) and the patient's movements are converted to a 'stick figure' prior to being saved in the system.
48660431|NCT03134209|DEVICE|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
48139178|NCT00653172|DRUG|comparator|comparator twice daily
48139179|NCT00653172|DRUG|NXL103|500mg orally twice daily
48139180|NCT03673605|DRUG|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
48139181|NCT03673605|DRUG|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
48139182|NCT00853528|OTHER|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
48139183|NCT00853528|PROCEDURE|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
48139184|NCT00853528|PROCEDURE|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
48139185|NCT00853528|RADIATION|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
48139186|NCT00853528|RADIATION|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
48139187|NCT05137366|DIAGNOSTIC_TEST|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~1. Suprasternal window~2. Parasternal long axis window~3. Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
48349982|NCT01832389|DEVICE|PiCCO|
48349983|NCT01802294|BEHAVIORAL|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
48349984|NCT04761575|OTHER|Validation of the FFQ65+ via eNutri app|All participants will provide two eNutri FFQ datasets within a 14-day interval along with three 24-hour dietary recalls and dried blood spot samples.
48502973|NCT02393248|DRUG|Trastuzumab|
48502974|NCT02393248|DRUG|Retifanlimab|
47984947|NCT02461901|OTHER|Fecal sampling|Collection of fecal samples for C. difficile spores
47984948|NCT04107233|BEHAVIORAL|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
48349985|NCT01809691|DRUG|TAK-700|300 mg, PO, twice daily
48349986|NCT01809691|DRUG|Bicalutamide|50 mg, PO, q daily
48349987|NCT02545452|DRUG|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
48349988|NCT02545452|DRUG|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
48349989|NCT02545452|DRUG|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
48502975|NCT02393248|DRUG|Cisplatin|
48502976|NCT02201212|DRUG|Everolimus|
48502977|NCT01363024|DRUG|MFGR1877S|Intravenous escalating dose
48502978|NCT01288144|OTHER|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
48502979|NCT04975009|BEHAVIORAL|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
48502980|NCT04643561|OTHER|Travelan OTC|5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
48502981|NCT04074616|DEVICE|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
48502982|NCT04074616|DEVICE|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
48349990|NCT02545452|DRUG|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
48502983|NCT04099550|DEVICE|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
48660432|NCT03134209|OTHER|Monocryl + Dermabond|conventional sutures and skin adhesive glue
48660433|NCT03134209|OTHER|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
48349991|NCT02545452|OTHER|Tampon|
48139188|NCT06270732|BEHAVIORAL|iMentalize Program (iMentalize)|"This is a 30-hour group training involving 30 sessions lasting 45 minutes and 7.5 hours of inter-sessions work.~Session 1: Program presentation; Session 2: Reflective Parenting; Session 3: Cartoon's session I (baseline); Session 3: What is Mentalization; Session 4: Fundamentals of Human Interaction; Session 5: Cartoon's session II (the beginnings); Session 6: Mentalization and Mental Health; Session 7: MISC context and cultural components; Session 8: Cartoon's session III (practice with MISC context comp.); Session 9: The importance of emotions in human interaction; Session 10: MISC emotional components; Session 11: Cartoon's session IV (practice with emotional comp.); Session 11: How mentalization is developed; Session 12: MISC cognitive components; Session 13: Cartoon's session V (practice with cognitive comp.); Session 14: How to foster children mentalization skills. Sessions 15 to 30: Cartoon's sessions using MISC components to foster children mentalization."
48139189|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 30-hour individual training involving 30-weekly online, individual, self-administered 45' sessions (22.5h) + 7.5h of between sessions work (readings, supervision, video- recordings for later video-feedback, reﬂection exercises). BLOCK I: Session 1: Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC; Sessions 9-18 (MISC practice and video-feedback); Summer break: Recording daily life interactions; BLOCK II: Session 19: Recap; Sessions 20-30: guided reﬂection and video-feedback.
48139190|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|"This is an equivalent 30-hour online self-administered training involving 30 x 45' individual online sessions (22.5h), mostly based on reﬂection exercises around brief readings, pills, and animated shorts, but not video- feedback and guided practice. This is complemented with 7.5h of between-sessions work based on looking for new information, adult-child (non-guided) activities (and not for later video- feedback) or out-of-line guided reﬂective exercises.~Session 1: Program presentation; Session 2-8: Theoretical bases of MISC and mentalization; Session 9-16: MISC and mentalization applied to mental health; 17-18: Benefits of MISC to improve children learning; 19-20: Benefits of MISC for self-esteem; 21-22: The importance of MISC to foster mentalization; 23-24: Mentalization and pro-social behavior; 25-26: The importance of MISC to promote secure attachment; 27: MISC impact in epistemic trust; 28-29: MISC and well-being; 30: MISC, mentalization and environmental enrichment."
48139191|NCT01894737|OTHER|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
48139192|NCT01894737|OTHER|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
48139193|NCT04034966|DEVICE|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
48139194|NCT01026207|DEVICE|Polysomnography|Sleep study polysomnography compared with portable monitoring
48139195|NCT03547167|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
48139196|NCT03547167|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
48139197|NCT03547167|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
48139198|NCT00003412|BIOLOGICAL|recombinant interleukin-12|
48660434|NCT00443456|DRUG|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
48660435|NCT00190957|DRUG|Atomoxetine|
48660436|NCT00190957|DRUG|placebo|
48660437|NCT01006395|DRUG|Zoledronic acid|yearly infusion
48660438|NCT01006395|DRUG|Placebo|yearly infusion
48139199|NCT00105846|PROCEDURE|Home care telemedicine|
48502984|NCT04099550|OTHER|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
48660439|NCT02495883|OTHER|Ethanol|50ml of 40% Ethanol
48660440|NCT02495883|DRUG|Propranolol|Beta blocker
48660441|NCT04429763|BIOLOGICAL|Umbilical cord derived mesenchymal stem cells|One dosis of 1\*10\^6 cells/Kg
48660442|NCT04429763|BIOLOGICAL|Placebo|Placebo
48660443|NCT04584723|OTHER|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
48660444|NCT01878448|DRUG|Anlotinib|
48660445|NCT04894864|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
48660446|NCT04894864|DRUG|Opioid-free Anesthesia-Analgesia Strategy|A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
48660447|NCT04918082|OTHER|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
47984949|NCT05713045|DIETARY_SUPPLEMENT|Konakion|Comparing 4 different regimen of Vitamin K administration in newborn
48139200|NCT05380115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|weekly one on one video or telephone interviews with a study coach
48660448|NCT04993261|PROCEDURE|Dual-Energy Computed Tomography|Undergo dual energy CT scan
48660449|NCT03225404|OTHER|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
48660450|NCT03225404|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
48660451|NCT03257657|BEHAVIORAL|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
48660452|NCT03257657|BEHAVIORAL|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
48660453|NCT02194179|DRUG|NVP XR 400 mg (KCR 25%)|
48502985|NCT04426812|OTHER|No intervention; just data collection|No intervention; just data collection
48660454|NCT02194179|DRUG|NVP XR 400 mg (KCR 20%)|
48139201|NCT03472352|BIOLOGICAL|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
48139202|NCT01324076|DRUG|doxorubicin-eluting beads|
48139203|NCT01324076|DRUG|sorafenib tosylate|
48139204|NCT01324076|OTHER|laboratory biomarker analysis|
48139205|NCT01324076|OTHER|pharmacogenomic studies|
48139206|NCT01324076|OTHER|pharmacological study|
48139207|NCT01324076|PROCEDURE|quality-of-life assessment|
48139208|NCT03333824|DRUG|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
48139209|NCT03333824|DRUG|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
48660455|NCT02194179|DRUG|NVP XR 300 mg (KCR 25%)|
48660456|NCT02194179|DRUG|NVP XR 300 mg (KCR 20%)|
48349992|NCT04971980|DRUG|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
48349993|NCT05949463|OTHER|Intermittent teaching unit|The intermittent group students performed an intermittent teaching unit twice a week for eight weeks aimed at promoting healthy physical activity habits. Specifically, the last 15 minutes of each lesson were used. The rest of lessons' time other contents were worked on with no relation to any health physical activity habit (i.e., acrosport, badminton, basketball, volleyball, soccer and athletics).
48349994|NCT05949463|OTHER|No intervention group|The control group students also carried out two Physical Education lessons a week during the intervention period. During these lessons, contents of handball, basketball, alternative sports and traditional games were developed. However, this group did not wear physical activity activity wristbands or receive any behavior modification specific strategy.
48349995|NCT05141344|DRUG|Melatonin 3 MG Oral Tablet|it will be given orally one hour preoperatively
48349996|NCT05141344|DRUG|Placebo|sugar-coated tablets will be given one hour preoperatively
48349997|NCT00879788|DRUG|Ramipril 10mg capsules|
48502986|NCT02185716|DRUG|Levobupivacaine 0.25 %|
48349998|NCT03605836|DRUG|Centanafadine SR|100 mg, BID, oral tablets
48502987|NCT02185716|DRUG|Levobupivacaine 0.5%|
48502988|NCT01064050|DEVICE|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
48502989|NCT00198237|DRUG|docetaxel & capecitabine|
48502990|NCT00006239|DRUG|sodium phenylbutyrate|
48349999|NCT03605836|OTHER|Placebo|BID, oral tablet
48502991|NCT00006239|DRUG|tretinoin|
48502992|NCT02932306|DRUG|IDP-121 Lotion|IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
48502993|NCT02932306|DRUG|IDP-121 Vehicle Lotion|IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
48502994|NCT02087189|DEVICE|First ICD/CRT-D implantation or upgrade from pacemaker|
48350000|NCT03605836|DRUG|Centanafadine SR|200 mg, BID, oral tablets
48350001|NCT02735044|DRUG|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])
48502995|NCT00090181|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
48502996|NCT00090181|DRUG|Comparator: diclofenac / Duration of Treatment: 4 weeks|
48502997|NCT02293863|DRUG|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
48502998|NCT02293863|DRUG|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
48502999|NCT02293863|DRUG|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
48660457|NCT02194179|OTHER|high-fat breakfast|
48660458|NCT02194179|DRUG|NVP IR 200 mg (Viramune®)|
48660459|NCT05206370|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
48660460|NCT05206370|DRUG|Placebo|film-coated oral tablets containing matched placebo
48660461|NCT05206370|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
47984950|NCT05766982|OTHER|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
47984951|NCT02331836|DEVICE|Arc Endocuff (AEC 110, 120, 130, 140)|
47984952|NCT02331836|DEVICE|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
48139210|NCT03333824|DRUG|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
48139211|NCT03333824|DRUG|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
48139212|NCT03333824|DRUG|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
48139213|NCT02558205|RADIATION|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
48139214|NCT02558205|RADIATION|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
48139215|NCT04759794|DIAGNOSTIC_TEST|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
48139216|NCT03035942|DRUG|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
48350002|NCT02735044|DRUG|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
48350003|NCT02735044|DRUG|Background therapy|Fast-acting mealtime insulin analogs
48350004|NCT02768844|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
48350005|NCT02768844|OTHER|Control|Absence of mattress Stochastic Vibratory Stimulation (SVS)
48350006|NCT01638676|DRUG|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
48350007|NCT01638676|DRUG|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
48350008|NCT03304392|BEHAVIORAL|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
48503000|NCT02518516|DRUG|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed \>120 days of the index date (i.e. no exposure within 120 days of the index date)."
48503001|NCT02518516|DRUG|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
48139217|NCT03035942|DRUG|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
48139218|NCT03035942|DRUG|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
48660462|NCT03248752|BEHAVIORAL|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
47984953|NCT02331836|DEVICE|Standard colonoscope|
48139219|NCT05937269|COMBINATION_PRODUCT|Near-infrared fluorescence lymphatic imaging|All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
48139220|NCT05937269|DEVICE|advanced pneumatic compression therapy|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy.
48139221|NCT06510608|DIAGNOSTIC_TEST|Biochemical analysis of saliva sample|It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.
48139222|NCT02676011|DRUG|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
48139223|NCT02676011|DRUG|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
48139224|NCT02676011|DRUG|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
48503002|NCT02518516|DRUG|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
48503003|NCT02518516|DRUG|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
48503004|NCT02518516|DRUG|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
47984954|NCT00851812|BEHAVIORAL|Exercise|Standard care monitoring
47984955|NCT00851812|BEHAVIORAL|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
47984956|NCT06320795|DEVICE|SOUNDI|Continuous monitoring of vital signs for diagnosis and follow-up of sleep-disordered breathing in adults.
47984957|NCT03863990|DRUG|PAH medication|Any PAH-targeted medication
47984958|NCT04737343|DRUG|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
47984959|NCT04737343|DRUG|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
48002575|NCT02243878|RADIATION|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
48139225|NCT02676011|DRUG|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
48139226|NCT02676011|DRUG|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
48139227|NCT02676011|DRUG|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
48139228|NCT06510829|DEVICE|Diode laser|Application of laser waves on the lesion
48139229|NCT05197127|DEVICE|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
48139230|NCT00597376|OTHER|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
48139231|NCT00597376|OTHER|Cerefolin NAC placebo|Placebo tablet once a day
48139232|NCT04604652|DRUG|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
48139233|NCT02760654|DEVICE|Proactive Self Management Program for Effects of Cancer Treatment|
48139234|NCT03543631|OTHER|Survey|Online survey
48139235|NCT01711294|DEVICE|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
48139236|NCT01711294|DEVICE|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
48139237|NCT01711294|DEVICE|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
47984960|NCT02335723|DEVICE|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
48350009|NCT03304392|BEHAVIORAL|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
48350010|NCT02253992|BIOLOGICAL|Urelumab|
48350011|NCT02253992|BIOLOGICAL|Nivolumab|
48350012|NCT04340089|BEHAVIORAL|squatting on the toilet|the patients could go to squatting on the toilet at any time as they want to after taking the capsule
48350013|NCT02022592|DRUG|Lormetazepam|
48350014|NCT02022592|DRUG|Midazolam|
48350015|NCT02520141|OTHER|Laboratory Biomarker Analysis|Correlative studies
48350016|NCT02520141|BIOLOGICAL|Ramucirumab|Given IV
48350017|NCT01601990|DRUG|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
48350018|NCT01601990|DRUG|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
48350019|NCT02249260|BEHAVIORAL|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
48350020|NCT00150150|PROCEDURE|Interstitial laser photocoagulation|
48350021|NCT03088332|PROCEDURE|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
48350022|NCT00791011|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
48350023|NCT00791011|OTHER|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
48350024|NCT00791011|OTHER|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
48350025|NCT04067440|DIAGNOSTIC_TEST|Microbial Swab|Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
48350026|NCT01563406|OTHER|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
48350027|NCT01563406|OTHER|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
48350028|NCT01563406|DRUG|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
48350029|NCT01563406|DRUG|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
48350030|NCT04064944|DEVICE|blood purification equipment|The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
48350031|NCT01701349|DRUG|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
48660463|NCT03248752|BEHAVIORAL|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
48350032|NCT01701349|DRUG|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
48350033|NCT00906334|DRUG|ON 01910.Na|The original dosing regimen was 800 mg/m\^2 ON 01910.Na.
48350034|NCT00906334|DRUG|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
48350035|NCT04619381|BEHAVIORAL|CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY|Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.
48350036|NCT00290355|BIOLOGICAL|GSK 249553 vaccine|Intramuscular injection, 13 doses
48350037|NCT00290355|BIOLOGICAL|Placebo|Intramuscular administration, 13 doses
48350038|NCT00509028|DRUG|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
48660464|NCT02341274|DRUG|Tacrolimus|Bioequivalence study
48350039|NCT00509028|DRUG|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
48350041|NCT02243306|DRUG|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
48350042|NCT03253029|DIETARY_SUPPLEMENT|Pure Encapsulations Branched Chain Amino Acid powder|
48350043|NCT03253029|DIETARY_SUPPLEMENT|control group (no BCAAs provided)|
48350044|NCT00268476|DRUG|Celecoxib|
48350045|NCT00268476|DRUG|Docetaxel|
48350046|NCT00268476|DRUG|Prednisolone|
48350047|NCT00268476|DRUG|ADT|
48350048|NCT00268476|DRUG|Zoledronic Acid|
48350049|NCT00268476|DRUG|Abiraterone|
48350050|NCT00268476|RADIATION|Radiotherapy to the prostate|
48350051|NCT00268476|DRUG|Enzalutamide|
48350052|NCT00268476|DRUG|Metformin|
48350053|NCT00268476|DRUG|Transdermal Oestradiol|
48350054|NCT05413356|DRUG|Ruxolitinib|Oral ruxolitinib twice daily
48350055|NCT04976309|DRUG|Lu AG09222|Single dose
48350056|NCT04976309|DRUG|Placebo|Single dose
48350057|NCT01221662|DRUG|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
48350058|NCT05566327|BEHAVIORAL|De-implementation Bundle|"A multicomponent intervention directed at the drivers of low value preoperative testing.~An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing scheduled surgery will be ordered at the discretion of a consulting anaesthesiologist only. Workshops will be delivered to surgical, internal medicine, and anaesthesia divisions. The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies.The clinical departments will commit to supporting the change in policy. Nurses will be coached to feel comfortable calling the anesthesiologist about any preoperative tests ordered, and the PAC nurses will have the authority to cancel tests. Check boxes will be removed from surgeons' and family physicians' order forms to reduce to ease of ordering the tests."
48350059|NCT03185091|OTHER|rapid ventricular pacing|
48350060|NCT03185091|PROCEDURE|Surgery|
48350061|NCT02485860|DEVICE|Melectis G|
48350062|NCT03821350|OTHER|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
48350063|NCT00941707|DRUG|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
48350064|NCT00941707|DRUG|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
48350065|NCT03194204|DRUG|Doxycycline Tablets|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
48350066|NCT04942769|DRUG|Selenium|selenium 100ug ，take it orally twice daily
48350067|NCT03742271|DEVICE|senofilcon A|TEST Lens
48350068|NCT04250610|OTHER|Survey|On-line survey.
48350069|NCT02788825|PROCEDURE|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
48350070|NCT03164122|DRUG|injection of microfat and plasma rich platelet PRP|intra-articular injections
48350071|NCT03164122|DEVICE|MRI|MRI 3T
48350072|NCT05478967|PROCEDURE|IVA injection before vitrectomy|Patients in IVA group received an IVA (0.5 mg/0.05 ml) injection before surgery (1 to 5 days before surgery)
48350073|NCT01300000|OTHER|Human Milk|ad lib
48350074|NCT01300000|OTHER|Investigational infant formula|ad lib
48350075|NCT01300000|OTHER|Milk based standard infant formula|ad lib
47984961|NCT02335723|DEVICE|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
48139238|NCT05522309|DRUG|ET0111|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
48139239|NCT01138384|DRUG|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
48350076|NCT00683774|DRUG|diazoxide|100mg orally three times per day for 10 days
48350077|NCT02349776|OTHER|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
48350078|NCT04246489|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, death, unacceptable toxicity and study withdrawal.
48660465|NCT03898011|DRUG|Lamotrigine|Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
48660466|NCT03898011|DRUG|Lamictal|Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
48139240|NCT01138384|DRUG|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
48139241|NCT00624637|OTHER|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
48139242|NCT05932303|DRUG|BMS-986278|Specified dose on specified days
48139243|NCT05932303|DRUG|Itraconazole|Specified dose on specified days
48139244|NCT05932303|DRUG|Gemfibrozil|Specified dose on specified days
48139245|NCT05932303|DRUG|Carbamazepine|Specified dose on specified days
48139246|NCT01262456|DRUG|Desmopressin|
48139247|NCT01262456|DRUG|Placebo|
48139248|NCT01217099|DRUG|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
48139249|NCT01217099|DRUG|azithromycin|control patients were iv azithromycin for 5 days.
48350079|NCT02381262|BEHAVIORAL|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
48350080|NCT04233840|DRUG|P1101 (Ropeginterferon alfa-2b)|solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
48139250|NCT00382941|DEVICE|Red and near infrared LED phototherapy device|
48139251|NCT03705572|DIETARY_SUPPLEMENT|Lacprodan PL20|Milk protein concentrate that is high in phospholipid content (min 16%).
48139252|NCT03705572|OTHER|Placebo|Placebo milk drink.
48139253|NCT04131257|BEHAVIORAL|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
48139254|NCT01792401|DRUG|Probiotics|
48139255|NCT01792401|DRUG|Placebo|
48139256|NCT04874649|OTHER|Balloon-blowing breathing|Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
48139257|NCT04874649|OTHER|Sustained maximal inspiration breathing|Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
48139258|NCT04288167|DIAGNOSTIC_TEST|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
48139259|NCT02785159|DRUG|IDP-118 Lotion|Lotion
48139260|NCT02785159|DRUG|Tazorac Cream|Cream
48139261|NCT02785159|DRUG|IDP-118 Vehicle Lotion|Lotion
48503005|NCT02518516|DRUG|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
48660467|NCT05605249|DEVICE|Cue X|The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
48139262|NCT02785159|DRUG|IDP-118 Vehicle Cream|Cream
48139263|NCT01349270|DRUG|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
48139264|NCT01349270|DRUG|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
48139265|NCT06509685|OTHER|Ladder Training|9 participants will perform only Ladder training exercise protocol. The training schedule included exercises such as Two foot run, Ladder traps, Lateral angle leg hops, Single leg forward hop, two-foot lateral run, Fight shuffle, Skiers, Carioca, Lateral in out, two in two out, Intermediate high knee run, Straddle squat hops, two foot laterals hop in \& out, Two-foot lateral hop, Ali shuffle, 180 Degree rotation, jumping jacks' variation, Advanced in in out, Quick hops cotch, Icky shuffle etc. For each session, ten stations were used and participants change the partner after every end of steps jumping exercise and continued each exercise at least 3 set, depending on the class design(22).
48139266|NCT06509685|OTHER|balance training|9 participants will perform balance training protocol. The balance training program includes exercises based around balance development in unilateral dynamic balancing positions. The program included balance and landing activities incorporating wobble boards and change of direction activities.
48139267|NCT03620955|OTHER|Justified risk stratification based on MRD after three course chemo therapy|All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
48139268|NCT02764970|DRUG|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
48139269|NCT02305498|OTHER|Vigorous yoga practice|
48139270|NCT02305498|OTHER|Restorative (gentle) yoga practice|
48139271|NCT01847859|PROCEDURE|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
48139272|NCT04847258|OTHER|Standard rehabilitation|Patients follow standard municipal rehabilitation
48660468|NCT03092518|PROCEDURE|Surgery|Heated Intraperitonial Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate
48660469|NCT03092518|DRUG|Cisplatin|Cisplatin (90 mg/m2) will be administered via circuit to the peritoneal cavity
48660470|NCT03092518|DRUG|Mitomycin C|Mitomycin C 10 mg/m2 will be administered via circuit to the peritoneal cavity
48139273|NCT00486304|OTHER|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
48660471|NCT03092518|DRUG|Sodium Thiosulfate|Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
48660472|NCT00398814|DRUG|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
48660473|NCT00398814|DRUG|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
48660474|NCT02129621|PROCEDURE|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
48660475|NCT02129621|DRUG|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
48660476|NCT00296712|DRUG|escitalopram + bupropion|same dosing as for monotherapy arms
48139274|NCT00486304|OTHER|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
48139275|NCT02790632|DRUG|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
48660477|NCT02085720|DEVICE|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
48660478|NCT03639935|DRUG|Rucaparib|Rucaparib 600 mg PO BID days 1-28
48660479|NCT03639935|DRUG|Nivolumab|Nivolumab 240 mg IV days 1 and 15
48660480|NCT01937065|OTHER|No treatment|
48660481|NCT05797623|DRUG|Trappa ethanolamine tablets ; ciclosporin|Trappa ethanolamine tablets combined with ciclosporin
48660482|NCT05797623|DRUG|Placebo ; ciclosporin|Placebo combined with ciclosporin
48660483|NCT01558167|DRUG|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~* Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~* Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~* Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~* Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~* Dose level 5: maximal tolerated dose"
48660484|NCT04167735|DEVICE|Hearing Aid without Reverberation Canceller (RevC).|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
48350081|NCT04233840|DRUG|Nivolumab|"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
48350082|NCT02421640|DRUG|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
48350083|NCT02421640|DRUG|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
48350084|NCT03419507|DEVICE|Endotracheal tube introducer|The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
48350085|NCT03419507|DEVICE|Macintosh laryngoscopy|The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
48350086|NCT06455358|DRUG|61Cu-NODAGA-LM3|Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.
48350087|NCT06455358|OTHER|Comparator|Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.
48350088|NCT05928624|DEVICE|Withings Home Blood Pressure Device and Scale|The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers. The investigators are not testing the efficacy of these approved devices.
48350089|NCT05928624|OTHER|Standard of Care|Standard of Care
48350090|NCT05925829|BIOLOGICAL|SVF and aaPRP|Stromal vascular fraction and autologous activated platelet-rich plasma
48350091|NCT00881023|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
48350092|NCT00881023|DEVICE|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
48350093|NCT01731275|DRUG|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
48350094|NCT01731275|DRUG|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
48139276|NCT02790632|DRUG|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
48350095|NCT03180021|PROCEDURE|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
48350096|NCT01144741|OTHER|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
48350097|NCT01144741|OTHER|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
48139277|NCT02553148|OTHER|Need for children's palliative care|Need for children's palliative care
48139278|NCT00010049|DRUG|imatinib mesylate|
48350098|NCT01144741|OTHER|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
48350099|NCT01144741|OTHER|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
48139279|NCT03511144|DEVICE|Unity Knee™ TKR using measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
48350100|NCT01144741|OTHER|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
48350101|NCT01144741|OTHER|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
48139280|NCT03511144|DEVICE|Unity Knee™ TKR using ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
48139281|NCT00741650|BEHAVIORAL|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
48660485|NCT04167735|DEVICE|Hearing Aid Reverberation Canceller enabled (RevC_1)|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
48139282|NCT00741650|BEHAVIORAL|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
48139283|NCT00022672|DRUG|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
48139284|NCT00022672|DRUG|anastrazole (Arimidex®)|1 mg tablet taken orally daily
48139285|NCT05085418|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
48139286|NCT04348669|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
48139287|NCT01429285|DRUG|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
48139288|NCT01429285|DRUG|Usual care|Attending administers any IV opioid in any dose he chooses
48139289|NCT00713596|DRUG|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
48350102|NCT01144741|OTHER|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
48660486|NCT00027599|BIOLOGICAL|bevacizumab|
48660487|NCT00027599|BIOLOGICAL|prostatic acid phosphatase-sargramostim fusion protein|
47984962|NCT06189651|DEVICE|wrist splint|The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
47984963|NCT06189651|PROCEDURE|5% dextrose injection using USG-guided nerve hydrodissection method|2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
47984964|NCT06371053|BEHAVIORAL|Community Intervention|"The intervention includes Cognitive Training: Activities targeting memory, attention, language, and executive functions to maintain cognitive abilities. This could involve cognitive games, memory exercises, and daily tasks.~Life Skills Training: Assistance in maintaining or relearning daily life skills such as personal hygiene, dressing, eating, and household chores. This could be through structured training programs and daily guidance.~Physical Exercise: Providing appropriate physical activities and exercises to maintain physical health and function, including walking, balance training, and light strength training.~Social Support: Organizing social activities and support groups to facilitate interaction and reduce social isolation and loneliness.~Emotional Support: Offering mental health support and psychosocial services to help individuals cope with emotional challenges such as anxiety and depression."
47984965|NCT00473460|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
47984966|NCT00473460|DRUG|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
47984967|NCT05195827|DRUG|PRM-125|Antihypertensive
47984968|NCT01518010|BEHAVIORAL|Play game|Participants engage in non-game activity (establish baseline) 7 \* 1 hr weekly; play single-player game 7 \* 1 hr weekly; play multi-player game 7 \* 1 hr weekly.
47984969|NCT05899309|DIAGNOSTIC_TEST|liver and spleen stiffness test and laboratory test|Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)
47984970|NCT00708643|DEVICE|Habitual Silicone Hydrogel Contact Lens|contact lens
47984971|NCT00708643|DEVICE|narafilcon A|contact lens
47984972|NCT06327867|DEVICE|Oro Tracheal Intubation by DL|DL
47984973|NCT06327867|DEVICE|Oro Tracheal Intubation by VL|VL
47984974|NCT03775057|OTHER|MyDoseCoach app|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
47984975|NCT05473338|DIAGNOSTIC_TEST|Stool and blood samples|fecal microbiome and metabolomics, as well as metabolites in plasma
47984976|NCT05473338|OTHER|Physical examination|physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
47984977|NCT05473338|OTHER|Questionnaires|Questionnaires measuring pain level, sleep, mood and diet parameters.
47984978|NCT06380088|OTHER|Isometric Task|The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.
47984979|NCT01647282|DRUG|locally-applied minocycline HCl (1 mg)|
47984980|NCT01647282|PROCEDURE|scaling and root planing (Sc/RP)|
48002576|NCT02243878|DRUG|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
48139290|NCT00713596|PROCEDURE|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
48139291|NCT00713596|PROCEDURE|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
48139292|NCT00713596|PROCEDURE|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
48660488|NCT00027599|BIOLOGICAL|sipuleucel-T|
48660489|NCT00027599|BIOLOGICAL|therapeutic autologous dendritic cells|
48660490|NCT00027599|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48660491|NCT05573672|COMBINATION_PRODUCT|Dietary Counselling combined with Omega-3 Supplementation|"Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal."
48660492|NCT04940078|DRUG|Cagrilintide|Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
48660493|NCT04940078|DRUG|semaglutide|Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
48660494|NCT04940078|DRUG|Cagrilintide and semaglutide|Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
47984981|NCT06278857|DRUG|Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]|The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.
48139293|NCT00713596|OTHER|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
48139294|NCT02950883|DRUG|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
48139295|NCT02950883|DRUG|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
48139296|NCT01698541|DRUG|Tacrolimus|Tested generic
48139297|NCT01698541|DRUG|Tacrolimus|Original formulation used as comparator
48660495|NCT04388631|OTHER|Coronavirus Disease 2019|male patients who have developed COVID-19
48139298|NCT05640505|BEHAVIORAL|School based Gratitude Interventions|Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
48139299|NCT06181656|BIOLOGICAL|Pneumonia vaccine|Given by SC
48660496|NCT02374255|BEHAVIORAL|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
48139300|NCT03667833|OTHER|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
48139301|NCT02554006|BEHAVIORAL|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
48139302|NCT02554006|BEHAVIORAL|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
48139303|NCT03543059|DRUG|GnRH analogue|gonadotrophin releasing hormone analogue
48139304|NCT02136654|BEHAVIORAL|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
48660497|NCT04450953|DRUG|Eplerenone 50mg/day (cross over design)|Eplerenone 50mg/day for 6 months followed
48660498|NCT04450953|OTHER|Period without eplerenone (cross over design)|6-month period without eplerenone
48660499|NCT00770679|DRUG|lipitor|80 mg everyday (QD) for 3 weeks
48660500|NCT00123630|DRUG|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
48660501|NCT00123630|DRUG|Placebo|Placebo given IV once every 2-4 weeks based on weight
48660502|NCT05385107|DIAGNOSTIC_TEST|Serum procalcitonin concentration|
48660503|NCT06255769|DEVICE|Magnetocardiography|Magnetocardiography
48660504|NCT06255769|DEVICE|Single photon emission computed tomography (SPECT)|Single photon emission computed tomography (SPECT)
48660505|NCT05851547|RADIATION|Prostate SBRT with Focal Boost|Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions
48660506|NCT05851547|DRUG|Triptorelin Injection|Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
47984982|NCT00846131|DRUG|Sorafenib|Randomized to Y-90 ± Sorafenib
47984983|NCT00846131|DRUG|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
47984984|NCT04360954|DIAGNOSTIC_TEST|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
47984985|NCT02161627|DEVICE|Saluda Medical External Trial System|
47984986|NCT02161627|DEVICE|Saluda Medical External Trial System|
47984987|NCT00743314|OTHER|screening questionnaire administration|
48139305|NCT02381132|DRUG|Norco 7.5mg/325|
48139306|NCT02381132|DRUG|MNK155|
48139307|NCT01281436|OTHER|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
48350103|NCT04062006|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
48350104|NCT04724291|DEVICE|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
48139308|NCT01281436|OTHER|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
48139309|NCT01933997|DRUG|Metadoxine (MG01CI )|
48139310|NCT04730206|DRUG|Camostat|100 milligram tablets
48139311|NCT04730206|DRUG|Placebo|oral tablets, identical in size and shape
48139312|NCT04730206|DRUG|Molnupiravir|200 milligram tablets
48139313|NCT00297349|DRUG|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
48139314|NCT04257799|OTHER|Structured Light Imaging (SLI) System|Investigation of SLI and Tomographic Imaging to see if they will identify cancer cells at the edge of tissue specimens removed during the operation.
48139315|NCT00724126|DRUG|Rifaximin|
48139316|NCT00724126|DRUG|Placebo|
48350105|NCT03686527|PROCEDURE|stenosis aortic valve|"The exams to be realized :~* a clinical examination with blood pressure~* a 12-lead surface electrocardiogram~* a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~* Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~* a cardiac MRI looking for fibrosis myocardial"
48350106|NCT00182234|BEHAVIORAL|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
48350107|NCT01666015|OTHER|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
48503006|NCT02518516|DRUG|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
48503007|NCT02518516|DRUG|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed \>120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
48139317|NCT01575015|DEVICE|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
48139318|NCT01575015|PROCEDURE|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
48139319|NCT01717066|DRUG|the ginsenoside Rg3|
48503008|NCT02205983|DRUG|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
48503009|NCT02205983|DRUG|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
48503010|NCT02205983|DRUG|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
48503011|NCT02205983|DRUG|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
48503012|NCT06493851|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 6 weeks protocol including 5 daily HBOT sessions per week (total of 30), each session lasts 90 minutes, of 100% oxygen at 2 atmosphere absolute (ATA) with 5-minute air breaks every 20 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel."
48618282|NCT03693196|OTHER|PICF, Perio-paper®|PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
48139320|NCT01717066|DRUG|Placebo|
48139321|NCT06135220|DIAGNOSTIC_TEST|New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.|The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
48503013|NCT05147324|BEHAVIORAL|"MyPlan - Individualized Planned Eating Pattern"|Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating pattern adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal at least three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of the eating pattern is based on adherence according to logs and youth/guardian acceptability.
48139322|NCT05036837|DRUG|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
48503014|NCT06505941|DRUG|umbilical cord mesenchymal stem cell|umbilical cord mesenchymal stem cell
48503015|NCT06505941|DRUG|Placebo|non-cell-containing placebo
48503016|NCT05596565|OTHER|Supervised Exercise by a physiotherapist via face to face|"Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference"
48503017|NCT04053049|OTHER|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
48350108|NCT01666015|OTHER|Standard Care|This group will be under standard care without any EX intervention.
48503018|NCT03547076|DIAGNOSTIC_TEST|Focused ultrasound diagnostics|"Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler)."
48503019|NCT06369597|PROCEDURE|Robotic telesurgery|Telesurgery by domestic surgical robot
48503020|NCT06369597|PROCEDURE|Laparoscopic surgery|Local laparoscopic surgery
48503021|NCT06552143|OTHER|Stone needle therapy follows the Belt channel|Stone needle therapy follows the Belt channel involves the use of stones by the intervener to follow the path of the Belt channel by pushing and rubbing the abdomen of patients with postpartum diastasis rectus abdominis.
48503022|NCT00720252|DEVICE|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
48503023|NCT00892996|DRUG|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
48503024|NCT00892996|DRUG|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
48503025|NCT00482586|OTHER|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
48503026|NCT00482586|OTHER|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
48503027|NCT00482586|PROCEDURE|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
47984988|NCT00743314|PROCEDURE|computed tomography|
47984989|NCT00743314|PROCEDURE|lymphoscintigraphy|
47984990|NCT00743314|PROCEDURE|single photon emission computed tomography|
47984991|NCT00743314|RADIATION|intensity-modulated radiation therapy|
47984992|NCT00743314|RADIATION|technetium Tc 99m sulfur colloid|
47984993|NCT00423150|DRUG|Temozolomide|Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
47984994|NCT00812370|DRUG|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
48503028|NCT00003324|PROCEDURE|conventional surgery|
48503029|NCT00003324|RADIATION|radiation therapy|
48350109|NCT01670825|PROCEDURE|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
48350110|NCT01670825|DRUG|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
48350111|NCT01670825|DRUG|Local anethestic injection|
48350112|NCT03189810|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
48660507|NCT06068621|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
48660508|NCT06068621|DRUG|"3+7"|"IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."
48660509|NCT05170334|DRUG|Binimetinib|Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
48660510|NCT05170334|DRUG|Belinostat|Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
48350113|NCT03189810|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
48660511|NCT06271915|OTHER|SNAGs - eccentric exercise|intervention done 2 times per week, 45 minutes each session for 4 weeks
47984995|NCT01075724|DEVICE|Patient Warming with Forced Air|Forced Air warming via BairHugger
48350114|NCT03189810|BEHAVIORAL|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
48350115|NCT04602013|DRUG|Sintilimab|Body weight \<60kg: 3mg/kg IV Q3W; Body weight ≥60kg: 200mg IV Q3W. Every three weeks is a cycle
48350116|NCT04602013|DRUG|Chemotherapy|"Chemotherapy drugs include cisplatin and albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).~Dosing on the first day, one cycle every three weeks, a total of 2 cycles. Cisplatin (25mg/m2 IV D1-3 Q3W)"
48350117|NCT04602013|RADIATION|Radiation Therapy|The total dose is 60-66 Gy, divided into 30-33 times (2.0 Gy/f, 5 f per week).
48350118|NCT05405569|OTHER|CPR Arms Angle 90º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 90º.
48350119|NCT05405569|OTHER|CPR Arms Angle 60º|Within each independent group, a randomized crossover design will be used: half of the group will start with arms position at 60º.
48350120|NCT04765176|DEVICE|Endovascular Repair|Endovascular repair of the infrarenal aorta using a AAA stent graft.
48660512|NCT05011383|DRUG|High dose testosterone|High dose testosterone is administered subcutaneously once monthly until progression or toxicity
48660513|NCT06040255|DRUG|methylprednisolone, prednisolone, prednisone|Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
48660514|NCT03242434|OTHER|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose \[5 grams (g)\]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
48660515|NCT03242434|OTHER|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
48660516|NCT05932498|PROCEDURE|Hip surgery|"Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively."
48660517|NCT06263699|PROCEDURE|ROM measurement of the MCP and PIP joints in digits 4 and 5|standardised picture of the hand in maximal active extension, with the back of the hand positioned on the table's surface
48660518|NCT05462704|DRUG|Ferric derisomaltose|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
48660519|NCT05462704|DRUG|Ferrous sulfate|325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
48660520|NCT02636010|DRUG|Pembrolizumab|
48660521|NCT02053155|BEHAVIORAL|Computer based patient education|
48660522|NCT04669795|DRUG|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
48660523|NCT03434730|RADIATION|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
48660524|NCT03434730|DRUG|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
47984996|NCT01075724|DEVICE|Resistive Warming|Resistive Warming via HotDog device
47984997|NCT00112593|DRUG|fludarabine phosphate|Given IV
47984998|NCT00112593|RADIATION|total-body irradiation|Undergo TBI
47984999|NCT00112593|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
47985000|NCT00112593|DRUG|cyclosporine|Given IV or PO
48660525|NCT03434730|DRUG|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
48660526|NCT03434730|DRUG|Tocilizumab|For participants \< 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
48660527|NCT03434730|DRUG|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; \> 60 kg = 480 mcg subcutaneously daily.
48660528|NCT03528733|DEVICE|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
48660529|NCT04321655|OTHER|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
48660530|NCT04321655|OTHER|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
48660531|NCT04321655|OTHER|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
48660532|NCT04321655|OTHER|Conventional Physiotherapy (CPT)|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
48660533|NCT01427478|DRUG|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
48660534|NCT01427478|DRUG|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
48660535|NCT04392076|PROCEDURE|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
48660536|NCT02373657|BEHAVIORAL|instruction in soap-making and hygiene education|
48660537|NCT01661673|DRUG|EVP-0962|Arms: 1,2,3,4
48660538|NCT01661673|DRUG|Placebo|Arm 5
48660539|NCT05905146|OTHER|personalized pharmaceutical plan|multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
48660540|NCT04192708|PROCEDURE|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
48660541|NCT04192708|PROCEDURE|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
48367457|NCT00582842|BEHAVIORAL|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
48660542|NCT04192708|PROCEDURE|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
47985001|NCT00112593|DRUG|mycophenolate mofetil|Given IV or PO
47985002|NCT00112593|OTHER|laboratory biomarker analysis|Correlative studies
47985003|NCT04893603|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter aortic valve replacement
47985004|NCT01977508|DEVICE|ePTFE vascular access grafts|
48660543|NCT05264454|DEVICE|high flow nasal cannulae|The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
48139323|NCT02987218|DRUG|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
48139324|NCT02987218|DRUG|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
48139325|NCT02542943|DEVICE|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
48139326|NCT02542943|DEVICE|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
48139327|NCT02542943|OTHER|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
48139328|NCT02542943|DRUG|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
48139329|NCT00198419|DRUG|Vitrase|
48139330|NCT03347409|OTHER|Changes in preoperative care|Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling
48139331|NCT03347409|OTHER|Changes in intraoperative care|Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
48139332|NCT03347409|OTHER|Changes in postoperative care|Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
48139333|NCT03855293|PROCEDURE|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
48660544|NCT02752542|BEHAVIORAL|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
48660545|NCT02752542|DRUG|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
48660546|NCT02743741|DRUG|Lutetium-177 Octreotate|Radiopharmaceutical
48660547|NCT06254261|DRUG|RAY1225|Administered SC
48660548|NCT06254261|DRUG|Placebo|Placebo
48660549|NCT00853684|DRUG|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
48660550|NCT00853684|DRUG|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
48660551|NCT04233892|DRUG|CBD-bFGF|CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
48660552|NCT04233892|DRUG|Collagen/BMMNCs|A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
48660553|NCT04233892|DRUG|Estrogen|Patients will receive regular estrogen therapy
48139334|NCT01579318|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
48139335|NCT01579318|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
48660554|NCT02448381|DRUG|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
48660555|NCT02448381|DRUG|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
47985005|NCT05725850|OTHER|EG (Experimental A. Oleracea extract gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
48139336|NCT01278030|PROCEDURE|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
48002577|NCT03139916|DRUG|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
48367458|NCT02837874|PROCEDURE|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
48367459|NCT02837874|PROCEDURE|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
48367460|NCT02778594|DRUG|BIA 3-202|nebicapone 50 mg tablets; oral use
47985006|NCT05725850|OTHER|GP (Gel placebo)|Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
48660556|NCT06247748|DRUG|Exendin-4 Fc fusion protein (JY09) injection|D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29, D36, D43, D50, D57, D64, D71, and D78 subjects returned to the study center to receive a subcutaneous abdominal injection of 2.4 mg of JY09 injection(total of 8 administrations).All doses were to be administered within 3 min.
48367461|NCT02778594|DRUG|Placebo|Nebicapone matching placebo tablets
48660557|NCT06247748|DRUG|Metformin Hydrochloride tablet|D1 to D4 continuous oral administration of 0.5 g metformin hydrochloride tablets twice daily (D4 was administered only in the morning, with a total of 7 administrations) for a washout period of 96 h;0.5 g metformin hydrochloride tablets orally twice a day continuously from D85 to D88 (D88 was given only in the morning, for a total of 7 doses).
48660558|NCT06247748|DRUG|Rosuvastatin calcium tablets|D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
48660559|NCT06247748|DRUG|Digoxin tablet|D15 received a single oral administration of 0.25 mg digoxin tablets in the morning, with a washout period of 168 h,oral 0.25 mg digoxin tablets 72 h±0.5 h after JY09 administration (D102)
48660560|NCT02860403|PROCEDURE|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
48660561|NCT02085980|DEVICE|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
48660562|NCT03137823|DIAGNOSTIC_TEST|throat culture|throat culture - from the tonsills and from the bucal surface
48660563|NCT01014312|BEHAVIORAL|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
48660564|NCT01014312|BEHAVIORAL|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
48660565|NCT05102370|DRUG|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
47985007|NCT05691296|BEHAVIORAL|Home training|Letter Chart Accomodative Rock Training for 2 minutes each time
47985008|NCT05691296|BEHAVIORAL|School training|Letter Chart Accomodative Rock Training for 2 minutes each time
47985009|NCT02715076|OTHER|Ambient Temperature 19°C|Ambient Temperature 19°C
47985010|NCT02715076|OTHER|Ambient Temperature 21°C|Ambient Temperature 21°C
47985011|NCT02715076|OTHER|Ambient Temperature 23°C|Ambient Temperature 23°C
47985012|NCT02715076|DEVICE|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
48367462|NCT02778594|DRUG|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
48367463|NCT02314299|DRUG|MTP-131|
47985013|NCT02715076|OTHER|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
47985014|NCT03695562|PROCEDURE|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
47985015|NCT03709160|DRUG|Bumetanide 1 MG|all patients will be taking the treatment recommended by heart failure guidelines
48002578|NCT03139916|DRUG|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
48367464|NCT02898662|DRUG|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
48367465|NCT02898662|DRUG|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
48367466|NCT00006162|BEHAVIORAL|exercise and diet|
48503030|NCT04276441|DEVICE|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
48503031|NCT04276441|DEVICE|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
48503032|NCT05926960|DRUG|encorafenib|encorafenib
48503033|NCT05926960|DRUG|binimetinib|binimetinib
48503034|NCT05926960|DRUG|pembrolizumab|pembrolizumab
48503035|NCT05926960|DRUG|ipilimumab|ipilimumab
48503036|NCT05926960|DRUG|nivolumab|nivolumab
48503037|NCT05719688|DEVICE|Mechanical thrombectomy|Treatment of ischemic stroke patients with Mechanical thrombectomy
48503038|NCT00529139|DEVICE|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
48503039|NCT00529139|DEVICE|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. \<90 mg/dL (\<15 mmol/L)
48660566|NCT02510586|DRUG|Sevoflurane|administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
48503040|NCT03151291|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
48503041|NCT03151291|DIETARY_SUPPLEMENT|L-carnitine (LC)|daily intake of 4 g LC
48503042|NCT03151291|DIETARY_SUPPLEMENT|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
48503043|NCT03151291|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
48503044|NCT05512637|DIAGNOSTIC_TEST|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
48503045|NCT01716689|DRUG|oral cyclophosphamide|50mg daily
48503046|NCT02260297|DEVICE|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
48503047|NCT05637619|DEVICE|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
48503048|NCT05637619|DEVICE|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
48503049|NCT05637619|BEHAVIORAL|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
48660567|NCT00212602|DRUG|ONO-7436|
48660568|NCT04906343|PROCEDURE|Colonoscopy|Colonoscopy surveillance in SPS patient after 3 years of the last colonoscopy.
48503050|NCT04653272|OTHER|Questionnaire|Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
48503051|NCT03249792|DRUG|MK-2118 (IT)|IT injection
48002579|NCT03139916|RADIATION|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
48503052|NCT03249792|DRUG|MK-2118 (SC)|SC injection
48503053|NCT03249792|BIOLOGICAL|Pembrolizumab|IV infusion
48503054|NCT02425163|DEVICE|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
48503055|NCT02425163|PROCEDURE|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
48503056|NCT02212613|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
48503057|NCT06353568|DEVICE|Photobiomodulation|The PBM Group will use a boot with 1344 LEDs, including 504 LEDs of 660 nm located on the sides of the boot (28.5 mW, 10 J per LED); 504 LEDs of 850 nm also located on the sides of the boot (23 mW, 8 J per LED); 168 LEDs of 660 nm located at the base of the boot (28.5 mW, 10 J per LED); and 168 LEDs of 850 nm also located at the base of the boot (23 mW, 8 J per LED) once daily for 6 minutes, over 60 days.
48660569|NCT03615638|OTHER|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
48660570|NCT02656056|OTHER|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
48660571|NCT03716596|RADIATION|SBRT|SBRT radiation dose is 40-50 Gy in total.
48350121|NCT01614275|BEHAVIORAL|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
48350122|NCT01614275|BEHAVIORAL|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
48350123|NCT01614275|BEHAVIORAL|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
48350124|NCT01614275|BEHAVIORAL|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
48350125|NCT04236531|OTHER|Cognitive tests and neuroimaging|comparison of cognitive performances and brain anatomy
48350126|NCT00688389|OTHER|case/control|case: infected dengue fever people control:healthy people
48350127|NCT04024449|OTHER|Group A|ovarian function test in control group
48350128|NCT05355324|OTHER|no intervention|no intervention
48350129|NCT04716712|DRUG|Azithromycin|Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
48350130|NCT04716712|DRUG|Placebo|Matching identical placebo in packaging, appearance, and taste.
48350131|NCT01836367|DRUG|Ingenol Mebutate 0.015%|Picato
48350132|NCT03253185|DRUG|SC-007|intravenous
48350133|NCT03846622|OTHER|Calculation of scoring systems for bleeding|
48350134|NCT04381533|BEHAVIORAL|Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)|The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.
48350135|NCT04381533|BEHAVIORAL|Psychoeducation, information on use of alcohol and its effects|The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
48350136|NCT01500421|DEVICE|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
48350137|NCT01500421|DEVICE|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
48350138|NCT01500421|DEVICE|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
48503058|NCT06353568|DEVICE|Simulation of Photobiomodulation|The Control Group will use a non-therapeutic LED boot (sham procedure) for 6 minutes once daily for 60 days. The boot used is identical to the active boot, but there is no light emission.
48503059|NCT06353568|BEHAVIORAL|Therapeutic education|Participants will receive therapeutic education regarding nutrition, foot examination, self-care, and guidance on physical activity.
48660572|NCT03716596|DRUG|anti-PD-1 antibody|Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
48350139|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
48350140|NCT00249912|DRUG|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
48503060|NCT04245956|PROCEDURE|Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire|The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
48503061|NCT02258854|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
48350141|NCT00249912|DRUG|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
48350142|NCT01551485|DRUG|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
48350143|NCT01551485|DRUG|Placebo|Pacebo tablet, blinded given on the first night after surgery
48350144|NCT01998906|DRUG|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
48350145|NCT01998906|DRUG|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
48350146|NCT01998906|DRUG|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
48503062|NCT00188110|PROCEDURE|Water-Enema Computed Tomography|
48503063|NCT06096922|OTHER|No intervention|No intervention
48503064|NCT02382055|BEHAVIORAL|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
48503065|NCT02382055|BEHAVIORAL|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
48503066|NCT02382055|BEHAVIORAL|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
48503067|NCT06362668|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
48503068|NCT06362668|DRUG|Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
48350147|NCT01998906|DRUG|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
48350148|NCT05933772|DEVICE|Lens A (comfilcon A toric lens)|One month wear
48503069|NCT02419144|BEHAVIORAL|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
48503070|NCT02472028|OTHER|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
48503071|NCT02472028|OTHER|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
48503072|NCT02662283|DRUG|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
47985016|NCT05951868|BEHAVIORAL|Continuum of support on breastfeeding.|A continuous support program for women from antenatal period till 6 months after delivery to initiate early breastfeeding, exclusively breastfeeding for 6 month and to continue breastfeeding till 2 years and beyond.
48350149|NCT05933772|DEVICE|Lens B (lehfilcon A toric lens)|One month wear
48350150|NCT05044351|DEVICE|Fluobeam LX|See arm description
48350151|NCT05044351|OTHER|Conventional surgery without NIRAF assistance|Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
48350152|NCT00981292|DIETARY_SUPPLEMENT|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
48660573|NCT05586373|DRUG|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
48350153|NCT00981292|DIETARY_SUPPLEMENT|Placebo|Pharmaceutical grade silica was utilized as placebo
47985017|NCT03838640|DEVICE|EPIQ 5|As described in summary Trade name of the device Philips EPIQ 5
48350154|NCT06387277|OTHER|RV1551P GB3224|"RV1551P GB3224 Approximately 2 mg/cm² of product is applied to the Z1 or Z3 study areas (randomization).~From D1 to D2, a single product application is done at the study center by the subject in the presence of the clinical research technician (CRT) after epidermal ablation with an erbium YAG laser. After application, a dressing is placed on the measurement area and removed the following day at the center on D2 and D3 by the CRT before measurements.~From D3 to D18, two product applications are done with a minimum 4-hour interval:~* On visit days (D3, D5, D8, D10, D12, D15): an application is done at the study center by the subject in the presence of the CRT after measurements. A second application is done at home in the evening.~* On non-visit days (D4, D6, D7, D9, D11, D13, D14, D16, D17, D18): the subject applies 2 product applications at home (morning and evening).~Subjects receive the product at the end of visit 3 and return it at the last visit (visit 9)."
48503073|NCT02662283|DRUG|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
48503074|NCT05918744|BEHAVIORAL|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
48503075|NCT01413490|DRUG|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
48503076|NCT04608435|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
48503077|NCT03456583|DEVICE|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
48503078|NCT05549323|DRUG|PF-07054894|Oral
48503079|NCT05549323|DRUG|Placebo|Placebo
48503080|NCT04318223|DRUG|Palbociclib|Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, every 28 days (+/- 7 days) thereafter starting from Day 1 of Cycle 1
47985018|NCT01518777|OTHER|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
47985019|NCT04715763|DRUG|Telmisartan Oral Product|Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
47985020|NCT04715763|DRUG|Placebo|Gelatin capsules filled with an inactive ingredient
47985021|NCT03388333|PROCEDURE|Catheter Ablation|
47985022|NCT05653687|DEVICE|Intraoperative fluoroscopy|Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
48002580|NCT02888327|DRUG|AL-794|
48002581|NCT02888327|DRUG|Oseltamivir|
48002582|NCT02888327|DRUG|Digoxin|
48002583|NCT02888327|DRUG|Midazolam|
48350155|NCT06289504|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously once weekly.
48350156|NCT06289504|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
48350157|NCT06289504|DRUG|Atorvastatin|Atorvastatin will be administered as a single dose orally 2 times during the study.
48503081|NCT00556400|DRUG|Lo-Ovral Oral Contraceptive Pills|
48503082|NCT00556400|DRUG|Placebo - sugar pill|
48503083|NCT04032236|OTHER|caffeine|At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
48503084|NCT00255710|BIOLOGICAL|filgrastim|
48503085|NCT00255710|DRUG|cyclophosphamide|
48503086|NCT00255710|DRUG|fludarabine phosphate|
48503087|NCT00255710|DRUG|mycophenolate mofetil|
48503088|NCT00255710|DRUG|tacrolimus|
48503089|NCT00255710|PROCEDURE|allogeneic bone marrow transplantation|
48660574|NCT05586373|DRUG|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
48660575|NCT03889379|DRUG|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
48660576|NCT03078868|DEVICE|Magnetic Resonance Scanner|MRI
48660577|NCT06375148|OTHER|Enteral nutrition|prone position ventilation
48660578|NCT06451146|PROCEDURE|PCI Facilitated with Orbital Atherectomy Device|Percutaneous coronary intervention for coronary artery disease supported by the Orbital Atherectomy Device
48660579|NCT00153231|DEVICE|IVS|Infracoccygeal sacropexy
48660580|NCT00153231|PROCEDURE|Sacrospinofixation|
48660581|NCT03152773|PROCEDURE|MRI Heart guidewire catheterization|to conduct left and right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary left and right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
48350158|NCT06289504|DRUG|Warfarin|Warfarin will be administered as a single dose orally 2 times during the study.
48350159|NCT04525560|OTHER|PEG-ELS-S|2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.
48660582|NCT03817580|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
48660583|NCT03817580|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
48660584|NCT03817580|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
48660585|NCT06237855|OTHER|Self-drain removal|Subjects will be trained to self-remove drain at home following ventral hernia repair.
48660586|NCT03594474|OTHER|Intravenous lipid emulsion|using higher dose of IV lipids after birth
48660587|NCT01993732|PROCEDURE|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
48350160|NCT04525560|OTHER|PEG-ELS-L|PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
48350161|NCT02343952|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
48350162|NCT01066169|BIOLOGICAL|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
47914798|NCT04890041|DRUG|TPO-RA|The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
47914799|NCT00685256|OTHER|counseling intervention|subjects and parents will receive genetic counseling
47985023|NCT04752150|OTHER|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
47985024|NCT05652998|BIOLOGICAL|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
47985025|NCT05652998|OTHER|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
47985026|NCT05652998|OTHER|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
48350163|NCT00947089|DEVICE|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
48350164|NCT00947089|DEVICE|iodoform gauze|one iodoform gauze
48660588|NCT05488483|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography Imaging|Each participants will undergo MSOT imaging of the suspicious breast tumor detected with ultrasound imaging and any additional lesion present in either breast before undergoing ultrasound-guided breast biopsy as the standard of care. Melanoma participants with pathologically confirmed ITM will undergo MSOT imaging following physical exam and biopsy. Melanoma patients receiving immunotherapy will undergo MSOT imaging prior to and following immunotherapy.
48660589|NCT05400564|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
48350165|NCT05628987|OTHER|no intervention|Observational studies, no intervention
48660590|NCT03682744|BIOLOGICAL|anti-CEA CAR-T cells|Intraperitoneal delivery of anti-CEA CAR-T cells
48660591|NCT02075060|PROCEDURE|IPOI (pre-operative)|
47914800|NCT00685256|OTHER|educational intervention|subjects and parents will receive education re: genetic testing
47914801|NCT00685256|OTHER|survey administration|surveys will be administered to subjects and parents
47914802|NCT00685256|BEHAVIORAL|psychosocial assessment and care|psychosocial assessment and counseling will be provided
47914803|NCT00685256|BEHAVIORAL|supportive care|parents and children will be provided with supportive care
47914804|NCT04087889|BIOLOGICAL|HB-adMSCs|Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative
47914805|NCT00552747|DRUG|fenofibrate|fenofibrate 160 mg capsules qd
47985027|NCT02097407|DRUG|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
48002584|NCT02888327|DRUG|Pitavastatin|
48350166|NCT00665691|OTHER|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
48350167|NCT00564265|OTHER|Observation|Not applied
48350168|NCT05993572|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessments include functional status, fraility comorbidity, cognition, mental health, social support, nutrition, and geriatric syndromes
48350169|NCT04962490|PROCEDURE|Repair: suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich)|Repair tendon flexor sections in the hand: Suture, reinsertion, tendon graft, surgery in two stages (Hunter, Paneva Holevich). The surgery depends on the anatomical area of the tendon section and the time between the injury and the operation.
48350170|NCT04484506|DRUG|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
48350171|NCT02597972|PROCEDURE|Fracture repair|
48350172|NCT02597972|PROCEDURE|Fracture repair with joint replacement|
48350173|NCT02493335|DRUG|Budesonide 0.5mg orodispersible tablet twice daily|
48350174|NCT02493335|DRUG|Budesonide 1mg orodispersible tablet twice daily|
48503090|NCT00255710|PROCEDURE|peripheral blood stem cell transplantation|
48503091|NCT00255710|RADIATION|radiation therapy|
48503092|NCT00872794|DEVICE|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
48002585|NCT02888327|DRUG|JNJ-63623872|
48002586|NCT06391788|PROCEDURE|thoracoscopic Morrow surgery|minimally invasive trans-mitral Morrow septal myectomy
48002587|NCT06391788|PROCEDURE|modified Morrow surgery|median open modified enlarged Morrow septal myectomy
48503093|NCT05405348|BEHAVIORAL|Intervention|The patients did not eat anything during hemodialysis.
48503094|NCT05296135|DIAGNOSTIC_TEST|OncoPrism-HNSCC™|OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
48503095|NCT03379389|DRUG|Methenamine + Methylthioninium|Methenamine + Methylthioninium
48503096|NCT03379389|DRUG|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
48503097|NCT03379389|DRUG|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
48503098|NCT00517556|DRUG|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
48660592|NCT02075060|PROCEDURE|IPOP (post-operative)|
48660593|NCT04089696|DEVICE|ExSprion|The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
48660594|NCT00633958|DRUG|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
48660595|NCT00633958|RADIATION|PET Imaging|
48660596|NCT00616720|BIOLOGICAL|aldesleukin|
48660597|NCT00616720|BIOLOGICAL|idiotype-pulsed autologous dendritic cell vaccine APC8020|
48660598|NCT00616720|BIOLOGICAL|recombinant interferon gamma|
48660599|NCT00616720|GENETIC|polymerase chain reaction|
48660600|NCT00616720|GENETIC|reverse transcriptase-polymerase chain reaction|
48660601|NCT00616720|OTHER|flow cytometry|
48660602|NCT00616720|OTHER|laboratory biomarker analysis|
48660603|NCT04770896|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
48660604|NCT04770896|DRUG|Lenvatinib|Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
48660605|NCT04770896|DRUG|Sorafenib|Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
48660606|NCT05993884|DRUG|iEPCs|Given: IV
48660607|NCT05993884|COMBINATION_PRODUCT|Clinical standard treatment (CST)|Clinical standard treatment
48660608|NCT04984200|PROCEDURE|Retinal imaging|Subjects will undergo retinal imaging before and/or after administration of mydriatic agent
48660609|NCT04984200|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
48350175|NCT02493335|DRUG|Placebo orodispersible tablet twice daily|
48350176|NCT02148952|BEHAVIORAL|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
48350177|NCT02331654|OTHER|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
48350178|NCT02331654|OTHER|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
48350179|NCT05800613|OTHER|Survey|Questionnaire
48350180|NCT02628899|DEVICE|Transfemoral TAVR|
48350181|NCT02628899|DEVICE|SAVR|
48503099|NCT00517556|DRUG|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
48503100|NCT00269243|DRUG|Quinapril|
48503101|NCT01467414|DRUG|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
48503102|NCT01913925|OTHER|Tyrosine-Containing Food Bar|
48503103|NCT01913925|OTHER|Placebo Bar|
48660610|NCT03925467|OTHER|Acupuncture|"Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21."
48350182|NCT06198894|PROCEDURE|steroid-eluting sinus stent implant|In-office bilateral placement of the steroid-eluting sinus stent in the ethmoid sinuses under local anesthesia
48350183|NCT06198894|DRUG|Systemic glucocorticoids|Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
48350184|NCT06198894|DRUG|saline irrigations|Patients were routinely treated with saline irrigations (250ml) twice daily
48350185|NCT06198894|DRUG|Placebo|Groups were given systemic glucocorticoid placebo
48350186|NCT06198894|PROCEDURE|sham procedure|The sham procedure was performed in-office under local anesthesia
48503104|NCT01852500|OTHER|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
48503105|NCT01852500|OTHER|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
48660611|NCT03058874|DEVICE|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
48660612|NCT03058874|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
48660613|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Microencapsulated Magnesium|Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
48660614|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Oxide|Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
48660615|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Citrate|Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
48660616|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Bisglycinate|Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
48350187|NCT04005755|DRUG|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
48350188|NCT05537272|DRUG|Tadalafil 5mg|Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
48660617|NCT06548048|DIETARY_SUPPLEMENT|Dietary supplement containing plant derived phenolics|Dietary supplement containing plant derived phenolics
48350189|NCT05537272|DRUG|Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule|Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
48660618|NCT06548048|DIETARY_SUPPLEMENT|Microcrystaline cellulose|Microcrystaline cellulose (MCC)
48350190|NCT05537272|OTHER|Placebo|Administration of placebo ( Vitamin C \[ascorbic acid\] 500mg tablet) once daily seven days before and seven days after prostate biopsy
48350191|NCT05935813|OTHER|Study characteristics of adolescents affected by dental caries|Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).
48503106|NCT00394524|DEVICE|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
48503107|NCT00394524|OTHER|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving \>80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
48350192|NCT05124262|OTHER|Low- FODMAPdiet group intervention|Diet intervention
48660619|NCT04692922|DIAGNOSTIC_TEST|MRI|MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).
48660620|NCT04692922|DIAGNOSTIC_TEST|EEG|The EEG will include resting, stimulus-based, and task-based assessments of brain function.
48660621|NCT01630109|DRUG|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
48660622|NCT01630109|DRUG|Placebo|A placebo capsule made to look like the metoclopramide capsule.
48660623|NCT02038036|DRUG|Best Available Therapy|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
48660624|NCT02038036|DRUG|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
48660625|NCT02478281|DRUG|Methylene Blue|
48660626|NCT04958603|PROCEDURE|"L type release surgery"|Lateral release of the lateral support belt
47914806|NCT00552747|DRUG|placebo|capsules placebo
48350193|NCT00747708|DRUG|Granulocyte-colony stimulating factor|5 days subcutaneous injection
48350194|NCT00747708|PROCEDURE|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
48660627|NCT04752826|DRUG|BI-1808|BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose \[Phase I, Part A\] and at Recommended Dose for Part B \[Phase I, Part B and Phase IIa\] by intravenous (IV) infusions every 3 weeks.
48660628|NCT04752826|DRUG|Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection|Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
48660629|NCT01542788|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
48660630|NCT01542788|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
48660631|NCT01542788|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
48660632|NCT01542788|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
48002588|NCT00916175|DIETARY_SUPPLEMENT|P1&P2|"* First period (4 weeks) intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from AG\&CC group, 4 weeks intake food product P1\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
48660633|NCT00655655|DRUG|everolimus|Given orally
48660634|NCT00655655|DRUG|vatalanib|Given orally
48660635|NCT00655655|OTHER|pharmacological study|Correlative study (Cohort IIA only)
48660636|NCT00655655|OTHER|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
48660637|NCT00655655|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
48660638|NCT00655655|PROCEDURE|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
48660639|NCT06456671|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
48660640|NCT06456671|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
48660641|NCT06456671|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
48660642|NCT06456671|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
48660643|NCT06239558|OTHER|Qualitative exploration|Semi-structured Interviews and focus group
48139337|NCT04755972|OTHER|Inhalation of N-acetylcysteine|Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
48139338|NCT04755972|OTHER|Inhalation of 5% sodium chloride|Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
48139339|NCT04755972|OTHER|Inhalation of 8,4% sodium bicarbonate|Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
48139340|NCT05277285|DRUG|Sodium Thiosulfate 25% Solution for Injection|The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml
48139341|NCT04495140|DRUG|[14C]PF-06882961, 50 mg|A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
48139342|NCT04495140|DRUG|PF-06882961, 50 mg and [14C]PF-06882961, 100 ug|A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
48139343|NCT01046292|DRUG|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
48139344|NCT03497052|OTHER|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
48660644|NCT02774694|DEVICE|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
48660645|NCT00319761|DRUG|Calcitriol|
48139345|NCT03497052|OTHER|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
48139346|NCT04252157|OTHER|Kinesiotaping|Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.
48139347|NCT04252157|OTHER|Plesebo Taping|An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.
48139348|NCT04252157|OTHER|Control|no kinesio or tape will be applied
48139349|NCT05949866|BEHAVIORAL|Movement and Cognition Intervention Group|"Preschool centers assigned to the Movement and Cognition (MAC) group will receive the 6-month intervention, which will be implemented 4 days per week. To ensure consistency of intervention delivery, centers will be provided with the MAC modules on a bi-weekly basis. The MAC intervention will be implemented using a train-the-trainer (gradual release) model. This will be a gradual release model, in which interventionist will first serve as a co-provider and will eventually serve in a support role, as providers become primary implementers.~The MAC intervention will consist of gross motor skill curriculum consists of 30 individual lesson plans. The number of days needed to instruct each lesson plan activities ranges between 3 to 5 days. In each lesson, specific instruction and activities are designed to teach fundamental movements (e.g., running, leaping, kicking, jumping, throwing, catching)."
48139350|NCT05949866|BEHAVIORAL|Health Tracker Group (Control Group)|Preschool centers assigned to the health tracker g group will be asked to maintain their usual daily schedule and to not participate in other physical activity programs during the 6-month intervention.
48139351|NCT05608070|DRUG|Oxytocin|Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
48139352|NCT05608070|DRUG|Placebo|0.9% saline infusion at the rate of 83.3 ml/h.
48660646|NCT04418245|DIAGNOSTIC_TEST|Imaging by thoracic scanner|Low-dose computed tomography
48660647|NCT02835105|DRUG|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
48660648|NCT02835105|DRUG|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
48660649|NCT01394185|DRUG|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
48660650|NCT01394185|DRUG|Placebo|Participants receive placebo
48660651|NCT01394185|DRUG|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
48660652|NCT03272932|OTHER|No intervention|No intervention
48660653|NCT05385822|BEHAVIORAL|Pelvic Floor Muscle Training|"* Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~* Constant tension for 30 seconds twice, with a 30-second pause~* Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months"
48660654|NCT01108874|DRUG|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
48660655|NCT01950520|DRUG|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
48139353|NCT01246804|DRUG|raltegravir single dose|single dose 400mg raltegravir
48660656|NCT01950520|DRUG|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
48660657|NCT01950520|DRUG|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
48660658|NCT01950520|DRUG|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
48660659|NCT01950520|DRUG|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
48660660|NCT01950520|DRUG|Qsymia|Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
48660661|NCT01950520|DRUG|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
48660662|NCT01950520|BEHAVIORAL|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
48002589|NCT00916175|DIETARY_SUPPLEMENT|P1&CC|"* First period (4 weeks) intake food product P1\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from AG\&P2 group, 4 weeks intake food product P1\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
48139354|NCT01246804|DRUG|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
48139355|NCT05125224|DRUG|Dihydropyridine calcium channel blocker|Dihydropyridine calcium channel blocker claim is used as the exposure group.
48139356|NCT05125224|DRUG|Hydrochlorothiazide|Hydrochlorothiazide claim is used as the reference group.
48139357|NCT04217252|DIAGNOSTIC_TEST|PMseqTM high-throughput sequencing technology|high throughput sequencing of infectious pathogens
48139358|NCT05075499|BIOLOGICAL|COVID-19 vaccination|Blood sample obtained before, 1 , 3 and 6 months after the intervention
48139359|NCT00944541|DRUG|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
48139360|NCT03975465|BEHAVIORAL|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
48139361|NCT03975465|BEHAVIORAL|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
48139362|NCT04666181|BEHAVIORAL|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
48139363|NCT05383989|BEHAVIORAL|UniVenture Hopelessness manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
48139364|NCT05383989|BEHAVIORAL|UniVenture Anxiety Sensitivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
48139365|NCT05383989|BEHAVIORAL|UniVenture Sensation Seeking manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
48350195|NCT00747708|PROCEDURE|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
48660663|NCT01950520|DRUG|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
48660664|NCT01950520|DRUG|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
48002590|NCT00916175|DIETARY_SUPPLEMENT|AG&P2|"* First period (4 weeks) intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P1\&CC group, 4 weeks intake food product AG\&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
48139366|NCT05383989|BEHAVIORAL|UniVenture Impulsivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Impulsivity (IMP) personality traits on the Substance Use Risk Profile Scale (SURPS).
48139367|NCT05383989|BEHAVIORAL|Service as usual provided by the University|It is the regular university-provided well-being services.
48350196|NCT03531710|BIOLOGICAL|UB-311|Intramuscular injection
48350197|NCT03531710|DRUG|Placebo|Intramuscular injection
48660665|NCT01950520|DRUG|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
48660666|NCT01950520|DRUG|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
48139368|NCT03068312|DRUG|Ivacaftor|IVA 150 mg tablet.
48139369|NCT03068312|DRUG|Placebo|Placebo matched to IVA tablet.
48139370|NCT04011930|DRUG|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
48139371|NCT04011930|DRUG|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
48350198|NCT04280484|OTHER|Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
48660667|NCT01950520|DRUG|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
48660668|NCT01950520|DRUG|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
48139372|NCT02708394|DRUG|olanzapine|atypical antipsychotic
48139373|NCT02708394|DRUG|placebo|placebo control
48139374|NCT05480540|BEHAVIORAL|Serious game|According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
48139375|NCT02773862|DEVICE|HS-1000|
48350199|NCT04280484|OTHER|Sham Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
48660669|NCT02919618|RADIATION|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
48660670|NCT01334255|DRUG|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
48660671|NCT00319007|DRUG|Sulindac (drug)|
48660672|NCT00319007|DRUG|VSL#3 (probiotic)|
48660673|NCT00319007|DRUG|Inulin (probiotic)|
48687867|NCT06242990|BEHAVIORAL|Y-PATH NI|"The Y-PATH NI intervention provides a whole of school approach with student, teacher, parent and guardian components. Student components: Y-PATH resources delivered by physical education teachers (6 lesson plans, resource cards to use as teaching prompts), student handbook. Posters are also displayed in the sports hall/ PE department.~Teacher components: Teachers will receive online and in-person training to deliver the Y-PATH programme. This component also targets all non-specialist PE teachers and includes workshops, information leaflets, development of a physical activity promotion charter and a step challenge.~Parent/guardian components: Information session and leaflets distributed across the intervention period."
48350200|NCT03518580|OTHER|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
48350201|NCT06464289|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
48350202|NCT06464289|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.
48350203|NCT02044822|DRUG|Idelalisib|150 mg tablets administered orally twice daily
48350204|NCT02044822|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly x 8 weeks
48503108|NCT05213455|BIOLOGICAL|booster vaccine for COVID 19|The effect of Booster vaccine will be seen in participants in terms of antibody response IgG
48660674|NCT03517605|OTHER|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
47985028|NCT02097407|DRUG|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
48139376|NCT04198467|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
48139377|NCT04198467|DRUG|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
48139378|NCT00647075|DIETARY_SUPPLEMENT|Yunzhi extract|3.5 g/day
48350205|NCT03846076|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
48350206|NCT01066650|DEVICE|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
48350207|NCT01066650|DEVICE|Xience V (Everolimus-eluting stent)|Drug eluting stent
48503109|NCT03980574|DIETARY_SUPPLEMENT|R Drink|R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
48503110|NCT05703269|RADIATION|single fraction stereotactic radiosurgery (SSRS)|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.
48503111|NCT05703269|RADIATION|fractionated stereotactic radiosurgery (FSRS)|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
48139379|NCT00647075|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
48139380|NCT02517385|DRUG|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
48139381|NCT01182532|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
48350208|NCT03827070|DRUG|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (\<5 μm) - only 19%
48350209|NCT03827070|DRUG|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (\<5 μm) - only 11%
48503112|NCT01539135|DRUG|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
48503113|NCT03741699|DRUG|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
48660675|NCT02339051|BEHAVIORAL|Jumping on one leg|
48350210|NCT02325440|DRUG|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
48350211|NCT02325440|DRUG|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
48687868|NCT05233501|PROCEDURE|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
48350212|NCT06003452|PROCEDURE|surface treatment with Bioactive Glass Air Abrasion|giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
48503114|NCT01631071|BIOLOGICAL|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
48503115|NCT04587063|BEHAVIORAL|Fear Appeals|Email
48503116|NCT04587063|BEHAVIORAL|Message about Future Healthcare Costs|Email
48503117|NCT04587063|BEHAVIORAL|Endorsement from a Doctor|Email
48503118|NCT04587063|BEHAVIORAL|Comparison Table|Email
48687869|NCT05233501|PROCEDURE|non-surgical periodontal treatment|standart periodontal therapy
48503119|NCT04587063|BEHAVIORAL|Highlighting Cost Savings and Convenience|Email
47985029|NCT05783115|PROCEDURE|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|transverse bone transport with bone marrow cell transplantation
47985030|NCT05783115|PROCEDURE|Tibial Transportation|transverse bone transport
48350213|NCT04583267|DRUG|tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration|Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
48350214|NCT00064623|DRUG|Capsaicin Dermal Patch|
48350215|NCT03435276|DRUG|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
48503120|NCT01735955|DRUG|Nilotinib|Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
48503121|NCT05629897|OTHER|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
47985031|NCT05565846|COMBINATION_PRODUCT|NTX-001|One-time use surgical product of three solutions and a device
47985032|NCT03596528|PROCEDURE|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
48350216|NCT03435276|OTHER|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
48350217|NCT04185740|DEVICE|CloudUPDRS - Tapping Task|The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
48503122|NCT01342900|DEVICE|connected to the InSpectra Monitor|
48503123|NCT04990427|DRUG|CLBS201|1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells
48350218|NCT03431623|BIOLOGICAL|CKD-11101(Darbepoetin alfa)|
48350219|NCT03431623|BIOLOGICAL|NESP(Darbepoetin alfa)|
48503124|NCT04575064|OTHER|Standard of Care (SoC)|Standard supportive care is expected to vary regionally and may change throughout the trial based on new and emerging data on best care guidelines for patients.
48503125|NCT04575064|DRUG|Remdesivir|Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days or until discharge from hospital, whichever occurs first
48503126|NCT02669030|DRUG|suvorexant|an FDA-approved sleep aid
48503127|NCT02669030|DRUG|Placebo|control group
48503128|NCT05267730|BEHAVIORAL|Conectar Jugando Game Program|Modern Board and Card Games as Cognitive Training in Rural Elementary Classrooms
48503129|NCT05310162|BEHAVIORAL|Food, fun and family|"The intervention consists of a series of change of habits in the way children eat, the reduction of the recreational time of screens and healthy habits of physical activity. This intervention, which is called Food, Fun \& Family (FFF), is aimed at parents and has been shown to be effective in reducing the consumption of empty calories by children. It teaches parents skills to reduce their daily energy intake of added sugars and saturated fats, it also seeks to reduce screen time.~The intervention contains information and recommendations, through guides, in which precise instructions are given about how to maintain a healthy environment at home."
48660676|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
48660677|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
48660678|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
48660679|NCT01950494|OTHER|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
48660680|NCT04705233|OTHER|sputum colour chart|5-point Sputum Colour Chart plus best standard care
48660681|NCT05044767|DEVICE|total hip arthroplasty|hip replacement surgery
48660682|NCT00159016|DRUG|Glivec|
48660683|NCT00663078|BEHAVIORAL|Brief CBT Group therapy|CBT based therapy also expert patient programme
48350220|NCT00424840|DRUG|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
48350221|NCT00424840|DRUG|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
48660684|NCT05147142|DEVICE|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
48660685|NCT06563817|DRUG|Rapamycin|All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.
48660686|NCT05388487|DRUG|HF1K16 /Arm 45 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
47985033|NCT00517621|DRUG|Paclitaxel|
48350222|NCT00424840|DRUG|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
47985034|NCT00517621|DRUG|EPO|
48350223|NCT00424840|DRUG|Carboplatin AUC 6|Carboplatin AUC6
48350224|NCT00424840|DRUG|Bevacizumab|Bevacizumab 15 mg/kg
47985035|NCT05016921|DEVICE|TcMS|Transcutaneous magnetic stimulation targeting the stellate ganglion
47985036|NCT03649633|DRUG|Stress-dose Hydrocortisone plus Vitamin C|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
47985037|NCT03649633|DRUG|isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
48350225|NCT00424840|DRUG|Taxotere|Taxotere 70 + G-CSF
48350226|NCT05766267|DRUG|Rifabutin|Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
48350227|NCT05766267|DRUG|Delamanid|Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
48350228|NCT05766267|DRUG|Bedaquiline|Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
48350229|NCT05766267|DRUG|Moxifloxacin|Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
48660687|NCT05388487|DRUG|HF1K16 /Arm 90 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
48660688|NCT05388487|DRUG|HF1K16 /Arm 120 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
48660689|NCT05388487|DRUG|HF1K16 /Arm 160 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
48660690|NCT05388487|DRUG|HF1K16 /Arm 120 mg or 180 mg|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
48660691|NCT06172088|OTHER|Fasting|Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).
48660692|NCT02209675|OTHER|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
48660693|NCT00397540|PROCEDURE|PEIT|Percutaneous Ethanol Injection Therapy
48660694|NCT00397540|PROCEDURE|RFTA|Radiofrequency Thermal Ablation
48660695|NCT00279695|PROCEDURE|high frequency ultrasound examination|high frequency ultrasound examination of the eye
48660696|NCT01332656|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
48660697|NCT01332656|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
48660698|NCT01332656|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
48660699|NCT01332656|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
48350230|NCT05766267|DRUG|Pyrazinamide|Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).
48350231|NCT05766267|DRUG|Isoniazid|Isoniazid is part of control regimen (HRZE).
48350232|NCT05766267|DRUG|Rifampin|Rifampin is part of control regimen (HRZE).
48350233|NCT05766267|DRUG|Ethambutol|Ethambutol is part of control regimen (HRZE).
48350234|NCT01865838|DEVICE|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
48350235|NCT01894555|DRUG|Aspirin|81 mg daily for 4 weeks
48350236|NCT04582162|OTHER|Unsplinted implants|Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
48350237|NCT04582162|OTHER|Splinted implants|Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
48350238|NCT00149110|PROCEDURE|Sleep deprivation|3 days with a normal night between
48350239|NCT00149110|PROCEDURE|Light therapy|Daily light therapy for 29 weeks
48660700|NCT01283672|OTHER|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
48660701|NCT05965219|DRUG|Emraclidine|Emraclidine tablets.
48660702|NCT05965219|DRUG|Itraconazole|Itraconazole oral solution.
48350240|NCT00149110|PROCEDURE|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
48350241|NCT00149110|BEHAVIORAL|Exercise|Moderate intensity daily exercise for 30 minutes at least
48350242|NCT00149110|DRUG|duloxetine|60 mg daily
48350243|NCT00149110|DRUG|duloxetine|60 mg daily
48660703|NCT05965219|DRUG|Carbamazepine|Carbamazepine tablets.
47985038|NCT02477254|BIOLOGICAL|Vaccination|A quadrivalent HPV vaccine
47985039|NCT00948623|BEHAVIORAL|physical activity counseling program|
47985040|NCT00948623|BEHAVIORAL|sham counseling program|
47985041|NCT01548482|OTHER|Laboratory Biomarker Analysis|Correlative studies
47985042|NCT01548482|OTHER|Pharmacological Study|Correlative studies
48350244|NCT05846269|OTHER|Educational Intervention|Educational intervention addressing trauma-informed care and resiliency.
48350245|NCT04712669|DRUG|rodatristat ethyl 300 mg tablet BID|rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
48350246|NCT04712669|DRUG|rodatristat ethyl 600 mg BID|2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
48350247|NCT04712669|DRUG|Placebo|2 matching placebo tablets on top of standard of care
48350248|NCT00184067|BIOLOGICAL|Montanide ISA 51|
48350249|NCT01866306|BIOLOGICAL|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
48350250|NCT01866306|DRUG|LABA|Asthmatic participants were treated with LABA as part of their standard of care
48350251|NCT00125697|PROCEDURE|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
48350252|NCT00872781|DRUG|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
47985043|NCT01548482|DRUG|Temsirolimus|Given IV
47985044|NCT01548482|BIOLOGICAL|Trebananib|Given IV
47985045|NCT02508402|DRUG|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
47985046|NCT02508402|DRUG|Placebo|two milliliters of normal saline given to placebo group .
48350253|NCT05627791|DRUG|Oxytocin|Oxytocin vaginal gel that have oxytocin 400IU/1ml of gel, base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0
48350254|NCT05627791|DRUG|Placebo|Placebo gel that have base gel contained HPMC 4,000 cps, 5% propylene glycol USP, 0.08% methylparaben, sterile water for irrigation and 0.02% propylparaben then adjusted pH by Lactic acid and sodium hydroxide keep pH 3.5-4.0 without oxytocin
48350255|NCT03928340|DRUG|Metformin|"40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy"
48660704|NCT05965219|DRUG|Metformin|Metformin tablets.
48660705|NCT02735460|DEVICE|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
48687870|NCT04424394|DEVICE|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
48687871|NCT04424394|BIOLOGICAL|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
48660706|NCT03713450|DEVICE|Control with imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
48350256|NCT03928340|DRUG|Insulin|40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
48660707|NCT03713450|DEVICE|Control without imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
48660708|NCT02772302|DEVICE|mindBEAGLE EEG-based brain-computer interface|
48660709|NCT00208338|DEVICE|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
48350257|NCT05190757|OTHER|Airway and Ventilation|Insertion of Laryngeal Mask airway for ventilation or use of Face Mask
48350258|NCT01023516|DRUG|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
48350259|NCT01023516|DRUG|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
48350260|NCT05186363|DRUG|Chemopreventive Agent - SPAQ|Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
48350261|NCT05186363|DRUG|Control Test - no drugs given|This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
48350262|NCT04383535|OTHER|Convalescent SARS COVID-19 plasma|Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
48350263|NCT04383535|OTHER|Placebo|Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.
48350264|NCT04849195|OTHER|No intervention|No intervention
48350265|NCT00000662|DRUG|Zidovudine|
48350266|NCT01508793|BEHAVIORAL|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
48350267|NCT03660280|DIETARY_SUPPLEMENT|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
48350268|NCT03660280|OTHER|Placebo|Placebo
48350269|NCT04535258|DEVICE|Blend-A|Treatment for alcohol use disorders will be offered also as an internet-based option.
48660710|NCT00208338|PROCEDURE|Rotator cuff repair|Standard surgical repair of torn rotator cuff
48660711|NCT04964700|DRUG|Natalizumab|Monthly Infusions
48350270|NCT06462716|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
48350271|NCT06049628|BEHAVIORAL|FIFA 11+ exercise program|FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
48350272|NCT06049628|BEHAVIORAL|routine program|This program consists of jogging, and stretching exercises.
48350273|NCT00804128|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
48350274|NCT00804128|DRUG|Gadavist|Gadavist injection is a paramagnetic macrocyclic contrast agent administered for magnetic resonance imaging
48350275|NCT03250819|OTHER|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
48350276|NCT05213676|DRUG|Inhaled Nitric Oxide (iNO) use|The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.
48350277|NCT05213676|OTHER|De-implementation of Inhaled Nitric Oxide (iNO) use|The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).
48350278|NCT05574712|DRUG|Neoadjuvant treatment|Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
47985047|NCT04220450|DIAGNOSTIC_TEST|T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
48350279|NCT02193854|DEVICE|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
48660712|NCT01324973|BEHAVIORAL|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
48660713|NCT01712373|DRUG|Ginseng|it is kind of drug
48350280|NCT01446991|DRUG|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
48350281|NCT01446991|DRUG|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
48350282|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
48350283|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
48350284|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
48350285|NCT03649386|DEVICE|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
48350286|NCT03649386|DEVICE|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
48350287|NCT00398086|DRUG|Gemcitabine|Administered by intravenous infusion over 30 minutes.
48350288|NCT00398086|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
48350289|NCT04118673|BEHAVIORAL|Lifestyle Prescription (LRx)|Standard care during consultations with the addition of a physical lifestyle prescription
48503130|NCT05310162|BEHAVIORAL|Counseling|"Simple verbal instructions will be given in the consultation to reduce the time of use of screens and refined sugar.~For refined sugar reduction, parents will be told to avoid sugary drinks, add sugar to drinks (juices, milk, etc.), and avoid snacks and sweets. It will also be indicated that the screen time should be less than two hours a day and in no case use them two hours before sleeping."
48503131|NCT05903014|DRUG|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
48503132|NCT05903014|BEHAVIORAL|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
47985048|NCT04850599|DRUG|Carfilzomib|Given IV
47985049|NCT04850599|BIOLOGICAL|Isatuximab|Given IV
47985050|NCT04850599|DRUG|Pomalidomide|Given PO
48350290|NCT02583464|DRUG|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
48350291|NCT04383106|OTHER|no intervention|no intervention
48350292|NCT04179604|DRUG|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
47985051|NCT03235154|DRUG|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
47985052|NCT04332354|OTHER|routine care. No intervention|no intervention
47985053|NCT04683536|PROCEDURE|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
48350293|NCT04179604|DRUG|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
48350294|NCT00693420|DRUG|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
48503133|NCT02967796|DIETARY_SUPPLEMENT|Proteochoc|
48660714|NCT01712373|DRUG|Placebo|it is placebo
48660715|NCT01623947|DIETARY_SUPPLEMENT|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
48660716|NCT01623947|DIETARY_SUPPLEMENT|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
48660717|NCT01623947|DIETARY_SUPPLEMENT|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
48660718|NCT05970328|DEVICE|Hexoskin Medical System|Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
48660719|NCT03662607|BEHAVIORAL|Virtual reality experience|"* Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~* Seated comfortably and free of direct obstruction~* Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~* Begin the VR experience. Study personnel stay in the room \& provide guidance and answer questions regarding the technology~* When VR experience concluded, wellness self-assessment will be administered again."
48687872|NCT04424394|OTHER|Saline|2 intracavernosal injections over a period of 7 weeks.
48660720|NCT00901914|BIOLOGICAL|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
48503134|NCT00186888|PROCEDURE|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
47985054|NCT06181097|DEVICE|negative pressure wound therapy|The intervention group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility.
47985055|NCT06181097|OTHER|standard dressing|The standard dressing group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The same PICO dressing will be applied, but without the suction.
47985056|NCT05534386|BEHAVIORAL|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
48350295|NCT00693420|DRUG|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
48350296|NCT01197495|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
48350297|NCT04460300|OTHER|Aromatherapy-inhalation method|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes."
48350298|NCT04460300|OTHER|Aromatherapy-foot massage group|"In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot)."
48350299|NCT03935685|DRUG|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
48350300|NCT03780088|BEHAVIORAL|mTranS-C|mobile health
48350301|NCT04171167|DRUG|Fluticasone Propionate|three visits: 0, after washout, after FP usage
48503135|NCT00186888|DRUG|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage\< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
47985057|NCT05534386|BEHAVIORAL|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
48350302|NCT00003282|DRUG|EF5|Given IV
48350303|NCT00003282|PROCEDURE|therapeutic conventional surgery|Undergo resection
48350304|NCT00003282|PROCEDURE|biopsy|Undergo biopsy
48350305|NCT00003282|OTHER|pharmacological study|Correlative studies
48350306|NCT02652546|DRUG|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
48350307|NCT02652546|DRUG|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
48350308|NCT02652546|DRUG|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
48660721|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
47985058|NCT05534386|BEHAVIORAL|First stage control intervention|A set of skill-based pamphlets will be given.
47985059|NCT05534386|BEHAVIORAL|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
48660722|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
48660723|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
48660724|NCT06643429|DIAGNOSTIC_TEST|colorectal cancer|Patients diagnosed with colorectal cancer by pathological biopsy.
48660725|NCT06643429|DIAGNOSTIC_TEST|colorectal neoplasm|Patients diagnosed with colorectal adenoma confirmed by colonoscopy.
48687873|NCT00683930|DRUG|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
48350309|NCT02652546|DRUG|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
48350310|NCT04434261|DIAGNOSTIC_TEST|PT-PCR test for SARS-CoV-2|Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
48350311|NCT02558972|DRUG|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
48350312|NCT02558972|DRUG|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
48350313|NCT02558972|DRUG|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
48350314|NCT02558972|DRUG|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
48350315|NCT05373940|DEVICE|ICD implantation|"This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation."
48350316|NCT05373940|DEVICE|No ICD implantation|"Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only."
48350317|NCT00186472|BEHAVIORAL|Brief Cognitive Behavioral Treatment|
48350318|NCT00644241|BIOLOGICAL|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
48350319|NCT00644241|PROCEDURE|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
48350320|NCT03135262|DRUG|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams \[mg\], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
48350321|NCT03135262|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
48350322|NCT03135262|DRUG|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
48350323|NCT03135262|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
48350324|NCT01314144|DRUG|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
48660726|NCT04458766|BEHAVIORAL|Monetary incentives|This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.
48660727|NCT02305992|PROCEDURE|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
48660728|NCT02305992|PROCEDURE|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
48660729|NCT02305992|PROCEDURE|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
47985060|NCT04630418|OTHER|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
48660730|NCT01092650|DRUG|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
48660731|NCT02394067|OTHER|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
48660732|NCT03611686|DRUG|Local chemotherapy|Local chemotherapy will be administrated according to local recommendation
48660733|NCT03088033|DEVICE|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
48139382|NCT01182532|DRUG|TCM Syndrome Differentiation and Treatment|"1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~   Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~   Dosage: Adjusting by age and weight of patients. Decoction.~2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
48139383|NCT01182532|OTHER|Western therapy plus TCM treatment|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
48139384|NCT03498365|BEHAVIORAL|MCDA|Experimental decision support
48139385|NCT03498365|BEHAVIORAL|Delphi|Standard support
48139386|NCT05119699|DEVICE|MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil|Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
48139387|NCT04239768|DEVICE|MonoDermà HA gel combined to a low level laser|"Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously."
48139388|NCT00595959|DEVICE|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
48139389|NCT03843606|OTHER|Modified ketogenic diets|Different diet composition
48139390|NCT03186248|PROCEDURE|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
48139391|NCT00385866|BEHAVIORAL|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
48139392|NCT00385866|BEHAVIORAL|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
48139393|NCT02966249|DRUG|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
48139394|NCT02966249|DRUG|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
48139395|NCT02966249|DRUG|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
48139396|NCT02966249|DRUG|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
48139397|NCT02966249|DRUG|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
48139398|NCT02966249|DRUG|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
48139399|NCT02412904|DRUG|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
48350325|NCT03551106|OTHER|Web based learning module|Web based learning module available on a especially designed website
48350326|NCT04915105|DIAGNOSTIC_TEST|Markers data from PBMCs|Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.
48350327|NCT01511640|DRUG|Pregabalin|pregabalin 2x daily for duration of study
48350328|NCT01511640|DRUG|Placebo|placebo 2x daily for duration of study
48350329|NCT05817591|OTHER|Questionnaires|In current practice, capsaicin patch treatment is offered to patients with a 24-hour average pain level measured by the EN numerical scale : EN scale is \> 4 Pain monitoring questionnaires will be completed by patients every 6 weeks : Neuropathic Pain Symptom Invetory (NPSI Score), Patients' Global Impression of Change (PGIC scale), Numerical pain scale
48350330|NCT06173349|DRUG|PLZ4-coated paclitaxel loaded micelles (PPM)|Given PLZ4-coated paclitaxel loaded micelles intravesically
48350331|NCT02916199|DEVICE|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
48350332|NCT01480791|DRUG|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
48350333|NCT01480791|DRUG|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
48660734|NCT03088033|OTHER|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
48660735|NCT05618925|DRUG|N803|nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\])
48660736|NCT05618925|BIOLOGICAL|CD19t-haNK suspension|Derived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).
48660737|NCT05618925|DRUG|Cyclophosphamide|Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate and has the molecular formula C7H15Cl2N2O2P•H2O and a molecular weight of 279.1.
48660738|NCT05618925|DRUG|Fludarabine|Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
48660739|NCT05618925|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
48660740|NCT05634005|BEHAVIORAL|Clinical Decision Support|In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).
48660741|NCT05137158|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation(iTBS) on the left DLPFC, the left DLPFC will be targeted utilizing the localite neuronavigation system. The stimulation intensity is set at 80% of resting motor threshold(RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 600 pulses per session, total duration of 3 minutes and 20 seconds.
48660742|NCT05137158|DEVICE|Sham stimulation|The same procedure will be performed in sham group including the RMT assessment and the neuronavigation system for target localization, but the sham coil will vertical to the brain surface and deliver a very slight magnetic field, which have the same appearance and sound, and provide the same tactile sensations as the active coils.
48660743|NCT04779008|OTHER|remote ischemic preconditioning （RIPC）|Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
48660744|NCT00855101|DRUG|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
48660745|NCT05896371|DRUG|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I\&T injected activity
48660746|NCT05896371|DRUG|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I\&T injected activity
47985061|NCT03642236|DRUG|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
48139400|NCT02412904|DRUG|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
48350334|NCT01983046|DRUG|Three different mixture of acetate, butyrate and propionate and palcebo|
48350335|NCT03288623|DIETARY_SUPPLEMENT|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
48503136|NCT00186888|PROCEDURE|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
48139401|NCT04990388|BIOLOGICAL|UX053|mRNA-based biologic
48350336|NCT03288623|DIETARY_SUPPLEMENT|White/Milk chocolate (<35% cocoa)|white or milk chocolate (\<35% cocoa) in tablet
48350337|NCT00772811|DRUG|Flu-Mel|"* Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~* Melphalan will be administered following the completion of Fludarabine infusion at day -2."
48350338|NCT00004690|DRUG|monolaurin cream|
48350339|NCT00621244|DRUG|LBH589|
48350340|NCT00273806|BEHAVIORAL|Intervention for 4 behavioral risks by medical assistants.|
48350341|NCT02255955|DRUG|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
48503137|NCT00186888|RADIATION|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
48660747|NCT05258292|DEVICE|Continuous glucose monitoring|Glucose levels will be measured using continuous glucose monitoring
48660748|NCT05258292|DRUG|Insulin|Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
48660749|NCT05258292|OTHER|Premenstrual symptoms|Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
48660750|NCT05258292|OTHER|Ovulation kits|Ovulation testing will be done using ovulation kits
48660751|NCT05258292|DEVICE|Fitbit Inspire 2|Physical activity will be assessed using the Fitbit Inspire 2
48660752|NCT05258292|OTHER|Keenoa|Food intake will be assessed using the Keenoa phone application
48660753|NCT05258292|OTHER|Menstrual cycle|The application My Calendar will be used to record information on the menstrual cycle
48660754|NCT02609594|OTHER|Weekly application of Amnioband|Weekly application of Amnioband.
48660755|NCT02609594|OTHER|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
48660756|NCT02609594|OTHER|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
48660757|NCT05108428|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 twice daily orally 5 days per week on days of planned radiation therapy.
48139402|NCT04990388|OTHER|Placebo|consists of the same components as the formulation buffer for UX053
48350342|NCT02255955|DRUG|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
48350343|NCT02255955|DRUG|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
48350344|NCT01197781|DRUG|FOSTAMATIN|Oral tablets - single dose
48350345|NCT01197781|DRUG|Verapamil|Oral tablets - administered 3 times daily over 4 days
48503138|NCT00186888|DRUG|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml\*hr, daily for 5 consecutive days, infused over 30 minutes.
48503139|NCT00186888|DRUG|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
48660758|NCT05108428|RADIATION|Radiation Therapy|Participants will receive varying doses of radiotherapy based on MRI guidance, beginning at 28-33 fractions (1.8 Gray units) .
48660759|NCT05108428|DRUG|FOLFOX regimen|Standard of Care FOLFOX regimen consists of 8 cycles (each cycle is 14 days) of 5-fluorouracil, leucovorin, and oxaliplatin. Dosage is as follows: Oxaliplatin 85 mg/m\^2 IV over 2 hours day 1 each cycle. Leucovorin (optional) 400 mg/m\^2 IV over 2 hours day 1 each cycle. 5-fluorouracil bolus\* (optional) 400 mg/m\^2 IV push day 1 of each cycle, and 5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours day 1 each cycle.
48660760|NCT02699307|BEHAVIORAL|Counseling|OT led counseling
48660761|NCT00221858|PROCEDURE|Ultrasound guided blocks|
48139403|NCT04990388|DRUG|Antipyretic|participants will receive oral premedication prior to infusion
48139404|NCT04990388|DRUG|H2 Blocker|participants will receive oral premedication prior to infusion
48139405|NCT04990388|DRUG|H1 Blocker|participants will receive oral premedication prior to infusion
48139406|NCT06397196|OTHER|Laser guided proprioceptive exercises|Participants will receive Laser guided Proprioceptive exercises on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
48139407|NCT06397196|OTHER|Routine Physical therapy|Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
48139408|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
48350346|NCT05225792|BEHAVIORAL|Promis Physical Function Questionnaire|Patient reported physical function outcomes
48350347|NCT05225792|BEHAVIORAL|L Test|Performance based measure assessing general physical function and balance ability.
48660762|NCT06529627|PROCEDURE|Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection|pituitary downregulation with GnRH agonist - ovarian stimulation with exogenous gonadotropin - hCG adminstration as trigger of oocyte maturation Oocyte retriveal via transvaginal ultrasound guided aspiration embryo transfer progesterone as luteal phase support
48660763|NCT06301373|DRUG|Methotrexate Combined With Tofacitinib|Methotrexate Combined With Tofacitinib
48660764|NCT06301373|DRUG|Methotrexate|Methotrexate
48660765|NCT04507204|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
48660766|NCT04507204|DRUG|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
48350348|NCT05225792|BEHAVIORAL|Narrowing Beam Walking Test|Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.
48350349|NCT05225792|BEHAVIORAL|PEQ-A|Survey on confidence, stumbles and falls.
48350350|NCT03786276|BEHAVIORAL|VR-WMR-Only|Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
48350351|NCT03786276|BEHAVIORAL|Exercise-only|Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
48350352|NCT03786276|BEHAVIORAL|Active VR-WMR|Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
48350353|NCT00781183|OTHER|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
48350354|NCT03769389|DIETARY_SUPPLEMENT|Birhi|"Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt"
48350355|NCT03769389|DIETARY_SUPPLEMENT|Khassab|34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
48350356|NCT03769389|DIETARY_SUPPLEMENT|placebo|50g of pure glucose dissolved in 100ml of water
48350357|NCT04096404|GENETIC|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
48660767|NCT05847153|BEHAVIORAL|MASC|"The intervention arm will be comprised of:~1. Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~2. At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
48139409|NCT05098405|DRUG|MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)|"The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST)."
48350358|NCT04096404|BEHAVIORAL|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
48350359|NCT03520426|DEVICE|Votiva RF|The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
48350360|NCT05604404|OTHER|Supine|The patient will be positioned supine with head-of-bed at zero degrees.
48350361|NCT05604404|OTHER|Semi-Recumbent|The patient will be placed in a semi-recumbent position with head-of-bed at thirty degrees.
48350362|NCT05604404|OTHER|Semi-Recumbent with Legs Flexed|The patient will be placed in a semi- recumbent position with head-of-bed at thirty degrees and legs flexed.
48350363|NCT04464473|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
48503140|NCT00186888|DRUG|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: \< 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin \< 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
48503141|NCT00186888|DRUG|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
48660768|NCT01336699|OTHER|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
48660769|NCT01336699|BIOLOGICAL|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
48660770|NCT01336699|BIOLOGICAL|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
48660771|NCT00757016|DRUG|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
48660772|NCT00757016|DRUG|Saline solution|Saline solution
48660773|NCT04602845|DRUG|Fentanyl|50ug Fentanyl intravenously
48660774|NCT04602845|DRUG|Flurbiprofen|50mg Fentanyl intravenously
48660775|NCT04602845|DRUG|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
48660776|NCT04602845|DRUG|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
48660777|NCT05536791|DRUG|Dabigatran Etexilate (DE)|Dabigatran Etexilate (DE)
48660778|NCT01076699|DRUG|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
48350364|NCT01199198|DRUG|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
48350365|NCT01199198|DRUG|Placebo|Placebo by mouth once a day for 14 days.
48350366|NCT02183610|DRUG|[14C] BI 1356 as oral (p.o.) solution|
48350367|NCT02183610|DRUG|[14C] BI 1356 solution for i.v. infusion|
48350368|NCT00987727|DRUG|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
48350369|NCT00987727|DRUG|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
48350370|NCT06030804|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
48503142|NCT00186888|PROCEDURE|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
48503143|NCT00186888|OTHER|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.
48503144|NCT02186626|BIOLOGICAL|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10\^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
48660779|NCT01076699|DRUG|0.125 mg RVX-100|This group is taking an average dose of RVX-100
48660780|NCT01076699|DRUG|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
48660781|NCT01076699|DRUG|placebo|This group is taking a placebo
48139410|NCT04693741|PROCEDURE|secondary alveolar bone graft|"Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps."
48139411|NCT04693741|PROCEDURE|Harvesting of the autogenous bone graft|Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
48139412|NCT04693741|PROCEDURE|Preparation of PRP|10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
48139413|NCT06509867|PROCEDURE|DGG+PRF|de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap
48660782|NCT04854304|DIAGNOSTIC_TEST|Fast Breast Abbreviated Magnetic Renounce Imaging|Fast Breast MRI Imaging
48660783|NCT03934294|OTHER|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
48660784|NCT03934294|DRUG|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
48660785|NCT03934294|OTHER|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
48660786|NCT04093453|OTHER|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
48660787|NCT04093453|OTHER|Exercise|1 hour exercise
48139414|NCT06509867|PROCEDURE|DGG|de-epithelialized subepithelial connective tissue grafts+ Coronally advanced flap
48350371|NCT06030804|DRUG|Placebo|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
48350372|NCT05789914|PROCEDURE|Flap surgery+bone graft+guided tissue regeneration|after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
48350373|NCT05476757|BIOLOGICAL|rDEN2Δ30-7169|rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
48350374|NCT02935907|DRUG|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
48350375|NCT03933072|PROCEDURE|obtaining of autologous human olfactory bulb, autologous sural nerve preparation|The operative procedure will be aimed to obtain one of the patient's olfactory bulbs. The operation will be performed using a minimally invasive intracranial microsurgical endoscopy-assisted or transnasal endoscopic approach. During the same operation the patient sural nerve will be prepared for a future grafting.
48660788|NCT04093453|DIETARY_SUPPLEMENT|Sodium Propionate|Participant receive Sodium Propionate
48660789|NCT01344226|DRUG|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
48367467|NCT05895591|OTHER|Anti-aging cosmetic care product|"* frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm"
48503145|NCT02186626|BIOLOGICAL|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
48503146|NCT06359106|DRUG|80% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 80%, and the total gas flow rate will be set at 2L/minute.
48503147|NCT06359106|DRUG|40% Oxygen|After successful anesthesia induction, the fraction of inspired oxygen (FiO2) will be adjusted to 40%, and the total gas flow rate will be set at 2L/minute.
48503148|NCT04338204|DRUG|tofacitinib|Observational study
48503149|NCT00759187|DRUG|Fluoride|Brush twice daily
48660790|NCT05901207|DIAGNOSTIC_TEST|blood test|blood test
48660791|NCT03781063|DRUG|Lasofoxifene|Estrogen receptor antagonist antineoplastic agent
48503150|NCT00759187|DRUG|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
48503151|NCT00759187|DRUG|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
48660792|NCT03781063|DRUG|Fulvestrant|Estrogen receptor antagonist antineoplastic agent
48660793|NCT03287986|OTHER|MRI|Structural and functional sequences
48660794|NCT01266980|DRUG|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
48660795|NCT00839579|OTHER|1x4 min interval|Aerobic interval training
48660796|NCT06563726|DIAGNOSTIC_TEST|point-of-care milk sodium testing|Data-driven interventions to improve early lactation success are lacking, and parents who deliver preterm are at high risk of lactation challenges. We will be studying feasibility, acceptability, and time cost of teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. As a secondary aim, we will assess the potential to use these POC sodium results to guide personalized lactation care in the form of altered pumping schedules in an attempt to reduce breastmilk Na. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.
48139415|NCT01317966|DRUG|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
47985062|NCT03219489|OTHER|Electronic medical record alert|"An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs \> or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records."
47985063|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product|PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING
48139416|NCT02650505|DRUG|LEO 43204|
48139417|NCT02650505|DRUG|LEO 43204 Vehicle|
47985064|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base|toothbrushing 2x a day for 2 minutes each time
48139418|NCT01128959|DRUG|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
48139419|NCT03965949|DRUG|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
48139420|NCT03965949|DRUG|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
48139421|NCT06124170|PROCEDURE|Preoperative pain managment|propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
48139422|NCT06124170|PROCEDURE|Intraoperative pain managment|Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
48139423|NCT06124170|PROCEDURE|Postoperative pain managment|The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
48139424|NCT00263757|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
48503152|NCT02394704|OTHER|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
48503153|NCT05934409|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy
47985065|NCT02772081|COMBINATION_PRODUCT|LISA combination product (Curosurf+catheter CHF6440)|Curosurf administration through brief insertion of a thin catheter into the trachea
48139425|NCT00263757|OTHER|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
48139426|NCT01079806|DRUG|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
48139427|NCT01079806|DRUG|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
48503154|NCT05934409|DRUG|Nicotinic Acid|Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
48503155|NCT05260112|OTHER|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
48503156|NCT06173778|DRUG|semaglutide 2.4mg|Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
48503157|NCT06173778|DRUG|Placebo|Non-active medication, self-administered
48503158|NCT06173778|DRUG|Nicotine Replacement Therapy (NRT, nicotine patch)|Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
47985066|NCT02772081|DRUG|Curosurf through conventional administration (endotracheal tube)|Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
47985067|NCT02184182|PROCEDURE|VLS ablation/portal ligation/hepatectomy|"Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight \> 0.5~- laparoscopic/laparotomic right trisectionectomy"
48367468|NCT03470272|DEVICE|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
48503159|NCT06173778|BEHAVIORAL|Brief Smoking Cessation Counseling|Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
48503160|NCT05597137|DIETARY_SUPPLEMENT|Zinc Gluconate|Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
48660797|NCT05632393|DRUG|Daridorexant|Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
48660798|NCT05236023|BEHAVIORAL|Zero separation and couplet care|"The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing."
48660799|NCT02552264|BEHAVIORAL|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
48660800|NCT02445911|DRUG|KQ-791|Capsules administered orally
47985068|NCT00003443|DRUG|bryostatin 1|
48139428|NCT04958837|OTHER|FIFA 11+ protocol with additional Core training exercises|Slow paced running exercises of 8 minutes' duration (2 rounds each), followed by Strength, plyometric and balance exercises including 3 sets of 20-30 sec of The Bench, Sideways Bench each side, Nordic Hamstring strengthening, single leg stance balance training, squatting and high speed running. The protocol will end with additional core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge. Each exercise plan will be progressively increased. Core training will be followed by 30 sec stretch of major muscle groups.
48139429|NCT04958837|OTHER|FIFA 11+ protocol|Slow paced running exercises of 8 minutes' duration including running straight, running with hip out, running hip in, running circling partner, running shoulder contact and running quickly forward and backwards (2 rounds each), followed by Strength, plyometric and balance exercises including The Bench, Sideways Bench each side, Nordic Hamstring strengthening and single leg stance balance training, squatting and jumping. All exercises will be progressively increased as per established protocol. The final phase of the study includes fast running for 2 minutes.
48139430|NCT00536120|BIOLOGICAL|BG00002 (natalizumab)|
48139431|NCT00536120|BIOLOGICAL|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
48350376|NCT03933072|BIOLOGICAL|production of Glial Neuropatch|The human autologous olfactory ensheathing glia and olfactory fibroblast isolated from the olfactory bulb will be used for production of Glial Neuropatch in a laboratory facility in accordance with good manufacture procedures (GMP). The final Product will consist of the aforementioned cell suspension embedded with collagen scaffold. The European Medicines Agency/Committee for Advanced Therapies (EMA/CAT) considers that the Product Glial Neuropatch falls within the definition of a tissue engineered product of an advanced therapy medicinal product (decision EMA/CAT/293903/2018 from 22 June 2018: Scientific recommendation on classification of advanced therapy medicinal products Article 17 - Regulation (EC) No 1394/2007).
47985069|NCT04840290|DRUG|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
47985070|NCT02338531|DRUG|PF-03084014|
47985071|NCT02338531|PROCEDURE|Breast cancer surgery|
47985072|NCT04106921|OTHER|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
48139432|NCT00536120|BIOLOGICAL|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
48618283|NCT03693196|OTHER|Subgingival Plaque, Hu-Friedy®|Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
47985073|NCT00877058|BEHAVIORAL|preventive home visit|
48660801|NCT02445911|DRUG|Placebo|Capsules administered orally
48660802|NCT03014115|DIETARY_SUPPLEMENT|combination ARA + DHA|combination ARA + DHA supplemented infant formula
48660803|NCT03014115|DIETARY_SUPPLEMENT|DHA|DHA supplemented infant formula
48660804|NCT06563986|DRUG|Systemic treatment (FTD-TPI and bevacizumab)|"Systemic treatment (FTD-TPI and bevacizumab) administration is according to standard clinical practice. Each treatment cycle will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1~* Days 8-12: oral intake of FTD-TPI~* Day 15: bevacizumab IV infusion~Bevacizumab 5.0mg/kg i.v. is repeated every 2 weeks. If toxicity occurs, dose modifications and dose delays should be administered and applied according to standard practice."
48660805|NCT06563986|DEVICE|Radioembolization with 166-Ho microspheres|"Individualized 166Ho radioembolization will be performed via a catheter during angiography. Before the treatment, a scout procedure will be performed to determine individualized 166Ho dose of the treatment. Dosimetry-based treatment planning will be individualized using Q- Suite software.~In case of bilateral disease, patients will be treated in two procedures to each hemi-liver, separated by 1 month. Before the first procedure, a scout procedure will be performed in which the individualized 166Ho dose of the first and second procedure will be calculated."
48660806|NCT05378464|BIOLOGICAL|Dendritic Cell (DC1) Vaccine|Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
48660807|NCT05378464|DRUG|Trastuzumab|Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
48660808|NCT05378464|DRUG|Pepinemab|Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
47985074|NCT00877058|BEHAVIORAL|senior meetings|
48350377|NCT03933072|PROCEDURE|microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges|The surgery will consists of laminectomy/laminotomy, midline durotomy above the area of spinal cord lesion, detethering of the spinal cord from fibrotic adhesions, resection of the posttraumatic spinal cord glial scar, delivering of cultured OEC/ONFs explants (Glial Neuropatch) to the area of spinal cord injury and finally bridging of the spinal cord gap by harvested autologous sural nerve grafts.
48618284|NCT03693196|OTHER|Williams probe, PCPNU-15 Hu-Friedy®|Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
47985075|NCT05076474|DRUG|Orlistat 60mg Cap|Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
47985076|NCT00061698|BEHAVIORAL|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
47985077|NCT00061698|BEHAVIORAL|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
47985078|NCT00344747|BEHAVIORAL|dietary, behavioral, physical activity|
47985079|NCT02645214|OTHER|Non-antiseptic scrubs|
48350378|NCT00792857|DRUG|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
48350379|NCT00792857|DRUG|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
48350380|NCT06225141|OTHER|Clinical Data reuse|Clinical Data reuse
48350381|NCT03699527|BEHAVIORAL|Multiple questionnaires administered|This is an observational trial
48139433|NCT01073761|DRUG|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
48139434|NCT04603300|DRUG|INT301|INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
48139435|NCT04603300|DRUG|Placebo|Fully functional toothpaste containing no immunotherapy agents
48139436|NCT02630966|DRUG|Vedolizumab|Vedolizumab 300 mg IV infusion
48660809|NCT05378464|BIOLOGICAL|T-Cell therapy|Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
48660810|NCT03298893|DRUG|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
48139437|NCT02630966|DRUG|Placebo|0.9% sodium chloride IV infusion
48139438|NCT03392194|BEHAVIORAL|Sleep hygiene intervention|The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
48139439|NCT03392194|BEHAVIORAL|Yoga intervention|Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
48139440|NCT00725972|OTHER|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
48139441|NCT00725972|PROCEDURE|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
48139442|NCT00348361|DRUG|Fluticasone Propionate|
48139443|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 40 mg every other week, subcutaneous
48350382|NCT04371913|RADIATION|600cGY x 5 fractions|Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for RT naïve patients at New York Presbyterian using EBRT.
48350383|NCT03606707|DRUG|Steroids|intra-articular steroid injection for atlantoaxial joint
48350384|NCT01344304|DRUG|Aprepitant / Fosaprepitant|"Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1"
48503161|NCT04581369|OTHER|Care Coordinator Intervention for Direct Intervention Group|"The First Visit: The care coordinator will conduct a visit within 72 hours of hospital discharge to assess the patient's physical, cognitive, and psychological status, and will complete a needs assessment for both the patient and family caregiver. These measures will be used to guide the use of care protocols and development of the individualized care plan. The care plan will be developed with an emphasis on coordinating services with the patient's providers.~The Second Visit: During the second visit, the coordinator will review the individualized care plan with both the patient and the family caregiver and will make revisions to the plan based on assessment outcomes.~The 6-month Interaction Period: Approximately every 2 weeks, the coordinator will meet with the participant to revisit the care plan and to facilitate care.~At the end of 6 months, all patients will be transitioned to receive full care by their primary care and specialty physicians."
48503162|NCT04581369|OTHER|Care Coordinator Intervention for Standard of Care Group|For participants randomized to this arm, a consultation with the care team will be arranged prior to hospital discharge. Outcome measures will be obtained by blinded research staff from all enrolled subjects at baseline, 3 months, and 6 months. This is the extent of interventions received for participants in this arm.
48660811|NCT03298893|DRUG|Cisplatin|40 mg/m2, once a week during radiotherapy
48687874|NCT00683930|DRUG|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
47914807|NCT02955043|BEHAVIORAL|Behavioral techniques|"Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns."
48139444|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 80 mg every other week, subcutaneous
48139445|NCT01159236|DRUG|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
48139446|NCT01159236|DRUG|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
48139447|NCT01159236|DRUG|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
48139448|NCT01159236|DRUG|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
48139449|NCT01159236|DRUG|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
48139450|NCT01159236|DRUG|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
48139451|NCT01372475|DEVICE|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
48139452|NCT01372475|PROCEDURE|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
48139453|NCT01776320|DRUG|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
48503163|NCT04581369|OTHER|Caregiver Intervention|Caregivers of the participants will be assessed for caregiver burden at 3 time points.
48503164|NCT02548130|OTHER|MELD score|introduction of MELD score
48503165|NCT06533098|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
48350385|NCT00438490|DRUG|Recombinant Human Prolactin|
48367469|NCT03470272|DEVICE|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
48350386|NCT06305819|BEHAVIORAL|self-management support program|The SEMPO program is inspired by established self-management principles and established rehabilitation strategies. The program is manualized and integrates components from rehabilitation strategies within relevant functional domains. The program includes elements, such as tailored psychoeducational content, action planning, guided skills mastery, learning and practicing helpful compensatory strategies, problem solving techniques and sharing of experiences. The intervention is delivered by a multidisciplinary team and the participants are provided with written materials and a work book containing information about each session and work tasks.
48660812|NCT03298893|RADIATION|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
47985080|NCT02645214|OTHER|Antiseptic scrubs|
47985081|NCT03206645|DRUG|Unesbulin|Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
48350387|NCT06305819|OTHER|Control group|Treatment as usual
47985082|NCT02867787|DRUG|Botox arm|
47985083|NCT04904887|PROCEDURE|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
47985084|NCT03036072|OTHER|Strict normothermia|
48139454|NCT02725372|DRUG|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
48139455|NCT02725372|DRUG|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
48350388|NCT00353340|DRUG|n acetylcysteine|
48350389|NCT00353340|DRUG|sodium bicarbonate|
48350390|NCT00353340|DRUG|sodium chloride|
48350391|NCT02021474|DRUG|AGX-201|Subcutaneous injection
48350392|NCT02021474|DRUG|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|Subcutaneous injection
48350393|NCT06239701|BEHAVIORAL|LPA+Fitbit Intervention|"1. In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~2. Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~3. Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences."
48503166|NCT06533098|DRUG|Intravenous immunoglobulins (IVIG)|IVIG will be administered intravenously.
47985085|NCT03036072|DEVICE|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
47985086|NCT05985018|OTHER|Traditional Diet|Provided as an educational leaflet
47985087|NCT05985018|OTHER|Mediterranean Diet|Provided as an educational leaflet
47985088|NCT01453712|RADIATION|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
48503167|NCT06533098|DRUG|Prednisone|Prednisone will be administered orally.
48660813|NCT04132297|BEHAVIORAL|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
47985089|NCT01453712|RADIATION|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
48618285|NCT03693196|OTHER|Demographic|Age, gender and state of smoking were compared between groups.
48618286|NCT02143648|DRUG|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
48618287|NCT02143648|DRUG|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
48618288|NCT02143648|DRUG|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
48660814|NCT04132297|BEHAVIORAL|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
48660815|NCT02026167|BEHAVIORAL|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
48660816|NCT03514940|DIAGNOSTIC_TEST|ultrasound|second trimester us scan will be made to pregnant women
48660817|NCT06101420|DRUG|Vonoprazan|Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
48660818|NCT04379830|DIETARY_SUPPLEMENT|Very Low Energy Diet|Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
48660819|NCT06507540|OTHER|No intervention (observational study)|Retrospective description of diagnostics and treatements of dental emergencies
48687875|NCT00683930|DRUG|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
47985090|NCT04379882|DEVICE|Digital Sedation (Silva)|Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
48139456|NCT05585710|OTHER|Pulsed Lavage Washout|Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
48139457|NCT05585710|PROCEDURE|Implant-based breast reconstruction|Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
48139458|NCT05585710|PROCEDURE|Bilateral or unilateral mastectomy|Standard of care
48139459|NCT05585710|DEVICE|Tissue expander|Standard of care
48139460|NCT05585710|OTHER|Acellular dermal matrix|Standard of care
48139461|NCT03900585|BEHAVIORAL|Interval walking|Interval walking administered by an app on the patient's telephone. Interval walking for 150 minutes/week for 10 weeks.
48350394|NCT06239701|BEHAVIORAL|Fitbit Only|"1. In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~2. Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~3. Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls."
48350395|NCT04684849|OTHER|APP Diary|Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks
48350396|NCT04684849|OTHER|Paper Diary|Subjects keep a multi-item paper survey of symptoms for 2 weeks
48350397|NCT06220240|OTHER|Modified Training Programme|Eccentric muscle contractions and 3-minute rest breaks will be used.
48350398|NCT06220240|OTHER|Routine Training Programme|A routine training program will be used.
48350399|NCT01466439|PROCEDURE|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
48350400|NCT01466439|PROCEDURE|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
48350401|NCT01440972|OTHER|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
48350402|NCT01440972|OTHER|low intensity resistance training|low intensity resistance training without partial blood flow restriction
48350403|NCT00164099|DRUG|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
48350404|NCT05155839|DRUG|MRG001|Administrated intravenously
48350405|NCT04146402|DRUG|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
48350406|NCT04146402|DRUG|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
48350407|NCT00865995|PROCEDURE|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
48350408|NCT01168375|DRUG|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
48350409|NCT01168375|DRUG|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
48350410|NCT00861094|DRUG|cisplatin|
48350411|NCT00861094|DRUG|5-FU|
48350412|NCT00861094|DRUG|oxaliplatin|
48618289|NCT05107037|DRUG|TQ-B3234 capsule|TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
47985091|NCT05258890|OTHER|Social Network Group Counseling|Researchers will identify the influential network members based on their network position, driving distance from the patient, speaking frequency, and whether they have high blood pressure. The index patient and social network members will meet with the study nurse on weeks 2, 6, and 12 after initial enrollment. The study nurse will begin the social network counseling session in which she will provide counseling on teamwork and blood pressure control. The teamwork specific topics will include how networks can work together as a team, communication tips for engaging with one another, spreading positive messages, and establishing the roles and responsibilities of each network team member. The blood pressure control specific topics will include the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. Patient and social network members will receive text messages every week in the weeks between sessions.
47985092|NCT05258890|OTHER|Individual Counseling|The index patient will meet individually with the study nurse on weeks 2, 6, and 12 after initial enrollment. The nurse will provide counseling on the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. The patient will receive text messages every week in the weeks between sessions.
48139462|NCT03572894|DEVICE|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~* T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~* T1 : Vt 8 mL/Kg of PBW during 5 minutes~* T2 : Vt 10 mL/kg of PBW during 5 minutes~* T3 : Vt 6 mL/kg of PBW during 5 minutes~* T4 : A single recruitment maneuver~Data will be recorded at each step."
48139463|NCT01536366|DRUG|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
48139464|NCT01536366|DRUG|Repaglinide|0.5 mg repaglinide (single-dose)
48139465|NCT01935375|BEHAVIORAL|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
48139466|NCT01935375|BEHAVIORAL|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
48350413|NCT00861094|RADIATION|radiation therapy|
48350414|NCT00861094|DRUG|Folinic Acid|
48350415|NCT06302868|BEHAVIORAL|Telemedicine Exposure Therapy Using Photos and Videos|Participants will complete 12 60-minute exposure therapy sessions using photos/videos and progress to in vivo exposures.
48618290|NCT01381120|DRUG|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
48139467|NCT04652869|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
48139468|NCT04652869|BEHAVIORAL|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
48660820|NCT06564766|OTHER|Debriefing|"In the experimental group, an expert instructor conducted a structured debriefing lasting about 10-15 minutes for each clinical scenario, while in the control group, no additional intervention was provided.~The debriefing used in this study has the following characteristics: brief (≤ 15 minutes), educator present, educator experienced in debriefing, focused on healthcare management or decision-making, and used the Plus-Delta method, where participants are asked to reflect on the simulation event and assess their performance by identifying what went well and areas for improvement."
48660821|NCT03514576|DRUG|Pasireotide 0.3 MG/ML|See arm description
48660822|NCT03514576|DIAGNOSTIC_TEST|Meal tolerance test (MTT)|Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
48660823|NCT00706173|DRUG|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
48660824|NCT00706173|DRUG|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
48350416|NCT06302868|BEHAVIORAL|Telemedicine-Based Virtual Reality Exposure Therapy|Participants will complete 12 60-minute exposure therapy sessions in a Virtual Reality Clinic using Virtual Reality stimuli and progress to in vivo exposures.
48503168|NCT03936712|DIETARY_SUPPLEMENT|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
48660825|NCT02531256|DEVICE|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
48660826|NCT06563869|DRUG|PEG-rhG-GSF|Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
48503169|NCT03936712|DIETARY_SUPPLEMENT|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
48660827|NCT06253650|DRUG|Experimental|6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
47985093|NCT01940679|DIETARY_SUPPLEMENT|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
47985094|NCT01306357|DRUG|Somatropin|4 mg or 10 mg delivered by needle-free device
47985095|NCT00010374|DEVICE|NeuRx DPS|Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
48139469|NCT02711332|OTHER|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
48139470|NCT02711332|OTHER|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
48139471|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
48503170|NCT06437574|DRUG|Vytorin|Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.
48660828|NCT06253650|DRUG|Control|4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
48660829|NCT01192074|DEVICE|Ultrasound|Preprocedure ultrasound examination of the spine
48660830|NCT04046744|PROCEDURE|Axillary brachial plexus block with a long-acting local anesthetic|axillary block with 15-30 ml Ropivacaine 0,5%.
48660831|NCT04046744|PROCEDURE|Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic|axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.
48660832|NCT04046744|DRUG|Ropivacaine|axillary block with 15-30 ml Ropivacaine 0,5%
48660833|NCT04046744|DRUG|Ropivacaine|radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%
48660834|NCT04046744|DRUG|Lidocaine|axillary block with 15-30 ml Lidocaine 1,5%
48503171|NCT06437574|DRUG|Ezetimibe|Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.
48660835|NCT04860466|DRUG|CC-96673|IV Infusion
48660836|NCT05748769|BEHAVIORAL|Practice (UL)|Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block
47914840|NCT04765085|BEHAVIORAL|comprehensive behavioral intervention therapy (CBIT)|"Comprehensive behavioral intervention for tics is an extension of habit reversal training. It includes an expanded set of strategies, such as psycho-education about tic disorders, tic awareness training, competing response training, relaxation training, and functional analysis.~According to the CBIT treatment manual (translated by sun Jinhua and Xu Wen, the author were Douglas W. woods et al., Oxford University Press, New York). The treatments consisted of 8 sessions for 10 weeks The first two phases were 1.5 hours, the last six stages were 1 hour.The treatment process was regularly supervised by a treatment supervisor."
48350417|NCT00489502|BEHAVIORAL|Brief Counseling|
48350418|NCT00489502|DEVICE|REE Assessment|
48350419|NCT02447068|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
48503172|NCT03573778|BEHAVIORAL|iHEAL|Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.
48660837|NCT05748769|BEHAVIORAL|Observation (SO)|Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.
48660838|NCT05748769|BEHAVIORAL|Nature Observation (NO)|The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
48660839|NCT03741855|DEVICE|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
48660840|NCT03741855|DEVICE|Cloud Dx Kit with remote-monitoring|"* Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~* A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~* The RT will also check on patients once a week irrespective of the value of the vitals."
48660841|NCT06375447|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for insomnia.
48660842|NCT06140225|BEHAVIORAL|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
48660843|NCT06140225|BEHAVIORAL|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
48660844|NCT06140225|BEHAVIORAL|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
48660845|NCT06140225|BEHAVIORAL|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
48350420|NCT02447068|DEVICE|Luma Light|NBUVB light
48350421|NCT02447068|DEVICE|Occlusive Dressing|Off-the-shelf occlusive dressing
48350422|NCT03518775|DEVICE|Biometry|Measurement of Cornea
48350423|NCT03052465|OTHER|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
48350424|NCT06246344|RADIATION|MRI Guided Simultaneous Integrated Boost Radiotherapy|MRI Guided Simultaneous Integrated Boost Radiotherapy
48139472|NCT00361907|PROCEDURE|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
48139473|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
48139474|NCT01645046|DRUG|Coenzyme A|Coenzyme A 200mg per day.
48350425|NCT02651376|COMBINATION_PRODUCT|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
48350426|NCT02449915|DRUG|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
48350427|NCT02449915|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
48350428|NCT02886338|DEVICE|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
48350429|NCT04901390|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added cane sugar|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
48350430|NCT05498792|DRUG|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
48350431|NCT05498792|DRUG|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
48350432|NCT05498792|DRUG|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
48350433|NCT00520091|DRUG|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
48350434|NCT00520091|DRUG|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
48503173|NCT03573778|BEHAVIORAL|Information about Community Services|Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
48503174|NCT02252991|OTHER|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
48503175|NCT05394311|OTHER|sports based mental health promotion program|sports related programs
48660846|NCT06140225|BEHAVIORAL|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
48503176|NCT02581397|DRUG|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
48503177|NCT02581397|DRUG|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
47985096|NCT03274414|DRUG|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)
47985097|NCT03274414|RADIATION|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
47985098|NCT03274414|PROCEDURE|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
48139475|NCT01645046|DRUG|Coenzyme A|Coenzyme A 400mg per day.
48503178|NCT02581397|DRUG|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
48503179|NCT04842773|DIAGNOSTIC_TEST|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
48660847|NCT06140225|BEHAVIORAL|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
47985099|NCT03274414|DRUG|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
48139476|NCT01645046|DRUG|Placebo|Capsule without coenzyme A.
48350435|NCT00520091|DRUG|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
48350436|NCT00520091|RADIATION|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
48350437|NCT00520091|PROCEDURE|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
48350438|NCT02252328|DRUG|Simvastatin|Simvastatin 80mg once daily
48350439|NCT02252328|DRUG|Placebo|Placebo tablets once daily
48503180|NCT00037024|PROCEDURE|fatigue assessment and management|
48503181|NCT00037024|PROCEDURE|nutritional support|
48503182|NCT00037024|PROCEDURE|physical therapy|
48503183|NCT00037024|PROCEDURE|psychosocial assessment and care|
48503184|NCT00037024|PROCEDURE|quality-of-life assessment|
48660848|NCT06140225|BEHAVIORAL|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
48139477|NCT04382313|PROCEDURE|the adequate hydration group guided by Vigileo|If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%\<SVV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV\<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
48660849|NCT06280989|OTHER|kinesio taping|"Before treatment, all female participants will undergo an allergic test on the anterior surface of the elbow.~To ensure cleanliness, alcohol will be used to clean the areas to be evaluated before applying the tape. The H technique will be employed to apply KT over the lumbar region. Participants will be instructed to bend forwards from the waist, and two vertical strips will be applied. These strips will stretch the Golgi tendon organ on both sides of the spine from the top of the buttock cleft upwards to a mid-point, with less than 25% stretch .~Additionally, a horizontal strip will be attached across the left and right sacroiliac joints. This strip will be stretched to 50% of its maximum capacity,."
48503185|NCT05631223|BEHAVIORAL|Telemedicine|The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).
48660850|NCT06280989|OTHER|myofascial release technique|"myofascial release technique will be applied from prone on lumbar paravertebral muscles by using the olecranon of the physical therapist for 3 minutes, thoracolumbar fascia by using cross-handed hold, with hands placed on the T12-L1 levels and on the sacrum for 5 minutes without repetition and quadratus lumborum by using elbow with low pressure obliquely towards the center of the column for 7 min.~Additionally, from supine on psoas muscle by transversal sliding of the psoas fascia. The therapist will place the hands laterally 3 cm from the umbilicus."
48660851|NCT01168596|DRUG|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
48139478|NCT05771857|DEVICE|Obesity|the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19
48139479|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: BGM|measurement of blood glucose concentration using different BGM
48139480|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: reference method|measurement of blood glucose concentration using reference Method
48503186|NCT06165601|PROCEDURE|Follow-up at D14|A blood test and urinary test will be performed at D14.
48503187|NCT06165601|PROCEDURE|Follow-up at M1|A blood test and urinary test will be performed at M1.
48503188|NCT01119794|DRUG|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
48503189|NCT04269681|DEVICE|High Flow Nasal Cannula|"Experimental intervention (HFNC) The HFNC (AIRVO 2 - Fisher \& Paykel Healthcare, Auckland, New Zealand) consists of a device that allows FiO2 adjustable from 21 to 100% and that delivers a flow of humidified and heated gas up to 60 l / min and 37 degrees C of temperature.~The HFNC will be offered until resolution of the ARF or until decision by the assisting team and the patient and/or their legal guardian, for the suspension of the treatment due to intolerance, and/or worsening of the discomfort and / or dyspnea.~The HFNC should be offered to the patient in ARF as follows:~* Initial parameters: Flow 45 ml / L, FiO2 50%, AIRVO 37oC temperature;~* Titrate the flow up to 60ml / L or up to the maximum tolerated;~* Titrate FiO2 to maintain SatO2 between 92% to 98%, starting with 50%;~* Keep the AIRVO temperature at 37oC, if not possible, acceptable down to 34oC."
48503190|NCT04269681|OTHER|Standard respiratory support|The patient randomized to standard respiratory support will be placed on conventional low flow oxygen therapy according to the center's standard of care aiming at SpO2 90 - 98% and improvement of dyspnea. For cases refractory to oxygen therapy, keeping SpO2 below 90% or if dyspnea does not improve, non-invasive positive pressure ventilation (NIPPV) may be offered at the discretion of the assistant team. NIPPV will be performed with the patient in a supine position at 45 degrees. The mask will be facial (oronasal or full face) with an appropriate size for each patient and adapted in a way to minimize leakage. A hydrocolloid dressing can be placed over the nose in order to avoid ulcerations and increase comfort. The NIPPV will be performed with the help of a ventilator with inspiratory and expiratory circuits or with Bilevel devices with a single circuit and exhalation valve according to the availability of each center.
48503191|NCT03504397|DRUG|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
48503192|NCT03504397|DRUG|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
48503193|NCT03504397|DRUG|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion
48002591|NCT00916175|DIETARY_SUPPLEMENT|AG&CC|"* First period (4 weeks) intake food product AG\&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~* Second period, cross over from P1\&P2 group, 4 weeks intake food product AG\&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
48139481|NCT02061124|DRUG|Sevelamer 1600 mg TID for 7 days|
48139482|NCT02061124|DRUG|Placebo 1600 mg TID for 7 days|
48139483|NCT05405244|DRUG|Placebo|2 capsules, orally administered once
48503194|NCT03504397|DRUG|folinic acid|Folinic acid will be administered as a 2-hour IV infusion.
48139484|NCT05405244|DRUG|Bromocriptine-QR|1.6mg (2 0.8mg capsules), orally administered once
48139485|NCT03762278|DIETARY_SUPPLEMENT|Leucine|Participants will ingest 15g of leucine supplementation/day during the immobilisation period. Leucine supplementation will be administered in powdered form (Infinit Nutrition, Canada) and participants will be required to consume 5g of leucine mixed with 250-300 ml of water during each meal. Leucine is a dietary supplement according to the US FDA. This supplementation protocol has been demonstrated in humans (Murphy et al., 2016, AJCN) with no reported side effects. The quantity of leucine supplementation falls well within the safe limits outlined by Rasmussen et al. (2016). Infinit Nutrition Leucine is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Infinit Nutrition Leucine is not a medicinal product.
48139486|NCT03762278|DIETARY_SUPPLEMENT|Placebo|"Participants will ingest 15g of placebo supplementation/day during the immobilisation period. Placebo supplementation will be administered in powdered form and participants will be required to consume 5g of placebo supplementation mixed with 250-300 ml of water during each meal (3x/day).~Placebo supplementation will contain 5g of non-essential amino acids (Infinit Nutrition, Canada) and will be calorically matched to the leucine supplementation.This supplementation protocol has been demonstrated previously in humans, with no reported side effects (Murphy et al., 2016, AJCN)."
48139487|NCT01123174|BEHAVIORAL|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
48139488|NCT00005869|DRUG|gemcitabine hydrochloride|
48139489|NCT00005869|DRUG|rubitecan|
48139490|NCT00846222|PROCEDURE|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
48139491|NCT03098199|DRUG|300IU Gonal-F|\<1.5 AMH group
48139492|NCT03098199|DRUG|150IU Menopur|\<1.5 AMH group
48139493|NCT03098199|DRUG|225IU Gonal-F|1.6-2.5 AMH group
48139494|NCT03098199|DRUG|75IU Menopur|1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
48139495|NCT03098199|DRUG|150IU Gonal-F|2.6-6.9 AMH group
48139496|NCT03098199|DRUG|75IU Gonal-F|\>7.0 AMH group
48503195|NCT03504397|DRUG|fluorouracil|Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
48503196|NCT01626443|DIETARY_SUPPLEMENT|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
48503197|NCT01626443|DIETARY_SUPPLEMENT|Folic acid|Folic acid (200 mcg); 2 x die
48660852|NCT01168596|DRUG|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
48660853|NCT00737360|DRUG|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
48660854|NCT01659294|BEHAVIORAL|Nurse Case Management|
48660855|NCT01659294|BEHAVIORAL|standard diabetologist care|routine care by diabetologist \& team
48660856|NCT03114865|DRUG|Blinatumomab 9ug|Cycle 1 - Days 1-7: 9 ug/day IV daily
48660857|NCT03114865|DRUG|Blinatumomab 28 ug|Cycle 1 - Days 8-28: 28 ug/day IV daily
48660858|NCT03114865|DRUG|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
48660859|NCT03114865|DRUG|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
48660860|NCT06054308|OTHER|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
48660861|NCT02510924|DEVICE|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
48660862|NCT04129398|DRUG|Letermovir tablet|A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
48660863|NCT04129398|DRUG|Letermovir IV|IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
48503198|NCT03983824|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48503199|NCT03983824|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48503200|NCT03983824|DRUG|Cytarabine|Given IV
48503201|NCT03983824|PROCEDURE|Echocardiogram Recording|Undergo ECHO
48503202|NCT03983824|DRUG|Etoposide Phosphate|Given IV
48503203|NCT03983824|DRUG|Mitoxantrone Hydrochloride|Given IV
48503204|NCT03983824|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48503205|NCT03983824|DRUG|Peposertib|Given PO
48503206|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
48503207|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
48503208|NCT01739348|DRUG|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
48503209|NCT01739348|DRUG|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
48660864|NCT03473587|BEHAVIORAL|Motivational interview|A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening
48660865|NCT03473587|BEHAVIORAL|Standard of care|A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
48660866|NCT04102566|DRUG|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
48660867|NCT04102566|BEHAVIORAL|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
48139497|NCT04252638|BEHAVIORAL|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
48350440|NCT04892394|OTHER|Information Types Before Endodontic Treatment|The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.
48139498|NCT04252638|BEHAVIORAL|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
48660868|NCT05664529|DIAGNOSTIC_TEST|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
48660869|NCT06324409|BEHAVIORAL|Reminder telephone call|A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
48660870|NCT00172367|DRUG|Lycopene|
48139499|NCT04497545|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
48660871|NCT01058746|OTHER|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
48350441|NCT03338881|DRUG|[14C]-TAK-659|\[14C\]-TAK-659 solution.
48350442|NCT03338881|DRUG|TAK-659|TAK-659 tablets.
48350443|NCT05379933|OTHER|Remote health coaching to improve self-care behaviors|Participants will be asked to wear an activity tracker, complete brief surveys, and participate in weekly health coaching sessions remotely for 8 weeks
48503210|NCT01739348|DRUG|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
48503211|NCT04618640|BIOLOGICAL|DTaP-IPV combination vaccine|Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years
48503212|NCT01366430|PROCEDURE|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
48503213|NCT01366430|PROCEDURE|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
48503214|NCT01366430|PROCEDURE|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
48503215|NCT05352165|DRUG|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
48503216|NCT05352165|DRUG|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
48503217|NCT05352165|DRUG|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
48503218|NCT05352165|DRUG|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
48503219|NCT05352165|DRUG|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
48503220|NCT05352165|DRUG|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
48503221|NCT05535153|OTHER|functional movement screen|The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
48503222|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
48350444|NCT05312099|OTHER|Case control|Case control study
48350445|NCT01131130|DEVICE|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
48503223|NCT02701270|DIETARY_SUPPLEMENT|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
48139500|NCT04497545|DEVICE|lower limb rotor|The duration of the overall therapeutic intervention in both groups will be the same.
48139501|NCT02359916|OTHER|Time delays on delivery of less healthy snacks|
48139502|NCT02359916|OTHER|25%/$0.25 discount on healthy snacks|
48139503|NCT02359916|OTHER|25%/$0.25 tax on less healthy snacks|
48139504|NCT05122026|DRUG|Rifapentine|As included in arm/group description
48139505|NCT05122026|DRUG|Isoniazid|As included in arm/group description
48350446|NCT01131130|DEVICE|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
47985100|NCT01776775|DEVICE|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
47985101|NCT00338702|PROCEDURE|Autologous Platelet Gel|
47985102|NCT00490854|DRUG|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
47985103|NCT00490854|DRUG|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
47985104|NCT00810290|BEHAVIORAL|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
47985105|NCT04387175|DEVICE|Carriere Motion 3D Class III Appliance|The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
47985106|NCT04387175|DEVICE|Facial mask|The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
47985107|NCT04367688|DRUG|Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg|daily use for PrEP
47985108|NCT04288648|DIAGNOSTIC_TEST|ultrasound examination|ultrasound examination of pelvic floor muscle will be conducted. In addition questionnaires regarding demographic characteristics and SUI will be performed.
48139506|NCT05611385|OTHER|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
48139507|NCT04801706|DIAGNOSTIC_TEST|Ultrasound|Association of each ultrasonographic parameter with FIGO clinical grading of placenta accreta and with histopathological diagnosis of placenta accreta in hysterectomy specimens
48139508|NCT03877783|DIETARY_SUPPLEMENT|mediterranean diet|The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
48350447|NCT01131130|DEVICE|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
48350448|NCT00821054|DRUG|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
48503224|NCT02701270|DIETARY_SUPPLEMENT|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
48503225|NCT02701270|DIETARY_SUPPLEMENT|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
48503226|NCT02992418|BIOLOGICAL|CYD Dengue Vaccine|0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
48503227|NCT02992418|BIOLOGICAL|Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|0.5 mL, intramuscularly (IM) at Month 1.
48503228|NCT02992418|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0.
47914841|NCT04765085|DRUG|Aripiprazole 5Mg Oral Tablet|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
48350449|NCT05431335|OTHER|Structured exercise program|"It consists of aerobic exercise combined with breathing, strengthening exercises, and stretching exercises. Aerobic exercise will be performed similarly to the other group, only consisting of a five-minute warm-up period and a 15-minute aerobic load period.~Strengthening exercises consist of deep cervical flexor muscles and shoulder region resistive exercises. Each exercise will be repeated as 15 repetitions, 2 sets.~Stretching exercises are neck region stretching exercises. Each exercise will be performed with 10 seconds of stretching and 5 repetitions."
48350450|NCT05431335|OTHER|Aerobic exercise program|Aerobic exercise intensity will be determined by the Perceived Fatigue Scale (Borg scale). It consists of a ten-minute warm-up period (Borg 11), a 15-minute aerobic load (Borg 13-14), and a five-minute cool-down period(Borg 11). The warm-up and cool-down periods include brisk walking combined with breathing, and calisthenic exercises involving the upper and lower extremities; the loading period consists of exercises using a step-dance board accompanied by music. The number of repetitions will be increased progressively to keep the exercise intensity constant.
48350451|NCT03452995|PROCEDURE|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
48350452|NCT05457400|DRUG|ENSO 16|30 g ENSO 16 dissolved in Water
48350453|NCT05457400|DRUG|Glucose Powder|30 g Glucose Powder dissolved in Water
48350454|NCT05345704|OTHER|cardiopulmonary resuscitation (CPR)|Data from observation and collected from simulation mannequin during simulated CPR of an infant and child.
48350455|NCT00998985|DRUG|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
48350456|NCT00998985|DRUG|Placebo|Placebo tablet, orally, once a day for 7 days
48350457|NCT03607994|DEVICE|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
48350458|NCT03607994|DEVICE|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
48350459|NCT05338944|BEHAVIORAL|Dialectical behavioral therapy|Working with psychologists through DBT skills training.
48350460|NCT05338944|BEHAVIORAL|Lifestyle|Working with kinesiologist and registered dietician to improve lifestyle habits.
48350461|NCT03034109|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
48350462|NCT05482594|DIAGNOSTIC_TEST|ELISA|During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
48350463|NCT05482594|DIAGNOSTIC_TEST|Videocapillaroscopy|Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
48350464|NCT05563259|RADIATION|Cognitive assessment, functional magnetic resonance imaging|Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.
48350465|NCT02918422|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
48350466|NCT01685372|BIOLOGICAL|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
48350467|NCT01685372|BIOLOGICAL|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
47985109|NCT04217473|BIOLOGICAL|TILT-123|TNFalpha and IL-2 coding oncolytic adenovirus TILT-123
47985110|NCT01712607|OTHER|Preoperative Warm-Up training|Preoperative Warm-Up training
47985111|NCT04234321|DRUG|basic fibroblast growth factor|Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
47985112|NCT04234321|DRUG|Kangfuxin Liquid|Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.
47985113|NCT04234321|DRUG|0.9% Normal saline|0.9% Normal saline,20ml / 100cm2 / time,three times a day.
47985114|NCT01460420|DRUG|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
47985115|NCT01460420|DRUG|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
47985116|NCT00074087|DRUG|pegylated liposomal doxorubicin hydrochloride|
48660872|NCT01058746|OTHER|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
48139509|NCT03877783|BEHAVIORAL|individualized fitness program|The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
48350468|NCT05604066|DIAGNOSTIC_TEST|Magnetic Resonance (MR) Elastography|Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
48350469|NCT05604066|DIAGNOSTIC_TEST|MRI structural imaging|MRI structural imaging will be done at the same time as MR elastography.
48350470|NCT05080504|DEVICE|Eko DUO|"Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days."
48350471|NCT02633917|BEHAVIORAL|Motor control exercises|exercises to strength the lumbar musculature and control the posture
48350472|NCT02633917|BEHAVIORAL|Standard exercises|general exercises
48350473|NCT00410514|DRUG|Mirabegron|oral
48503229|NCT01996683|DRUG|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation"
48503230|NCT04012151|OTHER|Physical measurement|Parturients of gestational week \>= 32 weeks will have their arms and fingers measured to generate the conicity index.
48350474|NCT00410514|DRUG|Placebo|oral
48350475|NCT00141206|DRUG|varenicline (CP-526,555)|
48503231|NCT04012151|OTHER|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
48350476|NCT03006926|DRUG|lenvatinib|4 mg capsules
48350477|NCT03006926|DRUG|pembrolizumab (200 mg)|30-minute intravenous infusion
48350478|NCT06179355|PROCEDURE|manual astigmatic keratotomy|manual astigmatic keratotomy using a diamond knife
48350479|NCT06179355|PROCEDURE|femtosecond laser astigmatic keratotomy|astigmatic keratotomy using femtosecond lase
48503232|NCT00609518|DRUG|pemetrexed|500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
48503233|NCT00609518|DIETARY_SUPPLEMENT|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
48503234|NCT00609518|DIETARY_SUPPLEMENT|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
48503235|NCT00609518|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
48503236|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
48503237|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
48503238|NCT02337296|BEHAVIORAL|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
47914842|NCT05687669|DRUG|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment|Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
47985117|NCT05219656|DRUG|Cyclosporine A|Rescue therapy in acute severe ulcerative colitis
48139510|NCT03877783|OTHER|recommended modified pharmacological treatment|"Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk \> 20% atorvastatin 40-80mg +ezetimib 10mg."
48139511|NCT05899699|DRUG|DAP-FLU ME|Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)
48139512|NCT05899699|DRUG|Adapalene .1% gel|Adapalene .1% gel
48139513|NCT02850939|BEHAVIORAL|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
48139514|NCT01379885|BEHAVIORAL|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
48139515|NCT01379885|BEHAVIORAL|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
48139516|NCT00524797|DIETARY_SUPPLEMENT|Profonycia|
48139517|NCT06452069|OTHER|IMMUNO19|"280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time."
48139518|NCT06015256|BIOLOGICAL|blood sample|Blood sample (56mL) taken in a heparin tube
48660873|NCT00952692|BIOLOGICAL|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~* One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~* One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
48139519|NCT04927078|OTHER|Observation of breathing pattern|Observations will be collected using a remote vision based patient monitoring and management system.
48139520|NCT06465550|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
48139521|NCT02934932|DRUG|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
48139522|NCT00826956|PROCEDURE|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
48139523|NCT01385800|BIOLOGICAL|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
48139524|NCT01385800|BIOLOGICAL|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
48139525|NCT01332266|DRUG|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
48139526|NCT01332266|DRUG|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
48139527|NCT01738698|DRUG|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
48139528|NCT01738698|DRUG|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
48139529|NCT01738698|DRUG|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
48660874|NCT00952692|DRUG|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
48139530|NCT01738698|DRUG|Placebo|Oral administration once-daily for 12 weeks
48139531|NCT00725959|BEHAVIORAL|Online social networking HIV prevention|messages about HIV posted in online social networking sites
48139532|NCT02251301|DIETARY_SUPPLEMENT|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
48139533|NCT02251301|BEHAVIORAL|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
48139534|NCT02251301|OTHER|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
48139535|NCT02251301|DIETARY_SUPPLEMENT|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
48139536|NCT00399685|DRUG|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
48139537|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
48139538|NCT00399685|DRUG|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
48139539|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
48660875|NCT04053504|BEHAVIORAL|Family Teamwork-Peer Delivery|Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
48660876|NCT03109457|OTHER|oral squamous cell carcinoma|Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
48350480|NCT00809614|BIOLOGICAL|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
48350481|NCT00809614|BIOLOGICAL|Placebo|Matching placebo to AIN457
48139540|NCT05201599|DEVICE|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
48139541|NCT05585632|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
48139542|NCT05585632|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
48139543|NCT05585632|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
48139544|NCT05585632|BIOLOGICAL|mRNA-1045|Formulation for injection
48139545|NCT05585632|BIOLOGICAL|mRNA-1230|Formulation for injection
48139546|NCT02322424|PROCEDURE|pancreaticoduodenectomy|
48139547|NCT00089791|DRUG|placebo|Placebo administered by subcutaneous injection
48139548|NCT00089791|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection
48139549|NCT03764020|DRUG|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
48139550|NCT03764020|DRUG|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
48350482|NCT00169013|DRUG|Gabapentin|
48139551|NCT05808205|DEVICE|• ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume|"According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~* Temporal / frontal area~* Orbital / Malar area~* Perioral area~* Lips."
48139552|NCT06194695|PROCEDURE|drug eluting beads-transcatheter arterial chemoembolization|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
48139553|NCT06194695|DRUG|envatinib plus anti-PD(L)1|oral use of lenvatinib plus intravenous injection of anti-PD(L)1 antibodies. Anti-PD-L1 antibodies includes duravalumab, atezolizumab, or envolizumab, and anti-PD1 antibodies include pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab, or toripalimab.
48139554|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).
48350483|NCT00537459|DRUG|16448|
48139555|NCT04660799|DRUG|Rituximab SC|Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
48139556|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.
48139557|NCT04660799|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
48139558|NCT04660799|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dose of 50 mg/m\^2
48139559|NCT04660799|DRUG|Vincristine|Vincristine will be administered IV at a dose of 1.4 mg/m\^2
48139560|NCT04660799|DRUG|Prednisone|Prednisone will be administered orally at a dose of 100 mg/day
48139561|NCT04660799|DRUG|Paracetamol|All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab
48350484|NCT04488991|OTHER|Cervical Cancer Rate|In the end of the Research, we will compare cervical cancer rates between groups
48503239|NCT04422782|OTHER|For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine|Interventional research protocol involving the human person category 2 at risk and minimal constraints
48503240|NCT03173430|DRUG|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
48139562|NCT04660799|DRUG|Diphenhydramine hydrochloride or alternative antihistamine|All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
48139563|NCT02732990|BEHAVIORAL|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
48139564|NCT02123953|DRUG|TAK-438|TAK-438 tablets
48139565|NCT02123953|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
48139566|NCT03954860|OTHER|Drainage Tube|The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
48139567|NCT03954860|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
48350485|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
48618291|NCT01381120|DRUG|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
48618292|NCT00362232|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
48350486|NCT00782106|BIOLOGICAL|Recombinant human hyaluronidase + immune globulin intravenous|"1. IV infusion of IGIV, 10% to determine pharmacokinetics~2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
48350487|NCT00487994|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
48350488|NCT00487994|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
48350489|NCT00487994|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
48503241|NCT01087489|DRUG|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
48503242|NCT01087489|DRUG|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
48660877|NCT04908228|DRUG|Ibrutinib and obinutuzumab|Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
48660878|NCT06373679|BEHAVIORAL|Switching to E-Cigarette|Participants will receive eleven weeks of e-cigarette products with instructions to switch completely at switch date
48139568|NCT03954860|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
48139569|NCT02343666|BIOLOGICAL|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
48139570|NCT02343666|DRUG|Carmustine|Given IV
48503243|NCT04478630|OTHER|Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract|Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
48503244|NCT00469911|PROCEDURE|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.
48503245|NCT00469911|PROCEDURE|Ex vivo heart biopsy|Heart transplant patients will have their normal clinical routine heart biopsy
48503246|NCT02599038|DIETARY_SUPPLEMENT|Serine supplementation|Serine supplementation (200 mg/kg/day)
48503247|NCT03833401|PROCEDURE|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
48503248|NCT03833401|PROCEDURE|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
48503249|NCT01955837|DRUG|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
48503250|NCT01955837|DRUG|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
48503251|NCT06286696|DIAGNOSTIC_TEST|Optic Nerve Sheath Diameter|Point of care ultrasonography of the optic nerve sheath diameter
48503252|NCT04602715|DRUG|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
48503253|NCT04602715|DRUG|Placebo|Placebo Control
48503254|NCT00006458|RADIATION|indium In 111 monoclonal antibody MN-14|
48503255|NCT00006458|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
48503256|NCT00004025|BIOLOGICAL|aldesleukin|
48503257|NCT00004025|BIOLOGICAL|dendritic cell-gp100-MART-1 antigen vaccine|
48660879|NCT06373679|BEHAVIORAL|Switching using Medication|Participants will receive eleven weeks of FDA approved medication, either varenicline or combination NRT, with instructions to quit smoking cigarettes at quit date
48139571|NCT02343666|BIOLOGICAL|Filgrastim|Given SC
48139572|NCT02343666|OTHER|Laboratory Biomarker Analysis|Correlative studies
48139573|NCT02343666|DRUG|O6-Benzylguanine|Given IV
48139574|NCT02343666|DRUG|Plerixafor|Given SC
48139575|NCT01558908|BIOLOGICAL|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
48503258|NCT05404945|DRUG|Pembrolizumab|Pembrolizumab 400 mg IV
48503259|NCT05404945|DRUG|Doxorubicin|Doxorubicin 25mg/m2 IV
48503260|NCT05404945|DRUG|Vinblastine|Vinblastine 6mg/m2 IV
48503261|NCT05404945|DRUG|Dacarbazine|Dacarbazine 375mg/m2 IV
48002592|NCT00916175|DIETARY_SUPPLEMENT|TA (concentrated 5:1 aloe vera gel)|"* First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
48139576|NCT03278977|BIOLOGICAL|Blood sample for specific analyzes|"Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
48139577|NCT02661932|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
48139578|NCT05049941|DIAGNOSTIC_TEST|lactat and blood gases|observational
48139579|NCT03977194|DRUG|Carboplatin|AUC 6 every 4 weeks
48139580|NCT03977194|DRUG|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
48139581|NCT03977194|DRUG|Atezolizumab|1200 mg every 3 weeks
48139582|NCT01660659|DEVICE|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
48350490|NCT04471532|BEHAVIORAL|Behavior change intervention|"It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks."
47985118|NCT06207773|OTHER|Educator verbal feedback|the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.
47985119|NCT02529618|DEVICE|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
47985120|NCT02529618|DEVICE|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
47985121|NCT02529618|DEVICE|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
47985122|NCT05008250|DRUG|Tongmai Yangxin Pill (TMYXP)|"TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction."
47985123|NCT05008250|DRUG|metoprolol tartrate|metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
47985124|NCT05008250|DRUG|placebo|simulated pills
47985125|NCT04741074|DRUG|Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution|Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
47985126|NCT04741074|DRUG|Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution|Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
47985127|NCT05864508|DRUG|Oxytocin nasal spray|intranasal oxytocin treatment once a day during 6 weeks
47985128|NCT00222196|PROCEDURE|lifestyle, PTA|
47985129|NCT05573945|BEHAVIORAL|Family Education and Active Listening|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator. In addition, weekly meetings of parent/s with a psychologist in a private location for an active listening counselling session.
47985130|NCT05573945|BEHAVIORAL|Family Education|Bedside intervention directly with infant with trained healthcare providers and parents. Includes family education meetings completed with individual infant parent/s and trained operator.
47985131|NCT01387347|DRUG|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
47985132|NCT01387347|DRUG|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
47985133|NCT00514033|BIOLOGICAL|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
48350491|NCT02868151|DRUG|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
48350492|NCT02868151|DRUG|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
48350493|NCT04630444|DRUG|Riluzole|30 PTSD patients with riluzole 100 mg daily (50 mg bid).
48660880|NCT06569550|DEVICE|Real Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The active side is an actively cooled figure-of-eight coil with an outer diameter of 65mm.~Intensity is 80% of resting motor threshold. It is kept the same across all 5 sessions.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
47985134|NCT03569631|DRUG|BPN14770|25 mg BPN14770 capsules
48139583|NCT02265107|OTHER|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
48139584|NCT00324948|DRUG|Topical alprostadil (PGE-1)|
48139585|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
48350494|NCT00374127|DRUG|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
48503262|NCT05404945|DRUG|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg IV
48503263|NCT02589314|DEVICE|Mechanical periodontal therapy|
48503264|NCT02589314|PROCEDURE|nonsurgical periodontal therapy|
48503265|NCT00152178|DRUG|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
48503266|NCT00152178|DRUG|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
48503267|NCT05888623|DEVICE|Computer Assisted Detection|Computer-aided polyp detection system that utilizes artificial intelligence (AI) during colonoscopy
48503268|NCT04028193|DIETARY_SUPPLEMENT|Calogen|Polyunsaturated liquid fat supplement
48503269|NCT04028193|DIETARY_SUPPLEMENT|Resource Energy|Carbohydrate Supplement
47985135|NCT03569631|DRUG|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
48139586|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
48139587|NCT02662816|DEVICE|Proton magnetic resonance spectroscopy (1H MRS)|
48139588|NCT02662816|OTHER|a protein rich breakfast at home|
48350495|NCT00374127|DRUG|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
48350496|NCT04840394|DRUG|BDB018|BDB018 is an immunotherapy agent.
48503270|NCT03320200|OTHER|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
48618293|NCT00362232|DRUG|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
48618294|NCT00362232|DRUG|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
48139589|NCT02662816|OTHER|a protein rich lunch at the Clinical Investigation Center|
48139590|NCT01968824|PROCEDURE|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
48139591|NCT05388045|OTHER|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
48139592|NCT05778409|BIOLOGICAL|Cordyceps cicadae extract|500mg/ day for one month
48139593|NCT01596231|DIETARY_SUPPLEMENT|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
48618295|NCT00362232|DRUG|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
48618296|NCT03287765|DRUG|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
48618297|NCT04042792|OTHER|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
48618298|NCT06222307|OTHER|Game-Based Exercises|Week 1: Dough Kneading, Sorting Legumes, Cutting Lines with Scissors, Coloring with Dry Crayons Week 2: Dough Rolling, Scissor Use, Crumpling Paper, Finger Exercises, Tying Knots with Rubber Bands Week 3: Dough Cutting, Dough Rolling, Dough Stretching, Sewing with Needles, Wrapping Thread like a Spool, Sorting Legumes, Untying Knots in String Week 4: Rhythm Exercises, Dough Kneading and Rolling, Scissor Use, Sorting Legumes, Untying Knots in String Week 5: Stringing Beads on Thread, Unlocking, Tearing Paper, Sorting Legumes, Untying Knots in String Week 6: Tying Shoe Laces, Opening-Closing Jar Lids, Sorting Legumes
48618299|NCT06404528|OTHER|Blood glucose stress combined with low-dose chemotherapy|By controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
48618300|NCT00962598|DRUG|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
48618301|NCT00962598|DIETARY_SUPPLEMENT|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
48139594|NCT01596231|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
48139595|NCT03905512|DRUG|SEL-212|Administered as specified in the treatment arm
48350497|NCT04840394|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
48350498|NCT04685655|OTHER|Therapeutic plasma exchange|Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.
48350499|NCT01001143|DRUG|Decitabine|
48350500|NCT01001143|DRUG|Bexarotene|
48350501|NCT00954473|OTHER|laboratory biomarker analysis|Correlative studies
48350502|NCT01095328|OTHER|screening|screening for Q-fever with a single blood sampling
48367470|NCT04797364|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 2ml (teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) developed by our group and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the child's current and future care
47914843|NCT03544333|DEVICE|transcranial magnetic stimulation|We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
48139596|NCT03905512|DRUG|KRYSTEXXA®|Administered as specified in the treatment arm
48139597|NCT00000872|DRUG|Abacavir sulfate|
48139598|NCT00000872|DRUG|Nelfinavir mesylate|
48139599|NCT00000872|DRUG|Nevirapine|
48139600|NCT00000872|DRUG|Lamivudine|
48139601|NCT00000872|DRUG|Stavudine|
48139602|NCT00000872|DRUG|Zidovudine|
48139603|NCT00783952|DEVICE|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
47985136|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose|50μg/dose
48139604|NCT00783952|DEVICE|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
48139605|NCT00220532|DRUG|Folic acid with riboflavin|
48139606|NCT03183050|BEHAVIORAL|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
48139607|NCT03624283|DRUG|Betahistine|Betahistine is used in the treatment of and vertigo.
48139608|NCT03624283|BEHAVIORAL|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
48139609|NCT03664882|DRUG|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
48139610|NCT03664882|DRUG|Placebo|Pharmaceutical form: tablet Route of administration: oral
48139611|NCT00705406|DRUG|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
48139612|NCT00705406|DRUG|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
48139613|NCT00427440|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
48139614|NCT00427440|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
48139615|NCT00518206|BIOLOGICAL|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
48503271|NCT03320200|OTHER|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
48503272|NCT03872934|BEHAVIORAL|implant anxiety|to determine the type of music that reduces anxiety in patients undergoing implant surgery.
48503273|NCT05269979|BEHAVIORAL|Prevention of hip fractures|Physical exercise and lifestyle advice on diet, smoking, walking and outdoor activities. Recommendations to use calcium and Vitamin D and do exercise at home by written instructions. Home visit by rehab team when needed. Group training with a physiotherapist. Gymnastics group and walking group. Walking aides and instructions of anti-slip protection. Home environment risk reduction was offered.
48503274|NCT01292226|DRUG|mycophenolate mofetil|1 g PO BID for 24 weeks
48503275|NCT01292226|DRUG|antibody induction|According to manufacturer recommendation
48503276|NCT01292226|DRUG|Cyclosporine|According to manufacturer recommendation
48503277|NCT01292226|DRUG|corticosteroid|According to manufacturer recommendation
48503278|NCT02058550|OTHER|survey administration|Receive reminder email survey
48503279|NCT02058550|OTHER|computer-assisted intervention|Receive reminder email survey
48503280|NCT02058550|BEHAVIORAL|telephone-based intervention|Receive reminder phone call
48503281|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes|In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.
48503282|NCT04844762|BEHAVIORAL|Usual brand menthol cigarettes and substitutes|In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.
48503283|NCT04844762|BEHAVIORAL|Menthol cigarettes substitutes and menthol cigarettes|In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.
48503284|NCT03612557|DRUG|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
48503285|NCT02377050|OTHER|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
48503286|NCT00368979|DRUG|Dutasteride|once daily
48503287|NCT00368979|DRUG|Placebo|once daily
48503288|NCT02871271|DIETARY_SUPPLEMENT|IQP-AS-121|
48503289|NCT00301093|BIOLOGICAL|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
48503290|NCT00301093|DRUG|imatinib mesylate|Participants will continue on current dose
48503291|NCT00135863|DRUG|tinzaparin|
48503292|NCT04959591|DRUG|intravenous acetaminophen|experimental(pre): administration of IV acetaminophen
47985137|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose|100μg/dose
47985138|NCT05549206|DRUG|Placebo|Saline solution
47985139|NCT00534274|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
47985140|NCT03402789|DRUG|Docosahexaenoic Acid|Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
48139616|NCT00518206|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
48139617|NCT00506844|DRUG|Cetuximab, Irinotecan, Capecitabine|
48139618|NCT00838994|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
48139619|NCT00391170|DRUG|Topical Dexamethasone|dexamethasone 0.01%
48503293|NCT04959591|DRUG|intravenous acetaminophen|experimental(post): administration of IV acetaminophen
48503294|NCT04959591|DRUG|Placebo|placebo comparator: administration of normal saline
48503295|NCT05819203|DEVICE|Healsea Babykids|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
48503296|NCT05819203|DEVICE|Placebo|7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
48503297|NCT01963286|DEVICE|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
48503298|NCT00004151|DRUG|acridine carboxamide|
47985141|NCT03402789|DRUG|Placebo Oral Tablet|Placebo tablet daily plus 2 hours of eye patching daily
48139620|NCT00391170|DRUG|Placebo|Placebo
48139621|NCT00057499|BIOLOGICAL|IBC-VS01|IBC-VS01
48139622|NCT00057499|BIOLOGICAL|IBC-VS01 placebo|IBC-VS01 placebo
48139623|NCT02954289|BEHAVIORAL|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
48139624|NCT03152435|BIOLOGICAL|EGFR CART|EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
48139625|NCT02481856|DRUG|SQ tree SLIT-tablet|
48139626|NCT02481856|DRUG|Placebo|
48367471|NCT04844866|GENETIC|MB-CART2019.1|MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
48503299|NCT05182320|DEVICE|OrthoPath|unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system
47985142|NCT04202991|OTHER|Exposure - pain|Groups are defined by their naturally occurring exposure to pain or not
48139627|NCT00877019|DEVICE|Sonicare elite medium brush head|
48139628|NCT00877019|DEVICE|Sonicare elite mini brushhead|
48139629|NCT00877019|DEVICE|GABA Elmex sensitive extra soft toothbrush|
48139630|NCT00877019|DEVICE|ADA reference toothbrush|
48139631|NCT03605732|BEHAVIORAL|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
48139632|NCT03605732|OTHER|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
48367472|NCT04844866|DRUG|R-GemOx or BR plus polatuzumab vedotin|Immunochemotherapy will be administered as per arm description.
48367473|NCT03370133|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
48503300|NCT05182320|DEVICE|Control|unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
48503301|NCT01037296|PROCEDURE|catheter ablation|ablation procedure performed with Hansen robotic navigation system
48503302|NCT01037296|PROCEDURE|catheter ablation|Ablation will be performed as normal treatment
48503303|NCT01545661|PROCEDURE|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
48503304|NCT01545661|PROCEDURE|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
48503305|NCT03960203|DIAGNOSTIC_TEST|InSight|Clinical decision support (CDS) system for severe sepsis detection and prediction
48503306|NCT01366950|BEHAVIORAL|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
48139633|NCT03316690|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
48139634|NCT03316690|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
48139635|NCT03316690|BEHAVIORAL|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
48139636|NCT02725697|OTHER|TCM treatment|
48503307|NCT00923273|DRUG|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
48503308|NCT00923273|DRUG|Pemetrexed|
48503309|NCT00923273|DRUG|Sirolimus|
48503310|NCT00923273|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
47985143|NCT00237601|OTHER|obstetric care|
47985144|NCT00231595|DRUG|topiramate|
47985145|NCT00463346|DRUG|Acamprosate|Acamprosate 1998 mg tid
47985146|NCT00463346|DRUG|Placebo|Placebo
48139637|NCT03183349|PROCEDURE|deprotienized bovine bone (tutogen)|
48139638|NCT03183349|PROCEDURE|platelet rich fibrin|
48139639|NCT01540591|DRUG|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
48503311|NCT00923273|DIETARY_SUPPLEMENT|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
48503312|NCT00923273|DRUG|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
48503313|NCT02028494|DRUG|Capecitabine|Two dosages comparison
48503314|NCT02377427|DRUG|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
48503315|NCT02675569|PROCEDURE|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
47985147|NCT02653287|BEHAVIORAL|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary.
48687876|NCT04072835|DRUG|Etripamil NS|Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
47985148|NCT02653287|OTHER|Control|The control group will receive four individual phone calls focusing on education for SLE disease management, as well as answering any questions the participants have about the study. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Each call will last about 10-15 minutes, and occur shortly after randomization, then at 1.5, 3, and 6 months.
47985149|NCT04232072|OTHER|Group ESPB|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
48139640|NCT01540591|DRUG|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
48139641|NCT00355888|DRUG|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
48139642|NCT06402552|DIAGNOSTIC_TEST|bp-MRI prostate|Biparametric MRI is considered less comprehensive compared to multiparametric MRI (mp-MRI), which includes additional parameters like dynamic contrast-enhanced MRI (DCE-MRI). However, bp-MRI offers a simpler, faster, and often less expensive alternative that still provides critical diagnostic information, particularly in the detection of clinically significant prostate cancer. It's commonly used where less comprehensive assessment is sufficient or in situations where contrast use is contraindicated.
48139643|NCT06402552|DIAGNOSTIC_TEST|mp-MRI prostate|Multiparametric MRI is highly valued for its ability to improve the detection and characterization of clinically significant prostate cancer, aid in biopsy guidance, and help in treatment planning and monitoring. Its comprehensive approach provides crucial insights that are not as readily available through simpler imaging modalities like biparametric MRI (bp-MRI).
48139644|NCT01540500|DRUG|Tasimelteon|5.66 mg dose on Day 1 and Day 8
48139645|NCT01540500|DRUG|Fluvoxamine|50 mg Dose on Days 2-8
48139646|NCT04888052|DEVICE|Acute ACL injury|Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits \> 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
48350503|NCT05389306|DIAGNOSTIC_TEST|MRI Scanning|MRI scanning will be performed with a 3.0-T magnetic resonance imaging system with a head and neck-combined coil employing spin-echo technique. The range of the MRI scanning will be from the suprasellar cistern to the inferior margin of the sternal end of the clavicle. The section thicknesses for the axial plane, the sagittal plane and the coronal plane will be 5 mm, 3 mm and 2 mm, respectively. The intersection gaps will be 1 mm. Before the intravenous injection of the MRI contrast agents, T1 weighted images, T2 weighted images and diffusion weighted images will be obtained in the axial planes, while only T1 weighted images will be obtained in the sagittal and coronal planes. After the intravenous injection of the MRI contrast agents, T1-weighted axial sequence, T1-weighted sagittal sequences and T1-weighted fat-suppressed coronal sequence will be performed.
48350504|NCT05389306|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasonography|A sonographer equipped with a 6-15 MHz linear array probe will be adopted for contrast-enhanced ultrasonography examination. Conventional high-frequency ultrasonography will be performed firstly before the intravenous injection of the ultrasound contrast agents. Then the ultrasound contrast agents will be injected intravenously, and contrast-enhanced ultrasonography examination will be performed. The mechanical index of contrast-enhanced ultrasonography examination will be 0.23. The wash-in and wash-out process within the lymph node will be dynamically observed during the arterial phase. During the Kupffer-phase, the degree of enhancement will also be observed.
47985150|NCT04232072|OTHER|Group Ibuprofen|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
48002593|NCT00916175|DIETARY_SUPPLEMENT|P3|"* First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~* Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
48139647|NCT03051568|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
48687877|NCT01101282|DEVICE|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
47985151|NCT05605392|OTHER|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~1. Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~2. Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~3. Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
47985152|NCT02913547|DEVICE|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
48139648|NCT00259116|DRUG|Relaxin|
48139649|NCT01722409|DRUG|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
48139650|NCT01722409|DRUG|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
48139651|NCT04149132|DEVICE|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
48139652|NCT04149132|DIAGNOSTIC_TEST|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
48139653|NCT03594305|BEHAVIORAL|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
48139654|NCT02470806|DEVICE|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
48139655|NCT02470806|DEVICE|tNPWT System|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
48139656|NCT01266369|DRUG|masitinib|
48139657|NCT00000127|PROCEDURE|Optic Nerve Sheath Decompression Surgery|
48139658|NCT02111551|DRUG|DMXB-A 150 mg|
48350505|NCT05389306|DIAGNOSTIC_TEST|Ultrasound-guided Lymph Node Aspiration|After the conventional high-frequency ultrasonography and contrast-enhanced ultrasonography examination was finished, ultrasound-guided aspiration of the target lymph node will be performed. The lymph node tissue obtained from ultrasound-guided lymph node aspiration will be subjected to pathologic evaluation. And the diagnostic performance of MRI and contrast-enhanced ultrasonography will be evaluated using the pathologic diagnosis of the lymph node as the gold standard.
48503316|NCT02675569|PROCEDURE|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
48139659|NCT02111551|OTHER|placebo|
48139660|NCT02111551|DRUG|DMXB-A 75 mg|
48139661|NCT05366478|DRUG|Autologous tumor infiltrating lymphocytes (TILs)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
48139662|NCT03239704|BEHAVIORAL|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
48350506|NCT00796549|DRUG|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
48503317|NCT05320601|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle
48503318|NCT05320601|PROCEDURE|Dry needling|Dry needling at trigger point of upper trapezius muscle
48503319|NCT06255158|BEHAVIORAL|INSIGHT Program|"INSIGHT Program:~the program targets the reduction of EMSs' interference in social information processing, which may otherwise lead to the use of deviant behavior to fulfill emotional and sexual needs. Furthermore, the program has specific goals: (1) developing insight about the offense cycle; (2) fostering empathy for victims; (3) enhancing intimate and social/ interpersonal skills; (4) increasing emotional regulation skills."
48503320|NCT06255158|OTHER|Treatment As Usual (TAU)|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
48503321|NCT03244501|OTHER|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
48139663|NCT03239704|OTHER|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
48139664|NCT03239704|BEHAVIORAL|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
48139665|NCT01472159|BEHAVIORAL|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
48350507|NCT03809195|BEHAVIORAL|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
48350508|NCT04280081|DRUG|Selpercatinib|Administered orally
48350509|NCT06009406|OTHER|Physiotherapy|This group will be applied to the soleus, gastrocnemius muscle and Achilles tendon with Graston, an instrumental myofascial mobilization technique, until they feel warmth in the skin and tonus relaxation in the target muscles. The control group will be subjected to 3 repetitions of passive stretching for 30 seconds for the same structures.
48350510|NCT05049642|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
48503322|NCT03244501|OTHER|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
48503323|NCT02029014|DEVICE|LAA closure system|
47985153|NCT02054416|DEVICE|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
47985154|NCT00746642|DEVICE|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
47985155|NCT05153044|OTHER|severe acute respiratory syndrome CoV-2 serology|diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
47985156|NCT03874897|DRUG|CAR-CLDN18.2 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"
47985157|NCT03874897|DRUG|PD-1 Monoclonal Antibody|Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
47985158|NCT03874897|DRUG|Chemotherapy|First-line systemic therapy according to physician's choice
47985159|NCT00109889|PROCEDURE|magnetic resonance imaging|magnetic resonance imaging (MRI)
47985160|NCT00109889|PROCEDURE|positron emission tomography|positron emission tomography (PET)
47985161|NCT04324554|DIAGNOSTIC_TEST|MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
47985162|NCT03930576|OTHER|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
47985163|NCT06203860|OTHER|Cardio-Metabolic Clinic|"The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment guidelines from the European Cardiovascular Society. The assessment will include the following points:~* Lipid management~* Blood pressure management~* Antithrombotic therapy~* Glycemic targets~* Prevention of diabetes-related complications~* Treatment of vascular disease affecting the lower extremities~* Evaluation of cardioprotective drugs~* Counseling on lifestyle factors, including diet, smoking, alcohol, and exercise~* Guidance on vaccinations"
47985164|NCT00022620|DRUG|paclitaxel|
47985165|NCT01725438|OTHER|sample blood|
47985166|NCT00503009|DRUG|fluticasone propionate/salmeterol|comparator
47985167|NCT00503009|DRUG|fluticasone propionate|Comparator
47985168|NCT00503009|DRUG|placebo|Placebo
47985169|NCT03604640|OTHER|Physical Training|Physical exercise program and health education
47985170|NCT00728780|DRUG|ABT-143|once
47985171|NCT00728780|DRUG|ABT-335 and rosuvastatin|once
47985172|NCT05796765|BIOLOGICAL|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
47985173|NCT05796765|BIOLOGICAL|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
47985174|NCT05796765|DRUG|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
48350511|NCT02972736|RADIATION|Radiation dose expressed as DAP|
48503324|NCT01220297|DRUG|Sirolimus|"Immunosuppressant administered orally to:~* Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~* Children \< 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
48503325|NCT01220297|DRUG|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
48350512|NCT03364062|PROCEDURE|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
48139666|NCT06356285|BEHAVIORAL|Presentation of Antimicrobial Resistance|Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.
48139667|NCT05235685|OTHER|Medical air|Exercise under medical air, both arms exposed.
48139668|NCT05235685|OTHER|Hyperoxia|Exercise under hyperoxia, only experimental arm exposed.
48139669|NCT05893615|BEHAVIORAL|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
48139670|NCT01833598|PROCEDURE|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
48139671|NCT01833598|PROCEDURE|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
48139672|NCT02377193|DRUG|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
48660881|NCT06569550|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Five sessions of real paired-pulse rTMS at 0.72Hz (inter-pulse interval of 30ms and inter-pair interval of 1381ms), for a total of 1300 pulse-pairs (30 minutes), across 5 sequential days, Monday to Friday.~The stimulation is applied with a MagPro XP Orange stimulator (MagVenture A/S, Farum, Denmark), through a B65-Cool-A/P-CO coil (Magventure A/S) with an active and placebo (sham) side. The sham side does not deliver a magnetic pulse to the participant.~The target is the left PMd, at MNI coordinates (34, -2, 66), transformed into patient space. Optimal coil placement, with respects to induced e-field at the target coordinates, is simulated with SimNIBS, based on the participants own MR images. The coil positioning is guided and monitored continuously with a neuronavigation system (Localite, Bonn, Germany) and the aid of robotic arm (Axilum Robotics, Schiltigheim, France )."
47985175|NCT05335564|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
47985176|NCT06013540|COMBINATION_PRODUCT|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
47985177|NCT06013540|COMBINATION_PRODUCT|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
47985178|NCT01002950|DRUG|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
47985179|NCT01002950|DRUG|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
47985180|NCT00969150|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
47985181|NCT00969150|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
48139673|NCT02377193|DRUG|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
48139674|NCT03754660|DRUG|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
48139675|NCT00367653|DRUG|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
48139676|NCT00367653|DRUG|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
48139677|NCT01691677|DRUG|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
48139678|NCT01691677|DRUG|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
48350513|NCT02958033|RADIATION|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
48350514|NCT03296072|DRUG|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres \[mL\] of tap water for 10 seconds before expectorating again.
48503326|NCT01220297|DRUG|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
48503327|NCT01220297|DRUG|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
47985182|NCT02977689|DRUG|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
47985183|NCT01103284|DRUG|DiaPep277|1.0 mg dose in 0.5 mL of solution
47985184|NCT01103284|DRUG|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
48002594|NCT01874834|OTHER|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
48002595|NCT06076694|DRUG|TNP-2198|Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
48002596|NCT06076694|DRUG|Rabeprazole Sodium|Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
48139679|NCT04688684|BEHAVIORAL|Family-based diet and exercise intervention|The participants will meet together weekly as a family unit to receive education and planning to implement diet and lifestyle changes under the supervision of a health coach. This coach will also be available during the week by telephone or messaging for additional individualized support if needed.
47985185|NCT06475950|OTHER|"Kid'EM app experimental group"|"In the Kid'EM app experimental group arm, only the application used differs. Visits are organized in the same way as in the controle app arm.~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
48139680|NCT01987518|OTHER|Procedure surgery behavioral and genetic diagnosis|Observational Study
48139681|NCT01987518|PROCEDURE|quality of life after different type of surgery|
48139682|NCT02241785|DRUG|natalizumab|Administered as specified in the treatment arm
48139683|NCT05100797|DEVICE|Vyntus CPX|To study the validity, precision and accuracy of the Vyntus CPX metabolic cart using both, in-vitro and in-vivo (i.e., human study) measures.
48139684|NCT00452114|DEVICE|In-Exsufflator Cough Assist Device|
48139685|NCT00452114|DEVICE|Active Comparator: Flutter Valve Device|Active Comparator
48139686|NCT03251456|OTHER|Tertiary care|"1. Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~2. The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~3. Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
48139687|NCT03251456|OTHER|Usual Care|"1. Inform the parents that there are abnormalities after eye disease screening of their children~2. Inform the parents that they should take their children to the hospital for further consultation~3. Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
48139688|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
48139689|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
48139690|NCT04466137|DRUG|rhG-CSF/PEG-rhG-CSF|rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
48139691|NCT04425980|OTHER|Modified Constraint-Induced Movement Therapy|intensive use of more affected arm in structured setting
48139692|NCT02666404|OTHER|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
48139693|NCT02656199|PROCEDURE|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
48139694|NCT02591056|DEVICE|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
48139695|NCT02591056|DEVICE|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
48002597|NCT06076694|DRUG|Amoxicillin|Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
48139696|NCT04982588|DEVICE|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)"
48139697|NCT05136794|OTHER|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
48139698|NCT05121142|DRUG|Ruxolitinib|Ruxolitinib will be given by mouth or enteral tube (if applicable).
48002598|NCT06255652|DRUG|Cephradin|Velosef
48139699|NCT05950607|BEHAVIORAL|TRAIN AD 2.0|"The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. ."
48139700|NCT00610558|DEVICE|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
48139701|NCT00610558|DEVICE|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
48139702|NCT00610558|DEVICE|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
48367474|NCT03370133|DRUG|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.
48367475|NCT03370133|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points.
48139703|NCT01331772|OTHER|Control arm|Dietetic follow-up only
48139704|NCT01331772|OTHER|Intervention arm|Dietetic follow up + adapted physical activity
48139705|NCT04486703|OTHER|Exercise with music|physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
48139706|NCT04751981|PROCEDURE|Patient Specific Guide|For lumbar fusion pedicle screws will be placed with the aid of patient specific guides.
48503328|NCT01220297|DRUG|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
48503329|NCT01220297|DRUG|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
48503330|NCT02933268|DIETARY_SUPPLEMENT|High water intake|High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
48503331|NCT02933268|OTHER|Ad libitum water intake|Water intake guided by thirst
48660882|NCT06048042|BIOLOGICAL|Autogenous Demineralized Dentin Graft|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high- speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill. Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid5 for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the intra-bony defect after modified minimally invasive surgical technique.
48660883|NCT06048042|BIOLOGICAL|Autogenous Bone Graft|Modified minimally invasive surgical technique (M-MIST) will be performed in the intra-bony defects, with autogenous bone graft placement. The graft will be harvested from the retromolar area using automatic chip maker (ACM) bur and a hand bone mill will be used to grind the chips into particles, then it will be placed in the defect.
48660884|NCT04910867|BEHAVIORAL|Components of Genetic Counseling|"The APOL1 testing program is designed to help living donor candidates to reduce their decisional conflict and enhance their informed consent regarding living donation. This intervention component entails: (1) an artificial intelligence-based conversational agent chatbot providing foundational information about the relationship between APOL1 and kidney disease and living donor outcomes, and APOL1 testing. The chatbot helps to relieve the workload on clinicians and scale up information giving. (2) The transplant nephrologist counseling component includes discussion about the APOL1 test results and shared decision making about donation, in a culturally competent manner, so as to enhance donor candidates' informed consent for living donation."
48503332|NCT03828916|OTHER|NuShield|SOC surgery with the addition of NuShield
47985186|NCT06475950|OTHER|Kid'EM app control group|"Use of control application without guidance for goal setting~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
47985187|NCT04905095|OTHER|EWS|Early Warning Score will be implemented in the computer system of the nursing station which belong to this intervention group. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
47985188|NCT04905095|OTHER|usual clinical care|Nurses perform their clinical monitoring activities as usual. EWS will not be implemented in their nursing station
47985189|NCT01122706|OTHER|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
47985190|NCT02892760|DEVICE|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
47985191|NCT00510133|BIOLOGICAL|GRNVAC1|Autologous dendritic cell vaccine
47985192|NCT00987077|DEVICE|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
47985193|NCT00827879|BEHAVIORAL|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
47985194|NCT00827879|BEHAVIORAL|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
47985195|NCT01974245|DRUG|Cholecalciferol|100,000 IU/week for 12 weeks
47985196|NCT01974245|DRUG|Placebo|100 drops/ week for 12 weeks
47985197|NCT03645980|DRUG|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
47985198|NCT03645980|DRUG|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
48139707|NCT04751981|PROCEDURE|Navigation|Conventional navigation will be used to place pedicle screws.
48367476|NCT04937127|BEHAVIORAL|I-LEARN training|Training of psycho-behavorial disorders care in neurodegenerative diseases: including a theoretical part in e-learning and a practical part
48503333|NCT03957252|DIAGNOSTIC_TEST|Blood test: ClarityDX Prostate|PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
47985199|NCT03645980|DRUG|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
48139708|NCT06372340|PROCEDURE|Personalized pelvic floor rehabilitation program generated by the intelligent diagnosis and treatment system.|Utilizing machine learning to process and analyze vast amounts of previously collected data, the investigators will establish an intelligent system that can generate personalized pelvic floor exercise prescription by matching factors such as general clinical information and pelvic floor muscle strength data. The experimental group will receive tailored program, including pelvic floor muscle training with diverse intensity and frequency, electrical stimulation, magnetic stimulation, biofeedback and other treatments. The results will ultimately be compared with those taking standardized pelvic floor muscle training only.
48139709|NCT06372340|PROCEDURE|Standard pelvic floor muscle training(PFMT) program|Participants will be given handbooks with detailed training program: the basic regimen consists of 3 sets of 8 to 12 contractions sustained for 8 to 10 sec each, performed 3 times a day. Patients should try to do this every day and continue for at least 15 to 20 weeks.
48139710|NCT04063124|DRUG|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
48139711|NCT02705976|OTHER|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
48139712|NCT02705976|OTHER|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
48139713|NCT05819294|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
48139714|NCT01077700|DRUG|ABT-288 Low Dose|
48139715|NCT01077700|DRUG|Placebo|inactive substance
48139716|NCT01077700|DRUG|ABT-288 High Dose|
48367477|NCT04937127|OTHER|usual care|usual care
48503334|NCT02868645|BIOLOGICAL|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
48503335|NCT00879957|DRUG|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
48503336|NCT00879957|DRUG|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
48503337|NCT00593736|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
48503338|NCT00593736|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
48503339|NCT00593736|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
48660885|NCT04910867|DIAGNOSTIC_TEST|APOL1 genetic testing|APOL1 genetic testing will be performed while live kidney donor candidates are undergoing donor evaluation to identify whether they are at elevated risk of kidney disease post-donation. This risk information is expected to better enable donor candidates to make meaningful informed decisions about donating.
48660886|NCT04910867|OTHER|EHR integration|APOL1 genetic test results will be integrated into the electronic health record to provide clinical decision support to transplant nephrologists in evaluating donor candidates.
48660887|NCT01537328|OTHER|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
48660888|NCT05866640|DEVICE|F2 filter and delivery system|Placement of F2 device in aorta to cover great cerebral vessels
48660889|NCT00001055|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
48660890|NCT00001055|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
48660891|NCT00001055|BIOLOGICAL|rgp120/HIV-1 SF-2|
48660892|NCT04432779|OTHER|no intervention|no intervention
48660893|NCT01483170|DRUG|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
48660894|NCT01483170|DRUG|Placebo|Placebo fexinidazole
48660895|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems with high-efficiency particulate air (HEPA) filters|This group will receive an intervention of true air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems with HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers with HEPA filters) operate during the home time in the intervention period (4 months anticipated).
48660896|NCT05016271|BEHAVIORAL|Air purifier and fresh air ventilation systems without high-efficiency particulate air (HEPA) filters|This group will receive an intervention of sham air purifiers. The air purifiers in classroom (air purifiers and fresh air ventilation systems without HEPA filters) will operate during the school time and the air purifiers in bedrooms (air purifiers without HEPA filters) operate during the home time in the intervention period (4 months anticipated).
48660897|NCT04907084|DIETARY_SUPPLEMENT|Serine|Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)
48660898|NCT04907084|DRUG|Fenofibrate|Fenofibrate 160mg pill, taken orally
48687878|NCT00909441|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
48687879|NCT02735057|DRUG|Carboplatin|
47985200|NCT04492618|DRUG|Ruxolitinib|Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
48139717|NCT00606333|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
48503340|NCT00593736|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
48503341|NCT06118606|OTHER|Case-manager led multidisciplinary follow-up after intensive care|Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
47985201|NCT05615571|GENETIC|Establishment of mitochondrial markers|Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.
48367478|NCT01965691|DIETARY_SUPPLEMENT|Protein intake|"Oral consumption of eight hourly experimental meals-~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals."
48367479|NCT03773146|OTHER|1X Airtime Incentive|An incentive given in the form of airtime
48503342|NCT06107335|DRUG|Human Albumin (colloid)|Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to \>13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
48660899|NCT02247921|OTHER|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
48660900|NCT04892589|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
48660901|NCT04198428|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).
48660902|NCT00815633|DRUG|Alefacept|15mg intramuscular injection weekly for 12 weeks
48660903|NCT03981510|DIAGNOSTIC_TEST|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
48139718|NCT00606333|DEVICE|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
48139719|NCT00830856|DRUG|Fluconazole|Fluconazole 800mg po qday
48139720|NCT00830856|DRUG|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
48139721|NCT00830856|DRUG|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
48350515|NCT03296072|DRUG|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
48139722|NCT05892445|BEHAVIORAL|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
48139723|NCT04546451|BEHAVIORAL|Music practice|Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
48139724|NCT04546451|BEHAVIORAL|Psychomotor therapy|Patients will be trained in body awareness and a wide range of of movement activities.
48350516|NCT03296072|DRUG|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
48350517|NCT03864627|DRUG|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
48503343|NCT06107335|DRUG|Lactated Ringer's Injection (crystalloid)|Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
48139725|NCT02430454|BEHAVIORAL|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
48139726|NCT05229952|DIETARY_SUPPLEMENT|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
48139727|NCT05229952|OTHER|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
48618302|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
48618303|NCT03092232|DRUG|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
48618304|NCT03092232|DRUG|PF-06865571|Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
48139728|NCT04358588|DRUG|iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System|Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
48350518|NCT03864627|DRUG|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
48350519|NCT01017692|PROCEDURE|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
48350520|NCT06186024|DEVICE|Bridge|Stent implantation
48618305|NCT03092232|DRUG|Placebo|Matching Placebo for PF-06865571 for each cohort.
48660904|NCT06564597|OTHER|Patient education|Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.
48660905|NCT00002673|PROCEDURE|infection prophylaxis and management|
47985202|NCT05615571|GENETIC|Sequencing tests|sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
47985203|NCT04392947|DEVICE|Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P
48139729|NCT00894218|PROCEDURE|Arthroplasty|Hip or knee arthroplasty
48139730|NCT03044652|DEVICE|WO2085 Moisturising Cream|2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
48350521|NCT05442125|OTHER|Using DNA methylome to select embryos|DNA methylation level Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
48350522|NCT05442125|OTHER|Using morphologic score to select embryos|blastocyst will transferred according to morphologic score or blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
48350523|NCT02980991|DRUG|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
48350524|NCT02980991|DRUG|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
48618306|NCT02196831|DRUG|tesamorelin|
48618307|NCT02196831|DRUG|Placebo|inactive substance that looks like tesamorelin
48139731|NCT03044652|DRUG|Estriol Cream 0.1%|0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
48139732|NCT01850342|PROCEDURE|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
48139733|NCT06250868|DEVICE|Kerato-Refracto Tonometer|measures pressure inside the eye and thickness of the cornea.
48139734|NCT02802488|PROCEDURE|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
48139735|NCT00667017|BIOLOGICAL|RFT5-dgA immunotoxin|
48139736|NCT00667017|OTHER|fluorescence activated cell sorting|
48139737|NCT00667017|OTHER|immunohistochemistry staining method|
48139738|NCT00750477|DIETARY_SUPPLEMENT|NEM|see Treatment Arms
48139739|NCT00750477|DIETARY_SUPPLEMENT|Placebo|Placebo comparator containing inactives
48139740|NCT02669576|BEHAVIORAL|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
48139741|NCT02669576|OTHER|Usual care|Patients continue usual care by their practitioner
48139742|NCT03591588|OTHER|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
48139743|NCT05419232|OTHER|Short Message Service (SMS) + Website Link Strategy|The intervention we are evaluating is the effectiveness of a participant receiving a SMS + Website Link as a vaccine uptake strategy
48139744|NCT05419232|OTHER|Phone Call with Peer Strategy|The intervention we are evaluating is the effectiveness of a participant having a phone call with a peer as a vaccine uptake strategy
48660906|NCT05614882|BEHAVIORAL|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
48139745|NCT01697683|DRUG|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
48139746|NCT01697683|DRUG|Placebo|
48139747|NCT03044457|PROCEDURE|TKA|"femoral and tibial positioning using the reversed gap technique"
48139748|NCT05481346|PROCEDURE|Multidomain training|"The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members."
48139749|NCT00718120|BIOLOGICAL|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
48139750|NCT06298266|BIOLOGICAL|infusion of GPRC5D-CD19 CAR T injection|Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
48139751|NCT05142774|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
48139752|NCT03072888|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation will be apply
48139753|NCT06238310|DIAGNOSTIC_TEST|Comparison of two external marker substance for measuring glomerular filtration rate|Two external marker substance compares for measuring GFR.
48139754|NCT05505227|BEHAVIORAL|Stigma-reduction training|While the details will be finalized by the intervention working group after the key modifiable features of OUD-stigma among rural HCPs are isolated in Aim 1, our intervention will include several new elements that distinguish it from existing stigma-reduction interventions. The prototype intervention includes several modules aimed at decreasing stigma, increasing knowledge about medications for OUD, and increasing willingness to prescribe buprenorphine (see Table 3) among rural HCPs currently in practice.
48139755|NCT05505227|BEHAVIORAL|Placebo|HCPs affiliated with clinics in the control arm will receive no training but will be provided with a link to the SAMHSA website where prescribers can learn more about buprenorphine prescribing and apply to receive an X-waiver.
48139756|NCT00031941|DRUG|lenalidomide|
48139757|NCT02331485|DEVICE|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
48139758|NCT05307952|DIAGNOSTIC_TEST|Tone Audiometry|Evaluation of the participants' audiometrical thresholds
48139759|NCT05307952|DIAGNOSTIC_TEST|Spectrotemporal Assessment|Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
48139760|NCT05307952|DIAGNOSTIC_TEST|Phoneme and Speech Perception|Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise
48139761|NCT05307952|DIAGNOSTIC_TEST|Digit Triplet Test|Evaluation of the participants' ability to discern speech in noise
48139762|NCT05307952|OTHER|Personalized fitting|Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception
48367480|NCT03773146|OTHER|Lottery Airtime Incentive|An incentive given in the form of airtime
48367481|NCT04647682|OTHER|physical activity program|"* 30 second chair test,~* balance with joint-feet and semi-tandem stance~* 4 meters comfortable walking test were evaluated"
48367482|NCT00340938|PROCEDURE|Blood testing|
48367483|NCT03081858|DRUG|TSD-001|Administered via intravesical instillation.
48367484|NCT06056245|PROCEDURE|Preoperative step|"* Explanation of the surgery and use of the IV-PCA pump.~* Signed informed consent."
48660907|NCT05614882|BEHAVIORAL|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
47985204|NCT04392947|DEVICE|Sham Transcranial Magnetic Stimulation|MagVenture Coil Cool B70 A/P without TMS being actively delivered
48503344|NCT06107335|DEVICE|Edwards HemoSphere monitor with ClearSight-Acumen finger cuff|Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
48503345|NCT05101681|DIAGNOSTIC_TEST|Teledentistry|Teledentistry using mobile photographs
48503346|NCT05569551|DEVICE|Adhesive pouch|Is a barrier dressing categorized under class C medical device. It is used to seal up the umbilical stump to prevent contamination until its cord detachment. It has an adhesive film that sticks to skin with a centrally located non-adhesive pouch ensuring that zero pressure is applied on the umbilicus. It is made of polyurethane, the same material as transparent intravenous cannula dressings making it hypoallergenic waterproof and breathable.
48503347|NCT03512418|BEHAVIORAL|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).
48503348|NCT03512418|DEVICE|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
48503349|NCT03512418|DRUG|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV.
48503350|NCT01889212|OTHER|11C-erlotinib PET/CT|
48503351|NCT05545371|BIOLOGICAL|immunization procedures|The subjects were vaccinated with rabies vaccine according to different immunization procedures
48503352|NCT04731753|DEVICE|mechanical debridement|The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
48503353|NCT06552065|OTHER|collagen with silk fibroin membrane|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
48139763|NCT05307952|BEHAVIORAL|Personalized training|Self-administered training exercises focused on the speech components the participants are experiencing difficulties into
48139764|NCT03698383|DRUG|Trastuzumab biosimilars(Herzuma), Gedatolisib|"* Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~* Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
48139765|NCT02767999|DRUG|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
48139766|NCT02767999|DRUG|Placebo|cellulose placebo per day from D0 to D90
48139767|NCT02767999|RADIATION|fMRI|functional resting state MRI
48139768|NCT05997563|DRUG|Micronized progesterone|Vaginal micronized progesterone effervescent once daily until delivery
48139769|NCT01296230|PROCEDURE|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
48139770|NCT02978183|BIOLOGICAL|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
48139771|NCT02978183|DRUG|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
48139772|NCT00223600|BEHAVIORAL|Nutritional and life style counseling|
48139773|NCT05161000|OTHER|Oral Nutritional Supplement|ONS plus dietary counseling
48139774|NCT05161000|OTHER|Dietary counseling|dietary counseling
48139775|NCT01830049|OTHER|Take blood|
48367485|NCT06056245|DRUG|Intraoperative|Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
48139776|NCT04907929|BEHAVIORAL|targeted speech and cognitive therapy|One month of targeted speech and cognitive therapy with a speech therapist and with home exercice at home by using a numeric solution
48139777|NCT00655824|DRUG|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
48139778|NCT06510569|DEVICE|U lab aligners|Aligner group change the aligner every 10 days
48139779|NCT06510569|DEVICE|oramco bracket|changing orthodontic wire every one month
48139780|NCT02983266|DEVICE|InTENsity MicroCombo|An electrotherapy device.
48139781|NCT04130490|DEVICE|ANTERION|3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
48139782|NCT00365885|OTHER|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
48139783|NCT05527808|DRUG|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
48139784|NCT05527808|DRUG|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
48139785|NCT05527808|DRUG|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
48139786|NCT05527808|DRUG|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
48139787|NCT00286325|DRUG|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
48139788|NCT03744026|DEVICE|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
48139789|NCT03744026|DRUG|Carboplatin|Dose of carboplatin infusion is AUC4-6
48660908|NCT04402216|BEHAVIORAL|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
48350525|NCT04114773|OTHER|SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)|"The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests."
48350526|NCT05219006|DIETARY_SUPPLEMENT|ketogenic dieting|Atkins modified diet: 1.2-1.5 g/kg/day of protein with a ratio 1:1 (fat: carbohydrate + protein)
48350527|NCT05219006|DIETARY_SUPPLEMENT|healthy dieting|Normocaloric diet established by a nutritionist. 1.2-1.5 g/kg/day of protein with a maximum contribution of 50 % carbohydrates of the total calorie intake eliminating industrialized food.
48350528|NCT00127816|PROCEDURE|Permanent prostate implant|
48350529|NCT03975517|BEHAVIORAL|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
48350530|NCT00467012|DRUG|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
48660909|NCT04402216|BEHAVIORAL|MRI preparation video|A descriptive video about what to expect when undergoing MRI
48660910|NCT04402216|BEHAVIORAL|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
48660911|NCT06565247|DRUG|[18F]PSMA-PET|Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.
48660912|NCT06565247|DEVICE|MRI sequences optimized for prostate cancer examinations|T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital
48139790|NCT02871661|DRUG|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
48139791|NCT02871661|OTHER|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
48139792|NCT02871661|DEVICE|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
48139793|NCT03094546|DIETARY_SUPPLEMENT|Polyamine|12 months of polyamine supplementation (6 capsules/day)
48139794|NCT03094546|DIETARY_SUPPLEMENT|Placebo|12 months of placebo intake (6 capsules/day)
48139795|NCT05538000|OTHER|Face to face and telephonic interviews|"face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment.~Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment."
48350531|NCT00467012|DRUG|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
48139796|NCT06322121|OTHER|MRI|Assessment of vascular reactivity and CAA/SVD MRI markers
48350532|NCT05399602|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and CSF sampling (sample 1 in NfL level measurement)
48350533|NCT05399602|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of CSF. It is test of responsivity to ventriculo-peritoneal shunt placement
48367486|NCT06056245|DRUG|Post-operative|Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
48139797|NCT00905294|OTHER|Blood draws|Observational: blood draws only
48139798|NCT04274790|PROCEDURE|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
48350534|NCT05399602|DIAGNOSTIC_TEST|Lumbar infusion test|Diagnostic test accompanying the first lumbar puncture made as i diagnostic test of hydrocephalus. Based on infusion of saline by 90 mL per hour with measurement of CSF pressure each 1 minute and then count of so-called Rout (index).
48350535|NCT05399602|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
48350536|NCT05399602|PROCEDURE|General Anesthesia|Standardized combinated general anesthesia with combination of i.v. and inhalated drugs according the protocol. Given by anesthesiologist.
48350537|NCT05399602|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of CSF (5 days, 1 month a 2 months after surgery)
48350538|NCT05399602|PROCEDURE|Blood sampling #1|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours prior surgery
48350539|NCT05399602|PROCEDURE|Blood sampling #2|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours after surgery
48350540|NCT05399602|PROCEDURE|Blood sampling #3|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 5 days after surgery
48350541|NCT05399602|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
48350542|NCT03605225|DEVICE|mobile cellphone application test|Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
48350543|NCT03285490|DRUG|KX2-391 Ointment 1%|Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
48350544|NCT03285490|DRUG|Placebo|Dosage form: Ointment; Route of administration: Topical
48350545|NCT01451957|OTHER|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)\]
48350546|NCT01451957|OTHER|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
48350547|NCT01451957|OTHER|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
48350548|NCT06245824|DRUG|Trastuzumab deruxtecan (T-DXd) with pyrotinib|T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.
48350549|NCT00781404|DRUG|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
48350550|NCT03814460|DIAGNOSTIC_TEST|Assessment of Tone, Pain and Thickness|Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
48350551|NCT03201484|OTHER|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
48350552|NCT03032523|DIAGNOSTIC_TEST|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
48350553|NCT05165004|BEHAVIORAL|Kangaroo Mother Care|the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation
48350554|NCT05165004|BEHAVIORAL|Hammock Positioning|After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed
48350555|NCT05165004|BEHAVIORAL|Routine Care of NICU|; encircling the neonate in a fetal position using rolled towel inside the incubator.
48350556|NCT06106685|DRUG|High-dose washed microbiota suspension|The high-dose group will be administered a high dose of washed microbiota suspension。
48350557|NCT06106685|DRUG|Low-dose washed microbiota suspension|The low-dose group will be administered a low dose of washed microbiota suspension.
48350558|NCT06106685|DRUG|Placebo|The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
48350559|NCT01962467|DRUG|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
48350560|NCT01962467|DRUG|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
48350561|NCT01962467|DRUG|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
48503354|NCT06552065|OTHER|cross linked collagen membrane|A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
48503355|NCT03924518|DRUG|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
48367487|NCT00863434|DRUG|clofarabine|Given IV
48367488|NCT00863434|DRUG|cytarabine|Given IV
48367489|NCT00863434|BIOLOGICAL|filgrastim|Given SC
48503356|NCT03924518|DRUG|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
48503357|NCT02777814|DRUG|Entecavir|anti hepatitis B virus
48503358|NCT04070235|DRUG|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
48139799|NCT03352713|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
48139800|NCT02399449|DRUG|Brand sodium ferric gluconate|brand product
48139801|NCT02399449|DRUG|Generic sodium ferric gluconate|generic product
48139802|NCT01894399|DRUG|HM61713|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
48139803|NCT04869605|DIAGNOSTIC_TEST|1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio|the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes
48350562|NCT01321658|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
48139804|NCT02969200|DRUG|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
48139805|NCT04586348|COMBINATION_PRODUCT|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
48139806|NCT04586348|COMBINATION_PRODUCT|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
48139807|NCT05794074|DIETARY_SUPPLEMENT|luteine and zeaxanthine|luteine and zeaxanthine
48139808|NCT05794074|DIETARY_SUPPLEMENT|luteine|luteine
48139809|NCT05794074|DIETARY_SUPPLEMENT|zeaxanthine|zeaxanthine
48139810|NCT05794074|DIETARY_SUPPLEMENT|Placebo|Placebo
48139811|NCT01289600|DEVICE|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
48139812|NCT00808496|OTHER|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
48139813|NCT00808496|OTHER|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
48139814|NCT00808496|OTHER|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
48139815|NCT04152824|BEHAVIORAL|Resilience-Supportive Leadership Training (RESULT)|Leaders will receive a training addressing supportive supervisor behaviors and resilience
48139816|NCT01087710|OTHER|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
48139817|NCT01087710|OTHER|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
48139818|NCT06002867|PROCEDURE|SAPB (Serratus Anterior Plan) Block|The patient will be in the supine position. The area where the procedure will be performed will be cleaned with povidone iodine. Using a 22-gauge, 80 mm insulated Quincke needle with a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath, the latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs. After determining the fascia between the two muscles, the block needle will be advanced from caudal to cranial and 40 ml of 0.25% bupivacaine (local anesthetic) will be injected on the serratus muscle between the two muscles.
48139819|NCT06427239|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
48139820|NCT06427239|DRUG|Adebrelimab|Adebrelimab will be administrated per dose level in which the patients are assigned
48350563|NCT06086236|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
48350564|NCT01814189|DRUG|Sumatriptan+Promethazine (SPr)|
48503359|NCT04070235|DRUG|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
48139821|NCT03710252|DRUG|paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin|OMB/PTV/r + DSV +/- RBV
48139822|NCT05891405|PROCEDURE|Cardiac surgery|Operations for congenital heart diseases
48139823|NCT00955162|DRUG|Buprenorphine (Subutex)|Sublingual tablet
48139824|NCT00955162|DRUG|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
48139825|NCT02466958|DRUG|levomilnacipran|antidepressant
48139826|NCT02466958|DRUG|Placebo|an inactive drug
48139827|NCT00491400|DRUG|Fenofibrate|140 mg/day for 8 weeks
48139828|NCT00491400|DRUG|Atorvastatin|20 mg/day for 8 weeks
48350565|NCT00471315|DRUG|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
48350566|NCT06446050|BIOLOGICAL|MSC-L|Human umbilical cord-derived mesenchymal stem cells (MSCs) genetically modified to express antitumor chemokine and co-stimulatory molecule will be administered intravenously at a dose of 1/2/3 x 10\^6 cells/kg, every 21 days for at least 6 cycles of treatment.
48350567|NCT05609162|PROCEDURE|neurosurgical resection|neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
48350568|NCT06507371|RADIATION|node-sparing modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
48350569|NCT06507371|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
48350570|NCT06507371|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
48350571|NCT06507371|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
48350572|NCT06507371|RADIATION|standard short-course radiotherapy|radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
48350573|NCT04721275|OTHER|measurement of pronostic sepsis scores|qSOFA, NEWS and MEDS sores are measured to each patient admitted in the emergency department with a suspicion of infection (excluding localized infection as abscess, angina, cystitis).
48350574|NCT01594086|DIETARY_SUPPLEMENT|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
48350575|NCT00300612|BIOLOGICAL|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
48139829|NCT01925144|DRUG|Baricitinib|Administered orally
48139830|NCT01925144|DRUG|Omeprazole|Administered orally
48139831|NCT05724966|DEVICE|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
48139832|NCT00857766|DRUG|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
48139833|NCT00857766|OTHER|Placebo|COPD subjects-Placebo DISKUS
48350576|NCT04154995|DIAGNOSTIC_TEST|Venipuncture|Blood testing at 3, 6 and 12 months
48350577|NCT04154995|DIAGNOSTIC_TEST|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
48350578|NCT03140722|DRUG|vadadustat|vadadustat
48350579|NCT03140722|DRUG|epoetin alfa|epoetin alfa
48350580|NCT04905836|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
48350581|NCT04905836|DRUG|Placebo|Excipient solution
48350582|NCT03658967|DRUG|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
48350583|NCT03658967|DRUG|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
48350584|NCT06505681|PROCEDURE|Pharmacopuncture|"The selection of acupoints, depth of insertion, and other parameters will be determined based on the clinical judgment of the Korean medicine practitioner, considering the patient's symptoms, imaging results, and degree of improvement. All acupoints where pharmacopuncture is administered will be recorded at the time of treatment.~The type and dosage of pharmacopuncture solution to be used during treatment will be determined entirely based on the clinical judgment of the Korean medicine practitioner performing the pharmacopuncture. Retrospective chart reviews will be conducted to record the type of pharmacopuncture solution used and the total amount administered (in ml).~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
48350585|NCT06505681|PROCEDURE|Physical therapy|"The selection of physical therapy methods, treatment areas, and treatment duration will be determined based on the clinical judgment of the physician, considering the patient's symptoms, imaging results, and degree of improvement. The type, frequency, and areas of prescribed and administered physical therapy will be recorded.~The treatment will be administered twice a week for a total of 3 weeks, and all sessions will be documented for accurate evaluation."
48350586|NCT06330766|PROCEDURE|No preoperative dental screening|Discontinuance of mandatory preoperative dental screening prior TAVI which also can include oral surgery.
48350587|NCT03659708|PROCEDURE|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
48503360|NCT06453629|DEVICE|Floreo VR|12 week VR program to help children with ASD to reduce the core symptoms of Autism
47985205|NCT00825747|DEVICE|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
47985206|NCT04993989|DRUG|Iberogast (STW5, BAY98-7411)|Survey without any intervention assigned in the study.
48139834|NCT06343493|DRUG|Normal saline heated up to 50 °C|Saline heated up to 50 °C used for irrigation
48139835|NCT05866575|OTHER|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
48350588|NCT03659708|PROCEDURE|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
48350589|NCT04075955|DRUG|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
48350590|NCT04075955|DRUG|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
48350591|NCT01644019|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
48350592|NCT01623856|OTHER|laboratory biomarker analysis|Correlative studies
48367490|NCT05277597|DIAGNOSTIC_TEST|The exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.|Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.
47985207|NCT05486468|DRUG|Yutiq 0.18 MG Drug Implant|YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
47985208|NCT05486468|OTHER|Sham Injection|Sham injection
47985209|NCT05324995|DRUG|Multimodal Drug|The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
48139836|NCT05866575|OTHER|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
48139837|NCT04784650|OTHER|Pre-dialysis population|Pre-dialysis population, consisting of both Diabetes Mellitus (DM) and non-DM patients
48139838|NCT04999072|PROCEDURE|Colectomy for colon cancer|Segmental or total colectomy was performed for colorectal cancer.
48139839|NCT01105975|DRUG|LY2484595|Administered daily by mouth for 12 weeks
48139840|NCT01105975|DRUG|Atorvastatin|Administered daily by mouth for 12 weeks
48139841|NCT01105975|DRUG|Simvastatin|Administered daily by mouth for 12 weeks
48139842|NCT01105975|DRUG|Rosuvastatin|Administered daily by mouth for 12 weeks
48139843|NCT01105975|DRUG|Placebo for LY2484595|Administered daily by mouth for 12 weeks
48139844|NCT01105975|DRUG|Placebo for Statins|Administered daily by mouth for 12 weeks
48139845|NCT04033250|DRUG|Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure|Bowel preparation
48139846|NCT03153176|BEHAVIORAL|Training|Training program 30 hours accumulated before, during and after intervention
48139847|NCT03153176|BEHAVIORAL|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
48139848|NCT03153176|BEHAVIORAL|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
48139849|NCT03758248|GENETIC|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19\*17 carriers) or higher (CYP2C19\*2 carriers) risk of major adverse cardiovascular events.
48139850|NCT05680857|OTHER|Placebo|Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
48139851|NCT05680857|OTHER|Product containing marine collagen peptide and Coenzyme Q10.|Product containing marine collagen peptide and Coenzyme Q10.
48139852|NCT00509756|DRUG|FXR-450|capsule, single oral doses from 10 mg to 450 mg
48139853|NCT00509756|DRUG|Placebo|capsule similar to active drug
48139854|NCT05103891|DRUG|Binimetinib Oral Tablet|two-period, crossover study
48139855|NCT02507869|BEHAVIORAL|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
48139856|NCT02507869|BEHAVIORAL|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
48350593|NCT06380556|DEVICE|ShotBlocker|The protruding surface of the ShotBlocker was placed on the heel lance procedure site. While applying pressure on the skin through the ShotBlocker, the nurse performed heel lancing with the needle through the opening in the center of the ShotBlocker. During the 10-second waiting phase, the ShotBlocker was kept at the procedure site with the same pressure. Then ShotBlocker was removed from the skin and routine capillary blood collection procedure was performed.
48503361|NCT06453629|DEVICE|VR Control|12 week program administered in VR
48139857|NCT03709797|PROCEDURE|Dry needling in infraspinatus muscle|Dry needling technique with multiple rapid needle insertion.
48139858|NCT05935605|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.
48139859|NCT05935605|DIAGNOSTIC_TEST|Lung ultrasound|A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
48139860|NCT01904097|DRUG|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
48139861|NCT01904097|OTHER|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
48503362|NCT06453629|DEVICE|VR Control Crossover|If opt in, this group will crossover at the end of 12 weeks to the Floreo VR program
48503363|NCT04236323|DRUG|Not used remifentanil infusion|Remifentanil is not used during operation
47985210|NCT05324995|DRUG|epinephrine|The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
47985211|NCT05324995|DRUG|celecoxib|The third group administered celecoxib (200 mg) orally immediately before the surgery
47985212|NCT04247581|DEVICE|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
47985213|NCT06369194|PROCEDURE|Colorectal Surgery|Postoperative Audit
47985214|NCT02985164|RADIATION|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
48139862|NCT01904097|OTHER|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
48139863|NCT01702376|DRUG|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
48139864|NCT01702376|DRUG|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
48503364|NCT05727072|DRUG|LY3848575|Administered IV.
48503365|NCT05727072|DRUG|LY3848575|Administered SC.
48503366|NCT05727072|DRUG|Placebo|Administered IV.
48139865|NCT01702376|DRUG|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
48139866|NCT01702376|DRUG|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
48350594|NCT06380556|DEVICE|Mechanical vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the baby's extremity and routine capillary blood collection procedure was performed.
48350595|NCT02461849|DRUG|Imatinib|Imatinib 400mg qd daily
48350596|NCT02410746|OTHER|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
48350597|NCT02410746|OTHER|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
48350598|NCT02410746|OTHER|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
48350599|NCT03266367|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
48350600|NCT02174328|DRUG|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
48350601|NCT02174328|DRUG|Placebo|Placebo once a day until 36 week
48350602|NCT00726310|DEVICE|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
48350603|NCT02020304|DRUG|combined spinal epidural|Combined Spinal Epidural
48350604|NCT00658450|BEHAVIORAL|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
48350605|NCT00005792|DRUG|etoposide phosphate|Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
48350606|NCT00005792|DRUG|melphalan|Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5
48503367|NCT05727072|DRUG|Placebo|Administered SC.
48503368|NCT04395144|PROCEDURE|Awake Prone Positioning|Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h
48503369|NCT04395144|PROCEDURE|Standard care|Patients will not receive any special instructions with regards to proning.
48503370|NCT05194137|OTHER|a proprioception protocol associated with vaginal palpation and feedback|A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.
48503371|NCT05194137|OTHER|a proprioception protocol associated with biofeedback|The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
48503372|NCT01865240|DEVICE|Renal Denervation|Renal Denervation Catheter
48503373|NCT05046964|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Radical-7 Pulse CO-Oximeter uses photospectroscopy to non-invasively measure the total hemoglobin (SpHb) in a patient's blood throughout their C-section.
48503374|NCT05396378|DIETARY_SUPPLEMENT|Oral glucose in liquid form|A glucose containing drink that has a fixed dose of 25 g of glucose per can.
48503375|NCT05840237|OTHER|"Anhydrous Enol-Oxaloacetate, a Medical Food"|"Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food"
48503376|NCT05840237|OTHER|White Rice Flour|"Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food"
48503377|NCT06008626|DEVICE|Cryosa Procedure|Cryotherapy
48503378|NCT03598868|DRUG|Vortioxetine|Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.
48503379|NCT03598868|DRUG|Placebo|Augmentation : Placebo for week 1,2,4,6
48503380|NCT00307437|DRUG|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
48503381|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
48503382|NCT00307437|DRUG|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
48503383|NCT02654860|DRUG|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
48139867|NCT02696200|DEVICE|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
48139868|NCT04943445|DRUG|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
48139869|NCT04943445|RADIATION|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
48139870|NCT04943445|DRUG|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
48139871|NCT01849536|DEVICE|SENSIMED Triggerfish®|
48350607|NCT00005792|DRUG|topotecan|Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
48350608|NCT00005792|PROCEDURE|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
48350609|NCT02698566|DRUG|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
48660913|NCT03709667|BEHAVIORAL|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
48660914|NCT03709667|BEHAVIORAL|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
47985215|NCT02985164|RADIATION|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
48350610|NCT06026423|OTHER|Clinical examination and pictures|A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.
48350611|NCT06026423|OTHER|Questionnaire|The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
47985216|NCT03638024|DIAGNOSTIC_TEST|Maternal plasma cell free fetal DNA levels|Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
47985217|NCT00768807|DEVICE|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
47985218|NCT05609045|BIOLOGICAL|Lyophilized COVID-19 mRNA Vaccine|RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
47985219|NCT05609045|DRUG|Sodium chloride|0.9% sodium chloride
47985220|NCT02746016|OTHER|Infant Formula supplemented with Oligosaccharides|sole source nutrition
48350612|NCT01251991|DRUG|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
48350613|NCT01251991|DIETARY_SUPPLEMENT|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
48350614|NCT01251991|DIETARY_SUPPLEMENT|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
48350615|NCT01251991|OTHER|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
48618308|NCT03069989|DRUG|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
48660915|NCT00100425|PROCEDURE|Viceral Perception Testing|
48660916|NCT06511778|DRUG|Hemoblast Bellows application|Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.
47985221|NCT02958150|DRUG|Dexmedetomidine|
47985222|NCT02958150|PROCEDURE|Standard Clinical Practice|
47985223|NCT05281185|DRUG|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
48350616|NCT02737371|DRUG|F901318 Dose level A oral|Adverse events days 1-10
48350617|NCT02737371|DRUG|Placebo dose level A oral|Placebo adverse events days 1-10
48503384|NCT02654860|DRUG|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
48503385|NCT02654860|DRUG|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
48503386|NCT05408936|DRUG|SGLT2 inhibitor|Patients receive an SGLT2 inhibitor as part of theirn routine care.
48503387|NCT06483347|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
48660917|NCT04797884|DEVICE|TheraBionic Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.
48660918|NCT04797884|DEVICE|Placebo Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.
48660919|NCT04797884|DEVICE|Quality of Life Assessment|Ancillary services
48660920|NCT06363292|DRUG|PRO-231|Moxifloxacin 0.5% Ophthalmic solution.
48660921|NCT06363292|DRUG|VIGAMOXI®|Moxifloxacin 0.5% Ophthalmic solution.
48660922|NCT04168125|DEVICE|Tilapia skin|Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
48660923|NCT04168125|DEVICE|Surgical Wound Dressing|Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
47985224|NCT05281185|DRUG|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
48139872|NCT06254976|BEHAVIORAL|exercise|2 weeks of home exercise
48350618|NCT02737371|DRUG|F901318 Dose level B oral|F901318 adverse events days 1-10
48350619|NCT02737371|DRUG|Placebo dose level B oral|Placebo adverse events days 1-10
48350620|NCT02737371|DRUG|F901318 Dose level C oral|F901318 adverse events days 1-10
48350621|NCT02737371|DRUG|Placebo Dose level C oral|Placebo adverse events days 1-10
48350622|NCT03632551|OTHER|Specific binaural hearing evaluations|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
48660924|NCT05507242|BIOLOGICAL|Tezepelumab|Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously
48660925|NCT05507242|OTHER|Placebo|Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
47985225|NCT01572194|BIOLOGICAL|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
47985226|NCT04056676|PROCEDURE|Thoracic paravertebral block under ultrasound guidance|Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
47985227|NCT04056676|PROCEDURE|Intraoperative modified PEC block|Pectoral nerve block by surgeon under direct vision after total mastectomy
48350623|NCT01905514|DEVICE|internet mobile application|
48350624|NCT06006143|DRUG|Varenicline|All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support
48503388|NCT01885026|BEHAVIORAL|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
48503389|NCT01885026|BEHAVIORAL|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
48503390|NCT01885026|BEHAVIORAL|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
48503391|NCT04216667|PROCEDURE|Catheter ablation|Catheter ablation
48660926|NCT00937105|DEVICE|lotrafilcon A contact lenses|FDA approved soft contact lenses
48660927|NCT00937105|DEVICE|Renu Multiplus|
48660928|NCT00937105|DEVICE|Clear Care|
48660929|NCT02363166|OTHER|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
48660930|NCT03870633|OTHER|Medical Chart Review|Undergo medical chart abstraction
48660931|NCT03870633|OTHER|Interview|Complete telephone interview
48660932|NCT03870633|OTHER|Questionnaire|Ancillary studies
48660933|NCT03870633|OTHER|Quality-of-Life Assessment|Ancillary studies
48660934|NCT02465008|DRUG|Levobupivacaine|
48660935|NCT02465008|DRUG|Placebo|
48660936|NCT01927913|DRUG|SPD602|32, 50 or 75 mg/kg/day BID, capsule
48660937|NCT01927913|DRUG|Deferasirox|Per approved country specific label
48660938|NCT00960245|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
48660939|NCT00960245|DRUG|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
48660940|NCT02748798|DRUG|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
48660941|NCT02748798|DRUG|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
48660942|NCT02748798|DRUG|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
48660943|NCT02748798|DRUG|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
47985228|NCT04056676|PROCEDURE|GA with ETT|General anesthesia with endotracheal intubation
48002599|NCT05008991|DEVICE|Spirometry|Spirometry assesses the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways by measuring the total volume of air exhaled from a full lung (total lung capacity \[TLC\]) to maximal expiration (residual volume \[RV\]). This volume, the forced vital capacity (FVC) and the forced expiratory volume in the first second of the forceful exhalation (FEV1), should be repeatable to within 0.15 L upon repeat efforts in the same measurement unless the largest value for either parameter is less than 1 L. In this case, the expected repeatability is to within 0.1 L of the largest value.
48002600|NCT02129803|DEVICE|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
48002601|NCT02129803|DEVICE|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
48503392|NCT04664790|DEVICE|Hyperbaric Oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
48503393|NCT04664790|BEHAVIORAL|Cognitive training|Neuropsychologist guided BrainHQ training
48503394|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
48503395|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
48503396|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
48660944|NCT02748798|DEVICE|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
48660945|NCT02748798|DEVICE|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
48660946|NCT02748798|DEVICE|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
48660947|NCT03648892|DRUG|[c11] raclopride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
47985229|NCT06275568|BEHAVIORAL|Usual Care Fresh Connect cardholder engagement|"Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~* About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~* Texts for all cardholders per month (1-2 outbound texts)~* Welcome call from About Fresh cardholder engagement team~* 1 text - notification that Fresh Connect funds have been reloaded~* As-needed program updates (e.g. new retailers), inactivity outreach~* Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc."
48002602|NCT00002115|DRUG|Adefovir|
48350625|NCT01573286|DRUG|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
48350626|NCT01573286|DRUG|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
48350627|NCT00740428|PROCEDURE|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
48350628|NCT00102336|BIOLOGICAL|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
48503397|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
48503398|NCT02866006|DRUG|BVAC-C|Autologous B cells and monocytes transfected with E6E7 gene of HPV
48503399|NCT02866006|DRUG|Topotecan|
48503400|NCT02912585|BIOLOGICAL|Oropharyngeal administration of own mother's colostrum|
48503401|NCT02912585|OTHER|Oropharyngeal administration of sterile water (placebo)|
48503402|NCT02912585|BIOLOGICAL|Oropharyngeal administration of donor human milk|
48618309|NCT03069989|DRUG|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
48139873|NCT06254976|BIOLOGICAL|intraarticular knee PRP injections|2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
48350629|NCT00102336|DRUG|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
48350630|NCT04116619|OTHER|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
48350631|NCT05393895|DRUG|CSF-1|One drop bilaterally twice daily for approximately 6 weeks
48350632|NCT05393895|DRUG|Vehicle|One drop bilaterally twice daily for approximately 6 weeks
48350633|NCT05162833|DEVICE|TheraNova Neuromodulation Device|TENS device
48350634|NCT05211492|OTHER|Questionnaire|Patients are asked to fill in an online questionnaire concerning their postoperative pain.
48350635|NCT01586962|DRUG|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
48350636|NCT00311090|DRUG|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
48503403|NCT04278950|DRUG|Povidone-Iodine|For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.
48503404|NCT04278950|DRUG|Placebos|The placebo will be 2.5mL of saline with brown food coloring.
48503405|NCT02449096|DEVICE|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
48660948|NCT03648892|DRUG|[18F]fallypride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
48660949|NCT06402305|DIAGNOSTIC_TEST|Lipid profile|Abdominal ultrasound and lipid profile will be done
48660950|NCT05817786|DEVICE|electrical stimulation of the brachial plexus nerve roots|treated by chronic electrical stimulation of the brachial plexus nerve roots
48139874|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
48503406|NCT02449096|OTHER|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
48503407|NCT00867503|DRUG|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
48503408|NCT04444674|BIOLOGICAL|ChAdOx1 nCoV-19|Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19
48503409|NCT04444674|BIOLOGICAL|Normal saline 0.9%|Normal saline 0.9% as placebo
48503410|NCT05453565|OTHER|Vasopressors|A haemodynamic resuscitation strategy based upon the restriction of IV fluids (by either volume or rate of infusion) with initiation or change of rate of vasopressors if required to meet perfusion targets
48139875|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
48350637|NCT00311090|DRUG|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
48350638|NCT00311090|DRUG|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
48350639|NCT00311090|DRUG|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
48350640|NCT01329172|OTHER|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
48350641|NCT01329172|OTHER|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
48350642|NCT00544505|DRUG|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
48350643|NCT04265092|DRUG|Incobotulinum toxin A|Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.
48503411|NCT05453565|OTHER|Fluids|A strategy of resuscitation with intravenous fluids as the primary intervention to achieve perfusion targets with subsequent initiation or change of rate of vasopressors if required.
48503412|NCT04184505|DRUG|Azacitidine|75mg/mq/day subcutaneously for 7 days every 28 days
48503413|NCT04184505|DRUG|Standard Chemotherapy|"1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)"
48660951|NCT05817786|OTHER|sham stimulation|treated by sham stimulation
48660952|NCT01731145|DEVICE|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
48660953|NCT04617860|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
48660954|NCT05166902|DEVICE|Lens A (comfilcon A lens)|1 month
48660955|NCT05166902|DEVICE|Lens B (lehfilcon A lens)|1 month
48660956|NCT06564103|COMBINATION_PRODUCT||
48660957|NCT05405608|DRUG|Ondansetron|hemodynamic stability in orthopedic surgeries
48660958|NCT02987387|DEVICE|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
48139876|NCT04012905|DRUG|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
48139877|NCT05406947|OTHER|Prospective observational study, no intervention|Prospective observational study, no intervention
48139878|NCT04958720|PROCEDURE|Surgery|Surgery
48139879|NCT04958720|DRUG|Chemotherapy, anti-targeted agents and immunotherapy|Chemotherapy, anti-targeted agents and immunotherapy
48139880|NCT04958720|RADIATION|Radiotherapy|Radiotherapy
48139881|NCT06211595|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
48139882|NCT03032198|DEVICE|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
48139883|NCT05581251|BEHAVIORAL|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
48139884|NCT01885559|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
48139885|NCT01885559|DRUG|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
48139886|NCT01885559|DRUG|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
48139887|NCT01271244|DRUG|Escitalopram|10-20mg daily for 12 weeks
48139888|NCT00076674|DRUG|Intravenous Levodopa|
48139889|NCT00028548|DRUG|R(+)XK469|
48139890|NCT06031818|OTHER|The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework.
48139891|NCT06031818|OTHER|The model prediction|The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction.
48139892|NCT06031818|OTHER|The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction.
48139893|NCT00622700|DRUG|Teriflunomide|Film-coated tablet Oral administration
48139894|NCT00622700|DRUG|Placebo|Film-coated tablet Oral administration
48139895|NCT03339466|DEVICE|Inspiratory muscle therapy|6 weeks of inspiratory muscle therapy
48139896|NCT01232101|DEVICE|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
48139897|NCT01319838|DRUG|Isotretinoin|\>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
48139898|NCT02076594|DRUG|Docetaxel|Powder for solution for infusion
48350644|NCT02382770|PROCEDURE|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
48660959|NCT01064726|DRUG|Ibuprofen|800 mg oral
48660960|NCT01064726|DRUG|Fluticasone propionate|200 mcg intra-nasal
48139899|NCT02076594|DRUG|Epirubicin|Solution for infusion
48139900|NCT02076594|DRUG|Oxaliplatin|Powder for solution for infusion
48139901|NCT02076594|DRUG|Capecitabine|Film coated tablets
48139902|NCT05534971|PROCEDURE|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
48139903|NCT04346875|PROCEDURE|Regularly changing of dressing|Conventional dressing
48139904|NCT04346875|PROCEDURE|No application|No dressing change
48139905|NCT02176577|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
48139906|NCT05856656|BEHAVIORAL|Music therapy|Music therapy is a technique of care, accompaniment and support, which aims to improve health and well-being.
48139907|NCT03884842|BIOLOGICAL|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
48139908|NCT03884842|BIOLOGICAL|Placebo|Matched placebo
48139909|NCT00655499|DRUG|Panitumumab|6 mg/kg
48139910|NCT00655499|DRUG|Irinotecan hydrochloride|180 mg/kg
48139911|NCT00655499|GENETIC|Chromogenic in situ hybridization|
48139912|NCT00655499|GENETIC|Fluorescence in situ hybridization|
48139913|NCT00655499|GENETIC|Gene expression analysis|
48139914|NCT00655499|OTHER|Laboratory biomarker analysis|
48139915|NCT00005799|DRUG|fludarabine phosphate|Given IV
48139916|NCT00005799|RADIATION|total-body irradiation|Undergo low-dose TBI
48139917|NCT00005799|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
48139918|NCT00005799|PROCEDURE|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
48139919|NCT00005799|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
48139920|NCT00005799|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
48139921|NCT00005799|DRUG|cyclosporine|Given PO
48139922|NCT00005799|DRUG|mycophenolate mofetil|Given PO
48139923|NCT00005799|OTHER|pharmacological study|Correlative studies
48660961|NCT01064726|DRUG|Placebo|Placebo
48660962|NCT00220662|BEHAVIORAL|Readiness and Motivation Therapy|
48350645|NCT02652572|DRUG|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
48350646|NCT04709250|PROCEDURE|interscalene block|The patient will be put in the supine position, with the arm adducted a high-frequency linear ultrasound probe is oriented transversely across the lateral neck. When visualizing the ''stoplight sign,''15 to 30 mL of 0.25% bupivacaine will be injected
48660963|NCT05696119|BEHAVIORAL|I-PROTECT|I-PROTECT is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes end-user-targeted information and injury prevention physical and psychological training, specifically tailored for youth handball. The intervention is delivered through a mobile application (I-PROTECT GO) specifically developed for the I-PROTECT project, including coach, player, club administrator, and caregiver modules. Tailored support to implement I-PROTECT is specifically developed for Swedish community youth handball.
48660964|NCT05696119|BEHAVIORAL|Control|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
47985230|NCT06275568|BEHAVIORAL|Enhanced engagement communication|Enhanced engagement involves additional outbound texts per month and additional ad hoc bi-monthly or quarterly texts, as well as tailored reminder text to use funds before the end of the month.
48367491|NCT05277597|DIAGNOSTIC_TEST|The same exercise training program without the sauna treatments|The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.
48503414|NCT04184505|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic stem cell transplantation
47985231|NCT05372328|OTHER|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
47985232|NCT00255827|BIOLOGICAL|HyperAcute-Pancreatic Cancer Vaccine|
47985233|NCT00344227|DRUG|Lucentis (Ranibizumab)|
47985234|NCT04830020|DRUG|HMW-HA|Aerolized administration b.i.d.
48002603|NCT06452940|OTHER|Exercise|A 16-week clinical pilates exercise program will be applied 3 days a week for 60 minutes each session. It will consist of a warm-up, main exercise and a cool-down period.Exercises will start with 10 repetitions and will be gradually increased in 3-week periods.
48002604|NCT06321874|PROCEDURE|Oxygen|
48139924|NCT00005799|OTHER|laboratory biomarker analysis|Correlative studies
48660965|NCT01531335|DIETARY_SUPPLEMENT|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
48660966|NCT01531335|DIETARY_SUPPLEMENT|Standard care|25 kcal per kg of body weight
48660967|NCT05603676|OTHER|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
48660968|NCT05603676|OTHER|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
48660969|NCT04252664|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
48660970|NCT04252664|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
48660971|NCT06549231|DRUG|Rituximab|one course of IV rituximab consisting of an infusion of 1000 mg rituximab (diluted in 500 mL of saline 0.9 % sodium chloride) will be given at day 1, day 15 and an infusion of 500 mg rituximab (in 500 mL of saline 0.9 % sodium chloride) at week 24;
48660972|NCT06549231|DRUG|Placebo|one course of intravenous placebo of rituximab consisting of an infusion of 500 mL of saline (0.9% sodium chloride) infusion will be given at day 1, day 15 and week 24;
48660973|NCT05177380|PROCEDURE|Personalized rehabilitation program of facial involvement in systemic sclerosis|Personalized rehabilitation program of facial involvement in systemic sclerosis
48660974|NCT05177380|OTHER|Delivery of a standard prescription for facial rehabilitation|Delivery of a standard prescription for facial rehabilitation
48660975|NCT02507726|DEVICE|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
48660976|NCT00004682|DRUG|immune globulin|
48660977|NCT05467410|BEHAVIORAL|COG-AM|Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
48660978|NCT05467410|BEHAVIORAL|COG-PM|Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
48660979|NCT03841279|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
48660980|NCT05594186|DRUG|Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.|Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
48350647|NCT04709250|PROCEDURE|selective nerve block|"the patient will be put in the sitting position, linear 38-mm high frequency 10-12 MHz transducer will be placed first on the scapula to view of the suprascapular nerve. 5-8 mL of 0.25% bupivacaine is injected to block the SSN.~The ultrasound probe put on the posterior aspect of the shoulder to view the circumflex artery, 10 mL of 0.25% bupivacaine this will lead to loss of sensation over the deltoid.lateral pectoral nerve block (LPNB) will be done by injecting a volume of 8 ml of a 0.25% bupivacaine The probe will be moved towards the biceps muscle until the musculocutaneous nerve is seen and 8 ml of 0.25% bupivacaine will be injected."
48660981|NCT04763109|OTHER|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
48660982|NCT05209035|DRUG|Trazodone|Trazodone 50mg daily
48660983|NCT05209035|OTHER|Placebo|Starch 50mg
48139925|NCT00253266|DRUG|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
48139926|NCT00253266|DRUG|Quetiapine|Quetiapine up to 200 mg/d for four weeks
48350648|NCT04709250|DRUG|bupivacaine|bupivacaine
48660984|NCT01358734|DRUG|Azacitidine|Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
48139927|NCT01513733|DRUG|tasquinimod|tasquinimod 0.25 mg continuously
48139928|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
48350649|NCT05817422|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
48139929|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
48139930|NCT02085512|PROCEDURE|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
48139931|NCT02085512|OTHER|Control, web-based tasks|No training modules
48139932|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
48139933|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
48139934|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
48503415|NCT02854592|DRUG|rtPA|intravenous thrombolysis with rtPa
48503416|NCT02854592|DRUG|urokinase|intravenous thrombolysis with urokinase
48503417|NCT01948713|OTHER|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
48139935|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
48350650|NCT05817422|OTHER|Placebo|0.9% NaCl solution for injection.
48503418|NCT01948713|OTHER|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
48503419|NCT02078427|BIOLOGICAL|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
48503420|NCT02078427|BIOLOGICAL|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
48503421|NCT00077753|DRUG|enoxaparin sodium|
48660985|NCT01358734|DRUG|Lenalidomide|Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
48660986|NCT01358734|OTHER|Best Supportive Care (BSC)|"The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support"
48618310|NCT03069989|DRUG|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
48660987|NCT06317844|BEHAVIORAL|Behavioral Writing Intervention|This behavioral intervention will require participants to write about certain aspects of their lives.
48660988|NCT01280669|DRUG|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
48660989|NCT01280669|DRUG|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
48660990|NCT03487133|DRUG|bortezomib/dexamethasone|"Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"
48660991|NCT04883463|DEVICE|Epidural stimulation|Epidural electrical stimulation implant weekly sessions for 21 months.
48350651|NCT04264494|PROCEDURE|PRP intra articular injection|Fifty RA patients were injected intra-articularly with 3 doses of PRP at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6 months post the last injection regarding the same evaluating tools.
48350652|NCT04264494|PROCEDURE|NACL intra articular injection|and 50 patients who serve as a control and injected intra-articularly with 3 doses of placebo (NaCl saline) at 4 weeks intervals for the joints with only tenderness (arthralgia without swelling or effusion) and revaluated at 3 and 6months post last injection regarding the same evaluating tools.
48350653|NCT01012037|DRUG|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
48350654|NCT01012037|DRUG|placebo|patient to receive placebo tablet(s) matching linagliptin
48350655|NCT01012037|DRUG|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
48350656|NCT06139094|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
48350657|NCT05371132|PROCEDURE|Positron Emission Tomography|Undergo PET
48350658|NCT05371132|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48350659|NCT05371132|DRUG|Zirconium Zr 89-Df-Crefmirlimab|Given IV
48350660|NCT05371132|RADIATION|Intensity Modulated Radiation Therapy|IMRT for Lymphoma patients only
48660992|NCT00933478|DEVICE|Clay|Small dime sized piece of clay.
48660993|NCT04227587|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
48350661|NCT03873428|OTHER|FES PET|FES injection
48503422|NCT06152406|PROCEDURE|Ablation and Pacemaker Implantation|All patients will be implanted with a pacemaker device with one lead positioned in right ventricle (control arm only) and an additional lead will be positioned on the distal (ventricular) HIS bundle if in intervention arm. All patients will undergo ablation.
48503423|NCT04676659|DRUG|TNK-tPA|Experimental arms for low, middle, and high dosing; and active control arm for the standard protocol
48503424|NCT00978263|DRUG|metformin-based Oral Antidiabetic Drugs|
48660994|NCT04227587|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
48660995|NCT04611243|BIOLOGICAL|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
48660996|NCT04611243|BIOLOGICAL|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
48660997|NCT04611243|BIOLOGICAL|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
48660998|NCT04611243|BIOLOGICAL|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
48660999|NCT06070376|DEVICE|Fully Covered Esophageal Prosthesis (FC-SEMS)|The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
48503425|NCT00978263|DRUG|Glargine|
48503426|NCT02111928|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
48350662|NCT02048657|DEVICE|Foley Airway Stylet Tool|
48350663|NCT02048657|DEVICE|introducer-tool|
48350664|NCT03582033|DRUG|SEA-BCMA|Given into the vein (IV; intravenously)
48350665|NCT03582033|DRUG|dexamethasone|Given by mouth (orally) or by IV
48350666|NCT03582033|DRUG|pomalidomide|Given orally
48350667|NCT03201744|PROCEDURE|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
48350668|NCT01661725|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
48350669|NCT03371303|OTHER|collection of prescription data|collection of prescription data before and after a hospitalization
48139936|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
48139937|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
48139938|NCT02570100|PROCEDURE|Biological collection|"Collection of blood samples and tumor specimens :~Biological collection before treatment :~* 1 tumor specimen (under echographic control)~* 4 blood collections~Biological collection during treatment :~* 1 tumor specimen after 3 cycles~* 4 blood collections after 3 and 6 cycles"
48139939|NCT05710757|OTHER|myofascial release|Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.
48139940|NCT05710757|DEVICE|blood flow restriction|Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.
48139941|NCT05710757|OTHER|myofascial release|Sham MFR.
48139942|NCT00236847|DRUG|topiramate|
48139943|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
48139944|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
48139945|NCT04819698|OTHER|Troponin I (cTnI ) monitoring|cTnI will be measured at baseline prior to surgery, as well as on 1h,12h, 24h and 72h after surgery for each patient in study B.
48139946|NCT02384382|DRUG|Enzalutamide|
48503427|NCT05487300|DRUG|Autonomic testing on and off levodopa|"Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa."
48139947|NCT03829553|RADIATION|Hypofractionated radiotherapy|4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
48139948|NCT03829553|RADIATION|Conventional radiotherapy|5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
48139949|NCT03540524|DRUG|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
48139950|NCT03540524|DRUG|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
48139951|NCT03540524|DRUG|GLPG2222|GLPG2222 tablet for oral use, daily.
48139952|NCT03540524|DRUG|GLPG2737|GLPG2737 capsules for oral use, daily.
48139953|NCT02386332|PROCEDURE|transplantation|
48139954|NCT05181735|DRUG|Luspatercept Injection [Reblozyl]|All patients will receive Luspatercept subcutaneously on day 1 of each 21 day cycle (every 3 weeks) at the selected dose according to part A : 1.75mg/kg or 1.33 mg/kg or 0.8 mg/kg
48139955|NCT05181735|DRUG|Eprex|Epoietin alfa will be adminstered as a subcutaneous injection at the selected dose according to part A : 30 000 UI/week or 60 000 UI/week, every week
48139956|NCT03868878|OTHER|Capoeira training|The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
48139957|NCT02843100|OTHER|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
48503428|NCT03801889|DRUG|SP-420|Self-administered by mouth
48661000|NCT06070376|DEVICE|Partially Covered Esophageal Prosthesis (PC-SEMS)|The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
48139958|NCT02843100|OTHER|Crohn's Disease Exclusion Diet|a limited whole food diet
48139959|NCT02843100|OTHER|Partial Enteral Nutrition|25-50% of Energy from formula
48139960|NCT02843100|OTHER|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
48139961|NCT02052687|DRUG|LFX453 H1|LFX453 high dose cream 1
48139962|NCT02052687|DRUG|LFX453 L1|LFX453 low dose cream 1
48139963|NCT02052687|DRUG|LFX453 H2|LFX453 high dose cream 2
48139964|NCT02052687|DRUG|LFX453 L2|LFX453 low dose cream 2
48139965|NCT02052687|DRUG|Imiquimod|Imiquimod cream
48139966|NCT02052687|DRUG|Placebo 1|Placebo cream 1
48139967|NCT02052687|DRUG|Placebo 2|Placebo cream 2
48139968|NCT04042298|OTHER|Arterial blood pressure|Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
48139969|NCT04042298|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
48139970|NCT04042298|OTHER|Brachial artery blood flow|A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
48139971|NCT04042298|OTHER|Venous blood draw|A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
48139972|NCT04988542|DIETARY_SUPPLEMENT|Circadian Wellness sleep SL strip|Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
48139973|NCT01282957|BEHAVIORAL|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
48139974|NCT01282957|BEHAVIORAL|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
48139975|NCT04388137|OTHER|No intervention.|No intervention.
48139976|NCT04740944|BEHAVIORAL|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
48139977|NCT05292066|DRUG|Duloxetine Tablets,|"Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,"
48139978|NCT05292066|DRUG|Pregabalin Tablets|Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
48139979|NCT02265120|BEHAVIORAL|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
48139980|NCT03631966|DRUG|Dysport|BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
48139981|NCT00147667|DRUG|Erythromycin|
48139982|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
48139983|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
48139984|NCT02753998|PROCEDURE|Conventional angioplasty|
48139985|NCT03269500|OTHER|use of nutrition education tools|"Use of different nutrition education tools :~* General advice: feeding seniors~* Oral supplementation: instructions for use~* Information about enriched food~* Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~* How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~* Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
48139986|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
48503429|NCT05986253|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
48139987|NCT01054859|OTHER|alcohol|0.5 g/kg alcohol
48139988|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD
48139989|NCT00349206|DRUG|sorafenib tosylate|Given orally
48139990|NCT00349206|DRUG|temsirolimus|Given IV
48139991|NCT01685268|DRUG|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
48139992|NCT01685268|DRUG|abiraterone acetate|1000 mg PO daily.
48139993|NCT01685268|DRUG|Prednisone|5 mg PO twice daily.
48350670|NCT02909920|OTHER|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
48503430|NCT05986253|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin solution
48350671|NCT02909920|OTHER|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
48350672|NCT02240992|BIOLOGICAL|PBSC|
48350673|NCT02240992|BIOLOGICAL|MSCs|
48350674|NCT01287988|DRUG|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
48350675|NCT01287988|DRUG|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
48350676|NCT02530827|DRUG|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
48350677|NCT03016832|DRUG|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
48350678|NCT03016832|DRUG|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
48350679|NCT03016832|DRUG|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
48350680|NCT03016832|DRUG|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
48350681|NCT03882736|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
48350682|NCT02026934|DEVICE|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
48350683|NCT03455504|DRUG|Venetoclax|Venetoclax add in combination with fludarabine, cyratabine and idarubicine
48139994|NCT00623337|BEHAVIORAL|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy \& 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify \& refer sick babies
48350684|NCT00934713|DRUG|montelukast|montelukast 4mg once per day for 8 weeks period
48350685|NCT02630394|DRUG|Azithromycin|
48350686|NCT01894776|DRUG|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
48350687|NCT01894776|DRUG|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
48350688|NCT01243203|DRUG|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
48350689|NCT00731952|DRUG|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
48350690|NCT03613168|DRUG|Trastuzumab|Trastuzumab plus gemcitabine/cisplatin
48350691|NCT03652506|DEVICE|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
48350692|NCT03652506|PROCEDURE|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
48350693|NCT03652506|PROCEDURE|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
48350694|NCT04717167|OTHER|Dry Needling|
48350695|NCT04717167|OTHER|Sham Needling|
48350696|NCT01599819|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
48350697|NCT01599819|BIOLOGICAL|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
48350698|NCT05939193|PROCEDURE|Urine-guided hydration|The target is to maintain urine output at 200 ml/h (3 ml/kg/h) or higher by intravenous injection/infusion of furosemide throughout surgery. That is, a loading dose of 20 mg is injected at the beginning of surgery; if urine output does not reach the target value, furosemide will be continuously infused at 10 mg/h until the end of surgery, with a cumulative dose not exceeding 250 mg. Intravenous rehydration is performed to balance urine output and to maintain the SVV ≤10%.
48350699|NCT05939193|PROCEDURE|Routine hydration|The target is to maintain urine output at 0.5 ml/kg/h or higher according to routine practice. That is, furosemide is only administered when clinically necessary or at discretion of responsible anesthesiologists; intravenous rehydration is performed to maintain the SVV ≤10%.
48350700|NCT05939193|DRUG|Forced administration of furosemide|Forced administration of furosemide
48350701|NCT05939193|DRUG|Routine administration of furosemide|Routine administration of furosemide
48350702|NCT02927535|DRUG|TNF blockers monotherapy|
48350703|NCT01498770|DRUG|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
48350704|NCT01498770|DRUG|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
48350705|NCT01498770|DRUG|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
48350706|NCT01498770|DRUG|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
48350707|NCT01498770|DRUG|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
48350708|NCT01498770|DRUG|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
48139995|NCT05328258|DRUG|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
48350709|NCT01498770|DRUG|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
48139996|NCT05328258|DRUG|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
48503431|NCT03062423|DRUG|Sofodelevier|1 tablet contains 400 mg sofosbuvir
48503432|NCT03062423|DRUG|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
48661001|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
48139997|NCT04828096|OTHER|Orthodontic retention|The stability of the mandibular anterior teeth after two resp. 5 years of retention
48139998|NCT05266300|GENETIC|DPYD genotype|"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)"
48139999|NCT03184987|DRUG|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
48140000|NCT03184987|DRUG|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
48503433|NCT03062423|DRUG|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
48140001|NCT03184987|DRUG|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
48140002|NCT03184987|OTHER|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
48140003|NCT03393559|PROCEDURE|leg elevation|Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
48140004|NCT02379000|DRUG|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
48140005|NCT02379000|PROCEDURE|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
48350710|NCT01498770|DRUG|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
48503434|NCT03683030|DEVICE|Multi-Electrode RF Balloon Catheter|Multi-Electrode RF Balloon Catheter will be inserted
48503435|NCT06273930|DRUG|5% CALCIUM SODIUM PHOSPHOSILICATE|Calcium sodium phosphosilicate is a particulate, bioactive glass material that degrades in the aqueous oral environment to release calcium and phosphate ions, leading to formation of hydroxycarbonate apatite on the dentine surface result in reduction in dentine hypersenstivity
48503436|NCT06273930|DRUG|8% Arginine|Arginine contributes to Whole Mouth Health. It also plays a role with respect to dental caries, helping to maintain a pH-neutral environment, and is proven to rapidly help relieve dentin sensitivity. Arginine is truly a remarkable ingredient now being used in oral care products.
48140006|NCT01976507|DRUG|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
48350711|NCT01498770|DRUG|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
48350712|NCT01498770|DRUG|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
48503437|NCT04868994|DIAGNOSTIC_TEST|Whole Body MRI and ENMG|Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
48503438|NCT05908630|OTHER|Hypothermia|"Accidental hypothermia is defined as: an involuntary drop in core body temperature \<35C"
48350713|NCT01498770|DRUG|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
48350714|NCT01498770|DRUG|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
48350715|NCT01498770|DRUG|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
48350716|NCT03249480|BIOLOGICAL|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
48350717|NCT02049294|BIOLOGICAL|Omalizumab (Xolair)|
48350718|NCT02049294|DRUG|Placebo|
48350719|NCT01071941|BIOLOGICAL|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
48350720|NCT02578095|DRUG|VK5211|Capsule
48503439|NCT06232798|OTHER|a dual energy catheter (RF and PFA) or PFA catheter only will be to treat PeAF,Cardiac Pulsed Electric Field Ablation Catheter|This study will be used two catheters, the contact force sensing catheter able to deliver both RF and PFA energy, this catheter provides both the radiofrequency (RF) energy and pulsed field ablation (PFA) energy to the catheter through the toggling of the two energy sources on the generator monitor. Another catheter is PFA catheter only.
48661002|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
48140007|NCT04572867|DEVICE|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
48140008|NCT04572867|DRUG|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
48503440|NCT06232798|OTHER|catheter ablation|catheter ablation
48140009|NCT05316259|DRUG|BPI-16350|Administered orally
48503441|NCT04604886|DIAGNOSTIC_TEST|Passive Leg Raising|Passive leg raising is induced by rasing the legs of patients to 45° from horizontal position.
48140010|NCT00144235|DRUG|Pharmaton PHL 00749|
48140011|NCT00144235|DRUG|Placebo|
48140012|NCT01368874|DEVICE|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
48140013|NCT03267537|BEHAVIORAL|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
48350721|NCT02578095|DRUG|Placebo|Capsule
48350722|NCT03552900|BEHAVIORAL|7cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
48350723|NCT03552900|BEHAVIORAL|Bliss|Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
48350724|NCT03209986|PROCEDURE|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
48350725|NCT03209986|OTHER|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
48350726|NCT05622968|DEVICE|Foley catheter|Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
48350727|NCT05622968|DRUG|Intravaginal prostaglandin E2|Insertion of intravaginal Dinoprostone
48350728|NCT04827173|PROCEDURE|transcutaneous medium-frequency alternating current|Patients receive nerve block of right forearm through transcutaneous medium-frequency alternating current
48661003|NCT05884125|DEVICE|Checkpoint BEST System|Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
48661004|NCT01495013|DRUG|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
48661005|NCT01495013|DRUG|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
48350729|NCT03190681|DRUG|Ritalin 10Mg Tablet|ingestion of an oral single-dose
48350730|NCT01378676|DRUG|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
48350731|NCT01378676|DRUG|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
48140014|NCT03267537|BEHAVIORAL|Conventional office-based CBT-I|Conventional office-based CBT-I
48140015|NCT02236611|DRUG|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
48140016|NCT02236611|DRUG|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
48140017|NCT01264172|PROCEDURE|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
48140018|NCT01264172|PROCEDURE|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
48140019|NCT01264172|PROCEDURE|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
48140020|NCT01315977|DIETARY_SUPPLEMENT|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
48140021|NCT01756599|BIOLOGICAL|blood samples|
48140022|NCT01779050|DRUG|Doxorubicin|
48140023|NCT01779050|BIOLOGICAL|Trastuzumab|
48140024|NCT01779050|DRUG|Cyclophosphamide|
48140025|NCT01779050|DRUG|Paclitaxel|
48350732|NCT01378676|DRUG|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
48503442|NCT04604886|DIAGNOSTIC_TEST|Dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. hemodynamic data were recorded from PAC and LiDCO after 5-10 minutes of continuous infusion.
48140026|NCT01779050|DRUG|Epirubicin|
48350733|NCT01378676|DRUG|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
48350734|NCT01378676|DRUG|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
48503443|NCT02740699|DRUG|Rosuvastatin|Participants will receive 20-40 mg once daily
48503444|NCT02740699|DRUG|Atorvastatin|Participants will receive 40-80 mg once daily.
48661006|NCT01495013|DRUG|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
47985235|NCT06297863|PROCEDURE|HEAD DOWN TILT -10° to -15°|"Head down tilt -10° to -15° (HDT15) is a positional therapy consisting of tilting the patient with the head -10° to -15° degrees below the rest of the body.~Application of HDT15 will not delay usual care. The standard in-hospital patient pathway, including transfer from neuroimaging room to the angiography suite and the required procedural steps of MT, will allow sufficient time for the application of HDT15. HDT15 duration is expected to be at least 30 minutes (estimated time 30 to 90 minutes), from start to the assessment of the primary efficacy endpoint.~The actual degree of HDT15 will be a range between -10° to -15°, depending on the angiographic system of each clinical site, but it will be maintained at -15° during the Emergency Room phase which is expected to account for \>50% of the total application time."
48140027|NCT01779050|DRUG|Docetaxel|
48140028|NCT01779050|DRUG|Carboplatin|
48140029|NCT01779050|DRUG|Fluorouracil|
48140030|NCT00199056|DRUG|Dexamethasone / Prednisolone|
48140031|NCT00199056|DRUG|Cyclophosphamide|
48140032|NCT00199056|DRUG|Methotrexate|
48140033|NCT00199056|DRUG|Vincristine / Vindesine|
48140034|NCT00199056|DRUG|Daunorubicin|
48503445|NCT02740699|RADIATION|Cardiac Computed Tomography (CT)|Cardiac CT angiography (CCTA) provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Performed at baseline, 12 months 24 months, and 36 months.
48661007|NCT01495013|DRUG|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
47985236|NCT04804410|DEVICE|LCR Meter (Brand: Keysight, Serial Number:E498AL)|The LCR meter is used for electric property analysis of tissues. It works by measuring impedance on multiple sections of excised tissue and translating those measurement into dielectric properties.
47985237|NCT01148121|OTHER|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
47985238|NCT03128112|OTHER|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
47985239|NCT00862745|DRUG|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
47985240|NCT00862745|DRUG|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
47985241|NCT02759679|OTHER|Human breath samples|
47985242|NCT05829889|PROCEDURE|FFR-Guided PCI|Fractional Flow Reserve-Guided PCI
48140035|NCT00199056|DRUG|Asparaginase|
48140036|NCT00199056|DRUG|G-CSF|
48140037|NCT00199056|DRUG|Cytarabine|
48140038|NCT00199056|DRUG|6-Mercaptopurine|
48140039|NCT00199056|DRUG|VP16|
48503446|NCT02740699|RADIATION|Cardiac Magnetic Resonance Image (MRI)|Provides a non-invasive method of evaluating both calcified and noncalcified plaque volume. Cardiac MRI may be performed at baseline, and 24 months (optional).
48661008|NCT01495013|DRUG|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
48661009|NCT01495013|DRUG|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
48661010|NCT01495013|DRUG|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
48140040|NCT00199056|DRUG|Adriamycin|
48140041|NCT00199056|DRUG|Thioguanine|
48140042|NCT00199056|DRUG|VM26|
48140043|NCT00199056|DRUG|Idarubicin|
48140044|NCT00199056|DRUG|Fludarabine|
48140045|NCT00199056|DRUG|Ifosfamide|
48140046|NCT00199056|PROCEDURE|CNS irradiation|
48140047|NCT00199056|PROCEDURE|Mediastinal irradiation (if residual tumor)|
48140048|NCT00199056|PROCEDURE|stem cell transplantation|
48140049|NCT00637104|DEVICE|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
48140050|NCT00637104|DEVICE|Vision Co-Cr stent implant|Implant of the Vision stent
48140051|NCT03939897|DRUG|Abemaciclib|Given PO
48140052|NCT03939897|PROCEDURE|Biopsy|Undergo tissue biopsy
48140053|NCT03939897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48140054|NCT03939897|DRUG|Copanlisib Hydrochloride|Given IV
48140055|NCT03939897|PROCEDURE|Diagnostic Imaging|Undergo imaging
48140056|NCT03939897|PROCEDURE|Echocardiography|Undergo ECHO
48140057|NCT03939897|DRUG|Fulvestrant|Given IM
48140058|NCT03939897|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48140059|NCT02746107|OTHER|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
48140060|NCT00806767|BIOLOGICAL|therapeutic immune globulin|
48140061|NCT00806767|DRUG|busulfan|
48140062|NCT00806767|DRUG|fludarabine phosphate|
48140063|NCT00806767|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48350735|NCT01378676|DRUG|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
48350736|NCT01378676|DRUG|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
48661011|NCT01495013|DRUG|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
48661012|NCT01495013|DRUG|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
48350737|NCT01378676|DRUG|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
48350738|NCT01378676|DRUG|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
48350739|NCT03304912|BEHAVIORAL|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
48350740|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
48350741|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
48350742|NCT03665493|BEHAVIORAL|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
48350743|NCT03665493|DRUG|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
48350744|NCT03665493|DRUG|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
48350745|NCT01401985|DRUG|TD-1211|Capsules
48350746|NCT01401985|DRUG|Placebo|Capsules
48350747|NCT02238236|DRUG|Alesion®|Dry Syrup
48503447|NCT01404832|DRUG|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
48661013|NCT01495013|DRUG|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
48140064|NCT02923479|DEVICE|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
48661014|NCT01495013|DRUG|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
48661015|NCT01495013|DRUG|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
48661016|NCT01495013|DRUG|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
48140065|NCT02923479|OTHER|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
48140066|NCT02923479|OTHER|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
48661017|NCT01495013|DRUG|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
47985243|NCT05829889|PROCEDURE|Angiography-Guided PCI|Angiography-Guided PCI
48140067|NCT02923479|DEVICE|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
48350748|NCT00054860|BIOLOGICAL|EP HIV-1090|
48350749|NCT04426240|DRUG|Cyclosporine microemulsion|Intervention group receives topical cyclosporine dry eye treatment before cataract surgery
48350750|NCT00554853|DRUG|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
48350751|NCT00554853|DRUG|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
48350752|NCT05454241|DRUG|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
48350753|NCT00632515|BEHAVIORAL|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
48350754|NCT02961400|OTHER|PUSH text messages|The intervention is designed to remind participants of treatment components.
48350755|NCT02961400|OTHER|PULL text messages|The intervention is designed to remind participants to recall treatment components.
48350756|NCT02961400|BEHAVIORAL|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
48350757|NCT02961400|BEHAVIORAL|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
48350758|NCT01271127|RADIATION|CT coronary angiography|patient will undergo one CT coronary angiography
48350759|NCT05200104|DRUG|PXL065|PXL065 22.5 mg QD
48661018|NCT05946551|DRUG|Cetirizine|Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
47985244|NCT00940394|BEHAVIORAL|mutual support group|bi-weekly, 12-session, family-led mutual support group
48140068|NCT02923479|DEVICE|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
48140069|NCT00239512|DRUG|Indomethacin and Ibuprofen|
48140070|NCT05014607|BIOLOGICAL|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 1-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
48140071|NCT02040870|DRUG|LDK378|750 mg once daily
48140072|NCT02540031|DRUG|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
48140073|NCT02540031|DRUG|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
48140074|NCT01619059|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
48140075|NCT01619059|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
48140076|NCT01619059|DRUG|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
48140077|NCT01619059|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
48140078|NCT03041961|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
48350760|NCT04634318|OTHER|Respiratory rehabilitation program (RR).|"Patients in the RR group will follow the respiratory rehabilitation program during a 4-week hospitalization in the respiratory diseases department of Renée Sabran hospital (Hyères, France).~The program includes for each week:~One medical consultation Four 40-min sessions of aerobic exercises on an ergocycle Four 1-hour sessions of walking in Renée Sabran Hospital's park Three 1-hour sessions of muscle strengthening exercises One 1-hour session of sophrology One 1-hour session of occupational therapy One 1-hour session of psychomotricity"
48503448|NCT05202730|PROCEDURE|New local anesthesia injection site and new local anesthetic drug formulation.|The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.
48503449|NCT03751618|PROCEDURE|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
48503450|NCT03139786|OTHER|Study the natural history of bicuspid|Study the natural history of bicuspid
48503451|NCT04277143|DRUG|Daptomycin|"Adult patients are given the recommended dose of daptomycin for injection. Patients with creatinine clearance (CLCR) ≥ 30 mL / min: 6 mg / kg every 24 hours.~Patients with creatinine clearance (CLCR) \<30mL / min (including hemodialysis or peritoneal dialysis): 6mg / kg every 48 hours. Dissolve 6mg / kg of this drug in 0.9% sodium chloride injection and instill it over a 30-minute time course once every 24 or 48 hours."
48503452|NCT03383237|DRUG|Apatinib|500mg/d,q.d.,p.o.
48503453|NCT03521466|BEHAVIORAL|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
48503454|NCT01679639|DRUG|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
48661019|NCT05946551|DRUG|Famotidine|Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.
48140079|NCT03041961|DIETARY_SUPPLEMENT|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
48140080|NCT03041961|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
48140081|NCT01662388|DEVICE|Separation ring|Separation ring placed along with automatrix band
48661020|NCT05946551|DRUG|Cetirizine Placebo|The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.
48661021|NCT05946551|DRUG|Famotidine Placebo|The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
48661022|NCT06455904|PROCEDURE|Training sessions|The training program will be performed during 15 weeks, with one session per week.
48661023|NCT04548960|OTHER|cancer patients|Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
47985245|NCT00940394|BEHAVIORAL|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
48140082|NCT01662388|DEVICE|automatrix band|band placed with a tightening device
48503455|NCT01679639|DRUG|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
48503456|NCT02555748|DRUG|Pazopanib|
48503457|NCT02555748|DRUG|Sunitinib|
48503458|NCT03463473|DRUG|3 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 3 mg/kg (Q3W)
48503459|NCT03463473|DRUG|10 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q3W)
48503460|NCT03463473|DRUG|20 mg/kg Q3W MSB2311 Injection|An intravenous infusion with concentration from 20 mg/kg (Q3W)
48503461|NCT03463473|DRUG|10 mg/kg Q2W MSB2311 Injection|An intravenous infusion with concentration from 10 mg/kg (Q2W)
48503462|NCT03483727|DEVICE|SIMMAXMARCHERYAN|Digital cognitive aid during the management of simulated combat wounded.
48503463|NCT04365218|DRUG|MEDI8367|Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.
48503464|NCT04365218|DRUG|Placebo|Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
48503465|NCT03681236|PROCEDURE|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
48503466|NCT05563376|DIAGNOSTIC_TEST|Univentricular Hearts|Prevention when factors are recognized
48503467|NCT03357835|OTHER|Trauma Decision System|At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
47985246|NCT00940394|OTHER|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
47985247|NCT00041327|BIOLOGICAL|filgrastim|5 ug/kg/d
47985248|NCT00041327|BIOLOGICAL|recombinant interferon alfa|9 mU subcutaneously per day for one year
47985249|NCT00041327|DRUG|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
47985250|NCT00041327|DRUG|cyclophosphamide|750 mg/m2 IV on day 5
47985251|NCT00041327|DRUG|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
47985252|NCT00041327|DRUG|lamivudine|150 mg bid
47985253|NCT00041327|DRUG|prednisone|60 mg/m2 given orally days 1-5
47985254|NCT00041327|DRUG|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
47985255|NCT00041327|DRUG|zidovudine|300 mg bid
47985256|NCT05710549|DEVICE|high-density electroencephalography (hdEEG)|EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
47985257|NCT05710549|DEVICE|Transcranial alternating current stimulation (tACS)|tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
47985258|NCT01779739|PROCEDURE|Perineorrhaphy|Procedure to build up the vaginal opening
47985259|NCT04053023|DRUG|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
47985260|NCT04053023|DRUG|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
47985261|NCT02998840|BIOLOGICAL|B244|odorless suspension
47985262|NCT02998840|BIOLOGICAL|Vehicle|odorless suspension
47985263|NCT00602147|OTHER|laboratory biomarker analysis|Blood or cheek cells wil be collected.
48140083|NCT00395759|DRUG|Optiva artificial tear by Allergan|
48140084|NCT04105751|DEVICE|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
48503468|NCT01085201|DRUG|Lexiscan|Given as an infusion
48503469|NCT04631952|BEHAVIORAL|Online exercise|SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
48503470|NCT04631952|BEHAVIORAL|SMS message|SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
48503471|NCT05646043|BEHAVIORAL|Physical training|Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.
48503472|NCT05646043|BEHAVIORAL|Muscle strength training|Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.
48503473|NCT00552851|DRUG|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
48661024|NCT04259216|BEHAVIORAL|IMPACT Intervention|Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
48661025|NCT04259216|OTHER|Control: Enhanced Online Resources (EOR)|EOR group participants will receive standardized information on cyberbullying.
48661026|NCT00656370|DRUG|recombinant human hyaluronidase|150 Units in 1mL
48661027|NCT03102086|PROCEDURE|Scaling|Scaling of dental calculus
48661028|NCT05393492|BEHAVIORAL|Dialectical Behavior Therapy and Radically Open dialectical behavior therapy|"Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions."
48661029|NCT03451851|DRUG|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
48661030|NCT03451851|DRUG|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
48661031|NCT03451851|DRUG|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
48661032|NCT01217892|DRUG|dapagliflozin|2.5 mg tablet, taken orally, twice daily
48661033|NCT01217892|DRUG|dapagliflozin|5 mg tablet taken orally, twice daily
48661034|NCT01217892|DRUG|dapagliflozin|10 mg tablet taken orally, once daily
48661035|NCT01217892|DRUG|metformin|\>/= 1500 mg total daily dose, tablets taken orally, twice daily
48661036|NCT01217892|DRUG|placebo|placebo
48661037|NCT00319189|DRUG|Nateglinide|
48661038|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
48661039|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
48661040|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
48661041|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
48661042|NCT01415947|DEVICE|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
48661043|NCT02908217|DRUG|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
48661044|NCT02908217|DRUG|Placebo|6 Intravenous infusions of placebo every 4 weeks.
48661045|NCT00661856|DIETARY_SUPPLEMENT|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
48661046|NCT01765387|BEHAVIORAL|Spa session|
48503474|NCT04459507|OTHER|No intervention|No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
48661047|NCT01859013|DRUG|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
48661048|NCT01859013|OTHER|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
48661049|NCT01781988|DRUG|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
48661050|NCT02136992|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
48661051|NCT02136992|DRUG|placebo|placebo will be taken two tablets 3 times a day during the whole study process
48661052|NCT06055283|OTHER|Aerobic exercise|The training group will receive aerobic exercise and the intensities will be controlled considering the percentage of estimated maximum heart rate. The training will be performed with a cycle ergometer with a total of 40 minutes of intradialytic aerobic exercise in the training group. To reduce the effects of intolerance to aerobic exercise, a week of adaptation will be performed, with a frequency of three sessions, in the first two hours of hemodialysis, lasting 40 minutes at maximum heart rate intensity of up to 74% and BORG up to 4 (low intensity). Afterwards, the patients will perform the prediction training for 12 weeks, at the frequency of three training sessions per week in the first two hours of hemodialysis. Each training session will start with a 5-minute warm-up at low intensity, 30 minutes of main training with maximum heart rate intensity 55% to 74% and BORG 5 to 7 (moderate intensity) and will end with a 5-minute cool-down at low intensity.
48661053|NCT06481631|BEHAVIORAL|The PEN-3 Intervention Model|The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta.
48661054|NCT06571539|DEVICE|AR-assisted EVD placement|Cfr. arm description
48661055|NCT06571539|PROCEDURE|Freehand EVD placement|External ventricular drain (EVD) placement using the conventional freehand technique. This intervention covers the matched, non-concurrent control group, retrospectively obtained without active enrollment to receive study treatment.
48503475|NCT03450174|DIETARY_SUPPLEMENT|Placebo|In control group, participants will receive only a placebo product
48503476|NCT03450174|BEHAVIORAL|Formative messgaes|In this group, participants will only receive daily formative messages
48503477|NCT03450174|DIETARY_SUPPLEMENT|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
48503478|NCT03450174|COMBINATION_PRODUCT|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
48661056|NCT05954884|OTHER|Telemedicine-based WHO HEARTS package|"Interventions in this study will include-~1. Community- and team-based model of hypertension care delivery~2. Opportunistic hypertension screening at Community Clinic (CC) by Community Health Care Provider (CHCP)~3. Use of a hypertension treatment protocol with amlodipine and losartan and standardized approach to measuring and monitoring BP, retaining participants in care, and promoting adherence~4. Use of Simple App to document BP readings and medications/dosage and to monitor hypertension care delivery at the CC through utilities including dashboards~5. Establishment of telemedicine service between CC and Upazila Health Complex (UHC)~6. Community-based, multi-month prescription refills from CC~7. Training of clinic and research staff on BP measurement following standard techniques~8. Site monitoring and mentorship to ensure screening and patient enrollment/registration~9. Use of text messages to promote follow-up visits and medication adherence"
48140085|NCT06510673|DRUG|Platelet rich plasma|Platelet-rich plasma for the heel
48140086|NCT06510673|OTHER|High power LASER|High power LASER sessions for the heel
48350761|NCT04634318|OTHER|Respiratory tele-rehabilitation program (TRR).|Patients in the TRR group will realize the 4-week respiratory tele-rehabilitation program at home. The TRR program for each week includes the same sessions as RR program. But, medical consultation, sophrology, occupational therapy, psychomotricity and muscle strengthening sessions are carried out through live videoconferences. Additionally, aerobic and walking sessions are carried out outside home. The intensity of each session will be controlled by heart rate monitor.
48350762|NCT01304927|DRUG|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
48350763|NCT01304927|OTHER|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
48503479|NCT01286935|DRUG|Safinamide|
48503480|NCT01286935|DRUG|Safinamide|
48503481|NCT01286935|DRUG|Placebo|
48503482|NCT06028321|DRUG|Part 1 Group 1 Regime A (ACM-001.1)|"Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B."
48661057|NCT05266495|OTHER|Brolucizumab|There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
48350764|NCT00166621|DRUG|Buspirone|
48350765|NCT00945269|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
48350766|NCT00945269|BIOLOGICAL|aldesleukin|Given SC
48350767|NCT00945269|BIOLOGICAL|denileukin diftitox|Given IV
48350768|NCT00945269|PROCEDURE|biopsy|Optional correlative studies
48503483|NCT06028321|DRUG|Part 1 Group 2 Regimen C (Pindolol)|Drug: Pindolol tablets for oral use.
48503484|NCT06028321|DRUG|Part 2 Group D (Pindolol)|Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
48140087|NCT06510673|OTHER|Shockwave therapy|Shockwave therapy sessions for the heel
48140088|NCT06510673|OTHER|Ice application|Ice application for the heel
48140089|NCT06510673|OTHER|Sham LASER|Sham LASER for the heel
48140090|NCT00861003|DEVICE|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
48140091|NCT05636397|DIETARY_SUPPLEMENT|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
48140092|NCT00775892|DEVICE|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
48140093|NCT02118922|PROCEDURE|Brillouin imaging|
48140094|NCT03294967|DIETARY_SUPPLEMENT|Caffeine|As in group descriptions
48350769|NCT00945269|OTHER|immunohistochemistry staining method|Correlative studies
48350770|NCT00945269|OTHER|laboratory biomarker analysis|Correlative studies
48350771|NCT00945269|GENETIC|polymerase chain reaction|Correlative studies
48503485|NCT06028321|DRUG|Part 2 Group E (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
48503486|NCT06028321|DRUG|Part 2 Group F (ACM-001.1 )|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
48661058|NCT00331721|DRUG|Enecadin|Dose escalating
48661059|NCT00331721|DRUG|Placebo|Placebo comparator
48661060|NCT05745922|BEHAVIORAL|Moderate intensity exercise|Treadmill walking/running with moderate intensity
48661061|NCT05745922|BEHAVIORAL|High intensity exercise|Treadmill walking/running with high intensity
48661062|NCT00934921|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
48661063|NCT00934921|DRUG|Zofran®|1 x 8 mg ODT
48661064|NCT04395547|DIETARY_SUPPLEMENT|JointAlive™|Combination herbal extract
48661065|NCT04395547|DIETARY_SUPPLEMENT|Placebo|Combination placebo product
48661066|NCT00140686|BIOLOGICAL|Rotavirus (vaccine)|
48350772|NCT03258450|BEHAVIORAL|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
48350773|NCT05387135|DEVICE|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
48350774|NCT05762965|DIETARY_SUPPLEMENT|GOS 1|1 sachet each morning
48350775|NCT05762965|DIETARY_SUPPLEMENT|GOS 2|1 sachet each morning
48350776|NCT02559115|RADIATION|68Ga-RM2 (RM2)|
48503487|NCT06028321|DRUG|Part 2 Group G (ACM-001.1)|Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
48503488|NCT06028321|DRUG|Part 1 Group 1 Regimen B (Pindolol)|Drug: pindolol tablets for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
48503489|NCT06028321|OTHER|Part 1 Group 1 Regimen A (Placebo)|Placebo for oral use. Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
48503490|NCT06028321|OTHER|Part 2 Group E (Placebo)|"Placebo for oral use. Subjects were dosed over a four day treatment period twice daily.~Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D."
48661067|NCT04440774|BIOLOGICAL|CHIK low dose|A single dose of 5x10\^9 vp ChAdOx1 Chik
48661068|NCT04440774|BIOLOGICAL|CHIK mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Chik
48661069|NCT04440774|BIOLOGICAL|CHIK high dose|A single dose of 5x10\^10 vp ChAdOx1 Chik
48661070|NCT04440774|BIOLOGICAL|ZIKA low dose|A single dose of 5x10\^9 vp ChAdOx1 Zika
48661071|NCT04440774|BIOLOGICAL|ZIKA mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Zika
48661072|NCT04440774|BIOLOGICAL|ZIKA high dose|A single dose of 5x10\^10 vp ChAdOx1 Zika
48661073|NCT04440774|BIOLOGICAL|Saline placebo|A single dose of isotonic saline solution (0.9%)
48661074|NCT05949593|DRUG|Tinlarebant|5 mg tablet taken orally once a day
48661075|NCT05949593|DRUG|Placebo|Placebo tablets for tinlarebant 5 mg prepared similarly.
48661076|NCT02978495|DRUG|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
48661077|NCT02978495|DRUG|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
48661078|NCT02978495|DRUG|Paclitaxel|80mg/m2 weekly for 12 weeks
48350777|NCT02559115|DEVICE|PET/CT Scan|
48350778|NCT02000544|DEVICE|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
48350779|NCT05794672|DRUG|Elarekibep|Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
48350780|NCT05794672|DRUG|Placebo|Subjects will receive single or multiple inhaled doses A, B or C.
48350781|NCT05067114|DEVICE|Screening, detection and referral for atrial fibrillation|In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
48350782|NCT02034539|DEVICE|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
48140095|NCT03294967|DIETARY_SUPPLEMENT|Vitamin E|As in group descriptions
48367492|NCT06453421|OTHER|Pulmonary rehabilitation|Enrolled patients are subjected to a personalized respiratory rehabilitation treatment aimed both at weaning from the tracheostomy tube and at functional recovery
48661079|NCT02978495|DRUG|Cyclophosphamide|600mg/m2 4 cycles each 21 days
48661080|NCT03935347|DRUG|Cyclophosphamide|Given IV
48661081|NCT03935347|DRUG|Fludarabine|Given IV
48661082|NCT03935347|DRUG|Fludarabine Phosphate|Given IV
48661083|NCT03935347|BIOLOGICAL|Pembrolizumab|Given IV
48661084|NCT03935347|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
48661085|NCT03935347|BIOLOGICAL|Aldesleukin|Given IV
48661086|NCT03781986|DRUG|APG-115|APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
48661087|NCT03781986|DRUG|Carboplatin|Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
48661088|NCT03067636|BEHAVIORAL|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
48661089|NCT03067636|BEHAVIORAL|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
48140096|NCT05387863|OTHER|Decision Aid (DA) Web Tool|The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information.
48661090|NCT03067636|BEHAVIORAL|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
48661091|NCT02692534|OTHER|Urine cocaine negative|Preoperative urine cocaine negative
48661092|NCT02692534|OTHER|Urine cocaine positive|Preoperative urine cocaine positive
48140097|NCT05387863|OTHER|Institutional Pamphlet|The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
48350783|NCT06077136|OTHER|whole body vibration|"3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~* WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~* frequency: 12 Hz~* Amplitude: 2 (fixed)~* duration of each exercise: 2-3 minutes~* starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~* upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~* coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises."
48350784|NCT06077136|OTHER|standard physical therapy|all children will receive regular exercises according to their developmental abilities such as stretching, strengthening, facilitation, or inhibition as well as functional exercises. exercise sessions will be 3 times per week fo
48350785|NCT00807443|DRUG|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp \& Dohme. A dose of 400 mg will be administered every 12 hours
48350786|NCT02407691|OTHER|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
48350787|NCT02407691|OTHER|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
48350788|NCT00823186|DRUG|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
48350789|NCT03566992|PROCEDURE|Gastric|Placement of a nasoenteric tube
48350790|NCT02647892|DRUG|lidocaine|local anesthesia
48350791|NCT02647892|DRUG|sodium bicarbonate|additional drug added to lidocaine
48350792|NCT05820282|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for increasing delivery of behaviour change interventions
48350793|NCT05820282|OTHER|Control condition|Participants are asked to identify situations and solutions and place a tick next to each one they think would be useful to them. Therefore, participants in the control condition are not asked to form implementation intentions.
48350794|NCT01427127|DRUG|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
48350795|NCT02411877|PROCEDURE|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
48503491|NCT06028321|OTHER|Part 2 Group F (Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
48503492|NCT06028321|OTHER|Part 2 Group G ( Placebo)|Placebo for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
48503493|NCT01724489|DRUG|Growth hormone|
48503494|NCT01724489|DRUG|Placebo|
48503495|NCT03850314|DIETARY_SUPPLEMENT|Glycine|Glycine powder to be dissolved in water.
48140098|NCT00772902|DRUG|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
48513407|NCT04060095|PROCEDURE|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
48513408|NCT01105793|DRUG|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
48513409|NCT06259435|BEHAVIORAL|Low-energy dense diet|Subjects will follow time-restricted eating of a low energy dense diet
48513410|NCT06259435|BEHAVIORAL|Usual diet|Subjects will follow time-restricted eating of the usual diet
48513411|NCT06222931|DEVICE|Triplanar vibrating platform|Mechanical vibration emitted by triplanar vibrating platforms
48140099|NCT00772902|DRUG|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
48350796|NCT02411877|PROCEDURE|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
48350797|NCT02411877|DEVICE|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
48350798|NCT02411877|DEVICE|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
48513412|NCT06222931|DEVICE|Side-alternating vibrating platform|Mechanical vibration emitted by side-alternating vibrating platforms
48350799|NCT04054219|DEVICE|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
48350800|NCT03922711|DRUG|Pridopidine|Oral capsule
48350801|NCT03922711|DRUG|Placebo|Oral capsule
48350802|NCT02573506|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.
48350803|NCT02573506|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
48350804|NCT05841069|PROCEDURE|Adhesiolysis|Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.
48350805|NCT05841069|RADIATION|X-ray examination|Plain X-ray of abdomen (1-4 times) with water insoluble contrast.
48350806|NCT05841069|PROCEDURE|Conservative treatment|A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.
48350807|NCT03080701|BEHAVIORAL|Auto Mailing Plus Money|Participant receives money as a thank you for completing CRC screening within 6 months.
48503496|NCT04973930|BEHAVIORAL|Interpersonal Psychotherapy|Time-limited, affect-focused, empirically supported psychotherapy
48503497|NCT04973930|DRUG|Venlafaxine HCl ER|FDA-approved antidepressant medications
48661093|NCT02663362|OTHER|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
48661094|NCT05054101|OTHER|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
48661095|NCT02494115|PROCEDURE|subcutaneous drainage|
48661096|NCT01829451|OTHER|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~--------------------------------------------------------------------------------"
48661097|NCT02020226|DRUG|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
47914844|NCT05181293|BEHAVIORAL|Mobile Gaming App for Nutrition Intervention|A mobile gaming app (BabyThrive) will be disseminated to teenage mothers to help them learn about exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency and dietary diversity. BabyThrive will also demonstrate how to prepare 30 nutritious recipes for complementary feeding; create a calendar and set reminders to prompt mothers to access child health services; and plot growth patterns of the baby to facilitate growth monitoring.
47914845|NCT01738477|BIOLOGICAL|Boostrix|Single dose intramuscular administration.
48140100|NCT04427124|OTHER|Multidisciplinary Team Based Care Model|All prospective patients admitted into the study will receive care based on multidisciplinary team collaboration and an institutional protocol for critical limb ischemia.
48350808|NCT03080701|BEHAVIORAL|Auto Mailing Plus Lottery|Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
48350809|NCT06424483|BEHAVIORAL|Awareness, Courage, and Love Group Psychotherapy|Awareness, Courage, and Love (ACL) groups are an outgrowth of functional analytic psychotherapy, which is an empirically-based behavioural therapy that emphasizes the principle of positive reinforcement within relationships (Holman et al., 2017; Kanter et al., 2010; Kohlenberg \& Tsai, 1991; Tsai et al., 2009a). Awareness involves the practice of mindfulness, and in particular, the noticing of emotions within oneself and in others (Tsai et al., 2009b). Courage refers to engaging in vulnerable self-disclosures and practicing boundaried support. Love encompasses healthy caring for oneself and others, and in particular, responding affirmingly to another person's self-disclosures.
48350810|NCT03044743|DRUG|Fludarabine|To modify immune micro-environment
48503498|NCT02730026|DRUG|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
48503499|NCT02730026|DRUG|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
48513413|NCT06222931|OTHER|Sham vibration|Simulated vibration
48513414|NCT06318312|OTHER|Hypoxia|Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%
48513415|NCT02441660|DRUG|Capsaicin 8% Patch|Applied topically for 1 hour
48513416|NCT02441660|DRUG|Low Dose Capsaicin 0.025% Well Patch|
48661098|NCT06434493|RADIATION|Proton Beam Therapy|All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)
48661099|NCT06434493|DRUG|Concurrent oral capecitabine chemotherapy|All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
48661100|NCT06434493|DRUG|Cisplatin & Gemcitabine intravenous chemotherapy|Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.
48661101|NCT06434493|PROCEDURE|Orthotropic Liver Transplant|If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.
48140101|NCT01720706|DEVICE|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
48350811|NCT03044743|DRUG|Cyclophosphamide|To modify immune micro-environment
48513417|NCT06329609|DEVICE|Airvo 3 with respiratory rate algorithm|Airvo 3 with respiratory rate algorithm is an active humidification system used to deliver high flow respiratory gases (air and/or oxygen) and monitor respiratory rate
48661102|NCT05538728|DEVICE|poly-l-lactic acid (Sculptra)|Sculptra
48140102|NCT02994524|PROCEDURE|Rerouting technique for transsphincteric perianal fistula|
48140103|NCT03441490|BEHAVIORAL|Guided-ICBT for adolescents with anxiety|Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
48140104|NCT03441490|BEHAVIORAL|Guided-ICBT with chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
48140105|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.
48140106|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
48140107|NCT01209195|DRUG|MM-121|increasing doses of MM-121 IV QW
48140108|NCT01209195|DRUG|Paclitaxel|Paclitaxel - 80 mg/m2 IV QW
48140109|NCT03479892|DRUG|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
48140110|NCT03479892|DRUG|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
48140111|NCT03879265|DIAGNOSTIC_TEST|Noninvasive chromosome screening|Screening based on MALBAC-NGS technology
48140112|NCT00529009|DRUG|UDCA|
48140113|NCT01708278|DRUG|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
48140114|NCT01708278|OTHER|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
48140115|NCT03914885|GENETIC|ATLCAR.CD30|Administered at a dose of 2 x 10\^8 cells/m2
48513418|NCT00979641|DRUG|Docetaxel|
48661103|NCT06496724|BIOLOGICAL|Albumin paclitaxel/neutrophil drug|Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel/neutrophil drug.
48140116|NCT03914885|DRUG|Bendamustine|Administered as a dose of 70mg/m2/day over 3 consecutive days; maybe dose reduced per treating physician discretion based on prior toxicities and the patient's clinical status
48140117|NCT03914885|DRUG|Fludarabine|Administered at a dose of 30mg/m2/day over 3 consecutive days; given concomitantly with bendamustine
48140118|NCT00315185|DRUG|Cetuximab|
48513419|NCT02914353|DRUG|EP=7041|Factor X!a Inhibitor
48513420|NCT02914353|DRUG|Placebo|Normal Saline
48661104|NCT01417767|DRUG|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
48661105|NCT01417767|DRUG|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
48140119|NCT01616537|OTHER|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
48140120|NCT02905292|OTHER|evaluation and treatment maneuver for BPPV|
48140121|NCT02399241|DEVICE|Bluetooth enabled nebuliser device (I-neb)|
48140122|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
48140123|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
48140124|NCT00831506|DRUG|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
48140125|NCT04862598|DEVICE|Oculus Virtual Reality|The patient will receive standard care, augmented with virtual reality. Their post-operative satisfaction score will be recorded.
48140126|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (A) for oral administration
48140127|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (B) for oral administration
48140128|NCT06142838|BEHAVIORAL|community pharmacist intervention|The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
48140129|NCT04275583|DRUG|TQB3602|This is a kind of proteasome inhibitor.
48140130|NCT01469585|DRUG|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
48350812|NCT03044743|DRUG|Interleukin-2|To sustain the survival of infused T cells
48350813|NCT01919086|DRUG|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22
48350814|NCT01919086|DRUG|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
48350815|NCT01919086|DRUG|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
48350816|NCT03537937|OTHER|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
48350817|NCT03537937|OTHER|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
48350818|NCT03537937|OTHER|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
48513421|NCT00754546|DRUG|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
48513422|NCT00754546|DRUG|Placebo: Normal Saline|Normal saline was nebulized.
48513423|NCT00754546|OTHER|Treadmill Exercise|
48513424|NCT00754546|OTHER|Cycle Exercise|
48513425|NCT00893269|DRUG|eszopiclone|Oral capsule at dose recommended for adults
48350819|NCT00898950|DRUG|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
48350820|NCT00898950|DRUG|Aspirin|300mgs/day orally for 2 weeks
48350821|NCT00898950|DRUG|Aspirin|aspirin 900mgs QID orally for 2 weeks
48350822|NCT00898950|OTHER|placebo tablet|placebo tablet with lactose and excipients.
48350823|NCT05579795|PROCEDURE|Detethering of the spinal cord|Release of the tethered spinal cord
48350824|NCT05339035|BEHAVIORAL|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
48350825|NCT00415246|DRUG|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
48513426|NCT00893269|DRUG|Placebo|Participants receive placebo prior to sleep
48661106|NCT06564662|DEVICE|Rapid Response EEG|The Ceribell(R) Rapid Response EEG is a relatively new device that is becoming standard of care in the adult critical care. In this pediatric study the device will be placed by trained ICU physicians
48661107|NCT02532101|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
48661108|NCT02001792|PROCEDURE|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
48661109|NCT02001792|DEVICE|pulse oximeter|
48350826|NCT03667573|DEVICE|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
48350827|NCT03667573|DEVICE|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
48350828|NCT03667573|OTHER|textured shoe insoles|textured shoe insoles
48350829|NCT00513370|BIOLOGICAL|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
48513427|NCT00893269|DRUG|ramelteon|ramelteon
48513428|NCT00893269|DRUG|zolpidem|zolpidem
48513429|NCT01241110|DRUG|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
48513430|NCT01241110|DRUG|azitromycin|azitromicin vs ofluxacin
48661110|NCT03033784|DRUG|8 International Units (IU) of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
48661111|NCT03033784|DRUG|24IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
48661112|NCT03033784|DRUG|48IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
48661113|NCT03033784|DRUG|Placebo|Participants will receive an intranasal placebo to match the oxytocin doses.
48350830|NCT04212403|DRUG|Levofloxacin|The control group receives AMP.
48350831|NCT02057276|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
48350832|NCT02057276|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|
48350833|NCT02057276|OTHER|Occupational Therapy|
48350834|NCT02685449|DRUG|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
48661114|NCT03586531|PROCEDURE|renal biopsy|Renal biopsy samples will be obtained by a percutaneous method using a spring-loaded Trucut® biopsy needle under real time ultrasound guidance. Biopsy samples will be processed for light microscopy with special staining will be done: Schiff periodic acid, Masson trichrome and methenamine silver.and immunofluorescence studies to evaluate IgA, IgG, IgM, complement C1q and C3, fibrin, and kappa and lambda light chain deposits.
48661115|NCT06337448|DEVICE|Blue LED|The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, and he LED will be positioned in the direction of the patient's genitalia, keeping the internal and external vulvar lips open, so the LED can reach the largest possible region for therapeutic action.
48140131|NCT00815100|DRUG|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
48661116|NCT00553254|DRUG|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
48661117|NCT05072379|DEVICE|colostomy self-care app|The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
48661118|NCT05036109|DRUG|Aspirin|by mouth every day for up to 90 days
48661119|NCT05036109|DRUG|Vitamin D|by mouth every day for up to 90 days
48661120|NCT05036109|DIETARY_SUPPLEMENT|Diet|Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.
48661121|NCT05036109|OTHER|Physical Activity|The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly
48661122|NCT05036109|BEHAVIORAL|Behavioral Support Counseling Sessions|Patients will undergo a one-on-one counseling session prior to day 1
48661123|NCT05433142|BIOLOGICAL|XmAb819|Monoclonal Bispecific Antibody
48661124|NCT03247101|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
48661125|NCT03247101|DRUG|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
48661126|NCT03247101|DRUG|Biotase group|Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
48661127|NCT02985944|PROCEDURE|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
48661128|NCT02228928|DRUG|CAPNP, 50 ug/cm2 capsaicin patch|
47985264|NCT01537510|BEHAVIORAL|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
47985265|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC or intravenous injection.
47985266|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC injection.
47985267|NCT02518828|OTHER|High SpO2|SpO2 range ≥96%
48503500|NCT01345578|DRUG|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
48503501|NCT01345578|RADIATION|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
48661129|NCT02228928|DRUG|CAPNP, 100 ug/cm2 capsaicin patch|
48661130|NCT02228928|DRUG|0.075% capsaicin cream|
48661131|NCT02228928|OTHER|Placebo patch|
48661132|NCT04194827|DIAGNOSTIC_TEST|Adalimumab serum trough concentration|Dose reduction based on adalimumab serum trough concentration
48661133|NCT04194827|DIAGNOSTIC_TEST|Disease activity|Dose reduction based on adalimumab diseas activity
48661134|NCT04194827|DRUG|Adalimumab|Adalimumab
48661135|NCT02801578|DRUG|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
48661136|NCT05334797|OTHER|hot application|a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes.
48661137|NCT06246396|DRUG|Minocycline Hydrochloride|Minocycline Hydrochloride 100 mg twice daily
48661138|NCT06246396|DRUG|Placebo|Placebo
47985268|NCT02518828|OTHER|Low SpO2|SpO2 range 90-92%
47985269|NCT05457673|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
48140132|NCT00815100|DRUG|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
48140133|NCT03836651|OTHER|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
48140134|NCT03836651|OTHER|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
48350835|NCT02685449|DRUG|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
48140135|NCT02792907|DEVICE|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
48503502|NCT01206101|DRUG|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
48350836|NCT02685449|DRUG|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
48140137|NCT02997410|DEVICE|Ozone|
48350837|NCT04120350|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
48350838|NCT04120350|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
48350839|NCT04120350|DRUG|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~\[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.\] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years."
48350840|NCT02828189|OTHER|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
48350841|NCT02828189|BEHAVIORAL|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
48140138|NCT02997410|DEVICE|Placebo (for Ozone)|
48140139|NCT02997410|DEVICE|Dental treatment with occlusal splint|
48350842|NCT02828189|OTHER|Therapeutic exercise-Physiotherapy|"1. Cardiovascular exercise~2. Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~3. Flexibilization exercises"
48350843|NCT02942693|DRUG|Apatinib|Apatinib will be used as induction therapy in experimental arm.
48350844|NCT02942693|RADIATION|Particle Therapy|Same total dose and fractionation will be used in both arms.
48350845|NCT01654328|DRUG|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
48661139|NCT04029779|BIOLOGICAL|I-PRF|Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
48661140|NCT04450550|DEVICE|VeNS device|VeNS treatment
48140140|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
48140141|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
48350846|NCT01654328|DRUG|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
48350847|NCT02096471|DRUG|PD-0325901|
48350848|NCT05182294|DEVICE|AIRVO 2, the new asymmetric nasal cannula|The AIRVO 2 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patient through a variety of patient interfaces. This is an FDA-approved 510k device for use in hospitals and nursing homes. During HFNT, oxygen will be passed through a heated humidifier (AIRVO 2, Fisher and Paykel Healthcare) and applied continuously through conventional large-bore binasal symmetric prongs or the new asymmetric prongs cannula device, with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep SaO2 ≥ 90% (Airvo 2, Fisher and Paykel Healthcare). Gas flow temperature will be adjusted based on patient's comfort and range from 34-37 degrees centigrade. After completion of the study, patients will be switched back to oxygen therapy administered by nasal prongs or mask..
48367493|NCT05853835|DRUG|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
48350849|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.0625 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
48350850|NCT05751252|DRUG|Ganirelix|An intra-venous cannula will be inserted and blood will be sampled at 10-min intervals for a 4-h baseline period commencing at 0800 h. Ganirelix will be then administered subcutaneously at single-dose regimen at 0.025 mg (n = 10 women with PCOS). After Ganirelix administration sampling will continue at 10-min intervals for 4 h.
48350851|NCT00456924|DRUG|VA2914|
48140142|NCT01812759|DRUG|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
48140143|NCT01812759|DRUG|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
48661141|NCT04450550|DEVICE|Sham VeNS device|Sham treatment of VeNS
48140144|NCT01812759|OTHER|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
48140145|NCT03450642|OTHER|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
48140146|NCT05918107|DRUG|PM8002|IV infusion
48140147|NCT05918107|DRUG|Pemetrexed|IV infusion
48140148|NCT05918107|DRUG|Cisplatin|IV infusion
48140149|NCT05918107|DRUG|Carboplatin|IV infusion
48140150|NCT05508854|GENETIC|prenatal genetic counselling|Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
48140151|NCT05960669|PROCEDURE|3D model guided secondary resection|A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
48350852|NCT00834392|BEHAVIORAL|Exercise|Walking exercise
48350853|NCT02777034|OTHER|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（\<2000ml/d）."
48350854|NCT02777034|OTHER|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（\>2000ml/d）."
48350855|NCT03045640|OTHER|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
48140152|NCT03929198|OTHER|Healthy Lifestyle|6 week Diet, Exercise training, Behavioral modification
48140153|NCT00729898|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48140154|NCT01801007|DEVICE|Flow Re-Direction Endoluminal Device (FRED)|
48140155|NCT01934036|DIETARY_SUPPLEMENT|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
48140156|NCT01934036|DRUG|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
48350856|NCT03645811|BEHAVIORAL|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
48350857|NCT03645811|BEHAVIORAL|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
48350858|NCT00902512|DRUG|Treatment A|Viagra® 100 mg tablet, administered with water single dose
48350859|NCT00902512|DRUG|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
48350860|NCT00902512|DRUG|Treatment B|Sildenafil 100 mg CT administered with water single dose
48661142|NCT02753972|BEHAVIORAL|Mindful Eating and Living|8 week mindfulness skills intervention
48661143|NCT02753972|BEHAVIORAL|Active Weight Loss Control|8 week active weight loss control group
48661144|NCT05295472|BEHAVIORAL|Grapholearn|GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
48661145|NCT05295472|BEHAVIORAL|Vector|A computer game focusing on children's development of mathematic skills
48661146|NCT05295472|BEHAVIORAL|Usual schooling|No GL or Math computer games, only the usual schooling
48140157|NCT01697228|DIETARY_SUPPLEMENT|Vitamin D|
48140158|NCT00241826|PROCEDURE|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
48140159|NCT00241826|PROCEDURE|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
48140160|NCT00357916|DRUG|PEP005 Topical Gel (0.01% concentration)|
48140161|NCT01570894|DRUG|Quetiapine Fumarate|25 mg tablet
48140162|NCT01252420|DRUG|Enoxaparin|1.5mg/kg daily for 2 weeks
48140163|NCT05743426|OTHER|Survey|Patient Reported Outcome (PRO) questionnaire
48140164|NCT05743426|OTHER|Toxicity Assessments|Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
48350861|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
48140165|NCT03177707|OTHER|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
48350862|NCT00902512|DRUG|Treatment C|Sildenafil 100 mg CT administered without water single dose
48140166|NCT02046304|DRUG|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
48140167|NCT02046304|RADIATION|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
48140168|NCT01794299|BIOLOGICAL|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
48140169|NCT03960645|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
48140170|NCT06509204|DIETARY_SUPPLEMENT|Glucotrojan|"Day 1: Start wearing the CGM sensor and let it self-calibrate for 24 h Day 2: Consume 1 serving of Test Meal for breakfast. Log the meal in the app. Day 3: Consume 1 serving of Test Meal with GlucoTrojan for breakfast. Log the meal in the app.~Days 4-8: Participants will be instructed to take GlucoTrojan twice per day. Once during their typical breakfast meal and once during their typical dinner meal. Each breakfast and dinner will be logged in the app.~Days 9-13: Participants will continue with their typical lives but continue to log meals - breakfast and dinner - in the app.~Day 14: end"
48140171|NCT05314049|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
48140172|NCT05314049|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
48140173|NCT05314049|DEVICE|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
48140174|NCT05314049|DEVICE|Heat Therapy|superficial heating for 20 minutes
48140175|NCT03062072|DRUG|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
48140176|NCT04574206|BEHAVIORAL|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
48140177|NCT04574206|BEHAVIORAL|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
48140178|NCT01156454|PROCEDURE|X-ray|surgical specimen taken to radiology and contents x-rayed
48140179|NCT00479375|PROCEDURE|Adding Human Papillomavirus testing to organised cervical screening|
48140180|NCT01034488|BIOLOGICAL|Suine|5000UI /mL
48140181|NCT01034488|BIOLOGICAL|Suine|5000UI/mL
48350863|NCT00902512|OTHER|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
48350864|NCT01547806|DRUG|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
48350865|NCT01547806|DRUG|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
48350866|NCT01547806|PROCEDURE|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
48350867|NCT00597532|DIETARY_SUPPLEMENT|Soy|soy (soy protein supplementation 50 grams/day)
48140182|NCT03693807|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
48140183|NCT03693807|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
48140184|NCT03693807|DRUG|Gemcitabine|Please see Detailed Description.
48140185|NCT03693807|DRUG|Oxaliplatin|Please see Detailed Description.
48140186|NCT03693807|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
48661147|NCT04133415|RADIATION|Lattice stereotactic body radiation therapy|-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
48661148|NCT04133415|PROCEDURE|Peripheral blood|-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
48661149|NCT03240328|BIOLOGICAL|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
48661150|NCT06540885|DRUG|Palonosetron (Group P)|Group P will be receiving palonosetron 1.5mcg/kg before the commencement of general anaesthesia
48140187|NCT03693807|DRUG|Fluorouracil|Please see Detailed Description.
48140188|NCT03693807|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
48140189|NCT05062343|DEVICE|Dilapan-S|Osmotic dilator
48140190|NCT05062343|DEVICE|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
48350868|NCT00597532|DIETARY_SUPPLEMENT|Milk|placebo (milk protein supplementation 50 grams/day)
48350869|NCT02718625|BIOLOGICAL|Santyl|Collagenase ointment applied topically
48350870|NCT02718625|BIOLOGICAL|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
48350871|NCT00062595|DRUG|phylloquinone (K1)|
48350872|NCT00062595|DRUG|menatetranone (MK4)|
48367494|NCT04805606|DRUG|CKD-843 A|Single Dose
48367495|NCT04805606|DRUG|CKD-843 B|Single Dose
48367496|NCT04805606|DRUG|CKD-843-R|QD, PO
48367497|NCT04515602|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
48367498|NCT04515602|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
48140191|NCT05870085|BEHAVIORAL|Neuro-linguistic program|"Intervention: Neuro-linguistic program developed by three specialists (a clinical psychologist, a social worker, and one education specialist).~4 (45 minutes) sessions for teachers, and 2 for children (total of 6 sessions)"
48140192|NCT06356532|BEHAVIORAL|intensive care unit diary|The intensive care unit diary is a notebook provided to patients during their stay in the intensive care unit, allowing them to record all events that occur during this period. Patients are encouraged to freely write about their experiences, which may include details about their treatment progress, daily activities, visits from family members, and other relevant aspects of their stay.
48140193|NCT04684095|BEHAVIORAL|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
48140194|NCT00987324|DEVICE|Taxus stent|Implantation of paclitaxel-eluting stent
48140195|NCT00987324|DEVICE|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
48350873|NCT04759898|DEVICE|transcranial direct current stimulation (noninvasive recording)|Subjects will enter the EEG lab and be seated in a chair. The 26-electrode EEG array will be placed using a conductive paste. The electrodes will be connected to a clinical grade EEG machine used in standard of care routine EEG monitoring. Next, a soft cloth cap will be placed over the subject's head with the tDCS electrodes pre-positioned in place. The cap will be positioned so that the tDCS electrodes cover the scalp without disturbing the underlying EEG electrodes. Conducting gel will be applied in direct contact with the scalp to facilitate stimulation. In addition, lidocaine jelly will be added topically to provide local anesthesia. The tDCS electrodes will be connected to a low-current generator. Participants receive 2.0 milliamps in electrical stimulation from the tDCS machine for 20 minutes. The device will be manually controlled by study personnel assisting with the experiment. A virtual reality environment will be utilized to collect kinematic data during the study.
48503503|NCT01206101|DRUG|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
48503504|NCT00003960|DRUG|busulfan|
48503505|NCT00003960|DRUG|cyclophosphamide|
48661151|NCT06540885|DRUG|Granisetron (Group G)|Group G participants will receive IV Granisetron 1mg at the start of wound closure
48661152|NCT05453461|DIAGNOSTIC_TEST|Validation of new COMs for non ambulant FSHD patients|Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
48661153|NCT03321942|DRUG|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
48661154|NCT03321942|DRUG|Control group|Conventional treatment were used to treat patients with chronic renal failure.
48661155|NCT05643404|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
48661156|NCT05643404|DIAGNOSTIC_TEST|Echocardioghaphy|Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
48661157|NCT01716702|BEHAVIORAL|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
47985270|NCT01716598|DEVICE|IPS System|TLD Therapy will be achieved bronchoscopically.
48140196|NCT00987324|DEVICE|Conventional Balloon Catheter|Ryuijin, Trek
48140197|NCT00143286|DRUG|varenicline (CP-526,555)|
48140198|NCT02104349|BEHAVIORAL|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
48140199|NCT00006045|BIOLOGICAL|lintuzumab|
48140200|NCT00006045|DRUG|cytarabine|
48140201|NCT00006045|DRUG|etoposide|
48140202|NCT00006045|DRUG|mitoxantrone hydrochloride|
48140203|NCT05696405|PROCEDURE|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
48140204|NCT01154504|OTHER|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
48140205|NCT01154504|PROCEDURE|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
48140206|NCT01154504|PROCEDURE|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
48503506|NCT00003960|DRUG|methylprednisolone|
48503507|NCT00003960|PROCEDURE|allogeneic bone marrow transplantation|
48503508|NCT00003960|PROCEDURE|in vitro-treated bone marrow transplantation|
48503509|NCT01685840|OTHER|Usual Care|Usual Care
48503510|NCT01685840|DEVICE|Biomarker-guided care NT-proBNP|Device: NT-proBNP
48503511|NCT04835623|DRUG|Cyclosporine 0.09% Ophthalmic Solution|one drop each eye twice daily
48503512|NCT04229173|DIAGNOSTIC_TEST|MRI acquisition|MRI acquisition
48350874|NCT04759898|DEVICE|sham transcranial direct current stimulation (noninvasive recording)|Subjects receiving sham undergo the same setup as the stimulation group with the exception that sham subjects experience stimulation for one minute only (30 second ramp-up to 2 milliamps immediately followed by 30 second ramp-down to 0 milliamps for the remaining 19 minutes). This provides similar sensory feedback to sham subjects that treatment subjects experience. The same electrode array, soft cloth cap, conducting gel application, and lidocaine are applied as in a stimulation subject. The tDCS electrodes will be connected to a low-current generator. A virtual reality environment will be utilized to collect kinematic data during the study.
48140207|NCT05850624|OTHER|ice massage|active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack
48140208|NCT05850624|OTHER|virtual reality animation|cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
48140209|NCT05663203|OTHER|Internet-Based Intervention|Attend CRCWeb intervention
48661158|NCT03622983|OTHER|collection of sample and data|Recovery of surgical waste during surgery planned in the current care and clinical data collection
48140210|NCT05663203|OTHER|Interview|Complete interview
48140211|NCT05663203|OTHER|Survey Administration|Complete survey
48140212|NCT05663203|OTHER|Electronic Health Record Review|Medical records are reviewed
48350875|NCT04759898|DEVICE|transcranial direct current stimulation (invasive recording)|Subjects are brought into the operating room. The scalp is prepped with a sterilizing solution. Following infiltration with local anesthetic and incision, a 6-contact electrocorticography strip is inserted into the burr hole covering primary motor cortex. Electrocorticography strip terminals are connected to an amplifier for signal recording. Gas-sterilized transcranial direct current stimulation electrodes are placed on the scalp directly overlying primary motor cortex. tDCS electrodes are connected to a low-current generator. During electrocorticographic recording, stimulation is turned on while subjects are asked to flex each arm. At the conclusion of the experiment, the electrocorticography strip and tDCS electrodes are removed and the surgery proceeds as planned.
48350876|NCT05942872|OTHER|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.|This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
48661159|NCT03645460|GENETIC|Direct intravenous injection of ivlv-ADA lentiviral vector|Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight
48661160|NCT00020683|DRUG|incyclinide|High dose given orally
48661161|NCT00020683|DRUG|incyclinide|Low dose given orally
48661162|NCT00020683|OTHER|laboratory biomarker analysis|Correlative studies
48661163|NCT03923868|DRUG|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
48661164|NCT01587560|DEVICE|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
48661165|NCT01587560|DEVICE|TITAN, Ascension Orthopedics, Inc.|
48661166|NCT05014152|DEVICE|Q-temp-w1|Q-temp-w1 is a contact type body temperature patch developed by Quanta Computer Co., Ltd. It is mainly used to measure the body temperature of the human body. It can be used for general body temperature measurement, home temperature measurement records and medical tracking.
48661167|NCT05014152|DEVICE|Omron thermometer(MC-171W)|Omron thermometer(MC-171W) is mainly used to measure the body temperature of the human body. The reference temperature patch used in this study is the OMRON thermometer, model: MC-171W.
48140213|NCT02342652|DRUG|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
48140214|NCT02342652|DRUG|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
48140215|NCT00998517|DIETARY_SUPPLEMENT|Soy/peanut fortified spread|75kcal/kg/day
48140216|NCT00998517|DIETARY_SUPPLEMENT|Milk fortified corn/soy blend|75 kcal/kg/day
48140217|NCT00998517|DIETARY_SUPPLEMENT|Supplementary Plumpy®|75 kcal/kg/day
48140218|NCT01965990|OTHER|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
48140219|NCT01746576|OTHER|Use of impedance threshold device during spontaneous ventilation|
48140220|NCT04798378|DEVICE|Neurosleeve|Myoelectric devices for restoration of independent arm function
48661168|NCT05986292|DRUG|LY3016859 ISA|Administered intravenously (IV)
48661169|NCT05986292|DRUG|LY3556050 ISA|Administered orally
48661170|NCT05986292|DRUG|LY3526318 ISA|Administered orally
48140221|NCT06332326|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation: patients will receive non-invasive vagus nerve stimulation.
48140222|NCT06332326|BEHAVIORAL|vestibular rehabilitation|vestibular rehabilitation: Patients will be given specially structured vestibular rehabilitation exercises.
48140223|NCT04701372|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
48140224|NCT01259570|DIETARY_SUPPLEMENT|Group 1|Skimmilk enriched with VD encapsulated in CM
48140225|NCT01259570|DIETARY_SUPPLEMENT|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
48140226|NCT01259570|DIETARY_SUPPLEMENT|group 3|3% fat milk wherein the VD will be in CM
48140227|NCT01259570|DIETARY_SUPPLEMENT|Group 4|Placebo: un-enriched skimmilk.
48140228|NCT01404000|DRUG|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
48350877|NCT04544436|DRUG|Ocrelizumab|"The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (participants's body weight \<75 kg) or 1800 mg (participant's body weight \>/=75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion every 24 weeks.~During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)."
48350878|NCT04544436|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 milligram (mg) every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg intravenous (IV) infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
48350879|NCT04544436|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
48350880|NCT04544436|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
48503513|NCT04229173|DIAGNOSTIC_TEST|DAT-SPECT|Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
48503514|NCT04229173|DIAGNOSTIC_TEST|blood sample, cerebrospinal fluid (optional)|blood sample, cerebrospinal fluid
48503515|NCT04229173|BEHAVIORAL|Evaluations about motor abilities, depression, cognition and lifestyle|Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)
48503516|NCT04229173|BEHAVIORAL|Evaluation about depression cognition|Evaluations about depression (BDI scale), cognition (MoCA scale)
48503517|NCT02106897|DRUG|BIIB059 (litifilimab)|See Arm Descriptions
48503518|NCT02106897|DRUG|Placebo|See Arm Descriptions
48503519|NCT02567643|RADIATION|Stereotactic Radiosurgery|
48503520|NCT05910112|PROCEDURE|Pleural interventions|eg thoracocentesis, chest drain, indwelling pleural catheters, thoracoscopy
48503521|NCT00553306|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
48503522|NCT00553306|BIOLOGICAL|aldesleukin|Given subcutaneously
48503523|NCT00553306|DRUG|cyclophosphamide|Given IV
48503524|NCT00553306|PROCEDURE|biopsy|Optional correlative studies
48503525|NCT00553306|OTHER|immunohistochemistry staining method|Optional correlative studies
48503526|NCT00553306|OTHER|flow cytometry|Correlative studies
48503527|NCT00553306|GENETIC|polymerase chain reaction|Correlative studies
48503528|NCT04953572|GENETIC|autologous peripheral blood mesenchymal stem cell|Transplantation of autologous peripheral blood mesenchymal stem cell
48503529|NCT04953572|PROCEDURE|Microfracture|Microfracture
48503530|NCT04953572|COMBINATION_PRODUCT|Microfracture + collagen membrane|Microfracture plus collagen membrane transplantation
48503531|NCT04953572|PROCEDURE|Autologous osteochondral transplantation|Autologous osteochondral transplantation
48503532|NCT04956432|DRUG|SHR4640|SHR4640 Dose 1 ,tablets, QD
48503533|NCT04956432|DRUG|Allopurinol|Allopurinol 300mg, tablets, QD
48503534|NCT00977886|DRUG|Placebo|Oral, 10 days
48503535|NCT00977886|DRUG|ELB353|Oral, 10 days
48503536|NCT03784053|OTHER|Immersive virtual reality|At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
48503537|NCT00186095|PROCEDURE|autologous followed by nonmyeloablative allogeneic transplant|
48503538|NCT04992650|PROCEDURE|Fat grafting|Fat grafting
48503539|NCT01648660|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
48661171|NCT05986292|DRUG|LY3857210 ISA|Administered orally
48661172|NCT05986292|DRUG|Placebo Oral|Placebo administered orally
48140229|NCT05402566|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
48140230|NCT05449366|DRUG|Intraperitoneal Paclitaxel Solution (Ml)|Weekly cycles of intraperitoneal paclitaxel monotherapy
48140231|NCT04979598|OTHER|Home exercise program|A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
48140232|NCT06269068|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
48140233|NCT06269068|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
48503540|NCT00806286|DRUG|CS7017 tablets|CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
48503541|NCT00806286|DRUG|Paclitaxel|Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks
48503542|NCT00806286|DRUG|Carboplatin|IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks
48503543|NCT00806286|DRUG|Placebo Tablets|Placebo tablets matching CS-7017 tablets
48661173|NCT05986292|DRUG|Placebo|Placebo administered IV
48140234|NCT06269068|OTHER|Oswestry Low Back Pain Disability Questionnaire|With this scale, it is questioned to what extent the patient is affected by low back pain in selected daily living activities under certain ten headings. In total scoring, disability is expressed as a percentage, and high scores are interpreted in favor of an increase in disability.
48350881|NCT04313673|DIAGNOSTIC_TEST|second trimester ultrasonography|Patients undergoing routine antenatal screening between 18-24 weeks and measuring cervical length with transabdominal ultrasonography in the same session
48350882|NCT02748785|DRUG|Methotrexate|Methotrexate will be continued
48503544|NCT00991705|DRUG|Atorvastatin|
48350883|NCT02748785|BIOLOGICAL|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
48350884|NCT03225651|BIOLOGICAL|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
48350885|NCT03225651|BEHAVIORAL|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
48350886|NCT03817749|DIETARY_SUPPLEMENT|Exogenous ketone monoester|Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
48350887|NCT05221489|OTHER|listening to lullabies or self-selected music|listening to lullabies for lullaby group and listening to music of their choice among various music for mix music group
48350888|NCT00095810|DRUG|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
48350889|NCT02669446|DEVICE|Medical devices|
48140235|NCT06269068|OTHER|Douleur Neuropathique 4|The questionnaire consists of 10 items; while the nature of pain is questioned in 7 items, the other 3 items include brief sensory examination. Patients with a score of 4 or more out of 10 are considered to have neuropathic pain.
48140236|NCT06269068|OTHER|Visual analogue scale|global pain score on a 0 to 10
48140237|NCT02568306|DRUG|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
48140238|NCT02568306|DRUG|placebo|Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
48661174|NCT00461318|PROCEDURE|Individual placement and support (vocational rehabilitation)|
48140239|NCT04318691|BIOLOGICAL|Blood sampling|Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.
48350890|NCT02669446|DEVICE|traditional household remedy|
48367499|NCT04515602|DRUG|PARPi|For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
48367500|NCT05699304|PROCEDURE|Thyroidectomy|Thyroidectomy
48367501|NCT03672006|BIOLOGICAL|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
48503545|NCT00991705|DRUG|Fimasartan|
48503546|NCT00685672|DRUG|adrenalin|adrenalin 2 microgram pr ml placebo
48503547|NCT00685672|DRUG|placebo|Saline instead of adrenaline in the epidural mixture
48503548|NCT05079581|OTHER|Pelvic floor exercises|"The participants in the intervention group will be taught exercises involving strengthening the muscles around the pelvic floor in sitting, standing and lying positions by a physiotherapist who has been trained in women's health for 4 years and will be asked to perform them as home exercises every day for 8 weeks. The exercises are as follows:~They will be asked to tighten the muscles around the urethra, vagina and rectum as hard as possible, upwards and inwards (from the bottom up) and hold it in this way for 8-10 seconds. It will be applied in different positions as in the table."
48661175|NCT06197581|RADIATION|Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)|Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
48661176|NCT05828173|DEVICE|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)|Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
48661177|NCT06570304|PROCEDURE|iCount Device|"Designed as single use. Intended purpose - To be used to count swabs and tampons after surgery in an objective manner. This is intended to be used in patients during and just after surgery.~This is a device accessory."
48350891|NCT03649815|COMBINATION_PRODUCT|App4Independence|"The mobile, app-based platform was designed to:~* Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~* Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~* Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~* Provide basic health/safety functionality and track level of wellness~* Provide an anonymous peer-peer online network for strategy sharing~* Provide an ambient sound detector to assist with identifying hallucinations"
48350892|NCT01816542|OTHER|patch tests on healthy skin|Patches will be placed on healthy skin.
48661178|NCT04409431|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol
48140240|NCT04318691|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.
48140241|NCT03383848|DEVICE|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
48140242|NCT01318850|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
48661179|NCT05617885|DRUG|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
48140243|NCT01318850|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
48140244|NCT01318850|OTHER|Healthy controls|No intervention
48140245|NCT06020300|DRUG|Oral Colchicine 0.6 mg|Anti-Inflammatory Effects
48140246|NCT06020300|DRUG|Oral Pyridoxine 10 mg|Colchicine look alike placebo
48140247|NCT01962597|OTHER|aerobic exercise|
48661180|NCT05617885|DRUG|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
48140248|NCT01962597|OTHER|resistance training|
48140249|NCT02434276|BIOLOGICAL|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
48140250|NCT02434276|BIOLOGICAL|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
48140251|NCT02906137|OTHER|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
48140252|NCT01341769|OTHER|Dietary Intervention|
48140253|NCT01341769|OTHER|Dietary Intervention|
48140254|NCT01341769|OTHER|Dietary Intervention|
48140255|NCT01341769|OTHER|Dietary Intervention|
48140256|NCT01354145|DRUG|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
48367502|NCT03672006|DRUG|Heparin|Medication administered to dwell in central venous catheter
48140257|NCT01354145|DRUG|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
48350893|NCT01339104|DRUG|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
48661181|NCT05617885|DRUG|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
48367503|NCT00003410|DRUG|motexafin gadolinium|
47985271|NCT05706142|OTHER|Motor Imagery Education|"Within the scope of motor imagery training, a presentation will be made to the students of pediatric rehabilitation lecture in the intervention group about what motor imagery is. PETTLEP model will be used for imagery training. In this model, imagery training will be prepared in accordance with our purpose, taking into account the physical, environmental, time, task, learning, emotion and personal subheadings. In the training sessions, relaxation exercises will be given for 5 minutes first. After the relaxation exercises, special colic massage imagery training will be given to newborns for 10 minutes. The massage will also be shown as practically at class."
47985272|NCT01892202|OTHER|Cohort|
48367504|NCT00003410|PROCEDURE|magnetic resonance imaging|
48367505|NCT00003410|PROCEDURE|surgical procedure|
48503549|NCT05691088|DEVICE|Paracetamol injection|"Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval)."
48503550|NCT04849962|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
47985273|NCT05193656|DIAGNOSTIC_TEST|Al_bladder|Detection of bladder tumor with help of Artificial intelligence
48503551|NCT04849962|OTHER|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
48503552|NCT02752906|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular
48503553|NCT02752906|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
48503554|NCT04918498|BEHAVIORAL|early physiotherapy programs|establishment of multidisciplinary teams, safety assessment, early activity physiotherapy and respiratory physiotherapy
48503555|NCT04918498|BEHAVIORAL|routine treatment|provide routine nursing and rehabilitation program
48503556|NCT05949710|BEHAVIORAL|aerobic exercise(AE)|The participants will receive AE three times per week.
48661182|NCT05617885|DRUG|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
48661183|NCT05617885|DRUG|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
48661184|NCT03787615|DEVICE|sipIT tools|Just in time drinking detection tools to promote increase fluid consumption
48661185|NCT03242447|BEHAVIORAL|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
48661186|NCT03242447|BEHAVIORAL|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
48661187|NCT04682847|DRUG|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
48661188|NCT06564753|DRUG|Drug: Placebo daily and orally|• Placebo comparator
48661189|NCT06564753|DRUG|NA-931, dose 1, daily and orally|"Drug: NA-931 dose 1, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
48661190|NCT06564753|DRUG|NA-931, dose2, daily and orally|"Drug: NA-931 dose 2, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
48140258|NCT03250793|DEVICE|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
48140259|NCT03136822|OTHER|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
48503557|NCT04074629|DIAGNOSTIC_TEST|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\\or GC-MS analysis"
48503558|NCT01129687|PROCEDURE|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
48367506|NCT04034225|DRUG|SNS-301|Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
48367507|NCT04034225|DRUG|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
48503559|NCT01129687|PROCEDURE|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
48661191|NCT06564753|DRUG|NA-931 dose 3, daily and orally|"Drug: NA-931 dose 3, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
48661192|NCT06564753|DRUG|NA-931 dose 4, daily and orally|"Drug: NA-931 dose 4, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist"
48503560|NCT04522323|BIOLOGICAL|MEDI5752|MEDI5752
48503561|NCT04522323|DRUG|Axitinib|INLYTA
48503562|NCT04522323|DRUG|Lenvatinib|LENVIMA
48661193|NCT00113373|DRUG|lapatinib ditosylate|Given orally
48661194|NCT00113373|OTHER|laboratory biomarker analysis|Correlative studies
48661195|NCT05935137|DIAGNOSTIC_TEST|Coagulation test on device ClotPro|The blood sample for coagulation test on device ClotPro will be take for both group and the test will be provided.
48661196|NCT04347967|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
48661197|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft|Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft
48661198|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft|Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
48661199|NCT05889091|OTHER|HRQOL instruments|These instruments include Face Q for Appearance, Eating \& drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
48503566|NCT01343316|DEVICE|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
48503567|NCT05263310|BEHAVIORAL|Prepare for Your Diabetes Care|Educational video and Action Plan handout
48503568|NCT05263310|BEHAVIORAL|Usual Care|Control arm patients will continue with usual care
48503569|NCT05971303|OTHER|Questionnaire|Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
48661200|NCT05889091|OTHER|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
48661201|NCT00693758|DRUG|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
48140260|NCT03136822|DEVICE|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
48140261|NCT01617707|DRUG|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
48350894|NCT06488014|PROCEDURE|Erector spina plan block (ESP)|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
48350895|NCT06488014|PROCEDURE|Paravertebral block|"In both groups, the relevant methods will be applied at the level of the surgical incision before the surgical incision (pre-emptive) after the patient is asleep and before the patient wakes up at the end of surgery.~The dose of local anaesthetic to be administered is the same for both groups.~Drug content to be administered\*: total 25 cc volume (13.5 ml 0.5% bupivacaine + 5 ml 2% lidocaine + 1.5 ml morphine (morphine diluted with 0.9% NaCl to 1mg/ml) + 5 ml 0.9% NaCl) (These doses are the routine doses applied in such surgeries in our clinic)~\* Local anaesthetic drug doses in regional anaesthesia: source: Kirk, P. H. I. I. L. I. I. P. P., \& Berde, C. B. (2020). Local anaesthetics. Miller's Anaesthesia. 9th ed. Philadelphia: Elsevier Inc, 878-9."
48350896|NCT02210455|BEHAVIORAL|Strongest Families FASD intervention|
48350897|NCT02210455|OTHER|Psychoeducation|
48661202|NCT00693758|OTHER|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
47914846|NCT03658590|DRUG|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
48140262|NCT01617707|DRUG|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
48350898|NCT04129190|BIOLOGICAL|Glucose|Oral Intake of Glucose
48350899|NCT02017067|PROCEDURE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
48140263|NCT02432066|DRUG|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
48350900|NCT00000199|DRUG|Piracetam|
48350901|NCT01936428|OTHER|interview|
48350902|NCT02525809|DEVICE|Novae E®|
48350903|NCT02525809|DEVICE|Sunfit®|
48350904|NCT02525809|DEVICE|Quartz®|
48350905|NCT00216229|BIOLOGICAL|Combined vaccine against hepatitis A and B (Twinrix)|
48350906|NCT01404806|DRUG|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
48661203|NCT00693758|OTHER|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
48661204|NCT00693758|DEVICE|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
48661205|NCT00693758|DEVICE|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
48140264|NCT02432066|DRUG|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
48350908|NCT04164849|DRUG|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
48661206|NCT06565130|OTHER|Attention skills training|Attention skills program planned with occupational therapy principles
48661207|NCT05073588|OTHER|Indo Mediterranean diet|Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.
48661208|NCT05073588|OTHER|Calorie restricted diet|One group will be given diet restricted in calories, which most of the patients follow to lose weight
48661209|NCT06564883|DEVICE|0.20% sodium hyaluronate gel|Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
48661210|NCT03411187|DEVICE|used of the Pressure adjustable foot-control method|Whether The Pressure adjustable foot-control method is used.
48661211|NCT03411187|DEVICE|direct exhaust|direct exhaust through the trocar.
48661212|NCT02971839|DRUG|VX-561|
48350909|NCT04164849|PROCEDURE|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
48350910|NCT04164849|PROCEDURE|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
48661213|NCT02971839|DRUG|Placebo|
48661214|NCT02971839|DRUG|IVA|
48661215|NCT05838287|DRUG|Pioglitazone|Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
48350911|NCT04164849|PROCEDURE|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
48350912|NCT02829606|OTHER|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
48350913|NCT02829606|OTHER|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
48661216|NCT05838287|DRUG|Placebo|Placebo for Pioglitazone
48661217|NCT05530525|DIAGNOSTIC_TEST|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
48661218|NCT05530525|DIAGNOSTIC_TEST|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
48661219|NCT05530525|DIAGNOSTIC_TEST|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
48661220|NCT05299190|OTHER|Yoga intervention plus TAU|The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
48661221|NCT05299190|OTHER|Clinical Monitoring plus TAU|clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
48350914|NCT00093158|DRUG|Angiomax (bivalirudin) anticoagulant|
48350915|NCT02365506|DRUG|Eleclazine|Tablets administered orally in a single dose
48503570|NCT05854394|BEHAVIORAL|Multimodal prehabilitation management Multimodal prehabilitation management|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including drug treatment recommendations for chronic disease, quit smoking and abstinence).
48503571|NCT03988283|BIOLOGICAL|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
48503572|NCT03988283|DEVICE|Papivax Biotech TDS-IM v2.0|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Papivax Biotech).
48661222|NCT06264310|DRUG|Placebo|Matching placebo SC injection
48661223|NCT06264310|DRUG|R2R01|Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
48350916|NCT02365506|DRUG|Placebo|Placebo to match tablets administered orally in a single dose
48350917|NCT06138392|DEVICE|Dental implant (ELEMENT RC INICELL, Thommen Medical)|Dental implant
48350918|NCT05752461|DRUG|SHR-2004 injection|low dose subcutaneous injection once
48350919|NCT05752461|DRUG|SHR-2004 injection|medium dose subcutaneous injection once
48350920|NCT05752461|DRUG|SHR-2004 injection|high dose subcutaneous injection once
48350921|NCT05752461|DRUG|Enoxaparin sodium injection|40 mg administered as subcutaneous injection once daily
48350922|NCT01415973|DIETARY_SUPPLEMENT|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
48350923|NCT01415973|DIETARY_SUPPLEMENT|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
48350924|NCT00420212|DRUG|BG00012|
48350925|NCT00420212|DRUG|Placebo|
48661224|NCT06036368|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
48661225|NCT04118101|DRUG|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
48503573|NCT03988283|PROCEDURE|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); no more than 2 weeks after the 3rd vaccine dose; no more than 2 weeks after the 6th vaccine dose; two weeks after the last dose; time of progression or discontinuation (optional)
48661226|NCT04118101|OTHER|control|no ESPB will be given.
48661227|NCT00784017|DRUG|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
48661228|NCT00784017|DRUG|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
48350926|NCT05060081|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
48350927|NCT05060081|OTHER|Traditional plank exercise program group|Traditional plank exercise program group will do a warm-up for 10 minutes and then perform five exercises includes prone bridge, side bridge, supine bridge on exercise ball, prone bridge on exercise ball, superman on exercise ball. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
48503574|NCT05413616|BEHAVIORAL|FITFOOD lifestyle intervention|Lifestyle intervention with a nutritional and exercise component.
48661229|NCT01924819|DRUG|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
48661230|NCT01924819|RADIATION|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
48661231|NCT01924819|PROCEDURE|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers \[Siewert Type II and Siewert Type III\] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
48661232|NCT02772692|BEHAVIORAL|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
48661233|NCT05179577|DRUG|Arbaclofen|Arbaclofen Extended Release Tablets
48661234|NCT05179577|DRUG|Placebo|Placebo tablets
48661235|NCT03289039|DRUG|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
48661236|NCT03289039|DRUG|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
48661237|NCT00737789|DRUG|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
48503575|NCT05255848|DRUG|Unfractionated heparin|Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
48661238|NCT00737789|DRUG|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
48661239|NCT05041504|BEHAVIORAL|Peer navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
48661240|NCT05041504|OTHER|Active wait list control|Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
48661241|NCT00748774|BEHAVIORAL|Questionnaire|Two questionnaires taking about 10 minutes to complete.
48661242|NCT03562637|BIOLOGICAL|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
48661243|NCT03562637|DEVICE|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
48661244|NCT03562637|OTHER|Standard of care treatment|Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
48661245|NCT04666610|DRUG|Brivaracetam|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered."
48661246|NCT04666610|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding.
48661247|NCT01596023|DEVICE|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
48661248|NCT01210781|PROCEDURE|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
48661249|NCT03424343|OTHER|Questionnaire bundle|Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
48661250|NCT03424343|OTHER|Obtaining information from survivors' medical file|After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
48661251|NCT00572559|DRUG|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
48661252|NCT00572559|DRUG|Linezolid|600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
48367508|NCT00490815|DRUG|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
48503576|NCT06024889|DRUG|Furosemide Injection|Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
48503577|NCT00822406|DRUG|homeopathic medicine|individualized homeopathic medicine
48503578|NCT00822406|DRUG|placebo|placebo - 6 months
48503579|NCT03294720|PROCEDURE|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
48503580|NCT03294720|DEVICE|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
48503581|NCT01639196|OTHER|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
48503582|NCT01639196|OTHER|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
48503583|NCT02308566|PROCEDURE|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
48503584|NCT02308566|PROCEDURE|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
48503585|NCT02640053|PROCEDURE|Cryotherapy|Applied topically
48503586|NCT02640053|DRUG|Paclitaxel|Given IV
48503587|NCT02640053|OTHER|Quality-of-Life Assessment|Ancillary studies
48503588|NCT02640053|OTHER|Questionnaire Administration|Ancillary studies
48503589|NCT03778398|OTHER|Neurologic music therapy|Customized piano training
48503590|NCT00002865|BIOLOGICAL|filgrastim|
48503591|NCT00002865|DRUG|cyclophosphamide|
48503592|NCT00002865|DRUG|cytarabine|
48503593|NCT00002865|DRUG|dexamethasone|
48503594|NCT00002865|DRUG|doxorubicin hydrochloride|
48503595|NCT00002865|DRUG|etoposide|
48503596|NCT00002865|DRUG|ifosfamide|
48503597|NCT00002865|DRUG|leucovorin calcium|
48503598|NCT00002865|DRUG|mesna|
48503599|NCT00002865|DRUG|methotrexate|
48503600|NCT00002865|DRUG|therapeutic hydrocortisone|
48503601|NCT00002865|DRUG|vincristine sulfate|
48503602|NCT00002865|RADIATION|low-LET cobalt-60 gamma ray therapy|
48503603|NCT00002865|RADIATION|low-LET photon therapy|
48503604|NCT01211938|RADIATION|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
48503605|NCT01211938|RADIATION|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
48503606|NCT06148142|BEHAVIORAL|Pharmacy based health promotion|This project will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; and third, end-line survey at 12 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Patients will attend the two sessions at the pharmacies where they collect their prescription medication. Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance.
48661253|NCT05781451|DRUG|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
48661254|NCT00164281|DRUG|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
48661255|NCT05230277|OTHER|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. \[8\] which consists in mobilizing the sacrum between the iliac bones.
48661256|NCT05230277|OTHER|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. \[13\] and proposed by others to perform simulated bone manipulations \[14\], will be applied to the sacrum
48661257|NCT03940248|RADIATION|Proton Accelerated Partial Breast Irradiation|38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
48140265|NCT05686499|OTHER|Didactic Lectures and demonstrations|"1. Trainees will receive 4-6 hours of didactic colonscopy lecture sessions based on the American Board of Surgery Flexible Endoscopy curriculum for general surgery residents, general surgery resident curriculum (SCORE) endoscopy module, and the Joint Advisory group on GI Endoscopy program adapted to Nigeria context.~2. Trainees will have the opportunity to practice colonoscopy on HF or LF simulators (depending on the arm) with immediate feedback from instructors."
48140266|NCT04300244|BIOLOGICAL|UV1 vaccine + leukine|The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.
48350928|NCT04969458|OTHER|survey application|"Data collection tools used in the study;~* Clinic and Demographic Evaluation Form~* Oswestry Low Back Pain Disability Index (ODI)~* Patterns of Activity Measure Pain (POAM-P)~* Roland-Morris Disability Questionnaire (RMDQ)~* Hospital Anxiety and Depression Scale (HADS)~* Graded Chronic Pain Scale Version 2.0 (GCPS 2.0)"
48350929|NCT03876704|DRUG|High dose of fat-Soluble Vitamin|Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
48350930|NCT03876704|DRUG|Conventional dose of fat-Soluble Vitamin|Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
48350931|NCT00035412|DRUG|St. John's Wort|
48350932|NCT02481323|DRUG|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
48350933|NCT02481323|DRUG|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
48350934|NCT03542890|DEVICE|Baska Mask|used in adult low risk females undergoing elective gynecological operations
48350935|NCT03542890|DEVICE|I-gel|used in adult low risk females undergoing elective gynecological operations
48350936|NCT03073369|DRUG|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
48661258|NCT06473688|PROCEDURE|Cholecystectomy|Robotic-assisted and laparoscopic cholecystectomy
48661259|NCT05276856|DRUG|Levothyroxine|"Step 1:~* Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.~* If serum T4 is normal, go to step 2.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 2:~* Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.~* If serum T4 is normal, go to step 3.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 3:~* Recheck serum TSH and T4 after 8 weeks.~* If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.~* If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure)."
48140267|NCT04300244|BIOLOGICAL|ipilimumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
48503607|NCT00823108|DRUG|GIK|12 hour infusion of GIK solution
48503608|NCT01086397|PROCEDURE|Urine sample collection|All subjects have non-invasive urine sample collection performed
48503609|NCT01224665|PROCEDURE|therapeutic conventional surgery|Patients undergo radical cystectomy
48503610|NCT01224665|PROCEDURE|therapeutic standard lymphadenectomy|Patients undergo standard pelvic lymphadenectomy.
48140268|NCT04300244|BIOLOGICAL|nivolumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
48140269|NCT05085704|DEVICE|Magnetic resonance imaging|Medical imaging technique used in radiology to form pictures of the anatomy.
48140270|NCT00681915|DRUG|AZD7325|Oral
48350937|NCT03073369|DRUG|Placebo|Oral Placebo - one capsule once daily for 6 weeks
48367509|NCT00490815|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
48367510|NCT05663775|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
48503611|NCT01224665|PROCEDURE|therapeutic extended lymphadenectomy|Patients undergo extended pelvic lymphadenectomy
48513431|NCT05931653|OTHER|Multimodal Physical therapy|• Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for \<5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.
48350938|NCT00911066|DRUG|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
48350939|NCT00911066|DRUG|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
48661260|NCT06563999|DRUG|Sunvozertinib|300 mg orally once a day, 28 days as one cycle.
48350940|NCT02149186|DEVICE|iCTuS-L|
48350941|NCT02900599|OTHER|Observationnal (no intervention)|
48503612|NCT05545384|DRUG|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
48661261|NCT06563999|DRUG|Crizotinib|300 mg orally once a day, 28 days as one cycle.
48661262|NCT06563999|DRUG|Pralsetinib|400 mg orally once a day, 28 days as one cycle.
48661263|NCT06563999|DRUG|Larotrectinib|100 mg orally twice daily, 28 days as one cycle.
48350942|NCT02979483|PROCEDURE|Integrative supportive care|"At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)~At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:~* Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patients will be treated by: FOLFOX7lightened"
48661264|NCT06563999|DRUG|Savolitinib|600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
48661265|NCT06563999|DRUG|Pyrotinib|400 mg orally once a day, 28 days as one cycle.
48661266|NCT06563999|DRUG|Dabrafenib+Trametinib|Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
48661267|NCT06563999|DRUG|Glecirasib|800 mg daily orally, 28 days as one cycle.
48661268|NCT06563999|DRUG|Ensartinib|225 mg daily orally, 28 days as one cycle.
48661269|NCT01969409|DRUG|Rituximab|i.v. rituximab given on two occasions 14 days apart.
48661270|NCT01969409|DRUG|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
48661271|NCT01467557|DEVICE|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
48350943|NCT06098586|BEHAVIORAL|Self-managed exercise therapy program|Exercise program focusing on functional re-learning and strengthening of the musculoskeletal system with the aim to create a stable wrist that can be used in a pain-free manner in activities of daily living.
48350944|NCT06098586|PROCEDURE|Partial wrist denervation|AIN and PIN neurectomy through a dorsal approach as described by Berger (Berger, 1998).
48661272|NCT01467557|DEVICE|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
48140271|NCT00586755|PROCEDURE|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
47985274|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
48140272|NCT01281657|DRUG|fingolimod|
48140273|NCT02848625|OTHER|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
48140274|NCT00431054|DRUG|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
48140275|NCT00431054|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour every 4 weeks
48503613|NCT05545384|DRUG|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
48140276|NCT06132009|PROCEDURE|Surgery of endometriosis|Cystectomy or unilateral oophorectomy due to endometriosis
48661273|NCT04031508|COMBINATION_PRODUCT|lipid injectable emulsion with Fish oil|TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
48661274|NCT03317873|DIETARY_SUPPLEMENT|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
47985275|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
48140277|NCT01989689|DRUG|Etanercept|Etanercept 50mg twice weekly
48140278|NCT01989689|DRUG|Placebo|
48140279|NCT02956109|DRUG|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
48140280|NCT02956109|DRUG|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
48140281|NCT02956109|DRUG|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
48503614|NCT05545384|DRUG|Standard of care|Patients in this group will be treated according to standard care
47985276|NCT01548092|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
47985277|NCT04389424|DRUG|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
48140282|NCT03087890|DRUG|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
48140283|NCT03087890|DRUG|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
48503615|NCT05719792|PROCEDURE|Transforaminal Epidural Steroid Injection|In the TFESI group, all patients were positioned prone. The injection site was cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) was applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle was inserted just below the pedicle. It was advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position was confirmed through a lateral view. Using lateral views, the needle was placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) was given and the distribution pattern was visualized. Once the epidural distribution of the contrast agent was confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 2 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride was injected.
48661275|NCT03317873|DIETARY_SUPPLEMENT|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
47985278|NCT04389424|DRUG|Exemestane|Use of exemestane for breast cancer recurrence prevention
47985279|NCT04389424|DRUG|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
47985280|NCT04389424|DIAGNOSTIC_TEST|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
47985281|NCT04389424|DIAGNOSTIC_TEST|Recurrence|Breast cancer recurrence under endocrine therapy
47985282|NCT00539331|DRUG|AZD2171|oral tablet
47985283|NCT00539331|DRUG|Paclitaxel|intravenous infusion
47985284|NCT00539331|DRUG|Carboplatin|intravenous injection
48140284|NCT02161458|DRUG|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
48140285|NCT02161458|DRUG|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
48661276|NCT06067698|DRUG|"Mesalamine and alpha-lipoic acid"|Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
48661277|NCT06067698|DRUG|"Mesalamine and Placebo"|Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
48350945|NCT05969262|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
48350946|NCT03442595|OTHER|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
48661278|NCT04978415|PROCEDURE|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
48661279|NCT03178682|DIAGNOSTIC_TEST|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
48661280|NCT01137084|DRUG|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
48661281|NCT01137084|DRUG|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
47985285|NCT04464122|DRUG|Somatostatin analog; chemotherapy|According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
48350947|NCT04660006|PROCEDURE|Cataract surgery|Patients undergoing uneventful cataract surgery were recruited to this study if they met the inclusion criteria of the three groups. Postoperative retinal vasculature measures, as recorded by the optical coherence tomography angiography imaging technique, were compared to baseline measures.
48350948|NCT01440504|OTHER|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
48350949|NCT03386006|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
48661282|NCT04451798|DEVICE|Impella CP microaxial pump|ramp test
48661283|NCT03707392|OTHER|Ostomy Education Video|Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
48661284|NCT03707392|OTHER|Control - Standard ostomy education|Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
48661285|NCT03906357|DRUG|Pemigatinib|
48661286|NCT04946214|BEHAVIORAL|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
48661287|NCT02898688|BEHAVIORAL|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
48350950|NCT00369408|DRUG|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
47914847|NCT03658590|DRUG|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
47914848|NCT01780064|BEHAVIORAL|interviews with a psychologist|interviews with a psychologist
47914849|NCT01780064|BEHAVIORAL|Questionnaires|Questionnaires
47914850|NCT06515808|DEVICE|Direct Laryngoscope|Patient receiving tracheal intubation with direct laryngoscope, GlideScope or Airway Scope
48350951|NCT00369408|DRUG|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
48350952|NCT06442176|DIAGNOSTIC_TEST|OCT|Enhanced depth imaging optical coherence tomography (EDI-OCT) using the Heidelberg Spectralis HRA + OCT (Heidelberg Engineering, Inc., Franklin, MA, USA)
48350953|NCT00245349|PROCEDURE|F-18 Fluorothymidine|
48350954|NCT01396031|BEHAVIORAL|Physical Therapy|Standard of care
48661288|NCT02898688|BEHAVIORAL|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
48140286|NCT02161458|DRUG|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
48503616|NCT05719792|PROCEDURE|Erector Spina Plane Block|Patients are placed in the prone position to determine the vertebrae in the middle of the involved area. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a high-frequency (8 MHz) linear ultrasound (USG) probe. The transverse process is, then, visualized approximately at the 3 cm lateral from the midline and the erector spinae muscle is visualized on it. The 22-gauge 50 mm block needle is advanced towards the in-plane section craniocaudally and the transverse process is touched. Then the needle is then withdrawn minimally to confirm that it is between the erector spinae muscle and the transverse process through hydrodissection. Following that, 5 mL from 0.5% bupivacaine hydrochloride, 8 mg dexamethasone and 3 ml saline is administered and local anesthetic spread is confirmed by USG.
47985286|NCT01839773|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
47985287|NCT01839773|DRUG|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
48140287|NCT02161458|DRUG|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
48140288|NCT00349232|BEHAVIORAL|lifestyle intervention (diet and physical activity)|
48503617|NCT01782430|PROCEDURE|- standard oxygenation|
48503618|NCT06397417|OTHER|Data collection|The data from hospital treatment will be used for research as well as subsequently, that is to say after discharge from the intensive care units, medical reports and correspondence with the attending physician will be used for the study.
48503619|NCT01663883|OTHER|Isometric exercise|use of a handgrip for 3x2 minutes
48503620|NCT05784532|DEVICE|STERN FIX|Sternotomy closure with STERN FIX and supplemented with wires
48661289|NCT02898688|BEHAVIORAL|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
48661290|NCT02898688|BEHAVIORAL|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
48661291|NCT02318433|DRUG|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
48661292|NCT02318433|DRUG|Saline|
48661293|NCT05818462|DIAGNOSTIC_TEST|Uroflow testing|Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
48661294|NCT05818462|DIAGNOSTIC_TEST|Bladder Scan|Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
48661295|NCT05818462|OTHER|Dysfunctional Voiding Scoring System Survey|The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
48140289|NCT01857076|PROCEDURE|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
48140290|NCT01857076|PROCEDURE|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
48140291|NCT01857076|OTHER|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
48140292|NCT00343083|DRUG|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
48661296|NCT05818462|DIAGNOSTIC_TEST|DEXA Scan of pelvis and sacral spine|DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
48140293|NCT00343083|RADIATION|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
48140294|NCT03653897|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
48350955|NCT03440892|DRUG|methotrexate|folate antagonist
48350956|NCT03440892|DRUG|sulfasalazine|Immunomodulatory
48661297|NCT05818462|DIAGNOSTIC_TEST|Urine tests for specific biomarkers|Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
48661298|NCT02458014|BIOLOGICAL|Blinatumomab|Given IV
48140295|NCT03653897|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
48140296|NCT03139526|OTHER|observational study so no intervention|observational study, so no intervention
48140297|NCT02454959|DEVICE|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
47985288|NCT00129493|BEHAVIORAL|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
48350957|NCT03440892|DRUG|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
48350958|NCT03440892|DRUG|tocilizumab|IL-6 receptor antagonist
48350959|NCT03440892|DRUG|tofacitinib/baricitinib|JAK inhibitor
48350960|NCT03674294|DRUG|Aprepitant|Aprepitant is manufactured by Merck \& Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
48350961|NCT03674294|DRUG|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
48350962|NCT03674294|DRUG|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
48350963|NCT03674294|DRUG|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
47985289|NCT05884047|DEVICE|Virtual Glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video."
47985290|NCT03965533|DRUG|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
47985291|NCT03965533|DRUG|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
48350964|NCT06169891|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|one s.c. injection of SSGJ-613 once, on Day 1.
48661299|NCT02458014|OTHER|Laboratory Biomarker Analysis|Correlative studies
48661300|NCT05482451|DRUG|Nivolumab|Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.
48661301|NCT05482451|DRUG|all trans retinoic acid|Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
47985292|NCT03310554|PROCEDURE|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
47985293|NCT03310554|PROCEDURE|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
47985294|NCT03310554|PROCEDURE|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
47985295|NCT05398601|OTHER|MOBILIZATION with MOVEMENT|"They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~1. Medial glide~2. Medial+ Internal rotation glide~3. Lateral Glide+ Internal Rotation glide~4. Anterior glide~5. Posterior glide"
48503621|NCT04638075|DEVICE|Supplemental Nursing System|The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence \& Lawrence, 2016).
48661302|NCT04847882|BEHAVIORAL|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
48661303|NCT00667121|DRUG|citalopram hydrobromide|
48661304|NCT00667121|DRUG|escitalopram oxalate|
48661305|NCT00667121|DRUG|gabapentin|
48661306|NCT00667121|DRUG|sertraline hydrochloride|
48661307|NCT00667121|DRUG|tamoxifen citrate|
48661308|NCT00667121|DRUG|venlafaxine|
48661309|NCT00667121|GENETIC|molecular genetic technique|
48661310|NCT00667121|OTHER|high performance liquid chromatography|
48661311|NCT00667121|OTHER|laboratory biomarker analysis|
48661312|NCT00667121|OTHER|pharmacological study|
48661313|NCT00667121|PROCEDURE|adjuvant therapy|
48661314|NCT06261255|PROCEDURE|ATT + EMD|All surgical treatments will be performed by the same experienced periodontist (IP) after the administration of local anesthesia. Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the remaining fragments will be extracted as minimally invasively as possible. A tooth-supported surgical guide will be used to prepare the recipient site following the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the CARP model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if osteotomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, EMD will be applied to the root surface of the donor tooth
48661315|NCT03814044|DEVICE|PEEK Suture Anchors|"Subjects who have undergone hip joint repair using PEEK Suture Anchors:~BIORAPTOR™ Knotless Suture Anchor and SpeedLock Hip Suture Anchor"
48661316|NCT05337566|DRUG|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
48661317|NCT05337566|DRUG|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
48661318|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
48140298|NCT02454959|DEVICE|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
48661319|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
48661320|NCT06447103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48140299|NCT03480815|DEVICE|Nocturnal Temperature Controlled Laminar Flow Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
48503622|NCT03244683|DIETARY_SUPPLEMENT|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
48503623|NCT03244683|OTHER|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
48503624|NCT03244683|OTHER|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
48661321|NCT06447103|PROCEDURE|Bone Scan|Undergo bone scan
48661322|NCT06447103|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and CT of the brain
48661323|NCT06447103|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of the brain
48661324|NCT06447103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48661325|NCT06447103|OTHER|Questionnaire Administration|Ancillary studies
48661326|NCT06447103|DRUG|Zirconium Zr 89 Girentuximab|Given IV
48661327|NCT06570044|DIAGNOSTIC_TEST|PerioMonitor|Collection of oral rinse specimen and perform the PerioMonitor test as per the method described in the instructions for use
48661328|NCT05790876|PROCEDURE|SSO2 therapy|SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
48661329|NCT06166433|BEHAVIORAL|Smoke-free homes intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.
48661330|NCT04588142|DIETARY_SUPPLEMENT|Probiotic|Non-elite athletes receive probiotic for 6 weeks
48661331|NCT04588142|DIETARY_SUPPLEMENT|Placebo|Non-elite athletes receive placebo for 6 weeks
48350965|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
48503625|NCT03210714|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47985296|NCT05398601|OTHER|Periosteal electrical dry needling|"They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~1. Medial femoral condyle~2. Lateral femoral condyle~3. Flare of the tibia~4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST."
47985297|NCT04242615|OTHER|Prognostic score|
48140300|NCT03480815|OTHER|None Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
48350966|NCT06169891|DRUG|Compound Betamethasone Injection|1 mL i.m. once on Day 1
48350967|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
48140301|NCT04638049|OTHER|Collection of human biofluids|Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT
48140302|NCT04638049|OTHER|Patient reported outcome measures|EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
48140303|NCT01961076|OTHER|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
47914851|NCT01251341|BEHAVIORAL|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
47914852|NCT01251341|BEHAVIORAL|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
47914853|NCT01251341|BEHAVIORAL|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
47914854|NCT01901913|DEVICE|MD-bolus calculator for pre-meal bolus|
47914855|NCT01901913|DEVICE|No MD-bolus calculator for pre-meal bolus|
48350968|NCT01430689|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
48350969|NCT01430689|BIOLOGICAL|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~* Home visits weekly until the infant is born and reaches 6 months of age~* If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
48350970|NCT01449344|DRUG|Rituximab|Rituximab 375mg/m² IV , day 1
48350971|NCT01449344|DRUG|High dose Ara-C|Ara-C 2000 mg/m² (patients \>65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
48350972|NCT01449344|DRUG|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
48350973|NCT01449344|DRUG|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
48503626|NCT03210714|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
48503627|NCT03210714|PROCEDURE|Bone Scan|Undergo a bone scan
48503628|NCT03210714|PROCEDURE|Computed Tomography|Undergo a CT scan
48503629|NCT03210714|DRUG|Erdafitinib|Given PO
48503630|NCT03210714|OTHER|Laboratory Biomarker Analysis|Correlative studies
48503631|NCT03210714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48503632|NCT03210714|OTHER|Pharmacological Study|Correlative studies
48503633|NCT03210714|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
48503634|NCT03210714|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
48503635|NCT03210714|PROCEDURE|X-Ray Imaging|Undergo an x-ray
48661332|NCT01651208|BEHAVIORAL|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
48350974|NCT04440085|DRUG|Midodrine Hydrochloride|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.
48350975|NCT04440085|DRUG|Placebo|All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.
48661333|NCT01651208|BEHAVIORAL|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
48661334|NCT06363760|OTHER|Safety and efficacy assessments|Assessed throughout the duration of the study.
48350976|NCT03862586|DRUG|N-acetyl cysteine|
48350977|NCT03862586|DRUG|Placebos|
48661335|NCT03003663|DEVICE|SensableCare System|The SensableCare System is evaluated for reducing bed falls.
47985298|NCT01172457|PROCEDURE|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
48350978|NCT01995422|OTHER|Physical activity program|One hour sessions of active walking occurring three times a week during three months
48350979|NCT05934708|BEHAVIORAL|Eccentric leg extension|Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.
48350980|NCT01897259|DRUG|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
48350981|NCT01897259|BEHAVIORAL|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
48350982|NCT01897259|DRUG|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
48661336|NCT05585320|DRUG|IMM-1-104 Monotherapy (Treatment Group A)|Once-daily, oral IMM-1-104 dose administered in 28-day cycles until treatment discontinuation criteria are met
48503636|NCT05021718|OTHER|Strengthening exercises|Back and hip strengthening exercises. The intensity of exercises was based on the exercise tolerance and pain thresholds of the individual subjects.
48503637|NCT05021718|DRUG|Pharmacological therapy|Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
48503638|NCT05021718|OTHER|Hot compression|Hot moist compression from week 4 to week 6.
48503639|NCT05021718|BEHAVIORAL|Activities to daily living instructions|"* Avoid forward bending.~* Avoid heavy weightlifting.~* Avoid prolong standing.~* Avoid prolong sitting.~* Use a plain firm bed.~* Lie down in a supine position."
48503640|NCT05546463|BEHAVIORAL|Digital games|"A digital game was played via iPad Air 2 32GB 9.7-inch wi-fi model tablet. The researcher created a folder with a range of selected games to appeal to different preferences. Children could choose from the following games: Word Travel, Talking Tom Candy Run, 384 Puzzles for Kids, Masha and The Bear, Subway Surfers, Head Ball 2 and Dream League Soccer."
47985299|NCT01172457|PROCEDURE|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
47985300|NCT00671502|DRUG|Carisoprodol SR|700 mg twice daily
47985301|NCT00671502|DRUG|Carisoprodol SR|500 mg twice daily
47985302|NCT00671502|DRUG|Placebo|Placebo tablet
48350983|NCT01897259|DRUG|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
48350984|NCT03157999|BEHAVIORAL|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~* care coordination and system navigation (including facilitating timely primary care follow-up);~* medication management;~* assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~* evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~* patient and caregiver education; and goal setting and problem-solving therapy."
48350985|NCT02617706|DEVICE|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
48661337|NCT05585320|DRUG|IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of gemcitabine and nab-paclitaxel until treatment discontinuation criteria are met.~Gemcitabine will be administered at a dose of 1000 mg/m\^2 nab-Paclitaxel will be administered at a dose of 125 mg/m\^2"
47985303|NCT03884218|OTHER|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
47985304|NCT04882267|BEHAVIORAL|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
47985305|NCT03946904|DEVICE|Er,Cr:YSGG Laser|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
47985306|NCT03109587|DIETARY_SUPPLEMENT|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
47985307|NCT03109587|DIETARY_SUPPLEMENT|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
47985308|NCT02408458|DEVICE|MIROMESH®|
47985309|NCT01408914|DRUG|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
47985310|NCT00759863|BEHAVIORAL|Lifezig|Personalized Reminiscence Video
47985311|NCT04358575|DEVICE|Triathlon CS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
47985312|NCT04358575|DEVICE|Triathlon CS Knee System with metal-backed modular components|Primary Total Knee Replacement
47985313|NCT03448822|PROCEDURE|sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
48140304|NCT02110381|DEVICE|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
48350986|NCT02339376|DEVICE|Low-frequency repetitive transcranial magnetic stimulation|
47985314|NCT03779789|DRUG|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index \[ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose\]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
47985315|NCT03779789|DRUG|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
48350987|NCT02339376|DEVICE|High-frequency repetitive transcranial magnetic stimulation|
48350988|NCT02339376|DEVICE|Sham repetitive transcranial magnetic stimulation|
48350989|NCT02903745|OTHER|observational|
48350990|NCT05589766|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside supplementation up to 3000mg daily in total.
48350991|NCT05589766|OTHER|Placebo|Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.
48350992|NCT01377324|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with \~200MBq 18F-FES
48350993|NCT02131389|DEVICE|Iconacy Hip System|
48350994|NCT05409118|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
48350995|NCT05409118|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
47985316|NCT03779789|DRUG|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
47985317|NCT03779789|DRUG|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
48140305|NCT02110381|DEVICE|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
48140306|NCT01915914|DRUG|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
48140307|NCT05421572|DIAGNOSTIC_TEST|Fibrotouch|Fibrotouch will be performed showing the stiffness and fat content of liver
48140308|NCT06510855|DEVICE|DurAVR™ THV System|DurAVR™ THV System - Transcatheter Aortic Valve Implantation (TAVI) Procedure
48140309|NCT02368041|DEVICE|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
48140310|NCT02744066|DEVICE|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
48140311|NCT04773145|PROCEDURE|Hemiarthroplasty with hydroaxyapatite coated stem|Hemiarthroplasty with non cemented femoral stem, using the hydroxyapatite-coated femoral stem Pharo
48140312|NCT02751710|OTHER|Whole-body FDG PET-CT alone|FDG PET-CT imaging
48140313|NCT03021616|OTHER|energy drink|32oz of commercially available energy drink
48140314|NCT03021616|OTHER|Moxifloxacin 400mg|400mg moxifloxacin active control drink
48140315|NCT03021616|OTHER|Placebo|Placebo drink
48140316|NCT03490032|DRUG|[68Ga]-PSMA-R2|radio-labelled PSMA ligand
48140317|NCT04290741|PROCEDURE|Auricular (Battlefield) Acupuncture|Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
48140318|NCT04290741|PROCEDURE|Peripheral Acupuncture|Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
48140319|NCT00434694|PROCEDURE|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
48503641|NCT01329549|DRUG|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
48503642|NCT01329549|DRUG|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
48503643|NCT01329549|DRUG|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
48140323|NCT00380250|DRUG|Lubiprostone|
48140324|NCT00380250|DRUG|Placebo|
48140325|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
48140326|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
48661338|NCT05585320|DRUG|IMM-1-104 + modified FOLFIRINOX (Treatment Group C)|"Once-daily, oral IMM-1-104 dose administered in 28-day cycles in combination with intravenous infusions of modified FOLFIRNOX until treatment discontinuation criteria are met.~FOLFIRINOX will be administered as follows:~Folinic Acid will be administered at 400 mg/m\^2 Fluorouracil will be administered at 2400 mg/m\^2 Irinotecan will be administered at 150 mg/m\^2 Oxaliplatin will be administered at 85 mg/m\^2"
48350996|NCT06358976|OTHER|Vibration plus anti-spastic hand splint|vibration stimulation will be applied to the spastic hand antagonistic muscles using a volar anti-spastic hand splint and the Myovolt Arm vibrator.
48350997|NCT06358976|OTHER|Anti-spastic hand splint|the use of anti-spastic hand splint alone.
48350998|NCT06358976|OTHER|Vibration|The use of hand vibrator alone
48350999|NCT02798640|DEVICE|Celliant|100% Celliant garment
48351000|NCT02798640|DEVICE|Control|Control Garment
48351001|NCT01522196|DRUG|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
48351002|NCT01522196|OTHER|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
48661339|NCT06563908|PROCEDURE|Lipiodol® uterine treatment prior to IVF/ICSI|Lipiodol®, treatment will be performed by a HSG technique with X-ray screening on day 3 or day 5 after oocyte retrieval. The contrast medium will be Lipiodol Ultra Fluide® (Guerbet, France), an iodized poppy seed oil obtained by substitution of ethyl esters for the glyceryl esters of Lipiodol®. One millilitre of Lipiodol Ultra Fluide® contains 0.48g iodine. Women will lie in the left lateral or supine position. Radiologists will use a 'no touch' technique after applying antiseptic solution to the cervix. Uterine cannulation using the Cook HSG catheter will be applied to conduct Lipiodol® treatment. Prewarmed (37oC) Lipiodol® will be slowly instilled, with intermittent fluoroscopic X-ray guidance. Up to 10 ml of Lipiodol® will be slowly injected into the uterus and directly monitored by fluoroscopy. If intravasation was observed on X-ray (contrast apparent in the venous system), instillation will be stopped immediately.
48661340|NCT02678533|DRUG|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
48661341|NCT02678533|DRUG|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
48351003|NCT03206983|DEVICE|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
48351004|NCT00419237|DRUG|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
48351005|NCT00152841|DRUG|Iron supplement 300-600 mg/day|
48351006|NCT00152841|DRUG|Vitamin E 800IU|
48503644|NCT03697863|PROCEDURE|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
48661342|NCT04164901|DRUG|Vorasidenib|Vorasidenib oral film-coated tablets
48661343|NCT04164901|DRUG|Matching Placebo|Matching Placebo oral tablets
48661344|NCT06563856|DRUG|TEPEZZA|Administered as a SubQ injection or IV injection.
48661345|NCT06563856|DRUG|EDP|Administered as a SubQ injection.
48661346|NCT03005002|BIOLOGICAL|Durvalumab|Given IV
48661347|NCT03005002|OTHER|Laboratory Biomarker Analysis|Correlative studies
48661348|NCT03005002|BIOLOGICAL|Tremelimumab|Given IV
48351007|NCT00177008|DRUG|Aripiprazole|
48351008|NCT05620485|PROCEDURE|laparoscopic-assisted CDC excision and hepaticojejunostomy|After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.
48351009|NCT04487418|PROCEDURE|Electro cautery surgery|"Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
48367511|NCT06346639|OTHER|16-day hot and cold acclimation|Acclimation program will consist of 8 brief cold water immersions (CWI; 14°C 5 min) and 8 hot water immersions (HWI; 45°C 5 min). Heat and cold sessions will be performed on separate days (i.e., 1st day hot exposure, 2nd day cold exposure, 3rd day hot exposure, etc.).
48367512|NCT04350749|BIOLOGICAL|PRF is added in the test group.|The PRF membrane can be considered as a biological membrane
48367513|NCT02160743|DIETARY_SUPPLEMENT|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
48503645|NCT06112496|DEVICE|EMG|Neuro-EMG-Micro, Neurosoft, Ivanovo, Russia, will be used for the assessment of muscle activity for muscles.
48503646|NCT03017612|DEVICE|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
48503647|NCT02345837|DEVICE|endometrial sampling|injury to the endometrium
48503648|NCT02345837|DRUG|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
48503649|NCT03024008|BIOLOGICAL|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
48503650|NCT03908515|DEVICE|Foldable Capsular Vitreous Body (FCVB)|FCVB can be regarded as an artificial vitreous and consists of a thin vitreous-shaped capsule, a drain tube, and a valve. After foldable implantation into the eye, then silicone oil is injected into the capsule which inflated to support the retina. The capsular material of FCVB is silicone rubber. The capsule was fabricated a computer simulation of the human and rabbit vitreous cavities. The control of the intraocular pressure is achieved with adjusting the amount of injected medium through the tube-valve system. After the medium was injected into the capsule through the tube-valve system, the valve was subsequently fixed onto the sclera surface similar to the glaucoma valve.
48140327|NCT05202366|DRUG|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
48661349|NCT03592017|DEVICE|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
48661350|NCT04862312|BEHAVIORAL|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
48661351|NCT04196621|DEVICE|High viscous artificial tears|Instillation of one drop high viscous artificial tears
48661352|NCT04196621|DEVICE|Low viscous artificial tears|Instillation of one drop low viscous artificial tears
48503651|NCT04122144|BEHAVIORAL|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL \& Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
48503652|NCT06102681|OTHER|intervention group|we will measure, consider and compare patients pain level, quality of life and recovery process. For these aims we will use numeric pain scale, nottingham health profile and postoperative recovery index.
48503653|NCT01616342|DEVICE|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
48503654|NCT00007527|DRUG|naloxone|
48661353|NCT04194242|DRUG|HEC96719 tablets|0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
48661354|NCT04194242|DRUG|Placebo tablet|0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
48661355|NCT02894398|DRUG|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
48661356|NCT02894398|DRUG|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
47985318|NCT03779789|DRUG|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
47985319|NCT03779789|DRUG|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
47985320|NCT03779789|DRUG|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
48503655|NCT00007527|DRUG|buprenorphine|
48140328|NCT05731206|OTHER|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
48140329|NCT05731206|OTHER|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
48140330|NCT01779700|DRUG|Fingolimod|0.5mg each day of 8 week cycle
48503656|NCT03608865|DRUG|Durvalumab with Tremelimumab|Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
48661357|NCT02894398|DRUG|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
48661358|NCT02894398|DRUG|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
48661359|NCT02894398|DRUG|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
48661360|NCT02149966|DRUG|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
48661361|NCT02149966|DRUG|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
48140331|NCT01779700|DRUG|placebo|1 tablet each day of 8 week cycle
48140332|NCT05313412|DEVICE|Lens A (comfilcon A lens)|6 hours
47985321|NCT05620550|PROCEDURE|ozonated oil|Post operative scar treatment with ozonated oil
47985322|NCT05620550|PROCEDURE|non ozonated oil|Post operative scar treatment with non ozonated oil
48140333|NCT05313412|DEVICE|Lens B (lehfilcon A lens)|6 hours
48661362|NCT01220687|DRUG|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
47985323|NCT04533308|BEHAVIORAL|Relaxation in virtual reality|Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
47985324|NCT00536406|BEHAVIORAL|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
47985325|NCT00536406|BEHAVIORAL|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
47985326|NCT01203046|DRUG|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
48140334|NCT04516226|OTHER|Vaginal cleansing with chlorhexidine gluconate solution|Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
48140335|NCT05240794|DEVICE|ABM-01|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
48140336|NCT05240794|DEVICE|Digital Control|Placebo control for ABM-01
48367514|NCT06381024|DEVICE|remote patient monitoring|"Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken."
48503657|NCT06160193|BEHAVIORAL|Brief behavioral parent training with optional care as usual|A brief behavioral parent training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of 120 minutes, and a third session of 60 minutes, in which the training will be evaluated and maintenance training will be provided.
48503658|NCT06160193|OTHER|Care as usual|Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
48503659|NCT06168110|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a non-invasive treatment method widely used for pain control
48503660|NCT04225910|DRUG|225Ac-PSMA|all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
48503661|NCT02529644|BEHAVIORAL|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
48503662|NCT02529644|BEHAVIORAL|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
48661363|NCT01220687|OTHER|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
47985327|NCT04905446|OTHER|Deuterated nicotinamide (D4-NAM) IV infusion|Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. D4-NAM (in normal saline) will be infused via an indwelling catheter.The IV infusion will continue for 8 hrs.
47985328|NCT04905446|PROCEDURE|Skeletal muscle biopsy|Participants will have a muscle biopsy performed on the muscle in the thigh. We will collect a small sample of blood before the biopsy. This procedure is used to sample muscle cells from the right or left leg Vastus Lateralis (thigh) muscle.
47985329|NCT04905446|PROCEDURE|Skin tissue biopsy|This procedure is used to sample skin tissue from the upper thigh via a punch biopsy.
47985330|NCT03090152|PROCEDURE|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
47985331|NCT03090152|PROCEDURE|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
47985332|NCT03090152|DRUG|Bupivacaine|EPCA: Bupivacaine 0.06%.
47985333|NCT03090152|DRUG|Placebo|EPCA: Saline.
47985334|NCT05416320|DRUG|Calcipotriol|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
48503663|NCT05699486|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
48503664|NCT05699486|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
48503665|NCT05014412|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
48140337|NCT02268240|BEHAVIORAL|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
48351010|NCT04487418|PROCEDURE|High power diode laser surgery|"Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt."
48503666|NCT05603377|DIAGNOSTIC_TEST|functional endoscopic evaluation of swallow|functional endoscopic evaluation of swallow
48503667|NCT01635283|BIOLOGICAL|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
48503668|NCT01635283|OTHER|laboratory biomarker analysis|Correlative studies
48503669|NCT01385449|PROCEDURE|interscalene catheter|interscalene catheter
48661364|NCT05112640|DEVICE|INSORB: subcuticular stapling device|Under the skin stapling device that delivers absorbable staples
48661365|NCT05112640|DEVICE|Subcuticular monocryl suture manufactured by Ethicon|Under the skin suture placed by hand
48661366|NCT02009267|DEVICE|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
47985335|NCT05416320|DRUG|Subject's already prescribed drug|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
48503670|NCT01385449|PROCEDURE|interscalene block|interscalene block
48503671|NCT04942743|DIAGNOSTIC_TEST|MRI|MRI OF TMJ
48661367|NCT02009267|PROCEDURE|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
48661368|NCT02009267|PROCEDURE|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
47985336|NCT04841902|OTHER|Life Style Intervention Manual (With Exercise Under Supervision)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.
47985337|NCT04841902|OTHER|General Advice|General advice to stay healthy and active
47985338|NCT04841902|OTHER|Life Style Intervention Manual (Home Based)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.
48503672|NCT04722146|DRUG|Teclistamab|Participants will receive teclistamab.
48503673|NCT04722146|DRUG|Daratumumab|Participants will receive daratumumab.
48503674|NCT04722146|DRUG|Pomalidomide|Participants will receive pomalidomide.
48503675|NCT04722146|DRUG|Lenalidomide|Participants will receive lenalidomide.
48503676|NCT04722146|DRUG|Bortezomib|Participants will receive bortezomib.
48503677|NCT04722146|DRUG|Nirogacestat|Participants will receive nirogacestat.
48503678|NCT05729685|OTHER|Interval training|"The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training."
48351011|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners are blinded to each other and to the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
48351012|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners is now being informed of the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
48351013|NCT05299502|BEHAVIORAL|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
48140338|NCT05654285|OTHER|Cola beverage with aspartame and acesulfame K|"Before starting the study: Subjects were asked to avoid non-nutritive sweetener consumption for 48 hours prior to the study sessions. A standardized menu of 346 Kcal was prescribed for dinner and fasting for at least 8 hours prior to each study session. A 7-day washout period was left between each study session.~Session 1: Weight, height, and waist circumference were measured, the BMI was calculated, and sociodemographic data of the participants and information on the habitual consumption of soft drinks were collected.~In each session: The beverages were offered at approximately 4°C, in standardized disposable cups, and the participants were asked to drink them in a maximum time of 10 minutes. Heart rate, respiratory rate, and blood pressure were measured before the intervention and every 30 minutes during the observation period. The subjects who manifested adverse sensations were referred to receive medical attention and withdrawn from the session."
48351014|NCT04143789|DRUG|AP-002|Dose escalation
48351015|NCT00011375|DRUG|Rolipram|
48351016|NCT04132128|OTHER|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
48351017|NCT02798445|OTHER|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
48351018|NCT02798445|OTHER|CONTROL|Multilayer bandages and wound care
48140339|NCT05654285|OTHER|Cola beverage with sucrose and stevia|
48351019|NCT01958268|PROCEDURE|Pretest and validation of a translated questionnaire|
48351020|NCT00024128|BIOLOGICAL|anti-thymocyte globulin|
48351021|NCT00024128|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48351022|NCT00024128|DRUG|cyclophosphamide|
48351023|NCT00024128|DRUG|cyclosporine|
48351024|NCT00024128|PROCEDURE|peripheral blood stem cell transplantation|
48351025|NCT00024128|RADIATION|radiation therapy|
48351026|NCT04202796|PROCEDURE|Catheter ablation|Catheter ablation of arrhythmia
48351027|NCT04941976|DRUG|0.3% benzydamine hydrochloride spray oromucosal solution|"Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
48661369|NCT05962489|OTHER|Clinically optimized deep brain stimulation|Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.
48661370|NCT06459440|BEHAVIORAL|Group Task oriented Training|Group Task-Oriented Training for individuals with Down syndrome is an approach that focuses on improving specific skills and promoting social interaction through collaborative activities. This training method involves organizing individuals with Down syndrome into small groups to work on tasks that target various developmental areas, such as motor skills, communication, and socialization. The tasks are designed to be meaningful, engaging, and relevant to the participants' daily lives.
48661371|NCT06459440|OTHER|Routine Treatment|"1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes)"
48351028|NCT04941976|DRUG|Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)|"Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.~In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution."
48367515|NCT01080157|DEVICE|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
48661372|NCT04576455|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.
48661373|NCT04576455|DRUG|Fulvestrant or an Aromatase Inhibitor (Physician Choice)|Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
48661374|NCT04576455|DRUG|LHRH Agonist|Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
48367516|NCT01087944|DEVICE|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
48661375|NCT05718531|DRUG|Rivaroxaban 2.5 Mg Oral Tablet twice daily|effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
48661376|NCT05718531|DRUG|Clopidogrel 75 Mg Oral Tablet|Used as control group in 2nd arm and 5th arm
48661377|NCT05718531|DRUG|Aspirin tablet 75 mg|Used as control group in 2nd arm and 5th arm
48661378|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
48503679|NCT05729685|OTHER|Continuous training|The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
48140340|NCT03967015|OTHER|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
48140341|NCT01760226|DRUG|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
48140342|NCT01760226|DRUG|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6."
48140343|NCT01760226|DRUG|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
48140344|NCT01760226|DRUG|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
48140345|NCT01760226|DRUG|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
48140346|NCT01760226|DRUG|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
48140347|NCT01760226|DRUG|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
48140348|NCT01760226|DRUG|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
48140349|NCT01760226|DRUG|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
48140350|NCT04743388|BIOLOGICAL|BNT162b2|Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
48661379|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
48661380|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
48661381|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
48661382|NCT06539481|DRUG|fluocinolone acetonide 190 micrograms|ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.
48661383|NCT02035657|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
48661384|NCT05199753|DRUG|LM-108|Administered intravenously
48661385|NCT05199753|DRUG|An Anti-PD-1 Antibody|Administered intravenously
48140351|NCT04743388|BIOLOGICAL|Other vaccine against SARS-Cov-2|Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
48140352|NCT01406106|DIETARY_SUPPLEMENT|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
48140353|NCT00738959|DRUG|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
48140354|NCT02423005|DEVICE|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
48140355|NCT02423005|DEVICE|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
48661386|NCT04840511|DRUG|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
48661387|NCT04840511|DRUG|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
48661388|NCT03589833|DRUG|Tripterygium Wilfordii|Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
48661389|NCT03589833|DRUG|Methotrexate|Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
48661390|NCT03589833|DRUG|Yisaipu|Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
48140356|NCT04711291|COMBINATION_PRODUCT|Conversion to Envarsus-XR and use of smart phone app, TransMedAx|"Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAx.~Patients in this arm will be trained to use the app along with conversion to Envarsus-XR. Once patient scan the code on medicine bottle and the app will remind them about the time and dose of the medication in their native language."
48140357|NCT04711291|DRUG|Convert to Envarsus XR once daily|Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
48140358|NCT00797056|DRUG|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
48140359|NCT00797056|DRUG|Placebo|Saline SQ daily for 10 days
48140360|NCT00797056|DRUG|Aspirin|Aspirin 75 mg/day for 14 days
48140361|NCT00797056|DRUG|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
48140362|NCT01687920|DRUG|BAY94-8862 (1.25mg)|
48140363|NCT01687920|DRUG|BAY94-8862 (2.5mg)|
48140364|NCT01687920|DRUG|BAY94-8862 (5mg)|
48140365|NCT01687920|DRUG|BAY94-8862 (7.5mg)|
48661391|NCT06256900|OTHER|Flow-controlled ventilation|FCV mode during robot-assisted laparoscopic surgery
48140366|NCT01687920|DRUG|BAY94-8862 (10mg)|
48661392|NCT06256900|OTHER|Pressure-controlled ventilation|PCVmode during robot-assisted laparoscopic surgery
48140367|NCT05667311|DEVICE|ECG|Finapres electrocardiography machine
48140368|NCT05847699|OTHER|MRI sequences and biopsies|Addition of a contrast injection and optimized SWI sequences during the pre-DH MRI examination performed as part of the care Addition of two 1x1 cm biopsy samples of cortex in two different non-functional ischemic areas, one of which is within the SWI hyposignal remodeling, during the DH. This will be a cold pial dissection without the use of coagulation.
48140369|NCT02208843|DRUG|Afatinib|Afatinib tablet once daily until progression
48661393|NCT00654732|DRUG|Bleomycin|Given IV
48661394|NCT00654732|DRUG|Dacarbazine|Given IV
48661395|NCT00654732|DRUG|Doxorubicin Hydrochloride|Given IV
48661396|NCT00654732|BIOLOGICAL|Rituximab|Given IV
48661397|NCT00654732|DRUG|Vinblastine|Given IV
48661398|NCT03624075|OTHER|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
48661399|NCT00863590|DRUG|odanacatib|\[Intervention Name: odanacatib (Panel A)\] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
48661400|NCT00863590|DRUG|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
48661401|NCT00863590|DRUG|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
48661402|NCT00863590|DRUG|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
48661403|NCT02947048|DRUG|L1-79|
48661404|NCT02947048|DRUG|Placebo|
48140370|NCT05033327|BEHAVIORAL|Nutrition and Exercise app|Personalized, home-based, interactive therapy app
48140371|NCT01412606|PROCEDURE|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
48140372|NCT03840096|DEVICE|Breg Flex|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
48140373|NCT05332613|BEHAVIORAL|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
48140374|NCT05332613|BEHAVIORAL|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
48140375|NCT05332613|BEHAVIORAL|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
48140376|NCT02647333|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
48351029|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min."
48351030|NCT01254786|PROCEDURE|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio \<0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
47985339|NCT04646707|DRUG|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|Bilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
48140377|NCT02647333|DIETARY_SUPPLEMENT|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
48140378|NCT03682614|DRUG|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
48140379|NCT03682614|OTHER|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
48351031|NCT03086148|DRUG|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
48351032|NCT03086148|DRUG|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
48351033|NCT00307944|DRUG|Pantoprazole|
48661405|NCT06385028|BEHAVIORAL|Physical activity promotion|The intervention will be delivered through a phone application: each week, the participant will define a new daily step goal for the following week. Then he/she will receive daily notifications (except Sundays) about physical activity, sedentary behavior and their consequences on general health and osteoarthritis specifically. These notifications are designed to promote physical activity in this specific population.
48661406|NCT05287451|OTHER|RIsk-Reducing Salpingectomy (RRS)|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
47985340|NCT04646707|DRUG|Erector Spinae (ESP) Block with placebo|Bilateral ESP block at T1 level with 20 ml of 0.9% normal saline
47985341|NCT03128333|OTHER|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
47985342|NCT03128333|OTHER|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
47985343|NCT03582202|PROCEDURE|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
47985344|NCT03582202|PROCEDURE|Standard care|Nutritional handling by nurse
47985345|NCT04170257|DIAGNOSTIC_TEST|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
48140380|NCT03846037|OTHER|Proprioceptive exercise on the vibratory platform|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
48140381|NCT03846037|OTHER|Proprioceptive exercise on the ground (stable surface)|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
48140382|NCT04318483|OTHER|survey|parents' telephone interview to collect medical history
48140383|NCT04700202|OTHER|Observational|Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
48140384|NCT05192382|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
48140385|NCT05192382|DRUG|Placebo|Placebo, tablets, once daily by mouth
48140386|NCT01517503|BEHAVIORAL|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
48351034|NCT02960308|RADIATION|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
48351035|NCT02058251|DRUG|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
48661407|NCT05287451|OTHER|Risk-Reducing Oophorectomy-RRO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
48661408|NCT05287451|OTHER|Risk-Reducing Salpingo-Oophorectomy-RRSO|complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
48661409|NCT00375713|DRUG|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
48140387|NCT01517503|BEHAVIORAL|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
48140388|NCT02106884|DRUG|Nab-paclitaxel|
48140389|NCT02106884|DRUG|Gemcitabine|
48140390|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
48661410|NCT00375713|DRUG|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
48661411|NCT00375713|DRUG|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
48661412|NCT00375713|DRUG|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
48661413|NCT00375713|DRUG|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
48661414|NCT05151926|PROCEDURE|Full weight-bearing|Instruction for full and immediate weight-bearing postoperatively
48661415|NCT05151926|PROCEDURE|Partial weight-bearing|Instruction for partial weight-bearing for 6 weeks postoperatively
48140391|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
48140392|NCT02284607|DRUG|Placebo|Matching placebo to MHAA4549A administration
48140393|NCT02576691|DEVICE|percutaneous coronary intervention|
48351036|NCT02058251|DRUG|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
48351037|NCT05570136|BEHAVIORAL|Functional Exercise|Treatment group will receive the 12-week STEP by a trained interventionist. During the intervention period, an occupational therapist will help the participant to learn the STEP exercise and principles and help the older adults to be more independent on functional exercising.
48351038|NCT05570136|BEHAVIORAL|Education|In the education group, participant will receive weekly health newsletters containing general health aging materials. A staff member will call the control group participants weekly to document any new exercise programs from usual community services.
48351039|NCT05078086|OTHER|No intervention|No intervention
48661416|NCT05151926|PROCEDURE|Intramedullary nailing|Intramedullary nailing of the fractured tibial shaft.
48661417|NCT02494414|OTHER|Long-term follow-up|Vital and neurological follow-up
48661418|NCT01447784|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
48661419|NCT01447784|BIOLOGICAL|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
48661420|NCT04041193|BEHAVIORAL|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
48661421|NCT04041193|BEHAVIORAL|Usual Care Program|Usual Care program activities (paper and pencil at home)
48140394|NCT04919395|DEVICE|Clip device for Nexplanon Removal|The clip device will be used to assist in the removal procedure to remove the Nexplanon implant from the subject.
48140395|NCT04919395|PROCEDURE|Standard of Care procedure|The participants Nexplanon will be removed per standard of care.
48140396|NCT03683615|PROCEDURE|repair of orbital floor fractures using resorbable plates|
48140397|NCT03650166|OTHER|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
48140398|NCT03650166|OTHER|Personal BP monitor|Battery-powered BP monitor for personal use
48140399|NCT02066155|BEHAVIORAL|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
48140400|NCT02066155|BEHAVIORAL|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
48140401|NCT02402270|DRUG|NuLYTELY® (PEG 3350)|
48140402|NCT02402270|DRUG|ECP-019|
48140403|NCT02402270|DRUG|MoviPrep® (PEG 3350)|
48140404|NCT06475079|OTHER|• FHP app (Pyeongtaek, South Korea) mobile application|FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle
48140405|NCT03369457|BIOLOGICAL|Isolation of multipotent cells|Isolation of multipotent cells from patient's cells. Analysis of CFU and differentiation potential
48140406|NCT04016207|DRUG|Guanfacine|regular treatment
48140407|NCT01451359|DEVICE|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
48661422|NCT06151483|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
48661423|NCT06151483|OTHER|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
48661424|NCT02478541|OTHER|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
48661425|NCT05349604|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
48661426|NCT05349604|DIETARY_SUPPLEMENT|Placebo|One intake in total
48661427|NCT04925427|BEHAVIORAL|Case Management and Peer Recovery|A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
48351040|NCT06245304|DEVICE|Dual chamber Medtronic pacemaker implantation.|"All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines.~Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830."
48661428|NCT04925427|BEHAVIORAL|Naloxone-Only|Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
48661429|NCT00969020|PROCEDURE|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
48661430|NCT03895372|DRUG|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
48661431|NCT03895372|DRUG|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
48140408|NCT00821288|BEHAVIORAL|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
48351041|NCT06245304|OTHER|DDD-50 pacing program|This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.
48351042|NCT06245304|OTHER|AAI-DDD 50 pacing program|This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.
48503680|NCT05649930|OTHER|Functional power training|The training consists of weighted running and walking exercises performed at high-velocity and is given three times a week for 12 weeks.
48661432|NCT05812859|DEVICE|Vaginal Orthosis (COSM Medical)|A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
47985346|NCT03630120|DRUG|Lenvatinib|"Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
48367517|NCT01087944|DEVICE|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
48367518|NCT00367146|DRUG|MMF|
48367519|NCT03334994|PROCEDURE|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
48503681|NCT00889369|DRUG|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
48661433|NCT02892370|DRUG|SHR0302|SHR0302 tablets (10 mg)
48661434|NCT00936936|DRUG|Gemcitabine|1800 mg/m\^2 IV over 3 hours on Days -5 to Day -2.
48661435|NCT00936936|DRUG|Docetaxel|Docetaxel 300 mg/m\^2 IV over 2 hours on Day -5.
48661436|NCT00936936|DRUG|Melphalan|50 mg/m\^2 IV over 15 minutes on Days -4 to Day -2.
48661437|NCT00936936|DRUG|Carboplatin|"Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3."
48661438|NCT00936936|DRUG|Mesna|3,000 mg/m\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
48661439|NCT00936936|DRUG|Ifosfamide|3,000 mg/m\^2 IV over 6 hours on Days -6 to -3
48503682|NCT01177475|OTHER|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
48503683|NCT01177475|OTHER|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
48140409|NCT00821288|BEHAVIORAL|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
48140410|NCT02075723|DIETARY_SUPPLEMENT|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
48140411|NCT02075723|BEHAVIORAL|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
48140412|NCT01567787|RADIATION|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
48140413|NCT01567787|RADIATION|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
48140414|NCT01632956|BEHAVIORAL|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
48351043|NCT01476553|PROCEDURE|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
48351044|NCT06102928|DRUG|Combined therapy of anlotinib and aumolertinib|Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
48140415|NCT01632956|BEHAVIORAL|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
48140416|NCT02707198|DRUG|kefir|4 ounces of kefir 3 times a day, with or without food.
48351045|NCT00705380|BEHAVIORAL|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
48503684|NCT01235832|OTHER|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
48503685|NCT01235832|OTHER|Lower-Fat Diet|The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
48503686|NCT01235832|OTHER|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
48503687|NCT06548555|OTHER|systematic educational intervention|This is a non-interventional study and does not impose a therapy protocol, or a diagnostic/therapeutic procedure. Patients are treated according to the local prescribing information, and routine medical practice in terms of visit frequency and types of assessments performed and only these data is collected as part of the study.
48351046|NCT00705380|BEHAVIORAL|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
48351047|NCT02510976|DRUG|prucalopride|
48351048|NCT02510976|DRUG|placebo|
48351049|NCT04371549|PROCEDURE|Glue (Dermabond®; Ethicon, Somerville, NJ).|Arm 1: Skin after cesarean section will be closed by glue
48661440|NCT00936936|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours, every 12 hours on Days -6 to -4.
48661441|NCT00936936|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
48661442|NCT00032812|DRUG|Raclopride|
48661443|NCT05158010|OTHER|HELIX's follow-up|"* Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~* Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples."
48661444|NCT01771497|DEVICE|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
48661445|NCT02213926|DRUG|ACP-196 (acalabrutinib)|
47985347|NCT03630120|DRUG|Sorafenib|"Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
48140417|NCT03678792|DRUG|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
48661446|NCT03781479|DRUG|Amifampridine Phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
48661447|NCT03781479|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
48687880|NCT05087433|OTHER|Progressive Relaxation Exercises|The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
47985348|NCT03630120|DRUG|Cabozantinib|"Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
47985349|NCT03630120|DRUG|Vandetanib|"Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
47985350|NCT02854735|OTHER|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
47985351|NCT00834860|DRUG|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
47985352|NCT00340080|DRUG|Abacavir|
47985353|NCT05147493|DRUG|Isatuximab|Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
47985354|NCT05147493|DRUG|Bortezomib|Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
47985355|NCT05147493|DRUG|Cyclophosphamide|Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
47985356|NCT05147493|DRUG|Dexamethasone|Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
47985357|NCT05147493|DRUG|Lenalidomide|Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
48351050|NCT04371549|PROCEDURE|Monocryl|Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
48351051|NCT04770025|DEVICE|High-density transcranial alternating current stimulation|High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
48351052|NCT04770025|DEVICE|Sham stimulation|High-density electrode configuration with sham stimulation
48351053|NCT04770025|BEHAVIORAL|Motivational interviewing|Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
48687881|NCT05764252|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
48140418|NCT03678792|DRUG|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
48140419|NCT03678792|DRUG|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
48140420|NCT00937287|OTHER|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
48140421|NCT01565187|BEHAVIORAL|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
48140422|NCT05671211|OTHER|Task-Oriented Training|Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
48351054|NCT03234075|OTHER|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation~* with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~* delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~* Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~* Helping to carry out the pre-graft assessments of patients by a care coordinator"
48351055|NCT01801774|DRUG|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
48351056|NCT01801774|DRUG|Placebo|
48351057|NCT00345956|BIOLOGICAL|Human rotavirus liquid vaccine|
48351058|NCT05439304|OTHER|No intervention|No intervention
48351059|NCT02038790|DRUG|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
48351060|NCT02038790|DRUG|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
48351061|NCT05687292|DEVICE|Clinical decision support system (CDSS) for ventilator weaning|A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
48351062|NCT04178434|BEHAVIORAL|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
48351063|NCT05074394|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody that is a neutralizing antibody to SARS-CoV-2
48351064|NCT05074394|DRUG|Placebo|Diluent solution
48351065|NCT03739099|DEVICE|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
48351066|NCT00899366|GENETIC|microarray analysis|
48351067|NCT00899366|GENETIC|mutation analysis|
48351068|NCT00899366|OTHER|immunologic technique|
48351069|NCT01291511|DRUG|Iloperidone|Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
48351070|NCT01291511|DRUG|Placebo|Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
48351071|NCT06064552|DIAGNOSTIC_TEST|blood sugar|"High and low risk women will undergo measuring fasting blood sugar after fasting 6-8hours with good hydration. then measuring blood sugar 1hrs and 2hrs postprandial. for patient with high results (FBS\>95mg/dl, 1hr postprandial\>126mg/dl, 2hrs postprandial \>140mg/dl) should do HA1C if \>5.6 consider it diabetic and dealing with whom positive as regard lifestyle management like diet and exercise 150 min. per week and whom not well controlled will be enrolled in pharmacological regimen as metformin.~For whom measures normal will be tested by the same method at 20- 24 wks of gestation"
48351072|NCT06217640|DIAGNOSTIC_TEST|Dual X Ray Absorptiometry|"* Dual X Ray Absorptiometry in the combination with functional tests~* Near-infrared spectroscopy in combination with hand grip strength"
48351073|NCT03879954|DEVICE|Catetherization approach|Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
48351074|NCT01847872|DRUG|IPV IM Needle|
48351075|NCT01847872|DRUG|IPV ID Needle|
48503688|NCT04696289|DIAGNOSTIC_TEST|Standardized catheterization assessment|"There are four components to the pulmonary vein assessment.~1. Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~2. Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~3. Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~4. Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon."
47985358|NCT01895660|BEHAVIORAL|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
48351076|NCT01847872|DRUG|IPV IM Device|
48351077|NCT01847872|DRUG|IPV ID Device|
48687882|NCT00260832|DRUG|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
47985359|NCT01637467|OTHER|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
48351078|NCT06048913|DRUG|Nimotuzumab|Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of Taixinsen is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.
48351079|NCT06048913|DRUG|Tigio|Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral tigio course from Monday to Friday is synchronized with radiation therapy.
48687883|NCT00260832|DRUG|Dacogen (decitabine) only|20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
48687884|NCT05148936|OTHER|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
48140423|NCT05671211|OTHER|Conventional Therapy|Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
48140424|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
48140425|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
48140426|NCT03331536|PROCEDURE|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
48140427|NCT03331536|PROCEDURE|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
48140428|NCT02697968|DEVICE|Electroacupuncture|
48140429|NCT00463502|DRUG|Metformin|
48140430|NCT04642898|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
48140431|NCT04642898|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
48140432|NCT04642898|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
48140433|NCT01472406|DEVICE|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
48140434|NCT01472406|DEVICE|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
48140435|NCT01472406|DEVICE|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
48367520|NCT05455060|DRUG|Chinese herbal formula (CHF)|Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
48367521|NCT05455060|DRUG|Placebo|The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
48687885|NCT05148936|OTHER|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
48687886|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
48687887|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
48140436|NCT01472406|DEVICE|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
48140437|NCT01472406|DEVICE|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
48140438|NCT01911156|DRUG|Continue NA treatment|Prescribed NA during the 72 week study period
47985360|NCT01637467|OTHER|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
47985361|NCT00314015|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
47985362|NCT00314015|PROCEDURE|Questionnaires|Questionnaires will be used
48140439|NCT01911156|DRUG|Discontinue NA Treatment|Discontinue NA Treatment
48140440|NCT06162182|DIAGNOSTIC_TEST|electrical impedance device,|The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager \& Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.
48140441|NCT06162182|DIAGNOSTIC_TEST|Reference test: Digital Radiographic examination|A digital periapical radiograph using paralleling technique was taken
48140442|NCT03110536|DIAGNOSTIC_TEST|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
48140443|NCT03110536|OTHER|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
48140444|NCT01714076|OTHER|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
48140445|NCT00237224|DRUG|Letrozole|
48140446|NCT01656512|DRUG|zolendronic acid|"patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg."
48140447|NCT01656512|DRUG|calcium & vitamin D|patients will receive calcium \& vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
48140448|NCT01703546|PROCEDURE|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band \& Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
48140449|NCT05804825|BEHAVIORAL|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
48687888|NCT06125171|DRUG|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，\<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m\^2, 500mg, qd, q4w BSA\<1.2m\^2, 250mg, qd, q4w"
47985363|NCT00191555|DRUG|olanzapine|
47985364|NCT00191555|DRUG|haloperidol|
47985365|NCT02390401|DEVICE|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
47985366|NCT02390401|DEVICE|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
47985367|NCT03280914|DEVICE|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
47985368|NCT02979847|PROCEDURE|hybrid approach|Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
48140450|NCT05804825|BEHAVIORAL|Simple forewarning message|Participants will be presented with a simple forewarning message.
48140451|NCT04817059|DEVICE|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
48140452|NCT04580004|OTHER|Med Optimization Arm|An evidence-based medication recommendation website that is provided to the patients.
48140453|NCT02684032|DRUG|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
48140454|NCT02684032|DRUG|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
48140455|NCT02684032|DRUG|Letrozole|Letrozole at 2.5 mg daily
48140456|NCT02684032|DRUG|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
48140457|NCT05165420|OTHER|Cosmetic product|RV4941A is a face cream product
47985369|NCT02979847|PROCEDURE|conventional endocardial approach|Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
47985370|NCT03465241|DIAGNOSTIC_TEST|the ctDNA dynamic monitoring|To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
48140458|NCT01972906|DEVICE|moxibustion|apply moxibustion according to traditional Chinese medicine
48140459|NCT01972906|DRUG|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
48140460|NCT05488405|DRUG|Mesalamine Oral Product|Mesalamine oral suspension for oral use
48140461|NCT00090415|BEHAVIORAL|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
48140462|NCT00000269|DRUG|Pergolide|
48687889|NCT04472481|DRUG|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
48367522|NCT01506310|BEHAVIORAL|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
48503689|NCT04475835|DRUG|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
48503690|NCT04475835|DRUG|Heparin|Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
48687890|NCT05690347|BEHAVIORAL|Back At work After Surgery (BAAS)|see protocol
48687891|NCT04102904|OTHER|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
47985371|NCT02172742|DRUG|BIA 2-093|BIA 2-093 1200 mg once-daily
47985372|NCT02172742|DRUG|Placebo|matching placebo
47985373|NCT02172742|DRUG|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
47985374|NCT03899142|BIOLOGICAL|a human hepatitis B immunoglobulin solution for injection for intramuscular administration|intramuscular administration
47985375|NCT04832685|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
47985376|NCT03910608|DEVICE|MagPro X100 device (MagVenture, Farum, Denmark)|Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
48140463|NCT03141918|DIETARY_SUPPLEMENT|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
48140464|NCT03141918|OTHER|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day."
48140465|NCT04412005|OTHER|No intervention|No intervention
48140466|NCT03735381|DEVICE|Pedometer watch 'Xiomi mi band2'|"1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group)."
48140467|NCT00774878|DRUG|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
48140468|NCT00774878|DRUG|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
48140469|NCT03385759|PROCEDURE|Unicompartmental knee arthroplasty|Implant to replace the medial compartment of a patient with knee osteoarthritis
48140470|NCT03385759|PROCEDURE|Total knee arthroplasty|Implant to replace the knee joint of a patient with knee osteoarthritis
48140471|NCT00570505|DEVICE|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
48140472|NCT00426205|BIOLOGICAL|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
48140473|NCT01479010|DRUG|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
48140474|NCT06272188|OTHER|web-based online preconceptional counselling|web-based online preconceptional counselling
48367523|NCT01506310|OTHER|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
48687892|NCT02998671|BIOLOGICAL|CJM112|
48140475|NCT01204996|DRUG|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
47985377|NCT01230801|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
47985378|NCT02579850|DRUG|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
47985379|NCT02579850|DRUG|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
47985380|NCT02579850|PROCEDURE|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
48503691|NCT00665938|OTHER|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
48503692|NCT03421795|OTHER|Let's Talk About Pain Training|See arm/group descriptions.
48503693|NCT03421795|OTHER|Family Centered Care Training|See arm/group descriptions.
48503694|NCT05943808|OTHER|Book reading|subjects are given an acupuncture textbook to read for 30 minutes
48687893|NCT02998671|OTHER|Placebo|
48687894|NCT00694577|RADIATION|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
48661448|NCT06132464|BEHAVIORAL|Expanding Communication and Language Generated in Conversation Treatment|ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
48661449|NCT05379530|DIAGNOSTIC_TEST|Thromboelastography (TEG)|Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
48140476|NCT01204996|DRUG|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
48140477|NCT01204996|DRUG|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
48140478|NCT01204996|DRUG|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
48140479|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
48140480|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%)."
47985381|NCT02579850|OTHER|COPD assessment test|COPD assessment test (CAT) at visit 1
48140481|NCT00787709|BEHAVIORAL|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
47985382|NCT02579850|PROCEDURE|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
48140482|NCT00065182|DRUG|Topotecan/Docetaxel combination|
48140483|NCT00065182|DRUG|Docetaxel|
48140484|NCT00778856|PROCEDURE|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
48140485|NCT04839809|DRUG|CC-92480|Oral
48140486|NCT04839809|OTHER|Placebo|Oral
48367524|NCT01506310|OTHER|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
48367525|NCT03319602|DEVICE|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
47985383|NCT02579850|OTHER|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
47985384|NCT02579850|OTHER|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
47985385|NCT06386133|DEVICE|MS Boost|remote monitoring digital tool based on functional tests (walking, dexterity, vision and cognition). These digital tests may be combined with a fatigue assessment via questionnaires and, if needed, a telerehabilitation program. This program includes an algorithm comprising fatigue management advice and/or physical activity recommendations personalised to the patients, aimed at improving fatigue-related symptoms. The patient can use the telerehabilitation program without supervision
47985386|NCT06386133|OTHER|Standard of care|General fatigue tips are given to patients who suffering from chronic fatigue such as stop smoking, eat a healthy diet...
48140487|NCT01496339|BIOLOGICAL|MenSCs transplantation|1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
48140488|NCT01496339|DRUG|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
48140489|NCT03340961|DRUG|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
48140490|NCT03340961|DRUG|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
48140491|NCT03340961|DRUG|Oraycea® (doxycycline) Capsules|Oral Treatment
48140492|NCT03340961|DRUG|Placebo Capsules|Oral Treatment
48140493|NCT06455306|PROCEDURE|Air-polishing with erythritol at different time points|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months
48140494|NCT06455306|PROCEDURE|Single Air-polishing with erythritol|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.
48367526|NCT00630942|DRUG|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
48661450|NCT05379530|OTHER|Anesthesia Provider Survey|Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
48661451|NCT02485886|DRUG|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
48687895|NCT00694577|RADIATION|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
48140495|NCT01535898|OTHER|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
48140496|NCT05945316|BEHAVIORAL|Accessing Confidence levels of Nursing students|Three mock CODE BLUE training events for Spring, Summer, and Fall Nursing Residents and Nursing Fellows are scheduled for 2022 followed by an actively participated CODE BLUE event. The PI plan to collect data from all new residents meeting the inclusion/exclusion criteria with voluntary participation to complete.
48140497|NCT01946594|OTHER|Acetaminophen|
48140498|NCT01946594|OTHER|Placebo|
48351080|NCT06048913|RADIATION|Concurrent radiation therapy|Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord \< 40 Gy and lung V20\<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
48351081|NCT01655940|DEVICE|Somanetics cerebral oximeter|Somanetics cerebral oximeter
48351082|NCT01655940|DEVICE|CASMED cerebral oximeter|CASMED cerebral oximeter
48687896|NCT00694577|RADIATION|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
48140499|NCT01409772|DRUG|Ethanol Lock|Ethanol Lock
48351083|NCT03593564|BEHAVIORAL|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
48351084|NCT00191386|DRUG|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
48351085|NCT00374101|DRUG|omeprazole|
48351086|NCT00374101|DRUG|pantoprazole|
48351087|NCT01776372|DEVICE|Medela Thopaz Thoracic Drainage System|
48351088|NCT01776372|DEVICE|Atrium Express Dry Seal Chest Drain|
48351089|NCT01661504|BEHAVIORAL|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
48503695|NCT05943808|OTHER|VR pre-recorded video watching|subjects are given an pre-recorded VR video to watch for 30 minutes
48503696|NCT02784873|OTHER|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
48503697|NCT04892225|BEHAVIORAL|Technology-supported behavioral intervention (text message)|A simple text message regarding the salt and fluid restriction in order to reduce the inter-dialytic weight gain will be send on daily basis to all the individuals in the intervention group.
48503698|NCT01027338|OTHER|Tai chi exercise|
47985387|NCT01335581|DEVICE|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
47985388|NCT01335581|DRUG|Retin-A and microdermabrasion|Microdermabrasion and topical lightening agent regimen
48140500|NCT04967118|BEHAVIORAL|Skin-to-skin contact|Diaper clad baby will be placed ventral position on bare chest of mother 30 minute prior to the heel lance
48140501|NCT04967118|BEHAVIORAL|Mother's heartbeats as sound and vibration|The mother's heartbeat will be recorded and the heartbeat sounds will be saved to the platform. The platform will be placed under the infant's mattress and the heartbeat will be started 30 minute prior to the heel lance.
48140502|NCT04967118|DRUG|30% oral glucose|The infant will be given 30% oral glucose solution 2 minutes before the injection
48140503|NCT01228734|DRUG|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
48503699|NCT04227847|DRUG|SEA-CD70|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
48503700|NCT04227847|DRUG|azacitidine|75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.
48140504|NCT01228734|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
48140505|NCT01228734|DRUG|Folinic Acid|FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
48140506|NCT01228734|DRUG|5Fluorouracil|5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
48140507|NCT01545583|DRUG|LY3016859 intravenous|Administered intravenously
48140508|NCT01545583|DRUG|Placebo intravenous|Administered intravenously
48140509|NCT01545583|DRUG|LY3016859 subcutaneous|Administered subcutaneously
48140510|NCT01545583|DRUG|Placebo subcutaneous|Administered subcutaneously
48140511|NCT04144088|DRUG|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
48140512|NCT04144088|DRUG|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
48661452|NCT04394494|OTHER|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
48661453|NCT04394494|OTHER|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
48351090|NCT01886352|DRUG|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
48351091|NCT01886352|DRUG|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
48351092|NCT01886352|DRUG|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
48351093|NCT01507441|GENETIC|gene mapping|
48351094|NCT01507441|GENETIC|microarray analysis|
48351095|NCT01507441|GENETIC|mutation analysis|
48351096|NCT01507441|GENETIC|nucleic acid sequencing|
48351097|NCT01507441|OTHER|laboratory biomarker analysis|
48503701|NCT06426615|DEVICE|Intracranial electrodes|Placement of intracranial electrodes in the cortico-subcortical system
48661454|NCT05600517|OTHER|Fluoride|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
48351098|NCT05263401|DIETARY_SUPPLEMENT|3-hydroxybutyrate|Orally administered pre-meal drinks.
48351099|NCT01501162|DRUG|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
48351100|NCT01501162|DRUG|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
48351101|NCT02689544|OTHER|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
48367527|NCT04752111|DRUG|Esmolol|administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
48503702|NCT04709367|OTHER|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
48661455|NCT00829998|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
48661456|NCT00829998|DRUG|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
48661457|NCT01188967|DRUG|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
48661458|NCT01188967|DRUG|Placebo|Placebo
48661459|NCT00754572|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
48661460|NCT00754572|DRUG|methotrexate|10-25mg oral or parenteral weekly.
48661461|NCT06316765|PROCEDURE|Intubation with stylet|The cohort of premature infants was intubated with stylet.
48687897|NCT04482439|DEVICE|Vivity Extended Depth of Focus intraocular lens (IOL)|Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
48687898|NCT01642901|DRUG|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
48140513|NCT04144088|DRUG|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
48140514|NCT02159794|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
48140515|NCT02106078|BEHAVIORAL|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
48140516|NCT02106078|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies"
48661462|NCT05423613|PROCEDURE|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
48351102|NCT02689544|OTHER|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
48661463|NCT03056469|OTHER|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
48661464|NCT05470686|BIOLOGICAL|blood gas via arterial catheter|Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
48503703|NCT03122288|BEHAVIORAL|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
48661465|NCT04869098|DIETARY_SUPPLEMENT|whey protein|Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
48503704|NCT03122288|OTHER|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
48140517|NCT02106078|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
48140518|NCT03925389|PROCEDURE|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
48503705|NCT00054665|DRUG|PS-341|1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
48503706|NCT00054665|DRUG|Etoposide|50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
48503707|NCT00054665|DRUG|Doxorubicin|10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
48503708|NCT00054665|DRUG|Vincristine|0.4 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
48140519|NCT00353691|DRUG|glimepiride|
48140520|NCT00353691|DRUG|metformin|
48351103|NCT02689544|OTHER|Control|The control group volunteers no received intervention
48351104|NCT03224156|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
48351105|NCT03463109|OTHER|Electrocutaneous stimulation|Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
48503709|NCT00054665|DRUG|Cyclophosphamide|750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
48503710|NCT00054665|DRUG|Prednisone|60 mg/m\^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
48661466|NCT04869098|DIETARY_SUPPLEMENT|Placebo|Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
48661467|NCT00095576|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10\^10 adenovirus genomes \[ad-vg\]/dose).~This dose is equivalent to 3x10\^10 vp/dose used in study V520-016."
48661468|NCT00095576|DRUG|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
48661469|NCT04849897|DEVICE|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
48140521|NCT04160559|OTHER|green tea|The investigators require patients to regularly drink green tea during the trial period.
48140522|NCT00002090|DRUG|Azithromycin|
48503711|NCT00054665|DRUG|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm\^3. Repeat cycle every 21 days.
48503712|NCT06448013|DRUG|Venetoclax|Given by PO
48503713|NCT06448013|DRUG|Gemtuzumab|Given by IV
48503714|NCT06448013|DRUG|Ziftomenib|Given by PO
48503715|NCT05004584|OTHER|Wheat home-based appetite assessment|Home-based appetite assessment with diet based on wheat cereal products.
48661470|NCT04849897|OTHER|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
48140523|NCT02334605|OTHER|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
48661471|NCT06207942|DEVICE|Feed back controlled temperature device|If core temperature exceeds 37.7 degrees celsius a feedback controlled-device will be used at set to 37.5 degrees celsius
47985389|NCT06073353|BEHAVIORAL|THRIVE-M|"THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~1. Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~2. Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~3. emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~4. Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~5. Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period."
47985390|NCT01830582|PROCEDURE|Advanced MR Imaging|
48351106|NCT03463109|OTHER|Assessment + Electrocutaneous stimulation|"Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
48351107|NCT02719210|BIOLOGICAL|High Volume Plasma Exchange|
48351108|NCT02719210|DRUG|Hypertonic 3% saline|
48351109|NCT02719210|DRUG|Mannitol|
48351110|NCT02719210|DEVICE|Elective positive pressure ventilation|
48351111|NCT00200889|DEVICE|active TEAS|non-painful active transcutaneous electro-acupoint stimulation will be delivered to the abdomen and leg
48351112|NCT03722992|OTHER|MBSR|Guided yoga and meditation practices
48351113|NCT01550614|GENETIC|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
48351114|NCT02812394|DRUG|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
48351115|NCT02812394|DRUG|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
48351116|NCT02812394|DRUG|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
48351117|NCT01646736|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
48351118|NCT01646736|DRUG|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
48351119|NCT01646736|DRUG|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
48351120|NCT05688540|OTHER|e book|e book
48351121|NCT05688540|OTHER|traditional education booklet|traditional education booklet
48351122|NCT05616052|DRUG|Semaglutide|treatment with different dosage regimes
47985391|NCT04431648|DRUG|DEFINITY|MRI-guided ultrasound-stimulated microbubble-treatment
47985392|NCT04431648|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
48140524|NCT02334605|DEVICE|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
48351123|NCT05518136|BEHAVIORAL|exercise-guidance on rehab APP|Training motions included sitting balance, hand support, crawling and squatting training12-14 were scheduled for 1 to 3 months postoperatively, moreover, climbing over obstacles was for 3 to 6 months.
48351124|NCT04574076|DRUG|Turoctocog alfa pegol (N8-GP)|Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
48351125|NCT04539665|PROCEDURE|Extended mesenteric resection.|Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
48503716|NCT05004584|OTHER|Rye home-based appetite assessment|Home-based appetite assessment with diet based on rye cereal products.
48351126|NCT04949776|DIAGNOSTIC_TEST|Mammograms|"In the women participating in the study, two strategies for reading mammograms will be carried out:~Strategy 1: Standard reading of the program. Double independent and non-consensual reading of all cases, without any artificial intelligence system (standard strategy).~Strategy 2: Reading strategy based on the global Score granted by Transpara® (strategy based on artificial intelligence):~* In studies with a Score \<8 (studies with a low probability of cancer): They will not be evaluated by any radiologist.~* In studies with a Score\> 7 (studies with a high probability of cancer): double reading will be carried out, assisted by Transpara®."
48351127|NCT02230787|DEVICE|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
48503717|NCT05004584|OTHER|Wheat clinic-based appetite assessment|Clinic-based appetite assessment with diet based on wheat cereal products.
48503718|NCT05004584|OTHER|Rye clinic-based appetite assessment|Clinic-based appetite assessment with diet based on rye cereal products.
48503719|NCT05004584|OTHER|Rye/Wheat clinic-based appetite assessment with blood sampling|Clinic-based appetite assessment with diet based on rye or wheat cereal products and continuous blood sampling.
48661472|NCT06207942|OTHER|High MAP|A mean arterial blood pressure (MAP) of \>85mmHg will be used. Vasopressors will be titrated to this target during 36 hours
48140525|NCT02334605|DEVICE|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
48661473|NCT06207942|OTHER|Deep sedation|Deep sedation for at least 36 hours
48661474|NCT06207942|OTHER|Fever control without a device|Management of fever in the intensive care unit without a device
48661475|NCT06207942|OTHER|Low MAP|A mean arterial blood pressure (MAP) of \>65mmHG will be used. Vasopressors will be titrated to this target during 36 hours
47985393|NCT05595356|DEVICE|transcranial direct current stimulation|"Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
48002605|NCT01871363|RADIATION|chemoradiation|"* radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
48351128|NCT02230787|DEVICE|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
48351129|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound and neurostimulator|
48351130|NCT02721290|PROCEDURE|Femoral nerve block using Ultrasound|
48661476|NCT06207942|OTHER|Minimal sedation|A strategy of minimal sedation in the intensive care unit, used only as needed to facilitate transport, imaging and invasive procedures
48661477|NCT05580705|OTHER|Routine Physical Therapy|The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises
48661478|NCT05580705|OTHER|Vibration Therapy|Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
48661479|NCT04994613|OTHER|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
48661480|NCT06001255|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
48661481|NCT02692027|OTHER|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
48140526|NCT04365959|PROCEDURE|Prone position|The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
48140527|NCT03411382|OTHER|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
48140528|NCT03411382|OTHER|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
48140529|NCT03411382|OTHER|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
48140530|NCT03411382|OTHER|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
48140531|NCT03932214|DEVICE|ACCUVEIN|The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
48140532|NCT02399605|OTHER|Stimulation|Subcutaneous abdominal electrical stimulation
48140533|NCT03536845|DRUG|Vitamin D 3|oral drops
48140534|NCT01670877|DRUG|Neratinib|
48140535|NCT01670877|DRUG|Fulvestrant|
48140536|NCT01670877|DRUG|Trastuzumab|
48140537|NCT01670877|PROCEDURE|Tumor biopsy|-Optional at baseline and disease progression
48140538|NCT01670877|PROCEDURE|Research blood sample|-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
48351131|NCT02721290|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
48140539|NCT01707303|OTHER|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
48002606|NCT01015352|DRUG|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
48140540|NCT01707303|OTHER|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
48140541|NCT01396629|PROCEDURE|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
48140542|NCT03942575|DEVICE|Negative pressure wound therapy|Wound dressing with negative pressure on closed incisions
48351132|NCT04557995|PROCEDURE|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
48351133|NCT03828864|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
48351134|NCT03828864|DEVICE|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
48351135|NCT00045045|PROCEDURE|positron emission tomography|
48140543|NCT01008917|DRUG|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
48140544|NCT04185818|OTHER|Reading a book|"Participants requested to specify usual genre of book they read.~1. Fiction~2. Non-Fiction~3. Other~4. Don't usually read a book in bed"
48140545|NCT02260726|PROCEDURE|Magnetic resonance imaging|
48140546|NCT02260726|PROCEDURE|Ultrasound|
48140547|NCT02531126|DRUG|RPC1063|
48140548|NCT01240590|DRUG|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
48140549|NCT01240590|DRUG|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
48351136|NCT00045045|RADIATION|fludeoxyglucose F 18|
48661482|NCT02692027|OTHER|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
48661483|NCT02278003|OTHER|memory test|
48661484|NCT02278003|DRUG|Propofol|
48661485|NCT06398184|OTHER|Exercise + motor imagery and action observation|A total of 8 sessions of 4 sets of knee extension exercises will be performed. During the breaks between each series, participants will perform a progressive protocol of action observation and motor imagery.
48661486|NCT06398184|OTHER|Exercise|A total of 8 sessions of 4 sets of knee extension exercises will be performed.
48661487|NCT02889874|RADIATION|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
48661488|NCT04541927|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
48661489|NCT04947189|DRUG|Seviteronel-D (Seivteronel in combination with dexamethasone)|Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
48661490|NCT04947189|DRUG|Docetaxel|Use of docetaxel chemotherapy for solid tumours
48661491|NCT02766855|DRUG|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
48351137|NCT04028024|DRUG|Ulinastatin|Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
48661492|NCT02704884|DIETARY_SUPPLEMENT|probiotic soy milk|
48661493|NCT01613651|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
48661494|NCT01613651|OTHER|questionnaire administration|Ancillary studies
48503720|NCT04136457|OTHER|Endurance training|Subjects perform a period of endurance training
48661495|NCT01613651|OTHER|intraoperative complication management/prevention|Undergo placement of pelvic drain
48503721|NCT04136457|OTHER|Resistance training|Subjects perform a period of resistance training
48503722|NCT04136457|OTHER|Sprint training|Subjects perform a period of sprint training
48661496|NCT00071032|BIOLOGICAL|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
48661497|NCT00071032|BIOLOGICAL|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
48661498|NCT00589524|DEVICE|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
48661499|NCT01539031|DRUG|E2020|"Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg"
48351138|NCT05743725|DRUG|Dexmedetomidine|dexmedetomidine loading 1 microgram/kg bolus in 10 minutes followed by 0.2-1 microgram/kg/hour till the end of surgery
48661500|NCT01539031|DRUG|E2020|"Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg"
48661501|NCT01896973|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
48661502|NCT04785638|COMBINATION_PRODUCT|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
48661503|NCT03859011|OTHER|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
48661504|NCT03859011|OTHER|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
48661505|NCT04884802|PROCEDURE|Tight pressure management|Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
48351139|NCT05743725|DRUG|Magnesium sulfate|2 gm magnesium infusion for 30 minutes
48661506|NCT04884802|PROCEDURE|Routine pressure management|ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
48687899|NCT01642901|DRUG|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
48687900|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
48687901|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
48002607|NCT01015352|DRUG|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
48661507|NCT06015009|OTHER|Symptom management mobile health application with personalised support|"Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
48661508|NCT02898038|DIETARY_SUPPLEMENT|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
48661509|NCT00561379|DRUG|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
48661510|NCT00561379|DRUG|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
48661511|NCT05645380|DRUG|Carboplatin|AUC=6, IV
47985394|NCT05595356|DEVICE|sham transcranial direct current stimulation|"Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
47985395|NCT05595356|DEVICE|run-in sham transcranial direct current stimulation|In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
48661512|NCT05645380|DRUG|Docetaxel|75 mg/m2, IV
48661513|NCT05645380|DRUG|Doxorubicin|60 mg/m2, IV
48661514|NCT05645380|DRUG|Cyclophosphamide|600 mg/m2, IV
47985396|NCT05595356|BEHAVIORAL|Psychoeducation video|Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
47985397|NCT05595356|BEHAVIORAL|Tutorial video|Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
48140550|NCT00529204|DRUG|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
48661515|NCT05645380|DRUG|Pembrolizumab|200 mg, IV
48661516|NCT00829868|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg
48661517|NCT00829868|DRUG|SONATA® 10 mg capsules|1 x 10 mg
48661518|NCT03728335|DRUG|Enasidenib Mesylate|Given PO
48661519|NCT02449187|DRUG|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
48661520|NCT02449187|DRUG|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
48661521|NCT04629430|OTHER|Pre-biotic foods/drinks|2 servings per day
48140551|NCT05722626|PROCEDURE|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
48140552|NCT05722626|OTHER|Normal Saline|NaCl 0.9%
47985398|NCT05744453|DIETARY_SUPPLEMENT|Olive Leaf Extract|experimental arm
47985399|NCT05744453|DIETARY_SUPPLEMENT|Cellulose|placebo comparator arm
47985400|NCT02605707|DRUG|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
48140553|NCT03142867|OTHER|non-applicable|non-applicable
48140554|NCT01211106|BEHAVIORAL|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
48140555|NCT01211106|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
48140556|NCT05936385|BEHAVIORAL|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
48140557|NCT05936385|BEHAVIORAL|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
48140558|NCT00347061|DRUG|afuzosin|
48140559|NCT02245529|DRUG|Tamsulosin|
48140560|NCT06510088|PROCEDURE|3-week multimodal prehabilitation program|"This program included four components:~Aerobic and Resistance Exercises A designated physical therapist supervises the resistance exercises and offers corrective guidance. Training intensity was continuously monitored and fine-tuned based on Borg scale assessments.~Respiratory Training Respiratory training was conducted using a respiratory trainer. Patients were instructed to engage in respiratory training at least three times daily, with each session lasting 10 minutes.~Nutrition Intervention Those in the multimodal prehabilitation group received daily whey protein powder to ensure a recommended protein intake of 1.5 g/kg/d. Protein supplements were to be consumed within one hour of exercise to promote muscle synthesis.~Psychological Intervention Anxiety-coping interventions included relaxation techniques and deep breathing exercises, administered in a one-to-one format by a nurse trained in psychological care."
48140561|NCT03735849|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
48140562|NCT02281266|PROCEDURE|curative resection|
48661522|NCT05786326|DEVICE|group 1|Insertion of fully covered self-expanding metallic stents with multi-holes (FCSEMS- MH) Biliary stent HANAROSTENT® CCC (M.I.Tech Co., Ltd, pyeongtaek, Korea) in a biliary tree through endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia by expertise in patients with malignant biliary obstruction
47985401|NCT04375137|DIAGNOSTIC_TEST|Oxidative Stress ELISA Kit|Checking oxidative stress markers and redox system status
47985402|NCT01778829|PROCEDURE|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
47985403|NCT01778829|PROCEDURE|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
48140563|NCT02281266|DRUG|thymalfasin|1.6mg twice a week, 12 months
48140564|NCT02281266|DRUG|nucleoside analog (suggest to use entecavir)|
48140565|NCT00834379|DRUG|pravastatin sodium|40 mg Tablet
48140566|NCT00834379|DRUG|Pravachol®|40 mg tablet
48661523|NCT05786326|DEVICE|group 2|Insertion of partially covered self-expanding metallic stents HANAROSTENT® Biliary (NCN) in the biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
48661524|NCT05786326|DEVICE|group 3|Insertion of uncovered self-expanding metallic stents (Biliary stent HANAROSTENT® NNN) (M.I.Tech Co., Ltd. Pyeongtaek, Korea) in a biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
48661525|NCT03064607|OTHER|Fluid collection|Fluids tested for biomarker S100beta
48661526|NCT01532154|DRUG|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
47985404|NCT05395806|OTHER|Health App|The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).
47985405|NCT05395806|OTHER|Usual Care|In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
47985406|NCT06261320|DRUG|Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate|4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.
48002608|NCT02801318|PROCEDURE|Polysomnography|
48002609|NCT04916184|OTHER|aerobic exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
48002610|NCT04916184|OTHER|combined exercise|exercise training rehabilitation (aerobic exercise with/without strength training)
47985407|NCT06021782|OTHER|All subjects-Observation|The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
47985408|NCT01647633|OTHER|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
48351140|NCT05202002|BEHAVIORAL|Video clip|"After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn."
48503723|NCT01987037|BEHAVIORAL|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
48140567|NCT03998059|PROCEDURE|splenectomy|These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
48140568|NCT00059826|BIOLOGICAL|interferon-alfa-2b|IV
48140569|NCT00059826|DRUG|cisplatin|IV
48140570|NCT00059826|DRUG|5-fluorouracil|IV
48140571|NCT00059826|RADIATION|radiation therapy|
48140572|NCT01095848|BIOLOGICAL|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
48140573|NCT00266656|DRUG|Humatrope|According to investigator's clinical practice and guided by the approved package insert
48140574|NCT01995214|DRUG|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
48140575|NCT01995214|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
48140576|NCT01020097|DRUG|fluorine F18 EF5|Given IV
48140577|NCT01020097|PROCEDURE|immunohistochemistry staining method|Correlative study
48140578|NCT01020097|PROCEDURE|biopsy|Correlative study
48351141|NCT05202002|BEHAVIORAL|No video clip|Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
48661527|NCT03112902|DEVICE|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
48140579|NCT01020097|PROCEDURE|Positron Emission tomography|Undergo scan
48140580|NCT01728298|BIOLOGICAL|SLITone ULTRA HDM immunotherapy|
48140581|NCT00346320|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
48140582|NCT05958966|OTHER|E-cigarette e-liquid self-administration|Participant will self-administer an experimenter-provided e-cigarette.
48140583|NCT03040856|DIETARY_SUPPLEMENT|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
48140584|NCT03040856|DIETARY_SUPPLEMENT|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
48140585|NCT03040856|OTHER|Placebo|Placebo capsules containing olive oil
48351142|NCT01606332|PROCEDURE|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
48351143|NCT03960385|BIOLOGICAL|CYD-TDV|Dengue vaccine
48351144|NCT00002394|DRUG|Terbinafine hydrochloride|
48351145|NCT01181297|OTHER|Extensively Hydrolyzed Formula with a Probiotic|
48503724|NCT01031030|DRUG|cyclophosphamide|
48503725|NCT01031030|DRUG|epirubicin hydrochloride|
48503726|NCT01031030|DRUG|fluorouracil|
47985409|NCT01169610|DRUG|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
48140586|NCT01892007|BEHAVIORAL|Cogmed RM - Online adaptive working memory training|
48140587|NCT01892007|BEHAVIORAL|Cogmed RM - Online non-adaptive (placebo) working memory training|
48140588|NCT06028659|OTHER|Coffee|Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
48140589|NCT06028659|OTHER|Water|150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
48140590|NCT01227746|PROCEDURE|Tumor biopsies|
48140591|NCT04192357|BEHAVIORAL|WLM3P|18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
48351146|NCT01181297|OTHER|Extensively Hydrolyzed Formula without a Probiotic|
48503727|NCT01031030|DRUG|methotrexate|
48503728|NCT01031030|OTHER|laboratory biomarker analysis|
48661528|NCT06332157|DRUG|Remimazolam besylate|In Remimazolam group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min and maintained with 1.0-2.0mg/min until the end of surgery.
48351147|NCT05976906|BIOLOGICAL|Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)|"1. Dose Escalation: After enrollment, participants will recieve preconditioning by lymphodepletion or not, and then will be treated with CNK-UT cells with a 3 +3 design to determine the maximum tolerated dose. 3 dose level of CNK-UK cells will be tested: 4.6E6/kg，1.5E7/kg，4.6E7/kg. The participants will first receive a single ascending dose(SAD) mode of administration. During the DLT observation period (21 days), if the participants do not experience DLT, they will receive a multiple ascending dose(MAD) mode of administration.~2. Indications Expansion: It will be carried out after all participants have completed the DLT observation in the Dose Escalation phase. The target population, dosage and frequency of drug administration in the indication expansion stage can be adjusted and determined according to the previous research results."
48351148|NCT03377829|PROCEDURE|PLA|During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.
48351149|NCT03377829|PROCEDURE|Thyroid Surgery|Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.
48351150|NCT01700647|OTHER|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
48351151|NCT01700647|OTHER|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
48351152|NCT06503133|OTHER|Birth preparation training|Birth preparation training is based on Albert Bandura's self-efficacy theory. It is a 60-minute training once a week. The first 10 minutes of the training are devoted to the initial activity, 40 minutes to sharing the training content, and 10 minutes to answering the participants' questions and receiving feedback. The training will be conducted in closed groups via the online meeting program (Zoom®).
48351153|NCT06503133|OTHER|Prenatal yoga practice|Prenatal yoga practice is a 60-minute practice once a week. The first 5 minutes of the prenatal yoga practice are devoted to guided meditation, 40 minutes to active asanas (yoga pose), 5 minutes to pranayama practice (breathing exercise) and 10 minutes to savasana (relaxing yoga pose). Prenatal yoga practice will be conducted in closed groups via the online meeting program (Zoom®)
48351154|NCT01803529|OTHER|heat-pack with massage|
48351155|NCT01803529|OTHER|heat-pack only|
48351156|NCT03906201|DIETARY_SUPPLEMENT|Ecdysterone|Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic
48351157|NCT03906201|OTHER|Placebo|no pharmacologic effect
48351158|NCT03908463|DEVICE|Percutaneous coronary intervention|All coronary intervention procedures will be performed according to current standard techniques.
48351159|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
48351160|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
48351161|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
48351162|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
48351163|NCT00357240|DRUG|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
48351164|NCT00357240|DRUG|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
48351165|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
48351166|NCT00357240|DRUG|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
48351167|NCT02019004|DRUG|Onabotulinum Toxin A|
48351168|NCT02019004|DRUG|Incobotulinum Toxin A|
48351169|NCT01966406|DEVICE|Nasogastric tube|
48503729|NCT01031030|PROCEDURE|adjuvant therapy|
48503730|NCT03724214|COMBINATION_PRODUCT|Pre-hospital interventional care bundle|"The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol."
48661529|NCT06332157|DRUG|Propofol Injection Emulsion|In Propofol group, anesthesia was induced with propofol injection emulsion at a rate of 2mg/kg and maintained with 6-8mg/kg/h until the end of surgery.
48661530|NCT06135090|BEHAVIORAL|Trauma Recovery Program (official title TBD)|See arm description
48351170|NCT01966406|OTHER|No nasogastric tube|
48351171|NCT04759612|OTHER|Action Observation|Participants will watch an upper extremity functionality test.
48351172|NCT00005629|BIOLOGICAL|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
48351173|NCT04137055|DRUG|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
48351174|NCT04137055|DRUG|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
48351175|NCT04137055|DRUG|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
48351176|NCT04137055|DRUG|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
48351177|NCT04137055|DRUG|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
48351178|NCT04137055|DRUG|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
48351179|NCT04137055|DRUG|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
48351180|NCT04137055|DRUG|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
48661531|NCT05095467|PROCEDURE|HIPEC|The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.
48351181|NCT04137055|DRUG|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
47985410|NCT02237950|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
48351182|NCT04137055|DRUG|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
48351183|NCT04137055|DRUG|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
48351184|NCT04137055|DRUG|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
48351185|NCT00733473|DRUG|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
48661532|NCT05095467|DRUG|Paclitaxel-albumin|albumin paclitaxel D1, D8; S-1: D1-D14
48661533|NCT05095467|DRUG|Tegafur-gimeracil-oteracil potassium|40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.
48661534|NCT05095467|PROCEDURE|Surgery+HIPEC|gastrectomy with D2 lymphadenectomy+HIPEC procedure
48661535|NCT03774381|DIETARY_SUPPLEMENT|Bifidobacterium breve B-3|160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
48661536|NCT03774381|DIETARY_SUPPLEMENT|Control group|160 mg of placebo is orally administered per day for 12 weeks.
47985411|NCT02237950|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
47985412|NCT02237950|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
47985413|NCT02919501|DRUG|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
48351186|NCT00733473|DRUG|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
48351187|NCT03986476|DIETARY_SUPPLEMENT|Probiotics|5x10\^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
48351188|NCT03986476|OTHER|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
48351189|NCT05305053|OTHER|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
48351190|NCT00081263|DRUG|Celecoxib|Given orally
48351191|NCT00081263|OTHER|Laboratory Biomarker Analysis|Correlative studies
48351192|NCT00081263|OTHER|Placebo|Given orally
48351193|NCT01708915|DRUG|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
48351194|NCT01708915|DRUG|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
48661537|NCT01811420|PROCEDURE|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
48661538|NCT01811420|PROCEDURE|Conventional method|Dental caries removal using rotatory instrument
48661539|NCT04826302|OTHER|Myofascial treatment|"40 minutes of myofascial intervention: 10 min in each of the following regions with the patient face up:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
48661540|NCT04826302|OTHER|Sham myofascial treatment|"40 minutes of sham myofascial intervention: 10 min in each of the following regions with the patient face up and with the contact of the physiotherapist through a towel and without any intention:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
48661541|NCT06486220|DRUG|Intestinal bacteria freeze-dried powder capsules|Oral healthy intestinal bacteria freeze-dried powder capsules, tid
48661542|NCT03468998|DEVICE|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
47985414|NCT02919501|OTHER|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
47985415|NCT02919501|DRUG|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
48002611|NCT04656067|DRUG|Oxytocin ,Tranexamic acid and Ethamsylate|Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate
48351195|NCT01708915|DRUG|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
48351196|NCT01708915|DRUG|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
48351197|NCT05247060|OTHER|no experimental intervention|There will not be any experimental intervention. The study will be conducted according with normal clinical practice
48351198|NCT02933372|DRUG|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
48351199|NCT05234190|DRUG|QEL-001|QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
48351200|NCT05847387|DIAGNOSTIC_TEST|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
48351201|NCT02956031|OTHER|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
48661543|NCT03468998|DEVICE|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
48351202|NCT02956031|OTHER|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
48351203|NCT02956031|PROCEDURE|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
48351204|NCT03317366|DRUG|ARQ 092|Open-label expanded access for ARQ 092 capsules
47985416|NCT06084403|DRUG|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.
47985417|NCT06084403|DRUG|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 30ml will be injected here.
48002612|NCT05768477|OTHER|Consultation|Consultation with the pain specialist, which might entail prescription of medication of vitamins.
48002613|NCT05768477|PROCEDURE|Interventions|Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation
48351205|NCT06347692|OTHER|antigravity treadmill|An Alter G treadmill (Alter G Pro 200, Alter G Inc, USA) was used to provide training to the patients in the antigravity treadmill group. The Alter G allows the patient to change their body weight from 20% to 100% in 1% increments. The air pressure inside the lower body positive pressure chamber can be adjusted from 0 to 2.0 kilopascal above atmospheric pressure. They are very comfortable to train in for long periods of time and have simple controls for adjusting body weight, speed, and inclination.
48351206|NCT06347692|OTHER|physical therapy exercise program|Both groups received the same traditional physical therapy program for 12 weeks, three times a week, for 30 min each. The conventional physical therapy treatment consisted of acupuncture transcutaneous electrical nerve stimulation, Hot moist pack, Ultrasound and quadriceps setting
48351207|NCT00561301|DRUG|GemDOx|gemcitabine oxliplatin
48351208|NCT02231489|DRUG|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
48351209|NCT02231489|DRUG|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
48351210|NCT02231489|DRUG|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
48351211|NCT03875872|DRUG|Propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
48351212|NCT03875872|DRUG|inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
48351213|NCT02706795|BIOLOGICAL|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
48351214|NCT02048852|OTHER|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
48351215|NCT02048852|OTHER|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
48351216|NCT02048852|OTHER|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
48351217|NCT02048852|OTHER|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
48503731|NCT03724214|COMBINATION_PRODUCT|In-hospital interventional care bundle|"In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available."
48351218|NCT03824964|BIOLOGICAL|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
48351219|NCT06243289|OTHER|Tolerance induction|Exposure of peripheral blood mononuclear cells extracted from donated patient blood to a combination of vitamin D3 and interleukin 10 to test whether tolerogenic dendritic cells can be generated and have the same functional capacity between donors with and without kidney disease (exposure of PBMC to the uremic environment)
48351220|NCT00428103|PROCEDURE|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
48351221|NCT04281823|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
48351222|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
48351223|NCT00732654|DRUG|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
48351224|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
48351225|NCT00732654|DRUG|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
48351226|NCT02625389|DRUG|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
48351227|NCT02463227|BIOLOGICAL|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
48351228|NCT06335160|DRUG|Mebendazole|mebendazole group, n = 23) which will receive the standard treatment for UC plus mebendazole 500 mg twice daily for 6 months
48351229|NCT04644965|DIAGNOSTIC_TEST|CombynTM Function & Spaces ECG|Multi-frequency impedance measurement to assess the muscle and fat mass
48351230|NCT04644965|DIAGNOSTIC_TEST|Blood Taking|Sampling of blood of the finger pad to assess liver function
48351231|NCT04644965|DIAGNOSTIC_TEST|Spiroergometry|Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
48351232|NCT04644965|DIAGNOSTIC_TEST|Dordel Koch Test (DKT)|Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
48351233|NCT04644965|DIAGNOSTIC_TEST|Ultrasound|Ultrasound for abdominal wall muscles
48351234|NCT04644965|DIAGNOSTIC_TEST|Stance and gait analyses|Stance and gait analyses for measuring the core stability
48351235|NCT00382551|BEHAVIORAL|Moderate daily consumption of Red wine|
48661544|NCT03468998|DEVICE|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
48661545|NCT03468998|DEVICE|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
47985418|NCT06084403|DRUG|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 40ml will be injected here.
48351236|NCT00382551|BEHAVIORAL|Moderate daily consumption of beer|
48351237|NCT00382551|BEHAVIORAL|Moderate consumption of fruit juice rich in polyphenolics|
48351238|NCT01128452|DRUG|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
48351239|NCT01128452|DRUG|Placebo|HPMC Placebo capsules, once daily for 28 days
48351240|NCT01245972|PROCEDURE|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
48351241|NCT01424865|GENETIC|fluorescence in situ hybridization|
48351242|NCT01424865|OTHER|immunohistochemistry staining method|
48351243|NCT01424865|OTHER|immunologic technique|
48503732|NCT00759850|DEVICE|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
48351244|NCT01424865|OTHER|laboratory biomarker analysis|
48351245|NCT02237144|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
48351246|NCT02237144|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
48351247|NCT02237144|OTHER|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
48503733|NCT02430831|DIETARY_SUPPLEMENT|Nidina|
48503734|NCT02430831|DIETARY_SUPPLEMENT|Placebo|
48503735|NCT00772421|DEVICE|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
48503736|NCT04584385|DIAGNOSTIC_TEST|EEG|EEG monitoring
48503737|NCT04362748|DRUG|AMG 256|AMG 256 administered as an intravenous (IV) infusion.
48661546|NCT04598425|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
48661547|NCT00663156|PROCEDURE|breast implants|patients will have breast augmentation using implants
48661548|NCT00663156|PROCEDURE|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
48661549|NCT03132142|DRUG|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
48351248|NCT02237144|BEHAVIORAL|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
48351249|NCT03399786|DRUG|evinacumab|IV administration of evinacumab
48351250|NCT03399786|DRUG|Placebo|IV administration of placebo
48351251|NCT02482389|RADIATION|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
48351252|NCT03531762|DRUG|Tepotinib|Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.
48351253|NCT03531762|DRUG|Omeprazole|Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.
48351254|NCT01646346|RADIATION|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
48351255|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|DBS Active Treatment Group - implanted with investigational device and activated for stimulation
48351256|NCT00617162|DEVICE|Deep Brain Stimulation, Libra Deep Brain Stimulation System|implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
48351257|NCT01253941|OTHER|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
48351258|NCT03525821|DRUG|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
48351259|NCT04418739|DRUG|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
48351260|NCT02432690|DRUG|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
48351261|NCT03973502|DRUG|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
48351262|NCT03404219|BEHAVIORAL|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
48351263|NCT02194452|RADIATION|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
48351264|NCT02194452|PROCEDURE|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
48351265|NCT02194452|PROCEDURE|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
48351266|NCT02194452|OTHER|laboratory biomarker analysis|Correlative studies
48661550|NCT03132142|DRUG|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
48661551|NCT03132142|DRUG|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
48661552|NCT03132142|DRUG|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
47985419|NCT01949168|DRUG|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
47985420|NCT01949168|DRUG|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
47985421|NCT01949168|DRUG|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
48351267|NCT04331210|DRUG|Diclofenac Sodium|Group 1 will take oral diclofenac sodium and group 2 will take Rectal diclofenac sodium as an analgesic
48351268|NCT04490265|BEHAVIORAL|Problem-solving treatment|included in arm descriptions
48351269|NCT04490265|BEHAVIORAL|Supportive Psychotherapy|included in arm descriptions
48351270|NCT05813860|DRUG|Azathioprine|azathioprine in combination with Infliximab, with a dose of 1-2 mg/kg/d.
48351271|NCT05813860|DRUG|Infliximab|5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.
48351272|NCT01929512|DRUG|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
48351273|NCT01929512|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
48351274|NCT01929512|DRUG|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
48351275|NCT01914991|PROCEDURE|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
48351276|NCT01914991|PROCEDURE|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
48661553|NCT04408885|OTHER|Rehabilitation|Non-surgical interventions to patients with an Anterior cruciate ligament injury. Rehabilitation regime is the regime provided by the physician at the rehabilitation clinic.
48661554|NCT04990583|BEHAVIORAL|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
48351277|NCT04484038|RADIATION|hypofractionated postoperative radiation therapy|The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
48351278|NCT02233608|BEHAVIORAL|Advanced Pelvic Floor Muscle Exercise (APFX)|
48351279|NCT00921570|DRUG|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
48351280|NCT00921570|DRUG|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
48351281|NCT05480631|PROCEDURE|autograft|autologous bone placed in the defect and then be secured with mini-screws to fill the fracture defect gap
48351282|NCT05480631|PROCEDURE|autograft with addition of concenterated growth factor|the bone particulate harvested from the donor site will then be mixed with concentrated growth factor to bridge the fracture defect.
48351283|NCT05480631|PROCEDURE|xenograft with concentrated growth factor|xenogenic bovine bone particulate mixed with platelet-derived concentrated growth factor to be held in place of fracture defect site.
48351284|NCT06322108|DRUG|Botensilimab + Balstilimab|Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).
48351285|NCT02515851|DRUG|Exparel|
48351286|NCT02515851|DRUG|Placebo|
48351287|NCT01711476|BEHAVIORAL|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
48351288|NCT01711476|OTHER|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
48351289|NCT06086886|DRUG|BMS-986454|Specified dose on specified days
48351290|NCT06086886|OTHER|Placebo|Specified dose on specified days
48351291|NCT04325919|OTHER|No intervention|No intervention
48351292|NCT03031990|BEHAVIORAL|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
48351293|NCT03031990|BEHAVIORAL|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
48661555|NCT04990583|BEHAVIORAL|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
48661556|NCT04183686|DRUG|ACT-1014-6470 (SAD)|Single dose of ACT-1014-6470; soft capsules for oral use.
48661557|NCT04183686|DRUG|ACT-1014-6470 (MAD)|Multiple doses of ACT-1014-6470; soft capsules for oral use.
47985422|NCT00847054|DRUG|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
48351294|NCT03031990|BEHAVIORAL|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
48351295|NCT06138704|PROCEDURE|Retrograde Intrarenal Surgery|All RIRS procedures were performed under general anesthesia with direct videoscopic and fluoroscopic guidance. The decision to use a flexible or semirigid ureteroscope depended on the location of the Stones. If this was not enough to pass the ureteroscope, we placed a JJ catheter for passive dilatation. Stones were fragmented using a holmium-YAG laser and grasped by a stone basket when applicable. Contrast injection was performed at the end of the procedures to confirm the absence of extravasation and stone-free status. Ultrasonography (USG) was performed three months, six months, and one year after the procedures to evaluate stone recurrence and hydronephrosis.
48351296|NCT03520894|RADIATION|Neoadjuvant radiotherapy|single 21 Gy fraction of Radiotherapy before surgery
48351297|NCT01037140|DRUG|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
48351298|NCT01037140|DRUG|placebo|oral placebo tablets similar to active comparator
48351299|NCT01995786|DEVICE|Goal Directed Fluid Therapy FloTrac/Vigileo|
48351300|NCT03037112|BEHAVIORAL|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
48661558|NCT04183686|DRUG|Placebo (SAD)|Single dose of matching placebo; soft capsules for oral use.
48351301|NCT03037112|BEHAVIORAL|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
48351302|NCT02181504|DRUG|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
48351303|NCT02181504|DRUG|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
48351304|NCT02181504|OTHER|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
48351305|NCT02758106|DEVICE|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
48351306|NCT02758106|DEVICE|placebo intervention|CCPT for 15 minutes then sputum suction.
48351307|NCT00762528|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
48351308|NCT00762528|DRUG|Sodium monofluorophosphate toothpaste|Twice daily usage
48503738|NCT01612299|DRUG|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml \>6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 \&2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml \>6 mo post transplant 4-7 ng/ml."
48503739|NCT06246214|DEVICE|Blue Light Therapy|The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
48503740|NCT06246214|DEVICE|ControlLT|The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
48661559|NCT04183686|DRUG|Placebo (MAD)|Multiple doses of matching placebo; soft capsules for oral use.
47985423|NCT03183375|DRUG|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
48002614|NCT05768477|DRUG|Baxter therapy|Ketamine or Linisol baxter therapy
48351309|NCT01108224|BEHAVIORAL|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
48351310|NCT06153628|OTHER|Virtual reality glasses|Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
48351311|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
48351312|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
48351313|NCT01445002|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
48351314|NCT01445002|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
48503741|NCT03425695|DEVICE|CheseeTM Diode Laser|low level laser therapy was utilized adjunct with free gingival graft.
48503742|NCT03425695|OTHER|Clinical examination|"The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery."
48503743|NCT02283008|BEHAVIORAL|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
48503744|NCT05893810|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
48661560|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer|Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
48661561|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer placebo|Single dose of matching placebo; soft capsules for oral use.
48661562|NCT05870631|BIOLOGICAL|vaccinate with DTaP|vaccinate with DTaP
48661563|NCT05870631|BIOLOGICAL|vaccinate with DT|vaccinate with DT
48661564|NCT04835259|DRUG|Selenium Amino Acid Chelate (Selenium ACE cream)|application of a topical agent over the whole face for 6 months
48661565|NCT06168344|OTHER|Web-Based Education Program|This study was assessed the impact of a web-based education program provided to mothers of infants with congenital heart diseases on their quality of life and self-efficacy levels
48661566|NCT03127930|BEHAVIORAL|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
48661567|NCT05348122|DRUG|TG103,Q2W|TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
48661568|NCT05348122|DRUG|TG103,QW|TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
48661569|NCT05348122|DRUG|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
48661570|NCT05348122|DRUG|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
48661571|NCT05348122|DRUG|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
48661572|NCT06388629|DEVICE|Rook Epicardial Access Kit|Access the epicardial surface of the heart via a subxiphoid approach with the subject device to facilitate guidewire placement into the pericardium.
48661573|NCT04998630|DEVICE|Extracorporeal shockwave therapy|Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate
48661574|NCT04198402|BIOLOGICAL|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
48661575|NCT00756340|DRUG|Bevacizumab|"* Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg"
48661576|NCT00756340|DRUG|Everolimus|"* Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2"
48661577|NCT02731560|DRUG|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor."
48661578|NCT04502914|PROCEDURE|Open-to-air strategy|In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
48661579|NCT04502914|PROCEDURE|Traditional closed-wound management|In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
48661580|NCT05847166|RADIATION|[99mTc]Tc-PSMA-T4|\[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
48661581|NCT01081392|BIOLOGICAL|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
48661582|NCT00001382|BIOLOGICAL|PROSTVAC|
47985424|NCT05728307|DEVICE|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
47985425|NCT06135701|DIAGNOSTIC_TEST|One-legged knee-extensor exercise with Doppler measurements|Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
48503745|NCT06125808|DRUG|HRO350|Active substance phospholipid esters from herring roe oil (PEHeRo)
48503746|NCT06125808|DRUG|Placebo|Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
48661583|NCT02474498|DRUG|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
48661584|NCT02474498|DEVICE|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
48661585|NCT02474498|PROCEDURE|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
48661586|NCT04210960|RADIATION|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) _ 9583 sec, echo time (TE) _ 25 sec, inversion time (TI) _ 3400 sec, IR delay _ 325 sec, echo train length (ETL) _ 17, 50 contiguous axial slices, thickness _ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
48503747|NCT02530658|OTHER|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
48503748|NCT02530658|OTHER|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
48661587|NCT04210960|RADIATION|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
48661588|NCT04839640|OTHER|Bredent denture teeth|composite resin denture teeth
48661589|NCT03246880|DRUG|Tamsulosin 0.2mg|per oral for 12weeks after 2\~4weeks run-in period
48503749|NCT02530658|OTHER|Informed Consent Follow-Up Visit|At or after enrollment but before the release of the gerline results, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
48503750|NCT02530658|OTHER|Return of Results Conversation|Participants will complete the assessment questionnaires.
48503751|NCT02530658|OTHER|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 28 ± 4 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
48661590|NCT03246880|DRUG|Tadalafil 5mg|per oral for 12weeks after 2\~4weeks run-in period
48661591|NCT05034081|PROCEDURE|body contouring|any post-bariatric body contouring surgery included
48661592|NCT05975424|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
48661593|NCT03171948|BEHAVIORAL|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
48661594|NCT03171948|BEHAVIORAL|Nut Free group|continue their diet without any nut consumption.
48661595|NCT00301860|BIOLOGICAL|anti-thymocyte globulin|
48661596|NCT00301860|BIOLOGICAL|filgrastim|
48661597|NCT00301860|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48661598|NCT00301860|DRUG|cyclosporine|
48661599|NCT00301860|DRUG|fludarabine phosphate|
48661600|NCT00301860|DRUG|melphalan|
48661601|NCT00301860|DRUG|methotrexate|
48661602|NCT00301860|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48661603|NCT00301860|PROCEDURE|peripheral blood stem cell transplantation|
48661604|NCT05429411|OTHER|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach \>21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
48661605|NCT06000683|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
48661606|NCT06000683|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
48661607|NCT06000683|BEHAVIORAL|Patient Reminders|Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.
48661608|NCT06000683|BEHAVIORAL|Provider Reminers|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
48661609|NCT06125405|DRUG|Telitacicept|The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
48661610|NCT03391882|DRUG|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
48661611|NCT03391882|DRUG|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
48661612|NCT03131479|DRUG|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
48661613|NCT00200239|BEHAVIORAL|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
48661614|NCT05021939|OTHER|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
48503752|NCT02530658|PROCEDURE|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
48661615|NCT05021939|OTHER|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
48661616|NCT04746755|DEVICE|Orthotic Insole: Lower Back|This Insole is a full-length shaped orthotic insole, with a heel cup and an arch support. The insole can cover several shoe sizes and can be cut to the correct size to fit in the shoe.
48661617|NCT04746755|DEVICE|Orthotic Insole: Heel|This Insole is a horseshoe shaped flexible heel cup with a softer area where the heel would be expected.
48503753|NCT02530658|PROCEDURE|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
48661618|NCT04746755|DEVICE|Orthotic Insole: Knee to Heel|This Insole is a ¾ length rigid orthotic insole with a softer area where the heel would be expected. Each insole will cover several shoe sizes.
48661619|NCT04746755|DEVICE|Orthotic Insole: Arch|"This Insole is a ¾ length shaped medical device with a softer area incorporated into the ball of foot and heel area and an external arch.~support and 6-8 mm metatarsal dome. The slim fit insole runs from the heel along under the arch of the foot and reaches to just behind the toes to prevent squashing the toes in tight fitting shoes."
48661620|NCT04425239|DRUG|Panitumumab|Continuous administation
48661621|NCT04425239|DRUG|Panitumumab|Intermittent administation
48351315|NCT04835688|PROCEDURE|Transmyringeal ventilation tube insertion|"In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted."
48351316|NCT04835688|PROCEDURE|Sham-treatment|For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
48351317|NCT03003013|PROCEDURE|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
48661622|NCT02695836|OTHER|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
48661623|NCT02695836|OTHER|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
48661624|NCT02695836|OTHER|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
48661625|NCT02695836|OTHER|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
48351318|NCT02244125|DRUG|PCD|"STUDY TREATMENT PHASE: All patients~* 4x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle\]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~* Melphalan 200mg/m2 followed by Autologous Transplantation~* 2x 28 days cycles of PCD, three months post transplantation~Arm B:~* 5x 28 days cycles of PCD~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle\]~\[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle\]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~\[Pomalidomide: 4mg/day oral route on 21 days per cycle\]~\[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle\]"
48351319|NCT02244125|PROCEDURE|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
48351320|NCT04299256|BEHAVIORAL|Benson relaxation combined with music therapy|In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
48351321|NCT04839679|BEHAVIORAL|Culturally Oriented Educational Brochure|Culturally appropriate educational brochure summarizing pertinent treatment information in a visual manner
48351322|NCT04839679|BEHAVIORAL|Mayo Clinic Educational Booklet|"An Introduction to Radiation Simulation and Treatment- Barbara Woodward Lips, Patient Education Center"
48351323|NCT00131534|BEHAVIORAL|Individual therapy|Stage-based individual therapy for trauma survivors
48661626|NCT02695836|OTHER|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
48661627|NCT06407011|OTHER|Control|The CON group did not have any intervention but usual care.
48661628|NCT06407011|OTHER|Swedish massage prior circuit breathing training group (SBT)|Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
48351324|NCT00131534|BEHAVIORAL|Group therapy|Stage-based group therapy for trauma survivors
48661629|NCT06407011|OTHER|Circuit breathing training group (CBT)|Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
48351325|NCT00058773|DRUG|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart."
48351326|NCT04916301|BEHAVIORAL|Early Mother-Infant Attachment|Early Mother-Infant Attachment Indicators will be observed.
48351327|NCT03800433|DRUG|Trental 400 MG Extended Release Oral Tablet|oral tablets
48351328|NCT02330601|PROCEDURE|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
48351329|NCT05714254|DRUG|MEDI0618|Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
48351330|NCT05714254|DRUG|Placebo|Four doses of IV placebo or SC placebo administered once every two weeks.
48661630|NCT01920243|BEHAVIORAL|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
48140592|NCT04192357|BEHAVIORAL|Low-carb diet|18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
48661631|NCT05077423|DRUG|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
48661632|NCT03005886|PROCEDURE|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
48661633|NCT03005886|PROCEDURE|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
48661634|NCT03005886|PROCEDURE|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
47985426|NCT04971473|BIOLOGICAL|rhTSH|Scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.
47985427|NCT01435954|DRUG|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
47985428|NCT01435954|DRUG|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
48140593|NCT04903080|BIOLOGICAL|HER2 Specific CAR T Cell|HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.
48661635|NCT05876520|PROCEDURE|Total pulpotomy with I-prf mixed with Nano-bioactive glass|Total pulpotomy is done in mature permanent molars followed by I-prf mixed with Nano-Bioactive glass application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
47985429|NCT01000441|DRUG|infliximab, etanercept, adalimumab|
47985430|NCT01000441|DRUG|abatacept, rituximab or tocilizumab|
48140594|NCT01021748|DRUG|MK-2206|Oral tablets
48140595|NCT01021748|DRUG|AZD6244|Oral capsules
48140596|NCT00456339|DRUG|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
48140597|NCT03542695|PROCEDURE|Computed Tomography|Undergo PET/CT
48140598|NCT03542695|DRUG|Copper Cu-64-DOTA-alendronate|Given IV
48351331|NCT03174808|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
47985431|NCT05743179|DRUG|Zoledronate|Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
47985432|NCT04120831|DRUG|Abatacept Injection|Drug
48002615|NCT05768477|BEHAVIORAL|Interdisciplinary therapy|Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.
48140599|NCT03542695|OTHER|Pharmacokinetic Study|Correlative studies
48140600|NCT03542695|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48140601|NCT04031794|DEVICE|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
48140602|NCT01595867|DRUG|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
48140603|NCT01595867|DRUG|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
48351332|NCT01599949|DRUG|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
48351333|NCT05529134|DRUG|PTW-002 10 mg/g gel|poloxamer hydrogel for topical administration
48351334|NCT05529134|DRUG|Placebo|placebo poloxamer hydrogel for topical administration
48661636|NCT01350076|DRUG|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
48661637|NCT01350076|DRUG|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
48661638|NCT01276951|DIETARY_SUPPLEMENT|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
48661639|NCT01276951|PROCEDURE|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
48140604|NCT01595867|DRUG|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
48351335|NCT03413228|OTHER|Questionnaire|An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
48661640|NCT01276951|PROCEDURE|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
48661641|NCT01276951|PROCEDURE|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
48140605|NCT01992965|OTHER|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
48140606|NCT00958048|DEVICE|non-invasive ventilation|CPAP, BiPAP
48140607|NCT00038038|DRUG|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
48140608|NCT00038038|PROCEDURE|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
48140609|NCT03676504|BIOLOGICAL|CD19.CAR T Cells|Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2
48351336|NCT03378128|PROCEDURE|Diagnostic laparoscopy|The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (\>1 cm residual disease) was performed.
48351337|NCT02894788|OTHER|ICU admission|
48351338|NCT02045979|DRUG|BI 695501|BI 695501 single s.c. injection
48351339|NCT02045979|DRUG|adalimumab-EU source|adalimumab-EU source single s.c. injection
48661642|NCT01276951|PROCEDURE|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
48661643|NCT01276951|PROCEDURE|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
48140610|NCT03676504|DRUG|Fludarabine|3 days of fludarabine 30 mg/m\^2/day
48351340|NCT02045979|DRUG|adalimumab-US source|adalimumab-US source single s.c. injection.
48351341|NCT00661414|BIOLOGICAL|ASONEP (sonepcizumab/LT1009)|"ASONEP \[sonepcizumab/LT1009\] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
48351342|NCT02828462|OTHER|CAPRI|
48351343|NCT02489851|PROCEDURE|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
48351344|NCT02489851|PROCEDURE|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
48661644|NCT02263547|DRUG|teriflunomide|
48140611|NCT03676504|DRUG|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m\^2/day
48351345|NCT02552823|OTHER|Group1|
48140612|NCT02446275|OTHER|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
48351346|NCT02552823|OTHER|Group2|
48351347|NCT04741204|DRUG|Metformin Extended Release Oral Tablet|initial dose of metformin of 750 mg Q.D. (with dinner) for 3-4 weeks. They then will be increased to the final dose of 750 mg BID (breakfast and dinner) until the end of the study.
48351348|NCT01174589|OTHER|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
48661645|NCT02263547|DRUG|Colestipol|
48661646|NCT05432167|DRUG|CIN-107|Patients will take CIN-107 tablets by mouth once daily.
48661647|NCT05432167|DRUG|Placebo|Patients will take placebo tablets by mouth once daily.
48661648|NCT01262105|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
48661649|NCT03286868|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
48661650|NCT03286868|DEVICE|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
48351349|NCT06442085|OTHER|Teaching of trauma resuscitation by using virtual reality simulation|"The intervention was teaching of trauma resuscitation by using VRS. Following welcome and a video lecture by Advance Trauma Life Support certified physician, the intervention group participants were orientated (15 minutes) to the VRS environment, head-mounted display (Oculus Rift S or Oculus Quest, Oculus, USA) and hand controllers by playing game First Steps (Oculus, USA). Then the participants were training by using the Internal Hemorrhage scenario in Trauma Simulator."
48661651|NCT01538199|DEVICE|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
48140613|NCT02446275|OTHER|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
48140614|NCT00978159|DRUG|esomeprazole|esomeprazole 20 mg po for 4 weeks
48140615|NCT00978159|DRUG|Famotidine|Famotidine 40 mg po for 4 weeks
48140616|NCT00952640|DIETARY_SUPPLEMENT|vitamin A|high dose vitamin A, 200.000 IU
48140617|NCT02139241|DRUG|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
48140618|NCT02139241|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
48140619|NCT01844401|DRUG|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
48351350|NCT06442085|OTHER|Teaching of trauma resuscitation by using mannequin based simulation|Volunteers were trained in groups of three or four by using mannequin-based rapid cycle deliberate practice simulation facilitated by a critical care physician. Next, the volunteers had 50 min training of the same trauma scenario as the intervention group. The simulation facility was set-up as close as possible to the virtual reality environment.
48351351|NCT05622656|DRUG|Dexmedetomidine|Dexmedetomidine 0.0005%
48661652|NCT01538199|DEVICE|Sham device|The sham device does not emit near-infrared radiation.
47985433|NCT02678845|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
48140620|NCT01844401|DRUG|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
48140621|NCT05528809|OTHER|Blood sampling|A blood sampling will be performed during the inclusion visit (day 0).
48351352|NCT05622656|DRUG|Placebo|0.9% Sodium Chloride Solution
48351353|NCT03592173|DIAGNOSTIC_TEST|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
48351354|NCT05565066|DEVICE|FNB group|Fine-needle-biopsy (Echotip ProCore Needle)
48351355|NCT05565066|DEVICE|FNA group|Fine-needle-aspiration (Echotip Needle)
48351356|NCT02447952|DEVICE|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
48140622|NCT03385291|DEVICE|music,name,and noise sound|A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
48140623|NCT06498609|BIOLOGICAL|iprf|i-PRF with leveling and alignment
48140624|NCT06498609|PROCEDURE|MOPs with leveling and alignment|mop
48140625|NCT01750424|PROCEDURE|Autologous Fat Grafting|
48140626|NCT01750424|OTHER|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
48351357|NCT02447952|DEVICE|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
47985434|NCT03892109|OTHER|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
47985435|NCT03892109|DEVICE|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
47985436|NCT03892109|OTHER|Gingitrac|packed into the sulcus
47985437|NCT02118012|DRUG|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
47985438|NCT02118012|DRUG|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
47985439|NCT05205746|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
48351358|NCT02447952|PROCEDURE|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
48351359|NCT01557127|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
48351360|NCT04287205|DRUG|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
48351361|NCT02145754|OTHER|MKP media|one half of skin specimen was put in MKP media
48351362|NCT02145754|OTHER|BSK-H media|one half of skin specimen was put in BSK-H media
48351363|NCT01687049|DRUG|Red yeast rice|
48351364|NCT02709941|OTHER|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
48351365|NCT02709941|OTHER|Placebo|
48503754|NCT02026115|BEHAVIORAL|PAINReportIt|PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
48503755|NCT02026115|BEHAVIORAL|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
48661653|NCT03261804|BEHAVIORAL|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
48661654|NCT03908047|OTHER|magnetic resonance imaging|functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
48661655|NCT04586257|PROCEDURE|Erector spinae plane block|While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
48661656|NCT04586257|PROCEDURE|Throacolumbar interfacial plane block|USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
47985440|NCT05205746|BIOLOGICAL|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
47985441|NCT00389363|DRUG|ALK HDM tablet|
47985442|NCT05000125|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
47985443|NCT01851564|DEVICE|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
47985444|NCT01851564|OTHER|Standard Therapy|Standard Medical and Endoscopic Therapy
47985445|NCT00449540|DEVICE|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
47985446|NCT00449540|DEVICE|Sham TMS Device|Simulated Sham treatment without TMS delivery
48351366|NCT05469152|DIAGNOSTIC_TEST|ds-MCE and EGD|"Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetic capsule endoscopy guidance system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. The capsule then could be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. Then, the examination of stomach under magnetic control and small bowel under the natural action of peristalsis follows.~Procedure of EGD: The EGD will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session."
48351367|NCT06097975|DRUG|Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV|Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
48661657|NCT00718432|BEHAVIORAL|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
47985447|NCT04997785|PROCEDURE|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
47985448|NCT00773292|DRUG|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
47985449|NCT04233554|BEHAVIORAL|Patient Priorities Care|Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
47985450|NCT00064844|BEHAVIORAL|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
48351368|NCT06097975|PROCEDURE|Neurosurgery and intracavitary injection nivolumab and ipililumab|The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir
48351369|NCT06097975|DRUG|Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary|Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
48351370|NCT03921606|BEHAVIORAL|Motivational Interviewing (i-BMI)|A brief MI via WhatsApp/WeChat
48503756|NCT02026115|BEHAVIORAL|PAINUCope|We tested the prototype of the PAINUCope component of the intervention in three completed studies. PAINUCope is a multimedia, computer generated tool that provides tailored patient information to overcome their misconceptions about pain and to help them engage in self-care activities that contribute to reducing their pain. PAINUCope focuses on two crucial aspects of pain management: 1) reporting cancer pain; and 2) safe and effective use of pain medicines. All the educational materials were written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person living with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt govern the specific health information that is shared with the patient via PAINUCope.
48503757|NCT02031458|DRUG|Atezolizumab|1200 mg IV every 3 weeks
48661658|NCT00718432|BEHAVIORAL|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
47985451|NCT00064844|DRUG|Nicoderm CQ nicotine patch|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
47985452|NCT00064844|DRUG|Placebo gum|Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
47985453|NCT00064844|DRUG|Nicotine gum - Nicorette®|Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
48351371|NCT03921606|BEHAVIORAL|Individual face-to-face generic health advice|Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
48351372|NCT06063837|BEHAVIORAL|Live Instruction and Fitness Tracking (LIFT-up)|A 12-week combined aerobic and resistance training exercise protocol
48351373|NCT01512329|BEHAVIORAL|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
48351374|NCT01512329|BEHAVIORAL|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
48661659|NCT00718432|BEHAVIORAL|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
47985454|NCT01859533|DEVICE|Neopuff|"* Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~* Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
48351375|NCT03952689|DEVICE|Serenno Medical Automatic Urine Output measuring device|"Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count)."
47985455|NCT03037255|OTHER|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
48351376|NCT03476928|DRUG|Vilaprisan (BAY1002670)|2mg, once daily, oral
48351377|NCT03066661|DRUG|Entrectinib|Open-label expanded access, capsules
48351378|NCT00671476|DRUG|pegylated liposomal doxorubicin hydrochloride|
48503758|NCT05245318|OTHER|Standard Clinical care|The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
48661660|NCT05077384|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
48687902|NCT06468891|OTHER|Incontinence Symptom Severity Index|"* The ISSI consists of eight items that assess different aspects of urinary incontinence symptoms, including emptying difficulties, nocturia, daytime frequency, stress incontinence, urge incontinence, leakage with activity, and pad use.~* Each item is scored on a scale of (0 to 3) or (0 to 4), depending on the severity of the symptom. Higher scores indicate more severe symptoms.~* The total ISSI score is obtained by summing the scores of all eight items, resulting in a range of 0 to 32 or 0 to 40, depending on the version used.~* The severity of urinary incontinence symptoms can be categorized based on the total ISSI score"
47985456|NCT05487638|OTHER|Nursing Education and Counseling Service Provided to Patients by Video Calling on the Phone|Nursing Education and Counseling Services were provided to the patients by video calling on the phone for the problems they may encounter in the postoperative period.
47985457|NCT05611879|DRUG|Tislelizumab|Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
47985458|NCT05611879|DRUG|Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
47985459|NCT05611879|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
48351379|NCT00671476|GENETIC|DNA methylation analysis|
48351380|NCT00671476|GENETIC|TdT-mediated dUTP nick end labeling assay|
48351381|NCT00671476|GENETIC|fluorescence in situ hybridization|
48351382|NCT00671476|GENETIC|loss of heterozygosity analysis|
48351383|NCT00671476|GENETIC|polymerase chain reaction|
48351384|NCT00671476|OTHER|immunoenzyme technique|
48351385|NCT00671476|OTHER|immunohistochemistry staining method|
48351386|NCT00671476|OTHER|laboratory biomarker analysis|
48351387|NCT00671476|PROCEDURE|breast duct lavage|
48351388|NCT00671476|PROCEDURE|neoadjuvant therapy|
48351389|NCT00671476|PROCEDURE|therapeutic conventional surgery|
48351390|NCT05960786|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
48351391|NCT05960786|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
48351392|NCT04080349|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
47985460|NCT02557698|OTHER|Balneum oil bath|
48351393|NCT04080349|DRUG|Misoprostol 200Mcg Tab|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
48351394|NCT04080349|DRUG|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
48351395|NCT04583228|DRUG|HLX71|Single-dose, intravenous infusion
48351396|NCT04583228|OTHER|Placebo|Single-dose, intravenous infusion
48661661|NCT05399173|DEVICE|infrared (gallium aluminum arsenide laser)|Patient Position will be in supine \& prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity
48661662|NCT05399173|DRUG|medical treatment(desmopressin acetate)|participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice
48661663|NCT02458235|DRUG|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
48661664|NCT02458235|BIOLOGICAL|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
48661665|NCT06198400|DIAGNOSTIC_TEST|Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye|The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
48661666|NCT03371212|DEVICE|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.
48661667|NCT03371212|DEVICE|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell
48661668|NCT04778566|DIAGNOSTIC_TEST|Cologuard test|Cologuard is a stool-DNA screening test for detecting colon cancer
48661669|NCT04846998|DRUG|BR9003|"Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it."
47985461|NCT02502643|DRUG|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
48140627|NCT05519306|BEHAVIORAL|Mental Practice|Each patient will perform the following two activity-based tasks via MP: wiping a table and picking up a cup. Prior to a scheduled OT session patients will perform MP of the assigned motor task. Following MP, a research therapist will facilitate repetitive task practice of the same motor task. MP sessions will be completed 5x/week for 2 weeks, (3x/week in combination with RTP, and 2x/week independently). The MP will be completed at an MP station equipped with a tablet and noise-canceling headphones. The audio recording will be from a first-person view as if they are performing it with their own UE. Each task will consist of 20 repetitions and will be facilitated by the use of multisensory cues (visual, tactile, auditory, and kinesthetic). For example, the task of picking up a cup will include describing how the drink looks (water with ice) and the temperature and feel of the cup (cold/moist).
48140628|NCT02638506|DRUG|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
48140629|NCT02638506|OTHER|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
48140630|NCT06287957|PROCEDURE|Labrida BioClean|Debriding the tissue around the implant with Labrida Bioclean
48661670|NCT04846998|DRUG|BR9003A|"Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state"
48661671|NCT06529484|OTHER|Warm Water Foot Bath Intervention|Participants will take a warm water foot bath at 38-40ºC for 20 minutes nightly for 7 days.
48661672|NCT04123704|DRUG|Sitravatinib|sitravatinib capsule
48661673|NCT06149182|BEHAVIORAL|Life stress interview according to EAET|This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
48661674|NCT06149182|BEHAVIORAL|"Psychiatric interview according to region stockholm - basutredning"|This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
48661675|NCT02966548|DRUG|Relatlimab|Specified dose on specified days
48661676|NCT02966548|DRUG|Nivolumab|Specified dose on specified days
48661677|NCT02733094|DRUG|Secukinumab|
48661678|NCT01074346|DRUG|Interferon-β-1a|Interferon-β-1a according to the standard practice
48661679|NCT05835648|DIETARY_SUPPLEMENT|Nutrasumma|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
48661680|NCT03410160|DIAGNOSTIC_TEST|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
48661681|NCT01117779|DEVICE|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
48661682|NCT01516476|DRUG|Placebo|Placebo for 12 weeks
48661683|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
48661684|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
48661685|NCT01516476|DRUG|liraglutide|liraglutide for 12 weeks
48661686|NCT02525198|DIETARY_SUPPLEMENT|fatty acid/flavonoid blend|see arm description
48661687|NCT02525198|DIETARY_SUPPLEMENT|Placebo|see arm description
48661688|NCT00304161|DRUG|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
48661689|NCT00304161|DRUG|Placebo|40 to 80 mg orally once daily for 8 weeks
48661690|NCT06126159|DIAGNOSTIC_TEST|multiparametric and fat-detection magnetic resonance imaging (MRI)|Differentiating of renal AMLs with minimal fat and RCCs
48661691|NCT02467270|DRUG|Ponatinib|Tablet, taken orally once daily.
48661692|NCT01952977|DIETARY_SUPPLEMENT|Test breakfast|
48661693|NCT03058952|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
48661694|NCT03058952|BEHAVIORAL|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
48661695|NCT00291837|DRUG|CT-2106|
48661696|NCT05577156|BEHAVIORAL|Self-questionnaires and semi-structured interview|Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
48661697|NCT04186832|DEVICE|FitBit|Wear FitBit
48661698|NCT04186832|DEVICE|Pedometer|Wear pedometer
48661699|NCT04186832|OTHER|Quality-of-Life Assessment|Ancillary studies
47985462|NCT02502643|DRUG|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
47985463|NCT00403663|DRUG|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
48661700|NCT04186832|OTHER|Questionnaire Administration|Ancillary studies
48661701|NCT00078260|DRUG|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression"
48661702|NCT03477422|DRUG|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
48661703|NCT03477422|DRUG|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
48661704|NCT00767780|DEVICE|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
48661705|NCT05601882|DRUG|Upadacitinib|Oral Tablets
48661706|NCT05601882|DRUG|Dupilumab|Subcutaneous Injection
48661707|NCT03699202|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
48661708|NCT03699202|DRUG|Placebo|The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
48661709|NCT02578082|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
48351397|NCT02703649|DRUG|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
48661710|NCT03840967|DRUG|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
48661711|NCT01296165|BEHAVIORAL|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.
48351398|NCT04451590|OTHER|VR-based simulation|Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.
48503759|NCT05245318|DEVICE|Blended physiotherapy program|The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
48503760|NCT01322867|DRUG|alprazolam tablet|0,25 mg oral tablets given once
48503761|NCT01322867|DRUG|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
48503762|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
47985464|NCT04610944|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication.
48503763|NCT01704794|DRUG|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
48503764|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
48661712|NCT06569862|PROCEDURE|Postoperative day 1 dressing|The patient's dressing will be removed on the first day after surgery, leaving the incision exposed to air, with daily cleaning.
48661713|NCT06569862|PROCEDURE|Postoperative day 6+/-1 dressing|The patient will have a daily dressing change according to the usual nursing procedures, including saline serum washing, until the sixth day (+/- 1 day) after surgery. This will be done while the patient is in hospital, or at home if discharged before the sixth day.
48661714|NCT03801590|DEVICE|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
47985465|NCT03838133|DRUG|TLC590|TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
48140631|NCT06287957|PROCEDURE|EMS Handy 3.0 Perio Premium|Debriding the tissue around the implant with Air-Flow Device
48140632|NCT00946972|DRUG|JNJ-38431055; Placebo|
48351399|NCT04451590|OTHER|Mannequin-based simulation|Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
48351400|NCT02946151|DEVICE|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
48351401|NCT03285061|DEVICE|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
48661715|NCT03931330|DEVICE|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
48661716|NCT00457626|DRUG|Valsartan|Extemporaneous suspension of valsartan, orally.
48661717|NCT04781179|BEHAVIORAL|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
48661718|NCT04781179|BEHAVIORAL|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
48661719|NCT03453216|BEHAVIORAL|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
48661720|NCT03730350|BEHAVIORAL|Clinical Hypnosis|Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
48661721|NCT03129906|DIETARY_SUPPLEMENT|Gluten|
48351402|NCT04562038|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|The Young Children's Participation in Environment Measure (YC-PEM) is an evidence-based option for comprehensive proxy assessment of a young child's current and desired participation in occupations across home, daycare, and community settings. The YC-PEM is an electronic patient-reported outcome (e-PRO) that provides individual caregivers a valid, reliable, and feasible way to communicate information about their child's current participation in home and community activities and areas of participation need. The gained information is then summarized and shared with the child's EI provide team to identify intervention priorities and goal attainment strategies in partnership with families. For quality improvement, EI programs can aggregate the YC-PEM e-PRO data to examine trends in participation as a function of EI service use. It is therefore a promising electronic health systems intervention to enhance the parent-practitioner relationship, and an NIH common data element for trials.
48661722|NCT03129906|DIETARY_SUPPLEMENT|Rice protein|
48661723|NCT03527667|BEHAVIORAL|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
48140633|NCT00701259|DRUG|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
48351403|NCT01955785|DEVICE|pressure controlled ventilator|
48351404|NCT01955785|DEVICE|Pressure Regulated Volume Controlled Ventilator|
48661724|NCT04893733|DRUG|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
47985466|NCT03838133|DRUG|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
47985467|NCT03838133|DRUG|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
47985468|NCT03838133|DRUG|Bupivacaine|Bupivacaine 50 mg (0.5%, 10 mL)
47985469|NCT03072628|OTHER|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
48140634|NCT00701259|DRUG|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
48140635|NCT00701259|DRUG|placebo|
48140636|NCT04198441|DEVICE|Wound dressing|Clean wound, fill wound, dress wound
48140637|NCT06261437|OTHER|CCAR|The CCAR will be consumed as the sole source of nutrition during a 7-day military training exercise.
48140638|NCT06261437|OTHER|FSR|The FSR will be consumed as the sole source of nutrition during a 7-day military training exercise.
48503765|NCT03323437|DRUG|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
48661725|NCT05587127|BEHAVIORAL|Cognitive Behavioral Therapy|Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
48661726|NCT02302287|DIETARY_SUPPLEMENT|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
48661727|NCT02302287|OTHER|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
48661728|NCT02302287|OTHER|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
48661729|NCT04118764|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
48661730|NCT04118764|DRUG|Definity|Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
48140639|NCT02516709|RADIATION|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
48140640|NCT04074252|DEVICE|Lofstrand Crutches|Device: Set of Lofstrand Crutches
48140641|NCT04074252|DEVICE|Axillary Crutches|Device: Set of Axillary Crutches
48503766|NCT01147107|DRUG|Raltegravir|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
48661731|NCT04118764|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.
48661732|NCT04118764|OTHER|Positron Emission Tomography (PET)|A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
48661733|NCT04118764|OTHER|Amyvid|To be used during the PET scan to determine uptake of Amyvid within the treated area.
47985470|NCT03072628|OTHER|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
48140642|NCT06466759|DEVICE|Mc Grath Videolaryngoscope|Use of Videolaryngoscope with Mc Grath versus direct laryngoscopy
48140643|NCT06021275|OTHER|Microneedling with topical application of regular insulin|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
48140644|NCT06021275|OTHER|Microneedling with topical application of saline|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
48140645|NCT02869802|PROCEDURE|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
48140646|NCT02869802|OTHER|Serial Collection of Plasma and Serum Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every 4 weeks until end of study.
48140647|NCT01342497|DRUG|isoniazide|Tablets, dosing 3 times daily, 12 weeks
48140648|NCT01342497|DRUG|placebo|tablets, dosing 3 times daily, 12 weeks
48503767|NCT01147107|DRUG|Efavirenz|Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
48503768|NCT01167101|DRUG|Rebamipide|Rebamipide 100mg Tid for 28days
48661734|NCT05756322|DRUG|LBS-007|Open Label.
48140649|NCT06196164|PROCEDURE|EUS-BD|We observe the bile duct through endoscopic ultrasound, then puncture through the gastric or duodenum wall and place a guide wire, expanding along the guide wire, finally place a stent between the bile duct and the stomach or intestine for drainage.
48140650|NCT06196164|PROCEDURE|ERCP-BD|We use a Duodenoscopy to pass through mouth down to the small opening where the bile duct and pancreatic drain. A small narrow catheter is passed through the scope to gain access to the drainage duct , followed by advancement of a wire deep into the duct. A small cut is made at the bile duct opening to help facilitate a stent placed in the bile duct.
48140651|NCT02431741|DEVICE|Mepilex Transfer Ag|
48351405|NCT06439004|OTHER|Quantitative Sensory Testing|Performing QST on the dominant hand, right forearm, right flank and lower back.
48351406|NCT01212120|BIOLOGICAL|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
48351407|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Probiotics|6 Billion CFU
48351408|NCT05905679|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|0 CFU per day
48351409|NCT04853056|DEVICE|virtual reality|wearing virtual reality glasses
48351410|NCT04853056|DEVICE|Cold vibration|Buzzy
48351411|NCT05659004|BEHAVIORAL|Qualitative interview|No intervention
48503769|NCT01167101|DRUG|pantoprazole|pantoprazole 40mg qd for 28days
48351412|NCT03713151|OTHER|Dividat FIT|The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
48503770|NCT06551779|PROCEDURE|inyección perineural con solución de dextrosa tamponada|Application of perineural injection with buffered dextrose solution, adding 2.5 ml of 7.5% sodium bicarbonate to a 250 ml bottle of glucose solution at 5% concentration, applying 1cc of the solution at different points on the path of the facial nerve.
48503771|NCT00170664|DRUG|Paclitaxel|
48503772|NCT00170664|DRUG|Carboplatin|
48503773|NCT05806619|OTHER|histopathological analysis; morphological and non-morphological magnetic resonance|The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.
48503774|NCT05819723|OTHER|CAM score|"The CAM scores assess the presence of delirium rapidly and accurately and also differentiates delirium from other cognitive impairment with a sensitivity of 94-100% and specificity of 90-95%.~It is an algorithm that consists of four features:~(i) Acute and fluctuating variation in mental status, (ii) Inattention, (iii) Incoherent or disorganized thinking, and (iv) Altered level of consciousness. CAM scores indicate delirium if the first two features are present and either the third or fourth feature is present."
48503775|NCT05901649|DRUG|Apalutamide|No interventions will be administered as a part of this study. Participants will receive apalutamide as per their routine clinical practice.
48661735|NCT02485184|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
48661736|NCT02485184|DRUG|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
48661737|NCT02485184|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
48661738|NCT02485184|DRUG|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
48661739|NCT00517790|DRUG|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
48661740|NCT00517790|DRUG|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
48661741|NCT00730327|DEVICE|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
48661742|NCT00730327|OTHER|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
48661743|NCT06158152|DIETARY_SUPPLEMENT|AM3 + Probiotic|Two capsules daily in the morning during 12 weeks. The capsule contains the mixture of AM3 Technology and probiotic SynBalance Metsyn.
48661744|NCT06158152|DIETARY_SUPPLEMENT|Placebo|Two capsules daily in the morning during 12 weeks. The capsule contains starch.
48661745|NCT06158152|DIETARY_SUPPLEMENT|AM3|Two capsules daily in the morning during 12 weeks. The capsule contains AM3 Technology.
48661746|NCT01596270|DRUG|SAR245409|Pharmaceutical form: tablet Route of administration: oral
48661747|NCT05121350|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
48661748|NCT05121350|DRUG|Epirubicin|Epirubicin can inhibit the synthesis of DNA and RNA.
48661749|NCT05121350|DRUG|Arotinib hydrochloride capsule placebo|Placebo of Anlotinib hydrochloride capsule
48351413|NCT00726167|DEVICE|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
48661750|NCT01527032|DRUG|melphalan, thalidomide and dexamethasone|
48661751|NCT05309655|DRUG|Adenosine Stress Cardiac Magnetic Resonance Imaging|Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.
48351414|NCT05819502|DRUG|Restylane line of injectables|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
48351415|NCT04130880|DIAGNOSTIC_TEST|Turkish Montreal Children's Hospital Feeding Scale|The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
48503776|NCT05901649|DRUG|Enzalutamide|No interventions will be administered as a part of this study. Participants will receive enzalutamide as per their routine clinical practice.
48503777|NCT04737096|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
48503778|NCT04737096|DRUG|Placebo|placebo
48503779|NCT04737096|DEVICE|tDCS|tDCS
48661752|NCT05309655|DIAGNOSTIC_TEST|Electrocardiogram|A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
48661753|NCT05309655|DIAGNOSTIC_TEST|Computed Tomography Angiogram|Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.
48661754|NCT05309655|OTHER|Laboratory Testing|10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.
48661755|NCT05309655|BEHAVIORAL|Quality of Life Survey|A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
48661756|NCT05378802|OTHER|different modes of mechanical ventilation|Four different ventilation modes were performed one by one and respiratory parameters were recorded.
48661757|NCT05534126|PROCEDURE|Stellate Ganglion Block Treatment|Stellate ganglion block procedure is a treatment that involves injection of local anesthetic around the stellate ganglion (located at the base of the neck) to block its transmission of pain signals.
48661758|NCT05534126|PROCEDURE|Placebo|Sham
48661759|NCT01748656|DEVICE|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
48503780|NCT01806766|PROCEDURE|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
48503781|NCT01806766|PROCEDURE|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
48503782|NCT06600126|BEHAVIORAL|Coping Skills Training|The Coping Skills Training arm will consist of 12 weekly 30-minute sessions via videoconferencing or phone. A trained research staff member will deliver sessions that focus on building coping skills for patients with COPD, such as progressive relaxation training, pleasant activity scheduling, and building communication skills. Caregivers will also participate, learning how to support the patient in using these skills. Participants will complete assignments between sessions to reinforce their learning. Additionally, participants will receive a Coping Skills Training workbook.
48503783|NCT06600126|BEHAVIORAL|COPD Education|The COPD Education arm will consist of 12 weekly 10-minute sessions via videoconferencing or phone. A trained research staff member will provide scripted general support and encouragement without using specific psychoeducational techniques. Caregivers will also participate. Additionally, participants will receive a COPD Education workbook with material from The COPD Foundation, which is also available on the Foundation's website. This program augments usual care, providing an attention control for comparison.
48351416|NCT03612674|PROCEDURE|Standard colonoscopy|Current standard of care colonoscopy.
48351417|NCT03612674|DEVICE|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
48351418|NCT05202184|PROCEDURE|Percutaneous thermal ablation|All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance
48351419|NCT04856969|DRUG|Olmesartan|First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
48351420|NCT04856969|DRUG|Dapagliflozin|First stage: ATB-1012 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration
48503784|NCT03262038|DRUG|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
48661760|NCT01748656|DEVICE|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
48351421|NCT02050828|DRUG|AKB-9778|
48351422|NCT02050828|DRUG|ranibizumab|
48351423|NCT02050828|DRUG|Placebo|
48351424|NCT02050828|DRUG|Sham|
48351425|NCT05399329|DRUG|Palbociclib|Palbociclib plus ET as first-line/second-line treatment for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) ABC
48351426|NCT05399329|DRUG|Endocrine therapy|Palbociclib plus ET as first-line/second-line treatment for HR+/HER2- ABC
48351427|NCT01281774|BIOLOGICAL|CSL112|reconstituted high density lipoprotein
48140652|NCT04171674|DRUG|Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).|High-dose ceftobiprole (500mg loading dose) will be administered to patients for 30 minutes followed by 2.5g under continuous infusion for 24 hours.
48140653|NCT06117215|OTHER|Data collection|data collection
48140654|NCT04867382|BEHAVIORAL|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
48140655|NCT01567852|DRUG|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
48140656|NCT01567852|DRUG|Methohexital|Methohexital (1.5mg/kg) will be given for induction
48140657|NCT05162469|DRUG|SHR-1909 injection|SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
48140658|NCT02506452|OTHER|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
48140659|NCT02506452|OTHER|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
48140660|NCT01942954|OTHER|Mobile health cognitive stimulation|
48140661|NCT04732611|OTHER|Pilates exercises|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
48140662|NCT04732611|OTHER|Walking protocol|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks.
48140663|NCT04067609|DRUG|Dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
48140664|NCT04067609|OTHER|placebo|100mL of normal saline (placebo)
48140665|NCT00874588|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
48140666|NCT04780152|DEVICE|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
48140667|NCT04780152|DEVICE|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
48140668|NCT04780152|DRUG|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
48140669|NCT04012242|DIAGNOSTIC_TEST|Ultrasound application|Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
48140670|NCT06177561|PROCEDURE|Lymphoplasma exchange|The LPE treatment regimen is: LPE\*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2\*2 times, gamma globulin 0.4g/kg/d\*5d.
48140671|NCT05847452|DRUG|Benralizumab|30mcg ever month for 3 months
48140672|NCT01738997|DEVICE|Dilation 10 sec|
48140673|NCT01738997|DEVICE|Dilation 2 min|
48140674|NCT03121885|BEHAVIORAL|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
48140675|NCT03121885|OTHER|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
48140676|NCT01338506|BEHAVIORAL|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
48140677|NCT03936192|DRUG|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
48140678|NCT03936192|DRUG|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
48140679|NCT03936192|DRUG|Placebos|Placebo administered once daily for 12 weeks.
48140680|NCT00366470|DRUG|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
48140681|NCT00366470|OTHER|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
48140682|NCT03310255|DIAGNOSTIC_TEST|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
48140683|NCT01593644|DRUG|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
48687903|NCT06468891|OTHER|Force platform|"Use the provided software or tools to analyze the recorded force data, including Step Cycle Duration (ms), Time of Contact (ms), Swing Duration (ms), Single Step Duration (ms), Double Support Duration (ms), Initial Contact (ms) , Loading Response (ms), Mid Stance (ms), Terminal Stance (ms), Step Cycle Length, Half Step Length for left and right lower limbs.~* Interpret the data to draw conclusions about the forces exerted during the subject's movements or activities."
48140684|NCT05825404|DEVICE|Smart Ambient Bright Light (SABL)|The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
48140685|NCT05825404|OTHER|Control|Usual light.
48140686|NCT01548703|DRUG|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
48140687|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
48351428|NCT01281774|BIOLOGICAL|Placebo|Normal saline (0.9%)
48661761|NCT04164277|BEHAVIORAL|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
48503785|NCT03262038|DRUG|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
48503786|NCT01955083|DEVICE|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
48503787|NCT01955083|DEVICE|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
48661762|NCT04164277|BEHAVIORAL|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
48661763|NCT04164277|BEHAVIORAL|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat \& Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
48661764|NCT06167239|OTHER|Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques|New techniques to train inspiratory muscles in mechanically ventilated patients
48661765|NCT01535482|BEHAVIORAL|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
48661766|NCT01535482|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
48140688|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
48503788|NCT02085135|DRUG|ALKS 5461|Sublingual tablet taken once daily
48503789|NCT01128608|PROCEDURE|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
48503790|NCT01128608|PROCEDURE|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
48503791|NCT04488835|OTHER|Electromagnetic field therapy and transcutaneous electrical nerve stimulation|Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
48503792|NCT03521843|DEVICE|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
48503793|NCT03521843|DEVICE|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
48503794|NCT03096912|DRUG|Ribociclib|Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
48503795|NCT01931696|DEVICE|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
47985471|NCT03072628|OTHER|nicotine inhaler|use a nicotine inhaler for 30 minutes
48140689|NCT03578965|DRUG|Cefazolin|-If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
48140690|NCT01338532|OTHER|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
48140691|NCT01338532|OTHER|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
48503796|NCT01931696|DEVICE|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
48503797|NCT02820649|OTHER|Sleep deprivation|40 hours of continuous wakefullness
48503798|NCT04383223|BEHAVIORAL|iTransition|Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
48503799|NCT06196814|DRUG|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy|PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.
48503800|NCT03621501|DEVICE|Percutaneous coronary intervention|At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
48661767|NCT03370315|OTHER|Dance Program|The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
48140692|NCT06407648|OTHER|Personalized Assessments|Personalized CBT will use individualized OCD symptom networks to guide CBT strategies to target central symptom nodes in contemporaneous networks.
48503801|NCT04880863|DRUG|NAP (Naptumomab estafenatox)|Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that is linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP will be administered in a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg will be administered on Day 1.
48503802|NCT04880863|DRUG|Docetaxel|Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel will be administered in combination with the study drug, NAP, on Day 2.
48503803|NCT04880863|DRUG|Obinutuzumab|Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
48503804|NCT01363882|OTHER|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
48503805|NCT01363882|OTHER|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
48503806|NCT04241315|DRUG|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
48503807|NCT04241315|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
48503808|NCT01216618|DEVICE|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
48140693|NCT06407648|OTHER|Standard of Care|The standard CBT condition will use standard-of-care approaches to guide CBT strategies to target OCD symptoms.
48140694|NCT02958566|DRUG|Acetaminophen|
48503809|NCT03729817|DEVICE|Submaximal balloon angioplasty|An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
48503810|NCT00777036|DRUG|Dasatinib|
48503811|NCT06584422|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
48140695|NCT02958566|DRUG|Gabapentin|
48140696|NCT02958566|DRUG|Orphenadrine|
48140697|NCT02958566|DRUG|Lidocaine|
48140698|NCT02958566|DRUG|Marcaine|
47985472|NCT03072628|OTHER|sham control|use an empty e-cigarette for 30 minutes
47985473|NCT05924750|DRUG|BL-M11D1|Administration by intravenous infusion
48140699|NCT02958566|DRUG|Ketamine|
48140700|NCT02958566|DRUG|Methadone|
48140701|NCT02958566|DRUG|Tramadol|
48140702|NCT02958566|DRUG|Ketorolac|
48140703|NCT02958566|DRUG|Morphine Sulfate|
48140704|NCT02958566|DRUG|Fentanyl|
48661768|NCT03370315|OTHER|Walking Program|The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
48140705|NCT02958566|DRUG|Dilaudid|
48661769|NCT01144650|DRUG|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
48661770|NCT01144650|DRUG|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
48140706|NCT02958566|DRUG|Hydrocodone-Acetaminophen Tab 5-325 MG|
48661771|NCT02970565|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
48661772|NCT02970565|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
47985474|NCT02344160|OTHER|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
48140707|NCT02958566|DRUG|Morphine Sulfate|PCA
48140708|NCT02958566|DRUG|Fentanyl|PCA
48140709|NCT02958566|DRUG|Dilaudid|PCA
48140710|NCT02958566|DRUG|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
48140711|NCT04914702|DEVICE|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
48140712|NCT04914702|DEVICE|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
48140713|NCT02798016|PROCEDURE|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
48140714|NCT02798016|PROCEDURE|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
48140715|NCT05260866|OTHER|national population-based study|No intervention
48140716|NCT01855165|BEHAVIORAL|Advice on DDIs|
48140717|NCT03429816|PROCEDURE|Biopsy|Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
48140718|NCT03332875|BEHAVIORAL|OurRelationship Online Program|OurRelationship.com is an online program designed to improve distressed romantic relationships.
48140719|NCT00726505|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
48140720|NCT02442037|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.
48140721|NCT02442037|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
48140722|NCT03233152|DRUG|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
48503812|NCT06584422|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
48661773|NCT04236076|DEVICE|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
48140723|NCT03233152|DRUG|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
48140724|NCT02140879|DIETARY_SUPPLEMENT|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
48140725|NCT02140879|DIETARY_SUPPLEMENT|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
48140726|NCT04880837|OTHER|Educational Intervention|Attend educational session
48140727|NCT04880837|OTHER|Informational Intervention|Receive handouts
48140728|NCT04880837|OTHER|Survey Administration|Complete surveys
48140729|NCT02976272|OTHER|bortezomib|
48140730|NCT02808832|BEHAVIORAL|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
48140731|NCT01709006|RADIATION|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
48140732|NCT04891978|BEHAVIORAL|AIRQ|A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.
48140733|NCT04891978|BEHAVIORAL|Asthma Checklist|A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .
48140734|NCT04891978|BEHAVIORAL|PRECISION Program (Educational Resources)|Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
48140735|NCT01553266|BEHAVIORAL|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
48140736|NCT02394613|DRUG|ANX776|Single intravenous injection
48140737|NCT01411657|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
48140738|NCT05953909|DRUG|Eribulin-Based Regimen|Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
48503813|NCT03993782|OTHER|A19010-R|A snus product
48503814|NCT03993782|OTHER|B19010-O|A snus product
48503815|NCT06348706|DRUG|Dipeptidyl peptidase 4 (DPP-4) inhibitor|Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
48503816|NCT04320251|PROCEDURE|cochlear implant revision surgery|Observation during routine cochlear implant revision surgery
48503817|NCT04248218|BEHAVIORAL|Active Rehabilitation Group/Case|If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
48503818|NCT02531750|OTHER|Immobilization due to an Achilles tendon rupture|
48503819|NCT00237965|BEHAVIORAL|Mole Mapping Diagram|
48503820|NCT04292652|PROCEDURE|AAA surgery|EVAR is a mini invasive procedure to exclude aortic aneurysms with the intention to prevent rupture. Open repair is the traditional open surgical procedure for the same condition.
48503821|NCT01708148|DIETARY_SUPPLEMENT|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
48503822|NCT01708148|OTHER|Placebo|control group would receive a oral lactose placebo
48503823|NCT00548470|DRUG|Varenicline|Varenicline 1-2 mg/day
48503824|NCT02293369|PROCEDURE|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
48661774|NCT04236076|DEVICE|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
47985475|NCT01108601|DRUG|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
47985476|NCT02368431|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
47985477|NCT02368431|DRUG|Placebo|Placebo
48503825|NCT02293369|PROCEDURE|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
48503826|NCT06160700|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA is a method for evaluating cognition. This assessment will be conducted at baseline, month 3, and month 6.
48661775|NCT04928547|DIAGNOSTIC_TEST|Test|Different test
48661776|NCT03323255|DEVICE|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
48661777|NCT03323255|DEVICE|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
47985478|NCT02769247|DRUG|Naproxen|Oral naproxen vs placebo
47985479|NCT02769247|DRUG|Lidocaine|Intrauterine lidocaine vs normal saline
47985480|NCT02769247|DRUG|placebo|either normal saline or empty oral capsule
47985481|NCT01304745|BEHAVIORAL|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
47985482|NCT01304745|BEHAVIORAL|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
47985483|NCT05991037|BIOLOGICAL|Blood sampling for psychoactive drugs dosage|4 blood samples for psychoactive drugs identification and dosage will be taken on arrival at the emergency room during fall management
48503827|NCT02418481|BIOLOGICAL|DC-CIK|DC-CIK cells will be used against tumor cells.
48503828|NCT02418481|BIOLOGICAL|γδ T Cell|γδ T cells will be used against breast tumor.
48503829|NCT02418481|BIOLOGICAL|Combination|γδ T/DC-CIK cells will be used against breast tumor.
48503830|NCT03473769|OTHER|Vital Signs at 2 Hours|Patients vital signs assessed at 2 hours of arrival at ICU
48661778|NCT04492384|OTHER|non-interventional|Interview on health conditions
48661779|NCT06559319|DIAGNOSTIC_TEST|blood sampling|Venous blood is collected, and sIgE and BAT will be detected using whole blood and serum, respectively.
48661780|NCT03199079|OTHER|Measurement|Measurement of cervix elasticity and length measurements is not an intervention
48661781|NCT01107886|DRUG|Saxagliptin|5 mg or 2.5 mg once daily
48661782|NCT01107886|DRUG|Placebo|
48661783|NCT03161873|DEVICE|Ava|Ava is a fertility monitoring bracelet that collects various physiological parameters
48661784|NCT04587492|DRUG|Nusinersen|Treatment with nusinersen
47985484|NCT00179400|DRUG|Pioglitazone 45 mg|
48140739|NCT05953909|DRUG|nab-paclitaxel based regimen|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
48503831|NCT03473769|OTHER|Confusion Assessment method for the ICU (CAM-ICU)|patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
48661785|NCT06572072|DEVICE|Negative Pressure Ventilation|Substitution of positive pressure ventilation by negative pressure ventilation
48503832|NCT05491915|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the occipital nerves. The SPRINT System includes up to two leads (small wires) that are placed through your skin at the top of your neck. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
48661786|NCT00182650|BIOLOGICAL|aldesleukin|
48661787|NCT00182650|BIOLOGICAL|rituximab|
48661788|NCT00182650|BIOLOGICAL|therapeutic autologous lymphocytes|
48661789|NCT00182650|DRUG|fludarabine phosphate|
48661790|NCT04152239|PROCEDURE|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
48661791|NCT04110145|DRUG|Linaclotide|Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
47985485|NCT00179400|DRUG|Placebo|
47985486|NCT00003903|PROCEDURE|management of therapy complications|
47985487|NCT04087694|PROCEDURE|Microdecompression|comparative surgical treatment
48140740|NCT05953909|DRUG|Other Chemotherapy Regimen|"TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)"
48140741|NCT00794807|DRUG|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
48661792|NCT04110145|DRUG|Placebo|Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
48661793|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
48661794|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
48661795|NCT01640080|DRUG|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
48661796|NCT02534922|BIOLOGICAL|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
48661797|NCT02884102|GENETIC|genetic sequencing|
48661798|NCT03185026|BEHAVIORAL|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :~1. Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix~2. Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.~3. and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)~5) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
48140742|NCT00850915|OTHER|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
48140743|NCT04597931|DRUG|Romosozumab|SC Romosozumab 210 mg/monthly
48661799|NCT03185026|OTHER|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
48661800|NCT05589025|PROCEDURE|pulpotomy technique with formocresol|The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
48661801|NCT05589025|PROCEDURE|pulpectomy technique with zinc oxide and eugenol|The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide \& eugenol.
48661802|NCT00376103|DRUG|temozolomide|75 mg/m2/day
48661803|NCT00376103|PROCEDURE|Brachytherapy|60 Gy to 1 cm
48661804|NCT00376103|PROCEDURE|External Beam Radiation Therapy|60 Gy
48661805|NCT05269186|DEVICE|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
48661806|NCT06107699|OTHER|Patient Navigation|Assigned a Patient Navigator to provide information on transitional care and community resources.
48661807|NCT00652834|PROCEDURE|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
48661808|NCT00652834|DRUG|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
48661809|NCT02395276|DEVICE|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
48661810|NCT06565052|BEHAVIORAL|Prehabilitation Program|A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.
48661811|NCT06395558|BEHAVIORAL|Lifestyle intervention|Multimodal web-based intervention programme on anxiety, depression and cognitive impairment consisting of knowledge development sessions and practical/gaming sessions focused on different domains: cognitive competence, socio-relational competence and emotions/affectivity, and physical activity-nutrition
48661812|NCT03561311|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
48661813|NCT03561311|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
48661814|NCT01006733|GENETIC|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
48351429|NCT06361706|BEHAVIORAL|VR-Enhanced Psychoeducational Program for Chronic Pain|Participants undergo eight weekly sessions that include VR to learn pain physiology, mindfulness, and self-management techniques. Each session is 90 minutes, with 15-20 minutes of VR activities designed to complement the educational content. Activities simulate pain management exercises and mindfulness meditation. The program, led by pain management and VR specialists, aims to improve pain management skills, emotional well-being, and quality of life.
48351430|NCT01186315|BEHAVIORAL|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
48351431|NCT01186315|BEHAVIORAL|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use \& CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
48351432|NCT05002036|DEVICE|Trium eyedrops|given three times daily from day 1 after surgery to end of Week 4
48661815|NCT01006733|DRUG|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
48661816|NCT02216526|OTHER|Cetaphil® Restoraderm|
47985488|NCT01197053|BIOLOGICAL|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
47985489|NCT01197053|BIOLOGICAL|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
48661817|NCT02216526|OTHER|Excipial|
47985490|NCT05417165|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
47985491|NCT05417165|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
47985492|NCT04010682|OTHER|urine sample collection|no drug/devise intervention. sample collection study only
48661818|NCT05388578|DEVICE|Blood pressure monitor|Participants will receive the Withings BPM connect monitor and do weekly self-measurements of blood pressure.
48661819|NCT05388578|DEVICE|Weighting scale|Participants will receive the Withings Body scale and do weekly self-measurements of their body weight and BMI.
48140744|NCT04597931|DRUG|Zoledronic Acid|IV Zoledronic acid 5 mg
48140745|NCT06140550|DEVICE|Drug balloon dilated|Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis
48140746|NCT06140550|DEVICE|balloon dilated|Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.
48140747|NCT02541318|BEHAVIORAL|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
48351433|NCT02324413|DRUG|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
48351434|NCT02324413|DRUG|Placebo|
48661820|NCT05388578|DEVICE|Activity tracker|Participants will receive the Withings Move to automatically keep track of their number of steps and activity type.
48661821|NCT05388578|DEVICE|ECG device|Participants will receive the Withings Move ECG to make daily measurements of heart rhythm, an algorithm will detect abnormalities in heart rhythm such as atrial fibrillation.
48661822|NCT01772654|DEVICE|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
48661823|NCT06565013|DRUG|Cabenuva 600/900|Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
48661824|NCT06565013|OTHER|Self administered questionnaires|Questionnaires on treatment satisfaction (HIVTSQs), quality of life (WHOQoL-HIV-BREF) and drug use assessment (DEBA-D) will be administered at baseline, M5 and M11
48661825|NCT06565013|OTHER|Semi-directed interview|At baseline and M11, participants will conduct a semi-directed interview about the perception of their HIV treatment and the global care they receive as a person living with HIV who is practicing chemsex.
48661826|NCT02330003|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
48661827|NCT02330003|BIOLOGICAL|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
48661828|NCT00490711|DRUG|gemcitabine|
48661829|NCT00490711|DRUG|carboplatin|
48661830|NCT00490711|DRUG|paclitaxel|
47985493|NCT03514784|DRUG|BB-12 with LGG (Higher Dose)|BB-12 with LGG - Higher Dose (10 billion CFUs)
47985494|NCT03514784|DRUG|Placebo|Maltodextrin
47985495|NCT03514784|DRUG|BB-12 with LGG (Lower Dose)|BB-12 with LGG - Lower Dose (1 billion CFUs)
47985496|NCT04319120|OTHER|questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
48351435|NCT02762136|DRUG|placebo|
48351436|NCT02762136|DRUG|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
48351437|NCT00951119|DEVICE|Resperate|device-guided breathing exercises
48351438|NCT00951119|DEVICE|Resperate|breathing device without slowing of breathing frequency
48351439|NCT05135182|DRUG|Furazolidone|Furazolidone-tetracycline-containing quadruple regimens
48351440|NCT05135182|DRUG|Metronidazole|metronidazole-tetracycline-containing quadruple regimens
48351441|NCT01755390|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
48351442|NCT00713557|DEVICE|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
47985497|NCT01396707|DRUG|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1"
48140748|NCT03842332|BEHAVIORAL|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
48140749|NCT02431442|DRUG|RM-493|
48140750|NCT02431442|DRUG|Placebo|
48140751|NCT02590198|OTHER|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
48140752|NCT02590198|OTHER|PCT algorithm|care based on PCT algorithm
48140753|NCT06148441|DIAGNOSTIC_TEST|bone morphogenetic protein-2 (BMP-2)|novel biomarkers associated with in-stent restenosis after percutaneous coronary intervention
48140754|NCT02326506|DEVICE|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
48140755|NCT02455557|OTHER|Laboratory Biomarker Analysis|Correlative studies
48140756|NCT02455557|DRUG|Montanide ISA 51 VG|Given SC
47985498|NCT00640445|BEHAVIORAL|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
48140757|NCT02455557|BIOLOGICAL|Sargramostim|Given SC
48140758|NCT02455557|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
48351443|NCT00713557|DRUG|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
48503833|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
47985499|NCT00640445|BEHAVIORAL|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
48140759|NCT02455557|DRUG|Temozolomide|Given PO or IV
48140760|NCT01221532|BEHAVIORAL|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~1. a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~2. two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~3. the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
48140761|NCT01974258|DRUG|Cobimetinib|Escalating dose
48140762|NCT01974258|DRUG|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
48140763|NCT01974258|DRUG|Onartuzumab|Administered by IV infusion every 2 weeks
48351444|NCT01834469|DRUG|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
48140764|NCT01974258|DRUG|Vemurafenib|Orally administered twice daily
48140765|NCT06253299|OTHER|marble stone|"Marble stones with dimensions of 4x5 cm will be used for cold application. When placed in the freezer compartment of the refrigerator at -10°C (Celsius) for 4 minutes, they cool down to 11°C. Subsequently, in 1 minute, the temperature rises to 12°C when held in the palm. After being placed on a table at room temperature, it reaches 18°C in 5 minutes."
48140766|NCT04514562|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
48140767|NCT04148378|OTHER|No intervention|There is no intervention for this study.
48140768|NCT02198417|DRUG|Metformin ER|Treatment with metformin ER for 12 weeks
48351445|NCT05224752|OTHER|Online Survey|Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
48351446|NCT03603574|DEVICE|EWA through the needle|In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.
47985500|NCT02543008|PROCEDURE|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
47985501|NCT02543008|PROCEDURE|Physical activity|Information already included in arm/group descriptions.
47985502|NCT02543008|PROCEDURE|Placebo|Information already included in arm/group descriptions.
48140769|NCT05543005|OTHER|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
48661831|NCT03419819|DIETARY_SUPPLEMENT|PKU Sphere|PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
48661832|NCT05803785|DRUG|BBC1501|BBC1501 solution for Intravitreal injection
48351447|NCT03603574|DEVICE|EWA through the catheter|In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
48351448|NCT02747329|DEVICE|BuMA Supreme™ stent|
48351449|NCT02747329|DEVICE|Xience V/Prime stent|
48661833|NCT01942369|DRUG|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
48661834|NCT03324841|DIAGNOSTIC_TEST|Caris MI Profiling|Customized comprehensive biomarker testing
48661835|NCT04272801|DRUG|tamoxifen, letrozole, anastrozole, or exemestane|choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist
48661836|NCT04272801|BEHAVIORAL|Patient reported outcomes|"Questionnaire inquiries include the following:~* how cancer affects daily living~* beliefs about medicines and sensitivity to medicine~* symptoms~* adherence to endocrine therapy~* general health and well being~* depression and anxiety~* preference regarding radiation therapy"
48661837|NCT06639178|OTHER|DECLARAN cream|Patients will apply 1 mL of DECLARAN cream, as a single pressure dispensing (1 for hands, 1 for feet), 2 times/day on hands and feet, starting 3 days before the beginning of treatment with capecitabine and for the first 24 consecutive weeks of treatment.
48661838|NCT04434755|OTHER|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
48661839|NCT03344484|OTHER|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
48661840|NCT04448379|DRUG|JMT101|IV infusion Q2W for 4 weeks (28-day cycles)
47985503|NCT01058889|DEVICE|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
48351450|NCT03675919|DEVICE|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
48351451|NCT03675919|DEVICE|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
48661841|NCT04726501|OTHER|Combined chemotherapy with or without involved-field radiotherapy|Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
48661842|NCT02878382|OTHER|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
48661843|NCT02878382|OTHER|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
48661844|NCT04992273|DRUG|casirivimab+imdevimab|Single dose administered based on weight
48661845|NCT03942744|DEVICE|on-line hemodiafiltration|on-line postdilutional hemodiafiltration with high convective transport above 21 liters
48661846|NCT03888105|DRUG|Odronextamab|Administered by intravenous (IV) infusion
48661847|NCT04995341|DEVICE|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
48661848|NCT04995341|DEVICE|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
47985504|NCT03593707|DRUG|Metformin|Metformin
48351452|NCT03675919|DEVICE|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
48351453|NCT03675919|OTHER|Access to the online portal|self-monitoring of health parameters
48351454|NCT03675919|OTHER|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
48351455|NCT02308553|DRUG|Nintedanib|Nintedanib (150 mg or 200 mg BID)
48351456|NCT02308553|DRUG|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
47985505|NCT03593707|DRUG|PF-06865571|PF-06865571
47985506|NCT04474067|OTHER|No intervention|This is an observational study, with no intervention.
47985507|NCT01365234|DEVICE|Pacing Lead|Implant and follow up of Model 20066 lead
47985508|NCT00001339|DRUG|doxorubicin, vincristine, and etoposide with mitotane|
47985509|NCT05867472|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
47985510|NCT05867472|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
48351457|NCT02308553|DRUG|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
48661849|NCT06034340|DEVICE|LET Gel after STAR Particle Application (Right or Left Arm)|STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the antecubital fossa.
48661850|NCT06034340|OTHER|LET Gel Application without STAR Particle Application (Contralateral Arm)|Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying aloe gel (control condition) to the volar surface of the antecubital fossa of the contralateral arm to the one receiving the STAR particle preparation.
48661851|NCT03893357|OTHER|Data extraction from medical files|Retrospective data extraction from the medical files
48140770|NCT00003088|DRUG|cyclophosphamide|given IV
47985511|NCT01622972|DRUG|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
47985512|NCT04876443|DIAGNOSTIC_TEST|Study questionnaire|Study questionnaire related to drinking behaviour
47985513|NCT03168308|DRUG|Sugammadex|Sugammadex 2 mg/kg
47985514|NCT03168308|DRUG|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
48140771|NCT00003088|DRUG|doxorubicin hydrochloride|given IV
48351458|NCT01703715|DEVICE|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
48351459|NCT05756894|DEVICE|Neurostimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
48351460|NCT05756894|OTHER|Repiratory training|Respiratory exercises will be completed immediately after completing neurostimulation. Respiratory exercises will involve inspiratory muscle training performing four sets of 6-10 breaths per day with two minutes of rest.
48351461|NCT05411263|DIAGNOSTIC_TEST|Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)|As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
48503834|NCT01103830|DRUG|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
48503835|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
48503836|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
48661852|NCT06560788|OTHER|collection of cerebrospinal fluid|CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
48661853|NCT01139151|DRUG|3 Day Thiarabine|Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
48661854|NCT01139151|DRUG|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
48661855|NCT02811887|BEHAVIORAL|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
48661856|NCT02811887|OTHER|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
48140772|NCT00003088|DRUG|paclitaxel|given IV
48140773|NCT05156606|DRUG|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
47985515|NCT05320523|DEVICE|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
47985516|NCT05320523|DEVICE|GPi stimulation|Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
48661857|NCT02811887|BEHAVIORAL|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
47985517|NCT05320523|DEVICE|NBM stimulation|Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
47985518|NCT05320523|DEVICE|Sham stimulation|Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
47985519|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
47985520|NCT02160158|DRUG|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
48140774|NCT05067101|PROCEDURE|Capsule Sparing Cystectomy (CSC)|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
48140775|NCT05067101|PROCEDURE|Conventional Radical Cystoprostatectomy (CRC)|According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles
48140776|NCT04912765|BIOLOGICAL|Neoantigen Dendritic Cell Vaccine|10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
48140777|NCT04912765|DRUG|Nivolumab|9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
48140778|NCT04573218|DRUG|Placebo|The placebo contains glucose
48140779|NCT04573218|DIETARY_SUPPLEMENT|250 mg OPP|250 mg Oil Palm Phenolics
48140780|NCT05543109|DRUG|Fentanyl|1 mic/kg during induction of anesthesia
48351462|NCT05249803|COMBINATION_PRODUCT|Patients with COVID-19 Pneumonia|Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
48351463|NCT03462030|DRUG|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
48351464|NCT03462030|DRUG|Placebo: Tapioca Powder|Placebo control.
48351465|NCT00255983|DRUG|Faropenem medoxomil|600 mg BID for 5 days
48351466|NCT00255983|DRUG|placebo|placebo tablets BID for 5 days
48351467|NCT02055729|BIOLOGICAL|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
48661858|NCT03906409|OTHER|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
48661859|NCT03906409|OTHER|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
48351468|NCT02055729|BIOLOGICAL|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)
48351469|NCT02055729|BIOLOGICAL|Stool sample|Stool samples will be collected on days 0 and 28.
48351470|NCT02055729|BIOLOGICAL|Urine sample|Urine samples will be collected on days 0 and 28.
48503837|NCT01103830|DRUG|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
48140781|NCT05543109|DRUG|Propofol|3mg/kg during induction of anesthesia
48140782|NCT05543109|DRUG|Rocuronium|0.9 mg/kg during induction of anesthesia
48140783|NCT05543109|DRUG|Sevoflurane|2-3% during maintanance of anesthesia
48140784|NCT05543109|DRUG|Ropivacaine|0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.
48140785|NCT03510416|DRUG|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
47985521|NCT02160158|DRUG|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
47985522|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
47985523|NCT02160158|DRUG|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
47985524|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
47985525|NCT02160158|DRUG|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
47985526|NCT02160158|DRUG|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
47985527|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
47985528|NCT02160158|DRUG|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
47985529|NCT01973166|DEVICE|Picosecond Q-switched Laser Treatment|
47985530|NCT01973166|DEVICE|Nanosecond Q-switched Laser Treatment|
47985531|NCT00337506|DRUG|Dexamethasone|
47985532|NCT00337506|DRUG|velcade|
48140786|NCT03510416|RADIATION|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
48140787|NCT00600353|DRUG|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
48140788|NCT00600353|DRUG|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
48351471|NCT04881110|DRUG|Liraglutide|Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.
48351472|NCT04881110|OTHER|Control|Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.
48351473|NCT02162264|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
48351474|NCT04683133|DIAGNOSTIC_TEST|Optical coherence tomography assessment|Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
48351475|NCT05488106|DIETARY_SUPPLEMENT|Placebo|Placebo
48351476|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 1.6mg/d|Riboflavin 1.6mg/d
48351477|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 5mg/d|Riboflavin 5mg/d
48661860|NCT04331639|DIETARY_SUPPLEMENT|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
48661861|NCT02798887|PROCEDURE|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
48140789|NCT00600353|DRUG|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
48140790|NCT05845398|DRUG|DCR-AUD|DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and update after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).
48351478|NCT05488106|DIETARY_SUPPLEMENT|Riboflavin 20mg/d|Riboflavin 20mg/d
48351479|NCT01076270|DRUG|plerixafor|Given SC
48351480|NCT01076270|BIOLOGICAL|filgrastim|Given SC
48351481|NCT01076270|PROCEDURE|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
48351482|NCT01076270|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
48661862|NCT00031733|BIOLOGICAL|MART-1 antigen|
48661863|NCT00031733|BIOLOGICAL|gp100 antigen|
48661864|NCT00031733|BIOLOGICAL|incomplete Freund's adjuvant|
48661865|NCT00031733|BIOLOGICAL|recombinant interleukin-12|
48661866|NCT00031733|BIOLOGICAL|sargramostim|
48661867|NCT00031733|BIOLOGICAL|tyrosinase peptide|
48351483|NCT05312385|DRUG|Isoflurane|Inhaled isoflurane administered by Sedaconda ACD-S
48351484|NCT05312385|DRUG|Propofol|Intravenous infusion of propofol
48503838|NCT01103830|OTHER|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
47985533|NCT00224315|DRUG|ziprasidone|
48503839|NCT05090488|BEHAVIORAL|Personal Health Coaching and Diabetes Education in Group|Health coaching was given as face to face with a trained coach from primary health care. Diabetes education in group, with trained educator team from primary health care
48503840|NCT06033092|DRUG|Tamoxifen 10 mg Tablet|One tablet of Tamoxifen 10 mg every other day for 6 months
48503841|NCT06033092|OTHER|Intermittent caloric restriction|"5:2 diet: 5 days a week at regular energy intake and 2 days/week at 75% energy deficit (diet will be restricted at 500-800 kcal corresponding to a 75% reduction compared to normal size)"
48503842|NCT06033092|BEHAVIORAL|Step counter Device|Participants will receive personal advice on healthy lifestyle and a step counter
48503843|NCT01707771|PROCEDURE|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
48661868|NCT00031733|DRUG|alum adjuvant|
48351485|NCT04251195|BEHAVIORAL|Cognitive Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
48351486|NCT04251195|BEHAVIORAL|Active Control Intervention|Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
47985534|NCT00224315|DRUG|risperidone|
47985535|NCT04597307|COMBINATION_PRODUCT|IN.PACT™ Admiral™ Drug Coated Balloon (DCB)|For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
47985536|NCT01496547|DRUG|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
47985537|NCT06314568|RADIATION|Radiochemotherapy plus interventional radiotherapy|All patients with vaginal cancer will undergo radiochemotherapy (45 Gy on pelvis and tumor in association with cisplatinum) plus interventional radiotherapy (28 Gy on residual disease) with exclusive intent
47985538|NCT05464160|DEVICE|Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|"FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes."
47985539|NCT05464160|OTHER|Conventional Rehabilitation|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
47985540|NCT01267812|DRUG|bortezomib|Given SC or IV
47985541|NCT01267812|BIOLOGICAL|rituximab|Given IV
48503844|NCT01707771|BEHAVIORAL|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
47985542|NCT01267812|OTHER|laboratory biomarker analysis|Correlative studies
48140791|NCT05845398|DRUG|Placebo|0.9% saline for injection.
48140792|NCT02082990|BEHAVIORAL|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
47985543|NCT01267812|OTHER|immunohistochemistry staining method|Correlative studies
47985544|NCT01267812|GENETIC|RNA analysis|Correlative studies
47985545|NCT01267812|GENETIC|gene expression analysis|Correlative studies
48140793|NCT02082990|BEHAVIORAL|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
48140794|NCT04336618|DEVICE|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
48140795|NCT05080257|DEVICE|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
48140796|NCT03605082|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
48140797|NCT03605082|OTHER|Placebo|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
48140798|NCT06297057|OTHER|Neurophysiological Recordings|"Eyes-open resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes open and staring at a white cross in the center of a light grey screen to limit their eye movements.~Eyes-closed resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes closed.~ASSR: this block will last approximately 6 minutes. Stimuli will consist of a train of sounds presented repeatedly at high frequency.~MMN: this block will last approximately 3 minutes. Stimuli will consist of a train of equal sounds presented alternating with a 'deviant' (rarer frequency) sound."
48351487|NCT03739060|DEVICE|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
48351488|NCT04224909|DIAGNOSTIC_TEST|Video Head Impulse Test|Diagnosis of dysfunction of the semicircular canals using the vHIT
48503845|NCT03552835|PROCEDURE|no caries removal|occlusal caries were treated with no caries removal and placement of stainless steel crown
48661869|NCT00031733|PROCEDURE|adjuvant therapy|
48661870|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
48661871|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
48661872|NCT01716000|OTHER|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
48661873|NCT01716000|BEHAVIORAL|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
48661874|NCT04153487|DRUG|Ascorbic Acid Injectable Product|Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
47985546|NCT01267812|GENETIC|DNA analysis|Correlative studies
47985547|NCT01267812|OTHER|pharmacological study|Correlative studies
47985548|NCT01267812|OTHER|pharmacogenomic studies|Correlative studies
47985549|NCT01267812|OTHER|Questionnaire Administration|
48351489|NCT01528618|DRUG|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
48503846|NCT03552835|PROCEDURE|partial caries removal upto soft dentin|occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
48503847|NCT03552835|PROCEDURE|partial caries removal upto firm dentin|occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
48503848|NCT00120679|DRUG|darbepoetin alfa|
48503849|NCT00120679|DRUG|recombinant human erythropoietin (rHuEPO)|
48661875|NCT04153487|DRUG|Placebo|Placebo saline / 6 hours for 96 hours
48661876|NCT01436227|OTHER|Laboratory Biomarker Analysis|Correlative studies
48140799|NCT04347941|PROCEDURE|Prone Positioning|Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 \<94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 \>94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula
48140800|NCT04347941|PROCEDURE|Standard of care.|Standard of care. Prone positioning may be administered as a rescue therapy
48140801|NCT01481974|DRUG|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
48140802|NCT00748982|DRUG|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
48351490|NCT01528618|DRUG|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
48351491|NCT03615664|DRUG|Bendamustine|Bendamustine (B) 90 mg/m2 i.v. day 1, 2
48351492|NCT03615664|DRUG|Gemcitabine|Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
48351493|NCT03615664|DRUG|Dexamethasone|Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
48351494|NCT03615664|DIAGNOSTIC_TEST|PET/CT|"PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~* in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~* in case of SMD - exclusion from the trial~* in case of PMD - exclusion from the trial"
48351495|NCT03615664|PROCEDURE|Autologous Stem Cell Transplant|"Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT."
48351496|NCT01047462|PROCEDURE|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
48351497|NCT05223686|DRUG|Human CD19-CD22 Targeted T Cells Injection|One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
47985550|NCT03740958|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
47985551|NCT03740958|DRUG|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
47985552|NCT01374620|DRUG|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90"
47985553|NCT01374620|DRUG|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
47985554|NCT01374620|DRUG|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days"
48351498|NCT06444997|DRUG|Oxycodone Hydrochloride|Oxycodone hydrochloride will be administered at a continuous infusion dose of 0.03-0.2 mg/kg/h.
48351499|NCT06444997|DRUG|Remifentanil|Remifentanil will be administered at a continuous infusion dose of 2-9 μg/kg/h.
48351500|NCT03356795|BIOLOGICAL|Cervical cancer-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
48351501|NCT04334044|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib 5 mg twice a day
47985555|NCT01374620|BIOLOGICAL|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
47985556|NCT03852940|OTHER|Parenteral nutrition|
48661877|NCT01436227|DRUG|Pazopanib Hydrochloride|Given PO
48661878|NCT01772940|DRUG|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
47985557|NCT03852940|OTHER|Enteral Nutrition|
47985558|NCT04918550|OTHER|no drug and device|there is no intervention
47985559|NCT01133301|DRUG|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
47985560|NCT01133301|DRUG|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
47985561|NCT05354752|DRUG|VC005 tablets|VC005 groups repeat administration for 7 days
48351502|NCT04600427|PROCEDURE|Epidural anesthesia|T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
48351503|NCT04348786|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
48351504|NCT04348786|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
48351505|NCT01079208|OTHER|test starter infant formula|infants are fed for 6 months with this starter formula
48351506|NCT01079208|OTHER|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
48351507|NCT01079208|OTHER|control standard formula|infant are fed 6 months with this formula
48351508|NCT02259127|DRUG|DTG|
48351509|NCT02044367|DRUG|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
48661879|NCT01772940|DRUG|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
48661880|NCT01772940|DRUG|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
48661881|NCT01772940|DRUG|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
48351510|NCT02044367|DRUG|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
48661882|NCT05078957|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
48661883|NCT05078957|OTHER|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
47985562|NCT05354752|DRUG|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
47985563|NCT00055263|DRUG|DN-101|
48351511|NCT02044367|DRUG|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
48351512|NCT04065815|OTHER|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
48661884|NCT05078957|OTHER|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
48140803|NCT00748982|DRUG|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
48140804|NCT04634851|BEHAVIORAL|Virtual home visits|These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
48351513|NCT04065815|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~* Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
48351514|NCT04065815|OTHER|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 2 training sessions per week"
48661885|NCT03091855|OTHER|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
48661886|NCT03091855|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
48661887|NCT03068000|BEHAVIORAL|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
48140805|NCT06151106|DRUG|Chidamide combined with Duvillisib|Specified dose on specified days
48140806|NCT05445557|DRUG|RZL-012|small synthetic molecule for submental fat reduction
48140807|NCT05445557|DRUG|Placebo|Placebo
47985564|NCT02592785|DRUG|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
48351515|NCT04065815|OTHER|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~* supervised cycle-ergometer training at at 80-95% HRmax~* time-effort per session: \~15 min~* 1 training session per week~Resistance Training:~* five exercises: exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 1 training session per week"
48351516|NCT06491992|DRUG|Chitosan Phonophresis|Chitosan Phonophresis, three times per week for four weeks.
48351517|NCT06491992|OTHER|selected physical therapy exercise|selected neck exercise and electrotherapy on cervical region
48661888|NCT03068000|BEHAVIORAL|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
48351518|NCT06380036|PROCEDURE|video assisted fistula tract surgery|in one group pt recieved VAAFTS
48661889|NCT06254833|OTHER|micro dosing of ICG|smaller dose of injection of ICG. All devices used are FDA approved in clinical use.
48661890|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
48351519|NCT01800162|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
48661891|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
48661892|NCT03375437|GENETIC|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2\*10mL EDTA)"
48661893|NCT03236545|OTHER|No to Low Endogenous Estrogen|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).
48661894|NCT03236545|OTHER|Estradiol|Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, \& Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane \& Kohrt, 2012).
48661895|NCT03572283|DRUG|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
48661896|NCT02150746|PROCEDURE|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
47985565|NCT06131242|OTHER|It is an observational study|It is an observational study
47985566|NCT03966001|OTHER|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
47985567|NCT03966001|OTHER|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
48140808|NCT01486459|DRUG|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
48140809|NCT00942344|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
48661897|NCT02150746|PROCEDURE|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
48661898|NCT04466358|PROCEDURE|Modified CLOSE protocol|Modified CLOSE protocol guided isolation of pulmonary veins.
48661899|NCT04466358|PROCEDURE|High density mapping guided pulmonary vein isolation|Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
48661900|NCT06477627|OTHER|change of environment|The participants will change from inland to coastal environment to see the effect. We will take VAMS blood samples and nose swabs from the participant to measure this effect.
48661901|NCT06477627|OTHER|no intervention|reference groups, stay in their coastal or inland environment
48351520|NCT01800162|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
48351521|NCT01800162|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
48351522|NCT04797494|DEVICE|acrylic removable appliance|"Hand-made, dental laboratory-manufactured, acrylic removable appliances were made on the mandible after intraoral impressions (Alginate, Cavex).~Patients were asked to wear the RA for a period of 3 weeks prior to restorative treatment, for 24 h per day, except for when eating."
48351523|NCT05118750|DRUG|ALTO-300 oral (PO) tablet|One tablet daily
48351524|NCT01085773|BEHAVIORAL|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
48351525|NCT01085773|BEHAVIORAL|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
48351526|NCT03637894|DIETARY_SUPPLEMENT|Feeding infants with fermented formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
48351527|NCT03637894|OTHER|Feeding infants with standard formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
48351528|NCT03637894|OTHER|Breastfeeding infants|Reference group
48661902|NCT00492544|BIOLOGICAL|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
48351529|NCT05051527|DRUG|Legalon® 140 mg|Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision
48351530|NCT01602744|OTHER|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
48351531|NCT04145193|DRUG|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
48351532|NCT04145193|DRUG|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
48661903|NCT04722354|OTHER|Hyperinsulemic euglycemic clamp|Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.
48661904|NCT04722354|PROCEDURE|Muscle Biopsy|One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.
48661905|NCT04722354|DIETARY_SUPPLEMENT|Oral abscisic acid (ABA)|Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)
48661906|NCT04722354|OTHER|Placebo|Those in this group will receive placebo (300 mg cornstarch)
48661907|NCT00922857|PROCEDURE|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
48661908|NCT00003451|BIOLOGICAL|recombinant interferon alfa|
47985568|NCT01806831|DEVICE|"Biocellulose Mask, Farhorm®"|
48351533|NCT04145193|DRUG|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
48351534|NCT04145193|DRUG|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
48661909|NCT00003451|BIOLOGICAL|recombinant interleukin-12|
48687904|NCT06468891|OTHER|The STT three-dimensional motion analysis (3DMA) system|The STT three-dimensional motion analysis (3DMA) system (STT Systems Company, Zuatzu Business Park, Easo Building, 2nd Floor, San Sebastián, Spain) was used for the assessment of spatiotemporal characteristics of gait. It is an indoor optical system that consists of four cameras, fifteen markers, and computer software for automatic three-dimensional motion capture and analysis. CLINICAL 3DMA V.6.11 is professional software with highly accurate marker tracking. The STT Helen Hayes protocol was used for the gait analysis in this study.
48351535|NCT02979340|PROCEDURE|MRI|non-invasive assessment of hepatic fibrosis and steatosis
48351536|NCT00364832|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
48351537|NCT05570708|DRUG|MDMA, LSD, psilocybin|"* MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"
48351538|NCT00002041|DRUG|Amphotericin B|
48687905|NCT02520388|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
48687906|NCT02520388|DRUG|Placebo|
47985569|NCT05357950|DRUG|PrimeC|Ciprofloxacin and celecoxib combination extended release formulation
47985570|NCT05357950|DRUG|Placebo|Placebo matches active drug in size, color and taste
47985571|NCT03407105|BIOLOGICAL|MDX-010|Specified dose on specified days
48140810|NCT00942344|DRUG|Amlodipine|amlodipine 5mg, 10mg
48140811|NCT00942344|DRUG|Losartan|Losartan 50mg, 100mg
48140812|NCT00853593|DEVICE|Pacing Lead|implant and follow-up of study device
48661910|NCT06467188|OTHER|Validity and reliability|"In order to evaluate the content validity of the Turkish version of the scale, 12 expert researchers in the field of gynecology and obstetrics were consulted. The experts were asked to evaluate the items as 1-Not Appropriate, 2-Somewhat Appropriate, 3-Reasonably Appropriate, and 4-Very Appropriate. Experts were asked to suggest items not evaluated as very appropriate. In the Davis technique, the content validity index which is calculated by dividing the number of experts who marked the options a (The item is appropriate) and b (The item needs minor revision) for each item by the total number of experts providing opinions is expected to be over 0.80 \[30\]. Based on expert opinions, the content validity index (CVI) value of the scale was calculated to be 96%, meaning that content validity was ensured. The items were reorganized by considering the experts' suggestions. The scale was administered to 252 women over 18 who were included in the study sample after scoring."
48351539|NCT05405855|BEHAVIORAL|eLIFEwithIBD|eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.
48351540|NCT05260190|DEVICE|tSMS|30-minute tSMS application in a comfortable seated position. The material used in the stimulation was a MAGxx1.1 helmet (Neurek Spain Toledo), with a Neodymium (NdFeB) magnet of 60mm diameter and 30mm height with Nickel (Ni-Cu-Ni) coating MAG60r+ (Neurek Spain, Toledo), placed over the primary motor cortex (M1) of the left cerebral hemisphere.
48351541|NCT05260190|DEVICE|Sham tSMS|30-minute sham tSMS application in a comfortable seated position. The device used in sham stimulation had the same weight and shape as the real stimulation helmet.
48351542|NCT04093206|DIETARY_SUPPLEMENT|EpiCor and Vitamin C|One daily dose
48351543|NCT04093206|DIETARY_SUPPLEMENT|Vitamin C|One daily dose
48351544|NCT00086242|BEHAVIORAL|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
48351545|NCT02033252|DEVICE|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
48351546|NCT02783651|OTHER|Other|No intervention other than routine medical care
48351547|NCT00446225|DRUG|Erlotinib|"150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib"
48351548|NCT00446225|DRUG|Carboplatin|"Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given."
48351549|NCT00446225|DRUG|Gemcitabin|Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
48351550|NCT00446225|DRUG|Docetaxel|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
48351551|NCT00446225|DRUG|Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
48351552|NCT03844139|DEVICE|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syringe to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
48503850|NCT04837924|PROCEDURE|fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)|Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.
48503851|NCT04837924|DRUG|paracetamol 1 gram IV|paracetamol 1 gram IV every six hours, 4 times in 24 hours
48503852|NCT04837924|DRUG|Rescue analgesic tramadol 100 mg IV if needed|Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours
48351553|NCT03609710|DEVICE|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
48351554|NCT03609710|PROCEDURE|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
48351555|NCT03609710|PROCEDURE|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
48351556|NCT03609710|DEVICE|Robotic surgery|Robotic low anterior resection for rectal cancer
48351557|NCT03827980|OTHER|no intervention, only clinical examination|standardised interview and clinical examination
48351558|NCT01758640|DRUG|Warfarin|Low dose warfarin of 5mg or less per day
48351559|NCT01758640|DRUG|phenindione|Phenindione of 100mg or less per day
48351560|NCT03083106|DEVICE|Elevoplasty|The Elevo™ Kit Snoring Intervention Device is designed to facilitate deployment of the Elevo™ suture implant into the submucosal tissue of the soft palate via a minimally invasive, outpatient procedure performed by an otolaryngologist in a medical office setting.
48351561|NCT03279146|DRUG|Tenofovir exalidex (TXL)|Oral formulations
48503853|NCT04837924|PROCEDURE|Sham injection|Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
48503854|NCT03904589|DIAGNOSTIC_TEST|Quality of Life assessment|Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
47985572|NCT02552563|BEHAVIORAL|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
47985573|NCT03269942|PROCEDURE|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
47985574|NCT03269942|PROCEDURE|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
48351562|NCT03566498|DIETARY_SUPPLEMENT|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
48351563|NCT03566498|DIETARY_SUPPLEMENT|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
48351564|NCT01129414|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
48351565|NCT01129414|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
48351566|NCT01129414|DRUG|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
48351567|NCT03363789|BIOLOGICAL|Brisement injection|An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
48351568|NCT03363789|PROCEDURE|Physical Therapy|Patients will receive a prescription for physical therapy.
48503855|NCT05119153|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo designed to mimic coffee color.
48351569|NCT01921959|BEHAVIORAL|Intervention|Postpartum women are randomized to intervention or control group
48503856|NCT05119153|DIETARY_SUPPLEMENT|Light Roasted Coffee|12 oz light roast coffee
48503857|NCT05119153|DIETARY_SUPPLEMENT|Medium Roasted Coffee|12 oz medium roast coffee
48503858|NCT05119153|DIETARY_SUPPLEMENT|Dark Roasted Coffee|12 oz dark roast coffee
48503859|NCT04132700|DEVICE|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
48503860|NCT02546466|PROCEDURE|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
48503861|NCT02546466|PROCEDURE|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
48687907|NCT05284500|PROCEDURE|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
48661911|NCT02296125|DRUG|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
48661912|NCT02296125|DRUG|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
47985575|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
48503862|NCT02546466|BEHAVIORAL|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
47985576|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
48503863|NCT02242032|DRUG|P-321 Ophthalmic Solution|
48503864|NCT02242032|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
48140813|NCT02203032|DRUG|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
48503865|NCT02525237|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
48503866|NCT02525237|DRUG|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
48503867|NCT04762277|DRUG|Spesolimab - solution for infusion|Solution for infusion
48503868|NCT04762277|DRUG|Placebo matching spesolimab - solution for infusion|Solution for infusion
48503869|NCT04762277|DRUG|Spesolimab- solution for injection|Solution for injection
48503870|NCT04762277|DRUG|Placebo matching to spesolimab- solution for injection|Solution for injection
48503871|NCT03610516|DRUG|CFZ533|Multiple doses of 10 mg/kg CFZ533 intravenous (IV) infusion. CFZ533 was administered every 4 weeks (Q4W; from Day 1 to Day 141), plus an additional dose of 10 mg/kg IV at Day 15, resulting in a Q2W loading regimen up to the third dose on Day 29.
48661913|NCT02296125|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
47985577|NCT05390957|BEHAVIORAL|Acceptance Based Behavioural Therapy - Revised|The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
47985578|NCT01509833|DRUG|rFSH|Administration of rFSH for ovarian stimulation.
47985579|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
48140814|NCT02203032|DRUG|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
48140815|NCT02203032|DRUG|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
48140816|NCT02203032|DRUG|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
47985580|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
47985581|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
47985582|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
47985583|NCT00917709|OTHER|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol
47985584|NCT00917709|OTHER|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
47985585|NCT00917709|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
48503872|NCT03610516|DRUG|Placebo|multiple doses of placebo intravenous infusion
48503873|NCT02917070|OTHER|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
48503874|NCT05477095|BIOLOGICAL|UB-313|A synthetic peptide-based immunotherapy
48140817|NCT01934322|OTHER|Case Management|"Furnish specific assistance and to provide referrals for the patients:~* If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~* If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~* If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~* In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
48351570|NCT05008549|DIETARY_SUPPLEMENT|Cranberry Juice Product|"The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)~The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)~The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)~The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)~L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)~The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum."
48687908|NCT01581528|GENETIC|gene expression analysis|
48503875|NCT05477095|BIOLOGICAL|Placebo|Normal saline
48503876|NCT05357482|RADIATION|TBI|300 cGy total body irradiation (TBI, day -2)
48351571|NCT06279052|BEHAVIORAL|Phone interview|Phone interview during which the experience of the transition to adulthood among adolescents and young adults with Prader Willi Syndrome will be retrieved
48351572|NCT01601873|DEVICE|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
48351573|NCT01601873|DEVICE|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
48503877|NCT05357482|DRUG|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
48503878|NCT05357482|BIOLOGICAL|briquilimab|briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
48503879|NCT05357482|DRUG|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
48503880|NCT05357482|DRUG|Sirolimus|For immune suppression (day -1)
48503881|NCT05357482|BIOLOGICAL|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
47985586|NCT04144556|OTHER|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
48503882|NCT05357482|DRUG|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
48503883|NCT00203593|BEHAVIORAL|Exercise|
48503884|NCT00203593|DEVICE|Blood volume|
48503885|NCT00203593|PROCEDURE|VO2max test|
48687909|NCT01581528|OTHER|cell culture procedure|
48687910|NCT01581528|OTHER|flow cytometry|
48687911|NCT01581528|OTHER|laboratory biomarker analysis|
48687912|NCT01581528|OTHER|metabolic assessment|
48140818|NCT03566901|DEVICE|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
48140819|NCT03566901|OTHER|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
48140820|NCT04565652|DEVICE|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
48140821|NCT03977805|DRUG|Hetrombopag Olamine|a single oral taking
48140822|NCT02405000|OTHER|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
48140823|NCT05225337|OTHER|Time restricted feeding (TRF)|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
48140824|NCT05225337|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
48503886|NCT00203593|PROCEDURE|Lower body negative pressure|
48503887|NCT00203593|BEHAVIORAL|Heart Rate|
48503888|NCT00203593|PROCEDURE|Blood Pressure|
48140825|NCT04378413|OTHER|exercise|exercise for low back pain
48140826|NCT03510195|OTHER|MEDICORP HO PREPARATORY MODULE|3 DAY course module to prepare medical graduates to become house officers
48503889|NCT00203593|BEHAVIORAL|Total Peripheral Resistance|
48687913|NCT02253433|OTHER|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
48140827|NCT04129372|BEHAVIORAL|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
48503890|NCT04717765|DEVICE|Preventive, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
48503891|NCT04717765|DEVICE|Curative, LLL Phototherapy and topical Vit E|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
48503892|NCT04717765|DEVICE|Preventive, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
48503893|NCT04717765|DEVICE|Curative, LLL Phototherapy and LPRF|Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.
47985587|NCT04144556|OTHER|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
47985588|NCT01404845|DIETARY_SUPPLEMENT|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
48140828|NCT04460066|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
48140829|NCT04460066|DRUG|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
47985589|NCT01404845|DIETARY_SUPPLEMENT|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
47985590|NCT02968745|OTHER|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
48140830|NCT04460066|DRUG|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
48140831|NCT04460066|DRUG|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
48140832|NCT04460066|PROCEDURE|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
48140833|NCT04541199|DEVICE|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
48503894|NCT06041152|DRUG|Psilocybin|2 macrodoses of 25mg separated by one week.
48503895|NCT06041152|DRUG|Placebo|2 doses of placebo separated by one week.
48503896|NCT04922320|BEHAVIORAL|Patient Priorities Care|A facilitator will schedule a PPC facilitation encounter 2-3 weeks before an upcoming PCP visit. The facilitator conducts a structured assessment using a written conversation guide that begins with general questions establishing what is most important to Veterans about their health and moves toward establishing specific goals (actionable outcomes), and what patients are willing/not willing to do to achieve these goals (care preferences). The result is a structured patient priorities report delivered to PCPs designed to facilitate changes in the patient's care plan to align it with his/her priorities. In the subsequent visit, the PCP will use one or more of the established PPC decisional strategies to align care with patients' priorities. Education for PCPs about the facilitation process, the patient priorities report, and the decisional strategies occurs prior to the PCP seeing any intervention patients. The PCP will document changes in care made to achieve the identified priorities.
48503897|NCT04922320|OTHER|Usual Care|PCPs will not be alerted when an encounter involves a UC group participant. UC participant visits will appear the same as all other unenrolled patient encounters. PCPs will be trained to address the needs of UC participants based on their typical approach without the use of a facilitator or explicit process for identifying patient priorities. UC participants will not receive any additional preparation
47985591|NCT02738450|BIOLOGICAL|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
48140834|NCT04541199|DEVICE|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
48140835|NCT00635700|DRUG|ziprasidone|20-160 mg/d
48140836|NCT00635700|DRUG|placebo|placebo
48503898|NCT01004653|BIOLOGICAL|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
48503899|NCT05243953|DRUG|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
47985592|NCT02738450|BIOLOGICAL|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
47985593|NCT02738450|BIOLOGICAL|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
47985594|NCT05505903|DIAGNOSTIC_TEST|Temerature measurement|Temerature measurement on admission to WBN or NICU
47985595|NCT01074866|DEVICE|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
47985596|NCT04239820|RADIATION|Imaging|MRI and TSPO-PET imaging at baseline and 18 months after baseline
48140837|NCT04009772|DRUG|Cefepime|Antibiotic prophylaxis
48140838|NCT04009772|DRUG|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
48140839|NCT03776760|DEVICE|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
48140840|NCT03776760|DRUG|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
48140841|NCT03776760|DRUG|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
48351574|NCT02576093|DRUG|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
48351575|NCT02576093|DRUG|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
47985597|NCT02689024|DRUG|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
48140842|NCT06510868|RADIATION|Peptide receptor radionuclide therapy (PRRT)|Specialized type of radionuclide therapy used to treat neuroendocrine tumors.
48351576|NCT02576093|DRUG|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
48351577|NCT02576093|DRUG|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
47985598|NCT02689024|DRUG|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
48140843|NCT06510868|DIAGNOSTIC_TEST|Blood collection|Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).
48140844|NCT00569439|DRUG|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
47985599|NCT02689024|DRUG|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
48140845|NCT00569439|DRUG|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
48351578|NCT03564327|PROCEDURE|Wide antrum circle ablation|As standard hospital policy
48503900|NCT05243953|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
48503901|NCT00869336|DRUG|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
48503902|NCT00869336|DRUG|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
47985600|NCT02689024|DRUG|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
47985601|NCT02689024|DRUG|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
47985602|NCT02689024|DRUG|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
47985603|NCT02689024|DRUG|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
47985604|NCT02689024|DRUG|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
47985605|NCT02689024|DRUG|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
47985606|NCT02689024|DRUG|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
47985607|NCT00301574|DRUG|galantamine|
47985608|NCT02145364|DEVICE|Ultherapy® treatment|Microfocused ultrasound treatment
47985609|NCT06244225|DRUG|Donafenib； Sintilimab； HAIC|"Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h."
47985610|NCT02178202|BEHAVIORAL|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
47985611|NCT02178202|DEVICE|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
47985612|NCT02326753|DEVICE|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
47985613|NCT02326753|DEVICE|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
47985614|NCT02326753|DEVICE|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
48140846|NCT00569439|DRUG|NS|Normal Saline solution at 125 cc/hr
48140847|NCT05077670|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.
48140848|NCT05077670|DEVICE|Atrial substrate mapping|Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.
48140849|NCT02622698|DIETARY_SUPPLEMENT|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
48140850|NCT02622698|OTHER|Placebo|Placebo- Patients did not take any protein supplementation after surgery
48140851|NCT06509321|PROCEDURE|subinguinal loupe-assisted varicocelectomy (LV)|to assess the efficacy and safety of sub inguinal loupe-assisted varicocelectomy with nitroglycerin instillation as a vasodilator and compare its results versus subinguinal microscopic varicocelectomy
48140852|NCT06509321|PROCEDURE|subinguinal microscopic varicocelectomy (MV)|we are using surgical microscope to perform varicocelectomy as control group
48140853|NCT01629420|DRUG|KLH-2109|
48140854|NCT01629420|DRUG|KLH-2109|
48140855|NCT03941509|BEHAVIORAL|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
48140856|NCT03774849|DEVICE|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
48140857|NCT03774849|DEVICE|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
48140858|NCT03774849|DEVICE|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
48503903|NCT00869336|DRUG|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
48503904|NCT00869336|DRUG|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
48503905|NCT04831463|BEHAVIORAL|Increasising Health Awareness Program for Immigrant Men|The IHAPIM program is a health promotion intervention. The aim of intervention improve health perception and responsibilitiy
48503906|NCT01158092|DEVICE|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
48140859|NCT01231178|DIETARY_SUPPLEMENT|Alginate beverage|The dosage is 3x500ml daily
47985615|NCT06258655|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational program for the neonatal staff to improve their skills to collaborate with parents and provide support to parenting during an infant's hospitalization. First, experienced nurses and doctors from the units will undergo a 14-day to become unit mentors. Then these unit mentors will train other members of staff. The training of the units is based on bedside practices, a reflection of the practices, and the application of the knowledge in everyday work. Theoretical learning, preceding clinical bedside mentoring, will occur through an e-learning module. Staff members will spend about 4 working days in training alongside their routine work. The unit mentors will function as facilitators for the staff, and they have dedicated time for this. The content of the bedside practices is guided by a manual. The training team will provide frequent remote and contact support for the implementation."
48140860|NCT01231178|DIETARY_SUPPLEMENT|Control beverage|The dosage is 3x500ml daily
48140861|NCT03494413|DIAGNOSTIC_TEST|Transpharyngeal Doppler sonography (TPS)|Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
48140862|NCT03494413|DIAGNOSTIC_TEST|Conventional colour-coded Duplex sonography (CDS)|Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
48503907|NCT01158092|OTHER|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
48503908|NCT04283201|OTHER|Physical activity|Moderate activity 150 min per week
47985616|NCT04537507|PROCEDURE|Coronary angiography|
47985617|NCT03298594|DIAGNOSTIC_TEST|specific cervicograph|
47985618|NCT06441344|DRUG|Toripalimab plus Anlotinib|For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
47985619|NCT06441344|DRUG|Toripalimab|For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
47985620|NCT01523574|DRUG|Vitamin E|Vitamin E 400mg PO orally
47985621|NCT01523574|DRUG|Placebo|Placebo, given orally
47985622|NCT04861155|DEVICE|SIVA-P3|Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.
48140863|NCT04843449|DRUG|ASC40|Oral tablets
47985623|NCT03533179|DRUG|Glucagon|"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."
47985624|NCT03533179|DRUG|Esmolol|Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
47985625|NCT03533179|DRUG|Physiologic saline - glucagon dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
47985626|NCT03533179|DRUG|Physiologic saline - esmolol dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
47985627|NCT04190615|DIAGNOSTIC_TEST|thromboelastometry test (TEM test)|TEM test from the whole blood sample
47985628|NCT03116607|OTHER|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
47985629|NCT00442975|BIOLOGICAL|Fluarix|
47985630|NCT01312688|OTHER|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
48140864|NCT04843449|DRUG|Itraconazole|Oral capsules
48140865|NCT04843449|DRUG|rifampicin|Oral capsules
48140866|NCT02851498|OTHER|Food product: high-protein pasta and cereal|
48503909|NCT04283201|OTHER|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
48503910|NCT03849183|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
48503911|NCT03849183|DRUG|Normal saline|Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
48503912|NCT03745716|DRUG|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
48503913|NCT03745716|DRUG|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
48503914|NCT05005312|DRUG|PF-07321332|Tablet
48140867|NCT04007705|BEHAVIORAL|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
48140868|NCT04007705|BEHAVIORAL|General healthy eating|Healthy eating counseling according to the World Health Organization
48140869|NCT03794219|OTHER|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
48140870|NCT03794219|DRUG|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
48351579|NCT03564327|PROCEDURE|External electric cardioversion|Three attempts (200-250 joules)
48351580|NCT02557815|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
48351581|NCT02158195|BIOLOGICAL|blood samples|
48351582|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
48140871|NCT05574309|DEVICE|Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer|Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test
48140872|NCT05574309|DEVICE|GAITRite Device|Walking parameter measured during a 10 m walking test with GaitRite device
48140873|NCT03470805|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
48140874|NCT06509308|OTHER|Psychological Questionnaires|Patients will be asked to complete a series of questionnaires regarding disease expectations, cognitions, and representations of their health status. Additionally, sociodemographic data and clinical variables will be collected from medical records.
48140875|NCT03909100|DEVICE|CoolSculpting® System|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
48140876|NCT01131546|DRUG|Levamlodipine besylate|Once daily, 7AM - 10AM
48140877|NCT01131546|DRUG|Amlodipine maleate|Once daily, 7AM - 10AM
48140878|NCT02356055|BEHAVIORAL|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
48351583|NCT01547676|PROCEDURE|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
48503915|NCT05005312|DRUG|Ritonavir|PK Boosting agent
48140879|NCT04154085|OTHER|Psychotherapy|Group psychotherapy
48140880|NCT04121234|OTHER|"Exposure:  being admitted to HDU with a red code to OEWS"|High Dependency Unit, a set of predefined variables was assessed at hospital admission, HDU admission and at discharge from HDU with the aim to investigate epidemiology, clinical outcomes and risk factors for mortality in critically-ill parturients admitted to an obstetric HDU in a high volume, urban resource-limited maternity hospital
48140881|NCT00513071|DRUG|saracatinib|Given orally
48140882|NCT00513071|OTHER|laboratory biomarker analysis|Correlative studies
48140883|NCT00655109|DRUG|Olopatadine|Ophthalmic solution
48140884|NCT00655109|DRUG|Fluticasone|Nasal spray
48140885|NCT00655109|DRUG|Saline|Nasal spray
48140886|NCT00655109|DRUG|Artificial tears|Ophthalmic Solution
48140887|NCT03579407|PROCEDURE|BMA cell therapy injection|The bone marrow aspirate will be injected into the affected knee joint.
48140888|NCT05996900|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
48140889|NCT05996900|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation both before and after implantation electrode surgery.
48140890|NCT01888484|BIOLOGICAL|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
48140891|NCT05750719|GENETIC|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
48140892|NCT00240175|OTHER|No Intervention|No Intervention
48351584|NCT00006062|DRUG|oxaliplatin|
48687914|NCT02253433|OTHER|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
47985631|NCT05662085|OTHER|No intervention|According to clinical practice.
48140893|NCT06494566|DIETARY_SUPPLEMENT|Omega-3|Omega-3 capsule
48140894|NCT06494566|DIETARY_SUPPLEMENT|Mineral Oil|Mineral Oil Capsule
48140895|NCT02562274|DIETARY_SUPPLEMENT|Placebo|Subjects are received placebo treatments once daily for 8 weeks
48140896|NCT02562274|DIETARY_SUPPLEMENT|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
48140897|NCT02562274|DIETARY_SUPPLEMENT|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
48140898|NCT04718259|DRUG|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
48140899|NCT04718259|DRUG|midazolam|midazolam
48351585|NCT00436722|DRUG|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
48351586|NCT04021628|OTHER|No intervention- not applicable|No intervention - not applicable
48351587|NCT00307892|DRUG|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
48351588|NCT00307892|DRUG|Placebo|placebo remedy
48351589|NCT03540641|DEVICE|MagVenture MagPro R30|the subjects will receive 1500 or 5000 pulses at 5Hz
48351590|NCT05993585|OTHER|Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control|(Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit
48351591|NCT05993585|OTHER|Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT|(CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
48351592|NCT01166386|BEHAVIORAL|FANCI|comprehensive neurobehavioral sessions with therapist administrating treatment components
48351593|NCT01166386|BEHAVIORAL|FANCI|Watching DVDs chosen by participants on various topics.
48351594|NCT03245294|PROCEDURE|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
48351595|NCT04601181|BIOLOGICAL|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight.~Intervention study"
48140900|NCT03973021|BIOLOGICAL|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
48140901|NCT00360269|DRUG|Atomoxetine|25 to 100 mg daily
48140902|NCT00360269|PROCEDURE|Motivational enhancement therapy|Three sessions
48140903|NCT00360269|DRUG|Placebo|25 to 100 mg daily
48140904|NCT03395600|DRUG|B1S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
48140905|NCT03395600|DRUG|B125S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
48140906|NCT03395600|DRUG|B1S10|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
48140907|NCT00761267|DRUG|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
48140908|NCT00761267|DRUG|Fluconazole|Subjects may be switched to oral fluconazole \[6-12 mg/kg/day (not to exceed 800mg/day\] provided they meet specified criteria. Maximum total treatment duration is 49 days.
48140909|NCT00951132|DRUG|rosuvastatin|10mg tablets, once daily in three months
48140910|NCT00951132|DRUG|Placebo|tablet, once daily, three months
47985632|NCT03964155|BIOLOGICAL|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
47985633|NCT02547610|DEVICE|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
48140911|NCT03428438|OTHER|Rehabilitation at home via SMS|Cardiac rehabilitation
48140912|NCT00004784|DRUG|methotrexate|
48140913|NCT00004784|DRUG|ursodiol|
48140914|NCT02321956|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound to determine the size of endotracheal tube
48140915|NCT00082966|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
48140916|NCT01351259|DEVICE|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
48140917|NCT01480375|DEVICE|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
48351596|NCT06396689|DIETARY_SUPPLEMENT|Synbiotic|The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
48351597|NCT06396689|DIETARY_SUPPLEMENT|Placebo|The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
48687915|NCT06140368|BEHAVIORAL|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
47985634|NCT04837157|DEVICE|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
47985635|NCT02227589|BEHAVIORAL|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
47985636|NCT02227589|BEHAVIORAL|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
48140918|NCT03192189|OTHER|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
48140919|NCT01755559|DRUG|Artesunate-amodiaquine|antimalarial ACT
48140920|NCT01755559|DRUG|Dihydroartemisinin-piperaquine|antimalarial ACT
48140921|NCT01755559|DRUG|Artemether-lumefantrine|antimalarial ACT
48140922|NCT06269029|OTHER|Chest mobility exercises|exercises were repeated 6 times on each side with rest of period for 30 seconds in between. The intervention will be carried out for one week with total of 7 sessions. Each Exercise will be accompanied by breathing pattern. In neutral position of exercises, subjects will be asked to exhale during flexion, turning or extension subject will be asked to do inhale.
48351598|NCT03737396|PROCEDURE|Self-administered electronic health screening|Health assessment using an electronic device
48351599|NCT05560074|DEVICE|Buzzy|In the Buzzy® group, 30 seconds before the blood collection procedure and during the procedure, the Buzzy® device ist placed 3-5 cm above the area from where the blood would be taken by the PhD qualified nurse researcher
48140923|NCT06269029|OTHER|proprioceptive neuromuscular facilitation|The technique used in this study Proprioceptive neuromuscular facilitation technique of hold and relax stretching for isolated clavicular head of the pectoralis major muscle. The subjects sitting on a chair with back support to keep spine in a neutral position and both their arms are extended and hands are placed behind the occipital region. His both arms will be positioned in glenohumeral horizontal extension, and glenohumeral abduction and external rotation with elbow bent to perform stretch position of pectoral muscle. Then ask him to contract the pectoral muscles .This isometric contraction is held for 6 seconds. The patient then relaxed and passive stretch in the opposite direction . and it was repeated 6 times with rest period 30 seconds. The session will be given every day for one week
48140924|NCT05295706|BEHAVIORAL|Counterfactual Intervention|"The intervention occurs during the third study visit. This is a counterfactual intervention, which will involve asking the subjects to think of an alternative reality that might have been based on the concurrency of their glucose readings and the meals they ate."
48140925|NCT04536766|BEHAVIORAL|Enhanced Sleep Health Education|The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
48140926|NCT04536766|BEHAVIORAL|Beds for Kids Standard Program|The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
48140927|NCT05818852|DRUG|VX-548|Tablets for oral administration.
48140928|NCT05818852|DRUG|Moxifloxacin|Capsules for oral administration.
48661914|NCT02296125|DRUG|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
48140929|NCT05818852|DRUG|Moxifloxacin Placebo|Capsules for oral administration.
48140930|NCT05818852|DRUG|VX-548 Placebo|Tablets for oral administration.
48140931|NCT06510400|OTHER|OMNICHROMA|supra nano filled composite
48140932|NCT06510400|OTHER|Ceram. x spectra|nano hybrid composite resin
48140933|NCT03312621|BEHAVIORAL|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
48140934|NCT02913300|DRUG|Lignocaine 1% concentration solution|
48140935|NCT02913300|DRUG|Lignocaine 2% concentration solution|
48140936|NCT04913532|RADIATION|Hypofractionation with simultaneous integrated boost|Hypofractionation with simultaneous integrated boost
48140937|NCT02409043|OTHER|Blood draw|Blood drawn for comparison with other groups
48351600|NCT05560074|OTHER|DistrACTION® Cards|In the DistrACTION® Cards group, picture cards containing various hidden pictures and patterns are used during blood collection by the PhD qualified nurse researcher
48351601|NCT01339676|DRUG|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
48351602|NCT01339676|DRUG|Placebo capsules|Identically appearing once weekly peroral placebo capsules
48503916|NCT01238380|OTHER|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 \& IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
48661915|NCT02296125|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
48661916|NCT02296125|DRUG|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
47985637|NCT02227589|OTHER|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
47985638|NCT04117425|BIOLOGICAL|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
48503917|NCT01539018|DRUG|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
48503918|NCT01539018|DRUG|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
48140938|NCT02409043|OTHER|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
48140939|NCT04530032|OTHER|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
48140940|NCT04530032|OTHER|Standard diet|standard (normal) diet use
48351603|NCT04857606|DRUG|AMG 609|Single dose of AMG 609 administered as a subcutaneous injection.
47985639|NCT02568150|BIOLOGICAL|Single group, open-label|
48140941|NCT03810170|BEHAVIORAL|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
48351604|NCT04857606|DRUG|Placebo|Single dose of placebo administered as a subcutaneous injection.
48351605|NCT05541250|BIOLOGICAL|Autologous Human Schwann Cell|A one-time dose of 1000 μl\* or 80 to 100 million ahSC prepared from segments of the sural nerve from the leg recovered from the participant.
48503919|NCT04934410|DRUG|Etomidate|Use of etomidate during induction as decided by attending anesthesiologist
48351606|NCT01245127|DRUG|Ilaris|"* Canakinumab 150 mg (or 2 mg/kg for patients weighing \<40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~* At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing \<40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing \<40 kg) every 8 weeks beginning at Week 8.~* Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~* If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
48351607|NCT00948194|DRUG|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
48503920|NCT04934410|DRUG|Midazolam|Use of midazolam during induction as decided by attending anesthesiologist
48503921|NCT04934410|DRUG|Sevoflurane|Use of sevoflurane during induction as decided by attending anesthesiologist
48503922|NCT04325204|BEHAVIORAL|Faith-based Home Activity Toolbox (Faith-HAT)|"They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project."
48503923|NCT03357653|DRUG|Losartan group|Losartan 50 mg daily
48503924|NCT03357653|DRUG|Placebo group|Placebo 1 pill daily
48503925|NCT05933863|DRUG|PD-(L)1 antibody immunotherapy|The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
48503926|NCT00519688|DRUG|Thalidomide|100 mg, BID
48140942|NCT03810170|OTHER|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
48503927|NCT00519688|DRUG|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
48503928|NCT04829110|OTHER|ETOH|Participants will consume Vodka
48503929|NCT04829110|OTHER|Sucrose|Participants will consume sucrose in solution with water
48503930|NCT04197817|DRUG|JS002|JS002, Subcutaneous or intravenous injection of a single dose of JS002, dose cohort according to ascending dose design
48503931|NCT04197817|DRUG|Placebo|Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
48140943|NCT01606098|PROCEDURE|Surgery of the primary tumour|Surgical resection of the colon tumour
48503932|NCT03335215|OTHER|cognitive remediation|The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
48351608|NCT04793243|DIETARY_SUPPLEMENT|Vitamin D3|Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
48351609|NCT04348136|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
48503933|NCT05297695|DRUG|Triple therapy for H. pylori infection|Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
48351610|NCT03317912|DRUG|Lidocaïne 2%|Continuous infusion during per and postoperative periods
48351611|NCT03317912|DRUG|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
48351612|NCT05307081|DRUG|Artificial Tears|Artificial Tears are an FDA approved intervention
48351613|NCT04513106|BEHAVIORAL|"ACP programme Have a Say"|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
48661917|NCT05444387|OTHER|Upper limb loading|1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
47985640|NCT00706407|DEVICE|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
48351614|NCT04513106|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
47985641|NCT04237090|DRUG|Diphenhydramine|Drug identification number : 02369567
48351615|NCT00175838|DRUG|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
48503934|NCT03673657|DIETARY_SUPPLEMENT|Early Nutrition Intervention from the start of CCRT|Nutrition counseling and oral nutritional supplements from the start of radiotherapy; weekly counseling sessions; daily energy intake of approximately 30 kcal/kg.
48503935|NCT03673657|RADIATION|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-68 Gy
48503936|NCT03673657|DRUG|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
48661918|NCT00651287|DRUG|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
47985642|NCT04237090|DRUG|Cetirizine|Drug identification number : 02231603
47985643|NCT04237090|DRUG|Lactose pill|Natural product number : 00501190
47985644|NCT04237090|DRUG|Sodium chloride 0.9%|Drug identification number : 00037796
48351616|NCT00175838|DRUG|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
48351617|NCT04111185|DEVICE|Receive Blood Volume Analysis Guided Treatment|The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
48351618|NCT02513394|DRUG|Palbociclib|
48351619|NCT02513394|DRUG|Standard Adjuvant Endocrine Therapy|
48661919|NCT00651287|DRUG|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
48661920|NCT00651287|DRUG|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
48503937|NCT06209541|BEHAVIORAL|Internet-based cognitive behavioral therapy (ICBT)|All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.
48661921|NCT05844618|DRUG|Triamcinolone Acetonide (Aristocort® C)|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
48661922|NCT05844618|DRUG|Vehicle|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
48661923|NCT05482295|BIOLOGICAL|Hepatitis B vaccine lot 1|3 doses of Hepatitis B vaccine lot 1
48661924|NCT05482295|BIOLOGICAL|Hepatitis B vaccine lot 2|3 doses of Hepatitis B vaccine lot 2
48661925|NCT05482295|BIOLOGICAL|Hepatitis B vaccine lot 3|3 doses of Hepatitis B vaccine lot 3
47985645|NCT04774874|DRUG|Topical formulation|Topical administration on the scalp once daily for 16 weeks
47985646|NCT03009565|OTHER|coronary artery disease|
47985647|NCT03143569|DEVICE|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
47985648|NCT03143569|DEVICE|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
47985649|NCT01831999|BEHAVIORAL|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
47985650|NCT00323115|BIOLOGICAL|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
47985651|NCT00323115|DRUG|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
48351620|NCT02729402|OTHER|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
48351621|NCT04945304|PROCEDURE|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
48351622|NCT04945304|PROCEDURE|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
48351623|NCT00996541|BEHAVIORAL|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
48661926|NCT05482295|BIOLOGICAL|Hepatitis B vaccine (registered)|3 doses of Hepatitis B vaccine (registered)
48661927|NCT03514134|BEHAVIORAL|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
48661928|NCT03514134|BEHAVIORAL|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
48661929|NCT01514357|DRUG|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
48661930|NCT01514357|DRUG|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
48661931|NCT05694494|BEHAVIORAL|internet-based Lifestyle-integrated Functional Exercise (iLiFE)|receiving internet-based LiFE training and home safety assessment
48661932|NCT05694494|BEHAVIORAL|upper limb exercise training|upper limb exercise training
48661933|NCT02878785|DRUG|Decitabine|DNA methyltransferase inhibitor
48661934|NCT02878785|DRUG|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
48661935|NCT06508346|BIOLOGICAL|anti-CD19-CAR-T cells|Intravenous injection
48661936|NCT01596920|OTHER|Tissue|Allograft Tissue Cellular Repair Matrix
48661937|NCT01596920|OTHER|Control|Non-adherent Dressing
48661938|NCT01868412|DEVICE|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
48661939|NCT01868412|DEVICE|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
48661940|NCT04543851|DEVICE|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
48140944|NCT01606098|DRUG|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
48140945|NCT01003743|DEVICE|endolumenal tissue approximation|
48140946|NCT06323369|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48140947|NCT06323369|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48140948|NCT06323369|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48140949|NCT06323369|PROCEDURE|Surgical resection|Standard of care
48503938|NCT03869034|COMBINATION_PRODUCT|HAIC+PD1|Sintilimab ( 200mg Q3W iv D1)+FOLFOX-HAIC（oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3), maximally 8 cycles Multi-disciplinary consultation was organized to decide the chance of surgery and subsequent treatment per 2 treatment cycles. Patients who achieved partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and were assessed as eligible for R0 resection go on to undergo surgical resection. After recovery from operation , sintilimab monotherapy was given per three weeks for maximally 16 doses. Patients who were ineligible for resection would continue to receive the combination therapy.
48503939|NCT03869034|DRUG|HAIC|FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
48503940|NCT03900286|DIETARY_SUPPLEMENT|Total Dietary Replacement|Total Dietary Replacement
48503941|NCT01438996|BIOLOGICAL|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
48503942|NCT02910063|DRUG|Blinatumomab|Blinatumomab monotherapy
48503943|NCT00409448|BEHAVIORAL|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
48661941|NCT00863304|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
48661942|NCT00863304|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
48661943|NCT00863304|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
48661944|NCT00863304|OTHER|placebo|placebo to match tanezumab and naproxen dosing
48661945|NCT02227745|DRUG|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
48661946|NCT02227745|DRUG|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
48661947|NCT03713801|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
48661948|NCT03713801|DRUG|Placebo|Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
48661949|NCT03901040|DEVICE|endoscopic ultrasound|endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
48140950|NCT06323369|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48140951|NCT06323369|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48140952|NCT06323369|RADIATION|Radiation|Recommended, standard of care
48140953|NCT06323369|DRUG|Carboplatin（neoadjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48140954|NCT06323369|DRUG|Carboplatin（adjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
48140955|NCT02707952|DRUG|ABT-493/ABT-530|Co-formulated tablet
48140956|NCT02707952|DRUG|OBV/PTV/r|Co-formulated tablet
48140957|NCT03703414|DIAGNOSTIC_TEST|Fecal microbiota composition analysis and blood cytokine level analysis|Fecal microbiota composition analysis and blood cytokine level analysis
48140958|NCT03890653|BEHAVIORAL|Performance-Based Financing|Incentive-based payments
48140959|NCT03890653|BEHAVIORAL|Decentralized Facility Financing|Financing not linked to service delivery.
48503944|NCT00409448|BEHAVIORAL|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
48503945|NCT00000326|DRUG|Heroin Dependence|
48661950|NCT06490159|DRUG|Paclitaxel|Gastric cancer second-line chemotherapy
48351624|NCT01250392|BEHAVIORAL|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
48661951|NCT00002035|DRUG|Zidovudine|
48351625|NCT04048057|OTHER|Exercise|"Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power."
48661952|NCT00002035|DRUG|Didanosine|
48351626|NCT02591251|DRUG|Povidone-iodine solution|
48351627|NCT02591251|DRUG|Normal saline solution|
48661953|NCT00000720|DRUG|Globulin, Immune|
48661954|NCT00000720|DRUG|Zidovudine|
48661955|NCT06536426|BEHAVIORAL|Knee Isometric Program (KIP)|"The KIP physical therapy protocol follows the schedule outlined below:~* Session 1 (Completed 4-5 days/week including HEP): Double Leg wall sit 3x30 seconds, Double Leg glute bridge hold 3x30 seconds, Single Leg Stance hold 3x1 minutes, Lunge hold 3x1 minutes~* Session 2 (Completed 4-5 days/week including HEP): Single Leg wall sit 3x20 seconds, Single Leg glute bridge hold 3x20 seconds, Single Leg stance hold 2x1.5 minutes, Lunge hold 2x1.5 minutes~* Session 3 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes~* Session 4 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes"
48661956|NCT05593055|DRUG|Eplerenone|After the Pre-Treatment Assessment, participants in the eplerenone arm will be given 50 mg eplerenone. At 2 weeks, eplerenone will be increased to 100 mg.
48661957|NCT05593055|DRUG|Chlorthalidone|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
48661958|NCT05593055|DRUG|Potassium|After the Pre-Treatment Assessment, participants in the chlorthalidone arm will be given 12.5 mg chlorthalidone + 10 mEq potassium. At 2 weeks, chlorthalidone will be increased to 25 mg + 20 mEq potassium.
48661959|NCT06344091|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
47985652|NCT00323115|PROCEDURE|Radiotherapy|RT is standard of care (SOC) post surgery
48351628|NCT03551704|BEHAVIORAL|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
48351629|NCT03551704|BEHAVIORAL|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
48661960|NCT01021527|OTHER|Comparator: Treatment A|No Treatment
48661961|NCT01021527|DRUG|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
48661962|NCT01021527|DRUG|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
48661963|NCT01021527|PROCEDURE|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
48351630|NCT00881686|DRUG|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
48503946|NCT05576883|BEHAVIORAL|Transdiagnostic emotion regulation intervention|"The intervention under study includes 5 therapeutic approaches, namely: Positive psychology \[PP\], Mindfulness, Acceptance and Commitment Therapy \[ACT\], Breathing and relaxation, and Self-compassion \[SC\].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills \[i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)"
47985653|NCT00323115|BIOLOGICAL|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
47985654|NCT05692765|BEHAVIORAL|smartphone application to enhance fruit and vegetables intake among adolescents|"This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups."
47985655|NCT04566354|OTHER|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
47985656|NCT05585151|DRUG|Evolocumab 140 MG/ML|Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
48351631|NCT06425406|DEVICE|high-flow nasal cannula|In group H, mask ventilation was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 90 %. The lower mask was taken and HFNC was used to record the patient 's safe apnea time.
48503947|NCT01250886|DRUG|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
48661964|NCT05194995|DRUG|JAB-21822|JAB-21822 administered orally as a tablet.
47985657|NCT05585151|DRUG|Intensive statin treatment|Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
48503948|NCT01250886|DRUG|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
48503949|NCT01250886|DRUG|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
48661965|NCT05194995|DRUG|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
48687916|NCT05648344|BEHAVIORAL|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
48661966|NCT04433182|DRUG|Copanlisib|"Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~* Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~* Rituximab (R): 375 mg/sqm i.v. day 1\*~* Bendamustine (B): 90 mg/sqm i.v. days 1-2\*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year"
48661967|NCT02683447|OTHER|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
48503950|NCT01140399|DRUG|Furosemide or Furosemide and Dopamine|"Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m."
48661968|NCT06570980|DRUG|sulfonylurease with metformin, DPP4 inhibitors with Metformin|Oral hypoglycemic agents
48661969|NCT05068583|OTHER|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
48140960|NCT04353050|PROCEDURE|Non-invasive adhesive system (patch)|The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
47985658|NCT03676933|DRUG|DS107E|
47985659|NCT03676933|DRUG|Vehicle|
48661970|NCT00415636|DRUG|IC83/LY2603618|40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.
48661971|NCT00415636|DRUG|IC83/LY2603618|70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
48661972|NCT00415636|DRUG|IC83/LY2603618|105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
48661973|NCT00415636|DRUG|IC83/LY2603618|150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
48661974|NCT00415636|DRUG|IC83/LY2603618|195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
48661975|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
48140961|NCT01092416|DEVICE|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
48140962|NCT06397586|OTHER|Routine volleyball|MOtor imagery
48503951|NCT01140399|DEVICE|Ultrafiltration|"All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~* less than 3 kg 200 ml/h~* more than 3 kg and less than 5 kg 300 mlh~* more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of \> 50% and \<70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited"
48661976|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
48661977|NCT01172392|DRUG|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
48661978|NCT01172392|DRUG|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
48661979|NCT04537650|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VFSS)|A standardized dynamic radiographic examination of oropharyngeal swallowing
48661980|NCT03135860|DRUG|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
48661981|NCT04033640|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
48661982|NCT04033640|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
48140963|NCT02588521|DRUG|AL-794|
48140964|NCT02588521|OTHER|Placebo/Vehicle|Suspension vehicle without active drug
48140965|NCT06301620|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
48503952|NCT00401609|DRUG|gemcitabine|
48503953|NCT00401609|DRUG|vinorelbine|
48503954|NCT00401609|DRUG|cisplatin|
48503955|NCT00401609|DRUG|etoposide|
47985660|NCT03676933|DRUG|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
47985661|NCT00549302|DRUG|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
48503956|NCT00401609|DRUG|carboplatin|
48661983|NCT04033640|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
48661984|NCT04033640|DIAGNOSTIC_TEST|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
48503957|NCT02864810|DRUG|[18F]GP1|\[18F\]GP1 PET/CT imaging for detecting thromboembolism
48503958|NCT05880212|OTHER|Usual physiotherapy care|In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.
48503959|NCT05880212|OTHER|Individualized (STOPS) physiotherapy|In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
48503960|NCT05546112|DEVICE|Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B|A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
48503961|NCT05546112|DEVICE|Sham Stimulation using YPS-401B|A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
48503962|NCT06633822|DIAGNOSTIC_TEST|Digital planning|The digital methodology will consist of obtaining a digital scan and a computed tomography (CBCT) that will be aligned using a digital program for the elaboration of a digital wax-up and fabrication of a printed surgical template.
48503963|NCT06633822|DIAGNOSTIC_TEST|Analogic planning|The analog wax-up will be elaborated based on a silicone impression and periapical radiographs with parallel technique, which will allow us to elaborate an essix-type surgical splint.
48503964|NCT03271723|OTHER|Observational study|No intervention
48661985|NCT06200948|OTHER|Aerobic Exercise|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
48687917|NCT05648344|BEHAVIORAL|Control|Usual care with information from myplate.gov
48661986|NCT06200948|OTHER|Complete Decongestive Treatment|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
48661987|NCT01605097|RADIATION|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
48661988|NCT00358878|DRUG|Satavaptan|oral administration once daily
48661989|NCT00358878|DRUG|placebo|oral administration once daily
48661990|NCT06571058|OTHER|Assistance|Assist patient with walking approximately 90 feet
48661991|NCT06571058|OTHER|Educational Intervention|Receive a short instructional session
48661992|NCT06571058|DEVICE|Medical Device Usage and Evaluation|Wear the B3 Buddy device
47985662|NCT00549302|DRUG|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
47985663|NCT02946645|DEVICE|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
48687918|NCT03972462|DRUG|NPC-12G Gel 0.2%|Period 1
48661993|NCT06571058|OTHER|Medical Device Usage and Evaluation|Secure the urinary drainage bag to the patient using the B3 Buddy device
48661994|NCT06571058|OTHER|Questionnaire Administration|Ancillary studies
48503965|NCT05346536|OTHER|Detection of circulating tumor cells expressing Axl: CTC-AXL(+)|"Detection of CTC-AXL(+) using 2 techniques:~* CellSearch®, FDA-USA approved technology~* EPIDROP System~CellSearch® (Menarini Company) The current gold-standard CellSearch® technique requires the use of CellSave tubes. This technique allows the isolation of fixed CTCs. This technique uses a positive (CellSearch® Epithelial Cell Kit) enrichment method from total blood using magnetic beads coupled to an EpCAM capture antibody. CTCs are then detected (anti-panCK antibodies, DAPI, anti-CD45 and characterized (anti-AXL antibody) by immunofluorescence (IF).~EPIDROP It requires the use of EDTA tubes. This technique is based on a method of negative enrichment of CTCs from total blood using a cocktail of tetrameric antibodies to eliminate unwanted blood cells and to preserve only purified tumor cells (RosetteSep - StemCell Technology).Then, cells are loaded in a microfluidic chip. The detection and characterization is done by IF to the single cell in micro-droplets."
48661995|NCT06571058|PROCEDURE|Remove|Remove the device and return urinary drainage bag to the standard position
48661996|NCT06571058|OTHER|Walking|Walk approximately 90 feet
48661997|NCT04743648|BEHAVIORAL|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
48661998|NCT03463655|DIAGNOSTIC_TEST|cirrhotic albumin|Ascites puncture
48661999|NCT03463655|DIAGNOSTIC_TEST|serum albumin|blood punctures
48503966|NCT06451055|BEHAVIORAL|Low-calorie diet|LCD diet is designed to provide \~1300 kcal/day with a macronutrient composition of 55% carbohydrate, 13% fat, 25% protein, and 2% fiber.
48503967|NCT06451055|BEHAVIORAL|Routine dietary and physical activity habits|Participants will be asked to maintain their habitual dietary and physical activity habits.
48503968|NCT02712580|DEVICE|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
48662000|NCT06635785|DRUG|AI-081|AI-081 is a humanized monoclonal antibody with a silenced Fc targeting PD-1 and VEGF.
48662001|NCT02530255|DIETARY_SUPPLEMENT|cycloastragenol|Oral telomerase activator - cycloastragenol.
48662002|NCT02530255|DIETARY_SUPPLEMENT|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
48662003|NCT05534867|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
48662004|NCT04245189|OTHER|Endoscopic ultrasound for detection of Chronic pancreatitis|Presence of Chronic pancreatitis in alcoholic cirrhosis patients.
48662005|NCT03477812|DEVICE|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
48662006|NCT04282148|DEVICE|ABT NG DES 48 EECSS|Each participant will receive ABT NG DES 48 EECSS with appropriate diameter
48662007|NCT01380665|DEVICE|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
48662008|NCT05130593|DIETARY_SUPPLEMENT|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
48662009|NCT03651206|DRUG|Niraparib|PARP Inhibitor
48662010|NCT03651206|COMBINATION_PRODUCT|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
48662011|NCT03651206|DRUG|Chemotherapy Drugs|Chemotherapies given in standard of care
48662012|NCT03469895|DRUG|ibrutinib ou idelalisib|treatment by ibrutinib or idelalisib for autoimmune cytopenia
48662013|NCT02878473|PROCEDURE|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
48662014|NCT06232616|PROCEDURE|vitrectomy combined with intravitreal dexamethasone implant|The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
48662015|NCT06343623|PROCEDURE|myomucosal resection and direct closure|myomucosal resection and direct closure
48662016|NCT06343623|PROCEDURE|superiorly based flap|superiorly based pharyngeal flap
47985664|NCT02946645|PROCEDURE|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~1. Place knuckle of index finger between top and bottom teeth.~2. Remove it, keeping the teeth separated one-knuckle apart.~3. Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
47985665|NCT02946645|OTHER|Placebo|No interventions.
48351632|NCT03276260|DEVICE|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
48351633|NCT03787901|OTHER|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
48503969|NCT02712580|DEVICE|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
48503970|NCT02712580|DEVICE|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
48503971|NCT02712580|DEVICE|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
48503972|NCT06224465|OTHER|aerobic exercises|"Antiaging diet instruction :Be aware of the amount of calories, Reduce overall fat and sugar intake, Drink at least 10 glasses of water every day in order to remain healthy.~d. Eat a variety of complex carbohydrates and vegetables instead of bread, rice, and corn."
48503973|NCT03928730|PROCEDURE|resection and removal|Surgical resection or removal for histopathological examination
48503974|NCT05918406|COMBINATION_PRODUCT|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
48503975|NCT02360176|PROCEDURE|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
48503976|NCT02360176|PROCEDURE|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
48503977|NCT00482807|DRUG|bicalutamide|
48503978|NCT00482807|DRUG|docetaxel|
48662017|NCT06532188|PROCEDURE|Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points according to the National Acupuncture Detoxification Association (NADA) protocol, needle retention after 7 days standardized medical hypnosis:~* Induction of a trance~* suggestions for calm and good sleep"
48662018|NCT06532188|PROCEDURE|Sham Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points inserted at non-specific points on the backside of the outer ear, needle retention after 7 days standardized sham hypnosis~- story without trance induction and suggestions"
47985666|NCT03356951|PROCEDURE|TAR through anterior approach and subtalar fusion|Simultaneous total ankle replacement through anterior approach and subtalar fusion
48351634|NCT05585983|BIOLOGICAL|Vaxigrip Tetra Sanofi Pasteur Europe|We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
48351635|NCT03286634|DRUG|Daunorubicin|Given IV
48351636|NCT03286634|DRUG|Prednisolone|Given PO or IV
48351637|NCT03286634|DRUG|Vincristine|Given IV
48351638|NCT03286634|DRUG|Epirubicin|Given IV
48503979|NCT00482807|DRUG|goserelin|
48503980|NCT00482807|RADIATION|intensity-modulated radiation therapy|
48503981|NCT05160272|DRUG|AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
48503982|NCT05160272|DRUG|Placebo matching AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
48687919|NCT03972462|DRUG|Rapamune® 2 mg tablet|Period 2
48140966|NCT06301620|BEHAVIORAL|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
48140967|NCT04378036|OTHER|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
47985667|NCT03356951|PROCEDURE|TAR through lateral approach and subtalar fusion|Simultaneous total ankle replacement through lateral approach and subtalar fusion
47985668|NCT04771507|DRUG|Ibrutinib|Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
48140968|NCT04378036|DEVICE|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
48140969|NCT05794594|DEVICE|3D printed personalized extendable prosthesis|3D printed personalized extendable prosthesis replacement for limb preservation in children
48140970|NCT03938272|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes Strain HC-1|Live, commensal bacteria
48140971|NCT06463145|DIETARY_SUPPLEMENT|Vanizem|Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol
48140972|NCT06463145|DIETARY_SUPPLEMENT|Placebo|Food grade Maltodextrin 12
48140973|NCT01279707|BIOLOGICAL|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
48140974|NCT01279707|BIOLOGICAL|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
48140975|NCT01279707|BIOLOGICAL|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
48140976|NCT05616494|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
48140977|NCT03477266|DRUG|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
48140978|NCT03477266|DRUG|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
47985669|NCT00503087|PROCEDURE|Saline Injection|
48140979|NCT05476900|DRUG|HR19042 Capsules|HR19042 Capsules
48140980|NCT04373967|DRUG|Victoza®.|Patients will receive Victoza®. Both products will be provided as pen-injector.
48140981|NCT04373967|DRUG|Metformin Hydrochloride|Patients who were receiving metformin prior to study will continue to receive it during the study.
48140982|NCT04373967|DRUG|TQZ2451|Patients will receive TQZ2451.Both products will be provided as pen-injector.
48140983|NCT04264884|DRUG|Daratumumab|Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
48140984|NCT04529928|DEVICE|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
48140985|NCT04908930|BEHAVIORAL|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
48140986|NCT04568213|DRUG|Hypochlorous Acid Gel 0.02%|0.02% Hypochlorous Acid Gel (OCusoft Hypochlor GEL) will be sprayed onto the closed eyelid of the surgical eye while covering the fellow eye with palm of the hand, left for 60 seconds, then wiped off with a clean gauze, tissue, or cotton ball.
48140987|NCT01005914|DRUG|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
48140988|NCT01005914|DRUG|cytarabine|Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4
48140989|NCT01005914|DRUG|dexamethasone|Day 1-4; 11-14: 40 mg daily
48140990|NCT01005914|DRUG|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
48140991|NCT01005914|DRUG|imatinib mesylate|600 mg/day
48140992|NCT01005914|DRUG|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
48503983|NCT03581591|BIOLOGICAL|Burosumab|recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
48503984|NCT04810637|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
47985670|NCT00503087|DEVICE|Pneumatic Skin Flattening (PSF)|
47985671|NCT01491503|DRUG|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
47985672|NCT01491503|DRUG|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
47985673|NCT01491503|DRUG|Montelukast & levocetirizine|Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
47985674|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
47985675|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
48662019|NCT06456658|OTHER|Interruptive Reminder|"The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
48662020|NCT06456658|OTHER|Non-interruptive Reminder|"The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason."
48140993|NCT01005914|DRUG|methylprednisolone|Day 1-3: 50mg IV BID
48140994|NCT01005914|DRUG|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
48140995|NCT01005914|DRUG|vincristine sulfate|Day 4 \& 11: 2 mg IV
48140996|NCT01531413|OTHER|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
48662021|NCT06456658|OTHER|No Reminder|No reminder recommending a statin will be displayed/available to the provider.
48662022|NCT01290991|DEVICE|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
48662023|NCT06482983|PROCEDURE|Mechanical Ventilation Mode|after intubation different ventilation mode (VC,PC,PC-VG)
48662024|NCT06424743|OTHER|exercise|exercise programs with different volumes
48140997|NCT05433441|PROCEDURE|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
48140998|NCT06511219|DEVICE|maxillary segmental distalization|maxillary segmental distalization using skeletal anchored digitally printed appliances
48140999|NCT06511310|OTHER|Exercise|High Intensity Exercise
48141000|NCT05707494|DEVICE|Efferon LPS NEO|Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.
48141001|NCT05532553|DEVICE|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
48141002|NCT03014791|OTHER|Brief lifestyle/medical history questionnaire|Core Measurement
48141003|NCT03014791|OTHER|Anthropometric measures|Core Measurement
48141004|NCT03014791|OTHER|Blood pressure and arterial stiffness|Core Measurement
48141005|NCT03014791|OTHER|Cardiac output and lung function|Core Measurement
48141006|NCT03014791|OTHER|Heart rate variability|Core Measurement
48503985|NCT01816659|DRUG|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
48141007|NCT03014791|OTHER|Blood sample & spot urine sample|Core Measurement
48141008|NCT03014791|OTHER|24 hour ambulatory blood pressure monitor|Detailed Measurement (Optional for participants).
48141009|NCT03014791|OTHER|24 hour urine collection|Detailed Measurement (Optional for participants).
48141010|NCT03014791|OTHER|Echocardiograph: Left ventricular mass|Detailed Measurement (Optional for participants).
48141011|NCT03014791|OTHER|Large artery structure: Carotid intima-media thickness|Detailed Measurement (Optional for participants).
48141012|NCT03014791|OTHER|Small artery structure: Minimum forearm vascular resistance|Detailed Measurement (Optional for participants).
48141013|NCT03014791|OTHER|Large artery endothelial function|Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
48141014|NCT03014791|OTHER|Small artery endothelial function: Forearm blood flow|Detailed Measurement (Optional for participants).
48141015|NCT03014791|OTHER|Dundee step test|Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
48141016|NCT03014791|OTHER|Detailed haemodynamic response to submaximal exercise|Detailed Measurement (Optional for participants).
48351639|NCT03286634|DRUG|E-coli L-asparaginase|Given IM or IV
48351640|NCT03286634|DRUG|6-Mercaptopurine|Given PO
48351641|NCT03286634|DRUG|Methotrexate|Given IV, PO or IT
48351642|NCT03286634|DRUG|Hydrocortisone|Given IT
48351643|NCT03286634|DRUG|Cytarabine|Given IV, IT or SC
48351644|NCT03286634|DRUG|Cyclophosphamide|Given IV
48351645|NCT00877227|DRUG|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
48351646|NCT03186040|DRUG|Lacosamide|Sodium channel blocker
48141017|NCT03014791|OTHER|Cardiopulmonary fitness: Maximum oxygen consumption|Detailed Measurement (Optional for participants).
48662025|NCT05443321|OTHER|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
48351647|NCT04050891|DEVICE|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
47985676|NCT06294964|BEHAVIORAL|sleep education, behavioral education|Provide health education materials which covering sleep education, behavioral education, chronic diseases such as cardiovascular diseases. Topics touch on such as why you need healthy sleep? What methods can be used to regulate insomnia, and how to regulate sleep breathing problems? How do the elderly maintain a good sleep? What are the risk factors for cardiovascular and cerebrovascular diseases? How to reduce the risk of developing sleep disorders or chronic diseases through changing everyday life?
48351648|NCT04222257|DRUG|Antibiotics|Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
47985677|NCT00927784|BIOLOGICAL|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
48351649|NCT04222257|DRUG|Antibiotics|Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
48351650|NCT04921969|DRUG|Ruxolitinib|The study cream will be applied topically twice a day for up to 52 weeks.
48351651|NCT04921969|DRUG|Vehicle Cream|Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
48351652|NCT03551392|DEVICE|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
48351653|NCT03551392|DEVICE|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
48662026|NCT06563609|BEHAVIORAL|Intensive physical Therapy, individualised Nutritional Support|An Intensive physical Therapy and individualised Nutritional Support intervention
48662027|NCT06563609|DIETARY_SUPPLEMENT|Probiotic treatment|Administration of probiotic yeast Saccharomyces boulardii twice daily
48141018|NCT03014791|OTHER|Haemodynamic response to mental stress|Detailed Measurement (Optional for participants).
48141019|NCT03014791|OTHER|Small artery dilatory function: Forearm blood flow|Detailed Measurement (Optional for participants).
48141020|NCT03585400|OTHER|Observational Study|Observational Study: Not Applicable for Observational Studies
48141021|NCT00109031|DRUG|palifermin|Administered as one daily intravenous bolus.
48141022|NCT00109031|RADIATION|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
48141023|NCT00109031|DRUG|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
48662028|NCT02663193|OTHER|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
48662029|NCT05549102|BEHAVIORAL|Cognitive Behavioural Therapy|In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.
48662030|NCT05549102|OTHER|Waiting List|In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
48662031|NCT02947971|DEVICE|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
48662032|NCT00966108|DEVICE|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
48662033|NCT06028750|PROCEDURE|Dynamic Computer Assisted Surgery|Surgical navigation system (X-Guide guided surgery system) Navigation system X-Guide
48662034|NCT06028750|PROCEDURE|Freehand|Freehand implant placement
48662035|NCT00520338|DRUG|celecoxib|"1. placebo~2. celecoxib 400 mg oral single dose"
48662036|NCT00038935|DRUG|ReFacto AF|
48662037|NCT06172140|DRUG|Ciprofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
48351654|NCT03551392|DEVICE|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
48351655|NCT03551392|DEVICE|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
48351656|NCT00528840|BIOLOGICAL|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
48351657|NCT02943668|DRUG|Deferasirox|Given PO
48351658|NCT02943668|OTHER|Laboratory Biomarker Analysis|Correlative studies
48351659|NCT00654576|DRUG|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
48351660|NCT00654576|BEHAVIORAL|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
48503986|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 1|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
48503987|NCT06077838|BEHAVIORAL|RELAXaHEAD Smartphone App Version 2|RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
48503988|NCT04523935|OTHER|Placebo|Fructose powder identical with the drugs was used
48503989|NCT04523935|DRUG|Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.|Drugs were used either singly or in combination guided by clinical findings and investigations.
48351661|NCT05972577|OTHER|Health Promotion and Education|Undergo GO!
48351662|NCT05972577|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
48351663|NCT05972577|OTHER|Quality-of-Life Assessment|Complete quality of life assessments and diary entries
48351664|NCT05972577|OTHER|Questionnaire Administration|Complete questionnaires
48351665|NCT02505269|DRUG|Brentuximab Vedotin|
48351666|NCT02505269|DRUG|Adriamycin|
48351667|NCT02505269|DRUG|Dacarbazine|
48351668|NCT00470873|DRUG|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
48351669|NCT02319564|DRUG|Beclomethasone|
48351670|NCT02319564|DRUG|Beclomethasone and Salbutamol|
48351671|NCT02319564|DRUG|Placebo|
48351672|NCT02319564|DEVICE|Aerochamber Max®|
48351673|NCT00441194|DEVICE|Visual Field (Octopus 311 and the HFA 700 series)|
48141024|NCT00109031|DRUG|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
48351674|NCT02033291|PROCEDURE|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
48351675|NCT01736930|DEVICE|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
48351676|NCT02621008|OTHER|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
48351677|NCT03971019|DRUG|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
48351678|NCT03971019|BEHAVIORAL|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol \< 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2\~3 g/d Water soluble dietary fiber 10\~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
48351679|NCT03362216|DRUG|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
48351680|NCT03362216|DRUG|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
48351681|NCT06326164|PROCEDURE|kinesio-taping.|A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.
48351682|NCT06326164|PROCEDURE|A designed physiotherapy program.|The designed physiotherapy program included passive stretching, weight bearing, muscle strengthening, functional exercises, neurodevelopmental treatment, splinting, balance training, and gait training. The treatment protocol will be repeated each session per weeks for twelve weeks.
48503990|NCT05794360|BEHAVIORAL|ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)|A diverse group of key informants (i.e., PE teachers, school athletic department director) and community stakeholders (i.e., professional soccer coaches, Houston Dynamo Academy director) were engaged to help the research team design, modify, and implement the ACCELERATION curriculum to ensure program relevance and appeal. There are several components that described below make our program design both comprehensive and highly adaptable for optimal reach and effectiveness. These include staff development training, parent workshops, on-site and virtual developmental programs, delivery and implementation support from community stakeholders, online resources, family engagement events, equipment donations to improve activity, and on-going support and mentoring services for parents and school-based educators.
48662038|NCT06172140|DRUG|Propofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of propofol, followed by intravenous injection of propofol (2 mg/kg) for 30 seconds. When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
48503991|NCT05479916|DIETARY_SUPPLEMENT|Low glycated milk protein|40 grams of protein dissolved in 600 mL of water
48141025|NCT00109031|DRUG|Placebo|Administered as one daily intravenous bolus.
48141026|NCT04128670|DEVICE|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
48141027|NCT03189303|DEVICE|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem
48351683|NCT04574141|DIETARY_SUPPLEMENT|a prolonged release tablet and a spray containing melatonin|prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.
48351684|NCT01657214|DRUG|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
48351685|NCT02292888|OTHER|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
48351686|NCT01308528|DRUG|Sodium enoxaparin|40 mg/mL
48351687|NCT01308528|DRUG|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
48351688|NCT01565460|OTHER|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
48141028|NCT00259766|DRUG|Budesonide|
48141029|NCT00259766|DRUG|Formoterol|
48141030|NCT00259766|DRUG|Terbutaline|
48351689|NCT00975442|OTHER|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
47985678|NCT00927784|DRUG|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
48351690|NCT00975442|DEVICE|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
48351691|NCT00975442|DEVICE|Forearm band|All patients were instructed to use a forearm band during all daily activities.
48351692|NCT02407665|BEHAVIORAL|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
48503992|NCT05479916|DIETARY_SUPPLEMENT|High glycated milk protein|40 grams of protein dissolved in 600 mL of water
48662039|NCT04037215|OTHER|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~* children controls not achieved with normal BMI;~* children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
48662040|NCT00779909|DRUG|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
48662041|NCT00779909|OTHER|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
48662042|NCT03512730|DEVICE|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
47985679|NCT00195676|DRUG|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
48351693|NCT05393544|BEHAVIORAL|Digitally assisted peer recovery coach|The certified peer recovery coach utilized an existing care coordination smartphone app to provide support to the patient during and after an inpatient detoxification treatment for alcohol use disorder. The coach utilized the telephone or text messages to send daily motivational messages, remind about upcoming appointments, and checked-in if responses were concerning. Follow-up by the coach continued for 30 days.
48351694|NCT03947099|DRUG|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
48351695|NCT00935961|DRUG|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
48503993|NCT00004378|PROCEDURE|Stem Cell Transplantation|
48503994|NCT02240030|DRUG|CVT-301 Low Dose|
48503995|NCT02240030|DRUG|CVT-301 High Dose|
48503996|NCT02240030|OTHER|Placebo|
47985680|NCT03231033|DRUG|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
47985681|NCT03273192|DRUG|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
47985682|NCT00879281|BEHAVIORAL|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
48503997|NCT06082895|BEHAVIORAL|Birth self-efficacy enhancement training based on motivational interviewing method|Birth self-efficacy enhancement training based on motivational interviewing method
48662043|NCT03512730|OTHER|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
48662044|NCT00659022|PROCEDURE|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
48141031|NCT01617811|PROCEDURE|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
48141032|NCT03115099|DRUG|LY3325656|Administered orally
48503998|NCT04495881|DRUG|Sitagliptin 100mg|Sitagliptin 100mg Qd
48503999|NCT06484842|OTHER|The combined psychological resilience and self-efficacy intervention|Based on the content of the literature analysis and the group's previous research, a joint intervention programme on psychological resilience and self-efficacy for patients undergoing surgery for oesophageal cancer has been developed. The programme consists of 6 sessions in total, including preoperative period and one month after discharge, covering the period when patients' postoperative symptoms occur most severely. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospital stay; considering the smooth implementation of the intervention after the patient will be discharged from the hospital, we will conduct the intervention in an individual, offline face-to-face format during the patient's outpatient review, and set up a WeChat group in case the patients are at home to conduct the intervention in the form of an online punch card.
48662045|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
48662046|NCT00659022|DRUG|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
48662047|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
48662048|NCT03910595|OTHER|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
48662049|NCT04759287|DEVICE|C-MAC VS|The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
48662050|NCT04759287|DEVICE|flexible fibreoptic bronchoscope|The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
48662051|NCT01129206|DRUG|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
48662052|NCT01129206|DRUG|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
47985683|NCT03487757|OTHER|Core Stabilization Exercises|Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
47985684|NCT03487757|OTHER|No Intervention|Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
48141033|NCT03115099|DRUG|Placebo|Administered orally
48141034|NCT03115099|DRUG|Liraglutide|Administered subcutaneously
48662053|NCT01129206|RADIATION|fludeoxyglucose F 18|Correlative studies
48662054|NCT01129206|PROCEDURE|positron emission tomography|Correlative studies
48141035|NCT03115099|DRUG|Sitagliptin|Administered orally
48662055|NCT05670184|DRUG|LSD|Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
48662056|NCT05670184|DRUG|Ethanol|Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
48662057|NCT00738127|PROCEDURE|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
48662058|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging plus peer support|Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
48662059|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging|Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
48662060|NCT03404882|BEHAVIORAL|Peer support only|face to face support from peer support workers but no interactive or daily supportive/reminder text messages
48662061|NCT05951907|PROCEDURE|Maxillary extraction without palatal injection|Extraction of maxillary premolars by only buccal injection without palatal by using articaine 4% HCL with epinephrine (1:100,000)
48662062|NCT05951907|PROCEDURE|Maxillary extraction with buccal and palatal injection|Extraction of maxillary premolars by only buccal and palatal injection by using lidocaine 2 % HCL with epinephrine (1:80,000)
48662063|NCT04661488|DEVICE|AI driven triage-system|AI driven triage-system
48662064|NCT05552404|OTHER|conservative therapy|bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
48662065|NCT05552404|DRUG|Aminophylline|conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
48662066|NCT05552404|PROCEDURE|trans nasal sphenopalatine ganglion block|conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
48662067|NCT05814159|DRUG|Anakinra|sub cutaneous daily injection
48662068|NCT05814159|DRUG|Placebo|sub cutaneous daily injection
48662069|NCT04694287|DIAGNOSTIC_TEST|Percutaneous DUS volume flow measurements|Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
48662070|NCT06249464|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
48662071|NCT06249464|DRUG|Lidocaine hydrochloride|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
48141036|NCT04111159|DRUG|HSK3486|Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
48141037|NCT04111159|DRUG|Propofol|Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
48662072|NCT02386956|OTHER|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
48662073|NCT02386956|OTHER|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
48662074|NCT02386956|OTHER|Control|10 minutes with the patient lying on a machine off of magnetotherapy
48662075|NCT03714516|BEHAVIORAL|Psychological internet intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
48141038|NCT03672032|DEVICE|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
48141039|NCT03672032|DEVICE|Franseen Needle|Franseen Needle will be used to obtain biopsy
48141040|NCT01138969|DRUG|esomeprazole|esomeprazole 20 mg qd for 6 months
47985685|NCT04599894|DRUG|37.5mg Pregabalin + 75mg Pregabalin|37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively
47985686|NCT04599894|DRUG|75mg Pregabalin|75mg pregabalin postoperatively
48618311|NCT02772731|PROCEDURE|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
47985687|NCT04090645|DEVICE|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
47985688|NCT05965089|BIOLOGICAL|Placebo|Placebo
47985689|NCT05965089|BIOLOGICAL|AX-202|Humanized monoclonal antibody
47985690|NCT00448474|BEHAVIORAL|Mailed Arthritis Self-Management Education|
47985691|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 1|Mango (pulp/flesh) (500 g)
48662076|NCT01155050|DEVICE|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
48662077|NCT01155050|BEHAVIORAL|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
48662078|NCT01155050|DEVICE|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
48662079|NCT01621646|OTHER|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
48662080|NCT00691509|GENETIC|gene expression analysis|
48662081|NCT00691509|GENETIC|polymorphism analysis|
48662082|NCT00691509|OTHER|high performance liquid chromatography|
48662083|NCT00691509|OTHER|laboratory biomarker analysis|
48662084|NCT00691509|OTHER|mass spectrometry|
48662085|NCT00691509|OTHER|questionnaire administration|
48662086|NCT02587910|DIETARY_SUPPLEMENT|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
48662087|NCT02587910|DIETARY_SUPPLEMENT|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
48662088|NCT03088683|DEVICE|Nathanson Retractor|Liver will be retracted with Nathanson retractor
48662089|NCT03088683|DEVICE|Reveel Retractor|Liver will be retracted with Reveel retractor
48662090|NCT00425620|DRUG|SinuNase|Lavage
48662091|NCT05840302|DEVICE|Activity monitor|Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
48662092|NCT05840302|OTHER|Questionnaire|Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
48662093|NCT00856557|BEHAVIORAL|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
48662094|NCT03527784|DEVICE|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
48662095|NCT03527784|DEVICE|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
48662096|NCT03527784|DEVICE|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
48662097|NCT05031832|DIAGNOSTIC_TEST|HIV test|HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
48662098|NCT01634152|DRUG|Placebo|2 actuations once daily in the evening
48662099|NCT01634152|DRUG|Tiotropium low dose mcg|2 actuations once daily in the evening
48662100|NCT01634152|DRUG|Tiotropium high dose|2 actuations once daily in the evening
48687920|NCT04984395|DIAGNOSTIC_TEST|Post-treatment CT-guided bone marrow biopsy|At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.
48687921|NCT04748679|BEHAVIORAL|Worry Intervention|The worry intervention is weekly individual therapy with a trained therapist
47985692|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
47985693|NCT03365739|DIETARY_SUPPLEMENT|Control Comparator|Vitamin C (100 mg)
47985694|NCT04055142|PROCEDURE|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
47985695|NCT04055142|DRUG|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
47985696|NCT04055142|DRUG|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
47985697|NCT03704454|DIETARY_SUPPLEMENT|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
47985698|NCT03704454|DIETARY_SUPPLEMENT|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
47985699|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
47985700|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
47985701|NCT02452346|DRUG|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
47985702|NCT03121547|DRUG|Tapentadol 50 mg Oral Tablet|1 tablet administered
47985703|NCT03121547|DRUG|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|1 tablet administered
48687922|NCT04748679|BEHAVIORAL|Befriending|The worry intervention is weekly individual therapy with a trained therapist
48687923|NCT05774015|DIETARY_SUPPLEMENT|Magnesium Oxide tablet 500 mg|To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
48504000|NCT06484842|OTHER|The mindfulness intervention|The oesophageal cancer surgery patients in the single intervention group will receive 5 sessions of mindfulness intervention consistent with the mindfulness intervention component of the combined intervention programme. The intervention will be conducted in an individual, offline face-to-face format during the patients' hospitalisation; we will conduct the intervention in an individual, offline face-to-face format during the patients' outpatient review, and set up a WeChat group in case the patients are at home in the form of an online punch card. Each session will include a pre-session reflection and post-session homework. The whole process will be supervised and reminded by interventionists, who will respond to patients' questions in a timely manner to ensure patients safety and the smooth implementation of the intervention. Adjustments and improvements will be made at any time according to the needs of patients undergoing oesophageal cancer surgery.
48662101|NCT02094391|DRUG|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
48504001|NCT03201432|DEVICE|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
48504002|NCT03201432|DEVICE|Bare metal stent (BES)|Bare metal stent
48662102|NCT00000438|DRUG|naltrexone (Revia)|
48662103|NCT00238394|DRUG|cediranib maleate|Given orally
48662104|NCT00238394|OTHER|laboratory biomarker analysis|Correlative studies
48662105|NCT05242939|OTHER|Video game|The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
48504003|NCT03454178|DIAGNOSTIC_TEST|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
48504004|NCT05614427|DIAGNOSTIC_TEST|Innova Lateral Flow Test|Lateral flow test performed on anterior nasal or buccal swabs
48662106|NCT05242939|OTHER|Watching cartoons|The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
48662107|NCT04935593|OTHER|The RENEW Intervention|An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
48662108|NCT06163339|OTHER|Cultural Formulation Interview|Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence
48662109|NCT00158678|PROCEDURE|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
48662110|NCT00158678|PROCEDURE|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
48662111|NCT00158678|DRUG|concomitant cisplatin|100 mg/m2 D1, D22, D43
48662112|NCT02965781|DRUG|SADBE|Topical solution
48662113|NCT02965781|OTHER|Placebo|Topical solution
47985704|NCT03121547|DRUG|Placebo Oral Tablet|calcium tablet
47985705|NCT01892501|PROCEDURE|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
48662114|NCT01427491|DEVICE|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
48662115|NCT01427491|DEVICE|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
48662116|NCT05453084|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
48662117|NCT04936555|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
48662118|NCT00129974|DRUG|pemetrexed and gemcitabine|
48662119|NCT03485157|BIOLOGICAL|Micronized dHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
47985706|NCT01892501|DEVICE|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
48662120|NCT03485157|DRUG|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
48662121|NCT04580550|OTHER|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
48351696|NCT01531933|DRUG|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
48351697|NCT01531933|DRUG|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
47985707|NCT06403995|BEHAVIORAL|Self-referred, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
48351698|NCT04098016|BEHAVIORAL|Digital Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
48351699|NCT04693312|DRUG|Depo medrol|local injection
48351700|NCT02655263|DRUG|Somatropin|Somatropin infusion (Genotropin®)
48504005|NCT06633328|DRUG|CD7 CAR-T cells injection|CD7 CAR T cells treat patients with severe aplastic anemia
48351701|NCT02655263|OTHER|Ketone bodies|ketone bodies infusion
48504006|NCT06633328|OTHER|Allogeneic hematopoietic stem cell transplantation|In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with severe aplastic anemia
48504007|NCT04808336|OTHER|PRP injection.|Group 1: thirty patients were injected in the facet joint capsule with a series of three ultrasound-guided PRP injections at four-week intervals,
48504008|NCT04808336|PROCEDURE|fixation surgical procedure|Group 2: thirty patients underwent surgery
48504009|NCT00134004|DRUG|cyclophosphamide|
48504010|NCT00134004|DRUG|fludarabine phosphate|
48687924|NCT01662557|BEHAVIORAL|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
48504011|NCT00134004|DRUG|mycophenolate mofetil|
48504012|NCT00134004|DRUG|tacrolimus|
48662122|NCT04585178|DEVICE|Biobeat patch|"The Biobeat device (BB-613WP) is a class IIa medical device and is a non-invasive patch used for monitoring vital signs in clinical and non-clinical settings. The sensor continuously records the photoplethysmographic waveform that allows the calculation of several physiological parameters: heart rate (HR), SPO2, systolic blood pressure (SBP) and change in SBP, diastolic blood pressure (DBP) and change in DBP, stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), and respiration rate (RR).~Translated with www.DeepL.com/Translator (free version)"
48002616|NCT01070316|DRUG|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
48141041|NCT05277454|DRUG|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
48141042|NCT02216084|DRUG|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
48351702|NCT01118585|PROCEDURE|TIF Procedure|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
48351703|NCT05399160|BEHAVIORAL|Nurse-led Supportive Care|Nurse-led supportive care was given to women who had breast surgery and planned to receive chemotherapy. Nurse-led supportive care was applied to women for eight weeks in the form of face-to-face clinic and telephone interviews.It took an average of 30 minutes to interview women with breast cancer at the clinic, and 15 minutes on average by phone.
48504013|NCT00134004|PROCEDURE|allogeneic bone marrow transplantation|
48504014|NCT00134004|RADIATION|radiation therapy|
48504015|NCT05575258|OTHER|44-Day Diet Conventionally Sourced - YELLOW Diet|Food for the conventional diet will be sourced from local grocery stores (non-organic produce) around Logan, UT, USA.
48504016|NCT05575258|OTHER|44-Day Diet Agro-Ecologically Sourced - GREEN Diet|Food for the agro-ecological diet will be sourced predominantly from the Greenacres farm (Cincinnati, OH, USA) and a limited number of other retailers that sell select foods from agro-ecological producers (Seal the Seasons, General Mills, Pecan Shop, Sol Simple).
48504017|NCT05632328|DRUG|AGEN1423|via IV, dosage per protocol, once every 2 weeks for up to 8 weeks
48504018|NCT05632328|DRUG|Botensilimab|via IV, dosage per protocol, once evert 2 weeks, up to 2 years
48504019|NCT05632328|DRUG|Gemcitabine|per standard care
48504020|NCT05632328|DRUG|Nab-paclitaxel|per standard care
48662123|NCT00916916|OTHER|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
48662124|NCT00654355|DRUG|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
48662125|NCT06384963|DEVICE|Atrial pacing with respiratory sinus arrhythmia (RSA) variability|The intervention in this study is a modification of the pacing output from a standard external pacemaker such that it will approximate the RSA variation found in healthy subjects. A pacemaker (PACE204, Osypka Medical AG), similar to those currently in common use in post-CABG patients, will be adapted to receive an additional input signal based on the respiratory signal (Ceryx device). The respiration signal will be combined with the ECG signal to determine the appropriate pacing interval. The pacing impulse will be delivered by the pacemaker unit.
48662126|NCT06384963|DEVICE|Monotonic right atrial overdrive pacing|Pacing is delivered by a PACE204 pacemaker (Osypka Medical AG) delivering standard monotonic right atrial pacing
48662127|NCT03331887|PROCEDURE|E-max CAD endocrown|endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
48504021|NCT00284024|DRUG|domperidone|
48504022|NCT05023837|DRUG|Pembrolizumab 100 MG Injection|Pembrolizumab iv 200mg q21d
48504023|NCT06388967|DIAGNOSTIC_TEST|PANcreatic cancer Exosome Early detectiON (PANXEON)|This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it
48141043|NCT02322372|DRUG|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
48141044|NCT02322372|DRUG|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
48351704|NCT05353907|RADIATION|Whole Body MRI|Once recruited, the participant will undergo a WB-MRI scan as part of their usual standard-of-care. As part of the research study, the participant will be consented to undertake an additional WB-DECT research scan at a time of their choosing (on the same day as the MRI scan, or on another day, if preferred)
48504024|NCT01144507|PROCEDURE|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
48504025|NCT01144507|OTHER|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
48351705|NCT04040166|DIAGNOSTIC_TEST|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
48504026|NCT04792762|OTHER|GIP(1-30)NH2|Intravenous administration of the peptide hormone GIP(1-30)NH2 during a stepwise glucose clamp
48504027|NCT04792762|OTHER|GIP(1-42)|Intravenous administration of the peptide hormone GIP(1-42) during a stepwise glucose clamp
48504028|NCT04792762|OTHER|Saline|Intravenous administration of saline during a stepwise glucose clamp
48504029|NCT01085123|DRUG|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
48662128|NCT03331887|PROCEDURE|E-max CAd crowns retained with fiber reinforced composite post|fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
48141045|NCT01052766|PROCEDURE|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (\~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
48141046|NCT01293292|DRUG|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
48662129|NCT00062764|DRUG|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
48662130|NCT04217317|DRUG|CPI 613|CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.
48662131|NCT04217317|DRUG|Bendamustine|Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
48141047|NCT05443698|DEVICE|Transvaginal ultrasound|Adult women in the U.S. who are eligible for the ultrasound trial on the basis of the inclusion/exclusion criteria will complete an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
48662132|NCT04066959|BEHAVIORAL|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
48662133|NCT04066959|BEHAVIORAL|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
48662134|NCT04066959|BEHAVIORAL|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
48662135|NCT06526234|DEVICE|MRI|MR enterography
48662136|NCT05129306|OTHER|Observational|In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
48662137|NCT03465683|OTHER|ESBL-producing Enterobacteriaceae|Data and biological sample collection
48141048|NCT04130282|BIOLOGICAL|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
48141049|NCT05037305|OTHER|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
48141050|NCT01275859|DRUG|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
48141051|NCT01524497|DRUG|Trazodone|75mg tablet/150 mg tablet
48662138|NCT03087071|OTHER|Laboratory Biomarker Analysis|Correlative studies
48662139|NCT03087071|BIOLOGICAL|Panitumumab|Given IV
48141052|NCT01524497|DRUG|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
48141053|NCT04851665|OTHER|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
48141054|NCT02169414|DRUG|BIA 9-1067 5 mg|OPC, Opicapone
48141055|NCT02169414|DRUG|BIA 9-1067 25 mg|OPC, Opicapone
48141056|NCT02169414|DRUG|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
48141057|NCT02169414|DRUG|Placebo|PLC, Placebo
48002617|NCT01622855|BEHAVIORAL|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
48351706|NCT03380169|OTHER|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
48351707|NCT03380169|OTHER|Prophylactic conventional wound dressing|Conventional gauze dressing
48351708|NCT05829915|DEVICE|ROXPro© system (A-Champs)|The intervention consisted in 24 sessions (3/week) of a cognitive-multisensory-physical exercise program carried out in the patient's own home. The exercise program was designed by qualified personal trainers and psychologists, and implemented with the ROXPro© system (A-Champs) (https://a-champs.com; accessed on 8 January 2022). This system consists of small devices that provide visual, auditory and vibration stimuli with which the patient interacts. Through its mobile application, it allows the development of numerous sensory-cognitive-motor exercises adapted to the characteristics of the patients.
48351709|NCT05829915|OTHER|No exercise program|The control group did not received the physical exercise program
48351710|NCT03298048|BIOLOGICAL|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
48662140|NCT03087071|DRUG|Trametinib|Given PO
48662141|NCT03493152|DRUG|Everolimus|mTOR inhibitor
48662142|NCT03670472|OTHER|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
48662143|NCT00441324|PROCEDURE|recombinant human LH|
48662144|NCT00378092|DRUG|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
48662145|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
48662146|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
47985708|NCT06403995|BEHAVIORAL|Recommended, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
48351711|NCT03298048|BIOLOGICAL|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
48351712|NCT03298048|BIOLOGICAL|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
48662147|NCT06306183|DIETARY_SUPPLEMENT|Acetaminophen and Vitamin C with Naproxen rescue|"900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
48662148|NCT06306183|OTHER|Acetaminophen and Placebo with Naproxen rescue|"Placebo taken orally twice a day (one in the morning and one in the evening) for a 7-day period after ED discharge for the treatment arm used in combination with extended-release acetaminophen 650 mg two pills every eight hours regularly.~Naproxen 500mg as rescue medication if still in pain 60 minutes after treatment with acetaminophen."
48662149|NCT00674102|DRUG|ASA404|
48141058|NCT02169414|DRUG|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
48351713|NCT03793790|BEHAVIORAL|Conditioning with partial reinforcement|Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
48351714|NCT03793790|BEHAVIORAL|Conditioning with continuous reinforcement|During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
48351715|NCT03793790|BEHAVIORAL|Counterconditioning|During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
48504030|NCT01085123|DRUG|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
48662150|NCT01461460|DRUG|TR-701 FA 1200 mg|6 tablet of T-701 FA
48662151|NCT01461460|DRUG|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
48662152|NCT01461460|DRUG|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
48662153|NCT01461460|DRUG|Placebo|6 placebo tablets
48662154|NCT06564571|DEVICE|Patients undergoing endoscopic ultrasound procedures|Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
48662155|NCT02480049|DRUG|Asmakast|1 tablet contains 10 mg of montelukast
48662156|NCT02480049|DRUG|Singulair|1 tablet contains 10 mg of montelukast
48662157|NCT03961672|DRUG|Duvelisib|Given PO
48662158|NCT01537432|DRUG|secukinumab|secukinumab
48662159|NCT01537432|DRUG|placebo|placebo comparator
48141059|NCT02246699|DEVICE|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
48141060|NCT02246699|OTHER|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
48141061|NCT05948995|DEVICE|Abduction external rotation brace|Abduction external rotation brace Arm position : Abduction , External rotation
48351716|NCT03793790|BEHAVIORAL|Extinction|During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
48351717|NCT03793790|BEHAVIORAL|Sham Conditioning|In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
48504031|NCT04331938|DRUG|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
48504032|NCT05209594|BEHAVIORAL|Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth|The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
48141062|NCT03658603|PROCEDURE|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
48141063|NCT03658603|PROCEDURE|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
48504033|NCT05209594|BEHAVIORAL|Standard GSA Programming|Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
48504034|NCT03326713|BEHAVIORAL|Telephone Counseling & Navigation (TCN)|A health coach will conduct a 15-30 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
48618312|NCT02772731|PROCEDURE|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
48351718|NCT05939700|DRUG|Mavacamten|Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
48141064|NCT03351400|BIOLOGICAL|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
48351719|NCT03426644|BEHAVIORAL|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
48662160|NCT04468360|BEHAVIORAL|3-day differential fear conditioning, extinction, and extinction retention testing paradigm|Day 1: Fear acquisition involving the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a conditioned stimuli (CS) (Expts. 1 and 2). The CS will be different colored shapes appearing on a computer monitor. An auditory stimulus will serve as the startle probe. Day 2: Either extinction training (Expt. 1) or fear memory reactivation by a single CS+ with no US (Expt. 2) will occur followed by IV Allo vs. IV placebo administration. Day 3: The effects of IV Allo vs. IV placebo (administered on Day 2) on extinction retention (Expt. 1) or reconsolidation blockade (Expt. 2), as well as reinstatement of conditioned fear (Expts. 1 and 2) will be assessed.
48662161|NCT04468360|DRUG|Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
48662162|NCT04468360|OTHER|Matching IV Placebo|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of the matching placebo formulation will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of the matching placebo formulation will be infused over 30 minutes immediately following presentation of a single CS+.
48662163|NCT03224884|PROCEDURE|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
48662164|NCT03224884|PROCEDURE|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
48662165|NCT03145220|DRUG|EA-230|Active intervention
48141065|NCT04386538|BEHAVIORAL|Low Starch Diet (LSD)|6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.
48141066|NCT04386538|BEHAVIORAL|General healthy eating|6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
48141067|NCT03305172|BEHAVIORAL|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
48141068|NCT02068053|DRUG|[14C] BMS-986020|
48141069|NCT03744052|OTHER|Motivational Messages|Messages regarding physical activity will be texted to participants.
48141070|NCT06146634|BEHAVIORAL|Hazard Perception Training|The hazard perception training is comprised of three modules. Each module is comprised of four scenarios. Each hazard perception scenario has two activities. The entire training is expected to take approximately an hour to complete.
48141071|NCT06146634|BEHAVIORAL|Vehicle Maintenance Training|For participants randomized into the placebo group, they will receive a brief training on vehicle maintenance using a series of short videos. These videos describe regular checks that drivers should do, such as checking windshield wiper fluid levels, and how to change engine oil. Altogether the videos will last approximately 1 hour.
48141072|NCT06146634|BEHAVIORAL|Attention Maintenance Training|The attention maintenance training is comprised of three modules. Each module is comprised of four scenarios, with each scenario corresponding to one activity. The entire training is expected to take approximately an hour to complete.
48141073|NCT06510244|DEVICE|EEG EMOTIV|The teeth will be dried with 2x2 gauze; then, Endo Ice will be applied. The patient response will be written on a sheet numbering to choose from 0 to 10, and at the same time, the brain waves will be recorded through EEG.
47985709|NCT06403995|BEHAVIORAL|Recommended, directed Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
48141074|NCT02114515|BEHAVIORAL|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
47985710|NCT06228040|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
48141075|NCT02114515|BEHAVIORAL|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
48141076|NCT02114515|BEHAVIORAL|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
48141077|NCT03075878|DRUG|ALXN1830|Administered via IV infusion.
48141078|NCT05582824|OTHER|Blood and urine test|Daily blood and urine samples
47985711|NCT06228040|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
48141079|NCT05224232|DEVICE|Access Socket|During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
48141080|NCT05224232|DEVICE|Rigid socket|During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
47985712|NCT05417945|DEVICE|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
47985713|NCT04262505|BEHAVIORAL|Mediterranean Diet Group|Participants will be advised to follow a traditional Mediterranean diet
47985714|NCT04262505|BEHAVIORAL|Healthy Eating Group|Participants will be advised to follow the Healthy Eating Guidelines in Ireland
48504035|NCT03326713|BEHAVIORAL|Mailed Targeted Print (TP)|Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
48504036|NCT03326713|OTHER|Usual Care (UC)|A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
48504037|NCT03694327|DEVICE|CT-101-M|Mobile Application
48504038|NCT03694327|DEVICE|QuitGuide|Mobile Application
48504039|NCT03914911|DEVICE|Smart Biopsy Device|The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
48504040|NCT04855149|OTHER|Patient satisfaction|Patient satisfaction evaluated with EVAN LR questionnaire
47985715|NCT05545566|PROCEDURE|Thoracic ultrasound versus chest X-ray|"Perform un ultrasound test, in addition to Chest X-Ray (usual practice), few hours after the surgery (D0), the next day (D1) and 4 to 6 hours after drain removal.~The data are collected in the standardized protocol for the two type of imaging.~The thoracic ultrasound and the Chest X-Ray are performed, blindly each other, in the same position for the patient and the same suction level of drain."
47985716|NCT05395468|OTHER|photographs of each eye|All subjects included will take 5 photographs of each eye according to a standardised procedure in terms of distance, lighting and framing
48504041|NCT02186834|DRUG|Selinexor|Selinexor orally as outlined in the study treatment arm.
48504042|NCT02186834|DRUG|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
48662166|NCT03145220|OTHER|Placebo (NaCl)|Placebo intervention
48662167|NCT04881084|OTHER|Digital storytelling group|Participants (intervention- group 1) will watch digital stories, short videos describing the experience of recovering from mental illness created as part of this project. Participants in the control group (group 2) will watch social marketing and/or fundraising campaigns on similar topics and complete a few questionnaires. The following standardized scales will be used: The Level of Familiarity Scale (LOF) (which will be used only before exposure to movies); Toronto Empathy Questionnaire (16 items; internal consistency coefficient .79; test-retest reliability coefficient .73), Compassionate Love Scale (21 items; Cronbach's alpha: .95; item-to-total correlations ranging from .46 to .81), Dispositional Positive Emotions Scale (DPES) (5 items; Cronbach's alpha for the compassion subscale: .80; inter-scale correlations: .44), Self-Stigma of Mental Illness Scale-Short Form (SSMIS-SF) (20 items; Cronbach's alpha: 0.91); Difference and Disdain Scales for Public Stigma (DDSPS) (9 items).
48662168|NCT04881084|OTHER|Social marketing/fundraising group|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
48662169|NCT01784484|OTHER|No intervention|
48662170|NCT02340195|DRUG|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
48141081|NCT03956407|DEVICE|Repetitive peripheral nerve stimulation|Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
48504043|NCT02186834|DRUG|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
48504044|NCT01535092|DRUG|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
47985717|NCT00810407|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
48504045|NCT01535092|DRUG|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
48504046|NCT02657265|DEVICE|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
48504047|NCT02657265|DEVICE|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
48504048|NCT00004137|BIOLOGICAL|filgrastim|
48504049|NCT00004137|DRUG|carboplatin|
48504050|NCT00004137|DRUG|paclitaxel|
48504051|NCT00004137|DRUG|topotecan hydrochloride|
48662171|NCT02014376|DRUG|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
48662172|NCT02014376|DRUG|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
48662173|NCT02014376|DRUG|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
48662174|NCT06225206|BEHAVIORAL|donor-derived cell free DNA in liver|Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant \<1 year PTX and \>1 year PTX
48662175|NCT03430999|DRUG|Calmangafodipir|Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
48662176|NCT03430999|DRUG|Placebo|Placebo
48662177|NCT02116023|OTHER|Orange flavored beverage|
48662178|NCT06266546|DRUG|Tranexamic acid|Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
48662179|NCT01343472|BEHAVIORAL|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
47985718|NCT03736291|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
47985719|NCT00739544|OTHER|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
48141082|NCT03956407|DEVICE|Sham Repetitive peripheral nerve stimulation|Sham repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For sham stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
48662180|NCT01343472|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
48662181|NCT03990987|OTHER|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
48662182|NCT05599100|BEHAVIORAL|STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)|For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
48662183|NCT01869673|DEVICE|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
48662184|NCT01869673|DEVICE|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
48662185|NCT03257501|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
48662186|NCT01446523|DRUG|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
48662187|NCT01446523|DRUG|Lactulose|Syrup 30 ml BD for 12 weeks
48662188|NCT01115504|DRUG|Thiamine|300 mg daily for 30 days
48662189|NCT02640300|DRUG|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
48662190|NCT03100279|BEHAVIORAL|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, \& Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
48687925|NCT01662557|OTHER|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
47985720|NCT05913180|DRUG|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
48141083|NCT00783146|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
48141084|NCT00783146|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
48141085|NCT00783146|DRUG|placebo|placebo, once daily for 15 days
48504052|NCT05053334|DRUG|Omalizumab Prefilled Syringe|150mg/ml of Omalizumab prefilled syringe
48141086|NCT01008787|BEHAVIORAL|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
48141087|NCT01008787|BEHAVIORAL|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
47985721|NCT05913180|DRUG|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
48141088|NCT01008787|BEHAVIORAL|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
48141089|NCT01008787|BEHAVIORAL|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
47985722|NCT05808491|RADIATION|online resilience intervention|online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
47985723|NCT00108667|DRUG|IV Levodopa|
48367528|NCT02114905|BEHAVIORAL|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
48504053|NCT04292665|BEHAVIORAL|Classical Massage|During the first interview, a booklet explaining the introduction, purpose, benefits and application steps of hand-foot massage will be given to the patients in the classical massage group. Hand and foot massage will be applied to the patients for 30 minutes in the form of right hand five minutes, left hand five minutes, right foot ten minutes, left foot ten minutes, using liquid vaseline in each session twice a day in the patient's own bed with individual applied sessions by the researcher. Patients will receive a total of 14 sessions of classical massage, twice a day, for seven days.
48618313|NCT06408597|PROCEDURE|Nitroglycerin Infusion|"Nitroglycerin prepared using a vial (50 mg nitroglycerin) transferred into a 500 ml glass bottle of sodium chloride injection (0.9%), this yields a concentration of 100 mcg/ml.~Patients in the nitroglycerin group will receive nitroglycerin infusion at a rate of 0.25 mic/kg/min all through the surgery, to be discontinued in the PACU."
48662191|NCT03100279|BEHAVIORAL|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
48662192|NCT04863404|OTHER|Face mask with hybrid-hyrax|Face mask with hybrid-hyrax
48662193|NCT04863404|OTHER|Face mask with conventional bonded RME|Face mask with conventional bonded RME
48662194|NCT01683812|DEVICE|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
48662195|NCT00004200|DRUG|prinomastat|
47985724|NCT00108667|DRUG|Talampanel|
47985725|NCT03415841|DEVICE|mHealth remote monitoring devices|"Blood Pressure and wearable vital signs monitor, Biovotion and Kardia mobile application"
47985726|NCT01427894|OTHER|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
47985727|NCT01603459|DRUG|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
47985728|NCT00756639|RADIATION|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
47985729|NCT00756639|OTHER|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
48662196|NCT00004200|DRUG|temozolomide|
48662197|NCT02106806|DIETARY_SUPPLEMENT|Zinc|35 mg of elemental zinc twice daily for 16 weeks
48662198|NCT02106806|OTHER|Placebo|One capsule, twice daily for 16 weeks
48662199|NCT00834574|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
48662200|NCT00834574|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
48662201|NCT03290027|DRUG|DFD-03|DFD-03 Lotion
48662202|NCT03290027|OTHER|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
48662203|NCT01965847|BEHAVIORAL|Medication therapy management|
47985730|NCT00649623|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
47985731|NCT00649623|DRUG|Benicar® Tablets 40 mg|40mg, single dose fasting
47985732|NCT04097808|DIETARY_SUPPLEMENT|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
47985733|NCT00753558|DRUG|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
47985734|NCT05321732|DRUG|DWP16001|DWP16001 A mg
47985735|NCT05321732|DRUG|DWP202010|DWP202010 B mg
47985736|NCT01928329|DRUG|Exenatide (Bydureon®)|
47985737|NCT01928329|DRUG|Placebo|
47985738|NCT05814939|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
48662204|NCT05005416|BEHAVIORAL|GOALS Intervention|Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.
48618314|NCT06408597|PROCEDURE|Mannitol Infusion|"Mannitol will be prepared through diluting 100 ml of the 20% solution with 180 ml of sodium chloride injection (0.9%).~Patients in the mannitol group will receive an infusion bolus of mannitol 20% 0.5gm/kg added to the standard fluid chart via centeral line.~Mannitol intake will be started directly after induction of anaesthesia and before intra-peritoneal gas insufflation, as an infusion over 15 minutes."
48662205|NCT05005416|BEHAVIORAL|Usual Care Physical Therapy|Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
48662206|NCT06052592|OTHER|Milk|Newborns will be fed with breast milk, formula milk or postbiotic formula milk
48662207|NCT05851963|DEVICE|Sonicare Diamond Clean 9000|Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment
47985739|NCT05814939|DRUG|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
47985740|NCT05814939|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
47985741|NCT05624203|DEVICE|Extracorporeal cardiac shock wave therapy(ECSW)|Extracorporeal cardiac shock wave therapy (CSWT) is a cutting-edge technology developed in the world for more than 20 years. It is mainly used in the treatment of refractory angina pectoris of coronary heart disease. The mechanism of extracorporeal cardiac shock wave therapy is mainly due to the small attenuation, small shear stress and strong penetration force of shock wave when propagating in human tissues. Shear stress and hole effect are generated in the focal area of shock wave, which leads to the repeated formation/rupture of microbubbles in tissue/cell microenvironment, resulting in various physical and biological effects. These physical mechanisms trigger a series of biological effects, such as promoting the expression of various intracellular cytokines and angiogenic factors, activating related signal transduction pathways, inhibiting apoptosis and oxidative stress, and finally increasing the number of new blood vessels in the treatment area and improving the ischemic state.
47985742|NCT05142865|DRUG|Camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
47985743|NCT05142865|DRUG|Etoposide|100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
47985744|NCT05142865|DRUG|Carboplatin|AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)
47985745|NCT05142865|DRUG|Cisplatin|25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
47985746|NCT05142865|DRUG|Apatinib|250 mg given orally, once daily in 21-day cycle
47985747|NCT05553002|OTHER|Deneroll cervical extension traction|"Participants will lie flat on their back on the ground with their legs extended and arms by their sides. The denneroll will placed on the ground and positioned in the posterior aspect of the neck depending on the area to be addressed . The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements:~1. In the upper cervical region (C2-C4) region.~2. The apex of the Denneroll orthotic is placed in the mid-cervical region (C4-C6) region.~3. The apex of the Denneroll orthotic is placed in the upper thoracic lower-cervical region (C6-T1) region."
47985748|NCT05553002|OTHER|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions
47985749|NCT06530342|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in all athletes.
47985750|NCT00643032|PROCEDURE|Transcutaneous iliohypogastric|
47985751|NCT00643032|PROCEDURE|Perioperative administration near the nerve|
47985752|NCT00391274|DRUG|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
47985753|NCT00391274|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
47985754|NCT05034770|OTHER|major ozone autohemotherapy|This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.
47985755|NCT02286505|DEVICE|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
47985756|NCT02286505|OTHER|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
47985757|NCT01060930|DRUG|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
47985758|NCT01334268|DEVICE|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
47985759|NCT01334268|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
47985760|NCT05487781|COMBINATION_PRODUCT|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
48141090|NCT04778813|DRUG|Artemether-lumefantrine|In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
48141091|NCT01858324|OTHER|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
48141092|NCT02541305|OTHER|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
48141093|NCT02541305|OTHER|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
48504054|NCT04292665|BEHAVIORAL|Benson Relaxation Exercise|During the first interview, patients will be given a booklet explaining the description, purpose, benefits and application steps of the Benson relaxation exercise. With individual counseling sessions, a total of 14 sessions of Benson relaxation exercises will be performed in a quiet room, twice a day for seven days, each session lasting 20 minutes. At the beginning of the application, patients will focus on their breaths by taking slow and natural breaths with the researchers' commands and will quietly say to yourself the words of the focus, sound, sentence or prayer they choose, which are meaningful to them.
48504055|NCT04292665|OTHER|Control|Patients will continue to receive standard nursing care and no further intervention will be made during the research.
48662208|NCT05851963|DEVICE|HydroSonic Pro|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
48662209|NCT05851963|DEVICE|Oral-B 123|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
48662210|NCT05851963|DEVICE|Curaprox CS 5460|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
48662211|NCT00122473|DRUG|Imatinib (Glivec)|
48141094|NCT00927966|DRUG|RAD001|Taken orally once a day.
48141095|NCT00927966|DRUG|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
48141096|NCT02123940|DEVICE|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
48662212|NCT00809822|DRUG|NPB-01|Intravenous immunoglobulin
48141097|NCT04910256|DRUG|HuaTuo Zaizao pill|Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
48141098|NCT04910256|OTHER|basic treatment|"It accordance with the Guidelines for diagnosis and treatment of ischemic stroke in China,and the drug and dosage will be formulated by the researchers according to the clinical situation."
48141099|NCT02499601|DEVICE|CORolla™ TAA device|
48141100|NCT01249638|DRUG|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
48141101|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
48141102|NCT01249638|DRUG|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
48141103|NCT01249638|DRUG|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
48662213|NCT00809822|DRUG|Placebo|Physiological saline
48504056|NCT01293539|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (\>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
48662214|NCT03707821|DEVICE|senofilcon A TEST Lens|JJVC Investigational Contact Lens
48662215|NCT03707821|DEVICE|senofilcon A CONTROL Lens|Acuvue Oasys
48662216|NCT05994846|DEVICE|RISES-T System|The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
48662217|NCT03320005|OTHER|Resistance training group|Resistive exercises for legs and arms
48662218|NCT03336229|BEHAVIORAL|Exercise intervention|Graduated walking programme, strengthening exercises and respiratory muscle training.
48662219|NCT06228378|OTHER|Raman microspectroscopy|Raman microspectroscopy is a non-destructive method for observing and characterising the molecular composition and external structure of a biological sample based on the phenomenon of inelastic light scattering (Raman effect).
48662220|NCT00005830|DRUG|Doxorubicin Hydrochloride|Given IV
48662221|NCT00005830|DRUG|Cisplatin|Given IV
48662222|NCT00005830|RADIATION|Radiation Therapy|Undergo radiation therapy
48687926|NCT02396108|DRUG|Paclitaxel + Carboplatin + ASLAN001|"Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
48687927|NCT05720052|DRUG|MS-553|MS-553 oral tablet BID x 28-days
48662223|NCT04605250|OTHER|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
48662224|NCT04103450|DRUG|Vibegron|oral administration
48662225|NCT01497730|DEVICE|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
48662226|NCT03064009|OTHER|Infection|This is an observational trial
48662227|NCT03931551|DRUG|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
48141104|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
48141105|NCT05643521|OTHER|Dietary composition of macronutrients and calories|Carbohydrate restriction
48504057|NCT03207737|BEHAVIORAL|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
48504058|NCT03207737|BEHAVIORAL|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
48504059|NCT00006043|DRUG|temozolomide|
48662228|NCT04728425|DRUG|subcutaneous immunoglobulin (SCIG)|20% subcutaneous immunoglobulin
48662229|NCT04728425|DRUG|intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)|10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin
48662230|NCT00321932|DIETARY_SUPPLEMENT|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
48662231|NCT00321932|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
48687928|NCT03979469|DRUG|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
48687929|NCT03979469|DRUG|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
47985761|NCT02425150|PROCEDURE|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
48141106|NCT04266496|OTHER|Questionnaires|ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
48141107|NCT04266496|DIAGNOSTIC_TEST|Frequency Volume Chart|Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
48141108|NCT04266496|DIAGNOSTIC_TEST|Collect urine during 1 day|Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested
48141109|NCT04266496|DIAGNOSTIC_TEST|Blood sample|Blood collection to measure plasma sodium and osmolality.
48141110|NCT04266496|DIAGNOSTIC_TEST|Measurement of the circumference of the lower legs|"Circumference of the lower legs wil be measured twice:~* After awakening, when still laying dowing in bed~* Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus"
48662232|NCT00321932|DRUG|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
48662233|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (Low dosage)|Deferiprone DR tablets 1000 mg
48504060|NCT03878667|DIETARY_SUPPLEMENT|Curves Calcium|Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
48504061|NCT03878667|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium (providing 950 mg/d as carbonate)
48662234|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (High dosage)|Deferiprone DR tablets 1000 mg
48662235|NCT02643485|PROCEDURE|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
48662236|NCT05391555|DRUG|Remifentanil Hydrochloride|Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes. Pupillary measurements will be taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
48504062|NCT03878667|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
48504063|NCT02873741|PROCEDURE|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
48504064|NCT02873741|PROCEDURE|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
48662237|NCT05391555|DEVICE|Pupillometry measurement|The pupil will be examined with the pupillometer at regular intervals, before during and after the opioid infusion
48662238|NCT06376825|BEHAVIORAL|MyLife: An internet-based self-help program to reduce burnout|MyLife is a internet-based and Acceptance and Commitment Therapy oriented self-help program to reduce burnout. In this study a tailored to teachers version of the program will be used.
48662239|NCT01695603|DEVICE|Intellivent|
48662240|NCT06564792|BEHAVIORAL|Contingency management|Once weekly contingency management visit involving 15 minutes+ of motivational interviewing and provision of incentives for stimulant-negative urine tests and/or tenofovir-positive urine tests.
48662241|NCT06486402|OTHER|participation rate|participation rate
48687930|NCT02940899|OTHER|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
48687931|NCT00500357|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
48687932|NCT06203938|DEVICE|Transcranial infrared light stimulation|Trancranial infrared light stimulation administered via light-emitting diodes
48687933|NCT06203938|DEVICE|Sham|Identical to TILS, but with lights off
48687934|NCT02565147|PROCEDURE|PPCI|PPCI for treatment of participants presenting with large STEMI.
48504065|NCT02873741|PROCEDURE|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
48504066|NCT02873741|PROCEDURE|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
48504067|NCT00951496|BIOLOGICAL|Bevacizumab|Given IV
48504068|NCT00951496|DRUG|Carboplatin|Given IV
48504069|NCT00951496|DRUG|Carboplatin|Given IP
48504070|NCT00951496|DRUG|Cisplatin|Given IP
48504071|NCT00951496|OTHER|Laboratory Biomarker Analysis|Correlative studies
48504072|NCT00951496|DRUG|Paclitaxel|Given IV
48504073|NCT00951496|DRUG|Paclitaxel|Given IP
48504074|NCT00951496|OTHER|Quality-of-Life Assessment|Ancillary studies
48504075|NCT01866098|DRUG|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
48141111|NCT02045498|DEVICE|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
48351720|NCT04252391|PROCEDURE|Perineural electrical dry needling|Standard care plus use of perineural electrical dry needling involving use of a monofilament needle of 15 or 30 mm length, 0.25 mm diameter will be placed utilizing the therapist's dominant hand following palpation of correct needle location. An electrical stimulation unit will be used to conduct an electrical impulse. The unit used will be an ES-130 by ITO (Japan) using a DC 9V battery producing an asymmetrical biphasic waveform. The unit has 6 available leads with alligator clamps, connecting to needle shafts. Parameters of PNED will include intensity set at a strong yet comfortable setting according to patient feedback. Treatment duration will be 15 minutes. Treatment frequency will be set to Medium at level 8 (80 Hz). Parameters will be set to elicit a sensory response.
47985762|NCT02425150|PROCEDURE|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
48141112|NCT02109913|DRUG|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
48141113|NCT03153306|DRUG|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
48351721|NCT04252391|PROCEDURE|Standard Care|cervical or thoracic manipulation or mobilization, muscle stretching, muscle strengthening, electrical trigger point dry needling , soft tissue release and prescribed therapeutic exercises .
48351722|NCT01100658|DRUG|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
48141114|NCT05832593|OTHER|Immunohistochemistry|Immunohistochemical expression of ERCC1
48141115|NCT01584674|DEVICE|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
48141116|NCT05146635|DRUG|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
48141117|NCT05146635|DRUG|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
48351723|NCT01100658|DRUG|Placebo|1 capsule per day for 1 week.
48351724|NCT03710291|DRUG|TRC101|Oral, non-absorbed, polymeric hydrochloric acid binder
48504076|NCT01866098|DRUG|Placebo|
47985763|NCT01455337|DRUG|pentoxifylline|400mg tid
47985764|NCT01455337|DRUG|Prednisolone|40mg qd
47985765|NCT06235788|BEHAVIORAL|Experimental Group ICEMS verbal feedback with pause group|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
47985766|NCT06235788|BEHAVIORAL|Experimental Group ICEMS audio feedback with pause and expert video|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
48141118|NCT03080805|DRUG|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
48141119|NCT03080805|DRUG|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
48141120|NCT04820491|DIAGNOSTIC_TEST|X-Ray|Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction
48351725|NCT03710291|DRUG|Placebo|Placebo comparator
48351726|NCT02477540|DRUG|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20\~25℃~Injection Method: Intramuscular"
48351727|NCT05087563|DEVICE|Neurolens spectacle lens|spectacle lens
48504077|NCT02131961|DRUG|Collagenase ointment|250 collagenase units/g
48504078|NCT02131961|DEVICE|Modified Contact Cast System|1 Unit
48141121|NCT04820491|DIAGNOSTIC_TEST|Ultrasound|Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
48687935|NCT02565147|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
48141122|NCT05357677|DRUG|SR419|SR419 capsule
48141123|NCT00481572|DRUG|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
48141124|NCT00481572|DRUG|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
48687936|NCT02565147|DRUG|Heparin|Heparin is an anticoagulant.
48687937|NCT04648488|OTHER|Experimental early mobilisation|early activ assisted exercises treatment
48141125|NCT00481572|DRUG|Norepinephrine|titrated norepinephrine over a period of 48 hrs
48141126|NCT04796792|DEVICE|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
48141127|NCT03560804|DRUG|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
48141128|NCT03560804|DRUG|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
48141129|NCT04070105|DEVICE|Compliant Adaptive Energy Storage and Return Foot|The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
48141130|NCT04070105|DEVICE|AllPro|Participants will be fit with a high activity foot designed to be used for walking and running
48141131|NCT01814605|PROCEDURE|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
48141132|NCT01814605|PROCEDURE|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
48141133|NCT00777894|RADIATION|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
48351728|NCT05087563|DEVICE|Placebo spectacle lens|spectacle lens for refractive correction
48351729|NCT03249441|BEHAVIORAL|Compassion-focused therapy|"Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~__________________________________________________________________________"
48351730|NCT01935570|DRUG|Magnesium chloride (ChronoMag Smart Tablet®)|
48504079|NCT06396767|DIAGNOSTIC_TEST|DIA measured via Ultrasonography|Ultrasound will be used to measure Diaphragmatic Inspiratory Amplitude (DIA) of patients before and after elective cardiac surgery to determine if there is a correlation between changes in DIA and postoperative pulmonary complications.
48504080|NCT05042544|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
47985767|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
47985768|NCT02153112|BIOLOGICAL|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
47985769|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
47985770|NCT02153112|BIOLOGICAL|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
47985771|NCT02153112|DRUG|Placebo|Placebo saline solution
47985772|NCT06242249|BIOLOGICAL|Anti-BCMA CAR-NK|"Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels:~* Dose Level 1: 1×10\^7/Kg~* Dose Level 2: 5×10\^7/Kg~* Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease."
47985773|NCT02350881|DEVICE|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
48351731|NCT01935570|DRUG|Magnesium carbonate (Mag2® Tablet)|
48351732|NCT02676050|OTHER|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
48504081|NCT02934659|DEVICE|Atlas(TM) Knee System|The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
48504082|NCT02123082|DEVICE|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
48504083|NCT02123082|DEVICE|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
48141134|NCT00777894|RADIATION|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
48141135|NCT00777894|RADIATION|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
48141136|NCT05123079|DRUG|Darigabat|Tablets
48141137|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
48141138|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
48141139|NCT04154007|DIAGNOSTIC_TEST|kidney function tests - urine output|"AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output \<0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output \<0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of \<0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy."
48141140|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 0.33 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
48141141|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 1 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
48351733|NCT02676050|DEVICE|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
47985774|NCT05893433|DEVICE|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~1. Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~2. Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
47985775|NCT05893433|OTHER|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
48351734|NCT02676050|DEVICE|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
48351735|NCT02144090|DEVICE|Fractional flow reserve measurement|Fractional flow reserve measurement
48351736|NCT05835167|PROCEDURE|Inferior part-sternotomy|A midline skin incision of 8 to 10cm in length is made over the sternum, starting from 2-3cm below the sternal angle inferiorly and extending slightly beyond the xiphoid process. A sternal saw is used to split the sternum from the xiphoid process to the second intercostal space where the sternum is partially transected by turning the saw rightward.
47985776|NCT05871268|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale response are shared with their physician.
47985777|NCT05871268|OTHER|Usual Care|The patients' pre-visit Control Preference Scale response are not shared with their physician.
47985778|NCT04462003|DRUG|Apixaban|10 mg/12 h for 1 week followed by 5 mg/12 h
48351737|NCT05835167|PROCEDURE|Full median sternotomy|A midline skin incision is made over the sternum, starting from the sternal angle and extending slightly beyond the xiphoid process. The sternum is fully split by a sternal saw.
47985779|NCT04462003|DRUG|Enoxaparin|1mg/Kg/sc/12h
48351738|NCT06407336|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent
48504084|NCT02841163|DRUG|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
48687938|NCT04648488|OTHER|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
48687939|NCT01074476|DIETARY_SUPPLEMENT|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
48141142|NCT06451159|DRUG|Chemotherapy: cyclophosphamide (CYC)|Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
48141143|NCT06451159|DRUG|Chemotherapy: fludarabine (FLU)|Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
48141144|NCT04181099|OTHER|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
48141145|NCT04093609|GENETIC|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
48141146|NCT04284878|GENETIC|PCR-RFLP|PCR-Restriction fragment length polymorphism
48662242|NCT00540631|BIOLOGICAL|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
48662243|NCT02881827|RADIATION|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
47985780|NCT03027726|BEHAVIORAL|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
48141147|NCT01083966|DRUG|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
48141148|NCT00357994|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
48141149|NCT00357994|DRUG|Placebo gel|
48141150|NCT00357994|DRUG|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
48141151|NCT00357994|DRUG|Placebo (PBO) oral capsules|
48141152|NCT00357994|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
48141153|NCT00357994|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
48141154|NCT00357994|DEVICE|J-tube|jejunal tube
48141155|NCT00872248|PROCEDURE|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
48141156|NCT00872248|PROCEDURE|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
48141157|NCT00259792|DRUG|Budesonide/formoterol Turbuhaler|
48351739|NCT06407336|OTHER|Refraction|Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.
48351740|NCT03189563|DRUG|DA-9805 45mg|DA-9805 15mg tid
48351741|NCT03189563|DRUG|DA-9805 90mg|DA-9805 30mg tid
48351742|NCT03189563|OTHER|Placebo|Placebo, tid
48351743|NCT05637073|DRUG|Dienogest|Some women in the cohort will be treated with dienogest for one year after consensus with the physician
48351744|NCT05637073|PROCEDURE|Laparoscopic cystectomy|Some women in the cohort will be treated with laparoscopic cystectomy after consensus with the physician
48351745|NCT05637073|OTHER|Control with ultrasound without other type of intervention|Some women in the cohort will be followed with ultrasound control, without other intervention, after consensus with the physician
48351746|NCT03953040|DIAGNOSTIC_TEST|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
48351747|NCT00369928|DRUG|PG-760564|100 mg BID, of oral PG-760564
48351748|NCT00369928|DRUG|Placebo dose|placebo, BID, oral for 12 weeks
48351749|NCT00369928|DRUG|PG-760564|25 mg BID, of oral PG-760564
48351750|NCT01271595|OTHER|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
48351751|NCT03381352|RADIATION|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
48141158|NCT00927849|PROCEDURE|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
48141159|NCT00927849|DRUG|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
48141160|NCT00927849|DRUG|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
48351752|NCT03381352|DRUG|Capecitabine|Capecitabine 825mg/m2 PO BID
48662244|NCT02881827|OTHER|Placebo|Simulation of treatment with the device switched off
48662245|NCT02881827|OTHER|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
48662246|NCT00581100|DRUG|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
48687940|NCT01074476|OTHER|Placebo|Placebo tablets, twice per day for 3 months
48141161|NCT05329519|BEHAVIORAL|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
48141162|NCT03398668|DEVICE|Relievion device- Treatment stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
48504085|NCT02841163|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
48687941|NCT02388165|BIOLOGICAL|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
48141163|NCT03398668|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
48141164|NCT00686257|DEVICE|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
48141165|NCT00686257|DEVICE|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
48141166|NCT00428714|DRUG|enzastaurin|Administered orally
48141167|NCT02410278|DRUG|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
48141168|NCT02410278|DRUG|montelukast|As described in the treatment arm
48141169|NCT02410278|DRUG|Placebo|Matched placebo
48141170|NCT03794232|DIETARY_SUPPLEMENT|NIUCHANG|
48141171|NCT03794232|DIETARY_SUPPLEMENT|Placebo|
48141172|NCT05716438|RADIATION|Forearm anteroposterior and lateral plain radiograph|2 view plain film of forearm after valving a short arm cast.
48141173|NCT03217123|DEVICE|Deep Brain stimulation|Electrical stimulation at subcortical level
48351753|NCT03381352|DRUG|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
48141174|NCT05127902|DIAGNOSTIC_TEST|Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)|"Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG_max) for comparison with normalization signal processing program in Noraxon System."
48141175|NCT02430766|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
48141176|NCT02430766|DEVICE|NanoKnife|
48141177|NCT03260998|DIAGNOSTIC_TEST|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
48141178|NCT04127552|PROCEDURE|Adrenalectomy|Adrenalectomy accordint to 2016 ESE guidelines
48141179|NCT03691441|PROCEDURE|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
48141180|NCT03691441|RADIATION|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
48141181|NCT03691441|DRUG|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
48141182|NCT03691441|PROCEDURE|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
48141183|NCT00162006|DRUG|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
48141184|NCT00446368|DRUG|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
48141185|NCT02157948|DRUG|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
48141186|NCT02157948|DRUG|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
48351754|NCT04135391|BEHAVIORAL|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
48351755|NCT04002258|DRUG|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
48662247|NCT03923088|BEHAVIORAL|jacobson's progressive muscle relaxation technique|This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
48141187|NCT03287232|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
48141188|NCT03287232|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
48141189|NCT00003984|BIOLOGICAL|lintuzumab|
48141190|NCT01668394|BEHAVIORAL|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
48662248|NCT03923088|BEHAVIORAL|audio-visual distraction technique|audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
48662249|NCT05194332|DEVICE|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
48662250|NCT04038879|DIAGNOSTIC_TEST|MRI|MRI of the heart
48141191|NCT01668394|OTHER|Control arm|Usual care. Teaching style: deductive.
48141192|NCT02424968|BIOLOGICAL|Anti-Thymocyte Globulin|Given per standard institutional practice
48141193|NCT02424968|DRUG|Cyclosporine|Given PO
48662251|NCT06501898|DIETARY_SUPPLEMENT|CoreBiome|300 mg, once daily of tributyrin for 4 weeks
48141194|NCT02424968|DRUG|Mycophenolate Mofetil|Given PO
48141195|NCT02424968|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Undergo nonmyeloablative allogeneic HSCT
48141196|NCT02424968|BIOLOGICAL|Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Receive CD8+ memory T-cells via IV
48662252|NCT06501898|DIETARY_SUPPLEMENT|Placebo|300 mg, once daily of placebo for 4 weeks
48662253|NCT02958865|DRUG|PF-06651600 or Placebo|Delivered orally for 8 weeks.
48141197|NCT02424968|RADIATION|Total Nodal Irradiation|Undergo TLI
48141198|NCT04905784|BEHAVIORAL|Differential learning|The patient will be requested to perform different exercises, each exercise one time a day for 3 days in a row before moving to the next exercise. All patient will be asked to do the exercises in the same sequence.
48141199|NCT04905784|BEHAVIORAL|Usual toothbrushing|The patients in this group will be provided with the regular oral health instructions, including the traditional toothbrushing recommendations.
48141200|NCT04338919|PROCEDURE|Percutaneous coronary intervention|PCI with stent implantation
48351756|NCT03506113|DRUG|Gram stain-guided antibiotic choice|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
48662254|NCT02958865|DRUG|PF-06700841 or Placebo|Delivered orally for 8 weeks.
48662255|NCT02958865|DRUG|PF-06700841|Delivered orally for 24 weeks.
48141201|NCT04338919|DRUG|Ticagrelor plus aspirin|Ticagrelor plus aspirin
48351757|NCT03506113|DRUG|Guidelines-based antibiotics choice|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
48141202|NCT00355745|DEVICE|Ultrasound breast scanning|breast scanning
48141203|NCT00362960|DRUG|Olmesartan medoxomil|
48141204|NCT00362960|DRUG|Losartan|
48141205|NCT02601859|DRUG|Lithium Carbonate|
48141206|NCT01672684|PROCEDURE|support group therapy|Complete at-home group video calling support sessions
48141207|NCT01672684|OTHER|educational intervention|Receive an educational workbook journal
48141208|NCT03056378|BIOLOGICAL|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
48141209|NCT04945538|OTHER|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
48351758|NCT05682326|DRUG|Daprodustat|Daprodustat will be administered up to Week 52.
48351759|NCT00976261|DRUG|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
48351760|NCT00976261|DRUG|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
48351761|NCT00976261|OTHER|Placebo|Comparator
48662256|NCT02958865|DRUG|PF-06651600|Delivered orally for 24 weeks.
48662257|NCT04063202|OTHER|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
48662258|NCT06564428|GENETIC|Suspective gene mutations and family history|To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
48662259|NCT03685149|DRUG|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
48662260|NCT03685149|DRUG|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
48662261|NCT04510311|DRUG|3-[18F]Fluoro-para-hydroxyphenethylguanidine|Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG
48662262|NCT04510311|DRUG|[123I] metaiodobenzylguanidine|Single IV injection of 10.0 mCi \[123I\]MIBG
48662263|NCT04510311|DIAGNOSTIC_TEST|Positron emission tomography/computed tomography scan|Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
47985781|NCT03027726|OTHER|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
47985782|NCT06159712|OTHER|Blood samples|Extra blood samples
48141210|NCT04377191|OTHER|exergame|Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
48141211|NCT04377191|OTHER|exergame|ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
48351762|NCT05631730|DRUG|Flecainide|Flecainide is mainly used for pharmacological conversion in patients with atrial tachyarrhythmias and to suppress ventricular arrhythmias in patients with structurally normal hearts.
47985783|NCT04913025|DRUG|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
48351763|NCT05631730|DRUG|Metoprolol|Metoprolol is a beta-blocker and class II antiarrhythmic drug considered standard care in most cardiac diseases predisposing to ventricular arrhythmias, including arrhythmic mitral valve prolapse.
47985784|NCT04913025|DRUG|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
47985785|NCT00000609|DRUG|amiodarone|
47985786|NCT00000609|DEVICE|defibrillators, implantable|
48351764|NCT01203111|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
48662264|NCT04510311|DIAGNOSTIC_TEST|Planar scintigraphy scan|Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG
48662265|NCT04510311|DIAGNOSTIC_TEST|Single photon emission computed tomography/computed tomography scan|SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
48662266|NCT06565117|DRUG|White yu green skin lotion|Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
48662267|NCT02985723|DEVICE|AT LISA tri toric 939MP|
48662268|NCT06215378|DRUG|Antagonization of heparin with protamine sulfate|A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium
48662269|NCT04876287|DRUG|Radioiodine|cancer therapy
48662270|NCT02903147|BEHAVIORAL|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
48662271|NCT02903147|BEHAVIORAL|The employer's training|
48662272|NCT05192278|OTHER|erector spinae block|The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
48662273|NCT03538847|OTHER|Numerical rating scale|Measure of postoperative pain
48662274|NCT00004128|BIOLOGICAL|aldesleukin|
48662275|NCT00004128|BIOLOGICAL|filgrastim|
48662276|NCT00004128|DRUG|busulfan|
48662277|NCT00004128|DRUG|cyclophosphamide|
48141212|NCT04377191|OTHER|exercise|Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
48141213|NCT06327282|BEHAVIORAL|education on pain and related knowledge|Before surgery, pain related knowledge was educated.
48141214|NCT04813666|DIAGNOSTIC_TEST|Urinary LAM ELISA:|
48141215|NCT01501825|DEVICE|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
48351765|NCT01203111|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
48662278|NCT00004128|DRUG|cytarabine|
48662279|NCT00004128|DRUG|daunorubicin hydrochloride|
48662280|NCT00004128|DRUG|etoposide|
48662281|NCT00004128|PROCEDURE|autologous bone marrow transplantation|
48662282|NCT00004128|PROCEDURE|peripheral blood stem cell transplantation|
48662283|NCT00004128|RADIATION|radiation therapy|
48687942|NCT02388165|OTHER|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
48687943|NCT02291783|DRUG|HTL0009936|Single dose
48687944|NCT02291783|DRUG|HTL0009936 placebo|Placebo single dose
48141216|NCT01501825|DEVICE|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
48141217|NCT01958346|OTHER|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
48141218|NCT01958346|OTHER|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
48141219|NCT01958346|DEVICE|Fiberoptic Intubation|
48141220|NCT01411137|DRUG|IPX066|"Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"
48141221|NCT02108171|DRUG|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
48141222|NCT02108171|DRUG|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
48141223|NCT01229176|BIOLOGICAL|Vi-CRM197 vaccine|
48141224|NCT01229176|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
48504086|NCT02841163|PROCEDURE|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48504087|NCT02841163|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48141225|NCT01229176|BIOLOGICAL|Pneumococcal conjugate vaccine|
48141226|NCT06230588|DRUG|TQH3906 capsule|TQH3906 is a kinase inhibitor.
48141227|NCT06230588|DRUG|TQH3906 placebo|Placebo Comparator
48141228|NCT02333318|DRUG|VVZ-149 injection|Colorless, transparent liquid in water for injection
48141229|NCT02333318|OTHER|Placebo|water for injection
48504088|NCT02841163|PROCEDURE|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
48141230|NCT05991804|OTHER|Transcutaneous spinal cord stimulation added to inpatient rehabilitation|Non-invasive electrical stimulation delivered over the spine, targetting movement of the upper limbs
48141231|NCT05991804|OTHER|Inpatient rehabilitation alone|Standard inpatient rehabilitation given at the Royal National Orthopaedic Hospital NHS Trust
48141232|NCT01686152|DRUG|Imiquimod Cream, 3.75%|
48141233|NCT01686152|DRUG|Zyclara®|
48141234|NCT01686152|OTHER|Vehicle of Test Product|
48141235|NCT01812330|DRUG|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
48141236|NCT01812330|DRUG|Ticagrelor|90mg Bid
48141237|NCT05873205|BIOLOGICAL|Isatuximab|All participants enrolled on the study will receive isatuximab intravenously as a single agent
48141238|NCT03578978|OTHER|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
48141239|NCT02761317|DRUG|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
48141240|NCT02761317|DRUG|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
48141241|NCT02761317|DRUG|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
48504089|NCT02944305|PROCEDURE|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
48141242|NCT00005921|DRUG|L-743,872|
48141243|NCT01307254|PROCEDURE|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
48141244|NCT05019859|BEHAVIORAL|low carb diet|low carb diet
48141245|NCT01582321|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
48141246|NCT01582321|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
48141247|NCT05370378|OTHER|Hold Relax with Agonist Contraction|"1. Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~2. Passive sustained stretch to piriformis will be applied for 10 seconds.~3. The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~4. Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~5. Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~6. This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished."
48141248|NCT05370378|OTHER|Active Release Therapy|"1. Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~2. Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~3. Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~4. This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~5. After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness"
48141249|NCT05830279|GENETIC|Pharmacogenetic testing|Genotyping for CYP2D6 and CYP2C19
48504090|NCT06634394|DRUG|APVO436|Infusion drug administered as a 4 hour infusion.
48504091|NCT06634394|DRUG|Venetoclax|Oral tablet given on days 1 through 22, of a 28 day cycle.
48141250|NCT05830279|OTHER|Drug-Drug interaction analysis|Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.
48141251|NCT05059106|BIOLOGICAL|Half dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
48141252|NCT05059106|BIOLOGICAL|Standard dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
48351766|NCT05260450|DEVICE|1064 nm Nd:YAG-laser therapy|"All interventions and mycological tests for each subject were performed over the course of one day.~After subjects were included, toenails with a clinical suspicion of OM were tested for fungal infection by culture and microscopy. At the same time, nail clippings from said toenails were obtained and randomised into one of two treatment groups, i.e., group A and group B.~The nail clippings were then treated with a 1064 nm Nd:YAG-laser with laser settings as specified by the treatment groups. All nail clippings were treated only once.~Immediately after treatment, nail clippings were again tested for fungal infection by culture and microscopy."
48351767|NCT03371589|DRUG|Dexamethasone|Solution for otic injection
48351768|NCT01713907|DEVICE|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
48351769|NCT02234024|DIETARY_SUPPLEMENT|Supplementation of dairy-derived concentrated gangliosides.|
48351770|NCT03644589|BIOLOGICAL|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
48351771|NCT03644589|DRUG|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
48351772|NCT01487694|DRUG|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
48351773|NCT01487694|DRUG|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
48351774|NCT01633528|DRUG|Asprin|100 mg
48351775|NCT01633528|DRUG|placebo|100mg
48351776|NCT02750501|DEVICE|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
48351777|NCT02750501|OTHER|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
48351778|NCT02983851|PROCEDURE|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
48351779|NCT02983851|PROCEDURE|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
48351780|NCT01432665|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
48351781|NCT01432665|DRUG|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
48504092|NCT06634394|DRUG|Azacitidine|Intravenous infusion given on days 1-8 of a 28 day cycle
48351782|NCT01432665|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
48351783|NCT01614366|DRUG|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
48351784|NCT01614366|DRUG|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
48351785|NCT01614366|DRUG|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
48351786|NCT01614366|DRUG|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
48351787|NCT04476108|DRUG|LY3016859|Administered IV
48351788|NCT04476108|DRUG|Placebo|Administered IV
48141253|NCT01640951|DRUG|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
48141254|NCT01640951|DRUG|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
48141255|NCT01640951|DRUG|Placebo|
48141256|NCT04197037|PROCEDURE|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
48141257|NCT04019067|DIAGNOSTIC_TEST|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
48141258|NCT05308589|DEVICE|CPPF|Continuous Postoperative Pericardial Flush
48141259|NCT00275444|DRUG|Tipranavir|
48141260|NCT03684993|DRUG|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
48141261|NCT03684993|DRUG|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
48141262|NCT03684993|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
48141263|NCT06144437|DIAGNOSTIC_TEST|Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy."
48351789|NCT00589602|PROCEDURE|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg.
48662284|NCT04881565|OTHER|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
48662285|NCT02382146|DRUG|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
48662286|NCT02382146|DRUG|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
48662287|NCT00217802|BEHAVIORAL|six-session telephone counseling program|
48662288|NCT02758028|BEHAVIORAL|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
48141264|NCT06193499|PROCEDURE|Platelet rich plasma (PRP)|Intra-articular injection of platelet rich plasma (PRP)
48141265|NCT06193499|OTHER|Placebo|Intra-articular Saline injection (0,6-1ml)
48141266|NCT03028285|DRUG|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
48141267|NCT03560271|DRUG|Cyclo-Z|Cyclo (His-Pro) and zinc
48141268|NCT03560271|OTHER|Placebo|Matching placebo
48141269|NCT01450007|DRUG|Ropivacaine|25 ml ropivacaine 0.5%
48141270|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (perineural)
48141271|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
48141272|NCT01450007|DRUG|Normal saline|5 ml normal saline (intravenous)
48141273|NCT01450007|DRUG|Normal saline|0.8 ml normal saline (perineural)
48351790|NCT00589602|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
48504093|NCT06633341|BIOLOGICAL|CD5 CAR T-cells|Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion
48504094|NCT05396235|BIOLOGICAL|MT-3921|Solution for infusion; Intravenous (IV)
48504095|NCT05396235|BIOLOGICAL|Placebo|Solution for infusion; Intravenous (IV)
48141274|NCT05178706|OTHER|upper extremity rehabilitation program|Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
48141275|NCT05178706|DIAGNOSTIC_TEST|Results of assessment|The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
48351791|NCT00589602|PROCEDURE|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
48662289|NCT01434940|OTHER|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
48662290|NCT04600284|DRUG|AD-2101|AD-2101 16/5mg
48351792|NCT00589602|RADIATION|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
48662291|NCT04600284|DRUG|AD-2102|AD-2102 25mg
48662292|NCT04600284|DRUG|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
48351793|NCT03344874|DEVICE|Stethee®|Stethee® is a new wireless digital stethoscope.
48662293|NCT04466007|DRUG|High dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
47985787|NCT05281445|BEHAVIORAL|Tic suppression task|Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
47985788|NCT01349803|DRUG|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
48351794|NCT03344874|DEVICE|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
48351795|NCT06235229|BIOLOGICAL|GC012F|GC012F is a BCMA/CD19 dual CAR product
48351796|NCT00468624|DRUG|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
48351797|NCT00468624|PROCEDURE|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
48662294|NCT04466007|DRUG|Low dose allogeneic mesenchymal stromal cells|Allogeneic mesenchymal stromal cells derived from adipose tissue administered intramuscularly
48351798|NCT00468624|PROCEDURE|blood sampling before and after pegvisomant/placebo|
48351799|NCT00468624|PROCEDURE|arginine stimulation test after each limb|
48351800|NCT03245944|PROCEDURE|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
48662295|NCT04466007|DRUG|Placebos|0,9% physiological saline
48662296|NCT01302886|DRUG|BHQ880|
48662297|NCT01714674|DIETARY_SUPPLEMENT|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
48662298|NCT01714674|DIETARY_SUPPLEMENT|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
48662299|NCT06294587|PROCEDURE|FGG Before GBR|Free Gingival Graft before the guided bone regeneration,
48662300|NCT06294587|PROCEDURE|FGG after GBR|Free Gingival Graft after the guided bone regeneration,
48662301|NCT06228937|OTHER|analysis of a sample of stool|typing of the gut microbiota from a stool sample
48662302|NCT04372485|BEHAVIORAL|mHealth Intervention|Adolescents will receive text messages to facilitate treatment adherence
48662303|NCT04175015|OTHER|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
48662304|NCT00955578|PROCEDURE|Punch Biopsy|5-6 punch biopsies of affected areas
48662305|NCT05012579|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
48662306|NCT06227949|DRUG|Luveris|Patients will self-administer a subcutaneous injection of Luveris in addition to Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached.
47985789|NCT01349803|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
48351801|NCT03245944|PROCEDURE|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
48351802|NCT00803296|OTHER|Oral glucose tolerance test (OGTT)|
48351803|NCT00803296|OTHER|Isoglycemic intravenous glucose infusion|
47985790|NCT01349803|DRUG|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
48504096|NCT05806294|BEHAVIORAL|Digital Metabolic Rehabilitation|Digital Metabolic Rehabilitation combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise Protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 20 based on physical ability and stage of COPD. Intervention has 3 phases. In phase 1, weekly videoconferences with the kinesiologist and dietitian and monthly sessions with psychologist and respiratory therapist are held for the first 3 months. Phase 2 lasts from months 4 to 6 and has biweekly videoconferences with health professionals. Phase 3 starts in month 6 and has monthly group sessions with health professionals.
47985791|NCT01349803|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
48351804|NCT02746991|DRUG|Sham Injection|Placebo
48351805|NCT02746991|DRUG|FAI Insert|Fluocinolone Acetonide
48351806|NCT05776355|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
48351807|NCT04602611|OTHER|Oncology Nurse Navigation|Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
48351808|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1\*10\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
48351809|NCT03303625|BIOLOGICAL|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5\*10\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
48351810|NCT03303625|DRUG|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
48504097|NCT01466010|PROCEDURE|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
48504098|NCT06633770|DIAGNOSTIC_TEST|proclcitonin and presepsin|"All included patients will be subjected to:~* laboratory investigations~  * Complete Blood Count (CBC),~ * Liver Function Test(LFT) ( ALT,AST, Billirubin, total protein and albumin)~ * Kidney function test (KFT) ( Urea and creatinine)~ * Random Blood Glucose (RBG).~ * Erythrocyte Sedimentation Rate(ESR )~ * Urine analysis -A special investigations include (blood culture, C Reactive protein (CRP), proclcitonin and presepsin)."
48504099|NCT06063616|OTHER|Reiki|Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.
48504100|NCT06063616|OTHER|Sham Reiki|Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
48504101|NCT01152619|DRUG|Placebo|Subcutaneous repeated dose
48504102|NCT01152619|DRUG|RO4989991|Subcutaneous repeated dose
48504103|NCT03083080|PROCEDURE|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
48662307|NCT04873908|OTHER|modified constraint-induced therapy|Patients received conventional rehabilitation and modified constraint-induced therapy schedule
48662308|NCT04873908|OTHER|Proprioceptive Training|Patients received conventional rehabilitation and Proprioceptive Training schedule
48662309|NCT04873908|OTHER|conventional rehabilitation|Patients received conventional rehabilitation schedule
48662310|NCT02647502|OTHER|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
48662311|NCT04482127|OTHER|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
48351811|NCT02450240|BEHAVIORAL|standardized diagnostic assessment|
48141276|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique|The laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique is defined as a surgical procedure that aims to remove the distal part of the pancreas while preserving the spleen by maintaining the splenic artery and vein (Hepatogastroenterology. 2003;50:2242).
48141277|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique|Warshaw technique laparoscopic spleen-preserving distal pancreatectomy is defined as a surgical procedure that aims to preserve the spleen while removing the distal part of the pancreas. It involves ligating the splenic artery and vein, while preserving the left gastroepiploic artery and short gastric vessels (Arch Surg. 1988;123:550).
48141278|NCT00620854|DRUG|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
48141279|NCT00620854|DRUG|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
48141280|NCT00620854|DRUG|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
48141281|NCT00620854|DRUG|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
48141282|NCT01275911|DRUG|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
48141283|NCT01275911|DRUG|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
48141284|NCT00776139|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
48662312|NCT01498809|DRUG|Midodrine|Single 10 mg dose
48662313|NCT06026098|BEHAVIORAL|Artificial Intelligence|Participants will use the Artificial Intelligence assistance tool for case reports.
48662314|NCT02258490|BIOLOGICAL|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
48662315|NCT00284128|DRUG|AVE7688|oral administration (capsules)
48662316|NCT00284128|DRUG|Losartan-potassium|oral administration (capsules)
48662317|NCT02997085|DEVICE|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
48662318|NCT02997085|DEVICE|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
48141285|NCT01539252|PROCEDURE|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
48141286|NCT01539252|PROCEDURE|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
48141287|NCT05015699|DEVICE|HT Supreme|HT Supreme ( R\&D by Sinomed, Tianjin, China)
48141288|NCT02144194|DRUG|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
48141289|NCT02144194|DRUG|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
48141290|NCT01542255|DRUG|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
48141291|NCT01542255|DRUG|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
48141292|NCT01542255|DRUG|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
48141293|NCT04179565|BEHAVIORAL|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
48141294|NCT06274203|DRUG|Vitamin D3|Subjects within SCD as well as healthy controls, received monthly oral vitamin D3 dose, for 6 months, according to the baseline status of vitamin D as follows: sufficient (\>30 ng/mL): 100,000 IU, insufficient (20-29.9 ng/mL): 150,000 IU, and deficient (\<20 ng/mL): 200,000 IU.
48141295|NCT04112810|DRUG|Tildrakizumab|100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
48141296|NCT00068107|DRUG|Replagal|enzyme replacement therapy
48141297|NCT01603108|DRUG|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
48141298|NCT01603108|DRUG|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
48141299|NCT04968509|DRUG|PCSK9 inhibitors and statins with or without ezetimibe|Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
48351812|NCT02450240|BEHAVIORAL|self-report questionnaires|
48351813|NCT02450240|BEHAVIORAL|behavioral tasks|
48141300|NCT04968509|DRUG|Statins with or without ezetimibe|Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
48141301|NCT00515242|BEHAVIORAL|massage|therapeutic massage
48141302|NCT00515242|BEHAVIORAL|thermotherapy|heat therapy
48141303|NCT00515242|BEHAVIORAL|relaxing environment|time in a relaxing environment
48141304|NCT00989755|OTHER|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
48141305|NCT02522104|DRUG|Siklos|
48141306|NCT00729547|BEHAVIORAL|Neurofeedback|enhance relative activity level of left frontal activity
48141307|NCT00729547|BEHAVIORAL|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
48662319|NCT03360344|DEVICE|Kinesio 12 inch Tape|Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.
48662320|NCT03360344|DEVICE|Kinesio 4 inch Tape|Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
48662321|NCT03360344|DEVICE|Cock up Splint and Lumbrical exercises|A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
48662322|NCT05026801|DRUG|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
48662323|NCT01854450|OTHER|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
48662324|NCT01854450|OTHER|control|usual obstetrical care
48662325|NCT06268106|BEHAVIORAL|Graphic novel visualization|Patients in interventional group do receive and visualize graphic novel, which is more informative than standard informed consent.
47985792|NCT01132131|OTHER|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
47985793|NCT00358228|DRUG|Rimonabant|
47985794|NCT05819554|PROCEDURE|Trans-sphenoidal surgery|Surgical removal of pituitary tumor by trans-sphenoidal approach
47985795|NCT05160831|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
47985796|NCT01547000|DRUG|placebo|Administered up to 8 weeks.
47985797|NCT01547000|DRUG|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
47985798|NCT00455429|DRUG|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
47985799|NCT00455429|DRUG|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
47985800|NCT00455429|DRUG|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
47985801|NCT00455429|DRUG|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
47985802|NCT00455429|DRUG|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
47985803|NCT02588833|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
48141308|NCT00635609|DRUG|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
48141309|NCT00635609|DRUG|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
48351814|NCT02450240|OTHER|physiological measurements|
48662326|NCT04724837|DRUG|Zibotentan|Participants will receive zibotentan as per the arms they are randomized.
48662327|NCT04724837|DRUG|Dapagliflozin|Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
48662328|NCT04724837|DRUG|Placebo|Participants will receive placebo as per the arms they are randomized to.
47985804|NCT06541288|DIAGNOSTIC_TEST|AI Prediction Model|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer. Further pelvic lymph node metastasis status was determined by artificial intelligence multimodal fusion prediction modeling
47985805|NCT06541288|DIAGNOSTIC_TEST|Conventional Imageing Assessment|Pelvic MRI was performed after pathologic diagnosis clarified the diagnosis of cervical cancer.Further pelvic MRI images are read by a specialized imaging physician to determine pelvic lymph node status.
47985806|NCT05061030|BIOLOGICAL|the ATMP Protrans|Protrans consists of Wharton's jelly derived mesenchymal stromal cells
47985807|NCT05955950|BEHAVIORAL|Gratitude list|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
48141310|NCT01171053|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
48141311|NCT01171053|BEHAVIORAL|Therapist support|Weekly therapist support without CBT-interventions
48141312|NCT02944981|DRUG|Gabapentin|Single oral dose
48141313|NCT02944981|DRUG|Placebo|Single oral dose
48141314|NCT02629666|BEHAVIORAL|ERS and/or Self-management Strategies|
48141315|NCT06353620|DIAGNOSTIC_TEST|High Density EEG recording|Recording of resting state high density EEG (128 channels)
48351815|NCT02450240|OTHER|structural and functional magnetic resonance imaging and EEG|
48351816|NCT02450240|OTHER|biomarker and microbiome assessments|
48351817|NCT02450240|OTHER|blood to derive induced pluripotent stem cells|
48141316|NCT06353620|DIAGNOSTIC_TEST|Rey Complex Figure Test|Memeory functioning evaluation
48141317|NCT05215249|PROCEDURE|Transnasal humidified high-flow oxygen delivery|The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
48141318|NCT02318810|DRUG|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
48141319|NCT02318810|DRUG|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
48141320|NCT02318810|DRUG|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
48141321|NCT02318810|DRUG|Placebo|Patients receive saline
48141322|NCT02892591|DRUG|Cannabis|vaporized plant material
48141323|NCT02892591|DRUG|Oxycodone|oral capsule
48141324|NCT02892591|DRUG|Placebo for Cannabis|vaporized placebo plant material
48141325|NCT02892591|DRUG|Placebo for Oxycodone|oral placebo capsule
48141326|NCT03854734|BEHAVIORAL|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
48141327|NCT03854734|BEHAVIORAL|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
48141328|NCT04440540|BEHAVIORAL|Dietitian led life style modification intervention|lifestyle changes supervised by dietitians
48141329|NCT04440540|BEHAVIORAL|Conventional care (control)|receive routine care
48141330|NCT04459572|DIAGNOSTIC_TEST|suPAR|Soluble Urokinase Plasminogen Activator Receptor (suPAR)
48141331|NCT02548299|OTHER|Nutrition Education|Nutrition classes will be led by a registered dietician.
48141332|NCT02548299|OTHER|Cooking Lecture|
48141333|NCT02548299|OTHER|Cooking Demo|
48141334|NCT02548299|OTHER|Hands-on Cooking|
48662329|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10\^8 cells will be given up to 3x10\^11 anti-MART-1 F5 TCR engineered TIL or PBL."
48351818|NCT02450240|OTHER|genetic and epigenetic assessments|
48351819|NCT01710904|DRUG|Targinact® (oxycodone/naloxone)|
48351820|NCT03938558|OTHER|MS-Dance|The experimental group will perform 10 weeks of dance training
48351821|NCT03938558|OTHER|MS-Art|The other group will contribute to the production in various ways (e.g. word art, photography, painting, ...)
48351822|NCT01358006|DRUG|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
48662330|NCT00509288|DRUG|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
48662331|NCT00509288|DRUG|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
48662332|NCT00509288|BIOLOGICAL|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
48351823|NCT01358006|DRUG|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
48351824|NCT05790967|OTHER|Sexual Education|Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
47985808|NCT05955950|BEHAVIORAL|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
48141335|NCT02548299|OTHER|e-Coaching|
48141336|NCT03516071|DRUG|Brivanib 800 mg, QD|Brivanib Alaninate 800 mg QD, PO
48141337|NCT03516071|DRUG|Brivanib 400 mg, BID|Brivanib Alaninate 400 mg BID, PO
48141338|NCT02311413|DRUG|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
48141339|NCT02311413|DRUG|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
48141340|NCT05469165|DRUG|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
48141341|NCT05469165|OTHER|Placebo|Placebo administration for 3months
48141342|NCT06368999|DIAGNOSTIC_TEST|EEG|registration of 8 minutes of EEG
48141343|NCT05885620|DEVICE|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
48141344|NCT01719172|DEVICE|Veriset™ Hemostatic Patch|Topical Hemostat
48141345|NCT01595269|OTHER|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
48141346|NCT01990625|DEVICE|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
48141347|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
48141348|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
48662333|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
48662334|NCT02878863|DRUG|Paeoniflorin + phosphatidylcholine or silymarin|
48662335|NCT02878863|DRUG|Phosphatidylcholine or silymarin|
48141349|NCT01049516|BEHAVIORAL|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
48141350|NCT01049516|BEHAVIORAL|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
48141351|NCT06195449|OTHER|ALKASITE RESTORATIVE MATERIAL|Restorative material for primary teeth
48141352|NCT06195449|OTHER|Glass Ionomer Cement|Restorative material for primary teeth
48141353|NCT03353961|BEHAVIORAL|Emotion regulation individual therapy|The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
48141354|NCT03353961|BEHAVIORAL|Treatment as usual|Treatment as usual as provided in the community.
48141355|NCT03800368|OTHER|Exercise|Indoor cycling exercise intervention
48141356|NCT03800368|OTHER|Non-exercise|Psycho-education
48141357|NCT00018512|PROCEDURE|Implant-supported denture|
48141358|NCT05826496|OTHER|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
48141359|NCT03862898|OTHER|Lumbar stabilization exercises|Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
48141360|NCT05478096|BEHAVIORAL|GetStarted|Guided internet-based intervention for procrastination.
48141361|NCT01959776|PROCEDURE|Vitrectomy|
48662336|NCT03360994|OTHER|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
48662337|NCT03360994|OTHER|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
48662338|NCT05759767|DRUG|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
48662339|NCT05759767|DRUG|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
48662340|NCT00006163|BEHAVIORAL|Personalized Self-management|
48141362|NCT01933100|OTHER|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
48141363|NCT03270709|DRUG|Vitamin D3 450,000 IU orally|Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
48141364|NCT00176319|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
48351825|NCT04124952|DEVICE|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
48662341|NCT00006163|BEHAVIORAL|Community Resources|
48662342|NCT02644070|DEVICE|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
48662343|NCT02644070|DEVICE|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
48662344|NCT02644070|DEVICE|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
48662345|NCT02386241|OTHER|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
48662346|NCT00246103|DRUG|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
48662347|NCT00246103|DRUG|Epirubicin|Beginning Dose, Level 1: 75 mg/m\^2.
48662348|NCT00246103|DRUG|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m\^2.
48662349|NCT00246103|DRUG|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
48141365|NCT03789357|DIAGNOSTIC_TEST|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
48141366|NCT04072133|BEHAVIORAL|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
48141367|NCT04250623|OTHER|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
48141368|NCT06128915|OTHER|vaccine|Vaccination against 20 serotypes of S. pneumoniae
48141369|NCT02084615|DRUG|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
48141370|NCT03864159|OTHER|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
48351826|NCT00159653|DRUG|Xalacom|
48351827|NCT00159653|DRUG|Xalatan|
48662350|NCT03638375|DRUG|Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha|"During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks."
48662351|NCT06564090|OTHER|robot assisted gait training|Morning Walk® is a new end-effector type robot developed by Hyundai Heavy Industries and Taeha Mechatronics for lower limb rehabilitation in the patients with gait disturbance.The RAGT group received RAGT with robot training for 30 minutes and conventional physiotherapy for 30 minutes per session.
48662352|NCT06564090|OTHER|conventional gait training|The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
48662353|NCT02259595|DRUG|HPN-07|500-1,500 mg oral capsules administered in a single dose
48662354|NCT02259595|DRUG|NAC|1,200mg NAC administered via oral capsule in single dose
48662355|NCT02259595|DRUG|Placebo|placebo oral capsule
48662356|NCT06571435|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST), and Posterior Shoulder Endurance Test|"The modified closed kinetic chain upper extremity stability test is reliable and is performed in an individualized manner by placing the hands on the floor at shoulder level. The evaluation process is the same as the original test; the total number of touches in 15 seconds is noted by lifting one hand, touching the other and placing it back. A total of 3 measurements are taken with a 45-second rest interval. The endurance capacity of the muscle group is an important factor for sports performance as it requires specific sports movements repeated in a certain period of time.~For posterior shoulder endurance test participants will lie with their face down. While the shoulder is hanging from the stretcher, individuals will be asked to lift the dumble calculated with the weight appropriate for their weight to 90 degrees abduction in accordance with the 60 bpm metronome. Their duration in seconds will be noted. 1 measurement will be made with each arm."
48662357|NCT03463187|BIOLOGICAL|SHR-1314|Administered subcutaneously
48662358|NCT03463187|DRUG|Placebo|Administered subcutaneously
48662359|NCT01606241|DRUG|Cyclophosphamide|Given PO
48662360|NCT01606241|OTHER|Laboratory Biomarker Analysis|Correlative studies
48662361|NCT01606241|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
48662362|NCT00497497|DRUG|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
48662363|NCT00497497|DRUG|cetuximab|Intravenous repeating dose
48662364|NCT00497497|DRUG|FOLFIRI regimen|Intravenous repeating dose
48662365|NCT00497497|DRUG|irinotecan|Intravenous repeating dose
48662366|NCT00497497|DRUG|PRO95780|Intravenous repeating dose
48662367|NCT03834740|DRUG|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
48662368|NCT03834740|DRUG|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
47985809|NCT01654094|DEVICE|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
48351828|NCT00159653|DRUG|Timolol|
48662369|NCT03359161|COMBINATION_PRODUCT|sc2Wear Furosemide Infusor|Subcutaneous furosemide for the treatment of fluid overload
48662370|NCT01505088|DRUG|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
48662371|NCT01505088|DRUG|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
48662372|NCT01505088|DRUG|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
48662373|NCT01505088|DRUG|Placebo Eyedrops|Placebo Eyedrops
48662374|NCT04305210|DRUG|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
48662375|NCT04305210|DRUG|18F-florbetapir|18F-florbetapir
48662376|NCT01734044|DRUG|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
48662377|NCT01734044|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
48662378|NCT03308279|DIAGNOSTIC_TEST|Ultrasound|Ultrasound and Anthropometric meassures
48662379|NCT03230214|DIAGNOSTIC_TEST|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
47985810|NCT01654094|OTHER|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
48141371|NCT03864159|OTHER|Foam roller|Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
48141372|NCT04970602|DRUG|Methylene Blue|Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
48141373|NCT02280759|DRUG|Gelatin Tannate|
48141374|NCT02280759|DRUG|Placebo|Placebo consists of an identical formulation, except active substance
48141375|NCT04413526|PROCEDURE|radiofrequency|radiofrequency combined with liver resection
48141376|NCT04413526|PROCEDURE|TACE|only TACE treatment
48662380|NCT04372953|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
48662381|NCT03532347|DEVICE|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
48662382|NCT03369158|PROCEDURE|patient specific pedicle screw positioning guide|
48662383|NCT03369158|PROCEDURE|Free hand technique pedicle screw positioning|
48662384|NCT03369158|DEVICE|MUST pedicle screw|
47985811|NCT04952142|OTHER|minimal water exchange|Use a new technique, minimal water exchange colonoscopy, which adds the infusion of modest amounts of water by constant pressure on the air-water valve button of the endoscope to achieve intubation.
47985812|NCT04396990|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
47985813|NCT04396990|DRUG|Topical Prednisolone|Standard of care topical drop treatment
47985814|NCT01453257|DRUG|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
47985815|NCT04356274|OTHER|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
47985816|NCT04356274|OTHER|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
47985817|NCT02983474|PROCEDURE|cholecystectomy|"Laparoscopic surgery~1. Reverse Trendelenburg position~2. Skin incision and trocar insertion~3. CO2 gas insufflation~4. Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction~6. Calot triangle exposure~7. Cystic artery and cystic duct isolation~8. Gallbladder bed dissection~9. Bleeding control~10. Gallbladder extraction~11. Trocar removal and wound closure~Open surgery~1. Supine position~2. Skin incision~3. Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
47985818|NCT00159640|DRUG|PD-217,014|
47985819|NCT04495842|OTHER|Essential Oil Blend|5 drops of on a tester strip
47985820|NCT04495842|OTHER|Control Blend|5 drops on a tester strip
47985821|NCT05633121|PROCEDURE|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
47985822|NCT02507674|DEVICE|ultrasound|
48141377|NCT04413526|PROCEDURE|TACE+radiofrequency|TACE followed by radiofrequency
48351829|NCT01222936|DRUG|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
48351830|NCT00169338|PROCEDURE|Deep brain stimulation|internal pallidal deep brain stimulation
48351831|NCT03284151|RADIATION|Cyberknife|
48351832|NCT01770093|OTHER|Questionnaire|
48351833|NCT04831606|PROCEDURE|debridement|Cleaning of the wound area
48504104|NCT03083080|DRUG|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
48141378|NCT04555668|OTHER|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
48662385|NCT05267496|DEVICE|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
48141379|NCT04555668|OTHER|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
48141380|NCT01051869|PROCEDURE|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
48141381|NCT01051869|PROCEDURE|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
48141382|NCT06403410|OTHER|Delirium Prevention Guideline|Each intervention group patient randomized will receive the Delirium Prevention Guideline. The guideline is designed to be followed by nurses. However, collaboration with the physician is required for some aspects of the guideline (pain control, ordering/follow-up of laboratory tests, etc.). Support will be obtained from the intensive care physician, who is a member of the research team, for these steps. The guideline includes standard practices used by intensive care nurses in patient monitoring. In addition to routine follow-ups, eye masks and earplugs will be applied to patients in the intervention group between 24:00 and 06:00.
48141383|NCT02255474|DEVICE|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
48141384|NCT02255474|DEVICE|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
48141385|NCT02255474|DEVICE|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
48141386|NCT05371821|DEVICE|Echocardiography|Echocardiographic parameters in obese and overweight
48141387|NCT01332552|DRUG|GSK2485852 70 mg|single dose
48141388|NCT01332552|DRUG|GSK2485852 420 mg|single dose
48141389|NCT01332552|DRUG|placebo|single dose
48141390|NCT01332552|DRUG|placebo|Repeat dose, once daily for 3 days
48141391|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
48141392|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
48141393|NCT01332552|DRUG|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
48662386|NCT05267496|PROCEDURE|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~* Directed ventilation~* Physical conditioning Post-surgical rehabilitation~* Diaphragmatic mobilization~* Thoracic expansion through incentive flow spirometry"
48141394|NCT01332552|DRUG|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
48141395|NCT01332552|DRUG|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
48141396|NCT01332552|DRUG|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
48351834|NCT04831606|DEVICE|Offloading|Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).
48351835|NCT04831606|DEVICE|Advanced dressing|Protect the wound with Advanced dressing
48662387|NCT03859219|DRUG|Rozanolixizumab|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
48662388|NCT03859219|DRUG|Placebo|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
48141397|NCT02698956|DEVICE|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
48351836|NCT04831606|DEVICE|Blue Light Photobiomodulation|2 minutes irradiation of blue light performed with EmoLED device
48351837|NCT04781725|DRUG|INT230-6|INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also known as SHAO-FA or SHAO as a sodium salt at 10mg/mL).
48351838|NCT04781725|OTHER|Saline injection|Standard 0.9 % NaCl Normal Saline
48662389|NCT02976805|DRUG|4L PegLyte + 15 mg bisacodyl|Randomized
48141398|NCT02165202|DRUG|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
48351839|NCT05535790|OTHER|Naturalistic LED light|Naturalistic LED light (bright light therapy) which affects Melanopic Equivalent Daylight Illuminance.
48351840|NCT05535790|OTHER|Standard/traditional lighting|Standard/tradtional lighting environment with fluorescent tubes
48662390|NCT02976805|DRUG|6L PegLyte + 15 mg bisacodyl|Randomized
48662391|NCT05339555|OTHER|Instructions for IUD Self-Removal Provided to Participant|The provider will offer any individual presenting for in-person IUD removal or exchange (removal-replacement) the option for self-removal. The participant will be provided a 'how to' instruction sheet with information on positioning and what to expect. The participant will first attempt removal with clean hands if desired, then utilizing non-sterile, clean gloves (not explicitly tested in prior studies) and if that fails, the use of a menstrual cup (a novel technique). If not successful, the provider will perform standard IUD removal in the clinic.
48351841|NCT02812615|DIETARY_SUPPLEMENT|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
48351842|NCT02812615|DIETARY_SUPPLEMENT|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
48662392|NCT05713487|OTHER|preventive treatment group|each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
48662393|NCT01409408|DRUG|Aliskiren|300 mg of aliskiren daily for 8 weeks.
48662394|NCT01409408|DRUG|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
48662395|NCT00973128|DRUG|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
48662396|NCT00973128|DRUG|Meglumine antimoniate|20mg/daily for 20 days
48662397|NCT02124408|BEHAVIORAL|Personalized Behavioral Intervention|
48662398|NCT06563648|OTHER|shotblocker|A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.
48662399|NCT06563648|OTHER|local cold application|Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed.
48662400|NCT06563648|OTHER|ShotBlocker placebo group|During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.
48662401|NCT00781261|DRUG|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
48662402|NCT00781261|DRUG|Placebo|Subjects in the control group will receive a placebo drug for a similar period
48662403|NCT04189614|DRUG|Cofetuzumab Pelidotin|Intravenous (IV) infusion
48662404|NCT05674955|DIAGNOSTIC_TEST|Circuit weight versus aerobic training|"Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)~B- Aerobic training:~This mode of exercise will be conducted for study group B as follows:~Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.~Frequency: Three times / week (Nishi et al., 2011).~C-Traditional medical treatment:~This treatment will be conducted for all group A, B and C."
48662405|NCT06296680|OTHER|Reiki|The patients in the intervention group received Reiki to the seven chakra regions and additional areas with pain for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
48351843|NCT02812615|DRUG|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
48351844|NCT02812615|BEHAVIORAL|Nutritional counselling|Parents/caregivers will be given nutritional counselling
48351845|NCT02812615|DIETARY_SUPPLEMENT|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
48141399|NCT02165202|DRUG|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
48141400|NCT00000388|BEHAVIORAL|Psychosocial treatment|
48141401|NCT00000388|DRUG|Anti-ADHD medication|
48141402|NCT00000388|BEHAVIORAL|Assessment-and-Referral|
48141403|NCT04723615|OTHER|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
48141404|NCT04723615|OTHER|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
48662406|NCT06296680|OTHER|Sham Reiki|The patients in the placebo group received Sham Reiki to the seven chakra regions for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
48141405|NCT04723615|OTHER|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
48662407|NCT06296680|OTHER|Progressive Relaxation Exercise|PRE group patients received PRE for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
48141406|NCT04723615|OTHER|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
48141407|NCT03590496|DIETARY_SUPPLEMENT|Calcium-Propionate 500mg|Calcium-Propionate capsules
48141408|NCT03590496|OTHER|Placebo|Placebo capsules without any active ingredient
48141409|NCT02955966|DEVICE|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
48141410|NCT02955966|BIOLOGICAL|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
48141411|NCT00360191|DRUG|Buspirone|
48141412|NCT00360191|PROCEDURE|Motivational enhancement therapy|
48141413|NCT01483885|DEVICE|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
48141414|NCT01483885|DEVICE|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
48141415|NCT01483885|PROCEDURE|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
48141416|NCT03136861|BIOLOGICAL|AIN457|anti IL-17a monoclonal antibody
48141417|NCT03136861|DRUG|AIN457 Placebo|Placebo matching AIN457
48141418|NCT05667441|COMBINATION_PRODUCT|Standard lifestyle recommendations + dietary supplementation|refrain from smoking; perform physical exercise regularly; increase the intake of dietary food groups such as green leafy vegetables, fruits, and fatty fish and recommendations for supplementation with antioxidants according an established formula
48141419|NCT05667441|COMBINATION_PRODUCT|Risk profiling|Personalized risk profiling for lifestyle and genetics.
48141420|NCT05667441|BEHAVIORAL|Coaching|Coaching
48141421|NCT01827761|BEHAVIORAL|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
48141422|NCT00790569|DRUG|nicotine|Given transdermally and orally
48141423|NCT00790569|DRUG|varenicline|Given orally
48141424|NCT00790569|OTHER|placebo|Given orally
48141425|NCT03584074|DRUG|Pregabalin 75mg|Orally taken twice daily for 8 weeks
48141426|NCT03584074|DRUG|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
48141427|NCT05350670|BEHAVIORAL|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
48141428|NCT04654390|DRUG|DWP16001 Amg|Tablets, Orally, Once daily
48141429|NCT04789174|DRUG|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
48141430|NCT04789174|DRUG|Placebo|Placebo
48141431|NCT01256359|DRUG|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
48141432|NCT01256359|DRUG|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
48141433|NCT00599196|DRUG|Rotigotine|"Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
48141434|NCT02095678|PROCEDURE|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
48141435|NCT02095678|DEVICE|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to \<8 seconds and validate quantifiable techniques which improve liver image quality
48141436|NCT03340259|PROCEDURE|Exposure(s) of interest: enterostomy|Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
48141437|NCT03477214|DIAGNOSTIC_TEST|Biomechanical and electromyography mapping|The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
48141438|NCT01670526|DRUG|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
48141439|NCT05982366|OTHER|distal radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the distal radial artery in the anatomical snuffbox area
48141440|NCT05982366|OTHER|conventional radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the forearm radial artery in the anatomical snuffbox area
48141441|NCT03138005|OTHER|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to \~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
48662408|NCT03184545|DEVICE|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
48351846|NCT04739995|DRUG|Low-dose naltrexone|4.5 mg LDN/day for 1 year
48141442|NCT03138005|OTHER|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
48141443|NCT06233552|PROCEDURE|conventional denture conversion|conventional workflow usually done to do immediate loading for full arch implant cases
48141444|NCT06233552|PROCEDURE|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
48141445|NCT04924166|DRUG|Placebo|Inactive dose of capsules that appear identical to active dose
48141446|NCT04924166|DRUG|Hydrocortisone|Hydrocortisone 180 mg in capsule form
48141447|NCT03488459|BEHAVIORAL|Routine preoperative information from a nurse|Routine preoperative information from a nurse.
48141448|NCT03488459|BEHAVIORAL|Additional information support from a psychologist|Routine preoperative information from a nurse + additional information support from a psychologist.
48351847|NCT05977374|OTHER|experimental and conventional group|Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
48351848|NCT06423001|DIETARY_SUPPLEMENT|PostbiotiX Slowing 4 g sachets PostbiotiX Slowing is a food supplement based on Fermented FOS from Lactobacillus paracasei CNCM I-5220.|Each patient will be supplied with the investigational product at Visit 0, PostibiotiX Slowing and at visit 3, based on the outcome of the randomization at V0 (Sequence AB, PostbiotiX Slowing/Placebo; Sequence BA, Placebo/PostbiotiX Slowing).
48351849|NCT03453346|DRUG|Sofosbuvir|Generic sofosbuvir tablet 400 mg
48351850|NCT03453346|DRUG|Ribavirin|Ribavirin was provided in 100-mg tablets.
48141449|NCT03683641|DEVICE|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
48141450|NCT03683641|DEVICE|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
48351851|NCT04785144|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
48351852|NCT04785144|BIOLOGICAL|mRNA-1273.351|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
48351853|NCT04527536|DIAGNOSTIC_TEST|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
48504105|NCT03083080|DRUG|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
48504106|NCT00422552|DRUG|Indacaterol (QAB149)|
48662409|NCT03184545|OTHER|Physical therapy|Standard physical therapy exercises
48662410|NCT05943678|DEVICE|Siemens Magnetom 7T Plus|Magnetic Resonance Spectroscopy
48662411|NCT05849558|DRUG|Ursoplus|Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)
48662412|NCT05849558|DRUG|UDCA 250mg|UDCA 250mg alone
48662413|NCT05849558|OTHER|Placebo|Placebo alone
48662414|NCT02997202|DRUG|gilteritinib|oral
48662415|NCT02997202|DRUG|Placebo|oral
48141451|NCT00845520|DEVICE|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
48662416|NCT00499447|PROCEDURE|radiofrequency ablation|
48141452|NCT00845520|DEVICE|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
48141453|NCT00845520|DEVICE|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
48662417|NCT00499447|RADIATION|radiation therapy|
48662418|NCT04708847|DRUG|GYM329|GYM329 subcutaneous injection
48141454|NCT03030365|DEVICE|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
48141455|NCT05536869|PROCEDURE|Caesarean|Two different caesarean section techniques : intra or extraperitoneal
48141456|NCT01630304|BEHAVIORAL|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
48141457|NCT05292118|DEVICE|Navitian|Patients in whom treatment with (Navitian) has been attempted
48141458|NCT00148122|DRUG|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
48141459|NCT00148122|DRUG|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
48141460|NCT04329585|DRUG|flumazenil|EEG is observed in both groups to compare the difference between two groups.
48141461|NCT04329585|DRUG|Placebos|Placebo is the normal saline, which is given in the controlled group.
48141462|NCT00075998|DRUG|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
48141463|NCT05528692|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI is a non-invasive imaging modality capable of producing precise soft-tissue images in all body areas. In contrast to CT scanning, MRI does not rely on ionizing radiation. There are no known risks associated with MRI as long as patients with contraindications such as pacemakers are identified and excluded. The MRI scans in this study will be performed without use of contrast media.
48141464|NCT00162318|DRUG|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
48504107|NCT05708092|BEHAVIORAL|NeuroResource Facilitation (NRF)|"NRF is defined as a specialized service that promotes access to services and coordinates care specific to the needs of individuals with brain injury.~Possible resources include vocational services, medical assistance, Social Security (SSI or SSDI if appropriate), and other organizations that can support reentry. If needed to gain access to services and organizations, the facilitator will also provide participants with a summary that includes results from brain injury screenings questionnaire, neurocognitive (thinking abilities) tests, and symptoms. The researchers will share information and coordinate with prison and parole staff about participation in the study. Participant's information will also be shared with resources that could help participants after release, such as funding sources and brain injury services. After release from SCI, the NRF facilitator will assist the participant with all the preparation and logistics associated with the resources the participant applied to."
48662419|NCT04708847|DRUG|Placebo|Placebo subcutaneous injection
48662420|NCT04345614|DRUG|Auxora|Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
48662421|NCT04345614|DRUG|Placebo|Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
48504108|NCT00003445|DRUG|docetaxel|
48504109|NCT00517127|DRUG|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
48504110|NCT00517127|DRUG|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
48504111|NCT04799938|BEHAVIORAL|Exercise|180 minutes of moderate-intensity exercise per week
48662422|NCT06005948|OTHER|exercise|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks
48662423|NCT06005948|OTHER|control|No intervention will be made.
48662424|NCT01920113|DRUG|Dexmedetomidine - remifentanil group|
48662425|NCT01920113|DRUG|Propofol - remifentanil group|
48662426|NCT01203345|DRUG|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
48662427|NCT01203345|DRUG|Placebo|An equal volume of 5 percent albumin solution
48662428|NCT00574015|DRUG|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
48662429|NCT00574015|DRUG|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
48141465|NCT02659540|DRUG|Nivolumab|Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.
48141466|NCT02659540|DRUG|Ipilimumab|Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.
48141467|NCT02659540|RADIATION|Radiotherapy|RT was delivered in accordance with cohort assignment and institutional practices.
48662430|NCT05729087|BEHAVIORAL|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
48662431|NCT00855361|DRUG|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
48662432|NCT00995787|DRUG|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
48662433|NCT00995787|DRUG|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
48662434|NCT05650996|BEHAVIORAL|ADL/Cast Care instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
48662435|NCT05650996|BEHAVIORAL|Cast Care Instruction|Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
48662436|NCT04049513|BIOLOGICAL|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
48662437|NCT04049513|DRUG|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
48662438|NCT03278522|DRUG|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
48662439|NCT05586750|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
48662440|NCT05586750|DRUG|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
48662441|NCT05152823|BIOLOGICAL|Gene Therapy|AAV9 carrying the IGHMBP2 gene.
48662442|NCT03599765|OTHER|Best Practice|Receive routine therapy
48141468|NCT01860300|DRUG|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
48662443|NCT03599765|PROCEDURE|Local Consolidation Therapy|Receive LCT
48662444|NCT04311307|BIOLOGICAL|[6,6-2H2]glucose|Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
48141469|NCT01860300|DRUG|placebo|
48141470|NCT02427191|OTHER|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
48141471|NCT02427191|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
48141472|NCT04498780|DRUG|Sacubitril-Valsartan|Observational study during the clinically indicated treatment
48141473|NCT00236509|DRUG|topiramate|
48141474|NCT01536964|DRUG|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
48141475|NCT01536964|DRUG|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
48141476|NCT01313663|DRUG|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
48141477|NCT01313663|DRUG|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
48662445|NCT02652247|PROCEDURE|molecular analysis of exhaled breath condensate|
48141478|NCT01116206|DRUG|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
48351854|NCT03283891|OTHER|Educational intervention - humanistic nursing practice|"Four educational sessions:~* Acquisition of core concepts of caring practice (I)~* Acquisition of core concepts of caring practice (II)~* Search for meaning: Influencing hope in persons through humanistic practice~* Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
47985823|NCT06404138|OTHER|The Geriatric Activation Program (GAPP) Home version|"The rehabilitation at home intervention consists of three 45 minutes session per week (total of 18 sessions) with a different focus for each session. The therapy is goal-oriented and includes functional exercises in the home where possible (e.g. transfers such as getting out of bed, walking to the toilet etc.). There are three sessions per week: 1 for training strength, 1 for training balance and 1 for speed, coordination and endurance. Each session will start with gait rehabilitation as a warming-up.~For each session, a set of exercises with varying levels of difficulty is available. As rehabilitation needs are diverse, the therapist is expected to choose the most appropriate exercise and the difficulty level of the exercise for the individual older person. This also includes scaling the exercises to the individual progression of the older person."
47985824|NCT06404138|OTHER|Standard of care|Standard of care, without any restrictions.
47985825|NCT01192282|PROCEDURE|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
47985826|NCT04733092|DRUG|Lipiodol|Lipiodol in emulsion with contrast agent
47985827|NCT01721642|DEVICE|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
47985828|NCT04097093|OTHER|No intervention|No intervention
48141479|NCT01116206|DRUG|Placebo|1 tablet, orally once dailyfor 12 weeks
47985829|NCT05400954|PROCEDURE|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
48141480|NCT06200090|OTHER|No intervention|No intervention
48141481|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide|
48141482|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide + Imiquimod|
48141483|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Imiquimod|
47985830|NCT05400954|PROCEDURE|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
47985831|NCT05400954|PROCEDURE|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
47985832|NCT02087527|DRUG|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
47985833|NCT02087527|DRUG|Normal Saline|IV normal saline every 6 hours for 48 hours
47985834|NCT01906151|DEVICE|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
48141484|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 intra nodal injection|
48141485|NCT05371899|DRUG|Chiauranib|Take Chiauranib 50mg orally once daily
48141486|NCT04705649|OTHER|Treatment de-escalation|De-escalation from standard treatment based on molecular profile
48662446|NCT02652247|PROCEDURE|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
48141487|NCT06208605|BEHAVIORAL|Transdiagnostic Network Informed Personalized Treatment|Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.
48662447|NCT02652247|PROCEDURE|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
48662448|NCT00894881|PROCEDURE|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
48662449|NCT03209258|OTHER|Care bundle of active management|"1. Intensive BP lowering to systolic target of \<140mmHg;~2. Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~3. Treatment of pyrexia to a target body temperature ≤37.5 ℃;~4. Reversal of anticoagulation to target INR \<1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
48662450|NCT03209258|OTHER|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
48662451|NCT02367456|DRUG|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
48662452|NCT02367456|DRUG|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
48141488|NCT06208605|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy for Eating Disorders|Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
48662453|NCT05852327|OTHER|Observation only|Observation only
48662454|NCT03592355|OTHER|Virtual Visit|Clinicians will have a synchronous video visit with their patients.
48662455|NCT00455702|DRUG|d-cycloserine|50mg dose d-cycloserine v placebo
48662456|NCT01908010|DRUG|ABT-354|ABT-354 Low Dose
48662457|NCT01908010|DRUG|ABT-354|ABT-354 High Dose
48662458|NCT01908010|DRUG|Placebo|Placebo
48662459|NCT06560190|OTHER|Orthopaedic Manual Physical Therapy|Individualized Treatment
48662460|NCT02445209|OTHER|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
48662461|NCT02445209|OTHER|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
48662462|NCT04088396|DRUG|Baricitinib|Administered orally
48662463|NCT04088396|DRUG|Tocilizumab|Administered SC
48662464|NCT03864848|DEVICE|Mitral Touch Implant|The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
47985835|NCT04060550|BIOLOGICAL|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
48141489|NCT03055988|DRUG|Tiotropium|Fixed Dose Combination
48141490|NCT03055988|DRUG|Olodaterol|Fixed Dose Combination
48141491|NCT03055988|DRUG|Fluticasone propionate|Fixed Dose Combination
48141492|NCT03055988|DRUG|Salmeterol|Fixed Dose Combination
48662465|NCT02156947|PROCEDURE|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
48662466|NCT05450211|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
48662467|NCT05450211|DEVICE|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
48662468|NCT01577316|BIOLOGICAL|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus."
48662469|NCT00003249|DRUG|carboxyamidotriazole|
47985836|NCT02677922|DRUG|AG-120|Specified dose on specified days
47985837|NCT02677922|DRUG|Azacitidine|Specified dose on specified days
47985838|NCT02677922|DRUG|AG-221|Specified dose on specified days
48141493|NCT04921709|OTHER|Medical tests|Blood tests
48141494|NCT00463944|BEHAVIORAL|Effect of an electronic voting system|
48141495|NCT05116098|COMBINATION_PRODUCT|zinc 50 mg + Epigallocatechin gallate|ZINC 50 MG and EGCG 200mg oral daily for 1 month
48141496|NCT05966272|DRUG|HRS9531 injection|single dose
48141497|NCT05966272|DRUG|HRS9531 injection Placebo|single dose
48141498|NCT03192501|DRUG|inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.|Choose appropriate targeted drugs according to NGS/IHC results.
48141499|NCT00252382|DRUG|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
48141500|NCT00774059|DEVICE|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
48662470|NCT00003249|DRUG|chemotherapy|
48662471|NCT00003249|DRUG|ketoconazole|
48662472|NCT01362790|DRUG|Pentostatin|Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle
47985839|NCT06459843|OTHER|pursed lip breathing techniques|Relax your neck and shoulder muscles. For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets. In each set, 10 times will be included. Then, instruct the patient to take deep breath through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
48141501|NCT00416975|OTHER|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
48662473|NCT01362790|DRUG|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
48662474|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
48662475|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
48662476|NCT00895804|DRUG|MDMA|capsule, 1.6 mg/kg body weight, single dose
48141502|NCT00416975|OTHER|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
48351855|NCT01722214|BIOLOGICAL|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
48351856|NCT01722214|OTHER|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
48351857|NCT00376675|DRUG|methylphenidate hydrochloride|Given orally
48504112|NCT06266650|OTHER|Osteopathic Treatment Technique- Muscle Energy Treatment|Muscle Energy Treatment involves a patient actively using their muscles on request from a precisely controlled position, in a specific direction, against a distinctly executed counter force. During Muscle Energy Treatment, the physician positions the area of treatment into a position of resistance, which is the restrictive barrier. The physician then instructs the patient to use the targeted muscles for 3-5 seconds in the direction of ease while the physician provides a counterforce. The physician then tells the patient to stop contracting their muscles and evaluate the area for decreased tension, then repositions the patient into their new restrictive barrier. These steps are repeated three to five times and then the dysfunction is reevaluated.
48662477|NCT00895804|DRUG|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
48662478|NCT05617079|OTHER|Survey|an electronic survey will be conducted
48351858|NCT00376675|OTHER|placebo|Given orally
48351859|NCT04837781|PROCEDURE|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
48351860|NCT02035410|PROCEDURE|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
48351861|NCT00001685|BIOLOGICAL|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
48351862|NCT05472376|OTHER|Retrospective study|Retrospective study
48662479|NCT03643237|BEHAVIORAL|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
48662480|NCT03643237|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
48662481|NCT01349478|DEVICE|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
48662482|NCT05103436|OTHER|TENS|Electrical nerve stimulation
48662483|NCT01085214|OTHER|Laboratory Biomarker Analysis|Correlative studies
48662484|NCT01085214|DRUG|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
48662485|NCT06288893|DRUG|SHEN211 Tablets|SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
47985840|NCT06459843|OTHER|coordinated breathing technique|Put one hand on your abdomen. Make your abdomen push out while you breathe in through your nose. Suck in your abdominal muscles. Breathe out using the pursed-lip technique. You should feel your abdomen go down. Repeat three times and rest for two minutes.
48141503|NCT00416975|PROCEDURE|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
48141504|NCT01044446|DRUG|Icodextrin|one exchange daily
48141505|NCT01044446|DRUG|glucose-based peritoneal dialysate|original exchange frequency
48141506|NCT04216641|DIETARY_SUPPLEMENT|Adapted food intervention|Adapted food intervention
48662486|NCT06288893|PROCEDURE|Placebo for SHEN211 Tablets|Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5
48141507|NCT02142595|DRUG|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
48504113|NCT03351465|BEHAVIORAL|Coordinated Anxiety Learning and Management|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
48662487|NCT00070304|BIOLOGICAL|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
48662488|NCT00070304|DRUG|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
47985841|NCT01811173|OTHER|Nurse-physician comprehensive care|"Components of the intervention include:~1. Complete assessment of the patient's and family's needs conducted by the nurse.~2. Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~3. Multimorbid care plan integrating all care aspects.~4. Action Plan for patients, supporting self management~5. Proactive monitoring according to the plan."
47985842|NCT05109351|BEHAVIORAL|Participating to Boost Meal Participation|The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
47985843|NCT03351179|COMBINATION_PRODUCT|clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes|The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
47985844|NCT02415751|BEHAVIORAL|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
47985845|NCT01403714|PROCEDURE|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
48141508|NCT02142595|DRUG|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
48141509|NCT03803150|PROCEDURE|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
48504114|NCT05594264|BEHAVIORAL|HBPStories|The objective of this arm was to pilot test the web-based storytelling program to determine the preliminary impact on blood pressure and medication adherence, and if the web-based approach was an engaging approach for individuals managing hypertension.
48504115|NCT05260060|BEHAVIORAL|Treatment as usual: Control|Treatment usually delivered in service that may include but is not limited to cognitive behaviour therapy, exposure, eye movement desensitisation and reprocessing , behaviour therapy, family therapy.
48662489|NCT00070304|DRUG|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
48662490|NCT01399853|BIOLOGICAL|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
48662491|NCT01399853|BIOLOGICAL|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
48662492|NCT01399853|BIOLOGICAL|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
48662493|NCT01399853|BIOLOGICAL|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
48141510|NCT03803150|PROCEDURE|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
48141511|NCT01115140|DRUG|metformin plus placebo|metformin 850 mg cp, 2 cps daily
48141512|NCT01115140|DRUG|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
48662494|NCT01399853|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
48662495|NCT04505800|DIETARY_SUPPLEMENT|Tryptophan supplement|"* Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
48662496|NCT04505800|DIETARY_SUPPLEMENT|Maltose|Maltose
48141513|NCT01115140|DRUG|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
48662497|NCT01335607|DRUG|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
48662498|NCT01335607|DRUG|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
48141514|NCT01115140|DRUG|placebo alone|placebo cp, 2 cps daily
48141515|NCT03043443|DRUG|Melatonin|Natural health product for sleep problems treatment
48141516|NCT03043443|DRUG|Placebo|Lactose containing pills
48141517|NCT03292406|DRUG|Placebo|Non active ingredients of CD11301
48141518|NCT03292406|DRUG|CD11301 0.03%|Topical Gel
48141519|NCT03292406|DRUG|CD11301 0.06%|Topical Gel
48141520|NCT01314066|DRUG|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
48141521|NCT01314066|DRUG|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
48141522|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
48141523|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
48662499|NCT03610048|DRUG|ALKS 5461|samidorphan + buprenorphine administered sublingually
48662500|NCT03864328|DRUG|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
48662501|NCT03864328|DRUG|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
48662502|NCT01657357|OTHER|Routine followup|questionnaires
48141524|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
48141525|NCT03172975|BIOLOGICAL|Placebo|Physiological sterile saline solution
48351863|NCT01462422|DRUG|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
48351864|NCT01462422|DRUG|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
48662503|NCT04872439|DIAGNOSTIC_TEST|Blood sample collection|Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
48662504|NCT00157872|DRUG|MK0966; rofecoxib|
48351865|NCT01910649|DRUG|Drisapersen|Subcutaneous and Intravenous
48351866|NCT05591430|PROCEDURE|Ganglion Impar Neurolysis|block of Ganglion Impar by neurolytic drug
48351867|NCT05591430|PROCEDURE|Bilateral S2, S3 and S4 Pulsed radiofrequency|Bilateral S2, S3 and S4 Pulsed radiofrequency
48351868|NCT03898752|DIETARY_SUPPLEMENT|Omega 3|Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
48351869|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises|All participants received a six-month intervention consisting of two phases: the first month was a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months were a formal practice phase of 45 minutes per session, once a day. In the first phase, participants learn four new movements per session and consolidate these exercises in the next session. After learning all the movements, the remaining time of the first phase was used to consolidate the exercises. In the second phase, participants perform a full Health Qigong - 12-Step Daoyin Health Preservation Exercises practice in each session.
48662505|NCT00157872|DRUG|Comparator: naproxen tablet 500 mg|
48662506|NCT05416814|DIETARY_SUPPLEMENT|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
48662507|NCT03986892|BEHAVIORAL|Physical Activity|Physical Activity
48141526|NCT03172975|DRUG|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
48351870|NCT06454565|BEHAVIORAL|Locked exercise|All participants received a six-month intervention of 45 minutes once a day. All participants performed blocked aerobic exercise.
48662508|NCT01370044|DRUG|Carbogen|3 minutes administration of carbogen
48662509|NCT01370044|DRUG|Placebo|3 minutes administration of oxygen
48141527|NCT03172975|OTHER|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
48141528|NCT01080404|PROCEDURE|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
48351871|NCT06454565|BEHAVIORAL|Multiplayer open exercise|All participants received a six-month intervention in the form of a balloon game competition. The intervention consisted of two phases: the first month consisted of a movement learning and consolidation phase of 45 minutes per session, once a day; the second five months consisted of a formal competition phase of 45 minutes per session, once a day. In the first phase, coaches taught participants the technical movements and rules. In the second phase, participants competed in groups during each session, with the coaches acting as referees.
48351872|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with locked exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed blocked exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Blocked Exercise group.
48662510|NCT02710032|BEHAVIORAL|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
48662511|NCT02710032|BEHAVIORAL|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
48662512|NCT02129972|DEVICE|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
48662513|NCT00146822|DEVICE|ENDOTAK RELIANCE G lead|
48662514|NCT02781363|OTHER|Thoracic ultrasound|
48662515|NCT02781363|OTHER|CXR|
48662516|NCT02625779|DRUG|Valproate and Placebo|
48662517|NCT02625779|DRUG|Valproate and Cytidine-containing Drug|
48662518|NCT02625779|DRUG|Valproate and Creatine-containing Drug|
48662519|NCT03107845|BEHAVIORAL|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
48141529|NCT01080404|DEVICE|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
48141530|NCT00950456|BIOLOGICAL|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
48351873|NCT06454565|BEHAVIORAL|Health Qigong - 12-Step Daoyin Health Preservation Exercises combined with open exercise|All participants received the intervention for six months, 45 minutes each time, once a day. All participants performed multiplayer Open Exercise followed by Health Qigong - 12-Step Daoyin Health Preservation Exercises exercises. The schedule was consistent with the Health Qigong - 12-Step Daoyin Health Preservation Exercises group and the Multiplayer Open Exercise group.
48351874|NCT04368741|DIETARY_SUPPLEMENT|SANZ®KINGWILL|20g nutrition product (SANZ®KINGWILL) was used as extra meal at 10:00am and 15:00pm, respectively.
48504116|NCT05260060|BEHAVIORAL|Group Metacognitive Therapy (Group-MCT): Experimental|Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
48662520|NCT03107845|BEHAVIORAL|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI \& OQ-30), interpersonal functioning (IIP-32 \& OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
48504117|NCT00150761|DRUG|Levocetirizine (drug)|
48504118|NCT05641090|OTHER|Nordic walking in water|Nordic walking in water will be based on nordic walking in water at temperature 34◦C. Nordic walking in water will be conducted at moderate intensity (40-60% heart rate reserve). The program was exercised 60 minutes include warm-up and cool down. At first 6 weeks, The exercise intensity was 40-50% heart rate reserve and it will be increased 50-60% heart rate reserve. The training program will be performed 3 times per week for 12 weeks.
48141531|NCT02223728|BEHAVIORAL|Lifestyle|
48141532|NCT02223728|BEHAVIORAL|Health Education|
48141533|NCT04809623|DRUG|Edecesertib|Tablets administered orally
48141534|NCT04809623|DRUG|Placebo|Placebo to match edecesertib tablets administered orally
48141535|NCT04809623|DRUG|Standard of Care|Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)
48141536|NCT04813991|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
48141537|NCT04813991|DRUG|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
48351875|NCT04368741|DIETARY_SUPPLEMENT|GLUCERNA SR®|17.5g nutrition product (GLUCERNA SR®) was used as extra meal at 10:00am and 15:00pm, respectively.
48351876|NCT05661175|PROCEDURE|one-handed technique|Traditional percutaneous nephrolithotripsy usually requires the left hand to hold the nephroscope and the right hand to control the fiber for lithotripsy.Our intervention is to control the depth and direction of the sheath with the left hand, the nephroscope in the right hand and control the fiber optic lithotripsy
48367529|NCT04196231|DRUG|IDegLira|IDegLira will be started at 16 dose steps (16 U insulin degludec plus 0.58 mg liraglutide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements doses of IDegLira will be titrated individually twice per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IDegLira could be titrated to 50 dose steps (50 U insulin degludec plus 1.8 mg liraglutide).
48504119|NCT05641090|OTHER|No exercise intervention|This group wasn't receive intervention program. The participants in this group will do following a physician who treat them. They can exercise according to the physician recommend.
48504120|NCT01276301|DRUG|Verapamil|single dose verapamil
48504121|NCT01276301|DRUG|BI 10773|single dose BI 10773
48504122|NCT01276301|DRUG|BI 10773|single dose BI 10773
48504123|NCT03850925|PROCEDURE|Laser therapy|4 consecutive sessions of laser therapy
48662521|NCT03107845|BEHAVIORAL|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
48662522|NCT00470522|DRUG|Methotrexate and folic acid|
48504124|NCT04591951|BEHAVIORAL|I2-ART|Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
48141538|NCT01331408|DEVICE|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
48662523|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
48662524|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
48662525|NCT01752049|DRUG|Topical timolol maleate|"* Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient"
48141539|NCT05199506|DEVICE|RAP|Treatment of cellulite with RAP device
48141540|NCT02661958|DRUG|S6G5T-3|once a day topical cream
48504125|NCT04591951|OTHER|Usual care|Care as usual
48141541|NCT02661958|DRUG|S6G5T-1|once a day topical cream
48141542|NCT02661958|DRUG|S6G5T-5|once a day topical cream
47985846|NCT03835611|OTHER|Game based treadmill Platform|"The protocol for the intervention group will be:~* Warm up exercised consisting of rhythmical large movements (10minutes)~* Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~* DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)"
48141543|NCT02661958|DRUG|S6G5T-6|once a day topical cream
48141544|NCT02661958|DRUG|S6G5T-7|once a day topical cream
48504126|NCT04855578|OTHER|In-Hopsital Patient Educational Brochure|The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.
48141545|NCT02661958|DRUG|S6G5T-8|once a day topical cream
48141546|NCT01846715|BIOLOGICAL|Implantation of SRC|
48141547|NCT03382704|DIAGNOSTIC_TEST|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
48141548|NCT01388413|DRUG|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
48141549|NCT01444365|DRUG|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
48141550|NCT01444365|DRUG|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
48141551|NCT00831948|GENETIC|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
48141552|NCT05749237|OTHER|respiratory exercises|respiratory exercises
48141553|NCT05749237|OTHER|relaxation exercises|relaxation exercises
48141554|NCT00424502|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
48504127|NCT04855578|OTHER|Physician Education about Gabapentinoid Prescription|An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
48662526|NCT01752049|DRUG|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
48662527|NCT06562829|DEVICE|Virtual reality technology|Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.
48662528|NCT06562829|OTHER|different timing of lidocaine injection|Group C (Lidocaine injection before puncture): Steps①was the same as in group B, After disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length.
48662529|NCT06278324|DEVICE|Nasal Spray HSV Treatment|Nasal treatment with the nasal spray Humer Stop Virus for 7 days, 2-3 puffs per nostril, 3-4 per day, space applications 4 hours apart.
48141555|NCT00424502|DRUG|Methotrexate|10-25mg po/week
48662530|NCT03524066|DRUG|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
48662531|NCT03524066|DRUG|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
48662532|NCT03524066|OTHER|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
48662533|NCT06243770|DRUG|mRNA-0184|Intravenous infusion
48662534|NCT02196350|BEHAVIORAL|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
47985847|NCT03835611|OTHER|Control Group|"* Warm-up exercise consisting of rhythmical large movements (10 minutes).~* Core standing balance exercises on a sponge surface (10 minutes).~* Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~* Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes)."
48141556|NCT05208294|DRUG|Sulpiride 400 MG|The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
48141557|NCT05208294|DRUG|Placebo|Participants receive an inactive placebo capsule.
48351877|NCT03644173|BEHAVIORAL|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
48351878|NCT02432911|DRUG|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
48351879|NCT02432911|DRUG|low dose cytarabine|cytarabine 20mg bid for 10 days.
47985848|NCT01905384|DEVICE|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
47985849|NCT01905384|DEVICE|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
48351880|NCT00198289|DRUG|Aurexis® (tefibazumab)|
48351881|NCT03501381|DRUG|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
48662535|NCT02196350|BEHAVIORAL|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
48662536|NCT02196350|BEHAVIORAL|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
48662537|NCT02327169|DRUG|MLN2480|MLN2480 tablets.
48662538|NCT02327169|DRUG|MLN0128|MLN0128 capsules.
48662539|NCT02327169|DRUG|Alisertib|Alisertib tablets.
48662540|NCT02327169|DRUG|Paclitaxel|Paclitaxel IV infusion.
48662541|NCT02327169|DRUG|Cetuximab|Cetuximab IV infusion.
48662542|NCT02327169|DRUG|Irinotecan|Irinotecan IV infusion.
48662543|NCT02423694|DEVICE|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\~1.0 mA"
48662544|NCT02423694|DRUG|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
48662545|NCT04883944|OTHER|Intervention group|"Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding;~* exposure to maternal voice."
48662546|NCT04883944|OTHER|Standard care group|"A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding."
48662547|NCT00824954|PROCEDURE|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
48662548|NCT06145412|DRUG|Xevinapan|Xevinapant (oral dose of 200mg per day on days 1-14 every 21 days for 3 cycles)
48662549|NCT06145412|DRUG|Cisplatin|Cisplatin (2-3 cycles, with 100mg/m2 per cycle q3 weeks)
48351882|NCT03501381|DRUG|Interleukin-2|In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
48662550|NCT06145412|RADIATION|External beam|60 - 66 Gy in 2 Gy fractions for patients without gross disease and 70 Gy for patients with early recurrence) with concurrent cisplatin (40 mg/m2 once weekly)
48662551|NCT00226356|DRUG|Supplements of L-methionine, betaine and folate|
48662552|NCT03798210|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
48662553|NCT03798210|DIETARY_SUPPLEMENT|Placebo|Placebo
48662554|NCT01710566|DRUG|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
48662555|NCT01710566|DRUG|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
48662556|NCT00294749|DRUG|Ciprofloxacine|
48662557|NCT04540367|DEVICE|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
48662558|NCT01405430|BIOLOGICAL|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
48662559|NCT01936831|DRUG|Isoniazid|INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
48662560|NCT01936831|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.
47985850|NCT03556007|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
48504128|NCT03452878|BEHAVIORAL|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
48662561|NCT00649584|DRUG|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
48662562|NCT00649584|DRUG|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
48662563|NCT01101126|OTHER|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
48662564|NCT01101126|OTHER|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
48662565|NCT04144920|BEHAVIORAL|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
47985851|NCT03556007|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
47985852|NCT02963207|OTHER|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
47985853|NCT02963207|OTHER|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
48351883|NCT01020929|DEVICE|Blunt Coude|Type of needle tip
48662566|NCT04144920|BEHAVIORAL|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
48662567|NCT04144920|BEHAVIORAL|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
48662568|NCT02101463|DEVICE|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
48662569|NCT01138722|RADIATION|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
48662570|NCT03198403|DRUG|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
48662571|NCT00601367|DRUG|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
48662572|NCT05790655|OTHER|oPRP|Prepared sample from patient's own blood collected and processed
48662573|NCT05494086|PROCEDURE|DPLDG|Dual-port laparoscopic distal gastrectomy
47985854|NCT00331279|DRUG|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
47985855|NCT00331279|DRUG|Placebo|Placebo pills in likeness of the cinnamon extract
47985856|NCT05256160|OTHER|TMS Paired-Pulse assessment of cortical excitability|Using the paired-pulse TMS paradigm, intracortical inhibition and facilitation of cortical circuitry will be assessed by stimulating the motor cortex and using the electromyographic (EMG) response of a target muscle as readout. In such studies, a conditioning stimulus modulates the amplitude of the motor-evoked potential (MEP) produced by the test stimulus. Depending on the inter-stimulus interval, effects can be attributed to different aspects of cortical processing. Brief intervals (1-5 ms) will be used to assess short-interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF), intermediate intervals (7-20 ms) to assess intracortical facilitation (ICF) and long intervals (50-200 ms) to assess long-interval intracortical inhibition (LICI).
48351884|NCT01020929|DEVICE|Quincke|Type of needle tip
48351885|NCT01020929|DEVICE|Trucath|Type of needle tip
48351886|NCT00846027|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
48504129|NCT01026987|DRUG|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
48504130|NCT01026987|DRUG|AMD3100|
48504131|NCT01026987|PROCEDURE|Leukapheresis|
48504132|NCT01026987|PROCEDURE|Stem Cell Infusion|
48504133|NCT03555006|OTHER|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
48351887|NCT00846027|DRUG|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
48662574|NCT05494086|PROCEDURE|LDG|Laparoscopic distal gastrectomy
47985857|NCT05256160|OTHER|Autonomic activity|Autonomic function will be determined using continuously recorded EKG and used as covariates to investigate any systematic impact on cortical excitability measures collected with the paired-pulse protocols.
47985858|NCT03284164|DRUG|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
47985859|NCT02657460|BIOLOGICAL|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
47985860|NCT02657460|DRUG|cisplatin|cisplatin is a traditional drug for lung cancer
47985861|NCT06494943|DRUG|Sintilimab|PD-1 inhibitor
48504134|NCT03555006|OTHER|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
48504135|NCT03112330|DEVICE|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
48504136|NCT03112330|DEVICE|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
48504137|NCT01877044|DIETARY_SUPPLEMENT|NAXUS|
48504138|NCT01877044|DIETARY_SUPPLEMENT|Placebo|
48504139|NCT02730117|DEVICE|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
48504140|NCT02730117|DEVICE|Mechanical ventilator|Invasive or noninvasive form of respiratory support
48504141|NCT02730117|DRUG|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
48504142|NCT02730117|DRUG|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
48662575|NCT04643379|DRUG|Olaparib|Supplied by Merck \& Co.
47985862|NCT06494943|DRUG|IBI110|LAG-3 inhibitor
47985863|NCT06494943|DRUG|Paclitaxel|Chemotherapy
47985864|NCT06494943|DRUG|Cis Platinum|Chemotherapy
47985865|NCT06494943|PROCEDURE|Surgery|Definitive surgery
47985866|NCT06494943|RADIATION|Adjuvant radiation|Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.
47985867|NCT01757054|DIETARY_SUPPLEMENT|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
47985868|NCT03509025|DRUG|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
47985869|NCT02396901|OTHER|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
48351888|NCT00846027|DRUG|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
48351889|NCT01247012|DIETARY_SUPPLEMENT|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
48351890|NCT01247012|DIETARY_SUPPLEMENT|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
48351891|NCT03565926|OTHER|Manual Therapy|"1. Articulation technique L4-S1~2. Lumbar neuromuscular technique~3. Fascial technique of crossed hands~4. Posteroanterior mobilizations of the lumbar vertebrae"
48351892|NCT03565926|OTHER|Hypopressive exercises|Protocol 5 Hypopressive exercises
48504143|NCT05176795|OTHER|Stool sample|Comparaison of the gut microbiota composition
48504144|NCT02101593|DRUG|ADI-PEG 20|
48504145|NCT00005399|OTHER|No interventions|No interventions
48504146|NCT05127512|OTHER|Education Video|A 6.47-minute education video was created by the research group based on American Urogynecology Society (AUGS) and International Urogynecologic Association (IUGA) patient education pamphlets. Participants in the intervention group will be asked to watch this video after completing a baseline knowledge questionnaire of pelvic floor disorders.
48504147|NCT02535871|DRUG|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
48504148|NCT02535871|DRUG|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
48662576|NCT04643379|DRUG|Pembrolizumab|Supplied by Merck \& Co.
48662577|NCT04643379|DRUG|Carboplatin|Commercially available
48662578|NCT04643379|PROCEDURE|Peripheral blood draw|Baseline (cycle 1 day 1), cycle 2 day 1, and at disease progression
48662579|NCT01344356|RADIATION|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
48141558|NCT05208294|BEHAVIORAL|High expectation manipulation|Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
48141559|NCT05208294|BEHAVIORAL|Low expectation manipulation|Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
48504149|NCT00946686|DRUG|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
48504150|NCT00946686|DRUG|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
48504151|NCT03885479|DIAGNOSTIC_TEST|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
48504152|NCT04859543|DEVICE|FoundationOneHeme|Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
48504153|NCT00371397|BEHAVIORAL|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
48504154|NCT00371397|BEHAVIORAL|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
48504155|NCT01410643|OTHER|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
48504156|NCT02755155|DRUG|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
48662580|NCT01344356|RADIATION|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
48662581|NCT01784302|DIETARY_SUPPLEMENT|Multivitamins|
48662582|NCT01784302|DIETARY_SUPPLEMENT|Sodium bicarbonate|
48662583|NCT01784302|DRUG|Maalox Plus extra|
48662584|NCT01784302|DRUG|Raltegravir 400 mg|
48662585|NCT01731782|DRUG|bupivacaine|
48662586|NCT01731782|DRUG|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
48662587|NCT01706185|OTHER|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
48662588|NCT01793389|PROCEDURE|Subepithelial connective tissue graft|
48662589|NCT01793389|PROCEDURE|Platelet Rich Fibrin|
48662590|NCT04023487|BEHAVIORAL|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
48662591|NCT00925275|DRUG|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
48662592|NCT06503185|BEHAVIORAL|Prehabilitation|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
48662593|NCT05938686|OTHER|Home_Based Digital Mindful Dance Program|Home_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
48662594|NCT04513236|OTHER|Pre-survey incentive|An incentive of is given in the form of airtime to motivate participants to complete the survey. Participants were sent 0.1X before the were sent a mobile phone survey and an additional 1X after completing the survey.
48662595|NCT04513236|OTHER|Post-survey incentive|An incentive in the form of airtime to motivate participants to complete the survey. Participants were given Bangladeshi Taka or Ugandan Shillings worth of certain airtime for completing the survey.
48662596|NCT01600287|OTHER|IAADS|"In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol."
48662597|NCT01600287|OTHER|Manual propofol administration|"In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value."
48662598|NCT03873545|PROCEDURE|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
48662599|NCT00023335|DRUG|Rifapentine|
48662600|NCT00023335|DRUG|Isoniazid|
48662601|NCT02625428|DRUG|Optison|
48141560|NCT04976764|OTHER||
48351893|NCT03001791|PROCEDURE|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
48351894|NCT03001791|PROCEDURE|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
48351895|NCT03001791|PROCEDURE|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
48504157|NCT02755155|DRUG|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
48504158|NCT05560061|OTHER|Gait practice on an uneven terrain surface|Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
48662602|NCT02625428|DIAGNOSTIC_TEST|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
48662603|NCT02625428|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
48662604|NCT04390282|BEHAVIORAL|Application-based support system|All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
48662605|NCT02880319|DRUG|Stereotactic Body Radiation Therapy (SBRT)|
48662606|NCT02880319|DEVICE|Stereotactic Linear Accelerator|
48662607|NCT05508347|DRUG|Nituzumab/placebo|"Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy"
48504159|NCT05560061|OTHER|Gait practice on a flat terrain surface|Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
48504160|NCT03870282|BEHAVIORAL|Sleep Extension|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
48504161|NCT02173314|OTHER|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
48662608|NCT02771301|BIOLOGICAL|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
48662609|NCT04830085|PROCEDURE|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
48662610|NCT04406454|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
48662611|NCT02602652|BIOLOGICAL|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
48662612|NCT02090764|DRUG|Ozenoxacin|
48662613|NCT02090764|DRUG|Placebo|
48662614|NCT06551649|OTHER|Venous blood draw and skin biopsy|The skin tissue will be used to isolate fibroblasts, which will then be reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs will be differentiated to develop patient-specific and control organoids. The blood samples will be used to isolate peripheral blood mononuclear cells (PBMC) to study the contribution of inflammation in the in vitro models developed.
48662615|NCT04669067|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
48662616|NCT04669067|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
48351896|NCT03083470|DRUG|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
48504162|NCT05080426|BEHAVIORAL|Family Supportive Supervisor Training 2.0|FSST 2.0 is a workplace intervention package designed to increase supervisors' family and leave supportive behaviors and leave supportive behaviors. The package includes Workplace Assessment tool, 2 45-60 minute online training modules (family-supportive supervisor training and supervisors' leave supportive behavior training), a webinar, behavior training, and individualized feedback reports.
48504163|NCT00418002|DRUG|AQW051|
48351897|NCT03083470|OTHER|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
48351898|NCT00003991|BIOLOGICAL|aldesleukin|
48351899|NCT00003991|DRUG|histamine dihydrochloride|
48662617|NCT01194596|BEHAVIORAL|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.
48662618|NCT01194596|BEHAVIORAL|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
48662619|NCT02010502|DIETARY_SUPPLEMENT|Beetroot juice|
48662620|NCT02010502|DIETARY_SUPPLEMENT|Beetroot powder|
48662621|NCT02010502|DIETARY_SUPPLEMENT|Placebo|
48662622|NCT06179537|DRUG|BLU-5937|Single and multiple doses assessment
48351900|NCT02496390|BIOLOGICAL|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
48351901|NCT02496390|BIOLOGICAL|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
48351902|NCT04085991|DRUG|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
48504164|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM)|PVI + Posterior Wall Isolation (PWI) + Electrogram Ablation (EGM) After performing PVI, electrogram mapping of the posterior left atrial wall is conducted. Subsequently, PWI and EGM ablation are performed. In this group, multipolar mapping catheters are used for EGM mapping. Target EGMs include spatially discrete potentials (STPs), localized short cycle length potentials (SCLPs), and focal activities.
48618315|NCT06408597|PROCEDURE|Fluid Regimen|"Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status."
48141561|NCT04017104|DIAGNOSTIC_TEST|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
48141562|NCT04017104|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
48141563|NCT04017104|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
48141564|NCT03014037|PROCEDURE|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
48141565|NCT03014037|PROCEDURE|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
48141566|NCT01274507|OTHER|Medical tests|All participants will undergo medical tests and will be observed.
48141567|NCT02677766|OTHER|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
48141568|NCT02677766|OTHER|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
48351903|NCT02251028|BEHAVIORAL|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
48351904|NCT02204111|OTHER|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
48351905|NCT01902654|OTHER|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
48504165|NCT06633523|PROCEDURE|PVI + Posterior Wall Isolation (PWI)|After performing PVI, the mapping catheter will be placed on the posterior wall to assess electrical activity and guide ablation. A bottom linear ablation (25-40W) will be performed, connecting the lowest points beneath the lower PVs. A top linear ablation (25-40W) will be conducted at the top of the left atrium, connecting the highest points above the upper PVs. If posterior wall isolation is not achieved after completing the bottom and top lines, mapping and localization of the earliest activation point within the box will be performed during pacing from the coronary sinus (CS). Posterior wall isolation will be completed by identifying and ablating local potentials at the entry and exit sites.
48504166|NCT06633523|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|The distance between the ablation lines on the posterior wall after circumferential pulmonary vein isolation should be at least 2 centimeters to limit the portion of the posterior wall within the PVI ablation zone. PVI will be confirmed by verifying entrance and exit block at the PV orifices.
48504167|NCT00581087|DRUG|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
48504168|NCT00581087|DRUG|Placebo|Treatment : 200 mg/day hard gelatine capsule
48618316|NCT02115386|DRUG|Nilotinib|supplied in 150 mg capsules to be taken orally
48662623|NCT05424588|DIAGNOSTIC_TEST|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
48662624|NCT00817609|DRUG|Angongniuhuang Pill|7 days of Angongniuhuang Pill
48662625|NCT00817609|DRUG|placebo|7 days of placebo
48662626|NCT00317122|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
48662627|NCT01069757|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
48662628|NCT05010473|BEHAVIORAL|Speech and non-speech sound stimulation|Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
48662629|NCT05790356|DRUG|Fecal Microbial transplant|Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
48662630|NCT05790356|OTHER|Placebo capsules|The placebo capsules will not contain FMT but will have the same appearance.
48662631|NCT00954447|DRUG|Placebo|Placebo, identical to Linagliptin tablet
48662632|NCT00954447|DRUG|Linagliptin|intended final marketed dose
48662633|NCT02587455|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
48662634|NCT02587455|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
48662635|NCT05458739|DEVICE|ClearCoast MR System|The removed specimen is scanned using the ClearCoast MR System.
48662636|NCT02003313|BIOLOGICAL|Group T|0.5ml, Intramuscular
48662637|NCT02003313|BIOLOGICAL|Group C|0.5ml, Intramuscular
48662638|NCT02784587|PROCEDURE|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
48662639|NCT01993550|BEHAVIORAL|Telephone counseling|
48662640|NCT01993550|BEHAVIORAL|Education|
48662641|NCT03682367|DRUG|Gabapentin|Use of Gabapentin peri- and post-operatively.
48662642|NCT03682367|DRUG|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
48662643|NCT00244985|BIOLOGICAL|rituximab|IV
48662644|NCT00244985|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
48662645|NCT03361449|OTHER|Flamingo exercise|Flamingo exercise
48662646|NCT03361449|OTHER|training with kinesthetic ability trainer|training with kinesthetic ability trainer
48662647|NCT00800644|PROCEDURE|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
48662648|NCT00642044|PROCEDURE|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
48662649|NCT00508456|DRUG|Temodar (Temozolomide)|150 mg/m\^2 orally once a day for 7 consecutive days (days 8 through 15).
48662650|NCT00508456|DIETARY_SUPPLEMENT|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
48662651|NCT05284643|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
48662652|NCT05284643|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
48662653|NCT02642757|BEHAVIORAL|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
48662654|NCT02642757|OTHER|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
48662655|NCT03350464|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
48351906|NCT01902654|OTHER|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
48351907|NCT01902654|OTHER|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
48351908|NCT02039089|DRUG|E2006 2.5 mg|
48662656|NCT03498716|DRUG|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
48662657|NCT03498716|DRUG|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.
48662658|NCT03498716|DRUG|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses"
48662659|NCT03498716|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
48662660|NCT02806661|PROCEDURE|Vagus nerve-preserving Robot-assisted Gastrectomy|
48662661|NCT02806661|PROCEDURE|Conventional Robot-assisted Gastrectomy|
48662662|NCT04766567|PROCEDURE|Cesarean section with cesarean myomectomy (serosal)|Serosal or endometrial myomectomy performed during cesarean section
48351909|NCT02039089|DRUG|E2006 10 mg|
48351910|NCT02039089|DRUG|E2006 25 mg|
48351911|NCT02039089|DRUG|Placebo|
48351912|NCT04722263|RADIATION|Radiotherapy|15 Gy in 3 fractions
48351913|NCT03908931|RADIATION|MRI|Follow up of osteochondral surgery by MRI and clinical examination
48351914|NCT02726607|BEHAVIORAL|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
48351915|NCT02726607|BEHAVIORAL|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
48662663|NCT04766567|PROCEDURE|Cesarean section without myomectomy|Cesarean delivery without performing myoemctomy
48141569|NCT05774262|PROCEDURE|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
48351916|NCT00075660|DRUG|triapine|
48351917|NCT05617248|BEHAVIORAL|Self-efficacy App|The training starts with a psychoeducational video and instructions to define two autobiographical self-efficacy The individuals will then receive three self-efficacy trainings per day based on their autobiographical memories and combined with a slow breathing exercise. Additionally, they will receive 10 daily EMA questionnaires on mood, social contacts, and virtual context.
48351918|NCT03882866|PROCEDURE|3D-printed non-coplanar template|3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
48351919|NCT03882866|PROCEDURE|3D-printed coplanar template|3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
48351920|NCT04489940|DRUG|Bintrafusp alfa|Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
48351921|NCT00611416|DIETARY_SUPPLEMENT|green tea|different catechin combinations
48351922|NCT00611416|DIETARY_SUPPLEMENT|Mix of catechins and caffeine|3 tablet a day
48351923|NCT00611416|DIETARY_SUPPLEMENT|EGCG|3 tablets a day
48351924|NCT00611416|DIETARY_SUPPLEMENT|EGC|3 tablets a day
48351925|NCT00611416|DIETARY_SUPPLEMENT|Caffeine|3 tablets a day
48351926|NCT00611416|DIETARY_SUPPLEMENT|Placebo|3 tablets a day
48662664|NCT04982796|DRUG|Psilocybin|See description of psilocybin-enhanced psychotherapy arm.
48662665|NCT04982796|BEHAVIORAL|Treatment-as-usual|See description of treatment-as-usual arm.
48662666|NCT04932148|OTHER|Incremental HD|Starting haemodialysis at twice weekly frequency
48662667|NCT04932148|OTHER|Conventional HD|Starting haemodialysis at thrice weekly frequency
48662668|NCT06341647|DRUG|AB-201|NK Cell Therapy
48662669|NCT06341647|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
48662670|NCT06341647|DRUG|Fludarabine|Lymphodepleting chemotherapy
48662671|NCT05164653|DRUG|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
48662672|NCT05164653|DRUG|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
48662673|NCT00543985|PROCEDURE|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
48662674|NCT04782375|DRUG|Stop group|discontinue antiviral treatment
48662675|NCT06080555|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
48662676|NCT06080555|DRUG|Ferric Carboxymaltose Injection [Ferinject]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
48662677|NCT05500534|DEVICE|Laser lithotripsy with stone recognition|Application of Revolix HTL+ which features automatic real-time stone recognition
48662678|NCT05500534|OTHER|Laser lithortripsy|Standard laser lithotripsy
48351927|NCT06119568|DEVICE|Robot assisted laparoscopic Radical/simple nephrectomy (RN), Partial nephrectomy (PN) or Radical Prostatectomy (RP).|Three different surgery interventions: 1. Radical Nephrectomy: Complete remove of the kidney; 2. Partial Nephrectomy: Partial remove of a section in the kidney. 3. Radical Prostatectomy: Complete remote of the prostate gland. During each of these procedures removal of regional lymph nodes (lymphadenectomy) and lysis of abdominal lesions may be performed according to patient medical condition and/or surgeon criteria.
48351928|NCT01092364|BEHAVIORAL|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
48662679|NCT04810624|BEHAVIORAL|Relapse Prevention and Changing Habits (REACH+)|Psychotherapy
48662680|NCT06495567|DIETARY_SUPPLEMENT|Creatine|For 7 days, participants will take a 20mg creatine supplement each day.
48141570|NCT05774262|PROCEDURE|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate \> 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
48662681|NCT06495567|DIETARY_SUPPLEMENT|Dietary methionine tracer and protein intake|On the study days participants will ingest 8 hourly meals of controlled amino acid intake, fortified with the necessary macronutrients. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g/kg/d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
48662682|NCT02757430|PROCEDURE|Cardiac Ablation|
48662683|NCT01295047|DRUG|Atenolol|
48141571|NCT04419207|DIAGNOSTIC_TEST|Breath test|Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
48662684|NCT01295047|DRUG|VERAPAMIL|240 MG SR
48662685|NCT01295047|DRUG|Perindopril|4 MG
48662686|NCT04198649|DRUG|Non-surgical periodontal treatment and azithromycin treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
48662687|NCT04198649|OTHER|Non-surgical periodontal treatment and placebo treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
48662688|NCT02001168|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
48662689|NCT02001168|DRUG|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
48351929|NCT02744781|DEVICE|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
48351930|NCT00542217|BIOLOGICAL|Imprime PGG|
48351931|NCT02052908|OTHER|Laboratory Biomarker Analysis|Correlative studies
48351932|NCT02052908|DRUG|Naproxen|Given PO
48351933|NCT02052908|OTHER|Placebo Administration|Given PO
48662690|NCT02001168|DRUG|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
48662691|NCT02001168|DRUG|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
48351934|NCT05194215|DEVICE|Ada WRA|The Ada WRA is a study-only device based on the Ada mobile app. The patient will use this device to answer questions regarding their symptoms but will not be given any feedback by the app.
48351935|NCT01564485|DIAGNOSTIC_TEST|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
48662692|NCT06564545|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
48662693|NCT06564545|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
48662694|NCT06564545|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
48662695|NCT00000600|DRUG|Vitamin E|
48662696|NCT00000600|DRUG|Vitamin C|
48662697|NCT06479356|BIOLOGICAL|Relma-cel|Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells
48351936|NCT01564485|BEHAVIORAL|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
48351937|NCT03884556|DRUG|TTX-030|Variable dose and schedule
48351938|NCT03884556|DRUG|Pembrolizumab|Dose and schedule per standard of care
48351939|NCT03884556|DRUG|Gemcitabine|Dose and schedule per standard of care
48351940|NCT03884556|DRUG|nab paclitaxel|Dose and schedule per standard of care
48351941|NCT04576663|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
48351942|NCT04576663|DRUG|Phenylephrine|Different infusion dose of phenylephrine simultaneous with subarachnoid block
48351943|NCT04691349|DRUG|CAR-T|The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
48662698|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 21 mg administered SC
48662699|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 35 mg administered SC
48662700|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 70 mg administered SC
48351944|NCT05780229|PROCEDURE|Conservative treatment|The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.
48351945|NCT05780229|PROCEDURE|Arthroscopic Decompression Surgery|Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.
48662701|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 140 mg administered SC
48662702|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 15 mg administered SC
48662703|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 25 mg administered SC
48662704|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 50 mg administered SC
48662705|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 100 mg administered SC
48662706|NCT04189484|BIOLOGICAL|Placebo|Placebo administered SC
48662707|NCT02882347|DRUG|Somatostatin|
48662708|NCT04765098|DRUG|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
48662709|NCT04765098|DRUG|Etoposide|etoposide 50mg/m2 daily
48662710|NCT04998513|DRUG|Medical Management Alone Arm|"The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group."
48662711|NCT04998513|PROCEDURE|Surgical Arm|"Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm."
48662712|NCT05945225|DEVICE|Sonicare DiamondClean 9000 Philips®|Brush teeth with the electric toothbrush daily during 3 months
48662713|NCT05945225|DEVICE|HydroSonic Easy Curaden®|Brush teeth with the hydrosonic toothbrush daily during 3 months
48662714|NCT05945225|DEVICE|Manual toothbrush Oral-B 123|Brush teeth with the manual toothbrush daily during 3 months
48662715|NCT05945225|DEVICE|Manual toothbrush Curaprox CS 5460|Brush teeth with the manual toothbrush daily during 3 months
48662716|NCT05737979|OTHER|Study chart review|Evaluation of the IVF cycle using the prescribed medication
48662717|NCT03757494|DEVICE|Alpha Stim|Use of Alpha Stim Device
48662718|NCT01691911|PROCEDURE|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
48662719|NCT01940055|BEHAVIORAL|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
48351946|NCT05780229|PROCEDURE|Reverse Prosthesis|The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.
48351947|NCT05780229|DRUG|Pain-Relief Medication|In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
48351948|NCT05780229|DEVICE|Reverse Prosthesis Device|In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
48351949|NCT03486769|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal transcranial direct current stimulation
48504169|NCT05667675|BEHAVIORAL|Community Support Worker|Participants in the intervention group will have a structured review of their financially related needs and resources with a trained CSW, who will have a thorough understanding of potential income supports and community support agencies. The CSW will use a structured approach to identify financial needs and benefits for which the family is eligible The CSW will work intensively with families in the intervention arm to identify and meet their goals. They will conduct weekly meetings to complete forms, and provide advocacy (in person and by telephone) as needed up to six meetings as needed for system navigation.
48351950|NCT03486769|DEVICE|PMC stimulation|stimulating premotor cortex with anodal transcranial direct current stimulation
48504170|NCT05667675|BEHAVIORAL|Control|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. For this proposal, participants in the comparator group will receive Usual care, defined as: Participants in both groups will receive a written summary of available resources.
48504171|NCT05994001|DRUG|cardonilizumab|cardonilizumab:PD1 and CTLA-4 bispecific antibody
48504172|NCT05994001|DRUG|LM-302|LM-302 :ClAUDIN 18.2-ADC
48662720|NCT01940055|BEHAVIORAL|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
48662721|NCT05751304|DRUG|Dexmedetomidine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
48662722|NCT05751304|DRUG|Ketamine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
48662723|NCT01836354|BEHAVIORAL|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
48662724|NCT03984240|DRUG|Midazolam|Participant will be sedated by midazolam.
48662725|NCT03984240|DRUG|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
47985870|NCT04106986|COMBINATION_PRODUCT|Pulsed electromagnetic field and Progressives resistance exercise|"The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
47985871|NCT04106986|OTHER|PRE|"The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
48351951|NCT03486769|DEVICE|aIPS stimulation|stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
48351952|NCT03486769|BEHAVIORAL|hand motor task|hand motor task for 30 minutes during transcranial direct current stimulation
48351953|NCT04396106|DRUG|AT-527|One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
48351954|NCT04396106|OTHER|Placebo|One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
48351955|NCT04396106|DRUG|AT-527|Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
48351956|NCT04396106|OTHER|Placebo|Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
48351957|NCT02054663|DRUG|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
48504173|NCT00634881|BIOLOGICAL|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
48351958|NCT01388491|DRUG|desogestrel/ethinyl estradiol and ethinyl estradiol|
48351959|NCT01388491|DRUG|desogestrel/ethinyl estradiol|
48351960|NCT02098629|DRUG|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
48662726|NCT04000880|BEHAVIORAL|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
48662727|NCT04000880|OTHER|Diet-Exercise|Diet-Exercise
48662728|NCT04000880|OTHER|Exercise-Diet|Exercise-Diet
48662729|NCT04000880|OTHER|Combined Diet and Exercise|Combined Diet and Exercise
48662730|NCT05930639|OTHER|Surgical Site Infection (SSI) prevention package|"Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.~Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.~Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.~In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.~Before the operation and before discharge, the patient is educated about infection prevention measures."
48662731|NCT06564116|BIOLOGICAL|Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.
48662732|NCT06564116|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of licensed hepatitis E vaccine intramuscularly at month 0, 1 and 6
48662733|NCT03495414|OTHER|Brain Imaging|"* Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation)."
48662734|NCT03495414|OTHER|Cognitive testing|"We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task)."
48662735|NCT03495414|OTHER|Psychometric|Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
48662736|NCT03495414|OTHER|Blood test|Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
48662737|NCT01799902|DRUG|Solifenacin|Oral
48662738|NCT03758521|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
48662739|NCT03758521|DEVICE|Magnetic resonance imaging (MRI)|These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
48351961|NCT02098629|DRUG|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
48662740|NCT03758521|DEVICE|Electroencephalogram (EEG)|These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
48504174|NCT00634881|BIOLOGICAL|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
48504175|NCT06124495|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
48351962|NCT02098629|DRUG|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
48351963|NCT04205474|DIAGNOSTIC_TEST|graded bicycle test|the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
48351964|NCT00432289|PROCEDURE|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
48504176|NCT02074917|PROCEDURE|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
48504177|NCT04308707|OTHER|Breaking bad news skills|Communication skills analyzed by a specialized questionnaire designed from a Breaking bad news protocol developed in 2018-2019 in Barcelona.
48504178|NCT00737750|DEVICE|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
48504179|NCT00737750|DEVICE|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
48351965|NCT01751373|BEHAVIORAL|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
48351966|NCT01751373|BEHAVIORAL|Standard Therapy|
48351967|NCT00004205|DRUG|letrozole|Letrozole 2.5 mg daily oral administration.
48351968|NCT00004205|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
48504180|NCT00737750|BEHAVIORAL|Control|Voluntary quadriceps muscle contractions.
48662741|NCT03758521|PROCEDURE|Bio-specimen Collection|Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
48351969|NCT01878175|BEHAVIORAL|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
48504181|NCT01340768|DRUG|Sitagliptin|One 100 mg tablet taken orally once daily
48504182|NCT01340768|DRUG|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
48504183|NCT01340768|DRUG|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
48662742|NCT01001689|BEHAVIORAL|Nutritional counseling + exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
48662743|NCT01331655|DRUG|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
48504184|NCT02600689|BEHAVIORAL|Physical exercise training|
48662744|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
48662745|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
48351970|NCT06267495|PROCEDURE|Epithelium-on corneal cross-linking (epi-on CXL)|In epithelium-on corneal cross-linking (epi-on CXL), the cornea is soaked with riboflavin for 10 minutes (Paracel® for 4 minutes and VibeX-xtra® for 6 minutes) . Thereafter, the cornea is subjected to ultraviolet A at a wavelength of 370 nm to give a total dose of 5.4 J/cm² through 10 milliwatt mW/cm² for 9 minutes.
48351971|NCT05789706|BEHAVIORAL|Dayamed Arthur a novel intelligent medication adherence platform|Novel smart phone adherence application configured with subject pharmacy data providing accurate reminders of when to take medications and providing auditable user feed back to clinical care teams for patient response directed provider intervention.
48351972|NCT01646255|DRUG|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
48351973|NCT01646255|DRUG|Placebo Patch|"Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
48351974|NCT01646255|DRUG|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
48351975|NCT00854568|DRUG|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
48351976|NCT00854568|DRUG|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
48351977|NCT00654394|DRUG|Rosuvastatin|
48351978|NCT01555541|DRUG|Ofatumumab|1000 mg IV days 0, 7, 14, 21
48351979|NCT01555541|DRUG|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
48351980|NCT01555541|DRUG|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
48351981|NCT03733132|DRUG|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
48351982|NCT03733132|DRUG|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
48351983|NCT00024544|DRUG|anti-IL-4 monoclonal antibody (pascolizumab)|
48351984|NCT02845440|OTHER|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
48662746|NCT03773484|BEHAVIORAL|Opioid naive|Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
48662747|NCT03773484|BEHAVIORAL|At-risk for long term use|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
48351985|NCT02845440|OTHER|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
48351986|NCT02845440|OTHER|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
48351987|NCT00002274|DRUG|Didanosine|
48351988|NCT05431972|DEVICE|Cardea SOLO|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
48351989|NCT05431972|DEVICE|12 Lead EKG|Neurologist cardiac rhythm translation with 12 lead EKG versus Cardea SOLO
48351990|NCT01541540|BEHAVIORAL|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
48351991|NCT01541540|BEHAVIORAL|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
48351992|NCT05859581|PROCEDURE|Beyond complete mesocolic excision surgery|If the participants were diagnosed with positive retroperitoneal resection margin (RPRM), they underwent beyond complete mesocolic excision surgery to ensure the R0 resection.
48351993|NCT02531919|DRUG|Sodium Bicarbonate|Given PO
48662748|NCT03773484|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
48662749|NCT01923922|RADIATION|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
48141572|NCT04406532|BEHAVIORAL|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
48141573|NCT04406532|BEHAVIORAL|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
48504185|NCT02600689|BEHAVIORAL|Cognitive exercise training|
48662750|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Erector Spinae block|Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
48662751|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Paravertebral block|Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
48662752|NCT05790447|DRUG|Thymalfasin|loading dose with thymalfasin based on the amounts of T lymphocyte
48141574|NCT06475521|OTHER|Infant Formula|Test group
48141575|NCT01837368|OTHER|observational research|It is a observational research, no intervention are performed
48141576|NCT04817345|DRUG|Plerixafor|Subcutaneous
48141577|NCT03806309|DRUG|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
48504186|NCT02040506|DRUG|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
48504187|NCT03251235|BEHAVIORAL|Cognitive Behaviour Therapy|
48504188|NCT04632511|DEVICE|MetaSAMP|Rectal Sampler
48618317|NCT04755517|OTHER|Frequent information of cytological/ HPV DNA screening results|"All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end."
48618318|NCT02205645|DEVICE|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
48618319|NCT02308878|BEHAVIORAL|Mobile health cognitive stimulation|
48618320|NCT02494024|DRUG|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
48618321|NCT02494024|DRUG|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
48618322|NCT01682525|OTHER|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
48618323|NCT03409380|DIETARY_SUPPLEMENT|Arginine Drink|10 g of arginine in a formulated drink
48618324|NCT03409380|DIETARY_SUPPLEMENT|Plain Drink|formulated drink
48618325|NCT00002302|DRUG|Epoetin alfa|
48618326|NCT00745602|PROCEDURE|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
48618327|NCT04804137|OTHER|Blood|Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.
48618328|NCT04804137|OTHER|sputum|induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.
48618329|NCT04804137|OTHER|saliva|spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.
48618330|NCT04804137|OTHER|stool|Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.
48618331|NCT03154606|OTHER|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
48618332|NCT03154606|OTHER|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
48618333|NCT03154606|OTHER|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
48618334|NCT03154606|OTHER|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
48662753|NCT05790447|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
48662754|NCT05790447|DRUG|PD-1/PD-L1 inhibitor|The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
48662755|NCT05790447|DRUG|GM-CSF|subcutaneous injection daily for 7 consecutive days
48662756|NCT04604431|OTHER|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
48662757|NCT04856280|BEHAVIORAL|Kinesiological taping|In KT Group, 6 sessions of KT were applied, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended.
48662758|NCT04856280|BEHAVIORAL|Aerobic exercise|In the AE group, walking and climbing stairs were given during the menstrual cycle, 3 days a week, 45 minutes.
48662759|NCT04608058|BEHAVIORAL|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
48141578|NCT03806309|DRUG|OSE2101|subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
48141579|NCT00357019|DRUG|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
48351994|NCT03632304|PROCEDURE|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
48351995|NCT02058706|DRUG|enzalutamide|Given PO
48351996|NCT02058706|DRUG|bicalutamide|Given PO
48351997|NCT02058706|PROCEDURE|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
48504189|NCT03311035|PROCEDURE|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
48662760|NCT04608058|BEHAVIORAL|Routine training|The control group received the clinics' routine training include face to face class education.
48351998|NCT02058706|DRUG|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
48141580|NCT01874366|DRUG|P11187|"* Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
48141581|NCT01874366|DRUG|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
48662761|NCT03100526|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
48662762|NCT02256748|DRUG|BIRT 2584 XX|
48662763|NCT02256748|DRUG|Midazolam|
48662764|NCT03748550|BEHAVIORAL|Aerobic exercise|All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
48662765|NCT02551783|PROCEDURE|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
48662766|NCT02551783|PROCEDURE|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
48662767|NCT01520181|DRUG|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
48662768|NCT04570202|BEHAVIORAL|EMDR|The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.
48662769|NCT01929694|DIETARY_SUPPLEMENT|Berocca Boost|
48662770|NCT01929694|DIETARY_SUPPLEMENT|Placebo|
48662771|NCT02248571|DRUG|Bevacizumab|administered as combined therapy with Capecitabine
48662772|NCT02248571|DRUG|Capecitabine|administered as combined therapy with Bevacizumab
48662773|NCT02248571|DRUG|Everolimus|administered as combined therapy with Exemestane
48662774|NCT02248571|DRUG|Exemestane|administered as combined therapy with Everolimus
48662775|NCT02248571|OTHER|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
48662776|NCT05701826|DRUG|HRS3797|HRS3797 for injection, low dose
48141582|NCT01939509|DRUG|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
48141583|NCT01939509|DRUG|Bisoprolol|
48141584|NCT05537532|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
48141585|NCT05537532|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
48662777|NCT05701826|DRUG|HRS3797|HRS3797 for injection, medium dose
48141586|NCT05537532|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
48141587|NCT02279485|DRUG|Perampanel|
48141588|NCT02459860|BEHAVIORAL|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
48351999|NCT02058706|DRUG|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
48662778|NCT05701826|DRUG|HRS3797|HRS3797 for injection, high dose
48662779|NCT05840263|BEHAVIORAL|Qualitative interview|Qualitative interviews will cover four main goals including: (1) key sources of distress in mCRC patients and partners; (2) perceptions of mindfulness, including benefits, definitions, and applications; (3) barriers and facilitators of participation (e.g. home-based and couple-based skills practice, enrollment); and (4) session format preferences, such as session length and frequency.
48662780|NCT05840263|BEHAVIORAL|Cognitive Interviews|The objective of the cognitive interviews (60 minutes, led by the PI) is to ensure the comprehensibility and appropriateness of the drafted participant materials. Published guidelines note a sample size of 12 participants (6 mCRC couples) should be sufficient. Participants will be asked to read, review, and mark up the participant materials in order to identify sections that were difficult to understand. They will also be asked to test playing segments of the audio/video recordings to ensure ease of use. A semi-structured interview format will be used to elicit feedback, including a standard verbal survey assessing ease of reading the material, any difficulties experienced, and suggestions they have for improving the ease of material use. Information generated will be used to update materials as necessary.
48662781|NCT02006511|DEVICE|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
48662782|NCT02006511|OTHER|Standard of Care wound therapy|Gauze type dressing.
48662783|NCT01676233|DRUG|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
48662784|NCT01676233|DRUG|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
48141589|NCT02459860|BEHAVIORAL|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
48504190|NCT03311035|PROCEDURE|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
47985872|NCT01425957|PROCEDURE|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
48141590|NCT01147471|DEVICE|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
48141591|NCT01147471|PROCEDURE|operative rib fixation surgery|
48141592|NCT02183272|DRUG|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
48141593|NCT02183272|DRUG|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
48352000|NCT02058706|OTHER|laboratory biomarker analysis|Correlative studies
48352001|NCT01345825|OTHER|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
48352002|NCT04022291|BIOLOGICAL|Humulin ®70/30|"Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
48352003|NCT04022291|BIOLOGICAL|Biocon Insulin 70/30|"Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
48352004|NCT01640067|BIOLOGICAL|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
48504191|NCT05326776|DRUG|Pitocin|At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
48504192|NCT05256524|DRUG|The effect of LMWH|Quantified by aFXa-levels
48504193|NCT05256524|DIAGNOSTIC_TEST|Monitoring frequency of aFXa-levels|The frequency of aFXa-levels being sampled, analysed and integrated as a possible part of the basis for clinical decisionmaking
48504194|NCT00345943|OTHER|MRI|Magnetic Resonance Imaging scans
48504195|NCT00345943|BEHAVIORAL|Neuropsychological Testing|Neuropsychological tests
48504196|NCT01695863|DRUG|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
48504197|NCT02452983|DRUG|Sertraline|
48504198|NCT02452983|PROCEDURE|Bone Marrow Aspirate/Biopsy|
48504199|NCT01151228|OTHER|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
48504200|NCT00637650|PROCEDURE|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
48504201|NCT00637650|PROCEDURE|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
48504202|NCT01521182|OTHER|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
48352005|NCT03714256|DEVICE|Device, patient mobility, powered|Pediatric mobility device
48662785|NCT04052165|PROCEDURE|Glaucoma Implant|
48662786|NCT05503277|DEVICE|LTSD|measuring seal pressure
48662787|NCT05503277|DEVICE|i-gel|measuring seal pressure
47985873|NCT02987400|DRUG|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
48352006|NCT03050606|OTHER|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
48352007|NCT03050606|OTHER|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
48352008|NCT01209117|DRUG|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
47985874|NCT02987400|DRUG|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
47985875|NCT04181502|PROCEDURE|pneumatic tourniquet|a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
47985876|NCT04181502|OTHER|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
48141594|NCT02689011|PROCEDURE|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
48141595|NCT02689011|PROCEDURE|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
48352009|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
48662788|NCT03484104|DIAGNOSTIC_TEST|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
48352010|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
48352011|NCT01209117|DRUG|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
48352012|NCT01209117|DRUG|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
48352013|NCT05505539|DRUG|5-fluorouracil|Given intralesionally by injection
48352014|NCT03973632|DRUG|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
48352015|NCT01653756|DRUG|IPI-145, a PI3K Inhibitor|Active drug
48352016|NCT01653756|DRUG|Placebo to match IPI-145|Comparator
48352017|NCT02820480|DEVICE|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
48352018|NCT06246136|PROCEDURE|ELIOS|Following cataract surgery, surgeon will proceed to ELIOS treatment.
48352019|NCT06246136|PROCEDURE|Competitor Device|Following cataract surgery, surgeon will proceed to Competitor treatment.
48352020|NCT04933253|PROCEDURE|Saline irrigation|Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
48352021|NCT01739374|OTHER|reduced mesh implants|mesh for pelvic floor reinforcement
48352022|NCT00883649|DIETARY_SUPPLEMENT|Hydroeye|2 Capsules BID
48352023|NCT00883649|OTHER|Inactive Capsule|2 Capsules BID
48662789|NCT05382130|DIAGNOSTIC_TEST|Test all|"In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results."
48662790|NCT05766605|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
48662791|NCT05766605|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
48141596|NCT04943640|OTHER|kinesio taping|Kinesio tape was developed by Kenzo Kase in the 1970s. It is an elastic tape, and its adhesive face is sinusoidal wavy. This feature has been shown to increase daily living activities and functions, as it supports the tissue while also allowing movement \[12\]. Kinesio tape lifts the skin and subcutaneous soft tissues of the fascia, which are painful and inflamed regions upon contractions seen in the tissue after tense adhesion to the skin. Therefore, it has been reported to reduce oedema and inflammation by creating more space and providing blood and lymphatic fluid flow.
48141597|NCT04943640|OTHER|rigid taping|The tape material used in rigid (athletic) tape application is hard. It is used to position and unite the soft tissue, to protect the tissue from impact and to prevent local swelling.There are studies in the literature supporting the sensorimotor and proprioceptive sensation-enhancing effect of the athletic band, which provides a very good sensory input through the skin.
48141598|NCT04943640|OTHER|placebo taping|Placebo taping was applied to the patients in this group, using betafix, an elastic fixation band, as the material. The patient was told that taping would be applied. A straight line betafix was applied to the non-painful scapular inferior level of the spine on the right and left sides of the standing patient.
48141599|NCT00553332|DRUG|selumetinib|Given orally
48141600|NCT00553332|OTHER|laboratory biomarker analysis|Correlative studies
48352024|NCT04422197|BIOLOGICAL|Botox|effect of botox injection in abdominal wall muscle post major abdominal surgery in terms of postoperative pain, incidence of incisional hernia.
48352025|NCT04422197|PROCEDURE|surgery without botox injection|surgery without botox injection
48352026|NCT02022644|DRUG|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
48504203|NCT01521182|OTHER|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
48504204|NCT03265288|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
48141601|NCT00254124|DEVICE|The Diet Plate (R) TM portion control plate and bowl|
48352027|NCT05373810|OTHER|Surgery|all interventions are allowed
48352028|NCT05870397|DIAGNOSTIC_TEST|HY-IREXB plus carbon 13 breath detector do the breath urea test after eradication at different times|Carbon 13 breath tests are generally performed 4-6 weeks after eradication therapy. The control group will perform breath urea test at 4-6 weeks after treatment. The experimental groups will perform the same test at different times after the same treatment, 6-8weeks and 8-10 weeks, respectively.
48504205|NCT03265288|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
48504206|NCT05792696|BEHAVIORAL|PPI guided strategies|For targeted MAP or lower, if PPI\<1, more fluid therapy. if PPI\>3, vasoconstriction therapy. For MAP\<65mmHg and 1\<=PPI\<3, test bolus of 250 ml crystalloid fluid.
48352029|NCT02807155|BEHAVIORAL|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
48352030|NCT02807155|BEHAVIORAL|Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
48352031|NCT02807155|BEHAVIORAL|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
48352032|NCT04347902|DRUG|Intravenous Lipid Emulsion|Various types of intravenous lipids
48504207|NCT05792696|BEHAVIORAL|Empirical strategies|Fluid therapy or vasoconstriction depended on experiences of anesthetic staffs.
48352033|NCT05013099|BIOLOGICAL|zirconium Zr 89 crefmirlimab berdoxam|Up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan, for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First (PETbaseline) within 14 days prior to the onset of IOT, and a second (PETEOC1) 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan (PETEOC1) should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.
48352034|NCT04949633|DRUG|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
48352035|NCT04949633|DRUG|Oxytocin|Induction of labor with oxytocin.
48352036|NCT03256006|OTHER|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
48662792|NCT05766605|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
48662793|NCT05766605|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
48662794|NCT05766605|DRUG|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
48141602|NCT01213940|BEHAVIORAL|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
48141603|NCT01213940|PROCEDURE|bariatric surgery|bariatric surgery for weight loss
48141604|NCT03876886|DRUG|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
48141605|NCT03876886|DRUG|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
48141606|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*4cycles
48352037|NCT00958191|DEVICE|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
48352038|NCT05098249|DRUG|Verum|The participant takes two capsules Phoscap® (3mmol/capsule) orally three times a day over 30 days beginning the day of Ferinject administration.
48352039|NCT05098249|DRUG|Placebo|The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
48662795|NCT05766605|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
48141607|NCT03876886|DRUG|Carboplatin|carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih
48141608|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*8cycles
48141609|NCT02832128|DRUG|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
48141610|NCT02832128|DRUG|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
48141611|NCT01084525|DRUG|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
48141612|NCT01084525|DRUG|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
48141613|NCT01084525|DRUG|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
48141614|NCT05395481|DRUG|LY3849891|Administered SC.
48141615|NCT05395481|DRUG|Placebo|Administered SC.
48141616|NCT06003244|OTHER|6-minute walk distance (6MWD) test|6-minute walk distance (6MWD) test will be performed according to clinical standards
48141617|NCT06003244|OTHER|6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)
48141618|NCT03553225|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
48141619|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 1|1 g Concord Grape extract in 2 capsules
48662796|NCT06453577|DRUG|Recompensation (guideline directed medical therapy)|Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.
48662797|NCT03589742|DEVICE|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
48662798|NCT00529048|OTHER|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
48662799|NCT00529048|OTHER|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
48662800|NCT00529048|OTHER|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
48141620|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 2|500 mg Concord Grape extract in 2 capsules
48141621|NCT03265756|DEVICE|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
48141622|NCT04518709|PROCEDURE|Posterior Mitral Annulus Elevation Technique|Posterior mitral annulus elevation technique is performed using a large pledget and non-absorbable braided suture starting from the subvalvular section of the posterior mitral valve sutured to the ring annuloplasty (if in the process of repairing the mitral valve, ring implantation is performed; if without the use of ring annuloplasty, the suture is placed in the left atrial wall / supravalvular of PML), so that the posterior annulus is slightly attracted upward toward the cranial and the PML moves toward the center.
48141623|NCT04518709|PROCEDURE|Conventional Mitral Valve Repair|Conventional mitral valve repair in the pediatric patient using annuloplasty, leaflet resection and plication, sliding-plasty of chordae technique
48352040|NCT03790267|OTHER|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
48352041|NCT01353066|DRUG|Intensive Medical Treatment|
48352042|NCT01353066|OTHER|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
48504208|NCT01873183|OTHER|Goal directed fluid therapy|
48662801|NCT04405531|OTHER|task-oriented training (TOT)|The study group received a TOT together with a conventional occupational therapy (COT). The study groups received a treatment for 20 sessions at a hospital setting.
48662802|NCT04405531|OTHER|conventional occupational therapy (COT)|The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.
48618335|NCT03154606|OTHER|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
48352043|NCT04341025|BEHAVIORAL|Mindfulness based psychosexual therapy ( MBPST)|The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.
48352044|NCT00824967|OTHER|Training and valuation of the treating personnel|Training and valuation of the treating personnel
48352045|NCT03698929|OTHER|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
48352046|NCT03698929|OTHER|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
48662803|NCT03222570|BEHAVIORAL|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
48662804|NCT03222570|DRUG|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
48662805|NCT03222570|OTHER|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
48662806|NCT04746898|OTHER|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
48662807|NCT04746898|OTHER|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
48662808|NCT04746898|OTHER|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
48662809|NCT06183021|PROCEDURE|Vital pulp cryotherapy|Shaved ice made from sterile distilled water will be applied around the treated tooth especially in contact with amputated pulp tissue until totally dissolves.
48662810|NCT06183021|PROCEDURE|Intracanal cryotherapy|After mechanical preparation, a 5-minute final irrigation with 20 mL cold saline (2.5 Centigrade degrees) will be applied using a negative pressure irrigation technique per canal.
48662811|NCT05991453|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
48662812|NCT05991453|OTHER|Anesthetic technique inhaled agent|Must administer inhaled agent.
48504209|NCT06130098|OTHER|control group|"Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients."
48662813|NCT01895192|OTHER|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
48662814|NCT04438824|DRUG|INCMGA00012|INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
48662815|NCT04438824|DRUG|Palbociclib|Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days
48662816|NCT04273061|DRUG|Atezolizumab|1200 mg by intravenous infusion every 3 weeks as tolerated
48662817|NCT00006004|DRUG|carboplatin|
48662818|NCT00006004|DRUG|cisplatin|
48352047|NCT05346380|DEVICE|Olympus VE2 NIR Imaging System|A prospective, (NSR), single-center feasibility study of the Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm.
48662819|NCT00006004|DRUG|gemcitabine hydrochloride|
48662820|NCT00006004|DRUG|paclitaxel|
48662821|NCT06327438|OTHER|Complex decongestive therapy|"1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care."
48662822|NCT06327438|DEVICE|Cryotherapy|It is a mature and safe-to-use system that cools the air to -32°C. Steps of application included: 1) Apply oil or cream to moisture the skin before cryotherapy application; 2) Initialize the mini cryo-air equipment at level 6.
48662823|NCT06327438|OTHER|Kinesio taping|It is a new choice in the field of physical therapy. The material used for the KT and the original concept of the taping technique were introduced by Dr Kenso Kase in 1973.
48662824|NCT06563518|DRUG|Meridol|toothpaste
48662825|NCT06563518|DRUG|Colgate Cavity Protection|toothpaste
48352048|NCT05346380|DRUG|Indocyanine green|intravenous delivery of low-dose 0.15 mg/kg of ICG combined with Olympus VE2 NIR Imaging System to assess perfusion using NIR during minimally invasive esophagectomy or pulmonary segmentectomy based on treatment arm
48352049|NCT01662128|DRUG|Xeloda|Xeloda as Adjuvant Therapy
48352050|NCT00312741|PROCEDURE|empirical versus microbiological guided treatment|
48662826|NCT06184802|BEHAVIORAL|TAU+Multisensory room|Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play
48352051|NCT04369586|DRUG|meplazumab for injection|single dose: 6 dose level, multiple dose: 0.3mg/kg/dose
48352052|NCT04369586|DRUG|Placebo|placebo
48352053|NCT01608555|DRUG|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
48352054|NCT06175104|BEHAVIORAL|HeartGPS|"HeartGPS includes three key components:~1. Sessions with a psychologist trained to deliver the intervention using attachment-based and trauma-informed therapy techniques, coupled with mind-body skills. The intervention can be delivered in-person or via telehealth, in accordance with participants' preferences.~2. Educational resources, including a series of modules to complement the sessions and evidence-based tools to support psychological adjustment and coping, parent-infant bonding and attachment, and parent-clinician communication.~3. A personalized care plan, charting mental health care needs, goals, and preferences, with evidence-based strategies to support longer-term wellbeing."
48352055|NCT02941042|DRUG|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
48352056|NCT02941042|DRUG|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
48352057|NCT02118402|DIETARY_SUPPLEMENT|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
48662827|NCT06184802|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
48662828|NCT04028258|DIETARY_SUPPLEMENT|Mixture of fibers + Placebo|Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
48662829|NCT04028258|DIETARY_SUPPLEMENT|Placebo + Mixture of fibers|Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
48662830|NCT02171728|DRUG|BIBW 2992|
48662831|NCT04667156|DRUG|SHR6390|SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
48662832|NCT01813383|OTHER|There is not any intervention|
48662833|NCT06565143|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak alternating currents.
48662834|NCT06565143|DEVICE|Sham transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
48618336|NCT03154606|OTHER|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
48662835|NCT03958331|BEHAVIORAL|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
48662836|NCT03958331|BEHAVIORAL|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
48662837|NCT03958331|BEHAVIORAL|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
48662838|NCT04267445|PROCEDURE|Embolization of prostatic artery under ultrasound guidance|Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
48662839|NCT03637348|DEVICE|TrueTear|Ues of TrueTear neurostimulator
48662840|NCT04975620|DEVICE|Fine needle biopsy|Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
48662841|NCT05607472|OTHER|blood sampling|blood samples for bio collection
48662842|NCT05607472|OTHER|questionnary of health estate during 18 month|clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
48662843|NCT02056769|RADIATION|CT Perfusion|Quantitative CT Perfusion imaging
48352058|NCT03526692|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
48352059|NCT01968915|DRUG|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
48618337|NCT03154606|OTHER|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
48662844|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Workshop|2 day workshop
48662845|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Online|Online curriculum
48662846|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Group|3 in person group sessions
48662847|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Individual|3 sessions in person one on one
48662848|NCT00416741|BEHAVIORAL|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose
48662849|NCT01121757|DRUG|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
48662850|NCT01121757|DRUG|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
48662851|NCT00922961|BIOLOGICAL|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
48662852|NCT00922961|PROCEDURE|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
48352060|NCT01968915|DRUG|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
48352061|NCT00674687|DRUG|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
48352062|NCT00674687|DRUG|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
48662853|NCT05478876|RADIATION|carbon ion radiation therapy CIRT|"CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol."
48662854|NCT06416475|DIETARY_SUPPLEMENT|Mankai supplementation|The overall dose of the three Mankai duckweed beverages/day contains \~10 grams of dry matter.
48662855|NCT06416475|OTHER|Water consumption|Water consumption
48662856|NCT02164864|DRUG|Dabigatran Etexilate 110mg|Active treatment
48662857|NCT02164864|DRUG|Warfarin 3mg|Active comparator
48352063|NCT01957215|DRUG|Indomethacin|Topical indomethacin
48352064|NCT01957215|DRUG|Placebo|Placebo patch
48352065|NCT02245230|DRUG|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
48662858|NCT02164864|DRUG|Aspirin|Active comparator
48352066|NCT02245230|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
48504210|NCT06130098|OTHER|experimental group|"Providing training before discharge Prepare an educational brochure and give it to patients. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale Evaluating the wound site in terms of complications within the first week and at the end of the fourth week. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, calling the patients in the study group at the end of the first week after discharge.~Providing training on the subjects included in the training brochure in the first phone call and recording any existing problems.~In the fourth meeting, tele-nursing service will be provided through the Telephone Counseling Protocol.~EQ-5D-5L and OKS forms must be filled out again by patients at the routine check-up at the end of the fourth and sixth weeks after discharge."
48662859|NCT02164864|DRUG|Dabigatran Etexilate 150mg|Active treatment
48662860|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
48662861|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
48662862|NCT02164864|DRUG|Warfarin 5mg|Active comparator
48662863|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
48662864|NCT02164864|DRUG|Warfarin 1mg|Active comparator
48662865|NCT05750407|BEHAVIORAL|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
48662866|NCT02167776|BEHAVIORAL|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
48662867|NCT02957838|DIETARY_SUPPLEMENT|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
48662868|NCT02957838|DIETARY_SUPPLEMENT|mock|Low fat banana milkshake without C18:0 supplement.
48662869|NCT00684385|DRUG|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H\&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H\&NC will take two tablets at each dose administration.
48662870|NCT01395745|DRUG|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
48662871|NCT01395745|DRUG|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
48352067|NCT02245230|DRUG|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
48352068|NCT04142762|DRUG|ABI-H2158|ABI-H2158 tablets
48352069|NCT04142762|DRUG|Itraconazole|Itraconazole capsules
48352070|NCT04142762|DRUG|Rifampin|Rifampin capsules
48352071|NCT04142762|DRUG|Midazolam|Midazolam syrup
48352072|NCT04142762|DRUG|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
48352073|NCT04142762|DRUG|Esomeprazole|Esomeprazole capsules
48352074|NCT04142762|DRUG|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
48352075|NCT04323098|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
48352076|NCT03351062|DRUG|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
48352077|NCT03351062|DRUG|Toremifene|Patients will be given 60mg Toremifene once a day.
48352078|NCT04166955|BEHAVIORAL|Promoting Physical Activity through mobile application|Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
48352079|NCT00592176|DRUG|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
48352080|NCT00939055|DEVICE|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
48352081|NCT00939055|PROCEDURE|Sham procedure|False procedure
48352082|NCT03500536|BEHAVIORAL|IntelliCare|A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
48352083|NCT04024735|DIAGNOSTIC_TEST|Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples|We will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days.
48352084|NCT04227119|DEVICE|Irrigated ablation catheter|After completion of ablation, the ablation catheter will be serially positioned in the cardiac chambers (either the left or right side of the heart). The stop cock will be turned to the pressure transducer and waveforms will be stored corresponding to each chamber.
48352085|NCT04227119|DEVICE|Balloon tipped PA catheter|After removal of the irrigated ablation catheter, a 5F balloon tipped PA catheter which will be positioned under fluoroscopic guidance in each previously evaluated chamber and the chambers will be measured again.
48352086|NCT01960452|BEHAVIORAL|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
48352087|NCT04520919|OTHER|anesthesia;Radial artery puncture|we chose the patients who need to monitor invasive blood pressure to obtain high-fidelity arterial waveforms
48352088|NCT05667194|DRUG|KH617|KH617 is s freeze-dried powder injection
48352089|NCT00964769|BIOLOGICAL|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
48662872|NCT00085527|DRUG|depsipeptide|
48662873|NCT00982280|DRUG|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
48662874|NCT05296161|DRUG|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
48662875|NCT01195974|DRUG|YASMIN|YASMIN for 21 days
48662876|NCT01195974|DRUG|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
48662877|NCT01195974|OTHER|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
48662878|NCT00563732|DRUG|Lecozotan|
48662879|NCT03690245|PROCEDURE|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
48352090|NCT02355925|DRUG|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
48352091|NCT02355925|DRUG|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
48352092|NCT02355925|OTHER|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
48352093|NCT00057928|DRUG|cisplatin|
48352094|NCT00057928|DRUG|gemcitabine hydrochloride|
48352095|NCT00057928|DRUG|paclitaxel|
48352096|NCT03489538|PROCEDURE|laparoscopic long limb roux-en-Y gastric bypass|standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
48504211|NCT05529667|DRUG|INCB054828, Paclitaxel|"phase 1\>~- Approximately 3-12 patients will be enrolled. The dose escalation will be three patients registered for each cohort until the first dose-limiting toxicity appears during the four weeks of treatment and observation.~phase 2\> Phase 2 studies will be extended to a total of 30 patients with a two-phase recommended dose. Patients will be treated until the time of disease progression, intolerable toxicity, rejection of the patient, or withdrawal of consent."
48504212|NCT01550627|OTHER|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
48662880|NCT02264366|BEHAVIORAL|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
48662881|NCT03715907|BEHAVIORAL|Financial Incentives|Incentives for gap closure.
48352097|NCT05833061|OTHER|The Stroke-Specific Quality of Life (SS-QoL) scale|The Stroke-Specific Quality of Life (SS-QoL) scale is a questionnaire-based tool that is used to assess the quality of life of individuals who have experienced a stroke. It was developed to evaluate the impact of stroke on various domains of life, including physical, psychological, and social aspects. The SS-QoL scale contains 49 items, which are organized into 12 domains such as mobility, self-care, work/productivity, language, social roles, and emotional well-being. The scale has been validated and is widely used by healthcare professionals and researchers to assess the effectiveness of interventions and treatments for stroke patients, as well as to evaluate the long-term impact of stroke on their quality of life.
48352098|NCT05833061|OTHER|The Stroke Self-Efficacy Questionnaire (SSEQ)|The Stroke Self-Efficacy Questionnaire (SSEQ) is a tool used to measure an individual's perceived self-efficacy or confidence in managing the consequences of a stroke. It consists of 13 items that assess an individual's ability to manage various stroke-related challenges, such as physical, emotional, and social difficulties. The SSEQ is designed to help healthcare professionals and researchers understand how an individual's perceived self-efficacy influences their ability to cope with the consequences of a stroke and manage their recovery effectively. By measuring an individual's perceived self-efficacy, the SSEQ can help identify areas where additional support and interventions may be needed to improve their overall recovery and quality of life.
48352099|NCT02591836|DRUG|Gemcabene|Gemcabene
48662882|NCT03715907|BEHAVIORAL|Information|Information on care gap and closure process.
48662883|NCT03405740|DEVICE|Remote Patient Management|"1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic.~2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years.~3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit)~4. VIRTUES access"
48662884|NCT03405740|DEVICE|Standard of Care|No intervention
48662885|NCT02499887|DRUG|beclamethasone dipropionate|Inhaler
48352100|NCT02591836|DRUG|Atorvastatin|Atorvastatin
48352101|NCT02591836|DRUG|Placebo|
48352102|NCT04191252|DIAGNOSTIC_TEST|A multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
48352103|NCT06053281|DRUG|Cholecalciferol|Daily Cholecalciferol 1000 IU in 24 weeks
48352104|NCT06053281|OTHER|Placebo|Placebo
48352105|NCT05648006|BIOLOGICAL|OH2|Oncolytic Type 2 Herpes Simplex Virus
48662886|NCT02499887|DRUG|albuterol|Inhaler
48662887|NCT02499887|DRUG|Prednisone|Oral corticosteroid
48352106|NCT05648006|DRUG|Capecitabine|1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
48352107|NCT05648006|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, intravenously, once every 3 weeks.
48352108|NCT03109444|DIAGNOSTIC_TEST|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be \>50%.
48352109|NCT03461705|DEVICE|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
48504213|NCT01550627|OTHER|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
48504214|NCT03283462|DIETARY_SUPPLEMENT|Mitopure|Mitopure (Urolithin A) containing softgels
48504215|NCT03283462|DIETARY_SUPPLEMENT|Placebo|Placebo containing softgels
48504216|NCT00963781|DEVICE|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
48504217|NCT00963781|DRUG|Reduced duration (6 months) DAPT|
48662888|NCT04835129|DRUG|Isatuximab (for run-in portion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles.
48662889|NCT04835129|DRUG|Isatuximab (for expansion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles.
48662890|NCT04835129|DRUG|Pomalidomide|4 mg PO days 1-21 of each cycle.
48662891|NCT04835129|DRUG|Elotuzumab|10 mg/kg on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles.
48662892|NCT04835129|DRUG|Dexamethasone|40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
48504218|NCT01323712|DIETARY_SUPPLEMENT|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
48504219|NCT02174380|OTHER|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
48662893|NCT05672901|DEVICE|StrataMGT|StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
48662894|NCT05672901|DRUG|Estrace 0.01% Vaginal Cream|Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
48504220|NCT00599378|BEHAVIORAL|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
48504221|NCT05937997|PROCEDURE|high intensity physiotherapy|high intensity exercises for 3 weeks inpatient rehabilitation
48504222|NCT05937997|PROCEDURE|moderate intensity physiotherapy|moderate intensity exercises for 3 weeks inpatient rehabilitation
48504223|NCT05937997|PROCEDURE|low intensity physiotherapy|low intensity exercises for 3 weeks inpatient rehabilitation
48504224|NCT04100863|OTHER|No Intervention|There is no intervention for this study.
48504225|NCT05456555|PROCEDURE|Flapless with Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
48504226|NCT05456555|PROCEDURE|Flapless without Enamel Matrix Derivatives (EMD)|Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
48504227|NCT05795738|BEHAVIORAL|Chinese character-based visuomotor training program|this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials
48662895|NCT04098588|BEHAVIORAL|BEAST|See Arm Description
48662896|NCT04098588|BEHAVIORAL|Descriptive Feedback|See Arm Description
48662897|NCT02128035|PROCEDURE|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
48662898|NCT04613388|OTHER|Assesment of Effectiveness and side effects|Case Report forms, Quality of life questionaire
47985877|NCT01219920|DRUG|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
48141624|NCT03559959|BEHAVIORAL|Vouchers for HIV self-testing kits|Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
48141625|NCT02442557|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injection
48141626|NCT02442557|OTHER|placebo comparator|intravenous injection
48141627|NCT04126577|BIOLOGICAL|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
48662899|NCT05539547|DEVICE|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: \>50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
48662900|NCT05539547|OTHER|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
48662901|NCT06454656|OTHER|MOBILE|"Intensive motor learning based intervention to target specific walking goals as identified using the Gait Outcome Assessment List.~Full Protocol outlining strategies available on request.~Three key principles underpin the intervention:~Principle 1: The type of task~Principle 2: The type of practice~Principle 3: The type of Feedback"
48662902|NCT04162834|DRUG|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
48662903|NCT04162834|DRUG|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
48662904|NCT03249818|DEVICE|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
48662905|NCT06123299|DEVICE|pHyph|vaginal tablet
47985878|NCT01219920|DRUG|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
47985879|NCT05725954|BEHAVIORAL|GUT LINK SmartPath|A virtual care delivery and referral support tool for primary healthcare providers.
47985880|NCT03434054|DRUG|Losartan|blood pressure medication
47985881|NCT03434054|OTHER|Placebo|non-active sham intervention
48141628|NCT02266927|DRUG|Flovent HFA|
48141629|NCT02266927|DRUG|OPTINOSE™ FLUTICASONE|
48141630|NCT04895774|OTHER|Probiotic strains|Fresh stools will be cultured in vitro in fermenters with adjunction of probiotic strains
48141631|NCT04895774|OTHER|Polyphenols|Fresh stools will be cultured in vitro in fermenters with adjunction of polyphenols
48141632|NCT04895774|OTHER|Fibers|Fresh stools will be cultured in vitro in fermenters with adjunction of fibers
48352110|NCT03461705|DEVICE|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
48662906|NCT04277312|BEHAVIORAL|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
48141633|NCT01536093|OTHER|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
48141634|NCT01536093|OTHER|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
48141635|NCT02296593|DEVICE|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
48141636|NCT02387385|DEVICE|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
48141637|NCT04768569|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
48352111|NCT01222416|RADIATION|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
48352112|NCT01222416|RADIATION|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
48352113|NCT02147106|OTHER|Videoconsultation|
48662907|NCT04277312|BEHAVIORAL|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
48352114|NCT06019390|DEVICE|Presage care|A screening questionnaire completed by the family caregiver focused on functional and clinical autonomy of the patient (ie, activities of daily life), possible medical symptoms (eg, fatigue, falls, and pain), changes in behavior (eg, recognition and aggressiveness), and communication with relative or their surroundings.
48352115|NCT01326676|DRUG|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
48352116|NCT01326676|DRUG|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
48662908|NCT01401673|DRUG|Indantadol|Titration
48662909|NCT04744103|DRUG|TCA|Patients will receive a TCA peel as a treatment for their actinic cheilitis.
48662910|NCT05728554|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
48662911|NCT05728554|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
48352117|NCT02812329|BEHAVIORAL|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
48352118|NCT02001922|OTHER|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
48662912|NCT05728554|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
48662913|NCT01073293|BIOLOGICAL|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
48662914|NCT01073293|BIOLOGICAL|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
48662915|NCT01073293|BIOLOGICAL|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
48662916|NCT03032484|DRUG|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
48662917|NCT03032484|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
48662918|NCT01148771|DRUG|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
48662919|NCT01148771|DRUG|ertapenem|1 gram 30 minute infusion q24h for 3 days
48662920|NCT04442009|OTHER|Group SCPB|In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
48141638|NCT04768569|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
48662921|NCT03069716|DEVICE|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
48662922|NCT03069716|DEVICE|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
47985882|NCT03502226|BEHAVIORAL|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
47985883|NCT03263442|DRUG|Thiamine|200 mg IV three times daily for seven days
47985884|NCT03263442|DRUG|Normal saline|Normal saline IV three times daily for seven days
47985885|NCT06290713|DRUG|Tadalafil|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
47985886|NCT06290713|DRUG|Placebo|Patients will be given either the intervention medication or a placebo (double-blinded, randomized trial) and will be asked to take the medication every day for 6 months in conjunction with weekly exercise sessions.
47985887|NCT06290713|OTHER|Exercise Training|The home-based cycling exercise training program is designed to improve muscle strength and endurance. Participants will engage in individualized exercise sessions up to four times per week, lasting up to 40 minutes each. Live video and heart rate monitoring will ensure proper exercise performance and allow for adjustments to the program throughout the study. The participants will receive the exercise equipment for use at home.
47985888|NCT00386776|OTHER|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
47985889|NCT04142554|DRUG|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
48141639|NCT03371316|BIOLOGICAL|ViaShield|Anti-adhesion scores using amnion patch
48141640|NCT04658784|DEVICE|2-0 dioxanone, glycolide and trimethylene carbonate|delayed absorbable, monofilament barbed suture
48141641|NCT04658784|DEVICE|2-0 polydioxanone|delayed absorbable, monofilament non-barbed suture
48352122|NCT00608803|DRUG|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
48662923|NCT06221007|PROCEDURE|Use of bone cement in otosclerosis surgery|Surgical technique; It involves separating the sclerosed stapes from the oval window and incus under an endoscope or microscope and replacing it with a Teflon piston, which is a middle ear prosthesis. In this way, a new connection between the incus and the oval window ensures the transmission of sound to the inner ear. Bone cement has long been used in primary and revision ossiculoplasty, including stapedotomy of the middle ear. During stapedotomy, the part of the Teflon piston that places the teflon piston on the incus is fixed with bone cement, aiming to keep the prosthesis in place for a long time and prophylactic treatment of incus necrosis.
48662924|NCT03490565|BEHAVIORAL|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
48352123|NCT03665987|BEHAVIORAL|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
48662925|NCT01259011|BEHAVIORAL|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
47985890|NCT02442960|DRUG|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
47985891|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
47985892|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
47985893|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
47985894|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
48141642|NCT06509529|OTHER|Motivational Interviewing Based on the COM-B Model|Motivational Interviewing Based on the COM-B Model will be applied to the women in the experimental group.
48352124|NCT05692986|DIAGNOSTIC_TEST|A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.|This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of \>5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
48504228|NCT05795738|BEHAVIORAL|traditional visuomotor training program|this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
48662926|NCT02935036|DRUG|ADPS topical product|topical product
48662927|NCT02935036|DRUG|Placebo Control|topical product
48662928|NCT02104193|DRUG|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
48662929|NCT02104193|RADIATION|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
48662930|NCT01827189|OTHER|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
48662931|NCT00505687|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."
48662932|NCT05629871|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
48662933|NCT05629871|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
48662934|NCT05629871|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
48662935|NCT05629871|PROCEDURE|Actimetry|Measurement of actimetrics for 14 days at inclusion and at 24 months
48141643|NCT02481804|OTHER|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
48141644|NCT02481804|OTHER|Standard treatment|Standard treatment will be continued
48662936|NCT05629871|DIAGNOSTIC_TEST|Fractional diuresis|Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration
48662937|NCT05629871|PROCEDURE|Internal temperature measurement|eCelsius capsule to measure internal temperature at inclusion and 24 months
48662938|NCT05629871|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
48662939|NCT05212909|BEHAVIORAL|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
48662940|NCT01150032|OTHER|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:~* hip and wrist Dual energy X-ray Absorptiometry (DXA)~* wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~* hip Quantitative Computed Tomography (QCT)~* High Resolution Digital X-Ray of calcaneum using BMA(tm) system~* low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
48662941|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of ≥65 mmHg|The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.
48141645|NCT05772338|DRUG|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
48141646|NCT05772338|OTHER|Placebo|Placebo. Up to six applications per day.
48141647|NCT05511545|OTHER|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
48141648|NCT05453630|BEHAVIORAL|Patient Navigation|Patients will receive navigation from a trained lay navigator at a community-based nonprofit organization that supports access to high quality healthcare. The patient navigator will work with patients to schedule their colonoscopy and identify, explore, and overcome barriers. They will educate patients about the colonoscopy procedure and preparation, provide resources, and coach and motivate patients.
48141649|NCT05453630|BEHAVIORAL|Usual Care Control|Educational brochure about colonoscopy
48141650|NCT03883828|DRUG|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
48141651|NCT03883828|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
48141652|NCT03985566|DIETARY_SUPPLEMENT|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
48141653|NCT03985566|DIETARY_SUPPLEMENT|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
48141654|NCT01446718|BIOLOGICAL|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
48141655|NCT01487837|DRUG|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
48141656|NCT01855399|BEHAVIORAL|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
48352125|NCT05679440|BEHAVIORAL|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
48352126|NCT05126654|DIETARY_SUPPLEMENT|Partially Hydrolyzed Guar Gum (PHGG)|Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
48352127|NCT03643198|DRUG|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
48504229|NCT04917042|DRUG|Tazemetostat|Subjects will receive 520 mg/m2/dose (subjects 12-17 years old) or 800 mg of tazemetostat orally twice daily in 28 day cycles. Subjects will receive treatment with tazemetostat up to 2 years or until disease progression or unacceptable toxicity occurs.
48662942|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of 85-90 mmHg|The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.
47985895|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
47985896|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
47985897|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
48352128|NCT03643198|OTHER|CONTROL|NO treatment
48504230|NCT01303770|BEHAVIORAL|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
48504231|NCT01303770|BEHAVIORAL|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
48662943|NCT06451133|OTHER|Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg|The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.
48662944|NCT05541718|BEHAVIORAL|Reiki|Reiki will be provided by a trained Reiki master with the aim of balancing the flow of energy in the patient's body.
48662945|NCT05541718|BEHAVIORAL|Sham Reiki|Sham Reiki will be delivered by an individual trained to simulate the Reiki interventionist's movements, but they will not visualize patient healing
48662946|NCT05541718|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation intervention will be adapted from a standardized mindfulness induction script validated in prior research. The mindfulness practice will guide patients to focus attention on breath and body sensations while monitoring and accepting discursive thoughts, negative emotions, and pain. The MM interventionist will be a trained mindfulness provider and have experience using MM in medical settings.
48141657|NCT01855399|BEHAVIORAL|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
48141658|NCT05733559|DEVICE|QIAstat-Dx® Respiratory Panel Plus (RPP)|An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection
48141659|NCT04027985|OTHER|Kinesiotaping|inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
48352129|NCT04733664|DEVICE|VFI using the FAST PV Technology|The bolus IV administered visible fluorescent injectate (VFI) agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
48352130|NCT02866773|BEHAVIORAL|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
48504232|NCT01675466|PROCEDURE|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
48662947|NCT05291910|DRUG|Inetetamab|Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
48662948|NCT05291910|DRUG|Toripalimab|240mg intravenously every 3 weeks
48662949|NCT05291910|DRUG|Albumin-Bound Paclitaxel|130mg/m2, IV , D1, D8, q3w
48662950|NCT05763667|DRUG|Liposomal bupivacaine|"Liposomal bupivacaine is FDA-approved for use single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
48352131|NCT02866773|BEHAVIORAL|PA2: Education sessions, Reminders|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
48504233|NCT01675466|PROCEDURE|General anaesthesia|
48504234|NCT01675466|DEVICE|Laparoscopic instruments|
48504235|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
48504236|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
48504237|NCT02117700|OTHER|Placebo twice/day|Placebo capsules twice/day for 16 weeks
48504238|NCT05572671|BEHAVIORAL|Laboratory task modeling smoking lapse behavior|Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
48504239|NCT01943110|DEVICE|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
48504240|NCT01943110|DEVICE|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
48504241|NCT05541653|OTHER|Financial Well-being Interventions|Tax preparation; access to public benefits; financial counseling and microgrants
48504242|NCT05541653|OTHER|Place-based Interventions|Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
48352132|NCT02866773|BEHAVIORAL|PA3: Education sessions, Whataps group|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
48662951|NCT05763667|DRUG|Bupivacain|"Bupivacaine is FDA-approved for use as a local or regional anesthetic for surgery. It is widely used in TAP blocks.~The solution will be placed into 20 mL syringes on 18-gauge needles for injection. The injections will be performed percutaneously by the surgeon along the midaxillary line at 4 equidistant points from the anterior superior iliac spine to the costal margin, as well as a single injection subcostally at the anterior axillary line. 20 mL will be injected at each site, 5 sites per side bilaterally, total of 10 sites. The depth of injection will be judged by laparoscopic visualization of a diffuse bulge during injection, indicating injection in the correct plane, just superficial to the transversus abdominis muscle."
48662952|NCT06164054|DEVICE|Virtual Reality Rehabilitation System|Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
47985898|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
47985899|NCT00198757|BEHAVIORAL|Medifast Plus for Diabetics Meal Replacement Supplements|
47985900|NCT00198757|BEHAVIORAL|Standard ADA recommended diet for type 2 diabetics|
47985901|NCT05886608|DEVICE|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
48352133|NCT02866773|BEHAVIORAL|PA4: Education sessions|"The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
48352134|NCT02866773|BEHAVIORAL|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
48352135|NCT02866773|BEHAVIORAL|HD2: Education sessions, Reminders|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
47985902|NCT03649711|DRUG|Ticagrelor 90mg|Ticagrelor Pill
47985903|NCT03649711|DRUG|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
47985904|NCT03649711|DRUG|Aspirin 81 mg|Aspirin Pill
47985905|NCT04667663|DRUG|Daratumumab|Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
47985906|NCT04667663|DRUG|Cyclophosphamide|Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
47985907|NCT04667663|DRUG|Pomalidomide|Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
47985908|NCT04667663|DRUG|Dexamethasone|Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
47985909|NCT00225251|DRUG|bupropion XL|Antidepressant medication
47985910|NCT00225251|OTHER|Placebo|Placebo
47985911|NCT01012856|BEHAVIORAL|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
48352136|NCT02866773|BEHAVIORAL|HD3:Education sessions, Whataps group|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
48141660|NCT04027985|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
48352137|NCT02866773|BEHAVIORAL|HD4: Education sessions|"The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
48352138|NCT02613338|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
48352139|NCT04770428|DRUG|MEDI7352|A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
48352140|NCT04770428|DRUG|Placebo|Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
48352141|NCT04248556|OTHER|Health care product|Health care product (gel) - to be applied on the participant's skin
48352142|NCT03626389|OTHER|Physiotherapy|
48352143|NCT04063397|DIAGNOSTIC_TEST|Echocardiogram|Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
48352144|NCT04063397|DIAGNOSTIC_TEST|Blood draw|Serial blood draws at same time points as echocardiograms for biomarker levels
48352145|NCT02993783|DRUG|Vedolizumab|Vedolizumab IV infusion
48352146|NCT02132416|DRUG|NSAID|Will be used if tolerated.
48352147|NCT02132416|DRUG|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
48352148|NCT02132416|DRUG|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
48352149|NCT02132416|DRUG|Paracetamol|1g QID will be given to all patients unless allergies.
48352150|NCT02132416|PROCEDURE|Surgical management|Fracture stabilization
48352151|NCT05608200|DRUG|Lenvatinib, sintilimab plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
48352152|NCT05608200|DRUG|Lenvatinib plus TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. The interruption, dose reduction and discontinuation of lenvatinib depended on the presence and severity of toxicities according to the drug directions.
48352153|NCT01369069|DRUG|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
48504243|NCT00683631|OTHER|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
48504244|NCT03648853|DEVICE|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
48504245|NCT01004003|DRUG|Sorafenib|
48504246|NCT01004003|DRUG|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
48504247|NCT03671889|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
48504248|NCT04407208|BIOLOGICAL|Convalescent plasma|The minimum titer of specific antibody is 1/80
48504249|NCT04886258|DRUG|DFV890|DFV890
48504250|NCT04886258|DRUG|Placebo|Placebo
48504251|NCT01851200|DRUG|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
48504252|NCT04007991|DRUG|Ecopipam|Ecopipam HCI tablets administered PO to establish 2 mg/kg/day
47985912|NCT01012856|BEHAVIORAL|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
48504253|NCT04007991|DRUG|Placebo|Matching Placebo
48504254|NCT02175316|DEVICE|Enhanced External Counterpulsation|Enhanced External Counterpulsation
48504255|NCT03795766|PROCEDURE|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
48504256|NCT05886010|DEVICE|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48504257|NCT05886010|DEVICE|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48141661|NCT04027985|OTHER|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
48352154|NCT01369069|DRUG|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
48352155|NCT00886691|BIOLOGICAL|Bevacizumab|Given IV
48352156|NCT00886691|DRUG|Everolimus|Given PO
48662953|NCT06164054|BEHAVIORAL|Traditional therapy|Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
48352157|NCT00886691|OTHER|Laboratory Biomarker Analysis|Correlative studies
48352158|NCT00886691|OTHER|Placebo|Given PO
48504258|NCT05886010|DEVICE|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48504259|NCT05886010|DEVICE|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48504260|NCT05886010|DEVICE|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
48662954|NCT05002725|DRUG|Lidocain|300mg (20ml) will be injected
48352159|NCT05953103|DRUG|Synbixin/Placebo|Synbixin/Placebo
48352160|NCT04316286|PROCEDURE|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
48352161|NCT04316286|OTHER|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
48352162|NCT04861506|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.
48352163|NCT01891604|DIETARY_SUPPLEMENT|breast milk with Bifidobacterium Longum subp. Infantis R0033|
48352164|NCT01891604|DIETARY_SUPPLEMENT|breast milk|
48352165|NCT00343395|DRUG|AVANDAMET|2/500 mg
48352166|NCT03185325|OTHER|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
48352167|NCT03185325|OTHER|venous blood samples|venous blood samples are collected in healthy voulnteers
48352168|NCT00574366|DRUG|erlotinib|"Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~  * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d"
48352169|NCT00574366|DRUG|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day"
48352170|NCT04050475|DIETARY_SUPPLEMENT|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
48352171|NCT05844254|PROCEDURE|novel overlapping rotated double (NORD) flap|"After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. Patients will be randomly allotted to either group by stratified block randomization after taking baseline measurement with respect to periodontal phenotype(PP) \[using transparency of periodontal probe through the gingival margin, when probe is visible, thin PP and when not visible, thick PP\] so that patients with thick and thin PP get an equal chance of being allocated to NORD and Sub epithelial connective tissue group.~1. Group 1(NORD group)- Patients treated with NORD flap~2. Group 2 (Sub epithelial connective tissue group)- Patients treated with sub epithelial connective tissue graft Patients will be followed up after 1 month,6, 12 and 15 months. 30 patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification."
48352172|NCT03807128|OTHER|No interventional study|No interventional study
48352173|NCT06339281|DRUG|apatinib mesylate+Capecitabine Tablets|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;"
48352174|NCT06339281|DRUG|apatinib mesylate+Fulvestrant injection|"Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;"
48352175|NCT04258449|DEVICE|DOvEEgene Fleur Sampling|Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
48352176|NCT04694794|OTHER|Educational Brochure|Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
48352177|NCT02171156|DRUG|nintedanib|soft gelatin capsule
48352178|NCT00112567|DRUG|fludarabine phosphate|
48352179|NCT00112567|DRUG|thiotepa|
48352180|NCT00112567|PROCEDURE|peripheral blood stem cell transplantation|
48352181|NCT00112567|RADIATION|radiation therapy|
48352182|NCT01490333|DIETARY_SUPPLEMENT|Vitamin D3|The vitamin D3 will be taken daily.
48352183|NCT01102946|DRUG|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
48352184|NCT01102946|PROCEDURE|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
48352185|NCT04729595|DRUG|Tempol|Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.
48352186|NCT04729595|OTHER|Placebo|Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.
48352187|NCT00223613|DRUG|daily intranasal administration of insulin|
48352188|NCT05238558|BIOLOGICAL|FMPV-1|Intradermal administration
48352189|NCT05238558|BIOLOGICAL|GM-CSF (as adjuvant)|Intradermal administration
48352190|NCT05302804|DRUG|Menthol Gel|5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
48352191|NCT05302804|DRUG|Control Gel|Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
48352192|NCT03508245|OTHER|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
48352193|NCT04162262|OTHER|Instrumental-assisted soft tissue mobilization (IASTM)|Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
48352194|NCT04162262|OTHER|High-Load Strength Training|Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
48367530|NCT04196231|DRUG|IGlarLixi|IGlarLixi will be started at 10 dose steps (10 U insulin glargine plus 5 mcg lixisenatide, once daily). On the basis of prebreakfast self-monitored blood glucose measurements, doses of IGlarLixi will be titrated individually once per week to achieve a prebreakfast plasma glucose of 80-130 mg/dL by use of an algorithm (adding 2 dose steps for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 dose steps for prebreakfast plasma glucose \< 80 mg/dL). The daily dose of IGlarLixi could be titrated to 60 dose steps (60 U insulin degludec plus 20 mcg lixisenatide).
48662955|NCT04725838|DEVICE|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
48352195|NCT04162262|OTHER|Plantar Flexor and Gastrocnemius Stretching|For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
48352196|NCT05391295|OTHER|Short daily questionnaire|This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
48352197|NCT03562689|OTHER|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
48352198|NCT02835235|DRUG|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
48352199|NCT02835235|DRUG|placebo|Administered daily subcutaneously (s.c., under the skin)
48352200|NCT03450486|OTHER|exercise|one 30 minute bout of mild exercise
48352201|NCT05402111|DRUG|SEP-363856|SEP-363856 will be supplied by 25 mg and 50 mg tablets. Multiple tablets may be required to achieve a single dose.
48662956|NCT02257320|DEVICE|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
48662957|NCT03412955|DRUG|Eribulin Mesylate|1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
48662958|NCT06569355|DRUG|VCT220|A small molecule GLP-1R agonist tablet, orally administration, once daily
48662959|NCT06569355|DRUG|Placebo|Placebo tablet
48662960|NCT01930500|BEHAVIORAL|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
48662961|NCT01930500|BEHAVIORAL|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
48352202|NCT05402111|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
48352203|NCT05773716|BEHAVIORAL|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2\~6-second and a 2\~6-second relaxation following each one.
48504261|NCT05980195|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy for 30 times within 50 days
48504262|NCT05980195|DRUG|Standard medical treatment|"Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months"
48662962|NCT06558435|OTHER|FEES|Single group
48662963|NCT03325231|OTHER|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
47985913|NCT00795756|DRUG|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
47985914|NCT00795756|DRUG|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
48662964|NCT02279056|BEHAVIORAL|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
47985915|NCT01705652|DRUG|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
48352204|NCT05773716|OTHER|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
48352205|NCT05773716|OTHER|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
48352206|NCT00396968|DRUG|AMD3100|
48352207|NCT00396968|PROCEDURE|Allogeneic Stem Cell Transplantation|
48352208|NCT05386004|OTHER|Birth-Specific Stereogram Cards (BSSC)|Focus on Birth-Specific Stereogram Cards (BSSC) during uterine contractions in latent active and transitional phase
48352209|NCT00099840|PROCEDURE|Procalcitonin guided antibiotic therapy|
48352210|NCT02870348|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as alpha1-antitrypsin.
48352211|NCT04531397|DRUG|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
48352212|NCT04531397|DRUG|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight\>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
48352213|NCT05575583|DEVICE|repetitive transcranial magnetic stimulation|The neural navigation system was used to accurately locate the stimulus target.Continuous theta short rapid pulse mode was used. CTBS mode consisted of a slave stimulus delivered every 0.2 seconds (5Hz), and each slave stimulus consisted of three bursts of 50Hz. A single stimulus lasts about 40 seconds and totals 600 pulses.
48352214|NCT05575583|DEVICE|pseudo repetitive transcranial magnetic stimulation|Participant in control group receive pseudo repetitive transcranial magnetic stimulation
48352215|NCT00291460|DEVICE|inspiratory muscle training|
48352216|NCT03898323|DEVICE|Alcohol Approach Bias Modification|Computerized training
48352217|NCT06168981|OTHER|Chewing Gum|The patient will be asked to chew gum before the surgery during the 2 minutes. Anxiety level will evaluated before and after chewing gum.
48352218|NCT00057265|DRUG|telbivudine or lamivudine|
48352219|NCT05322083|DRUG|Doravirine|Doravirine will be given to patients after failure on the first NNRTI regimen.
48352220|NCT05841953|DEVICE|Transcutaneous neuromuscular electrical stimulation|Transcutaneous electrical stimulation will be delivered to the anal sphincter and anal resting and squeezing pressures as a result of the stimulation will be recorded for different stimulation protocols using approved electrotherapy units
48352221|NCT02488356|DIETARY_SUPPLEMENT|Litramine|
48352222|NCT01662986|DRUG|tiotropium bromide|18 mcg once a day (QD)
48352223|NCT01662986|DRUG|Placebo|Once a day (QD)
48662965|NCT02279056|BEHAVIORAL|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
48662966|NCT04016714|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
48662967|NCT04016714|DRUG|Prevenar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
48662968|NCT04016714|DRUG|Vaxelis™|Intramuscular 0.5 mL single dose
48662969|NCT04016714|DRUG|M-M-R®II|Subcutaneous 0.5 mL single dose
48662970|NCT04016714|DRUG|VARIVAX™|Subcutaneous 0.5 mL single dose
48662971|NCT01285102|COMBINATION_PRODUCT|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
48687945|NCT05594485|DEVICE|Carebot AI CXR|Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
48352224|NCT03075930|DEVICE|Extended Electrocardiogram|ECG with 3 additional leads and a 5 minute recording
48352225|NCT03075930|DEVICE|Body surface potential map|ECG with 184 leads and a 5 minute recording
48352226|NCT00641745|DRUG|Lurasidone HCl|40 - 120mg per day
48352227|NCT00641745|DRUG|Risperidone|Risperidone
48352228|NCT02981173|DRUG|0.143 mg/kg Psilocybin or 10 mg Psilocybin|0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
48352229|NCT02981173|DRUG|0.0143 mg/kg Psilocybin or 1 mg Psilocybin|0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)
48352230|NCT02981173|DRUG|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
48352231|NCT00706264|DEVICE|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
48352232|NCT03474237|OTHER|Hormone study and Imaging study|"1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging"
48141662|NCT04515992|BEHAVIORAL|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
48352233|NCT01763632|DEVICE|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
48352234|NCT05124067|DRUG|Dexamethasone|patients will receive dexamethasone (0.15 mg/kg IV; maximum 5 mg)
48352235|NCT05124067|DRUG|Ondansetron|patients will receive ondansetron (0.05 mg/kg IV; maximum 4 mg)
48352236|NCT05124067|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine (0.3 μg/kg)
48504263|NCT05980195|BEHAVIORAL|Risk factor management|Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
48504264|NCT00087282|DRUG|alvocidib|
48141663|NCT05056948|OTHER|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
48141664|NCT02680015|BEHAVIORAL|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
48141665|NCT03156738|DRUG|MT-2990|Subjects will receive a single IV dose of MT-2990
48141666|NCT03156738|DRUG|Placebo|Subjects will receive a single IV dose of placebo
48352237|NCT05124067|DRUG|normal Saline|patients will receive normal saline.
48504265|NCT00087282|DRUG|irinotecan hydrochloride|
47985916|NCT05434260|DEVICE|Surgiphor Irrigation Solution|use of Surgiphor wound irrigation solution during surgery
47985917|NCT05434260|DEVICE|Sterile saline|Use of sterile saline as a irrigation solution during surgery
48141667|NCT05589337|BEHAVIORAL|Baduanjin|The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
48141668|NCT05589337|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
48352238|NCT05265585|DIAGNOSTIC_TEST|Ultrasound - Cardiac Acquisition|"The evaluation of the algorithm takes place on patients with an indication for echocardiography.~This examination is done in a standard way with the potential specific explorations related to the indication of the examination. During the echocardiography, the operator records the search phase for the following reference views:~* Parasternal window (Parasternal long axis, Parasternal minor axis)~* Apical window (Apical 4 cavities, Apical 3 cavities, Apical 2 cavities~* Sub costal window, Sub costal 4 cavities, Inferior vena cava)"
48352239|NCT00491751|DRUG|atorvastatin|atorvastatin 40 or 80 mg/day
48352240|NCT00491751|DRUG|ascorbic acid|ascorbic acid 500 mg/day
48352241|NCT00491751|DRUG|Placebo|matching placebo
48352242|NCT00603876|DIETARY_SUPPLEMENT|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
48352243|NCT01251081|OTHER|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
48352244|NCT01251081|OTHER|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
48352245|NCT02812290|PROCEDURE|Lung transplant biopsy bites.|In the second phase of the study, two biopsy bites from the same patient will be collected to assess tissue sampling variability.
48504266|NCT03322930|DIAGNOSTIC_TEST|Rod sensitivity|diagnostic test for rod loss in central retina
48504267|NCT00403637|DRUG|indacaterol maleate|
48504268|NCT06584890|OTHER|decision|decision-making process regarding patient discharge from the Intensive Care Unit (ICU)
47985918|NCT04615923|DRUG|Pridopidine|"Administration: Oral~Dose: 45mg twice daily"
48504269|NCT03462849|OTHER|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
48618338|NCT03154606|OTHER|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
47985919|NCT04615923|DRUG|Matching Placebo|"Administration: Oral~Dose: one capsule twice daily"
47985920|NCT00002490|BIOLOGICAL|BCG vaccine|
48141669|NCT04816305|DEVICE|rTMSc|In all rTMS protocols the patient will remain seated in a comfortable chair with adjustable arms and head rests. Before the start of the conventional rTMS (rTMSc), the resting motor threshold (RMT) of the first dorsal interosseous muscle contralateral to the lesioned hemisphere will be determined. The RMT will be defined as the lowest RMT intensity necessary to produce a motor evoked potential amplitude greater than or equal to 50 µV in at least 5 out of 10 attempts.
47985921|NCT00002490|DRUG|mitomycin C|
48141670|NCT04816305|BEHAVIORAL|Neurofunctional physiotherapy|All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.
48141671|NCT04816305|DEVICE|rTMS sham|During the rTMS sham sessions the same procedures will be used as the rTMSc protocols, however, the magnetic stimulator and its coil will be turned off.
48141672|NCT02343094|DRUG|PBA 7,5g/d|Treatment for 14 days with PBA
48141673|NCT02343094|DRUG|PBA 15g/d|Treatment for 14 days with PBA
48141674|NCT02404844|DRUG|BKM120|daily oral
48141675|NCT02404844|DRUG|Tamoxifen|daily oral
48141676|NCT05077475|DRUG|C52R1H Tab. and C52R2 Tab.|Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
48662972|NCT01285102|PROCEDURE|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
48141677|NCT05077475|DRUG|AJU-C52L|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
48141678|NCT03658915|DEVICE|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
48352246|NCT02649075|OTHER|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
48352247|NCT02649075|OTHER|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
48662973|NCT03650023|DIETARY_SUPPLEMENT|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
48662974|NCT03650023|DIETARY_SUPPLEMENT|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
48662975|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
48662976|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
48662977|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
48662978|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
48662979|NCT02424162|DEVICE|+2.75 diopters multifocal intraocular lens|
48662980|NCT02424162|DEVICE|+3.25 diopters multifocal intraocular lens|
48662981|NCT06244589|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy: Cholecystectomy that performed with laparoscopic method
48662982|NCT06244589|PROCEDURE|Open-conversion cholecystectomy|Open-conversion cholecystectomy: Cases in which laparotomy (Generally right subcostal incision) was performed based on intraoperative findings.
48662983|NCT04828954|OTHER|Immobilization for 2-weeks postoperative|Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks
48662984|NCT04828954|OTHER|Immobilization for 6-weeks postoperative|Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
48662985|NCT04481841|DRUG|oryzanol + vitamin B2 (riboflavin) + vitamin E|"1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
48662986|NCT04125602|OTHER|High fat low carbohydrate diet|Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
48141679|NCT03146026|BEHAVIORAL|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
48662987|NCT04125602|OTHER|Low fat high carbohydrate diet|Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
48662988|NCT05638113|PROCEDURE|Pleural injection of autologous blood|120 ml autologous blood will be drawn from simple venous puncture and immediately injected through the drain into the pleural cavity followed by flushing with 50ml of saline.
48662989|NCT02852915|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
48662990|NCT02399293|BEHAVIORAL|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
48662991|NCT02399293|BEHAVIORAL|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
48141680|NCT04017611|DEVICE|INVSENSOR00038|Noninvasive regional oximeter
48141681|NCT05559697|DEVICE|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
48352248|NCT01138462|OTHER|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
48141682|NCT05559697|DEVICE|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
48141683|NCT02231970|PROCEDURE|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
48141684|NCT04998552|RADIATION|Cyberknife|5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
48141685|NCT01523392|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
48352249|NCT02400840|PROCEDURE|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
48352250|NCT02400840|DRUG|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
48662992|NCT01312831|OTHER|Vitamin B12 (cyanocobalamin)|
48352251|NCT00736606|DRUG|simvastatin|One single dose of 40mg
47985922|NCT00002490|RADIATION|radiation therapy|
47985923|NCT03973840|DRUG|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
47985924|NCT00121550|DRUG|clarithromycin|
48141686|NCT01523392|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
48662993|NCT04652297|DRUG|HS-10356|Single dose of HS-10356
48662994|NCT04652297|DRUG|Placebo|Single dose of Placebo
48662995|NCT04652297|DRUG|HS-10356|Multiple doses of HS-10356
48662996|NCT04652297|DRUG|Placebo|Multiple doses of Placebo
48662997|NCT02577809|DRUG|Morphine100|100mcg added to the spinal anaesthetic
48662998|NCT02577809|DRUG|Morphine50|50mcg added to the spinal anaesthetic
48662999|NCT02577809|DRUG|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
48663000|NCT02577809|DRUG|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
48663001|NCT02577809|DRUG|Indomethacin|100mg Indomethacin suppository
48141687|NCT00826826|PROCEDURE|Catheter ablation|(Pulmonary vein isolation)
48141688|NCT00826826|DRUG|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
48141689|NCT00826826|DRUG|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
48141690|NCT06317623|DIAGNOSTIC_TEST|Prenatal and postnatal ultrasound examination|Prenatal ultrasound examination of fetus with urinary tract dilation in second trimester and next in third trimester and when the dilation is persist, the child is managed after birth by pediatric nephrologist.
48663002|NCT06563882|OTHER|Home-based exercise program|"The program will comprise of six exercises aimed at improving the mobility of the thoracic spine and shoulders, strengthening the extensor muscles of the spine, and enhancing the flexibility of the chest and anterior shoulders. Progression within the program will involve increasing exercise duration or repetitions/sets, along with implementing postural corrections in compound exercises. Participants will be instructed to perform the exercises at least three times a week.~To heighten participants awareness of their daily posture, they will receive a daily scheduled message via WhatsApp reminding them to focus on their posture. Once a week, participants will be asked to submit a home exercise tracking report to monitor their adherence to the program. Additionally, exercises execution will be reviewed every two weeks, and adjustments to the program will be made accordingly."
48352252|NCT00736606|DRUG|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
48352253|NCT04344015|OTHER|Plasma Donation|Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
48141691|NCT02177825|DRUG|Imatinib Mesylate|oral administration
48367531|NCT04196231|DRUG|Insulin/Canaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to canaglifozin, according to the current clinical practice and the drugs' data sheet. Canagliflozin will be started at 100 mg daily per oral administration, and augmented to 300 mg/per day if required (HbA1c \>7.5 after 12 weeks).
48663003|NCT06563882|OTHER|No intervention|No intervention
48663004|NCT04770207|DRUG|Injection of drug-eluting microspheres with multiple drugs into solid tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
48663005|NCT00643279|DEVICE|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
48663006|NCT00643279|OTHER|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
48663007|NCT05121090|BEHAVIORAL|Educational program|"The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, ...).~Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses."
48663008|NCT01441492|PROCEDURE|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
48663009|NCT01441492|PROCEDURE|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
48663010|NCT03525847|DIAGNOSTIC_TEST|Endosonography|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
48663011|NCT02644551|DRUG|CELEXT07|
48663012|NCT02644551|DRUG|Penlac|
48663013|NCT02644551|OTHER|vehicle solution|
48663014|NCT01604317|PROCEDURE|Resuscitation-torso plastic bag|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
48663015|NCT01604317|PROCEDURE|Resuscitation-partial-head plastic bag|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
48663016|NCT06420700|PROCEDURE|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty in the treatment of adults with obesity
48663017|NCT04433195|DIAGNOSTIC_TEST|Xpert MTB/RIF test|Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
48663018|NCT02900014|PROCEDURE|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
48141692|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
48141693|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
48663019|NCT04997850|DRUG|lenvatinib + sindilimab/carrelizumab|4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next treatment cycle was carried out. The trial was terminated if the drug was stopped for more than 28 days due to adverse drug reactions or other reasons. Patients with PD after 6 cycles of sindilimab/carrelizumab treatment were terminated. The follow-up treatment was based on the principle of individualization, multidisciplinary discussion and patients' willingness.
48663020|NCT04997850|PROCEDURE|TACE|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
48663021|NCT00552136|PROCEDURE|Ankle Arthroplasty|
48663022|NCT00552136|PROCEDURE|Ankle Arthrodesis|Ankle fusion surgery
48141694|NCT03644082|BEHAVIORAL|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
48663023|NCT02921256|DRUG|Capecitabine|Given PO
48663024|NCT02921256|DRUG|Fluorouracil|Given IV
47985925|NCT00553150|DRUG|everolimus|
47985926|NCT00553150|DRUG|temozolomide|
47985927|NCT00553150|RADIATION|radiation|
47985928|NCT04483011|DIETARY_SUPPLEMENT|RiaGev|Dietary supplementation
47985929|NCT06220422|PROCEDURE|Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021
48141695|NCT03644082|BEHAVIORAL|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
48663025|NCT02921256|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
48663026|NCT02921256|DRUG|Leucovorin|Given IV
48663027|NCT02921256|DRUG|Oxaliplatin|Given IV
48663028|NCT02921256|BIOLOGICAL|Pembrolizumab|Given IV
48663029|NCT02921256|DRUG|Veliparib|Given PO
48663030|NCT05486507|DIETARY_SUPPLEMENT|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
48663031|NCT05486507|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
48663032|NCT03573050|DRUG|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
48663033|NCT03573050|DRUG|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
48663034|NCT05921786|DEVICE|Electrophysiological system|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
48663035|NCT05921786|DEVICE|Multiphoton microscope|Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
48663036|NCT02546323|DRUG|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
48663037|NCT02546323|DRUG|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
48141696|NCT03644082|BEHAVIORAL|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
48504270|NCT05924854|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~1. Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
47985930|NCT06220422|PROCEDURE|New Department procedure for managing direct-acting oral anticoagulants|New Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021
47985931|NCT00494988|DRUG|insulin aspart|
48504271|NCT04120038|DEVICE|Self-Management for Amputee Rehabilitation using Technology [SMART]|Participants will complete a 6-week tablet-based education program for individuals with LLA that will provide them with self-management education.
48504272|NCT04683744|OTHER|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
48618339|NCT03154606|OTHER|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
47985932|NCT00494988|DRUG|insulin NPH|
47985933|NCT01365325|OTHER|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
47985934|NCT01365325|OTHER|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
47985935|NCT05701774|DRUG|DCCR|Once daily oral administration
48663038|NCT02644304|DRUG|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
47985936|NCT06160960|OTHER|OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.
48663039|NCT02644304|DRUG|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
48663040|NCT02644304|OTHER|Placebo|placebo(half tablet) every 3 days (4 doses).
48663041|NCT05467657|DEVICE|repetitive Transcranial Magnetic Stimulation|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
47985937|NCT04258345|OTHER|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
47985938|NCT02769325|DRUG|Atropine|IV atropine 0.1%, 10 ml
47985939|NCT02769325|DRUG|Placebo|IV saline, 10 ml
47985940|NCT02769325|DRUG|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
47985941|NCT02769325|DRUG|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
47985942|NCT02769325|DRUG|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
47985943|NCT02769325|DRUG|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
47985944|NCT02769325|DRUG|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
47985945|NCT02769325|DRUG|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
47985946|NCT00646529|DRUG|budesonide/formoterol (Symbicort)|
47985947|NCT00646529|DRUG|budesonide (Pulmicort)|
47985948|NCT03480750|DRUG|trientine dihydrochloride|trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
47985949|NCT03480750|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg/m2 IV D1
48663042|NCT03578055|DRUG|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
48663043|NCT03578055|DRUG|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
48141697|NCT03644082|BEHAVIORAL|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
48663044|NCT06129955|DRUG|Pucotenlimab Combined With Lenvatinib|Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
48663045|NCT03332147|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
48663046|NCT03332147|DEVICE|reference group-Earlysense system|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
47985950|NCT03480750|DRUG|carboplatin|carboplatin AUC 4 IV D1
48141698|NCT03644082|BEHAVIORAL|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
47985951|NCT01759030|DRUG|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
48504273|NCT04683744|OTHER|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
48504274|NCT04326465|DEVICE|Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage|Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.
47985952|NCT03701347|DEVICE|Reeve's model|Reeves, K. O., Young, A. E., \& Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
47985953|NCT03701347|DEVICE|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., \& Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
48504275|NCT06355999|BEHAVIORAL|Color Feedback|Feedback is given about the correctness of the response on the color dimension
48504276|NCT06355999|BEHAVIORAL|Shape Feedback|Feedback is given about the correctness of the response on the shape dimension
48504277|NCT03994601|DRUG|BMS-986288|Specified dose on specified days
48504278|NCT03994601|DRUG|Nivolumab|Specified dose on specified days
48504279|NCT03994601|DRUG|Regorafenib|Specified dose on specified days
48504280|NCT03803930|DEVICE|Using 22G FNB, the first pass is SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
48663047|NCT04586933|DIETARY_SUPPLEMENT|Omega-3|It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
48663048|NCT04586933|DIETARY_SUPPLEMENT|Placebo (soya)|Placebo (soya)
48663049|NCT04586933|BEHAVIORAL|Dietary guidance|Dietary guidance
47985954|NCT03701347|DEVICE|Ida's model|Reusable, portable and modular 3D printed simulator
47985955|NCT03872219|COMBINATION_PRODUCT|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
48141699|NCT03644082|BEHAVIORAL|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
48141700|NCT03644082|BEHAVIORAL|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
47985956|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation B|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
47985957|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation C|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
48141701|NCT03644082|BEHAVIORAL|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
48663050|NCT00867152|DRUG|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
48663051|NCT00867152|DRUG|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
48663052|NCT00867152|DRUG|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
48663053|NCT00867152|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
47985958|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation A|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
47985959|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation D|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
47985960|NCT03958799|BIOLOGICAL|Licensed Tdap vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
48141702|NCT03644082|BEHAVIORAL|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
48141703|NCT03019289|DRUG|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
48141704|NCT00895596|DRUG|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
48141705|NCT00006203|DRUG|naltrexone (Revia)|
48141706|NCT01085513|DEVICE|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
48663054|NCT00867152|DRUG|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
48141707|NCT04402476|DEVICE|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
48141708|NCT04648670|BEHAVIORAL|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
48663055|NCT04853121|PROCEDURE|Tapered Implants|Tapered Implants are placed in fresh socket via dynamic navigation
48141709|NCT04026256|DRUG|Teriparatide|teriparatide daily subcutaneous injection
48663056|NCT04853121|PROCEDURE|Straight Implants|Straight Implants are placed in fresh socket via dynamic navigation
48141710|NCT04026256|DRUG|Denosumab|denosumab subcutaneous injection
48141711|NCT01018550|DRUG|AMG 853|AMG 853 5 mg (BID)
48141712|NCT01018550|DRUG|AMG 853|AMG 853 200 mg (QD)
48663057|NCT03769155|BIOLOGICAL|Ipilimumab|Given IV
48663058|NCT03769155|BIOLOGICAL|Nivolumab|Given IV
48663059|NCT03769155|BIOLOGICAL|VX15/2503|Given IV
48663060|NCT03769155|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
48663061|NCT03898427|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
48663062|NCT03898427|DEVICE|Polysomnography|Sleep Monitor
48663063|NCT03898427|DEVICE|Videography|Thermal Camera
48663064|NCT00318617|DRUG|GW510516X|
48663065|NCT01656122|DRUG|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
48663066|NCT01656122|DRUG|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
48141713|NCT01018550|DRUG|AMG 853|AMG 853 25 mg (BID)
48663067|NCT05595239|DEVICE|blood purification(CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
48141714|NCT01018550|DRUG|AMG 853|AMG 853 100 mg (BID)
48141715|NCT01018550|DRUG|Placebo|Placebo
48141716|NCT01331174|DEVICE|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
48141717|NCT01431118|OTHER|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
48141718|NCT01431118|OTHER|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
48141719|NCT00454194|DRUG|pemetrexed disodium|given IV
48663068|NCT05595239|DEVICE|blood purification(TPE+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
48663069|NCT05595239|DEVICE|blood purification(HP+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
48663070|NCT04629742|OTHER|Seawater Pizza|A seawater pizza administered to 12 healthy subjects
48663071|NCT04629742|OTHER|Standard pizza|A standard pizza administered to 12 healthy subjects
48663072|NCT04628806|DIAGNOSTIC_TEST|CTC isolation by HSP70|patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
48663073|NCT03947957|DIAGNOSTIC_TEST|collection of expectoration, stools and blood|collection of expectoration, stools and blood
48663074|NCT05923684|BEHAVIORAL|NLP-based Feedback|Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
48141720|NCT00454194|DRUG|sorafenib tosylate|given orally
48504281|NCT03803930|DEVICE|Using 22G FNB, the first pass is MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
48663075|NCT03732755|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
48663076|NCT03281213|OTHER|Thoracotomy|
48663077|NCT01203397|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
48663078|NCT02998307|PROCEDURE|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
48663079|NCT00236041|DRUG|ACTIQ®|
48663080|NCT00711373|PROCEDURE|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
48504282|NCT03803930|DEVICE|Using 20G FNB, the first pass is SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
47985961|NCT00749918|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
47985962|NCT06005844|DIAGNOSTIC_TEST|Cerebellar Cognitive-Affective Syndrome Scale|The CCASS will be administered by a neuropsychologist starting with version 1A. An alternative version (1B, 1C or 1D) will also be administered. An interval of approximately 30 minutes should be observed between the two administrations. In order to assess the inter-rater reliability of the scale, a second neuropsychologist will be present in the room and will independently evaluate (i.e., blind to his/her colleague's rating) patient's responses. The choice of alternative version (i.e., 1B, 1C, or 1D) will be randomized.
47985963|NCT00412763|DRUG|Silymarin (Silybum marianum)|
47985964|NCT02597348|PROCEDURE|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
47985965|NCT03233906|DIETARY_SUPPLEMENT|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
47985966|NCT04811391|BIOLOGICAL|COVID-19 vaccine|Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
47985967|NCT06200233|DRUG|Rivoceranib|700mg once daily
47985968|NCT01730157|BIOLOGICAL|ipilimumab|Given IV
48141721|NCT04530370|BIOLOGICAL|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
48141722|NCT02191540|DRUG|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
48663081|NCT01741129|DEVICE|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
48141723|NCT05552105|OTHER|Blood test|Before and after 6-months of anti TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and LPS-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response, cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS)
48141724|NCT03118206|DEVICE|lumbar traction|
48663082|NCT01741129|DEVICE|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
48663083|NCT04144907|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
48663084|NCT02902614|PROCEDURE|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
47985969|NCT01730157|RADIATION|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
47985970|NCT01730157|OTHER|laboratory biomarker analysis|Correlative studies
48141725|NCT03118206|PROCEDURE|spinal manipulation|
48141726|NCT03118206|PROCEDURE|surgery|
48504283|NCT03803930|DEVICE|Using 20G FNB, the first pass is MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
48618340|NCT03154606|OTHER|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
47985971|NCT05683054|BIOLOGICAL|Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
47985972|NCT05683054|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
47985973|NCT05683054|OTHER|Dermatology Life Quality Index (DLQI)|The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
48504284|NCT04744883|OTHER|Spinal Manipulation Therapy (SMT)|2 SMT techniques are administered each session, both of which are scripted interactions between the physical therapist (PT) providing the SMT and the subjects: 1) Participants will lie on the SMT table for 20 mins, while the PT sits approximately 6 ft away. As part of the script, the PT will review with subjects the inclusion/exclusion criteria ostensibly to ensure that nothing has changed. 2) The PT will perform the 2 SMT techniques during the next 20 mins. 3) Subjects will sit upright in a chair for the remaining 20 mins, while the PT sits approximately 6 feet away. The PT will review home exercises with participant.
48504285|NCT04744883|DRUG|Naloxone|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
48504286|NCT04744883|DRUG|Placebo|In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
48504287|NCT04744883|BEHAVIORAL|Mindfulness Based Stress Reduction Therapy (MT)|Each MT session consists of (a) body scan meditation accompanied by awareness of breathing and other bodily sensations while in a lying position, (b) sitting meditation, focusing on awareness of breathing, bodily sensations, thoughts, and emotions (c) gentle movement exercises intended to develop awareness (mindfulness) during movement. In-session activities include suggestions for application of mindfulness as a method for responding positively to stress; dealing with the challenges of pain; and exercises focusing on the challenges and achievements patients experience in integrating mindfulness into their lives and the stressful situations they encounter. Additional discussion will focus on stress reactivity and they will be taught problem-solving skills to develop solutions to meet MT goals. Finally, patients will develop a written maintenance plan that includes a list of short- and long-term goals for applying mindfulness methods and a plan for dealing with possible setbacks.
48504288|NCT03156335|DEVICE|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
48504289|NCT03074773|DRUG|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
48504290|NCT03074773|DEVICE|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
48504291|NCT03074773|PROCEDURE|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
48504292|NCT03074773|DRUG|Bupivacaine|it is an amino amide local anesthetic drug
48504293|NCT03074773|OTHER|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
48504294|NCT06231056|DIETARY_SUPPLEMENT|Probiotic iNatal®|iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215)
48504295|NCT00403507|BEHAVIORAL|Participation in a monitored exercise program|No contact with control group during 20 weeks.
48504296|NCT00403507|BEHAVIORAL|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
48504297|NCT06385561|DRUG|Tramadol|Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
48504298|NCT06385561|DRUG|Placebo|Placebo is administered orally twice daily.
48504299|NCT03797716|DEVICE|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
48504300|NCT01982812|DRUG|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
48504301|NCT01982812|DRUG|Standard AED|Active comparitor, Standard AED
47985974|NCT05683054|OTHER|EQ-5D-5L questionnaire|The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
47985975|NCT05683054|PROCEDURE|Dried blood spot sampling|A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
48352254|NCT03856749|OTHER|Remote wheelchair skills training|"Prior to the first training session, the trainer will be provided with the results from the assessment immediately preceding training to provide him/her time to individualize the training session. Trainer will provide self-study materials (the Caregiver Handbook and caregiver-training video-recording) and an explanation on how these materials should be used.~The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual using remote technology. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last up to 60 minutes at intervals a minimum of 3 days."
48352255|NCT06139445|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage (MLD), one of the components of complex decongestive physiotherapy, is a gentle massage technique with proven positive effects on lymphatic circulation. MLD can be applied to different parts of the body (e.g., arms, legs, neck, abdomen, and trunk), with a different technique for each region (stationary circle, scoop, pump, and rotary)
48663085|NCT02902614|PROCEDURE|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
48352256|NCT06139445|OTHER|Plasebo Group|random superficial touches not involved in any manual technique
48352257|NCT04028414|OTHER|Early Weight Bearing|Patients will be instruction to weight bear as tolerated while in a boot.
48663086|NCT01239940|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
48352258|NCT05147597|OTHER|Questionnaire|"Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study.~The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician."
48504302|NCT04290273|DIAGNOSTIC_TEST|MED Test|Participant is irradiated with several doses of UV light on small areas of the outer thigh. 24 hours later this area is visually inspected for erythema, and the minimal erythemal dose (MED) is determined.
48352259|NCT00031915|DRUG|imatinib mesylate|
48352260|NCT00952588|DRUG|AZD1152|1200 mg, iv, 7 day infusion
48504303|NCT04290273|DEVICE|Wearing device|Participants wear a portable erythema measurement device for 48 hours. The device shines light on the skin at frequent intervals and measures skin 'redness'. The device is removed by a technician after the 48 hours.
48504304|NCT06627491|BEHAVIORAL|Imagined muscle contractions|The intervention involved imagining, with no physical movement, of muscle contractions.
48663087|NCT01239940|DEVICE|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
48663088|NCT02798341|OTHER|Biospecimen Collection|
48663089|NCT01959932|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
48663090|NCT01959932|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
48663091|NCT01959932|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
48663092|NCT05161468|DRUG|Lidocaine injection|2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
48663093|NCT05161468|DRUG|Corticosteroid Injection|1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
48663094|NCT05161468|DRUG|Protein Rich Plasma(PRP) Injection|30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
47985976|NCT04650802|DEVICE|Gait training|Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
47985977|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in
47985978|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT) + Air Stacking|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity
48352261|NCT00952588|DRUG|LDAC|20 mg, sc, bd, 10 days
48352262|NCT06336447|OTHER|Experimental: Group #1: Virtual Reality Headset|Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the device for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
48352263|NCT06336447|OTHER|Group 2 No Virtual Reality Headset|Group 2 will receive standard care without the use of the Virtuality Reality Heaset.
48504305|NCT06186180|OTHER|inspiratory muscle training|They will perform 5 sets of 10 repetitions with a 1-minute rest between sets, 5 days a week, using a specific respiratory muscle training device
48504306|NCT04885153|DRUG|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
47985981|NCT02248389|DEVICE|Sonatherm 600i ablation system|HIFU ablation of tumor.
48352264|NCT04237610|BEHAVIORAL|behavioral assessment|Probabilistic learning task
48352265|NCT01135004|PROCEDURE|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
48352266|NCT05010395|BEHAVIORAL|Letter intervention|Letter intervention
48352267|NCT01748903|DEVICE|Target 360°, 2D Coils, Nano Coils|
48352268|NCT02659137|OTHER|HV measurement|Electrophysiology (EP) study during the TAVI procedure
48352269|NCT06185686|OTHER|Cognitive testing|NIH Toolbox Cognitive Battery and the Novel Cognitive Measure (NCM)
48504307|NCT04885153|DRUG|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
48352270|NCT06185686|DEVICE|Resting State MRI/Precision functional mapping|At baseline (before the end of radiation therapy) and approximately 12 months after the completion of radiation therapy.
48352271|NCT00840385|DRUG|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
48352272|NCT02274766|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
48504308|NCT05083130|BEHAVIORAL|a wake prone positioning|The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
48663095|NCT03573674|BEHAVIORAL|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
48663096|NCT03573674|BEHAVIORAL|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
48504309|NCT02955758|BIOLOGICAL|Pembrolizumab|Given IV, 200mg fixed dose, every 3 weeks
47985982|NCT04827550|OTHER|STUDY|Fibromyalgia Patient
48352273|NCT02274766|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
48352274|NCT03149497|PROCEDURE|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
48352275|NCT03202589|OTHER|FOCUS Echocardiography|FOCUS Echocardiography
48352276|NCT06237218|BEHAVIORAL|COTID program|COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
48352277|NCT05746689|DRUG|Sirolimus|Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
48352278|NCT00740818|OTHER|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
48352279|NCT00740818|PROCEDURE|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
48352280|NCT00740818|PROCEDURE|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
48141727|NCT06227988|PROCEDURE|patients with liver disease who undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
48141728|NCT06227988|PROCEDURE|patients with liver disease who do not undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
48352281|NCT02074761|DEVICE|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
48352282|NCT01200563|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
48352283|NCT01200563|DEVICE|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
48352284|NCT01200563|DEVICE|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
48504310|NCT01794897|DRUG|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
48504311|NCT01794897|DRUG|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
48504312|NCT05640336|PROCEDURE|Single Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
48504313|NCT05640336|PROCEDURE|Planned Double Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
48504314|NCT03317834|DEVICE|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
48663097|NCT05593939|BEHAVIORAL|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
48663098|NCT05593939|BEHAVIORAL|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
48663099|NCT05593939|DIETARY_SUPPLEMENT|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
48141729|NCT03900988|DRUG|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
48504315|NCT05915975|BEHAVIORAL|Behavioral Care Coordinated with Medical Care Intervention|Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.
48663100|NCT02716441|DEVICE|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
48141730|NCT03900988|DRUG|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
48663101|NCT06000787|RADIATION|External beam radiotherapy|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
48504316|NCT05915975|BEHAVIORAL|Behavioral Care Not Coordinated with Medical Care Intervention|Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
48141731|NCT03466983|DRUG|Iron Isomaltoside|administered IV
48141732|NCT03466983|DRUG|Ferric Carboxymaltose|administered IV
48504317|NCT03967171|OTHER|before uterine incision oxytocin|blood loss during elective cesarean section
48504318|NCT03967171|OTHER|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
48504319|NCT04289480|DEVICE|ENTERPRISE 2 device|The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.
48504320|NCT00824616|DRUG|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
48504321|NCT00824616|DRUG|Placebo|Placebo tablets, taken 3 times daily.
48504322|NCT00824616|DRUG|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
48663102|NCT06000787|RADIATION|131I-Metaiodobenzylguanidine (MIBG)|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
48663103|NCT06109727|DEVICE|cerebellar transcranial electrical stimulation|Cerebellar transcranial electrical stimulation - 20 mA - 20 min
48141733|NCT00466037|BIOLOGICAL|Influenza vaccine|
48141734|NCT00248898|PROCEDURE|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
48141735|NCT00532350|DRUG|QAT370|
48141736|NCT00532350|DRUG|Placebo|
48504323|NCT00963560|DEVICE|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
48504324|NCT00963560|DEVICE|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
48504325|NCT00963560|DEVICE|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
48504326|NCT03002129|OTHER|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
48504327|NCT00467935|DRUG|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
48663104|NCT03152201|DIAGNOSTIC_TEST|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
48663105|NCT05547035|BEHAVIORAL|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~* assess the depression severity by using MADRS scale~* assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~* the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
48663106|NCT00180284|DEVICE|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
47985983|NCT04265781|DRUG|BAY1817080|Three different doses over the course of study
47985984|NCT04265781|DRUG|Matching Placebo|Matching Placebo to BAY1817080
48141737|NCT00532350|DRUG|Tiotropium|
48141738|NCT00893009|DRUG|Theophylline|100 mg twice a day
48141739|NCT00893009|DRUG|Placebo|Placebo
48141740|NCT03949257|DEVICE|colonic transendoscopic enteral tubing|Colonic transendoscopic enteral tubing (TET) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (FMT) and the whole-colon enema treatment.
48141741|NCT04659382|DRUG|Atezolizumab|Atezolizumab combined to standard chemotherapy (XELOX + bevacizumab) and targeted therapy in patients whose tumour has been made immunogenic by radiotherapy (Therasphere) and ICI (atezolizumab).
48504328|NCT03343652|DRUG|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
48504329|NCT03343652|DRUG|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
48504330|NCT01166165|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
48504331|NCT01166165|DRUG|Placebo|3 placebo tablets daily for 20 weeks
48141742|NCT04659382|DEVICE|Therasphere|Therasphere injected to patients to promote the release of neoantigens from their tumour and convert it into an immunogenic tumour.
48663107|NCT05205863|BIOLOGICAL|Cofact|Human prothrombin complex concentrate
48663108|NCT00212004|DRUG|pioglitazone|
48663109|NCT00212004|OTHER|control|
48663110|NCT05575102|OTHER|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
48663111|NCT04687930|DRUG|genicular nerve block|nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
48663112|NCT04687930|DRUG|intra-articular steroid injection|Triamcinilone injection into the knee joint under ultrasound guidance.
48663113|NCT00000340|DRUG|Pemoline|
48663114|NCT05321602|DRUG|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
48663115|NCT05321602|DRUG|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
48663116|NCT05321602|DRUG|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
48663117|NCT05321602|DRUG|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
48663118|NCT02578901|DRUG|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
48663119|NCT02578901|DRUG|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
48663120|NCT04078867|PROCEDURE|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
48663121|NCT02583841|PROCEDURE|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
48663122|NCT02208765|DEVICE|Stress Single Photon Emission Computed Tomography|
48663123|NCT03014635|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
48141743|NCT04659382|DRUG|XELOX|standard chemotherapy for first line treament of metastatic CRC (in pMMR and/or MSS patients)
48141744|NCT04659382|DRUG|Bevacizumab|standard targeted therapy associated with XELOX for first line treament of metastatic CRC (in pMMR and/or MSS patients)
48141745|NCT02631655|OTHER|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
48141746|NCT05075200|DRUG|Tranexamic acid|Participants in both groups will be given single intravenous bolus of TXA 20 mg/kg over 15 min after induction of spinal (or other regional technique) or general anesthesia as per standard of care.
48141747|NCT00786188|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
48141748|NCT00786188|DRUG|Sugar pill|Subjects will receive a sugar pill.
48141749|NCT03652493|DRUG|Carboplatin|Tumoral evaluation every 3 cycles
48141750|NCT00077558|DRUG|fludarabine phosphate|
47985985|NCT02564042|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
48141751|NCT00077558|DRUG|triapine|
48504332|NCT04830059|BEHAVIORAL|Exercise|Two types of exercise intervention and control group
48663124|NCT03014635|BIOLOGICAL|Placebos|Intramuscular injection
48663125|NCT06545006|OTHER|isometric contractions|Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
48663126|NCT06545006|OTHER|stroboscopic glasses|"This training involves performing skill exercises with a rugby ball while wearing stroboscopic glasses. The glasses have alternating opaque and clear sections, causing multiple and/or fragmented vision.~The goal is to improve the processing of visual information at the level of higher functions. This aids in decision-making. It does not involve the same structures and functions implicated in reflexive muscle recruitment strategies as the Quick Release, so it should not be a confounding factor. However, it provides a beneficial, stimulating, and enjoyable training session, increasing subject adherence as they work on a skill useful in their sport."
47985986|NCT02564042|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
48141752|NCT00055991|DRUG|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
48141753|NCT01703598|DEVICE|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
48141754|NCT01703598|PROCEDURE|DBS surgery|Placement of DBS electrodes
48141755|NCT02581904|DEVICE|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
48141756|NCT02581904|DEVICE|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
48141757|NCT05044416|DEVICE|VieScope|intubation with VieScope laryngoscope
48141758|NCT05044416|DEVICE|Videolaryngoscopy|intubation with videolaryngoscope
48141759|NCT02120807|DRUG|Certolizumab|
48141760|NCT02120807|DRUG|cisplatin|
48141761|NCT02120807|DRUG|pemetrexed|
48504333|NCT04830059|BEHAVIORAL|Air purification|Air purification in order to reduce the PM2.5 and PM10
47985987|NCT02564042|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
47985988|NCT00840554|OTHER|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
48141762|NCT04053699|DRUG|Von Willebrand Factor-Containing Product|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
48504334|NCT01925300|DRUG|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
48504335|NCT01925300|DRUG|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
48504336|NCT01925300|DRUG|Concor 5mg 2T and Crestor 20 mg 1Tab|
48504337|NCT03429010|PROCEDURE|"New guideline anesthesia strategy team"|"New guideline anesthesia strategy team"
48504338|NCT03914092|DRUG|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
48663127|NCT06545006|OTHER|Quick Release|"The distance (in mm) of the anterior head translation will be measured using a linear displacement sensor. The subject will be instructed to recruit their extensor muscles as quickly and as strongly as possible to minimise the head displacement distance. They will be aware of their score after each repetition (real-time feedback).~Subjects must react to a rapid forward displacement of the cervical spine, without impact. To generate this forward displacement without impact, subjects are positioned with support in front of the forehead, holding their head and neck. The subject must exert an isometric flexion effort against this frontal support (energy storage), with the intensity set by the examiner based on the Maximum Isometric Force measured during a prior maximal isometric test. The frontal resistance will suddenly release, and the head displacement in the sagittal plane will be measured until the recruitment of the cervical spine extensor muscles stops this displacement"
48663128|NCT04183348|BEHAVIORAL|Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2|"During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
48663129|NCT04183348|BEHAVIORAL|Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2|"During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
48663130|NCT04336826|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
48663131|NCT01622478|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
48663132|NCT01622478|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
48663133|NCT01622478|PROCEDURE|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
48663134|NCT01622478|PROCEDURE|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
48663135|NCT00791648|DRUG|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
48663136|NCT00791648|DRUG|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
47985989|NCT00840554|OTHER|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
47985990|NCT05611203|PROCEDURE|An Oropharyngeal swab|An Oropharyngeal swab performed for diagnostic purposes
47985991|NCT05611047|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
47985992|NCT05611047|OTHER|Classical cognitive evaluation of several domains:|Information processing speed (IPS) Working memory (WM) Executive functions (EF) Episodic memory (EM) Premorbid intelligence quotient (IQ) Multidomain or complex task
48504339|NCT03914092|BEHAVIORAL|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
48504340|NCT04849065|DRUG|MNC (Mononuclear cells)|"* Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)"
48504341|NCT04849065|DRUG|Placebo / Saline|- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
48504342|NCT04492657|OTHER|no intervention|Natural exposure of iodine.
48504343|NCT00463697|DRUG|GW642444H (100mcg)|H salt
48663137|NCT02119273|DRUG|Prednisone|See arm description
48663138|NCT02119273|DRUG|Placebo|See arm description
47985993|NCT05611047|OTHER|Ecological evaluation|Virtual reality task : Urban DailyCog©
48141763|NCT05410106|DEVICE|PneuX Endotracheal Tube|The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
48141764|NCT05410106|DEVICE|Standard care (Taperguard, Covidien)|Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
48141765|NCT05773235|DIAGNOSTIC_TEST|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
48141766|NCT06372600|DEVICE|Extracorporeal shock wave therapy device|In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
47985994|NCT05611047|BEHAVIORAL|Patent reported outcomes (PRO's)|"Patent reported outcomes (PRO's) : Beck Depression Inventory (BDI), European Quality of Life-5 Dimensions (EQ-5D-5L) for Health-Related Quality of Life (HRQOL), Multiple Sclerosis Impact Scale-29 Items (MSIS-29), French version of the Modified Fatigue Impact Scale (EMISEP) and State trait anxiety inventory (STAI).~Subjective cognitive deficits: Perceived Deficits Questionnaire (PDQ) and Cognitive Activities Questionnaire (DCAQ)"
48141767|NCT06372600|BIOLOGICAL|Platelet-rich plasma|Autologous Platelet-rich plasma injection was performed under ultrasound guidance
48141768|NCT01329406|DRUG|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
48141769|NCT01329406|DRUG|Placebo|1 tablet by mouth twice daily for 28 days
48141770|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
48141771|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
48141772|NCT04269694|DRUG|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
48141773|NCT04269694|DEVICE|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
48141774|NCT03686839|BEHAVIORAL|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
48352285|NCT01731808|BEHAVIORAL|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
48352286|NCT05458492|DRUG|Sirolimus|"Sirolimus, tablets 2 mg/day with dose adjustment of 1 to 3 mg/day for residual concentrations between 4 and 10 ng/mL~1 dose daily for 16 weeks"
48141775|NCT00689351|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
48352287|NCT02528799|BIOLOGICAL|Nexvax2|Nexvax2 intra-dermal injections twice weekly
48352288|NCT02528799|BIOLOGICAL|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
48352289|NCT00802880|DRUG|Dacarbazine|
48352290|NCT06256094|DIETARY_SUPPLEMENT|a2 Platinum Premium Infant Formula Stage 1|Oral intake of a2 Platinum Premium Infant Formula Stage 1 milk powder (dissolved in water)
48352291|NCT06256094|DIETARY_SUPPLEMENT|Frisolac Infant Formula Stage 1 (Dutch Edition)|Oral intake of Frisolac Infant Formula Step 1 (Dutch Edition) milk power (dissolved in water)
48352292|NCT05555251|DRUG|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
48352293|NCT05555251|DRUG|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
48352294|NCT05555251|DRUG|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
48504344|NCT00463697|DRUG|placebo|placebo
47985995|NCT05611047|OTHER|Telerehabilitation : active procedure|The Cognitive rehabilitation (CR) consists of weekly 45 minutes online individual session with the unblinded Speech Therapist.
47985996|NCT05611047|OTHER|Telerehabilitation : comparator procedure|Once per week over a 12-week period completed by daily online exercises performed by the patient 4 days a week.
48141776|NCT00689351|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
48141777|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
48141778|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
48352295|NCT00262561|DRUG|Aspirin|The effect of Aspirin on platelet function was assessed.
48352296|NCT00440102|DRUG|Ketamine|Ketamine
48352297|NCT00440102|DRUG|Etomidate|Etomidate
48352298|NCT04955652|BEHAVIORAL|Health Maintenance Topic|Alert
48352299|NCT04955652|BEHAVIORAL|Actionable Sidebar Item|Alert
48141779|NCT03131713|DRUG|Acetaminophen|Acetaminophen 1000mg
48504345|NCT00463697|DRUG|GW642444M (25, 100 & 400 mcg)|M salt
48504346|NCT05735340|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
48141780|NCT02116075|PROCEDURE|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
48141781|NCT02116075|PROCEDURE|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
48141782|NCT01873898|DEVICE|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
48141783|NCT01313884|DRUG|Irinotecan|50 mg/m2/day x 5 days
48141784|NCT01313884|DRUG|Vincristine|2 mg/m2 to a maximum of 2 mg
48141785|NCT01313884|DRUG|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
48141786|NCT01313884|DRUG|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
48141787|NCT01313884|DRUG|Cytoxan|1200 mg/m2
48141788|NCT01313884|DRUG|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
48141789|NCT00524069|BIOLOGICAL|bevacizumab|
48352300|NCT04955652|BEHAVIORAL|Best Practice Alert|Alert
48352301|NCT03968588|DRUG|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
48352302|NCT03968588|DRUG|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
48352303|NCT02916628|BEHAVIORAL|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
48352304|NCT02916628|DEVICE|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
48352305|NCT02916628|DEVICE|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
48663139|NCT02385071|DRUG|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
48663140|NCT02385071|DRUG|Treatment B|Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
48663141|NCT02385071|DRUG|Treatment C|Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
48663142|NCT02385071|DRUG|Treatment D|\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions.
48663143|NCT02385071|DRUG|Treatment E|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
48663144|NCT02385071|DRUG|Treatment F|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
47985997|NCT04750720|OTHER|Sampling by venipuncture (and eventually by nasopharyngeal swab)|"Biological samples :~* Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~* PBMC (peripheral blood mononuclear cells)~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to SARS-CoV-2 infection~* Notion of hospitalization/ambulatory follow-up~Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~* Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells"
47985998|NCT03794557|DRUG|Sterile Water Injection|Inhaled Sterile Water Injection
47985999|NCT03794557|DRUG|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution
47986000|NCT01647412|DRUG|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
47986001|NCT01647412|DIETARY_SUPPLEMENT|Nutraceutical Combination|
47986002|NCT01647412|OTHER|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
47986003|NCT01647412|OTHER|Placebo Growth Hormone|
48141790|NCT00524069|DRUG|capecitabine|
48141791|NCT00524069|DRUG|gemcitabine hydrochloride|
48141792|NCT00524069|OTHER|flow cytometry|
48663145|NCT04446052|DRUG|GM-CSF priming|
48141793|NCT00524069|OTHER|laboratory biomarker analysis|
48663146|NCT04446052|DRUG|Placebo|Placebo
48663147|NCT01971918|BIOLOGICAL|anti drug antibodies dosage|anti drug antibodies dosage
48141794|NCT00524069|PROCEDURE|adjuvant therapy|
48141795|NCT00524069|PROCEDURE|computed tomography|
48141796|NCT00524069|PROCEDURE|neoadjuvant therapy|
48141797|NCT00154115|DRUG|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
48141798|NCT00154115|DRUG|placebo|Placebo
48141799|NCT00108589|DRUG|S-adenosylmethionine|
48141800|NCT00792337|DRUG|simvastatin|10 mg per oral once daily for 8 weeks
48141801|NCT00792337|DRUG|B1-6-12|1 table per day for 8 weeks
48141802|NCT06435481|DRUG|3D printed chewable formulation of hydrocortisone|Administration of a novel hydrocortisone formulation provided as chewable tablets. Each tablet, manufactured with a volume dosing device (3D printer), contains a precise dosage of hydrocortisone.
48141803|NCT06435481|DRUG|Oral suspension of hydrocortisone|Administration of a standard hydrocortisone oral suspension. The solution, based on simple syrup, contains 1mg of hydrocortisone per milliliter.
48352306|NCT04802395|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
48141804|NCT05318963|BIOLOGICAL|LCAR-AIO cells product|before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
48141805|NCT06050941|DRUG|idarubicin|Idarubicin 6mg/m2 d5-7
48141806|NCT06050941|DRUG|Cytarabine|Cytarabine 60mg/m2 d5-9
48141807|NCT00439686|DRUG|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
48141808|NCT04640584|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
48141809|NCT05621902|OTHER|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
48141810|NCT01695291|DRUG|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
48141811|NCT01695291|OTHER|Placebo|A placebo pill will be administered twice a day (BID) for 12 weeks.
48141812|NCT03100188|OTHER|modified PD prescription|For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
48663148|NCT04631692|BEHAVIORAL|Health literacy intervention|"We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant."
47986004|NCT01720992|OTHER|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
48141813|NCT06140888|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract 8 pills three times per day is administrated.
48141814|NCT00869856|DRUG|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
48141815|NCT02515123|DEVICE|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
48352307|NCT04154111|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; double blinded
48352308|NCT04154111|DEVICE|Sham TBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
48352309|NCT04154111|DEVICE|Real TBS to the dlPFC|This will be delivered with the Magventure Magpro system (double blinded).
48504347|NCT05735340|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
48504348|NCT02116608|DRUG|Betadine|Apply locally as needed.
48504349|NCT02116608|DRUG|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
48504350|NCT02116608|DRUG|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
47986005|NCT02433756|DEVICE|CRTD|
47986006|NCT02187484|DRUG|BIBR 277|
47986007|NCT05520944|DRUG|ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray|Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
47986008|NCT00735592|OTHER|Observational|Retrospective data obtained from electronic files
47986009|NCT03523754|DRUG|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
47986010|NCT05399381|DEVICE|Transcranial alternating current stimulation (tACS)|Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
47986011|NCT04489329|DEVICE|Ingestible Capsule|Participants will swallow capsule and undergo X-rays to establish transit
48141816|NCT02515123|DEVICE|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
48141817|NCT00972920|PROCEDURE|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
48141818|NCT02865785|DRUG|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
48141819|NCT02865785|DRUG|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
48663149|NCT06349213|RADIATION|FDOPA injection before PET imaging|Fluorodopa labelled with fluorine 18 (physical half-life of 109.6 min) is used at a dosage of 1 to 2 MBq/kg in neuroimaging, depending on the sensitivity of the PET camera used. For these reasons, a dose of 2 MBq/kg will be administered slowly intravenously (approximately 1 minute for a maximum bolus of 10 mL). PET acquisitions will be performed at 90 minutes post-injection and will last 30 minutes. Participants will be asked to have fasted for at least 4 hours at the time of injection, with no restriction on fluid intake.
48663150|NCT06349213|BEHAVIORAL|Time perception tasks|The main tasks involves the comparison of duration to assess aging effects on the precision of temporal representations
48141820|NCT00756574|DEVICE|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
48663151|NCT06349213|DEVICE|fMRI imaging|Imaging of brain structure during the completion of the time perception task
48141821|NCT00756574|DEVICE|N95 mask|N95 mask worn for patients with febrile respiratory illness
48663152|NCT06349213|DEVICE|EEG imaging|Recording of neural dynamics during the completion of the time perception task
48663153|NCT06349213|BEHAVIORAL|3 year follow-up|Behavioral and EEG follow-up (for older adults only)
48663154|NCT04750083|DRUG|HX008|HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles
48141822|NCT00841711|BEHAVIORAL|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
48352310|NCT04154111|DEVICE|Sham TBS to the dlPFC|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
48352311|NCT03062670|OTHER|Retreat|Full day off-site training session
48663155|NCT04750083|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles
48663156|NCT04750083|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles
48141823|NCT00569166|BEHAVIORAL|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
48141824|NCT00569166|BEHAVIORAL|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
48141825|NCT00569166|BEHAVIORAL|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
48141826|NCT04439825|DRUG|Botulinum Neurotoxin|glabella, forehead lines and/or lateral canthal lines
48141827|NCT04439825|DRUG|Placebo|Saline solution (preservative free)
48141828|NCT03713476|OTHER|Motor task training|motor task specific training
48352312|NCT03700086|DEVICE|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
48352313|NCT03700086|DEVICE|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
48352314|NCT00284167|BEHAVIORAL|tailored web-based weight management intervention|
48352315|NCT02194192|DRUG|Placebo|Normal saline 10 ml
48663157|NCT04750083|DRUG|cisplatin/carboplatin|cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
48663158|NCT05888064|DIAGNOSTIC_TEST|diffusion MRI sequences|Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
48352316|NCT02194192|DRUG|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
48352317|NCT02194192|DRUG|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
48352318|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
48352319|NCT00601653|BEHAVIORAL|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
48504351|NCT05375071|OTHER|Blood Flow Restriction (BFR) Therapy|BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.
48352320|NCT01788111|OTHER|Low back exercises 1|Excentric / concentric extension type exercises
48504352|NCT05375071|OTHER|Physical Therapy|Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
48352321|NCT01788111|OTHER|Low back exercise 2|Traditional low back training
48352322|NCT00723086|DRUG|docetaxel (XRP6976)|combined treatment with prednisolone
48352323|NCT04327895|BEHAVIORAL|evaluation of the need for training|analyse of results of survey
48352324|NCT05736042|DEVICE|Lens fragmentation|Lens fragmentation with the microinterventional microfilament loop device (miLOOP)
48352325|NCT04668547|DEVICE|Hysteroscopic Embryolysis|Hysteroscopic removal of the products of conception for induced abortion using a hysteroscopic morcellator. If this method of induced abortion fails, a traditional Dilation and Curettage procedure is performed
48352326|NCT05465967|PROCEDURE|Quadratus lumborum Block|1-Transverse transmuscular Quadratus lumborum block: ultrasound transducer will placed transverse to the abdominal flank to visualise abdominal muscle layers. moving the probe posteriorly, the transverse process of the lumbar vertebra, Quadratus lumborum, Psoas Major and erector spinae muscles identified as a 'Shamrock sign'. the needle will inserted through the back muscles to fascial plane between the Quadratus lumborum and Psoas Major, local anesthetic will injected .2- paraspinous sagittal Quadratus lumborum block: ultrasound transducer will be directed caudally in a sagittal plane lateral to the spinous process of L4. moving laterally until the Quadratus lumborum is evident in its long axis with a characteristic sonographic image of three muscle layers appearing from posterior to anterior as: erector spinae, Quadratus lumborum, and Psoas major muscle the needle will be advanced through the muscles, until it pierces the Quadratus lumborum. local anesthetic will be injected.
48352327|NCT04347434|DRUG|Atorvastatin 80mg|Atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in addition to the standard therapy
48504353|NCT01690741|DRUG|Nerofe|Nerofe administered intravenously 3x/week
48141829|NCT00540111|DIETARY_SUPPLEMENT|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
48141830|NCT01989416|DRUG|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
48141831|NCT01989416|DRUG|Soap|The ICU patients will be bathing with Soap
48352328|NCT05973240|OTHER|Participation in an web-based survey|Patients who agree to participate will access a web-based survey (SurveyMonkey) via social media, mobile messages, or emails. The invitation will provide study details, eligibility criteria, and tasks. Patients will confirm inclusion/exclusion criteria upon access, and those ineligible will opt out. Data collection will take approximately 10 minutes per patient. Collected data will be sent to an electronic data collector and saved as an eCRF file in REDCap. The study will conduct two cross-sectional data collection rounds using web surveys to ensure anonymity. Convenience sampling will target anticoagulated patient associations' webpages and social media (e.g., Feder-AIPA, AICCA). In the second round, participants will be informed not to resubmit if they have already completed the survey to avoid overlapping responses.
48504354|NCT01421173|DRUG|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
48141832|NCT04329598|OTHER|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
48352329|NCT03061149|OTHER|Low-level laser therapy|
48352330|NCT03061149|OTHER|Ultrasound treatment|
48352331|NCT04511091|PROCEDURE|VATS lobectomy|VATS lobectomy allows surgeons to carry out exactly the same operation within the chest that is performed by thoracotomy, but it is done through 3-4 small incisions without rib spreading rather than the large incision with rib spreading that a thoracotomy entails. The surgeon gains his view inside the chest from a small video camera inserted through one of the small incisions, and the procedure is carried out with long instruments passed through the other small incisions.
48352332|NCT00005555|BEHAVIORAL|Exercise|
48352333|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.
48352334|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
48504355|NCT01421173|DRUG|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
48504356|NCT01421173|DRUG|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
48141833|NCT04329598|OTHER|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
48663159|NCT04312802|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|"The participant will undergo a cardio-pulmonary exercise test (CPET) on a cycle ergometer (Ergoline) connected to a 12-lead electrocardiogram, oxygen saturation monitor and continuous non-invasive blood pressure cuff. Respiratory gas exchanged will be measured from a tight fitting facemask. An initial 2-min period of baseline data will be collected at rest before a 180-s period of unloaded cycling. A ramp protocol will then be applied and the participant will be instructed to continue cycling at a constant cadence of 60 rpm as long as they can. The test will be terminated if the participant indicates that:~* they cannot continue~* cadence falls to \<55 rpm due to fatigue or dyspnoea~* they develop abnormal cardiac signs or symptoms, such as ischaemia and arrhythmia."
48141834|NCT02540369|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
48352335|NCT05400811|BIOLOGICAL|MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)|Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.
48352336|NCT05400811|BIOLOGICAL|Placebo subcutaneous|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
48663160|NCT02457065|BEHAVIORAL|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
48141835|NCT00359203|DEVICE|Dual chamber pacemeker|
48352337|NCT05400811|BIOLOGICAL|Placebo sublingual|The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
48352338|NCT05855421|DEVICE|Auricular Acupuncture|Aplication of semi-permanents needls in the ear by an experient and specialized professional using tradicional chinese maps and a specific device to find acupuncture points. There is a gap of one day minimum between sessions and two non-consecutive absences are allowed.
48504357|NCT01421173|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
48352339|NCT04383171|DEVICE|Motomed cycle ergometer (MOTOmed letto2 - Reck, Reckstr 1-5, Betzenweiler 88422, Germany).|
48352340|NCT02208505|DRUG|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
48352341|NCT02208505|DRUG|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
48352342|NCT02892305|PROCEDURE|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
48352343|NCT01994109|DRUG|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
48352344|NCT01994109|OTHER|PLACEBO|
48352345|NCT01875666|DRUG|Trastuzumab|8 mg/kg IV, single dose
48352346|NCT01875666|DRUG|pertuzumab|840 mg IV single dose
48352347|NCT01875666|DRUG|lapatinib|1000 mg daily for 7 days
48367532|NCT04196231|DRUG|Insulin/Dapaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to dapaglifozin, according to the current clinical practice and the drugs' data sheet. Dapagliflozin will be started at 10 mg daily per oral administration
48504358|NCT01421173|PROCEDURE|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
48504359|NCT01421173|DRUG|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
48504360|NCT01421173|DRUG|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
48504361|NCT01421173|DRUG|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
48504362|NCT01421173|DRUG|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
48141836|NCT01328496|DRUG|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
48504363|NCT02796794|DIETARY_SUPPLEMENT|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
48504364|NCT02796794|OTHER|enteral nutrition only|These are the patients receiving enteral nutrition
48663161|NCT01943227|OTHER|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
48141837|NCT02950961|BEHAVIORAL|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators offered in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators trained appropriate MH providers in CALM and studied the ways in which the intervention needs to be tailored to women Veterans.
48141838|NCT03765385|OTHER|High-intensity training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
48141839|NCT03765385|OTHER|Moderate-intensity continuous training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
48141840|NCT03734978|DIAGNOSTIC_TEST|Diagnosis|biochemistry
48352348|NCT01122823|BEHAVIORAL|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
48504365|NCT03680066|OTHER|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~* cookies, max 30 g;~* chocolate, max 30 g;~* breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
48504366|NCT02684630|DEVICE|Trima Accel System|Platelet Apheresis Procedure
48504367|NCT00205803|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
48504368|NCT00205803|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
48504369|NCT06336395|DRUG|Prednisolone|Oral
48663162|NCT01943227|OTHER|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
48663163|NCT00846157|BIOLOGICAL|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
48663164|NCT06564909|DRUG|L-Carnitine|L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)
48141841|NCT04251923|DEVICE|Retro pubic sling|patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
48141842|NCT04886284|DRUG|Ertapenem|Adjunctive ertapenem
48141843|NCT04886284|DRUG|Placebo|Saline placebo
48141844|NCT02005172|DEVICE|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
48141845|NCT02166684|DEVICE|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
48141846|NCT04255225|BEHAVIORAL|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
48141847|NCT04255225|BEHAVIORAL|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
48141848|NCT04255225|BEHAVIORAL|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
48141849|NCT04855747|DRUG|REL-1017|REL-1017 tablet
48504370|NCT06336395|DRUG|Dexamethasone|Oral
48141850|NCT04855747|DRUG|Placebo|Placebo tablet
48141851|NCT04569188|BIOLOGICAL|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
48141852|NCT03427996|PROCEDURE|Rotational atherectomy|Percutaneous coronary intervention with rotational atherectomy
48504371|NCT06336395|DRUG|Vincristine|Intravenous
48663165|NCT06564909|DRUG|The standard care for the management of myocardial infarction post PCI|include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
48141853|NCT00724737|PROCEDURE|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
48141854|NCT00724737|PROCEDURE|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
48504372|NCT06336395|DRUG|Methotrexate|Oral/ intrathecal/intravenous/subcutaneous
48663166|NCT03770702|DRUG|Angiotensin receptor blockers|Candesartan
48504373|NCT06336395|DRUG|L-Asparaginase|Intramuscular
48504374|NCT06336395|DRUG|Pegylated asparaginase|Intravenous
48504375|NCT06336395|DRUG|Erwinase|Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
48663167|NCT03770702|DRUG|Statins|Atorvastatin
48663168|NCT04754490|DIAGNOSTIC_TEST|Speech Recognition|Speech Recognition
48141855|NCT05770115|PROCEDURE|Vicryl 1|Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
48141856|NCT05770115|PROCEDURE|Vicryl 2/0|Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
48141857|NCT06505993|BEHAVIORAL|Health Communication|Participants will experience a coordinated social marketing campaign including targeted messaging related to vaccine education, self-efficacy, and informative resources to receive the COVID-19 vaccine. The intervention messaging will be strategically layered and disseminated to this intervention arm predominately via Facebook by trusted and local communicators in the study counties.
48141858|NCT06505993|BEHAVIORAL|Health Communication + Structural|This multi-level intervention will include the defined health messaging intervention components, as well as a combination of structural-level intervention strategies targeted to better facilitate access to community-based vaccination delivery. Health organizations will receive a toolkit, which will include community-specific resources and training modules such as: up to date evidence-based vaccination guidance that can be delivered to patients; strategies for navigating conversations with patients about vaccination; any applicable reimbursement, insurance, or qualifying enrollment information specific to the healthcare organization; identifying locations that facilitate access for the community members; provided advertising to promote the locations and timing of the vaccinations; and generating community-based branding for all vaccination delivery based on the trusted information sources identified.
48141859|NCT00269022|DRUG|SB-705498|
48141860|NCT00281905|DRUG|carboplatin|
48141861|NCT00281905|DRUG|cisplatin|
48141862|NCT00281905|DRUG|cyclophosphamide|
48352349|NCT04865224|DIAGNOSTIC_TEST|hemoglobin estimation|In this method, in which different deep learning models are used together, the age range is intended to be as wide as possible to provide a quick solution with a high accuracy and low error values.
48352350|NCT03432936|DEVICE|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
48352351|NCT03954184|BEHAVIORAL|NIATx-TI with Product Training/On-line Support|NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
48141863|NCT00281905|DRUG|methotrexate|
48504376|NCT06336395|DRUG|Dasatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
48141864|NCT00281905|DRUG|vincristine sulfate|
48141865|NCT00281905|RADIATION|radiation therapy|
48141866|NCT06294145|BEHAVIORAL|Savoring Intervention|The savoring intervention is the first module of the Positive Affect Treatment (PAT) developed by Michelle Craske and colleagues to treat anhedonia, or loss of interest or pleasure in usual activities. The investigators focus here on the behavioral activation and savoring components of the intervention, which are administered first and are considered the basis for other components. Of note, a variety of other positive psychology interventions include a savoring component, but PAT is unique in its inclusion of six sessions devoted to savoring. These sessions involve pleasant events scheduling in which participants: 1) plan activities that generate anticipation of reward, 2) engage in activities that generate reward and 3) practice therapist-guided-in-the-moment recounting of positive emotions, sensations, and thoughts generated by these activities. The investigators will additionally include an introductory psychoeducation session before the savoring module, as PAT does.
48352352|NCT05677854|OTHER|Health literacy based motivaonal interview|Motivational interviewing technique was used based on health literacy.
48504377|NCT06336395|DRUG|Imatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
48504378|NCT06336395|DRUG|Cyclophosphamide|Intravenous
48663169|NCT00967499|DRUG|Ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
48141867|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 7.5 µg administered IM
48141868|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 15 µg administered IM
48141869|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 30 µg administered IM
48141870|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 31.25 µg administered SC
48352353|NCT05677854|OTHER|Health literacy based health education|Health education based on health literacy was used.
48352354|NCT03363568|BEHAVIORAL|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
48504379|NCT06336395|DRUG|Cytarabine|Subcutaneous/ Intravenous
48504380|NCT06336395|DRUG|Mercaptopurine|Oral
48504381|NCT06336395|DRUG|Thioguanine|Oral
48504382|NCT06336395|DRUG|Rituximab|Intravenous
48504383|NCT06336395|DRUG|Doxorubicin|Intravenous
48504384|NCT06336395|DRUG|Fludarabine|Intravenous
48504385|NCT00855179|DRUG|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
48663170|NCT00967499|DRUG|Palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
48141871|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 62.5 µg administered SC
48141872|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 125 µg administered SC
48141873|NCT04183491|BIOLOGICAL|Placebo|Placebo (administered either IM or SC)
48141874|NCT06465537|GENETIC|BD113vVLP|CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.
48141875|NCT05454943|BEHAVIORAL|Standardized TRE Protocol|A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.
48141876|NCT05454943|BEHAVIORAL|Personalized TRE Protocol|A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.
48352355|NCT03363568|BEHAVIORAL|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
48352356|NCT04410835|DIAGNOSTIC_TEST|Online Survey|Psychological questionnaires
48352357|NCT00004127|DRUG|FOLFOX regimen|
48352358|NCT00004127|DRUG|fluorouracil|
48141877|NCT05454943|BEHAVIORAL|External Support for TRE|External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.
48352359|NCT00004127|DRUG|leucovorin calcium|
48352360|NCT00004127|DRUG|oxaliplatin|
48352361|NCT03096886|BEHAVIORAL|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
48352362|NCT03824457|DRUG|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
48352363|NCT03824457|DRUG|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
48663171|NCT05557708|DRUG|212-Lead Pentixather|Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
48141878|NCT05454943|BEHAVIORAL|Peer Support for TRE|Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
48141879|NCT06474039|DRUG|Trelegy or Anoro|Both drugs delivered via Ellipta device and blinded package appearance
48141880|NCT06196853|DRUG|Aminophylline|Give aminophylline for 5 days to keep serum theophylline level 5-15 mg/dl
48141881|NCT05626907|OTHER|Diet modification #1|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 130% of estimated daily caloric needs and for the other 7 days, meals will be low in calories, consistent with recommendations for weight loss.
48141882|NCT05626907|OTHER|Diet modification #2|Participants will be provided all meals for a 14-day period. For 7 of the days, meals will be 150% of estimated daily caloric needs and for the other 7 days, meals will be meals will be low in calories, consistent with recommendations for weight loss.
48352364|NCT05858437|DIETARY_SUPPLEMENT|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
48504386|NCT00855179|DRUG|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
48504387|NCT00359593|BEHAVIORAL|Knowledge translation intervention package|
48504388|NCT04540406|DRUG|NBT-NM108|Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
48663172|NCT05557708|DIAGNOSTIC_TEST|203-Lead Pentixather SPECT/CT|Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
48504389|NCT04540406|OTHER|Usual Care Only|Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.
48504390|NCT02470533|RADIATION|Radiation therapy|6 fractions of 8-9Gy
48504391|NCT02470533|DEVICE|chemoembolization|Up to 4 sessions
48504392|NCT05937984|DEVICE|Active Controlled Transcranial Magnetic Stimulation (cTMS)|cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.
48504393|NCT05937984|DEVICE|Sham Controlled Transcranial Magnetic Stimulation (cTMS)|A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
48663173|NCT06565351|OTHER|eGFR estimated from creatinine and cystatin C|eGFR estimated from creatinine and cystatin C was compared to GFR measured by 99mTc-DTPA clearance (gold standard)
48663174|NCT03772535|DIAGNOSTIC_TEST|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
48504394|NCT00094003|DRUG|NS-9 [Poly I: Poly C]|
48504395|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; first study group: 10E7_TCID50
48504396|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; second study group: 10E8_TCID50
48141883|NCT05626907|OTHER|Diet modification #3|Participants will be provided all meals for a 14-day period to be approximately 100% of estimated daily caloric needs.
48141884|NCT02387606|DRUG|Placebo|Participants will receive placebo once daily.
48504397|NCT06009627|DRUG|Dalcelli、Exemestane、Gosserine|"Dalcelli: once a day, 125 mg each time, taken for 3 weeks, stopped for 1 week, 1 for 4 weeks~Period. It is recommended to take the medication at approximately the same time every day, delivered in warm water, on an empty stomach, at least before taking the medication~Fasting for 1 hour before and after.~Exemestane: 25mg, oral, once a day, continuous administration.~Gosserine: 3.6mg, subcutaneous injection, once every four weeks, continuous administration"
48504398|NCT06009627|DRUG|Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection|"Docetaxel for injection: 75mg/m2, intravenous drip, approximately 30 minutes. Dose reduction and delayed administration are allowed every three weeks, with a maximum of three weeks of delayed administration allowed since the last administration time~Calculate, otherwise terminate treatment.~5. Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction~And delayed administration, with a maximum allowable delay of 3 weeks, calculated from the last administration time. Otherwise~Stop treatment.~6. Cyclophosphamide for injection: 500mg/m2, intravenous drip. Once every three weeks, allowing for dose reduction and~Delayed administration, allowed up to 3 weeks, calculated from the last administration time, otherwise terminated treat"
48141885|NCT02387606|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
48141886|NCT04847180|PROCEDURE|Biopsy|The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
48141887|NCT01847456|DRUG|human insulin as nasal spray|
48141888|NCT01847456|DRUG|Placebo|
48141889|NCT04866160|DRUG|BI 1291583|BI 1291583
48141890|NCT04866160|DRUG|Placebo|Placebo
48141891|NCT05483166|BEHAVIORAL|ImPACT|"During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on:~1. Becoming aware of the child's core strengths and difficulties~2. Helping the child to be optimally responsive to the guidance of the parent(s), and~3. Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home."
48141892|NCT03649191|OTHER|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
48141893|NCT03649191|OTHER|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
48504399|NCT01473524|DRUG|Obeticholic Acid (OCA)|OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
48141894|NCT03719352|PROCEDURE|Experimental: Deep dry needling|Deep dry needling until achieving twitch response of the muscle
48141895|NCT03719352|PROCEDURE|Experimental: Superficial dry needling|Superficial dry needling to achieve sensitive pain with needle rotation
48504400|NCT01473524|DRUG|Placebo|Matching placebo tablets were administered orally once daily.
48504401|NCT06048965|OTHER|No intervention to be performed|No intervention to be performed. Anonymous survey only.
48504402|NCT03384082|PROCEDURE|hysteroscopic treatment|treatment
48504403|NCT05436067|DEVICE|Vestibular rehabilitation app|Delivery of vestibular rehabilitation through an app on a tablet or other portable device. The app takes patients through their rehabilitation session that has been prescribed by a clinician. Exercises are presented in the forms of games that are controlled by head or torso motion via a motion sensor that is placed on that body part. Data on the motion of the patient are calculated from sensor data and sent over the cloud for the clinician to access remotely.
48663175|NCT00195780|DRUG|Divalproex Sodium (Depakote ER)|
47986012|NCT04489329|DIETARY_SUPPLEMENT|Probiotic|Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
48141896|NCT03719352|PROCEDURE|Placebo Comparator: Placebo Gastrocnemius dry needling|Simulate pain with de plastic needle guard in the gastrocnemius muscle
47986013|NCT04945902|BEHAVIORAL|Synchronous Intervention|Weekly one-hour support groups. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connection and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
48663176|NCT04282785|DIAGNOSTIC_TEST|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
48663177|NCT06063655|DIETARY_SUPPLEMENT|Control: Water|Water will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
48663178|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV hydration multiplier|Liquid IV hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
48663179|NCT06063655|DIETARY_SUPPLEMENT|Liquid IV sugar-free hydration multiplier|Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
48663180|NCT04638309|DRUG|APR-548 + Azacitidine|APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
48663181|NCT00453492|DRUG|risedronate sodium|
48663182|NCT00175500|DEVICE|Large Diameter Femoral Head|
48663183|NCT04961593|DRUG|Caspofungin|For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
48663184|NCT04838067|DEVICE|Cefaly|Transcutaneous trigeminal nerve electrical neuromodulation
48663185|NCT01807884|PROCEDURE|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
48663186|NCT01807884|OTHER|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
48663187|NCT01502527|DIETARY_SUPPLEMENT|Femarelle|Twice daily oral treatment with Femarelle
48663188|NCT01233947|DRUG|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
48663189|NCT01233947|DRUG|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
48504404|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
48504405|NCT01659086|BIOLOGICAL|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
48504406|NCT01659086|BIOLOGICAL|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
48504407|NCT06632561|DRUG|Empagliflozin 10 mg|Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
48663190|NCT01241123|PROCEDURE|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
48663191|NCT01241123|DRUG|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
48663192|NCT01241123|RADIATION|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
48663193|NCT01241123|DEVICE|pedometers|to record the amount of ambulation
47986014|NCT04945902|BEHAVIORAL|Asynchronous Intervention|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include: (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
47986015|NCT05059067|DEVICE|Direct laryngoscopy for endotracheal intubation|Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
47986016|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics|pharmacogenomics
47986017|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics \& therapeutic drug monitoring
47986018|NCT04207385|DRUG|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
47986019|NCT03038633|OTHER|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
47986020|NCT05266742|OTHER|web based education|"An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF."
47986021|NCT02711540|PROCEDURE|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
47986022|NCT04653805|OTHER|Current clinical practice in primary care of patients with type 2 diabetes mellitus|
48504408|NCT06632561|DRUG|Placebo|Sugar pills one tablet daily for 6 months
48663194|NCT06528080|GENETIC|LY-M001|LY-M001 Injection by Single Intravenous Infusion
48663195|NCT06029790|OTHER|gum chewing|For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence.
48141897|NCT03135782|OTHER|Communication Skills Training|Undergo motivational interviewing training
48141898|NCT03135782|OTHER|Medical Chart Review|Undergo medical chart review
48141899|NCT03135782|OTHER|Questionnaire Administration|Ancillary studies
48504409|NCT01879163|BIOLOGICAL|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
48504410|NCT01879163|BIOLOGICAL|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
48141900|NCT03135782|OTHER|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
48141901|NCT04723979|DRUG|Eptacog alfa|Recombinant coagulation factor VII activated
48141902|NCT04723979|OTHER|Standard of care|Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
48141903|NCT00300404|DRUG|daraprim|
48141904|NCT00300404|DRUG|pyrimethamine|
48141905|NCT00300404|DRUG|folinic acid|
48352365|NCT05858437|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
48687946|NCT03625869|DEVICE|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
48141906|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
48141907|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
48141908|NCT03735459|BEHAVIORAL|Patient reminders and accountability questionnaires|Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
48141909|NCT04255498|DRUG|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
48504411|NCT02405884|OTHER|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
48352366|NCT00766181|BEHAVIORAL|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
48352367|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
48352368|NCT00444951|BIOLOGICAL|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
48352369|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
48352370|NCT01594411|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
48504412|NCT03467880|OTHER|Clinical Observation|No treatment given but observation with IOS
48504413|NCT00093561|DIETARY_SUPPLEMENT|lycopene|
48504414|NCT03828786|PROCEDURE|Endometrial scratching|Endometrial Biopsy by aspiration with a pipelle
48504415|NCT01064752|DRUG|Minocycline|100 mg po bid for 8 weeks
48352371|NCT06154759|OTHER|Watson Human Caring Model-based psychoeducation|It is a psychoeducation program based on the Watson human care model, one of the theories of the nursing profession, that includes healing processes, and consists of sessions that address the hopelessness, death anxiety and care burden of individuals.
48352372|NCT00417391|DRUG|RR110 (Tamibarotene)|1 mg RR110
48141910|NCT04255498|DRUG|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
48141911|NCT03940339|OTHER|Suboccipital myofascial release|The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
48141912|NCT03940339|OTHER|Conventional Physiotherapy|The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
48141913|NCT00489879|DEVICE|Mobile Health Care System (DrUB)|
48141914|NCT01427400|DRUG|Botulinum Toxin-A|100 Units diluted in 25cc saline
48141915|NCT01427400|DRUG|Saline|Dispensed in a 25cc syringe
48141916|NCT02298998|OTHER|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
48141917|NCT02298998|OTHER|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
48141918|NCT03728452|PROCEDURE|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
48141919|NCT06186349|GENETIC|Genomic sequencing|Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
48141920|NCT06172036|DRUG|irinotecan liposome + oxaliplatin + 5-FU / LV|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
48141921|NCT06172036|DRUG|Adebellizumab|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
48141922|NCT02309294|DEVICE|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
48141923|NCT02309294|DEVICE|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
48504416|NCT04603235|BEHAVIORAL|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
48141924|NCT02309294|DEVICE|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
48141925|NCT02309294|DEVICE|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
48141926|NCT02309294|DEVICE|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
48141927|NCT00927706|DEVICE|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
48141928|NCT05461755|COMBINATION_PRODUCT|Fractional radiofrequency and topical Tretinoin|Treatment of striae with fractional radiofrequency and topical tretinoin in combination
48141929|NCT05461755|DRUG|Topical Tretinoin|Treatment of striae with topical tretinoin alone
48141930|NCT05461755|DEVICE|Fractional radiofrequency|Treatment of striae with fractional radiofrequency alone
48141931|NCT01192555|BIOLOGICAL|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10\^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
48504417|NCT03243058|BIOLOGICAL|ILT-101 (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin-2 (ILT-101) for two years
48141932|NCT01192555|DRUG|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
48141933|NCT05413993|RADIATION|photobiomodulation|Laser application intraorals and extraoral points in the region of the salivary glands bilaterally
48141934|NCT05143125|BIOLOGICAL|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
48352373|NCT00417391|DRUG|RR110 (Tamibarotene)|4 mg RR110
48352374|NCT04172376|PROCEDURE|Minimally invasive puncture aspiration plus rt-PA|Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
48504418|NCT03243058|OTHER|Treatment-Placebo Arm|Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
48141935|NCT06272032|PROCEDURE|High-intensity focused ultrasound (HIFU)|Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
48141936|NCT06272032|DRUG|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
48141937|NCT02099188|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
48141938|NCT02099188|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
48141939|NCT02099188|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
48141940|NCT02099188|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
48141941|NCT02099188|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
48141942|NCT02099188|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
48141943|NCT02099188|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
48141944|NCT02099188|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
48663196|NCT06352346|BEHAVIORAL|Compensatory brain game supporting Goal Management Training intervention|o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
48663197|NCT05099315|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
48141945|NCT02099188|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
48141946|NCT02099188|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
48141947|NCT04783766|DRUG|CK-3773274|CK-3773274- Tablets
48141948|NCT04783766|DRUG|Placebo|Placebo- Tablets
48141949|NCT05694832|BEHAVIORAL|Expressive Writing|Creative writing, discussion and social support, in a group setting via videoconference
48141950|NCT05325099|DRUG|Azacitidine|azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
48141951|NCT05325099|DRUG|Placebo|Placebo (subcutaneous injection) QOD x 3 times
48141952|NCT01529632|DRUG|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
48141953|NCT01529632|DRUG|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
48141954|NCT01529632|DRUG|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
48141955|NCT01529632|DRUG|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
48141956|NCT02693288|PROCEDURE|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
48141957|NCT00546156|DRUG|Doxorubicin|Standard chemotherapy regimen
48141958|NCT00546156|DRUG|Cyclophosphamide|Standard chemotherapy regimen
48141959|NCT00546156|DRUG|Paclitaxel|Standard chemotherapy regimen
48141960|NCT00546156|DRUG|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
48141961|NCT05764057|DRUG|Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)|"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
47986023|NCT03978429|OTHER|Community-based Pre-eclampsia/Eclampsia Detection and Management|Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
47986024|NCT03978429|OTHER|Strengthened Referral Network from Community to Referral hospital levels|ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
47986025|NCT02234453|DEVICE|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
47986026|NCT06093009|PROCEDURE|pancreatectomy|
47986027|NCT00103142|BIOLOGICAL|falimarev|Given subcutaneously and intradermally
47986028|NCT00103142|BIOLOGICAL|inalimarev|Given subcutaneously and intradermally
47986029|NCT00103142|BIOLOGICAL|sargramostim|Given subcutaneously
47986030|NCT00103142|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
47986031|NCT03440710|PROCEDURE|BET|Balloon Eustachian Tuboplasty
47986032|NCT02826707|BEHAVIORAL|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
47986033|NCT05248945|DRUG|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
47986034|NCT05248945|DRUG|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
47986035|NCT04476433|OTHER|Ten Vida (10Vida)|10Vida is a psychoeducational and emotional programme for chronic illness in adolescents and their families.
47986036|NCT04528654|OTHER|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
47986037|NCT02314650|OTHER|acupoint stimulation|stimulation was given at acupoints
47986038|NCT02314650|OTHER|non-acupoint stimulation|stimulation was given at non-acupoints
47986039|NCT02314650|OTHER|electrodes attached|electrode were attached to skin
47986040|NCT00321282|PROCEDURE|Atrial Fibrillation|
47986041|NCT00751647|OTHER|Physical Therapy|Treatment
47986042|NCT03657758|DRUG|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
47986043|NCT03657758|DRUG|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
47986044|NCT02463474|BEHAVIORAL|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
47986045|NCT03095391|DEVICE|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
47986046|NCT03095391|DEVICE|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
47986047|NCT04405648|BEHAVIORAL|CVS GROUP|the students will respond to CVS-F3 questionnaire to report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors.
47986048|NCT06313931|DEVICE|cognitive training via immersive virtual reality|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
47986049|NCT06313931|OTHER|cognitive training via paper and pencil|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.
47986050|NCT06313931|OTHER|motor stimulation|motor stimulation for 12 sessions (20 minutes per session)
47986051|NCT02637700|DRUG|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
48141962|NCT05764057|DRUG|Placebo comparator|"Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
48141963|NCT02819999|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
48141964|NCT02819999|DRUG|Cisplatin|
48141965|NCT02819999|DRUG|Etoposide|
48141966|NCT06340984|DRUG|Montelukast 10 Mg Oral Tablet|group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group
48141967|NCT00336791|DRUG|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle."
47986052|NCT02637700|DRUG|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
47986053|NCT01966640|BIOLOGICAL|Basophil Activation Test|blood sample for Basophil Activation Test
47986054|NCT03019107|DEVICE|Breath synchronized abdominal NMES|VentFree prototype (VF03) that delivers electrical stimulation pulses to the abdominal muscles during exhalation with a frequency of 30 Hz, a pulse width of 350 µs and 90% of the maximum current that the participant can tolerate. These stimulation parameters were selected to cause a tetanic (continuous) contraction of the abdominal muscles, without pain for the patient. Stimulation will be administered for 30 minutes 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
47986055|NCT03019107|DEVICE|Sham breath synchronized abdominal NMES|Modified VentFree prototype (VF03) that delivers stimulation pulses to the abdominal muscles during exhalation with a frequency of 10 Hz, a pulse width of 100 µs and current set to 10 milliamp. These stimulation parameters were chosen to cause a twitch contraction of the abdominal wall muscles. Stimulation will be administered for 30 minutes, 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
47986056|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system
47986057|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
47986058|NCT04964154|BEHAVIORAL|Protect Your Elders Campaign|This is a behavioral intervention where participants will receive cultural appropriate educational information about COVID-19 testing and vaccination.
47986059|NCT03138395|DIAGNOSTIC_TEST|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
47986060|NCT06493396|DRUG|Opioid-free Analgesics|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
47986061|NCT06493396|DRUG|Opioid group|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
48352375|NCT04172376|DRUG|Conservative medical treatment|Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
47986062|NCT02692599|BIOLOGICAL|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
47986063|NCT02692599|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
47986064|NCT03437720|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
47986065|NCT03437720|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
47986066|NCT04217746|DEVICE|High Flow Nasal Cannula|The HFNC group will receive heated and humidified oxygenated gas delivered at high flow.
48141968|NCT00336791|DRUG|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle."
48141969|NCT00336791|DRUG|Doxorubicin|FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
48141970|NCT00336791|DRUG|Paclitaxel|80 mg/m\^2 by vein (IVPB) over 1 hour every week for 12 weeks
48141971|NCT00336791|DRUG|Epirubicin|FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
48141972|NCT00004939|DRUG|,4-diaminopyridine|
48141973|NCT05283018|DEVICE|Electroencephalogram recording|Brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
48141974|NCT05283018|OTHER|Auditory stimulation|Monotonous sounds are sent via binaural headphones: a standard item and a distractor item (rough sound). Each stimulus lasts about 300 ms and they are separated by 1.5 to 2 seconds between them; the deviant sound/standard sound ratio is fixed between 1/5 and 1/6.
48352376|NCT06218628|DRUG|Talazoparib|pacritinib in combination with talazoparib
48352377|NCT06218628|DRUG|pacritinib|pacritinib in combination with talazoparib
48352378|NCT00584987|DRUG|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
48352379|NCT00584987|DRUG|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
48352380|NCT00584987|DRUG|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
48352381|NCT00584987|DRUG|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
48352382|NCT06135454|PROCEDURE|Open Wedge High Tibial Osteotomy|For OWHTO,The osteotomy plane, directed from 30 to 35 mm distal to the medial tibial plateau to 10-15 mm distal to the lateral tibial plateau in the coronal plane, was marked by two Kirschner wires with threaded tips. A transverse osteotomy was performed, leaving the lateral cortex intact as a hinge. After the ascending osteotomy and opening. The medial opening gap was filled with two β-TCP wedges and fixed with a TomoFix anatomical plate and locking screws .
48352383|NCT06135454|PROCEDURE|Double Level Osteotomy|The DLO was started from a lateral DFO. A 5-6-cm incision was made proximally at the distal femur from the lateral femoral epicondyle.Two Kirschner wires with threaded tips were inserted to make a length between the wires that was preoperatively planned as the lateral closed osteotomy. Transverse and ascending osteotomies were performed using a Precision Oscillating Tip Saw. The gap was closed and fixed using a TomoFix medial distal femur anatomical plate , which was bent for the lateral distal femur. The subsequent OWHTO was performed as described above.
48352384|NCT04653727|OTHER|Cross-sectional survey|No intervention.
48504419|NCT03243058|OTHER|Placebo Arm|Participants in this group will receive a placebo injection for two years.
48504420|NCT02943928|DEVICE|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
48504421|NCT02943928|DEVICE|traditional method by experience|Operator inserted the double lumen tube by experience
48504422|NCT03146962|DRUG|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
47986067|NCT01998633|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
48504423|NCT01203020|DRUG|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
48504424|NCT01203020|DRUG|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
48352385|NCT05483764|DEVICE|Ultrasonographic evaluations|"Ultrasonographic evaluations of the talar cartilage will be performed with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) by the same physiatrist according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS).~Ultrasonographic evaluations of the Achilles tendon will be performed by the same physiatrist with an 8 MHz linear probe (B-K Medical Ultrasound Scanner Class I Type B) according to the European Musculoskeletal Ultrasound Study Group (EURO-MUSCULUS)."
48663198|NCT06022640|BEHAVIORAL|Educational and supportive care|The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
48504425|NCT02271139|DRUG|Alectinib|Alectinib 600 mg administered orally with food.
48663199|NCT05452668|DEVICE|Laser Therapy|- Laser will be applied with the specified wave length using a diode laser device over 4 consecutive days.
48663200|NCT05452668|DEVICE|Sham procedure|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current Protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
48663201|NCT03022721|OTHER|No interventions are planned for this study.|No interventions are planned for this study, it is purely observational.
47986068|NCT01243970|DRUG|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg \*~\* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
48141975|NCT05283018|DEVICE|Transcranial Doppler|Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography. For all patients, CFV (unit cm/s) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at inspired oxygen fraction (FiO2) of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period.
48141976|NCT05283018|DEVICE|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at FiO2 of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period."
48141977|NCT02193932|OTHER|EEG Triggered fMRI using Micro Maglink|
48141978|NCT01683669|OTHER|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
48352386|NCT05749874|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
48504426|NCT03343444|DRUG|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
48504427|NCT03343444|DRUG|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
48504428|NCT00499421|PROCEDURE|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
48504429|NCT00437840|DRUG|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
48504430|NCT00437840|DRUG|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
48504431|NCT05314816|DIAGNOSTIC_TEST|Blood culture identification panel|multiplex PCR panel to be performed on positive blood cultures
48504432|NCT00900198|PROCEDURE|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
48663202|NCT04389697|DIETARY_SUPPLEMENT|Clear fluids and food up to up to 1 hour before the procedure|Clear fluids and food up to up to 1 hour before the start of the procedure
48663203|NCT05743309|BEHAVIORAL|Video call sessions|Investigators made video call sessions with the participants.
48663204|NCT06565364|DIAGNOSTIC_TEST|"ZYMUTEST™ HIA immunoglobulin g ELISA (enzyme-linked immunosorbent assay )"|The enzyme-linked immunosorbent assay is an in vitro test done in the laboratory to detect specific antibodies against heparin/platelet factor-4 and protamine/heparin complexes.
48663205|NCT02489279|BEHAVIORAL|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
48663206|NCT02489279|BEHAVIORAL|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
48663207|NCT06033560|DEVICE|High flow nasal oxygen (HFNO, more than 15 L/min)|Non-invasive respiratory support strategy
48663208|NCT05827341|OTHER|No intervention|No intervention needed
48663209|NCT02845882|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
48663210|NCT02845882|DRUG|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
48663211|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
48352387|NCT05749874|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based onChinese guideline on the primary prevention of cardiovascular diseases and Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition), including health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc."
48352388|NCT00438776|DRUG|olanzapine|2.5mg to 15mg daily
48352389|NCT00438776|DRUG|sugar pill|matching placebo to olanzapine
48352390|NCT01376908|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
48352391|NCT01376908|OTHER|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
48352392|NCT03104829|BEHAVIORAL|Motivational interviewing|
48352393|NCT03104829|DRUG|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
48504433|NCT01247883|DRUG|PF-04634817|single dose, 20mg, tablet
48504434|NCT01247883|DRUG|PF-04634817|single dose, 20mg, solution
48504435|NCT03555292|DRUG|11C-PiB|11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
48504436|NCT00237640|DRUG|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
48504437|NCT00087620|DRUG|XELODA [capecitabine]|
48504438|NCT03357965|OTHER|Questionnaire|Women who had gave birth in 6 weeks
48504439|NCT00598572|DRUG|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
48504440|NCT00866658|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
48504441|NCT00866658|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
48504442|NCT00866658|DEVICE|Pen auto-injector|
48504443|NCT00866658|DRUG|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
48504444|NCT00866658|DRUG|Basal Insulin|To be continued at a stable dose.
48504445|NCT03925350|DRUG|Niraparib|300 mg PO daily
48504446|NCT02955381|DEVICE|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
48504447|NCT02955381|DEVICE|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
48504448|NCT00497861|PROCEDURE|Activator Methods Chiropractic Technique|
48504449|NCT01504958|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS."
48663212|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
48663213|NCT02845882|DRUG|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
48663214|NCT02845882|DRUG|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
48352394|NCT01481428|BEHAVIORAL|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
48352395|NCT01481428|BEHAVIORAL|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
48504450|NCT01504958|BEHAVIORAL|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group."
48504451|NCT02457663|PROCEDURE|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
48504452|NCT01996618|DRUG|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
48504453|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
48504454|NCT01507363|DRUG|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
48504455|NCT01507363|DRUG|Placebo|Placebo tablets for 7 days, starting on the day of surgery
48352396|NCT05957328|DRUG|Ferric Pyrophosphate Liposomal|Liposomal iron, a form of ferric pyrophosphate is transported within a phospholipid membrane, absorbed by the intestinal M cells, reaches to the liver directly through lymphatics and finally released. Due to this mechanism, liposomal iron has been reported to have better bioavailability than traditional iron preparations thus requiring lesser dose and producing fewer adverse effects The group would be given liposomal iron syrup at a dose of 1mg per kg per day once a day for 3 months
48352397|NCT05957328|DRUG|ferrous ascorbate|one of the most commonly used forms of iron syrup in children. The group would be given ferrous ascorbate syrup at a dose of 3mg per kg per day once a day for 3 months
48352398|NCT04814706|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
48352399|NCT04823689|PROCEDURE|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
48352400|NCT00772889|BIOLOGICAL|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
48352401|NCT00772889|BIOLOGICAL|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
47986069|NCT01243970|DRUG|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. \*~\* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
47986070|NCT04298554|OTHER|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration
47986071|NCT04298554|OTHER|Hemp Oil|CBD PURE HEMP OIL
47986072|NCT03330522|OTHER|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
47986073|NCT03330522|OTHER|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. .... If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
47986074|NCT02404376|DRUG|Exenatide|Intravenous administration of Exenatide
47986075|NCT02404376|OTHER|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
48352402|NCT01699776|DRUG|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
48352403|NCT01699776|DRUG|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
48352404|NCT00236106|DRUG|tacrolimus ointment 0.1%|
48504456|NCT05084716|BEHAVIORAL|Enhanced PrEP provision|At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
48504457|NCT06232473|BEHAVIORAL|Patient Education|Please see arm desciption
48504458|NCT06232473|DRUG|Duloxetine|Please see arm description
48504459|NCT06232473|DRUG|Benztropine Mesylate 0.5 MG and passive placebo RAP|Please see arm description
48504460|NCT06232473|BEHAVIORAL|Enhanced usual care|Please see arm description
48504461|NCT03821181|DEVICE|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
48504462|NCT03821181|DEVICE|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
48504463|NCT01531543|DEVICE|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
48504464|NCT02204306|GENETIC|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
48504465|NCT03553953|DEVICE|BIS device|Recording data from BIS device from patients who undergo elective surgery under general anesthesia
48663215|NCT02845882|DRUG|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
48663216|NCT05533840|DIAGNOSTIC_TEST|ultra-high-resolution computed tomography exams|Participants in the age groups undergo ultra-high-resolution computed tomography exam
47986076|NCT02404376|DRUG|Placebo|Intrevenous administration of Placebo
48352405|NCT00236106|DRUG|mometasone furoate 0.1%|
48663217|NCT05005533|OTHER|Observational|Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System
47986077|NCT05589207|DIAGNOSTIC_TEST|Vascular wall invaded|Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
47986078|NCT01189812|DRUG|Lithium Carbonate|300 mg one time per day for 4 weeks
48141979|NCT01683669|OTHER|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
48141980|NCT05785650|DIAGNOSTIC_TEST|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
48141981|NCT01597674|DRUG|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
48141982|NCT06212661|DRUG|Ubrogepant|Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
48663218|NCT06547320|BEHAVIORAL|Eat Less Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the amount of food eaten.
47986079|NCT01189812|DRUG|Placebo|Take one time daily for 4 weeks
47986080|NCT01189812|DRUG|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
47986081|NCT03407378|DRUG|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
47986082|NCT03407378|GENETIC|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
47986083|NCT03407378|OTHER|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
47986084|NCT03407378|OTHER|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
47986085|NCT03407378|OTHER|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
48141983|NCT06212661|DRUG|Rimegepant|Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
48141984|NCT06212661|DRUG|Atogepant|Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
48141985|NCT06212661|DRUG|Eptinezumab|Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
48352406|NCT00003687|DRUG|dextromethorphan hydrobromide|
48352407|NCT00003687|DRUG|morphine sulfate|
48504466|NCT04186351|BEHAVIORAL|Encounter notification service|The caring support and services provided by SCHSA will consist of multiple components, including standard call \& care center support, medical appointment reminder, assistance to reschedule appointment, follow-up calls with either nurse or health workers to monitor health situation of service recipients, assessing needs of service recipient for elderly home care and/or rehabilitation services, providing elderly home care and/or rehabilitation services based on assessment, assessing needs of service recipient for emotional and community support, providing additional emotional support via either social calls by volunteers or counseling by social workers, and making referrals for community support services.
48352408|NCT04501965|COMBINATION_PRODUCT|Hydroxychloroquine/Azithromycine|Dual treatment with Hydroxychloroquine and Azythromycin
48504467|NCT01899443|OTHER|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
48504468|NCT00355953|DRUG|Genistein|
48504469|NCT04809051|OTHER|Stratified Transplant Survival Metric|"Both transplant metric conditions display the number of hearts offered to each center, the number of hearts accepted by each center, and the number of transplants performed at each center (in a year), in addition to the condition-specific metrics below. The stratified condition instead features a pair of values corresponding to each center's offers/acceptances/transplant survival rates for donor hearts of optimal or adequate quality."
48504470|NCT04809051|OTHER|SRTR Information Format|The information format varies based on how the transplant hospital statistics are organized when presented to participants on the choice screen. The SRTR conditions mimic the information format present on the SRTR public reporting website.
48663219|NCT06547320|BEHAVIORAL|Eat Slower Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the rate of eating.
48663220|NCT02482311|DRUG|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
48141986|NCT06212661|DRUG|Fremanezumab|Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
48352409|NCT04501965|COMBINATION_PRODUCT|Quinquina-Stevia/Azythromycin|Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin
48352410|NCT04501965|COMBINATION_PRODUCT|4Plants/Azythromycin|Dual treatment with 4 plant species drug and Azythromycin
48352411|NCT03644316|DEVICE|BandGrip skin closure device|topical skin closure device
48352412|NCT05272306|OTHER|Number of attempts for successful transesophageal echocardiography|Transesophageal echocardiography probe will be inserted after induction of anesthesia. Number of attempts for successful transesophageal echocardiography will be recorded.
48141987|NCT06212661|DRUG|Galcanezumab|Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
48141988|NCT06212661|DRUG|Erenumab|Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
48141989|NCT06212661|DRUG|Botulinum toxin A|Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
48141990|NCT02714777|DEVICE|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
48141991|NCT00669474|PROCEDURE|Suction curettage|Suction curettage
48141992|NCT00669474|DRUG|Treatment with Botox|Treatment with Botox
48141993|NCT01420757|PROCEDURE|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
48141994|NCT02916576|DEVICE|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
47986086|NCT03407378|OTHER|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
47986087|NCT02069990|DRUG|Cholecalciferol|
48141995|NCT00681109|DRUG|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
48141996|NCT00681109|DRUG|Placebo|custom eye drop to be applied three times a day in both eyes for three months
48141997|NCT00681109|DRUG|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
48141998|NCT02888821|BEHAVIORAL|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
48141999|NCT03346733|DIETARY_SUPPLEMENT|Psyllium Fibre|Viscous soluble psyllium fibre
48142000|NCT03137784|DRUG|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
48142001|NCT03137784|DRUG|Placebo|In each treatment arm, patient will receive placebo
48142002|NCT01705756|DRUG|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
48142003|NCT05474950|DRUG|minocycline|minocycline capsule (100mg) per day orally
48142004|NCT00364975|BEHAVIORAL|gourmet cooking workshop|
48142005|NCT03960359|OTHER|Clinical, microbiological and inflammatory phenotype|Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
48142006|NCT00130091|DRUG|clonidine|2 mcg clonidine added to local anesthetic
48142007|NCT06432257|DEVICE|head mounted magnifying glass assistance|When performing thyroid surgery for patients in the experimental group, the surgeon uses a head mounted magnifying glass for assistance
48663221|NCT05006495|PROCEDURE|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
48663222|NCT05006495|PROCEDURE|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
48352413|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for cardiologist satisfaction|A questionnaire for cardiologist satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
48352414|NCT05272306|DIAGNOSTIC_TEST|A questionnaire for patient satisfaction|A questionnaire for patient satisfaction will be measured on a grade of 0-4 (1= very bad, 2= bad, 3= good, 4= very good).
48504471|NCT02226757|DRUG|Paclitaxel-trastzumab|"Trastuzumab~* Dose:~  * First dose: 4 mg/kg IV~ * Subsequent doses: 2 mg/kg every week IV.~* The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
48504472|NCT04276363|BEHAVIORAL|Thrive Professional Learning plus ParentCorps|led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.
48504473|NCT04276363|BEHAVIORAL|Thrive Professional Learning only|Part of the Professional Learning Track system for all Pre-K for All teachers and leaders. The NYC DOE schedules Thrive Professional Learning training days for staff on non-attendance days. Teachers attend four Professional Learning days annually, and leaders attend three days annually, over a two-year period.
48504474|NCT04276363|BEHAVIORAL|Inspire Professional Learning|Delivered to leaders in groups of 20 - 40 three times a year over the same two-year period. Content covers best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders
48504475|NCT03581409|DRUG|Aspirin|Aspirin protect tablet
48504476|NCT03581409|DRUG|Prasugrel|Prasugrel tablet
48504477|NCT03581409|DRUG|Clopidogrel|Clopidogrel 75mg tablet
48504478|NCT03581409|DRUG|Cilostazol|Cilostazol tablet
48504479|NCT00397774|BEHAVIORAL|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
47986088|NCT03141242|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
47986089|NCT03141242|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
47986090|NCT00988455|RADIATION|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
48504480|NCT00397774|OTHER|best supportive care|
48504481|NCT05372653|DRUG|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
48504482|NCT05011747|PROCEDURE|single-site rigid probe viscotrabeculotomy (VT)|single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.
48504483|NCT05011747|PROCEDURE|two-site rigid probe viscotrabeculotomy (VT)|Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
48504484|NCT04260971|DEVICE|Abbott St Jude Medical Infinity 7 neurostimulator|The stimulator has the capability to deliver both continuous and cyclical modes of stimulation which is being investigated in this study
48618341|NCT03154606|OTHER|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
47986091|NCT02983331|PROCEDURE|complications during procedure|patients may have anesthesia related complications during procedure
47986092|NCT02497950|DEVICE|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
47986093|NCT02312895|OTHER|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
48352415|NCT04323917|DIAGNOSTIC_TEST|Liquid biopsy|Detection and quantification of EMT-transcription factor mRNA levels in blood
48352416|NCT00776581|PROCEDURE|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
48352417|NCT00776581|PROCEDURE|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
48352418|NCT00776581|PROCEDURE|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
48352419|NCT00776581|PROCEDURE|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
47986094|NCT02312895|OTHER|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
48663223|NCT03049644|PROCEDURE|Mechanical Diagnosis and Therapy|Identification of directional preference.
48663224|NCT03049644|PROCEDURE|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
48663225|NCT02489084|OTHER|Blood sampling|
48663226|NCT04282915|OTHER|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
48663227|NCT04282915|OTHER|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
47986095|NCT02312895|OTHER|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
47986096|NCT03992157|DEVICE|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
47986097|NCT04235049|DRUG|Glecaprevir/pibrentasvir|Treatment for HCV Infection
47986098|NCT04886050|DRUG|LC350189 Tablet|Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
47986099|NCT04886050|DRUG|LC350189 Capsule|Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
47986100|NCT02734381|OTHER|Elderly patients|Elderly patients who visited the Emergency Department
47986101|NCT03019302|DEVICE|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
47986102|NCT05328882|OTHER|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
47986103|NCT04831203|DIETARY_SUPPLEMENT|An egg-protein hydrolysate (NWT-03)|As described in the experimental arm
47986104|NCT04831203|DIETARY_SUPPLEMENT|Placebo|As described in the Control arm
47986105|NCT04699708|DEVICE|Carbon dioxide monitoring|Blinded recording of CO2 during preterm resuscitation.
47986106|NCT01408030|DRUG|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
47986107|NCT01408030|DRUG|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
47986108|NCT01408030|DRUG|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
47986109|NCT01408030|DRUG|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
47986110|NCT05022784|DRUG|Nintedanib|Nintedanib
47986111|NCT05517382|OTHER|supportED|suicide prevention videogame
47986112|NCT05517382|OTHER|Control|non-health related videogame
47986113|NCT06340828|OTHER|Washing Microbiota Transplantation|Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
47986114|NCT01942187|DRUG|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
47986115|NCT01942187|DRUG|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
47986116|NCT01942187|BEHAVIORAL|Problem Solving Therapy|Weekly specialized psychotherapy
47986117|NCT06045026|OTHER|Stannous fluoride|Anti-sensitivity toothpaste containing 0.454% Stannous Fluoride
47986118|NCT00350714|OTHER|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
47986119|NCT01586390|OTHER|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
47986120|NCT01586390|OTHER|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
47986121|NCT04264598|BIOLOGICAL|sIPV|The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
47986122|NCT04264598|BIOLOGICAL|Commercialized sIPV|The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
47986123|NCT04264598|BIOLOGICAL|Commercialized IPV|The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
48142008|NCT02372318|DRUG|Nalmefene|18mg of Nalmefen will be administered orally
48142009|NCT02372318|DRUG|Placebo|Placebo tablet
48618342|NCT03154606|OTHER|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
48352420|NCT03163940|BEHAVIORAL|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
48352421|NCT05742789|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor
48352422|NCT05742789|DRUG|Isoflurane|В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.
48352423|NCT05742789|DRUG|Sevoflurane|в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.
48352424|NCT03209791|OTHER|Biopsies|Biopsy will be done on the Vastus Lateralis muscle in all groups
48352425|NCT05203744|DRUG|Tafenoquine prophylaxis|"The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose."
48142010|NCT04848532|BEHAVIORAL|Weight loss treatment|The intervention will consist of group-based, weekly or biweekly weight loss coaching (75 minutes per session), which will occur via Zoom videoconferencing software. This intervention is designed to facilitate a 5-10% weight loss and engagement in up to 250 min/week of moderate-to-vigorous physical activity, which is the standard recommendation in lifestyle modification programs for adolescents. Participants will also be asked to download and utilize the smartphone app, Fitbit, to track eating behavior. Weight loss coaches will be experts in lifestyle modification who have graduate degrees in psychology or a related field. Participants will be given guidance on how to reduce your calorie intake (using a balanced deficit diet) and gradually increase your physical activity. Participants will learn to set goals for diet, weight, and physical activity.
48352426|NCT02300844|DRUG|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
48352427|NCT02300844|DRUG|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
48352428|NCT05825014|OTHER|No intervention|No intervention
48352429|NCT01467024|OTHER|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
48352430|NCT00171067|DRUG|valsartan|
48352431|NCT00171067|DRUG|lisinopril|
48352432|NCT04012762|DEVICE|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
48352433|NCT06078306|DRUG|Azacitidine Injection|Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
48618343|NCT06281613|DEVICE|AMCOP group|Patients were treated with AMCOP for 18 months.
48663228|NCT05156528|BIOLOGICAL|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine|Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
48142011|NCT00005962|BIOLOGICAL|sargramostim|
48142012|NCT00005962|DRUG|cyclophosphamide|
48352434|NCT06078306|DRUG|Venetoclax|Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
48352435|NCT06078306|DRUG|CD19CD22 CAR-T|After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion
48352436|NCT02448095|DRUG|Ponatinib|Observation of tolerability and safety profiles
48352437|NCT03421262|DIAGNOSTIC_TEST|IADPSG Criteria|One-step: 2 hr 75 gr OGTT
48352438|NCT03421262|DIAGNOSTIC_TEST|NDDG Criteria|Osullivan test + 3 h 100 g OGTT
48352439|NCT03826316|DRUG|Nalbuphine|Pharmacokinetic study under fasting conditions
48352440|NCT00002749|DRUG|carboplatin|
48618344|NCT06281613|DEVICE|High-pull headgear|Patients were treated with high-pull headgear for 18 months.
48663229|NCT05156528|BIOLOGICAL|Placebo|Single intramuscular dose contains 0.15\~0.25 mg of aluminum ion
48663230|NCT00347269|BEHAVIORAL|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
48663231|NCT00347269|DRUG|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
48663232|NCT00347269|BEHAVIORAL|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
48352441|NCT01609491|DRUG|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
48352442|NCT01609491|DRUG|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
48352443|NCT02302586|DRUG|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
48618345|NCT01267032|BEHAVIORAL|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
47986124|NCT06399588|BEHAVIORAL|Intervention for Adolescent Tobacco Initiation Prevention (IATIP)|The IATIP is an evidence-based tobacco prevention program tailored for Bangladeshi adolescents, integrating Behavior Change Techniques, the Behavior Change Wheel, and the Theoretical Domains Framework. Utilizing the Arena Blended Connected (ABC) model ensures effective delivery. Six key learning types are integrated to optimize knowledge acquisition, concept exploration, collaboration, discussions, practical application, and skill development. The curriculum comprises three core components addressing adolescents' challenges: the information curriculum cultivates factual awareness, the social competence curriculum strengthens refusal skills and social competencies, and the social influence curriculum builds resilience against tobacco-promoting social influences.
48142013|NCT00005962|DRUG|cytarabine|
48142014|NCT00005962|DRUG|gemtuzumab ozogamicin|
48142015|NCT00005962|DRUG|liposomal daunorubicin citrate|
48142016|NCT00005962|DRUG|topotecan hydrochloride|
48142017|NCT04254549|DRUG|Rifaximin|550 mg by mouth three times daily for 14 days
48142018|NCT04254549|DRUG|Placebo|By mouth three times daily for 14 days
48142019|NCT00316797|DRUG|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
47986125|NCT06276439|PROCEDURE|Surgical removal of breast cancer and lymph nodes|The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.
47986126|NCT02867033|PROCEDURE|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
48352444|NCT02302586|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
48142020|NCT03210324|DRUG|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
48142021|NCT01374152|OTHER|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
48618346|NCT01267032|BEHAVIORAL|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
48663233|NCT03728803|DEVICE|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
48663234|NCT00629603|GENETIC|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
47986127|NCT02867033|OTHER|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
47986128|NCT02867033|PROCEDURE|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
48142022|NCT02433444|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
48142023|NCT03069209|BIOLOGICAL|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
48142024|NCT04901416|BIOLOGICAL|DVX201|"Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included."
48142025|NCT02110407|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
48352445|NCT02006394|DIETARY_SUPPLEMENT|Fish Oil|fish oil capsules
48142026|NCT02110407|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
48352446|NCT02006394|DIETARY_SUPPLEMENT|Polyphenol Capsules|delphinidin polyphenol capsules
48352447|NCT02006394|DIETARY_SUPPLEMENT|Corn Oil Capsules|Corn Oil Capsules
48352448|NCT02006394|DIETARY_SUPPLEMENT|Corn starch capsules|Maltodextrin capsules
48352449|NCT02006394|OTHER|Reduced glycemic index bread products|Made by Zone Labs
48352450|NCT02006394|OTHER|Market variety bread products|placebo bread products
48352451|NCT01935674|DRUG|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
48352452|NCT01935674|DRUG|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
48618347|NCT01267032|BEHAVIORAL|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
48618348|NCT00262925|BIOLOGICAL|alemtuzumab|Given subcutaneously
48618349|NCT00262925|DRUG|asparaginase|Given IM
48618350|NCT00262925|DRUG|methotrexate|Given IV or orally
48618351|NCT00262925|DRUG|dexamethasone|Given orally
48618352|NCT00262925|DRUG|leucovorin calcium|Given IV
47986129|NCT02867033|PROCEDURE|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
48352453|NCT05256290|DRUG|BDTX-1535 monotherapy|BDTX-1535 is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
48352454|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
48352455|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
48352456|NCT04449718|DIETARY_SUPPLEMENT|Vitamin D|200,000 IU on admission
48352457|NCT04449718|DIETARY_SUPPLEMENT|Placebo|200,000 IU on admission
48352458|NCT02772835|DEVICE|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
48352459|NCT04095962|OTHER|Exercise|The MT program will be conducted for 6 months, twice a week in 60 minutes sessions. Sessions will be divided in warm-up (10 minutes, including slow walk, postural and mobility exercises for general activation, and stretching exercises), specific training (35-45 minutes, including balance/coordination training, strength and aerobic exercises) and cool down (5 minutes with breathing and stretching exercises for the main worked joints and muscles) following the main guidelines recommended by the American College of Sports Medicine \[18\] and the WHO \[19\].
48352460|NCT00865202|DRUG|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
48352461|NCT00865202|DRUG|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
48352462|NCT06283303|BIOLOGICAL|T3011 hepatic artery infusion|The study was divided into two dose groups, T3011 3×10\^8 PFU/time (HAI) and T3011 1×10\^9 PFU/time (HAI), with a 3+3 dose escalation design. After the completion of the lead-in period, the patient entered the combination therapy period（combination therapy with T3011 hepatic artery infusion , Regorafenib and Toripalimab）,and the dosage of T3011 was determined according to the safety observation results of the lead-in period, the dose of toripalimab was 80mg intravenously, and regorafenib was 80mg orally once a day.
48352463|NCT06283303|DRUG|toripalimab|The combination therapy period: toripalimab, 80mg intravenous ,D2 and D16, 4 weeks per cycle
48352464|NCT06283303|DRUG|regorafenib|The combination therapy period: regorafenib ,80mg orally once a day, D1-D21,4 weeks per cycle
48352465|NCT00599222|BIOLOGICAL|ranibizumab|0.5 mg intravitreal injection
47986130|NCT02867033|OTHER|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
47986131|NCT02867033|PROCEDURE|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
47986132|NCT03951740|DEVICE|Fitbit Charge 2|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
47986133|NCT03951740|DEVICE|Mio Slice|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
48142027|NCT02535221|DRUG|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
48352466|NCT00599222|PROCEDURE|TTT|Transpupillary thermotherapy (TTT)
48352467|NCT00599222|PROCEDURE|Sham TTT|Sham Transpupillary thermotherapy (TTT)
48352468|NCT02766049|BIOLOGICAL|DC|Autologous dendritic cells (3x10e7)
48352469|NCT02766049|BIOLOGICAL|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
48352470|NCT02766049|BIOLOGICAL|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
48352471|NCT05379764|OTHER|Embodiment|Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
48142028|NCT02535221|DRUG|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
48142029|NCT01068977|DRUG|bevacizumab|Repeating intravenous dose
48142030|NCT01068977|DRUG|MetMAb|Repeating escalating intravenous dose
48142031|NCT01068977|DRUG|MetMAb|Repeating intravenous dose
48142032|NCT02930317|DRUG|Recombinant Factor VIII (50 IU/kg)|
48142033|NCT02930317|DRUG|Recombinant Factor VIII (On-demand treatment)|
48142034|NCT05995730|OTHER|Lavender oil inhalation|Lavender inhalation will be administered to this group. Participants will be asked to drop three drops of lavender oil solution on a small piece of cotton on the 1st, 2nd, and 3rd days of their first menstrual bleeding after enrollment in the study, hold it 7-10 cm from their noses, and sniff for 5 minutes. Participants will be asked to apply this application immediately after the onset of dysmenorrhea pain on the first day of their menstruation and to continue regularly every 8 hours for the first three days of menstrual bleeding. Participants will be asked to apply this application in the same way in two consecutive menstrual cycles and the participants will be followed in this process.
48142035|NCT05995730|OTHER|Placebo|Olive oil will be administered to the placebo group. The application will be similar to the experimental group.
48352472|NCT05379764|OTHER|Observation|The person is looking at the VR scenario as if s/he was looking at a TV
48352473|NCT01785940|PROCEDURE|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
48618353|NCT00262925|DRUG|mercaptopurine|Given orally
48618354|NCT00262925|DRUG|vincristine|Given IV
48618355|NCT06125418|PROCEDURE|customized healing abutment|patients will undergoes one-stage implant placement with customized healing abutments with different macrogeometry and emergence angle made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
48618356|NCT06125418|PROCEDURE|standard healing abutment|patients will undergoes one-stage implant placement with standard titanium healing abutment made prior to the surgery and will be inserted without sutures, after osseointegration completed patients will received single crown on implant.
48663235|NCT00629603|GENETIC|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
48663236|NCT00629603|GENETIC|cytokine polymorphism|fibrosis-relating cytokine polymorphism
48352474|NCT02894294|OTHER|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine \[SP\] + Amodiaquine \[AQ\]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
48663237|NCT06141421|PROCEDURE|procedure|procedure
48663238|NCT00468091|DRUG|exendin(9-39)amide|
48663239|NCT00468091|DRUG|atropine|
48142036|NCT02003872|DEVICE|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
48142037|NCT05018143|BEHAVIORAL|STARS|This intervention will use an online mobile application for teach life skills, coupled with peer mentoring to support the use of safety planning.
48142038|NCT05018143|BEHAVIORAL|Control condition|In this intervention, participants will receive the safety planning intervention.
48142039|NCT02736188|DRUG|Aceneuramic Acid Extended-Release Tablets|
48142040|NCT04788810|OTHER|Administration of d12-Cl2BPA|Administration of d12-Cl2BPA
48142041|NCT00004474|DRUG|Anti-thymocyte globulin|Given via IV over 4 hours
48142042|NCT00004474|DRUG|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
48142043|NCT00004474|PROCEDURE|Bone marrow transplantation|Given on Day 0
48352475|NCT00610714|DRUG|AZD0530|oral once daily dose
48352476|NCT00610714|DRUG|Carboplatin|intravenous injection
48352477|NCT00610714|DRUG|Paclitaxel|intravenous infusion
47986134|NCT03951740|DEVICE|Oxycon Mobile|"The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF)."
47986135|NCT06077292|BEHAVIORAL|15% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
48142044|NCT04707807|DIAGNOSTIC_TEST|IIEF-5|IIEF-15 form will be filled out by all participants
48352478|NCT00998036|DRUG|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
48352479|NCT00998036|DRUG|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
48504485|NCT04697836|PROCEDURE|ST|"After a computer-generated randomization list with a 1:1 intergroup ratio, ensuring equal distribution in the two groups, 30 opaque sealed envelopes numbered 1-30 were prepared. The patients were randomly divided into the Group with bilateral CPB with 15 ml 0.5% bupivacaine or the patients with translaryngeal block with 5 ml 2% lidocaine in addition to bilateral CPB.~Following inclusion, two research assistants, with no further involvement in the study, prepared 15mL syringes and 5 ml syringes according to the envelope's specifications. The syringes were marked with the patient's randomization number. All other investigators, staff, and patients were blinded to group allocations. Before surgery, the patients were transferred to the specified block room area monitored with 3-lead electrocardiography, pulse oximetry, and non-invasive blood pressure. All patients had two intravenous cannula lines, and then bilateral CPB block procedures were performed in awake non-sedated patients."
48504486|NCT03902886|DIAGNOSTIC_TEST|gait analysis|gait analysis using an optoelectronic system and a surface EMG
48504487|NCT01773837|DRUG|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
48504488|NCT01773837|DRUG|placebo|placebo (pill) p.o.
48663240|NCT05844982|DRUG|Faricimab|6.0 mg intravitreal injection at randomization and every 3 months
48663241|NCT05844982|DRUG|fluocinolone acetonide|0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
48663242|NCT03484897|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
48663243|NCT06513247|DIAGNOSTIC_TEST|screening for Islet autoantibody|IAA, GADA, IA-2A, Zn-transporter 8 autoantibodies
48663244|NCT06513247|DIAGNOSTIC_TEST|HLA phenotype and genetic risk score|using DBS filter paper
48663245|NCT05593289|OTHER|telerehabilitation|Physical activity that is planned, structured with repeated muscle movements with the aim of relearning motor skills, resistance of neck muscles and postural correction.
48663246|NCT04380142|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
48663247|NCT04380142|DRUG|Placebo for Levodopa/Carbidopa (LD/CD)|Oral capsule
48663248|NCT04380142|DRUG|Levodopa/Carbidopa (LD/CD)|Oral encapsulated tablet
48663249|NCT04380142|DRUG|Placebo for ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
48663250|NCT04462289|BEHAVIORAL|Proactive Outreach|Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
48663251|NCT00057148|PROCEDURE|massage treatment|
48663252|NCT05496049|DEVICE|Triburter|Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.
48663253|NCT05496049|DEVICE|Incentive spirometry|They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.
48663254|NCT03741673|OTHER|Quality-of-Life Assessment|Ancillary studies
48663255|NCT03741673|OTHER|Questionnaire Administration|Ancillary studies
48663256|NCT03741673|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48663257|NCT01888016|OTHER|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
48663258|NCT01888016|OTHER|standard physiotherapies treatment|"10 standard treatments in 2 weeks~* Deltoid and infraspinatus muscles electrotherapy~* Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~* Scar massage~* Upper limb, cervical spine and scapula massages~* Passive and assisted/active shoulder mobilization exercises~* Scapula micro-mobilizations~* Gleno-humeral decoaptation~* Elbow, wrist and hand active mobilization~* Proprioceptive exercise with and without the aid of the mirror"
48663259|NCT03386773|BEHAVIORAL|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
48663260|NCT03386773|BEHAVIORAL|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
47986136|NCT06077292|BEHAVIORAL|35% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
47986137|NCT03764137|DRUG|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
47986138|NCT04021589|DRUG|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
48142045|NCT02721407|DRUG|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
48142046|NCT05073822|DRUG|Tacrolimus|reduction of both standard Tacrolimus \& Mycophenolate mofetil does in one arm
48142047|NCT02604251|DEVICE|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
48142048|NCT02604251|DEVICE|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
48142049|NCT00912171|DRUG|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
48142050|NCT00912171|DRUG|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
48142051|NCT01650051|DRUG|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
48142052|NCT01650051|DRUG|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
48142053|NCT01106885|BEHAVIORAL|Medication Care Management (MCM)|"* Basic physical activity counseling~* Notify PCP and facilitate initiation of antidepressants~* Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks\*~* 1/mo monitoring in continuation phase (mos. 4-12)\*~* Report \& recommendations to PCP after each patient call~* Note: \*average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
48142054|NCT01106885|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"* Notify PCP~* CBT Manual~* Weekly CBT focused counseling for 12 weeks\*\*~* Monthly CBT in months 4-12\*\*~* Behavioral physical activity counseling~* Report \& recommendations to PCP after each patient call~* Note: \*\*average of 50 minutes of telephone time each"
48142055|NCT01267552|PROCEDURE|Non drains will be placed during operation|Non drains will be placed during operation
48142056|NCT01267552|PROCEDURE|Closed suction drainage|Closed suction drainage will be placed during operation
48142057|NCT01852045|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
48142058|NCT02476929|DEVICE|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
48142059|NCT02476929|DEVICE|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
48142060|NCT00035048|DRUG|aprepitant|
48142061|NCT00035048|DRUG|Comparator: placebo (unspecified)|
48142062|NCT01474382|DRUG|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
48142063|NCT01474382|OTHER|Sham injection|No drug administered, simulation of injection used in same manner as drug
48142064|NCT00269815|DRUG|methylphenidate HCl|
48142065|NCT02829398|PROCEDURE|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
48142066|NCT05407051|BEHAVIORAL|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
48352480|NCT00998036|DRUG|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
48352481|NCT01922518|PROCEDURE|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
48352482|NCT01922518|PROCEDURE|Apex pacing|Put RV lead around the apex
48504489|NCT01449448|DRUG|Ketorolac|Subacromial injection
48504490|NCT01449448|DRUG|Triamcinolone|Subacromial Injection
48663261|NCT03868501|BEHAVIORAL|n-back task|All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
48663262|NCT00309283|DRUG|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
48663263|NCT00309283|OTHER|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
48663264|NCT05374616|GENETIC|Observation|Retrospective and prospective Natural History Study
48663265|NCT00693550|OTHER|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
47986139|NCT04021589|DRUG|Chemotherapy|chemotherapy
47986140|NCT05792631|DEVICE|Near infra red imaging|"The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization."
47986141|NCT00280956|DRUG|natalizumab|
47986142|NCT03070392|BIOLOGICAL|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
48142067|NCT05407051|BEHAVIORAL|Treatment as Usual|"All participants (parents) would receive follow-up calls from a MetroHealth research personnel at 3 months and 6 months to measure changes in parent mental health outcomes, as well as satisfaction.~Children of parents in both conditions will receive treatment as usual which includes brief consultation for 3-5 sessions with an integrated MetroHealth behavioral health provider which is already standard practice in the clinic. Sessions typically occur monthly. Teens will be re-administered the Patient Health Questionnaire -9 by the integrated behavioral health provider as a part of clinical practice to measure treatment progress and this information will be obtained at the end of 6 months of treatment via chart review (see data sheet). Repeated measurement of patient's symptoms over the course of several months of treatment is common in clinical practice to measure patient's symptom improvement."
48142068|NCT03775213|BEHAVIORAL|Decision Support Tool with Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.
48142069|NCT03775213|BEHAVIORAL|Decision Support Tool without Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
48142070|NCT01698918|DRUG|Everolimus|Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
48142071|NCT01698918|DRUG|Letrozole|1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
48142072|NCT01698918|DRUG|Exemestane|2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
48142073|NCT01698918|DRUG|Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)|Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
48142074|NCT01698918|DRUG|Standard of care to treat stomatitis (Stomatitis sub-study)|Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
48142075|NCT05707598|PROCEDURE|Laparoscopic surgery|The laparoscopic approach was used for the treatment of clinical T4b colorectal cancer
48663266|NCT03952845|OTHER|Capsaicinoid|This is a tolerability study on doses lower than previously published for the use of intranasal capsaicinoid in the treatment of rhinitis
48142076|NCT03676088|PROCEDURE|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
48142077|NCT02326220|DRUG|Placebo|
48142078|NCT02326220|DRUG|Alirocumab|
48142079|NCT02340806|DEVICE|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
48142080|NCT01596686|DRUG|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
48142081|NCT00233610|DRUG|Bicalutamide|
48142082|NCT00233610|DRUG|Tamoxifen|
48142083|NCT05237999|BEHAVIORAL|KopOpOuders-PTSD|See arm description
48352483|NCT00478530|PROCEDURE|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
48663267|NCT04434183|DEVICE|Exercises of rehabilitation|Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
48352484|NCT03746145|DIETARY_SUPPLEMENT|Bifidobacterium longum 1714|This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
48352485|NCT03746145|DIETARY_SUPPLEMENT|placebo sachet containing maltodextrin and magnesium stearate.|placebo sachet containing maltodextrin and magnesium stearate.
48352486|NCT04819724|DIAGNOSTIC_TEST|3D motion analysis|30° arm abduction in the scapular plane will be performed with and without a handheld weight of 1, 2, 3, and 4 kg. All movements will be done bilaterally. Electromyographic (EMG) data of arm and trunk muscles will be recorded using surface electrodes. Participants will be asked to perform full arm abduction with different rotations (internal, neutral and external rotation), flexion and internal-/external rotations movements (without additional handheld weight).
48352487|NCT04819724|DIAGNOSTIC_TEST|isometric shoulder strength by dynamometer|isometric shoulder strength for abduction and internal/external rotation will be assessed with a isometric shoulder strength for abduction and internal/external rotation will be assessed with a dynamometer
48352488|NCT04819724|DIAGNOSTIC_TEST|fluoroscopic images of each shoulder|fluoroscopic images (Multitom Rax, Siemens Healthineers, Erlangen, Germany) of each shoulder will be taken during the 30° arm abduction test with and without a handheld weight (0, 2, and 4kg)
48663268|NCT01779960|OTHER|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
48663269|NCT01779960|OTHER|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
48663270|NCT04120987|DRUG|Lifitegrast 5% Ophthalmic Solution|BID OU
47986143|NCT03070392|DRUG|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
48142084|NCT01603836|BIOLOGICAL|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
48142085|NCT05548049|DEVICE|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
48142086|NCT05548049|DEVICE|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
48142087|NCT02610322|BEHAVIORAL|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30\~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
48142088|NCT02610322|BEHAVIORAL|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5\~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and \<30% of energy as total fat.
48142089|NCT02233998|OTHER|Mouth Rinse 1|
48142090|NCT02233998|OTHER|Mouth Rinse 2|
48142091|NCT02233998|OTHER|Mouth Rinse 3|
48504491|NCT05268835|DRUG|Dalacin C|The objective of the intervention is to determine the effect of antibiotic prophylaxis with three different doses of clindamycin on preventing infection and other complications after surgical extraction of impacted mandibular third molars
48504492|NCT06016036|DRUG|SAL-0951|"SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
48504493|NCT06016036|DRUG|Placebo|"SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
48504494|NCT00009815|DRUG|etoposide|
48504495|NCT00009815|DRUG|leucovorin calcium|
48663271|NCT05072899|PROCEDURE|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
47986144|NCT03070392|BIOLOGICAL|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
47986145|NCT03070392|BIOLOGICAL|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
47986146|NCT01820481|DRUG|WIN-901X dose level 1|100mg Bid, PO, 12weeks
47986147|NCT01820481|DRUG|WIN-901X dose level 2|200mg Bid, PO, 12weeks
48142092|NCT02286869|PROCEDURE|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
48142093|NCT00630500|DRUG|Memantine|Tablets, 5 or 10 mg, twice daily
48142094|NCT00630500|DRUG|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
48142095|NCT00715182|DRUG|TKI258|
48352489|NCT04819724|DIAGNOSTIC_TEST|Bilateral shoulder Magnetic Resonance Imaging (MRI)|MRI of both shoulders will be taken
48504496|NCT00009815|DRUG|tegafur-uracil|
48504497|NCT04810949|DIETARY_SUPPLEMENT|Vitamine D3 supplementation|1. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
48504498|NCT04810949|DIETARY_SUPPLEMENT|Diet and sun exposure|"2. Hygienic-dietary recommendations will consist of 2 steps~1. Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~2. Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms"
48504499|NCT05670574|PROCEDURE|Surgery with extended (D3) mesenterectomy for small bowel tumors|
48663272|NCT05072899|PROCEDURE|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
48663273|NCT03375242|DRUG|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
47986148|NCT01820481|DRUG|WIN-901X dose level 3|300mg Bid, PO, 12weeks
48504500|NCT04751929|DRUG|Abemaciclib|Taken orally 2x daily
47986149|NCT01820481|DRUG|Placebo|Bid, PO, 12weeks
47986150|NCT04071496|OTHER|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
47986151|NCT03623360|DIAGNOSTIC_TEST|Free breathing DCE-MRI|Free breathing DCE-MRI
48504501|NCT04751929|DRUG|Atezolizumab|Intravenously Day 1 of 21 day cycle
48504502|NCT03578666|OTHER|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
47986152|NCT04284618|DIAGNOSTIC_TEST|assessment of standardized and off axis view radiographs|Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
47986153|NCT00732615|DRUG|Placebo|Placebo for subcutaneous injection
48142096|NCT05878106|DIETARY_SUPPLEMENT|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
48142097|NCT05878106|OTHER|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
48142098|NCT05445050|DIAGNOSTIC_TEST|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
48142099|NCT00770874|DRUG|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
47986154|NCT00732615|DRUG|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
47986155|NCT01918761|DRUG|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
48504503|NCT03578666|OTHER|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
48663274|NCT05478317|PROCEDURE|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
48663275|NCT05478317|PROCEDURE|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
48352490|NCT04819724|OTHER|data collection by health questionnaires|data collection by health questionnaires
48352491|NCT05961397|DRUG|baxdrostat|single oral dose of baxdrostat 10 mg
48504504|NCT01730066|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
48504505|NCT02188914|RADIATION|Positron emission tomography scan|
48504506|NCT02188914|OTHER|Magnetic resonance imaging|
48504507|NCT04605224|BEHAVIORAL|Culinary class|This hands-on, optional course teaches students how to measure and weigh ingredients, read and follow recipes, apply various food preparation, cooking and assembly techniques, as well as prepare meals, as per the provincial curriculum
48504509|NCT05531292|DEVICE|Model C0002|Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.
48142100|NCT00770874|DRUG|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
48142101|NCT03543904|PROCEDURE|Pre-operative physiotherapy education|"Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
48504510|NCT05531292|DEVICE|Model ZCB00/DCB00|Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.
48352492|NCT03257306|PROCEDURE|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
48352493|NCT03257306|PROCEDURE|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
48352494|NCT01469637|DRUG|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
48352495|NCT01469637|DRUG|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
48352496|NCT02513355|BIOLOGICAL|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
48352497|NCT02513355|DRUG|Changchun marina|25mg/m2,d1 and d8,q21d×4
47986156|NCT01864733|OTHER|Physical rehabilitation (exercise).|
47986157|NCT02715323|OTHER|Cross-sectional study|
47986158|NCT03287505|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
47986159|NCT06380842|OTHER|Necrotizing Pancreatitis patients' organ dysfunction progression|Study the dynamic nature of organ dysfunction
47986160|NCT00079118|DRUG|docetaxel|
47986161|NCT00079118|DRUG|irinotecan hydrochloride|
47986162|NCT01073982|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
48504511|NCT03783039|DEVICE|SURGICEL Powder|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
48504512|NCT03783039|DEVICE|SURGICEL Original|Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
47986163|NCT01319903|BIOLOGICAL|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
47986164|NCT03447990|DRUG|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
47986165|NCT03447990|DRUG|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
47986166|NCT05688046|DRUG|Immune checkpoint inhibitors plus angiogenesis inhibitors|PD-(L)1-based therapy plus Bevacizumab or Anlotinib
47986167|NCT05688046|DRUG|Immune checkpoint inhibitors without angiogenesis inhibitors|PD-(L)1-based therapy
47986168|NCT04791566|DRUG|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
48142102|NCT03543904|PROCEDURE|Post-operative physiotherapy intervention|"Post-operative physiotherapy intervention which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
48142103|NCT03140670|DRUG|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
48142104|NCT03918096|OTHER|Questionnaire|Questionnaire to the parents after the hospital discharge
48142105|NCT05132049|DRUG|DA-5211|single dose administration (DA-5211 one tablet once a day)
48142106|NCT05132049|DRUG|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
48142107|NCT03418922|DRUG|Lenvatinib|Specified doses will be administered orally on specified days.
48142108|NCT03418922|DRUG|Nivolumab|Specified doses will be administered intravenously on specified days.
48352498|NCT02513355|DRUG|cisplatin|80mg/m2,d1, q21d×4
48352499|NCT02513355|DRUG|Taxol|135-175mg/m2,d1,q21d×4
48352500|NCT02513355|DRUG|parapl|AUC=5-6,d1,q21d×4
48142109|NCT03849937|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
48142110|NCT03681132|OTHER|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
48352501|NCT00859716|BIOLOGICAL|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
48663276|NCT03801525|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion"
48142111|NCT00142246|DRUG|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
48142112|NCT00142246|OTHER|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
48504513|NCT00996138|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
48663277|NCT03801525|DRUG|Umbralisib|"* inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form"
47986169|NCT04791566|DRUG|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
47986170|NCT03909295|DRUG|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
48352502|NCT00859716|BIOLOGICAL|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
48352503|NCT04255992|DIETARY_SUPPLEMENT|Calcium Arm|1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
48504514|NCT03813953|PROCEDURE|Liver resection|Resection of diseased liver
48504515|NCT05928286|DRUG|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
48504516|NCT06141967|DEVICE|WITHINGS Sleep Analyzer|"Potentially eligible patients will be offered to participate in the study, the information leaflet will be given to them and the informed consent form will be signed if the patient agrees to participate in the study.~In hospitalization in Endocrinology:~* Realization of the current care report~* Including systematic achievement of EPWORTH and BERLIN scores~* Activation of the WSA throughout the duration of the hospitalization~* Completion of a feasibility questionnaire for the team~* Quantification of the non-usable screening technique~* Completion of a patient experience questionnaire at the end of the stay~* In the event of published positive criteria either for the BERLIN questionnaires, EPWORTH questionnaires or WSA, the patient will be referred to the VISAS center for definitive diagnostic evaluation by polygraphy or polysomnography."
48504517|NCT02315196|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
48352504|NCT04255992|DIETARY_SUPPLEMENT|Vitamin D/Calcium|1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
48504518|NCT02315196|DRUG|epirubicin hydrochloride|Given IV
48504519|NCT02315196|DRUG|carboplatin|Given IV
48504520|NCT02315196|PROCEDURE|therapeutic conventional surgery|Undergo definitive surgery
48504521|NCT02315196|DRUG|paclitaxel|Given IV
48504522|NCT02315196|OTHER|laboratory biomarker analysis|Correlative studies
48504523|NCT02315196|OTHER|quality-of-life assessment|Ancillary studies
48504524|NCT00661011|PROCEDURE|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
48504525|NCT01960712|DEVICE|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
48618357|NCT04507321|DRUG|GSK3640254 Oral tablet|GSK3640254 will be available as white film-coated round tablets to be administered via oral route with meal in the morning with 240 milliliter (mL) of water at room temperature.
48618358|NCT04507321|DRUG|[14C]-GSK3640254 intravenous infusion|\[14C\]-GSK3640254 will be available as clear, colorless solution free from visible particulates to be administered via the IV route.
48618359|NCT04507321|DRUG|[14C]-GSK3640254 powder|\[14C\]-GSK3640254 will be available as white powder to be reconstituted into a suspension with 25 mL of vehicle before dosing so as to administer 85 mg dose with meal in the morning.
48663278|NCT03801525|DRUG|Venetoclax|"* B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form"
48663279|NCT01448616|DRUG|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
47986171|NCT03451344|OTHER|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
47986172|NCT03451344|OTHER|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
47986173|NCT01272414|DRUG|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
47986174|NCT01272414|DRUG|Saline injection|Injection of 0.4cc 0.9% normal saline
48352505|NCT01389895|DRUG|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
48352506|NCT01389895|DRUG|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
48352507|NCT05127356|DEVICE|DIAGNOdent|Laser fluorescence device
48352508|NCT05127356|DIAGNOSTIC_TEST|ICDAS II|International Caries Detection and Assessment System (ICDAS II)
48352509|NCT03079518|DRUG|Ferric Carboxymaltose|single shot infusion
48352510|NCT03079518|OTHER|blood withdrawal|for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
48352511|NCT03273699|DEVICE|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
48352512|NCT03687827|DRUG|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
48352513|NCT03687827|DRUG|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
48352514|NCT04258904|COMBINATION_PRODUCT|Skin Care Program|The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.
48352515|NCT00374062|BEHAVIORAL|relaxation therapy 1|relaxation therapy 1
48352516|NCT00374062|BEHAVIORAL|relaxation therapy 2|relaxation therapy 2
48352517|NCT00374062|BEHAVIORAL|relaxation therapy 3|relaxation therapy 3
48352518|NCT04128072|DRUG|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
48352519|NCT04128072|RADIATION|Total Skin Electron Beam Therapy (TSEB)|"* After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~* In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~* If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~* Mogamulizumab is stopped during TSEB administration."
48142113|NCT03179046|DIAGNOSTIC_TEST|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
48352520|NCT04128072|DRUG|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
48352521|NCT01132768|DRUG|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
48352522|NCT01132768|DRUG|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
48352523|NCT05891470|DEVICE|MonaLisa Touch device|sessions with intra-vaginal CO2 laster system
48352524|NCT05891470|DEVICE|Vaginal dilatators|Home use of vaginal dilatators (at least twice a week for minimum 5 minutes)
48352525|NCT04145505|PROCEDURE|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
48352526|NCT02430389|DRUG|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
48663280|NCT01448616|DRUG|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
48663281|NCT01448616|DRUG|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
48352527|NCT02430389|DRUG|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
48352528|NCT02375464|DRUG|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
48352529|NCT00038142|DRUG|Vincristine|2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
48352530|NCT00038142|DRUG|Doxorubicin|90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
48352531|NCT00038142|DRUG|Cyclophosphamide|2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
48352532|NCT00038142|DRUG|Dexrazoxane|900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
48352533|NCT00038142|BIOLOGICAL|ImmTher|900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
48352534|NCT04161313|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
48352535|NCT04161313|OTHER|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
48352536|NCT04161313|OTHER|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
48142114|NCT03978065|DIAGNOSTIC_TEST|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
47986175|NCT04137003|OTHER|Rouge et Or Program|It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
48142115|NCT05404997|DEVICE|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
48352537|NCT04161313|OTHER|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
48352538|NCT04161313|OTHER|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
48352539|NCT04412668|DRUG|Efzofitimod 1 mg/kg|Concentrate for solution for infusion
48663282|NCT01448616|DRUG|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
48663283|NCT02433938|PROCEDURE|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
48663284|NCT02433938|PROCEDURE|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
47986176|NCT04137003|OTHER|CHU intervention guide|From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
47986177|NCT00298545|DRUG|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
47986178|NCT00298545|DRUG|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
47986179|NCT03012958|OTHER|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
47986180|NCT05481073|DEVICE|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
47986181|NCT06155942|PROCEDURE|7 Tesla MRI|Patients will have a 7T MRI and questionnaires
47986182|NCT00176826|PROCEDURE|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
47986183|NCT00176826|DRUG|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
47986184|NCT01743131|DRUG|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
47986185|NCT01743131|DRUG|placebo|
47986186|NCT04379089|OTHER|Observational study only|No Intervention
47986187|NCT03913650|PROCEDURE|0.25% bupivacaine|nerve block procedure will be decided by patients' will for post-op pain
47986188|NCT04599920|DIETARY_SUPPLEMENT|Partial replacement of red meat with legume-based foods|560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
47986189|NCT02884674|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
47986190|NCT02884674|DEVICE|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
47986191|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
47986192|NCT00166088|DIETARY_SUPPLEMENT|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
47986193|NCT05863910|DRUG|Medical Cannabis|Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.
47986194|NCT04229615|DRUG|Fluzoparib; Apatinib|Drug: Fluzoparib Orally twice daily; Apatinib Orally once daily
47986195|NCT04229615|DRUG|Fluzoparib|Fluzoparib Orally twice daily
47986196|NCT04229615|DRUG|Placebo|Placebo
48142116|NCT05404997|OTHER|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
48142117|NCT00309439|PROCEDURE|ALA-rich diet|
47986197|NCT02424747|OTHER|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
47986198|NCT05309564|DRUG|Botulinum toxin type A|Single intervention
47986199|NCT03140020|PROCEDURE|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
47986200|NCT03140020|PROCEDURE|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
47986201|NCT02014844|DRUG|250 mg/m2 aldoxorubicin|
47986202|NCT02014844|DRUG|350 mg/m2 aldoxorubicin|
47986203|NCT00842712|DRUG|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
47986204|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
48142118|NCT03138499|BIOLOGICAL|Nivolumab|Specified dose on specified days
48142119|NCT03138499|BIOLOGICAL|Brentuximab vedotin|Specified dose on specified days
48142120|NCT04326478|DRUG|Azithromycin|Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
48663285|NCT04770584|OTHER|Fear Conditioning|Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, \& yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color (blue \& red - shock; yellow - no shock).
48663286|NCT04770584|OTHER|Avoidance conditioning|Via button pressing. Only one stimulus-CS (i.e. blue colored light) will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock. CS stays on for 6 seconds after the button is pressed. If the button is pressed, no shock will be administered. After 6 seconds, the light ends and the relief epoch ('good feeling') begins. Pressing the button to the other CS (i.e. red colored light) will not prevent the shock from occurring- the participant will still receive the mild shocked at CS offset (after 6 seconds). The third CS (i.e. yellow light) will serve as a control CS, so while the button is available, pressing it or not is of no consequence.
48663287|NCT04770584|OTHER|Pavlovian fear extinction learning|After avoidance conditioning, the CS+ associated with avoidance responding (i.e. blue light) appears with no button to press and no shock is administered.
48663288|NCT04770584|OTHER|Willingness to pay to avoid shock|"On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. No shocks will be delivered on day 2, regardless of money paid.~This and all previously described experimental phases noted above will occur inside of the fMRI scanner."
48663289|NCT05849207|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
48663290|NCT05950321|PROCEDURE|Paramedian cervical epidural steroid injection|For paramedian cervical epidural steroid injection, the cervical 7 (C7) - thoracic 1 (T1) interval is determined by taking an appropriate angle with C-arm fluoroscopy to determine the interlaminar space from the posterior cervical region. The epidural space is recognized by the negative pressure reflected on the resistance syringe.
48663291|NCT05950321|PROCEDURE|Selective nerve root pulsed radiofrequency|For selective nerve root PRF, an 8-12 Hz linear ultrasound probe is first placed posterolateral to the neck. The level of the cervical nerve roots is determined according to the morphology of the anterior and posterior vertebral tubercles. The corresponding nerve root is visualized hypoechoically between the tubercles. The radiofrequency cannula is inserted in the same plane as the ultrasound probe (in plane) and the relevant nerve root is approached. Pulsed radiofrequency current, which has therapeutic properties in chronic pain, is applied to the relevant nerve root for 240 seconds.
48663292|NCT04281667|DRUG|Oral Antibiotics|Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
48663293|NCT04281667|DRUG|Placebo|Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
48663294|NCT04281667|DRUG|Mechanical Bowel Preparation|Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
47986205|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.
47986206|NCT00842712|DRUG|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.
47986207|NCT00842712|DRUG|Cisplatin|Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.
47986208|NCT00842712|DRUG|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m\^2 as intravenous infusion on Days 1 and 8.
47986209|NCT00842712|DRUG|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.
48142121|NCT04326478|BIOLOGICAL|Placebo|Enrolled children in the placebo arm of this study will receive a single dose of non-antibiotic placebo administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.
47986210|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
47986211|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
47986212|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m\^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
48142122|NCT04463004|DRUG|Mavrilimumab|Treatment infusion
48142123|NCT04463004|DRUG|Placebos|Placebo infusion
48142124|NCT01522014|DEVICE|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
48142125|NCT01522014|DEVICE|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
48142126|NCT00163358|DRUG|Ciclesonide|
48142127|NCT03885544|OTHER|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
48142128|NCT03885544|OTHER|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
48142129|NCT03885544|OTHER|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
48142130|NCT04084522|DIETARY_SUPPLEMENT|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
48142131|NCT04084522|DIETARY_SUPPLEMENT|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
48142132|NCT02695199|PROCEDURE|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
48142133|NCT02695199|PROCEDURE|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
48142134|NCT05188066|DIAGNOSTIC_TEST|Histology|Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
48504526|NCT03337243|PROCEDURE|HAM and HUMCWJ Injections|SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
48504527|NCT00928161|DRUG|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
48142135|NCT01823406|PROCEDURE|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
48142136|NCT01823406|PROCEDURE|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
47986213|NCT00842712|DRUG|Chemotherapy|Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
47986214|NCT01968668|DRUG|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
47986215|NCT01968668|DRUG|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
47986216|NCT01968668|DRUG|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
47986217|NCT01968668|DRUG|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
48142137|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
48142138|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
48352540|NCT04412668|DRUG|Efzofitimod 3 mg/kg|Concentrate for solution for infusion
48352541|NCT04412668|DRUG|Placebo|Concentrate for solution for infusion
48352542|NCT05937490|DRUG|Enantone|administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle.
48352543|NCT05937490|DRUG|Dienogest 2 MG (milligram)|Before COH, patients will be treated with DNG at high dose (2 mg+2 mg/day) for 28 days, from the first day of previous menstrual cycle. COH will be performed using a long GnRH agonist protocol (administration of depot leuprorelin 3.75 mg on day 21 of the previous luteal phase of the stimulation cycle).
48352544|NCT05937490|DRUG|Enantone|COH will be performed using a ultra-long GnRH agonist protocol (administration of the first depot leuprorelin 3.75 mg on day 21 of menstrual cycle, repeated after 28 days for other two times).
48352545|NCT05937490|DRUG|long GnRH agonist or flexible GnRH antagonist protocol.|During TV-US monitoring, when at least one follicle reached 14 mm in diameter, to achieve LH suppression avoiding spontaneous ovulation, GnRH antagonist 0.25 mg/day will be added subcutaneously until the day of HCG administration.
48504528|NCT00827632|DRUG|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
48504529|NCT00827632|DRUG|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
48504530|NCT05146297|BEHAVIORAL|Clinical trial match-list|Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
48504531|NCT05146297|BEHAVIORAL|Match-list intervention|Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
48663295|NCT06259019|DEVICE|Liquid Biopsy System (LBS)|Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
47986218|NCT01968668|DRUG|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
47986219|NCT01968668|DRUG|Placebo|Placebo tablet once daily in the morning
47986220|NCT01968668|DRUG|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
47986221|NCT01968668|DRUG|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
47986222|NCT05411679|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
47986223|NCT05411679|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
47986224|NCT04966507|DRUG|Listerine Antiseptic Mouthwash Product|COOL MINT LISTERINE® Antiseptic Mouthwash will be used as the 'active' study drug condition. This is a commercially available, over the counter mouthwash product. Active ingredients for this product include Eucalyptol 0.092%, Menthol 0.042%, Methyl salicylate 0.060%, Thymol 0.064%. This product also contains 21% alcohol. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
47986225|NCT04966507|DRUG|Biotene Mouthwash|Biotène Rinse is designed with a moisturizing formula to help relieve dry mouth symptoms and is specifically designed to have a pH similar to saliva. This is a commercially available, over the counter mouthwash product. Biotène Mouthwash Ingredients include: Purified Water, Propylene Glycol, Hydrogenated Starch Hydrolysate, Poloxamer 407, Hydroxyethylcellulose, Sodium Benzoate, Flavor (Peppermint Oil), Benzoic Acid, Disodium Phosphate, Zinc Gluconate, Lactoferrin, Lysozyme, Lactoperoxidase, Potassium Thiocyanate, Aloe Vera Gel, Calcium Lactate, Glucose Oxidase. Participants will be asked to rinse and gargle their mouth with 20mL of mouthwash daily.
47986226|NCT05102383|DEVICE|Comfilcon A Toric contact lenses|Monthly replacement contact lenses
47986227|NCT05102383|DEVICE|Verofilcon A for Astigmatism Daily Disposable contact lenses|Daily disposable contact lenses
47986228|NCT02078609|DRUG|LGH447|LGH447 in patients with AML or MDS
47986229|NCT02078609|DRUG|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
47986230|NCT01341262|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
47986231|NCT01341262|DRUG|Dexamethasone|"* INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~* AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
48142139|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose open label
48142140|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose
48352546|NCT00935662|DRUG|AZD8329|Oral solution, single ascending doses
48352547|NCT00935662|DRUG|Placebo|Oral solution, placebo
48352548|NCT02710110|DEVICE|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
48352549|NCT02710110|DEVICE|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
48352550|NCT02710110|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
48352551|NCT02710110|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
48352552|NCT02710110|OTHER|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
48352553|NCT02710110|DEVICE|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
48352554|NCT02710110|DRUG|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
48352555|NCT05148429|OTHER|Ultrasound exam|Ultrasound exam
48352556|NCT05148429|OTHER|Fetal MRI|Fetal MRI
48352557|NCT05148429|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
48352558|NCT05148429|OTHER|Pediatric Follow up|Pediatric Follow up
48352559|NCT00267657|DRUG|Reserpine|
48352560|NCT00090766|DRUG|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
48352561|NCT00364468|DRUG|pegfilgrastim|
48352562|NCT05008367|DRUG|Dexamethasone|24 mg intravenous Dexamethasone (6 ml)
48352563|NCT05008367|DRUG|Isotonic saline|6 ml of isotonic saline
48352564|NCT00241657|BIOLOGICAL|BCG|
48352565|NCT02892734|BIOLOGICAL|Ipilimumab|Given IV
48352566|NCT02892734|OTHER|Laboratory Biomarker Analysis|Correlative studies
48352567|NCT02892734|BIOLOGICAL|Nivolumab|Given IV
48352568|NCT03527836|DRUG|Lidocaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
48352569|NCT03527836|DRUG|Bupivacaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
48142141|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
48352570|NCT03527836|DRUG|Mixture brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
48352571|NCT05525065|DRUG|GlucoCorticoid|Glucocorticoid as calculated in prednisone oral equivalents.
48352572|NCT01266070|DRUG|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
48352573|NCT00885729|PROCEDURE|stem cells|Stem cells or chondrocytes under a commercial available membrane
48352574|NCT00885729|PROCEDURE|Chondrocytes|Implantation of chondrocytes
48352575|NCT00885729|OTHER|Rehabilitation program|Strength exercises, neuromuscular exercises
48352576|NCT04547491|DEVICE|HPI - hypotension prediction index|treatment of hypotension before the appearance following HPI algorithm
48352577|NCT04547491|DEVICE|GDT|cardiac optimization and treatment of hypotension following standard clinical practice
48352578|NCT02098148|DRUG|Xenon|
48352579|NCT02098148|DRUG|Placebo|
48352580|NCT03676465|OTHER|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
48663296|NCT01958749|PROCEDURE|Fat graft with Platelet Rich Plasma|
48142142|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily low dose
48142143|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
48352581|NCT03676465|OTHER|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject \& their parent had during the week about the participant's diabetes management.
48352582|NCT06248944|OTHER|observational-retrospective and prospective|observational-retrospective and prospective
48352583|NCT00372489|DRUG|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
48142144|NCT00043589|DRUG|donepezil|
48142145|NCT00043589|PROCEDURE|Memory-training class|
48352584|NCT06186622|DRUG|Orforglipron|Administered orally.
48352585|NCT06186622|DRUG|Simvastatin|Administered orally.
48352586|NCT06186622|DRUG|Digoxin|Administered orally.
48352587|NCT06186622|DRUG|Rosuvastatin|Administered orally.
48352588|NCT06186622|DRUG|Acetaminophen|Administered orally.
48352589|NCT06186622|DRUG|Midazolam|Administered orally.
48352590|NCT06186622|DRUG|Sodium Bicarbonate|Administered orally.
48352591|NCT01674972|OTHER|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
48352592|NCT03501615|DRUG|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
48352593|NCT04076904|DIAGNOSTIC_TEST|transvaginal us with 2D and 3D SHG|transvaginal us is made to all women with SHG
47986232|NCT01341262|DRUG|Zoledronic acid|"* INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~* AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
48352594|NCT04200391|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
48352595|NCT02899104|DRUG|Xofigo (Radium-223 dichloride, BAY88-8223)|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
48352596|NCT00454350|DRUG|Hectorol (doxercalciferol injection)|
47986233|NCT01341262|DRUG|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
47986234|NCT01341262|DRUG|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
47986235|NCT04051762|DEVICE|High flow nasal cannula vs. Nasal continuous positive airway pressure|High flow nasal cannula
47986236|NCT04778579|DRUG|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
47986237|NCT04730245|DRUG|sodium phosphate enema, oral rifaximin and polyethylene glycol|Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
47986238|NCT02355119|DRUG|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
47986239|NCT02355119|DRUG|Gemcitabine|
47986240|NCT03472469|DRUG|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
48142146|NCT01590134|DIETARY_SUPPLEMENT|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
48142147|NCT01590134|DRUG|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
48352597|NCT00454350|DRUG|Zemplar (Paricalcitol injection)|
48352598|NCT02639754|BEHAVIORAL|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
48352599|NCT02639754|BEHAVIORAL|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
48352600|NCT02165644|DRUG|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
48352601|NCT02165644|DRUG|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
48352602|NCT00315523|DRUG|Levocetirizine|
48352603|NCT03236506|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet|Drugs will be given to participants to treat hepatitis C infection
48352604|NCT03236506|BEHAVIORAL|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
47986241|NCT03472469|DRUG|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
48352605|NCT03236506|DRUG|Sofosbuvir 400 MG|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
48352606|NCT02077972|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
48352607|NCT03978286|DRUG|Vortioxetine|10 mg per day
48352608|NCT03978286|DRUG|Sertraline|75 mg per day
48352609|NCT05178680|OTHER|relaxation session combining music and soft light|The caregiver will install a device consisting of a light bubble column, a multicolored light projector, and relaxing music chosen by the patient from a proposed panel. This session will last 30 minutes the day after the surgery
48352610|NCT01018615|DRUG|silymarin|capsules, 700 mg, twice daily, 12 days
47986242|NCT03472469|DRUG|Ketorolac|Ketorolac 30mg IV once
47986243|NCT03472469|DRUG|Celebrex|Celebrex 200mg PO every 12 hours
48352611|NCT01018615|DIETARY_SUPPLEMENT|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
48352612|NCT01107340|DEVICE|AMIStem Hip System|
48352613|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
48352614|NCT03701061|BIOLOGICAL|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
48352615|NCT00403390|DRUG|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
48352616|NCT00403390|DRUG|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
48352617|NCT04801355|PROCEDURE|full-thickness laparo-endoscopic colon adenomas excision|Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
48352618|NCT04801355|PROCEDURE|laparoscopic colon resection|Standard laparoscopic colon resection
48352619|NCT01487928|DIETARY_SUPPLEMENT|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
48352620|NCT01841086|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
48352621|NCT01841086|DRUG|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
48352622|NCT03669107|DRUG|Gum|no gum
48352623|NCT00853112|DRUG|PF-00489791|tablet form, 1 mg, single dose (Day 1)
48352624|NCT00853112|DRUG|PF-00489791|tablet form, 2 mg, single dose (Day 1)
48352625|NCT00853112|DRUG|PF-00489791|tablet form, 4 mg, single dose (Day 1)
48352626|NCT00853112|DRUG|PF-00489791|tablet form, 10 mg, single dose (Day 1)
48352627|NCT00853112|DRUG|PF-00489791|tablet form, 20 mg, single dose (Day 1)
48352628|NCT00853112|DRUG|placebo|tablet form, single dose (Day 1)
48352629|NCT00853112|DRUG|sildenafil|tablet form, 20 mg, single dose (Day 1)
47986244|NCT03472469|DRUG|Naproxen|Naproxen 500mg PO every 12 hours
48142148|NCT03314259|DRUG|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
48142149|NCT03314259|DRUG|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
48352630|NCT01965028|DEVICE|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
48352631|NCT01784250|DRUG|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
48352632|NCT01784250|DRUG|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
48352633|NCT01784250|DRUG|Placebo|Sugar pill manufactured to mimic a drug
48352634|NCT01045876|DRUG|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
48142150|NCT00986752|DEVICE|Stenting (Smart Stent)|Nitinol stent
48142151|NCT00986752|DEVICE|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
48352635|NCT01045876|OTHER|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
48352636|NCT00726492|OTHER|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
48352637|NCT00726492|OTHER|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
48352638|NCT04916106|DEVICE|Transcutaneous Electroacupuncture|give diffrent parameter TEA treatment for 4 weeks.
48352639|NCT04829006|DEVICE|Understand Me For Life|The aim of the current investigation is to test the efficacy of an app to measure sentence intelligibility in noise in speakers with Parkinson's disease and in healthy controls.
48352640|NCT01424306|OTHER|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
48352641|NCT01424306|OTHER|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
47986245|NCT03472469|DRUG|Tramadol|Tramadol 100mg PO every 6 hours
47986246|NCT03472469|DRUG|Pregabalin|Pregabalin 100mg PO every 8 hours
48352642|NCT01424306|OTHER|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
48352643|NCT00786461|PROCEDURE|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
47986247|NCT03472469|DRUG|Gabapentin|Gabapentin 300mg PO every 8 hours
47986248|NCT03472469|DRUG|Lidocaine|Lidocaine patch every 12 hours
48142152|NCT00986752|PROCEDURE|Atherectomy (SilverHawk device)|Atherectomy
48352644|NCT00786461|PROCEDURE|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
48352645|NCT02309216|OTHER|Whol-Body MRI scan|
48352646|NCT03640728|DRUG|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
48352647|NCT03640728|DRUG|Entecavir|Entecavir 0.5 mg/day orally
48352648|NCT03640728|DRUG|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
48352649|NCT00693563|BEHAVIORAL|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
48352650|NCT00332046|DRUG|GW679769|
48352651|NCT02896751|DEVICE|3D printed NIV mask|use of 3D printed mask
48352652|NCT03450824|OTHER|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
48352653|NCT00044694|DRUG|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
48352654|NCT00044694|DRUG|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
48352655|NCT00044694|DRUG|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
48352656|NCT00044694|DRUG|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
48352657|NCT00044694|DRUG|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
48352658|NCT00044694|DRUG|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
48352659|NCT00044694|DRUG|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
48352660|NCT00044694|DRUG|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
48352661|NCT03942640|OTHER|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
48352662|NCT03942640|OTHER|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
48352663|NCT05042570|OTHER|Instrument Assisted Soft Tissue Mobilization|"* This technique will be performed using instruments of different sizes, shapes and treatment styles.~* During the application, instruments will be applied to loosen the muscle tissue and fascia by gliding on the tissue at certain angles.~* The muscle groups to be treated with IASTM are gastrocnemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* The instrument will be sterilized before treatment.~* IASTM treatment will be applied without damaging the tissue after massaging cream is applied to the muscle fibers with the instrument."
48352664|NCT05042570|OTHER|Stretching Exercises|"* The muscle groups to be applied stretching exercises are gastrocinemius, soleus and tibialis posterior. It will also be applied to the superficial and deep fascia.~* 3 different functional stretching exercises will be applied;~* With the hands supported on the wall and with the help of the physiotherapist, the affected extremity is behind the knee in full extension m. gastrocnemius stretching exercise,~* With the hands supported on the wall and with the help of the physiotherapist, the knee is partially flexed, with the affected extremity behind. soleus stretching exercise,~* It is a stretching exercise that will be applied by asking the patient to squat without lifting his heels, with the patient's hands supported by the physiotherapist."
48352665|NCT05042570|OTHER|Control Group / NDT program|"* Efforts to eliminate tone disorders,~* Sensory-perception-motor integrity development studies,~* Activities aimed at facilitating movements in daily life,~* Stretching and strengthening exercises due to muscle shortness and weakness,~* Studies to increase lower and upper extremity functionality,~* It will include the training of activities such as standing up, walking and balance."
48352666|NCT05565599|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage with the Laminar Left Atrial Appendage Closure System.
48504532|NCT04472793|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
48504533|NCT04245241|OTHER|High-flow nasal cannula (HFNC)|24 patients who receiving HFNC within 24 hours after extubation were prospectively enrolled in this study. EIT was used to monitor regional lung ventilation distributions at baseline (conventional oxygen therapy) and three flow rate levels of HFNC therapy (20, 40 and 60 L/min).
48142153|NCT03041155|BEHAVIORAL|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
48504534|NCT01635218|DRUG|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
48504535|NCT01635218|DRUG|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
48504536|NCT01635218|DRUG|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
48504537|NCT01318486|OTHER|Heparin free dialysis technique|Saline flushes or predilution
48504538|NCT01318486|DEVICE|Evodial|Evodial dialyer
48504539|NCT01802450|DRUG|Dasatinib|
48352667|NCT04174872|DRUG|Dexmedetomidine|it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
48352668|NCT04174872|DRUG|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
48504540|NCT03929276|DEVICE|high-intensity laser therapy & exercises|A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
48504541|NCT03929276|DEVICE|Shame laser & exercises|Sham laser treatment (the same device to be used, 0 watts) will be given.
48687947|NCT04055272|BEHAVIORAL|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
48352669|NCT03930277|DIAGNOSTIC_TEST|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
47986249|NCT03472469|DRUG|Opioids|Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
47986250|NCT03472469|DRUG|Regional anesthesia|Regional anesthesia
47986251|NCT01981291|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
47986252|NCT01981291|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
47986253|NCT01981291|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
48142154|NCT05794841|DIAGNOSTIC_TEST|Tongue coating sample collection and multi-omics analysis|Tongue coating sample collection and multi-omics analysis for building a diagnostic model
48352670|NCT03416517|DRUG|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
48352671|NCT03416517|DRUG|Irinotecan|Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
48504542|NCT03929276|OTHER|exercise|Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
48687948|NCT02840318|OTHER|Compassion Intervention|See arm description
48687949|NCT02388464|DRUG|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
48687950|NCT02388464|DRUG|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
47986254|NCT01981291|PROCEDURE|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
47986255|NCT01981291|DRUG|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
47986256|NCT03192943|DRUG|BMS-986205|Specified dose on specified days
47986257|NCT03192943|BIOLOGICAL|Nivolumab|Specified dose on specified day
47986258|NCT01124136|DEVICE|Neurostimulation + Medication Management (Standard of Care)|In addition to medication management, adding investigational implanted neurostimulator to heart
48352672|NCT01940549|DEVICE|Trauma Focused Therapy + tDCS|
48352673|NCT02269904|DRUG|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
48352674|NCT02269904|DRUG|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
48352675|NCT04230590|OTHER|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
48352676|NCT01307046|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
47986259|NCT01124136|DRUG|Standard of Care (Control)|Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
47986260|NCT03060239|OTHER|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
48142155|NCT02196259|DRUG|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
48142156|NCT04565717|DRUG|ALN-HSD|ALN-HSD will be administered by subcutaneous (SC) injection.
48352677|NCT01307046|DRUG|Losartan|Tablet containing losartan potassium (100 mg), once daily
48352678|NCT01307046|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
48352679|NCT01307046|DRUG|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
48352680|NCT01307046|DRUG|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
48504543|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of single fertilized embryo through IVF
48504544|NCT05854810|PROCEDURE|fertilized embryo Insertion|insertion of double fertilized embryo through IVF
48504545|NCT06314347|DIAGNOSTIC_TEST|Figure of 8 walk test|clinical measurement
48504546|NCT05665829|PROCEDURE|Awake transnasal laser-assisted surgery (TNLS)|The experimental intervention would be awake transnasal laser-assisted surgery under local anesthesia, carried out in minor operation theater as a day-case basis in ENT ambulatory center.
48663297|NCT06240676|BEHAVIORAL|AWARENESS-BASED COGNITIVE THERAPY|A 6-week training program based on mindfulness practices will be applied to the experimental group determined by the single-blind method, after the 3rd month after birth. In order to observe the change in the experimental group, breast milk will be taken for pre-test (morning and evening) before training. After 6 weeks of training, a cortisol test will be performed by taking breast milk at 09:00 in the morning and 09:00 in the evening. Taken milk will be stored in the deep freezer for 1 week at -18 degrees. After the samples are prepared for testing under appropriate conditions (centrifuge), biochemical measurements will be made and recorded with the help of the SUNREDBIO brand human cortisol kit (the serial number is not known since we did not purchase the cortisol kit).A sleep diary will be used to measure newborn circadian rhythm.
48663298|NCT04368208|OTHER|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
48663299|NCT06477770|PROCEDURE|Clorhexidine soap|surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap
47986261|NCT05545254|GENETIC|genetic testing|Two questionnaires were included in the link, one referring to the demographic information, and another one involving the health-promoting lifestyle. In the demographic information, the genetic test results were not requested to be written, but the participants need to answer whether they understand the results. The HPLP-Ⅱ is an scale instrument used to evaluate a person's health-promoting lifestyle behaviors, which contains 52 items and has been translated into Chinese in 1997. It contains 6 subscales: self-actualization, health responsibility, physical activity, nutrition, interpersonal relationships and stress management.
48142157|NCT04565717|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
48142158|NCT05484336|OTHER|Glucose as reference food|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose diluted in 250ml, tested two times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48352681|NCT04065295|DRUG|BI 1356225|Oral Dose
48352682|NCT04065295|DRUG|Placebo|Oral dose
48352683|NCT05011331|DEVICE|MedCline Shoulder Relief System|Patients will receive a customized pillow to aid with sleep
48504547|NCT05665829|PROCEDURE|Microlaryngeal surgery (MLS)|For traditional MLS under general anesthesia, laryngeal lesions are visualized and removed with under microscopic or endoscopic approach.
48504548|NCT04702438|BEHAVIORAL|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
48504549|NCT00222521|DRUG|Glargine insulin|
48142159|NCT05484336|OTHER|Beverage containing 4g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 4g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48352684|NCT06357429|OTHER|Cold Application|Cold application was applied to the LI4 acupressure point on the patients' hands using an ice battery.
48352685|NCT04409340|DEVICE|Magnetic Resonance Viscoelastography|Magnetic Resonance Viscoelastography
48352686|NCT04409340|DEVICE|QUS|QUS
48352687|NCT04840849|BIOLOGICAL|nirsevimab|Drug: injection, a single fixed IM dose on day 1 only.
48352688|NCT04840849|OTHER|Placebo|Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.
48352689|NCT01877005|DRUG|Ruxolitinib|
48352690|NCT04453618|DRUG|FE-SYHA1402 100mg|in either a fasted state or with a meal
48352691|NCT04453618|DRUG|SYHA1402-25mg|SYHA1402 25mg, oral tablets
48352692|NCT04453618|DRUG|Placebo-25mg|Matching placebo tablets
48352693|NCT04453618|DRUG|SYHA1402-50mg|SYHA1402 50mg, oral tablets
48352694|NCT04453618|DRUG|Placebo-50mg|Matching placebo tablets
48352695|NCT04453618|DRUG|SYHA1402-150mg|SYHA1402 150mg, oral tablets
48352696|NCT04453618|DRUG|Placebo-150mg|Matching placebo tablets
48352697|NCT05885906|DRUG|Aloevera|Mouthwash
48504550|NCT02368951|DRUG|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
48504551|NCT02586246|DRUG|CDP870|Self-injection
48504552|NCT00537303|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
48352698|NCT05885906|DRUG|Thyme honey|Mouthwash
48352699|NCT05885906|DRUG|Saline|Mouthwash
48352700|NCT06392867|DEVICE|intermittent theta-burst stimulation (iTBS)|"iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients.~Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en_eur/products/magpro-x100/ ) and a Cool-B70 A/P Butterfly Coil, available at each participating centre."
48352701|NCT03463213|BEHAVIORAL|SHE Tribe|Social network-based peer-facilitated intervention to promote adoption of health behavior
48352702|NCT01960179|DRUG|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
48352703|NCT02675829|DRUG|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
48352704|NCT03288311|OTHER|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
48352705|NCT03288311|OTHER|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
48352706|NCT02569645|DRUG|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
48352707|NCT02564562|DRUG|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + \[14C\] PF-06463922
48352708|NCT04468464|OTHER|Occlusal Splint Treatment|Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
48352709|NCT04468464|OTHER|Osteopathic Manual Treatment|Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
48352710|NCT02468804|DEVICE|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
48352711|NCT02468804|DEVICE|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
48352712|NCT04225806|DEVICE|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
48352713|NCT06014476|OTHER|questionnaires|Sent questionnaires to caregivers and used CRS-R to assess patients with DoC
48352714|NCT03401216|DEVICE|SYNERGY 48 mm|Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
48352715|NCT03401216|PROCEDURE|PCI|Standard PCI procedure
48504553|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
48504554|NCT00537303|DRUG|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
48504555|NCT02879357|BEHAVIORAL|Training|"1. Clinician training~2. System for patient selection~3. System of triggering and tracking conversations~4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~5. Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
48504556|NCT02143635|DRUG|HDM201|
48504557|NCT02143635|DRUG|ancillary treatment|
48504558|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
48663300|NCT06477770|OTHER|Sucrose|75 g of sucrose will be administered to the surgical wound at 8:00 am every day, once a day, and then it will be covered with sterile gauze.
47986262|NCT03311815|DIAGNOSTIC_TEST|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
48142160|NCT05484336|OTHER|Beverage containing 6g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 6g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48142161|NCT05484336|OTHER|Beverage containing 8g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48142162|NCT02602548|OTHER|Culture|Specimens will be obtained and sent to the lab for cultures.
48142163|NCT01798498|DEVICE|Princess® VOLUME|
48142164|NCT04103099|DIETARY_SUPPLEMENT|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
48142165|NCT04594525|OTHER|Low-Intensity Psychosocial Interventions through Telemental health|Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
48142166|NCT04567459|DIETARY_SUPPLEMENT|Premium Amino Acids|after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
48142167|NCT04571437|DRUG|Capecitabine|Capecitabine metronomic combined with Letrozole
48142168|NCT04571437|DRUG|Letrozole 2.5mg|Letrozole daily alone
48142169|NCT02981329|DRUG|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
48504559|NCT06049927|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
48142170|NCT02981329|BEHAVIORAL|Questionnaires|Questionnaires will be completed to assess the impact quality of life
48142171|NCT06275594|DRUG|Byfavo|For induction and maintenance of sedation
48663301|NCT05991713|BEHAVIORAL|Modifying Exploration|Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
47986263|NCT02723669|DRUG|AR10|effervescent tablet
47986264|NCT02723669|DRUG|acetylcysteine|oral solution
47986265|NCT06477614|BIOLOGICAL|DC cell Vaccine|Deliver DC cell vaccine into patients for anti-ancer therapy.
48142172|NCT06275594|DRUG|Midazolam|For induction and maintenance of sedation
48142173|NCT05766943|DEVICE|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
48142174|NCT05766943|DEVICE|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
48142175|NCT05751733|DRUG|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
48142176|NCT05751733|DRUG|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
48504560|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
48663302|NCT02296099|DRUG|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
47986266|NCT00202644|DRUG|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
47986267|NCT00202644|DRUG|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
47986268|NCT04299412|DEVICE|DPP Fever Panel II assay|Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds
48142177|NCT03097549|DEVICE|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
48142178|NCT03097549|DEVICE|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
48142179|NCT03683849|OTHER|Training|One hour of training, twice a week, for six months.
48142180|NCT04741009|DEVICE|CI632 Slim Modiolar Electrode|Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode
48663303|NCT02296099|DRUG|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
48352716|NCT03401216|PROCEDURE|3 month OCT follow-up|Optical coherence tomography imaging of target vessel within 3 month after PCI
48352717|NCT03401216|PROCEDURE|6 month OCT follow-up|Optical coherence tomography imaging of target vessel within 5 month after PCI
48352718|NCT04012294|DRUG|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
48352719|NCT02132169|DRUG|Drug: AC-170 0.24%|
48352720|NCT02132169|DRUG|AC-170 0%|
48352721|NCT06446830|DRUG|multimodal analgesia and vitamin B|B1, B6 , B9 , B12 in addition to the routine paracetamol and NSAID
48352722|NCT06446830|DRUG|standard multimodal analgesia|Routine Paracetamol and NSAID
48352723|NCT00606229|DRUG|Aripiprazole|oral, 24mg/day
48352724|NCT02928081|PROCEDURE|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
48352725|NCT02928081|PROCEDURE|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
48352726|NCT00141167|DRUG|varenicline|
48352727|NCT03564210|BEHAVIORAL|Screen time permitted|Cohort will not be directed to abstain from screen time
48352728|NCT03564210|BEHAVIORAL|Screen Time Abstain|Cohort will be directed to abstain from screen time
47986269|NCT00710710|DRUG|BI 2536|Intravenous Infusion
47986270|NCT03828357|OTHER|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
48352729|NCT00789659|OTHER|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
48352730|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
48352731|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
48352732|NCT03215849|DEVICE|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
48352733|NCT05675475|OTHER|Exposure|Higher education students from health technologies field exposed to digital devices.
48352734|NCT05675475|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The orthoptic assessment is a non-invasive assessment that will last for 30 min to determine visual parameters related to binocular vision. It will be carried out by the research team in the orthoptics and vision sciences laboratories of the Lisbon School of Health Tecnology.
48352735|NCT05675475|DIAGNOSTIC_TEST|Tear film Break Up Time (BUT) test (Outcome measure)|The BUT test is a tear film rupture assessment test that allows the stability of the tear film to be evaluated. To perform these tests, it is necessary to instill fluorescein and then it is observed in the slit lamp under illumination with a cobalt blue filter, to count the break-up time.
47986271|NCT00456131|BEHAVIORAL|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
48504561|NCT06049927|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.
48504562|NCT05328635|DRUG|Candesartan|Multdisciplinary approach
47986272|NCT04895215|DRUG|AB-2004|Taken 3 times daily with food
47986273|NCT04895215|DRUG|Placebo|Take 3 times daily with food
47986274|NCT00310531|DRUG|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
47986275|NCT00310531|DRUG|Raloxifene|Raloxifene tbl. (60 mg/day)
47986276|NCT00827983|DRUG|Progesterone|25 mg, s.c., once à day
47986277|NCT00827983|DRUG|Progesterone|90 mg, vaginally, once à day
47986278|NCT03613012|DIAGNOSTIC_TEST|Pain index|Record the patients' EEG and extract pain index before and after pain treatments
48352736|NCT01748006|OTHER|Standard of care therapy for severe decompensated heart failure|
48352737|NCT05297383|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid.|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA).
48352738|NCT05297383|DIETARY_SUPPLEMENT|Safflower Oil|4 grams safflower oil (AlaskOmega®) per day.
48352739|NCT05297383|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
48352740|NCT05297383|BEHAVIORAL|Flexibility Training|30 min of stretching 3 days/week for 6 weeks
48352741|NCT04009824|BIOLOGICAL|AGS-v PLUS Vaccine|Administered by subcutaneous injection
48352742|NCT04009824|BIOLOGICAL|Montanide ISA-51 Adjuvant|Administered by subcutaneous injection
48352743|NCT04009824|BIOLOGICAL|Alhydrogel® Adjuvant|Administered by subcutaneous injection
48352744|NCT04009824|BIOLOGICAL|Saline Placebo|Administered by subcutaneous injection
48352745|NCT00036946|BIOLOGICAL|ziv-aflibercept|
48352746|NCT02937090|OTHER|Blood Draw|Blood sample will be drawn from participants at study entry.
48352747|NCT02937090|OTHER|Stool collection|Stool will be collected from participants at study entry.
48352748|NCT05363618|DIETARY_SUPPLEMENT|Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)|Active study product
48352749|NCT05363618|OTHER|Placebo 1.4 ml|Placebo
48352750|NCT01836549|DRUG|imetelstat sodium|Given IV
48352751|NCT02186535|DIETARY_SUPPLEMENT|Vitamin D and Calcium|
47986279|NCT00588848|DEVICE|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
47986280|NCT00588848|DEVICE|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
47986281|NCT00065507|DRUG|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
47986282|NCT00065507|DRUG|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
48352752|NCT03227692|DEVICE|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
48352753|NCT03227692|PROCEDURE|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
48352754|NCT03227692|DEVICE|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
48352755|NCT05375240|DRUG|Propranolol|Propranolol will be given at a dose of 10 mg orally, 3 times per day, for 7 consecutive days after stroke onset.
48663304|NCT06564233|BEHAVIORAL|care.coach Avatar™|"care.coach Avatar™ (avatar) is a conversational relational agent that serves as a virtual companion and appears on a tablet device as an animated pet avatar. Each avatar is supervised by a 24x7 remote team of trained human staff whose abilities are augmented by artificial intelligence (AI) and software-driven health coaching and clinical protocols for consistency, automation, and scale. This unique human-in-the-loop design enables safe, empathic, natural conversations that form the basis for trusting relations and lasting behavior change. In addition to being a companion, the avatar educates patients about their condition, helps manage symptoms, and reinforces other healthy habits. Independent studies have demonstrated improved outcomes at a reduced cost of care. A pilot study demonstrated the feasibility of care.coach Avatar™ as a psychosocial support and health coach in hospitalized HCT patients. More research is needed to assess efficacy and applications in other HCT settings."
48352756|NCT05375240|DRUG|Ceftriaxone|Intravenously 2.0g/day for 7 consecutive days.
48352757|NCT05220293|DRUG|Betamethasone Dipropionate Nasal Cream 0.0644%|Betamethasone Dipropionate Nasal Cream 0.0644%, up to 5g per sinus.
48352758|NCT05220293|DEVICE|Pre-filled syringe and applicator device|Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
48352759|NCT04273568|OTHER|Scapular PNF|Rhythmic initiation and repetitive stretching techniques in scapula anterior elevation-posterior depression and anterior depression-posterior elevation patterns were applied twice a week for 6 weeks.
48352760|NCT04273568|OTHER|Exercise program|An exercise program consisting of exercises used in the conservative treatment of shoulder impingement syndrome for both groups was applied twice a week for 6 weeks.
48352761|NCT01138293|DEVICE|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
48352762|NCT05384990|DEVICE|Stochastic Resonance Electric Stimulation|Subjects will be asked to perform postural transitions like sit to stand, gait initiation, sit to walk and Timed up and the Go (TUG) functional test. This will entail a subsensory electrical signal with a white noise frequency distribution. Proprioceptive SR electrical stimulation will be delivered by BIOPAC Systems, Inc. stimulators that are current limited to deliver less than 10 milli ampere of current. Electrical stimulation will be delivered to muscles and joints along the legs and hips. The stimulation intensity will be very low, below the sensory threshold of the participant.
48352763|NCT04536350|DRUG|Aviptadil 67μg|Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
48352764|NCT04536350|DRUG|Placebo 0.9% NaCl solution|Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
48687951|NCT02388464|DRUG|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
48687952|NCT02388464|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
47986283|NCT02384707|OTHER|allegic food|"Reintroduction procedure for small doses :~* Administration of the first dose~* Clinical monitoring for 45 minutes~* Administration of the second dose"
47986284|NCT02384707|OTHER|Placebo|
47986285|NCT05058248|PROCEDURE|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
47986286|NCT03838822|DIETARY_SUPPLEMENT|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
47986287|NCT01846507|DRUG|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
48352765|NCT04315298|DRUG|Sarilumab|Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
48352766|NCT04315298|DRUG|Placebo|Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
48352767|NCT05757466|DRUG|Prolgolimab|Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
48352768|NCT05757466|DRUG|Combination with prolgolimab and bendamustine|Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
47986288|NCT01471106|DRUG|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
47986289|NCT05052385|DRUG|Ruxolitinib|As per treating physician's decision - non interventional study
47986290|NCT05052385|DEVICE|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
47986291|NCT05052385|DRUG|Ibrutinib|As per treating physician's decision - non interventional study
48663305|NCT03761550|COMBINATION_PRODUCT|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
48142181|NCT05038202|DRUG|Bencycloquidium Bromide Nasal Spray|"The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis."
48142182|NCT05038202|DRUG|Mometasone Furoate Aqueous Nasal Spray|"Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment."
48142183|NCT03533894|DEVICE|colic capsule|colic polyp diagnosis
48142184|NCT04220983|RADIATION|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
48142185|NCT00668226|DRUG|Lactic acid (Dermacid)|
48142186|NCT00706888|DIETARY_SUPPLEMENT|Vitamins B6, B9 and B12 and polyphenols|
48142187|NCT00706888|DIETARY_SUPPLEMENT|placebo|
48352769|NCT03117699|DEVICE|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair"
48352770|NCT05465668|DRUG|DWP16001 Drug A|DWP16001 Drug A
48687953|NCT01020409|PROCEDURE|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
48142188|NCT02038049|DRUG|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
48142189|NCT02038049|DRUG|Placebo|Placebo to VAY736
48142190|NCT03004989|BEHAVIORAL|Programme|The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
48142191|NCT02729246|PROCEDURE|Laparoscopic Gastric Bypass|
48142192|NCT05028465|PROCEDURE|Endoscopic Papillectomy|A snare devicewas inserted via the working channel, and the endoscopist adjusted the snare to securely grasp the lesion, which was then excised by using standard electrocautery.
48142193|NCT05028465|PROCEDURE|Endobiliary Radiofrequency Ablation|The RFA catheter was then placed under fluoroscopic guidance across the distal common bile duct. An ERBE VIO200D generator (ERBE Elktromedizin, Tubingen, Germany) was connected for RFA at 10 W for 90 seconds.
48142194|NCT02455427|DEVICE|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
48142195|NCT02455427|OTHER|Physical Therapy|Physical therapy will be administered for 60 minutes
48142196|NCT02455427|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
48352771|NCT05465668|DRUG|DWP16001 Drug C|DWP16001 Drug C
48352772|NCT05939076|DEVICE|Pulmonary vein isolation|Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
48352773|NCT05939076|DRUG|dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™|Antiarrhythmic drugs
48352774|NCT01728766|OTHER|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at \>37 weeks by and birth weight \<2500 g
48352775|NCT01728766|OTHER|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at \>37 weeks and birth weight \>2800 g
48352776|NCT00133185|DRUG|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
48142197|NCT04422392|DRUG|Carboplatin|(IV, Q3W)
48142198|NCT04422392|DRUG|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
48142199|NCT04422392|DRUG|PD-1 antibody|(IV, Q3W)
48142200|NCT06269497|PROCEDURE|Scaffold placement|The scaffold is placed in the alveola following extraction
48142201|NCT06269497|RADIATION|CBCT|A Cone Beam Computer Tomography (CBCT) is taken of the area of interest after surgery
48142202|NCT02078518|OTHER|Questionnaires|
48142203|NCT05729386|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
48352777|NCT00133185|DRUG|losartan 50 mg/hydrochlorothiazide 12.5 mg|
48352778|NCT02865681|DRUG|Menopur|Nasal versus injectable
48352779|NCT02865681|DRUG|Synarel|nasal
48352780|NCT02865681|DRUG|HCG trigger|injectable
48352781|NCT02865681|DRUG|Clomiphene citrate|oral
48142204|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
48142205|NCT05729386|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
48142206|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
48142207|NCT06313632|DRUG|Bupivacaine injection|Erector spinae plane block with bupivacaine (0.5%) 30 mL once
48142208|NCT06313632|DRUG|Placebo|ESP with matching saline placebo
48142209|NCT06313632|OTHER|Monitored Anesthesia Care|Standard monitored anesthesia care
48142210|NCT03926806|OTHER|Plain yoghurt|cups of 200 g yoghurt
48142211|NCT03926806|OTHER|Vitamin B yoghurt|cups of 200 g yoghurt
48142212|NCT01308684|DRUG|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
48142213|NCT01308684|DRUG|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
48142214|NCT01580436|PROCEDURE|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
48142215|NCT05785325|DRUG|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
48142216|NCT04221711|DEVICE|Repetitive pulsed magnetic stimulation|"OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable."
48142217|NCT04221711|PROCEDURE|Eccentric Calf Muscle Training for Achilles Tendinopathy|"Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling."
48142218|NCT06390449|OTHER|Kahoot intervention|Kahoot, one of the WEB-2.0 tools, will be applied to students who are second-year students of the nursing department and taking the basic principles and practices in nursing course after the course.
48142219|NCT05396885|BIOLOGICAL|anitocabtagene-autoleucel|Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
48142220|NCT05958537|DEVICE|High flow nasal oxygen|Use of High-flow nasal oxygen at 60% 50 L/min.
48142221|NCT05605132|OTHER|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~* head relocation~* gaze stability~* eye follow~* saccadic eye movement~* head and eye coordination"
48663306|NCT05386966|OTHER|questionnaire|Patient demographic data ( age, gender, residence , work ,Level of education) .Detailed history about the trauma (type, site , manner , mechanism of injury , actual cause of assault , post traumatic period till arrival to hospital ) .Clinical assessment ( Rapid neurological assessment , assesment of Scalp injury ,Presence of other body trauma ,Degree of severity of head injury according to GCS , Radiological finding. Treatment (Conservative or operative intervention ) .Follow up and outcome at the time of discharge by using the GOS .Expected time for healing (\<20 day or \>20 day ).Expectance for permanent infirmity
48142222|NCT05605132|OTHER|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
48142223|NCT05605132|OTHER|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
48142224|NCT00386399|DRUG|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
48142225|NCT01344980|PROCEDURE|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
48142226|NCT01344980|PROCEDURE|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
48142227|NCT01344980|BEHAVIORAL|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
48142228|NCT01344980|BEHAVIORAL|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
48142229|NCT05120674|BEHAVIORAL|NAP|During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
48142230|NCT05120674|BEHAVIORAL|CPT|Cognitive Therapy for PTSD
48352782|NCT02865681|DRUG|Letrozole|Oral
48663307|NCT00437073|DRUG|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
48142231|NCT05120674|BEHAVIORAL|ERRT|ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
48663308|NCT00437073|DRUG|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
48663309|NCT00437073|DRUG|lapatinib|lapatinib administered 1250mg once daily orally
48663310|NCT04597801|DRUG|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
48663311|NCT01160185|DRUG|paclitaxel|paclitacel
48663312|NCT01160185|DRUG|cisplatin|cisplatin monotherapy
48663313|NCT01160185|DRUG|topotecan|topotecan
48663314|NCT00619866|DRUG|Elagolix|Elagolix tablets administered orally
48663315|NCT00619866|DRUG|placebo|Placebo tablet administered orally
48663316|NCT05222711|DEVICE|Use of the PICO(TM) monitoring device|The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
48663317|NCT05523908|RADIATION|High-dose hypofraction Arm|Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f
48663318|NCT05523908|RADIATION|Low-dose hypofraction Arm (Standard BED)|Patients in this arm would receive low-dose fractionated radiotherapy with 48Gy/12f
48663319|NCT06089603|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed)
48663320|NCT06089603|DRUG|Conventional pharmacological treatment|Usual treatment of the patient
48352783|NCT02291328|OTHER|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
48663321|NCT06089603|OTHER|Sleep ,diet and life style recomendations|Daily recomendatios
48142232|NCT05120674|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
48352784|NCT02291328|OTHER|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
48352785|NCT01979380|DRUG|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
48352786|NCT01979380|DRUG|placebo|PO, once in the morning
48142233|NCT02056847|DRUG|Pitavastatin calcium 4mg|taking once a day
48142234|NCT02056847|DRUG|Pitavastatin calcium 2mg|Taking once a day
48142235|NCT04738149|DRUG|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
48142236|NCT04738149|DEVICE|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
48142237|NCT04738149|DEVICE|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
48142238|NCT01319032|OTHER|Extraction of whole blood|Extraction of DNA from whole blood
48352787|NCT03769857|DIETARY_SUPPLEMENT|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
48352788|NCT03769857|DIETARY_SUPPLEMENT|Placebo|Placebo
48352789|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
48352790|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
48663322|NCT00000222|DRUG|Buprenorphine|
48663323|NCT03735355|PROCEDURE|Surgery|Surgical resection of fibrostenotic area
48663324|NCT03735355|PROCEDURE|TTS balloon dilation|Dilation of a stricture using TTS balloon
48663325|NCT05298930|OTHER|Physical activity program|"The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges."
48663326|NCT00064857|DRUG|Pycnogenol|
48663327|NCT03622151|OTHER|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
48663328|NCT00895921|DRUG|Olanzapine|Single intramuscular 10-mg dose
48663329|NCT00895921|DRUG|Aripiprazole|Single intramuscular 9.75-mg dose
48663330|NCT02740270|DRUG|GWN323|
48663331|NCT02740270|DRUG|PDR001|
48352791|NCT05972122|DRUG|Analgesia management; group S and C|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
48352792|NCT02898792|DRUG|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
48352793|NCT05422833|OTHER|Evaluation and analysis of clinical data|Evaluation and analysis of clinical data (baseline demographic features (sex, age at diagnosis, age at first symptoms, age at first visit), initial presenting symptoms, affected bone sites (monostotic FD or polyostotic FD), renal phosphate wasting, MAS, Mazabraud syndrome, endocrine disease, fractures, bone specific treatment especially bisphosphonate and surgery, pain and disease's severity.
48352794|NCT02890940|BEHAVIORAL|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
48663332|NCT05704387|PROCEDURE|individualized GDFT|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
48352795|NCT04099225|DIAGNOSTIC_TEST|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
48663333|NCT05704387|PROCEDURE|Restrictive fluid therapy strategy|from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
48663334|NCT05765721|BEHAVIORAL|FRAIL-SM Program|Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
48352796|NCT00718991|DEVICE|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
48504563|NCT05899491|PROCEDURE|ARMA|Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
48504564|NCT05899491|PROCEDURE|UGI Endoscopy|"UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire."
48504565|NCT04715932|DRUG|Hesperidin|Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
48504566|NCT04715932|DRUG|Placebo|Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
48504567|NCT02474875|OTHER|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
48504568|NCT05199090|DRUG|MBL949|subcutaneous injections administered for 14 weeks
48504569|NCT05199090|DRUG|Placebo|Placebo Comparator to MLB949
48504570|NCT04423029|DRUG|DF6002|Specified dose on specified days
48504571|NCT04423029|DRUG|Nivolumab|Specified dose on specified days
48504572|NCT01952210|BEHAVIORAL|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
48663335|NCT01048957|BEHAVIORAL|Real Time Feedback Training|
48663336|NCT04179422|OTHER|anthropometric measurement|weight, height, BMI
48663337|NCT04179422|OTHER|nutritional questionnaire|24hs food recall, presence of feeding disorders
48663338|NCT05176067|RADIATION|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
48663339|NCT01156844|DRUG|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
48663340|NCT01156844|DRUG|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
48663341|NCT00168376|DEVICE|Transcranial Magnetic Stimulation|
48663342|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
48663343|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
48352797|NCT01402375|DRUG|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
47986292|NCT03134989|DEVICE|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
47986293|NCT01628601|DRUG|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
47986294|NCT05106855|RADIATION|Low Laser Radiation|One group will receive laser application to check if there is acceleration of healing.
47986295|NCT05106855|OTHER|Changing the implant surface|Changing the treatment surface of the dental implant to see if osseointegration occurs more quickly.
47986296|NCT05106855|RADIATION|Low Laser Radiation off|This group will receive laser application off.
48142239|NCT06001515|DEVICE|Dual scan protocol|one CBCT scan for the patient while wearing the scan appliance and another scan for the appliance alone
48142240|NCT06001515|DEVICE|triple scan protocol|3D facial Scanning for the patients while wearing their dentures in addition to the dual scan protocol
48142241|NCT01947114|DRUG|Propofol|
48352798|NCT01402375|DRUG|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
48352799|NCT01402375|DRUG|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
47986297|NCT05106855|PROCEDURE|Implant placement immediately after tooth extraction|When the last alternative is tooth extraction, this will be done, and in the same surgical intervention the dental implant will be placed.
47986298|NCT05106855|PROCEDURE|Installing the dental crown with early loading|The installation of the dental crowns will be performed in a period of 6 to 8 weeks, after the dental implant has been installed.
47986299|NCT04425265|PROCEDURE|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
48142242|NCT01947114|DRUG|Ketamine|
48142243|NCT01947114|DRUG|Remifentanil|
48142244|NCT02594709|RADIATION|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
48142245|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
48142246|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
48142247|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
48352800|NCT01402375|DRUG|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
48504573|NCT01952210|BEHAVIORAL|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
48504574|NCT06410235|OTHER|Thoracic manipulation and exercise program|The group received exercises and manipulation with physiotherapist follow-up for eight weeks and thoracic manipulation was performed once a week.
48504575|NCT06410235|OTHER|exercise program|The group received exercise
48504576|NCT04440670|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
48504577|NCT04440670|BIOLOGICAL|normal saline|preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
48504578|NCT05652738|DEVICE|Passive cooling application|Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics
48142248|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
48142249|NCT03507244|DRUG|Pemetrexed|Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
48142250|NCT03507244|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
48352801|NCT01402375|DRUG|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
48352802|NCT01402375|DRUG|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
48352803|NCT00397631|DRUG|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
48504579|NCT05652738|DEVICE|cooling using Blanket roll III|standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
48504580|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
48504581|NCT00168818|DRUG|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
48504582|NCT00168818|DRUG|enoxaparin|40 mg once daily
48352804|NCT00397631|DRUG|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
48663344|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
48663345|NCT03038087|DEVICE|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
48663346|NCT05150626|DRUG|DBPR108 tablets|Drug: DBPR108, tablets, oral
48663347|NCT05334836|DIAGNOSTIC_TEST|MRI for pancreatic fat and liver fat quantitation|MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.
48663348|NCT01900184|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
48663349|NCT01900184|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
48663350|NCT02743962|DEVICE|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
48663351|NCT02743962|OTHER|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
48663352|NCT02040909|DRUG|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
48663353|NCT06108947|DRUG|Aspirin|Aspirin discontinuation
48663354|NCT05032378|BEHAVIORAL|Kinesthetic Awareness Training|One physical or occupational therapy session per week for 8 weeks during which the participant with disordered movement will attempt to perform desired movements while wearing the KAT device
48663355|NCT05032378|BEHAVIORAL|Provision of KAT-assisted physical or occupational therapy|Physical or occupational therapy professionals will provide one KAT-assisted therapy session per week for 8 weeks to one or more participants with movement disorder.
48142251|NCT03507244|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
48142252|NCT00364988|DRUG|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
48142253|NCT00364988|DRUG|losartan|losartan (100 mg daily)
48142254|NCT01246635|DEVICE|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
48352805|NCT01081951|DRUG|olaparib|Tablets Oral BID
48352806|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
48352807|NCT01081951|DRUG|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
48352808|NCT01081951|DRUG|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
48352809|NCT01081951|DRUG|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
48504583|NCT05808920|GENETIC|Molecular Analyses|Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
48352810|NCT04807244|PROCEDURE|Selective Caries Removal with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; peripheral caries is removed until only hard dentin is left, while the pulp wall is excavated until reaching leathery dentin~4. Disinfection of the leathery dentin 5 ml 1% NaOCl (speed: 1 ml per min)~5. Indirect pulp capping (layer of 1-2 mm) of the carious lesion with Biodentine™ (15 min setting time after mixing)"
48352811|NCT04807244|PROCEDURE|Partial Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of 2-3 mm pulp tissue; irrigation with 2 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, transfer of the case to Intervention: full pulpotomy with Biodentine~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
47986300|NCT04425265|PROCEDURE|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
48504584|NCT05523024|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
47986301|NCT06137716|DEVICE|Training with a Robotic Hand Exoskeleton|The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
48663356|NCT06234514|DRUG|Jueling Mingmu decoction|Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
47986302|NCT04566081|OTHER|iTALKbetter: deterministic|A word retrieval therapy application
47986303|NCT04566081|OTHER|iTALKbetter: reactive|A word retrieval therapy application
47986304|NCT06107712|OTHER|Online yoga exercise|"The basic yoga poses of Shivananda Yoga included in the online yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.~In the scope of the study, the physiotherapist researcher who is a certified as the Shivananda Yoga instructor, performed the same yoga practice flow and steps in the both groups during six-week."
47986305|NCT06107712|OTHER|Face-to-face yoga exercise|"The basic yoga poses of Shivananda Yoga included in the face-to-face yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath."
48504585|NCT05523024|DIETARY_SUPPLEMENT|Berberine|The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
48663357|NCT06234514|DRUG|intravitreal injections of 0.5mg ranibizumab|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
48663358|NCT06281457|OTHER|Stimulus properties: task-defining feature|The feature used to determine which stimulus feature to attend to will be varied across trials using a letter cue (M = motion-attend, C = color-attend, F = fixation-attend)
48687954|NCT06471699|DEVICE|Continous Glucose Monitoring|The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes
48142255|NCT01246635|PROCEDURE|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
48142256|NCT02206815|DRUG|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
48142257|NCT02206815|DRUG|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
48142258|NCT05843448|BIOLOGICAL|PD-L1/IDO Peptide Vaccine|Given SC
48142259|NCT05843448|BIOLOGICAL|Pembrolizumab|Given IV
48142260|NCT04528524|OTHER|Questionnaire|QoR-15Dt
48663359|NCT04696029|DRUG|Difluoromethylornithine|"DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C)."
48663360|NCT04942145|DEVICE|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
48142261|NCT04884191|DRUG|Pacritinib|Pacritinib
48142262|NCT03847545|DRUG|Fampridine|sustained-release tablet 10 mg morning and evening.
48142263|NCT03486509|DRUG|Afatinib|afatinb 40mg po bid
48142264|NCT05760950|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.
48142265|NCT06261905|DRUG|[11C]-PHNO|PHNO is used as a tracer for in-vivo imaging.
48142266|NCT06261905|DIETARY_SUPPLEMENT|Calcitriol|Calcitriol is an active form of Vitamin D and is given in 3 0.5mcg capsules per dose.
48142267|NCT06261905|OTHER|Placebo Control|A placebo is an inert capsule, which contains no active ingredients. The placebo will be given in 3 0.5mcg capsules per dose.
48142268|NCT06261905|PROCEDURE|PET Scan|A high resolution PET Scan performed using a NeurExplorer CT scanner.
48142269|NCT03055598|DRUG|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
48142270|NCT00296790|DRUG|zolpidem tartrate|
48142271|NCT04468191|DEVICE|Experimental expiratory muscle strength training (EMST)|The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
48142272|NCT04468191|DEVICE|Sham expiratory muscle strength training (EMST)|The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
48142273|NCT03340922|DEVICE|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
48504586|NCT05523024|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
48142274|NCT03340922|DEVICE|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
48142275|NCT03776604|DRUG|PEG-rhG-CSF|"Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
48504587|NCT05523024|DIETARY_SUPPLEMENT|Probiotc and Berberine|Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
48504588|NCT06148168|DRUG|Bupivacaine plus normal saline|"Unlike specific peripheral nerve blocks, TAP block is a non-dermatomal field block. Even with the same US-guided technique, the extent of spread of local anesthetics can be variable due to individual anatomical variations (18). In order to perform the blocks, abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest .Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study."
48663361|NCT02298621|OTHER|pomegranate juice|Randomized clinical trial or RCT
48142276|NCT03637075|OTHER|intranasal insulin|intranasal administration of insulin (160 IU)
48142277|NCT03637075|OTHER|Placebo|placebo intranasal administration
48142278|NCT02426931|DEVICE|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
48142279|NCT02426931|DEVICE|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
48352812|NCT04807244|PROCEDURE|Full Pulpotomy with Biodentine™|"1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of the entire pulp chamber roof; full pulpotomy to stump level with a high-speed round bur under continuous irrigation with 5 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, exclusion.~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)"
48352813|NCT04807244|PROCEDURE|Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy|"1. Dentin cleaning with a low-speed round bur~2. Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation"
48352814|NCT01758172|DRUG|6% hydroxyethyl starch 130/0.4|
48352815|NCT01758172|DRUG|Albumin|
48352816|NCT01700595|PROCEDURE|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
48352817|NCT02655211|PROCEDURE|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
48352818|NCT02655211|PROCEDURE|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
48352819|NCT02655211|OTHER|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
48367533|NCT04196231|DRUG|Insulin/Empaglifozin|Patients in this arm will continue the basal insulin used before the randomization, with dosage titration on the basis of the following algorithm: adding 2 units for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units for prebreakfast plasma glucose \< 80 mg/dL. Moreover, they will be assigned to empaglifozin, according to the current clinical practice and the drugs' data sheet. Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required (HbA1c \>7.5 after 12 weeks).
48504589|NCT06148168|DRUG|Bupivacaine plus normal saline containing MgSO4|Bupivacaine plus normal saline containing MgSO4
48504590|NCT03882528|BIOLOGICAL|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
48504591|NCT02287155|BEHAVIORAL|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
48663362|NCT02298621|OTHER|placebo|Randomized clinical trial or RCT
48663363|NCT03965923|DRUG|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
48663364|NCT03965923|DRUG|Truvada Tablet|Tablet taken orally
48663365|NCT06120205|DEVICE|Teal Wand Self-Collection Device Group|Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.
48663366|NCT06281418|DRUG|Granisetron 1 Mg/mL Intravenous Solution|2mL intraperitoneal adminstration of granisetron (1 mg/mL)
48663367|NCT06281418|OTHER|Normal saline|2 ml IP normal saline (0.9% NaCl)
48663368|NCT05207384|PROCEDURE|Ozone (O2-O3) injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
48663369|NCT05207384|PROCEDURE|Corticosteroid injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
48663370|NCT04940169|PROCEDURE|anterior cruciate ligament recontruction|Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
48663371|NCT02169596|DRUG|Ticagrelor|Blood tests taken for flow cytometry
48663372|NCT02169596|OTHER|EndoPAT - endothelial assessment|
48663373|NCT01880463|DRUG|Omega-3 fatty acids (fish oil)|
48663374|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3|
48663375|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
48663376|NCT01880463|DRUG|Fish oil placebo|
48663377|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
47986306|NCT02615054|DEVICE|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
47986307|NCT02615054|DEVICE|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
48504592|NCT04113863|DRUG|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
48504593|NCT04113863|DRUG|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
48504594|NCT06039189|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
48504595|NCT06039189|DRUG|Placebo|Placebo will be administered as subcutaneous injection.
48504596|NCT01008332|BIOLOGICAL|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
48504597|NCT01008332|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
48504598|NCT03139227|PROCEDURE|Bio specimen Collection|Patients undergo collection of blood and urine
48663378|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
48663379|NCT05858814|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
47986308|NCT02245074|OTHER|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
48504599|NCT03139227|DIETARY_SUPPLEMENT|Dietary Intervention|Consume celery-banana bread
48504600|NCT03139227|OTHER|Laboratory Biomarker Analysis|Correlative studies
48504601|NCT06341829|OTHER|Prismatic adaptation|Participants will fit with prismatic goggles that deviate their visual field by 13° either leftward or rightward. They will seat in front of a white horizontal board on which three target dots (5 mm diameter) were positioned at 0, -10 and +10° from their body midline at a distance of 57 cm from their eyes. They will perform a total of 150 verbally instructed pointing movements with their right index finger towards the right (+10°) and left (-10°) targets in a pseudorandom order.
48504602|NCT00565617|DEVICE|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
48504603|NCT02856438|DRUG|Elotuzumab|Specified dose on specified days
48504604|NCT02856438|DRUG|Lenalidomide|Specified dose on specified days
48504605|NCT02856438|DRUG|Dexamethasone|Specified dose on specified days
48504606|NCT04708574|BEHAVIORAL|Lifestyle intervention|
48504607|NCT04708574|OTHER|Placebo - Control|
48504608|NCT06233331|DRUG|Dose Level 1 ACU-D1 ointment|"ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks."
48504609|NCT06233331|DRUG|Dose Level 2 ACU-D1 ointment|Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
48504610|NCT06233331|DRUG|Dose Level 3 ACU-D1 ointment|Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
48663380|NCT02899403|OTHER|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
48687955|NCT06471699|OTHER|Self monitoring blood glucose|Capillary testing as in standard procedure
48687956|NCT04538118|BEHAVIORAL|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
48352820|NCT05532462|PROCEDURE|Trans-nasal complete nasalabial cyst excision|The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.
48352821|NCT03935594|BIOLOGICAL|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
48352822|NCT03935594|DRUG|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
48352823|NCT00634751|DRUG|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
48352824|NCT00634751|DRUG|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
48352825|NCT00634751|DRUG|Sorafenib|"Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days"
48352826|NCT04731194|BEHAVIORAL|Performance-based financial incentive program|"1. Enhance policy awareness through verbal communication with patients, distributing picture-rich fliers to patients, and putting up large posters in public places of the villages.~2. Support patients' registration in the reimbursement system~3. Follow-up patients after the first, third, and sixth months after the start of the study, measuring blood pressure and blood glucose level. Encourage patients to purchase medications from public institutions and to take their medications on time.~4. Receive financial incentives based on performance in the amount of 3 RMB per patient enrolled (first month) and 5 RMB per patient (at third and sixth month) buying medications with reimbursement from the policy."
48352827|NCT03336476|DEVICE|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
48352828|NCT03336476|DEVICE|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
48352829|NCT04743869|DEVICE|Kyphos FS™ Bone Substitute|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KyphOs FS™ bone cement will be introduced in the fractured vertebral body.
48352830|NCT04743869|DEVICE|KYPHON ActivOs® Bone Cement with Hydroxyapatite|Dorsal instrumentation via Longitude II (Medtronic Austria GmbH/Vienna) and balloon kyphoplasty are performed. KYPHON ActivOs® Bone Cement with Hydroxyapatite will be introduced in the fractured vertebral body.
48352831|NCT02094612|DEVICE|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
48352832|NCT02094612|BEHAVIORAL|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
48663381|NCT03896763|OTHER|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
48504611|NCT06233331|PROCEDURE|Vulvar/ Perianal Biopsy|3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).
48352833|NCT06178458|OTHER|No intervention|To collect data of pain score and opioid consumption of index and previous cesarean delivery
48663382|NCT06378840|RADIATION|Nab-paclitaxel/Platinum, Sintilimab|Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy
48504612|NCT02365194|BEHAVIORAL|Prehabilitation|information included in arm description
48504613|NCT02365194|BEHAVIORAL|Standard counseling|information included in arm description
48504614|NCT01445210|PROCEDURE|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
48504615|NCT01445210|PROCEDURE|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
48504616|NCT02529215|BEHAVIORAL|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
48504617|NCT03777618|PROCEDURE|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
48663383|NCT04053387|DRUG|tapinarof cream, 1%|Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
48663384|NCT05188014|BEHAVIORAL|Luteal Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
48663385|NCT05188014|BEHAVIORAL|Follicular Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
48663386|NCT01580787|DEVICE|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
48663387|NCT01580787|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
48687957|NCT04538118|DEVICE|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
48352834|NCT04207125|BEHAVIORAL|Multilevel psychotherapeutic intervention programme|"Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes."
48352835|NCT06030076|DRUG|Tildrakizumab|As provided in real-world clinical practice.
48687958|NCT04538118|BEHAVIORAL|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
48504618|NCT02699060|PROCEDURE|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|we analyzed esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects, as well as the appearance of the gastric and duodenal mucosa.
48504619|NCT02699060|PROCEDURE|Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring|we analyzed following HRM parameters: the distal contractile integral (DCI), the lower esophageal sphincter resting pressure (LES RP) and standard measuring parameters were be collected: percentage of total time when pH was \<4, longest reflux event, number of reflux events longer than 5 minutes, and number of reflux episodes in 24 hours.
48504620|NCT02391480|DRUG|ABBV-075|ABBV-075 Oral tablets
48504621|NCT02391480|DRUG|Venetoclax|Venetoclax tablets, film-coated
48504622|NCT02008435|BEHAVIORAL|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
48504623|NCT02008435|BEHAVIORAL|Standard GLB|This arm is the standard Group Lifestyle Balance program
48504624|NCT05850585|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
48504625|NCT05850585|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
48504626|NCT06288230|DRUG|vesemnogene lantuparvovec|Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
48504627|NCT05337371|DEVICE|ECG patch (Philips ePatch® 2.0)|The ECG patch will be put on the patients chest to monitor cardiac activity for a total time period of 14 days after cardiac arrest.
48504628|NCT00094861|DRUG|Palifermin|
48504629|NCT00094861|DRUG|Placebo|
48504630|NCT00094861|RADIATION|Radiotherapy|
48504631|NCT00094861|DRUG|Paclitaxel|
48504632|NCT00094861|DRUG|Carboplatin|
48504633|NCT03269227|RADIATION|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
48504634|NCT06086392|DRUG|Placebo|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block
48504635|NCT06086392|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block
48504636|NCT06086392|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
48504637|NCT00294775|DRUG|Candesartan|
48504638|NCT04918589|DRUG|Tranexamic acid|3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
48504639|NCT04918589|DRUG|Normal Saline|40 mL topical of 0.9% normal saline
48504640|NCT06158256|OTHER|Voluntary apnoea|Series of static apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds until completing the 6 minutes.
48504641|NCT01210612|DEVICE|Unilateral CAI|five-toed socks usage
48504642|NCT05528471|OTHER|Dietary intervention|To compare an iso-caloric, low fructose diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
48504643|NCT06332989|OTHER|stroke-APP|Ambulane paramedics will use an online application to fill in several observations on scen
48504644|NCT03411096|PROCEDURE|Quadratus lumborum block using ropivacaine|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with 0.75% ropivacaine (20cc) under ultrasound guidance.
48504645|NCT03411096|PROCEDURE|Quadratus lumborum block with normal saline|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with normal saline (20cc) under ultrasound guidance.
48663388|NCT03765931|DRUG|Doxycycline|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
48504646|NCT06105827|DRUG|Control group|Give antibiotics or diclofenac sodium suppository as needed.
48504647|NCT06105827|DRUG|Ningmitai capsule|Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
47986309|NCT05126784|BIOLOGICAL|AVT03|AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection
47986310|NCT05126784|BIOLOGICAL|Prolia|Prolia (denosumab) will be given as single subcutaneous injection
47986311|NCT02496650|DRUG|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
47986312|NCT05481645|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
47986313|NCT05481645|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
48142280|NCT01037868|OTHER|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
48504648|NCT06105827|DRUG|Combined group (Ningmitai plus tamsulosin)|Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
48663389|NCT03765931|DRUG|Amoxicillin|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
48663390|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
48663391|NCT00518180|BIOLOGICAL|Tdap Vaccine|One dose of vaccine administered intramuscularly
48663392|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
47986314|NCT05481645|DRUG|Carboplatin Injection|Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
48504649|NCT05982288|OTHER|Virtual Reality Software|Training of intensive care nurses with virtual reality software
48504650|NCT03696238|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
48504651|NCT03696238|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
48504652|NCT06050161|DEVICE|Articulating laparoscopic instrument|The Artisential articulating laparoscopic instrument will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
48504653|NCT06050161|DEVICE|Conventional laparoscopic instrument|Conventional laparoscopic instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
48504654|NCT06050161|DEVICE|Robotic surgical instrument|Robotic surgical instruments will be evaluated for efficacy and safety in suturing during minimally invasive gynecologic surgery.
48504655|NCT06634030|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
48504656|NCT06634030|DRUG|Saline|Normal saline
48504657|NCT03275064|BIOLOGICAL|LNA043|LNA043 intra-articular injection
48504658|NCT03275064|OTHER|Placebo|Placebo intra-articular injection
48504659|NCT02504671|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
48504660|NCT02504671|DRUG|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
48663393|NCT05719220|BEHAVIORAL|Group preoperative pelvic floor training|Patients will receive PFT from a trained physical therapist delivered in a group setting of 8-10 people. The investigators allow patients in the PFT group to attend group classes as many times as they want prior to surgery to see if the frequency of training has an effect on outcomes. The treatment group could be required to go to at least 1 group class 4 weeks prior to their procedure, but they could be welcome to attend more if they want further practice and review of the material. A 45-minute group class with basic PFT guidelines could be presented weekly during the study.
48663394|NCT01846312|OTHER|No treatment given|The participants will not receive any treatment.
48663395|NCT05613231|BEHAVIORAL|Aerobic plus muscle-strengthening physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting both aerobic and muscle-strengthening physical activity for Latina women.
48504661|NCT02504671|DRUG|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
48504662|NCT02504671|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
48504663|NCT01192867|DRUG|Placebo|Placebo will be administered orally QD for 56 weeks
48504664|NCT01192867|DRUG|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
48504665|NCT01192867|DRUG|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
48504666|NCT04522817|BIOLOGICAL|CLBS119|Peripheral blood derived autologous CD34+ cells
48504667|NCT00642278|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
47986315|NCT05481645|DRUG|Paclitaxel Injection|Paclitaxel is a diterpene alkaloid with anticancer activity
48352836|NCT02196090|BEHAVIORAL|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
48352837|NCT02196090|DEVICE|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
48352838|NCT01464398|BEHAVIORAL|Stress reduction|8 weekly sessions
48352839|NCT01464398|BEHAVIORAL|Stress reduction with Health education|8 weekly sessions
48352840|NCT00113555|DEVICE|ACT (Adjustable Continence Therapy)|surgically implanted device
48663396|NCT05613231|BEHAVIORAL|Original physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting aerobic physical activity for Latina women.
48663397|NCT02648360|BEHAVIORAL|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
48663398|NCT03629704|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
48663399|NCT03556891|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
48663400|NCT03035630|DRUG|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
48663401|NCT03035630|DRUG|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
48663402|NCT00851084|DRUG|aflibercept|administration: IV infusion
48663403|NCT00851084|DRUG|oxaliplatin|administration: IV infusion
48663404|NCT00851084|DRUG|5-FU|administration: IV infusion
48142281|NCT06305143|DRUG|Conbercept|participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
48142282|NCT01452867|DEVICE|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
48142283|NCT01452867|DEVICE|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
48142284|NCT01452867|DEVICE|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
48142285|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance relaxometry|Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
48142286|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
48142287|NCT06216704|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.
48663405|NCT00851084|DRUG|Folinic Acid|administration: IV infusion
48663406|NCT06048458|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance with stress perfusion|Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
48663407|NCT06048458|DIAGNOSTIC_TEST|CT coronary angiography|CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
48663408|NCT06048458|DIAGNOSTIC_TEST|Retinal OCT angiography|Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
48663409|NCT06048458|DIAGNOSTIC_TEST|Sublingual microscopy (GlycoCheck)|To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
48663410|NCT06048458|DIAGNOSTIC_TEST|Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)|Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
48687959|NCT06154148|PROCEDURE|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
48663411|NCT04641351|DRUG|Zilretta Injectable Product or Placebo|The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
48663412|NCT00916487|DIETARY_SUPPLEMENT|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
48663413|NCT06563778|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
48663414|NCT06563778|DRUG|Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody|Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
48663415|NCT02498366|OTHER|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
48663416|NCT03057756|COMBINATION_PRODUCT|Km+ Mfx+ Pto + H + Cfz +E+Z|Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
48142288|NCT06216704|DIAGNOSTIC_TEST|DXA|DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
48142289|NCT06216704|DIAGNOSTIC_TEST|pQCT|pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.
48352841|NCT01223690|DRUG|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
48352842|NCT01223690|DRUG|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
48663417|NCT02476227|PROCEDURE|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
48663418|NCT01987414|BEHAVIORAL|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
47986316|NCT05481645|DRUG|Doxorubicin Hydrochloride Injection|Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
47986317|NCT05481645|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.
48663419|NCT01987414|DEVICE|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
48663420|NCT01987414|OTHER|No treatment|Participants will maintain their daily routines during the no treatment period.
48142290|NCT03160976|OTHER|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
48142291|NCT05473117|DIAGNOSTIC_TEST|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
48663421|NCT01728246|DRUG|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
48663422|NCT01728246|DRUG|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
48663423|NCT04373200|BIOLOGICAL|Blood samples collection|Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
48663424|NCT04373200|OTHER|Saliva collection|Saliva collection at Month 4 for 25 survivors COVID-19 patients
48663425|NCT02051192|BEHAVIORAL|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
48663426|NCT02051192|OTHER|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
48663427|NCT06087835|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
48663428|NCT06087835|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized to
48663429|NCT02796651|DRUG|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
47986318|NCT05481645|DRUG|Docetaxel injection|Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
47986319|NCT02703909|DRUG|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
47986320|NCT02703909|DEVICE|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
47986321|NCT01996826|DRUG|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
48142292|NCT04447898|DRUG|PPV-06 10 μg|Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
48142293|NCT04447898|DRUG|PPV-06 50 μg|High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
48142294|NCT04447898|DRUG|Placebo|Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
48663430|NCT02796651|DRUG|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
48663431|NCT02796651|DRUG|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
48142295|NCT00368394|DRUG|Insulin glulisine|
48663432|NCT02796651|DRUG|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
48663433|NCT02796651|DRUG|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
48663434|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenate|200 µg selenium as selenate
48663435|NCT00271245|DIETARY_SUPPLEMENT|400 µg selenium as selenate|400 µg selenium as selenate
48663436|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
48663437|NCT00271245|DIETARY_SUPPLEMENT|Placebo|Placebo
48663438|NCT04519333|PROCEDURE|drug(intradermal injection)|"The mesotherapy was performed by an experienced and trained physician using a disposable 4 mm and 6 mm long, 30 Gauge needles. Initially, a pharmacological mixture of 1 cc (2 mg) thiocolchicoside, 1 cc (16.2 mg) lidocaine and 1 cc (5 mg) tenoxicam was prepared for each treatment session, and 0.1-0.2 cc of this mixture was applied to each injection point with a depth of 1-3 mm using point by point intradermal method without causing papules.~In the systemic therapy group, we applied a 50 mg dexketoprofen (Revafen, Haver Pharma Pharmaceutical Co., Turkey) in 100 cc isotonic solution intravenously for 5 minutes."
48142296|NCT03360617|DEVICE|Syringe IV Push over 2-3 minutes|IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
48142297|NCT03360617|DEVICE|Piggyback over 30 minutes|IV antibiotics will be administered by IV Piggyback over 30 minutes.
48142298|NCT04949113|DRUG|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
48504668|NCT00642278|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
48504669|NCT00642278|DRUG|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
48504670|NCT01140555|DEVICE|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
48504671|NCT01248013|BEHAVIORAL|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
48663439|NCT06030635|DEVICE|Measurement of compartment compressibility using the CPMX1 device|Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
48663440|NCT02371889|DRUG|Topiramate|Max therapeutic dose of 200mg/day
48663441|NCT02371889|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
48663442|NCT02371889|DRUG|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
48663443|NCT02867137|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
47986322|NCT01996826|DRUG|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
47986323|NCT03794414|PROCEDURE|PEEP challenge|apply PEEP 10 mmHg in one-lung ventilating patients.
47986324|NCT03282188|BIOLOGICAL|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
48142299|NCT04949113|DRUG|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
48142300|NCT02633085|DEVICE|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
48142301|NCT03819543|DEVICE|Transcranial Direct Current Stimulation|Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
48142302|NCT02684656|PROCEDURE|Hemodialysis|Hemodialysis \>/=4h
48142303|NCT02684656|PROCEDURE|Hemodiafiltration|Hemodiafiltration \>/=4h, \> 20l convection
48504672|NCT00898638|OTHER|biologic sample preservation procedure|
48142304|NCT00005826|DRUG|rubitecan|
48352843|NCT03610867|DRUG|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
48504673|NCT00898638|OTHER|medical chart review|
48663444|NCT05913674|DRUG|Modified early post-operative intraperitoneal chemotherapy (mEPIC)|"On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2."
48663445|NCT00103844|DRUG|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
48663446|NCT00103844|DRUG|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
48663447|NCT00584857|DRUG|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
48663448|NCT04164719|DRUG|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
48663449|NCT03401866|DIAGNOSTIC_TEST|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
48663450|NCT03278561|PROCEDURE|Sputum induction|Sputum induction according to the ERS protocol
48142305|NCT06129981|BEHAVIORAL|Imaginary exposure therapy augmented by vocal feedback|"The procedure specific to the study~* adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent)~* including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW)~* including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used~* adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6)~* adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI)~* adding psychometric measures specific to the study during the usual follow-up visit at 3 months~* adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site."
48142306|NCT06275841|DRUG|vepdegestrant|experimental
48142307|NCT06275841|DRUG|esomeprazole|Experimental treatment to assess an endpoint
48142308|NCT01573338|DRUG|Roniciclib (BAY1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
48142309|NCT01573338|DRUG|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
48142310|NCT01573338|DRUG|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
48663451|NCT03278561|PROCEDURE|Blood sample|A blood sample of 100ml will be taken.
48663452|NCT01831908|OTHER|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
48663453|NCT02662751|OTHER|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
48142311|NCT01573338|DRUG|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
48142312|NCT03167008|DIAGNOSTIC_TEST|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
48142313|NCT03167008|DIAGNOSTIC_TEST|blood sample|blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
48142314|NCT03679299|OTHER|Observational - No intervention|See outcomes
48142315|NCT04920799|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
48142316|NCT04920799|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.
48142317|NCT01157195|BEHAVIORAL|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
48142318|NCT01157195|BEHAVIORAL|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
48142319|NCT04305340|DEVICE|Myant SKIIN Device|"1. Supine position: Participant lays on a bed on their back for 5 minutes~2. Sitting position: Participant sits on a chair for 5 minutes~3. Standing position: Participant stands for 5 minutes.~4. Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~5. Cool-down: Participants cool-down for 5 minutes"
48142320|NCT01673256|DEVICE|SJM Confirm ICM|
48142321|NCT01958385|DEVICE|placement of g-Cath EZ suture anchors|
48142322|NCT01958385|PROCEDURE|Sham procedure|
47986325|NCT03282188|DRUG|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
47986326|NCT03791476|DRUG|rhC1INH|C1 esterase inhibitor
48142323|NCT01958385|BEHAVIORAL|Diet and Exercise|A structured diet and exercise plan
48142324|NCT00590759|DEVICE|GORE TAG® Thoracic Endoprosthesis|implant
48352844|NCT03610867|DRUG|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
48663454|NCT02662751|DEVICE|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
48663455|NCT03007433|OTHER|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
47986327|NCT03791476|OTHER|Saline Solution|saline solution
47986328|NCT01012518|DEVICE|Standard PCT|The standard technique, performed without video guidance
48142325|NCT04920786|DRUG|TB006|TB006
48142326|NCT04920786|OTHER|Sterile saline (Placebo)|Sterile saline
48142327|NCT01229332|DRUG|Saline|Continuous 24 h administration
48142328|NCT01229332|DRUG|Carbidopa|Continuous 24 h administration
48142329|NCT01785056|BIOLOGICAL|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
48142330|NCT04150809|OTHER|No intervention|There is no intervention for this study
48142331|NCT06231680|DRUG|Camrelizumab|Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity
48352845|NCT03610867|DRUG|Placebo (SAD)|Each subject will receive the sample once by oral administration.
48352846|NCT03610867|DRUG|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
48352847|NCT01228838|DRUG|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
48663456|NCT05992272|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of PIT effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
48142332|NCT06231680|DRUG|Thalidomide 50mg|Thalidomide 50mg，po qd；
48142333|NCT06231680|DRUG|Thalidomide 100mg|Thalidomide 100mg，po qd；
48142334|NCT06231680|DRUG|Thalidomide 200mg|Thalidomide 200mg，po qd；
48142335|NCT06231680|DRUG|Chemotherapy|"Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles."
48352848|NCT01228838|DRUG|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
48352849|NCT00391495|PROCEDURE|Blood drawing|
48663457|NCT05992272|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
48504674|NCT01265433|BIOLOGICAL|Galinpepimut-S + Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
47986329|NCT01012518|DEVICE|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
47986330|NCT02823288|OTHER|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~1. Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~2. Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~3. Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
47986331|NCT03864211|PROCEDURE|Thermal ablation|Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.
48663458|NCT05992272|BEHAVIORAL|Trier Social Stress Test|Will be used to assess the effect of acute stress induction on behavioral and neural PIT effects. The induced stress is generated in a social context, where the participants are asked to prepare a job interview for their dream job and to present it in front of a three-member jury.
48663459|NCT05992272|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
48687960|NCT06154148|PROCEDURE|Traditional prone position|The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
48687961|NCT02601638|OTHER|Demographics and Health History Questionnaire|
48142336|NCT01065532|DEVICE|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
48142337|NCT01065532|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
47986332|NCT03864211|DRUG|Toripalimab|"Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation."
48142338|NCT05068050|PROCEDURE|Horse-assisted therapy|"12 horse-assisted therapy sessions (45 mins each) for 6 weeks.~Each session will comprise the next stages:~Groundwork, Approachment and preparation of the horse, Warm up exercises~Development of the main part (riding):~Introduction - beginning: Breathing control and body awareness, maintain sitting (riding position) while walking on the horse, perceiving the movement Exercises for the postural and balance control: Variations in the walking of the horse, realize different figures in the arena (circles, serpentines, change direction...), Stopping and Walking, Arms situation combined with the movement of the horse All exercises are determined in the track design protocol Exercises for the acquisition of motion skills: Finished the riding with relaxation activities. Final part: Dismount the horse, Unsaddled and unbridle, feedback and goodbye procedure."
48504675|NCT01265433|BIOLOGICAL|Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
48504676|NCT02707445|DRUG|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
48663460|NCT05992272|BEHAVIORAL|Counting Stroop task|Will be used to assess interference at stimulus level. Here either one, two, three or four identical digits from 1 to 4 are shown. Number and denotation of digits are either congruent (1, 22, 333, 4444; 88 trials) or incongruent (111, 2222, 3, 4444; 88 trials). Subjects have to indicate how many digits were shown
48663461|NCT05992272|BEHAVIORAL|No-go Simon task|Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.
48663462|NCT05992272|DIAGNOSTIC_TEST|Stop Signal Task|"Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped."
48663463|NCT05992272|DIAGNOSTIC_TEST|blood samples|for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
48663464|NCT05992272|DIAGNOSTIC_TEST|questionnaires for chronic stress|"* Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic"
48663465|NCT05992272|DIAGNOSTIC_TEST|hair samples|Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.
48663466|NCT05992272|DIAGNOSTIC_TEST|saliva samples|Assessing acute stress effects in AUD.
48663467|NCT05992272|DIAGNOSTIC_TEST|EMA assessment|We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).
47986333|NCT02416440|OTHER|blood sample|blood sample
48663468|NCT05992272|DIAGNOSTIC_TEST|clinical diagnostic|SKID-I Interview neurocognitive and psychopathological testing
48663469|NCT04998942|BEHAVIORAL|virtual cardiac wellness program|Participants assigned to this arm will participate in the experimental intervention.
48663470|NCT04998942|BEHAVIORAL|Placebo comparator|Participants assigned to this arm will participate in a placebo intervention.
48663471|NCT03808935|DRUG|Medical Cannabis|The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
48663472|NCT03808935|DRUG|Placebo|The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
48663473|NCT06563076|OTHER|Vestibular Rehabilitation|supervised vestibular rehabilitation program
48663474|NCT06563076|OTHER|Vestibular Electrical Stimulation|80 Hz high frequency transcutaneous vestibular electrical stimulation (VES)
48663475|NCT05168293|OTHER|Detection of HBV-DNA in Peripheral Blood Mononuclear cells|Detection of HBV-DNA level in Peripheral Blood mononuclear cells
48663476|NCT03000881|OTHER|standard adhesive|This is a standard adhesive (hydrocolloid)
48663477|NCT03000881|OTHER|New adhesive strip|This is a newly developed adhesive strip
48663478|NCT01645202|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
48663479|NCT03309202|DRUG|PF-05221304|25 mg dose
47986334|NCT02560233|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
47986335|NCT02560233|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
47986336|NCT06493422|BEHAVIORAL|Reaching Movements|participants will perform a perceptual decision making task while moving their hand.
48142339|NCT05068050|PROCEDURE|Physical exercise|"12 physical exercise sessions (45 mins each) for 6 weeks. Each session Each session Lessons will be held by physical activity professionals. The proposed exercises are focussed on improving the articular movements, aerobic resistance and the proprioception, always on the premises of No Pain.~Lessons will be divided in three parts :~1. Warmup - 2. Main part - 3. Return to calm~Lessons will be hold online"
48142340|NCT02445404|DRUG|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
48142341|NCT02445404|DRUG|fractionated ICED|ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
48142342|NCT02000752|DEVICE|Acupuncture|
48142343|NCT02000752|DEVICE|Sham acupuncture|Sham point acupuncture
48142344|NCT05831566|DRUG|Budesonide/Formoterol fumarate dihydrate|"The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders."
48142345|NCT01366456|DEVICE|Moxibustion|Comparison of different kinds of moxibustion
48142346|NCT05738785|OTHER|Document review and scanning|Osteoporosis risk and osteoporotic fracture risk will be calculated by examining the patients' files.
48142347|NCT04082598|DRUG|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
48142348|NCT04082598|DIETARY_SUPPLEMENT|Bifidobacterium longum and Lactoferrin|
48142349|NCT02761356|OTHER|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
48142350|NCT02222506|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
48142351|NCT04828109|DEVICE|Virtual Reality|Use of any virtual reality experiences available
48142352|NCT04828109|DEVICE|Fitbit|Use of a Fitbit wearable activity device to track daily step goals.
48663480|NCT06527677|DRUG|ANT3310|ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.
48663481|NCT06527677|DRUG|Meropenem|meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.
48663482|NCT00209131|DRUG|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
48663483|NCT00209131|DRUG|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
48663484|NCT06387342|DRUG|Namodenoson 25mg|oral capsule
48663485|NCT00758563|DRUG|Fluoride|Brush twice daily
47986337|NCT03566823|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
47986338|NCT03566823|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
48142353|NCT04637100|OTHER|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
48142354|NCT04637100|OTHER|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
48142355|NCT01640340|DRUG|aprepitant|Given by mouth
48142356|NCT01640340|DRUG|palonosetron hydrochloride|Given IV(intervenous infusion)
48663486|NCT00758563|DRUG|Triclosan/Fluoride|Brush twice daily
48663487|NCT04253600|BEHAVIORAL|Risk profile screening questionnaire|Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
48663488|NCT04253600|PROCEDURE|Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)|MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
47986339|NCT04818281|BIOLOGICAL|SARS-CoV-2 VLP Vaccine|VLP adjuvanted vaccine
47986340|NCT04818281|BIOLOGICAL|Placebo|0.9% NaCl
47986341|NCT02278588|DRUG|Rasagiline|
47986342|NCT01729507|OTHER|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
48142357|NCT01640340|DRUG|ondansetron|Given PO
48142358|NCT01640340|DRUG|dexamethasone|Given PO
48142359|NCT01014559|DRUG|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
48142360|NCT01014559|DRUG|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
48663489|NCT04253600|BEHAVIORAL|Online investigation of predictive factors associated with DLD and LANCOM app development|Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
48687962|NCT02601638|OTHER|Pre-Class Laryngectomy Survey|
48687963|NCT02601638|BEHAVIORAL|Counseling session with speech pathologist|
48352850|NCT02409264|OTHER|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
48352851|NCT00722475|DRUG|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
48352852|NCT00722475|DRUG|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
48352853|NCT05226572|DIAGNOSTIC_TEST|endoscopic ultrasound-guided fine needle biopsy|repeated endoscopic ultrasound-guided fine needle-biopsy after a previous non diagnostic or incoclusive endoscopic ultrasound-guided tissue aquisition for pancreatic solid lesions.
48687964|NCT02601638|BEHAVIORAL|Total Laryngectomy Preoperative Education Class|
48687965|NCT02601638|OTHER|Day of Hospital Discharge Laryngectomy Survey|
48687966|NCT02601638|OTHER|Day of Discharge Practicum|
48687967|NCT02601638|OTHER|Laryngectomy Education Study Exit Survey|
48687968|NCT04461873|OTHER|Reiki|Reiki by touching
48352854|NCT02921906|OTHER|High protein meal|Breakfast with high protein / low carbohydrate content
48352855|NCT02921906|OTHER|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
48687969|NCT04461873|OTHER|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
48352856|NCT02921906|DRUG|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
48352857|NCT02921906|OTHER|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
48352858|NCT01263470|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
48352859|NCT01263470|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
48352860|NCT01263470|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
48352861|NCT01263470|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
48352862|NCT01263470|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
48352863|NCT01263470|DRUG|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
48352864|NCT05700760|BEHAVIORAL|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
48504677|NCT01607307|DRUG|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
48504678|NCT01607307|DRUG|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
48504679|NCT02529891|OTHER|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
48504680|NCT01595763|OTHER|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
48504681|NCT04053361|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
48504682|NCT04601610|DRUG|KN046 （PD-L1/CTLA4 BsAb）|KN046 5mg/kg Q3W
48504683|NCT04601610|DRUG|Ningetinib Tosylate（multi-target TKI）|ningtinib QD, dose will be decided by investigator
48504684|NCT03805711|DEVICE|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
48504685|NCT02936414|DRUG|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
47986343|NCT01729507|BEHAVIORAL|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
48142361|NCT05454332|DRUG|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
48142362|NCT05454332|OTHER|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
48142363|NCT04620252|DRUG|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
48142364|NCT04620252|DRUG|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
48142365|NCT04620252|DRUG|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
48142366|NCT04620252|DRUG|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
48142367|NCT04620252|DRUG|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
48142368|NCT04620252|DRUG|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
48142369|NCT04620252|DRUG|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
48352865|NCT05700760|BEHAVIORAL|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
48352866|NCT04111926|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
48687970|NCT01551654|DEVICE|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
48687971|NCT03719001|DRUG|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
48687972|NCT03719001|DRUG|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
48687973|NCT03719001|DRUG|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
47986344|NCT01747941|DRUG|PF-06305591|single dose, solution
47986345|NCT01747941|DRUG|Placebo|matching placebo
47986346|NCT01747941|DRUG|PF-06305591|single dose, solution
47986347|NCT01747941|DRUG|Placebo|matching placebo
47986348|NCT01747941|DRUG|PF-06305591|single dose, solution
47986349|NCT01747941|DRUG|Placebo|matching placebo
47986350|NCT02140788|DRUG|Metformin|
47986351|NCT02140788|DRUG|Fish Oil|
47986352|NCT03956745|BEHAVIORAL|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep \~12h opposite their usual sleep time.
47986353|NCT03956745|BEHAVIORAL|constant routine|Study participants will spend \~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
47986354|NCT01577056|DIETARY_SUPPLEMENT|Fish oil capsule|4g Omega capsule for 12 weeks
47986355|NCT01577056|DRUG|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
47986356|NCT03463343|OTHER|Cervical spine manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
48352867|NCT04111926|DRUG|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
48352868|NCT04063540|DRUG|Amiloride|Treatment by Amiloride vs placebo in crossover
48352869|NCT04063540|DRUG|Placebos|Treatment by Amiloride vs placebo in crossover
48352870|NCT04168905|DEVICE|AOTI Inc. TWO2 topical oxygen therapy equipment|Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
48352871|NCT03219554|DRUG|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
48504686|NCT02936414|DRUG|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
48504687|NCT05952518|DEVICE|Sprint PNS system|Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator
48504688|NCT05952518|PROCEDURE|Radiofrequency Ablation|Thermal ablation of the medial nerve
48504689|NCT06362694|DRUG|Dabrafenib + Trametinib|Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
48687974|NCT03719001|OTHER|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
47986357|NCT03463343|OTHER|Cervical spine mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
48504690|NCT03238612|DRUG|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
48504691|NCT03238612|DRUG|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
48504692|NCT03725332|BEHAVIORAL|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance use counselor or perinatal nurse facilitator. Consultations will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
48687975|NCT03719001|OTHER|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
48687976|NCT03719001|DRUG|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
48687977|NCT05743127|DEVICE|3D-Printed Hyrax Expander|This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
48352872|NCT01814449|OTHER|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
48352873|NCT01814449|DRUG|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
48352874|NCT02811081|PROCEDURE|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
48352875|NCT02811081|PROCEDURE|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
48352876|NCT02811081|PROCEDURE|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
47986358|NCT03463343|OTHER|Placebo intervention|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
47986359|NCT06241079|OTHER|non-intervention|non-intervention
47986360|NCT00807157|DIETARY_SUPPLEMENT|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
47986361|NCT00807157|DIETARY_SUPPLEMENT|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
48663490|NCT04253600|BEHAVIORAL|Individual behavioral and cognitive assessment|Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
48663491|NCT04253600|BEHAVIORAL|Automated analysis of language development and environment|"Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours."
48663492|NCT02333448|BIOLOGICAL|Blood sample taken on the day the treatment is initiated|
48663493|NCT02333448|BIOLOGICAL|Blood sample taken on day 3 after initiation of treatment|
48663494|NCT02333448|BIOLOGICAL|Blood sample taken on day 5 after initiation of|
48663495|NCT02333448|BIOLOGICAL|Blood sample taken on day 7 after initiation of treatment|
48663496|NCT02333448|BIOLOGICAL|Blood sample taken on day 10 after initiation of treatment|
48663497|NCT05210543|OTHER|not applicable, observational study|Patients do not receive intervention; observational study
48663498|NCT05086380|BEHAVIORAL|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
48663499|NCT05086380|DEVICE|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
48663500|NCT05086380|BEHAVIORAL|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
48663501|NCT05086380|DEVICE|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
48663502|NCT05086380|DEVICE|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
48663503|NCT05086380|DEVICE|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
48663504|NCT05086380|BEHAVIORAL|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
48663505|NCT03493165|DRUG|Everolimus|mTOR inhibitor
48142370|NCT01967394|OTHER|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
48142371|NCT01967394|OTHER|No use of social media|No social media ads will be available in these counties.
48142372|NCT02202317|DEVICE|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
48142373|NCT04085952|PROCEDURE|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
48142374|NCT04085952|PROCEDURE|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
48142375|NCT01933945|PROCEDURE|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
48142376|NCT01933945|DRUG|Sorafenib (Nexavar, BAY43-9006)|
48663506|NCT05880524|DRUG|Dornase Alfa|Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
48352877|NCT03655418|OTHER|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
48663507|NCT05880524|DRUG|Isotonic Saline Solution|Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
48352878|NCT00614042|DRUG|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
48663508|NCT05843604|OTHER|Functional MRI|Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
47986362|NCT01132404|DRUG|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
47986363|NCT01132404|DRUG|TAK-448|"Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
47986364|NCT06343194|DEVICE|Bruxoff ®|Bruxoff ® is a holter that measures the masseter muscle contraction and heart rate.
48663509|NCT00019448|DRUG|gp100 antigen|
48663510|NCT00019448|DRUG|interleukin-2|
47986365|NCT01403246|DRUG|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
47986366|NCT03081507|BEHAVIORAL|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
47986367|NCT03081507|BEHAVIORAL|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
47986368|NCT04892888|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
47986369|NCT01857466|PROCEDURE|Floseal|
47986370|NCT01857466|PROCEDURE|Bipolar coagulation|
48352879|NCT00278967|DRUG|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
48352880|NCT00278967|DRUG|HalfLytely - Reformulation|
48352881|NCT00470977|DRUG|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
48663511|NCT00567580|RADIATION|PBRT|1.8 Gy per fraction once daily, 5 days a week totaling 64.8-70.2 Gy. 3D-CRT or IMRT required.
48663512|NCT00567580|RADIATION|PLNRT|1.8 Gy per fraction once daily, 5 days a week, totaling 45 Gy. 3D-CRT or IMRT required.
48663513|NCT00567580|DRUG|AA|Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
48663514|NCT00567580|DRUG|LHRH agonist|Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
48687978|NCT05743127|DEVICE|Conventional Laboratory Fabricated Hyrax Expander|This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
48687979|NCT02761681|BEHAVIORAL|ACT-CL Web-based guided self-help|
48687980|NCT02761681|BEHAVIORAL|Control Web-based guided self-help|
47986371|NCT01411696|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
48142377|NCT00444743|DRUG|MM-093|60 mg, administered subcutaneously, weekly
48142378|NCT00444743|OTHER|Placebo|Placebo
48142379|NCT01450397|BIOLOGICAL|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
48142380|NCT03765658|DRUG|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
48352882|NCT05849064|BEHAVIORAL|Behavioral Control|Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
48352883|NCT05849064|BEHAVIORAL|Targeted Intervention|Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
48352884|NCT03072368|OTHER|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
48663515|NCT05029388|OTHER|Aerobic Exercise|The participants will complete three training sessions per week over 10 weeks. The aerobic training program will last for one hour. The session will include a 10-minute warm-up period, followed by a 45-minute aerobic workout, wherein the participants can choose to use either a treadmill, a cycle ergometer, or a rowing ergometer. After the workout, a five-minute period of stretching will be provided for cooling down. The intensity during the workout will be set at 40%-55% of the individual's maximum heart rate.
48663516|NCT05029388|OTHER|High Intensity Interval Training|The intervention will be conducted over a period of 10 weeks, while the participants will complete three training sessions per week. The HIIT training program will last for 30 minutes. The session will include a 10-minute warm-up period, followed by a 15-minute HIIT workout, and a 5-minute period of stretching to cool down. The exercises will include repeated, high-intensity intermittent bursts of vigorous activity at maximal effort. The HIIT will mainly include bodyweight exercises (e.g., push-ups, squats, lunges) that disregards equipment usage. The intensity during the workout will be set to 85%-95% of the individual's maximum heart rate. A half-day training workshop will be provided to the personal trainer to ensure that he/she knows the exercises and can demonstrate them to the participants.
47986372|NCT03834701|DEVICE|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
47986373|NCT02066974|GENETIC|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
47986374|NCT02939898|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
48687981|NCT03493672|DIAGNOSTIC_TEST|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
47986375|NCT02939898|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
47986376|NCT03522974|DIETARY_SUPPLEMENT|Strawberry powder|Freeze dried strawberry powder
48687982|NCT01299337|DRUG|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
48142381|NCT03765658|DRUG|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
48142382|NCT00415649|BIOLOGICAL|VRC-HIVDNA016-00-VP|
48142383|NCT00415649|BIOLOGICAL|VRC-HIVADV014-00-VP|
48142384|NCT00415649|BIOLOGICAL|Vaccine placebo|Placebo comparator
48142385|NCT06205836|DRUG|Cemiplimab|Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
48142386|NCT06205836|DRUG|Fianlimab|Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
48142387|NCT04218877|OTHER||There will be no intervention, only observation
48142388|NCT01989793|DRUG|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
48142389|NCT01989793|DRUG|Placebo|Placebo will be given to those in placebo arm
48663517|NCT02648945|OTHER|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
48663518|NCT05606107|DRUG|Tofacitinib|Tofacitinib combined with other csDMARDs, but no glucocorticoids.
48663519|NCT05606107|DRUG|Glucocorticoid|Glucocorticoid
47986377|NCT03522974|DIETARY_SUPPLEMENT|Placebo powder|40 g/d placebo powder matched for taste and appearance
47986378|NCT00946959|PROCEDURE|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
47986379|NCT03352323|DRUG|Oxymetazoline|RLD
48142390|NCT00128765|BEHAVIORAL|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
48142391|NCT00128765|BEHAVIORAL|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
48142392|NCT00128765|BEHAVIORAL|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
48352889|NCT05727631|OTHER|gentle human touch|Mother will apply gentle human touch touch technique during venous blood collection from preterm babies between 32-37 weeks of gestation
48352890|NCT00882362|DRUG|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
48352891|NCT02661256|DEVICE|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
48352892|NCT02661256|DIETARY_SUPPLEMENT|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
48663520|NCT03014089|BIOLOGICAL|mRNA-1325|Escalating dose levels
48663521|NCT03014089|OTHER|Placebo|
47986380|NCT04659967|BEHAVIORAL|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
47986381|NCT03679650|DRUG|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
47986382|NCT03679650|BIOLOGICAL|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
47986383|NCT03018509|DRUG|JTE-451|Active drug tablets containing JTE-451
47986384|NCT03018509|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
47986385|NCT06033521|DRUG|Menopausal hormone therapy Intervention Type: Drug|Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
47986386|NCT04532957|DRUG|KBP-7072|QD oral capsules
47986387|NCT04532957|DRUG|Placebo|matching placebo capsules
48142393|NCT01049854|DRUG|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
48142394|NCT01049854|DRUG|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
48352893|NCT06141889|DRUG|Azelaprag|oral, apelin receptor (APJ) agonist
48352894|NCT02482415|OTHER|Psycho-educational|
48352895|NCT04140474|DEVICE|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
48352896|NCT02945852|DRUG|apatinib|apatinib 500mg/d until progressive Disease
48352897|NCT06174116|DRUG|Lumateperone|Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
48352898|NCT06174116|DRUG|Placebo|Subject will take placebo for 12 weeks, in addition to their regular medications.
48352899|NCT01359111|DEVICE|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
48687983|NCT05541822|DRUG|ABN401|"Tablets~Route of Administration: Oral"
48663522|NCT04957589|DIETARY_SUPPLEMENT|Very Low Calorie Diet|"A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day."
48663523|NCT04957589|OTHER|High Intensity Interval Training|The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
48663524|NCT01230060|DEVICE|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
48663525|NCT03254784|DRUG|BMS-986165 Capsule|Oral capsule
48663526|NCT03254784|DRUG|BMS-986165 Tablet|Oral tablet
48663527|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone IV drip
48663528|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
48663529|NCT02784340|DRUG|Saline (IV fluids)|IV fluids 500 cc saline infusion
47986388|NCT06471595|BEHAVIORAL|Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component|The PILI Lifestyle Program (PLP) is an adapted 3-month behavioral lifestyle intervention focused on addressing and initiating weight loss in Native Hawaiians and Pacific Islanders (NHPIs). The PLP covers 8 lessons that offer empirically supported strategies (e.g., plate method, stimulus control) based on the social cognitive theory to improve healthy eating, physical activity, and time and stress management across the 3 months. In this study, the PLP will be enhanced with social determinants of health (SDOH) components that address challenges such as access to healthy foods, housing, and employment issues. There will be 4 SDOH activities relevant to participants' needs and lives. These activities will be delivered during the 3-month PLP.
47986389|NCT05919381|DRUG|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
47986390|NCT05919381|DRUG|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
48352900|NCT01165294|DRUG|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
48352901|NCT01165294|DRUG|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
48352902|NCT05907005|BEHAVIORAL|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
48663530|NCT02784340|DRUG|Bupivicaine and Fentany|
48663531|NCT02784340|DEVICE|25G spinal needles|
48663532|NCT04026802|OTHER|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
48663533|NCT04026802|OTHER|Standard of Care|Does not include early implementation of physical therapy
48663534|NCT00003561|BIOLOGICAL|recombinant interferon alfa|
48663535|NCT00003561|BIOLOGICAL|sargramostim|
48663536|NCT04430998|DRUG|Zinc L-Carnosine|Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
48663537|NCT04430998|DRUG|Chlorhexidine|Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
48663538|NCT04430998|OTHER|Water|Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
48663539|NCT00797303|DRUG|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
48663540|NCT01078532|OTHER|SMART PHR|Patient receives an active PHR
48663541|NCT01078532|OTHER|usual care|Usual passive PHR
48663542|NCT00474903|DRUG|acetylsalicylic acid|Given orally
48663543|NCT00474903|DRUG|esomeprazole magnesium|Given orally
48663544|NCT00474903|OTHER|placebo|Given orally
48663545|NCT06571942|DRUG|Vilanterol / Umeclidinium (25/62.5 mcg)|One inhalation daily from Ellipta device for three months
48663546|NCT06571942|DRUG|Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)|One inhalation daily from Ellipta device for three months
48663547|NCT06571942|DRUG|Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg|Two inhalations twice daily form pMDI device for three months
48663548|NCT06571942|DRUG|Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg|Two inhalations twice daily form pMDI device for three months
48663549|NCT01435343|DRUG|fludarabine|30 mg/m2/day intravenously on days 1 to 4
48663550|NCT01435343|DRUG|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
48663551|NCT01435343|DRUG|cytarabine|2 g/m2/day intravenously on days 1 to 4
48663552|NCT01435343|DRUG|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
48663553|NCT01435343|DRUG|plerixafor|intravenously from days 1 to 4
48663554|NCT05478278|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
48663555|NCT05478278|DRUG|Moxifloxacin|The positive comparator used in this study is a 400 mg moxifloxacin tablet.
48663556|NCT05478278|DRUG|Micro-Crystalline Cellulose|The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
48663557|NCT04217434|PROCEDURE|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
48663558|NCT04217434|PROCEDURE|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
48663559|NCT04217434|PROCEDURE|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
48663560|NCT04217434|PROCEDURE|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
48663561|NCT01626742|OTHER|Ready to Drink Flavored Beverage|2 servings a day
48663562|NCT01626742|OTHER|Ready to drink flavored beverage w/ AN 777|2 servings a day
48663563|NCT05872412|DRUG|Doxorubicin|60 mg/m2 IV bolus on day 1 every three weeks for four cycles.
48663564|NCT05872412|DRUG|Cyclophosphamide|600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.
48663565|NCT05872412|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour weekly for 12 weeks
48663566|NCT05872412|DRUG|Carboplatin|Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles
48663567|NCT06206590|OTHER|Whole-proteomic assay|Whole-proteomic analysis was performed on all the blood samples
48663568|NCT05556902|DEVICE|Permanent Epidural Spinal Cord Stimulation|Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain.
48687984|NCT06516991|DEVICE|Temporal Interference Stimulation|"Specific electrode sites are customized for the subject through magnetic resonance scanning, the deep nucleus cluster to be stimulated-nucleus accumbens is calibrated through electric field simulation before treatment, and the stimulation target can be accurately positioned by stimulating the specific electrode sites of the subject during treatment.~During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA."
48687985|NCT04072952|DRUG|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
47986391|NCT01067456|RADIATION|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
47986392|NCT04751344|DRUG|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
47986393|NCT04751344|DRUG|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
47986394|NCT03406351|OTHER|Observational|Observational deep phenotyping physiological readouts
47986395|NCT03752112|DRUG|Cefixime|Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
48142395|NCT01049854|DRUG|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
48663569|NCT06563557|OTHER|Hemodynamic changes between epidural and paravertebral during esophagectomy|The thoracic epidural technique remains the gold standard for perioperative pain management for this procedure. The placement of a paravertebral catheter homolateral with the thoracic incisions is strongly recommended. A goal directed fluid therapy is proposed to guide fluid management and limit postoperative complications. Few studies suggested less side effects in the paravertebral group. The vasoplegia due to the epidural can cause significant hypotension especially as reverse Trendelenburg position is required during surgery. The aim is to bring more light to the hemodynamic changes caused by two different locoregional techniques. An algorithm for fluid and vasopressor management has been proposed. We defined hypotension as 20% of decrement of the median arterial pressure during anesthesia. To reduce bias, the locoregional techniques is performed by an experienced anesthesiologists and the rest of the perioperative management is conducted by another blinded anesthesiologist.
48663570|NCT02014987|BEHAVIORAL|Training programmes|"Runners with a high body mass index follow two types of training programmes:~1. a running programme of 3 kilometres per week~2. a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week."
48663571|NCT02693756|OTHER|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
48663572|NCT03152448|BEHAVIORAL|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
48663573|NCT03942081|DEVICE|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
48663574|NCT06283966|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
48663575|NCT06283966|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and formoterol fumarate pressurized inhalation suspension
48663576|NCT02361892|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
48663577|NCT02135484|DRUG|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
48663578|NCT06078345|OTHER|Carbohydrate|400 Kcal glucose (100g oGTT)
48663579|NCT06078345|OTHER|Fat|400 Kcal glucose rapeseed oil.
48663580|NCT06078345|OTHER|Protein|400 Kcal Moltein PURE (111g)
48663581|NCT02666053|DRUG|BMS-663068|BMS-663068
48663582|NCT06058416|BIOLOGICAL|Healive (hepatitis A vacine(human diploid cell), inactivated)|"The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively."
48352903|NCT03151538|BEHAVIORAL|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
48663583|NCT06505226|BEHAVIORAL|in person meditation|in person guided meditation
48663584|NCT06505226|BEHAVIORAL|in person meditation using headphones|in person meditation using headphones
48663585|NCT06505226|BEHAVIORAL|virtual meditation|virtually guided meditation via Zoom
48687986|NCT04072952|DRUG|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
48663586|NCT05238792|BIOLOGICAL|Tumor-associated antigen-specific T cell (TAA-T)|"Patients will receive an infusion of partially HLA-matched TAA-T any time \>1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy \>2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells"
48663587|NCT05140421|BEHAVIORAL|Data to Suppression (D2S)|Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
48663588|NCT05973955|BEHAVIORAL|Insomnia Treatment|The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.
48352904|NCT03151538|OTHER|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
48663589|NCT05973955|BEHAVIORAL|Education Control|The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
48663590|NCT03373435|DRUG|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
48663591|NCT03373435|OTHER|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
48352905|NCT04760691|DRUG|Truvada alone|TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily
48663592|NCT02969577|BEHAVIORAL|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
48663593|NCT02969577|BEHAVIORAL|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
48663594|NCT02969577|OTHER|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
48663595|NCT04615546|BEHAVIORAL|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
48663596|NCT04615546|OTHER|"Use of Cardea Solo monitoring"|"Participants will wear a Cardea Solo patch during blinded CGM use"
48663597|NCT00565747|DEVICE|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
48663598|NCT00565747|DEVICE|Control culture|The same standard culture medium, but without any additions (ready-to-use)
48663599|NCT06424639|DRUG|Luspatercept|Luspatercept (dose of 1.0 mg/kg, subcutaneous injection every 3 weeks) Cyclosporine (3-5mg/kg/day)
48663600|NCT06424639|DRUG|cyclosporine|Cyclosporine (3-5mg/kg/day)
48663601|NCT04023019|BIOLOGICAL|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
48687987|NCT05040165|DEVICE|Iceform liner and sleeve|Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
48142396|NCT01049854|DRUG|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
48352906|NCT04760691|DRUG|Truvada plus Leuprolide|TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once
48352907|NCT04760691|DRUG|Truvada plus Estradiol 1 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
48352908|NCT04760691|DRUG|Truvada plus Estradiol 6 mg|TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
48352909|NCT04760691|DRUG|Estradiol 6 mg alone|Estradiol 3 mg by mouth twice daily
47986396|NCT03752112|DRUG|Benzathine penicillin 2.4 million units|Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
47986397|NCT00866684|DRUG|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
47986398|NCT00866684|DRUG|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
47986399|NCT00866684|DRUG|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
48142397|NCT03964974|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
48142398|NCT03964974|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
48142399|NCT04389788|DEVICE|carboxy therapy|6 sessions of carboxy therapy every 2 weeks
48142400|NCT04389788|DEVICE|Dermapen with topical glutathione|6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
48142401|NCT02356198|DRUG|EXPAREL|transversus abdominis plane injection
48352910|NCT05719415|OTHER|Measurement of pulmonary functional capillary surface area|Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro
48142402|NCT02356198|DRUG|Intrathecal hydromorphone|Intrathecal opioid administration
48142403|NCT04003792|DRUG|oxaliplatin|intra-arterial oxaliplatin administration
48142404|NCT04003792|DRUG|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
48142405|NCT04003792|DRUG|Bevacizumab|systemic bevacuzimab therapy
48142406|NCT05927259|DRUG|n acetyl cysteine|A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
48142407|NCT05927259|DRUG|standard treatment|stabilization and antidotes
48142408|NCT00937014|OTHER|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
48142409|NCT00937014|OTHER|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
48142410|NCT04577326|DRUG|cyclophosphamide|A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
48352911|NCT00691054|DRUG|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
48352912|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
48352913|NCT04144933|DRUG|Acetaminophen, Gabapentin|975 mg, 300 mg
48352914|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
48352915|NCT04144933|DRUG|Dexamethasone, Ondansetron|6 mg, 4 mg
48663602|NCT04023019|BIOLOGICAL|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
48663603|NCT04023019|BIOLOGICAL|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
48663604|NCT04023019|BIOLOGICAL|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
48663605|NCT04023019|BIOLOGICAL|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
48504693|NCT03725332|BEHAVIORAL|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator or substance use counselor, with a peer support specialist. Small group care meetings will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
48663606|NCT04023019|BIOLOGICAL|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
48663607|NCT05790694|DRUG|HBM9378 (SKB378) Injection|Strength: 225 mg (1.5 mL)/vial
48663608|NCT05790694|DRUG|Placebo|Strength: 225 mg (1.5 mL)/vial
48663609|NCT04863742|DRUG|Dextenza 0.4Mg Ophthalmic Insert|sustained released dexamethasone, 0.4mg
48663610|NCT04863742|DRUG|Prednisolone Acetate|Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
48663611|NCT03505060|BIOLOGICAL|DNA CON-S env|Administered by intramuscular injection in the deltoid.
47986400|NCT00866684|DRUG|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
47986401|NCT00866684|DRUG|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
47986402|NCT00229099|DRUG|GerEPO|
47986403|NCT00390325|DRUG|Sorafenib Tosylate|Given PO
47986404|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
47986405|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
47986406|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
47986407|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
47986408|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
47986409|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
47986410|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
47986411|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
47986412|NCT01053611|DRUG|propofol + remifentanil 0 ng/ml|
48663612|NCT03505060|BIOLOGICAL|IHV01|Administered by intramuscular injection in the deltoid.
48663613|NCT03505060|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
48663614|NCT00255502|DRUG|metoprolol succinate|
48663615|NCT03048682|DEVICE|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
47986413|NCT01053611|DRUG|propofol + remifentanil 2 ng/ml|
47986414|NCT01053611|DRUG|propofol + remifentanil 4 ng/ml|
47986415|NCT01053611|DRUG|propofol + remifentanil 6 ng/ml|
47986416|NCT04758819|PROCEDURE|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)|In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
47986417|NCT06542952|OTHER|seizure|epileptic children
47986418|NCT03407768|BEHAVIORAL|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
47986419|NCT02093481|OTHER|Test meal|
47986420|NCT02093481|OTHER|Reference|
47986421|NCT02093481|OTHER|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
47986422|NCT02093481|OTHER|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
47986423|NCT00562939|BIOLOGICAL|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
47986424|NCT00562939|BIOLOGICAL|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
47986425|NCT02244489|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
47986426|NCT02244489|DRUG|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
47986427|NCT02244489|DRUG|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
47986428|NCT05815472|DEVICE|Fitbit charge|Internet of Things Technologies Device
48142411|NCT04577326|BIOLOGICAL|CAR T cells|A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10\^7 T cells/kg or until the MTD has been reached.
48142412|NCT05630859|BIOLOGICAL|NgG low dose investigational vaccine|Two doses of NgG low dose investigational vaccine, administered intramuscularly.
48142413|NCT05630859|BIOLOGICAL|NgG medium dose investigational vaccine|Two doses of NgG medium dose investigational vaccine, administered intramuscularly.
48142414|NCT05630859|BIOLOGICAL|NgG high dose investigational vaccine|Two doses of NgG high dose investigational vaccine, administered intramuscularly.
48663616|NCT03048682|DEVICE|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
47986429|NCT03513302|DIETARY_SUPPLEMENT|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
47986430|NCT03513302|DIETARY_SUPPLEMENT|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
48142415|NCT05630859|BIOLOGICAL|Placebo|Two doses of placebo, administered intramuscularly.
48142416|NCT05630859|BIOLOGICAL|NgG HTD investigational vaccine|Two doses of NgG HTD investigational vaccine, administered intramuscularly.
48142417|NCT05630859|BIOLOGICAL|NgG below HTD investigational vaccine|Two doses of NgG below HTD investigational vaccine, administered intramuscularly.
47986431|NCT02480543|DRUG|Misoprostol (cytotec)|
47986432|NCT04517253|DRUG|Baricitinib|Administered orally
47986433|NCT03936543|OTHER|Position change|Different position during central line catheterization
48142418|NCT00213759|DRUG|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
48142419|NCT00213759|DRUG|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
48142420|NCT02206867|BIOLOGICAL|LBAL|Anti-inflammatory agents
48142421|NCT02206867|BIOLOGICAL|Humira|Anti-inflammatory agents
48352916|NCT04144933|DRUG|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
48352917|NCT04144933|DRUG|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
48663617|NCT04717401|PROCEDURE|Strain-Counterstrain|Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
48352918|NCT04144933|DRUG|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
48352919|NCT02031510|DRUG|placebo|transversus abdominis plane block with saline 0.9%
48352920|NCT02031510|DRUG|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
47986434|NCT03936543|OTHER|Conventional position|Conventional position during central line catheterization
47986435|NCT02233309|OTHER|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
47986436|NCT02776423|PROCEDURE|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
47986437|NCT01133054|PROCEDURE|revascularization|surgery or stenting
47986438|NCT02689401|DRUG|Ferumoxytol|
47986439|NCT02689401|DEVICE|MRI 3T scanner|
47986440|NCT00256945|PROCEDURE|dental restorative material surface preparation|
47986441|NCT04996888|DEVICE|AI based preoperative automatic reminder system|the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
48142422|NCT02499809|OTHER|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
48352921|NCT02031510|DRUG|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
48352922|NCT05295836|OTHER|PLACEBO|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
48352923|NCT05295836|DIETARY_SUPPLEMENT|GLYCEROL|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
48663618|NCT04717401|PROCEDURE|Muscle Energy Technique|Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
48663619|NCT05616442|DRUG|Ketotifen|Mast cell stabilizer
48663620|NCT05616442|DRUG|Vitamin E|Dietary supplement
48142423|NCT04552015|DIAGNOSTIC_TEST|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
47986442|NCT04489576|PROCEDURE|Keratin hair treatment (Keratin Cure ®) versus (QOD Max ®)|Hair will be treated with 2 different types of keratin in groups 1 \& 2. All steps of keratin application will be done in group 3 without keratin application as a control group.
47986443|NCT05138575|DRUG|Empagliflozin + Potassium Chloride|"Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control."
48142424|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head \& neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
48142425|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
48142426|NCT01054118|DRUG|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
48142427|NCT01054118|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
48142428|NCT01054118|DRUG|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
48142429|NCT01054118|DRUG|Placebo|Placebo suspension and placebo capsule administered as single doses
48142430|NCT03964779|DIAGNOSTIC_TEST|Hormonal assay|Measurement of Thyroid stimulating hormone
48142431|NCT03964779|DIAGNOSTIC_TEST|Antibody assay|antithyroglobulin and antithyroid peroxidase
48142432|NCT01064609|PROCEDURE|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
48142433|NCT01064609|PROCEDURE|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
48142434|NCT01549951|DRUG|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
48142435|NCT01758068|PROCEDURE|Coconut Oil Application|Coconut oil - 4 ml
48142436|NCT05584748|DEVICE|transcranial direct current stimulation|tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
48142437|NCT00947895|DRUG|Methylprednisolone|IV 1000 mg daily for 3 days
47986444|NCT05138575|DRUG|Empagliflozin + Potassium Nitrate|Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
47986445|NCT05138575|DRUG|Potassium Chloride + Placebo for Empagliflozin|Active control.
48142438|NCT00947895|DRUG|ACTH|IM ACTH 80 mg/day for 5 days.
48142439|NCT00947895|OTHER|IV placebo|IV placebo (saline) daily for 3 days.
48352924|NCT04683952|DEVICE|Exercise training with Humified High Flow Nasal Cannula|The experimental group will be trained using HHFNC with the most adequate continuous flow, in a range between 25 and 30 L / min.
48142440|NCT00947895|OTHER|IM placebo|IM placebo (saline) daily for 5 days.
48142441|NCT02923349|DRUG|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
48142442|NCT05330000|DRUG|4 mg/kg Voriconazole|Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
48142443|NCT05330000|DRUG|6 mg/kg Voriconazole|High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
48142444|NCT00362219|OTHER|Placebo|Gel with no active ingredient.
48142445|NCT00362219|DRUG|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
48142446|NCT00362219|DRUG|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
48142447|NCT00362219|DRUG|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
48142448|NCT01945372|OTHER|EEG NeuroFeedback|
47986446|NCT02069366|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive dronabinol.
48663621|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane|Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
48663622|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane|Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
47986447|NCT02069366|DRUG|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
47986448|NCT05946850|PROCEDURE|Caudal analgesia|Caudal analgesia for chronic lumbosacral pain
48142449|NCT00047385|DEVICE|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
48142450|NCT00047385|DEVICE|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
48142451|NCT02368652|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
48142452|NCT02368652|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
48142453|NCT01841385|OTHER|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
48142454|NCT00635635|BEHAVIORAL|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
48142455|NCT00635635|BEHAVIORAL|Music Audio|Music only audio to be listened to 5x per week
48142456|NCT06369844|OTHER|Pressure injury education|Pressure injury education will be provided to participants in the intervention group in three separate sessions covering the topics of Pressure Injury Definition and Classification, Risk Assessment, Prevention, and Care.
48663623|NCT05571293|DRUG|Botensilimab|Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.
48663624|NCT05571293|DRUG|Balstilimab|Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.
48663625|NCT01596426|DRUG|Sancuso|granisetron transdermal system
48663626|NCT01596426|DRUG|IV granisetron|IV granisetron
48142457|NCT05395299|PROCEDURE|SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
48142458|NCT02142725|DRUG|LT-02|four times per day
48142459|NCT02142725|DRUG|LT-02|two times per day
48142460|NCT02142725|DRUG|Placebo|four times per day
48142461|NCT03093064|DRUG|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
48142462|NCT03093064|OTHER|Placebo: normal saline|Normal saline, intravenous infusion
48142463|NCT02845609|DRUG|Sialic Acid-Extended Release|Oral drug of Sialic acid
48142464|NCT04301999|PROCEDURE|Photodynamic therapy|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
48142465|NCT04301999|PROCEDURE|radiofrequency ablation|an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
48142466|NCT06207006|BEHAVIORAL|eConquerFear-HK|The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
48663627|NCT05465304|DRUG|Azithromycin|The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
48663628|NCT03910075|BEHAVIORAL|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
48663629|NCT03910075|BEHAVIORAL|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
48663630|NCT03910075|BEHAVIORAL|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U\&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
48663631|NCT06295419|OTHER|dual task|cerebral palsy and healthy controls will be evaluated dual task conditions
48663632|NCT06295419|OTHER|single task|cerebral palsy and healthy controls will be evaluated single task conditions
47986449|NCT05252000|DEVICE|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
47986450|NCT05252000|DEVICE|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
47986451|NCT05252000|DEVICE|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
48352925|NCT04683952|OTHER|Exercise training - Control Group|The control group will perform exercise training in spontaneous breathing.
48663633|NCT05432973|PROCEDURE|Percutaneous Electrical Nerve Stimulation|In the PENS treatment, a biphasic continuous waveform current with a frequency of 2 Hz, a pulse width of 50 microseconds and an intensity that produces visible motor responses of the innervated muscles was used, below the patient's pain threshold. The NT6021 Percutaneous Neuromodulation equipment of the Nutek® brand distributed by Fisiolab Ibérica® was used. This equipment has the CE marking, which denotes compliance with the requirements of the legislation of Royal Decree 414/1996 of March 1, which regulates medical devices. B.O.E. of April 24, 1996
48352926|NCT05444829|DEVICE|specific screw holes locating surgical guide and pre-bent plates|Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the pre-bent plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
48352927|NCT05444829|DEVICE|classical reduction and internal fixation.|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
48352928|NCT05830240|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
48352929|NCT01395966|DRUG|DF289|Ear drops
48352930|NCT01395966|DRUG|DF277|Ear drops
48663634|NCT05432973|PROCEDURE|Neurodynamic and manual therapy|"The manual therapy consisted of passive-assisted mobilization and massage therapy of the muscular and fascial tissue, beginning with the cervical area, kneading while asking the patient to rotate the neck and then in the same way along the muscles and soft tissues innervated by the target nerve.~Neurodynamic was performed in a passive-assisted manner, combining the patient's cervical mobilizations with the mobility of the upper limbs adapted to each case."
48663635|NCT02399852|DRUG|Lomitapide|
48352931|NCT01395966|DRUG|DF289 plus DF277|Ear drops
48352932|NCT06388460|OTHER|Asthma Link|Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
48352933|NCT06388460|OTHER|Enhanced Usual Care|Providers enroll patients to receive an asthma educational workbook
48142467|NCT06207006|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
48663636|NCT06288438|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
48663637|NCT06288438|OTHER|Physical Therapy Interventions|Strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise.
48663638|NCT06288438|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene, etc.
48663639|NCT06288438|OTHER|Health Status Updates|Health Status Updates will be completed by a trained assessor. The assessor will ask about adverse events, general health topics, medication changes, and changes in social circumstances.
48352934|NCT00534924|DRUG|Vit C|
48352935|NCT00534924|PROCEDURE|Postconditioning|
48504694|NCT01043224|DRUG|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
48504695|NCT00256438|DEVICE|Transcranial Direct Current Stimulation|
48352936|NCT00534924|OTHER|no intervention|
48352937|NCT01625611|DRUG|Naltrexone|Naltrexone 100 mg titrated over one week
48352938|NCT03227094|DIAGNOSTIC_TEST|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training \& delivery of Jelly-Bean/75g glucose beverage
48352939|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
48352940|NCT03227094|DIAGNOSTIC_TEST|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
48352941|NCT05903391|DEVICE|3D-Printed Finger Splints|The intervention is wearing a novel finger splint produced by a 3D-printer
48352942|NCT05903391|DEVICE|Conventional Finger Splints|This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
48352943|NCT00656994|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
48663640|NCT06288438|OTHER|Physical Therapy Consult|Participants in the control condition will be offered a physical therapy consult at the end of their 24 week study involvement.
48663641|NCT03896633|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
48663642|NCT03896633|DRUG|Azopt 1%|Azopt 1%, RLD
48663643|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
48352944|NCT00656994|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
48352945|NCT00638274|PROCEDURE|Air|3 mls used for identifying epidural space
47986452|NCT03287440|BEHAVIORAL|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
48352946|NCT00638274|PROCEDURE|Saline|3 mls of saline used to identify epidural space
48352947|NCT03705741|BEHAVIORAL|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
47986453|NCT03287440|BEHAVIORAL|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
47986454|NCT05693675|DRUG|Postoperative methadone|Participants will receive intraoperative methadone (0.2 mg/kg ideal body weight intravenously but not exceeding 20mg) followed by oral/IV methadone postoperatively according to the following scheme: A) Opioid naïve patients will receive 5mg twice daily dosage of methadone on postoperative days 1 and 2 followed by 5 mg daily on postoperative days 3, 4, and 5. B) Patients taking opioids preoperatively will continue to receive their regular opioids and additionally receive 5 mg twice a day of methadone on postoperative days 1 and 2, followed by 5 mg per day on days 3, 4 and 5.
47986455|NCT05693675|DRUG|Postoperative placebo|Participants will receive intraoperative methadone intravenously 0.2mg/kg followed by oral placebo postoperatively according to the following scheme: Opioid naïve patients and patients taking opioids preoperatively will receive placebo tablets twice daily on day 1 and day 2 and once daily day 3, 4 and 5. Patients taking preoperative opioids will be able to return to their baseline opioids immediately after surgery.
48352948|NCT04543630|PROCEDURE|Sinus floor augmentation|Sinus floor augmentaion using the lateral window technique
48352949|NCT00578890|PROCEDURE|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
48352950|NCT06386536|DEVICE|Intelligent stationary bike|A stationary motorized bike prototype that can evaluate lower limb functions such as strength, coordination, range of motion, and tonus. Based on the evaluation results, the iBike proposes a training program that is specific to each individual needs. Moreover, the intelligent bike offers diverse pedaling modes such as forward and backward pedaling, assisted pedaling, isotonic pedaling and pedaling with sensory stimulations.
48352951|NCT06386536|DEVICE|Conventional stationary bilke|A conventional stationary bike that can be found in gyms or rehab centers.
48352952|NCT06096012|DRUG|Anti-MRSA therapy|chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.
48504696|NCT05911880|BEHAVIORAL|Plant-based diet for 14 days in patients with rheumatoid arthritis.|Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
48504697|NCT06197373|PROCEDURE|Laparoscopic cholecystectomy|Doing laparoscopic cholecystectomy after ERCP at different intervals
48504698|NCT06460285|BEHAVIORAL|EmRes|There will be six, one hour, treatment sessions across nine weeks of emotional resolution therapy, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a licensed therapist.
48504699|NCT06460285|BEHAVIORAL|Mindfulness|There will be six, one hour, treatment sessions across nine weeks of a mindfulness intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained member of the study staff.
48504700|NCT00839254|BIOLOGICAL|Pneumococcal conjugate vaccine Synflorix (GSK1024850A)|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
48504701|NCT00839254|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children \< 12 months of age at the time of first study vaccination.
48504702|NCT00839254|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children \>= 12 months of age at the time of first study vaccination.
48504703|NCT03207243|DRUG|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
48504704|NCT03207243|DRUG|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
48504705|NCT03207243|DRUG|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
48504706|NCT03207243|DRUG|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
48504707|NCT02049450|DRUG|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
48504708|NCT05552963|DEVICE|Multi-Channel Irreversible Electroporation (IRE) Generator|The multi-channel IRE Generator is intended for use during cardiac Pulsed Field Ablation (PFA) therapy. This device is used in conjunction with a compatible ablation catheter to create a closed electrical circuit capable of delivering pulsed electrical field energy.
48663644|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
48663645|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
48663646|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
48663647|NCT01333436|OTHER|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
48663648|NCT03402841|DRUG|Olaparib|300 mg twice daily - oral
48663649|NCT01342055|DRUG|Apetrol ES|sequences of administered drugs
48663650|NCT03551093|DEVICE|ISS SPG stimulation|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
48352953|NCT03510403|DEVICE|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
48352954|NCT00600236|PROCEDURE|blood sample|
48352955|NCT03765177|BIOLOGICAL|CLIC-1901|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
48352956|NCT00194415|BEHAVIORAL|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
48352957|NCT00194415|PROCEDURE|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
48352958|NCT03968211|BIOLOGICAL|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
48352959|NCT00198731|BEHAVIORAL|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
48352960|NCT00846911|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
48352961|NCT03729908|BEHAVIORAL|Animal assisted mindfulness based intervention|A mindfulness based intervention in the presence of an animal
48352962|NCT03729908|BEHAVIORAL|Anti-stress program|A mindfulness based intervention with no reference to animals
48352963|NCT03529734|OTHER|12 min running|This was already explained in the description of arm
48352964|NCT03529734|OTHER|Local strengthening exercises|This was already explained in the description of arm
48352965|NCT00000995|DRUG|Zidovudine|
48504709|NCT05552963|DEVICE|Multi-Channel Circular IRE Catheter|The multi-channel circular IRE Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) and when used with an IRE Generator, for cardiac ablation.
48504710|NCT05180357|OTHER|FASENRA(benralizumab)|This is a retrospective, observational study with secondary data collection utilizing medical chart review in hospitals or clinical centres that treated SEA + NP patients with benralizumab. Patient data including demographics, clinical characteristics, medication history, biologic treatment, and NP and asthma clinical outcomes will be abstracted from patient medical charts onto a pre-approved electronic case report form. No personal identifiable data will be collected. Data from all participating centres will be combined into a single anonymised dataset for analysis.
48504711|NCT05110482|DRUG|Syntocinon|uterotonic drugs
48687988|NCT05153603|DRUG|Olaparib mono-maintenance therapy|Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
47986456|NCT05693675|DRUG|Rescue Analgesia|PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
47986457|NCT05916729|DRUG|Miconazole|Protocol for active control groups includes use of Miconazole Oral gel for 14 days with frequency of four time per day.
47986458|NCT05916729|DIETARY_SUPPLEMENT|CandBerrol® lozenges|Protocol for experimental groups includes use of Miconazole Oral gel and CandBerrol® lozenges for 14 days with frequency of four time per day
48504712|NCT05110482|DRUG|Carbetocin|uterotonic drug
47986459|NCT03071627|OTHER|New items with spin|Interpretation of news items with spin
47986460|NCT03071627|OTHER|New items without spin|Interpretation of news items without spin
47986461|NCT03303079|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
48352966|NCT00000995|DRUG|Ganciclovir|
48352967|NCT03316742|COMBINATION_PRODUCT|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
48352968|NCT03316742|COMBINATION_PRODUCT|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
48352969|NCT00836316|DRUG|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
48352970|NCT04451395|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|"The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000"
48352971|NCT04233957|DIETARY_SUPPLEMENT|High Sodium|10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
48352972|NCT04233957|OTHER|Placebo|10 days of enteric capsules filled with dextrose.
48352973|NCT02455843|OTHER|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
48352974|NCT02543606|DRUG|Esomelone|powder for injection/ infusion Esomeprazole 40mg
48352975|NCT02543606|DRUG|Nexium|powder for injection/ infusion Esomeprazole 40mg
48352976|NCT00878644|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
48352977|NCT00878644|OTHER|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
48352978|NCT02907801|BEHAVIORAL|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
48352979|NCT00026039|DRUG|estrogen|
48352980|NCT02458352|DEVICE|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
48504713|NCT00397059|DRUG|Escitalopram|
47986462|NCT03303079|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
47986463|NCT03303079|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
47986464|NCT02984189|OTHER|Inspiratory muscle training|The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
48352981|NCT02458352|DEVICE|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
48352982|NCT00449995|PROCEDURE|confocal laser microscopy|
48663651|NCT03956160|OTHER|A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.|"4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~* Define the case-manager's profile, and required knowledge and skills~* Identify the resources and tools to be proposed on the Internet platform~* Test the tools and content~* Refine the program evaluation criteria~* Test and validate the study procedures."
48663652|NCT04719156|DRUG|Indocyanine green solution administered at 2.0mg/kg.|Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.
48663653|NCT04719156|DEVICE|Stryker SPY-PHI Imaging Device|The SPY-PHI system is used with the ICG dye to provide fluorescence images.
48663654|NCT01296204|DRUG|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
48663655|NCT02294864|DEVICE|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
47986465|NCT00681655|OTHER|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
47986466|NCT00681655|OTHER|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
47986467|NCT02533037|OTHER|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
47986468|NCT02533037|OTHER|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
47986469|NCT03222596|BEHAVIORAL|Exercise training|Exercise programme includes breathing and upper limbs exercises.
47986470|NCT03741179|DRUG|ASA-withdrawn group|Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
47986471|NCT06323889|BEHAVIORAL|Modified Alternate Day Fasting|Participants are instructed to fast every other day.
47986472|NCT06323889|BEHAVIORAL|Time-Restricted Eating|Participants are instructed to limit food intake to two main meals consumed in maximum 8 hours per day
47986473|NCT06323889|BEHAVIORAL|Weight-loss counseling|Participants will receive nutrition counseling to structure their main meals according to the plate model for weight-loss and to reduce number of consumed plates.
47986474|NCT06441175|OTHER|Intubation device order|"D-V group: the group that performs direct laryngoscopy first and then videolaryngoscopy.~V-D group: the group that performs video laryngoscopy first and then directlaryngoscopy."
47986475|NCT02743650|DIETARY_SUPPLEMENT|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
47986476|NCT05641051|DRUG|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
47986477|NCT05641051|DRUG|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
47986478|NCT02848157|DRUG|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
47986479|NCT02848157|DRUG|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
47986480|NCT02848157|DRUG|Ropivacaine|
48352983|NCT00636506|DEVICE|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
48352984|NCT03424213|OTHER|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
48663656|NCT02294864|PROCEDURE|Physical Therapy|
48663657|NCT03358082|DRUG|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
48663658|NCT03358082|DRUG|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
48663659|NCT02305121|DEVICE|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
48663660|NCT01722669|DRUG|isoquercetin or quercetin|Single dose PK/PD study
48352985|NCT05098808|OTHER|Acoustic features (from signals obtained during phonation)|"Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient"
48352986|NCT01626755|PROCEDURE|Sciatic name block|Ultrasound-guided sciatic nerve block.
48352987|NCT01174940|DRUG|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
48352988|NCT05874947|DEVICE|linear measurement|Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
48352989|NCT02233491|BEHAVIORAL|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
48352990|NCT02233491|OTHER|Control|No additional support other than lifestyle advice by clinician
48352991|NCT03960372|BEHAVIORAL|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
48352992|NCT04742621|PROCEDURE|Liver transplant|Eligibility for liver transplantation will be limited to patients with histologically confirmed metastatic colorectal adenocarcinoma who have achieved stability of liver metastasis on chemotherapy for at least 6 months prior to transplantation. All patients who undergo liver transplantation will start immunosuppressive therapy per protocol. Patients who undergo a successful liver transplant will not receive adjuvant therapy.
48352993|NCT06216054|DRUG|LPM3770164 sustained release tablet|administrated orally
48352994|NCT06216054|DRUG|LPM3770164 sustained release tablet simulant|administrated orally
48352995|NCT03793894|BEHAVIORAL|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
48352996|NCT03793894|BEHAVIORAL|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
48142468|NCT04317937|OTHER|Jaw opening-closing movements|"Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward)."
47986481|NCT03886233|DRUG|Corticosteroid Series|immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
48142469|NCT04317937|OTHER|Specific Active exercises|"Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements."
48352997|NCT03793894|BEHAVIORAL|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare \& Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
48352998|NCT03793894|BEHAVIORAL|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
48352999|NCT00711412|DRUG|Induction Therapy - Capecitabine|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
48353000|NCT00711412|DRUG|Induction Therapy - Oxaliplatin|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
48353001|NCT00711412|DRUG|Combination Therapy - Capecitabine|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
48353002|NCT00711412|DRUG|Combination Therapy - Oxaliplatin|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
48353003|NCT00711412|RADIATION|Combination Therapy - Radiation|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
48353004|NCT00711412|PROCEDURE|Evaluation for response and surgery|Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
48353005|NCT00369889|DRUG|bevacizumab|iv every 21 days
48353006|NCT00369889|DRUG|Erlotinib|oral daily
48353007|NCT01571167|DRUG|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
48353008|NCT01571167|DRUG|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
48353009|NCT01571167|DRUG|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
48353010|NCT04904640|DEVICE|Hip stem|In every hip (with appropriate CT scan), 3 different stem designs will be positioned using a 3D Ct based software for surgical pre-operative planning.
48353011|NCT00671515|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
48353012|NCT04830176|OTHER|dentifrice|use of dentifrices for brushing
48353013|NCT06261840|DRUG|Metronidazole 500 mg|Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men
48353014|NCT06261840|DRUG|Secnidazole 2000 MG|Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
48504714|NCT01045538|DRUG|Vorinostat, capecitabine, and cisplatin|Vorinostat 200\~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
48504715|NCT02188173|DRUG|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
48504716|NCT02024113|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
48353015|NCT03755167|DRUG|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
48353016|NCT01500265|BIOLOGICAL|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
47986482|NCT00158509|DRUG|Valacyclovir|
48142470|NCT04317937|OTHER|Exercise Therapy|"Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension \& rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured."
48142471|NCT04317937|OTHER|Supportive Treatment|"Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~* Avoid prolonged neck bending.~* Avoid twisting movement of the neck.~* Use a suitable pillow to maintain cervical spine.~* Adjust computer screen at eye level.~* Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~* Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~* Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~* Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~* Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~* Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record."
48142472|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
48142473|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
48142474|NCT00299507|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
48142475|NCT04957277|OTHER|load modulation|Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
48142476|NCT00001628|DRUG|Angiotensin II type 1 receptor antagonists|
48142477|NCT05068232|RADIATION|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
48142478|NCT05068232|DRUG|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
48142479|NCT05068232|DRUG|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
48142480|NCT05068232|DRUG|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
48142481|NCT03576092|DIAGNOSTIC_TEST|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
48142482|NCT00070486|DRUG|carboplatin|given IV
48142483|NCT00070486|DRUG|celecoxib|given PO
48142484|NCT00070486|DRUG|gemcitabine hydrochloride|given IV
48142485|NCT00070486|DRUG|zileuton|given PO
48142486|NCT03682003|DIAGNOSTIC_TEST|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
48142487|NCT03185793|DRUG|Placebo|Placebo once daily for 5 weeks
48142488|NCT03185793|DRUG|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
48142489|NCT03185793|DRUG|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
48142490|NCT03020433|DEVICE|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
48142491|NCT03020433|DEVICE|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
48142492|NCT03020433|DEVICE|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
48142493|NCT03020433|DEVICE|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
48142494|NCT02203656|DRUG|Placebo|placebo supplement
48142495|NCT02203656|DIETARY_SUPPLEMENT|Nutritional Supplement|protein supplement
48142496|NCT02203656|BEHAVIORAL|In-home exercise|In-home exercise program
48142497|NCT02203656|DRUG|Testosterone|Testosterone injection
48142498|NCT04592926|DEVICE|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
48142499|NCT04592926|OTHER|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
48142500|NCT03090698|DRUG|Hylan G-F 20|intra-articular administration
48142501|NCT03090698|DRUG|Triamcinolone|Intra-articular administration
48353017|NCT03042585|RADIATION|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
48353018|NCT04838340|OTHER|Standart care|This group will leave in the hospital's usual care and no intervention will be applied.
48142502|NCT03138629|DRUG|VAL-083|VAL-083 will be administered intravenously
48142503|NCT06122025|DEVICE|Patient Access|A 6-month pilot prospective interventional study with an independent groups design.
48353019|NCT04838340|BEHAVIORAL|Hypnobirthig training|"Hypnobirthing training of the Hypnobirthing group will carry out with its partner. Hypnobirthig training will be given in small groups of 5 or 6 couples for 4 weeks and 3 hours a week. In addition, the usual care will be provided by healthcare professionals to this group.~Breathing, relaxation exercises, birth stories and birth videos will be used to reduce fears of chlildbirt women.~Deepening and endorphin massage techniques will be given for labor pain. After the endorphin massage technique will be applied individually by the researcher, it will be applied by the couples and they will ask for repeating all exercises at home.~In the last week of the training, there will be a birth rehearsal with Hynobirthing methods with the partners.~The second meeting will take place when labor begins and after labor."
47986483|NCT03386942|DRUG|Farletuzumab Ecteribulin|Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
48142504|NCT04919668|BEHAVIORAL|Simulated grocery shopping exercise|Participants will click a link and simulate an online grocery shopping experience by selecting items for 12 grocery categories.
48142505|NCT01286311|BEHAVIORAL|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
48142506|NCT04784988|DRUG|EHL-FVIII|prophylaxis with EHL-FVIII targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
48142507|NCT04784988|DRUG|FVIII concentrate|standard prophylaxis with FVIII concentrate according to current guidelines
48142508|NCT01446640|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10\^6 MSCs per kg; intrathecal administration of up to 1x10\^6 MSCs per kg.
48142509|NCT01181232|DRUG|Zolpidem MR|oral
48142510|NCT01181232|DRUG|Zolpidem IR|oral
48142511|NCT02926118|DIETARY_SUPPLEMENT|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
48142512|NCT02926118|DIETARY_SUPPLEMENT|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
48142513|NCT01042184|DRUG|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
48142514|NCT01042184|DRUG|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
48142515|NCT01042184|DRUG|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
48142516|NCT05211596|BEHAVIORAL|Deaf Weight Wise intervention|The DWW intervention consists of groups of 5 subjects who meet together for 16 weeks, 2 hours each week. Group meetings will be held virtually on Zoom. A trained, deaf, ASL-fluent counselor will lead the sessions. Each session includes group sharing, problem solving, discussion of a weight management topic, and goal setting and action planning for the next week. A key principle of DWW is motivational interviewing, in which the counselor acts as a facilitator to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The maintenance phase starts immediately after the 16-week intervention, and consists of two meetings of the original group via Zoom; one at month 3 and one at month 6 of the maintenance period. Counselors also email participants bi-weekly to check in and provide additional support.
48142517|NCT06240351|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a Janus kinase (JAK) inhibitor
48142518|NCT03114215|DRUG|MD1003|capsules 100mg 3 times per day
48142519|NCT03114215|DRUG|Placebo oral capsule|capsules 100mg lactose 3 times per day
48142520|NCT05905549|PROCEDURE|extended pancreatic transection during laparoscopic pancreaticoduodenectomy|the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy
48142521|NCT03711279|DRUG|SHR-1210 plus Apatinib|SHR-1210 200 mg q3w+ Apatinib 500 mg qd
48142522|NCT03711279|DRUG|ADM plus IFO or IFO alone|ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
48142523|NCT00643409|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
47986484|NCT02721927|OTHER|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
47986485|NCT00697203|DRUG|Placebo|po daily for 12 weeks
48142524|NCT00643409|OTHER|placebo|placebo
48142525|NCT00643409|DRUG|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
48142526|NCT00643409|OTHER|placebo|placebo
48142527|NCT02077374|DRUG|IDN-6556|25 mg BID for 28 days
48142528|NCT02077374|OTHER|Placebo|Placebo BID for 28 Days
48142529|NCT02353507|DEVICE|Opticell Ag+|
48142530|NCT02353507|DEVICE|Aquacel Ag+|
48142531|NCT01499979|PROCEDURE|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
48142532|NCT00849446|DEVICE|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
48142533|NCT05149963|OTHER|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
48142534|NCT01122134|DRUG|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
48142535|NCT02262988|PROCEDURE|Total knee replacement|Total knee replacement (TKA)
48142536|NCT05569343|OTHER|No intervention|This is an observational study without any intervention
48142537|NCT05247307|BIOLOGICAL|convalescent plasma infusion covid 19|"Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts."
48142538|NCT06510413|DRUG|Loxoprofen Sodium Patches(reference product)|Single dose of one patch in each period; Apply for 24 hours each time
47986486|NCT00697203|DRUG|Pravastatin|40mg po daily for 12 weeks
47986487|NCT00697203|DRUG|Dalcetrapib|300mg po daily for 12 weeks
47986488|NCT00697203|DRUG|Dalcetrapib|600mg po daily for 12 weeks
47986489|NCT00697203|DRUG|Dalcetrapib|900mg po daily for 12 weeks
47986490|NCT01638806|PROCEDURE|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
47986491|NCT02137733|DRUG|Bisoprolol|
47986492|NCT02137733|DRUG|Carvedilol|
48142539|NCT06510413|DRUG|Loxoprofen Sodium Patches(test product )|Single dose of one patch in each period; Apply for 24 hours each time
48353020|NCT00032305|DRUG|Visilizumab|
48353021|NCT02951728|DRUG|Rituximab|
48353022|NCT02951728|DRUG|Cyclophosphamide|
48353023|NCT02951728|DRUG|Doxorubicin|
48353024|NCT02951728|DRUG|Vincristine|
48353025|NCT02951728|DRUG|Prednisone|
48353026|NCT02951728|DRUG|Decitabine|
48353027|NCT01512693|DRUG|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
48353028|NCT00910936|BEHAVIORAL|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
48353029|NCT04224350|DRUG|TacroBell SR cap.|"* Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment."
48353030|NCT04224350|DRUG|Tacrolimus cap.|"* Orally, twice a day in the morning and night~* After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 7\~12ng/ml for 0 to 3months and then at 5\~8ng/ml for 3 to 6months of study treatment."
47986493|NCT05797155|BEHAVIORAL|CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips|CoQuit App (Cognitive Dissonance Based Smoking Cessation) Use of the CoQuit app, completion of cognitive dissonance activities, sharing of videos with online group, and providing support to other group members
48142540|NCT03086226|DRUG|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
48142541|NCT03086226|DRUG|Itraconazole|This will be the active comparator
48142542|NCT05995691|DRUG|ABP 501|SC injection
48353031|NCT03446313|BEHAVIORAL|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
48353032|NCT01834638|DRUG|ABT-126|capsule(s)
48142543|NCT05995691|DRUG|Adalimumab|SC injection
48142544|NCT02488798|PROCEDURE|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
48353033|NCT06118944|DEVICE|ICB00 IOL|Bilateral implantation of ICB00 IOL
48353034|NCT06118944|DEVICE|ZCB00 IOL|Bilateral implantation of ZCB00 IOL
48353035|NCT06118944|DEVICE|CNA0T0 IOL|Bilateral implantation of CNA0T0 IOL
48353036|NCT02296905|DRUG|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
47986494|NCT05797155|BEHAVIORAL|Tips for Smoking Cessation App|App containing daily tips for smoking cessation
48142545|NCT02488798|PROCEDURE|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
48142546|NCT02488798|PROCEDURE|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
47986495|NCT00310583|DRUG|Pregabalin|
47986496|NCT05156489|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28±4) and at visit 4 (day 56±4) into vestibule, following the IFU of the device.
48353037|NCT02296905|DRUG|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
48353038|NCT02005211|DRUG|AZD3293|Oral solution
48353039|NCT02005211|DRUG|Placebo|Oral solution
48353040|NCT03187210|DRUG|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
48353041|NCT03187210|DRUG|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
48353042|NCT02844322|DRUG|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
48353043|NCT02844322|DRUG|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
48353044|NCT01833026|DEVICE|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
48353045|NCT01833026|DRUG|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
48353046|NCT05212467|BEHAVIORAL|AIR-program|This is a guided self management program that is added on the treatment as usual.
48353047|NCT05212467|BEHAVIORAL|HUS Internet therapy|This is a guided self management program that is added on the treatment as usual.
48353048|NCT05212467|BEHAVIORAL|Treatment as usual|The patients receive routine care from their physician which may include drugs, visits or rehabilitation
48353049|NCT01512108|DRUG|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
48353050|NCT01512108|DRUG|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
48353051|NCT01902927|OTHER|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
48353052|NCT02809391|DEVICE|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
48353053|NCT02809391|DEVICE|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
48353054|NCT03709940|DRUG|MPH|Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
48353055|NCT00161746|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
48353056|NCT00667940|BEHAVIORAL|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
48353057|NCT01213849|DRUG|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
48663661|NCT01427673|PROCEDURE|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
48353058|NCT01213849|DRUG|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
48353059|NCT01213849|DRUG|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
48353060|NCT01213849|DRUG|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
48353061|NCT01665040|DEVICE|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
48663662|NCT05687344|DRUG|Nifedipine ER|Postpartum BP treatment to \<140/90 mmHg
48663663|NCT05709847|OTHER|Coffee|24 ounces of coffee will be consumed daily
48353062|NCT01738074|BIOLOGICAL|trivalent rotavirus genetic reassortment vaccine|
48353063|NCT01738074|BIOLOGICAL|Placebo|
48687989|NCT03076060|BEHAVIORAL|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
48687990|NCT03076060|BEHAVIORAL|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
48687991|NCT02429193|DRUG|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
47986497|NCT02003612|OTHER|Not applicable - observational study|No intervention exists as this is a retrospective observational study
48353064|NCT04317794|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
47986498|NCT00841087|DRUG|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
48142547|NCT06272526|OTHER|Internet Based Intervention - GUIDED|The experimental group participants will be in treatment through web-based intervention consisting of five to seven weeks. The intervention program will be offered to participants through the website https://kendikendineyardim.org, the online self-help platform in Turkey. Participants will be able to use the system with their e-mail addresses and passwords.The intervention consists of five modules consisting of behavioral, emotional and cognitive content. The modules include text, interactive forms, animated videos, audio recordings, and images. Participants in this arm will receive weekly feedback from guides via the platform's message sending feature.
48142548|NCT03887611|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
48353065|NCT03888976|PROCEDURE|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
48687992|NCT02429193|DRUG|Enzalutamide|Enzalutamide (160 mg/day p.o.)
47986499|NCT00841087|DRUG|insulin detemir|Injection subcutaneously at bedtime
47986500|NCT00841087|DRUG|insulin aspart|Injection subcutaneously immediately before each meal.
47986501|NCT04999150|PROCEDURE|Micro-Osteoperforations|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)"
47986502|NCT04999150|PROCEDURE|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)"
47986503|NCT01986660|DRUG|Ibuprofen Cream (SST-0225)|
47986504|NCT06071091|DEVICE|Intracranial stenting|"In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication."
47986505|NCT06071091|OTHER|Optimal medical care, without additional endovascular procedures|"The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~* Nursing~* Nursing care~* Symptomatic treatments: analgesics for example~* Systematic clinical monitoring and control imaging if necessary~* Rehabilitation if necessary)"
47986506|NCT06538337|RADIATION|External beam Radiotherapy|Five fractions of radiation therapy using adaptive planning and CT or MRI guidance (6 Gy per fraction) delivered once every other day excluding weekends and holidays
47986507|NCT05931939|PROCEDURE|Ileal Interposition|Bariatric surgery by laparoscopic Ileal Interposition
48142549|NCT04620642|BIOLOGICAL|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
48353066|NCT00478595|DRUG|Rimonabant|Tablet, oral administration
48353067|NCT00478595|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
48353068|NCT00478595|DRUG|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
48353069|NCT00177606|BEHAVIORAL|withdrawal of life sustaining treatments|
48353070|NCT04568434|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
48687993|NCT05151692|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
48687994|NCT05007197|BEHAVIORAL|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
48687995|NCT03211611|BEHAVIORAL|Questionnaire given to the two groups|"Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP"
47986508|NCT05931939|PROCEDURE|Traditional surgical technique|Bariatric surgery by laparoscopic traditional technique
48142550|NCT04864834|BIOLOGICAL|SOK583A1 (40 mg/mL)|IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
48142551|NCT04864834|BIOLOGICAL|Eylea EU (40 mg/mL)|IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
48142552|NCT03608436|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
48142553|NCT03608436|DRUG|Rocuronium Bromide|Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
48142554|NCT01056159|DRUG|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
48142555|NCT01056159|DRUG|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
48142556|NCT03152214|OTHER|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at \> 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
48142557|NCT03152214|OTHER|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
48142558|NCT02431767|BIOLOGICAL|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
48142559|NCT02431767|BIOLOGICAL|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
48142560|NCT02431767|BIOLOGICAL|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
48142561|NCT03105960|DRUG|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
48353071|NCT04568434|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
47986509|NCT06209645|DEVICE|tDCS (Transcranial Direct Current Stimulation)|The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.
48353072|NCT03797794|DEVICE|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
48353073|NCT03797794|DEVICE|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
48353074|NCT06362928|DEVICE|ATC System|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
48353075|NCT04849676|OTHER|visual neurofeedback|"Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity."
48353076|NCT02413086|PROCEDURE|Early-stage amputation|Individuals with DFU were given early-stage amputation.
48687996|NCT04169503|DRUG|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
48687997|NCT04052750|BEHAVIORAL|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
48687998|NCT01835977|DEVICE|Irreversible Electroporation (Nanoknife)|
48687999|NCT01878578|DRUG|Eslicarbazepine acetate|Tablets containing ESL 600 mg
48688000|NCT01878578|DRUG|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
48688001|NCT01878578|DRUG|Placebo|Tablets containing matching placebo
48353077|NCT02413086|PROCEDURE|Amputation|Individuals with DFU were given amputation.
48353078|NCT02413086|OTHER|External herbs chitosan|Wound was given external herbs chitosan after amputation.
48353079|NCT02413086|OTHER|Traditional gauze|Wound was given traditional gauze after amputation.
48663664|NCT01910454|BEHAVIORAL|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
48663665|NCT01910454|BEHAVIORAL|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
48663666|NCT05957627|PROCEDURE|Saleem's protocol|It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
48663667|NCT02383784|DIETARY_SUPPLEMENT|Low GI index diet|Low glycemic index diet
48663668|NCT02383784|DIETARY_SUPPLEMENT|High GI diet|High glycemic index diet
48353080|NCT04742140|DRUG|Magnesium sulfate|each patient injected 0.5ml in each TrPs of magnesium sulphate according to the treatment group by the same operator
48353081|NCT04742140|DRUG|Saline|each patient injected 0.5ml in each TrPs of saline according to the treatment group by the same operator
48353082|NCT05059184|OTHER|This is an observational cross-sectional study, there is no need for intervention|This is an observational cross-sectional study. There is no need for intervention
48353083|NCT02950311|DRUG|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
48142562|NCT03105960|DRUG|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
48353084|NCT02950311|OTHER|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
48353085|NCT04918069|DRUG|Capsaicin|Topical capsaicin ointment
48353086|NCT04918069|DRUG|Placebo|Topical placebo ointment
48353087|NCT06216769|DRUG|Rivaroxaban|"Those in the non-interrupted anticoagulation group, anticoagulation is continued regardless of atrial fibrillation recurrence.~Those in the pill-in-the POCKET anticoagulation group will receive direct oral anticoagulation only if they have atrial fibrillation recur over 6 hours."
48353088|NCT03773601|OTHER|Sleep Profiler|A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
48353089|NCT03773601|OTHER|PSQI|Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
48142563|NCT03200574|DIAGNOSTIC_TEST|4D Cardiac CT Scan|4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
48142564|NCT03200574|DEVICE|LivaNova Bioprothetic Aortic Valve Implant|Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
48142565|NCT01394835|DRUG|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
48353090|NCT03773601|OTHER|TQR|Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
48353091|NCT05807191|OTHER|Kangaroo care based on kangaroo care guide|Under the supervision of the researcher, a kangaroo care practice was applied to premature babies by their mothers based on the kangaroo care guide. This practice took 65 minutes. In addition, before the application, the kangaroo application information was explained to the mothers through a brochure.
48353092|NCT04594889|PROCEDURE|angioplasty|Balloon releasing a drug inflated in the target vessel
48353093|NCT01035216|DRUG|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
48142566|NCT01394835|DRUG|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
48663669|NCT00718185|PROCEDURE|Obtain blood specimens|Obtain blood samples at multiple timepoints.
48142567|NCT01394835|DRUG|AAT|Inhalation twice daily' 160mg
48142568|NCT05302115|DEVICE|S-ICD|Implantation of an S-ICD
48142569|NCT04751097|OTHER|CUSH Health Digital platform|Remote mobility monitoring and physiotherapy video app
48142570|NCT02196610|OTHER|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
48353094|NCT04173481|OTHER|Rood's Group|"ROOD'S sensory motor training~Brushing \& strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
48353095|NCT04173481|OTHER|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
48353096|NCT05084768|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|As mentioned previously
48353097|NCT00896662|OTHER|immunologic technique|immunologic technique
48353098|NCT00896662|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
48353099|NCT00896662|OTHER|pharmacological study|pharmacological study
48663670|NCT00492453|PROCEDURE|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
48663671|NCT03035747|PROCEDURE|conventional surgery|high ligation and stripping of incompetent saphenous veins
48142571|NCT03281928|DIETARY_SUPPLEMENT|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
48142572|NCT03281928|DIETARY_SUPPLEMENT|Placebo|Sodium without Potassium Citrate
48142573|NCT04158206|OTHER|Maternal voice|Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
48142574|NCT02413138|DRUG|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
48142575|NCT01528683|RADIATION|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
48142576|NCT05420584|PROCEDURE|Arterial chemoembolization|The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.
48142577|NCT05420584|DRUG|Tislelizumab Injection|Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.
48142578|NCT05420584|DRUG|XELOX|Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
48142579|NCT05420584|DIAGNOSTIC_TEST|Pelvic MRI|Pelvic MRI to evaluate efficacy
48142580|NCT05420584|PROCEDURE|Laparoscopic radical resection of rectal cancer|Surgical treatment for patients who meet the surgical conditions
48142581|NCT00986869|PROCEDURE|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
48353100|NCT01312285|DEVICE|Resonator device|low level magnetic fields
48353101|NCT03734133|OTHER|Foot insoles|Different foot insoles of different hardness
48353102|NCT03030261|DRUG|Elotuzumab|During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
48353103|NCT03030261|DRUG|Pomalidomide|During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
48663672|NCT03035747|PROCEDURE|endovenous laser ablation|endovenous laser ablation of incompetent saphenous veins
48663673|NCT03035747|PROCEDURE|sclerotherapy|ultrasound guided or catheter or or any other methods sclerotherapy of incompetent saphenous or varicose veins
48663674|NCT03035747|PROCEDURE|endovenous radiofrequency ablation|endovenous radiofrequency ablation of incompetent saphenous veins
48663675|NCT03035747|PROCEDURE|phlebectomy|hooks phlebectomy of varicose veins
48663676|NCT00811460|DRUG|Placebo|sc for 4 days
48353104|NCT03030261|DRUG|Dexamethasone|During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
48353105|NCT00794859|DRUG|Sorafenib|400mg twice daily
48353106|NCT04026646|PROCEDURE|Proprioceptive Neuromuscular Facilitation stretching exercise|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
48353107|NCT04026646|PROCEDURE|Static stretching exercise|Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
48353108|NCT02572089|DRUG|Naloxone|
48353109|NCT01406730|OTHER|exercise|16 week of periodized progressive running exercise 2-4 times/week
48353110|NCT02743546|DRUG|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
48353111|NCT02743546|DRUG|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
48353112|NCT05414175|DRUG|Mavacamten|Specified dose on specified days
48353113|NCT04363723|OTHER|Pulmonary Rehabilitation|Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
48353114|NCT00732472|DRUG|GSK573719|7 day repeat dose
48353115|NCT04474392|OTHER|N/A (Observational Study)|Observational study, no intervention will be administered.
48353116|NCT02518568|DRUG|V0355|Oral administration (2 tablets)
48353117|NCT02150291|DIETARY_SUPPLEMENT|Folic acid|
48353118|NCT02150291|DRUG|Neurobion|
48353119|NCT02150291|DRUG|placebo|
48353120|NCT04984070|DRUG|Oral Contraceptives, Combined|One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.
48353121|NCT04984070|DRUG|Metformin Pill|Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
48663677|NCT00811460|DRUG|taspoglutide|300micrograms/day sc for 2 days
48663678|NCT00811460|DRUG|taspoglutide|800 micrograms/day sc for 2 days
48663679|NCT02329808|PROCEDURE|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
48353122|NCT04984070|OTHER|lifestyle intervention|Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients
48353123|NCT03095157|DIETARY_SUPPLEMENT|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
48353124|NCT06364306|PROCEDURE|Robotically-assisted ventral hernia repair (RVHR)|"3 8mm robotic trocars are placed intraabdominally and the DaVinci Xi-robotic system is docked. Adhesiolysis from any adherent structures to the abdominal wall is performed. Incision of the lateral verge of the retromuscular space and retromuscular dissection. Superior and inferior cross-over to the contralateral retromuscular space and dissection of the hernia sac.~Unilateral or bilateral transversus abdominis release (TAR) is performed, if necessary. Running suture with absorbable barbed suture of the posterior rectus sheath and peritoneum, as appropriate. Synthetic retromuscular mesh placement with a mesh-size as large as the prepared surface allows. Closure of the anterior rectus sheath with absorbable barbed running suture. Port extraction, skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes."
48353125|NCT06364306|PROCEDURE|Open ventral hernia repair (OVHR)|Median laparotomy with a minimal length of the previous scar (in case of incisional hernia) and adhesiolysis is performed, where necessary, to liberate the abdominal wall and the ventral hernia from adhesions. Bilateral dissection of the posterior rectus sheath under visualisation and sparing of the epigastric vessels and neurovascular bundles. Closure of the posterior rectus sheath with a slowly-absorbable running suture. Indication for a uni- or bilateral TAR identical to the intervention group. Retromuscular synthetic mesh placement with a mesh-size as far as the prepared surface allows. Mesh fixation optional with either absorbable sutures to the posterior sheath or with glubran glue. Closure of the anterior rectus sheath with a slowly-absorbable running suture. Skin closure. Dressing from xyphoid to pubis and 6 lateral dressings for blinding purposes.
48663680|NCT01342666|DIETARY_SUPPLEMENT|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
48663681|NCT01342666|DIETARY_SUPPLEMENT|Cucumber consumption|Daily consumption of 300g of cucumber.
48663682|NCT02418091|BEHAVIORAL|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
48663683|NCT05438329|DRUG|DB-1305/BNT325|Administered Injection of Vein (I.V.)
48663684|NCT05438329|COMBINATION_PRODUCT|Pembrolizumab|Administered I.V.
48663685|NCT05438329|DRUG|BNT327|Administered I.V.
48663686|NCT00009178|DRUG|Fluoxetine|
48663687|NCT00009178|BEHAVIORAL|Guided Self-Help|
48663688|NCT02257684|DRUG|pegcrisantaspase|
48663689|NCT00006167|DRUG|oxandrolone|
48663690|NCT00006167|BEHAVIORAL|Progressive Resistance Training|
48663691|NCT00441025|DRUG|Alemtuzumab|
48353126|NCT01392014|DRUG|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
48353127|NCT01392014|DRUG|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
48663692|NCT04339062|DRUG|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
47986510|NCT06209645|DEVICE|tACS (Transcranial Alternating Current Stimulation)|The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.
48663693|NCT04339062|DRUG|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
48663694|NCT04339062|DRUG|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
48663695|NCT04339062|DRUG|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
48663696|NCT05549544|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
48663697|NCT05549544|DEVICE|Biventricular pacing|Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
48663698|NCT06408376|PROCEDURE|Physiological cord clamping|Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation \>85% and HR\>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.
48663699|NCT04204824|OTHER|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
48663700|NCT03703557|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
48663701|NCT03703557|DIAGNOSTIC_TEST|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
48663702|NCT06092437|OTHER|Urine sodium guided diuretic algorithm|Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol/L is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
48663703|NCT06092437|OTHER|Usual care|Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
48663704|NCT00020748|DRUG|epirubicin hydrochloride|
48663705|NCT00020748|DRUG|irinotecan hydrochloride|
48663706|NCT01659060|OTHER|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
48663707|NCT01659060|OTHER|Placebo Chocolate|Placebo intervention
48663708|NCT00222820|DRUG|escitalopram|
48663709|NCT00222820|BEHAVIORAL|Interpersonal Psychotherapy|
48663710|NCT05900752|DIETARY_SUPPLEMENT|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
48663711|NCT05900752|DIETARY_SUPPLEMENT|Placebo product|consume one sachet of the assigned product, once a day after meals.
48663712|NCT06341335|DRUG|cadonilimab|iv, q3w
48353128|NCT03988790|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
48353129|NCT05567679|DRUG|Tazverik|Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
48353130|NCT06500234|DRUG|Megestrol Acetate and olanzapine|megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday
48663713|NCT06341335|DRUG|pulocimab|iv, q3w
48663714|NCT06341335|DRUG|paclitaxel|iv, q3w
48663715|NCT06341335|DRUG|placebo|iv, q3w
48663716|NCT03896191|PROCEDURE|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
48663717|NCT03896191|OTHER|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
48663718|NCT00906763|DIETARY_SUPPLEMENT|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
48663719|NCT02354521|OTHER|NO INTERVENTIONS|
47986511|NCT03559465|PROCEDURE|skin biopsy|"A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.~In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy."
47986512|NCT03559465|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte
47986513|NCT00469560|DRUG|Deferasirox|
47986514|NCT06391164|DRUG|XC243 25 mg|Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
47986515|NCT06391164|DRUG|XC243 50 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
47986516|NCT06391164|DRUG|XC243 75 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
48663720|NCT04337047|OTHER|questionnaire assesment|questionnaire assesment
48663721|NCT00529295|DRUG|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
48663722|NCT03372616|DIAGNOSTIC_TEST|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
47986517|NCT06391164|DRUG|Placebo|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
47986518|NCT01969240|OTHER|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
47986519|NCT04860791|OTHER|questionnaires|Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
48353131|NCT06500234|DRUG|Starch powder 50 mg|Starch powder 50 mg, oral, everyday
48663723|NCT03372616|DIAGNOSTIC_TEST|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
48663724|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
48663725|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor \[AtCor Medical, Australia\], PulsePen \[DiaTecne SRL, Italy\], and Mobil-O-Graph \[IEM, Germany\] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
48663726|NCT05769114|PROCEDURE|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
48353132|NCT05822284|DIAGNOSTIC_TEST|NGS and ctDNA-MRD detection|NGS and ctDNA-MRD detection
48663727|NCT05004415|DRUG|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
48663728|NCT02009566|RADIATION|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
48353133|NCT02514213|BIOLOGICAL|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
48663729|NCT04856527|BEHAVIORAL|Physical therapist support|Participants will receive physical therapist support to reduce postural sway variability while completing an upper limb precision aiming task in virtual reality.
48353134|NCT02514213|BIOLOGICAL|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
48353135|NCT02514213|BIOLOGICAL|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
48353136|NCT02514213|BIOLOGICAL|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
48353137|NCT02514213|DEVICE|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
48353138|NCT03185169|COMBINATION_PRODUCT|Replens and coconut oil|
48353139|NCT05834179|OTHER|cold endotracheal tube|patients who were intubated with an ETT which kept in the fridge.
48353140|NCT06041230|DEVICE|Ozone Generator|Ultrasound guided ozone therapy
48353141|NCT06041230|DEVICE|Extracorporeal shock wave therapy device|Extracorporeal shock wave therapy device
48504717|NCT02609776|DRUG|Amivantamab|The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
48663730|NCT04417530|DRUG|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
48353142|NCT02170558|DEVICE|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
48663731|NCT04417530|DEVICE|Suprachoroidal Microinjector|Suprachoroidal Injection Device
48663732|NCT04417530|DEVICE|PDT Laser|Laser Administration
48663733|NCT05358327|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
48663734|NCT03136055|DRUG|Pembrolizumab|Given Intravenously (IV)
48663735|NCT03136055|DRUG|Irinotecan|Given IV
48663736|NCT03136055|DRUG|Paclitaxel|Given IV
48663737|NCT02328495|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
48663738|NCT02328495|OTHER|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
48663739|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 3|One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
48663740|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 2|One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
48663741|NCT04138056|BIOLOGICAL|Boostrix-ex-US|One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
48663742|NCT04138056|BIOLOGICAL|Boostrix-US|One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
48663743|NCT04138056|DRUG|Placebo|One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
48663744|NCT03518021|DRUG|Naloxone, intranasal|"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
48663745|NCT03518021|DRUG|placebo, intranasal|"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
48663746|NCT03518021|DRUG|Naloxone, intramuscular|Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
48663747|NCT03518021|DRUG|placebo, intramuscular|Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
48663748|NCT02526914|DRUG|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
48663749|NCT02526914|DRUG|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
48663750|NCT02526914|DRUG|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
48663751|NCT01655277|PROCEDURE|Ultrasound Guided Adductor Canal Block|
48663752|NCT01655277|PROCEDURE|Ultrasound Guided Femoral Nerve Block|
48663753|NCT00287560|DRUG|propofol (drug)|
48663754|NCT03212729|RADIATION|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
48688002|NCT05527782|DRUG|modified TPF|modified TPF: modified docetaxel-cisplatin-fluorouracil followed by concurrent chemoradiotherapy
48353143|NCT02111954|DIAGNOSTIC_TEST|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
48353144|NCT04673630|BIOLOGICAL|Tezepelumab|Single dose subcutaneous injection
48353145|NCT00821756|BEHAVIORAL|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
48353146|NCT01945190|DEVICE|Electroacupuncture|
48353147|NCT05018273|BIOLOGICAL|VB10.NEO|The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
48353148|NCT05437692|DRUG|zimberelimab combined With concurrent radiotherapy and chemotherapy|zimberelimab: 240 mg Q2W Intravenous drip，The maximum duration of medication shall not exceed one years; chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min; Radiotherapy: intensity modulated radiation therapy (IMRT) was used for external irradiation. The total dose of pelvic cavity and lymph drainage planning target area (PTV) was 45-50 gy/25-28f. The metastatic lymph nodes should be able to supplement or synchronously push 10-15 Gy; The internal irradiation was started within 2 weeks after the end of external irradiation treatment. The image-guided three-dimensional brachytherapy was used, and 30-40gy was added to make the total dose of point a reach 80-85 Gy, twice a week, 5-6gy each time. All radiotherapy was completed within 8 weeks.
48353149|NCT00010244|RADIATION|radiation therapy|
48353150|NCT04189380|OTHER|HLQ (Health literacy questionnaire)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
48353151|NCT04189380|OTHER|MoCA (Montreal Cognitive Assessment)|each patient complete survey and self-assessment questionnaire before or after his medical consultation
48367534|NCT04196231|DRUG|Basal Bolus|Patients in this arm will continue the basal insulin (glargine, degludec or glargine-300) used before the randomization. The insulin titration will be guided by the medical staff, according to the following algorithm: adding 2 units of basal insulin for prebreakfast plasma glucose \>130 mg/dL; no dose change for prebreakfast plasma glucose of 80-130 mg/dL; reducing 2 units of basal insulin for prebreakfast plasma glucose \< 80 mg/dL. The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day) and will be titrated twice a week until achieving pre-prandial glucose values ranging from 80-130 mg/dL.
48504718|NCT02609776|DRUG|Amivantamab|Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
48504719|NCT02609776|DRUG|Lazertinib|Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
47986520|NCT03729856|BEHAVIORAL|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
47986521|NCT03729856|OTHER|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
47986522|NCT03729856|OTHER|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
48504720|NCT02609776|DRUG|Carboplatin|Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
48504721|NCT02609776|DRUG|Pemetrexed|Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
48504722|NCT03106454|DRUG|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
48504723|NCT03106454|DRUG|Norethindrone|Norethindrone 1.05mg
48504724|NCT02077218|PROCEDURE|computed tomography|Undergo cardiac CT
48504725|NCT02077218|OTHER|cytology specimen collection procedure|Undergo collection of blood samples
48504726|NCT02077218|OTHER|laboratory biomarker analysis|Correlative studies
47986523|NCT05570565|PROCEDURE|Erector spinae plane block|ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process
48367535|NCT01967082|BEHAVIORAL|APPSPIRE|Given APPSPIRE app
48504727|NCT02077218|OTHER|questionnaire administration|Ancillary studies
47986524|NCT05570565|PROCEDURE|local field block|infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
48504728|NCT00001474|DRUG|Interleukin-2|
48504729|NCT03058432|RADIATION|Radiotherapy alone|
48504730|NCT03058432|RADIATION|Concurrent chemoradiotherapy|
48504731|NCT06071169|OTHER|progressive relaxation exercise|Nurses will be asked to perform relaxation exercises 3 days a week for 5 weeks, 20 minutes in each practice.
48504732|NCT06262802|DEVICE|Active decompression|Intracystic active negative pressure
48504733|NCT02612259|DIETARY_SUPPLEMENT|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
48504734|NCT02612259|OTHER|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
48504735|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
48504736|NCT05980663|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
48504737|NCT00313339|DRUG|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
48688003|NCT05527782|OTHER|Quality of life assessment (QoL)|Quality of life assessment with questionnaires: EORTC QLQ-C30 and QLQ H\&N-35
48353152|NCT02845115|DEVICE|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
48504738|NCT05193643|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues.
48504739|NCT00960635|DRUG|1,25-dihydroxy-vitamin D3 (calcitriol)|
48504740|NCT00960635|DRUG|placebo|pill without agent
47986525|NCT05031533|RADIATION|Dose-Painting Radiation|"Radiation therapy:~1. Delineation of target area:~   The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~2. Exposure dose:~1) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
47986526|NCT05821842|DEVICE|Sonu|Acoustic energy delivery
48353153|NCT02845115|DEVICE|optimized implantation with laser velocimetry|
47986527|NCT03518073|DRUG|Zagotenemab|Administered IV
47986528|NCT03518073|DRUG|Placebo|Administered IV
47986529|NCT02033122|OTHER|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
48353154|NCT05581927|DEVICE|modified Whole-Body Hypothermia|patients were allocated to modified Whole-Body Hypothermia with normal base excess and blood pressure
48353155|NCT05581927|DEVICE|standard Whole-Body Hypothermia|patients were allocated to standard Whole-Body Hypothermia
48353156|NCT02258191|DEVICE|telemonitoring|
48353157|NCT02258191|DEVICE|sham telemonitoring|
48353158|NCT02098915|DRUG|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
48353159|NCT02098915|OTHER|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
47986530|NCT02033122|OTHER|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
47986531|NCT01879501|BEHAVIORAL|Low Vision Self-Management Program|The program has been describe above.
47986532|NCT00541073|DIETARY_SUPPLEMENT|vitamin B12|
47986533|NCT00541073|DRUG|cisplatin|
47986534|NCT00541073|DRUG|pemetrexed disodium|
47986535|NCT00541073|GENETIC|gene expression analysis|
48353160|NCT04990531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
48353161|NCT04990531|DIAGNOSTIC_TEST|Blood sample|Blood sample for diagnostic testing
48663755|NCT03212729|PROCEDURE|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
48663756|NCT01511302|DRUG|RNS60|RNS60, 2ml, nebulized twice daily.
48663757|NCT01511302|DRUG|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
48663758|NCT01511302|DRUG|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
48663759|NCT05387746|BEHAVIORAL|Caring Science, Mindful Practice and Reiki Training|Participants will complete a) 4 week internet-based course on Caring Science Mindful Practice and b) 12 hour Reiki training. The participants will also complete online post-training survey with the same questions included in pre-training survey.
48663760|NCT04636996|OTHER|artificial intelligence assisted follow-up|We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
48663761|NCT00931281|DRUG|ABT-450|capsules, QD or BID, 14 days, ascending doses
48663762|NCT00931281|DRUG|ritonavir|capsules, QD or BID, 14 days, ascending doses
48663763|NCT00931281|DRUG|Placebo for ABT-450|capsule, QD or BID, 14 days
48663764|NCT00931281|DRUG|Placebo for ritonavir|capsule, QD or BID, 14 days
48663765|NCT05826509|OTHER|Surgery alone|Radical prostatectomy with lymph node dissection will be performed.
48663766|NCT05826509|DRUG|Peri-operative darolutamide + surgery.|"Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment."
48663767|NCT01912014|BEHAVIORAL|Psychosocial support and counselling|
48663768|NCT02865174|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
48663769|NCT02865174|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
48663770|NCT02865174|DRUG|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
48663771|NCT00760760|DRUG|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
48663772|NCT00760760|DRUG|control|equivalent amount of fat as butter
48663773|NCT02321475|DRUG|EGb761®|
48663774|NCT05853965|DRUG|Belantamab mafodotin, Venetoclax|Belantamab mafodotin (IV) Venetoclax (PO)
48663775|NCT02692573|OTHER|positioning|prone positioning for the initial 5 minutes of life
47986536|NCT00541073|OTHER|laboratory biomarker analysis|
47986537|NCT00541073|OTHER|pharmacological study|
47986538|NCT05933512|BIOLOGICAL|SCTV01E-2|intramuscular injection
47986539|NCT05933512|BIOLOGICAL|SCTV01E|intramuscular injection
47986540|NCT04577118|DEVICE|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
47986541|NCT02536352|DRUG|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
48367536|NCT01967082|BEHAVIORAL|Focus Group|Attend focus group
48663776|NCT02692573|OTHER|positioning|supine positioning for the initial 5 minutes of life
48663777|NCT03038620|DRUG|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
48688004|NCT00641238|DEVICE|Radiofrequency ablation|Radiofrequency ablation
48663778|NCT03038620|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
48663779|NCT04609982|DEVICE|ear plugs|giving half of the patients ear plugs
48663780|NCT01668680|DRUG|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
48663781|NCT06442982|DEVICE|insole-type gait analyzer|Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined.
48663782|NCT00822094|DRUG|CPX-351|
48353162|NCT04672317|DRUG|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
48353163|NCT06338813|DEVICE|Digital Manometry|"The Compass Lumbar Puncture Pressure Transducer (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer. After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted."
48353164|NCT04261218|DRUG|tomivosertib|Tomivoserib is supplied as a 100 mg capsule, to be taken orally.
48353165|NCT04261218|DRUG|paclitaxel|Taken weekly according to the current market label in combination with experimental tomivosertib.
48663783|NCT00822094|DRUG|Intensive Salvage Therapy|
48663784|NCT06537388|PROCEDURE|Ventilation type|Type of ventilation used during the EBUS procedure, either HFJV or IPPV
48663785|NCT00619775|DEVICE|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
48663786|NCT03594708|DIETARY_SUPPLEMENT|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
48663787|NCT03594708|DIETARY_SUPPLEMENT|Placebo supplement|rice starch, light olive oil, vegetable oil
48663788|NCT00251992|DRUG|Esomeprazole|
48663789|NCT00953628|DRUG|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
48663790|NCT00953628|DRUG|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
47986542|NCT02536352|DIETARY_SUPPLEMENT|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
47986543|NCT06366867|DEVICE|VibrantMinds|VibrantMindVibrantMinds offers five tablet games targeting cognitive stimulation in older adults: Whack-A-Mole, Word Search, Bejeweled, Mahjong Solitaire, Memory Game, and Glenrose Grocery Game (GGG). These games vary from nostalgic (e.g., Mahjong Solitaire) to leisure-oriented (e.g., Bejeweled), aiming to blend fun with cognitive exercises. Especially designed for ease of use, they cater to older individuals, including those with dementia, gradually increasing in difficulty to match player skill levels. The GGG stands out by integrating game design with everyday cognitive tasks, offering a practical simulation of grocery shopping. Developed with older adult input, VibrantMinds aims to enhance cognitive health in seniors through engaging, meaningful gameplay, supporting its clinical trial's focus on cognitive wellness in the aging.
47986544|NCT05682781|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Oral Nutritional Supplement
47986545|NCT05682781|OTHER|Dietary Counseling|Dietary Counseling
47986546|NCT02842918|PROCEDURE|Spinal Manual Therapy|
47986547|NCT02842918|PROCEDURE|Spinal Range of Motion|
47986548|NCT03401424|PROCEDURE|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
48663791|NCT03524599|OTHER|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
47986549|NCT03401424|PROCEDURE|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
48353166|NCT05956028|PROCEDURE|Ultrasound guided SCV cannulation|receive ultrasound guided SCV cannulation
48353167|NCT05956028|PROCEDURE|Ultrasound guided IJV cannulation|receive ultrasound guided IJV cannulation
48367537|NCT01967082|OTHER|Survey Administration|Complete survey
48367538|NCT05607927|PROCEDURE|Parks surgery|Parks surgery
48367539|NCT05607927|PROCEDURE|PE-Bacon surgery|PE-Bacon surgery
48367540|NCT03014700|BIOLOGICAL|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
48367541|NCT03014700|BIOLOGICAL|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
48663792|NCT03817684|DRUG|BPN14770|Drug BPN14770
48663793|NCT03817684|DRUG|Placebo|Placebo
48663794|NCT04881760|DRUG|LY3437943|Administered SC
48663795|NCT04881760|DRUG|Placebo|Administered SC
48663796|NCT01852981|BEHAVIORAL|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
48142582|NCT03696056|BEHAVIORAL|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
48142583|NCT03696056|BEHAVIORAL|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
48142584|NCT03132636|DRUG|cemiplimab|Regimen as per protocol
48142585|NCT03177226|DEVICE|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
48142586|NCT03177226|DEVICE|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
48142587|NCT05491291|OTHER|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
48142588|NCT03230448|OTHER|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
48504741|NCT03953989|DRUG|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
48504742|NCT05427201|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique designed to alter network function
48504743|NCT05427201|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
48663797|NCT01852981|BEHAVIORAL|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
48663798|NCT04955288|PROCEDURE|Aortic balloon assisted resuscitation|On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
48663799|NCT04955288|PROCEDURE|Traditional cardiopulmonary resuscitation|"Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds."
48663800|NCT04955288|PROCEDURE|Esophageal cooling|The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
48663801|NCT04955288|PROCEDURE|traditional cooling|The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
47986550|NCT04671225|BEHAVIORAL|Groups Psychoeducation|Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
48142589|NCT01005693|OTHER|questionnaire administration|
48142590|NCT01005693|PROCEDURE|cognitive assessment|
48142591|NCT01005693|PROCEDURE|examination|
48142592|NCT01005693|PROCEDURE|management of therapy complications|
48142593|NCT01929161|DRUG|Oxytocin|24 International Units
48142594|NCT01929161|DRUG|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
48142595|NCT01929161|BEHAVIORAL|Lovingkindness Meditation|
48142596|NCT01929161|BEHAVIORAL|Mindfulness Meditation|
48142597|NCT05494658|DIETARY_SUPPLEMENT|BCAA|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
48142598|NCT05494658|DIETARY_SUPPLEMENT|water|600ml water was consumed by patients 2-4h before suegery.
48353168|NCT02611934|PROCEDURE|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
48353169|NCT02789800|BEHAVIORAL|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups(FMG) related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
48353170|NCT03261037|OTHER|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
48353171|NCT03261037|OTHER|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
48353172|NCT03261037|OTHER|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
48353173|NCT01789099|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
48353174|NCT05484726|OTHER|perioral sensory motor stimulation|"Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times"
48353175|NCT02971072|PROCEDURE|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
48353176|NCT02971072|OTHER|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
48353177|NCT01962116|DRUG|Citrate 4%|
48353178|NCT01962116|DRUG|unfractionated heparin|
48353179|NCT03407027|DRUG|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
48353180|NCT03407027|DRUG|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
48353181|NCT03407027|DRUG|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
48353182|NCT06359886|PROCEDURE|B-Lynch Transverse Compression Suture|closure of uterine and utero ovarian arteries bilaterally with one suture
48353183|NCT00906828|DRUG|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
48353184|NCT00906828|DRUG|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
48504744|NCT00237783|DRUG|dialysate sodium (140 mmol/L)|
47986551|NCT04671225|BEHAVIORAL|Waiting-list|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
47986552|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
48353185|NCT00906828|DRUG|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
48353186|NCT03160066|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
48353187|NCT03160066|DIETARY_SUPPLEMENT|Placebo|Placebo
48353188|NCT02336191|PROCEDURE|living donor liver transplantation|living donor liver transplantation
48353189|NCT02875782|BEHAVIORAL|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
48353190|NCT02875782|BEHAVIORAL|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
48353191|NCT03113799|DEVICE|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
48353192|NCT00364611|DRUG|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
48353193|NCT00364611|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
48367542|NCT04138758|DRUG|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
48504745|NCT00237783|DRUG|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
48504746|NCT01650701|DRUG|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
48504747|NCT01650701|DRUG|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
48353194|NCT00364611|DRUG|Trastuzumab|"* A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
48353195|NCT04700228|DRUG|Bupivacaine Hydrochloride|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
48353196|NCT04700228|DRUG|Dexmedetomidine|We are going to see the effects of dexmedetomidine as an adjunct to bupivacaine in caudal block. In first (control) group (group C) only bupivacaine will be given. Group BD1 patients will be given bupivacaine plus 1mcg/kg dexmedetomidine. Group BD2 patients will get bupivacaine plus 0.5mcg/kg dexmedetomidine. All the groups will be given a volume of 0.5ml/kg.
48353197|NCT03946644|DEVICE|EVLA with keeping of securuty distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
48353198|NCT03946644|DEVICE|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
48353199|NCT00408772|BIOLOGICAL|bevacizumab|
48353200|NCT00408772|DRUG|capecitabine|
48353201|NCT00408772|DRUG|oxaliplatin|
48353202|NCT00408772|PROCEDURE|conventional surgery|
48353203|NCT00408772|PROCEDURE|neoadjuvant therapy|
48353204|NCT00408772|PROCEDURE|radiofrequency ablation|
48353205|NCT05399589|COMBINATION_PRODUCT|use on1 abutment instead of healing cap in test group|We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.
48353206|NCT05399589|COMBINATION_PRODUCT|use healing cap in control group|use healing cap in control group
48353207|NCT01782612|PROCEDURE|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
48353208|NCT01782612|PROCEDURE|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
48353209|NCT00564915|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
48353210|NCT05813405|OTHER|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors|Experimental: Antihypertensive therapy Hypotension and improved ventilation treatment Intervention treatment for other risk factors
48353211|NCT01886092|DEVICE|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
48504748|NCT01650701|DRUG|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
48504749|NCT01650701|DRUG|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
48504750|NCT01650701|DRUG|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
48353212|NCT01886092|DEVICE|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
48353213|NCT01886092|DEVICE|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
48353214|NCT01886092|DEVICE|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
48353215|NCT03644875|DEVICE|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
48353216|NCT04451694|OTHER|nutritional intervention|nutritional evaluation and intervention and orientation towards adapted care establishment
48353217|NCT00619216|DRUG|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
48663802|NCT03639402|BEHAVIORAL|Health education classes|Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
48663803|NCT04821167|PROCEDURE|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
48353218|NCT05091918|DEVICE|MotionSense|MotionSense Wearable: Remote patient monitoring
48353219|NCT04454840|BIOLOGICAL|Plasma from healthy young people treatment + Riluzole|Intravenous injection: the subjects received 400ml of intravenous plasma infusion every 2 weeks, with a continuous course of 2 treatments and a course of treatment every 3 months. The course of treatment lasted 10 months, with a total of 3200ml of plasma infusion.
48353220|NCT04454840|DRUG|Riluzole|The basic treatment is Riluzole 25\~50mg twice daily
48353221|NCT01406366|BEHAVIORAL|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
48142599|NCT05670457|DRUG|Diosmin|diosmin 500 mg twice daily
48142600|NCT05227898|DEVICE|Device: Attune™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
48142601|NCT05227898|DEVICE|Device: Cerena™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
48353222|NCT01406366|BEHAVIORAL|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
48353223|NCT02619929|DRUG|Vinorelbine oral|
48353224|NCT04488601|DRUG|Rapamycin|Rapamycin in 2 different dosage forms.
48353225|NCT04488601|DRUG|Placebo|Placebo capsules
48353226|NCT00827125|DEVICE|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
48353227|NCT02061163|DEVICE|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
48353228|NCT02061163|DRUG|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
48353229|NCT03894267|DEVICE|Cutimed Siltec Heel and Sacrum dressing|The dressing has been developed to facilitate exudate management in the treatment of wounds. Newly formed tissue enjoys optimal protection under a moist environment. The foam core with super-absorbers ensures reliable absorption in slightly to heavily exuding wounds. This core has an excellent retention capacity, even under compression. Hydrogen bridges bind the water so securely that, even when subject to pressure, the water is not released. Vertical absorption through the polyurethane foam and the hydro- phobic wound contact layer minimizes the risk of macerations in the peri-ulcer skin.
48353230|NCT02396264|OTHER|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
48504751|NCT05436262|DEVICE|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
48142602|NCT06094166|DIAGNOSTIC_TEST|MRI|Quantitative imaging MR parameters
48142603|NCT05837806|DRUG|tislelizumab+disitamab-vedotin|patients in group will receive 3 cycles of tislelizumab 200 mg in combination with disitamab-vedotin 120 mg intravenously.
48142604|NCT02747537|DRUG|Sorafenib|
48142605|NCT02747537|DRUG|Irinotecan|
48142606|NCT02302157|BIOLOGICAL|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
48142607|NCT06234020|OTHER|To see the frequency of vertebrospinal anomalies in patients presenting with Anorectal Malformation|The patients presenting with anorectal malformation go through x-ray. We will get the reporting of x-ray done to see the vertebral anomalies and the patients presenting with fecal/urinary incontinence will go through MRI for spinal anomalies.
48142608|NCT04918394|OTHER|Questionnaire of Mold / moisture exposure|"Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor"
48142609|NCT06509191|DRUG|Intervention 1|Melatonin 5mg/day
48142610|NCT06509191|DRUG|Intervention 2|Melatonin 8 mg/day
48142611|NCT06509191|OTHER|Control|Placebo
48142612|NCT03865732|DRUG|Ganaxolone|active drug
48142613|NCT03865732|DRUG|Placebo|inactive
48142614|NCT04111991|BEHAVIORAL|Usual Care|Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need
48353231|NCT02396264|OTHER|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
48367543|NCT04138758|DRUG|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
48663804|NCT03014804|BIOLOGICAL|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
48663805|NCT03014804|OTHER|Laboratory Biomarker Analysis|Correlative studies
48663806|NCT03014804|BIOLOGICAL|Nivolumab|Given IV
48663807|NCT03014804|OTHER|Quality-of-Life Assessment|Ancillary studies
47986553|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
48142615|NCT04111991|BEHAVIORAL|C-STEP (Cognitive Behavioral Therapy)|The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
48142616|NCT03863405|DRUG|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
48142617|NCT03863405|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
48142618|NCT03863405|DRUG|Placebo Oral Tablet|oral tablet
48142619|NCT02697552|DRUG|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly \[BIW\].
48142620|NCT03196869|DEVICE|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
48142621|NCT03196869|DEVICE|Routine intravenous drip|Routine intravenous drip-chemotherap
48142622|NCT03196869|DRUG|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
48142623|NCT03196869|DRUG|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
48142624|NCT03196869|DRUG|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
48663808|NCT03014804|OTHER|Questionnaire Administration|Ancillary studies
47986554|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
48142625|NCT03196869|DRUG|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
48353232|NCT04830657|OTHER|Distant reiki|In order to determine the sample size of the study, it is planned to study with a total of 62 patients, including at least 31 patients in each group, in the power analysis based on the statistics of the statistician and previous studies. The remote reiki group will be given remote reiki 3 times a week for 4 weeks by the researcher who has a reiki application certificate. Remote reiki sessions will be performed by the reiki practitioner the night before the hemodialysis day of the patient, and the session duration will take approximately 36-40 minutes. After the individuals receive 12 sessions of remote reiki (1 month later), the questionnaire will be filled in for the second measurement. In order to determine whether reiki has an effect in the long term, 4 weeks (1 month) after the second measurement, the questionnaire for the third measurement will be completed and the research will be completed.
48663809|NCT02115529|DRUG|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
48663810|NCT02115529|DRUG|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
48663811|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
47986555|NCT02393547|DRUG|Varenicline|All subjects receive Varenicline
48663812|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP
47986556|NCT02393547|DRUG|Lorcaserin|All subjects receive Lorcaserin
47986557|NCT05718258|DRUG|Venglustat (GZ402671)|"Pharmaceutical form: tablet~Route of administration: oral"
47986558|NCT01521455|DRUG|HCP0910|250/50, BID for 2 weeks
47986559|NCT01521455|DRUG|Seretide Diskus|250/50, BID for 2 weeks
47986560|NCT00876629|DEVICE|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
48142626|NCT03196869|RADIATION|intensity-modulated radiation therapy|control group is similar to Experimental group
48142627|NCT02170532|DRUG|levalbuterol|0.5 ml. levalbuterol
48142628|NCT02170532|DRUG|saline|0.5ml saline
48142629|NCT02170532|OTHER|levalbuterol MDI|
48142630|NCT02170532|DEVICE|breath actuated nebulizer|
48142631|NCT02170532|DEVICE|aerochamber max|
48142632|NCT02170532|DRUG|ipratroprium|
48142633|NCT04913506|OTHER|Group Mirror|For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)
48142634|NCT04913506|DEVICE|Group NMES|NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
48142635|NCT04913506|OTHER|Group Mirror+NMES|The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
48353233|NCT03837821|DRUG|Abemaciclib|Abemaciclib 200 mg oral, every 12 hours
48663813|NCT04510207|BIOLOGICAL|Placebo|The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
48663814|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort|Subjects will have up to 9 DOSI scans at 6 different time points during the course of their neoadjuvant chemotherapy. The time course of chemotherapy may vary between 3-9 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 6 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-60 minutes, although scans at infusion time point will take longer in total due to repeated or continuous measurements.
48663815|NCT02510456|DEVICE|Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort|Subjects will have 1 DOSI scan at baseline. The DOSI scan will take about 30-60 minutes.
48663816|NCT02190500|OTHER|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
48663817|NCT01233544|PROCEDURE|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
48663818|NCT06075784|OTHER|reiki|placebo reiki
48663819|NCT06405633|DRUG|WVE-006|RNA editing oligonucelotide
48663820|NCT00030264|DRUG|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
48663821|NCT00030264|DRUG|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
48663822|NCT00741377|DRUG|BHQ880|
48663823|NCT00741377|DRUG|Zoledronic acid|
47986561|NCT01479153|PROCEDURE|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
47986562|NCT01455142|DRUG|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
47986563|NCT05454956|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
47986564|NCT05454956|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
47986565|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
47986566|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
47986567|NCT05838885|DRUG|rhGH|rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
48353234|NCT03990051|DRUG|Pro-ocular™ topical gel|Topical gel for forehead dermal application
47986568|NCT05838885|DRUG|rhGH|rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
48353235|NCT03990051|DRUG|Placebo topical gel|Topical gel for forehead dermal application
47986569|NCT05554757|DEVICE|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
48353236|NCT01731756|OTHER|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
48353237|NCT01731756|DRUG|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
48353238|NCT01731756|OTHER|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
47986570|NCT05554757|DEVICE|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
47986571|NCT03833973|BEHAVIORAL|Overtraining Monitoring|Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
47986572|NCT04535960|DRUG|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
48353239|NCT05319886|DRUG|Anlotinib and Penpulimab|Anlotinib 12mg, po, qd, with 2 weeks off for 1 week. Penpulimab 200mg, ivgtt, q3w. Efficacy was evaluated every 2 cycles. Efficacy evaluation was performed every 2 cycles during the follow-up study. Patients with disease control (CR+PR+SD) and tolerable adverse reactions continued to take the drug until the investigator considered that the patient was not suitable to continue the drug or the efficacy was evaluated as PD. Safety evaluations were performed concurrently with the dosing period. No other antitumor therapy can be administered until PD.
48504752|NCT05436262|BEHAVIORAL|At-home therapy|"Participants are assigned to groups where the participants will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that the participants are finger tapping in time with the flashing cue, using the imagery strategies identified during participants' previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
48504753|NCT00763061|DRUG|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo \& 9 PM
47986573|NCT04535960|DRUG|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
48353240|NCT06352502|DRUG|Furmonertinib|Patients treated with Furmonertinib mesilate tablets orally
48353241|NCT02339454|DEVICE|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
48353242|NCT02339454|DEVICE|Placebo group|Placebo Applicator
48353243|NCT04493489|DRUG|Propranolol Hydrochloride|Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
48353244|NCT04493489|DRUG|BCG|Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
48353245|NCT04883099|DEVICE|APIOC for Presbyopia and APIOC for Presbyopia for Astigmatism|Contact Lenses for Presbyopia
48353246|NCT03628040|DRUG|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
48504754|NCT00763061|DRUG|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM \& 9 PM
48353247|NCT03628040|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane
48504755|NCT03573310|DRUG|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
48504756|NCT05778487|DIETARY_SUPPLEMENT|Gatorade Thirst Quencher|Gatorade Thirst Quencher, 710ml (45g of carbohydrates, 6.3% carbohydrates, 25.4kcal/100ml)
48142636|NCT06461585|OTHER|Sprint interval training|Group A the Interventional group will receive SIT . Group A will perform SIT 3 times a week for 30-second sprints on a cycle ergometer with 4 minutes of rest between each sprint, complete session will be for 30 -40 minutes. Group B will receive the aerobic exercise. Group B will perform the aerobic exercise for 30-40 minutes of moderate-intensity continuous exercise on a treadmill and stationary cycle
48142637|NCT03929471|OTHER|Target weight correction protocol|The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
48353248|NCT05690711|DRUG|HRS8179|HRS8179 injection
48353249|NCT05690711|DRUG|Placebo|physiological saline
48353250|NCT00261378|DEVICE|Transarterialchemoembolisation (TACE)|
48504757|NCT06058286|OTHER|Continuous quality improvement|Continuous quality improvement (CQI) is an approach to develop healthcare providers' capacity to improve quality of care processes and improve adherence to clinical guidelines. Key features of CQI include systematic, data-guided activities, designing interventions (or changes to facility processes) with local conditions in mind, and iterative development and testing of interventions. The approach is based on the premise that valuable improvement in organisational processes can be achieved through bottom-up initiatives of stakeholders and providers. It requires a 'team-based' culture of staff working together to collect and use available data to evaluate the effect of local solutions. Facility staff drive the development of solutions to quality of care shortcomings that they feel are best suited to the local context, and CQI works within existing resource constraints so it does not require large long-term investments to sustain improvements.
48353251|NCT00261378|DEVICE|DC Bead with Doxorubicin|
48353252|NCT01308853|DEVICE|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
48353253|NCT03683095|PROCEDURE|Lymphovenous bypass|"Lymphovenous bypass will be performed under general anesthetic. Indocyanine green lymphangiography will be performed by injecting indocyanine green into each finger / toe web of the lymphedematous limb and mapping the lymphatic system with the NOVADAQ SPY Fluorescence Imaging (Mississauga, Canada).~Subdermal dissection of lymphatics and venules will be carried out under a surgical microscope. Lymphatic vessels will be anastomosed to adjacent recipient venules to create the bypass between the lymphatic and the venous systems. In total, 1-5 anastomoses will be performed. This will require 1-5 incisions, each with a length of 2-3 cm.~Postoperatively, the limb will be wrapped loosely with compression bandages. No special postoperative monitoring is required.~The surgery will be performed on an outpatient basis with no planned hospital stay."
48367544|NCT03534089|OTHER|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
48504758|NCT06633237|OTHER|Core training program in female amateur basketball players|The intervention consists of a core training program specifically designed to improve core and trunk stability in female amateur basketball players. The program is integrated into the warm-up routine and is applied twice a week over an 8-week period. Each session lasts approximately 12-15 minutes and includes five exercises. The training program is divided into three phases of progression, gradually increasing the difficulty of the exercises over the 8 weeks by incorporating more dynamic and functional movements.
48663824|NCT02154061|DRUG|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
48663825|NCT02154061|DRUG|Metronidazole|This is a standard antibiotic
48663826|NCT02154061|DRUG|Neomycin|This is a standard antibiotic.
48663827|NCT02154061|DRUG|Vancomycin|This is a standard antibiotic.
48663828|NCT03148002|DRUG|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
48504759|NCT00555360|BEHAVIORAL|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
48504760|NCT00555360|BEHAVIORAL|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
48504761|NCT04939194|BEHAVIORAL|Fast Track Protocol|We will apply 22 items of ERAS society
48504762|NCT06195319|DRUG|Simufilam|100 mg of \[14C\]-simufilam
48504763|NCT00829803|DEVICE|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
48663829|NCT03148002|DRUG|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
48142638|NCT01903902|DEVICE|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length \< 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
48504764|NCT05470283|DRUG|OBX-115|Given by IV
48504765|NCT05470283|DRUG|Acetazolamide|Given by PO
48504766|NCT05470283|DRUG|Cyclophosphamide|Given by IV
48504767|NCT05470283|DRUG|Furosemide|Given by IV
48504768|NCT05470283|DRUG|Mesna|Given by IV
48504769|NCT05470283|DRUG|Fludarabine Phosphate|Given by IV
48504770|NCT00094406|PROCEDURE|Bronchoscopy|
48504771|NCT00094406|PROCEDURE|Bronchoalveolar lavage|
48504772|NCT00094406|DRUG|Endotoxin|
48504773|NCT00094406|DRUG|Carbon Monoxide|
48504774|NCT04949711|BEHAVIORAL|ridesharing voucher|Ridesharing vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
48504775|NCT04949711|BEHAVIORAL|online shopping voucher|Online shopping vouchers will be given for completing each of the online surveys, for a possible total of $80 if you complete all three surveys. You will be paid with electronic vouchers that will be sent to your cell phone.
48663830|NCT01300026|DRUG|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
48663831|NCT05524233|DEVICE|Active Transcranial Direct Stimulation|Subjects will receive a stimulation device to use up to 20 minutes daily for 4 weeks.
48688005|NCT00703274|BEHAVIORAL|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
48688006|NCT00277810|DRUG|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
48353254|NCT05371795|DEVICE|Comfort Marker 2.0|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
48353255|NCT05371795|DEVICE|Lancets|The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
48353256|NCT02460172|DEVICE|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
48353257|NCT02460172|DEVICE|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision
48353258|NCT05143736|DIAGNOSTIC_TEST|gut and nasal microbiota detection|The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
48353259|NCT01145404|DRUG|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
48353260|NCT01145404|DRUG|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
48353261|NCT00562536|PROCEDURE|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
48353262|NCT03389867|DIETARY_SUPPLEMENT|Kaempferia parviflora extract|
48353263|NCT02391298|BEHAVIORAL|Mindfulness Meditation|
48353264|NCT03231592|OTHER|CSA Group|Already included in the arm descriptions.
48353265|NCT03231592|OTHER|Enhanced Usual Care Group|Already included in the arm descriptions.
48353266|NCT05704595|OTHER|Initial outpatient management strategy, including outpatient IV diuretics in clinic|Management strategy including IV diuretic in the outpatient clinic
48504776|NCT05121792|BEHAVIORAL|Web Based Therapist Tutorial on Prolonged Grief Disorder Therapy|The tutorial consists of 10 online modules following the main procedures of the Prolonged Grief Disorder Therapy (formerly known as Complicated Grief Treatment). Each module includes didactic information and interactive activities and videos, and takes approximately 30 minutes to review. Participants can study the material at their own pace.
48504777|NCT00020371|DRUG|BMS-247550|
48504778|NCT00020371|DRUG|filgrastim|
48504779|NCT05721118|DIAGNOSTIC_TEST|CBCT and DXA exams performed in current practice in Nantes University Hospital|40 patients will be enrolled in order to study DXA/CBCT acquisitions of 16 osteoporotic women vs 34 osteopenic/healthy women (Estimated osteoporotic rate = 20%)
48504780|NCT01200992|BIOLOGICAL|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
48504781|NCT01200992|BIOLOGICAL|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
48504782|NCT06634251|OTHER|No intervention|This study is purely observational and does not involve any direct intervention. It utilizes retrospective analysis of computed tomography (CT) scans to simulate the fluoroscopic visualization and screw placement technique in the anterior column fixation corridor (ACFC) of the acetabulum. The objective is to define the optimal antegrade entry point and assess anatomical parameters without performing any physical intervention on the participants.
48688007|NCT02077777|DRUG|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
48353267|NCT05704595|OTHER|Initial hospitalization-based management strategy|Direct admission to the hospital
48504783|NCT02172235|DRUG|Pioglitazone|
48353268|NCT00190606|DRUG|Duloxetine|
48353269|NCT00190606|PROCEDURE|Pelvic Floor Muscle Training (PFMT)|
48353270|NCT00190606|PROCEDURE|Imitation PFMT|
48353271|NCT00190606|DRUG|placebo|
48353272|NCT01894685|DRUG|Mesalazine|Mesalazine 3 grams, once daily for six months
48353273|NCT01894685|DRUG|Placebo|Placebo 3 grams, once daily for six months
48353274|NCT05063760|BEHAVIORAL|aerobic-strength exercise intervention (6-months)|6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week),
48353275|NCT00422968|DEVICE|Percutaneous coronary intervention|Using silorimus eluting stent
48353276|NCT00422968|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
48504784|NCT02172235|DRUG|Pioglitazone - low dose|
48504785|NCT02172235|DRUG|BI 10773 - low dose|
48504786|NCT02172235|DRUG|BI 10773 - medium dose|
48688008|NCT00128024|DRUG|lipid-lowering treatment|
48142639|NCT05109598|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
48142640|NCT01680432|DIETARY_SUPPLEMENT|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
48367545|NCT03534089|OTHER|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
48504787|NCT02172235|DRUG|BI 10773 - high dose|
48504788|NCT06498869|DRUG|Ketamine Hcl 50Mg/Ml Inj|This group will be administered ketamine (0.25-0.50 mg/kg)
48688009|NCT00807586|DRUG|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
48688010|NCT00807586|DRUG|Placebo|Normal saline (1.6 cc)
48688011|NCT02654821|BIOLOGICAL|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
48663832|NCT05032586|DEVICE|wearing virtual reality headsets|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
48663833|NCT06505460|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
48663834|NCT02960737|DEVICE|Oral neuromuscular training using an oral device|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
48663835|NCT01272427|DIETARY_SUPPLEMENT|water with glucose|0.75 g/kg body weight of glucose added to water
48663836|NCT01272427|DIETARY_SUPPLEMENT|water and whey protein|0.75 g/kg body weight of whey protein added to water
48663837|NCT01272427|DIETARY_SUPPLEMENT|water with noncaloric sweetener|0.15 g of sucralose added to water
48663838|NCT01817387|BEHAVIORAL|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
48663839|NCT01817387|BEHAVIORAL|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
48663840|NCT01055028|DRUG|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
48663841|NCT01055028|DRUG|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
48663842|NCT04955041|OTHER|MRI|T2\* MRI
48663843|NCT06059950|BEHAVIORAL|Mindfulness Flow Program|The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
48663844|NCT00726908|DIETARY_SUPPLEMENT|Low carbohydrate|43% CHO
48663845|NCT03612570|DEVICE|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
48663846|NCT05819957|OTHER|Therapeutic Education Program (TEP)|the TEP lasts 12 months, being structured into 6 modules.
48663847|NCT05428644|BEHAVIORAL|massage therapy|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
48663848|NCT06180837|BEHAVIORAL|Sleep Extension Intervention|Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.
48663849|NCT06067984|DEVICE|Study App|An investigational prescription digital therapeutic in the form of a smartphone app.
48663850|NCT04606927|OTHER|Natriuresis|Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
48663851|NCT05540483|DRUG|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
48663852|NCT03318094|DRUG|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
48663853|NCT03318094|OTHER|Saline|Intrabrachial saline will be given this day
48663854|NCT03318094|DRUG|Sodium Nitroprusside|Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
48663855|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
48663856|NCT00573768|DRUG|Placebo|Vehicle 2 times daily
48663857|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
48142641|NCT01680432|DIETARY_SUPPLEMENT|Regular Cheese|
48663858|NCT03419182|PROCEDURE|Open Reduction internal Fixation|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
48663859|NCT03419182|PROCEDURE|Open Reduction Internal Fixation with Total Hip Arthroscopy|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
48663860|NCT00833521|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
48663861|NCT00833521|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
48663862|NCT03961126|DRUG|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
48663863|NCT03961126|DRUG|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
48663864|NCT03089294|DEVICE|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
48663865|NCT01090947|DEVICE|ProtoCAD|Aquiring acoustic signals from heart patients.
48688012|NCT02654821|PROCEDURE|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
48142642|NCT05681611|DRUG|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
48142643|NCT03009344|DRUG|Tazemetostat|Tazemetostat tablets.
48142644|NCT03971552|PROCEDURE|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
48663866|NCT04411992|DEVICE|Vibrating Device|The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection
48663867|NCT04954664|BIOLOGICAL|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
48663868|NCT04954664|BIOLOGICAL|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
48663869|NCT00239915|DRUG|Pagoclone|
48663870|NCT02786407|DRUG|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
48663871|NCT02786407|DRUG|Placebo|In these studies,patients received placebo administered to 20 injection sites
48663872|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 25 mg.
48663873|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 50 mg.
48663874|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 75 mg.
48663875|NCT00864357|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
48663876|NCT00864357|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
48663877|NCT02803905|BIOLOGICAL|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
48663878|NCT03094052|DRUG|Neratinib|Given orally (PO)
48663879|NCT03094052|BIOLOGICAL|Trastuzumab|Given Intravenously (IV)
48663880|NCT03094052|DRUG|Loperamide|Given PO
48663881|NCT03094052|DRUG|Diphenoxylate Hydrochloride/Atropine Sulfate|Given PO
48663882|NCT06563765|OTHER|FAP-targeting PET/CT imaging will be performed on the enrolled patients.|FAP-targeting PET/CT imaging will be performed on the enrolled patients.
48663883|NCT05526729|OTHER|Beovu|Prospective observational study. There is no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema are eligible to enroll into this study.
48663884|NCT00601744|BEHAVIORAL|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
48663885|NCT00601744|BEHAVIORAL|Questionnaire|5-10 minute questionnaire to be completed after the interview.
48663886|NCT00221767|DEVICE|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
48663887|NCT01914588|PROCEDURE|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
48663888|NCT01914588|OTHER|Standard care|"* Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits"
48142645|NCT02833948|DRUG|Acetylsalicylic acid|"Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)"
48142646|NCT02833948|DRUG|Clopidogrel|Drug: Clopidogrel 75 mg OD for first 90 days
48142647|NCT02833948|DRUG|Rivaroxaban|"Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)"
48142648|NCT01619319|OTHER|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
48663889|NCT00406796|DRUG|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
48663890|NCT00794430|DRUG|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
48663891|NCT00794430|DRUG|Placebo|Capsule, bid, for 13 weeks
48663892|NCT01734525|DRUG|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
48663893|NCT04116255|OTHER|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
48663894|NCT04116255|OTHER|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
48142649|NCT01619319|OTHER|computer games|computer games that that consist of word puzzles
48142650|NCT03595670|OTHER|standardized questionnaires|standardized questionnaires concerning the perception
48142651|NCT03595670|OTHER|interview|Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
48353277|NCT06161324|OTHER|PFM exercises program through the Mobile app in cooperation with the superficial sensor|"The mobile app will offer a personalized progressive protocol to the user based on his needs, via 12 levels of games(from the easiest to the hardest).The cooperating PFM superficial sensor will indicate the activity of the PFMs during the contraction.Νο face-to-face meetings will be incurred between participants and therapist.~Participants will follow a program for 12 weeks(3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).Endurance training will involve slow velocity contraction and speed training will involve quick (i.e.1 sec duration) strong contractions.Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)."
48353278|NCT06161324|OTHER|Face-to face PFM exercises program in Healthcare environment|"The therapy will include face-to-face meetings weekly, regarding the progress of the treatment and its smooth transition (intra-vaginally assessment when it needs, correction, encouragement, motivation, etc).~Participants will follow a personalized progressive PFM exercise program for 12 weeks (3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).The endurance training will involve slow velocity contraction and the speed training will involve quick (i.e.1 sec duration) strong contractions. The Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks.It will be followed the order of supine, side, prone, quadruped support, sitting and standing position"
48367546|NCT03534089|OTHER|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
48367547|NCT00511966|OTHER|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
48367548|NCT00511966|DRUG|Rabeprazole|As prescribed
48663895|NCT03271333|OTHER|lung function tests|Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
48142652|NCT05983861|DIAGNOSTIC_TEST|Identification o Multi Drug Resistant Bacteria|Identification o Multi Drug Resistant Bacteria
48142653|NCT03547154|BIOLOGICAL|Pegylated interferon alfa-2b|Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg
48142654|NCT03547154|BIOLOGICAL|Interferon alfa-2b|Daily SC injection of interferon alfa-2b, 5 MIU/m\^2
48663896|NCT04648020|DRUG|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
48663897|NCT04648020|DRUG|Placebo Mucoadhesive Buccal Tablet|Placebo
48663898|NCT05755750|DRUG|Genipin|Intratendinous genipin injection
48663899|NCT02334657|OTHER|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
48663900|NCT04546789|DRUG|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
48142655|NCT01681823|DIETARY_SUPPLEMENT|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
48142656|NCT05815420|DEVICE|Non invasive ventilation|Treatment by non invasive ventilation
48142657|NCT01337752|DRUG|BHQ880|
48142658|NCT01337752|DRUG|BHQ880 Placebo|Intravenous infusion
48142659|NCT01337752|DRUG|bortezomib|intravenous injection
48353279|NCT06161324|OTHER|PFM exercises program via home-leaflet(without suprevision)|"The participants of the CG will be advised to follow a personalized PFM exercise program at home based on their 1st meeting assessment. They will receive a comprehensive leaflet, with instructions and images about the PFM exercises at home. The PFM exercise program will last 12 weeks (3 times weekly, 1-5 sessions daily), without meetings, guidance and supervision by the physiotherapist. Similarly to the other two intervention groups, the program will contain endurance training (slow velocity contraction), speed training (quick contractions), Knack maneuver training (pre-contraction before coughing), and changing positions every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)"
48353280|NCT03053713|BEHAVIORAL|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
48353281|NCT03053713|BEHAVIORAL|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
48353282|NCT04959786|DRUG|Ivermectin,ribavirin ,nitazoxanide and zinc|oral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc
48353283|NCT05705960|OTHER|Chestnut|Daily consumption of roasted chestnut (150g) for 14 days
48353284|NCT05863806|OTHER|Mulligan Mobilzation|"Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets."
48353285|NCT05863806|OTHER|Trasverse Friction Massage|"Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration."
48353286|NCT05743413|PROCEDURE|Armeo Spring physiotherapy|Study subjects will undergo physiotherapy sessions using the Armeo Spring device.
48353287|NCT05743413|PROCEDURE|Standard physiotherapy|Study subjects will undergo standard physiotherapy sessions.
48353288|NCT03879694|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
48353289|NCT03879694|DRUG|Octreotide Acetate|Given IM
48353290|NCT03879694|BIOLOGICAL|Sargramostim|Given SC
48353291|NCT03879694|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
48353292|NCT05564754|DEVICE|Feedback-controlled temperature device|If core body temperature exceeds 37.7°C a feedback controlled-device will be used and set at 37.5°C.
48353293|NCT05564754|OTHER|High MAP|A MAP target of \>85mmHg will be used. Vasopressors will be titrated to this target during 36h.
48504789|NCT04102280|DEVICE|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
48504790|NCT05387850|OTHER|no intervention|no intervention
48504791|NCT00378612|DEVICE|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
48504792|NCT05296538|OTHER|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
48504793|NCT05296538|OTHER|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
48353294|NCT05564754|OTHER|Deep sedation|Deep sedation for at least 36h
48353295|NCT05564754|OTHER|Fever control without a device|Management of fever in the ICU without a device
48504794|NCT03901963|DRUG|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
48504795|NCT03901963|DRUG|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
48663901|NCT04729790|DRUG|PRIM-DJ2727|oral FMT capsules
48663902|NCT01040247|OTHER|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
48663903|NCT02012517|DRUG|Prolonged antibiotic treatment|
48353296|NCT05564754|OTHER|Low MAP|A MAP target of \>65mmHg will be used. Vasopressors will be titrated to this target during 36h.
48353297|NCT05564754|OTHER|Minimal sedation|A strategy of minimal sedation in the ICU, used only as needed to facilitate transport, imaging and invasive procedures.
48504796|NCT06332729|DEVICE|universal exercis unit|Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
48663904|NCT02012517|DRUG|Short antibiotic course (standard of care)|
48663905|NCT05615064|OTHER|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players
48504797|NCT06332729|DEVICE|functional electrical stimulation|Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
48504798|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
48504799|NCT02938559|BEHAVIORAL|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
48504800|NCT00089024|DRUG|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 \& 2; Repeat one 3-week cycle starting day 22
48504801|NCT00089024|DRUG|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 \& 2; Repeat one 3-week cycle starting day 22
48504802|NCT00089024|DRUG|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
48504803|NCT00089024|DRUG|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
48504804|NCT00089024|PROCEDURE|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
48142660|NCT01337752|DRUG|dexamethasone|Oral
48353298|NCT04771390|DRUG|Selitrectinib (BAY2731954) Adult tablet|Tablet, oral administration
48504805|NCT00089024|PROCEDURE|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 \[negative margins\] or R1 \[positive microscopic margins\]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
48504806|NCT00089024|PROCEDURE|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
48504807|NCT00089024|RADIATION|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
48504808|NCT00152698|DRUG|Irbesartan|
48663906|NCT05023109|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
48663907|NCT02822664|BEHAVIORAL|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
47986574|NCT05087095|BEHAVIORAL|CALM Intervention|"The CALM intervention includes 6 individual therapy sessions, each approximately 45-60 minutes in length, delivered over 3 months. Participants will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~* Within one week before initiating the CALM intervention therapy~* Within one week after its completion,~* 3 months after the CALM intervention is complete~  * After each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components"
47986575|NCT01846611|DRUG|Trabectedin|1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
48663908|NCT02822664|BEHAVIORAL|Healthy subjects|cerebral MRI and/or cerebral PET imaging
48663909|NCT02822664|DEVICE|PET/MRI|
47986576|NCT01846611|DRUG|DOXIL|30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
47986577|NCT01846611|DRUG|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
48142661|NCT06303128|DRUG|Amoxicillin 250 MG|Liquid amoxicillin 250mg PO
48142662|NCT06303128|DRUG|Placebo|Given prior to amoxicillin 250mg in one-dose group
48353299|NCT04771390|DRUG|Selitrectinib (BAY2731954) Pediatric tablet|Tablet, oral administration
48353300|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral solution|Oral solution after reconstitution
47986578|NCT01846611|DRUG|DOXIL|50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
47986579|NCT05313074|BIOLOGICAL|CoronaVac vaccine|An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
47986580|NCT01529879|DEVICE|New Abutment Connection implant|New abutment connection implant
47986581|NCT01529879|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
47986582|NCT01881230|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
48504809|NCT00979914|OTHER|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
48504810|NCT02424643|BEHAVIORAL|Monetary Incentive|$20 Amazon.com gift card
48504811|NCT02424643|BEHAVIORAL|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
48504812|NCT02424643|BEHAVIORAL|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
48504813|NCT05748106|DEVICE|Ultrasound-based imaging|Ultrasound-based imaging
48504814|NCT02425904|DRUG|Clofarabine|second-generation purine nucleoside analog
47986583|NCT01881230|DRUG|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
47986584|NCT01881230|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
47986585|NCT01346839|BEHAVIORAL|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
47986586|NCT01034462|DRUG|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
47986587|NCT01034462|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
47986588|NCT03164096|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
47986589|NCT06067386|OTHER|Dissemination of a selective reporting for antibiotic susceptibility testing|For each E. coli positive urine culture analyzed by LabOuest, GPs will receive an antibiotic susceptibility testing report, with the list of antibiotics restricted according to four E. coli susceptibility profiles, with an emphasis on narrower-spectrum antibiotics. The selected antibiotic susceptibility testing was developed following a targeted literature review and consultation with a steering committee including GPs, biologists and infectiologists. At the GP's request, a full antibiogram can be provided.
47986590|NCT06067386|OTHER|Standard antibiotic susceptibility testing report|GPs will receive a standard antibiotic susceptibility testing report for each E. coli positive urine culture.
47986591|NCT02428660|GENETIC|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
47986592|NCT02428660|OTHER|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
47986593|NCT02428660|OTHER|MTM|Medication Therapy Management
48142663|NCT06303128|DRUG|Amoxicillin 62.5mg|Given first in two-dose group, liquid amoxicillin 62.5mg PO
48504815|NCT03812744|DRUG|Whole coffee cherry extract (WCCE)|100mg WCCE
48504816|NCT03812744|DRUG|Placebo Oral Capsule [CEBOCAP]|Silica Oxide
48663910|NCT01534559|OTHER|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
48663911|NCT04466891|DRUG|ZW25 (Zanidatamab)|Administered intravenously
48663912|NCT04768153|BIOLOGICAL|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
48663913|NCT04942847|DEVICE|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
48663914|NCT04942847|DEVICE|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
48663915|NCT05521984|DRUG|Dapagliflozin|Commercially available
48353301|NCT04771390|DRUG|Selitrectinib (BAY2731954) Oral suspension|Oral suspension after reconstitution
48353302|NCT00921908|OTHER|2 mBq radioactive technetium diluted in 20 mL saline|
48663916|NCT05521984|DRUG|Carmustine|Standard of care
48663917|NCT05873088|DIAGNOSTIC_TEST|Isometric|Effects of Isometric Exercise in Female Patients With Osteoarthritis
48663918|NCT05873088|DIAGNOSTIC_TEST|Isotonic Exercise|Effects of Isotonic Exercise in Female Patients With Osteoarthritis
48663919|NCT04409444|DIAGNOSTIC_TEST|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
48353303|NCT03042195|OTHER|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
48353304|NCT05111184|BEHAVIORAL|Education groupe|Education
48353305|NCT03145506|DEVICE|Multimodal Spectroscopy|optical measurement of excised tissue
48353306|NCT03477344|DRUG|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
48353307|NCT03477344|DRUG|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
48353308|NCT05597111|DIAGNOSTIC_TEST|DHA levels of blood and cervical mucus|DHA levels of blood and cervical mucus of the control and the study groups will be measure
48353309|NCT03930810|PROCEDURE|Surgical biliary diversion|Surgical interruption of enterohepatic circulation
48353310|NCT04726124|DEVICE|Microwave Ablation Therapeutic Apparatus|The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.
48353311|NCT01728649|OTHER|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
48504817|NCT04084600|OTHER|Kinesiotherapy Protocol|Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
48504818|NCT04084600|OTHER|Manual Therapy Protocol|Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
48504819|NCT04084600|OTHER|Traditional Massage|Traditional Massage is a gentle and superficial massage.
48504820|NCT06632717|DRUG|Cisplatin|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
48663920|NCT04409444|DIAGNOSTIC_TEST|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
48142664|NCT06303128|DRUG|Amoxicillin 187.5mg|Given second in two-dose group, liquid amoxicillin 187.5mg PO
48504821|NCT06632717|DRUG|5-fluorouracil|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
48504822|NCT06632717|PROCEDURE|Lipiodol embolization|"Lipiodol embolization protocol~* Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush.~* The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization."
48504823|NCT04098289|PROCEDURE|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
48504824|NCT04098289|PROCEDURE|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
48504825|NCT05148260|BEHAVIORAL|Learning Through Play plus (LTP+)|Group-1: Experimental (n=40 participants) will receive the LTP+ which consist of a total of 12-group integrated treatment sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother/child pair per sub-group.
48504826|NCT05148260|BEHAVIORAL|Psychoeducation|Group-2: Controlled (n=40 participants) will receive 'psychoeducation' which consist of a total of 12-group sessions lasting approximately 60-90 minutes per session every fortnight with 10 mother-child pair per sub-group.
48504827|NCT06633536|DRUG|Ravulizumab|open-label arm with ravulizumab administrated within the scope of routine clinical practice
48504828|NCT06582056|PROCEDURE|Investigational Procedure|It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.
48504829|NCT02278055|DRUG|Radium-223|
48504830|NCT03220347|DRUG|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
48504831|NCT01963143|BIOLOGICAL|Gammaplex (5%)|
48504832|NCT01963143|BIOLOGICAL|Gammaplex 10|
48504833|NCT04622215|DIAGNOSTIC_TEST|ICIQ questionnaire|questionnaire
48663921|NCT04626934|OTHER|specific cognitive intervention|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
48663922|NCT04626934|OTHER|conventional occupational therapy treatment|The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
48504834|NCT02875652|BIOLOGICAL|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
48663923|NCT05586295|OTHER|Placebo|Microcrystalline α-cellulose, shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, palm wax.
48663924|NCT05586295|OTHER|EX plus|Furanthiamine hydrochloride (vitamin B1), pyridoxine hydrochloride (vitamin B6), cyanocobalamin (vitamin B12), DL-alpha-tocopheryl acetate 50% (DL-alpha-tocopheryl acetate, sucrose, caprylic acid) Sodium alkenyl succinate starch, corn starch, water, sodium aluminosilicate), shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, γ-oryzanol (γ-oryzanol, rice bran powder ), sucrose, silica, inositol, taurine, talc, oxidized starch, gelatin, magnesium stearate, calcium panpolyate, microcrystalline α-cellulose, riboflavin (vitamin B2), palmar wax.
48663925|NCT05152602|PROCEDURE|Bilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
48663926|NCT05152602|PROCEDURE|Unilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
48353312|NCT03378973|DRUG|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
48353313|NCT02593994|DEVICE|Onyx Drug Eluting Stent group|
48504835|NCT03853148|BEHAVIORAL|Otago|Exercise program for strength and balance
48504836|NCT03853148|BEHAVIORAL|Gentle yogic breathing|yogic breathing
48663927|NCT06508619|DEVICE|Corsano CardioWatch 287-2 non-invasive blood pressure (NIBP) monitoring|Patients receive Corsano CardioWatch 287-2 for continous NIBP monitoring and perform several spot-checks using an automated BP cuff as a reference during the start or uptitration of BP lowering medication
48353314|NCT02680366|DEVICE|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
48353315|NCT02680366|DEVICE|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
48353316|NCT02149628|DRUG|propofol|
48353317|NCT02149628|DRUG|Desflurane|
48353318|NCT05601765|OTHER|Standard communication pathways after discharge|Standard communication pathways after discharge
48353319|NCT05601765|OTHER|Digital team-based communication after discharge|Standard communication pathways plus digital team-based communication after discharge
48353320|NCT04652349|DRUG|HGP1910|Take it once daily for 8 weeks orally.
48353321|NCT04652349|DRUG|HCP1903|Take it once daily for 8 weeks orally.
48353322|NCT04652349|DRUG|HGP1909|Take it once daily for 8 weeks orally.
48353323|NCT04652349|DRUG|HGP1911|Take it once daily for 8 weeks orally.
48353324|NCT00381472|DRUG|Ropinirole|
48353325|NCT02542566|PROCEDURE|Physiotherapy rehabilitation|Physiotherapy rehabilitation
48353326|NCT05414669|DRUG|Allopurinol Tablet 300 mg|Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
48353327|NCT05414669|DRUG|Control Group|Placebo was given orally for a total of 3 days, beginning a day before ESWL.
48353328|NCT01635387|DRUG|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
48353329|NCT02980263|DRUG|Canakinumab|
48353330|NCT00088595|DRUG|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
48504837|NCT03853148|BEHAVIORAL|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
48353331|NCT05956990|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
48353332|NCT04347252|DRUG|Glucagon|Intravenous infusion of glucagon at fasting or elevated glycemia. Blockade of the GLP-1 receptor during hyperglycemia with and without glucagon.
48353333|NCT02117492|PROCEDURE|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
48353334|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of multiple IVT injection
48353335|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of single IVT injection
48353336|NCT05489718|BIOLOGICAL|IBI324|Dose 1 IBI324 of single IVT injection
48353337|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of single IVT injection
48353338|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of multiple IVT injection
48353339|NCT03106857|OTHER|Group A|Group A Physical activity and low caloric diet for
48353340|NCT02833610|DRUG|Denosumab Q4W|
48504838|NCT03853148|BEHAVIORAL|Caregiver Gentle yogic breathing|yogic breathing
48663928|NCT04304560|DRUG|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
48353341|NCT02274311|DRUG|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
48353342|NCT04225936|DRUG|BMS-986263|Single Dose
48353343|NCT04822090|OTHER|Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)|red cell transfusion; plasma exchange; renal replacement therapy; intravenous immunoglobulin. plasma exchange
48353344|NCT04321590|DIETARY_SUPPLEMENT|Combination of oat beta-glucan of different richness (35 and 70%) at low (3g) and high (5g) doses with green coffee bean extract (600 mg)|Dose-response study on the effect of two different types of oat beta-glucan with different b-glucan content (35% vs. 70%) in combination with a green coffee bean extract rich in polyphenols. Consumption of 2 sachets/day (providing 3 or 5 g/d beta-glucan plus 600 mg polyphenols) during 6 weeks
48353345|NCT02809846|DEVICE|Quell|
48353346|NCT02809846|DEVICE|Sham Quell|
48353347|NCT02565576|DRUG|Placebo|
48353348|NCT02565576|DRUG|CFZ533|
48663929|NCT04304560|DRUG|Placebo oral tablet|Similar Placebo oral tablet
48663930|NCT01484249|DEVICE|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
48663931|NCT03057704|DRUG|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
48663932|NCT03057704|DRUG|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
48688013|NCT02654821|PROCEDURE|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
48353349|NCT00338806|BEHAVIORAL|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
48353350|NCT00338806|BEHAVIORAL|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
48353351|NCT02440828|DRUG|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
48353352|NCT02440828|DRUG|placebo|NaCl 0.9% inhalation 4 ml twice daily
48353353|NCT05698394|DRUG|Esketamine|0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth
48353354|NCT05698394|DRUG|Placebo|20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
48353355|NCT05347563|PROCEDURE|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment...)
48353356|NCT04819711|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is an evidence-based intervention that is based on principles of cognitive behavioral therapy. It includes strategies that incorporate behavioral activation, active listening, collaboration with the family, guided discovery, and homework. The adapted THP consists of 5 integrated sessions. Session 1 introduces the programme and focuses on engagement of participants, introduction of THP, and breathing exercises. Session 2 focuses on psychoeducation and problem solving. Session 3 focuses on the mother's well-being and introduces activities such as physical exercises, good sleep practices and ensuring a balanced diet. Session 4 focuses on the mother's relationship with the unborn baby. Session 5 focuses on activating social support from family, friends and peers and provides closure of therapy.
48353357|NCT03881644|DRUG|Imigran|All patients will undergo this intervention on one of two study days
48353358|NCT03881644|OTHER|Isotonic Saline|All patients will undergo this intervention on one of two study days
48353359|NCT03881644|OTHER|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
48663933|NCT03224845|BEHAVIORAL|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
48663934|NCT04942002|DRUG|Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]|Retrobulbar injection performed by care provider
48663935|NCT04942002|DRUG|Placebo Comparator: Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
48663936|NCT04549454|BEHAVIORAL|FITSTART+ PBI|Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
47986594|NCT03744923|PROCEDURE|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
47986595|NCT03744923|PROCEDURE|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
47986596|NCT01270711|DRUG|Study Drug|non interventional study - usage as per usual care
47986597|NCT00589914|DRUG|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
47986598|NCT00589914|DRUG|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
47986599|NCT02773355|DRUG|liraglutide 3.0 mg|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
47986600|NCT02658357|DRUG|Risperidone Implant|
47986601|NCT04953221|DRUG|YJ001|Skin spray
47986602|NCT05502900|DRUG|Melatonin|White round tablets, each with a dose of 5 mg Melatonin. 4 tablets taken simultaneously at night. Tablets can be crushed and/or taken with a glass of water if the patient wish.
47986603|NCT00519818|DRUG|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
47986604|NCT00519818|DRUG|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
47986605|NCT06176573|PROCEDURE|Chlorhexidine|Pre-operative and post-operative vaginal cleansing.
47986606|NCT01750099|PROCEDURE|Combined Spinal-epidural|See arm description
47986607|NCT01750099|PROCEDURE|Continuous Lumbar epidural|See arm description
47986608|NCT02839915|DRUG|Folinic Acid|Liquid levo-leucovorin via oral route. L-leucovorin is the active isomer.
48663937|NCT04549454|BEHAVIORAL|General Parenting Advice|General parenting advice
48663938|NCT02083978|OTHER|MRI scanning|
47986609|NCT02839915|OTHER|Placebo|Inactive placebo comparator
48353360|NCT01860794|DRUG|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
48353361|NCT04543565|DRUG|Pradefovir Mesylate;Placebo of Tenofovir disoproxil fumarate tablet|Once daily
48353362|NCT04543565|DRUG|Tenofovir disoproxil fumarate tablet;Placebo of Pradefovir Mesylate|Once daily
48353363|NCT02814812|PROCEDURE|CT scan|
48353364|NCT06177223|BEHAVIORAL|Cognitive Behavioral therapy|CBT-based treatment plan would be designed to address PTSD and associated problems.
48353365|NCT00274352|DRUG|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
48663939|NCT03255616|OTHER|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
48663940|NCT03255616|OTHER|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
48663941|NCT05557396|OTHER|Internal Tube Length Measurement Procedures for Nazogastric Tube|Different Internal Tube Length Measurement Procedures will used for the correct placement of nasogastric tube.
47986610|NCT05770947|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy (CBT) is a psychological treatment or talk therapy that integrates how people think, feel, and behave to create new behavior patterns that improve thinking processes and reduce distress."
47986611|NCT05770947|BEHAVIORAL|Mindfulness|"Mindfulness is a psychological treatment or talk therapy that practices different coping skills to improve thinking processes and reduce distress."
47986612|NCT02956265|DEVICE|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
47986613|NCT01951742|BIOLOGICAL|ANT-1401|Active
47986614|NCT01951742|BIOLOGICAL|Vehicle|Vehicle
47986615|NCT03087760|DRUG|Pembrolizumab|Concurrent Pembrolizumab after proton reirradiation
47986616|NCT02297269|DEVICE|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
47986617|NCT02297269|DEVICE|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
48353366|NCT00146224|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
48353367|NCT00146224|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
48353368|NCT05141565|OTHER|No intervention|No intervention
48663942|NCT02285881|BEHAVIORAL|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
48663943|NCT06171061|DRUG|Yangxinshi tablet|In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
48663944|NCT06171061|OTHER|Basic medication|The control group will be given basic medication only. The treatment period is 24 weeks.
47986618|NCT02047747|DRUG|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
47986619|NCT01366560|DRUG|Active|GSK962040 125mg
47986620|NCT01366560|DRUG|Placebo|Matching Placebo
47986621|NCT00439426|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
47986622|NCT00439426|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
47986623|NCT02657382|BEHAVIORAL|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
48353369|NCT03001765|OTHER|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
48353370|NCT00742391|DRUG|PEP005 (ingenol mebutate) Gel|two day treatment
48353371|NCT00742391|DRUG|Vehicle gel|two day treatment
48663945|NCT02793960|DRUG|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
48663946|NCT03429140|DRUG|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
48663947|NCT03429140|OTHER|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
48142665|NCT04183023|GENETIC|Collection of a salivary sample|"Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and 4,000 of them will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~A subset of 4,000 individuals will be selected to provide a homogeneous geographic coverage and to avoid inclusion of related individuals who will share large genomic regions. Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
48504839|NCT05420870|BEHAVIORAL|exercise|"Six weeks of exercise intervention~To meet weekly 150 min of moderate to vigorous physical activity and twice weekly strength exercise General description of the exercise program~Main goal of the supervised exercise (1 hour per session, twice a week) are three folds. 1) Instruct participants to correctly perform prescribed exercises. 2) Encourage participants to be compliant to exercise program. 3) Participants were encouraged to hand in their exercise diary~Main goal of the home-based exercise is to perform calisthenics exercise daily. Participants were encouraged to perform at least one set of exercise (8-12 different exercises) and stretching (At least 3 days per week, but preferably most of the days) daily~Basic 8 exercises which increase ROM and strength of shoulder, lower back, Hip, Knee and ankle Additional 4 exercise to increase core strength and stability"
48504840|NCT02358135|OTHER|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
47986624|NCT02657382|OTHER|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
48504841|NCT02358135|OTHER|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
47986625|NCT01770379|BIOLOGICAL|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
48142666|NCT06358794|DIAGNOSTIC_TEST|Machine learning-based predictive model|The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
48142667|NCT00800176|DRUG|Placebo|po daily for 12 weeks
48142668|NCT00800176|DRUG|RO4998452|2.5mg po daily for 12 weeks
47986626|NCT01770379|BIOLOGICAL|Placebo|
48142669|NCT00800176|DRUG|RO4998452|5mg po daily for 12 weeks
48142670|NCT00800176|DRUG|RO4998452|10mg po daily for 12 weeks
48142671|NCT00800176|DRUG|RO4998452|20mg po daily for 12 weeks
48142672|NCT00800176|DRUG|RO4998452|40mg po daily for 12 weeks
48353372|NCT04188210|OTHER|Presence of elbow pain in patients with end stage renal disease|The Beck Depression Inventory (BDI), the Nottingham Health Profile (NHP) scores were measured for all patients to evaluate depression symptoms and health-related quality of life. The elbow pain presence was asked to all the patients, the patients with elbow pain were also evaluated with The Disabilities of the Arm, Shoulder and Hand Score (Q-DASH) and Visual Analogue Scale (VAS). VAS detected as pain during rest, activity, night and pain at last week.
48353373|NCT00494195|GENETIC|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
48353374|NCT00494195|GENETIC|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
48353375|NCT02681068|OTHER|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
48353376|NCT04741867|OTHER|Education|Patients will be educated to determine their level of coping with stress and their adaptation.
48353377|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
48353378|NCT03608462|DEVICE|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
48353379|NCT05799911|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
48142673|NCT05606900|BEHAVIORAL|addiction-focused eye movements desensitization and reprocessing (AF-EMDR)|AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
48142674|NCT01567150|DEVICE|Novel Dressing|Topical wound dressing
48142675|NCT00655785|BIOLOGICAL|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
48142676|NCT00655785|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
48142677|NCT01742494|PROCEDURE|Water-jet POEM|Water-jet assisted POEM procedure was performed
48142678|NCT01742494|PROCEDURE|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
48142679|NCT02766361|BEHAVIORAL|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
48142680|NCT02766361|OTHER|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
48142681|NCT05025813|DRUG|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
48142682|NCT02240472|PROCEDURE|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
48142683|NCT05689073|DEVICE|Conversational AI system|The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
48142684|NCT05689073|OTHER|Printed educational Brochure|A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
48142685|NCT02469025|OTHER|Manual caudal traction mobilization in resting position|
48142686|NCT02469025|OTHER|Manual caudal traction mobilization in end range position|
48142687|NCT02469025|OTHER|Selftreatment|Each subject is advice to do some exercises at home
48142688|NCT01253798|OTHER|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
48142689|NCT02597166|DRUG|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
48142690|NCT04899557|PROCEDURE|Single Port Robotic Splenectomy|Pediatric patient with splenomegaly underwent a single port robotic splenectomy.
48142691|NCT03136159|DEVICE|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
48142692|NCT02414594|DRUG|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
48142693|NCT02414594|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
48142694|NCT04787198|DRUG|hypertonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
48142695|NCT04787198|DRUG|isotonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
48142696|NCT03605420|OTHER|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
48353380|NCT05799911|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
48663948|NCT00538850|DRUG|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
48663949|NCT00538850|DRUG|Placebo|Matching placebo to fentanyl sublingual spray.
48142697|NCT05004909|DRUG|0.05% Tretinoin|Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
48353381|NCT05237414|DEVICE|Active tDCS|20 minutes of 2.0 mA direct current applied over the right DLPFC
48353382|NCT05237414|DEVICE|Sham tDCS|15 seconds of 2.0 mA direct current applied over the right DLPFC
48353383|NCT05237414|BEHAVIORAL|Active CT|Active memory inhibition CT (i.e., training of memory inhibition specifically for alcohol-related memories).
48353384|NCT05237414|BEHAVIORAL|Sham CT|Sham memory inhibition CT (i.e., participants have to categorize alcoholic and non-alcoholic images but they do not have to inhibit the memories related to these images).
48663950|NCT01170663|BIOLOGICAL|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
48353385|NCT03685643|BEHAVIORAL|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
48353386|NCT03685643|BEHAVIORAL|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
48353387|NCT01021293|BIOLOGICAL|Poliorix™|3 doses, intramuscular administration
48353388|NCT01021293|BIOLOGICAL|Oral Poliovirus vaccine|3 doses, oral administration
48353389|NCT04782492|PROCEDURE|graft configuration in coronary artery bypass grafting|Saphenous vein could be used as Y-composite graft or aortocoronary conduit during coronary artery bypass grafting
48353390|NCT02995811|OTHER|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
48663951|NCT01170663|DRUG|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
48663952|NCT01170663|DRUG|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
48663953|NCT06517290|OTHER|Non applicable|Non applicable
48663954|NCT02357303|DRUG|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
48353391|NCT00652522|DEVICE|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
48353392|NCT00652522|PROCEDURE|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
48353393|NCT00652522|OTHER|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
48504842|NCT01162746|DRUG|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
48504843|NCT01162746|DRUG|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
48504844|NCT02494986|DRUG|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
48504845|NCT05183152|DEVICE|NMES Feedback|Electroencephalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.
48663955|NCT02357303|DRUG|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
48663956|NCT02357303|OTHER|Placebo|100mL of water
48663957|NCT03534492|DRUG|Durvalumab|Infusion
48663958|NCT03534492|DRUG|Olaparib|P.O.
48663959|NCT00242606|DRUG|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
48663960|NCT00242606|DRUG|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
48663961|NCT02059447|OTHER|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
48663962|NCT02059447|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
48663963|NCT02059447|BEHAVIORAL|Relaxation Therapy|
48663964|NCT06561139|BEHAVIORAL|Mindfulness|Weekly group sessions of mindfulness, for eight weeks
48663965|NCT00924274|DIETARY_SUPPLEMENT|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
48663966|NCT00924274|DIETARY_SUPPLEMENT|sunflower oil|sunflower oil
48663967|NCT01468155|DRUG|dabigatran|30 days pre ablation and 90 days post ablation
48663968|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled|Each patient will receive 12µg/kg of levosimendan by inhalation over 10 min. During 10h following inhaled dose, plasma concentrations will be measured.
48663969|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous|Each patient will receive 12µg/kg of levosimendan by intravenous (IV) administration over 10 min and at the same timepoints plasma samples will be measured
48663970|NCT00305396|DRUG|Sirolimus|
48663971|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
48353394|NCT03178175|PROCEDURE|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
48353395|NCT03178175|PROCEDURE|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
48353396|NCT00471276|DRUG|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
47986627|NCT03341533|PROCEDURE|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
48353397|NCT02802657|PROCEDURE|Treat-and-Extend regimen|For the T\&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
47986628|NCT03341533|OTHER|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
47986629|NCT01303887|DRUG|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
47986630|NCT01303887|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
47986631|NCT01303887|DRUG|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
47986632|NCT01303887|DRUG|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
47986633|NCT01303887|DRUG|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
47986634|NCT05156879|DRUG|Aspirin|75mg, one time/day
47986635|NCT05156879|DRUG|Drospirenone ethinyl estradiol|1 table/day, 21 consecutive days, 28 days as a cycle of use
47986636|NCT00432471|PROCEDURE|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
48142698|NCT06210152|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. Each session involved the delivery of 1000 pulses at a frequency of 10Hz and an air pressure setting of 1.0 bar.
48142699|NCT06210152|DEVICE|Sham Extracorporeal Shockwave Therapy|Sham Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. In each session, the device was held against the achilles tendon without being powered on.
48142700|NCT04529824|DEVICE|Dexcom G6 Continuous Glucose Monitor (CGM) System|Participants wear a blinded Dexcom G6 CGM and a Fitbit Charge 3 activity tracker for 10 days.
48142701|NCT01828021|BIOLOGICAL|Margetuximab|Anti-HER2 monoclonal antibody
48142702|NCT01835652|OTHER|Active Exercise|
48142703|NCT01835652|OTHER|Passive Exercise|
48504846|NCT05183152|DEVICE|Visual Feedback|Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.
48663972|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
48663973|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
48663974|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
48663975|NCT06405750|PROCEDURE|left atrial appendage closure|systematic closure of the left atrial appendage in addition to the planned heart surgery
47986637|NCT00149084|DRUG|Lansoprazole, clarithromycin, amoxicillin|
47986638|NCT01808287|DEVICE|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
47986639|NCT04563689|OTHER|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
47986640|NCT04563689|OTHER|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
47986641|NCT06461533|DRUG|Susoctocog Alfa (Genetical Recombination)|Susoctocog Alfa (Genetical Recombination), Intravenous injection
47986642|NCT04656145|DEVICE|3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing|On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
47986643|NCT03053414|DIETARY_SUPPLEMENT|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
47986644|NCT00750711|PROCEDURE|Radiofrequency ablation for atrial flutter by catheters|
47986645|NCT03346499|BIOLOGICAL|NK cells and IL-2|Natural Killer Cells
47986646|NCT06430138|DIETARY_SUPPLEMENT|300ml Orange Juice|Acute intervention in populations with and without colon
47986647|NCT01953055|RADIATION|Stereotactic ablative radiotherapy|
47986648|NCT04608851|DRUG|E. coli Nissle|1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
47986649|NCT04608851|OTHER|Placebo control|1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.
47986650|NCT06493695|BEHAVIORAL|Both EGChat and CES intervention|"1. A exercise-promoting chatbot called EGChat, integrated into an established online health promotion platform.~2. Intervention of CES (Cranial Electrotherapy Stimulation) at Home"
47986651|NCT06493695|OTHER|Exercise Chatbot|Exercise Chatbot
47986652|NCT06493695|DEVICE|CES (Cranial Electrotherapy Stimulation)|Intervention of CES (Cranial Electrotherapy Stimulation)
47986653|NCT02962804|DRUG|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
47986654|NCT02962804|RADIATION|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
48504847|NCT05183152|DEVICE|TESS|Transcutaneous Electrical Spinal Stimulation (TESS) is applied over the C5-C6 spinal segment for 20 minutes at 30Hz with 5kHz carrier frequency.
48504848|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
48663976|NCT00135083|DRUG|insulin glulisine|"* Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
48663977|NCT02347410|DEVICE|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
48663978|NCT06564025|BEHAVIORAL|Pilot program study|To assess program feasibility, acceptability, and preliminary efficacy, we will pilot the intervention with a purposive sample of 50 father-teen pairs (100 participants total). All participants will receive the program.
48663979|NCT06559332|DIAGNOSTIC_TEST|Risk-based CAD management|Patients will not undergo routine coronary angiography prior to TAVI. For patients without known atherosclerotic cardiovascular disease, a calcium score will be derived from the available routine CT and in case of a score \>100, statin treatment of at least moderate intensity is recommended.
48663980|NCT06559332|DIAGNOSTIC_TEST|Invasive coronary angiography|Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
48663981|NCT00746811|DRUG|P-OM3|4 grams/day - 4 one gram capsules
48663982|NCT00746811|DRUG|Placebo|4 grams/day - 4 one gram capsules
47986655|NCT00574509|RADIATION|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
47986656|NCT00574509|DRUG|BEAM|Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
47986657|NCT05479955|OTHER|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
47986658|NCT05479955|OTHER|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
47986659|NCT01179945|OTHER|benzoate containing test drinks|"Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.~Each solution will be consumed over 5 minutes."
47986660|NCT01179945|OTHER|non sodium benzoate containing test drinks|"Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.~Each solution will be consumed over 5 minutes."
47986661|NCT01792674|OTHER|In situ simulation|
48367549|NCT03727685|BEHAVIORAL|Our Care Wishes|A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
48367550|NCT01922336|BIOLOGICAL|SB2|IV infusion
48504849|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
48504850|NCT03678285|OTHER|HIFRT Workout|A single high intensity functional resistance training (HIFRT) exercise bout.
48504851|NCT05275920|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
48504852|NCT05275920|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
48663983|NCT03552016|DRUG|Oral Riboflavin|The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
48663984|NCT04312022|DIETARY_SUPPLEMENT|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
48663985|NCT04312022|OTHER|Placebo|Placebo (flour capsule)
48142704|NCT04320914|OTHER|High Intensity LASER Therapy|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks."
48353398|NCT02802657|PROCEDURE|Pro Re Nata|For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
48353399|NCT02802657|DRUG|Conbercept|
48353400|NCT05575024|DEVICE|oXiris membrane|Perform continuous renal replacement therapy with oXiris membrane
48353401|NCT05575024|DEVICE|Polysulfone membrane|Perform continuous renal replacement therapy with polysulfone membrane
48353402|NCT05375786|BIOLOGICAL|Vaccination completion status|the relation between vaccination completion status and the target population
48353403|NCT04631016|BIOLOGICAL|MEDI3506|Dose 1
48353404|NCT04631016|OTHER|Placebo|Dose 1
48353405|NCT03254849|DRUG|Empagliflozin|1 tablet
48504853|NCT03141866|OTHER|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
48504854|NCT03141866|OTHER|Exercise Intervention 2: Machine-based resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
48663986|NCT01224314|OTHER|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
48663987|NCT01297855|DRUG|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
48663988|NCT01297855|DRUG|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
48663989|NCT04658485|DEVICE|Active tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
48504855|NCT02164474|BEHAVIORAL|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at \~85-90% peak oxygen uptake \[VO2peak\] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at \~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
48663990|NCT04658485|DEVICE|Sham tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
48663991|NCT01741961|PROCEDURE|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
47986662|NCT01792674|OTHER|Off site simulation|
48353406|NCT03254849|DRUG|Hydrochlorothiazide 25 mg|1 tablet
48353407|NCT02455440|DRUG|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
48353408|NCT02455440|DRUG|Placebo|
48353409|NCT02455440|DRUG|Propofol and sevoflurane|
48353410|NCT00730249|DRUG|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
48663992|NCT03185221|DEVICE|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
47986663|NCT00227162|BEHAVIORAL|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
48353411|NCT00730249|DRUG|Placebo|twice daily according to an individual titration schedule
48353412|NCT04216511|DIAGNOSTIC_TEST|Tumor autoantibody detection|Level of a set of autoantibodies potentially relative with lung cancer will be tested for each of the participants.
48353413|NCT02839590|DEVICE|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
48353414|NCT02839590|DEVICE|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
48353415|NCT02839590|DEVICE|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
48353416|NCT02839590|DEVICE|STARflo|Suprachoroidal Shunt Surgery (STARflo)
48353417|NCT02839590|DEVICE|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
48353418|NCT02839590|DEVICE|iStent implant|Trans-trabecular meshwork implants (iStent implant).
48353419|NCT02839590|DEVICE|Kahook Dual Blade|It removes part of the trabecular meshwork
48367551|NCT01922336|BIOLOGICAL|EU Remicade|IV infusion
48367552|NCT01922336|BIOLOGICAL|US Remicade|IV infusion
48663993|NCT03185221|DEVICE|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
48504856|NCT06603987|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
48663994|NCT01475721|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
48663995|NCT01475721|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
48663996|NCT01475721|DRUG|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
47986664|NCT00227162|BEHAVIORAL|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
48663997|NCT01475721|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
48142705|NCT04320914|OTHER|Ibuprofen gel phonophoresis|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
48353420|NCT05707195|OTHER|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
47986665|NCT00227162|BEHAVIORAL|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
47986666|NCT04394104|OTHER|Survey|No intervention is being administered.
47986667|NCT01864447|BEHAVIORAL|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
48504857|NCT06603987|DIAGNOSTIC_TEST|［18F］FBPA|Intravenous injection of ［18F］FBPA and radiation exposure from PET-CT scan.
48663998|NCT01475721|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
48663999|NCT01475721|DRUG|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
48664000|NCT04225767|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
48664001|NCT05963126|OTHER|No intervention.|No intervention.
48664002|NCT02789982|DRUG|β-adrenergic blocker propranolol|
48664003|NCT02789982|BEHAVIORAL|Treatment as usual|
47986668|NCT01848002|DRUG|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
47986669|NCT01848002|DRUG|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
47986670|NCT00617045|DRUG|duloxetine|"Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks"
47986671|NCT00909389|DRUG|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
47986672|NCT02418507|DIETARY_SUPPLEMENT|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
47986673|NCT02418507|OTHER|Placebo|The placebo is administered to randomized healthy participants
47986674|NCT02445482|PROCEDURE|Biopsy|archival tissue or fresh biospsy
47986675|NCT03254927|DRUG|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
48142706|NCT06501027|BEHAVIORAL|Mindfulness Based Self Compassion|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of
48353421|NCT03731975|PROCEDURE|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
48353422|NCT03731975|PROCEDURE|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
48504858|NCT06387602|PROCEDURE|Cryotherapy|Take an icepack and wrap it in a moisture-absorbing towel. The temperature of the icepack should be between 1˚ to 10˚. Any temperature below 0˚ can damage the skin. The icepack will be on strained adductors for 5-7 minutes. Patients will be advised to do cryotherapy at home for 24-42 hours after every 2 hours.
48664004|NCT06544460|PROCEDURE|Secondary cytoreduction|Repeated tumor cell reduction surgery for recurrent ovarian cancer patients
48664005|NCT06544460|DRUG|Hyperthermic intraperitoneal chemotherapy|Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.
48664006|NCT06417060|DRUG|Caudal block anesthesia|Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
48664007|NCT06417060|DRUG|Dorsal penile block anesthesia|Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
48664008|NCT01798602|DRUG|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
48664009|NCT01798602|DRUG|Placebo|Identical placebo for rosuvastatin
48353423|NCT00469976|DRUG|bevacizumab|
48353424|NCT00469976|DRUG|carboplatin|
48353425|NCT00469976|DRUG|enzastaurin hydrochloride|
48664010|NCT02974192|OTHER|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
48664011|NCT06564285|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
48664012|NCT06564285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
48664013|NCT06300775|DEVICE|modified hyrax|Appliance used for rapid maxillary expansion
48664014|NCT06300775|DEVICE|quad helix|device use for slow maxillary expansion
48664015|NCT05902897|DEVICE|Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis.|Heart Valve Replacement
48664016|NCT03150264|DEVICE|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
48664017|NCT03150264|DEVICE|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
47986676|NCT06430203|BEHAVIORAL|Peer mentoring|Indigenous young adult peer mentors who will develop and deliver the program based on needs and wants of our participants. The program will be built on their experience and ideas. They will be empowered to guide the program in the direction they see best for their communities.
48142707|NCT04693169|DRUG|11C-Choline|1、PSMA137 labeled with \[Al18F\] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the \[Al18F\]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
48353426|NCT00469976|DRUG|gemcitabine hydrochloride|
48504859|NCT06387602|PROCEDURE|Strengthening of adductors|"Both groups will perform the following strengthening of adductors which includes adductor isometrics, Side-lying adductor strengthening, and Adductor resistance with a stepper and will be done 10 repetitions, 3 times a week.~After the performance of the Adductor strengthening protocol, Group A will be given the Active release technique while Group B will be given post-isometric relaxation by the therapist."
48353427|NCT04502199|OTHER|non interventional study|observational study
48504860|NCT06387602|PROCEDURE|Active release technique|"Step 1: Place the body in a position (Dorsiflex ankle, flex the knee, extend the hip, flex the spine) so that the nerve is moved proximally. In this position, the nerve is relaxed on the distal side of the entrapment site and the nerve is tractioned on the proximal side.~Step 2: Place contact between the distal Gracilis and the Sartorius and push the muscle proximally. The contact should not compress the nerve.~Step 3: Move each joint so that the nerve moves distally past the muscle. The new position (Plantarflex and evert the ankle, extend the knee, flex the hip, extend the spine) will be achieved.~Step 4: Move the contact to the proximal side of the muscles and push the muscle distally.~Step 5: Move the nerve proximally again by pushing the muscle distally. This brings the position of the patient back to Step 1.~Contact will be held for a short time 5-20 seconds with repetitions 3-5 times to the injury site and 2 sessions per week."
48504861|NCT06387602|PROCEDURE|Post-Isometric Relaxation|"Step 1: Position the patient's limb at a point with the highest resistance felt during abduction.~Step 2: The patient is asked to bring the leg back into adduction using only 20% of strength against firm resistance given by the therapist.~Step 3: The patient will contract the agonist (the muscle that needs to be released) while holding an inhaled breath. Contraction should be held between 7-10 seconds without any jerking, bouncing, or wobbling.~Step 4: The patient is asked to release their effort slowly and completely. As the patient relaxes, the limb is guided into a new resistance barrier where a bind is felt again.~Step 5: After PIR, a 10-20-second latency period exists and the muscle can be stretched more easily.~Contract adductor muscle for 7-10 seconds and relax the same for 7-10 seconds with repetitions 7 times and 2 sessions per week."
48664018|NCT05691920|PROCEDURE|Pectointercostal plane block and external oblique intercostal plane block|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
48664019|NCT05691920|PROCEDURE|Fentanyl infusion|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
48664020|NCT02988076|DEVICE|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
48664021|NCT03841409|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
48353428|NCT02668328|BEHAVIORAL|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
47986677|NCT01730209|DRUG|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
47986678|NCT01730209|DRUG|Placebo|
48353429|NCT01017549|RADIATION|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
48353430|NCT00348075|DEVICE|Neurovision|
48353431|NCT02239029|DRUG|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
48353432|NCT02239029|DRUG|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
48353433|NCT00532064|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48664022|NCT01323608|DRUG|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
48664023|NCT01323608|DRUG|Placebo|Placebo
48664024|NCT01113684|DEVICE|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
48664025|NCT00104884|DRUG|Depsipeptide|Given IV
48664026|NCT01459627|OTHER|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
48353434|NCT00532064|OTHER|Questionnaire Administration|Ancillary studies
47986679|NCT04961554|OTHER|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
47986680|NCT00324324|DRUG|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
47986681|NCT00324324|DRUG|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
48142708|NCT05870163|DEVICE|RefluxStop implantation|Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
48142709|NCT05870163|PROCEDURE|Nissen fundoplication|Standard of care Nissen fundoplication surgery
48504862|NCT06272981|DEVICE|Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation|THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
48504863|NCT01822275|DRUG|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
48504864|NCT01822275|RADIATION|Radiation therapy|
48504865|NCT06020287|PROCEDURE|the robot-assisted laparoscopic radical prostatectomy|We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
48504866|NCT03399799|DRUG|Talquetamab|Participants will receive IV infusion or SC injection of Talquetamab.
48504867|NCT00372151|DIETARY_SUPPLEMENT|L-Theanine|400 mg/day, caps.
48504868|NCT00372151|OTHER|Placebo|caps.
48664027|NCT01459627|OTHER|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
48664028|NCT00514189|BIOLOGICAL|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
48664029|NCT01096004|DRUG|AZD4017|oral suspension, 1200mg, once daily, for 10 days
48664030|NCT01096004|DRUG|Placebo|
48142710|NCT02715388|DEVICE|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
48142711|NCT03773497|OTHER|Common Snack Combination|Combination of Chips, Pretzels, and Popcorn.
48142712|NCT03773497|OTHER|Cheesy Broccoli Snack|Oven-roasted, freeze-dried, cheese flavored broccoli
48142713|NCT03773497|OTHER|Cheesy Broccoli with Daikon Radish Snack|Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
48142714|NCT03773497|OTHER|Uncooked Broccoli Snack|Uncooked, freeze-dried broccoli with ranch-type dip
48353435|NCT02369211|DRUG|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
48353436|NCT02369211|OTHER|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
48353437|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 (25 ug ) Dose 1 administered once daily for 7 days
48353438|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 (50 ug ) administered once daily for 7 days
48353439|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 (100ug) administered once daily for 7 days
48353440|NCT01426009|DRUG|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
48142715|NCT04348357|OTHER|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
48664031|NCT06546124|OTHER|Deep Fascia Dry needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating subcutaneously to the deep fascia. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
48664032|NCT06546124|OTHER|Intramuscular Trigger Point Dry Needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating through the deep fascia into the upper trapezius muscle. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
48664033|NCT00420706|DRUG|SCA-136|
48664034|NCT03015285|BEHAVIORAL|Cognitive Behavioural Therapy|A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
48142716|NCT04348357|OTHER|Office visit|Patient comes to the office to receive routine postoperative care
48664035|NCT03243864|DRUG|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
48664036|NCT00754884|DRUG|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
48664037|NCT00754884|DRUG|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
47986682|NCT04225728|DRUG|Iron Sucrose IV|"Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14."
47986683|NCT04225728|DRUG|Ferric polymaltose hydroxide complex IM|Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
47986684|NCT04225728|OTHER|Saline solution|100 ml i.v. of normal saline administered at Day 0 and at day 14.
48142717|NCT03772132|BIOLOGICAL|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
48142718|NCT04817293|OTHER|Questionnaire|Questionnaire SSD-12 and EQ5D5L
48142719|NCT04817293|OTHER|medical consultation|Medical consultation during the visit with data collection
48353441|NCT01426009|DRUG|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
48664038|NCT00833690|DRUG|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
48664039|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
48664040|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
48664041|NCT02460276|DRUG|Lenalidomide|
48664042|NCT02460276|DRUG|Ibrutinib|
48664043|NCT02460276|DRUG|Rituximab|
47986685|NCT03893422|OTHER|WB-010|Medical food formulation
47986686|NCT03893422|OTHER|WB-011|WB-011 medical food product
47986687|NCT03893422|OTHER|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
48142720|NCT00235937|DRUG|Anastrozole and goserelin|
48142721|NCT02542696|DRUG|APL-130277|"Used to treat up to 5 OFF episodes per day"
48353442|NCT01426009|DRUG|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
47986688|NCT00541034|BIOLOGICAL|rituximab|
47986689|NCT00541034|DRUG|cyclophosphamide|
47986690|NCT00541034|DRUG|pentostatin|
47986691|NCT03036761|PROCEDURE|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
48142722|NCT03854565|DIAGNOSTIC_TEST|Glycocalyx measurement，respiratory mechanics measurement|ELASA measure glycocalyx, measure plateau pressure, driving pressure
48142723|NCT00213278|DRUG|vinblastine sulphate injection|Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
48142724|NCT00299676|DRUG|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
48142725|NCT05545800|DRUG|metformin+empagliflozin+insulin glargine|Randomization was performed with the use of a computer-generated system provided by the sponsor. The dose of metformin will be initiated at 0.5 grams three times a day (the maximum dose is 2g/day); the dose of empagliflozin will be 10 milligrams once a day; insulin glargine will be received once daily at bedtime and the dose will be initiated at the 50% of 0.4-0.5 units/kg/day. All groups received counseling on lifestyle modification.
48353443|NCT01426009|DRUG|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 (200) ug administered once daily for 7 days
48664044|NCT00158093|DRUG|Nebivolol|
48142726|NCT05545800|DRUG|IDegLira|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.
48353444|NCT02060903|DRUG|Abametapir Lotion 0.74% w/w|Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
48353445|NCT02060903|DRUG|Vehicle Lotion|Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
48353446|NCT00590941|PROCEDURE|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
47986692|NCT02252198|OTHER|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
47986693|NCT04317456|DEVICE|Hearing Aids and Hearing Implants|Hearing Aids and Hearing Implants (age at first fitting and implantation and aided audibility)
47986694|NCT04317456|BEHAVIORAL|Family Centred Early Intervention|Family Centred Early Intervention
47986695|NCT06490263|DRUG|Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects|Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
47986696|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with single dose in healthy subjects|Parts Two: Administered by swallowing after meals with four distinct dosage groups.
47986697|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
47986698|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
48142727|NCT05545800|DRUG|premixed insulin analogues|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will received twice a day. The total daily insulin dose will be initiated at 0.4-0.5 units/kg/day and adjusted according to the plasma glucose. All groups received counseling on lifestyle modification.
48142728|NCT00470483|DRUG|Placebo treatment during 8 weeks|comparator
48142729|NCT00470483|DRUG|Paroxetine treatment during 8 weeks|treatment drug
48142730|NCT05485493|BEHAVIORAL|Internet-Based Solution Focused Short-Term Group Counseling|Sessions will be held online once a week, with an average duration of 60-90 minutes, in the form of 6 sessions, via video-conference applications.
48353447|NCT04448340|DIAGNOSTIC_TEST|machine learning model|Two classification algorithms, logistic regression and K-Nearest Neighbors (K-NNs), were investigated for their ability to predict successfully whether patients suffered from PDD or DLB.
48353448|NCT05592444|DIAGNOSTIC_TEST|Low iodine Spectral Detector CT Pulmonary Angiography|Low iodine Spectral Detector CT Pulmonary Angiography
48664045|NCT00158093|DRUG|Atenolol|
47986699|NCT01392976|DRUG|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
48142731|NCT05485493|OTHER|healthy nutrition education|60-minute single session healthy eating training
48142732|NCT06149299|PROCEDURE|Greater occipital nerve block|Greater occipital nerve block using ultrasound guidance
48142733|NCT01815359|PROCEDURE|Cytoreductive Surgery|Optimal Surgical Debulking
48142734|NCT01815359|DRUG|HIPEC with Mitomycin-C|
48142735|NCT01815359|DRUG|EPIC with FUDR and Leucovorin|
48664046|NCT00158093|DRUG|Moxifloxacin|
48664047|NCT02829372|DRUG|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
47986700|NCT01392976|DRUG|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
48142736|NCT01415206|BEHAVIORAL|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
48142737|NCT01415206|BEHAVIORAL|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
48142738|NCT05732727|DRUG|Antihypertensive algorithm|Antihypertensive algorithm based on diuretics agents
48142739|NCT05732727|DRUG|Standard of care|standard of care management for antihypertensive therapy intensification
48142740|NCT02317172|OTHER|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
48142741|NCT00002801|DRUG|leucovorin calcium|
48353449|NCT02325089|DEVICE|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
48353450|NCT02325089|DEVICE|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
48367553|NCT01379599|BEHAVIORAL|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
48664048|NCT06563921|BEHAVIORAL|physical exercise programme|resistance/hypertrophy-oriented resistance programme
48664049|NCT06563921|DIETARY_SUPPLEMENT|probiotics supplementation|probiotics supplementation
48664050|NCT06563921|DIETARY_SUPPLEMENT|placebo|placebo
48664051|NCT04548908|DIAGNOSTIC_TEST|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
47986701|NCT00229632|DRUG|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
47986702|NCT02133027|PROCEDURE|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
47986703|NCT02133027|DEVICE|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
47986704|NCT00176007|PROCEDURE|Hypoxia|
48142742|NCT00002801|DRUG|tegafur-uracil|
48142743|NCT00002801|RADIATION|radiation therapy|
48142744|NCT05704192|PROCEDURE|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
48142745|NCT05563571|DRUG|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
48142746|NCT05563571|OTHER|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
48142747|NCT02745756|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
48142748|NCT02745756|BIOLOGICAL|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
48142749|NCT05544305|OTHER|Digital Home Based Care pathway|The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
48142750|NCT02662205|OTHER|Psychotherapy Group|Traditional process group
48142751|NCT02662205|OTHER|Yoga class|Yin yoga class
48142752|NCT02662205|OTHER|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
48142753|NCT00519207|DRUG|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
48142754|NCT00519207|DRUG|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
48142755|NCT00664599|DRUG|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
48664052|NCT04388826|DRUG|Veru-111|Respiratory Distress Syndrome, Adult
48664053|NCT03822026|OTHER|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
48664054|NCT04882865|DEVICE|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
47986705|NCT02725242|DRUG|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
48142756|NCT00664599|DRUG|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
48142757|NCT04672174|DIAGNOSTIC_TEST|Questionnaire: DemTect|Questionnaire is handed out to subjects
48142758|NCT03732807|DRUG|PF-06651600 Induction Dose|Oral tablets taken once daily (QD)
48142759|NCT03732807|DRUG|PF-06651600 Maintenance Dose #1|Oral tablets taken QD
48142760|NCT03732807|DRUG|PF-06651600 Maintenance Dose #2|Oral tablets taken QD
48142761|NCT03732807|DRUG|PF-06651600 Maintenance Dose #3|Oral tablets taken QD
48142762|NCT03732807|DRUG|Placebo|Oral tablets taken QD
48142763|NCT02815865|DEVICE|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
48142764|NCT02815865|DEVICE|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
47986706|NCT02725242|DRUG|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
48142765|NCT02815865|DRUG|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
48142766|NCT04153851|PROCEDURE|neurectomy of nasopalatine nerve|Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
48142767|NCT01070537|DEVICE|Bonfils fiberscope intubation|
48142768|NCT03150758|DEVICE|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
47986707|NCT03945487|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|Taken a dose of 1.0\*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
48142769|NCT03150758|DEVICE|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
48142770|NCT03150758|DEVICE|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
48142771|NCT03150758|DEVICE|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
48142772|NCT03593785|DRUG|AZD8233|Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
48664055|NCT01832727|DRUG|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
48664056|NCT01832727|DRUG|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
48142773|NCT04730726|DEVICE|MSOT Acuity Echo|Hybrid optoacoustic and ultrasonography imaging
48142774|NCT00650169|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
48664057|NCT04866719|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
47986708|NCT03945487|OTHER|Comprehensive treatment|"1. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~2. Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers)."
48664058|NCT04533945|DEVICE|FreeStyle Libre|The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
48142775|NCT00650169|DRUG|Plavix® Tablets 75 mg|75mg, single dose fed
48142776|NCT00039884|DRUG|NESP - Novel Erythropoiesis Stimulating Protein|
48142777|NCT00071500|DEVICE|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
48353451|NCT00594789|OTHER|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
48353452|NCT00949104|DRUG|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
47986709|NCT05643768|BEHAVIORAL|Inspiratory muscle strength training (IMST)|30 breaths/day, 5 days/week, 6 weeks
47986710|NCT06120920|OTHER|Assigned Interventions|Conventional physical therapy consists of hot pack application and transcutaneous electric stimulation (TENS) and routine knee strengthening exercises in addition with core stability exercises in three sessions per week for 4 weeks. Core stability exercises include bent knee hollow hold, bridging, supine toe tap and knee strengthening exercises include knee flexion strengthening exercises and knee extension isometric exercises.
48142778|NCT00856362|DRUG|Moxidectin|
48142779|NCT00856362|DRUG|Midazolam|
48142780|NCT04106739|DEVICE|Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)|"This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary."
48142781|NCT01862159|PROCEDURE|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
48142782|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) implemented at the patient home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
48142783|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living."
48142784|NCT05727111|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) at the patient's home|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 1 hour per day (4 hours per week in autonomy and 1 hour per week under supervision).
48142785|NCT05727111|BEHAVIORAL|Usual care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
48353453|NCT00949104|DRUG|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
48353454|NCT03857464|DIAGNOSTIC_TEST|Near Patient Testing|Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
48664059|NCT04039932|BEHAVIORAL|FLAME|The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
48353455|NCT03857464|DIAGNOSTIC_TEST|SOP for C. difficile diagnostics|Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
48504869|NCT03769714|DRUG|Saline Solution for Injection|Injection of 20mL of 0.9%Normal Saline
48504870|NCT03769714|DRUG|Exparel|Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
48664060|NCT05665283|DRUG|Ensartinib Hydrochloride|oral ALK inhibitor
48664061|NCT05170802|OTHER|NanoKnife procedure|clinical data regarding use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion will be collected.
48664062|NCT05568862|DIAGNOSTIC_TEST|Doppler ultrasound, Urodynamic assessment.|The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later
48664063|NCT05568862|DIAGNOSTIC_TEST|Urodynamic assessment.|A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
48664064|NCT05303883|OTHER|Pediatric Constrained Induced Movement Therapy|Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
48142786|NCT06169566|DIETARY_SUPPLEMENT|synbiotics|synbiotics
48142787|NCT06169566|COMBINATION_PRODUCT|placebo|placebo
48504871|NCT02819700|BEHAVIORAL|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
48504872|NCT05390801|OTHER|Survey|Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
48504873|NCT06164093|OTHER|RNA sequencing is performed on the remaining LPCs|RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial \[NCT03655808\])
48142788|NCT00495066|DRUG|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
48142789|NCT03967197|DRUG|Saline spray|Physiologic saline spray
48142790|NCT03967197|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
48142791|NCT02791295|OTHER|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
48142792|NCT03830320|DRUG|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
48353456|NCT03196973|DRUG|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
48353457|NCT03196973|DRUG|DF289|1 vial into the affected ear twice daily for 7 days
48504874|NCT06164093|OTHER|Immunofluorescence staining is performed in the surgically resected lung tissue sections|The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
48504875|NCT05744180|OTHER|Interventional|The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
48664065|NCT02487511|OTHER|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
48664066|NCT03396159|DIAGNOSTIC_TEST|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
48664067|NCT04329884|PROCEDURE|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
48664068|NCT04329884|DRUG|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
48664069|NCT05751109|PROCEDURE|ipack+adduktor kanal|nerve block
48664070|NCT05288192|DRUG|Suprachoroidal triamcinolone acetonide (SCTA) injection|Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
48664071|NCT06315998|DEVICE|Magnetocardiography|Magnetocardiography
48664072|NCT03322566|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
48664073|NCT03322566|DRUG|Epacadostat|Epacadostat administered orally twice daily.
48664074|NCT03322566|DRUG|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
48664075|NCT03322566|DRUG|Placebo|Matching placebo administered orally twice daily.
48664076|NCT03685942|DEVICE|active light therapy (LUMINETTE®)|light therapy on a portable light visor device
48664077|NCT03685942|DEVICE|placebo light therapy|placebo portable light visor device
48664078|NCT03481439|OTHER|Collection of a Pharmaceutical intervention|collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
48664079|NCT00019825|DRUG|decitabine|
48664080|NCT04806152|OTHER|High intensity exercise|Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.
48504876|NCT05214105|OTHER|Biospecimen/DNA collection and analysis|Patients will be followed longitudinally with collection of CBC and chemistries as well as research biomarkers (urine, plasma, and genomic materials).
47986711|NCT06120920|OTHER|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|Conventional physical therapy consists of hot pack application, Tens and routine knee exercise program same as group A and in addition with hip strengthening exercises. Hip strengthening exercises include hip flexion and extension strengthening exercises and hip internal rotation and external rotation and hip adduction and abduction strengthening exercises.C
47986712|NCT06153511|PROCEDURE|Robot assisted spinal transpedicular fixation|Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
47986713|NCT00022633|DRUG|gemcitabine hydrochloride|
47986714|NCT00022633|DRUG|paclitaxel|
47986715|NCT03065244|DRUG|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
47986716|NCT03065244|DRUG|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
47986717|NCT04826770|DRUG|BNT162b2|vaccination against COVID-19
47986718|NCT04826770|DRUG|AZD 1222|vaccination against COVID-19
48504877|NCT04260555|DRUG|DW1601|Total 7 days of treatment and The daily dose is tid. (DW1601 20ml + Placebo of DW16011 20ml + Placebo of DW16012 9ml)
48504878|NCT04260555|DRUG|DW16011|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + DW16011 20ml + Placebo of DW16012 9ml)
48504879|NCT04260555|DRUG|DW16012|Total 7 days of treatment and The daily dose is tid. (Placebo of DW1601 20ml + Placebo of DW16011 20ml + DW16012 9ml)
48504880|NCT04156958|DRUG|Fruquintinib|Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
48504881|NCT06013839|DRUG|talfirastide|TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
48504882|NCT03017703|DRUG|Eplerenone|
48504883|NCT00872638|PROCEDURE|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
48504884|NCT00872638|PROCEDURE|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
48504885|NCT00000378|DRUG|Sertraline|12 week trial dose up to 200mgs
48504886|NCT00000378|DRUG|Nortriptyline|12 week trial dose adjusted to therapeutic level
48504887|NCT05266339|OTHER|Cross-education training|The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
47986719|NCT04826770|DRUG|mRNA-1273|vaccination against COVID-19
47986720|NCT00087581|DRUG|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
48142793|NCT03830320|DEVICE|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
48142794|NCT03830320|PROCEDURE|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
48142795|NCT03830320|PROCEDURE|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
48353458|NCT03196973|DRUG|DF277|1 vial into the affected ear twice daily for 7 days
48504888|NCT05266339|OTHER|Standard exercise program|The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
48504889|NCT01624701|OTHER|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
48504890|NCT01844856|DRUG|Eravacycline|
48504891|NCT01844856|DRUG|Ertapenem|
48504892|NCT01844856|DRUG|Placebo|Administered IV to maintain the blind.
48504893|NCT04780568|DRUG|Osimertinib|Given PO
48504894|NCT04780568|DRUG|Tegavivint|Given IV
48504895|NCT05888194|DEVICE|Mucogyne® gel|In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
48504896|NCT04106661|OTHER|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
48504897|NCT03778827|BEHAVIORAL|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
48664081|NCT04806152|OTHER|Usual care home exercise|Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week
48664082|NCT02735200|DRUG|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
47986721|NCT00087581|DRUG|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
47986722|NCT00087581|DRUG|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
47986723|NCT01744990|OTHER|Oral food challenges to multiple nuts|
47986724|NCT04900831|DIAGNOSTIC_TEST|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
48142796|NCT03741621|DIETARY_SUPPLEMENT|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
48142797|NCT03741621|DIETARY_SUPPLEMENT|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
48142798|NCT03741621|DIETARY_SUPPLEMENT|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
48142799|NCT00134186|DRUG|motexafin gadolinium|
48353459|NCT05283785|PROCEDURE|End To End or End to side sutures|End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
48353460|NCT03097497|OTHER|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
48353461|NCT03097497|OTHER|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
48353462|NCT01875874|BIOLOGICAL|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
48664083|NCT02735200|OTHER|Application of Aloe vera gel|"aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily"
48664084|NCT05903534|OTHER|Pediatric Endurance and Limb Strengthening Program (PEDALS) and Lower Limb Strength Training|Pediatric Endurance and Limb Strengthening Program (PEDALS) Group This will receive stationary cycling
48664085|NCT05903534|OTHER|Lower Limb Strength Training Group|Lower Limb Strength Training Group
48664086|NCT01387867|PROCEDURE|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
48664087|NCT01387867|PROCEDURE|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
48664088|NCT01387867|PROCEDURE|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
48664089|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
47986725|NCT00670865|OTHER|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
47986726|NCT02965274|DRUG|Torrent's Fluoxetine Tablets|
48353463|NCT05655416|PROCEDURE|Endovenous chemical ablation with Trendelenburg's operation (eCAT)|Endovenous chemical ablation with trendelenburg's operation (e CAT) is a method for the treatment of varicose veins
48504898|NCT06259188|DEVICE|Respiratory Muscle Training Device|In the both groups the initial pressure load will be set to the resistance level corresponding to the 40% of the MIP and MEP measurement. Participants will be asked to rest following 5 breathing cycles and repeat the training for 10 sets. In each set, there will be a one-minute rest break between repetitions. In breathing exercise device group participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle. In IMT+EMT group, patients will be able to practice different to device. As the progression progresses, the perceived exertion level will be increased by 5-10% every week, to be in the range of 4-6 according to the Modified Borg scale.
48504899|NCT06259188|DEVICE|Personalized Breathing Exercise Device|Personalized Breathing Exercise Device
48504900|NCT05792579|PROCEDURE|stoma closure|early closure of stoma in trauma patients
48504901|NCT00752648|DRUG|TMC435350|
48504902|NCT00752011|DRUG|TAS-106|Starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
48504903|NCT00752011|DRUG|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
48504904|NCT02816411|DIETARY_SUPPLEMENT|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
48504905|NCT02816411|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
48664090|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
47986727|NCT02965274|DRUG|Warner Chilcott LLC's Sarafem Tablet|
47986728|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
47986729|NCT04658095|DEVICE|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
48664091|NCT06073522|OTHER|Artificial Intelligence for combining multi-domain data acquisition|Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )
48664092|NCT02112656|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
47986730|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
47986731|NCT05054959|OTHER|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
47986732|NCT05054959|OTHER|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
47986733|NCT01045889|OTHER|Rituximab and CHOP regimen + PBSCT|
47986734|NCT02046109|PROCEDURE|Repair|
47986735|NCT02046109|PROCEDURE|Replace|
47986736|NCT02939235|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
47986737|NCT02939235|DRUG|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
47986738|NCT02699528|DRUG|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
47986739|NCT00083681|DRUG|Thalidomide|
48353464|NCT01935167|DRUG|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
48353465|NCT01935167|DRUG|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
48353466|NCT01935167|DRUG|Placebo|Placebo 2 tablets b.i.d.
48353467|NCT02227433|DRUG|Brentuximab Vedotin|
48353468|NCT02092324|OTHER|Laboratory Biomarker Analysis|Correlative studies
48353469|NCT02092324|OTHER|Quality-of-Life Assessment|Ancillary studies
48353470|NCT02092324|OTHER|Questionnaire Administration|Ancillary studies
48353471|NCT02092324|DRUG|Ruxolitinib Phosphate|Given PO
48504906|NCT00018356|PROCEDURE|exercise|
48504907|NCT00018356|DRUG|testosterone|
48504908|NCT06628947|OTHER|Placebo (Sterile Saline)|A control 50 μl injection of clear sterile saline liquid
48664093|NCT02112656|DRUG|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
48664094|NCT01318681|DRUG|cetirizine 10 mg|cetirizine 10 mg over encapsulated
48664095|NCT01318681|DRUG|fluticasone furoate|nasal spray 25ug per dose
48664096|NCT01318681|DRUG|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
48664097|NCT03842397|DEVICE|Kephalios Device 1|The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
48664098|NCT03814759|DRUG|TS-1 + cisplatin|S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
47986740|NCT00083681|DRUG|Dexamethasone|
47986741|NCT00083681|DRUG|Cytoxan|
48142800|NCT02791204|DEVICE|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
48142801|NCT02791204|DEVICE|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
48142802|NCT03543332|DIAGNOSTIC_TEST|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
48353472|NCT01655641|DRUG|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
47986742|NCT00083681|DRUG|Etoposide|
48142803|NCT02337114|BEHAVIORAL|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
48353473|NCT01655641|OTHER|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
48142804|NCT02337114|BEHAVIORAL|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
48142805|NCT04431128|BEHAVIORAL|infant feeding position|correlation with allergy, GER or feeding position
48353474|NCT03114072|DEVICE|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
48353475|NCT03114072|DEVICE|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
48353476|NCT01960192|DRUG|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
48353477|NCT01960192|DRUG|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
48353478|NCT06148818|OTHER|Progressive neck motor control exercise therapy|The exercise programme will be conducted as a single session two days a week for 6 weeks. The sessions will always be conducted by the same physiotherapist. Each exercise session will consist of 10 minutes of warm-up exercises, 40 minutes of neck motor control exercises and 10 minutes of cool down exercises. Each exercise will be performed as 2 sets of 10 repetitions.
48504909|NCT06628947|DRUG|100 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
48504910|NCT06628947|DRUG|50 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
48504911|NCT05713383|BEHAVIORAL|Auditory Feedback|Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
48504912|NCT03463408|DRUG|nivolumab|240 mg every 2 weeks
47986743|NCT00083681|DRUG|Cisplatin|
47986744|NCT00083681|DRUG|G-CSF|
47986745|NCT00849381|BIOLOGICAL|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
47986746|NCT05381467|PROCEDURE|immediate implant placement with The Dual-Zone Therapeutic Concept|After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.
47986747|NCT05381467|PROCEDURE|Immediate implant placement with the bone shielding concept|After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
48142806|NCT00506896|DRUG|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
48142807|NCT02392507|DRUG|Necitumumab|Administered IV
48142808|NCT02392507|DRUG|Nab-Paclitaxel|Administered IV
48142809|NCT02392507|DRUG|Carboplatin|Administered IV
48142810|NCT02991118|DRUG|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
48504913|NCT03463408|DRUG|ipilimumab|1 mg/kg every 6 weeks
48504914|NCT04691726|DRUG|lidocaine 10mg/ml|bolus i.v. + continuous i.v. infusion
47986748|NCT02626637|OTHER|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
47986749|NCT02850393|OTHER|Functional magnetic resonance imaging|
47986750|NCT02850393|BEHAVIORAL|behavioral measures|
47986751|NCT02850393|OTHER|physiological measurements|
47986752|NCT05356455|BEHAVIORAL|motivational interview technique|Difference between pre-test and post-test
48353479|NCT06148818|OTHER|Patient education|The content of this education consists of information about the disease and symptoms, chewing recommendations, dietary changes, parafunctional habits, activities to be avoided, posture recommendations.
48353480|NCT05061758|DRUG|LY3056480|LY3056480 is an inhibitor of gamma-secretase
48353481|NCT01889615|OTHER|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
48664099|NCT03814759|RADIATION|radiation|radiation 45Gy per 5 weeks
47986753|NCT04416464|OTHER|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
47986754|NCT05576740|PROCEDURE|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
48353482|NCT05077280|RADIATION|stereotactic body radiotherapy|Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY
47986755|NCT05576740|PROCEDURE|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
48353483|NCT05077280|DRUG|Immunotherapy|Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
48353484|NCT00636038|DIETARY_SUPPLEMENT|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
48504915|NCT04691726|DRUG|Placebo|bolus i.v. + continuous i.v. infusion
48504916|NCT04691726|DRUG|Metamizole|2,5 g i.v. BD
48504917|NCT04691726|DRUG|Morphine|continuous i.v. infusion adjusted to VAS scale score
48504918|NCT02180178|OTHER|observational only- no intervention|
48504919|NCT02141035|DRUG|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
48504920|NCT02141035|DRUG|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
47986756|NCT05576740|PROCEDURE|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
47986757|NCT05576740|PROCEDURE|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
47986758|NCT05576740|PROCEDURE|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
47986759|NCT05576740|DEVICE|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
48504921|NCT03231566|BEHAVIORAL|Pain Neuroscience Education|See arm/group description
48664100|NCT04085250|OTHER|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
47986760|NCT05576740|OTHER|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
47986761|NCT05576740|DEVICE|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
48353485|NCT03523806|BEHAVIORAL|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
48353486|NCT02590406|PROCEDURE|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
48353487|NCT02590406|PROCEDURE|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
48353488|NCT05455645|OTHER|targeted intrinsic foot muscle exercises|4 targeted intrinsic foot muscle exercises
48353489|NCT04825704|DRUG|Bupivacaine|Topical administration of bupivacaine via gauze swab in the tonsillar fossae after removal of throat tonsils.
48504922|NCT00111423|DRUG|Pegsunercept (PEG sTNF-RI)|
48504923|NCT04820530|DRUG|Iptacopan (LNP023)|Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
48504924|NCT01783548|DRUG|BDP Nasal Aerosol|
48504925|NCT01783548|DRUG|Placebo|
48504926|NCT01740635|DEVICE|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
48664101|NCT04085250|OTHER|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
48664102|NCT04085250|RADIATION|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose
47986762|NCT05576740|PROCEDURE|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
48353490|NCT04825704|DRUG|Sodium chloride|Topical administration of 0,9% sodium chloride via gauze swab in the tonsillar fossae after removal of throat tonsils.
48353491|NCT03271411|BEHAVIORAL|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
48353492|NCT03271411|BEHAVIORAL|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
48353493|NCT05283122|PROCEDURE|Mostafa Maged Technique|pfannestiel incision . dissection of the bladder downwards , and Ligation of the uterine arteries on both sides then , we turn over the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity .We do this turnover (flipping ) by our hands and holding the imaginary line by two Allis forceps and by making three knots by three needles in the lower edge of the uterine incision and we enter the needles of simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) Third , we stitch the both sides of the flipped lower uterine segment , then we do plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and place a drain in the doglus pouch
48353494|NCT03004833|DRUG|Nivolumab|Infusion of Nivolumab
48353495|NCT03004833|DRUG|Adriamycin|Infusion of Adriamycin
48353496|NCT03004833|DRUG|Vinblastine|Infusion of Vinblastine
48353497|NCT03004833|DRUG|Dacarbazine|Infusion of Dacarbazine
48353498|NCT02139280|DRUG|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
48504927|NCT05145179|DRUG|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
48664103|NCT04085250|DRUG|Nivolumab|Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
47986763|NCT05576740|PROCEDURE|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10\^6/μL), hematocrit (%), white blood cells (10\^3/μl), platelets (10\^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
48353499|NCT04409691|DRUG|prednison and Sirolimus|If the intravenous prednisolone 4 mg / kg / d (one time in the morning and one time in the evening, 2mg / kg body weight each time) is effective, it will be gradually reduced to 2mg / kg / D (one time in the morning and one time in the evening, 1mg / kg body weight each time), gradually converted to oral prednisone of equal dose, and the hormone will be removed within 4-6 weeks. At the same time, the dosage of sirolimus oral liquid is 0.8 mg / m2 twice a day, with an interval of 12 hours, maintaining the blood concentration of 8-15 ng / ml. if there is no intolerable side effect, the treatment will last for 6 months
48353500|NCT04409691|DRUG|prednison|Prednison is taken at a dose of 4mg/kg/d. If the hormone treatment is effective, it will be gradually reduced to 2mg / kg / d (one time in the morning and one time in the evening, 1 mg / kg body weight each time), and repeated after 2 months of continuous treatment and 1 month of drug withdrawal.
48353501|NCT05375656|OTHER|Cross-over study|Traditional Inuit Diet and Western Diet.
48353502|NCT02871570|DRUG|Rivipansel|A single dose of IV Rivipansel over 20 minutes
48353503|NCT03388554|DEVICE|tDCS|
48353504|NCT03702166|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
48353505|NCT04211857|DEVICE|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.|Round XTENDOBUTTON Fixation Device used in suture fixation of ligaments and tendons in conjunction with an ULTRABUTTON™ product or ENDOBUTTON™ device.
48353506|NCT00002590|BIOLOGICAL|filgrastim|
48353507|NCT00002590|DRUG|cyclophosphamide|
48504928|NCT06633224|PROCEDURE|Blood Specimen Collection|Blood samples will be obtained throughout the course of the study
48504929|NCT06633224|OTHER|Stool Specimen Collection|Stool samples will be obtained throughout the course of the study
48504930|NCT06633224|OTHER|Quality of Life (QOL) Questionnaires|Surveys will be given throughout the course of the study.
48504931|NCT05487534|OTHER|Observational|The same self-reported questionnaires and cognitive tests will be completed by both groups. There is no intervention.
48504932|NCT05663866|DRUG|Dexamethasone|Dexamethasone will be administered orally.
48664104|NCT04085250|OTHER|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
47986764|NCT05576740|PROCEDURE|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
47986765|NCT05576740|PROCEDURE|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
48504933|NCT05663866|DRUG|Montelukast|Montelukast will be administered orally.
48504934|NCT05663866|DRUG|Methotrexate|Methotrexate will be administered subcutaneously.
48504935|NCT05663866|DRUG|Amivantamab|Amivantamab will be administered intravenously.
48504936|NCT05663866|DRUG|Lazertinib|Lazertinib tablets will be administered orally.
48664105|NCT00769054|DRUG|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
48664106|NCT00769054|DRUG|Isotonic NaCl|Local Infiltration with NaCl
48664107|NCT04185779|DIAGNOSTIC_TEST|Colonoscopy|Diagnostic colonoscopy
48664108|NCT03144401|DRUG|Misoprostol|mesotac
48664109|NCT03144401|OTHER|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
48664110|NCT04902612|DEVICE|HM242-Solution|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
48664111|NCT04902612|DEVICE|Saline|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
48664112|NCT04641026|OTHER|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
48664113|NCT04641026|OTHER|Deuterium oxide-labelled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
48664114|NCT04641026|OTHER|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
48664115|NCT04641026|OTHER|Deuterium oxide-labelled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
48664116|NCT02746809|DEVICE|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut 34R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)"
48664117|NCT05458531|OTHER|Questionnaire|A single questionnaire
48664118|NCT05458531|OTHER|Semi-structured interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
48664119|NCT05434468|OTHER|Sustained neutral apophyseal glides|gong mobilization
47986766|NCT05576740|OTHER|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
47986767|NCT05576740|PROCEDURE|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
47986768|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
48142811|NCT02991118|DRUG|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
48353508|NCT00002590|DRUG|cytarabine|
48504937|NCT06097455|GENETIC|ARI0003|Treatment with ARI0003 cells
48664120|NCT01313533|DRUG|Polyarginine|Vein soak treated with polyarginine
47986769|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
47986770|NCT01141439|DRUG|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
47986771|NCT01141439|DRUG|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
47986772|NCT01141439|DRUG|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
47986773|NCT01141439|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
48142812|NCT05771688|DEVICE|FETO therapy|placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
48142813|NCT01053650|DRUG|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
48504938|NCT05999058|PROCEDURE|Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation|The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
48664121|NCT01313533|DRUG|Vein soak treated with Lactated Ringers Solution|Vein soak
48664122|NCT01777867|PROCEDURE|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
48664123|NCT01777867|PROCEDURE|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
48664124|NCT03226691|DRUG|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
48664125|NCT04618471|DEVICE|Boston Scientific WaveWriter SCS System|WaveWriter SCS Programming
48664126|NCT00890500|DRUG|Fludarabine|30mg/m2/day IV x 6 days
48664127|NCT00890500|DRUG|Melphalan|100 mg/m2/day IV x 1 day
48664128|NCT00890500|DRUG|Antithymocyte Globulin|1mg/kg/day x 4 days
48664129|NCT00890500|DRUG|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
48664130|NCT00890500|DRUG|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
48142814|NCT01217736|DRUG|aliskiren|single dose, tablet
48353509|NCT00002590|DRUG|daunorubicin hydrochloride|
48504939|NCT02390687|DRUG|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
48504940|NCT02390687|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
47986774|NCT00755287|DRUG|insulin glargine|starting dose 10 IU daily
47986775|NCT00755287|DRUG|metformin|As prescribed
47986776|NCT00755287|DRUG|taspoglutide|10 mg once weekly
47986777|NCT00755287|DRUG|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
48353510|NCT00002590|DRUG|doxorubicin hydrochloride|
48353511|NCT00002590|DRUG|etoposide|
48353512|NCT00002590|DRUG|leucovorin calcium|
48353513|NCT00002590|DRUG|methotrexate|
48353514|NCT00002590|DRUG|pegaspargase|
48664131|NCT03747055|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
48664132|NCT03747055|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
48142815|NCT01217736|DRUG|placebo|single dose, tablet
48353515|NCT00002590|DRUG|prednisone|
48664133|NCT04345393|BEHAVIORAL|Digital Transformation Network (DTN) Program|Patients will be screened based on ePRO and online assessment tool results to be identified to be eligible for enrollment into the DTN program. The results of ePROs and online assessments will be used to precision match patients to in-person care at the IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points. For example, a patient with mild depression or anxiety, maybe offered an online DTx and if not useful, link to telepsychiatry or in-person psychiatry consultation. Patients will transition into the intervention DTN arm at set intervals by site.
48142816|NCT01217736|DRUG|VTP-27999|single dose, tablet
48353516|NCT00002590|DRUG|thioguanine|
48353517|NCT00002590|DRUG|vincristine sulfate|
48353518|NCT00002590|RADIATION|radiation therapy|
48664134|NCT06460272|OTHER|Medically Tailored Meals|Meals culturally tailored to provide essential nutrition
48664135|NCT02903485|OTHER|nurses perform presurgical assessement and surveillance during surgery|
48664136|NCT02903485|OTHER|the anesthetic team performs presurgical assessement and surveillance during surgery|
48353519|NCT05174351|OTHER|beta blocker discontinuation|beta blocker discontinuation
48353520|NCT03832023|OTHER|Screening and initiating preventive therapy in communities|Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
48353521|NCT04367740|DIAGNOSTIC_TEST|To assess for development of IgG antibodies against SARS-CoV2|Swabs will be collected to assess for COVID-19 if PPE supplies allow.
48353522|NCT01774227|PROCEDURE|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
48353523|NCT01774227|PROCEDURE|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
48353524|NCT05876949|BIOLOGICAL|AVT03|AVT03 will be given as 1 time subcutaneous injection
48353525|NCT05876949|BIOLOGICAL|Denosumab|Xgeva (denosumab) will be given as 1 time subcutaneous injection
48664137|NCT05520684|DIAGNOSTIC_TEST|urine culture and urinalysis|urine culture and urinalysis
47986778|NCT03394092|DIAGNOSTIC_TEST|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
48353526|NCT03419351|DIAGNOSTIC_TEST|Smartphone|Smartphone based measurement of refractive error and visual acuity testing using these measurements.
48353527|NCT03419351|DIAGNOSTIC_TEST|Autorefractor|Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
47986779|NCT00224055|DRUG|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
48142817|NCT03645161|DIAGNOSTIC_TEST|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
48353528|NCT03419351|DIAGNOSTIC_TEST|Individual|Individual, human measurement of refractive error and visual acuity testing using these measurements.
48664138|NCT03950856|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
48142818|NCT05569382|DRUG|Verapamil|"1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
48664139|NCT03950856|DRUG|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
48664140|NCT01649193|OTHER|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
48664141|NCT05638828|DRUG|RD14-01 Cell injection|RD14-01 Cell injection
47986780|NCT00224055|DRUG|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
47986781|NCT05670990|OTHER|Equine assisted therapy|"A structured program that has been developed under several years at Humlamaden horse farm, for further information see under the description of the experimental group."
47986782|NCT01843751|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
47986783|NCT00000976|DRUG|CD4-IgG|
47986784|NCT00000976|DRUG|Zidovudine|
48353529|NCT03652090|PROCEDURE|cell sampling|nasal brushing to collect cells
48353530|NCT00337740|PROCEDURE|endoscopic variceal banding|
48353531|NCT00337740|DRUG|propranolol|
48353532|NCT03140488|DRUG|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
48353533|NCT03092622|OTHER|Exercise|Exercise training intervention as described earlier.
48664142|NCT02185183|DRUG|Alequel|Alequel
48664143|NCT03235050|DRUG|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
48664144|NCT03235050|DRUG|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
48664145|NCT03235050|DRUG|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
48664146|NCT03235050|DRUG|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
48664147|NCT03235050|DRUG|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
48664148|NCT01688804|BEHAVIORAL|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
48664149|NCT02903862|BEHAVIORAL|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support \& assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
48664150|NCT02903862|DEVICE|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
48142819|NCT05569382|DRUG|Bisoprolol|"1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
48353534|NCT04585113|RADIATION|CT-scanning|All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.
48504941|NCT04327739|OTHER|Intervention 1 Exercise|• Exercise programme Endurance and Resistant training exercise program (Duration: 45 minutes) • Muscle retraining of longus colli and endurance training of the deep cervical flexors. • Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM). • Active ROM exercises for the neck muscles • Upper limbs exercises with resistant bands • Stretching exercises for the neck and upper limbs muscles
48664151|NCT05905562|OTHER|core stabilization exercises|Core muscles activation exercises will be performed on patients to target the abdominals.
48664152|NCT05905562|OTHER|Spinal mobilization techniques|lumbar spine joint mobilization techniques will be performed to patient in prone lying.
48664153|NCT04577781|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
48664154|NCT04577781|DRUG|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
47986785|NCT01313936|DRUG|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
48353535|NCT01579162|DEVICE|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
48353536|NCT01917591|DEVICE|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
48353537|NCT01917591|DEVICE|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
48664155|NCT01599286|DRUG|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
48142820|NCT05569382|DRUG|Placebo|"1. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration"
48353538|NCT01004874|DRUG|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
48664156|NCT01599286|DRUG|Placebo|Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
48664157|NCT04165837|DRUG|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
48664158|NCT04165837|DRUG|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
47986786|NCT00881933|OTHER|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, \& -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, \& -8) total body irradiation (3G on days -1)
48664159|NCT01389687|BIOLOGICAL|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
48142821|NCT01436214|DRUG|APC-100|Daily oral, dose escalation, 28-day cycle(s)
48664160|NCT04902872|DRUG|CBX-12|CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
48664161|NCT05162248|DIAGNOSTIC_TEST|Microsatellite instability analysis|Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
48664162|NCT00383344|PROCEDURE|FDG PET/CT|
47986787|NCT04991155|DRUG|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
47986788|NCT06049745|DRUG|Misoprostol 400 Microgram Oral Tablet|S.L misoprostol 400 mcg
47986789|NCT06014489|DRUG|azacitidine|during run-in and extention phase: from Cycle 1 until relapse
47986790|NCT06014489|DRUG|Venetoclax|during run-in and extention phase: from Cycle 1 until relapse
47986791|NCT06014489|DRUG|Cobicistat|"during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse"
47986792|NCT04648345|PROCEDURE|Erector spinal plane block|After induction of general anesthesia, pre-operative ultrasound-guided bilateral erector spinae plane block/ vertebral side block will be performed in the ESPB/VSB group. Local block will be performed at the surgical incisions after the surgery under general anesthesia. All the intervention will be performed without patients' awareness.
47986793|NCT04166435|DRUG|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
47986794|NCT01632969|BEHAVIORAL|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
48142822|NCT01676298|DEVICE|Spartan FRX CYP2C19 Test System|
48142823|NCT02074228|DRUG|Methylphenidate (Concerta)|
48142824|NCT04121741|OTHER|Singing with Music Therapist|Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
48353539|NCT01004874|DRUG|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
48353540|NCT01004874|RADIATION|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
48353541|NCT01004874|DRUG|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
48353542|NCT00537810|DRUG|Sibutramine|15 mg daily
48353543|NCT00537810|DRUG|Placebo|Daily
48664163|NCT05896748|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
48664164|NCT05896748|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
48664165|NCT05348421|PROCEDURE|FTPB|A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
48664166|NCT05348421|PROCEDURE|PENG Block|A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
48664167|NCT06557304|DRUG|BTK inhibitor|patients with treatment naive or R/R CLL who treatment with BTK inhibitor
48664168|NCT05714982|OTHER|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
48664169|NCT05714982|OTHER|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
48664170|NCT05714982|OTHER|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
48664171|NCT01463033|DRUG|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
48664172|NCT01146002|DRUG|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
48664173|NCT01061788|DRUG|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
48664174|NCT03580954|DEVICE|Transcranial Magnetic Stimulation|Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
48664175|NCT03808571|OTHER|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
48664176|NCT00502918|DEVICE|CLM - HA Continuous Monitoring System Heart Application|
48664177|NCT04035031|DRUG|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
47986795|NCT04544098|DRUG|177Lu-DOTATATE|The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
47986796|NCT03715166|DRUG|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
47986797|NCT03715166|DRUG|Placebo|Oral Solution Taken twice daily
47986798|NCT01037608|DRUG|Sativex(Registered Trademark)|
48504942|NCT04327739|OTHER|Intervention 2 Exercise and INIT|"* Exercise programme same as Intervention Group 1 and~* Integrated Neuromuscular Inhibition Technique application. Integrated Neuromuscular Inhibition Technique application. (Duration: 15min) The protocol was applied to the following muscles: • Upper border of the trapezius muscle • sternocleidomastoid • levator scapulae muscle • splenius capitis muscle Integrated Neuromuscular Inhibition Technique includes the combination of the following technique: • Ischemic compression • Muscle energy technique • Straincounterstrain technique"
48504943|NCT04327739|OTHER|Intervention 3 Exercise and SMT|"* Exercise programme same as Intervention Group 1 and~* Manipulation Care. Participants allocated to this group received Spinal Manipulation Therapy after the therapeutic exercise programme. Treatment was delivered by 1 chiropractor with a minimum 5-year experience of clinical practice. Pain provocation and static/motion palpation findings were used to determine areas of treatment in the cervical spine. The Manipulation Therapy technique included joint motion using a diversified thrust technique, and mobilization, a low-velocity type of joint oscillation. The type and the force of the applied spinal manipulation were individualized according to the age and physical condition of each participant. Soft passive stretching, light massage and hot packs were applied to the cervical and upper thoracic area before manipulation in order to prepare each participant."
48504944|NCT04327739|OTHER|Control|Participants allocated to this group received general consulting istructions and a home based general exercise sheet
48664178|NCT04035031|DRUG|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
48664179|NCT01021800|BIOLOGICAL|MIS|Cell infusion
47986799|NCT01037608|DRUG|THC|
47986800|NCT00001889|PROCEDURE|Myocardial contrast echocardiography|
47986801|NCT00001889|PROCEDURE|Stress echocardiography with dobutamine|
47986802|NCT02625155|OTHER|Urine diagnostic testing as SOC, drug regimen changes per SOC|
47986803|NCT02625155|OTHER|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
47986804|NCT04906044|DRUG|Sintilimab|Sintilimab combined withTotal Neoadjuvant Treatment
48142825|NCT04121741|OTHER|Singing with Guided Video|The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
48142826|NCT04121741|OTHER|Control Arm|30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
48142827|NCT01466569|DRUG|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
48142828|NCT01466569|DRUG|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
48142829|NCT01357902|DRUG|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
48142830|NCT00231699|PROCEDURE|Plastic wrap (study group) and cotton (control group) wrap.|
48142831|NCT00982527|DRUG|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
48142832|NCT00982527|DRUG|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
48142833|NCT01120457|DRUG|BMS-936564 (Anti-CXCR4)|
48353544|NCT00537810|BEHAVIORAL|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
47986805|NCT05800795|DEVICE|Er: YAG laser|surface treatment with Er: YAG laser for heating abutments
47986806|NCT05800795|DEVICE|plasma spray|surface treatment with plasma spray for heating abutments
47986807|NCT00351260|PROCEDURE|Coronary Angioplasty|
47986808|NCT03657706|PROCEDURE|group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
47986809|NCT03657706|PROCEDURE|group B (Tunnel procedure with modified free gingival graft (mFGG))|modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
47986810|NCT02308410|PROCEDURE|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
47986811|NCT03695107|DRUG|Nifedipine controlled released tablets|lower blood pressure
47986812|NCT04565431|DRUG|Tysabri|Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.
47986813|NCT00255047|BIOLOGICAL|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
47986814|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
47986815|NCT00255047|BIOLOGICAL|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
47986816|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
47986817|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
47986818|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
47986819|NCT01686633|DRUG|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
48142834|NCT00046475|DRUG|Midodrine Hydrochloride|
48142835|NCT06509555|OTHER|non-intervention|non-intervention
48142836|NCT03233542|BEHAVIORAL|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
48142837|NCT00797550|BIOLOGICAL|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
48142838|NCT00797550|PROCEDURE|Autologous bone graft|
48142839|NCT00504205|DRUG|multitargeted receptor tyrosine kinase inhibitor MP470|
48142840|NCT00504205|OTHER|laboratory biomarker analysis|
48142841|NCT00504205|OTHER|pharmacological study|
48142842|NCT00504205|PROCEDURE|positron emission tomography|
48353545|NCT00537810|BEHAVIORAL|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
47986820|NCT00656474|DRUG|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
47986821|NCT00656474|DRUG|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
47986822|NCT05070117|BEHAVIORAL|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
47986823|NCT05212649|DIAGNOSTIC_TEST|cardiopulmonary exercise test|CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
47986824|NCT02671591|BEHAVIORAL|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
47986825|NCT02671591|BEHAVIORAL|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
48142843|NCT00019604|PROCEDURE|computed tomography|Scan to assess the effects of ablation.
48142844|NCT00019604|PROCEDURE|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
48142845|NCT00019604|PROCEDURE|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
48664180|NCT00951392|DRUG|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
48664181|NCT00951392|PROCEDURE|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip"
48664182|NCT00951392|DEVICE|indirect calorimetry|energy expenditure measurement
48664183|NCT00571714|DRUG|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
48142846|NCT00019604|PROCEDURE|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
48142847|NCT00019604|PROCEDURE|radionuclide imaging|Imaging following injection of a radioactive material.
48142848|NCT00019604|PROCEDURE|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
48142849|NCT00019604|RADIATION|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
48142850|NCT00019604|RADIATION|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
48142851|NCT01181115|DRUG|Avonex|Interferon treatment for MS
48142852|NCT05205213|OTHER|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
48367554|NCT01404884|PROCEDURE|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
48504945|NCT02549586|DRUG|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
48504946|NCT02863055|DRUG|Nintedanib|Nintedanib 200 mg administered twice daily
48504947|NCT02863055|DRUG|Placebo|Matching placebo administered twice daily
48504948|NCT06632392|OTHER|Simulation training|Theory and simulation training
48504949|NCT06632392|OTHER|Theory training|Theory training
48504950|NCT05133791|DRUG|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
48504951|NCT05866185|BEHAVIORAL|Therapy|The standard of care procedures for adults with clinically elevated anxiety and/or depression from their mental health provider.
48504952|NCT05866185|BEHAVIORAL|Therapy + Adhere.ly|Participants receive therapy as usual enhanced with a simple, HIPAA-compliant, web-based application to help mental health providers implement homework during therapy for adults with elevated anxiety and/or depression. The three major components of the app help providers to (1) Practice interactive, digitized therapeutic exercises with patients in-session; (2) Remind patients to practice exercises for homework, and (3) Review homework during the next session.
48504953|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
48504954|NCT05599061|OTHER|FFR>0.80+ OCT with findings indicative of vulnerable plaque|OPTIMAL MEDICAL TREATMENT (OMT)
48504955|NCT04142957|OTHER|COPD Pal|'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
48504956|NCT05443581|BEHAVIORAL|dietary intervention|Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
48664184|NCT00571714|DRUG|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
48664185|NCT03436667|DIAGNOSTIC_TEST|Spirometry|Lung volumes will be measured using spirometry.
48664186|NCT03436667|DIAGNOSTIC_TEST|Reaction Time|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
48142853|NCT03111706|PROCEDURE|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
47986826|NCT01119131|DRUG|Vitamin D3|Vitamin D3 at 10,000 IU a day
47986827|NCT01119131|DIETARY_SUPPLEMENT|calcium|1000mg calcium daily
47986828|NCT01119131|OTHER|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
48142854|NCT01349998|DRUG|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
48142855|NCT01269307|PROCEDURE|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
47986829|NCT01433601|BEHAVIORAL|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
47986830|NCT04351087|DEVICE|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
47986831|NCT00002546|DRUG|cisplatin|
48142856|NCT01269307|PROCEDURE|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
48142857|NCT03715985|DRUG|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
48504957|NCT03839823|COMBINATION_PRODUCT|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle. Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²/day)"
48504958|NCT03839823|COMBINATION_PRODUCT|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion ).~Capecitabine twice daily on day 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles.~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2/day \[oral\] or (25 to 30 mg/m2 \[IV infusion\]"
48504959|NCT03839823|COMBINATION_PRODUCT|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 - 1250 mg/m2)"
48504960|NCT03839823|DRUG|Ribociclib|Dose: 600 mg (200 mg \* 3) Days 1 to 21 of each 28 day cycle Tablets for oral use
48504961|NCT03839823|DRUG|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
48504962|NCT03839823|DRUG|Goserelin|"Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant"
48504963|NCT06427837|OTHER|Same 2nd course|The same snack food will be served in the second course
48504964|NCT06427837|OTHER|Different 2nd course|A different snack food will be served in the second course
48504965|NCT04782674|DIAGNOSTIC_TEST|Saliva Testing|Saliva EBV-DNA Detection comparing with PBMC and plasma EBV-DNA
48504966|NCT03290703|DRUG|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
48504967|NCT03290703|DRUG|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
48504968|NCT05795556|OTHER|Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients|Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
48504969|NCT00005827|DIETARY_SUPPLEMENT|genistein|
48504970|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of \~ 80-100 TEE clips per case).
48504971|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
48504972|NCT01917981|DEVICE|Personal Heart Rhythm Monitor|
48504973|NCT05557032|PROCEDURE|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
48504974|NCT01679717|OTHER|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
48504975|NCT05307510|DEVICE|Prefabricated splint|Subjects will be provided either a prefabricated splint
48504976|NCT05307510|DEVICE|Custom Orthosis|Subjects will be evaluated by an occupational therapist who will fabricate a custom orthosis.
48504977|NCT03393663|OTHER|CKD-related outcomes|the study is observational
47986832|NCT00002546|DRUG|ifosfamide|
47986833|NCT00002546|PROCEDURE|adjuvant therapy|
47986834|NCT00002546|RADIATION|radiation therapy|
47986835|NCT01441310|PROCEDURE|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
47986836|NCT06226766|DRUG|JSKN033 Injection|JSKN033 is a combination drug product comprised of JSKN003 and envafolimab for subcutaneous injection.
47986837|NCT02138760|PROCEDURE|MRI UroNav fusion biopsy|
47986838|NCT06024057|DRUG|LX101|LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
48142858|NCT04921540|PROCEDURE|Ingrown toenails with surgery with chemical cauterisation|Removal of the ingrown lateral part of the toenail and chemical cauterisation
48353546|NCT04961502|BIOLOGICAL|Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly|3 blood samples taken to compare the immunization response of the elderly with that of younger adults (priority caregivers): the first carried out before the anti-Coronavirus Disease 2019 (COVID-19) vaccination; the second shortly before the vaccination booster injection and the third approximately two months after the first vaccine injection
48353547|NCT00028964|DIETARY_SUPPLEMENT|Chinese herbs|
48353548|NCT00028964|DRUG|cyclophosphamide|
48353549|NCT00028964|DRUG|doxorubicin hydrochloride|
48353550|NCT00028964|PROCEDURE|adjuvant therapy|
48353551|NCT04696328|BIOLOGICAL|Human (allogeneic) iPS cell derived-cardiomyocyte sheet|Transplantation
48353552|NCT00806494|DRUG|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
48664187|NCT02234362|DRUG|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
48664188|NCT02146378|DRUG|Vyndaqel|20mg/day
48664189|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)|Given via ICT delivery
47986839|NCT00055081|BEHAVIORAL|Critical Time Intervention|
47986840|NCT02175888|DIETARY_SUPPLEMENT|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
47986841|NCT02175888|DIETARY_SUPPLEMENT|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
47986842|NCT01408979|DRUG|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
47986843|NCT01408979|DRUG|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
47986844|NCT06346990|OTHER|Holy Quran Recital|Holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each
48353553|NCT01172340|BEHAVIORAL|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
48664190|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)|Given via ICT/ICV dual delivery
47986845|NCT02350725|DRUG|Furosemide injection solution for subcutaneous administration (80 mg)|
47986846|NCT02350725|DRUG|Oral Furosemide tablets (80 mg)|
47986847|NCT00457782|DRUG|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
47986848|NCT02450110|DEVICE|Spinal cord stimulation|
47986849|NCT05383560|BIOLOGICAL|mRNA-1273.214 Vaccine|Omicron Variant-Matched Vaccine
47986850|NCT05383560|BIOLOGICAL|MRNA-1273 Vaccine|Moderna's commercial COVID-19 Vaccine
47986851|NCT05383560|BIOLOGICAL|Placebo|Normal Saline for injection
47986852|NCT05383560|BIOLOGICAL|MRNA-1273.222 Vaccine|Moderna's commercial COVID-19 Vaccine
47986853|NCT05157490|BEHAVIORAL|Mindfulness training|Guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
47986854|NCT03010254|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
47986855|NCT03010254|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
47986856|NCT03010254|PROCEDURE|Cataract surgery|IOL bilateral implantation
47986857|NCT00774319|RADIATION|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
48142859|NCT04921540|PROCEDURE|Ingrown toenails with only surgery|Removal of the ingrown lateral part of the toenail with directed Healing pad
48142860|NCT03592407|DRUG|Epacadostat|Given PO
48142861|NCT03592407|OTHER|Laboratory Biomarker Analysis|Correlative studies
48353554|NCT01172340|BEHAVIORAL|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
48353555|NCT00476190|DRUG|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
48353556|NCT00476190|DRUG|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
48353557|NCT00476190|DRUG|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
48664191|NCT05245903|DEVICE|Emerald Device Monitoring|The study participants will have the Emerald device deployed in their home for up to 12 weeks as they participate in the parent study (ClinicalTrials.gov identifier NCT04430517). The device will be deployed in the bedroom of each subject to capture behavior continuously. The Emerald device is a radio-wave sensor that will use signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of these subjects via low-powered radio signals. Reflections of the radio signals are processed using algorithms to convert them into movement data, sleep stages, and key sleep parameters. These data will supplement bioenergetic, imaging, and biochemical data with digital biomarkers and phenotyping using this device.
48664192|NCT05944510|DRUG|Dextromethorphan|Dextromethorphan 30mg will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
48664193|NCT05944510|DRUG|Placebo|Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
48142862|NCT03592407|BIOLOGICAL|Pembrolizumab|Given IV
48142863|NCT03592407|OTHER|Pharmacodynamic Study|Correlative studies
48142864|NCT04370561|PROCEDURE|ORIF non-locking|Open reduction and internal fixation using 1/3 tubular plate
48142865|NCT04370561|PROCEDURE|ORIF locking|Open reduction and internal fixation using active ankle polyaxial locking plate
48142866|NCT03372252|DEVICE|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
48142867|NCT04301752|DIAGNOSTIC_TEST|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.
48142868|NCT02067663|DEVICE|Paragard|The IUD will be placed as part of standard clinical care.
48142869|NCT02067663|DRUG|Mirena|The IUD will be placed as part of standard clinical care.
48142870|NCT03496545|DRUG|Bromocriptine 5 MG|Bromocriptine 5 mg every 4 hours PO/NG/FT
48142871|NCT03496545|DRUG|Acetaminophen 650 MG|Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours
48142872|NCT04871555|OTHER|MRI|structural imaging
48142873|NCT01564498|OTHER|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
48142874|NCT03845699|DEVICE|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
48142875|NCT04253951|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
48142876|NCT06477549|DRUG|Bendamustine Hydrochloride|Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days
48142877|NCT06477549|DRUG|Ruxolitinib|Days -7 through -2: ruxolitinib 5 mg tid per os
48353558|NCT00476190|DRUG|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
48353559|NCT00476190|DRUG|Cyclophosphamide|Consolidation IB: Intravenously on day 1
48664194|NCT06399055|DRUG|CKD-387|1 Tablet
48664195|NCT06399055|DRUG|D484|1 Tablet
48664196|NCT06146816|DEVICE|photobiomodulation treatment in the infrared (IR) range.|The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
48664197|NCT02553096|DEVICE|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
48664198|NCT01853280|DRUG|L-methylfolate|15mg/day L-methylfolate.
48142878|NCT06459544|DIAGNOSTIC_TEST|Bobath Technique with core stability|exercise to improve balance motor learning stretegy is basically used. Bobath in which we assess patient's posture, inhibit the abnormal muscle tone and facilitate normal patterns and posture through handling and posture. we also use sensory inputs like propioception to promote normal pattern. we take some exercise based on bobath technique with core stability like Bridging with core stability, quadroped with core stability, sitting and standing with core stablity, single leg standing , dynamic balance with core stability.treatment plan based on 45 minutes per day, 6 days a week for 4 week.
48142879|NCT06459544|OTHER|Conventional treatment for balance|like stretching, strenthening the Lower extremity muscles , PROMS, AAROMS,AROMS, RROMS,some balance exercise like sitting and standing
48353560|NCT00476190|DRUG|Methylprednisone|Prophase: Intravenously on days 1-3
48353561|NCT00476190|DRUG|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
48353562|NCT00476190|DRUG|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
48142880|NCT03076853|OTHER|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
48142881|NCT01270282|DRUG|AM-101 0.81 mg/mL|
48142882|NCT01270282|DRUG|Placebo|
48142883|NCT04242797|DEVICE|Calmare|Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at \~47 Hz.
48142884|NCT04242797|DEVICE|TENS|Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
48142885|NCT01000467|DRUG|probucol|group 3: 250 mg 1 tablet in the morning and evening
48142886|NCT01000467|DRUG|probucol|group 1: 250 mg
48142887|NCT01000467|DRUG|probucol|group 2: 250 mg 2 tablets at once in the morning
48142888|NCT05757674|OTHER|Sample examination|No intervention will be performed
48142889|NCT00157794|DEVICE|Search AV+ algorithm|
48142890|NCT04658888|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
48142891|NCT01116609|DRUG|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
48142892|NCT01240785|DRUG|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
48142893|NCT01240785|DRUG|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
48353563|NCT00476190|DRUG|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
48367555|NCT05824273|BEHAVIORAL|LungTalk|LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.
48353564|NCT00476190|DRUG|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks."
48353565|NCT00476190|DRUG|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
48353566|NCT00476190|DRUG|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
48353567|NCT00476190|PROCEDURE|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
48664199|NCT01853280|DRUG|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
48664200|NCT01853280|DRUG|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
48664201|NCT04373304|OTHER|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
48664202|NCT01939145|DRUG|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
48664203|NCT01939145|DEVICE|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
48664204|NCT01128478|PROCEDURE|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
48664205|NCT04414787|BEHAVIORAL|PCplanner|PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
48664206|NCT03116126|DRUG|Guanfacine|2mg oral daily tablet
48664207|NCT03116126|DRUG|Placebo|inactive oral daily tablet
48664208|NCT02715284|BIOLOGICAL|Dostarlimab|Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
48664209|NCT00688714|DRUG|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
48664210|NCT00688714|DRUG|Placebo|
48664211|NCT03271515|BIOLOGICAL|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
48664212|NCT02429960|DEVICE|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
48664213|NCT02429960|DEVICE|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
48664214|NCT02429960|DEVICE|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
48664215|NCT02429960|DRUG|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
48664216|NCT01347060|DRUG|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
48664217|NCT01347060|DRUG|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
48353568|NCT00476190|DRUG|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
48353569|NCT05646160|OTHER|Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)|IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
48353570|NCT00348192|DRUG|SB-742457|
48353571|NCT00348192|DRUG|donepezil|
48353572|NCT00850629|BEHAVIORAL|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
48353573|NCT00850629|BEHAVIORAL|placebo|no intervention, only follow up
48353574|NCT00086489|DRUG|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
48353575|NCT00086489|DRUG|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
48353576|NCT03709914|DRUG|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
48353577|NCT03709914|DRUG|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
48353578|NCT01265173|DRUG|Cefotaxime|3 g
48353579|NCT01265173|DRUG|Ceftriaxone|2 g
48353580|NCT01265173|DRUG|Ciprofloxacin|400 mg
48142894|NCT04566185|OTHER|FDG PET|"IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained."
48142895|NCT04566185|OTHER|CT scan|"Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25."
48142896|NCT04566185|OTHER|Magnetic resonance imaging (MRI)|"If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 \*, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium"
48142897|NCT05458466|OTHER|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
48664218|NCT00470015|BIOLOGICAL|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
48664219|NCT00470015|BIOLOGICAL|IL-2|0.5x10\^6/m\^2
48142898|NCT00392652|DRUG|oral microencapsulated diindolylmethane|Given PO
48353581|NCT05837234|DEVICE|ULF SCS|Ultra low frequency spinal cord stimulation
48353582|NCT01381731|DRUG|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
48664220|NCT00470015|BIOLOGICAL|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
48353583|NCT01381731|DRUG|placebo|opthalmic solution 2 drops in each eye QID
48504978|NCT02941757|BEHAVIORAL|Mediterranean diet Intervention|"1. Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~2. Peer-education and support~3. Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~4. Email or text message encouragement and reminders during the intervention."
48504979|NCT02621749|DEVICE|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
48504980|NCT06483503|DEVICE|EFOV Colonoscope|Routine colonoscopy using the EFOV lens in the colonoscope.
48504981|NCT04461158|BEHAVIORAL|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
48504982|NCT05567146|BEHAVIORAL|Experimental group|"It is planned to use the social media platform WhatsApp application to carry out the study. technique of gamification will have content in the form of points, ranking, penalties and rewards, which are the basic principles of gamification.~Studies have shown that these contents are effective techniques to increase the interest, encouragement, motivation and purpose of the participants."
48664221|NCT00470015|BIOLOGICAL|GM-CSF|300mcg
48664222|NCT00470015|BIOLOGICAL|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
48664223|NCT01636284|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
48664224|NCT02850341|DEVICE|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
48664225|NCT01331590|DRUG|G-CSF|
47986858|NCT00774319|RADIATION|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
48353584|NCT01486940|DRUG|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
48353585|NCT01486940|DRUG|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
48353586|NCT01486940|DRUG|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
48353587|NCT01486940|DRUG|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
48353588|NCT02213081|DRUG|Ulipristal|Patient will take 15mg every other day, or every 4 days per week.
48664226|NCT01331590|DRUG|Ifosfamide|
48664227|NCT01331590|DRUG|Etoposide|
48664228|NCT01331590|DRUG|Dexamethasone|
48664229|NCT01331590|DRUG|Mesna|
48664230|NCT00208130|DRUG|Topiramate|
48664231|NCT03164161|DEVICE|Cold pressor test|Described before.
48504983|NCT01649401|DEVICE|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
47986859|NCT02716064|BEHAVIORAL|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
48142899|NCT02444195|BEHAVIORAL|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
48142900|NCT01282645|DEVICE|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
48142901|NCT02324790|DEVICE|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
48142902|NCT04627168|DEVICE|Non-invasive, surface electrical stimulation device, DS5 Digitimer|Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
48504984|NCT01649401|DEVICE|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
48504985|NCT03223792|OTHER|Control|Routine cow's milk-based infant formula
48504986|NCT03223792|OTHER|Investigational|Partially-hydrolyzed cow's milk protein infant formula
48504987|NCT01467986|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
48664232|NCT03164161|OTHER|β-endorphins evaluation in saliva|Described before.
47986860|NCT00357487|DEVICE|peroperative scintillating probe|
47986861|NCT00357487|DEVICE|operative gamma camera|
47986862|NCT03935191|DEVICE|Dexcom CGM System|Dexcom CGM System
48142903|NCT02499094|OTHER|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
48142904|NCT03567278|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
48142905|NCT04307056|PROCEDURE|Radical Prostatectomy|The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA \> 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.
48142906|NCT04307056|PROCEDURE|High Intensity Focused Ultrasound (HIFU) Treatment|The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
48142907|NCT03555812|OTHER|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
48142908|NCT00539084|DEVICE|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
48142909|NCT00840775|DEVICE|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
48142910|NCT03443206|OTHER|anonymous social support|Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
48142911|NCT03443206|OTHER|psychoeducation|educational materials related to mental health
48142912|NCT03443206|OTHER|online resources|links to online mental health resources
48142913|NCT00386685|DRUG|larotaxel (XRP9881)|intravenous administration
48142914|NCT00386685|DRUG|trastuzumab|intravenous administration
48142915|NCT01784107|DRUG|Belotecan and Ifosfamide|
48142916|NCT00868894|DRUG|DE-104 medium concentration|Topical ocular application
48142917|NCT00868894|DRUG|DE-104 high concentration|Topical ocular application
48504988|NCT01467986|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
48504989|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
48142918|NCT00868894|DRUG|Placebo|Topical ocular application
48142919|NCT00868894|DRUG|0.005% latanoprost|Topical ocular application
48142920|NCT05889494|OTHER|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
48142921|NCT05889494|OTHER|Standard Care involving allogenic and/or derivative transfusion.|Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
48142922|NCT06093490|DEVICE|Eysz Hyperventilation Recorder|App used to guide and record hyperventilation
48142923|NCT01753674|DIETARY_SUPPLEMENT|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
48142924|NCT01753674|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
48142925|NCT05244967|OTHER|vaginal swab|self-sampling, vaginal swab
48142926|NCT00836537|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
48142927|NCT00836537|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
48142928|NCT01920126|DRUG|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
48142929|NCT01920126|DRUG|Saline|
48142930|NCT03176407|DIAGNOSTIC_TEST|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
48142931|NCT04689932|DRUG|Triferic AVNU|Ferric Pyrophosphate Citrate
48142932|NCT05376397|BEHAVIORAL|iTHRIVE 365|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
48142933|NCT02630186|DRUG|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
48142934|NCT02630186|DRUG|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
48142935|NCT02941744|DRUG|nivolumab|low fixed dose ipilimumab in combination with nivolumab
48142936|NCT02941744|DRUG|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
48142937|NCT05267093|PROCEDURE|Acupuncture|Sterile single-use stainless steel needles (size 0.3 mm × 25 mm) will be utilized. After local skin disinfection with 75% alcohol wipes, acupuncturists will insert needles perpendicularly into the Ashi points to a depth of approximately 2-3 mm; horizontally into the Baxie points toward the wrist to a depth of 5-10 mm; and perpendicularly into Houxi (SI3) and Waiguan (TE5) to a depth of approximately 5-10 mm. The depth of needling will vary based on the participant's body sizes. After insertion, all needles except those in the Ashi points will be manually manipulated to achieve De qi sensations. All the needles will be retained for 30 min and then gently removed. Participants will take acupuncture treatment three times per week for a total of 12 sessions in 4 consecutive weeks.
48142938|NCT05267093|PROCEDURE|Sham acupuncture|The sham needles with blunt tips (size 0.3 mm × 25 mm) will be used in the control group. Acupuncturists will gently lift and twist the sham needles to simulate the treatment procedure, thus blinding the patients to the intervention. Acupuncturist will firstly sterilize the areas of acupoints, then apply the adhesive pads on the surface of Ashi points, Baxie points, Houxi (SI3) and Waiguan (TE5) and insert the sham needles without penetrating. The duration and frequency of treatment sessions will be the same as in the acupuncture group.
48142939|NCT00097409|DRUG|Ispinesib|
48142940|NCT01951703|DEVICE|senofilcon A|Control, senfilcon A
48142941|NCT01951703|DEVICE|senofilcon A|Test, senofilcon A
48142942|NCT02867982|PROCEDURE|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
48142943|NCT02867982|PROCEDURE|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
48142944|NCT02867982|DRUG|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
48664233|NCT03164161|OTHER|β-endorphins evaluation in blood plasma|Described before.
48142945|NCT02867982|DEVICE|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
48664234|NCT00220090|DRUG|dexloxiglumide|
48142946|NCT02867982|RADIATION|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
48664235|NCT01490021|PROCEDURE|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
48664236|NCT01490021|PROCEDURE|rTMS/Placebo TBS|rTMS/Placebo TBS
48664237|NCT03924414|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
48664238|NCT03924414|OTHER|Placebo|Normal Saline 100 ml (placebo) IV infusion
48664239|NCT04120467|OTHER|Dance|"One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity."
48664240|NCT04120467|OTHER|Standard rehabilitation|The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
48664241|NCT00400101|BIOLOGICAL|Virosome-formulated synthetic peptides (malaria vaccine)|
47986863|NCT04506476|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
47986864|NCT03761147|OTHER|Paula exercises|structured exercises aimed to stimulate ring muscles
47986865|NCT03293810|OTHER|Observational study|Post-Authorization Safety Study
47986866|NCT02187601|DEVICE|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
47986867|NCT02187601|DEVICE|BreathID|BreathID is the name of the original Exalenz breath analyzer system
47986868|NCT00637507|OTHER|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., \>10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 \>150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
47986869|NCT04458233|PROCEDURE|long axis FNA method|"). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen"
47986870|NCT03181087|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
47986871|NCT06018259|PROCEDURE|healthy volunteers blood sampling|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them PBMC will be activated in vitro (e.g. using LPS or PHA) in the presence or absence of the lipid of interest.
47986872|NCT04723550|DEVICE|Hospital telemedicine management system|Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
47986873|NCT04723550|OTHER|Usual care|Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
47986874|NCT01437215|DEVICE|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
47986875|NCT01341964|DRUG|Clopidogrel|600mg (2 pills)
47986876|NCT01341964|DRUG|Aspirin|325mg (1 pill)
47986877|NCT01341964|DRUG|Aspirin|81mg (1 pill)
48142947|NCT02177292|RADIATION|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
48142948|NCT00681941|DRUG|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
48142949|NCT03046706|BEHAVIORAL|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
48664242|NCT01995097|BEHAVIORAL|Scheduled Gradual Reduction Text Messages|
48142950|NCT03046706|BEHAVIORAL|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
48142951|NCT01604122|OTHER|No drug|No drug.
48142952|NCT01604122|OTHER|No drug|No drug.
48142953|NCT04933474|BEHAVIORAL|painTRAINER®|PainTRAINER is among the most widely-validated mHealth interventions for pain management.18-25 Originally developed by members of our team at Duke and Northwestern University under NIH funding, the app teaches evidence-based pain coping skills using a self-administered, home-based software program. The system delivers eight sessions via any web-connected platform, including Android or iOS smartphones, tablets, or personal computers. The digital curriculum covers progressive muscle relaxation, activity/rest cycling, pleasant activity scheduling, recognizing negative automatic thoughts, pleasant imagery/distraction, problem solving, and monitoring for maintenance. Patients complete one session per week in a pre-determined order. The program can be completed in a flexible manner to accommodate life and medical events.
48142954|NCT04933474|DEVICE|PICO G2 4k|Patients allocated this arm will use a multi-modal, skills-based, selfmanagement VR program, called EaseVRx. Developed by AppliedVR (Los Angeles, CA) in partnership with Stanford pain psychologist Dr. Beth Darnall, the program teaches and trains users based on evidenced-based strategies and biofeedback exercises. EaseVRx combines psychoeducation, pain education, breathing training, relaxation exercises, and executive functioning games to provide a mind-body approach toward living better with pain. The standardized, reproducible, 56-day program delivers a combination of skills training and CBT-related treatments through scheduled daily virtual experiences. Each VR experience lasts between 2-16 minutes.
48142955|NCT04810832|OTHER|Evoked related potentials|"Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~* with scalp electrodes in the department of neurophysiology~* with intracranial electrodes in the department of neurosurgery."
48142956|NCT02418689|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
48142957|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
48142958|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
48142959|NCT04609735|OTHER|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
48142960|NCT04609735|OTHER|Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
48142961|NCT01197924|OTHER|IRMf Bold|IRMf BOLD of the working memory
48142962|NCT04559698|BEHAVIORAL|LGBTQ-affirmative CBT training|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
48142963|NCT01883609|BIOLOGICAL|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
48142964|NCT01883609|BIOLOGICAL|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
48142965|NCT01883609|BIOLOGICAL|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
48142966|NCT03470597|OTHER|dietary iodine restriction on subjects with iodine overload|In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
48142967|NCT00262366|DEVICE|Comparison of automatic CPAP versus fixed CPAP|
48142968|NCT03393390|DIAGNOSTIC_TEST|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
48142969|NCT03393390|OTHER|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
48664243|NCT01995097|BEHAVIORAL|Support Text Messages|
48664244|NCT03758183|PROCEDURE|total knee arthroplasty|
48664245|NCT06079983|DRUG|JSKN003|Administered intravenously according to protocol.
48664246|NCT06079983|DRUG|Capecitabine tablets|Administered according to protocol, as one option for investigator's choice (determined before randomization).
48664247|NCT06079983|DRUG|Gemcitabine hydrochloride for injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
48664248|NCT06079983|DRUG|Vinorelbine tartrate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
48664249|NCT06079983|DRUG|Paclitaxel for injection (albumin-bound type)|Administered according to protocol, as one option for investigator's choice (determined before randomization).
48664250|NCT06079983|DRUG|Docetaxel injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
48142970|NCT00003041|DRUG|pyrazoloacridine|
48142971|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
48142972|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
48142973|NCT04890457|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
48142974|NCT04890457|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
48142975|NCT02291406|PROCEDURE|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
48142976|NCT02291406|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
48142977|NCT03597152|DIETARY_SUPPLEMENT|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
48142978|NCT03597152|DIETARY_SUPPLEMENT|Placebo|Inert placebo custom manufactured for the sponsor
48142979|NCT01209156|DRUG|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
48142980|NCT04890145|DEVICE|RW-Precision-Coupler|Implantation of the RW-Precision-Coupler together with FMT-VORP 503
48142981|NCT03726593|DRUG|Artesunate and Pyronaridine|Standard weight based dosing
48142982|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
48142983|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
48142984|NCT00541996|DRUG|vabicaserin|
48664251|NCT06079983|DRUG|Eribulin mesylate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
48664252|NCT02191618|DEVICE|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
48664253|NCT05532800|DRUG|JS002|JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
48664254|NCT05532800|DRUG|Placebo|JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
47986878|NCT03327298|PROCEDURE|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
47986879|NCT06543069|DRUG|Sintilimab, Bevacizumab , Pemetrexed , Cisplatin|Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
48142985|NCT04559074|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
48142986|NCT00074607|DRUG|Gemcitabine|"Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
48142987|NCT02538094|DEVICE|Sham Transcranial direct current stimulation|Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.
48142988|NCT02538094|DEVICE|Anodal Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes.
48142989|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First deflation of 3cc of air occurred 1 hour after inflation. Deflations occurred every 15 minutes unless bleeding was noted. If bleeding was noted, balloon was reinflated (1-3cc of air) until bleeding stopped. Next deflation occurred 30 minutes later, at which point regular 15 minutes deflations occurred if no bleeding noted. Band was removed 1 hour after final deflation."
48353589|NCT01572480|DRUG|Carfilzomib|Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
48664255|NCT03938649|RADIATION|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
48664256|NCT03938649|DRUG|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
48664257|NCT04544280|DRUG|Xeomin Injectable Product|Intramuscular injection
48664258|NCT05059275|PROCEDURE|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
48664259|NCT02001519|DRUG|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
48664260|NCT02317627|DRUG|KD025|
47986880|NCT06486090|BEHAVIORAL|#Utviklingsklar|The intervention consists of 1) an e-learning course, 2) a workshop to create plans and practices for injury-prevention, 3) a mid-season meeting
48353590|NCT01572480|DRUG|Revlimid|Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
48367556|NCT05824273|BEHAVIORAL|Non-tailored intervention - Standard of practice|ACS Lung Screening Informational Video
48142990|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First balloon deflation of 3cc of air occurred 15 minutes after initial inflation. Deflations occurred every 15 minutes unless bleeding was noted. If active bleeding was noted, the balloon was re-inflated (1-3cc) until bleeding stopped. The next deflation occurred 15 minutes later. If no bleeding occurred, deflations continued every 15 minutes until the balloon was completely deflated. The band was removed 15 minutes after final deflation."
48664261|NCT02876731|DEVICE|PET-CT|NaF PET-CT
48142991|NCT01326455|DEVICE|Clo-Sur-P.A.D.|"A hydrophilic dressing has a high affinity for water, and absorbs and controls body fluid. The positively charged 4x4 centimetre pad reacts with the neuraminic acid residue on red blood cells causing agglutination of the cells. The Clo-Sur P.A.D. works outside of the clotting cascade.~The radial catheter was removed and occlusive pressure applied on the radial artery. Pressure was released just until bleeding noted \& the pad was applied with approximately 5 minutes of manual compression. The pad was assessed every 15 minutes for 90 minutes to ensure hemostasis. The pad was removed on post-CATH day 1."
48142992|NCT00222898|PROCEDURE|DNA analysis of pancreatic cyst fluid / buccal swab|
48142993|NCT03146845|DEVICE|ALLEVYN Life Non-Bordered|Foam Dressing
48142994|NCT03146845|DEVICE|Standard Care|Foam Dressing
48504990|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
48142995|NCT03451461|OTHER|No intervention|Observational study. Clinical data recorded
48142996|NCT04024982|OTHER|Sequence of teaching (Lecture first followed by Simulation)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
48142997|NCT04024982|OTHER|Sequence of teaching (Simulation first followed by Lecture)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
48142998|NCT01995981|DRUG|Pazopanib|
48142999|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
48143000|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an IV infusion.
48143001|NCT05139615|DRUG|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
48664262|NCT02876731|DEVICE|MRI|DWMRI
48664263|NCT06032611|DIAGNOSTIC_TEST|COGNUM_ALZVR|"Participants will complete a battery of tests/quizzes:~* cognitive tests~* medical questionnaire~* lifestyle/fragility questionnaire~* digital clock test~* fine motor skills tests They will also wear a connected watch for 7 days."
48143002|NCT00446576|DRUG|Epoetin Alfa|
48143003|NCT04863365|DRUG|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
48143004|NCT04863365|DRUG|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
48143005|NCT05081726|DIAGNOSTIC_TEST|Functional MRI|Series of MRI scans of the brain
48664264|NCT03270995|BEHAVIORAL|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
48664265|NCT03270995|BEHAVIORAL|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
48504991|NCT01467986|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
48664266|NCT06116097|BEHAVIORAL|Nutrition education|Fifty participants took 6 physical nutrition education lectures and the other group (n=33) didn't have any nutrition education. Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
48664267|NCT01287299|OTHER|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
48664268|NCT01287299|OTHER|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
48664269|NCT03220009|PROCEDURE|Conventional Surgery|Undergo surgery
48664270|NCT03220009|BIOLOGICAL|Ipilimumab|Given IV
48664271|NCT03220009|OTHER|Laboratory Biomarker Analysis|Correlative studies
48664272|NCT03220009|BIOLOGICAL|Nivolumab|Given IV
48664273|NCT03220009|OTHER|Patient Observation|Undergo active surveillance
48664274|NCT03220009|RADIATION|Radiation Therapy|Undergo RT
47986881|NCT00567892|DEVICE|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
47986882|NCT00454610|BEHAVIORAL|FLOW|
47986883|NCT00454610|BEHAVIORAL|SelfHelp|
47986884|NCT04461015|DRUG|0.4mU Insulin followed by withdrawal period followed by 0.8mU study|Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
48367557|NCT02698020|PROCEDURE|Room-air|Provision of room-air
48664275|NCT01605994|DRUG|BMS-933043|
48664276|NCT01605994|DRUG|Placebo matching with BMS-933043|
48664277|NCT01605994|DRUG|Antacid Buffer Predose Solution|
48664278|NCT05790291|OTHER|Checklist|the experimental group will practice using the checklist
48664279|NCT01958086|DEVICE|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
48664280|NCT00690339|DEVICE|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
47986885|NCT04461015|DRUG|0.8mU Insulin followed by withdrawal period followed by 0.4mU study|Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
47986886|NCT06347666|BEHAVIORAL|Caregiver coaching|Speech language pathologists will meet with caregivers to talk through strategies to promote child development.
47986887|NCT01238679|DRUG|PF-04958242|Administered as specified in the treatment arm
47986888|NCT01238679|DRUG|Placebo|Administered as specified in the treatment arm
47986889|NCT01404390|DRUG|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
47986890|NCT01404390|DRUG|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
47986891|NCT00740142|DRUG|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
48367558|NCT05038007|DRUG|Liposomal bupivacaine|As prior described
48664281|NCT06066086|PROCEDURE|A hinge flap will be performed to reinforce the buccal advancement flap to close the oroantral fistula at the most posterior area of the maxilla|The hinge flap is raised via circular incision around the oral side of the oroantral fistula then sutured with purse suture to close the sinus membrane perforation and it is used as an additional layer that reinforce the buccal advancement flap
48664282|NCT06066086|PROCEDURE|An anteriorly based palatal flap will be performed to close the oroantral fistula at the most posterior area of the maxilla|Two paralleling incisions will be performed on the palatal side of the fistula. The distance between the two incisions will be 2 to 3 mm greater than the width of the fistula. Then the two incisions will be connected together via a circular incision at the bony end of the hard palate. The flap reflection will be performed, and the greater palatine vessels will be legated and cauterized to allow lateral repositioning of the flap over the fistula. The flap will be sutured to the buccal tissues.
48664283|NCT03695445|DRUG|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
48664284|NCT05574881|DRUG|Dalpiciclib|150 mg qd
48664285|NCT05574881|DRUG|Fulvestrant|500mg d1, 15, 29, and then q4w
48143006|NCT05492513|BEHAVIORAL|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 1.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
48664286|NCT05574881|DRUG|Pertuzumab|840mg q3w, and then 420 mg q3w
48143007|NCT00327730|DRUG|Eperisone|
48353591|NCT01572480|DRUG|Dexamethasone|Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
48353592|NCT02116582|DRUG|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
48353593|NCT04177394|DEVICE|MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system.
48664287|NCT05574881|DRUG|Trastuzumab|8 mg/kg q3w, and then 6 mg/kg q3w
48664288|NCT01627184|DEVICE|Dexcom G4 CGM System|
48664289|NCT01526200|PROCEDURE|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
47986892|NCT00740142|DRUG|placebo and lactulose|placebo 3 times a day for 7 days
47986893|NCT03120819|BEHAVIORAL|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
47986894|NCT03120819|BEHAVIORAL|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
48664290|NCT06209866|DEVICE|PTA|Percutaneous Trans lumenal Angioplasty
47986895|NCT04028596|DRUG|Paracetamol|once, 1000mg, 2 h before ECT session
47986896|NCT04028596|DRUG|Nimotop|once, 60mg, 2 h before ECT session
47986897|NCT00276159|DRUG|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
47986898|NCT01456104|BIOLOGICAL|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
47986899|NCT04728581|DRUG|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
48143008|NCT03739606|BIOLOGICAL|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
48143009|NCT04602949|DIAGNOSTIC_TEST|Breath Biopsy Analysis|Analysis of a single breath Biopsy
48143010|NCT00491101|OTHER|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
48143011|NCT00491101|OTHER|spirometry|spirometry
48143012|NCT02417350|OTHER|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
48143013|NCT02417350|OTHER|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
48143014|NCT05658094|DEVICE|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
48353594|NCT02132689|DRUG|Actilyse (Thrombolytic therapy)|
48353595|NCT02132689|DRUG|Heparine (Standard anticoagulation therapy)|
48353596|NCT02582151|DEVICE|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
48353597|NCT02084472|OTHER|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
48353598|NCT02084472|OTHER|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
48353599|NCT02084472|OTHER|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
48353600|NCT00424099|DRUG|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
47986900|NCT04728581|DRUG|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
47986901|NCT04728581|DRUG|Placebo|a gelatinous capsule without an active ingredient
47986902|NCT01883830|DEVICE|gaming therapy (Xbox)|
47986903|NCT01883830|DEVICE|Dynamic balance platform (Biodex)|
47986904|NCT04540757|PROCEDURE|Surgery|Participants will be randomised to receive surgery as part of multi-modality treatment
47986905|NCT04540757|PROCEDURE|No surgery|Participants will be randomised to receive no surgery as part of multi-modality treatment
48353601|NCT00424099|BEHAVIORAL|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
48367559|NCT05038007|DRUG|Bupivacaine Hydrochloride|As prior described
48664291|NCT06412887|DEVICE|Virtual reality headset|Meta-Quest 2 virtual reality headset was used in this study
48664292|NCT02769793|DRUG|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
48664293|NCT02769793|DRUG|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
48664294|NCT03830879|OTHER|No intervention|This cohort study have any no intervention.
48143015|NCT06346652|OTHER|Routine Physical Therapy|Routine physical therapy involving muscle strengthening exercises, range of motion exercises and stretching exercises up to patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks.
48143016|NCT06346652|OTHER|Routine Physical Therapy+ PNF and Core Stregthening|Routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks.
48504992|NCT01467986|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
48664295|NCT03205267|DRUG|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to \<G2.
48664296|NCT04656561|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT
48664297|NCT04656561|OTHER|Sham comparator|Form and Route of Administration: pressure to mimic IVT injection
48664298|NCT05805202|OTHER|Blood sampling and urine analysis|A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
48664299|NCT00006427|DRUG|Amitriptyline|
48664300|NCT02284191|RADIATION|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
48664301|NCT03586921|BEHAVIORAL|Psychosocial Group Intervention|The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
48664302|NCT03586921|OTHER|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
48664303|NCT06537791|BEHAVIORAL|Home-Based Rehabilitation Program|Physical Therapy: 32 sessions, 60 minutes each Occupational Therapy: 8 sessions, 60 minutes each Nutrition Counseling: 4 sessions, 60 minutes each Psychological Support: 8 sessions, 60 minutes each Nursing and Podiatry Care: 4 sessions, 60 minutes each Total Duration: Approximately 4 months
48664304|NCT02421757|DEVICE|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
48664305|NCT02421757|DEVICE|Placebo|The placebo Transcutaneous device
48664306|NCT02143882|DRUG|Fluenz|Live attenuated influenza vaccine
48664307|NCT03408353|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48143017|NCT03617575|DIETARY_SUPPLEMENT|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)
48143018|NCT03617575|DIETARY_SUPPLEMENT|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
48143019|NCT03617575|DIETARY_SUPPLEMENT|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
48143020|NCT03617575|DIETARY_SUPPLEMENT|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
48143021|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
48143022|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
48143023|NCT03067337|DEVICE|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
48143024|NCT03067337|DEVICE|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
48143025|NCT02102724|DIETARY_SUPPLEMENT|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
48143026|NCT02102724|DIETARY_SUPPLEMENT|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
48143027|NCT05093894|DEVICE|Group 1|Microlyte will be cut into strips and placed on the subcutaneous space
48664308|NCT03408353|PROCEDURE|Mammography|Undergo standard of care mammography
48664309|NCT03408353|OTHER|Questionnaire Administration|Complete questionnaires
48143028|NCT01399606|DRUG|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
48353602|NCT00424099|DRUG|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
48664310|NCT05599724|OTHER|Biocollection|"For the FERTITHEQUE, will be collected:~* Clinical characteristics~* Biological characteristics measured as part of the usual follow-up~* consultation n°2 : DNA~* consultation n°2 : plasma~* consultation n°2 : serum~* consultation n°2 : vaginal microbiota~* consultation n°3 : follicular fluid (puncture fluid)~* consultation n°4 : plasma~* consultation n°4 : vaginal microbiota."
48664311|NCT06128057|OTHER|Blood products|Massive blood transfusion
48664312|NCT05801887|DEVICE|Extracorporeal shockwave device|"Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves."
48664313|NCT05801887|DEVICE|No ESWT|the osteoblast like cells are not exposed to shockwaves
48143029|NCT03210298|COMBINATION_PRODUCT|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
48143030|NCT02160600|OTHER|Standard multiphase CT|
48143031|NCT02160600|OTHER|split bolus Dual energy CT|
48143032|NCT00012688|DRUG|Doxycycline HCI 10mg po for 2 weeks|
48504993|NCT03052010|OTHER|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
48504994|NCT03052010|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
48143033|NCT00012688|PROCEDURE|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
48504995|NCT03052010|DRUG|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
48504996|NCT04423185|DRUG|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
48504997|NCT04423185|DRUG|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
48664314|NCT04994977|DRUG|Melphalan|Given at 0.5 mg/ml.
48143034|NCT00774592|BEHAVIORAL|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
48143035|NCT00774592|BEHAVIORAL|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
48143036|NCT00774592|BEHAVIORAL|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
48143037|NCT00774592|BEHAVIORAL|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
48664315|NCT04994977|DRUG|Carboplatin|Given at 5 mg/ml.
48664316|NCT04994977|DRUG|Topotecan|Given at 0.2 mg/ml.
48664317|NCT05933811|PROCEDURE|exploratory laparoscopy|Laparoscopic exploration for impalpable maldescended testis in pediatric age group
48143038|NCT00774592|BEHAVIORAL|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
48143039|NCT00774592|BEHAVIORAL|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
48143040|NCT02333565|DRUG|Everolimus|
48143041|NCT02333565|DRUG|Octreotide|
48143042|NCT03042767|BIOLOGICAL|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
48143043|NCT03042767|OTHER|Placebo|Matched Placebo
48353603|NCT00424099|BEHAVIORAL|Non NTI|Non NTI are calls from research staff 3 times weekly.
48353604|NCT03523715|DIETARY_SUPPLEMENT|Prunes|12 oz of prunes daily
48504998|NCT04423185|DRUG|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
48664318|NCT06459726|OTHER|shi style mobilization|Step 1 soothing tendon stepTherapist will aerate patient's neck 3 to 6 times.Step 2 moblization step Therapist will apply low velocity small amplitude oscillatory movement without thrust. Head will be in 45 degrees of flexion or extension. Repeat this for 3 to 6 times. Then distraction force is applied to the cervical. Step 3 dredging collateral step Therapist holds thenar and hypothenar muscles of patient's hand on affected side and gently shook the upper limb ebb and flow with small shaking and high frequency. Repeat the procedure 3 times 6 sesions over 2 weeks for 20minutes
48664319|NCT06459726|OTHER|SNAGS|Patient will receive sustained natural apophyseal glides as described by brian mulligan. Patient position will be upright sitting when therapist will apply a sustained passive assesory glide while patient moves actively through available physiological range of motion in the direction in which symptoms are produced. the headache SNAG technique will be performed with the patient sitting on a chair in the erect posture. The therapist will handle C2 spinous process with the middle phalanx of one hand. With the other hand, he will perform ventral gliding on C2 for 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Patient will be asked to report dizziness or any other symptom after procedure. If patient reports symptom then angle of application is changed to ensure symptom free treatment in all patientsNumber of repetitions are increased gradually from 6 to 10 and end physiological movement is maintained for 10second
48688014|NCT04057924|OTHER|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
48143044|NCT05977985|DRUG|Rotator interval hydro-dissection with dextrose 5%|Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
48353605|NCT03523715|DRUG|Docusate Sodium|Oral docusate sodium twice daily
48504999|NCT04423185|DRUG|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
48505000|NCT04423185|DRUG|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
48505001|NCT04423185|DRUG|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
48505002|NCT04423185|DRUG|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
48505003|NCT04423185|DRUG|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
48505004|NCT04423185|DRUG|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
48505005|NCT04423185|DRUG|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
48505006|NCT04423185|DRUG|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
48505007|NCT06633952|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
48143045|NCT05977985|DRUG|Rotator interval hydro-dissection with corticosteroid solution|Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
48143046|NCT04851782|DEVICE|ivEAD tubing kit|ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
48143047|NCT01981746|PROCEDURE|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
48143048|NCT00458185|DRUG|etanercept|
48353606|NCT01424267|DEVICE|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
48143049|NCT04514081|DRUG|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
48353607|NCT00712764|DRUG|Adenosine|
48353608|NCT00712764|DRUG|Placebo|
48353609|NCT02954952|DEVICE|PSI Rev 1.X|PSI Rev 1.X is an older version of the PSI measurement.
48353610|NCT02954952|DEVICE|PSI Rev 2.X|PSI Rev 2.X is a newer version of the PSI measurement.
48353611|NCT05791669|DRUG|Silver diamine fluoride|Silver diamine fluoride is a topical medication composed of 25% silver, 5% fluoride, 8% ammonia, and 62% Deionized water, used to treat and prevent dental caries and relieve dentinal hypersensitivity.
48143050|NCT04514081|DRUG|Decitabine+Camrelizumab|Decitabine+Camrelizumab
48143051|NCT00610337|DRUG|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
48143052|NCT00610337|PROCEDURE|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
48143053|NCT04108858|DRUG|Copanlisib|Given IV
48143054|NCT04108858|BIOLOGICAL|Pertuzumab|Given IV
48143055|NCT04108858|BIOLOGICAL|Trastuzumab|Given IV
48143056|NCT02113449|DRUG|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
48143057|NCT04181385|DRUG|Olanzapine 10 milligram|Oral olanzapine capsule
48664320|NCT01823055|PROCEDURE|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
48143058|NCT04181385|DRUG|Bromocriptine 5 milligram|Oral bromocriptine capsule
48143059|NCT04181385|DRUG|Placebo oral tablet|oral placebo capsules
48143060|NCT06180226|DIAGNOSTIC_TEST|PET CT with 18 FDG .|Impact exerted by the use of 18FDG PET in the process of functional monitoring of the patient undergoing radiotherapy treatment.
48143061|NCT06148636|DRUG|[212Pb] VMT-α-NET|Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
48143062|NCT06148636|DIAGNOSTIC_TEST|[203Pb] VMT-α-NET SPECT/CT|The \[203Pb\] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . \[203Pb\] VMT-α-NET, a radioactive tracer drug.
48143063|NCT05300672|DRUG|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
48143064|NCT05579184|DRUG|[177Lu]Ludotadipep|"Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
48143065|NCT03072810|BEHAVIORAL|Positive mindfulness program|4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
48143066|NCT05392972|BEHAVIORAL|Assessment of stress, resilience and associated factors in anesthesia professionals|Assessment of stress, resilience and associated factors in anesthesia professionals
48143067|NCT01109979|DRUG|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
48143068|NCT01109979|DRUG|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
48143069|NCT02162082|DEVICE|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
48143070|NCT04186377|OTHER|Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers|Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
48143071|NCT04186377|DRUG|S26E|Daily application of S26E extract on wound site
48143072|NCT06510972|PROCEDURE|Strategy for continuing oral intake|Patients will be able to ingest liquids or solid food orally, at any frequency and in any quantity they wish, according to their tolerance, with paramedical assistance if necessary.
48664321|NCT02145936|OTHER|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
48143073|NCT06510972|PROCEDURE|Fasting strategy|The patient will not be able to ingest liquids or solid food.
48143074|NCT02496559|PROCEDURE|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
48143075|NCT04338178|BEHAVIORAL|Cognitive Remediation Therapy (CRT)|This intervention consists of mental exercises aimed at improving executive function via practice. Simple cognitive tasks that encourage reflective learning and insight into patient's own thinking process are administered. Exercises target set-shifting (i.e., cognitive flexibility), estimating, organization and planning.
48143076|NCT04338178|BEHAVIORAL|Emotional Skills Training (EST)|EST places emphasis on the improvement of inner emotion awareness, facial and body expression recognition and intra- and interpersonal emotion regulation skills. Different modules and interactive exercises are designed to help patients learn about i) the functions and manifestations of emotions, ii) the identification and labelling of own's and others' emotions, iii) tolerating and communicating emotions, and iiii) balancing between negative and positive emotions.
48143077|NCT04338178|BEHAVIORAL|Cognitive Behavioral Therapy|CBT intervention aimed to manage food craving by teaching group members cognitive (e.g., restructuring of urge-related thoughts) and behavioural strategies (e.g., increasing awareness through food diaries, relaxation skills, identification of cues that trigger craving, avoidance of high-risk situations for craving, distraction).
48143078|NCT04338178|PROCEDURE|Multidisciplinary outpatient program|Multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches. Patients are regularly followed and educated about the importance of lifestyle changes including healthy dietary habits and exercise in weight reduction and maintenance. Patients are also usually given information about nutritional value of various foods and few simple exercises for decreasing and maintaining body weight. This program is therefore planned as part of the usual care and responds to the recommendations of good practice for obesity
48143079|NCT01970878|DRUG|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
48143080|NCT01970878|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
48664322|NCT02437318|DRUG|Fulvestrant|
48664323|NCT02437318|DRUG|Alpelisib|
48664324|NCT02437318|DRUG|Alpelisib placebo|
48664325|NCT00862940|DRUG|Memantine|10 mg tablets twice daily
48143081|NCT01970878|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
48143082|NCT01970878|DRUG|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
48143083|NCT04665583|OTHER|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
48143084|NCT02358304|DRUG|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
48353612|NCT05791669|DRUG|Sodium fluoride varnish|It is a topical application with an active ingredient of 5% sodium fluoride(22,600ppm fluoride).it prolongs the contact time between the fluoride and tooth surface and promotes remineralization and inhibits demineralization.
47986906|NCT03189758|OTHER|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
47986907|NCT03189758|OTHER|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
48143085|NCT02358304|DRUG|Placebo|
48353613|NCT04942522|BIOLOGICAL|probiotics PS128|6×10\^10 CFU/capsule
48353614|NCT04942522|DRUG|placebo (Microcrystalline cellulose )|450 mg/capsule
48353615|NCT03742687|RADIATION|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
48664326|NCT00862940|DRUG|Placebo|Tablets twice daily
48664327|NCT03676387|OTHER|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation \[ETT OD=0.55\*(subglottic diameter)+1.16\] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
48664328|NCT04696003|COMBINATION_PRODUCT|Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter|The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.
48664329|NCT02755350|DRUG|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
48664330|NCT01186757|DRUG|PF-03715455|PF-03715455 1.6 mg BID
48664331|NCT01186757|DRUG|PF-03715455|PF-03715455 4mg BID
48664332|NCT01186757|DRUG|PF-03715455|PF-03715455 10 mg BID
48664333|NCT01186757|DRUG|Placebo|Placebo
48664334|NCT04113889|DRUG|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
48664335|NCT04113889|DRUG|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
48664336|NCT00928668|DRUG|Placebo|Placebo device for comparison
48664337|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
48664338|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
48664339|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
48664340|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
48664341|NCT04389060|DIETARY_SUPPLEMENT|Grape seed extract|Two capsule grape seed extract (total 600 mg)
48664342|NCT04734392|PROCEDURE|TAVR|TAVR implantation in cusp overlay technique
48664343|NCT06122168|OTHER|Mandala|verbal interview, standard health care, sheet of paper showing a mandala to be colored at will
48664344|NCT06122168|OTHER|Standard care|verbal interview and standard health care
48664345|NCT03045952|PROCEDURE|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
48664346|NCT02369536|DIETARY_SUPPLEMENT|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
48143086|NCT02763657|OTHER|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
47986908|NCT06413342|DRUG|Sintilimab|Patients should receive their first dose of sintilimab within 42 days after completing the final radiotherapy session and continue treatment until disease progression, occurrence of intolerable toxicity, loss to follow-up, death, or as determined by the investigator, whichever comes first. The maximum duration of sintilimab treatment is 12 months (from the initiation of therapy). No other anti-tumor therapies are permitted during the treatment period.
48353616|NCT02355665|DRUG|Nicotine Spray|Nicotine Spray
48143087|NCT03100370|DEVICE|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
48143088|NCT03100370|DEVICE|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
48143089|NCT03100370|DEVICE|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
48143090|NCT03100370|DEVICE|Robotic-assisted training of arm and hand functions|70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.
48143091|NCT01916109|DRUG|Gemcitabine|
48143092|NCT01916109|DRUG|Carboplatin|
48143093|NCT01916109|DRUG|Panitumumab|
48353617|NCT02355665|DRUG|Placebo|Placebo to match nicotine spray
48353618|NCT01057394|DEVICE|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
48143094|NCT01916109|PROCEDURE|radical cystectomy|
48143095|NCT01276275|DRUG|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
48143096|NCT04798066|BIOLOGICAL|HB-adMSCs|Autologous adipose derived mesenchymal stem cells
48143097|NCT00113308|DRUG|GW406381|
48143098|NCT02941094|DEVICE|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
48353619|NCT01057394|DEVICE|RF PVI Ablation|Radiofrequency ablation
48143099|NCT02941094|DEVICE|Ultrasound|Xario, Toshiba Tokyo Japan
48143100|NCT01038934|PROCEDURE|samples collected by buccal cytobrush|
48143101|NCT04895085|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
48143102|NCT05056376|BEHAVIORAL|Digital Diabetes Prevention Program (dDPP)|"The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc."
48143103|NCT05056376|BEHAVIORAL|Human Coach-based Diabetes Prevention Program (hDPP)|The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
48143104|NCT03770429|DRUG|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
48143105|NCT01869465|OTHER|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
48353620|NCT04387695|RADIATION|SBRT+TACE+Sorafenib|SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
47986909|NCT05421390|OTHER|Reduced fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. Skim milk, fat-free yogurt, and ≤22 % fat cheese
48353621|NCT04387695|DRUG|Sorafenib|Sorafenib 800 mg/day orally
48353622|NCT00957723|DEVICE|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
48353623|NCT02675582|OTHER|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
48353624|NCT03237390|DRUG|Gemcitabine Hydrochloride|Given IV
48353625|NCT03237390|OTHER|Laboratory Biomarker Analysis|Correlative studies
48353626|NCT03237390|OTHER|Pharmacological Study|Correlative studies
48353627|NCT03237390|DRUG|Ribociclib|Given PO
48353628|NCT00992485|DRUG|ADIPOPLUS|autologous adipose-derived stem cell
48353629|NCT02993289|OTHER|Different well-known treatments|
48664347|NCT02369536|DIETARY_SUPPLEMENT|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
48664348|NCT06450743|DIAGNOSTIC_TEST|Lymphocyte Immunophenotyping Test|Absolute enumeration of peripheral blood lymphocyte subpopulations
48664349|NCT04704193|OTHER|Survey of Decision Aid|The decision aid will be evaluated by a survey administered to those who have used the tool.
48664350|NCT01533545|DRUG|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
48664351|NCT01533545|DRUG|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
48143106|NCT01869465|BEHAVIORAL|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
48353630|NCT06039904|DEVICE|Natural rubber knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).
48505008|NCT06633952|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
48664352|NCT01738243|DRUG|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
48664353|NCT01738243|DRUG|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
48664354|NCT01621100|DRUG|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
47986910|NCT05421390|OTHER|Regular fat dairy|Serving sizes will be: 250 mL milk, 175 g yogurt, and 50 g cheese. 3.25% fat milk, ≥2% fat yogurt, and ≥28% fat cheese
48505009|NCT06633952|DEVICE|noninvasive neurostimulation device|A noninvasive neurostimulation device will be used to deliver theta frequency stimulation or sham stimulation to the frontal part of the brain.
48143107|NCT06041932|DRUG|Carvedilol|Carvedilol
48505010|NCT06633952|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
48664355|NCT04163757|DIETARY_SUPPLEMENT|crocin|2 tablets crocin per day
48664356|NCT04163757|DIETARY_SUPPLEMENT|placebo|2 tablets placebo per day
48664357|NCT04260477|DRUG|6EH³R³Z|"A triple dose is defined as the triple of the routine dose used for a specific WHO weight band. Hence, the mg/kg within a weigh-band varies, as is the case in routine practice.~Dosing takings into consideration the fixed dose combination (FDC) tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E). Dosage relies on tables with dosage by weight-bands used by WHO for the Cat. 1 regimen. The dosage used for the intensive phase of the Cat. 1 regimen applies for the whole treatment duration. A double dose of H and R is added to the recommended normal dose for adults (WHO,2003)"
48664358|NCT04260477|DRUG|6EHRZ|"Recommended normal dose adults (WHO, 2003)~* H: 5 (4-6) mg/kg/day~* R: 10 (8-12) mg/kg/day~* Z: 25 (20-30)mg/kg/day~* E: 15 (15-18)mg/kg/day"
48664359|NCT02993263|DEVICE|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
48664360|NCT00478257|DEVICE|bright white light|Intervention: Bright white light administered for 30 minutes each morning
48143108|NCT06041932|DRUG|Pentoxifylline|Pentoxiphylline
47986911|NCT00749372|OTHER|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
48143109|NCT03784105|DRUG|Codeine Phosphate|30 mL of codeine phosphate 10mg/5mL
48143110|NCT03784105|DRUG|Siripus simplex|Sugar syrup
48505011|NCT04480710|DRUG|CRV431 75mg|1 x 75mg softgel capsule
48505012|NCT04480710|DRUG|Placebo (1 softgel)|1 x placebo softgel capsule
48664361|NCT00478257|DEVICE|comparator red light treatment|dim red light administered for 30 minutes every morning
47986912|NCT06293885|DRUG|Dextrose 50|a solution of 50% glucose (D50) will be injected into your pleural space
48143111|NCT04864899|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
48505013|NCT04480710|DRUG|CRV431 225mg|3 x 75mg softgel capsule
48505014|NCT04480710|DRUG|Placebo (3 softgels)|3 x placebo softgel capsule
48505015|NCT03148561|DRUG|Misoprostol|received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
48353631|NCT06039904|DEVICE|Sponge knee support|The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
48353632|NCT00860704|DRUG|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
48143112|NCT04864899|DIAGNOSTIC_TEST|Blood test|Blood investigation
48143113|NCT04864899|DIAGNOSTIC_TEST|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
48143114|NCT02128893|DRUG|Isavuconazole|oral
48143115|NCT02128893|DRUG|Esomeprazole|oral
48143116|NCT01824849|PROCEDURE|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
48143117|NCT01824849|PROCEDURE|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
48143118|NCT04288869|OTHER|Continuous monitoring of arterial blood pressure|For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
48143119|NCT04288869|OTHER|Transcranial Doppler|"Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
48143120|NCT04288869|OTHER|Bispectral Index (BIS)|"Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation"
48143121|NCT04288869|OTHER|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
48143122|NCT02502019|DEVICE|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
48353633|NCT02520102|DRUG|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
47986913|NCT06293885|OTHER|Standard of Care - No Dextrose 50|Standard of Care
48143123|NCT04325425|DRUG|FOLFOXIRI Protocol|Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
48143124|NCT04325425|DRUG|Cisplatin injection|"Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3"
48143125|NCT03788811|DEVICE|ERG assessment (RSPA)|Processing and analysis of retinal signals
48143126|NCT05469516|DEVICE|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~- Non-invasive treatment of Axillary Hyperhidrosis"
48143127|NCT05469516|DEVICE|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
48353634|NCT04118140|OTHER|Somatic Acupressure|7-week self-acupressure plus usual care (an education booklet)
48353635|NCT04118140|OTHER|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
47986914|NCT06267950|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48353636|NCT04118140|OTHER|Usual care|Usual care only (an education booklet)
48353637|NCT05576415|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days.
48353638|NCT04520295|GENETIC|ctDNA screening|Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
48353639|NCT00646191|DRUG|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
48353640|NCT00646191|DRUG|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
48505016|NCT04868968|DRUG|DFV890|100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.
48664362|NCT01769027|DRUG|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
47986915|NCT06267950|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48143128|NCT00738348|DRUG|sivelstat|sivelstat sodiumhydrate
48143129|NCT00738348|DRUG|glucose|glucose
48143130|NCT05114993|DEVICE|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
48143131|NCT01211509|DRUG|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
48143132|NCT04705389|OTHER|Samples|blood samples
48505017|NCT06079346|DRUG|OT-101|OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene
48505018|NCT06079346|DRUG|mFOLFIRINOX|Folinic acid, 5-FU, Irinotecan, Oxaliplatin
48505019|NCT05423795|OTHER|Telemedicine-based intervention|Telemedicine-based intervention Multifaceted intervention including daily videoconferences with audit and feedback, educational interventions, and dissemination of published works
48505020|NCT05423795|OTHER|Standard of care arm|Classic expertise (as routinely performed in the participating ICU)
48505021|NCT04300283|BEHAVIORAL|Hypnosis|See previous description
48505022|NCT06522217|DEVICE|nasoalveolar molding appliance|making impression then make the conventional lab procedures for group A for the production of conventional appliances
48505023|NCT06522217|DEVICE|digital nasoalveolar molding appliance|group B scanning the model and designing the appliances on 3shap and 3d printing the appliances
47986916|NCT06267950|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
47986917|NCT01127412|BEHAVIORAL|Physical activity stimulating program|
47986918|NCT04130126|BEHAVIORAL|Taking cold showers|Showering behaviour
47986919|NCT03472404|PROCEDURE|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
47986920|NCT03472404|PROCEDURE|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
47986921|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with a patented fermented rye bran|During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
47986922|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with common refined wheat|During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
47986923|NCT00004323|DRUG|anti-thymocyte globulin|
47986924|NCT00004323|DRUG|cyclophosphamide|
47986925|NCT00004323|DRUG|cyclosporine|
47986926|NCT00004323|DRUG|mesna|
47986927|NCT00004323|DRUG|methotrexate|
47986928|NCT00004323|DRUG|methylprednisolone|
48143133|NCT05770609|DRUG|SPH3127 Tablets with Dose A|See Arm description
48143134|NCT05770609|DRUG|SPH3127 Tablets with Dose B|See Arm description
48143135|NCT05770609|DRUG|SPH3127 Tablets placebo|See Arm description
48143136|NCT03078205|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
48143137|NCT03078205|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
48143138|NCT05118100|DRUG|Clearfil Protect Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
48143139|NCT05118100|DRUG|Clearfil SE Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
48505024|NCT04502212|DEVICE|Hepatic Ultrasound Insonification|Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
48505025|NCT01421511|DRUG|TR-701 FA|"* TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily"
48505026|NCT01421511|DRUG|Linezolid|"* Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours"
48505027|NCT05798026|DRUG|EU103|EU103 will be administered via intravenous infusion.
48505028|NCT03288181|DEVICE|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
48664363|NCT01769027|DRUG|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
48143140|NCT01788371|DRUG|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
48143141|NCT01788371|DRUG|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
48143142|NCT00639418|BIOLOGICAL|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
48353641|NCT00646191|DRUG|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
48353642|NCT04989140|DRUG|Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone|Treatment was continued until disease progression, unacceptable toxicity
48353643|NCT04179370|OTHER|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
48505029|NCT00684489|DRUG|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
48664364|NCT01769027|BIOLOGICAL|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
48664365|NCT05115266|BEHAVIORAL|Animal-assisted therapy (AAT|The activity program consists of 10 sessions with a duration of about 60 minutes. During the 10 sessions the animal is presented, in this case a dog. They caress it, dress it, educate it ...
48664366|NCT05115266|BEHAVIORAL|Usual treatment|receive usual treatment (group activities)
48664367|NCT01179373|DEVICE|TMS, H coil|TMS, H Coil, High/ Low Frequency
48664368|NCT05892107|PROCEDURE|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
48664369|NCT05892107|PROCEDURE|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
48664370|NCT05892107|PROCEDURE|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
48664371|NCT03766672|DIAGNOSTIC_TEST|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
48664372|NCT00867607|DRUG|MRX-6|b.i.d treatment for 21 days
47986929|NCT00447642|DRUG|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
47986930|NCT00447642|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
47986931|NCT05175417|OTHER|MRI|3 tesla (T) MRI to provide higher resolution and quality brain images.
47986932|NCT05896527|DRUG|DC-806|DC-806 will be supplied as tablets to be administered orally.
47986933|NCT05896527|OTHER|Placebo|Matching placebo will be supplied as tablets to be administered orally.
47986934|NCT05063747|OTHER|No intervention.|Observational study. No intervention.
47986935|NCT04573595|DEVICE|Blood Pressure Measurement|The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.
47986936|NCT04349670|PROCEDURE|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
47986937|NCT01738854|PROCEDURE|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
47986938|NCT05029674|DEVICE|Whoop|Wear WHOOP Strap, complete surveys
47986939|NCT05133947|OTHER|Non interventional|Non interventional
47986940|NCT05540301|OTHER|Modified sleeper stretching|Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
48143143|NCT00985088|BIOLOGICAL|GSK2340274A|one or two intramuscular injections
48143144|NCT00985088|BIOLOGICAL|GSK2340273A|one or two intramuscular injections
48143145|NCT00985088|BIOLOGICAL|Saline placebo|One injection
48143146|NCT02504411|DEVICE|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
48143147|NCT02504411|DEVICE|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
48353644|NCT03491852|BEHAVIORAL|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
48664373|NCT00867607|DRUG|Steroid|b.i.d. 21 days
48664374|NCT00286286|DEVICE|Intraperitoneal Aerosolization System, IntraMyst|
48143148|NCT05914532|OTHER|lab testing|Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
48143149|NCT00594282|DEVICE|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
48143150|NCT04493359|DRUG|Renin-angiotensin system inhibitors|switch anti-hypertensive class
48143151|NCT04334252|OTHER|Questionnaire|Questionnaire
48143152|NCT04685395|DRUG|Ribamipide gargle \benzdymine HCL gargel|ribamipide gargle 6 time daily 5ml dosage
48143153|NCT02893800|DEVICE|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
48664375|NCT00004157|BIOLOGICAL|filgrastim|
48664376|NCT00004157|BIOLOGICAL|recombinant interleukin-11|
48143154|NCT04569526|DEVICE|use of intraoperative ultrasound|Ultrasonography guided brain lesions resection intra operatively for good localization
48143155|NCT03349944|BEHAVIORAL|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
48143156|NCT03673618|DRUG|Soluble Corn Fiber|Fiber or placebo
48143157|NCT05213182|BEHAVIORAL|Young Women of Today|Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
48664377|NCT01728103|DEVICE|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
47986941|NCT05540301|OTHER|Modified cross-body adduction stretch|Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
47986942|NCT00468416|DEVICE|Compression Anastomosis Ring (CAR)|
47986943|NCT01681732|OTHER|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
48143158|NCT01040312|DRUG|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
48143159|NCT01040312|DRUG|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
47986944|NCT01681732|OTHER|Control Standard Care|This is the standard care arm
47986945|NCT04823039|OTHER|Blood sample taken|For patients with sepsis who require vaccination during hospitalization, we will analyze the immunogenicity of pneumococcal conjugate vaccine (PCV13) by taking blood samples
47986946|NCT05846906|DRUG|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
48143160|NCT06195345|DIAGNOSTIC_TEST|MR Imaging|MR imaging pertaining to the patient and project (ICHOR 1)
48143161|NCT00234000|DRUG|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
48143162|NCT00234000|DRUG|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
48143163|NCT04266821|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case."
48143164|NCT04249440|PROCEDURE|Preoperative systemic treatment|neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
47986947|NCT05846906|DRUG|Clomiphene Citrate 50mg|used for ovionulation induct
47986948|NCT00204607|BIOLOGICAL|mRNA|
47986949|NCT00204607|DRUG|GM-CSF s.c.|
48143165|NCT02648555|BEHAVIORAL|Daily walking|Participants will be instructed to walk briskly for \>40 minutes, 7 days a week.
48664378|NCT06142591|DRUG|Oxycodone 10mg|10mg of oxycodone was added to Octenisept in the wound dressing.
48664379|NCT06142591|DRUG|Oxycodone 20mg|20mg of oxycodone was added to Octenisept in the wound dressing.
48664380|NCT02767076|PROCEDURE|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
48664381|NCT02767076|DEVICE|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
48664382|NCT00799565|GENETIC|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
48688015|NCT04033081|DEVICE|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
47986950|NCT05891587|DRUG|Semaglutide|Semaglutide pen injector
47986951|NCT05891587|DRUG|Placebo|Saline solution
47986952|NCT04940650|DIAGNOSTIC_TEST|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
48688016|NCT00104728|DRUG|ZD1839|
48143166|NCT02648555|BEHAVIORAL|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
48143167|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
48143168|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
48143169|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
48143170|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
48143171|NCT02253966|DRUG|Methylprednisoloneacetate|
48143172|NCT02253966|DRUG|Lidocaine|
48143173|NCT02253966|OTHER|sodium chloride|
48143174|NCT00407888|DRUG|doxorubicin hydrochloride|Given IV
48143175|NCT00407888|DRUG|cyclophosphamide|Given orally
48143176|NCT00407888|BIOLOGICAL|filgrastim|Given SC
48143177|NCT00407888|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
48143178|NCT00407888|BIOLOGICAL|trastuzumab|Given IV
48143179|NCT00407888|OTHER|laboratory biomarker analysis|Correlative studies
48143180|NCT00407888|PROCEDURE|quality-of-life assessment|Ancillary studies
48143181|NCT05160779|OTHER|Analysis of genetic polymorphisms of vasoactive peptides in COVID-19|Evaluate the frequency of the insertion/deletion (I/D) polymorphism in the ACE gene; to assess the frequency of polymorphism in the bradykinin B2 receptor gene; to assess the frequency of the polymorphism in the CK-M gene and compare the frequencies of these polymorphisms between patients with severe and mild conditions.
48143182|NCT02877524|OTHER|Adaptive support ventilation|ASV during NIV
48143183|NCT02877524|OTHER|Pressure support ventilation|PSV during NIV
48143184|NCT03213028|OTHER|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
48143185|NCT05056194|DRUG|Valiloxybate|XW10172 MR Granules for Oral Suspension
48143186|NCT05056194|OTHER|Placebo|Placebo Granules for Oral Suspension
48143187|NCT00074425|DRUG|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
48143188|NCT00074425|DRUG|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
48143189|NCT00074425|DRUG|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
48143190|NCT05541289|BIOLOGICAL|BBV152|Single Arm; BBV152 (COVAXIN™)
48688017|NCT04601259|COMBINATION_PRODUCT|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
48143191|NCT05097638|DIAGNOSTIC_TEST|spirometry|Patient do spirometry
48688018|NCT04601259|DEVICE|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
48688019|NCT02620878|DEVICE|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
48143192|NCT01847768|BIOLOGICAL|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
48143193|NCT01847768|PROCEDURE|Bronchoalveolar Lavage|
48143194|NCT01847768|DRUG|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
48143195|NCT01847768|PROCEDURE|Nasal Lavage|
48143196|NCT01847768|PROCEDURE|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
48143197|NCT01847768|PROCEDURE|Bronchial Brushings|
48143198|NCT01847768|PROCEDURE|Lung Mucosal Biopsy|
48143199|NCT01847768|PROCEDURE|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer \& glycerol negative control.
48143200|NCT01847768|PROCEDURE|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
48143201|NCT01847768|PROCEDURE|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
48143202|NCT01847768|PROCEDURE|Spirometry|
48143203|NCT01327014|DRUG|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
48143204|NCT01327014|DRUG|Placebo|4 capsules twice a day for 12 weeks.
48143205|NCT01553617|DRUG|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
48143206|NCT01553617|DRUG|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
48143207|NCT03102632|OTHER|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
48143208|NCT02225288|DRUG|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
48143209|NCT04986371|DRUG|Niraparib|Usage following drug insert is recommended
48143210|NCT06310707|DEVICE|ePatch ® Extended Wear Holter (EWH)|"Diagnostic Test: Extended ECG investigation~• An ambulatory ECG recordings with a duration of 7 days using Philips ePatch (https://www.myheartmonitor.com/device/epatch/) will be applied"
48143211|NCT03357237|OTHER|medical device|"patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo"
48143212|NCT02915211|DIETARY_SUPPLEMENT|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
48143213|NCT01448109|DRUG|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
48143214|NCT01448109|DRUG|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
48143215|NCT03839550|COMBINATION_PRODUCT|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
48143216|NCT03839550|PROCEDURE|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
48143217|NCT04726657|DRUG|Premixed Human Isophane Insulin Suspension + Human Insulin Injection|premixed human insulin
48143218|NCT04726657|DRUG|Premixed Insulin|Premixed Insulin Analog Biphasic Aspart 30
48143219|NCT06466681|OTHER|All included subjects|Administration of the subtest of divided attention of the Test of Attentional Performance (TAP), recording of the event related potentiels N200 and P300, measure of the variation of power in several frequency bands (theta, alpha and beta) and measure of the high-resolution EEG connectivity during an attentional task at several time-points : a first time during interictal period (no seizure for more than 24 hours) and 1, 3, 6 and 24 hours after a focal seizure.
48143220|NCT01726998|OTHER|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
48143221|NCT01726998|OTHER|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
48505030|NCT00684489|DRUG|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
48143222|NCT00006200|DRUG|thalidomide|
48143223|NCT00006200|DRUG|dacarbazine|
48143224|NCT00920985|DRUG|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
48143225|NCT00920985|DRUG|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
48143226|NCT02757911|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
48143227|NCT02027350|DEVICE|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
48688020|NCT02620878|OTHER|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
48688021|NCT00512850|DIETARY_SUPPLEMENT|Folic acid|Intervention group 1g folic acid per day
47986953|NCT04940650|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
48688022|NCT00512850|OTHER|Placebo|One placebo pill per day
47986954|NCT02753101|DRUG|[18F]-FTC-146|10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
47986955|NCT05543122|DRUG|either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe|This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.
48143228|NCT01179100|DRUG|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
48353645|NCT03491852|BEHAVIORAL|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
48353646|NCT05565209|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
48353647|NCT04330040|DRUG|Olaparib|Tablet
48353648|NCT00005054|DRUG|temozolomide|
48353649|NCT04787835|PROCEDURE|Forearm nerve block|Local anesthesia will be used to perform a forearm block of the median, radial, and ulnar nerves.
48353650|NCT04787835|PROCEDURE|Local anesthetic infiltration|Local anesthesia will be infiltrated at the site of injury
48353651|NCT02574520|DRUG|SABER-Bupivacaine (Part 1)|5 ml once at end of surgery
48353652|NCT02574520|DRUG|SABER-Bupivacaine (Part 2)|5 ml once at end of surgery
48353653|NCT02574520|DRUG|Saline Placebo|5 ml once at end of surgery
48353654|NCT02574520|DRUG|Bupivacaine HCl|0.5%, 15 ml, once at end of surgery
48353655|NCT00075413|DRUG|arsenic trioxide|
48353656|NCT01250782|DRUG|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
48353657|NCT01250782|DRUG|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
48353658|NCT05178511|DRUG|Ensartinib|Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
48353659|NCT04624529|OTHER|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
48353660|NCT00050570|BEHAVIORAL|Web-based intervention to reduce eating disorder risk factors|
48353661|NCT05931068|OTHER|Pre- and postoperative assessment|Pre- and postoperative assessment will consist of measurement of energy expenditure (direct and indirect calorimetry), aerobic capacity (cardiopulmonary exercise test), and physical activity (accelerometry).
48353662|NCT06366854|PROCEDURE|Personalised fluid and haemodynamic resuscitation|individualised resuscitation
48353663|NCT00242944|DRUG|Pitavastatin|Pitavastatin 4mg per day
48353664|NCT00242944|DRUG|Atorvastatin|Atorvastatin 20mg per day
48353665|NCT02313506|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
48353666|NCT02313506|BEHAVIORAL|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
48353667|NCT02596425|PROCEDURE|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
48353668|NCT02596425|PROCEDURE|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
48353669|NCT02596425|PROCEDURE|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
48353670|NCT03166228|DRUG|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
48353671|NCT03166228|DRUG|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
48353672|NCT00407251|DRUG|Patupilone|
48505031|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+virtual reality+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.frequency:Stimulation perform for 30 minutes per day for 4 weeks .~duration 600 pulses (intratrain pulse) frequency =20 Hz ; Pulse duration =0.3ms ,lasting 30 seconds each time ,stimulating once every 5 minutes"
47986956|NCT04200456|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
48353673|NCT00600249|DRUG|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
48353674|NCT00600249|DRUG|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
48353675|NCT00517634|DRUG|FP|Fluticasone Propionate 100 mcg BD
48353676|NCT00517634|DRUG|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
48353677|NCT00517634|DRUG|Placebo|Matching Placebo
48353678|NCT00801216|DRUG|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 \& 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
48353679|NCT02416765|OTHER|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
48353680|NCT02416765|DRUG|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
48353681|NCT02416765|DRUG|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
48353682|NCT02416765|OTHER|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
48353683|NCT04561050|OTHER|Comparison of score performances (Overall performance, discrimination and calibration)|"Our Study is an observational non-interventional study based on a multicentric anonymized registry. It's an external validation of pre-existing prognostic scores of traumatic haemorrhages at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion and haemorrhagic death.~The statistic intervention will be a comparison of score performances (Overall performance, discrimination and calibration)."
48353684|NCT05255497|DEVICE|Biodex Balance Exercise System|Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management.
48353685|NCT06232187|BEHAVIORAL|Artificial Intelligence feedback for ultrasound EFW standard plane images|AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.
48353686|NCT05441436|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Allogeneic hematopoietic stem cell transplantation
48353687|NCT05441436|PROCEDURE|Solid organ transplantation|Solid organ transplantation
48353688|NCT00554346|DRUG|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
48353689|NCT04686929|DRUG|Abatacept s.c.|subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.
48353690|NCT05544214|DRUG|CKD-371|PO
48353691|NCT05181215|DRUG|Monomethyl Fumarate 190 Mg|2 x oral 95 mg capsules, delayed-release
48353692|NCT05181215|DRUG|Diroximel Fumarate 462 mg|2 x 231 mg capsules, delayed-release
47986957|NCT04200456|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
48143229|NCT03851094|BEHAVIORAL|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
48143230|NCT03351504|OTHER|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
48353693|NCT00053105|DRUG|cisplatin|
48353694|NCT00053105|DRUG|cytarabine|
48353695|NCT00053105|DRUG|methylprednisolone|
48353696|NCT00053105|DRUG|pixantrone dimaleate|
48353697|NCT03180294|DRUG|Bupropion 150 mg XL|By mouth
48353698|NCT03180294|DRUG|Placebo|By mouth
48353699|NCT02350192|BEHAVIORAL|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
48353700|NCT03345849|DRUG|Upadacitinib|Oral; Tablet
48353701|NCT03345849|DRUG|Placebo for Upadacitinib|Oral; Tablet
47986958|NCT06542120|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by pediatrician and echocardiography by echocardiologist
47986959|NCT06542120|DIAGNOSTIC_TEST|Chest Auscultation and Chest imaging examinations|Chest auscultation will be done by pediatrician and chest imaging examinations by radiologist
47986960|NCT06542120|DIAGNOSTIC_TEST|Abdominal Auscultation and Abdominal imaging examinations|Abdominal auscultation will be done by pediatrician and chest imaging examinations by radiologist
48353702|NCT05937399|BEHAVIORAL|Intervention video|This intervention is an integrated health video provides individual (smoking) and environmental risk communication on intention to obtain lung cancer screening.
48353703|NCT05937399|BEHAVIORAL|Control video|This intervention is an integrated health video provides individual (smoking) risk communication on intention to obtain lung cancer screening.
47986961|NCT00535223|BEHAVIORAL|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
48353704|NCT03648502|DIAGNOSTIC_TEST|Cognitive tests and hearing tests|Several cognitive and hearing (peripheral and (central) auditory process) tests
48353705|NCT03247218|DRUG|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
48353706|NCT03607292|PROCEDURE|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
48353707|NCT03607292|PROCEDURE|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
48353708|NCT02463331|DRUG|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
48353709|NCT02463331|DRUG|prednisone|Prednisone 5-15 mg/day until the end of the study
48353710|NCT02463331|DRUG|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
48353711|NCT06014021|BEHAVIORAL|Pelvic floor muscle training with biofeedback device|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure.
48353712|NCT06014021|BEHAVIORAL|Pelvic floor muscle training|Use of the Smartphone application to perform a strengthening program for pelvic floor musculature.
48353713|NCT06014021|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the Smartphone application with access to information about pelvic floor and direct communication with healthcare team.
48353714|NCT01660529|BIOLOGICAL|hTERT|
48505032|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.Stimulation perform for 30 minutes per day for 4 weeks .~Routine physical therapy Stretching Areas :upper chest ,neck flexors ,shoulder flexor and adductors ,elbow and wrist flexors 10 minute per session,and stretches will held for 10s -30swith four repetition of each.30 minutes per day for 4 weeks Upper extremity Proprioception ,coordination,speed and agility increase such as followReach and grasp Handle turning simulated eating task Inserting object Opening bottle strenghtening exercise Muscles biceps brachii brachialis Coracobrachialis triceps brachii wrist extensors 10 minute per session for 4 weeks"
48505033|NCT06484725|GENETIC|Oncotype DX assay|Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.
48505034|NCT06213493|DIAGNOSTIC_TEST|measurement of RNAs|RNAs will be measured in heart tissues and in peripheral blood mononuclear cells
48664383|NCT05367947|BEHAVIORAL|In-phase Bilateral Exercises of the upper limbs|"The intervention protocol consists of in-phase bilateral exercises for the upper limbs, which are adapted to different sport activities and to fitness functional exercises, organized in a circuit training. Specifically, each session will consist of 1-3 sets, consisting of 10-15 repetitions of 9 different exercises targeting large muscle groups of the upper limbs.~The specific exercises will include sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises will include shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, using resistance elastic bands, as well as exercises with the patients' own body weight (e.g., pushups, TRX).~The intervention phase for each participant will consist of 12 consecutive weeks, for 3 times per week, 30-60 minutes each session."
47986962|NCT00535223|BEHAVIORAL|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
48143231|NCT03985397|OTHER|discharge training|Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
48143232|NCT05015842|OTHER|Conventional Physical Therapy|This is a combine protocol of different therapeutic exercises and heat therapy.
48353715|NCT06147232|DRUG|Sotagliflozin|Sodium-glucose-co-transporter 1 and 2 inhibitor
48353716|NCT06147232|DRUG|Placebo|Placebo tablet
48353717|NCT01381289|DRUG|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
48353718|NCT04399304|PROCEDURE|simultaneous bilateral high tibial osteotomy|One-stage simultaneous bilateral high tibial osteotomy
48353719|NCT04399304|PROCEDURE|Staged bilateral high tibial osteotomy|Two-stage bilateral high tibial osteotomy
48353720|NCT03053973|DEVICE|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
48353721|NCT03053973|OTHER|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
48353722|NCT04310592|BIOLOGICAL|CYNK-001|CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
48353723|NCT03305913|DRUG|TAS 102|TAS-102 tablet
48353724|NCT03305913|DRUG|Regorafenib|Regorafenib tablet
48353725|NCT00381108|DRUG|Placebo Tablet|Two tablets, twice daily.
48353726|NCT00381108|DRUG|Pomegranate Tablet|Two tablets, twice daily.
48353727|NCT02270190|DEVICE|Percutaneous Tibial Nerve Stimulation (PTNS)|
48353728|NCT00994890|DRUG|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
48353729|NCT00994890|DRUG|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
48353730|NCT00994890|DRUG|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
48505035|NCT03072979|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy
48505036|NCT06625892|BEHAVIORAL|the multidimensional interventions|The study participants will receive cognitive behavior therapy intervention for six weeks, one session per week, 45 minutes each time, and exercise training for twelve weeks, twice sessions per week, 60 minutes each time.
48143233|NCT05015842|OTHER|Kinesio Tapping|Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
48143234|NCT00980616|DRUG|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
48143235|NCT02624830|DRUG|Sulfonylurea|See Arm description.
48353731|NCT04605458|COMBINATION_PRODUCT|Contingency Management|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
48353732|NCT04605458|COMBINATION_PRODUCT|Standard Care|Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
48353733|NCT06435117|OTHER|Patient Navigation|CO-CAPTAIN focuses on co-designing and piloting and evaluating the implementation of patient navigation (PN) for primary cancer prevention in people with mental ill-health. Patient Navigators, trained professionals with experience working with people with mental ill-health, will assist people with mental ill-health in gaining access to and utilizing appropriate primary cancer prevention measures offered within the respective healthcare and social system (including smoking cessation and physical activity and nutritional interventions). For this purpose, Patient Navigators will offer regular appointment with participants, apply motivational interviewing and aid in accessing appropriate materials while aiming at empowering participants in taking an active role and making better and more informed decisions regarding their health.
48353734|NCT05592145|DEVICE|ViOptix|ViOptix machine
48353735|NCT03999333|DEVICE|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
48353736|NCT01030757|RADIATION|Tomotherapy treatment|"* A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~* Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~* Dose will be prescribed to the isodose line which covers at least 90% of the PTV~* Dose homogeneity +/- 5%"
48505037|NCT02302053|DIETARY_SUPPLEMENT|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
48505038|NCT02302053|DIETARY_SUPPLEMENT|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
48505039|NCT01231399|DRUG|fluorouracil|Given IV
48505040|NCT01231399|DRUG|leucovorin calcium|Given IV
48505041|NCT01231399|DRUG|oxaliplatin|Given IV
48505042|NCT01231399|DRUG|everolimus|Given orally
48505043|NCT01231399|OTHER|laboratory biomarker analysis|Correlative studies
48505044|NCT01231399|OTHER|immunohistochemistry staining method|Correlative studies
48353737|NCT03080441|DEVICE|pressure stockings|pressure stockings worn during dialysis throughout treatment period
48353738|NCT03080441|DRUG|Midodrine|administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
48353739|NCT03080441|OTHER|pressure stockings and midodrine|combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
48353740|NCT04874350|DRUG|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
48353741|NCT04874350|DRUG|Placebo|Oral matching placebo capsule
48353742|NCT03817931|DRUG|Anticholinergic|Tablet taken once daily.
48353743|NCT03817931|DRUG|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
48353744|NCT03817931|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
48505045|NCT01231399|GENETIC|microarray analysis|Correlative studies
48353745|NCT03817931|DIAGNOSTIC_TEST|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
48353746|NCT01832844|PROCEDURE|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
48353747|NCT01832844|PROCEDURE|"Group  without scan "|
48353748|NCT06166251|BEHAVIORAL|low ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 57-63% maximum heart rate.
48353749|NCT06166251|BEHAVIORAL|moderate ıntensity aerobic exercise|The exercise intervention was 30 min of treadmill jogging/running. After a two-minute warm-up walk at 1.0 m/s, the treadmill speed was increased to 64-76% maximum heart rate.
48505046|NCT04711902|DRUG|AIN457|Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
48505047|NCT04711902|OTHER|Secukinumab Placebo|Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
48505048|NCT00002444|DRUG|Nitazoxanide|
48505049|NCT01307111|DRUG|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
48505050|NCT01307111|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
48505051|NCT04172116|DEVICE|Continuous glucose monitoring|see arm/group descriptions
48505052|NCT03577548|OTHER|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
48143236|NCT05377476|OTHER|Motor Imagery training|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.
48353750|NCT05136209|PROCEDURE|PCCC procedure without A-vit|In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.
48353751|NCT05136209|PROCEDURE|PCCC+A-Vit procedure|PCCC+A-Vit procedure
48353752|NCT06388356|OTHER|Educational intervention - Yksityisyyttä ensihoitoon / Informational privacy for preospital emergency care|"Educational intervention is a self-study, online course on Koulumaali platform about patient's informational privacy (IP) in prehospital emergency care (PEC).~It comprises three separate educational modules approximately 30 min. long: module I) the meaning and significance of IP and its protection, module II) legislation regarding IP and its protection in healthcare and module III) breaches of IPand its protection in PEC.~Each module contains theoretical sections as well as case-exercises and tests.~Participants will have four weeks time to execute the entire course independently. Participants can execute the modules according to their own schedule. The modules need to be completed in certain order by following the numerical order from first to third. Only one of the modules is open at a time and the second module activates after the previous modules has been completed. Already completed modules become inactive."
48353753|NCT00515944|DRUG|Botulinum neurotoxin type A, free of complexing proteins|
48353754|NCT03687710|BEHAVIORAL|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
48353755|NCT04184921|DRUG|Aspirin 100mg|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
48664384|NCT01280942|BEHAVIORAL|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
48664385|NCT01280942|DEVICE|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
48505053|NCT06634290|DEVICE|intramedullary nailing augmentation|Treatment of pertrochanteric hip fractures with intramedullary nailing with cephalic augmentation with bone cement
48505054|NCT06634290|DEVICE|intramedullary nailing|Treatment of pertrochanteric hip fractures with intramedullary nailing without cephalic augmentation
48505055|NCT02342639|DRUG|Rifaximin|550mg pills
48505056|NCT02342639|DRUG|Placebo|Placebo pill
48505057|NCT02832180|DRUG|OC containing EE and NET|
48505058|NCT02832180|DRUG|BMS-986142|
48505059|NCT06396065|DRUG|AK112 Injection|Subjects will receive AK112 Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, AK112 Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
48505060|NCT06396065|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
48664386|NCT02946203|OTHER|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
48664387|NCT02946203|OTHER|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
48664388|NCT01188187|DRUG|Custirsen|
48664389|NCT01188187|DRUG|Docetaxel|
48664390|NCT01188187|DRUG|Prednisone|
48664391|NCT01188187|DRUG|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
48664392|NCT02862886|OTHER|myometrium biopsy|
48664393|NCT00414154|BEHAVIORAL|Group based multidisciplinary patient education programme|
48143237|NCT05377476|OTHER|Action Observation training|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.
48143238|NCT05377476|OTHER|standard rehabilitation|40 minutes of standard rehabilitation.
48143239|NCT02323776|OTHER|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
48664394|NCT01515371|DRUG|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
48664395|NCT01515371|DRUG|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
48664396|NCT01221116|DRUG|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
48664397|NCT03656354|DEVICE|Seismocardiography|Seismocardiography recording
48664398|NCT00629928|DRUG|Esomeprazole|20mg oral capsule daily
48664399|NCT00629928|DRUG|Esomeprazole|40mg oral capsule daily
48664400|NCT00629928|DRUG|Placebo|
48664401|NCT00205959|DEVICE|Locking proximal humerus plate|
48664402|NCT00205959|DEVICE|Proximal Humerus Internal Locking System|
48664403|NCT00205959|DEVICE|Proximal Humerus Nail|
48664404|NCT00725985|DRUG|Cladribine|Cladribine tablets were administered until CDMS conversion, whichever occur first.
48664405|NCT00725985|DRUG|Placebo|Placebo matched to cladribine tablets were administered.
48664406|NCT00725985|DRUG|Rebif® new formulation (RNF)|Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
48664407|NCT03403686|BIOLOGICAL|blood draw|Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
48664408|NCT02264314|BEHAVIORAL|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
48353756|NCT04184921|DRUG|Osimertinib 80 MG|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
48353757|NCT00467506|DRUG|bispecific antibody and di-DTPA-131I|
48353758|NCT01191138|PROCEDURE|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
48353759|NCT01191138|PROCEDURE|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
48143240|NCT05064072|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure."
48353760|NCT06092840|DIETARY_SUPPLEMENT|Transform Burn|Study product Transform Burn contains dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract, and african mango (Irvingia gabonensis) seed extract.
48353761|NCT03333512|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
48353762|NCT02607865|DRUG|semaglutide|Oral administration once-daily
48353763|NCT02607865|DRUG|sitagliptin|Oral administration once-daily
48353764|NCT02607865|DRUG|placebo|Oral administration once-daily
48353765|NCT05747664|DRUG|DWP16001|0.3mg
48664409|NCT02264314|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
48353766|NCT01084811|PROCEDURE|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
48353767|NCT04061304|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
48353768|NCT04061304|DEVICE|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
48353769|NCT05651269|DRUG|Milciclib Dose: 150 mg/day Mode of administration: oral|milciclib plus gemcitabine
48353770|NCT05022706|OTHER|Community-based accompaniment and home visits|"Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support."
48664410|NCT00404248|DRUG|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
48353771|NCT05022706|BEHAVIORAL|Directly Observed Therapy|Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.
48353772|NCT05022706|BEHAVIORAL|Monthly Peer Support Groups|The investigators will assign ALWH to a social support group with 9 to 11 other adolescents also participating in the research. The goal of the social support groups is to provide a venue for participants to share experiences and resources and provide encouragement and support to one another. Each group will last approximately 3 to 4 hours. Support groups will be led by adult peers or trained community health workers. The final group session will incorporate a discussion about the group experience, how it may change behavior, recommendations for improvement, and unmet needs that should be considered for a future intervention.
48353773|NCT03315702|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
48505061|NCT03462979|DEVICE|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
48664411|NCT00404248|OTHER|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
48664412|NCT03297658|DEVICE|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
48664413|NCT03297658|DEVICE|sham|Micro electrodes will be placed but there will be no stimulation
48664414|NCT05775939|OTHER|Fludeoxyglucose F-18|Given FDG
48664415|NCT05775939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
48664416|NCT05775939|PROCEDURE|Computed Tomography|Undergo PET-CT
48664417|NCT05775939|OTHER|Questionnaire Administration|Ancillary studies
48664418|NCT04927221|DRUG|DC371739 Tablets|Participants received one of 5 dose levels of DC371739 administered as single oral doses.
48353774|NCT01810289|BEHAVIORAL|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
48353775|NCT02161224|DRUG|FG-4592|Oral
48353776|NCT04330456|RADIATION|Preoperative stereotactic radiation therapy in hypofractionation mode|"At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.~At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.~GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy."
48353777|NCT04330456|PROCEDURE|Surgery|In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
48353778|NCT04330456|RADIATION|Postoperative conformal radiation therapy in normofractionation mode|"In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.~PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery."
48353779|NCT02628366|OTHER|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
48353780|NCT02268760|DRUG|BILN 2061 ZW single rising doses|
48353781|NCT02268760|DRUG|Placebo|
48353782|NCT02268760|DRUG|BILN 2061 ZW fixed dose|
48505062|NCT04888598|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT) Angiography|Measurement of retinal vessel density and distribution in the macula using new generation OCT device
48505063|NCT05375877|DEVICE|iATROS|"The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences."
48505064|NCT05519319|PROCEDURE|RFA|RFA will be performed
48664419|NCT04927221|DRUG|Placebo|Placebo orally administered as comparison
48353783|NCT02268760|OTHER|Standardized breakfast|
48353784|NCT01942395|BEHAVIORAL|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
48353785|NCT01942395|BEHAVIORAL|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
48353786|NCT01289561|DRUG|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
48353787|NCT01289561|DRUG|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
48353788|NCT03979495|OTHER|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
48353789|NCT02259764|DRUG|KUC 7483 CL - single rising dose|
48353790|NCT02259764|DRUG|Placebo|
48353791|NCT02259764|OTHER|standardized high fat meal|
48353792|NCT01786278|RADIATION|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
48353793|NCT01786278|PROCEDURE|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
48353794|NCT05333289|BIOLOGICAL|mRNA-1030|Sterile liquid for injection
48505065|NCT05519319|PROCEDURE|PDT|PDT will be performed
48664420|NCT00587119|DRUG|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
48664421|NCT00410683|OTHER|clinical observation|
48664422|NCT00410683|PROCEDURE|adjuvant therapy|
48664423|NCT00410683|RADIATION|3-dimensional conformal radiation therapy|
48505066|NCT05519319|PROCEDURE|RFA combined with PDT|RFA and PDT will be performed
48505067|NCT04668911|OTHER|Swab|PCR test for SARS-CoV2, oral and nasal swab
48505068|NCT01265810|OTHER|supersaturated calcium-phosphate|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
48505069|NCT01265810|OTHER|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
48505070|NCT01808820|BIOLOGICAL|Dendritic Cell Vaccine|Between 1.2 to 12 million DC per dose administered once a week via intradermal injection for 4 weeks.
48505071|NCT01808820|BIOLOGICAL|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
48664424|NCT04697927|OTHER|Questionnaires|The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.
48664425|NCT04926376|DEVICE|Eye90 Microspheres|Y90 glass microspheres
48664426|NCT06179264|BEHAVIORAL|ACT Guide for Chronic Health Conditions|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. The current project is an online, self-guided, 6-session intervention based on ACT. The program is intended to help individuals with chronic health conditions improve their quality of life and mental health. Each session is expected to take about 30 minutes each, and the entire program will take 6 weeks to complete, as users will be encouraged to work on one session per week. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and chronic health condition specific vignettes, and apply ACT concepts to their own lives and situations related to their chronic health condition. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
48664427|NCT06537687|OTHER|Control|A standardized handout on HPV and vaccine education will be given
48664428|NCT06537687|OTHER|Intervention|A video about HPV and vaccines on a tablet provided by a research assistant
48664429|NCT04943861|BEHAVIORAL|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
48664430|NCT04943861|OTHER|Usual Care|There is no peer navigation within usual care.
48353795|NCT05333289|BIOLOGICAL|mRNA-1020|Sterile liquid for injection
48353796|NCT05333289|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
48353797|NCT05333289|BIOLOGICAL|Active Comparator|Sterile liquid for injection
48505072|NCT01808820|DRUG|Imiquimod|5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
48353798|NCT01948323|BEHAVIORAL|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
48353799|NCT01829867|DRUG|sNN0031|
48353800|NCT00381524|BEHAVIORAL|Increase condom use|Voluntary increase in condom use
48353801|NCT01585909|PROCEDURE|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
48353802|NCT00230373|DRUG|imiquimod 5% cream (Aldara)|
48353803|NCT06296043|PROCEDURE|Progressive Muscle Relaxation Exercise Group|Exercise Group
48353804|NCT06296043|PROCEDURE|Su-Jok Intervention|Hand massage with seeds
48353805|NCT05723276|DRUG|Psilocybin|Psilocybin 25mg PO
48353806|NCT04966611|DRUG|Anlotinib|This is an observational study
48353807|NCT06386367|BEHAVIORAL|Monastery-based health education by Buddhist monks|During the three-month intervention from July to September 2022, a total of 18 health education sessions were conducted across the three intervention villages, with an average of 50 attendees per session, totaling 921 attendees across all sessions.
48353808|NCT01018251|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Given IV
48353809|NCT01018251|PROCEDURE|Positron Emission Tomography/computed tomography|
48353810|NCT01018251|RADIATION|FLT-PET/CT|
48664431|NCT02323048|DRUG|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
48664432|NCT02323048|DRUG|placebo|Placebo (sugar pill)
48664433|NCT04818710|PROCEDURE|skin incision with a scalpel|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)"
48664434|NCT04818710|PROCEDURE|skin incision with diathermy|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)"
48143241|NCT05064072|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the pain felt by the infants evaluated with Neonatal Infant Pain Scale and the score recorded in the chart. Since the hydrocolloid barrier tape can stay on the skin for 7 days and the assessment of the pain realized in 7th day and noted down to the chart. Pain score evaluated in 7th day 3 min. before procedure, during and 3 min after procedure"
48143242|NCT05064072|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape on the silk tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure"
48143243|NCT02516085|DRUG|Metformin|
48143244|NCT02516085|DRUG|L-Arginine|
48143245|NCT04432155|DRUG|Xenon|30% xenon, 30% oxygen, and 40% nitrogen
48664435|NCT04017858|BEHAVIORAL|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
48688023|NCT00179062|DRUG|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
48143246|NCT04432155|DRUG|Placebo|30% oxygen, and 70% nitrogen
48143247|NCT04328467|DRUG|Hydroxychloroquine|Hydroxychloroquine; 200mg tablet; oral
48143248|NCT04328467|OTHER|Placebo|Placebo; tablet; oral
48353811|NCT00432263|DRUG|Genotropin (PN-180,307) Somatropin|
48353812|NCT04444323|OTHER|3D Telemedicine|The intervention is a consultation conducted using a 3D form of telemedicine
48353813|NCT01327573|DRUG|eculizumab|"* Eculizumab Induction 600mg IV every 7 days for 4 doses~* Eculizumab 900mg IV 7 days later~* Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
48353814|NCT01213511|PROCEDURE|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
48143249|NCT04976556|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
48143250|NCT04686617|DIAGNOSTIC_TEST|Mechanical Vibration|Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
48143251|NCT02500082|DRUG|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
48143252|NCT01806207|DEVICE|Durolane injection|
48143253|NCT01806207|OTHER|Saline injection|
48143254|NCT01840722|OTHER|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
48143255|NCT05925335|DEVICE|Transseptal Transcatheter Mitral valve-in-valve Replacement|Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
48143256|NCT04970732|PROCEDURE|Gum chewing|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
48143257|NCT03390166|BIOLOGICAL|GPO Tri Fluvac vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
48143258|NCT03390166|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
48143259|NCT05991882|BEHAVIORAL|Condition 1: Craving daily+PBS daily|Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
48353815|NCT01213511|PROCEDURE|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
48353816|NCT00777686|PROCEDURE|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
48353817|NCT05393661|OTHER|inpatient physical therapy poststroke|routine care
48353818|NCT01495260|DRUG|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
48505073|NCT01808820|PROCEDURE|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
48664436|NCT04017858|BEHAVIORAL|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
48505074|NCT06386289|DEVICE|Cereglide 92|Aspiration of cerebral large vessels occlusions
48505075|NCT05900258|DRUG|Tirbanibulin|Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
48664437|NCT05703399|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48505076|NCT04129073|OTHER|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
48505077|NCT02493192|DRUG|pethidine and haloperidol injection|
48505078|NCT02493192|OTHER|birth ball|
48664438|NCT05703399|OTHER|Questionnaire Administration|Complete questionnaire
48353819|NCT01495260|DRUG|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
48353820|NCT01495260|DRUG|vitamin E|vitamin E, 150-300 mg daily for 2 months
48353821|NCT03094494|OTHER|none intervention|none intervention
48353822|NCT02653989|BIOLOGICAL|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
48353823|NCT05616572|BEHAVIORAL|OncoWhiz|OncoWhiz is an online educational tool designed to supplement current institutional caregiver education. OncoWhiz requires low graphical demands, has no-end user downloads, and is compatible with both desktop and mobile phones. Questions are derived from the institutional binder and are written at a fifth-grade reading level for user accessibility.
48353824|NCT02672644|DEVICE|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
48353825|NCT02672644|DEVICE|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
48353826|NCT03201133|DIAGNOSTIC_TEST|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
48353827|NCT06117956|DIAGNOSTIC_TEST|Rapid urease test for h pylori|"Tonsillectomy will be done with the dissection method and one tonsil per patient will be collected. A 2 mm gross specimen will be washed with normal saline. The specimen will be placed in a test tube well containing Rapid Urease Enzyme (GASTRO CURE SYSTEM RUT DRY TEST Batch No. A1060).~The initial color will be read at 0 min. Subsequent color changes will be read at 30 min, 6 hours, and 24 hours. Any color change from the initial yellow color to either pink or red will be recorded as positive. Any test that will be remained yellow after 24 hours will be recorded as negative.~Tonsillar tissue samples will be fixed in 10% formalin for 24 h Each slide will be separately evaluated for the presence or absence of Helicobacter-like organisms at a high-power magnification"
48353828|NCT01440829|DRUG|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
48353829|NCT02551328|DRUG|sevofluorane|Continuous infusion of sevofluorane
48353830|NCT01355224|GENETIC|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
48353831|NCT01355224|BEHAVIORAL|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
48353832|NCT03659240|OTHER|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
48353833|NCT03659240|OTHER|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
48664439|NCT00163189|DRUG|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
47986963|NCT04139187|OTHER|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
47986964|NCT00394628|DRUG|AQ4N|
48353834|NCT05500391|OTHER|Oncological Follow-up|Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
48353835|NCT01137448|BEHAVIORAL|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
48353836|NCT02272244|BEHAVIORAL|Decision Support & Navigation|
48353837|NCT02272244|BEHAVIORAL|Standard|
48353838|NCT03844061|DRUG|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
48505079|NCT01345487|OTHER|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
48505080|NCT01345487|OTHER|Animal protein|Protein in the form of minced pork/beef
48664440|NCT00261339|DRUG|Pantoprazole|
48664441|NCT02305186|DRUG|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
48664442|NCT02305186|RADIATION|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
48664443|NCT02348021|PROCEDURE|Percutaneous coronary intervention (PCI)|
48664444|NCT02348021|DRUG|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
48143260|NCT05991882|BEHAVIORAL|Condition 2: Craving daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
48143261|NCT05991882|BEHAVIORAL|Condition 3: Craving trigger+PBS daily|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
48353839|NCT03844061|DRUG|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
48353840|NCT03844061|OTHER|Placebo Subcutaneous Injection|Normal Saline
48353841|NCT03844061|OTHER|Placebo Infusion|Normal Saline
48353842|NCT03844061|DRUG|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
48664445|NCT06478862|DRUG|Promitil|The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent.
48664446|NCT00569179|DEVICE|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
48664447|NCT00841815|DRUG|Amlodipine Besylate|10 mg Tablet
48664448|NCT00841815|DRUG|Norvasc®|10 mg Tablet
48664449|NCT04633239|DRUG|Abemaciclib|Given PO
48664450|NCT04633239|PROCEDURE|Biopsy|Undergo tumor biopsy
48664451|NCT04633239|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48664452|NCT04633239|DRUG|Olaparib|Given PO
48664453|NCT00666263|BIOLOGICAL|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
47986965|NCT00394628|DRUG|Temozolomide|
47986966|NCT00394628|PROCEDURE|Radiotherapy|
48664454|NCT00666263|BIOLOGICAL|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
48664455|NCT05314660|DRUG|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
48664456|NCT05314660|PROCEDURE|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
48143262|NCT05991882|BEHAVIORAL|Condition 4: Craving trigger+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
48143263|NCT05991882|BEHAVIORAL|Condition 5: PBS daily+ PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
48353843|NCT06305923|OTHER|colostrum cream|the intervention in our study is everyday using a cream with active ingridient
48664457|NCT05314660|PROCEDURE|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
48664458|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
48353844|NCT06305923|OTHER|placebo cream|using a placebo cream
48353845|NCT03628391|DRUG|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
48353846|NCT03628391|DRUG|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
48353847|NCT04572724|DRUG|Sacubitril / Valsartan Oral Tablet|Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP\>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.
48353848|NCT04572724|DRUG|RAS Inhibitors|RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
48353849|NCT00515554|DRUG|Rituximab|addition of Rituximab to BEACOPP escalated
48353850|NCT00515554|DRUG|BEACOPP escalated|chemotherapy with BEACOPP escalated
48353851|NCT04346004|DRUG|Normal saline|"Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery."
48353852|NCT04346004|DRUG|Iron isomaltoside|"Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) \& IM Vitamin B12 (1mg) 1 day before surgery."
48353853|NCT01453686|DRUG|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
48353854|NCT01453686|DRUG|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
48353855|NCT00578396|DIETARY_SUPPLEMENT|grapes|1 pound of seedless red grapes
48353856|NCT00578396|DIETARY_SUPPLEMENT|grapes|2/3 lb/day fresh red grapes
48353857|NCT00578396|DIETARY_SUPPLEMENT|grapes|1/3 lb/day fresh red grapes
48353858|NCT05947695|BEHAVIORAL|Palliative and Survivorship Care Model|The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
48143264|NCT05991882|BEHAVIORAL|Condition 6: Craving daily+Craving trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.
48143265|NCT05991882|BEHAVIORAL|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
48353859|NCT04481711|PROCEDURE|Total Knee Arthroplasty|Osteoarthritis (OA) is one of the most common chronic peripheral joint diseases increasing among the aging population.Pathogenesis is not fully known.One of the most common risk factors and causes are loss of pain and function. Knee joint osteoarthritis adversly affects the person's life quality. Total Knee Arthroplasty (TKA) is a surgical approach to restore tibiofemoral joint alignment, especially in the severe level of knee OA.
48143266|NCT05991882|BEHAVIORAL|Condition 8: No daily or trigger craving or PBS|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will not receive any further intervention strategies.
48353860|NCT03712670|DRUG|Aflibercept|monthly intravitreal injections
48353861|NCT03712670|DRUG|Pranoprofen|0.1% pranoprofen 3 times a day topical eye drops administration
48353862|NCT03712670|DIETARY_SUPPLEMENT|Carotenoids|daily supplementation of nutraceutical tablets containing the AREDS2 formulation
48353863|NCT03656146|OTHER|Food Insecurity Screening Tablet|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
48353864|NCT03656146|OTHER|Food Insecurity Screening Verbal|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
48353865|NCT02325128|BEHAVIORAL|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
48353866|NCT06378606|BEHAVIORAL|cognitive therapy|"intervention : group A: recive computer cognitive traing by rehacom system and omega 3 supplement .~group B: recive smart phone cognitive application and omega 3 supplement . group c recive omega 3 supplement only."
48353867|NCT02204059|DRUG|hMAb BIWA 4|
48353868|NCT04607291|OTHER|Community Health Service|Receive Witness CARES services
48353869|NCT04607291|OTHER|Survey Administration|Ancillary studies
48353870|NCT00561067|DRUG|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
48353871|NCT00561067|DRUG|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
48353872|NCT01446549|OTHER|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
48353873|NCT01446549|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation implantation
48353874|NCT04768049|OTHER|Tool Translation|Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with help of two professional translators and then it will be back translated into English to cross check the clarity of text. The translation will focus more on the context and understanding of the text rather literal word-to-word meanings. The translation will be done according to the WHO guidelines
48353875|NCT06245395|DEVICE|Virtual Reality|Meta Quest 2 Headset
48143267|NCT04495153|BIOLOGICAL|Aglatimagene besadenovec|Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
48143268|NCT04494399|DRUG|Interferon beta-1b|5-day course of daily subcutaneous injection of interferon β-1b 16 million IU
48353876|NCT06059521|DEVICE|Software refraction with Eye Test Technology in a mobilerone|Refraction is done by software App by a mobilerone software installed.
48353877|NCT06059521|DEVICE|Retinoscopy|Retinoscopy is an objective refraction method with retinoscope.
48353878|NCT01627041|DRUG|Cytarabine|Given IV
48353879|NCT01627041|DRUG|Daunorubicin Hydrochloride|Given IV
48353880|NCT01627041|DRUG|Decitabine|Given IV
48143269|NCT04494399|DRUG|Ribavirin|5-day course of oral ribavirin 400mg twice daily
48353881|NCT01627041|OTHER|Laboratory Biomarker Analysis|Correlative studies
48353882|NCT01627041|OTHER|Pharmacological Study|Correlative studies
48353883|NCT03887286|DEVICE|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
48353884|NCT03887286|DEVICE|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
47986967|NCT02969512|OTHER|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
47986968|NCT02969512|OTHER|OASIS Online Educational Webinars|2-hour online educational large group sessions
48143270|NCT05200624|DEVICE|2RT subthreshold nanosecond laser|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
48143271|NCT00963924|DRUG|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
48143272|NCT00963924|DRUG|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
48353885|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and morphine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. Serratus Anterior Plane Block (SAPB) will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine + 2 mg (1mL) of morphine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 6 mg of morphine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
48664459|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
48664460|NCT00048984|OTHER|laboratory biomarker analysis|Correlative studies
48664461|NCT04637061|COMBINATION_PRODUCT|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
48664462|NCT04637061|DIAGNOSTIC_TEST|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
48664463|NCT04637061|DIAGNOSTIC_TEST|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
48664464|NCT03274778|DRUG|Ruxolitinib 20 MG|tablets
48664465|NCT01140204|DEVICE|Implantation of a bare metal stent|Bare Metal Stent
48664466|NCT03341936|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
48664467|NCT03341936|DRUG|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
48143273|NCT00963924|BEHAVIORAL|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
48664468|NCT06186232|PROCEDURE|guided bone regeneration (GBR).|guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
48143274|NCT05328817|DRUG|Antibiotics|In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
48353886|NCT05843344|DRUG|erector spinae plane block with a combination of ropivacaine and dexmedetomidine|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +0.5 mcg/kg (1mL) of dexmedetomidine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 200 mcg of dexmedetomidine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
48353887|NCT05843344|DRUG|erector spinae plane block with ropivacaine only|Before surgery, a US guided ESPB will be performed, and a catheter will be placed. SAPB will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine +1 mL of normal saline will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 3 mL of normal saline will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr
48353888|NCT03248817|DRUG|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
48353889|NCT03248817|DRUG|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
48353890|NCT03248817|DRUG|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
48353891|NCT03248817|DRUG|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
48353892|NCT04647695|DRUG|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
48353893|NCT04647695|DRUG|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
48353894|NCT02253680|PROCEDURE|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
48664469|NCT06157073|DEVICE|Closed-loop ventilator|Fully automated closed-loop ventilator using the INTELLIVENT software
48353895|NCT02315833|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
48505081|NCT01846910|BEHAVIORAL|Tooth Whitening|1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
48664470|NCT06157073|DEVICE|Open-loop ventilator|Conventional closed-loop ventilator with manual adjustments by the physician in charge
48664471|NCT03626766|BEHAVIORAL|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
48143275|NCT01918176|DRUG|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
48353896|NCT02315833|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
48353897|NCT02608892|BEHAVIORAL|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
48353898|NCT02180191|OTHER|Comparison of the gut microbiota composition|
48353899|NCT00022906|DRUG|Iodine-131 Anti-B1 Antibody|
48353900|NCT00411879|DRUG|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin \[20 IU IV maximum dose = 100 IU\] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
48353901|NCT00411879|DRUG|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
48353902|NCT00367627|DRUG|Albendazole|
48664472|NCT03626766|BEHAVIORAL|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
48664473|NCT03626766|BEHAVIORAL|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
48143276|NCT01918176|DRUG|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
48143277|NCT04630119|OTHER|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
48143278|NCT05097105|DEVICE|MRI|MRI sequences: TI. T2 and diffusion weighted
48143279|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
48143280|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
48143281|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
48143282|NCT02050555|DIETARY_SUPPLEMENT|Placebo|
48143283|NCT02050555|DIETARY_SUPPLEMENT|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
48143284|NCT05495711|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
48143285|NCT05495711|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
48143286|NCT06114537|DRUG|Acetazolamide|"The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks."
48143287|NCT00630357|DRUG|Levetiracetam (Keppra)|
48143288|NCT05885516|PROCEDURE|intrauterine insemination|Giving washed sperm concentrate into uterine cavity via a soft catheter
48143289|NCT00042926|OTHER|immunohistochemistry staining method|
48143290|NCT00042926|PROCEDURE|conventional surgery|
48143291|NCT00042926|PROCEDURE|lymphangiography|
48143292|NCT00042926|PROCEDURE|radionuclide imaging|
48143293|NCT00042926|PROCEDURE|sentinel lymph node biopsy|
48143294|NCT00042926|RADIATION|technetium Tc 99m sulfur colloid|
48143295|NCT02604693|OTHER|Nothing|No interventions will be administered.
48143296|NCT04928937|PROCEDURE|Roux-en-Y gastric bypass, sleeve gastrectomy|bariatric surgery with the goal loosing weight
48143297|NCT02573129|OTHER|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
48143298|NCT02573129|OTHER|Red Meat Rich|Mediterranean diet rich in red meat
48143299|NCT03138720|DRUG|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
48353903|NCT01573611|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
48353904|NCT01573611|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
48664474|NCT04035226|OTHER|No intervention|No intervention will be administered as a part of this study.
48143300|NCT02730091|DRUG|Letrozole|Letrozole 2.5 mg daily
48143301|NCT02730091|DRUG|Anastrozole|anastrozole 1 mg daily
48143302|NCT02730091|DRUG|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
48143303|NCT06377137|BEHAVIORAL|Small-sided soccer games groups (SSSG)|Physical exercise intervention
48143304|NCT06377137|BEHAVIORAL|Traditional soccer training groups (TSG)|Physical exercise intervention
48143305|NCT02267109|BIOLOGICAL|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
48143306|NCT02267109|BIOLOGICAL|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
48143307|NCT02435485|DEVICE|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
48353905|NCT04022590|DEVICE|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
48353906|NCT04022590|BEHAVIORAL|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
48353907|NCT01357720|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
48353908|NCT01357720|BIOLOGICAL|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
48353909|NCT00204802|BEHAVIORAL|Patient-Centered Advance Care Planning|
48353910|NCT06108440|OTHER|action observation training|Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks.
48353911|NCT06108440|OTHER|motor imagery training|Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks.
48353912|NCT03324867|DRUG|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
48353913|NCT03324867|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
48353914|NCT01096966|DRUG|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
47986969|NCT00721773|DRUG|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
47986970|NCT00721773|DRUG|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
47986971|NCT00721773|DRUG|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
47986972|NCT00721773|DRUG|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
47986973|NCT03486795|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
47986974|NCT03486795|DEVICE|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
47986975|NCT03486795|DEVICE|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
47986976|NCT05941923|OTHER|respiratory critical care support|Patients in the intervention group will be received respiratory critical care support
47986977|NCT05791266|DEVICE|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
48143308|NCT02435485|OTHER|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
48143309|NCT04240197|DEVICE|CompuFlo|The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
48353915|NCT01096966|DRUG|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
47986978|NCT02891460|DEVICE|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
47986979|NCT02891460|DEVICE|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
47986980|NCT04688762|OTHER|e-consult application (tool)|A numeric application used as a support in consultation to explain the surgical management of the patient.
47986981|NCT03627689|OTHER|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
47986982|NCT03627689|OTHER|Sham air purifier|control arm
48353916|NCT03601091|DRUG|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
48353917|NCT03601091|DRUG|DORMICUM 5MG/5 ML|Infusion therapy of the drug
48353918|NCT01657253|DRUG|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
48353919|NCT01657253|DRUG|Systane|Instill 1 drop in each eye four times a day, for 60 days
47986983|NCT03494309|PROCEDURE|Open Reduction & Internal Fixation|Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
47986984|NCT03494309|PROCEDURE|Closed Reduction & External Fixation|Patients underwent closed reduction of the fracture and external fixation by arch bars \& guided elastics
48353920|NCT04400669|OTHER|Mechanical Bowel Preparation|oral sodium phosphate (NaP) enema
48664475|NCT06495606|DIAGNOSTIC_TEST|Voice sample; Recording with microphone + Questionnaire|Voice sample recording with microphone; afterwards digitalization and comparison between GERD and Non-GERD Group and also between GERD-Group before and after GERD treatment; searching for vocal biomarkers typical for GERD
48664476|NCT06143189|OTHER|Hosting conditions|"Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments."
48664477|NCT06143189|OTHER|Hospital Clowns|"The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes."
48664478|NCT00000628|DRUG|L-697,661|
48664479|NCT00000628|DRUG|Zidovudine|
47986985|NCT06216145|OTHER|formative evaluation|"Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method"
48664480|NCT04772794|OTHER|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
48664481|NCT04017234|OTHER|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
48664482|NCT02415556|DRUG|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
48664483|NCT02415556|DRUG|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
48664484|NCT05107076|DIAGNOSTIC_TEST|2D Echocardiography with color Doppler assessment & Galactin-3 level in blood|"* Measurements will be~  1. Pulsed wave (PW) Doppler~ 2. E (early diastolic)/A (late diastolic) - Using PW Doppler~ 3. IVRT (isovolumic relaxation time)~ 4. Deceleration time (DT) - from the peak of E wave to baseline.~ 5. E/e'- PW tissue Doppler imaging (TDI)~ 6. Left atrial volume and left atrial volume index (LAVI)~* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level."
47986986|NCT04333784|OTHER|Exercise training|Exercise with blood flow restriction (with a pneumatic cuff).
47986987|NCT04853927|DRUG|Proxalutamide|Proxalutamide 300mg q.d suspension
47986988|NCT04853927|DRUG|Placebo|Proxalutamide 300mg q.d placebo
48143310|NCT02704052|DRUG|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
48353921|NCT04400669|DIETARY_SUPPLEMENT|Low fibre diet|3 days
48353922|NCT04400669|OTHER|MBP plus low-fibre diet|3 days low fibre diet preoperative mechanical bowel preparation
48353923|NCT00942656|OTHER|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
48353924|NCT00942656|OTHER|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
48353925|NCT00942656|OTHER|VA|base diet plus 3.0% energy added from vaccenic acid
48353926|NCT00942656|OTHER|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
48353927|NCT04800484|DEVICE|Tall Soft|Tall heel wedge made of soft foam
48353928|NCT04800484|DEVICE|Tall Firm|Tall heel wedge made of firm foam
48353929|NCT04800484|DEVICE|Short Soft|Short heel wedge made of soft foam
48664485|NCT00399529|BIOLOGICAL|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
47986989|NCT02201186|OTHER|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
48353930|NCT04800484|DEVICE|Short Firm|Short heel wedge made of firm foam
48353931|NCT03541590|PROCEDURE|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
48353932|NCT03194672|BEHAVIORAL|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
48353933|NCT00806611|PROCEDURE|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
48353934|NCT06390293|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete. The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
48143311|NCT02704052|DRUG|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
48353935|NCT06390293|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
48353936|NCT01961128|BEHAVIORAL|Exercise Intervention|
48353937|NCT06065241|DIETARY_SUPPLEMENT|LLP-01|Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
48353938|NCT06065241|OTHER|Placebo|Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
48353939|NCT00180206|DEVICE|Birmingham Hip Resurfacing|
48353940|NCT01751269|DRUG|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
48353941|NCT01751269|DRUG|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
48353942|NCT02220530|DRUG|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
48664486|NCT00399529|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
48664487|NCT00399529|DRUG|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
48664488|NCT02092714|OTHER|laboratory biomarker analysis|Correlative studies
48664489|NCT03232788|PROCEDURE|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
48353943|NCT03262064|COMBINATION_PRODUCT|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
48353944|NCT00486148|OTHER|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
48143312|NCT05748184|DEVICE|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
48353945|NCT03795545|PROCEDURE|SWL|Shock wave lithotripsy
48353946|NCT06099678|BEHAVIORAL|Elastic Band Training|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
48353947|NCT06099678|BEHAVIORAL|Elastic Band Training with Maximal Mental Effort|This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
48664490|NCT03232788|DEVICE|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
47986990|NCT03194555|DRUG|Low-Dose Naltrexone and Acetaminophen Combination|Twice daily
47986991|NCT03194555|DRUG|Placebo|Twice daily
47986992|NCT00674661|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
48143313|NCT05748184|DEVICE|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
48143314|NCT05748184|DEVICE|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
48353948|NCT06037265|DEVICE|PAVmed PortIO™ Intraosseous Infusion System|The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
48353949|NCT01960556|OTHER|Simulation Training|Simulation training provided to one group
48353950|NCT06049251|OTHER|ELDOA exercises|"The patients will be asked to sit down on a floor in upright position and keep their legs apart and knees semi-flexed, feet in outward and upward position, knees constantly pushing downwards, straight lower back, raise arms with palms facing upward, and chin should be pulled back.~ELDOA stretch for L5-S1 level Patients will be asked to lay on floor and flatten and bring their legs up and straight with the support of wall, straight knees and keep distance between them, connect their toes, raise arm and externally rotate with wrist extension than press their heels and palms out.~ELDOA exercises will be performed with 2 sets of 5 repetitions with 45 second hold and15 sec rest between each set once a day."
48353951|NCT06049251|OTHER|Lumbar SNAGS and motor control exercises|"The patient will be seated and his pelvis will be stabilized with belt at the level of the anterior superior iliac spine while the SNAGs are administered. The ulnar aspect of the therapist's hand will be placed over the spinous processes of the affected segment's superior vertebrae, for flexion glide and inferior vertebrae for extension glide respectively. A passive glide will be applied and kept up until the patient finished a full movement arc. The glides will be given for six repetitions for three sets every session. Glide can be given unilateral for other movements.~Motor Control Exercises:~Exercise training with 7sec Hold and 10 reps"
48353952|NCT00861302|BEHAVIORAL|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
48353953|NCT04214106|DRUG|intravenous Thiamine|patients who received Thiamine,100-500 mg/day for at least one day
48353954|NCT03740139|OTHER|The Police-Mental Health Linkage System|When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
48353955|NCT05802290|DRUG|Nivolumab 240 MG in 24 ML Injection|nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
48353956|NCT02092506|DRUG|10 day triple therapy|10 day triple therapy
48143315|NCT02060084|DRUG|a control group|the same dose of luke warm water
48353957|NCT02092506|DRUG|10 day sequential therapy|10 day sequential therapy
48353958|NCT02092506|DRUG|10 day concomitant therapy|10 day concomitant therapy
48353959|NCT05509556|OTHER|talocalcaneal angle measurement|talocalcaneal angle measurement on lateral foot radiographs
48353960|NCT00926562|DRUG|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
48143316|NCT02060084|DRUG|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
48143317|NCT05521256|DRUG|NNC0113-6856|Participants will receive NN0113-6856 orally or intravenously.
48143318|NCT05521256|DRUG|Placebo|Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
48143319|NCT01947491|DRUG|DFD01 Spray|
48143320|NCT01947491|DRUG|Comp01 Lotion|
48143321|NCT01947491|DRUG|Vehicle Lotion|
48143322|NCT01947491|DRUG|Vehicle Spray|
48353961|NCT00926562|DRUG|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
48664491|NCT03232788|DEVICE|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
48664492|NCT01186276|DIETARY_SUPPLEMENT|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
48143323|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
48664493|NCT01186276|DIETARY_SUPPLEMENT|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
48664494|NCT03386162|DRUG|Alpelisib|fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
48664495|NCT03386162|DRUG|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
48664496|NCT04767321|DRUG|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
48143324|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
48143325|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
48143326|NCT02443909|DEVICE|Holmium laser device|
48143327|NCT01918033|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
48143328|NCT01918033|DRUG|Placebo|Matching placebo to desloratadine 5 mg tablets
48143329|NCT02345551|BEHAVIORAL|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
48143330|NCT00329914|DRUG|Progesterone|Vaginal pessaries, 200 mg/day
48143331|NCT00329914|DRUG|Placebo|Placebo pessaries containing peanut oil
48143332|NCT00022165|DIETARY_SUPPLEMENT|selenium|
48353962|NCT05071391|PROCEDURE|Roux-en-Y gastric bypass|"Gastric bypass, also called Roux-en-Y gastric bypass, is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine. After gastric bypass, swallowed food will go into this small pouch of stomach and then directly into the small intestine, thereby bypassing most of your stomach and the first section of your small intestine.~Gastric bypass is one of the most commonly performed types of bariatric surgery. Gastric bypass is done when diet and exercise haven't worked or when you have serious health problems because of your weight."
48664497|NCT04767321|DRUG|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
48664498|NCT05481684|OTHER|Normal Progesterone group|No progesterone supplementation
48664499|NCT05481684|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, vaginal pills (Lutinus 2\*1) or SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day. Progesterone supplementation was discontinued if there was no pregnancy. Progesterone supplementation at the same dose was continued until 10 gestational weeks for viable pregnancies.
48664500|NCT06443853|DIAGNOSTIC_TEST|Dental plaque scoring and dental plaque coated tooth surface measuring|"The Turesky Modified Quigley Hein Plaque Index of anterior teeth of the volunteers' was recorded using clinical visual examination.~Intraoral photographs of the volunteers were taken by using a digital camera and 3D images were recorded by an intraoral scanner. The plaque-covered area and the total surface area of the teeth were marked in the manual mode of the Image J program and the areas were measured in square pixels. The correlation between clinical visual scoring, dental plaque areas on images were compared."
48664501|NCT04701554|OTHER|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
48664502|NCT04701554|OTHER|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
47986993|NCT00674661|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
48143333|NCT04084262|DEVICE|Intramedullary Nail|Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
48143334|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
48143335|NCT00641537|DRUG|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
48143336|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
48143337|NCT00641537|DRUG|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
48143338|NCT00641537|DRUG|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
48143339|NCT03104530|OTHER|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
48143340|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
48143341|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
48353963|NCT03602638|DRUG|Sitagliptin|Sitagliptin 100mg QD
48353964|NCT03602638|DRUG|Acarbose|Acarbose
48664503|NCT01837355|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
48664504|NCT01837355|DIETARY_SUPPLEMENT|Placebo|
48664505|NCT04908293|OTHER|Biorepair toothpaste|Use of New Biorepair Advanced Sensitive for home oral care.
48664506|NCT04908293|OTHER|Colgate toothpaste|Use of Colgate toothpaste for home oral care.
47986994|NCT04855825|DEVICE|Robotic Exoskeleton Rehabilitation|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
48143342|NCT04860999|PROCEDURE|Osteopathic Manipulative Treatment|The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
48143343|NCT02504762|PROCEDURE|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
48353965|NCT03639688|PROCEDURE|Threading on the left lip commissure|Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
48664507|NCT01862354|PROCEDURE|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
48664508|NCT01862354|PROCEDURE|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
48664509|NCT04748887|OTHER|oxidative stess markers|markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
48664510|NCT03014466|BEHAVIORAL|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
48664511|NCT03014466|BEHAVIORAL|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
48353966|NCT03639688|PROCEDURE|Threading on the right lip commmissure|Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
48353967|NCT06117072|OTHER|diet plan|One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months
48664512|NCT01432444|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
47986995|NCT04855825|OTHER|Conventional Gait Therapy|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
48664513|NCT03256487|DRUG|Buprenorphine|buprenorphine 0.3mg IV
48664514|NCT03256487|DRUG|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
48664515|NCT00178009|BEHAVIORAL|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
47986996|NCT05485766|DRUG|Pembrolizumab|200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
47986997|NCT05485766|DRUG|Paclitaxel|80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
48664516|NCT01195597|DEVICE|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
48664517|NCT01057979|BEHAVIORAL|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
47986998|NCT05485766|DRUG|Carboplatin|Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
47986999|NCT05485766|DRUG|Olaparib|300 mg BID (twice daily) orally
48664518|NCT01057979|BEHAVIORAL|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
48664519|NCT06564805|DRUG|Candida Albicans Antigen Injection|subcutaneous administration of Candida albicans antigen
48664520|NCT01737905|DRUG|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
47987000|NCT05485766|PROCEDURE|Definitive Surgery|Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
47987001|NCT03866343|OTHER|Diet low or high in advanced glycation endproducts|All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
47987002|NCT04484363|DRUG|Pevonedistat|Pevonedistat 20 milligram per square meter (mg/m\^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
47987003|NCT04484363|DRUG|Azacitidine|Azacitidine 75 mg/m\^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.
47987004|NCT00353912|DRUG|valsartan + amlodipine|
47987005|NCT03285620|DRUG|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
47987006|NCT03285620|DRUG|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
47987007|NCT04850690|DIAGNOSTIC_TEST|2D Gait analysis|"The gait with four different conditions (single gait, Cognitive Task, Motor Task and Cognitive Task\&Motor Task) was evaluated by Kinovea video analysis method on a 10-meter course.~* Single: Walking without task at a self-selected speed~* Cognitive Task (CT): Walking while counting down rhythmically from 20 in threes~* Motor Task (MT): Walking while carrying an empty box~* CT + MT: Walking while carrying an empty box and counting down rhythmically from 20 in threes"
48143344|NCT02504762|PROCEDURE|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
48664521|NCT01737905|DRUG|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
48664522|NCT01570387|DRUG|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle
48664523|NCT01570387|DRUG|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
48688024|NCT04635254|OTHER|Halophites-based cream 24 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
48688025|NCT04635254|OTHER|Halophites-based cream 48 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
48143345|NCT03353285|PROCEDURE|intracytoplasmic sperm injection (ICSI)|All eggs will be fertilized by ICSI
47987008|NCT01216527|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Surgery|"1. Radiotherapy combined with concomitant chemotherapy:~   Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~   neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~   Number of cycles:two~2. surgery:Mckeown Modification Surgery and total two-field lymphadenectomy"
47987009|NCT01216527|PROCEDURE|surgery|two field lymphadenectomy
48664524|NCT03733548|BEHAVIORAL|RELAX|Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
47987010|NCT02464345|BEHAVIORAL|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
47987011|NCT02464345|BEHAVIORAL|CBT-E|CBT-E therapy
47987012|NCT00338689|DIETARY_SUPPLEMENT|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
48664525|NCT03230188|OTHER|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
48664526|NCT03230188|OTHER|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
48664527|NCT03230188|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
48664528|NCT05830929|PROCEDURE|Ovarian tissue freezing and subsequent auto-transplantation after thawing|Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
48664529|NCT00808873|OTHER|socio-educational intervention|brief mental health education and 6 follow-up visits
48664530|NCT05896241|OTHER|non-interventional study|non-interventional study
48664531|NCT04068922|BEHAVIORAL|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
48664532|NCT05310253|DRUG|Fludrocortisone|pill of fludrocortisone
48664533|NCT05310253|DRUG|Placebo|placebo pill
48664534|NCT05310253|BEHAVIORAL|Trier Social Stress Test (TSST)|psychosocial stress induction
48664535|NCT05310253|BEHAVIORAL|Placebo Trier Social Stress Test (P-TSST)|control condition
48664536|NCT04894682|BIOLOGICAL|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
48664537|NCT00267176|DRUG|lumiracoxib|
48664538|NCT05744479|DRUG|Metformin|Metformin oral, 2000mg/day, for 24 weeks.
48664539|NCT05744479|DRUG|Placebo|Oral placebo for 24 weeks
48664540|NCT05744479|BEHAVIORAL|Lifestyle Intervention|Participants from both groups will meet a dietician and a diabetes educator at the study start to obtain advice regarding healthy diet, portion size, and meal planning to improve physical health. All participants will be invited to monthly group meetings to learn skills which will help them in a variety of wellness areas such as physical exercises and diet. Attendance in these sessions will be encouraged but not mandatory, and attendance will be recorded. Fidelity with these interventions will be captured using diet and physical activity questionnaires at RCT start, midpoint and end, and end of open label phase.
48664541|NCT04254406|OTHER|Descriptive study|Evaluation of routine treatment
48664542|NCT05069519|BEHAVIORAL|Personalized Smartwatch|"Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies."
48688026|NCT04635254|OTHER|Vehicle cream 24 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
48688027|NCT04635254|OTHER|Vehicle cream 48 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
48664543|NCT05069519|BEHAVIORAL|Facebook Health Education|Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
48664544|NCT04573972|BEHAVIORAL|Social Incentive|Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
48664545|NCT04573972|BEHAVIORAL|Standard Incentive|Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
47987013|NCT05726812|BEHAVIORAL|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
47987014|NCT04108520|OTHER|Exercise|Exercise with respiratory training
47987015|NCT01988259|PROCEDURE|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
47987016|NCT01988259|PROCEDURE|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
47987017|NCT01988259|PROCEDURE|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
47987018|NCT01988259|PROCEDURE|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
47987019|NCT05337007|OTHER|high protein diet|48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
47987020|NCT05337007|OTHER|moderate protein diet|48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
47987021|NCT03232801|BEHAVIORAL|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
47987022|NCT03232801|BEHAVIORAL|general health education group|A general health and aging education group
47987023|NCT02888522|BIOLOGICAL|immunomodulation|Immunomodulation depending on chimerism
48143346|NCT04262115|BEHAVIORAL|AM-EX|AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
48353968|NCT01732861|DRUG|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
48664546|NCT03585387|PROCEDURE|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
48143347|NCT04262115|BEHAVIORAL|PM-EX|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
48353969|NCT01732861|DRUG|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
48353970|NCT03445962|DIAGNOSTIC_TEST|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~* Anthropometric evaluation~* biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~* rest electrocardiogram~* motor assessment (strenght, flexibility and balance)~* actigraphy~* Autonomic nervous system assessment during sleep~* Autonomic nervous system assessment during head up tilt test before and after physical exercise~* maximal treadmill test (VO2 max measure)~* polysomnography~* seismocardiography~* questionnaires :sleep and physical activity"
48353971|NCT04307589|OTHER|Observation|An observational follow-up study will be implemented over a period of 2 years, consisting of 3 test occasions with a fixed time interval of 1 year in between (T0 = baseline, T1 = 12 months, T2 = 24 months). Data will be collected in participants who provide grandchild care in a non-residential grandparent context as well as in a sample of non-caregiving grandparents and a sample of middle-aged and older adults not being a grandparent. All three samples will thus be prospectively monitored over a period of 2 years.
48353972|NCT04193605|BEHAVIORAL|Mindfulness|The traditional MBSR intervention consists of the following: (1) a series of eight weekly session of 2.5 to 3 hours; (2) a silent retreat during the sixth week; (3) daily home assignments including formal and informal mindfulness practices; and (4) didactic presentations on stress and the consequences of stress. We are culturally tailoring the intervention with the goal of maintain fidelity.
48353973|NCT01984294|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
48664547|NCT06005402|BIOLOGICAL|CSX-1004|Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs
48664548|NCT06005402|BIOLOGICAL|Placebo|Sterile saline for injection
48664549|NCT05450562|BIOLOGICAL|SAR444200|Sterile lyophilized powder for solution for infusion Route of administration: intravenous (IV) infusion
48664550|NCT05450562|BIOLOGICAL|Atezolizumab|concentrate for solution for infusion Route of administration: intravenous (IV) infusion
48664551|NCT04556253|DRUG|AK104|Subjects will receive AK104 by intravenous administration.
47987024|NCT02608749|BEHAVIORAL|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
47987025|NCT02608749|BEHAVIORAL|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
47987026|NCT02608749|BEHAVIORAL|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
47987027|NCT06112444|OTHER|scale|The scale of Short Western Ontario Rotator Cuff İndex
47987028|NCT01900327|RADIATION|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
47987029|NCT01900327|DRUG|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
47987030|NCT01900327|PROCEDURE|Surgery|Upfront pancreato-duodenectomy
47987031|NCT01900327|DRUG|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
48505082|NCT01846910|BEHAVIORAL|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
48505083|NCT02454127|BEHAVIORAL|Atkins Diet|Dietary counseling for 1 year
48505084|NCT02454127|BEHAVIORAL|Zone Diet|Dietary counseling for 1 year
48505085|NCT02454127|BEHAVIORAL|Weight Watchers Diet|Dietary counseling for 1 year
48505086|NCT02454127|BEHAVIORAL|Ornish Diet|Dietary counseling for 1 year
48505087|NCT01758588|DRUG|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
48664552|NCT05159050|DRUG|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m\^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1\*: 50 mg/m\^2; Dose Level 2: 100 mg/m\^2; Dose Level 3: 135 mg/m\^2; Dose Level 4: 175 mg/m\^2; Dose Level 5: 200 mg/m\^2~\*Starting Dose"
48664553|NCT01891955|BEHAVIORAL|Healthy diet A|"Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
48664554|NCT01891955|BEHAVIORAL|Healthy diet B|"Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
48664555|NCT03162432|DRUG|Vitamin D3|Oral Vitamin D3 therapy.
48664556|NCT02101255|DEVICE|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360"
48664557|NCT02101255|DEVICE|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
48664558|NCT06571344|DRUG|Cholecalciferol|"The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm."
48664559|NCT05558904|DRUG|Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Given IV
48664560|NCT05558904|PROCEDURE|Computed Tomography|Undergo PET/CT
48664561|NCT05558904|OTHER|Laboratory Biomarker Analysis|Correlative studies
48664562|NCT05558904|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48664563|NCT03146260|PROCEDURE|Conventional TESE|usual procedure for sperm extraction
47987032|NCT05901779|DRUG|live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules|Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained\>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
47987033|NCT04813094|OTHER|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.
47987034|NCT04813094|OTHER|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
48353974|NCT01984294|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48353975|NCT01984294|DRUG|GS-9669|GS-9669 tablet(s) administered orally once daily
48353976|NCT02696590|DIETARY_SUPPLEMENT|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
48353977|NCT06322589|DIETARY_SUPPLEMENT|SOD like Super Drink|consume 1 bottle per day
48353978|NCT06322589|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
48353979|NCT04526444|DEVICE|Fitness tracker|Fitness tracker Mi Smart Band 5 with the computational algorithm PAI
48353980|NCT04526444|OTHER|Online training|Les Mills On Demand
48505088|NCT01807286|DRUG|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
48664564|NCT03146260|PROCEDURE|Microdissection TESE|Procedure of extraction is performed under the operating microscope
48353981|NCT04526444|OTHER|Peer support via social media|Facebook group
48664565|NCT00499044|OTHER|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
48664566|NCT00499044|OTHER|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
48664567|NCT05119530|DIAGNOSTIC_TEST|AcuVid COVID-19 Rapid Antigen Saliva Test|The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens
48664568|NCT01006148|BIOLOGICAL|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
48664569|NCT01086527|DRUG|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
48664570|NCT02554955|DRUG|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
48664571|NCT02554955|DRUG|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
48664572|NCT02554955|DRUG|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
48664573|NCT01238887|DIETARY_SUPPLEMENT|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
48664574|NCT01238887|DIETARY_SUPPLEMENT|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
48664575|NCT01238887|DIETARY_SUPPLEMENT|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
48505089|NCT01807286|DRUG|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
48505090|NCT01807286|DRUG|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
48505091|NCT01807286|BEHAVIORAL|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
48505092|NCT04648696|DRUG|Vancomycin CI|The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin
48664576|NCT03822611|BEHAVIORAL|Targeted Subsidy|Voucher
48664577|NCT00090376|DRUG|GPI 1485|
48664578|NCT02950259|DRUG|Cyclophosphamide|One dose of cyclophosphamide 300 mg/m2 IV infusion
48664579|NCT02950259|DRUG|Indomethacin|Indomethacin 25 mg three times a day for 21 days
48664580|NCT02950259|DRUG|Omeprazole|One tablet of omeprazole daily for 21 days
48143348|NCT00362284|BEHAVIORAL|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
48143349|NCT00532766|DRUG|Jusline|
48143350|NCT00780793|DRUG|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 \> 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 \> 2.6 and DAS28 change \> 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop"
48353982|NCT00957034|DRUG|placebo|placebo patch
48505093|NCT04648696|DRUG|Vancomycin II|Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
48505094|NCT00592618|DRUG|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
48143351|NCT00780793|DRUG|DMARD maintenance|DMARD maintenance
48143352|NCT03065400|DRUG|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
48505095|NCT02001220|PROCEDURE|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
48664581|NCT02950259|DIETARY_SUPPLEMENT|Multivitamin|Daily multivitamin containing 15-30 mg of zinc for 21 days.
48664582|NCT05035888|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
48664583|NCT05035888|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
48664584|NCT01363102|PROCEDURE|SOMS|Apply a number to mobilization goal for patient
48353983|NCT00957034|DRUG|testosterone|300 or 450 micrograms/day transdermal testosterone patch
48664585|NCT01291589|BEHAVIORAL|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
48664586|NCT01907282|BEHAVIORAL|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
48353984|NCT04101162|DIAGNOSTIC_TEST|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
48664587|NCT01907282|BEHAVIORAL|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
48664588|NCT02552225|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
48353985|NCT01326910|DRUG|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
48353986|NCT01326910|DEVICE|Topical Cream|Topical cream applied twice daily (or as needed)
48353987|NCT00070837|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
48664589|NCT02552225|OTHER|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
48664590|NCT05904483|OTHER|PFA|PFA
48664591|NCT02756052|DEVICE|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
48353988|NCT02125812|OTHER|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
48353989|NCT02125812|OTHER|scaling and root planing|scaling and root planing
48353990|NCT02626299|DRUG|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
48353991|NCT02626299|DRUG|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
48353992|NCT02626299|OTHER|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
48353993|NCT05637541|DRUG|GST-HG141|The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
48353994|NCT03727776|DRUG|Adrenocorticotropic Hormone|Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
48353995|NCT03592927|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
48143353|NCT00001930|DRUG|Amantadine|
48143354|NCT03890484|BEHAVIORAL|Peer Type - New Peer|Participants drink with 2 unfamiliar confederate peers
48143355|NCT03890484|BEHAVIORAL|Peer Type - Close Friends|Participants drink with 2 close friends
48143356|NCT01386372|DRUG|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
48353996|NCT03592927|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
48353997|NCT03307213|DEVICE|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
48143357|NCT01386372|OTHER|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
48353998|NCT03307213|DEVICE|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
48353999|NCT03617471|PROCEDURE|Venopuncture for PK profiling|Blood samples at T0, T0.5, T1, T2, T4, T6
48354000|NCT01215786|DRUG|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
48354001|NCT01215786|DRUG|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
48354002|NCT01215786|DRUG|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
48354003|NCT05357924|PROCEDURE|robotic-assisted laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
48354004|NCT05357924|PROCEDURE|Conventional laparoscopy|Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
48664592|NCT02756052|DEVICE|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
48664593|NCT03106714|DIAGNOSTIC_TEST|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
48664594|NCT00156195|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 months
48664595|NCT00156195|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
48664596|NCT02398019|DEVICE|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
48664597|NCT04781491|BEHAVIORAL|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
48664598|NCT05754125|DIETARY_SUPPLEMENT|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
48143358|NCT04213807|BIOLOGICAL|MAA868 Cohort 1|Subcutaneous injection: low dose
48664599|NCT05754125|DIETARY_SUPPLEMENT|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
48143359|NCT04213807|BIOLOGICAL|MAA868 Cohort 2|Subcutaneous injection: high dose
48143360|NCT04213807|BIOLOGICAL|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
48143361|NCT04213807|OTHER|Placebo|Subcutaneous injection: Placebo
48143362|NCT05643222|DEVICE|red tint contact lenses|to compare the performance of these lenses.
48143363|NCT04413994|DIETARY_SUPPLEMENT|Humavant|"Premature infants are randomized to either:~1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR~2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.~After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included."
48143364|NCT02741557|DRUG|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
48143365|NCT02741557|DRUG|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
48143366|NCT02741557|DRUG|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
48143367|NCT04364230|DRUG|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
48143368|NCT04364230|DRUG|NeoAg-mBRAF|BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
48143369|NCT04364230|DRUG|PolyICLC|polyICLC, local adjuvant
48143370|NCT04364230|DRUG|CDX-1140|CDX-1140, local adjuvant
48143371|NCT01439854|DRUG|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
48143372|NCT01439854|DRUG|Placebo|Patients are treated with placebo
48664600|NCT05754125|DIETARY_SUPPLEMENT|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
48354005|NCT00112840|DRUG|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
48354006|NCT00112840|DRUG|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
48143373|NCT00364455|DRUG|Epoetin alfa|
48143374|NCT04001777|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
48143375|NCT04001777|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
48143376|NCT01271894|DRUG|Efavirenz|600 mg once daily; given as 3 x 200 mg once
48143377|NCT01271894|DRUG|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
48143378|NCT02504801|DRUG|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
48354007|NCT04460391|BEHAVIORAL|Intensive rehabilitation|Early standing training and routine rehabilitation
48664601|NCT01960491|DEVICE|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
48664602|NCT02783833|DRUG|MMV390048 40mg|
48664603|NCT02783833|DRUG|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
48143379|NCT01124552|DRUG|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
48143380|NCT01124552|DRUG|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
48143381|NCT01124552|OTHER|Vehicle|Vehicle Control
48664604|NCT06262542|OTHER|moxibustion and Chinese herbal medicine group|"Apply 15g of Chinese herbal powder (a mixture of scientific Chinese herbs: Jiseng Shenqi Pill, Xuanfu Daizheshi Tang, and Wendi Tang mixed in a 1:1:1 ratio, mixed with water to form a paste) to the Shénquè acupoint. Then, use 3g of 80:1 moxa wool placed in a moxibustion box for moxibustion on the lower abdomen (between the Guānyuán, Zhōngjí, and Shénquè acupoints) for 1 hour, once a day, six times a week, for a total of 12 sessions.~sham moxibustion and placebo herbal medicine group): Same acupoint frequency, but use 15g of flour instead of herbal paste and replace moxibustion with a heated nightlight for sham moxibustion."
48664605|NCT00889005|OTHER|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
48664606|NCT05946798|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
48664607|NCT05946798|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
48143382|NCT01124552|DRUG|Placebo|Placebo Comparator
48354008|NCT01521260|PROCEDURE|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
48664608|NCT06418282|DEVICE|Dayspring|NPCD
48664609|NCT05755581|DRUG|Hormonal Antineoplastics|the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
48354009|NCT01521260|PROCEDURE|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
48354010|NCT03731169|GENETIC|Voriconazole genotype-specific dosing|"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
48143383|NCT01829594|OTHER|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
48354011|NCT03731169|DRUG|Standard of Care|Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
48354012|NCT01740765|OTHER|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
48354013|NCT03827967|BIOLOGICAL|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
48354014|NCT02462811|DRUG|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
48354015|NCT02462811|DRUG|Placebo|
48354016|NCT02462811|DRUG|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
48354017|NCT03228836|DRUG|Sintilimab|Sintilimab (IBI308) 200mg IV Q3W
48354018|NCT01855139|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
48354019|NCT00685828|DRUG|imatinib mesylate|By mouth
48354020|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
48354021|NCT00702741|DRUG|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
48664610|NCT05755581|DRUG|Chemotherapy drug|the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
48143384|NCT04996407|DEVICE|survival thermal blanket|patients were given a thermal blanket
47987035|NCT04741061|BIOLOGICAL|Sputnik Light|"Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose."
47987036|NCT04741061|OTHER|Placebo|Placebo
47987037|NCT00064376|DRUG|paricalcitol|
47987038|NCT02401594|DRUG|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
47987039|NCT02401594|DRUG|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
47987040|NCT00167882|DRUG|5-aminosalicylate (Pentasa, Ferring)|
48143385|NCT04996407|DEVICE|draping fabric|Patients were given a draping fabric
48143386|NCT03507179|OTHER|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional processing
48143387|NCT03507179|OTHER|conventional dentures|conventional dentures
48354022|NCT00702741|DRUG|Placebo|Intra-articular injection of Hyaluronan
48664611|NCT00003888|DRUG|cisplatin|
48664612|NCT00003888|DRUG|docetaxel|
48664613|NCT00003888|DRUG|fluorouracil|
48664614|NCT00003888|RADIATION|radiation therapy|
48664615|NCT00158106|PROCEDURE|Speech and Language therapy for dysarthria and/or aphasia|
48688028|NCT04635254|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
48664616|NCT01675947|DRUG|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
48664617|NCT01675947|DRUG|Lidocaine|Lidocaine 2%
48664618|NCT06167148|DEVICE|Biolase Epic X 940nm wavelength Diode laser|Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).
48664619|NCT06167148|DEVICE|Doctor smile simpler 980nm wavelength Diode laser|Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).
48664620|NCT04206761|DRUG|QVM149|QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
48664621|NCT04206761|DRUG|High Dose Dual Therapy (ICS/LABA)|High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
48664622|NCT04881058|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the PicoSure device.
48664623|NCT00010478|PROCEDURE|Acupuncture|
48664624|NCT02724202|DRUG|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
48143388|NCT06372899|OTHER|E-cigarettes|Participants randomized to ECIGS are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. They will be provided with an e-cigarette device and nicotine pods.
48143389|NCT06372899|OTHER|Oral nicotine pouches|Participants randomized to ONPS are instructed to switch from smoking combustible cigarettes to using nicotine pouches for 6 weeks. They will be provided with nicotine pouches.
48143390|NCT01138657|BIOLOGICAL|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
48143391|NCT01138657|DRUG|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
48354023|NCT04272814|OTHER|Compression therapy|Compression application
48354024|NCT04272814|DIAGNOSTIC_TEST|initial clinical assessment|Initial clinical assessment (includes history, vascular assessment, limb examination and wound assessment where necessary)
48664625|NCT02724202|DRUG|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
48664626|NCT02996929|DEVICE|LC System|Subjects will undergo CIED lead extraction with the LC system
48664627|NCT02027792|OTHER|Cabbage leave wraps|
48664628|NCT02027792|DRUG|Diclofenac Gel|
48143392|NCT01138657|DRUG|Placebo|Administered by subcutaneous injection
48143393|NCT06464302|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
48143394|NCT06464302|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation
48354025|NCT00017524|DRUG|pelitrexol|
48354026|NCT01282190|BEHAVIORAL|Motivational interview|Motivational interview
48664629|NCT02501447|BEHAVIORAL|Guided audio-visual relaxation|
48664630|NCT04096066|DRUG|Carfilzomib|"* 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
48664631|NCT04096066|DRUG|Lenalidomide|- 25 mg orally on days 1-21 of each cycle.
48688029|NCT04635254|OTHER|Cowhage|The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
48688030|NCT03604172|BEHAVIORAL|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
48664632|NCT04096066|DRUG|Dexamethasone|"- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
48143395|NCT03150589|DRUG|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
48143396|NCT03150589|DRUG|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
48143397|NCT06088576|OTHER|Together|"Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month."
48143398|NCT04039776|DIAGNOSTIC_TEST|"Cone Beam Computed Tomography (CBCT)"|"Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism."
48354027|NCT01551628|DRUG|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
48354028|NCT03333434|DEVICE|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
48354029|NCT03333434|DEVICE|Hinged AFO|
48664633|NCT03192436|DEVICE|Ultrasound|Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
48664634|NCT02004626|DRUG|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
48664635|NCT02004626|DRUG|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
48664636|NCT03393104|BEHAVIORAL|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
48143399|NCT00247507|DRUG|acetylcysteine|
48143400|NCT00620139|BIOLOGICAL|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
48143401|NCT03163472|PROCEDURE|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
48143402|NCT03163472|PROCEDURE|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
48143403|NCT00125723|OTHER|PI Discretion|PI Discretion
48354030|NCT01320527|DIETARY_SUPPLEMENT|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
48354031|NCT01320527|OTHER|Placebo|A mixture of 6 vitamins and nutriceuticals
48354032|NCT01097434|DEVICE|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
48354033|NCT01097434|DEVICE|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
48664637|NCT03393104|BEHAVIORAL|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
48354034|NCT02625363|OTHER|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
48354035|NCT02625363|OTHER|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
48354036|NCT02625363|OTHER|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
48354037|NCT02625363|OTHER|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
48354038|NCT02625363|OTHER|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
48354039|NCT02491528|BIOLOGICAL|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
48664638|NCT02279927|DEVICE|Ureteroscopy|Ureteroscopy with laser stone fragmentation
48354040|NCT02491528|BIOLOGICAL|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
47987041|NCT03240796|PROCEDURE|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
47987042|NCT03240796|PROCEDURE|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
48143404|NCT02732132|DRUG|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
48143405|NCT02732132|DRUG|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
48354041|NCT04576273|DIAGNOSTIC_TEST|Pathology examination|Gross and microscopic evaluation
48354042|NCT05711511|PROCEDURE|conventional obturation technique|cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer
48354043|NCT05711511|DEVICE|Obtura II|"is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle"
48354044|NCT00004833|DRUG|Immune globulin|
48354045|NCT05057884|BEHAVIORAL|Breathing training|Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
48505096|NCT02001220|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
48505097|NCT00908310|DRUG|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
48664639|NCT03060837|DIAGNOSTIC_TEST|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
48664640|NCT03060837|OTHER|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
48664641|NCT03060837|OTHER|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
48664642|NCT03060837|OTHER|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
48664643|NCT03060837|PROCEDURE|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
48664644|NCT03060837|PROCEDURE|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
48664645|NCT05819359|DRUG|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
48664646|NCT05819359|DRUG|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
48664647|NCT05819359|DRUG|Placebo|Placebo, once daily, oral administration.
48664648|NCT00062257|DRUG|irofulven|
48664649|NCT02006927|DEVICE|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
48664650|NCT02519842|DRUG|Fosaprepitant|
48664651|NCT02519842|DRUG|Placebo for fosaprepitant|
48664652|NCT02519842|DRUG|Ondansetron|
48664653|NCT02519842|DRUG|Dexamethasone|
48664654|NCT02519842|DRUG|5-HT3 antagonist|
48664655|NCT06044792|OTHER|differences in CD4 reconstruction|Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
48664656|NCT03825705|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48664657|NCT03825705|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
48664658|NCT04454515|DRUG|Dexmedetomidine|Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
48664659|NCT04454515|DRUG|placebo|normal saline infusion
47987043|NCT03731884|OTHER|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
47987044|NCT01980875|DRUG|Idelalisib|150 mg tablet administered orally twice daily
47987045|NCT01980875|DRUG|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
47987046|NCT01980875|DRUG|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
47987047|NCT04323280|DRUG|Dexamethasone therapy|Dexamethasone 20MG once daily for 4 days with additional colchicine therapy for 3 months
47987048|NCT04323280|DRUG|NSAID therapy|NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months
47987049|NCT03350633|DRUG|Tocilizumab Injection|Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
47987050|NCT03350633|DRUG|Azathioprine|Azathioprine will be orally given at a dose of 2-3 mg/kg/d
48505098|NCT05812443|OTHER|Shabad Kriya Meditation|The Shabad Krya meditation technique, used in Kundalini Yoga, will be performed by the participants of this intervention group for 8 consecutive weeks, for 30 minutes, before going to sleep. This group will be trained by a Kundalini Yoga teacher with extensive experience in Shabad Krya meditation. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
48505099|NCT05812443|OTHER|Relaxing reading|Relaxing reading will be performed by the participants of this control group for 8 consecutive weeks, for 30 minutes, before going to sleep. The evaluation of Sleep Quality, Mental Health and Spirituality parameters will be measured through specific questionnaires, shortly after the end of the eighth week of intervention, and also one month and three months after the end of the intervention.
47987051|NCT04486781|DRUG|Pembrolizumab + sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
48505100|NCT00292058|DEVICE|Videoconference equipment (telepsychiatry)|
48505101|NCT04576923|DIAGNOSTIC_TEST|Velacur by Sonic Incytes|liver stiffness measurement
48664660|NCT05493410|OTHER|TREATMENT GROUP (TG)|In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.
47987052|NCT01902264|DRUG|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
47987053|NCT04557657|DRUG|Active bio Activa|Cement that release fluoride
47987054|NCT04557657|DRUG|Resin Cement|Resin Cement Convinonal
47987055|NCT00403793|DRUG|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
47987056|NCT00403793|DRUG|Placebo|42 or 44 weeks with placebo implant and placebo injections
47987057|NCT05200533|OTHER|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
47987058|NCT05200533|OTHER|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
48143406|NCT05924113|BEHAVIORAL|Latin Dance|Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
48143407|NCT00191542|DRUG|Atomoxetine|
48505102|NCT05705648|DIETARY_SUPPLEMENT|medium chain triglyceride oil|Medium chain triglyceride oil
48505103|NCT05705648|DIETARY_SUPPLEMENT|Safflower oil|Safflower oil
48505104|NCT05379816|PROCEDURE|5% DW perineural injection|5% DW perineural injection to intercostal nerve
48505105|NCT03717025|PROCEDURE|SUCTION BLISTER EPIDERMAL GRAFTING|"1. Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~2. Blister formation is induced by using suction apparatus.~3. Recipient site is surgically prepared by doing dermabrasion.~4. After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~5. The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~6. The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~7. Donor area is dressed with dry sterile pads.~8. The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
48143408|NCT00191542|DRUG|Placebo|
48354046|NCT05790902|DRUG|Silodosin|The patients used Silodosin for Medical expulsive therapy of ureteric calculi
48354047|NCT05790902|DRUG|Tamsulosin|The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi
48354048|NCT06098794|DIETARY_SUPPLEMENT|Sodium Bicarbonate|Capsules containing 0.3 g/kg of body weight of sodium bicarbonate were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
48354049|NCT06098794|DIETARY_SUPPLEMENT|Placebo|Capsules containing 0.3 g/kg of body weight of celulose were ingested in two doses. The first intake (0.2 g/kg) was performed together with a carbohydrate-enriched meal 2 h before a repeated sprint exercise protocol, and the second (0.1 g/kg) occurred 1 h later.
48664661|NCT05493410|OTHER|CONTROL GROUP (CG)|"For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate."
48354050|NCT01557140|DRUG|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
48354051|NCT02890511|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
48505106|NCT03717025|PROCEDURE|MINI PUNCH GRAFTING|"1. Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~2. The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~3. The donor area is either upper lateral portion of thigh or gluteal region.~4. Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~5. Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~6. For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~7. For the donor area only surgipad and micropore are used.~8. Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
48664662|NCT04848194|PROCEDURE|skin biopsy and blood sampling|"* 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~* A blood sample"
48664663|NCT01657981|DRUG|YM150|14C-labeled YM150, oral solution
47987059|NCT05879835|DEVICE|KiteLock 4% Sterile Catheter Lock Solution|KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
47987060|NCT05879835|DEVICE|Heparin Lock Solution|Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
47987061|NCT00765375|DRUG|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
47987062|NCT00765375|DRUG|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
48664664|NCT01478425|DEVICE|Lipidic Microemulsion|Topical nasal, twice a day
47987063|NCT05747092|PROCEDURE|gingival graft|"investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope"
47987064|NCT04938557|DEVICE|Automated closed-loop insulin delivery (AiD)|Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
47987065|NCT04938557|DEVICE|A standard insulin delivery system|Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
47987066|NCT03398057|OTHER|Health education|SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
47987067|NCT03398057|OTHER|Control group|Placebo health education (pamphlets) will be applied to this group participants during study.
47987068|NCT02855216|OTHER|Manual technique of sub-occipital inhibition|
48143409|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
48143410|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
48143411|NCT05441293|PROCEDURE|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
48143412|NCT02394054|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
48664665|NCT01478425|DEVICE|Saline|Topical Nasal, twice a day
48688031|NCT03604172|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
47987069|NCT02855216|OTHER|Self-treatment by way of Occipivot®|
48143413|NCT02394054|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
48143414|NCT03500276|BEHAVIORAL|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
48143415|NCT03500276|BEHAVIORAL|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
48143416|NCT02180932|BIOLOGICAL|periodontal pocket samples|
48143417|NCT05790759|OTHER|No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait|Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
48143418|NCT02809755|DRUG|4% Lidocaine|
48143419|NCT02809755|OTHER|Saline|
48143420|NCT03820024|BEHAVIORAL|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
48143421|NCT00995683|DRUG|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
48354052|NCT00957060|DRUG|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
48354053|NCT00957060|DRUG|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
47987070|NCT02248194|DEVICE|Tactile electrosurgical ablation probe|
47987071|NCT02248194|DEVICE|Hysteroscopic endometrial ablation|
48354054|NCT01220596|DRUG|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
48354055|NCT01220596|DRUG|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
48354056|NCT02531633|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
48354057|NCT02531633|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
48354058|NCT02531633|DRUG|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
48354059|NCT02531633|DRUG|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
48354060|NCT01624974|DRUG|MK-1029|MK-1029 150 mg tablets taken QD
48664666|NCT05241366|DEVICE|Transcranial Magnetic Stimulation|"The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over the right dorsolateral prefrontal cortex with a total of 1500 pulses in each session. Each session will last approximately 30 minutes. There will be one session per day, five sessions per week. The total duration of the treatment will be four weeks.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
47987072|NCT03106220|BEHAVIORAL|exercise|home exercise program
47987073|NCT03106220|OTHER|placebo|encourage walking and physical therapy per standard care.
47987074|NCT03654950|OTHER|No intervention|Interviews and questionnaires
47987075|NCT01834014|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
47987076|NCT01834014|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
47987077|NCT01834014|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
47987078|NCT01834014|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
48143422|NCT00995683|DRUG|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
48354061|NCT01624974|DRUG|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
48354062|NCT01624974|DRUG|Montelukast (ML)|ML 10 mg tablets QD
48354063|NCT01536938|DRUG|LEO 90100|
48354064|NCT01536938|DRUG|Calcipotriol|
48354065|NCT01536938|DRUG|Betamethasone|
48354066|NCT03439722|OTHER|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
48354067|NCT02299206|DRUG|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
48664667|NCT05241366|DEVICE|Sham Transcranial Magnetic Stimulation coil|"Simulated TMS stimulation will be performed with a Sham TMS coil, which has a sound and scalp contact similar to those experienced during active stimulation. The duration of the treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
48664668|NCT01681147|BEHAVIORAL|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
48664669|NCT01681147|BEHAVIORAL|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
48664670|NCT03577457|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
47987079|NCT01834014|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
47987080|NCT01834014|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
48354068|NCT02299206|DRUG|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
48354069|NCT06146140|DIETARY_SUPPLEMENT|Oral herbal supplement|Take one capsule daily
48354070|NCT06146140|DIETARY_SUPPLEMENT|Oral placebo supplement|Take one capsule daily
48354071|NCT04591704|OTHER|hospitalisation, necessity of ICU, mortality rate, lung involvement|hospitalisation, necessity of ICU, mortality rate, lung involvement
48354072|NCT02203916|DRUG|Azilsartan medoxomil|Azilsartan medoxomil tablets
48354073|NCT02203916|DRUG|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
48664671|NCT03577457|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
48664672|NCT03577457|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
48664673|NCT03577457|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
48664674|NCT01891929|BEHAVIORAL|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
48664675|NCT01891929|BEHAVIORAL|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
47987081|NCT02829281|DRUG|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
47987082|NCT02829281|DRUG|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
48354074|NCT01560754|DRUG|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
48354075|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use bergamot essential oil
48354076|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use chamomile essential oil
48688032|NCT01713647|DRUG|Amlodipin, losartan, HCTZ|
48688033|NCT04193904|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
48688034|NCT04193904|RADIATION|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
47987083|NCT02829281|DRUG|Saline|Joint injection of Saline
48354077|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use ginger essential oil
48354078|NCT03858855|PROCEDURE|Aromatherapy and Essential Oils|Use almond essential oil
47987084|NCT02615587|DRUG|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
47987085|NCT04082325|DRUG|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
47987086|NCT04082325|DRUG|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
47987087|NCT04082325|DRUG|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
48354079|NCT03858855|OTHER|Subject Diary|Complete journal
48354080|NCT01620658|DEVICE|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
48354081|NCT01620658|DEVICE|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
48354082|NCT01620658|DEVICE|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
47987088|NCT04082325|DRUG|Placebo|Placebo to Lu AF88434 oral solution, single dose
47987089|NCT03473808|BEHAVIORAL|task-practice therapy|Standardized hand therapy program
48354083|NCT03330548|BEHAVIORAL|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
48664676|NCT00548886|DRUG|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
48664677|NCT03598348|DRUG|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
48664678|NCT03598348|DRUG|Apatinib|Apatinib 250mg po Qd
48664679|NCT00002193|DRUG|Amprenavir|
48664680|NCT01704157|DEVICE|Cryo-Touch III|Study treatment at Day 0.
47987090|NCT03473808|OTHER|Vibration|Peripheral vibration applied to the wrist skin at an imperceptible level
47987091|NCT06268093|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
48354084|NCT03330548|BEHAVIORAL|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
48354085|NCT06298838|DEVICE|AURA10® Specimen PET/CT imager|The AURA10 PET-CT specimen imager detects and measures the electron density distribution of a specimen and the radiotracer distribution within a specimen. The function of the system is to acquire and visualize PET and CT images of a specimen, based on which a healthcare professional can rapidly verify whether the correct tissue has been resected. It can be used in any condition that requires resection surgery to visualize the resected specimen. The device is automated and semi-quantitative, i.e., qualitative regarding visualization of structure and radiotracer distribution and quantitative regarding tissue density (Hounsfield units) and radiotracer uptake in the specimen (Bq/ml). The type of specimen required is resected tissue from a patient undergoing resection surgery.
48354086|NCT00758004|DRUG|Atorvastatin|A single dose of 80 mg atrovastatin tablet
48354087|NCT00758004|DRUG|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
48505107|NCT03717025|PROCEDURE|NON CULTURED EPIDERMAL CELL SUSPENSION|"1. About one-tenth the size of recipient area is selected as the donor site.~2. Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~3. The area is dressed with Bactigras gauze.~4. Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~5. Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~6. Epidermal cell suspension is carefully transferred to a tuberculin syringe.~7. With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~8. This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~9. The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
48664681|NCT05308810|PROCEDURE|Major Gynecologic- oncologic Surgery|Major Gynecologic-Oncologic surgery between january 2020 - january 2022
48664682|NCT02477748|DRUG|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
48664683|NCT02477748|DRUG|Placebo|Tablet PO, taken once daily for 10 weeks.
48664684|NCT04885621|DIETARY_SUPPLEMENT|nutrisystem-D|Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
48664685|NCT04503369|BEHAVIORAL|Non-technical skills|"Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team."
48664686|NCT02688439|OTHER|Sciatic Nerve block|
48664687|NCT02688439|OTHER|Leg raised 30°|
48505108|NCT04272749|BEHAVIORAL|Assess opinons on the milk beverages|Questionnaires and consumption behaviors of dairy and non-dairy milks, including whole, 2% fat, 1% fat, skim, unsweetened almond, sweetened almond, unsweetened coconut, sweetened coconut, unsweetened soy, sweetened soy, unsweetened rice, and sweetened rice.....
48505109|NCT00140348|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
48664688|NCT02688439|OTHER|Distal tourniquet placed on the lower part of the leg|
48505110|NCT05209152|DRUG|AMG 176|Administered as an intravenous (IV) infusion.
48505111|NCT05209152|DRUG|Azacitidine|Administered as an IV infusion or subcutaneous (SC) injection.
48505112|NCT04492644|OTHER|No intervention|No intervention
48505113|NCT00741286|DRUG|Aspirin|Asprin (100mg) plus placebo
48505114|NCT00741286|DRUG|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
47987092|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 10 mg, once daily
47987093|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 30 mg, once daily
47987094|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 100 mg, once daily
47987095|NCT01142700|DRUG|Placebo|Capsule, Oral, 0 mg, once daily
47987096|NCT01142700|DRUG|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
47987097|NCT01142700|DRUG|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
47987098|NCT02651298|DEVICE|Fractional Co2-laser|laser treatment
47987099|NCT05278247|DIAGNOSTIC_TEST|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
47987100|NCT04995133|DRUG|Colistin|intravenous administration
47987101|NCT03453684|DRUG|Administration of Vancomycin|Intravenous Vancomycin Administration
47987102|NCT00498602|BIOLOGICAL|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
48354088|NCT00381784|BEHAVIORAL|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
48354089|NCT00381784|BEHAVIORAL|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
48664689|NCT02688439|OTHER|Leg in a neutral position|
48664690|NCT06252233|BEHAVIORAL|patient- and physician-centered QoL monitoring|Electronic QoL monitoring including QoL diagnosis and therapy (pain therapy, psychotherapy, social support, nutrition, physiotherapy, fitness, respiratory counselling, palliative care). Patients and treating physicians have access to the results of their QoL monitoring and to a network of local healthcare providers.
48505115|NCT02697240|DRUG|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
48505116|NCT05923463|BEHAVIORAL|precision-enhanced feedback email messages|Providers receive customized messages prioritizing metrics in an optimal formatting.
47987103|NCT00498602|BIOLOGICAL|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
47987104|NCT00498602|OTHER|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
47987105|NCT00498602|BIOLOGICAL|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
47987106|NCT02260479|PROCEDURE|Preheated|Skin disinfection solution is preheated in a warming cupboard
47987107|NCT04225351|PROCEDURE|MCAF+CM|CAF procedure + collagen matrix
47987108|NCT04225351|PROCEDURE|MCAT+CM|Tunnel procedure + collagen matrix
47987109|NCT05830201|BEHAVIORAL|No Dog Present|Dog is not present during pin removal
47987110|NCT05830201|BEHAVIORAL|Dog is Present|Dog is present during pin removal
47987111|NCT00737620|PROCEDURE|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
48505117|NCT05923463|BEHAVIORAL|standard feedback email messages|Providers receive metrics in a common format.
48664691|NCT06252233|OTHER|Placebo|Electronic QoL monitoring without QoL diagnosis and therapy. Patients and treating physicians have no access to the results of their QoL monitoring. The therapist network is also available for control arm.
48664692|NCT01480687|DIETARY_SUPPLEMENT|DHA-EPA|1800 mg/day
48664693|NCT01480687|DRUG|Ciprofibrate|100 mg/day
48664694|NCT00763828|DEVICE|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
47987112|NCT01862198|DEVICE|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
47987113|NCT00602576|DRUG|sorafenib tosylate|Given orally
47987114|NCT00602576|DRUG|temozolomide|Given orally
47987115|NCT01537029|DRUG|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
47987116|NCT01537029|DRUG|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
47987117|NCT04299308|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
47987118|NCT01358591|DIETARY_SUPPLEMENT|High calcium milk|High calcium milk (9 mg/kgBM)
48143423|NCT04050514|DEVICE|H-MAD with a hinge system according to Herbst|"The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD"
48143424|NCT02383693|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
48143425|NCT01963598|DRUG|REGN1033 (SAR391786)|
48143426|NCT01963598|DRUG|placebo|
48143427|NCT05087407|PROCEDURE|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
48354090|NCT04682795|DEVICE|Needle-free injector|Using needle-free injector as insulin carrier to treat T2DM
48143428|NCT05087407|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
48143429|NCT02378376|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|
48143430|NCT02378376|DIETARY_SUPPLEMENT|Dietary fiber enriched bran|
48143431|NCT06463301|OTHER|Treadmill Training In CP child|"Treadmill training for children should be carefully tailored to their developmental level, physical ability, and specific therapeutic goals. Initial Sessions start with shorter sessions, around 5-10 minutes, especially for children with disabilities.~Progression will be made when the child becomes more accustomed to the treadmill. Aim for a total of 20-30 minutes per session, including breaks if necessary then then Start at a slow walking pace, approximately 0.5 to 1.0 miles per hour (mph) or 0.8 to 1.6 kilometers per hour (kph). Adjust the speed based on the child's comfort and ability to maintain a safe and effective walking pattern.~Older Children (8-12 years Begin with a walking pace of 1.0 to 1.5 mph (1.6 to 2.4 kph). Gradually increase the speed to a brisk walk or light jog, up to 2.0 to 3.0 mph (3.2 to 4.8 kph), depending on the child's progress and comfort level along with conventional physical therapy."
48143432|NCT06463301|OTHER|Conventional Physical Therapy|conventional physical therapy session would typically include gentle stretching, joint mobilization, range of motion exercises for both the upper and lower body, gait training, and standing frame activities. Each component is designed to improve various aspects of physical function, ensuring a comprehensive approach to rehabilitation
48664695|NCT04363346|DRUG|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
48664696|NCT01842659|GENETIC|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
48143433|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
48143434|NCT00983294|DRUG|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
48354091|NCT04682795|DEVICE|Insulin pen|Using insulin pen as insulin carrier to treat T2DM
48354092|NCT05130229|BEHAVIORAL|Sleep Well Bee Well|Sleep program to help toddlers sleep better
48505118|NCT05393518|BEHAVIORAL|Anxiety-induced task|Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
48664697|NCT03060889|DRUG|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
48505119|NCT05393518|BEHAVIORAL|Neuropsychiatric assessment|Screening for depression and anxiety
48505120|NCT06632249|OTHER|Practice with the virtual reality game|4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
48505121|NCT04201691|OTHER|classic rehabilitation|The intervention is conventional rehabilitation that included streching, balance and coordination training. The intervention is applied to participants, manually.
48664698|NCT04313582|BEHAVIORAL|SmartPrompt smartphone application|The SmartPrompt is a smartphone application designed specifically for older adults with difficulties remembering to do daily tasks due to cognitive difficulties.
48664699|NCT01533623|DEVICE|Mandibular Advancement Device|Nightly wearing time
48664700|NCT02331758|BEHAVIORAL|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
48664701|NCT05751577|PROCEDURE|TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery
48664702|NCT05751577|PROCEDURE|TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
48664703|NCT04120207|BEHAVIORAL|Home-based Pilates|The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.
48143435|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
48354093|NCT04011137|OTHER|Exercise|Arm-cranking exercise
48354094|NCT02627196|DEVICE|BAROSTIM NEO® System|
48354095|NCT02627196|DRUG|Medical Management|
48354096|NCT01661231|DEVICE|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
48354097|NCT04139772|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
48664704|NCT04120207|OTHER|Delayed-start Pilates|The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
48354098|NCT04139772|DRUG|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
48354099|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
48354100|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
48505122|NCT04201691|OTHER|classic rehabilitation+mobilization|Another intervention is manuel therapy that included gliding technics, rotational technics at cervical region. (in addition to classic rehabilitation). The intervention is applied to participants, manually.
48664705|NCT03493139|BEHAVIORAL|Physical Activity Across the Curriculum|Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
48664706|NCT04277247|DRUG|Botulinum toxin type A|A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
48664707|NCT04277247|DRUG|Placebo|0.9% saline placebo injection
48664708|NCT02561962|DRUG|AMG 224|Administered as an IV infusion.
48664709|NCT00388609|DRUG|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
48664710|NCT00388609|DRUG|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
48664711|NCT02103465|DRUG|Rotigotine|transdermal patch
48664712|NCT02103465|DRUG|Placebo|transdermal patch
48664713|NCT05875857|BEHAVIORAL|Opioid destruction education|Intervention group will receive a specialized handout and patient education on the safe storage of opioid medications, importance of opioid destruction, opioid destruction options and medication destruction (Deterra) bag before discharge.
48664714|NCT06131190|BEHAVIORAL|mindfulness training|it focuses on attention and has gained empirical support as a complementary or alternative intervention
47987119|NCT01358591|DIETARY_SUPPLEMENT|Control|Regular Milk
47987120|NCT04380259|BEHAVIORAL|Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)|"MBTR-R is a mindfulness-based group intervention of nine 2.5-hour weekly sessions. MBTR-R format and structure parallel MBSR (mindfulness-based stress reduction) and MBCT (mindfulness-based cognitive therapy). MBTR-R includes systematic training in formal and informal mindfulness practices with trauma-sensitive adaptations and home practice. Trauma-sensitive adaptations include a safe place practice, psychoeducation about posttraumatic stress, stress reactivity, as well as self-compassion practices to cope with fear, self-judgement, guilt and shame. Socio-cultural adaptations include real-time linguistic translation of each session by a cultural mediator from the refugee community and use of socio-culturally specific metaphors. MBTR-R groups were conducted for men and women separately and delivered in an accessible, safe space in the local refugee community. Group meetings included a shared meal of traditional Eritrean food and female participants were offered free child care."
47987121|NCT05301426|OTHER|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
47987122|NCT05301426|OTHER|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
47987123|NCT05301426|OTHER|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
47987124|NCT05920174|DEVICE|NEO|Subjects will be implanted with the NEO device.
47987125|NCT01761656|DRUG|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
48664715|NCT00916227|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
48664716|NCT02065284|OTHER|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
48664717|NCT02200601|DEVICE|Seipher Wellness|
48354101|NCT00586833|PROCEDURE|O2 consumption max bike test|Single visit exercise study
48354102|NCT03232502|DIAGNOSTIC_TEST|Pharmacogenetic testing|Basic pharmacogenetic panel
48354103|NCT03094338|BEHAVIORAL|stress, psychological|students respond to questionnaires
48505123|NCT04173832|DRUG|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
48505124|NCT04173832|DRUG|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
48505125|NCT00818987|OTHER|Open reduction internal fixation; reduction and immobilization|
48664718|NCT06351514|DEVICE|Accelerated iTBS|Patients will be assigned to receive iTBS over the left dorsolateral prefrontal cortex or Frontal Medea with 5 sessions a day, every weekday for 1 week and total of 25 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 100%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions. All TBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.
48664719|NCT03218865|DEVICE|VIE high flux dialyzer|Asssesment of the therapeutic effect of the vitamin E coating
48664720|NCT03218865|DEVICE|Leoceed H high flux dialyzer|Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
48688035|NCT04188834|DEVICE|Customized version of DAVID device|A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
48664721|NCT05990686|DRUG|Tramadol Hydrochloride|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)"
48664722|NCT05990686|DRUG|Fentanyl injection|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~."
48664723|NCT01164826|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
48505126|NCT03888781|DEVICE|Echocardiography|An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
48664724|NCT01164826|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
48664725|NCT06511063|DRUG|tenofovir disoproxil/emtricitabine|Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
48664726|NCT06511063|DRUG|Selzentry|Participants will take Selzentry for 90 days.
48505127|NCT03109561|OTHER|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
48664727|NCT06511063|DRUG|Placebo|Matching placebo.
48664728|NCT05288556|DEVICE|Placement of stoma site enteral feeding tube accessory|The study stoma site accessory will be attached at the stoma site during an enteral tube replacement procedure the patient is scheduled to have as a standard of care procedure. The study stoma site accessory is compatible with commercially available enteral nutrition feeding tubes ranging from size 16 to 20 French tubing that are adjustable to variable length.
48664729|NCT04706988|OTHER|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
48664730|NCT00718315|DRUG|erlotinib [Tarceva]|150mg po daily
47987126|NCT01761656|DRUG|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
48664731|NCT00718315|DRUG|fusidic acid [Verutex]|topical, daily for 30 days.
48664732|NCT00718315|DRUG|erythromycin [Eritex]|topical, daily for 30 days.
48664733|NCT00718315|DRUG|Fisiogel|topical, daily for 30 days
48664734|NCT06224023|DIAGNOSTIC_TEST|Determination of presepsin levels in ascites|A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
47987127|NCT03733691|DRUG|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
47987128|NCT03733691|DRUG|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
47987129|NCT00084981|DRUG|decitabine|Given IV
47987130|NCT00084981|DRUG|valproic acid|Given PO
47987131|NCT00084981|OTHER|pharmacological study|Correlative studies
47987132|NCT00084981|OTHER|laboratory biomarker analysis|Correlative studies
47987133|NCT02877082|BIOLOGICAL|Thymoglobulin|Given IV
47987134|NCT02877082|DRUG|Bortezomib|Given IV
47987135|NCT02877082|DRUG|Tacrolimus|Given IV and PO
47987136|NCT00561080|BIOLOGICAL|Zostavax|
48505128|NCT03109561|GENETIC|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
47987137|NCT04366076|DIAGNOSTIC_TEST|Fetal heart rate (FHR) monitoring through computerized cardiotocography (cCTG) analysis antepartum|The investigator conducted antepartum surveillance through computerized cardiotocography (cCTG) analysis antepartum. This is a non-invasive method to study fetal well being. For each patient, a cCTG was attended using a computerized cardiotocography machine. External cCTG was practised for no less than 20 min (max 60 min), two transducers were fixed on the maternal abdomen: one above the fetal heart level and the other at the uterine fundus
48664735|NCT05454865|DIETARY_SUPPLEMENT|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
48664736|NCT05454865|DIETARY_SUPPLEMENT|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
48664737|NCT00893802|OTHER|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
48664738|NCT04136145|DRUG|Belimumab for IV|Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
48664739|NCT04136145|DRUG|Belimumab for SC|Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
48664740|NCT00365950|DRUG|Duration of anticoagulation|
47987138|NCT06130345|BIOLOGICAL|SPIKEVAX|Intramuscular injection
48143436|NCT03477799|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
48143437|NCT00798863|PROCEDURE|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
48354104|NCT05320224|OTHER|Patient-Oriented Music Intervention (POMI)|The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
48354105|NCT02339441|DRUG|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
48354106|NCT02339441|DRUG|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
48354107|NCT02339441|DRUG|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
48354108|NCT01742182|OTHER|Light exposure|
48505129|NCT03109561|DIAGNOSTIC_TEST|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
48505130|NCT03109561|OTHER|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
48505131|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOXIRI schedule|3200 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
48505132|NCT05062889|DRUG|5-Fluorouracil bolus FOLFOX schedule|400 mg/sqm iv bolus, day 1. To be repeated every two weeks for a maximum of 12 cycles.
48505133|NCT05062889|DRUG|5-Fluorouracil continuous infusion FOLFOX schedule|2400 mg/sqm 48 h-continuous infusion, starting on day 1. To be repeated every two weeks for a maximum of 12 cycles.
48505134|NCT05062889|DRUG|Oxaliplatin FOLFOX and FOLFOXIRI schedule|85 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
48505135|NCT05062889|DRUG|Oxaliplatin CAPOX schedule|130 mg/sqm iv over 2 hours, day 1. To be repeated every three weeks for a maximum of 8 cycles.
48505136|NCT05062889|DRUG|L-Leucovorin|200 mg/sqm iv over 2 hours, day 1. To be repeated every two weeks for a maximum of 12 cycles.
48664741|NCT00365950|DRUG|Warfarin duration|
47987139|NCT01829581|OTHER|no intervention, only descriptive data analysis|
47987140|NCT03931421|BIOLOGICAL|CAR-T treatment|a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
47987141|NCT05829486|PROCEDURE|gastroscopy|anaesthetic management of ambulatory endoscopic procedures
47987142|NCT05568147|DRUG|Aspirin tablet|When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
47987143|NCT05568147|DRUG|Placebo|When patients are randomized into the placebo group, they will receive placebo orally once a day.
48143438|NCT00221065|DEVICE|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
47987144|NCT03218007|BIOLOGICAL|blood samples|to evaluate expression and functionnaly activity of A2AR
47987145|NCT03864250|DRUG|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
48143439|NCT01572805|DRUG|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
48143440|NCT01572805|DRUG|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
48505137|NCT05062889|DRUG|Capecitabine|Capecitabine 1000 mg/sqm/bid per os from day 1 to day 14. To be repeated every 3 weeks until 8 cycles. Available as 500 and 150 mg tablets.
48505138|NCT05062889|DRUG|Irinotecan|165 mg/sqm iv over 60 minutes, day 1. To be repeated every two weeks for a maximum of 12 cycles.
48664742|NCT02018211|OTHER|control|passive recovery following exercise test
48664743|NCT02018211|DEVICE|graduated compression socks|graduated compression socks worn after test exercise
48143441|NCT01572805|DRUG|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
48143442|NCT05649891|OTHER|Emergency Manual|Collection of crisis checklists and fact sheets
48664744|NCT02018211|DEVICE|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
48143443|NCT05647538|PROCEDURE|Bilateral uterine artery ligation|Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
48143444|NCT01429454|DRUG|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
48664745|NCT01008826|DIETARY_SUPPLEMENT|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
48143445|NCT01429454|DRUG|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
48143446|NCT04738214|OTHER|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
48664746|NCT03122184|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
48143447|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 1|Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
48354109|NCT03592134|OTHER|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
48664747|NCT03122184|BEHAVIORAL|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
48664748|NCT06564493|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
47987146|NCT03864250|DRUG|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
47987147|NCT03358901|DRUG|YC-6|
47987148|NCT03358901|DRUG|Vehicle|
48505139|NCT05062889|DRUG|Trifluridine/Tipiracil|35 mg/m2/bid per os days 1-5 and 8-12. To be repeated every 4 weeks until 6 cycles. Available as 20 and 15 mg tablets.
48505140|NCT05062889|DRUG|Trastuzumab|4 mg/kg iv over 30 minutes, day 1 (loading dose: 6 mg/kg iv over 90 minutes). To be repeated every two weeks for a maximum of 12 cycles.
48505141|NCT05062889|DRUG|Tucatinib|300 mg (two 150 mg tablets)/bid orally twice daily (approximately 8 to 12 hours between doses with or without a meal) for a maximum of 12 biweekly cycles.
47987149|NCT04372667|BEHAVIORAL|Community score card approach|"The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~1. Phase I: Planning and preparation~2. Phase II: Conducting the Score Card with the community~3. Phase III: Conducting the Score Card with service providers~4. Phase IV: Interface meeting and action planning~5. Phase V: Action plan implementation and follow-up"
48143448|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 2|Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
48143449|NCT05488990|DRUG|AKVANO vehicle formulation 1|Novel lipid based formulation (AKVANO) vehicle 1
48664749|NCT06564493|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
48354110|NCT03248960|DIAGNOSTIC_TEST|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
48354111|NCT03248960|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
48664750|NCT06564493|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
47987150|NCT05526612|OTHER|Group 1 Motor imagery and Bobath Therapeutic Approach (BTA+MI)|Motor imagery (MI) is the mental rehearsal of motor abilities to improve function. Without revealing any movement in the body, the representation of the movement is created in the mind, the person imagines that he/she is performing the movement. Eating activity will be applied in motor imagery. Individualized therapy sessions in the Bobath Therapeutic Approach will also be received by the Physiotherapist along with Motor imagery. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
48664751|NCT02023437|DEVICE|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
48664752|NCT02023437|DEVICE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
48664753|NCT06565299|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery about congenital heart defects with cardiopulmonary bypass
48664754|NCT02441218|DRUG|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
48143450|NCT05488990|DRUG|AKVANO vehicle formulation 2|Novel lipid based formulation (AKVANO) vehicle 2
48143451|NCT05488990|DRUG|Daivonex solution|Daivonex solution containing Calcipotriol (50 μg/g)
48143452|NCT05488990|DRUG|Daivonex cream|Daivonex cream containing Calcipotriol (50 μg/g)
48143453|NCT06365905|OTHER|Non-Interventional Study|Non-Interventional Study
48354112|NCT03248960|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
48354113|NCT03248960|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
48664755|NCT02441218|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
48664756|NCT06565273|DRUG|FBL-MTX|Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.
48354114|NCT04395989|DRUG|A1: Pyrotinib with nab-paclitaxel|A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
48664757|NCT06014762|BIOLOGICAL|P-CD19CD20-ALLO1|Single weight-based IV administration
48664758|NCT06014762|DRUG|Rimiducid|Single weight-based IV administration
48664759|NCT01435161|DRUG|Nifedipine,|Nifedipine 30-60mg/day
48664760|NCT01435161|DRUG|Telmisartan|Telmisartan 80-160mg/day
48664761|NCT04829513|PROCEDURE|Home Exercise|This is a home exercise programme that involves flexibility and strengthening of the waist, hip girdle and sacroiliac region. These exercises are first shown by the physiotherapist in hospital, and then they are asked to do the exercises at home using illustrated forms. Patients continue the exercises as a home programme once a day for 1 month.
48664762|NCT04829513|PROCEDURE|Ligament Correction Kinesiotaping|Ligament correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
48664763|NCT04829513|PROCEDURE|Lymphatic Correction Kinesiotaping|Lymphatic correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
48664764|NCT02727608|DRUG|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
48664765|NCT03447873|DRUG|Continue with triple therapy|To continue with triple therapy
48664766|NCT03447873|DRUG|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
48664767|NCT03447873|DRUG|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
48664768|NCT01390623|DRUG|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
47987151|NCT05526612|OTHER|Group 2 Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)|Individualized therapy sessions in the Bobath Therapeutic Approach with motor imagery will be performed by the physiotherapist, and in addition to these, 5 repetitions of the eating activity used in motor imagery will be practiced. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
47987152|NCT01165554|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
48002618|NCT02829749|DEVICE|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
48002619|NCT02829749|PROCEDURE|Control|traditional mitral valve repair performed under cardiac arrest
48143454|NCT05662930|BEHAVIORAL|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
48143455|NCT05662930|BEHAVIORAL|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
48664769|NCT04667689|BEHAVIORAL|CAMPFIRE Online Cognitive Assessment for Cancer Patients|Subjects will complete PROMIS Cognitive Function/Anxiety/Depression survey assessments and a short neuropsychological battery (NIH Toolbox) on an iPad while in clinic prior to beginning chemotherapy, again before a clinic visit scheduled between 6 - 9 weeks and, lastly, before a post-chemotherapy follow-up clinic visit. Within two weeks of their post-chemotherapy assessment, subjects will be asked to complete a feedback survey. The physician providers and/or their clinical team (e.g., nurse practitioners, registered nurses) will be asked to review subjects' cognitive assessment results and discuss referrals and/or recommendations, if appropriate.
48664770|NCT04670796|DRUG|HLX02|subject receive one dose of HLX02
48664771|NCT04670796|DRUG|EU-sourced Trastuzumab (Herceptin®)|subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
48354115|NCT04395989|DRUG|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
48354116|NCT04395989|DRUG|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
48354117|NCT04395989|DRUG|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
48143456|NCT05662930|BEHAVIORAL|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
48143457|NCT05662930|BEHAVIORAL|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
48143458|NCT05662930|BEHAVIORAL|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
48143459|NCT05662930|BEHAVIORAL|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
48354118|NCT04395989|DRUG|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
48354119|NCT04395989|DRUG|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
48505142|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
48664772|NCT04670796|DRUG|US-licensed Trastuzumab (Herceptin®)|subject receive one dose of US-licensed Trastuzumab (Herceptin®)
48664773|NCT04882943|OTHER|questionnaires|Quality of life questionnaires
48664774|NCT00688740|DRUG|Docetaxel|intravenous
48664775|NCT00688740|DRUG|5-fluorouracil|intravenous
48664776|NCT00688740|DRUG|Doxorubicin|intravenous
47987153|NCT04122898|OTHER|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
48664777|NCT00688740|DRUG|Cyclophosphamide|intravenous
48664778|NCT02803684|OTHER|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
47987154|NCT00038207|DRUG|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
48002620|NCT02071524|DRUG|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
48002621|NCT02071524|DRUG|Cristalloid administration|Only Ringer Lactate administration
48143460|NCT06365892|DRUG|open-label placebo|Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1.
48143461|NCT06365892|OTHER|Treatment as usual|Each oral opioid dose is a 5mg Oxycodone tablet. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
48143462|NCT01295099|DRUG|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
48143463|NCT01295099|RADIATION|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
48143464|NCT01295099|DRUG|Triamcinolone|TAC 10mg in 1ml injected intralesional
48505143|NCT04434300|DRUG|Daptomycin|Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
48664779|NCT01197547|DEVICE|Genesys HTA|Genesys HTA Endometrial Ablation
48664780|NCT03616821|DRUG|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
48664781|NCT03616821|DRUG|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
48664782|NCT06560333|DRUG|N0892|1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg
48664783|NCT06560333|DRUG|Januvia® + Glifage XR® + Placebo|1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg
48354120|NCT04395989|DRUG|D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
47987155|NCT03658850|DRUG|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
48354121|NCT04395989|DRUG|D2: nab-paclitaxel, with maintenance of capecitabine|D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
48505144|NCT02895152|BEHAVIORAL|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
47987156|NCT03658850|DRUG|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
48664784|NCT06560333|DRUG|Forxiga® + Glifage XR® + Placebo|1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg
48664785|NCT05325684|DRUG|PD-L1 inhibitor|Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
47987157|NCT05931250|DEVICE|DC-Stimulator Plus (NeuroConn GmbH, Germany)|Transcranial alternating current stimulation
47987158|NCT05931250|DEVICE|Sooma direct current stimulator (Sooma, Finland)|Transcranial direct current stimulation
47987159|NCT04620720|DRUG|capule gabapentin|neuropathic analgesic
47987160|NCT03695679|BEHAVIORAL|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~1. Perceived Susceptibility and Perceived Severity~2. Perceived Benefits and Perceived Barriers~3. Cue to Action~4. Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
47987161|NCT05007964|DEVICE|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
47987162|NCT05451147|DRUG|Chhinnavahni Kashaya Vati along with Agnimantha Kwatha|Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
47987163|NCT05451147|DRUG|Metformin Hydrochloride|Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
47987164|NCT00128570|BEHAVIORAL|behavioral dietary intervention|
47987165|NCT00128570|OTHER|educational intervention|
47987166|NCT00128570|OTHER|internet-based intervention|
47987167|NCT00128570|OTHER|preventative dietary intervention|
47987168|NCT00128570|PROCEDURE|evaluation of cancer risk factors|
47987169|NCT06288412|DRUG|Insulin icodec|Participants will receive insulin icodec subcutaneous (s.c.) once weekly.
47987170|NCT06288412|DRUG|Insulin degludec|Participants will receive insulin degludec s.c. once daily.
48354122|NCT04395989|DRUG|E1: everolimus with nab-paclitaxel|E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
48354123|NCT04395989|DRUG|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
48505151|NCT03214029|DIAGNOSTIC_TEST|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
48505152|NCT03307616|BIOLOGICAL|Ipilimumab|Given IV
48505153|NCT03307616|BIOLOGICAL|Nivolumab|Given IV
48505154|NCT03307616|RADIATION|Radiation Therapy|Undergo radiation therapy
48664786|NCT04970914|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
48664787|NCT04970914|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
48505155|NCT04943276|DEVICE|Embr Device|The Embr thermal device will be worn at all times from study start to the study endpoint.
48505156|NCT01136967|DRUG|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
48664788|NCT02695654|DRUG|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
48664789|NCT02695654|DRUG|Clonidine|Clonidine 100 mcg
48664790|NCT02629861|DRUG|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
48354124|NCT06099808|OTHER|Audit and Feedback Emails|Monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. This will include rates of GDMT utilization and percentage of patients on \>50% of the target dose of GDMT stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard.
48354125|NCT06099808|OTHER|Patient Specific Targets|Monthly emails include a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. This data will be obtained from VHA national HF dashboard.
48354126|NCT06099808|OTHER|Educational Resources|Monthly educational webinars on pharmacist HF management and access to material and protocols on HF medication management.
48354127|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
48354128|NCT00474136|DRUG|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
48354129|NCT00474136|DRUG|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
48354130|NCT02912741|DRUG|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
48354131|NCT02912741|DRUG|resin infiltration|low viscous light cure resin applied in layers and cured
48354132|NCT03595982|DRUG|Procardia XL 30Mg|Procardia XL 30 mg XL Q 12h
48354133|NCT03595982|DRUG|Procardia XL 60Mg|Procardia XL 60 mg Q 24h
48354134|NCT03611946|BIOLOGICAL|rZIKV/D4Δ30-713 (Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection)|Administered at a dose of 10\^3 plaque-forming units (PFUs) by subcutaneous injection
48354135|NCT03611946|BIOLOGICAL|Placebo|Administered by subcutaneous injection.
48354136|NCT03611946|BIOLOGICAL|rZIKV/D4Δ30-713 (Administered at a dose of using 10^4 plaque-forming units (PFUs) by subcutaneous injection).|Administered at a dose of using 10\^4 plaque-forming units (PFUs) by subcutaneous injection.
48354137|NCT00566332|DRUG|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
48354138|NCT00566332|DRUG|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
48354139|NCT02249351|DRUG|Talsaclidine|
48354140|NCT02249351|DRUG|Placebo|
48354141|NCT01370772|DRUG|Rituximab|"* Cycle 1 Rituximab : 375 mg/m² i.v on day 1~* Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
48354142|NCT01370772|DRUG|Rituximab|"* Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~* Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
48354143|NCT01370772|DRUG|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
48354144|NCT01370772|DRUG|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
48354145|NCT02495584|DIETARY_SUPPLEMENT|Fortified milk (10µg vitamin D3)|
48354146|NCT02495584|DIETARY_SUPPLEMENT|Unfortified milk (placebo)|
48354147|NCT02495584|DIETARY_SUPPLEMENT|10µg vitamin D3 supplement|
48354148|NCT02495584|DIETARY_SUPPLEMENT|Placebo supplement|
48354149|NCT05529862|GENETIC|Pre-treatment biopsy|Pre-treatment fragments will be collected during the biopsy visit organised as part of routine medical practice, prior to the start of treatment with ribociclib + ET
48354150|NCT05529862|GENETIC|Post treatment biopsy|Post-treatment fragments will be collected during a biopsy visit specifically planned for Trans-RosaLEE study.
48354151|NCT05529862|GENETIC|Pre treatment blood sampling|Sampling of 4 EDTA Tubes (4ml) and 2 Streck tubes (10ml)
48354152|NCT05529862|GENETIC|Post treatment blood sampling|Sampling of 2 Streck tubes (10ml)
48354153|NCT03211104|DIETARY_SUPPLEMENT|curcumin|
48354154|NCT03211104|DIETARY_SUPPLEMENT|Placebo|
48354155|NCT06094686|DIAGNOSTIC_TEST|epicardial adipose tissue thickness|EATT measured via transthoracic echocardiography
48354156|NCT06101355|OTHER|Telerehabilitation|"Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation. With the exercises, there will be video links, exercise visuals, and written explanations. Videos and visuals of the exercises recorded by the physiotherapist and uploaded to the Rehab My Patient application.~Digital exercise forms will be prepared through the Rehab My Patient application. The intervention group will receive exercises, which prepared from the Rehab My Patient application ,digitally through WhatsApp. In this group, exercise sessions will be conducted with the physiotherapist once a week through video calls. Additionally, there will be one instance of messaging and one phone call for follow-up. Video calls and messaging will be conducted through WhatsApp."
48354157|NCT06101355|OTHER|Standard Home Based Exercise Group|Control group, standard home exercise program group , will receive the program as brochures. Although there will be no video supplement, the brochure will include visuals of the exercises. The control group will be monitored through three weekly voice calls.
48354158|NCT02825238|OTHER|Supervised exercise program|
48354159|NCT05066802|DRUG|neoadjuvant modified FOLFIRINOX|oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42\~46h continuous infusion, every other week for 6 cycles (12 weeks) before surgery.
48354160|NCT04722289|BEHAVIORAL|Together on Diabetes|Social and emotional support'; 'Assistance in daily management'; and 'Linkage to healthcare services'
48354161|NCT01158885|DRUG|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
48664791|NCT02629861|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
48354162|NCT01158885|DRUG|Cytarabine intravenous|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
47987171|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care group|Self-hypnosis/self-care
47987172|NCT04218227|BEHAVIORAL|Music/self-care|Music-therapy/self-care
47987173|NCT04218227|BEHAVIORAL|Self-care|Self-care
47987174|NCT04218227|BEHAVIORAL|Psycho-education|Psycho-education
48143465|NCT02243449|PROCEDURE|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
48143466|NCT02243449|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
48143467|NCT03836885|DRUG|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
48143468|NCT03836885|DRUG|Placebo|Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
48143469|NCT00955565|PROCEDURE|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
48143470|NCT00955565|PROCEDURE|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
48143471|NCT00135018|DRUG|celecoxib and chemotherapy|
48354163|NCT01158885|DRUG|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
48354164|NCT01158885|DRUG|Intrathecal (IT) Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
48505157|NCT04732910|DRUG|Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor|observational
48505158|NCT00006019|DRUG|azacitidine|
48505159|NCT00006019|DRUG|sodium phenylbutyrate|
48505160|NCT03051932|DRUG|Ofiramev® (IV Acetaminophen)|Post -op pain medication
48664792|NCT02857972|DEVICE|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
48664793|NCT01503320|DIETARY_SUPPLEMENT|Enteral glutamine|Dosage of glutamine: 0.57g/kg, \~ 30g/day= 3sachets
47987175|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care motivation|Motivation to learn self-hypnosis/self-care
47987176|NCT03704272|BEHAVIORAL|SunBrite|SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
47987177|NCT03594292|DEVICE|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
47987178|NCT03594292|PROCEDURE|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
47987179|NCT01857232|DRUG|Ondansetron|5HT3-antagonist
47987180|NCT01857232|DRUG|Placebo|Comparator
47987181|NCT01857232|DRUG|Dexamethasone|Corticosteroid
47987182|NCT01857232|DRUG|Fosaprepitant|NK1 antagonist
48664794|NCT01503320|DIETARY_SUPPLEMENT|Placebo|Similar appearing nutritional supplement without glutamine.
48505161|NCT03051932|DRUG|Placebo IV administration|Post -op pain
48664795|NCT01348893|BEHAVIORAL|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
48664796|NCT01482715|DRUG|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
48664797|NCT05517408|DRUG|ciprofol|The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
48664798|NCT02427490|BEHAVIORAL|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
48143472|NCT03211988|DRUG|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
48143473|NCT00608699|DRUG|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
48143474|NCT03540329|DEVICE|Internal Osteogenesis distractor|Internal distraction osteogenesis in mandible
48143475|NCT03540329|DEVICE|External Osteogenesis distractor|External distraction osteogenesis in mandible
48143476|NCT06055491|DRUG|Vitamin D3 or Saline injection at ipsilateral deltoid muscle|study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
48143477|NCT03950661|OTHER|Walking|
48664799|NCT02427490|OTHER|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
47987183|NCT01857232|DRUG|APD403 IV|Amisulpride IV 20 mg
47987184|NCT01857232|DRUG|APD403 oral|Amisulpride oral 10, 20 or 40 mg
47987185|NCT01013701|DRUG|fluticasone furoate|nasal steroid spray
48505162|NCT04596514|PROCEDURE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)
48505163|NCT04596514|PROCEDURE|usual procedure according to guidelines|Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines
48505164|NCT04429438|BIOLOGICAL|4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2|Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells
48143478|NCT05702788|DRUG|Jaktinib hydrochloride tablets|75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
48143479|NCT05702788|DRUG|Jaktinib hydrochloride tablets|100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
48143480|NCT05702788|OTHER|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
48143481|NCT05379166|DRUG|Azacitidine|Given IV
48143482|NCT05379166|OTHER|Quality-of-Life Assessment|Ancillary studies
48505165|NCT02151877|DRUG|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
47987186|NCT01013701|OTHER|placebo|nasal steroid vehicle without drug
47987187|NCT00003644|DRUG|carboplatin|
47987188|NCT00003644|DRUG|paclitaxel|
47987189|NCT04992455|OTHER|Older Patients Receiving Chemotherapy|No Intervention
47987190|NCT04435015|DRUG|Camostat Mesylate|Participants will be given Camostat mesylate three times daily.
47987191|NCT04435015|DRUG|Microcrystalline Cellulose, NF|Participants will be given Microcrystalline Cellulose (placebo) three times daily.
47987192|NCT02685020|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
48143483|NCT05379166|OTHER|Questionnaire Administration|Ancillary studies
48143484|NCT05379166|DRUG|Venetoclax|Given PO
48143485|NCT05243459|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.
48505166|NCT02151877|DRUG|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
48664800|NCT05129800|OTHER|Platelet-rich plasma|"PRP preparation involved, withdrawal 8-10ml from each patient into a tube containg either 3,8 % sodium citrate and either enoxaparin gel or thixotropic cell-separation gel. The tubes were centrifuged at either 3900 rpm for 10 minutes or at 1500g for 5 minutes, resulting in four layers: a cell-rich layer at the bottom of the tube covered by the separating gel, a PRP layer on top of the gel, and a platelet-poor plasma (PPP) layer at the top. The tube was gently agitated in order to mix the PPP with the PRP. The solution, cca 4-5ml, was withdrawn with a needle and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or an injector. According to the protocol of our hospital, the injections to the scalp were spaced 0.5-1cm apart.~PRP was applied once every month for 3 months. Macroscopic and digital phototrichographic photos were taken before the beginning of treatment, 1 month after the last injection, and 3 months after the end of treatmert."
48143486|NCT05243459|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
48664801|NCT05129800|OTHER|Mesotherapy|"For mesotherapy, usually around 5ml of saline solution was withdrawn using a needle and released to the selected ampule containing adipose tissue stem-cell conditioned media and mixture of recombinant growth factors, in a powder form. We used preparations from two different companies, differing in the combination and concentration of ingredients. After the injection of normal saline, the ampule was gently agitated in order to disperse the powder and injected to the scalp-frontoparietal region using either a syringe and a 4mm needle or a gun injector. The injections were spaced 0.5-1cm apart.~Mesotherapy was repeated every 1-2 weeks for 6-7 times according to the protocol recommended for each preparation. Macroscopic and phototrichographic photos were taken before the beginning of treatment, a month after the last injection and 3 months after the end of treatment."
48354165|NCT04234399|DIAGNOSTIC_TEST|Fluciclovine PET/CT using a digital PET/CT|Fluciclovine is a radiotracer that will be used in conjunction with the high resolution digital Vereos PET/CT scanner.
48664802|NCT06042946|PROCEDURE|Microsurgical resection of ISCM|Microsurgical resection of ISCM defines the surgical removal of cancerous tumors that have spread to the spinal cord, using advanced microsurgical techniques and equipment like ultrasound, neuromonitoring, ultrasonic aspirator to prevent damage to the spinal cord.
48664803|NCT01901692|RADIATION|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
48664804|NCT01901692|DRUG|Sorafenib|Sorafenib 800 mg/day orally
48664805|NCT02697357|BEHAVIORAL|Psychosocial Instruments|
48143487|NCT05243459|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
47987193|NCT02685020|BIOLOGICAL|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
48664806|NCT02697357|BEHAVIORAL|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
48664807|NCT06547931|OTHER|Data collection and analysis|Retrospective collection of clinical and laboratory data relating to the definition of the nature of neutropenia
47987194|NCT02685020|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
47987195|NCT05092685|GENETIC|AAVLK03hOTC|Peripheral intravenous infusion of AAVLK03hOTC.
47987196|NCT00909116|PROCEDURE|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
47987197|NCT04035928|DEVICE|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
47987198|NCT02673489|DRUG|DCV|
47987199|NCT02673489|DRUG|SOF|
47987200|NCT02673489|DRUG|RBV|
47987201|NCT01683955|DRUG|Tranexamic acid|Topical tranexamic acid (2g/100mL 0.9% saline)
48143488|NCT04265235|OTHER|Home-based exercise program|see 'arm' section
48143489|NCT04237857|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
47987202|NCT01683955|DRUG|Placebo|100mL 0.9% sterile saline
48143490|NCT03903978|BEHAVIORAL|Cognitive Behavioral Therapy|"The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~1. Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~2. Autonomy, building my way: Enhancement of autonomy~3. Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~4. Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~5. Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~6. Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future."
48354166|NCT04299750|PROCEDURE|Tooth extraction and Alveolar ridge preservation|Tooth extraction and alveolar ridge preservation with deproteinized bovine bone mineral and a collagen matrix seal
48354167|NCT04299750|PROCEDURE|Tooth extraction|Tooth extraction and socket natural healing
48354168|NCT00003606|DRUG|cisplatin|
48354169|NCT00003606|DRUG|cyclophosphamide|
48354170|NCT00003606|DRUG|epirubicin hydrochloride|
48354171|NCT00003606|DRUG|etoposide|
48354172|NCT00003606|RADIATION|radiation therapy|
48664808|NCT01507740|DRUG|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
48664809|NCT01507740|DRUG|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
48664810|NCT01507740|DRUG|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
48143491|NCT03903978|BEHAVIORAL|Healthy lifestyle|"1. Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~2. Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~3. Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~4. Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health."
48143492|NCT05300594|DIETARY_SUPPLEMENT|Plant extracts, vitamins and mineral|"Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)"
48664811|NCT01972659|DRUG|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
48664812|NCT01972659|DRUG|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
48664813|NCT01972659|DRUG|sugammadex|4 mg/kg iv bolus at the end of the surgery
48664814|NCT00105898|PROCEDURE|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
48505167|NCT03968978|BIOLOGICAL|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
47987203|NCT04419454|DEVICE|BodyTite|retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.
48143493|NCT05300594|DIETARY_SUPPLEMENT|Placebo|Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
48143494|NCT02577939|BEHAVIORAL|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
48143495|NCT00860457|DRUG|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
48143496|NCT00860457|DRUG|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
48143497|NCT00860457|DRUG|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
47987204|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
47987205|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
47987206|NCT02143440|BEHAVIORAL|The initial assessment of daily insulin dose.|
47987207|NCT01040897|BEHAVIORAL|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
48505168|NCT03968978|BIOLOGICAL|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
48505169|NCT06633718|DRUG|Meropenem and Pralurbactam|3g，q8h，120min infusion
48505170|NCT06633718|DRUG|Saline|100mL，q8h，60min infusion
48505171|NCT06633718|DRUG|Ceftazidime-avibactam|2.5g，q8h，120min infusion
48664815|NCT00105898|PROCEDURE|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
48354173|NCT05727527|PROCEDURE|Local Anesthesia 1|Local anesthesia injection after applying a candy flavor
48664816|NCT00105898|PROCEDURE|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
48354174|NCT05727527|PROCEDURE|Local Anesthesia 2|Local anesthesia injection after applying sterile water
48354175|NCT04519476|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.
48354176|NCT04519476|DRUG|Lenalidomide|Immunomodulatory drug
48354177|NCT04519476|DRUG|Methylprednisolone|Glucocorticoid, steroid
48354178|NCT04139603|OTHER|Lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
48354179|NCT04139603|OTHER|Abdominal supported lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
48354180|NCT04139603|OTHER|Placebo tapng|"Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
47987208|NCT01040897|BEHAVIORAL|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
48664817|NCT01998477|BIOLOGICAL|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain \[A/H1N1-like, A/H3N2-like, and B-like\]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
48664818|NCT01998477|BIOLOGICAL|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain \[A/ H1N1-like, A/H3N2-like, and B-like\]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
48664819|NCT03687281|OTHER|Survey|"The questionnaire consists of three parts:~* knowledge assessment;~* socio-demographic, medical and lifestyle data;~* use of Chemsex."
48664820|NCT00654108|DRUG|Ciprofloxacin|500 milligrams(mg) will be administered orally twice daily for 5 days.
47987209|NCT04934345|DIAGNOSTIC_TEST|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
47987210|NCT04974112|OTHER|Apply SGA and NRS2002|Special researchers appointed by the research unit apply SGA and NRS2002 and other data measurement tools to collect patient information
47987211|NCT00119002|DRUG|dexamethasone|1mg/kg dexamethasone
48354181|NCT06081387|OTHER|Resistance training|Sarcoplasm stimulating training system. This program will run for 15 weeks and three sessions a week. This exercise plan is designed in three 5-week periods.
48354182|NCT03662789|DRUG|Iron Isomaltoside 1000|Intravenous infusion
48664821|NCT00654108|BIOLOGICAL|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.
47987212|NCT00119002|DRUG|Placebo|1mg/kg placebo
47987213|NCT00955591|OTHER|Papanicolaou test|
48143498|NCT02442622|OTHER|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
48354183|NCT03662789|OTHER|Placebo: NaCl 0,9%|Intravenous infusion
48354184|NCT04105595|DEVICE|Septal defect closure|Device closure of atrial septal defect
48354185|NCT03887325|DRUG|Maxipost|To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
48505172|NCT06633718|DRUG|Metronidazole|0.915g，q8h，60min infusion
48664822|NCT00654108|OTHER|Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
48354186|NCT03887325|DRUG|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
48354187|NCT03260673|OTHER|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
48354188|NCT01609673|DRUG|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
48354189|NCT02946008|RADIATION|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
48664823|NCT05936658|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
47987214|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
47987215|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
47987216|NCT01262950|OTHER|portable motion detector|
47987217|NCT04234282|PROCEDURE|Manual Physical Therapy|Orthopedic manual physical therapy targeting the knee joint and soft tissues with complementary exercises targeted at their impairment.
47987218|NCT02333695|DEVICE|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
47987219|NCT05168267|BEHAVIORAL|Cognitive Processing Therapy|CPT: a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
47987220|NCT02506140|DRUG|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
48354190|NCT02946008|PROCEDURE|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
48354191|NCT03227601|DEVICE|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
48354192|NCT04366128|DRUG|CAPA indution immunotherapy|"1. Camelirumab 200mg Intravenous injection on day 1.~2. Apatinib 250mg taken orally once daily.~3. Pegaspargase 2000U/m2 Intramuscular injection on day 1."
48143499|NCT02442622|DEVICE|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
48354193|NCT05823428|PROCEDURE|Augmentation with subacromial bursa + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
48354194|NCT05823428|PROCEDURE|Rotator cuff debridement + acromioplasty|Two intervention was planned. Rotator cuff debridement + acromioplasty group is mentioned as Group A (18 patients) and augmentation with subacromial bursa + acromioplasty is Group B
48354195|NCT03262285|PROCEDURE|phacoemulsification|removal of cataract using ultrasound waves
48354196|NCT03262285|PROCEDURE|extracapsular cataract extraction|removal of cataract using surgical corneal incision
48354197|NCT00857116|DRUG|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
48354198|NCT00857116|DRUG|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
48354199|NCT02289118|DRUG|[18F]-T807 imaging tracer|Tau Imaging tracer
48664824|NCT04507763|DRUG|Etanercept|Patients with ankylosing spondylitis as provided in real world practice
48143500|NCT04973306|PROCEDURE|Neoadjuvant Chemoradiotherapy|"Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)"
48143501|NCT04973306|DRUG|Tislelizumab|"Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);"
48143502|NCT04973306|PROCEDURE|Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)|After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
48664825|NCT02164409|PROCEDURE|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
48143503|NCT04885673|DEVICE|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
48143504|NCT04885673|DEVICE|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
48143505|NCT02675322|DRUG|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
47987221|NCT02506140|DRUG|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
48143506|NCT02675322|OTHER|Placebo|Placebo with no chemical effects.
48143507|NCT02799849|OTHER|Sleep and metabolism assessment|
48505173|NCT03242200|OTHER|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
48664826|NCT01575574|DRUG|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
47987222|NCT00189657|PROCEDURE|5FU/LV Mayo Clinic or LV5FU2|
47987223|NCT00189657|PROCEDURE|LV5FU2 + irinotecan|
47987224|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class II-IV|"New york Heart Association Class II-IV  study of markers"
47987225|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class I|New york Heart Association Class I
47987226|NCT06096272|DEVICE|Augment Reality Exergames|Adaptive physical activity AR gaming modules were created in collaboration with physical therapists with expertise in CP and the Augment Therapy app development team. The program will consists of 5 games adapted for children with cerebral palsy.
47987227|NCT00560079|DRUG|Allopurinol|Allopurinol 600mg/day bid for 28 days
47987228|NCT00560079|DRUG|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
47987229|NCT00560079|DRUG|Placebo|Placebo
47987230|NCT02184689|DRUG|fexinidazole|
47987231|NCT05855031|DIAGNOSTIC_TEST|Transient Elastography|One transient elastography 1-2 weeks after randomization
47987232|NCT05813795|DRUG|Ecnoglutide Low Dosage|Subcutaneous Injection
48143508|NCT05222100|DIAGNOSTIC_TEST|Mammography screening|Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.
48143509|NCT05985265|PROCEDURE|Fat grafting|Nano fat grafting followed by fractional carbon dioxide laser resurfacing
48143510|NCT00126958|PROCEDURE|urinary analysis|
48143511|NCT05906966|OTHER|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
48143512|NCT01772199|DRUG|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
48143513|NCT01772199|DRUG|Placebo|White to almost white, round tablets. Once daily orally.
48143514|NCT00825344|DRUG|Etanercept|50 mg subcutaenous preoperatively
48143515|NCT00825344|DRUG|Saline|Given subcutaneously preoperatively
48143516|NCT01802619|OTHER|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
48143517|NCT01802619|OTHER|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
48664827|NCT04047485|DIAGNOSTIC_TEST|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
48143518|NCT05017909|BEHAVIORAL|Face to face education|Face to face education techniques on the acquisition of the mothering Role
48505174|NCT04928092|PROCEDURE|Standard of care Ultra Low Contrast PCI|PCI using low amounts of contrast media which is standard of care at VCU Medical Center
48505175|NCT06632119|DEVICE|high-intensity laser therapy|high-intensity laser therapy (HILT) machine, ASA laser
48143519|NCT05017909|BEHAVIORAL|Web based education|web based education techniques on the acquisition of the mothering Role
48143520|NCT05017909|BEHAVIORAL|No education|Control group will not be educated
48143521|NCT04918719|DRUG|Acetylcysteine|The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
48143522|NCT04918719|DRUG|Dextrose in Water|The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
48505176|NCT06632119|DEVICE|Sham-HILT|Sham-HILT, HILT machine without laser release
48505177|NCT03184155|DRUG|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
48505178|NCT03184155|DRUG|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
48505179|NCT05713253|DEVICE|ELITA System|Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
48505180|NCT03013855|DEVICE|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
48505181|NCT03013855|DEVICE|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
48505182|NCT06330181|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart"
48505183|NCT06330181|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
48505184|NCT00492024|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
48505185|NCT00492024|DRUG|Placebo|Placebo - 380 mg Microcrystalline Cellulose
48505186|NCT04776538|BIOLOGICAL|Stem cells|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
48505187|NCT04776538|BIOLOGICAL|Placebo|Each participant will be double-blindly randomized to receive either adipose-derived allogeneic stem cells or placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO).
48505188|NCT00424918|BEHAVIORAL|Physical Activity, reduced sedentary behavior|
48505189|NCT05930548|OTHER|Low Shrinkage Giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
48505190|NCT04987385|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
48664828|NCT04047485|DIAGNOSTIC_TEST|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
47987233|NCT05813795|DRUG|Ecnoglutide Medium Dosage|Subcutaneous Injection
47987234|NCT05813795|DRUG|Ecnoglutide High Dosage|Subcutaneous Injection
48505191|NCT04987385|DIETARY_SUPPLEMENT|Oral urea|Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, ...) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
48664829|NCT04047485|DIAGNOSTIC_TEST|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
48354200|NCT04068220|OTHER|intraoperative FVEPs monitoring|During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
48664830|NCT04047485|DIAGNOSTIC_TEST|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
48664831|NCT04047485|DIAGNOSTIC_TEST|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
48664832|NCT04047485|DIAGNOSTIC_TEST|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
48664833|NCT04047485|DIAGNOSTIC_TEST|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
48664834|NCT03790748|PROCEDURE|Standard Lumbar Epidural Technique|Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
48354201|NCT04533360|DIAGNOSTIC_TEST|VITROS Anti-SARS-CoV-2 IgG test|The VITROS Anti-SARS-CoV-2 IgG test is a lateral flow immunoassay produced by Ortho-Clinical Diagnostics Inc.
48354202|NCT05705687|DRUG|BEP Protocol|anticancer therapy
48354203|NCT05705687|DRUG|Dose-dense regimen|T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
48354204|NCT05705687|PROCEDURE|Early tumor resection or HD-CT|TIP protocol + early surgery or high-dose chemotherapy if surgery not feasible or metastatic disease
48354205|NCT01050140|DIETARY_SUPPLEMENT|high sugar diet|25% of dietary energy from fructose or glucose
48354206|NCT00686699|DRUG|Preladenant|capsules
48354207|NCT00686699|DRUG|Placebo|capsules
48354208|NCT04955574|OTHER|SH-DS01 + Antibiotic Placebo|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
48354209|NCT04955574|DRUG|SH-DS01 + Metronidazole|Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
48354210|NCT04955574|OTHER|Probiotic Placebo + Antibiotic Placebo|Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
48354211|NCT00547989|DRUG|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
48664835|NCT03790748|PROCEDURE|25G Dural Puncture Epidural Technique|25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
48664836|NCT03790748|PROCEDURE|27G Dural Puncture Epidural Technique|27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
48664837|NCT00969423|DEVICE|5mm videoscope|use of 5mm videoscope
48664838|NCT00969423|DEVICE|10mm videoscope|use of 10mm videoscope
48354212|NCT00547989|DRUG|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
48354213|NCT00547989|DRUG|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
48505192|NCT04430478|DIAGNOSTIC_TEST|Volume flow guided angioplasty|Volume flow measurements using DUS will be obtained at the end of each balloon dilation, at 24 hours, 6 months, and one year after index procedure.
48505193|NCT04117919|DRUG|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
48505194|NCT04117919|DRUG|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
48505195|NCT05093361|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty for the treatment of hip arthritis.
48664839|NCT01511133|PROCEDURE|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
48664840|NCT01511133|PROCEDURE|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
48143523|NCT06178380|OTHER|rehabilitation|"For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed"
48143524|NCT00585793|DRUG|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
48143525|NCT01868061|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
48143526|NCT01868061|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
48143527|NCT01419184|DRUG|Daptomycin|
48143528|NCT01419184|DRUG|Vancomycin|
48143529|NCT00853411|DRUG|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
48143530|NCT03482102|DRUG|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
48143531|NCT03482102|DRUG|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
48143532|NCT03482102|RADIATION|Radiation|Radiation therapy is used to shrink cancer cells.
48143533|NCT03434600|OTHER|Oxford UKA vs Sigma UKA|
48354214|NCT06015191|BEHAVIORAL|Remote Cardiac Rehabilitation|Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.
48354215|NCT06015191|BEHAVIORAL|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
48354216|NCT02079415|OTHER|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
48354217|NCT04419597|DEVICE|HEMOPATCH|The treatment will be performed with the HEMOPATCH collagen patch and hemostatic PEG sealant (Baxter), applying two units of the large patch to reinforce the primary dural closure (HEMOPATCH 4.5x9cm, 1506253).
48505196|NCT05093361|PROCEDURE|Physical Therapy|Self-driven training according to the training plan instructed by physical therapist.
48505197|NCT05657119|BEHAVIORAL|MI FSN - Lethal Means Reduction|"Motivational Interviewing lethal means reduction, firearm storage supplies, Tailored text messages~* Participate in a 15-20-minute motivational interviewing (MI) session conducted by trained University of Michigan research staff focused on encouraging suicide lethal means~* Be offered to take home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
48354218|NCT04419597|DEVICE|Standard of care|Usual clinical practice techniques for reinforcing primary dural closure.
48354219|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.
48354220|NCT00676806|BIOLOGICAL|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
48354221|NCT06084065|DEVICE|CART-I Plus|Photoplethysmography based ring-type blood pressure measurement device
48354222|NCT03260062|BEHAVIORAL|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
48143534|NCT03690557|BEHAVIORAL|IncentaHealth|IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
48143535|NCT06061978|PROCEDURE|left bundle branch of His pacing|left bundle branch of His pacing
48143536|NCT06061978|PROCEDURE|right ventricular pacing|right ventricular pacing
48143537|NCT04393402|PROCEDURE|lung ultrasound (LUS)|Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
48143538|NCT04598139|OTHER|Study group|The study group uses a web-based medication error notification system
48143539|NCT04171011|DEVICE|Stimulator device|The stimulator device will be used to electrically stimulate the NVB
48143540|NCT01939288|DEVICE|Neuromuscular stimulation, followed by intermittent pneumatic compression|
48143541|NCT01939288|DEVICE|Intermittent pneumatic compression, followed by neuromuscular stimulation|
48143542|NCT03241810|DRUG|Seribantumab|Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
48143543|NCT03241810|DRUG|Fulvestrant|Fulvestrant is an estrogen receptor antagonist with no agonist effects
48143544|NCT03241810|DRUG|Placebo|Placebo
48143545|NCT00297466|DRUG|transdermal nicotine patches|
48143546|NCT00297466|BEHAVIORAL|Motivational interview|
48143547|NCT03528304|BEHAVIORAL|Contingency management|Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
48143548|NCT02826954|OTHER|Upper airway assessment, including nasal biopsy|
48143549|NCT01130870|DEVICE|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
48143550|NCT01130870|DEVICE|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
48664841|NCT03283241|DEVICE|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
48143551|NCT01130870|DEVICE|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
48143552|NCT03173625|DRUG|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
48143553|NCT03173625|DRUG|Placebo|Sterile 0.9% w/v sodium chloride solution
48143554|NCT01444404|DRUG|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
48143555|NCT01866800|DEVICE|Renal Guard|Renal Guard
48143556|NCT01866800|DRUG|Conventional Treatment|Saline and N-acetylcysteine
48143557|NCT05071677|PROCEDURE|Discussion|Participate in treatment planning meeting
48143558|NCT05071677|OTHER|Interview|Participate in interview
48143559|NCT05071677|OTHER|Survey Administration|Complete survey
48143560|NCT01506700|DEVICE|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
48143561|NCT03191448|PROCEDURE|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
48143562|NCT03191448|DEVICE|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
48354223|NCT03260062|OTHER|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
48505198|NCT05657119|BEHAVIORAL|Scripted FSN - Lethal Means Reduction|"Scripted lethal means reduction, firearm storage supplies, tailored text messages~* Participate in a 10-15-minute scripted session focused on gun safety and lethal means reduction~* Be offered to home gun safety and lethal means reduction materials, including trigger locks, cable locks, ammo boxes, medication boxes and mental health resources~* Receive 4 weeks of tailored text message reminders and encouragement"
48664842|NCT03283241|DEVICE|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
48143563|NCT03191448|DEVICE|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
48143564|NCT02315118|DRUG|T-cell therapy + Rituximab + IL-2|"* T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients"
48143565|NCT04119947|DRUG|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
48143566|NCT02398955|DEVICE|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
48354224|NCT04277052|DEVICE|Determination muscles sections by Ultrasonography|Determination muscles sections by Ultrasonography
48505199|NCT05657119|BEHAVIORAL|General Firearm Safety Intervention - General Firearm Safety|"General information on gun safety, firearm storage supplies, tailored text messages~* Participate in a 10-minute scripted conversation about safe gun storage practice~* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes~* Receive 4 weeks of tailored text message reminders and encouragement"
48664843|NCT06544720|BIOLOGICAL|SCG142 TCR-T cells|Monotherapy of SCG142
47987235|NCT05813795|DRUG|Placebo|Subcutaneous Injection with matched volume
47987236|NCT00119418|DRUG|TU 025 Keishi Bukuryo Gan|
48505200|NCT05657119|BEHAVIORAL|General Firearm Comparison - General Firearm Safety|"firearm storage supplies~\* Be offered to take home safe gun storage materials, including trigger locks, cable locks, and ammo boxes"
48664844|NCT06062693|DEVICE|smart sensor egg training|The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
48143567|NCT04163432|DRUG|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh \>30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
48143568|NCT04163432|DRUG|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is \< 45 mL/min, pemetrexed is dosed at 400 mg/m2.
48143569|NCT04163432|DRUG|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
48143570|NCT04803045|OTHER|Follow up email|Patients received an email 3 months after an initial consult asking why they had not returned to care. Patients were provided with 4 options and a space to write in comments. The email asked if the patient had any questions and offered support.
48143571|NCT03345979|COMBINATION_PRODUCT|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
48143572|NCT03345979|DRUG|Paliperidone Palmitate|Intramuscular injection
48143573|NCT05774626|BEHAVIORAL|Contraceptive usage|Continued use of injectable contraception, administered on a quarterly basis
48143574|NCT05432518|DRUG|Afatinib|Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
48143575|NCT05432518|DRUG|Dasatinib|Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
48143576|NCT05432518|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
48143577|NCT05432518|DRUG|Everolimus|Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
48143578|NCT05432518|DRUG|Olaparib|Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
48143579|NCT05086874|OTHER|butylphthalide|Observational only and no predesigned interventions in this study
48143580|NCT04244032|BEHAVIORAL|Working Memory Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
48143581|NCT04244032|BEHAVIORAL|Inhibitory Control Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
48143582|NCT04244032|BEHAVIORAL|Bias Modification Training|Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
48664845|NCT06446128|BIOLOGICAL|CD19/CD20/BCMA CAR T cells|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CD19/CD20/BCMA CAR T cells.~Cyclophosphamide and fludarabine will be given from day-5 to day-3 before the infusion for lymphodepletion. On day0 subjects will receive one dose treatment with CD19/CD20/BCMA CAR T cells by intravenous (IV) injection"
47987237|NCT03304574|BEHAVIORAL|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
47987238|NCT05428488|DRUG|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
48143583|NCT00286039|PROCEDURE|Blood sampling|Blood sampling is used.
48143584|NCT02782000|OTHER|lessons,long-term supervision and message|
48143585|NCT02782000|OTHER|lessons,short-term supervision and message|
48505201|NCT06197269|OTHER|Short duration antibiotics|antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
48505202|NCT06197269|OTHER|Standard duration antibiotics|Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.
48664846|NCT02048007|DRUG|Azithromycin|Biannual mass oral azithromycin to children
48664847|NCT02048007|DRUG|Placebo|Biannual mass oral placebo to children
48143586|NCT03674788|DEVICE|Transcatheter valve intervention|
48143587|NCT03339544|DRUG|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
48143588|NCT03339544|DRUG|Placebo|placebo is given as a tablet before initiation of endodontic treatment
48143589|NCT02099409|DEVICE|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
48143590|NCT04901585|PROCEDURE|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
48505203|NCT03426163|DEVICE|Virtual reality|Application of knee MRI transformed virtual reality system
48505204|NCT04029311|DEVICE|Nuance Pro|Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
48505205|NCT04029311|DEVICE|autoPAP|autoPAP
48505206|NCT04029311|DEVICE|TAP PAP|TAP PAP
48505207|NCT00593905|DRUG|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
48664848|NCT03852030|BEHAVIORAL|Text or email message|Text or email messages sent to research participants
48354225|NCT02114918|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
48664849|NCT06312215|OTHER|Closed-system catheter|Closed-system catheters was applied
48664850|NCT02323711|DEVICE|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
48354226|NCT02114918|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
48664851|NCT02972307|OTHER|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
48664852|NCT02232360|DRUG|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
48664853|NCT02232360|DRUG|Rosuvastatin alone|Rosuvastatin 10mg per day
48664854|NCT01510574|DRUG|Misoprostol|3 x 200mcg tablets of oral misoprostol
48664855|NCT01510574|DRUG|placebo|3 x placebo tablets resembling misoprostol taken orally
48664856|NCT05815888|DIAGNOSTIC_TEST|Lung Ultrasound Score|"one hemithorax is consisted of 6 scanning zones. Each of them are evaluated via ultrasonography in terms of presence of vertical B lines (\<4 B lines: 1 point; \>3 B lines or thick B lines: 2 points; marked disturbance in pleural line: 3 points). Higher scores reflect worse outcomes such as atelectasis and consolidation, and totally 12 zones are evaluated.~Three different time points are defined for LUS:~T1: 5 minutes after orotracheal intubation T2: At the end of surgery, before extubation T3: 30 minutes after extubation, in postanesthesia care unit.~DeltaT= T2LUS-T1LUS~Blood gas analysis will be evaluated hourly throughout the surgery"
48664857|NCT04146155|DRUG|Liraglutide+standard-of-care treatment|"Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines."
48664858|NCT04146155|OTHER|standard-of-care treatment|Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
48664859|NCT05597384|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
48664860|NCT01959685|DRUG|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
48354227|NCT02711410|DRUG|Clopidogrel|
48354228|NCT00820963|DRUG|temozolomide|Given orally
48354229|NCT00820963|RADIATION|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
48664861|NCT01959685|DRUG|Placebo|Placebo, single dose
48354230|NCT00820963|RADIATION|radiation therapy|Patients undergo standard radiotherapy
48505208|NCT00593905|DRUG|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
47987239|NCT05428488|DRUG|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
48664862|NCT06547606|OTHER|Usual Care|Participants in the control group will recieve usual care.
48664863|NCT03005392|OTHER|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
47987240|NCT05428488|DRUG|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
48354231|NCT03894306|OTHER|Medication lock box|given a lock box and instructed on how to use the device.
48354232|NCT03894306|OTHER|medication lock bag|given a lock bag and instructed on how to use the device.
48354233|NCT03894306|OTHER|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
48354234|NCT02986165|DIETARY_SUPPLEMENT|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
48354235|NCT02986165|DIETARY_SUPPLEMENT|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
48354236|NCT02986165|DIETARY_SUPPLEMENT|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
48354237|NCT05124600|DEVICE|SavvyHealth|Participants will use the new app, SavvyHealth, for 21 days.
48354238|NCT01989936|DRUG|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
48354239|NCT01989936|DRUG|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
48354240|NCT01989936|DRUG|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
48354241|NCT05091073|DRUG|NNC0385-0434|All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
48354242|NCT06412640|DRUG|Keverprazan|Potassium-competitive acid blocker
48354243|NCT06412640|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
48354244|NCT02972294|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
48354245|NCT02972294|DRUG|Tranexamic Acid|Tranexamic acid will be use.
48664864|NCT05825040|BEHAVIORAL|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
48354246|NCT02972294|DRUG|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
48664865|NCT05825040|BEHAVIORAL|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
48354247|NCT02972294|DRUG|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
48505209|NCT02299115|DRUG|Prednisolone|Corticosteroid
48505210|NCT02299115|DRUG|Vigabatrin|Antiepileptic
48505211|NCT04778085|BEHAVIORAL|Illness management and recovery|Treatment given in groups, weekly for 10-12 months.
48505212|NCT04778085|OTHER|Semi-structured interviews|Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
48505213|NCT02929524|DRUG|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
48664866|NCT05825040|BEHAVIORAL|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
48664867|NCT02148848|DRUG|Risedronate|Take risedronate 35 mg orally every week
48664868|NCT03683979|BEHAVIORAL|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
48143591|NCT05162352|DRUG|Donafenib+sintilimab|"Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity."
48354248|NCT04812665|BEHAVIORAL|mHealth solution based on emotional and behavioral change techniques|"Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs."
48354249|NCT03231228|DRUG|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg
48664869|NCT03683979|BEHAVIORAL|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
48664870|NCT00842621|PROCEDURE|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
48664871|NCT00842621|OTHER|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
48664872|NCT02676037|DEVICE|foot pressure plate form|
48664873|NCT04666792|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
48664874|NCT03505333|PROCEDURE|conventional suture|we use Liga-sure device for hysterectomy
47987241|NCT01079091|DEVICE|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
47987242|NCT01079091|PROCEDURE|Standard Medical Therapy|Standard of care treatment
47987243|NCT00528398|DRUG|cytarabine|
47987244|NCT00528398|DRUG|idarubicin|
48143592|NCT00969007|BEHAVIORAL|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
47987245|NCT00702819|DRUG|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
48354250|NCT03231228|DRUG|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
48354251|NCT05243940|DRUG|dexmedetomidine-ketamine-lidocaine (DKL)|"patients will be administered 0.25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1 mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving~1mL/10kg/h of the aforementioned solution."
48354252|NCT05243940|DRUG|remifentanil infusion|remifentanil infusion under the Minto model (target controlled infusion-TCI aiming at 4ng/ml blood concentration
47987246|NCT02902640|DRUG|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
47987247|NCT02902640|DRUG|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
48354253|NCT03593005|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
48354254|NCT03593005|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
48354255|NCT01165463|BEHAVIORAL|SOPT basic training|10 hours of basic training
48354256|NCT01165463|BEHAVIORAL|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
48354257|NCT01165463|BEHAVIORAL|SOPT booster training|4 hours of subsequent booster-training
48354258|NCT02233894|DRUG|Atrovent® - inhalets|
48664875|NCT05120492|PROCEDURE|bariatric surgery followed by total knee replacement|The only intervention is the randomization of the priority of the 2 procedures.
48664876|NCT00788112|DRUG|vorinostat|
47987248|NCT02902640|DRUG|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
48354259|NCT02465541|PROCEDURE|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
48354260|NCT02465541|OTHER|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
48354261|NCT02465541|OTHER|educational intervention|Undergo enhanced usual care
48354262|NCT02465541|OTHER|quality-of-life assessment|Ancillary studies
48354263|NCT02465541|OTHER|questionnaire administration|Ancillary studies
47987249|NCT02980887|OTHER|No Intervention|There is no intervention in this observational study
48354264|NCT02640430|DEVICE|standard treatment|20 minutes, twice a day for 10 sessions
48354265|NCT02640430|DEVICE|Free Aspire|20 minutes, twice a day for 10 sessions
48354266|NCT02721446|BEHAVIORAL|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
48354267|NCT02721446|BEHAVIORAL|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
48354268|NCT02721446|BEHAVIORAL|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
48354269|NCT02721446|BEHAVIORAL|Incentive + Salience|Combined message of incentive plus salience.
48354270|NCT05917392|DIETARY_SUPPLEMENT|Fermented Vegetables (Kimchi) supplementation|Fermented Vegetables (Kimchi) supplementation with 50 gm daily for two months and effects of DNA methylation, serum proteome and microbiota
48354271|NCT05917392|DIETARY_SUPPLEMENT|probiotic|Supplementation with Kimchi plus LGG 50 grams daily for two months
48354272|NCT05917392|DIETARY_SUPPLEMENT|polyphenol|Supplementation with Kimchi plus polyphenol 50 grams daily for two months
48354273|NCT00476515|DRUG|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
48354274|NCT05791773|PROCEDURE|the robot assisted total knee arthroplasty|the robot assisted total knee arthroplasty
48354275|NCT05791773|PROCEDURE|the conventional jig-based total knee arthroplasty|the conventional jig-based total knee arthroplasty
48354276|NCT05245695|OTHER|Observational study, no intervention|Observational study, no intervention
48354277|NCT00995215|PROCEDURE|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
48354278|NCT00995215|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
48354279|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo posterior spinal tumor resection
48354280|NCT01308489|PROCEDURE|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
48664877|NCT00788112|GENETIC|protein expression analysis|
48664878|NCT00788112|OTHER|immunohistochemistry staining method|
48664879|NCT00788112|OTHER|laboratory biomarker analysis|
48664880|NCT00788112|PROCEDURE|neoadjuvant therapy|
48664881|NCT00788112|PROCEDURE|therapeutic conventional surgery|
48664882|NCT02260037|DRUG|Epinastine nasal|
47987250|NCT03212612|DIAGNOSTIC_TEST|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
47987251|NCT02631954|DRUG|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
48664883|NCT02260037|DRUG|Placebo|
48664884|NCT01173744|DEVICE|Gamma-3 Nail|Gamma-3 Nail (stryker)
48664885|NCT01173744|DEVICE|DHS|DHS (Zimmer)
48143593|NCT04425837|BIOLOGICAL|SARS-CoV-2 convalescent plasma treatment|Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration
48143594|NCT04425837|OTHER|Standard care|Standard care according to guidelines and national regulations
48143595|NCT03936699|DEVICE|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet \& Exercise Subjects to be instructed on a healthy 1200 calorie diet."
48354281|NCT01308489|PROCEDURE|quality-of-life assessment|Ancillary studies
48354282|NCT03177954|BEHAVIORAL|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
48664886|NCT03279952|DRUG|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
48664887|NCT00681070|OTHER|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
48664888|NCT00681070|OTHER|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
47987252|NCT02631954|DRUG|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
48354283|NCT03304769|DEVICE|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
48664889|NCT00900614|DRUG|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
47987253|NCT02539277|DRUG|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
48354284|NCT03880123|DRUG|Selinexor|"Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib."
48354285|NCT03880123|DRUG|Ixazomib|"Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food."
47987254|NCT02539277|DRUG|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
47987255|NCT02539277|DRUG|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
47987256|NCT02539277|DRUG|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
48664890|NCT02298725|OTHER|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
48664891|NCT02298725|OTHER|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
48143596|NCT03936699|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
48143597|NCT02027584|OTHER|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
48143598|NCT04976829|DEVICE|Antibiotic stewardship and healthcare-associated infections surveillance assisted by computer|Implementation - in our tertiary care university hospital - of a computerized-decision support system (CDSS) facilitating antibiotic stewardship and of an electronic surveillance software (ESS) facilitating infection prevention and control activities
48664892|NCT04378868|DRUG|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
48664893|NCT04378868|DRUG|No antibiotics|No antibiotics are given while waiting surgery.
48664894|NCT04378868|OTHER|urgent schedule|Patients can wait up to 8 hours for surgery.
48664895|NCT04378868|OTHER|less urgent schedule|Patients can wait up to 24 hours for surgery.
48664896|NCT06564584|DRUG|TLC-2716 Dose 1|Capsules administered orally
48664897|NCT06564584|DRUG|TLC-2716 Dose 2|Capsules administered orally
48664898|NCT06564584|DRUG|Placebo|Capsules administered orally
48664899|NCT05173090|DRUG|Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery|Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
48664900|NCT00637351|PROCEDURE|Blood sample|One blood sample will be collected at the time of screening for subjects
48664901|NCT00637351|PROCEDURE|Urine sample|One urine sample will be collected at the time of screening for subjects
48664902|NCT00435448|DRUG|Lonidamine|
47987257|NCT04962009|COMBINATION_PRODUCT|Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug|Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.
47987258|NCT00255450|DRUG|ferumoxytol or placebo|
47987259|NCT00151099|DRUG|high caloric drink with protein|
47987260|NCT00091351|PROCEDURE|conventional surgery|
48664903|NCT03869112|BEHAVIORAL|Physical activity intervention|Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.
48664904|NCT03869112|OTHER|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
47987261|NCT00091351|RADIATION|radiation therapy|
47987262|NCT00383279|OTHER|counseling intervention|
47987263|NCT00383279|OTHER|study of socioeconomic and demographic variables|
47987264|NCT01867021|BIOLOGICAL|Fluvirin(TIVf)|
48143599|NCT05646407|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
48143600|NCT00673088|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
47987265|NCT01867021|BIOLOGICAL|Agriflu (TIV)|
48354286|NCT05714852|BEHAVIORAL|Healthy eating|Promotion of healthy eating
48354287|NCT02936115|OTHER|TruSkin®|
48354288|NCT02936115|OTHER|Wound Cover|
48505214|NCT02929524|DRUG|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
48505215|NCT04626648|BEHAVIORAL|Pause with a sugar containing drink|Three-minute long intraoperative pause, including a sugar-containing drink
48664905|NCT03715790|BEHAVIORAL|EP referred group|Referred for sudden cardiac death (SCD) risk stratification and management
48664906|NCT03715790|BEHAVIORAL|Non-Referred group|Not referred for sudden cardiac death (SCD) risk stratification and management.
47987266|NCT02728895|DRUG|Vedolizumab|Vedolizumab Injection.
48143601|NCT01255800|DRUG|IPI-926 and Cetuximab|"* Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
48143602|NCT03262714|OTHER|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
48664907|NCT06350279|DRUG|HSK39297|50-600mg
48664908|NCT00677794|DRUG|Clear fluids|Clear fluids only after lunch.
48664909|NCT00677794|DRUG|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
48664910|NCT00677794|DRUG|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
48664911|NCT04473560|DEVICE|Catheter-directed thrombectomy|Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate \<100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
48664912|NCT01696643|DRUG|CB-5945|
47987267|NCT00982592|DRUG|oxaliplatin|Given IV
47987268|NCT00982592|DRUG|leucovorin calcium|Given IV
47987269|NCT00982592|DRUG|fluorouracil|Given IV
48354289|NCT06059274|OTHER|Topical serum|Participants are asked to apply the topical serum twice daily for 84 days.
48354290|NCT05013385|DRUG|Spesolimab|Spesolimab
47987270|NCT00982592|OTHER|placebo|Given PO
47987271|NCT00982592|DRUG|vismodegib|Given PO
48354291|NCT05013385|DRUG|Placebo|Placebo
48354292|NCT02184390|OTHER|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
48354293|NCT04043416|OTHER|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
48354294|NCT04510844|DRUG|Evolocumab|Evolocumab is commercially available in the United States and is manufactured by Amgen. Drug and placebo, will be supplied by the manufacturer. The SureClick® pre-filled auto injector contain Evolocumab (140 mg) acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in water for Injection. Evolocumab will be administered at a dose of 420 mg subcutaneously once monthly.
48354295|NCT04510844|OTHER|Placebo|Placebo will be supplied by the manufacturer. Placebo auto injectors will be identically packaged but will lack the active ingredient. Placebo will be administered at an equivalent volume to Evolocumab and given subcutaneously once monthly.
48354296|NCT04029649|DRUG|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
48354297|NCT04029649|DRUG|Placebo|Placebo capsule three times daily for 90 days
48354298|NCT01620437|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
48505216|NCT05189834|DIETARY_SUPPLEMENT|Gelsectan|Xyloglucan, vegetable protein and xylooligosaccharides
48505217|NCT05252598|DRUG|Psilocybin|1mg encapsulated psilocybin
48505218|NCT05252598|DRUG|Inonotus Obliquus Whole Extract|1mg encapsulated chaga mushroom
47987272|NCT00982592|OTHER|laboratory biomarker analysis|Correlative studies
47987273|NCT02946047|DRUG|Ixazomib 1 MG|1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
47987274|NCT02946047|DRUG|Ixazomib 2 MG|2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
48143603|NCT03262714|OTHER|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
48143604|NCT03262714|OTHER|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
48143605|NCT04396938|DRUG|Lamotrigine|Active Drug Capsule
48143606|NCT04396938|DRUG|Placebos|Placebo Capsule
48664913|NCT01696643|DRUG|Placebo|
48664914|NCT00575666|DRUG|Insulin or Placebo|intranasal, 40IU, 4 times daily
48664915|NCT05595109|DRUG|Silymarin|"Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice."
48664916|NCT05595109|DRUG|Placebo|which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
48664917|NCT03601299|OTHER|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
47987275|NCT02946047|DRUG|Ixazomib 3 MG|3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
47987276|NCT02946047|DRUG|Ixazomib 4 MG|4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
47987277|NCT01362374|DRUG|5-FU|5-FU at a dose level of 400 mg/m\^2 as intravenous (IV) injection followed by a dose of 2400 mg/m\^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
47987278|NCT01362374|DRUG|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m\^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
48664918|NCT05458960|BEHAVIORAL|Social needs navigator program|4 months of assistance tailored to the needs of the participant
48664919|NCT05458960|BEHAVIORAL|Enhanced usual care|Referral to United Way 2-1-1
47987279|NCT01362374|DRUG|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
47987280|NCT01362374|DRUG|Ipatasertib|Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
47987281|NCT01362374|DRUG|Leucovorin|Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
48664920|NCT00560417|DRUG|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
48143607|NCT03137446|OTHER|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
48354299|NCT01197872|OTHER|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
48664921|NCT00560417|DRUG|Insulin Glargine|Administered subcutaneously once a day at bedtime
48143608|NCT00284466|PROCEDURE|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
48354300|NCT06136910|DRUG|Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy|"1. Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~2. tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~3. platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d."
48354301|NCT04722692|DIAGNOSTIC_TEST|Delayed SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients have received SPIO in the breast at the first operation, prior to dissection and resection and the SLN has already been marked with SPIO. These SLNs are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the radioactive counts are registered for each SLN that has been excised. When the procedure is completed successfully with SPIO, then background axillary isotope counts are registered and, if present, SLND continues as described above with the isotope as primary tracer."
48354302|NCT04722692|DIAGNOSTIC_TEST|Late SLND|"SLND performed after surgery for DCIS or other pre-invasive lesions, where final pathology showed invasive breast cancer. Patients will be injected with radioisotope in the operated breast before SLND according to standard of care. Any SLNs detected with this intervention are to be removed.~SLND is divided into the following steps:~1. Transcutaneous signal~2. Incision in the axilla (skin, subcutaneous fat and fascia) and In situ signal~3. SLN identification in situ~4. SLN excision and signal ex vivo~5. Background axillary counts. For step d the magnetic counts are registered for each SLN that has been excised. When the procedure is completed successfully with the isotope, then background axillary iSPIO counts are registered and, if present, SLND continues as described above with the SPIO as primary tracer."
48354303|NCT05680090|DIAGNOSTIC_TEST|Artificial intelligent system for eye emergency triage and primary diagnosis|An intelligent triage and diagnostic system for ophthalmic emergencies has been developed. In the prospective test, patients with acute ocular symptoms can achieve remote self-triage and primary diagnosis after uploading metadata and ocular images.
48354305|NCT00443534|DRUG|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
48354306|NCT00984152|DRUG|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
48354307|NCT00984152|DRUG|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
48354308|NCT03422744|PROCEDURE|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
48354309|NCT03422744|PROCEDURE|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
48664922|NCT02229357|BIOLOGICAL|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
48664923|NCT04749914|DRUG|Lasmiditan|Administered orally.
48664924|NCT04749914|DRUG|Dabigatran Etexilate|Administered orally.
48664925|NCT04749914|DRUG|Rosuvastatin|Administered orally.
48664926|NCT00787150|DRUG|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
48354310|NCT03463044|DRUG|nangibotide|Continous i.v. infusion
48354311|NCT03463044|DRUG|Placebo|Placebo
48354312|NCT03932591|PROCEDURE|kinesio taping method|Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.
48664927|NCT00787150|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
48664928|NCT00787150|DRUG|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
48664929|NCT05342168|DIAGNOSTIC_TEST|Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa|A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
48664930|NCT05754866|PROCEDURE|Transbronchial lung cryobiopsy|Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.
48664931|NCT05754866|PROCEDURE|Transbronchial lung biopsy|Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.
48664932|NCT02176915|BEHAVIORAL|Group program|
48664933|NCT02176915|BEHAVIORAL|Print Materials|
48664934|NCT05165472|OTHER|Quadri-pulse theta burst stimulation|High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
48664935|NCT01198587|DRUG|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
48664936|NCT01198587|DRUG|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
48664937|NCT03120845|PROCEDURE|One visit RCT|Root canal treatment in one vist
48664938|NCT03120845|PROCEDURE|Post operative pain in two-visits RCT|Root canal treatment in Two visits
47987282|NCT01362374|DRUG|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m\^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
47987283|NCT01362374|DRUG|Paclitaxel|Paclitaxel at a dose of 90 mg/m\^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
48143609|NCT00254241|DRUG|Seroquel and Risperidone|
48143610|NCT00511316|DRUG|Montelukast/ Singulair|20 mg daily for six months
48354313|NCT03932591|PROCEDURE|Sham kinesio taping|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
48664939|NCT00006021|DIETARY_SUPPLEMENT|ascorbic acid|
47987284|NCT04597996|OTHER|web based education for students|"Web-based education will include modules on the following subjects;~* Mental health literacy knowledge level~* Improving help-seeking behavior~* Avoiding self-stigmatization in seeking psychological help"
47987285|NCT00955942|DIETARY_SUPPLEMENT|flaxseed|Given orally
48354314|NCT05320211|DEVICE|3D-printed hand orthosis|3D-printed hand orthoses (intervention) will be compared with custom-fabricated conventional orthoses (control condition at baseline)
48354315|NCT04835051|BEHAVIORAL|Breastfeeding promotion|The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child \<6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
48354316|NCT04459442|PROCEDURE|Umbilical cord clamping at birth.|Umbilical cord clamping after delivery.
48354317|NCT02545049|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
48664940|NCT00006021|DRUG|arsenic trioxide|
48664941|NCT06153563|OTHER|Data collection on patient history and intraoperative results.|Data collection on patient history and intraoperative results.
48664942|NCT01280331|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
48664943|NCT01280331|DRUG|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
48664944|NCT01280331|DRUG|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
48664945|NCT02300545|DRUG|Pazopanib|
48664946|NCT01409096|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
48664947|NCT01409096|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
48664948|NCT06156150|BIOLOGICAL|tumor vaccine|DC vaccine produced by the Team
48664949|NCT00114348|PROCEDURE|R-Blocks|
48664950|NCT00114348|PROCEDURE|Protocol II-Ida|
48664951|NCT05924802|DIETARY_SUPPLEMENT|Ketone Ester|Added to water or lemonade 3 times per day.
48664952|NCT05924802|DIETARY_SUPPLEMENT|Placebo|Added to water or lemonade 3 times per day.
48664953|NCT01216488|DRUG|Xylocaine|40 ml or 25 ml of Xylocaine injection
47987286|NCT00955942|OTHER|placebo|Given orally
47987287|NCT03996954|DEVICE|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
47987288|NCT06152757|BIOLOGICAL|First dose|1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled
48143611|NCT00511316|DRUG|Placebo|Placebo 20 mg daily for 6 months
48143612|NCT03811665|PROCEDURE|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
48143613|NCT03811665|RADIATION|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
48143614|NCT00540956|DRUG|cytarabine|
48143615|NCT00540956|OTHER|laboratory biomarker analysis|
48664954|NCT05554679|DRUG|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
48664955|NCT05788094|DRUG|Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)|"* Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
48664956|NCT05788094|DRUG|Chloroquine plus Tafenoquine (450 mg adult dose)|"* Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
48688036|NCT04188834|DEVICE|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
48688037|NCT03026816|DEVICE|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
48143616|NCT03128099|BEHAVIORAL|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
48354318|NCT02545049|DRUG|Placebo|Matching placebo to be taken orally, once daily.
48354319|NCT03498989|OTHER|preterm formula milk|"A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound."
48354320|NCT03498989|OTHER|exclusive breast milk|exclusive breast milk
48354321|NCT01654406|DEVICE|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
48354322|NCT01654406|DEVICE|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
48354323|NCT02540655|BIOLOGICAL|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
48354324|NCT02540655|PROCEDURE|Excipients|Patients will receive excipients through intravenous infusion
48354325|NCT00597857|DRUG|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
48354326|NCT00597857|DRUG|placebo|receipt of a placebo pill for 16 days
48354327|NCT03826992|DRUG|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
47987289|NCT06152757|BIOLOGICAL|Second dose|3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
47987290|NCT06152757|BIOLOGICAL|The third dose|1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
47987291|NCT06152757|BIOLOGICAL|The fourth dose|3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
47987292|NCT02786316|OTHER|HIT program|HIT program for the rehabilitation of persons with NSCLBP
47987293|NCT02786316|OTHER|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
48664957|NCT05788094|DRUG|Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)|"* Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given."
48664958|NCT05271357|PROCEDURE|Bilateral TMS|Stimulation begins with continuous TBS to the right dorsolateral prefrontal cortex (DLPFC) (120 seconds of uninterrupted bursts; 600 pulses per session) followed by intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds per hemisphere.
47987294|NCT05218473|DIAGNOSTIC_TEST|Prolonged ECG monitoring|Using 14-day continuous electrocardiography patch monitoring to increase the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation.
48664959|NCT05271357|PROCEDURE|Unilateral TMS|Stimulation involves only intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds.
48664960|NCT00223145|RADIATION|Radiotherapy 70 Gy|Radiotherapy to the prostate
47987295|NCT05218473|DIAGNOSTIC_TEST|Conventional procedure group|Using serial 12-lead electrocardiograms once daily for five days or conventional 24-h Holter monitoring to detect new atrial fibrillation
47987296|NCT04110093|DRUG|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
47987297|NCT05461677|DEVICE|SAIRE smart walker|Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
47987298|NCT05461677|DEVICE|Standard 4-wheeled walker|Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
48143617|NCT05320094|DRUG|Mavacamten|Specified dose on specified days
48354328|NCT03826992|DRUG|Venetoclax|"Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days"
48354329|NCT02074397|PROCEDURE|Distant extrafascial injection|
47987299|NCT05461677|OTHER|No walking aid|Participants will walk along the 10-meter walkway 5 times without using a walking aid
48664961|NCT00223145|RADIATION|Radiotherapy 76 Gy|Radiotherapy to the prostate
48664962|NCT00223145|DRUG|Androgen blockade|Duration : 6 months
47987300|NCT01660607|BIOLOGICAL|Conventional T cells (Tcon) and Regulatory T cells (Treg)|A baseline cell dose of conventional T cells of 1x10\^6/kg will be used with escalation to the maximum tolerated dose up to 1x10\^7/kg
48143618|NCT05320094|DRUG|Activated Charcoal with Sorbitol|Specified dose on specified days
48354330|NCT02074397|PROCEDURE|Subfascial injection|
48354331|NCT00767494|DRUG|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
48354332|NCT00767494|DRUG|Azopt|Eye Drop Suspension, 1 drop BID
48354333|NCT00767494|DRUG|Travatan|Eye Drop Solution, 1 drop BID
48354334|NCT00939094|DRUG|AZD2066|Capsule, once daily
48354335|NCT00939094|DRUG|Placebo|Capsule, once daily
48354336|NCT00572065|DRUG|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
48505219|NCT02064985|DRUG|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
48354337|NCT00572065|DRUG|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
48354338|NCT04337528|OTHER|Osteopathic manipulation type thrust|The osteopathic manipulation type thrust is applied to solve the sacroiliac joint dysfunction. This technique applies a high velocity and intensity push in a specified direction to correct the dysfunction produced by a not correct position or movement of one joint.
48505220|NCT02169700|PROCEDURE|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
48505221|NCT02495623|DRUG|SYN-010 21 mg|
48664963|NCT05982093|DRUG|Elacestrant|Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
48664964|NCT05982093|DRUG|Triptorelin|Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
48664965|NCT04079660|DIAGNOSTIC_TEST|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
47987301|NCT05530174|OTHER|Antibiotic dosage practice|"Patient inclusion starts day one, cross-over of departments from treatment A (single-dose) to B (multiple-dose) or vice versa after one year and end of inclusion happens after 2 years.~All centers in Denmark use either Cloxacillin/Dicloxacillin, Cefuroxime or both drugs as standard prophylactic antibiotic practice for THA. In cases of cephalosporin allergy or general beta lactam allergy, the antibiotic clindamycin may be administered.~In this trial, patients will be administered the standard prophylactic antibiotic practice of either single-dose (A) or multiple-doses (B) of antibiotics administered at each respective cluster that respective year. Both practices of dose administration for antibiotic prophylaxis (i.e. single- or multiple-dose) follow current standards of treatment and are based on present clinical practice guidelines."
47987302|NCT02432534|DRUG|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
47987303|NCT02432534|OTHER|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
47987304|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
47987305|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
48143619|NCT05190172|RADIATION|Radiation therapy|Radiation therapy either with protons or photons
48143620|NCT03763968|OTHER|treatment and outcome|
48505222|NCT02495623|DRUG|SYN-010 42 mg|
48505223|NCT02495623|DRUG|Placebo|
48505224|NCT00062400|PROCEDURE|psychosocial assessment and care|
48505225|NCT01998724|BEHAVIORAL|Tai Chi|24 week tai chi intervention designed for individuals with COPD
48664966|NCT04490681|DRUG|Ertugliflozin|Fixed dose Ertugliflozin (5mg)
48664967|NCT04490681|DRUG|Placebo|Placebo group
48664968|NCT04361279|DRUG|SIBP-02|Injection，100mg/10ml
48664969|NCT04361279|DRUG|Rituximab|Injection，100mg/10ml
48688038|NCT03572959|DRUG|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
48505226|NCT01998724|BEHAVIORAL|Group Walking|24 week group walking intervention
48143621|NCT03604809|OTHER|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
48143622|NCT05786378|BIOLOGICAL|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
48143623|NCT05786378|DRUG|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
48143624|NCT05786378|PROCEDURE|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
48143625|NCT03183804|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
48143626|NCT03183804|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
48143627|NCT01170936|DRUG|canakinumab|Single dose of canakinumab 300mg s.c. injection
48143628|NCT00893100|DRUG|Diltiazem|2%,3 times daily
48505227|NCT05063435|DIAGNOSTIC_TEST|Carotid ultrasonography|"1. Study takes 10 - 15 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~4. Blood pressure and heart rate will be obtained during the study~5. Results will be anonymized, digitized and stored on CD with unique identifier"
48505228|NCT05063435|DIAGNOSTIC_TEST|Echocardiography, transthoracic|"1. Study takes 15 - 20 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~4. Results will be digitized and stored on CD"
48505229|NCT05063435|PROCEDURE|Venipuncture|"1. 10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~2. Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
48664970|NCT04015388|DEVICE|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
48664971|NCT05694247|DEVICE|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
48664972|NCT02992730|BEHAVIORAL|No Intervention|No Intervention
48664973|NCT01090596|DRUG|Naproxen|500mg naproxen, twice daily for 7 days
48664974|NCT01090596|DRUG|Placebo|1 tab,twice a day for a seven days
48143629|NCT00653185|DRUG|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
48143630|NCT00653185|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
48143631|NCT00653185|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
48143632|NCT00653185|DRUG|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
48143633|NCT00653185|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
48143634|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
48664975|NCT02725684|OTHER|Observational study, no intervention|Observational study, no intervention
48664976|NCT04336189|DRUG|Sulfadoxine-pyrimethamine (SP)|SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.
48664977|NCT04336189|DRUG|Dihydroartemisinin-piperaquine (DP)|DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
48664978|NCT05014984|BEHAVIORAL|mental contrasting with implementation intentions|"To deliver MCII, Dr. Oettingen developed a step-wise procedure called WOOP (Wish, Outcome, Obstacle, Plan; Figure 1).36 In a quiet setting, patients identify an important wish (e.g., losing weight) and then name and vividly imagine the best outcome (e.g., feeling healthier). Next, they name a current internal obstacle (e.g., urge to eat when feeling stressed) and try to vividly imagine their experience when they encounter this obstacle. Finally, they address their obstacle with an if-then plan specifying when, where, and how to overcome it (e.g., If I have the urge to eat when feeling stressed, I will go for a walk) and then imagine themselves experiencing the obstacle and carrying out the action of surmounting it. To facilitate use of the WOOP technique, Dr. Oettingen developed a free, publicly available WOOP app"
48664979|NCT05014984|BEHAVIORAL|telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!|MOVE! is a national VA weight management and health promotion program to improve the quality of life of Veterans.6,75 This effective program encourages healthy eating behavior and increased physical activity. MOVE! will be delivered via telephone (16 sessions) by existing staff consistent with national MOVE! program guidelines. The program has 16 modules and will offered weekly, but Veterans will be able to make up sessions at their own pace if they miss one. MOVE! staff use the MOVE! facilitator guide that provides instruction on delivering the program via telephone. Update as of 11-2023, the New York Harbor VA paused their offering of telephone-delivered MOVE!. Participants in both arms are offered the in-person or video-delivered MOVE! program. For participants who do not want or are unable to attend group-based MOVE!, they are offered TeleMOVE!.
48664980|NCT05014984|BEHAVIORAL|Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All|All participants will receive handouts that they review with a lay educator on weight management, adapted from the educational materials developed for our FIReWoRk Study.Topics include losing weight at a healthy rate, setting a 6-month weight loss goal of 5-10%, limiting sugar-sweetened beverages and portion sizes, making better choices when eating at restaurants, self-monitoring diet and weight, and participating in at least moderate-intensity physical activities.
48143635|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
48143636|NCT00173706|DRUG|L-Carnitine Injection|
48143637|NCT05352737|DIAGNOSTIC_TEST|methylmalonic acid testing|
48143638|NCT02860949|DRUG|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
48143639|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
48143640|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
48143641|NCT03979937|PROCEDURE|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
48143642|NCT05435105|BEHAVIORAL|Virtual reality|Distraction method
48143643|NCT05435105|BEHAVIORAL|Local cold-vibration|Distraction method
48143644|NCT05897905|BEHAVIORAL|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~* Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~* Detailed biopsychosocial review.~* Understand participant priorities and jointly set goals.~* Agreeing onward referrals if needed.~* Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~* Review priorities identified in post stroke review checklist.~* Review goals and plans from first appointment.~* Address any new or persistent information gaps.~* Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~* Agreeing onward referrals and action plan.~* Written summary and plan sent to GP."
48143645|NCT02232737|OTHER|Very low nicotine content cigarettes|
48143646|NCT02351791|OTHER|Patch 1|Patch 1:standard adhesive with own feces in sleeve
48143647|NCT02351791|OTHER|Patch 2|Patch 2:standard adhesive with own feces mixture in sleeve
47987306|NCT04260542|BEHAVIORAL|Ketogenic diet/ fasting|1 month of fasting-mimicking ketogenic diet and subsequent 2-days of refeeding. The subjects will be instructed by nutritional specialist to follow isocaloric ketogenic diet consisting of 6% carbohydrates, 17 % of proteins and 77% fat to cover individual energy demand. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
48143648|NCT02351791|OTHER|Patch 3|Patch 3: standard adhesive with simulated feces in sleeve
48143649|NCT02351791|OTHER|Patch 4|Patch 4:standard adhesive with simulated feces mixture in sleeve
48143650|NCT02351791|OTHER|Patch 5|Patch 5:standard adhesive with buffer in sleeve
48143651|NCT02351791|OTHER|Patch 6|Patch 6:standard adhesive with buffer mixture in sleeve
48505230|NCT04229667|OTHER|Improved Community Health Volunteer (CHV) program|"Multi-modal intervention targeting intensive household monitoring of high-needs patients using monthly visits to measure blood pressure and blood sugar, adherence to treatments and compliance with clinics visits, and motivational interviewing to facilitate behavior change and psychosocial support."
47987307|NCT06540209|DRUG|Bacillus clausii|Children will be give Bacillus clausii for 5 days
48354339|NCT04337528|OTHER|Osteopathic manipulation type muscle-energy|The muscle-energy manipulation is applied to solve the sacroiliac joint dysfunction. This technique applies a movement with an intermittent resistance in a specified direction to correct the position or movement of one joint. The therapist applies the movement in the correct direction since he feels a limitation of movement. When he feels the limitation he requests to the participant pushing in the contrary direction without movement. After five or seven seconds the participant finishes the contraction and the therapist continues the correct movement since he feels once again the limitation, and he request to the participant contraction another five or seven seconds. The therapist request to the participant only three times, when he finish the three contraction and the therapy applies the last movement to correct direction the intervention finishes.
48664981|NCT05014984|BEHAVIORAL|Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)|The lay educator will review and practice the WOOP technique based on protocols from prior studies.12 To probe Veterans' comprehension, the lay educator will ask for their four steps and ask about their WOOP use and experiences. If needed, the lay educator will help the Veteran to create a new WOOP for the next month and address any questions and concerns about using WOOP.
48354340|NCT04337528|OTHER|Placebo technique|The therapist simulates a false technique. The therapist applies movement in the sacroiliac joint without dysfunction, he applies movement since ninety degrees of pelvic flexion, and he wait sixty seconds. Whit this placebo technique the sacroiliac joint with the dysfunction is not altered.
48664982|NCT01701882|DRUG|tenofovir/emtricitabine/rilpivirine|
48664983|NCT02259803|DRUG|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
48664984|NCT02259803|DRUG|Telmisartan|
48664985|NCT02259803|DRUG|Amlodipine|
48664986|NCT03455686|OTHER|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
48664987|NCT01088685|DEVICE|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
48664988|NCT01088685|DEVICE|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
48664989|NCT05539326|OTHER|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
48664990|NCT05495022|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) program|Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
48664991|NCT06040788|PROCEDURE|immediate implant placement with customized healing abutment|immediate implant placement with customized healing abutment
48664992|NCT00137592|BEHAVIORAL|small media, group education (multicomponent)|
48664993|NCT06325215|OTHER|Hidrocolloid Bant|In this group, after the columella and nasal area of preterm infants were cleaned and dried with sterile water, hydrocolloid dressings were applied to the areas in contact with the nasal cannula. NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. If the hydrocolloid dressings melted or peeled off, they were removed, the area was cleaned, and then reapplied.
48664994|NCT05684302|OTHER|The free-toroidal design lenses|Participants were asked to wear the new design lenses (the free-toroidal design lenses) for 1 week
48664995|NCT00002325|DRUG|Fluconazole|
48664996|NCT05170685|BIOLOGICAL|Nivolumab plus Relatlimab FDC|
48664997|NCT04190264|DEVICE|Thermal Rehabilitation Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
47987308|NCT06540209|DRUG|Saccharomyces boulardii|Children will be give Saccharomyces boulardii for 5 days
47987309|NCT06540209|DRUG|Zinc|Zinc will be given to all children for 5 days
47987310|NCT06540209|DRUG|ORS|ORS will be given to all children for 5 days
47987311|NCT00825045|DRUG|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
48266823|NCT05666557|OTHER|manual erector spinae myofascial realease|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After physical therapist manual mobilization, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
48354341|NCT04498390|DRUG|LY3493269|Administered orally.
48354342|NCT04498390|DRUG|Placebo|Administered orally.
48664998|NCT04190264|OTHER|Cold Water Immersion|Whole-body immersion in cold water.
48664999|NCT00924092|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces Cerevisia|
48665000|NCT00924092|DRUG|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
48143652|NCT04701645|COMBINATION_PRODUCT|Microdevice|"Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~* Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~* Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)"
48143653|NCT04482556|DEVICE|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
48143654|NCT04482556|DEVICE|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
48143655|NCT03652610|BIOLOGICAL|MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
48143656|NCT03652610|BIOLOGICAL|Licensed GSK MenACWY vaccine (Menveo)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
48143657|NCT03192709|DRUG|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
48143658|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
48143659|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
48143660|NCT04117100|PROCEDURE|Polypectomy or myotomy|Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
48143661|NCT00390845|DRUG|SB681323|15 milligrams (mg)/day
48143662|NCT00390845|DRUG|Placebo|
48354343|NCT03748875|BEHAVIORAL|mindfulness-based relapse prevention|mindfulness-based relapse prevention, 8 weeks
47987312|NCT04262232|BEHAVIORAL|Adapted Ca-HELP for Geriatric Cancer Patients|Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
47987313|NCT00259077|DRUG|Omeprazole|
48143663|NCT02298166|DRUG|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:~* Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT) d 1-3~* Cytarabine 1000 mg/m² IV (500 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (\> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
48143664|NCT02298166|DRUG|Placebo|"Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy."
48354344|NCT04837690|PROCEDURE|UEMR|(1) the colorectal lumen was completed deflated with 500-1000 mL sterile water using a flushing pump; (2) the lesion and 2-3 mm of normal mucosa surrounding the base of the polyp were snared and subsequently resected with an electrosurgical generator
48665001|NCT02874092|DRUG|Ticagrelor|
47987314|NCT04415788|DEVICE|Test of Incremental Respiratory Endurance - IMT|The TIRE training regimen will involve the use of a tablet provided to assigned subjects with the training software installed and a PrO2® device through which they will train. The software allows subjects to track their inspiratory muscle performance via real-time graphic representations of their efforts as training progresses.
48665002|NCT02874092|DRUG|MTX therapy|
48665003|NCT04825743|DRUG|zalunfiban|zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
48665004|NCT04825743|DRUG|Placebo|A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
48665005|NCT02271880|OTHER|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
48665006|NCT02271880|OTHER|STAR|Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
48665007|NCT01196715|DRUG|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
47987315|NCT04415788|DEVICE|Threshold - IMT|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
47987316|NCT04415788|DEVICE|Sham IMT (Low resistence)|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
48354345|NCT05840393|OTHER|Discharge training based on Roy adaptation model|The Roy Adaptation Model consists of four main areas of adaptation. In this study, the content of the discharge education given within the scope of the adaptation areas of the Roy Adaptation Model will be continued with information such as home nutrition process, pain, anxiety, fear, stress and coping methods, addressing changing roles and responsibilities, communication, problem solving and utilizing social support. A booklet will be prepared to increase the effectiveness of discharge training based on the Roy Adaptation Model and the booklet will be used as a guide in the training program.
48354346|NCT01880879|DEVICE|helios stent|the group with helios stent implanted
48354347|NCT03607604|GENETIC|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
48354348|NCT04613635|DEVICE|Stratafix|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
48665008|NCT01196715|DRUG|Filgrastim|300 mcg vials twice a week, 3-4 days apart
48665009|NCT01196715|PROCEDURE|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
48665010|NCT02612246|DRUG|GLPG1972 single ascending doses|single dose, oral solution
48665011|NCT02612246|DRUG|Placebo single dose|single dose, oral solution, matching placebo
47987317|NCT01519453|BEHAVIORAL|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
47987318|NCT03129243|DIAGNOSTIC_TEST|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
48354349|NCT04613635|DEVICE|Vicryl|Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
47987319|NCT02617511|DIETARY_SUPPLEMENT|Omega-3 Supplementation|
47987320|NCT02617511|DIETARY_SUPPLEMENT|Placebo|
48354350|NCT00166244|DRUG|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
48354351|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
48354352|NCT04993430|DRUG|HRS8807|HRS8807 monotherapy
48354353|NCT04993430|DEVICE|HRS8807、SHR6390|HRS8807 in combination with SHR6390
48354354|NCT04993430|DRUG|HRS8807、SHR6390|HRS8807 in combination with SHR6390
48665012|NCT02612246|DRUG|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
48665013|NCT02612246|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
48665014|NCT02456129|DRUG|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
48665015|NCT02456129|DRUG|[14C] Vilaprisan|an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
47987321|NCT05308745|DIETARY_SUPPLEMENT|Yakult®|Fermented milk drink containing over 6.5×10\^9 CFUs of L. casei Shirota/65 ml
47987322|NCT05308745|DIETARY_SUPPLEMENT|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
47987323|NCT00449046|DRUG|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
48354355|NCT01478581|DRUG|PCI-32765|
48665016|NCT02456129|OTHER|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
48665017|NCT03641196|DEVICE|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
48143665|NCT02298166|DRUG|Crenolanib|"Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
48143666|NCT02298166|OTHER|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
48143667|NCT00729794|DRUG|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
48143668|NCT00729794|DRUG|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
48143669|NCT02323945|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
48143670|NCT02323945|OTHER|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
48143671|NCT02323945|OTHER|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
48354356|NCT01478581|DRUG|Dexamethasone|
48354357|NCT05451602|DRUG|HEC169096|Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2.
48354358|NCT03199131|PROCEDURE|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
48354359|NCT04143490|OTHER|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
48354360|NCT04752631|DRUG|Tenecteplase|The participants received TNK-tPA thrombolytic therapy
48354361|NCT01818128|DEVICE|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
48354362|NCT01818128|DEVICE|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
48354363|NCT00086385|DRUG|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
48354364|NCT01435122|DRUG|Axitinib|Axitinib Administration as outlined in Arm description
48354365|NCT00096824|BEHAVIORAL|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
47987324|NCT05505019|OTHER|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
48143672|NCT03936166|DRUG|CRN01941 Oral Solution|Investigational drug
48354366|NCT06274775|OTHER|Educational Video|Educational video about the nail biopsy procedure
48354367|NCT06408987|PROCEDURE|arthroscopically assisted|Arthroscopically-Assisted reduction through anterolateral portal for visualization and other accessory portals for instrumentation to achieve reduction and postoperative immobilization in a hip spica.
48354368|NCT06408987|PROCEDURE|open surgical reduction|Open reduction through a bikini incision anterior approach and postoperative immobilization in a hip spica.
48143673|NCT03936166|DRUG|CRN01941 Oral Capsule|Investigational drug
48143674|NCT03936166|DRUG|Placebo Oral Solution|Placebo
48143675|NCT03936166|DRUG|Placebo Oral Capsule|Placebo
48143676|NCT00336882|DRUG|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
48143677|NCT00336882|DRUG|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
48354369|NCT04713644|DRUG|Standardized Propofol Administration|Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
48354370|NCT01238705|DRUG|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
48354371|NCT01238705|DRUG|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
48354372|NCT04839328|DRUG|60mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
48354373|NCT04839328|DRUG|Placebo|Placebos are the same as drugs, but contain no Hemay005.
48354374|NCT04295668|BEHAVIORAL|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
48665018|NCT03641196|PROCEDURE|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
48665019|NCT02568657|DEVICE|Celox group|
48665020|NCT02568657|DEVICE|Bakri Balloon|
48665021|NCT05828108|DRUG|Bitopertin|Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
48354375|NCT04295668|BEHAVIORAL|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
48354376|NCT03663972|BEHAVIORAL|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
48354377|NCT03663972|BEHAVIORAL|phonologic treatment|children receive instruction in producing new sounds at the word level
48354378|NCT02846766|DRUG|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
48354379|NCT03307473|BEHAVIORAL|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
48354380|NCT05804071|DRUG|Niferex|"Daily iron supplement scheme (QD)：Oral polysaccharide iron complex capsule (Niferex)150mg/300mg daily.~Alternative iron supplement scheme（QOD）：Oral polysaccharide iron complex capsule(Niferex) 150mg/300mg every other day.~Intravenous iron supplement(MonoFer):use as instructions"
48354381|NCT01830322|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing \[MTD\]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
48354382|NCT01830322|DRUG|Gemcitabine|
48354383|NCT01830322|DRUG|Any non-gemcitabine chemotherapies or best supportive care|
48354384|NCT00205374|DRUG|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
48354385|NCT00205374|DRUG|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
48354386|NCT03152175|DRUG|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
48354387|NCT03152175|DRUG|Placebo|1mg / kg of matched placebo, oral capsule
48354388|NCT02187133|DRUG|Carfilzomib|"Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2"
48354389|NCT02187133|DRUG|Bendamustine|"Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2"
48354390|NCT02187133|DRUG|Rituximab|Given IV; 375 mg/m\^2
48354391|NCT02331316|OTHER|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
48354392|NCT04714554|DRUG|Relugolix/E2/NETA FDC|Relugolix/E2/NETA (40 mg/1 mg/0.5 mg) FDC tablet; oral administration.
48665022|NCT00930124|PROCEDURE|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
48665023|NCT00930124|PROCEDURE|Distraction osteogenesis|
48665024|NCT03464773|OTHER|PIUO Pathway|See arm descriptions
48665025|NCT04790500|OTHER|mobilization technique|Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.
48665026|NCT04790500|OTHER|muscle energy technique|Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
48665027|NCT06465238|DRUG|SHR-A2009|Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
48665028|NCT06465238|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
48665029|NCT05126420|PROCEDURE|biopsy|biopsy to identify the lesion in the oral mucosa
48665030|NCT05189665|PROCEDURE|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
48354393|NCT04714554|DRUG|Relugolix|Relugolix 120-mg tablets; oral administration.
48354394|NCT04714554|DRUG|Erythromycin|Erythromycin 500-mg tablets; oral administration.
48354395|NCT06482138|PROCEDURE|Biopsy and Cytobrush|Collection of olfactory cleft biopsies and cytobrushes
48665031|NCT05189665|PROCEDURE|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
48143678|NCT03717207|OTHER|ecg Holter,|all patients before to perform an head up tilt test for syncope evaluation will be steadied by ecg Holter to assess heart rate, heart rate variability.
48143679|NCT03717207|DIAGNOSTIC_TEST|cardiac scintigraphy|all patients before to perform an head up tilt test for syncope evaluation will receive a the 123I-MIBG, which is a norepinephrine analogous, to calculate the late heart-to-mediastinum ratio (H/Mlate) and washout rate (WR). Thus, we evaluated the H/Mlate as the index of global neuronal function due to norepinephrine uptake and the WR as the index of sympathetic tone.
48665032|NCT06091904|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
48143680|NCT06170125|OTHER|Tiotropium treated patients|Patients who are not satisfied with their COPD treatment and will be on additional tiotropium scheme.
48143681|NCT02993926|DRUG|Enantone|Enantone suspension for injection
48665033|NCT06091904|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
48143682|NCT02993926|DRUG|GnRH agonist|A non-Enantone GnRH agonist
48143683|NCT04511286|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
48143684|NCT03511495|DIAGNOSTIC_TEST|Galilei Corneal Topographer|A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
48143685|NCT01030315|DRUG|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
48143686|NCT00851513|DRUG|Lidocaine|local anesthetics
48665034|NCT04064905|BIOLOGICAL|mRNA-1893|Zika vaccine
48665035|NCT04064905|OTHER|Placebo|0.9% sodium chloride
48665036|NCT04212663|PROCEDURE|The tendon release of musculi tibialis posterior|To release the tendon of musculi tibialis posterior.
48665037|NCT04212663|PROCEDURE|Anterior tibial tendon transfer(TATT)|To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
48665038|NCT04212663|PROCEDURE|Achilles tendon lengthing|To lengthen the achilles tendon by using two incisions.
48665039|NCT04212663|PROCEDURE|Fascial release|To cut off the metatarsal fascia in the middle part.
48143687|NCT00851513|DRUG|Depmedrol|local steroids
48143688|NCT00851513|OTHER|physiological serum|important volumes of physiological serum
48143689|NCT06165978|BEHAVIORAL|Self-monitoring|pedometer/activity band provided to each participant
48354396|NCT05728424|DRUG|Vonoprazan, Amoxicillin, Levofloxacin|No additional information
48665040|NCT03739619|DRUG|Bendamustine|Given IV
48665041|NCT03739619|DRUG|Gemcitabine|Given IV
48665042|NCT03739619|BIOLOGICAL|Nivolumab|Given IV
48665043|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
48143690|NCT06165978|BEHAVIORAL|Goal setting and review|Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)
48354397|NCT03592589|DEVICE|high flow nasal canula|high flow nasal canula to obtain a positive expiratory pressure
48354398|NCT02586116|DEVICE|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
48665044|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
48665045|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
48665046|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)
48665047|NCT01561976|DRUG|Metformin hydrochloride prolonged release|1000mg in fasting state
48665048|NCT01561976|DRUG|metformin hydrochloride prolonged release|1000mg in fed state
48665049|NCT01561976|DRUG|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
48143691|NCT06165978|BEHAVIORAL|Education|Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)
48665050|NCT02908711|DRUG|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
48665051|NCT04542928|BEHAVIORAL|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
48665052|NCT02390076|DEVICE|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
48143692|NCT06165978|BEHAVIORAL|Feedback|Daily or weekly feedback for patients (emotional/social support)
48143693|NCT06165978|BEHAVIORAL|Contact|Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)
48143694|NCT06165978|BEHAVIORAL|Exercise|Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2\>88%, HRmax\<96%, Borg\<9)
48143695|NCT06165978|BEHAVIORAL|Report|Daily or weekly reporting for therapists (messages)
48354399|NCT02586116|DEVICE|C-Plus|C-Plus PEEK IBF Device with autograft
48665053|NCT02390076|OTHER|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
47987325|NCT05505019|OTHER|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
48354400|NCT02884193|PROCEDURE|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
48354401|NCT02884193|PROCEDURE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
48665054|NCT02390076|DEVICE|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
48665055|NCT02390076|DEVICE|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
48665056|NCT02071901|DRUG|eltrombopag olamine|Given PO
48143696|NCT06165978|BEHAVIORAL|Social support|Support meetings (in-person), parallel to educational sessions
47987326|NCT04357392|DRUG|Prednisone|Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
47987327|NCT04541576|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
47987328|NCT01499550|DEVICE|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
48143697|NCT06165978|BEHAVIORAL|Group activities|Group activities (e.g., walking on familiar routes - parks, monumental areas, etc.)
48143698|NCT06165978|BEHAVIORAL|World Health Organization recommendations for being physically active|World Health Organization's recommendations to maintain physical activity levels (i.e., 150-300 minutes/week of moderate to vigorous intensity physical activity; a weekly average of 10,000 steps/day or 100-120 minutes walking, which implies maintaining a pace of 100 steps/minute - corresponding to the average cadence across different age and gender groups).
48143699|NCT02718339|BEHAVIORAL|Intensive counseling|
48143700|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
48143701|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
47987329|NCT01499550|OTHER|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
48143702|NCT00458094|BEHAVIORAL|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
47987330|NCT03113019|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
48143703|NCT00458094|BEHAVIORAL|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
48143704|NCT01128322|DRUG|S-Amlodipine, Telmisartan|
48143705|NCT01128322|DRUG|S-Amlodipine|
48143706|NCT01128322|DRUG|Telmisartan|
48354402|NCT02884193|PROCEDURE|Sham Ice Bag|"Placebo application through an ice bag empty."
48143707|NCT01128322|DRUG|Placebo|
48143708|NCT06363604|PROCEDURE|VOMEI + PVI + linear ablation of mitral isthmus|The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
48143709|NCT06363604|PROCEDURE|Posterior wall isolation|PWI is additionally performed for experimental group with linear ablation of LA roof and bottom line, and verified by mapping with a multielectrode catheter.
48665057|NCT04809337|OTHER|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
48665058|NCT00002366|DRUG|Ritonavir|
48665059|NCT04269421|PROCEDURE|calcaneo-stop: arthrosis of the subtalar joint|arthrosis of the subtalar joint with a screw in the talus bone to stop pathological pronation of the heel
48665060|NCT05619237|DEVICE|NanoSALV Catalytic|NanoSALV Catalytic Antimicrobial Wound Dressing Gel is a Health Canada approved medical device for the management of Chronic Wounds.
48665061|NCT00776230|BIOLOGICAL|IC51|6 mcg im. at day 0 and day 28
48665062|NCT04736355|DRUG|DAOIB|oral, for 24 weeks
48665063|NCT04736355|DRUG|Placebo|oral, for 24 weeks
48665064|NCT05119816|OTHER|music therapy intervention|Received a customize playlists prepared by a certified music therapist to listening to during KB
48665065|NCT06173869|DRUG|FE 999049|FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
48143710|NCT02053298|DRUG|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
48143711|NCT02434705|OTHER|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
48143712|NCT01463475|PROCEDURE|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
48143713|NCT04707820|DIAGNOSTIC_TEST|ELISPOT|"The evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to Spike glycoprotein (Spike glycoprotein) will be assessed by enumeration in ELISPOT method at 4 measurement times: D0 (confirmation of infection by PCR), D+7, D+14 or at hospital departure (D+Departure) and D+56±14 days.~The ELISPOT method consists in stimulating peripheral blood mononuclear cells (isolated by density gradient and containing a known CD3+ T lymphocyte count) over a short period of time (16 to 20 hours) with a pool of 15 amino acid peptides (overlapping on 11 amino acids) representative of the S protein."
48143714|NCT05076825|OTHER|Neurodynamic Sliding|Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.
48143715|NCT05076825|OTHER|Static Stretching|Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.
48143716|NCT04877756|DRUG|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
48354403|NCT05724147|BEHAVIORAL|Mandala Activity|Three sessions of mandala activity, once a week, will be applied to the participants from the elderly people in the nursing home included in the study. The mandala activity planned to be done with the group will be done in addition to the standard monitoring applied in the institution, so it will be held at an appropriate time according to the flow in the institution. Before leaving the individuals, the most appropriate time for the next mandala session will be determined by taking into account the preferences of the individuals. Individuals to be included in the study will be grouped in groups of 10. Mandala activity application time is planned to last approximately 2 hours. If individuals have any physical symptoms, the time of the mandala activity is rescheduled, and each individual is expected to attend five sessions during the total study period.
48505231|NCT02572414|BEHAVIORAL|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
48505232|NCT02572414|BEHAVIORAL|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
48665066|NCT06173869|DRUG|GONAL-F|"GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed."
48665067|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Auditory Training|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
48665068|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Control Condition|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
48665069|NCT03537703|COMBINATION_PRODUCT|Sham tDCS + Auditory Training|Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
48665070|NCT00622726|DRUG|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
48354404|NCT04562727|DRUG|Chemotherapy|perioperative chemotherapy or postoperative chemotherapy
48665071|NCT00622726|PROCEDURE|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
48665072|NCT04612426|DEVICE|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
47987331|NCT01278485|DRUG|Sulphonylurea|SU administered according to usual practice.
47987332|NCT01278485|DRUG|Metformn|Metformin administered according to usual practice.
47987333|NCT00473642|DRUG|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
47987334|NCT00473642|DRUG|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
47987335|NCT00473642|DRUG|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
47987336|NCT06154954|DIAGNOSTIC_TEST|Semen analysis|Semen analysis for extracellular matrix proteins analysis
47987337|NCT04427774|DRUG|Surufatinib plus Sintilimab|Surufatinib will be given orally. Sintilimab will be given intravenously
48354405|NCT01314456|DEVICE|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
48665073|NCT04612426|DEVICE|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
47987338|NCT06101667|DRUG|Best medical management|Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
47987339|NCT06101667|PROCEDURE|Endovascular treatment|The strategies that were used for endovascular treatment included :stent retrievers (e.g., Solitaire® \[Medtronic, USA\], Trevo® \[Stryker, USA\], EMBOTRAP® \[Johnson \& Johnson, USA\], Captor® \[HeartCare, China\] and other stent-retriever systems) thromboaspiration (e.g., Penumbra® \[Penumbra, USA\], Afentta® \[HeMo, China\] and other aspiration systems)) balloon angioplasty (e.g., Gateway® \[Stryker, USA\], Neuro RX® \[SinoMed, China\], FocuStar® \[HeMo, China\] and other intracranial balloon catheter systems) stent deployment (e.g., Wingspan® \[Stryker, USA\], Apollo® \[MircoPort, China\], Enterprise® \[Johnson \& Johnson, USA\], Neuroform EZ® \[Stryker, USA\] and other Intracranial stent systems)) intraarterial thrombolysis (with alteplase or urokinase) combinations of above approaches that were left to the discretion of the treating team
47987340|NCT00240903|BIOLOGICAL|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
47987341|NCT01297140|BEHAVIORAL|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
47987342|NCT03953573|OTHER|Survey|Survey completed at 1 day, 8 days 1 or 3 months post delivery
47987343|NCT03322254|OTHER|respiratory pathogen panel|lab testing for respiratory pathogens
47987344|NCT04859881|OTHER|No intervention|No intervention
47987345|NCT03042247|DIAGNOSTIC_TEST|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
48143717|NCT02203799|BIOLOGICAL|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
48143718|NCT03868774|PROCEDURE|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
48143719|NCT02640703|BIOLOGICAL|Infanrix + Prevenar 13|Different time of application
48143720|NCT02797743|OTHER|Whole blood|"* Adults ≥18 yrs of age: up to 50 mL (5 tubes)~* Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~* Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
48143721|NCT05197452|BEHAVIORAL|COVID-19 Testing|"For in-person PCR testing, a nasal swab will be inserted shallowly into the participant's nose and rotated in each nostril. The swab will be broken off into a designated test tube and placed into a specimen bag along with a label. All specimens will be stored in a cooler until they are transported the Rush Laboratory for COVID-19 analysis.~For at home antigen testing, participants will download an app to their mobile phone and watch an informational video. The test will be self-administered by inserting a nasal swab into the nostril until a cap containing the swab touches the nose; rubbing the swab tip around the nose cavity 3 times; removing the swab and repeating in the other nostril. The nasal swab, a dropper, processing fluid, and a blue tooth connected analyzer are provided with the testing kit to analyze the sample for COVID-19. COVID-19 home test results are displayed on the participants smart phone after 15 minutes."
48143722|NCT05364515|DRUG|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)"
48143723|NCT05364515|DRUG|Clobetasol Propionate|0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
48143724|NCT04131855|OTHER|Pumice prophylaxis|Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
48354406|NCT01270113|BEHAVIORAL|contingency management|
48665074|NCT00642291|DRUG|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if \>=7 to \<15kg; 10/2.5 mg/kg BID if \>=15 to \<=40 kg)
48665075|NCT00642291|DRUG|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
48665076|NCT01818778|OTHER|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
48665077|NCT01818778|OTHER|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
48665078|NCT04846179|DIETARY_SUPPLEMENT|Ginkgo biloba extract|Patients recruited to Ginkgo Biloba Extract (GBE) group will be advised to take Webber Natural Ginkgo Biloba 120 mg soft gel, 1 tablet twice a day for 4 months.
48665079|NCT02946996|DRUG|Metformin|
48665080|NCT02946996|OTHER|OPC|OPC is a derivative of grape seed extract
48665081|NCT03257384|OTHER|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
48665082|NCT02646410|OTHER|FPD+NDOT|
48665083|NCT02646410|OTHER|FPD+DOT|
48665084|NCT02646410|OTHER|DDD+NDOT|Door to door delivery + non directly observed treatment
48665085|NCT02646410|OTHER|DDD+DOT|Door to door delivery + directly observed treatment
48665086|NCT02407119|DRUG|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
48665087|NCT02407119|DRUG|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
48665088|NCT00005835|DRUG|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
48665089|NCT00005835|DRUG|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
48665090|NCT00005835|PROCEDURE|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
48665091|NCT00005835|OTHER|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC \>/= 1500 mm3 for three consecutive days.
48665092|NCT05521932|OTHER|endometrium collected|endometrium tissue collected following adhesiolysis surgery
48665093|NCT00143884|PROCEDURE|Reduced intensity conditioning|
48665094|NCT00143884|PROCEDURE|Prophylactic donor leukocyte infusions|
48665095|NCT05781789|OTHER|Telehealth for preoperative evaluation|Conduct of preoperative evaluation remotely using Zoom application
48665096|NCT04962516|DEVICE|single-use precision filtered infusion sets|single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)
47987346|NCT00434655|PROCEDURE|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
47987347|NCT04474860|DIAGNOSTIC_TEST|gene sequencing|Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
47987348|NCT05114785|DIAGNOSTIC_TEST|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
47987349|NCT05966168|DEVICE|Medtronic Micra AV Device|Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
48665097|NCT04962516|DEVICE|single-use precision filter infusion set with needle|single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)
48665098|NCT00906061|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
48665099|NCT00427700|DRUG|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
48665100|NCT00427700|DRUG|raloxifene|100mg PO on days 5-9 of the menstrual cycle
47987350|NCT02859779|BEHAVIORAL|education programs|Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
48665101|NCT00626080|DRUG|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
48665102|NCT00626080|DRUG|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
48665103|NCT02037529|DRUG|Eribulin Mesylate|Given IV
47987351|NCT01755884|DIETARY_SUPPLEMENT|Wheat oral immunotherapy|Cooked spaghetti
47987352|NCT05844189|PROCEDURE|Physical therapy modalities on pelvic floor (manual therapy)|Intravaginal treatment (perineal massage)
47987353|NCT05844189|DEVICE|CRMRF|"CRMRF application on pelvic floor:~* Externally over the urogenital triangle of the patient,~* Intracavitary application (intravaginal)~* Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal),~The device used is named Intradermik and it is the portable CRMRF device of the brand RÖS'S Estética SL.~It has these features:~* Frequency: 448kHz~* Capacitive power: 450 voltamperes~* Resistive power: 200 watts"
47987354|NCT05844189|DEVICE|Sham CRMRF|The physical therapist applies the same treatment as the Treatment Group but the device is switched off.
47987355|NCT01166763|DRUG|vitamin D3|oral capsules, 10,000 IU per week for 6 months
48143725|NCT04131855|OTHER|No pumice prophylaxis|Pumice prophylaxis will not be used as per manufacturers instructions.
48665104|NCT02037529|OTHER|Laboratory Biomarker Analysis|Correlative studies
48665105|NCT02037529|DRUG|Paclitaxel|Given IV
48665106|NCT02037529|OTHER|Quality-of-Life Assessment|Ancillary studies
48665107|NCT02225535|OTHER|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
48665108|NCT02225535|OTHER|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
48665109|NCT02225535|OTHER|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
48665110|NCT05419245|OTHER|Guided Health History for Freeman-Burian Syndrome Questionnaire|Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
48665111|NCT05419245|OTHER|Freeman-Burian syndrome Semi-Structured Quality of Life Interview|Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.
48665112|NCT05419245|OTHER|Medical Records Review|Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.
48143726|NCT04337593|DRUG|Basiliximab|20mg d1,8, repeated every 3 weeks
48665113|NCT05419245|OTHER|PTSD Checklist for DSM-5|"Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms."
48665114|NCT05419245|OTHER|Modified Flanagan Quality of Life Scale|"Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being Terrible and 7 being Delighted. Higher scores suggest the person may be experiencing a better quality of life."
48143727|NCT04337593|DRUG|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
48143728|NCT05904210|DRUG|SEVENFACT®|Coagulation Factor VIIa (Recombinant)
48143729|NCT05594732|BEHAVIORAL|Weak outdoor light|Stay and stare far on the balcony or under the tree
48143730|NCT05594732|BEHAVIORAL|Strong outdoor light|Stay and stare far in the sunlight
48354407|NCT03215745|BEHAVIORAL|Delirium prevention program|Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
48665115|NCT05419245|OTHER|Center for Epidemiologic Studies Depression Scale|"Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being Rarely or none of the time (less than 1 day) and 3 being Most or all of the time (5-7 days). Lower scores suggest the person may be experiencing fewer symptoms."
48665116|NCT05419245|OTHER|Review of Systems|Completed during the interview. A review of systems is a checklist of medical problems.
48665117|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance of the Face"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face."
47987356|NCT04814433|DRUG|Tranexamic acid|"FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given."
48143731|NCT04803734|DRUG|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
48143732|NCT04803734|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
48143733|NCT01536704|DRUG|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
48143734|NCT01536704|DRUG|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
48143735|NCT01380145|BIOLOGICAL|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
48143736|NCT02022293|DRUG|Atorvastatin|Patients in this group will take 20mg per night.
48143737|NCT02022293|OTHER|Placebo|
48143738|NCT05851898|DRUG|Duloxetine 30 mg|Duloxetine 30mg daily prescribed at discharge
48143739|NCT02283086|BEHAVIORAL|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
48143740|NCT03611556|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
48354408|NCT03997552|PROCEDURE|Non-incised papillae surgical approach (NIPSA)|Periodontal reconstructive surgery
48143741|NCT03611556|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
48143742|NCT03611556|DRUG|Gemcitabine|Participants will receive IV infusion of gemcitabine as stated in arm description.
48354409|NCT03997552|PROCEDURE|marginal approach by palatal incision|Periodontal reconstructive surgery
48354410|NCT03997552|PROCEDURE|Minimally invasive surgical technique (MIST)|Periodontal reconstructive surgery
48665118|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance Distress"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face."
48143743|NCT03611556|DRUG|Nab-paclitaxel|Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
48143744|NCT03611556|DRUG|Oxaliplatin|Participants will receive IV infusion of oxaliplatin as stated in arm description.
48143745|NCT03611556|DRUG|Folinic acid|Participants will receive IV infusion of folinic acid as stated in arm description.
48143746|NCT03611556|DRUG|5-FU|Participants will receive IV infusion of 5-FU as stated in arm description.
48665119|NCT05419245|OTHER|"FACE-Q | Craniofacial - Facial Function"|"Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning."
48143747|NCT02962024|DRUG|Morphine Sulfate|
48143748|NCT02962024|DRUG|Bupivacaine Hydrochloride|
48143749|NCT04317885|BIOLOGICAL|Prizloncabtagene Autoleucel|Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
48143750|NCT04057261|DRUG|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
48354411|NCT03942172|DEVICE|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
48354412|NCT01693289|DRUG|metformin plus letrozole|
48354413|NCT01693289|PROCEDURE|ovarian drilling|
48665120|NCT02940925|OTHER|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
48665121|NCT02940925|OTHER|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
48665122|NCT06377501|OTHER|Whole-food, plant-based diet|Subjects will be instructed to adopt a whole-food, plant-based diet for 8 weeks. They will attend weekly group cooking classes led by a RD and receive weekly health coaching sessions.
48665123|NCT01508364|DRUG|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
48143751|NCT04057261|DRUG|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
48143752|NCT06417372|DIAGNOSTIC_TEST|intraoperative fluorescent staining combined with microscopy|Through the modified formulation of sodium fluorescein and methylene blue, the surface of the suspected cut edge of the patient's glioma was stained intraoperatively, and the surgical microscope image acquisition and processing system was used to determine whether the cut edge of the surgically resected tissue was positive or not.
48143753|NCT03692845|PROCEDURE|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
48665124|NCT02898948|BIOLOGICAL|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
48665125|NCT04506684|DEVICE|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
48665126|NCT03499756|BEHAVIORAL|Couple-based interpersonal psychotherapy|The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
48665127|NCT00293176|DRUG|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
48665128|NCT00293176|DRUG|Placebo|Subjects will receive matching placebo tablets.
48665129|NCT01413815|DIETARY_SUPPLEMENT|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
48665130|NCT01413815|OTHER|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
48665131|NCT05214365|DEVICE|Pacemaker implantation and conventional cardiac pacing|Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.
48665132|NCT05214365|DEVICE|Conduction system pacing implant|Right ventricular lead was placed to get his bundle or left bundle branch.
48143754|NCT02851134|GENETIC|genetic analysis|genetic (Whole Exome Sequencing )
48143755|NCT02851134|BIOLOGICAL|blood and stools samples|biological collection
48143756|NCT06300294|OTHER|acupressure|After the CAG procedure, acupressure will be applied to individuals whose vital signs are within the normal range.
48665133|NCT06176547|DIAGNOSTIC_TEST|HbA1c|Blood glucose in last 3 months
48665134|NCT02891226|DRUG|Mirikizumab|
48354414|NCT00944476|PROCEDURE|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
48354415|NCT03961139|OTHER|Method of feeding; continuous feeding OR bolus feeding|"CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes."
48354416|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-correction|Capsule with 50.000 UI cholecalciferol
48354417|NCT04778865|DIETARY_SUPPLEMENT|Vitamin D-RDA|Capsule with 4.2000 UI cholecalciferol
48354418|NCT01078779|DRUG|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
48354419|NCT01078779|DRUG|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
47987357|NCT04814433|DRUG|Aminocaproic acid|"FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given."
48354420|NCT00741741|DRUG|TMC278|
48354421|NCT03793270|DIAGNOSTIC_TEST|for patients and healthy donors|"1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate"
48354422|NCT05017727|DEVICE|Closed-loop automated oxygen control with Oxygenie Auto-O2 software (SLE6000)|The 'Oxygenie' is a closed loop automated oxygen control system that has been incorporated into a software module for the SLE6000 infant ventilators. This software control system allows targeting SpO2 values by controlling FiO2.
48505233|NCT01609712|PROCEDURE|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
48665135|NCT02891226|DRUG|Placebo|
48665136|NCT01078948|DEVICE|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
48143757|NCT00307216|BEHAVIORAL|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
48143758|NCT00307216|BEHAVIORAL|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
48143759|NCT02699099|DIETARY_SUPPLEMENT|Vitamin A|Oral administration of Vitamin A (1 dose)
48143760|NCT02699099|BIOLOGICAL|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
48143761|NCT02699099|BIOLOGICAL|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
48143762|NCT02699099|BIOLOGICAL|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
48354423|NCT05761236|OTHER|Exercise|Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
48354424|NCT04170374|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
48354425|NCT04170374|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
48354426|NCT05064943|DIAGNOSTIC_TEST|2-minute step test|"The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg."
48665137|NCT04647760|BEHAVIORAL|JOIN for ME|JOIN for ME is an empirically tested, effective weight management program for children ages 6-12 years.The curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are attended by the parent/caregiver and child, and occur at a location within their community setting (public housing or patient-centered medical home). Each session is 60 minutes and led by a certified Community Health Worker, with a private weigh-in for each dyad prior to the start of each session. Key behavioral targets include self-monitoring of dietary intake and physical activity, limiting LESS foods, limiting screen time, and weekly attendance. A family-based incentive structure is incorporated into the program such that parents/caregivers reinforce their children for achieving goals. Due to the COVID-19 pandemic, in-person sessions will be conducted virtually until it is safe to resume in-person group sessions.
48665138|NCT04786964|DRUG|Cosibelimab|IV infusion
48665139|NCT04786964|DRUG|Cisplatin|IV infusion
48665140|NCT04786964|DRUG|Carboplatin|IV infusion
48665141|NCT04786964|DRUG|Pemetrexed|IV infusion
48665142|NCT04786964|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
48665143|NCT04786964|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
48665144|NCT04786964|DRUG|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
48665145|NCT01574144|DEVICE|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
48665146|NCT03381599|DRUG|Filgrastim Injection|Filgrastim of 10 ug/kg/day will be given for four serial days.
48143763|NCT00291941|BIOLOGICAL|Henogen HBV vaccine|20µg, Month 0, 2 and 6
48143764|NCT00291941|BIOLOGICAL|FENDRIX|20 µg,Months 0, 1, 2 and 6
48143765|NCT06244914|DEVICE|tDCS stimulation|tDCS 1mA will be applied for 20min. tDCS will be applied around the infract area. taVNS or sham taVNS wil be applied before tDCS. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
48665147|NCT05482022|DEVICE|Shiley™ phonate speaking valve|The device connects to the tracheostomy tube. Usually used to aid vocalization.
48665148|NCT05482022|OTHER|control|no intervention
48665149|NCT04541667|OTHER|Air|Air will be used for luminal inflation.
48665150|NCT04541667|OTHER|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
48665151|NCT01365754|PROCEDURE|standard|fusion
48665152|NCT01365754|PROCEDURE|new|dynamic stabilization
48665153|NCT01349114|DRUG|aliskiren 300 mg once daily|aliskiren 300 mg daily
48665154|NCT01349114|DRUG|Placebo/sugar pill|Sugar pill/placebo
48665155|NCT04741906|PROCEDURE|Dental implant surgery|Dental surgery in patients treated with antiresorptive medication
48665156|NCT04741906|PROCEDURE|Prosthetic treatment|Prosthetic treatment and loading of the dental implants
48665157|NCT00024934|DRUG|B-Lymphocyte Stimulator (BLyS)|
48354427|NCT05820776|OTHER|pulmonary rehabilitation|The intervention is PR delivered via a telemedicine. The intervention is PR delivered via a telemedicine. The program is delivered by the multidisciplinary via a remote application for two sessions per week for ten weeks. Remotely supervised exercise includes: 1) deep breathing reinforcing pursed lip and diaphragmatic breathing; 2) warm up breathing and stretching exercise; 3) a cardiorespiratory aerobic exercise battery; 4) resistance training, and; stretching cool down. There is also an educational component. The secondary (maintenance) program includes ongoing remotely supervised exercise and education once a week for six months (24 sessions). All patients successfully completing the initial PR are offered the maintenance program.
48665158|NCT05026164|DIETARY_SUPPLEMENT|CHI-202|Blend of cannabinoids \& other ingredients
48665159|NCT05026164|DIETARY_SUPPLEMENT|CHI-101|Placebo
48665160|NCT03276442|OTHER|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
48665161|NCT03276442|OTHER|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
47987358|NCT04814433|DRUG|Recombinant Human Thrombin|"Topical thrombin is FDA approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is not sufficient.~Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution. When reconstituted as directed, the final solution contains 1000 units/mL.~For topical application, a total of 10000 units per open surgical study arm involving use of Thrombin will be given"
47987359|NCT04814433|DRUG|Lidocaine Hydrochloride with Epinephrine|"Topical lidocaine product is FDA approved as an amide local anesthetic in any indication for relief of pain associated with superficial minor surgery and as an adjunct for local infiltration anesthesia. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains lidocaine hydrochloride and epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid as a stabilizer.~Total of 5 mLs per open surgical study arm involving lidocaine hydrochloride and epinephrine will be given"
48143766|NCT06244914|DEVICE|taVNS stimulation|taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of taVNS will be adjusted under the patient's pain threshold. After taVNS, tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
48354428|NCT01893879|DRUG|placebo for study drug|Given PO
48354429|NCT01893879|DRUG|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
48354430|NCT01893879|OTHER|laboratory biomarker analysis|Correlative studies
48354431|NCT06286267|DIAGNOSTIC_TEST|imaging|Patient medical imaging materials including ultrasound, mammography, CT, MRI
48354432|NCT02591511|DEVICE|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
48505234|NCT05129007|DEVICE|Oura ring|Photopletysmography based noninvasive device
48505235|NCT05832567|DEVICE|Active rTMS|Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
48505236|NCT05832567|DEVICE|Sham rTMS|Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.
48505237|NCT05832567|DIETARY_SUPPLEMENT|Open Placebo|The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
48505238|NCT04237935|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
48505239|NCT04237935|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
48505240|NCT04669301|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.
48505241|NCT04669301|BEHAVIORAL|Supportive therapy (time and attention control)|"Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing."
48505242|NCT00024284|DRUG|carboplatin|
48505243|NCT00024284|DRUG|irinotecan hydrochloride|
48143767|NCT06244914|DEVICE|sham tDCS stimulation|sham tDCS 1mA will be applied for 20min. sham tDCS will be applied around the infract area. The stimulation will be applied for only 10 seconds and no stimulation afterward. taVNS or sham taVNS wil be applied before sham tDCS.The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
48665162|NCT06047938|RADIATION|ultrasound on carotid|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
48143768|NCT06244914|DEVICE|sham taVNS stimulation|sham taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of sham taVNS will be adjusted under the patient's pain threshold. The stimulation was only applied for 5 seconds and no stimulation afterward. After sham taVNS, tDCS or sham tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
48143769|NCT06509009|DRUG|Nimotuzumab|nimotuzumab, toripalimab, gemcitabine, cisplatin
48143770|NCT02467985|PROCEDURE|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
48143771|NCT02322489|DEVICE|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
48143772|NCT02322489|DEVICE|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
48143773|NCT00120549|PROCEDURE|Assisted embryo hatching|
48143774|NCT02010866|BEHAVIORAL|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
48143775|NCT01427517|DRUG|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
47987360|NCT04814433|DRUG|Bupivacaine Hydrochloride with Epinephrine|"Topical bupivacaine is FDA approved as indicated for the production of local anesthesia for procedures by infiltration injection. It is frequently used as a standard local anesthetic for surgical procedures.~Each mL contains bupivacaine hydrochloride and 0.005 mg epinephrine, with 0.5 mg sodium metabisulfite as an antioxidant and 0.2 mg citric acid (anhydrous) as stabilizer.~Total of 5 mLs per open surgical study arm involving Bupivacaine Hydrochloride with Epinephrine will be given"
48143776|NCT02941692|DRUG|Oxytocin|
48143777|NCT02941692|DRUG|Placebo|Placebo for Oxytocin
48143778|NCT05678725|DEVICE|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
48143779|NCT05678725|DEVICE|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
48143780|NCT05678725|DEVICE|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The stimulation lasted for 20 minutes and included a 10-second ramp-up and 10-second ramp-down.
48143781|NCT01228565|OTHER|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
48143782|NCT01228565|OTHER|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
48143783|NCT06360224|DEVICE|MiraQ systems with Transit Time Flow Measurement (TTFM) and High Frequency Ultrasound (HFUS) probes|The objective of this study is to harvest a wide dataset of high quality to allow exploratory analysis and training of machine learning
48143784|NCT02404298|DRUG|IVIg|
48354433|NCT02591511|OTHER|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
48354434|NCT03114462|RADIATION|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
48143785|NCT03742622|BEHAVIORAL|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48665163|NCT03378102|BIOLOGICAL|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
48665164|NCT02690142|DRUG|Placebo|Single dose i.v.
48665165|NCT02690142|DRUG|ABY-035 i.v.|Single dose i.v.
48665166|NCT02690142|DRUG|ABY-035 s.c.|Single dose s.c.
48665167|NCT06216977|OTHER|Clear Liquids|Participants will not take anything by mouth after midnight the day before surgery but will be given 12 ounce clear liquid (Sugar-free Gatorade) at bedside at the pre-operative holding area
48665168|NCT06216977|OTHER|Standard of Care|Participants will not take anything my mouth after midnight day before surgery
48665169|NCT04013178|BEHAVIORAL|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
48665170|NCT04013178|BEHAVIORAL|Conventional resistance training|A conventional approach to resistance training
48665171|NCT01604460|PROCEDURE|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
48665172|NCT01604460|PROCEDURE|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
48665173|NCT02635295|BEHAVIORAL|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
48665174|NCT00806585|DRUG|MK-0736|
48665175|NCT00806585|DRUG|Comparator: Placebo|
48143786|NCT03742622|BEHAVIORAL|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
48354435|NCT03114462|BEHAVIORAL|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
48354436|NCT03198728|DRUG|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
48354437|NCT03198728|DRUG|AndroGel|topical testosterone gel 1.62%
48354438|NCT05191381|BIOLOGICAL|Application of exosomes in a whole blood assay|Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
48354439|NCT01881906|OTHER|Usual care|
48354440|NCT01881906|OTHER|Exercise|
48354441|NCT00005623|DRUG|cyproterone acetate|
48354442|NCT00005623|PROCEDURE|quality-of-life assessment|
48505244|NCT05444257|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
48505245|NCT01336452|RADIATION|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
48505246|NCT05249452|OTHER|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
48505247|NCT01398215|PROCEDURE|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
48505248|NCT02315430|DRUG|Cabozantinib S-malate|Given PO
48505249|NCT02315430|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48354443|NCT05327244|OTHER|Real-world vibration feedback gait retraining|Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
48354444|NCT02016586|DIETARY_SUPPLEMENT|Maternal Nutritional Supplement|S348S0
48665176|NCT00806585|DRUG|Comparator: HCTZ|
48665177|NCT00615888|PROCEDURE|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
48665178|NCT00615888|PROCEDURE|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
48665179|NCT03400423|DRUG|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
48665180|NCT03400423|BEHAVIORAL|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.
48665181|NCT06513208|DRUG|Ketorolac Tromethamine|IV Ketorolac 15mg every 6 hours, x 4 doses
48665182|NCT06513208|DRUG|Placebo|IV saline as placebo
48354445|NCT04394013|BEHAVIORAL|Mindfulness intervention|Gentle body stretching with the incorporation of breathing technique
48354446|NCT04394013|BEHAVIORAL|Non-Mindfulness intervention|Gentle body stretching without the incorporation of breathing technique
48354447|NCT01610414|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
48505250|NCT02338804|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
48505251|NCT02338804|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
48354448|NCT01610414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
48354449|NCT00645190|DRUG|Galantamine HBr|
48354450|NCT03239769|PROCEDURE|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
48505252|NCT04349943|OTHER|nutrition therapy|With enteral nutrition as the preferred solution, the gradual transition from slow to fast, from lean to dense, from essential to whole protein type is conducted.
48505253|NCT03769207|DEVICE|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
48505254|NCT00819637|DRUG|arformoterol (RR formoterol)|"Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses."
48505255|NCT00819637|DRUG|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
48665183|NCT02998190|DRUG|Single Ascending Doses of EB8018|
48665184|NCT02998190|DRUG|Single Ascending Doses of placebo|
48665185|NCT02998190|DRUG|Multiple Ascending Doses of EB8018|
48354451|NCT01351714|PROCEDURE|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
48505256|NCT00819637|DRUG|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
48665186|NCT02998190|DRUG|Multiple Ascending Doses of placebo|
48665187|NCT04519970|BEHAVIORAL|Case Management|Each tier will have a different level of case management and support, all with the goal of increasing adherence to Biktarvy for HIV management.
48665188|NCT05313490|DIETARY_SUPPLEMENT|Beetroot Juice|7 days of 140 mL per day of beetroot juice
48665189|NCT05313490|OTHER|Placebo Beetroot Juice|7 days of 140 mL per day of placebo beetroot juice
48665190|NCT04375358|BIOLOGICAL|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
48665191|NCT05182918|OTHER|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
48665192|NCT05731609|OTHER|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
48665193|NCT03207347|DRUG|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
48665194|NCT04342247|DRUG|external testosteron|external testosteron
48665195|NCT05323656|DRUG|Setanaxib|Oral tablets, 400 mg per tablet
48665196|NCT05323656|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
48143787|NCT03742622|BEHAVIORAL|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48665197|NCT05323656|DRUG|Placebo|Oral tablets
48665198|NCT00475098|DRUG|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
48143788|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 supplement|
48665199|NCT00949533|DRUG|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
48665200|NCT00309218|DRUG|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
48143789|NCT01662193|DIETARY_SUPPLEMENT|calcium supplement|
48505257|NCT03624686|OTHER|peripheral blood|draw peripheral blood
48505258|NCT05580965|OTHER|20 N pressure for 1 minute|After blood collection, 20 N pressure applied for 1 minute
48505259|NCT05580965|OTHER|20 N pressure for 3 minute|After blood collection, 20 N pressure applied for 3 minute
48665201|NCT01447992|DEVICE|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
48665202|NCT01967745|PROCEDURE|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
48665203|NCT01967745|PROCEDURE|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
48665204|NCT03178409|PROCEDURE|Hepatectomy|Removal of a part of the liver
48665205|NCT00907621|PROCEDURE|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
48665206|NCT04856878|DRUG|Vancomycin|The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
48505260|NCT05580965|OTHER|20 N pressure for 5 minute|After blood collection, 20 N pressure applied for 5 minute
48505261|NCT05856643|DRUG|SZ011 CAR-NK|In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
48665207|NCT01055951|DEVICE|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
48665208|NCT01142180|PROCEDURE|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
48665209|NCT01142180|PROCEDURE|No TAE|No TAE procedure will be performed after endoscopic treatment
48665210|NCT02873156|DRUG|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
48665211|NCT02873156|DRUG|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
48665212|NCT02009826|RADIATION|[18F]-PBR111 Positron Emission Tomography (PET)|\[18F\]-PBR111 radioligand to assess binding to TSPO
48665213|NCT02009826|BEHAVIORAL|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
48665214|NCT02009826|BIOLOGICAL|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
48143790|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 and calcium supplement|
48143791|NCT01662193|DIETARY_SUPPLEMENT|placebo|
48143792|NCT03031509|BIOLOGICAL|Human Amniotic Epithelial Cells|Human Amniotic Epithelial Cells transplant after debridement
48143793|NCT03031509|PROCEDURE|debridement|debridement
48143794|NCT03711058|DRUG|Copanlisib|"Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV"
48505262|NCT01114100|DRUG|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
48143795|NCT03711058|DRUG|Nivolumab|"Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV"
48665215|NCT05210816|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
48143796|NCT04037033|BEHAVIORAL|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
48143797|NCT03441009|OTHER|Physio-/occupational therapy|Physio-/occupational therapy, ADL
48143798|NCT00217152|DRUG|CellCept|
48143799|NCT03386500|DRUG|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
48143800|NCT04336709|DRUG|Calcipex II|Water based intracanal medicament
48143801|NCT04336709|DRUG|Metapex|Oil based intracanal medicament
48505263|NCT01114100|DRUG|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
48505264|NCT03460639|RADIATION|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
48505265|NCT03460639|RADIATION|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
48505266|NCT03460639|DIAGNOSTIC_TEST|Control group|In this group, we will only induce fatigue.
48505267|NCT03134092|OTHER|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
48505268|NCT03134092|OTHER|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of \~ 2-minute length and recorded.
48505269|NCT04308226|BEHAVIORAL|Patient Navigation|The navigator's principal role is to guide participants through the lung cancer screening (LCS) process. The navigator will work within the existing Boston Health Care for the Homeless (BHCHP) clinical structure and collaborate with participants' primary care providers (PCPs) to facilitate LCS low-dose computed tomography (LDCT) referral, completion, and timely follow-up by addressing participants' barriers to LCS completion and enhancing participants' self-efficacy. The navigator's secondary role is to offer brief tobacco counseling for participants who currently smoke.
48505270|NCT02903030|DRUG|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
48505271|NCT02903030|DRUG|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
48143802|NCT05135234|BEHAVIORAL|Muscular Exercise|Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
48143803|NCT05608772|PROCEDURE|revision surgery|revision procedure after failed sleeve gastrectomy
48143804|NCT03038490|DIETARY_SUPPLEMENT|ABOUND|an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
48143805|NCT00780741|PROCEDURE|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
48143806|NCT00780741|PROCEDURE|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
48143807|NCT00953355|DRUG|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
48143808|NCT00953355|DRUG|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
48143809|NCT03051074|BEHAVIORAL|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
48143810|NCT03051074|BEHAVIORAL|Comparison|Watching a relaxing film for up to 90 minutes
48143811|NCT00944359|DIETARY_SUPPLEMENT|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
48505272|NCT00245830|PROCEDURE|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
48505273|NCT04342715|DRUG|Sodium stibogluconate / paramomycin|Treatment with Sodium stibogluconate / paramomycin
48505274|NCT00985179|BEHAVIORAL|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
48505275|NCT04437459|OTHER|High-fat shake|Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.
48665216|NCT01530958|BEHAVIORAL|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials"
48665217|NCT01530958|BEHAVIORAL|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
48665218|NCT01530958|BEHAVIORAL|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
47987361|NCT03417453|DEVICE|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
47987362|NCT03417453|DEVICE|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
47987363|NCT04905173|OTHER|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
47987364|NCT04905173|DRUG|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
47987365|NCT04905173|OTHER|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
47987366|NCT03659591|BEHAVIORAL|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
47987367|NCT03659591|BEHAVIORAL|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
47987368|NCT01394523|DRUG|Bupivacaine|0.25% or 0.5%
47987369|NCT00725556|OTHER|Speech Therapy|Speech Therapy
47987370|NCT04208204|OTHER|somatocognitive physiotherapy|Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
47987371|NCT04086290|PROCEDURE|RARP|Radical prostatectomy + extended pelvic lymph node dissection
47987372|NCT04086290|RADIATION|SBRT|Stereotactic body radiotherapy to osseous lesions
47987373|NCT04086290|DRUG|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
47987374|NCT06203847|DRUG|Combination group|Combination of epinephrine (Adrenaline® 1mg/vial) every 3 minutes, vasopressin (Pitressin® 20Unints/vial) every 3 minutes up to 4 vials (a total of 80Units), methylprednisolone (Solu-Medrol® 40mg/vial)
47987375|NCT06203847|DRUG|Standard group|standard doses of epinephrine (Adrenaline® 1mg/vial) every 3 minutes
47987376|NCT05849103|OTHER|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
47987377|NCT05849103|OTHER|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
48143812|NCT00944359|DIETARY_SUPPLEMENT|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
48143813|NCT00944359|DIETARY_SUPPLEMENT|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
48143814|NCT00944359|OTHER|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
48143815|NCT01971255|BIOLOGICAL|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
48143816|NCT04663256|OTHER|Cognitive stimulation group|Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
48143817|NCT01915888|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
48665219|NCT04435626|DRUG|Finerenone (BAY94-8862)|"For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD.~For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets."
48143818|NCT04335474|PROCEDURE|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
48143819|NCT04335474|PROCEDURE|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
48143820|NCT03111368|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
48143821|NCT01849523|BEHAVIORAL|Web-based information and support|
48505276|NCT04437459|OTHER|Pure glucose solution|Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
48505277|NCT00871273|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
48143822|NCT05526937|OTHER|Bread|Bread portions of 50 gram available carbohydrates.
48143823|NCT03271359|BEHAVIORAL|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
48143824|NCT03271359|BEHAVIORAL|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
48143825|NCT05347849|DRUG|BPL-003|A single dose of BPL-003 will be administered intranasally
48143826|NCT05347849|OTHER|Placebo|A single dose of placebo will be administered intranasally
48143827|NCT01779245|DIETARY_SUPPLEMENT|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
48143828|NCT01779245|DIETARY_SUPPLEMENT|Placebo|
48143829|NCT01959009|OTHER|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
48505278|NCT04182724|DRUG|Camrelizumab, Apatinib and Nab-paclitaxel|Camrelizumab was administered 200mg iv every 2 weeks, Apatinib was administered 250 mg p.o. qd Nab-paclitaxel was administered 125 mg/m2, 150 mg/m2, 175 mg/m2 or 200 mg/m2, iv. q2w
48505279|NCT01341782|DRUG|paricalcitol|
48505280|NCT01341782|DRUG|maxacalcitol|
48505281|NCT01341782|DRUG|paricalcitol placebo|
48505282|NCT01341782|DRUG|maxacalcitol placebo|
48505283|NCT00925366|OTHER|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
48665220|NCT04435626|OTHER|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
48665221|NCT04826380|PROCEDURE|Trapeziectomy|Simple trapeziectomy (without LRTI)
48665222|NCT05085132|BEHAVIORAL|MindFi app: Standard content|Digital wellness training in this study will be delivered via the MindFi app, designed by Jaedye Labs. Content includes learning, assesesment, and practice tracks A core component of the exercises in this app is mindfulness training; however, the app also incorporates other exercises drawn from positive psychology such as journaling and diaphragmatic breathing. The app goes beyond traditional guided meditation through content that reinforces the principles and attitudes taught during in-person training, and also seeks to maximize user experience by using interactive tasks and progress charts.
48143830|NCT00157105|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
48143831|NCT04794244|BEHAVIORAL|ASGE-FABES Program|In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
48354452|NCT04317898|PROCEDURE|serratus plane block by ultra-sound|To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.
48354453|NCT04317898|PROCEDURE|paravertebral block by ultra-sound|TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
48505284|NCT04670276|PROCEDURE|injection of emulsified adipose tissue stromal vascular fraction|Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
48505285|NCT04086407|DEVICE|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
48665223|NCT05085132|BEHAVIORAL|Mindfi app: Standard content without practice|In this condition, participants will receive a version of the MindFi app that does NOT contain the practice tracks, only the learning and assessment tracks.
48665224|NCT06129747|RADIATION|Radiation Therapy|"Weeks 1, 2 and 3~* Weeks 1, 2 and 3 will include 5 days of treatment.~* One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes."
48665225|NCT00114491|DRUG|Rosuvastatin|
47987378|NCT05245747|DEVICE|Vitls Tego Device|The Tégo VSS Sensor is a battery-operated adhesive patch with integrated sensors and wireless transceiver which is worn on the upper body and records heart rate (HR), respiration rate, blood oxygen levels (SpO2), and body temperature. The Tégo VSS Sensor continuously gathers multiparameter physiological data from the person being monitored and then transmits the encrypted data via bi-directional communication to a third-party connectivity relay.
47987379|NCT01589744|DEVICE|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
47987380|NCT00212030|DRUG|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
47987381|NCT00212030|DRUG|placebo|Control
47987382|NCT00257842|PROCEDURE|Standard treatment, sham feedback and biofeedback therapy|
47987383|NCT03045081|BEHAVIORAL|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
47987384|NCT02576561|BIOLOGICAL|TVGV-1|Antigen + Adjuvant
47987385|NCT02576561|BIOLOGICAL|GPI-0100|Adjuvant Alone
47987386|NCT02576561|BIOLOGICAL|Placebo|Placebo
47987387|NCT05855005|DEVICE|DTC Hearing Aids|DTC hearing aid programmed to the individual participant.
47987388|NCT00121420|DRUG|Motexafin gadolinium|
48665226|NCT00431964|DRUG|azithromycin 250 mg tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
48665227|NCT00431964|DRUG|placebo tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
48665228|NCT02786056|OTHER|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
48665229|NCT02834364|DRUG|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
48665230|NCT02834364|DRUG|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
48665231|NCT05332704|DRUG|ONO-4685|-Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A5).
48665232|NCT05332704|DRUG|Placebo|-Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).
47987389|NCT02128633|DRUG|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
47987390|NCT02128633|DRUG|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
47987391|NCT02128633|DRUG|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
47987392|NCT00878527|DEVICE|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
48354454|NCT01732133|DEVICE|Nexfin|
48354455|NCT02870244|BIOLOGICAL|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10\^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10\^7/kg TIL 1383I TCR transduced T cells."
48354456|NCT01563952|DEVICE|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
48354457|NCT01563952|DEVICE|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
48354458|NCT01563952|DEVICE|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
48354459|NCT01563952|DEVICE|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
48354460|NCT03616470|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
48354461|NCT03616470|DRUG|Placebo|Saline, 0.9% Sodium Chloride
48354462|NCT02352428|OTHER|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
48505286|NCT03529825|DRUG|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
47987393|NCT03047642|DIAGNOSTIC_TEST|Biomarker assay|There is no intervention on the patients but biomarker assays are being evaluated for their performance to distinguish bacterial infection from non-bacterial infections in febrile patients
48002622|NCT05781438|BEHAVIORAL|In-home standing and walking intervention|"Parents/legal guardians will be educated on and provided an activity booklet on intensive standing and walking play activities for their infant in a 9 by 9 foot body-weight support system (BWS). Activities include: squatting play at a couch or table, cruising along and between furniture, walking with a push toy or with one or two hands held, walking without support, and kicking and throwing a soft ball.~For 16 weeks, parents/legal guardians will be encouraged to implement the parent-led, intensive standing and walking intervention using BWS for at least 5 days/week for 30-60 min/day, with weekly telehealth calls and monthly home visits to coach parents in identifying key activities and progressing the program."
48505287|NCT05739253|PROCEDURE|Transcatheter aortic valve replacement|All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
48505288|NCT01327508|DEVICE|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
48505289|NCT01327508|OTHER|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
48505290|NCT03232632|DRUG|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
48143832|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
48665233|NCT05332704|DRUG|ONO-4685|-Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)
48665234|NCT05332704|DRUG|Placebo|-Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
48665235|NCT05332704|DRUG|ONO-4685|-Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort C1 and C2).
48665236|NCT05332704|DRUG|Placebo|-Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
48665237|NCT04862494|OTHER|clinical surveillance|regular clinical follow up including chest X-rays, pulmonary investigations, etc...
48665238|NCT04862494|PROCEDURE|diaphragmatic plication|plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
48665239|NCT06022926|PROCEDURE|warmed with electric blankets|warmed with electric blankets
48665240|NCT06022926|OTHER|patients without warming|patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
48354463|NCT04742764|COMBINATION_PRODUCT|Standard medical therapy|Standard medical therapy (according to the Surviving Sepsis Campaign) will include standard monitoring (pulseoximetry, 5-lead ECG, continuous invasive blood pressure monitoring, central venous cannulation and 24 with PiCCO-technology. Norepinephrine as a vasopressor and dobutamine - if needed - as an inotrope will be administered by the attending physician.
48354464|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours|Standard medical therapy, as discussed above will be applied. Furthermore, Cytosorb will be administered as soon as it is possible after randomization but not later than 2 hour (start of the treatment, T0). In a blood pump circuit in pre-haemofilter position, using a kidney replacement device of Fresenius Multifiltrate as a solo therapy or in combination with renal replacement therapy. It will be run in CVVHD, CVVHDF or CVVH mode with a 150 and 200 ml/min blood flow. Anticoagulation will be applied intravenously with heparin, low molecular weight heparin or citrate. The aim of the pump flow rate will be 100-400 mL/min, and the flow rate will be recorded. Possible shock reversal will be assessed by the physician attending. Adsorber cartridges will be changed in every 12 hours. End of the study period (Te): 12 hours after shock reversal, death of the patient, or maximum of five days, whichever happens first.
48354465|NCT04742764|DEVICE|Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours|The standard medical therapy and method of Cytosorb treatment as detailed above will be applied. Adsorber cartridges will be changed in every 24 hours.
48354466|NCT00901394|DRUG|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
48354467|NCT00901394|DRUG|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
48354468|NCT00901394|OTHER|Placebo|Saline
48354469|NCT00901394|OTHER|oxygen nitrogen|60% air and oxygen mix.
48354470|NCT02672150|BEHAVIORAL|Core|
48665241|NCT02725463|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant|
48665242|NCT02621892|DRUG|Tenapanor|
48665243|NCT02621892|DRUG|Placebo|
48002623|NCT05881473|DIAGNOSTIC_TEST|pain assessment after clavicular fracture repair|This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
48002624|NCT00963339|DEVICE|Foresee Home|Home Monitoring
48354471|NCT02672150|BEHAVIORAL|Enhanced|
48354472|NCT05516264|BEHAVIORAL|Dog visits/control visits|See arm description above
48354473|NCT05516264|BEHAVIORAL|Control visits/dog visits|See arm description above
48665244|NCT05425160|OTHER|Progressive lower limb activities (Chair rise and Step ups)|Progressive lower limb activities (Chair rise and Step ups) were be carried out weekly for upto 6 weeks. Before initiation, cardiopulmonary parameters i.e. Heart rate, oxygen saturation, cardiac output and stroke volume were measured at baseline and later at the termination of activity on each week. Initially, five repeated chair rise were conducted through SPPB and the time was noted to complete the task and step ups through 6MWD for a total period of 30 min. Lastly, fatigue component was assessed via FAS.
48665245|NCT05425160|OTHER|Standard aerobic exercise i.e. low intensity walking|Standard aerobic exercise i.e. low intensity walking were conducted in both the groups. Follow up phone calls and 1 OPD visit were scheduled accordingly
48002625|NCT01433107|DRUG|Terbinafine|1% single application
48143833|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
48354474|NCT00218452|BEHAVIORAL|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
48665246|NCT02471144|BIOLOGICAL|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
48665247|NCT02471144|BIOLOGICAL|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
48143834|NCT01061658|OTHER|Placebo|Placebo
48143835|NCT06444087|OTHER|secukinumab|This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
48665248|NCT02471144|BIOLOGICAL|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
48665249|NCT02471144|BIOLOGICAL|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
48665250|NCT01669512|BIOLOGICAL|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
48665251|NCT01669512|BIOLOGICAL|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
48665252|NCT01669512|BIOLOGICAL|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
48665253|NCT02470702|DRUG|Oritavancin|
48665254|NCT02470702|DRUG|Placebo (D5W)|
48665255|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
48665256|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
48002626|NCT01433107|DRUG|Terbinafine Placebo|single application
48002627|NCT01794403|RADIATION|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
48143836|NCT04951791|DRUG|SMOFlipid|will receive intravenous infusion of 2ml\\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed
48143837|NCT04951791|OTHER|Normal saline 0.9%|will receive intravenous infusion of 2ml\\kg of normal saline 0.9%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed.
48505291|NCT06194942|OTHER|chiropractic manipulation|Chiropractic manipulation is a manual therapy technique commonly used by chiropractors. It involves the application of controlled, sudden force to a specific joint, often with the goal of improving joint function, reducing pain, and promoting overall musculoskeletal health.In the context of thoracic chiropractic manipulation, the chiropractor focuses on the vertebrae and joints in the thoracic spine.
48505292|NCT06194942|OTHER|sham manipulation|"Sham manipulation refers to a simulated or placebo form of a manual therapy intervention, often used in research studies, especially in clinical trials involving chiropractic or physical therapy. the term sham manipulation likely implies a procedure that mimics the physical aspects of a real chiropractic manipulation but does not involve the actual therapeutic forces or movements.~The chiropractic treatment group received thoracic chiropractic manipulations (HVLA) twice a week for a total of six sessions over three weeks, while the control group received sham manipulations."
48505293|NCT02803424|OTHER|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
48505294|NCT02803424|OTHER|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
48665257|NCT00914576|DRUG|Placebo|2 capsules/day for 14 days
48665258|NCT00914576|DRUG|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
48143838|NCT06470633|DRUG|Adebrelimab|Adebrelimab 1200mg iv q3w
48143839|NCT06470633|PROCEDURE|High Intensity Focused Ultrasoun（HIFU）|HIFU treatment at lesion site
48143840|NCT06470633|DRUG|Cyclophosphamide|600mg/m2 iv q3w
48143841|NCT06470633|DRUG|Epirubicin|90mg/m2 iv q3w
48354475|NCT01644812|BEHAVIORAL|Aerobic exercise|
48354476|NCT01644812|BEHAVIORAL|Stretching|
48665259|NCT00914576|DRUG|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
48665260|NCT03197519|BEHAVIORAL|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
48665261|NCT03197519|BEHAVIORAL|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
47987394|NCT06219447|DEVICE|VRRS Home Tablet or Medico Amico Kids APP|Tele-rehabilitation (TR) permits intensive and personalized intervention monitored by clinicians in an ecological friendly, home setting. The VRRS Home Kit, comprising a tablet and peripheral devices, permits TR of cognitive, speech and motor functions. These peripherals such as sensors and balances allow motor rehabilitation across different body districts involved (upper and lower limbs, trunk). Touch screen activities, enables neuropsychological and speech therapy sessions. Medico Amico APP, offers a wide library of cognitive, language and motor exercises, stratified by difficulty levels, targeting specific functions. An avatar guides real-time movements, offering visual references. Adjustable parameters include duration, repetitions, difficulty, speed, movement amplitude. Both technologies facilitate TR sessions via a dedicated platform, that can occur in real-time, involving interaction with patients, or independently with continuous monitoring by clinical staff.
48143842|NCT06470633|DRUG|Docetaxel|75mg/m2 iv q3w
48143843|NCT06401590|DIAGNOSTIC_TEST|FROZEN SENTINEL LYMPH NODE BIOPSY|FROZEN SENTINEL LYMPH NODE BIOPSY
48354477|NCT03422757|DEVICE|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
48143844|NCT02551705|OTHER|functional Imaging|Brain responses associated with emotional memory will be investigated
48354478|NCT03422757|DEVICE|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
48354479|NCT02804685|OTHER|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
48354480|NCT04081051|OTHER|diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)|Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
48354481|NCT06399068|DRUG|CKD-387|1 Tablet
48354482|NCT06399068|DRUG|D484|1 Tablet
48354483|NCT04507490|DEVICE|Whole body vibration|315/5000 application of whole body vibration with pre-established parameters for each group. All patients will participate in all groups, an interval of at least one week. They will be instructed to climb on the platform and to position a semi knee flexion and remain stationary during the vibration
48354484|NCT03485404|DRUG|methylcobalamin|methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
48505295|NCT04774848|DEVICE|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
48505296|NCT04774848|DEVICE|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
48505297|NCT05543343|DRUG|High dose or normal dose staphylococcus albicans|8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
48665262|NCT02297516|DRUG|Azzalure or Dysport|Glabellar lines
48665263|NCT02297516|DEVICE|Restylane or Emervel filler|Facial tissue augmentation
48665264|NCT02297516|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
48665265|NCT05391776|DRUG|TST002 Injection|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
48143845|NCT01607320|DRUG|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
48354485|NCT03485404|DRUG|Folic Acid|folic acid tablets, 5mg/tablet, 1 tablet/day
48354486|NCT03485404|OTHER|Placebo for methylcobalamin|orange tablets that looks exactly like methylcobalamin
48354487|NCT03485404|OTHER|Placebo for folic acid|yellow tablets that looks exactly like folic acid
48354488|NCT03485404|PROCEDURE|non-cardiac surgery|patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
48354489|NCT03485404|BEHAVIORAL|NPB test|participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
48354490|NCT04220658|OTHER|Biomarker study|Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation
48354491|NCT03817424|DRUG|VIB7734|Participants will receive VIB7734 via injection.
48354492|NCT03817424|DRUG|Placebo|Participants will receive placebo matching to VIB7734 via injection.
48505298|NCT05543343|DRUG|Placebo|8 placebo tablets 3 times daily
48354493|NCT04950933|DRUG|Huolingshengji Granules|1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;
48354494|NCT04950933|DRUG|Riluzole tablet|Huolingshengji granules simulation agent 1 bag each time + Riluzole tablet 1 tablet each time, 2 times a day, orally.
48354495|NCT03140046|PROCEDURE|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
47987395|NCT02355691|DEVICE|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
47987396|NCT04212247|BEHAVIORAL|Well-Being Therapy|Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
47987397|NCT04212247|BEHAVIORAL|Control condition|The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
48143846|NCT01607320|DRUG|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
48143847|NCT00168506|DRUG|SSRI|
48354496|NCT04340687|DEVICE|Pancreatic duct stenting|A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
48354497|NCT05386641|OTHER|measurement of tissue stiffness (N/m)|Stiffness values will be measured with myotonPro on centers of coordination located along the myofascial chain
48354498|NCT05386641|OTHER|measurement of passive muscle tone (Hz)|muscle tones will be measured with myotonPro on centers of coordination located along along the myofascial chain
48354499|NCT05386641|OTHER|measurement of creep of tissue|creep of tissue will be measured with myotonPro on centers of coordination located along the myofascial chain
48354500|NCT05386641|OTHER|measurement of the range of shoulder joint motion|The range of shoulder flexion, abduction, extension and external-internal rotation movements will be measured with a universal goniometer.
48505299|NCT04856410|OTHER|Spaceflight|Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.
48354501|NCT05386641|OTHER|measurement of skin temperature|measurements will be taken by the thermographic camera
48505300|NCT04856410|OTHER|Controls|No intervention
48505301|NCT06633796|DEVICE|AMADEO|304 / 5.000 The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy, functional occupational therapy and polyarticular mobilization of the fingers with a robotic arm (Amadeo). The sessions will be scheduled 2 times a week for 5 consecutive weeks.
48143848|NCT00168506|DRUG|CBT|
48143849|NCT00168506|DRUG|CBT/SSRI|
48354502|NCT05386641|OTHER|measurement of pain|Pain will be evaluated by visual analog scale (VAS)
48354503|NCT05386641|OTHER|measurement of pain pressure threshold|Pain pressure threshold will be evaluated by a digital algometer
48354504|NCT05386641|OTHER|measurement of grip strength|"The grip strength of both hand will be evaluated by hand-held dynamometer."
48354505|NCT01323933|DRUG|AB0024|Comparison of different dosages of drug
48505302|NCT06633796|PROCEDURE|Standard of care|The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy and occupational therapy for functional purposes. The sessions will be scheduled 2 times a week for 5 consecutive weeks.
48505303|NCT01966588|OTHER|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
48665266|NCT05391776|DRUG|placebo|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
48505304|NCT01966588|OTHER|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
48665267|NCT02896946|RADIATION|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
48665268|NCT03906526|DRUG|VTX-2337|Motolimod
48665269|NCT03906526|DRUG|Nivolumab|IV Nivolumab
48665270|NCT02105129|DRUG|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
48665271|NCT02105129|DRUG|Placebo|Oral administration
48665272|NCT04049773|PROCEDURE|haemodialysis|haemodialysis, thrice weekly in-center
48665273|NCT02748447|DEVICE|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
48665274|NCT02461186|DRUG|Arterolane maleate-piperaquine phosphate (Synriam)|
48354506|NCT06228781|PROCEDURE|Autologous haemopoietic stem cell transplantation|"Immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT).~Stem cell mobilization with cyclophosphamide 2g/m2 and filgrastim 10 ug/kg/d x 5 day.~Stem cell collection with cobe cpectra stem cell purification with Miltenyi CliniMACS Stem cell transplant conditioning with busulphan 3.2 mg/kg ; fludarabine 30mg/m2 or cladribine 10mg ；cytarabine 1-2g/m2 or idarubicin 8mg/m2；cyclophosphamide 40mg/kg followed by CD34 selected autologous hematopoietic stem cell transplant."
48665275|NCT02461186|DRUG|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
48665276|NCT05809947|OTHER|Neuromuscular electrical stimulation|One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg
48665277|NCT03081104|DEVICE|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
48665278|NCT03081104|DEVICE|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
48665279|NCT03081104|PROCEDURE|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
48665280|NCT01280968|BIOLOGICAL|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
48665281|NCT01280968|BIOLOGICAL|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
48665282|NCT04154722|DRUG|Meropenem Injection|inj meropenum for 10 days
48354507|NCT03172013|DIAGNOSTIC_TEST|Platelet indices|MPV, PDW
48354508|NCT02573012|DRUG|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
48354509|NCT02573012|DRUG|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
48143850|NCT02073214|OTHER|Probiotic|Standard treatment plus probiotic
48354510|NCT02573012|BIOLOGICAL|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
48354511|NCT00233324|DRUG|Surfactant|Intubation and administration of surfactant by 1 hour of age.
48354512|NCT00233324|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
48354513|NCT00233324|DRUG|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
48665283|NCT04154722|DRUG|Azithromycin Powder|syp azithromycin for10days
48665284|NCT01346124|RADIATION|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
48665285|NCT01152437|DRUG|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
48665286|NCT01152437|DRUG|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
48665287|NCT03093714|DRUG|FDL169|CFTR corrector
47987398|NCT00969176|DRUG|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
47987399|NCT00653146|BEHAVIORAL|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
47987400|NCT00653146|BEHAVIORAL|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
48143851|NCT02073214|OTHER|Placebo|Standard treatment plus placebo
48143852|NCT04693637|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
48354514|NCT00233324|DRUG|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
48354515|NCT04790734|DRUG|Sedation drugs|Different sedation drugs
48505305|NCT05766514|DRUG|Cladribine|Subjects will be given 5 mg/m2 cladribine intravenously on days 1-5 of cycle 1 and on days 1-3 of cycles 2, 5, 6, 9, 10, 13, 14, 17 and 18.
48505306|NCT05766514|DRUG|Cytarabine|Subjects will be given 20 mg cytarabine subcutaneously twice daily on days 1-10 of cycles 1, 2, 5, 6, 9, 10, 13, 14, 17 and 18.
48505307|NCT05766514|DRUG|Decitabine|Subjects will be given 20 mg/m2 decitabine intravenously on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15 and 16
48505308|NCT05766514|DRUG|azacitidine or decitabine|Subjects will be given either 20 mg/m2 decitabine intravenously on days 1-5 of each cycle or 75 mg/m2 azacitidine intravenously or subcutaneously on days 1-7 of each cycle. The treating physician will determine which drug each subject will receive.
48505309|NCT05766514|DRUG|Venetoclax|Subject will take 400 mg venetoclax orally once daily on days 1-21 of each cycle.
48505310|NCT02069431|DRUG|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
48505311|NCT02069431|OTHER|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
48505312|NCT02598947|OTHER|Manual therapy|Exercise, behaviour change interventions and manual therapy
48505313|NCT02465268|BIOLOGICAL|pp65-shLAMP DC with GM-CSF|
48505314|NCT02465268|BIOLOGICAL|unpulsed PBMC and saline|
48505315|NCT02465268|DRUG|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
48505316|NCT02465268|DRUG|Saline|
48505317|NCT02465268|BIOLOGICAL|pp65-flLAMP DC with GM-CSF|
48665288|NCT03093714|DRUG|Placebo|Placebo for FDL169
48665289|NCT03447392|BEHAVIORAL|Discharge Education of Chinese Medicine|Discharge Education of Integrated Traditional and Western Medicine
48665290|NCT03017001|DIETARY_SUPPLEMENT|CHO (carbohydrate)|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia
48665291|NCT03017001|DRUG|intravenous w-3 PUFA|Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
48665292|NCT03017001|OTHER|CHO (carbohydrate) plus intravenous w3-PUFA|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
48665293|NCT02673021|PROCEDURE|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
48665294|NCT02896205|DRUG|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
48665295|NCT02896205|DRUG|Placebo|Subjects will be given matching placebo for 6 months
48665296|NCT04653792|DRUG|Pregabalin 75mg|75 mg capsule
48665297|NCT04653792|DEVICE|Placebo|75 mg
48665298|NCT02746315|DRUG|HS-20004|
48665299|NCT02746315|DRUG|Placebo|
48665300|NCT01862003|DRUG|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
48665301|NCT01862003|DRUG|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
48354516|NCT01240772|DEVICE|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
48354517|NCT01240772|DEVICE|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
48354518|NCT03756285|DRUG|AZD4831|AZD4831 tablet taken orally for 90 days.
48354519|NCT03756285|DRUG|Placebo|Placebo tablet taken orally for 90 days.
48354520|NCT03519776|DIAGNOSTIC_TEST|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
48505318|NCT04630158|OTHER|SAF312 Placebo|Topical ocular, suspension eye drops
48505319|NCT04630158|DRUG|SAF312|Topical ocular, suspension eye drops
48505320|NCT05738317|DRUG|Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel|Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
48505321|NCT00637767|DRUG|melphalan|
48505322|NCT00637767|PROCEDURE|autologous hematopoietic stem cell transplantation|
48505323|NCT00637767|RADIATION|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
48505324|NCT03267563|BEHAVIORAL|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
48665302|NCT01862003|DRUG|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
48665303|NCT01862003|DRUG|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
48665304|NCT01862003|DRUG|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
48505325|NCT03267563|BEHAVIORAL|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
47987401|NCT06317155|OTHER|Occupational therapy|Occupation Therapy, specifically interoception informed interventions which aim to improve sensory integration and emotional regulation. Additionally, occupational therapy models which focus on augmenting well-being and functionality, facilitating participation and engagement within communities, and promoting involvement in meaningful activity.
47987402|NCT02135146|DRUG|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
47987403|NCT02135146|DRUG|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
47987404|NCT02111850|BIOLOGICAL|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
48505326|NCT03267563|BEHAVIORAL|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
48505327|NCT04180631|DIAGNOSTIC_TEST|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
48505328|NCT04494880|DRUG|Bupivacaine Injection|Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
48505329|NCT04888559|OTHER|Breakfast product: Whole grain|This intervention is a whole grain-based breakfast product containing oats and barley.
48505330|NCT04888559|OTHER|Breakfast product: Reference|This intervention is a rice-based breakfast product.
48505331|NCT04719260|BEHAVIORAL|Nutrition Thinking®|In the first session, the nutritionist will carry out the anamnesis through the Empathy Map and assessment of the nutritional status to define the Nutrition Briefing. The steps described by Design Thinking as understanding, observation, and point of view comprise the first phase of this session. The ideation process will proceed from the definition of the Nutrition Challenge. Prototyping is the final stage of the first session, where an initial prototype of the diet will be co-created based on visual thinking tools and the description underlying the creation of diets. Within 24 hours the individual will receive a summary of the material developed by email. The period between sessions will comprise the testing phase and the follow-up sessions the iteration phase where the experience and previous steps are revisited in order to create new insights, anthropometric measurements will be seen as reflections of the experience and not as primary outcomes of the intervention.
48505332|NCT04719260|BEHAVIORAL|Standard Nutritional Approach|In the first session the nutritionist will carry out the food and nutritional anamnesis and assessment of the nutritional status. From this information, the nutritionist will generate the diagnostic hypothesis and determine the specific nutritional needs. The professional will be responsible for generating the dietary prescription defining the characteristics of the diet that will be delivered printed to the individual after a period of 15 days, in the second session of the protocol. The follow-up session will be based on adherence to the established conduct and monitoring of anthropometric variations.
48505333|NCT06113016|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48505334|NCT06113016|OTHER|Educational Intervention|Receive handout on physical activity
48505335|NCT06113016|OTHER|Exercise Intervention|Receive individually tailored exercise intervention
48665305|NCT00582907|DRUG|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
48665306|NCT00582907|DRUG|Placebo|placebo by subcutaneous injection weekly for 3 months
47987405|NCT02111850|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
47987406|NCT02111850|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
47987407|NCT02111850|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
48505336|NCT06113016|DRUG|Fisetin|Given PO
48505337|NCT06113016|OTHER|Physical Performance Testing|Ancillary studies
48505338|NCT06113016|DRUG|Placebo Administration|Given PO
48505339|NCT06113016|OTHER|Quality-of-Life Assessment|Ancillary studies
48505340|NCT06113016|OTHER|Questionnaire Administration|Ancillary studies
48505341|NCT01953978|DRUG|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
48505342|NCT01953978|OTHER|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
48505343|NCT01953978|DRUG|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
48505344|NCT01953978|DRUG|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
48505345|NCT01953978|DRUG|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
48505346|NCT01953978|DRUG|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
48505347|NCT04067453|OTHER|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
48665307|NCT06563622|PROCEDURE|Pericapsular Nerves Group Block|USG-guided single-shot PENG in a dose of 0.5 ml/kg of 0.25% bupivacaine per side.
48665308|NCT06563622|PROCEDURE|Caudal Epidural Block|USG-guided single-shot CEB in a dose of 0.5 mL/kg of 0.25% bupivacaine.
48665309|NCT05901272|OTHER|Local clinical champion|A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
48665310|NCT05901272|OTHER|Learning collaborative|Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
48354521|NCT04678193|DRUG|Coromec Registry with ECL-19|Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
48354522|NCT03870893|BEHAVIORAL|hippotherapy|16weeks hippotherapy program
48354523|NCT05487092|DRUG|Letrozole|Letrozole 2.5mg daily for 6 months
48354524|NCT05487092|OTHER|Placebo|Placebo
48354525|NCT01981096|BEHAVIORAL|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
48354526|NCT01981096|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
48354527|NCT00971191|DRUG|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
48354528|NCT02357524|DRUG|Oritavancin|
48505348|NCT03536533|OTHER|Exergame|Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
48505349|NCT04131738|DRUG|Baricitinib|Baricitinib may be taken without regard to food. It should be taken at the same time every day.
48505350|NCT04708548|OTHER|Health-related Quality of Life|Health-related quality of life (HRQOL) is an individual's or a group's perceived physical and mental health over time.
47987408|NCT00438087|DRUG|methylprednisolone|methylprednisolone administrated intra and post operatively
48505351|NCT04708548|OTHER|Psychological Distress|Measured of the distress experienced by patients
48665311|NCT05901272|OTHER|External facilitation|. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
48665312|NCT05120804|BEHAVIORAL|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
48665313|NCT05120804|BEHAVIORAL|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus relationship skills training
47987409|NCT01172184|PROCEDURE|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
48002628|NCT01794403|RADIATION|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
48505352|NCT04708548|OTHER|Fatigue|Measure of the extreme tiredness resulting from mental or physical exertion or illness
48505353|NCT04708548|OTHER|Cognitive Functioning|Cognitive functioning refers to multiple mental abilities, including learning, thinking, reasoning, remembering, problem solving, decision making, and attention. This will be measured through self-report and cognitive testing.
48505354|NCT04384835|BIOLOGICAL|Blood sample collection (one tube)|Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
48665314|NCT05155982|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
48665315|NCT05155982|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
48505355|NCT04384835|BIOLOGICAL|Blood sample collection (five tubes)|Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
48505356|NCT06452667|PROCEDURE|platelet-rich fibin|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich fibin therapy on one side of the face. The other side of the face was treated with platelet-rich palsma.
48505357|NCT06452667|PROCEDURE|platelet-rich palsma|Each case will receive 3 sessions of microneedling therapies with one month interval. Each case will receive platelet-rich palsma therapy on one side of the face. The other side of the face was treated with platelet-rich fibin.
48505358|NCT00253448|RADIATION|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
48505359|NCT00253448|RADIATION|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
48665316|NCT06392425|OTHER|caspase 3 and ADAM 17 biomarkers|Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
48354529|NCT01859884|BEHAVIORAL|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
48665317|NCT03526263|PROCEDURE|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
48665318|NCT04541524|DEVICE|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
48665319|NCT05329220|BIOLOGICAL|ABNCoV2|ABNCoV2 100μg single dose
48354530|NCT05395728|OTHER|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
48665320|NCT05329220|BIOLOGICAL|Comirnaty|Comirnaty
48665321|NCT04044157|OTHER|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
48665322|NCT02563327|DRUG|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
48143853|NCT05697536|OTHER|Pilates training|"It consists of patients who will receive pilates exercise training sessions 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercise programs follow the basic principles of pilates method but particularly movements with low and medium difficulty levels will be chosen to adapt the program to the physical capacity of the patients.~Protocol will be compromise of 9 modules: postural education, search for neutral position, sitting exercise, antalgic exercise, stretching exercises, proprioceptively improvement exercises and breathing exercises."
48354531|NCT05395728|OTHER|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
48143854|NCT05697536|OTHER|Aerobic Exercise|"It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 45 minutes.~It will include warm up phase, active phase and"
48143855|NCT00916110|DRUG|ATN-103|1.5 mg solution, single subcutaneous injection
48354532|NCT05571852|DEVICE|CogniFit's CCT Post COVID-19|The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
48354533|NCT04474366|DRUG|Ropivacaine 0.2% Injectable Solution|Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block
48354534|NCT04474366|OTHER|Saline (0.9%)|Saline injection as sham block in identical fashion as Pectoralis Nerve Block
48354535|NCT04684706|DEVICE|intermittent Theta Burst Stimulation|The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
48354536|NCT05092867|OTHER|Po Tra tool|Healthcare workers filled the 2 VAS of the tool but it did not impact or change the care of the patient. (observational)
48665323|NCT02563327|DRUG|Moxifloxacin|A fluoroquinolone
48665324|NCT02563327|DRUG|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
48665325|NCT02563327|DRUG|Isoniazid|An anti-tuberculosis agent
48665326|NCT02563327|DRUG|Pyrazinamide|An anti-tuberculosis agent
48665327|NCT02563327|DRUG|Ethambutol|An anti-tuberculosis agent
48665328|NCT02563327|DIETARY_SUPPLEMENT|Pyridoxine|An essential vitamin
48665329|NCT01966146|DEVICE|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
48665330|NCT01359124|BEHAVIORAL|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
48143856|NCT00916110|DRUG|ATN-103|4 mg solution, single subcutaneous injection
48143857|NCT00916110|DRUG|ATN-103|10 mg solution, single subcutaneous injection
48143858|NCT00916110|DRUG|ATN-103|25 mg solution, single subcutaneous injection
48143859|NCT00916110|DRUG|ATN-103|25 mg solution, single intravenous injection
48143860|NCT00916110|DRUG|ATN-103|50 mg solution, single subcutaneous injection
48143861|NCT00916110|DRUG|ATN-103|100 mg solution, single subcutaneous injection
48143862|NCT00916110|DRUG|ATN-103|200 mg solution, single subcutaneous injection
48665331|NCT01359124|BEHAVIORAL|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
48665332|NCT01359124|BEHAVIORAL|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
48665333|NCT05903079|DEVICE|s-Tdcs|Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
48665334|NCT04627714|OTHER|Adapted Physical Activity|Intervention consists in 1h30/week of adapted fencing
48665335|NCT00784615|PROCEDURE|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
48665336|NCT00317811|DIETARY_SUPPLEMENT|ascorbic acid|
48665337|NCT00317811|DRUG|bortezomib|
48665338|NCT00317811|DRUG|melphalan|
48665339|NCT00753532|DIETARY_SUPPLEMENT|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
48665340|NCT02873728|PROCEDURE|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
48665341|NCT02873728|OTHER|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
48665342|NCT05759403|DIAGNOSTIC_TEST|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
48143863|NCT00916110|DRUG|ATN-103|200 mg solution, single intravenous injection
48143864|NCT01354080|OTHER|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
48143865|NCT01354080|OTHER|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
48143866|NCT03690466|DEVICE|Study device treatment|The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
48143867|NCT03690466|DEVICE|Sham device treatment|A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
48665343|NCT03690778|DRUG|"Metformin and Rosuvastatin seperately"|"administration of Metformin and Rosuvastatin seperately"
48665344|NCT03690778|DRUG|JLP-1310|administration of JLP-1310
48665345|NCT05745714|DRUG|Ruxolitinib|oral
48665346|NCT05745714|DRUG|Venetoclax|oral
48665347|NCT05745714|DRUG|Dexamethasone|oral/intravenous
48665348|NCT05745714|DRUG|Cyclophosphamide|intravenous
48665349|NCT05745714|DRUG|Cytarabine|intravenous
48665350|NCT05745714|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
48665351|NCT04603183|DRUG|Abemaciclib|Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
48665352|NCT04603183|DRUG|Paclitaxel|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
48665353|NCT04603183|DRUG|Letrozole|Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
48665354|NCT04603183|DRUG|Fulvestrant|Patients will receive 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
48665355|NCT00410579|OTHER|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
48665356|NCT05334238|DRUG|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
48505360|NCT04641585|DIAGNOSTIC_TEST|Patients affected by Brugada Syndrome 1|ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
48665357|NCT06008444|OTHER|Physical Evaluations of post-COVID-19 individuals|In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
48665358|NCT06008444|OTHER|Physical Evaluations of non-post-COVID-19 individuals|In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
48665359|NCT05132972|BIOLOGICAL|Normoxic Allogenic UCMSC|Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10\^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)
48665360|NCT05132972|OTHER|Normal saline solution|Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
48665361|NCT00523978|DEVICE|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
48665362|NCT00523978|DRUG|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
48665363|NCT01677988|DRUG|Neo-adjuvant Chemotherapy|"1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
48665364|NCT01677988|RADIATION|Chemoradiation|"1. Chemoradiation may be administered at selected approved CTN sites.~2. Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~   1. Unresectable → Off study. Subsequent treatment per patient's primary MD.~  2. Resectable → Continue to Registration #3 for Surgical Resection"
48665365|NCT01677988|PROCEDURE|Surgical Resection|"1. Meets criteria for resectable\* →pancreaticoduodenectomy (POD)~2. At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
48665366|NCT00929266|BIOLOGICAL|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
48665367|NCT04517435|DRUG|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
48665368|NCT04517435|DRUG|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
48665369|NCT04517435|DRUG|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
48665370|NCT04517435|DRUG|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
48665371|NCT04517435|DRUG|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
48665372|NCT04517435|DRUG|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
48505361|NCT01405014|BEHAVIORAL|Hold Me Tight|Relationship enhancement group
47987410|NCT06002347|BEHAVIORAL|STAC Parent Module for Middle School|"The STAC Parent Module is a 30-minute pre-recorded online presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies parents can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
48505362|NCT02940132|DRUG|SC10914|SC10914 will be administered orally.
48665373|NCT00422487|DRUG|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
48354537|NCT05067010|OTHER|Detailed ophthalmologic examination|"* Visual acuity~* Eye pressure measurement~* Eye crystalline examination~* Fundus examination~* Optical coherence tomography of the retina~* Retinophotos"
48665374|NCT00422487|DRUG|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
48665375|NCT00422487|DRUG|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
48665376|NCT00422487|DRUG|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
48665377|NCT00422487|DRUG|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
48665378|NCT00422487|DRUG|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
48665379|NCT00422487|DRUG|Placebo for MBX-2044|Placebo Intervention
48665380|NCT02969135|BEHAVIORAL|Progressive early passive and active movement|Post-surgical physical therapy including active exercise
48665381|NCT02969135|BEHAVIORAL|Limited early passive movement|Post-surgical physical therapy including passive mobilisation
48665382|NCT02935764|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
48665383|NCT02935764|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
48665384|NCT02935764|DRUG|Leucovorin|400mg/m2 iv gtt,d1
48665385|NCT03669887|BEHAVIORAL|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
48665386|NCT01784029|DRUG|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
48665387|NCT02983409|RADIATION|Pstone|A adult patients who were diagnosed as urinary stone by the urinary CT
48665388|NCT03787654|DEVICE|electroacupuncture|"BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60\~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total."
48665389|NCT03787654|DEVICE|sham electroacupuncture|"In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group."
48665390|NCT03787654|DRUG|Solifenacin|Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
48665391|NCT02434081|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
48665392|NCT00213070|DRUG|Miglitol|
48665393|NCT01685684|DRUG|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
47987411|NCT04123847|OTHER|Standing and Stepping|Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.
48354538|NCT05350800|DRUG|BMS-986369|Specified dose on specified days
48665394|NCT01685684|DRUG|Placebo|Placebo, divided into 2 doses, q12h
48665395|NCT03674281|DEVICE|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
48665396|NCT03674281|DEVICE|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
48354539|NCT02080494|DRUG|Tranexamic Acid|
48354540|NCT03517735|DEVICE|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
48505363|NCT05942625|DRUG|HS-10390 tablet|Oral administration of specified dose of HS-10390
48505364|NCT05942625|DRUG|Placebo tablet|Oral administration of matching dose ofplacebo
48665397|NCT06205121|DRUG|OATD-01|OATD-01 is an oral inhibitor of chitinase-1 (CHIT1)
48665398|NCT06205121|DRUG|Placebo|Matching placebo tablets
48665399|NCT01276626|DIETARY_SUPPLEMENT|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
48665400|NCT01276626|OTHER|Maltodextrin|Powder containing only maltodextrin
48665401|NCT03663582|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
48665402|NCT03663582|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
48665403|NCT03663582|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
48665404|NCT03663582|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
48354541|NCT03517735|DRUG|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
48354542|NCT03517735|DRUG|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
48354543|NCT00716040|BEHAVIORAL|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
48354544|NCT00716040|OTHER|Usual care|The control group will be submitted to the usual care of the health service
48354545|NCT04142840|DRUG|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
48354546|NCT04142840|DRUG|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
48354547|NCT04780594|PROCEDURE|The study evaluates all surgical patients operated, both elective scheduled and emergent cases|Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
48354548|NCT01751243|OTHER|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
48354549|NCT01751243|OTHER|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
48354550|NCT06355206|COMBINATION_PRODUCT|endoscopic intervention, surgery or conservative treatment|Personal information and treatment of the enrolled subjects will be collected.
48354551|NCT05283499|DRUG|OPIOID|Analgesic assignment
48505365|NCT03058094|DRUG|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
48505366|NCT03058094|DRUG|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
48505367|NCT03058094|DRUG|AC0010|300mg, orally, BID
48505368|NCT04639492|DIETARY_SUPPLEMENT|MBS oral solution|Oral BIDAC, twice a day before breakfast and dinner times
48505369|NCT05287256|DRUG|Oral Delta-8-THC Cannabis|Delta-8-THC cannabis will be orally self-administered by study participants
47987412|NCT04123847|DEVICE|Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation|Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
48354552|NCT05283499|DRUG|NON-OPIOID|Analgesic assignment
48354553|NCT00451074|DRUG|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
48354554|NCT02094196|OTHER|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
48505370|NCT05287256|DRUG|Oral Delta-9-THC Cannabis|Delta-9-THC cannabis will be orally self-administered by study participants
48505371|NCT05287256|DRUG|Oral Placebo|Placebo will be orally self-administered by study participants
48505372|NCT05287256|DRUG|Vaporized Delta-8-THC Cannabis|Delta-8-THC cannabis will be self-administered by study participants using a vaporizer
48354555|NCT01680562|OTHER|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
48354556|NCT03930927|DRUG|Self Assembling peptide|enamel regeneration
48354557|NCT03930927|DRUG|remineralizing agent|enamel regeneration
48505373|NCT05287256|DRUG|Vaporized Delta-9-THC Cannabis|Delta-9-THC cannabis will be self-administered by study participants using a vaporizer
48505374|NCT05287256|DRUG|Vaporized Placebo|Placebo will be self-administered by study participants using a vaporizer
48665405|NCT01951391|OTHER|Control Hand Soap|Commercially available soap will be used to wash the subject's forearms
48665406|NCT01951391|OTHER|Benzalkonium Chloride Soap|Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms
48665407|NCT01951391|OTHER|Triclocarban Soap|Commercially available soap containing triclocarban will be used to wash the subject's forearms
48665408|NCT03972527|DEVICE|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
48665409|NCT03972527|OTHER|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
48665410|NCT00789555|DRUG|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
48665411|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
48665412|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
48665413|NCT05664373|PROCEDURE|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
48143868|NCT03559296|DIAGNOSTIC_TEST|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
48143869|NCT04139486|PROCEDURE|combined EMBOTRAP II or III and Contact Aspiration|refer to title
48505375|NCT04875936|BEHAVIORAL|Motor Imagery and Real-Time fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will use right-hand motor imagery coupled with fMRI neurofeedback to help them re-engage the left hemisphere by shifting brain activation leftward relative to the initial left-right asymmetry. Following group assignment, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. During the MRI sessions they will receive real time neurofeedback about how well they are engaging the left side of their brain compared to the right side. They will also practice the same task for 30 min a day as homework using the most effective motor imagery strategy that worked for them in the MRI scanner.
48665414|NCT01252680|BIOLOGICAL|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
48665415|NCT01252680|BIOLOGICAL|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
48665416|NCT01252680|BIOLOGICAL|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
48665417|NCT01252680|BIOLOGICAL|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
48665418|NCT04883138|DRUG|GIGA-2050|Recombinant Hyperimmune Polyclonal Antibody
48665419|NCT03342560|DEVICE|Sonographic SWE measurements with 4 different ultrasound systems|Sonographic Shear wave elastography will be performed to quantify liver fibrosis
48665420|NCT02001246|BEHAVIORAL|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
48505376|NCT04875936|BEHAVIORAL|Motor Imagery and Sham fMRI Neurofeedback|Survivors of left-hemisphere stroke (\<10 weeks post-stroke) or healthy volunteers will practice right-hand motor imagery coupled with sham fMRI neurofeedback. As the experimental group, participants will perform a motor imagery task and complete 3 sessions of motor imagery and reading tasks in the MRI scanner over 3 weeks. However, during the MRI sessions they will receive sham neurofeedback on the basis of another participant's brain activity. Like the experimental group, they will also practice the same task for 30 min a day as homework.
48665421|NCT02001246|BEHAVIORAL|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
48505377|NCT06093438|DRUG|Toripalimab|Patients enrolled in this arm would receive three cycles of induction treatment before receiving definitive chemoradiotherapy. The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d. Patients would receive pelvic MRI to evaluate the regression status of tumor after three cycles of induction treatment. Patients with satisfying tumor regression would receive definitive chemoradiotherapy afterwards. During chemoradiotherapy, patients would receive weekly cisplatin (40mg/m2) and 240mg toripalimab every three weeks. After chemoradiotherapy, patients would receive another three cycles of consolidated treatment (regimen identical to induction treatment).
48505378|NCT03460314|DRUG|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
48505379|NCT01269333|DRUG|omeprazole|omeprazole 20mg for 7 days
48505380|NCT01269333|DRUG|fluvoxamine|fluvoxamine 50mg for 7 days
48505381|NCT01269333|DRUG|placebo|placebo for 7 days
48505382|NCT00163488|DRUG|Ciclesonide|
48665422|NCT05762432|DEVICE|Wound Dressing|RTD Wound Dressing that is being investigated
48665423|NCT05762432|DEVICE|NHS Standard Dressing|This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
47987413|NCT01354847|DEVICE|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
48143870|NCT04139486|PROCEDURE|Contact Aspiration alone|refer to title
48665424|NCT01708044|DRUG|Pramlintide acetate|
48665425|NCT01708044|OTHER|Placebo|Placebo Comparator
48665426|NCT03830437|OTHER|Evaluation of newborn stress|Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
48665427|NCT03830437|OTHER|Evaluation of body weight trend|Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
48665428|NCT02017184|BIOLOGICAL|Noninvasive core temperature thermistor|
48665429|NCT03532360|OTHER|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
48665430|NCT03048370|PROCEDURE|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
48665431|NCT03048370|PROCEDURE|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
48665432|NCT03048370|PROCEDURE|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
48665433|NCT03048370|PROCEDURE|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
48665434|NCT03048370|PROCEDURE|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
48665435|NCT03048370|PROCEDURE|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
48665436|NCT00614224|BEHAVIORAL|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
48665437|NCT02347384|DEVICE|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head \& SL-TWIN Stem
48665438|NCT02347384|DEVICE|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head \& SL-PLUS Stem
48665439|NCT00056823|DRUG|rhuFab V2 (ranibizumab)|
48665440|NCT03195569|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
48665441|NCT03195569|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
48665442|NCT03195569|DRUG|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
48665443|NCT03195569|DRUG|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
48665444|NCT05772871|DRUG|Huaiqihuang granule|Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
48665445|NCT05772871|DRUG|Prednisone|Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
48665446|NCT05772871|DRUG|Levamisole placebo|Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
48665447|NCT05772871|DRUG|Levamisole|Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
47987414|NCT04729569|PROCEDURE|Feather edge finish line preparation|Tooth preparation with feather edge finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
48354558|NCT04715659|DIAGNOSTIC_TEST|Performance of step test (number of steps) for the assessment of exercise capacity|"The development of the step test will be designed according to the characteristics of other validated field tests - the walking tests (6-minute walk test and the incremental shuttle walking test) The step test will be performed on a 20 cm tall, single-step device with no handles. The criteria for stopping the test will be the same as described in standard operating procedures for the walking field tests, with the addition of the inability to follow the work rate for a period of 10 seconds.~The main outcome of the test will be the highest number of steps and work rate achieved."
48354559|NCT03721549|BIOLOGICAL|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
48143871|NCT03979040|BEHAVIORAL|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
48354560|NCT01332851|BEHAVIORAL|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
48665448|NCT05772871|DRUG|Huaiqihuang Granule placebo|Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
48665449|NCT04243486|DRUG|UHE-105|Topical shampoo containing active drug
48665450|NCT04243486|DRUG|Vehicle|Topical shampoo containing no active drug
48354561|NCT01332851|BEHAVIORAL|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
48354562|NCT05278884|BEHAVIORAL|Advanced Cardiac Life Support Training|Advanced Cardiovascular Life Support (ACLS) is a resuscitation course to teach recognition and treatment of cardiopulmonary arrest in patients.
48354563|NCT05278884|BEHAVIORAL|Vital Anesthesia Simulation Training|The Vital Anesthesia Simulation Training (VAST) Course focuses on core clinical practices and non-technical skills needed to respond to the most common urgent and emergent clinical challenges found in hospitals in resource-limited settings like Rwanda.
48354564|NCT00414973|DRUG|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
48354565|NCT00414973|DRUG|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
48505383|NCT05458180|DRUG|Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)|"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."
48665451|NCT01966627|OTHER|ogtt|oral glucose tolerance test
48665452|NCT01966627|OTHER|genotyping|genotyping to look for risk alleles
48665453|NCT01966627|OTHER|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
47987415|NCT04729569|PROCEDURE|Deep chamfer finish line preparation|Tooth preparation with deep chamfer finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
48354566|NCT03028532|DRUG|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
48354567|NCT06367335|DRUG|Ribociclib, palbociclib, abemaciclib|evaluate the presence of predictors useful to predict the development of DILI during treatment with CKI
48354568|NCT06258265|DRUG|TAK-279|TAK-279 capsule.
48354569|NCT06258265|DRUG|TAK-279 Placebo|TAK-279 matching placebo capsule.
48354570|NCT06258265|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
48354571|NCT06258265|DRUG|Moxifloxacin Placebo|Moxifloxacin matching placebo capsule.
48354572|NCT06238349|DRUG|Oral bifidobacterium triple live powder|The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8℃ away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
48665454|NCT01966627|OTHER|stool sample|stool sample taken to investigate metabolites
48665455|NCT01966627|OTHER|liver biopsy|liver biopsy to examine for cellular change and steatosis
47987416|NCT02221284|DRUG|Alogliptin|Alogliptin tablets
48665456|NCT01441960|DRUG|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
48354573|NCT06238349|OTHER|Sunbathing|The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
48505384|NCT03748030|RADIATION|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
48505385|NCT03516253|DIETARY_SUPPLEMENT|Fish oil + EPO|Supplementation with both fish oil and EPO
48505386|NCT02782806|DEVICE|Masimo Rad-67 Pulse Oximeter|Noninvasive pulse oximeter
48505387|NCT05164887|PROCEDURE|Laparoscopic colorectal resection|the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
48505388|NCT01094886|DRUG|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
48505389|NCT03196635|DEVICE|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC \& MLO.
48505390|NCT03196635|DEVICE|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
48505391|NCT05469555|PROCEDURE|High Resolution Oesophageal Manometry|High Resolution Oesophageal manometry assesses how well the muscles of the oesophagus are working when you swallow. It also checks the relaxation of the valves at the top and bottom of the oesophagus.
48505392|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
48505393|NCT01548118|BIOLOGICAL|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
48505394|NCT01548118|BIOLOGICAL|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
48505395|NCT01548118|BIOLOGICAL|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
48505396|NCT01028924|DRUG|Teduglutide|subcutaneous (SC), single dose
48505397|NCT00790335|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
48505398|NCT02326441|DRUG|KX2-361|
48505399|NCT02422589|DRUG|ceritinib|
48505400|NCT02422589|DRUG|warfarin|
48505401|NCT02422589|DRUG|midazolam|
48505402|NCT05876767|DRUG|SAR444336|Single or repeated dose subcutaneous injection
48665457|NCT01441960|DRUG|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
48505403|NCT05876767|DRUG|Placebo|Single or repeated dose subcutaneous injection
48505404|NCT01796418|DRUG|Beraprost sodium|
48665458|NCT05821946|OTHER|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
48665459|NCT01664624|DRUG|Roflumilast|Roflumilast tablets
48143872|NCT03979040|BEHAVIORAL|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and Depression (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
48143873|NCT02314975|DEVICE|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
48143874|NCT02314975|DEVICE|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
48143875|NCT02314975|OTHER|Fixed appliance only|Fixed appliance treatment only
48143876|NCT02260973|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
48143877|NCT01696500|DRUG|Intravenous immunoglobulin|
48143878|NCT05636345|OTHER|pain science education|A full day of pain science education
48143879|NCT03052517|DRUG|QAW039 150 mg|One tablet of QAW039 150 mg once daily
48143880|NCT03052517|DRUG|QAW039 450 mg|One tablet of QAW039 450 mg once daily
48143881|NCT03052517|DRUG|Placebo|One tablet of Placebo once daily
48143882|NCT00506025|DIETARY_SUPPLEMENT|Cranberry Juice|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
48505405|NCT03168581|DRUG|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
48505406|NCT05742763|COMBINATION_PRODUCT|Ibuprofen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
47987417|NCT06180590|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Evaluate the efficacy of Vosevi in DAAs-experienced patients
47987418|NCT04099927|DRUG|SHR0410|SHR0410 monotherapy,given intravenously
47987419|NCT02968927|DRUG|Everolimus 0.5 MG|
47987420|NCT02968927|DRUG|Auranofin 6 MG|
47987421|NCT02968927|DRUG|Vitamin D3|
47987422|NCT02968927|DRUG|CC-11050|
47987423|NCT02968927|DRUG|2HRbZE/4HRb|
47987424|NCT05483855|OTHER|Objective 1 Only: Telehealth Satisfaction Survey|Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
47987425|NCT05483855|OTHER|Objective 2 Only: ArthritisPower Joint Assessment|RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
48002629|NCT00393679|DRUG|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
48143883|NCT00506025|DIETARY_SUPPLEMENT|De-Activated Cranberry juice|De-Activated Cranberry juice in the am, then placebo (P) in the pm
48143884|NCT04373772|OTHER|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
48143885|NCT01111006|DEVICE|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
48143886|NCT05437328|BIOLOGICAL|bi-4SCAR GD2/CD56 T cells|Infusion of bi-4SCAR GD2/CD56 T cells at 10\^6 cells/kg body weight via IV
48143887|NCT04017299|OTHER|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
48143888|NCT03072706|DEVICE|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
48143889|NCT03072706|OTHER|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
48665460|NCT01664624|DRUG|Alogliptin|Alogliptin tablets
48665461|NCT01664624|DRUG|Exenatide|Exenatide solution
48665462|NCT01664624|DRUG|Placebo to roflumilast|Placebo-matching roflumilast tablets
48665463|NCT01664624|DRUG|Placebo to alogliptin|Placebo-matching alogliptin tablets
48143890|NCT04266626|OTHER|kinesiotaping therapy|Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
48143891|NCT04266626|OTHER|oral motor manipulation therapy|Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
48143892|NCT05729126|OTHER|Questionnare|A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
48354574|NCT06238349|OTHER|Sunbathing and the Oral bifidobacterium triple live powder|The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
48505407|NCT05742763|COMBINATION_PRODUCT|Acetaminophen and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
48505408|NCT05742763|COMBINATION_PRODUCT|Placebo and PRP|The primary research purpose is to determine if the use of ibuprofen \[arm #1\] vs acetaminophen \[arm #2\] vs a placebo control group \[arm #3\] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
48505409|NCT01794559|DEVICE|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
48665464|NCT00116571|DRUG|Lemuteporfin for injection|
48665465|NCT00116571|DEVICE|Transurethral drug delivery system|
48665466|NCT00116571|DEVICE|Transurethral light delivery system|
48665467|NCT04857060|BEHAVIORAL|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
48665468|NCT00970398|OTHER|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
48665469|NCT00970398|OTHER|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
48665470|NCT00506623|DRUG|Capecitabine, Irinotecan|
48665471|NCT05572294|BEHAVIORAL|Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy|Sickle cell patients admitted with a vaso-occlusive pain crisis over a consecutive 12-week period will be offered participation in the study. After providing informed consent, participants will have access to 4 videos containing guided mindfulness meditation, breathing exercises, and gentle yoga therapy. The videos are 5-12 minutes long and taught by a physical therapist who is also certified in yoga therapy. Participants may turn off the video at any time. Participants will have access to the videos for the duration of their hospitalization, and they may watch the videos as many times as they desire.
48354575|NCT06238349|OTHER|Conventional treatment|Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.
48665472|NCT05787015|BEHAVIORAL|Vaccine Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about vaccination rates and hesitant attitudes.
48143893|NCT02393456|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
48143894|NCT02393456|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
48143895|NCT03902626|OTHER|Physiotherapy students|
48143896|NCT03902626|OTHER|Medical students|
48143897|NCT02964793|OTHER|intervention group|"The intervention will include~1. clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~2. the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~3. the use of the EFW values mentioned on US report, to plot EFW on the customised chart~4. and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
48143898|NCT02845921|OTHER|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
48143899|NCT02845921|OTHER|leg wrapping|Esmarch bandage is used to wrap each lower limb
48143900|NCT02845921|OTHER|control|no intervention has been done
48505410|NCT05998512|OTHER|Observational register|This is a non-interventional observational registry on patients
48665473|NCT05787015|BEHAVIORAL|Alcohol Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about alcohol use.
48665474|NCT00943644|DEVICE|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
48665475|NCT00943644|DEVICE|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
48143901|NCT05479708|DEVICE|ctDNA-based MRD detection|Postoperative circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection for predicting relapse and survival benefit
48143902|NCT04321109|OTHER|Allograft|Corticocancellous mineralized allograft
48143903|NCT04321109|OTHER|Collagen cone|Collagen matrix
48143904|NCT04346784|BEHAVIORAL|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
48143905|NCT04346784|BEHAVIORAL|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
48143906|NCT04346784|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
48143907|NCT04346784|BEHAVIORAL|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
48665476|NCT04501432|OTHER|No intervention|This study does not include an intervention
48665477|NCT01777061|DRUG|[11C]Acetate|intravenous injection of an average of 40 mCi of \[11C\]Acetate
48665478|NCT03986957|OTHER|No interventions|No interventions - observational study
48665479|NCT02897336|PROCEDURE|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
48665480|NCT02897336|PROCEDURE|interlaminar|interlaminar epidural corticosteroid injection
48665481|NCT04870866|DRUG|Nicotinamide ribonucleoside|Two year intervention
48354576|NCT01172990|PROCEDURE|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (\< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
48505411|NCT05592314|OTHER|No intervention|No intervention
48665482|NCT04616898|DEVICE|Venus Bliss|The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
48665483|NCT02550002|DRUG|Aflibercept|Intravitreal injection
48665484|NCT02998229|DEVICE|Artisse™ Intrasaccular Device|Intrasaccular Device
48665485|NCT03260712|DRUG|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
48665486|NCT03260712|DRUG|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
48665487|NCT03260712|DRUG|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
48665488|NCT00344981|DRUG|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
48665489|NCT00344981|DRUG|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches \>400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
48665490|NCT02815163|OTHER|Empowerment education|"1. admission (1 hour)~   ▪partnership~2. 2 ds after THR (30-45min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~3. 2 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~4. 6 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~5. 10 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback"
48665491|NCT00861887|DRUG|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
48665492|NCT00861887|DRUG|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
48665493|NCT00772057|DRUG|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
48665494|NCT00772057|DRUG|Placebo|Placebo tablets given two times daily.
48665495|NCT04069442|OTHER|This is a non-interventional study|This is a non-interventional study
48665496|NCT03085901|DEVICE|Precizon toric intraocular lens|Phacoemulsification and implantation of Precizon toric intraocular lens
48143908|NCT04997798|DRUG|Trastuzumab Pyrotinib Exemestane Dalpiciclib|Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
48354577|NCT01172990|PROCEDURE|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
48354578|NCT02663115|OTHER|Biopsy of the diaphragmatic muscle|
48505412|NCT03516279|DRUG|Dasatinib|Given PO
48505413|NCT03516279|DRUG|Imatinib Mesylate|Given PO
48505414|NCT03516279|OTHER|Laboratory Biomarker Analysis|Correlative studies
48505415|NCT03516279|DRUG|Nilotinib|Given PO
48665497|NCT03085901|DEVICE|Tecnis toric intraocular lens|Phacoemulsification and implantation of Tecnis toric intraocular lens
48505416|NCT03516279|BIOLOGICAL|Pembrolizumab|Given IV
48505417|NCT01746459|OTHER|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
48143909|NCT01279694|DRUG|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
48354579|NCT02663115|OTHER|Skeletal muscle biopsy|
48354580|NCT03416972|RADIATION|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
48354581|NCT02875366|DRUG|LUM/IVA|
48665498|NCT03837509|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
48665499|NCT03837509|BIOLOGICAL|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
48665500|NCT03767868|OTHER|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
48665501|NCT02702050|OTHER|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
48354582|NCT02875366|DRUG|Placebo|
48665502|NCT02702050|OTHER|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
48665503|NCT00060944|DRUG|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
48665504|NCT00060944|DRUG|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
48665505|NCT00060944|DRUG|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
48665506|NCT00060944|DRUG|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
48665507|NCT03563547|BEHAVIORAL|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
48665508|NCT03563547|BEHAVIORAL|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
48665509|NCT02988908|DRUG|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
48354583|NCT04726566|PROCEDURE|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
48354584|NCT04726566|PROCEDURE|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
48505418|NCT01746459|OTHER|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
48505419|NCT04516993|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
48505420|NCT04516993|DRUG|The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)|Best treatment arm
48505421|NCT06633081|DEVICE|handheld dynamometer|handheld dynamometer is a device that measure muscle strength
48665510|NCT02988908|DRUG|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
48665511|NCT06449560|OTHER|Practice Group|Participants in this group engage in the traditional core course (1-hour lecture on upper limb soft tissue differential diagnosis and assessment techniques. They have the opportunity to observe teacher demonstrations, and the course content and instructional demonstrations are consistent and delivered by the same therapist), followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.
48665512|NCT06449560|OTHER|Video Feedback Group|Participants receive the traditional core course (as the same in the practice group) along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
48665513|NCT04862754|OTHER|interval training exercise|interval training exercise
48665514|NCT04337151|DEVICE|MAGEC Spine Rod|Magnetically controlled growing spine rod used for the surgical treatment of scoliosis.
48002630|NCT00393679|DRUG|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
48002631|NCT00393679|DRUG|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
48143910|NCT01279694|DRUG|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
48143911|NCT01279694|DRUG|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
48143912|NCT06428656|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule of postbiotics supplement per day
48143913|NCT06428656|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule of placebo per day
48665515|NCT04337151|DIAGNOSTIC_TEST|Titanium blood test|A blood test captured to measure the level of titanium
48665516|NCT03089814|PROCEDURE|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
48665517|NCT02740985|DRUG|AZD4635|AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
48665518|NCT02740985|DRUG|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
48665519|NCT02740985|DRUG|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
48665520|NCT02740985|DRUG|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
48665521|NCT02740985|DRUG|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
48665522|NCT02740985|DRUG|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
48665523|NCT05077969|DRUG|Famotidine|80 mg tablet, QID for 14 days
48665524|NCT05077969|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
48665525|NCT05077969|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
48665526|NCT04256850|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Teaches acceptance, mindfulness, and values-based skills
48665527|NCT04256850|BEHAVIORAL|Self-Regulation (SR)|Teaches monitoring and reinforcement strategies designed to improve motivation and adherence to positive weight loss behavioral prescriptions.
48665528|NCT03688971|DRUG|Omiganan|Omiganan Topical Gel
48665529|NCT03688971|DRUG|Ketoconazole|Ketoconazole Cream
48665530|NCT03688971|DRUG|Placebo|Vehicle
48665531|NCT00340054|OTHER|questionnaire administration|
48665532|NCT00340054|PROCEDURE|study of high risk factors|
48665533|NCT06467409|DRUG|Placebo|patient-controlled analgesia(PCA) administration
48665534|NCT06467409|DRUG|morphine hydrochloride injection|patient-controlled analgesia(PCA) administration
48665535|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
48665536|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
48665537|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
48665538|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
48665539|NCT04705805|BEHAVIORAL|Self-assessment of olfactory disorders through two questionnaires.|"* Assessment of sense of smell or loss of smell using an Analogue Visual Scale~* Carrying out the objective smell test (Sniffin' sticks test) (gold standard)~* Information from two self-questionnaires translated into French: a quality of life questionnaire (The Questionnaire Olfactory Disorders (QOD)) and a self-assessment questionnaire of his olfactory capacities (Self-Mini Olfactory Questionnaire (Self-MOQ))"
48143914|NCT02234999|DRUG|CC-122|3mg \[14C\]-CC-122 will be administered as a single dose
48143915|NCT04470089|DRUG|Myramistin|Oromucosal application
48143916|NCT01294644|DRUG|Deoxycholic acid injection|
48665540|NCT06397092|PROCEDURE|transapical beating-heart septal myectomy|The patients with hypertrophic cardiomyopathy undergoing TA-BSM
48143917|NCT01294644|DRUG|Placebo|Phosphate buffered saline placebo for injection
48143918|NCT00561249|PROCEDURE|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
48143919|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
48143920|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
48665541|NCT01428791|BEHAVIORAL|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
48665542|NCT01428791|BEHAVIORAL|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health \& health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
48665543|NCT03028701|DRUG|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
48665544|NCT04879407|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
48665545|NCT04879407|DRUG|Warfarin|Any warfarin dispensing claim is used as the reference group
48354585|NCT02309372|BEHAVIORAL|Beating the Blues|Computerized depression treatment intervention
48354586|NCT05841277|DRUG|LY3819469|Administered SC.
48354587|NCT00025090|DRUG|cisplatin|
48354588|NCT00025090|DRUG|fluorouracil|
48354589|NCT00025090|DRUG|mitomycin C|
48665546|NCT00420186|DRUG|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
48665547|NCT02408744|DRUG|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
48665548|NCT01450345|DRUG|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
48665549|NCT01923376|DRUG|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
48665550|NCT01923376|DRUG|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
48354590|NCT00025090|RADIATION|radiation therapy|
48354591|NCT05015062|BEHAVIORAL|Mobile-based HIV-related educational message delivery|HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
48354592|NCT05015062|BEHAVIORAL|Incentive policies evaluation|village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
48665551|NCT05472142|OTHER|UP FOR IT - practice facilitation|"Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices."
48665552|NCT05472142|OTHER|UP FOR IT - health information technology|Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
48143921|NCT01434732|PROCEDURE|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
48143922|NCT01434732|PROCEDURE|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
48143923|NCT05514678|BEHAVIORAL|Cognitive Stimulation Therapy|CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
48354593|NCT06161233|DEVICE|CAPABLE cohort|The CAPABLE cohort receives the mobileapplication and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months. The CAPABLE app serves three main functionalities for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing
48665553|NCT03825627|DEVICE|Transcranial Direct Current Stimulation|"Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total)."
48665554|NCT00427037|DRUG|Cholecalciferol|50,000 IU weekly by mouth
48665555|NCT00427037|DRUG|Placebo|identical placebo pill orally by mouth
48665556|NCT05308121|OTHER|Evaluation of biomechanics and viscoelastic properties of Achilles tendon|The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from two different points with the ankle in the neutral position.
48665557|NCT05308121|OTHER|Evaluation of foot characteristics|The mobility of foot, morphological changes of foot and foot posture will be evaluated
48665558|NCT02614820|PROCEDURE|Remote Ischemic Preconditioning Training Apparatus|
48665559|NCT04193735|DIAGNOSTIC_TEST|MRI scans after a liquid meal|Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times
48665560|NCT02406417|DEVICE|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
48665561|NCT02406417|DEVICE|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
48665562|NCT02862093|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
48665563|NCT02511106|DRUG|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
48665564|NCT02511106|DRUG|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
48665565|NCT02511106|DRUG|Open-label AZD9291 80 mg/40 mg|Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
48665566|NCT04820023|DRUG|BBT-176|BBT-176 given orally alone
48665567|NCT04983043|DRUG|Low dose QiShen YiQi Dripping Pills 3 bags|Low dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 2 bags(0.52g dripping pills per bag) and QiShen YiQi Dripping Pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
48665568|NCT04983043|DRUG|High dose QiShen YiQi Dripping Pills 3 bags|High dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
48665569|NCT04983043|DRUG|QiShen YiQi Dripping Pills placebo 3 bags|QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
48665570|NCT01135966|BEHAVIORAL|Conventional resistance training program|Conventional resistance training program is followed.
48665571|NCT01135966|BEHAVIORAL|Whole body vibration resistance training program|WBV training on FITVIBE
48665572|NCT02051426|OTHER|D-serine|single P.O. administration of D-serine (2.1g)
48665573|NCT02051426|OTHER|Placebo|single P.O. administration of Placebo
48665574|NCT06289374|OTHER|Biosample collection|Collection of saliva, urine, blood, breath and quality of life questionnaires.
48665575|NCT06544070|DEVICE|Entia Liberty System|Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
48665576|NCT03398330|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
48143924|NCT00488267|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
48143925|NCT00488267|DRUG|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
48143926|NCT00488267|DRUG|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
48143927|NCT00022490|DRUG|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
48143928|NCT00022490|DRUG|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
48143929|NCT02064283|PROCEDURE|Diffusion MRI|
48665577|NCT03398330|DRUG|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
48665578|NCT01935453|BIOLOGICAL|Recombinant hGM-CSF Herpes Simplex Virus Injection|
48665579|NCT02940548|DRUG|Nifedipine GITS|Nifedipine GITS 30\~60mg/day for 8 weeks
48665580|NCT02940548|DRUG|Amlodipine besylate|Amlodipine besylate 5\~10mg/day for 8 weeks
48665581|NCT05782348|BEHAVIORAL|Cognitive behavioral intervention|A six-session CBI Intervention component will be used with the TEST GROUP I. This will examine a cognitive behavioral intervention designed to improve tooth brushing and oral hygiene. The components include oral health education, values-based activities, motivational interviewing, goal setting, problem solving skills, cognitive restructuring, verbal reinforcement and stress management.
48665582|NCT05782348|OTHER|Colgate smart toothbrush|A Colgate smart toothbrush that provides the user with details on toothbrushing habits and frequency
48665583|NCT00749346|DEVICE|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
48665584|NCT02327377|BEHAVIORAL|Online Cognitive Behavior Therapy|
48143930|NCT05637944|PROCEDURE|oro tracheal intubation|chest trauma requiring oro tracheal intubation
48143931|NCT00201825|DRUG|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
48665585|NCT02327377|BEHAVIORAL|Online Education|
48665586|NCT03498573|OTHER|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
48665587|NCT06034626|PROCEDURE|Intense pulsed light|Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
47987426|NCT06279377|OTHER|Stabilization Exercises|"* Stabilizer Pressure Biofeedback device will be used in deep neck flexors training. Once the starting level is determined, training will be carried out with 2 mmHg pressure increases until the target value is 30 mmHg.~* During the exercises performed with the elastic resistance band, the patient will be asked to move the band with his hands (neck extension, right-left lateral flexion).~* During the exercises with the elastic ball, you will be asked to press your head on the ball at 90 degree angles (in 4 positions).~* Exercises will be performed in 10 repetitions by maintaining muscle contraction for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the color of the elastic resistance band or the level of the exercise will be changed and continued."
48665588|NCT06034626|DRUG|0.3% hyaluronic acid eye drops|0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
48665589|NCT01471184|DEVICE|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
48665590|NCT01471184|DEVICE|Placebo|Placebo Eye Drops/Nasal Spray
47987427|NCT06279377|OTHER|Standard Exercises|"* Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Cervical movements will be limited to approximately 30 degrees in the early period.~* As posture exercises, you will be asked to do scapular retraction and turning your shoulders forward and backward. In addition to these movements, pectoral stretching, anterior and posterior capsule stretching exercises will be performed.~* Elastic resistance bands will be used during neck exercises. Patients will be asked to perform cervical flexion, extension and right-left lateral flexion movements against the fixed band.~* Patients will be asked to continue each exercise for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the elastic resistance band color will be changed and the exercise will progress."
47987428|NCT02786342|PROCEDURE|blood sample collection|
47987429|NCT05602987|PROCEDURE|enema|receiving enema at the night before anal surgery
48505422|NCT05597735|DRUG|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
48505423|NCT05597735|DRUG|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
48505424|NCT06632431|OTHER|Endometrial cancer (EC)|"Endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) Histopathological slides for these cases will be reexamined and staged according to both the Federation of Gynecology and Obestetrics (FIGO) 2009 and updated Federation of Gynecology and Obestetrics (FIGO) 2023 endometrial staging systems. Upstaging refers to reclassification to a higher stage in the FIGO 2023 system compared to Federation of Gynecology and Obestetrics (FIGO)2009, while downstaging is the opposite.~All patients underwent lymph node dissection except those with Stage IA-Grades I and II endometrioid endometrial cancer and tumor size \<2 cm."
48505425|NCT06262932|DRUG|Amiodarone|Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
48505426|NCT01823835|DRUG|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
48505427|NCT01823835|DRUG|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
48505428|NCT01823835|DRUG|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
48505429|NCT04400682|DRUG|FAVIRA 200 MG Film Tablet|FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.
48505430|NCT04400682|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
48505431|NCT02675439|DRUG|ADU-S100|
48505432|NCT02675439|BIOLOGICAL|ipilimumab|
48505433|NCT01104779|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
48505434|NCT01104779|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
48665591|NCT00601341|OTHER|lumbosacral joint manipulation|lumbosacral joint manipulation
48665592|NCT00601341|OTHER|lumbar passive range of motion|lumbar passive range of motion
48665593|NCT00601341|OTHER|No active intervention|Lie on exam table for 3 minutes
48665594|NCT00687076|DRUG|Ezetimibe|Daily dose of 10 mg of Ezetimibe
48665595|NCT00687076|DRUG|Niaspan|Daily dose of 1500 mg of Niaspan
48665596|NCT00687076|DRUG|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
48665597|NCT00687076|BEHAVIORAL|Standard care|Standard of medical care for PAD
48665598|NCT00687076|DRUG|Aspirin|Daily dose of 325 mg of aspirin
48665599|NCT00687076|DRUG|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
48505435|NCT06524453|BEHAVIORAL|Wheelchair accessible exercise program|"1. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes~2. Aerobic exercise~   * High intensity interval training~  * Arm ergometer or wheelchair running~  * 20 mins~3. Strengthening exercise~   * Shoulder and chest, elbow joint major muscle; shoulder and trunk stabilization exercise~  * 3 sets of 10~  * 20 minutes~4. Stretching exercise~   * Dynamic and static~  * Neck, shoulder, elbow, wrist, trunk~  * 10 minutes"
48665600|NCT00687076|DRUG|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
47987430|NCT05602987|PROCEDURE|no enema|no enema before anal surgery
47987431|NCT01909479|DRUG|MOD-4023|Individualized once weekly dose of MOD-4023
47987432|NCT01909479|OTHER|Placebo|Once weekly administration of placebo
47987433|NCT02150954|DRUG|pitocin|
48505436|NCT01996449|DRUG|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
48665601|NCT00687076|DRUG|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
48665602|NCT00687076|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
48665603|NCT06222021|GENETIC|Genetic analysis of polymorphism of membrane receptors involved in lactate transport|The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).
48665604|NCT02071615|DRUG|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
48665605|NCT02071615|DRUG|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
48665606|NCT02071615|DRUG|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
48665607|NCT02071615|DRUG|placebo|
47987434|NCT03888547|OTHER|Occupational Therapy Health & Wellness Education|The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
47987435|NCT03208842|RADIATION|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity"
47987436|NCT05888246|DIAGNOSTIC_TEST|Magnetocardiogram|Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
48143932|NCT00201825|DRUG|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
48143933|NCT01244997|PROCEDURE|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
48505437|NCT01996449|DRUG|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
48665608|NCT01296308|OTHER|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
48665609|NCT04164381|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
48665610|NCT03119220|DEVICE|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
48665611|NCT05802901|PROCEDURE|Spinal manipulation|Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
48665612|NCT05802901|PROCEDURE|Dry needling|Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
48665613|NCT05802901|PROCEDURE|Spinal manipulation and dry needling|The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
48665614|NCT02378480|DRUG|Omadacycline|Injection for IV dosing; Tablets for oral dosing
48354594|NCT03896087|DIAGNOSTIC_TEST|Abbott RealTime HCV assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
48354595|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 6800/8800 Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 6800/8800 Systems for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
48354596|NCT03896087|DIAGNOSTIC_TEST|Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays Aptima® HCV Quant Dx Assay from DBS for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
48354597|NCT03896087|DIAGNOSTIC_TEST|HCV for use on the cobas® 4800Systems from PSC and DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays cobas® 4800 for detection of HCV RNA. Results of testing DBS samples on the HCV assay will not be used to make any clinical decisions, and should not be communicated to study participants.
48665615|NCT02378480|DRUG|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
48665616|NCT05135728|BEHAVIORAL|Unstuck and On Target: Preschool|Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
48665617|NCT05313581|BEHAVIORAL|START NOW WebApp|"The WebApp is based on the existing manualized START NOW skills training. START NOW aims to improve emotion- and stress regulation, social competence, effective management of encountered problems/crises, subjective well-being and resilience through improving an individual's level of psychological flexibility. It primarily employs a cognitive behaviourally oriented group skills training with integrated components from Dialectical Behavioural Therapy (DBT), Acceptance and Commitment Therapy (ACT), trauma-informed care and Motivational Interview (MI) techniques.~During the training, participants will encounter different exercises to help them train their skills. There are several mindfulness exercises in the form of audio tracks, containing, e.g., instructions on a breathing exercise. The skills training phase takes place over a period of 9 weeks (sessions 1+2, 9+10 and 11+12 are double session)."
48665618|NCT04910620|DRUG|Placebo|Placebo only
48665619|NCT04910620|DRUG|TCI378|TCI378 (Lactobacillus plantarum TCI378)
48665620|NCT04910620|DRUG|TCI507|TCI507 (Lactobacillus plantarum TCI507)
48665621|NCT02152748|GENETIC|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
48665622|NCT04149743|DIAGNOSTIC_TEST|Standard of Care with Hemotag|Comparison of outcomes
48665623|NCT05871957|DRUG|Vitamin D Drops|Supplement 2000IU of vitamin D, no matter the brand or manufacturer for 1 month.
48665624|NCT05023161|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample in each of the 200 patients included.
48665625|NCT00251108|PROCEDURE|Cardiorespiratory fitness training|
48665626|NCT00902330|PROCEDURE|energy-based therapy|Given once a day for 18 weeks
48665627|NCT00902330|PROCEDURE|sham intervention|Given once a day for 18 weeks
48665628|NCT06254625|OTHER|Fecal Microbiome|Fecal microbiome transplantation from a healthy donor.
48665629|NCT06254625|OTHER|Placebo|Place capsules
48665630|NCT00107575|BEHAVIORAL|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
48665631|NCT00107575|OTHER|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
48665632|NCT05392816|OTHER|Single meal non-heme iron absorption|Two study groups, each designed as cross-over single-blinded iron isotope trials in apparent healthy Swedish women of the ages 18-45 years. Each participant serves as their own control. Meals are tagged with radiolabeled non-heme iron 55Fe and 59Fe.
48665633|NCT03901430|BEHAVIORAL|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
48665634|NCT01003223|OTHER|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
47987437|NCT01364207|OTHER|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
48665635|NCT03229538|DRUG|Methylprednisolone|IV Steroid pre-operative and intra-operative
48665636|NCT03229538|DRUG|Isotonic saline|Isotonic saline pre-operative and intra-operative
48665637|NCT04955548|PROCEDURE|arthroscopic micro-fracture with autologous adipose gel|Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
47987438|NCT01364207|OTHER|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
48354598|NCT04661891|OTHER|Isometric contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of applying joint torque to reach a pre-defined torque level based on the subject's maximal voluntary contraction (i.e., 25%, 60%, 70%, 80%, 90%). The participant will control torque intensity by responding to a biofeedback displayed on a screen. The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
48354599|NCT04661891|OTHER|Isokinetic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Isometric contractions will consist of moving a joint to completing a set of contractions (10-20 contractions) at various velocities (i.e., 10 degrees per second, 30 degrees per second, 60 degrees per second). The joint will be secured with non-compliant bands to prevent any movement of the participant. The order of the joints tested (i.e., dominant ankle, knee, or hip joint) will be randomized.
48354600|NCT04661891|DEVICE|Dynamic contractions|HD-EMG grids will be applied to the lower limb muscles of interest. Multi-joint tasks (i.e. walking, squatting, cycling) will be performed at a given frequency. A motion capture system will be used to record the joint angles and ground reaction forces simultaneously.
48354601|NCT04661891|DEVICE|Isometric contraction with muscle fatigue|"An identical experiment will be performed as stated in Isometric contraction with the addition of induced muscle fatigue by repeatedly maintaining 40% of muscle torque until failure to maintain a contraction for 5 seconds."
48354602|NCT04661891|DEVICE|Multi-joint functional activities while wearing exoskeleton|Participants will be measured and fitted with the bilateral exoskeleton, and sufficient range of motion to used exoskeleton will be confirmed. HD-EMG grids will be applied to the lower limb muscles of interest. The participant will perform single-joint movements to calibrate the decoder parameters. The participant will then perform multi-joint activities (e.g., standing, squatting, walking overground or on a treadmill, cycling, or stair climbing) in a movement analysis laboratory
48354603|NCT04661891|OTHER|Clinical Assessments|Subjects may complete a 10 meter walk test (10MWT) overground or over a pressure-sensitive walkway, 6 minute walk test (6MWT), Berg Balance scale (BBS), and/or Functional Gait Assessment (FGA). They may also complete step ups or squats.
48665638|NCT04955548|PROCEDURE|arthroscopic micro-fracture|Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
48665639|NCT03322904|DIAGNOSTIC_TEST|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula \[IEC-PC¬\] - \[CC-PC\] / \[CC-PC\]."
48665640|NCT05363592|DRUG|CT-L01 12.5/500 mg|FDC tablet, 2 tablets at a time, oral administration
48665641|NCT05363592|DRUG|Alogliptin Benzoate 12.5 mg|Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
48665642|NCT05363592|DRUG|Metformin HCl XR 500 mg|Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
47987439|NCT02173912|DRUG|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
47987440|NCT02173912|DRUG|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
48665643|NCT03076684|OTHER|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.
48665644|NCT03076684|DRUG|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
48665645|NCT05815602|DRUG|Ebastine|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
48665646|NCT05815602|DRUG|Duspatalin|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
47987441|NCT04460547|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion to COVID-19 infected patients.
47987442|NCT04460547|DRUG|Hydroxychloroquine|Hydroxychloroquine administration to COVID-19 infected patients.
48354604|NCT02689141|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
48665647|NCT00451737|DEVICE|Isokinetic test|
48665648|NCT04382092|DIAGNOSTIC_TEST|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
48665649|NCT05205837|DRUG|Letrozole 2.5mg, hCG|Drug -Treatment Intramuscular injektion - Treatment
48665650|NCT05205837|DRUG|Placebo|Drug - Placebo Intramuscular injektion - placebo
47987443|NCT04460547|DRUG|DAS181|DAS181 administration to COVID-19 infected patients.
47987444|NCT04460547|DRUG|Ivermectin|Ivermectin administration to COVID-19 infected patients.
47987445|NCT04460547|DRUG|Interferon Beta-1A|Interferon Beta-1A administration to COVID-19 infected patients.
47987446|NCT02015650|DRUG|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
48354605|NCT02689141|DRUG|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
48665651|NCT01766687|DIETARY_SUPPLEMENT|Hydration|
48665652|NCT00121979|DRUG|Racivir, a non-nucleoside reverse transcriptase inhibitor|
48665653|NCT05189678|OTHER|No intervention|No intervention
48665654|NCT00867334|DRUG|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
48665655|NCT00867334|DRUG|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
48665656|NCT04747301|DEVICE|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
48665657|NCT04747301|DRUG|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
48665658|NCT01910155|DRUG|Ciprofloxacin/Dexamethasone|
48665659|NCT01910155|DRUG|Ciprodex (R)|
48665660|NCT01910155|DRUG|Placebo|
48665661|NCT00000395|DRUG|Methotrexate|
48665662|NCT00000395|DIETARY_SUPPLEMENT|Folinic acid|
48665663|NCT00000395|DIETARY_SUPPLEMENT|Folic acid|
47987447|NCT02015650|DRUG|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
47987448|NCT00134251|DRUG|SLV308|
47987449|NCT04146025|BEHAVIORAL|Nature Coach Intervention|"1. Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~2. Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~3. Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
48354606|NCT02689141|DRUG|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
48354607|NCT02148601|OTHER|Fecal Microbiota Transplantation|
48354608|NCT02148601|DRUG|Standard Antibiotic Therapy|
48665664|NCT06150430|DEVICE|APO|"Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol."
48665665|NCT00283192|DRUG|Sertraline|
48665666|NCT02854163|DRUG|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
48665667|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
48665668|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.
48665669|NCT01505855|DRUG|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
47987450|NCT01042236|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
47987451|NCT04111679|OTHER|Music|Participant selected music, applied using noise cancelling headphones
47987452|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the upper arm
48665670|NCT02481557|DEVICE|Oxalate Salt Solution|Applied by dentist
48665671|NCT01990690|DRUG|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
48665672|NCT02008643|OTHER|filling questionnary to quality of life|filling questionnary to quality of life
48665673|NCT06032182|BEHAVIORAL|CRESTR Intervention|15 1-hour sessions of CRT + SRT
48665674|NCT06032182|BEHAVIORAL|CRESTR Control|15 1-hour sessions of SRT alone
47987453|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the lower abdomen
47987454|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the thigh
47987455|NCT01953341|DRUG|AMG 333|Oral administration available in varying dose strength.
47987456|NCT01953341|DRUG|Placebo|Placebo containing no active drug
47987457|NCT05943145|OTHER|Group Dance and Movement Training|Dance movement-based sessions including personalized tasks and imagery, mirroring, and inscription, plus warm-up and cool down practices to ensure physical safety
47987458|NCT01287689|OTHER|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
47987459|NCT02677987|DEVICE|Intervention systematic light exposure|Bright light using Litebook device.
48665675|NCT00877656|BIOLOGICAL|HuMax-CD4|Active treatment
48665676|NCT01474109|DRUG|macitentan 3mg|macitentan 3mg tablet once daily
48665677|NCT01474109|DRUG|macitentan 10mg|macitentan 10mg tablet once daily
48665678|NCT01474109|DRUG|placebo|matching placebo once daily
48665679|NCT01785030|DRUG|50% Nitrous oxide|
48665680|NCT02212860|RADIATION|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
47987460|NCT02677987|DEVICE|Comparison systematic light exposure|Dim light using modified Litebook device.
47987461|NCT03104595|DRUG|EC-18|oral administration
48665681|NCT03426527|DRUG|Levobupivacaine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
48665682|NCT03426527|DRUG|Levobupivacaine-Dexmedetomidine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
48665683|NCT03426527|OTHER|General Anaesthesia|Using propofol, fentanyl and atracurium
48665684|NCT04329767|DEVICE|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
48665685|NCT02665260|DRUG|Cantharidin|cantharidin 0.7% topical liquid
48665686|NCT02665260|DRUG|Placebo|Placebo topical liquid
48665687|NCT02665260|DEVICE|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
48665688|NCT02134184|BIOLOGICAL|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
48665689|NCT01647854|PROCEDURE|Teleconsultation|Teleconsultation in prehospital emergencies
47987462|NCT03523975|DRUG|Venetoclax|PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
47987463|NCT03523975|DRUG|Lenalidomide|10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
47987464|NCT03523975|DRUG|Rituximab|375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
47987465|NCT04061096|DIAGNOSTIC_TEST|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
48354609|NCT02148601|DRUG|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
48354610|NCT01888965|DRUG|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
48354611|NCT02738294|DEVICE|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
48354612|NCT05375838|BIOLOGICAL|mRNA-1073|Sterile liquid for injection
48354613|NCT05375838|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
48505438|NCT01996449|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
48505439|NCT01996449|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
48505440|NCT01996449|PROCEDURE|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
48505441|NCT01996449|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
48665690|NCT03190421|DIAGNOSTIC_TEST|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
48665691|NCT03190421|DIAGNOSTIC_TEST|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
48665692|NCT01073969|OTHER|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
48665693|NCT01073969|OTHER|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
47987466|NCT04061096|DIAGNOSTIC_TEST|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
48354614|NCT05375838|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
48354615|NCT05375838|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48354616|NCT03782467|BIOLOGICAL|ATOR-1015|Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
47987467|NCT04061096|DIAGNOSTIC_TEST|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
47987468|NCT04244279|OTHER|Ergonomic workshop|Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.
47987469|NCT04244279|OTHER|Brochure|Participant will receive a brochure summarizing the main contents of the workshop.
47987470|NCT04244279|OTHER|Videos|During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
48354617|NCT00094640|DRUG|Intramuscular Olanzapine Depot|
48354618|NCT02881151|DEVICE|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
48354619|NCT00438724|BEHAVIORAL|Information, counseling and support|
48354620|NCT01841164|DRUG|Montelukast|
48354621|NCT01841164|DRUG|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
48354622|NCT01841164|OTHER|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
47987471|NCT02956486|DRUG|Elenbecestat|Oral tablet.
48665694|NCT02796456|OTHER|blood sample|
47987472|NCT02956486|DRUG|Placebo|Oral tablet.
47987473|NCT01710033|DRUG|Placebo|Placebo tables twice daily (BID) for 28 days
47987474|NCT01710033|DRUG|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
47987475|NCT01710033|DRUG|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
47987476|NCT01710033|DRUG|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
48143934|NCT04271865|OTHER|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
48505442|NCT01996449|PROCEDURE|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
47987477|NCT02950454|OTHER|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
48665695|NCT00492557|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
47987478|NCT02950454|OTHER|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
48143935|NCT04271865|OTHER|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
48505443|NCT01996449|PROCEDURE|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
48505444|NCT01398514|DRUG|Escitalopram|Escitalopram 10mg/day or matched pill placebo
48505445|NCT05180201|DIETARY_SUPPLEMENT|Synbiotic|Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
47987479|NCT06350292|BEHAVIORAL|SLEEP: COPE|Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
47987480|NCT05087147|DEVICE|0.7 mm stainless steel orthodontic wire|0.7 mm stainless steel orthodontic wire
47987481|NCT05087147|DEVICE|Banded space maintainer|band and loop space maintainer
47987482|NCT00254540|DRUG|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
47987483|NCT02154581|DEVICE|SLActive implant|
47987484|NCT03959293|DRUG|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
47987485|NCT03959293|DRUG|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
47987486|NCT03959293|DRUG|FOLFIRI Protocol|"* Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
47987487|NCT05529043|BEHAVIORAL|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
47987488|NCT05529043|BEHAVIORAL|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
47987489|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
47987490|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
48505446|NCT05180201|DIETARY_SUPPLEMENT|Probiotic|Lactiplantibacillus plantarum ATCC 202195
48505447|NCT05180201|OTHER|Placebo|Maltodextrin
48665696|NCT00492557|BIOLOGICAL|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
48665697|NCT00002487|DRUG|dipyridamole|
48665698|NCT00002487|DRUG|methotrexate|
48665699|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))|"Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
47987491|NCT05048628|OTHER|Comparıson|"Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated."
48354623|NCT04296721|BEHAVIORAL|Intensive weigh-loss program|Intervention group: Intensive weight-loss program: 0-3 months very low calorie diet, 15 days substituting three meals for low calorie shakes, from 15 to 120 days substituting 1 meal and from 120 days to 12 months on a low calorie diet while starting a progressive exercise programme. Recommendations for good sleep habits will be given. The program will be carried out through group and individual sessions with the hospital dietician. After 3 months: group sessions with a nurse in the basic area. Group sessions led by hospital dietician. From 3 to 12 months: group sessions led by primary care nurse.
47987492|NCT05070468|DRUG|Dexamethasone 0.5mg|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
48143936|NCT04271865|OTHER|recipe book|3) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
48354624|NCT04296721|BEHAVIORAL|Standard Dietary recommendations|Patients will be managed according to the usual recommendations: The common written diet (designed by a hospital nutritionist) and an exercise advice will be given according to patient age and level of activity, without any other assessment or additional visits.
48505448|NCT02887456|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
48505449|NCT02887456|DRUG|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
48505450|NCT00235209|DEVICE|Collagen ORC Antimicrobial Matrix (CAM)|
48505451|NCT03990597|OTHER|Placebo Administration|Applied topically
48354625|NCT01003067|DEVICE|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
48505452|NCT03990597|OTHER|Questionnaire Administration|Ancillary studies
48505453|NCT03990597|DRUG|Wound Dressing Material|Applied StrataXRT topically
48505454|NCT05445583|BEHAVIORAL|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
48665700|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)|"Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
48665701|NCT03379974|DRUG|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
48665702|NCT03379974|BEHAVIORAL|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
48665703|NCT01329133|PROCEDURE|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
48665704|NCT01891279|OTHER|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
47987493|NCT05070468|DRUG|Placebo|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
48665705|NCT01891279|OTHER|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
47987494|NCT04208399|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally in fed condition.
47987495|NCT01805024|DRUG|Omigapil|Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
47987496|NCT05164042|BIOLOGICAL|Allogeneic CD19 CAR-T cells|infusion of allogeneic CD19 CAR-T cells
47987497|NCT05343975|PROCEDURE|biopsy with audio-guided Meditation|biopsy with audio-guided Meditation
48665706|NCT03202394|DRUG|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
47987498|NCT05951010|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation was delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min. The anode was placed 2 cm under the inion and the cathode was placed over the right deltoid muscle (CD-tDCS) or the spinal lumbar enlargement (2 cm under T11) as described by Benussi et al. (CS-tDCS). An electroconductive gel was applied to the electrodes to reduce contact impedance and the electrodes were held in place using elastic gauzes.
47987499|NCT01028365|OTHER|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
48354626|NCT04264182|OTHER|ICD programming|Re-programming of the ICD device for VA detection (see above)
48354627|NCT03088410|DRUG|Zidovudine|neonatal 4 weeks prophylactic
48354628|NCT03088410|DRUG|Nevirapine|neonatal 4 weeks prophylactic
48354629|NCT04882124|DRUG|CSJ117|CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
48354630|NCT04882124|DRUG|Placebo|Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
48354631|NCT01812395|DEVICE|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
48354632|NCT01812395|PROCEDURE|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
48354633|NCT02292524|OTHER|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
48354634|NCT04300842|DEVICE|smart bracelet|to measure the stress, fatigue, and activity.
48354635|NCT03013426|DRUG|NVX-508|Administration of NVX-508 emulsion intravenously
48354636|NCT02453139|BEHAVIORAL|Exercise|6 month supervised and home based aerobic exercise intervention
48505455|NCT05445583|BEHAVIORAL|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
48354637|NCT00490126|OTHER|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
48665707|NCT03202394|DRUG|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
48665708|NCT03620396|PROCEDURE|Scaling and root planing|After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
48665709|NCT04311450|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
47987500|NCT05787691|OTHER|Individualised pain management|"TPS pain management consists in an evaluation by a pain physician, followed by specific measures for patients identified as having a particularly high risk of CPSP. The choice of these measures will be individualised according to specific risk factors and left to the discretion of the pain physician.~Potential measures: patient education, adjustment of analgesic therapy, referral to a psychiatrist or psychologist, cognitive behavioural therapy, hypnosis, use of locoregional analgesia for surgery, infusions of ketamine and/or lidocaine, introduction of gabapentins and/or antidepressants."
47987501|NCT02680912|DEVICE|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
48354638|NCT01762592|DRUG|Iodine (124I) Girentuximab|i.v.
48354639|NCT03755362|PROCEDURE|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
48505456|NCT05445583|BEHAVIORAL|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
48505457|NCT05445583|BEHAVIORAL|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
48665710|NCT03558217|DEVICE|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
48665711|NCT03558217|DEVICE|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
48665712|NCT01418456|DRUG|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
47987502|NCT02680912|DEVICE|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
47987503|NCT02734446|DRUG|Reuterin D3 drops|5 drops/day for 3 months
47987504|NCT02734446|OTHER|Placebo|5 drops/day for 3 months
47987505|NCT03984591|DRUG|Eplerenone|Eplerenone according to guidelines
48354640|NCT03755362|PROCEDURE|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
48354641|NCT00004256|BIOLOGICAL|sargramostim|
48354642|NCT00004256|PROCEDURE|quality-of-life assessment|
48354643|NCT00004256|RADIATION|radiation therapy|
48354644|NCT01335438|DEVICE|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
48354645|NCT01335438|DEVICE|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
48143937|NCT04271865|OTHER|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
48354646|NCT06186895|DRUG|Dexmedetomidine|received an intravenous loading dose of DEX (1 μg/kg) over 15 minutes prior to the anesthetic induction. Following the intubation procedure, a maintenance infusion of DEX was delivered at a rate of 0.6 μg/kg/h. The infusion was discontinued upon trocars removal.
48354647|NCT06186895|DRUG|Fentanyl|fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. Following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. The infusion was discontinued upon the removal of the trocars.
48354648|NCT06048068|BEHAVIORAL|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
48665713|NCT05539482|BEHAVIORAL|Community-based Health Education based on core intervention package|"Community-based Health Education will potentially include the following three components:~1. A manual of emergency preparedness and self-protection against COVID-19 infection. The main content will include hand washing, mask wearing and social distancing guidelines.~2. Early testing. Participants will be trained on how to recognize the early symptoms of COVID-19 and appropriate practice to take in a response, and they will be provided with testing resources.~3. Knowledge of vaccines and their benefits and resources for vaccination.~Collaborators should design and implement health programs based on the core intervention package."
48354649|NCT05989815|OTHER|Muscle damage protocol training|The adopted protocol of muscle damage will follow the recommendations from American College of Sports Medicine (ACSM) in 2009 for trained individuals. It consists of 8-12 repetitions above 70% of 1 Repetition Maximum (1RM) with 1 minute of rest between sets and 2 minutes between exercises. The protocol will be composed as follows: 3 sets of 10 repetitions for each exercise, with an emphasis on producing microlesions in the muscle tissue (muscle damage protocol).
48354650|NCT05989815|DEVICE|Photobiomodulation therapy (PBMT)|PBMT will be administered using the Joovv Elite System, which has 6 panels of red LEDs (660±10nm) and 74 panels of infrared LEDs (850±10nm), totaling 900 LEDs covering an area of 12,193 cm². Athletes will stand 20 cm in front of the device, wearing only swim shorts to expose their thigh muscles and other body areas to the light. The total irradiation time will be 20 minutes, with 10 minutes (600 seconds) of irradiation for the anterior region and another 10 minutes (600 seconds) for the posterior region. The active PBMT dose applied in each region (anterior or posterior) will be 48.97 J/cm², with an irradiance of 81.62 milliwatt (mW)/cm². The PBMT Sham dose applied in each region (anterior or posterior) will be 0 J/cm², with an irradiance of 0 mW/cm².
48354651|NCT01950364|DRUG|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
48354652|NCT01950364|DRUG|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
48354653|NCT03323086|BEHAVIORAL|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
48354654|NCT03323086|OTHER|Brochure|Brochures provided one time
48505458|NCT06632756|BEHAVIORAL|Individual and Group Treatment for Smoking Cessation|Positive psychology-based individual treatment and groups
48665714|NCT05539482|BEHAVIORAL|Health Information Sharing Group|Collaborators are encouraged to collect and share health information to the participants. Shared information should be previewed by researchers.
48665715|NCT05504499|DEVICE|Interspinous Fusion|The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
47987506|NCT03984591|DRUG|Spironolactone|Spironolactone according to guidelines
47987507|NCT03852641|OTHER|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
47987508|NCT05405192|DRUG|Dostarlimab|First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
47987509|NCT04554277|BIOLOGICAL|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
47987510|NCT03280290|BIOLOGICAL|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
47987511|NCT01590238|BIOLOGICAL|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
47987512|NCT00897247|GENETIC|microarray analysis|
47987513|NCT00897247|GENETIC|protein expression analysis|
47987514|NCT00897247|GENETIC|proteomic profiling|
47987515|NCT00897247|OTHER|laboratory biomarker analysis|
47987516|NCT01411709|DRUG|Vitano|two 200mg tablets per day for 14 days
47987517|NCT00277433|OTHER|Buccal Swab|collection of buccal swab
48505459|NCT06525311|DRUG|K-808|K-808 single or multi dose extended-release tablets
48665716|NCT06518304|OTHER|GentleWave|GentleWave System employs a degassing process that removes dissolved gases from the solution. This optimization prevents the vapor-lock effect and ensures effective energy transmission through the root canal. As the solution enters the pulp chamber, hydrodynamic cavitation occurs, creating microbubbles that implode and generate sound waves across a broad frequency spectrum
48354655|NCT02136329|DRUG|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo \[4,3-d\] pyrimidin-5-yl)-4-ethoxyphenyl\] sulfonyl\]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
48354656|NCT05546957|DRUG|Aspirin|Administered orally once per day (QD)
48354657|NCT05546957|DRUG|rivaroxaban low dose|Administered orally twice per day (BID)
48354658|NCT05546957|DRUG|rivaroxaban high dose|Administered orally QD
48354659|NCT03592693|DRUG|Combined Vitamin C and Stress-Dose Hydrocortisone|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
48354660|NCT03592693|DRUG|Placebo plus placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
48354661|NCT05634837|BEHAVIORAL|Decision Support System counseling|Decision Support System counseling to improve diet and lifestyle in pregnancy
48354662|NCT05634837|BEHAVIORAL|Standard nutritional counseling|Counseling to improve diet and lifestyle in pregnancy
48354663|NCT05349474|DRUG|Metformin 500 Mg Oral Tablet, up to 4 tablets a day|Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose
48354664|NCT05349474|DRUG|Placebo oral tablet identical to metformin, up to 4 tablets a day|Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
48354665|NCT00462488|DRUG|Vicinium|Intravesical administration of Vicinium
48354666|NCT04409990|DIAGNOSTIC_TEST|Shear Wave Elastography|SWE value of rectal lesions
48354667|NCT03049085|DRUG|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
48354668|NCT03049085|DRUG|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
48354669|NCT04241536|PROCEDURE|Blood draw and urine collection|Patients will collect blood and urine for metabolome analysis
48354670|NCT01142791|DEVICE|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
48354671|NCT02460094|DRUG|BIIB092|See Arm Descriptions for dosing information.
48354672|NCT02460094|DRUG|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
48354673|NCT00026195|DRUG|irinotecan hydrochloride|
48354674|NCT06093152|DRUG|Salbutamol|Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
48354675|NCT02445352|DRUG|Rosuvastatin 5mg|
48354676|NCT02445352|DRUG|DP-R207 5/10mg|
48354677|NCT02445352|DRUG|Rosuvastatin 10mg|
48354678|NCT02445352|DRUG|DP-R207 10/10mg|
48354679|NCT02445352|DRUG|Rosuvastatin 20mg|
48354680|NCT02445352|DRUG|DP-R207 20/10mg|
48354681|NCT02445352|DRUG|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
48354682|NCT02445352|DRUG|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
48354683|NCT02445352|DRUG|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
48665717|NCT06518304|OTHER|Conventional Protocol|Delivers irrigants (NaOCl, EDTA) through a needle-syringe system, often fails to reach the entire working length. This inadequacy can result in residual bacteria and necrotic tissue, potentially compromising treatment efficacy and increasing the risk of treatment failure.
48665718|NCT03316430|OTHER|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
48665719|NCT00542178|DRUG|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
48665720|NCT00542178|DRUG|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
48665721|NCT00542178|DRUG|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
48665722|NCT00542178|DRUG|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
48665723|NCT00542178|DRUG|Fenofibrate|Blinded fenofibrate
48665724|NCT00542178|DRUG|Simvastatin|Simvastatin 20-40 mg/d
47987518|NCT06437899|DRUG|intravesical botulinum toxin A injection unter local anaesthesia|"Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor."
47987519|NCT00261677|DRUG|epoetin alfa|
47987520|NCT00758030|DRUG|Paliperidone ER OROS|
47987521|NCT03571074|OTHER|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
48665725|NCT00542178|DRUG|Placebo|Placebo
47987522|NCT04442204|OTHER|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
47987523|NCT03099876|PROCEDURE|treatment period|7 days treatment or 10 days treatment
47987524|NCT06443840|DEVICE|AutonHome® device|The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
47987525|NCT03876431|DEVICE|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
47987526|NCT03876431|OTHER|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
47987527|NCT06456060|DRUG|Alvogyl|Alvogyl soaked in a sterile gauze will be applied to cover the socket.
47987528|NCT06456060|DRUG|Honey|Honey soaked in a sterile gauze will be applied to cover the socket.
47987529|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
47987530|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
47987531|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
47987532|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
47987533|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
47987534|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
47987535|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
47987536|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
47987537|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
47987538|NCT01254526|DRUG|GDC-0980|Oral repeating dose
47987539|NCT01254526|DRUG|bevacizumab|Intravenous repeating dose
47987540|NCT01254526|DRUG|paclitaxel|Intravenous repeating dose
47987541|NCT03770390|PROCEDURE|Surgical correction of pectus excavatum|Surgical correction of pectus excavatum
47987542|NCT01874847|DIETARY_SUPPLEMENT|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
47987543|NCT01874847|DIETARY_SUPPLEMENT|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
47987544|NCT01069107|OTHER|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
47987545|NCT01525550|DRUG|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
47987546|NCT01554423|OTHER|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
47987547|NCT01554423|BEHAVIORAL|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
48354684|NCT00040066|PROCEDURE|Cocaine (IV)|
48354685|NCT01077310|DRUG|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
48505460|NCT06604884|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Vantage Embolization Device with Shield Technology™
48665726|NCT01142570|OTHER|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
48665727|NCT01142570|OTHER|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
48665728|NCT01142570|DIETARY_SUPPLEMENT|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
48354686|NCT01077310|DRUG|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
48354687|NCT02276690|BIOLOGICAL|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
48665729|NCT01142570|DIETARY_SUPPLEMENT|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
48354688|NCT02276690|BIOLOGICAL|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
48354689|NCT03832166|OTHER|Fruits and Vegetables|Fruits and vegetables delivery, once/week for 24 weeks
48354690|NCT03832166|OTHER|Cooking|Nutrition education and cooking instruction class, one class/week for 6 weeks
48354691|NCT00740090|DRUG|AMA1-C1/Alhydrogel plus CPG 7909|
48354692|NCT04952116|OTHER|Eyelid reconstruction|Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
48354693|NCT05613491|DRUG|Intranasal insulin|Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
48354694|NCT05613491|DRUG|Intranasal saline|Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
48354695|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
48354696|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
48354697|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
48354698|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
48354699|NCT00192465|BIOLOGICAL|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
48665730|NCT01142570|DIETARY_SUPPLEMENT|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
48665731|NCT05452473|OTHER|CDSS-assisted upper GI endoscopy|Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.
48665732|NCT05452473|OTHER|no intervention|Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
48665733|NCT00484263|DRUG|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
48665734|NCT06563947|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
48665735|NCT02009579|DRUG|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
48665736|NCT02009579|DRUG|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
48665737|NCT05563948|DRUG|Cannabis|Vaporized cannabis will be administered 3x/day for 15 days.
48665738|NCT03182855|DRUG|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
48665739|NCT03182855|DRUG|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
48665740|NCT03515421|DEVICE|Frazier 3 Verio|In vitro diagnostic device (IVDD)
48665741|NCT03515421|DEVICE|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
48665742|NCT02714348|OTHER|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
48665743|NCT05383742|DRUG|Rifampicin (RIF)|Rifampicin 35 mg/kg
48665744|NCT05383742|DRUG|Isoniazid (INH)|Isoniazid 10 or15 mg/kg
48665745|NCT05383742|DRUG|Linezolid (LZD)|1200 mg
48665746|NCT05383742|DRUG|Pyrazinamide (PZA)|25 mg/kg
48665747|NCT05383742|DRUG|ethambutol (EMB)|20 mg/kg
47987548|NCT01554423|BEHAVIORAL|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
48665748|NCT05383742|DRUG|Rifampicin|10 mg/kg
48354700|NCT04265859|BEHAVIORAL|Cognitive Behavioral Training|The CBT-based regulation training involves using a cognitive strategy that instructs participants to reappraise situations in positive or less negative ways.
48665749|NCT05383742|DRUG|Isoniazid|5 mg/kg
48665750|NCT03624725|PROCEDURE|modified BII+Braun|modified BII+Braun digestive tract reconstruction
48665751|NCT03544463|DEVICE|iNAP® Sleep Therapy System|The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
48665752|NCT02595515|OTHER|Chiropractic treatment|Procedure: chiropractic treatment.
47987549|NCT05025189|OTHER|Table Grape Powder|Freeze Dried Whole Table Grape Powder
47987550|NCT05025189|OTHER|Beige Diet|Low Fiber, low polyphenol Diet
47987551|NCT05119283|OTHER|Scraping and straightening of the crown and root and rinsing with mouthwashes|Patients will answer a questionnaire about their socioeconomic conditions, and soon after undergoing the examination for bleeding, probing, clinical attachment level, probing depth and plaque index for initial clinical evaluation. Basic periodontal treatment will be carried out with the same operator (blind to the treatments performed), with complete removal of plaque and calculi, prophylaxis with pumice and prophylactic paste and oral hygiene instructions. After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®.
47987552|NCT05876741|DIAGNOSTIC_TEST|history taking , vital signs and labaratory investigations|"1. Complete history taking:~   With stress on age, sex, epigastric pain, comorbidities (ischemic heart disease, diabetes, liver cirrhosis, renal failure, malignancy), syncope, disturbed conscious level, blood transfusion, drug history .~2. Clinical examination:~   Pulse, blood pressure, calculating the shock index, pallor, jaundice, cachexia, purpura, ecchymosis, conscious level, abdominal examination.~3. Laboratory investigations:~   * Complete blood count (CBC).~  * Creatinine and blood urea nitrogen (BUN).~  * liver function tests (serum bilirubin, serum albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), prothrombin concentration (PC), and international normalized ratio (INR)).~  * Serum electrolytes and arterial blood gases.~  * Fasting blood sugar.~4. Assessment of risk and predicting outcomes by:~   * Pre-endoscopic Rockall score (pRS).~  * Glasgow-Blatchford score (GBS).~  * AIMS65 score.~  * ABC score.~  * Horibe score."
48354701|NCT04265859|BEHAVIORAL|Mindfulness|The MBT-based regulation training involves using a mindfulness strategy that instructs participants to notice and accept their feelings without judgment or intent to act upon them.
48665753|NCT02595515|OTHER|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
48665754|NCT00060125|DRUG|tipifarnib|Given orally
48665755|NCT00060125|OTHER|laboratory biomarker analysis|Correlative studies
48665756|NCT00416507|DRUG|fluorouracil|
48665757|NCT00416507|DRUG|gemcitabine hydrochloride|
48665758|NCT00416507|DRUG|liposomal cisplatin|
48665759|NCT05096130|BEHAVIORAL|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
48354702|NCT03052634|DRUG|RC48-ADC 1.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
48354703|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
48354704|NCT03052634|DRUG|RC48-ADC 2.5 mg/kg (HER2 Positive)|15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
48354705|NCT03052634|DRUG|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
48354706|NCT01576887|DRUG|Bardoxolone Methyl 20 mg|Oral, once daily
48354707|NCT01576887|DRUG|Placebo|Oral, once daily
48354708|NCT06049706|DEVICE|Active Priming|"It will be applied an active priming stimulation in the supplementary motor area previously to the main stimulation to analyse if that will enhance the response to TMSr, compared to inactive priming.~To apply intervention, it will be used Repetitive Transcranial Magnetic Stimulation Model MagPro R20 (MagVenture Brazil, country Brazil) and the butterfly coil MCF-B70 (MagVenture Brazil, country Brazil).~Each session will last around 20 minutes, and it will be used a 1 Hz frequency, 1200 pulses/day, with 100% of Motor Threshold, once a day, 5 days a week, for two consecutive weeks.~Active Priming group participants will be previously stimulated for 10 minutes (20 trains of 5 seconds with intertrain interval of 25 seconds), with 6Hz frequency over Supplementary Motor Area, receiving 80% of Motor Threshold, with a total of 600 stimulations."
48143938|NCT04027452|BEHAVIORAL|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
48354709|NCT06049706|DEVICE|Sham Priming|Sham Priming group participants will receive a placebo stimulation for ten minutes, with the same parameters and target area as the active group, they will hear the equipament noise and might feel any sensation in the scalp, but there won't be effective stimulation.
48354710|NCT00298311|BEHAVIORAL|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
48354711|NCT04143256|OTHER|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
48354712|NCT04143256|OTHER|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
48354713|NCT04143256|OTHER|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
48354714|NCT04143256|OTHER|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
48665760|NCT05041829|OTHER|Dietary sodium|Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
48665761|NCT06328712|DRUG|EN001|"* Cohort 1: EN001 1.25×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals.~* Cohort 2: EN001 2.5×10\^6 cells/kg administered intravenously (IV) 2 times at 4 week intervals."
48665762|NCT04858373|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48665763|NCT04858373|OTHER|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48354715|NCT04143256|OTHER|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
48354716|NCT04143256|OTHER|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
48354717|NCT04143256|OTHER|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
48354718|NCT04143256|OTHER|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
48354719|NCT04143256|OTHER|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
48354720|NCT04143256|OTHER|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
48665764|NCT04858373|OTHER|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
48354721|NCT04366739|DRUG|CHLORPROMAZINE (CPZ)|"Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum"
48354722|NCT04366739|COMBINATION_PRODUCT|Standard of Care (SOC)|"In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm"
47987553|NCT01272609|DRUG|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
48354723|NCT03229876|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
48354724|NCT06456411|PROCEDURE|Functional Near-Infrared Spectroscopy|Undergo fNIRS
48354725|NCT06456411|OTHER|Questionnaire Administration|Ancillary studies
48354726|NCT06456411|OTHER|Virtual Technology Intervention|Undergo relaxation period using VR
48354727|NCT05847556|OTHER|video game hearing tests|Video game hearing tests (as a non-medical device) used to monitor ototoxicity
48665765|NCT04858373|OTHER|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
47987554|NCT01272609|DEVICE|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
47987555|NCT02307955|DEVICE|firefly|
47987556|NCT02307955|OTHER|Standard of care|
47987557|NCT01065233|GENETIC|DNA extraction|DNA extraction of blood sample for DNAship analysis
47987558|NCT02699554|PROCEDURE|Single-event multilevel surgery|
47987559|NCT04814420|DEVICE|Delayed enhancement magnetic resonance imaging (DE-MRI)|The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
47987560|NCT02039674|BIOLOGICAL|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
47987561|NCT02039674|DRUG|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
48354728|NCT05847556|OTHER|Audio-training|Audio-training (as a non-medical device) used to determine if it can improve spatial hearing perception.
47987562|NCT02039674|DRUG|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
47987563|NCT02039674|BIOLOGICAL|Bevacizumab|IV on Day 1 of each 3-week cycle
47987564|NCT02039674|DRUG|Pemetrexed|IV on Day 1 of each 3-week cycle
47987565|NCT02039674|BIOLOGICAL|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
47987566|NCT02039674|DRUG|Erlotinib|Orally tablet once daily
47987567|NCT02039674|DRUG|Gefitinib|Oral tablet once daily
47987568|NCT04136184|DRUG|Eplontersen|Eplontersen by subcutaneous injection
47987569|NCT04136184|DRUG|Inotersen|Inotersen by subcutaneous injection
47987570|NCT03420469|DRUG|Bupropion|Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
48354729|NCT06325644|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
48354730|NCT06325644|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
48354731|NCT06325644|BIOLOGICAL|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
48354732|NCT06325644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
48002632|NCT00393679|DRUG|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
48354733|NCT06325644|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
48505461|NCT04264026|DRUG|3,4-methylenedioxymethamphetamine|Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
48665766|NCT00647647|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
48665767|NCT00647647|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fasting
48665768|NCT00600340|BIOLOGICAL|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
48354734|NCT06325644|OTHER|Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .|Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
48354735|NCT04849338|DIAGNOSTIC_TEST|Bleeding score ( questionnaire )|Bleeding score is done for children diagnosed as von Willebrand's disease .
48354736|NCT01913509|DEVICE|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
48354737|NCT01913509|DEVICE|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
48354738|NCT01416506|OTHER|No Drug|It's a surveillance
48354739|NCT02085486|DEVICE|Ultrasound-assisted puncture|Portable ultrasound device
48665769|NCT00600340|BIOLOGICAL|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
48665770|NCT04836533|OTHER|Experimental: Computerized Cognitive Training|Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.
48354740|NCT02085486|OTHER|Standard|Standard inspection, palpation.
48354741|NCT01620801|BIOLOGICAL|AAV8-hFIX19|One-time IV vector administration.
48354742|NCT01641341|DRUG|Bifidobacterium infantis|once a day for seven to eight weeks
48354743|NCT01641341|DRUG|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
48354744|NCT01641341|DRUG|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
48354745|NCT01641341|DRUG|Placebo|Placebo capsule will not contain active treatment ingredients.
48354746|NCT04411225|DRUG|Cannabidiol oral solution|Both the active drug (cannabidiol) and placebo will be in oral solution.
48665771|NCT04836533|DRUG|Experimental: Open-label antidepressant treatment|Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
48665772|NCT04836533|OTHER|Active Comparator: Solitaire Training|Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.
48665773|NCT04836533|OTHER|Placebo Comparator: Placebo-controlled antidepressant treatment|Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
48002633|NCT02179996|BIOLOGICAL|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
48002634|NCT02179996|BIOLOGICAL|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
48002635|NCT03689556|DIAGNOSTIC_TEST|FLT PET/CT|Patients will receive 3'-deoxy-3'-\[18F\]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
48002636|NCT03669445|DRUG|Ixazomib|21-day cycles induction and 28-day cycles consolidation
48354747|NCT00221689|DRUG|baclofen (drug)|
48354748|NCT04656717|OTHER|Measure of the total cost of performing next-generation sequencing (NGS)|Resources consumed were collected for each laboratory using a standardized questionnaire. The production costs were calculated for the overall process and resources consumed for each step were identified.
48354749|NCT00476502|GENETIC|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
48354750|NCT02640924|RADIATION|Proton radiotherapy|
48354751|NCT02640924|PROCEDURE|Radiofrequency Ablation|
48354752|NCT04052594|DRUG|LY3475766 - IV|Administered IV
48354753|NCT04052594|DRUG|LY3475766 - SC|Administered SC
48354754|NCT04052594|DRUG|Placebo - IV|Administered IV
48354755|NCT04052594|DRUG|Placebo - SC|Administered SC
48354756|NCT01199640|DRUG|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
48354757|NCT05028166|DRUG|Mirdametinib (MEK Inhibitor)|Patients will receive oral mirdametinib.
48665774|NCT04890184|DIETARY_SUPPLEMENT|grape juice|grape juice
48002637|NCT03669445|DRUG|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
48354758|NCT03042494|DIETARY_SUPPLEMENT|Control|Isocaloric food without the test prebiotic.
48354759|NCT03042494|DIETARY_SUPPLEMENT|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
48354760|NCT03775473|DIAGNOSTIC_TEST|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
48354761|NCT02717429|BEHAVIORAL|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
48505462|NCT02400853|DEVICE|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
48665775|NCT04890184|OTHER|control|no intervention
48665776|NCT06341894|DRUG|Dalpiciclib|CDK4/6 inhibitor dalpiciclib, 100mg orally qd
48665777|NCT06341894|DRUG|Endocrine therapy|Fulvestrant/AI
48665778|NCT00724763|DEVICE|acupuncture|to Liv 3 and PE 9.
48665779|NCT00724763|DEVICE|sham needle treatment|needle not in meridian area
48665780|NCT00337168|DRUG|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
48002638|NCT03669445|DRUG|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
47987571|NCT03649698|BEHAVIORAL|Home-based training program|Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.
48143939|NCT04027452|BEHAVIORAL|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
48143940|NCT02409407|DRUG|Misoprostol , Prostaglandins E1 analogue|
48143941|NCT05859659|DIAGNOSTIC_TEST|This study does not intervene in this process.|This study does not intervene in this process.
47987572|NCT03649698|DIETARY_SUPPLEMENT|High-quality protein supplement|The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.
48143942|NCT01596465|OTHER|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
47987573|NCT03649698|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.
47987574|NCT03649698|DRUG|Placebo protein powder|Isocaloric maltodextrin powder. Amount based on food diary.
47987575|NCT03649698|DRUG|Placebo omega-3|Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
47987576|NCT01359449|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
47987577|NCT01359449|BIOLOGICAL|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
47987578|NCT01391390|DRUG|Melatonin|10mg/day, 12-week treatment
47987579|NCT01391390|DRUG|Placebo|10mg/day, 12-week treatment for TD
47987580|NCT06221514|OTHER|Core Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
47987581|NCT06221514|OTHER|Shoulder Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
47987582|NCT01396460|OTHER|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
47987583|NCT02934906|PROCEDURE|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
47987584|NCT02812147|DRUG|L-DOPS|Added as described in the Arm/Group Descriptions.
48143943|NCT01596465|OTHER|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
48505463|NCT02400853|PROCEDURE|Cord blood analysis|Cord blood will be collected during deliverance and analysed
48505464|NCT00128271|DRUG|Bavituximab|
47987585|NCT02812147|DRUG|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
47987586|NCT02145728|BEHAVIORAL|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
48002639|NCT03669445|DRUG|Daratumumab|21-day cycles induction and 28-day cycles consolidation
48002640|NCT00895791|DEVICE|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
48505465|NCT05102214|DRUG|HLX301|A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
48505466|NCT00667901|DRUG|riluzole|
48002641|NCT00895791|DEVICE|culotte stenting (Xience V)|implantation of stent
48002642|NCT03957512|PROCEDURE|Heart surgery|All invasive procedures
48002643|NCT00593307|OTHER|high GI|high GI and high carb breakfast
48002644|NCT00593307|OTHER|Low GI|low GI, high carb breakfast
48665781|NCT00337168|DRUG|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
48665782|NCT02286063|DRUG|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
48665783|NCT04194450|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
48665784|NCT04194450|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
48665785|NCT04745091|PROCEDURE|total mesorectal excision|excision of the rectum with complete excision of the mesorectum
48665786|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
48665787|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
48665788|NCT00710619|DRUG|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
48665789|NCT00710619|DRUG|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
48665790|NCT05657158|OTHER|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
48665791|NCT01027676|DRUG|Study treatment|Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
48143944|NCT02065297|OTHER|1 blood sample|
48143945|NCT02065297|OTHER|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
48143946|NCT03527888|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
48143947|NCT00407706|PROCEDURE|blood test|
48143948|NCT01754389|DRUG|Tacrolimus|
48143949|NCT01754389|DRUG|Methotrexate|
48143950|NCT01754389|DRUG|Bortezomib|
48143951|NCT01754389|DRUG|Sirolimus|
48143952|NCT01230970|DRUG|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
48505467|NCT00667901|GENETIC|protein expression analysis|
48665792|NCT01673126|DEVICE|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
48665793|NCT01673126|DEVICE|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
48665794|NCT00314977|DRUG|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
48665795|NCT00314977|DRUG|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
48665796|NCT00314977|DRUG|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
48665797|NCT05928988|DRUG|SHR8554；Itraconazole|Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
48665798|NCT05389072|DEVICE|control contact lens|control CRT lens
47987587|NCT02145728|BEHAVIORAL|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
48143953|NCT02320097|OTHER|Foot pressure measurement|"Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
48143954|NCT01763307|DRUG|RECONVAL CREAM|
48143955|NCT01763307|DRUG|PLACEBO|
48143956|NCT05193526|OTHER|No intervention|No intervention
48143957|NCT01005030|OTHER|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
48143958|NCT05504447|OTHER|"Rong-Yang Zhengyifang tea bag"|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
48143959|NCT05504447|OTHER|placebo tea bag|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
48143960|NCT05943054|OTHER|Temporal perception tasks|"A long temporal perception task in which the duration of the stimulus, around 2 min, is materialized by a video. For each trial, two videos are displayed to the participants, and then the task of the participant is to indicate the longest video and to give his level of confidence in his answer. A short temporal perception task which will take place in the same way as the long task except that the duration of the stimulus, around 2 seconds, is materialized by still frames from the videos used in the previous task."
48143961|NCT02627794|DEVICE|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
48505468|NCT00667901|GENETIC|reverse transcriptase-polymerase chain reaction|
48505469|NCT00667901|GENETIC|western blotting|
48505470|NCT00667901|OTHER|immunohistochemistry staining method|
48505471|NCT00667901|OTHER|laboratory biomarker analysis|
48665799|NCT05829837|OTHER|Ultrasonographic evaluation|Ultrasonographic evaluation for the thickness of piriformis muscle
48665800|NCT03254810|BIOLOGICAL|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
48665801|NCT03254810|BIOLOGICAL|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
48665802|NCT03254810|BIOLOGICAL|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
48665803|NCT01047540|DRUG|AIC316|Oral administration
48665804|NCT01047540|DRUG|AIC316|Oral administration
48665805|NCT01047540|DRUG|AIC316|Oral administration
48665806|NCT01047540|DRUG|AIC316|Oral administration
48665807|NCT01047540|DRUG|Placebo|Oral administration
47987588|NCT03043989|DRUG|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
47987589|NCT03043989|DRUG|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
47987590|NCT03043989|DRUG|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
48143962|NCT02627794|DEVICE|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
48143963|NCT04247906|DRUG|Narsoplimab|
48143964|NCT01775657|DEVICE|Thopaz (Digital drainage)|
48143965|NCT01775657|DEVICE|Pleur Evac (Analogue drainage)|
48143966|NCT01049152|DEVICE|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
48354762|NCT02717429|BEHAVIORAL|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
48354763|NCT02726204|OTHER|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
48354764|NCT02726204|OTHER|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
48354765|NCT02726204|OTHER|Path Assistance and Gravity Elimination|
48354766|NCT00949949|DRUG|everolimus|Given PO
48665808|NCT00516282|DRUG|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
48665809|NCT00516282|DRUG|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
48665810|NCT02000102|DRUG|Intravitreal Injection of Aflibercept|
48665811|NCT02400684|BIOLOGICAL|blood samples|Evolution of AMH before and after deep endometriosis surgery
48665812|NCT03944395|OTHER|Assisted Partner Notification Services|Three options for partner Notification services; contract referral, provider referral and dual referral
48665813|NCT05628571|COMBINATION_PRODUCT|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
48665814|NCT05628571|COMBINATION_PRODUCT|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
48665815|NCT00557440|DRUG|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
48665816|NCT00557440|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
47987591|NCT05736107|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
47987592|NCT05736107|OTHER|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
47987593|NCT01738763|DIETARY_SUPPLEMENT|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
47987594|NCT00665847|DRUG|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
48002645|NCT00593307|OTHER|Low GI Low Carb|low GI low carb breakfast
48002646|NCT00593307|OTHER|High GI Low carb|high GI low carb breakfast
48143967|NCT04453488|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
48143968|NCT04453488|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
48143969|NCT00048932|DRUG|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
48143970|NCT00048932|DRUG|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
48665817|NCT00557440|DRUG|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
48665818|NCT00557440|DRUG|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
48143971|NCT00048932|DRUG|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
48665819|NCT05822310|PROCEDURE|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
48354767|NCT00949949|DRUG|gemcitabine hydrochloride|Given IV
48665820|NCT05822310|PROCEDURE|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
48665821|NCT05822310|PROCEDURE|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
48143972|NCT03006393|DRUG|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
48143973|NCT03006393|OTHER|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
48665822|NCT03157947|BEHAVIORAL|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
48665823|NCT03157947|BEHAVIORAL|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
48665824|NCT03157947|BEHAVIORAL|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
48665825|NCT03282266|PROCEDURE|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
48665826|NCT03282266|PROCEDURE|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
48665827|NCT00710099|DRUG|sildenafil|systemic absorption of sildenafil
48665828|NCT00710099|DRUG|nitroprussiate iontophoresis|nitroprussiate iontophoresis
48665829|NCT05635006|OTHER||No special intervention, randomly classify the subjects
48665830|NCT03474276|DRUG|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
48665831|NCT03474276|DIETARY_SUPPLEMENT|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
48665832|NCT03474276|DRUG|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
47987595|NCT00665847|DRUG|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
47987596|NCT03851042|DEVICE|Virtual Reality Head set in PACU|Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
47987597|NCT03851042|OTHER|No intervention|Routine post laparoscopic hysterectomy management (no VR headset)
47987598|NCT01821534|OTHER|No Intervention|No treatment (intervention) was administered.
47987599|NCT02810392|DRUG|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
48143974|NCT02054208|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
48143975|NCT02054208|OTHER|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
48143976|NCT02372799|DRUG|Vilazodone|
48354768|NCT00949949|DRUG|cisplatin|Given IV
48354769|NCT01881724|BEHAVIORAL|Sleep education|
48354770|NCT04576390|DRUG|Ondansetron 4 mg|Antiemetic drug
47987600|NCT02810392|DRUG|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
47987601|NCT03396614|DIAGNOSTIC_TEST|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
48002647|NCT04060407|DRUG|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 6 times.
48143977|NCT02372799|DRUG|Placebo|
48143978|NCT02372799|DRUG|Fluoxetine|
48143979|NCT01221402|DRUG|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
48354771|NCT04576390|DRUG|Palonosetron 75 mcg|Antiemetic drug
48354772|NCT00001925|DRUG|Alcohol|
48354773|NCT02171806|DRUG|BI 1744 CL|
48354774|NCT02171806|DRUG|Placebo|
48354775|NCT01941212|BEHAVIORAL|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
48354776|NCT01087229|DRUG|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
48665833|NCT03474276|DIETARY_SUPPLEMENT|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
48665834|NCT04179344|OTHER|Integrated e-healthcare services (IeHS) web-based app|Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
47987602|NCT01572233|BEHAVIORAL|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"1. Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~2. The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
48665835|NCT06186310|OTHER|Aquatic Therapy Group|After the initial evaluations, patients will be given aquatic exercises including personalized strengthening, balance and breathing exercises accompanied by a physiotherapist 3 days a week for total 5 weeks. At the same time, the exercises taught as a home program will be asked to be repeated every day for 5 weeks.
48354777|NCT01087229|DRUG|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
48665836|NCT06186310|OTHER|Conventional Physical Therapy Group|After the initial evaluations, patients in the control group will be taught passive, active, actively assisted or resistant upper and lower extremity exercises as a home program, appropriate to each patient's functional level and muscle strength. Subjects will be asked to perform the exercises every day for 5 weeks, not exceeding an average of 45 minutes, 5 to 10 repetitions of each exercise, depending on fatigue.
48665837|NCT03518151|OTHER|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
47987603|NCT03409172|OTHER|CTR|no counseling or nutritional therapy and no exercise
48665838|NCT03518151|OTHER|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
48665839|NCT01180127|DIETARY_SUPPLEMENT|Flavanol containing food product|12 weeks, 2X/day, 20g serving
47987604|NCT03409172|OTHER|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
47987605|NCT03409172|OTHER|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
47987606|NCT05635227|DRUG|Dexamethasone phosphate|See description of arms
47987607|NCT05635227|DRUG|Isotonic sodium chloride (0.9%)|See description of arms
48665840|NCT01180127|BEHAVIORAL|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
47987608|NCT05635227|DRUG|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
47987609|NCT05635227|DRUG|Placebo capsule|capsule identical to capsule containing olanzapine
47987610|NCT05635227|PROCEDURE|Flow-targeted hemodynamic management|See description of arms
47987611|NCT05635227|PROCEDURE|Pressure-targeted hemodynamic management|See description of arms
47987612|NCT05635227|PROCEDURE|Low tidal-volume ventilation|See description of arms
47987613|NCT05635227|PROCEDURE|No ventilation|See description of arms
47987614|NCT01643811|PROCEDURE|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
47987615|NCT01643811|PROCEDURE|Endoscopic submucosal dissection|endoscopic submucosal dissection
48354778|NCT01635244|DEVICE|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
48665841|NCT01180127|DIETARY_SUPPLEMENT|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
47987616|NCT00877877|PROCEDURE|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
47987617|NCT04946292|BEHAVIORAL|Theory-derived intervention|The intervention will be delivered through multimedia materials and group activities, as appropriate. Participants will spend approximately 30-45 minutes for the intervention. Intervention materials and activities will be carefully designed to address all the constructs/ domains of the selected theoretical model(s). The effectiveness of the interventions will be evaluated using behavioural outcomes (diet, brushing, flossing) and clinical outcomes (oral hygiene, caries and periodontal conditions).
47987618|NCT04946292|BEHAVIORAL|Conventional health education|The conventional health education will be delivered through an oral health talk and oral health booklet. Topics covered are: (i) common oral diseases and its consequences; (ii) common dental problems among older adults; (iii) importance of oral health measures (healthy diet, toothbrushing and dental flossing); and (iv) proper techniques for toothbrushing and dental flossing.
47987619|NCT02429895|DRUG|ABT-122|Injection
47987620|NCT01566461|DEVICE|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
47987621|NCT01566461|DEVICE|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
47987622|NCT00410046|DRUG|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
48665842|NCT01180127|BEHAVIORAL|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
48665843|NCT04284111|DEVICE|Orthokeratology lenses|Orthokeratology lenses
47987623|NCT00003150|BIOLOGICAL|rituximab|
48354779|NCT05933993|OTHER|Elective cesarean section|The study does not contain an intervention in itself, but women are included if they undergo an elective cesarean section
48143980|NCT04326894|DRUG|25 mg/week oral methotrexate tablets|
48354780|NCT04458311|DRUG|Abiraterone Acetate|Supplied as 125 mg tablets
48354781|NCT04458311|DRUG|Tildrakizumab|Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
48354782|NCT04306770|OTHER|OPTIMUM programme|"OPTIMUM programme encompass of telehealth service to support the patient. Study participants will be given devices (Bluetooth-enabled blood pressure machine, weighing scale and glucometer) to monitor their parameters at home. Care team will use the Phillips Vital Health to perform tele-monitoring, tele-management (individualized on-line health coaching and timely interventions), and to deliver education content."
48665844|NCT01988077|BIOLOGICAL|Adoptive cell transfer|Adoptive cell transfer
48665845|NCT01988077|DRUG|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
48665846|NCT00127855|BIOLOGICAL|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
48665847|NCT00127855|BIOLOGICAL|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
47987624|NCT00003150|DRUG|CHOP regimen|
47987625|NCT00003150|DRUG|cyclophosphamide|
48354783|NCT00948714|BEHAVIORAL|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
48354784|NCT00948714|BEHAVIORAL|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
48354785|NCT00948714|OTHER|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
48354786|NCT02983695|DRUG|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
48354787|NCT01636739|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
48354788|NCT01636739|OTHER|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
48665848|NCT00127855|BIOLOGICAL|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
48665849|NCT00127855|BIOLOGICAL|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
47987626|NCT00003150|DRUG|doxorubicin hydrochloride|
47987627|NCT00003150|DRUG|prednisone|
47987628|NCT00003150|DRUG|vincristine sulfate|
47987629|NCT02049307|DRUG|Losartan 100mg daily|
48143981|NCT04326894|DRUG|25mg/week oral placebo tablets|
48354789|NCT06239649|PROCEDURE|Genicular nerve Radiofrequency Ablation block|Genicular nerve Radiofrequency Ablation block
48354790|NCT06246864|OTHER|Hydrocolloid dressing|After the oral gastric tube is placed on the premature baby and fixed with a Hydrocolloid dressing, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
48354791|NCT06246864|OTHER|Hypoallergenic Flexible|After the oral gastric tube is placed on the premature baby and fixed with a hypoallergenic flexible patch, the fixed patch will be removed after 24 hours using a silicone-based spray remover.
48354792|NCT03708484|OTHER|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
48354793|NCT03708484|OTHER|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
47987630|NCT02049307|DRUG|Matching placebo|
47987631|NCT05217420|BEHAVIORAL|Moving Well|Experimental arm
47987632|NCT05217420|BEHAVIORAL|Staying Well|Active comparator arm
47987633|NCT04320381|BEHAVIORAL|Qualitative Interview|2 Semi-Structured Qualitative Interviews
47987634|NCT05847231|BEHAVIORAL|Perceived Stress, Mandala application|Mandala
47987635|NCT06536803|OTHER|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks|high load strength training and Tissue-specific plantar fascia stretching exercise for 12 weeks
47987636|NCT06536803|OTHER|high-load strength training with routine physiotherapy|high load strength training with routine physiotherapy for 12 weeks
47987637|NCT05982509|DEVICE|EasyDew Regen MD Cream|For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.
47987638|NCT06478160|DEVICE|Closed-Blood Sampling Devices|blood collection with Closed-Blood Sampling System (CBSD)
47987639|NCT06478160|OTHER|Waste discard volume|Blood collection without CBSD, usual practice, need to waste discard volume
47987640|NCT02367677|OTHER|Method comparison|
47987641|NCT00704925|DRUG|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
47987642|NCT00875225|BEHAVIORAL|DVD|Control group will receive usual care DVD from health professionals
47987643|NCT00875225|BEHAVIORAL|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
48143982|NCT01562964|BEHAVIORAL|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
48143983|NCT01562964|BEHAVIORAL|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
48143984|NCT05549466|DRUG|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
48143985|NCT05549466|DRUG|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
48143986|NCT05549466|DRUG|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
48143987|NCT05549466|DRUG|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.
48143988|NCT03456856|DRUG|Ivabradine|Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
48143989|NCT03367299|DRUG|Chemotherapy + Blinatumomab|Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
48354794|NCT04331808|DRUG|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.
48354795|NCT04456803|DRUG|Ferric citrate tablet|250mg/tablet, manufactured by Sinomune Pharmaceutical
47987644|NCT02838563|OTHER|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
48354796|NCT04456803|DRUG|Sevelamer carbonate tablet|800 mg/tablet, manufactured by Genzyme Ireland Limited
48354797|NCT04563624|DRUG|composite blocks|cad cam composite blocks
48354798|NCT04563624|DRUG|ceramic cad cam blocks|ceramic cad cam blocks
48505472|NCT00667901|OTHER|pharmacological study|
48665850|NCT00127855|BIOLOGICAL|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
48665851|NCT00127855|BIOLOGICAL|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
48665852|NCT00127855|BIOLOGICAL|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
48665853|NCT05641766|DRUG|THC|Participants will receive THC into a rapidly flowing IV infusion.
48665854|NCT05641766|OTHER|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
48665855|NCT03880357|DRUG|Betamethasone Scalp Suspension 0.064%;0.0005%|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
47987645|NCT02220933|DRUG|MD1003 100mg capsule|
47987646|NCT02220933|DRUG|Placebo|
47987647|NCT04976166|BEHAVIORAL|Education|More informed and detailed education
47987648|NCT04976166|BEHAVIORAL|Education|Shared decision making
47987649|NCT04976166|BEHAVIORAL|Education|education as usual
47987650|NCT00492115|DEVICE|Continuous positive airway pressure (CPAP)|therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
47987651|NCT00492115|DEVICE|Placebo CPAP|Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
47987652|NCT04692428|PROCEDURE|Locoregional analgesia|the supra-inguinal fascia iliaca block versus the femoral nerve block
47987653|NCT00830843|DRUG|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
47987654|NCT00830843|DRUG|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
47987655|NCT00207207|PROCEDURE|Alternate site blood glucose testing|
47987656|NCT00306761|DEVICE|Dynamic Wheelchair Seating System|
48143990|NCT01706159|DRUG|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
48143991|NCT01706159|DRUG|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
48143992|NCT05205083|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
48143993|NCT03302091|DRUG|BI 1467335|28 day treatment period
48143994|NCT05309057|DIETARY_SUPPLEMENT|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
48505473|NCT00667901|PROCEDURE|neoadjuvant therapy|
48505474|NCT00667901|PROCEDURE|therapeutic conventional surgery|
48505475|NCT02288156|DRUG|Capsaicin|via nasal spray
48505476|NCT02288156|DRUG|placebo|via nasal spray
48665856|NCT03880357|DRUG|Taclonex®|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
48665857|NCT03880357|DRUG|Placebo topical suspension|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
48143995|NCT05352555|DEVICE|Automated vertigo repositioning chair|"Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll (for horizontal canal involvement)~3. (Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~1. Epley's and/or Semont's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~3. Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest."
48143996|NCT05352555|OTHER|Canalith Reposition Maneuver|"Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~1. Epley's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest."
48143997|NCT05533905|DIAGNOSTIC_TEST|Lumbar puncture|A thin needle is inserted between the bones in the spine.
48143998|NCT05533905|DIAGNOSTIC_TEST|MRI|A scan of the head.
48143999|NCT03937609|DRUG|Infliximab|infliximab iv 5mg/kg
48144000|NCT06241300|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program is an evidence-based group parenting intervention designed to reduce disruptive behavior in young children (2-8 years old).
48144001|NCT02364856|DEVICE|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
48144002|NCT01856062|DRUG|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
48144003|NCT01856062|DRUG|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
48144004|NCT02489357|PROCEDURE|Cryosurgery|Undergo whole gland cryoablation
48144005|NCT02489357|DRUG|Degarelix|Given SC
48144006|NCT02489357|OTHER|Laboratory Biomarker Analysis|Correlative studies
48354799|NCT03630185|DEVICE|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
48354800|NCT03630185|DEVICE|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
48354801|NCT05880303|PROCEDURE|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
47987657|NCT02389244|DRUG|Regorafenib|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
47987658|NCT02389244|DRUG|Placebo|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
48144007|NCT02489357|BIOLOGICAL|Pembrolizumab|Given IV
48144008|NCT00837291|DRUG|CF101|CF101 tablets 1 mg BID
48354802|NCT03918213|DIAGNOSTIC_TEST|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
48354803|NCT05894486|DRUG|Lutetium[177Lu] Oxodotreotide Injection|Lutetium\[177Lu\] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium\[177Lu\] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity
48354804|NCT04080700|PROCEDURE|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
47987659|NCT00208039|DRUG|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
47987660|NCT01209364|DEVICE|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
47987661|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
47987662|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
48144009|NCT00837291|DRUG|Placebo|Placebo tablets BID
48144010|NCT03224988|DEVICE|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
48144011|NCT04648904|RADIATION|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
48354805|NCT01108263|DRUG|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
48354806|NCT02508506|DRUG|ALKS 5461|Single dose, given orally
48665858|NCT04539171|OTHER|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
48665859|NCT04573985|BEHAVIORAL|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
48354807|NCT02935595|DRUG|Ketamine|Ketamine Hydrochloride Injection
48665860|NCT00243035|DRUG|bortezomib|Given IV
48665861|NCT00243035|DRUG|tipifarnib|Given orally
48144012|NCT05606796|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
48354808|NCT04773964|DRUG|MET642|MET642 active treatment
48354809|NCT04773964|DRUG|Placebo|Placebo comparator
48665862|NCT00243035|OTHER|laboratory biomarker analysis|Correlative studies
48665863|NCT06189794|OTHER|Rosa damascena oil|Essential oils will used by inhalation
47987663|NCT00894322|OTHER|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
47987664|NCT00469092|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
47987665|NCT00469092|DRUG|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
48354810|NCT01066637|DRUG|[18F](+/-)NOS|Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
48144013|NCT02332824|DRUG|TAK-272|TAK-272 tablets
48144014|NCT02332824|DRUG|TAK-272 Placebo|TAK-272 placebo-matching tablets
48354811|NCT00281528|DRUG|ABI-007 (Abraxane)|30 minute infusions
48354812|NCT00281528|DRUG|bevacizumab|infusions
48354813|NCT00090246|DRUG|MK0869, aprepitant|
48354814|NCT00090246|DRUG|Comparator: ondansetron IV|
48505477|NCT01977274|OTHER|gynecological cancer|blood and tumor samples
48665864|NCT00468247|DEVICE|Navigator|Navigator circulatory mgt system
48665865|NCT00468247|OTHER|Conventional care|Conventional haemodynamic care
48665866|NCT01209767|DEVICE|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
48665867|NCT01209767|PROCEDURE|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
48144015|NCT02332824|DRUG|Candesartan cilexetil|Candesartan cilexetil tablets
48144016|NCT02332824|DRUG|Candesartan cilexetil Placebo|Candesartan cilexetil placebo-matching tablets
48354815|NCT01979328|DEVICE|geko|
48354816|NCT01979328|DEVICE|Plaster cast|
48354817|NCT04932694|OTHER|Core stabilization training|Exercise training will be given to the participants in the study group in the form of core training exercises for 8 weeks.
48354818|NCT05120375|DRUG|BAT6021|Ⅳ infusions
48354819|NCT01926652|DRUG|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
48354820|NCT02672306|BIOLOGICAL|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10\^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
48665868|NCT01209767|OTHER|Control|
48354821|NCT02672306|BIOLOGICAL|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
48354822|NCT02664740|DRUG|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
48505478|NCT04961463|BEHAVIORAL|psychoeducation|
48505479|NCT04863599|OTHER|Questionnaire|Patients will be asked to complete the Bauer and Brice questionnaire at post-operative day 1.
48505480|NCT00006630|DRUG|Vaccinia Immune Globulin (Human)|
48505481|NCT02565537|PROCEDURE|LASIK|WFG vs. WFO LASIK
48505482|NCT05254600|BEHAVIORAL|RISE for Nurse Leaders Program|Psychoeducational sessions designed to impact resilience, insight, self-compassion, and empowerment
48505483|NCT03323047|DRUG|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
48505484|NCT03323047|DRUG|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
48505485|NCT03323047|DRUG|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
48505486|NCT03323047|DRUG|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
48665869|NCT01567722|GENETIC|DNA analysis|This sample will be used for germline DNA analysis.
48665870|NCT01567722|GENETIC|RNA analysis|RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.
48144017|NCT05770492|DIAGNOSTIC_TEST|anterior segment optical coherence tomography|Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
48665871|NCT01567722|GENETIC|gene expression analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
48665872|NCT01567722|GENETIC|polymorphism analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
48665873|NCT01567722|OTHER|biologic sample preservation procedure|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
48665874|NCT01567722|OTHER|flow cytometry|Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.
48665875|NCT01567722|OTHER|medical chart review|Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.
48665876|NCT03531255|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
48665877|NCT04415554|DIAGNOSTIC_TEST|echocardiography|echocardiography exam of the infant
48144018|NCT05894291|OTHER|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
48144019|NCT05894291|OTHER|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
48144020|NCT06506357|DIETARY_SUPPLEMENT|Good Girl Probiotics|Participants will take one capsule of the Good Girl Probiotics supplement daily in the morning for eight weeks.
48354823|NCT02664740|DRUG|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
48354824|NCT05085327|DRUG|ChapStick Lip Moisturizer Original|Sunscreen lip balm.
48354825|NCT05085327|DRUG|ChapStick Lip Moisturizer Mint|Sunscreen lip balm.
48354826|NCT05085327|DRUG|ChapStick Lip Moisturizer Black Cherry|Sunscreen lip balm.
48354827|NCT05085327|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
48354828|NCT00104273|DRUG|Rasagiline|
47987666|NCT00469092|DRUG|metformin|Tablets, 2550 mcg. Administered once daily.
47987667|NCT00469092|DRUG|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
48354829|NCT02070081|PROCEDURE|Roux-en-Y gastric bypass surgery or sleeve surgery|
48354830|NCT01913015|DRUG|abiraterone acetate|Given PO
48354831|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive low fat breakfast
48354832|NCT01913015|DIETARY_SUPPLEMENT|dietary intervention|Receive high fat breakfast
48354833|NCT01913015|OTHER|pharmacological study|Correlative studies
48354834|NCT01913015|OTHER|questionnaire administration|Ancillary studies
48354835|NCT01913015|OTHER|laboratory biomarker analysis|Correlative studies
48665878|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
48665879|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
48665880|NCT01051661|BIOLOGICAL|Placebo|Intramuscular injection, one dose
48665881|NCT06203223|OTHER|Ova-max|use Ova-max 3 months prior to treatment initiation
47987668|NCT05704608|OTHER|Aerobic training|Exercises on a treadmill at different speeds and inclination were performed.
48665882|NCT06203223|OTHER|placebo|use placebo 3 months prior to treatment initiation
48144021|NCT00691691|RADIATION|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
48144022|NCT04317430|DRUG|Niclosamide|Niclosamide tablets 1 gram once daily
48144023|NCT04317430|DRUG|Placebo oral tablet|lactose tablets
48144024|NCT01443572|DRUG|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
48144025|NCT01443572|DRUG|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
48144026|NCT03795532|PROCEDURE|SWL|Shock wave lithotripsy
48144027|NCT01941576|DRUG|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
48144028|NCT01941576|DRUG|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
48665883|NCT04250792|DRUG|Naltrexone Pill|role of low dose naltrexone in patients affected with psoriasis
48144029|NCT00001255|DRUG|ADA PBSC|
48144030|NCT00001255|DRUG|ADA Umbilical Cord Blood Cells|
48144031|NCT00001255|DRUG|Transduced Lymphocytes|
48144032|NCT05498051|PROCEDURE|Sentinel lymph node identification|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
48144033|NCT00317928|DRUG|Metformin|
48144034|NCT05570227|OTHER|[U-13C]Glucose Infusion|Peri-operative infusion of \[U-13C\]glucose
48354836|NCT06423404|BEHAVIORAL|the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom|The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective
47987669|NCT00372931|DRUG|AL-37807|
47987670|NCT02686879|DEVICE|Multifocal contact lenses|
47987671|NCT02686879|DEVICE|Single vision contact lenses|
48144035|NCT01247077|OTHER|selenium|200 ug selenium once daily
48354837|NCT06237608|BEHAVIORAL|Dialectical behavioural therapy (DBT)-informed skills group|16 week 1.5hr DBT-informed skills group facilitated by the lead researcher and two charity facilitators
48354838|NCT00646347|OTHER|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
48144036|NCT01247077|OTHER|placebo|
48144037|NCT05579717|BEHAVIORAL|Equine Assisted Learning|EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. It is 16 sessions in length, at a rate of two sessions per week.
48665884|NCT03289754|DEVICE|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
48144038|NCT02751294|DRUG|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
48144039|NCT02751294|DRUG|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
48144040|NCT02751294|DRUG|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
48144041|NCT00004085|BIOLOGICAL|filgrastim|as prescribed by physician
48144042|NCT00004085|PROCEDURE|autologous bone marrow transplantation|1-2 weeks prior to treatment
48144043|NCT00004085|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
48144044|NCT00004085|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
48665885|NCT00485173|DEVICE|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
48665886|NCT02181920|DRUG|Metamizole|
48665887|NCT02181920|DRUG|Diclofenac|
48665888|NCT02181920|DRUG|Diclofenac placebo|
48665889|NCT02181920|DRUG|Metamizole placebo|
48665890|NCT02234193|DEVICE|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
48665891|NCT02234193|PROCEDURE|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
48665892|NCT05114928|PROCEDURE|Transepithelial Corneal Collagen Cross-linking|Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
48665893|NCT05114928|DIAGNOSTIC_TEST|Scheimpflug camera|Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
48665894|NCT02665091|BEHAVIORAL|Peer Education Program|
48144045|NCT01535352|BEHAVIORAL|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
48665895|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel|
48665896|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
48665897|NCT00567554|DRUG|paclitaxel|
47987672|NCT00451386|DRUG|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
47987673|NCT00451386|DRUG|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
47987674|NCT04458545|DRUG|Placebo|Intranasal placebo 0mg
47987675|NCT04458545|DRUG|Oxy 25 mg|Intranasal oxycodone 25mg
48665898|NCT00567554|DRUG|paclitaxel + everolimus (RAD001)|
48665899|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
48665900|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + lapatinib|
47987676|NCT04458545|DRUG|OXY 50 mg|Intranasal oxycodone 50mg
47987677|NCT04458545|DRUG|OXY 100 mg|Intranasal oxycodone 100mg
47987678|NCT04458545|DRUG|Heroin|Intranasal heroin 100mg
47987679|NCT04052269|DRUG|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
47987680|NCT05982275|GENETIC|CARTemis-1|A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).
47987681|NCT01950845|DEVICE|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
48665901|NCT03643081|DEVICE|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
48665902|NCT03749239|DIETARY_SUPPLEMENT|Collagen protein|Collagen protein
48665903|NCT02055508|BEHAVIORAL|Exercise Intervention|
48665904|NCT02055508|OTHER|Care-Management-Phone-Calls|
48665905|NCT03223675|RADIATION|hippocampal-sparing WBRT|
48665906|NCT05687370|PROCEDURE|Modified dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.
48665907|NCT05687370|PROCEDURE|Long-axis technique|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
48665908|NCT03673176|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
48665909|NCT04661527|DRUG|Sarilumab|Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
48354839|NCT00646347|DEVICE|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~1. NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~2. The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
48665910|NCT02146157|DIETARY_SUPPLEMENT|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
48354840|NCT00192712|DRUG|irinotecan, gemcitabine|
48354841|NCT05099718|PROCEDURE|palatal soft tissue harvesting|A 6x2mm palatal soft tissue graft will be harvested.
48354842|NCT05099718|DEVICE|Hyaluronic acid|application 3-times per day for 7 days
48665911|NCT02146157|DIETARY_SUPPLEMENT|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
48354843|NCT05099718|OTHER|Saline solution (placebo)|application 3-times per day for 7 days
48354844|NCT06259591|BEHAVIORAL|Pedometer follow-up|The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
48354845|NCT06259591|BEHAVIORAL|Ambulation coaching|Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
48354846|NCT03990922|PROCEDURE|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
48665912|NCT06032130|OTHER|Clinical measurements|Optometric measurements
48665913|NCT06032130|OTHER|Oculomotor or perceptual therapy|Oculomotor or perceptual visual learning exercices
48354847|NCT03990922|PROCEDURE|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
48354848|NCT03990922|DRUG|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
48354849|NCT05365906|OTHER|Delphi-procedure consisting of four survey rounds|This study will use a modified Delphi approach, consisting of a set of iterative questionnaires. In round 1, an expert panel will grade the relevance of UTI-related items, after which a smaller core research team will compose a reference standard in a series of (online) meetings. In round 2, clinical vignettes will be used to party validate the reference standard and expert panel agreement with the new reference standard will be assessed.
48354850|NCT02105168|PROCEDURE|Blood sample|Optional
48354851|NCT02105168|PROCEDURE|Tumorous biopsy|Optional
48665914|NCT06389032|BEHAVIORAL|Peer Mentor Support and Caregiver Education|12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.
48665915|NCT06389032|BEHAVIORAL|Caregiver Education|12-weeks of receiving weekly curated list of Lewy Body Dementia (LBD) educational resources based on the weekly topics via email.
48665916|NCT01705392|DRUG|Bevacizumab|Bevacizumab 10 mg/kg q3w
48665917|NCT01705392|DRUG|Propranolol|Propranolol 80 mg x 1
48665918|NCT01705392|DRUG|Enalapril|Enalapril 5 mg x 1
48665919|NCT01705392|DRUG|Dacarbazine|dacarbazine 1000 mg/m2 q3w
48665920|NCT01734902|DRUG|Hyoscine butylbromide|sugar coated tablets for oral administration
48665921|NCT01734902|DRUG|Hyoscine butylbromide|drops for oral administration
48665922|NCT00355043|DRUG|Zinc sulphate 20 mg|
48665923|NCT04466839|OTHER|Questionnaire and interview|The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
48665924|NCT01368094|PROCEDURE|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
48665925|NCT01368094|PROCEDURE|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
47987682|NCT01950845|DEVICE|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
47987683|NCT00805311|PROCEDURE|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
48354852|NCT02105168|PROCEDURE|Healthy material sample|Optional
48354853|NCT00149006|PROCEDURE|Cell therapy|
48665926|NCT02733757|DRUG|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
48665927|NCT01404234|DRUG|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
48665928|NCT03027596|PROCEDURE|Remote ischemic conditioning|
48665929|NCT03503409|DRUG|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
48665930|NCT00621283|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
48665931|NCT04798677|DIETARY_SUPPLEMENT|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
47987684|NCT00805311|DRUG|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
48354854|NCT01996228|DEVICE|Stem Cell Educator|
48354855|NCT03166189|BIOLOGICAL|bone marrow-derived MSC and HRT|"* Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation."
48354856|NCT03166189|OTHER|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer."
48354857|NCT05232461|DRUG|PrimeC-ER 748 mg|PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
48354858|NCT05232461|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
48354859|NCT05232461|DRUG|Celecoxib 200mg|Celecoxib
48354860|NCT02316379|DRUG|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
48354861|NCT02316379|DEVICE|MRI|
48665932|NCT04798677|DIETARY_SUPPLEMENT|Placebo|Powder for dissolution in water, excipents. Lemon flavor
48665933|NCT05663684|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
48665934|NCT05663684|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
48665935|NCT05977296|DEVICE|CPAP|To use CPAP
48665936|NCT03526211|DEVICE|FES cycling|On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
48144046|NCT01535352|BEHAVIORAL|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
48144047|NCT03116191|DRUG|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
48144048|NCT03116191|DRUG|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
48354862|NCT00856115|OTHER|medical chart review|Patient charts are reviewed to obtain medical data.
48354863|NCT00856115|OTHER|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
48354864|NCT00856115|OTHER|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
48354865|NCT00856115|OTHER|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
48505487|NCT04933448|OTHER|Ketogenic Diet|The ketogenic diet (KD) is an alternative feeding regimen that has been in use since 1921. It is a high-fat, low carbohydrate, and moderate protein diet. There are various forms of the KD. The classic KD consists of long-chain triglycerides with a fat-to-combined-protein-and-carbohydrate ratio that can vary. At the investigating institution, it is standard of care to initiate a ketogenic diet at a ratio of 2:1, and to increase the ratio to 3:1 or 4:1 as needed to achieve ketosis.
48665937|NCT00775658|DRUG|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
48665938|NCT00775658|DRUG|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
48665939|NCT02665377|DRUG|ANP|
48665940|NCT02665377|DRUG|Placebo|
48665941|NCT03730519|DEVICE|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
48665942|NCT02972645|DRUG|LY3305677|Administered SC
48665943|NCT02972645|DRUG|Placebo|Administered SC
48144049|NCT05596006|DRUG|ASIMOMMY®|ASIMOMMY 500 mg
48144050|NCT05596006|DRUG|Domperidon|Domperidone capsule 10 mg
48144051|NCT05596006|DRUG|Placebo|Capsules of placebo 500mg.
48144052|NCT03125148|DEVICE|Enteral stenting|Enteral stent for malignant duodenal obstruction
48144053|NCT01062438|GENETIC|DNA analysis|
48144054|NCT01062438|GENETIC|RNA analysis|
48144055|NCT01062438|GENETIC|gene expression analysis|
48144056|NCT01062438|GENETIC|gene rearrangement analysis|
48144057|NCT01062438|GENETIC|mutation analysis|
48144058|NCT01062438|OTHER|laboratory biomarker analysis|
48665944|NCT03158831|DRUG|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
48665945|NCT00047034|DRUG|eribulin mesylate|Given IV
48665946|NCT00047034|OTHER|pharmacological study|Correlative studies
48665947|NCT00047034|OTHER|laboratory biomarker analysis|Correlative studies
48354866|NCT02239562|DRUG|sPIF|
48354867|NCT02239562|DRUG|Placebo|
48354868|NCT04563130|BEHAVIORAL|Cryocompression|Cryocompression will be administered using ice bags and compression socks/ surgical gloves
48354869|NCT03075865|DEVICE|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
48354870|NCT04321291|OTHER|Generic information leaflet|The information about the biosimiliars is realized only by the transmission of the information leaflet in addition to the information given by the investigator.
48665948|NCT03820076|OTHER|AZT-04|Staphylococcus epidermidis
48665949|NCT05212207|OTHER|CGM, smartwatch, and electronic diary|Participants wear a CGM and a smartwatch while keeping an electronic diary with information such as meals, sleep, and activity.
48665950|NCT00467441|DRUG|VSF-173|
47987685|NCT05153031|OTHER|lithiasic|Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.
47987686|NCT05153031|PROCEDURE|Emergency surgery|Emergency cholecystectomy
47987687|NCT05153031|PROCEDURE|cholecystectomy|cholecystectomy
47987688|NCT03893812|DEVICE|MRI|diffusion weighted MR
48665951|NCT05128747|OTHER|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
48665952|NCT03383666|DEVICE|PulseRider® Aneurysm Neck Reconstruction Device|Neck Reconstruction Device
48665953|NCT05218707|OTHER|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
48665954|NCT03226041|DEVICE|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
48665955|NCT05438147|OTHER|CT-100 DiNaMo|Active Treatment (Study App)
48665956|NCT05438147|OTHER|Care-as-Usual|Care-As-Usual control
48665957|NCT04565730|OTHER|Grup I= General anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
48665958|NCT04565730|OTHER|Grup II= Spinal anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
47987689|NCT03893812|DEVICE|Ultrasound|Color Doppler ultrasound
47987690|NCT00384722|DEVICE|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
47987691|NCT04922983|DRUG|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
47987692|NCT04922983|BEHAVIORAL|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
48144059|NCT01774240|OTHER|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
48144060|NCT04377542|PROCEDURE|LIFT|Ligation of the fistula tract in the intersphincteric plane
47987693|NCT04922983|BEHAVIORAL|Placebo|Used as placebo
47987694|NCT05581758|DRUG|AMG 510|Oral Tablet
48354871|NCT04321291|OTHER|Individual information by nurse on biosimilars|Delivery of the same information leaflet, completed if asked by the patient, by individual meeting with specialist nurse, including generic and standardized informations on specificities, advantages and current scientific knowledge about biosimilars in inflammatory rheumatic diseases. This is in addition to the information given by the investigator
48354872|NCT05496855|OTHER|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
48354873|NCT05496855|OTHER|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
48354874|NCT01250899|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
48665959|NCT04618094|OTHER|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
48665960|NCT02136784|DRUG|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
48665961|NCT02136784|DRUG|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
48354875|NCT04191694|OTHER|Chewing Gum|Patients will be given a packet of chewing gum on arrival in the post-operative recovery room. They will be asked to start chewing gum in the recovery room and then asked to chew gum according to their preference over course of the following 24 hours.
48354876|NCT04191694|DRUG|Ondansetron 4 MG|Ondansetron 4mg intravenously, intra-operatively as part of standard hospital caesarean section protocol
48354877|NCT02978911|PROCEDURE|preoperative cerebral MRI and operative findings|
48354878|NCT06191991|DRUG|Atorvastatin|40 mg
48354879|NCT06191991|DRUG|ALG-055009|0.9 mg
48354880|NCT06191991|DRUG|Rosuvastatin|10 mg
48354881|NCT01252992|GENETIC|Genetic analysis|"1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
48354882|NCT01252992|RADIATION|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
48354883|NCT01252992|OTHER|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
48665962|NCT02136784|DRUG|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
48665963|NCT02136784|DRUG|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
48665964|NCT02136784|DRUG|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
48665965|NCT02136784|DRUG|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
48354884|NCT01252992|OTHER|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
48354885|NCT06129006|PROCEDURE|hydrodilatation with steroid in group A versus hyalase in group B|"Hydrodilatation technique:~the ultrasound transducer will be placed on the posterior surface of the shoulder in the longitudinal plane to identify the posterior glenohumeral joint, bony glenoid, humeral head, and infraspinatus muscle.Then, after sterilizing the area to be injected, the needle will be advanced to the target point between the humeral head cartilage and the infraspinatus tendon using the ultrasound-guided in-plane technique.To ensure the injection into the glenohumeral joint, the Doppler mode will be used to confirm the widening of the space between the humeral cartilage and the innermost synovial line of the infraspinatus muscle by the injected solution."
48354886|NCT01731197|DIETARY_SUPPLEMENT|Dry-Blended Beverage|
48354887|NCT05103501|DRUG|PF regimen (cis-platinum ; 5-fluorouracil ) combined with PD-1 inhibitors（pembrolizumab）|immunotherapy:PD-1 inhibitor chemotherapy:5-Fu and DDP
48354888|NCT03155776|DIAGNOSTIC_TEST|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
48354889|NCT06210165|DRUG|Sugammadex|IV Sugammadex 4mg/kg stat once TOF ratio 0.7-0.9 after completing surgery
48354890|NCT06210165|DRUG|Neostigmine and atropine|IV neostigmine 40mcg/kg in combination with IV atropine 10mcg/kg stat once TOF ratio 0.7-0.9 after completing surgery
48354891|NCT01742663|DRUG|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
48354892|NCT01742663|DRUG|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
48354893|NCT01742663|DRUG|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
48354894|NCT01430910|DRUG|CAZ104|IV infusion
48354895|NCT01430910|DRUG|Avibactam|IV infusion
48354896|NCT01430910|DRUG|Ceftazidime|IV infusion
48354897|NCT03814057|DIAGNOSTIC_TEST|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
48354898|NCT05547594|BEHAVIORAL|Multimodal surgical prehabilitation|Participants will be encouraged to engage in regular physical activity (endurance and resistance exercise), eat healthily and undergo cognitive behavioural therapy (the latter only if required) during the weeks prior to surgery.
48354899|NCT01910272|DEVICE|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
48354900|NCT00003465|DRUG|temozolomide|
48354901|NCT01607749|BEHAVIORAL|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
48354902|NCT01607749|OTHER|Usual Asthma Information for teachers|Common asthma information for teachers
48354903|NCT05084820|COMBINATION_PRODUCT|Action observation treatment|Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
48354904|NCT05084820|COMBINATION_PRODUCT|conventional treatment|conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
48354905|NCT03615690|OTHER|Fasting Mimicking Diet|5 day reduced calorie diet
48505488|NCT05395390|BEHAVIORAL|Exercise (Resistance Training|Resistance Training done both at home and on site using either dumbells or keiser pneumatic exercise machines respectively
48665966|NCT02136784|DRUG|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
48354906|NCT03615690|OTHER|Regular Diet|Regular Diet
48354907|NCT00536094|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
48354908|NCT00536094|BEHAVIORAL|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
48354909|NCT02790450|DRUG|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
48354910|NCT01808365|PROCEDURE|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
48354911|NCT01808365|OTHER|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
48354912|NCT06193161|BEHAVIORAL|Therapist-supported internet delivered prolonged exposure|Therapist-supported internet delivered prolonged exposure for eight weeks.
48354913|NCT03842761|DRUG|BI 685509|Tablet
48354914|NCT03842761|DRUG|Placebo|Tablet
48505489|NCT03510026|DEVICE|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
47987695|NCT06496139|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavioural therapy|The intervention consists of 8 weeks of therapist-guided self-help ICBT.
48144061|NCT04377542|PROCEDURE|Parks|Modified Parks fistulotomy with complete internal anal sphincterotomy
48144062|NCT04377542|PROCEDURE|Seton|Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
48144063|NCT05752370|DEVICE|High flow oxygen|Use of HFO
48144064|NCT05752370|OTHER|Usual care|Room air or normal flow oxygen
48144065|NCT00690079|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
48144066|NCT00690079|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
48144067|NCT04083209|BEHAVIORAL|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
48144068|NCT05575687|OTHER|Water (reference)|Ingestion of 500 ml mineral water
48144069|NCT05575687|OTHER|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
48144070|NCT05575687|OTHER|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
48144071|NCT05575687|OTHER|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
48144072|NCT05575687|OTHER|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
48144073|NCT05575687|OTHER|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
47987696|NCT02308852|DEVICE|tDCS|
47987697|NCT01082965|DRUG|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
47987698|NCT01082965|DRUG|Placebo|matching placebo
48144074|NCT03875729|BIOLOGICAL|teplizumab|Treatment
48144075|NCT03875729|BIOLOGICAL|Placebo|Control
48144076|NCT00001615|DRUG|Corticosteroid|
47987699|NCT05233618|DRUG|Tagraxofusp|inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
47987700|NCT00555750|DRUG|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
47987701|NCT00555750|DRUG|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
47987702|NCT00460408|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
47987703|NCT02653807|OTHER|mobilization with movement|manual therapy intervention
48144077|NCT02336802|BEHAVIORAL|Avoidance experiment|Participants complete an avoidance task
48144078|NCT04848740|DEVICE|ReLex-smile|Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
48144079|NCT03587415|DIAGNOSTIC_TEST|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
48144080|NCT03661398|DEVICE|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
47987704|NCT02653807|OTHER|osteopathic mobilization|manual therapy intervention
48144081|NCT01581099|PROCEDURE|Digestive Adaptations III surgery|
48144082|NCT03190148|OTHER|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
48144083|NCT03190148|OTHER|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
48144084|NCT03190148|OTHER|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
48144085|NCT00033748|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
48144086|NCT00033748|BIOLOGICAL|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
47987705|NCT04585022|DEVICE|Magnum, Zimmer Biomet, Warsaw, IN|
47987706|NCT04585022|DEVICE|Recap, Zimmer Biomet, Warsaw, IN|
47987707|NCT01963403|DRUG|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
48144087|NCT01487954|DIETARY_SUPPLEMENT|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
48144088|NCT01487954|DIETARY_SUPPLEMENT|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
47987708|NCT01963403|DRUG|Placebo|1 pill per day; daily during study participation (up to 84 days)
47987709|NCT01927666|DIETARY_SUPPLEMENT|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
47987710|NCT05412654|DIETARY_SUPPLEMENT|High potassium water|High potassium water Potassium 6.2 mg/100ml
47987711|NCT05412654|DIETARY_SUPPLEMENT|Control low potassium water|Control water Potassium 0.2 mg/100ml
47987712|NCT05214482|DRUG|AK112|IV infusion,Specified dose on specified days
47987713|NCT05214482|DRUG|AK117|IV infusion,Specified dose on specified days
47987714|NCT05214482|DRUG|Chemotherapy|IV infusion,Specified dose on specified days
47987715|NCT00000633|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
47987716|NCT00000633|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
47987717|NCT01161914|DRUG|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
47987718|NCT01161914|DRUG|ISU302|administered by IV infusion for a dose of 60 U/kg
48665967|NCT02287610|DRUG|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
48665968|NCT03352947|DRUG|Dabrafenib|150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
48665969|NCT03352947|DRUG|Trametinib|Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
48665970|NCT05294302|BEHAVIORAL|eSCCIP/eSCCIP-SP|eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
48665971|NCT05294302|BEHAVIORAL|Coping Space|Coping Space is a psychosocial informational website for PCCC.
48665972|NCT03140111|DEVICE|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
48665973|NCT03140111|DEVICE|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
48665974|NCT06203834|DIETARY_SUPPLEMENT|I-Fiber Pearl|Eat 200g for once, and once a day.
48144089|NCT01487954|RADIATION|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
48144090|NCT01584648|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily
48144091|NCT01584648|DRUG|Trametinib|Trametinib 2 mg once daily
48665975|NCT06203834|DIETARY_SUPPLEMENT|placebo|Eat 200g for once, and once a day.
48144092|NCT01584648|DRUG|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
48144093|NCT04108104|DRUG|Cyproheptadine|3-month treatment
47987719|NCT06182826|PROCEDURE|Core Stability protocol|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Curl Up Side Planks Bird Dog Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
47987720|NCT06182826|PROCEDURE|Routine exercise therapy|5 Minutes Warm up Hamstring stretch Back Extensor Stretch Hip Flexor Stretch Jumping Rope Stair Stepping Mountain Climbers Frequency: 3 sessions per week for six weeks. Time Duration: Approx. 30 to 45 minutes
47987721|NCT03076957|DRUG|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
48665976|NCT00740181|DRUG|chemotherapy|
48144094|NCT04108104|DRUG|Alpress LP|3-month treatment
48354915|NCT00519571|DEVICE|ImplantLock device|dental implant
48354916|NCT03784716|OTHER|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
48354917|NCT03784716|OTHER|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
48354918|NCT02299544|DEVICE|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
48354919|NCT01682759|DRUG|Omarigliptin|
48354920|NCT01682759|DRUG|Placebo to Omarigliptin|
48665977|NCT02073474|DRUG|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
48665978|NCT05492266|DEVICE|Expiratory Muscle Strength Training|At visit 1, participants will be block randomized based on PWSS score (3-6 or 7+) to Expiratory Muscle Strength Training (EMST) for 6 to 8 weeks or no exercises. Participants in the EMST-150 group will perform 5 sets of 5 resistive expirations once a day with a 10-15 second rest between each repetition and a 1-2 minute rest between each set of 5 repetitions.
48665979|NCT05492266|DEVICE|Maintenance Training|"At visit 2, participants with improved (decreased) PWSS of 2 or more points, for whom the family and/or surgeon is not currently considering surgical intervention for VPI, will be further randomized to continue maintenance EMST exercises or no exercises for 6 months. Participants in the maintenance group will complete 3-5 sessions exercise sessions each week (rather than daily training), with 2 sets of 5 resistive expirations (rather than 5 sets)"
48665980|NCT00267930|DRUG|Vernakalant (oral)|
48665981|NCT00267930|DRUG|Placebo comparator|
48665982|NCT01098422|DEVICE|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
47987722|NCT00410553|DRUG|Eribulin Mesylate|Given IV
47987723|NCT00410553|DRUG|Gemcitabine Hydrochloride|Given IV
47987724|NCT00867425|BEHAVIORAL|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
47987725|NCT00220402|DRUG|SPM 907|
47987726|NCT01675128|DRUG|ISIS 183750|
47987727|NCT01675128|DRUG|Irinotecan|
47987728|NCT02335099|DRUG|ticagrelor|ticagrelor 90 mg twice a day for 6 months
48665983|NCT05939726|OTHER|Moisturising cream with vitamin E concentrate|The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
48665984|NCT05939726|OTHER|Moisturising cream without vitamin E concentrate|This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
48354921|NCT01682759|DRUG|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
48354922|NCT01682759|DRUG|Glimepiride Placebo|
48354923|NCT01682759|DRUG|Metformin|Participants will continue on their stable dose (\>=1500 mg/day) of open-label metformin throughout the trial.
48354924|NCT01682759|DRUG|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
48354925|NCT04978922|DEVICE|Machine Learning: ML (Artificial Intelligence System)|To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)
48354926|NCT04236440|DRUG|BAY2586116 (A1)|160 μg BAY2586116 (nasal spray administration)
48354927|NCT04236440|DRUG|Placebo (A2)|Placebo matching BAY2586116 (nasal spray administration)
48354928|NCT04236440|DRUG|BAY2586116 (B1)|160 μg BAY2586116 (nasal drops)
48354929|NCT04236440|DRUG|BAY2586116 (B2)|80 μg BAY2586116 (nasal spray)
48354930|NCT04236440|DRUG|BAY2586116 (B3)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
48354931|NCT04236440|DRUG|BAY2586116 (C)|160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
48354932|NCT04783961|PROCEDURE|Cold snare endoscopic resection|Cold snare endoscopic resection
48665985|NCT05939726|OTHER|Urea cream|Urea cream (10%w/w) is used as the standard of care for PPE.
48665986|NCT02143284|DEVICE|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
48665987|NCT00371124|DRUG|Atropine Eye drops|
47987729|NCT02335099|DRUG|Placebo|1 pill twice a day for 6 months
48354933|NCT05310006|OTHER|Exercise|Exercise sessions were performed in the morning (07:00 am-12:00 am) under the supervision of at least two fitness instructors in the rehabilitation unit of the nursing home.HSRE and TRE were designed according to the peculiarities of each type of resistance exercise (Chodzko-Zajko et al., 2009). During TRE, participants performed four sets of 8-10 repetitions at 70-75% of the maximal strength. The concentric and eccentric phases were carried out for 2 s. For HSRE, exercises were performed eight times (sets) with 4-5 repetitions at 70-75% of the maximal strength. The concentric phase was performed as fast as possible, and the eccentric phase was carried out for 2 s. Bilateral calf raise was performed using the same load as unilateral knee extension.
48665988|NCT02538796|OTHER|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
48665989|NCT02538796|OTHER|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
48665990|NCT02538796|OTHER|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
47987730|NCT00378274|BEHAVIORAL|Observation|
48354934|NCT03760302|OTHER|analgesics|analgesics given to a patient treated from HEMS
48354935|NCT03760302|OTHER|hypnotics|hypnotics given to a patient treated from HEMS
48354936|NCT01633372|DRUG|itacitinib|
48354937|NCT01814891|OTHER|Orange maize feeding|This group was fed orange maize.
48354938|NCT01814891|OTHER|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
48354939|NCT01814891|OTHER|Oil only|This group received a small amount of plain oil without vitamin A.
48354940|NCT05466591|DIAGNOSTIC_TEST|Pre-hospital rule-out strategy|Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
48354941|NCT06022497|OTHER|Tidal Model Based Emotion Regulation Interventions|The Tidal Model is a nursing model and was developed by Phil Barker. It is an important model for psychiatric nursing care. In the research, nursing interventions for emotion regulation were structured by using the Tidal Model.At each session, emotion regulation interventions were applied within the Tidal Model care domains.
48665991|NCT02538796|OTHER|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
48354942|NCT01842191|DIETARY_SUPPLEMENT|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
48354943|NCT01842191|DIETARY_SUPPLEMENT|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
48354944|NCT01569724|OTHER|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
48354945|NCT03371004|DRUG|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
48354946|NCT05749276|DRUG|Darzalex|"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"
48354947|NCT02563886|OTHER|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
48354948|NCT02563886|OTHER|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
48354949|NCT05010291|BEHAVIORAL|Standard of Care (SOC) text message reminder to attend clinic appointment|SOC one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
48354950|NCT05010291|BEHAVIORAL|Loss aversion framed text message reminder to attend clinic appointment|Loss aversion framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
48354951|NCT05010291|BEHAVIORAL|Social norms framed text message reminder to attend clinic appointment|Social norms framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
48354952|NCT05010291|BEHAVIORAL|Altruism framed text message reminder to attend clinic appointment|Altruism framed one-way text message reminding recipient of care to either 1) attend a scheduled clinic appointment or 2) visit the clinic after a missed appointment.
48354953|NCT05709587|OTHER|Virtual reality training|Virtual reality Training for 12 sessions, two to three times for one week, one training session last for 20 minutes
48354954|NCT04489602|OTHER|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
48354955|NCT02079506|DRUG|Candesartan|
48354956|NCT02079506|DRUG|Rosuvastatin|
48505490|NCT02542553|PROCEDURE|Bilateral BAL|
48665992|NCT04694911|BEHAVIORAL|Focus Group|Participate in focus group
48665993|NCT04694911|OTHER|Interview|Complete cognitive interview
48665994|NCT04694911|OTHER|Research or Clinical Assessment Tool|Receive OOCAT
48665995|NCT06256055|BIOLOGICAL|UCMYM802 Injection|1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
48665996|NCT01617473|PROCEDURE|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
48665997|NCT01435590|PROCEDURE|Curette v/s endocervical brush|
48354957|NCT05715840|DRUG|SG001 injection|360 mg，Q3W，IV infusion
48354958|NCT05715840|DRUG|Paclitaxel|175 mg/m\^2，Q3W，IV infusion
48354959|NCT05715840|DRUG|Cisplatin|50 mg/m\^2，Q3W，IV infusion
48354960|NCT05715840|DRUG|Carboplatin|AUC=5，Q3W，IV infusion
48354961|NCT05715840|DRUG|Bevacizumab injection|15 mg/kg，Q3W，IV infusion
48354962|NCT05715840|DRUG|SG001 placebo|Q3W，IV infusion
48354963|NCT03184766|DRUG|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
48354964|NCT03184766|DRUG|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen \& 30 mg pseudoephedrine
48505491|NCT00927797|DRUG|Cyclophosphamide, Pentostatin, Rituximab|
48505492|NCT06189729|BEHAVIORAL|Text reminder|Participants will receive trimonthly text reminders through instant messaging mobile applications or short message service.
48505493|NCT06189729|BEHAVIORAL|HIV self-test|Participants will receive trimonthly text messages asking them to choose a pickup point run by the delivery company to collect the free HIV self-test. Upon receiving the delivery instruction, the self-test kit with bilingual (Chinese and English) instructions would be delivered to the designated location.
48665998|NCT00694863|DRUG|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
48665999|NCT03782415|DRUG|MN-166|MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
48354965|NCT03184766|DRUG|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
48354966|NCT00078455|DRUG|ILX651|
48354967|NCT01829672|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
48354968|NCT01970124|DRUG|KPS-0373, High dose|
48354969|NCT01970124|DRUG|KPS-0373, Low dose|
48354970|NCT03083964|BEHAVIORAL|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
48354971|NCT03083964|BEHAVIORAL|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
48354972|NCT01962272|BEHAVIORAL|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
48354973|NCT01962272|DIETARY_SUPPLEMENT|Forticare®.|
48666000|NCT03782415|DRUG|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
47987731|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(non freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
47987732|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
48144095|NCT03845881|DRUG|Oxycodone|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
48144096|NCT03845881|DRUG|Placebo Oral Tablet|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
48354974|NCT00811395|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
48354975|NCT00811395|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
48354976|NCT00811395|DRUG|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
48354977|NCT00811395|DRUG|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
48354978|NCT04979338|OTHER|Ultrasound guided Continuous Infraclavicular Brachial Plexus Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
48666001|NCT02464748|OTHER|TiM telehealth arm|
48354979|NCT04979338|OTHER|Ultrasound guided Continuous Femoral Nerve Block|20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
48666002|NCT04326738|DRUG|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
48666003|NCT04326738|DRUG|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
48354980|NCT04979338|OTHER|Ultrasound guided Pudendal Nerve Block|20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
48354981|NCT04979338|DRUG|Bupivacaine|0.25% or 0.5% with or without 1:200K epinephrine
48354982|NCT04979338|OTHER|Bilateral ultrasound guided Transversus Abdominis Plane Block|40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
48666004|NCT03735914|OTHER|MRI|Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
48666005|NCT04597749|DIAGNOSTIC_TEST|PSG|In-lab sleep polysomnography test
48354983|NCT04979338|OTHER|Bilateral spermatic cord block|10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
47987733|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
48144097|NCT03556410|BEHAVIORAL|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
48144098|NCT03556410|BEHAVIORAL|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
48354984|NCT04979338|OTHER|Pecs I & II Block|0.25% bupivacaine: 15-30mL per side for Pecs I-III
48354985|NCT04979338|OTHER|Local anesthetic|0.25% or 0.5% bupivacaine into the appropriate surgical site
48666006|NCT04597749|DIAGNOSTIC_TEST|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
48666007|NCT04597749|OTHER|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
48666008|NCT02347605|DRUG|Nicotine lozenge 4 mg|
48666009|NCT02347605|DRUG|Placebo lozenge|
48666010|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48666011|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48666012|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48666013|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48144099|NCT00105170|DRUG|hCBE-11|
48666014|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48144100|NCT05363397|DRUG|TBO-309|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.
48666015|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48144101|NCT00163501|DRUG|Ciclesonide|
48144102|NCT02562521|BEHAVIORAL|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
48144103|NCT02562521|DRUG|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
48666016|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48666017|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
48144104|NCT02562521|DRUG|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
48144105|NCT02562521|BEHAVIORAL|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
48144106|NCT00637663|DRUG|Entecavir|entecavir 0.5 mg QD
48144107|NCT00637663|DRUG|Lamivudine|lamivudine 100 mg QD
48144108|NCT04201314|DIETARY_SUPPLEMENT|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
48144109|NCT04201314|DIETARY_SUPPLEMENT|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
48144110|NCT03265132|BIOLOGICAL|anakinra|sub cutaneous injection
48144111|NCT03265132|DRUG|Placebo|sub cutaneous injection
48666018|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
48144112|NCT00515892|DRUG|Immunotoxin therapy|
48666019|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
48666020|NCT03680521|DRUG|Sitravatinib|Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
48666021|NCT03680521|DRUG|Nivolumab|Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
48666022|NCT05006664|DRUG|Adcetris 50 MG Injection|Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.
48666023|NCT05006664|DRUG|Endoxan|Treatment by study drug Cyclophosphamide (Endoxan) in combination.
48666024|NCT05006664|DRUG|Doxorubicin|Treatment by study drug Doxorubicin in combination.
48666025|NCT05006664|DRUG|Etoposide|Treatment by study drug Etoposide in combination.
48666026|NCT05006664|DRUG|Prednisone tablet|Treatment by study drug Prednisone in combination.
48666027|NCT03332030|DIAGNOSTIC_TEST|Collection of Stem Cells|One time collection of a 20 ml blood sample
48144113|NCT00515892|DRUG|CAT-8015 Immunotoxin|
48144114|NCT00515892|PROCEDURE|Biological therapy|
48144115|NCT00515892|PROCEDURE|Antibody Therapy|
48144116|NCT00515892|PROCEDURE|Monoclonal Antibody Therapy|
48144117|NCT02924051|BEHAVIORAL|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
48144118|NCT02924051|BEHAVIORAL|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
48666028|NCT01693367|DEVICE|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
48144119|NCT04169802|DIAGNOSTIC_TEST|Retinal Health Monitoring System Visual Acuity Module|Assessment of corrected near visual acuity
48144120|NCT04169802|DIAGNOSTIC_TEST|Sloan letter, logarithmic near visual acuity chart (Reference Chart)|Assessment of corrected near visual acuity
48144121|NCT00913055|DRUG|octreotide acetate|subcutaneous implant
48144122|NCT05534776|OTHER|Investigator Global Assessments (IGAs)|5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
48144123|NCT03288506|BEHAVIORAL|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
48144124|NCT03528915|OTHER|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
48354986|NCT05789940|PROCEDURE|hysteroscopy|The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.
48144125|NCT03528915|OTHER|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
48144126|NCT05126537|OTHER|no intervention|prospective and observational study with no intervention
48144127|NCT03026166|DRUG|Ipilimumab|Administered by intravenous infusion
48144128|NCT03026166|DRUG|Nivolumab|Administered by intravenous infusion
48144129|NCT03026166|DRUG|Rovalpituzumab tesirine|Administered by intravenous infusion
48354987|NCT05789940|PROCEDURE|Aspiration|The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.
48354988|NCT00294229|PROCEDURE|manipulative therapy|
48354989|NCT04885075|DRUG|IV diazepam|inj.diazepam 0.2mg/kg/dose stat
48354990|NCT04885075|DRUG|I/N Midazolam|intranasal midazolam 0.2mg/kg/dose stat
48354991|NCT00639808|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
48354992|NCT00639808|DRUG|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
48354993|NCT05864391|DRUG|AZD7503|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
48354994|NCT01097564|GENETIC|COL4A1 genetic testing|genetic testing
48354995|NCT04646850|OTHER|Color duplex ultrasound of the carotid arteries|Examinations carried out according to the American Society of Echocardiography guidelines 25 using a Vivid 7 US instrumentation with a linear M12L probe (14 MHZ; General Electric).
48354996|NCT03727802|DRUG|TRK-250|single and multiple doses (4 weeks)
48354997|NCT03727802|DRUG|Placebo|single and multiple doses (4 weeks)
48144130|NCT02822703|DEVICE|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
48354998|NCT03583502|DIETARY_SUPPLEMENT|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
48354999|NCT05637294|DEVICE|splinting|neutral-positioned wrist orthosis
48666029|NCT01693367|DEVICE|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
48666030|NCT02157909|DEVICE|Lotrafilcon B sphere modified design contact lenses|
48666031|NCT02157909|DEVICE|Lotrafilcon B sphere contact lenses|
48666032|NCT04426474|DRUG|LY3502970|Administered orally.
48144131|NCT02822703|DEVICE|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
48144132|NCT01488084|PROCEDURE|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
48144133|NCT01488084|PROCEDURE|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
48144134|NCT04062578|BEHAVIORAL|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
48144135|NCT06413888|PROCEDURE|pancreaticoduodenectomy|Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period
48666033|NCT04426474|DRUG|Placebo|Administered orally.
48666034|NCT00312286|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
47987734|NCT01782664|DRUG|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
47987735|NCT01782664|DRUG|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
48355000|NCT02258841|BEHAVIORAL|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
48355001|NCT02258841|BEHAVIORAL|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
48355002|NCT02258841|BEHAVIORAL|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
48355003|NCT02258841|BEHAVIORAL|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
48355004|NCT02258841|BEHAVIORAL|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
48355005|NCT05907083|RADIATION|cone beam computer tomography|Cone Beam CT Radiation
48355006|NCT05192044|OTHER|Fast track Care pancreatico-duodenectomy.|Enhanced recovery after pancreatico-duodenectomy, with early oral intake, mobilization \& discharge
48355007|NCT05192044|OTHER|Conventional Care|Conventional Care
48355008|NCT03224832|PROCEDURE|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~* The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
48355009|NCT03224832|PROCEDURE|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
48355010|NCT01349842|BIOLOGICAL|Blood sampling|20ml of patient peripherical blood will be collected
48355011|NCT01349842|OTHER|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
48355012|NCT04837768|DRUG|Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \>9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the traditional twice-daily vaginal progesterone supplementation till 12 weeks gestation.
48355013|NCT04837768|DRUG|Twice-weekly intramuscular + Twice-daily transvaginal progesterone supplementation|Patients with serum progesterone levels \<9.2 ng/ml on the day of embryo transfer in artificial frozen cycles will receive the twice-daily vaginal progesterone in addition to twice-weekly intramuscular progesterone supplementation till 12 weeks gestation.
48666035|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
48666036|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
48666037|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
48666038|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
48144136|NCT06278194|PROCEDURE|Gasserian Ganglion Radiofrequency Thermocoagulation|Gasserian ganglion radiofrequency thermocoagulation is performed in the operating room under fluoroscopy. In sterile condition, the foramen ovale is shown by the pain management specialist under fluoroscopy guidance. After this condition, the entry of the needle is marked and anaesthetised with local anaesthetic. After the entry of the gasserian ganglion with the radiofrequency needle, 10 cm long, the location is checked with sensory and motor stimulation. If the placement is correct, 70 degrees 70 seconds of radiofrequency thermocoagulation is applied.
48144137|NCT05689684|DIETARY_SUPPLEMENT|AG+XOS+AXOS|4-month parallel randomized controlled study
48144138|NCT05689684|DIETARY_SUPPLEMENT|Placebo Maltodextrin|4-month parallel randomized controlled study
48144139|NCT05904652|DEVICE|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
48144140|NCT05904652|DEVICE|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
48144141|NCT02451072|DRUG|Placebo|Capsules containing mannitol looking identical to LSD per os
48144142|NCT02451072|DRUG|LSD|100µg per os, single dose
48144143|NCT02451072|DRUG|Ketanserin|40mg per os, single dose looking identical to LSD per os
48144144|NCT01790542|OTHER|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
48144145|NCT01790542|OTHER|Iron fortified cereal with fruit|
48144146|NCT01790542|OTHER|Meat|
48144147|NCT04475406|OTHER|PICF (Periopaper)|After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
48666039|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
48666040|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
48144148|NCT04475406|OTHER|Subgingival plaque, Gracey curette (Hu-Friedy)|After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
48144149|NCT04475406|OTHER|Clinical data, williams probe PCPNU (Hu-Friedy)|"A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton."
48144150|NCT05035563|BEHAVIORAL|Intervention. Early and integral communication strategy (EICS)|"This intervention will be implemented in patients since they are hospitalized in the ICU where is expected:~* Facilitate contact and communication between patients, families and the health team.~* Respond to the communication needs of family members.~* Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support.~* Build a positive and trusting relationship of relatives and patients with health teams.~The intervention considers the following actions:~1. - Training in communication to the health team~2. - Written material~3. - Family website~4. - Standardized and daily telephone information~5. - Health Team Support Strategy~6. - Weekly multidisciplinary virtual meeting with the family~7. - ICU diaries for family members"
48144151|NCT06176014|PROCEDURE|implant placement|5 implant were placed in intraforaminal area using surgical guide
48355014|NCT04411472|BIOLOGICAL|Recombinant human alkaline phosphatase|patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.
48666041|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
47987736|NCT01782664|DRUG|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
48144152|NCT03165305|OTHER|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
48144153|NCT02258178|BIOLOGICAL|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
48144154|NCT06134193|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
48355015|NCT04411472|OTHER|Placebo|Placebo
47987737|NCT01782664|DRUG|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
48355016|NCT00428285|PROCEDURE|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
48355017|NCT02158962|BEHAVIORAL|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
48355018|NCT05988086|PROCEDURE|platelet rich fibrin|12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
48355019|NCT05988086|PROCEDURE|collagen membrane|12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
48355020|NCT04101786|OTHER|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
48355021|NCT05010434|DRUG|Sintilimab and Bevacizumab Combined with Radiotherapy|Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.
48355022|NCT01608139|DRUG|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
48355023|NCT01608139|DRUG|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
48666042|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
48666043|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
48666044|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
48666045|NCT01202162|DRUG|Desflurane|Administratino of Desflurane
48666046|NCT01202162|DRUG|Administration of Sevoflurane|Administration of Sevoflurane
47987738|NCT01402674|DRUG|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
47987739|NCT05894733|OTHER|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
47987740|NCT05894733|OTHER|control group|first and sixth month face to face interwiew
47987741|NCT05925023|DRUG|Sirolimus|Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
47987742|NCT02989740|PROCEDURE|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
47987743|NCT00390533|DRUG|Saredutant|oral administration (capsules)
47987744|NCT00390533|DRUG|Placebo|oral administration (capsules)
48666047|NCT04595435|PROCEDURE|Lumpectomy|Removal of lump/tumor from breast utilizing an approach that saves as much breast as possible.
48666048|NCT04595435|RADIATION|Intraoperative Radiation Therapy|Delivery of low energy radiation therapy directly at surgical site, immediately removal of lump and tissue prior to final surgical closure
48666049|NCT03855904|DEVICE|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
48666050|NCT05213741|DEVICE|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
48666051|NCT06489015|DRUG|Recombinant Human Serum Albumin|Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
48144155|NCT06134193|DRUG|Surufatinib|250mg PO d1, Q3W
48144156|NCT06134193|DRUG|Tislelizumab|200mg IV d1, Q3W
48666052|NCT01082939|DRUG|Fludarabine|25 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
48355024|NCT01608139|DRUG|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
47987745|NCT03724851|DRUG|TEW-7197|"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."
48355025|NCT04106011|DRUG|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
48355026|NCT04106011|DIAGNOSTIC_TEST|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
47987746|NCT01918904|DRUG|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
47987747|NCT01918904|DRUG|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
48666053|NCT01082939|DRUG|Cyclophosphamide|250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
48666054|NCT01082939|DRUG|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
48666055|NCT01082939|DRUG|Rituximab|"Cycle 1 (Week 1): 375 mg/m\^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV on Day 2 over 4- 6 hours"
48666056|NCT04843592|DEVICE|SOKARY Mobile|Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
48666057|NCT01151267|OTHER|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.
48666058|NCT01151267|DEVICE|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
48666059|NCT02157610|BEHAVIORAL|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
47987748|NCT06422260|OTHER|Prosthesis superstructure|Prosthesis superstructure for 2 implant supported short span fixed bride constructed from different materials
48002648|NCT04060407|DRUG|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4.
48002649|NCT04060407|DRUG|Nivolumab|Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.
48144157|NCT01005615|DEVICE|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
48355027|NCT04106011|DIAGNOSTIC_TEST|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
48355028|NCT04106011|DIAGNOSTIC_TEST|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
48355029|NCT04106011|DIAGNOSTIC_TEST|SLP9|Assessment of Sleep
48355030|NCT04106011|DIAGNOSTIC_TEST|NPSI|Assessment of neuropathic components
48666060|NCT02157610|DRUG|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke \>10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
48666061|NCT02157610|BEHAVIORAL|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
48666062|NCT02157610|PROCEDURE|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
48002650|NCT02143570|DRUG|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
48666063|NCT02157610|BEHAVIORAL|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
48144158|NCT01005615|DEVICE|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
48666064|NCT02157610|DRUG|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
48666065|NCT00158587|DRUG|primaquine|
48666066|NCT05383261|OTHER|exercise|aerobic and resisted ex
48666067|NCT04787315|DEVICE|Conventional intensive functional rehabilitation + Workstations|Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation
48355031|NCT03323372|DRUG|3% potassium nitrate and 0.25% sodium fluoride|
48666068|NCT04787315|BEHAVIORAL|Conventional intensive functional rehabilitation|Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
48355032|NCT03323372|DRUG|5% potassium nitrate and 2% sodium fluoride|
48666069|NCT05036135|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
48666070|NCT05036135|DRUG|Placebo|Placebo administered via dry powder inhalation
48666071|NCT02567903|DEVICE|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
48355033|NCT04319835|DEVICE|OnZurf Probe|
48355034|NCT01002040|BIOLOGICAL|Arepanrix|Group A receives one dose of Arepanrix
48355035|NCT01002040|BIOLOGICAL|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
48355036|NCT05096442|DEVICE|GENOSS® DCB|Drug Coated Balloon
48355037|NCT05096442|DEVICE|SeQuent® Please NEO|Drug Coated Balloon
48355038|NCT03042728|BEHAVIORAL|Dog Interaction|A therapy dog will visit the patients.
48355039|NCT03042728|BEHAVIORAL|Human Interaction|A human will visit the patients.
48355040|NCT03756142|DIAGNOSTIC_TEST|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
48355041|NCT00826540|DRUG|sorafenib tosylate|Given orally
48666072|NCT02567903|PROCEDURE|Knee arthroscopy|Knee arthroscopy
48666073|NCT01190319|OTHER|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
48666074|NCT01190319|OTHER|Placebo|Placebo beverage, 8 weeks
48666075|NCT00460213|DRUG|Valsartan 80mg daily|
48666076|NCT00460213|DRUG|Valsartan 160mg daily|
48666077|NCT03381326|PROCEDURE|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
48666078|NCT06134882|BEHAVIORAL|Contingency management|Monetary incentives are delivered via reloadable debit card based on verified engagement in target behaviors, including drug abstinence, appointment attendance, and completion of self-paced cognitive behavior therapy modules.
48666079|NCT06134882|BEHAVIORAL|Cognitive-Behavior Therapy Modules|Self-paced cognitive-behavior therapy modules delivered via smartphone.
48144159|NCT05376839|DRUG|Cedirogant|Capsule, Oral
48144160|NCT04187482|OTHER|Exercise training|All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
48144161|NCT03701607|OTHER|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
48144162|NCT00239967|DRUG|Rimonabant (SR141716)|
48144163|NCT00239967|DRUG|Placebo|
48144164|NCT05836844|DEVICE|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
48144165|NCT01187888|DRUG|Rasagiline|tablet once daily 1 mg 1 year
48144166|NCT01187888|DRUG|Sugar pill|tablet once daily one year
48144167|NCT06312592|BEHAVIORAL|Entrepreneurship School with Gender Lens|"The Entrepreneurship School with Gender Lens (ESGL) is an approach that targets gender based violence survivors and women at-risk to help them develop business ideas, access needed support for the prevention of and response to GBV, exploitation and trafficking, and improve participants' overall self-reliance. Participants will go through a general business curriculum, work on business plans and learn gender issues and ways to mitigate GBV risks. Upon training completion, participants are eligible to pitch their business idea to a panel of experts and receive $800 of seed capital. They will also receive follow-up business advisory support for at least six months, focusing on access to markets and finance and building support networks, in order to continue building self-reliance.~The ESGL will also include a mental health and psychosocial support module."
48144168|NCT02390778|BEHAVIORAL|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
48355042|NCT00826540|BIOLOGICAL|bevacizumab|Given IV
48666080|NCT06134882|BEHAVIORAL|Peer Contingency Management (CM) Guide|Peer supports delivered via telehealth. Support is informed by the community reinforcement approach and includes motivational interviewing
47987749|NCT04267133|DIAGNOSTIC_TEST|Facial video of detection of cardiac disease|This project proposes to evaluate a non-contact video recording technology to detect the presence of AF. The technology extracts a pulsatile signal by measuring the subtle variations in skin color of a patient's face (flushing) due to the variations of blood volume underneath the skin. The technology uses a standard web camera. This technique is videoplethysmography (VPG).
47987750|NCT01089959|DRUG|Esomeprazole|40 mg daily for 7 days
47987751|NCT01089959|DRUG|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
47987752|NCT06443970|DEVICE|Exsalta Suction Device|Low flow endotracheal suction device
47987753|NCT00284661|PROCEDURE|FAST FIX|Fast fix repair of a meniscal tear
47987754|NCT00284661|PROCEDURE|Meniscal suturing|standard suturing of meniscal tear
47987755|NCT06427018|OTHER|No intervention.|Observational study with no intervention.
47987756|NCT06450626|OTHER|Listening Music Intervention|Participants will listen to a music playlist while vitals are monitored, along with completing a pre- and post-assessment survey (both of which are the Edmonton Symptom Assessment Scale). Participants will also be asked a set of qualitative questions about their overall experience with the music therapy session.
48144169|NCT02390778|BEHAVIORAL|leisure activity (film showing)|
48355043|NCT06348862|BEHAVIORAL|Listening to either Quran, Music, and or Natural sound|Patients will be assigned into one of the four groups based on their preferences. These groups are people who will listen to either Quran, Music, Natural sound, and or nothing (control group).
48355044|NCT00890396|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
48355045|NCT03553264|DEVICE|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
48355046|NCT03553264|OTHER|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
47987757|NCT01428453|DRUG|250mg rilapladib|Experimental Drug
47987758|NCT01428453|DRUG|placebo|Placebo comparator
47987759|NCT00840294|DRUG|Ciprofloxacin|
47987760|NCT03688477|DEVICE|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
47987761|NCT05113615|DRUG|Tiotropium Bromide|respimat inhaler 2.5mcg/puff
47987762|NCT05113615|DRUG|Matching placebo|matching placebo Respimat inhaler
47987763|NCT04532866|BEHAVIORAL|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
48666081|NCT06134882|BEHAVIORAL|Drug testing|Self-performed salivary drug testing with incentives contingent upon proper completion of test procedures as confirmed by video.
48666082|NCT06134882|BEHAVIORAL|Wellness modules|Basic health and wellness information delivered via self-paced learning modules.
48505494|NCT05600465|BEHAVIORAL|Behavioral Activation + Occupational Therapy|In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.
48355047|NCT02087241|DRUG|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
47987764|NCT04484233|DEVICE|iAnemia Decision Support System|iAnemia permits to display the appropriate guideline using several inputs about a patient: age, type and delay of the surgery, gender, hemoglobin level, and iron deficiency status.
48355048|NCT02087241|DRUG|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
48355049|NCT02087241|DRUG|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
48505495|NCT05600465|BEHAVIORAL|Enhanced Usual Care|Fitbit, 1 hour training, handout on managing chronic conditions
48666083|NCT06134882|BEHAVIORAL|Peer technical support|Peer support for promoting engagement and addressing technical issues delivered via a mobile digital platform.
47987765|NCT03184350|RADIATION|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
47987766|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
47987767|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
48505496|NCT05162014|DRUG|empagliflozin|empagliflozin
48505497|NCT05162014|DRUG|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents|Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
47987768|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
47987769|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
47987770|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
47987771|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
47987772|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
47987773|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
48505498|NCT03499210|DEVICE|ReWalk ReStore device|The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
47987774|NCT00056563|DEVICE|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
47987775|NCT00056563|OTHER|best medical therapy|"Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months."
47987776|NCT03192592|OTHER|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
48505499|NCT01550029|BEHAVIORAL|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
48505500|NCT01550029|BEHAVIORAL|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
48505501|NCT06226012|DEVICE|pulsed magnetic field|Children in this group received pulsed magnetic therapy in addition to traditional exercise program
48505502|NCT06226012|DEVICE|Low level laser|Children in this group received low level laser therapy in addition to traditional exercise program
47987777|NCT02011347|DRUG|Ketamine|
47987778|NCT02011347|DRUG|Placebo|
47987779|NCT00539409|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
47987780|NCT00075582|PROCEDURE|conventional surgery|Some patients may undergo second-look surgery
47987781|NCT00075582|DRUG|dactinomycin|Given IV
47987782|NCT00075582|DRUG|cyclophosphamide|Given IV
48505503|NCT06067269|DRUG|Apalutamide|Given PO
48505504|NCT06067269|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48505505|NCT06067269|PROCEDURE|Computed Tomography|Undergo PSMA-PET/CT
48505506|NCT06067269|OTHER|Gallium Ga 68 Gozetotide|Undergo PSMA-PET/CT
48505507|NCT06067269|RADIATION|Guided Stereotactic Body Radiation Therapy|Undergo guided SBRT
48505508|NCT06067269|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo multiparametric MRI
48666084|NCT00883155|DRUG|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
48355050|NCT02087241|DRUG|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
48355051|NCT00930501|BIOLOGICAL|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
48505509|NCT06067269|PROCEDURE|Positron Emission Tomography|Undergo PSMA-PET/CT
48144170|NCT01199185|BEHAVIORAL|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
47987783|NCT00075582|DRUG|vincristine sulfate|Given IV
47987784|NCT00075582|RADIATION|radiation therapy|Undergo radiotherapy
48144171|NCT01199185|BEHAVIORAL|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
48355052|NCT01183572|DIETARY_SUPPLEMENT|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
48505510|NCT06067269|OTHER|Questionnaire Administration|Ancillary studies
48355053|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
48355054|NCT01183572|DIETARY_SUPPLEMENT|Folic Acid|Daily oral dose of 0.4 mg folic acid
48355055|NCT03153124|OTHER|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
48355056|NCT00225628|BEHAVIORAL|Computerized Reminders Medications Monitoring|
48355057|NCT00225628|BEHAVIORAL|Computerized Test Results Management Application|
48355058|NCT00225628|BEHAVIORAL|Computerized Reminders Hypertension Management|
48355059|NCT00225628|BEHAVIORAL|Computerized Reminders Osteoporosis Screening and Mgt|
48355060|NCT04296929|OTHER|Complex Decongestive Physiotherapy|Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
48355061|NCT03194256|BEHAVIORAL|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
48505511|NCT04123561|DRUG|TLC599|TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
48505512|NCT04123561|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
48505513|NCT04123561|OTHER|Normal Saline|0.9% normal saline
48505514|NCT03218124|OTHER|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
47987785|NCT04416087|OTHER|Exercise|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
47987786|NCT04984993|DEVICE|MED3000 (Male)|Gel formulation
47987787|NCT04984993|DRUG|Tadalafil 5mg (Male)|Tablets
47987788|NCT04984993|DEVICE|MED3000 (Female)|Gel formulation
47987789|NCT04984993|DRUG|Tadalafil 5mg (Female)|Tablets
47987790|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
47987791|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
47987792|NCT00694213|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
47987793|NCT00694213|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
48144172|NCT04897347|DEVICE|Robotic Trunk-Support-Trainer (TruST)|"This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
48144173|NCT04897347|DEVICE|Static Trunk Support|"This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~- Twelve 2hr training sessions (3 times per week for 4 weeks)"
48355062|NCT02140762|BIOLOGICAL|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
48144174|NCT03132909|OTHER|Feelings Determination|Determine the feelings of doctors caring for their colleagues
48355063|NCT02140762|OTHER|Placebo|0.5 mL saline solution (IM)
48144175|NCT04437004|DRUG|Fenfluramine|The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
48355064|NCT02140762|BIOLOGICAL|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
48355065|NCT01352624|BEHAVIORAL|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
48144176|NCT01685476|DEVICE|Echodia® hand-held equipment|
48144177|NCT00442507|DRUG|Erlotinib|
48355066|NCT03351140|OTHER|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
48355067|NCT03351140|OTHER|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
48355068|NCT00743184|DRUG|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
48355069|NCT00743184|DRUG|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
48355070|NCT01807676|DEVICE|ET View Double Lumen Tube|
48144178|NCT00442507|DRUG|Avastin|
48355071|NCT01807676|DEVICE|conventional Double Lumen Tube|
48355072|NCT03202667|DRUG|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
48355073|NCT03202667|DRUG|Placebo|Treatment with Placebo oral tablet once daily for 28 days
48355074|NCT00099606|DRUG|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
48355075|NCT02159001|DEVICE|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
48355076|NCT00419029|BEHAVIORAL|telephone-administered motivational interviewing|telephone motivational interviewing
48355077|NCT00419029|BEHAVIORAL|control|brief telephone check-in (no motivational interviewing)
48355078|NCT02858596|DIETARY_SUPPLEMENT|Semi-solid feed (Terumo PG soft)|
48355079|NCT02858596|DIETARY_SUPPLEMENT|Liquid feed (Meibalance)|
48355080|NCT01185912|PROCEDURE|Ventricle muscle tissue samples|
48355081|NCT00648973|DRUG|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
48355082|NCT00648973|DRUG|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
48355083|NCT00648973|DRUG|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
48355084|NCT00443365|PROCEDURE|Mitral valve repair|mitral valve annuloplasty
48355085|NCT05664828|DRUG|SN132D|Manganese-based macromolecular MRI contrast agent
48355086|NCT04588376|BEHAVIORAL|Peer comparison feedback monthly|Monthly emailed data on performance for guideline-concordant use of antibiotics for three acute upper respiratory tract infections either at the clinician and clinic levels or at the clinic level only
47987794|NCT00375739|DRUG|PEP005|
47987795|NCT02736045|DEVICE|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
47987796|NCT02835807|BEHAVIORAL|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
47987797|NCT02835807|BEHAVIORAL|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
47987798|NCT01372501|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
48144179|NCT03792178|OTHER|Bulk fill composite|Composite resin dental material
48144180|NCT03792178|OTHER|Nano resin composite|Dental composite material
48144181|NCT05211726|OTHER|Low Added Sugar Diet|Consumption of 10 days of a diet low in added sugars (5% of total caloric intake)
48144182|NCT05211726|OTHER|High Added Sugar Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
48144183|NCT04927468|PROCEDURE|supramaximal rectus recession|inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
48144184|NCT04927468|PROCEDURE|normal rectus recession|inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
48144185|NCT01273298|DRUG|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
48666085|NCT00883155|DRUG|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
48666086|NCT02490189|BEHAVIORAL|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
48144186|NCT01273298|DRUG|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
48144187|NCT06380959|OTHER|Art Based Activity|"Art Based Activity Module consists of 3 art-based activities under the titles My Life Journey, The Power Within Me and Letter to the Future. Each activity consists of three stages. In the first stage, the participants were made to practice breathing exercises. At this stage, the participant was expected to become aware of himself and his ideas. In the second stage, art activity was carried out. In the final stage, the revealed art object was concretized by the participants with a verbal expression. The materials used in the activities (dry paint, pastel paint, watercolor) are dermatologically tested and consist of anti-allergen products."
48144188|NCT00703092|DRUG|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
48355087|NCT01393665|DRUG|PENNEL capsule|"hard capsule DDB 25mg \& GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
48355088|NCT01393665|DRUG|Placebo|Placebo
48355089|NCT06187051|DEVICE|FEVAR|Relining the EVAR with FEVAR
48355090|NCT06187051|DEVICE|Explantation|open surgery to explant the previous EVAR
48355091|NCT00172003|DRUG|Zoledronic acid|
48355092|NCT04395521|BEHAVIORAL|Diabetic foot self-management support|Daily educational organic or inorganic posts (2 to 5) released in a timed sequence through a Hootsuite application plus peer interactions/support for three months.
48355093|NCT01545089|OTHER|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
48355094|NCT01545089|OTHER|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
48355095|NCT01433328|DRUG|Lidocaine|Lidocaine
48355096|NCT01433328|DRUG|Placebo|Placebo
48355097|NCT01321333|BIOLOGICAL|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
48355098|NCT02924987|DRUG|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
48355099|NCT01711944|BEHAVIORAL|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
48355100|NCT01695928|DEVICE|Extracorporeal shockwave therapy|1000 impulses
48666087|NCT02490189|BEHAVIORAL|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
48666088|NCT05046314|BIOLOGICAL|TK216+Vincristin|TK216 was continuously administered for 14 days，then rest for 14 days. Vincristin is given before TK216 only in the first day of each cycle, the first cycle of VCR is 0.75mg/m\^2 and 1.5mg/m\^2 from the second cycle，every 28 days is a study cycle.
48666089|NCT05370092|OTHER|Percutaneous needle electrolysis|Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
47987799|NCT03649685|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
47987800|NCT03649685|DEVICE|shame rTMS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
47987801|NCT02308254|DRUG|Lixisenatide|Abdominal administration
47987802|NCT02308254|DRUG|Placebo|Abdominal administration
47987803|NCT05555212|DRUG|QLH11811|"In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D."
48144189|NCT01477866|DIETARY_SUPPLEMENT|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
48355101|NCT01695928|DEVICE|ESWT placebo|0 impulses, acoustic effect
47987804|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
48144190|NCT01477866|OTHER|conventional therapy|conventional therapy for colon-rectal cancer
48144191|NCT06301048|PROCEDURE|Stent Placement in Pancreatic and Bile Ducts|Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.
48355102|NCT04202029|DEVICE|thoracic impedance monitoring|Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
48666090|NCT05370092|OTHER|Therapeutic exercise|The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
48666091|NCT05370092|OTHER|Manual therapy|The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
48666092|NCT00066040|DRUG|Cervitec chlorhexidine varnish|
48666093|NCT00066040|DRUG|Duraphat fluoride varnish|
48144192|NCT05232357|DRUG|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
48666094|NCT00066040|DRUG|xylitol gum from Fennobon, Finland|
48144193|NCT01632085|DEVICE|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
48144194|NCT00552591|BEHAVIORAL|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
48144195|NCT00088166|DRUG|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
48144196|NCT00088166|DRUG|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
48355103|NCT04202029|DEVICE|pulseoxymetry|Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
48355104|NCT04202029|DEVICE|non-invasive blood preassure monitoring|Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
48355105|NCT02217449|OTHER|Prediction of histology|
47987805|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
48355106|NCT04844450|DRUG|JNJ-75220795|JNJ-75220795 will be administered subcutaneously.
48355107|NCT04844450|DRUG|Placebo|Matching placebo will be administered subcutaneously.
48355108|NCT03661983|DRUG|Aripiprazole|Participants received aripiprazole tablets, orally as per the regimen specified in the arm description.
48355109|NCT03661983|DRUG|Placebo|Participants received aripiprazole matching-placebo tablets, orally as per the regimen specified in the arm description.
48355110|NCT01021839|PROCEDURE|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
48355111|NCT00854984|BEHAVIORAL|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
48505515|NCT01181362|PROCEDURE|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
48666095|NCT05789251|DIAGNOSTIC_TEST|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
48666096|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
48666097|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
47987806|NCT03578029|DRUG|RGN-137|It will be applied topically to the appropriate wound once a day for up to 84 days.
47987807|NCT03578029|DRUG|Placebo|It will be applied topically to the appropriate wound once a day for up to 84 days.
47987808|NCT04688307|BEHAVIORAL|Motivational interviewing|Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
48355112|NCT01015066|DRUG|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
48355113|NCT01015066|DRUG|Naltrexone|Oral tables, 50 mg/d, once a day for six months
48355114|NCT04376736|OTHER|Home visit|Home visit by medical provider
48355115|NCT00279266|DRUG|Thiamine|
48355116|NCT06199492|DEVICE|tVisio-1|Standard of Care Biopsy
48666098|NCT04436744|DRUG|Giredestrant|During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
48666099|NCT04436744|DRUG|Anastrozole|During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
48666100|NCT04436744|DRUG|Palbociclib|During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
48666101|NCT04436744|PROCEDURE|Surgery|Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
48666102|NCT00744744|OTHER|informational intervention|Patient educational information
48666103|NCT00744744|OTHER|questionnaire administration|Survey
48666104|NCT00744744|PROCEDURE|management of therapy complications|Survey
47987809|NCT02201654|OTHER|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
48355117|NCT05882435|OTHER|Organization with AI|X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
48355118|NCT04749368|DRUG|BRII-835 (VIR-2218)|BRII-835 (VIR-2218) will be given by subcutaneous injection
48355119|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601) with IFN-α|BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
48355120|NCT04749368|BIOLOGICAL|BRII-179 (VBI-2601)|BRII-179 (VBI-2601) will be administered by intramuscular injection
48355121|NCT04818112|BEHAVIORAL|ATVV|A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.
48355122|NCT04818112|BEHAVIORAL|Attention control|Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.
48666105|NCT00744744|PROCEDURE|psychosocial assessment and care|Survey
47987810|NCT00251446|DRUG|Vinflunine|320 mg/m2 as a 20-minute IV infusion
47987811|NCT04408482|DEVICE|Biliary cannulation|Cannulation of biliary duct by sphincterotome
47987812|NCT01457066|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
47987813|NCT05603689|DIETARY_SUPPLEMENT|Isocaloric ketogenic diet|The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
47987814|NCT04565301|DRUG|Dexamethasone|adductor canal block
48355123|NCT06028906|DIAGNOSTIC_TEST|Multimodal physiological monitoring and cerebral autoregulation monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) and ECG.~Non-invasive cerebral autoregulation index Mx will by calculated as a Pearson correlation coefficient between slow ABP and slow CBFV waves.~Invasive cerebral autoregulation index (Pressure reactivity index PRx) will by calculated as a Pearson correlation coefficient between slow ABP and slow ICP waves.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
47987815|NCT04565301|DRUG|neostigmine|adductor canal block
47987816|NCT04565301|OTHER|NaCl solutions|adductor canal block
48355124|NCT02282774|DRUG|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
48355125|NCT02282774|DRUG|Sham subtenon block|
48355126|NCT04605068|PROCEDURE|Transverse preputial island flap (Duckett's technique)|
48666106|NCT00744744|PROCEDURE|quality-of-life assessment|Survey
48666107|NCT00645502|DRUG|risperidone|
48666108|NCT02682056|DEVICE|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
48666109|NCT02682056|DEVICE|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
48666110|NCT02682056|DEVICE|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
47987817|NCT03410940|DEVICE|CLS Brevius stem with Kinectiv technology|
47987818|NCT01897142|BIOLOGICAL|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
47987819|NCT01897142|DRUG|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
47987820|NCT01897142|BIOLOGICAL|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
47987821|NCT01897142|DRUG|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
48144197|NCT05177432|DEVICE|QPOP|QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
48144198|NCT02369328|DEVICE|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
48666111|NCT03903783|OTHER|Cefotaxime|"Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
48666112|NCT03903783|OTHER|Ceftriaxone|"Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
47987822|NCT01897142|BIOLOGICAL|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
47987823|NCT01897142|DRUG|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
47987824|NCT01897142|BIOLOGICAL|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
48505516|NCT04380090|DRUG|Propylene Glycol|Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
48144199|NCT02814409|DRUG|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
48144200|NCT02814409|DRUG|Intravenous Tenecteplase|IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
48505517|NCT04380090|DRUG|Docusate Sodium|Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
48505518|NCT06168279|PROCEDURE|hand occlusal articulation|The upper and lower cast will be scanning separately then will be articulated manually in the final occlusion then scanned after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
48505519|NCT06168279|PROCEDURE|digital occlusal articulation|Both upper and lower casts will be scanning separately, then the 3D casts will be articulating by using 3d virtual program to obtained the final occlusion after that the stl file will insert to the software to complete virtual planning of orthognathic surgery to made splints that will be using in the operation
48505520|NCT05499949|DIAGNOSTIC_TEST|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
48505521|NCT05499949|DIAGNOSTIC_TEST|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
48505522|NCT05499949|DIAGNOSTIC_TEST|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
48666113|NCT04871620|DIAGNOSTIC_TEST|>15% SV increase during fluid challenge|The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
48666114|NCT04862780|DRUG|BLU-945|Oral administration
48666115|NCT04862780|DRUG|osimertinib|Osimertinib tablets for oral administration
48666116|NCT06431880|OTHER|External oblique intercostal plane block|Patients will receive external oblique intercostal plane block
48144201|NCT04413188|OTHER|Warm foot bath|The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
48144202|NCT04323800|BIOLOGICAL|Anti- SARS-CoV-2 Plasma|SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
48144203|NCT04323800|BIOLOGICAL|SARS-CoV-2 non-immune Plasma|Normal human plasma collected prior to December 2019
48355127|NCT04605068|PROCEDURE|Double-faced preputial flap (DFPF)|
48355128|NCT05815862|DRUG|AL2846 capsule|AL2846 is a multi-target tyrosine kinase inhibitor.
48144204|NCT02819609|PROCEDURE|myomectomy|Myomectomy as part of routine clinical care
48144205|NCT02819609|PROCEDURE|endometrial ablation|Endometrial ablation as part of routine clinical care
48355129|NCT02581098|OTHER|No interventions|No interventions
48355130|NCT05467033|DRUG|Desmopressin|desmopressin 0,3ug/kg in 100ml 0,9% NaCl managed as intravenous infusion;
48355131|NCT05467033|DRUG|intravenous infusion NaCl|0,9% NaCl managed as intravenous infusion
48666117|NCT06431880|OTHER|Thoracic paravertebral block|Patients will receive thoracic paravertebral block
48355132|NCT05197985|BEHAVIORAL|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
47987825|NCT01897142|DRUG|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
47987826|NCT01897142|BIOLOGICAL|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
47987827|NCT01897142|DRUG|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
48144206|NCT02819609|PROCEDURE|uterine artery embolization|Uterine artery embolization as part of routine clinical care
48144207|NCT02819609|PROCEDURE|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
48144208|NCT01230359|DIETARY_SUPPLEMENT|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
48144209|NCT01230359|OTHER|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
48144210|NCT03678688|DRUG|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
48144211|NCT03678688|DRUG|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
48144212|NCT03678688|DRUG|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
48355133|NCT01051856|DEVICE|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
48666118|NCT03257891|DRUG|Cabazitaxel|Cabazitaxel will be administered every 21 days
48666119|NCT04844125|DRUG|SHR-1209|SHR-1209
48666120|NCT04844125|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
48666121|NCT00145730|DRUG|Ibuprofen|
48666122|NCT05871060|DIETARY_SUPPLEMENT|Whey Protein Concentrate|Whey protein concentrate consumed 30 minutes prior to breakfast and lunch meals
48144213|NCT03678688|DRUG|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
48144214|NCT03678688|DRUG|RHEZ|"RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~* Participants weighing 30 to 37 kg received 2 tablets per day~* Participants weighing 38 to 54 kg received 3 tablets per day~* Participants weighing 55 to 70 kg received 4 tablets per day~* Participants weighing \> 70 kg received 5 tablets per day"
48144215|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
48355134|NCT01051856|PROCEDURE|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
48355135|NCT06485661|DRUG|Captopril Tablets|Patients will be given captopril to see effect on global longitudinal strain
48355136|NCT03619369|PROCEDURE|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
48666123|NCT05871060|DIETARY_SUPPLEMENT|Placebo|Flavoured water consumed 30 minutes prior to breakfast and lunch meals
48666124|NCT05871060|DIETARY_SUPPLEMENT|Whey hydrolysate|Whey hydrolysate consumed 30 minutes prior to breakfast and lunch meals
48666125|NCT01602484|DEVICE|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
48666126|NCT01602484|DEVICE|Bulk splint supplies|Applying splint by using the bulk splint supplies
48666127|NCT02843633|DEVICE|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
48666128|NCT02843633|DRUG|Antiplatelet Drug|Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
48666129|NCT01240057|PROCEDURE|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
48666130|NCT01240057|OTHER|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
48666131|NCT02115087|PROCEDURE|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
48666132|NCT02115087|DRUG|Morphine|
47987828|NCT01897142|BIOLOGICAL|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
47987829|NCT01897142|DRUG|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
48666133|NCT05477888|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
47987830|NCT06122701|DIETARY_SUPPLEMENT|Thiamin|"A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
48355137|NCT01969565|DRUG|Carfilzomib|
48505523|NCT02459535|OTHER|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
48505524|NCT02459535|OTHER|oral stimulation saccharin|
48505525|NCT02459535|OTHER|oral stimulation aspartame|
48666134|NCT00664222|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
48666135|NCT00054262|DRUG|T900607|
48666136|NCT05839925|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II|The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
48666137|NCT02884453|DRUG|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
48666138|NCT02308514|DEVICE|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
48666139|NCT02308514|OTHER|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
47987831|NCT04275440|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
47987832|NCT04275440|BEHAVIORAL|Caloric restriction|"1. In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~2. According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~3. Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3)."
47987833|NCT00304499|DRUG|Oxybutynin|
47987834|NCT00605670|BEHAVIORAL|questionnaires|patients will fill out two questionnaires post surgery
48355138|NCT01969565|DRUG|Dexamethasone|
47987835|NCT00605670|BEHAVIORAL|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
47987836|NCT05517889|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography is a non-invasive scanner which generates real-time in-vivo images of the skin and its adnexal structures. Images are generated by light-interferometry.
47987837|NCT06071442|DRUG|Vemircopan|Participants will receive oral tablets of Vemircopan.
48355139|NCT06069622|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
48355140|NCT06069622|DIETARY_SUPPLEMENT|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
48505526|NCT02459535|OTHER|oral stimulation sucralose|
48505527|NCT01886196|DRUG|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
48505528|NCT01886196|OTHER|placebo|placebo designed to mimic experimental drug (ibuprofen)
48505529|NCT01886196|BEHAVIORAL|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
48505530|NCT01886196|BEHAVIORAL|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
48505531|NCT06237439|BEHAVIORAL|Move with HaRT|Move with HaRT is a group-based, manualized mind-body intervention.
48505532|NCT06382480|OTHER|Diet with specific macronutrient composition.|The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.
48355141|NCT05669573|PROCEDURE|Early feeding group|Patients in the early diet group started oral intake 6 hours after ESWL of the day of procedure with a soft diet comprised 200 mL with 170 kilocalories.
48355142|NCT05669573|PROCEDURE|Standard fasting group|Patients in the standard fasting group were fasted for 24 hours after the first ESWL operation, and close observation during this fasting period.
48355143|NCT02073227|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
48355144|NCT02073227|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
48355145|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
48505533|NCT00593151|OTHER|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
48505534|NCT00593151|BIOLOGICAL|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
48505535|NCT03908879|PROCEDURE|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
48505536|NCT03908879|PROCEDURE|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
48505537|NCT03908879|PROCEDURE|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
48505538|NCT00056394|BEHAVIORAL|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
48505539|NCT00056394|BEHAVIORAL|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
48505540|NCT00056394|BEHAVIORAL|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
48666140|NCT02895555|PROCEDURE|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.
48666141|NCT02895555|PROCEDURE|Allograft|Approx 50 g of allograft bone in the fused site
48666142|NCT00800826|DRUG|dexmedetomidine|
48666143|NCT04976777|DEVICE|Updated DEX PS DDS Applicator|Intravitreal Administration
48666144|NCT04976777|DEVICE|Approved DEX PS DDS Applicator|Intravitreal administration
48666145|NCT04976777|DRUG|Dexamethasone|Dexamethasone 0.7 mg in a solid polymer drug delivery system
47987838|NCT06071442|DRUG|Rosuvastatin|Participants will receive oral coated tablets of Rosuvastatin.
48355146|NCT02073227|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
48355147|NCT05268601|DRUG|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
48355148|NCT05268601|DRUG|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
48355149|NCT05268601|DRUG|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
48355150|NCT05268601|DRUG|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
48666146|NCT02628535|BIOLOGICAL|MGD009|B7-H3 x CD3 DART protein
48666147|NCT02675400|DRUG|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
48666148|NCT02675400|BEHAVIORAL|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
48666149|NCT02675400|DRUG|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
48666150|NCT02446002|DRUG|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
47987839|NCT06071442|DRUG|Metformin|Participants will receive oral film-coated tablets of Metformin.
47987840|NCT06071442|DRUG|Levonorgestrel / Ethinyl Estradiol|Participants will receive oral tablets of Levonorgestrel/ Ethinyl Estradiol.
48666151|NCT05644873|DRUG|magnesium sulfate group|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
48144216|NCT03678688|DRUG|30 mg OPC-167832 + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
48144217|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
48144218|NCT03022825|DRUG|N-803 and BCG|BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
48144219|NCT03022825|DRUG|N-803|N-803 will be administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.
48144220|NCT05647642|DRUG|Precedex and dormicum|Premedication
48144221|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2.5 grams
48144222|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
48505541|NCT06017024|DEVICE|microprocessor-controlled knee (MPK) assessment|The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
48144223|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
48144224|NCT03110809|DIETARY_SUPPLEMENT|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
48144225|NCT03110809|DIETARY_SUPPLEMENT|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
48144226|NCT04499898|DRUG|Carvedilol|Carvedilol
48144227|NCT04499898|PROCEDURE|Endoscopic band ligation|Endoscopic band ligation
48144228|NCT01498614|BEHAVIORAL|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
48505542|NCT02634359|DEVICE|EarlySense home device|Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
48505543|NCT02634359|PROCEDURE|Vaginal ultrasound|Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
48505544|NCT02634359|PROCEDURE|Blood Test|Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
47987841|NCT06071442|DRUG|Carbamazepine|Participants will receive oral chewable tablets of Carbamazepine.
47987842|NCT02561637|BEHAVIORAL|Case management|
47987843|NCT02561637|BEHAVIORAL|Control group|
47987844|NCT01585428|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
47987845|NCT01585428|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
47987846|NCT01585428|BIOLOGICAL|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
47987847|NCT01585428|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
48144229|NCT03794388|DRUG|Capsaicin|Application of capsaicin patches at 8% on painful area
48144230|NCT03794388|DRUG|Pregabalin|Taking Pregabalin tablets
48144231|NCT04180943|DRUG|interscalene nerve block|intra and post-operative analgesia
48144232|NCT03606863|DRUG|Perioperative peripheral parenteral nutrition|
48144233|NCT01078051|PROCEDURE|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
48505545|NCT03589040|DRUG|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
48505546|NCT03589040|DRUG|rilpivirine|Oral rilpvirine 25mg
48505547|NCT03589040|DRUG|darunavir|Oral darunavir+ritonavir 600/100mg
48505548|NCT00049530|BIOLOGICAL|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
48505549|NCT04577833|DRUG|Niraparib|Niraparib will be administered orally.
48505550|NCT04577833|DRUG|Abiraterone Acetate (AA)|Abiraterone Acetate will be administered orally.
48505551|NCT04577833|DRUG|Prednisone|Prednisone will be administered orally.
48505552|NCT03869086|OTHER|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
47987848|NCT02766062|OTHER|metabolic syndrome|metabolic syndrome
48002651|NCT02143570|PROCEDURE|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
48505553|NCT03869086|OTHER|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
48002652|NCT02242838|DRUG|Telmisartan|
48002653|NCT03164967|BIOLOGICAL|Bivigam|
48144234|NCT01078051|DRUG|optimal medical therapy|optimal medical therapy
48144235|NCT00500604|DRUG|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
48144236|NCT00500604|DRUG|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
48144237|NCT00500604|DRUG|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
48144238|NCT01762982|DRUG|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
48144239|NCT01762982|DRUG|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
48144240|NCT01762982|DRUG|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
48144241|NCT01762982|OTHER|Empty Finn Chamber|Empty Finn Chamber
48144242|NCT00644306|DRUG|Thalidomide|100 mg/day continuously for 18 months
48144243|NCT00644306|DRUG|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
48144244|NCT00644306|DRUG|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
48355151|NCT01238276|DRUG|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
48355152|NCT01238276|DEVICE|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
48355153|NCT06397157|OTHER|Virtual Reality|Participants will recieve treatment(Virtual reality) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
48355154|NCT06397157|OTHER|Motor Imagery|Participants will recieve treatment(Motor Imagery) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
48505554|NCT04856501|BEHAVIORAL|PALS intervention condition|The Play and Learning Strategies (PALS) intervention provides parents with behaviors that, collectively, are known as a responsive parenting style. Four constructs make up this responsive parenting style: 1) contingent responsiveness, (responses are conditionally linked to the child's signals) 2) warm sensitivity (high levels of affection and understanding of child states), 3) maintaining vs. redirecting attention, and 4) verbal scaffolding (providing child appropriate language supports). Parents assigned to this intervention will be paired with a coach who will guide them through the program over the course of 9 weekly sessions. The intervention (ePALS) will be implemented via an internet adaptation through the Children's Learning Institute's ENGAGE platform. However, ePALS could easily be adapted for other platforms and accessed with any web-enabled device.
48666152|NCT05644873|DRUG|control group saline|Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
48666153|NCT04876911|BEHAVIORAL|Simulated Presence Therapy|A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
48666154|NCT00966459|PROCEDURE|Computed Tomography|1 low-dose CT is taken
48002654|NCT02045511|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
48355155|NCT06397157|OTHER|Routine Physical therapy|Participants will recieve treatment(Routine physical therapy) for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
48355156|NCT02169726|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
48355157|NCT04957810|BEHAVIORAL|WeChat Mini Program|Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
48355158|NCT01858337|OTHER|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
48355159|NCT01858337|OTHER|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
48355160|NCT01858337|OTHER|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
48666155|NCT05204121|DRUG|Elpida|elsulfavirine, capsules
48666156|NCT04570384|DRUG|L-Citrulline|L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
48002655|NCT02045511|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
48144245|NCT02188459|DRUG|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
48144246|NCT00147615|DRUG|Eplerenone|
48144247|NCT04101045|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
48144248|NCT00688415|DRUG|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
48144249|NCT06459167|OTHER|The position adopted when patients undergoing procedure or surgery|For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.
48144250|NCT05870761|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48144251|NCT05870761|PROCEDURE|Computed Tomography|Undergo MRI/CT
48144252|NCT05870761|BIOLOGICAL|Dostarlimab|Given IV
48144253|NCT05870761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
48144254|NCT05870761|DRUG|Niraparib|Given PO
48144255|NCT05208788|DIAGNOSTIC_TEST|Biomarker test|collection of 500µl to 1 ml of a spot urine sample
48144256|NCT03294187|DEVICE|Wrist-worn wearables|See arm/group description.
48144257|NCT03155022|DEVICE|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of \[1 min balloon inflation followed by 1 min balloon deflation\] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
48144258|NCT03155022|DEVICE|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
48144259|NCT00885625|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
48144260|NCT00378898|DEVICE|BRAVO capsule|
48144261|NCT00378898|PROCEDURE|Fluoroscopy|"one time xray to determine evacuation of bravo"
48144262|NCT00378898|OTHER|sham BRAVO capsule placement|
48144263|NCT03259126|DEVICE|SCUT|Two different home made curtains were attached to the angiographic table
48144264|NCT05260944|DEVICE|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
48144265|NCT05260944|DEVICE|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
48144266|NCT05260944|OTHER|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
48144267|NCT03279367|DIAGNOSTIC_TEST|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
48144268|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
48144269|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
48144270|NCT01858688|DEVICE|Multiparametric MRI|an MRI of the prostate will be performed
48144271|NCT01858688|PROCEDURE|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
48144272|NCT00020527|DRUG|caspofungin acetate|
48144273|NCT00886548|PROCEDURE|Ultrasound performed|Nurse-driven ultrasound performed
48144274|NCT00003259|DRUG|vinorelbine tartrate|
48144275|NCT06282926|DIAGNOSTIC_TEST|Echocardiography assessment|"Group 1 will have healthy adult volunteers recruited at the workplace following specific criteria to participate in the study. A research cardiac ultrasound protocol to assess the RV will be performed at two different visits, with a maximum interval of two weeks between them.~Group 2 will have ACHD patients with known moderate or severe pulmonary regurgitation after ToF repair, following specific criteria to participate in the study. This group of patients will be studied in two separate visits. The patients will be recruited during the first visit when attending to an existing hospital appointment for ACHD CMR. A research cardiac ultrasound protocol to assess the RV will be performed on the same day, either before or after the CMR. For all patients who will have a second follow-up visit at the ACHD outpatient clinic within a maximum interval of one year, the same research protocol will be performed, in addition to the usual cardiac ultrasound."
48144276|NCT04446949|OTHER|Register follow-up|Number of adverse pregnancy outcomes
48144277|NCT00598234|DRUG|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
48355161|NCT01858337|OTHER|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
48144278|NCT05514184|DIETARY_SUPPLEMENT|PLAFOND diet|PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-proteins.
48144279|NCT00748891|DRUG|Recentin (Cediranib)|30mg once daily, oral dose
48144280|NCT03927794|OTHER|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
48144281|NCT05670561|DRUG|Esketamine|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min.The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
48144282|NCT05670561|DRUG|Sufentanil|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
48144283|NCT02142309|DRUG|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
48144284|NCT02142309|DRUG|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) \<45 mL/min
48505555|NCT04856501|BEHAVIORAL|Control condition|Families assigned to the control condition will be provided with a website with information corresponding to milestones of toddler development. Control families will be asked to review that week's materials before the each of the 9 weekly coach calls. The active control condition serves three important purposes: 1) Maintains an active line of communication and accurate contact records for Post-test 1 and Post-test 2 session scheduling; 2) Masks participant's awareness of intervention vs. control assignment; and 3) Approximates communication with intervention staff such that results showing ePALS effects are attributable to intervention rather than regular communication with an interventionist.
48666157|NCT04570384|DRUG|Placebo|Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
48666158|NCT05074914|PROCEDURE|oesophagectomy|removal of oesophagus
48666159|NCT06009302|PROCEDURE|US guided block of mandibular nerve|Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
48144285|NCT02142309|DRUG|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
48144286|NCT02142309|DRUG|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
48144287|NCT04946734|DEVICE|PFO closure device|Device PFO closure.
48144288|NCT04946734|DRUG|Aspirin and clopidogrel|Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
48144289|NCT04946734|DRUG|Triptans|If migraine recurred, Triptans would be administered during the acute phase.
48144290|NCT04490694|DRUG|Lenvatinib|Intervention Description：lenvatinib will be administered daily (for patients \<60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48355162|NCT02910492|DEVICE|enLighten Laser|Dual-pulse duration laser for the treatment of skin rejuvenation
48355163|NCT00836953|BIOLOGICAL|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
48505556|NCT01463215|DRUG|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
48666160|NCT06009302|PROCEDURE|Intraoral block of lower alveolar nerve|Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
48666161|NCT01400711|OTHER|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
48666162|NCT01400711|OTHER|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
48666163|NCT02816814|OTHER|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
48666164|NCT02816814|OTHER|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
48666165|NCT03849261|DRUG|CKD-387|Test drug
48666166|NCT03849261|DRUG|D635|Reference drug
48666167|NCT01974284|DRUG|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
48666168|NCT01726764|OTHER|St John's Wort|
48666169|NCT01726764|DRUG|Metformin|
48666170|NCT00183248|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
48666171|NCT00183248|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
47987849|NCT00916747|DRUG|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
47987850|NCT06126133|DEVICE|Near Infrared Spectroscopy|Two NIRS probes will be attached to the extremity to be operated on and to the other lower extremity on the opposite side, at a level approximately coinciding with the midline above the quandriceps femoris muscle.
47987851|NCT02412566|DRUG|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
48505557|NCT06634121|DEVICE|Transcatheter mitral valve edge-to-edge repair (M-TEER)|M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
48505558|NCT00927732|DRUG|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
48666172|NCT00183248|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
48666173|NCT00183248|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
48666174|NCT00183248|PROCEDURE|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
47987852|NCT06056050|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)|1 dose of Tdcp vaccine (0.5ml) on Day 0
47987853|NCT06056050|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）|1 dose of PPV23 vaccine (0.5ml) on Day 0
47987854|NCT06056050|BIOLOGICAL|Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)|1 dose of DT vaccine (0.5ml) on Day 0
47987855|NCT03070379|PROCEDURE|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
48144291|NCT04490694|PROCEDURE|TACE|Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
48144292|NCT06305078|OTHER|Personalized ADHD Medication Experiment|All parent/adolescent dyads will select and complete a medication experiment.
48144293|NCT01853384|BIOLOGICAL|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
48144294|NCT01853384|OTHER|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
48144295|NCT03032757|DIETARY_SUPPLEMENT|Essential amino acids|240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
48505559|NCT00927732|DRUG|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
48505560|NCT06034197|DRUG|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
48666175|NCT00183248|PROCEDURE|Kidney transplant|Occurs at study entry
48144296|NCT01381445|DRUG|GW870086 0.2%|White to slightly coloured opaque cream
48144297|NCT01381445|DRUG|GW870086 2%|White to slightly coloured opaque cream
48144298|NCT01381445|DRUG|Clobetasol Propionate|White cream
48144299|NCT01381445|DRUG|Placebo|White to slightly coloured opaque cream
48144300|NCT02430909|BIOLOGICAL|Bimekizumab|"* Pharmaceutical form: Solution for infusion~* Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~* Route of administration: iv infustion"
48144301|NCT02430909|BIOLOGICAL|Certolizumab Pegol|"* Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
48355164|NCT05868408|OTHER|Control Formula|Infant formula made with intact protein - minimum 1.8g protein/100kcal
48355165|NCT05868408|OTHER|Experimental Formula 1|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
48355166|NCT05868408|OTHER|Experimental Formula 2|Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal
48355167|NCT02483611|DRUG|Magnesium Sulfate|
48355168|NCT02483611|DRUG|Lidocaine|
48666176|NCT05017558|DIAGNOSTIC_TEST|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~1. Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~   * High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~  * Low risk (maternal VL \<1000 cp/ml): NVP for 6 weeks.~2. virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~3. In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~4. support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
48666177|NCT03901586|OTHER|Satisfaction assessment|Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
47987856|NCT06185504|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows~1. The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~2. Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~3. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~4. Direct feeding training: with powdered milk, once a day, 5 days a week."
48355169|NCT02483611|DRUG|Isotonic Solution|
48355170|NCT02483611|DRUG|Cisatracurium|
48355171|NCT05768568|DEVICE|Manual Toothbrush and Powered Toothbrush|Manual Toothbrush will be mechanically (hand) driven Powered Toothbrush will be battery operated
48355172|NCT03849092|BEHAVIORAL|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers who achieve continuous abstinence from smoking when attending a group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
48355173|NCT03849092|BEHAVIORAL|Campaigns|Municipalities will design anti-smoking campaigns targeting smokers, recommending to use a municipal free group-based smoking cessation program. Aimed at smokers with low socioeconomic status but other smokers are also included.
48355174|NCT01225211|DRUG|Lumacaftor|Tablet
48355175|NCT01225211|DRUG|Ivacaftor|Tablet.
48355176|NCT01225211|DRUG|Lumacaftor Placebo|Matching placebo tablet.
48355177|NCT01225211|DRUG|Ivacaftor Placebo|Matching placebo tablet.
48355178|NCT04966091|OTHER|Completion of questionnaires|The quality of life questionnaire will be completed before starting the treatment and then during the embryo transfer and will be followed up at each embryo transfer over a maximum period of 18 months. We will also evaluate by means of a specific questionnaire the importance of work/life interactions management and consequences of absenteeism at work, consequences on professional evolution, anxious repercussions in the professional and private domains).
48355179|NCT02340936|DRUG|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
48355180|NCT02340936|DRUG|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
48355181|NCT02340936|DRUG|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
48355182|NCT02340936|DRUG|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
48505561|NCT03885752|DRUG|chewed mint gum|In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
48666178|NCT03901586|OTHER|Quality of life|The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
48666179|NCT03901586|OTHER|Gynecological assessment|An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
48666180|NCT04958057|BEHAVIORAL|SAIL|6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.
48666181|NCT06058091|DRUG|RY_SW01 cell injection|Administer basic treatment with an injection of RY_SW01 cell solution
48666182|NCT06058091|DRUG|Basic treatment|Basic treatment for SSc
48355183|NCT05076552|DRUG|TACH101|Orally via capsules
48355184|NCT05701475|PROCEDURE|Subcutaneous disinfection|After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.
48355185|NCT05701475|PROCEDURE|Benzoyl peroxide preparation|In the days prior to surgery, the skin will be prepared using Benzoyl Peroxide gel according to a standardised protocol.
48355186|NCT05989152|RADIATION|FDG-PET at the end of treatment for IE|FDG-PET at the end of treatment for IE in patients with a prosthetic valve
48355187|NCT03416036|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|TV003 contains 10\^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
48355188|NCT03416036|BIOLOGICAL|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
48355189|NCT03416036|BIOLOGICAL|rDEN3Δ30 (DENV-3)|Administered at a dose of 10\^3 PFU by subcutaneous injection in the deltoid region of the upper arm
48355190|NCT03416036|BIOLOGICAL|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
48355191|NCT04974944|DRUG|Camrelizumab|IV injection
48505562|NCT03885752|OTHER|swallow twice|asked to swallow twice without any additional treatment.
48666183|NCT02499744|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
48666184|NCT02499744|DEVICE|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
48666185|NCT06546332|DEVICE|KeriFuse®|The intramedullary arthrodesis Implant (KeriFuse®) is indicated for consolidation or bone fusion (arthrodesis) of degraded or arthritic distal interphalangeal (DIP) of hand digits or interphalangeal (IP) joint of the hand thumb.
48355192|NCT04974944|DRUG|Apatinib|Oral
48355193|NCT04974944|DRUG|Paclitaxel|IV injection
48355194|NCT04974944|DRUG|Cisplatin|IV infusion
48355195|NCT04974944|DRUG|Carboplatin|IV infusion
48355196|NCT04974944|DRUG|Bevacizumab|IV infusion
48355197|NCT05261594|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 150 mg, oral intake
48355198|NCT05261594|DRUG|Placebo|Placebo capsule, oral intake
48355199|NCT05592600|BEHAVIORAL|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
48355200|NCT02710422|BIOLOGICAL|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
48355201|NCT02710422|BEHAVIORAL|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
48355202|NCT02710422|OTHER|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
48355203|NCT02710422|BEHAVIORAL|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
48355204|NCT03147495|DIAGNOSTIC_TEST|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.|Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
48355205|NCT01481714|DRUG|Sodium picosulphate, magnesium oxid and citric acid|"* A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation"
48505563|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
48505564|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
48505565|NCT03819049|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
48505566|NCT03819049|BIOLOGICAL|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
48505567|NCT03819049|BIOLOGICAL|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
48505568|NCT03819049|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
48505569|NCT02646852|DRUG|PLX038|
48505570|NCT02015559|DRUG|mucoadhesive oral wound rinse|Given PO
48505571|NCT02015559|OTHER|laboratory biomarker analysis|Correlative studies
48355206|NCT01481714|DRUG|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
48355207|NCT03394196|DIAGNOSTIC_TEST|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
48355208|NCT03394196|DRUG|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
48355209|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
48355210|NCT03394196|DRUG|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
48355211|NCT02824315|DRUG|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
48355212|NCT02824315|DRUG|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
48355213|NCT02824315|DRUG|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
48355214|NCT03998345|DRUG|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
48355215|NCT01774838|DRUG|Prasugrel|3 months treatment
48355216|NCT01774838|DRUG|Clopidogrel|3 months treatment
48355217|NCT04327115|PROCEDURE|"Control strategy"|"Patients included in the control group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams."
48355218|NCT04327115|PROCEDURE|"Intervention strategy"|"Patients included in the intervention group will received the usual cares of the unit during their stay : support in the gestures of daily life and walking according to their ability and at the discretion of the care teams.~They will also get a physical activity program realized with a nurse or a nursing assistant, twice a day (morning and evening) for 5 days. The intervention consists of physical support with mimed instructions, the nature of which depends on the falling risk of the participant :~* High falling risk : out of bed exercise (on a chair for at least 30 min)~* Mild falling risk : out of bed exercise + in front of chair (The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes, on both feet or one foot)~* Low falling risk : out of bed exercise + in front of chair + FTSS exercise (The participant performs a transfer activity of sitting to standing repeated 5 times, with physical assistance or not)"
48355219|NCT02678156|DEVICE|Lyoplant Onlay|
48355220|NCT01590810|DRUG|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
48355221|NCT01590810|DRUG|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
48355222|NCT01590810|DRUG|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
48666186|NCT00346723|BIOLOGICAL|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
48144302|NCT02430909|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Concentration: 0.9% saline~* Route of administration: Intravenous infusion"
48355223|NCT01590810|DRUG|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
48355224|NCT01590810|DRUG|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
48355225|NCT01590810|DRUG|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
48355226|NCT01590810|DRUG|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
48355227|NCT01590810|DRUG|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
48355228|NCT01590810|DRUG|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
48355229|NCT01590810|DRUG|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
48355230|NCT01590810|DRUG|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
48355231|NCT01590810|DRUG|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
48355232|NCT01590810|DRUG|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
48355233|NCT01590810|DRUG|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
48355234|NCT01590810|DRUG|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
48355235|NCT01590810|DRUG|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
48355236|NCT01590810|DRUG|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
48355237|NCT01590810|DRUG|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
48355238|NCT01590810|DRUG|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
48355239|NCT06101290|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
48355240|NCT04437329|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
48355241|NCT04437329|DRUG|Docetaxel, cisplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
48355242|NCT04437329|DRUG|Nedaplatin|Concurrent chemotherapy. Nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
48505572|NCT01934335|DRUG|Vandetanib|
48505573|NCT01934335|OTHER|Placebo|
48666187|NCT04290624|OTHER|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
48666188|NCT04290624|DEVICE|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
48666189|NCT04290624|OTHER|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
48666190|NCT01533415|DEVICE|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of \<1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
48144303|NCT04393571|OTHER|Mobile application|telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data
48144304|NCT06369532|DEVICE|Active tDCS|During the whole therapy period, active tDCS group will receive active tDCS after CBT. They also receive active home-based tDCS.
48144305|NCT06369532|DEVICE|Sham tDCS|The sham tDCS group will receive sham tDCS after CBT. They also receive sham home-based tDCS.
48144306|NCT05813990|OTHER|recostructive ear surgery|recostructive ear surgery in pediatric population
48144307|NCT04892251|COMBINATION_PRODUCT|MORE+KAP|Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
48144308|NCT04892251|BEHAVIORAL|MORE|Mindfulness-Oriented Recovery Enhancement
48355243|NCT04437329|DRUG|Cisplatin|Concurrent chemotherapy. Cisplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
48144309|NCT01727167|DRUG|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
48355244|NCT04437329|RADIATION|Intensity modulated-radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
48355245|NCT00123786|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
48355246|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
48144310|NCT01727167|OTHER|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
48144311|NCT05858606|DIAGNOSTIC_TEST|Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation|"1. pre-inclusion consultation~2. inclusion consultation~   * personal history~  * height, weight, cranial perimeters, and spans of both parents~  * clinical examination of the child~  * photographs of the child~  * additional X-rays"
48355247|NCT04928521|PROCEDURE|bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
48355248|NCT04764591|OTHER|Lateral sagittal approach|Lateral sagittal approach for ultrasound guided infraclavicular brachial plexus block
48505574|NCT03200912|DRUG|Ingenol Mebutate (Picato®)|Brand product
48505575|NCT03200912|DRUG|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
48505576|NCT03200912|DRUG|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
48505577|NCT06518603|DRUG|Caffeine citrate 20mg/kg/day|Caffeine citrate 20mg/kg/day given orally once daily for 28 days
48355249|NCT04764591|OTHER|Costoclavicular approach|Costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
48355250|NCT03990441|DEVICE|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
48355251|NCT03990441|DEVICE|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
48355252|NCT02402049|DRUG|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
48355253|NCT02402049|DRUG|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
48355254|NCT02402049|DRUG|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
48355255|NCT02402049|DRUG|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
48355256|NCT02402049|DRUG|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
48355257|NCT02402049|DRUG|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
48355258|NCT02402049|DRUG|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
48355259|NCT02402049|DRUG|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
48355260|NCT02402049|DRUG|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
48355261|NCT02402049|DRUG|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
48355262|NCT02402049|DRUG|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
48355263|NCT02402049|DRUG|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
48355264|NCT00517725|DRUG|carvedilol|
48355265|NCT00517725|DRUG|bisoprolol|
48355266|NCT00517725|DRUG|Nebivolol|
48355267|NCT05093244|DEVICE|SeQuent Please ReX|The SeQuent Please ReX is a conventional rapid exchange balloon tip catheter with a drug-coated balloon (DCB). The surface of the SeQuent Please ReX balloon is coated with paclitaxel, embedded in a soluble matrix (resveratrol).
48355268|NCT05093244|DEVICE|Plain old balloon angioplasty (POBA)|Any commercially available semi-compliant PTCA balloon may be used per the investigator's discretion.
48355269|NCT03923829|DRUG|Zinc Sulfate|systemic administration of Zinc sulfate with scaling and root planing
48355270|NCT03923829|PROCEDURE|scaling and root planing|scaling and root planing
48355271|NCT00418444|BEHAVIORAL|Group Therapy Intervention|
48666191|NCT01533415|DEVICE|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
48355272|NCT03656536|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
48355273|NCT03656536|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
48355274|NCT03656536|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
48355275|NCT03018340|DRUG|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
48355276|NCT03018340|OTHER|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
48355277|NCT06257394|DRUG|Dasatinib(Sprycel) arm|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
48355278|NCT06257394|DRUG|Non-Dasatinib(Sprycel) arm|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
48505578|NCT06518603|DRUG|Placebo-Sterile water 1ml/kg/day|Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
48355279|NCT02093741|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
48355280|NCT04502394|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
48355281|NCT04502394|DRUG|acalabrutinib|acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
48666192|NCT02741050|BEHAVIORAL|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
48666193|NCT02741050|BEHAVIORAL|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
48355282|NCT05555914|OTHER|Neurostimulation|Implantation of 3 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
48355283|NCT01890733|DEVICE|Best Repair of torn Rotator Cuff|
48355284|NCT01890733|DEVICE|InSpace™ system|
48355285|NCT03271944|DEVICE|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
48355286|NCT05412160|DRUG|Arginine|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
48355287|NCT05412160|DRUG|Placebo|During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
48666194|NCT00128999|PROCEDURE|Intensity-Modulated Radiation Therapy|
48666195|NCT02394561|BIOLOGICAL|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
48355288|NCT02813434|BIOLOGICAL|florbetapir|18F-AV-45 or 18F-Florbetapir
48355289|NCT02857205|OTHER|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
48355290|NCT03779828|DEVICE|HOME LINK|Telemonitoring system which include web platform and connected devices.
48355291|NCT05012514|DEVICE|LLLT RED|"Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap. A cluster applicator was used using the parameters described in table 1.~For therapy, the equipment Antares® was used, IBRAMED- Indústria Brasileira de Equipamentos Eletromédicos EIRELI \[EIRELI Brazilian Industry of Electromedical Equipment\], approved by Anvisa Nº 10360310037. Figure 1."
48355292|NCT02161614|DRUG|Estradiol valerate|
48666196|NCT05903703|DRUG|Canagliflozin and Gemcitabine|"on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle"
48666197|NCT05903703|DRUG|Gemcitabine|on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
48355293|NCT02161614|DRUG|Placebo|
48355294|NCT00939146|OTHER|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
48355295|NCT00939146|OTHER|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
48666198|NCT00775255|DRUG|clarithromycin 250 mg/5 mL powder for oral suspension|
48355296|NCT02278159|PROCEDURE|Peritoneal dialysis|
48355297|NCT02278159|PROCEDURE|Home hemodialysis|
48355298|NCT04780191|DEVICE|MyoRegulator®|Trans-spinal DC stimulation paired with peripheral DC stimulation
48355299|NCT02749552|BEHAVIORAL|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
48355300|NCT00506740|DEVICE|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
48144312|NCT05858606|PROCEDURE|analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team|"multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation:~* either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology)~* or to the authentified idiopathic short stature group"
48355301|NCT00506740|DEVICE|monopolar electrosurgery generator and tip|
48355302|NCT02056665|DRUG|MINOCYCLINE|Pill Minocycline 50 mg capsule
48355303|NCT02056665|DRUG|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
48355304|NCT01202643|DRUG|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
48355305|NCT01202643|DRUG|Saline|One intrauterine saline infusions of 1 cc
48355306|NCT01814228|PROCEDURE|transcatheter ablation of ganglionated plexi in right atrium|
48355307|NCT05598840|OTHER|Care for today Mobile Application|"C4T (Care for Today) Education is a digital application (app) designed to offer quality educational materials.~The APP will be provided to the patients in the outpatient centre four months before surgery. Patients will be able to download the APP using a QR code that will be provided during the visit. They'll realize the download immediately or at home, in both cases a detailed explication of how to use the APP and its contents will be provided using an example version."
48144313|NCT05858606|GENETIC|Whole genome analysis for authentified idiopathic short stature|"For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research.~For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis."
48355308|NCT02745795|BEHAVIORAL|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
48355309|NCT02745795|BEHAVIORAL|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
48355310|NCT05905601|BEHAVIORAL|NORTH|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
48505579|NCT03361774|DRUG|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
48355311|NCT05905601|BEHAVIORAL|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
48355312|NCT03795051|DEVICE|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
48355313|NCT00549354|DEVICE|Endoluminal Graft|
48355314|NCT03675685|BIOLOGICAL|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
48505580|NCT03361774|DRUG|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
48355315|NCT05731362|OTHER|MDCIT Intervention|"The MidWest Multidisciplinary Community Intervention Teams (MDCIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time. This is provided in the patient's home after an acute hospital admission, thereby facilitating early discharge. The MDCIT intervention is composed of occupational therapy, physiotherapy, and healthcare assistants, with nursing support as required.~The MDCIT therapists aim to make their first visit to patients within 24-48 hours of hospital discharge. Patients receive two-three visits per week, over a period of two to four weeks dependant on the patient's rehabilitation needs. Upon discharge from the MDCIT service, patients can be referred to community services as indicated by therapists."
48355316|NCT03192228|OTHER|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
48505581|NCT02942030|OTHER|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
48355317|NCT01115114|BEHAVIORAL|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
48355318|NCT01115114|BEHAVIORAL|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
48355319|NCT01115114|BEHAVIORAL|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
48355320|NCT03059511|DRUG|Nalbuphine|Opioid Pain Medicine
48355321|NCT03808844|DRUG|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
48355322|NCT03808844|DRUG|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
48505582|NCT04141826|DIETARY_SUPPLEMENT|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
48505583|NCT04141826|DIETARY_SUPPLEMENT|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
48505584|NCT04141826|DIETARY_SUPPLEMENT|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
48666199|NCT02661750|DRUG|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
48666200|NCT04470414|DIAGNOSTIC_TEST|IgG antibodies immunoassay|Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
48666201|NCT00058747|DRUG|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
48666202|NCT01466088|DRUG|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
48666203|NCT01466088|DRUG|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
48666204|NCT05683366|DEVICE|No Intervention|There is no intervention in this study
48666205|NCT01892566|OTHER|mHealth Intervention|See arm description
48666206|NCT00744614|PROCEDURE|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
48144314|NCT05391867|DRUG|Lenvatinib|Tyrosine kinase inhibitor
48144315|NCT01929291|BIOLOGICAL|Boostrix|Single intramuscular injection
48144316|NCT01929291|OTHER|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
48144317|NCT03871075|DEVICE|intermittent pneumatic compression|Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
48144318|NCT03871075|BEHAVIORAL|exercise|Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
48505585|NCT03722667|BEHAVIORAL|Technology-based Component|This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.
48666207|NCT04843631|DRUG|BFI-751|Single use vial, solution
48666208|NCT04843631|DRUG|EU-STELARA®|Pre-filled syringe, solution
48666209|NCT04843631|DRUG|US-STELARA®|Pre-filled syringe, solution
48666210|NCT05375630|DIETARY_SUPPLEMENT|Placebo|Placebo
48666211|NCT05375630|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
48144319|NCT03871075|DEVICE|Sham device|The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
48355323|NCT01431456|DRUG|Dabigatran|Dabigatran
48355324|NCT01431456|DRUG|Rivaroxaban|Rivaroxaban
48355325|NCT01431456|DRUG|Nadroparin|Nadroparin
48355326|NCT02701569|OTHER|Rebound exercise|Repeated jumping on a mini trampoline was administered
48355327|NCT04618549|PROCEDURE|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
48002656|NCT03764722|DRUG|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
48355328|NCT04618549|PROCEDURE|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
48355329|NCT04618549|PROCEDURE|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
48355330|NCT01363154|OTHER|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
48355331|NCT01363154|OTHER|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
48355332|NCT01363154|OTHER|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
48355333|NCT04770259|OTHER|Timely pre-surgical conditioning|Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
48355334|NCT04176328|DRUG|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
48355335|NCT04809649|DRUG|SUBA-itraconazole|Participant will receive treatment with SUBA-itraconazole
48355336|NCT05297292|DRUG|MW02|MW02 is a recombinant anti-VEGF humanized monoclonal antibody injection.
48355337|NCT05297292|DRUG|Lucentis|a recombinant anti-VEGF humanized monoclonal antibody injection
48666212|NCT02630641|DRUG|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
48666213|NCT01011608|OTHER|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
48666214|NCT01011608|OTHER|standard hospital food|standard hospital diet ad. lib.
48666215|NCT02657148|DRUG|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
48355338|NCT05348564|BEHAVIORAL|Direct contact of family members for cascade screening of relevant variants|Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
48355339|NCT03930394|DIAGNOSTIC_TEST|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
48355340|NCT04744766|PROCEDURE|major duct excision|2 methods of major/central mammary duct excision are compared as regard the outcome
48355341|NCT03530059|OTHER|Home-based rehabilitation|Observational study
48355342|NCT04177186|OTHER|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
48355343|NCT04177186|COMBINATION_PRODUCT|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
48355344|NCT00536640|DRUG|Erlotinib|150 mg per os, given daily until tumor progression
48355345|NCT00536640|DRUG|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
48355346|NCT00536640|DRUG|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
48666216|NCT02657148|DRUG|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.
48355347|NCT00536640|DRUG|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
48355348|NCT03849014|PROCEDURE|Dynamic Hip Screw|Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 7-10 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.
48355349|NCT03849014|PROCEDURE|Proximal Femoral Nail|Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 2-3 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. After palpating the greater trochanter tip, the nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
48355350|NCT04745065|BEHAVIORAL|Connect2BWell|Please see the description provided for arm 1.
48144320|NCT03871075|BEHAVIORAL|Health Education|Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
48355351|NCT00906555|PROCEDURE|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
48144321|NCT05588388|DRUG|Bevacizumab|Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
48355352|NCT02074475|OTHER|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
48355353|NCT06336876|OTHER|Survey|Online survey launched via the Survey Monkey® portal
47987857|NCT06185504|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
48002657|NCT04434885|OTHER|Clinical and imaging examination of symptoms and signs suggestive of axial involvement|Clinical and imaging examination including X-rays and magnetic resonance imaging of sacroiliac joints and spine
48002658|NCT03050879|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
48002659|NCT03857087|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
48355354|NCT01649752|BIOLOGICAL|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
48355355|NCT01649752|BIOLOGICAL|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
48144322|NCT03028805|OTHER|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
48355356|NCT02495714|BEHAVIORAL|Active learning|Physical activity one hour a day as part of academic learning
48355357|NCT02495714|BEHAVIORAL|Dietary councelling|Teaching children and parents about a healthy diet
48355358|NCT00911144|BIOLOGICAL|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
48355359|NCT00911144|BIOLOGICAL|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
48355360|NCT00911144|BIOLOGICAL|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
48355361|NCT03946189|DIAGNOSTIC_TEST|Obtaining arterial blood gases|Obtaining arterial blood sample
48355362|NCT00596895|DIETARY_SUPPLEMENT|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
48355363|NCT03109535|BEHAVIORAL|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
48355364|NCT03109535|BEHAVIORAL|Fitbit only|Users receive a Fitbit Zip to wear daily.
48355365|NCT01982669|OTHER|No Intervention|
48355366|NCT04919694|PROCEDURE|combination of orbital compression surgery and strabismus surgery|combination of orbital compression surgery and strabismus surgery at the same time
48355367|NCT04919694|PROCEDURE|orbital compression|orbital compression
48355368|NCT01865136|OTHER|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
48505586|NCT03722667|BEHAVIORAL|TechSupport|"The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence."
48505587|NCT04890301|BEHAVIORAL|CT guided biopsy for pulmonary nodule|"The technical process of the experimental group: ① design of puncture path, positioning and fixation of patients; ② puncture point positioning; ③ installation of navigation frame and template; ④ percutaneous lung biopsy guided by PT combined with CT.~The technical process of the active comparator group: ① planning puncture path, positioning and fixation of patients; ② positioning puncture point; ③ CT guided percutaneous lung biopsy.~The operation related information, complications and postoperative pathological results were collected."
48505588|NCT04636164|DIAGNOSTIC_TEST|Model Dermatology (deep neural networks; Build 2020)|Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
48505589|NCT04628793|DRUG|PF-07258669|PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
48505590|NCT04628793|DRUG|Placebo|Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
48505591|NCT00062985|BEHAVIORAL|Mail-based weight loss intervention|
48505592|NCT00062985|BEHAVIORAL|Phone-based weight loss intervention|
48505593|NCT03477903|DRUG|TAK-954|TAK-954 infusion
48505594|NCT03477903|DRUG|Metoclopramide|Metoclopramide infusion
48355369|NCT00676728|DRUG|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
48144323|NCT03028805|OTHER|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
48355370|NCT02537275|DEVICE|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
48666217|NCT02724839|BEHAVIORAL|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).
48666218|NCT02724839|DEVICE|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
48355371|NCT02537275|DEVICE|EyeLIKe Shine, Koryo Eyetech Co|clear lens
48144324|NCT05829668|BEHAVIORAL|ABA-based functional analysis and treatment|Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
47987858|NCT06185504|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
47987859|NCT05020392|DRUG|BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
48144325|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
48144326|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
48355372|NCT01631006|DEVICE|CPAP|A low or high CPAP pressure is delivered for 20 minutes
48666219|NCT05267782|DEVICE|Masimo's O3 Regional Oximetry|Correlation between new O3 regional oximetry monitoring, electroencephalography and somatosensory evoked potential in carotid endarterectomy and data collection during different stages of anaesthesia and correlation with new O3 regional oximetry
48666220|NCT03827317|RADIATION|[18F]GE-226|\[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
48666221|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by DPI|Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
48666222|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by MDI|Budiair 200 mcg or Atimos 12 mcg
47987860|NCT05020392|DRUG|Fludarabine-based chemotherapy + CAR-T-CD19 Cells|Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
47987861|NCT00237757|BEHAVIORAL|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
47987862|NCT00237757|BEHAVIORAL|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
48355373|NCT05656131|DRUG|Fluzoparib|Arms A will be treated with fluzoparib alone
48355374|NCT05656131|DRUG|Fluzoparib+Camrelizumab|Arms B will be treated with fluzoparib in combination with camrelizumab
48355375|NCT04002206|OTHER|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
48355376|NCT04002206|OTHER|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
48355377|NCT04663828|OTHER|Structured counseling|Structured patient education and counselling is considered as providing information to patients in order to empower them to better manage their disorder
48505595|NCT03477903|DRUG|Normal Saline|0.9% sodium chloride for injection
48666223|NCT01468064|GENETIC|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
48355378|NCT04663828|DEVICE|Hearing aids|Hearing aids are considered medical devices and are recommended to patients with a certain degree of hearing loss. Hearing aids amplify environmental sounds.
48666224|NCT01468064|GENETIC|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
48666225|NCT01468064|GENETIC|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
47987863|NCT04079829|OTHER|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data|No interventions
48355379|NCT04663828|OTHER|Cognitive behavioral therapy|This is a structured intervention and consists of a several week program both with noise exposure and structured interviews and expert-patient as well as patient-patient interaction in groups
48355380|NCT04663828|OTHER|Sound therapy|Several sounds and music are used for tinnitus disorder
48355381|NCT06142162|DIAGNOSTIC_TEST|flow cytometry|Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils
48355382|NCT06142162|DIAGNOSTIC_TEST|ELISA|estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum
48355383|NCT06142162|DIAGNOSTIC_TEST|RFLP|assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique
47987864|NCT01646515|DRUG|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
47987865|NCT01646515|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
47987866|NCT05332509|DEVICE|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
47987867|NCT05332509|DEVICE|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
47987868|NCT02188589|DEVICE|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
47987869|NCT03762109|DRUG|Dantrolene|muscle relaxant
47987870|NCT03762109|DRUG|Placebo Oral Tablet|inactive pill
48002660|NCT03857087|PROCEDURE|Magnetic Resonance Imaging (MRI)|Given PET/MRI
48355384|NCT02685839|DEVICE|Intelligent POWER Rehabilitation Cluster Machine|
48355385|NCT02685839|OTHER|general physical therapy|
48355386|NCT00249522|BEHAVIORAL|Contingency management|
48355387|NCT01066611|DRUG|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
48144327|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
48666226|NCT03470025|OTHER|Psychological Intervention|"1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
47987871|NCT03792308|DRUG|SPR206|"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
48144328|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
48144329|NCT00788541|OTHER|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
48144330|NCT02695004|DRUG|DKF-310|
47987872|NCT03792308|DRUG|Placebo|0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
47987873|NCT02174055|BEHAVIORAL|Patient Interviews|participate in a brief interview
48144331|NCT02695004|DRUG|Placebo|
48144332|NCT04749797|DRUG|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
48144333|NCT04749797|DRUG|Bupivacaine Injection|Used as cranial block for craniotomy surgery
48144334|NCT04749797|DRUG|Saline|Used as cranial block for craniotomy surgery
48144335|NCT00911404|BEHAVIORAL|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
48144336|NCT00911404|DIETARY_SUPPLEMENT|High CHO diet|Diet with 55% total calories from carbohydrates.
48144337|NCT01697826|DRUG|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
48355388|NCT01066611|DRUG|Placebo|CAL-263 10 mg or placebo once daily for 7 days
48355389|NCT00717951|DRUG|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
48355390|NCT05275127|OTHER|changes of gingival crevicular fluid miRNA|Evaluation of changes of gingival crevicular fluid miRNA after periodontal treatment
48355391|NCT00021281|DRUG|FOLFIRI regimen|
47987874|NCT02174055|BEHAVIORAL|newly developed questionnaire|10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
48144338|NCT01697826|DRUG|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
48355392|NCT00021281|DRUG|fluorouracil|
48144339|NCT06213545|DIAGNOSTIC_TEST|In-clinic interpretation|Reading patch test result at clinic
48144340|NCT06213545|DIAGNOSTIC_TEST|Photo interpretation|Reading patch test result by sending photo to clinic
48144341|NCT02709044|DRUG|Ringer lactate|
48355393|NCT00021281|DRUG|irinotecan hydrochloride|
48355394|NCT00021281|DRUG|leucovorin calcium|
48505596|NCT04521582|DRUG|Amlodipine|The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).
48505597|NCT04521582|BEHAVIORAL|Lifestyle counselling|Female Community Health Volunteer will provide lifestyle counseling at the participant's home
48002661|NCT03857087|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET/MRI
48002662|NCT05030142|PROCEDURE|Mechanical Thrombectomy|Mechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
48002663|NCT05030142|DRUG|Best medical treatment alone|Best medical treatment alone (usual care)
48355395|NCT00021281|DRUG|semaxanib|
48355396|NCT02110550|OTHER|IPS.emmax endocrown|
48355397|NCT05850962|OTHER|Individualised MAP target|The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
48355398|NCT02650193|DRUG|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
48355399|NCT03289494|OTHER|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
48355400|NCT03289494|OTHER|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
48355401|NCT05238844|DRUG|ATI-2173 25mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth.
48355402|NCT05238844|DRUG|Vebicorvir 300mg|Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein
48355403|NCT05238844|DRUG|Viread 300Mg Tablet|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
48666227|NCT02639689|DEVICE|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
48666228|NCT02684461|DRUG|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
48355404|NCT02618512|DRUG|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
48505598|NCT06030986|DIAGNOSTIC_TEST|ILCOR Utstein OHCA Core Outcome|ILCOR Utstein OHCA Core Outcome
48666229|NCT06387082|DRUG|HMPL-506|HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
47987875|NCT02174055|BEHAVIORAL|Pilot Testing the Draft Measure|The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
48355405|NCT02393612|DRUG|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
48355406|NCT02393612|DRUG|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
48355407|NCT03309293|BIOLOGICAL|blood samples|blood samples
48355408|NCT05564715|DEVICE|NeuroElectric StarStim|10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks
48355409|NCT05564715|DEVICE|Sham Treatment|Sham stimulation for 10 sessions over 2 weeks
48355410|NCT01341925|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
48505599|NCT00358410|DRUG|GW679769 oral tablets|2x GW679769 60mg tablets
48505600|NCT00358410|DRUG|Placebo|Placebo oral tablets to match experimental intervention
47987876|NCT03597958|GENETIC|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
48505601|NCT04199871|OTHER|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
48505602|NCT04235361|DIAGNOSTIC_TEST|Differential RPA tests|The mobile diagnostic suitcases will be deployed at Ebola Treatment centres in DRC. Samples of patients refered for diagnostic testing will be tested by PCR by existing diagnostic teams, and will be additionally tested by the mobile suitcase laboratory using differential RPA tests for 6 parameters.
48505603|NCT06626399|DIAGNOSTIC_TEST|Diagnosis of SSI|Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
48355411|NCT01341925|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
48355412|NCT01341925|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
48355413|NCT05985616|OTHER|High Intensity Resistance Training|High intensity resistance training will be performed 3 times a day for sixteen weeks
48505604|NCT06525103|DEVICE|electromagnitic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology.~* Frequency : 50 or 60 Hz.~* Intenisty: 0-100 .Input voltage: 230 V"
48666230|NCT03836404|DEVICE|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
48666231|NCT00691626|BEHAVIORAL|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
48666232|NCT00691626|BEHAVIORAL|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
48144342|NCT05600439|BEHAVIORAL|CareME|"CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust \& secure base (figures and environment); (v) professionals' stories of attachment \& caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision."
48355414|NCT05898854|DRUG|68Ga-FAPi-46|Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
48666233|NCT04897022|DRUG|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
48355415|NCT04050228|DEVICE|Quantitative ultrasound to guide adaptive chemotherapy|Quantitative ultrasound results will be used to measure chemotherapy response and guide an adaptive chemotherapy strategy for patients who are found to be nonresponders to their chemotherapy.
48355416|NCT04384991|DRUG|HU007|Cyclosporine 0.02% with Trehalose 3%
48505605|NCT06525103|DEVICE|whole body vibration|"Crazy fit machine.~* Input voltage:220 V.~* Frequency : 30 Hz.~* Maximum power: 1500W.~* Intensity:1 to 50 levels."
48355417|NCT04384991|DRUG|Restasis eye drop|Cyclosporine 0.05%
48355418|NCT03398174|BEHAVIORAL|Motor Control Exercise|"Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
48355419|NCT03398174|BEHAVIORAL|Patient Education|"Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
48505606|NCT02521376|DRUG|Entospletinib|Entospletinib 100 mg tablet administered orally
48505607|NCT00788944|PROCEDURE|blood draw|Test Article was not provided to subjects for this study.
48505608|NCT01054404|DRUG|Furosemide|Furosemide 0.3 mg/kg
48505609|NCT01054404|DRUG|Placebo|Placebo (up to 5mL)
48505610|NCT02776137|DRUG|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
48505611|NCT02776137|RADIATION|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
48505612|NCT03558386|BEHAVIORAL|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
48355420|NCT00684463|DRUG|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
48355421|NCT04469556|DRUG|Folfirinox|Chemotherapy
48355422|NCT04469556|DRUG|Gemcitabine/nab-paclitaxel|Chemotherapy
48355423|NCT01572844|DEVICE|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
48355424|NCT01572844|DRUG|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
48505613|NCT04399486|OTHER|Physical Therapy|Physical Therapy is a therapeutic exercise, education and functional activities provided on a one to one basis with a licensed Physical Therapist to meet functional goals.
48505614|NCT06467110|DEVICE|transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)|The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
48355425|NCT04729010|OTHER|Acupuncture to treat anxiety in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
48355426|NCT03537001|OTHER|Penthrox|Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
48505615|NCT01790477|PROCEDURE|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
48666234|NCT04897022|RADIATION|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
48144343|NCT05688891|OTHER|Virtual reality|"5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Audio and video settings were made and started to be watched. Video monitoring with Virtual Reality continued throughout the entire dressing. This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings."
48144344|NCT05688891|OTHER|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.~After the process was finished, the music was turned off and the headphones were removed.~This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
48144345|NCT02790788|DRUG|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
48144346|NCT02790788|DRUG|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
48355427|NCT05686876|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
48355428|NCT03640715|OTHER|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
48355429|NCT03726749|DRUG|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
48666235|NCT05437991|DIAGNOSTIC_TEST|Independent morphological quantifications by echo-doppler using ECST method|The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
48666236|NCT02623244|PROCEDURE|Laparoscopic oophorocystectomy or oophorectomy|
48666237|NCT02563015|DIETARY_SUPPLEMENT|cholecalciferol|liquid drops
48666238|NCT02563015|DIETARY_SUPPLEMENT|Reference 400|liquid drops
48144347|NCT01177449|PROCEDURE|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
48144348|NCT04436549|PROCEDURE|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
48355430|NCT03726749|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
48355431|NCT05006651|DEVICE|McGrath MAC|Intubaion with McGrath MAC
48355432|NCT05006651|DEVICE|Trachway|Intubaion with Trachway
48505616|NCT03503526|BEHAVIORAL|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
48505617|NCT04127630|PROCEDURE|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
48505618|NCT02826512|DRUG|Niraparib|niraparib 300 mg QD continuously
48505619|NCT05722522|DRUG|Secukinumab|The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
48505620|NCT05722522|DRUG|Placebo|The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
48505621|NCT04340596|BIOLOGICAL|N-803 (IL-15 Superagonist)|Administered by subcutaneous (SQ) injection
48505622|NCT04340596|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
48505623|NCT04340596|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
48505624|NCT01900561|BEHAVIORAL|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
48505625|NCT01900561|BEHAVIORAL|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
48505626|NCT03303196|DEVICE|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
48505627|NCT01404923|DRUG|anti spasmodic agents|best standard of care prescriptions
48144349|NCT04436549|DIAGNOSTIC_TEST|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
48355433|NCT03998995|DEVICE|Immersive Virtual Reality|"An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff."
48355434|NCT00779116|DRUG|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
48355435|NCT00779116|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
48355436|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
48355437|NCT03037333|PROCEDURE|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
48355438|NCT02367690|DRUG|Selinexor|Topical gel
48355439|NCT02367690|OTHER|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
48355440|NCT02367690|OTHER|Vehicle Gel|Topical vehicle gel with no active ingredients.
48355441|NCT04492306|OTHER|Dimethyl Sulfoxide|DMSO \[(CH3)2SO\] is a polar aprotic solvent that dissolves both polar and non-polar compounds.
48355442|NCT04492306|OTHER|3M ESPE Single bond 2|Total etch adhesive bond
48355443|NCT04492306|OTHER|Filtek Z350 XT, 3 M ESPE, St Paul, MN, USA)|Composite Resin
48355444|NCT04492306|OTHER|3m ESPE etch|32% phosphoric acid
48355445|NCT01162967|DRUG|Benznidazole|Standard dosage
48355446|NCT01162967|DRUG|Posaconazole|
48355447|NCT05661838|PROCEDURE|transfusion|transfusion
48355448|NCT03491475|DRUG|Ajmaline test|Administration of Ajmaline
48355449|NCT04898088|BIOLOGICAL|Mesenchymal Stem Cells Transplantation|Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals
48355450|NCT02178592|DRUG|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
48355451|NCT02178592|DRUG|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
48355452|NCT04509635|DRUG|Cetuximab|Cetuximab is used for only patients with ctDNA test RAS wild type.
48355453|NCT04509635|DRUG|Chemotherapy|The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
48355454|NCT05319158|OTHER|MIT-PB, movement imitation therapy for preterm.|The instant an infant showed CS or PR movements, the therapists (or a therapist and a parent) intervened by gently guiding the infants' limbs so as to maneuver and smoothen their movements, thereby imitating normal GM sequences as closely as possible, adding variability to the movement
48355455|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
48505628|NCT01404923|DRUG|alverine citrate, simeticone|on-demand therapy
48355456|NCT03745391|DIAGNOSTIC_TEST|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
48355457|NCT05102344|BEHAVIORAL|Behavioral Social Skills Training|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.
48355458|NCT05102344|BEHAVIORAL|Animal Assisted Intervention|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
48355459|NCT06258772|DRUG|Mepolizumab Auto-Injector|Mepolizumab 100 mg in pre-filled injector
48355460|NCT04604028|DRUG|Lenalidomide [Leavdo®]|Complete remission and partial remission rate
48355461|NCT03310099|BEHAVIORAL|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
48355462|NCT05990140|OTHER|peppermint flavored mouthwash|The Effect of Peppermint Flavored Mouthwash Applied to Patients in the First 30 Days After Bariatric Surgery on Nausea-Vomiting, Anxiety and Biochemical Parameters
48355463|NCT05392101|DRUG|Deferasirox 360 MG|Deferasirox 360 MG p.o. once daily
48355464|NCT03148249|OTHER|interview|control group: interview, study group: explanation and exploration
48505629|NCT03814525|RADIATION|Photobiomodulation|PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
48355465|NCT05178329|BEHAVIORAL|Lifting exercise|Patients are instructed for a light lifting exercise after mastectomy.
48355466|NCT05178329|BEHAVIORAL|Standard exercise|Standard exercise program after mastectomy
48355467|NCT02380703|BEHAVIORAL|Aggression Prevention Training (APT)|
48355468|NCT02380703|OTHER|Enhanced Usual Primary Care (EU-PC)|
48355469|NCT00912639|DRUG|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
48355470|NCT06115512|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
48355471|NCT06115512|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
48355472|NCT04473495|DEVICE|educational video|educational video before intervention
48355473|NCT01497665|DRUG|GRN1005|650 mg/m2 IV every 3 weeks
48355474|NCT01425528|DRUG|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
48355475|NCT00003958|BIOLOGICAL|dactinomycin|Given IV
48355476|NCT00003958|DRUG|vincristine sulfate|Given IV
48355477|NCT00003958|DRUG|cyclophosphamide|Given IV
48144350|NCT01404338|DRUG|Halobetasol 0.05% ointment|
48144351|NCT01404338|DRUG|Placebo Ointment|
48355478|NCT00003958|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48355479|NCT00003958|RADIATION|radiation therapy|Undergo radiotherapy
48144352|NCT01636726|DRUG|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
48144353|NCT04131036|OTHER|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
48144354|NCT04931966|PROCEDURE|block|Adductor canal block
48144355|NCT04931966|PROCEDURE|adductor canal block|adductor canal block bupivacain
48144356|NCT04931966|PROCEDURE|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using bupivacaine
48144357|NCT04931966|PROCEDURE|adductor Canal Block plus PAI Block|Adductor Canal Block plus PAI Block using bupivacaine
48144358|NCT06306937|DIAGNOSTIC_TEST|Evalution of serum levels of vitamin D and IL8|"Group 1 (Periodontitis Group): The intervention involves observing and analyzing individuals diagnosed with periodontitis based on established clinical criteria. The focus is on assessing vitamin D and IL8 levels in the serum and correlating these levels with the severity of periodontitis, determined by clinical indices such as probing depth, clinical attachment loss, and bleeding on probing.~Group 2 (Control Group): The intervention involves observing and analyzing individuals without any signs or history of periodontal disease. The focus is on assessing vitamin D and IL8 levels in the serum for comparison with the periodontitis group. This group serves as the healthy control for the study."
48355480|NCT00003958|DRUG|topotecan hydrochloride|Given IV
48355481|NCT00003958|BIOLOGICAL|filgrastim|Given SC
48355482|NCT00003958|BIOLOGICAL|sargramostim|Given SC
48355483|NCT00003958|OTHER|laboratory biomarker analysis|Correlative studies
48355484|NCT05187494|OTHER|Conventional local palatine injection|Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
48355485|NCT05187494|DRUG|EMLA cream only|Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
48355486|NCT05187494|DRUG|chemical permeability enhancer DMSO with EMLA cream|Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
48355487|NCT05187494|DRUG|Oral patches with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
48355488|NCT05187494|DRUG|Micro-needle patches dissolved with EMLA Cream|EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
48355489|NCT01637792|OTHER|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
48355490|NCT01637792|OTHER|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
48355491|NCT03140267|DIAGNOSTIC_TEST|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
48144359|NCT06199115|PROCEDURE|Photobiomodulation|"In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy. Photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies.~Patients in the experimental group will receive 3 photobiomodulation sessions per week during their oxaliplatin treatments (6 months), for a total of 72 sessions. Exposition to laser light is 30 minutes for each session."
48144360|NCT01403285|DRUG|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
48355492|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (self-report questionnaires)|"All participants will be asked to fill in the PID-5-BF+M and the LPFS-BF 2.0 to examine personality disorders as defined by the AMPD and ICD-11.~PID-5-BF+M consists of 36 self-report items. It has 18 facet scales and 6 domain scales (Anankastia, Negative Affectivity, Antagonism, Disinhibition, Psychoticism and Detachment).~The LPFS-BF 2.0 has 12 items, measuring 4 domains of personality functioning (identity, intimacy, self-direction and empathy)."
48666239|NCT04924348|PROCEDURE|Experimental: WALANT procedure|"The WALANT technique, performed under ultrasound, includes two punctures.~* The first is a puncture through a medial approach above the wrist and includes two injections. A first subcutaneous injection reproducing a bar above the wrist flexion line, and a second injection above the median nerve. The volumes injected vary from 8 to 10 milliliters (ml).~* The second puncture is performed at the base of the palmar surface of the hand and consists of a 10 ml subcutaneous injection of the local anesthetic in order to take advantage of the vasoconstrictive effects of adrenaline, thus allowing the surgical procedure to be performed without a pneumatic tourniquet."
48666240|NCT04924348|PROCEDURE|Active Comparator: Axial ALR|The anesthetic protocol in the axillary block consists of performing a puncture, using a needle (50 mm 22G with a short bevel), under the armpit at the level of the axillary hollow after skin disinfection. This puncture, performed under ultrasound, allows the injection of the local anesthetic around the median, radial, ulnar and musculocutaneous nerves. The volume injected per nerve can vary from 5 to 8 ml depending on the visual appreciation during the injection.
48666241|NCT04924348|PROCEDURE|Active Comparator: Truncal ALR|The anesthetic protocol in truncal block consists in injecting the local anesthetic around the median and ulnar nerves by a puncture performed at the elbow or forearm (depending on the practitioner's experience). The volumes injected remain the same and the puncture is also performed under ultrasound guidance. Additional local anesthesia is administered by injecting an additional 5 ml above the wrist flexion line to block the sensory territory of the musculocutaneous nerve.
48666242|NCT06564415|PROCEDURE|Transperineal Laser Ablation of Prostate|Transperineal Laser Ablation of the Prostate is an ultra minimally-invasive procedure that consists in the insertion trough the perineum skin of laser fibers into the prostatic adenoma, under US guidance. Laser energy generates an area of coagulative necrosis that will bring to a reduction of the prostatic volume.
48666243|NCT01627886|DRUG|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
48666244|NCT02497105|OTHER|Ketogenic Diet|Dietary
48666245|NCT04999410|BEHAVIORAL|High Intensity Interval Training|Interventions will contrast alternative training protocols
48666246|NCT03819309|PROCEDURE|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
48666247|NCT03819309|PROCEDURE|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
48144361|NCT01403285|BIOLOGICAL|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
48144362|NCT01403285|BIOLOGICAL|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
48144363|NCT01403285|DRUG|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
48505630|NCT03814525|RADIATION|Placebo Photobiomodulation|The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
48666248|NCT02468583|DRUG|FX006 32 mg|Experimental
48666249|NCT02468583|DRUG|TCA IR 40 mg|Comparator
48666250|NCT04271293|DRUG|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
48666251|NCT00415090|DRUG|Nevirapine|Switch one of ARV drugs to Nevirapine
48666252|NCT05799755|DRUG|Nintedanib|Nintedanib 150 mg BID
48666253|NCT05799755|DRUG|Placebo|Placebo comparator
48666254|NCT05799755|DRUG|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
48666255|NCT06570122|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
48666256|NCT06570122|OTHER|Health warning leaflet|The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
48666257|NCT06570122|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
48666258|NCT04946058|PROCEDURE|hyebrid Mathieu Urethroplasty|incision of the urethral plate during the procedure
48355493|NCT05548946|OTHER|Secondary Questionnaires (self-report and informant questionnaires)|"The patients fill in a standard test battery during the first weeks of their admission in the institutions, including questionnaires and interviews. The research team will analyze the results retrospectively.~This includes:~YSQ- SF16 (Young \& Brown, 1994; Pauwels et al., 2018) GPS (van Alphen et al., 2006) HoNOS 65+ (Burns et al., 1999) HAP 2.0 (Barendse \& Thissen, 2006) SCL-90-R (Derogatis, 1983; Dutch version: Arrindell, \& Ettema, 1975, 1986, 2005) ADP-IV (Schotte \& De Doncker, 1998) CERQ (Garnefski et al., 2007) UCL (Scheurs et al., 1994; 1988) BIS/BAS Scales (Carver \& White, 1994) EC Scale of the ATQ (Rothbart et al., 2000) BSI (Derogatis, 1975; Dutch version: Beurs, 2008) SIPP-SF (derived from the SIPP-118; Verheul et al., 2008) SMI (Young et al., 2008) WHO-5 (Dutch version: WHO, 1998) SQ3-SF (Young \& Brown, 2005) SCID-5-P (First et al., 2017; Dutch translation: Arntz et al., 2017)"
48666259|NCT00909701|DIETARY_SUPPLEMENT|PreOP Booster|1 serving of 400 ml per study arm
48666260|NCT00909701|DIETARY_SUPPLEMENT|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
48666261|NCT03747692|PROCEDURE|study group|local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
47987877|NCT03627754|DRUG|Glasdegib 100 mg single oral dose|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
48002664|NCT05198570|OTHER|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
48144364|NCT05866354|DRUG|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
48144365|NCT00310609|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
48355494|NCT05548946|DIAGNOSTIC_TEST|Clinical Ratings of the dimensional model|"Clinical ratings of criteria A and B will also be collected. Only a small part of the patients will be selected for this, in order to make the research more feasible. The rater (a clinician or researcher) assesses the patient (in terms of level of personality functioning and personality traits) by means of (structured) clinical interviews. Given clinical ratings of the dimensional criteria are not part of the standard care in either institution, the ratings can be conducted by the doctorandus and Master Thesis students, trained by the doctorandus (in order not to overburden the clinicians).~The clinical interviews that will be used for the ratings are:~* The Semigestructureerd Interview voor Persoonlijkheidsfunctioneren DSM-5 (STIP) (Hutsebaut et al., 2014).~* The Structured Clinical Interview for the DSM-5 (SCID-5-AMPD) (First et al., 2018), only if a Dutch translation is available by the time of this intervention."
48355495|NCT05548946|OTHER|PID-5-BF+M and LPFS-BF 2.0 (Informant questionnaires)|In the clinical population, participants will be asked to include an informant (family member, partner, friend, acquaintance), to fill in an informant version of the PID-5-BF+M and LPFS-BF 2.0 questionnaires. It is also possible for the patient to participate in the study without giving permission to include an informant. The informant will be asked to fill in the informant versions of the questionnaires, which contain the exact same items as the self-report versions, adjusted to the third person.
48355496|NCT03507270|DIAGNOSTIC_TEST|FABP|Assessment of changes in FABP concentrations
48144366|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
48144367|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
48355497|NCT00909194|BEHAVIORAL|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
48355498|NCT04276831|DEVICE|Laryngoscope McCoy|Subjects who fulfill inclusion criteria will be intubated using laryngoscope McCoy
48355499|NCT04276831|DEVICE|Laryngoscope Macintosh|Subjects who fulfill inclusion criteria will be intubated using laryngoscope Macintosh
48355500|NCT04437602|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEM)|Additional CEM in preoperative staging
48355501|NCT00886587|DEVICE|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
48355502|NCT00886587|DEVICE|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
48355503|NCT04182165|DEVICE|Gili BioSensor System/ Gili Pro X BioSensor System|Usability study
48355504|NCT05762224|OTHER|Effect of kinesio taping on upper limb lymphedema|Group A received Kinesio taping 2 times a week for 3 weeks to reduce lymphedema and Group B received pressure garments(20-60 mm Hg) for at least 15 to 18 hours per day for 3 weeks
48355505|NCT00766272|DEVICE|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
48355506|NCT01536418|DRUG|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
48355507|NCT01536418|DRUG|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
48144368|NCT01930188|DRUG|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
48144369|NCT01930188|DRUG|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
48144370|NCT01930188|DRUG|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
48505631|NCT02437435|OTHER|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
48505632|NCT02437435|OTHER|Placebo Intervention|Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
48505633|NCT02527538|DEVICE|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
48144371|NCT01930188|DRUG|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
48355508|NCT04532281|DRUG|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
48355509|NCT05738928|DIAGNOSTIC_TEST|blood and sputum culture|Noninvasive sampling ( Endo Tracheal Aspiration) for staining and culture. Blood culture .
48505634|NCT05750862|PROCEDURE|Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye|The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
48505635|NCT02651259|DRUG|Rifapentine (RPT)|900 mg of RPT
48505636|NCT02651259|DRUG|Isoniazid (INH)|900 mg of INH
48505637|NCT02651259|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
48505638|NCT04553016|BIOLOGICAL|Vaccine|IM vaccination with ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4
48505639|NCT04553016|BIOLOGICAL|Placebo|IM administration of 0.9% sterile sodium chloride solution
48355510|NCT03631849|PROCEDURE|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
48355511|NCT03631849|OTHER|Care|descaling and maintenance of implants
48355512|NCT00245635|DRUG|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
48355513|NCT00245635|DRUG|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
48355514|NCT02089178|PROCEDURE|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
48355515|NCT02089178|PROCEDURE|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
48355516|NCT02089178|DRUG|propofol-remifentanil|
48355517|NCT02089178|DRUG|sevoflurane-remifentanil|
48355518|NCT03140033|DRUG|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
48355519|NCT03140033|DRUG|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
48355520|NCT03245099|OTHER|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
48355521|NCT05569356|BIOLOGICAL|Prospective|-Additional blood samples -Myocarditis biopsy sample (routine care) -Additional pericardial fluid sample (routine care)
48355522|NCT05569356|OTHER|Retrospective|None (only data collection)
48355523|NCT01495689|BEHAVIORAL|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
48355524|NCT01495689|BEHAVIORAL|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
48355525|NCT03727386|OTHER|Coconut oil|Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
48505640|NCT02771535|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
48505641|NCT02771535|BEHAVIORAL|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
48505642|NCT04851873|GENETIC|OAV101|Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
48505643|NCT04505748|DEVICE|Self-transfusion device|The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
48505644|NCT05655221|DRUG|B1344|multi-site abdominal s.c. injections (maximum 2 mL at each site)
48505645|NCT05655221|OTHER|Placebo|multi-site abdominal s.c. injections (maximum 2 mL at each site)
48505646|NCT03103139|PROCEDURE|Transpapillary Stent|ERCP with placement of short stent
48505647|NCT03103139|PROCEDURE|Stent across bile leak|ERCP with long stent
48355526|NCT03727386|OTHER|Sunflower oil|Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
48355527|NCT06482892|DRUG|TP03HN106|"During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia."
48355528|NCT01749436|OTHER|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
48355529|NCT03474939|DRUG|Midazolam Oral Tablet|Midazolam Oral tablet
48355530|NCT03474939|OTHER|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
48355531|NCT00807989|DRUG|Carbamazepine|
48355532|NCT00807989|DRUG|Lamotrigine/Valproate|
48505648|NCT00887055|DEVICE|CRT device|
48666262|NCT03747692|PROCEDURE|control group|each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
48666263|NCT00419744|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|
48666264|NCT00419744|DRUG|Formoterol Turbuhaler|
48666265|NCT04120870|DRUG|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
48666266|NCT04120870|DRUG|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
48144372|NCT05298540|BEHAVIORAL|Home-based computerised cognitive training with BrainHQ|Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
48144373|NCT04613284|DRUG|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
48144374|NCT04613284|RADIATION|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
48144375|NCT02271906|DRUG|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
48144376|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
48505649|NCT04710979|BEHAVIORAL|Yoga Intervention|This group will have in-person, 60 minute yoga sessions three times per week for 12 weeks. These sessions will also include a sharing circle to provide group feedback as to how the practice felt and integration into ones' daily life. There will be biweekly themes established for these sessions (i.e. common yoga poses, importance of breath) and biweekly in-person workshops will be offered. These will be specialty classes for participants to experience additional exposure to meditation and breathing. They will be a longer format so participants can delve deeper into yogic philosophy and practice. There will also be a private Facebook group for participants to connect with each other and for the research staff to maintain contact and share information with the participants (eg. weekly reminder for yoga sessions and workshops).
48666267|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
48666268|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
48144377|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
48666269|NCT01217034|DRUG|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
48666270|NCT01217034|PROCEDURE|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
48144378|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
48144379|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
48144380|NCT00310037|DRUG|bortezomib|Given IV
48144381|NCT02054429|DRUG|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
48666271|NCT04622592|BIOLOGICAL|Instramuscular vaccine|On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
48666272|NCT01101776|DRUG|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
48666273|NCT01175122|BIOLOGICAL|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
48144382|NCT02011360|OTHER|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
48144383|NCT02011360|OTHER|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
48144384|NCT03442777|DEVICE|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).
48144385|NCT03442777|DEVICE|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
48144386|NCT01052272|DRUG|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
48144387|NCT01052272|DRUG|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
48144388|NCT01052272|DRUG|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
48666274|NCT01051245|BEHAVIORAL|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
48144389|NCT06031714|OTHER|Saliva sampling|HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
48355533|NCT03637166|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
48355534|NCT03637166|OTHER|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
48355535|NCT03325933|OTHER|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
48355536|NCT03325933|OTHER|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
48355537|NCT02516891|DEVICE|Drug-Eluting Stents implantation in bifurcation lesions|
48666275|NCT01051245|OTHER|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
48666276|NCT01916031|BEHAVIORAL|Education|
48666277|NCT04487509|OTHER|THROMBOLYSE|the treatment delivered to the emergency room, in particular the nature of the treatment for obstruction (primary angioplasty or thrombolysis)
48666278|NCT01221506|DRUG|Pazopanib|800 mg PO QD x 28 days
48666279|NCT01221506|DEVICE|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
48666280|NCT04908644|DRUG|MS-20 oral solution|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
48666281|NCT04908644|OTHER|Placebo|Placebo
48666282|NCT05057507|DIAGNOSTIC_TEST|Atrial cardiac magnetic resonance imaging|To include assessment of atrial size, shape, function, fibrosis and fat
48355538|NCT01744340|DRUG|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
48355539|NCT01744340|DRUG|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
48355540|NCT04271202|DRUG|Emgality 120 MG in 1 ML Prefilled Syringe|Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
48355541|NCT05686629|DRUG|Jaktinib hydrochloride tablets|2 doses per day, each containing two 50mg Jaktinib or placebo tablets
48355542|NCT03833349|BEHAVIORAL|Spinning Class|Spinning Class twice a week for six weeks.
48355543|NCT03833349|BEHAVIORAL|Yoga Class|Yoga Class twice a week for six weeks.
48505650|NCT04487951|OTHER|Pro BNP , Vitamin D|This study is designed to assess the difference between level of NT-pro-BNP, and Vitamin D in moderate cases who progressed to severe or critically ill category compared to those who did not.
48505651|NCT05926271|DRUG|Clopidogrel|See arm description earlier.
48355544|NCT03833349|BEHAVIORAL|Dance Class|Dance Class twice a week for six weeks.
48355545|NCT02777164|DEVICE|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
48355546|NCT04366089|OTHER|Oxygen-ozone therapy, probiotic supplementation and Standard of care|- systemic autohemotherapy with Ozone 30 mcg / ml 250ml 2 times / day for 7 days
48355547|NCT04366089|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
48505652|NCT05668130|PROCEDURE|Sacrospinous ligament fixation|Women with stage II or higher pelvic organ prolapse with apical compartment involvement planned for surgical management will be randomised to either sacrospinous ligament fixation arm or uterosacral ligament suspension arm. those raandomized to sacrospinous ligament fixation arm will undergo unilateral (right) sided sacrospinous ligament fixation of apex as a part of pelvic organ prolapse surgery.
48666283|NCT05057507|DIAGNOSTIC_TEST|Atrial electro-anatomic mapping|To include assessment of atrial voltage and local activation time
48666284|NCT05057507|OTHER|Atrial fibrillation symptom questionnaire|To include assessment of atrial fibrillation symptoms and quality of life
48666285|NCT05057507|DIAGNOSTIC_TEST|Patch-based 2 week ambulatory monitor|To assess atrial fibrillation burden post-ablation
48144390|NCT06031714|OTHER|Blood sampling|"Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out."
48144391|NCT06031714|OTHER|Interviews|V2 and/or V3
48144392|NCT06031714|OTHER|Clinical examination|V2 and/or V3
48144393|NCT01366976|DRUG|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
48505653|NCT05668130|PROCEDURE|Uterosacral Ligament Suspension|Similarly women randomised to uterosacral ligament suspension arm will undergo modified high uterosacral ligament suspension of apex. Both arms will be followed up in 6 months and 12 months for anatomical and functional outcome.
48666286|NCT04850326|DIETARY_SUPPLEMENT|AP green tea extract|single intake of AP green tea extract
48666287|NCT00626236|DRUG|SPN-810|capsule taken three times a day
48666288|NCT00626236|DRUG|SPN-810|capsule taken TID
48666289|NCT00626236|DRUG|SPN-810|capsule taken TID
48666290|NCT00626236|DRUG|SPN-810|capsule taken TID
48666291|NCT01937702|OTHER|0.9% NaCl (sodium chloride)|
48666292|NCT06331377|OTHER|Non-Interventional Study|Non-interventional study
48666293|NCT01103414|DRUG|Mitoglitazone|50 mg capsules, once daily for 84 days
48666294|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
48666295|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
48666296|NCT01103414|DRUG|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
48666297|NCT01103414|DRUG|Placebo|Placebo, once daily for 84 days
48666298|NCT05417178|OTHER|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
48002665|NCT01013233|BEHAVIORAL|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
48002666|NCT01013233|OTHER|control group|no intervention
48144394|NCT04624906|DRUG|Acalabrutinib|100 mg oral capsules twice daily for 1 year
48144395|NCT04624906|DRUG|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
48666299|NCT02145884|DRUG|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
48666300|NCT00185341|DRUG|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
48666301|NCT00185341|DRUG|Placebo|Placebo
48666302|NCT05671250|COMBINATION_PRODUCT|PRP gel and SOC-treatment|Platelet-lysate loaded sustained release thermo-gelling formulation
48666303|NCT05671250|COMBINATION_PRODUCT|EPO/ISDN/UFH cryogel dressing|Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold
48666304|NCT05671250|PROCEDURE|Standard of Care|Sharp debridement, saline washing and regular saline dressing
48666305|NCT05511948|DRUG|DBI-102|Topical application on dorsal hand and upper volar arm
48666306|NCT05511948|DRUG|Vehicle gel|Inactive comparator
48666307|NCT05511948|DRUG|Hydroquinone Cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
48666308|NCT01418521|DRUG|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
48666309|NCT01418521|DRUG|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
48666310|NCT00575224|DRUG|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
48666311|NCT06537869|BEHAVIORAL|iCBT for depression|iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)
48666312|NCT01936558|OTHER|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
48666313|NCT00160563|DRUG|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
48505654|NCT05056662|DIAGNOSTIC_TEST|Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR|Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
48144396|NCT04624906|DRUG|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
48144397|NCT05862402|DRUG|Dose-adjustment by PKPD|Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
48505655|NCT01624792|DIETARY_SUPPLEMENT|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
48505656|NCT01624792|DIETARY_SUPPLEMENT|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
48144398|NCT00926107|DRUG|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
48505657|NCT01624792|DIETARY_SUPPLEMENT|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
48505658|NCT05345743|PROCEDURE|Surgery|All types of surgery requiring general anesthesia
48505659|NCT02640092|DRUG|[18F]GTP1|Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
48505660|NCT03638414|OTHER|ePainQ questionnaire|This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
48505661|NCT04283968|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation in adults with Atopic Dermatitis
48666314|NCT00160563|OTHER|Placebo|Oral drops, bid for 18 months
48666315|NCT04635852|DRUG|Fentanyl|
48666316|NCT04635852|DRUG|Immediate release morphine|
48505662|NCT04283968|BIOLOGICAL|placebo fecal transplantation|placebo fecal transplantation
48355548|NCT04366089|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
48355549|NCT04366089|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
48355550|NCT01885104|DRUG|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
48666317|NCT06133023|PROCEDURE|Plastic stent|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed."
48355551|NCT01885104|DRUG|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
48355552|NCT01885104|DRUG|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
48355553|NCT02227901|DRUG|Tipifarnib|Given PO
48505663|NCT00054574|BIOLOGICAL|panitumumab|
48666318|NCT06133023|PROCEDURE|LAMS|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed."
48666319|NCT01038323|OTHER|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
48666320|NCT01038323|BEHAVIORAL|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
48666321|NCT01038323|DRUG|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
48666322|NCT01528592|DRUG|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
48505664|NCT00760851|OTHER|probiotic strain Bb-12|10\^9 CFU Bb-12 per 4 oz yogurt
48505665|NCT00760851|OTHER|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
48505666|NCT00252200|DRUG|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
48355554|NCT02227901|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48355555|NCT02227901|DRUG|Temozolomide|Given PO
48355556|NCT02227901|OTHER|Laboratory Biomarker Analysis|Correlative studies
48355557|NCT02368730|DRUG|desmopressin|
48355558|NCT03833336|OTHER|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
48355559|NCT03833336|DRUG|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
48355560|NCT03833336|DRUG|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
48355561|NCT03833336|DRUG|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
48355562|NCT04058795|BEHAVIORAL|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
48355563|NCT04058795|BEHAVIORAL|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
48666323|NCT06560944|DRUG|Combined oral contraceptive pill|Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
48355564|NCT04058795|BEHAVIORAL|mCBT|8 mobile sessions with a therapist to receive cognitive behavioral therapy.
48144399|NCT00487045|DEVICE|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
48144400|NCT01735214|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
48144401|NCT05396365|DIAGNOSTIC_TEST|Dynamometry|Hand grip dynamometer measure of strength and anthropometric measurements
48144402|NCT05671549|PROCEDURE|Arthrocentesis of the temporomandibular joint|Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
48355565|NCT01871233|DRUG|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
48355566|NCT06471088|DRUG|Dovprela|Daily dose: 200 mg
48355567|NCT05071222|GENETIC|ARTEGENE drug product|Each patient will receive a single intravenous infusion of ARTEGENE drug product at D0.
48666324|NCT03939390|DRUG|time of administration of Corifollitropin Alfa|The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
48666325|NCT00760552|OTHER|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
47987878|NCT01973907|OTHER|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
48355568|NCT05307965|DEVICE|Retriever Thrombectomy|The SolitaireTM X revascularisation device is a self-expanding stent designed for dynamic clot integration with radiopaque markers that enhance visualisation of the optimal working length. After a thrombotic occlusion has been identified and crossed with a guidewire, the stent-retriever thrombectomy proceeds. A microcatheter (e.g., PhenomTM, MarksmanTM) is advanced over the guidewire and once it has traversed the thrombotic occlusion, the SolitaireTM X device is advanced through the microcatheter until the usable length of the stent extends past each side of the thrombus in the vessel. As the microcatheter is retracted to the proximal radiopaque marker of the stent, the stent self-expands and entangles the thrombus. The microcatheter and SolitaireTM X Revascularisation Device are withdrawn as a unit into the guide catheter under continuous aspiration. PCI then proceeds driven by clinical decision making and department guidelines.
48666326|NCT00760552|OTHER|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, \& possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
48666327|NCT00760552|OTHER|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
48666328|NCT02183584|DRUG|Rifampicin|
48355569|NCT05307965|PROCEDURE|Percutaneous Coronary Intervention|Standard of care
48355570|NCT05307965|PROCEDURE|Thrombus Aspiration|Standard of care treatment with manual thrombectomy catheter
48355571|NCT00703781|DRUG|bromfenac ophthalmic solution|sterile ophthalmic solution
48355572|NCT00703781|DRUG|placebo|sterile ophthalmic solution
48355573|NCT02492542|DEVICE|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50\*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
48505667|NCT06354452|OTHER|Person-level linkage of the database looking for relationship with sepsis survival and previous intake of certain drug families and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted to hospitals in the region will be carried out.~Both the overall data of patients admitted to hospitals in any ward and those admitted to ICU will be analysed. The survival data of patients will be compared with their previous individual drug consumption, trying to find out the relationship between chronic consumption of certain families of drugs and inhospital survival to sepsis. In addition, drug dependence and dependence on health services of sepsis survivors will be studied in comparison with their situation prior to sepsis."
47987879|NCT04810676|DRUG|CKD-501, D745, D150|QD, PO
48355574|NCT04034069|DEVICE|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
48505668|NCT02115932|OTHER|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
48505669|NCT05670535|OTHER|Visual analogue scale (VAS) for dyspareunia|Dyspareunia scores between 0 to 10 points
48505670|NCT05670535|OTHER|Visual analogue scale (VAS) for vaginal dryness|Vaginal dryness scores between 0 to 10 points
48144403|NCT03293043|DEVICE|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
48666329|NCT02183584|DRUG|Linagliptin|
48666330|NCT01365455|DRUG|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
48666331|NCT01365455|DRUG|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
48666332|NCT00767026|BEHAVIORAL|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
48666333|NCT00767026|BEHAVIORAL|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
48666334|NCT02750969|DEVICE|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
48666335|NCT02750969|OTHER|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
48666336|NCT02750969|PROCEDURE|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
48666337|NCT02750969|OTHER|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
47987880|NCT04810676|DRUG|CKD-383|QD, PO
47987881|NCT03164200|OTHER|High fat breakfast|High fat breakfast
48505671|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)|Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points
48505672|NCT05670535|OTHER|The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)|Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
47987882|NCT03164200|OTHER|Higher carbohydrate breakfast|Higher carbohydrate breakfast
47987883|NCT01199289|DRUG|AMG 827|SC injection.
47987884|NCT01199289|DRUG|Placebo|SC injection.
47987885|NCT02570906|DEVICE|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
47987886|NCT02053467|OTHER|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
47987887|NCT05195112|DRUG|MT921|Active ingredient
47987888|NCT05195112|DRUG|Placebo|Normal Saline
48144404|NCT03713580|DRUG|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
48144405|NCT03205488|DRUG|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
48144406|NCT03205488|DRUG|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
48144407|NCT03205488|DRUG|Placebo|2 capsules taken once daily
48505673|NCT00674349|PROCEDURE|surgery|staging surgery
48505674|NCT06618001|DRUG|JNJ-89853413|JNJ-89853413 will be administered.
48505675|NCT06080854|DRUG|Toripalimab|Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
48505676|NCT06080854|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks
48666338|NCT02104934|PROCEDURE|Adductor Canal Block|
47987889|NCT03256539|BEHAVIORAL|Sleep intervention|Behavioral sleep intervention program
47987890|NCT03256539|BEHAVIORAL|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
48002667|NCT02457325|DRUG|Surgery with 2%Articaine first, then Surgery with 4% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
48666339|NCT06489002|OTHER|Implementation Support|Health centers receiving the intervention will have access to implementation support strategies designed to support adoption of social needs screenings and referrals to community organizations for patients with unmet social needs receiving care management. Implementation support will be provided by an OCHIN trainer, practice facilitators, workflow engineer, and analysts.
48666340|NCT02348203|DRUG|Aspirin|Given PO
48666341|NCT02348203|OTHER|Laboratory Biomarker Analysis|Correlative studies
48666342|NCT02348203|OTHER|Placebo Administration|Given aspirin placebo PO
48144408|NCT05884515|DIAGNOSTIC_TEST|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
48355575|NCT04034069|BEHAVIORAL|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
48355576|NCT04559867|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP.
48505677|NCT06080854|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
48505678|NCT06080854|OTHER|SBRT|SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions
48505679|NCT02969174|OTHER|zimin Lu,Guo Sa|chengzhong Liu
48505680|NCT01683292|DRUG|Inhaled VR040|
48505681|NCT01683292|DRUG|Placebo for VR040|Placebo arm
48505682|NCT03535389|DIAGNOSTIC_TEST|Knee 4DCT|Dynamic knee 4DCT
48505683|NCT05734430|GENETIC|Genetic profiling|Whole exome sequencing
48505684|NCT05734430|OTHER|Retrospective tissue procurement|Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
48666343|NCT02348203|OTHER|Placebo Administration|Given zileuton placebo PO
48666344|NCT02348203|DRUG|Zileuton|Given PO
48666345|NCT04961905|DRUG|NVP-2002-R1+NVP-2002-R2|NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
48666346|NCT04961905|DRUG|NVP-2002|NVP-2002 is a combination of NVP-2002-R1 and NVP-2002_R2 NVP-2002, 1 tablet, once daily
48666347|NCT02188966|DEVICE|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
48666348|NCT01518413|DRUG|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
48666349|NCT01518413|DRUG|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
48666350|NCT04781582|PROCEDURE|Lung volume reduction surgery|Surgical lung volume reduction
48666351|NCT04781582|PROCEDURE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction by endobronchial valves
47987891|NCT01005420|DIETARY_SUPPLEMENT|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
47987892|NCT01005420|DIETARY_SUPPLEMENT|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
47987893|NCT05814887|DEVICE|ReLink|Medical device
47987894|NCT04659889|DIAGNOSTIC_TEST|Blood sampling (venesection)|"All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping."
47987895|NCT01794806|PROCEDURE|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
47987896|NCT01794806|PROCEDURE|Tooth extraction|Minimally traumatic single-rooted tooth extraction
47987897|NCT00427258|DRUG|MOA-728|
47987898|NCT02040454|DRUG|Paclitaxel|
47987899|NCT02040454|PROCEDURE|Standard Therapy|
48144409|NCT03608111|OTHER|single task balance training|single task balance training
48144410|NCT03608111|OTHER|dual task balance training|dual task balance training
48144411|NCT02133625|DRUG|carboplatin|
48144412|NCT02133625|DRUG|pioglitazone|
48144413|NCT03560206|BEHAVIORAL|Family SWaP intervention|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
48666352|NCT02151240|DRUG|Foscarnet Sodium|
48666353|NCT02151240|DRUG|Acyclovir|
48355577|NCT04559867|PROCEDURE|Sphincterotomy|A sphincterotomy uses a heated metal wire to cut the opening to the bile duct after a wire has been passed into it.
48355578|NCT03595176|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
48355579|NCT00000244|DRUG|Dynorphin 1 - 13|
48355580|NCT00004147|DRUG|incyclinide|
48355581|NCT02411006|BEHAVIORAL|Prediction mailing|Ask people to predict their upcoming medication adherence
48355582|NCT02411006|BEHAVIORAL|Commitment mailing|Ask people to commit to their upcoming medication adherence
48355583|NCT02411006|BEHAVIORAL|Reminder|Remind people to take their medicine
48355584|NCT02411006|BEHAVIORAL|Anonymity|Keep patient predictions and commitment anonymous
48355585|NCT02411006|BEHAVIORAL|Identification|Ask patients to report their predictions and commitments
48355586|NCT01362049|OTHER|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
48355587|NCT01362049|OTHER|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
48355588|NCT06250452|COMBINATION_PRODUCT|Halotherapy (Salt Therapy)|"Personal Information Form, SPO2 measurement and Asthma Symptom and Treatment Need Scoring / Daily Follow-up Form will be applied to the children in the experimental group before they are taken to the salt therapy room. Scales and SPO2 measurement will be performed before, during and after therapy. The same procedure will be applied to the children in the control group, but no therapy will be applied. In the study planned to be carried out for 6 weeks, it is recommended that children repeat the session for 10 minutes daily, the first 5 sessions every day and the other 5 weeks once a week."
48355589|NCT01437059|DRUG|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
48355590|NCT01437059|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
48666354|NCT05669365|BEHAVIORAL|Care Ecosystem|"Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols."
48355591|NCT02202161|DRUG|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
48355592|NCT02202161|DRUG|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
48666355|NCT03070626|DIETARY_SUPPLEMENT|PreOp®|No preoperative drink.
48666356|NCT00443742|PROCEDURE|Validation|
48144414|NCT03560206|BEHAVIORAL|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
48355593|NCT02202161|DRUG|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
48355594|NCT02202161|DRUG|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
48505685|NCT01400802|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
48505686|NCT04011163|DEVICE|VPIA pump|The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
48505687|NCT04011163|DRUG|Morphine|Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
48505688|NCT04762849|PROCEDURE|Laparoscopic one anastomosis gastric bypass|Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
48666357|NCT05149729|PROCEDURE|Shortened hip arthroplasty|Crowe type 3 and 4 patients who underwent shortened hip prosthesis
48666358|NCT02918448|OTHER|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
48666359|NCT03870048|DEVICE|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
48666360|NCT03362671|DEVICE|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
48666361|NCT03362671|DEVICE|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
48666362|NCT02210676|OTHER|PROMIS Upper Extremity|
48666363|NCT02210676|OTHER|Likert Pain Scale|
48666364|NCT02210676|OTHER|Mallet Finger Extensor Lag Measurement|
47987900|NCT02484729|DRUG|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
47987901|NCT02484729|DRUG|Placebo, oral suspension|Matching placebo
47987902|NCT02484729|DRUG|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
47987903|NCT06136702|BEHAVIORAL|Educational session|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
47987904|NCT06136702|BEHAVIORAL|Self-sampling|Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.
48505689|NCT04762849|DEVICE|A shape-memory ring for adjustable gastric banding|A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
48505690|NCT01942889|DIETARY_SUPPLEMENT|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
48666365|NCT05213806|OTHER|Withholding feeds around transfusion|Withholding enteral feeds for preterm infants (\<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.
47987905|NCT06136702|BEHAVIORAL|Follow-up assessment|To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.
47987906|NCT05453344|DEVICE|DexCom one|Provision of DexCom One for glucose monitoring
47987907|NCT03527095|DRUG|FDL169|CFTR corrector
47987908|NCT00362908|BEHAVIORAL|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
47987909|NCT00362908|BEHAVIORAL|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
48144415|NCT06092307|DIAGNOSTIC_TEST|Bioelectrical impedance|Resistance, reactance, phase angle,free-fat mass, body cell mass, body cell mass index and total body will be recorded
48144416|NCT06092307|DIAGNOSTIC_TEST|Handgrip strength test|Handgrip strength test using a hydraulic hand dynamometer and sit-to-stand test will be performed.
48505691|NCT06633692|OTHER|Head down tilt (HDT)|In the head-down tilt intervention, a participant is positioned on a tilt table, initially in supine position and afterwards with their head inclined downward at a specific angle. This position causes a shift of body fluids towards the head, mimicking the fluid redistribution observed in microgravity conditions in space.
48666366|NCT05213806|OTHER|Continued feeds around transfusion|Continued enteral feeds
48666367|NCT02478151|DEVICE|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
48666368|NCT02141009|BIOLOGICAL|Prevnar 13|
48666369|NCT00133705|DRUG|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
48666370|NCT00133705|DRUG|Inert Capsule|sugar pill
48666371|NCT03891888|PROCEDURE|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
48666372|NCT06461780|OTHER|Line-based questionnaire follow-up|The participant will use LINE group to report irAE severity, distress, financial toxicity and change trajectory of quality of life in one-year follow-up. If the severity grade of irAE reach the threshold and require referral, an alarm will appear to notify the research team to conduct and transfer to a clinical specialitst, or refer to the emergency room for treatment. Additionally, the Line group will also provide clinical relevant immunotherapy health education information currently and routinely used in study site. Patients can view it according to their interests, but the APP will not actively promote it.
48666373|NCT06204783|OTHER|Pressure volume (PV) loop measurement|Pressure volume (PV) loop measurement using a conductance catheter
48666374|NCT02838667|PROCEDURE|Standard of Care plus Nephrology Care|
47987910|NCT01526616|DRUG|Metformin|Metformin 850 mg twice a day for six months
47987911|NCT01526616|DRUG|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
47987912|NCT06472908|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg, one pill a day, oral intake
48355595|NCT05684367|BEHAVIORAL|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
48355596|NCT05684367|BEHAVIORAL|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
48355597|NCT02438670|DEVICE|PID control algorithm|
48355598|NCT02438670|DEVICE|MPC control algorithm|
48355599|NCT00692393|PROCEDURE|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
48355600|NCT00692393|PROCEDURE|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
48355601|NCT02504957|PROCEDURE|Photodynamic therapy using polyhematoporphyrin|
48355602|NCT03638362|DIETARY_SUPPLEMENT|Placebo|Participants consumed placebo beverage for 4 weeks.
48355603|NCT03638362|DIETARY_SUPPLEMENT|Tart cherry juice|Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
48355604|NCT05759949|DRUG|RLY-5836|RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
48355605|NCT05759949|DRUG|Fulvestrant|Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
48355606|NCT05759949|DRUG|Palbociclib|Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
48355607|NCT05759949|DRUG|Ribociclib|Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
48355608|NCT05759949|DRUG|Abemaciclib|Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
48355609|NCT02660060|DRUG|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
48355610|NCT02660060|DRUG|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
48355611|NCT02330471|PROCEDURE|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
48355612|NCT02330471|PROCEDURE|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
48355613|NCT02186886|DRUG|Golimumab|Physiological Intermolecular Modification Spectroscopy
48355614|NCT02620631|DRUG|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
48355615|NCT02620631|DRUG|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
48355616|NCT04995666|DEVICE|Phonak Audeo hearing aid|Rechargeable hearing aid
48355617|NCT04844567|DEVICE|COVVR_Synch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration."
47987913|NCT06472908|DRUG|Colchicine 0.375 mg|Colchicine 0.375 mg, one pill a day, oral intake
47987914|NCT06472908|DRUG|Placebo|Placebo, one pill a day, oral intake
47987915|NCT00786487|DRUG|20% lipid infusion|1.5 ml/min for 6 hours
47987916|NCT00786487|DRUG|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
47987917|NCT02089633|BIOLOGICAL|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
47987918|NCT01650233|BEHAVIORAL|Mindfulness-based stress reduction|
48355618|NCT04844567|DEVICE|COVVR_Asynch|"Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.~COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration."
48355619|NCT04361721|DRUG|Erenumab|First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
48355620|NCT02332694|DEVICE|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
48355621|NCT01914510|DRUG|ENMD-2076|
48355622|NCT06186089|DIETARY_SUPPLEMENT|probiotics|patients undergoing total gastrectomy take probiotics qd for 3 months
48355623|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccine 202210001|Immunization program and dosage:3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
48355624|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210002|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
48666375|NCT04844333|OTHER|Extubation under deep anesthesia|When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
48666376|NCT04242680|DEVICE|Brainstim DLPFC|"The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min."
48666377|NCT04242680|DEVICE|Brainstim PPC|"The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min."
48666378|NCT04242680|DEVICE|Brainstim Sham|The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.
48666379|NCT04242680|BEHAVIORAL|Cognitive Training|"A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation)."
48666380|NCT01263119|DRUG|Warfarin|10-mg warfarin oral dose
48666381|NCT01263119|DRUG|LY2216684|18-mg LY2216684 oral dose
48666382|NCT06095895|OTHER|venipuncture|An additional measurement of exposure of mycophenolic acid and/or tacrolimus will be performed
48666383|NCT00730054|DRUG|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
48666384|NCT05003414|DEVICE|GMK Sphere cementless Knee Replacement|Performance of Total Knee Arthroplasty (TKA) with GMK Sphere cementless Knee Replacement
48666385|NCT02191163|DRUG|Antistax®|
48666386|NCT02191163|DRUG|Placebo|
48666387|NCT03378960|DRUG|Omeprazole 20mg|
48666388|NCT05406583|DRUG|Dolutegravir 0.5 mg/kg oral suspension|DTG 0.5 mg/kg liquid suspension administered orally
48666389|NCT05406583|DRUG|Dolutegravir 5 mg Dispersible Tablets|DTG 5 mg DT administered orally
48666390|NCT04803279|DEVICE|Collection of Pure tone thresholds from audiogram measured prior to fitting of Ponto 3 SuperPower|Unmasked and if available masked BC thresholds from audiogram obtained prior to Ponto 3 SuperPower were fitted.
48505692|NCT05669963|DRUG|lactoferrin|"study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
48666391|NCT04803279|DEVICE|Collection of BC In-situ thresholds from BC In-situ audiogram measured during fitting of Ponto 3 SuperPower|BC In-situ thresholds will be collected from the BC In-situ audiogram obtained when Ponto 3 SuperPower were fitted
48666392|NCT04803279|DEVICE|Collection of Aided sound field thresholds measured with the Ponto 3 SuperPower|Sound field thresholds for frequencies 500Hz, 1kHz, 2 kHz, 3kHz and 4kHz will be collected from sound field audiogram obtained as follow-up after Ponto 3 SuperPower fitting, typically this is collected 3 months post fitting, alternatively from the fitting visit. Thresholds will be obtained aided, and when available unaided
48666393|NCT04803279|DEVICE|Collection of speech intelligibility scores|"Speech intelligibility is measured in a sound treated room using sentence tests. The sentence tests used at Norwich and Norfolk hospital is the BKB (Bamford-Kowal-Bench) and/or the The AB\[s\] Isophonemic Monosyllabic Word test (7).~The sentence tests are measured in quiet and/or with background speech-weighted noise."
48666394|NCT04803279|DEVICE|Skin reaction|Classification of skin reactions around skin penetrating implants will be made using the Holgers score. The Holgers classification is a scale from 0 to 4 that is used to grade skin reactions
47987919|NCT02428946|DRUG|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
47987920|NCT03611790|DEVICE|NeVa VS|mechanical dilatation
48666395|NCT04803279|DEVICE|Collection of Glasgow Benefit Inventory|The Glasgow Benefit Inventory (GBI) contains 18 health status questions, which ask specific questions about how the health problem, in this study hearing loss, has affected their quality of life at the time the GBI is completed. In this study GBI has been collected on patients before intervention and 3 months after fitting of Ponto 3 SuperPower on abutment.
47987921|NCT05212012|DRUG|Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)|Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)
48355625|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210003|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
48666396|NCT04803279|DEVICE|Collection of power-on usage time with Ponto 3 SuperPower|Average power-on usage hours from Ponto 3 SuperPower will be collected.
47987922|NCT02305108|OTHER|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week)."
48666397|NCT04243148|COMBINATION_PRODUCT|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
48355626|NCT05939219|BIOLOGICAL|15-valent pneumococcal conjugate vaccineY202210004|Immunization program and dosage: 3 month old group: basic immunization at 0, 1, and 2 months, and strengthened immunization at 12 to 15 months old, with a total of 4 doses administered. 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
48355627|NCT05939219|BIOLOGICAL|13 valent pneumococcal polysaccharide conjugate vaccine|Immunization program and dosage: 7-11 month old group: baseline immunization at 0 and 2 months; Strengthen one dose after 12 months of age; A total of 3 doses were administered. 12-23 month old group: Immunized with 2 doses of 0 and 2 month program, a total of 2 doses were administered. 2-5 year old group: 1 dose administered
48355628|NCT05910983|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Bipolar enucleation of the prostate (BipolEP)
48355629|NCT05910983|DRUG|Intravesical Botox injection|Intravesical botox injection given only in experimental group.100 units of Botox will be used and diluted in 10 mL of normal saline. 0.5 cc injections will be administered in 20 injection sites (trigone sparing).
47987923|NCT02305108|OTHER|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
48666398|NCT04243148|COMBINATION_PRODUCT|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435\*, Bifidobacterium infantis DSM 24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440\*\*~\* Re-classified as B. lactis \*\* Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
47987924|NCT03036787|BEHAVIORAL|family based intervention|behavioural advises to family for normal motor development
47987925|NCT00487747|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
47987926|NCT06468631|BEHAVIORAL|Complex Nursing Intervention|"Training prepared as an expert opinion on patient handover, starting to use the standard patient handover form for each patient, ensuring standardization in handover and supporting this improvement work by managers were expressed as interventions.~Training offered; It includes the importance of patient handover, how to ensure standardization and why we should use the standard patient handover form."
47987927|NCT06155331|DRUG|Fenofibrate|It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).
47987928|NCT06155331|OTHER|Placebo|Placebo is made to look exactly like a real drug but is made of an inactive substance.
48355630|NCT02334137|BEHAVIORAL|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
48355631|NCT02334137|BEHAVIORAL|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
47987929|NCT06155331|DRUG|Doxorubicin|Anthracycline derived chemotherapy used in treatment of breast cancer
47987930|NCT06155331|DRUG|Cyclophosphamide|Alkylating agent used in treatment of breast cancer
48355632|NCT02334137|BEHAVIORAL|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
48355633|NCT05506306|OTHER|Assessment|Clinical, biological and imagery before and after 6 weeks of using AtalanteTM exoskeleton
48355634|NCT00377468|DRUG|Delta9-Tetrahydrocannabinol|
48355635|NCT05474924|DRUG|Budesonide intrapolyp injection|intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids
48355636|NCT05474924|DRUG|Budesonide nasal wash|Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.
48355637|NCT05474924|DRUG|Prednisolone tablets|oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
48355638|NCT02094664|DEVICE|Heated and humidified oxygen|
48666399|NCT04243148|COMBINATION_PRODUCT|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
47987931|NCT05395520|OTHER|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
47987932|NCT02550548|DRUG|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
47987933|NCT02550548|DRUG|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
47987934|NCT02550548|DRUG|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
47987935|NCT05538754|DEVICE|EVO ICL|The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
47987936|NCT05089227|DRUG|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
47987937|NCT05089227|DRUG|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
47987938|NCT05089227|BIOLOGICAL|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
48355639|NCT04154761|PROCEDURE|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
47987939|NCT05651633|DRUG|lidocaine hydrochloride 5mg/g|1-2 drops up to six times daily for a maximum of 7 days
48144417|NCT06092307|DIAGNOSTIC_TEST|muscle ultrasound.|The following ultrasound parameters will be evaluated: radial, ulnar, rectus femoris, rectus abdominis and medial gastrocnemius muscle thickness and echo intensity with gray-scale-index; rectus femoris muscle cross sectional area; gastrocnemius muscle fiber length and pennation angle.
48355640|NCT05027776|BIOLOGICAL|2-doses Group among 9-14 years|Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
48355641|NCT05027776|BIOLOGICAL|3-doses Group among 9-19 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
48666400|NCT04243148|COMBINATION_PRODUCT|No specific intervention.|Follow up as a clinical practice
48666401|NCT05056857|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
48666402|NCT05056857|OTHER|Electronic Health Record Review|Medical charts are reviewed
48666403|NCT01416350|DRUG|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
48666404|NCT01416350|DRUG|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
47987940|NCT03264495|OTHER|Weight the food served minus the left-overs|
48355642|NCT05027776|BIOLOGICAL|3-doses Group among 20-26 years|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
48666405|NCT01416350|DRUG|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
48666406|NCT03606577|DRUG|Carfilzomib|Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
48666407|NCT03606577|DRUG|Daratumumab|induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
48666408|NCT03606577|DRUG|Lenalidomide|induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
48666409|NCT03606577|DRUG|Dexamethasone|induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
48666410|NCT02704208|BEHAVIORAL|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
48666411|NCT02704208|BEHAVIORAL|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
48666412|NCT03218969|DRUG|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
48666413|NCT03218969|DRUG|Placebo|matching placebo
48666414|NCT00557193|DRUG|Asparaginase|Given IV, IM, or PO
48666415|NCT00557193|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48666416|NCT00557193|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48666417|NCT00557193|DRUG|Cyclophosphamide|Given IV
48666418|NCT00557193|DRUG|Cytarabine|Given IV or IT
48666419|NCT00557193|DRUG|Daunorubicin Hydrochloride|Given IV
47987941|NCT01019642|DRUG|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
47987942|NCT01019642|DRUG|placebo|no active principles given.
48355643|NCT02233140|DEVICE|Extra-corporeal pulsed-activated therapy or shockwave therapy|
48355644|NCT05754372|DIAGNOSTIC_TEST|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia|user-friendly and widely applicable algorithm to tailor the treatment of acute neonatal hyperammonemia, based on kinetic modelling
48355645|NCT00003992|BIOLOGICAL|trastuzumab|
48666420|NCT00557193|DRUG|Dexamethasone|Given IV or PO
48666421|NCT00557193|PROCEDURE|Echocardiography|Undergo ECHO
48666422|NCT00557193|DRUG|Etoposide|Given IV
48666423|NCT00557193|BIOLOGICAL|Filgrastim|Given IV or SC
48666424|NCT00557193|OTHER|Laboratory Biomarker Analysis|Correlative studies
48666425|NCT00557193|DRUG|Lestaurtinib|Given PO
48666426|NCT00557193|DRUG|Leucovorin Calcium|Given IV
48666427|NCT00557193|DRUG|Mercaptopurine|Given PO
48666428|NCT00557193|DRUG|Methotrexate|Given IV, IT, or PO
48666429|NCT00557193|DRUG|Methylprednisolone|Given IV
48666430|NCT00557193|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48666431|NCT00557193|DRUG|Pegaspargase|Given IM
48666432|NCT00557193|OTHER|Pharmacological Study|Correlative studies
48666433|NCT00557193|DRUG|Prednisone|Given PO
48666434|NCT00557193|DRUG|Therapeutic Hydrocortisone|Given IT
47987943|NCT06296108|OTHER|acute kidney injury|The incidence of acute kidney injury was determined in patients included to the study
47987944|NCT03814291|DRUG|IBI302|0.05mg/eye;Intraocular injection
47987945|NCT03814291|DRUG|IBI302|0.15mg/eye;Intraocular injection
47987946|NCT03814291|DRUG|IBI302|0.5mg/eye;Intraocular injection
47987947|NCT03814291|DRUG|IBI302|1mg/eye;Intraocular injection
47987948|NCT03814291|DRUG|IBI302|2mg/eye;Intraocular injection
47987949|NCT03814291|DRUG|IBI302|4mg/eye;Intraocular injection
48666435|NCT00557193|DRUG|Vincristine Sulfate|Given IV
48666436|NCT03364504|OTHER|urine collection|3 urine collections during 24 hours
48666437|NCT06490692|OTHER|Blood Flow Restriction Training|The affected limb will have a cuff placed proximally and inflated to occlude the blood flow by 40% attested using a golden standard vascular doppler after which the individuals will perform the strengthening program set forth by the physical therapist. This is preceded by other tennis elbow interventions such as ultrasound, stretching, and deep friction massage at the extensor origin.
48666438|NCT06490692|OTHER|Conventional Strength Training|The individuals in this group will undergo the same conventional physical therapy program as the other group including ultrasound, stretching, and deep friction massage. In addition, they will undergo the same strengthening program set forth by the physical therapist however with no blood flow restriction of any kind.
48666439|NCT01133847|DRUG|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
48666440|NCT01133847|BEHAVIORAL|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
48666441|NCT01133847|BEHAVIORAL|Parent Training|Nine sessions on parenting a child with ADHD
48666442|NCT01133847|DRUG|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
48666443|NCT01133847|DRUG|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
48666444|NCT01133847|DRUG|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
48666445|NCT00462826|BIOLOGICAL|ziv-aflibercept|
48355646|NCT00003992|DRUG|cyclophosphamide|
48355647|NCT00003992|DRUG|doxorubicin hydrochloride|
48355648|NCT00003992|DRUG|paclitaxel|
48355649|NCT00003992|DRUG|tamoxifen citrate|
48666446|NCT05700409|BEHAVIORAL|Intensive lifestyle consultations|detailed above
47987950|NCT02547467|OTHER|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
48355650|NCT00685308|PROCEDURE|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
48355651|NCT00865358|BEHAVIORAL|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
48666447|NCT00626041|OTHER|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
48666448|NCT06267417|DEVICE|Laser therapy|- Laser will be applied with the specified wave length using Diode laser (Sirrolaser Blue ™, USA) device over 5 consecutive days from start of chemotherapy cycle beside the standard preventive protocol applied in the hospital
47987951|NCT03631901|DRUG|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
47987952|NCT03631901|DRUG|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
48355652|NCT00118924|BIOLOGICAL|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
47987953|NCT06412939|DEVICE|Agile Nail|Intramedullary implantation of the Agile intramedullary rigid nail in femur to provide bone fixation
47987954|NCT01463319|OTHER|air insufflation|air insufflation during insertion phase colonoscopy
48355653|NCT00118924|BIOLOGICAL|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
48355654|NCT05540015|PROCEDURE|Third molar extraction by cutting and rotary tools|Extraction of the impacted lower third molar will be conducted using cutting and rotary tools under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). Scalpel will be used for the incision of the soft tissues, rotary instruments will be used for the bone tissue and tooth fragmentation. After the extraction the wound will be sutured by the suture material.
48666449|NCT06267417|DEVICE|Mock treatment|The exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital
48144418|NCT03000725|BEHAVIORAL|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
48144419|NCT03000725|BEHAVIORAL|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
48666450|NCT01198665|DRUG|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
48666451|NCT06547736|DRUG|SHR-A2102 or/and HRS-4642|"Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
48666452|NCT06547736|DRUG|SHR-A1904 or/and HRS-4642|"Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
48666453|NCT06547736|DRUG|SHR-A1811 or/and HRS-4642|"Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
48666454|NCT04733027|COMBINATION_PRODUCT|Dose escalation, first-in-human phase I clinical trial with an Expansion phase|PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion. Treatment will be administered until disease progression, unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Each cycle will be of 21 days duration.
48666455|NCT06247137|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with components of natural origin: artichoke, bergamot, folic acid, astaxanthin, Chromium picolinate and excipients.~Oral administration: 1 tablet/day at evening meal"
48666456|NCT06247137|OTHER|Placebo|"Placebo (microcrystalline cellulose, calcium carbonate, magnesium stearate, silica dioxide and iron oxides).~Oral administration: 1 tablet/day at evening meal."
48666457|NCT01659502|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
48666458|NCT03186547|DRUG|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
48666459|NCT03186547|PROCEDURE|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
47987955|NCT01463319|OTHER|warm water irrigation|warm water irrigation during insertion phase colonoscopy
47987956|NCT03988192|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
48666460|NCT04627129|DRUG|SHR2554 and Itraconazole|Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
48666461|NCT00247546|BEHAVIORAL|Multifactorial prevention|
48666462|NCT04476784|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
48666463|NCT04476784|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
48666464|NCT04476784|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
48666465|NCT05104827|OTHER|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
48666466|NCT02826187|OTHER|Early complications data|"Early complications of interest are :~* New arthroplasty for any reason~* Related to the implant :~  * Wrong position of the implant~ * Early displacement of the implant~* Related to the intervention :~  * Hematoma~ * Dislocation (or not causing the resumption of joint replacement)~ * Deep vein thrombosis~ * Pulmonary embolism~ * Acute Infection"
48144420|NCT01571947|OTHER|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
47987957|NCT04517565|DIAGNOSTIC_TEST|Brain magnetic resonance imaging|Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
47987958|NCT04517565|BEHAVIORAL|Neuro-psychology testing|Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
47987959|NCT00240253|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC injection
47987960|NCT01758783|DRUG|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
48144421|NCT00249405|DRUG|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
48144422|NCT00249405|BEHAVIORAL|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
48144423|NCT01910194|DRUG|Luyxumia versus Lantus|
48144424|NCT00799409|DRUG|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
47987961|NCT04183920|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
47987962|NCT04183920|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
47987963|NCT03376854|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
48144425|NCT00799409|DRUG|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
48144426|NCT06035354|DRUG|AK120|subcutaneous injection once a week
48144427|NCT06035354|DRUG|AK120|subcutaneous injection once a week
48144428|NCT06035354|DRUG|Placebo|subcutaneous injection once a week.
48355655|NCT05540015|PROCEDURE|Third molar extraction by erbium laser with wavelength 2.94 nm|Extraction of the impacted lower third molar will be conducted using erbium laser with wavelength 2.94 nm under the local anesthesia (Ultracain D-S 1:100000 40 mg/ml, active substance- articaine+epinephrine, registration № П N015119/01 ). The soft tissue and bone tissue will be dissected by erbium laser with wavelength 2.94 µm (Erbium laser Smart 2940D plus with the wavelength 2,94 µm, company- DEKA, Italy, registration № 2005/1245). After the extraction the wound will be sutured by the suture material (registration № ФСЗ 2010/06040; 07.08.2018)
48666467|NCT02826187|OTHER|Late stage complications data|"Late complications taken into account are:~* New arthroplasty for any reason~* Aseptic loosening~* Delayed hypersensitivity reaction type IV~* Solid Tumors~* Recurrent dislocation (causing or not the resumption of joint replacement)~* Allergic reactions of any kind~* Chronic infection"
48666468|NCT02826187|OTHER|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
48666469|NCT02826187|OTHER|Efficacity|Efficacity as evaluated by Harris HIP score
47987964|NCT03376854|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
47987965|NCT03376854|DEVICE|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
47987966|NCT04919577|DIAGNOSTIC_TEST|X-ray|We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
47987967|NCT02109120|PROCEDURE|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
47987968|NCT00597766|DRUG|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
47987969|NCT00597766|DRUG|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
47987970|NCT00597766|DRUG|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
47987971|NCT00597766|DRUG|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
47987972|NCT00320099|DRUG|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
47987973|NCT00320099|DRUG|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
47987974|NCT00320099|DRUG|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
47987975|NCT00320099|DRUG|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
47987976|NCT03505944|DRUG|Venetoclax|venetoclax + lenalidomide + rituximab
47987977|NCT03103919|DEVICE|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
48144429|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
48144430|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
48144431|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
48144432|NCT06035354|DRUG|Placebo|subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
48666470|NCT02826187|OTHER|Radiographic evaluation|Bone reaction visible in radiography
47987978|NCT03103919|DEVICE|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
48144433|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks
48144434|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
48144435|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
48144436|NCT03783936|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
48144437|NCT03783936|DRUG|Leucovorin|Leucovorin 400 mg/m2
48144438|NCT03783936|DRUG|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
48144439|NCT03783936|DRUG|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
48144440|NCT03783936|DRUG|Avelumab|Avelumab 800 mg
48355656|NCT01562379|DIETARY_SUPPLEMENT|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
48666471|NCT01527565|DRUG|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
48666472|NCT01451021|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
48666473|NCT05775445|PROCEDURE|Blood draw|2 6ml blood tubes will be collected from patient
48666474|NCT02164110|BIOLOGICAL|Euvichol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
48144441|NCT06169345|OTHER|Echocardiographic evaluation|Echocardiographic follow-up
48144442|NCT00141232|DRUG|Atorvastatin and Omega-3 fatty acids|
48144443|NCT04680988|DRUG|SHR-1210|SHR-1210 intravenously every 3 weeks
48144444|NCT04680988|DRUG|SHR-1020|SHR-1020 Orally once daily
48144445|NCT04680988|DRUG|Physician's choice chemotherapy|Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection
48144446|NCT06357455|DEVICE|Cell Salvage Autotransfusion: SAME™ device|"* Intervention studied: processing of salvaged blood using the SAME™ autotransfusion device~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Treatment group.~All perioperative measures will be performed according to international, national and in-house standards."
48144447|NCT06357455|DEVICE|Cell Salvage Autotransfusion: Autolog™ device|"* Intervention studied: processing of salvaged blood using the Autolog™ (Medtronic) autotransfusion device (in-house standard device).~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Control group~All perioperative measures will be performed according to international, national and in-house standards."
48144448|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet."
48144449|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet."
48144450|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form."
48144451|NCT05550441|DRUG|Dapagliflozin|The experimental group received dapagliflozin (10 mg qd) for 1 year.
48144452|NCT05550441|DRUG|Placebo|The Placebo group received placebo for 1 year.
48144453|NCT00010868|DRUG|Omega-3 Fatty Acids|
48144454|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
48144455|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
48144456|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
48144457|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
48144458|NCT05556304|OTHER|assessment in the 8th month of pregnancy and during delivery|"* Day 0: presentation of the study~* During pregnancy between Day 0 and 36-38SA: inclusion~* During pregnancy: collection of pelvic MRI data if performed during pregnancy for maternal or fetal reasons~* Between 36 and 38 WG: collection of demographic, obstetrical, fetal ultrasound and clinical data / Perineal elastographic recording / Recording of the perineal deformation by stereovision camera~* In the delivery room, at the beginning of labor and before pushing: collection of clinical data / Collection of obstetrical ultrasound data / Perineal elastographic recordings / Recording of the perineal deformation by stereovision camera~* In the delivery room, during expulsion : recording of the perineal deformation by stereovision camera~* In the delivery room, after childbirth: collection of obstetrical, clinical and neonatal data / Perineal elastographic recordings / Cephalic and shoulder measurements of the newborn with a tape measure"
48144459|NCT01745666|OTHER|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
48144460|NCT01745666|OTHER|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
48144461|NCT06434584|OTHER|without AI assistance|provide insulin dosage and confidence score without AI assistance
48144462|NCT06434584|OTHER|with AI dosage assistance|provide insulin dosage and confidence score with AI dosage assistance
48355657|NCT01562379|DIETARY_SUPPLEMENT|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
48666475|NCT02164110|BIOLOGICAL|Shanchol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
48666476|NCT05136716|OTHER|Traditional Physical Therapy|Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.
48666477|NCT05136716|DEVICE|Hyperbaric oxygen therapy|HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
48144463|NCT06434584|OTHER|with explainable AI assistance|provide insulin dosage and confidence score with explainable AI assistance
48144464|NCT06434584|OTHER|with faulty explainable AI assistance|provide insulin dosage and confidence score with faulty explainable AI assistance
48355658|NCT01562379|DIETARY_SUPPLEMENT|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
48666478|NCT04623944|BIOLOGICAL|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
48666479|NCT02350452|PROCEDURE|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
48666480|NCT02350452|PROCEDURE|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
48666481|NCT02180789|DRUG|Tamsulosin OCAS|oral
48666482|NCT02796716|DEVICE|Testing on new technology called Accelerate ID/AST system|
47987979|NCT03103919|DRUG|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
48355659|NCT01562379|DIETARY_SUPPLEMENT|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
47987980|NCT04505774|DRUG|theraputic heparin|increased dose of heparin above standard of care.
47987981|NCT04505774|DRUG|prophylactic heparin|standard of care dose of heparin
47987982|NCT04505774|DRUG|P2Y12|added P2Y12 inhibitor
48666483|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
47987983|NCT04505774|DRUG|Crizanlizumab Injection|crizanlizumab injection
48144465|NCT05210309|PROCEDURE|Stem Cell Therapy|Application of Darvadstrocel locally, after fistula tract curettage and internal opening closure.
48355660|NCT01228695|OTHER|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
48355661|NCT02902692|OTHER|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
48355662|NCT03750344|DEVICE|Diagnostic test|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
48355663|NCT02483351|OTHER|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
48355664|NCT02483351|OTHER|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of \<=80g/L
48666484|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
48666485|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
48666486|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
48666487|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
47987984|NCT04505774|DRUG|SGLT2 inhibitor|sglt2 inhibitor
47987985|NCT05810792|DRUG|Histamine Dihydrochloride (HDC)|HDC is administrated in combination with IL-2 as peri- and post-operative treatment in patients undergoing surgery. 0.5 mg HDC is administered twice daily by subcutaneous injections 1 to 3 minutes after each IL-2 injection during three 3 week cycles, with 3-week resting periods inbetween. The first treatment cycle is initated 2 weeks prior to surgery, with an additional 2-3 days rest period during the surgical procedure, before the third treatment week is initiated.
47987986|NCT05810792|DRUG|Interleukin-2 (IL-2)|IL-2 is administrated in combination with HDC during three 3 week cycles as peri- and post-operative treatment in patients undergoing surgery. IL-2 is administered twice daily as a subcutaneous injection 1 to 3 minutes prior to the administration of histamine dihydrochloride; each dose of IL-2 is 16,400 IU/kg (1µg/kg).
47987987|NCT01830660|DRUG|Hetrombopag Olamine Tablets|
47987988|NCT01830660|DRUG|placebo|
47987989|NCT05969873|OTHER|Pilates exercise|Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.
47987990|NCT05969873|OTHER|Balance training|Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
47987991|NCT00941018|DRUG|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
48144466|NCT05647759|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will aim to complete 150 minutes of moderate-intensity exercise a week with the help of a virtual exercise coach
48144467|NCT00131404|DRUG|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
48144468|NCT00131404|DRUG|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
48144469|NCT00555932|PROCEDURE|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
48144470|NCT02095145|OTHER|Laboratory Biomarker Analysis|Correlative studies
48144471|NCT02095145|OTHER|Pharmacological Study|Correlative studies
48355665|NCT00518739|DRUG|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 \& beyond).
48666488|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
48666489|NCT02096107|DRUG|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
48666490|NCT02096107|OTHER|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
48666491|NCT01778413|DRUG|ATRIPLA|
48666492|NCT06109935|DRUG|Somapacitan|Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.
48144472|NCT02095145|OTHER|Placebo|Given PO
48144473|NCT02095145|DRUG|Pomegranate-Extract Pill|Given PO
48144474|NCT02779426|BEHAVIORAL|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
48355666|NCT01085695|DRUG|rabeprazole|10 mg normal tablet
48666493|NCT04541615|PROCEDURE|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
48666494|NCT04541615|PROCEDURE|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
48355667|NCT01085695|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
48355668|NCT01085695|DRUG|rabeprazole|Type 2 granule containing rabeprazole 10 mg
48355669|NCT01085695|DRUG|rabeprazole|Type 3 granule containing rabeprazole 10 mg
48355670|NCT02516306|DRUG|EV06 Ophthalmic Solution|
48355671|NCT02516306|DRUG|Placebo Ophthalmic Solution|
48666495|NCT04541615|PROCEDURE|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
48666496|NCT04541615|PROCEDURE|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
48666497|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose
48666498|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
48666499|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
48666500|NCT01067807|DRUG|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
48666501|NCT05466305|DEVICE|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
48355672|NCT05086094|DRUG|BHV3241, verdiperstat|BHV3241/Verdiperstat 600mg BID
48355673|NCT01641354|PROCEDURE|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
48666502|NCT00601731|BIOLOGICAL|MenACWY-CRM197|Blood test, 40-months and 60-months children
48666503|NCT00601731|BIOLOGICAL|Blood test|Blood test, 40-months and 60-months children
48666504|NCT04740151|PROCEDURE|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
48666505|NCT04740151|PROCEDURE|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
47987992|NCT04698031|DRUG|Clopidogrel treatment|After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
48144475|NCT04472715|PROCEDURE|follicular unit extarcation and platelet rich plasma|hair transplantation procedure
48144476|NCT02673359|DRUG|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
48355674|NCT05626465|OTHER|Blood test|Proteomic analyses on serum
48505693|NCT05811897|BEHAVIORAL|Self-Managed Online Treatment|"Self-help online cognitive-behavioural therapy focusing on post-traumatic stress, sleep and mood. The content is divided into three modules :~* Coping with my trauma: psychoeducation about PTSD, cognitive restructuring prolonged exposure to avoided situations and memories (14 sessions)~* Sleeping better: psychoeducation about, sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education), Imagery Rehearsal Therapy (10 sessions)~* Improving my mood: psychoeducation about depression, behavioural activation; relaxation and mindfulness exercises; problem-solving strategies (6 sessions)~A small portion of material is unlocked each week, and access to one module will be accessible after the completion of a previous one. Access to the online material will be unlimited in time. Participants complete self-report questionnaires after each module, the platform then provides feedback and suggests corresponding modules."
48666506|NCT04118660|OTHER|Tissue Banking|Blood, tissue, and fluid collection
48355675|NCT02473016|DRUG|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
48355676|NCT02839655|DEVICE|Da Vinci Xi|
48355677|NCT02393989|PROCEDURE|posterior restoration|restorations for caries effected teeth
48355678|NCT02098655|OTHER|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
48505694|NCT05811897|BEHAVIORAL|Therapist-Assisted Online Treatment|Same online intervention. Supervised graduate psychology students will provide brief regular weekly contacts for up to 30 weeks by video chat or phone, according to the participant's preference.
48002668|NCT02457325|DRUG|Surgery with 4%Articaine first, then Surgery with 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
48355679|NCT01804413|DRUG|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
48355680|NCT01804413|DRUG|Regular insulin|0.1-0.15 units/kg
48355681|NCT04690556|DRUG|Lucentis (ranibizumab)|Lucentis® 0.5 mg via intravitreal injection once monthly
48355682|NCT04690556|DRUG|LUBT010 (proposed ranibizumab biosimilar)|LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly
48666507|NCT02320188|OTHER|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
48144477|NCT02673359|PROCEDURE|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
48505695|NCT06066294|BIOLOGICAL|Regimen 1|WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7
48666508|NCT02320188|OTHER|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
48666509|NCT06518967|DIAGNOSTIC_TEST|analytical performance study|analytical performance study on left-over samples with the SiMoT IVD system for in vitro diagnostic tests
48666510|NCT02895217|OTHER|ergocycle|
48666511|NCT02065219|DRUG|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
48666512|NCT02065219|DRUG|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
48666513|NCT04485702|DRUG|Midazolam injection|2mg IV
48666514|NCT04485702|DRUG|Ketamine Injectable Product|6mg IV
48666515|NCT04485702|DRUG|MELT-100|midazolam 3mg and ketamine 25mg SL tablet
48666516|NCT04039243|BEHAVIORAL|Being Brave|Up to 12 weekly sessions
48666517|NCT04039243|OTHER|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
48666518|NCT01263210|BIOLOGICAL|Prevenar|
48666519|NCT05730842|DRUG|EDG-5506 Tablet|Single Oral Dose - Tablet
48666520|NCT05730842|DRUG|Radiolabeled EDG-5506 Suspension|Single Oral Dose
47987993|NCT04698031|DRUG|Aspirin treatment|After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
47987994|NCT03370354|BEHAVIORAL|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
47987995|NCT03103607|DIAGNOSTIC_TEST|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
47987996|NCT03103607|DIAGNOSTIC_TEST|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
47987997|NCT03300479|DRUG|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
47987998|NCT03300479|DRUG|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
47987999|NCT01229423|DRUG|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
48666521|NCT05730842|DRUG|Radiolabeled EDG-5506 Intravenous|Single Intravenous Dose
48666522|NCT02683902|DEVICE|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
48666523|NCT02683902|BEHAVIORAL|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
48666524|NCT02683902|DEVICE|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
48666525|NCT02541591|OTHER|Neuroprotective goal directed hemodynamic optimization|
48666526|NCT02541591|OTHER|MAP > 65mmHg|MAP \> 65mmHg
48666527|NCT01689948|BEHAVIORAL|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
48666528|NCT01126073|DRUG|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
48666529|NCT01126073|DRUG|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
48666530|NCT02256995|DEVICE|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
48666531|NCT00404807|DEVICE|CPAP(Continuous Positive Airway Pressure)|
48666532|NCT05410730|DRUG|SHR-1501|SHR-1501 single agent dose escalation will consist of 3 dose groups: 200 μ g、400 μ g and 600 μ g, and in combination of BCG. The administration method is intravesical instillation.
48666533|NCT06071676|OTHER|conventional impression group|Silicon impression material loaded on plastic tray and inserted inside the patient mouth
48666534|NCT06071676|OTHER|digital impression group|direct scanning was done using intraoral scanner to the female housing of the attachments on position
48666535|NCT05155111|DIAGNOSTIC_TEST|Telemedicine consult|A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
47988000|NCT04787029|DEVICE|Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735))|Compression stockings worn on the arm or partial swelling of the hand after trauma or surgery.
48144478|NCT04131556|DRUG|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
48144479|NCT00258115|DRUG|salsalate|
48144480|NCT00396487|DRUG|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
48144481|NCT05848856|BEHAVIORAL|Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up|Study of different types of risk-informed screening approaches and the measurement of patient compliance with screening recommendations based on different approaches to patient engagement
48144482|NCT01542983|BEHAVIORAL|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
48144483|NCT01542983|BEHAVIORAL|treatment as usual|Standard treatment for fatigue and insomnia
48144484|NCT00410748|DRUG|OROS hydromorphone HCI CR|
48144485|NCT03806205|OTHER|regular follow-up|we give a regular follow-up and supervision on the study group
48144486|NCT05484297|BEHAVIORAL|Crisis Caring Contacts post cards|A series of post cards with Crisis Caring Contacts content sent over 10 months
48144487|NCT05484297|BEHAVIORAL|Control post cards|"A series of post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention"
48144488|NCT04874142|DRUG|YYC506-T|single administration
48144489|NCT04874142|DRUG|YYC506-A|single administration
48144490|NCT04874142|DRUG|YYC506-T + YYC506-A|concomotant administration
47988001|NCT04615663|BEHAVIORAL|Score SMI|the investigator will complete the SMI score
48144491|NCT04874142|DRUG|YYC506-A + YYC506-T|concomotant administration
47988002|NCT00730912|DRUG|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
47988003|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
47988004|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
47988005|NCT04061811|DIAGNOSTIC_TEST|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
47988006|NCT05587400|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
47988007|NCT05587400|DRUG|dobutamine test|infusion dobutamine
47988008|NCT05587400|DRUG|inhaled nitric oxide|nitric oxide inhalation
47988009|NCT05331287|OTHER|Head position|Influence of different head position on nasal endotracheal intubation
47988010|NCT01314833|DRUG|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6"
47988011|NCT01314833|DRUG|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3"
47988012|NCT01314833|DRUG|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4"
47988013|NCT00131833|BIOLOGICAL|Typhoid Vi vaccine|
47988014|NCT00131833|BIOLOGICAL|Meningococcal A (control)|
47988015|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
47988016|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
47988017|NCT00156533|DRUG|Zolpidem|10 mg of Zolpidem
47988018|NCT00156533|DRUG|Sugar Pill|
47988019|NCT00242957|BEHAVIORAL|Intervention with Microfinance for AIDS and Gender Equity|
47988020|NCT02426892|BIOLOGICAL|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
47988021|NCT02426892|DRUG|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
47988022|NCT01291758|DIAGNOSTIC_TEST|Submaximal bicycle exercise stress tests performed 24 hr apart|Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
47988023|NCT05874076|BEHAVIORAL|Physiotherapy|Physiotherapy
48002669|NCT06496126|DEVICE|Cerasmart 270 (GC Coop, Tokyo, Japonya)|Hybrid Ceramic Block
48002670|NCT06496126|DEVICE|EverX Flow (GC Coop, Tokyo, Japonya)|Fiber Reinforced Composite Resin
48002671|NCT06496126|DEVICE|: G-CEM ONE (GC Coop, Tokyo, Japonya)|Universal Self Adhesive Resin Cement
48144492|NCT03864237|BEHAVIORAL|Alcohol texts|A text message each day for 10 weeks, containing factual information about campus drinking norms.
48144493|NCT03864237|BEHAVIORAL|Attention control|"A text message each day for 10 weeks, containing this day in history facts."
48144494|NCT02733484|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
48144495|NCT02733484|DIETARY_SUPPLEMENT|Placebo|the patients in this arm will receive placebo intervention
48144496|NCT06407375|DIAGNOSTIC_TEST|mpMRI|mpMRI
48144497|NCT03564106|DRUG|intraarticular radiofrequency + intraarticular methylprednisolone|intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
48144498|NCT03564106|DRUG|intraarticular methylprednisolone|intraarticular methylprednisolone (30 mg)
48144499|NCT04534738|BEHAVIORAL|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
48144500|NCT02362386|DEVICE|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
48666536|NCT06230965|PROCEDURE|Lung protective ventilation strategy|They were divided into 2 groups: traditional ventilation strategy group (control group) and lung protective ventilation strategy group (experimental group), with 30 cases in each group. In the conventional ventilation strategy group, the conventional ventilation strategies were followed: tidal volume （VT）=10-12ml/kg, respiratory rate（f） =12 times/minute, PEEP=0 cmH₂O, fraction of inspired oxygen=0.5; Lung protective ventilation strategies were implemented in the Lung protective ventilation strategy group: VT=6-8ml/kg, f=12 times/min, PEEP=6-8 cm H₂O,fraction of inspired oxygen=0.5 Manual lung reexpansion was performed every 30 minutes after mechanical ventilation (continuous positive airway pressure of 30 cm H₂O for 30 seconds).
48355683|NCT04863118|OTHER|Strength training in shallow water and dry land|"Dry land: The intervention will last for 60 minutes, consisting of exercises to strengthen the global extensor musculature, that is, involving the upper limbs, trunk and lower limbs. Weights and equipment for strength training will be used. The sessions will start with 10 minutes of warm-up, the central part of exercises to strengthen the extensor muscles and the last part will consist of oriented stretches. In the central part, a typical strength training will be performed (2-6 series; 85% of RM), using submaximal subjective effort and with repetition control.~Shallow water: The intervention performed on dry land will be adapted and produced in an aquatic environment. Aquatic implements will be used for strength training."
48666537|NCT00800735|DRUG|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
48666538|NCT00800735|DRUG|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
48355684|NCT04863118|OTHER|High-intensity training in shallow and deep water|"Shallow water: The intervention will last 60 minutes. The exercises consist of: immersion, balance, strength, agility and displacement in the water. As they will start with 10 minutes of warm-up and the last part will consist of stretches oriented along the edge of the pool and on the depth reduction platform. In the main part of the intervention, different styles of exercises will be performed, with or without the use of implements. Displacements will have varying speeds in the same session, defined by Borg's Scale of subjective sensation of effort.~Deep water: The intervention carried out in shallow water will be adapted with the use of floating belts and reproduced in deep water."
48666539|NCT05482061|OTHER|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
48666540|NCT03716648|DIAGNOSTIC_TEST|DISE-assisted titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
48666541|NCT03716648|DIAGNOSTIC_TEST|PSG-guided titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
48666542|NCT03716648|DEVICE|subjective titration|Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
48666543|NCT01731925|DRUG|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
48666544|NCT01731925|DRUG|Placebo (for sunitinib)|
48144501|NCT01633359|DRUG|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
48505696|NCT06066294|BIOLOGICAL|Regimen 2|WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
48505697|NCT03480386|BEHAVIORAL|Home Based Pulmonary Rehabilitation|Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
48666545|NCT01731925|DRUG|Sunitinib|Sunitinib 37.5 mg daily
48666546|NCT00006379|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
48666547|NCT00006379|BIOLOGICAL|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
48666548|NCT00006379|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
48666549|NCT00006379|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
48666550|NCT00006379|PROCEDURE|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
48002672|NCT06496126|DEVICE|G-Premio Bond (GC Coop, Tokyo, Japonya)|Universal Adhesive
48505698|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
48666551|NCT06113861|DIAGNOSTIC_TEST|Quantiferon Gold|Test for TB infection
48002673|NCT06496126|DEVICE|G-ænial A'CHORD|Conventional Composite Resin
48144502|NCT01633359|DRUG|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
47988024|NCT02709031|DRUG|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
47988025|NCT02709031|DRUG|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,
47988026|NCT00826020|DRUG|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
47988027|NCT04352114|DRUG|LY3461767 - SC|Administered SC.
47988028|NCT04352114|DRUG|LY3461767 - IV|Administered IV.
47988029|NCT04352114|DRUG|Placebo - SC|Administered SC.
48505699|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
48505700|NCT00973609|DRUG|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
48505701|NCT05822258|OTHER|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without addition of additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions."
48505702|NCT05801718|DIAGNOSTIC_TEST|Growth parameters & body mass index|measuring the anthropometric measurements including: Weight, height/ length, head circumference, mid arm circumference\& skin fold thickness and measuring body mass index.
47988030|NCT04175769|DIETARY_SUPPLEMENT|Nutritional supplement|Subjects will orally consume two gelatin capsules of nutritional supplement (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
47988031|NCT04175769|OTHER|Placebo|Subjects will orally consume two gelatin capsules of placebo (1 gram), 2 times per day with meals, and 1 capsule at one additional meal or snack, totaling five capsules per day beginning the first day of treatment and continuing for the duration of their treatment.
47988032|NCT03716882|DEVICE|Song Meter (SM)4|Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
47988033|NCT03753347|BIOLOGICAL|2018-19 quadrivalent inactivated influenza vaccine|A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
47988034|NCT00523250|DRUG|AR-102 0.003% Ophthalmic Solution|
47988035|NCT00523250|DRUG|AR-102 0.005% Ophthalmic Solution|
47988036|NCT00523250|DRUG|AR-102 0.01% Ophthalmic Solution|
47988037|NCT00523250|DRUG|AR-102 0.03% Ophthalmic Solution|
47988038|NCT00523250|DRUG|AR-102 Vehicle Ophthalmic Solution|
47988039|NCT02378701|BEHAVIORAL|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
47988040|NCT02378701|BEHAVIORAL|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
47988041|NCT04210310|DRUG|Oxytocin|The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
47988042|NCT04210310|OTHER|Placebo nasal spray|A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
47988043|NCT05769790|DIAGNOSTIC_TEST|ddPCR|The search for cfDNA will be performed using assays available in the literature for the search for E. granulosus cfDNA developed for PCR analysis in biological samples, targeting EgG1 Hae III repeat region, cox1 and nad1 (Zhao et al 2021). Appropriate controls (synthetic sequences and Parasitic reference DNA, provided by the Echinococcosis Reference Center of the Istituto Superiore di Sanità, Rome) will be included in each experiment.
47988044|NCT05670366|DEVICE|Activity tracker and chest strap|During the study, the participants will be asked to wear a commercially-available activity tracker during day and night, and a chest strap during sport activities to collect data on physical activity (type, intensity and duration of activity).
47988045|NCT05670366|DEVICE|Diary app|During the study, the participants will be asked to log the ingestion of carbohydrates, periods and type of physical activity, feelings (e.g. sick, stress, ...) in a diary app.
47988046|NCT04157608|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
48355685|NCT06450782|OTHER|Post-isometric Relaxation Technique|"Sternocleidomastoid muscle Participants are asked to stretch their necks in a spuni position and then turn their heads as far to the side of the target muscle (right side) as possible until a sensation occurs that causes discomfort in the targeted SCM. In this case, the participants are asked to moderately isometrically contract the SKM muscle for 5 seconds and then relax for 3 seconds and the cervical spine is moved to the new barrier.~Masseter muscle Participants are positioned in a sitting position. The jaw is opened as wide as possible. The index and middle fingers of one hand are placed over the lower teeth. The weight of the hand is allowed to provide flexion and traction is applied directly to the midline. In this case, the participants are asked to moderately isometrically contract the bilateral masseter muscles for 5 seconds, then relax for 3 seconds and the participant moves his chin to the new barrier."
47988047|NCT04157608|DEVICE|Energy-Harvesting Mesofluidic Impulse Prosthesis|e-MIP is an experimental lower limb ankle-foot prosthesis.
48355686|NCT06450782|OTHER|Myofascial Release Technique|"Sternocleidomastoid muscle The head is slightly elevated with the help of a folded towel to prevent discomfort that may develop depending on the position. The researcher sits in a chair next to the participant's head. The chair is placed at approximately 45° to the participant's neck. The participant's head is rotated 30° towards the opposite side of the treated side. The Graston instrument contacts the upper part of the SCM approximately 2 cm below the mastoid process.~Masseter muscle It works both ways. The Graston instrument is placed on the zygomatic process of the temporal bone, approximately 1 cm in front of the ear. The soft tissue is pressed until the bone is contacted. This connection with the periosteum is maintained and a lower tension line is created towards the mandible angle. This line of tension is continued up to the mandible, where the periosteum also comes into play. It is repeated several times."
48355687|NCT06450782|OTHER|Control|Participants will rest for thirty minutes.
48355688|NCT00263406|DRUG|Administration of an ACE-inhibitor or not|
48355689|NCT03114670|BIOLOGICAL|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
48355690|NCT05963165|BEHAVIORAL|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
48355691|NCT02868801|DRUG|Placebo|same intervention as the experimental group
48355692|NCT02868801|DRUG|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
48355693|NCT02868801|DRUG|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
48355694|NCT02868801|DRUG|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
48355695|NCT04027140|DEVICE|M/L Taper with Kinectiv Technology Stems and Necks|Patients that have been implanted with a M/L Taper with Kinectiv Technology Stem and/or neck to repair hip malfunction/disease.
48505703|NCT04128683|DRUG|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
48505704|NCT04128683|DRUG|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
48505705|NCT03812549|DRUG|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
47988048|NCT00624052|DRUG|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
47988049|NCT00624052|DRUG|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
47988050|NCT00996047|GENETIC|cytogenetic analysis|
47988051|NCT00996047|GENETIC|fluorescence in situ hybridization|
47988052|NCT01806753|PROCEDURE|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
48002674|NCT05016388|OTHER|Collaborative Multidimensional Model (CMD)|The teams enrolled in the CMD intervention will have a 22-hour training that integrates current knowledge of depression with skills for the management of functional variables, interpersonal, social, emotional regulation, and history of biographical adversity from childhood considering the trauma informed care paradigm. After the training, the PHC teams will implement the depression treatment according to a collaborative model.
48505706|NCT03812549|RADIATION|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
48505707|NCT03812549|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
48505708|NCT02940808|DIETARY_SUPPLEMENT|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
48144503|NCT05409170|PROCEDURE|COVID|Each surgical procedure was considered an independent event. Moreover, the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
48505709|NCT02940808|OTHER|Placebo|Oral consumption of capsule containing a placebo substance.
48505710|NCT05414344|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
48666552|NCT06113861|DIAGNOSTIC_TEST|HIV serology|Test for HIV infection
48666553|NCT06113861|DIAGNOSTIC_TEST|Respiratory secretion culture (sputum or gastric aspirate_|TB culture by MODS
48666554|NCT06113861|DIAGNOSTIC_TEST|Chest radiograph|Chest imaging test by traditional X ray
48355696|NCT02021149|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
48355697|NCT02021149|BEHAVIORAL|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
48355698|NCT02021149|OTHER|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
48355699|NCT02021149|DEVICE|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
48355700|NCT02773511|PROCEDURE|Surgical treatment|Closed reduction and Kirschner wire fixation
48666555|NCT06113861|DIAGNOSTIC_TEST|Lung ultrasound|Chest imaging test by ultrasound
48666556|NCT06113861|DIAGNOSTIC_TEST|cell free DNA test|Blood test for TB infection
48666557|NCT02599116|OTHER|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
48666558|NCT02599116|OTHER|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
48666559|NCT04275804|DEVICE|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm)
48666560|NCT04275804|OTHER|Conventional Dressing|Alternate Day Dressing
48666561|NCT01145950|DRUG|LBEC0101|Etanercept 25mg, single dose
48355701|NCT01235494|OTHER|polarised 3 helium|1 inhalation (= 1 litre)
48355702|NCT01628718|BEHAVIORAL|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
48355703|NCT01628718|BEHAVIORAL|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
48666562|NCT01145950|DRUG|Enbrel|Etanercept 25mg, single dose
48666563|NCT01219257|BIOLOGICAL|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
48666564|NCT02806414|DRUG|Ivermectin|
48666565|NCT02244515|DRUG|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
48666566|NCT01015950|DIETARY_SUPPLEMENT|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
48666567|NCT01015950|DIETARY_SUPPLEMENT|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
48666568|NCT01015950|DIETARY_SUPPLEMENT|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
48666569|NCT01015950|DIETARY_SUPPLEMENT|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
48666570|NCT00946595|DRUG|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
48666571|NCT00946595|DRUG|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
48666572|NCT04076033|OTHER|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
48355706|NCT02788851|DRUG|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
48355707|NCT02788851|BEHAVIORAL|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
48355708|NCT01768702|BIOLOGICAL|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
48355709|NCT01768702|BIOLOGICAL|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
48355710|NCT00731666|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
48355711|NCT04602299|OTHER|Set the minimum time of gastroscopy|This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
48355712|NCT01517828|DRUG|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
48355713|NCT01517828|DRUG|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
48355714|NCT04957745|BEHAVIORAL|Binocular visual confusion (unilateral opaque)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the binocular visual confusion condition, the non-transparent (opaque) peripheral target will be displayed on only one eye (unilateral opaque display)."
48355715|NCT04957745|BEHAVIORAL|Unilateral monocular visual confusion (unilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For the unilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on only one eye (unilateral see-through display)."
48355716|NCT04957745|BEHAVIORAL|Bilateral monocular visual confusion (bilateral see-through)|"The peripheral target was a horizontally drifting grating measuring 10° by 10°, with a spatial frequency of 1 cycle per degree and a temporal frequency of 3 Hz, and located at 10° above the fixation.~For bilateral monocular visual confusion condition, the half-transparent peripheral target will be displayed on both eyes (bilateral see-through display)."
48355717|NCT01112189|PROCEDURE|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
48144504|NCT03942107|PROCEDURE|Group 1: single-visit RCT|both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
48144505|NCT03942107|PROCEDURE|Group 2: two-visit RCT|after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
48144506|NCT03733951|DRUG|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
48144507|NCT06440915|OTHER|Theraputic drug monitoring|High Performance Liquid Chromatography (HPLC) is used to determine the plasma concentrations of isavuconazole
48144508|NCT06440915|DRUG|Isavuconazole|Isavuconazole
48144509|NCT00278928|DRUG|Liposyn III 20% (lipid infusion)|
48144510|NCT00278928|DRUG|Intralipid 20% (lipid infusion)|
48144511|NCT05793866|BEHAVIORAL|BUTEYKO RESPIRATORY TECHNIQUE|Buteyko Breathing Technique In recent years, breathing exercises have been used as one of the non-pharmacological, alternative and/or complementary approaches in the management of many chronic diseases and conditions. Buteyko Breathing Technique (BST), Russian Dr. It was developed by Konstantin Buteyko in the 1950s. Dr. Buteyko evaluates the normal respiration over carbon dioxide, the respiratory holding time used in the technique is defined as a control pause, and this value shows the body's oxygenation and carbon dioxide tolerance. BST is a technique performed only through the nose, which includes respiratory control and respiratory hold after inhalation.
48355718|NCT01112189|OTHER|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
48355719|NCT01359527|DEVICE|Hip Resurfacing|
48355720|NCT01359527|DEVICE|Total Hip Arthroplasty|
48505711|NCT05414344|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
48505712|NCT05414344|BEHAVIORAL|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
47988053|NCT01806753|PROCEDURE|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
47988054|NCT00003147|BIOLOGICAL|Ad5CMV-p53 gene|
47988055|NCT02370979|BIOLOGICAL|Blood samples|
47988056|NCT02602860|RADIATION|[11C]UCB-J|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 20 mCi~* Route of Administration: iv"
47988057|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 10 mg/ml~* Route of Administration: iv"
47988058|NCT02602860|DRUG|Levetiracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 100 mg/ml~* Route of Administration: iv"
47988059|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Tablets for oral intake~* Concentration: 25 mg~* Route of Administration: oral"
47988060|NCT04830787|OTHER|no intervention|there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
47988061|NCT06069960|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
47988062|NCT04517214|DRUG|Toripalimab|PD-1 inhibitor
48505713|NCT03523078|PROCEDURE|Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.
48666573|NCT04106505|BEHAVIORAL|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
48666574|NCT04106505|BEHAVIORAL|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
48666575|NCT01295489|OTHER|Laboratory Biomarker Analysis|Correlative studies
47988063|NCT04517214|RADIATION|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
47988064|NCT04517214|DRUG|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
47988065|NCT04517214|DRUG|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
47988066|NCT06406192|DIAGNOSTIC_TEST|Height, Weight, and Blood Pressure Measurement Procedures Improvement|"In the intervention group, the investigators improve the process of measuring blood pressure, height, and weight, requiring timely recording of these measurements. The intervention includes:~i. Enlisting the assistance of nurses and volunteers to improve the accessibility of measurement environments and provide guidance on instrument operation.~ii. Using paper reminders at check-in stations to prompt patients to complete blood pressure and weight recordings before entering examination rooms; providing paper for recording if patients forget their health insurance cards.~iii. Providing alcohol and hand wipes outside examination rooms for disinfecting measurement instruments.~iv. Promoting the recording mode outside the check-in station.~v. Ensuring that physicians or nurses in examination rooms accurately record measurements in the medical order system.~vi. Encouraging patients to ask physicians during consultations, Is my blood pressure and weight okay?"
47988067|NCT03014323|DRUG|Galantamine|Galantamine 4 mg twice a day for 4 weeks
47988068|NCT03014323|DRUG|Placebo|Placebo 1 capsule twice a day for 4 weeks
47988069|NCT02282670|DRUG|DA-5204|
47988070|NCT02282670|DRUG|Stillen tab.|
47988071|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
48666576|NCT03006055|DEVICE|Circulating tumor cells|
48666577|NCT00285779|DRUG|Etanercept|etanercept 50 mg twice weekly for 12 weeks
48666578|NCT00285779|DRUG|Placebo|
48666579|NCT06187389|OTHER|1 Grups|This methodological study was conducted using a cross-sectional observational approach at a leading teaching and research hospital. The study duration was from March to June 2023
48666580|NCT00152126|PROCEDURE|Stem Cell Transplantation|Autologous stem cell transplantation
47988072|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
47988073|NCT04672447|DIETARY_SUPPLEMENT|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
48666581|NCT00152126|DRUG|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
48666582|NCT04636632|DRUG|fosaprepitant|fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
47988074|NCT04672447|DIETARY_SUPPLEMENT|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
48666583|NCT04841408|OTHER|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
48666584|NCT01596114|OTHER|Stopping treatment with TKI|stopping until loss of MMR
48666585|NCT04494789|DRUG|Fludrocortisone Acetate|50mcg
48666586|NCT04494789|DRUG|Fludrocortisone Acetate|100mcg
48666587|NCT04494789|DRUG|Fludrocortisone Acetate|200mcg
48666588|NCT04494789|OTHER|Standard Therapy|NO Fludrocortisone
48144512|NCT04081532|PROCEDURE|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
48144513|NCT03187548|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
48144514|NCT02906657|OTHER|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
48144515|NCT01623609|DRUG|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
48144516|NCT01623609|DRUG|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
48355721|NCT04994275|OTHER|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or \<300 µg/L And TSAT\<20%) or no iron deficiency
48355722|NCT04945499|DRUG|d-glucose|using d-glucose as an contrast agent on CEST MR Imaging
48355723|NCT02362256|DRUG|Naltrexone|
48355724|NCT02362256|DRUG|Clonidine|
48355725|NCT02362256|DRUG|Lorazepam|
48355726|NCT03233672|RADIATION|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
48355727|NCT06375694|DIETARY_SUPPLEMENT|Herbiotics Oral + Ent Probiotic|Chewable Tablets containing Lactobacillus species.
48355728|NCT06375694|DIETARY_SUPPLEMENT|Placebo|Honest Placebo Pills by Zeebo
48666589|NCT00822380|DIETARY_SUPPLEMENT|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
47988075|NCT02969824|BEHAVIORAL|Supervised Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period. For the remotely supervised sessions, exercise intensities and heart rate will be monitored via FitBit.
47988076|NCT04779489|RADIATION|personalized ultrafractionated stereotactic ablative radiotherapy|next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
48355729|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - weekly
48355730|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - fortnightly
48355731|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - weekly
48355732|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - fortnightly
48355733|NCT00854685|DRUG|Placebo|Placebo s.c. - weekly
48666590|NCT00822380|DIETARY_SUPPLEMENT|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
47988077|NCT04062838|DRUG|Dextrose 50|As above
47988078|NCT03032367|DRUG|bedaquiline|
48355734|NCT00854685|DRUG|Placebo|Placebo s.c. - fortnightly
48355735|NCT00542139|DRUG|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
47988079|NCT00910312|DEVICE|Ice-Sense|Ice-Sense Cryoprobe
47988080|NCT06113432|DIAGNOSTIC_TEST|Arterial blood gases|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio
47988081|NCT06113432|DIAGNOSTIC_TEST|Respiratory rate (RR)|Measurement of respiratory rate by waveform analysis using a ventilator
48144517|NCT00114452|BIOLOGICAL|Provacel|ex vivo cultured adult mesenchymal stem cells
48144518|NCT00114452|BIOLOGICAL|Placebo|Placebo
48355736|NCT00542139|DRUG|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
48355737|NCT00004141|DRUG|Cisplatin|
48355738|NCT00004141|DRUG|dacarbazine|
48355739|NCT00004141|DRUG|Granulocyte-macrophage colony-stimulating factor|
48355740|NCT03773016|BEHAVIORAL|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
48666591|NCT00822380|DIETARY_SUPPLEMENT|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
48666592|NCT00822380|DIETARY_SUPPLEMENT|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
48666593|NCT00822380|DIETARY_SUPPLEMENT|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
48355741|NCT03504384|OTHER|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
48355742|NCT05344235|OTHER|SBRT|stereotactic radiotherapy of the primary prostate
48666594|NCT05678140|DEVICE|soft tissue mobilization|soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
48666595|NCT05678140|OTHER|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
48355743|NCT05557240|DRUG|NeoPep Vaccine1 plus Poly-ICLC|"NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
48666596|NCT04143776|PROCEDURE|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
48666597|NCT03681756|BEHAVIORAL|WALK|Walking program
48666598|NCT01994876|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
48666599|NCT01994876|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
48666600|NCT00498628|DRUG|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
48666601|NCT00498628|OTHER|Placebo|Placebo
48666602|NCT05960578|DRUG|Apalutamide|Given PO
48666603|NCT05960578|PROCEDURE|Biopsy|Undergo tumor biopsy
48666604|NCT05960578|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48666605|NCT05960578|PROCEDURE|Computed Tomography|Undergo CT scan
48666606|NCT05960578|DRUG|Golimumab|Given SC
48355744|NCT05557240|DRUG|NeoPep Vaccine2 plus Poly-ICLC|"NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.~Poly-ICLC:~Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations."
48666607|NCT05960578|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48355745|NCT01578525|OTHER|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
48355746|NCT00032110|DRUG|erlotinib hydrochloride|Given orally
48355747|NCT00032110|OTHER|pharmacological study|Correlative studies
48355748|NCT00032110|OTHER|laboratory biomarker analysis|Correlative studies
48355749|NCT00269620|DRUG|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
48666608|NCT05960578|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
48355750|NCT00269620|DRUG|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
48666609|NCT05904717|DRUG|PXS-4728 (A)|Participants will receive once daily (QD) for period of 12 weeks
48666610|NCT05904717|DRUG|Matching Placebo (B)|Participants will receive once daily (QD) for period of 12 weeks
48666611|NCT03981874|OTHER|telephonic interview|Telephonic interview
47988082|NCT06113432|DIAGNOSTIC_TEST|Pulseoximeter|Peripheral capillary oxygen saturation (SpO2) measurement and the ROX-index calculation (SpO2/FiO2/RR)
47988083|NCT06113432|DIAGNOSTIC_TEST|Assessment of accessory respiratory muscles work|Patrick score calculation. Score: 0. No visible tonic or phasic use of neck muscles. 1. Neck muscles taut but with no respiratory modulation (i.e., tonic activity). 2. Mild respiratory modulation in neck muscle contraction. 3. Moderate phasic activity (no supraclavicular or intercostal indrawing). 4. Vigorous phasic activity with indrawing. 5. Vigorous phasic activity with abdominal paradox.
48355751|NCT05193890|GENETIC|retrospective analysis of a panel result|retrospective analysis of a exome clinical solution
48355752|NCT00717561|DRUG|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
48355753|NCT00717561|DRUG|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
48355754|NCT03410602|PROCEDURE|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
48355755|NCT03410602|PROCEDURE|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
48355756|NCT03410602|DRUG|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
48355757|NCT01633775|PROCEDURE|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
48355758|NCT00240929|DRUG|MEDI-493|Active Comparator
48666612|NCT01651988|DRUG|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures \> 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
48666613|NCT02666560|DEVICE|Auditory Cueing|Auditory cueing set at different frequency rates
48666614|NCT04801576|OTHER|Flouride in mouthrinses|Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.
48666615|NCT04801576|OTHER|Placebo mouthrinse|Mouthrinses without flouride
48666616|NCT00375258|DRUG|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
48666617|NCT00375258|DRUG|Sodium Chloride 0.9%|Visual matched placebo
47988084|NCT06113432|DIAGNOSTIC_TEST|Esophageal pressure measurement|Esophageal pressure measurement on inspiration and expiration with calculation of delta esophageal pressure, transpulmonary pressure and delta transpulmonary pressure
47988085|NCT06113432|DIAGNOSTIC_TEST|Discomfort Visual Analog Scale (VAS)|From 1 to 10 points, where 1 point - maximal discomfort, 10 points - minimal discomfort.
47988086|NCT06113432|DIAGNOSTIC_TEST|Noninvasive blood pressure|Noninvasive blood pressure
47988087|NCT06113432|DIAGNOSTIC_TEST|Heart rate|Heart rate calculation using electrocardiogram monitoring
48666618|NCT04843280|PROCEDURE|FORCE therapeutics (physical therapy)|6 weeks of internet based physical therapy following arthroscopic knee surgery
47988088|NCT00281684|DRUG|SB705498 400 mg|SB705498 400 mg
47988089|NCT00281684|DRUG|SB705498 1000 mg|SB705498 1000 mg
47988090|NCT00281684|DRUG|Placebo|Placebo
48666619|NCT04843280|PROCEDURE|Traditional Outpatient Physical Therapy|6 weeks of outpatient physical therapy following arthroscopic knee surgery
48666620|NCT04518137|DRUG|ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle|48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
48666621|NCT01202695|DRUG|AVP-21D9|intravenously, single dose
48666622|NCT01202695|DRUG|Placebo|Placebo comparator
48666623|NCT00332696|DRUG|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
48666624|NCT00332696|DRUG|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
48666625|NCT00332696|DRUG|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
47988091|NCT00281684|DRUG|Co-Codamol|Co-Codamol
47988092|NCT06054087|PROCEDURE|Basal therapy+EA|"1. Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.~2. Main acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). Supporting acupoints: for pain in the upper limbs, add Baxie, Quchi (LI11), Shousanli (LI10), Hegu (LI4), and Ashixue; for pain in the lower limbs, add Bafeng, Neiting (ST44),Kunlun (BL60). Operation: Acupuncture needles of size 25\*40mm will be used. The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject."
47988093|NCT06054087|OTHER|Basal therapy|Participants are not set up with uniform medication. High blood sugar is controlled by hypoglycaemic drugs, patients with hypertension and hyperlipidaemia can take antihypertensive and lipid-lowering drugs, while other drugs are based on the patient's current medication.
47988094|NCT05569187|DRUG|Ribociclib|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
48144519|NCT05625230|BEHAVIORAL|Behavioral Activation plus Dynamic Mental Imagery|This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.
48144520|NCT05625230|BEHAVIORAL|Behavioral activation|"The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity."
48144521|NCT05819268|BEHAVIORAL|ReACT|ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
48666626|NCT00332696|DRUG|Placebo|Physiologic saline solution
48666627|NCT01854684|DRUG|Temoporfin|Given IV
48666628|NCT01854684|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48666629|NCT01854684|DRUG|Photodynamic Therapy|Undergo intraoperative PDT
48666630|NCT01854684|OTHER|Laboratory Biomarker Analysis|Correlative studies
48666631|NCT01854684|OTHER|Pharmacological Study|Correlative studies
48666632|NCT05503082|DRUG|Ubrogepant 50 MG [Ubrelvy]|Ubrogepant 50 MG \[Ubrelvy\]
47988095|NCT03301038|DRUG|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
47988096|NCT02569216|DEVICE|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
47988097|NCT05542264|DRUG|SEP-363856|SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
48666633|NCT05503082|DRUG|Ubrogepant 100 MG [Ubrelvy]|Ubrogepant 100 MG \[Ubrelvy\]
48666634|NCT02031614|PROCEDURE|Phlebotomy|Withdrawal of 500 mL of whole blood.
48666635|NCT01658059|OTHER|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
48666636|NCT01658059|OTHER|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
48666637|NCT02982226|OTHER|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
48666638|NCT02982226|OTHER|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
48666639|NCT01775384|DIETARY_SUPPLEMENT|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
48666640|NCT01775384|DIETARY_SUPPLEMENT|Placebo|
48355759|NCT05499689|DRUG|Bupivacaine Hydrochloride|2.5 cc bupivacain injection will be administered by approaching the greater occipital nerve under ultrasound guidance.
48355760|NCT05499689|OTHER|Transcutaneous pulsed radiofrequency qurrent|Pulsed radiofrequency current will be applied through transcutaneous pads adhered over the greater occipital nerve trace on the nape.
48355761|NCT05012709|BEHAVIORAL|multisensory stimulation therapy|The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
48355762|NCT03621124|PROCEDURE|Resting Energy Expenditure|During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
48355763|NCT03621124|OTHER|Thermal Comfort Questionnaire|Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
48355764|NCT04754906|OTHER|Sequence 1|perform arm movements towards a target
48355765|NCT04754906|OTHER|Sequence 2|judge the verticality of an object
48355766|NCT04754906|OTHER|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
48355767|NCT02286752|DRUG|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
48355768|NCT02286752|DRUG|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
48355769|NCT05550857|OTHER|eccentric resistance exercise|The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
47988098|NCT05542264|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
48144522|NCT05819268|BEHAVIORAL|CATCH-IT|CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
48355770|NCT05550857|OTHER|myofascial release|The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
48355771|NCT04262557|DIAGNOSTIC_TEST|Sunrise® solution|Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
48355772|NCT04262557|DIAGNOSTIC_TEST|Polysomnography|Gold standard method to diagnose SAS used as comparator
48355773|NCT06219876|DEVICE|low level laser treatment|The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.
48355774|NCT06219876|DEVICE|High intensity laser treatment|The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.
48355775|NCT06219876|OTHER|wrist splint|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
48355776|NCT06019091|DEVICE|Compass Health TENS 3000, 3 mode Analog Unit|The TENS unit Compass Health TENS 3000, 3 mode Analog Unit will be configured based on randomization to 20 Hz, 50 Hz, or 100 Hz. Pulse width 200 microseconds, Normal (N) Mode. It will be used on the posterior tibial nerve via a patch that is supplied each day for 30 minutes of the day. These 30 minutes of intervention will occur at the participants most painful time of the day for their pain.
48355777|NCT05790915|COMBINATION_PRODUCT|Standardized interventions|Standardized interventions according organ dysfunction
47988099|NCT04057014|DRUG|Amoxicillin|Antibiotic given at different dosages and durations.
48355778|NCT02254304|DRUG|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
48355779|NCT03137173|DRUG|ceftobiprole medocaril|ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
48355780|NCT03137173|DRUG|vancomycin+aztreonam|"Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.~Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was \< 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit."
48355781|NCT02144376|DIETARY_SUPPLEMENT|Ispaghula|
48355782|NCT02144376|DIETARY_SUPPLEMENT|Maltodextrin|
48355783|NCT01183104|DRUG|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=\< \<50).
48355784|NCT01183104|DRUG|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
48666641|NCT03981276|OTHER|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
48355785|NCT02679430|DEVICE|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
48666642|NCT03981276|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
48355786|NCT06496789|DRUG|Serplulimab+SOX|Serplulimab+Oxaliplatin+S1
48355787|NCT05687266|DRUG|Datopotamab deruxtecan|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
48666643|NCT00729950|BIOLOGICAL|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
48666644|NCT05685303|DEVICE|Alleviant ALV1 System|Creation of interatrial shunt
48666645|NCT05685303|OTHER|Sham-Control|Cardiac imaging
47988100|NCT04057014|PROCEDURE|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
48355788|NCT05687266|DRUG|Durvalumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
47988101|NCT03163550|DRUG|ACHN-383|Oral dose
47988102|NCT03163550|DRUG|ACHN-789|Oral dose
47988103|NCT03163550|DRUG|Placebo|Oral dose
48355789|NCT05687266|DRUG|Carboplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
48355790|NCT05687266|DRUG|Pembrolizumab|Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
48355791|NCT05687266|DRUG|Cisplatin|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
48355792|NCT05687266|DRUG|Pemetrexed|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
48355793|NCT05687266|DRUG|Paclitaxel|Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
48355794|NCT03200028|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
48666646|NCT00630617|BEHAVIORAL|Diet, Physical activity, Physical inactivity|Community based participatory research design
48666647|NCT00272181|DRUG|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
48666648|NCT03719131|DRUG|Nivolumab|Receive standard of care nivolumab therapy
48666649|NCT03719131|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given IV or SC
48144523|NCT06154161|DIETARY_SUPPLEMENT|Whey protein supplement|A monthly supply of 35 g of whey protein isolate will be provided to participants in individual sachet packets with instructions of preparation. Every month, participants will come to the center to provide the standard monthly blood sample. At this time, the PI will have participants complete the quality-of-life instrument, ask if there have been any changes in their dietary habits, and collect weights for up to 6-months. Additionally, participants will indicate if they had consumed the protein daily and/or bring back their empty/full satchel packets. As this is a feasibility trial, it is necessary to determine the compliancy of consuming protein daily and the amount. Furthermore, understanding how protein markers may be affected by consumption of the protein daily vs less frequently throughout the week is important to establish improved recommendations for consumption of protein supplements.
48144524|NCT04478409|BIOLOGICAL|one additional blood sample during a planned blood test|The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients.
48144525|NCT04474171|BEHAVIORAL|SCI&U online health coaching program|Online secure videoconferencing health coaching platform with resource library to promote self-management. Maximum number of sessions is 14 over 6 months and covers health related topics to reduce secondary complications
48355795|NCT03208504|DEVICE|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
48505714|NCT04878848|OTHER|Proprioceptive Neuromuscular Facilitation Exercises|Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.
48505715|NCT04878848|OTHER|Conventional Rehabilitation Group|Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
48666650|NCT03719131|DRUG|Ipilimumab|Receive standard of care ipilimumab therapy
48666651|NCT06529432|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose
48666652|NCT06529432|DRUG|Bupivacaine Hydrochloride Injection|Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
48666653|NCT06458556|DEVICE|Treatment with Morpheus|Radiofrequency device treatment
48666654|NCT04474132|DEVICE|toxoplasma ICT IgG-IgM BK|a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody
48666655|NCT01593540|DEVICE|metal-free interdental brush|one time per day
48666656|NCT01593540|DEVICE|metal-core interdental brush|one time per day
48666657|NCT00668629|DRUG|Lactic acid (Dermacid)|
48666658|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
48666659|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
48666660|NCT00094276|BEHAVIORAL|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
48666661|NCT00094276|BEHAVIORAL|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
48355796|NCT01592110|DRUG|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
48355797|NCT01592110|OTHER|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
48355798|NCT01592110|DRUG|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
48666662|NCT03829592|DRUG|misoprostol in a neutral media|giving misoprostol in a neutral media
48666663|NCT03829592|DRUG|misoprostol in an acidic media|giving misoprostol in an acidic media
48666664|NCT03829592|DRUG|misoprostol in an alkaline media|giving misoprostol in an alkaline media
48666665|NCT01194037|DRUG|recombinant variant of interferon-alpha 2b|SC, Weekly
48666666|NCT01194037|DRUG|Peginterferon alfa-2a|SC Weekly
48666667|NCT03625076|DRUG|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
48666668|NCT03625076|DRUG|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
48666669|NCT05662657|DIAGNOSTIC_TEST|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
48666670|NCT05036343|DEVICE|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
48666671|NCT01775540|DRUG|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
48666672|NCT01775540|DRUG|Saline solution|Saline solution,1 drop used QID for 4 weeks
48666673|NCT01775540|DRUG|Maxidex|Eyedrop-1 drop QID for 4 weeks
48666674|NCT00151177|DEVICE|non-invasive continuous positive airway pressure ventilation|
48666675|NCT00151177|DEVICE|CPAP-treatment|night time CPAP-mask ventilation
48666676|NCT02835690|BIOLOGICAL|Pembrolizumab|IV infusion
48666677|NCT02007629|DRUG|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
48666678|NCT03454035|DRUG|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
48666679|NCT03454035|DRUG|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
48666680|NCT04353687|DEVICE|Robotic-assisted inguinal hernia repair|Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
48666681|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
48666682|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
48666683|NCT03044145|BEHAVIORAL|Treatment as usual|Standard mental health treatment at FHMC
48666684|NCT05640089|OTHER|fMRI-based neurofeedback|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
48666685|NCT06511583|PROCEDURE|Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department|For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient\&#39;s head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.
48666686|NCT06511583|PROCEDURE|Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department|"Equipment Setup:~A sterile bronchoscope will be connected to the suction apparatus.~Procedure:~The bronchoscope will be gently inserted through the patient\&#39;s nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions."
47988104|NCT03609515|OTHER|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
47988105|NCT03486132|PROCEDURE|repair of episiotomy|Different techniques for repair of episiotomy incsicion
48144526|NCT04549688|PROCEDURE|high-intensity focused ultrasound, HIFU|see above
48666687|NCT04582214|DEVICE|MetaNeb® System|The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
48144527|NCT01579071|PROCEDURE|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
48144528|NCT04154891|GENETIC|Trio Whole Genome Sequencing|WGS trio analysis will be performed using the genome data of the index case in addition to the genome data of his parents. This analysis will follow a consensus protocol that contains 3 obligatory steps: first of all, de novo variants (SNV, CNV and others SV) will be examined in the whole genome data set; then, a SNV/CNV/other SV analysis will be performed under a AR or X linked Mendelian mode hypothesis in the whole genomic regions of a OMIM extended list (that contains all genes already involved in human genetic diseases). Finally, analysis will focus on inherited pathogenic variants under an AD mode hypothesis (analysis of variations already reported as pathogenic in clinVar or HGMD pro; CNV or truncating variation in OMIM genes, etc). When these 3 steps analysis is completed then variants of interest identified at each step will be recorded until examination by a specific multidisciplinary meeting.
48144529|NCT04154891|GENETIC|Simplex Whole Genome Sequencing|This analysis will be performed using only the index case following a similar strategy than the one used for the WGS trio
48666688|NCT01421056|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
47988106|NCT05837416|DRUG|blue®m Gel|Oxygen will be released after application Oxygen Releasing Oral Gel (blue®m gel) creating a partially high oxygen pressure (pO2), which aids in restoring the micro-environment for a healthy oral cavity
47988107|NCT05837416|DRUG|NBF GINGIVAL GEL®|Anti-oxidant gel (Nano-emulsion complex propolis and vitamin C - NBF GINGIVAL GEL®) is a nano bio fusion gel containing propolis, nano vitamin C, E and herb extract
48144530|NCT04154891|GENETIC|Current French Reference strategy|Actual ANPGM recommendations defined by the following analysis: Fra-X + chromosomal microarray analysis + 44GPS
48144531|NCT00687297|DRUG|vandetanib induction|100 mg daily by mouth
48144532|NCT00687297|DRUG|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
48144533|NCT00687297|DRUG|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
48144534|NCT00687297|DRUG|Placebo|
48144535|NCT00687297|DRUG|Vandetanib maintenance|300 mg daily by mouth
48144536|NCT02232997|OTHER|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
48144537|NCT02232997|OTHER|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
48144538|NCT02748200|RADIATION|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
48144539|NCT04305496|DRUG|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
48144540|NCT04305496|DRUG|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
48355799|NCT01592110|DRUG|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
47988108|NCT05837416|DRUG|COE-PAK™|It is non eugenol periodontal dressing. It is supplied in two tubes, the contents of which are mixed immediately before use. One tube contains zinc oxide, oil, a gum, and lorothidol. The other tube contains liquid coconut fatty acids thickened with colophony resin and chlorothymol
47988109|NCT01228357|DRUG|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
47988110|NCT01228357|DRUG|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
47988111|NCT01028339|DRUG|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
47988112|NCT01028339|DRUG|Mannitol|Mannitol
47988113|NCT05803811|DIETARY_SUPPLEMENT|Riboflavin|Colon delivered vitamin B2 (Riboflavin) for 12 weeks
47988114|NCT03993431|DRUG|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
48355800|NCT02728310|DRUG|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
48355801|NCT02728310|DRUG|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
48666689|NCT01421056|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
48666690|NCT01421056|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
48666691|NCT03930953|DRUG|CC-99282|Specified dose on specified days
48666692|NCT03930953|DRUG|Rituximab|Specified dose on specified days
47988115|NCT03993431|DRUG|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
47988116|NCT01220882|RADIATION|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
48666693|NCT03930953|DRUG|Obinutuzumab|Specified dose on specified days
48666694|NCT03930953|DRUG|Tafasitamab|Specified dose on specified days
48666695|NCT03930953|DRUG|Valemetostat|Specified dose on specified days
48666696|NCT05876156|BEHAVIORAL|Virtual Reality Physical Therapy|Participants are allowed to freely choose one game from the game list. Participant will be asked to wear a validated activity tracker - ActiGraph. Baseline heart rate will be collected for 1 minute. Participants will be wearing the ActiGraph during Physical Therapy session. Participants receiving VR intervention will be instructed to wear an Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in VR applications under the supervision of the physical therapist.
48666697|NCT05876156|BEHAVIORAL|Traditional Physical Therapy|Participants will receive traditional Physical Therapy sessions (standard care) under the supervision of the accredited physical therapist. Participants will be wearing the Actigraph during Physical Therapy session. Participants will perform regular physical exercise, such as 20 minutes walking or biking on a stationary bike, under the supervision of a physical therapist.
48666698|NCT04250701|OTHER|Body Posture Assessment|Application of three evaluations above at a one time.
48666699|NCT01166035|DRUG|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
48666700|NCT01166035|DRUG|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
48666701|NCT04955821|DIAGNOSTIC_TEST|mNGS diagnose of VAP|This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
48666702|NCT03890211|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
48666703|NCT04980248|BIOLOGICAL|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
48666704|NCT03985202|OTHER|Structured exercise programme|9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
48666705|NCT05639959|DRUG|Mometasone Nasal 50 Mcg/Inh Nasal Spray|Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
48666706|NCT05639959|DEVICE|Nasal spray|device can work properly for actuation during trials
48666707|NCT02872038|DRUG|Cefepime|Cefepime intraperitoneal continuous dosing
48666708|NCT02872038|DRUG|Cefazolin plus Ceftazidime|
47988117|NCT04835025|DRUG|PD-1/PD-L1 inhibitor|In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
47988118|NCT04751396|OTHER|Best Practice|Receive standard educational information
47988119|NCT04751396|OTHER|Educational Intervention|Navigate educational tool
47988120|NCT04751396|OTHER|Interview|Participate in interview
47988121|NCT04751396|OTHER|Questionnaire Administration|Complete questionnaire
47988122|NCT04751396|OTHER|Survey Administration|Complete surveys
48505716|NCT06633445|PROCEDURE|botulinum toxin type A injection in lateral pterygoid muscle|"* Needle insertion guide will be placed on upper teeth.~* Needle will be inserted from needle insertion sleeve and 25-30 units of botulinum toxin type A will be injected.~* Aspiration will be done before injection, and then, the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle."
47988123|NCT04416503|OTHER|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
47988124|NCT00003752|DRUG|bexarotene|
47988125|NCT04689295|OTHER|exercise programme 1|Schroth three dimensional scoliosis therapy method
48355802|NCT04198311|BEHAVIORAL|CBT-I|CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
48144541|NCT04305496|DRUG|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
48355803|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 400 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
48355804|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 200 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
48355805|NCT06269406|OTHER|The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure|The combination of ibuprofen 400 mg and placebo 100 mg in patients after 2-4 molars procedure
48355806|NCT00289302|DEVICE|Cardiac resynchronization therapy device|
48355807|NCT03581565|OTHER|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
47988126|NCT04689295|OTHER|exercise programme 2|Traditional scoliosis exercises
47988127|NCT03675802|DRUG|misoprostol|giving misoprostol to this group
47988128|NCT03675802|DRUG|dinoprostone|giving dinoprostine
47988129|NCT02085187|OTHER|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
47988130|NCT02627430|DRUG|Hsp90 Inhibitor AT13387|Given IV
47988131|NCT02627430|OTHER|Laboratory Biomarker Analysis|Correlative studies
47988132|NCT02627430|OTHER|Pharmacological Study|Correlative studies
47988133|NCT02627430|DRUG|Talazoparib|Given PO
48144542|NCT02539576|DRUG|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
48666709|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"* Brief advise to quit smoking~* Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
48666710|NCT04107857|BEHAVIORAL|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
48355808|NCT00098865|DRUG|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
48666711|NCT04107857|BEHAVIORAL|Data Driven Feedback reports|-Feedback reports will be based on data
48666712|NCT02196922|DEVICE|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
48666713|NCT02196922|OTHER|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
48666714|NCT02128022|DRUG|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
48666715|NCT02128022|DRUG|Glibenclamide|Oral Glibenclamide 5mg
48666716|NCT00318682|DEVICE|FIBROSCAN|diagnostic examination of the hepato fibrosis
48666717|NCT05333926|DEVICE|MHNA-001|3-month digital therapy program designed to reduce the severity of IBS symptoms
48666718|NCT00004264|DRUG|amifostine trihydrate|
48666719|NCT00004264|DRUG|cisplatin|
48666720|NCT00004264|DRUG|docetaxel|
48666721|NCT02332811|DRUG|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
47988134|NCT03913884|PROCEDURE|Concentrated growth factor|CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
47988135|NCT03913884|OTHER|Non-Concentrated growth factor Group|To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
47988136|NCT00726076|BEHAVIORAL|WebEase|"Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
48355809|NCT00098865|DRUG|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
48355810|NCT04614194|DRUG|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
48355811|NCT04614194|DRUG|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
48666722|NCT02332811|DRUG|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
48666723|NCT06228950|BEHAVIORAL|Mindfulness-Based Stress Reduction|A therapeutic approach called mindfulness-based stress reduction, or MBSR, aims to reduce emotional and behavioral problems by fostering mindfulness, which is an impartial awareness of the present moment. MBSR will be an 8-week training course for students with visual impairment. MBSR training, translated and adapted in Urdu language that includes 8 audios and worksheets corresponding to each week. Worksheets to record home practice will be filled upon receiving oral feedback from the students with visual impairment. Face-to-face group-based sessions will be conducted weekly.
48666724|NCT05775250|DRUG|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
48666725|NCT05547672|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
48666726|NCT01928433|DRUG|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
48666727|NCT01928433|DRUG|Finafloxacin placebo i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
48666728|NCT01928433|DRUG|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
48666729|NCT01928433|DRUG|Finafloxacin placebo tablets once daily|Administered as four tablets
48666730|NCT01928433|DRUG|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
48666731|NCT01928433|DRUG|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
48666732|NCT01928433|DRUG|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
48666733|NCT01928433|DRUG|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
48666734|NCT00006384|BIOLOGICAL|recombinant interferon alfa|
47988137|NCT00726076|BEHAVIORAL|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
48144543|NCT04907383|OTHER|quality of life|QoL assessment
48144544|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
48144545|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
48666735|NCT00006384|DRUG|semaxanib|
48666736|NCT05820503|PROCEDURE|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
48666737|NCT05820503|PROCEDURE|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
48666738|NCT01786122|OTHER|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
48666739|NCT01786122|BEHAVIORAL|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
48666740|NCT05159674|DEVICE|Dexmedetomidine+electroacupuncture compound anesthesia|Dexmedetomidine and acupuncture were given together to induce anesthesia
48666741|NCT04445103|DIAGNOSTIC_TEST|Assessment of cardiac function|Echocardiographic examination and assessment of cardiac biomakers
48666742|NCT04155398|PROCEDURE|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
48666743|NCT02906111|DRUG|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
48666744|NCT02906111|PROCEDURE|vaginal surgery|Control Group
48666745|NCT00660218|DRUG|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
48666746|NCT00660218|BIOLOGICAL|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
48666747|NCT00660218|RADIATION|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
48666748|NCT02259114|DRUG|Birabresib|Birabresib 10, 20 and/or 40 mg oral capsules
47988138|NCT01382979|BEHAVIORAL|AlcoholEdu for College|Online course for college freshmen.
47988139|NCT01256554|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
47988140|NCT01256554|BEHAVIORAL|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
48144546|NCT02444962|DEVICE|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
48144547|NCT05253092|OTHER|Virtual mindfulness meditation|Subjects will participate in 30 minutes of a virtual mindfulness meditation session, totaling eight sessions.
48144548|NCT03737110|DRUG|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
48144549|NCT03737110|DRUG|Placebo|Placebo SC injections once weekly
48144550|NCT01052714|BEHAVIORAL|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
48144551|NCT04876430|DRUG|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR \< 50mL/min.
48144552|NCT03396445|DRUG|Boserolimab|IV infusion
48144553|NCT03396445|BIOLOGICAL|Pembrolizumab|IV infusion
48144554|NCT03396445|DRUG|Pemetrexed|IV infusion
48144555|NCT03396445|DRUG|Carboplatin|IV infusion
48144556|NCT03396445|DRUG|Nab-paclitaxel|IV infusion
48144557|NCT03822806|OTHER|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
48144558|NCT03102892|PROCEDURE|Scaling root planing|Treatment by scaling and root planing alone.
48144559|NCT03102892|PROCEDURE|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
48144560|NCT00490789|DRUG|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
48144561|NCT02579109|OTHER|memory test|
48144562|NCT01214070|OTHER|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
48666749|NCT06204484|OTHER|CAPEOX adjuvant therapy|In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
48666750|NCT06204484|OTHER|deferred CAPEOX adjuvant therapy|In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
48355812|NCT04844970|DRUG|Anamorelin Hydrochloride|Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
48355813|NCT04844970|DRUG|Placebo|Anamorelin placebo
48666751|NCT06204484|OTHER|mFOLFOXIRI intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
48666752|NCT05464602|OTHER|Intervention group Lavender|This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
47988141|NCT04765579|BEHAVIORAL|visual analogy scala|We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
47988142|NCT01026792|DRUG|Temsirolimus|Given IV
47988143|NCT01026792|OTHER|Laboratory Biomarker Analysis|Correlative studies
48144563|NCT01214070|BEHAVIORAL|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
48144564|NCT01214070|BEHAVIORAL|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
48355814|NCT02949687|PROCEDURE|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
48355815|NCT02946268|DRUG|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
47988144|NCT03902535|OTHER|Comprehensive Geriatric Assessment|Complete comprehensive geriatric assessment
47988145|NCT03902535|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
47988146|NCT03902535|OTHER|Questionnaire Administration|Complete questionnaires
47988147|NCT02059057|DEVICE|LVRC System|
47988148|NCT03387839|OTHER|Stress X-Ray|Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
47988149|NCT01973647|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
47988150|NCT01973647|BEHAVIORAL|COPD Education|Six weekly sessions of COPD education
47988151|NCT01973647|BEHAVIORAL|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
48666753|NCT05464602|OTHER|Intervention group Geranium|This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
48666754|NCT06113757|DEVICE|Signal Therapy provided by Dr.Biolyse device|Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
48355816|NCT00720720|DIETARY_SUPPLEMENT|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
48666755|NCT06113757|OTHER|Liquid Support Treatment|The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
48666756|NCT04863794|DRUG|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
47988152|NCT05590065|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
48355817|NCT00720720|DIETARY_SUPPLEMENT|placebo margarine|
47988153|NCT02592174|OTHER|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
47988154|NCT02592174|OTHER|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
47988155|NCT02592174|RADIATION|cerebral images sub-study|Standard magnetic resonance imaging
47988156|NCT01571414|DRUG|PA-824|200-mg tablets once a day
47988157|NCT01571414|DRUG|Efavirenz (EFV)|600-mg tablets once a day
47988158|NCT01571414|DRUG|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
47988159|NCT01571414|DRUG|Rifampin (RIF)|300-mg capsules once a day
47988160|NCT05239273|OTHER|Complex Decongestive Therapy|Phase 1 of CDT will be applied. This application consists of manual lymph drainage, skin care, compression bandage and exercises.
47988161|NCT05239273|OTHER|Control|No intervention
47988162|NCT02461355|BEHAVIORAL|Aphasia therapy|Aphasia therapy using a computerized scripting program
47988163|NCT02461355|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
48355818|NCT05119790|DRUG|[14C] BIIB122 ([14C] DNL151)|Oral dose
48355819|NCT00772980|DRUG|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
48355820|NCT00772980|DRUG|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
48355821|NCT01697189|BEHAVIORAL|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
48355822|NCT04752228|OTHER|Philadelphia ACE Survey|The Philadelphia ACE survey assesses the three major domains featured within the original ACE Study Questionnaire developed by Felitti et al. (abuse, neglect, and family dysfunction), in addition to five community-level stressors.
48144565|NCT01214070|BEHAVIORAL|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
48355823|NCT04752228|OTHER|Lifestyle Assessment|The Lifestyle Assessment questionnaire features the Short Form (36) Health Survey, Patient Health Questionnaire-9, General Anxiety Disorder-7 questionnaire, Seattle Angina Questionnaire-7, and modified Perceived Need for Card Questionnaire, which are validated questionnaires for the assessment of quality of life, depression, anxiety, angina, and perceived need for care, respectively.
48355824|NCT05435092|RADIATION|3D-reconstruction CT|Three dimensional CT (3D CT):Method of surface rendition of anatomy by means of a special computer software to capture 3D bone models used to improve the outcomes of Total Knee Arthroplasty (TKA).
48355825|NCT00083616|BIOLOGICAL|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
48355826|NCT00407420|DEVICE|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
48355827|NCT00407420|BEHAVIORAL|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
48144566|NCT03002194|DEVICE|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
48144567|NCT03002194|OTHER|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
48144568|NCT01329107|BEHAVIORAL|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care."
48144569|NCT02892318|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
48355828|NCT02411266|OTHER|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
48355829|NCT03928509|OTHER|No intervention|No intervention
48355830|NCT03108742|DEVICE|INSORB|dermal stapler for skin closure
48355831|NCT03108742|PROCEDURE|classic intradermal suture|intradermal suture for skin closure
47988164|NCT02461355|DEVICE|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
47988165|NCT03118154|OTHER|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
47988166|NCT01287897|DRUG|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
47988167|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
48144570|NCT02892318|DRUG|Guadecitabine|Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.
47988168|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
48355832|NCT05497622|DIAGNOSTIC_TEST|Quantitative Ultrasound|Ultrasound assessment of Trapezius muscle
48355833|NCT05497622|DIAGNOSTIC_TEST|Osteopathic TART Assessment|"Evaluation of the 4 diagnostic criteria:~1. Tissue Texture abnormality~2. Asymmetry~3. Restriction of Motion~4. Tenderness"
48355834|NCT05497622|PROCEDURE|Osteopathic Manipulation Treatment|Use of manual techniques such as soft tissue stretching, resisted isometric stretches, fascial relaxation and counter strain.
48355835|NCT01110928|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
48355836|NCT00320632|DRUG|Desipramine|
48355837|NCT03128255|OTHER|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
47988169|NCT04482842|DEVICE|Gene detection (CYP2C9*3, VKORC1)|Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
47988170|NCT04482842|DRUG|Warfarin Sodium|Warfarin is administered at a gene-guided dose or at a regular dose.
47988171|NCT03780868|PROCEDURE|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
48355838|NCT03039907|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty
48355839|NCT03371394|OTHER|no intervention|no intervention
48666757|NCT03243461|DRUG|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
48666758|NCT02604511|DRUG|Ibrutinib|
47988172|NCT03780868|PROCEDURE|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
47988173|NCT01156311|DRUG|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
48144571|NCT00004496|DRUG|alpha-melanocyte stimulating hormone|
48144572|NCT06309355|DRUG|YR001 ointment|The intervention is YR001 ointment on a range of body surface area for multiple topical administration
48144573|NCT06309355|OTHER|Placebo|The intervention is Placebo on a range of body surface area for multiple topical administration
48144574|NCT05414825|OTHER|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
48144575|NCT01084772|OTHER|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
48144576|NCT01084772|OTHER|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
48144577|NCT00861874|DRUG|Decitabine|20 mg/m2 IV, Days 1-5
48144578|NCT00861874|DRUG|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
48666759|NCT05857397|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
48666760|NCT05287321|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg with Aspirin 100mg
48666761|NCT06264635|BIOLOGICAL|Platelet-Rich-Plasma|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
48666762|NCT06264635|OTHER|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
48002675|NCT05016388|OTHER|Standard Model (SM)|The teams enrolled in the SM intervention will have a 22-hour training that integrates the current national clinical guide for Depression in Chile. This guide offers a staggered treatment according to the severity of the depression. After the training, the PHC teams will implement the depression treatment according to the SM.
48144579|NCT00455715|DRUG|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
48666763|NCT04047446|DRUG|Exparel 133 MG Per 10 ML Injection|10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
48666764|NCT04047446|DRUG|Dexamethasone|15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
48666765|NCT04768244|OTHER|maternal SARS-CoV-2 infection|positive PCR in nasopharinx and/or presence of antibodies in serum
48666766|NCT05326737|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
48666767|NCT05326737|OTHER|In hospital questionnaires|Patients are required to fill out the PCS questionnaire between on day -1 or +1.
48002676|NCT05611242|PROCEDURE|MT+CAS with IV-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added intravenous antiplatelet therapy.
48666768|NCT05326737|OTHER|Telephone contact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires DN4 and EQ5D5L.
48666769|NCT00448448|DEVICE|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
48355840|NCT01241318|DRUG|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
48355841|NCT01241318|PROCEDURE|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
47988174|NCT01693575|DEVICE|Pupil expansion with APX 100 device|Patients with small pupils (\<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
47988175|NCT00157703|DRUG|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
47988176|NCT02068443|DRUG|Alogliptin|Alogliptin tablets
48144580|NCT04728100|OTHER|LQT|Patients with LQT syndrome diagnosis.
48144581|NCT03137849|OTHER|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
48355842|NCT05701085|OTHER|Educational Intervention|The intervention will occur at a separate dedicated in-person visit with the patient navigator estimated to last 30-45 minutes. The Pre-Intervention Survey will be scored to generate a list of barriers identified for each patient. This list of barriers will be reviewed by the patient navigator prior to the intervention date. The patient will be asked to view educational videos on an iPad that correspond with each identified barrier. Afterwards, the patient navigator will lead a discussion based on the topics discussed.
48355843|NCT06010992|DRUG|Nitazoxanide|Nitazoxanide oral capsules 500 mg twice daily
48355844|NCT02499640|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
48355845|NCT00515905|DRUG|Sevoflurane/propofol|Sevoflurane/propofol
48144582|NCT03137849|OTHER|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
48144583|NCT03137849|OTHER|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
48355846|NCT03549585|OTHER|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
48505717|NCT06633445|PROCEDURE|botox injection in lateral pterygoid muscle|"* A 27- gauge needle electrode will be inserted lateral to the maxillary tuberosity, just above the maxillary molars to inject 25-30 units of botulinum toxin type A under electromyographic guidance.~* Aspiration will be done before injection, and then the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.~* The intramuscular injection will be confirmed when the electromyographic device produces a distinct loud sound."
48505718|NCT06633250|OTHER|Test Formula|Hydrolyzed rice protein formula
48505719|NCT06633250|OTHER|Control Formula|Commercially available extensively hydrolyzed cow's milk formula
48505720|NCT04777149|OTHER|transcranial Random Noise Stimulation (tRNS)|Two electrodes will be placed over the targeted areas on participant's head. A current of random frequency and intensity will be delivered. TRNS will be applied during the first 20 min of functional task practice.
48505721|NCT04777149|OTHER|transcranial Direct Current Stimulation (tDCS)|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered. TDCS will be applied during the first 20 min of functional task practice.
48505722|NCT04777149|OTHER|sham-stimulation|Two electrodes will be placed over the targeted areas on participant's head. A continuous low intensity current will be delivered for 1- 2 min.
48505723|NCT04784533|DRUG|CTP-543|Oral dosing
48505724|NCT04784533|DRUG|Placebo|Oral dosing
48505725|NCT01229579|DRUG|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
48505726|NCT01229579|OTHER|Placebo|2.5 ml placebo syrup daily with containing no elemental zinc from day 14 to 18 weeks of age.
48505727|NCT05831241|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
48666770|NCT00448448|OTHER|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
48666771|NCT04846595|OTHER|self questionnaire|Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region
48666772|NCT05894603|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
48666773|NCT05894603|DRUG|Molnupiravir|Molnupiravir
48355847|NCT04841681|BEHAVIORAL|Video-based Psychotherapy|"Participants in the group watched three short videos. Therapeutic elements in the three consecutive short videos included relaxation therapy, managing thoughts and feelings, and mindfulness. Each video has a duration of just over 10 minutes.~In the first video, the participants were introduced to the purpose and benefits of relaxation techniques. These included rhythmic breathing techniques, progressive muscle relaxation, imagining a comforting and quiet place, and positive self-talk. In the second video about managing thoughts and feelings, the participants were introduced to the notion of acceptance of their condition. They were invited to recognize the emergence of negative feelings and thoughts related to acceptance. In the last video about mindfulness, patients were introduced to three basic mindfulness skills: observation, elaboration, and participation."
48666774|NCT04845256|DEVICE|SOMAVAC 100 Sustained Vacuum System|Evaluate performance of sustained vacuum system compared to manual suction bulbs
48355848|NCT06277609|DRUG|Lu AF28996|Capsule
48355849|NCT06277609|DRUG|Acetylsalicylic Acid|Tablet
48666775|NCT03655067|BEHAVIORAL|CATCH-IT|The CATCH-IT internet program consists of 14 modules and exercises and activities based on best practices components of depression prevention. They will be instructed to complete at least 2 modules a week, over a period of 6 weeks. This would require at least 40 minutes per week (approximately 20 minutes minimum per module).
48666776|NCT05201807|DEVICE|Dailies Total 1 (DT1)|TEST Lens
48505728|NCT05831241|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
48144584|NCT04942288|OTHER|The first group is acupressure and massage, the second group is massage|In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
48355850|NCT06277609|DRUG|Mefenamic Acid|Tablet
48355851|NCT06277609|DRUG|Amoxicillin/clavulanic acid|Tablet
48355852|NCT01856179|DIETARY_SUPPLEMENT|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
48355853|NCT00150514|DRUG|Oralgen|
48355854|NCT00150514|PROCEDURE|Nasal biopsy|
48355855|NCT00150514|PROCEDURE|Nasal washing|
48355856|NCT00150514|PROCEDURE|Peak nasal inspiratory flow|
48666777|NCT01849276|DRUG|metformin hydrochloride|Given orally
48666778|NCT01849276|DRUG|cytarabine|Given IV
48666779|NCT01849276|OTHER|laboratory biomarker analysis|Correlative studies
48666780|NCT02590107|DIETARY_SUPPLEMENT|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
48355857|NCT04313309|OTHER|Integrative Yoga Therapy|Individualised intervention developed, consists of a six one to one sessions with patients, followed by home self practiced sessions. The intervention includes yoga movements, yoga breathing, relaxation techniques, reasoning, and other techniques designed to enhance awareness and acceptance of the psychological factors underlying the chronic pain problem.
48666781|NCT02590107|DIETARY_SUPPLEMENT|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
48666782|NCT02590107|DIETARY_SUPPLEMENT|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
48666783|NCT02590107|OTHER|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
48355858|NCT03944551|DEVICE|Bubble CPAP|Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
48355859|NCT03944551|OTHER|Standard Therapy|For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 \< 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
48355860|NCT00355615|DRUG|Rosuvastatin|oral
48355861|NCT00355615|DRUG|Placebo|oral
48355862|NCT01020994|DRUG|LAS41003|Once daily, topically
48355863|NCT01020994|DRUG|LAS189962|Once daily, topically
48505729|NCT06175988|OTHER|Visceral adiposity|Visceral adiposity assess by the visceral adiposity index
48505730|NCT00856375|DRUG|NKTR-102|IV every 3 weeks
48666784|NCT02008617|DRUG|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
48666785|NCT02008617|DRUG|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
48355864|NCT01020994|DRUG|LAS189961|Once daily, topically
48505731|NCT00856375|DRUG|irinotecan|IV every 3 weeks
48505732|NCT04799301|BEHAVIORAL|Diet with no soda|Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
48505733|NCT04799301|BEHAVIORAL|Diet with 50% of carb intake from soda|Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
48666786|NCT00001066|DRUG|Lamivudine|
48666787|NCT00001066|DRUG|Zidovudine|
48666788|NCT00001066|DRUG|Didanosine|
48666789|NCT06531681|DEVICE|MR-Linac|Radiation therapy with the MR-Linac
48666790|NCT03542617|DRUG|Dexamethasone|
48666791|NCT03542617|DRUG|Normal Saline Solution|
48666792|NCT02281045|DEVICE|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
48666793|NCT02281045|DEVICE|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
48666794|NCT02501421|BIOLOGICAL|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
48666795|NCT02501421|BIOLOGICAL|Placebo|Buffer
48666796|NCT02520778|DRUG|Navitoclax|Given PO
48666797|NCT02520778|DRUG|Osimertinib|Given PO
48666798|NCT06324656|PROCEDURE|crystallized phenol + platelet rich plasma application|"At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.~For enhanced healing, crystallized phenol + platelet-rich plasma application patients will receive platelet-rich plasma injections to minimize infection risk and promote tissue regeneration, all under strict sterilization to maintain cleanliness and efficacy."
48666799|NCT06324656|PROCEDURE|crystallized phenol|At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.
48666800|NCT03053128|DEVICE|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
48666801|NCT03053128|OTHER|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
48666802|NCT04348474|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
48666803|NCT04348474|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
48666804|NCT00002930|PROCEDURE|positron emission tomography|
48666805|NCT00002930|RADIATION|fludeoxyglucose F 18|
48666806|NCT05890209|DEVICE|Continuous Glucose Monitoring device|A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
48666807|NCT05943262|DEVICE|mesoscale nonlinear optical microscope|The mesoscale nonlinear optical microscope based on the principles of nonlinear optics and computed-algorithms can acquire large-area image within few minutes.
48666808|NCT03810976|DRUG|Eribulin, gemcitabine|Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
48666809|NCT02356237|OTHER|No episiotomy|Avoidance of episiotomy
48666810|NCT06095960|BEHAVIORAL|Telehealth MOM|Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.
48666811|NCT06095960|OTHER|Enhanced Standard of Care|Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.
48666812|NCT05105724|BIOLOGICAL|PRP|PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
48505734|NCT04799301|BEHAVIORAL|Diet with 20% of carb intake from soda|Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
48505735|NCT05372640|DRUG|Abemaciclib|Given PO
48666813|NCT01014871|DRUG|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
48144585|NCT02802111|DRUG|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
48505736|NCT05372640|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
48505737|NCT05372640|PROCEDURE|Biopsy|Undergo biopsy
48505738|NCT05372640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48666814|NCT01014871|DRUG|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
48666815|NCT01198626|DRUG|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
48666816|NCT01198626|DRUG|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
48666817|NCT01198626|DRUG|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
48666818|NCT01766102|PROCEDURE|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
48666819|NCT01766102|PROCEDURE|Standard Mammography|There is not an added device associated with this arm.
48666820|NCT02299245|DRUG|rosuvastatin|different dose of rosuvastatin treatment
48666821|NCT06326021|DRUG|autologous FL-33 CAR T therapy|Autologous FL-33 CAR T cells are infused intravenously.
48144586|NCT02802111|DRUG|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
48666822|NCT06326021|DRUG|prior-HSCT donor-derived FL-33 CAR T therapy|Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.
48666823|NCT00000621|DRUG|all trans retinoic acid|
48666824|NCT00000621|DRUG|13 cis retinoic acid|
48666825|NCT00000621|DRUG|placebo|
48666826|NCT02020161|DRUG|Atra|
48666827|NCT02020161|DRUG|Idarubicin|
48666828|NCT02020161|DRUG|methotrexate|
48666829|NCT02202564|PROCEDURE|LT|Orthotopic LT
48666830|NCT02202564|DRUG|ADV-TK|
48666831|NCT02202564|DRUG|ganciclovir|
48666832|NCT01397253|OTHER|Automated communication tools|"Automated communication tools will include:~* PCP notification of patient admission and location~* Data on medications begun on admission~* Automated alerts on changes in patient status and location while the patient is hospitalized~* Links to the EMR and to hospital physician contact information on all email alerts~* Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~* Automatic reporting to PCPs of test results pending at discharge~* Electronic delivery of final discharge summaries"
48666833|NCT00773188|DRUG|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
48666834|NCT00773188|DRUG|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
48666835|NCT00773188|DRUG|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
48144587|NCT03615833|DRUG|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
48144588|NCT01584167|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
48505739|NCT05372640|PROCEDURE|Diagnostic Imaging|Undergo imaging evaluation
48505740|NCT05248035|OTHER|Adult patient hospitalized in ICU|acquisition of dynamic parameters in addition to pupillary diameter, such as . pupillary diameter, variation of the pupillary diameter, pupillary constriction speed, pupillary dilatation speed, photomotor reflex latency, NPi and symmetry of pupillary responses after a standardized light stimulus
48505741|NCT01439009|DRUG|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
48505742|NCT01439009|DRUG|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
48505743|NCT04460482|DEVICE|Near-infrared spectroscopy (NIRS)|NIRS-guided PCI
48505744|NCT04460482|DEVICE|Angiography|Angiography guided PCI
48505745|NCT06455540|PROCEDURE|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
48505746|NCT02021513|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
48505747|NCT02021513|DIETARY_SUPPLEMENT|Olive Oil|Placebo group
48505748|NCT02398383|OTHER|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
48505749|NCT02398383|OTHER|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
48505750|NCT02398383|OTHER|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
48505751|NCT00292786|BEHAVIORAL|Walking Practice with Functional Electrical Stimulation|
48505752|NCT00292786|BEHAVIORAL|Walking Practice|
48505753|NCT06007911|DRUG|Navitoclax Dose Level -1|25 mg by mouth on days 1-7.
48505754|NCT06007911|DRUG|Navitoclax Dose Level 0|50 mg by mouth on days 1-10.
48505755|NCT06007911|DRUG|Navitoclax Dose Level 1|75 mg by mouth on days 1-10.
48505756|NCT06007911|DRUG|Navitoclax Dose Level 2|100 mg by mouth on days 1-10.
48505757|NCT06007911|DRUG|Venetoclax Dose Level -1|400 mg by mouth on days 1-7.
48505758|NCT06007911|DRUG|Venetoclax Dose Levels 0 to 2|400 mg by mouth on days 1-14.
48505759|NCT06007911|DRUG|Cladribine|5 mg/m\^2 intravenously days 1-5.
48505760|NCT06007911|DRUG|Cytarabine (Cladribine Low Dose Cytarabine Backbone)|20 mg/m\^2 subcutaneous days 1-10.
48505761|NCT06007911|DRUG|Cytarabine (CLAG-M Backbone)|1.5 g/m\^2 intravenously days 1-5.
48505762|NCT06007911|DRUG|Mitoxantrone|10 mg/m\^2 intravenously days 1-3.
48505763|NCT06007911|DRUG|Granulocyte Colony-Stimulating Factor|300 mcg subcutaneously days 1-5.
48505764|NCT04005014|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
48505765|NCT04051034|DIETARY_SUPPLEMENT|Omega 3|"Active: 1.25 g capsules/420 35-count bottles \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles \[1.25-gram high oleic safflower oil capsule\]"
48505766|NCT04051034|OTHER|Placebo|Active: 1.25 g capsules \[1.25-gram high oleic safflower oil capsule\] and heat therapy, increase internal body temperature 1.2 C above baseline.
48355865|NCT06202677|DEVICE|Self-guided program on obsessive compulsive disorder|This is an 8-day program that provides psychoeducational on what obsessions and compulsions are, and how to identify them. Subsequently, through a series of content learning and daily exercises that increase in difficulty, participants are guided to conduct exposure exercises while tolerating distress and refraining from compulsions. Participants are also guided to set goals and type down the specific content of their intrusive thoughts and compulsive behaviours to keep track of their progress. Each session of the program is estimated to be approximately 5 minutes.
48355866|NCT06202677|DEVICE|Self-guided program on cooperation|This 8-day program on cooperation aims to improve participants' collaborative skills and interpersonal wellness through a series of content learning and practice exercises. The time and duration of this program is matched to the obsessive compulsive disorder program to ensure that participants spend a similar amount of time and effort across both the intervention and active control conditions.
48355867|NCT03067064|OTHER|no intervention|Clinical examination
48355868|NCT06011785|DRUG|Silica 12CH|Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
48355869|NCT04420065|DEVICE|Preferential left ventricular pacing|Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
48355870|NCT04420065|DEVICE|Biventricular pacing|Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
48355871|NCT02029365|OTHER|Autoquestionnary|autoquestionnary completed during the consultation for infertility
48355872|NCT02029365|OTHER|semi-structured interview|phone interview
48355873|NCT03797144|DEVICE|CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement|The CD HORIZON® Legacy™ and Solera™ Fenestrated Screw Spinal System consists of a variety of cannulated screws with a series of fenestrations to allow polymethylmethacrylate (PMMA) bone cement (Fenestrated Screw Cement) to be injected into the treated site. The Fenestrated Screw Cement is used to augment screw fixation in subjects with compromised bone quality.
48355874|NCT05206682|DRUG|Leuprorelin|Leuprorelin will be used to postpone period after vaginal repair.
48355875|NCT04971759|DRUG|Levobupivacaine|Levobupivacaine 5%
48355876|NCT04971759|DRUG|Dexmedetomidine Hydrochloride|Levobupivacaine 5% + 1 µg/kg dexmedetomidine.
48355877|NCT04971759|DRUG|Fentanyl|Levobupivacaine 5% + 1µg/kg fentanyl
48505767|NCT06633484|OTHER|functional magnetic resonance imaging|non-diagnostic, non-invasive, passive measurement of the brain\&#39;s structure and function
48355878|NCT03478592|OTHER|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
48355879|NCT03478592|OTHER|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
48355880|NCT02139176|BEHAVIORAL|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
48355881|NCT02139176|BEHAVIORAL|patient referral|A patient agrees to recruit their partner using the invitation.
48355882|NCT02721654|DRUG|Plasma-Lyte 148®|Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution \& when administered intravenously it is a source of water, electrolytes \& calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
48355883|NCT02721654|DRUG|0.9% sodium chloride|The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile \& non-pyrogenic solution \& is indicated for extracellular fluid replacement \& in the management of metabolic alkalosis in the presence of fluid loss, \& for restoring or maintaining the concentration of sodium \& chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailability (absorption) of the active components is complete (100 per cent).
48355884|NCT01549028|BEHAVIORAL|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
48355885|NCT05162300|COMBINATION_PRODUCT|Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)|Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
48355886|NCT01550770|DRUG|propofol|peripheral IV of propofol at increasing dose levels
48355887|NCT00366106|DRUG|bortezomib|Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
48355888|NCT00366106|DRUG|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
48355889|NCT00366106|DRUG|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
48355890|NCT03596320|PROCEDURE|colonoscopy|description of the results of colonoscopy im managment of children with rectal bleeding
48505768|NCT01778686|DRUG|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
48505769|NCT01778686|OTHER|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
48505770|NCT01778686|DIETARY_SUPPLEMENT|Acute tryptophan depletion|
48505771|NCT05386030|COMBINATION_PRODUCT|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
48355891|NCT04589832|DRUG|PAC-1|Pharmacokinetic (PK) and pharmacodynamic (PD) assay for PAC-1 will be performed during Days 1 and 21 of Cycle 1. PAC-1 will be given on Day 1 of Cycle 1, withheld on Day 2 and Day 3 of Cycle 1 then reinitiated on Day 4 of Cycle 1 to continue for 21 days of the 28-day cycle. For each successive cycle, PAC-1 therapy will be initiated on Day 1 and continue for 21 days of the 28-day cycle.
48355892|NCT04589832|DRUG|Entrectinib|Pharmacokinetic and pharmacodynamic assay for entrectinib will be performed during Days 3 and 21 of Cycle 1. Entrectinib therapy will be withheld on Day 1 and Day 2 of Cycle 1, initiated on Day 3 of Cycle 1 and continue for the remainder of the 28 day cycle. For each successive cycle, entrectinib will be intiated on Day 1 and continue for 28 days of the 28-day cycle.
48355893|NCT05007301|DEVICE|geko device|Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.
48355894|NCT04446494|PROCEDURE|Identification and preservation of arm lymphatics (DEPART)|Indocyanine green was utilized to identify arm sentinel nodes, and 0.1 ml MB was injected into the arm sentinel nodes to reveal the subsequent-echelon nodes and lymphatics. Gross arm lymph nodes were examined by intraoperative partial frozen section and were removed if positive.
48355895|NCT00740688|PROCEDURE|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
48666836|NCT02133573|DRUG|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
48505772|NCT05386030|COMBINATION_PRODUCT|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
48355896|NCT00740688|PROCEDURE|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
48666837|NCT02133573|DRUG|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
48666838|NCT02081586|BEHAVIORAL|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
48505773|NCT00773630|DRUG|Cilostazol|100 mg Cilostazol
48505774|NCT02714426|BEHAVIORAL|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
48666839|NCT02081586|DEVICE|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
48355897|NCT01784211|DRUG|LY2605541|
48355898|NCT01784211|DRUG|Insulin Glargine|
48355899|NCT01579526|DRUG|FP01|comparison of different dosages
48355900|NCT01836029|DRUG|VTX-2337|TLR8 Agonist
48355901|NCT01836029|DRUG|Carboplatin|
48355902|NCT01836029|DRUG|Cisplatin|
48355903|NCT01836029|DRUG|5-fluorouracil|
48355904|NCT01836029|DRUG|Placebo|
48355905|NCT03261739|BIOLOGICAL|RYI-018|Anti-CB1 monoclonal antibody
48355906|NCT03261739|BIOLOGICAL|Placebo|Placebo
48355907|NCT00011128|BEHAVIORAL|Antiretroviral Treatment Interruption|
48355908|NCT06164743|DRUG|VVN461 Ophthalmic Solution 1.0%|Topical ocular drug
48355909|NCT06164743|DRUG|VVN461 Ophthalmic Solution 0.5%|Topical ocular drug
48355910|NCT06164743|DRUG|Vehicle|Topical ocular drug
48666840|NCT02081586|OTHER|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
48355911|NCT01830829|DRUG|Jalyn|study drug
48355912|NCT01830829|DRUG|Placebo|Placebo
48666841|NCT03243721|DIAGNOSTIC_TEST|7T MRI|A high field MRI that will take approximately one hour.
48666842|NCT03243721|DIAGNOSTIC_TEST|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
48666843|NCT02036346|DIETARY_SUPPLEMENT|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
48505775|NCT02714426|OTHER|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
48666844|NCT02036346|OTHER|Advise on calculated oral fluid requirements|
48666845|NCT02036346|OTHER|No nutritional advice will be given|
48666846|NCT05092750|DEVICE|FerroTraceTM|A magnetic
48355913|NCT00883792|PROCEDURE|Colonoscopy|Once-only colonoscopy screening
48355914|NCT05703490|DIAGNOSTIC_TEST|IADLSys system|Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.
48355915|NCT02828644|DEVICE|EVO|videogame-like digital therapy
48505776|NCT00391963|DEVICE|Bispectral index, Entropy|
48505777|NCT02686138|DRUG|Tenapanor|
48505778|NCT02686138|DRUG|Placebo|
48505779|NCT01567475|DRUG|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
48666847|NCT05092750|DRUG|indocyanine green (ICG)|Given by SC injection
48666848|NCT01212900|DRUG|Statins, HMG CoA|Statin therapy
47988177|NCT02068443|DRUG|Metformin hydrochloride|Metformin hydrochloride tablets
48355916|NCT04542395|BEHAVIORAL|Increasing Willingness and Uptake of COVID-19 Testing and Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 related risk and challenges and increase willingness and uptake in COVID-19 testing and vaccination.
48355917|NCT01582191|DRUG|Everolimus|Given PO
48505780|NCT03125980|DRUG|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)"
48666849|NCT02428829|PROCEDURE|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
48666850|NCT02428829|PROCEDURE|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
48666851|NCT04448951|OTHER|transcriptomics|transcriptomics
48666852|NCT04448951|OTHER|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
48666853|NCT04448951|OTHER|cytokines|peripheral blood cytokine analysis
48666854|NCT05231863|DRUG|TKIs|tyrosine kinase inhibitors based therapy
48666855|NCT03057184|BEHAVIORAL|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
48505781|NCT03125980|DRUG|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Q3W"
48505782|NCT02366429|BEHAVIORAL|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
48505783|NCT02366429|OTHER|TAU|Treatment as usual provided at antenatal clinics and other health care instances
48505784|NCT00014352|DRUG|docetaxel|
48505785|NCT00014352|DRUG|doxorubicin hydrochloride|
48666856|NCT00002529|DRUG|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
48505786|NCT00014352|DRUG|estramustine phosphate sodium|
48505787|NCT00014352|DRUG|ketoconazole|
48505788|NCT00014352|DRUG|warfarin|
48505789|NCT06292533|DEVICE|Er:YAG laser|Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
48505790|NCT06486805|DRUG|N acetyl cysteine|N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily accessible to the intracellular compartment
48505791|NCT06486805|OTHER|normal saline|the same volume of normal saline
48505792|NCT04691154|COMBINATION_PRODUCT|L606 inhalation suspension|L606 inhalation suspension, twice daily dosing
48505793|NCT05850806|DEVICE|The KmAsthma self-management smart phone app intervention|KmAsthma is a free app which enables users to track their symptoms, access their action plan, learn about asthma and set goals to make change
48505794|NCT01434810|DEVICE|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
48505795|NCT01434810|DEVICE|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
48666857|NCT00002529|DRUG|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
48666858|NCT00002529|DRUG|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
48666859|NCT00002529|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily.
48666860|NCT00002529|DRUG|toremifene|Toremifene 60 mg daily.
48666861|NCT02893891|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
48666862|NCT02893891|PROCEDURE|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
48666863|NCT02893891|PROCEDURE|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
48666864|NCT02893891|DEVICE|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
48666865|NCT01997164|DRUG|REGN910-3|
48355918|NCT01582191|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48666866|NCT01997164|DRUG|REGN910|
48666867|NCT01997164|DRUG|Intravitreal Aflibercept Injection (IAI)|
48666868|NCT05486156|OTHER|A Time with e-Nature|"Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group."
48666869|NCT04190368|OTHER|Team Clinic Care|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient.~Selected providers will be trained in the Team Clinic Care protocol for completing medical appointments. Team Clinic Care key components:~(1) Shared decision making: Providers, AYA, parent/caregiver will mutually agree on priorities for each medical visit using a shared decision making tool (2) Autonomy supportive care: Providers will be trained in skills building, patient centered key elements, intervention bites, reviewing plans, designed to support AYA autonomy and intrinsic motivation. AYA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach AYA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate. (4) Fidelity Review and process for self-assessment"
48666870|NCT04190368|OTHER|Standard Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
48666871|NCT01229566|DRUG|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
48666872|NCT05388851|OTHER|Educational Intervention|Complete educational training module
48666873|NCT05388851|OTHER|Questionnaire Administration|Complete questionnaire
48666874|NCT01020357|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
48666875|NCT01020357|DRUG|placebo|normal saline
48666876|NCT05978934|BEHAVIORAL|Static Lighting Condition (L1)|This indoor lighting condition keeps a constant brightness and correlated color temperature.
48666877|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L2)|This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.
48355919|NCT01582191|OTHER|Pharmacological Study|Optional correlative studies
48355920|NCT01582191|DRUG|Vandetanib|Given PO
48355921|NCT04893395|OTHER|Pharmacogenomic Screening|"First telehealth appointment:~1. Pharmacogenomics education and informed consent~2. Medical history~3. Sample collection~Second telehealth appointment:~1. Results of pharmacogenomic testing~2. Utility and limitations of pharmacogenomic testing~3. Patient-specific potential impacts on current or future medication therapies~4. Answering of patient questions~5. Referral to mental health provider(s) for treatment-specific recommendations"
48355922|NCT03170089|BEHAVIORAL|Oral Health Educational Program|Oral Hygiene methods learned
48505796|NCT05955196|PROCEDURE|BLOOD AND TUMOR|sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
48666878|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L3)|This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
48666879|NCT03026179|BEHAVIORAL|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
48666880|NCT01246960|BIOLOGICAL|Ramucirumab|Administered intravenously
48666881|NCT01246960|DRUG|Placebo|Administered intravenously
48666882|NCT01246960|DRUG|Oxaliplatin|Administered intravenously
48666883|NCT01246960|DRUG|Leucovorin|Administered intravenously
48666884|NCT01246960|DRUG|5-Fluorouracil|Administered intravenously
48666885|NCT03326908|DEVICE|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
48505797|NCT01025271|DRUG|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
48505798|NCT04851535|DRUG|Jaktinib Hydrochloride Tablets|Jaktinib 100mg Bid
48666886|NCT05892341|DEVICE|AQUACEL® Ag+ Extra™|Wound treatment with AQUACEL® Ag+ Extra™ dressing
48666887|NCT05892341|DEVICE|Cutimed® Sorbact®|Wound treatment with Cutimed® Sorbact® dressing
48666888|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
48666889|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
48666890|NCT03615885|DIETARY_SUPPLEMENT|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
48666891|NCT05943821|DRUG|Allopurinol 200 mg|The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
48505799|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
48505800|NCT00552578|DRUG|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
48505801|NCT01221363|BEHAVIORAL|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
48505802|NCT04137016|OTHER|Mobile application|
48505803|NCT05290727|OTHER|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
48505804|NCT05290727|OTHER|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
48666892|NCT05943821|DRUG|Optional intervention|"Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels \>5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up."
48666893|NCT05111067|GENETIC|DNA and whole transcriptome mRNA sequencing|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
47988178|NCT02068443|DRUG|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
48144589|NCT01584167|DEVICE|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
48144590|NCT05237869|DEVICE|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
48355923|NCT01427829|BEHAVIORAL|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
48355924|NCT01377038|OTHER|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
48355925|NCT04992000|OTHER|4-free app + PHN intervention|same mentioned in groups
48355926|NCT01944254|PROCEDURE|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
48355927|NCT01944254|PROCEDURE|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
48505805|NCT03940131|DRUG|Panitumumab|FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
48505806|NCT00529282|DRUG|Ceftobiprole Medocaril|500 mg every 8 hours
48505807|NCT00529282|DRUG|Cefepime with or without vancomycin|120-minute infusion \[250 mL\]
48505808|NCT04730037|DRUG|Edoxaban|- Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
48505809|NCT04730037|DRUG|Warfarin Potassium|- Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
48505810|NCT04730037|DRUG|Warfarin Potassium placebo|- Warfarin K 1 mg placebo tablets once daily
48505811|NCT04730037|DRUG|Edoxaban placebo|- Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
48505812|NCT02109653|DRUG|LGX818|Oral LGX818 300mg daily
48666894|NCT04362735|DRUG|Vedolizumab|Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.
48505813|NCT03654599|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
48505814|NCT03654599|BEHAVIORAL|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
48666895|NCT01765400|DRUG|Prasugrel 10 mg daily x 2 weeks|
48666896|NCT01765400|DRUG|Clopidogrel 75 mg daily x 2 weeks|
48666897|NCT02791243|DRUG|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
48666898|NCT02791243|DRUG|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
48666899|NCT02791243|DRUG|Negative Control|0.9% aqueous NaCl
48666900|NCT01846702|DRUG|Placebo|Given as a SC injection.
48144591|NCT05237869|OTHER|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
48355928|NCT01944254|PROCEDURE|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
48144592|NCT04020172|DRUG|Dobutamine|intraoperative fluid administration will be guided by cardiac output monitoring
48355929|NCT00218569|DRUG|Naltrexone|Naltrexone
48355930|NCT00218569|DRUG|Placebo|Placebo
48666901|NCT01846702|DRUG|LY3084077|Given as a SC injection.
48666902|NCT06563843|PROCEDURE|Robotic-assisted TKA|Robotic-assisted Total Knee Arthroplasty or total knee replacement is a surgical procedure using a robot to resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
48144593|NCT02584426|DEVICE|Ultrasonic Distribution of Cefazolin|
48355931|NCT05424744|BEHAVIORAL|Telemedicine Management of Hypertension|Telemedicine Management of high blood pressure using home blood pressure monitoring and telemedicine based hypertension self- management support and pharmacotherapy. This will be supplemented by support from community health workers.
48355932|NCT04853264|DEVICE|Ultrasound-guided peripheral venipuncture|Ultrasound-guided peripheral venipuncture performed by a proficient vascular access registered nurse. The procedure will be performed according to the standard operational protocol for ultrasound guided peripheral venipuncture instituted at the hospital where the study will be conducted. Site Rite 8 or Site Rite 5 ultrasound machines (Bard Access Systems, Inc., USA) will be used on the procedures.
48355933|NCT04853264|DEVICE|Conventional peripheral venipuncture|Conventional peripheral venipuncture performed by a registered nurse at the clinical inpatient unit. The procedure will be performed according to the standard operational protocol for peripheral venipuncture instituted in the hospital where the study will be conducted.
48666903|NCT06563843|PROCEDURE|Conventional TKA|Conventional Total Knee Arthroplasty or total knee replacement is a surgical procedure to manually resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
48666904|NCT05459662|DIETARY_SUPPLEMENT|oat based porridge|Consume one preparation per day, orally
48666905|NCT05459662|DIETARY_SUPPLEMENT|plant based preparation|Consume one preparation per day, orally
47988179|NCT05589233|BIOLOGICAL|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
48144594|NCT01260259|PROCEDURE|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
48666906|NCT03377751|PROCEDURE|Additional posterior wall isolation|"PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
48666907|NCT03377751|PROCEDURE|Voltage-guided substrate homogenization|"PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
48666908|NCT03377751|PROCEDURE|PVI only group|PVI will be performed in this arm.
48666909|NCT00133445|BIOLOGICAL|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
48666910|NCT00133445|BIOLOGICAL|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
48666911|NCT00133445|DRUG|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
48666912|NCT04676100|OTHER|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
48666913|NCT02180828|DRUG|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
48666914|NCT02180828|DRUG|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
48666915|NCT00360945|DRUG|cisplatin|
48666916|NCT00360945|DRUG|temozolomide|
48355934|NCT04984811|DRUG|efineptakin alfa|1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
48355935|NCT04984811|DRUG|Atezolizumab|1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
48666917|NCT00360945|GENETIC|fluorescence in situ hybridization|
48666918|NCT00360945|GENETIC|loss of heterozygosity analysis|
48666919|NCT00360945|OTHER|immunohistochemistry staining method|
48666920|NCT00360945|OTHER|laboratory biomarker analysis|
48666921|NCT00360945|RADIATION|radiation therapy|
48666922|NCT05548426|DRUG|Group B, Linezolid 10d|Oral Linezolid 600mg, taken twice a day for 10 days
48666923|NCT05548426|DRUG|Group A, Penicillin|Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
48666924|NCT03163511|COMBINATION_PRODUCT|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
48666925|NCT04443114|OTHER|Organ Donation Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
48666926|NCT04443114|OTHER|End of Life Care Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
48666927|NCT00773084|DRUG|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
48666928|NCT02825108|DRUG|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
48355936|NCT04428762|DEVICE|I-Port Advance use|participants will apply I-port advance for 4 weeks and will inject all insulin through the port. follow up 3 months with/ without i-port.
48355937|NCT02378610|OTHER|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
48666929|NCT02825108|DRUG|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
48666930|NCT02825108|PROCEDURE|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
48666931|NCT04056247|OTHER|Plasma sample collection|Collect at least two plasma samples
48144595|NCT01260259|PROCEDURE|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
48666932|NCT02060981|BEHAVIORAL|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
47988180|NCT05404919|DRUG|Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide|Anti-hepatitis B medications
47988181|NCT00000381|DRUG|Fluoxetine|
47988182|NCT05361993|DRUG|Drug Aripiprazole|Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
48144596|NCT02151084|DRUG|Selumetinib|
48144597|NCT02151084|DRUG|Cisplatin|
48144598|NCT02151084|DRUG|Gemcitabine|
48144599|NCT00003599|DIETARY_SUPPLEMENT|Vitamin E (AT)|Orally daily
48144600|NCT00003599|DRUG|Isotretinoin|Orally daily
48144601|NCT01404637|DRUG|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
48144602|NCT01404637|DRUG|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
48144603|NCT00651326|DRUG|bicalutamide|
48144604|NCT00651326|DRUG|buserelin|
48144605|NCT00651326|DRUG|flutamide|
48666933|NCT02060981|BEHAVIORAL|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
48666934|NCT02060981|BEHAVIORAL|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
48666935|NCT01138410|BIOLOGICAL|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
48666936|NCT05432310|COMBINATION_PRODUCT|A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme|Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan
48666937|NCT02398214|BEHAVIORAL|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to \< 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
48666938|NCT03549520|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
48666939|NCT04933149|DRUG|Ketamine Infustion|Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
48666940|NCT02526784|DRUG|degarelix|
48666941|NCT02109276|DEVICE|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
48666942|NCT02109276|DEVICE|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
48666943|NCT04423432|OTHER|Lower Extremity Resistance Exercise Training|3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
48666944|NCT04423432|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)"
48666945|NCT04423432|DEVICE|Electrotherapy + Heating|Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes
48666946|NCT04423432|PROCEDURE|Joint Mobilization|"1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization"
48666947|NCT04423432|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
48666948|NCT04423432|DIETARY_SUPPLEMENT|Glucoseamine/ Chondritin Sulfate Supplementation|Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
48666949|NCT00003156|DRUG|topotecan hydrochloride|
48666950|NCT00548535|PROCEDURE|Reliability of complication assessment|
48144606|NCT00651326|DRUG|goserelin|
48144607|NCT00651326|DRUG|leuprolide acetate|
48144608|NCT00651326|PROCEDURE|neoadjuvant therapy|
48144609|NCT00651326|PROCEDURE|quality-of-life assessment|
48666951|NCT04983784|BEHAVIORAL|walking|walking for 12 weeks at home
48666952|NCT04983784|OTHER|Routine care|Routine care
48666953|NCT00670644|OTHER|questionnaire administration|Completed self-report form
48666954|NCT00670644|OTHER|survey administration|Completed self-report form-other
48666955|NCT00670644|PROCEDURE|quality-of-life assessment|Completed self-report form qol
48666956|NCT02161536|DEVICE|Motus Cleansing System|
48666957|NCT06085547|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
48666958|NCT06085547|BEHAVIORAL|Rural-Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
48666959|NCT03748914|OTHER|Intervention Group|After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
48666960|NCT03748914|OTHER|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
48666961|NCT00011544|PROCEDURE|Performance Measure|
48666962|NCT03888560|DEVICE|Micro-osteoperforations|MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
48666963|NCT05106556|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.
48666964|NCT05106556|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
48666965|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
48666966|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
48144610|NCT00651326|RADIATION|radiation therapy|"46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks"
48144611|NCT00651326|DRUG|Docetaxel|
48144612|NCT04159545|OTHER|Qualitative and quantitative interviews|Qualitative semi-structured interviews and quantitative questionnaires
48144613|NCT05944094|DEVICE|Clorhexidine|Antiseptic treatment aimed at reducing potential bacterial overgrowth consisted of 10 days (1 box) of vaginal ovules of CLX (CumLaude CLX ® , CLX digluconate 0.2%) always starting between 10+0 and 16+0 weeks.
48144614|NCT05912049|DRUG|9MW3811 Injection|Single dose intravenously infused on day 1
48144615|NCT05912049|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
48144616|NCT01303471|DRUG|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
48505815|NCT03654599|BEHAVIORAL|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
48666967|NCT01214837|BIOLOGICAL|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
48666968|NCT05338138|DEVICE|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
47988183|NCT05361993|DEVICE|biofeedback|Biofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training（using the Infiniti3000A biofeedback system，Thought Technology Ltd.）.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.
47988184|NCT04273217|DRUG|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
48505816|NCT06633848|PROCEDURE|spinal surgery|spinal surgery
48144617|NCT00089609|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
48144618|NCT00089609|DRUG|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
48144619|NCT00089609|DRUG|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
48144620|NCT00089609|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
48505817|NCT03579927|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
48505818|NCT03579927|DRUG|Carmustine|Given IV
48505819|NCT03579927|DRUG|Cytarabine|Given IV
48505820|NCT03579927|DRUG|Etoposide|Given IV
48505821|NCT03579927|BIOLOGICAL|Filgrastim|Given SC
48666969|NCT05901610|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
48666970|NCT05901610|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive past events.
48666971|NCT05901610|DEVICE|Low-intensity Focused Ultrasound|A transducer device will use focused ultrasound energy to neuromodulate the insular cortex. The participant's brain will be mapped based on information from the CT and MRI scans, and the transducer will deliver brief ultrasound pulses to the insular cortex.
48666972|NCT05901610|DEVICE|Sham Low-intensity Focused Ultrasound|All of the same actions done during LIFU will be performed, but the device will be inactive.
48666973|NCT05093608|DRUG|Selinexor Pill|Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
48666974|NCT05093608|DRUG|Bevacizumab|Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
48666975|NCT05093608|DRUG|Atezolizumab|Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
47988185|NCT04273217|DRUG|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
48144621|NCT00089609|GENETIC|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
48144622|NCT00089609|OTHER|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
48144623|NCT00089609|OTHER|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
48505822|NCT03579927|DRUG|Melphalan|Given IV
48505823|NCT03579927|BIOLOGICAL|Rituximab|Given IV
48505824|NCT03579927|BIOLOGICAL|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
48505825|NCT00460135|BEHAVIORAL|resistance training|2 times a week resistance training
48666976|NCT03134040|BEHAVIORAL|Incentives (Rebate)|
48666977|NCT03134040|BEHAVIORAL|Incentives (Donation)|
48666978|NCT03134040|BEHAVIORAL|Feedback|
48666979|NCT02824679|DRUG|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
48666980|NCT02824679|DRUG|saline|0.9%normal saline
48666981|NCT00251433|DRUG|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
48666982|NCT05181345|OTHER|Sleep recording (at home)|Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.
48666983|NCT05181345|OTHER|Heat exposure|"The subjects will be exposed twice (2 different visits) to heat (45°C; 60-70% humidity rate) for 3 hours in a climate chamber.~The subjects will be equipped with various external sensors allowing the continuous recording of core temperature, mean skin temperature (9 skin measurement points), heart rate, cerebral electrical activity, cerebral oxygenation, skin vascular conductance (blood flow by laser-doppler), blood pressure and skin conductance.~Neurophysiological and cognitive exploration (NPCE) includes the Stroop test, the Psychomotor Vigilance Task (PVT) and the odd-ball test."
47988186|NCT06231212|DRUG|ECa 233|Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.
47988187|NCT06231212|DRUG|Ibuprofen|Ibuprofen group was given capsules containing 200 mg of ibuprofen
47988188|NCT06231212|OTHER|Placebo|Placebo-controlled group received capsules containing 250 mg of lactose
47988189|NCT00002733|BIOLOGICAL|aldesleukin|
47988190|NCT00002733|BIOLOGICAL|recombinant interferon alfa|
48144624|NCT00089609|OTHER|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
48355938|NCT04251377|DEVICE|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
48355939|NCT05481944|DIAGNOSTIC_TEST|MRI in patients|Injected MRI
48355940|NCT05481944|DIAGNOSTIC_TEST|MRI in healthy volunteers|non injected MRI
48505826|NCT00919854|DRUG|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and \<20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
48505827|NCT00919854|DRUG|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
48505828|NCT01173081|DRUG|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
48505829|NCT01173081|DRUG|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
48505830|NCT03048552|BEHAVIORAL|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
48666984|NCT05181345|OTHER|Normal sleep|"The night before one of the two heat exposures (first visit for the Normal sleep first group and second visit for the Reduced sleep first group), the participants will have a normal night at home. The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
48666985|NCT05181345|OTHER|Sleep restriction|"The night before one of the two heat exposures (first visit for the Reduced sleep first group and second visit for the Normal sleep first group), the participants' sleep will be restricted. The sleep restriction will correspond to a reduced sleep period with a bedtime of 3 hours (04:00 - 07:00). This night of sleep restriction will be carried out in a sleep apartment (at the lab). The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
48666986|NCT01871376|DRUG|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
48355941|NCT03908268|BEHAVIORAL|Family Nurture Intervention (FNI)|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will attend eight group FNI sessions within sixteen weeks.
48666987|NCT03306550|DRUG|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
47988191|NCT00002733|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
47988192|NCT00002733|DRUG|cimetidine|
47988193|NCT03564145|DRUG|S5G4T-1|Once a day topical cream
47988194|NCT04019314|PROCEDURE|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
47988195|NCT04019314|PROCEDURE|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
47988196|NCT02249533|OTHER|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
47988197|NCT06366321|OTHER|relining technique|construction of complete denture by flasking and casting the relining impression
48144625|NCT04987528|DIAGNOSTIC_TEST|Aminoterminal type III peptide of procollagen|Serial Measurement of PIIINP in serum and/or BAL
48144626|NCT04987528|DIAGNOSTIC_TEST|Lung computed tomography|Screening for the presence of reticulation or bronchiectasia within lung parenchyma
48144627|NCT05175794|DIAGNOSTIC_TEST|Xpert® MTB/XDR|The Xpert MTB/XDR Assay, performed on the GeneXpert Instrument Systems, is a nested real-time polymerase chain reaction(PCR) in vitro diagnostic test for the detection of extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) complex DNA in unprocessed sputum samples or concentrated sediments prepared from sputum. In specimens where MTB is detected, the Xpert MTB/XDR Assay can also detect isoniazid (INH) resistance associated mutations in the katG and fabG1 genes, oxyRahpC intergenic region and inhA promoter; ethionamide (ETH) resistance associated with inhA promoter mutations only; fluoroquinolone (FLQ) resistance associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR); and second line injectable drug (SLID) associated mutations in the rrs gene and the eis promoter region.
48144628|NCT03315338|DRUG|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
48144629|NCT03315338|DRUG|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
48144630|NCT03315338|DRUG|Glucose|75 g in 300 mL solution, orally administered
48505831|NCT02138058|DRUG|Topiramate|
48505832|NCT02138058|BEHAVIORAL|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
48505833|NCT06436066|OTHER|Self-Acupressure|"Applications include the following parameters;~1. Patient Information Form (before and after application)~2. Neuropathic Pain Questionnaire - DN4 (before and after application)~3. Neuropathic Pain Questionnaire - Short Form (before and after application)~4. Providing self-acupressure training (before application)~5. Delivery of the self-acupressure training booklet (before application)~6. Sending weekly reminder messages (during implementation)~7. Calling the patient for a check-up after 3 months and re-evaluating with the same scales (After the application)~8. Self-Acupressure - Satisfaction Evaluation Form with Visual Analogue Scale (After application)"
48666988|NCT03306550|DRUG|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
48666989|NCT06561802|DIAGNOSTIC_TEST|GCF and saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.
48666990|NCT04754464|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water
48666991|NCT04754464|DIETARY_SUPPLEMENT|microcrystalline cellulose|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
48144631|NCT03315338|DRUG|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
48144632|NCT03315338|DRUG|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
48144633|NCT03315338|DRUG|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
48144634|NCT03315338|DRUG|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
48144635|NCT03315338|DRUG|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
48144636|NCT03315338|DRUG|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
48355942|NCT03908268|BEHAVIORAL|Standard Children's Learning Center (CLC) Program|Typical, age-tailored CLC curriculum taught by CLC teachers. Children attend CLC as usual and parents do not take part in group sessions.
48505834|NCT02554565|PROCEDURE|Tumor biopsy|Tumor biopsy before treatment
48505835|NCT02554565|PROCEDURE|Blood sampling|Blood sample before, during and after treatment
48505836|NCT05347212|DRUG|Nivolumab|Given by IV
48505837|NCT05347212|DRUG|Relatlimab|Given by IV
48505838|NCT01005277|OTHER|Laboratory Biomarker Analysis|Correlative studies
48505839|NCT06043687|DRUG|Dentifrice Paste|Scaling and Root planing followed by dentifrice usage
48505840|NCT04916444|DEVICE|rTMS|repetitive transcranial magnetic stimulation is a painless, noninvasive form of neurostimulation. This study uses an accelerated protocol in which the neurostimulation pulses are delivered in 4 sessions per day over 4 consecutive days (16 total sessions). Active or sham rTMS will be provided at 9 weeks following botox injections.
48505841|NCT03877991|DRUG|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
48666992|NCT00413114|DRUG|Obatoclax mesylate (GX15-070MS)|
48666993|NCT00016354|DRUG|benzoylphenylurea|
48505842|NCT03877991|DRUG|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
48666994|NCT05829876|OTHER|High Frequency ECG Mapping|A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.
48666995|NCT05829876|OTHER|Q-LV Measurement|Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.
48666996|NCT03929692|BEHAVIORAL|Multi-layer health promotion program|
48666997|NCT03929692|OTHER|Standard health education|
48666998|NCT06173089|DEVICE|Remote monitoring|Remote monitoring for patients with an ICD/CRT device
48666999|NCT06297148|OTHER|Self-management|"Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.~Participants will have access to study material, including exercise alternatives and a podcast."
48667000|NCT06297148|OTHER|Usual care|Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
48667001|NCT02803385|OTHER|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
48355943|NCT04829864|BEHAVIORAL|STEP|"The program is offered by two facilitators to groups of three to seven women, in-person or online. The program is divided in three phases entitles Becoming a mother; A look at my own history and Looking ahead. The first phase aims to explore and normalize the emotions experienced by the participants in the course of their pregnancy and to support the use of healthy emotion regulation strategies. The second phase aims to support mentalization of trauma, by discussing the nature of trauma and its impact; by validating participants' feelings as understandable responses to trauma; by supporting a reflection on positive and harsh experiences with significant others and the ways both types of experiences influenced participants' mental states; and identifying how participants coped with trauma. In the last phase, discussions focus on participants' needs and strengths, on available resources to support resilience and envision positive and challenging moments with the child."
48667002|NCT02803385|OTHER|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
48667003|NCT01019265|DRUG|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
48667004|NCT03175029|DRUG|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
48667005|NCT03175029|DRUG|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
48667006|NCT06278454|DRUG|NRT6008 Injection + Systematic chemotherapy|"-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and estimated tumor average absorbed dose."
48667007|NCT05512624|BEHAVIORAL|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
48667008|NCT04544306|OTHER|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
48667009|NCT00057161|BEHAVIORAL|Coordinated Representative Payeeship with Case Management|
48667010|NCT00948350|PROCEDURE|awake intubation|two anesthesia techniques
48667011|NCT04278404|DRUG|The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:|The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
48667012|NCT00657267|DRUG|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
48667013|NCT00918619|DEVICE|Sangustop|Application of Sangustop haemostatic agent on resection area
48667014|NCT00918619|DRUG|Tachosil|Application of Tachosil fibrin sealant on resection area
48667015|NCT06426979|DRUG|Methotrexate|Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.
48667016|NCT06426979|DRUG|Letrozole|FEMARA 2.5 mg tablets two tablets daily
48667017|NCT00387088|DEVICE|Respimat|
48667018|NCT00387088|DRUG|Tiotropium|
48667019|NCT02791464|BEHAVIORAL|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
48667020|NCT02114645|DRUG|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
48667021|NCT02114645|DRUG|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
48505843|NCT03877991|DRUG|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
48355944|NCT02837549|OTHER|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
47988198|NCT06366321|OTHER|CAD/CAM milling technique|construction of complete denture by milling of the scanned relining impression
47988199|NCT01982747|DRUG|MGN-Placebo|
48505844|NCT02556463|DRUG|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
48505845|NCT02556463|BIOLOGICAL|durvalumab|Subjects will receive durvalumab every 4 weeks
48505846|NCT04244578|DEVICE|Active tDCS|Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
48505847|NCT04244578|DEVICE|Sham tDCS|Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
48505848|NCT06551714|PROCEDURE|Phase 1 cardiac rehabilitation|"Day 1:Patients were informed about the surgery, positioning and mobilization.Range of motion (ROM), respiratory control, diaphragmatic breathing, pursed lip breathing, thoracal expansion exercises, assisted coughing,forced expiration techniques, which are the components of active breathing techniques cycle (ABTC), were taught.The use of incentive spirometry (IS) was demonstrated.Patients were performed 10 repetitions of IS exercises, and 5 repetitions ABTC and were asked to repeat them every hour.The patient was made to sit for 10 minutes and was walked 60 meters twice a day.~2:ROM, IS and diaphragmatic breathing exercises were applied 10 times each.ABTC was repeated in 5 sets. 120 meters was walked 5 times during the day.~3:Sitting time was increased to 30 minutes and walking distance was increased to 240 meters.5 steps were climbed.~4:Walking distance was increased to 360 meters.One flight of stairs was climbed.Discharge training was given."
48144637|NCT03315338|DRUG|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
48144638|NCT03315338|DRUG|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
48144639|NCT03315338|DRUG|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
48144640|NCT03315338|DRUG|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
48144641|NCT03315338|DRUG|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
48144642|NCT03315338|DRUG|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
48144643|NCT03315338|DRUG|Placebo oral capsule|Placebo capsules, orally administered
48144644|NCT03315338|DRUG|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
48144645|NCT06499142|DEVICE|Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.|"The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample. The Parakeet is a point of care test completely controlled by the surgeon and operating team. It uses the scientific principle of Lateral Flow of antibody-antigen-conjugate complexes being arrested in a Test Line."
48144646|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
48144647|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
48144648|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
48144649|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
48144650|NCT04990856|PROCEDURE|Exercise|Tumor blood flow after acute exercise
48144651|NCT03015220|DRUG|Semaglutide|Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
48355945|NCT06135766|BEHAVIORAL|A Lust for Life|A Lust for Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
48355946|NCT06135766|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life (ALFL) programme.
47988200|NCT01982747|DRUG|Placebo-MGN|
48144652|NCT03015220|DRUG|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
48144653|NCT06330116|DEVICE|IQoro|Please refer to arm/group description for information
48144654|NCT06330116|DEVICE|eXciteosa|Please refer to arm/group description for information
48144655|NCT06330116|BEHAVIORAL|Grouptraining|Please refer to arm/group description for information
48144656|NCT03730038|DRUG|Treatment of pitavastatin 4 mg qd for 12 weeks|Treatment of pitavastatin 4 mg qd for 12 weeks
48144657|NCT03730038|BEHAVIORAL|Life-style modification|Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
48355947|NCT04802928|DRUG|Isoniazid 300 milligram|Tablets 150 milligram b.i.d.
48355948|NCT04802928|DRUG|Placebo|Placebo
48355949|NCT00370825|DRUG|Combination therapy with AmBisome and miltefosine|
48355950|NCT01911884|BEHAVIORAL|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
48355951|NCT00175318|BEHAVIORAL|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
47988201|NCT00000278|DRUG|Disulfiram|
48144658|NCT03542747|DEVICE|Time to ventilation with the iLTS|Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
48144659|NCT03542747|DEVICE|Time to ventilation with the Fastrach|Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
48144660|NCT04588207|DRUG|Urea|"Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day."
48144661|NCT05922774|DEVICE|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
48144662|NCT01497184|PROCEDURE|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
48144663|NCT01497184|GENETIC|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
48667022|NCT02114645|DRUG|4 mg oral estradiol valerate|estrofem is given twice a day
48667023|NCT05420571|PROCEDURE|digital impression|3D printed models after digital impressions
48144664|NCT02827201|DRUG|FOLFIRI.3|For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
48144665|NCT02827201|DRUG|nab-paclitaxel+ gemcitabine|For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
48144666|NCT05469607|DEVICE|Vagus Nerve Stimulator|The device consists of implantable (inside the body) and external (outside the body) components. Implantable components consist of a stimulating/recording electrode assembly that is placed around the vagus nerve in the abdomen, between the diaphragm and the stomach, a cable connecting the electrode assembly to an implantable pulse generator (IPG) that generates the stimulus and records nerve responses. The external components include a Clinical Control/Review Tool (used by the study team after implantation to adjust and periodically review the stimulation settings) and a Patient Control Unit and Charger (to turn on/off the system and perform limited adjustment of the stimulation strategy).
48667024|NCT05420571|PROCEDURE|alginate impression|Alginate impressions after plaster model infusion to make models
48667025|NCT00968409|RADIATION|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
48667026|NCT00968409|OTHER|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
48667027|NCT00968409|OTHER|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
48667028|NCT00968409|DRUG|F18-FFNP|injection of F18-FFNP
48667029|NCT01585727|PROCEDURE|TME|Total mesorectal excision
48144667|NCT00407498|DRUG|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
48355952|NCT04728880|DRUG|Remdesivir|This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study we will analyze the data collected during treatment.
48667030|NCT01585727|PROCEDURE|TME|Total mesorectal excision
48667031|NCT01585727|PROCEDURE|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
48667032|NCT02645864|DRUG|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
48667033|NCT02645864|DRUG|Irinotecan|150mg/m\^2 i.v. q2w
48667034|NCT05170971|OTHER|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times
48667035|NCT01295710|BIOLOGICAL|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
48667036|NCT01295710|BIOLOGICAL|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
48667037|NCT00859833|DRUG|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
48667038|NCT00859833|DRUG|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
48667039|NCT02692196|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
48667040|NCT02862119|PROCEDURE|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
48667041|NCT02862119|OTHER|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
48667042|NCT01162759|BEHAVIORAL|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
48144668|NCT02006641|DRUG|Placebo|Once daily, matching placebo capsules, orally
48144669|NCT02006641|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
48144670|NCT03692871|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
48144671|NCT03692871|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
48144672|NCT00614614|BIOLOGICAL|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
48144673|NCT00614614|BIOLOGICAL|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
48144674|NCT00614614|BIOLOGICAL|Infanrix®|One dose as intramuscular injection
48667043|NCT00214565|DRUG|Galida|
48667044|NCT06527885|DRUG|Lurasidone|Patients treated with Lurasidone in according to routine clinical practice, in Italy
48667045|NCT06220110|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
48667046|NCT06220110|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
48667047|NCT05962944|DEVICE|Olympus Cellsens software|Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
48667048|NCT02441894|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
48144675|NCT00614614|BIOLOGICAL|ActHIB®|Three doses in the priming phase as intramuscular injection
48144676|NCT00614614|BIOLOGICAL|Pediarix®|Three doses in the priming phase as intramuscular injection
48144677|NCT01995292|DEVICE|bronchoscope|
48144678|NCT01995292|DEVICE|Enk Fiberoptic Atomizer|
48144679|NCT01695044|DRUG|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
48144680|NCT04818476|PROCEDURE|diagnostic endoscopic resection|diagnostic endoscopic resection
48144681|NCT03944889|DRUG|Capsaicin|Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
48144682|NCT03944889|DEVICE|Delsys Trigno Galileo System|This device is a wireless surface EMG device.
48144683|NCT03944889|DEVICE|Cadwell Sierra Wave|Intramuscular EMG recording machinery
48144684|NCT03944889|DEVICE|Sonosite Ultrasound Machine|Ultrasound System
48144685|NCT03944889|DEVICE|Goniometer|A device to measure angular position
48144686|NCT00188812|DRUG|donepezil hcl|
48144687|NCT05149950|BEHAVIORAL|Active internet treatment|The patient gets access to the internet treatment via a secure login to 1177 The care guide e-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
48144688|NCT02393976|DIETARY_SUPPLEMENT|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
48144689|NCT02393976|DIETARY_SUPPLEMENT|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
48144690|NCT05230433|DIETARY_SUPPLEMENT|High-fat Challenge|The shake will be composed of a mixture of BOOST Glucose Control(R) (Nestlé Products) supplemented with palm oil. Each participant will consume a volume of liquid equivalent to 25% of their estimated daily caloric needs, calculated by the USDA Dietary Reference Intakes using a moderate activity factor.
48144691|NCT00278499|BEHAVIORAL|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
48144692|NCT00278499|BEHAVIORAL|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
48144693|NCT03093532|OTHER|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
48144694|NCT03093532|OTHER|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
48144695|NCT02346357|PROCEDURE|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
48144696|NCT02346357|DRUG|Ropivacaine|
48144697|NCT02346357|DRUG|Placebo Saline|
48144698|NCT02673866|DRUG|DS-1971a|
48667049|NCT02441894|DRUG|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
48667050|NCT02441894|DRUG|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
48144699|NCT02673866|DRUG|placebo|
48144700|NCT02673866|DRUG|pregabalin|pregabalin
48144701|NCT02224755|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
48144702|NCT02224755|DEVICE|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
48144703|NCT00161122|BIOLOGICAL|trivalent inactivated influenza vaccine|
48144704|NCT00161122|BIOLOGICAL|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
48144705|NCT01567007|BEHAVIORAL|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
48355953|NCT02311140|OTHER|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
48667051|NCT02441894|DRUG|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
48355954|NCT02477800|DRUG|Aducanumab (BIIB037)|Low dose
48355955|NCT02477800|DRUG|Aducanumab (BIIB037)|High dose
48355956|NCT02477800|DRUG|Placebo|Placebo
48355957|NCT02906098|BEHAVIORAL|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
48667052|NCT02441894|DRUG|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
48667053|NCT02441894|DRUG|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
48667054|NCT02441894|DRUG|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
48355958|NCT02906098|BEHAVIORAL|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
48355959|NCT00765830|DRUG|vildagliptin|50mg qd
48355960|NCT00765830|DRUG|Placebo|qd
48355961|NCT00293319|BIOLOGICAL|filgrastim|
48355962|NCT00293319|RADIATION|iobenguane I 131|
48355963|NCT00912496|BIOLOGICAL|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
48355964|NCT00912496|BIOLOGICAL|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
48355965|NCT00912496|DRUG|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
48355966|NCT04210232|DEVICE|TECNIS® TORIC II Intraocular Lens (IOL)|Surgeons will perform standardized, small-incision, cataract surgery and implant in one or both eyes the study lenses.
48355967|NCT00675129|BEHAVIORAL|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
48355968|NCT00675129|BEHAVIORAL|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
48355969|NCT00736450|BIOLOGICAL|oblimersen sodium|Given IV
48355970|NCT00736450|BIOLOGICAL|rituximab|Given IV
48355971|NCT00736450|DRUG|cyclophosphamide|Given IV
47988202|NCT01053689|DRUG|Glimepiride tablets 1 mg|
47988203|NCT05749445|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
47988204|NCT03542344|DRUG|BI 1015550|Single rising oral dose
47988205|NCT03542344|DRUG|Placebo|Single rising oral dose
47988206|NCT03949205|OTHER|Leg Extension Isometric Training|The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
48355972|NCT00736450|DRUG|doxorubicin hydrochloride|Given IV
48355973|NCT00736450|DRUG|vincristine sulfate|Given IV
48355974|NCT00736450|DRUG|prednisone|Given orally
48355975|NCT00736450|PROCEDURE|biopsy|Correlative studies
48355976|NCT00736450|GENETIC|microarray analysis|Correlative studies
48355977|NCT00736450|OTHER|immunohistochemistry staining method|Correlative studies
48355978|NCT00736450|GENETIC|gene expression analysis|Correlative studies
48355979|NCT00736450|GENETIC|cytogenetic analysis|Correlative studies
48355980|NCT02390362|DRUG|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
48355981|NCT02390362|DRUG|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
48355982|NCT00571051|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week course in mindfulness training
48355983|NCT05685849|DEVICE|Echocardiography|Maternal and fetal echocardiography：Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of five echocardiographic examinations will be performed in the first trimester(11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester(29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
48355984|NCT03376776|PROCEDURE|Vitrectomy|
48355985|NCT02442375|RADIATION|standard dose prescription|"* standard elective dose~* no intermediate dose-level~* visual interpretation of FDG-PET-scan"
48355986|NCT02442375|RADIATION|FDG-PET guided gradient dose prescription|"* de-escalation of elective dose~* intermediate dose-level~* standardized methods to evaluate FDG-PET-scan"
48355987|NCT03623204|OTHER|Dyspnea evaluation|
48355988|NCT02541994|DEVICE|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
48355989|NCT02541994|DEVICE|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
48355990|NCT02736942|PROCEDURE|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
48355991|NCT02736942|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
48355992|NCT04139629|DIAGNOSTIC_TEST|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
48667055|NCT01368614|DEVICE|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
48667056|NCT01368614|DEVICE|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
48667057|NCT01368614|DEVICE|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
48667058|NCT03190122|PROCEDURE|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
48667059|NCT00360139|DEVICE|Sculptra Injection|
48667060|NCT04062058|RADIATION|SIB-IMRT|45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target
48667061|NCT04062058|DRUG|S-1|40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
48667062|NCT04062058|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
47988207|NCT05754515|PROCEDURE|target controlled infusion (TCI) group|"Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation."
48144706|NCT01567007|BEHAVIORAL|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
48144707|NCT01567007|BEHAVIORAL|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
48667063|NCT04062058|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
48667064|NCT00151021|BEHAVIORAL|Tailored web-based walking program|
47988208|NCT05882240|OTHER|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
47988209|NCT01754233|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
47988210|NCT03705507|DRUG|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
47988211|NCT03705507|DRUG|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
47988212|NCT06363006|DRUG|TKI+Cardunilimab|Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience
47988213|NCT00130416|BEHAVIORAL|E-mail coaching to improve patient communication with doctor|
47988214|NCT01114165|OTHER|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
47988215|NCT01114165|OTHER|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
47988216|NCT02177045|DRUG|Sonovue, Bracco|Intravenous injection
47988217|NCT04382573|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
48144708|NCT02237937|DRUG|Paroxetine|
48144709|NCT02237937|DRUG|Sertraline|
48144710|NCT02237937|DRUG|Citalopram|
48144711|NCT02237937|DRUG|Venlafaxine|
48667065|NCT06348095|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
48667066|NCT06348095|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
48667067|NCT06127238|DRUG|ST-1898 tablets|Supplied as 5 mg and 40 mg tablets
48667068|NCT02712788|DRUG|Milrinone|
48144712|NCT02237937|DRUG|Amitriptyline|
48667069|NCT02712788|DRUG|Placebo|
48667070|NCT01402310|OTHER|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
47988218|NCT00197730|DRUG|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
47988219|NCT00197730|DRUG|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
47988220|NCT05882799|PROCEDURE|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
48144713|NCT02237937|DRUG|Escitalopram|
48144714|NCT02237937|DRUG|Amitriptylinoxide|
48144715|NCT02237937|DRUG|Nortriptyline|
48144716|NCT02237937|DRUG|Trimipramine|
48144717|NCT04775537|DEVICE|OssiMend™ Bioactive Moldable|Lumbar Spine fusion with OssiMend™ Bioactive Moldable
48667071|NCT06400784|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
48667072|NCT06164158|OTHER|Procedural Videos|A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.
48667073|NCT06164158|OTHER|No procedural videos|No procedural videos
48667074|NCT01352884|DRUG|AMP-224|Escalating doses of AMP-224
47988221|NCT05882799|PROCEDURE|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
48355993|NCT04139629|DRUG|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
48355994|NCT00822640|DEVICE|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
48667075|NCT01352884|DRUG|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
48355995|NCT01657149|PROCEDURE|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
48355996|NCT01657149|PROCEDURE|individual physiotherapy only|individual physiotherapy only
48355997|NCT02458742|DRUG|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
48667076|NCT04989361|PROCEDURE|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
48667077|NCT04989361|PROCEDURE|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
47988222|NCT05492331|OTHER|Music Therapy|Patient preferred artist or music genre to be playing from an iPad
47988223|NCT02902185|DRUG|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
47988224|NCT02902185|DRUG|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
47988225|NCT06313970|DRUG|QL1706|QL1706 5mg/kg，IV，D1, Q3W
47988226|NCT06313970|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W
47988227|NCT06313970|DRUG|Gemcitabine|gemcitabine，1000mg/m2，IV，D1、8；Q3W.
47988228|NCT06313970|DRUG|Bevacizumab|bevacizumab, 7.5mg/kg，IV，D1；Q3W.
47988229|NCT02964962|DEVICE|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
47988230|NCT02208947|BEHAVIORAL|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
47988231|NCT02208947|BEHAVIORAL|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
47988232|NCT00636909|DRUG|Cyclophosphamide|preparative cytoreduction
47988233|NCT00636909|DRUG|fludarabine|preparative cytoreduction
47988234|NCT00636909|DRUG|cyclosporine|immunosuppressive therapy
47988235|NCT00636909|DRUG|methotrexate|immunosuppressive therapy
47988236|NCT00636909|BIOLOGICAL|G-CSF|foster engraftment
48144718|NCT03080350|DRUG|Fentanyl sublingual|Fentanyl sublingual
48144719|NCT03080350|DRUG|Fentanyl ev|Fentanyl ev
47988237|NCT02269020|PROCEDURE|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
47988238|NCT00100815|BIOLOGICAL|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
47988239|NCT00100815|DRUG|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
47988240|NCT00100815|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
47988241|NCT04057079|COMBINATION_PRODUCT|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
47988242|NCT04057079|COMBINATION_PRODUCT|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
47988243|NCT00772772|DRUG|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
48144720|NCT03080350|DRUG|Placebo sublingual|Placebo sublingual
48144721|NCT03080350|DRUG|Placebo ev|Placebo - NaCL 0,9% ev
48144722|NCT05840185|DEVICE|Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
48144723|NCT02102698|DRUG|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
48355998|NCT02458742|DRUG|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
48355999|NCT01594463|OTHER|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
48356000|NCT01594463|OTHER|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
48356001|NCT05914233|DEVICE|Non-invasive ultrasound retinal stimulation Device|Record user feelings during the device is working
48356002|NCT00408785|DRUG|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
48356003|NCT00408785|DRUG|sodium chloride|sodium chloride 0.9 mg
48356004|NCT02363673|OTHER|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
48667078|NCT04033458|DRUG|JNJ-64140284|Participants will receive JNJ-64140284 orally.
48667079|NCT01591629|DRUG|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
47988244|NCT05178966|BEHAVIORAL|Bp OneDay psychoeducation program|"The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~* Representation of BD~* Definition, diagnosis and awareness of the disorder~* Depressive, hypo / manic symptoms~* Vulnerability to BD causes of BD, risk factors for relapses~* Drug treatments, drug compliance and non-drug treatments~* Early detection of prodromal signs~* Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour."
48356005|NCT01389076|DRUG|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
48356006|NCT01389076|DRUG|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
48356007|NCT05257915|DRUG|Perampanel|"For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator."
48356008|NCT04972890|BIOLOGICAL|stem cells|Using umbilical cord stem cells 15x10\^6 cells in 2 cc saline/NaCl 0,9% solution
48667080|NCT01591629|DRUG|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
48667081|NCT01591629|DRUG|Placebo|Placebo
48667082|NCT05688085|DRUG|Irbesartan High/Amlodipine FDC|Irbesartan High/Amlodipine FDC
47988245|NCT04072211|BIOLOGICAL|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
47988246|NCT04915833|DIAGNOSTIC_TEST|Standard high-definition colonoscopy|"Evaluation of the colonic mucosa with a high definition colonoscope (EPKi7010 video processor).~The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) only by one expert endoscopist, randomly assigned.~The number, location and polyps' features (Paris classification) will be recorded by the operator. If a polyp is detected, the endoscopist will remove the polyp endoscopically with a cold snare and forceps biopsy."
48356009|NCT04972890|OTHER|placebo|using 2 cc saline/NaCl 0,9% solution
48356010|NCT06102291|OTHER|Yanqing Zhitong Ointment Acupoint application|Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.
48356011|NCT06102291|OTHER|Acupuncture|The main acupoints are Ashi points, Shenshu (BL23), Guanyuanshu (BL26). There are three sessions per week with each session lasting for 20 min. There will be 4 weeks of treatment for each participant in total.
48356012|NCT05030662|OTHER|Walking stick exercise|"1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge."
48667083|NCT05688085|DRUG|Irbesartan High|Co-administration of Irbesartan High and Amlodipine
48667084|NCT05688085|DRUG|Amlodipine|Co-administration of Irbesartan High and Amlodipine
48667085|NCT03489694|PROCEDURE|Skin test endpoint titration|An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
48667086|NCT00499837|DRUG|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
48667087|NCT05349734|OTHER|overbody blanket|applying overbody blanket with forced-air blower set to 43℃
48667088|NCT05349734|OTHER|underbody blanket|applying underbody blanket with forced-air blower set to 43℃
48667089|NCT00617864|DRUG|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
48667090|NCT00617864|DRUG|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
48667091|NCT04250545|DRUG|Sapanisertib|Given PO
48667092|NCT04250545|DRUG|Telaglenastat Hydrochloride|Given PO
48667093|NCT05862688|OTHER|antimicrobial therapy|antimicrobial therapy
48667094|NCT05753176|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
48667095|NCT03525509|DRUG|Methadone hydrochloride|Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
48144724|NCT01564472|OTHER|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
48144725|NCT05687214|OTHER|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~* Pompage Cv4;~* Occipital-sternal technique;~* Relaxining manipulation of the diaphragmatic domes;~* Pelvic and abdominal diaphragm synchronization;~* Dynamogenic technique;~* Mesenteric traction;~* Release of colic angles;~* Manipulation and mobilization of the sacrum."
48144726|NCT01228500|DEVICE|PriMatrix|Dermal Repair Scaffold
48144727|NCT04598646|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
48144728|NCT04598646|BEHAVIORAL|Support|Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.
48144729|NCT03535636|OTHER|Polysomnography|Sleep architecture will be assessed by polysomnography
48144730|NCT01494766|DIETARY_SUPPLEMENT|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
48144731|NCT00929526|PROCEDURE|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
48667096|NCT03525509|DRUG|Morphine Sulfate|Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
48667097|NCT05015231|DIAGNOSTIC_TEST|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
48144732|NCT00929526|PROCEDURE|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
48144733|NCT03072862|DEVICE|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
48144734|NCT02740426|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
48144735|NCT02183909|OTHER|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
48144736|NCT02183909|BEHAVIORAL|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
48144737|NCT02183909|OTHER|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
48144738|NCT02183909|DRUG|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
48356013|NCT03151772|DRUG|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
48356014|NCT03151772|DRUG|Metformin|Metformin 850 mg x 3 taken preoperatively
48356015|NCT00041535|DRUG|OGT 918|
48356016|NCT03943940|BIOLOGICAL|BM-MNC and UC-MSC|"Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10\^6 cells/kg"
48667098|NCT00992550|DRUG|Cigarette|
48667099|NCT00992550|DRUG|Hookah|
47988247|NCT04915833|DIAGNOSTIC_TEST|Colonoscopy with real-time AI assisted automated polyp detection|The same patient will be submitted to a second, same session, computed aided real-time colonoscopy using the DISCOVERY, AI assisted polyp detector. Colonoscopy will be performed by a same-level-of-expertise operator in comparison to the initial procedure. Any polyp or lesion detected with the AI system will be recorded and endoscopically removed and considered as a missed lesion from standard colonoscopy.
48356017|NCT03943940|OTHER|Control|Standard medicine
48356018|NCT01873196|BEHAVIORAL|Receive extra oil|
48356019|NCT01873196|BEHAVIORAL|Receives behavior changed messages on CSB package|
48667100|NCT03678441|BEHAVIORAL|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
48667101|NCT03678441|PROCEDURE|Cognitive Assessment|Receive pen and paper cognitive assessment
48667102|NCT02728024|OTHER|Missing items, Errors in Completion, Difficulties|
47988248|NCT05503641|OTHER|Cognitive and psychomotor stimulation|"Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users."
47988249|NCT01818154|OTHER|LED phototherapy|
47988250|NCT01818154|OTHER|narrowband UVB phototherapy|
47988251|NCT00489398|DRUG|epinastine HCL and olopatadine HCL|
48667103|NCT04239248|DIETARY_SUPPLEMENT|Tasty&Healthy intervention group|"patients will receive dietary advice to exclude pro-inflammatory dietary components based on the book Tasty\&Healthy."
48667104|NCT04239248|DIETARY_SUPPLEMENT|EEN intervention group|Oral exclusive feeding of formulated food (EEN), using Modulen formula only, for 8 weeks in amount based on the Daily Recommendations Intake. Those not tolerating oral EEN can receive EEN via a nasogastric tube.
48667105|NCT01819740|OTHER|"determine the levels of the HEM substance in seminal plasma"|
48667106|NCT05244161|BEHAVIORAL|RMV-ECD|Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
48356020|NCT01172704|BEHAVIORAL|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
48356021|NCT00608894|DRUG|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
48667107|NCT02466828|DRUG|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
48667108|NCT06488755|DRUG|SIM0718 injection|"Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks.~Duration of medication: 52 weeks"
47988252|NCT02316041|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
47988253|NCT02316041|DEVICE|ReLEx® (SMILE)|
47988254|NCT05581537|OTHER|Systematic Desensitization|"Systematic desensitization: 2 techniques~1. Jacobson's technique (progressive muscle relaxation):~   It involves tensing and releasing muscles that progress through the body throughout focusing on mental relaxation throughout releasing muscle tension~2. Guided imagery (vividly imagining):~It includes 2 types of imagery training/mental practice (MP) which includes visual imagery is based on the sensory (visual) perception of the imagined movement and Kinesthetic imagery is based on sensory-motor information (proprioceptive). MP will be conducted in a quiet room, where each patient will be given detailed instructions to perform both visual and kinesthetic practice"
47988255|NCT04329169|OTHER|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
47988256|NCT05618964|OTHER|Deep Neck Flexors & Extensors exercises|"Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
47988257|NCT01326767|DRUG|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
47988258|NCT01326767|DRUG|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
47988259|NCT00728130|PROCEDURE|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
47988260|NCT02144441|DRUG|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
48667109|NCT06488755|DRUG|SIM0718 injection of placebo|"Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks.~Duration of medication: 52 weeks"
48667110|NCT05160389|DRUG|PBI-200|Single dose of PBI-200
48667111|NCT02317692|BEHAVIORAL|Parent training|
48667112|NCT00189423|DEVICE|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
48144739|NCT00724009|DRUG|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
48667113|NCT00189423|PROCEDURE|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
48667114|NCT06410521|BEHAVIORAL|Exercise|Patients randomised to the intervention arm will undergo non-consecutive training sessions three times a week for a period of 12 weeks. The training session is divided into an aerobic and a resistance training component, with a 5-min warm-up (stretching exercises) and a 5-min cool-down (stretching and relaxing exercises). The cardiovascular component will comprise a progressive exercise duration from 30 to 40 minutes, an exercise intensity promoting moderate to severe claudication pain between 5-10 minutes, with rest time until the pain disappears, and a personalised load progression manipulated based on the claudication pain level, reaching a total of 50 minutes of walking per session. The resistance training component will comprise dynamic muscle contraction exercises (shoulders width squat, unilateral chair leg extension, and bilateral plantar flexion), with a load progression gradually increasing from one set of 10 repetitions to three sets of 15 repetitions.
48144740|NCT04878679|OTHER|Strenght training combined with WB-EMS|Bodyweight exercise training combined with WB-EMS (2 times/week) with a 85Hz electrical impulse
48667115|NCT06410521|BEHAVIORAL|Usual care|Patients randomised to the active comparator arm will be advised about the importance of lifestyle modification (including general advice to increase walking but without specific recommendations about the exercise program) for a period of 12 weeks.
48667116|NCT06410521|BEHAVIORAL|Home-based exercise|Patients who transitioned to the home-based exercise will undergo regular walking in or near the home at least three times week, with each walking taking approximately 30-40 minutes for a period of 12 weeks. The pace of intermittent walking will be self-selected in order to induce mild-to-moderate claudication pain between 5-10 minutes, with rest time until the pain disappears.
48144741|NCT04878679|OTHER|Cardiovascular training with WB-EMS|Cardiovascular training , using the rowing machine, combined with WB-EMS (2 times/week) with a 7Hz electrical impulse
48144742|NCT04878679|OTHER|Control group|No physical activity
48144743|NCT01883063|DEVICE|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
48144744|NCT01883063|DEVICE|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
48356022|NCT00608894|DRUG|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
48356023|NCT01948791|DRUG|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
48356024|NCT02617199|DRUG|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
48144745|NCT02646098|PROCEDURE|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
48144746|NCT00540566|DEVICE|Optical Biopsy imaging|Optical Biopsy imaging
48144747|NCT02086461|DEVICE|Pneumatic pyloric dilatation|
48356025|NCT02617199|DRUG|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
48356026|NCT05779176|PROCEDURE|Therapeutic hypothermia|The study intervention is therapeutic hypothermia. After intubation, patients assigned to therapeutic hypothermia will receive central venous catheterization through right jugular vein or femoral vein depending on the cooling application and the unique needs, a flexible catheter will be inserted and iced saline was circulated through the multiple balloons of the catheter in a closed-loop design to induce therapeutic hypothermia. This system also has a hydrophilic coating with heparin and a triple-lumen central venous catheter to satisfy the need of fluid or drug infusion, blood draw and central venous pressure monitoring. After central venous catheterization, patients assigned to TH will receive intravascular temperature management to achieve the target temperature of 34-35 °C.
48356027|NCT02811640|OTHER|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
48144748|NCT02086461|OTHER|15 mm pyloric balloon dilatation|
48144749|NCT02994004|OTHER|no intervention|
48144750|NCT00054197|DRUG|gemcitabine hydrochloride|
48144751|NCT00054197|DRUG|paclitaxel poliglumex|
48144752|NCT00054197|DRUG|vinorelbine tartrate|
48144753|NCT04090502|OTHER|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
48144754|NCT04090502|OTHER|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
48667117|NCT05185076|DEVICE|CureSight|watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks
48356028|NCT06410794|DEVICE|Virtual Reality with Beat Saber|The VR activity used in the intervention was an add-on activity that did not replace any other activities in the programme. The off-the-shelf product Beat Saber (Beat Games, Prague, The Czech Republic) is the VR game of choice in our study. In collaboration with the participating clinics a systematic VR activity plan will be developed. This includes the selection of games and designing a plan that is interesting and motivating both for patients and clinicians.
48667118|NCT05475808|DEVICE|Static wrist splint treatment|Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.
48144755|NCT04237792|DRUG|dexmedetomidine|dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
48144756|NCT04237792|DRUG|propofol|propofol IV administration will be given if needed to maintain sedation
48144757|NCT03755115|DRUG|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
48144758|NCT05147155|BIOLOGICAL|Mepolizumab|This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.
48144759|NCT04849091|DEVICE|iReadMore|Digital Alexia Therapy
48144760|NCT06177821|DEVICE|Rezum®|Rezum® Water vaporization device
48667119|NCT05475808|OTHER|Tendon and nerve gliding exercises|"Tendon and nerve gliding exercises will be applied 5 sessions a day for 8 weeks. Each session will hold 10 repetitions and approximately 7 seconds in each exercise position.~These exercises involve a sequence of finger movements (for tendon gliding) and wrist and fingers movements (for median nerve gliding)."
48667120|NCT05475808|DRUG|Wrist local steroid injection|"Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance."
48144761|NCT00519935|BEHAVIORAL|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
48144762|NCT05386537|COMBINATION_PRODUCT|MyoMo orthosis and VR games|Combining Wearable Robotic Orthosis with Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons with Acute SCI
48144763|NCT05386537|DEVICE|MyoPro robot only|Using the MyoPro wearable robotic orthosis only
48144764|NCT05386537|OTHER|Games only|Using VR-video games only
48356029|NCT01738594|DRUG|carfilzomib|Given IV
48356030|NCT01738594|DRUG|romidepsin|Given IV
48356031|NCT01738594|OTHER|laboratory biomarker analysis|Correlative studies
48356032|NCT00735072|DRUG|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
48667121|NCT06278493|DRUG|AL2846 capsules|AL2846 is a multi -target receptor tyrosine kinase inhibitor.
48667122|NCT06278493|DRUG|Gemzar|It is a chemotherapeutic drug.
48667123|NCT06329219|DEVICE|water-filtered Infrared-A radiation|The water-filtered Infrared-A radiation device is designed for self-administered home treatments. The regimen prescribes 30-minute sessions, five times weekly, spanning 12 weeks.
48667124|NCT00775957|PROCEDURE|FLT-PET scan|imaging scan
48667125|NCT00775957|PROCEDURE|FDG-PET scan|imaging scan
48144765|NCT05386537|OTHER|Control|conventional UE therapy at a rehabilitation facility
48144766|NCT01299285|DRUG|LY3009104|Administered orally
48144767|NCT05466630|DIAGNOSTIC_TEST|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
48144768|NCT05466630|DIAGNOSTIC_TEST|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
48144769|NCT05466630|DIAGNOSTIC_TEST|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
48144770|NCT05466630|DIAGNOSTIC_TEST|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
48144771|NCT01799603|DRUG|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
48144772|NCT02873897|DIETARY_SUPPLEMENT|Session A: Experimental products (selected enriched products)|
48667126|NCT04033692|DEVICE|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
48667127|NCT02059421|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"- Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~* Sleep restriction therapy~* Stimulus control instructions~* Sleep hygiene education"
48144773|NCT02873897|DIETARY_SUPPLEMENT|Experimental session: to select enriched products|
48144774|NCT02873897|DIETARY_SUPPLEMENT|Session B: Control (standard products without enrichment)|
48356033|NCT00735072|DRUG|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
48356034|NCT05757791|DRUG|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
48356035|NCT06030154|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
48356036|NCT06030154|BEHAVIORAL|Amplification of Positivity Therapy|Amplification of Positivity Therapy
48356037|NCT06030154|BEHAVIORAL|Surveys and Interviews|Participants will answer questions regarding their mental and physical health as well as their substance use on the computer and in an interview format.
48356038|NCT05439629|DRUG|BAT5906 injection|4.0 mg/eye/time, 50 μl, intravitreal injection
48356039|NCT05439629|DRUG|Lucentis|0.5 mg/eye/time, 50 μl, intravitreal injection
48356040|NCT02599324|DRUG|ibrutinib|Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
48356041|NCT02599324|DRUG|everolimus|Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
48356042|NCT02599324|DRUG|paclitaxel|Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.
48356043|NCT02599324|DRUG|docetaxel|Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.
48356044|NCT02599324|DRUG|cetuximab|Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.
48356045|NCT02599324|DRUG|pembrolizumab|Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
48667128|NCT02059421|OTHER|Johrei therapy|"* Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~* Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~* Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~* Therapy will be administered without physical contact.~* During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
48356046|NCT04003064|DIAGNOSTIC_TEST|Blood|3ml blood
48356047|NCT00715949|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
48356048|NCT01808040|DRUG|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
48356049|NCT03527290|BEHAVIORAL|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
48356050|NCT03527290|BEHAVIORAL|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
48356051|NCT02411773|DRUG|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).
48356052|NCT02411773|DRUG|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
48667129|NCT01241630|PROCEDURE|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
48667130|NCT04958486|DRUG|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
48144775|NCT02873897|DIETARY_SUPPLEMENT|Control session|
48144776|NCT04221165|DRUG|Opioids|Opioids will be prescribed as per institutional standards.
48144777|NCT04221165|DRUG|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
48144778|NCT01868230|BEHAVIORAL|Lifestyle Intervention|
48144779|NCT03226600|DEVICE|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
48356053|NCT02411773|BEHAVIORAL|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
48667131|NCT02507986|DEVICE|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
48667132|NCT02507986|DEVICE|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
48667133|NCT00133133|DRUG|ALGRX 4975|
48667134|NCT03627702|RADIATION|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
48667135|NCT04462575|PROCEDURE|Onlay bone block covered using collagen membrane|The ratio is 40% of xenogenic bone particles (low resorption rate) to 60% of autogenous bone particles (contains viable cells) to be placed in recipient decorticated site and covered by onlay bone block..
48667136|NCT04462575|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block without collagen membrane
48667137|NCT00197821|BIOLOGICAL|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
47988261|NCT05404373|OTHER|Normobaric Hyperoxia (NBO)|NBO was inhaled as early as possible before revascularization, and inhaled for 1h/2h/4h according to different groups
47988262|NCT05404373|OTHER|Low flow oxygen|immediately given oxygen inhalation at a ventilation rate of 1L/ min using a oxygen storage mask and keep giving oxygen for 4 hours.
48667138|NCT03982160|DRUG|L-Arginine|Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
47988263|NCT04217174|BEHAVIORAL|My Personal Health Guide|My Personal Health Guide is a theory-based mobile phone app that uses an Avatar as a personal health guide to increase patient knowledge of HIV disease and its complications and rationale for healthy behavior, increase self-efficacy and motivate participants to improve retention in care and medication adherence, and explain and illustrate behavioral skills related to retention in care, and adherence, with a result of improved behavior that leads to personal and population benefits through viral suppression and decreased risk of transmission, respectively. The relational aspect of the Avatar may be a powerful supplement to clinical care. The Avatar can encourage healthy behavior, acknowledge stigma and speak with empathy, audibly teach persons with low literacy, employ credible culturally appropriate phrasing, and invite the user to hear advice and motivational stories of other HIV-positive people and caregivers.
47988264|NCT04217174|BEHAVIORAL|My Personal Food Guide|My Personal Food Guide is a mobile phone app that contains a talking realistic avatar who teaches about food safety, sugar content in selected foods, and some other food related information. The avatar motivates safe food behavior in order reduce the likelihood of food poisoning and promotes a healthy diet.
47988265|NCT00628992|OTHER|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
47988266|NCT00628992|OTHER|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
47988267|NCT00628992|OTHER|Cycloergometer training|Muscular rehabilitation of the leg
47988268|NCT00628992|OTHER|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
47988269|NCT05047328|BIOLOGICAL|inolimomab|"1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase).~Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28.~In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28.~Total duration of treatment is 28 ±2 days."
47988270|NCT01035203|BEHAVIORAL|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
47988271|NCT01035203|BEHAVIORAL|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
47988272|NCT01829750|GENETIC|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
47988273|NCT04931355|OTHER|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
47988274|NCT04931355|OTHER|Western medicine|Western medicine
47988275|NCT01271660|DRUG|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
47988276|NCT01271660|DRUG|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
48144780|NCT03226600|DEVICE|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
48144781|NCT06065930|DEVICE|Subcutaneous microdialysis|"Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1."
48356054|NCT02411773|BEHAVIORAL|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
48356055|NCT01693562|DRUG|MEDI4736|Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
48356056|NCT03139773|DIETARY_SUPPLEMENT|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
48667139|NCT03982160|OTHER|Placebo|Saline
48356057|NCT03139773|DIETARY_SUPPLEMENT|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
48667140|NCT04194424|OTHER|Multidisciplinary weight loss program|Diet and behavioral therapy,and supervised exercise sessions
48667141|NCT04194424|OTHER|Standard Care|General lifestyle tips
48667142|NCT04194424|DRUG|Metformin Hcl 850Mg Tab|1 tablet, twice daily
48667143|NCT01656161|DRUG|Triptorelin embonate 22.5 mg|
48667144|NCT03333603|DRUG|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
48667145|NCT04325308|PROCEDURE|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
48667146|NCT04325308|PROCEDURE|Usual human milk diet|Human-based protein will not be added to the human milk administered.
48667147|NCT01502735|BIOLOGICAL|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
48667148|NCT01502735|BIOLOGICAL|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
48667149|NCT00050804|DRUG|sertraline|
48667150|NCT05629988|DEVICE|IA with TheraSorb ® column|IA cycle is 5 days, repeat cycles will be given to responders at months 3 and 6
48356058|NCT04509297|DIETARY_SUPPLEMENT|high protein milk|This intervention consisted of high protein milk consumption concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
48667151|NCT03700177|DRUG|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
48667152|NCT03700177|DRUG|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
48667153|NCT03700177|DRUG|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
48667154|NCT04400435|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
48667155|NCT06050980|DRUG|HSK40118|Oral administration, QD
48002677|NCT05611242|PROCEDURE|MT+CAS with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy.
48144782|NCT02338999|RADIATION|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
48144783|NCT02338999|DRUG|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
48144784|NCT02338999|DRUG|Placebo|
48144785|NCT00893698|PROCEDURE|bilateral allotransplantation|bilateral allotransplantation of upper limbs
48667156|NCT01876381|DRUG|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
48144786|NCT00814749|PROCEDURE|midureteral sling|midureteral sling
48667157|NCT06497309|DEVICE|Treadmill training|Therapy with treadmill-based advanced technology device.
48667158|NCT06497309|DEVICE|Overground training|Therapy using an advanced technological device enables exercise on the ground.
48667159|NCT06497309|DEVICE|DIERS|The examination starts and ends with the DIERS motion analysis system, a light-optical scanning method based on VRS (Video Raster Stereography) and a sensor-equipped treadmill that allows the measurement of several parameters of gait and balancing ability.
48667160|NCT06497309|OTHER|Traditional physiotherapy assessments|Traditional physiotherapy assessment methods (Timed Up and Go, Berg Balance Test, 6-minute gait test, 10-metre gait test, Functional Independence Measure, Barthel) are used to assess gait pattern and self-sufficiency.
48667161|NCT06183398|OTHER|Skin prick test|Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
48667162|NCT04400825|OTHER|Dry needling|Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)
48667163|NCT00805389|BIOLOGICAL|Engerix-B™|2 doses intramuscular injections
48667164|NCT00805389|BIOLOGICAL|Fendrix™|2 doses intramuscular injections
48667165|NCT00805389|BIOLOGICAL|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
48667166|NCT00805389|BIOLOGICAL|HBsAg (Booster injection)|Single dose intramuscular injection
48667167|NCT04534673|DRUG|Lambda 180 mcg S.C|Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7
48667168|NCT02030626|DEVICE|active or placebo rTMS or active or placebo tDCS|
48667169|NCT04314622|DRUG|Supaglutide|Administered SC
48667170|NCT04314622|DRUG|Placebo|Administered SC
48667171|NCT00545779|DRUG|Ibandronate|150 mg orally once monthly for 6 months
48667172|NCT00818194|DRUG|extended release tacrolimus|oral
48356059|NCT04509297|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of the consumption of a maltodextrin drink with a 9% solution with a vanilla flavor concomitant with 6 weeks of resistance training. Subject ingested consumed 1 x 250 mL immediately after resistance training and 1 x 250 mL half an hour before bedtime.
48356060|NCT05412693|DEVICE|Functional orthosis|See arm descriptions
48667173|NCT00818194|DRUG|cyclosporine A microemulsion|oral
48356061|NCT05412693|DEVICE|Cast immobilization|See arm descriptions
48356062|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablet
48667174|NCT03588754|DRUG|Propranolol|Propranolol Extended Release (160mg/day).
48667175|NCT03588754|DRUG|Placebo|Placebo pill administered orally.
48667176|NCT03098095|BEHAVIORAL|Physical Activity|Moderate physical activity
48667177|NCT02172794|DRUG|Tiotropium|
48356063|NCT00648544|DRUG|Pravastatin|Single-dose 80 mg oral immediate-release tablets
48356064|NCT03752840|OTHER|Visual acuity (presenting and pinhole)|Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
48356065|NCT03752840|OTHER|Optical coherence tomography (OCT)|OCT will be used to image the anterior segment, the macula, and the retinal nerve fiber layer. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
47988277|NCT05704504|BEHAVIORAL|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with EMA and personalized telephone support. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer and three 15-minute personalized telephone sessions delivered by research personnel. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and third group exercise sessions will include (1) reviewing exercise goals and EMA data, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
48356066|NCT03752840|OTHER|Intraocular pressure|Intraocular pressure will be measured using an iCare tonometer. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
48356067|NCT03752840|OTHER|Active linkage to care|Referred participants will be followed closely by study staff to ensure completion of follow-up visits.
48356068|NCT00103779|DRUG|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
48667178|NCT02172794|DRUG|Placebo to tiotropium|
48667179|NCT02172794|DRUG|Salmeterol|
48667180|NCT02172794|DRUG|Placebo to salmeterol|
48667181|NCT05294887|DRUG|Bisoprolol|beta-adrenergic receptor blocker
48667182|NCT05294887|DRUG|Diltiazem|calcium channel blocker
48667183|NCT05294887|DRUG|Placebo|Placebo
48667184|NCT03464825|OTHER|Specific and progressive balance training|Specific and progressive balance training for the intervention group
48667185|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous"
48667186|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous"
48667187|NCT02493764|DRUG|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
48667188|NCT02493764|DRUG|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
48667189|NCT02493764|DRUG|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
48667190|NCT02493764|DRUG|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
48144787|NCT00814749|OTHER|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
48144788|NCT02764905|BEHAVIORAL|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
48144789|NCT00703352|DRUG|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
48144790|NCT02731066|OTHER|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
48144791|NCT02731066|OTHER|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
48144792|NCT02731066|OTHER|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
48144793|NCT02731066|OTHER|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
48144794|NCT06275802|BEHAVIORAL|Nutrition Education|Nutrition interventions consisting of 8 modules (powerpoint supported classroom lesson, video demonstration, role-play, healthy plate model game, poster preparation, bookmarks, refrigerator magnets, etc. preparation of reminder messages, competitions such as slogan-painting contest, activities such as sports and nutrition festival).
48356069|NCT02847000|DRUG|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
48356070|NCT02847000|DRUG|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
48667191|NCT02493764|DRUG|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
48667192|NCT02493764|DRUG|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
48667193|NCT03586960|DEVICE|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
48667194|NCT03005340|DRUG|Treatment B|Bazedoxifene 20 mg
48667195|NCT03005340|DRUG|Treatment C|Cholecalciferol granule 10 mg
48667196|NCT03005340|DRUG|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
48002678|NCT05611242|PROCEDURE|MT+CAT with PO-AP|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Carotid stenting is a procedure that is deployed within the lumen of the carotid artery which treats the narrowing of the carotid artery. With added oral antiplatelet therapy
48144795|NCT06275802|BEHAVIORAL|nutritional status, eating habits|At the beginning of the study (June 2022), an introductory form (sociodemographic characteristics, body image (Stunkart scale), dietary habits, knowledge about weight status) was applied to all students. Adolescent Nutrition Literacy Scale (ANLS), Instrument of Nutrition Literacy, Mediterranean Diet Quality Index (KID-MED), Eating Attitudes Test 26 (EAT-26), International Physical Activity Questionnaire Short Form (IPAQ) were applied, anthropometric measurements and three-day food consumption records were taken
48144796|NCT04251988|DEVICE|Oculus Go VR|virtual reality headset
48144797|NCT01363128|DRUG|Cyclophosphamide|Given IV
48144798|NCT01363128|DRUG|Cytarabine|Given IV
48667197|NCT01668004|BIOLOGICAL|Golimumab|GLM 50 mg subcutaneously once monthly.
48667198|NCT02219152|DRUG|tranexamic acid|
48667199|NCT02219152|DRUG|saline|
48667200|NCT02573064|DRUG|Colistin|
48667201|NCT02573064|DRUG|Tigecycline|
48667202|NCT02573064|DRUG|Vancomycin|
48144799|NCT01363128|DRUG|Dexamethasone|Given IV or PO
48144800|NCT01363128|DRUG|Doxorubicin Hydrochloride|Given IV
48144801|NCT01363128|OTHER|Laboratory Biomarker Analysis|Correlative studies
48144802|NCT01363128|DRUG|Methotrexate|Given IV
48144803|NCT01363128|BIOLOGICAL|Ofatumumab|Given IV
48144804|NCT01363128|DRUG|Vincristine Sulfate|Given IV
48667203|NCT05748002|OTHER|Pentacam and Corvis ST|morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST
48667204|NCT02538614|DRUG|Idelalisib|Tablets administered orally twice daily
48667205|NCT02538614|DRUG|BI 836826|Intravenous administration as a rate-controlled infusion
48667206|NCT05188989|DRUG|TPN171H 2.5mg group|TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
48667207|NCT05188989|DRUG|TPN171H 5mg group|TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
48667208|NCT05188989|DRUG|TPN171H 10mg group|TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
48667209|NCT05188989|DRUG|Placebo group|Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
48667210|NCT05651828|DRUG|Vismodegib 150 MG Oral Capsule|Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
48144805|NCT05585398|DRUG|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
48144806|NCT02322645|DRUG|Eszopiclone Tablets 3 mg|
48144807|NCT05866432|DRUG|Datopotamab deruxtecan|Will be given until PD or withdraw
48144808|NCT05441176|OTHER|Questionnaires|Scoring of the DASH is performed according to references.
48144809|NCT00418119|DRUG|erythropoietin|
48144810|NCT02309515|OTHER|Laboratory Biomarker Analysis|Correlative studies
48144811|NCT02309515|DRUG|Lenalidomide|Given PO
48667211|NCT02466919|DRUG|Pantoprazole|H. pylori eradication therapy
48667212|NCT02466919|DRUG|Amoxicillin|H. pylori eradication therapy
48667213|NCT02466919|DRUG|Metronidazole|H. pylori eradication therapy
48667214|NCT02466919|DRUG|Levofloxacin|H. pylori eradication therapy
48667215|NCT02466919|DRUG|Clarithromycin|H. pylori eradication therapy
48667216|NCT03126487|PROCEDURE|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
48667217|NCT00399022|DRUG|Duloxetine|
48667218|NCT01058850|BIOLOGICAL|Rindopepimut|250 or 500 mcg; intradermal injection
48144812|NCT02309515|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
48667219|NCT00508521|DEVICE|Functional Electrical Stimulation|commercially available surface electrical stimulator
48667220|NCT00508521|OTHER|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
48667221|NCT01594242|DRUG|Bortezomib|
48667222|NCT01968343|BEHAVIORAL|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
48667223|NCT01968343|OTHER|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
48144813|NCT02813304|BEHAVIORAL|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
48667224|NCT05472792|RADIATION|Accelerated Partial Breast Irradiation (APBI)|Radiation treatment delivered to the lumpectomy cavity.
48667225|NCT05472792|DRUG|tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene|Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
48667226|NCT01907893|BEHAVIORAL|Trauma Collaborative Care Plus Treatment as Usual|
48667227|NCT02483364|OTHER|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
48144814|NCT02813304|BEHAVIORAL|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
48144815|NCT00445757|PROCEDURE|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
48144816|NCT00445757|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
48667228|NCT01042314|DRUG|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
48667229|NCT01042314|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
48667230|NCT02951507|OTHER|O T unilateral attachment|O T unilateral attachment system
48667231|NCT02951507|OTHER|New design of extracoronal attachment system|O T unilateral attachment
48144817|NCT00878189|DRUG|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
48667232|NCT01071161|DRUG|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
48667233|NCT01071161|DRUG|placebo|placebo
48505849|NCT06551714|PROCEDURE|Neurophysiological facilitation techniques|"In addition to the phase 1 cardiac rehabilitation program for the group receiving neurophysiological facilitation (NPF) techniques:~NPF techniques such as perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, moderate manual pressure and abdominal co-contraction were applied for ten times for ten seconds.~Diaphragm facilitation exercise was performed by inhaling against resistance and holding the breath against resistance for 5 seconds.~Unilateral and bilateral upper extremity proprioceptive neuromuscular facilitation (PNF) movements combined with breathing were performed.~NPF techniques were performed 10 times each day throughout the treatment, while other applications (diaphragm facilitation, combined breathing exercise with upper extremity PNF technique and respiratory facilitation) were performed 5 times on the first day and 10 times on the other three days."
48667234|NCT05597176|OTHER|Spinal Cord Injury Exercise Group|Participants will have an initial accommodation period of 4 weeks, during which four 10-minute exercise bouts/day will be interspersed with 5 minutes of rest. The bouts will gradually increase until at least continuous 40-minute sessions. The remaining 12-week intervention will be set at 70% max heart rate for a total of 16 weeks.
48667235|NCT00922129|DRUG|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
48505850|NCT03954834|DRUG|Tirzepatide|Administered SC
48505851|NCT03954834|DRUG|Placebo|Administered SC
48144818|NCT02430259|DRUG|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
48144819|NCT01296100|BEHAVIORAL|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
48144820|NCT01296100|BEHAVIORAL|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
48144821|NCT05281081|DRUG|intraperitoneal levobupivacaine and morphine|istillation of the peritoneum with levobupivacaine mixture with morphine
48667236|NCT00922129|DRUG|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
48667237|NCT04435158|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous injection
48667238|NCT04435158|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous injection
48667239|NCT02491879|DRUG|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
48144822|NCT00753259|OTHER|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
48144823|NCT00753259|OTHER|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
48667240|NCT02491879|OTHER|Placebo|Placebo gel with a 2 g local use
48667241|NCT03268564|BEHAVIORAL|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders"
48144824|NCT03610620|PROCEDURE|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
48667242|NCT03434834|DEVICE|optical coherence tomography|OCT measurements of 5 locations in the esophagus
48667243|NCT04279743|DIETARY_SUPPLEMENT|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
48144825|NCT03541525|OTHER|Biological sampling|Biological samples including blood, surgical remainder, urine,...
48144826|NCT01552083|OTHER|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
48144827|NCT06352307|OTHER|Diagnosis of ACM|Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.
48667244|NCT04279743|DIETARY_SUPPLEMENT|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
48667245|NCT05290532|OTHER|Individualized exercise training|The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
48667246|NCT03582579|BEHAVIORAL|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
48667247|NCT03582579|BEHAVIORAL|Training on a computer screen|Action Video Game Based Training on a computer screen
48667248|NCT04063813|BEHAVIORAL|Experimental: 40 minute up trial|
48667249|NCT04063813|BEHAVIORAL|Experimental: 40 minute down trial|
48667250|NCT04063813|BEHAVIORAL|Experimental: Two 20 minute up trials|
48667251|NCT04063813|BEHAVIORAL|Experimental: Two 20 min down trials|
48667252|NCT04063813|BEHAVIORAL|Active Comparator: Sedentary trial|
48667253|NCT03755193|DRUG|"SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug"|To examine the effects of SERM and ELD in osteoporosis patients
48667254|NCT03755193|DRUG|"Bisphosphonates and ELD Edirol®Tablet 0.75ug"|To examine the effects of BP and ELD in osteoporosis patients
48667255|NCT03755193|DRUG|"ELD Edirol®Tablet 0.75ug"|To examine the effects of ELD in osteoporosis patients
48667256|NCT05472493|BIOLOGICAL|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, \~3 mm). CETO (\~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from \~0-90 minutes.
48667257|NCT05318508|OTHER|Measurements of sagittal spinopelvic parameters|Sagittal spinopelvic parameters will be measured from lateral cervicothoracolumbar radiographs of patients with lower extremity amputation.
48144828|NCT02932124|DEVICE|mechanical chest compression device|
48144829|NCT05168280|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
48144830|NCT05168280|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
48356071|NCT01007318|PROCEDURE|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
48144831|NCT00853606|DRUG|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
48356072|NCT01007318|PROCEDURE|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
48356073|NCT03085342|DIAGNOSTIC_TEST|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
48667258|NCT03894085|DRUG|Paroxetine|Paroxetine treatment for 4 weeks usage:20-80mg Qd
48667259|NCT01661283|DRUG|everolimus|10 mg tablet once daily
48667260|NCT01661283|DRUG|bevacizumab|10 mg/kg dose every 14 days
48667261|NCT05683379|DIAGNOSTIC_TEST|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
48667262|NCT02908178|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
48667263|NCT01218269|DEVICE|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
48356074|NCT01009333|DEVICE|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
48356075|NCT01009333|DEVICE|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
48356076|NCT01009333|DEVICE|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
48667264|NCT06400498|BEHAVIORAL|Prompted Palliative Care Consult|When a patient is randomized to the Palliative Care Consultation Prompt Group, a clinical decision support tool in the electronic health record will inform the treating clinician of the patient's serious illness and the results of the Surprise Question and prompt the treating clinician to consider a palliative care consultation. If the treating clinician feels a palliative care consultation would be indicated for the patient, the clinical decision support tool will facilitate the placement of a palliative care consultation by the treating clinician. If the treating clinician feels that a palliative care consultation would not be indicated, then the clinical decision support will record a reason it is not indicated.
48667265|NCT00590317|DRUG|Prochlorperazine|Patients receiving Prochlorperazine
48667266|NCT00590317|DRUG|Ondansetron|Patients receiving Ondansetron
48667267|NCT06400667|DEVICE|Upper limb Kinematic Assessment with Optoelectronic system|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks. During the data acquisition protocol, the subject perform five trial for each upper limb of a determinate functional task for each session. Every subject repeat this operations 2 times with 2 different operators.
48667268|NCT03346993|DRUG|Bupivacaine Hydrochloride 5 MG/ML|Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
48667269|NCT04931576|PROCEDURE|no drainage tube applied|No drainage tube implacement after TOETVA
48667270|NCT05470400|BIOLOGICAL|FP conjugate vaccine (25 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
48356077|NCT06237361|OTHER|Pilates exercises|participants underwent a 12-week intervention involving three Pilates sessions per week. The Pilates exercises comprised warm-up activities, Pilates routines, and cool-down exercises.
48356078|NCT06237361|OTHER|traditional physical therapy program|The program included a variety of exercises such as range of motion exercises, aerobic exercises, resistance exercises, scar management, occupational therapy, and hand therapy.
48356079|NCT03671642|DEVICE|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
48356080|NCT03671642|PROCEDURE|White light perfusion assessment|Traditional visual perfusion assessment in white light
48356081|NCT03671642|PROCEDURE|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
47988278|NCT05704504|BEHAVIORAL|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer at the Chinese University of Hong Kong. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and the third group exercise sessions will include (1) reviewing exercise goals, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
48505852|NCT00899041|PROCEDURE|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
47988279|NCT02862613|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
47988280|NCT02862613|BIOLOGICAL|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
47988281|NCT00453544|OTHER|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
48356082|NCT02429089|DRUG|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
48356083|NCT02845284|BEHAVIORAL|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
48356084|NCT02845284|BEHAVIORAL|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
48356085|NCT00269958|DRUG|epoetin alfa|
48356086|NCT00819052|DRUG|Nevirapine XR|Nevirapine XR
48356087|NCT00819052|DRUG|Nevirapine XR|Nevirapine extended release
48356088|NCT00819052|DRUG|Nevirapine IR|Nevirapine Immediate Release
48505853|NCT05462171|DIAGNOSTIC_TEST|Questionnaires|Participants will be asked to complete validated questionnaires (the five-item International Index of Erectile Function - IIEF-5, Premature Ejaculation Diagnostic Tool - PEDT, International Prostate Symptom Score - IPSS, Overactive Bladder - Validated 8-question Screener - OAB-V8, Hospital Anxiety and Depression Scale - HADS, Athens Insomnia Scale - AIS).
48505854|NCT06549283|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation|Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
48505855|NCT04020289|BEHAVIORAL|"Psychoeducational Program BalancingMySwing"|"Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy"
47988282|NCT00453544|OTHER|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
48144832|NCT05097534|OTHER|iDSMES|Intensive Diabetes Self-Management Education and Support combined with Addressing Social Determinants of Health
48144833|NCT05097534|OTHER|Standard of Care|Standard of Care for patients with type 2 diabetes
48144834|NCT03270384|DEVICE|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
48505856|NCT05299606|DEVICE|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
48505857|NCT06634199|DRUG|Durvalumab|Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
48505858|NCT02804022|DEVICE|VPIA analgesia|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
48505859|NCT02804022|DRUG|Morphine|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
48667271|NCT05470400|BIOLOGICAL|FP conjugate vaccine (200 mcg)|"FP8v1-rTTHC (FP conjugate vaccine) is an HIV-1 fusion peptide conjugated to recombinant tetanus toxoid heavy chain fragment C (rTTHC) via sulfo-SIAB chemical linker.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
47988283|NCT01601249|PROCEDURE|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
47988284|NCT04299204|PROCEDURE|Percutaneous nephrolitotomy|Pediatric PCNL
47988285|NCT01337947|DRUG|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
47988286|NCT04983992|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
47988287|NCT02792556|DEVICE|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
48144835|NCT04392648|DRUG|TAK-573|TAK-573 intravenous infusion.
48144836|NCT04392648|DRUG|Pomalidomide|Pomalidomide capsules orally.
48144837|NCT04392648|DRUG|Bortezomib|Bortezomib injection subcutaneously.
48144838|NCT04392648|DRUG|Cyclophosphamide|Cyclophosphamide tablets orally.
48144839|NCT04392648|DRUG|Dexamethasone|Dexamethasone tablets orally.
48144840|NCT06404983|OTHER|Opioid Free Anaesthesia (OFA)|Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.
48144841|NCT06404983|OTHER|Conventional General Anaesthesia (CGA)|Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.
48144842|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
48144843|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
48144844|NCT01560429|PROCEDURE|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
47988288|NCT03600974|PROCEDURE|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
47988289|NCT03600974|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
48356089|NCT03700931|BEHAVIORAL|Eating recall condition|Recall of eating episodes would increase subsequent intake of fruit or vegetable items
48356090|NCT03700931|BEHAVIORAL|Non-eating recall condition|Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
48356091|NCT04207944|DRUG|Sulindac 400 MG|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
48356092|NCT04207944|OTHER|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
48356093|NCT03128606|DRUG|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
48356094|NCT03128606|DRUG|Placebo single dose|Placebo, oral suspension, daily
48356095|NCT03128606|DRUG|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
47988290|NCT03600974|DRUG|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
47988291|NCT03600974|DRUG|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
47988292|NCT03600974|DRUG|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
47988293|NCT03600974|DRUG|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
48356096|NCT03128606|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
48356097|NCT03128606|DRUG|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
48356098|NCT03128606|DRUG|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
48356099|NCT03128606|DRUG|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
48356100|NCT03128606|DRUG|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
48356101|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
48356102|NCT03128606|DRUG|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
48356103|NCT04625530|DRUG|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
48356104|NCT04625530|DRUG|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
48356105|NCT04625530|DRUG|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
48356106|NCT05267899|DRUG|WGI-0301|WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.
48356107|NCT05692206|OTHER|evaluation|Surveys will be administered to the participants. Participants will be given a stroop TBAG test.
48356108|NCT04995731|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)|Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
48667272|NCT05470400|BIOLOGICAL|Trimer 6931 (100 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
47988294|NCT00004489|DRUG|alendronate sodium|
47988295|NCT00004489|DRUG|calcium carbonate|
47988296|NCT00004489|DRUG|cholecalciferol|
47988297|NCT02062879|DRUG|Ketamine|Ketamine administered as patient-controlled analgesia.
47988298|NCT02062879|DRUG|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
47988299|NCT03253887|DRUG|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
47988300|NCT02671994|OTHER|G8 screening|
47988301|NCT02671994|OTHER|Geriatric assessment|
47988302|NCT02169739|DEVICE|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
48144845|NCT01560429|PROCEDURE|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
48356109|NCT04995731|PROCEDURE|transvaginal ultrasound examination|All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
47770675|NCT06674993|BIOLOGICAL|OpRegen|Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space.
48356110|NCT00362297|DRUG|acyclovir|800 mg orally three times daily for 7 weeks
48356111|NCT00362297|DRUG|valacyclovir|500 mg orally once daily for 7 weeks
48356112|NCT02471586|PROCEDURE|Coronary PCI guided by IVUS|Imaging type
48356113|NCT02471586|PROCEDURE|Coronary PCI guided by OCT|Imaging type
48356114|NCT02471586|PROCEDURE|Coronary PCI guided by Angiography|Imaging type
47988303|NCT05985655|DRUG|GTAEXS617|GTAEXS617 tablets daily
47988304|NCT06309212|OTHER|Observation|Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
47988305|NCT05346159|DIAGNOSTIC_TEST|the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS|"Laboratory assessment Serum dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) will be measured using an enzyme mediated chemiluminescence for all participants Gender-typed behavior assessment~* Parents of girls aged two to six years will evaluate their children's gender-typed behavior using the Pre school Activities Inventory~* For girls above 6 years gender characteristics and gender role behavior will be evaluated using The Children's Sex Role Inventory (Child-adapted version of the original Bem Sex Role Inventory)~* For all participants a Parent-Report Gender Identity Questionnaire for Children will be used to evaluate gender role behavior"
47988306|NCT04070391|DIETARY_SUPPLEMENT|vitamin B6|oral administration
47988307|NCT04070391|OTHER|control|oral administration
48144846|NCT05794295|OTHER|Acoustic Stimulation (AS)|Acoustic Stimulation will be administered while participants have their sleep monitored.
48144847|NCT05794295|OTHER|SHAM Stimulation|No stimulation will be administered while participants have their sleep monitored.
48356115|NCT03483012|DRUG|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
48356116|NCT03483012|PROCEDURE|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
48144848|NCT01029704|DRUG|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
48144849|NCT01029704|DRUG|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
48144850|NCT01596985|PROCEDURE|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
48144851|NCT01596985|PROCEDURE|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
48144852|NCT04976946|OTHER|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
48144853|NCT05891002|DEVICE|Cirq® Robotic Alignment Module Cranial|Robotic navigation for cranial biopsy procedure
48144854|NCT06012409|DEVICE|Hall Technique Prefabricated Metal Crown|The Hall Technique is a type of minimally invasive dental treatment. Hall Technique involves sealing the carious lesion under a Prefabricated Metal Crown to stop its progression preventing pain and/or infection.This makes the technique less invasive and it can be more acceptable to children than a traditional filling involving injections and drilling.
48144855|NCT06246890|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
48667273|NCT05470400|BIOLOGICAL|Trimer 6931 (200 mcg)|"HIV-1 Trimer 6931 (Trimer 6931) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from consensus clade C sequence (ConC).~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
48667274|NCT05470400|BIOLOGICAL|Trimer 4571 (200 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
48667275|NCT05470400|BIOLOGICAL|Trimer 4571 (100 mcg)|"HIV-1 Trimer 4571 (Trimer 4571) is a synthetic soluble HIV-1 envelope product that consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505.~Study vaccines will be admixed with Adjuplex adjuvant and administered intramuscularly (IM) via needle and syringe in two injection sites."
48667276|NCT01985230|DEVICE|ReActiv8 Implantable Stimulation System implanted and activated.|
48667277|NCT05059886|OTHER|completion of a questionnaire on the practice of sports and possible injuries|completion of a questionnaire on the practice of sports and possible injuries
48667278|NCT04581811|OTHER|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
47988308|NCT04855097|DIAGNOSTIC_TEST|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
48667279|NCT04581811|OTHER|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
48667280|NCT05958602|BEHAVIORAL|Technology|See previous response.
48667281|NCT05958602|BEHAVIORAL|Standard DSMES Only|See previous response.
48667282|NCT05958602|BEHAVIORAL|Traditional Recruitment Methods|See previous response.
48667283|NCT05958602|BEHAVIORAL|CHW-Led Recruitment Methods|See previous response.
48667284|NCT01428635|DRUG|Eltrombopag Olamine|Given PO
48667285|NCT04756830|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
48667286|NCT00465673|DRUG|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
48667287|NCT00730886|DEVICE|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
48667288|NCT00730886|PROCEDURE|Myomectomy|Invasive surgical procedure for fibroid removal
47988309|NCT00732147|DRUG|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
47988310|NCT00732147|DRUG|Placebo|120 micrograms given subcutaneously before each meal x 3.
47988311|NCT00816231|BEHAVIORAL|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
48667289|NCT03339596|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
48667290|NCT03339596|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
48667291|NCT03448328|DIETARY_SUPPLEMENT|NUTRALYS pea protein supplement|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
48144856|NCT01214200|DEVICE|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
48144857|NCT05074212|OTHER|Factorial Assignment|At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
48356117|NCT05131035|BEHAVIORAL|SCORES (Specific COgnitive Remediation with Support)|"This study evaluates the effectiveness of a 10-week cognitive remediation program plus group coaching and therapy to improve processing speed and, in turn, social functioning and attenuated positive symptoms in CHR subjects. The SCORES (Specific COgnitive Remediation with Support) intervention is a novel CR program combined with group coaching, performance-based rewards, game-like tasks, and therapy elements to increase engagement and retention.~In the 2 year, R61 phase, all participants will complete 40 hours of CR (4 hrs per week) with a mid-point assessment (20 hours of CR at 5 weeks) to determine the impact of CR on processing speed as measured by the MCCB.~The second phase of the study (R33) will compare the 40 hours of speeded brain training to 40 hours of non-speeded brain training. This three year study will allow for a replication and assessment of specificity of the targeted intervention."
48144858|NCT05020067|RADIATION|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
48356118|NCT03245840|DRUG|Budesonide oral suspension|BOS 10 mL twice daily.
48356119|NCT05696652|BEHAVIORAL|Acute exercise|40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.
48144859|NCT04383392|DEVICE|Rate adaptive pacing|Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
48667292|NCT03448328|DIETARY_SUPPLEMENT|Whey Protein|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
48356120|NCT05696652|BEHAVIORAL|Cardiac rehabilitation|12 week program of standard clinical cardiac rehabilitation for patients with symptomatic heart failure. Patients undergo 3-times weekly sessions of monitored exercise for 12 weeks. This is the same cardiac rehabilitation patients would get as part of clinical care.
48356121|NCT06134076|OTHER|Unfermented chickpea|Frozen meals containing 100 g unfermented chickpeas
48356122|NCT06134076|OTHER|Fermented chickpea|Frozen meals containing 100 g fermented chickpeas
48667293|NCT03448328|DIETARY_SUPPLEMENT|Apple juice|1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
48667294|NCT01079312|DEVICE|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
47988312|NCT00816231|OTHER|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
48667295|NCT01079312|DEVICE|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
48667296|NCT01079312|DRUG|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
47988313|NCT00816231|OTHER|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
47988314|NCT00243581|BEHAVIORAL|Dean Ornish Heart Disease Reversing Program|
47988315|NCT04347239|DRUG|Placebos|Placebos
47988316|NCT04347239|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
48667297|NCT01079312|DRUG|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
48144860|NCT06298747|OTHER|Selective cervical nerve root pulsed radiofrequency|A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root.
48144861|NCT06050850|BEHAVIORAL|NOURISH-ALL|Our NOURISH-ALL intervention will build on this existing NOURISH-T family based behavioral intervention with families of cancer survivors. The intervention, NOURISH-ALL, will adapt these family-based health promotion strategies to the early ALL treatment context.
48144862|NCT01316913|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
48356123|NCT01675141|DRUG|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
48667298|NCT01079312|DRUG|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
48144863|NCT01316913|DRUG|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
48505860|NCT05659693|BEHAVIORAL|digital literacy education specific to menopause|Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
48505861|NCT04139759|OTHER|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
48667299|NCT01079312|DRUG|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
48144864|NCT01316913|DRUG|GSK573719|125 mcg once-daily
48144865|NCT01316913|DRUG|tiotropium bromide|18 mcg once-daily
48505862|NCT04139759|OTHER|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
48505863|NCT00103220|DRUG|SJG-136|Given IV
48505864|NCT06633068|DRUG|Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block|Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries
48505865|NCT01838668|DRUG|Placebo|Two placebo capsules orally BID
48505866|NCT01838668|DRUG|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
48505867|NCT04202003|DRUG|TJ011133|This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
48505868|NCT05142397|PROCEDURE|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
48505869|NCT01693510|BEHAVIORAL|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
48144866|NCT00003167|BIOLOGICAL|Ad5CMV-p53 gene|Given intravesically
48144867|NCT03731767|PROCEDURE|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
48144868|NCT00234676|DRUG|Premarin ®|Premarin ® 0.625 mg per day orally
48144869|NCT02309892|DRUG|L-DOS47|A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
48144870|NCT00690313|DRUG|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
48144871|NCT02486939|DRUG|CHS-0214|Open label
48144872|NCT02367794|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
48356124|NCT04854785|OTHER|[18F]FEPPA PET scan|One \[18F\]FEPPA PET for TSPO VT, and one MRI scan
48356125|NCT04854785|OTHER|[11C]SL25.1188 PET scan|One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan
48356126|NCT01603615|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
48356127|NCT04626570|OTHER|Cognitive and Behavioral Therapy|12 sessions of CBT using a standardized approach
48505870|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
48505871|NCT00729573|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
48667300|NCT01561911|DRUG|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
48505872|NCT00729573|DRUG|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
47988317|NCT03130842|DRUG|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
47988318|NCT03130842|DRUG|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
47988319|NCT04900194|BEHAVIORAL|mindfulness-based sexual counseling|Mindfulness-based sexual counseling was planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session lasted 30-40 minutes on average. The sessions were carried out individually by determining the appropriate days of pregnant women in the pregnancy class.In the study, the meditation techniques of the Mindfulness Therapy constituted the backbone/framework of the psychoeducation program. Body and breath, body scanning, mindfulness movement and three-minute respiration techniques were practiced during the psychoeducation program, practically every session in accordance with the researchers' directives.
47988320|NCT03933150|DEVICE|ultrasound guided caudal epidural injection|"A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor"
47988321|NCT03038958|DRUG|Isobaric 2-chloroprocaine|intrathecal injection of 50 mg isobaric 2-Chloroprocaine
47988322|NCT03038958|DRUG|Hyperbaric prilocaine|intrathecal injection of 50 mg hyperbaric prilocaine 2%
47988323|NCT05001074|DRUG|Extended release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
47988324|NCT05001074|DRUG|Immediate release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
47988325|NCT03077802|OTHER|Modified Seldinger technique, Experienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
48144873|NCT02367794|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
48144874|NCT02367794|DRUG|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
48144875|NCT02367794|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\^2 IV.
48505873|NCT00729573|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
48505874|NCT05811806|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
48505875|NCT04816591|DEVICE|Experimental: Interventional Cohort: Treatment Arm|Standard of Care Surgery + Embolization
48505876|NCT04816591|OTHER|Active Comparator: Interventional Cohort: Control Arm|Standard of Care Surgery Only (Control)
48505877|NCT04816591|DEVICE|Experimental: Observational Cohort: Treatment Arm|Standard of Care Medical Management + Embolization
48505878|NCT04816591|OTHER|Active Comparator: Observational Cohort: Control Arm|Standard of Care Medical Management Only (Control)
48505879|NCT06355011|DEVICE|Total Elbow Replacement|Total elbow replacement is a procedure that involves replacing the elbow joint with an implanted device to alleviate pain and improve function.
48505880|NCT05450601|DRUG|HCP2102-1|Take once daily for 2 weeks orally
48505881|NCT05450601|DRUG|HPP2104-1|Placebo drug. Take once daily for 2 weeks orally
48667301|NCT01999530|DRUG|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
48356128|NCT01951326|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
48356129|NCT01951326|DRUG|Placebo|5 placebo capsules administered orally BID
48356130|NCT01896466|DEVICE|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
48356131|NCT01896466|BEHAVIORAL|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
48356132|NCT06247475|OTHER|Answers generated by ChatGPT|Participants will assign a satisfaction score based on the appropriateness of each answer.
48356133|NCT04241120|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
48356134|NCT04241120|BEHAVIORAL|Reminder bracelet control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
48356135|NCT01960764|DRUG|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
48505882|NCT05450601|DRUG|HCP2102-2|Take once daily for 6 weeks orally
48505883|NCT05450601|DRUG|HPP2104-2|Placebo drug. Take once daily for 6 weeks orally
48505884|NCT05450601|DRUG|RLD2106-1|Take once daily for 2 weeks orally
48505885|NCT05450601|DRUG|HPP2103-1|Placebo drug. Take once daily for 2 weeks orally
48505886|NCT05450601|DRUG|RLD2106-2|Take once daily for 6 weeks orally
48505887|NCT05450601|DRUG|HPP2103-2|Placebo drug. Take once daily for 6 weeks orally
48505888|NCT01283035|DRUG|Akt Inhibitor MK2206|Given PO
48505889|NCT01283035|OTHER|Laboratory Biomarker Analysis|Correlative studies
48505890|NCT04037774|DRUG|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
48505891|NCT04037774|OTHER|placebo|addition of placebo with local anesthetic to create a control group
48505892|NCT01804348|DEVICE|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
48505893|NCT05886387|OTHER|High PEEP + Recruitment maneuvers|The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
48505894|NCT05886387|OTHER|Standard PEEP. Low positive end-expriatory pressure|Mechanical ventilation is managed with a low standard PEEP without recruitment manneuvers
48505895|NCT06423092|OTHER|Music therapy songwriting|"Session 1: The goal of the first music therapy session is to know the parents musically and to provide information about song creation. This is achieved by exploring their favorite songs. Options for creating a song (original song or song parody) are presented and possibilities for creating lyrics are discussed.~Sessions 2-7: The structure of the song will be created and discussed with the parents. Parents will also be invited to include written messages from other family members in the lyrics if they wish. In each session, the developing welcome song is sung together with the parents, accompanied by the music therapist, who provides vocal or instrumental support.~The final sessions (Sessions 8-9) are dedicated to singing the final version of the song with the parents and their infant. Should the parents desire, a final recording of the song will also be made and the digital songbook will be created."
48505896|NCT04232280|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
48505897|NCT04232280|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
48356136|NCT01960764|OTHER|Control|
48505898|NCT05160857|DRUG|Herombopag Olamine|The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
48505899|NCT04697082|PROCEDURE|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
48667302|NCT05739448|OTHER|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
48144876|NCT03195998|DIAGNOSTIC_TEST|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
48144877|NCT01355445|DRUG|Vincristine, Irinotecan|"* D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
48144878|NCT01355445|DRUG|Vincristine, Irinotecan, Temozolomide|"* D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience \> grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
48144879|NCT05493488|BIOLOGICAL|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with tinea pedis
48144880|NCT05493488|BIOLOGICAL|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with tinea pedis
48144881|NCT05493488|BIOLOGICAL|Aqueous Gel|Topical application of Aqueous gel on foot/feet affected with tinea pedis
48144882|NCT02239614|BIOLOGICAL|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
48144883|NCT02239614|BIOLOGICAL|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
48144884|NCT02129751|DRUG|bupropion hydrobromide|study drug
48144885|NCT02129751|DRUG|Placebo|placebo arm
48144886|NCT04920968|DRUG|Obinutuzumab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
48144887|NCT04920968|DRUG|Rituximab|Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
48144888|NCT01584596|BEHAVIORAL|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
48667303|NCT05739448|OTHER|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
48144889|NCT01584596|BEHAVIORAL|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
48144890|NCT02174146|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
48144891|NCT01838603|OTHER|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
48144892|NCT04269044|DIAGNOSTIC_TEST|non-contact EKG|ultra-sensitive, non-contact EKG pad will be placed beneath the infant
48144893|NCT01489683|DRUG|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
48667304|NCT03261830|DRUG|Cefazolin|Primary intervention
48144894|NCT01489683|DRUG|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
48144895|NCT04781868|DRUG|Multi-nutrient supplement|Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants
48144896|NCT04781868|DRUG|Placebo|Placebo
48667305|NCT03261830|DRUG|Clindamycin|For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
48667306|NCT03261830|DRUG|Saline|Placebo Intervention
48667307|NCT02987608|DEVICE|Power Up|Smartphone phone app
48667308|NCT05558969|DRUG|pregnant women taking magnesium|The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
48144897|NCT03531242|BIOLOGICAL|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
48144898|NCT02399956|OTHER|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
48144899|NCT01662713|DEVICE|OFDI|Imaging of skin
48144900|NCT00886834|DRUG|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
48144901|NCT00886834|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
48144902|NCT03166605|DRUG|Simethicone|Giving simethicone before and after capsule ingestion.
48144903|NCT00315848|DRUG|Buprenorphine transdermal delivery system|
48144904|NCT04718285|DRUG|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
48144905|NCT04718285|DRUG|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
48144906|NCT04718285|DRUG|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
48144907|NCT04865744|DRUG|Semaglutide 7 MG Oral Tablet|Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
48144908|NCT04865744|DRUG|Placebo|Placebo tablet is taken after an overnight fast with up to120 ml of water.
48144909|NCT04865744|DRUG|Semaglutide 14 MG Oral Tablet|Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
48144910|NCT01058018|DRUG|RVX000222|RVX000222 twice a day for 12 weeks
47988326|NCT03077802|OTHER|Seldinger technique, Experienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
47988327|NCT03077802|OTHER|Modified Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
47988328|NCT03077802|OTHER|Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
47988329|NCT03077802|OTHER|Long-axis technique|Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.
47988330|NCT03077802|OTHER|Short-axis technique|Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
47988331|NCT00819351|DRUG|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
47988332|NCT00819351|DRUG|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
48144911|NCT01058018|DRUG|Placebo|Placebo twice a day for 12 weeks
48144912|NCT01110096|BEHAVIORAL|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
48144913|NCT01110096|BEHAVIORAL|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
48144914|NCT01110096|BEHAVIORAL|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
48144915|NCT05062070|DRUG|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
48144916|NCT05062070|DRUG|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
48144917|NCT02064686|OTHER|Exhaled breath temperature|
48144918|NCT05652907|DRUG|FSD201|Tablets for oral administration.
48144919|NCT05652907|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
48144920|NCT05583656|PROCEDURE|Pulmonary valve replacement|Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
48144921|NCT00446095|DRUG|fostamatinib|200 mg PO BID
48144922|NCT03001635|DRUG|Oxytocin|26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
48144923|NCT03001635|DRUG|Placebos|26 patients will receive 0.9% normal saline infusion for 6h as placebo
48144924|NCT02765867|DRUG|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
48144925|NCT00487240|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
48144926|NCT00487240|DRUG|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
48144927|NCT05575349|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 12 mandala coloring pages given to each participant by the researcher for 6 weeks, 1 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
48505900|NCT04697082|PROCEDURE|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
48667309|NCT05558969|DRUG|Placebo|Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
48144928|NCT01955499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48144929|NCT01955499|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48505901|NCT04697082|OTHER|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
48505902|NCT01729455|BIOLOGICAL|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
48505903|NCT01729455|OTHER|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
48505904|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^9 CFU/day)|
48505905|NCT02032056|DIETARY_SUPPLEMENT|Probiotic (10^8 CFU/day)|
48505906|NCT02032056|OTHER|Placebo|
48505907|NCT06332495|OTHER|Questioning the patient during hygiene care|The study examines how patients and caregivers feel when using the bedpan. Over the course of a day, collecting all this information would take just under 7 minutes. Over the duration of patient participation (2 days), we estimate that it would take a total of 15 minutes per patient to collect this information. The objectives are focused on pain and discomfort, and on the alteration of the (patient's) skin condition through objective observation of redness or stage I pressure sores by the caregiver.
48505908|NCT00343356|DRUG|Trement|
48505909|NCT03712514|OTHER|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
48505910|NCT00206323|DRUG|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
48505911|NCT00206323|DRUG|placebo/sugar pill|placebo
48505912|NCT04467450|DRUG|botulinum toxin type A|ultrasound guided injection of the botulinum toxin type A in the inflamed subacromial subdeltoid bursa
48667310|NCT00633841|BIOLOGICAL|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
48667311|NCT02194413|PROCEDURE|therapeutic touch|receiving healing touch
48667312|NCT02194413|OTHER|quality-of-life assessment|Ancillary studies
48667313|NCT02194413|OTHER|questionnaire administration|Ancillary studies
48667314|NCT04824833|PROCEDURE|Serratus anterior plane block|local anesthetic application between serratus anterior muscle and 5th rib
48667315|NCT03588702|DEVICE|RF and PEMF treatment|Treatment with Venus Legacy LB2 body applicator
47988333|NCT02190084|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
48144930|NCT01955499|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48144931|NCT01955499|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
48144932|NCT01955499|DRUG|Ibrutinib|Given PO
48667316|NCT01402921|DEVICE|V0322 BC|"* Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment"
48144933|NCT01955499|DRUG|Lenalidomide|Given PO
48144934|NCT01955499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48505913|NCT04467450|DRUG|Methyl Prednisolonate|ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa
48505914|NCT02189980|OTHER|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
48505915|NCT02189980|OTHER|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
48505916|NCT02189980|OTHER|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
48667317|NCT01006161|DRUG|SCH 527123|Low dose
48667318|NCT01006161|DRUG|SCH 527123|Medium dose
48667319|NCT01006161|DRUG|SCH 527123|High dose
48667320|NCT01006161|DRUG|SCH 527123|Placebo to match SCH 527123
48667321|NCT05768191|DRUG|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
48144935|NCT01955499|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48144936|NCT01894503|DRUG|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
48144937|NCT04834804|OTHER|Physical activity|12 weeks of exercise training
48356137|NCT03543449|OTHER|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
48356138|NCT02819583|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
48356139|NCT00394654|BIOLOGICAL|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
48356140|NCT00394654|OTHER|Placebo|Placebo administered as a single intravenous infusion
48356141|NCT02705547|DRUG|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
48356142|NCT06227416|OTHER|Biopsy|punch biopsy (2-4 mm) depending on the size of the AK lesion.
48356143|NCT04799340|BEHAVIORAL|cognitive training|training to improve encoding and recognition of faces
48356144|NCT00004885|DRUG|FOLFIRI regimen|
48505917|NCT01596738|DRUG|Tranexamic Acid|"1. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~2. Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
48505918|NCT01596738|DRUG|Saline|"1. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~2. Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
48505919|NCT03471923|DIAGNOSTIC_TEST|Neurological Examination|The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
48505920|NCT03471923|DIAGNOSTIC_TEST|Assessment of Non-Motor Features|All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
48505921|NCT06633198|PROCEDURE|Passive Heting|The lower limbs will be immersed in warm (42C) circulating water for 60 minutes.
48505922|NCT05867121|DRUG|RO7496353|RO7496353 will be administered as per the schedules specified in the respective arms.
48505923|NCT05867121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
48505924|NCT05867121|DRUG|Capecitabine|Capecitabine will be administered as per the schedules specified in the respective arms
48505925|NCT05867121|DRUG|S-1|S-1 will be administered as per the schedules specified in the respective arms.
48356145|NCT00004885|DRUG|fluorouracil|
48505926|NCT05867121|DRUG|Nivolumab|Nivolumab will be administered as per the schedules specified in the respective arms.
48356146|NCT00004885|DRUG|irinotecan hydrochloride|
48505927|NCT05867121|DRUG|Oxaliplatin|Oxaliplatin will be administered as per the schedules specified in the respective arms.
48505928|NCT05867121|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the schedules specified in the respective arms.
48667322|NCT05768191|DRUG|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
48667323|NCT03243084|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
48667324|NCT03243084|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
48667325|NCT02939755|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
48144938|NCT02176694|BEHAVIORAL|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
48144939|NCT05351697|DRUG|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
48144940|NCT03122548|BIOLOGICAL|CRS-207|Administered by IV infusion over 1 hour.
48356147|NCT00004885|DRUG|leucovorin calcium|
48356148|NCT02310724|OTHER|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
48505929|NCT05867121|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedules specified in the respective arms.
48505930|NCT04646876|DRUG|Magnesium Sulfate|Prospective , comparative , double blind study
48505931|NCT04646876|DRUG|Placebo|Prospective , comparative , double blind study
48505932|NCT03265418|DEVICE|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
48505933|NCT03265418|OTHER|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
48667326|NCT02939755|BEHAVIORAL|Enhanced Usual Care|usual care from health providers
48667327|NCT01987557|BEHAVIORAL|rate group|walking with a high cadence (steps per minute)
48667328|NCT01987557|BEHAVIORAL|magnitude treadmill group|
48667329|NCT01987557|BEHAVIORAL|regular treadmill walking|
48667330|NCT03965845|DRUG|Telaglenestat (CB-839)|Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
48667331|NCT03965845|DRUG|Palbociclib Oral Capsule or Tablet [Ibrance]|Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
48667332|NCT05631444|BIOLOGICAL|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
48667333|NCT05187234|OTHER|Education|Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
48667334|NCT06458569|OTHER|Rehabilitation|3-weeks rehabilitation in hospital
48667335|NCT05010590|DRUG|Romosozumab|Monthly romosozumab
48667336|NCT05010590|DRUG|Denosumab|Every 6 months denosumab
48667337|NCT03621280|DRUG|Levoketoconazole|Levoketoconazole up to 1200 mg daily
48667338|NCT02320656|OTHER|Blood sampling|Longitudinal (3 stages of the disease)
48667339|NCT02320656|OTHER|Bone marrow aspirate|Longitudinal (3 stages of the disease)
48667340|NCT02320656|OTHER|Skin biopsy|Single biopsy (optional)
48144941|NCT03122548|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over 30 minutes.
48667341|NCT02320656|OTHER|Buccal swab|Single sampling.
48667342|NCT04931381|OTHER|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
48667343|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
48667344|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
48667345|NCT05141695|DEVICE|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
48667346|NCT05141695|DEVICE|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
48667347|NCT05201651|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
48667348|NCT05201651|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
48667349|NCT00926614|DRUG|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
48667350|NCT00926614|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
48667351|NCT06563960|OTHER|carbonated water|Participants will drink carbonated water during videofluoroscopy.
48667352|NCT06078566|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
48667353|NCT03296982|OTHER|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
48667354|NCT03296982|DRUG|edoxaban|
48667355|NCT03296982|DRUG|Enoxaparin|
48667356|NCT03296982|DRUG|Saline sham|
48667357|NCT00366457|DRUG|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
48144942|NCT02332889|BIOLOGICAL|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be \> 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
48356149|NCT05000866|BEHAVIORAL|Communication skills training video|The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.
48505934|NCT03265418|PROCEDURE|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
48667358|NCT00366457|DRUG|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
47988334|NCT05870709|OTHER|sacubitril/valsartan|There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.
48144943|NCT02332889|DRUG|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
48667359|NCT00366457|DRUG|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
48667360|NCT05918848|DEVICE|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
48667361|NCT03508050|DEVICE|Clamping the Double Lumen Tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
48667362|NCT04542681|DRUG|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
48667363|NCT04542681|DRUG|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
48667364|NCT04542681|DRUG|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
48667365|NCT05270525|DRUG|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
48667366|NCT05270525|DRUG|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
48667367|NCT02288130|DRUG|GnRHa|
48667368|NCT02288130|DRUG|Ulipristal|
48667369|NCT03064308|OTHER|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
47988335|NCT02814123|OTHER|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
47988336|NCT00509782|DRUG|ZIO-101|Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
47988337|NCT02646280|OTHER|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
48667370|NCT04800692|DRUG|Tetrahydrobiopterin 10 mg/kg|10mg/kg of Tetrahydrobiopterin daily.
47988338|NCT02646280|OTHER|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
48667371|NCT04800692|DRUG|Tetrahydrobiopterin 20 mg/kg|20mg/kg of Tetrahydrobiopterin daily.
48667372|NCT04800692|DRUG|L-Ascorbate|3300 mg of l-ascorbate once daily
48667373|NCT04800692|DRUG|L-Arginine|3400mg of l-arginine once daily
47988339|NCT03454750|DRUG|177Lu-PSMA|177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
47988340|NCT00298220|BEHAVIORAL|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
47988341|NCT00298220|BEHAVIORAL|Dissemination guideline and patient information letters|
48667374|NCT00342134|PROCEDURE|Stem Cell Transplanataion|
48667375|NCT05779930|BIOLOGICAL|CD19 specific Chimeric Antigen Receptor T Cell|Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
48667376|NCT03796910|DRUG|SPR720 for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
48667377|NCT03796910|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
48144944|NCT05816707|BIOLOGICAL|PRF|"Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture"
48144945|NCT05816707|BIOLOGICAL|Curcuma Longa gel|Curcuma Longa gel
48144946|NCT05816707|OTHER|extraction socket|extraction socket
48144947|NCT01347294|DRUG|Bleomycin|Intralesional
48144948|NCT01347294|DRUG|Fibrovein|Intralesional
48144949|NCT01347294|DRUG|Bleomycin + Fibrovein|Intralesional
48144950|NCT05396001|BEHAVIORAL|LowSalt4Life Application|LowSalt4Life is a dietary sodium intervention mobile application that promotes lower sodium intake.
48144951|NCT05396001|BEHAVIORAL|Just-In-time Adaptive Intervention (JITAI)|LowSalt4Life is a dietary sodium application with a just-in-time adaptive intervention (JITAI) component enabled.
48144952|NCT01368484|DIETARY_SUPPLEMENT|Sunflower oil|1500 mg sunflower/day for 10 weeks
48144953|NCT01368484|DIETARY_SUPPLEMENT|Docosahexanoic acid|1500mg/day for 10 weeks
48144954|NCT02204202|DRUG|[18F]FDG|10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
48144955|NCT02204202|DRUG|[18F]ISO-1|8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
48144956|NCT03686345|DRUG|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
48144957|NCT06358599|DRUG|Cisplatin|Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
48144958|NCT03611985|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
48144959|NCT03611985|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
48144960|NCT06510985|DEVICE|transcutaneous vagus nerve stimulation|The study employs a CE-certified tVNS® E device, ensuring European safety standards (EU regulation 2017/745 on medical devices). This device features a stimulation cycle of 28 seconds on and 32 seconds off, with a 25 Hz impulse frequency. For the high-intensity group, the stimulation intensity will be individually adjusted in the session before starting the high-intensity tVNS stimulation at home. Recommended daily usage is max. 4 hours, after which it automatically shuts off.
48144961|NCT06510985|BEHAVIORAL|Monitoring|Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.
48144962|NCT06510985|DEVICE|cardiowatch bracelet|The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.
48144963|NCT03847727|DRUG|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
48144964|NCT03853889|PROCEDURE|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
48505935|NCT03679182|DRUG|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
48667378|NCT03796910|DRUG|SPR720 for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
48667379|NCT03796910|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
47988342|NCT00298220|BEHAVIORAL|Tailored educational training|for GP(T)s
48144965|NCT01020578|OTHER|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
48144966|NCT00579839|PROCEDURE|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
48144967|NCT00579839|PROCEDURE|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
48144968|NCT02124044|DRUG|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
48505936|NCT04514068|PROCEDURE|Acupuncture|In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.
48144969|NCT02124044|DRUG|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
48667380|NCT05217173|OTHER|telerehabilitation|It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks
48667381|NCT03464266|COMBINATION_PRODUCT|FTC/TDF and DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
48144970|NCT04514978|PROCEDURE|Blood donation and blood transfusion|24 subjects (12 female, 12 male) is phlebotomized and four weeks later \~130 mL packed red blood cells are re-infused in the same subjects.
48144971|NCT03942094|DRUG|Nilotinib|"Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily"
48667382|NCT03464266|DRUG|FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
48667383|NCT03464266|DRUG|DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
47988343|NCT00298220|BEHAVIORAL|Tailored outreach based facilitator support|in the practices of the GPTs
47988344|NCT00298220|BEHAVIORAL|Facilitation of co-operation with local addiction services|
47988345|NCT00298220|BEHAVIORAL|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
47988346|NCT00298220|BEHAVIORAL|Reminder-card for GP's desk|
47988347|NCT00298220|BEHAVIORAL|Personal feedback to patients|Patients receive advise based on their premeasurement answers
47988348|NCT02299986|OTHER|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
47988349|NCT03261947|DRUG|TAK-931|TAK-931 hard gelatin capsules
48144972|NCT03180476|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
48144973|NCT01840085|DRUG|0.03% DSC127 topical gel|
48144974|NCT00861991|BEHAVIORAL|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
48144975|NCT06554509|DRUG|SHR-1819 injection|SHR-1819 injection
48144976|NCT06554509|DRUG|Placebo|placebo
48144977|NCT00863902|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
48144978|NCT00863902|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
48144979|NCT04917315|DRUG|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
48144980|NCT04917315|DRUG|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
48144981|NCT05645445|DEVICE|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
48144982|NCT01124045|DRUG|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
48144983|NCT01124045|DRUG|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
48144984|NCT04257916|OTHER|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
48144985|NCT04257916|OTHER|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
48144986|NCT06030739|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
48144987|NCT04190485|OTHER|Placebo|Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
48667384|NCT03464266|OTHER|Neither DMPA nor FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
48667385|NCT00713011|DRUG|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
47988350|NCT04881708|DEVICE|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
47988351|NCT02716103|OTHER|blood collection|
47988352|NCT02716103|OTHER|bone marrow collection|
47988353|NCT03064191|COMBINATION_PRODUCT|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
47988354|NCT03064191|OTHER|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
47988355|NCT05725720|OTHER|Gut microbiome analysis|Characterization of the compositional and functional modifications of gut microbiome in patients affected by lymphoma undergoing therapy with CAR-T cells from baseline until the restaging after 18 months from the CAR-T cell infusion
47988356|NCT00309842|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days.
47988357|NCT00309842|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
47988358|NCT00309842|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \> 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
47988359|NCT00309842|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
47988360|NCT00309842|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
47988361|NCT00309842|PROCEDURE|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
47988362|NCT00309842|RADIATION|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
47988363|NCT03652844|PROCEDURE|AAM|Subcutaneous injection procedure
47988364|NCT06359782|DRUG|C1 Esterase Inhibitor Injection [Cinryze]|C1 Esterase Inhibitor Injection \[Cinryze\]
48144988|NCT04190485|OTHER|GMNL-143 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
48144989|NCT04190485|OTHER|GMNL-464 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
48144990|NCT03775252|DIETARY_SUPPLEMENT|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
48144991|NCT01061580|DEVICE|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
48144992|NCT06317610|OTHER|growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI|biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment
48144994|NCT02958553|DEVICE|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
48144995|NCT02958553|DEVICE|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
48144996|NCT04272385|OTHER|Observational|Observational
48144997|NCT00069706|DRUG|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
48144998|NCT00069706|OTHER|AL-12182 Ophthalmic Solution Vehicle|Placebo
48667386|NCT00713011|DRUG|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
48667387|NCT05324241|DIETARY_SUPPLEMENT|Fat Microcapsules|Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
48667388|NCT05166668|DRUG|Letrozole 2.5mg tablet|letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
48667389|NCT01357681|DRUG|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
48144999|NCT00069706|DRUG|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
48667390|NCT01357681|DRUG|Placebo|Placebo
48667391|NCT05578014|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
48145000|NCT00069706|DRUG|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
48145001|NCT00069706|DRUG|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
48145002|NCT05255744|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
48145003|NCT02959411|DRUG|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
48505937|NCT04514068|PROCEDURE|Sham acupuncture|Sham acupuncture
48505938|NCT03040557|DEVICE|Flexible footwear|- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
48667392|NCT04088903|DRUG|Daratumumab|\>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
48667393|NCT02995590|DRUG|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
48145004|NCT02959411|DRUG|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
48145005|NCT00388726|DRUG|E7389|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
48145006|NCT00388726|DRUG|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
48145007|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
48145008|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
48145009|NCT01196364|OTHER|Dietary Supplement: water with noncalorie sweetener|
48145010|NCT01196364|OTHER|Activity: With noncalorie sweetener or glucose|
48505939|NCT03040557|DEVICE|Orthopedic insole|- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
48505940|NCT06201156|DEVICE|Metered Dose Inhaler With Spacer Device|Bronchodilator Therapy
48505941|NCT06632470|DRUG|Secretome injection|Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
48505942|NCT06632470|DRUG|Vitamin B12 Injection|Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months
48505943|NCT04920500|DRUG|Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. d1,3,5 Induction 2: \[100 U/m²\] i.v. d1,3
48667394|NCT03913351|BEHAVIORAL|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
48145011|NCT05615285|OTHER|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
48145012|NCT04277156|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063|7 drops contain Lactobacillus rhamnosus GG 5x10\^9 CFU; and Lactobacillus reuteri 1x10\^8 CFU.
48145013|NCT04277156|DIETARY_SUPPLEMENT|L rhamnosus ATCC 53103|5 drops contain Lactobacillus rhamnosus 5x10\^9 CFU.
48145014|NCT04669366|DRUG|sunitinib|As provided in real world
48145015|NCT04669366|DRUG|axitinib|As provided in real world
47988365|NCT06359782|DRUG|Placebo|Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
47988366|NCT06087783|DIETARY_SUPPLEMENT|Experimental product - Fortifit® Powder|Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
48145016|NCT03122860|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
48145017|NCT03122860|OTHER|Placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
48145018|NCT03122860|OTHER|Sham|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
48667395|NCT06118658|DRUG|tislelizumab|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
48667396|NCT03763747|DEVICE|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
48667397|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
47988367|NCT06087783|OTHER|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
47988368|NCT00505843|DRUG|MK0657|7mg MK0657 capsules
47988369|NCT00505843|DRUG|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
48145019|NCT02817386|OTHER|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
48145020|NCT04709185|DRUG|Dexamethasone 1 MG Oral Tablet|oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
48145021|NCT04709185|DRUG|Placebo|oral placebo at 23:00-24:00 the night before AVS
48667398|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
48667399|NCT01138514|DRUG|Placebo|Placebo
47988370|NCT00505843|DRUG|Comparator: levodopa|levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
47988371|NCT00505843|DRUG|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
47988372|NCT06507449|DEVICE|Lithotripsy|Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent
47988373|NCT06507449|DEVICE|Orbital atherectomy|Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent
47988374|NCT06507449|DEVICE|High-pressure non-compliant balloon|Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent
47988375|NCT06507449|DEVICE|Optical coherence tomography|Optical coherence tomography assessment of coronary arteries.
47988376|NCT06507449|DEVICE|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.
47988377|NCT04345263|PROCEDURE|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
47988378|NCT01068119|PROCEDURE|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
47988379|NCT01729754|DRUG|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
48145022|NCT06129188|DRUG|Remimazolam|Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
48145023|NCT06129188|DRUG|Propofol|Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
48145024|NCT00186563|PROCEDURE|Micro-plasmapheresis|
48145025|NCT01750788|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
48145026|NCT06297603|DRUG|Retatrutide|Administered SC
48145027|NCT06297603|DRUG|Placebo|Administered SC
48145028|NCT01031056|PROCEDURE|Blood Draw|
48145029|NCT01031056|PROCEDURE|Frozen Tumor Specimens|
48667400|NCT01459120|OTHER|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
47988380|NCT01729754|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
47988381|NCT01729754|DRUG|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
48667401|NCT01459120|OTHER|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
47988382|NCT01729754|DRUG|Etanercept Placebo|Matching placebo to etanercept administered SC
47988383|NCT01729754|DRUG|Etanercept 50 mg|Etanercept 50 mg administered SC
47988384|NCT05494450|DEVICE|ExufiberAG+|confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
47988385|NCT02662127|DEVICE|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
48145030|NCT01204502|BIOLOGICAL|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg"
48145031|NCT00003152|BIOLOGICAL|filgrastim|
48505944|NCT04920500|DRUG|Vyxeos、Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: \[100 U/m²\] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
48505945|NCT06634108|DRUG|Genistein|The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
48667402|NCT05951426|PROCEDURE|1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage|"1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium"
47988386|NCT00002433|DRUG|Interferon gamma-1b|
47988387|NCT05429190|RADIATION|Short MRI surveillance (SMS) protocol|Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging
47988388|NCT05429190|RADIATION|Bi-annual ultrasonography screening|Bi-annual ultrasonography for screening of HCC in high-risk patients
47988389|NCT05298280|DEVICE|Pendulum appliance|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
47988390|NCT05298280|DEVICE|clear aligners|The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
47988391|NCT02284711|DEVICE|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
48145032|NCT00003152|BIOLOGICAL|recombinant interferon alfa|
48505946|NCT03364868|DRUG|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
48505947|NCT03364868|OTHER|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
48505948|NCT02907255|DEVICE|Oximetry monitor|Wireless respiratory monitoring system
48505949|NCT05653284|DRUG|AK130|IV infusion, specified dose on specified days.
48505950|NCT04530435|DEVICE|PEP flute|Participants are advised to use a PEP flute at least three times daily at an appropriate resistance. Ideally, each session consists of 15 breaths (for approximately 1 minute) repeated twice at an upright position.
48505951|NCT05438914|DEVICE|Repair of the subscapularis|"The subscapularis will be repaired using the suture through bone and prosthesis holes surgical technique."
48505952|NCT05603312|GENETIC|AAV-GAD Dose 1|Bilateral infusion of AAV-GAD Dose 1
48505953|NCT05603312|GENETIC|AAV-GAD Dose 2|Bilateral infusion of AAV-GAD Dose 2
48505954|NCT05603312|PROCEDURE|Sham Surgery|Sham infusion
48505955|NCT01832779|OTHER|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
48667403|NCT02976181|DEVICE|IPG|Patient might require IPG device to be implanted under standard of care
48667404|NCT05648708|PROCEDURE|Combine Adductor Canal & Sciatic Nerve Block|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia
48667405|NCT05648708|PROCEDURE|Combine Femoral & Sciatic Nerve Block|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia
48667406|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
48145033|NCT00003152|DRUG|cyclophosphamide|
48667407|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
48667408|NCT03984279|OTHER|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
48667409|NCT04015804|OTHER|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
48667410|NCT01788878|BEHAVIORAL|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
48145034|NCT00003152|DRUG|prednisone|
48145035|NCT00003152|DRUG|vincristine sulfate|
48356150|NCT05000866|BEHAVIORAL|Drug use module|The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
48356151|NCT04755699|DEVICE|Transcutaneous Electrical Stimulation|The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
48356152|NCT03164746|OTHER|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
48667411|NCT00066872|DRUG|imiquimod|
48667412|NCT00066872|PROCEDURE|conventional surgery|
48667413|NCT05857748|DRUG|lifitegrast|patient newly started on medication will be followed for 6 months
48667414|NCT01822925|DRUG|DA-9801 300mg|300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
48356153|NCT03164746|OTHER|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
48667415|NCT01822925|DRUG|DA-9801 600mg|600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
48667416|NCT01822925|DRUG|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
48667417|NCT01822925|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
47988392|NCT02284711|DEVICE|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
48145036|NCT00003152|PROCEDURE|autologous bone marrow transplantation|
48145037|NCT00003152|PROCEDURE|bone marrow ablation with stem cell support|
48145038|NCT00003152|PROCEDURE|peripheral blood stem cell transplantation|
48145039|NCT00003152|RADIATION|radiation therapy|
48145040|NCT02486107|PROCEDURE|surgical procedure|
48145041|NCT05918549|DEVICE|Motion Analysis in Musculoskeletal Oncology|Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
48145042|NCT04500665|DRUG|Colchicine|Colchicine
48356154|NCT01749865|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
48667418|NCT01146145|DRUG|Ketamine|intravenous morphine titration combined to ketamine
48667419|NCT05910658|BEHAVIORAL|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
48667420|NCT01991860|DRUG|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
48667421|NCT01991860|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
48667422|NCT00658268|DRUG|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
48667423|NCT00658268|DRUG|Placebo|10 ml, single dose mixed in bone graft at operation
48667424|NCT00481936|DRUG|VB6-845|Intravenous infusion once weekly for 4 weeks
48145043|NCT04500665|DRUG|Placebo|Placebo
48145044|NCT00330499|DRUG|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
48145045|NCT00330499|RADIATION|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
48145046|NCT00799331|DRUG|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
48145047|NCT00799331|DRUG|placebo|Oral suspension.
48145048|NCT01019135|BEHAVIORAL|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
48145049|NCT05534230|DRUG|Dexmedetomidine Injectable Solution|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
48667425|NCT02536664|DRUG|Rituximab|
48667426|NCT06446570|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
48667427|NCT04715035|OTHER|Physical therapy interventions|mobilization, stretch, education, eccentric exercises
47988393|NCT01648907|OTHER|Imaging exams|"Radiological examinations:~* Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~* MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~* Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~* Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~* Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
47988394|NCT03817385|DEVICE|repetitive TMS|rTMS x 10 times
48667428|NCT05678426|BEHAVIORAL|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
48356155|NCT00236574|DRUG|Galantamine hydrobromide|
48505956|NCT06632899|BEHAVIORAL|combined physical and cognitive training and 1 hour of risk factor prevention and healthy lifestyle development|"Dosage: a 2-hour session once a week for 12 weeks. Each multidomain intervention session includes 1 hour of combined physical (balance, strength and aerobic exercises) and cognitive (attention, memory, calculation, visual-spatial ability, processing speed and executive function) training and 1 hour of risk factor prevention (nutrition, chronic disease management, oral health, fall prevention and transportation safety, psychosocial factors and sleep) and healthy lifestyle development (Discussion and sharing on topics such as self-health management, goal setting, and the health journal.)"
47988395|NCT03817385|DEVICE|robotic GT|robotic gait training for 20 times
47988396|NCT00744627|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
47988397|NCT00744627|DRUG|Placebo|Vortioxetine placebo-matching capsules
47988398|NCT03916757|BIOLOGICAL|V-Boost|Open label setting
47988399|NCT00528099|DRUG|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
47988400|NCT03506607|OTHER|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
47988401|NCT03506607|OTHER|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
47988402|NCT03506607|OTHER|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
47988403|NCT00130221|DRUG|2% chlorhexidine gluconate impregnated cloth|
47988404|NCT00130221|OTHER|Daily bathing with Bar soap|bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
47988405|NCT02441608|DEVICE|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
47988406|NCT04983576|PROCEDURE|spinal fusion|patients undergoing spinal fusion
47988407|NCT03888196|DIETARY_SUPPLEMENT|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
47988408|NCT03888196|DIETARY_SUPPLEMENT|Placebo Supplementation|500 mg/day of Cellulose
48145050|NCT05534230|DRUG|Saline|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
48145051|NCT03695185|DRUG|Ravagalimab 600 mg|Ravagalimab 600 mg was administered intravenously (IV).
48145052|NCT03695185|DRUG|Ravagalimab 300 mg|Ravagalimab 300 mg was administered subcutaneously (SC).
48145053|NCT02441829|DRUG|Eleclazine|Eleclazine tablets administered orally in morning with food
48356156|NCT03754842|OTHER|Placebo (twice daily)|Matching placebo
48356157|NCT03754842|OTHER|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
48356158|NCT05594667|DRUG|Psilocybin|25mg of psilocybin provided by Filament Health
48356159|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
48356160|NCT03030794|DEVICE|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
48356161|NCT00439699|DRUG|Memantine|Mematine administration
48356162|NCT04558385|DIAGNOSTIC_TEST|IgG SARS CoV2|IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population
48356163|NCT04635111|DRUG|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
48505957|NCT04293900|OTHER|24-hour dietary recall|Dietary intake assessment conducted by a Registered Dietitian Nutritionist. This assessment will occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
48356164|NCT03575780|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
48356165|NCT00333736|DEVICE|Biojector|All patients received biojector to use with BID enfuvirtide doses
48356166|NCT04091451|BIOLOGICAL|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly
48356167|NCT04091451|DRUG|Placebo|2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
48356168|NCT00908895|PROCEDURE|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
48356169|NCT00908895|PROCEDURE|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
48667429|NCT05678426|BEHAVIORAL|Intermittent fasting|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
48505958|NCT04293900|OTHER|Hand grip strength|Measurement of grip strength using a hand dynamometer. This will test occur prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
48667430|NCT05678426|BEHAVIORAL|Intermittent fasting with ketogenic supplement|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
48667431|NCT03276182|DEVICE|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
48145054|NCT03266419|DRUG|Deep NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: 0.7 mg/kg~* Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
48505959|NCT04293900|OTHER|International Physical Activity Questionnaire|Survey about physical activity over the previous 7 days. This survey will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
48667432|NCT04179617|OTHER|5% nicotine content JUUL pod|JUUL pods that contain 5% nicotine
48667433|NCT04179617|OTHER|3% nicotine content JUUL pod|JUUL pods that contain 3% nicotine
48667434|NCT02045602|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
48667435|NCT02045602|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
48356170|NCT02444689|BEHAVIORAL|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
48356171|NCT02444689|BEHAVIORAL|Standard of care education|
48356172|NCT00997607|BIOLOGICAL|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
48356173|NCT00997607|BIOLOGICAL|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
48356174|NCT00997607|OTHER|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
48356175|NCT01215877|DRUG|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~* the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC \< 1,500/mm3, a platelet count \< 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~* for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
48356176|NCT01864629|BEHAVIORAL|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
48667436|NCT02045602|DRUG|Abraxane®|125 mg/m2 intravenous administration
48145055|NCT03266419|DRUG|Moderate NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: none~* Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
48145056|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
48667437|NCT01326442|OTHER|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
48145057|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
48145058|NCT04994093|OTHER|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
48145059|NCT01078272|OTHER|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
48145060|NCT01078272|OTHER|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
48145061|NCT01867307|DRUG|Empagliflozin|
48145062|NCT01867307|DRUG|BI 10773|open label
48145063|NCT05397509|OTHER|Olive leaf tea|250 mL of Olive leaf tea and a high-glycemic breakfast
48667438|NCT01326442|DIETARY_SUPPLEMENT|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
47988409|NCT04834427|DRUG|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h.~2. Intramuscular injection：The dose is 2\~4 mg/kg."
47988410|NCT04834427|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
47988411|NCT03582020|DIETARY_SUPPLEMENT|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
47988412|NCT00778089|DEVICE|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
48145064|NCT05397509|OTHER|Placebo tea|250 mL of placebo tea and a high-glycemic breakfast
48145065|NCT04705051|DRUG|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
48145066|NCT00443274|OTHER|NBIR - US National Breast Implant Registry|NBIR is intended to be a surveillance tool to track patient safety and real-world outcomes associated with breast implants used for aesthetic or reconstructive purposes..
48667439|NCT06282341|OTHER|Race: Simulated marathon|Participants will take part in a race: simulated marathon. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
48667440|NCT06282341|OTHER|Race: Simulated trail|Participants will take part in a race: simulated trail. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
48667441|NCT06282341|OTHER|Race: Trail in nature|Participants will take part in a race: trail in nature. Before, during, immediately after and the month after the race, neuromuscular, physiological and biomechanical assessments will take place.
48145067|NCT00443274|DEVICE|410 Arm|Anatomically shaped silicone gel-filled breast implants.
48145068|NCT00443274|DEVICE|BIFs - Breast Implant Follow-Up Study|Round silicone gel-filled breast implants and saline-filled breast implants
48145069|NCT03070548|DRUG|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
48145070|NCT02936544|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
48145071|NCT02704156|DEVICE|Cyberknife plus Pembrolizumab and Trametinib|Radiation therapy plus drug
48145072|NCT02704156|DEVICE|Cyberknife plus Gemcitabine|Radiation therapy plus drug
48145073|NCT01297595|DRUG|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
48145074|NCT01829711|DRUG|Moxetumomab pasudotox|
48356177|NCT02850276|DRUG|Pyridostigmine|
48505960|NCT04293900|OTHER|Patient-reported outcomes survey|Survey about symptoms and side effects experienced during cancer treatment. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
48505961|NCT04293900|OTHER|Pittsburgh Sleep Quality Index|Survey about sleep habits and quality over the past month. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
48667442|NCT02192957|DEVICE|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion"
48667443|NCT00335881|BIOLOGICAL|hepatitis B vaccine|
48667444|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
48145075|NCT01829711|DRUG|IV Bag Protectant for Moxetumomab pasudotox|
48145076|NCT02065609|DRUG|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
48145077|NCT02065609|DRUG|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
48145078|NCT00044759|DRUG|Piperacillin/Tazobactam (Tazocin)|
48145079|NCT02042092|DEVICE|Ultrasound|
48145080|NCT02042092|DEVICE|MRA|
48356178|NCT01355094|DEVICE|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
48505962|NCT04293900|OTHER|Functional Assessment of Cancer Treatment - Lymphoma|Survey about quality of life for people with a diagnosis of lymphoma. This will be administered prior to starting R-CHOP chemotherapy, during the clinic visits for each round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
47988413|NCT04447079|BEHAVIORAL|Assertive Community Treatment (ACT)|"Assertive Community Treatment (ACT) is part of a 6-month program ARFAs will undergo.~ACT teams will engage with ARFAs on a dedicated schedule. Each visit would last an average of 60 minutes. There will not be a re-arrangement of no-show visits. ACT teams will re-engage the ARFA over the phone to plan for the next visit as per the schedule.~In keeping with principles of ACT, ARFA's will be assertively sought out in the community and provided intensive engagement, with holistic and supportive care alongside a harm reduction approach. Care will also involve case management and involvement of SSA's.~Each interaction during the treatment period will focus on various aspects covering physical health, mental health, and addiction"
47988414|NCT05047679|BEHAVIORAL|Perioperative Pain Neuroscience Education|Perioperative pain neuroscience education addresses modifiable preoperative risk factors, and in particular cognitive and emotional risk factors, such as fear of movement and pain catastrophizing (i.e., excessively negative orientation toward pain). This education is a cognitive-based therapeutic intervention which reconceptualizes pain, informs patients about what to expect from the evolution of their pain, de-emphasizes the patho-anatomical content and focuses on factors contributing to the development of pain. It explains this all within a biopsychosocial framework, which means that it aims to optimize patients' beliefs. Furthermore, it intends to reassure the patient about the decision to have surgery, to potentially decrease perioperative distress.
48667445|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
47988415|NCT05047679|BEHAVIORAL|Perioperative Biomedical Education|Perioperative biomedical education will discuss the anatomy, physiology and biomechanics of the lumbar spine with the patient. Additionally, the content of this education includes the expected course of postoperative back and leg pain, as well as ergonomic advice on patient-specific daily activities. This education will be given within a biomedical framework, which means that it aims to explain the patients' complaints and recovery while focusing on anatomy and biomechanics, as opposed to patients' beliefs and cognitions.
47988416|NCT05216731|PROCEDURE|Femoro-popliteal bypass|Under general or local anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
47988417|NCT05216731|PROCEDURE|Endovascular procedure|Under general anesthesia, local anesthesia or sedation: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
47988418|NCT02723032|DEVICE|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
47988419|NCT04853979|OTHER|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
47988420|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
47988421|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
47988422|NCT00616655|DRUG|Placebo|Placebo total daily dose 0.9 mg
47988423|NCT02045706|OTHER|Community Health Worker Trainings|
47988424|NCT02055014|DRUG|Liraglutide|
48667446|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
48667447|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
48667448|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
48145081|NCT05749120|PROCEDURE|Recipient vessel selected for microanastomosis|Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
48145082|NCT03338166|OTHER|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
48505963|NCT04293900|OTHER|urine sample (optional)|Collect three urine samples either in the clinic or at home. This specimen collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
48505964|NCT04293900|OTHER|fecal sample (optional)|Collect a fecal sample either in the clinic or at home. This sample collection will occur prior to starting R-CHOP chemotherapy, after the third round of R-CHOP chemotherapy, and again at the end of the scheduled course of R-CHOP chemotherapy.
48505965|NCT00001049|DRUG|Zidovudine|
48505966|NCT00001049|DRUG|Didanosine|
48505967|NCT05228535|DIETARY_SUPPLEMENT|Human milk fortifier|Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
48505968|NCT03212170|DRUG|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
48667449|NCT01395134|DEVICE|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
48667450|NCT03984825|DRUG|GSK3640254|GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
48667451|NCT03984825|DRUG|Portia|Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
47988425|NCT02055014|DEVICE|Duodenal-jejunal bypass liner - Endobarrier device|
47988426|NCT00437099|DRUG|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
47988427|NCT00437099|DRUG|Placebo|Placebo
48145083|NCT03919851|DRUG|Antibiotics|Administration of antibiotics
48145084|NCT02050815|DRUG|MEK162|
48667452|NCT00473174|DRUG|Ramipril|Dosing on awakening versus bedtime
48667453|NCT00473174|DEVICE|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
48667454|NCT05831943|DIAGNOSTIC_TEST|Contrast enhanced Kidney CT|"* Test group : Patient undergoing CT scan with 80kVP protocol and using low concentration intravascular contrast media ( Iobrix 270 mgl/MI , Taejoon pharm, Seoul, South Korea)~* Control group : Patient undergoing CT scan with 120kVP protocol and using high concentration intravascular contrast media ( Iobrix 320 mgl/MI , Taejoon pharm, Seoul, South Korea)"
48667455|NCT04700150|OTHER|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
48667456|NCT04700150|OTHER|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
48667457|NCT03189732|DRUG|Metformin Oral|
48667458|NCT03189732|DRUG|Metformin local in AT|
48667459|NCT03189732|OTHER|Exercise|
48667460|NCT03906214|OTHER|Web-based Survey|"Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use."
48667461|NCT01938729|PROCEDURE|Liver resection and placement of hepatic artery infusion pump|
48667462|NCT01938729|DRUG|FLOXURIDINE|
48667463|NCT01938729|DRUG|DEXAMETHASONE|
48667464|NCT01938729|DRUG|GEMCITABINE|
48667465|NCT05617027|OTHER|actual transcranial direct current stimulation (tDCS)|"tDCS is a non-invasive brain stimulation technique that would influence the brain's pain control mechanisms.~The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA."
48145085|NCT04150965|DRUG|Elotuzumab, pomalidomide, dexamethasone|Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
48356179|NCT01355094|DEVICE|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
48505969|NCT06292585|PROCEDURE|MMA embolization plus medical therapy|Patients assigned to the intervention group will receive endovascular embolization treatment within 2 hours after enrollment.
48667466|NCT05617027|OTHER|placebo transcranial direct current stimulation (tDCS)|The anode is attached to the skull above the M1 opposite the painful side (in case of unilateral pain) or opposite the dominant hand (in case of bilateral pain). The cathode (at the supraorbital level opposite the stimulated M1) will be positioned using the 10-20 EEG system and the tDCS intensity will be 2 mA for 30 secondes, and then 0 mA for the rest of the 20-minute session.
48667467|NCT03732989|DEVICE|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
48667468|NCT03732989|DEVICE|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
48667469|NCT04490278|OTHER|Medical Record Review - Inpatient Treatment|Patient characteristics, medical history, and information regarding their inpatient treatment from the electronic medical record
48667470|NCT04490278|OTHER|Online Questionnaires|Patients will complete online questionnaires related to their physical, cognitive and mental health function and inquire about current treatments. The multiprofessional CoV-PICS clinic practitioners will evaluate their responses and, combined with information obtained during their virtual visits, formulate a suggested treatment plan and needed referrals.
48356180|NCT06257615|BEHAVIORAL|Education provided via TeleNursing|"Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42)."
48356181|NCT01365715|PROCEDURE|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
48356182|NCT01365715|PROCEDURE|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
48356183|NCT00784459|DRUG|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
48356184|NCT00784459|DRUG|Placebo|Treatment with Placebo, IV
48356185|NCT05378893|DRUG|DR10624 for injection|administered via subcutaneous injection
48356186|NCT05378893|DRUG|Placebo|administered via subcutaneous injection
48667471|NCT04335071|DRUG|Tocilizumab (TCZ)|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
48667472|NCT04335071|DRUG|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
47988428|NCT01797692|OTHER|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
47988429|NCT02864251|BIOLOGICAL|Nivolumab|Specified dose on specified days
47988430|NCT02864251|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48356187|NCT02734849|DRUG|AK001 low dose|25 mg AK001 will be administered as multiple doses
48356188|NCT02734849|DRUG|AK001 high dose|250 mg AK001 will be administered as multiple doses
48505970|NCT06292585|DRUG|Medical therapy alone|Patients will receive the best conservative treatment recommended by the guidelines, and conservative treatment will be the same in both groups. Conservative treatment includes medication and general treatment. Drug therapy can be divided into hemostatic treatment, antihypertensive treatment, and symptomatic treatment. Specific local clinical diagnosis and treatment standards shall prevail or refer to corresponding clinical guidelines.
47988431|NCT02864251|DRUG|Pemetrexed|Specified dose on specified days
48356189|NCT02734849|DRUG|Placebo|Placebo will be administered as multiple doses
48356190|NCT04030819|BEHAVIORAL|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
48356191|NCT05885373|DIETARY_SUPPLEMENT|SIM01|SIM01 consists of a blend of food-grade Bifidobacterium as active probiotics
48505971|NCT04856423|DIAGNOSTIC_TEST|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
48667473|NCT03655847|DRUG|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
48667474|NCT03768323|OTHER|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
48667475|NCT03768323|OTHER|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
47988432|NCT02864251|DRUG|Cisplatin|Specified dose on specified days
47988433|NCT02864251|DRUG|Carboplatin|Specified dose on specified days
47988434|NCT00713154|DRUG|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
48667476|NCT01889914|DRUG|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
48505972|NCT05864963|PROCEDURE|Medial tab-type fasciocutaneous flap|"The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect."
48145086|NCT04150965|DRUG|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
48145087|NCT04150965|DRUG|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
48505973|NCT00444379|DRUG|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
48505974|NCT01939574|OTHER|Chemoradiation Therapy|"* Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~* Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
48505975|NCT01939574|OTHER|Adjuvant Therapy|"* Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events\> grade 2 are noted.~* Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
48505976|NCT01688492|DRUG|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
48667477|NCT04079738|DRUG|TAK-659|TAK-659
48667478|NCT04079738|DRUG|Ixazomib|Ixazomib
48667479|NCT00000305|DRUG|Dextroamphetamine|
48667480|NCT02647671|DRUG|Aquamin®|90 days of Aquamin
48667481|NCT02647671|DRUG|Calcium Carbonate|90 days of Calcium Carbonate
48667482|NCT02647671|DRUG|Placebo|90 days of placebo
48356192|NCT03869489|DEVICE|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
48667483|NCT00874601|DRUG|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
48667484|NCT00977210|DRUG|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
48667485|NCT02179034|DRUG|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
47988435|NCT00713154|DRUG|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
47988436|NCT02375191|DRUG|fentanyl|
48145088|NCT04150965|DRUG|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
48145089|NCT04150965|DRUG|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
48356193|NCT03869489|DEVICE|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
48667486|NCT02179034|OTHER|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
48356194|NCT03869489|DEVICE|Sham tDCS stimulation|Sham tDCS stimulation will be applied
48356195|NCT04904991|PROCEDURE|Chan-Chuang qigong|"This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, \& Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance."
48667487|NCT02179034|OTHER|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
48145090|NCT02085941|DEVICE|Cryoablation|Cryoablation using 17G Galil cryoprobe
48145091|NCT02085941|DEVICE|Biopsy|Biopsy using 18G Temno core biopsy needle
48356196|NCT04507516|OTHER|Water-only Fasting|Water-only fasting for at least 10 days followed by 5 days of refeed.
48145092|NCT01655082|DRUG|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
48145093|NCT01655082|DRUG|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
48145094|NCT03133572|DEVICE|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
48145095|NCT03133572|DEVICE|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
48356197|NCT02261311|OTHER|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
48356198|NCT01913652|DRUG|Cabazitaxel|
48356199|NCT04574791|DRUG|TiZANidine 2 MG Oral Capsule|Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
48356200|NCT06410729|OTHER|Observational study, no intervention|
48356201|NCT05823376|DRUG|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.
48356202|NCT05846542|OTHER|Video-game based therapy|Video-game based therapy will be designed for the individual basis for the upper extremity.
48356203|NCT05846542|OTHER|Conventional physiotherapy|Conventional physiotherapy within a specific program
48356204|NCT01310192|DEVICE|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
48505977|NCT04928716|OTHER|voiding phase evaluation|Assessment of voiding phase in multiple sclerosis patients
47988437|NCT02375191|DRUG|dexmedetomidine|
48356205|NCT03192384|BEHAVIORAL|Educational programme|Educational programme for ward staff
48356206|NCT02807194|OTHER|spinal anesthesia|
47988438|NCT02375191|DRUG|Ropivacaine|
48356207|NCT02807194|OTHER|general anesthesia|
48505978|NCT05585879|DEVICE|Pure-Vu EVS|"Subjects will be enrolled until 115 inadequate bowel prep cases via SOC are accrued and subsequently treated with Pure-Vu EVS. Inadequate OCs defined as such if any of the following are met:~* Boston Bowel Preparation Score (BBPS) \< 6 (Adequacy is defined as BBPS of 2 or greater in each segment)~* Inability to identify \> 5mm polyps"
47988439|NCT04669392|DRUG|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
47988440|NCT04572074|OTHER|Guided imagery|10 minutes of guided imagery experience
47988441|NCT04572074|OTHER|Virtual reality|10 minutes of virtual reality experience
47988442|NCT05695690|DEVICE|Ultrasonography|Comparing between value of ultrasound vs MRI in uterine fibroids
47988443|NCT01735643|DEVICE|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
47988444|NCT01735643|OTHER|waiting|waiting for 12 weeks
47988445|NCT01375985|DRUG|AVI-7100|Single intravenous administration
47988446|NCT01375985|DRUG|Placebo|Single intravenous administration
48356208|NCT02807194|PROCEDURE|lumbar disc herniation|
48356209|NCT00928733|DEVICE|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
47988447|NCT04790760|DIETARY_SUPPLEMENT|Supplement Consumption|Participants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6.
47988448|NCT04790760|DEVICE|Continuous Glucose Monitors|Participants will wear a CGM on the back of their left and right arm for weeks 1-6.
47988449|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C antibody test|Qualitative point-of-care test for hepatitis C antibodies (saliva sample)
48145096|NCT02394912|DEVICE|vena cava filter implantation (LUMIFI with Crux VCF System)|
48145097|NCT02637063|BEHAVIORAL|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
48145098|NCT02637063|BEHAVIORAL|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
48145099|NCT02637063|OTHER|Usual care|No intervention beyond participants' own medical care.
48356210|NCT03035409|DRUG|Anamorelin Hydrochloride|Given PO
48356211|NCT03035409|BEHAVIORAL|Exercise Intervention|Undergo physical activity
48356212|NCT03035409|OTHER|Laboratory Biomarker Analysis|Correlative studies
48356213|NCT03035409|OTHER|Nutritional Assessment|Undergo nutritional counseling
48356214|NCT03035409|OTHER|Quality-of-Life Assessment|Ancillary studies
48356215|NCT03035409|OTHER|Questionnaire Administration|Ancillary studies
48667488|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
48667489|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
48667490|NCT02450825|DEVICE|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
48667491|NCT05613556|DEVICE|Orpyx SI® Sensory Insole System|Orpyx SI Sensory Insole System consists of Orpyx Custom Insoles and Orpyx Sensory Technology. The Orpyx Custom Insoles are precisely fabricated for an individual's feet. The Orpyx Sensory Technology, a powered limb overload warning technology, is compatible with the Orpyx Custom Insoles. It is intended for monitoring physiological parameters, such as plantar pressure, motion and temperature, and providing real-time cues for pressure offloading as the patient goes about their daily activities
48145100|NCT01597856|BEHAVIORAL|SBIRT|"SBIRT Therapy overview-~1. Therapist explains purpose of the therapy.~2. Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~3. Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~4. Discuss treatment needs, administer screening, provide feedback."
48145101|NCT04270032|DIAGNOSTIC_TEST|ABUS and HHUS|Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
48667492|NCT00025415|DRUG|imatinib mesylate|Given orally
48667493|NCT00025415|OTHER|pharmacological study|Correlative studies
48667494|NCT05058326|DIAGNOSTIC_TEST|Portable endoanal manometry|Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.
48667495|NCT05058326|DIAGNOSTIC_TEST|Endoanal ultrasound|To assess the integrity of the anal canal.
48667496|NCT05058326|OTHER|Incontinence severity scale questionaires|Wexner and St. Mark's scales.
48667497|NCT04641091|DEVICE|Multispectral Optoacustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
48667498|NCT03021096|OTHER|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
48667499|NCT01680211|DIETARY_SUPPLEMENT|Salacia bark extract|
47988450|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis C RNA test|Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)
47988451|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antibody test|Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)
48145102|NCT02544191|DRUG|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
48145103|NCT02560961|OTHER|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
48667500|NCT01680211|DIETARY_SUPPLEMENT|Salacia leaf extract|
48667501|NCT01680211|DIETARY_SUPPLEMENT|Sesame seed extract|
48667502|NCT01680211|BEHAVIORAL|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
48667503|NCT01680211|OTHER|Placebo|
48667504|NCT02150707|DRUG|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
48667505|NCT02150707|DRUG|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
48667506|NCT05447403|OTHER|Chewing gum combined with WeChat enhanced instructions|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
47988452|NCT05839522|DIAGNOSTIC_TEST|Point-of-care hepatitis B surface antigen test|Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)
47988453|NCT05839522|DIAGNOSTIC_TEST|Point-of-care HIV antibody test|Qualitative HIV antibody point-of-care test (saliva sample)
48145104|NCT02560961|OTHER|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
48145105|NCT01428583|DRUG|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
48356216|NCT00017225|BIOLOGICAL|filgrastim|
48356217|NCT00017225|DRUG|carboplatin|
48667507|NCT05415904|OTHER|HANTA-NE|Observational cohort study
48667508|NCT01542970|DIETARY_SUPPLEMENT|Placebo|Olive oil
48667509|NCT01542970|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
48667510|NCT01542970|DIETARY_SUPPLEMENT|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
48667511|NCT01542970|DIETARY_SUPPLEMENT|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
48667512|NCT01378143|DRUG|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
48667513|NCT00839969|PROCEDURE|Cystoscopy|Saline cystoscopy under general anaesthesia
48667514|NCT00839969|PROCEDURE|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
48667515|NCT01358162|OTHER|Placebo|Placebo given orally, daily for 14 consecutive days
48667516|NCT01358162|DRUG|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
48667517|NCT00938301|DRUG|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
48667518|NCT00938301|DRUG|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
48667519|NCT02428426|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
48667520|NCT03586973|DRUG|Cabozantinib|Cabozantinib tablet
48667521|NCT00650507|PROCEDURE|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
48667522|NCT00650507|PROCEDURE|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
48667523|NCT06272604|BEHAVIORAL|Personalized Exercise Rehabilitation|The experimental group will participate in a 12-week exercise intervention program, carefully transitioning from moderate-intensity interval training to high-intensity interval training. The progression of exercise intensity will be regularly adjusted based on each child's tolerance, ensuring a personalized approach to the regimen. The exercise program is structured into three phases: an adaptation phase, an intensification phase, and a consolidation phase. For each participant, the intensity of the exercises is calculated based on their reserve heart rate, allowing for a tailored and scientifically-grounded progression. This approach aims to optimize the exercise program's effectiveness while maintaining safety and adaptability to individual fitness levels and asthma conditions.
48667524|NCT03857776|OTHER|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
48145106|NCT02761499|DEVICE|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
48145107|NCT01811615|OTHER|alcohol-free experimental mouth rinse|
48145108|NCT01811615|OTHER|alcohol-containing mouth rinsing|
48667525|NCT03857776|OTHER|Standard care|Standard care including referral to a homepage about CAM
48667526|NCT01116284|PROCEDURE|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
48145109|NCT04697615|DEVICE|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
48356218|NCT00017225|DRUG|cisplatin|
48356219|NCT00017225|DRUG|cyclophosphamide|
48356220|NCT00017225|DRUG|dacarbazine|
48356221|NCT00017225|DRUG|doxorubicin hydrochloride|
48356222|NCT00017225|DRUG|etoposide|
48667527|NCT04284709|OTHER|cognitive-physical training|combined physical and cognitive training
48505979|NCT04730648|DRUG|PCSK9 inhibitor|For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
48667528|NCT00716820|DRUG|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
48667529|NCT00713687|DRUG|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility"
48667530|NCT04815863|DIAGNOSTIC_TEST|Assessment of somatic symptom disorder with SSS-CN|SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms
48667531|NCT04815863|DIAGNOSTIC_TEST|Assessment of depressive symptoms disorder with PHQ-9|PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms
48667532|NCT04815863|DIAGNOSTIC_TEST|Assessment of anxiety disorder with GAD-7|GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
48667533|NCT00269581|OTHER|Educational CD-rom|Educational CD-Rom
47988454|NCT05839522|BEHAVIORAL|Interview-style survey|Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
47988455|NCT02922608|OTHER|simulation practice|simulation session
47988456|NCT02468869|BEHAVIORAL|"Communication skills training empathy skills"|
47988457|NCT02468869|BEHAVIORAL|"Communication skills training information structuring skills"|
47988458|NCT04695925|DRUG|Osimertinib 80 MG [Tagrisso]|osimertinib 80 mg po qd until disease progression
47988459|NCT04695925|DRUG|Pemetrexed 500 MG Injection|pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
47988460|NCT04695925|DRUG|Carboplatin|carboplatin area under curve 5 intravenously every 3 weeks for four cycles
47988461|NCT03219294|DRUG|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
47988462|NCT03219294|DRUG|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
47988463|NCT05598775|OTHER|Non Interventional long term safety follow up|Non Interventional long term safety follow up
47988464|NCT00319917|DRUG|tacrolimus|oral
48145110|NCT05145348|BIOLOGICAL|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
48145111|NCT00837044|DRUG|Treximet|Treximet
48145112|NCT00837044|DRUG|Migraine rescue medication of choice|Migraine rescue medication of choice
48505980|NCT06393946|DRUG|Dupilumab|This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
48505981|NCT05842044|DRUG|Ketorolac|15-30mg Ketorolac administered via injection during intraoperative period every six (6) hours during post-surgery (inpatient) period.
47988465|NCT00319917|DRUG|placebo|oral
47988466|NCT03573895|OTHER|Foam-Roller|Application of foam roller in the posterior part of thigh.
47988467|NCT03573895|OTHER|Neuromuscular stretching|Use of a neuromuscular stretching applied to the hamstring muscles
47988468|NCT03573895|OTHER|Pasive stretching|Use of a pasive stretching applied to the hamstring muscles
47988469|NCT03572140|DIAGNOSTIC_TEST|RAVS In relapsed and resistent cases|assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
48145113|NCT04827849|OTHER|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
48356223|NCT00017225|DRUG|ifosfamide|
48356224|NCT00017225|DRUG|melphalan|
48356225|NCT00017225|DRUG|tretinoin|
48505982|NCT05842044|DRUG|Acetaminophen|1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.
48505983|NCT05842044|DRUG|Oxycodone|"Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization."
48505984|NCT05842044|DRUG|Hydromorphone|Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.
48667534|NCT00269581|OTHER|Headstrong CD-rom|Headstrong CD-rom
48667535|NCT00708357|DRUG|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
47988470|NCT03414619|BEHAVIORAL|Cognitive Control Tasks and Script Driven Imagery|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
48667536|NCT01729039|BEHAVIORAL|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
48145114|NCT03569241|RADIATION|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
48356226|NCT00017225|DRUG|vincristine sulfate|
48667537|NCT01729039|BEHAVIORAL|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
48145115|NCT03569241|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
48356227|NCT00017225|DRUG|vindesine|
48356228|NCT00017225|PROCEDURE|autologous bone marrow transplantation|
48667538|NCT01729039|BEHAVIORAL|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
48356229|NCT00017225|PROCEDURE|conventional surgery|
48356230|NCT00017225|PROCEDURE|peripheral blood stem cell transplantation|
48356231|NCT00017225|RADIATION|radiation therapy|
48356232|NCT06032429|OTHER|Shared Medical Appointments|SMA is a subset of such clinics and are defined by groups of patients meeting over time for comprehensive care for a defining chronic condition or health care state, which involved both a person trained or skilled in delivering patient education or facilitating patient interaction.
48667539|NCT00000684|DRUG|Dextran sulfate|
48667540|NCT02916264|PROCEDURE|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
48667541|NCT03377660|OTHER|Clinical treatment|Patients undergo clinical treatment as indicated, they are studied before and after.
47988471|NCT00361855|DRUG|NX-CP105|
47988472|NCT04262843|DRUG|Cyclophosphamide|Given IV
48356233|NCT03479658|BEHAVIORAL|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
48356234|NCT03479658|BEHAVIORAL|Nutritional education|School-based nutritional education on healthy dietary habits
48356235|NCT03810261|DIETARY_SUPPLEMENT|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
48356236|NCT03810261|DIETARY_SUPPLEMENT|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
48356237|NCT03810261|DIETARY_SUPPLEMENT|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
47988473|NCT04262843|DRUG|Fludarabine|Given IV
47988474|NCT04262843|DRUG|Fludarabine Phosphate|Given IV
47988475|NCT04262843|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Growth factor therapy
48356238|NCT00474539|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
48356239|NCT00474539|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
47988476|NCT04262843|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
47988477|NCT04262843|PROCEDURE|Intensity-Modulated Radiation Therapy|Undergo TMLI
47988478|NCT04262843|DRUG|Mycophenolate Mofetil|Immunosuppressive therapy
47988479|NCT04262843|DRUG|Tacrolimus|Immunosuppressive therapy
47988480|NCT02631850|BEHAVIORAL|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
48145116|NCT03569241|PROCEDURE|salvage Lymph Node Dissection|metastasis-directed treatment
48145117|NCT03569241|DRUG|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
48145118|NCT03600207|OTHER|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
48145119|NCT03600207|OTHER|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
48145120|NCT04867772|OTHER|Home based rehabilitation|
48145121|NCT05673109|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
48667542|NCT05233839|OTHER|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
47988481|NCT02631850|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
48145122|NCT06216002|DIAGNOSTIC_TEST|Train of four nerve stimulator|Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
48145123|NCT06121765|OTHER|Tyrosine kinase inhibitor|Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI
48145124|NCT04493411|PROCEDURE|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
48145125|NCT04493411|PROCEDURE|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
48145126|NCT04299009|DEVICE|Bright light therapy glasses|Bright light therapy delivered through glasses
48145127|NCT01083706|DRUG|azacitidine|Given SC or IV
48356240|NCT06212505|OTHER|blood test|blood test at the inclusion 10 tubes of 2.7mL blood
48356241|NCT05337735|DRUG|XmAb20717|Given by vein (IV)
48356242|NCT03174392|OTHER|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
48505985|NCT05842044|DRUG|Ibuprofen|400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
48505986|NCT03938623|OTHER|Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
48505987|NCT03887793|OTHER|VACs|The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
48505988|NCT06500624|DRUG|Pizotifen|Each subject will be given 0.5mg pizotifen with 10-20mg escitalopram in patients with depressive disorder
48667543|NCT05233839|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
47988482|NCT02631850|BEHAVIORAL|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
48667544|NCT06325787|PROCEDURE|thyroid lobectomy|thyroid lobectomy
48667545|NCT06325787|PROCEDURE|image-guided thermal ablation|radiofrequency ablation or microwave ablation or laser ablation
48667546|NCT06250829|OTHER|Observational|Observational study of body composition, cytokine profile, immune status, ctDNA, serial radiology.
47988483|NCT02631850|BEHAVIORAL|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
48145128|NCT01083706|OTHER|laboratory biomarker analysis|Correlative studies
48145129|NCT04660110|DRUG|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
48145130|NCT00351026|DRUG|Methadone|short-term methadone maintenance
48145131|NCT05733494|OTHER|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
48505989|NCT04234659|DEVICE|Clinical placement of a temporary IMPELLA® mechanical circulatory support device.|Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
48505990|NCT01260519|DRUG|Heparin|unfractionated heparin 2000 unites
48667547|NCT02835469|DRUG|Menotrophin|
48667548|NCT00633126|DRUG|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
48667549|NCT03904160|BEHAVIORAL|Weight management|Please see the arm descriptions.
48667550|NCT03291522|PROCEDURE|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
48667551|NCT00160953|PROCEDURE|Endorectal Coil Magnetic Resonance Images|
48667552|NCT03012750|DRUG|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
48667553|NCT00003794|PROCEDURE|psychosocial assessment and care|
48667554|NCT00003794|PROCEDURE|quality-of-life assessment|
48667555|NCT00353002|DRUG|Ametop (4% Amethocaine cream )|
48667556|NCT00353002|DRUG|Maxilene (4% Liposomal Lidocaine)|
47988484|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 65 mg|"Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
47988485|NCT04465851|DIETARY_SUPPLEMENT|Curcumin|"HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
47988486|NCT04465851|OTHER|Placebo (Ferrous Sulphate)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
48145132|NCT05695599|DEVICE|Whole body vibration training|3 times per week of 20 to 30 minute sessions during 16 weeks of training
48145133|NCT03345706|PROCEDURE|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
48145134|NCT03345706|PROCEDURE|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
48145135|NCT04806906|DRUG|CC-486|Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
48145136|NCT02319707|DRUG|Oxytocin|"The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
48505991|NCT04261907|DRUG|ASC09/ritonavir group|ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment
48505992|NCT04261907|DRUG|lopinavir/ritonavir group|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment
48667557|NCT00744861|DEVICE|Exospine sham|Inactive Exospine LIPUS device (dual transducers)
48667558|NCT00744861|DEVICE|Exospine|Active Exospine LIPUS device (dual transducers)
48667559|NCT00744861|DEVICE|Exogen 4000+|Active Exogen LIPUS device (single transducer)
48667560|NCT00744861|DEVICE|Exogen 4000+ sham|Inactive Exogen 4000+ LIPUS device (single transducer)
48667561|NCT00987350|DEVICE|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
48667562|NCT00987350|DEVICE|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
48667563|NCT00987350|BIOLOGICAL|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
48667564|NCT06486909|DIAGNOSTIC_TEST|Cerebrospinal Fluid (CSF) Sample|Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).
48667565|NCT06486909|DIAGNOSTIC_TEST|Blood Serum Sample|Samples for glucose in blood serum will be completed every day, for the first 14 days.
48667566|NCT02862574|DRUG|Andecaliximab|Administered via subcutaneous injection once weekly
48667567|NCT02862574|DRUG|Placebo|Administered via subcutaneous injection once weekly
48667568|NCT02862574|DRUG|Methotrexate|Administered orally weekly as part of the participant's current treatment regimen
48667569|NCT02862574|DRUG|TNF Inhibitor|An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
48667570|NCT00700206|DRUG|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
47988487|NCT04465851|OTHER|Placebo (Curcumin)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
48145137|NCT02319707|DRUG|Oxytocin in 100 ml NaCl 0.9%|"The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
48145138|NCT02134782|BEHAVIORAL|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
48356243|NCT03174392|OTHER|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
48356244|NCT00514592|OTHER|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
48356245|NCT03720106|OTHER|GOAL therapy plan|The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
48356246|NCT05707520|DRUG|enteric-coated mycophenolate (MPAs)|Immunosuppression protocol with enteric-coated mycophenolate sodium
48356247|NCT05707520|DRUG|None MPA|Immunosuppression protocol without enteric-coated mycophenolate sodium
48356248|NCT00026624|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
48356249|NCT00026624|DRUG|Keyhole-Limpet Hemocyanin|
48356251|NCT00728572|PROCEDURE|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
48356252|NCT00728572|OTHER|Surface EMG|Surface EMG only, no intervention
48356253|NCT00728572|PROCEDURE|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
48356254|NCT02020213|DRUG|Posaconazole|400 mg po bid for 8 weeks
48356255|NCT05119244|OTHER|blood and hair sampling|3.5 ml blood sample Hair sample
48356256|NCT05696613|DRUG|SNP-ACTH (1-39) Gel|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
48356257|NCT05696613|DRUG|Rituximab|Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
48356258|NCT01234337|DRUG|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
48145139|NCT02134782|OTHER|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
48505993|NCT01160003|DRUG|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
48505994|NCT01160003|DRUG|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
48356259|NCT01234337|DRUG|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
48356260|NCT01234337|DRUG|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
48356261|NCT01159886|PROCEDURE|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
48356262|NCT02159365|DRUG|Elotuzumab|
48356263|NCT02159365|DRUG|Lenalidomide|
48356264|NCT02159365|DRUG|Dexamethasone|
48505995|NCT06550973|PROCEDURE|pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique|Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.
48505996|NCT04365777|OTHER|OAA/S=5|Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.
48356265|NCT05673785|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
48356266|NCT05673785|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion
48356267|NCT05673785|DRUG|Doxorubicin|Doxorubicin IV infusion
48356268|NCT05673785|DRUG|Prednisone|Prednisone tablets
48356269|NCT00207636|BEHAVIORAL|Computer-based prostate cancer screening decision aid|
48356270|NCT00129376|DRUG|Doxorubicin|
48356271|NCT00129376|DRUG|Cyclophosphamide|
48356272|NCT00129376|DRUG|Docetaxel|
47988488|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 18mg|"Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
48356273|NCT00397449|BIOLOGICAL|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
48356274|NCT04443257|OTHER|assessment of the sequelae after hospitalization for Sars-COV-2|the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases
48356275|NCT05614700|RADIATION|Brachytherapy|High Dose-Rate Brachytherapy
48356276|NCT05614700|RADIATION|Sterotactic Body Radiotherapy|Hypofractionated External Beam Radiotherapy
48356277|NCT05340816|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage will apply to the neck, abdominal, bilateral inguinal lymph nodes, bilateral anterior/posterior thighs, and lumbal area. Treatment duration will be approximately 30 minutes for 5 days.
48356278|NCT05340816|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation will be apply to abdominal and lumbal area as 100 Hz and 100 msn. Treatment duration will be approximately 20 minutes for 5 days.
48356279|NCT00006185|DRUG|Avandia administration for 6-12 weeks|
48356280|NCT06135142|OTHER|Connective Tissue Massage|It involves manipulating the soft and deep tissues of the body.
48505997|NCT04365777|OTHER|OAA/S=3|Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.
48505998|NCT04365777|OTHER|OAA/S=1|Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
48505999|NCT06633510|DEVICE|massimo|masimo is a device for the continuous noninvasive measurement of arterial hemoglobin functional oxygen saturation (SpO2), pulse rate (PR), pleth variability index (PVi) and pleth respiratory rate (Rrp) PI (perfusion index).
48506000|NCT01497808|DRUG|Ipilimumab|
48506001|NCT01497808|RADIATION|Stereotactic Body Radiation Therapy|
48506002|NCT05986591|COMBINATION_PRODUCT|Test Product - Tiotropium Bromide Inhalation Powder 18 mcg|Test Product
48506003|NCT05986591|COMBINATION_PRODUCT|Spiriva Handihaler (Tiotropium Bromide) 18 mcg|RLD
47988489|NCT02478801|DIETARY_SUPPLEMENT|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
47988490|NCT02742584|PROCEDURE|Cough Stress Test|Varying bladder volumes during cough stress test.
47988491|NCT03035708|DRUG|Varenicline|1 mg BID
47988492|NCT03035708|DRUG|Placebo oral capsule|1 mg BID
47988493|NCT01264146|PROCEDURE|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
47988494|NCT01264146|PROCEDURE|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
47988495|NCT03538158|BEHAVIORAL|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
47988496|NCT03538158|BEHAVIORAL|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
47988497|NCT04311996|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
47988498|NCT04311996|OTHER|TSST|Participants will, via an online session, complete the TSST which is a standardized speech \& math performance known to elicit a cortisol stress response.
47988499|NCT01770548|GENETIC|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
47988500|NCT01770548|GENETIC|DNA collection|DNA collection
48356281|NCT06135142|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
48356282|NCT06135142|OTHER|Classical Massage|It involves manipulating the soft tissues of the body.
48356283|NCT06135142|DEVICE|Therapatic Ultrasound|The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.
48356284|NCT06135142|OTHER|Heat Treatment|Applying heat to an affected area to treat damaged muscles, joints or tissues in the body.
48356285|NCT02404909|OTHER|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
48356286|NCT03052699|PROCEDURE|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
48356287|NCT00670813|DRUG|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
48356288|NCT00670813|DRUG|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
48356289|NCT04615429|BIOLOGICAL|Mesenchymal stromal cells|Administration of one single dose of allogenic Mesenchymal stromal cells
48506004|NCT05986591|COMBINATION_PRODUCT|Placebo|Placebo Product
48356290|NCT04615429|OTHER|Placebo|Administration of placebo (solution identical to experimental treatment, without the MSC)
48145140|NCT02636114|PROCEDURE|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
48506005|NCT04960033|BEHAVIORAL|FRAX|The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
48506006|NCT03251339|DRUG|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
48506007|NCT03251339|DRUG|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
48667571|NCT01820000|PROCEDURE|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
48667572|NCT03168139|DRUG|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
48667573|NCT03168139|DRUG|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
48667574|NCT04156139|DEVICE|HFNC|The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
48667575|NCT04156139|DEVICE|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
47988501|NCT01770548|OTHER|Auditory evoked potentials|auditory evoked potentials
47988502|NCT01721421|OTHER|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
47988503|NCT01721421|OTHER|Standard treatment time|
47988504|NCT06064474|BEHAVIORAL|High ventilation breathwork with retention (HVBR)|Intervention
47988505|NCT06064474|BEHAVIORAL|Placebo HVBR|Placebo
47988506|NCT04567433|DRUG|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
47988507|NCT04567433|DRUG|Hydrocortisone|Hydrocortisone compared to Placebo
47988508|NCT04567433|PROCEDURE|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
48145141|NCT04614129|DIAGNOSTIC_TEST|Low Dose CT|All participants will have a low dose chest CT either within one year of enrollment or after enrollment
48145142|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
48145143|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
48356291|NCT01116128|DRUG|dasatinib|100 mg QD continuously (from day 1 to day 28)
48356292|NCT01116128|DRUG|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
48356293|NCT01116128|DRUG|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
48356294|NCT00780676|DRUG|Dasatinib|100 mg tablet by mouth daily
48356295|NCT00780676|DRUG|AZD6244|75 mg by mouth twice daily.
48356296|NCT02176005|DEVICE|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
48356297|NCT02176005|DRUG|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
48506008|NCT02473523|OTHER|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
48506009|NCT02473523|OTHER|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
48506010|NCT02473523|DEVICE|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
48506011|NCT02473523|DEVICE|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
48667576|NCT04422496|DRUG|HEC96719|"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."
48356298|NCT02176005|OTHER|Negative Control|Moxifloxacin is used alone
48145144|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
48145145|NCT04353856|OTHER|quality of life assessment|quality of life assessment using the EQ5D questionnaire once a month
48145146|NCT01960972|OTHER|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
48145147|NCT03377049|DRUG|Acetazolamide|1 g acetazolamide through a peripheral IV line
48356299|NCT03000764|OTHER|skin biopsies|"Biopsies (12 G) will be performed :~* in non-irradiated breast skin~* in irradiated breast skin"
48356300|NCT03000764|OTHER|blood samples|"blood samples are collected:~* 10 ml in EDTA tube~* 2,5 ml in PAXgene Blood RNA tube~* 4 ml in EDTA tube"
47988509|NCT05864560|DEVICE|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
47988510|NCT00645073|DRUG|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
47988511|NCT00645073|DRUG|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
47988512|NCT03781609|BEHAVIORAL|Roller system group (RG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
47988513|NCT03781609|BEHAVIORAL|Overground group (OG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
47988514|NCT03781609|BEHAVIORAL|Placebo - Wheelchair skills group (WSG)|They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
47988515|NCT02982850|DRUG|Dabigatran|
47988516|NCT02982850|DRUG|Acetylsalicylic acid|
47988517|NCT02982850|DRUG|Warfarin|
47988518|NCT04828447|DIETARY_SUPPLEMENT|Olive Oil|Subjects will be randomized to either high or low dose of olive oil and follow a whole food plant based diet.
47988519|NCT02180633|OTHER|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
47988520|NCT06064890|PROCEDURE|Intrathalamic AAV.PGRN administration|One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
47988521|NCT06064890|GENETIC|Intrathalamic AVB-101|AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
47988522|NCT04216654|DIAGNOSTIC_TEST|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
48145148|NCT02751957|BEHAVIORAL|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
48145149|NCT01000649|DRUG|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
48145150|NCT01000649|DRUG|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
48145151|NCT01000649|DRUG|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
48145152|NCT01000649|OTHER|Placebo|Isotonic saline infused.
48145153|NCT01005602|OTHER|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
48145154|NCT01005602|DRUG|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
48356301|NCT01970735|BIOLOGICAL|Blood test|
48356302|NCT05155540|DEVICE|Trevo and or Merci devices for stent retreival|FDA approved devices for stent retrieval during mechanical thrombectomy
48356303|NCT05155540|DEVICE|Penumbra system for stent aspiration|FDA approved devices for stent aspiration during mechanical thrombectomy
48356304|NCT05155540|DRUG|recombinant tissue plasminogen activator|FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
48356305|NCT00908050|DRUG|Botulinum toxin type A|Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
48356306|NCT00908050|DRUG|Placebo arm|Placebo comparator
48356307|NCT02532075|OTHER|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
48356308|NCT02532075|OTHER|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
48356309|NCT02532075|OTHER|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
48356310|NCT02532075|OTHER|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
48667577|NCT04108650|OTHER|Fit & Strong! group|Consistent with the original format of F\&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
48667578|NCT03920891|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
48667579|NCT03920891|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
48667580|NCT03199833|DEVICE|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
47988523|NCT01462084|DEVICE|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
47988524|NCT01462084|DEVICE|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
47988525|NCT04712773|DEVICE|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
47988526|NCT04712773|DEVICE|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
47988527|NCT02743806|DRUG|Vedolizumab|Vedolizumab IV infusion
47988528|NCT00385242|PROCEDURE|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
47988529|NCT00385242|OTHER|PET imaging|PET viability imaging
47988530|NCT02100059|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
47988531|NCT02741882|OTHER|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
47988532|NCT00755157|DRUG|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
47988533|NCT00755157|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
48145155|NCT01071317|DRUG|Naproxen|Naproxen 500mg PO bid prn headache
48145156|NCT01071317|DRUG|Sumatriptan|100mg po q day prn headache
48356311|NCT06282302|OTHER|Group control|Group control The control session will consist of keeping the volunteer sitting in a calm, air-conditioned environment for 40 minutes.
48356312|NCT06282302|OTHER|Isometric Exercise|The intervention with isometric exercise for the lower limbs, the volunteers will start in a vertical position, with shoulders and hips in contact with the wall, feet parallel and shoulder-width apart and hands at the sides of the body. Then (second phase), the volunteers, maintaining contact with the wall, squatted and advanced their feet in the desired position until the knee joint angle reached the previously determined value. The third phase referred directly to the isometric effort of the isometric exercise session. For the isometric wall squat exercise session, volunteers will be asked to perform 4 repetitions of 2 minutes, with a 2-minute rest interval in a seated position for adequate rest between each repetition.
48356313|NCT06282302|OTHER|Aerobic Exercise|Volunteers will perform 50 minutes of horizontal exercise cycling (brand: pro-user), continuously and at moderate intensity (50% to 60% of HR reserve).
48356314|NCT04491292|OTHER|Questionnaire Administration|Complete questionnaires
48667581|NCT03199833|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
48667582|NCT03626233|OTHER|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
48667583|NCT02213250|DRUG|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
48667584|NCT00967616|DRUG|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
48667585|NCT00967616|DRUG|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
48667586|NCT04626102|BEHAVIORAL|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
48667587|NCT04626102|BEHAVIORAL|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
48667588|NCT04944784|DRUG|Reldesemtiv|Reldesemtiv Oral Tablet
48667589|NCT04944784|DRUG|Placebo|Placebo Oral Tablet
48667590|NCT06064487|DIAGNOSTIC_TEST|renal cell arrest and damage biomarkers assessment|measurement of TIMP2 and IGFBP7, KIM-1
48667591|NCT05994430|OTHER|End-of-life care awareness training in intensive care|End-of-life care awareness training in intensive care
48667592|NCT02228538|DEVICE|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system \& off-the-shelf standard knee implant system from various manufacturers
48667593|NCT02100826|DRUG|Cephalexin|Administered orally.
48667594|NCT02449525|PROCEDURE|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
48667595|NCT00618761|OTHER|hyperglycemic clamp test|hyperglycemic clamp test
48667596|NCT04145596|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
48667597|NCT03516721|OTHER|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
48667598|NCT00093509|DRUG|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
48667599|NCT00093509|DRUG|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
48667600|NCT00093509|PROCEDURE|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
48667601|NCT00093509|RADIATION|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of \> 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
48667602|NCT03914690|DRUG|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
48667603|NCT03914690|DRUG|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
47988534|NCT01168531|DRUG|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
48667604|NCT03419494|DRUG|PLD|PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
48667605|NCT03419494|DRUG|DNR|DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
48667606|NCT01078727|DEVICE|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
48667607|NCT01203007|DIETARY_SUPPLEMENT|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
48667608|NCT01203007|DIETARY_SUPPLEMENT|Low antigen content diet|Low-antigen content diet for one month
47988535|NCT01168531|DRUG|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
47988536|NCT01168531|DRUG|placebo|vitamin B complex formula
47988537|NCT03736317|DEVICE|sham TBS|Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
47988538|NCT03736317|DEVICE|real mPFC cTBS|Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
47988539|NCT03736317|DEVICE|real dlPFC iTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
47988540|NCT03736317|DEVICE|real dlPFC iTBS + real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
48667609|NCT01877174|DEVICE|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
48667610|NCT01877174|PROCEDURE|transcarotid stenting|
48667611|NCT05682937|DEVICE|HFOV-sigh|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention
48667612|NCT03478605|DRUG|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
48667613|NCT03478605|DRUG|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
48667614|NCT03478605|DRUG|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
48667615|NCT03478605|DRUG|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
48145157|NCT01071317|BEHAVIORAL|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
48145158|NCT01071317|BEHAVIORAL|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
48145159|NCT01071317|OTHER|Typical care|Care to be determined by attending physician
48145160|NCT01455948|DEVICE|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
48145161|NCT01455948|PROCEDURE|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
48145162|NCT05888844|DRUG|INCB099280|Administered as specified in the treatment arm description.
48667616|NCT02499614|DRUG|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
48145163|NCT04546555|DEVICE|Dual chamber pacemaker|Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
48667617|NCT01690533|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
48667618|NCT05513963|BEHAVIORAL|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
48506012|NCT02473523|OTHER|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
48145164|NCT04546555|OTHER|Accelerated Physiologic Pacing|The lower rate limit will be programmed to an individualized heart rate.
48145165|NCT04546555|OTHER|Nocturnal Pacing|In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
48667619|NCT03497377|DRUG|18F-DCFPyL Injection|
48145166|NCT04555226|PROCEDURE|Lymph node dissection|Open/minimaly invasive pelvic and para-aortic lymph node dissection
48356315|NCT02604628|BEHAVIORAL|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
48356316|NCT04218513|DRUG|Compound Edaravone Injection|30 min intravenous infusion
48667620|NCT03497377|DRUG|18F-NaF|
48667621|NCT03904485|RADIATION|cardiac magnetic resonance(CMR) T2 mapping|T2 value before transplant，3 month and 6month after transplant
48667622|NCT01225952|DEVICE|Crystalens AO|Bausch \& Lomb model silicone multi-piece accommodating IOL.
48667623|NCT01225952|DEVICE|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
48356317|NCT04218513|DRUG|Edaravone Injection|30 min intravenous infusion
48356318|NCT04218513|DRUG|2-Aminoethanesulfonic Acid Injection|30 min intravenous infusion
48145167|NCT04555226|RADIATION|Standard chemoradiation|"1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: image-positive common iliac lymph nodes with short diameter ≥10mm and/or image-positive para-aortic lymph node~3. Target doses for the image-positive nodes can range from 55 to 60Gy~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed."
48145168|NCT04555226|RADIATION|Chemoradiation|"1. A point/HCR-CTV D90 ≥80Gy（+20%）~2. Extended-field EBRT: Pathlogical positive para-aortic lymph node~3. Target doese for pelvic and/or abdomal lymph nodes is usually 45Gy. After operation, the residual lymph node need to be labeled and the target doses for it ranges from 55-60Gy.~4. Concurrent 5 cycles platinum-containing chemotherapy (Cisplatin 40mg/m2 q1w or Carboplatin AUC=2 q1w, Window period 1 week)~5. CCRT will be completed in 56 days~6. After CCRT if the cervix biopsy shows residual tumor and/or imaging (CT/MRI/PET/CT) indicates that there are still positive lymph nodes with short diameter ≥15mm in the pelvic and abdominal cavity, 3 cycles adjuvant chemotherapy (TP: Paclitaxel 135mg/m2, Cisplatin 50mg/m2, q3w or TC: Paclitaxel 135mg/m2, Carboplatin AUC=4, q3W; Window period 2 weeks) ± brachytherapy (if point A or HR-CTV D90 \< 96Gy) will be performed."
48145169|NCT06058130|DRUG|Anticoagulant Oral|Anticoagulation alone
48356319|NCT05472194|BEHAVIORAL|InSchool Training Program|The goal of the intervention is to promote and boost the development of executive functions in preschool and elementary school-aged children by means of engagement in meaningful and challenging activities. The method to achieve this consists on weekly intervention sessions run by teachers with a set of games specially developed to train executive functions.
48356320|NCT05472194|BEHAVIORAL|Regular school activities|Children in the control group will be playing with the regular school activities.
47988541|NCT05237908|DEVICE|Transforaminal Lumbar Interbody Fusion|Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
47988542|NCT00620828|OTHER|Placebo saline injection|20 cc of sterile, injectable saline
48356321|NCT00508820|BIOLOGICAL|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
48356322|NCT03030157|DRUG|pirarubicin(THP)|
48356323|NCT06168929|DRUG|SHR4640|SHR4640, 2.5mg\*4 - 10mg\*1
48356324|NCT06168929|DRUG|SHR4640|SHR4640, 10mg\*1 - 2.5mg\*4
48356325|NCT02884440|DRUG|TAP block ropivacaine|
48356326|NCT02884440|DRUG|TAP block placebo|
48356327|NCT02884440|DRUG|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
48356328|NCT03735017|OTHER|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
48356329|NCT03735017|OTHER|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
48356330|NCT03170765|BIOLOGICAL|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
48356331|NCT01627379|DRUG|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
48667624|NCT01225952|DEVICE|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
48667625|NCT00637910|DRUG|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
48667626|NCT00637910|DRUG|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
47988543|NCT00620828|DRUG|Ropivicaine 0.5%|Ropivicaine
47988544|NCT05390944|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
47988545|NCT05390944|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
47988546|NCT02051829|OTHER|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
47988547|NCT00082355|DRUG|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
47988548|NCT01214954|OTHER|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
48356332|NCT01627379|DRUG|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
48356333|NCT06432361|BEHAVIORAL|Resource Allocation|Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.
48667627|NCT00127439|PROCEDURE|Manually Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
48667628|NCT00127439|OTHER|Robotic Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
48145170|NCT06058130|DRUG|Anticoagulation combined with antiplatelet therapy|Anticoagulation combined with antiplatelet therapy
48145171|NCT00638456|DRUG|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
48145172|NCT00638456|DRUG|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
48145173|NCT03438565|DEVICE|Asahi Chikai Black 18 neurovascular guidewire|"The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback."
48145174|NCT03311880|BEHAVIORAL|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
48667629|NCT03639610|DRUG|Melflufen|Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
48145175|NCT00105222|DRUG|Sodium Nitrite|
48356334|NCT06432361|OTHER|assessment only control|participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
48667630|NCT03639610|DRUG|Dexamethasone|Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
48667631|NCT02002325|DRUG|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
48145176|NCT04008953|DEVICE|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
48145177|NCT02502136|PROCEDURE|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
48356335|NCT02570581|OTHER|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
48356336|NCT02570581|OTHER|Jelly with Furosemide|
48667632|NCT02002325|OTHER|Standard care|Standard treatment for acute stroke without intravenous alteplase.
48667633|NCT01935388|OTHER|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
47988549|NCT01214954|OTHER|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
47988550|NCT04843644|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
48145178|NCT02502136|PROCEDURE|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
48356337|NCT02570581|OTHER|Jelly with Levothyroxine sodium salt|
48356338|NCT02570581|OTHER|Jelly with Memantine|
48145179|NCT04497415|OTHER|Video-Based intervention|Three minutes video of a nurse that shares her personal story
48356339|NCT02570581|OTHER|Jelly with Zopiclone|
48356340|NCT02570581|OTHER|Jelly with Alprazolam|
48356341|NCT02570581|OTHER|Jelly with Oxazepam|
48356342|NCT02570581|OTHER|Jelly with Donepezil|
48356343|NCT02570581|OTHER|Jelly with Clopidogrel|
48356344|NCT02570581|OTHER|Jelly with Ramipril|
48356345|NCT02570581|OTHER|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
48145180|NCT04648215|OTHER|lavender oil|aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown
48356346|NCT02570581|OTHER|Plain jelly control|
48356347|NCT02570581|OTHER|Apple compote Paracetamol|
48356348|NCT02570581|OTHER|Apple compote Furosemide|
48356349|NCT02570581|OTHER|Apple compote Levothyroxine sodium salt|
48356350|NCT02570581|OTHER|Apple compote Memantine|
48667634|NCT02474810|DRUG|Alteplase|Alteplase for CVC dysfunction.
48667635|NCT03571490|DRUG|Ropivacaine|Single shot of ropivacaine 0.325%
48145181|NCT04648215|OTHER|Grapeseed Oil|aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
48145182|NCT01407874|DRUG|Placebo|Oral dose administered daily for 84 days.
48145183|NCT01407874|DRUG|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
48145184|NCT01407874|DRUG|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
48356351|NCT02570581|OTHER|Apple compote Zopiclone|
48356352|NCT02570581|OTHER|Apple compote Alprazolam|
48356353|NCT02570581|OTHER|Apple compote Oxazepam|
48356354|NCT02570581|OTHER|Apple compote Donepezil|
48356355|NCT02570581|OTHER|Apple compote Clopidogrel|
48356356|NCT02570581|OTHER|Apple compote Ramipril|
48356357|NCT02570581|OTHER|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
48356358|NCT02570581|OTHER|Plain apple compote control|
48356359|NCT06369584|PROCEDURE|prone position|The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring. The process of monitoring includes ECMO flow and the vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed on the patient's forehead, ears, anterior chest, and iliac crest to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation until their condition improves enough to discontinue ECMO support. Each session should last between 16 to 24 hours.
48356360|NCT02670187|BIOLOGICAL|GLS-5300|
48356361|NCT00553904|DIETARY_SUPPLEMENT|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
48356362|NCT04239573|PROCEDURE|Computed Tomography|Undergo CT
48356363|NCT04239573|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
48356364|NCT04239573|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48356365|NCT04239573|OTHER|Quality-of-Life Assessment|Ancillary studies
48356366|NCT04239573|OTHER|Questionnaire Administration|Ancillary studies
48667636|NCT03571490|DRUG|Saline|Single shot of saline 0.9%
48667637|NCT01882816|RADIATION|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
48667638|NCT01882816|DEVICE|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
48145185|NCT05005351|DEVICE|Digital ACT|Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.
48145186|NCT05005351|DEVICE|Digital Symptom Tracker|Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.
48356367|NCT05924997|DRUG|adebrelimab, camrelizumab plus apatinib|adebrelimab (RP2D, Q3W)+ camrelizumab 200mg Q3W+ apatinib 250mg qd, with 3 weeks (21 days) as a treatment cycle
48667639|NCT01882816|DRUG|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
48667640|NCT01882816|OTHER|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
48667641|NCT00865748|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
48145187|NCT00165048|DRUG|Vioxx (Rofecoxib)|
48356368|NCT02912832|DEVICE|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
48356369|NCT04429828|OTHER|COVID-19 e-package: Psychological wellbeing for healthcare workers|All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
48506013|NCT02473523|OTHER|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
48667642|NCT00865748|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
48667643|NCT02951260|DRUG|Metformin|17 days treatment with metformin
48667644|NCT02951260|OTHER|Placebo|17 days treatment with placebo
48145188|NCT00539955|BEHAVIORAL|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
48667645|NCT04951349|DRUG|GX-03|Same dosage used in Bactroban Nasal studies.
48667646|NCT04951349|DRUG|Petrolatum ointment|Viscous ointment similar in form to study drug.
48667647|NCT01018602|DRUG|vildagliptin|100 mg per day over 24 months
48667648|NCT01018602|DRUG|inactive pill|1 pill per day over 24 months
48667649|NCT04621578|DEVICE|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
48145189|NCT00539955|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
48356370|NCT01246921|DRUG|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
48356371|NCT05228236|DIETARY_SUPPLEMENT|Plant based protein|A single dose of \~30 g of a plant-based protein blend was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
48667650|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 4 weeks
48667651|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 24 weeks
48667652|NCT00068289|DRUG|bortezomib|
48667653|NCT04620161|DRUG|Pradigastat Tablets 20mg|20mg, once daily, oral administration
48667654|NCT04620161|DRUG|Pradigastat Tablets 40mg|40mg, once daily, oral administration
48667655|NCT04620161|DRUG|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
48667656|NCT04620161|DRUG|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
47988551|NCT04843644|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
47988552|NCT04843644|BEHAVIORAL|Control|usual care
47988553|NCT05383300|DRUG|Oxytocin nasal spray|Intranasal spray containing 40 IU of oxytocin
47988554|NCT05383300|OTHER|Placebo spray|Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin
47988555|NCT05959330|OTHER|Neural Tension Technique(ulnar, median, radial)|Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
47988556|NCT05959330|OTHER|Neural Slider Technique (ulnar, median, radial)|Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
47988557|NCT05959330|OTHER|Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)|Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
47988558|NCT03367481|DEVICE|Toothbrush type|In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
47988559|NCT00775645|DIETARY_SUPPLEMENT|acetyl-L-carnitine hydrochloride|Given orally
47988560|NCT00775645|OTHER|placebo|Given orally
48145190|NCT01049490|BIOLOGICAL|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
48145191|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
48145192|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
48667657|NCT05767281|BEHAVIORAL|prevention program|introduction of the developed comprehensive prevention program among the child population with the participation of primary health care personnel, which will improve not only the dental health of children, their quality of life, but will also help reduce foci of chronic oral sepsis.
48145193|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
48356372|NCT05228236|DIETARY_SUPPLEMENT|Whey protein|A single dose of \~30 g of whey protein was ingested 30-60 min after physical practice in training days or 30-60 min before bedtime in resting days.
48356373|NCT00126386|DRUG|Zoledronic acid (Zometa)|
48356374|NCT00000641|DRUG|Ciprofloxacin hydrochloride|
48356375|NCT00000641|DRUG|Ethambutol hydrochloride|
48667658|NCT06149169|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor(CAR) T Cells|Relma-cel be administered at one dose level:1×10\^8 CAR+T cells
47988561|NCT06384716|OTHER|rehabilitation programme based on motor control of core muscles|The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
48356376|NCT00000641|DRUG|Amikacin sulfate|
48356377|NCT00000641|DRUG|Azithromycin|
48356378|NCT00000641|DRUG|Rifampin|
48667659|NCT02348190|OTHER|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
48145194|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
48356379|NCT00000641|DRUG|Clofazimine|
48667660|NCT00003525|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48667661|NCT06338163|COMBINATION_PRODUCT|Polihexanide-based bundle|Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products
48356380|NCT05675202|DRUG|TQ-B3525|TQ-B3525 is a new PI3K α/δ Kinase inhibitor
48356381|NCT02394028|DRUG|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
48667662|NCT06338163|COMBINATION_PRODUCT|Standard bundle|Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
48667663|NCT00671086|DRUG|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
48667664|NCT00671086|DRUG|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
48506014|NCT02473523|OTHER|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
48356382|NCT02394028|DRUG|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
48356383|NCT02331927|BIOLOGICAL|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
48356384|NCT05737004|DIAGNOSTIC_TEST|functional magnetic resonance imaging examination、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II|fMRI examination 、Zung Self Rating Anxiety Scale and Beck Depression Inventory-II were performed in these patients within 1 week before biopsy .
48356385|NCT05159063|DEVICE|Ultrasound imaging|"Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled."
48356386|NCT02994927|DRUG|Avacopan|"Avacopan 30 mg twice daily orally for 52 weeks (364 days):~- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day."
48356387|NCT02994927|DRUG|Prednisone|"Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day."
48356388|NCT02994927|DRUG|Cyclophosphamide|Orally or intravenously administered
48356389|NCT02994927|BIOLOGICAL|Rituximab|Intravenously administered
48356390|NCT02994927|DRUG|Azathioprine|Orally administered
48356391|NCT01828463|DRUG|Nitisinone|doses 1, 2, 4 \& 8 mg plus no treatment arm
48667665|NCT04116684|DEVICE|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
48667666|NCT05663060|DRUG|Probiotic Formula|Probiotic Formula
48667667|NCT03062943|DRUG|Nintedanib|
48667668|NCT01060943|DEVICE|KOKEN|"atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
48667669|NCT01060943|DEVICE|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
48667670|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 35mg TID
48667671|NCT00034814|DRUG|Placebo|Enzyme-inducing placebo TID
48667672|NCT00034814|DRUG|Talampanel|Enzyme-inducing Talampanel 35 mg TID
48667673|NCT00034814|DRUG|Talampanel|Enzyme-inducing TLP 50mg TID
48667674|NCT00034814|DRUG|Placebo|Non-enzyme-inducing placebo TID
48667675|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 25mg TID
48667676|NCT04471311|PROCEDURE|Sub-lay mesh supported closure|A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above the arcuate line, posterior layer is reinforced suturing the peritoneum and the posterior rectus sheath; below the arcuate line, the posterior layer is reinforced suturing the peritoneum and the trasversalis fascia. Anterior layer is re-established suturing the anterior rectus sheath. A 3 cm BIO-A Mesh strip is sutureless placed between the posterior rectus sheath and the rectus muscle with an overlap of 1,5 cm at each side. In laparotomies \>20 cm two stripes of 15 cm each is designed. The midline anterior rectus sheath is closed using a running slowly absorbable suture , covering the mesh.
48667677|NCT04471311|DEVICE|BIO-A (GORE) mesh|3 cm BIO-A Mesh strip
48667678|NCT00831389|DEVICE|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
48667679|NCT01226108|DEVICE|Patch|"One patch per day, Duration: three weeks, Administration: behind the ear~--------------------------------------------------------------------------------"
48667680|NCT05305924|DRUG|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
48667681|NCT03641287|OTHER|Exercise Counseling|Meet with exercise physiology
48667682|NCT03641287|OTHER|Aerobic Exercise|Receive prescription for moderate aerobic exercise
48667683|NCT03641287|OTHER|Physiological Support|Receive motivational support via telephone care
48667684|NCT03641287|OTHER|Quality-of-Life Assessment|Ancillary studies
48667685|NCT03641287|OTHER|Questionnaire Administration|Ancillary studies
48667686|NCT03641287|OTHER|Best Practice|Undergo habitual level of physical activity
48667687|NCT01940419|DRUG|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
47988562|NCT01685931|DRUG|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
47988563|NCT02429518|DRUG|Miltefosine|
48506015|NCT02473523|OTHER|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
48667688|NCT01940419|DRUG|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
48145195|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
48145196|NCT01208506|DRUG|placebo|A single dose of NNC0114-0000-0005 placebo.
48667689|NCT03985735|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
48667690|NCT05181228|BEHAVIORAL|Web-Based Education Based on Family-Centered Empowerment Model|Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
48667691|NCT01093014|BEHAVIORAL|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
48667692|NCT01093014|BEHAVIORAL|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
48667693|NCT01093014|BEHAVIORAL|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
48667694|NCT03490994|DRUG|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
48667695|NCT03490994|DRUG|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
48506016|NCT03690661|BEHAVIORAL|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
48506017|NCT03690661|BEHAVIORAL|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
48145197|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
48145198|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
48145199|NCT02742805|DRUG|Omalizumab|Standard of care dose.
48145200|NCT05796141|BEHAVIORAL|Core Behavioral Weight Loss (BWL) intervention|Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
48145201|NCT05796141|BEHAVIORAL|Dyadic Action Planning|Participants will develop dyadic action plans together.
48145202|NCT05796141|BEHAVIORAL|Joint Feedback|Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
48145203|NCT05796141|BEHAVIORAL|Autonomy Support Training|Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.
48145204|NCT05796141|BEHAVIORAL|Home Environment Modifications|Participants will be trained in how to structure their home environment to support health behavior.
48145205|NCT00996242|DRUG|L-lysine|6 g/day for four weeks
48145206|NCT00615368|DRUG|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
48145207|NCT00615368|DRUG|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
48356392|NCT06504433|DIAGNOSTIC_TEST|Confirmed variant/deletion in either nuclear or mitochondrial genes involved in the mitochondrial respiratory chain|This is a 10-year, longitudinal, non-randomised, retrospective and prospective, observational study that will be used to characterise the natural history of primary mitochondrial disease (MITO) in 400 participants and their asymptomatic family members (with no genetic risk), non-MITO healthy controls (100 participants) and form a biobank that can be used in future research using separate ethics approved protocols to identify biomarkers of disease onset and progression.
48356393|NCT00528814|OTHER|Active Hand Sanitizer|Active Hand Sanitizer
48356394|NCT02382276|DRUG|Nalmefene hydrochloride|
48356395|NCT05621876|DEVICE|IgG deficiency rapid screening test|We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
48145208|NCT05766202|OTHER|An group intervention for multiparas with fear of childbirth|The intervention consists of 4 group meetings, three during pregnancy and once after giving birth. It also includes a phone call.
48145209|NCT04062383|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
48145210|NCT00453440|PROCEDURE|Cheek swab & blood test|Cheek swab \& blood test
48145211|NCT03108430|OTHER|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
48145212|NCT03732456|PROCEDURE|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
48145213|NCT01705366|PROCEDURE|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
48145214|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
48145215|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
48145216|NCT01705366|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
48356396|NCT04297176|DRUG|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
47988564|NCT01313767|DRUG|Botulinum toxin type A|Botulinum toxin type A
47988565|NCT01313767|DRUG|Botulinum Toxin type A|Botulinum Toxin type A
48356397|NCT04297176|DRUG|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
48356398|NCT00362440|DRUG|Leptin|
48356399|NCT00362440|DRUG|Pioglitazone or metformin|
48356400|NCT00362440|DRUG|Placebo|
48356401|NCT04490499|BIOLOGICAL|HBVAXPRO™|Single 0.5 mL intramuscular dose
48356402|NCT00151528|DRUG|Pregabalin|
48145217|NCT01705366|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
48145218|NCT01705366|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
48145219|NCT06452121|OTHER|triglyceride glucose index|"The TyG index was calculated using the following equation: Ln \[TG (mg/dL)×FPG (mg/dL) / 2\].~CAD was referred to as at least one major coronary artery with≥50% stenosis evaluated by CAG"
48667696|NCT06030518|DIAGNOSTIC_TEST|Magnet Assisted Capsule Endoscopy|Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
48667697|NCT05807126|PROCEDURE|Biopsy|Undergo biopsies
48667698|NCT05807126|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48667699|NCT05807126|PROCEDURE|Computed Tomography|Undergo CT
48667700|NCT05807126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48667701|NCT05807126|BIOLOGICAL|Magrolimab|Given IV
48667702|NCT05807126|DRUG|Olaparib|Given PO
48667703|NCT00365807|BEHAVIORAL|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
48667704|NCT00365807|OTHER|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
48667705|NCT05453214|DRUG|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
48667706|NCT02224170|DRUG|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
48667707|NCT02224170|DRUG|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
48667708|NCT05287750|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
48667709|NCT04562415|DEVICE|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
48667710|NCT04562415|DEVICE|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
48667711|NCT04562415|DEVICE|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
48667712|NCT03314090|DRUG|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
47988566|NCT01170507|DRUG|vitamin D3 1000 IU orally daily for 5 months|
48667713|NCT00271544|DEVICE|Pacing Lead|implant and follow-up of study device
48667714|NCT03824951|BIOLOGICAL|Anti-CD19 iCAR NK Cells|Anti-CD19 iCAR NK Cells injection
47988567|NCT01170507|DRUG|vitamin D3 3000 IU orally daily for 5 months|
47988568|NCT01170507|DRUG|vitamin D3 5000 IU orally daily for 5 months|
47988569|NCT01170507|DRUG|Placebo orally daily for 5 months|
48356403|NCT00989664|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
48688039|NCT03572959|DEVICE|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
47988570|NCT00010075|DRUG|fluorouracil|
47988571|NCT00010075|DRUG|leucovorin calcium|
47988572|NCT00010075|DRUG|mitoxantrone hydrochloride|
47988573|NCT05003076|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
47988574|NCT05003076|DRUG|Placebo|Participants will be given a placebo capsule that will only contain lactose.
47988575|NCT03535350|DRUG|Ibrutinib|"Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.~November 2020:~420 mg of ibrutinib plus temozolomide and radiation was found to be safe - up to 36 participants can betreated at the expansion cohort in both arm 1 and arm 2."
47988576|NCT03535350|RADIATION|Radiation|2Gy x 30minutes for 6 weeks.
47988577|NCT03535350|DRUG|Temozolomide (TMZ)|Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
47988578|NCT04836728|BIOLOGICAL|CIK cell injection|CIK cells, more than 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W.
47988579|NCT04836728|DRUG|Sintilimab Injection|Sintilimab Injection intravenous infusion 200mg d1
48356404|NCT05348499|OTHER|Questionnaire/Interview|Questionnaire/Interview
47988580|NCT04836728|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d2
47988581|NCT04836728|DRUG|Albumin paclitaxel|Albumin paclitaxel intravenous infusion 260mg/m2 d2
47988582|NCT04836728|DRUG|Carboplatin|Carboplatin intravenous infusion AUC5 d2
47988583|NCT03446742|OTHER|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
47988584|NCT00503308|PROCEDURE|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
47988585|NCT01572909|DRUG|Bendavia (MTP-131)|0.05 mg/kg/hr
47988586|NCT01572909|DRUG|Placebo|Identically appearing placebo
47988587|NCT05775315|OTHER|Action Observation Therapy|"Exercises of AO protocol MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
47988588|NCT05775315|OTHER|Action Observation Therapy along with visual feedback|"Exercises of AO protocol in front of a mirror MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
47988589|NCT01477840|DRUG|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
47988590|NCT01053364|DEVICE|NL-Prow interspinous spacer implant|Interspinous spacer implant
48667715|NCT00876941|BEHAVIORAL|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
48667716|NCT00876941|BEHAVIORAL|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
48667717|NCT00876941|BEHAVIORAL|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
48667718|NCT01359956|DRUG|Dacarbazine|900 mg / m2 every 3 weeks
48667719|NCT01359956|DRUG|Fotemustine|100 mg / m2 every 3 weeks
47988591|NCT02318511|PROCEDURE|Knee injection|Injection into knee for the treatment of Osteoarthritis
48667720|NCT01359956|DRUG|Interferon Alfa-2b|5 M units every 3 weeks
48667721|NCT01394159|PROCEDURE|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
47988592|NCT02318511|OTHER|ReNu amniotic allograft|
48145220|NCT03453645|PROCEDURE|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
47988593|NCT02318511|DEVICE|placebo saline|
47988594|NCT02318511|DEVICE|Hyaluronic Acid|
47988595|NCT04814225|OTHER|Test Product 1|Pea Protein powder
47988596|NCT04814225|OTHER|Test Product 2|Pea \& Oat Protein Powder
47988597|NCT04814225|OTHER|Test Product 3|Oat Protein Powder
47988598|NCT04814225|OTHER|Comparator|Whey Protein Isolate
47988599|NCT05642754|OTHER|Overall uncertainty language|Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
48145221|NCT02079259|PROCEDURE|Ultrafiltration|
47988600|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 24%|transfusion
47988601|NCT00651573|PROCEDURE|Blood transfusion at hematocrit value less than 28%|transfusion
47988602|NCT05130619|DIETARY_SUPPLEMENT|Ethanol|Crossover meal study
47988603|NCT03331679|BEHAVIORAL|HIIT|2 Weeks of High Intensity Interval Training on a Cycle ergometer
47988604|NCT05673044|PROCEDURE|modified Studer ileal neobladder|orthotopic ileal neobladders
48356405|NCT02207738|DEVICE|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
47988605|NCT01541969|DEVICE|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
48145222|NCT02671266|DRUG|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
48145223|NCT02671266|DRUG|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
48356406|NCT02207738|DEVICE|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
48145224|NCT04699578|DIAGNOSTIC_TEST|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
48145225|NCT00978718|DIETARY_SUPPLEMENT|high-selenium baker's yeast|Given orally
48145226|NCT00978718|DIETARY_SUPPLEMENT|selenium|Given orally
48145227|NCT00978718|OTHER|placebo|Given orally
48145228|NCT03274648|DIETARY_SUPPLEMENT|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
48145229|NCT03274648|DIETARY_SUPPLEMENT|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
48145230|NCT03274648|DIETARY_SUPPLEMENT|Habitual diet|Patients follow the habitual diet
48145231|NCT01841515|DRUG|Desmopressin administration|
48145232|NCT03719547|PROCEDURE|Abdominal radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
48145233|NCT03719547|PROCEDURE|Robot-assisted radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
48145234|NCT03719547|DIAGNOSTIC_TEST|Sentinel lymph node biopsy|Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
48145235|NCT02381028|OTHER|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
48145236|NCT02381028|OTHER|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
48145237|NCT01219127|OTHER|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
48145238|NCT05188378|BIOLOGICAL|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
48145239|NCT05188378|BIOLOGICAL|EU-approved RoActemra,|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
48145240|NCT02506192|DRUG|Modified-Release Prednisone|Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
48145241|NCT02506192|DRUG|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
48145242|NCT00006079|DRUG|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
48356407|NCT05229575|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
48145243|NCT00006079|OTHER|Placebo|Patients receive oral placebo daily for 28 days.
48145244|NCT03730727|BEHAVIORAL|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
48145245|NCT03730727|DIETARY_SUPPLEMENT|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
48356408|NCT02186340|PROCEDURE|Inspiratory muscle training|
48506018|NCT06374758|OTHER|The Accelerate model of care|"Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider."
48145246|NCT05033756|DRUG|Pembrolizumab Injection [Keytruda]|The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.
48356409|NCT01609361|OTHER|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
48356410|NCT02331706|DRUG|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
48145247|NCT05033756|DRUG|Olaparib Oral Tablet [Lynparza]|All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
48145248|NCT01502839|OTHER|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
48145249|NCT05989178|OTHER|Data Registry|Follow-up questionnaires sent every year for the 5 years following the patient's initial visit.
48145250|NCT02932176|DEVICE|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
48145251|NCT02932176|DEVICE|machine-learning algorithm|
48145252|NCT02798653|DRUG|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
47988606|NCT01541969|DEVICE|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
48506019|NCT06374758|DRUG|bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg|Same as above, it is the same intervetion
48667722|NCT01394159|PROCEDURE|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
48667723|NCT03502681|DRUG|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2"
48667724|NCT03502681|DRUG|Avelumab|Days 1, 15 Avelumab (10mg/kg)
48667725|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(RESTORE DEB）|
48667726|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(SeQuent® Please）|
48667727|NCT03694028|OTHER|Limb Loading|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
48667728|NCT03694028|OTHER|Conventional Training|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
48667729|NCT01746524|DEVICE|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
48667730|NCT04272164|OTHER|technical taekwando training|Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks
48667731|NCT04272164|OTHER|weighted rope jump training|Basic bounce step with both feet 2. Bell jump with both feet 3. Skier's jump 4. Right foot skipping 5. Left foot skipping, 6. Alternate foot step 7. Boxer shuffle 8. Side straddle 9. Scissors 10. Bonus jump with both feet After the preparatory weighted rope jump training (WRJT) for 1 week, subjects in experimental group followed jumping training by repetition method 3 days in a week for 8 weeks in addition to the routine taekwondo training program. 3 sets per week with 30 seconds training duration and 30 seconds rest duration. with progressive increase in the intensity and no. of sets.
48667732|NCT02102009|DIETARY_SUPPLEMENT|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months."
48667733|NCT02102009|OTHER|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
47988607|NCT04814576|BEHAVIORAL|Collaborative cares|The intervention consists of the co-design and implementation of therapeutic activities by the nurse and the mental health day hospital users following a collaborative care model. For this purpose, the participatory action research (PAR) method will be used and semi-structured interviews and focus groups will be used as data collection techniques.
48506020|NCT04332393|DRUG|Metformin|Metformin tablets according to glycemic control. Initial dose: 425 mg before meals (breakfast, lunch and supper) and 1700 mg around 22:00. Modifications may take place according to glycemic control
48667734|NCT03454789|DRUG|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
48506021|NCT06457893|OTHER|The health belief model-based exercise training program and health belief model-based education|The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
47988608|NCT01251549|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
47988609|NCT06526637|OTHER|Paper Package|Paper based (as per current practice at Central and North West London (CNWL) NHS Foundation Trust) version of Palliate.
47988610|NCT06526637|OTHER|V1 + Preparation Sheet|Paper based version of Palliate plus a preparation sheet, that provides visual cues as to what equipment is required for the preparation and administration of the medications.
48506022|NCT06633159|DEVICE|MitraClip|surgical intervention to correct mitral regurgitation by percutaneous transcatheter implantation of the MitraClip G4 clip on the mitral valve leaflets
48506023|NCT05819710|DRUG|TS-142|Single dose of 5 mg of TS-142
48506024|NCT05819710|DRUG|TS-142|Single-dose of 10 mg of TS-142
48667735|NCT03454789|DRUG|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
48506025|NCT05819710|DRUG|Zopiclone|Single-dose of 7.5 mg of zopiclone
48506026|NCT05819710|DRUG|Placebo|Single-dose of placebo
48506027|NCT06181708|OTHER|N/A - Questionnaire based study|Questionnaire based study
48356411|NCT03138798|DEVICE|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
48356412|NCT04090827|OTHER|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
48356413|NCT01078974|DRUG|pomalidomide|Taken orally once a day
48356414|NCT01078974|DRUG|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
48356415|NCT01078974|DRUG|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
48356416|NCT05095779|BEHAVIORAL|Coaching calls|OTH coaching calls
48356417|NCT05095779|DRUG|Nicotine replacement therapy|8 weeks of nicotine replacement therapy
48356418|NCT05095779|BEHAVIORAL|Financial Incentives|Escalating financial incentives for completing up to 5 coaching calls
48667736|NCT03454789|DRUG|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
48667737|NCT03454789|DRUG|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
47988611|NCT06526637|OTHER|V2 + Video Training|Hybrid - paper based materials, preparation sheet, and video instructions available via an interactive portable document format (PDF) version of the training materials.
47988612|NCT03721276|BEHAVIORAL|EQuIP (Empowering Queer Identities in Psychotherapy)|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
47988613|NCT02484742|BEHAVIORAL|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
47988614|NCT05289414|DEVICE|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency treatment
48356419|NCT03778424|DRUG|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
48356420|NCT05499091|PROCEDURE|Skin biopsy, blood sample, urine sample|blood samples, urine samples, skin samples.
48356421|NCT01242072|DRUG|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
48356422|NCT05373186|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
48356423|NCT05373186|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
48506028|NCT06633107|BEHAVIORAL|Cardiac、rehabilitation、exercise|"Routine cardiac rehabilitation treatment + corresponding rehabilitation exercise therapy prescription according to the condition: (1) slow walking + stairs climbing + standing aerobic exercise for patients with cardiac function level I; Grade II patients should take slow walking + standing aerobics; Grade III patients undergo bedside chair aerobics; Class IV aerobic exercises on bed.~After discharge aerobic exercise with the help of community exercise equipment. The duration is gradually increased from 10-20min to 30-40min each time; Gradually increase the intensity from 55% to 60% of the maximum heart rate and not exceed 85% (maximum heart rate (times / min) = 220 - age (years)); The frequency gradually increased from 3 days/week to 5 days/week"
48356424|NCT05373186|DRUG|Euglycemic clamp with Humalog® and Lantus®|Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
48356425|NCT04516629|DIAGNOSTIC_TEST|heart rate variability, pulse diagnosis device|check heart rate and pulse rate
48356426|NCT03590613|DRUG|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
48506029|NCT03879434|DEVICE|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
48506030|NCT06229548|DRUG|SYH2053|subcutaneous injection
47988615|NCT05289414|PROCEDURE|Greater occipital nerve block|patients with diagnosis of cervicogenic headache will be subjected to Greater occipital nerve block
47988616|NCT00654160|DRUG|fluorouracil|
47988617|NCT00654160|DRUG|irinotecan hydrochloride|
47988618|NCT00654160|DRUG|leucovorin calcium|
47988619|NCT00654160|OTHER|pharmacogenomic studies|
47988620|NCT00654160|OTHER|pharmacological study|
48145253|NCT02798653|DRUG|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
48356427|NCT03590613|DRUG|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
48356428|NCT03746340|DRUG|Propofol|Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30\~60s. Continuous intravenous infusion of Propofol (7\~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
48356429|NCT03746340|DRUG|Sevoflurane|Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0\~2.5Vol%) was maintained
48506031|NCT06229548|DRUG|Placebo|subcutaneous injection
48356430|NCT06246162|DRUG|Lipo-MIT combination regimen|"Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed."
48356431|NCT02871791|DRUG|Palbociclib|
48667738|NCT03512093|OTHER|Retrospective chart review|A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct \< 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born \< 34+0 weeks of gestation.
48356432|NCT02871791|DRUG|Everolimus|
48356433|NCT02871791|DRUG|Exemestane|
48506032|NCT06632847|OTHER|IMT based Resistance training|IMT with device group is trained twice daily, with the morning session and afternoon session. The intensity will increase progressively in this group, starting at 60% Maximal Inspiratory Pressure (MIP) and reaching 75% by the end of study. POSITION: Patient will be in sitting position. FREQUENCY: 4 TO 5 times per week. INTENSITY: 60 to 75% of MIP (gradually increment the load by 10%every 2 weeks to reach 75 to 80 %MIP). Time: 15 to 20 minutes.
48667739|NCT03512093|OTHER|Focus Group Discussion (FGD) of the medical staff|Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
48667740|NCT03512093|OTHER|Interviews of mothers|Interviews of mothers who delivered preterm neonates (\< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
48667741|NCT04769284|OTHER|Mental health student|"An ad-hoc questionnaire was designed that included sociodemographic variables related to the characteristics of the students. The variables sex, age, degree, employment situation, coexistence situation, economic situation, origin environment, country of origin, time of residence in the Spanish State were collected.~Personal variables:~* Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).~* International Physical Activity Questionnaire (IPAQ)~* Abbreviated Goldberg Anxiety Scale EADG~* Modified version of EPP-10 related to COVID-19 (EPP-10-C)"
48667742|NCT00248924|BEHAVIORAL|Social Services|
48667743|NCT00399087|DRUG|Perifosine|Perifosine oral administration
48667744|NCT00399087|DRUG|Docetaxel|IV administration
48667745|NCT00399087|DRUG|Prednisone|Oral administration
48145254|NCT02798653|DRUG|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
48145255|NCT04263688|OTHER|Non-Intervention|Non-Intervention
48506033|NCT06632847|OTHER|Theraband Resistive training|IMT training is form of exercise designed to strengthen the muscle that are involve in inhalation, primarily the diaphragm and intercostal muscles. Thera-band resistive training perform twice daily, with morning and afternoon session. Training will be perform 3 times per week. POSITION: patient will be in standing position. INTENSITY: moderate intensity (black and green thera-band used to provide medium resistance). Time: 15 to 20 minutes
48506034|NCT01577589|DRUG|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
48506035|NCT01577589|DRUG|Placebo in 50 ml infusion volume|IV infusion
48506036|NCT01577589|DRUG|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
48506037|NCT01577589|DRUG|Placebo in 250 ml infusion volume|IV infusion
48506038|NCT01577589|DRUG|600 mg ceftaroline in 100 ml infusion volume|IV infusion
48506039|NCT01577589|DRUG|Placebo in 100 ml infusion volume|IV infusion
48506040|NCT00038532|DRUG|Amprenavir/ritonavir|
48506041|NCT00038532|DRUG|Saquinavir/ritonavir|
48356434|NCT00400868|BEHAVIORAL|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
48506042|NCT00038532|DRUG|Efavirenz|
48506043|NCT03664492|OTHER|Educational whiteboard video|Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
48506044|NCT02616965|DRUG|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
48506045|NCT02616965|DRUG|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
48506046|NCT00911027|DRUG|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
48506047|NCT00911027|PROCEDURE|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
48506048|NCT02421224|BEHAVIORAL|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
48506049|NCT02421224|BEHAVIORAL|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
48145256|NCT06488742|OTHER|3% kanuka oil|To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.
48145257|NCT05158426|DRUG|Propofol|anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
48356435|NCT05798702|PROCEDURE|roux -en-y- gastric bypass|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
48145258|NCT03033667|DIETARY_SUPPLEMENT|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
48145259|NCT03033667|DIETARY_SUPPLEMENT|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
48145260|NCT03033667|DIETARY_SUPPLEMENT|Group C|Over night fasting with no supplementation
48667746|NCT05443828|OTHER|Breakfast Control Meal|The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
48667747|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
48667748|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
48667749|NCT02004158|BEHAVIORAL|Positive psychology intervention|
48667750|NCT00335829|BIOLOGICAL|bevacizumab|
48667751|NCT00335829|DRUG|chemotherapy|
48667752|NCT00335829|DRUG|embolization therapy|
48667753|NCT00335829|PROCEDURE|hepatic artery infusion|
48667754|NCT04089020|BEHAVIORAL|Support for walking to school|5 modules that address psychosocial skills, with ongoing text messaging.
48667755|NCT01010464|PROCEDURE|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
48667756|NCT02549066|PROCEDURE|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
47988621|NCT03315208|BEHAVIORAL|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
48145261|NCT03954106|DRUG|Defibrotide|"* Part 1: Defibrotide 2.5 mg/kg/dose or 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).~* Part 2 Recommended Phase 2 Dose: Defibrotide 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7)."
48506050|NCT02421224|BEHAVIORAL|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
48145262|NCT02325154|DEVICE|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
48145263|NCT02983721|PROCEDURE|transradial|transradial route for coronary angiography and PCI
48145264|NCT02983721|PROCEDURE|Transfemoral|transfemoral route for coronary angiography and PCI
48145265|NCT03400007|DEVICE|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
48145266|NCT03400007|DEVICE|Colpocystodefecography|Colpocystodefecography (CCD)
48145267|NCT03603691|DIAGNOSTIC_TEST|Modified Manual Muscle Test|Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
48145268|NCT03603691|DIAGNOSTIC_TEST|BMRC manual muscle test|muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
48145269|NCT03603691|DIAGNOSTIC_TEST|MicroFET2 handhold dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
48506051|NCT02421224|BEHAVIORAL|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
48506052|NCT02421224|BEHAVIORAL|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
48145270|NCT03603691|DIAGNOSTIC_TEST|Modified Tardieu Scale|Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
48356436|NCT05798702|DIETARY_SUPPLEMENT|intensive life style modification|Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
48356437|NCT02366715|DEVICE|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. \[3\] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
48356438|NCT03446664|DEVICE|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
48356439|NCT05495009|OTHER|Standard of care+virtual reality glasses|At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
48356440|NCT04035473|DRUG|HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules|"HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules~Oral paclitaxel capsules"
48356441|NCT03926780|DRUG|Rivaroxaban 20 MG|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
48356442|NCT03926780|DRUG|Warfarin Sodium|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
48356443|NCT04671576|OTHER|Control Infant Formula|Powder, standard commercial infant formula.
48356444|NCT04671576|OTHER|Organic Infant Formula|Powder, organic milk-based infant formula.
48356445|NCT04486404|OTHER|Online survey|Online survey including questions related to PPE availability, perceptions, emotions and EASE scale (Acute Stress Scale).
48356446|NCT03678506|DRUG|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
48356447|NCT05390034|BEHAVIORAL|ART|Session 1: Description of the group \& Psychoeducation Session 2: Breathing and muscle relaxation Session 3: Importance of practice/motivation Session 4: Nonjudgemental awareness Session 5: Acceptance and tolerance Session 6: Self-support Session 7: Analysis of emotions Session 8: Modification of emotions Session 9: Practice and contextual applications + end of group
48356448|NCT05390034|BEHAVIORAL|Relaxation|Session 1: Description of the groupe \& Psychoeducation Session 2: Breathing control 1 Session 3: Breathing control 2 Session 4: Muscle relaxation Session 5: Visualisation Session 6: Stretching Session 7: Schultz relaxation Session 8: Schultz relaxation Session 9: Summary and end of group
48145271|NCT03603691|DIAGNOSTIC_TEST|Fatigue Scale for Motor and Cognitive Functions|Measures cognitive and motor fatigue for people with MS
48356449|NCT02108795|DRUG|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
48506053|NCT02421224|BEHAVIORAL|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
48506054|NCT02482961|DRUG|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
48506055|NCT04200898|DEVICE|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
48506056|NCT01685450|DEVICE|Echodia® hand-held equipment|
48506057|NCT01763190|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
48506058|NCT01381666|DRUG|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
48506059|NCT01381666|DRUG|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
48506060|NCT04372108|DRUG|Ustekinumab|Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
48506061|NCT04372108|DRUG|Other Biologic Therapies|Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
48506062|NCT00261092|DRUG|Oxaliplatin|
48506063|NCT05212389|DRUG|Femicept|150 μg levonorgestrel +30 μg ethinylestradiol
48506064|NCT05212389|DRUG|Placebo|Placebo
48506065|NCT00093275|DRUG|HP184|
48506066|NCT03448497|OTHER|Non-interventional|Non-interventional
48506067|NCT04181827|DRUG|JNJ-68284528|Cilta-cel infusion will be administered at a target dose of 0.75 \* 10\^6 CAR-positive viable T cells/kilogram (kg).
48506068|NCT04181827|DRUG|Pomalidomide|Pomalidomide 4 mg will be administered orally.
48506069|NCT04181827|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter square (mg/m\^2) will be administered subcutaneously (SC).
48506070|NCT04181827|DRUG|Dexamethasone|Dexamethasone 20 mg/day (10mg/day for participants \>75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants \>75 years of age) in DPd treatment.
48356450|NCT02108795|DRUG|Placebo|
48356451|NCT06377215|DEVICE|Open-source master hearing aid|The investigators will administer the intervention by fitting the device to the participant's audiometric profile. Testing will be counter-balanced across conditions with half the conditions requiring no intervention and the other half with the intervention.
48356452|NCT02934061|DEVICE|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
48356453|NCT02934061|DRUG|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
48356454|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
48356455|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
48356456|NCT00795938|DRUG|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
48356457|NCT04650685|DEVICE|The novel Salvadora persica toothbrush|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
48667757|NCT02549066|DRUG|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) \< 12 %."
48667758|NCT03416816|DRUG|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
48667759|NCT01646827|DRUG|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
48667760|NCT03304366|DIAGNOSTIC_TEST|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
48145272|NCT03603691|DIAGNOSTIC_TEST|numeric rating scale Fatigue|visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
48145273|NCT01602302|DRUG|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
48667761|NCT03838835|BEHAVIORAL|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
48667762|NCT03838835|BEHAVIORAL|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
48667763|NCT03838835|OTHER|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
47988622|NCT03315208|OTHER|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
48145274|NCT02105571|BEHAVIORAL|Intervention|
48145275|NCT02450084|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
48356458|NCT04650685|DEVICE|The Salvadora persica (miswak) chewing stick|The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
48356459|NCT04650685|DEVICE|Standard toothbrush and toothpaste (control)|The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
48145276|NCT02450084|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
48145277|NCT02450084|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
48145278|NCT02450084|DRUG|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
48356460|NCT03686462|DEVICE|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
48356461|NCT03686462|DEVICE|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
48356462|NCT03200418|OTHER|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
48356463|NCT03200418|OTHER|P-4|This patch is made of new adhesive
48356464|NCT03200418|OTHER|P-15|This patch is made of new adhesive
48356465|NCT03200418|OTHER|P-16|This patch is made of new adhesive
48506071|NCT04181827|DRUG|Daratumumab|Daratumumab 1800 mg will be administered SC.
48506072|NCT04773522|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
48506073|NCT00468260|DRUG|Patupilone|
48506074|NCT06624878|DRUG|esketamine|0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.
48667764|NCT00603681|DRUG|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
48667765|NCT00603681|DRUG|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
48667766|NCT00841139|DRUG|Perhexiline|100mg o bd
48667767|NCT00841139|DRUG|Placebo|1 tablet bd
48667768|NCT05747248|DEVICE|Ultrasonography|Tracheal, diaphragmatic and lung ultrasonography
48356466|NCT06184165|PROCEDURE|Personalized rTMS|"5 personalized targets accessible to TMS (at less than 3.5 cm distance from the scalp or the coil's hot spot) are placed in the hyper-perfused premotor regions.~The patient is installed on the robotic device. The technician puts a neuro-navigation tracker on the subject's forehead and proceeds to the co-registration. The motor threshold is defined, and stimulator output's intensity is adjusted accordingly (120%) The robotic system ensures that the actual stimulation is performed according to the personalized protocol. This adequacy will be evaluated secondarily based on the recordings of the coil positions during each"
48667769|NCT01968980|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
48667770|NCT01968980|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
48667771|NCT01502384|OTHER|neurological examination|motor and cognitive functions
48667772|NCT04847687|DRUG|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
48667773|NCT04450732|DRUG|GQ1001|anti-HER2 antibody drug conjugate
48667774|NCT01983111|DRUG|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
48667775|NCT01983111|DRUG|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
47988623|NCT04634747|DRUG|PVX-410|PVX-410 in combination with pembrolizumab and chemotherapy
47988624|NCT04453033|DEVICE|Celeste Specialized Phototherapy Device|Ocular phototherapy light panel
48145279|NCT00502684|DRUG|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
48356467|NCT03566849|OTHER|KC group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2. 2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3. 3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4. 4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
48506075|NCT06624878|DRUG|placebo|a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
48506076|NCT01090752|DRUG|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
48506077|NCT01090752|DRUG|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
48506078|NCT01371383|DIETARY_SUPPLEMENT|n-3 fatty acids|EPA 1680 mg/d + DHA 880 mg/d
48506079|NCT01371383|DIETARY_SUPPLEMENT|placebo|Soybean oil
48506080|NCT03067597|DRUG|Dinoprostone|The DVI contains 10 mg dinoprostone
48506081|NCT00933361|DRUG|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
48506082|NCT02875964|DEVICE|electroencephalogram|Implanting electrode to measure brain activity
48506083|NCT02875964|DEVICE|magnetoencephalogram|Implanting electrode to measure brain activity
48506084|NCT04651413|DIAGNOSTIC_TEST|PCR Value|Data collection and interpretation
48506085|NCT06568055|OTHER|No Intervention|This is non-interventional study.
48506086|NCT03165838|BEHAVIORAL|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
48506087|NCT03165838|BEHAVIORAL|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
48506088|NCT00000116|DIETARY_SUPPLEMENT|Vitamin A|15000 IU/d as retinyl palmitate
48506089|NCT00000116|DIETARY_SUPPLEMENT|Docosahexaenoic acid|1200 mg/d
48506090|NCT00000116|DIETARY_SUPPLEMENT|Control fatty acid|
48506091|NCT04996550|DRUG|Carvedilol|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
48506092|NCT04996550|DRUG|Metoprolol Succinate|To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
48506093|NCT01404130|DRUG|Isotretinoin|0.5-1mg/kg daily for 4-6 months
48506094|NCT05367050|BEHAVIORAL|Lucid Lane Therapy Program|This intervention is designed to aid participants with pre-surgery anxiety management and surgery prep and pain management post-surgery. Participants will be assigned a Lucid Lane pain coach who will utilize mindfulness, cognitive behavioral therapy, group therapy, and mind-body therapies, to accomplish those goals.
48667776|NCT03547427|OTHER|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
48356468|NCT03566849|OTHER|CT group|"1. 1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2. 2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3. 3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4. 4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
48356469|NCT04282967|BEHAVIORAL|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
48667777|NCT03547427|OTHER|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
48667778|NCT03547427|OTHER|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
48667779|NCT03547427|OTHER|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
48356470|NCT03704090|BEHAVIORAL|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
48356471|NCT03704090|BEHAVIORAL|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
48356472|NCT04610320|DRUG|Daratumumab-SC|\>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.
48356473|NCT04677803|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
48356474|NCT04272996|PROCEDURE|Craniotomy only|evacuation of SDH
48356475|NCT04272996|PROCEDURE|Craniotomy + Endovascular embolization of the middle meningeal vessels|evacuation of SDH + Embolization of middle meningeal vessels using standard techniques.
48667780|NCT03547427|OTHER|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
48667781|NCT03547427|OTHER|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
48667782|NCT05486767|DIAGNOSTIC_TEST|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
48667783|NCT03554655|DEVICE|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
48667784|NCT04509258|DRUG|N-acetyl cysteine|a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
48667785|NCT04509258|DIETARY_SUPPLEMENT|acetyl L-carnitine|Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care
48667786|NCT04509258|DRUG|medicated paraffin oil|refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
48667787|NCT04509258|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
48667788|NCT00668759|DRUG|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
48667789|NCT00668759|DRUG|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
48356476|NCT01002196|BEHAVIORAL|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
48145280|NCT01622049|DEVICE|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
48356477|NCT01002196|BEHAVIORAL|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
48506095|NCT05367050|BEHAVIORAL|Surgical Preparedness Course|This intervention is designed to help the participant prepare for their upcoming surgery. Classes will include discussions around managing chronic pain before surgery, building mental resilience, dealing with the uncertainty of a new diagnosis or treatment plan, questions to ask their anesthesiologist before and on the day of surgery, what to expect during their potential stay at the hospital, and how to optimize their recovery after surgery. Sessions will often include expert doctors who focus on surgery and medical management around it.
48506096|NCT03489109|BEHAVIORAL|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
48506097|NCT03489109|OTHER|Standard of Care|Subject will receive standard of care recommendations for healthy diet and lifestyle
48506098|NCT04832126|GENETIC|Genetic analysis|Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).
47988625|NCT05766475|BEHAVIORAL|ROSE Program: In Person|In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
48145281|NCT01130298|DRUG|Testosterone Gel 1.62%|5 grams
48356478|NCT05541159|DRUG|TNO155|Single oral dose of TNO155 on Day 1
48506099|NCT00134667|DRUG|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
48667790|NCT01265485|DRUG|coated suppository|Dose escalating study
48667791|NCT00205127|PROCEDURE|Cardiac PET imaging- rest and pharmacological stress|
48667792|NCT05858931|PROCEDURE|vaginal repair|vaginal repair
48667793|NCT02890875|OTHER|Ethanol lock|
48667794|NCT02890875|OTHER|Heparin lock|
48667795|NCT05784012|DRUG|Dostarlimab|Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
48667796|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
48667797|NCT05784012|DRUG|cisplatin plus radiotherapy|In the concurrent phase
48667798|NCT05784012|DRUG|Niraparib|Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
48667799|NCT06165055|DIAGNOSTIC_TEST|DNA Sample Collection + DNA genotyping|Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
48667800|NCT04816032|OTHER|Pennebaker's expressive writing intervention|It focuses on the emotional aspect of the written event
48667801|NCT04816032|OTHER|Neutral writing|Description of neutral topics with less emotional involvement
48667802|NCT01170351|DRUG|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
48667803|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
48667804|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
48667805|NCT03412929|DEVICE|Honey Impregnated Dressing|The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
48506100|NCT00134667|DRUG|Macugen (pegaptanib sodium)|
48506101|NCT06447129|OTHER|Exercise|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist."
48667806|NCT05480007|DRUG|sitagliptin and metformin|sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
48667807|NCT05480007|DRUG|Sitagliptin|sitagliptin treatment (100mg per day)
48667808|NCT05480007|DRUG|Metformin|metformin group who received metformin (500mg three times per day)
48667809|NCT02576626|DRUG|indacaterol/glycopyrronium 110/50 Breezhaler®|
48667810|NCT02576626|DEVICE|Placebo by Breezhaler®|
48667811|NCT02576626|DRUG|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
48667812|NCT02576626|DEVICE|Placebo by nebulisation|
48667813|NCT05631847|PROCEDURE|Endovascular treatment|It is the emergency surgical removal of emboli which are blocking blood circulation. The strategies that were used for endovascular treatment included stent retrievers, thromboaspiration, balloon angioplasty, stent deployment, intraarterial thrombolysis (with alteplase), or combinations of these approaches that were left to the discretion of the treating team.
48667814|NCT05631847|DRUG|Intravenous thrombolysis (Alteplase)|Alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
48667815|NCT03548129|DRUG|phosphomycin|Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
48667816|NCT03548129|DRUG|Culture specific antibiotic therapy|Culture-specific antibiotic treatment for 5 days
48667817|NCT03548129|DIAGNOSTIC_TEST|Pre-treatment Urine Culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
48356479|NCT05161624|DIAGNOSTIC_TEST|Accuracy evaluation|The design of the diagnostic trial will include 160 cases of liver tumors with indications for microwave ablation after a multidisciplinary consultation with clinicians (Multiple Disciplinary Team, MDT), including primary liver cancer and metastatic liver tumors, and the tumor diameter is less than 3 cm. The test subjects consist of three groups: a. path planning model, b. junior ablation specialists, c. senior ablation specialists. The three groups will perform microwave ablation path planning on 160 selected cases of liver tumors. The attending professor of the clinical medical group of the department is responsible for scoring, evaluating whether the design of the plan is reasonable, and then comparing the scoring results by using statistical methods to evaluate the accuracy and effectiveness of the path planning model established in this study.
48356480|NCT02315794|DEVICE|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
48356481|NCT02315794|DEVICE|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
48356482|NCT05744830|OTHER|Overdenture|15 patients will receive removable complete dentures, then a single implant is placed in the midline of the mandible, then loaded with the denture.
48356483|NCT05744830|OTHER|Complete Denture|15 patients will only receive removable complete dentures
48356484|NCT00748176|PROCEDURE|spinal anesthesia|spinal anesthesia with bupivacaine
48356485|NCT05452187|DRUG|Assess the effectiveness and safety of DAAs in patients with IBD.|Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
48506102|NCT06447129|OTHER|Neuromuscular electrical stimulation|The Neuromuscular Electrical Stimulation (NMES) will be applied for 20 minutes. The patient will be seated with hips and knees flexed at 90°. Electrodes will be placed on the proximal and distal ends of the vastus medialis obliquus and vastus lateralis muscles. The intensity will be increased as much as the patient can tolerate, and the patient will be asked to relax and not make voluntary muscle contractions.
48667818|NCT03548129|DIAGNOSTIC_TEST|Antimicrobial sensitivity testing|Susceptibility of urinary pathogens to various antimicrobials
48506103|NCT05612672|OTHER|GeoHAI|A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
47988626|NCT05766475|BEHAVIORAL|ROSE Program: Virtual|Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
47988627|NCT02326376|DRUG|anakinra (Kineret)|
47988628|NCT04846660|OTHER|Production pressure|Participant exposed to production pressure
48145282|NCT06464666|PROCEDURE|Renal interlobar artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
48145283|NCT06464666|PROCEDURE|Renal inter-lobular artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
48506104|NCT03897803|DIAGNOSTIC_TEST|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii and rectus femoris muscles will be performed to the patients and control groups at baseline evaluation and after 4 months follow up in the patients groups only.
48506105|NCT04546880|OTHER|Breathing exercises|"Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing."
48667819|NCT03548129|DIAGNOSTIC_TEST|Post-treatment urine culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
48667820|NCT00673920|DRUG|Methotrexate|Oral or parenteral repeating dose
48667821|NCT00673920|DRUG|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
48667822|NCT00673920|DRUG|Placebo|Intravenous repeating dose
48145284|NCT05858359|BEHAVIORAL|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~1. Becoming aware of the patient's core strengths and difficulties~2. Helping the patient to be optimally responsive to the guidance of the carer, and~3. Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
48667823|NCT06488664|BIOLOGICAL|GNR-068|GNR-068 was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 52.
48356486|NCT05452187|DRUG|Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.|Variables evaluated: Interactions.
48356487|NCT05452187|OTHER|Assessment of the impact of DAAs on the course of IBD.|Qualitative variables will be expressed as a percentage and 95% confidence interval and quantitative variables as median and interquartile range. A priori it is difficult to determine which statistical analysis should be performed. It is basically a descriptive study, and the subsequent statistical analysis will depend on the evolution that the patients have presented in relation to the DAA treatment. If the drugs have been well tolerated without adverse effects, further statistical analysis will not be necessary. Instead, if the DAAs trigger activity outbreaks, variables related to the appearance of these outbreaks will be evaluated (type of DAA, immunomodulator, ...). To compare whether there are differences between the established groups, Chi Square (in qualitative independent variables), a t-student or ANOVA or their corresponding non-parametric tests (in quantitative independent variables) will be used. Statistical significance has been set at a probability level of \<0.05.
17067408|NCT05845606|BEHAVIORAL|Benzodiazepine Taper|The BZ-TP is a 14-week intervention that assists participants in reducing their benzodiazepine prescription through a gradual taper at approximately 10%-20% reduction per week for a total of 12 weeks. Dose reduction will be recommended but not required. This intervention is identical in both arms.
17067409|NCT05845606|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The telehealth delivered CBT is an 11-week intervention that includes psychoeducation, interoceptive exposure, somatic skills, and cognitive restructuring.
48667824|NCT06488664|BIOLOGICAL|Stelara®|Stelara® was administered subcutaneously at weeks 0 and 4 weeks then every 12 weeks thereafter until week 28 and then all patients receive GNR-068 45 mg until week 52.
48667825|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in CT|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
47988629|NCT04063956|BEHAVIORAL|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
48145285|NCT02535585|DEVICE|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
48356488|NCT02853903|BIOLOGICAL|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
48356489|NCT00199368|DRUG|Istradefylline ( KW-6002)|
17067410|NCT05845606|BEHAVIORAL|Health Education|The Health Education (HE) intervention will include 11 weeks of an interactive health education program to match for therapy time. The HE is a published multimedia program addressing various health, wellness and lifestyle topics such as nutrition, dental care, immunizations, health screening, smoking, and time management.
48356490|NCT02130635|DRUG|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
48356491|NCT02130635|DRUG|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
48356492|NCT02130635|DRUG|PLACEBO|Lactose administered using a matching dry powder inhaler device
48356493|NCT02320591|OTHER|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
48667826|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in CT|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
48688040|NCT04704297|DRUG|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
48667827|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in CT|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
48356494|NCT02320591|OTHER|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
48506106|NCT04546880|OTHER|Stabilization exercises|"Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability."
48667828|NCT06527027|OTHER|Lymph node assessment according to RECIST 1.1 in MRI|RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.
48667829|NCT06527027|OTHER|Lymph node assessment according to Node-RADS in MRI|Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
48667830|NCT06527027|OTHER|Lymph node assessment according to LN-RADS in MRI|"LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node"
48667831|NCT04713189|DRUG|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
48667832|NCT04713189|DRUG|Placebo|Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
48667833|NCT01871649|DRUG|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
48667834|NCT01871649|DRUG|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
48667835|NCT03652155|PROCEDURE|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
48667836|NCT01524406|DRUG|HPP593|Oral, twice a day.
48667837|NCT01524406|DRUG|Placebo|Oral, twice a day.
48667838|NCT01993082|BEHAVIORAL|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
48667839|NCT05006066|OTHER|Temporal Summation|4 type of stimulations applied on the right arm
48667840|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
48667841|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
48667842|NCT00000276|DRUG|Bupropion|
48145286|NCT02535585|DEVICE|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
48667843|NCT04778202|DIAGNOSTIC_TEST|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
48667844|NCT03213509|OTHER|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
48667845|NCT02515318|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
48667846|NCT02515318|DRUG|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
48667847|NCT02108288|DRUG|OPC-1085EL ophthalmic solution|
48667848|NCT02108288|DRUG|Carteolol long-acting ophthalmic solution|
47988630|NCT04063956|BEHAVIORAL|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
47988631|NCT06495346|OTHER|self-questionnaires exploring|At each stage, subjects are asked to fill in self-questionnaires exploring the quality of their sleep, their potential distressing symptoms, their psychological state and the quality of their life at that moment. They complete the self-questionnaires at t
48145287|NCT05503407|PROCEDURE|Baseline V-RESOLVE score-guided PCI|"Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting."
48356495|NCT02320591|OTHER|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
48356496|NCT01207921|DRUG|Lenalidomide|
47988632|NCT03577704|DRUG|HLX07+Gemcitabine+Cisplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."
47988633|NCT03577704|DRUG|HLX07+Paclitaxel+Carboplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."
47988634|NCT03577704|DRUG|HLX07+mFOLFOX6|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."
47988635|NCT04417881|OTHER|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
47988636|NCT04923087|DEVICE|Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements|"Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?"
47988637|NCT04666233|PROCEDURE|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
48356497|NCT04778644|DRUG|CBD|Oral gel capsule CBD
48356498|NCT04778644|DRUG|Placebo|Oral gel capsule placebo
48667849|NCT02108288|DRUG|Latanoprost ophthalmic solution|
48667850|NCT04516278|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
48667851|NCT00261833|BIOLOGICAL|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
48667852|NCT00261833|OTHER|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
48667853|NCT02514655|DEVICE|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
48667854|NCT02514655|OTHER|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
48356499|NCT04319861|PROCEDURE|Anal fistula plug procedure|A fistula probe was used to identify fistula tracts, and internal and external openings. Gentle mechanical debridement was performed with a blunt curette to remove the necrotic tissue with care not to enlarge the track, then hydrogen peroxide and sterile saline were used to repeatedly to irrigate the fistula. The anal fistutla plug was filled into the fistula, and sutured with a figure-of-eight 2-to-0 Vicryl suture to ensure the plug was fixed in the internal opening of the fistula, avoiding the anal fistula plug being extruded. Trimming the plug at the external fistula and the external opening was left open to ensure adequate drainage.
48356500|NCT02773849|BIOLOGICAL|ADSTILADRIN|
48356501|NCT04566523|OTHER|telerehabilitation|Patients undergo an online exercise training program via a certified host of health data website.
48356502|NCT03899389|DIAGNOSTIC_TEST|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
48356503|NCT00218283|DRUG|Nicotine Lozenge|Oral Nicotine replacement product
48356504|NCT00218283|BEHAVIORAL|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
47988638|NCT04666233|PROCEDURE|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
47988639|NCT05666258|DIAGNOSTIC_TEST|GEP|GEP before surgery to determine need for neoadjuvant chemotherapy
47988640|NCT00633386|DRUG|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
47988641|NCT00633386|OTHER|Placebo|Matched placebo
47988642|NCT00249444|DRUG|Mirtazapine|Mirtazapine
48356505|NCT06144411|OTHER|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
48356506|NCT05673382|BEHAVIORAL|Internet-based cognitive behavioral therapy|The intervention (the treatment) within this study is based on cognitive behavioral therapy principles and adapted to target psychological symptoms related to life crises. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
48356507|NCT00942422|DIETARY_SUPPLEMENT|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
48356508|NCT00942422|GENETIC|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
48356509|NCT00942422|GENETIC|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
48356510|NCT00942422|OTHER|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
48356511|NCT00114764|DRUG|filgrastim|Filgrastim given daily after induction chemotherapy
48356512|NCT00114764|DRUG|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
48356513|NCT05801016|BEHAVIORAL|Emerging Technologies and Training in Neurosciences|Combination of body-swapping technique, Virtual Reality Body Size estimation tasks and Autobiographic Recall
48356514|NCT02532816|DIETARY_SUPPLEMENT|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
48356515|NCT00045006|DRUG|vorinostat|
48356516|NCT01804504|BEHAVIORAL|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
48356517|NCT02355860|BEHAVIORAL|assessment|assessment
48356518|NCT04525911|DIAGNOSTIC_TEST|Diagnostic Test: serology test for COVID-19|a serology test will be performed at M3
48506107|NCT06016491|BEHAVIORAL|acupressure|Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
47988643|NCT00249444|DRUG|Placebo|placebo
47988644|NCT06105151|DRUG|VV119(SAD)|VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
47988645|NCT06105151|DRUG|VV119 Placebo(SAD)|VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
48145288|NCT05503407|PROCEDURE|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
48667855|NCT01255280|BEHAVIORAL|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
48667856|NCT01255280|BEHAVIORAL|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
48667857|NCT02660229|DRUG|Oxycodone Hydrochloride|Oxycodone injection
48145289|NCT03918005|OTHER|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
48145290|NCT05477407|DRUG|Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine|Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
48145291|NCT05765526|DEVICE|A novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
48145292|NCT03162614|BIOLOGICAL|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
48145293|NCT03162614|BIOLOGICAL|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
48145294|NCT03162614|PROCEDURE|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
48145295|NCT04288388|BEHAVIORAL|massage group|In recent years, in the literature, it is known that many non-pharmacological techniques are applied to reduce the pain of birth in addition to local anesthesia. One of these nonpharmacological methods is the application of pressure to LI4 point on hand with ice.
48145296|NCT06500104|DIETARY_SUPPLEMENT|Kefir peptide|Dosage: 1.2 gram kefir peptide daily oral intake for 12 weeks
48506108|NCT06016491|BEHAVIORAL|Sham acupressure|Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
48667858|NCT02660229|DRUG|Morphine Sulphate|Morphine sulphate injection
48667859|NCT04264000|DRUG|platelet-rich plasma|Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
48667860|NCT04264000|DRUG|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
48145297|NCT06500104|DIETARY_SUPPLEMENT|Placebo|Glucose powder
48145298|NCT05781932|PROCEDURE|Dermal barb suture combined with medical glue|In the experimental group, after tension reduction and suture were completed, the wound and surrounding skin were wiped clean with normal saline and clean gauze, and the blood accumulated in the wound was squeezed out. Histoacryl medical tissue glue (specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4\[(toluene)amino\]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)) were evenly spread on the surgical incision and kept in the butt state for 4 to 6 seconds. After it got solidify and dry, a sterile gauze covered the surgical incision. There was no need to disinfect and change the dressings after the operation. Patients can shower normally on the day after the operation by just avoiding rubbing the incision covered with glue. Patients can move normally 1-2 days after the operation, and the glue film falls off on its own within 5-10 days.
48667861|NCT05381480|BEHAVIORAL|In-home Preventive Health Visits by Advanced Practice Nurse|Elements of Comprehensive Geriatric Assessment used as a preventive, health risk assessment, with recommendations tailored for health risks identified and offered to building tenants
48667862|NCT05381480|BEHAVIORAL|On-site Evidence-based Physical Activity, Health and Wellness Classes|Weekly calendar of health promotion and injury/illness prevention classes offered to building tenants.
48667863|NCT06006104|DRUG|HRS-4357 injection|HRS-4357 injection
48667864|NCT01736917|DRUG|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
48667865|NCT01736917|DRUG|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
48667866|NCT01736917|DRUG|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
48667867|NCT05931731|OTHER|Mechanical interference|The patients will receive mechanical interference treatment in the form of five techniques, including wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, the release of palmar hand fascia, gliding of the finger flexor tendons (using the oscillatory flexion-extension movement of the metacarpophalangeal joint) and release of the upper forearm muscle and fascia were applied. Manual techniques were performed total of 15 minutes in each session each technique included 3 sets for 3 minutes and conventional treatment
48145299|NCT05732909|DIETARY_SUPPLEMENT|D-β-hydroxybutyrate/D 1,3 butanediol monoester|Ketone monoester
48667868|NCT05931731|OTHER|Neural mobilization|the patients will receive neurodynamic mobilizations, including sliding techniques and tensioning techniques which are thought to enhance ulnar nerve gliding and restore neural tissue mobility and conventional treatment
48145300|NCT03770897|PROCEDURE|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
48145301|NCT03770897|PROCEDURE|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
48145302|NCT02364648|DIETARY_SUPPLEMENT|MitoQ|Mitochondria targeted antioxidant
48145303|NCT02364648|DIETARY_SUPPLEMENT|Placebo|Placebo
48145304|NCT02567591|OTHER|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
48145305|NCT05884567|OTHER|Isometric exercises|These exercises are used to increase muscle endurance, power and ROM
48356519|NCT04491331|PROCEDURE|prone position|Unsupported prone position with arms along the body in neutral position will be used first without any supportive device except support of heels with a soft cylindrical device, head will be held in a neutral position using prone head rest. After recording of all measered values, the prone position using the prone position support system will be tested. The support system allows free movement of the lower thorax and abdomenal wall, upper arms are elevated and angled in 90 degrees (in shoulders and elbows). Heels will be positioned at the level of the heart using a supportive cylindrical device. Head will be held in a neutral position using prone head rest.
48356520|NCT05874700|DRUG|Sivelestat sodium was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
48356521|NCT05874700|DRUG|Placebo was given intravenously|Anesthesia induction began with a 0.2mg/Kg/h pump test drug until 48 hours after endotracheal intubation was removed or up to 7 days. If the patient was judged to have successfully removed the endotracheal tube, drug administration was discontinued; If the endotracheal intubation was not removed successfully up to 7 days, drug administration was also discontinued. During CPB, 0.1mg/100mL of the experimental drug was injected into the circulating pump immediately after CPB began.
48356522|NCT03497390|OTHER|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
48356523|NCT03497390|OTHER|Usual care|Usual care without any workshop or program
48356524|NCT03851224|PROCEDURE|control group|immediate implant with immediate loading using no graft
48667869|NCT05931731|OTHER|conventional treatment|the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.
48667870|NCT04046939|DRUG|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
48145306|NCT05884567|OTHER|Mobilization|These exercises are used to increase ROM and used for pain reduction
48145307|NCT00493688|OTHER|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
48145308|NCT02327442|RADIATION|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
48145309|NCT00689416|DRUG|rosuvastatin|40 mg, tablet, once daily for 3 months.
48145310|NCT00689416|DRUG|placebo|40 mg, tablet, once daily for 3 months
48145311|NCT01579955|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
48145312|NCT02166632|PROCEDURE|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
48145313|NCT02166632|PROCEDURE|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
48667871|NCT04046939|DRUG|Placebo|placebo twice daily oral dosing for up to 12 weeks
48356525|NCT03851224|PROCEDURE|study group|immediate implant with immediate loading using autogenous bone graft
48667872|NCT00433485|DRUG|sirolimus|
48667873|NCT00433485|GENETIC|comparative genomic hybridization|
48667874|NCT00433485|GENETIC|gene expression analysis|
48667875|NCT00433485|GENETIC|microarray analysis|
48667876|NCT00433485|GENETIC|protein expression analysis|
48667877|NCT00433485|GENETIC|proteomic profiling|
48356526|NCT03851224|PROCEDURE|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
48356527|NCT04726436|OTHER|Dextrose 5% in water|One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
48356528|NCT04726436|OTHER|Dextrose 10%|One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
48356529|NCT04726436|OTHER|Saline placebo|One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
48356530|NCT00606931|DEVICE|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
48356531|NCT03799133|DEVICE|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
48667878|NCT00433485|OTHER|laboratory biomarker analysis|
48145314|NCT04775732|BIOLOGICAL|infliximab therapeutic drug monitoring|dose optimization of infliximab based on a predefined dosing algorithm
48356532|NCT05039411|BIOLOGICAL|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
48667879|NCT00433485|OTHER|mass spectrometry|
48667880|NCT00433485|PROCEDURE|biopsy|
48667881|NCT04269954|DRUG|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin
48667882|NCT00940602|DRUG|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
48667883|NCT00940602|DRUG|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
48667884|NCT02434861|DRUG|Rolapitant|
48667885|NCT02434861|DRUG|Digoxin|P-gp substrate
48667886|NCT02434861|DRUG|Sulfasalazine|BCRP substrate
48667887|NCT02434861|DRUG|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
48667888|NCT00710593|BIOLOGICAL|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
48667889|NCT01342094|DRUG|DE-111 ophthalmic solution|
48667890|NCT01342094|DRUG|Timolol ophthalmic solution 0.5%|
48667891|NCT01342094|DRUG|Placebo ophthalmic solution|
48667892|NCT03719014|DEVICE|NovaCross|The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
48667893|NCT02362685|DEVICE|functional test|subjects perform a metabolic exercise testing
48667894|NCT02362685|GENETIC|matching genotype with phenotype|
48145315|NCT04195789|OTHER|Lung sonography|"Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist."
48145316|NCT05214521|DEVICE|"digital interactive technology Smart glove SensoRehab"|"Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks."
48667895|NCT01343212|OTHER|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
48667896|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
48667897|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
48667898|NCT04256655|DRUG|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
48145317|NCT03950726|PROCEDURE|ileocolic resection|Ileocolic resection through McBurney incision
48145318|NCT02717208|BIOLOGICAL|HL036|
48145319|NCT02717208|BIOLOGICAL|Vehicle|
48145320|NCT05888740|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf
48145321|NCT03911297|OTHER|Women with polycystic ovary syndrome|Prospective cohort study in women with polycystic ovary syndrome to identify the risk of developing metabolic disease
48145322|NCT05763823|DRUG|Letermovir|Letermovir 240 mg or 480 mg oral tablets or IV once daily dose
48145323|NCT06030037|BIOLOGICAL|Responder-Derived Fecal microbiota transplantation (R-FMT|R-FMT (induction) via colonoscopy on C1D1 and C3D1. R-FMT (maintenance) via sigmoidoscopy will be repeated every 9 weeks.
47988646|NCT06105151|DRUG|VV119(FE)|A：4 mg VV119, following an overnight fast of at least 10 hours for Period 1; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 2; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 3; B: 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1; 4 mg VV119, following an overnight fast of at least 10 hours for Period 2; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 3; C: 4mg VV119, administered 30 minutes after the start of a standard meal for Period 1; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2;4 mg VV119, following an overnight fast of at least 10 hours for Period 3.
47988647|NCT05003154|OTHER|Digitalized management|"In addition to conventional management, Patients also receive digitalized management, which provides personalized guidance in diet, excercise, prenatal visit, blood glucose monitoring,etc., from artificail intelliegence (AI) supevised by obstetricians, through a smartphone application and some werable devices (like sports bracelet).~The pivotal AI are based on clinical experience from obstetricians, therapeutic principle from official Guidelines and abundant data in previous work, and it will works under strict supervision."
47988648|NCT03249233|DEVICE|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
47988649|NCT03249233|DEVICE|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
48356533|NCT04787276|DIETARY_SUPPLEMENT|E.coli Nissle 1917|Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
48356534|NCT04787276|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
48356535|NCT04787276|DRUG|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
48356536|NCT01149161|PROCEDURE|Routine central neck dissection|Level VI neck node dissection during thyroid operation
48356537|NCT00626795|DRUG|TD1414 2% cream|BID 7 days
48356538|NCT00626795|DRUG|TD1414 2% cream|TID 7 days
48356539|NCT00626795|DRUG|Bactroban® (mupirocin) 2% cream|BID 7 days
48356540|NCT04397757|BIOLOGICAL|COVID-19 Convalescent Plasma|2 units of COVID-19 convalescent plasma compatible with their blood type
47988650|NCT03589950|DRUG|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
47988651|NCT03589950|DRUG|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
47988652|NCT02116400|OTHER|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
47988653|NCT02116400|OTHER|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
48356541|NCT01320033|DRUG|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
48356542|NCT01320033|DRUG|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
48356543|NCT01320033|DRUG|Placebo|Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
48356544|NCT05408403|OTHER|Regional anesthesia TFPB|Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
48356545|NCT05408403|OTHER|Regional anesthesia QLB|Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
48356546|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
47988654|NCT02116400|BIOLOGICAL|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
48145324|NCT06030037|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)
48145325|NCT06030037|DRUG|Lenvatinib|Lenvatinib will be administered at 20 mg daily
48145326|NCT03481985|OTHER|Fenestration status|The exposure variable will be status of the Fontan fenestration
48145327|NCT03112005|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
48145328|NCT03112005|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
48145329|NCT04251455|PROCEDURE|Arthroscopy or discectomy with sampling of synovial fluid and synovial tissue|"Arthroscopic lysis and lavage: performed under general anaesthesia. Before initiation of arthroscopy synovial fluid was sampled with a push-and-pull method. The TMJ was investigated with an arthroscope during irrigation with sterile saline solution. Adhesions were addressed with a coblator. Synovial tissue biopsies were taken from the posterior attachment of the disc.~Discectomy without replacement: performed under general anaesthesia. Before initiation of surgery, synovial fluid was sampled as above described. During surgery synovial tissue biopsies were taken as described above."
48145330|NCT03342261|DRUG|DAA treatment|Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
48145331|NCT00909909|RADIATION|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
48145332|NCT00909909|RADIATION|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
48145333|NCT04277494|OTHER|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
48356547|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
48356548|NCT00397891|DRUG|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
48506109|NCT04170751|DRUG|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
48145334|NCT03326037|GENETIC|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
48145335|NCT03286907|BEHAVIORAL|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 \& 8.
48145336|NCT03286907|BEHAVIORAL|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, \& 8.
48145337|NCT03286907|BEHAVIORAL|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
48145338|NCT01884207|OTHER|MRI|
48506110|NCT04170751|DRUG|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
48506111|NCT04483206|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
48667899|NCT04256655|DRUG|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
48688041|NCT04704297|DRUG|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
47988655|NCT01714154|DRUG|danoprevir|100 mg orally every 12 hours
47988656|NCT01714154|DRUG|ritonavir|100 mg orally every 12 hours
47988657|NCT01714154|DRUG|setrobuvir|200 mg orally every 12 hours
47988658|NCT00616681|DRUG|Oxcarbazepine|
48356549|NCT04196049|PROCEDURE|fragmatome|Patients with massive subretinal hemorrhage from age related macular degeneration and organized subretinal blood clot were managed by inferior retinectomy. The subretinal organized blood clot was dragged to the preretinal space and removed by fragmatome. The retinal was reattached with perfluorocarbon liquid and laser was applied at the margin of retinectomy. Silicon oil was infused at the end of surgery.
48356550|NCT04793893|DEVICE|ReLex Smile|With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
48356551|NCT01038635|DRUG|5-Azacytidine|75 mg/m\^2 IV daily x 5 days on days 1 to 5.
48356552|NCT01038635|DRUG|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
48356553|NCT05038111|DRUG|Dexmedetomidine|perioperative dexmedetomidine infusion
48356554|NCT00934791|DRUG|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
48356555|NCT00934791|DRUG|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
48356556|NCT00934791|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
48667900|NCT04256655|DRUG|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
48667901|NCT02847403|DRUG|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
48667902|NCT02847403|OTHER|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
48667903|NCT04883268|OTHER|Expand Your Horizon|Expand Your Horizon is an online programme, comprising three 15min writing exercises delivered over the course of 1 week. In each writing exercise, participants are asked to describe the functions of their body, and why those are personally meaningful to them.
48667904|NCT03186638|DRUG|Ibuprofen|Given PO
48667905|NCT03186638|OTHER|Placebo|Given PO
48667906|NCT03186638|OTHER|Questionnaire Administration|Ancillary studies
48667907|NCT01101529|DRUG|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
48667908|NCT01101529|DRUG|Placebo|Placebo will be administered instead of Emend
48667909|NCT05018364|DIAGNOSTIC_TEST|Serum erythropoietin level|Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group
48667910|NCT02208219|BEHAVIORAL|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
48667911|NCT02208219|BEHAVIORAL|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
48667912|NCT02208219|BEHAVIORAL|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~* Passive mobilization: controlled manipulation of movements to release a joint.~* Stretch and progressive resistance training.~* Task-specific training: reaching and manipulation of different objects.~* Intense physical training: repetition of sequence of movements."
48667913|NCT00185094|DRUG|Olmesartan medoxomil|
48667914|NCT00185094|DRUG|Losartan potassium|
48667915|NCT00185094|DRUG|Atenolol|
48667916|NCT03926455|BIOLOGICAL|Typhax (investigational typhoid fever candidate vaccine)|
48667917|NCT03926455|BIOLOGICAL|Placebo|Placebo is administered to the control group on Day 0 and 28
48667918|NCT03926455|BIOLOGICAL|Active Comparator Typhim Vi|A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
48667919|NCT05320978|DEVICE|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
48667920|NCT04196530|DRUG|BDB001|BDB001 is an immunotherapy agent.
48356557|NCT00934791|DRUG|Prednisone|Prednisone tapered to 5 mg/day by day 92
48356558|NCT00898690|GENETIC|cytogenetic analysis|
48356559|NCT00898690|GENETIC|gene expression analysis|
48356560|NCT00898690|GENETIC|microarray analysis|
48356561|NCT00898690|GENETIC|mutation analysis|
48356562|NCT00898690|GENETIC|reverse transcriptase-polymerase chain reaction|
48356563|NCT00898690|OTHER|immunohistochemistry staining method|
48356564|NCT00004084|RADIATION|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
48356565|NCT00004084|RADIATION|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
48356566|NCT02951585|DEVICE|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
48356567|NCT02951585|DEVICE|PLACEBO|Intra-articular injection of physiological serum (saline solution)
48356568|NCT02407236|DRUG|Placebo IV|Placebo will be administered as intravenous infusion.
48506112|NCT04483206|DRUG|Melphalan|Given IV
48667921|NCT04196530|DRUG|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
48145339|NCT03132571|DRUG|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
47988659|NCT05373329|DEVICE|Sanvello (app)|Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.
47988660|NCT03241355|DIETARY_SUPPLEMENT|prebiotic inulin-type fructan|
47988661|NCT03241355|DIETARY_SUPPLEMENT|Placebo maltodextrin|
48667922|NCT02041793|PROCEDURE|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
48667923|NCT02041793|PROCEDURE|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
47988662|NCT03173599|DRUG|PNA 40mg|The beginning dose is 40mg.
47988663|NCT03173599|DRUG|PNA 80mg|The single dose is 80mg.
48145340|NCT03132571|DRUG|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
48667924|NCT06061692|DRUG|Tongxinluo Capsule|4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
48667925|NCT03136120|DRUG|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
48667926|NCT03136120|PROCEDURE|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
47988664|NCT03173599|DRUG|PNA 160mg|The single dose is 160mg.
47988665|NCT03173599|DRUG|PNA 240mg|The single dose is 240mg.
48145341|NCT03132571|OTHER|Placebo|Oral placebo taken once daily for the course of the study (16 week)
48145342|NCT05051826|OTHER|Resistance training that combines water and land|"Device: Swimmers in the experimental group received resistance training in water for 12 weeks, and the resistance training in the experimental group was divided into 3 categories:Resistance palm and resistance umbrella, resistance suit.~Device: The swimmers in the experimental group underwent core strength training on land for 12 weeks, and the resistance training in the experimental group was divided into 4 types of resistance zones: Swiss ball, medicine ball and drive zone.The combination of two resistance training methods can improve teenagers' swimming performance."
47988666|NCT03173599|DRUG|PNA 360mg|The single dose is 360mg.
47988667|NCT03173599|DRUG|PNA 480mg|The single dose is 480mg.
47988668|NCT03173599|DRUG|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
47988669|NCT04177342|DRUG|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
47988670|NCT04177342|DRUG|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
47988671|NCT01837979|PROCEDURE|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
47988672|NCT02278250|DRUG|M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988673|NCT02278250|DRUG|M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48145343|NCT00392197|DRUG|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
48145344|NCT02009332|DRUG|ABI-009|ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
48145345|NCT02009332|DRUG|Gemcitabine|Gemcitabine is administered after ABI-009 in the Phase 2 study.
48145346|NCT01039610|DRUG|GSK945237|Dose detailed in Arm description
48667927|NCT03361878|DRUG|Metformin Hydrochloride|Single dose of 500mg oral metformin
48667928|NCT01858727|OTHER|forced air warming group|30 minutes before the preoperative will use forced air warming
48145347|NCT01039610|DRUG|Placebo|matching placebo tablet
48356569|NCT02407236|DRUG|Placebo SC|Placebo will be administered Subcutaneously.
48356570|NCT02407236|DRUG|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
48145348|NCT01039610|DRUG|Linezolid|600 mg BID, 14 Days
48145349|NCT01039610|DRUG|Moxifloxacin|40 mg single dose
48145350|NCT02137785|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
48356571|NCT02407236|DRUG|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
48356572|NCT01185613|DEVICE|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~* IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~* Cool Point™ Irrigation Pump~* Cool Point™ Tubing set~* Data Logger"
48506113|NCT04483206|OTHER|Questionnaire Administration|Ancillary studies
48667929|NCT01858727|OTHER|control group|do not heating group
48667930|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine pattern diagnosis.
48145351|NCT02137785|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
48145352|NCT02137785|DEVICE|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
48145353|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
48356573|NCT01430598|PROCEDURE|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
48356574|NCT01430598|OTHER|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
48356575|NCT00004844|PROCEDURE|tissue implantation|
48356576|NCT06439342|DRUG|Maribavir|Maribavir tablets
47988674|NCT02278250|DRUG|M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988675|NCT02278250|DRUG|M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48356577|NCT04759040|DIETARY_SUPPLEMENT|Migraineguard|2 Capsules per day for 7 Months
48356578|NCT04835740|OTHER|High intensity Interval Training|All the participants underwent 5 weeks of High intensity interval training.
48356579|NCT05072834|PROCEDURE|Upper Gastrointestinal Endoscopy|"Procedure Upper gastro-intestinal endoscopic procedure involves collection of intestinal samples and it can be helpful in identifying the causes of malnutrition. Upon parental approval, the child along with two relatives will be provided transportation to Karachi, accommodation and the compensation for their time and expenses.~For this procedure the child will be admitted to the hospital a day before the procedure till one day after the procedure. This procedure takes 30 minutes, requires general anesthesia and involves insertion of a flexible tube with a small TV camera and a light on one end and an eyepiece on the other. The endoscope will allow the doctor to examine the inside of certain tube-like structures in the body. Some tissue samples for laboratory testing will be taken."
48356580|NCT01843933|DEVICE|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
47988676|NCT02278250|DRUG|M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48145354|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day placebo capsule|Once per day, 12 weeks
48145355|NCT02290548|DEVICE|high flow nasal cannula|High flow nasal cannula used in postextubation patients
47988677|NCT02278250|DRUG|M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48145356|NCT06099444|DEVICE|Conventional High Intensity Gait Training|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity. The participants will complete 18 training sessions.
48145357|NCT06099444|DEVICE|Standard FES to the Tibialis Anterior (TA)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while wearing a FES stimulator on the tibialis anterior muscle of their more affected leg. Stimulation will be triggered prior to swing phase to combat drop foot. The participants will complete 18 training sessions.
48145358|NCT06099444|DEVICE|Synergy-Based Multichannel FES (MFES)|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while FES is applied to multiple muscles of the leg throughout the gait cycle based on the healthy muscle synergies. The goal will be to have the FES applied for at least 20 minutes of each gait training session. The participants will complete 18 training sessions.
48145359|NCT06099444|DEVICE|Muscle Synergy Visual Biofeedback|Participants during a training session will complete at least 30 minutes of treadmill walking at the target intensity while receiving visual feedback of the similarity of their muscle synergies to healthy muscle synergies. They will be instructed to try to optimize the similarity score. The participants will complete 18 training sessions.
48145360|NCT03328637|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
48145361|NCT05518214|DIETARY_SUPPLEMENT|Beetroot|Participants receive a 12-week supply of beetroot juice.
48145362|NCT05518214|DIETARY_SUPPLEMENT|Placebo|Participants receive a 12-week supply of placebo beetroot juice.
48356581|NCT04262674|OTHER|Cognitive-motor training|Simultaneous cognitive-motor training and strength training
48356582|NCT00866606|BIOLOGICAL|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
48356583|NCT00062842|DRUG|Irinotecan|
48506114|NCT04767191|DRUG|artemether lumefantrine|The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria. The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
48506115|NCT04767191|DRUG|dihydroartemisinin piperaquine|Antimalarial Combinations
48506116|NCT01831258|DEVICE|SensAwake On|
48506117|NCT01831258|DEVICE|SensAwake Off|
48506118|NCT02066948|OTHER|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
48145363|NCT01509183|DEVICE|Propeller Health System (formerly Asthmapolis System)|The Propeller (formerly Asthmapolis) system works through the provision of information to patients and their providers. With the Propeller (formerly Asthmapolis) device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller (formerly Asthmapolis) where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
47988678|NCT02278250|DRUG|M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48145364|NCT03693989|DRUG|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
48145365|NCT03693989|DRUG|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic"
48145366|NCT00304642|DRUG|dapivirine (TMC120) vaginal gel|
48356584|NCT02734472|OTHER|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
48356585|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
48356586|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
48356587|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
48356588|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
48356589|NCT02556346|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
48356590|NCT03669263|DRUG|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
48356591|NCT04334902|DEVICE|mPDia|Clinical decision support system for diagnosing neurodegenerative parkinsonism
48356592|NCT03869632|DRUG|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
48145367|NCT00607607|DRUG|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
48145368|NCT05809466|OTHER|Vegan diet|A self-composed 12 week fully plant-based diet
48145369|NCT05809466|OTHER|Resistance exercise|Biweekly resistance exercise for 12 weeks
48145370|NCT05809466|OTHER|Omnivorous diet|Habitual diet containing both animal- and plant-based food products
48145371|NCT02163850|DEVICE|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
48145372|NCT02163850|DEVICE|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
48145373|NCT01661972|DRUG|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."
48356593|NCT04283773|COMBINATION_PRODUCT|p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)|Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
48356594|NCT04283773|COMBINATION_PRODUCT|Ki67 antibody (DAKO) for malignant cases only|Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
48356595|NCT04915937|OTHER|Study Infant Formula|RTF milk-based infant formula with oligosaccharides
48356596|NCT05143645|OTHER|Plasma vancoymcin measurements|
48356597|NCT00536354|OTHER|Postural Orientation|
48145374|NCT05185973|DIETARY_SUPPLEMENT|"For Baby supplements provided as powder"|One sachet daily
48356598|NCT02265445|DRUG|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
48356599|NCT02265445|DRUG|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
48506119|NCT02066948|OTHER|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
48506120|NCT02066948|OTHER|meal pattern|skew or even
48506121|NCT02066948|DIETARY_SUPPLEMENT|even|even amount of protein distributed between each meal
47988679|NCT02278250|DRUG|M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988680|NCT02278250|DRUG|M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988681|NCT02278250|DRUG|M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988682|NCT02278250|DRUG|M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48145375|NCT05185973|DIETARY_SUPPLEMENT|Micronutrient powder provided as powder|One sachet daily
48145376|NCT06411561|BEHAVIORAL|SLEEP + COG|Combination of SLEEP and COG interventions
47988683|NCT02278250|DRUG|M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988684|NCT02278250|DRUG|M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48356600|NCT01731600|DRUG|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
48667931|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine tongue diagnosis.
48667932|NCT04747288|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
48145377|NCT06411561|BEHAVIORAL|COG|Daily 30-minute session of computerized cognitive training
48145378|NCT06411561|BEHAVIORAL|SLEEP|Nighttime use of both ear plugs and eye masks
48145379|NCT06411561|BEHAVIORAL|AC|Educational modules on cognitive and sleep health
48667933|NCT04747288|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
47988685|NCT02278250|DRUG|M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48145380|NCT00462072|DRUG|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
48145381|NCT00065611|DRUG|Oral dexamethasone|"Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.~Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.~over 36 weeks."
48145382|NCT05642806|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
48145383|NCT05642806|OTHER|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
48145384|NCT05962099|BEHAVIORAL|Lifestyle and weight loss advice|Commercially available lifestyle and weight loss intervention
48356601|NCT01753843|PROCEDURE|early cord clamping|early ( \<20 seconds)
48356602|NCT01753843|PROCEDURE|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
48356603|NCT03990324|PROCEDURE|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
48356604|NCT01910142|DIETARY_SUPPLEMENT|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
47988686|NCT02278250|DRUG|M4344 400 mg|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
48667934|NCT04747288|DIAGNOSTIC_TEST|Ocular Surface Diseast Index (OSDI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
48356605|NCT01910142|DIETARY_SUPPLEMENT|calcium|
48667935|NCT04747288|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
48667936|NCT04747288|DIAGNOSTIC_TEST|36-Item Short Form Survey (SF-36)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
47988687|NCT02278250|DRUG|M4344 500 mg|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988688|NCT02278250|DRUG|Carboplatin|Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
47988689|NCT05436951|BEHAVIORAL|Brief on-shift nap|The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.
47988690|NCT00411645|DRUG|maribavir|100 mg twice daily for up to 12 weeks
47988691|NCT00411645|OTHER|placebo|twice daily for up to 12 weeks
48145385|NCT02016365|DRUG|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
48145386|NCT02016365|DRUG|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
48145387|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|3 capsules daily.
48145388|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|2 capsules twice daily.
48145389|NCT01061307|DIETARY_SUPPLEMENT|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
48506122|NCT02066948|DIETARY_SUPPLEMENT|skew|a skewed amount of protein is distributed between each meal
48506123|NCT01675843|PROCEDURE|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
48145390|NCT01555307|OTHER|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
48145391|NCT01555307|OTHER|Typical group|Seven typical exercises, 10 times each, 3 times a day
48667937|NCT04242147|DRUG|KD033 (SAR445710)|Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
48667938|NCT01480102|DRUG|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
48667939|NCT01480102|OTHER|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
48667940|NCT05090787|DEVICE|Investigational mDCB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
47988692|NCT03021239|PROCEDURE|Echo Guided Testing|
47988693|NCT03021239|PROCEDURE|Hemodynamic-Echo Ramp Testing -|
47988694|NCT01226446|DRUG|vitamin D|Vitamin D on top of the standard treatment
47988695|NCT02099097|OTHER|web-based video game (Quit IT)|
47988696|NCT02099097|BEHAVIORAL|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
47988697|NCT02099097|OTHER|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
47988698|NCT00695396|DRUG|Placebo|Matching volume 2 mLfor 48 weeks
47988699|NCT00695396|DRUG|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
47988700|NCT00695396|DRUG|Placebo|Matching volume 1 mL for 48 weeks
47988701|NCT00695396|DRUG|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
47988702|NCT03193931|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
48145392|NCT01345708|DRUG|prednisone, low dose rituximab|"Patients with warm AIHA will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)~Patients with CHD will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
48145393|NCT06153784|DRUG|Hydroxyurea and Thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
48145394|NCT05008003|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
48356606|NCT03479541|BEHAVIORAL|Rehabilitation|"Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task."
48667941|NCT05090787|DEVICE|Control DCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
48145395|NCT05008003|DIETARY_SUPPLEMENT|Vitamin D3|A daily dose of 5000 IU vitamin D3 for 7 days.
48145396|NCT00000532|BEHAVIORAL|diet, fat-restricted|
48667942|NCT04868292|DRUG|SPR206|Three 100 mg SPR206 intravenous doses administered every 8 hours
48667943|NCT02542618|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
48667944|NCT02542618|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
48667945|NCT01147302|BIOLOGICAL|Placebo|
47988703|NCT03193931|DRUG|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
47988704|NCT02922907|DIETARY_SUPPLEMENT|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
47988705|NCT02922907|DIETARY_SUPPLEMENT|Placebo for arabinoxylan rice bran|inactive product
47988706|NCT05938933|BEHAVIORAL|PHP|personalized health planning (PHP)
47988707|NCT05938933|BEHAVIORAL|SMA|shared medical appointments (SMAs)
47988708|NCT04450147|BEHAVIORAL|Tai Chi/Qigong vs. Walking/Stretching|Both interventions can be thought of as a form of movement and exercise.
47988709|NCT04034173|DRUG|Panitumumab|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes."
47988710|NCT04034173|DRUG|Irinotecan|Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
47988711|NCT04034173|DRUG|Folinic acid|Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
47988712|NCT04034173|DRUG|5-FU|5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
47988713|NCT05017506|OTHER|A survey will be made.|A survey will be made.
48667946|NCT01147302|BIOLOGICAL|C1 Esterase Inhibitor (Human)|
48667947|NCT02665910|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
48667948|NCT02665910|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
48667949|NCT03848780|DRUG|Desflurane|
48667950|NCT00003287|DRUG|FOLFOX regimen|
48667951|NCT00003287|DRUG|fluorouracil|
48667952|NCT00003287|DRUG|leucovorin calcium|
48667953|NCT00003287|DRUG|oxaliplatin|
48667954|NCT05964686|COMBINATION_PRODUCT|Conventional group (NaOCl/EDTA)|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
48667955|NCT05964686|COMBINATION_PRODUCT|Dual laser group (Er,Cr:YSGG/Diode):|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
48506124|NCT06443411|OTHER|Monitoring of cerebral hemodynamics|A specially designed pair of goggles will be put on the patient's head. The closed eyelids, along with the surrounding tissues, will be in contact with a thin, elastic, non-allergic film used to seal water filled inside the goggles. Pulse waves, including those originating from cerebrospinal fluid pulsation, will be transmitted from the eyelids to the water, where they will be detected by a pressure sensor and recorded with a laptop.
48667956|NCT05964686|COMBINATION_PRODUCT|Combined group (EDTA/Diode):|17% EDTA was used to remove smear layer followed by diode laser for disinfection
48667957|NCT04268238|PROCEDURE|Hygiene Guidance|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
47988714|NCT00631566|DRUG|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
48145397|NCT04103164|DEVICE|Cutera excel V™ Laser|The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
48145398|NCT01697605|DRUG|BGJ398|
48145399|NCT04501744|DRUG|Cohort 1 of M701|Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
48145400|NCT04501744|DRUG|Cohort 2 of M701|Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
48145401|NCT04501744|DRUG|Cohort 3 of M701|Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
48145402|NCT04501744|DRUG|Cohort 4 of M701|Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
48145403|NCT04501744|DRUG|Cohort 5 of M701|Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
48145404|NCT04501744|DRUG|Cohort 6 of M701|Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
48356607|NCT01337791|DRUG|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
48506125|NCT06012461|OTHER|Closed-loop DBS stimulation for 24 hours|Continuous closed-loop modulation for 24 hours
48667958|NCT04268238|PROCEDURE|Sealant Application|Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
47988715|NCT00631566|DRUG|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
47988716|NCT01066247|DRUG|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
47988717|NCT01066247|DRUG|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
47988718|NCT03978585|DEVICE|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
47988719|NCT03978585|DEVICE|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
47988720|NCT01843764|DEVICE|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
47988721|NCT00023543|BEHAVIORAL|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
47988722|NCT00023543|BEHAVIORAL|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
47988723|NCT00475176|DRUG|Peginterferon alfa-2a|
47988724|NCT00475176|DRUG|Ribavirin|
47988725|NCT00475176|DRUG|S-adenosyl methionine for Chronic Liver Disease|
47988726|NCT00299013|DRUG|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
47988727|NCT00299013|DRUG|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
47988728|NCT02736409|DRUG|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
47988729|NCT02736409|DRUG|Placebo|Matching Placebo dose
48145405|NCT04501744|DRUG|Cohort 7 of M701|Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
48145406|NCT05799534|OTHER|Physical Therapy Rehabilitation|Physical Therapy Rehabilitation program to to establish a novel physiotherapeutic plan to determine the effects on post-COVID-19 patients' psychoemotional condition, lung capacity, cardiorespiratory condition, and muscle strength.
48145407|NCT00228657|DRUG|4% Albumin / 0.9% Sodium Chloride|
48145408|NCT01500070|DEVICE|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
48145409|NCT04617925|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose
48145410|NCT02068157|OTHER|Laboratory Biomarker Analysis|Correlative studies
48145411|NCT02068157|DRUG|Photodynamic Therapy|Undergo image-guided I-PDT
48667959|NCT04268238|RADIATION|Low Level Laser Application|Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
48145412|NCT02068157|DRUG|Porfimer Sodium|Given IV
48356608|NCT03493373|OTHER|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
48356609|NCT03493373|OTHER|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
48356610|NCT05760651|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test and osteoporosis awareness scale
48356611|NCT05760651|DIAGNOSTIC_TEST|Timed up - and - go test|. The timed up-and-go test involves rising from a seated position, walking a distance of 3 meters, pivoting, returning to the initial point, and resuming a sitting position. It demonstrates strong inter-rater and intra-rater reliability, offering a reliable means of quantifying functional mobility and balance.
48145413|NCT06143124|DRUG|Bismuth Subcitrate|shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
48145414|NCT05963074|DRUG|Ibrutinib|Ibrutinib capsules will be administered orally.
48145415|NCT05963074|DRUG|Venetoclax|Venetoclax tablets will be administered orally.
48145416|NCT06034977|DRUG|ADI-PEG20|Lenvatinib + ADI-PEG20 combination treatment.
48145417|NCT00617708|BIOLOGICAL|cixutumumab|Given IV
48356612|NCT00366444|DRUG|diclofenac potassium (XP21L)|25 mg every 6 hours
48356613|NCT00366444|DRUG|Placebo|Placebo every 6 hours
48145418|NCT00617708|DRUG|erlotinib hydrochloride|Given PO
48145419|NCT00617708|DRUG|gemcitabine hydrochloride|Given IV
48145420|NCT02066636|DRUG|Nivolumab|
48356614|NCT06282952|DIETARY_SUPPLEMENT|Fecal transplant|At delivery, the fecal transplant is thawed and 0.5 mL representing 3.5 mg of the mother's or donors' fecal sample is dissolved in 5 mL of the mother's own milk or when not available pasteurized bank milk. The sample is given orally to newborn infants as soon as possible but not later than 6 h of delivery and not later than two hours after defrosting.
48356615|NCT02374944|PROCEDURE|Hardware removal|Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
48667960|NCT00823173|BIOLOGICAL|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
48667961|NCT02518529|BIOLOGICAL|G17DT|
48145421|NCT00151866|PROCEDURE|platelet transfusion|
48145422|NCT03674476|DRUG|BMS-986036|Specified dose on specified days
48145423|NCT04740541|OTHER|Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)|Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
48145424|NCT06133569|BEHAVIORAL|ReDirection|Self help program based on principles for cognitive behavioral therapy
48145425|NCT06134232|DRUG|Sipuleucel-T Injection|Single Infusion
48145426|NCT00871715|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
48145427|NCT00871715|BEHAVIORAL|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
48667962|NCT04055974|BEHAVIORAL|Be a Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
48356616|NCT04688827|OTHER|Exercise therapy|15 weeks of resistance training (additional to endurance training)
48356617|NCT01646151|DRUG|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
48356618|NCT01511549|DRUG|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
48356619|NCT01511549|DRUG|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
48356620|NCT01675401|OTHER|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
48667963|NCT01740687|DEVICE|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
48667964|NCT01740687|PROCEDURE|NovaSure|Nova Sure Endometrial Ablation
48356621|NCT01675401|OTHER|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
48356622|NCT05825365|DRUG|Selumetinib|Selumetinib
48356623|NCT05825365|DRUG|Placebo|Placebo (Transfer to selumetinib on REiNS-defined PD)
48356624|NCT02785861|BEHAVIORAL|supervision of physical activity|
48667965|NCT04497714|DIAGNOSTIC_TEST|Ultrasonic image collection|Ultrasonic image collection,consist of three static images and one dynamic image
48667966|NCT00571883|OTHER|questionnaire administration|
48356625|NCT02785861|BEHAVIORAL|distance supervised physical activity|
48356626|NCT02436915|OTHER|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
48356627|NCT02436915|OTHER|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
48356628|NCT02117973|PROCEDURE|iAssist Technique using Persona system vs. the conventional technique using Persona system|
48356629|NCT00962416|DEVICE|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
48356630|NCT00962416|DEVICE|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
48356631|NCT02646891|BIOLOGICAL|Trivalent P2-VP8 Subunit Rotavirus Vaccine|Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
48356632|NCT02646891|BIOLOGICAL|Placebo|Sodium Chloride 0.9%, USP for Injection
48667967|NCT00571883|PROCEDURE|psychosocial assessment and care|
48667968|NCT00571883|PROCEDURE|quality-of-life assessment|
48667969|NCT00571883|PROCEDURE|regional lymph node dissection|
48667970|NCT00571883|PROCEDURE|therapeutic conventional surgery|
48667971|NCT06029205|BEHAVIORAL|Conscious Awareness-Based Educatıon|The effect of Conscious Awareness-Based Education on nurses
48667972|NCT06029205|BEHAVIORAL|Stress coping training|The effect of stress coping training on nurses
48145428|NCT00871715|BEHAVIORAL|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
48145429|NCT00788606|DRUG|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
48356633|NCT02002637|DEVICE|Latella Knee Implant System|
48667973|NCT06018987|OTHER|No-Treatment Control|Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
48667974|NCT06018987|DEVICE|HAC 20L|Subdermal Injections
48667975|NCT01161771|PROCEDURE|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
48667976|NCT05811325|OTHER|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
48667977|NCT05811325|OTHER|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
48667978|NCT04574336|PROCEDURE|Surgical treatment|We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.
48667979|NCT04574336|DEVICE|Non-surgical treatment|Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.
48667980|NCT04857554|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
48667981|NCT04857554|OTHER|White bread as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
48667982|NCT04857554|OTHER|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread together with apricot jam along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
48667983|NCT04857554|OTHER|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from a cereal bar with cranberries along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
48145430|NCT05200286|DRUG|Olorofim|Single oral dose
48356634|NCT04123340|DIAGNOSTIC_TEST|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
48356635|NCT00170846|DRUG|Everolimus (RAD001)|
48145431|NCT04252950|BEHAVIORAL|CB-SET|Community-based structured exercise therapy (CB-SET) programs for PAD have potential merit as an alternative to hospital-based SET, as they may provide similar benefit to hospital-based programs but in a convenient location for the exercise to be completed
48145432|NCT04252950|PROCEDURE|Revascularization|Endovascular revascularization is a primary treatment option for patients with PAD
48145433|NCT06466551|OTHER|intravenous catheterization|This randomized experimental study was planned to examine the effect of virtual reality goggles and squeezing a stress ball as a distraction method during intravenous catheter application on pain and fear in children aged 6-12 years.
48145434|NCT03441256|DEVICE|LION procedure|Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.
48145435|NCT03441256|DEVICE|NMES|Conventional neuromuscular electrical stimulation via surface electrodes.
48145436|NCT00005654|DRUG|clomiphene citrate|
48145437|NCT00005654|DRUG|metformin|
48145438|NCT02584257|OTHER|methacholine chloride|
48145439|NCT02584257|DRUG|placebo ProAir HFA|
48145440|NCT02584257|DRUG|ProAir HFA|
48145441|NCT02584257|DRUG|Lupin albuterol HFA MDI|
48145442|NCT02584257|DRUG|placebo Lupin albuterol HFA MDI|
48145443|NCT00861315|DRUG|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
48145444|NCT00861315|DRUG|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
48145445|NCT00861315|DRUG|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
48356636|NCT00170846|DRUG|Calcineurin Inhibitors (CNI)|
48145446|NCT00861315|DRUG|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
48145447|NCT02243800|OTHER|cholecalciferol versus placebo|
48145448|NCT05703659|DIETARY_SUPPLEMENT|B. longum subsp. infantis|Infants will receive 1 dose of a B. infantis probiotic daily for 4 weeks
48145449|NCT05703659|DIETARY_SUPPLEMENT|L. reuteri probiotic|Infants will receive 1 dose of an L. reuteri probiotic daily for 4 weeks
48145450|NCT04267523|BEHAVIORAL|Web parenting intervention|Parents participate in the self-delivered web-based parenting intervention for 6 modules. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
48145451|NCT04267523|BEHAVIORAL|Group parenting intervention|Parents participate in face-to-face a weekly 2-hour group for 4 sessions. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
48145452|NCT01045057|DEVICE|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
48145453|NCT01307540|DEVICE|phototherapy|low level light therapy, broad band light wavelengths.
48145454|NCT00230269|PROCEDURE|PET-CT|
48145455|NCT04926259|DRUG|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
48145456|NCT00904085|DRUG|Oxymorphone IR|5 mg
48145457|NCT00911014|OTHER|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
48145458|NCT04653285|BEHAVIORAL|motor skill practice|Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.
48145459|NCT04653285|BEHAVIORAL|aerobic exercise|A bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice.
48145460|NCT04653285|BEHAVIORAL|rest|Seated rest following motor skill practice.
48145461|NCT00997750|DRUG|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
48145462|NCT03784898|OTHER|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
48145463|NCT03791190|OTHER|Regional citrate anticoagulation|Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
48145464|NCT03791190|OTHER|No-anticoagulation|Patients accepted CRRT without anticoagulant.
48145465|NCT04529200|OTHER|electrotherapy treatment|physical therapy management like EMS IFT
48145466|NCT04737993|DRUG|licocain|pulsed radiofrequency stimulation
48145467|NCT04737993|OTHER|pulsed radiofrequency stimulation|pulsed radiofrequency stimulation of joint capsel
48145468|NCT01319344|DRUG|Eplerenone|25 mg o.d. per os
48145469|NCT02954783|BEHAVIORAL|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
48145470|NCT02954783|BEHAVIORAL|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
48145471|NCT05615337|BEHAVIORAL|MBSR|"The MBSR is an eight-week group-based psychoeducational program. It is performed in weekly group sessions with the duration of 2.5 hours and a half-day retreat of 4 hours.~The program involves focused attention, consisting of body scan, yoga, and meditation. This program trains participants to be attentive to their thoughts, emotions, and sensations. There are also discussions on relevant topics related to the physiology of stress and strategies of coping. Materials for home practice are provided."
48145472|NCT05615337|BEHAVIORAL|HPP|The HPP has the same structure of MBSR, including different components such as music, nutrition, cognitive enhancement, risk factors for dementia, and physical activity. During the half-day retreat participants are involved in watercolor painting activities. Materials for home practice are also provided.
48145473|NCT05283876|DEVICE|Excimer light|Excimer light sessions
48145474|NCT05488509|DRUG|Cannabis|Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
48145475|NCT05488509|DRUG|Placebo|Participants will inhale vapor from a placebo product.
48145476|NCT01466556|OTHER|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
48667984|NCT04857554|OTHER|Cocoa drink|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from cocoa powder mixed with 500ml fat-free milk, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
48356637|NCT00170846|DRUG|Mycophenolate acid (MPA)/Azathioprine (AZA)|
48667985|NCT00544206|OTHER|standard enteral feeding product|16 hrs daily x 5 days
48356638|NCT00170846|DRUG|Steroids|
48356639|NCT04495322|DRUG|TG-1000|Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
48356640|NCT04495322|DRUG|Placebo|Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
48145477|NCT02341222|DEVICE|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
48145478|NCT02341222|DEVICE|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
48145479|NCT02410109|BEHAVIORAL|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
48145480|NCT02270502|DEVICE|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
48145481|NCT02270502|OTHER|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
48145482|NCT02270502|OTHER|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
48145483|NCT05924373|DRUG|Human Dental Fulp Stem Cells|Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
48145484|NCT00027014|DRUG|St. John's Wort|
48145485|NCT00027014|DRUG|oxycodone|
48145486|NCT00027014|DRUG|fentanyl|
48145487|NCT05026541|BEHAVIORAL|Nap Practitioners|Regular nappers will be given a 30 minute nap opportunity to nap for as long as they please.
48145488|NCT05026541|BEHAVIORAL|Shoonya Meditation|This is a 15 minute meditation, described as a process of conscious non-doing.
48145489|NCT00330785|DRUG|Amlodipine/Atorvastatin|
48145490|NCT02840045|DEVICE|high-density electroencephalography|Musical stimulation during electroencephalography recording
48145491|NCT00264888|DRUG|PTC124|
48506126|NCT06012461|OTHER|Open-loop DBS stimulation for 24 hours|Continuous open-loop modulation for 24 hours
48506127|NCT06012461|OTHER|Closed-loop DBS stimulation for 72 hours|Continuous closed-loop modulation for 72 hours
48506128|NCT06012461|OTHER|Open-loop DBS stimulation for 72 hours|Continuous open-loop modulation for 72 hours
48506129|NCT05123183|OTHER|acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36 and CV17 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to CV17 point (single point) and ST36 point (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
48667986|NCT00544206|OTHER|Diabetes specific feeding product|16 hrs daily for 5 days
48667987|NCT05469919|DRUG|Ceralasertib|Ceralasertib taken orally
48145492|NCT04327089|DRUG|Setanaxib|Nox 1/4 inhibitor
48145493|NCT00879827|BIOLOGICAL|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
48145494|NCT00879827|BIOLOGICAL|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
48506130|NCT05123183|OTHER|back massage group|The mother sits in the chair and leans forward, placing her arms on the table at her level and resting her head on her arms. The mother's breasts are naked and freely released. The researcher massages the mother from top to bottom on both sides of the spine between the scapula bones. At this time, his fists are clenched and the thumb is open. While pressing firmly with his fists, small circular friction movements are made with his thumb. From the neck to the scapula, both sides of the spine are rubbed at the same time for 3 minutes. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch.
48667988|NCT01071954|BIOLOGICAL|Romiplostim|Administered by subcutaneous injection once a week.
48145495|NCT04313699|DRUG|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
48145496|NCT06113393|PROCEDURE|GRV thresholds|Hold enteral feeding when GRV reaches 200 mL(current standard)
48145497|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
48145498|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
48145499|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
48145500|NCT00668057|DRUG|Placebo|5 mg matching placebo
48145501|NCT00668057|DRUG|Placebo|10 mg matching placebo
48145502|NCT00668057|DRUG|Placebo|20 mg matching placebo
48145503|NCT03223688|BEHAVIORAL|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
48145504|NCT03223688|BEHAVIORAL|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
48145505|NCT03223688|BEHAVIORAL|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
48145506|NCT01485809|DRUG|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
48145507|NCT06225323|DRUG|Lidocaine|"Patients will receive Lidocaine infusion for 6 hours. After cord clamping and according to ideal body calculate the bolus dose 1.5 mg/kg of lidocaine 1% and complete the dose by normal saline to 20 ml total volume will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of lidocaine 1% for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
48145508|NCT06225323|OTHER|Saline|"Patients will receive normal saline infusion for 6 hours. After cord clamping 20 ml total volume normal saline will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of normal saline for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
48145509|NCT02058992|DRUG|Ramelteon|Ramelteon 8 mg tablets
48145510|NCT01186809|BIOLOGICAL|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
48145511|NCT04534699|DRUG|KBP-5074|KBP-5074 tablet
48145512|NCT02789488|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|Furocyst one caps BID
48145513|NCT04483102|DEVICE|Declined liver in Normothermic Machine Perfusion (NMP)|The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study.
48145514|NCT04483102|PROCEDURE|Standard cold preservation of liver|"The study will have three comparison groups - one local comparison group and two comparison groups from the national UNOS data.~Comparison group 1 will be patients who received a standard liver transplantation and follow-up care at the Washington University/ Barnes Jewish Hospital (n=50). Patients will be matched by a 5-year age category, sex, MELD score, donor liver graft type (e.g., DCD, DBD), donor age (5-year category), and donor sex. Washington University/ Barnes Jewish Hospital maintains a liver transplantation database that prospectively collects pre- and post-transplantation patient data.~Comparison group 2 will be patients who received DBD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex.~Comparison group 3 will be patients who received DCD liver transplantation in the OPTN/UNOS database (n=100). Patients will be matched by age, sex, MELD score, donor age, and donor sex."
48145515|NCT03072745|DIAGNOSTIC_TEST|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
48145516|NCT01631409|OTHER|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
48145517|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
48145518|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
48145519|NCT01631409|PROCEDURE|PCA|Percutaneous coronary angioplasty
48145520|NCT01631409|PROCEDURE|CABG|Coronary artery bypass grafting
48145521|NCT01631409|DEVICE|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
48145522|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
48145523|NCT05702892|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
48145524|NCT05841342|OTHER|No intervention|No intervention
48145525|NCT05939505|OTHER|Su Jok therapy|Sujok therapy will be applied with Mexican bean seeds 14 times with an interval of one day.
48145526|NCT05939505|OTHER|placebo|Instead of the Mexican bean seed applied in sujok therapy, plastic beans will be applied 14 times with an interval of one day.
48145527|NCT05939505|OTHER|routine interventions|routine applications in the hemodialysis unit
48145528|NCT06251791|OTHER|conventional physiotherapy+ IMT|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
48145529|NCT06251791|OTHER|conventional physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
48145530|NCT01519882|OTHER|Placebo|"Placebo patches size equivalent to 4, 6 \& 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
48145531|NCT01519882|OTHER|Rotigotine|"Rotigotine patches of 4,6 \& 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
48145532|NCT03008785|OTHER|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
48145533|NCT03008785|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
48145534|NCT03008785|OTHER|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
48145535|NCT01729793|DIETARY_SUPPLEMENT|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
48145536|NCT01729793|OTHER|Placebo|Capsule containing microcrystalline cellulose
48145537|NCT00017355|BIOLOGICAL|filgrastim|
48145538|NCT00017355|BIOLOGICAL|therapeutic autologous dendritic cells|
48506131|NCT05123183|OTHER|control group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
48506132|NCT02183181|DRUG|Meloxicam capsule|
48145539|NCT05790317|PROCEDURE|Surgical Procedure with ERAS Protocol|It covers the period before, during and after the surgery.
48145540|NCT06402292|PROCEDURE|OSTEOMYELITIS SURGICAL TREATMENT WITH LOCAL ANTIBIOTICS AND PEROSSAL|25 PATIENTS WITH FRI WILL BE SURGICALLY TREAT WITH DESBRIDMENT AND PEROSSAL WITH ANTIBIOTCS
48145541|NCT05582226|PROCEDURE|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
48506133|NCT02183181|DRUG|Meloxicam tablet|
48145542|NCT05582226|PROCEDURE|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
48145543|NCT01260883|DRUG|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
48356641|NCT01592942|DEVICE|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
48356642|NCT01592942|DEVICE|Progrip|self-gripping mesh
48506134|NCT01713452|PROCEDURE|Purse string closure|"1. An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~2. Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~3. Diameter of the skin defect should then be measured.~4. A postoperative photo will then be taken."
48667989|NCT04287972|PROCEDURE|DPC|The anterior fat pad is dissected until the left crura is visible, pars flaccida is open and the right crura exposed. Phreno-oesophageal ligament is sectioned starting from the right crura. Posterior and anterior vagal nerve are recognized before the oesophageal dissection. An intra-abdominal oesophagus lengths of 2 or 3 cm is obtained in order to reduce tension. Left and right crura are sutured with 2 or 3 non absorbable 2-0 stitches; an additional anterior stitch is posed if necessary to calibrate hiatus size without oesophageal deviation.
48356643|NCT01592942|DEVICE|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
48356644|NCT01571973|PROCEDURE|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
48356645|NCT04585633|OTHER|Quality of Recovery-15|Quality of Recovery-15 is a scale consisting of 15 questions indicating the recovery quality of the patient after anesthesia and a score between 0-150.
48667990|NCT04287972|PROCEDURE|LSG|After omental section close to gastric insertion, gastric stapling is realised with triple line endo stapler (normally 5 or 6 re-loads). The gastrectomy begins 5-6 cm from the pylorus; gastric fundus is totally resected keeping a distance of 5-10 mm from oesophagus. Any bleeding on staple line is controlled with surgical clips or coagulator.
48667991|NCT03461718|DRUG|Ketamine|Experimental arm for sedation.
48667992|NCT03461718|DRUG|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
48667993|NCT03461718|DRUG|Fentanyl|Part of standard sedation regimen
48667994|NCT06372795|OTHER|pure effortful swallowing|"The investigator instructed the patient to swallow forcefully while squeezing the tongue upward and backward in the direction of the soft palate based on the sounds of an electronic timer."
48356646|NCT04585633|OTHER|Glasgow Result Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
48506135|NCT01713452|PROCEDURE|Primary closure|"1. An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~2. Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (\<1.5cm). No subcutaneous drains will be placed.~3. Length of the incision should be measured in centimeters.~4. A postoperative photo will then be taken."
48506136|NCT02489253|OTHER|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
48506137|NCT04258319|DIAGNOSTIC_TEST|Ultrasound Procedure|Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
48506138|NCT04395014|DIAGNOSTIC_TEST|2D Echocardiography|In this echocardiographic imaging acquisition protocol, the pregnancy patients, are colocated in the left lateral decubitus position on a clinical bed with the left arm flex and the hand behind the head. All the echocardiographic measurements are taken by the examiner in this position.
48506139|NCT03951025|DIETARY_SUPPLEMENT|Melatonin oral administration|One tablet with1 mg of melatonin and 82 mg of excipients
48506140|NCT03951025|DIETARY_SUPPLEMENT|Melatonin sublingual administration|One tablet with 1 mg of melatonin and 82 mg of excipients
48506141|NCT06079567|DIAGNOSTIC_TEST|Validation of new COMs for FSHD2 patients|Monitoring of commonly used and new COMs in FSHD2 patients
48506142|NCT02466685|DRUG|JNJ-18038683|JNJ-18038683 10-20 mg/day tablet for 8 weeks
48506143|NCT02466685|DRUG|Placebo|placebo tablet daily
48506144|NCT00660400|DRUG|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M\^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
48506145|NCT00660400|PROCEDURE|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~* Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~* The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~* All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
48145544|NCT01260883|DRUG|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
48145545|NCT01260883|DRUG|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
48145546|NCT01818999|DRUG|IXABEPILONE|injection
48145547|NCT01818999|RADIATION|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
48145548|NCT00964171|DRUG|efavirenz|
48145549|NCT00964171|PROCEDURE|quality-of-life assessment|
48145550|NCT00184444|BEHAVIORAL|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
48145551|NCT00184444|BEHAVIORAL|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
48145552|NCT04482413|DRUG|AstroStem|Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
48145553|NCT04482413|DRUG|Placebo|Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
48145554|NCT01378884|DRUG|Domperidone|Patient to receive treatment with Domperidone
48145555|NCT01667159|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
48145556|NCT01667159|BEHAVIORAL|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
48145557|NCT05448222|DIAGNOSTIC_TEST|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
48145558|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
48145559|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-2|Taking 7 capsules a day for six months
48145560|NCT00070421|PROCEDURE|complementary or alternative medicine procedure|
48145561|NCT00070421|PROCEDURE|management of therapy complications|
48145562|NCT00070421|PROCEDURE|psychosocial assessment and care|
48145563|NCT01724905|DIETARY_SUPPLEMENT|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
48145564|NCT01724905|DIETARY_SUPPLEMENT|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
48145565|NCT01588522|DRUG|compound 31543 Calcitriol|topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
48145566|NCT04633200|OTHER|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
48145567|NCT02782260|DRUG|Dipyridamole|
48145568|NCT02782260|DRUG|Placebo|
48145569|NCT03511781|RADIATION|Hypofractionated Radiotherapy|Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
48145570|NCT05529485|PROCEDURE|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
48145571|NCT03994809|OTHER|Okada Purifying Therapy|The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.
48506146|NCT03891030|OTHER|Checklist Based Box system intervention|The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
48506147|NCT04688905|DIAGNOSTIC_TEST|Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion|Invasive hemodynamics of left ventricle will be done by the conductance method. Left ventricular stiffness constant will be obtained by temporary vena cava occlusion. Right heart catherization will be done by pulmonary artery catherization and cardiac output will be estimated by thermodilution and Fick´s method.
48506148|NCT02816008|BEHAVIORAL|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
48506149|NCT02816008|BEHAVIORAL|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
48506150|NCT03302026|BEHAVIORAL|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
48506151|NCT02263950|DRUG|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
48506152|NCT02340052|DRUG|Pain treatment|Registration af actual analgesic treatment and outcomes
48506153|NCT01568970|BEHAVIORAL|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
48506154|NCT01568970|BEHAVIORAL|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
48667995|NCT06372795|OTHER|progressive resistance swallowing training|Patients in the test group, resistance swallowing exercise was performed by providing external resistance through Iowa Oral Performance Instrument (IOPI), and all other protocols were performed the same as those in the control group.
48667996|NCT04542122|BEHAVIORAL|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
48667997|NCT01470157|DRUG|Ketamine|5mg/kg as oral suspension
48667998|NCT01470157|DRUG|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
48667999|NCT01555060|DIETARY_SUPPLEMENT|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
48668000|NCT01911351|DRUG|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
48145572|NCT03803657|DEVICE|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
48145573|NCT03734432|DEVICE|IGAR-Breast TeleOp|Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
48668001|NCT04009980|OTHER|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
48145574|NCT00033241|DRUG|erlotinib hydrochloride|
48145575|NCT00033241|DRUG|gemcitabine hydrochloride|
48145576|NCT02072330|DRUG|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
48145577|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
48145578|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
48356647|NCT04585633|OTHER|Risk Factors|Pre-operative: medical histories, drugs used, demographic features, additional diseases, ASA class, pre-operative routine parameters, operation history, GCS, tumor histology, location, dimensions and intracerebral radiological data, laboratory values Intraoperative; hemodynamic data of patients; highest and lowest values of heart rate, diastolic, systolic and mean arterial pressures, fluid and blood products given, anesthetic and other drugs administered, duration of anesthesia, duration of surgery, surgical position, blood loss, urine output and blood gas samples Post-operation; extubation time, MAS score, use of mechanical ventilation, post-operative complications, hemodynamic data, blood gas data
47988730|NCT04192877|DIAGNOSTIC_TEST|Vagus Nerve Neurodynamic test|The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve. The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table. Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion. The ipsilateral neck rotation had been selected for loading the cervical tract. Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver. The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
47988731|NCT04136054|BEHAVIORAL|Adjusted group CBT-i for Depression, Anxiety and PTSD|Adjusted group CBT-i for Depression, Anxiety and PTSD. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.
48506155|NCT04386616|DRUG|MSTT1041A|Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
47988732|NCT04136054|OTHER|Care as usual wait-list control group|Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, such as mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
47988733|NCT05325879|OTHER|VAGUS-NDT|Neurodynamic test for vagus nerve
47988734|NCT04660448|DIAGNOSTIC_TEST|Bedside lung ultrasound examination|Lung ultrasound exploring 12 areas (6 in each lung) at 12 +/- 6 hours and at 48-72 hours from PICU admission. Clinical and analytical data collection coinciding with ultrasound imaging and during follow-up while admitted to PICU.
47988735|NCT05028179|DIAGNOSTIC_TEST|EchoGo|EchoGo Pro is an software Medical Device which is able to assess Stress Echocardiograms and provide a binary classification of risk of CAD
47988736|NCT04651088|DRUG|Potassium citrate|Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
48356648|NCT02099292|DRUG|Rituximab and DexaBEAM|combination treatment
48356649|NCT02367859|DRUG|Dabrafenib|Given PO
48506156|NCT04386616|DRUG|MSTT1041A-matched Placebo|Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
48506157|NCT04386616|DRUG|UTTR1147A|Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
48506158|NCT04386616|DRUG|UTTR1147A-matched Placebo|Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
48668002|NCT04009980|OTHER|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
47988737|NCT04651088|DRUG|Sodium bicarbonate|650mg tabs. Take 3 tabs twice daily.
47988738|NCT04651088|DIETARY_SUPPLEMENT|Litholyte|One packet is taken with 170ml of water. Two packets daily.
48145579|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
48145580|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
48145581|NCT03799809|DRUG|Intrabronchial Voriconazole instillation|Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
48145582|NCT01986348|DRUG|Selinexor|One cycle is 28 days (4 weeks).
48145583|NCT03630549|OTHER|Standard of Care|Clinic-based HIV care
48145584|NCT03630549|OTHER|Village-based ART refill|Option to get ART refill and care by the village health worker
48145585|NCT00805441|DRUG|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
48145586|NCT00805441|DRUG|Placebo|Daily by oral route for 12 weeks
48145587|NCT00000111|PROCEDURE|Oral mucosal graft|
48145588|NCT02676726|PROCEDURE|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
48145589|NCT02676726|PROCEDURE|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
48145590|NCT03788226|DRUG|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
47988739|NCT04651088|DIETARY_SUPPLEMENT|Crystal Lite|The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
48145591|NCT03788226|DRUG|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
48145592|NCT06500195|PROCEDURE|implantation of the hybrid instrumentation system|Surgery corrections were performed using the hybrid instrumentation system (screws and bands).
48668003|NCT00176748|DRUG|AG 6013736|5 mg po bid
48668004|NCT00320606|DRUG|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
48668005|NCT01589614|DRUG|PH-797804|Tablet, 6mg, single
47988740|NCT04651088|DRUG|Potassium Bicarbonate|20 mEq tablets, one tablet twice daily
47988741|NCT03966703|BEHAVIORAL|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
47988742|NCT01243879|OTHER|Stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
47988743|NCT01243879|OTHER|No stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
47988744|NCT06249412|DEVICE|MI-E with PEP function activated during the pause|PEP function will be activated during the pause when using the EOVE-70. The PEP function in cmH2O will start at 8 cmH2O; the PEP setting can be decreased or increased at the discretion of the practitioner to optimize. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
47988745|NCT06249412|DEVICE|MI-E without PEP function activated during the pause|The PEP function will not be activated during the pause when using the EOVE-70. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
47988746|NCT04275791|OTHER|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
48145593|NCT01164176|DRUG|everolimus|
48145594|NCT01164176|OTHER|laboratory biomarker analysis|
48145595|NCT05121285|OTHER|Delivery of contrast fluid by lower GI endoscopy|Each participant will receive one delivery of 440 ml contrast fluid by lower GI endoscopy to the cecum of the colon. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. An colon X-ray is obtained within 10 minutes after the contrast fluid is delivered. The participants is in a supine position fram delivery and until the colon x-ray is obtained.
48356650|NCT02367859|DRUG|Trametinib|Given PO
48356651|NCT02158000|OTHER|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
48356652|NCT00675844|DRUG|Elvucitabine|10 milligrams (mg) elvucitabine daily as part of an ART regimen
48356653|NCT03619902|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
48668006|NCT01589614|DRUG|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
48668007|NCT01321814|BEHAVIORAL|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
48668008|NCT04750161|OTHER|No intervention|No intervention will be given to participants. It is purely observational.
48668009|NCT05099263|DEVICE|Vivaer Arc Stylus|The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal airway in a single study session.
48668010|NCT00530881|DRUG|PHX1149|
48145596|NCT05121285|OTHER|Delivery of contrast fluid by enema with and without positioning|"Each participant will receive one delivery of 440 ml contrast fluid by enema. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. The enema procedure includes:~1. The participant lies on his/her left side in neutral position when the enema is delivered~2. X-ray of the colon is obtained with the participant lying on his/her back.~3. The participant is positioned back to his/her left sided position and tilted in a Trendelenburg position. The position is held for two minutes~4. The participant is turned to an abdominal position while the bed remains tilted in Trendelenburg position.~5. Participant turne to the right side. When positioned the bed is tilted the opposite way (anti-Trendelenburg.) The position is held for two minutes.~6. A second colon X-ray is obtained after the participants has rested for ten minutes in a supine neutral position"
48145597|NCT01865695|DRUG|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
48145598|NCT01865695|OTHER|Placebo|
48145599|NCT05172232|DIAGNOSTIC_TEST|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
48145600|NCT03345407|DRUG|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
48145601|NCT03345407|DRUG|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
48145602|NCT03345407|DRUG|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
48145603|NCT03345407|DRUG|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
47988747|NCT04896320|DRUG|Tucatinib|Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
48145604|NCT03345407|DRUG|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
48145605|NCT03345407|DRUG|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
48145606|NCT03345407|DRUG|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
48145607|NCT03345407|DRUG|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
48145608|NCT02279732|BIOLOGICAL|Paclitaxel|
48145609|NCT02279732|BIOLOGICAL|Carboplatin|
48145610|NCT02279732|BIOLOGICAL|Ipilimumab|
48145611|NCT02279732|OTHER|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
48668011|NCT01624753|DEVICE|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
48668012|NCT00241150|DRUG|VALSARTAN|
47988748|NCT06031454|DRUG|Midazolam|oral
47988749|NCT06031454|DRUG|Omeprazole|oral
47988750|NCT06031454|DRUG|Rosuvastatin|oral
47988751|NCT06031454|DRUG|Verapamil|oral
47988752|NCT06031454|DRUG|Rifampin|oral
47988753|NCT06031454|DRUG|Leritrelvir|oral
47988754|NCT04711473|BEHAVIORAL|Colonoscopy Only|Mailed letter asking participants to complete CRC screening by colonoscopy
47988755|NCT04711473|BEHAVIORAL|Choice|Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT
48145612|NCT04582994|BEHAVIORAL|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
47988756|NCT04711473|BEHAVIORAL|FIT Only|Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
47988757|NCT04385823|DEVICE|patients receiving nasal high flow|patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow
47988758|NCT05193864|DEVICE|Device: JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
48145613|NCT04582994|BEHAVIORAL|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
48145614|NCT04582994|BEHAVIORAL|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
48668013|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
48145615|NCT04780607|DEVICE|mitral valve repair|different repair techniques to construct rheumatic mitral valve lesion
48145616|NCT02958722|PROCEDURE|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
48668014|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
48145617|NCT02958722|DRUG|physiological solution|
48145618|NCT02958722|DRUG|carbon dioxide|
48668015|NCT00402987|DRUG|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
48668016|NCT00402987|DRUG|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
48668017|NCT06277440|OTHER|cognitive training|cognitive training, 15 min, three times per week, for 12 weeks
48145619|NCT01558726|BEHAVIORAL|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
48145620|NCT01558726|BEHAVIORAL|Usual Treatment|The usual treatment used for regular patients of CAPSad
48145621|NCT06026462|DIAGNOSTIC_TEST|Observation of clinical indicators related to asthma|Observe the severity of asthma, drug compliance, comorbidities, asthma control, pulmonary function, FeNO, and the number of acute episodes of asthma
48145622|NCT04017364|DEVICE|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
48145623|NCT04017364|DEVICE|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
48145624|NCT05341700|BEHAVIORAL|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
48145625|NCT05341700|BEHAVIORAL|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
48145626|NCT02881086|DRUG|Rituximab|
48145627|NCT02881086|DRUG|Nelarabine|
48145628|NCT02881086|DRUG|PEG-Asparaginase|
48668018|NCT06277440|OTHER|active control|Traditional rehabilitation programs
48668019|NCT02835586|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
47988759|NCT06112951|PROCEDURE|Extracorporeal Photopheresis|Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
47988760|NCT04554329|PROCEDURE|bandage contact lens|bandage contact lens
47988761|NCT05298332|DRUG|ATI-2173 50 mg|ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
47988762|NCT04032041|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
47988763|NCT03746769|BIOLOGICAL|Allogenic Human Islet Cells|islet cells transplanted into the portal vein in the liver
47988764|NCT03746769|DRUG|Gastrin 17|"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."
47988765|NCT01111149|OTHER|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
47988766|NCT01111149|DRUG|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
47988767|NCT01111149|DRUG|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
47988768|NCT04679792|DIAGNOSTIC_TEST|Dynamic posturography|Balance evaluation
47988769|NCT03892590|BIOLOGICAL|Gut microbiota|Status of microbiota
47988770|NCT00480272|DRUG|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
47988771|NCT00480272|DRUG|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
47988772|NCT01778933|DRUG|EC17|
47988773|NCT04609787|DEVICE|Immersive Virtual Reality|Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
47988774|NCT06157723|OTHER|None (Observational study)|"Data related to the knee osteoarthritis will be extracted from patients' medical records:~The sociodemographic and clinical participants' characteristics: age, weight, height, duration of the condition, and occupational activity.~The healthcare costs: the number of visits in primary and specialized care, diagnostic tests, surgical interventions, and emergencies at both health centers and hospitals, physical rehabilitation and number of sessions.~Charlson Comorbidity Index (CCI). Pharmacotherapy (type of drug and dose). Work absences (temporary and permanent)."
47988775|NCT05333393|BEHAVIORAL|DİABOT (mobile application robot )|Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
47988776|NCT01348347|DRUG|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
47988777|NCT01348347|DRUG|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
47988778|NCT01348347|DRUG|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
47988779|NCT00187811|PROCEDURE|Delta amino leavulinic acid photodynamic therapy|
47988780|NCT02734979|DEVICE|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
47988781|NCT05715073|DIETARY_SUPPLEMENT|TeaCrine and Caffeine|Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
47988782|NCT05715073|DIETARY_SUPPLEMENT|Caffeine|Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
48145629|NCT02881086|PROCEDURE|Cranial irradiation|
48145630|NCT02881086|DRUG|Imatinib|
48145631|NCT02881086|DRUG|Idarubicin|
48145632|NCT02881086|DRUG|Dexamethasone|
48145633|NCT02881086|DRUG|Cyclophosphamide|
48145634|NCT02881086|DRUG|Fludarabine|
48145635|NCT02881086|DRUG|Vincristine|
48145636|NCT02881086|DRUG|Mercaptopurine|
48145637|NCT02881086|DRUG|VP16|
48356654|NCT00782756|OTHER|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
48356655|NCT05312359|DEVICE|Transcranial alternating current stimulation-true stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. Before the intervention, the individual alpha frequency (IAF) of the subjects was measured according to the average peak value of α waves at dorsolateral prefrontal cortex in the closed state. Then an alternating current at θ frequency (θ = IAF - 5Hz) was applied to each subject based on its IAF value. The amplitude of stimulation was increased with a step of 20μA starting from 0. When the subjects had a slight prickling sensation or optical illusion, the stimulation current was decreased with a step of 20μA until the sensation disappeared. The current value at this time was used as the stimulation current of the subjects.
48668020|NCT01059747|OTHER|no intervention applied|no intervention applied
48668021|NCT00613106|DRUG|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
48668022|NCT00613106|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
48668023|NCT03576235|DRUG|PG102P|Daily dose of 1.5g
48668024|NCT03576235|DRUG|Placebo|Daily dose of placebo
48668025|NCT01750853|DRUG|LY3045697|Administered orally
48145638|NCT02881086|DRUG|Daunorubicin (DNR)|
48668026|NCT01750853|DRUG|Placebo|Administered orally
48668027|NCT01137890|DRUG|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
48668028|NCT01137890|DRUG|Placebo|capsules administered in split doses at 22:00 and 09:00.
48668029|NCT01137890|DRUG|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
47988783|NCT05715073|OTHER|Placebo|Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
48145639|NCT02881086|DRUG|Methotrexate|
48145640|NCT02881086|PROCEDURE|Stem cell transplantation|
48145641|NCT02881086|DRUG|Cytarabine|
48145642|NCT02881086|DRUG|Vindesine|
48145643|NCT02881086|DRUG|Adriamycin|
48145644|NCT02881086|DRUG|Prednisolone|
48145645|NCT03249805|DEVICE|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
48145646|NCT03249805|DEVICE|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
48668030|NCT01137890|BEHAVIORAL|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
48668031|NCT01137890|BEHAVIORAL|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
48668032|NCT01455480|DRUG|RPh201, botanical drug product|topical
48668033|NCT05262569|OTHER|ileus|retrospectively allocation according to a postoperative outcome-ileus
48668034|NCT03425955|DEVICE|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
48145647|NCT04707599|OTHER|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
48145648|NCT05474326|DEVICE|intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)|application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
48145649|NCT03492853|GENETIC|DNA extraction and sequencing|DNA extraction from peripheral blood and KASP sequencing
48145650|NCT00053118|BIOLOGICAL|filgrastim|IV
48145651|NCT00053118|DRUG|carboplatin|IV
48145652|NCT00053118|DRUG|etoposide|IV
48145653|NCT00053118|PROCEDURE|bone marrow ablation with stem cell support|IV
48145654|NCT00053118|PROCEDURE|peripheral blood stem cell transplantation|IV
48145655|NCT02377544|DIETARY_SUPPLEMENT|Probiotic|
48145656|NCT02377544|OTHER|Placebo|
48145657|NCT02978066|OTHER|Spinal anaesthesia|
48145658|NCT01992276|BIOLOGICAL|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
48668035|NCT03425955|DEVICE|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
48668036|NCT00442702|DRUG|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
48668037|NCT00442702|DRUG|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
48668038|NCT02022540|DRUG|PAN-90806 Ophthalmic Solution|
48668039|NCT02022540|DRUG|Lucentis|
48668040|NCT03023345|DEVICE|Microwave trans rectal focal treatment|Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
48668041|NCT02167711|DRUG|SIRT Yttrium-90|
48145659|NCT01992276|BIOLOGICAL|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
48145660|NCT01992276|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
48145661|NCT01760876|DEVICE|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
48668042|NCT03186339|PROCEDURE|TAVI|transfemoral transcatheter aortic valve implantation
48145662|NCT04828915|OTHER|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
48145663|NCT04828915|OTHER|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
48145664|NCT00872859|PROCEDURE|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
48145665|NCT03346590|BEHAVIORAL|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
48145666|NCT04090476|OTHER|Exercise|During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
48145667|NCT04235894|DRUG|Propofol|Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
48145668|NCT00708266|DEVICE|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
48145669|NCT00708266|DIETARY_SUPPLEMENT|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
48668043|NCT03186339|PROCEDURE|SAVR|isolated surgical valve replacement
48668044|NCT03186339|OTHER|MM|management of aortic stenosis by medical treatment only
48668045|NCT02345239|DRUG|Pantoprazole|proton pump inhibitor
48668046|NCT04101773|PROCEDURE|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
48668047|NCT03992950|OTHER|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
48145670|NCT00708266|OTHER|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
48145671|NCT05148052|DEVICE|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
48145672|NCT05148052|BEHAVIORAL|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
48145673|NCT03949478|DRUG|Ibuprofen|Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
48145674|NCT03949478|DRUG|Nifedipine|Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
48506159|NCT04685408|BEHAVIORAL|TEAM|TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.
48506160|NCT04685408|BEHAVIORAL|ETAU|ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
48668048|NCT00536289|DEVICE|Blunt needle|Blunt tipped suture needle
48668049|NCT00285051|DRUG|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
48668050|NCT05423184|OTHER|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
48668051|NCT05423184|OTHER|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
48668052|NCT03139448|DEVICE|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
48145675|NCT03949478|DRUG|Placebo|Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
48145676|NCT02574286|DRUG|Velaglucerase alfa|Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
48145677|NCT02574286|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive 800 IU vitamin D orally daily.
48145678|NCT05099562|DEVICE|Acupuncture|Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.
48145679|NCT00667953|DRUG|Gleevec|Gleevec (600 mg) daily.
48145680|NCT00667953|DRUG|Temodar|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
48145681|NCT01333709|DRUG|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
48145682|NCT01333709|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
48145683|NCT01333709|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
48145684|NCT01333709|RADIATION|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
48145685|NCT01333709|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
48145686|NCT04675268|DIAGNOSTIC_TEST|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
48145687|NCT04313985|DEVICE|Tennant Biomodulator-Pro™ Device|Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
48668053|NCT03139448|DEVICE|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
48668054|NCT01204788|PROCEDURE|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
48668055|NCT01204788|PROCEDURE|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
48668056|NCT02128737|BEHAVIORAL|Sleep|
48668057|NCT00338637|DEVICE|APOS shoe kit|
48668058|NCT03377517|RADIATION|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
48145688|NCT01906905|DEVICE|Transcranial Magnetic Stimulation|
48145689|NCT01482325|DEVICE|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
48145690|NCT01074034|DEVICE|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
48356656|NCT05312359|DEVICE|Transcranial alternating current stimulation-sham stimulus|The adhesive electrodes were placed at F3 and F4 positions of the 64-bit EEG caps of the 10-20 system, corresponding to bilateral prefrontal lobes respectively. The actual stimulation waveform was just implemented in the first 60 s (or more longer) and then faded out.
48668059|NCT01615783|OTHER|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
48668060|NCT01615783|OTHER|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
48668061|NCT03124186|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
48668062|NCT06451588|DRUG|FMT|Active FMT
48668063|NCT06451588|DRUG|Placebo|The placebo treatment will be prepared based on the patients' fecal samples (autologous).
48668064|NCT01307449|BIOLOGICAL|PNEUMOVAX|1 dose of PNEUMOVAX
48668065|NCT01307449|BIOLOGICAL|Prevnar|1 dose of Prevnar
48668066|NCT05973643|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia.~The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week.~Blood samples will be done during the anesthesia process."
48668067|NCT02177383|DIETARY_SUPPLEMENT|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
48145691|NCT04419571|PROCEDURE|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
48506161|NCT06498635|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48506162|NCT06498635|PROCEDURE|Computed Tomography|Undergo CT
48145692|NCT03012490|OTHER|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
48145693|NCT03012490|OTHER|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
48145694|NCT03012490|OTHER|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
48145695|NCT06075641|PROCEDURE|Gingival depigmentation|Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers
48145696|NCT04938453|DRUG|nintedanib 25 mg|soft gelatin capsule
48145697|NCT04938453|DRUG|nintedanib 100 mg|soft gelatin capsule
48356657|NCT03058276|BEHAVIORAL|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
48356658|NCT03058276|OTHER|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
48668068|NCT02177383|DIETARY_SUPPLEMENT|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
47988784|NCT06521359|DEVICE|flow cytometry|Two ml of peripheral venous blood samples will be collected in heparinized tubes from patients and controls for assessment of levels of TFH and TFReg cells by flow cytometry.
47988785|NCT03054545|DRUG|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
47988786|NCT03670550|DEVICE|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
47988787|NCT01093547|PROCEDURE|Blood samples|Samples taken monthly
47988788|NCT01093547|PROCEDURE|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
48506163|NCT06498635|BIOLOGICAL|Durvalumab|Given IV
48506164|NCT06498635|OTHER|Patient Observation|Undergo active surveillance
48506165|NCT06498635|OTHER|Questionnaire Administration|Ancillary studies
47988789|NCT04016246|DRUG|Propofol-Lipuro|sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
47988790|NCT04016246|DRUG|Placebos|injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
47988791|NCT06520852|OTHER|Group using artificial intelligence tools in addition to traditional tools in preparing educational materials|Students in the intervention group used AI tools in addition to tools such as books, journals, and websites.
47988792|NCT04923724|DEVICE|tourniquet|tourniquet is a device used during total knee surgery.
47988793|NCT04923724|DEVICE|No tourniquet|tourniquet is a device used during total knee surgery, this group does not get one
47988794|NCT02176850|DRUG|Micardis®|
48506166|NCT04500093|PROCEDURE|Capsulotomy with Repair|Capsulotomy with Repair
48506167|NCT04500093|PROCEDURE|Capsuloectomy|Capsuloectomy
48506168|NCT06008275|DRUG|Neratinib Oral Tablet|240mg oral daily. Dosing will follow standard dose escalation procedures
48506169|NCT06008275|DRUG|Ruxolitinib Oral Tablet|20mg oral twice daily. Dosing will follow standard initial dose recommendation procedure
47988795|NCT04890639|PROCEDURE|Acute Intermittent Hypoxia|Four hypoxia sessions, consisting of 15 cycles of hypoxia (21%, 17%, 13% or 9% O2), each of which lasts up to 60 seconds, interspersed with up to 90-second normoxic episodes.
47988796|NCT02988921|DEVICE|MRI and CT|
47988797|NCT02988921|RADIATION|Ratiotherapy|
47988798|NCT02988921|DRUG|Paclitaxel, platinum-based drug|
48145698|NCT06245564|DRUG|Ketamine 0.5%|Ketamine cream 0.5% will be applied in a 4x4 area in the forearm of each participant.
48145699|NCT06245564|DRUG|Amitriptyline|Amitriptyline cream 1% will be applied in a 4x4 area in the forearm of each participant.
48145700|NCT06245564|DRUG|ketamine + amitriptyline|A cream containing ketamine 0.5%, amitriptyline 1%, will be applied in a 4x4 area in the forearm of each participant.
48145701|NCT06245564|OTHER|Vehicle|A vehicle cream will be applied in a 4x4 area in the forearm of each participant.
48145702|NCT06245564|OTHER|Histamine|After the cream removal, itch will be induced using histamine in the first session
48145703|NCT06245564|OTHER|Cowhage|After the cream removal, itch will be induced using cowhage in the second session
48145704|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms without self-affirmation|
48506170|NCT01085721|DRUG|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
48506171|NCT01085721|DRUG|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
48506172|NCT04819841|GENETIC|nula-cel Drug Product|nula-cel is administered via IV infusion following a myeloablative conditioning regimen
48506173|NCT00001028|DRUG|Pentamidine isethionate|
48506174|NCT00001028|DRUG|Dapsone|
48145705|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms with self-affirmation|
48145706|NCT01864590|DEVICE|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
48145707|NCT01864590|DEVICE|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
48145708|NCT03489811|OTHER|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
48145709|NCT03489811|OTHER|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
48145710|NCT03489811|OTHER|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
48356659|NCT03058276|OTHER|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
48356660|NCT04367649|OTHER|Hall technique|"* Orthodontic separators will be used to create space for fitting the stainless crown, then removed after 3-5 days~* Occlusion will be measured assessing the patient's occlusal-vertical dimensions (OVD) using a modified version of van der Zee and van Amerongen method with a millimeter probe measuring the distance from the lowest point of the gingiva, around the lower canine on the vestibular side up to the point where the tip of the upper canine ends in order to assess the degree of overbite after mounting of the crown.~* The correct crown size will be selected. The crown should cover all the cusps and approaches the contact points, with a slight feeling of spring back. till reaching the gingival margin. Cementation will be done using glass ionomer cement"
48356661|NCT04367649|OTHER|Atraumatic restorative treatment|Caries removal using excavators, then restoration using glass ionomer (GIC)
48356662|NCT04367649|OTHER|Conventional restorative treatment|Complete caries removal using high-speed hand piece, and an excavator to clear carious dentin from the pulpal wall. Then, stainless steel crown preparation, selection of the proper size with the smallest crown size that completely covers the preparation chosen. The correct occlusogingival crown length will be established. Cementation will be done using glass ionomer cement
48506175|NCT06608485|DEVICE|HARMONIC 700 Shears|There is no intervention, beyond necessary clinical care, in this study. HARMONIC 700 Shears for vessel transection were used according to instructions for use.
48506176|NCT01246063|DRUG|carfilzomib|
48668069|NCT04490798|PROCEDURE|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat the different painful syndromes. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation.
48668070|NCT04817150|PROCEDURE|Laparoscopic ventral mesh rectopexy|Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore
47988799|NCT04745598|BEHAVIORAL|Control group: Dental Model|- Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
47988800|NCT04745598|BEHAVIORAL|Computer-assisted teaching format group|- Patients receive a Powerpoint presentation containing:
47988801|NCT04745598|BEHAVIORAL|Plaque-disclosing group|- Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
47988802|NCT04745598|BEHAVIORAL|Intra-oral camera group|- An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
47988803|NCT02178631|BEHAVIORAL|Deprexis|Online self-help
47988804|NCT02178631|OTHER|CAU|Care as usual
47988805|NCT03940664|OTHER|immunohistochemistry on Formalin fixed and paraffin embedded blocks|
48145711|NCT02383797|BIOLOGICAL|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
48145712|NCT05851157|DRUG|VX-548|Tablets for oral administration.
48668071|NCT02235324|BIOLOGICAL|ziv-aflibercept|Given IV
47988806|NCT04728061|DRUG|Gen1E-1124|Intravenously-infused Gen1E-1124 in vehicle.
47988807|NCT04728061|DRUG|Placebo|Intravenously-infused vehicle.
47988808|NCT01014429|DRUG|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
47988809|NCT01466348|DRUG|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
47988810|NCT01466348|DRUG|Paracetamol|Paracetamol 1000 mg
47988811|NCT06297109|DEVICE|Patient-specific implants|Application of patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
47988812|NCT06297109|DEVICE|Conventional mini-plates|Application of conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
47988813|NCT02278263|DRUG|Tranexamic Acid|Given intravenously or topically
47988814|NCT02278263|DRUG|Normal saline (0.9% NaCl)|Administered in all 3 groups
47988815|NCT01967212|DEVICE|Game-based swallow biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
47988816|NCT01967212|BEHAVIORAL|Swallow training without biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
47988817|NCT05744947|OTHER|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
48145713|NCT04955054|DIAGNOSTIC_TEST|diagnose|Patients from UAP and AMI meet the criteria of UAP or STEMI.
47988818|NCT06493708|OTHER|Trauma focused psychotherapy: EMDR|14 sessions of psychotherapy with EMDR will be carried out with patients. One session per week, lasting 90 minutes. The first two sessions will be used for the description of the EMDR method and for stabilization, then there will be treatment sessions.
48356663|NCT02839512|DEVICE|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
48356664|NCT06337942|PROCEDURE|Bladder Transplantation|A bladder transplantation will be performed. The bladder will be recovered from a brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the recipient's ureter(s) to the new bladder.
47988819|NCT02189473|RADIATION|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
47988820|NCT01761110|BEHAVIORAL|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
47988821|NCT03324854|PROCEDURE|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
47988822|NCT03324854|PROCEDURE|Drainage|Placement of active-close drainage in surgical site.
48356665|NCT06337942|PROCEDURE|Combined Kidney and Bladder Transplantation|For patients who qualify for a combined kidney and bladder transplant, both a kidney and a bladder transplant will be performed. Both kidney and bladder allografts will be recovered from the same brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the kidney transplant ureter to the transplanted bladder. If the recipient has continued urine output, new connections between the native ureters and the transplanted bladder will also be made.
48356666|NCT02996175|BEHAVIORAL|Behavioral Sleep Treatment|"1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
47988823|NCT03324854|DRUG|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
48506177|NCT01246063|DRUG|pegylated liposomal doxorubicin (PLD)|
48506178|NCT01246063|DRUG|Dexamethasone|
48506179|NCT00000591|PROCEDURE|lymphocyte depletion|
48506180|NCT01434082|BEHAVIORAL|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
48506181|NCT00229723|DRUG|gefitinib (Iressa)|250 mg oral tablet
48506182|NCT00229723|DRUG|cisplatin|intravenous infusion
48668072|NCT02235324|DRUG|leucovorin calcium|Given IV
48668073|NCT02235324|DRUG|fluorouracil|Given IV
48506183|NCT00229723|RADIATION|radiotherapy|radiation therapy
48668074|NCT02235324|OTHER|laboratory biomarker analysis|Correlative studies
48506184|NCT00229723|DRUG|Gefitinib (Iressa)|500 mg oral tablet
47988824|NCT05820308|BEHAVIORAL|Companion Dog Walking|Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
47988825|NCT05820308|BEHAVIORAL|Attention Control Group|Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
47988826|NCT03442621|DRUG|Relacorilant Fasted|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
47988827|NCT03442621|DRUG|Relacorilant with a high fat breakfast|Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
47988828|NCT03442621|DRUG|Relacorilant with a moderate breakfast|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
47988829|NCT06408623|DRUG|chidamide combined with Sintilimab and bevacizumab|chidamide combined with Sintilimab and bevacizumab
48506185|NCT03458182|OTHER|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
48668075|NCT06486883|DRUG|Trastuzumab deruxtecan (T-DXd, DS-8201a)|Patients will receive T-DXd 5.4 mg/kg body weight administered as an intravenous (IV) infusion on Day 1 (D1) of each 21-day cycle. The initial dose will be administered as a 90-minute IV infusion.
48668076|NCT06486883|DRUG|CDK4/6i plus ET|Patients will receive physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib; physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane.
48668077|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
48668078|NCT00516724|DRUG|Carboplatin|intravenous injection
48668079|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
48668080|NCT00516724|DRUG|Paclitaxel|Intravenous injection
48668081|NCT00516724|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
48668082|NCT00516724|DRUG|Paclitaxel + Carboplatin|Intravenous injection
48145714|NCT00448344|BEHAVIORAL|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
48668083|NCT01713439|BIOLOGICAL|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10\^7/kg, 10\^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10\^4/kg and rising to 10\^7/kg (10\^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10\^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be \<1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
47988830|NCT05403138|DRUG|Daratumumab|Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
48145715|NCT00448344|BEHAVIORAL|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
48145716|NCT06073587|DIAGNOSTIC_TEST|Scintigraphy scan|Scans will be performed as specified in the arm description.
48145717|NCT04834830|DIAGNOSTIC_TEST|Pleural effusion will be examined for various cytokines and PD1-lymphocytes.|Examination of pleural effusion
47988831|NCT05403138|DRUG|Placebo|Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
48145718|NCT04008004|DRUG|EDP-514|Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
48356667|NCT02996175|BEHAVIORAL|Standard of care sleep treatment enhanced with psychoeducation|"1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns"
48668084|NCT02670473|DEVICE|fanfilcon A (test)|contact lens
48668085|NCT05542888|PROCEDURE|Sacroiliac joint mobilization|Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.
48668086|NCT05542888|PROCEDURE|Standard therapy|Postural education, Hot pack, Antenatal exercises
48668087|NCT01099488|PROCEDURE|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
47988832|NCT05773820|DRUG|WJB001|"Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts."
47988833|NCT03907293|BEHAVIORAL|Exercise-based cardiac rehabilitation|Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
47988834|NCT04834635|PROCEDURE|FundoRingOAGB|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
48145719|NCT04008004|DRUG|Placebo|Placebo to match EDP-514
48145720|NCT03995394|OTHER|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
48145721|NCT02391259|DRUG|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
48145722|NCT02391259|DRUG|Placebo|contains no active drug
48145723|NCT00634998|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C capsules orally twice daily
48145724|NCT00634998|DIETARY_SUPPLEMENT|Placebo|1000mg Placebo capsules orally twice daily for 90 days
48506186|NCT04821700|BIOLOGICAL|Carotid Stenosis|To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
48668088|NCT05181488|RADIATION|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
48145725|NCT00704340|DEVICE|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
48145726|NCT00704340|OTHER|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
48145727|NCT00919815|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
48356668|NCT00888316|PROCEDURE|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
48145728|NCT00919815|DRUG|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
48668089|NCT06096766|DIAGNOSTIC_TEST|blood test|Detection of serum levels of copper ions, iron ions, ceruloplasmin (CP), CuZn SOD, malondialdehyde (MDA), etc. Blood samples will be retained from the rest samples for sex hormones samples for testing sex hormones, which don't increase times of blood collection.
48145729|NCT06398015|PROCEDURE|Surgical reconstruction of hip abductor tendon tear|"If the patient is allocated to surgical reconstruction, the incision from the sham surgery is continued into the iliotibial band (ITB) and down to the hip abductor tendon complex/greater trochanter. A standardized reconstruction of the HAT with bone anchors is then performed.~This standardized procedure has been used by the surgeons for the last 6 years. The ITB is then closed with looped suture, the subcutaneous tissue sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing is applied."
48356669|NCT00888316|PROCEDURE|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
48356670|NCT04022304|BIOLOGICAL|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
48668090|NCT06168240|OTHER|Manual lymphatic drainage. will be applied three days per week for four weeks.|Training will applied 3 days a week, for a total of 4 weeks.
48668091|NCT03625921|BEHAVIORAL|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
48668092|NCT03625921|BEHAVIORAL|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
48668093|NCT00429988|GENETIC|fluorescence in situ hybridization|
48668094|NCT00429988|GENETIC|polymerase chain reaction|
48356671|NCT04022304|BIOLOGICAL|Humulin® N|Humulin® N (human insulin \[recombinant deoxyribonucleic acid origin\] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
48356672|NCT05366374|OTHER|Swallowing assessment with Swallis DSA™ Device|The WALLIS DSA™ investigative device is designed to capture and display pharyngolaryngeal activity in subjects with or at risk of swallowing disorders. The DM is non-invasive: a miniaturized microphone and accelerometer are integrated into the form of a necklace, which will be positioned around the patient's neck to capture the vibroacoustic signals of swallowing during mealtime.
47988835|NCT04834635|PROCEDURE|OAGB|laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
47988836|NCT05685082|BEHAVIORAL|Standardized patient simulation|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
47988837|NCT05685082|BEHAVIORAL|Manikin-based simulation|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
48668095|NCT00429988|GENETIC|proteomic profiling|
48668096|NCT00429988|OTHER|cytology specimen collection procedure|
48668097|NCT00429988|OTHER|immunohistochemistry staining method|
48668098|NCT00429988|PROCEDURE|breast duct lavage|
48668099|NCT05180968|DRUG|Nabilone 0.5 MG Oral Capsule|This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
48668100|NCT05180968|DRUG|Placebo Nabilone|This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
48668101|NCT00512564|OTHER|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
48668102|NCT04546100|OTHER|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
48668103|NCT03789708|DIETARY_SUPPLEMENT|Gum Arabic|Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
48145730|NCT06398015|PROCEDURE|Sham surgery of hip abductor tendon tear|If the patient is allocated to sham surgery, the incision will only include the skin and subcutaneous tissue. Subsequently, the subcutaneous tissue will be sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing applied. The patient will be kept in general anesthesia for 10 minutes after the procedure is finalized to mimic a true intervention (to hinder staff or relatives to comment on the duration of the procedure). The normal standard procedure takes approximately 40 minutes.
48506187|NCT01025115|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
48506188|NCT01025115|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
48506189|NCT00746876|DEVICE|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
47988838|NCT03089606|DIAGNOSTIC_TEST|FDG PET/CT scan|18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).
48668104|NCT03789708|OTHER|Placebo|Maltodextrin powder, easily soluble
48668105|NCT00004103|DRUG|cisplatin|
48506190|NCT00746876|DEVICE|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
48668106|NCT00004103|DRUG|floxuridine|
47988839|NCT03089606|DIAGNOSTIC_TEST|C11-AMT PET scan|11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).
47988840|NCT03089606|DRUG|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
47988841|NCT03089606|DIAGNOSTIC_TEST|CT scan|Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
47988842|NCT02357901|DRUG|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
48668107|NCT00004103|DRUG|irinotecan hydrochloride|
48668108|NCT00004103|PROCEDURE|adjuvant therapy|
47988843|NCT02357901|DRUG|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
47988844|NCT02357901|DRUG|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
48145731|NCT05389202|OTHER|Perfusion CT scanning|Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
48145732|NCT02174978|BIOLOGICAL|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
48145733|NCT02174978|OTHER|P falciparum Controlled Human Malaria Infection (CHMI)|
48506191|NCT01734200|DIETARY_SUPPLEMENT|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
48668109|NCT00004103|PROCEDURE|conventional surgery|
48668110|NCT00004103|PROCEDURE|neoadjuvant therapy|
48668111|NCT03144167|OTHER|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
48668112|NCT02346669|PROCEDURE|gastroscopy|as detailed in arm description
47988845|NCT03439020|PROCEDURE|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
47988846|NCT03439020|PROCEDURE|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
48668113|NCT02346669|DRUG|Fecal Microbiota Transplantation|as detailed in arm description
48668114|NCT02346669|OTHER|high fat low fiber diet|as detailed in arm description
48668115|NCT02346669|OTHER|sham diet|as detailed in arm description
48668116|NCT02346669|OTHER|low fat high fiber diet|as detailed in arm description
48668117|NCT05799274|DRUG|RAD301 ([68Ga]-Trivehexin)|Whole body PET scan
48668118|NCT03773809|OTHER|Vitamin D capsule|The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
48668119|NCT03773809|OTHER|placebo|oral administration of placebo
48145734|NCT04717687|PROCEDURE|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
48145735|NCT00551421|BIOLOGICAL|pertuzumab|Given IV
48145736|NCT00551421|BIOLOGICAL|cetuximab|Given IV
48145737|NCT00551421|DRUG|irinotecan hydrochloride|Given IV
48668120|NCT03204760|DRUG|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
48145738|NCT00551421|OTHER|immunohistochemistry staining method|Correlative study
48145739|NCT00551421|OTHER|fluorescence in situ hybridization|Correlative study
48668121|NCT03204760|DRUG|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
48145740|NCT00551421|OTHER|gene expression analysis|Correlative study
48145741|NCT00551421|OTHER|mutation analysis|Correlative study
48668122|NCT05130073|PROCEDURE|Computed Tomography|Undergo PET/CT
48668123|NCT05130073|OTHER|Electronic Health Record Review|Review of medical records
48145742|NCT00551421|OTHER|polymerase chain reaction|Correlative study
48145743|NCT00551421|OTHER|laboratory biomarker analysis|Correlative study
48145744|NCT03430440|DEVICE|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
48145745|NCT03430440|DEVICE|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
48356673|NCT04711395|DEVICE|measure the preoperative DLI、 SS-OCT image of the lens,、take photos of the anterior segment and self-scoring of the preoperative visual quality assessment scale.|subjects in the observation group and Healthy used iTrace ocular aberration analyzer（itracey Technologies）and IOL-Master 700 biometer to measure the preoperative DLI(Dysfunctional lens index) and SS-OCT image of the lens, and The researchers used the anterior segment slit lamp to take photos of the anterior segment of the subject's lens in a state of dilated pupils .and self-scoring of the preoperative visual quality assessment scale.
48668124|NCT05130073|PROCEDURE|Follow-Up|Undergo follow-up
48668125|NCT05130073|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
47988847|NCT03730493|BEHAVIORAL|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
48668126|NCT06047743|OTHER|Alternating unilateral Isometric Handgrip Exercise|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
48668127|NCT06047743|OTHER|Dominant knee extension Isometric Exercise|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
47988848|NCT04263207|OTHER|No intervention|No intervention
48145746|NCT03455140|DRUG|PEG- BCT-100|PEGylated recombinant human arginase 1
48145747|NCT01234584|PROCEDURE|spk|implants using SPK Abutments
48145748|NCT01234584|PROCEDURE|CPK Abutments|implants using CPK Abutments
48145749|NCT02858206|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
48356674|NCT02658149|DRUG|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
48356675|NCT02658149|DRUG|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
48145750|NCT02858206|DRUG|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
48145751|NCT02858206|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
48145752|NCT02858206|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
48145753|NCT02858206|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
48145754|NCT03369483|OTHER|Abdominal pressure assessment|We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
48145755|NCT01544894|DRUG|Raloxifene|60 mg/d for one year
48145756|NCT01544894|DRUG|Strontium ranelate|2 g/d, for one year
48356676|NCT02658149|DRUG|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
48356677|NCT02658149|DRUG|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
48145757|NCT05013398|BEHAVIORAL|The Together Webinar Programme|"The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT)."
48145758|NCT05226728|DRUG|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
48145759|NCT05539118|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
48145760|NCT05539118|DRUG|Toripalimab|Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
48145761|NCT05539118|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
48145762|NCT06499116|DRUG|Topiramate|Treatment will be prescribed for GPs and they will decide the specific dosage 25-100 mg/12h.
48145763|NCT06499116|DRUG|Flunarizine|Treatment will be prescribed for GPs and they will decide the specific dosage 2,5-10 mg mg/24h.
48145764|NCT06499116|DRUG|Amitriptyline|Treatment will be prescribed for GPs and they will decide the specific dosage 10-75 mg/24h.
48145765|NCT06499116|DRUG|Propranolol|Treatment will be prescribed for GPs and they will decide the specific dosage 20-120 mg/12h.
48356678|NCT02658149|DRUG|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
48356679|NCT04589117|BEHAVIORAL|Expressive writing|"The 4-week study intervention will invite participants through a progression of expressive writing exercises designed to support emotional expression and enhance personal resilience. Weekly instruction writing sessions will be conducted via Zoom. The sessions will not be recorded, but participants who cannot attend the sessions live (or prefer not to, for any reason) will receive each week's instructions and prompts via email.~The progression of writing exercises flows as follows:~* Week 1: Writing to expressive difficult emotions~* Week 2: Writing to cultivate compassion \& forgiveness~* Week 3: Writing to nurture positive emotions~* Week 4: Writing to invite insight, perspective, \& growth"
48356680|NCT01927640|DRUG|Dexmedetomidine|Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
48356681|NCT01927640|DRUG|Normal Saline|Normal saline infusion (10 cc)
48356682|NCT01927640|DRUG|Intranasal cocaine|Intranasal cocaine (2 mg/kg)
48356683|NCT03792412|OTHER|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
48145766|NCT05953025|BEHAVIORAL|Questionnaire|No intervention on care- questionnaire to see effect of standard care treatment on symptoms
48356684|NCT03210415|OTHER|Observational Study Model|There is no intervention for the study.
48688042|NCT04704297|DRUG|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
48688043|NCT04474197|DRUG|VX-864|Tablets for oral administration.
47988849|NCT03781128|DRUG|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
47988850|NCT03781128|DRUG|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
47988851|NCT01649531|PROCEDURE|1 Implant|
47988852|NCT01649531|PROCEDURE|2 Implants|
48356685|NCT02469597|DRUG|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
48145767|NCT02596737|BEHAVIORAL|wittyFit concept|
48145768|NCT02951806|DRUG|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
48145769|NCT02951806|DRUG|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
48145770|NCT03560154|OTHER|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
48145771|NCT06361212|DRUG|Ethoximod|Ethoximod is a S1P1 modulator.
48145772|NCT04725266|BEHAVIORAL|Family-based intervention|The intervention aims to motivate drug abusers to stay drug abstinence and improve family functioning with the support of their own families. In the component of engagement, we will use effective and appropriate skills to engage clients, understand their concerns, and provide necessary resources to them. In the component of role identification, we will help drug abusers identify their family roles through providing education on family roles and responsibilities. The component of affection is designed to learn affective responsiveness and enhance their emotional bonds with each other, while in the component of competence, we will enhance their competency to take care of the family. The intervention will be conducted in group sessions with 4-6 families per group. A total of 17 sessions will be delivered with 1.5-2 hour for each session (6 sessions for Engagement, 3 sessions for Role identification, 3 sessions for Affection, and 3 sessions for Competence).
48145773|NCT04725266|OTHER|routine care|Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.
48145774|NCT02412540|BEHAVIORAL|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
48145775|NCT05887609|DRUG|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
48668128|NCT01362101|BEHAVIORAL|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
48356686|NCT02469597|DRUG|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
48356687|NCT02814799|OTHER|bone removal|
48356688|NCT03681873|DIAGNOSTIC_TEST|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
48668129|NCT03319576|OTHER|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
48356689|NCT02064829|DRUG|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
48356690|NCT02064829|DRUG|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
48356691|NCT05466240|DRUG|AT-752|AT-752 for 5 days
48356692|NCT05466240|DRUG|Placebo|Placebo for 5 days
48356693|NCT03112499|PROCEDURE|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
48506192|NCT01734200|DIETARY_SUPPLEMENT|Placebo|Placebo (1.5g/day)
47988853|NCT01524510|RADIATION|CT scan|low dose radiation scan without contrast without and with MRA
48506193|NCT04608123|OTHER|none (observational study)|DBS
48506194|NCT05804916|DEVICE|Surface Guided Radiation Therapy (SGRT)|SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection
48506195|NCT06609226|DRUG|Etavopivat A|Participants will receive an oral dose of Etavopivat A.
48506196|NCT06609226|DRUG|Etavopivat B|Participants will receive an oral dose of Etavopivat B.
48506197|NCT01192763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
48506198|NCT01192763|OTHER|laboratory biomarker analysis|Correlative studies
48506199|NCT01192763|OTHER|pharmacological study|Correlative studies
48506200|NCT01192763|PROCEDURE|neoadjuvant therapy|
48506201|NCT01192763|PROCEDURE|therapeutic conventional surgery|
48506202|NCT02704403|DRUG|Elafibranor|
48506203|NCT02704403|DRUG|Placebo|
48506204|NCT01930565|OTHER|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
48506205|NCT01930565|OTHER|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
48506206|NCT00940316|BIOLOGICAL|panitumumab|Given intravenously 6mg/kg every 2 weeks
48506207|NCT00940316|DRUG|erlotinib hydrochloride|Given orally 150mg daily
48506208|NCT00940316|DRUG|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
47988854|NCT01524510|DEVICE|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
47988855|NCT05635240|OTHER|Interview / questionnaires|At each of the 4 visits, the participant will have to answer several questions regarding trauma-related data, employment and sport practice.
48506209|NCT01890447|OTHER|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
48506210|NCT01667237|BEHAVIORAL|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
48506211|NCT00644852|OTHER|Retrospective chart review study|Retrospective study chart review long acting risperidone
48506212|NCT05026996|DRUG|Pelacarsen|Single subcutaneous injection of pelacarsen
48506213|NCT00117910|DRUG|pegfilgrastim|
48668130|NCT02870426|PROCEDURE|Frontal Craniotomy and retrieval of OBs|For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
48668131|NCT02870426|PROCEDURE|OB Retrieval During Anterior Cranial Surgery|Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
48668132|NCT05702307|OTHER|Glucose as reference food|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48668133|NCT05702307|OTHER|Tagliatella control|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48668134|NCT05702307|OTHER|5% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48668135|NCT05702307|OTHER|16% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48506214|NCT06633679|BEHAVIORAL|Se Cuida Intervention|The intervention consist in an internet based cognitive behavioural therapy program delivered through a online platform. Intervention consist of 8 weeks with 8 weekly modules assigned to the participants. The program has been translated and adapted to the Brazilian and is based on CBT techniques focused on managing psychological symptoms of anxiety and depression in young people. Out of a total 14 modules adaptaded, 8 will be delivered in the treatment: 5 will be available to all participants and 3 will be tailored according to the initial assessment and interviews. The intervention is self-guided with support on demand, meaning that when participants need support, they could chat directly through the platform text message channel with a psychoteraphist responsible for them. Also, once a week each participants receive feedbacks regarding their work on the program\&#39;s exercises.
47988856|NCT06397352|OTHER|ShotBlocker®|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors.It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.
48506215|NCT03494335|OTHER|Online surveys|The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
48506216|NCT01882972|BEHAVIORAL|Exercise|
48506217|NCT01882972|BEHAVIORAL|Meditation|
48506218|NCT00737152|OTHER|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
48506219|NCT02842138|BIOLOGICAL|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
48506220|NCT05097794|DRUG|BR1015-1|- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
48668136|NCT05702307|OTHER|16% sunflower penne|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48145776|NCT05887609|DRUG|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
48145777|NCT03332316|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone injection
48145778|NCT03332316|DRUG|Ropivacaine Hydrochloride Inj 2 mg/ml|Ropivacaine injection
48145779|NCT03332316|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
48145780|NCT01237977|DRUG|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
48145781|NCT01237977|DRUG|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
48145782|NCT05082688|BIOLOGICAL|Herpes zoster vaccination (Shingrix, GSK)|Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations
48145783|NCT05082688|BIOLOGICAL|Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)|Fluarix Tetra is a quadrivalent inactivated influenza vaccine
48145784|NCT05082688|BIOLOGICAL|Placebo|0.9% NaCl
48145785|NCT00272415|DRUG|INO-1001|Intravenous repeating dose
48145786|NCT00272415|DRUG|temozolomide|Oral repeating dose
48145787|NCT02067689|DEVICE|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
48145788|NCT04417309|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
48145789|NCT04417309|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for 30 minutes.
48506221|NCT05097794|DRUG|BR1015-2|- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
48145790|NCT01135719|PROCEDURE|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
48145791|NCT02099058|DRUG|Osimertinib|It is administered orally everyday.
48145792|NCT02099058|DRUG|Nivolumab|It is an intravenous infusion administered every 14 days.
48145793|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 21-day dosing cycles.
48145794|NCT02099058|DRUG|Telisotuzumab vedotin|It is administered by infusion in 28-day dosing cycles.
48506222|NCT05097794|DRUG|BR1015-1 + BR1015-2|- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
48668137|NCT05702307|OTHER|16% sunflower fusilli|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
48688044|NCT04474197|DRUG|Placebo|Placebo matched to VX-864 for oral administration.
48688045|NCT04628702|BEHAVIORAL|tablet training|1.5 year training period
48688046|NCT02634775|OTHER|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
48145795|NCT02099058|DRUG|Erlotinib|It is administered orally everyday.
48145796|NCT03917732|BEHAVIORAL|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
48145797|NCT03917732|BEHAVIORAL|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
48145798|NCT05308888|DIAGNOSTIC_TEST|18F-FDG PET-CT|The 18F-FDG PET-CT will be performed in the nuclear medicine department of the CHU of Brest. For this exam, the administration of 2-3 MBq/kg of 18F-FDG (\[18F\]F-fluorodeoxyglucose) will be performed to the patient in a single intravenous injection.
48145799|NCT01916057|DEVICE|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
48145800|NCT03009123|OTHER|Erectile dysfunction|Patients with ED are considered belonging to the exposure group.
48145801|NCT05870995|DRUG|CALGE-VEN- RIC-conditioning|Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation
48145802|NCT03782285|PROCEDURE|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
48145803|NCT06139835|BIOLOGICAL|Tartarase|Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
48506223|NCT05485987|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
48506224|NCT00289120|DRUG|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
48145804|NCT06031506|DEVICE|Implant supported hybrid maxillary prosthesis|All patients will receive immediately loaded hybrid prosthesis supported by 4 zygomatic implants.
48145805|NCT06305910|DRUG|Treatment with CD200AR-L|Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
48356694|NCT03112499|PROCEDURE|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
48356695|NCT03112499|PROCEDURE|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
48356696|NCT02177604|OTHER|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
48356697|NCT02177604|OTHER|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
48356698|NCT02177604|OTHER|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
48506225|NCT00289120|DRUG|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
48688047|NCT01959178|DEVICE|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
48356699|NCT05734144|PROCEDURE|The intraoperative ERCP has been performed immediately before LC|combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy
48356700|NCT05734144|PROCEDURE|POES followed by LC|Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
48506226|NCT03749083|OTHER|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
48506227|NCT03040700|OTHER|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
48506228|NCT03040700|OTHER|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX-Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
48506229|NCT06632600|DRUG|LXE408|LXE408 administered by oral route
48506230|NCT06632600|DRUG|Placebo|Placebo administered by oral route
48145806|NCT03015688|RADIATION|x-ray images|
48145807|NCT05779696|OTHER|No-intervention|This is a non-intervention study.
48145808|NCT00488969|DRUG|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
48145809|NCT00488969|DRUG|Placebo|
48356701|NCT00302575|BEHAVIORAL|Collaborative Behavioral Management|
48356702|NCT00302575|PROCEDURE|Integrated parole and outpatient addiction treatment|
48356703|NCT03066687|DRUG|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
48356704|NCT03634852|DRUG|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
48356705|NCT03634852|DRUG|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
48506231|NCT06632600|DRUG|Benznidazole|Benznidazole administered by oral route (administered as standard of care)
48506232|NCT02399319|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
48506233|NCT02399319|PROCEDURE|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
48506234|NCT06598878|PROCEDURE|AR gait training|Participants will walk on a pathway projected in augmented reality (AR), following the instructions provided on the pathway Each session will last for 60 minutes, conducted three times per week, over a period of six weeks.
48668138|NCT02167321|DRUG|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
48668139|NCT02167321|DRUG|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
48668140|NCT06107530|OTHER|semi structured interview|Women fulfilling the inclusion / exclusion criteria will be asked to participate to a semi structured interview with a psychiatrist or a psychologist
48668141|NCT03315585|DEVICE|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
48688048|NCT01959178|DEVICE|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
48688049|NCT02713113|DRUG|sugammadex reversal of neuromuscular blockade|
48145810|NCT05804357|BEHAVIORAL|Manual Therapy|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
48145811|NCT05804357|BEHAVIORAL|Exercise|It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
47988857|NCT06397352|OTHER|Buzzy® Group|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child
48145812|NCT03471884|PROCEDURE|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
48145813|NCT03471884|PROCEDURE|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
48356706|NCT03634852|DRUG|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
48356707|NCT03634852|DRUG|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
48145814|NCT04553809|PROCEDURE|ENB|ENB for biopsy sampling of peripheral lung lesion
48145815|NCT04553809|PROCEDURE|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
48688050|NCT03393897|OTHER|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
47988858|NCT02758015|OTHER|Standardized Meal|
47988859|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
48356708|NCT01524809|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
48356709|NCT01524809|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
47988860|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
47988861|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
48145816|NCT04555057|PROCEDURE|Music therapy|Music selected according to the patient's individual preferences.
47988862|NCT04342845|BEHAVIORAL|Experimental: Motivational interviewing Placebo Comparator: Traditional lectures|Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
48145817|NCT00754325|DRUG|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
48145818|NCT00754325|DRUG|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
48145819|NCT02499497|DRUG|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
48356710|NCT03125681|PROCEDURE|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
48356711|NCT03125681|PROCEDURE|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
48688051|NCT03393897|OTHER|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
48145820|NCT02499497|DRUG|Placebo|The participants will receive pills containing no active drug.
48145821|NCT06315465|DIETARY_SUPPLEMENT|Modified Atkin's Diet with standard of care|children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.
47988863|NCT00144976|DRUG|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
48145822|NCT06315465|OTHER|Standard of Care|Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
48145823|NCT00004807|DRUG|dextromethorphan|
48145824|NCT00004807|DRUG|topiramate|
48145825|NCT00004807|DRUG|Donepezil|
48145826|NCT00803985|PROCEDURE|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
48145827|NCT00803985|PROCEDURE|Lichtenstein|Operation for primary inguinal hernias i men
48145828|NCT01198314|PROCEDURE|immunosuppression withdrawal|tapering off immunosuppressant
48506235|NCT05530187|DEVICE|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
48145829|NCT01198314|PROCEDURE|continue of taking immunosuppressant|maintain immunosuppression
48145830|NCT02690792|OTHER|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
48145831|NCT02690792|DIETARY_SUPPLEMENT|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
48356712|NCT00965744|DEVICE|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
48356713|NCT01509157|DEVICE|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
48356714|NCT01509157|PROCEDURE|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
48356715|NCT02981238|DIETARY_SUPPLEMENT|Phytostandard® Eschscholtzia / Valerian|
48356716|NCT03953690|OTHER|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
48506236|NCT02092467|DRUG|tofacitinib|Oral tablet, 5 mg BID
48506237|NCT02092467|DRUG|tofacitinib|Oral tablet, 10 mg BID
48506238|NCT02092467|BIOLOGICAL|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
48506239|NCT02092467|BIOLOGICAL|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
48506240|NCT06579534|OTHER|Health education strategy|Based on the concept of precise health care, investigators design risk awareness, self-health management and fall prevention care measures, and provide inpatients with high-risk groups with frailty and falls with health education guidance on muscle endurance training and fall prevention. This study adopts purposive sampling, randomization, assignment, and parallel experiments to divide into a control group and an experimental group. The control group uses conventional health education guidance to provide fall prevention education, and the experimental group uses multimedia health education videos to provide education to patients or primary caregivers. Provide health education on the risk, management and prevention of falls.
48506241|NCT06459128|DEVICE|Limbic Care|"Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three courses (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the to do list section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener."
48506242|NCT06459128|DEVICE|Digital Workbook|The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).
48506243|NCT04017650|BIOLOGICAL|Cetuximab|Given IV
48506244|NCT04017650|DRUG|Encorafenib|Given PO
48506245|NCT04017650|BIOLOGICAL|Nivolumab|Given IV
48356717|NCT00000231|DRUG|Buprenorphine|
48506246|NCT06389539|OTHER|SBD111 medical food|SBD111 medical food is a defined microbial assemblage (DMA) consisting of oligofructose and dried berry powder (prebiotics), a Pseudomonas fluorescens, a Lactobacillus brevis, a Leuconostoc mesenteroides, a Lactobacillus plantarum, and a Pichia kudriavzevii (yeast).
48506247|NCT06389539|OTHER|Placebo|Placebo
48506248|NCT00034008|BEHAVIORAL|Healing Touch|
48506249|NCT00041626|GENETIC|INGN 201|
48506250|NCT02113553|DRUG|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
48356718|NCT03258762|DRUG|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
48356719|NCT03258762|DRUG|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
48356720|NCT00004064|BIOLOGICAL|oregovomab|
48356721|NCT06189027|DRUG|MDMA|Adjunctive administration of MDMA to assist psychotherapeutic process
48145832|NCT06052943|BEHAVIORAL|Mindfulness-Based Intervention|Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
48145833|NCT06052943|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.
48145834|NCT06052943|BEHAVIORAL|Physical Activity|Combines aerobic and resistance training though game play.
48145835|NCT06052943|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education based on the Learning to BREATHE curriculum.
48145836|NCT06052943|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
48145837|NCT06052943|BEHAVIORAL|Cooking Matters|Nutrition education and hands-on cooking lessons for the whole family
48145838|NCT02013804|DRUG|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
48145839|NCT05692245|DRUG|Ondansetron|Administered Medication
48356722|NCT06189027|BEHAVIORAL|Psychotherapy|Psychotherapy aimed at assisting with PTSD symptom reduction
48356723|NCT00696540|DRUG|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
48145840|NCT05692245|DRUG|Dexamethasone|Administered Medication
48356724|NCT00696540|DRUG|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
48506251|NCT02678650|DRUG|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
48506252|NCT02678650|DRUG|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
48506253|NCT04702243|DIAGNOSTIC_TEST|Genetic Testing for PCD or PID|Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.
48506254|NCT04702243|OTHER|Unaffected Family Member Genetic Testing|Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.
48145841|NCT01048385|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
48145842|NCT01048385|DIETARY_SUPPLEMENT|Placebo|Treated with capsules containing the vehicle (Sesame oil).
48145843|NCT03388957|DRUG|Propranolol|This drug will be given before the extraction procedure
48145844|NCT03388957|DRUG|Midazolam|This drug will be given before the extraction procedure
48145845|NCT03630653|PROCEDURE|Sentinel LN in breast cancer recurrence|Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
48145846|NCT00391066|DRUG|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
48145847|NCT00391066|DRUG|FCR|Dose, schedule, and duration specified in protocol
48356725|NCT04545931|DEVICE|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
48356726|NCT04545931|DRUG|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
48356727|NCT00381836|DRUG|Darbepoetin Alfa|
48356728|NCT02084316|BEHAVIORAL|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
48356729|NCT02084316|BEHAVIORAL|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
48145848|NCT03471117|DRUG|Pioglitazone|Pioglitazone 15mg daily for 1 month
48145849|NCT03471117|OTHER|Placebo|Placebo pills for 1 month
48145850|NCT02056925|OTHER|Echocardiography|
48145851|NCT04997408|DEVICE|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
48145852|NCT04997408|OTHER|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
48668142|NCT05547113|DIAGNOSTIC_TEST|posturography|In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
48145853|NCT04347005|DRUG|Cohort 1: AR882|Single dose of AR882 or matching placebo
48145854|NCT04347005|DRUG|Cohort 2: AR882|Single dose of AR882 or matching placebo
48145855|NCT04347005|DRUG|Cohort 3: AR882|Single dose of AR882 or matching placebo
48145856|NCT04347005|DRUG|Cohort 4: AR882|Single dose of AR882 or matching placebo
48145857|NCT04347005|DRUG|Cohort 5: AR882|Single dose of AR882 or matching placebo
48145858|NCT04347005|DRUG|Cohort 6: AR882 Food Effect|Single dose of AR882 or matching placebo in a fed state
48145859|NCT04347005|DRUG|Cohort 7: AR882 Solid Oral Formulation|Single dose of AR882 or matching placebo
48668143|NCT03323957|DIAGNOSTIC_TEST|nutritional screening tool|screening of disease associated malnutrition in sick infants
48145860|NCT04347005|DRUG|Cohort 8: AR882 in combination with allopurinol|Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
48356730|NCT03871764|DIAGNOSTIC_TEST|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
48356731|NCT04139421|BEHAVIORAL|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
48506255|NCT06430359|DIAGNOSTIC_TEST|urine and blood test|3 urine collections of an 8h period. One blood sample for liver function test and copper assessment
48506256|NCT02317289|DEVICE|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
48506257|NCT01427530|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
48506258|NCT01753297|DRUG|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
48506259|NCT01110135|DRUG|bendamustine hydrochloride|Given IV
48668144|NCT01528579|OTHER|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
48145861|NCT04347005|DRUG|Cohort 9: AR882 in combination with febuxostat|Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
48145862|NCT05224245|DEVICE|ACURATE Prime XL Transfemoral Aortic Valve System|ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
48145863|NCT03860129|DRUG|Isoflurane|Group A: Isoflurane (0.5 MAC)
48145864|NCT03860129|DRUG|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
48145865|NCT03860129|DRUG|Desflurane|Group C: Desflurane (0.5 MAC)
48145866|NCT02813174|BEHAVIORAL|Compassionate Mind Training from Compassion-Focused Therapy|
48145867|NCT02032004|BIOLOGICAL|Allogeneic Mesenchymal Precursor Cells (MPCs)|Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved
48145868|NCT02032004|OTHER|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
48145869|NCT00659373|DRUG|Tamoxifen|
48145870|NCT00659373|DRUG|triptorelin|
48145871|NCT00659373|DRUG|Exemestane|
48145872|NCT00652600|DRUG|Propranolol|ER Capsules, 160 mg, single-dose
48145873|NCT00652600|DRUG|Inderal-LA|ER Capsules, 160 mg, single-dose
48145874|NCT06279416|PROCEDURE|fiberoptic intubation|awake nasal fiberoptic intubation
48145875|NCT06279416|PROCEDURE|laryngeal mask airway-mediated aintree catheter|awake intubation with laryngeal mask airway-mediated aintree catheter
48145876|NCT06279416|PROCEDURE|videolaryngoscopy|awake intubation with videolaryngoscopy
48145877|NCT01503450|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
48145878|NCT05656456|OTHER|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
48356732|NCT01594749|DRUG|Fosaprepitant dimeglumine|
48356733|NCT01594749|DRUG|Fosaprepitant Placebo|
48356734|NCT01594749|DRUG|Dexamethasone|
48356735|NCT01594749|DRUG|Ondansetron|
48356736|NCT01594749|DRUG|Dexamethasone Placebo|
48356737|NCT01594749|DRUG|Ondansetron Placebo|
48356738|NCT01594749|DRUG|Rescue Therapy|
48356739|NCT01430364|DEVICE|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
48356740|NCT01430364|DEVICE|BIOSS Lim|
48356741|NCT01430364|DEVICE|CarloS|
48506260|NCT01110135|DRUG|dexamethasone|Given PO
48506261|NCT01110135|BIOLOGICAL|filgrastim|Given SC
48506262|NCT01110135|PROCEDURE|leukapheresis|Given IV
48506263|NCT01110135|OTHER|laboratory biomarker analysis|Correlative studies
48356742|NCT01809327|DRUG|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
48506264|NCT01110135|OTHER|flow cytometry|Correlative studies
48506265|NCT01110135|DRUG|etoposide|Given IV
48668145|NCT01528579|BEHAVIORAL|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
48668146|NCT01528579|OTHER|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
48668147|NCT03245918|DRUG|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
48668148|NCT03245918|DRUG|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
48668149|NCT05251649|DEVICE|tACS combined with 40 Hz sound stimulation|"The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off."
48668150|NCT05251649|DEVICE|Transcranial alternating current stimulation|The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).
48668151|NCT05251649|DEVICE|40 Hz sound stimulation|Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
48668152|NCT00003486|DRUG|antineoplaston A10|
48668153|NCT00003486|DRUG|antineoplaston AS2-1|
48668154|NCT00003486|PROCEDURE|alternative product therapy|
47988864|NCT04730830|OTHER|Questionnaire|Patients completing emergence assessment questionnaires at the time of the first dressing placement, as well as at the scheduled weekly placement. As part of a planned repair, the emergence will be assessed at most once a week, preferably at the beginning of the week by the patient. In any other case of dressing change, an emergence assessment will be requested.
47988865|NCT02074787|DEVICE|Thermography|Standard thermographic images
47988866|NCT02074787|DEVICE|Laser Doppler|standard laser doppler analysis
47988867|NCT02074787|DEVICE|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
47988868|NCT05745558|BEHAVIORAL|Prehabilitation|"The prehabilitation program consists of 4 components:~1. Fitness training led by a physiotherapist. The patients will receive personalized training schedules to perform at home. The training sessions focus on improving aerobic fitness (biking or walking) and muscle strength (specific exercises for the different patient groups) and respiratory exercises aimed to relax.~2. Nutritional counseling led by a dietician. All patients will be offered an intake with a dietician (60 min) to discuss current eating habits and give personalized advices. Based on indication, patients will receive follow-up consults.~3. Smoking cessation counseling led by a trained social worker. For patients that are currently smoking, a social worker will offer counseling sessions to coach the patient in the process of smoking cessation.~4. Psychosocial counseling led by a psychologist. All patients will be offered counselling by a psychologist."
47988869|NCT00487851|PROCEDURE|surgery|hepaticojejunostomy and gastroenterostomy
47988870|NCT00487851|PROCEDURE|endoscopic strategy|Stent insertion
47988871|NCT05397665|DRUG|AT-007|AT-007, aldose reductase inhibitor
47988872|NCT05397665|DRUG|Placebo|Liquid oral suspension
47988873|NCT02013648|DRUG|Dasatinib|
47988874|NCT02013648|DRUG|Cytarabine|
47988875|NCT02013648|DRUG|Daunorubicin|
47988876|NCT02013648|DRUG|Idarubicin|
47988877|NCT01269424|BIOLOGICAL|MGMTP140K-encoding retroviral vector|
47988878|NCT01269424|DRUG|O6-benzylguanine|
47988879|NCT01269424|DRUG|temozolomide|
47988880|NCT01269424|OTHER|laboratory biomarker analysis|
47988881|NCT01269424|PROCEDURE|autologous hematopoietic stem cell transplantation|
47988882|NCT01269424|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
47988883|NCT01269424|RADIATION|radiation therapy|
47988884|NCT01564121|DRUG|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
47988885|NCT03006744|BEHAVIORAL|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
47988886|NCT03006744|BEHAVIORAL|Reading enjoyment training|Training on how to make reading enjoyable for children.
48356743|NCT01809327|DRUG|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
48356744|NCT01809327|DRUG|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
48356745|NCT04019197|DRUG|Semaglutide Injectable Product|semaglutide subcutaneous injection
48506266|NCT03196219|DRUG|C16G2|C16G2
48506267|NCT03196219|DRUG|Placebo|Varnish Placebo
48668155|NCT00003486|PROCEDURE|biological therapy|
48668156|NCT00003486|PROCEDURE|biologically based therapies|
48668157|NCT00003486|PROCEDURE|cancer prevention intervention|
48668158|NCT00003486|PROCEDURE|complementary and alternative therapy|
48668159|NCT00003486|PROCEDURE|differentiation therapy|
48668160|NCT03868358|DEVICE|transcranial magnetic stimulation|"The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks"
48668161|NCT05732038|BEHAVIORAL|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to complete a minimum of 10 minutes per day of meditation for 12 weeks. For the first four weeks, participants will listen to prescribed meditations that will teach them the foundations of mindfulness. During weeks 5-12, participants will have full access to the HMP meditation library.
48668162|NCT05732038|BEHAVIORAL|Wellness App (WA)|"Participants in the WA group will listen to a minimum of 10 minutes per day of a caregiver specific educational podcast (including topics such as Caring for the Caregiver or Folate and Preventing Alzheimer's) delivered via a mobile app for the 12 weeks. The app contains one podcast per day for twelve weeks."
48668163|NCT03025126|OTHER|Multimedial Rehabilitation|
48668164|NCT03025126|OTHER|Usual care program|Usual care at home program according to healthcare professional's advice
48668165|NCT05471921|BEHAVIORAL|SBIRT|SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.
47988887|NCT03864471|OTHER|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
47988888|NCT03864471|OTHER|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
48356746|NCT04019197|DRUG|Placebo|placebo injection
48356747|NCT05288179|DRUG|Pirfenidone Capsules|After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
48356748|NCT05288179|DRUG|placebo capsules|After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
48356749|NCT05875194|DEVICE|active transcranial direct current stimulation (tDCS)|2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
48668166|NCT05471921|BEHAVIORAL|Treatment as usual|Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
48668167|NCT05639010|DEVICE|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
48356750|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 300 mg|300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
48356751|NCT04697589|DIETARY_SUPPLEMENT|Memophenol 600 mg|600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
48356752|NCT04697589|DIETARY_SUPPLEMENT|Placebo|Colored maltodextrin
48145879|NCT06445140|BEHAVIORAL|Collecting the variables and Implementation of a behavioural intervention|"The observational phase (during 15 days)~* Two measurements per day for motivational variables and physical activity and nutrition~* Two measurements per day for nutrition~* Three measurements per day for fatigue~* Continuous PA measurement by accelerometer~The interventional phase :~Part A (during 7 days)~* measuring physical activity (PA)~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue~Part B: BEHAVIORAL INTERVENTION (10 weeks),the APA teacher will call a patient once a week for follow-up.~Answer questionnaires and scales on the digital platform will be done :~* Motivational factors~* Self-evaluation of nutrition~* Self-assessment of fatigue~Part C : End of interventional phase(during 7 days)~* measuring physical activity~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue"
48145880|NCT03648749|BEHAVIORAL|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
48145881|NCT06324097|DIAGNOSTIC_TEST|endocytoscopy|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue.
48145882|NCT02198898|DEVICE|GUARDIX-SG|
48145883|NCT01682928|DRUG|IV/Oral Hydration and Bedrest|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs"
48145884|NCT01682928|OTHER|Hydrotherapy|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
48145885|NCT02160301|DRUG|Gabapentin|PO
48145886|NCT02160301|DRUG|Acetaminophen|PO
48145887|NCT02160301|DRUG|Acetaminophen|IV
48145888|NCT02160301|DRUG|Celecoxib|PO
48145889|NCT02160301|DRUG|Dexamethasone|IV
48145890|NCT02160301|DRUG|Oxycodone|PO
48145891|NCT02356874|BEHAVIORAL|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
48356753|NCT05675124|DEVICE|Needlescopic laparoscopic adrenalectomy|Compared with traditional laparoscopic surgery using 5-12 mm instruments, the wound of needlescopic laparoscopic surgery is smaller. Postoperative pain and recovery are also better than traditional laparoscopic surgery.
48356754|NCT05675124|DEVICE|conventional laparoscopic adrenalectomy|conventional laparoscopic adrenalectomy
48356755|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
48356756|NCT01925014|DIAGNOSTIC_TEST|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
47988889|NCT04767854|BEHAVIORAL|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
47988890|NCT04767854|OTHER|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
48145892|NCT01648114|OTHER|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
48356757|NCT02177942|OTHER|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
48356758|NCT02177942|OTHER|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
48356759|NCT00435929|DRUG|Ritonavir|100mg po bid
48356760|NCT00435929|DRUG|saquinavir [Invirase]|1000mg po bid
48356761|NCT00533780|PROCEDURE|Healing Touch|A gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy.
47988891|NCT04767854|OTHER|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
47988892|NCT01132157|DRUG|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
47988893|NCT01132157|DRUG|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
48145893|NCT04907617|OTHER|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.
48145894|NCT04907617|OTHER|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
48145895|NCT04907617|OTHER|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
48145896|NCT04907617|OTHER|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
48668168|NCT05639010|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
48145897|NCT00525616|DRUG|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
48668169|NCT05101070|DRUG|S-531011|Administered by intravenous infusion
48668170|NCT05101070|DRUG|pembrolizumab|Administered by intravenous infusion
48668171|NCT01864434|DEVICE|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
48668172|NCT01864434|DEVICE|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
47988894|NCT03305198|BIOLOGICAL|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
47988895|NCT04834947|PROCEDURE|prone position|Choice of prone positioning a patient is at the discretion of the anesthesia physician.
47988896|NCT04512209|PROCEDURE|MRI|"Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity)."
47988897|NCT00705107|BIOLOGICAL|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
47988898|NCT00705107|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
47988899|NCT06473259|DRUG|Docetaxel|6 courses of docetaxel 75 mg/sqm iv
48145898|NCT02815345|DEVICE|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
48145899|NCT00838045|DEVICE|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch \& Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
48145900|NCT02296307|OTHER|Blood test: CA-125 biomarker|"* CA-125 biomarker blood test at visit 1, day 1.~* CA-125 biomarker blood test at visit 2, week 6."
48145901|NCT02296307|OTHER|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
47988900|NCT06473259|DRUG|Apalutamide Oral Tablet|240 mg /daily orally
47988901|NCT06473259|DRUG|Enzalutamide Oral Tablet|600 mg /daily orally
47988902|NCT06473259|DRUG|Abiraterone acetate tablets|1000 mg /daily orally
47988903|NCT06473259|DRUG|Darolutamide Oral Tablet|600 mg/daily orally
47988904|NCT06473259|RADIATION|radiotherapy|radical radiotherapy on primary tumor
48145902|NCT02296307|OTHER|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
48145903|NCT02868983|OTHER|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
48668173|NCT05847634|DEVICE|Masimo O3 NIRS cerebral oximetry and SedLine processed EEG|Non-invasive neuromonitoring device for observational study
48668174|NCT04089514|DRUG|Adalimumab|Administered as specified in the treatment arm
48668175|NCT01580228|DRUG|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m\^2 on Day 1, 10 mg/m\^2 on Day 8, and 14 mg/m\^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
48668176|NCT01580228|DRUG|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
48668177|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
48668178|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
48668179|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
48668180|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
48145904|NCT05999448|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
48145905|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Individual|CICBT-Individual will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
48145906|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Group|CICBT-Group will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
48145907|NCT05999448|BEHAVIORAL|Dialectical Behavioral Therapy (DBT)|DBT will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
48145908|NCT05999448|BEHAVIORAL|Durand Sleep Intervention|Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.
48145909|NCT05999448|BEHAVIORAL|RUBI Intervention|RUBI will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
48145910|NCT05999448|BEHAVIORAL|Naturalistic Communication Intervention (NCI)|NCI will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
48145911|NCT05999448|BEHAVIORAL|Self-Guided Resources|Participants will be provided a self-guided resource notebook that includes 12 weeks of content that parallels the topics examined in other support programs (child behavior management, child sleep, child communication, caregiver mental health, caregiver health behaviors, community connection)
48356762|NCT04170491|DIAGNOSTIC_TEST|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
48356763|NCT04844892|DEVICE|Lungpacer PROTECT Diaphragm Pacing Therapy|PROTECT diaphragm pacing therapy is intended to stimulate the diaphragm to preserve and improve inspiratory muscle strength in mechanically ventilated patients.
48668181|NCT03170375|BEHAVIORAL|Performance of WHEELS-I in promoting DASH/SRD adoption|Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.
48668182|NCT03170375|BEHAVIORAL|Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors|Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
48668183|NCT00735657|DEVICE|needle|Peribulbar blockade with standard (25 mm) needle
48668184|NCT00735657|DEVICE|needle|Peribulbar blockade with short (12.5 mm) needle
48668185|NCT00735657|PROCEDURE|Pars Plana Vitrectomy|Peribulbar block
48668186|NCT06186609|DRUG|PD-1 inhibitor 200mg per three to four weeks, for one year|"PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction."
48668187|NCT02911727|PROCEDURE|Fast-track discharge|As described above
47988905|NCT06473259|DRUG|Triptorelin|3,75 mg im/4 w
47988906|NCT03663725|DRUG|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
47988907|NCT03663725|DRUG|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
47988908|NCT02166554|OTHER|Saline|On the day of initial surgery
47988909|NCT02166554|DEVICE|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
47988910|NCT04020393|PROCEDURE|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
47988911|NCT00000901|DRUG|Indinavir sulfate|
47988912|NCT00000901|DRUG|Lamivudine|
47988913|NCT00000901|DRUG|Stavudine|
47988914|NCT03158051|BEHAVIORAL|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
47988915|NCT03158051|BEHAVIORAL|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
47988916|NCT05003453|DRUG|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
48668188|NCT01510093|DRUG|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
48668189|NCT02095106|DEVICE|Waterproof Cast|
48668190|NCT02095106|DEVICE|Traditional cast|
48145912|NCT05999448|BEHAVIORAL|Participation Enhancement Intervention (PEI)|"A standardized PEI intervention will be conducted by trained peer coaches who are also rare disorder caregivers. Each peer coach will work with their clients to complete a Change Plan Worksheet and will complete two booster sessions at midpoint and end of treatment. Coaches will also meet with their clients after follow-up data are complete to support connection back to community resources and patient-specific rare disorder communities."
48145913|NCT00917098|BEHAVIORAL|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
48145914|NCT00917098|BEHAVIORAL|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
48145915|NCT01890278|RADIATION|Whole Brain IMRT|
48506268|NCT05871723|OTHER|Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound|o measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.
48506269|NCT05871723|OTHER|Berg Balance Scale|The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56. The Berg Balance Scale is commonly used in clinical and research settings to assess balance impairment and monitor changes in balance over time, particularly in individuals with neurological conditions such as stroke. The test has good reliability and validity and is considered a gold standard for assessing balance in these populations.
48668191|NCT02286895|BIOLOGICAL|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
48668192|NCT02286895|BIOLOGICAL|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
48668193|NCT02286895|BIOLOGICAL|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
48668194|NCT02286895|BIOLOGICAL|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
48668195|NCT05655767|OTHER|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
48356764|NCT00004654|DRUG|soy protein isolate|
48506270|NCT00272051|DRUG|SR57746A|
48506271|NCT00203710|DEVICE|Concentric Retriever Device|
47988917|NCT05003453|DRUG|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
47988918|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
47988919|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
48145916|NCT01890278|RADIATION|Conventional Whole Brain RT|
48506272|NCT01932723|BEHAVIORAL|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
48506273|NCT04917471|DIETARY_SUPPLEMENT|Beet root juice|70 ml bid
48506274|NCT04917471|DIETARY_SUPPLEMENT|Placebo juice|70 ml bid
47988920|NCT01395433|DRUG|Escitalopram|1 x 20 mg, single dose
48356765|NCT05433233|BEHAVIORAL|Walking|Participants will perform 3,000 additional steps/day on 5 days/week.
48356766|NCT05433233|OTHER|HAPA Behavior Change Counseling|Structured dialogue for initiating behavior change.
48356767|NCT04754724|DIAGNOSTIC_TEST|GIMate|Use of GIMate to detect lactose malabsorption
48356768|NCT04754724|DIAGNOSTIC_TEST|H2 Check|Use of H2 Check to detect lactose malabsorption
48356769|NCT01599611|PROCEDURE|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
48506275|NCT01275430|DEVICE|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
47988921|NCT05874661|OTHER|External Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an external focus being thinking about a target or outcome in the environment.
48356770|NCT06058338|BEHAVIORAL|Produce Prescription|Produce prescriptions mitigate health and food access inequities by partnering with healthcare providers to prescribe fruits and vegetables via financial incentives to patients experiencing food insecurity, low income, and/or chronic disease(s) risk.
48668196|NCT02259816|DRUG|Telmisartan|
48668197|NCT02259816|DRUG|Amlodipine|
48668198|NCT01823289|DRUG|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
48668199|NCT02230345|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
48668200|NCT02230345|DIETARY_SUPPLEMENT|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
48668201|NCT02877017|BEHAVIORAL|Family safety reporting intervention|family safety reporting intervention for families and providers
48668202|NCT00871026|PROCEDURE|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
48668203|NCT00871026|PROCEDURE|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
47988922|NCT05874661|OTHER|Internal Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an internal focus being thinking about what one's body is doing.
47988923|NCT05009940|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
47988924|NCT04022720|PROCEDURE|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
47988925|NCT04291391|OTHER|North American-type diet|All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
47988926|NCT02742987|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily
47988927|NCT02742987|DRUG|Clopidogrel|Clopidogrel 150 mg once daily
47988928|NCT02742987|DRUG|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
47988929|NCT00483379|BIOLOGICAL|alglucosidase alfa|intravenous infusion
48668204|NCT04211363|DRUG|Roflumilast 0.3% cream|Roflumilast 0.3% cream for topical application.
48668205|NCT04211363|DRUG|Vehicle Cream|Vehicle cream for topical application.
48668206|NCT04328389|BEHAVIORAL|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
48668207|NCT04328389|PROCEDURE|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
48668208|NCT04744584|OTHER|Medication reconciliation|MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
48668209|NCT04744584|OTHER|Medication reconciliation|After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
48668210|NCT06142864|OTHER|Data collection|Data collection
48668211|NCT04767711|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri with cholecalciferol compared to cholecalciferol only.
48668212|NCT04767711|DRUG|Prednisolone|Oral glucocorticoid 25 mg daily for 7 days.
48668213|NCT04807738|DEVICE|"Neuroproprioceptive facilitation and inhibition in virtual reality"|"The 110 outpatients will be randomized into groups: First arm, individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) in a real environment and the second arm, the same therapy in virtual reality environment. All participants will undergo 15 sessions, 60 minutes each, twice a week in a period of two months.~The therapy in a second, interventional group, uses virtual reality and new software that was developed specifically for inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The software allows immediate feedback and moreover, movement is corrected by a present therapist. Evaluation of speed and performance quality might be extracted from the software of virtual reality."
48668214|NCT04807738|OTHER|"Neuroproprioceptive facilitation and inhibition"|The first arm of the study will consist of a physiotherapeutic approach based on neurophysiological principles using proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) approaches. MPAT makes use of particular motor patterns that evolve in postural control development. The repetition of activated programs, a set of stimuli, applied to change the posture with anatomical centration of the joint under various conditions in leading to better support of postural stabilization while seated, while getting up, stepping forward, and standing, in order to teach the patients to use the acquired motor skills automatically in daily life. PNF is a method used for learning effective movement patterns with high biomechanical effectiveness based on repetitive stimulation of cooperating alfa-motoneurons and proprioceptors in muscle, tendons and joint capsules. Therapy will be individualized and led in the standard face-to-face regiment.
48668215|NCT06131788|BEHAVIORAL|Educational hand hygiene intervention|The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
48668216|NCT04358406|DRUG|Recombinant human plasma gelsolin (Rhu-pGSN)|Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
48668217|NCT04358406|OTHER|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
48668218|NCT00153660|DRUG|Celecoxib(drug)|Celecoxib 100 mg bd
48668219|NCT00153660|DRUG|Naproxen(drug)|Naproxen 500 mg bd
48668220|NCT02977078|BEHAVIORAL|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
48668221|NCT02977078|DEVICE|Inhaler casing|Monitors inhaler use
48668222|NCT02977078|DEVICE|Mobile application|Mobile application software linked to inhaler casing
48668223|NCT04943237|DRUG|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
48668224|NCT04943237|DRUG|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
48668225|NCT02972996|OTHER|Blueberry|22 g freeze-dried whole blueberry powder
48668226|NCT02972996|OTHER|Placebo|22 g placebo blueberry powder
48668227|NCT02070653|DRUG|Ticagrelor|
48668228|NCT02070653|DRUG|Placebo|
48668229|NCT05229016|BEHAVIORAL|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
48668230|NCT06074432|OTHER|Emergency Colorectal Resection|Patients underwent resection due to colorectal carcinoma in emergency surgery
48668231|NCT05228418|DRUG|Naltrexone Pill|Naltrexone oral bridge to IM naltrexone maintenance therapy
48668232|NCT01887717|DEVICE|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
47988930|NCT03178773|BEHAVIORAL|TExT-MED|messages designed to inspire motivation and behavior change
48506276|NCT01275430|OTHER|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
48668233|NCT01887717|DRUG|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
48668234|NCT02030132|BEHAVIORAL|Feedback compared to 75th percentile|
48668235|NCT02030132|BEHAVIORAL|Forgiveness|
48668236|NCT02030132|BEHAVIORAL|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
48668237|NCT02030132|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
48668238|NCT01347814|DRUG|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
48668239|NCT01347814|DRUG|Placebo|Homeopathic (Sugar) pill-Placebo
48668240|NCT03181191|OTHER|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
48668241|NCT02185300|DRUG|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
48668242|NCT02185300|DRUG|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
48668243|NCT05013554|DRUG|SAR443216 IV|Pharmaceutical form: Powder for solution; Route of administration: IV infusion
48668244|NCT05013554|DRUG|SAR443216 SC|Pharmaceutical form: Powder for solution; Route of administration: SC injection
48668245|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
48668246|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
48668247|NCT00961038|DRUG|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
48668248|NCT01469247|RADIATION|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
48668249|NCT04594746|DRUG|Amiodarone Hydrochloride|Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food
47988931|NCT03178773|BEHAVIORAL|FANS|SMS delivered messages to family members to improve social support
48506277|NCT02207712|DEVICE|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
48506278|NCT02207712|DRUG|Ranibizumab|Standard ranibizumab treatment only
48506279|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to hemodynamic parameters|Patient who will be adjusted according to hemodynamic parameter
48506280|NCT06558149|PROCEDURE|Those whose opioids were adjusted according to NOL monitoring|Patient who will be adjusted according to NOL monitoring
48506281|NCT03558061|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
48506282|NCT04829058|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures that were performed in subjects within this study are identical to the surgical procedures the subjects would have received as part of SOC.
48506283|NCT01470495|OTHER|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
48506284|NCT01470495|OTHER|RFA|treat Recurrent HCC with RFA
48506285|NCT05316311|DEVICE|CERENOVUS ENTERPRISE 2 Intracranial Stent|CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.
47988932|NCT04890327|OTHER|Web-based family health history tool|Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
47988933|NCT03006159|DRUG|SHR0534|
48356771|NCT06379672|OTHER|Resonance breathing|Resonant breathing was used on the subjects, using nasal inhalation and oral exhalation, for a total of 12 weeks.
48356772|NCT05637567|DRUG|Acetylsalicylic acid|100 mg per os once daily
48356773|NCT05637567|DRUG|Placebo|Placebo pill per os once daily
48356774|NCT03391375|BIOLOGICAL|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
48668250|NCT04594746|DRUG|Placebo|Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
48668251|NCT02384421|DEVICE|Adaptive DBS (Activa PC+S Neurostimulator)|
48668252|NCT02384421|DEVICE|Continuous DBS (Activa PC+S Neurostimulator)|
48668253|NCT04714593|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
48668254|NCT04796584|OTHER|Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus|mRNA vaccination for SARS-CoV-2 is not provided by the study
48668255|NCT04457024|OTHER|classification statistics|Without any intervention
48668256|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (meta-cognitive imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of meta-cognitive imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
48668257|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (Imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
48668258|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (promoting positive imagery de novo)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of promoting positive imagery de novo.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
48688052|NCT03645941|BEHAVIORAL|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
47988934|NCT03006159|DRUG|Placebo|
48356775|NCT05391412|DRUG|Fibrinogen Concentrate Human|Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.
48145917|NCT03564184|BEHAVIORAL|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
48145918|NCT03564184|BEHAVIORAL|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
48145919|NCT03564184|OTHER|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
48145920|NCT05934175|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
48145921|NCT05934175|BEHAVIORAL|Weekly delivered prolonged exposure|Weekly delivered prolonged exposure sessions for 15 weeks
48145922|NCT02055079|DRUG|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
48145923|NCT02055079|DRUG|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
48145924|NCT00204399|BEHAVIORAL|Telephone counseling support|
48145925|NCT04661774|OTHER|reflexology massage|reflexology massage of the foot zone implicated in diaphragm stimulation
48145926|NCT04661774|OTHER|sham massage|traditional massage of the foot
48145927|NCT03488498|OTHER|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
48145928|NCT02626117|DEVICE|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
48145929|NCT02626117|DEVICE|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
48356776|NCT00764322|DRUG|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
48356777|NCT00764322|GENETIC|gene expression analysis|Genetic analysis of blood sample.
48356778|NCT00764322|OTHER|pharmacogenomic studies|Genetic analysis of blood sample.
48356779|NCT00764322|OTHER|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
48356780|NCT00764322|PROCEDURE|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
48356781|NCT02220660|DRUG|BI 1744 CL|
48356782|NCT02220660|DRUG|BI 54903 XX|
48356783|NCT02220660|DRUG|BI 1744 CL + BI 54903 XX FDC|
48356784|NCT02220660|DRUG|Placebo|
48356785|NCT03934515|OTHER|etCO2|"At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. The authors will find the threshold value of etCO2 collected when the NGT is well positioned in trachea. The study manager is not directly involved in the measurement and recording of etCO2 values."
47988935|NCT04092101|OTHER|Cigarettes with varying nicotine content|1) Altering the nicotine content of the tobacco research cigarette
47988936|NCT04092101|OTHER|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
48688053|NCT02384044|DEVICE|Crest® Sensi-Stop™ Strips|
47988937|NCT05364931|DRUG|Cotadutide|Cotadutide administered subcutaneously once daily
47988938|NCT05364931|DRUG|Placebo|Placebo administered subcutaneously once daily
48688054|NCT02384044|DEVICE|Colgate® Sensitivity Relief Pen|
48145930|NCT03462966|DRUG|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
48145931|NCT04681209|BEHAVIORAL|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
48356786|NCT03934515|OTHER|pH|"At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. The authors will find the threshold value of pH collected when the NGT is positioned in the esophagus and in the stomach. The study manager is not directly involved in the measurement and recording of pH values."
48356787|NCT04833049|DRUG|TAK-994 Oral Tablet|TAK-994 tablet.
48356788|NCT04833049|DRUG|[14C]TAK-994 Intravenous Infusion|\[14C\]TAK-994 intravenous infusion.
48668259|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (visuospatial working memory tasks)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of visuospatial working memory tasks.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
48668260|NCT04293198|DEVICE|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
48668261|NCT04293198|DEVICE|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
48356789|NCT04833049|DRUG|[14C]TAK-994 Oral Suspension|\[14C\]TAK-994 oral suspension.
48668262|NCT04345055|OTHER|Treatment of the lumbar fasciae|Treat the lumbar facial with a manual technique
48668263|NCT04345055|OTHER|Placebo intervention|Introduce in a machine off
47988939|NCT05566990|BIOLOGICAL|LIV-GAMMA SN Inj.10%|LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
47988940|NCT01967251|DRUG|Udenafil|Udenafil tablets
47988941|NCT01967251|DRUG|Placebo|Udenafil placebo-matching tablets
48356790|NCT05823389|PROCEDURE|Re-instrumentation with flapless Emdogain application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive flapless administration of EMD
48668264|NCT01561833|DRUG|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
48668265|NCT00437749|DRUG|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
48668266|NCT00437749|OTHER|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
48668267|NCT04662164|DRUG|hepalatide|3 different dosage will be given sequentially to T2D patients
48668268|NCT04397380|DEVICE|Thermography|Measure Temperature using Thermal Camera
48668269|NCT04397380|DEVICE|Tympanic Temperature|Measure Temperature using Tympanic Temperature
48668270|NCT03279926|BEHAVIORAL|PLAY|Activity trackers + curriculum information
48668271|NCT03279926|BEHAVIORAL|PLAY Parents|Enhanced parental engagement
48668272|NCT03279926|BEHAVIORAL|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
48668273|NCT04991220|PROCEDURE|Preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
48668274|NCT02040714|PROCEDURE|Osteotomy + Long Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that requires patient to maintain non-weight bearing for 6 months.
47988942|NCT03362073|DRUG|Ketamine|"Application of ketamine using continuous intravenous infusion method during 5 days~* Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~* Dose schedule: 0.05mg/kg/hr -\> 0.10mg/kg/hr -\> ... -\> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)"
48356791|NCT05823389|PROCEDURE|Re-instrumentation with placebo application|Teeth with deep probing pocket depths were randomized to receive re-instrumentation with adjunctive placebo application
48356792|NCT00727350|RADIATION|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
48356793|NCT02605889|OTHER|Laser acupuncture|Laser acupuncture
48356794|NCT01566981|PROCEDURE|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
48356795|NCT02869451|DRUG|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
48668275|NCT02040714|PROCEDURE|Osteotomy + Short Term Non-Weight Bearing|Surgical procedure that improves femoral head containment, plus a post-operative protocol that allows early return to function after 6 weeks of non-weight bearing.
48668276|NCT02040714|PROCEDURE|Nonoperative Observation|Group will not undergo any surgical or invasive procedures during course of treatment.
48668277|NCT02040714|PROCEDURE|Multiple Epiphyseal Drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
48668278|NCT05941286|DEVICE|CGM system with both glucose predictive alerts and threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with both glucose predictive alerts and threshold alerts on
48668279|NCT05941286|DEVICE|CGM system with only glucose threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with only glucose threshold alerts on
48668280|NCT05941286|DEVICE|CGM system with glucose alerts off|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
48668281|NCT01215851|DRUG|PA-824|200 mg tablet, once daily for 14 days
48668282|NCT01215851|DRUG|Pyrazinamide|Dosed by Weight
48668283|NCT01215851|DRUG|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
48668284|NCT01215851|DRUG|Rifafour|Rifafour e-275
48668285|NCT01215851|DRUG|Moxifloxacin|moxifloxacin 400 mg
48668286|NCT06026865|DIETARY_SUPPLEMENT|S-Adenosyl-L-methionine (SAMe)|S-adenosyl-L-methionine 1200 mg/daily as 2400mg S-Adenosyl-L-methionine disulfate tosylate
48668287|NCT06026865|OTHER|Placebo|Placebo of identical appearance, smell and taste, with the same schedule.
48668288|NCT03313973|PROCEDURE|with self stretching same muscle|with self stretching
48668289|NCT03313973|PROCEDURE|with self stretching of forearm muscles|without self stretching
48668290|NCT05666830|DEVICE|Lando® artificial dermal regeneration matrix|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
48668291|NCT03899350|OTHER|No intervention|No intervention
48668292|NCT04814914|OTHER|KB109 + Self Supportive Care|KB109 is a novel glycan
47988943|NCT06226233|OTHER|Juniver program|The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
48356796|NCT02869451|DRUG|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
47988944|NCT06336460|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Under sterile technique, physician will identify relevant landmarks including the femoral artery, femoral vein, femoral nerve, ileopubic eminence (IPE), anterior inferior iliac spine (AIIS), psoas tendon (PT). Target area is bony space between AIIS and IPE adjacent to PT.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting fascial plane below the psoas tendon, above ilium bone. Landmark lies between the AIIS and IPE, just lateral to psoas tendon.~As needle tip reaches target, small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, lifting the psoas tendon from ilium, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush line of remaining anesthetic. Needle will then be withdrawn."
48356797|NCT02869451|DRUG|Nicotine polacrilex|Initiated at smoking quit date.
48668293|NCT04814914|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
48356798|NCT02869451|DRUG|nicotine lozenge|Initiated at smoking quit date.
48356799|NCT02869451|BEHAVIORAL|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
48356800|NCT02869451|BEHAVIORAL|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
48668294|NCT00624845|DRUG|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
48668295|NCT00624845|DRUG|Vehicle|Maximum of 6 bags of vehicle irrigation solution
48668296|NCT01206127|OTHER|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
48668297|NCT01206127|OTHER|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
48668298|NCT01690754|OTHER|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
48668299|NCT01541371|DRUG|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
48668300|NCT00854360|DRUG|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
48668301|NCT00854360|DRUG|Placebo|HFA Vehicle Aerosol
48668302|NCT02966483|PROCEDURE|TaTME|Transanal Total Mesorectal Excision
48668303|NCT02966483|PROCEDURE|LpTME|Conventional Laparoscopic Total Mesorectal Excision
48668304|NCT00640003|DRUG|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
48668305|NCT00640003|DRUG|Placebo|placebo drug
48668306|NCT03410654|DRUG|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
48668307|NCT05223673|BIOLOGICAL|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
48356801|NCT05235802|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) (including functional MRI)|"Patients will undergo magnetic resonance imaging including the following protocols:~* 3D T1w MPRAGE~* 3D T2w FLAIR SPACE~* 3D T2w SPACE~* 3D T1w PSIR (cortical visualization)~* 2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~* Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~* 3D SWI~* DWI b1000 32 directions and b3000 64 directions."
48668308|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
48668309|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
48668310|NCT05469178|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
48668311|NCT05469178|DRUG|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as part of CIT every 3 weeks.
48668312|NCT05469178|DRUG|Pemetrexed|Pemetrexed will be administered as an IV infusion as part of CIT every 3 weeks.
48668313|NCT05469178|DRUG|Carboplatin|Carboplatin will be administered as an IV infusion as part of CIT every 3 weeks.
48668314|NCT03217617|BIOLOGICAL|Direct intravenous injection of ivlv-X1 lentiviral vector|ivlv-X1 LV intravenous injection at a dose of \~1x10e9/kg body weight.
48668315|NCT01942109|DRUG|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
48668316|NCT01942109|DRUG|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
48668317|NCT02847897|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
48668318|NCT00173719|DEVICE|Standard cane|
48668319|NCT00980044|DRUG|Tramadol|Oral Medication
48668320|NCT00980044|DRUG|Placebo|Oral Medication
48668321|NCT02421094|DRUG|GR-MD-02|GM-MD-02 active
47988945|NCT06336460|PROCEDURE|Fascia Iliaca Compartment (FIC) Block for Patients with Isolated Hip Fractures|"Under sterile technique, physician will identify relevant landmarks, including femoral artery, femoral vein, femoral nerve, iliacus muscle with overlying fascia iliaca.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting the fascial plane above iliacus muscle.~As needle tip reaches the target, a small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush the line of remaining anesthetic. The needle will then be withdrawn."
47988946|NCT01581307|DRUG|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
47988947|NCT01581307|DEVICE|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
48668322|NCT02421094|DRUG|Placebo|Placebo
48668323|NCT02639390|DEVICE|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
48668324|NCT02639390|OTHER|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
48668325|NCT01092884|DIETARY_SUPPLEMENT|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
48668326|NCT01092884|OTHER|Placebo|This placebo capsule will be taken orally three times daily
47988948|NCT02232633|DRUG|BBI503|
48356802|NCT05235802|DIAGNOSTIC_TEST|Blood sampling (serum/plasma preparation)|Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.
48356803|NCT05235802|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF)|CSF will be analyzed for inflammatory and neurodegenerative biomarkers.
48668327|NCT04228458|DEVICE|Thermal Imaging|Testing the effectiveness of using a Thermal Imaging camera in participants with Juvenile Arthritis.
48668328|NCT00444106|DRUG|Artesunate-mefloquine|
48668329|NCT00444106|DRUG|Atovaquone-proguanil|
48668330|NCT00444106|DRUG|Artemether-lumefantrine|
48668331|NCT00986882|DRUG|SAF312A|
48668332|NCT00986882|DRUG|Placebo|
48668333|NCT00986882|DRUG|Ibuprofen|
48668334|NCT04313465|OTHER|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
48668335|NCT04484857|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
48668336|NCT00147329|DRUG|MM-093|
48668337|NCT04906694|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
48668338|NCT04906694|DRUG|Placebo|Diluent solution
48668339|NCT03323164|DRUG|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
48668340|NCT03323164|DRUG|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
48668341|NCT03969173|PROCEDURE|applying PEEP3|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
48668342|NCT03969173|PROCEDURE|applying PEEP6|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
48668343|NCT03969173|PROCEDURE|applying PEEP9|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
48668344|NCT00138684|PROCEDURE|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
48668345|NCT00642486|OTHER|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
48668346|NCT00642486|OTHER|Standard polysomnography (PSG)|laboratory-based testing
48668347|NCT00273884|DRUG|Amonafide L-Malate|
48668348|NCT00273884|DRUG|Cytarabine|
48668349|NCT00960089|DEVICE|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
48668350|NCT06487520|OTHER|group watching hot environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Peaceful mountain snow image was shown. This image includes a cold winter day.~Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
48668351|NCT06487520|OTHER|group watching cold environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Deep space relaxation image was shown. This image contains a hot environment image with explosions in space.Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
48668352|NCT02411409|BEHAVIORAL|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
48668353|NCT06230809|BEHAVIORAL|Web-based self-help|Web-based self-help with 5 modules, lasting 5 weeks.
48668354|NCT05203380|DRUG|dupilumab|Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
48668355|NCT04031729|DRUG|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
48668356|NCT04031729|DRUG|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
48668357|NCT05157360|DRUG|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
48668358|NCT05157360|DRUG|Placebo|normal saline solution
47988949|NCT06219850|OTHER|No intervention|The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
48668359|NCT05340413|DRUG|Olaparib|300mg twice daily
48668360|NCT03201120|BEHAVIORAL|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
48668361|NCT03201120|BEHAVIORAL|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
48668362|NCT04784156|PROCEDURE|Subtalar (Talocalcaneal) Arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
48668363|NCT04784156|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
48668364|NCT03659578|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
48145932|NCT04681209|BEHAVIORAL|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
48356804|NCT05235802|DIAGNOSTIC_TEST|Clinical assessments / questionnaires|"* Glasgow Outcome Scale Extended (functional outcome)~* Short-Form 36 (quality of life),~* EQ-5D (quality of life),~* Mini-Mental State Extended (MMSE) (mental state assessment).~* Barthel Index (daily living disabilities),~* Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~* Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed."
48356805|NCT03429166|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation|A non-trauma-focused treatment
48668365|NCT03659578|RADIATION|split-course radiotherapy|Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost
48668366|NCT03659578|DRUG|thymosin alpha 1|subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
48668367|NCT03834896|OTHER|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
48668368|NCT00140140|DRUG|ABI-007|Weekly intravenous infusions over 30 minutes.
48668369|NCT00140140|DRUG|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
48668370|NCT00140140|DRUG|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
48668371|NCT00140140|BIOLOGICAL|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
48668372|NCT01172028|DRUG|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
48668373|NCT01172028|DRUG|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
48668374|NCT00279214|DRUG|drotrecogin alfa (activated)|
48668375|NCT04015258|DIETARY_SUPPLEMENT|Blueberries|fresh spanish blueberries
48668376|NCT04015258|DIETARY_SUPPLEMENT|Blueberry powder|freeze-dried blueberry powder
48668377|NCT04015258|DIETARY_SUPPLEMENT|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
48668378|NCT04614324|DEVICE|RhinAer ARC Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG815), which is a cleared (FDA - K192471) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. RhinAer has CE Marking in EU. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy was cleared for use in the US (FDA - K162810) and has CE Marking in the EU (CE639608).
48668379|NCT05441514|DRUG|Cobimetinib|Given PO
48668380|NCT05441514|DRUG|Enasidenib Mesylate|Given PO
48668381|NCT03037970|DRUG|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
48668382|NCT03037970|OTHER|Placebo|Collagen Wound Dressing wetted with buffer.
47988950|NCT04892043|BIOLOGICAL|SQZ-AAC-HPV|Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16
48356806|NCT03429166|BEHAVIORAL|Present Centered Therapy|A non-trauma-focused treatment
48668383|NCT01597817|OTHER|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
48668384|NCT01597817|OTHER|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
48668385|NCT02589821|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
48668386|NCT02589821|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
47988951|NCT04892043|DRUG|Ipilimumab|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
48668387|NCT04734860|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
48668388|NCT04734860|DRUG|Placebo|Diluent solution
48668389|NCT02107612|DEVICE|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
48668390|NCT02107612|OTHER|Denture|
47988952|NCT04892043|DRUG|Nivolumab|Programmed cell death 1 (PD-1) blocking antibody
47988953|NCT01194479|DRUG|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
47988954|NCT01194479|OTHER|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
47988955|NCT04759703|DRUG|Pramipexole|0.25 mg pramipexole tablets
47988956|NCT04759703|DRUG|Placebo|Matching placebo tablets
48145933|NCT04635657|OTHER|Long-term Cognitive testing|These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
47988957|NCT04994990|DRUG|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
48145934|NCT03155399|OTHER|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
48145935|NCT03155399|OTHER|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
48145936|NCT02680145|DEVICE|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
48145937|NCT02771366|DRUG|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
48145938|NCT02771366|OTHER|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
48145939|NCT03738592|OTHER|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
48145940|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
47988958|NCT04994990|DRUG|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
48356807|NCT02296528|DEVICE|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
48356808|NCT05049122|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
48668391|NCT03429088|BEHAVIORAL|Motivational interviewing telephone counseling|
48668392|NCT04073056|DRUG|Bupivacaine|Bupivacaine Hcl 0.25% Inj
48668393|NCT02637986|DIETARY_SUPPLEMENT|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
47988959|NCT01673451|DRUG|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
47988960|NCT01673451|DRUG|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
47988961|NCT04862845|DRUG|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
47988962|NCT04862845|DRUG|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
47988963|NCT04862845|DRUG|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
47988964|NCT02566083|DEVICE|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
48356809|NCT05032287|DRUG|Tamsulosin|Tamsulosin 0.4 mg once daily
48356810|NCT05032287|DRUG|Placebo|Placebo once daily
48356811|NCT06100367|COMBINATION_PRODUCT|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
48668394|NCT02637986|OTHER|Placebo - capsule with no active ingredient|2 capsules will be given per day
48668395|NCT03537443|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
48668396|NCT03564886|DRUG|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
48668397|NCT03564886|DRUG|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
48668398|NCT04256447|DIAGNOSTIC_TEST|Urinary sodium concentrations|The urinary sodium excretion was measured using an immunochemical methodology
47988965|NCT02566083|DEVICE|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
47988966|NCT04803669|PROCEDURE|Intrument-assisted soft tissue mobilization technique|This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
47988967|NCT04803669|PROCEDURE|Conventional Treatment|Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
47988968|NCT00864149|DRUG|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
48145941|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
48145942|NCT04388748|BEHAVIORAL|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
48145943|NCT04097509|BIOLOGICAL|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
48145944|NCT04097509|BIOLOGICAL|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
48145945|NCT04097509|OTHER|control|no application
48145946|NCT02860702|OTHER|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
47988969|NCT00864149|DRUG|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
48145947|NCT02860702|OTHER|Human/Bovine Milk|Bovine milk derived fortification
48145948|NCT00053300|DRUG|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
48145949|NCT00053300|PROCEDURE|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
48145950|NCT03933241|BEHAVIORAL|nasal irrigation|nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
48145951|NCT05503485|BEHAVIORAL|Existential group treatment|The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
48145952|NCT05503485|BEHAVIORAL|Supportive telephone calls|"The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself."
48145953|NCT06510959|OTHER|Digital course|The course aims to enhance participants' digital skills concerning the use of smartphones, specifically focusing on daily utility apps such as email apps, eGov apps, mobility apps, etc. The course is structured into the following ten 90-minute weekly lessons.
48145954|NCT01714908|OTHER|Erlotinib w Concurrent Radiotherapy|
48145955|NCT01714908|OTHER|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
48145956|NCT01760005|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
48145957|NCT01760005|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
48356812|NCT02385292|DEVICE|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
48356813|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
47988970|NCT03637972|OTHER|Ventilated cigarettes only|Participants given vouchers that are exchanged for ventilated cigarettes study cigarettes.
48145958|NCT01760005|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
48668399|NCT01645176|DRUG|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
48145959|NCT01760005|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
47988971|NCT03637972|OTHER|Unventilated cigarettes only|Participants given vouchers that are exchanged for unventilated cigarettes study cigarettes.
47988972|NCT03637972|OTHER|Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems|Participants given vouchers that are exchanged for ventilated cigarettes + alternative nicotine delivery systems cigarettes.
47988973|NCT03637972|OTHER|Access to Experimental Marketplace: Unventilated cigarettes + ANDS|Participants given vouchers that are exchanged for unventilated cigarettes + ANDS.
48506286|NCT05187130|OTHER|Mindfulness|60 patients in the mindfulness-based breathing and music therapy group were divided into subgroups of 5 participants each. Each 6-person group started by having participants complete the pretest State Anxiety Inventory, Beck Depression Inventory, and Psychological Well-Being Scale via Survey Monkey. Mindfulness-based breathing and music therapy was applied to each patient group in approximately 45-minute sessions per day. At the end of the session, participants re-filled the posttest State Anxiety Inventory, Work-Related Tension Scale, and Psychological Well-Being Scale. A total of 3 sessions were completed with an interval of two days.
47988974|NCT00656344|OTHER|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
47988975|NCT04959942|OTHER|scapular stabilization exercise|In the supine position, the subject will instruct to take a deep breath to relax the body. In croock-lying position, the subject will raise his dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. In the quadruped position, the subject lifts up his arms alternatively with shoulder abduction and 120 ° flexion. In a sitting position with 90° knee flexion on a stool or bed without back support, the subject held a pair of dumbbells (2 kg) in each hand and laterally lifted them up while maintaining the height of scapulae below 80°. Each stage will instruct to be held for 10 seconds before returning to the starting position and three laps of 10 repetitions with a 30-second break in between will perform. In the sitting position, a mirror will place in front of the patient. The subject will instruct to check and correct his posture by him
47988976|NCT04959942|OTHER|postural correction exercise|The program consisted of two strengthening (deep cervical flexors and scapular retractors) and two stretchings: cervical extensors (sub-occipital muscles) and pectoral muscles). The program was based on a program by Harman and Kendall.
47988977|NCT04959942|OTHER|advice|all subjects will be instructed to maintain normal alignment of the cervical vertebry
47988978|NCT00091273|BIOLOGICAL|incomplete Freund's adjuvant|
47988979|NCT00091273|BIOLOGICAL|ovarian cancer peptide vaccine|
48145960|NCT01760005|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks at escalating doses
48145961|NCT01760005|DRUG|E2814|Administered intravenously in a blinded fashion
48145962|NCT01760005|DRUG|Lecanemab|Administered intravenously
48668400|NCT05270993|BEHAVIORAL|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
47988980|NCT00091273|BIOLOGICAL|sargramostim|
48145963|NCT01760005|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
48668401|NCT05270993|BEHAVIORAL|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
47988981|NCT00091273|BIOLOGICAL|tetanus toxoid helper peptide|
48145964|NCT05719909|BEHAVIORAL|Cognitive Training|8 sessions of web-based cognitive training
48356814|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
48356815|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
47988982|NCT00091273|PROCEDURE|adjuvant therapy|
47988983|NCT04994379|DEVICE|1 mA tDCS|One session with stimulation intensity of 1 mA.
47988984|NCT04994379|DEVICE|1.5 mA tDCS|One session with stimulation intensity of 1.5 mA.
47988985|NCT04994379|DEVICE|Sham tDCS|One session of sham stimulation.
47988986|NCT03914040|OTHER|IPSE program|"1. Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~2. Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours."
47988987|NCT00866411|PROCEDURE|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
47988988|NCT00866411|PROCEDURE|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
48145965|NCT05719909|BEHAVIORAL|Sham Training|8 sessions of web-based sham training
48145966|NCT03121417|BIOLOGICAL|Nivolumab|240 mg given IV
48145967|NCT00994851|DRUG|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
48145968|NCT00994851|DRUG|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
48506287|NCT04854889|DRUG|Decitabine|Demethylating agents
48668402|NCT01115907|DEVICE|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
48668403|NCT01429688|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
48145969|NCT05547724|OTHER|Virtual reality|Virtual reality visit of the birth room, cesarean and pediatric hospitalization department: neonatology and neonatal intensive care
48668404|NCT05222685|BEHAVIORAL|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
48668405|NCT05089292|BEHAVIORAL|Narrative breast health education|Health education program utilizing narrative messages to promote breast cancer screening in Chinese immigrant women will be delivered in a group format in the community
48668406|NCT04232852|DIETARY_SUPPLEMENT|Probiotic mix|The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.
48668407|NCT04232852|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive an identical capsule of maltodextrin.
48506288|NCT06227572|BEHAVIORAL|CATNAP MI|"Three motivational interviewing (MI) sessions will be facilitated by trained MI staff and will focus on improving participants' knowledge about their OSA diagnosis, understanding of sleep health, and increasing PAP use. Sessions will also provide information about health benefits associated with good sleep and will help participants create an action plan regarding their PAP use and indicators of success, when appropriate.~Electronic messaging will be standardized for frequency and content but personalized to participants' preferred mode of delivery. Messages will focus on PAP adherence or non-adherence."
47988989|NCT03296657|DRUG|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
47988990|NCT00811473|DRUG|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
47988991|NCT00811473|DRUG|Placebo|Oral treatment once daily in the evening
47988992|NCT00405587|DRUG|PLX4032|Oral capsules administered BID
47988993|NCT00674453|DRUG|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
47988994|NCT00674453|OTHER|Placebo|Matching placebo tablet given once daily for 2 years
47988995|NCT00326950|DRUG|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
48145970|NCT01189552|BEHAVIORAL|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
48145971|NCT01189552|BEHAVIORAL|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
48145972|NCT06360276|BEHAVIORAL|Seated Exercises|A quasi-experimental research was conducted in the main University Hospital, Alexandria, Egypt. women practiced seated exercises
48145973|NCT06360276|BEHAVIORAL|Psychoeducational Rehabilitation|Women received Psycho-educational Rehabilitation, including mindfulness breathing, problem-solving training, cognitive re-framing technique, and thought stopping.
48145974|NCT06360276|BEHAVIORAL|Routine Care|Women received routine health education in the unit, where nurses provided general instructions about the postoperative activities for women with breast cancer.
48145975|NCT05431322|DRUG|Dexmedetomidine|Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation.
48356816|NCT06425224|DEVICE|Tens therapy|"There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation."
48356817|NCT06425224|DRUG|Dapoxetine placebo|Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.
48356818|NCT06425224|DRUG|Standard treatment (dapoxetine 30 mg as needed)|Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
48668408|NCT04757233|BEHAVIORAL|GlucoType|GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
48668409|NCT06345404|DRUG|Soquelitinib|Tablets
48668410|NCT06345404|DRUG|Placebo|Soquelitinib matching placebo tablets
48668411|NCT01816984|DRUG|PI3K inhibitor BKM120|Given PO
48668412|NCT01816984|BIOLOGICAL|cetuximab|Given IV
48668413|NCT03968874|DEVICE|Light box therapy|The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
48668414|NCT03968874|DEVICE|Negative Ion Generator|The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
48668415|NCT00172809|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
48668416|NCT00172809|DRUG|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
48668417|NCT02141321|DRUG|Misoprostol|
47988996|NCT00502177|BEHAVIORAL|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
47988997|NCT03195543|DIAGNOSTIC_TEST|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
47988998|NCT03195543|DIAGNOSTIC_TEST|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
47988999|NCT03195543|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
47989000|NCT03195543|DIAGNOSTIC_TEST|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
47989001|NCT00445159|DRUG|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
47989002|NCT01002469|OTHER|sodium [1-13C] acetate|
47989003|NCT04339296|DEVICE|Spencer|The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
47989004|NCT01342146|DRUG|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
48668418|NCT02141321|DRUG|Placebo|
48668419|NCT04161664|DRUG|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
48356819|NCT06425224|DEVICE|Placebo therapy|In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
48356820|NCT02505009|DRUG|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
48356821|NCT02505009|DRUG|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
48668420|NCT04722666|DRUG|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
48668421|NCT04722666|DRUG|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
48668422|NCT00164580|BEHAVIORAL|Community-Level Intervention|
47989005|NCT01342146|DRUG|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
47989006|NCT01342146|DRUG|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
47989007|NCT04997993|DRUG|Leflunomide|Leflunomide, 20-50mg PO daily
48668423|NCT03051191|DIAGNOSTIC_TEST|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
48668424|NCT03890510|OTHER|Ringer's Lactate solution|Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
48668425|NCT03890510|PROCEDURE|Spine surgery under general Anesthesia in the prone position|The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
48668426|NCT04561856|DRUG|Dexamethasone|Intravenous 4mg
48668427|NCT04561856|DRUG|Dexamethasone|Perineural 4mg
48668428|NCT04561856|DRUG|Placebo|Normal Saline 2ml
48668429|NCT04167943|DRUG|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
47989008|NCT03124914|OTHER|Neuromuscular tests|Neuromuscular tests
47989009|NCT02278107|DEVICE|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
48145976|NCT01217697|DRUG|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
47989010|NCT02278107|DEVICE|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
47989011|NCT00690092|BIOLOGICAL|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
47989012|NCT01986855|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
48145977|NCT01217697|DRUG|Prednisone\Prednisolone|Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).
48145978|NCT00508144|DRUG|Alimta|500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks
48145979|NCT01984099|DRUG|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
48145980|NCT01984099|DRUG|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
48356822|NCT02505009|DRUG|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
48356823|NCT01428414|DRUG|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
48356824|NCT01428414|DRUG|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
48356825|NCT01428414|DRUG|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
48356826|NCT01428414|DRUG|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
48356827|NCT02638753|OTHER|education|Patients will be educated about pain neurophysiology.
48668430|NCT04682665|DRUG|Icosapent Ethyl Oral Capsule|Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
48668431|NCT04682665|OTHER|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
48668432|NCT04470765|DEVICE|Zida|Transcutaneous Tibial Nerve Stimulation
48668433|NCT00674921|DRUG|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
48668434|NCT00674921|DRUG|Placebo|starch, magnesium stearate, sodium lauryl sulphate
48145981|NCT02318628|DEVICE|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
48145982|NCT02198105|DEVICE|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~1. PTA with Cutting-Balloon (60-120 seconds).~2. PTA with DC-Balloon (60 seconds).~Technical success is defined as~1. no recoil \>30%~2. no dissection \>Type B~3. no stenting \>30% of lesion length."
48145983|NCT00828178|DRUG|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
48145984|NCT00828178|DEVICE|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
48145985|NCT00828178|OTHER|corn starch|3 capsules qd for 12weeks
48145986|NCT01762839|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
48145987|NCT01762839|DRUG|Placebo|Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
48356828|NCT02638753|OTHER|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
48356829|NCT02967172|DRUG|Ropivacaine|
48356830|NCT02967172|DRUG|Epinephrine|
48668435|NCT00624858|DRUG|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise"
48668436|NCT04607343|DEVICE|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
48145988|NCT01762839|DRUG|Moxifloxacin|Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
48145989|NCT01456156|RADIATION|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
48356831|NCT02967172|DRUG|Morphine|
48356832|NCT02967172|DRUG|0.9% sodium chloride solution|
48356833|NCT01087073|BEHAVIORAL|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
48356834|NCT01087073|BEHAVIORAL|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
48356835|NCT01087073|BEHAVIORAL|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
48356836|NCT01087073|BEHAVIORAL|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
48356837|NCT00320619|DRUG|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
48356838|NCT00320619|DRUG|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
48356839|NCT02554201|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
48356840|NCT02554201|DEVICE|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
48356841|NCT05385172|OTHER|No any intervation.|This research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years.
48356842|NCT01707940|DRUG|Ketoconazole|Ketoconazole 400 mg / day
48356843|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
48356844|NCT01707940|DRUG|BI 144807|BI144807 oral solution, intermediate dose
48356845|NCT02837055|DEVICE|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
48356846|NCT02837055|DEVICE|conventional intubation|patients are intubated with a conventional endotracheal tube
48356847|NCT04838587|OTHER|No intervention will be done|No intervention,Only passive surveillance of Diarrhoea cases will be done
48356848|NCT04131127|DEVICE|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
48356849|NCT02901106|DRUG|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
48356850|NCT04764838|OTHER|Yoga|"Breath Awareness Training (5 minutes) Asanas (20 minutes)~* Bending sideways in Mountain Stance~* Standing Pelvic Shaking Warrior Stance II Squatting and malasana (wreath pose) Breath awareness in lotus pose (sitting) Cane pose Fixed Butterfly / Angel Pose~* Sitting wide in Angel Pose Cat Pose Tiger Breath Mudra and meditation (10 minutes)"
48356851|NCT05920109|PROCEDURE|ESP block|Patients in the experimental group will have a continuous Erector Spinae Plane Block within the first 6 hours post-admission, with a continuous 1ml/h infusion of Ropivacaine (2mg/ml) associated with a 25 ml bolus every 6h. The catheter will be used from the trauma bay to the ICU as long as possible with a dedicated infusion pump (with a bolus mode). In case of accidental catheter removal, a second introduction of ESP block catheter is allowed within the first 24 hours. In case of continuous ESP block failure (incidence \< 5% of the total experimental group), patients will be switched to the control group.
48356852|NCT00813774|BIOLOGICAL|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
48356853|NCT00813774|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
48356854|NCT00813774|BIOLOGICAL|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
48356855|NCT04905563|DRUG|Acetaminophen-Hydrocodone|Narcotic
48356856|NCT04905563|DRUG|Acetaminophen and Ibuprofen|Non-narcotic
48356857|NCT03603340|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
48506289|NCT05884294|DEVICE|PowerGlide Pro Midline catheter.|The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
48506290|NCT04963543|OTHER|FID123238|Lubricant applied to the ocular surface
48506291|NCT05938907|OTHER|concentrated growth factor|Implanting concentrated growth factor into the area of root apical bone defect
48506292|NCT05938907|OTHER|bone substitute|Implanting bone substitute into the area of root apical bone defect
48145990|NCT05479565|DIAGNOSTIC_TEST|venous blood sample for determining the value of highly sensitive C-reactive C protein from serum|The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
48145991|NCT00749827|DRUG|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
48145992|NCT00749827|DRUG|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
48145993|NCT02802332|BEHAVIORAL|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
48506293|NCT05938907|COMBINATION_PRODUCT|concentrated growth factor + bone substitute|Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
48145994|NCT01525459|PROCEDURE|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
48145995|NCT01525459|OTHER|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
48145996|NCT00004400|DRUG|testosterone|
48145997|NCT03615404|BIOLOGICAL|CMV-DCs with GM-CSF|CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
48145998|NCT03615404|BIOLOGICAL|Td (tetanus toxoid)|Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
48145999|NCT03410420|DRUG|Pimonidazole hydrochloride|administration of pimonidazole-HCl
48146000|NCT05206994|BEHAVIORAL|Close to Home|Close to Home (C2H), a community mobilization model developed in Boston and adapted for California, is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms. The C2H model guides communities through four phases: 1) Assess, 2) Talk, 3) Build, and 4) Act. C2H mobilizes diverse groups of people residing in a shared geography and linked by social and political ties to engage in joint actions for SV prevention
48146001|NCT01117402|RADIATION|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
48146002|NCT02795741|DEVICE|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
48356858|NCT03603340|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
48356859|NCT02280109|DRUG|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
48356860|NCT02280109|DRUG|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
48668437|NCT04750421|DEVICE|Transillumination Venolux®|Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
48668438|NCT03483948|DRUG|HMPL-523|HMPL-523 tablet
48356861|NCT00542425|DRUG|teriparatide|teriparatide 20 µg subcutaneous daily
48356862|NCT00542425|DRUG|Placebo|Placebo subcutaneous daily
48356863|NCT00542425|DRUG|BA058 20 µg|BA058 20 µg subcutaneous daily
48356864|NCT00542425|DRUG|BA058 40 µg|BA058 40 µg subcutaneous daily
48356865|NCT00542425|DRUG|BA058 80 µg|BA058 80 µg subcutaneous daily
48356866|NCT06183255|OTHER|Observation and evaluation of clinical parameters in the two cohorts|During medical history evaluation, all factors that could negatively affect male fertility, like prevalent comorbidities, previous testis surgery, and any disorder affecting testicular function will be investigated in fertile and infertile men. Moreover, family history will be deeply investigated, including fertility status and prevalence of malignant Non Communicables Diseases. A comprehensive physical examination will be performed on each infertile and fertile man.
48356867|NCT04009252|BEHAVIORAL|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
48506294|NCT05471492|DRUG|Investigational Product|PF-06480605 150 mg
48506295|NCT05471492|DRUG|Placebo|Placebo
48668439|NCT03483948|DRUG|Azacitidine|Azacitidine Injection
48668440|NCT06122441|BEHAVIORAL|Complex lifestyle intervention|The complex lifestyle intervention comprise high-intensity aerobic and strength exercise, behavioral counselling based on Acceptance and Commitment Theory (ACT), and dietary counselling based on Norwegian nutritional guidelines. The different intervention elements are introduced step-wise to reduce initial overload. Participants are progressively transitioned over to the Tromsø municipality and local NGO's, who delivers activities harmonized with the intervention elements. Participants are at this stage also supported by an eTool which digitally reinforces the intervention through web-based information and videos.
48146003|NCT04856384|OTHER|synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations
48668441|NCT06122441|BEHAVIORAL|Physical activity monitoring and recommendations|Wrist-worn activity trackers that are worn throughout the trial, which monitors steps, activity intensity and energy expenditure. Access to Norwegian physical activity guidelines via the Directorate of Health.
48668442|NCT00027560|BIOLOGICAL|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
48668443|NCT00027560|DRUG|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
48668444|NCT00027560|DRUG|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
48146004|NCT03660527|OTHER|Not refered|No intervention was refered.
48356868|NCT03665233|DEVICE|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
48356869|NCT04316780|OTHER|Retrospective observational study- no intervention to occur.|Subject data will be grouped based on the anti-fibrotic medication at the time of lung transplant listing eligibility and when medication was stopped relative to the transplant.
48356870|NCT04671745|BEHAVIORAL|Music|patient receiving care with interactive music
48356871|NCT04671745|BEHAVIORAL|No music|patient receiving care without interactive music
48356872|NCT04451486|DRUG|SB cells|1x10\*5 CD61-Lin- cells /0.25mL DPBS
48356873|NCT04451486|DRUG|SB cells|1x10\*6 CD61-Lin- cells /0.25mL DPBS
48506296|NCT04869215|OTHER|EverVita Pro|EverVita Pro is composed of barley and corn, grown and mechanically processed in Europe, with non-GMO grains.
48668445|NCT00027560|DRUG|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
48668446|NCT00027560|PROCEDURE|allogeneic bone marrow transplantation|
48356874|NCT04451486|DRUG|SB cells|1x10\*7 CD61-Lin- cells /0.25mL DPBS
48506297|NCT04869215|OTHER|Control bread|Bread baked with normal Bakers flour
48668447|NCT00027560|PROCEDURE|peripheral blood stem cell transplantation|
48668448|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
47989013|NCT01986855|DRUG|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
47989014|NCT01986855|DRUG|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
48356875|NCT00482209|DRUG|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
48356876|NCT00482209|DRUG|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
48668449|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
48146005|NCT01184105|DRUG|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
48668450|NCT00090506|BEHAVIORAL|Yoga|
48668451|NCT06101810|BEHAVIORAL|COMET|information already included in arm/group descriptions.
48668452|NCT06101810|BEHAVIORAL|CBT|information already included in arm/group descriptions.
48668453|NCT02789852|DEVICE|Orthosis|use orthosis
48668454|NCT04487444|DRUG|Thymalfasin|Synthetic 28 amino acid peptide identical to naturally circulating compound
48668455|NCT02975960|BIOLOGICAL|injection of autologous stromal vascular fraction|"1. Acquiring autologous stromal vascular fraction (SVF) from liposuction~2. purifying SVF from lipoaspirates and making syringe filled with SVF~3. SVF injection - Inject SVF on fingers subcutaneously."
48668456|NCT06528626|DIAGNOSTIC_TEST|rapid HIV and HCV serological tests|In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.
48668457|NCT00461708|DRUG|Erlotinib|100 mg, PO, once per day
48668458|NCT00461708|DRUG|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
48668459|NCT04552054|DEVICE|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
48668460|NCT04552054|DEVICE|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
48668461|NCT00899912|GENETIC|microarray analysis|
48668462|NCT00899912|OTHER|diagnostic laboratory biomarker analysis|
48146006|NCT01184105|DRUG|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
48146007|NCT06248255|OTHER|Pads|Single arm design in which each participant act as its own control. Wet or Dry pads are applied to the participants forearms.
48146008|NCT05914285|DRUG|5ml of inhaled normal saline|After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
48146009|NCT05914285|DRUG|2.5mg (2.5ml) of inhaled salbutamol and 2.5ml of inhaled normal saline|After the initiation of OLV, mixture of salbutamol 2.5mg and normal saline 2.5ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
48668463|NCT02914938|DRUG|ME-401|60 mg
48668464|NCT02914938|DRUG|Rituximab|IV infusion 375 mg/m2
48668465|NCT02914938|DRUG|Zanubrutinib|80 and 160 mg bid
48668466|NCT04972279|BEHAVIORAL|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
48668467|NCT00651222|OTHER|No intervention was required|Death records were reviewed, therefore, there was no intervention
48668468|NCT00125788|DRUG|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
48668469|NCT00125788|DRUG|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
48668470|NCT06205693|PROCEDURE|Fast Degradable, Biodegradable ARCHEMEDES stent|Fast Degradable, Biodegradable ARCHEMEDES stent. Placed in the pancreaticojejunostomy.
48146012|NCT00000617|DRUG|azithromycin|
48668471|NCT04515888|OTHER|PFDI-20 / PFIQ-7 questionnaires|PFDI-20 / PFIQ-7 questionnaires (one shot)
47989015|NCT01986855|DRUG|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
47989016|NCT04051047|DRUG|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
48668472|NCT03292237|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
48668473|NCT05921344|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
48668474|NCT00224393|DRUG|Enbrel|
48668475|NCT04129307|BEHAVIORAL|Motor imagery|This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.
48668476|NCT04129307|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.
48668477|NCT04129307|BEHAVIORAL|Action observation|This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
48356877|NCT05951374|PROCEDURE|Madany triangle|"After dissection of the proximal part of the gallbladder from its bed and scarification of the cystic artery and its branches, the traction applied to the Hartman pouch created an angle between the skeletonized cystic duct and the skeletonized posterior surface of the GB (Fig. 3).~Also, this traction creates a dynamic triangle visualized from both the left and right sides according to the traction applied to the Hartman pouch to the right or left and the direction of the angled scope of the camera lens. From the left-side view, when right traction is applied to the Hartman pouch, it is bound laterally by the skeletonized proximal part of the cystic duct. Superiorly, it is bound by the posterior surface of the proximal part of the skeletonized gallbladder. It was bounded medially by an imaginary line between a point at the junction of the cystic duct with the CBD and a point at the anterior end of the dissected cystic plate (the Madany triangle)"
48506298|NCT05055830|DRUG|The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.|The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
48506299|NCT02445274|PROCEDURE|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
48668478|NCT01337570|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
48668479|NCT01337570|OTHER|Placebo|Vaginal Ring containing no drug substance
48506300|NCT04773301|DRUG|Levobupivacaine|Local anaesthetic drug belonging to the amino amide group. It is the S-enantiomer of bupivacaine
48668480|NCT01337570|DRUG|Dapivirine|
48668481|NCT02900430|OTHER|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
48668482|NCT02900430|DRUG|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
48668483|NCT03580044|COMBINATION_PRODUCT|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
48668484|NCT03580044|DRUG|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
48668485|NCT05427292|OTHER|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
48668486|NCT04117633|DEVICE|Laparoscopy|Laparoscopic Procedures for Rectopexy
48668487|NCT03861338|DRUG|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
47989017|NCT04051047|PROCEDURE|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
48146013|NCT03837093|DRUG|ILT101|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
48506301|NCT04773301|DRUG|Ropivacaine|Local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer.
48506302|NCT02123758|DRUG|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
48506303|NCT02123758|DRUG|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
47989018|NCT03510520|DEVICE|Medium Cut-Off Haemodialysis|Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
47989019|NCT03510520|DEVICE|On-Line Haemodiafiltration|Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
48506304|NCT02123758|DRUG|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
48506305|NCT01724086|DRUG|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
48506306|NCT01724086|DRUG|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
47989020|NCT05705986|OTHER|Blood Draw|Single blood draw
48146014|NCT03837093|DRUG|Placebo|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
48146015|NCT00211926|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
48146016|NCT00211926|BIOLOGICAL|placebo|single dose of placebo
48146017|NCT05792852|BEHAVIORAL|ENGAGE|ENGAGE is a group intervention designed to improve social participation within the context of the COVID-19 pandemic.
48146018|NCT00297297|OTHER|No intervention. Applying gene profiling on needle aspirates|
48146019|NCT02839850|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
48146020|NCT04853654|OTHER|exercise|exercise training for 8 weeks
48146021|NCT02197702|DIETARY_SUPPLEMENT|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
48146022|NCT02197702|DIETARY_SUPPLEMENT|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
48146023|NCT02264847|DRUG|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
48146024|NCT02264847|DRUG|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
48146025|NCT00476294|OTHER|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
48146026|NCT01453764|PROCEDURE|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
48146027|NCT06371950|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis|5 billion colony forming units (CFU) per day for 9 weeks (3 weeks before surgery to six weeks after surgery)
47989021|NCT03195088|DRUG|BI 473494|Solution for injection
47989022|NCT03195088|DRUG|Placebo|Solution for injection
48146028|NCT06371950|OTHER|Placebo|Placebo
48146029|NCT03311997|PROCEDURE|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
48146030|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
48146031|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
48146032|NCT00987272|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
48146033|NCT00987272|DRUG|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
48668488|NCT01447537|OTHER|Exercise + relaxation|Exercise + relaxation
48668489|NCT01447537|OTHER|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
47989023|NCT02976623|OTHER|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
47989024|NCT03531307|OTHER|Data correlation|Correlation between lactate levels and Ki-67 index
48146034|NCT04604717|OTHER|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
48146035|NCT05051072|PROCEDURE|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"
48146036|NCT05325983|OTHER|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
47989025|NCT04919278|PROCEDURE|Chiropractic adjustments|Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
47989026|NCT00256373|PROCEDURE|Mod. functional restoration-Individ. dynamic back-muscle|
47989027|NCT06065033|BEHAVIORAL|Exercise|"Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance."
47989028|NCT01593423|BEHAVIORAL|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
48506307|NCT01724086|DRUG|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
48668490|NCT04322461|DIETARY_SUPPLEMENT|Betaquik MCT supplement|50g/day divided in 3. Breakfast, lunch and dinner
48146037|NCT05325983|OTHER|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
48146038|NCT03052998|DRUG|Ivermectin|Effect of Ivermectin on frequency of seizures
48146039|NCT02160496|BEHAVIORAL|Weight loss interventional study with 20% protein-diet|
48146040|NCT02160496|BEHAVIORAL|Weight loss interventional study with 27% protein-diet|
48146041|NCT02160496|BEHAVIORAL|Weight loss interventional study with 35% protein-diet|
48146042|NCT06222437|DRUG|Semaglutide|effectiveness of semaglutide in PCOS
48146043|NCT03507504|OTHER|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
48146044|NCT00195819|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
48146045|NCT00195819|BIOLOGICAL|placebo|Placebo every other week (eow)
48146046|NCT06354725|OTHER|Plyometric|Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.
48146047|NCT00674037|OTHER|monetary incentive|75 euros for each patient included
48146048|NCT06157684|BEHAVIORAL|Postprandial ambulation|See arm description
48146049|NCT00734682|DRUG|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
48146050|NCT06220123|DRUG|SHR-2004|Investigational product arm: SHR-2004
48146051|NCT06220123|DRUG|Enoxaparin Sodium Injection; Rivaroxaban Tablets|Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets
48146052|NCT06253962|OTHER|coronary agiongraphy|severity of coronary atherosclerosis
48146053|NCT06505577|OTHER|No additional intervention|All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.
48146054|NCT02354144|OTHER|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
48146055|NCT02354144|OTHER|Control gel|A gel not containing carrageenan
48146056|NCT05578807|PROCEDURE|without reverse ureteral catheter insertion|In contrast to conventional total tubeless percutaneous nephrolithotomy, there was no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no change in position, and no repeated disinfection.
48146057|NCT03822897|RADIATION|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
48146058|NCT03822897|DRUG|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
48146059|NCT02135315|DRUG|Isosorbide Dinitrate|administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
48146060|NCT05207397|OTHER|Lactate infusion|The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions will be made by the O'Brien Pharmacy (Mission, Kansas) and tested to be sterile and pyrogen free.. Upon arriving to the KU Clinical and Translational Science Unit, a catheter will be placed in the subject's hand, which will be placed into a heated hand box for collection of arterialized blood. A second catheter will be placed in the opposing forearm vein for the infusion of lactate isotope solution and unlabeled lactate infusion cocktail. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. We will then administer priming doses of 57.5 mg \[3-13C\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[3-13C\]lactate at 10 mg/min and D2-glucose at 2 mg/min \[53\]. Along with the continuous isotope infusion we will begin infusion of the Na-lact
48146061|NCT03096132|BEHAVIORAL|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
48668491|NCT04008914|OTHER|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
48668492|NCT01880957|DRUG|Lithium|
48668493|NCT01880957|DRUG|Lamotrigine|
48668494|NCT00698841|DRUG|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m\^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m\^2 over 60 minutes.
48668495|NCT04968483|OTHER|Data collection|The general data, data of postoperative complications, data of nutritional assessment and nutritional support will be collected.
48356878|NCT02814591|DEVICE|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
48356879|NCT00504452|DRUG|KP-1461|Oral dosage, 1600 mg bid for 124 days
48506308|NCT01724086|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
48506309|NCT01724086|DRUG|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
48668496|NCT01603654|DRUG|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
48668497|NCT01603654|DRUG|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
48668498|NCT01205516|DRUG|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
48668499|NCT01205516|DRUG|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
48668500|NCT05796687|BEHAVIORAL|My Future Self|My Future Self is based upon the Theory of Possible Selves, which promotes the capacity of young people to construct goals for a successful adulthood. Youth who hold a balanced set of negative and positive images of their future have both a) a positive goal to strive for and b) awareness of the personally relevant consequences of not meeting that goal. My Future Self also includes two new supportive gaming elements that reinforce learning of relevant knowledge and skills as well as provide opportunities for youth to individually practice these skills in a personalized virtual environment. Gaming interventions using interactive technology can significantly increase self-reported abstinence and lower reports of diagnosed STD in young women, as well as reduce risky sex in high-risk young men who have sex with men. Youth will participate in these gaming elements on tablets provided by CHLA. My Future Self will be implemented as a ninety-minute small group 5-week program.
48668501|NCT05140343|DIAGNOSTIC_TEST|KARDIA Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
48668502|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
48668503|NCT00665834|DRUG|placebo|placebo 20 mg from day 0 to (maximum) day 6
48668504|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
48668505|NCT00665834|DRUG|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
48668506|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 1|Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
48356880|NCT00840528|OTHER|ozone|0.4 ppm ozone for 2 hours
48356881|NCT02065479|DRUG|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
48356882|NCT02065479|DRUG|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
48356883|NCT01815099|DEVICE|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
48356884|NCT00294528|DEVICE|Nexgen LPS-flex and AGC|
48356885|NCT03701932|BEHAVIORAL|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
48356886|NCT03701932|BEHAVIORAL|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
48506310|NCT01724086|DRUG|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
48668507|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 2|Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
48668508|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 3|Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
48668509|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 4|Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
48356887|NCT05027711|RADIATION|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)|ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)
48356888|NCT05027711|RADIATION|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)|MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)
48506311|NCT01667835|BEHAVIORAL|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
48668510|NCT00506142|DRUG|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
48668511|NCT00619996|DRUG|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
48668512|NCT00619996|DRUG|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
48668513|NCT02691156|DIAGNOSTIC_TEST|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
48668514|NCT02691156|DIAGNOSTIC_TEST|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
48668515|NCT02691156|DIAGNOSTIC_TEST|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
48668516|NCT03781414|BIOLOGICAL|CFZ533|Comparison with standard of care immunosuppression
48668517|NCT03781414|DRUG|Tacrolimus - MMF - corticosteroids|Standard of care immunosuppresive regimen
48668518|NCT00163098|DRUG|UK-369,003|
48668519|NCT00002219|DRUG|Nelfinavir mesylate|
48668520|NCT00002219|DRUG|Levocarnitine|
48668521|NCT00002219|DRUG|Adefovir dipivoxil|
48668522|NCT00384943|BEHAVIORAL|Moderate-intensity Exercise|
48668523|NCT01499537|DEVICE|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
48668524|NCT01499537|DEVICE|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
48668525|NCT01164007|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
48668526|NCT01164007|DRUG|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.
48668527|NCT00844506|DRUG|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
48668528|NCT00844506|DRUG|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
48668529|NCT04782921|DEVICE|Xenogenic bone graft material|After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
48668530|NCT01761578|DEVICE|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
48668531|NCT03949517|DRUG|68-Ga RM2|Radioactive agent
48668532|NCT03949517|DRUG|68-Ga PSMA11|Radioactive agent
48668533|NCT03949517|DEVICE|Investigational software and coils in PET/MR Scan|Investigational software and coils in PET/MR Scan by General Electric Healthcare
48668534|NCT03949517|PROCEDURE|PET/MRI|Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
48668535|NCT01879007|DRUG|Factive® Tab / Factive IV|
48668536|NCT06484582|OTHER|workers|This study will be conducted as a face-to-face survey. Surveys will be created with Google Forms and will be filled out by the physiotherapist according to the participant's response.
48668537|NCT04273269|GENETIC|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
48668538|NCT03885700|BEHAVIORAL|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition \&Healthy Eating by Mayo clinic \& CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet \& the 2nd month covered the physical activity as follow:~* 1st \& 5th week: A 60-minutesession in health education.~* 2nd \& 6th week: Group counselling.~* 3rd \& 7th week: Students were divided into 8 groups \& each group was asked to make presentation about a task related to the topic.~* 4th \& 8th week: Discussing the presentation."
48356889|NCT05299216|OTHER|Manual Diaphragm Technique|Treatment group will receive Manual Diaphragm Technique in addition to Conventional Physical Therapy. Therapist will make physical contact to the underside of the 7th to 10th rib costal cartilages. During the inspiratory phase, the therapist will use both hands to gently pull the points of contact in the direction of the head. During exhalation, the therapist will maintain resistance. The procedure will be done in two sets of ten deep breaths, separated by a one-minute pause.
48668539|NCT04928378|OTHER|Descriptive retrospective study|characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).
48668540|NCT00151840|DRUG|IVIG-L|
48356890|NCT05299216|OTHER|Conventional Physical Therapy|"Conventional Physical Therapy group comprises electrotherapeutic treatment and exercise plan. Subjects will undergo a thermal continuous ultrasound, conventional transcutaneous electrical nerve stimulation and a hot pack.~Stretching activities for the back, iliopsoas, and hamstring muscles, as well as abdominal muscle strengthening exercises, will be included in the workout."
48668541|NCT05617261|OTHER|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
48668542|NCT05364398|PROCEDURE|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
48668543|NCT00738296|DRUG|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
47989029|NCT01593423|BEHAVIORAL|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
47989030|NCT01593423|BEHAVIORAL|a comparison group|No intervention.
47989031|NCT02159690|DRUG|Enzalutamide|160mg
47989032|NCT02159690|DRUG|Abiraterone acetate|1000mg
47989033|NCT02159690|DRUG|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
47989034|NCT02159690|DRUG|Dutasteride|0.5mg
47989035|NCT02159690|DRUG|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
47989036|NCT04109755|DRUG|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
47989037|NCT02118844|DRUG|rocuronium|
47989038|NCT02945033|DRUG|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
48668544|NCT00738296|DRUG|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
48668545|NCT00738296|DRUG|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
48668546|NCT04009148|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
48668547|NCT05610735|DRUG|DOXIL|DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.
47989039|NCT02945033|DRUG|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
47989040|NCT02945033|PROCEDURE|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
47989041|NCT02945033|BIOLOGICAL|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
47989042|NCT02945033|BIOLOGICAL|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
47989043|NCT05560997|DIAGNOSTIC_TEST|10-year ASCVD risk estimation|High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.
47989044|NCT05503147|DRUG|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
47989045|NCT01909154|BIOLOGICAL|Mesenchymal stromal cell therapy|Stem cells administration locally
47989046|NCT00470639|DEVICE|Transcranial Magnetic Stimulation|
47989047|NCT02074631|DRUG|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
48356891|NCT05299216|OTHER|Sham Diaphragm Manual Technique|The Control group will also receive a sham diaphragm release technique. The therapist and participant will have the same manual contacts, duration, and placement as the treatment group, but the therapist will simply use a light touch with the same anatomical landmarks and will not apply pressure.
48506312|NCT02033057|PROCEDURE|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
47989048|NCT02074631|DRUG|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
47989049|NCT03556189|DEVICE|Case management|Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
47989050|NCT02391155|PROCEDURE|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
47989051|NCT02391155|PROCEDURE|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
47989052|NCT00040937|BIOLOGICAL|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
47989053|NCT00040937|BIOLOGICAL|sargramostim|"PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis~1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery"
47989054|NCT00040937|DRUG|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
47989055|NCT00040937|DRUG|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
47989056|NCT00040937|DRUG|melphalan|"1. st trans: 140 mg/m2 IV over 20 mins day -1~2. nd trans: 200mg/m2 IV over 20 mins day -1"
47989057|NCT00040937|DRUG|prednisone|maint: 50 mg/d PO every other day until progression
47989058|NCT00040937|DRUG|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
47989059|NCT00040937|PROCEDURE|peripheral blood stem cell transplantation|2-4 x 10\^6/kg IV day 0
47989060|NCT06476457|BEHAVIORAL|STAIR Coach|STAIR is a brief, low-intensity intervention targeting difficulties in affective and interpersonal regulation that tend to be a significant problem for those exposed to traumatic events.
47989061|NCT00455364|DRUG|Voriconazole|
47989062|NCT02913079|BEHAVIORAL|Sit-stand desk|
47989063|NCT02913079|BEHAVIORAL|Sitting desk|
47989064|NCT01349790|DRUG|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
47989065|NCT00949325|DRUG|temsirolimus plus liposomal doxorubicin|Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
48146062|NCT03096132|BEHAVIORAL|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
48146063|NCT02648841|RADIATION|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
48146064|NCT02648841|DRUG|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
48146065|NCT02648841|DRUG|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
48146066|NCT03279094|BIOLOGICAL|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
48356892|NCT03538899|DRUG|AProArt|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
48506313|NCT02862561|DRUG|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
48506314|NCT02862561|BIOLOGICAL|Precision Cells|DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
48506315|NCT04312386|OTHER|OPTIMAT|Baseline menue, not optimized
48146067|NCT02365597|DRUG|Erdafitinib|8 mg orally once daily for 28 days on a 28 day cycle.
48146068|NCT02365597|DRUG|Midazolam|Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.
48146069|NCT02365597|DRUG|Metformin|Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.
48356893|NCT03538899|DEVICE|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
48356894|NCT03538899|DRUG|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
48356895|NCT04913792|DEVICE|ZXR00|This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
48506316|NCT00046241|DRUG|Extended-release bupropion hydrochloride|
48506317|NCT04733261|OTHER|Diaphragmatic mobility|Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.
48356896|NCT03350724|DEVICE|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
48356897|NCT03350724|DEVICE|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
48356898|NCT02831894|DRUG|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
48356899|NCT02831894|DRUG|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
48356900|NCT02831894|DRUG|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
48506318|NCT04733261|OTHER|Chest Physiotherapy|Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
48668548|NCT05610735|DRUG|Withaferin A|Ashwagandha in the form of tablets will be administered orally on daily basis.
48668549|NCT05610735|DRUG|Ashwagandha|Administered orally on daily basis twice a day
48668550|NCT05610735|DRUG|Combination of ASWD and DOXIL|DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
48668551|NCT05177250|DEVICE|HPLC|taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
48668552|NCT03767049|OTHER|Colection of clinical data|Colection of clinical data
48668553|NCT01918189|BEHAVIORAL|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
48668554|NCT01373281|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
48668555|NCT01373281|BIOLOGICAL|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
48668556|NCT01084889|DEVICE|surgical mesh implantation (TiLOOP® Total 6)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
48668557|NCT00772759|DRUG|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
48668558|NCT00772759|DRUG|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
48356901|NCT02880930|DIETARY_SUPPLEMENT|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
48356902|NCT05544110|DEVICE|Active transcranial magnetic stimulation|The coil parallel to the scalp is placed on the target for real and effective stimulation.
48356903|NCT05544110|DEVICE|Sham transcranial magnetic stimulation|The coil is placed perpendicular to the scalp above the target for ineffective stimulation.
48506319|NCT06060379|OTHER|GiochiAMO a 626|The subjects of the intervention group will play three different games: a role-playing game, a card game and a board game.
48668559|NCT06193707|OTHER|the Remote Intervention|Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
48668560|NCT06193707|OTHER|the Traditional Intervention|Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
48668561|NCT03522402|DRUG|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
48668562|NCT01378195|BEHAVIORAL|CBT-based program for dementia caregivers|Participants will receive a CBT-based program \[Cognitive Behavioral Therapy\], containing videos, workbook, and website.
48356904|NCT00761033|BEHAVIORAL|music|
48356905|NCT04891510|DEVICE|REVOLVE Advanced Adipose System|The REVOLVE system is an all-in-one fat processing device that harvests, filters, actively washes, and removes strands from lipoaspirate and allows for reinjection without any additional manipulation (REVOLVE 2020).
48356906|NCT04891510|DEVICE|LipoGrafter|The LipoGrafter system is designed to be a start-to-finish closed system with minimal processing of the lipoaspirate, minimizing the risk of contamination and fat cell damage (LipoGrafter 2020).
48668563|NCT01378195|BEHAVIORAL|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
48668564|NCT01872884|DRUG|Sevorane Remifentanil|Sevorane Remifentanil
48668565|NCT01872884|DRUG|Remifentanil|Remifentanil
48146070|NCT01043614|BEHAVIORAL|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
48146071|NCT03450811|PROCEDURE|Inguinal hernia repair|Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
48146072|NCT06134557|PROCEDURE|conventional stents|performed the study to compare the safety and efficacy between flow diverters and conventional stents in IVADA patients undergoing endovascular therapy. Stent-assisted coiling is the preferred option for most surgeons. In addition,It is believed that dense packing is not necessary as long as the aneurysm neck is covered to isolate the dissection. How ever,whether it is really necessary to adjunct coil,and if it is necesary, what is the ideal packing density of coils, there is no clear conclusion at present.This study aimed to compare the safety and efficacy between flow diverter and conventional stents in patients with IVADA, determine the ideal packing density of coils after FD stent placement,and to observe the hemodynamic changes before and after the treatment of FD stent.
48146073|NCT01533194|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48146074|NCT01533194|BIOLOGICAL|Wild-type Reovirus|Given IV
48668566|NCT05820035|DEVICE|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
48668567|NCT01737892|DRUG|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
47989066|NCT05304156|OTHER|Biobanking blood and bone marrow specimens|"Interventions, procedures added for research purposes :~Blood Samples :~* Peripheral blood (20mL EDTA) (at Screening, pre-ICT Day 1, Day1 H8, Day 2, Day 3, Day 4 and Day of EOI evaluation~Bone Marrow samples :~* Biopsy at Screening and at EOI Evaluation~* Additional volume (2mL EDTA) on the Screening,2 and EOI Evaluation aspirations for single-cell analyses.~* Aspiration at D8 for Smears and 2 mL EDTA for single-cell analyses (instead of D15 standard care)."
47989067|NCT05701410|DIAGNOSTIC_TEST|DPD scintigraphy|Bone tracer scintigraphy, diagnostic for transthyretin amyloidosis.
48146075|NCT03874949|DEVICE|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
48146076|NCT03874949|DEVICE|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
48146077|NCT00942266|DRUG|fluorouracil|Given IV
48146078|NCT00942266|DRUG|leucovorin calcium|Given IV
48146079|NCT00942266|DRUG|vorinostat|Given orally
48146080|NCT00942266|OTHER|pharmacological study|Correlative study
48668568|NCT01737892|DRUG|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
48668569|NCT04794933|OTHER|Conventional therapy|
48668570|NCT04794933|OTHER|CT+ PNF in extremity pattern|
48668571|NCT04794933|OTHER|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|
48668572|NCT04419246|OTHER|interscalene block|ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
47989068|NCT02535845|BEHAVIORAL|Project Voice|Project Voice tablet-based intervention plus informational video
47989069|NCT02535845|BEHAVIORAL|HPV Informational Video|Informational video only
47989070|NCT05835609|DRUG|PM534|PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
47989071|NCT05220163|DIAGNOSTIC_TEST|CAD|It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.
47989072|NCT05220163|DIAGNOSTIC_TEST|Xpert|A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
47989073|NCT01518920|DRUG|PF-04958242|PF-04958242 0.35 mg oral solution
47989074|NCT01518920|DRUG|PF-04958242|PF-04958242 0.27 mg oral solution
47989075|NCT01518920|DRUG|Placebo|Placebo oral solution
48146081|NCT01583959|DRUG|Folic Acid|Folic acid tablets 5 mg
48146082|NCT01583959|DRUG|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
48146083|NCT00584675|DEVICE|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
48146084|NCT03507699|RADIATION|Liver radiation therapy|21 Gy in three fractions to one liver metastasis
48146085|NCT03507699|DRUG|Nivolumab Injection [Opdivo]|administered IV at a dose of 3mg/kg every 2 weeks
48668573|NCT04419246|DRUG|tranexamic acid|10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
48668574|NCT04419246|OTHER|general anesthesia|general anesthesia will be applied in accordance with standard procedures
48146086|NCT03507699|DRUG|Ipilimumab Injection [Yervoy]|administered IV at a dose of 1mg/kg every 6 weeks
48146087|NCT03507699|DRUG|CMP-001|A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
48146088|NCT02822599|DRUG|RiaStAP|To decrease post-operative bleeding volume.
48146089|NCT02822599|DRUG|Saline|Placebo consisting of normal saline 0.9%
48668575|NCT05638074|PROCEDURE|Interlaminar Epidural Steroid Injection|"The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience."
48668576|NCT04549467|DRUG|Lamivudine 300 MG|Experimental arm
48668577|NCT04549467|DRUG|Emtricitabine / Tenofovir Disoproxil Pill|Active Comparator
48668578|NCT01131052|DRUG|Insulin Glargine|glargine once a day
48668579|NCT01131052|DRUG|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
48668580|NCT01131052|DRUG|Insulin glulisine|glulisine given as needed before meals
48668581|NCT04626726|DRUG|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
48668582|NCT04626726|DRUG|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
48356907|NCT04891510|PROCEDURE|Viality|The Viality system uses the AuraClens solution that acts as a surfactant to bring impurities like blood, free oil, and cellular debris into solution, where they can be flushed out through suction.
48356908|NCT00606710|DEVICE|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
48356909|NCT03441399|OTHER|Financial incentives|Providing money for taking antidepressant medication
48356910|NCT00423267|DRUG|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
48506320|NCT00509795|BIOLOGICAL|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48506321|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48356911|NCT00423267|DRUG|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
48356912|NCT02050672|DIETARY_SUPPLEMENT|Myo-inositol|
48146090|NCT03609450|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
48146091|NCT03609450|BEHAVIORAL|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
48146092|NCT02899533|DRUG|[18F] FES|\[18F\] FES PET/CT scan, imaging tracer
48146093|NCT00420368|DIETARY_SUPPLEMENT|No food supplement|
48146094|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: fortified spread|
48146095|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|
48146096|NCT04214457|PROCEDURE|Biopsy and peripheral blood collection|"After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record."
48356913|NCT02050672|OTHER|untreated|
48356914|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
48506322|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48506323|NCT00509795|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
48506324|NCT01990482|DIETARY_SUPPLEMENT|caffe|
48356915|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 6 months
48356916|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
48356917|NCT01882439|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
48356918|NCT01882439|OTHER|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
48356919|NCT01882439|DRUG|Tofacitinib|tablets, 10 mg BID x 3 months
48506325|NCT01990482|DIETARY_SUPPLEMENT|Water|
48506326|NCT05971693|DEVICE|OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator|Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping \[stimulating and recording\] and, when used with a Generator, for cardiac ablation).
48506327|NCT01630577|OTHER|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
48356920|NCT02112149|BEHAVIORAL|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (\< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
48356921|NCT00242814|DRUG|Micardis|
48356922|NCT00242814|DRUG|Amlodipine|
48356923|NCT00242814|PROCEDURE|Abdominal biopsy|
48356924|NCT01008436|DRUG|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
48356925|NCT01008436|DRUG|Control|Traditional surgical Hemostasis
48356926|NCT00805649|PROCEDURE|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
48356927|NCT00805649|PROCEDURE|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
48506328|NCT03363386|PROCEDURE|Proprioceptive Exercises|Patients trained for proprioceptive exercises
48506329|NCT03363386|PROCEDURE|Resistive Exercises|Patients trained for resistive exercises
48506330|NCT03363386|PROCEDURE|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
48506331|NCT06483789|DRUG|HB-1|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
48356928|NCT00805649|DRUG|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
48356929|NCT00805649|DRUG|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
48356930|NCT00805649|PROCEDURE|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
48356931|NCT00805649|DRUG|triamcincolone|intravitreal injection of 8 mg triamcincolone
48356932|NCT02881892|OTHER|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
48668583|NCT04626726|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
48668584|NCT04626726|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
48668585|NCT04626726|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
48356933|NCT01132391|DRUG|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
48356934|NCT03837301|PROCEDURE|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
48356935|NCT00564135|PROCEDURE|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
48506332|NCT06483789|DRUG|Telmisartan Only Product in Oral Dose Form|Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
48356936|NCT01693666|BEHAVIORAL|Lifestyle intervention|"1. To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~2. To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~3. To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
48506333|NCT06483789|DRUG|Verapamil Only Product in Oral Dose Form|Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
48506334|NCT06483789|DRUG|Placebo|Matched Placebo will be supplied as a tablet.
48506335|NCT05803174|DIAGNOSTIC_TEST|blood sample|"Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am.~Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST).~Saliva collection Saliva samples were collected via the passive drool method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period."
48506336|NCT03510780|PROCEDURE|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
48356937|NCT04089228|OTHER|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
48356938|NCT04089228|OTHER|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
48506337|NCT03510780|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
48506338|NCT03764098|DRUG|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
48506339|NCT03764098|OTHER|Placebo|Placebo
48506340|NCT01602718|OTHER|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
48668586|NCT05309525|DRUG|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
48668587|NCT05309525|DRUG|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
48668588|NCT01270529|OTHER|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
48356939|NCT06372405|BEHAVIORAL|Cognitive reappraisal|Cognitive reappraisal is a psychotherapeutic strategy utilized to regulate emotions by reinterpreting the meaning of stimuli. Participants will receive instructions on generating and implementing cognitive reappraisal (distancing and reframing) in both misophonic and non-misophonic contexts and will be practicing it within psychotherapeutic sessions. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
48356940|NCT06372405|BEHAVIORAL|Schultz Autogenic Training|Schultz Autogenic Training is a relaxation technique aimed at promoting relaxation and reducing physiological arousal. It consists of six exercises focusing on sensations of heaviness, warmth, heartbeat, breathing, abdominal warmth, and coolness of the forehead. The program consists of four weekly online psychotherapeutic sessions: the first session will be a 90-minute group session, followed by three individual sessions, each lasting 30 minutes.
48668589|NCT01323192|DRUG|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
48668590|NCT01323192|DRUG|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
48668591|NCT05380687|DIAGNOSTIC_TEST|Inspiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.
48668592|NCT05380687|DIAGNOSTIC_TEST|Expiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP \& occlusion pressure, ∆Pocc) and is frequently used in clinical practice.
48668593|NCT05380687|DIAGNOSTIC_TEST|Ultrasound of respiratory muscles|Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.
48668594|NCT05380687|OTHER|PEEP 10|Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
48668595|NCT05380687|OTHER|PEEP 5|Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
48668596|NCT05380687|OTHER|PEEP 0|Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
48668597|NCT02373592|BEHAVIORAL|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
48668598|NCT02373592|DEVICE|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
48668599|NCT01066845|DRUG|tadalafil|prescribed in accordance with usual clinical practice
48668600|NCT01276704|DRUG|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
48668601|NCT01276704|DRUG|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
48668602|NCT05253040|OTHER|KEEP Intervention|Educational intervention
48356941|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
48668603|NCT05253040|OTHER|control|booklet from Parkinson's UK
48356942|NCT00640575|DRUG|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
48506341|NCT00324727|DRUG|melphalan|Given throug isolated hepatic artery infusion
48506342|NCT00324727|DRUG|regional chemotherapy|Patients receive the best alternative therapy
48506343|NCT00324727|DRUG|systemic chemotherapy|Patients receive the best alternative therapy
48146097|NCT06318572|BEHAVIORAL|Psychological intervention|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will begin the program of psychological intervention. A first, session of psychoeducation will be performed, and thereafter sessions of psychotherapy will be performed at home during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days. A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
48146098|NCT06318572|BEHAVIORAL|Placebo|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will be instructed to take a capsule containing 0.5 g during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days, A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
48668604|NCT01346176|OTHER|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
48668605|NCT04987372|DRUG|Dexmedetomidine|The use of multimodal painkillers pre, per and postoperative
48668606|NCT01969734|DEVICE|Zephyr endobronchial valve placement|
48668607|NCT00786422|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
48668608|NCT01855386|OTHER|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
48146099|NCT06002672|DIETARY_SUPPLEMENT|Placebo comparator: Control group. To the control group was assigned lettuce without any change in salinity but with the same characteristic of eustress lettuce (soil, water, harvesting time).|Lettuce without any eustress was assigned to each participant belonging to the control group which ate 100gr every day for 12 day
48668609|NCT01855386|OTHER|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
48668610|NCT06317935|OTHER|ArmeoSenso|ArmeoSenso is an upper extremity virtual reality application with three motion sensors and one hand grip sensor. The device detects the person's body, arm, forearm and hand movements and displays the reflection of the movements on the screen. The application includes studies on upper extremity functions.
48668611|NCT06317935|OTHER|Traditional Rehabilitation|It includes traditional occupational therapy and physiotherapy approaches.
48668612|NCT03175107|DEVICE|Exergaming|
48668613|NCT05636839|RADIATION|UVB treatment|UVB treatment 3 times per week for 10 weeks
47989076|NCT04025307|DRUG|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
48146100|NCT06002672|DIETARY_SUPPLEMENT|Experimental: Eustress group. To the intervention Eustress group was assigned the eustress lettuce.|100gr of eustress lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 12 days
48146101|NCT06131957|COMBINATION_PRODUCT|Fluoride varnish with SBGC|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA) mixed with 7.5% SBGC (Dencare (Chongqing) Oral Care Co., Ltd).
48146102|NCT06131957|DRUG|Fluoride varnish|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
48668614|NCT02551588|PROCEDURE|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
48668615|NCT03121521|DRUG|Melatonin 10 mg|melatonin 10mg daily p.o.
48668616|NCT03121521|DRUG|Placebo|Placebo 10mg daily p.o.
48668617|NCT03836443|OTHER|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
48668618|NCT01987076|DRUG|Prednisone|"Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
48668619|NCT01987076|DRUG|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
48668620|NCT04885959|BEHAVIORAL|Traditional Asian Diet|The personalized traditional Asian diet will be formulated based on dietary components of a typical Asian diet characterized by high intake of fruits and vegetables, whole grains, legumes, nuts, seeds, soy foods and herbs and spices; moderate intake of fish, poultry, eggs, healthy cooking oils, yogurt or functional foods and low intake of meats and sweets (Ismail et al., 2020). The diet design also considering the recommendation of personalized dietary approach by including the element of individual preferences, requirement, cultural preferences, affordability and foods availability to facilitate the adherence and response to the diet.
48668621|NCT00043602|BEHAVIORAL|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
48146103|NCT02790645|OTHER|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
48146104|NCT02790645|OTHER|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
48146105|NCT02790645|OTHER|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
48146106|NCT02790645|OTHER|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
48146107|NCT01106807|DRUG|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
48146108|NCT01106807|DRUG|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
48146109|NCT01106807|DRUG|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
48146110|NCT01106807|DRUG|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
48146111|NCT00952003|DRUG|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
48356943|NCT04601779|BEHAVIORAL|VIPP-PUF|The VIPP-PUF Intervention is developed as an add-on to the existing PUF-program to address infants with major cognitive and regulatory vulnerabilities identified at age 9-10 months and adapted to the settings of community health nurses. The intervention (VIPP-PUF) will be created from an evidence-based method, the Video-based Intervention to Promote Positive Parenting (VIPP), to comprise six therapeutic sessions delivered by the community health nurse during home visits over a three months period. The VIPP -PUF builds on teaching the health nurses to promote parents' sensitivity to meet infants' cognitive and regulatory vulnerabilities, while taking in account the particular needs of families of psycho-social disadvantage.
48356944|NCT01351233|PROCEDURE|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
48356945|NCT05830331|OTHER|ERASS Pathway|Enhanced Recovery After Spinal Surgery
48506344|NCT00324727|PROCEDURE|hepatic artery embolization|Patients receive the best alternative therapy
48668622|NCT00043602|BEHAVIORAL|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
48668623|NCT02971371|DEVICE|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
48668624|NCT00691392|DRUG|Linezolid|Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
48668625|NCT00691392|DRUG|Microcrystalline Methylcellulose - Placebo|The placebo will be over-encapsulated microcrystalline methylcellulose
48668626|NCT01501357|BEHAVIORAL|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
47989077|NCT03056391|DRUG|Paracetamol|"\>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
47989078|NCT00790881|DRUG|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
47989079|NCT00790881|DRUG|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
47989080|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin|Augmentation of horizontal deficient anterior maxilla using the conventional protocol of cortical shell technique
47989081|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin using patient specific surgical guide then positioned with another guide|using a patient-specific surgical guide to harvest bone cortical shell from the chin and another patient-specific surgical guide to fix it in the atrophied maxillary anterior area
47989082|NCT04611750|DRUG|AD036|AD036 will be given for 14 days
47989083|NCT04611750|DRUG|Placebo|Placebo will be given for 14 days
47989084|NCT06482476|DIAGNOSTIC_TEST|Measurement of Lp(a) levels|Collection of a venous blood sample for the measurement of Lp(a) levels using standardized laboratory methods
47989085|NCT03008083|DRUG|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
47989086|NCT03008083|DRUG|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
47989087|NCT06001554|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
47989088|NCT00263146|PROCEDURE|recruitment maneuver|
47989089|NCT02904473|OTHER|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
47989090|NCT02155647|DRUG|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
48668627|NCT01501357|BEHAVIORAL|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
48356946|NCT03377452|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)|Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
48356947|NCT03377452|BEHAVIORAL|Non-directive sleep apnea education control|Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.
48506345|NCT05408234|OTHER|Smart Foot Exercise|"The patient lies supine (supine) with the legs raised 450 while supported for 1-3 minutes until blanching occurs (the skin becomes pale).~The patient sits on the edge of the bed with the legs hanging down and then performs dorsiflexion, plantarflexion, inversion, and eversion for 3 minutes until the skin appears red.~The patient lies supine with the legs covered with a blanket for 3-5 minutes. This whole cycle is repeated 3-6 times per session, and each session is repeated 2-4 times a day.~Movement using newspaper media, namely by:~Place a sheet of newspaper on the floor, then shape the sheet into a ball with both feet.~The ball shape is then opened into a sheet as before with both feet. Tear the newspaper into two parts, and separate the two parts of the newspaper. Tear the first newspaper into small pieces with both feet. Remove the bunch of stubs and place them in a second, whole newspaper. Wrap everything into a ball shape with both feet. This step is enough to do once."
48668628|NCT03183310|DRUG|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
48146112|NCT03006718|OTHER|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
48146113|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
48146114|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
48146115|NCT00813709|DRUG|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
48506346|NCT00177359|BEHAVIORAL|gait intervention|
48668629|NCT03183310|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
48668630|NCT03183310|DRUG|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
48668631|NCT00313560|DRUG|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
48146116|NCT00813709|DRUG|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
48146117|NCT05606185|PROCEDURE|retraction method|Three dimensional evaluation of root resorption using cone beam computed tomography
48356948|NCT02425813|DRUG|Budesonide|Given PO
48668632|NCT00963872|DRUG|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
48356949|NCT02425813|DRUG|Methylprednisolone Sodium Succinate|Given IA and IV
48356950|NCT01984359|OTHER|Obtaining Human tissue|
48356951|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ machined bone allograft|Participant will undergo primary, elective one-level to four-level ACDF using machined bone allograft
48668633|NCT00963872|DRUG|fludarabine phosphate|40 mg/m\^2 over 1 hour on Days -6 through -2.
48146118|NCT03034863|BEHAVIORAL|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
48356952|NCT05986006|PROCEDURE|Anterior Cervical Disc Fusion (ACDF) Surgery w/ Iliac Crest Bone Graft|Participant will undergo primary, elective one-level to four-level ACDF using iliac crest bone allograft
48668634|NCT00963872|RADIATION|Total body irradiation|200 cGy on Day -1
48668635|NCT00963872|BIOLOGICAL|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
48668636|NCT00963872|BIOLOGICAL|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
48146119|NCT03034863|BEHAVIORAL|Individual Safety Planning Intervention|The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).
48668637|NCT01912235|OTHER|2-15N glutamine|Glutamine with N15 isotope tracer
48668638|NCT01912235|OTHER|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
48668639|NCT01912235|OTHER|1-13C glutamine|Glutamine carbon isotope tracer
48356953|NCT06178835|DRUG|Erythropoietin|500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
48356954|NCT06178835|DRUG|normal saline|The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
48356955|NCT00060567|DRUG|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
48356956|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
48356957|NCT00060567|DRUG|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
48356958|NCT05237609|DIETARY_SUPPLEMENT|rehabilitation with muscle strengthening + Oral Nutritional Supplements|Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group
48356959|NCT05237609|OTHER|rehabilitation with muscle strengthening|Physical activity with only muscle strengthening
48356960|NCT02067104|DRUG|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
48356961|NCT02067104|DRUG|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
48356962|NCT03110757|BIOLOGICAL|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
48356963|NCT03110757|BIOLOGICAL|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
48356964|NCT03110757|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
48356965|NCT01383551|BEHAVIORAL|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
48668640|NCT02052973|OTHER|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
48668641|NCT02025790|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"* Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~* Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~* Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~* Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~* Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
48668642|NCT02025790|PROCEDURE|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
48668643|NCT02144467|DEVICE|MRI|fMRI, sMRI, ASL and DTI
48668644|NCT03728933|DRUG|Rotigotine 1 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
48668645|NCT03728933|DRUG|Rotigotine 2 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
48668646|NCT03728933|DRUG|Placebo|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
48668647|NCT05690425|DRUG|BC3402 Injection|Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
48668648|NCT01876212|BIOLOGICAL|DC vaccine|
48668649|NCT01876212|DRUG|Dasatinib|
48356966|NCT06409975|BEHAVIORAL|Mindful Self-Compassion (MSC)|MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.
48356967|NCT00413777|DRUG|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
48356968|NCT00066443|BIOLOGICAL|pegfilgrastim|Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2
48356969|NCT00066443|DRUG|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
48356970|NCT00066443|DRUG|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
48356971|NCT04543656|BEHAVIORAL|AI-Based Lifestyle Recommendations|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
47989091|NCT01982851|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
47989092|NCT01982851|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
48356972|NCT04543656|OTHER|No Lifestyle Recommendations|The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
48356973|NCT05734040|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
48356974|NCT05734040|BIOLOGICAL|Fluarix Tetra|One single administration intramuscularly at Day 1
48356975|NCT05734040|BIOLOGICAL|Afluria Quad|One single administration intramuscularly at Day 1
47989093|NCT01107587|BIOLOGICAL|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
47989094|NCT01107587|BIOLOGICAL|Placebo|Oral, two doses.
47989095|NCT04028076|BEHAVIORAL|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
47989096|NCT05044754|PROCEDURE|Local treatment of the prostate (SCAP or HIFU)|Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)
47989097|NCT05282173|BEHAVIORAL|Siyakhana CHW Training|Please see arm description.
47989098|NCT00575913|DRUG|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
48356976|NCT05734040|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
48356977|NCT00324454|BIOLOGICAL|Levetiracetam|Levetiracetam 1500 mg BID
48356978|NCT04651647|PROCEDURE|Revision surgery with / without open bone graft|Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
48356979|NCT04648995|DEVICE|High energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
48356980|NCT04648995|DEVICE|Low energy (UltraPulse)|Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
48356981|NCT01118884|DRUG|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
48356982|NCT00003899|BIOLOGICAL|filgrastim|
48356983|NCT00003899|DRUG|cyclophosphamide|
48356984|NCT00003899|DRUG|melphalan|
48356985|NCT00003899|DRUG|paclitaxel|
48356986|NCT00003899|DRUG|thiotepa|
48356987|NCT00003899|PROCEDURE|autologous bone marrow transplantation|
48356988|NCT00003899|PROCEDURE|peripheral blood stem cell transplantation|
48356989|NCT00065351|DRUG|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
48356990|NCT03865160|DRUG|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
48356991|NCT03865160|DRUG|Atropine eye drops, 0.02%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
48356992|NCT03865160|DRUG|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
48506347|NCT05853042|DIAGNOSTIC_TEST|high-sensitivity cardiac troponin testing|Lithium heparin plasma samples will be measured with Mindray Bio-Medical CL-1200i Chemiluminescence Immunoassay Analyzer.
48506348|NCT01449812|BIOLOGICAL|Infanrix+Hib™|Intramuscular, one dose
48506349|NCT01449812|BIOLOGICAL|Poliorix™|Intramuscular, one dose
48356993|NCT05822349|BEHAVIORAL|picograms-enriched label|The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).
47989099|NCT02461108|BEHAVIORAL|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
48668650|NCT02328872|DEVICE|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
48356994|NCT06307210|OTHER|inpatient rehabilitation|physiotherapy (strength and endurance training), occupational therapy and neuropsychological training
48356995|NCT01726504|DEVICE|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
48668651|NCT02328872|DEVICE|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
47989100|NCT02461108|BEHAVIORAL|Tax|Frame the price difference as a 10% tax on less nutritious food items.
47989101|NCT02461108|BEHAVIORAL|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
47989102|NCT00383149|DRUG|Ixabepilone|Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
47989103|NCT00383149|DRUG|Cetuximab|Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
47989104|NCT02672423|DRUG|Abemaciclib Capsules (Reference Formulation)|Administered orally
47989105|NCT02672423|DRUG|Abemaciclib Tablet (Test Formulation)|Administered orally
48146120|NCT03662841|PROCEDURE|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
48146121|NCT01854866|OTHER|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
48146122|NCT06080087|BEHAVIORAL|I-TEAM|I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
48146123|NCT06067295|OTHER|Non-Interventional Study|Non-interventional study
47989106|NCT06209229|BIOLOGICAL|sodium nucleinate|"* Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~* Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~* Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~* sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~* Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
47989107|NCT04378140|OTHER|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
47989108|NCT01655979|DIETARY_SUPPLEMENT|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
47989109|NCT01655979|OTHER|Control|Bed rest without dietary supplement
47989110|NCT04135833|DRUG|BPI-7711|BPI-7711 60 mg
47989111|NCT04135833|DRUG|BPI-7711|BPI-7711 180 mg
47989112|NCT04135833|DRUG|Itraconazole|Itraconazole 200 mg
47989113|NCT04135833|DRUG|Rifampicin|Rifampicin 600 mg
47989114|NCT00355862|DRUG|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
48146124|NCT00458783|BIOLOGICAL|Prolonged RBC storage|Transfusion with oldest available matching RBCs
48146125|NCT00458783|BIOLOGICAL|Short RBC storage|Transfusion with youngest available matching RBCs
48146126|NCT01386632|DRUG|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
48146127|NCT01386632|DRUG|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
48146128|NCT04815135|OTHER|Observational study|Observational study, the study did not involve any interventions
48506350|NCT03994783|DRUG|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
48668652|NCT05971095|DEVICE|Percutaneous neuromodulation using the EPTE® Bipolar System device|"The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied in order to produce potentiation of the non-nociceptive pathway, using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts. Adjustments to amplitude and pulse width are made until the patient experiences paresthesias at a perceptible but not painful intensity, and the intensity will be set 200 μA above the detection threshold for each subject.~In order to depress the nociceptive pathway, the low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to. To ensure the recruitment of higher threshold type C nociceptive fibers, the intensity level will be programmed at the pain threshold for each subject."
48146129|NCT03741985|BEHAVIORAL|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
48668653|NCT00875914|PROCEDURE|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
48146130|NCT03741985|BEHAVIORAL|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
48506351|NCT03994783|DRUG|Methylprednisolone|Intravenous infusion of methylprednisolone
48668654|NCT04551300|DRUG|VS-505|4 dosages of experimental drug
48668655|NCT04551300|DRUG|Sevelamer Carbonate|Active Comparator
48146131|NCT05058157|DIETARY_SUPPLEMENT|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
48506352|NCT03994783|DRUG|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
48506353|NCT03994783|PROCEDURE|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
48506354|NCT06634381|BEHAVIORAL|CRF Visual Aid|After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
47989115|NCT00355862|DRUG|Sirolimus|Sirolimus based immunosuppression
48506355|NCT02217254|PROCEDURE|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
48506356|NCT00820443|DEVICE|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
48506357|NCT00143923|BEHAVIORAL|Nutrition, Exercise, Stress Management Counseling|Individualized advice
48506358|NCT00143923|OTHER|usual care|usual care
48146132|NCT02792738|BEHAVIORAL|hypnosis|
48146133|NCT04202822|OTHER|Oral soft tissues biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
48146134|NCT03030651|BEHAVIORAL|Breastfeeding Education and Support|Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
48146135|NCT00000892|DRUG|Ritonavir|
48146136|NCT00000892|DRUG|Nelfinavir mesylate|
48506359|NCT05479656|OTHER|Training program|8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
48506360|NCT02341391|BIOLOGICAL|TissueGene-C(Low dose)|3.0 x 10\^6 cells
48506361|NCT02341391|BIOLOGICAL|TissueGene-C(Medium dose)|1.0 x 10\^7 cells
48506362|NCT02341391|BIOLOGICAL|TissueGene-C(High dose)|3.0 x 10\^7 cells
47989116|NCT03054870|DRUG|Xe-133|Xe-133 ventilation scintigraphy
47989117|NCT03054870|DRUG|Technegas|Technegas ventilation scintigraphy
47989118|NCT00374725|BEHAVIORAL|Administration of probiotic (L. rhamnosus and L. acidophilus)|
47989119|NCT05200520|BEHAVIORAL|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
47989120|NCT00555607|DRUG|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
47989121|NCT03410355|PROCEDURE|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
47989122|NCT03410355|PROCEDURE|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
47989123|NCT04395209|OTHER|assesment|muscle strength assessment in stroke individuals
47989124|NCT03580317|OTHER|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
47989125|NCT03580317|OTHER|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
47989126|NCT03580317|OTHER|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
47989127|NCT03580317|OTHER|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
47989128|NCT05061979|DRUG|BAY1747846|Solution for intravenous (IV) injection, single dose
47989129|NCT03401983|OTHER|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
47989130|NCT03401983|OTHER|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
47989131|NCT00798044|BEHAVIORAL|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
47989132|NCT00798044|BEHAVIORAL|Patient Feedback|Weekly feedback reports provided to counselors
48146137|NCT00000892|DRUG|Levocarnitine|
48146138|NCT00000892|DRUG|Adefovir dipivoxil|
48146139|NCT00000892|DRUG|Saquinavir|
48146140|NCT00000892|DRUG|Delavirdine mesylate|
48506363|NCT03458260|DRUG|Pixantrone|6 cycles - dose = 80mg/m²
48506364|NCT03458260|OTHER|Ifosfamide|6 cycles - 1500 mg/m2
48506365|NCT03458260|OTHER|Etoposide|6 cycles - 150 mg/m2
48506366|NCT03458260|OTHER|Rituximab|6 cycles - 375 mg/m2
48356996|NCT01726504|DEVICE|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
48356997|NCT04815291|DEVICE|Receives SCOUT at biopsy|SCOUT Reflector
48356998|NCT04727411|PROCEDURE|XEN45 Gel stent|XEN Gel stent implantation either combined or as a stand-alone procedure
47989133|NCT01304966|PROCEDURE|biopsy|excisional biopsy
47989134|NCT05014750|OTHER|None intervention|There is no intervention included in this study.
47989135|NCT04515342|DIAGNOSTIC_TEST|DXA|Each participant will undergo one DXA scan
47989136|NCT04515342|OTHER|Muscle strength and function assessment|Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).
48506367|NCT03458260|PROCEDURE|Transplant|after 2 or 6 cycles
48506368|NCT06633939|BEHAVIORAL|Behavioral Treatment|The theoretical framework for the Move \&amp; Eat 2 Live intervention is guided by the health belief model (HBM), socioecological model (SEM) and motivational interviewing (MI) approach. Tailoring to the target community will include a standard cultural adaptation that will replace curriculum content and examples with Native American relevant foods, physical activities, and representation in materials. For this study, the intervention will be piloted in the target population and will include the first 5 sessions of the original 12-session program.
48506369|NCT04290975|OTHER|Task-shifting of follow-up care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be shifted to be performed primarily by Community Health Workers (CHWs) with specialized epilepsy training
48506370|NCT04290975|OTHER|Enhanced usual care for pediatric epilepsy|For the intervention arm, follow-up care of children with epilepsy will be performed primarily by physicians, with CHWs serving to collect standardized data regarding outcomes
47989137|NCT04515342|OTHER|Blood samples|Each patient will undergo a physical examination and also deliver blood samples.
47989138|NCT05779878|OTHER|Post Isometric Relaxation|Post-isometric relaxation (PIR) is a soft tissue stretching technique used by many health care professionals to lengthen both acute and chronic short muscles.
47989139|NCT05779878|OTHER|Myofascial arm pull technique|Myofascial therapy is described as the promotion of psychophysiological, neurological and structural adaptive capability as multiplexed via the myofascial system. Fascia covers all body structures, particularly muscles and their constituent myofibrils
47989140|NCT03529240|DEVICE|Kinesiology Taping|Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
47989141|NCT05880810|DEVICE|Continuous Glucose Monitor Dexcom G6 PRO|Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
48506371|NCT00734396|PROCEDURE|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
47989142|NCT00016146|BIOLOGICAL|GPI-0100|
47989143|NCT00016146|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
47989144|NCT03303378|DRUG|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
47989145|NCT03303378|DRUG|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
47989146|NCT05643365|RADIATION|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
47989147|NCT02796040|DEVICE|MRI|
47989148|NCT03797209|DEVICE|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
47989149|NCT03025867|DRUG|Niraparib|
47989150|NCT03895996|DRUG|AVT001|autologous dendritic cell therapy
47989151|NCT03895996|OTHER|Placebo|matched placebo
48356999|NCT04727411|PROCEDURE|Trabeculectomy|XEN Gel stent implantation either combined or as a stand-alone procedure
48357000|NCT02048774|BEHAVIORAL|Designation of Social Positioning|
48357001|NCT05960656|DRUG|Empagliflozin 25 MG|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
48357002|NCT05960656|OTHER|Placebo|Inert tablet
48357003|NCT05960656|DRUG|Pioglitazone 30mg|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
48668656|NCT02403544|RADIATION|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
48668657|NCT02403544|DRUG|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
47989152|NCT01687959|OTHER|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
47989153|NCT02181439|DEVICE|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
48146141|NCT04850092|OTHER|Positional change from supine to prone|Patient is turned from supine to prone position for spine surgery
48146142|NCT00296309|DRUG|Tacrolimus|Immunosuppression
48146143|NCT04720209|OTHER|CARE|CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site
48146144|NCT04720209|OTHER|TARE|TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site
48146145|NCT04720209|OTHER|Home-Based Stretching|This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
48146146|NCT05798598|OTHER|Scientific writing training course|Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
48146147|NCT02542332|OTHER|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
48146148|NCT03033056|BEHAVIORAL|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
48146149|NCT05041894|OTHER|tilt table|The tilt table provides passive standing for the stroke patients with tracheotomy
48146150|NCT04433052|BEHAVIORAL|personalised prevention program (PPP)|Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.
47989154|NCT06447727|DRUG|SIRT with Yttrium-90 Microspheres|Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
47989155|NCT06447727|DRUG|FOLFIRI and Bevacizumab|FOLFIRI and Bevacizumab
47989156|NCT03577743|DRUG|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
48146151|NCT00811239|DRUG|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
48146152|NCT00811239|OTHER|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
48146153|NCT06226116|PROCEDURE|socket preservation|After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
48146154|NCT06226116|PROCEDURE|placement of experimental implants|After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
48146155|NCT06226116|PROCEDURE|histological sample collection|"Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long."
48146156|NCT05954247|DRUG|DWJ1543|DWJ1543
48146157|NCT05954247|DRUG|DWC202216|DWC202216
48146158|NCT01586416|BEHAVIORAL|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
48146159|NCT02312258|DRUG|Placebo|Ixazomib placebo-matching capsules.
48146160|NCT02312258|DRUG|Ixazomib|Ixazomib capsules.
48146161|NCT04806659|DRUG|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
48668658|NCT02403544|DRUG|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
48668659|NCT04445948|DRUG|Esomeprazole 40 milligrams Oral Tablet|Proton Pump inhibitor
48668660|NCT04445948|DRUG|Amoxicillin 1000 milligrams tablets|Penicillin derivative antibiotic
48668661|NCT04445948|DRUG|Clarithromycin 500 milligrams Tablets|Macrolide antibiotic
47989157|NCT04906551|DEVICE|laser Doppler|A direct measure of blood flow
47989158|NCT06376747|PROCEDURE|In line sampling|closed technique of sample collection
48146162|NCT01711788|PROCEDURE|Intrabone infusion of umbilical cord blood stem cells|
48668662|NCT04445948|DRUG|MetroNIDAZOLE 500 milligrams Oral Tablet|Antiprotozoal
48668663|NCT04445948|DRUG|Lactoferrin Bovine sachets 200 milligrams|a protein found naturally in milk from humans and cows
48668664|NCT04811690|BEHAVIORAL|front-of-package modification|testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
48668665|NCT00148356|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
48668666|NCT00148356|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
48146163|NCT06118008|DRUG|HS-20094 5mg|Administrated by subcutaneous injection
48146164|NCT06118008|DRUG|HS-20094 10mg|Administrated by subcutaneous injection
48668667|NCT04127318|BEHAVIORAL|Pedaling Group|Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
48146165|NCT06118008|DRUG|HS-20094 15mg|Administrated by subcutaneous injection
48146166|NCT06118008|DRUG|HS-20094 20mg|Administrated by subcutaneous injection
48146167|NCT03477084|BIOLOGICAL|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
48146168|NCT03477032|BIOLOGICAL|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
48146169|NCT04094207|DRUG|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
48146170|NCT04094207|DRUG|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
48146171|NCT03800771|DEVICE|Cycléo BRAU|Practice dual-task tests.
48146172|NCT03800771|DEVICE|GAITRITE®|Routine practice dual-task tests.
48146173|NCT01047709|DEVICE|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
48146174|NCT03153475|DEVICE|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
48146175|NCT05483985|DEVICE|Hera Score|The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
48146176|NCT02051218|DRUG|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
48668668|NCT00487916|DRUG|AMA1-C1/ISA 720|
47989159|NCT06376747|PROCEDURE|Standard blood sampling technique|Blood draws using standard steps: blood withdrawal for catheter, decontamination (disposed),blood draw for laboratory analysis,catheter flush
48146177|NCT02051218|DRUG|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
48146178|NCT03368274|DRUG|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
48146179|NCT02378584|OTHER|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
48146180|NCT04105907|DEVICE|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
48146181|NCT04830345|BIOLOGICAL|ATGC-100 100U|Clostridium botulinum toxin type A
48146182|NCT04830345|BIOLOGICAL|Botox 100U|Clostridium botulinum toxin type A
48146183|NCT02009865|DRUG|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
48146184|NCT02009865|DRUG|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
48146185|NCT05907070|OTHER|Mandala group|Mandala group will participate in 2 sessions of individual mandala drawing art activity with the theme of 'Emotions' accompanied by classical or instrumental music. In each session, a mandala will be created.
48146186|NCT05907070|OTHER|Value clarification group|Value clarification groups will participate in the value clarification activity by writing 2 sessions individually with the theme of 'Emotions' accompanied by classical or instrumental music.
48506372|NCT01510626|DIETARY_SUPPLEMENT|Food proteins|Food proteins
48506373|NCT01510626|DRUG|Omalizumab|Drug
48506374|NCT00754715|DRUG|AZD2516|Solution administered once orally
48506375|NCT00754715|DRUG|Placebo|Solution administered only once
48506376|NCT02757573|PROCEDURE|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
48506377|NCT01755767|DRUG|Tivantinib|Tivantinib tablets
48506378|NCT01755767|DRUG|Placebo|Matching placebo tablets
48506379|NCT03654820|DEVICE|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
48506380|NCT03654820|DEVICE|SDF solution|Annual application of 38% SDF solution
48506381|NCT02618135|OTHER|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
48506382|NCT02618135|OTHER|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
48506383|NCT03021889|BEHAVIORAL|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
48668669|NCT06370390|BEHAVIORAL|swallowing function training|"The group rehabilitation program comprised daily 60-minute sessions, five times per week for a duration of 4 weeks.~The group rehabilitation program included: Rehabilitation oral and facial exercises, Game-based surface electromyographic biofeedback training, Participants experience sharing, Individual direct feeding training"
48668670|NCT04863430|DRUG|Apatinib|500mg oral qd
48146187|NCT01220999|DRUG|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).
48146188|NCT00558441|DEVICE|IVMRI|Intra Vascular Magnetic Resonance Imaging
48668671|NCT04863430|DRUG|Oxaliplatin|130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
48668672|NCT04863430|DRUG|S1|According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
47989160|NCT05554198|BEHAVIORAL|Attend Behavior Parent Training|Attend Behavior is a Parent Training intervention available in application form for smartphones or online. Attend Behavior consists of 12 instructional modules and it is recommended that parents complete one module a week in addition to practicing the techniques taught in that course. Each learning module typically around 30 minutes to complete and includes an introductory video to give parents an overview of the different features of the application. At the start of the intervention, parents will take an assessment that will provide information for the program to create individualized goals, plans, reinforcement agents, and even daily schedules. A HIPPA compliant clinician portal within the application allows the clinician to have real time access to monitor the parent learning progress, tracked behaviors, parental notes, and message with the parent.
48146189|NCT04432415|DEVICE|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
48146190|NCT04432415|DEVICE|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
48146191|NCT04432415|DEVICE|Placebo|biannual application of artificial saliva
48146192|NCT02926313|OTHER|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
48146193|NCT00110032|DRUG|EF5|Given IV
48146194|NCT00110032|PROCEDURE|conventional surgery|Undergo surgery
48146195|NCT00110032|PROCEDURE|positron emission tomography|Undergo PET
48146196|NCT00110032|RADIATION|fluorine F 18 EF5|Given IV
48146197|NCT00110032|OTHER|pharmacological study|Correlative studies
48146198|NCT06204653|DEVICE|HFNO group|100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)
48146199|NCT06204653|DEVICE|MV group|Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
48146200|NCT05360537|DRUG|Insulin Degludec / Liraglutide Injectable Product|administration of Insulin Degludec/Liraglutide
48146201|NCT05360537|DRUG|Insulin Glargine|Administration of glargine insulin
48506384|NCT03021889|BEHAVIORAL|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
48668673|NCT01074931|DRUG|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
48668674|NCT00586157|DRUG|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
48668675|NCT00586157|DRUG|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
48146202|NCT02994498|DRUG|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
48668676|NCT00458549|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
48146203|NCT06552351|DEVICE|Needle-Free Jet Injection of 1 % lidocaine|The needle-free jet injection device delivers 1% lidocaine through high-pressure fluid without the use of a needle. This method aims to reduce the pain associated with needle-based anesthesia during infant lumbar punctures.
48146204|NCT06552351|OTHER|traditional needle infiltration of 1% lidocaine|Traditional needle infiltration involves injecting 1% lidocaine with a needle to provide local anesthesia before an infant lumbar puncture. This method is the standard practice for pain management in such procedures.
48146205|NCT01474356|OTHER|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
48146206|NCT06462248|DRUG|CUCART19|anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)
48146207|NCT03175406|DIAGNOSTIC_TEST|Manipal cervical scoring system|
48146208|NCT05197179|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
48146209|NCT05197179|OTHER|FB2001 placebo|Subjects will be administered with FB2001 by intravenous (IV) infusion
48357004|NCT05960656|DRUG|Pioglitazone 30mg + Empagliflozin (25 mg)|Combination of two medications used in the management and treatment of type 2 diabetes mellitus in the thiazolidinedione and sodium-glucose co-transporter (SGLT-2) class of medications, respectively.
48357005|NCT02182856|DRUG|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
48357006|NCT02182856|DRUG|Ipratropium 500 µg|
48357007|NCT02182856|DRUG|Salbutamol sulphate 3 mg|
48357008|NCT02182856|DRUG|Salbutamol sulphate 6 mg|
48506385|NCT00006460|DRUG|hyperbaric oxygen|
48506386|NCT00006460|RADIATION|radiation therapy|
48506387|NCT05129605|DIAGNOSTIC_TEST|Prostate cancer screening|Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate
48506388|NCT00422500|BEHAVIORAL|Questionnaire|Surveys about symptoms, mood, and quality of life.
48506389|NCT00422500|BEHAVIORAL|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
48668677|NCT00458549|PROCEDURE|biopsy|
48146210|NCT00900302|GENETIC|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
48668678|NCT05352802|BEHAVIORAL|Multimodal prehabilitation program|Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.
48668679|NCT05352802|BEHAVIORAL|ERAS protocol|The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
47989161|NCT02558712|OTHER|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
48357009|NCT00276224|DRUG|ferrous sulphate (drug)|
48357010|NCT01786499|BEHAVIORAL|Relaxation Response Training|
48357011|NCT05453929|DRUG|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
48506390|NCT00422500|OTHER|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
48506391|NCT06357806|DRUG|Sintilimab|100mg/10ml/1bottle
48506392|NCT06357806|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
48506393|NCT06357806|DRUG|NAs|tablets
48668680|NCT02950337|RADIATION|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
48668681|NCT02950337|RADIATION|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
48668682|NCT02950337|RADIATION|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
48668683|NCT05173779|PROCEDURE|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
48668684|NCT01603017|DEVICE|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
48668685|NCT01603017|DEVICE|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
47989162|NCT00531024|DRUG|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
47989163|NCT00531024|DRUG|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
47989164|NCT06242587|DEVICE|Pericoccygeal nerve block|The coccygeal corneas are visualised with a linear probe under ultrasound guidance. The pericoccygeal nerves are located medial to the cornu and a combination of local anaesthetic and dexamethasone is injected.
47989165|NCT06242587|PROCEDURE|Impar ganglion block|The sacrum is visualised with fluoroscopy. A needle is inserted through the sacrococcygeal junction. The optimal image is obtained by administering contrast material. A combination of local anaesthetic and dexamethasone is injected.
47989166|NCT05254457|BIOLOGICAL|EN3835|Treatment or retreatment with up to two doses of EN3835
47989167|NCT02158338|OTHER|Asthma|mothers who have children that have been diagnosed with respiratory issues
47989168|NCT02158338|OTHER|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
47989169|NCT01912287|BEHAVIORAL|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
47989170|NCT01912287|BEHAVIORAL|Stress Education|Active control group (12 sessions)
47989171|NCT01912287|BEHAVIORAL|Yoga|12 sessions, mindfulness components
47989172|NCT06388863|DRUG|Healthy donor-derived FMT capsule|Participants will be treated with healthy donor-derived fecal microbiota transplantation in the form of oral capsules.
47989173|NCT06388863|DRUG|Placebo capsule|Capsules whose appearance and smell are identical as FMT capsules but contain milk powder
47989174|NCT05506852|BEHAVIORAL|Web-based training strategy|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game using specific strategies, in order to optimize the performance."
48357012|NCT05453929|DRUG|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
48357013|NCT06230003|DRUG|Ropivacaine|Ultrasound guided ESP block either with the local anesthetic of 0.5% of Ropivicane 20 mL bilaterally (intervention group) or normal saline (control group) before surgery which will take 5-10 minutes in a 1:1 ratio.
48357014|NCT06230003|DRUG|normal saline|Ultrasound guided bilateral ESP block either with normal saline
48357015|NCT02176434|PROCEDURE|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
48357016|NCT02176434|BIOLOGICAL|hematopoietic stem cell|
47989175|NCT05506852|BEHAVIORAL|Web-based regular training (no strategy)|"Participants will undergo a web-based training protocol where they will play an online game that simulates a breakfast environment and will perform everyday activities as cooking and setting tables in a multi-tasking fashion. Participants will learn to play the game under regular game instructions."
48146211|NCT00900302|OTHER|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
48146212|NCT00900302|OTHER|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
48668686|NCT02659085|DRUG|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
48668687|NCT02659085|PROCEDURE|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
48668688|NCT01769924|OTHER|Nephrectomy|Nephrectomy for the purposes of living kidney donation
48668689|NCT02765048|BEHAVIORAL|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
48668690|NCT05176587|OTHER|Follow-up of patients undergoing bariatric surgery : integrated pathway|Integrated pathway : multidisciplinary, pre- and post-operative, care course for patients undergoing bariatric surgery
48146213|NCT00900302|PROCEDURE|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
48146214|NCT01821040|DRUG|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
48357017|NCT05761405|COMBINATION_PRODUCT|mannitol-enhanced aminoglycoside|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes."
48357018|NCT05761405|DRUG|Ceftriaxon|"Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes."
48357019|NCT05761405|DRUG|Amikacin|Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
48357020|NCT02709889|DRUG|Rovalpituzumab tesirine|
48357021|NCT02709889|DRUG|Dexamethasone|Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
48668691|NCT00003562|DRUG|carboplatin|
48668692|NCT00003562|DRUG|docetaxel|
48668693|NCT05393700|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.
48668694|NCT03929679|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
48668695|NCT06264609|DRUG|Alendronate|Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.
48668696|NCT06264609|DRUG|Teriparatide|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.
48668697|NCT06264609|DRUG|Alendronate|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
48668698|NCT04672135|DRUG|REM0046127|Oral solution: 100 mg/mL REM0046127
47989176|NCT01601782|PROCEDURE|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
47989177|NCT01601782|DEVICE|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
48146215|NCT01821040|DRUG|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
48146216|NCT05928754|DIAGNOSTIC_TEST|care strategy|"Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7."
48146217|NCT04645849|BIOLOGICAL|Immunomonitoring|"16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules."
48146218|NCT05672485|DIAGNOSTIC_TEST|SPECT/CT imaging with 99mTc-P137 nuclide probe|inject the tracer 99mTc-P137 to subjects and perform SPECT/CT scans
48146219|NCT02614157|PROCEDURE|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
48146220|NCT02614157|DEVICE|labeled line|
48146221|NCT02613052|DRUG|normal saline|10 mL of normal saline agitated prior to IV administration
48146222|NCT02613052|DRUG|human albumin|10 mL of 5% albumin agitated prior to IV administration
48146223|NCT02613052|DRUG|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
48146224|NCT01794273|DRUG|ephedrine and phenylephrine|
48146225|NCT00816205|DRUG|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
48146226|NCT01303744|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
48146227|NCT01303744|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
48146228|NCT01303744|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
48357022|NCT04581291|OTHER|Moderate Intensity Aerobic Exercises|Participants in the exercise group performed a two weeks aerobic exercise program. The exercise program consisted of walking/running on a treadmill or bicycling on a stationary bicycle. Each session is composed of five-minute warm-up slow walking or bicycling. Then the main intervention which composed of thirty-minutes of moderate-intensity aerobic exercises (walking/running or bicycling). Lastly, a five-minute of cool-down exercises (walking/running or bicycling). The exercise intensity was 60-75% of the predicted MHR (calculated as MHR=210-age).
48357023|NCT03062605|DRUG|Iodine (Betadine)|
48357024|NCT03062605|BIOLOGICAL|NaOCL|
48357025|NCT01768039|DRUG|Vitamin D|
48357026|NCT01768039|DRUG|Placebo|
48668699|NCT04672135|DRUG|Placebo|Oral solution with 0 mg/mL REM0046127
48668700|NCT02092181|DRUG|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
48146229|NCT01303744|DRUG|Placebo|oral tablet, once a day in the morning for 12 weeks
48146230|NCT04454112|DEVICE|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
48146231|NCT02052167|DEVICE|methotrexate prefilled pen|
48146232|NCT00882856|DRUG|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
48146233|NCT00882856|DRUG|Placebo|placebo
48357027|NCT01371799|DRUG|Drug|Placebo
48357028|NCT01371799|DRUG|Drug|4mg and 8mg Study drug
48357029|NCT02293265|DRUG|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
48357030|NCT02301728|OTHER|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
48357031|NCT01252927|OTHER|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
48357032|NCT05093842|BEHAVIORAL|Sedentary Behavior Reduction|Participants receive bimonthly behavioral health coaching, a sit-stand desk attachment or table, and an activity prompter if they do not already have one (e.g., fitbit, as needed).
48357033|NCT05093842|BEHAVIORAL|Information on Physical Activity Recommendations during Pregnancy|Participants in the study will receive educational materials provided one time by email about the currently recommended physical activity during pregnancy.
48357034|NCT04848129|BEHAVIORAL|Feeding clinic|These children have all attended a multidisciplinary feeding clinic with severe food refusal and were commonly receiving tube feeding or supplement drinks. The clinic helps children progress onto a normal oral diet
48357035|NCT04184466|DRUG|Insulin Aspart|insulin aspart in doses 0.3 IU/kg
48357036|NCT04184466|DRUG|NovoRapid® Penfill®|insulin aspart in doses 0.3 IU/kg
48357037|NCT01542632|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
48668701|NCT02092181|DRUG|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
47989178|NCT06519188|OTHER|Nebulization application with 5 ml isotonic sodium chloride|Nebulization application with 5 ml isotonic sodium chloride in the morning and evening for two months.
48146234|NCT04917601|BEHAVIORAL|Evira Care treatment|The intervention aim to examine the effectiveness of using a digital support system (Evira) in treatment of childhood obesity. Through daily weighings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored. Participants can be randomized to either the intervention group or the control group. The control group will receive local standard treatment.
48146235|NCT04917601|BEHAVIORAL|Standard Lifestyle Care|The control group will receive the local standard care of treatment addressing lifestyles for childhood obesity without any restriction in visits or clinical support. This is the current standard care of treatment for childhood obesity.
48146236|NCT00516399|DRUG|povidone-iodine 1.25% ophthalmic solution|
48146237|NCT00516399|DRUG|natamycin ophthalmic suspension, USP 5%|
48146238|NCT06395207|BEHAVIORAL|Proactive community case management|Community health workers conduct proactive visits to households in their community every two weeks for two months to screen for fever and test and treat febrile individuals for malaria.
48146239|NCT06395207|BEHAVIORAL|Strengthened SBCC and stock out mitigation|Ensure CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed in the national strategy.
48146240|NCT02436070|BEHAVIORAL|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
48146241|NCT02436070|BEHAVIORAL|General text messages|Subjects received text messages generalized to children with asthma
48146242|NCT01425398|DRUG|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
48146243|NCT01425398|DRUG|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
48146244|NCT00658632|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
48146245|NCT00658632|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
48146246|NCT04105699|DEVICE|Blood sampling|Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
48146247|NCT04509102|DRUG|Adderall-XR|Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
48668702|NCT01697111|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
47989179|NCT04571710|DRUG|SHR1258|Drug: SHR1258 400mg
48146248|NCT04509102|DRUG|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
48146249|NCT06430086|OTHER|Walnut consumption|Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.
48146250|NCT06430086|OTHER|HCHS consumption|"Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality."
48146251|NCT04226118|DEVICE|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
48146252|NCT00197444|DRUG|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
48146253|NCT00197444|RADIATION|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
48146254|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
48146255|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
48357038|NCT01542632|BIOLOGICAL|TDV New Formulation|TDV New Formulation subcutaneous injection
48357039|NCT01542632|DRUG|Placebo|Placebo subcutaneous injection
48357040|NCT01542632|DRUG|New Formulation Placebo|New Formulation placebo subcutaneous injection
48357041|NCT06374316|DEVICE|Ceiling-Mounted Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
48357042|NCT06374316|DEVICE|Portable Air Purifiers|The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
47989180|NCT02201706|PROCEDURE|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
47989181|NCT05422677|DRUG|Hanmi Tams® Capsule|Hanmi Tams®, Once daily administered per the locally approved product information
47989182|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.
47989183|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.
47989184|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 1|Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.
47989185|NCT04368988|OTHER|Normal saline solution (NSS), Placebo - Phase 2|Intramuscular (deltoid) injections of placebo (0.5 mL).
47989186|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.
48668703|NCT01697111|DRUG|Placebo|One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively
48668704|NCT01697111|DRUG|Dienogest|Dienogest 1mg twice a day (bid)
48146256|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
48146257|NCT01537497|DRUG|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
48146258|NCT04981431|DRUG|Elinzanetant (BAY3427080)|Oral administration
48146259|NCT04981431|DRUG|Placebo|Oral administration
48146260|NCT03878407|OTHER|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
48146261|NCT04347148|PROCEDURE|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
48146262|NCT04347148|PROCEDURE|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
48146263|NCT01634802|OTHER|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
48146264|NCT01634802|OTHER|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
48146265|NCT01199315|DRUG|AZD1446|oral capsule, Moderate Release
48146266|NCT01199315|DRUG|Placebo|oral capsule
48146267|NCT02399072|OTHER|No intervention|No intervention administered in this study
48146268|NCT03049332|BEHAVIORAL|self- and family-management intervention sessions|The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
48146269|NCT00482911|DRUG|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
48668705|NCT00598507|DRUG|ZK-EPO|Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
48668706|NCT05266547|DEVICE|OCT guided coronary intervention|patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group
48668707|NCT03399448|BIOLOGICAL|NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
48668708|NCT03399448|DRUG|Cyclophosphamide|a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
48146270|NCT00482911|DRUG|lenalidomide|10 mg by mouth once daily on days 1-28.
48146271|NCT00482911|DRUG|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
48506394|NCT02789553|OTHER|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
48668709|NCT03399448|DRUG|Fludarabine|a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
48668710|NCT03399448|DEVICE|NY-ESO-1 expression testing|Testing to determine if NY-ESO-1 is expressed on tumor tissue.
48668711|NCT03247829|DEVICE|Hemodynamic management using CardioMEMS HF System|Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges
48668712|NCT05716945|DRUG|Fluorometholone 0.1% Oph Susp|"Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily."
48668713|NCT05716945|DRUG|Dexamethasone 0.1% ophthalmic suspension|Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
47989187|NCT04368988|OTHER|Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.
48146272|NCT06451107|OTHER|specific strength training with static neck stretching|The intervention will consist of specific strength training composed of 5 exercises performed with dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. In addition to the following static stretches: stretching towards lateral flexion of the upper part of the trapezius muscle, the scalene muscles, and the sternocleidomastoid muscle on both sides; extension of the extensor muscles; flexion of the flexor muscles; and contralateral flexion and rotation combined with scapular depression of the scalene muscles and elevation of the scapula on both sides, holding each stretch for 10 seconds. This sequence of stretches will constitute one set, with 6 sets performed with a 30-second rest between sets, lasting 8 minutes. Therefore, the intervention will have a total duration of 28 minutes per session, conducting 3 sessions per week.
48146273|NCT06451107|OTHER|Specific Strength Training|The intervention will consist of specific strength training comprised of 5 exercises using dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. Four sets will be performed, with a 1-minute rest between sets. Each exercise will be executed for 30 seconds, followed by a 25-second rest between exercises. Three 20-minute sessions will be conducted per week.
48146274|NCT00799838|DRUG|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
48668714|NCT05716945|OTHER|Stop steroids|Half the patients in each study arm will discontinue steroids.
48357043|NCT06374316|DEVICE|Portable or Ceiling Mounted Air Purifiers|The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
48357044|NCT05659459|DRUG|KIN001|Oral tablet
48357045|NCT05659459|DRUG|KIN001-Placebo|Comparator - Oral tablet with same appearance of KIN001
48357046|NCT00215228|DRUG|duloxetine vs. escitalopram|
48357047|NCT03299621|DEVICE|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
48357048|NCT03299621|DRUG|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
48357049|NCT01807494|DEVICE|Total hip replacement components|All patients will receive the same implants
48357050|NCT02469662|DEVICE|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
48357051|NCT00040911|PROCEDURE|electroacupuncture therapy|
48357052|NCT00040911|PROCEDURE|sham intervention|Undergo electroacupuncture therapy to sham points
48357053|NCT00040911|PROCEDURE|quality-of-life assessment|Ancillary studies
48357054|NCT00397644|BEHAVIORAL|Prompting (survey instrument/resources list) (behavior)|
48357055|NCT05473442|DRUG|EQU-001|20 mg pills of EQU-001
48668715|NCT03703050|DRUG|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
48668716|NCT03703050|DRUG|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
48668717|NCT00020254|BIOLOGICAL|aldesleukin|
48668718|NCT00020254|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
48668719|NCT00020254|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
48668720|NCT00020254|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
48668721|NCT00020254|BIOLOGICAL|sargramostim|
48668722|NCT00020254|DRUG|nilutamide|
48668723|NCT03941132|DRUG|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously."
48668724|NCT03941132|DRUG|Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously."
47989188|NCT04368988|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2|Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
47989189|NCT06245590|DRUG|Albumin|20 grams/ week Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).
47989190|NCT06245590|DRUG|Midodrine|Midodrine
48357056|NCT05473442|OTHER|Matching Placebo|20 mg matching placebo pills
48357057|NCT01278810|DRUG|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
48357058|NCT00869063|DRUG|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
48357059|NCT00869063|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
48357060|NCT02967406|BEHAVIORAL|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
48668725|NCT00361712|PROCEDURE|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
48668726|NCT00361712|DRUG|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
48668727|NCT03895073|OTHER|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
47989191|NCT06245590|OTHER|Standard of Care|Standard of Care
47989192|NCT00992082|DRUG|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
47989193|NCT00992082|DRUG|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
47989194|NCT04696952|DRUG|TS-142|TS-142
47989195|NCT04696952|DRUG|Zopiclone|Zopiclone
48668728|NCT04326452|DEVICE|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
48357061|NCT06038968|DRUG|Methotrexate 25 MG/ML|Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
48357062|NCT06038968|PROCEDURE|parsplana vitrectomy|Pars plana vitrectomy (PPV) is a technique in vitreoretinal surgery that enables access to the posterior segment for treating tractional retinal detachment in advanced proliferative diabetic retinopathy, in a controlled, closed system.
48357063|NCT05446181|BEHAVIORAL|Postoperative delirium|Postoperative delirium
48357064|NCT05446181|PROCEDURE|Hip surgery|Orthopedic hip joint surgery under spinal anesthesia
48357065|NCT01987609|DRUG|Hylenex|
48357066|NCT01987609|DRUG|Normal Saline|
48668729|NCT03991585|BEHAVIORAL|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
48668730|NCT01883921|OTHER|Immunoglobulin Therapy|
48668731|NCT00078221|DEVICE|Rheopheresis blood filtration|
48668732|NCT04330976|BEHAVIORAL|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
48668733|NCT04330976|BEHAVIORAL|Control|Messages sent on general health during pregnancy
48668734|NCT03259295|DEVICE|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
47989196|NCT04696952|DRUG|Placebo|Placebo
48146275|NCT00799838|DRUG|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
48146276|NCT00799838|DRUG|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
48357067|NCT02796495|DEVICE|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
48506395|NCT02789553|OTHER|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
48668735|NCT01523938|BEHAVIORAL|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
48668736|NCT05967754|DIAGNOSTIC_TEST|polysomnography|polysomnography and serum uric acid measurement
48668737|NCT02605902|BEHAVIORAL|(i)Comprehensive Behavioral Intervention for Tics|
48668738|NCT02605902|BEHAVIORAL|internet-delivered psychoeducation and relaxation training|
48668739|NCT05947006|OTHER|Standard care|Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure, consisting of a medical assessment of the child, followed by 6 hours of supervision of the child and his parent in the waiting room, a reassessment of the child by the doctor, and finally they can return home
48668740|NCT05947006|OTHER|CONSULFE consultation|In addition to the standard care, patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE) during the 6 hour supervision time in the waiting room
48668741|NCT01463527|DEVICE|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
48146277|NCT03742882|DRUG|CC-90001|CC-90001
48357068|NCT00095394|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
48357069|NCT00095394|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
47989197|NCT06135233|OTHER|No intervention|all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization
48357070|NCT00501930|DRUG|GSK189075|
48357071|NCT03884049|PROCEDURE|Embolization|transcatheter arterial embolization of neovessels around the knee
48357072|NCT03884049|PROCEDURE|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
48668742|NCT05700825|BEHAVIORAL|Expiratory Muscle Strength Training + Cough Skill Training|"Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles.~Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback."
48357073|NCT00939341|DRUG|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
48357074|NCT06317415|BEHAVIORAL|WeChat-based health education on antibiotic use|Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.
48357075|NCT06317415|BEHAVIORAL|Regular public health education|Health education information on the prevention and control of common chronic diseases
48357076|NCT03436992|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
48357077|NCT03436992|DIETARY_SUPPLEMENT|Resveratrol|1500 mg trans-resveratrol
48357078|NCT03436992|OTHER|Placebo|placebo
48146278|NCT06500546|PROCEDURE|Treatment of cervical lesions|"Four non-carious cervical lesions from patients will be separated into four groups according to according to the adhesion trategies described below:~1. adhesive material will be applied in total-etch mode,~2. adhesive material will be applied in self-etch,~3. universal adhesive material will be applied for 10 sec. in total-etch mode, which includes rubbing,~4. universal adhesive material will be applied for 10 sec. in self-etch mode, which includes rubbing,"
48357079|NCT02439866|DRUG|placebo|gelatinous capsules filled with sugar as placebo
48357080|NCT02439866|DRUG|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
48668743|NCT01039389|DRUG|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
48668744|NCT01039389|DRUG|Placebo|bid placebo
48668745|NCT04191226|DIAGNOSTIC_TEST|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
48668746|NCT05443529|OTHER|Adaptive sports|Participation in community adaptive sports programs
48357081|NCT02439866|DRUG|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
48357082|NCT04272372|DRUG|Ketoprofen|PO and local therapy
48357083|NCT02335567|OTHER|there is no intervention|
48357084|NCT00392210|GENETIC|Voiding Trial|Post-void residual and uroflow study will be done twice
48357085|NCT02417935|DRUG|Duloxetine|Administered orally
48668747|NCT02266160|DRUG|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
48357086|NCT02417935|DRUG|Pregabalin|Administered orally
48668748|NCT02266160|OTHER|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
48668749|NCT06021132|DEVICE|cochlear implant|Insertion of a electrode into the cochlear with the aim of providing deaf and severe hearing handicapped with the ability to hear speech.
48668750|NCT01344343|OTHER|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
48357087|NCT02417935|DRUG|Placebo|Administered orally
48357088|NCT00405275|DRUG|Etanercept|etanercept, subcutaneous injection
48357089|NCT00405275|DRUG|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
48668751|NCT00005935|DRUG|Mycophenolate mofetil|
48357090|NCT00405275|DRUG|Sulfasalazine|sulfasalazine, oral
48357091|NCT00405275|DRUG|Hydroxychloroquine|hydroxychloroquine, oral
48357092|NCT00405275|DRUG|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
48357093|NCT00405275|DRUG|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
48506396|NCT05833698|DIAGNOSTIC_TEST|Elevation of NLR|Blood test
48668752|NCT00005935|DRUG|Cyclosporine|
48668753|NCT04864691|BIOLOGICAL|endovascular recanalization|to recanalize the occlusion cerebral artery with intravascular intervention
48668754|NCT06351618|OTHER|No intervention will be conducted.|No intervention will be conducted.
48668755|NCT01497756|DEVICE|CAPP use|Any abdominal pelvic pressure
48668756|NCT03144284|OTHER|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
48668757|NCT01013571|DRUG|insulin glargine|pre-filled disposable pen, in package of 5.
48668758|NCT01013571|DRUG|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
48668759|NCT01924780|DEVICE|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
48357094|NCT02027285|DIETARY_SUPPLEMENT|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
48357095|NCT01924260|DRUG|alisertib|Given PO
48357096|NCT01924260|DRUG|gemcitabine|Given IV
48357097|NCT01327924|DRUG|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
48357098|NCT00722735|DRUG|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
48357099|NCT00722735|DRUG|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
48357100|NCT01970540|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
48357101|NCT01970540|DRUG|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
48357102|NCT00258596|DEVICE|sirolimus-eluting stent|
48357103|NCT03049852|DRUG|CBT-001 single dose|One drop in the study administered one time
48357104|NCT03049852|DRUG|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
48357105|NCT03049852|DRUG|CBT-001 Multi-dose|One drop in the study administered three times daily (TID) for 4 weeks
48357106|NCT05840627|OTHER|Fruit juice|Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
47989198|NCT06249425|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48357107|NCT05487976|DRUG|Recombinant human activated coagulation factor VII for injection|Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
48357108|NCT04735211|PROCEDURE|Surgery|Pediatric Surgery with hospitalized
48357109|NCT04808492|DEVICE|CureWave High Intensity Laser|"* The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~  * Power (44 Watts)~ * Mode (continues wave)~ * Time on (60000 ms)~ * Time off (1 ms)~ * Repeats (9)~* Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~* The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted."
48357110|NCT04808492|OTHER|Placebo|"The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes."
48357111|NCT02306148|OTHER|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
48357112|NCT02557867|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
48357113|NCT06278584|DEVICE|iLUX Treatment System|Local heat using an electrical warming mask for 5 minutes.
48668760|NCT01924780|DEVICE|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
48357114|NCT00545740|DRUG|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
48357115|NCT00545740|DRUG|SPD476 (2.4 g)|2.4g SPD476 QD orally
48357116|NCT00545740|DRUG|SPD476 (4.8 g)|4.8g SPD476 QD orally
48357117|NCT00545740|DRUG|Placebo|QD orally
48357118|NCT03444831|DRUG|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
48357119|NCT03444831|DRUG|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
48668761|NCT01924780|DEVICE|NEMOS Device sham stimulation 10 minutes|
48668762|NCT05788445|DEVICE|nrTMS treatment|Using the nrTMS treatment coli to stimulation with high frequency
48668763|NCT05788445|DEVICE|nrTMS sham|Using the nrTMS sham coli to stimulation with high frequency
48668764|NCT03559270|DRUG|Baricitinib|Administered orally
48668765|NCT05504122|PROCEDURE|inguinal hernia repair|Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
48668766|NCT02220634|DRUG|Regadenoson|Injection for intravenous administration
48668767|NCT02840630|OTHER|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
48668768|NCT03295344|OTHER|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
48668769|NCT03295344|OTHER|Tissue Doppler|Determine the threshold value for diaphragm mobility
48668770|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
48146279|NCT01527643|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
48357120|NCT05335785|DEVICE|High-intensity lazer therapy|Patients in the laser group will be given hiltherapy (high-intensity laser) with the HIRO 3 device every other day. One session of laser therapy application consists of 3 phases: the beginning, the middle and the ending phase. The initial phases are fast scanning and the ending phase is slow scanning. A total of 2000 J will be applied to the rotatorcuff muscles, the upper part of the trapezius muscle, the deltoid muscle and the pectoralis major muscle, 1000 J in the rapid scan phase and 1000 J in the finishing phase. In the middle phase, 50 J will be applied for the trigger point (hard intramuscular points that cause referred pain) in each muscle and a maximum of 500 J in total. The total dose prescribed for patients in one session will be 2500 J. Each phase will be 15 minutes on average and the session will last for 45 minutes in total. The laser probe will be applied with 90 degrees. During the application, the practitioner and the patient will have protective glasses.
48357121|NCT05335785|OTHER|Exercises|Exercise program including Codman, Range of motion and streightening exercises three times in a week.
48357122|NCT04789564|DIAGNOSTIC_TEST|cardiovascular magnetic resonance (CMR)|Testing CMR on patients of 7 days and 6 months after myocardial infarction
48357123|NCT04084873|BEHAVIORAL|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
48357124|NCT04084873|BEHAVIORAL|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
48357125|NCT04084873|BEHAVIORAL|Control|Participants do not receive the intervention.
48357126|NCT00142818|DRUG|Naltrexone|150 mg daily for males; 100 mg daily for females
48357127|NCT00142818|DRUG|Modafinil|400 mg daily
48357128|NCT00142818|DRUG|Placebo|400 mg and/or 100-150 mg placebo pills
48357129|NCT01730625|BEHAVIORAL|Cognitive behavioral therapy for anxiety|
48357130|NCT01730625|BEHAVIORAL|Attention Bias Modification Treatment|
48357131|NCT05538585|DRUG|Galicaftor|Oral
48357132|NCT05538585|DRUG|Navocaftor|Oral
48357133|NCT02411669|OTHER|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
48357134|NCT02615808|OTHER|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
48357135|NCT00161720|DRUG|Protein C Concentrate (Human) Vapor Heated|Protein C Concentrate (Human) Vapor Heated
48357136|NCT01741584|BEHAVIORAL|stationary bike exercise|
48357137|NCT01741584|BEHAVIORAL|aerobic|
48357138|NCT01038544|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
48357139|NCT01038544|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
48357140|NCT02358928|OTHER|Diet Intervention|
48357141|NCT04889937|DEVICE|PointCheck|PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
48357142|NCT00352170|DIETARY_SUPPLEMENT|calcium supplementation|calcium carbonate 1500 mg/day
48357143|NCT00352170|DIETARY_SUPPLEMENT|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
48357144|NCT00352170|DIETARY_SUPPLEMENT|Placebo|calcium and vitamin D3 placebo
48357145|NCT04670042|DEVICE|SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)|Same as Arm Description.
48357146|NCT00231491|DRUG|Botulinum Toxin A (Botox )|
48357147|NCT04966806|PROCEDURE|LASIK refractive surgery|laser vision correction for myopic eyes
48357148|NCT00114257|DRUG|decitabine|
48357149|NCT00114257|DRUG|romidepsin|
48357150|NCT05724654|DIETARY_SUPPLEMENT|Skin roasted peanuts|Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
48357151|NCT01938391|DEVICE|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
48357152|NCT00790491|BEHAVIORAL|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
48146280|NCT01927484|DRUG|25 mg/week oral methotrexate tablets|active oral methotrexate drug
48146281|NCT01927484|DRUG|25mg/week oral placebo tablets|placebo comparator oral drug
48357153|NCT01119924|DRUG|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
48357154|NCT01119924|DRUG|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
48357155|NCT01601093|DRUG|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
48357156|NCT01601093|DRUG|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
48357157|NCT01601093|DRUG|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
48357158|NCT00816894|DRUG|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
48146282|NCT06425289|OTHER|Macrohemodynamic parameters|"Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)"
48146283|NCT06419257|DEVICE|VRDS|VRDS is an augmented virtual reality driving simulator.
47989199|NCT06249425|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48146284|NCT03677167|OTHER|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
48146285|NCT05856409|DIAGNOSTIC_TEST|68Ga-FAPI|\[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)
48146286|NCT03266432|OTHER|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
48146287|NCT00224835|BEHAVIORAL|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
48146288|NCT00224835|BEHAVIORAL|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
48146289|NCT00990314|DRUG|Beraprost Sodium Modified Release|
48146290|NCT06509230|OTHER||The fibrosis grades were grouped without drug intervention
48146291|NCT03133299|DRUG|Glucocorticoids|Oral prednisolone for four months
47989200|NCT06249425|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
47989201|NCT03416257|OTHER|No intervention|
47989202|NCT06072950|OTHER|Usual care|Patients received usual care
48146292|NCT03133299|DRUG|Vitamin D|Oral vitamin D for two months
48146293|NCT00807599|PROCEDURE|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
48357159|NCT00816894|DRUG|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
48668771|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
47989203|NCT06435533|DEVICE|low energy argonplasma coagulation|see above
48668772|NCT05589454|DRUG|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
48668773|NCT05589454|DRUG|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
47989204|NCT02619292|BEHAVIORAL|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
48146294|NCT00807599|DRUG|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
48146295|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
48146296|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
48146297|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
48146298|NCT00696241|DRUG|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
48357160|NCT01676649|BIOLOGICAL|Ipilimumab|3 mg/kg
48357161|NCT01676649|DRUG|Carboplatin|AUC = 6
48357162|NCT01676649|DRUG|Paclitaxel|175 mg/m2
48668774|NCT01658046|OTHER|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
48668775|NCT01658046|OTHER|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
48668776|NCT01658046|OTHER|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
48668777|NCT01340456|DRUG|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
48668778|NCT04630483|OTHER|INHA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
47989205|NCT05435079|DEVICE|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
48146299|NCT00696241|DRUG|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
48668779|NCT04630483|OTHER|TIVA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
48357163|NCT05747768|DRUG|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin|Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate, 10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
48506397|NCT01410500|DRUG|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
48668780|NCT05792748|PROCEDURE|Pulp hemostasis with a dry cotton pellet|Application of a dry cotton pellet, then the chamber was filled with ZOE directly over the pulp
48668781|NCT05792748|PROCEDURE|Pulp hemostasis with a wet cotton pellet impregnated with FS|Application of a a wet cotton pellet impregnated with FS, then the chamber was filled with ZOE directly over the pulp
48668782|NCT05792748|PROCEDURE|Stainless steel crown|Stainless steel crown placed as a final restoration
48668783|NCT05833828|PROCEDURE|on-pump surgery|"the surgery will be performed on-pump"
47989206|NCT01684631|DEVICE|Total Hip arthroplasty|
47989207|NCT05899907|DRUG|Telitacicept|160mg once a week for 48 weeks
47989208|NCT05899907|DRUG|Standard of Care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
48146300|NCT03430518|DRUG|Durvalumab|1.12g given IV on day 1 every 21 day cycle
48357164|NCT05678504|DEVICE|The phlebotomy procedure|The process of blood collection with a vascular imaging device
48506398|NCT00111826|DEVICE|Celacade™ system|
48506399|NCT04622319|DRUG|DS-8201a|Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
48506400|NCT04622319|DRUG|T-DM1|Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
48506401|NCT05149859|OTHER|Observational|(no intervention)
48506402|NCT02283983|OTHER|mittens and booties|
48506403|NCT02283983|OTHER|cooling helmet|
48506404|NCT00834496|PROCEDURE|Liver biopsy|percutaneous liver biopsy
48506405|NCT03058289|DRUG|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations."
48506406|NCT03058289|BIOLOGICAL|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
48506407|NCT03058289|BIOLOGICAL|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
48506408|NCT00335114|DRUG|cyclosporine ophthalmic emulsion|
48668784|NCT05833828|PROCEDURE|off-pump surgery|"the surgery will be performed off-pump"
48668785|NCT02272127|DRUG|icotinib|
48668786|NCT00790673|DRUG|CF 102|Oral capsules
48668787|NCT00790673|DRUG|Placebo|Matching placebo capsules
48668788|NCT01092221|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, BID
48668789|NCT01092221|DRUG|Placebo|Placebo 1 capsule, 300 mg, BID
48357165|NCT05248100|BEHAVIORAL|Conditional Cash Transfer|The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
48357166|NCT03653286|OTHER|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
48357167|NCT03653286|OTHER|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
48668790|NCT01832610|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
48668791|NCT03340714|DEVICE|Monitoring Device|Wear ADAMM
48146301|NCT03430518|DRUG|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
48146302|NCT02602691|OTHER|AlloMap®|
48146303|NCT02602691|PROCEDURE|Endomyocardial biopsies|
48357168|NCT02971449|DEVICE|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
48357169|NCT02971449|OTHER|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
48357170|NCT04525989|RADIATION|Radiation therapy|5 x 5 Gy external radiation therapy
48357171|NCT04864184|BEHAVIORAL|Normal physiologic rate breathing|2-minute breathing exercises will be completed every 15 minutes.
48357172|NCT04864184|BEHAVIORAL|Slow breathing|2-minute breathing exercises will be completed every 15 minutes.
48357173|NCT01204489|BEHAVIORAL|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
48357174|NCT03170635|BEHAVIORAL|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
48357175|NCT05407376|OTHER|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
48668792|NCT03220438|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
48668793|NCT02479191|DEVICE|Ovation Abdominal Stent Graft Platform|
48668794|NCT00822302|DRUG|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
48668795|NCT00822302|DRUG|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
48668796|NCT00073125|DRUG|ABT-510/Thrombospondin-1 mimetic|
48668797|NCT05442736|DRUG|Ciprofloxacin|studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
48668798|NCT01663792|OTHER|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
48668799|NCT01663792|OTHER|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
48668800|NCT01663792|OTHER|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
48668801|NCT01151657|DIETARY_SUPPLEMENT|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
47989209|NCT03844360|DRUG|Bortezomib|bortezomib was administered follow the doctor's advice.
47989210|NCT03844360|DRUG|Eltrombopag|eltrombopag was administered follow the doctor's advice.
48668802|NCT01151657|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing maltodextrin
48668803|NCT04201704|OTHER|Balanced crystalloid solution volume administration|Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
48668804|NCT04201704|OTHER|Packed Erythrocytes Units, Blood Product Unit volume|For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
48146304|NCT00120107|DRUG|Black Tea|
48146305|NCT00578344|DRUG|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
48146306|NCT00578344|BIOLOGICAL|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
48146307|NCT00578344|DRUG|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
48146308|NCT00655213|DEVICE|Symphony D 2450|
48146309|NCT00655213|DEVICE|Symphony DR 2550|
48146310|NCT01504984|DRUG|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
48146311|NCT01504984|DRUG|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)
48146312|NCT00602732|BEHAVIORAL|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
47989211|NCT03844360|DRUG|Imatinib|imatinib was administered follow the doctor's advice.
48357176|NCT05131659|BEHAVIORAL|Executive function group therapy|This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
48146313|NCT00602732|BEHAVIORAL|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
48146314|NCT00303537|DRUG|metformin|
48146315|NCT03622580|DRUG|Aflibercept|Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
48146316|NCT03622580|DRUG|Faricimab|Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
48146317|NCT03622580|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
48357177|NCT03099512|OTHER|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
48668805|NCT04201704|OTHER|Plasma volume|For patients designated as Bleeding, where International Normalized Ratio (INR) \> 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
48668806|NCT04201704|OTHER|Platelets volume|For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
48668807|NCT02523950|PROCEDURE|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
48668808|NCT02523950|PROCEDURE|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
48668809|NCT02523950|DEVICE|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
47989212|NCT03844360|DRUG|dasatinib|dasatinib was administered follow the doctor's advice.
48146318|NCT00454922|BEHAVIORAL|standard of care|no intervention
48146319|NCT00454922|OTHER|education|meet with trained glaucoma educator 6 times over life of study
48357178|NCT03099512|OTHER|Exercise|Exercises which improves muscle strength, ROM...
48668810|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
47989213|NCT03844360|DRUG|Pegaspargase|pegaspargase was administered follow the doctor's advice.
47989214|NCT03844360|DRUG|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
47989215|NCT03844360|DRUG|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor|pegaspargase was administered follow the doctor's advice.
47989216|NCT00788892|DRUG|CPX-351|
47989217|NCT00788892|DRUG|Cytarabine|
47989218|NCT00788892|DRUG|Daunorubicin|
47989219|NCT04731987|BEHAVIORAL|Beverage consumption|"Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal."
47989220|NCT04542135|DRUG|Sulindac Pill|Randomized participants will receive either 150 mg oral sulindac twice daily.
47989221|NCT04542135|DRUG|Placebo|placebo pills twice daily
47989222|NCT00824044|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
48146320|NCT02803866|BEHAVIORAL|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
48146321|NCT01444690|DRUG|Dimiracetam|Capsules for oral administration twice daily
48146322|NCT01444690|DRUG|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
48146323|NCT03706872|OTHER|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
48146324|NCT03275467|OTHER|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
48146325|NCT00240994|DRUG|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
48357179|NCT01444144|OTHER|Fracture union|Retrospective records review post-operatively until fracture resolved.
48357180|NCT05241756|DEVICE|FLACS using FEMTO LDV-Z8|Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
48668811|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
48668812|NCT00953706|DRUG|Ivacaftor|Tablet
48668813|NCT00953706|DRUG|Placebo|Tablet
48668814|NCT04927702|DEVICE|Synthetic Hybrid-Scale Fiber Matrix|A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
48146326|NCT00240994|DRUG|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
48357181|NCT00820014|DRUG|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
48357182|NCT05496166|COMBINATION_PRODUCT|chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy|Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
48357183|NCT04229082|OTHER|observational|
48357184|NCT00554424|DRUG|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
48668815|NCT04927702|DEVICE|Standard of Care|To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
48668816|NCT04927702|DEVICE|Living Cellular Skin Substitute|An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
48668817|NCT02383316|OTHER|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
48668818|NCT04106778|DRUG|DMT310|Topical Powder
48668819|NCT04106778|DRUG|Placebo|Placebo Topical Powder
48668820|NCT00373542|DRUG|ropinirole CR-RLS|
48668821|NCT01468480|DRUG|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
48668822|NCT01468480|DRUG|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
48668823|NCT01468480|DRUG|MultiCal|application of Multical in forth group as a pulp dressing agent
48668824|NCT01468480|DRUG|Dycal|application of Dycal in first group as a pulp dressing agent
48668825|NCT05532969|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
48668826|NCT02957630|DRUG|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
48357185|NCT00554424|DRUG|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
48357186|NCT00630318|DEVICE|MRI|15-20 minutes MR imaging
48357187|NCT00362141|DRUG|levetiracetam (add-on)|
48357188|NCT04723303|DRUG|Umbilical Cord Lining Stem Cells|An IV infusion of ULSCs will be administered.
48357189|NCT01402622|DRUG|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
48357190|NCT02543801|DRUG|Liposomal Bupivacaine|Periarticular injection
48668827|NCT02957630|DRUG|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
48668828|NCT02957630|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
48668829|NCT03778801|DIAGNOSTIC_TEST|fibromyalgia syndrome and chronic neck pain|We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
48668830|NCT01442987|DRUG|Irbesartan/Atorvastatin A|once daily, P.O. 8week
48668831|NCT01442987|DRUG|Irbesartan|once daily, P.O. 8week
48668832|NCT01442987|DRUG|Atorvastatin A|once daily, P.O. 8week
48668833|NCT01442987|DRUG|Placebo|once daily, P.O. 8week
48357191|NCT02543801|DRUG|Ropivacaine|Periarticular injection
48357192|NCT02543801|DRUG|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
48357193|NCT02543801|DRUG|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
48357194|NCT02543801|DRUG|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
48668834|NCT01442987|DRUG|Irbesartan/Atorvastatin B|once daily, P.O. 8week
48668835|NCT01442987|DRUG|Atorvastatin B|once daily, P.O. 8week
48668836|NCT01192880|DRUG|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
48146327|NCT00240994|DRUG|Mycophenolate mofetil|Per recommendation
48146328|NCT00240994|DRUG|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
48357195|NCT02543801|DRUG|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
48357196|NCT05258565|DRUG|IV tPA (Activase)|Any patients eligible came with acute ischemic stroke with or without COVID-19 infection within the time window for thrombolytic therapy (within 4 hours of onset)
48357197|NCT06373224|OTHER|Flush|After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
48357198|NCT00329199|BEHAVIORAL|Attachment-Based Family Therapy|
48357199|NCT00672139|DRUG|Methylnaltrexone bromide|
48668837|NCT01192880|DRUG|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
47989223|NCT00824044|DRUG|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
47989224|NCT01382446|DRUG|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
48668838|NCT01192880|DRUG|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
47989225|NCT01382446|OTHER|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
47989226|NCT02154191|PROCEDURE|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
47989227|NCT01505868|DRUG|Cabazitaxel|Given IV
48146329|NCT02530892|PROCEDURE|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
48146330|NCT06460389|DIAGNOSTIC_TEST|Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
48357200|NCT03453528|DRUG|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
48357201|NCT04176562|DEVICE|RTI Spine products|"* Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~* Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~* Bone graft substitute - is intended to aid in fusion."
48668839|NCT03767881|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
48357202|NCT03316755|BEHAVIORAL|Exposure|Exposure to pamphlet
48357203|NCT03552809|DEVICE|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
48668840|NCT04252014|BEHAVIORAL|Hookah tobacco messages|Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
47989228|NCT01505868|DRUG|Carboplatin|Given IV
47989229|NCT01505868|OTHER|Laboratory Biomarker Analysis|Correlative studies
48357204|NCT03552809|PROCEDURE|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
48357205|NCT06378164|BEHAVIORAL|Exercise|For the combined step training group, the participants will receive training on both volitional and reactive stepping. The training will last for 1 hours per session, 2 session per week for 4 weeks.
48668841|NCT02979587|DEVICE|Harmony TPV System|"The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.~The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience).~The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter."
48668842|NCT01706484|DRUG|BNO 1016|comparison of different dosages of drug and placebo
48668843|NCT01093131|OTHER|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
48146331|NCT04155814|DRUG|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
48146332|NCT04155814|DRUG|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
48146333|NCT03731741|DRUG|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
48146334|NCT03064256|BEHAVIORAL|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
48146335|NCT03064256|BEHAVIORAL|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
48146336|NCT01442766|DRUG|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
48146337|NCT01442766|DRUG|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
48146338|NCT02382172|BEHAVIORAL|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
48146339|NCT02382172|OTHER|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
48146340|NCT03374423|PROCEDURE|radiofrequency|"The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered."
48146341|NCT03374423|PROCEDURE|radiofrequency|The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
48146342|NCT00430586|DRUG|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
48146343|NCT00430586|DRUG|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
48668844|NCT01093131|DRUG|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
48668845|NCT01093131|OTHER|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
48668846|NCT01093131|DRUG|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
48668847|NCT05098392|BEHAVIORAL|Sibling-mediated intervention|Typically developing siblings will be trained to use an explicit instruction strategy (model-lead-test) and a checklist to self-monitor their teaching when working with their siblings with ASD on reading and social skills.
48668848|NCT01599884|DRUG|N-acetylcysteine|1800 mg twice daily for 8 weeks
48668849|NCT01599884|DRUG|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
48146344|NCT00220805|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
48668850|NCT04252209|OTHER|natural herbs of coconut, aloe vera, and pepperint|mixture of herbal oils of coconut, peppermint, aloe vera
48668851|NCT04252209|OTHER|carboxy methyl cellulose|a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
48668852|NCT02031406|OTHER|Post-discharge counseling on medication adherence & literacy|
48668853|NCT01662206|DIETARY_SUPPLEMENT|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
48668854|NCT01662206|DIETARY_SUPPLEMENT|Placebo|2 capsules daily containing 348.25 mg of potato starch
47989230|NCT00001758|DRUG|Abacavir|
48146345|NCT00220805|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
48357206|NCT06378164|BEHAVIORAL|Active Control|An active control group will be used to minimise the placebo and history effect. The group will also receive a 4-week programme with the frequency and duration of the training and the instructor-to-participant ratio that match the combined step training group. During training, they will perform exercises not specific to reducing fall risk.
47989231|NCT00001758|DRUG|Amprenavir|
48146346|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
48146347|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
48357207|NCT05961514|DIAGNOSTIC_TEST|Target biopsies|MRI/Fusion target biopsies combine magnetic resonance imaging (MRI) with ultrasound-guided biopsy techniques to obtain tissue samples from areas of the prostate gland that appear abnormal on MRI.
48357208|NCT05961514|DIAGNOSTIC_TEST|systemic biopsies|transrectal ultrasound (TRUS) guided prostate systemic biopsies
48146348|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
48146349|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
48146350|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
48357209|NCT01396486|DRUG|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
48357210|NCT01396486|DRUG|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
48357211|NCT01392391|PROCEDURE|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
48357212|NCT01392391|PROCEDURE|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
47989232|NCT00001758|DRUG|Efavirenz|
47989233|NCT03756688|DEVICE|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
48668855|NCT04201535|DIAGNOSTIC_TEST|Protein arrays on plasma samples|Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
47989234|NCT03756688|DEVICE|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
48668856|NCT02566863|DRUG|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
48668857|NCT04104347|OTHER|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz \& Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
47989235|NCT06137404|OTHER|Splint|Comparison of splints for trigger finger
47989236|NCT05569200|DEVICE|Haifu Focused Ultrasound tumor therapeutic System|The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In Uterine benign tumor female, the investigators will observe the possibility of complication and tumor response of treatment.
48668858|NCT04104347|OTHER|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
48146351|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
48146352|NCT05935839|DEVICE|Multispectral optoacoustic tomography|Molecular Imaging of tissue changes using MSOT in macroangiopathy in diabetes. Dual imaging before and after physical stress.
48146353|NCT05935839|DIAGNOSTIC_TEST|Ankle Brachial Index|Dual measurement of ABI index before and after physical exercise.
48146354|NCT05935839|DIAGNOSTIC_TEST|Neuropathy Disability Score|Single measurement of the NSS
48146355|NCT01307306|DRUG|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
48146356|NCT01307306|DRUG|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
48146357|NCT04166084|OTHER|Active ROM Exercises|Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
48146358|NCT04166084|OTHER|Trunk Stabilization Exercises Training|Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
48146359|NCT06179485|DRUG|Ketamine|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
48146360|NCT06179485|DRUG|Etomidate|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
48146361|NCT04179526|BEHAVIORAL|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
48146362|NCT00184743|DRUG|somatropin|
48146363|NCT03434106|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
48146364|NCT03434106|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
48146365|NCT01381198|PROCEDURE|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
48146366|NCT00244556|DRUG|Methotrexate plus ENBREL or ENBREL alone|
48146367|NCT02439892|BEHAVIORAL|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
48357213|NCT06016595|DIAGNOSTIC_TEST|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
48668859|NCT01777477|DRUG|Chloroquine|Addition of Chloroquine to Gemcitabine
48668860|NCT01777477|DRUG|Gemcitabine|
48668861|NCT01171911|DRUG|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
48357214|NCT02729870|DRUG|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
48357215|NCT02729870|OTHER|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
48668862|NCT01077063|PROCEDURE|paracentesis|surgical drainage of malignant ascites
48668863|NCT01077063|DEVICE|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
47989237|NCT01430390|BIOLOGICAL|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
48357216|NCT05486689|OTHER|Pulmonary Rehabilitation|"The enrolled subjects will receivePR program. The 3 weeks inpatient PR will include education, exercise training, nutritional and psychological counselling.~Education: individualized session of 20 minutes each and group session of 45 minutes each. Endurance training: at least twelve 30-minute daily sessions of supervised incremental exercise training according to Maltais, continuous cycling at 50-70% of the maximal load calculated on the basis of the baseline 6MWT according to Hill. Strength training: twelve 30-minute daily sessions of peripheral limb muscle strength training: 2 set of 8 repetitions during the first week, increased at 12 from the second. The initial load will be set at 30/50% of maximal voluntary isometric strength (MVS). Psychological intervention: individual tailored intervention will be offered when the Hospital Anxiety and Depression Scale (HADS) score is \>10 or judged necessary by clinicians, after verifying the subject's motivation."
48357217|NCT03607461|DEVICE|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
48357218|NCT03607461|COMBINATION_PRODUCT|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
48357219|NCT02863406|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
48357220|NCT03330106|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
48357221|NCT03330106|DRUG|Docetaxel|Docetaxel intravenous infusion.
48357222|NCT03330106|DRUG|Carboplatin|Carboplatin intravenous infusion.
48357223|NCT03330106|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
48357224|NCT00935467|DRUG|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
48357225|NCT04211649|DRUG|3 days of antibiotherapy|Reduce at 3 days of antibiotherapy for the treatment of mild leptospirosis
48357226|NCT03996525|DEVICE|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
48668864|NCT05354219|OTHER|Imaging|Imaging with 3 iris cameras
48668865|NCT01573117|DEVICE|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
48668866|NCT01573117|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
48668867|NCT01258673|DRUG|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
48668868|NCT01258673|DRUG|Fimasartan|Fimasartan 60mg, 120mg
48668869|NCT00413348|DRUG|Lactobacillus acidophilus NCFM|
48668870|NCT04804527|OTHER|Intensified physiotherapy|Physiotherapy x2
48668871|NCT04804527|OTHER|Usual care physiotherapy|Physiotherapy x1
48668872|NCT00646386|DRUG|adalimumab|40 mg eow Week 0 - Week 24
48668873|NCT00646386|DRUG|placebo for adalimumab|40 mg eow Week 0 - Week 24
48668874|NCT04907630|BEHAVIORAL|Antenatal Education|educational intervention
48668875|NCT02916485|DEVICE|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
48668876|NCT03555058|OTHER|Treatment escalation|Treatment escalation per TDM and physician's decision.
48668877|NCT01424800|DEVICE|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
48357227|NCT03996525|DEVICE|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
48357228|NCT03479203|DRUG|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
48146368|NCT02439892|BEHAVIORAL|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
48357229|NCT00914095|DRUG|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
48357230|NCT00914095|DRUG|placebo|tablets of placebo 3 times a day
48357231|NCT05116111|DRUG|SYHA1402 tablets|SYHA1402 tablets, oral, twice daily
48357232|NCT05116111|DRUG|Placebo|Placebo, oral, twice daily
48357233|NCT00945685|DEVICE|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~* Pulse energy (J);~* RF frequency (1MHz);~* Pulse duration (30 sec);~* Treatment hand piece (skin tightening);"
48357234|NCT02067806|DRUG|2-chloroprocaine hydrochloride, 1%|Study included male and female adult patients undergoing spinal anesthesia with chloroprocaine, when the planned surgical procedure was not expected to exceeded 40 minutes.
48357235|NCT00631969|DRUG|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
48357236|NCT00631969|DRUG|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
48357237|NCT06193837|DRUG|Augmentin|Use of prophylactic antibiotics in lap cholecystectomy
48357238|NCT00534664|DEVICE|TheraBionic device|Daily outpatient treatment with theraBionic device
48357239|NCT01513694|PROCEDURE|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
48357240|NCT00394277|DRUG|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
48357241|NCT00394277|DRUG|Ribavirin|1200 mg po daily for 48 weeks
48357242|NCT00394277|DRUG|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
48357243|NCT00394277|DRUG|Ribavirin|1400-1600 mg po daily for 48 weeks
48668878|NCT02182518|DRUG|Epinastine|
48668879|NCT02182518|DRUG|Pseudoephedrine|
48668880|NCT02182518|DRUG|Placebo|Placebo during run-in period
48146369|NCT01765855|DRUG|Betrixaban single oral dose|
48146370|NCT06046807|OTHER|Phone call|This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
48357244|NCT04958551|OTHER|No intervention|No intervention
48357245|NCT00697255|DRUG|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
48357246|NCT00697255|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
48668881|NCT02236676|BEHAVIORAL|Nap after rehearsal trials|Behavioral
48688055|NCT04196855|DRUG|Teriparatide|"Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone."
48357247|NCT00697255|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
48357248|NCT00697255|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
48357249|NCT02894892|DRUG|(A)Bismuth|
48357250|NCT02894892|DRUG|(B)Bismuth|
48357251|NCT02894892|DRUG|(C)Bismuth|
48357252|NCT02894892|DRUG|(D)Esomeprazole and Bismuth|
48357253|NCT02894892|DRUG|(E)Esomeprazole and Bismuth|
48357254|NCT02894892|DRUG|(F)Esomeprazole and Bismuth|
48357255|NCT02894892|OTHER|(G)Control|
48688056|NCT06119971|DEVICE|ACUPRESSURE|Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
48357256|NCT05619432|DEVICE|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
48357257|NCT01343576|DIETARY_SUPPLEMENT|milk fat|45 g milk fat per day in 4 weeks
47989238|NCT01430390|DRUG|Cyclophosphamide-based chemotherapy|Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
48146371|NCT00827294|BEHAVIORAL|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
48146372|NCT02039401|BIOLOGICAL|VM202|
48146373|NCT04235920|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
48146374|NCT01729767|DRUG|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
48146375|NCT01729767|DRUG|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
48146376|NCT02514824|DRUG|MLN0128|Investigational mTOR kinase inhibitor
48146377|NCT05344209|BIOLOGICAL|UV1|UV1 vaccine
48146378|NCT05344209|DRUG|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
48146379|NCT05344209|DRUG|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
48146380|NCT02446015|DRUG|SYSTANE® ULTRA Lubricant Eye Drops|
48146381|NCT02125292|DRUG|Mesalamine|
48146382|NCT00311545|BIOLOGICAL|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
47989239|NCT01045642|DRUG|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
48146383|NCT00986505|DRUG|Lidocaine|Intravenous lidocaine once a week
48146384|NCT00444054|BEHAVIORAL|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
48146385|NCT03547206|DRUG|RPh201 Cohort A|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
48146386|NCT03547206|OTHER|Placebo Cohort A|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
48146387|NCT03547206|DRUG|RPh201 Cohort B|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
48146388|NCT03547206|OTHER|Placebo Cohort B|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
48146389|NCT05466786|OTHER|Standard Management|Standard Management
48357258|NCT06335589|OTHER|EBP-Massed|CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)
48357259|NCT06335589|OTHER|EBP-TAU|CPT or PE will be delivered treatment as usual, which is typically once per week.
48357260|NCT01054339|DRUG|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
48357261|NCT03362723|DRUG|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A \[reference\], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
48357262|NCT02840552|DRUG|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
48357263|NCT02074436|DRUG|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
48357264|NCT02074436|OTHER|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
48357265|NCT04048876|DRUG|CC-90001|oral
48357266|NCT04048876|DRUG|Placebo|oral
48357267|NCT01845766|OTHER|exercise rehabilitation|
48357268|NCT00122824|DRUG|duloxetine hydrochloride|
48357269|NCT00122824|DRUG|placebo|
48357270|NCT02052154|BIOLOGICAL|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
48357271|NCT05819424|DIETARY_SUPPLEMENT|Yeast Fermentate (EpiCor)|"Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding"
47989240|NCT02193373|OTHER|Osteopathic Manual Medicine|Osteopathic Manual Medicine
47989241|NCT02193373|OTHER|Sham|Osteopathic Manual Medicine
48146390|NCT05333666|OTHER|Data collection|This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
48146391|NCT01323244|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
48146392|NCT02194907|BEHAVIORAL|Brain activity training - anterior insula|training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain
48146393|NCT02194907|BEHAVIORAL|Brain activity training - medial prefrontal cortex|training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain
48146394|NCT03536767|DRUG|AG10|AG10 800mg twice daily, oral administration
48357272|NCT00264511|OTHER|Hyperbaric Oxygen Treatment|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
48357273|NCT00215904|DRUG|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (\~2g/day). Second arm : adjuvant treatment with placebo (\~2g/day).
48357274|NCT00748111|OTHER|Blood sample|Blood sample and thrombus sample
48357275|NCT03085212|BEHAVIORAL|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
48357276|NCT00806533|DRUG|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
47989242|NCT04469114|DRUG|Tofacitinib 10 mg|Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
47989243|NCT04469114|DRUG|Placebo|Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
47989244|NCT04568057|DEVICE|NIR Transcranial phototherapy device|1068 nm NIR helmet
48357277|NCT03996655|DRUG|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
48357278|NCT03996655|DRUG|Neostigmine|Reversal of neuromuscular blockers
48146395|NCT02773082|DEVICE|Reclaim™ DBS Therapy|DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
48668882|NCT05784857|OTHER|Touch Methods|"The Yakson touch method continue for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes). In this method, the palms of the practitioner and all fingers keep in close contact so that the babies don't feel pressure.~Gentle human touch refers to steady contact of the skin without caressing or massaging. While the practitioner place one hand on the crown of the preterm infant on the eyebrow line with the fingertip touch for 15 minutes, the other hand was place on the lower abdomen covering the waist and hip of the infants."
48146396|NCT05899348|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
48146397|NCT03142932|DEVICE|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
48146398|NCT03142932|OTHER|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
48146399|NCT03142932|BEHAVIORAL|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
48146400|NCT03026920|PROCEDURE|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
48146401|NCT02471872|BEHAVIORAL|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
48146402|NCT02471872|OTHER|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
48146403|NCT04749329|DEVICE|Mesh Group|"All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients."
48146404|NCT00346398|BIOLOGICAL|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
48146405|NCT00346398|BIOLOGICAL|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
48146406|NCT03234010|OTHER|FT21092|An electronic cigarette
48146407|NCT03234010|OTHER|FT21093|An electronic cigarette
48357279|NCT06461195|OTHER|Monitoring of patients|Data from a spirometer and a stethoscope are captured to develop algorithms to detect and classify respiration sounds to support therapists and patients in future therapy.
48357280|NCT05454709|DRUG|Dasiglucagon|Use of dasiglucagon in the AP system.
48506409|NCT03947944|PROCEDURE|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
48668883|NCT03997032|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
48668884|NCT03537638|BEHAVIORAL|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
48668885|NCT02359656|PROCEDURE|surgical treatment|C1-C1 arthrodesis
48668886|NCT02359656|OTHER|non operative treatment for odontoid non unions|specific non operative treatment protocol
48688057|NCT01110525|DRUG|AZD1981|4X100 mg per oral, twice daily for 28 days
48688058|NCT01110525|DRUG|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
48146408|NCT03234010|OTHER|FT21096|An electronic cigarette
48146409|NCT03234010|OTHER|FT21097|An electronic cigarette
48146410|NCT04207372|DIETARY_SUPPLEMENT|whey protein isolate|whey protein isolate
48146411|NCT04207372|DIETARY_SUPPLEMENT|Zein|zein protein
48146412|NCT04207372|OTHER|protein-free|protein free
48146413|NCT06244563|DEVICE|Face mask with Hybrid-Hyrax|Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.
48146414|NCT06244563|DEVICE|Face mask with Bonded RME|Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.
48146415|NCT06244563|PROCEDURE|Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)|In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.
48146416|NCT06244563|PROCEDURE|Routine Rapid Maxillary Expansion Protocol|In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.
48146417|NCT00230906|PROCEDURE|Haemodialysis with either low or high flux membranes|
48146418|NCT01623011|PROCEDURE|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
48146419|NCT01623011|PROCEDURE|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
48146420|NCT01623011|OTHER|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
48146421|NCT00606788|DEVICE|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
48146422|NCT00606788|PROCEDURE|Conventional weaning|Patients received physician-directed non-protocolized weaning
48146423|NCT05557695|DRUG|Acalabrutinib|Acalabrutinib
48146424|NCT02304289|DRUG|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
48146425|NCT04788407|DRUG|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
48146426|NCT04788407|DRUG|Placebo|Subjects will receive placebo TID for 7 days
48146427|NCT02807285|DRUG|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
48146428|NCT05790135|DEVICE|shear wave elastography|Shear wave elastography and CEUS will be used to evaluate the reliability in diagnosing graft versus host disease of the gut after hematopoietic stem cell transplantation
48146429|NCT04510493|DRUG|Canakinumab|Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours
48146430|NCT04510493|DRUG|Placebo|Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
48146431|NCT02723799|BEHAVIORAL|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
48146432|NCT02723799|OTHER|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
48146433|NCT00709787|OTHER|Usual Care|Normal care for hypertensive patients with risk factors for CHD
48146434|NCT01334606|DEVICE|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
48146435|NCT01334606|DEVICE|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
48688059|NCT01110525|DRUG|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
48146436|NCT00063089|DRUG|S. aureus Immune Globulin Intravenous (Human) 5%|
48146437|NCT02991573|DEVICE|Prime & Bond Universal|Prime \& Bond Universal
48146438|NCT02991573|DEVICE|Ceram X|
48146439|NCT02991573|DEVICE|Prime & Bond XP|Control
48146440|NCT02991573|PROCEDURE|technique 1|
48146441|NCT02991573|PROCEDURE|technique 2|
48146442|NCT03436537|OTHER|Periodontal Aesthetic Perception Scale|Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
48146443|NCT01543204|DRUG|Etanercept|Administered by subcutaneous injection
48146444|NCT05823714|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
47989245|NCT04568057|DEVICE|Placebo Transcranial Device|The placebo device looks like the active device.
47989246|NCT05654155|OTHER|auricular acupressure|Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
48146445|NCT06307951|OTHER|No intervention|No intervention
48146446|NCT02644980|DRUG|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
48146447|NCT02644980|DRUG|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
48146448|NCT02644980|DEVICE|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
48146449|NCT02644980|DRUG|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
48357281|NCT05454709|DRUG|GlucaGen|Use of GlucaGen in the AP system.
48357282|NCT03737344|DRUG|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
48357283|NCT03737344|OTHER|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
48357284|NCT05230069|OTHER|Interview|Patients will be interviewed post an emergency call and evaluation.
48357285|NCT03719768|DRUG|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
47989247|NCT06197815|BEHAVIORAL|The assistance type during ERCP|The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
47989248|NCT00525174|DEVICE|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
47989249|NCT00525174|DEVICE|Patching|2 hours daily patching of the sound eye
48146450|NCT02644980|DRUG|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
48146451|NCT02644980|OTHER|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
48146452|NCT01529866|DEVICE|New Abutment Connection implant|New abutment connection implant
48146453|NCT01529866|DEVICE|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
48357286|NCT03719768|RADIATION|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
48357287|NCT04857840|DRUG|Firibastat (QGC001) Period 1|1000 mg (2 x 500 mg) tablets QD per Os
48357288|NCT04882826|DRUG|Sildenafil film-coated tablet 100 mg|Sildenafil is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 100 mg of sildenafil.
48357289|NCT04882826|DRUG|Viagra® film-coated tablet 100 mg|Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
48357290|NCT02417129|DRUG|Rituximab|BI 695500 375 mg/M2
48357291|NCT02417129|DRUG|BI 695500|BI 695500 375 mg/M2
48357292|NCT02485431|DRUG|Deflazacort|
48357293|NCT01792024|DEVICE|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
48357294|NCT01792024|PROCEDURE|magnetic resonance imaging|Undergo MR-guided LITT
48357295|NCT01236131|OTHER|no intervention|Not Applicable- no intervention
48357296|NCT01058395|DRUG|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
48357297|NCT06053086|RADIATION|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
48668887|NCT02286609|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
48668888|NCT00198900|BEHAVIORAL|survey of information|
48357298|NCT06053086|RADIATION|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
48357299|NCT04615728|PROCEDURE|laparoscopic or open appendicectomy|Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
48357300|NCT03855358|DRUG|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
48357301|NCT00779818|DEVICE|Electrical acupuncture|Treatment by electrical acupuncture
48357302|NCT00779818|DEVICE|Laser|Treatment by laser
48357303|NCT05516615|OTHER|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
48506410|NCT03947944|PROCEDURE|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
48668889|NCT01105663|OTHER|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
48668890|NCT06315933|PROCEDURE|General anesthesia|General anesthesia inluding inhaled and intravenous
48668891|NCT03265184|DIETARY_SUPPLEMENT|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
48668892|NCT06376955|OTHER|High intensity interval exercise|HIIT is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high intensity movements followed by short periods of lower intensity movements 2 times per week for 4 months.
48506411|NCT00025012|DRUG|isotretinoin|
47989250|NCT00525174|PROCEDURE|Near activities|one hour near visual activities
48146454|NCT01747538|DRUG|Placebo|Solution for subcutaneous injection
48146455|NCT01747538|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
48146456|NCT01747538|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
48146457|NCT06133595|BEHAVIORAL|Behavioral: MiBridge|A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
48146458|NCT03326856|BIOLOGICAL|botulinum toxin, Type A|topical liniment
48146459|NCT03326856|BIOLOGICAL|Vehicle|Vehicle Formulation
48146460|NCT00512902|DRUG|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
48146461|NCT00512902|DRUG|Imatinib|Up to 600 mg QD PO for up to 1 year.
48668893|NCT06376955|OTHER|Focused ultrasound|Focused ultrasound will be applied over the anterior abdominal, two sessions per week for 4 months, each session 40 minutes.
48668894|NCT03467516|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
48668895|NCT00639457|DRUG|Pioglitazone|Oral 30mg/day for 16 weeks
48668896|NCT00639457|BEHAVIORAL|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
48668897|NCT01731561|DRUG|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are \> to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
47989251|NCT01528956|GENETIC|DNA methylation analysis|
47989252|NCT01528956|GENETIC|RNA analysis|
47989253|NCT01528956|GENETIC|gene expression analysis|
47989254|NCT01528956|GENETIC|nucleic acid sequencing|
47989255|NCT01528956|GENETIC|polymorphism analysis|
47989256|NCT02519530|BEHAVIORAL|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
47989257|NCT02081079|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
47989258|NCT01947439|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
47989259|NCT02498457|OTHER|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
47989260|NCT01701843|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
47989261|NCT01701843|DRUG|Placebo|Twice daily topical treatment for 14 days
47989262|NCT03642210|COMBINATION_PRODUCT|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
47989263|NCT01682590|PROCEDURE|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output \> 1000ml/24 hr or \>2000ml/24hr with diuretics), RRT is not mandatory."
47989264|NCT00413192|DRUG|E7389|1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
47989265|NCT03826979|OTHER|Pliates method treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
47989266|NCT00999791|DRUG|Bevacizumab|
47989267|NCT00999791|DRUG|Diclofenac|
47989268|NCT03585439|PROCEDURE|Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion|First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
47989269|NCT01254227|DRUG|Deferasirox and Deferoxamine|
47989270|NCT02882854|DRUG|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
47989271|NCT02882854|DRUG|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
48146462|NCT03883724|BEHAVIORAL|Brief behavioral treatment of insomnia (BBTI)|The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
48146463|NCT03883724|BEHAVIORAL|Information-only control (IC)|The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
48146464|NCT01233245|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
48146465|NCT03738826|BEHAVIORAL|Behavioral Intervention|Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
48146466|NCT00135278|PROCEDURE|CSF Drainage|See Detailed Description
48146467|NCT00135278|PROCEDURE|No CSF Drainage|See Detailed Description
48357304|NCT00868738|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
48357305|NCT05421585|OTHER|observational drug study|Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
48357306|NCT05801185|OTHER|Unilateral lower limb suspension|Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
48668898|NCT01731561|DRUG|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
48668899|NCT01486888|DRUG|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
48668900|NCT06424223|PROCEDURE|Horizontal Ridge augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
48668901|NCT01554748|PROCEDURE|Total joint arthroplasty|
48668902|NCT01957865|DEVICE|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
48668903|NCT01957865|DEVICE|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
48668904|NCT00390377|PROCEDURE|Cutting scalp hair|
47989272|NCT01622361|DRUG|Adriamycin+Cyclophosphamide>Docetaxel|"1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle"
47989273|NCT01622361|DRUG|GnRHa with Tamoxifen|"1. Goserelin(GnRHa) 3.6mg~   * Route: subcutaneously under the abdominal skin~  * Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~2. Tamoxifen 20mg/day~   * Route: Oral~  * Schedule: everyday"
47989274|NCT03564847|BEHAVIORAL|LTP Plus|"LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
47989275|NCT02709161|BEHAVIORAL|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
48146468|NCT06509594|OTHER|Protocol of Scapular Stabilization Exercises;|"Exercise for the middle trapezius and rhomboid muscles: Participants were instructed to stand with their arms hanging beside their bodies. Then, they were instructed to flex their elbows 90◦ holding an elastic band and performing an external rotation of the shoulder, pulling both scapula together. Subsequently, they returned to a neutral shoulder position with elbow flexion.~Exercise for the lower trapezius muscle: Participants were instructed to lie down in a prone position while holding an elastic band attached at one end under a mattress. They were then instructed to raise their shoulder 140◦.~Exercise for the serratus anterior muscle: Participants were instructed to stand and flex their elbows 90◦ while holding an elastic band fixed behind the participants. Next, they were instructed to move the arm forward with a protracted scapula."
48146469|NCT06509594|OTHER|Protocol of Muscle Energy technique;|"During upper trapezius stretching, the participants were in seated position by holding the chair with one arm, and laterally tilted the head to the opposite side with the other hand pushing the head to increase lateral stretch.~For pectoralis muscle stretch, participants were asked to stand in front of the Doorframe with elbow bent at 90 degree and was asked to lean forward without Taking a step forward. The stretch is felt across the anterior chest, which is held for 15-30 seconds with 2-3 repetitions. For levator scapulae stretch, the subjects were asked to take the seated position while holding the chair with one hand in order to maintain shoulder depression, then To flex and rotate neck to the opposite side by placing the other hand at the back of their head and to slowly pull it down toward the armpit."
48146470|NCT00864188|DIETARY_SUPPLEMENT|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
48146471|NCT00864188|DIETARY_SUPPLEMENT|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
48146472|NCT00864188|DIETARY_SUPPLEMENT|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
48146473|NCT00864188|DIETARY_SUPPLEMENT|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
48668905|NCT05201131|PROCEDURE|Rezum|Rezum
48668906|NCT01564342|PROCEDURE|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
48668907|NCT03249363|PROCEDURE|Group A - Pulsed PVP-I Irrigation|
48668908|NCT03281057|BEHAVIORAL|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
48668909|NCT02943694|DEVICE|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
48668910|NCT02588014|OTHER|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
48146474|NCT03571906|BEHAVIORAL|Tele - Cardiac Pre-Rehabilitation|We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
48146475|NCT03798132|DIAGNOSTIC_TEST|laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy
48146476|NCT02144285|DRUG|LY3113593|Administered IV
48146477|NCT02144285|DRUG|LY3113593|Administered SC
48146478|NCT02144285|DRUG|Placebo|Administered IV
48146479|NCT02144285|DRUG|Placebo|Administered SC
48668911|NCT00082121|DRUG|TP10|
48668912|NCT06292819|DEVICE|Bright light|Bright light will use a 5000-10,000 Lux LED light source. Exposure is for 60 minutes daily, between 7pm and 9pm.
48668913|NCT06292819|DEVICE|Near-infrared light|Near-infrared light will use a wavelength of 850nm and a dose range of 1 - 6.5 joules/cm2. It is fixed on the neck with a band, the light source contacts the back of the neck, and is used for 60 minutes before going to bed.
48668914|NCT06292819|DEVICE|Bright light+ near-infrared light|After using the bright light device, then use the near-infrared light device on the back of the neck before going to bed.
48668915|NCT02736071|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
48668916|NCT02736071|DRUG|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
48668917|NCT02736071|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
48668918|NCT02736071|DRUG|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
48668919|NCT05770284|OTHER|12 weeks exercise|12 weeks exercise
48146480|NCT03367416|BEHAVIORAL|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~1. educating executives on how to promote effective process change techniques~2. training staff teams in the theory and practice of organizational change techniques~3. training staff to develop and implement a process improvement intervention~4. implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
48146481|NCT01731210|DEVICE|implantation of the new LV lead: NANO system.|
48146482|NCT03105024|OTHER|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
48146483|NCT03105024|OTHER|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
48146484|NCT02407899|DRUG|Saxagliptin|Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
48146485|NCT02407899|DRUG|Vitamin D3|Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
48146486|NCT02407899|DRUG|Insulin|For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
48146487|NCT02407899|DRUG|Metformin|Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
48146488|NCT02034188|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
48146489|NCT01328756|DRUG|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
48146490|NCT06509295|OTHER|Calcium Hypochlorite as Root Canal Irrigant|Calcium Hypochlorite used as root canal irrigant during chemo-mechanical preparation
48146491|NCT02889900|DRUG|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
48146492|NCT01617889|OTHER|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
48357307|NCT01113411|DEVICE|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
48357308|NCT01113411|OTHER|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises."
48357309|NCT01113411|OTHER|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
48668920|NCT05770284|OTHER|Standard Medical Treatment|Standard Medical Treatment
48668921|NCT06087380|PROCEDURE|auricular acupressure|Auricular pressure The experimental group commenced auricular acupressure intervention post-surgery. Questionnaire assessments and heart rate variability measurements were conducted in the experimental group on the first, second, third, and fourth days before discharge.
48668922|NCT06087380|OTHER|standard ward care|standard ward care
48668923|NCT03573492|OTHER|Education|Type of teaching being assigned to student arms
48146493|NCT01617889|OTHER|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
48146494|NCT00237809|DRUG|D-serine|D-serine (30 mg/kg)
48146495|NCT00237809|BEHAVIORAL|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
48146496|NCT00237809|DRUG|Placebo|Placebo D-serine Drug
48146497|NCT00237809|BEHAVIORAL|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
48146498|NCT00942500|PROCEDURE|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade \<2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
48146499|NCT03948958|OTHER|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
48146500|NCT03948958|OTHER|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
48146501|NCT03948958|OTHER|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
48668924|NCT06306001|DRUG|Methylene Blue|Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
48668925|NCT06306001|OTHER|Placebo|Subjects in the placebo arm will receive normal saline in the same volumetric dose as methylene blue in the intervention arm
48668926|NCT00187109|DRUG|Recombinant Human Thrombopoietin|
48668927|NCT06235580|OTHER|Biological Samples|"For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used."
48357310|NCT01628458|PROCEDURE|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
48357311|NCT04121052|DRUG|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
48668928|NCT05907811|PROCEDURE|Neuromuscular blocker usage|The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
48357312|NCT04540614|OTHER|Strengthening exercises programme|Strengthening exercises for Deep Cervical Flexors, Shoulder external rotators, scapular adductors and thoracic erector muscles
48506412|NCT06470178|COMBINATION_PRODUCT|corhot1: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
48506413|NCT06470178|COMBINATION_PRODUCT|corhot2: chemotherapy combined with fruquintinib|"Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles."
48506414|NCT06382610|DIETARY_SUPPLEMENT|Melatonin|Melatonin will be administered in three different forms
48506415|NCT01542151|OTHER|Time of labor induction|Assigned time of labor induction - morning or evening
48668929|NCT00285571|BEHAVIORAL|Controlled Feeding Intervention|
48506416|NCT00193466|DRUG|Rituximab|
48146502|NCT03948958|OTHER|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
48357313|NCT03318822|DEVICE|Q-Collar|An externally-worn medical device that applies mild jugular compression
48506417|NCT00193466|DRUG|Fludarabine|
48506418|NCT00193466|DRUG|CAMPTH-1H|
48668930|NCT02078869|DRUG|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
48668931|NCT02078869|DRUG|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
48668932|NCT05595928|OTHER|position|To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
48668933|NCT03324789|OTHER|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
48668934|NCT03324789|OTHER|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
48668935|NCT01650454|OTHER|2 night polysomnography|Polysomnography
48146503|NCT03948958|OTHER|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
48357314|NCT05830656|BEHAVIORAL|Exposure to nearby nature|Participants spend a minimum of 20 minutes in their favourite place in nearby nature.
48357315|NCT05830656|BEHAVIORAL|Exposure to virtual nature|Participants spend a minimum of 20 minutes watching virtual nature videos.
48357316|NCT02962102|DRUG|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
48668936|NCT01650454|OTHER|battery of neuropsychological tests|
48668937|NCT01650454|OTHER|virtual reality test|
48668938|NCT01650454|OTHER|subjective evaluation of sleep and somnolence|
48668939|NCT02363530|DEVICE|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
48668940|NCT02363530|DEVICE|BSS|Balanced Salt Solution including normal saline and glucose
48668941|NCT00401076|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
48668942|NCT05390788|OTHER|Application Of Neuromuscular Bands; Kinesio Taping|"Kinesio tape is a specialized elastic and adherent adhesive tape that mimics the elasticity of skeletal muscle, in that it can be extended up to 140% of its original length, before application to the skin, without allowing restrictions in the range of motion. of structures. Subsequently, it provides a tensile (shear) force on the skin, consisting of a fabric with special characteristics, such as air permeability and water resistance, and can be used for repeated days. Kinesio will be applied from a point 10 cm below the anterior superior iliac spine and divided in a Y shape above the patella, ending at the tibial tuberosity; from the upper third of the medial thigh to the medial border of the patella; from the greater trochanter of the femur, ending at the lateral margin of the patella."
48668943|NCT03906643|DRUG|HS-201|HS-201 will be administered intravenously as a single dose
48668944|NCT05485558|DRUG|N-acetyl cysteine|10 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
48668945|NCT05485558|DRUG|Placebo|15 patients will receive standard antiepileptic drug plus placebo capsules for 6 months.
48668946|NCT05485558|DRUG|NAc|40 mg/kg of N-acetyl cysteine capsules together with their standard antiepileptic drug for 6 months.
48146504|NCT00265902|PROCEDURE|diagnostic imaging|
48146505|NCT04236297|DEVICE|bite block|Physicians performing transesophageal echocardiogram in patients under sedation or general anesthesia will use either standard or modified bite block.
48146506|NCT01626833|DRUG|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE\* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
48357317|NCT02962102|DRUG|Calcitriol|Calcitriol 4mcg orally daily x 5
48357318|NCT02962102|DRUG|Placebos|Placebo (medium chain triglyceride oil) orally daily x 5
47989276|NCT02709161|BEHAVIORAL|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
48146507|NCT01626833|BIOLOGICAL|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
48146508|NCT04089202|OTHER|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
48357319|NCT04374149|PROCEDURE|Therapeutic Plasma Exchange|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy
48357320|NCT04374149|DRUG|Ruxolitinib|TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
48357321|NCT03480841|BEHAVIORAL|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
48357322|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
48668947|NCT02797821|DRUG|Asfotase alfa|
48668948|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
48668949|NCT00457392|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
48668950|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
48668951|NCT00457392|DRUG|placebo|Placebo daily by oral capsules in a continuous regimen
48668952|NCT00477984|DRUG|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
47989277|NCT01589445|DRUG|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
48146509|NCT04089202|OTHER|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
47989278|NCT01589445|DRUG|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
48146511|NCT02487680|DIETARY_SUPPLEMENT|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
48146512|NCT02487680|DIETARY_SUPPLEMENT|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
48668953|NCT01830985|DRUG|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
48668954|NCT01931917|BEHAVIORAL|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
48146513|NCT00992745|DRUG|123-I-MIP-1072|Single 10 mCi intravenous injection
48357323|NCT00425191|DRUG|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
48506419|NCT01892280|BEHAVIORAL|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
48506420|NCT01892280|BEHAVIORAL|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
48668955|NCT01931917|BEHAVIORAL|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
48506421|NCT03097848|PROCEDURE|RFA|for eligible cases, radiofrequency ablation will be given only.
48506422|NCT03097848|DRUG|Sorafenib|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
48668956|NCT06078826|OTHER|passive music therapy|30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
48668957|NCT06078826|OTHER|foot massage|Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
47989279|NCT02409459|DRUG|Injectafer|
47989280|NCT02409459|DRUG|Placebo|Normal saline solution
47989281|NCT04171687|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg tablet
47989282|NCT04171687|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
47989283|NCT04171687|DRUG|RAPA113|RAPA113 tablet
47989284|NCT03326973|BEHAVIORAL|EuroQoL EQ-5D-3L|Overall QOL
47989285|NCT03326973|BEHAVIORAL|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
48146514|NCT00992745|DRUG|111-In capromab pendetide|Single 5 mCi intravenous injection
48146515|NCT00992745|DRUG|123-I-MIP-1072|Single 5 mCi intravenous injection
47989286|NCT03326973|OTHER|PRO-CTCAE|Additional potential immune-specific symptoms
47989287|NCT03326973|BEHAVIORAL|Fatigue severity score questionnaire|Fatigue severity
47989288|NCT03326973|BEHAVIORAL|The COST|Financial toxicity; satisfaction with ability to work
48146516|NCT02216994|DRUG|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
48506423|NCT02114385|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
48506424|NCT02114385|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
48668958|NCT02782910|DEVICE|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
48668959|NCT04887532|DRUG|HR19042 capsule|phase 1 :8mg; phase 2:12mg; phase 3:16mg
48668960|NCT01158859|DRUG|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
48668961|NCT06176209|DIAGNOSTIC_TEST|screening tool with biomarkers for prediction of chronic post traumatic neck pain|Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
48668962|NCT03753048|PROCEDURE|Y-Graft|Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
48357324|NCT00425191|DRUG|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
47989289|NCT03326973|BEHAVIORAL|Physician information|Details on outside health providers
47989290|NCT02223273|BEHAVIORAL|Multifaceted Strategy|"1. Simulation Based Team Training~2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~3. Reminders -~4. Check lists - decision support algorithm~5. Distribution of educational materials: guidelines and recommendations for best practices"
47989291|NCT02661542|DRUG|FF-10502-01|
47989292|NCT05587205|BIOLOGICAL|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
47989293|NCT05587205|OTHER|Sham injection|Sham injection
47989294|NCT02448654|DRUG|Tolcapone|Tolcapone will be compared to sugar pill
48688060|NCT04807608|OTHER|Usability Assessment|A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
48146517|NCT02216994|BEHAVIORAL|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
47989295|NCT02448654|DRUG|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
47989296|NCT02930551|DRUG|Lidocaine|
47989297|NCT02930551|DRUG|Isotonic Saline|
48146518|NCT02216994|DRUG|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
48357325|NCT06328608|DRUG|PRX-102 1 mg/kg every two weeks|Drug: PRX-102 1 mg/kg every two weeks
48357326|NCT05869526|DIETARY_SUPPLEMENT|Fish oil|EPA rich fish oil
48357327|NCT05869526|DIETARY_SUPPLEMENT|Kril oil|Superba Krill Oil
47989298|NCT05629390|DRUG|Lotilaner|Lotilaner Ophthalmic Solution
47989299|NCT05629390|DRUG|Vehicle Control|Vehicle of TP-03 ophthalmic solution
47989300|NCT04782089|DRUG|Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors|Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
48146519|NCT03031353|DRUG|Misoprostol|Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
48146520|NCT03031353|DRUG|Placebos|placebos tablet will be given before elective Cesarean sections
48357328|NCT05869526|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
48357329|NCT03643276|DRUG|Blinatumomab|Experimental therapy in randomizations R-HR and R-MR
48357330|NCT03643276|DRUG|Bortezomib|Experimental therapy in randomization R-eHR
48668963|NCT03753048|PROCEDURE|In-Situ|In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
48668964|NCT04592809|DRUG|Ketamine Hydrochloride|infused over a 40 minute period
48357331|NCT03643276|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
48668965|NCT04592809|DRUG|Midazolam Hydrochloride|infused over a 40 minute period
48668966|NCT04255771|DRUG|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
48668967|NCT04255771|DRUG|Placebos|Use a placebo as a comparison
48668968|NCT03064828|RADIATION|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
48668969|NCT03064828|RADIATION|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
48668970|NCT03722810|OTHER|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
48668971|NCT03722810|OTHER|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
48668972|NCT01246882|BEHAVIORAL|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
48668973|NCT01246882|BEHAVIORAL|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
48668974|NCT04486040|PROCEDURE|Drainage|Use of the suction drainage after hip revision arthroplasty
48668975|NCT04486040|PROCEDURE|No-drainage|Patients without drainage after surgery
48668976|NCT04101097|OTHER||
48668977|NCT01465841|DEVICE|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
48668978|NCT04778592|DRUG|ETX-018810|Study Drug
48668979|NCT04778592|DRUG|Placebo|Placebo
48668980|NCT00165828|DRUG|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
48668981|NCT05962021|DRUG|Toripalimab plus Chemotherapy|Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
48668982|NCT01593917|DEVICE|Trifecta™ Valve|Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
48668983|NCT03720366|DRUG|enasidenib|enasidenib
48668984|NCT03720366|DRUG|Arm 1 probes|caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
48668985|NCT03720366|DRUG|Arm 2 Probes|digoxin and rosuvastatin
48668986|NCT03720366|DRUG|Arm 3 probes|pioglitazone
48668987|NCT00175279|BEHAVIORAL|Opinion leader generated and endorsed evidence summaries|
48146521|NCT05274490|PROCEDURE|intubation and mechanical ventilation|patients who were in need were intubated and mechanically ventilated
48146522|NCT05691400|DRUG|Palbociclib 125Mg Tab|125 mg single dose
48146523|NCT05691400|DRUG|Ribociclib 200Mg Oral Tablet|200 mg single dose
48146524|NCT05691400|DRUG|Abemaciclib 150 MG Oral Tablet|150 mg single dose
48668988|NCT06148246|BEHAVIORAL|Family Fit Condition|Dyads in the Family Fit condition will use the Family Fit app and a Fitbit for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.
48668989|NCT06148246|BEHAVIORAL|Fitbit Only Condition|Dyads in the Fitbit only condition will use a Fitbit and the Fitbit app for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.
48146525|NCT00164996|PROCEDURE|Local pharyngeal anaesthesia|
48146526|NCT00164996|DEVICE|Ultrathin endoscope|
48668990|NCT01329861|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
48668991|NCT02801786|DRUG|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
48668992|NCT02801786|DRUG|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
48668993|NCT02801786|DRUG|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
48146527|NCT03229291|DRUG|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
48146528|NCT03229291|DRUG|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
48668994|NCT03198871|DRUG|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
48668995|NCT03198871|DRUG|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
48668996|NCT04608708|OTHER|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
48668997|NCT01061528|DRUG|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
48668998|NCT01471613|PROCEDURE|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
48668999|NCT01471613|DRUG|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
48669000|NCT01471613|BIOLOGICAL|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
48669001|NCT01471613|OTHER|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
48669002|NCT02243358|DRUG|Folfox6|
48669003|NCT02243358|DRUG|Gemcitabine|
48357332|NCT03643276|DRUG|Cytarabine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
48357333|NCT03643276|DRUG|Daunorubicin|Part of standard chemotherapy
48669004|NCT02243358|RADIATION|Radiation Therapy|
48669005|NCT02243358|PROCEDURE|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
48669006|NCT03112876|OTHER|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
48669007|NCT01917318|DRUG|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
48669008|NCT01917318|DRUG|Placebo|During 8 weeks subjects will receive oral placebo
48688061|NCT02697760|RADIATION|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
48506425|NCT03226028|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
48146529|NCT03258788|PROCEDURE|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.~Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.~Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
48669009|NCT02096978|PROCEDURE|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
48669010|NCT04734457|DRUG|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
48669011|NCT01641575|DRUG|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
48146530|NCT00923169|DRUG|Anti-Transforming Growth Factor-beta (GC 1008)|
48146531|NCT03420040|DEVICE|QS-M Needle Free Injector|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
48146532|NCT03420040|DEVICE|Glargine pen|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
48146533|NCT06241183|DRUG|Intravenous Famotidine|Patients in this group will receive 20mg IV Famotidine.
48146534|NCT06241183|DRUG|Oral Maalox/ Mylanta|Patients in this group will receive 30 ml Maalox/ Mylanta.
48357334|NCT03643276|DRUG|Myocet|Part of intensification block Myocet-FLA for patients with very high relapse risk
48357335|NCT03643276|DRUG|Dexamethasone|Part of standard chemotherapy
48357336|NCT03643276|DRUG|Doxorubicin|Part of standard chemotherapy
48357337|NCT03643276|DRUG|Etoposide|Part of standard chemotherapy
48506426|NCT01920607|DEVICE|magnetic anal sphincter|
48506427|NCT01920607|DEVICE|sacral nerve stimulation|
48669012|NCT00003616|DRUG|irinotecan hydrochloride|
47989301|NCT05681455|DEVICE|Neuromodulation NESA NXSIGNAL® device|"Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7."
47989302|NCT02794103|DEVICE|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
48357338|NCT03643276|DRUG|Fludarabine Phosphate|Part of intensification block Myocet-FLA for patients with very high relapse risk
48357339|NCT03643276|DRUG|Ifosfamide|Part of standard chemotherapy
48357340|NCT03643276|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
48357341|NCT03643276|DRUG|Methotrexate|Part of standard chemotherapy
48506428|NCT02906358|BEHAVIORAL|Community-based pain self-management|
48506429|NCT02906358|BEHAVIORAL|Clinic-based pain self-management|
48669013|NCT01744015|BEHAVIORAL|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
48357342|NCT03643276|DRUG|Pegaspargase|Part of standard chemotherapy
48357343|NCT03643276|DRUG|Prednisolone|Part of standard chemotherapy
48357344|NCT03643276|DRUG|Tioguanin|Part of standard chemotherapy
48688062|NCT01441947|DRUG|Cabozantinib|Part of combination arm
48688063|NCT01441947|DRUG|Fulvestrant|part of combination arm
48669014|NCT01744015|OTHER|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
48146535|NCT04420351|DRUG|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
48357345|NCT03643276|DRUG|Vincristine|Part of standard chemotherapy
48357346|NCT03643276|DRUG|Vindesine|Part of standard chemotherapy
48669015|NCT02303262|DRUG|Mocetinostat|Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
48669016|NCT02303262|DRUG|Gemcitabine|Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
48669017|NCT05489471|OTHER|Artificial intelligence review|The AI looks for ten different abnormalities on each chest X-ray and produces a heat map and percentage confidence score if it detects an abnormality.
48669018|NCT01597739|DRUG|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
48669019|NCT01597739|DRUG|Placebo|Form=capsule; route=oral use; twice daily.
48669020|NCT03545048|OTHER|Internet based exercises|Exercises for knee OA (online- digital health)
48669021|NCT04567524|DRUG|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
48669022|NCT03622047|DRUG|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
48669023|NCT03622047|DRUG|No analgesia labor|No analgesia labor control group
48669024|NCT05805163|BEHAVIORAL|FABI tailored COVID-19 testing pamphlet|FABI adapted COVID-19 educational pamphlet
48669025|NCT05805163|BEHAVIORAL|Standard COVID-19 home-based test kit|Standard COVID-19 home-based test kit
48669026|NCT05361460|OTHER|Cognitive decline|This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
48669027|NCT03085680|DRUG|Curcumin|Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
48146536|NCT04420351|DRUG|Aspirin;Clopidogrel|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
48146537|NCT00720161|DRUG|Metformin|daily 850 mg
48146538|NCT00720161|DRUG|Placebo|placebo
48146539|NCT00916656|BIOLOGICAL|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
48146540|NCT00916656|BIOLOGICAL|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
48357347|NCT03643276|DRUG|Erwinase|Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
48357348|NCT00522652|DRUG|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
48357349|NCT00201058|BEHAVIORAL|Tailored Web-based Asthma Management|Web-based asthma management
48357350|NCT00201058|BEHAVIORAL|Generic web-based asthma education|4 computer sessions over a period of 180 days
48357351|NCT04543201|BEHAVIORAL|Early START visit using checklist over telephone or zoom|"Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey"
48669028|NCT03085680|DRUG|microcrystalline cellulose|Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
48669029|NCT00108381|BEHAVIORAL|tailored cognitive behavior therapy|tailored psychological treatment
48669030|NCT00108381|BEHAVIORAL|standard care|standard psychological treatment
48669031|NCT05612230|OTHER|Data analysis|Data analysis is based on a single database from the National Health Medical Data (North Center).
48669032|NCT03823989|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
48669033|NCT03823989|RADIATION|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
48669034|NCT00451230|DRUG|cocaine|
48669035|NCT00451230|DRUG|hydrocortisone|
48669036|NCT05321290|OTHER|Robotic Therapy Program|
48669037|NCT04324281|OTHER|Investigation|cadaveric dissection
47989303|NCT01447810|OTHER|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
48146541|NCT03840447|BEHAVIORAL|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
48146542|NCT00884676|DRUG|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle."
48146543|NCT00884676|DRUG|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
48146544|NCT04093115|DRUG|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
48146545|NCT00823966|DRUG|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
48146546|NCT01248715|DRUG|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
48146547|NCT05459584|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
48146548|NCT01896609|BIOLOGICAL|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
48357352|NCT05372289|DIETARY_SUPPLEMENT|Immuno-nutrition|The experimental group of 68 older adults will be subjected to a preoperative immuno-nutrition for 30 days prior to surgery and up to 3 days after surgery. The oral feed provides energy, omega-3 fatty acids, arginine, nucleotides, and soluble fibre.
48506430|NCT06632912|BIOLOGICAL|2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Two doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0 and 6 months.
48669038|NCT01480778|DRUG|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
48669039|NCT01480778|DRUG|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
48669040|NCT04624984|DRUG|PD-1 inhibitor|PD-1 Inhibitor, intravenous drip, d1.
47989304|NCT06046456|OTHER|Prenatal Affective CogntiiveTraining|A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
48146549|NCT01896609|DRUG|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
48146550|NCT01896609|DRUG|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
48146551|NCT01896609|DRUG|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
48146552|NCT01218048|DRUG|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
48146553|NCT01218048|PROCEDURE|Surgery|Surgery for tumor
48146554|NCT01218048|RADIATION|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
48669041|NCT04624984|DRUG|PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome|PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
48669042|NCT00095550|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
48669043|NCT00095550|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
48669044|NCT00095550|DRUG|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
48669045|NCT01999192|DRUG|Tregalizumab|humanized anti-CD4 mAb
48669046|NCT01999192|DRUG|Placebo|identical end formulation buffer
48669047|NCT00882089|DEVICE|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
48669048|NCT06102395|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle
48669049|NCT06102395|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
48669050|NCT06102395|DRUG|Carboplatin|Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
48669051|NCT06102395|DRUG|Nedaplatin|Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
48669052|NCT06102395|DRUG|Nab paclitaxel|Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
47989305|NCT01656590|OTHER|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"1. High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age \& gender~2. 500 cc Formula - Nutren Replete with Fiber overnight \[8 hours\] via gastrostomy tube~3. Conditioning Exercise once daily"
47989306|NCT02152579|DRUG|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
47989307|NCT06527131|DEVICE|pulsed electromagnetic field therapy|PEMF is regarded as an efficient physical therapy method that has been utilized clinically to treat a variety of orthopedic conditions, including delayed union and nonunion of fractures. According to studies, PEMF has been authorized for its biological effects, which include the mineralization of bone matrix, osteogenic differentiation of mesenchymal stem cells, and osteoblast proliferation
47989308|NCT06527131|DEVICE|Transcutanous electrical nerve stimulation|Electrical stimulation consider a safe and cost-effective method for pain management. It has no side effects and few contraindication in addition to no drug interaction . According to studies ,electrical stimulation decreases pain through reducing central transmission of pain signals because of nociceptive inhibition at the presynaptic level in the dorsal horn.
47989309|NCT06527131|DRUG|Vancomycin|medical antibiotics
48357353|NCT03611179|DRUG|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
48506431|NCT06632912|BIOLOGICAL|3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)|Three doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0, 2, and 6 months.
48506432|NCT05041309|BIOLOGICAL|Axicabtagene Ciloleucel|No investigational product will be administered
48669053|NCT06102395|DRUG|Docetaxel|Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
48669054|NCT06102395|DRUG|Liposomal paclitaxel|Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
48669055|NCT06102395|DRUG|Fluorouracil|Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
48669056|NCT04349683|DRUG|Jinshuibao|6 capsules at a time, 3 times a day (tid).
48669057|NCT04349683|DRUG|Placebo|6 capsules at a time, 3 times a day (tid).
48669058|NCT00928967|DRUG|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
48669059|NCT01310972|OTHER|Registry|Registry
48669060|NCT01990742|BEHAVIORAL|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
48669061|NCT00879489|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
48146555|NCT01218048|DRUG|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
48146556|NCT04022707|OTHER|High-speed circuit resistance training|The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
48146557|NCT04022707|OTHER|Educational control|Lectures on health and fitness
48506433|NCT05041309|BIOLOGICAL|Brexucabtagene Autoleucel|No investigational product will be administered
48669062|NCT01606150|DRUG|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
48669063|NCT01606150|DRUG|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
48669064|NCT06456840|DIAGNOSTIC_TEST|ULTRASOUND|Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.
47989310|NCT02847546|DEVICE|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
48669065|NCT06060873|OTHER|Non-Interventional Study|Non-interventional study
47989311|NCT00333866|DRUG|pregabalin|600mg/day
47989312|NCT00333866|DRUG|pregabalin|450mg/day
47989313|NCT00333866|DRUG|pregabalin|300mg/day
47989314|NCT00333866|DRUG|placebo|placebo
48506434|NCT05041309|BIOLOGICAL|KITE-585|No investigational product will be administered
48506435|NCT05041309|BIOLOGICAL|KITE-718|No investigational product will be administered
48506436|NCT05041309|BIOLOGICAL|KITE-439|No investigational product will be administered
48506437|NCT05041309|BIOLOGICAL|KITE-222|No investigational product will be administered
48669066|NCT01444105|DEVICE|iStent|Implantation of two iStent devices
48669067|NCT01444105|OTHER|SLT|Laser treatment
48669068|NCT01083602|DRUG|panobinostat|PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
48669069|NCT01083602|DRUG|bortezomib|
48669070|NCT01083602|DRUG|dexamethasone|
48146558|NCT04594876|OTHER|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
48146559|NCT02793557|DRUG|FOL-005|Intradermal injection of 50 μl solution
48146560|NCT02793557|OTHER|Placebo|
48146561|NCT05050097|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
48146562|NCT05050097|DRUG|Carfilzomib|Carfilzomib will be administered as an IV infusion.
48146563|NCT05050097|DRUG|Daratumumab SC|Daratumumab will be administered subcutaneously.
48146564|NCT05050097|DRUG|Lenalidomide|Lenalidomide will be self-administered orally.
48146565|NCT05050097|DRUG|Pomalidomide|Pomalidomide will be self-administered orally.
48146566|NCT02148120|DRUG|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
48146567|NCT02148120|DRUG|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
48146568|NCT02148120|DRUG|Placebo|
48146569|NCT02226237|PROCEDURE|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
48146570|NCT02226237|PROCEDURE|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
48506438|NCT05041309|BIOLOGICAL|KITE-363|No investigational product will be administered
48669071|NCT06544915|DIETARY_SUPPLEMENT|Synbiotic, Probiotic, Placebo|Use of dietary supplements to improve gut microbiome and cardiometabolic health
48669072|NCT01067430|DRUG|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
48669073|NCT01067430|DRUG|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
48669074|NCT03612024|BEHAVIORAL|questionnaire|a standardized questionnaire was sent to all participants
48669075|NCT05992129|OTHER|foot exercise|These are foot and ankle muscle strengthening exercises described and evaluated by the literature
48357354|NCT01969604|BEHAVIORAL|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
48357355|NCT02630459|DRUG|Placebo|placebo via subcutaneous injection
48506439|NCT04815655|PROCEDURE|Cartilage tympanoplasty|is the reconstruction of the tympanic membrane (TM) by using catilage
48506440|NCT06292403|OTHER|Strength Training|training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.
48506441|NCT06292403|OTHER|Mirror therapy|Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
48506442|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
48506443|NCT06399653|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS devices look identical to active devices and participants will undergo identical training for self-administration on upper anterior cervical area (overlying carotid artery). Sham devices do not stimulate the vagus nerve.
48506444|NCT03900897|DEVICE|MED-EL SYNCHRONY PIN Cochlear Implant|Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
48506445|NCT03900897|OTHER|Cochlear Implant|Chart review of subjects implanted with a MED-EL cochlear implant under 6 years of age between January 2005 and October 2020.
48669076|NCT01370148|DRUG|conivaptan hydrochloride|Intravenous
48669077|NCT02455167|DRUG|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
48669078|NCT02455167|DRUG|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
48669079|NCT02455167|DRUG|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
48669080|NCT04582591|DRUG|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
48669081|NCT00897884|DRUG|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
48669082|NCT05109741|BEHAVIORAL|Internet-based Psychodynamic Therapy|Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
47989315|NCT01917201|PROCEDURE|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
48506446|NCT03279692|DRUG|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
48669083|NCT05109741|BEHAVIORAL|Internet-based Behavioral Activation|Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
48669084|NCT06120322|OTHER|Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies|During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected
48669085|NCT01306292|DRUG|SonoVue|dose of 4.8 mL administered intravenously one time
48669086|NCT01306292|DRUG|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
48669087|NCT05101720|PROCEDURE|Ultrasound Guided Axillary Venous Access|Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.
48669088|NCT05101720|PROCEDURE|Fluoroscopy-Guided Axillary Venous Access|Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
48669089|NCT05817461|DRUG|AZD0780 tablet|oral, fasted
48146571|NCT03236727|DRUG|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
48357356|NCT02630459|DRUG|Erenumab|erenumab via subcutaneous injection
48357357|NCT02630459|DRUG|Erenumab|erenumab via autoinjector (AI)/pen
48669090|NCT05817461|DRUG|[14C]AZD0780 Solution for Infusion|intravenous
48669091|NCT05817461|DRUG|[14C]AZD0780 Oral Solution|oral, fasted
48669092|NCT05242289|DEVICE|CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
48669093|NCT05699200|OTHER|Arterial Tonometry|We will measure arterial stiffness using arterial tonometry.
48669094|NCT05699200|DIAGNOSTIC_TEST|Echocardiogram|We will collect limited ultrasound images of the heart.
48669095|NCT05699200|DIAGNOSTIC_TEST|Carotid Ultrasounds|We will perform ultrasound imaging of the carotid artery.
48669096|NCT05699200|DIAGNOSTIC_TEST|Elastography|We will measure the elastic properties of the arteries using elastography.
48669097|NCT05699200|OTHER|Ankle-Brachial Index|We will measure the ankle-brachial index to assess peripheral artery blood flow.
48669098|NCT05699200|OTHER|Microneurography with sympathoexcitatory maneuvers|We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
48669099|NCT00525421|DRUG|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
48669100|NCT00525421|DRUG|Placebo|
48357358|NCT03960593|OTHER|Evaluation of the influence of geriatric factors|Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
47989316|NCT01917201|PROCEDURE|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
47989317|NCT02289976|PROCEDURE|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
47989318|NCT05268614|RADIATION|Radiation therapy|"Participants will receive either 70 gray (Gy), 60 Gy, or 50 Gy of radiation based on the following criteria:~70 Gy: Pretreatment level of plasma circulating free HPV DNA (cfHPV DNA) ≤ 12 copies/mL~60 Gy: Tumor tissue positive for HPV subtype other than 16 OR Pretreatment level of cfHPV DNA 13-99 copies/mL OR Pretreatment level of cfHPV DNA ≥ 100 copies/mL AND \<95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy~50 Gy: Tumor tissue positive for HPV subtype 16, pretreatment level of cfHPV DNA ≥ 100 copies/mL, AND ≥ 95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy"
47989319|NCT05268614|DRUG|Cisplatin|"All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to an alternative chemotherapy regimen per institutional practice, but chemotherapy should not be discontinued unless mandated by the patient's condition."
48506447|NCT05623618|BEHAVIORAL|PACE labelling|PACE labelling implemented near at least one discretionary food item in secondary school canteens for up to 6 weeks.
48669101|NCT02150161|DRUG|Lidocaine/ ketamine|
48669102|NCT02150161|DRUG|Fentanyl|
47989320|NCT01996709|DEVICE|Hydrogen peroxide-based contact lens solution|
48357359|NCT00303329|DRUG|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
48357360|NCT05421416|DRUG|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
48357361|NCT05421416|DRUG|Placebo|Placebo sugar pill
48357362|NCT04681573|DIAGNOSTIC_TEST|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
48357363|NCT00000952|DRUG|Ritonavir|
48357364|NCT00000952|DRUG|Lamivudine|
48669103|NCT00982384|OTHER|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
48669104|NCT00982384|OTHER|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
48669105|NCT06032039|DRUG|Triamcinolone|Standard treatment for osteoarthritis knee pain
48669106|NCT06032039|OTHER|Platelet Rich Plasma|Alternative treatment for osteoarthritis knee pain
48669107|NCT05544487|PROCEDURE|Colorectal Anastomosis|Differences in intra-operative techniques and surgeon grades
48688064|NCT02223052|DRUG|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
48688065|NCT02223052|DRUG|Vidaza|75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
48688066|NCT03899025|RADIATION|CT|CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
48357365|NCT00000952|DRUG|Zidovudine|
48357366|NCT03761628|DEVICE|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of VVC
48357367|NCT04060628|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
48357368|NCT02442765|DRUG|AVP-786|
48357369|NCT02442765|DRUG|Placebo|
48357370|NCT04248972|DEVICE|PBM|A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes
48357371|NCT04248972|OTHER|PLACEBO PBM|A placebo whole body red light will be carried out during 20 minutes
48357372|NCT00017173|BIOLOGICAL|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
48357373|NCT00017173|DRUG|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
48146572|NCT00670488|DRUG|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
48669108|NCT05578066|OTHER|Developing teams of Local Leaders|A team of local leaders, consisting of 3-5 PHC providers and 1-2 users at each CESFAM will be developed in months 1-3 of the intervention.The teams will comprise some individuals who have provided critical support and input, including participating in the exploratory research phase and the Community-Based Participatory Research (CBPR) adaptation of the intervention framework for the Chilean context developed previously. The teams will assist with the data collection process throughout the study by encouraging colleagues to complete questionnaires and recruit users, as well as oversee and implement the intervention at their respective CESFAM. They will receive training to develop their skills as leaders and support the implementation process at their respective CESFAM.
48688067|NCT01008761|DRUG|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
48357374|NCT00017173|PROCEDURE|conventional surgery|conventional surgery
48357375|NCT00017173|RADIATION|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
48688068|NCT01008761|DRUG|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
48146573|NCT00785031|OTHER|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
47989321|NCT01996709|DEVICE|Habitual contact lens solution|Biguanide-preserved
47989322|NCT01996709|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
47989323|NCT03245008|DRUG|MT-5547|Solution for injection in pre-filled syringe
47989324|NCT03245008|DRUG|MT-5547-matching placebo|Solution for injection in pre-filled syringe
48357376|NCT05490849|DRUG|68Ga-HX01|"For pharmacokinetics, healthy volunteer underwent 68Ga-HX01 PET imaging. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~Cancer patients,~1. Subjects should have 68Ga-HX01 and 18F-FDG PET scans two days apart.~2. Blood tests, liver and kidney function, tumor markers (CA125, CA199, CEA, etc.), and other biochemical markers must be performed one week prior to and after imaging.~3. Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
48357377|NCT03322540|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
48357378|NCT03322540|DRUG|Epacadostat|Epacadostat administered orally twice daily.
48688069|NCT04234386|RADIATION|GammaPod Radiation|The basic design is a dose-escalation phase Ib study with 4 predefined dose levels. With this study treatment, participants will receive the dose level assigned treatment of radiation therapy before the lumpectomy surgery.
47989325|NCT02492620|DRUG|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
47989326|NCT03418298|BEHAVIORAL|Prehabilitation group|Subjects will performed an internet-based exercise program before surgery
47989327|NCT04564456|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test oproduct in one study period
47989328|NCT04564456|DRUG|ADVAIR DISKUS® 500/50|2 inhalations Reference product in one study period
47989329|NCT02044744|BEHAVIORAL|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
47989330|NCT01528254|DRUG|Placebo of vildagliptin|
48146574|NCT01966679|DRUG|AZD7325|
48146575|NCT01966679|DRUG|Placebo|
48146576|NCT00604396|DRUG|insulin detemir|
48146577|NCT00604396|DRUG|insulin NPH|
48357379|NCT03322540|DRUG|Placebo|Matching placebo administered orally twice daily.
48357380|NCT05108311|OTHER|Manual therapy and therapeutic exercise|"1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy"
48506448|NCT06410313|DEVICE|ChampioNIR Ridaforolimus Eluting Peripheral Stent System|ChampioNIR implantation in Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery disease
48506449|NCT05955508|DRUG|Linvoseltamab|Administration by intravenous (IV) infusion
48506450|NCT02084602|DRUG|Artesunate|Orally administration of artesunate 4mg/Kg by three days
48506451|NCT02084602|DRUG|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
48506452|NCT01729403|DRUG|aleglitazar|150 mcg orally daily, 16 weeks
48669109|NCT05578066|OTHER|Analysis of Internal Policies, Procedures and Protocols|This component involves evaluating CESFAM policies, procedures, and protocols using an anti-stigma/pro-recovery approach to identify strengths and areas for improvement in service delivery for individuals affected by MISUI. This will be completed using a policy analysis tool based on existing frameworks, such as the Health Equity Impact Assessment Tool (PHO \& OMHLTC, 2012) and the QualityRights Toolkit (WHO, 2012). At least 5 policies, procedures, or protocols to be analyzed will be selected by the local leaders at intervention CESFAM during months 3-6 of the intervention. Recommendations concerning health equity, prevention of stigma, and promotion of recoveryoriented practices for individuals with MISUI will be developed and shared following analysis. Each intervention CESFAM will be expected to implement at least one recommendation and make the necessary efforts to educate PHC providers about the policy change in months 7-18 of the intervention.
47989331|NCT01528254|DRUG|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
47989332|NCT01528254|DRUG|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
48506453|NCT01729403|DRUG|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
48506454|NCT01729403|DRUG|placebo|orally daily, 16 weeks
48506455|NCT01922804|DIETARY_SUPPLEMENT|K2 vitamin|K2 vitamin tablet
48506456|NCT01922804|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
48506457|NCT05394324|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with subject devices of this study.
48506458|NCT06083012|DEVICE|Cardiac mapping|"All patients enrolled are treated for their atrial fibrillation/tachycardia via a catheter ablation procedure using VX1/Volta AF-Xplorer/Volta AF-Xplorer II software (used in accordance with its approved indication as per of its IFU) during the mapping phase to identify areas of interest specific to the patient.~The ablation approach is free and chosen by the operator according to his standard practice. The two main phases of the ablation procedure are:~* 3D mapping of the atria and location of areas of interest;~* Catheter ablation at the operator\&amp;#39;s discretion."
48506459|NCT03207386|BEHAVIORAL|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
48506460|NCT02188186|DRUG|Initial triple combination|Initial triple combination arm
48506461|NCT02188186|DRUG|Conventional treatment|Conventioanl treament with dose escalation
48688070|NCT05503979|DRUG|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
48506462|NCT05022589|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, 5 sessions per week, \~30 minutes per session.
48688071|NCT01527591|BIOLOGICAL|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
47989333|NCT05124951|RADIATION|Whole-ventricle irradiation|Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
47989334|NCT05124951|DRUG|Carboplatin/etoposide|Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
48357381|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution Erector Spinae Plane Block|ultrasound guided ESPB - L4 level, unilateral
48357382|NCT06083428|DRUG|Ropivacaine 0.2% Injectable Solution - PENG block|ultrasound guided PENG block
48357383|NCT06083428|DRUG|Control Test|Only spinal anesthesia
48506463|NCT03714828|DRUG|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
48506464|NCT03714828|DRUG|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
48506465|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
48146578|NCT01303822|BEHAVIORAL|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
48669110|NCT05578066|OTHER|Raising Awareness|Various forms of media will be used to raise awareness about stigma related to MISUI among PHC providers and users. Local leaders at intervention CESFAM will determine the type of media they would like to use; this may include images, film, music, or a combination of media. The research team will work with local leaders to develop messaging to include in the media and assist with showcasing these pieces within each intervention CESFAM. This component will be implemented throughout the intervention (intervention months 1-18). Depending on the type of media, instances of use will be tracked accordingly. For example with posters, data on the number of posters posted at a CESFAM over what time period and an estimation of the number of PHC providers and users who have viewed the posters will be collected.
48688072|NCT06014853|DRUG|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
48146579|NCT01845337|DRUG|Teysuno|
48146580|NCT01845337|DRUG|Capecitabine|
48146581|NCT06160453|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions
48146582|NCT06160453|DEVICE|Serious game with augmented reality|The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game will be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions
48357384|NCT03128372|DEVICE|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
48506466|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
48146583|NCT00647465|DRUG|vaccine|IFNalpha 2b
48506467|NCT02591186|PROCEDURE|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
48506468|NCT02676583|PROCEDURE|Tonsillectomy|Closure or not closure of tonsil fossa
48506469|NCT02774642|BEHAVIORAL|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
48506470|NCT02774642|BEHAVIORAL|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
48506471|NCT05691517|PROCEDURE|Biopsy|Undergo tumor biopsy
48506472|NCT05691517|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48506473|NCT05691517|PROCEDURE|Computed Tomography|Undergo CT scan
48506474|NCT05691517|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
48146584|NCT00647465|DRUG|Placebo|Placebo
48357385|NCT03460665|PROCEDURE|Arteriography|knee arteriography
48357386|NCT01943136|DRUG|papaya 1% extract ointment|
48357387|NCT01943136|DRUG|mupirocin 2% ointment|
48357388|NCT03684460|DEVICE|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
48506475|NCT03147755|OTHER|No intervention|No intervention
48506476|NCT06619769|BEHAVIORAL|eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
48506477|NCT06619769|BEHAVIORAL|Navigator support for eSense-Cancer|The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.
48506478|NCT06619769|BEHAVIORAL|Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
48669111|NCT05578066|OTHER|Innovative Contact-Based Education|Educational workshops will include anti-stigma and recovery principles, along with specific MISUI topics relevant to PHC providers. This will be determined by findings from the exploratory phase, current research, best practices, and the perspectives of local leaders. It may include (1) supporting CESFAM PHC providers in preventing stigma and promoting recovery in their practice and (2) enhancing the competencies of CESFAM PHC providers for discussing MISUI with their users, identifying MISUI signs and symptoms, and referring users to psychosocial centres for treatment. The key feature of these workshops is the contact-based educational element, where people with lived experience participate in developing and delivering the curriculum to CESFAM PHC providers. Four three-hour workshops will be held at each intervention CESFAM and will be facilitated by two academic/clinical trainers with expertise in stigma research and practice, and one person with lived experience.
48357389|NCT03684460|DEVICE|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
48357390|NCT01414439|BEHAVIORAL|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
48357391|NCT02913885|DRUG|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
48357392|NCT02913885|DRUG|fluoride varnish|fluoride inhibit the progression of white spot lesion
47989335|NCT05124951|DRUG|Ifosfamide/cisplatin/etoposide|Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
47989336|NCT05124951|PROCEDURE|Second-look surgery|Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
48357393|NCT00911326|DRUG|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
48357394|NCT02423733|OTHER|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
48357395|NCT04430036|DRUG|AGEN1884|A fully human monoclonal Anti-PD-1 Antibody
48146585|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
48357396|NCT04430036|DRUG|AGEN2034|A fully human monoclonal Anti-PD-1 Antibody
48357397|NCT04430036|DRUG|Cisplatin|Alkylating antineoplastic agent
48357398|NCT04430036|DRUG|Gemcitabine|Antimetabolite antineoplastic agent
48357399|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
48357400|NCT00644033|DRUG|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
48357401|NCT00644033|DRUG|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
48357402|NCT00388128|DRUG|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
48357403|NCT03236649|DRUG|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
48357404|NCT03236649|DRUG|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
48506479|NCT05384171|BEHAVIORAL|Measurement-Based Transition Assistance (MBTA)|Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
48357405|NCT00006463|DRUG|ECTEINASCIDIN 743|
48357406|NCT02879864|DEVICE|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
48506480|NCT04709211|PROCEDURE|Facia Iliaca block|patients will receive Ultrasound-guided Facia Iliaca block using 50 ml 0f Bupivacaine 0.25%
48506481|NCT04709211|PROCEDURE|Anterior Quadratus Lumbroum block|patients will receive Ultrasound-guided Anterior Quadratus Lumbroum block using 50 ml 0f Bupivacaine 0.25%
48506482|NCT04709211|DRUG|bupivacaine|bupivacaine
48506483|NCT02647827|OTHER|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
48688073|NCT06014853|DRUG|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
48688074|NCT03047967|DIAGNOSTIC_TEST|lung function tests|baby-body plethysmography
48688075|NCT03047967|DIAGNOSTIC_TEST|Nasal brushing|Epithelial sample collecting for in vitro study
48146586|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
48146587|NCT04320472|OTHER|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
48146588|NCT01420198|BEHAVIORAL|Lifestyle intervention|Increased physical activity and improved food habits
48357407|NCT02879864|DEVICE|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
48357408|NCT04789005|DRUG|Norepinephrine|Norepinephrine 8mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
48357409|NCT04789005|DRUG|Phenylephrine|Phenylephrine 100mcg was administered manually by the anaesthesiologist every time the SBP was 20% lower than baseline and the HR ≥60 bpm.
48357410|NCT05968794|PROCEDURE|Vaginal cerclage|A vaginal cerclage is a short and minor surgical procedure performed under general or regional anesthesia. An unabsorbable suture is placed around/through the cervix to close the cervical canal and to increase its firmness, in order to reduce cervical insufficiency.
48357411|NCT05835544|OTHER|Active Comparator: HIIT Control|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.
48357412|NCT05835544|OTHER|Experimental: HIIT + BFR between cycling sets|Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied for 2 minutes during the passive rest at 80% of limb occlusion pressure.
48357413|NCT05835544|OTHER|Experimental: HIIT + BFR moderate occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 50% of limb occlusion pressure and deflated during passive rest periods.
48357414|NCT05835544|OTHER|Experimental: HIIT + BFR high occlusion during cycling|Complete 3 sets of five repetitions of 30 seconds cycling at 70% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets. Blood flow restriction is applied during and between exercise repetitions at 80% of limb occlusion pressure and deflated during passive rest periods.
48357415|NCT00252499|DRUG|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
48506484|NCT02647827|DEVICE|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
48357416|NCT00252499|DRUG|fenofibrate|PPAR-alpha agonist, reduces triglycerides
48357417|NCT00252499|DRUG|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
48357418|NCT00252499|DRUG|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
48357419|NCT05551234|OTHER|Regular exchanges|The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
48357420|NCT01104922|DRUG|Cetuximab|Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: \* Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) \* Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery.
48357421|NCT01104922|DEVICE|Stereotactic radiosurgery|Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy)
48357422|NCT04875195|BIOLOGICAL|Pembrolizumab|Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.
48506485|NCT02647827|DRUG|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
48506486|NCT00926783|PROCEDURE|CFAE ablation|CFAE ablation (targeted vs. generalized)
48506487|NCT00405808|DRUG|Rimonabant|Once daily in the morning
48506488|NCT00405808|DRUG|Placebo|Once daily in the morning
48506489|NCT04657926|DRUG|APPA|APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).
48506490|NCT04657926|DRUG|Placebo|Placebo capsules
48506491|NCT05826795|PROCEDURE|Early goal-directed therapy (EGDT)|The principle of hemodynamic optimization to achieve the defined goals.
48506492|NCT03037437|DRUG|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
48669112|NCT05578066|OTHER|Recovery-Based Arts|Local leaders at CESFAM will select one PHC provider member and recruit one artist to develop an arts curriculum and facilitate the art sessions. The facilitators will select an art form to use throughout the sessions, and in collaboration with local leaders they will determine themes related to MISUI to cover in each session (planning process will be completed in intervention months 7-8). Arts workshops will be held for 10 weeks, with each session lasting up to three hours (during intervention months 9-12). Ten users affected by MISUI and at least three CESFAM PHC providers will participate in the workshops each week. At the end of the 10-week program, each CESFAM will host an exhibition to showcase the artwork that has been produced (during intervention months 13-18). All PHC providers and users, as well as community members, will be invited to attend the exhibition. PHC providers and users will be invited to speak about their experiences learning and working together to create art.
48506493|NCT03037437|DRUG|Hydroxychloroquine (HCQ)|400mg by mouth daily
48506494|NCT04939376|PROCEDURE|IVF|In vitro fertilization
48669113|NCT02209467|OTHER|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
48669114|NCT05489328|OTHER|Candidate-1|Biological
48669115|NCT05489328|OTHER|Candidate-2|Biological
48669116|NCT05489328|OTHER|Candidate-3|Biological
48669117|NCT05489328|OTHER|Candidate-4|Biological
48357423|NCT02056249|OTHER|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
48506495|NCT06102863|DRUG|statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
48357424|NCT00869375|DEVICE|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
48357425|NCT02221570|DRUG|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
48506496|NCT04547842|DRUG|Mirtazapine 30 MG|mirtazapine is given in arm M to prevent PONV
48506497|NCT04547842|DRUG|Dexamethasone|Dexamethasone is given in arm D to prevent PONV
48506498|NCT03783429|DRUG|Digoxin|Digoxin tablets will be given orally
48506499|NCT03783429|DRUG|Placebos|Placebo tablets will be given orally
48506500|NCT02542605|DRUG|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
48506501|NCT02542605|DRUG|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
48506502|NCT02542605|DRUG|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
48506503|NCT06053684|DEVICE|Standard Non-Invasive Mechanical Servo Ventilation|The active comparator arm will utilize a standard non-invasive mode to provide ventilation support
48506504|NCT06053684|DEVICE|Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation|The experimental arm will utilize a NAVA mode to provide non-invasive ventilation support
48506505|NCT05050110|OTHER|Fruits and Vegetable increase|Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
48506506|NCT01164696|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
48506507|NCT03145181|DRUG|Teclistamab (IV)|Participants will receive IV infusion of Teclistamab.
48506508|NCT03145181|DRUG|Teclistamab(SC)|Participants will receive SC injection of Teclistamab.
48506509|NCT04597632|DRUG|brolucizumab|brolucizumab 6 mg/0.05 mL solution for intravitreal injection
48506510|NCT05772247|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound score was calculated by the results of lung ultrasound examination
48506511|NCT04590040|OTHER|Placebo|0% nano-HAP toothpaste
48669118|NCT05489328|OTHER|Candidate-5|Biological
48669119|NCT05489328|OTHER|Candidate-6|Biological
48506512|NCT04590040|DEVICE|15% nano-HAP toothpaste|Toothpaste with identical base formulation as the placebo containing 15% nano-HAP
48506513|NCT04590040|DEVICE|5% KNO3 toothpaste|Toothpaste with identical base formulation as the placebo containing 5% KNO3
48506514|NCT06353542|DIAGNOSTIC_TEST|Software analysis|The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case
48506515|NCT06353542|DIAGNOSTIC_TEST|Ophthalmologist examination|The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case
48506516|NCT05873829|OTHER|Hand-foot exercises|Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
48506517|NCT02553759|OTHER|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
48506518|NCT05286801|BIOLOGICAL|Atezolizumab|Given IV
48506519|NCT05286801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48506520|NCT05286801|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
48506521|NCT05286801|OTHER|Fludeoxyglucose F-18|Given FDG
48506522|NCT05286801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48506523|NCT05286801|PROCEDURE|Positron Emission Tomography|Undergo PET-CT and/or FDG-PET
48506524|NCT05286801|BIOLOGICAL|Tiragolumab|Given IV
48506525|NCT05286801|PROCEDURE|X-Ray Imaging|Undergo x-rays
48506526|NCT01329900|DRUG|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
48506527|NCT01329900|DRUG|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
48506528|NCT01329900|DRUG|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
48669120|NCT05489328|OTHER|Candidate Control|Biological
48669121|NCT05489328|BIOLOGICAL|13vPnC|13-valent pneumococcal conjugate vaccine
48669122|NCT05489328|BIOLOGICAL|PCV15|15-valent pneumococcal conjugate vaccine
48357426|NCT00624741|DRUG|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
48357427|NCT03475355|BEHAVIORAL|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
48357428|NCT03475355|BEHAVIORAL|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
48357429|NCT03475355|BEHAVIORAL|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
48357430|NCT03475355|BEHAVIORAL|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
48357431|NCT03475355|BEHAVIORAL|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
48357432|NCT03475355|BEHAVIORAL|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
48357433|NCT02827331|OTHER|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)"
48357434|NCT02827331|OTHER|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)"
48357435|NCT02827331|OTHER|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
48506529|NCT01329900|DRUG|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
48506530|NCT01329900|DRUG|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
48506531|NCT01329900|PROCEDURE|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
48669123|NCT00101348|DRUG|erlotinib hydrochloride|Given orally
48506532|NCT01069874|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
48506533|NCT01069874|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
48506534|NCT02876107|DRUG|Carboplatin|Given IV
48506535|NCT02876107|OTHER|Laboratory Biomarker Analysis|Correlative studies
48506536|NCT02876107|DRUG|Paclitaxel|Given IV
48506537|NCT02876107|BIOLOGICAL|Panitumumab|Given IV
48506538|NCT05803421|DRUG|Orforglipron|Administered orally once daily
48669124|NCT00101348|BIOLOGICAL|cetuximab|Given IV
48669125|NCT00101348|BIOLOGICAL|bevacizumab|Given IV
48669126|NCT00101348|OTHER|laboratory biomarker analysis|Correlative studies
48669127|NCT04858581|DIAGNOSTIC_TEST|Virological and serological tests|Survey, RT-PCR test and blood test
48669128|NCT00157118|DRUG|Protein C Concentrate (Human) Vapor Heated|
48669129|NCT03159182|DEVICE|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
48669130|NCT03159182|DEVICE|Pressure garment|Custom made fabric pressure garment
48357436|NCT02827331|OTHER|Administrative and medical data|"* Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
48357437|NCT02194634|DRUG|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
48357438|NCT02194634|OTHER|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
48357439|NCT02194634|PROCEDURE|Laser|Laser treatment at first month, then repeated as needed.
48357440|NCT02194634|OTHER|Sham laser|Sham laser at first month, then repeated as needed.
48357441|NCT00284609|BEHAVIORAL|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
47989337|NCT00584142|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
48146589|NCT04680598|DRUG|ICI|Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)
48146590|NCT04680598|DRUG|Antiviral Prophylaxis|Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
48357442|NCT00284609|BEHAVIORAL|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
48357443|NCT04530318|OTHER|Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
48357444|NCT04530318|OTHER|Placebo|The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).
48357445|NCT00887913|DEVICE|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
48357446|NCT02180464|DRUG|LAS41004|
48357447|NCT02180464|DRUG|control|
48357448|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
48357449|NCT03626844|PROCEDURE|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
48506539|NCT05803421|DRUG|Insulin Glargine|Administered SC once daily
48506540|NCT05369312|DRUG|BPI-442096|Subjects will receive BPI-442096 until disease progression
48506541|NCT05054478|DRUG|Daratumumab|Daratumumab added to induction, first consolidation and second consolidation
48688076|NCT02382731|BEHAVIORAL|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
47989338|NCT02340598|OTHER|cold vest|The lowering of body temperature increases basal metabolic rate
47989339|NCT04087252|BIOLOGICAL|tumor neoantigen|tumor neoantigens
47989340|NCT03454919|DRUG|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
48357450|NCT04528693|BEHAVIORAL|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
48357451|NCT01566006|DRUG|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
47989341|NCT06339073|DEVICE|mechanical ventilation|Abdominal trauma patients were treated with mechanical ventilation according to their conditions.
48146591|NCT04070937|DIAGNOSTIC_TEST|vestibular test 1|videonystagmography
48146592|NCT04070937|DIAGNOSTIC_TEST|vestibular test 2|video head impulse test
48357452|NCT04427904|DRUG|Bupivacaine 0.5% with 1:200 000 epinephrine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
48146593|NCT04070937|DIAGNOSTIC_TEST|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
48146594|NCT04070937|DIAGNOSTIC_TEST|audiometry|tonal liminar audiometric thresholds
48146595|NCT04070937|DIAGNOSTIC_TEST|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
48146596|NCT04070937|GENETIC|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
48146597|NCT05735379|DRUG|Deprescribing anticholinergic and sedative mediications|Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
48688077|NCT02382731|BEHAVIORAL|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
48146598|NCT06482528|OTHER|Motor Imagery|"After the measurement devices are connected to the individuals, they will be seated in a comfortable chair.~After the calibration of the devices, individuals will undergo a 2-minute relaxation session. During the relaxation session, individuals will be asked to focus on their breathing and relax as much as possible.~Then, heart rate variability, electrodermal activities and respiratory frequencies of the individuals will be measured in a sitting position for 5 minutes. In case of rest, after taking the variables, individuals will be kept to rest for 10 minutes.~After 10 minutes, the devices will be placed on the individuals again and a 2-minute relaxation session will be held.~Then, individuals will be asked to imagine running through kinesthetic imagery for 5 minutes.~Feedback will be given to individuals throughout the entire session. These feedbacks will be given verbally with an audio recording prepared by the physiotherapist."
48146599|NCT06413459|OTHER|Luminex; scRNAsec|Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
48146600|NCT02949297|DEVICE|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
48146601|NCT06306222|DEVICE|Laser lithotripsy|Ureteroscopic laser lithotripsy
48146602|NCT00534677|DRUG|Terlipressin|2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
48146603|NCT00534677|DRUG|Octreotide|Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
48506542|NCT03578549|DEVICE|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
48506543|NCT05517811|DIAGNOSTIC_TEST|TEG indices|Blood samples
48506544|NCT00676780|DRUG|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
48146604|NCT00006084|BIOLOGICAL|lintuzumab|
48506545|NCT03987321|DEVICE|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
48146605|NCT03014349|OTHER|Analysis of medical records|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
48146606|NCT01722097|DRUG|Rocuronium|
48506546|NCT05823324|BEHAVIORAL|Therapeutic play group|The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
48506547|NCT06116786|DRUG|JNJ-86974680|JNJ-86974680 will be administered.
48506548|NCT06116786|DRUG|Cetrelimab|Cetrelimab will be administered.
48506549|NCT06116786|RADIATION|Radiation Therapy|Radiation therapy will be administered.
48506550|NCT03881423|DRUG|Rocuronium Bromide|DEEP block to PTC 1-3
48506551|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 weeks
48506552|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 g once a day for 8 weeks
48506553|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g + Maltodextrin 10 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks
48146607|NCT01722097|DRUG|placebo|
48506554|NCT04716868|DIETARY_SUPPLEMENT|Psyllium plantago|Psyllium plantago 15 g once a day for 8 weeks
48506555|NCT06296082|DRUG|Botulinum toxin type A|Botulinum toxin type A injections are a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a chimical disruption of dysfunctional endplates.
48506556|NCT06296082|OTHER|Dry Needling|Dry Needling is a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a mechanical disruption of dysfunctional endplates.
48357453|NCT04427904|DRUG|Lidocaine 2% with 1:100 000 epinephrine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
48357454|NCT04771650|OTHER|CAMI|The CAMI is a culturally adapted motivational interview. It is a single 75 minute session that focuses on promoting motivation to change drinking and drug use behavior.
48357455|NCT01021553|DRUG|GSK557296|50 mg GSK557296
48357456|NCT01021553|DRUG|GSK557296|150 mg GSK557296
48357457|NCT01021553|DRUG|placebo|placebo
48357458|NCT03824444|DEVICE|PODS|Percutaneous Osseointegrated device for transhumeral patients
48357459|NCT03574987|OTHER|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
48357460|NCT03908866|OTHER|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
48357461|NCT03908866|OTHER|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
48357462|NCT01126281|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
48357463|NCT01997333|DRUG|CDX-011|
48357464|NCT01997333|DRUG|Capecitabine|
48669131|NCT05544253|PROCEDURE|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
48669132|NCT02455739|OTHER|chewing gum|postoperative gum chewing to improve gastrointestinal function
48669133|NCT03769350|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
48669134|NCT03302767|OTHER|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
48669135|NCT03200470|OTHER|No intervention: sample collection study|Sample collection and collection of laboratory values
48669136|NCT04350684|DRUG|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
48669137|NCT04350684|DRUG|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
48669138|NCT04350684|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
48357465|NCT03773068|DRUG|BAY1817080 - Formulation A|Formulation A
48357466|NCT03773068|DRUG|BAY1817080 - Formulation B|Formulation B
48357467|NCT03773068|DRUG|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
48357468|NCT04888195|OTHER|Questionnaire|Participants will complete a set of validated questionnaires (TRSC-C and demographic sheet) before chemotherapy. They also have to complete the same questionnaires (TRSC-C) again within 1 week after the 1st, 2nd, 3rd, 4th , 5th and 6th courses of chemotherapy via telephone interview by our research assistants.
48357469|NCT05143853|PROCEDURE|non-absorbable tape fixation around AC joint|fixation around AC joint with tape in different configurations
48357470|NCT05143853|PROCEDURE|no fixation around AC joint|there will be no additional fixation around AC joint in this group
48357471|NCT05143853|PROCEDURE|coracoclavicular (CC) fixation|mandatory coracoclavicular fixation with to suspensory systems, comprised of non-absorbable tapes and metal buttons
48357472|NCT00336466|DRUG|Human recombinant erythropoietin|
48357473|NCT03506828|PROCEDURE|Surgical sympathectomy|thoracoscopic sympathectomy
48357474|NCT03506828|PROCEDURE|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
48357475|NCT00162630|PROCEDURE|Fascia Iliaca Compartment Blockade|
48357476|NCT04994886|PROCEDURE|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
48357477|NCT04335357|DRUG|TBR-760|TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.
48357478|NCT04335357|DRUG|Placebo|Placebo
48357479|NCT01849549|BEHAVIORAL|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
48357480|NCT01849549|OTHER|MRI|Anatomical, diffusion, and/or functional MRI
48357481|NCT04804072|DRUG|Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|MOUD for OUD
48357482|NCT04804072|DIAGNOSTIC_TEST|HIV testing|HIV testing
48357483|NCT04804072|DRUG|HIV treatment for participants living with HIV not already in care|HIV treatment for participants living with HIV not already in care
48357484|NCT04804072|DRUG|PrEP for participants without HIV|PrEP for participants without HIV
48357485|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Testing and referral for vaccination or treatment for HAV and HBV
48357486|NCT04804072|DIAGNOSTIC_TEST|Testing and referral for treatment for hepatitis C virus (HCV)|Testing and referral for treatment for HCV
48357487|NCT04804072|DIAGNOSTIC_TEST|Sexually transmitted infection (STI) testing and treatment|STI testing and treatment
48357488|NCT04804072|OTHER|Primary care|Primary care
47989342|NCT01264978|DEVICE|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
47989343|NCT06415409|OTHER|Water|Plain water
47989344|NCT06415409|OTHER|Gatorade|Sport Drink Gatorade
47989345|NCT06415409|OTHER|BodyArmor|Sport Drink BodyArmor
48506557|NCT05996562|PROCEDURE|Pulmonary Artery Denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA."
48506558|NCT05868512|DIAGNOSTIC_TEST|Dry needling|Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
47989346|NCT06415409|OTHER|GoodSport|Sport Drink GoodSport
48146608|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
48146609|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
48146610|NCT00734253|DRUG|Placebo|Placebo capsules taken twice a day for 1-year
48146611|NCT03776565|OTHER|Ultrasound|Ultrasound of antrum of stomach
48146612|NCT06318377|DIETARY_SUPPLEMENT|Peanut group|These are commercially available peanuts that are high in antioxidants and are believed to be beneficial for physiological health
47989347|NCT06000254|DEVICE|High energy density pulse electromagnetic field|The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.
48146613|NCT04968886|DIAGNOSTIC_TEST|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
47989348|NCT06000254|OTHER|physiotherapy|Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.
47989349|NCT06000254|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
48146614|NCT02939742|DRUG|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
48146615|NCT02939742|DRUG|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
48506559|NCT05868512|DIAGNOSTIC_TEST|Therapeutic ultrasound|Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
48669139|NCT04350684|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
47989350|NCT01075204|DRUG|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
48146616|NCT00383383|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
48146617|NCT00383383|BIOLOGICAL|Engerix-B|
48146618|NCT03516877|BEHAVIORAL|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
48146619|NCT00209885|DRUG|Gabapentin|
48146620|NCT00209885|DRUG|S-ketamine|
48146621|NCT00209885|DRUG|Lidocaine|
48506560|NCT05468931|DEVICE|Prostate stimulator|Prostate stimulation device for sexual dysfunction
48506561|NCT06050304|BEHAVIORAL|Observation of behavior and search of biomarkers with 3 blood tests.3 weeks wearing an actimeter|In the form of a small watch, which collects the level of motor activity throughout the day and night. Patients will be asked to indicate each moment of crack-cocaine use by pressing the button in the center of the watch. We want to know if certain uses lead to more behavioral problems (especially after periods of cessation).
48146622|NCT00209885|DRUG|Droperidol|
48357489|NCT04804072|BEHAVIORAL|Harm reduction services|Harm reduction services
48357490|NCT04804072|BEHAVIORAL|Peer navigation|Peer navigation
48357491|NCT04804072|DIAGNOSTIC_TEST|COVID-19 testing and referral for further evaluation, care and/or treatment|COVID-19 testing and referral for further evaluation, care and/or treatment
48146623|NCT02626494|DRUG|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
48357492|NCT02615561|DEVICE|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
48506562|NCT06050304|BIOLOGICAL|3 blood tests|We will try to identify biomarkers of BS: blood proteins, genetic markers passed on by your parents, or the expression of proteins in particular situations
48506563|NCT02927366|DRUG|QCC374|0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
48506564|NCT02927366|DRUG|Placebo Matching|"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"
48506565|NCT02332954|DRUG|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
48506566|NCT06608537|DRUG|neoadjuvant SCRT followed by Sintilimab plus CAPOX|Patientsreceived neoadjuvant treatment consisting of SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.
48506567|NCT01865942|PROCEDURE|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
48506568|NCT01865942|PROCEDURE|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
48506569|NCT03149757|BEHAVIORAL|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
48506570|NCT03149757|BEHAVIORAL|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
48506571|NCT02926482|BEHAVIORAL|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
48506572|NCT03527381|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
48506573|NCT03527381|OTHER|Standard CPB|Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
48506574|NCT04496284|OTHER|Vitrification via slush nitrogen|blastocyst stage embryos will be vitrified via slush nitrogen
48669140|NCT04350684|DRUG|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
48669141|NCT03768037|DRUG|Anlotinib plus Pemetrexed|"Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects"
48669142|NCT03768037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
48146624|NCT02626494|DRUG|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
48146625|NCT01501721|BEHAVIORAL|Exercise|Home-based exercise program
48146626|NCT01501721|BEHAVIORAL|Diet|Nutritional counseling aiming to reduce suggar intake
48146627|NCT05260437|BIOLOGICAL|CV2CoV (2 µg)|Study vaccine was administered as a single intramuscular injection.
48146628|NCT05260437|BIOLOGICAL|CV2CoV (4 µg)|Study vaccine was administered as a single intramuscular injection.
48146629|NCT05260437|BIOLOGICAL|CV2CoV (8 µg)|Study vaccine was administered as a single intramuscular injection.
48146630|NCT05260437|BIOLOGICAL|CV2CoV (12 µg)|Study vaccine was administered as a single intramuscular injection.
48146631|NCT05260437|BIOLOGICAL|CV2CoV (16 µg)|Study vaccine was administered as a single intramuscular injection.
48357493|NCT02615561|OTHER|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
48357494|NCT02615561|OTHER|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
48357495|NCT02393365|OTHER|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
48357496|NCT02393365|PROCEDURE|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
47989351|NCT05323942|OTHER|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
47989352|NCT02063490|BEHAVIORAL|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
47989353|NCT00378209|DRUG|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
47989354|NCT00378209|DRUG|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
47989355|NCT00378209|DRUG|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
47989356|NCT03202147|DRUG|Cromolyn|Active capsules for inhalation.
47989357|NCT03202147|OTHER|Placebo|Non-active capsules for inhalation.
48146632|NCT05260437|BIOLOGICAL|CV2CoV (20 µg)|Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.
48146633|NCT01355809|DRUG|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
48146634|NCT01355809|DRUG|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
48146635|NCT01355809|DRUG|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
48146636|NCT00002086|DRUG|Zidovudine|
48669143|NCT00641264|DRUG|Omeprazole|
48669144|NCT00641264|BEHAVIORAL|Quality of Life questionnaire|
48669145|NCT05795907|DRUG|SAR443820|Capsule / Oral
48146637|NCT00002086|DRUG|Zalcitabine|
48146638|NCT00002086|DRUG|Interferon alfa-n1|
48146639|NCT02823340|DEVICE|Fractional microneedle RF(United, Peninsula Medical, China)|
48357497|NCT03432208|PROCEDURE|GI consult|
48357498|NCT02029885|DEVICE|Investigational Therapy (Surround Sound)|
48669146|NCT05795907|DRUG|Placebo|Matching Capsule / Oral
48669147|NCT04708522|BEHAVIORAL|Breath Control - Equal Breathing Technique|The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.
48669148|NCT04708522|BEHAVIORAL|Guided Mindfulness Exercise|The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.
48357499|NCT02029885|DEVICE|Sham Control|
48669149|NCT04708522|BEHAVIORAL|Control|The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
48669150|NCT02055846|PROCEDURE|Realisation of blood sample, urinary sample and tumor biopsy|
48357500|NCT03452397|DRUG|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
48357501|NCT03452397|DRUG|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
48357502|NCT03452397|DRUG|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
48357503|NCT03452397|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
48357504|NCT03689270|PROCEDURE|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
48357505|NCT03689270|PROCEDURE|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
48357506|NCT04096469|BEHAVIORAL|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
48357507|NCT04096469|BEHAVIORAL|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
48357508|NCT03035058|DRUG|Vedolizumab|Vedolizumab intravenous infusion
48357509|NCT03035058|DRUG|Placebo|Placebo
48357510|NCT02990065|DIETARY_SUPPLEMENT|PROTEIN SUPPLEMENTATION|
48357511|NCT00134589|BEHAVIORAL|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
48357512|NCT02116192|BEHAVIORAL|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
48357513|NCT02116192|BEHAVIORAL|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
48357514|NCT05505201|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
48357515|NCT05505201|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
48357516|NCT03431415|PROCEDURE|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
48357517|NCT03431415|RADIATION|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
48357518|NCT00698139|DEVICE|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
48357519|NCT03898856|DRUG|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
48357520|NCT03898856|DIAGNOSTIC_TEST|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
48357521|NCT03511924|BEHAVIORAL|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise \& Sports Science Australia (Smart et al., 2013).
48357522|NCT02065635|PROCEDURE|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
48357523|NCT02065635|PROCEDURE|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
48357524|NCT02814747|OTHER|quantitive study: 500 patients likely to be candidates for HTS|
48357525|NCT02814747|OTHER|qualitative study: 30 patients who have benefited from HTS|
48357526|NCT06074133|PROCEDURE|Blood collection|Undergo blood draw
48357527|NCT06074133|PROCEDURE|Chest Computed Tomography|Undergo standard of care chest Computed Tomography
48357528|NCT00002852|DRUG|paclitaxel|Given IV
48357529|NCT00002852|DRUG|carboplatin|Given IV
47989358|NCT03553407|DEVICE|Low Level Laser - Pulse|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
47989359|NCT03553407|DEVICE|Low Level Laser - continuous|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
47989360|NCT03553407|DEVICE|Low Level Laser - placebo|placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
47989361|NCT01195428|DRUG|Simvastatin|Simvastatin 40 mg daily
48506575|NCT00224419|BEHAVIORAL|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
48669151|NCT04069988|BEHAVIORAL|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
48669152|NCT03763630|DRUG|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
48669153|NCT03763630|DRUG|Normal saline|Normal saline administered in same frequency and manner as intervention
47989362|NCT01195428|DRUG|Placebo|Placebo
47989363|NCT04576611|OTHER|face-to-face protocol|The intervention is based on education (on pain neurophysiology and healthy lifestyle habits) and physical exercise (strength, flexibility, joint mobility and self-massage).
47989364|NCT04576611|OTHER|self-managed protocol|Subjects of this group receive the same intervention content as the other experimental group, but through a mobile application.
47989365|NCT03327311|DEVICE|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
47989366|NCT03959020|PROCEDURE|Anti-reflux surgery|Anti-reflux surgery for verified GERD
47989367|NCT02045797|DRUG|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
47989368|NCT02045797|DRUG|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
47989369|NCT04979169|BEHAVIORAL|Text Messaging|A series of theory-informed text messages encouraging them to contact their primary care provider and the UR LCS Program's Patient Navigator to coordinate screening, along with contact information to do so.
48357530|NCT00002852|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48506576|NCT00224419|BEHAVIORAL|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
48506577|NCT00224419|DRUG|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
48506578|NCT04750798|DEVICE|BWI Medical Device|Participants will be treated with commercially approved BWI medical devices following routine clinical practice. No specific intervention will be observed for this study.
48506579|NCT04750798|DEVICE|Varipulse Catheter|Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study. No specific intervention will be observed for this study.
48506580|NCT06397027|DRUG|Ziftomenib|Given by IV
48506581|NCT06397027|DRUG|Venetoclax|Given by PO
48506582|NCT06397027|DRUG|Azacitidine|Given by PO
48506583|NCT00602368|OTHER|histological technique|
48506584|NCT00602368|OTHER|laboratory biomarker analysis|
48506585|NCT00602368|PROCEDURE|colposcopic biopsy|
48506586|NCT00602368|PROCEDURE|colposcopy|
48506587|NCT00602368|PROCEDURE|light-scattering spectroscopy|
48506588|NCT00602368|PROCEDURE|loop electrosurgical excision procedure|
48506589|NCT05158036|OTHER|Classic massage group|Classic massage application will be given to the Classic massage group
48506590|NCT05158036|OTHER|Connective tissue masage|Connective tissue masage application will be given to the Connective tissue masage group
48506591|NCT02013674|BIOLOGICAL|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
48506592|NCT00833001|DEVICE|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
48506593|NCT05782127|DRUG|Onureg + Venetoclax|Combination of Onureg and Venetoclax
48506594|NCT06017076|OTHER|Oral energy drinks|Patients drank energy drinks (Red Bull®) 250ml about 2-2.5 hours before operation.
48506595|NCT06017076|DEVICE|Warming matress|From the end of anesthesia, warming matriss at 40 ℃ was used to keep warm until the end of surgery.
48506596|NCT01326923|DRUG|Cetuximab|Single arm phase II study of chemotherapy
48146640|NCT03796364|DRUG|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
48146641|NCT03796364|DRUG|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
48146642|NCT06336798|DRUG|Pioglitazone 30mg|Study participants will take Pioglitazone 30 mg PO daily
48146643|NCT06336798|DRUG|Placebo|Study participants will take a placebo PO daily
48146644|NCT06336798|DIAGNOSTIC_TEST|Labs|Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
48146645|NCT00520663|DRUG|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
48146646|NCT03531892|DRUG|AJM300|AJM300 film-coated tablets.
48146647|NCT03531892|DRUG|Placebo|Placebo matched to AJM300 tablets.
48146648|NCT06091969|DIETARY_SUPPLEMENT|Active multi-ingredient supplement (Fertility Enhancer, FE)|Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
48146649|NCT06091969|DIETARY_SUPPLEMENT|Inactive placebo (Placebo; PLA)|Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
48146650|NCT00236535|DRUG|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
48146651|NCT02452567|OTHER|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose \~8-10% of their body weight through diet-intervention.
48146652|NCT03478306|DRUG|Melatonin 4 mg Tablet|Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
47989370|NCT04814758|DIAGNOSTIC_TEST|MRI DWI sequence (ADC values)|Initially and after pre-operative chemotherapy To evaluate the differences in ADC values according to the malignancy degree of nephroblastoma in children
48146653|NCT04101188|OTHER|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
48146654|NCT04101188|OTHER|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
48146655|NCT04101188|OTHER|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
48146656|NCT03938207|DIAGNOSTIC_TEST|Whole-genome genotyping|Using Whole-genome genotyping from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
47989371|NCT05533450|DEVICE|Multi-focal rigid scleral contact lens|True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
47989372|NCT05533450|DEVICE|Rigid gas permeable contact lens|"RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect."
47989373|NCT03519347|OTHER|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
48146657|NCT03938207|DIAGNOSTIC_TEST|Whole-genome sequencing|Using whole-genome sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
48146658|NCT03938207|DIAGNOSTIC_TEST|TCM pattern|We want to use TCM pattern to investigate the difference among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
48146659|NCT03938207|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease will take to do the DNA Exome sequencing.
48146660|NCT03938207|DIAGNOSTIC_TEST|Physical examination indicators, blood, urine and biochemical function test|To investigate the difference of Physical examination indicators, blood, urine and biochemical function test among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
48146661|NCT03938207|DIAGNOSTIC_TEST|Demographics, personal health behavior, living environment, dietary status, family history|To investigate the difference among the demographics, personal health behavior, living environment, dietary status, family history of among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
48357531|NCT04073472|DRUG|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
48357532|NCT00089505|DRUG|Emtricitabine|200 mg taken orally
48357533|NCT00089505|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
48357534|NCT00089505|DRUG|Lopinavir/Ritonavir|400/100 mg taken orally
48357535|NCT00089505|DRUG|Nevirapine|200 mg taken orally
48357536|NCT00089505|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally
47989374|NCT03519347|OTHER|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
47989375|NCT03519347|OTHER|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
47989376|NCT03519347|OTHER|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
47989377|NCT03519347|DIAGNOSTIC_TEST|Point of Care Testing|POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).
48146662|NCT03938207|DIAGNOSTIC_TEST|HLA typing|Using HLA typing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
48146663|NCT03938207|DIAGNOSTIC_TEST|Full-length 16S Amplicon Sequencing|Using Full-length 16S Amplicon Sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
48146664|NCT03938207|DIAGNOSTIC_TEST|Epigenomic|Using Epigenomic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
48146665|NCT03938207|DIAGNOSTIC_TEST|Metabolomics|Using Metabolomics from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
48506597|NCT01001624|OTHER|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
48146666|NCT03938207|DIAGNOSTIC_TEST|Environmental Toxic|Using Environmental Toxic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
48146667|NCT03938207|DIAGNOSTIC_TEST|Medical Image|Using Medical Image from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
48146668|NCT00936819|BIOLOGICAL|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
48146669|NCT00936819|BIOLOGICAL|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
48146670|NCT00936819|BIOLOGICAL|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
48146671|NCT02674399|DRUG|JointStem|
48146672|NCT02674399|DRUG|Synvisc-One|
48146673|NCT06299748|BIOLOGICAL|Efgartigimod|Efgartigimod IV or SC
48146674|NCT02040038|BEHAVIORAL|LIVE|3-D Virtual Environment for DSMT/S
48146675|NCT02040038|BEHAVIORAL|Website|2-D Website participation for DSMT/S
48506598|NCT01001624|OTHER|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
48506599|NCT02397187|BEHAVIORAL|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
48506600|NCT03411135|OTHER|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
48506601|NCT06232330|DEVICE|Group A|This group will receive TOA which include Weight transfers from a standing position and stepping in various star-type directions, Sit-ups from different heights with the hemiplegic lower limb behind the normal lower limb, From a kneeling position alternately projecting the lower limb forward, From a standing position with a limited base of support turning head and trunk right to left, Continuous walking on a treadmill for 10 minutes, Ascending and descending of stairs, Crossing 4 obstacles with continuous walking, Walking while simultaneously pushing a stroller, Walking while holding an object, Walking on different surfaces and slopes, The intervention took place for 5 days a week for 6 week for 20 minutes. Pre measurement was taken before the intervention and after 6 weeks post measurement was taken.
48506602|NCT06232330|DEVICE|Group B|This group will receive PNF techniques for trunk control. Rhythmic initiation and Rhythmic stabilization for a span of 20 minutes on both sides. In rhythmic initiation patient will move passively from trunk flexion into extension and then back to the flexed position When the patient is relaxed and moving easily, ask for active assisted motion Then begin resisting the motion then patient will perform independently in rhythmic stabilization Resist an isometric contraction of the patient's trunk flexor muscles patient will match the resistance in front and then in back
48357537|NCT01906814|DRUG|3 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.
48669154|NCT01906268|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
48669155|NCT01906268|OTHER|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
48669156|NCT04692389|DEVICE|Jalosome soothing gel|This study has not got other intervention
48669157|NCT05003193|DEVICE|pedometer|2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
48669158|NCT03577899|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
47989378|NCT03519347|DEVICE|Cardiac Monitor|Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.
47989379|NCT05325450|PROCEDURE|Program A|Presentation of the sentence to the implant alone
48146676|NCT02806752|DRUG|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
48146677|NCT02806752|DRUG|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
48146678|NCT00523900|DIETARY_SUPPLEMENT|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
48146679|NCT03610685|DRUG|Prednisolone|Given daily for 2 weeks
48506603|NCT05756283|BEHAVIORAL|Multimodal Prehabilitation|"EXERCISE~* Supervised exercise~  * High intensity interval training~ * Strength exercise~* Home-based exercise / promotion of physical activity~  * Low-moderate intensity aerobic training~ * Inspiratory muscle training~ * Low-moderate intensity strength training~NUTRITION: nutrition education and optimization. Intake of 0.4g/kg of whey isolate after every supervised training.~PSYCHOSOCIAL: mindfulness, cognitive reframing and coping strategies."
48357538|NCT01906814|DRUG|6 cycles chemotherapy|Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
48357539|NCT03512028|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
48506604|NCT06376851|DIAGNOSTIC_TEST|AI-enabled quantitative coronary plaque analysis (AI-QCPA)|The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.
48506605|NCT05810584|DEVICE|Revision LR femoral stem|Revision LR is a modular femoral stem used for hip replacement
48506606|NCT01035983|DRUG|Frovatriptan 2.5 mg|
48506607|NCT01900951|DRUG|Temozolomide|
48506608|NCT04666805|DRUG|Tamoxifen|20 mg/d, oral administration
48506609|NCT04666805|DRUG|Toremifene|60 mg/d, oral administration
48506610|NCT04666805|DRUG|Anastrozole|1 tablet (1 mg) per day, oral administration
47989380|NCT05325450|PROCEDURE|Program B|Presentation of the sentence to the implanted ear, associated for the non-implanted ear
47989381|NCT05325450|PROCEDURE|Control|Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
47989382|NCT03854656|OTHER|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~1. The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~2. The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
47989383|NCT01742507|DEVICE|Resolute Integrity Stent|Resolute Integrity Stent
47989384|NCT01742507|DEVICE|Biomatrix stent|Biomatrix stent
47989385|NCT02775734|DRUG|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
47989386|NCT02775734|DRUG|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
47989387|NCT02204787|DEVICE|transcranial direct current stimulation|
48146680|NCT03610685|DRUG|Placebo oral capsule|Given daily for 2 weeks
48669159|NCT03577899|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
48669160|NCT03577899|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
48506611|NCT04666805|DRUG|Letrozole|Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.
48669161|NCT06258005|DIAGNOSTIC_TEST|PocDoc|PocDoc is a digital rapid 5-marker lipid test
48669162|NCT01119638|DRUG|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
48669163|NCT01119638|DRUG|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
48669164|NCT03041220|PROCEDURE|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
48669165|NCT04951531|PROCEDURE|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
48506612|NCT04666805|DRUG|Exemestane|The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
48506613|NCT01922440|OTHER|No intervention|This is a non-interventional study.
48506614|NCT00898573|DRUG|lapatinib ditosylate|
48506615|NCT00898573|GENETIC|fluorescence in situ hybridization|
48506616|NCT00898573|GENETIC|gene expression analysis|
48506617|NCT00898573|GENETIC|mutation analysis|
48506618|NCT00898573|GENETIC|polymerase chain reaction|
48506619|NCT00898573|GENETIC|reverse transcriptase-polymerase chain reaction|
48506620|NCT00898573|OTHER|cell sorting|
48506621|NCT00898573|OTHER|immunohistochemistry staining method|
48506622|NCT00898573|OTHER|laboratory biomarker analysis|
48506623|NCT02264912|DRUG|antiplatelet drugs - P2Y12 antagonists|
48506624|NCT05336383|DRUG|Radiation Therapy|Given by Infusion
48506625|NCT05555823|DRUG|ATR-002|300 mg tablets for oral intake
48506626|NCT05555823|DRUG|Placebo|matching tablets for oral intake
48506627|NCT05555823|DRUG|Repaglinide|0,5 mg tablets for oral intake
48506628|NCT05555823|DRUG|Celecoxib|100 mg capsules for oral intake
48506629|NCT01329783|OTHER|maraviroc|No intervention is distributed during this trial.
48669166|NCT04951531|PROCEDURE|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
48669167|NCT04951531|PROCEDURE|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
48669168|NCT01885988|DRUG|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
48669169|NCT01885988|DRUG|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
48669170|NCT00099255|DRUG|SGN-30|
48688078|NCT01527240|DRUG|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
48688079|NCT01527240|DRUG|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
48688080|NCT03998514|DRUG|CB4211 Dose 1|Administered by subcutaneous injection
48506630|NCT04610879|DRUG|Carbamazepine|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
48669171|NCT05081830|BEHAVIORAL|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
48669172|NCT05081830|BEHAVIORAL|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
48669173|NCT00382226|DRUG|Azopt|
48669174|NCT01563055|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
48669175|NCT01563055|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
48669176|NCT01752803|DIETARY_SUPPLEMENT|Probiotic|mix probiotic
48669177|NCT01752803|DIETARY_SUPPLEMENT|Placebo|placebo
48506631|NCT04610879|DRUG|Levetiracetam|Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.
48669178|NCT05124730|DRUG|Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
48669179|NCT05124730|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of Reference (R) Product was administered orally with 240 mL of water.
48506632|NCT04610879|BEHAVIORAL|Parent based sleep (PBS) intervention|The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
48669180|NCT06338111|DIAGNOSTIC_TEST|ELISA Sepsis Biomarkers dosage|Observational
48669181|NCT06041321|DEVICE|Reparel Sleeve|For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.
48669182|NCT06041321|DEVICE|Placebo Sleeve|Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
48669183|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) study capsule|The Study mHDx capsule has a mechanism that allows the mHDx to remain resident in the stomach for no more than six (6) hours. After this residency period, the Study mHDx will disassemble and pass safely through the subject's gastrointestinal system.
48688081|NCT03998514|DRUG|CB4211 Dose 2|Administered by subcutaneous injection
48357540|NCT03512028|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
48669184|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) control capsule|The Control mHDX capsule does not have a functional residency mechanism so it will disassemble once safely through the esophagus (within 10 minutes) and will then pass safely through the subject's gastrointestinal system.
48669185|NCT00152438|DRUG|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
48669186|NCT00152438|OTHER|Placebo|3 identical placebo pills daily, no active ingredient.
48669187|NCT03047135|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
48669188|NCT03436342|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
48669189|NCT04476992|DRUG|Nitric Oxide-Sessions|Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
48669190|NCT04476992|DRUG|Nitric Oxide-Continuous and Sessions|"Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm."
48669191|NCT00976456|DRUG|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
48669192|NCT00976456|DRUG|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
48669193|NCT00716274|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
48669194|NCT00716274|DRUG|Placebo|oral, daily, for 16 weeks
48669195|NCT00226005|DRUG|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
47989388|NCT04267991|DRUG|Tacrolimus ointment|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
48506633|NCT03813615|BEHAVIORAL|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology. setting.
48669196|NCT02444754|OTHER|Medical Chart Review|Obtain medical data
48669197|NCT02444754|OTHER|Questionnaire Administration|Complete demographics questionnaires
48669198|NCT02444754|OTHER|Survey Administration|Complete surveys
48669199|NCT00049543|DRUG|gefitinib|Given PO
48669200|NCT00049543|OTHER|placebo|Given PO
48669201|NCT00049543|OTHER|laboratory biomarker analysis|Correlative studies
48669202|NCT01498861|DRUG|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
48669203|NCT01498861|DRUG|Dolutegravir|Dolutegravir is an experimental HIV drug
48669204|NCT01498861|DRUG|Placebo|Placebo is a tablet with no drug in it
47989389|NCT04267991|PROCEDURE|phototherapeutic keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
48669205|NCT01229124|GENETIC|RNA analysis|
48669206|NCT01229124|GENETIC|nucleic acid sequencing|
47989390|NCT00891644|OTHER|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
48669207|NCT01229124|GENETIC|reverse transcriptase-polymerase chain reaction|
48669208|NCT01229124|OTHER|laboratory biomarker analysis|
48688082|NCT03998514|DRUG|CB4211 Dose 3|Administered by subcutaneous injection
48688083|NCT03998514|DRUG|CB4211 Dose 4|Administered by subcutaneous injection
48688084|NCT03998514|DRUG|CB4211 Dose 5|Administered by subcutaneous injection
48688085|NCT03998514|DRUG|CB4211 Dose 6|Administered by subcutaneous injection
48688086|NCT03998514|DRUG|CB4211 Dose TBD|Administered by subcutaneous injection
48688087|NCT03998514|DRUG|Placebo|Administered by subcutaneous injection
48688088|NCT00358319|DRUG|Karenitecin|
48688089|NCT00358319|DRUG|Valproic Acid|
48669209|NCT04316416|PROCEDURE|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
48688090|NCT06513130|OTHER|Geriatric assessment in the 7 days following ICU discharge.|ICU survivors will be assessed by a geriatric physician, in a global (clinical, physical, psyochological and social) approach at the end of the ICU stay or in the 7 days following ICU discharge.
48146681|NCT01928732|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
48146682|NCT01928732|BEHAVIORAL|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
47989391|NCT00891644|OTHER|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
47989392|NCT00891644|OTHER|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
47989393|NCT03438812|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
47989394|NCT02338960|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
47989395|NCT02338960|DRUG|Placebo|Placebo
48146683|NCT02589613|DIETARY_SUPPLEMENT|tap water|300ml tap water via nasogastric tube
48146684|NCT02589613|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g Glucose via nasogastric tube
48146685|NCT02589613|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g Fructose via nasogastric tube
48146686|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
48688091|NCT06513130|OTHER|No geriatric assessment in the 7 days following ICU discharge.|No geriatric assessment in the 7 days following ICU discharge.
48506634|NCT03813615|BEHAVIORAL|treadmill walking Dose-Finding / Escalation|Six doses of aerobic training ( 90mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/wk \& 450mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity \& duration) or non-linear (i.e., exercise dose is continually altered \& progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 3 to 6 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented \& may be monitored using TeleEx. Patients may also perform up to three aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided a plan for their unsupervised session(s) verbally or via Portal Secure Messaging (PSM), as appropriate.
47989396|NCT02632552|BEHAVIORAL|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
47989397|NCT02632552|BEHAVIORAL|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
47989398|NCT05693714|DIAGNOSTIC_TEST|Pcr|Polymerase chain reaction
47989399|NCT01722240|DRUG|Liraglutide 1.8mg|
47989400|NCT01722240|DRUG|Placebo|
47989401|NCT03787251|DRUG|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
47989402|NCT03787251|DRUG|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
47989403|NCT05300906|BEHAVIORAL|personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the personalized condition will receive the optimal combination of content, feedback and design, based on their baseline engagement scores.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
48357541|NCT03512028|BEHAVIORAL|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
48506635|NCT05177302|OTHER|HAGOS-C|The subjects will be instructed to complete HAGOS-C at the initial contact and again after 1 week and 4 month for reliability and responsiveness test, respectively
48506636|NCT05177302|OTHER|SF-36v2|The subjects will be instructed to complete SF-36v2 at the initial contact to determine the validity of HAGOS-C
48688092|NCT05801848|DIAGNOSTIC_TEST|[18F]NaF PET/CT scan|Patients will have their lower back scanned using \[18F\]NaF PET/CT
47989404|NCT05300906|BEHAVIORAL|non-personalized 2-week mobile wellbeing intervention|"For the study, 27 versions of a 2-week mobile wellbeing intervention are created. These versions vary on content (Cognitive Behavioral Therapy, meaning, positive psychology), feedback (text, text with avatar, pre-recorded video) and design (non-gamified, competitively gamified, storyline gamified). At baseline, participants preview all variations and indicate their expected engagement. Participants in the non-personalized condition will receive a random version of the intervention.~Each version of the intervention consists of a module per day. Each module contains psychoeducation and exercises based on content of the version. Moreover, each module contains pre-specified general feedback and supportive messages."
47989405|NCT05359666|DEVICE|Irrisept|"Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris.~Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines."
48146687|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
48146688|NCT05919732|DRUG|Bupivacaine, Dexmedetomidine, Caffeine, Tylenol|bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
48146689|NCT05919732|DRUG|Propofol, rocuronium, caffeine, Tylenol, bupivacaine|"propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)"
48146690|NCT01666821|OTHER|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (\>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
48506637|NCT05924607|OTHER|Standard clamshells method|The patient is asked to lie in a side-lying position with the weak limb up, both hips flexed at 45°, the knees flexed at 90°, and neither the feet nor back not in contact with the wall. Keeping both their heels and the first metatarsal head together, the patient separated their knees and rotated the weak limb upward. The patients is instructed not to tip it backward and to hold the pelvis in a neutral position
48146691|NCT05777772|BEHAVIORAL|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
48146692|NCT06098833|DRUG|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
48146693|NCT06098833|DRUG|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
48146694|NCT05504135|DIAGNOSTIC_TEST|Pharmacogenomics Testing|To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
48146695|NCT00002977|BIOLOGICAL|filgrastim|
47989406|NCT05359666|DEVICE|Standard of Care|"Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as normal, warm and/or sterile saline or saline solution); Sodium Chloride (recorded as sodium chloride (NACL) or NACL 0.9%); SoC; Irrisept (recorded as normal saline \& Irrisept and Irrisept); Chloraprep; Gentamicin \& saline; unknown; and none."
48146696|NCT00002977|DRUG|melphalan|
48146697|NCT00002977|DRUG|thiotepa|
48146698|NCT00002977|PROCEDURE|peripheral blood stem cell transplantation|
48146699|NCT01491815|DRUG|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
48146700|NCT01491815|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
48146701|NCT01491815|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
48146702|NCT01491815|BIOLOGICAL|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
48146703|NCT04885140|BEHAVIORAL|Feedback-based health education|This study was approved by the Tianjin Hospital Ethics Committee, (2019082).The CONSORT 2010 statement: extension to cluster-randomised trials checklist.(Campbell et al., 2012) was used to guide reporting outcomes (File S1).Specific measures have been listed above.
48506638|NCT05924607|OTHER|Targeted VMO strengthening|Targeted VMO strengthening The patient is asked to lie in a supine lying position with arm next to the body. After that asked the patient to perform SLR exercise in an external hip rotation with the simultaneous contraction of the ankle dorsiflexors. Common treatment will be given to each patient includes hot pack for 10 minutes and knee isometric contraction exercises and SLR( 3-5 sets of 10 repetitions
48688093|NCT04499781|BEHAVIORAL|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
48146704|NCT04885140|BEHAVIORAL|Routine health education|Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method.
48146705|NCT06429956|BEHAVIORAL|Mindful emotion awareness|"The mindful emotion awareness module will follow the manual by Barlow et al. (2018). In session 1, the participant will receive psychoeducation about the purpose of mindful emotion awareness (i.e., to cultivate present-focused, non-judgmental attention to one's emotional experiences) and will complete an in-session guided meditation exercise which they will be asked to practice daily using an audio file. In session 2 and 3, two additional exercises are introduced. With mindful mood induction, the participant is instructed to induce emotions and then practice mindful emotion awareness in this context. With anchoring in the present, the participant is taught four steps to help them use mindful emotion awareness to pull themself back to the present whenever they feel an emotional response start to build in their everyday life. For homework, the participant will practice mindful emotion using these exercises and the audio file."
48357542|NCT03512028|BEHAVIORAL|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
48688094|NCT04499781|BEHAVIORAL|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
48688095|NCT02676700|BEHAVIORAL|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
48669210|NCT04316416|PROCEDURE|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
48669211|NCT04316416|DRUG|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
48669212|NCT00191711|DRUG|Gemcitabine|
48669213|NCT02217969|BEHAVIORAL|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
48357543|NCT03512028|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
47989407|NCT01067014|DEVICE|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
48669214|NCT05503329|DIAGNOSTIC_TEST|arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients
48669215|NCT03666390|DRUG|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
48669216|NCT03666390|DRUG|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
48669217|NCT04147273|DEVICE|Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods|"One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany)."
48669218|NCT05123326|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.
47989408|NCT05851950|OTHER|group rumination focused cognitive behavioural therapy|Psychotherapy
48506645|NCT03787134|BEHAVIORAL|working memory and attention|Behavioral tests of working memory and attention
48506646|NCT05673811|DRUG|Nab-paclitaxel|Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
48506647|NCT05673811|DRUG|Gemcitabine|Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
48506648|NCT05673811|GENETIC|VCN-01|VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
48669219|NCT05123326|DIAGNOSTIC_TEST|Genetic tests for Thrombophilia|Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
48669220|NCT05123326|DIAGNOSTIC_TEST|ELISA tests/ Functional assays|Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
47989409|NCT05851950|OTHER|Treatment as usual|opus treatment
47989410|NCT04136925|OTHER|questionnaire|questionnaire before and after race
47989411|NCT01613625|PROCEDURE|Elastography|
47989412|NCT04300595|PROCEDURE|Combination of General anesthesia and local anesthesia in dacryocystorhinostomy surgery|"all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).~In both groups, general anesthesia was induced with 2 mg/kg propofol and tracheal intubation was facilitated by 0.1 mg/kg cisatracurium. All patients underwent mechanical ventilation with 100% oxygen. Anesthesia was maintained with isoflurane, and muscle relaxation was provided by an injection of cisatracurium 0.02 mg/kg every 20 minutes."
48357544|NCT04101227|DRUG|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
48357545|NCT04101227|DRUG|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
48357546|NCT04101227|DEVICE|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
48506649|NCT05651789|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.
48506650|NCT05651789|DRUG|Propranolol|Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
48669221|NCT02525679|DRUG|BI 655130 (spesolimab)|
48669222|NCT02525679|DRUG|Placebo|
48357547|NCT04101227|BEHAVIORAL|Brief Psychological Counseling|Brief Psychological Counseling
48669223|NCT02455869|DRUG|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
48669224|NCT02455869|DRUG|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
48669225|NCT02455869|DRUG|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
48669226|NCT03791879|DRUG|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
47989413|NCT04907539|DRUG|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
47989414|NCT04907539|BIOLOGICAL|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
47989415|NCT04907539|BIOLOGICAL|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
47989416|NCT03272607|OTHER|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
48669227|NCT04068805|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
48669228|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
48669229|NCT01444781|BIOLOGICAL|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
48669230|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
48669231|NCT02771405|DRUG|Sofosbuvir|Sofosbuvir 400 mg orally once daily
48669232|NCT02771405|DRUG|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48669233|NCT02771405|DRUG|Simeprevir|Simeprevir 150 mg orally once daily
48669234|NCT02771405|DRUG|daclatasvir|Daclatasvir 60 mg orally once daily
48669235|NCT02771405|DRUG|Ledipasvir|Ledipasvir 90 mg orally once daily
48669236|NCT02672995|RADIATION|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5\~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5\~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
47989417|NCT05846061|OTHER|Prevalence study population|No intervention
47989418|NCT05217329|OTHER|smart phone App rehabilitation|stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks
48357548|NCT06160362|BIOLOGICAL|CART-19 and 20 cells|Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.
47989419|NCT05217329|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
47989420|NCT02248350|BEHAVIORAL|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
47989421|NCT02248350|BEHAVIORAL|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
47989422|NCT04325958|DRUG|Cannabis|750mg cigarette of plant material
47989423|NCT04325958|DRUG|Placebos|750mg cigarette of plant material
48357549|NCT06160362|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
48357550|NCT06160362|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).
48357551|NCT06010836|BEHAVIORAL|Script guided conversation|Patients getting script guided intervention of 3 domains in the preoperative period
48357552|NCT03841773|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
48357553|NCT03841773|DRUG|Placebo SL Tablets|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
48357554|NCT06375811|DRUG|Elagolix 200 MG|Elagolix tablet
48357555|NCT06375811|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
48357556|NCT04588909|PROCEDURE|Colorectal resections|All patients admitted with colorectal cancer were subjected to various types of colorectal resections
48357557|NCT00298792|BEHAVIORAL|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
48357558|NCT00298792|BEHAVIORAL|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
48357559|NCT05734703|DRUG|Nutraceutical Topical|Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
48357560|NCT02251366|PROCEDURE|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
48357561|NCT01146262|OTHER|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
48357562|NCT01146262|PROCEDURE|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
48357563|NCT03411356|BEHAVIORAL|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
48506651|NCT01657812|DRUG|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
48506652|NCT04940559|DRUG|Danicopan - Tablet|Oral tablet.
47989424|NCT00818428|BEHAVIORAL|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
48357564|NCT03411356|BEHAVIORAL|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
48357565|NCT00864539|DIETARY_SUPPLEMENT|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
48357566|NCT00864539|DIETARY_SUPPLEMENT|plain milk|daily intake of 200 ml plain milk
48357567|NCT00864539|DIETARY_SUPPLEMENT|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
48357568|NCT00864539|DIETARY_SUPPLEMENT|plain orange juice|daily intake of 250 ml plain orange juice
48357569|NCT00864539|DIETARY_SUPPLEMENT|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
48357570|NCT00864539|DIETARY_SUPPLEMENT|Placebo|daily placebo
48357571|NCT01070628|DRUG|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
48357572|NCT01070628|DRUG|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
48357573|NCT01551381|DRUG|EV-077|twice daily oral administration
48357574|NCT01551381|DRUG|Placebo|twice daily oral administration
48357575|NCT04839211|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the highest tolerable load and will be gradually increased.
48357576|NCT04839211|DEVICE|Sham inspiratory muscle training|Sham inspiratory muscle training will be performed three sessions per week as one supervised and two unsupervised for 8 weeks using an inspiratory muscle training device (PowerBreath). The inspiratory muscle training session will consist of 7 cycles including a 2:1 ratio of work and rest interval. Resistance will be adjusted to the unloaded.
48357577|NCT02312375|DRUG|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
48357578|NCT02312375|DRUG|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
48357579|NCT05209204|DIAGNOSTIC_TEST|ASOCT|Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).
48357580|NCT05209204|DIAGNOSTIC_TEST|Pentacam|Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
48357581|NCT05507515|DRUG|ONO-2020|ONO-2020 tablets
48357582|NCT05507515|DRUG|Placebo|Placebo tablets matching ONO-2020 tablets
48357583|NCT04443205|OTHER|Data record|Data record
48357584|NCT03935893|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
48357585|NCT03935893|DRUG|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
48357586|NCT04651699|DEVICE|Active Transcranial Direct Current Stimulation|The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
47989425|NCT00818428|BEHAVIORAL|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
47989426|NCT00818428|BEHAVIORAL|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
47989427|NCT00818428|BEHAVIORAL|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
47989428|NCT05647473|BEHAVIORAL|Routine treatment|Participants will be educated on ways to avoid induced hypotensive states, such as avoiding prolonged standing, standing after exercise, being nervous, eating several carbohydrate-rich foods, drinking alcohol, and being in a warm environment (such as a sauna). Participants will be encouraged in a comfortable home environment, such as a sit-down bath. If there are no contraindications, they are advised to increase their salt intake to approximately 10 grams per day and adjust their fluid intake to 2-3 liters per day. They will also be encouraged to perform lower-body strength training and moderate, non-strenuous activities. Seriously ill patients will be proposed to raise the head of their bed during sleep, wear tight clothing, eat small meals, and reduce alcohol intake.Concomitant treatment with cholinesterase inhibitors, memantine, or both was allowed.
47989429|NCT05647473|DRUG|add-on low dose Astragalus|Participants received an additional 10g of astragalus per day.
47989430|NCT05647473|DRUG|add-on high dose Astragalus|Participants received an additional 20g of astragalus per day.
48357587|NCT04651699|DEVICE|Sham Transcranial Direct Current Stimulation|The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
48357588|NCT05505942|BEHAVIORAL|LPA Sessions|"A study interventionist will conduct phone/video sessions and provide information regarding the acute and long-term psychological and physical benefits of increasing PA. Participants will be introduced to the concept of utilizing brief bouts of PA as a coping strategy for managing emotions and urges to drink alcohol in-the-moment. Participants will also be given information on the public health guidelines for PA (and how these translate into step counts) as well as how to determine if their PA is moderate intensity (e.g., measuring heart rate and identifying rate of perceived exertion). Study clinicians will also orient participants to the proper use of the Fitbit activity tracker and tips for self-monitoring step counts with the tracker and on the app and/or website."
48357589|NCT05505942|OTHER|Fitbit Only|Interventionists will provide participants information about the proper use of the Fitbit activity tracker and offer tips for self-monitoring step counts with the tracker and on the app and/or website.
48357590|NCT04045873|DEVICE|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
48357591|NCT00112554|DRUG|cytarabine|Given IV
48357592|NCT00112554|DRUG|laromustine|Given IV
48357593|NCT00112554|OTHER|placebo|Given IV
48357594|NCT02169466|DRUG|BIA 9-1067|OPC, Opicapone
48357595|NCT02169466|DRUG|Placebo|PLC, Placebo
48357596|NCT02169466|DRUG|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
48357597|NCT05503966|BEHAVIORAL|Attentional Bias Modification|The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
48357598|NCT06371326|DRUG|ZT002 Injection|Participants will receive ZT002 by subcutaneous (SC) injection.
48357599|NCT06371326|DRUG|Placebo|Participants will receive Placebo by subcutaneous (SC) injection.
48357600|NCT04383665|DEVICE|STN DBS 10Hz|Stimulation of existing DBS device at 100Hz, with other parameters at baseline
48357601|NCT04383665|DEVICE|STN DBS 130Hz|Stimulation of existing DBS device at 130Hz, with other parameters at baseline
48357602|NCT04383665|DEVICE|STN DBS off|Existing DBS device turned off
48357603|NCT00325949|DRUG|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
48357604|NCT00325949|DRUG|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
48357605|NCT00325949|DRUG|placebo|2 tablets BID
48506653|NCT04940559|DRUG|Danicopan - Softgel|Oral softgel capsule.
48357606|NCT02415582|OTHER|Aerobic exercise|Aerobic exercise on treadmill
48357607|NCT02415582|OTHER|Combined exercises|Combined resistance and aerobic exercise
48357608|NCT02415582|OTHER|Control|45 minutes resting sitting
48506654|NCT04940559|DRUG|Danicopan - LFC|Oral LFC.
48669237|NCT02672995|DRUG|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
48669238|NCT01385579|OTHER|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
48669239|NCT03701243|PROCEDURE|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
48669240|NCT03701243|PROCEDURE|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
48669241|NCT03979300|OTHER|Learning process during role play on psychiatric interview|"Methodology: Mixed method study with:~* Quantitative features:~  * Self-reported questionnaries :  Learning Effectiveness Inventory Scale  (18)~ * Sociodemographical data and others questions~* Qualitative : Grounded Theory~  * Video-record of simulation and audio-record and briefing and debriefing, quoted with conversational analysis~ * Semi-structured interview of learners and teachers"
48669242|NCT06357104|DEVICE|electroencephalogram biofeedback|EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
48669243|NCT06357104|DEVICE|electrical brain stimulation|EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
48669244|NCT06357104|DEVICE|ultra-low frequency transcranial magnetic stimulation|ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.
48669245|NCT06357104|DRUG|Sertraline Hydrochloride|Sertraline is taken in the morning for 150 mg per day.
47989431|NCT05227794|BEHAVIORAL|Compassion Cultivation Training (CCT)|CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
48357609|NCT03438591|DEVICE|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
48357610|NCT05353218|PROCEDURE|Intermediate cervical plexus block|Intermediate cervical plexus block will be applied in transverse plane using posterior approach at C4.
48357611|NCT05353218|PROCEDURE|Deep cervical plexus block|Deep cervical plexus block will be appliedin transverse plane using anterior approach at C2-3-4.
48357612|NCT02506972|OTHER|Classic Quaker Quick Oats|Various doses of oats without or with sugar
48506655|NCT06634186|DIETARY_SUPPLEMENT|Dietary intervention|The aim of the dietary intervention is the implementation of a fiber-enriched diet. Therefore, patients receive dietary counseling, supplemented with propionate, that functions as fiber-surrogate.
48506656|NCT01621477|DRUG|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
48669246|NCT06357104|DRUG|Clonazepam|Clonazepam is taken in the morning for 1 mg per day.
48669247|NCT06357104|DRUG|Alprazolam|Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
48506657|NCT01621477|DRUG|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
48506658|NCT01621477|DRUG|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
48669248|NCT06357104|DRUG|Metoprolol|Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
48506659|NCT01621477|DRUG|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
48669249|NCT06357104|DRUG|Olanzapine|Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
48357613|NCT02506972|OTHER|Cream of Rice Cereal|Various doses of cereal without sugar
48357614|NCT04115891|OTHER|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
48357615|NCT04115891|OTHER|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
48357616|NCT04115891|OTHER|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
48357617|NCT04115891|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
48357618|NCT06460935|BEHAVIORAL|sexual health training|The 20-hour sexual health training will be given online for 5 weeks. Case discussions using the Plissit Model will be held in the training content.
48506660|NCT01621477|DRUG|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
48669250|NCT06357104|DRUG|Pravastatin Sodium 20 MG|Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
48357619|NCT04884633|PROCEDURE|Pancreatic islet transplantation|New method of pancreatic islet transplantation into the omentum using a biodegradable scaffold
48669251|NCT06357104|DRUG|Sacubitril Valsartan Sodium Hydrate|Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
48357620|NCT05240781|DEVICE|Zotarolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used by CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and Chronic Coronary Syndrome (CCS). Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
48669252|NCT01031888|DRUG|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
48669253|NCT01031888|DRUG|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
48669254|NCT01932684|OTHER|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
48669255|NCT01932684|OTHER|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
48669256|NCT01932684|DEVICE|5000 Voldyne ® Sherwood Medical, USA|
48669257|NCT01932684|DEVICE|Silicone face mask|
48506661|NCT01621477|DRUG|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
48669258|NCT04247438|OTHER|12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.|"Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm."
48669259|NCT05098314|OTHER|Personalized interventions regarding the Cicat-Occitanie network|"First of all, healthcare professionals from EHPAD in the intervention arm were invited by email to answer a closed questionnaire. It was built by the authors, on Google forms, and consisted of 11 questions divided into 2 sections.~Section 1 collected data about the participants. In section 2, they were asked to score from 0 to 4 (ranging from not at all to a lot ) the various obstacles to teleconsultations reported by the literature."
48506662|NCT01621477|BIOLOGICAL|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
48506663|NCT01621477|DRUG|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
48669260|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
48669261|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
48669262|NCT00678704|DRUG|Placebo|Placebo tablet prior to intercourse on demand
48669263|NCT02749747|DRUG|Sulpiride use|50mg sulpiride once a day use for 60 days
48669264|NCT02749747|DRUG|Placebo|50mg placebo once a day use for 60 days
48146706|NCT06429956|BEHAVIORAL|Cognitive flexibility|The cognitive flexibility module will follow the manual by Barlow et al. (2018) which is based on the principles by Beck (1976). In session 1, the participant will be psychoeducated about the purpose of cognitive flexibility (i.e., to encourage flexible thinking through reappraisal of one's automatic thinking), and how their thoughts influence their emotional reactions. For homework, the participant will be asked to monitor their automatic thoughts. In session 2, the participant will be introduced to the technique of cognitive flexibility (i.e., generating other possible interpretations), and this technique will be practiced throughout session 2 and 3. For homework, the participant will continue to monitor their automatic thoughts and generate and record other possible interpretations.
47989432|NCT05227794|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
47989433|NCT02555332|OTHER|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
48146707|NCT01754363|DEVICE|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
48357621|NCT05240781|DEVICE|Sirolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used in accordance with the CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and CCS. Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
48506664|NCT01621477|DRUG|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
48506665|NCT02257385|DRUG|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
48506666|NCT02257385|DRUG|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
48669265|NCT06153056|DIAGNOSTIC_TEST|Bloed-, ontlasting- en speekselmonsters|"In addition, the blood collected (24 mL) will be used for the following analyses:~GLP-1, PYY, branched-chain amino acids, Adipokines, leptin, adiponectin Blood bile acid levels: total and detailed analyzed by HPLC MS/MS Serum microbiome profile Genome-wide association study.~The stool sample will be used to establish the :~Intestinal bile acid profile Intestinal microbiota profile Saliva sampling for oral microbiota profiling."
48669266|NCT02249078|DRUG|E6011|E6011 solution for injection
48669267|NCT02249078|DRUG|Placebo|Placebo 2-mL vial solution for injection
48669268|NCT04259593|OTHER|exercise training|
48669269|NCT06546527|DRUG|[177Lu]Lu-PSMA-137|\[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
48669270|NCT05955339|OTHER|NOTES|The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
48669271|NCT05955339|OTHER|AUDIO|The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
47989434|NCT06398054|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg tablet
47989435|NCT06398054|DRUG|Hyoscine N-Butil Bromide|Hyoscine N-Butil Bromide 10 mg two tablets
48357622|NCT02079311|DEVICE|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
48506667|NCT02257385|DRUG|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
48506668|NCT02257385|DRUG|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
48669272|NCT03590886|OTHER|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
48669273|NCT05497375|DIAGNOSTIC_TEST|The amount of intraoperative bleeding|Total amount of intraoperative bleeding will be calculated in milliliters after the end of surgery.
48669274|NCT05497375|DIAGNOSTIC_TEST|Quality of the intraoperative surgical field|Quality of the intraoperative surgical field will be measured on a grade of 0-10 (0-1. no bleeding, 2-3. mild bleeding, 4-5. Mild to moderate bleeding, 6-7. moderate bleeding, 8-9. moderate to severe bleeding, 10. Severe bleeding)
47989436|NCT06398054|DRUG|placebo|Two tablets
47989437|NCT01633892|PROCEDURE|Fat Grafting|
47989438|NCT00795522|DRUG|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
47989439|NCT00832585|DRUG|Alefacept|Alefacept 15mg IM every week for 12 weeks
48146708|NCT05234489|BIOLOGICAL|Signature Cord Prime|"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."
47989440|NCT01599871|DRUG|theophylline|theophylline 100 mg, twice at day
48357623|NCT02079311|DEVICE|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
48357624|NCT04170855|DRUG|Furosemide Injection|"We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~* A reduction in fractional spot urinary sodium~* An increase in urinary volume~* A \>1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection."
47989441|NCT01599871|OTHER|placebo|Placebo
47989442|NCT05153954|OTHER|Quantitative Indocyanine Green Fluorescence Angiography|Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
47989443|NCT00687765|DRUG|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
48506669|NCT02257385|DRUG|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
48357625|NCT03123549|DEVICE|Simplify Disc|Simplify Disc at two levels of the cervical spine
48506670|NCT02257385|DRUG|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
48506671|NCT02257385|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
48506672|NCT05652335|DRUG|JNJ-79635322|JNJ-79635322 will be administered as SC injection.
48506673|NCT03349086|BEHAVIORAL|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
48506674|NCT01274676|DEVICE|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
48506675|NCT01274676|DEVICE|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
48506676|NCT03815526|OTHER|Dynamic tape|Dynamic tape apply 1 time
48506677|NCT03815526|OTHER|Kinesio tape|Dynamic tape apply 1 time
48506678|NCT03815526|OTHER|Sport tape|Dynamic tape apply 1 time
48506679|NCT00428116|DRUG|HAART|Combination first line antiretrovirals as previously described.
48506680|NCT05916274|BIOLOGICAL|Blood and fecal samples|Blood and fecal samples will be performed
48506681|NCT05916274|PROCEDURE|Coolonic biopsies|colonic biopsies will be analysed
48506682|NCT03277755|DRUG|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
48506683|NCT03277755|DRUG|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
48506684|NCT03277755|DRUG|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
48506685|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsolateral Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
48506686|NCT03840369|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.
48669275|NCT05497375|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon Satisfaction will be measured on a grade of 0-5 (1= very bad, 2= bad, 3= moderate, 4= good, 5= very good).
48669276|NCT05497375|DIAGNOSTIC_TEST|Heart rate|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
48146709|NCT03620474|DRUG|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
47989444|NCT02972554|DRUG|Propanolol hydrochloride|One-time dose of 40mg of propranolol
47989445|NCT02972554|OTHER|Placebo|Outside casing matching that of active drug
47989446|NCT00003055|DRUG|cisplatin|
47989447|NCT00003055|DRUG|irinotecan hydrochloride|
48146710|NCT03335059|COMBINATION_PRODUCT|Synergo® RITE + MMC|Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
48146711|NCT05513027|DEVICE|Augmented Whole-body Scanning via Magnifying PET|-Added at the end of the SOC PET/CT scan. Will take approximately 3-5 minutes longer.
48146712|NCT05513027|DEVICE|PET/CT|-Standard of care
48357626|NCT02005718|DRUG|Cholecalciferol|
48357627|NCT05022303|DRUG|Larazotide Acetate|AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
48357628|NCT05022303|DRUG|Placebo|Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
48357629|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
48357630|NCT01553695|OTHER|questionary|Subjects have to fill out a booklet of questionnaires
48357631|NCT01590446|DRUG|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
48357632|NCT01590446|DRUG|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
48146713|NCT01995253|DEVICE|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
48669277|NCT05497375|DIAGNOSTIC_TEST|Mean arterial pressure|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
48669278|NCT05497375|DIAGNOSTIC_TEST|Peripheral oxygen saturation|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
48669279|NCT00314457|DRUG|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
48669280|NCT02652221|DEVICE|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
48669281|NCT02953912|PROCEDURE|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
48669282|NCT02953912|PROCEDURE|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
48669283|NCT01876498|PROCEDURE|Xiaflex surgery|Xiaflex surgery
48669284|NCT06392308|OTHER|none intervention|No interventions are administered to either group of patients.
48669285|NCT04427293|DRUG|Lenvatinib|Lenvatinib 12mg daily for 7 days prior to surgery
47989448|NCT04903249|BEHAVIORAL|Core Exercise Promotion Intervention|"Participants are instructed to increase weekly time spent exercising to \>90 minutes over 12 weeks. Exercise will be defined as activities that use large muscle groups, increase heart rate and breathing rate, and are performed intentionally for the purpose of exercise (as opposed to physical activities of daily living, e.g., housework). Participants complete a videoconferencing visit with the study team and are given task and safety related information pertaining to exercise for survivors of cancer. Participants engage in exercise-related goal-setting and action planning and are provided activity trackers to monitor their activity levels over the 12-week study period."
47989449|NCT01710956|RADIATION|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
47989450|NCT04964128|DEVICE|MiniMed™ 780G insulin pump with Klue Health app utilizing meal gesture micro insulin dosing (meal gesture dosing)|The AHCL system with Meal Gesture Dosing evaluated in this study includes a commercial/CE-Marked insulin pump with investigational software, and the Klue Health mobile app with investigational software (installed on Apple Watch) for meal gesture detection and micro dosing.
48669286|NCT04427293|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on day 1
48669287|NCT01593371|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
47989451|NCT06371404|DRUG|Bavarostat|Up to two injections of ≤ 5 mCi \[F18\] Bavarostat
47989452|NCT01895855|BIOLOGICAL|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 5x10\^8
47989453|NCT01895855|BIOLOGICAL|placebo|
48146714|NCT01995253|DEVICE|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
48669288|NCT01593371|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
48669289|NCT03549962|PROCEDURE|TKA|Total Knee Arthroplasty
48669290|NCT04663074|DIAGNOSTIC_TEST|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
48669291|NCT01416025|DRUG|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
48146715|NCT01578629|OTHER|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
48146716|NCT01578629|OTHER|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
48146717|NCT01020435|OTHER|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
48146718|NCT01020435|OTHER|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
48669292|NCT05759780|DEVICE|Optical imaging of the tissues|OCT vibrography
48669293|NCT04999735|BEHAVIORAL|CHDR Monitoring Remotely (MORE)|CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).
48669294|NCT04999735|BEHAVIORAL|Withings Steel HR|The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
48669295|NCT04999735|BEHAVIORAL|Withings Body+ scale|Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
48146719|NCT00911638|BEHAVIORAL|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
48146720|NCT00911638|BEHAVIORAL|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
48146721|NCT06022198|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar Lavage
48146722|NCT03654482|DEVICE|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
48146723|NCT03122314|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
48146724|NCT03122314|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
48146725|NCT02399202|DRUG|osilodrostat|
48146726|NCT00753337|DEVICE|Assurant® Cobalt Iliac Stent System|Iliac Stenting
48146727|NCT06508762|DRUG|VX-993|Tablet and Suspension for Oral Administration.
48669296|NCT04999735|BEHAVIORAL|Withings Blood Pressure Monitor|Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
48669297|NCT04284137|BEHAVIORAL|Modified FE-SaLiR|Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
48669298|NCT04284137|BEHAVIORAL|Unmodified Chinese Medicine Exercise|Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
48146728|NCT04979702|BEHAVIORAL|Active Control|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
48146729|NCT04979702|BEHAVIORAL|mHealth technology assisted exercise counselling|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
48357633|NCT01637844|DRUG|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
48357634|NCT00633425|DRUG|GLIMEPIRIDE|
48357635|NCT04729699|OTHER|Aerobic exercise and exercise for TMJ|Aerobic exercise
48669299|NCT04284137|BEHAVIORAL|Active Control|Participants will attend a 60-minute health education program once a week.
48669300|NCT01182350|DRUG|Bevacizumab|
48146730|NCT04338568|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
48669301|NCT01182350|DRUG|Erlotinib|
48669302|NCT01182350|DRUG|Temozolomide|•
48669303|NCT01182350|RADIATION|Radiation|
48669304|NCT03534388|OTHER|Sodium Hypochlorite Cleanser|Cleansing with CLn BodyWash
48146731|NCT01475110|DRUG|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
48146732|NCT03400748|DEVICE|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
48357636|NCT04729699|OTHER|Aerobic exercise at home|Aerobic exercise
48357638|NCT02141529|PROCEDURE|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
47989454|NCT03610022|DRUG|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
47989455|NCT00706979|OTHER|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
48357639|NCT02141529|PROCEDURE|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
48357640|NCT02992912|DRUG|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
48506687|NCT03840369|DEVICE|Repetitive Transcranial Magnetic Stimulation to Right Dorsomedial Prefrontal Cortex|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
48506688|NCT05080153|DIETARY_SUPPLEMENT|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
48506689|NCT00052299|DRUG|cytarabine|
48669305|NCT00579644|DRUG|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
48506690|NCT00052299|DRUG|etoposide|
48506691|NCT00052299|DRUG|gemtuzumab ozogamicin|
48506692|NCT00052299|DRUG|idarubicin|
48506693|NCT00052299|DRUG|mitoxantrone hydrochloride|
48669306|NCT00579644|DRUG|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
47989456|NCT00706979|BEHAVIORAL|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
47989457|NCT06287528|BIOLOGICAL|19-28z/IL-18 CAR T cells|19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL
47989458|NCT01106898|DRUG|cyclophosphamide|Given IV
48357641|NCT02992912|PROCEDURE|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
48357642|NCT03582839|BEHAVIORAL|PROTECT+|The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
48357643|NCT04503473|BEHAVIORAL|High Intensity Stepping Training|"The goals will be to maximize stepping activity at high intensities for 40 minutes per 1 hour session, with rest breaks as needed~Conventional Therapy: : Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions"
48357644|NCT04503473|BEHAVIORAL|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions
48357645|NCT00004236|DRUG|pegylated liposomal doxorubicin hydrochloride|
48357646|NCT05510791|DIETARY_SUPPLEMENT|Nuun Sport Drink|Subjects will consume a total of 24 ounces water and 1.5 tablets of Nuun SPORT. Specifically, subjects will drink 12 ounces of Nuun drink 15 minutes prior to the 60 min run and 4 ounces of Nuun drink at 15 min, 30 min, and 45 min during the run.
48357647|NCT05510791|DIETARY_SUPPLEMENT|Control|Subjects will consume a total of 24 ounces water. Specifically, subjects will drink 12 ounces of water 15 minutes prior to the 60 min run and 4 ounces of water at 15 min, 30 min, and 45 min during the run.
48146733|NCT06123936|OTHER|Reminder|"At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software~* This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software~* In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address~* The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit.~The type of recall and the date of it will be notified in the medical file of each patient."
48146734|NCT02858115|OTHER|Fluid challenge|100 ml of crystalloid was infused over 1-min
48146735|NCT02858115|OTHER|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
48146736|NCT00257556|DRUG|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
48146737|NCT00257556|DRUG|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
48146738|NCT05972161|DEVICE|Thermal Imaging camera|Thermal Imaging camera used to measure respiratory flow.
47989459|NCT01106898|DRUG|paclitaxel|Given IV
47989460|NCT01106898|BIOLOGICAL|trastuzumab|Given IV
47989461|NCT01106898|OTHER|laboratory biomarker analysis|Correlative studies
47989462|NCT03477227|DEVICE|Short stocking|Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
47989463|NCT03477227|DEVICE|Usual stocking|Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
48357648|NCT03530189|DRUG|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
48506694|NCT05377892|OTHER|Dietary protein|High protein followed by reduced protein diet
48669307|NCT04622735|COMBINATION_PRODUCT|nefopam hydrochloride 30mg / paracetamol 500mg X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
48146739|NCT06313268|DRUG|Bevacizumab Biosimilar MB02|5 mg/kg to 15 mg/kg in combination with chemotherapy.
48146740|NCT02128269|BIOLOGICAL|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
48669308|NCT04622735|DRUG|Paracetamol 500 Mg Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
48669309|NCT04622735|DRUG|Nefopam HCl 30 MG Oral Tablet X2|The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
48146741|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
48146742|NCT00070642|DRUG|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
48146743|NCT00070642|DRUG|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2"
48146744|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
48146745|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
48146746|NCT05202444|PROCEDURE|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
48506695|NCT05946616|OTHER|Transcranial alternating current stimulation (tACS) combined with behavioral intervention|Transcranial alternating current stimulation (tACS) combined with behavioral intervention (memory interference).
48506696|NCT05946616|OTHER|Inactive (sham) stimulation combined with behavioral intervention|Inactive (sham) stimulation combined with behavioral intervention (memory interference)
48506697|NCT06002789|DRUG|MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy|For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.
48506698|NCT06002789|DRUG|All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy|For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
48506699|NCT04320342|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
48669310|NCT00706147|DRUG|Arimoclomol|Drug: Arimoclomol capsules given three times per day
48669311|NCT00706147|DRUG|Placebo|Drug: Placebo capsules given three times per day
48506700|NCT04320342|DRUG|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
48506701|NCT04320342|DRUG|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
48669312|NCT03271775|OTHER|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
48669313|NCT03271775|OTHER|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
48669314|NCT05093972|DRUG|Ulonivirine|Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
48669315|NCT06345885|BIOLOGICAL|HPV vaccine|Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
48669316|NCT04406987|PROCEDURE|decompression|surgical technique for neural decompression varied based on surgeon's preference, but always with preservation for spinous processes. Either open with or without microscope or using tubular retractors.
48669317|NCT04406987|PROCEDURE|fusion|fusion techniques consisted besides decompression of additional implantation of pedicle screws with rods, with or without intervertebral fusion and cage(s). Non-instrumented technique with allograft bone. Fusion technique on surgeon's discretion.
48669318|NCT02196532|DEVICE|Device: Optical coherence tomography|
48669319|NCT06049914|BEHAVIORAL|Experimental group|"1. Exercise interventions~   * Measuring blood pressure and weight: before starting exercise~  * Flexibility exercises: 5-10 minutes of stretching~  * Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~  * Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~2. Nutritional interventions~   * Well nourished: Overall diet check and correction~  * at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~  * Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~  * Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~  * Confirm compliance and provide feedback once every 2 weeks"
48669320|NCT02805790|DRUG|Elamipretide|4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
48669321|NCT02805790|DRUG|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
47989464|NCT05212714|DEVICE|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
48146747|NCT03500406|DEVICE|RestoreX|Penile traction therapy in the straight position
48146748|NCT03500406|OTHER|Control|No treatment
48506702|NCT04522115|OTHER|exercises|"Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated."
48506703|NCT06270186|DIAGNOSTIC_TEST|Type 1 myotonic dystrophy|"To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients"
48506704|NCT03640286|DEVICE|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
48506705|NCT02097680|DRUG|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
48506706|NCT02097680|DRUG|Placebo|One placebo capsule every two days during four months
48506707|NCT04035915|PROCEDURE|Limited driving pressure|Keep driving pressure \<15 cmH2O
48506708|NCT04035915|PROCEDURE|Conventional mechanical ventilation strategies|Keep tidalvolume \</= 8
48506709|NCT01053000|DRUG|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
48506710|NCT03845803|OTHER|Reducing sedentary behaviour|Implementing sit/stand workstations at work
48146749|NCT00709605|DRUG|VRC-HIVADV014-00-VP|
48146750|NCT01905566|DRUG|Clopidogrel|75mg once a day
48146751|NCT01905566|DRUG|Ticagrelor|90mg twice a day
48506711|NCT00070200|BIOLOGICAL|filgrastim|
48506712|NCT00070200|DRUG|cisplatin|
48357649|NCT03530189|DRUG|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
48357650|NCT03338699|DEVICE|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
48357651|NCT03338699|DEVICE|Mogen clamp|Mogen clamp circumcision
48357652|NCT02424890|OTHER|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
48669322|NCT01855893|OTHER|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
48669323|NCT01855893|OTHER|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
48357653|NCT04652466|DEVICE|farukcicekci2|To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition
48357654|NCT04098029|BIOLOGICAL|Low HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
48357655|NCT04098029|BIOLOGICAL|High HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
48357656|NCT04098029|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training, etc.
48357657|NCT06194721|PROCEDURE|Cold intrapulpal anesthesia|Intrapulpal cold local anesthesia at 4-5 c temperature
48357658|NCT06194721|PROCEDURE|Room temperature intrapulpal anesthesia|Intrapulpal cold local anesthesia at room temperature
48669324|NCT01678521|PROCEDURE|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
48357659|NCT03131258|PROCEDURE|Donor Nephrectomy|48 Donor Nephrectomy Patients
48506713|NCT00070200|DRUG|cyclophosphamide|
48506714|NCT00070200|DRUG|doxorubicin hydrochloride|
48506715|NCT00070200|DRUG|etoposide|
48506716|NCT00070200|DRUG|isotretinoin|
48506717|NCT00070200|DRUG|melphalan|
48506718|NCT00070200|DRUG|topotecan hydrochloride|
48669325|NCT01141530|OTHER|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
48669326|NCT01816295|DRUG|Testosterone Solution|Administered topically to axillae.
48669327|NCT01816295|DRUG|Placebo Solution|Administered topically to axillae.
48669328|NCT00743470|DRUG|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
48669329|NCT00743470|DRUG|rifabutin|rifabutin capsule; see arms for intervention description
48669330|NCT00328172|DRUG|Placebo|Placebo matching BI 1356
48669331|NCT00328172|DRUG|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
48669332|NCT00328172|DRUG|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
48669333|NCT00328172|DRUG|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
48669334|NCT00328172|DRUG|Metformin|Metformin
48688096|NCT02676700|BEHAVIORAL|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
48669335|NCT01709357|OTHER|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
48669336|NCT01709357|OTHER|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
48669337|NCT01709357|OTHER|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
48669338|NCT01709357|OTHER|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
48669339|NCT04240054|DRUG|Bortezomib|Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15
48669340|NCT04240054|DRUG|Isatuximab|Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
48669341|NCT04240054|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
48669342|NCT04240054|DRUG|Dexamethasone|Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
48669343|NCT00872300|DRUG|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
48669344|NCT02647684|BEHAVIORAL|Self-Directed Triple P|10 Week Triple P Self directed workbook
48669345|NCT00897026|DRUG|cyclophosphamide|
48669346|NCT00897026|DRUG|doxorubicin hydrochloride|
48669347|NCT00897026|DRUG|paclitaxel|
48669348|NCT00897026|GENETIC|fluorescence in situ hybridization|
48669349|NCT00897026|OTHER|immunohistochemistry staining method|
48669350|NCT00529633|DRUG|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
48669351|NCT00529633|OTHER|Sugar pill|Placebo by mouth at night for a total of 24 weeks
48669352|NCT02118155|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
48146752|NCT02525185|OTHER|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
48146753|NCT06252454|DRUG|Furosemide 40 mg|Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.
48146754|NCT06252454|DRUG|Levodropropizine|Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
48357660|NCT04049344|DRUG|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
48357661|NCT04062240|DEVICE|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
48506719|NCT00070200|DRUG|vincristine sulfate|
48669353|NCT01517984|DRUG|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
48669354|NCT01517984|DRUG|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
48669355|NCT01985789|DRUG|Diphenhydramine|
48669356|NCT01985789|DRUG|cetirizine|
48669357|NCT01985789|DRUG|desloratadine|
48669358|NCT01985789|DRUG|placebo|
48669359|NCT06382844|DIAGNOSTIC_TEST|Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).|Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)
48669360|NCT05446714|DEVICE|CH 4 band|expansion of maxilla and observation improvement of the air way
48669361|NCT05446714|DEVICE|HH 2 bands|expansion of maxilla and observation improvement of the air way
48669362|NCT05446714|DEVICE|MSE 2 bands and 4|expansion of maxilla and observation improvement of the air way
48146755|NCT06252454|OTHER|Placebo - saline|Placebo will be used as a comparator
48146756|NCT00100009|DRUG|TAC-PF|
48146757|NCT00100009|DRUG|Triamcinolone Acetonide|
48357662|NCT04554394|DEVICE|CellFX Device|The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
48357663|NCT00309192|DRUG|Triamcinolone Acetonide|Intravitreal Injection 4mg single dose
48357664|NCT00309192|PROCEDURE|Grid laser|Grid laser as specified in ETDRS
48357665|NCT00309192|PROCEDURE|Sham Injection|Simulation procedure for triamcinolone injection
48506720|NCT00070200|PROCEDURE|conventional surgery|
48506721|NCT00070200|PROCEDURE|peripheral blood stem cell transplantation|
48506722|NCT00070200|RADIATION|radiation therapy|
48669363|NCT05317130|OTHER|Athlete health monitoring|Observational study
48669364|NCT03784248|OTHER|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
48146758|NCT01204879|BEHAVIORAL|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
48146759|NCT02382640|DRUG|Febuxostat XR|Febuxostat extended-release (XR) capsules
48146760|NCT02382640|DRUG|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
48146761|NCT05959902|OTHER|Forward Walking|During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.
48146762|NCT05959902|OTHER|Physiotherapy Exercises|"Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise."
48146763|NCT00160758|PROCEDURE|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
48146764|NCT06196294|BIOLOGICAL|Cell therapy for solid tumors|Transfer γδT cells into patients for anti-ancer therapy.
48146765|NCT00774605|DRUG|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
48146766|NCT00774605|DRUG|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
48146767|NCT00787475|OTHER|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
48146768|NCT03982797|BIOLOGICAL|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
48506723|NCT00513279|DRUG|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
48669365|NCT01370187|DRUG|Montelukast|Montelukast 4mg daily for 2 months
48669366|NCT03198156|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
48669367|NCT03198156|DEVICE|Sham stimulation|Sham stimulation
48669368|NCT04050384|DEVICE|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
48669369|NCT05760274|DIAGNOSTIC_TEST|multichannel intraluminal impedance and pH monitoring (MII/pH)|A pH-MII probe is inserted nasally into the esophagus, and the position verified by chest radiograph. pH-MII data are evaluated using manufacturer's software, and each tracing is manually reviewed and validated.
48146769|NCT04078217|DEVICE|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
48506724|NCT00513279|DRUG|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
48506725|NCT06442462|DRUG|SPG302|small synthetic molecule
48669370|NCT02433964|OTHER|Grupo LED|
48669371|NCT02433964|OTHER|Placebo|ledterapia off + price
48669372|NCT01082302|DRUG|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
48146770|NCT04078217|OTHER|Booklet|Home-based exercise program using a paper booklet (not the technology).
48146771|NCT00439218|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
48146772|NCT02312544|DRUG|OTX-TP|OTX-TP and placebo drops
48146773|NCT02312544|DRUG|Timolol|Timolol drops and placebo punctum plug
48146774|NCT02070276|PROCEDURE|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
48146775|NCT02070276|PROCEDURE|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
48506726|NCT06442462|DRUG|Placebo|Placebo
48506727|NCT02432157|DRUG|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
48506728|NCT02432157|DRUG|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
48506729|NCT06469632|OTHER|Active Comparator: Experimental Group 1|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique."
48669373|NCT01082302|OTHER|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
48146776|NCT02070640|DRUG|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
48146777|NCT02070640|DEVICE|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
48146778|NCT04281355|PROCEDURE|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
48146779|NCT04281355|RADIATION|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
48146780|NCT02518399|OTHER|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
48357666|NCT01089933|PROCEDURE|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
48357667|NCT01089933|PROCEDURE|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
47989465|NCT04954547|BEHAVIORAL|Subsidy Treatment|Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
47989466|NCT04954547|BEHAVIORAL|Cash Treatment|Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
48146781|NCT02518399|OTHER|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
48357668|NCT00395720|BIOLOGICAL|MVA85A (TB vaccine)|Intradermal vaccine
48357669|NCT00395720|BIOLOGICAL|MVA 85A|Intradermal vaccine
48357670|NCT04831892|OTHER|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Study lotion containing 0.1% colloidal oatmeal along with 4% HydraSynol® DOI (Isosorbide Dicaprylate) and 4% HydraSynol® IDL/(Isosorbide Disunflowerseedate)
47989467|NCT01482247|DIETARY_SUPPLEMENT|L-Arginine|Dietary Supplement
48357671|NCT04831892|OTHER|Moisturizer containing Colloidal Oatmeal only|Vehicle lotion containing 0.1% colloidal oatmeal.
48357672|NCT02996240|DIETARY_SUPPLEMENT|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
48669374|NCT01952938|PROCEDURE|LINK SL versus EnduRo|
47989468|NCT01482247|DIETARY_SUPPLEMENT|Placebo Supplement|Dietary Supplement
47989469|NCT01862562|PROCEDURE|Open surgery|Conventional technique
47989470|NCT01862562|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
47989471|NCT00569296|BIOLOGICAL|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
48357673|NCT01031108|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
48669375|NCT02622269|DEVICE|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
47989472|NCT00569296|BIOLOGICAL|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
47989473|NCT00569296|BIOLOGICAL|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
48669376|NCT02622269|DEVICE|Standard compression device|Compression of the abdomen with the standard compression device
48669377|NCT03218917|DRUG|Brensocatib 10 mg|Administered once per day for 24 weeks
48669378|NCT03218917|DRUG|Brensocatib 25 mg|Administered once per day for 24 weeks
48669379|NCT03218917|DRUG|Placebo|Administered once per day for 24 weeks
48669380|NCT01220661|DRUG|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
48669381|NCT00778427|DRUG|metformin hydrochloride 1000 mg tablets|
48669382|NCT05669222|DIAGNOSTIC_TEST|FAST Technique|The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
48669383|NCT05669222|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
48669384|NCT02107885|DRUG|DS-1971|6 subjects in each group will receive DS-1971.
48669385|NCT02107885|DRUG|placebo|2 subjects in each group will receive placebo.
48669386|NCT05786287|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
48669387|NCT05786287|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
48669388|NCT05677880|OTHER|Study Procedures|"Participants will experience~* Neurocognitive Tests and Self-Report Measures~* Clinical Interviews~* Neurological Exam~* MRI screening at baseline, 18 months, 36 months~* Fasted Blood draw"
48669389|NCT06447909|BEHAVIORAL|Treatment App|"The behavioral treatment app content consists of tasks that caregivers can assign to their children in the app (e.g., finish homework, make bed, etc.). These tasks are completed offline, and then caregivers approve the child's completion of those tasks through the app, administering a token reward (coins) in-app. In the child version of the app, children take care of a virtual pet by feeding, cleaning, buying various accessories (using in-game coins), and exploring different lands with the virtual pet. The caregiver-assigned token coins can be used to redeem items needed to raise their pet, and access virtual lands. Caregivers can also choose to have their child redeem virtual tokens for real-life rewards. Ultimately, the app combines a video game with evidence-based principles to help children practice important tasks and behaviors as administered by caregivers."
48688097|NCT01437111|DRUG|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
48357674|NCT01031108|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
48688098|NCT00887159|DRUG|Cisplatin|Given IV
48688099|NCT00887159|BIOLOGICAL|Cixutumumab|Given IV
48688100|NCT00887159|DRUG|Etoposide|Given IV
48688101|NCT00887159|OTHER|Laboratory Biomarker Analysis|Correlative studies
47989474|NCT01700855|PROCEDURE|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
48146782|NCT04439591|OTHER|Computerised cognitive training|A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
48688102|NCT00887159|DRUG|Vismodegib|Given PO
48688103|NCT02578134|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
47989475|NCT01700855|PROCEDURE|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3\~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
47989476|NCT01893073|BEHAVIORAL|Mindful walking program|
47989477|NCT03234751|DRUG|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
47989478|NCT03234751|DRUG|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
47989479|NCT03234751|DRUG|Placebo|48 hours of placebo.
47989480|NCT04890366|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
48357675|NCT00253422|DRUG|anastrozole|
48357676|NCT00253422|DRUG|exemestane|
48357677|NCT00253422|DRUG|fulvestrant|
48357678|NCT00184366|DRUG|efalizumab|efalizumab
48688104|NCT02578134|OTHER|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
48688105|NCT01325051|DRUG|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
48688106|NCT01042587|OTHER|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
47989481|NCT01910090|DRUG|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
47989482|NCT01910090|DRUG|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
47989483|NCT02870660|OTHER|Registry|
47989484|NCT06163846|DIAGNOSTIC_TEST|Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification|Assess the combination of baseline and follow-up image mining, together with ctDNA, in predicting disease relapse and progression.
47989485|NCT05421728|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
48357679|NCT05956327|PROCEDURE|Aerobic Endurance Training|Aerobic endurance training on a bicycle ergometer (week 1 to 6: three units per week á 40 minutes, week 7 to 12: three units á 45 minutes, in groups of up to three patients over 13 weeks)
48357680|NCT05956327|PROCEDURE|Flexibility, strengthening and balance training|Flexibility, strengthening and balance training (exercises from the areas of stretching, strength, balance and relaxation, 3x40 min from week 1-2, 3x45 min from week 3-4 and 3x50 min from week 5-13, in groups of up to three patients over 13 weeks)
48357681|NCT01874587|RADIATION|adaptative radiotherapy|weekly replanning
48357682|NCT05131815|BEHAVIORAL|Virtual group based physical activity (BurnAlong) and Social Media Discussion Board|Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
48357683|NCT06295822|DRUG|Nuan-gong-ye|In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
48146783|NCT04476524|OTHER|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
48146784|NCT03406390|PROCEDURE|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
48146785|NCT04894942|OTHER|American Orthopaedic Foot and Ankle Society Score (AOFASS)|calculation of the score AOFASS before and after the surgery
48357684|NCT06295822|OTHER|Placebo|The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
47989486|NCT05421728|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
47989487|NCT02386904|DRUG|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
47989488|NCT02424383|DEVICE|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
47989489|NCT04249310|DRUG|Tiotropium/Olodaterol|Soft Mist Inhaler product
48357685|NCT05270265|BIOLOGICAL|Pvs25-IMX313/Matrix-M1|Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations
48357686|NCT01213342|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~* EPA (Eicosapentaenoic Acid) 1300mg~* DHA (Docosahexaenoic Acid) 900 mg~* Other Omega-3's 360mg~* Total Omega 3's 2560 mg"
48357687|NCT01213342|DIETARY_SUPPLEMENT|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
48357688|NCT03757299|DIAGNOSTIC_TEST|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
48357689|NCT02612792|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
48669390|NCT06447909|BEHAVIORAL|Sham app|As described above, the child will access a virtual pet that they can feed, clean and buy various accessories by redeeming virtual coins. They will not be able to explore different lands with that pet. Coins in the placebo version will be rewarded non-contingently. Additionally, children will not be able to redeem coins for real-life rewards as above in the treatment app. Caregivers will not need to review and approve tasks in order to redeem coins. The caregiver-version of the app will not contain the Assigned or Review tabs as assigned above, since the child will earn coins regardless of whether or not they complete tasks, so caregivers will not be able to review nor assign tasks. Instead, caregivers in this group will only have access to the guide tab which will contain helpful articles the parent can read about disruptive behavior problems in children.
48669391|NCT05589909|DIAGNOSTIC_TEST|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
48669392|NCT01527994|DRUG|Aprepitant|Aprepitant 125 mg oral tablets
48669393|NCT01527994|DRUG|Placebo pill|Placebo oral pill- inactive compound
48669394|NCT03634956|DRUG|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
47989490|NCT04249310|DRUG|Tiotropium|Soft Mist Inhaler product
48146786|NCT06321094|DRUG|Vericiguat|Investigators divide our participants into two groups ;one group is required to take vericiguat,and the other isnot required to take vericiguat.Expect this,no intervention is used in the research.
48146787|NCT02313077|BIOLOGICAL|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
48146788|NCT02313077|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
48146789|NCT02313077|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
48146790|NCT06037044|OTHER|Sensory integration therapy for balance and gait training|Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)
48357690|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
48357691|NCT02612792|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
48146791|NCT06037044|OTHER|Traditional Physiotherapy for balance and gait training|Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
48146792|NCT04971902|OTHER|Pharmacogenetic Test|Cheek swab sample with PGx results lab analysis
48357692|NCT02499172|BIOLOGICAL|Shanchol|
48357693|NCT00403689|DIETARY_SUPPLEMENT|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
48357694|NCT00403689|DIETARY_SUPPLEMENT|placebo|1.5 g waxy maize starch daily
48357695|NCT03542292|DIAGNOSTIC_TEST|placental drainage|
48688107|NCT01042587|OTHER|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
48669395|NCT04065321|PROCEDURE|PET-CT examination|All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
48669396|NCT04065321|PROCEDURE|Peripheral blood detection|All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
48669397|NCT03780257|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
48669398|NCT03780257|OTHER|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
48669399|NCT02947984|RADIATION|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
48357696|NCT04849260|BIOLOGICAL|Pexa-Vec combined with ZKAB001|"1. Intratumoral injection of low dose Pexa-Vec (3×10\^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.~2. Intratumoral injection of high dose Pexa-Vec (1×10\^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle."
48669400|NCT02947984|RADIATION|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
48669401|NCT00561990|DRUG|Nimotuzumab|
48669402|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg twice daily
48669403|NCT01242514|DRUG|Fostamatinib|Fostamatinib 150mg once daily
48669404|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg once daily
48669405|NCT03663855|DRUG|Tiopronin|Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
48669406|NCT04773665|BIOLOGICAL|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
48669407|NCT04773665|BIOLOGICAL|Placebo|0.9% sodium chloride
48669408|NCT04773665|BIOLOGICAL|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
48669409|NCT01959529|DRUG|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
48669410|NCT01959529|DRUG|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
48669411|NCT01464879|DRUG|Testosterone Gel (FE 999303)|
48669412|NCT05568329|DEVICE|Hearing Aid Program|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
48669413|NCT01905540|DRUG|SSP-004184AQ|Magnesium salt
48669414|NCT01905540|DRUG|SSP-004184SS|Disodium salt
48669415|NCT01071460|DEVICE|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~* Contralateral retrograde common femoral cross-over access or antegrade access~* Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~* Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~* Deployment of an appropriately sized FlexStent® to cover target lesion~* Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~* Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
48669416|NCT01227057|BEHAVIORAL|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
48669417|NCT01227057|BEHAVIORAL|Case Management|Case management
48669418|NCT01651468|DIETARY_SUPPLEMENT|HEMOFIX|unique complex herbal mixture
48669419|NCT02254291|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
48146793|NCT02169609|DRUG|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
48669420|NCT02254291|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
48669421|NCT02254291|DRUG|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
48669422|NCT04108273|BEHAVIORAL|Organizational Skills Training|OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
48669423|NCT05221892|DRUG|Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin|Tablets to be taken 30 minutes before each of 4 trips.
48669424|NCT05221892|DRUG|Ginger|Tablets to be taken 30 minutes before each of 4 trips.
48669425|NCT02170064|DRUG|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
48669426|NCT03721250|OTHER|epidural|thoracic epidural analgesia
48669427|NCT03849209|DEVICE|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
48688108|NCT00000870|DRUG|Indinavir sulfate|
47989491|NCT05594914|DRUG|AK104|AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
47989492|NCT00937443|OTHER|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
47989493|NCT00937443|BIOLOGICAL|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
48146794|NCT03814226|OTHER|Evaluation of headache inducing capabilities of PACAP38|We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
48357697|NCT04849260|BIOLOGICAL|ZKAB001 monotherapy|ZKAB001 monotherapy
48688109|NCT00000870|DRUG|Lamivudine|
47989494|NCT03319355|BEHAVIORAL|cognitive behavioral therapy|exercise therapy
48688110|NCT00000870|DRUG|Stavudine|
48688111|NCT00000870|DRUG|Zidovudine|
48669428|NCT03849209|DEVICE|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
48669429|NCT03290352|OTHER|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
48669430|NCT04270643|DIETARY_SUPPLEMENT|Vitamin D3|ATC code A11CC05 (cholecalciferol)
48357698|NCT00003736|DRUG|motexafin gadolinium|
48357699|NCT00003736|PROCEDURE|biopsy|
48357700|NCT00003736|PROCEDURE|breast imaging study|
48357701|NCT00003736|PROCEDURE|comparison of screening methods|
48669431|NCT04270643|DIETARY_SUPPLEMENT|Placebo|Ethyl oleate
48669432|NCT00414375|PROCEDURE|Operation on Admission|Laparoscopic appendectomy on admission
48146795|NCT02580227|DRUG|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
48146796|NCT02580227|OTHER|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
48146797|NCT01049698|BEHAVIORAL|Resistance Training|3 d/wk resistance training
48146798|NCT01049698|BEHAVIORAL|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
48146799|NCT04929509|OTHER|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
48146800|NCT04929509|OTHER|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
48146801|NCT04929509|OTHER|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
48146802|NCT05605158|DRUG|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
48146803|NCT05605158|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
48146804|NCT04188353|DEVICE|Optic nerve sheath diameter measurement|ONSD measurements done at screening (T1), 30 minutes after mannitol infusion (T2), 60 minutes (T3) and 120 minutes (T4)
48146805|NCT04188353|DRUG|Mannitol|Mannitol at dose of 0.25 to 1 gm/kg over 20 minutes via a dedicated IV line
48357702|NCT00003736|PROCEDURE|magnetic resonance imaging|
48357703|NCT00003736|PROCEDURE|study of high risk factors|
48357704|NCT03681808|DEVICE|Control|Contact Lens
48357705|NCT03681808|DEVICE|Test|Soft Contact Lens
48357706|NCT01289028|DRUG|Nilotinib|
48357707|NCT03698214|OTHER|reversed shock index < 1|Among patients with isolated TBI, those with an RSI \< 1 had higher mortality
48669433|NCT00414375|PROCEDURE|Drainage and Interval Appendectomy|drainage with interval appendectomy
48669434|NCT00294034|DEVICE|Pacemaker|
48357708|NCT03698214|OTHER|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
48357709|NCT04479306|DRUG|Alisertib|Given PO
48357710|NCT04479306|DRUG|Osimertinib|Given PO
48357711|NCT04479306|DRUG|Sapanisertib|Given PO
48357712|NCT03508973|OTHER|Sculpta|
48357713|NCT02655315|DRUG|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
48357714|NCT02655315|DRUG|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
48357715|NCT04651751|BEHAVIORAL|Facilitating an Exercise Habit and Identity via the Multi-Process Action Control Model- A Randomized-Controlled Trial|Participants attended a workshop which consisted of a presentation and an exercise planning exercise.
48669435|NCT04660734|PROCEDURE|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
48146806|NCT06201949|OTHER|Articaine infiltration technique|infiltration will be performed with articaine and epinephrine 1/100 000 (Artinibsa, Inibsa, Barcelona, Spain) for all patients on their second pri-mary molar. The needle tip was placed in the buccal vestibule and then directed to the apex of the tooth and about one-third to one-fourth of the cartridge will be slowly discharged
48357716|NCT01310985|DRUG|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
48357717|NCT01833793|DRUG|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
48357718|NCT02113644|OTHER|Lifestyle intervention|
48357719|NCT05839002|PROCEDURE|nCRT|ESCC patients that recieved surgery and nCRT.
48357720|NCT01879891|OTHER|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
48357721|NCT02347202|OTHER|Online counseling via Zoom teleconferencing|
48357722|NCT02347202|OTHER|Telephone support as needed|
48357723|NCT01022918|DRUG|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
48357724|NCT01022918|DRUG|Temodal/radiotherapy|
48357725|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels baseline|Measuring vitamin D plasma levels at baseline
48357726|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry at baseline|Measuring T-score and Z-score of the femur and lumbar spine at baseline
48357727|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials at baseline|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured.
48669436|NCT05804721|DRUG|Apipe (Aripiprazole10 mg)|Test drug
48669437|NCT05804721|DRUG|Abilify (Aripiprazole10 mg)|Reference drug
48669438|NCT00237042|BEHAVIORAL|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
48669439|NCT00237042|BEHAVIORAL|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
48669440|NCT00237042|DRUG|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
48669441|NCT00004466|DRUG|Atorvastatin|
48669442|NCT00004466|DRUG|Placebo|
48669443|NCT02951780|DRUG|LY3185643|Administered SC
48669444|NCT02951780|DRUG|rGlucagon|Administered SC
48669445|NCT00314613|DRUG|Antipsychotic/Risperidone Consta|
48669446|NCT02189889|DRUG|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
48669447|NCT02189889|DRUG|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
48669448|NCT04089410|DEVICE|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
48669449|NCT04089410|DEVICE|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
48669450|NCT04089410|OTHER|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
48357728|NCT05322538|DIAGNOSTIC_TEST|Audiogram at baseline|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score.
48357729|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure at baseline|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test
48357730|NCT05322538|DIAGNOSTIC_TEST|cold pressor test at baseline|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function.
48357731|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels one year after recruitment|Measuring vitamin D plasma levels one year after recruitment
48357732|NCT05322538|DIAGNOSTIC_TEST|vitamin D plasma levels two years after recruitment|Measuring vitamin D plasma levels two years after recruitment
48357733|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry one year after recruitment|Measuring T-score and Z-score of the femur and lumbar spine one year after recruitment
48357734|NCT05322538|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry two years after recruitment|Measuring T-score and Z-score of the femur and lumbar spine two years after recruitment
48357735|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials one year after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured one year after recruitment
48357736|NCT05322538|DIAGNOSTIC_TEST|cervical Vestibular evoked myogenic potentials two years after recruitment|cVEMP is a vestibular test for saccular function, an otolith organ in the inner ear. the electrical response of the stermocledomastoid muscle to saccular stimulation is measured via two distinct waves - P13 and N23. the latency, amplitude and peak to peak amplitude will be measured two years after recruitment
48357737|NCT05322538|DIAGNOSTIC_TEST|Audiogram one year after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed one year after recruitment
48357738|NCT05322538|DIAGNOSTIC_TEST|Audiogram two years after recruitment|hearing measurement will be performed. Hearing level in dB will be performed in the 250-8,000 Hz frequency. The test includes Speech reception threshold and word recognition score performed two years after recruitment
48357739|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure one year after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed one year after recruitment
48357740|NCT05322538|DIAGNOSTIC_TEST|Measuring Orthostatic Blood Pressure two years after recruitment|blood pressure will be measure two minutes after lying supine and repeated 3 minutes after standing. A drop of at least 20mmHg systolic pressure or at least 10mmHg diastolic blood pressure is considered a positive test. The test will be performed two year after recruitment.
48357741|NCT05322538|DIAGNOSTIC_TEST|cold pressor test one year after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed one year after recruitment.
48357742|NCT05322538|DIAGNOSTIC_TEST|cold pressor test two years after recruitment|The cold pressor test is an indicator for sympathetic system function. A rise of at least 15mmHg of systolic pressure after putting the subject's hand in cold water (4 deg Celsius) is indicative of normal sympathetic function. The test will be performed two years after recruitment.
48669451|NCT04089410|OTHER|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
48357743|NCT04081987|DEVICE|non-invasive monitoring|Comparing blood pressure (diastolic \& systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
48357744|NCT03687931|DRUG|Dexamethasone|Drop
48357745|NCT01265940|DRUG|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
48357746|NCT03322592|DIAGNOSTIC_TEST|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
48357747|NCT03322592|DIAGNOSTIC_TEST|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
48357748|NCT04102410|OTHER|Sprints|"Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after."
48688112|NCT00000870|DRUG|Didanosine|
48688113|NCT00000870|DRUG|Aldesleukin|
48688114|NCT04314024|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
48357749|NCT04102410|OTHER|Vertical jumps|"Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after."
48357750|NCT04102410|OTHER|Questionary Short Form-12 (SF-12)|"Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after."
48357751|NCT04102410|DEVICE|activity actigraph|"Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after."
48357752|NCT04102410|OTHER|Program composed of two 2 training strategies|"Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~* Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~* Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed."
48357753|NCT04102410|OTHER|Program of usual practice|Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
48357754|NCT05326932|PROCEDURE|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
48357755|NCT04624581|DEVICE|Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device|"This intervention measures the response to electrical stimulation of the sural nerve using a pair of percutaneous electrodes placed at the external malleolar retro passage of the nerve (2 cm apart) and connected to the stimulation device (Nicolet Vicking). Reflex muscle responses will be collected using surface electrodes placed on the femoral biceps muscle of the participant and connected to an Electromyogram recording device.~The RIII will be determined twice (rest period between each 10-minute). In order to induce the reflex nociceptive flexion response, repeated cutaneous electrical stimulations (30 to 40) will be applied at the level of the sural nerve following a variable interval of 6 to 10 seconds in order to overcome the phenomena of habituation and predictability. Each stimulus test will consist of a single rectangular pulse of 0.5 ms, of variable intensity (0-100mA) until a reflex nociceptive flexion threshold is detected or a maximum current of 100 mA is reached"
48357756|NCT01006915|PROCEDURE|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
48357757|NCT01511692|DRUG|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
48357758|NCT01511692|DRUG|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
48357759|NCT01511692|DRUG|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
48669452|NCT04089410|OTHER|Autonomic Balance, Orthostatic and Hypoxic tolerance|"1. Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~2. Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~3. The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
48669453|NCT04089410|OTHER|Psychological Testing|"1. Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~2. Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~3. Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~4. Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
48669454|NCT04089410|OTHER|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
48357760|NCT01511692|DRUG|glimepiride|Dose individually adjusted, administered orally for 4 weeks
48506730|NCT06469632|OTHER|Experimental: Experimental Group 2|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique.~Non-ablative radiofrequency: using capacitive superficial electrodes and resistive superficial and intravaginal electrodes."
48506731|NCT02213289|DRUG|Trastuzumab|Trastuzumab
48146807|NCT06201949|OTHER|Articaine nerve block technique|this technique will be performed with articaine and epinephrine 1/100 000 for all patients on their second primary molar with conventional technique inferior alveolar nerve block. The thumb will be placed on the occlusal surface of intended side and protruded toward the inner oblique ridge of ramus and then placed in touch with retromolar pad. The syringe will be directed between the two mandibular primary molars of opposite side and the needle will be pushed forward until hitting the bone, then the injection will be slowly done. After three to five minutes, treatment will be started, after numbness in the lower lip is achieved
48669455|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
48669456|NCT03522064|DRUG|Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
48146808|NCT04570488|OTHER|EPIC risk score display|Display of risk score/ colored flag in Epic patient list column
48146809|NCT03841253|PROCEDURE|Trans-epithelial PTK|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
48146810|NCT03841253|DEVICE|EpiMaster Application Software|The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
48146811|NCT05125549|DRUG|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
48146812|NCT05125549|DRUG|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
48146813|NCT05167825|DRUG|Macitentan|Macitentan will be administered orally as a tablet.
48146814|NCT04779463|DIAGNOSTIC_TEST|Parasternal intercostal muscles thickness ultrasound indicies|"Parasternal intercostal muscles thickness ultrasound indicies includes:~* Parasternal Intercostals Thickness Fraction.~* Parasternal Intercostals Thickness at the End of Inspiration.~* Parasternal Intercostals thickness at the End of Expiration."
48669457|NCT03700229|DRUG|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
48506732|NCT02213289|DRUG|ABT-806|ABT-806
48506733|NCT02213289|DRUG|Bemarituzumab|Bemarituzumab
48669458|NCT03700229|DRUG|Rituximab|rituximab intravenously 500 mg for one dose
48669459|NCT03166748|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
48669460|NCT06546462|OTHER|Osteopathic Manipulative Treatment (OMT)|The active arm will receive osteopathic manipulative treatment which is a hands-on treatment modality use to treat a variety of health concerns.
48669461|NCT06546462|OTHER|Sham Light touch arm|Sham arm will receive a light touch sham treatment.
48688115|NCT02731820|DIETARY_SUPPLEMENT|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
47989495|NCT02937779|DRUG|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
47989496|NCT02937779|DEVICE|Rapid tests HBe Ag|For all HBs Ag positive women
48688116|NCT02731820|DIETARY_SUPPLEMENT|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
47989497|NCT00213083|DRUG|Carraguard (PC-515)|
47989498|NCT01817933|BEHAVIORAL|physical therapy|
47989499|NCT01375907|DRUG|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
47989500|NCT05023265|RADIATION|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
47989501|NCT04949165|DIETARY_SUPPLEMENT|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
47989502|NCT06237595|DEVICE|Vagus nerve stimulation|Electrical stimulation of the vagus nerve.
47989503|NCT06237595|DRUG|Medical treatment|Medical treatment for fibromyalgia patients
47989504|NCT06237595|COMBINATION_PRODUCT|Combined vagus nerve stimulation and medical treatment|Combination of the two interventions
47989505|NCT02116244|DRUG|Civamide Nasal Spray|
47989506|NCT04349618|OTHER|PROTECTIVE VENTILATION|Protective ventilation with tidal volume 6 mL/kg of predicted body weight further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
47989507|NCT04349618|OTHER|ULTRAPROTECTIVE VENTILATION|Ultraprotective ventilation with tidal volume reduction down to 4 mL/kg further adjusted to keep plateau pressure below 30 cm H2O and pH above 7.20, and PEEP set using the PEEP FiO2 table of the ARMA trial
47989508|NCT04769310|DEVICE|Cardiac and Brain MRI|"A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
47989509|NCT00967993|DRUG|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
48688117|NCT02731820|DIETARY_SUPPLEMENT|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
47989510|NCT03247075|BEHAVIORAL|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
48688118|NCT02731820|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
47989511|NCT03247075|BEHAVIORAL|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
47989512|NCT00696852|BEHAVIORAL|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
47989513|NCT00696852|BEHAVIORAL|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
47989514|NCT00696852|BEHAVIORAL|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
48146815|NCT01817894|DRUG|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
48146816|NCT00149409|DIETARY_SUPPLEMENT|Omacor|
47989515|NCT04389567|DRUG|Famotidine|Use of oral Famotidine.
48357761|NCT06085040|BEHAVIORAL|Multidisciplinary weight loss|12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
48506734|NCT02213289|DRUG|Ramucirumab|Ramucirumab
48506735|NCT02213289|DRUG|Nivolumab|Nivolumab
48688119|NCT00600106|DRUG|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
48688120|NCT00600106|DRUG|Placebo|1 mg placebo
48688121|NCT01088204|PROCEDURE|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
48688122|NCT01088204|PROCEDURE|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
48688123|NCT04242576|DEVICE|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
48688124|NCT04242576|OTHER|Action Observation|Videos of cervical movements.
48688125|NCT04242576|BEHAVIORAL|Exercise|Evidence based exercises for the neck.
48688126|NCT03127917|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline capsules given at 6 g/day
48688127|NCT03127917|OTHER|Placebo|Maltodextrin capsules given as placebo
48688128|NCT05818540|DEVICE|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
48688129|NCT05818540|DEVICE|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
48688130|NCT04817475|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
48688131|NCT01243008|DRUG|Application of SHB001|"* Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas"
48688132|NCT02574078|DRUG|Nivolumab|
48688133|NCT02574078|DRUG|Bevacizumab|
48688134|NCT02574078|DRUG|Pemetrexed|
48688135|NCT02574078|OTHER|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
48688136|NCT02574078|DRUG|nab-Paclitaxel|
48688137|NCT02574078|DRUG|Paclitaxel|
48688138|NCT02574078|DRUG|Docetaxel|
48688139|NCT02574078|DRUG|Gemcitabine|
48688140|NCT02574078|DRUG|Erlotinib|
48688141|NCT02574078|DRUG|Crizotinib|
48688142|NCT02574078|DRUG|Carboplatin|
48146817|NCT06301945|DIAGNOSTIC_TEST|Artificial Intelligence Diagnostics|AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.
48146818|NCT06301945|DIAGNOSTIC_TEST|Recurrence Prediction Tool|This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.
48357762|NCT01558791|OTHER|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
48688143|NCT00922376|DEVICE|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
47989516|NCT02505620|PROCEDURE|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
47989517|NCT02505620|PROCEDURE|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
47989518|NCT02970409|DEVICE|saline|catheter lock using saline
47989519|NCT02970409|DEVICE|Heparin|catheter lock using Heparin
47989520|NCT03432741|DRUG|Belinostat|Given intralesionally
47989521|NCT03432741|DRUG|Carfilzomib|Given intralesionally
48146819|NCT00559572|BEHAVIORAL|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
48146820|NCT00559572|OTHER|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
48146821|NCT01751295|DRUG|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
48146822|NCT01690000|DRUG|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
48357763|NCT00002024|DRUG|Ganciclovir|
48506736|NCT02213289|DRUG|Standard cytotherapy|FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
48506737|NCT03155945|DRUG|Olorinab|Olorinab active treatment for 8 weeks.
48688144|NCT02052661|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
47989522|NCT03432741|DRUG|Copanlisib Hydrochloride|Given intralesionally
47989523|NCT03432741|BIOLOGICAL|Daratumumab|Given intralesionally
47989524|NCT03432741|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET
47989525|NCT03432741|DRUG|Gemcitabine Hydrochloride|Given intralesionally
47989526|NCT03432741|OTHER|Laboratory Biomarker Analysis|Correlative studies
47989527|NCT03432741|BIOLOGICAL|Nivolumab|Given intralesionally
47989528|NCT03432741|BIOLOGICAL|Obinutuzumab|Given intralesionally
47989529|NCT03432741|BIOLOGICAL|Pembrolizumab|Given intralesionally
48146823|NCT05871788|DIAGNOSTIC_TEST|identify biomarkers|Identify the epidemiological profile of the biological signature (PD-L1 / TMB / MSI/HRD/ TILs) of patients with locally advanced or metastatic breast carcinoma
48146824|NCT06226441|PROCEDURE|Continuous Renal Replacement Therapy|CRRT
48146825|NCT03432871|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
47989530|NCT03432741|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
47989531|NCT03432741|BIOLOGICAL|Rituximab|Given intralesionally
47989532|NCT03432741|DRUG|Romidepsin|Given intralesionally
47989533|NCT03432741|OTHER|Saline|Given intralesionally
47989534|NCT03432741|BIOLOGICAL|Trastuzumab|Given intralesionally
48357764|NCT02630381|DEVICE|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
48357765|NCT05569915|BEHAVIORAL|Trauma Expressive Writing|Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.
48669462|NCT04242069|BEHAVIORAL|Healthy for my Baby|"Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application."
48669463|NCT04242069|OTHER|Usual Care|"Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits."
48357766|NCT05569915|BEHAVIORAL|Stigma Expressive Writing|Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.
48357767|NCT05569915|BEHAVIORAL|Control|Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
48357768|NCT00266695|DRUG|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
48357769|NCT00018694|DRUG|Chenodeoxycholic Acid|
48357770|NCT03720067|DRUG|Propranolol|40mg to 320mg / day
48357771|NCT03720067|DRUG|Carvedilol|6.25mg to 25mg / day
48357772|NCT03720067|DRUG|Rosuvastatin|20mg / day
48357773|NCT03720067|DRUG|Placebo|Placebo of rosuvastatin
48357774|NCT01011764|BEHAVIORAL|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
48357775|NCT04974411|OTHER|infection|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
48357776|NCT04974411|OTHER|sepsis|this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
48357777|NCT04919135|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the IV route with a 3-month intervening interval
48357778|NCT04919135|DRUG|standard frailty treatment and supplementary medication|Hightamine (Hankook Korus Pharm, Korea), Total calcium (Nugale Pharmaceutical, Canada), Bioflex (Ausbiomed, Australia)
48357779|NCT05247515|DEVICE|Endoscopic mucosal resection with nexpowder|At the end of the EMR procedure, the patient will be randomized. In the treated group, Nexpowder will be sprayed thanks to a catheter inserted through the operating channel of the endoscope.
48357780|NCT04652102|BIOLOGICAL|CVnCoV|Intramuscular (IM) injection.
48357781|NCT04652102|BIOLOGICAL|Placebo|Intramuscular (IM) injection.
48357782|NCT04652102|BIOLOGICAL|Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program|Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
48357783|NCT02353806|DRUG|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
48357784|NCT02924766|DRUG|Niraparib|Participants will start with niraparib 200 mg once daily.
48357785|NCT02924766|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
48357786|NCT02924766|DRUG|Abiraterone Acetate|Participants will receive 1000 mg (4\*250mg) once daily.
48669464|NCT00220506|DRUG|Provigil|
48669465|NCT03070678|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
48357787|NCT02924766|DRUG|Prednisone|Participants will receive 10 mg (1\*5 mg twice daily).
48357788|NCT02425995|PROCEDURE|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
48357789|NCT01349491|DRUG|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
47989535|NCT01137045|BIOLOGICAL|SPEEDA and TRCS SPEEDA|"For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.~For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.~For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI"
48357790|NCT01349491|DRUG|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
48357791|NCT05857215|DRUG|amilo-5MER|amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
48357792|NCT00051194|DRUG|Combination IOP Lowering Therapy|
48357793|NCT03566563|OTHER|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
48357794|NCT04090515|BEHAVIORAL|Project Health|This intervention involves a one-hour group meeting for six consecutive weeks.
48357795|NCT04090515|OTHER|Educational Video Control|This intervention involves a one-hour educational video control viewing for six consecutive weeks.
48357796|NCT05231928|PROCEDURE|Argon Laser Iridoplasty|"Argon Laser is applied to the anterior iris surface at sites and with parameters tailored according to iris configuration, pupil size, iris colour.~The device used is Nidek Argon Laser device with YAG capsulotomy or Abraham Iridotomy lens as auxilliary lenses.~-Topical Pilocarpine 2% and ocular surface anesthetic are applied prior to the procedure and Brimonidine 0.2% bid is used fo a week after the procedure together with topical dexamethasone ophthalmic solution."
48357797|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
48357798|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
48357799|NCT00808028|BIOLOGICAL|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
48357800|NCT00808028|OTHER|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
48357801|NCT04290000|OTHER|additional biological samples during CAR-T CELL treatment|"Blood samples (additional tubes) and marrow (quantity taken in addition from the same aspiration) will be collected in addition to those useful for the follow up of the patients (progress of their disease after treatment with CAR-T Cells) at specific points in his treatment journey.~The following samples will also be collected during Apheresis and at Car-T Cells reinjection :~* Apheresis sampling~* CAR-T Cells collected from bag rinsate~In case of invasion, a skin biopsy will be made, 2 days and 8 days after the beginning of the CAR T Cell Treatment, during the patient's hospitalization and during a consultation visit in case of therapeutic progression or failure."
48669466|NCT03070678|DRUG|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
47989536|NCT00058604|BIOLOGICAL|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
47989537|NCT00450333|DRUG|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
47989538|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
47989539|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
47989540|NCT00450333|DRUG|Dynepo|subcutaneous, Q2W for 24 weeks
48146826|NCT05979766|OTHER|Manual lymphatic drainage versus marian clark drainage|Manual lymphatic drainage versus marian clark drainage
48357802|NCT00396344|OTHER|Çontrol|Intravenous saline
48357803|NCT00396344|DRUG|Hydrocortisone|Intravenous stress dose of hydrocortisone
48357804|NCT00396344|DRUG|Hydrocortisone|Intravenous pharmacologic hydrocortisone
48357805|NCT05202106|BEHAVIORAL|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
48357806|NCT05202106|OTHER|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
48357807|NCT05617872|DRUG|Vinegar 20ml|20ml vinegar infused into duodenum and suction for 5 minutes via EUS
48357808|NCT05617872|DRUG|Saline|20ml saline infused into duodenum and suction for 5 minutes via EUS
47989541|NCT04760912|DRUG|Rocuronium|Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
47989542|NCT04760912|PROCEDURE|General anesthesia for surgery|General anesthesia with standard anesthetic monitoring,
48357809|NCT05617872|DRUG|Vinegar 40ml|40ml vinegar infused into duodenum and suction for 5 minutes via EUS
48357810|NCT05617872|DRUG|Vinegar 20ml, 3 phases|20ml vinegar infused into duodenum and pancreatic juice collected via EUS suction during the first 5 minutes, 5-10 minutes, and 10-15 minutes, separately.
48357811|NCT00826787|DRUG|Levetiracetam|750 mg tablet
48669467|NCT04321408|DRUG|Ziconotide Injection|Intrathecal analgesia with Ziconotide
48669468|NCT06192563|DRUG|Dupilumab|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
47989543|NCT04759209|DIAGNOSTIC_TEST|Biopsies|
47989544|NCT00196716|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
48669469|NCT00416117|PROCEDURE|Manual Physical Therapy and Exercise|
48669470|NCT00416117|PROCEDURE|Minimal Intervention|
48669471|NCT05358002|PROCEDURE|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
48669472|NCT04812327|DIAGNOSTIC_TEST|BD Veritor Plus System for Rapid Detection of SARS CoV-2|Nasal Sawb for the conduct of the Veritor Antigen Test
48669473|NCT04812327|DIAGNOSTIC_TEST|rt-PCR|Nasopharyngeal Swab for the conduct of a rt-PCR
48669474|NCT04812327|DIAGNOSTIC_TEST|viral culture|Nasopharyngeal Swab for the conduct of viral culture
48357812|NCT03096691|DEVICE|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
48506738|NCT05875311|DEVICE|telemonitoring|"The system consists of the following elements:~Professional website at the ambulatory centre, which allows:~To set up an individualised care plan To establish the patient's risk profile and targets for improvement. Long-term monitoring of the evolution of cardiovascular risk factors and events that occurred Advise the patient on self-management strategies.~Mobile application software with the following functions:~Scheduled exercise sessions Medication reminder Measurement reminder (weight, blood pressure, heart rate, waist circumference, etc.) Messages: Inbox folder for system messages and messages generated by professionals for a specific patient or video conference.~Training monitor: guides the patient in the performance of their exercise. Access to certified health information for patients"
48506739|NCT05875311|OTHER|control follow-up|Patients are instructed to perform 150 minutes per week of moderate physical activity and follow healthy lifestyles
48506740|NCT05476952|PROCEDURE|"he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K."|Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.
47989545|NCT02929823|DRUG|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
47989546|NCT02929823|DRUG|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
48506741|NCT04386486|OTHER|Bathe anamnesis method|BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.
48506742|NCT04386486|OTHER|standart anamnesis|standart anamnesis is applied to second group and preoperative examinations are completed.
48506743|NCT02305160|DRUG|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
48506744|NCT02305160|DRUG|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
48506745|NCT05352347|DRUG|NuSepin® 0.2 mg/kg|NuSepin® 0.2 mg/kg in 100mL NS bid
48506746|NCT05352347|DRUG|NuSepin® 0.4 mg/kg|NuSepin® 0.4 mg/kg in 100mL NS bid
48506747|NCT05352347|DRUG|Placebo|Normal saline (NS) 100mL bid
48506748|NCT06200545|OTHER|PrEP eligibility assessment|PrEP eligibility assessment
48506749|NCT06200545|DIAGNOSTIC_TEST|Rapid HIV antibody testing prior to provision and/or refill of PrEP|Rapid HIV antibody testing prior to provision and/or refill of PrEP
48506750|NCT06200545|OTHER|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
48506751|NCT06200545|BEHAVIORAL|Evaluation of barriers and facilitators to ongoing PrEP use|Evaluation of barriers and facilitators to ongoing PrEP use
48506752|NCT06200545|OTHER|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
48506753|NCT06200545|OTHER|Tracing for any missed PrEP visits|Tracing for any missed PrEP visits
48506754|NCT06200545|OTHER|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"
48506755|NCT04680858|OTHER|DECT|Use of a digital enhanced telecommunication headset for team communication
48506756|NCT06427707|DRUG|Intravenous Infusion of propofol, lidocaine, Magnesium sulfate|intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. the effect of either Propofol injection, or ketamine injection or dexmeditomidine injection on intraoperative bleeding
48506757|NCT06427707|DRUG|Intravenous infusion of ketamine, lidocaine, Magnesium sulfate|Patients will receive intravenous infusion of Ketamine 0.1-0.2 mg.kg-1.h-1 (intravenous infusion of propofol 6-10 mg.kg-1.h-1, lidocaine (lidocaine 2% 400mg in 20 ml) bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1. dose of 1 mg.kg-1), lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1.
47989547|NCT02929823|DRUG|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
47989548|NCT01365507|DRUG|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
47989549|NCT03160534|OTHER|preoperative exercise|Each intervention session contains a stretching part and aerobic training
47989550|NCT03742154|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
47989551|NCT03164928|DRUG|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
47989552|NCT03164928|OTHER|Placebo|SC Q6M placebo
47989553|NCT05899608|BIOLOGICAL|Ivonescimab Injection|Subject will receive ivonescimab and chemotherapy as an IV injection
47989554|NCT05899608|BIOLOGICAL|Pembrolizumab Injection|Subject will receive pembrolizumab and chemotherapy as an IV injection
48357813|NCT02382952|DEVICE|Differential Dissector|
48357814|NCT02382952|OTHER|Standard Dissection Method|
48357815|NCT04257006|DEVICE|oXiris membrane|Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
48506758|NCT06427707|DRUG|Intravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate|Dexmeditomidine (Precedex® 200 mcg.2ml-1) with a rate of 0.2-0.6 mcg.Kg-1.h-1. lidocaine bolus of 1.5 mg.kg-1 followed by infusion with a rate of 1.5 mg.kg-1.h-1 and magnesium sulfate 40 mg.kg-1 loading followed by infusion of 20 mg.kg-1.h-1
48669475|NCT03944850|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
48669476|NCT03435380|BEHAVIORAL|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
48357816|NCT01702402|BEHAVIORAL|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
48357817|NCT01702402|OTHER|Comparison Group|A comparison area received standard government health services.
48669477|NCT03435380|BEHAVIORAL|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
48357818|NCT05613192|DRUG|Cholecalciferol|patients receive the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months.
48357819|NCT03883295|PROCEDURE|Control|The specimens will be root canal treated conventionally
48357820|NCT03883295|PROCEDURE|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
47989555|NCT03508817|DRUG|Atropine Sulfate 0.01% Eye Drops|atropine eye drop in study eye once nightly for two years.
48357821|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
48357822|NCT00753025|PROCEDURE|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
48357823|NCT00753025|PROCEDURE|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
48357824|NCT00278486|BIOLOGICAL|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
48506759|NCT01354379|BIOLOGICAL|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
48506760|NCT01354379|BIOLOGICAL|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
48669478|NCT03435380|BEHAVIORAL|Control|Mailed educational materials.
48669479|NCT00491478|DRUG|sertraline|
48669480|NCT04500145|RADIATION|SIB-IMRT|60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time
48669481|NCT04500145|RADIATION|routine IMRT|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
48669482|NCT05375422|OTHER|SARAH|Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
48669483|NCT05375422|OTHER|Educational intervention|Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
48669484|NCT01688297|BIOLOGICAL|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
48357825|NCT04238286|PROCEDURE|Dry needling|All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
48357826|NCT04003415|DEVICE|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
48357827|NCT04003415|DIAGNOSTIC_TEST|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
48357828|NCT04003415|DIAGNOSTIC_TEST|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
48357829|NCT04003415|DIAGNOSTIC_TEST|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
48506761|NCT04251520|DIAGNOSTIC_TEST|Pharmacogenomics testing|Participants will undergo pharmacogenomics testing and will be asked to provide a one-time buccal scraping. These results will be utilized for clinical treatment decisions.
48669485|NCT01688297|BIOLOGICAL|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
48669486|NCT04391920|DEVICE|CytoSorb 300 mL device|CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
48669487|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
48669488|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
48669489|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
48669490|NCT01564017|BIOLOGICAL|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
48669491|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
48669492|NCT01564017|BIOLOGICAL|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
48669493|NCT04224519|BIOLOGICAL|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
48506762|NCT04251520|OTHER|Pharmacist review|Participants will have their medical information, including patient demographics, problem list, medication list, allergies, and relevant lab work reviewed by a One Point pharmacist. The pharmacist will work with the Palliative Medicine team to make medication related recommendations to improve individual patient care. The pharmacist will call the patient roughly 48 hours following their outpatient consultation or hospital discharge to review the medication list and address any medication-related questions. The pharmacy will send refill reminders to the patients.
48506763|NCT06551571|OTHER|Intrapartum Care Model|- The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations
48506764|NCT01903135|PROCEDURE|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
48669494|NCT04224519|BIOLOGICAL|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
48669495|NCT04224519|BIOLOGICAL|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
48669496|NCT04456907|OTHER|platelet rich plasma|Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.
48146827|NCT03746015|BIOLOGICAL|TDV|TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
48669497|NCT04456907|OTHER|saline injection|saline injection
48688145|NCT05135585|OTHER|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
48688146|NCT05135585|OTHER|Questionnaires|data collection (health data, vaccination data, etc.)
48669498|NCT03140618|OTHER|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
48669499|NCT02040389|BEHAVIORAL|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
48669500|NCT02040389|BEHAVIORAL|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
48669501|NCT03430167|OTHER|home therapy|Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
48669502|NCT03430167|OTHER|formal therapy|Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises
48146828|NCT06049407|BEHAVIORAL|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires. (5) They will answer the follow-up (T3) questionnaires.
48669503|NCT00688597|DRUG|Duvoglustat|Powder in a bottle for dissolution in water for oral administration
48669504|NCT06420206|OTHER|Standard of Care (Acute Cancer Care Center)|In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.
48669505|NCT06420206|OTHER|Standard of Care (Goals of Care)|In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
48669506|NCT00734448|DIETARY_SUPPLEMENT|myo-inositol|2 g twice a day until delivery
47989556|NCT05771233|OTHER|Prevention|"First, an anamnesis is performed to collect information on illnesses, previous and current injuries, medication, sports practice outside of dance, diet, sleep hours and, where appropriate, information on menstruation.~Subsequently, an individual pre-intervention assessment of each participant is carried out, where personal data is collected, motor, elasticity and flexibility, muscle strength and stability tests are performed.~After the initial assessment, group sessions are stablished, divided by classes according to the type of specialty of 6th grade dance. The first session is focused on teaching the different exercises and the importance of muscle strengthening, the subsequent sessions are focused on the correction of the exercises, the resolution of doubts and the incorporation of progressions regarding strength and stabilization.~At the end of the intervention, each participant is re-evaluated and results are compared."
48146829|NCT05352854|DRUG|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
48146830|NCT01999335|DRUG|Oprozomib|Extended release (ER) tablets administered orally
48146831|NCT01999335|DRUG|Pomalidomide|Capsules for oral administration
48146832|NCT01999335|DRUG|Dexamethasone|Tablets for oral administration
48669507|NCT02768207|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
48669508|NCT02768207|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
48669509|NCT00400686|BIOLOGICAL|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
48669510|NCT00097279|DRUG|biphasic insulin aspart|
48669511|NCT00097279|DRUG|pioglitazone|
48669512|NCT00097279|DRUG|metformin|
48669513|NCT05656157|DEVICE|Medical device|Clinical decision support system
48669514|NCT05822414|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
48669515|NCT03501628|DIETARY_SUPPLEMENT|Placebo|Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
48669516|NCT03501628|DIETARY_SUPPLEMENT|L-leucine + maltodextrin|Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
48669517|NCT03501628|DIETARY_SUPPLEMENT|Whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
48669518|NCT03501628|DIETARY_SUPPLEMENT|Hydrolyzed whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
48669519|NCT03501628|DIETARY_SUPPLEMENT|Soy protein concentrate|Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
48146833|NCT05871905|DRUG|TY-9591|C14 TY-9591
48146834|NCT03761199|OTHER|whole body cryostimulation|In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
48146835|NCT01393600|DRUG|NBI-98854|12.5 mg powder in bottle once daily for 14 days
48146836|NCT01393600|DRUG|NBI-98854|50 mg powder in bottle once daily for 14 days
48146837|NCT01393600|DRUG|Placebo|Solution containing no active substance
48146838|NCT01887002|DRUG|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
48669520|NCT01854528|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
47989557|NCT05718895|DRUG|ATG-022|"Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design."
48146839|NCT01887002|DRUG|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
48357830|NCT00827112|DRUG|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
48669521|NCT01854528|DRUG|Ribavirin|Tablet
48146840|NCT01612897|OTHER|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
48669522|NCT01854528|DRUG|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
48669523|NCT01854528|DRUG|Telaprevir|Film-coated tablet
48669524|NCT03963284|PROCEDURE|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
47989558|NCT04422054|PROCEDURE|Open Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
48146841|NCT00651599|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
48669525|NCT03963284|DEVICE|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
48669526|NCT04785209|OTHER|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
48669527|NCT04429464|DEVICE|AcQBlate Force Sensing Ablation Catheter|Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
48669528|NCT04946604|BEHAVIORAL|Ashtangayoga|This is an active and intense type of yoga, focused on physical activity and breath control
48146842|NCT00651599|DRUG|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
48146843|NCT01107509|DRUG|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
48146844|NCT00599625|DRUG|Pravastatin|80mg administered daily for 6 consecutive weeks
48146845|NCT02696109|BEHAVIORAL|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
48146846|NCT02696109|BEHAVIORAL|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
48146847|NCT06593691|OTHER|conventional treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise
48146848|NCT06593691|OTHER|Conventional treatment + multi-wave locked system laser treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise + multi-wave locked system laser treatment
48669529|NCT01814982|DRUG|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
48669530|NCT03555877|DRUG|Ribociclib|Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
48669531|NCT03555877|DRUG|Anastrozole|1mg once daily as indicated in the SmPC
48146849|NCT03754166|OTHER|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
48506765|NCT01903135|PROCEDURE|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
48506766|NCT02871219|DRUG|Lenalidomide|Given PO
48506767|NCT02871219|BIOLOGICAL|Obinutuzumab|Given IV
48669532|NCT03555877|DRUG|Letrozole|2,5mg once daily as indicated in the SmPC
48669533|NCT03555877|DRUG|Exemestane|25mg once daily as indicated in the SmPC
48669534|NCT03555877|DRUG|Fulvestrant|(prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
48669535|NCT00011583|DEVICE|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
47989559|NCT04422054|PROCEDURE|Endovascular Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
48146850|NCT02684136|DRUG|suvorexant|suvorexant 20 mg taken before sleep
48146851|NCT02684136|DRUG|placebo|placebo taken before sleep
48146852|NCT05863676|PROCEDURE|Oophorectomy|Ovary will be removed for fertility preservation.
48669536|NCT00011583|DEVICE|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
48146853|NCT05863676|DIAGNOSTIC_TEST|Infectious Disease Testing|Infectious Disease Testing will be done on participants.
48146854|NCT01079104|DEVICE|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
48146855|NCT01079104|PROCEDURE|Standard Medical Therapy|Standard of care treatment
48146856|NCT05756101|DEVICE|Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery|According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
48146857|NCT06061588|DEVICE|Virtual Reality|The use of virtual reality as an adjunct to routine treatment.
48146858|NCT02560155|DRUG|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
48146859|NCT02560155|DRUG|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
48146860|NCT01163214|DRUG|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
48146861|NCT01163214|DRUG|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
48146862|NCT05159271|DEVICE|Azeol spray nasal|Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
48146863|NCT05159271|DEVICE|Placebo nasal spray|with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
48146864|NCT04112563|PROCEDURE|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
48146865|NCT04112563|PROCEDURE|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
48146866|NCT05214092|BEHAVIORAL|Speech sound stimulation|Participants will listen to repetitive speech sound stimuli, presented through headphones, which will induce a neural response (frequency-following response) to be measured via electroencephalography and pupillometry
48146867|NCT01613599|DRUG|Rituximab|Participants received rituximab at the discretion of their treating physicians.
48357831|NCT00827112|DRUG|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
47989560|NCT00233896|DRUG|Oral beclomethasone dipropionate (drug)|
47989561|NCT00907985|DRUG|Placebo|Single dose of placebo will be provided.
48146868|NCT00002599|BIOLOGICAL|filgrastim|
48146869|NCT00002599|BIOLOGICAL|recombinant interferon alfa|
48146870|NCT00002599|BIOLOGICAL|sargramostim|
48146871|NCT00002599|DRUG|carmustine|
48146872|NCT00002599|DRUG|cyclophosphamide|
48146873|NCT00002599|DRUG|doxorubicin hydrochloride|
48146874|NCT00002599|DRUG|melphalan|
48146875|NCT00002599|DRUG|methylprednisolone|
48146876|NCT00002599|DRUG|prednisone|
48146877|NCT00002599|DRUG|vincristine sulfate|
48146878|NCT00002599|RADIATION|low-LET cobalt-60 gamma ray therapy|
48146879|NCT00002599|RADIATION|low-LET photon therapy|
48357832|NCT00278044|PROCEDURE|blood sampling and medical records|
48357833|NCT04481724|DIETARY_SUPPLEMENT|gamma-linolenic acid|3 capsules per day of GLA for 24 months
48357834|NCT04481724|DIETARY_SUPPLEMENT|placebo|3 capsules per day of placebo for 24 months
48688147|NCT00069134|DIETARY_SUPPLEMENT|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
48688148|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
48688149|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
48688150|NCT02038777|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
47989562|NCT00907985|DRUG|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
48146880|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 500 ml alginate beverage per meal test
48357835|NCT04322266|DRUG|HCP1701|Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium
48357836|NCT04322266|DRUG|HCP1306|Ezetimibe /Rosuvastatin
48357837|NCT04322266|DRUG|HGP0904|Amlodipine
48357838|NCT04322266|DRUG|HGP0608|Losartan potassium
48357839|NCT02815072|OTHER|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
48357840|NCT03698695|DRUG|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
48357841|NCT03698695|DRUG|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
48669537|NCT02112084|BEHAVIORAL|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
48669538|NCT06438991|OTHER|Adjustment of spinal cord stimulation parameters for voluntary motor control|All patients will receive a spinal cord stimulator and undergo adjustment of stimulation parameters for optimal voluntary lower extremity motor control during research visits. Muscle strength will be assessed with the stimulation turned on and off.
48688151|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
47989563|NCT00907985|DRUG|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
48146881|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 330 ml alginate beverage per meal test
48146882|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 500 ml placebo beverage per meal test
48146883|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 330 ml placebo beverage per meal test
48357842|NCT03698695|DRUG|Placebo|Donepezil placebo and Mefloquine placebo
48357843|NCT00945594|DEVICE|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
48357844|NCT00653198|OTHER|No intervention|
48357845|NCT02826083|DIETARY_SUPPLEMENT|XXS|
48357846|NCT02826083|DIETARY_SUPPLEMENT|non-XXS|
48357847|NCT06054594|OTHER|Resistance exercise|After baseline testing, participants followed a progressive resistance training program 3 times a week for 4 months.
48357848|NCT02176226|BEHAVIORAL|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
48357849|NCT02404038|DRUG|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
48357850|NCT02404038|DEVICE|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
48357851|NCT02404038|DRUG|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
47989564|NCT02306629|BIOLOGICAL|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
47989565|NCT02306629|BIOLOGICAL|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
47989566|NCT06161220|DRUG|Carbidopa capsule|Dose: 4x 100 mg
47989567|NCT06161220|DRUG|Moxifloxacin Tablets, USP|Dose: 400 mg
48146884|NCT03717558|DRUG|ivermectin T1|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
48146885|NCT03717558|DRUG|ivermectin T2|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
48146886|NCT03717558|DRUG|ivermectin T3|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
48146887|NCT02593552|DEVICE|DriveCam|Video event monitoring device
48669539|NCT05732064|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
48669540|NCT05732064|DRUG|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
47989568|NCT06161220|DRUG|Placebo|Placebo capsules matching the carbidopa capsules
47989569|NCT03474120|PROCEDURE|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
47989570|NCT03985514|DRUG|Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).|Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
47989571|NCT03985514|OTHER|Active observation|In-hospital observation without antibiotics
47989572|NCT03659981|OTHER|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
47989573|NCT00946426|OTHER|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
47989574|NCT00604331|DRUG|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
47989575|NCT02877823|BEHAVIORAL|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
47989576|NCT02877823|BEHAVIORAL|Control|Healthy Lifestyle Education
47989577|NCT03352986|BIOLOGICAL|biological analysis|biological analysis will be performed in the 6 groups of patients
48357852|NCT03838666|DRUG|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
48357853|NCT03312127|DEVICE|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
48357854|NCT00536458|PROCEDURE|radiotherapy|mini chep+ radiotherapy
47989578|NCT03352986|OTHER|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
48146888|NCT01903954|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
48357855|NCT00536458|DRUG|MINI CHEP|chemotherapy minichep 6 courses
48357856|NCT00645229|DRUG|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
48357857|NCT02952430|PROCEDURE|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
48357858|NCT05507086|OTHER|Antimicrobial therapy|Antimicrobial therapy
48669541|NCT05732064|DRUG|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
48669542|NCT05013814|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
48669543|NCT05013814|DIAGNOSTIC_TEST|Box and Block Test|Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
48688152|NCT02038777|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
47989579|NCT05710107|OTHER|PENG + LFC Block|Subjects assigned to this group will receive PENG + LFC Block
47989580|NCT05710107|OTHER|QL Block|Subjects randomized to this group will receive a QL Block
47989581|NCT00630279|DRUG|Placebo|Placebo
47989582|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
47989583|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
47989584|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
47989585|NCT06209892|PROCEDURE|Extended anticoagulation|This study plan will extend the duration of rivaroxaban 20mg in the experimental group to 12 months. The regular anticoagulation group will take the drug for 6 months
47989586|NCT01541774|DEVICE|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
47989587|NCT05318183|OTHER|Whole Wheat Bread|Standardized whole wheat bread (128 g daily)
47989588|NCT05318183|OTHER|White Bread (control)|Standardized white bread (128 g daily)
47989589|NCT04015245|DRUG|Stronger Neo-Minophagen C|intravenous injection after TACE
47989590|NCT03178747|DIAGNOSTIC_TEST|Methylene blue|working solution methylene blue
48146889|NCT01903954|DRUG|placebo|Orally b.i.d.
48146890|NCT01903954|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
48357859|NCT05612191|DRUG|AL3818|It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
48357860|NCT00421616|BEHAVIORAL|High protein diet study|
48506768|NCT03996629|OTHER|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
48506769|NCT04798131|OTHER|Active neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.
48669544|NCT05013814|DIAGNOSTIC_TEST|9-Hole Peg Test|9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
48669545|NCT05013814|DIAGNOSTIC_TEST|Duruöz Hand Index (DHI)|Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
48669546|NCT05013814|DIAGNOSTIC_TEST|Jamar hand dynamometer|Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
48669547|NCT05013814|DIAGNOSTIC_TEST|Hydraulic pinch gauge|Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
48669548|NCT03738917|DRUG|Dextromethorphan 15 milligrams|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
48669549|NCT03738917|DRUG|Ipratropium Bromide 20Micrograms Inhaler|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
48669550|NCT03738917|DIETARY_SUPPLEMENT|Honey 30 g (full tablespoon)|This study product will be provided free to the participants by the sponsor.
48669551|NCT03738917|OTHER|Usual clinical practice|Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
48669552|NCT00240851|DRUG|acetaminophen extended release|
48669553|NCT03545672|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
48669554|NCT05287243|OTHER|inspiratory muscle training|Participants will complete inspiratory muscle training daily in their homes for 12 weeks. The dosage will depend on their initial maximum pressure. At the end of the 12 week intensive period, participants will reduce the inspiratory resistance by a third and continue a maintenance training for an additional 12 weeks.
48669555|NCT02016521|OTHER|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
48669556|NCT02016521|OTHER|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
48146891|NCT01903954|DRUG|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
48146892|NCT02568059|DRUG|Sahastara remedy alcoholic extract|comparison of different dose of drug
48357861|NCT05086640|OTHER|Lemon foot to prevent blister|The investigators make the hypothesis that the local application of Lemon allows a reduction of the number of blisters on ultra-trail.
48669557|NCT02398331|OTHER|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~* Educational footage~* Clinical neurological examination with educational aim~* Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
48669558|NCT01127620|DRUG|Bilastine|20 mg encapsulated tablets
48669559|NCT01127620|DRUG|Cetirizine|10 mg encapsulated tablets
48669560|NCT01127620|DRUG|Placebo|encapsulated tablets
48669561|NCT00030147|DRUG|Raloxifene|60 mg a day orally administered
47989591|NCT03178747|DIAGNOSTIC_TEST|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
48146893|NCT02264444|OTHER|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
48357862|NCT02136264|OTHER|PCFA interventional dietary counselling|
48357863|NCT02136264|OTHER|conventional DASH diet counselling|
48357864|NCT06481410|DRUG|Methylene Blue Intervention Group|In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
48357865|NCT06481410|DRUG|Normal Saline Control Group|In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
48357866|NCT04083521|DIETARY_SUPPLEMENT|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10\^9 CFU once a day for 90-days.
48357867|NCT00141544|DRUG|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
48357868|NCT00141544|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
48357869|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
48357870|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
48357871|NCT00599144|PROCEDURE|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
48357872|NCT00783263|DRUG|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
48357873|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
48357874|NCT00783263|DRUG|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
48357875|NCT00783263|DRUG|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
48357876|NCT04719533|OTHER|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
48357877|NCT00000151|DRUG|Aspirin|
48357878|NCT00000151|PROCEDURE|Argon Laser Photocoagulation|
48357879|NCT00933387|DRUG|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
48357880|NCT05075434|OTHER|Conventional Treatment|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
48357881|NCT05075434|OTHER|Diacutaneous fibrolysis|"15 minutes of the treatment technique. The FD intervention will be carried out with the same duration and protocol for all participants.~The intervention protocol will be: Start with the point of maximum tension between the two muscle bellies of the calf and hamstring (reverse hook). Then work on the peroneus longus lateralis and soleus. Then the external calf muscle belly and soleus and the internal calf muscle belly and soleus. Then work on the tendon of the flexor hallucis proprio of the big toe and the inner edge of the Achilles tendon and peroneus longus. Then treatment of the peroneus longus with the peroneus brevis. Scraping of the insertion of the Achilles tendon, hooking of the internal and external part of the plantar fascia. Finally, longitudinal friction of the plantar fascia."
48357882|NCT00554840|DRUG|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
47989592|NCT06187610|BEHAVIORAL|Digital education|Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
47989593|NCT04343599|OTHER|Hypopressive exercises|The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
48357883|NCT00554840|DRUG|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
47989594|NCT04320485|DIAGNOSTIC_TEST|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
47989595|NCT02671279|DIETARY_SUPPLEMENT|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
47989596|NCT04682184|DRUG|Propranolol|Administered orally.
47989597|NCT04682184|DRUG|Pseudoephedrine|Administered orally.
47989598|NCT04682184|DEVICE|Wearable Biosensor Patch Device|Biosensor patch device attached to the chest and worn throughout the trial with replacement of biosensor every 7 days.
47989599|NCT05612633|DRUG|zelavespib|Oral zelavespib 100 mg will be administered once daily
47989600|NCT01275833|DEVICE|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
47989601|NCT00606476|DRUG|Bapineuzumab (AAB-001)|IV q13w
47989602|NCT05040854|GENETIC|HLA-DQA1*05 and DRB1|All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1
47989603|NCT01873001|DRUG|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
47989604|NCT01873001|DRUG|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
47989605|NCT02320149|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
47989606|NCT02320149|DRUG|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
48357884|NCT01140464|OTHER|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
48357885|NCT01140464|OTHER|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
48669562|NCT00030147|DRUG|Rimostil|1000 mg twice a day administered orally
48357886|NCT05624892|DIAGNOSTIC_TEST|Mirror Therapy with Virtual Reality Application|Researchers will apply Mirror Therapy with Virtual Reality Application to increase individuals' quality of life and motor sense gains.
48357887|NCT04825106|OTHER|Diagnostic context|A life-threatening situation occurs in 3 different contexts
48357888|NCT04697888|DRUG|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
48357889|NCT01369667|DIETARY_SUPPLEMENT|Vitamin D3|
48357890|NCT01369667|OTHER|Placebo|
48357891|NCT05433064|DEVICE|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
48357892|NCT04387591|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.
48357893|NCT04387591|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (\>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction
48357894|NCT02394366|OTHER|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
48669563|NCT00030147|DRUG|Transdermal Estradiol|100 microgram per day transdermal estradiol
47989607|NCT01883414|DEVICE|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
47989608|NCT02964468|RADIATION|3DCRT treatment (sequential boost)|"Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers."
47989609|NCT02964468|RADIATION|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers."
47989610|NCT04092790|DEVICE|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
47989611|NCT02436356|DEVICE|Osteoprobe-Reference Point Indentation (RPI)|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
47989612|NCT02436356|RADIATION|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
48146894|NCT01217294|PROCEDURE|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
48357895|NCT02394366|OTHER|OHS base only|Olive and beeswax salve base
48357896|NCT04155866|OTHER|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
48357897|NCT01487863|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
48357898|NCT01487863|DRUG|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
48357899|NCT03432585|BEHAVIORAL|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
48506770|NCT04798131|OTHER|Sham neurofeedback procedure|Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
48506771|NCT01827865|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
48506772|NCT01827865|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
48669564|NCT00030147|DRUG|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
48669565|NCT02588885|BEHAVIORAL|Trauma-sensitive Care|"Psychological intervention~1. education~2. empowerment~3. desensitization~4. relaxation tools~Physical therapy intervention~1. techniques to address muscular tension~2. empowerment~3. comfort~4. encouragement of trauma-related coping skills"
48669566|NCT04256525|DRUG|Rivaroxaban 10mg|10mg orally per day
48669567|NCT04256525|DRUG|Aspirin 100mg|100mg orally per day
48357900|NCT02986425|OTHER|STRIP intervention|"The STRIP intervention consists of 9 steps:~1. structured history taking of medication~2. recording medication and diagnoses in STRIPA~3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~5. shared decision-making with the patient with possible adaptation of the recommendation~6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~7. generation of general practioner (GP) report~8. delivery of the report to the patient and to the GP (optional additional direct communication)~9. follow-up"
48357901|NCT02986425|OTHER|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
48357902|NCT02481986|BEHAVIORAL|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
48669568|NCT04256525|DRUG|low molecule heparin|0.4ml per day subcutaneous injection
47989613|NCT02436356|RADIATION|MRI|Determines bound water and pore water of bone.
47989614|NCT03475381|DRUG|Ivacaftor+lumacaftor|1 year follow-up after initiation of ivacaftor+lumacaftor
47989615|NCT00308503|DRUG|eplivanserin (SR46349)|oral administration
48357903|NCT02481986|BEHAVIORAL|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
48357904|NCT02297204|PROCEDURE|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
48357905|NCT02297204|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
47989616|NCT00308503|DRUG|placebo|oral administration
48146895|NCT01217294|PROCEDURE|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
48146896|NCT06364514|OTHER|Clinical Stability Assessment|Base total days of antibiotics on clinical stability vs utilizing predetermined total days of antibiotics
48357906|NCT04093544|DEVICE|Deep brain stimulation|Steered stimulation using directional leads
48357907|NCT02616328|OTHER|No intervention|No intervention administered in this study
48506773|NCT02836210|DEVICE|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
47989617|NCT01331954|DEVICE|Ultrasonic ablation device|One or two HIFU procedures
47989618|NCT06346873|DEVICE|JOGO|AI driven mobile app and wearable sensors to provide virtual treatments
48357908|NCT01685060|DRUG|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
48357909|NCT03066505|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
48357910|NCT03066505|DEVICE|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
48357911|NCT00002986|DRUG|carmustine|
48506774|NCT02977312|DRUG|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
48506775|NCT05326230|DEVICE|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
48506776|NCT05326230|DEVICE|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
48506777|NCT05289973|DEVICE|TruNatomy Files|Newly introduced endodontic file with high flexibility.
48506778|NCT05289973|DEVICE|HyFlex EDM Files|Endodontic files
48669569|NCT00863161|DRUG|AZD3355|capsule, oral, single dose
48357912|NCT00002986|DRUG|topotecan hydrochloride|
48357913|NCT05488028|PROCEDURE|Piezo-electric surgery of impacted lower third molars|"During lower third molar surgery, osteotomy is performed using piezoelectric instrumentation.~When necessary, tooth sectioning was performed with a high-speed tungsten carbide slit drill under saline irrigation and the tooth removed in single or multiple segments."
48357914|NCT05488028|PROCEDURE|Rotary bur surgery of impacted lower third molars|During lower third molar surgery, osteotomy is performed using rotary instruments
47989619|NCT00947479|OTHER|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
47989620|NCT00090311|DRUG|quetiapine fumarate|
48357915|NCT01597934|DRUG|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
48669570|NCT00558818|DRUG|Clevudine|clevudine 30 mg qd
48669571|NCT05457595|RADIATION|carbon ion radiation therapy|"CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted."
48669572|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
48669573|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
48669574|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
47989621|NCT05714956|BEHAVIORAL|Mothers and Babies Online (eMB)|"This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention."
48357916|NCT01597934|DRUG|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
48357917|NCT00523172|PROCEDURE|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
48357918|NCT00523172|PROCEDURE|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
47989622|NCT01840709|BEHAVIORAL|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
47989623|NCT06120556|DRUG|GLP-1 receptor agonist|Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
47989624|NCT05284669|OTHER|Experimental e-learning|Interactive lecture based on the guidelines for the management of LBP with a focus on self-management and patient's reassurance
47989625|NCT05284669|OTHER|Traditional e-learning|Traditional lecture based on the guidelines for the management of LBP with a focus on diagnostic triage and specific cause of LBP
47989626|NCT00417807|DRUG|Imatinib mesilate|
47989627|NCT03711487|DRUG|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
47989628|NCT00560950|BIOLOGICAL|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
47989629|NCT02808026|DRUG|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
47989630|NCT02068586|DRUG|Sunitinib|Given PO
47989631|NCT02068586|DRUG|Valproic Acid|Given PO
47989632|NCT02068586|DRUG|Sunitinib Malate|Given PO
47989633|NCT02068586|DRUG|Sunitinib Malate + Valproic Acid|Given PO
47989634|NCT01184625|OTHER|Physical Exercise|12 weeks of physical exercise.
48357919|NCT00523172|PROCEDURE|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
48357920|NCT05953129|DIAGNOSTIC_TEST|Right Jugular Vein Collapsibility Index|Ultrasonography will be used to evaluate the diameter of the jugular vein (minimum and maximum values) and carotid diameter. The jugular vein collapsibility index will be measured by the anesthesiologist using non-invasive ultrasonography. Jugular vein collapsibility index will be calculated using the measured diameters.
48357921|NCT02365324|BEHAVIORAL|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
48357922|NCT02365324|BEHAVIORAL|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
48357923|NCT02765191|OTHER|Plasma expansion with Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 5-10 minutes will be administered intravenously
48357924|NCT02931955|OTHER|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
47989635|NCT05224674|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
48357925|NCT02160639|OTHER|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
48357926|NCT02462200|PROCEDURE|Breast-conserving surgery (BCS)|
48357927|NCT02462200|PROCEDURE|Cavity shave margins (CSM)|
48357928|NCT02462200|BEHAVIORAL|BREAST-Q Questionnaire|
48506779|NCT06552013|OTHER|MERV 13 filter|This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.
47989636|NCT04234035|BEHAVIORAL|Decision Aid|Decision aid to facilitated shared decision-making
47989637|NCT04234035|OTHER|Standardized Educational Material (informational pamphlet)|Pamphlet with information about kidney stones
47989638|NCT00660530|DRUG|Lanthanum Carbonate Chewable Product|Lanthanum carbonate 1 g to be chewed, three times daily with meals
47989639|NCT00660530|DRUG|Lanthanum carbonate crushed powder|Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
48146897|NCT03925909|DIETARY_SUPPLEMENT|Eriocitrin|The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
48146898|NCT00648895|DRUG|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
48146899|NCT00648895|DRUG|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
48357929|NCT02462200|DEVICE|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
48357930|NCT02462200|OTHER|Indocyanine green|
48357931|NCT02462200|DEVICE|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
48357932|NCT02462200|PROCEDURE|Peripheral blood draw|-Time of surgery if coordinator is available
48357933|NCT02882451|DIETARY_SUPPLEMENT|pinaverium bromide|
48357934|NCT02882451|DIETARY_SUPPLEMENT|Vitamin C|
48357935|NCT02010567|DRUG|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
48146900|NCT05868356|DRUG|Treatment A|Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
48357936|NCT02010567|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
48357937|NCT02010567|RADIATION|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if \<T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
48669575|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
48669576|NCT01425814|DRUG|Reference|Dry powder inhalation (capsule),single dose
48146901|NCT05868356|DRUG|Treatment B|Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
48357938|NCT02010567|PROCEDURE|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
48357939|NCT04990999|PROCEDURE|Vestibular Root Extraction|a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
48357940|NCT04990999|PROCEDURE|Atraumatic extractions using periotomes followed by conventional forceps|a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
48357941|NCT06376812|BEHAVIORAL|Physical activity intervention|Physical activity
48357942|NCT01183728|OTHER|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
48357943|NCT00095134|DRUG|risperidone|
48357944|NCT04748250|DEVICE|Acupuncture needles|Standard acupuncture needle which is 3 cm long with diameter o.3 mm
48357945|NCT04748250|DIETARY_SUPPLEMENT|Soy phytoestrogens|100 millilitre of soy milk every day or 100 gram of cooked soy beans per day.
48357946|NCT04808167|DEVICE|autoRIC®|The autoRIC device will be modified by the company from the standard cuff inflation of 200 mmHg to 180 mmHg for the purposes of this study. Three cuff sizes are available from the company: small, medium, and large, correlating to standard adult cuff sizes. The remote ischemic preconditioning cycles will be performed daily by trained research personnel during the preparative regimen through day 0 (see Figure 1), defined as transplantation of stem cells (last preconditioning cycle on day -1). A control group will undergo a similar procedure, however, the cuff will not be inflated.
48357947|NCT04249791|PROCEDURE|Transplantation of the uterus from live donor.|Laparoscopic-robotic hysterectomy for uterine transplantation in live-donor patient.
48357948|NCT03006276|DRUG|DFN-15 Active|
48357949|NCT03006276|OTHER|DFN-15 Placebo|
48669577|NCT01425814|DRUG|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
48688153|NCT02038777|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
48688154|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
48688155|NCT02038777|DRUG|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
48688156|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
48688157|NCT02038777|DRUG|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
48669578|NCT02930148|OTHER|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
48669579|NCT04477616|DRUG|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
48669580|NCT04477616|DRUG|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
48669581|NCT06467682|OTHER|tele-exercise|The 12-week tele-exercise program will be performed and supported via the USTEP digital platform, with each patient taking part in 3 training sessions per week with a 60-min duration period per training session. There will be personalized training sessions: i) warm-up and warm-down, ii) aerobic exercise, and iii) strength exercises. All tele-exercise program participants, will use wearable-based tracking to assessment the cardio-oxygenation.
48669582|NCT05703230|OTHER|Structured preoperative multidisciplinary team meeting|"The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~* Is the proposed surgical intervention appropriate care for the patient?~* Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~* Should the patient's condition be optimized before undergoing the proposed surgical intervention?"
48669583|NCT06368570|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery with neuraxial anesthetic
48669584|NCT06089993|OTHER|Exercise|"The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
48669585|NCT06089993|OTHER|Rest|"The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
48146902|NCT03542604|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
48146903|NCT03542604|BEHAVIORAL|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
48506780|NCT06552013|OTHER|Sham filter|This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
47989640|NCT00664742|DRUG|Fluvastatin XL®|Fluvastatin extended release 80 mg
47989641|NCT01948128|DRUG|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
48357950|NCT04627805|BEHAVIORAL|MyPath tool|MyPath is a reproductive decision support tool that utilizes a patient-centered approach to help women frame their reproductive decisions in the context of their goals, preferences, and health needs. This tool was developed by Dr. Lisa Callegari with funding from the Veterans Administration (VA) Health Services Research \& Development to be used in primary care settings with women veterans. It is conceptually grounded in Self-Determination Theory, which postulates that health care that meets patients' psychological needs in three key domains - autonomy, competence, and relatedness - will result in improved health behaviors and health outcomes. This is particularly relevant in reproductive health care, given the highly individualized and personal nature of these decisions, and the importance of centering a woman's aspirations and goals in her health care decision making.
48669586|NCT03060902|BEHAVIORAL|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
48146904|NCT02010684|BEHAVIORAL|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
48146905|NCT04151030|PROCEDURE|PEG placement|Push PEG placement
48357951|NCT02765854|DRUG|Dexamethasone|Given PO
48357952|NCT02765854|DRUG|Ixazomib|Given PO
48357953|NCT02765854|DRUG|Lenalidomide|Given PO
48669587|NCT01126957|DRUG|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
48669588|NCT01126957|DRUG|Placebo|Placebo given as an bolus to control group.
48669589|NCT01126957|DRUG|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
48669590|NCT01126957|DRUG|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
48357954|NCT00968929|DRUG|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
48357955|NCT00968929|DRUG|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
48357956|NCT03165799|BEHAVIORAL|Mindfulness Education|Mindfulness Education
48669591|NCT04753775|DRUG|Aloe vera gel|
47989642|NCT01948128|OTHER|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
47989643|NCT05945654|PROCEDURE|Anastomotic Leak after Ivor Lewis Oesophagectomy|Surgical resection of the esophagus with oesophagogastrostomy. Groups depend on postoperative complication
47989644|NCT06069973|OTHER|No intervention, observational study|No intervention
47989645|NCT01144442|DRUG|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
48357957|NCT00312728|DRUG|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
48669592|NCT00077974|DRUG|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
48669593|NCT05406973|DEVICE|SBK microkeratome versus femtosecond laser in flap creation|prospective comparative non randomized interventional clinical study
48669594|NCT02250248|BIOLOGICAL|AttraX Putty|
48669595|NCT02250248|OTHER|Iliac Crest Bone Graft (ICBG)|
48669596|NCT01752218|DEVICE|arcuate incision|
48669597|NCT03139058|OTHER|Evaluation of the hepatic fibrosis|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
48669598|NCT02234765|OTHER|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
48669599|NCT02234765|OTHER|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
48669600|NCT04405817|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
48669601|NCT00071955|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
48669602|NCT00071955|BIOLOGICAL|sargramostim|
47989646|NCT01144442|OTHER|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
48146906|NCT02173990|DRUG|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
48146907|NCT03763162|DRUG|Bortezomib|Given SC
48146908|NCT03763162|BIOLOGICAL|Daratumumab|Given IV
48146909|NCT03763162|DRUG|Dexamethasone|Given IV or PO
48146910|NCT03763162|DRUG|Ixazomib|Given PO
48146911|NCT03763162|OTHER|Quality-of-Life Assessment|Ancillary studies
48146912|NCT01065779|DRUG|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
48146913|NCT01065779|DRUG|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
48669603|NCT04650581|DRUG|Ipatasertib|400 mg PO QD days 1-21 every 28 days
48669604|NCT04650581|DRUG|Fulvestrant|500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
48669605|NCT04650581|OTHER|Placebo|PO QD days 1-21 every 28 days
48669606|NCT03493646|DRUG|Azacitidine|75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
47989647|NCT01144442|PROCEDURE|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
47989648|NCT01144442|DRUG|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
47989649|NCT01144442|DRUG|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
48146914|NCT02743039|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
48146915|NCT02917148|OTHER|Peripheral Venipuncture or Blood draw from Central Line|
48146916|NCT04222088|DRUG|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
48146917|NCT04222088|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
48146918|NCT04222088|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
48357958|NCT00312728|DRUG|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
48357959|NCT00312728|DRUG|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
48669607|NCT03493646|DRUG|CC-486|100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
48669608|NCT02681393|BEHAVIORAL|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
48669609|NCT02681393|BEHAVIORAL|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
48669610|NCT04931238|DRUG|JS016|Single Intravenous Injection of JS016 with a dose of 50mg/kg
48146919|NCT02718885|DIETARY_SUPPLEMENT|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
48146920|NCT02718885|DIETARY_SUPPLEMENT|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
48146921|NCT01490047|DRUG|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
48146922|NCT01490047|DRUG|Liposomal doxorubicin|Infusion over 60 minutes
48669611|NCT01150292|DIETARY_SUPPLEMENT|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
48669612|NCT01150292|DIETARY_SUPPLEMENT|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
48669613|NCT06098326|DRUG|cyclophosphamide, fludarabine, and antithymocyte globulin|"1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)"
48669614|NCT00147576|DRUG|CP-866,087|
48669615|NCT01282073|DRUG|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
47989650|NCT06018714|DRUG|Fruquintinib|"Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules."
47989651|NCT02474992|BEHAVIORAL|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
47989652|NCT02047357|OTHER|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
48357960|NCT04834258|OTHER|Walking and respiratory training|"Walking and respiratory muscle training group ( W+ RMT) received walking training in addition to respiratory muscle training for a period of 8 weeks.~Walking training was performed at least 5 days a week, twice a day, for 15 min. Walking distance was calculated according to patients' 6 minute walking distance.~Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training.~Patients were called for the hospital once a week to asses mouth pressure and 6 minute walking test (6 MWT) and their training intensity was arranged"
48357961|NCT04834258|OTHER|Respiratory muscle training|In the Respiratory muscle training group, Respiratory muscle training was performed using the threshold loading method as inspiratory and expiratory muscle training. This training was applied at least 5 days per week, twice a day, 15 minutes each session. (15 minutes inspiratory muscle training + 15 minutes expiratory muscle training). A Threshold Inspiratory Muscle Trainer (IMT) and threshold positive expiratory pressure (Threshold PEP) were used for the training. Patients were called for the hospital once a week to asses mouth pressure and their training intensity was arranged.
47989653|NCT02702440|OTHER|Liquid calories from sugars|
48669616|NCT01282073|DRUG|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
48357962|NCT05504018|PROCEDURE|ACL reconstruction|Anterior cruciate ligament reconstruction surgery
48146923|NCT01490047|DRUG|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
48357963|NCT00543842|DRUG|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
48357964|NCT00543842|DRUG|Capecitabine|Starting Dose 650 mg/m\^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
48357965|NCT00543842|DRUG|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
48357966|NCT00543842|RADIATION|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
48357967|NCT00543842|PROCEDURE|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
48357968|NCT02261246|PROCEDURE|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
48357969|NCT01678794|DRUG|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
48669617|NCT06161584|DRUG|Pegcetacoplan|Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
48669618|NCT03807089|DEVICE|Conventional Pediatric Colonoscope|
48357970|NCT01678794|DRUG|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
48357971|NCT00928499|DEVICE|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
48357972|NCT01468844|DRUG|Minocycline|100 mg pink opaque capsule
48669619|NCT03807089|DEVICE|Short-Turn Radius Colonoscope|
48669620|NCT02175186|DRUG|ALBIS|
48357973|NCT01468844|DRUG|Placebo|Placebo
48357974|NCT01468844|DRUG|Bevacizumab|1.25 mg bevacizumab injection
48669621|NCT02175186|DRUG|Placebo|
48669622|NCT00444314|DRUG|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
48669623|NCT00444314|DRUG|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
48669624|NCT02066649|DRUG|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
48669625|NCT02066649|PROCEDURE|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
48669626|NCT02199041|DRUG|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
48146924|NCT01490047|DRUG|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
48506781|NCT03398070|OTHER|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~1. delivery of a rule-in diagnosis~2. providing educational materials~3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~4. referring to FND-related cognitive behavioral therapy (CBT)~5. psychotropic medication management based on standard psychiatric care"
47989654|NCT01482754|DRUG|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
47989655|NCT01832870|DRUG|sipuleucel-T|
48146925|NCT00115167|DRUG|Placebo|Q4W
48146926|NCT00115167|DRUG|Darbepoetin alfa|Q4W
48146927|NCT05508477|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
48146928|NCT05508477|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
48146929|NCT06478979|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).
48146930|NCT04140526|DRUG|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
48146931|NCT04140526|DRUG|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
47989656|NCT01832870|DRUG|ipilimumab|
48146932|NCT04140526|DRUG|Docetaxel|Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).
47989657|NCT03674242|DRUG|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
48146933|NCT05596916|OTHER|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
48146934|NCT05596916|OTHER|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
48146935|NCT04418609|OTHER|further processing of health data|further processing of biological materials and health related personal data for research
47989658|NCT03674242|DRUG|Gemcitabine|IV infusion 1000 mg/m2
48146936|NCT00523458|DRUG|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
48357975|NCT06250933|OTHER|Postpartum Maternal Care and Premature Infant Care Training|"Intervention groups of women will receive a single-session intervention program in addition to their routine care.~The intervention, conducted in a single session, encompasses the provision of an educational program designed to enhance women's breastfeeding and maternal self-efficacy and mitigate the risk of postpartum depression.~During the educational phase, women will receive training on postpartum maternal care and premature infant care"
48357976|NCT03021707|DEVICE|WaveLight® Ultraviolet Femtosecond (FS) Laser System|Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
48357977|NCT03021707|PROCEDURE|Laser Assisted Lenticular Extraction|Used for refractive error correction
48357978|NCT01295632|DRUG|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
48357979|NCT01295632|DRUG|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
48669627|NCT02199041|DRUG|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
48669628|NCT02199041|DRUG|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
48669629|NCT02199041|DRUG|Melphalan|Given by intravenous infusion as part of the preparative regimen.
48669630|NCT02199041|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
47989659|NCT03674242|DRUG|Carboplatin|IV infusion AUC2
47989660|NCT00150839|DRUG|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
47989661|NCT00150839|DRUG|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
47989662|NCT00373867|BEHAVIORAL|Standard physical therapy|Treatment-based classification physical therapy
47989663|NCT00373867|BEHAVIORAL|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
48146937|NCT04150016|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
48146938|NCT05637684|DEVICE|low intensity pulsed ultrasound|mechanical sound waves
48506782|NCT04727047|DEVICE|neuromuscular electrical stimulation|All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
47989664|NCT00373867|OTHER|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
47989665|NCT04674384|DIETARY_SUPPLEMENT|Optifast meal replacement shakes|Optifast® is provided as 53g sachet. Each sachet replaces one meal. It is available in 5 flavours: vanilla, strawberry, chocolate and coffee shakes and vegetable soup.
48146939|NCT01532609|BEHAVIORAL|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
48146940|NCT05159427|DRUG|Glucotrol XL 5Mg Extended-Release Tablet|Participants are randomized to take one tablet of this study drug by mouth.
48146941|NCT05159427|DRUG|Glipizide ER 5 MG 24 HR Extended Release Oral Tablet|Participants are randomized to take one tablet of this study drug by mouth.
48146942|NCT05159427|DRUG|Rifaximin 200Mg Tab|Participants will take one tablet of this study drug by mouth.
48357980|NCT01295632|DRUG|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
48146943|NCT05159427|DRUG|13C6-Glipizide|Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
48357981|NCT00775138|DRUG|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
48146944|NCT06330701|DEVICE|Robotic-assisted mini-PCNL|This robotically enabled hybrid procedure called the MONARCH Mini-PCNL will allow the clinician to obtain retrograde and percutaneous access to participant's kidney under continuous visualization for therapeutic applications (i.e., stone removal).
48146945|NCT02697656|BEHAVIORAL|IPS|Individualized job support provided by an employment specialist
48146946|NCT02697656|BEHAVIORAL|Self-help|Self-help resources on obtaining employment and coping with chronic pain
48146947|NCT02697656|BEHAVIORAL|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
48146948|NCT04466735|DIETARY_SUPPLEMENT|Active group|2 x 12 g of EKS/day
48357982|NCT00775138|DRUG|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
48506783|NCT00000693|DRUG|Zidovudine|
48506784|NCT00000693|DRUG|Acyclovir|
48146949|NCT04466735|DIETARY_SUPPLEMENT|Placebo group|Isocaloric placebo supplement with similar salt load but no EKS
48146950|NCT05073393|BEHAVIORAL|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
48146951|NCT05967845|PROCEDURE|cartilage tympanoplasty|cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.
48146952|NCT05967845|PROCEDURE|platelet rich fibrin augmented tympanoplasty|platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
48146953|NCT02089425|DRUG|K-103-IP|
48146954|NCT02089425|DRUG|Placebo|Placebo comparator
48357983|NCT00775138|DRUG|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
48506785|NCT04864314|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start
48669631|NCT02199041|BIOLOGICAL|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) \>2000 for 3 consecutive days.
47989666|NCT05109988|BEHAVIORAL|Breastfeeding telephone support|The intervention consists of four weekly 20-30 minutes telephone-administered counselling sessions on breastfeeding, delivered individually in the first month postpartum for mothers and fathers.
48357984|NCT00775138|DRUG|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
48357985|NCT00106496|DRUG|Protopic|topical
47989667|NCT03984604|DRUG|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
48357986|NCT00106496|DRUG|Corticosteroid|topical
48357987|NCT00106496|DRUG|placebo|topical
48357988|NCT00138853|DEVICE|Tibial component|Tibial component inserted at the time of surgery
48357989|NCT04569890|DRUG|Certolizumab Pegol 200 MG/ML [Cimzia]|CZP 200mg twice a week subcutaneous.
47989668|NCT03984604|DRUG|Placebo|Placebo is a vehicle oil will match CHI-921
48357990|NCT04569890|DRUG|Hydroxychloroquine|400mg HCQ orally daily
48357991|NCT04569890|DRUG|Prednisone|10mg GC orally daily
48357992|NCT05021666|DRUG|Placebo|matching placebo
48357993|NCT05021666|DRUG|PB 718|dose in the next group will be determined following a review of data from the previous group
48357994|NCT00003684|DRUG|theophylline|
48357995|NCT00003684|PROCEDURE|quality-of-life assessment|
48146955|NCT04936048|BEHAVIORAL|Music Therapy|Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.
48146956|NCT04936048|BEHAVIORAL|Play therapy|Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.
48146957|NCT02815800|DIETARY_SUPPLEMENT|ETHNODYNE VISIO|
48146958|NCT05485025|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
48146959|NCT05485025|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
48146960|NCT04540926|DRUG|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
48357996|NCT04377399|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (40,000 IU weekly) or low dose vitamin D (5,000 IU weekly) for 24 weeks
48357997|NCT03444246|DIETARY_SUPPLEMENT|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
48506786|NCT04864314|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start
48506787|NCT03333044|BEHAVIORAL|Community Health Worker (CHW)-led health|Patients contacted a maximum of 10 times over 2 weeks to attend diabetes management sessions led by community health workers. Enrolled patients attend 5 Monthly group sessions led by a CHW held at the clinic
48506788|NCT03333044|BEHAVIORAL|HIT-enabled|During one on one visit, CHWs will assess social needs of patients using mobile technology. CHWs will give referral sources to patients generated by mobile app, and they will track through mobile app.
48506789|NCT03333044|BEHAVIORAL|Physician enabled care coordination|Forms on patient goal setting and referrals made are uploaded into EHR to physician
48506790|NCT03670290|PROCEDURE|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
48506791|NCT03670290|PROCEDURE|epidural catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
48506792|NCT03670290|PROCEDURE|patient controlled analgesia|Patient will evaluate and if VAS score \>3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
48506793|NCT06505447|OTHER|Daytime light exposure|Participants will be exposed to a 10,000 lux light source within 3 feet of their face/eyes to promote the natural circadian rhythm for 2-3 hours from 10am to 12/1pm depending on their nap time at home
48506794|NCT06505447|OTHER|Daytime restricted feeding|Participant's nutrition, parenteral or enteral, will be restricted to the hours when they are normally awake at home.
48506795|NCT06633432|OTHER|Acupuncture|Administer medication at each acupoint a total of three times: (1) the night before surgery, (2) the night of surgery, and (3) the first night after surgery. In the acupuncture group, the acupuncture and moxibustion successively acupunctured four points with a depth of 10-20mm. Select the specific depth based on the subject\&#39;s body type (tall, short, fat, thin). After the puncture, the acupuncture and moxibustion lifted and twisted the needle handle, and then retained the needle for 20 minutes.
48506796|NCT06633432|OTHER|Sham-acupuncture stimulation|The sham acupuncture group received non skin breaking comfort needles at the corresponding points for acupuncture and moxibustion and retained the needles for 20 minutes. Non transdermal comfort needles can cause patients to experience a needle like sensation similar to piercing the skin, but in reality, they do not break the skin.
48506797|NCT04182282|BEHAVIORAL|CARES Dementia-Friendly Hospitals Online Training and Certification Program|The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
48506798|NCT04592835|DRUG|DWRX2003|"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"
48506799|NCT00801099|DRUG|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
48506800|NCT05261295|DIAGNOSTIC_TEST|PEEP|PEEP of 7 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
48506801|NCT05261295|DIAGNOSTIC_TEST|ZEEP|PEEP of 0 cmH2O will be applied 5 minutes after classical LMA or i-gel insertion.
48506802|NCT03791723|DRUG|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
48506803|NCT03791723|DRUG|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
48506804|NCT03675230|DEVICE|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
48506805|NCT03675230|DEVICE|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
48357998|NCT03444246|DIETARY_SUPPLEMENT|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
48506806|NCT01328665|OTHER|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
48669632|NCT02199041|DRUG|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
48146961|NCT02399111|DEVICE|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
48146962|NCT03005106|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
48146963|NCT03005106|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
48146964|NCT05756569|PROCEDURE|Biospecimen Collection|Undergo collection of blood
47989669|NCT06442514|BEHAVIORAL|PASS-IVR|An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls to report smoking status, pain, and pedometer-measured step counts, which the clinician will use to provide individualized feedback.
48146965|NCT05756569|PROCEDURE|Computed Tomography|Undergo CT
48506807|NCT02556229|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
48506808|NCT06621004|DRUG|Patients will receive propranolol 1-2 mg.|Patients will receive propranolol 1-2 mg. prepared in a 10 ml syringe (100 ug/ml).
48506809|NCT06621004|DRUG|Patient receives magnesium sulphate|Magnesium sulphate 10%: 1g ampoule (10ml), will be prepared in a syringe pump to be given at a rate of 40 ml/hr . Another syringe of 10 ml 0.9% sodium chloride will be prepared to be given in group (P).
48506810|NCT04702308|OTHER|Clinical Decision Rule Alerts|The
48506811|NCT04496115|BEHAVIORAL|Mindfulness|Mindfulness training
47989670|NCT06442514|OTHER|Treatment as Usual|Referral to the local smoking cessation VA clinic.
47989671|NCT05241522|DIAGNOSTIC_TEST|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
48357999|NCT06028178|DIAGNOSTIC_TEST|Droplet digital PCR|Droplet digital PCR has potential in resolving polymicrobial infection because it simultaneously achieves unprecedented high sensitivity , high specificity, and absolute quantification without the need for a standard curve.
48358000|NCT01156012|DRUG|T2345|One drop of T2345
48358001|NCT01156012|DRUG|Prostaglandin|One drop
48358002|NCT00757354|PROCEDURE|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
48506812|NCT06551441|BEHAVIORAL|High Intensity Interval Training (HIIT)|"The HIIT intervention consist of 4 intervals with each lasting 4 minutes (4x4min). If a participant reports discomfort related to the length of the intervals or start to feel unmotivated by performing the same exercise, we will use another HIIT protocol: 10x1min.~The 4x4min HIIT consists of a warm-up period of 10 minutes with a target heart rate at 60-70% of HRmax, followed by 4 HIIT intervals with a target HR ≥85%. The intervals are separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following this, a cool down period of three minutes at warm up intensity is performed.~The 10x1min HIIT consists of a 10-minute warm-up period.The warm-up is followed by 10 intervals, each lasting 1 min at 100% of maximal workload, separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following the intervals, a cool down period of three minutes at warm up intensity is performed."
48506813|NCT06370286|BEHAVIORAL|concurrent exercise (CE)|Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
47989672|NCT04132960|DRUG|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
47989673|NCT04778189|DRUG|Placebo|while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
47989674|NCT04778189|DRUG|i.v dexmethasone|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
47989675|NCT03972280|BIOLOGICAL|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
48146966|NCT05756569|DRUG|Enfortumab Vedotin|Given IV
48146967|NCT05756569|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48146968|NCT05756569|BIOLOGICAL|Pembrolizumab|Given IV
48146969|NCT05756569|OTHER|Questionnaire Administration|Ancillary studies
48146970|NCT00162409|DRUG|Folic acid|
48146971|NCT01924117|OTHER|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
48146972|NCT06342128|OTHER|No intervention|No intervention
48358003|NCT06145438|DRUG|Dienogest|Drug is administered orally at the same time every day
48358004|NCT06145438|DRUG|Depo Medroxyprogesterone acetate|Drug is injected intramuscularly on the buttock
48506814|NCT06370286|BEHAVIORAL|aerobic exercise (AE)|Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve \[HRR\]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
48506815|NCT04222972|DRUG|Pralsetinib|Administered orally
48358005|NCT06145438|DRUG|Leuprolide (as Leuprolide Acetate)|Drug is injected intramuscularly on the buttock
48669633|NCT02199041|DRUG|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
48669634|NCT02199041|DRUG|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
48669635|NCT02199041|RADIATION|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
48506816|NCT04222972|DRUG|Carboplatin|Administered IV
48506817|NCT04222972|DRUG|Cisplatin|Administered IV
48669636|NCT02199041|BIOLOGICAL|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
48358006|NCT06145438|DRUG|Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)|Drug is administered orally at the same time every day
48358007|NCT02638363|BEHAVIORAL|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
48358008|NCT02802735|DRUG|Apremilast|Tablet for oral administration
48358009|NCT02802735|DRUG|Placebo|Tablet for oral administration
48506818|NCT04222972|DRUG|Pemetrexed|Administered IV
48506819|NCT04222972|DRUG|Pembrolizumab|Administered IV
48506820|NCT04222972|DRUG|Gemcitabine|Administered IV
48669637|NCT02199041|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
48669638|NCT02916316|DRUG|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
48669639|NCT01465009|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
48358010|NCT02324049|DRUG|SBC-103|
48358011|NCT02504606|DRUG|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
48506821|NCT04222972|DRUG|Paclitaxel|Administered IV
48506822|NCT04222972|DRUG|Nab-Paclitaxel|Administered IV
48506823|NCT05156905|DRUG|Cirmtuzumab|Cirmtuzumab will be given in combination with docetaxel.
48506824|NCT06633900|DRUG|IM naltrexone|The study drug is an intramuscular injection of naltrexone (380mg), administered every 4 weeks via an injection in the ventrogluteal region.
48506825|NCT06633900|BEHAVIORAL|Usual Care|Participants assigned to usual care will receive a harm reduction bundle in clinic. It will include the following components: 1) intranasal naloxone 4mg x 2, 2) participant choice of safer consumption kits based on substances and route used (specific materials for inhaled use vs. injecting, based on common use practices in the region), 3) fentanyl test kits with 2 lateral flow assays per package along with instructions to minimize false positive results, and 4) information about universal overdose precautions (behavioral modifications to optimize safety like using in the presence of others, use a test dose of new substances, etc.)
48506826|NCT06374797|DRUG|Auxora|1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
48506827|NCT06374797|DRUG|Placebo|1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
48506828|NCT05055050|DRUG|UGN-201|Intravesical 200 mg /50 ml x 1 dose
48669640|NCT01465009|DRUG|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
48669641|NCT01465009|DRUG|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
48669642|NCT02007304|BEHAVIORAL|Eccentric exercise training|12 weeks of lower leg eccentric training
48358012|NCT02504606|DRUG|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
48358013|NCT04847167|PROCEDURE|Single balloon enteroscopy assisted ERCP using a mechanistic loop resolution strategy group|The SBE was introduced alternately with an overtube apparatus (ST-SB1S; Olympus Corp., Japan) following the mechanistic loop resolution strategy under endoscopic and fluoroscopic guidance. The overtube was advanced along the enteroscope, by gently pulling the enteroscope, like as ERCP accessory advancement over the guidewire.
48358014|NCT03441516|DRUG|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
48358015|NCT03441516|DRUG|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
48358016|NCT02299128|OTHER|Physical Therapy Treatment|
48358017|NCT04545086|BEHAVIORAL|Video Based Education, Music Therapy|Video Based Education and Music Therapy was given as a part of Interventions to relieve anxiety of patients undergoing Magnetic Resonance Imaging
47989676|NCT05098860|OTHER|Home Exercise Program|Educational training program includes active stretching, strengthening, and stabilization exercises of head and neck muscles as well as relaxation and breathing exercises.
48669643|NCT01434004|BEHAVIORAL|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
48146973|NCT06041438|DRUG|BI 1584862|BI 1584862
48358018|NCT02030457|DRUG|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
48669644|NCT03759496|BIOLOGICAL|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
48669645|NCT00216281|DRUG|Clozapine augmented with atomoxetine up to 40 mg or placebo|
48669646|NCT04834921|DEVICE|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
48669647|NCT02004301|DRUG|Radiolabelled T4 Tablet|
48669648|NCT02004301|DRUG|Radiolabelled T6 Tablet|
48669649|NCT03346525|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
47989677|NCT05098860|OTHER|Manual Therapy Combined with Home Exercise Program|Manual Therapy program includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae.
47989678|NCT05098860|OTHER|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. Patients will apply active cervical and thoracic region mobilizations called self-mobilization.
47989679|NCT06241339|OTHER|Mat Pilates|"Mat Pilates training will last 12 weeks, with three weekly trial sessions being held at 48-72h intervals. Each session will last approximately 60 minutes, including: 5 minutes of warm-up (light calisthenic exercises for the shoulder and pelvic girdles); 50 minutes of Mat Pilates exercises; 5 min back to calm.~Upon arriving at the training site, volunteers will rest for 10 minutes in a sitting position, after which BP measurements will be taken and HR at rest. Throughout consecutive training sessions, participants will perform Pilates method exercises with a progressively greater degree of difficulty and complexity, following the official recommendations for prescription of resistance exercise for individuals with BP elevated and post-stroke. The exercises will be performed in single sets of 10 repetitions. Groups will be advised to maintain daily activities without physical exercise during the 12-week period."
47989680|NCT01994629|BIOLOGICAL|MenACWY-CRM|MenACWY-CRM
47989681|NCT01994629|BIOLOGICAL|MenACWY-TT|MenACWY-TT
48358019|NCT02030457|DRUG|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
48358020|NCT06447935|OTHER|No intervention|not applicable - no intervention required
48358021|NCT02258516|BEHAVIORAL|CHIME 3-M|behavioral intervention for self-management in heart failure
47989682|NCT03929718|DRUG|Spironolactone|receive spironolactone treatment after CTI ablation
47989683|NCT03929718|DRUG|No Spironolactone|no spironolactone treatment
48146974|NCT06041438|DRUG|itraconazole|itraconazole
48146975|NCT01366352|DRUG|MNTX tablet (Formulation 1)|
48146976|NCT01366352|DRUG|MNTX tablet (Formulation 2)|
48146977|NCT01794689|DRUG|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
48146978|NCT01794689|DRUG|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
48146979|NCT01794689|BEHAVIORAL|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
48358022|NCT02258516|BEHAVIORAL|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
48358023|NCT03421236|BIOLOGICAL|Ty21a|intravesical administration of Ty21a
48669650|NCT01627691|DEVICE|Lotus Valve System|"* bioprosthetic bovine pericardial aortic valve~* delivery system"
48358024|NCT00812591|PROCEDURE|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
48358025|NCT04360291|OTHER|Eye tracker|In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
48358026|NCT05967728|DEVICE|Remote ischemic conditioning (RIC) progammable device|RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
48669651|NCT02989181|DEVICE|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
48358027|NCT03847272|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
48358028|NCT03847272|OTHER|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
48358029|NCT03847272|OTHER|Questionnaires|VFQ-25 and SF-36
48358030|NCT03847272|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
48506829|NCT03854682|PROCEDURE|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
48506830|NCT03854682|BEHAVIORAL|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
48669652|NCT01527630|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
48669653|NCT00916448|DRUG|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
48669654|NCT00916448|DRUG|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
48146980|NCT01794689|BEHAVIORAL|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
48358031|NCT06231251|OTHER|upper gastrointestinal endoscopy|reduction of ghrelin rich gastric mucosa with band ligation or argon plasma
48358032|NCT03125902|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
48358033|NCT03125902|DRUG|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
48358034|NCT03125902|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
48358035|NCT03990155|PROCEDURE|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
48669655|NCT05064228|BEHAVIORAL|Mobile Rewarding Activity Centered Treatment (m-ReACT)|Participants will utilize m-ReACT for 12-weeks, reporting daily on substance-free activity engagement and enjoyment (EMA). m-ReACT will utilize these EMA reports to generate brief, automated, and personalized feedback about enjoyed categories of substance-free activities as well as make suggestions for increasing engagement in those rewarding, goal-oriented substance-free activities, and provide personalized suggestions of activities of interest.
48669656|NCT01843530|DRUG|Berinert|
48506831|NCT04898855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Treatment includes sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
48358036|NCT06351735|PROCEDURE|Deep cervical lymph node-vein bypass surgery|Deep cervical lymph node-vein bypass surgery, connecting deep cervical lymph node input lymphatic vessel
48358037|NCT01886144|DEVICE|Knee OA Brace|
48146981|NCT00237926|BEHAVIORAL|Exercise|aerobic or resistance training
48146982|NCT06505096|PROCEDURE|cataract surgery|Phaco+IOL implention
48146983|NCT03895567|DRUG|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)|"Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche)."
48146984|NCT03895567|DRUG|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule"
48146985|NCT03895567|DRUG|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet"
48146986|NCT00212459|BEHAVIORAL|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
48506832|NCT00575887|DRUG|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
48146987|NCT00212459|BEHAVIORAL|Control|No more contacts are made with control patients after the initial counseling session.
48146988|NCT03605147|DIETARY_SUPPLEMENT|CaHMB|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
48146989|NCT03605147|DIETARY_SUPPLEMENT|Placebo|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
48146990|NCT04922359|DRUG|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
48146991|NCT04922359|DRUG|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
48146992|NCT00623649|DRUG|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
48146993|NCT00623649|DRUG|Placebo|Dose escalation study with a full review of all safety data following each cohort.
48146994|NCT01128673|DEVICE|mRI|
48358038|NCT04125199|DIETARY_SUPPLEMENT|supplement consumption|"Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days)."
48358039|NCT05257668|OTHER|High Intensity Interval Exercise Training|High Intensity Interval Training Group
48358040|NCT05257668|OTHER|Moderate Intensity Exercise Training|Moderate Intensity Training Group
48506833|NCT02359994|DEVICE|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
48146995|NCT02521337|OTHER|observation|observation
48358041|NCT03196206|DRUG|BMS-986177|Oral Suspension
48358042|NCT01149044|PROCEDURE|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
48358043|NCT03160872|DIAGNOSTIC_TEST|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
48358044|NCT00917878|DIETARY_SUPPLEMENT|Milk|500 mL low-fat milk added to high-fat meal
48358045|NCT00917878|DIETARY_SUPPLEMENT|Protein|Milk protein in 500 mL water added to high-fat meal
48669657|NCT01843530|DRUG|Clemastin|
48146996|NCT01675063|DEVICE|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
48146997|NCT01995734|DRUG|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
48146998|NCT02799537|OTHER|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
48146999|NCT01884571|DRUG|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
48358046|NCT00917878|DIETARY_SUPPLEMENT|Calcium|Milk calcium in 500 mL water added to high-fat meal
48358047|NCT00917878|DIETARY_SUPPLEMENT|Control|Lactose in 500 mL water added to high-fat meal
48358048|NCT01577927|OTHER|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
48147000|NCT01884571|DRUG|Methylprednisolone|125 mg, IV (in the vein) on day 1.
48358049|NCT01577927|BEHAVIORAL|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
48669658|NCT01843530|DRUG|Cortisone acetate|
48669659|NCT01843530|DRUG|NaCl|
48669660|NCT05187299|OTHER|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
48506834|NCT02359994|DEVICE|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
48506835|NCT06010849|DIAGNOSTIC_TEST|Trunk control|Trunk control
48506836|NCT04693897|DRUG|Mirabegron 50 MG|Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
48147001|NCT01884571|DRUG|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
48147002|NCT01884571|DRUG|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
48147003|NCT01884571|DRUG|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
48147004|NCT05923788|DIAGNOSTIC_TEST|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
48669661|NCT02121093|PROCEDURE|vibration|
48669662|NCT00317837|PROCEDURE|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
48669663|NCT00317837|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty
48506837|NCT04693897|DRUG|Solifenacin Succinate 5 MG|Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
48358050|NCT02356042|OTHER|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
48147005|NCT03784222|DRUG|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
48358051|NCT05454631|DEVICE|surgical mask (5 different types)|All the participants will wear 5 different types of surgical mask, in random order.
48506838|NCT00426361|BIOLOGICAL|Boostrix ® Polio|One dose of vaccine administered intramuscularly
48506839|NCT00426361|BIOLOGICAL|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
48669664|NCT03732469|DRUG|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
48669665|NCT03732469|DRUG|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
48669666|NCT03732469|DRUG|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
48506840|NCT06552156|DIETARY_SUPPLEMENT|Dietary Emulsifier|Intervention was delivered by supplying dietary emulsifiers or placebo through 3 brownies a day that participants had to consume.
48669667|NCT05193006|OTHER|No intervention|No intervention
48669668|NCT05619393|DEVICE|Mobilie Bi-planar X-ray Imaging system|on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
48669669|NCT02152189|OTHER|Screening for Fabry disease|
48669670|NCT00185887|DRUG|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
48147006|NCT03784222|OTHER|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
48147007|NCT01681511|DEVICE|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
48669671|NCT05040776|DRUG|EP-7041 Injection|EP-7041 infusion
48669672|NCT01155557|DEVICE|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
48147008|NCT01681511|DEVICE|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®\* silver alloy coating and BARD® hydrogel.
48147009|NCT02652845|BEHAVIORAL|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
48358052|NCT01373099|PROCEDURE|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
48506841|NCT05151354|OTHER|Psychotherapy|Patients receive 8 weeks of inpatient psychotherapeutic treatment. Treatment consists of individual and group psychodynamic psychotherapy, as well as an individual combination of art, music, body-oriented and relaxation therapies, which are also carried out in group settings. Treatments is provided by an interdisciplinary team of psychotherapists with a medical or psychology degree, art of music therapists, social workers, physiotherapists and specialist nurses.
48506842|NCT05503810|BEHAVIORAL|Social support|Contact ones a week with Informal caregiver or peer support
48669673|NCT01155557|BEHAVIORAL|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
48506843|NCT06027385|DIAGNOSTIC_TEST|molecular-based screening|Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
48506844|NCT02642848|PROCEDURE|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
48669674|NCT00749437|RADIATION|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
48147010|NCT02757378|PROCEDURE|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
48669675|NCT06214403|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
48669676|NCT06214403|DRUG|Placebo|Microcrystalline Cellulose
48669677|NCT02912819|OTHER|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
48669678|NCT03479983|DIETARY_SUPPLEMENT|AMX160|500 mg Phyllanthus emblica L. fresh fruit extract capsules
48147011|NCT02757378|PROCEDURE|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
48147012|NCT05304676|OTHER|Experimental: KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation
48147013|NCT05304676|OTHER|Active Comparator: conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
48147014|NCT00721734|DRUG|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
48147015|NCT00442559|DRUG|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
48506845|NCT02642848|PROCEDURE|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
48506846|NCT02642848|PROCEDURE|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
48506847|NCT03457935|OTHER|blood samples|Blood samples
48506848|NCT00945100|DEVICE|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
48506849|NCT00945100|DEVICE|Eye Patch|2 hours patching daily
48506850|NCT04423887|OTHER|Lower Extremity Resistance Exercise Training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
48147016|NCT00442559|DRUG|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
48147017|NCT02330900|OTHER|Study group|Exposure to cell phone interference of the ICD
48147018|NCT00055068|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
48506851|NCT04423887|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
48506852|NCT04423887|DEVICE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
48147019|NCT00055068|BEHAVIORAL|Relaxation Training|
48506853|NCT04423887|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
48506854|NCT04423887|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
48506855|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~* Respiratory rate, respiratory signs, stridor : first and second visit~* 24h holter-ECG : first and second visit~* 24h impedance pH-metry : first visit~* Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~* 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit~* succimetry procedure : at first visit only between birth and 2 months"
48669679|NCT03479983|DIETARY_SUPPLEMENT|Placebo|500 mg roasted rice powder in visually identical capsules
48669680|NCT05225909|DEVICE|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
48669681|NCT04343092|DRUG|Ivermectin (IVM)|Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
48669682|NCT04656587|DEVICE|Philips Respironics V60 Non-invasive ventilator, BPAP|Continuous albuterol will be administered through the BPAP circuit.
48669683|NCT04656587|OTHER|Standard Therapy|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
48669684|NCT00325143|BIOLOGICAL|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
48669685|NCT00325143|BIOLOGICAL|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
48669686|NCT06546891|BEHAVIORAL|Adaptive Rowing|12 supervised and coached sessions of 10-20 minutes of moderate to vigorous exercise using an adaptive rower.
48669687|NCT02299310|DRUG|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
48669688|NCT02299310|DRUG|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
48669689|NCT03868410|DEVICE|New rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
48669690|NCT03868410|DEVICE|Conventional rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
48669691|NCT03147183|DRUG|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
48669692|NCT01144000|DRUG|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
48669693|NCT04229888|DEVICE|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
48669694|NCT04229888|DEVICE|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
48669695|NCT00477815|BIOLOGICAL|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
48669696|NCT00477815|DRUG|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
48669697|NCT00477815|BIOLOGICAL|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
48669698|NCT00477815|BIOLOGICAL|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
48669699|NCT00477815|RADIATION|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
48669700|NCT00477815|BIOLOGICAL|111In Zevalin|5.0 mCi by IV
48669701|NCT04035889|DIETARY_SUPPLEMENT|Melatonin|Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
48669702|NCT04035889|DIETARY_SUPPLEMENT|Placebo|Placebo
48669703|NCT02606630|DRUG|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
48669704|NCT00508482|OTHER|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
48147020|NCT04409392|OTHER|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
48147021|NCT05346588|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
48147022|NCT05346588|OTHER|Anesthetic technique inhaled agent|must administer inhaled agent.
48147023|NCT00388856|DRUG|Vitamin C 1000mg and E 400IU|
48147024|NCT02205255|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
48147025|NCT02205255|DRUG|Placebo|
48358053|NCT01373099|PROCEDURE|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
48669705|NCT00508482|DRUG|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
48358054|NCT00058448|DRUG|docetaxel|
48358055|NCT03796923|OTHER|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
48358056|NCT03796923|OTHER|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
48358057|NCT03796923|OTHER|Continued geriatric care|Continued specialized geriatric care after discharge
48358058|NCT03796923|OTHER|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
48358059|NCT03830463|DRUG|CTP-692|Single oral dose
48358060|NCT03830463|DRUG|Placebo|Single oral dose
48358061|NCT04449614|PROCEDURE|Thoracoscopic CPAM resection|Surgical removal of lung lesion
48358062|NCT00404326|DRUG|Hydralazine and magnesium valproate|
48358063|NCT00404326|PROCEDURE|Punch biopsy of the primary tumor|
48669706|NCT00508482|OTHER|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
48147026|NCT02772510|DEVICE|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
48358064|NCT04599660|OTHER|Treatment of Low Risk GISTs according clinical practice (includes drugs, surgery or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments
48358065|NCT00992615|PROCEDURE|prostate biopsy|prostate cores - 12 or 20
48358066|NCT01228435|DRUG|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
48358067|NCT06205979|DRUG|Ranibizumab Injection [Lucentis]|Three consecutive monthly intravitreal injections of Ranibizumab at a dosage of 0.5mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
48358068|NCT06205979|DRUG|Aflibercept Injection [Eylea]|Three consecutive monthly intravitreal injections of Aflibercept at a dosage of 2mg/0.05ml were administered in a sterile manner using a 30-G needle toward the center of the vitreous at 4mm in phakic or 3.5mm in pseudo phakic eyes from the limbus.
48358069|NCT05528068|BEHAVIORAL|supervised lifestyle intervention|Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
48358070|NCT05528068|BEHAVIORAL|healthy lifestyle education|Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
48358071|NCT06353529|DRUG|Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution|2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
48358072|NCT06353529|DRUG|Placebo|2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
48358073|NCT00739440|BIOLOGICAL|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
48358074|NCT05970146|DRUG|Ultrasound guided Stellate ganglion block|Under visualization with ultrasound, a 22-gauge, 5-cm needle inserted perpendicular to the skin to rest anteriorly to the precervical fascia. 6 mL lidocaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL is used. After injection of a 0.5-mL test dose to exclude intravascular positioning, the remainder of the appropriate dose was administered. The patient will be encouraged to lie flat for 3 minutes after the injection and then to sit up.
48669707|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
48147027|NCT02772510|DEVICE|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
48147028|NCT05991518|COMBINATION_PRODUCT|Injection of IAH0968+Gemcitabine+Cisplatin|Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
48506856|NCT03423017|OTHER|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~* General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~* Respiratory rate, respiratory signs, stridor~* 24h holter-ECG~* 24h impedance pH-metry~* Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~* 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index~* Succimetry procedure : at first visit only between birth and 2 months"
47989684|NCT04698720|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
48147029|NCT05991518|COMBINATION_PRODUCT|Gemcitabine+Cisplatin|Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
48147030|NCT03392805|BEHAVIORAL|physical activity|beginning of regular physical activity under the supervision of a coach
48147031|NCT04804202|OTHER|Bicycling with and without virtual reality|In one session: Exercise intensity and enjoyment are measured while participants bicycle in a virtual compared to non-virtual environment. Cycling takes places in two modes continous and interval. In a second session exercise intensity and enjoyment are compared during bicycling with virtual reality presented in two different ways.
47989685|NCT04698720|BEHAVIORAL|Hypnosis with Guided Imagery|"In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance."
48506857|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
48506858|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
48147032|NCT00693836|GENETIC|genetic linkage analysis|
48506859|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
48506860|NCT04197661|DRUG|HSK3486|Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
48506861|NCT06108076|DRUG|Ketone Monoester (KE)|Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
48506862|NCT02456935|DRUG|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
48147033|NCT00693836|GENETIC|loss of heterozygosity analysis|
48147034|NCT00693836|GENETIC|mutation analysis|
48506863|NCT02456935|DRUG|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
48506864|NCT03629756|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
48506865|NCT03629756|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
48506866|NCT02665845|DRUG|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
48147035|NCT00693836|GENETIC|polymerase chain reaction|
48147036|NCT00693836|GENETIC|polymorphism analysis|
48147037|NCT00693836|OTHER|biologic sample preservation procedure|
48147038|NCT00693836|OTHER|medical chart review|
48506867|NCT02665845|DRUG|Corticosteroids|Corticosteroids will be given to all patients.
48669708|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
48147039|NCT00693836|OTHER|questionnaire administration|
48147040|NCT00693836|PROCEDURE|evaluation of cancer risk factors|
48147041|NCT00003754|DRUG|cyclophosphamide|
48147042|NCT00003754|DRUG|thalidomide|
48147043|NCT04300270|DEVICE|Smartphone PPG recordings|Smartphone camera PPG recordings using a novel software application.
48147044|NCT04300270|DEVICE|Smartphone ECG|Smartphone connected one-lead ECG recordings.
48147045|NCT01302106|DRUG|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
48147046|NCT00449254|DRUG|oleoyl-estrone (MP-101)|
48506868|NCT01138982|BEHAVIORAL|Youth Mentoring program|
48506869|NCT02153463|BEHAVIORAL|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
48669709|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
48506870|NCT03510962|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
48669710|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
48669711|NCT03937479|DRUG|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
48669712|NCT05291533|OTHER|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
48669713|NCT01874392|DRUG|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
48147047|NCT02527694|DEVICE|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
48147048|NCT02527694|DEVICE|mechanical CPR|
48147049|NCT01584999|BIOLOGICAL|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
48147050|NCT01523184|DRUG|Placebo Capsule|This is the placebo capsule
48147051|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
48358075|NCT05970146|DRUG|unilateral cervical epidural|Aseptic betadine skin preparation will be performed and sterile drapes will be applied. Local anesthetic infiltration of the skin at C7-T1 interspace will be done using 2-3 mL of lidocaine 2% with guidance of the C-arm an 18-gauge. Tuohy needle will be inserted at C7-T1 interspace and directed towards either right or left epidural recess according to the site of the operation. Identification of entering the epidural space will be confirmed by hanging drop technique. The position of the needle is the confirmed by injection of 1 mL of non-ionized diluted dye (omnipause 300) to confirm unilateral spread of the dye. After that, a test dose was administrated, consisting of 2 mL of 2% lidocaine with 1:200,000 epinephrine.
48358076|NCT04890730|OTHER|Esophagogastroduodenoscopies|Each enrolled patient needs to undergo Esophagogastroduodenoscopies and elastography
48358077|NCT03234257|DEVICE|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
48358078|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
48358079|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
48358080|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
48358081|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
48358082|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
48506871|NCT03510962|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
48506872|NCT03510962|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
48669714|NCT01874392|DEVICE|Artificial Pancreas (AP) device (APS©)|"Device includes:~* OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~* Dexcom® G4® CGM System (CGM) from Dexcom® Corp~* Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
48669715|NCT05993741|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
48147052|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
48147053|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
48147054|NCT05830032|DIETARY_SUPPLEMENT|Soluble corn fibre|As a powdered beverage
48147055|NCT05830032|DIETARY_SUPPLEMENT|Inulin|As a powdered beverage
48147056|NCT05830032|DIETARY_SUPPLEMENT|soluble corn fibre and inulin|As a powdered beverage
48147057|NCT05830032|DIETARY_SUPPLEMENT|Maltodextrin|As a powdered beverage
48147058|NCT05264714|DRUG|Rimegepant|150 mg oral disintegrating tablet every other day for one week
48669716|NCT05804929|OTHER|Observation without intervention|Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
48669717|NCT03709966|DEVICE|Portable monitoring device|similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status
48669718|NCT03709966|BEHAVIORAL|Routine|Physical activity promotion supported by a kinesiologist
48147059|NCT03838575|DRUG|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
48147060|NCT03838575|DEVICE|Iodophor Antimicrobial Incise Drapes (DRAPE)|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied."
48358083|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
48358084|NCT01137006|BIOLOGICAL|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
48358085|NCT01227252|DRUG|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
48358086|NCT01227252|DRUG|Placebo|Administered orally as capsules, daily for 14 days
48669719|NCT03155139|DIAGNOSTIC_TEST|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
48669720|NCT03155139|DIAGNOSTIC_TEST|Confirmatory tests|Captopril challenge test, Saline infusion test
48358087|NCT01040494|DRUG|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
48669721|NCT01120405|DRUG|Xenon|
48669722|NCT01120405|DRUG|Sevoflurane|
48147061|NCT03838575|DEVICE|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
48669723|NCT03563092|PROCEDURE|Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery|Standardized minimally invasive approach to inguinal hernia repair
48147062|NCT03838575|OTHER|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
48669724|NCT05794607|OTHER|Rehabilitation group|The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
48669725|NCT01923883|PROCEDURE|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
48669726|NCT01923883|DEVICE|Echoendoscope Olympus GF-UCT240|
48669727|NCT00256126|DRUG|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
48669728|NCT00256126|DRUG|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
48669729|NCT02412150|DRUG|Desflurane|Anesthesia is maintained with desflurane
48147063|NCT00433706|PROCEDURE|Control position by 3DOBI before the fraction|
48147064|NCT00433706|PROCEDURE|Standard imaging|
48358088|NCT01040494|DRUG|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
48358089|NCT03932292|DRUG|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
48358090|NCT03932292|DRUG|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
48358091|NCT00109239|DRUG|rhuMAb VEGF (Bevacizumab)|
48669730|NCT02412150|DRUG|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
48669731|NCT02412150|PROCEDURE|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
48358092|NCT03831607|DRUG|KHK7791|KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
48358093|NCT00879593|DEVICE|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
48506873|NCT03510962|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
47989686|NCT04698720|BEHAVIORAL|Neutral Guided Imagery|This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
47989687|NCT03375801|OTHER|Decision Aid|This will be an online tool giving evidence based information and explanation on their options.
48506874|NCT03510962|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
48147065|NCT00973414|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
48147066|NCT00973414|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
48147067|NCT01799005|DIETARY_SUPPLEMENT|Flavanol (410 mg)|
48147068|NCT01799005|DIETARY_SUPPLEMENT|Control (no flavanols)|
48147069|NCT06244394|RADIATION|intensity-modulated radiotherapy|All patients were staged according to the 8th edition of the TNM classification by the American Joint Committee on Cancer/Union for International Cancer Control and received a standardized treatment regimen including IMRT and concurrent or adjuvant chemotherapy. Inverse IMRT treatment planning was performed on a Varian Inspiration Platform (version 10.0), using the simultaneous integrated boost technique. The prescribed doses were 68-75 Gy to the PTV of the GTVnx in 32-34 fractions; 64-75 Gy to the PTV of the GTVnd in 32-34 fractions; 60 Gy to the PTV of CTV1 in 32 fractions; and 50 Gy to the PTV of CTV2 in 28 fractions. All patients were given one fraction daily 5 days a week. The dose-volume-histograms (DVHs) of the organs at risk were evaluated as described in the radiation therapy oncology group (RTOG) 0225 protocol to prevent violation of the tolerance limits.
48147070|NCT00591136|DRUG|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
48669732|NCT02412150|OTHER|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
48669733|NCT02412150|BEHAVIORAL|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. \[Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)\]
48669734|NCT02412150|BEHAVIORAL|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~1. Awake Patient anxious and agitated or restless or both!~2. Patient cooperative, oriented and tranquil!~3. Patient responds to commands only!~4. Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~5. A sluggish response to a light glabellar tap or loud auditory stimulus!~6. No response to a light glabellar tap or loud auditory stimulus"
48669735|NCT02412150|OTHER|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
48669736|NCT02412150|BEHAVIORAL|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
48669737|NCT02412150|OTHER|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
48669738|NCT02412150|OTHER|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
48669739|NCT02412150|OTHER|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
48669740|NCT02412150|DRUG|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
47989688|NCT05161169|GENETIC|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
47989689|NCT00807807|DIETARY_SUPPLEMENT|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
47989690|NCT00807807|DRUG|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
47989691|NCT05365633|BEHAVIORAL|Empowerment activity-enhanced tobacco cessation assistance|Participants will receive standard Tobacco Treatment Research Program (TTRP) tobacco cessation assistance either remotely or in-person: 6 weekly counseling sessions and 12 weeks of combination NRT (nicotine patches + nicotine gum or lozenges). During the 6 weeks of counseling, participants will also engage in at least 4 'empowerment activities' (i.e., SGM social change mobilization and community-building activities48) for a total of at least 8 hours. Activities will be tailored to each participant's comfort level and provide COVID-19 risk-reduction options (e.g., remote or masked outdoor activities). Examples are: (i) running tobacco-free Pride events that occur in Jun and Oct in OK; (ii) organizing a virtual SGM town hall to inform the OK State Plan on Aging; (iii) SGM-relevant legislative phone banking (e.g., regarding transgender student participation in school athletics); and (iv) follow-up surveying of Freedom OK's name and gender marker change clinic72 participants.
48147071|NCT05814809|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet
48147072|NCT05814809|DRUG|JP-1366 20mg capsule|R : JP-1366 20mg capsule
48147073|NCT05080348|PROCEDURE|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
48669741|NCT02412150|DRUG|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
48669742|NCT02823002|PROCEDURE|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
48669743|NCT02823002|PROCEDURE|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
48669744|NCT02823002|PROCEDURE|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
48506875|NCT03510962|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
48669745|NCT02823002|PROCEDURE|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
48669746|NCT02823002|PROCEDURE|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
48669747|NCT02823002|PROCEDURE|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
48669748|NCT02823002|DRUG|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
48669749|NCT02823002|DRUG|Buffer|Sodium Bicarbonate
48669750|NCT02772029|DRUG|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
47989692|NCT02872493|PROCEDURE|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
47989693|NCT00195182|BEHAVIORAL|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
48669751|NCT05106348|DIAGNOSTIC_TEST|Aerobic Fitness Test|aerobic fitness test to assess wheelchair rugby players capacity
48669752|NCT00002143|DRUG|Acitretin|
48669753|NCT05528575|DIETARY_SUPPLEMENT|Blueberry, cranberry, green tea extract, cocoa|tablet supplements, available readily.
48669754|NCT05528575|DIETARY_SUPPLEMENT|GOS, Inulin, RS2|Prebiotic combination, Inulin, GOS and RS2
48669755|NCT05528575|DIETARY_SUPPLEMENT|prebiotics and polyphenols|combination of the same prebiotics and polyphenols as above
48669756|NCT05528575|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin, 10g per day
48669757|NCT03895190|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
47989694|NCT01558388|DRUG|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
47989695|NCT01558388|DRUG|Placebo|One vaginal tablet daily for 10 days.
48669758|NCT01176617|DEVICE|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
48669759|NCT04409834|DRUG|Unfractionated Heparin IV|Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE
48669760|NCT04409834|DRUG|Enoxaparin 1 mg/kg|Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
48669761|NCT04409834|DRUG|Clopidogrel|Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
47989696|NCT01859754|BIOLOGICAL|Octagam 5%|Intravenous immunoglobulin 5%
47989697|NCT01859754|BIOLOGICAL|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
48147074|NCT05080348|PROCEDURE|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
48147075|NCT02871245|PROCEDURE|Laparoscopic Surgery|
48147076|NCT02871245|DEVICE|Acupuncture treatment|
48506876|NCT04152187|OTHER|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
48506877|NCT02878122|PROCEDURE|Cancer treatment|Chemotherapy and laparoscopic surgery
48506878|NCT06532851|OTHER|Progressive Resistance Exercise (PRE)|A structured exercise regimen focusing on increasing muscular strength and endurance through progressive resistance.
48669762|NCT04409834|DRUG|Unfractionated heparin SC|Heparin 5,000 units administered subcutaneous three times daily
48669763|NCT04409834|DRUG|Enoxaparin 40 mg SC|Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
48669764|NCT03179878|DRUG|Placebo|Placebo
48669765|NCT03179878|DRUG|SYNB1020|Investigational Product
48669766|NCT00827229|DEVICE|Labor Monitor|
48669767|NCT00022438|BIOLOGICAL|aldesleukin|
48669768|NCT00022438|BIOLOGICAL|incomplete Freund's adjuvant|
48669769|NCT00022438|BIOLOGICAL|recombinant tyrosinase-related protein-2|
48358094|NCT00550615|DRUG|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
48358095|NCT00550615|DRUG|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
48358096|NCT02822924|PROCEDURE|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
48358097|NCT03408457|PROCEDURE|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
48358098|NCT04528836|DRUG|BBP-398 (Formerly known as IACS-15509)|oral capsules
48358099|NCT05281549|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
48358100|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
48358101|NCT05281549|DRUG|Tenecteplase|Tenecteplase 0.4mg/kg are being used.
48669770|NCT06431425|BEHAVIORAL|eCG Family Clinic|The DNA-poli is an online tool which is designed as an addition to the current genetic counseling method to make the process more efficient and to increase the uptake without compromising counseling quality. Probands can invite their at-risk family members by entering their email addresses. The family members are invited to the DNA-poli via which they can get all the information needed to make a well-considered decision about genetic testing. The information is provided in different formats, for example via a virtual assistant and via videos, which they can evaluate at their own pace, and which can be reread or rewatched. Afterwards they can request an appointment with a health care professional and make a definite decision about genetic testing.
48669771|NCT04815187|DRUG|Montelukast|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
48358102|NCT04011462|DEVICE|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
48358103|NCT04011462|DEVICE|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
48358104|NCT02241356|DEVICE|bifocals|bifocal glasses with an addition of 2.5 Dioptres
48358105|NCT02241356|DEVICE|single vision glasses|single vision glasses
48358106|NCT06336694|PROCEDURE|surgery or diagnostic staging laparoscopy|diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)
48358107|NCT03267576|DRUG|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
48669772|NCT04815187|DRUG|Placebo|Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
48669773|NCT02622191|DEVICE|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
48669774|NCT04280575|PROCEDURE|Percutaneous coronary intervention|Coronary artery stenting for stable angina
48358108|NCT03267576|DRUG|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
48358109|NCT03267576|DRUG|Metformin|Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.
48358110|NCT02730546|DRUG|Carboplatin|Given IV
48358111|NCT02730546|PROCEDURE|Computed Tomography|Undergo CT scan
48358112|NCT02730546|DRUG|Fluorouracil|Given IV
48358113|NCT02730546|OTHER|Laboratory Biomarker Analysis|Correlative studies
48358114|NCT02730546|DRUG|Leucovorin Calcium|Given IV
48358115|NCT02730546|DRUG|Oxaliplatin|Given IV
48358116|NCT02730546|DRUG|Paclitaxel|Given IV
48147077|NCT04410445|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
48669775|NCT02750514|BIOLOGICAL|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
48669776|NCT02750514|DRUG|Dasatinib|
48669777|NCT02750514|BIOLOGICAL|Relatlimab|
48669778|NCT02750514|BIOLOGICAL|Ipilimumab|
48669779|NCT02750514|DRUG|BMS-986205|Specified dose on specified days
48506879|NCT06532851|OTHER|Aerobic Exercise|An exercise program focusing on cardiovascular conditioning using a stationary bike.
48506880|NCT06532851|OTHER|Control|A set of general strength and balance exercises that do not target the specific therapeutic goals of the other interventions.
48506881|NCT03609320|BEHAVIORAL|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
48358117|NCT02730546|BIOLOGICAL|Pembrolizumab|Given IV
48358118|NCT02730546|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48669780|NCT05178186|PROCEDURE|Thyroidectomy|Surgery for thyroid carcinoma
48669781|NCT03007771|DEVICE|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
48358119|NCT02730546|RADIATION|Radiation Therapy|Undergo radiation therapy
48669782|NCT02665325|DRUG|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
48669783|NCT04372303|BEHAVIORAL|Compassion Fatigue Resiliency Program (CFRP)|The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
48358120|NCT02730546|PROCEDURE|Therapeutic Conventional Surgery|Undergo curative-intent surgery
48669784|NCT04306328|DEVICE|Neurostimulation|Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
48358121|NCT03082066|OTHER|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
48358122|NCT00457158|DEVICE|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
48147078|NCT04410445|BIOLOGICAL|Nivolumab|Specified dose on specified days
48358123|NCT05265494|DEVICE|Non invasive neuromodulation NESA (XSIGNAL device)|"The study volunteers are treated with the NXSIGNAL® device in sessions of 60 minutes, twice a week and for 5 weeks (10 sessions).~• The skin must be clean, free of creams and grease, lectrodes are connected to the control console and the targeting electrode located in over the intervertebral area between C7 and T1 (cervical area) and will follow the central treatment pattern with the following combination:~* 2 sessions: Program 1 (30 min), Program 7 (15min) and Program 8 (15min).~* 4 sessions: Program 2 (15min), Program 7 (30 min) and Program 8 (15min)~* 4 sessions: Program 7 (60min)"
48358124|NCT00453453|DRUG|Nesiritide|Nesiritide given orally in the emergency department
48358125|NCT03781154|BEHAVIORAL|Group Exercise|Patients will exercise in a virtual group for 60 minutes, twice a week. Five social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
48506882|NCT01941082|DRUG|RO6867461|Single or multiple ascending dose by intravitreal injection
48506883|NCT04667754|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
48506884|NCT04637932|PROCEDURE|Percutaneous Dilatation Tracheostomy|pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
48506885|NCT00338312|DRUG|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
48669785|NCT03347630|DIAGNOSTIC_TEST|MRI|Thoraco-abominal MRI
48669786|NCT03960047|BEHAVIORAL|Virtual Reality Training|This group gets trained to cross streets using virtual reality
48669787|NCT03960047|BEHAVIORAL|Streetside Training|This group is trained to cross streets based on streetside experiences
48669788|NCT05977998|DRUG|Paclitaxel|Given by IP (Intraperitoneal injection)
48669789|NCT05977998|DRUG|Dexamethasone|Given by IV (vein)
48669790|NCT05977998|DRUG|Diphenhydramine|Given by IV (vein)
48147079|NCT01090258|DEVICE|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate \[RR\], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
48147080|NCT01090258|OTHER|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
48147081|NCT02359929|BIOLOGICAL|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
48147082|NCT00201656|PROCEDURE|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
48506886|NCT00338312|DRUG|Placebo patch|placebo patch changed twice a week for one year
48506887|NCT02437240|BEHAVIORAL|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
48147083|NCT00201656|PROCEDURE|Removal of Cerclage|Immediate removal of Cerclage following randomization
48147084|NCT00201656|PROCEDURE|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
48147085|NCT01190436|DRUG|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
48147086|NCT00405834|DEVICE|Envision® Patient Support System|
48147087|NCT03958266|DEVICE|MyIBD Care|Novel mobile phone application
48147088|NCT02779972|OTHER|Echo stress test|Echo stress test
48506888|NCT02437240|BEHAVIORAL|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
48147089|NCT03145545|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
48147090|NCT01009645|BEHAVIORAL|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
48147091|NCT01009645|BEHAVIORAL|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
48147092|NCT01009645|BEHAVIORAL|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
48147093|NCT01009645|BEHAVIORAL|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
48147094|NCT03804866|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
48147095|NCT03804866|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
48147096|NCT03804866|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
48147097|NCT03647449|DIETARY_SUPPLEMENT|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
48147098|NCT03647449|BEHAVIORAL|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
48147099|NCT03647449|DIETARY_SUPPLEMENT|Plant-based meal|Participants will be eating \~900 kcal/day in pre-prepared plant-based meals.
48147100|NCT04805008|OTHER|Lactation cookies|1 serving of 2 OZ of cookies per day for 30 consecutive days. These cookies will contain ingredients thought to increase breast milk production.
48147101|NCT04805008|OTHER|Control cookies|"1 serving of 2 OZ of cookies per day for 30 consecutive days.~The cookies will not contain ingredients thought to increase breast milk production."
48147102|NCT04285645|OTHER|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
48147103|NCT05917158|DRUG|RC48-ADC and JS001|Patients in group will receive 6 x 2 week cycles of JS001 (Toripalimab) 3mg/kg in combination with RC48-ADC (Disitamab Vedotin) 2mg/kg intravenously.
48506889|NCT02167854|DRUG|BYL719|
48506890|NCT02167854|DRUG|LJM716|
48506891|NCT02167854|DRUG|TRASTUZUMAB|
48506892|NCT01878461|DRUG|Vehicle|
48506893|NCT01878461|DRUG|M518101|
48506894|NCT03456453|BEHAVIORAL|NIDA Standard for HIV Prevention|The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
48147104|NCT04562883|OTHER|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
48147105|NCT05711589|PROCEDURE|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
48147106|NCT05711589|PROCEDURE|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
48147107|NCT01039909|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
48147108|NCT01039909|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
48147109|NCT04522661|PROCEDURE|Vitrectomy|Vitrectomy within 48 hours of randomisation
48147110|NCT04522661|PROCEDURE|Intravitreal antibiotics|Intravitreal Antibiotics at 48 hours
48147111|NCT01494467|DRUG|CD5024|CD5024 1% Cream, once daily
48506895|NCT05092152|DRUG|Esketamine hydrochloride|2 mg per kilogram of body weight
48147112|NCT01494467|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
48147113|NCT03575494|OTHER|Intraoral and Radiographic Dental Examination|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
48147114|NCT05193175|BEHAVIORAL|Prolonged sitting|Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
48147115|NCT05764395|DRUG|Rigosertib|Given by mouth
48147116|NCT05764395|BIOLOGICAL|Pembrolizumab|Given by IV
48147117|NCT05764395|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48147118|NCT05764395|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48506896|NCT05092152|DRUG|Propofol|1.5 mg per kilogram of body weight
48506897|NCT01382654|DRUG|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
48506898|NCT01382654|DRUG|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
48506899|NCT01382654|DRUG|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
48506900|NCT01382654|DRUG|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
48506901|NCT01382654|DRUG|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
48147119|NCT05764395|PROCEDURE|Biopsy|Undergo tissue biopsy
48147120|NCT01082159|PROCEDURE|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
48147121|NCT03029585|DRUG|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
48147122|NCT03029585|DRUG|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
48147123|NCT03029585|DRUG|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
48506902|NCT01308905|DEVICE|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
48506903|NCT02644005|DEVICE|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG \& Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
48506904|NCT00745784|BEHAVIORAL|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
48506905|NCT05438043|DRUG|Daratumumab|Daratumumab will be administered either intravenously or subcutaneously.
48669791|NCT05977998|DRUG|Famotidine|Given by IV (vein)
48147124|NCT03029585|DRUG|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
48147125|NCT03029585|DRUG|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
48147126|NCT02869230|PROCEDURE|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
48506906|NCT05438043|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
48506907|NCT05438043|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
48506908|NCT05438043|DRUG|Lenalidomide|Lenalidomide will be administered orally.
48506909|NCT05438043|DRUG|Pomalidomide|Pomalidomide will be administered orally.
48506910|NCT01056042|DRUG|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
48506911|NCT01056042|DRUG|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
48147127|NCT02869230|PROCEDURE|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
48147128|NCT02820506|PROCEDURE|SLN mapping and removal of PET-positive lymph nodes|Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
48358126|NCT05381194|DRUG|BPaL(M) regimen|"Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day"
48358127|NCT00439309|DEVICE|Gelfoam/Thrombin|Gelfoam/Thrombin
48506912|NCT03359954|RADIATION|Radiation Therapy|Undergo radiation therapy
48358128|NCT00439309|DEVICE|VascuSeal|VascuSeal
48358129|NCT05193292|DRUG|Camrelizumab|200mg, iv, 21d for a treatment cycle
48358130|NCT05193292|DRUG|Trastuzumab|8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
48358131|NCT05193292|DRUG|XELOX regimen|Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
48358132|NCT05193292|DRUG|mFOLFOX6 regimen|Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
48358133|NCT05193292|DRUG|FOLFIRI regimen|Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
48358134|NCT05193292|DRUG|mXELIRI regimen|Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
48358135|NCT05193292|DRUG|mIRIS regimen|Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
48358136|NCT01739868|OTHER|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~* 1 visit the first year (inclusion visit)~* 1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~* 1 intermediary visit (in 3 years) or activated by the following conditions:~  * Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~ * Normalization of the glycemia (fasting blood glucose \< 1 g/l)"
48506913|NCT03359954|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast surgery
48506914|NCT06378398|DRUG|Omeprazole|Two 20 mg/day omeprazole tablets taken before the first meal each day for 25-45 days.
48506915|NCT06378398|DRUG|Aspirin|Two 81 mg/day aspirin tablets taken before the first meal each day for 25-45 days.
48506916|NCT04471129|OTHER|HFO/O2C/NIV|High-flow oxygen therapy + O2C + Non invasive ventilation
48506917|NCT04471129|OTHER|NIV/O2C/HFO|Non invasive ventilation + O2C + High-flow oxygen therapy
48506918|NCT06296927|OTHER|Emotional Freedom Technique|The researcher will apply the Emotional Freedom Technique to women in the intervention group who apply for mammography screening for 30-40 minutes before the screening.
48147129|NCT01984216|PROCEDURE|Roux-en-Y for the gastrojejunostomy reconstruction|
48147130|NCT01984216|PROCEDURE|Billroth II for the gastrojejunostomy reconstruction|
48147131|NCT00374998|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
48147132|NCT00374998|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
48506919|NCT02683512|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
48506920|NCT03526783|PROCEDURE|Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
48147133|NCT06144723|DRUG|HS-20105|Administered intravenously every 21 days.
48147134|NCT04970472|BIOLOGICAL|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
48358137|NCT02476903|DRUG|Monovisc|
48358138|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
48358139|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
48506921|NCT03526783|PROCEDURE|Mini/One anastomosis gastric bypass|Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
48506922|NCT02602600|DRUG|Liraglutide|"* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks"
48506923|NCT05042895|PROCEDURE|Group A|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
48669792|NCT01010607|DEVICE|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
48147135|NCT04526132|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
48669793|NCT01010607|DEVICE|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
48669794|NCT01010607|DEVICE|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
48669795|NCT00102661|DRUG|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
48358140|NCT03267511|DRUG|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
48669796|NCT03507127|DRUG|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
48669797|NCT03507127|DRUG|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
48669798|NCT03082924|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
48669799|NCT03082924|DEVICE|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
48358141|NCT03267511|DRUG|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
48669800|NCT03082924|DEVICE|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
48669801|NCT03082924|DEVICE|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
47989698|NCT00322842|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
48147136|NCT04526132|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
48147137|NCT02138838|DRUG|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
48147138|NCT02138838|DIETARY_SUPPLEMENT|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
48358142|NCT02881918|OTHER|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
48358143|NCT03097562|PROCEDURE|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
48669802|NCT03495401|DIETARY_SUPPLEMENT|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
48669803|NCT03495401|DIETARY_SUPPLEMENT|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
48669804|NCT04106245|BEHAVIORAL|Behavioral Intervention|Participate in PACK Health
48669805|NCT04106245|OTHER|Survey Administration|Complete survey
48147139|NCT03437655|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
48147140|NCT03437655|PROCEDURE|Relative isolation|Relative isolation with cotton and gauze.
48669806|NCT01911468|DRUG|metformin|
48147141|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
48669807|NCT01911468|DRUG|liraglutide|
48669808|NCT01911468|DRUG|metformin and liraglutide|
48358144|NCT00794989|DIETARY_SUPPLEMENT|Ground Flaxseed|Given orally
48358145|NCT00794989|OTHER|No Intervention|Participants randomized to Arm 2 do not receive any intervention
48147142|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
47989699|NCT03893604|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2) 2mA or sham
47989700|NCT05461651|PROCEDURE|Knee arthroplasty|total or unilateral knee arthroplasty
47989701|NCT04138329|PROCEDURE|Lichtenstein Technique|In this group was used the Lichtenstein technique for inguinal repair
48147143|NCT03437655|PROCEDURE|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
47989702|NCT04138329|PROCEDURE|Onstep Technique|In this group was used the Onstep technique for inguinal repair
47989703|NCT01786954|DEVICE|Icare rebound tonometry|
47989704|NCT01786954|DEVICE|Tonopen applanation|
47989705|NCT01786954|DEVICE|Goldmann applanation|
47989706|NCT01452607|DRUG|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
47989707|NCT01452607|DRUG|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
47989708|NCT01481142|DEVICE|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
47989709|NCT01887574|OTHER|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
47989710|NCT00301444|DEVICE|mirror-box treatment|
47989711|NCT00301444|BEHAVIORAL|Mental visualization|
47989712|NCT01675687|BEHAVIORAL|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
48147144|NCT03437655|PROCEDURE|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
48147145|NCT01127737|BEHAVIORAL|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
48147146|NCT01127737|BEHAVIORAL|Placebo|Completed surveys
48147147|NCT05238337|DRUG|[14C]-PBI-200|\[14C\]-radio-labeled-PBI-200
48147148|NCT00380809|PROCEDURE|Rotational Atherectomy + PES|
48358146|NCT04102696|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
48358147|NCT04102696|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
48358148|NCT03869931|DRUG|Fenofibrate|Fenofibrate 100 mg or 300 mg (according to CrCl)
48358149|NCT01056601|DRUG|Bortezomib|1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
48358150|NCT01056601|DRUG|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
48358151|NCT03336281|DRUG|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
47989713|NCT03447509|DEVICE|iTMS|Small magnetic pulse will be given to the brain in a non invasive manner.
47989714|NCT03447509|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
47989715|NCT03447509|DEVICE|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner.
47989716|NCT03447509|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
47989717|NCT06186531|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
47989718|NCT06186531|DRUG|Placebo|Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
47989719|NCT00525733|DRUG|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
47989720|NCT00525733|DRUG|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
47989721|NCT00525733|DRUG|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
47989722|NCT00525733|DRUG|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
47989723|NCT00525733|DRUG|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
47989724|NCT02432846|BIOLOGICAL|Intuvax (INN: ilixadencel)|Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
47989725|NCT02432846|DRUG|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
47989726|NCT00049101|DRUG|erlotinib hydrochloride|
47989727|NCT00049101|DRUG|fluorouracil|
47989728|NCT00049101|DRUG|leucovorin calcium|
47989729|NCT00049101|DRUG|oxaliplatin|
48147149|NCT00380809|PROCEDURE|Standard Treatment (PES without Rotational Atherectomy)|
48147150|NCT05020236|DRUG|Elranatamab|subcutaneous
48147151|NCT05020236|DRUG|Daratumumab|Daratumumab / hyaluronidase, subcutaneous
48147152|NCT05020236|DRUG|Pomalidomide|oral
48147153|NCT05020236|DRUG|Dexamethasone|oral
48147154|NCT01450774|DRUG|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
48147155|NCT01450774|DRUG|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
48147156|NCT03733860|PROCEDURE|Cavernous tissue sparing penile prosthesis implantation|Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
48147157|NCT03733860|PROCEDURE|Conventional penile prosthesis implantation|Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
48147158|NCT03733860|PROCEDURE|Intracavernosal injection of alprostadil|Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
48506924|NCT05042895|PROCEDURE|Group B|"Office diagnostic hysteroscopy for assessment of the following:~* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.~* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.~* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.~Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.~Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle."
48669809|NCT01171677|BEHAVIORAL|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
48669810|NCT04651530|PROCEDURE|Phaco|phacoemulsification of cataract only
48669811|NCT04651530|PROCEDURE|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
48669812|NCT03343561|BEHAVIORAL|Nutrition Advice|Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
48669813|NCT01130792|DIETARY_SUPPLEMENT|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
48147159|NCT01811459|DRUG|Quetiapine|PO
47989730|NCT05034107|OTHER|Aromatherapy|Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
48147160|NCT01811459|DRUG|Haloperidol|IV
48147161|NCT01811459|DRUG|Placebo|PO or IV
48147162|NCT00091572|DRUG|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
48147163|NCT00091572|DRUG|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
48147164|NCT00990184|DRUG|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
47989731|NCT03774953|DIETARY_SUPPLEMENT|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
47989732|NCT05584644|DRUG|Palbociclib plus hormonal treatment - first line treatment|Palbociclib plus hormonal treatment
48147165|NCT00990184|OTHER|placebo|tablet (s) orally given with evening meal
48147166|NCT02632188|PROCEDURE|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
48147167|NCT02632188|BIOLOGICAL|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
48358152|NCT01173328|BEHAVIORAL|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
48358153|NCT01173328|BEHAVIORAL|Normal Breathing|
48669814|NCT01130792|DIETARY_SUPPLEMENT|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
47989733|NCT05584644|DRUG|Palbociclib plus hormonal treatment - second line treatment|Palbociclib plus hormonal treatment
48147168|NCT06032156|DIETARY_SUPPLEMENT|Low Dose β-OHB|Ingestion of a low dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
48358154|NCT04254575|OTHER|None, observational study only (no interventions)|None, observational study only (no interventions)
48358155|NCT00174876|DRUG|Drug Abilify|
48358156|NCT03971227|DEVICE|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
48358157|NCT03971227|DEVICE|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
48358158|NCT03011424|DEVICE|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
48358159|NCT02576652|OTHER|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
48358160|NCT02576652|OTHER|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
48358161|NCT02576652|PROCEDURE|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
48358162|NCT05993455|DRUG|Oral sotorasib + IV Panitumumab|Oral sotorasib at a dose of 960 mg once daily with Panitumumab is administered intravenously (IV) at a dose of 6 mg/kg every 14 days, infused over 60 minutes (≤ 1,000 mg) or 90 minutes (\> 1,000 mg).
47989734|NCT02126956|DRUG|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
47989735|NCT02382679|DIETARY_SUPPLEMENT|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
48358163|NCT05704140|OTHER|Catheter based Dialysis|We will conduct a cross-section analysis regarding patients with catheter-based VA in Vienna.
48358164|NCT01775995|BEHAVIORAL|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
48358165|NCT01775995|OTHER|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
48358166|NCT00886314|DRUG|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
48358167|NCT00886314|OTHER|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
48358168|NCT00715039|DRUG|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
48358169|NCT00715039|DRUG|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
48358170|NCT00715039|DRUG|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
48358171|NCT00485121|DRUG|Ezetimibe|
47989736|NCT02382679|DIETARY_SUPPLEMENT|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
48358172|NCT06482801|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
47989737|NCT05872711|OTHER|Low carbohydrate diet|"In order to maintain equal intensity of treatment, each patient will get a cooking workshop and received a personalized diet regime at baseline, based on the randomly assigned diet. Format and quality of the materials are similar.~All diet plans are individualized and matched for energy intake personally . Participants will meet individually with the dietitian for diet instruction and support at week 1,2,4,7,10,12 and thereafter at 24 weeks for a total of seven frontal meetings. Twice during the first 12 weeks the dietician will conduct 10-15-minute motivational telephone calls with all the participants."
47989738|NCT01568931|DRUG|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
47989739|NCT01568931|DRUG|Saline|intracoronary, saline, bolus 1 cc
47989740|NCT04602832|OTHER|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
48358173|NCT04062513|OTHER|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
47989741|NCT05690555|OTHER|Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks and 6 weeks postoperatively. The following interventions will be performed:~3 weeks:~* Subjective assessment of bowel and bladder function~* Visual and external palpation and assessment of external pelvic floor region~* Intravaginal pelvic floor assessment~* Pelvic floor muscle dynamics and coordination assessment~* Instruction of pelvic floor coordination and lengthening~* Discussion of dilator program and progression~* Home program with instructions~  6 weeks:~* External scar assessment and treatment if tissue healing allows~* Instruction to patient of scar mobilizations~* Intravaginal pelvic floor assessment and treatment if indicated~* Review of pelvic floor lengthening and coordination~* Review and progression of dilator program if appropriate~* Assessment of current bowel/bladder symptoms; home program and instructions to address these symptoms"
48358174|NCT04062513|OTHER|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
48358175|NCT04062513|OTHER|Standard care|Preterm infants will receive sucrose during heel prick.
48358176|NCT06406829|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
48669815|NCT04444089|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
48147169|NCT06032156|DIETARY_SUPPLEMENT|High Dose β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
48358177|NCT06406829|DRUG|Normal saline|In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group
48506925|NCT06500611|OTHER|Sensory Integration and Vestibular Exercise with Routine Physical Therapy|"1. Stand with feet hip-width apart 5 rep~2. Sit in chair without backrest 5 rep~1.Stand with feet hip -width apart 5 rep~2.Sit to stand sit on chair without backrest and perform sit to stand repeatedly 5 rep~1.Tandem Walk one foot directly in front of the other.2 sets 5 steps forward and backward~2.Patientwalk forward cross an obstacle, continue walk. Walk Lateral Walk Backward 2 sets~1. Stand and slowly move head side to side and up down 10 repetition~2. Fix gaze and move head side to side or up and down 10 repetitions~1. Stand on one leg for 10 seconds hold on. Repeat 5 times on each leg.~2. Stand and rotate body to right and left 10 rotations~1. Walk on straight line , zigzag pattern, walk while looking your shoulder 5 rep~2. Sit and swing your legs back and forth 5rep~3. Play catch in standing. 2 sets 5-8 catches.~Static stretching 30 sec hold 5 times"
48147170|NCT06032156|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
47989742|NCT05690555|OTHER|No Pelvic Floor Physical Therapy (PFPT)|"Patients will present to see the physical therapist 3 weeks postoperatively. The following interventions will be performed:~Subjective assessment of bowel and bladder function. Visual and external palpation and assessment of external pelvic floor region. Intravaginal pelvic floor assessment. Pelvic floor muscle dynamics and coordination assessment. Review of pelvic floor anatomy and function."
48147171|NCT06505356|PROCEDURE|Prostate biopsy|Transrectal prostate biopsy
48358178|NCT06406829|OTHER|Local analgesic techniques|The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.
48358179|NCT06406829|OTHER|no Local analgesic techniques|No Local analgesic techniques will be given.
48358180|NCT02706535|DRUG|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
48358181|NCT02706535|DRUG|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
48358182|NCT02706535|DRUG|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
48358183|NCT01951976|OTHER|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
48147172|NCT03662009|OTHER|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
48147173|NCT02749253|OTHER|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
48147174|NCT03949959|OTHER|Multimodal physiotherapy|Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
48147175|NCT05160909|PROCEDURE|Beach Chair Position|Patients positioned in beach chair during arthroscopic shoulder stabilization
48358184|NCT01951976|OTHER|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
48358185|NCT05168189|DRUG|Ivabradine|follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
48358186|NCT05168189|DIAGNOSTIC_TEST|transthoracic echo|performing baseline transthoracic echo for all patients to exclude any chamber dilatation
48358187|NCT05168189|DEVICE|24 hours holter|perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months
48669816|NCT00943761|DRUG|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
48147176|NCT05160909|PROCEDURE|Lateral Decubitus Position|Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
48358188|NCT01586286|DRUG|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
48358189|NCT01586286|DRUG|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
48669817|NCT00943761|DRUG|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
48669818|NCT00943761|DRUG|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
48147177|NCT01184027|BEHAVIORAL|nutrition /swallowing counseling|general nutrition and swalling information
48147178|NCT01184027|BEHAVIORAL|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
48147179|NCT01184027|BEHAVIORAL|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
48147180|NCT01322386|DRUG|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
48147181|NCT02590770|BEHAVIORAL|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
48147182|NCT02590770|OTHER|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
48147183|NCT02788435|BEHAVIORAL|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
48669819|NCT00943761|DRUG|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
48147184|NCT00861354|DEVICE|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
48147185|NCT06506409|DEVICE|Smart-Video Based Game Therapy|The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. Selected games focus on balance, coordination and weight transfer.
48506926|NCT06500611|OTHER|Vestibular Exercise with Routine Physical Therapy|"Vestibular exercise~1. Stand with feet hip -width apart and slowly move head side to side and up down.10 repetitions for each direction.~2 .Fix your gaze on object while moving your head side to side or up and down. 10 repetitions for each movement.~1.Patient will stand on one leg for 10 second. Hold onto a stable support if needed. 5 times on each leg.~2. Stand with feet hip-width apart and rotate body to the right and left. 10 rotations in each direction.~1. Walk on a straight line or in a zigzag pattern or walk while looking over your shoulder. (5 rep)~2. Sit on a stable chair and swing your legs back and forth, similar to a pendulum. (5rep)~3. Catch and Throw play catch with a partner while standing. 2 sets of 5-8 catches.~Routine Physical Therapu Static stretching exercises for 30 sec hold with 30 sec rest. 5 times for each muscle group"
48506927|NCT06625632|DRUG|Antiemetic Drug|All participants in the two groups will receive antiemetic drugs (ondansetron 4 mg) every 12 hours, for 5 days.
48506928|NCT06625632|DIETARY_SUPPLEMENT|Vitamin B6|All participants in the two groups will receive vitamin B6 (50 mg), once daily, for 5 days.
48669820|NCT00605059|DRUG|[123I]AV94|Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
48506929|NCT06625632|OTHER|Home care advice|All participants in both groups will be advised to eat small portions of food, drink plenty of liquids, and avoid fatty and fried foods. Additionally, they should steer clear of highly spiced foods, foods and beverages with strong odors, caffeine, and consume neither very hot nor very cold foods and liquids.
48506930|NCT06625632|OTHER|Kinesiotaping|It will be applied for all participants in the experimental group only for 5 days. The participant will be asked to stand in erect position, her hands beside her body then applying the kinesiotape from origin (from top to bottom where the stomach is placed on the abdominal region) to insertion (alongside the gastric curvature) with tension 25% for 5 days.
48506931|NCT06389799|DRUG|Pemigatinib|selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
48506932|NCT06389799|DRUG|Retifanlimab|PD-1 inhibitor, Intravenous infusion
48147186|NCT06506409|OTHER|Otago Based Structured Exercise|Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.
48147187|NCT06506409|OTHER|No intervention|A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
48669821|NCT05195203|DRUG|HS-10353|Single or multiple dose(s) of HS-10353
48147188|NCT02131454|OTHER|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
48669822|NCT05195203|DRUG|Placebo|Single or multiple dose(s) of placebo
48147189|NCT06284356|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
48147190|NCT02020902|OTHER|Cetrizine hydrochloride|As provided on the patient information leaflet
48358190|NCT05538689|DRUG|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
48147191|NCT03363100|BEHAVIORAL|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
48147192|NCT05815459|DEVICE|OCOsense|Volunteers wear OCOsense glasses continuously during testing to monitor biobehavioural responses to tasks
48147193|NCT04970459|BIOLOGICAL|collection of samples of blood and urine|extra samples of blood and urine will be collected and stored for research utilisation
48147194|NCT02644941|BIOLOGICAL|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
48147195|NCT02644941|DEVICE|ePTFE graft|Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
48147196|NCT00624377|DRUG|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
48147197|NCT01640288|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
48358191|NCT02939196|PROCEDURE|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
48358192|NCT02939196|PROCEDURE|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
48358193|NCT03636009|OTHER|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
48358194|NCT03636009|OTHER|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
48506933|NCT00304837|GENETIC|pVGI.1 (VEGF-2)|
48669823|NCT01697709|DRUG|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
48669824|NCT01697709|DRUG|Placebo|placebo capsules
48669825|NCT04549480|DRUG|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
48358195|NCT03636009|OTHER|active exercise program|Participants will have 4-5 exercises to perform at each session
48358196|NCT03636009|OTHER|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
48669826|NCT04549480|DRUG|Bosutinib tablet|100 mg dose of bosutinib tablet
48669827|NCT02442050|OTHER|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
48147198|NCT01640288|OTHER|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
48147199|NCT00489554|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
48147200|NCT00489554|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
48147201|NCT00489554|BIOLOGICAL|Rotarix|Oral, 2 doses.
48147202|NCT02045914|OTHER|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
48147203|NCT03129009|DRUG|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
48669828|NCT02442050|OTHER|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
48669829|NCT00590967|RADIATION|IMRT extended field external beam radiation therapy|
48669830|NCT00590967|RADIATION|Brachytherapy|
47989743|NCT05690555|OTHER|Preoperative PFPT and Postoperative PFPT|Preoperative Diaphragmatic breathing Discuss dilator positioning/introduce dilator program External pelvic floor assessment Teach pelvic floor coordination Current bowel/bladder symptoms; home program and instructions 3 weeks Assessment of bowel and bladder function Visual and external palpation and assessment of external pelvic floor region Intravaginal pelvic floor assessment Pelvic floor muscle dynamics and coordination assessment Instruction of pelvic floor coordination and lengthening Discussion of dilator program and progression Home program with instructions 6 weeks External scar assessment and treatment if tissue healing allows Instruction to patient of scar mobilizations Intravaginal pelvic floor assessment and treatment if indicated Review of pelvic floor lengthening and coordination Review and progression of dilator program if appropriate Current symptoms; home program and instructions
48147204|NCT03129009|DRUG|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
48147205|NCT04690309|DRUG|Treatment with human insulin preparations or treatment with insulin analogues|The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)
48147206|NCT05668845|OTHER|PG-ANB performed at the outset of LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the outset of the LSG.
48147207|NCT05668845|OTHER|PG-ANB performed at the end of the LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the end of the LSG\>
48147208|NCT05427942|DRUG|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
48358197|NCT01594489|DRUG|Aminophylline|"* 200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
48506934|NCT04147585|OTHER|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
48506935|NCT04175600|DRUG|Selexipag|Selexipag tablet will be administered orally.
48506936|NCT04175600|DRUG|Placebo|Matching placebo tablets will be administered orally.
48506937|NCT05228938|PROCEDURE|VNOTES|vaginal Natural Orifice Transluminal Endoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
48506938|NCT05228938|PROCEDURE|laparoscopic|laparoscopic Surgery approach for Elective bilateral salpingectomy or Salpingo-oophorectomy
48506939|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under High Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
48669831|NCT00590967|DRUG|Cisplatin|
48669832|NCT04133168|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
48669833|NCT04792385|DRUG|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
47989744|NCT05690555|OTHER|Cross-over Treatment|Any patients in the No PFPT arm who are determined to have pelvic floor dysfunction or symptoms that may benefit from PFPT referral, will be referred after the 12-week mark. Any patient in one of the PFPT arms who is determined to still need PFPT for persistent pelvic floor dysfunction or symptoms will be referred for continued care.
47989745|NCT03854617|DRUG|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
47989746|NCT03854617|DRUG|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
47989747|NCT02296385|DIETARY_SUPPLEMENT|Triple Strength Fish Oil|Triple Strength Fish Oil
48147209|NCT02385539|DRUG|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
48358198|NCT01594489|DRUG|Hydration plus N-acetylcisteine|"* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
48358199|NCT03390127|OTHER|PEEP|After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.
48506940|NCT05666245|BEHAVIORAL|No Intervention - Under High Air Hygiene|"No intervention~High air hygiene is achieved by filtration and/or use of germicidal UV-C."
48358200|NCT01563224|DRUG|Baclofen 10mg|Baclofen 10mg single dose po
48358201|NCT01563224|DRUG|Baclofen 60mg|Baclofen 60mg single dose po
48358202|NCT01563224|DRUG|placebo|placebo
48358203|NCT05986890|PROCEDURE|Roux-en-Y Bypass|laparoscopic Roux-en-Y
48358204|NCT05986890|PROCEDURE|gastrojejunostomy|surgical gastrojejunostomy
48506941|NCT05666245|BEHAVIORAL|Personal Protective Equipment (PPE) - Under Low Air Hygiene|"Intervention Recipients (IRs) will be required to wear a lightweight plastic face shield, comply with hand hygiene (i.e., using a hand sanitization product every 15 minutes, plus periodic hand washing with soap and water), and avoid face touching during each planned exposure event. The face shield may only be removed after leaving the exposure room to go to the bathroom, for other short comfort breaks, and at mealtimes. In these instances, hand hygiene will be used after removing or replacing the face shield; and Donors will not be present. Hand washing with soap and water will be required before meals. IR will be separated from Donors by more than 6 feet during meals. The exposure room will be supervised by a trained member of the study staff who will monitor to ensure that Intervention Recipients wear the face shield continuously, are separated from Donors at meals, and do not touch their faces.~Low air hygiene is achieved with minimal ventilation."
48506942|NCT05666245|BEHAVIORAL|No Intervention - Under Low Air Hygiene|"No intervention~Low air hygiene is achieved with minimal ventilation."
48506943|NCT05987319|DEVICE|RadioFrequency Microneedling Device|RadioFrequency device will be used for the treatment of dermatologic conditions.
48506944|NCT05742932|DEVICE|Trauma surgery using Global D's implants.|Major or minor participants who will be treated by an trauma surgery with ORTRAUTEK® or MINITEK/MICROTEK® implant(s).
48669834|NCT00015847|BIOLOGICAL|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
48669835|NCT00015847|DRUG|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
47989748|NCT05016557|DIETARY_SUPPLEMENT|Protein ingestion|Bolus ingestion of 25g protein
47989749|NCT01066754|DRUG|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
48669836|NCT01357343|OTHER|Chiropractic|Spinal manipulation and active and passive therapy.
48669837|NCT01357343|OTHER|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
47989750|NCT05383547|DRUG|Bortezomib|Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
47989751|NCT00937872|DRUG|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
47989752|NCT00937872|DRUG|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
47989753|NCT03804944|RADIATION|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
47989754|NCT03804944|DRUG|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
47989755|NCT03804944|BIOLOGICAL|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
48358205|NCT01780285|DEVICE|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
48506945|NCT03247192|DIETARY_SUPPLEMENT|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
48669838|NCT03139461|OTHER|PT-REFER Capacity-building Toolkit|"1. Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~2. Support from Change Agent~3. Technical Assistance Calls"
48669839|NCT00370292|DRUG|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
48669840|NCT00370292|DRUG|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
48669841|NCT00087217|DRUG|tanespimycin|Given IV
47989756|NCT05125328|DRUG|Remifentanil|First start with remifentanil 6.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. An ANI lower than 30 and hyperdynamics (the increased heart rate and mean blood pressure up 20% of baseline or heart rate\>100bpm and arterial blood pressure\>180/100mmHg) indicates insufficient analgesia, therefore increase it by 0.5 ng/ml; an ANI higher than 30 and stable hemodynamics (the changes of HR and MBP within 20% of baseline or HR\<50bpm and ABP\<90/50mmHg) indicates that analgesia is acceptable, and the next patient will decrease it by 0.5 ng/ml during skull pin fixation.
48147210|NCT03878394|OTHER|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
48358206|NCT01780285|DEVICE|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
48358207|NCT05516316|DRUG|EP395|Capsule for oral use
48358208|NCT05516316|DRUG|Placebo|Capsule for oral use
48669842|NCT00087217|DRUG|paclitaxel|Given IV
48358209|NCT00309361|DRUG|Phentolamine Mesylate (NV-101)|
48669843|NCT00087217|OTHER|laboratory biomarker analysis|Correlative studies
48669844|NCT00087217|OTHER|pharmacological study|Correlative studies
48669845|NCT02572531|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
48669846|NCT02572531|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
48669847|NCT03540680|OTHER|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
48669848|NCT00288145|BEHAVIORAL|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
48669849|NCT03593148|OTHER|Lifestyle|Lifestyle treatment
48669850|NCT03921905|DIAGNOSTIC_TEST|ABI measurement|ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
48669851|NCT01193101|DRUG|LCZ696|LCZ696
48669852|NCT01193101|DRUG|Placebo|matching placebo to LCZ696
48147211|NCT03878394|OTHER|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
48147212|NCT04572165|DRUG|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
48147213|NCT04572165|DRUG|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
47989757|NCT04768465|DRUG|Pyridostigmine, Prednisone, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
47989758|NCT04768465|DRUG|Pyridostigmine, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
48147214|NCT04572165|DRUG|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
47989759|NCT03540147|DEVICE|Hokanson Cuffs|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
48147215|NCT02152384|DRUG|Insulin Peglispro|Administered SC
48147216|NCT02152384|DRUG|Insulin Lispro|Administered SC
48147217|NCT02152384|DRUG|Insulin Glargine|Administered SC
48147218|NCT01950689|DRUG|Nimorazole|
47989760|NCT03540147|DEVICE|BStrong Bands|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
47989761|NCT05608044|DRUG|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
48147219|NCT01950689|RADIATION|Radiotherapy|
48147220|NCT01870336|DEVICE|Combined treatment of medial knee osteoarthritis|
48147221|NCT01051648|DRUG|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy
48358210|NCT03086954|BIOLOGICAL|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
48147222|NCT02733731|DRUG|Chinese Herbal Compound Ointment|
48147223|NCT02733731|DRUG|Estriol|
48147224|NCT03681067|DRUG|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
48147225|NCT03681067|DRUG|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
48358211|NCT01587599|BEHAVIORAL|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
48358212|NCT03961724|DEVICE|magnetic resonance image (MRI)|serum metabolomics
48358213|NCT03974711|OTHER|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
48358214|NCT04453345|DRUG|thalidomide + prednisone + methotrexate|thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
48669853|NCT03733327|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
48669854|NCT03733327|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
48669855|NCT03733327|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
48358215|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization"
48358216|NCT01464177|RADIATION|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~* Planning tumor volume (PTV) equals GTV plus 3mm margin.~* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~* RT to begin in a maximum of 2 weeks after randomization."
48669856|NCT01072526|DRUG|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
48669857|NCT01072526|DRUG|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
48669858|NCT02569853|DRUG|DFN-11|
48669859|NCT02569853|OTHER|Placebo|
48669860|NCT02398812|OTHER|Medication assessment and treatment plan based on it|"Intervention~* Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~* Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
48147226|NCT03123224|BEHAVIORAL|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
48358217|NCT00000756|DRUG|Lymphocytes, Activated|
48358218|NCT04839913|DIAGNOSTIC_TEST|Antibodies testing|Serologic test for both SARS-COV-2 IgG and IgM
48358219|NCT04185792|DIAGNOSTIC_TEST|NBSS, Qualiveen and SF-Qualiveen|NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
48358220|NCT05746572|DRUG|MDMA|Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
48358221|NCT03323385|DRUG|N1539|Once Daily
48358222|NCT03323385|DRUG|Placebo|Once Daily
48669861|NCT04632017|DIAGNOSTIC_TEST|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
48669862|NCT02874729|PROCEDURE|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
48669863|NCT02874729|PROCEDURE|Urine collection|Urine will be collected in appropriate sterile holders provided.
48669864|NCT02874729|PROCEDURE|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
48669865|NCT02874729|PROCEDURE|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
48669866|NCT05105321|DRUG|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
48669867|NCT05105321|BEHAVIORAL|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
48358223|NCT04180475|DEVICE|MedRem application|Medication adherence smartwatch application
48358224|NCT03223740|OTHER|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
48669868|NCT02759445|OTHER|routine treatment|No intervention, only observation and describing
48669869|NCT00002414|DRUG|CPI-1189|
48669870|NCT04859192|OTHER|gamified flipped classroom|moodle will be gamified
47989762|NCT05608044|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
48669871|NCT04002375|OTHER|pectouteropexy|The surgical procedure was initiated after adhesiolysis had been performed by opening the peritoneal layer along the round ligament toward the pelvic side wall. Preparation started at the right external iliac vein and was performed in the medial and caudal direction. A segment of area approximately 3- 4 cm2 of the right lateral part of the iliopectineal ligament (Cooper ligament) adjacent to the insertion of the iliopsoas muscle was exposed.The peritoneum of the bladder was dissected, and the anterior parts of the distal uterus were prepared for mesh fixation. The uterus was elevated to the intended tension-free position using the transvaginal probe (POP-Q level 0-1). The mesh was fixed anteriorly to the cervix using four polyester permanent sutures (Ethibond Excel®; Ethicon). Finally, the mesh was covered with peritoneum using a continuous monofilament absorbable suture (Maxon™; Medtronic).
48669872|NCT00427193|BEHAVIORAL|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
48358225|NCT03223740|OTHER|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
48358226|NCT00477867|PROCEDURE|quality-of-life assessment|
48358227|NCT02994576|DRUG|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
48358228|NCT03598140|DRUG|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
48358229|NCT03598140|DRUG|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
48669873|NCT00427193|BEHAVIORAL|Control|Participants continue their current diet for 24 months
48669874|NCT05407701|DIETARY_SUPPLEMENT|Cranberry Juice|100% cranberry juice
48669875|NCT05407701|DIETARY_SUPPLEMENT|Placebo|Placebo juice
48669876|NCT04755647|DRUG|Nitric Oxide-Releasing Solution|Active antimicrobial
48358230|NCT03640104|BEHAVIORAL|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
48358231|NCT03640104|BEHAVIORAL|Nutrition guidelines|Nutritional recommendations based on international guidelines
48358232|NCT06319677|DEVICE|ECMO treatment|Critically ill patients were treated with ECMO while receiving antimicrobial therapy
48358233|NCT06144333|DIAGNOSTIC_TEST|RIPH2|"* Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:"
48358234|NCT05853640|OTHER|Usual care|Usual care at the orthopedic department consists of a clinical examination, radiological imaging, and a diagnostic injection. A recommendation to get physical therapy treatment in primary care will be provided, but this intervention will not be controlled by the investigators in any capacity.
48358235|NCT05853640|OTHER|HIPSTER|"Patients will be provided with usual care at the orthopedic department, which consists of a clinical examination, radiological imaging, and a diagnostic injection.~In addition, participants in this group will be referred to physical therapists trained in administering a semi-structured, individualized, progressive treatment. This 16-week intervention targets known physical and psychological impairments in people with long-standing hip and groin pain, using exercise therapy and patient education."
48669877|NCT04755647|DRUG|Saline solution, hypotonic|Placebo
48669878|NCT04219410|PROCEDURE|Fully minimally invasive esophagectomy|Esophagectomy using a novel fully minimally invasive approach
48669879|NCT03496116|OTHER|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
48669880|NCT01480167|DEVICE|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
48669881|NCT01480167|OTHER|Non-operative Management|Conservative Care
48669882|NCT03690908|OTHER|no intervention (descriptive study)|no intervention (descriptive study)
48669883|NCT02821325|OTHER|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
48358236|NCT03874208|OTHER|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
48358237|NCT03874208|OTHER|MRI|MRI exam
48358238|NCT01249521|DRUG|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
48147227|NCT03123224|BEHAVIORAL|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
48147228|NCT05034588|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameter
48669884|NCT05987982|PROCEDURE|Oral exercises and oral hygiene|The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
48669885|NCT05987982|PROCEDURE|Oral care|The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
48669886|NCT01578161|DRUG|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
48669887|NCT01578161|DRUG|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
48669888|NCT04527835|DIAGNOSTIC_TEST|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
48669889|NCT04707079|DRUG|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
48669890|NCT01818687|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
48669891|NCT03793621|DRUG|BI 730357|single rising oral dose
48669892|NCT03793621|DRUG|Placebo|single rising oral dose
48669893|NCT06157034|OTHER|Placebo|Inert Material
48669894|NCT06157034|DIETARY_SUPPLEMENT|Zingier officinale powder|The raw form of Zingiber officinale will be grounded in powder by manual grinding and will be encapsulated.
48669895|NCT06157034|DIETARY_SUPPLEMENT|Carum carvi, L powder|The raw form of Carum carvi, L will be grounded in powder by manual grinding and will be encapsulated.
48669896|NCT06157034|DIETARY_SUPPLEMENT|Mentha spicata oil|Mentha spicata L will be extracted in the form of oil and will be encapsulated.
48669897|NCT05152511|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy is a specially designed cabinet for infants and neonates with a barometric pressure equal to 760 mmHg for 20 minutes daily, then gradually increase up to one hour daily for 5 days per week (fig. 1). The chamber was kept warm. The babies were fed before entering the chamber and if signs of hunger appear during therapy. The baby was continuously monitored with pulse oximeter. Older children are managed in the conventional Hyperbaric oxygen chamber with the same regimen.
48669898|NCT01926132|DRUG|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
48669899|NCT01926132|DRUG|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
48147229|NCT03559777|OTHER|closed sinus lifting by Osteotome|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
48358239|NCT01521637|PROCEDURE|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
48358240|NCT01521637|PROCEDURE|Sham-treatment: no NMES|Sham comparator
48358241|NCT04129242|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
48358242|NCT05580107|DRUG|MDPK67b|24 mg or 48 mg
48669900|NCT05471986|DEVICE|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ
48669901|NCT02382354|DRUG|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
48669902|NCT02382354|DEVICE|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
48669903|NCT02382354|DEVICE|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
48669904|NCT02382354|DRUG|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
48669905|NCT04102007|DRUG|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
48669906|NCT05952050|DRUG|Dexmedetomidine|Different Administration Routes of Dexmedetomidine
48669907|NCT00928343|DRUG|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
48669908|NCT00928343|DRUG|Placebo|Matching subcutaneous or oral placebo
48669909|NCT05641935|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
48669910|NCT05641935|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
48669911|NCT05641935|PROCEDURE|Computed Tomography|Undergo CT
48669912|NCT05641935|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48147230|NCT03559777|OTHER|closed sinus lifting by Densah bur|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
48147231|NCT02162394|DEVICE|Observational ambulatory ECG monitoring|
48147232|NCT06504719|DRUG|Antibody-Drug Conjugates|Patients with advanced breast cancer treated with ADCs
48147233|NCT05873296|BEHAVIORAL|Health Education|The intervention will last for 12 weeks, a health education program (face-to-face meetings and information in social networks).
48147234|NCT06359977|OTHER|Quantitative EEG monitoring and beside ultrasound evaluation|After successful spontaneous breathing trial, neurocritical patients undergo at least 2 hours of quantitative EEG monitoring before extubation. Additionally, bedside ultrasound assesses the thickness and variability of the diaphragm, intercostal muscles, rectus abdominis, transversus abdominis, and external oblique muscles. The sputum volume for the 24 hours prior to extubation is also recorded. Reintubation within 48 hours after extubation is defined as weaning failure.
48669913|NCT05641935|OTHER|Electronic Health Record Review|Review electronic medical record
48147235|NCT05143099|DRUG|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
48147236|NCT02053506|DIETARY_SUPPLEMENT|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
48147237|NCT02053506|DIETARY_SUPPLEMENT|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
48147238|NCT02053506|DIETARY_SUPPLEMENT|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
48147239|NCT01697956|DRUG|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
48147240|NCT01697956|DRUG|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
48147241|NCT01431157|PROCEDURE|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
48358243|NCT03094481|PROCEDURE|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
48669914|NCT06226961|DEVICE|cupping|The dynamic cupping will be performed for ten minutes, at a slow pace, and consisted of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
48147242|NCT01431157|OTHER|No nasal oxygen|Patients will have no intervention for sleep apnea
48147243|NCT04631874|DRUG|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
48147244|NCT04405180|DRUG|Placebos|Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
48147245|NCT04405180|DRUG|20mg sodium nitrite tid|Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
48147246|NCT01970527|BIOLOGICAL|Ipilimumab|Given IV
48147247|NCT01970527|OTHER|Laboratory Biomarker Analysis|Correlative studies
48147248|NCT01970527|OTHER|Pharmacological Study|Correlative studies
48669915|NCT05598814|BIOLOGICAL|Mepolizumab Injection|All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.
48147249|NCT01970527|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48669916|NCT05598814|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS).|The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.
48147250|NCT02367248|DRUG|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
48147251|NCT02367248|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
48358244|NCT03094481|PROCEDURE|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
48358245|NCT03094481|PROCEDURE|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
48358246|NCT03094481|DRUG|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
48358247|NCT03087110|BIOLOGICAL|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (\>1x10\^7 cells/kg)
48358248|NCT01568983|DIETARY_SUPPLEMENT|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
48669917|NCT04715126|OTHER|Oxyjun|One capsule to be taken after breakfast with water.
48669918|NCT04715126|OTHER|Placebo|One capsule to be taken after breakfast with water.
48669919|NCT01489904|BIOLOGICAL|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
48669920|NCT03152578|OTHER|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
48669921|NCT03152578|OTHER|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
48147252|NCT02367248|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
48147253|NCT06034145|OTHER|No intervention|No intervention
48147254|NCT00417885|DRUG|exemestane|25 mg, oral, daily dosing
48147255|NCT00417885|DRUG|sunitinib malate|37.5 mg, oral, continuous dosing, daily
48147256|NCT06220578|DEVICE|Oculus pentacam HR|Examination of corneal parameters by pentacam
48147257|NCT04188457|OTHER|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
48147258|NCT04188457|OTHER|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
48669922|NCT03152578|OTHER|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
48147259|NCT03938792|DRUG|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
48358249|NCT01568983|DIETARY_SUPPLEMENT|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
48669923|NCT01920490|DEVICE|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
48669924|NCT01920490|DEVICE|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
48669925|NCT02598037|DIETARY_SUPPLEMENT|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
48147260|NCT00059384|BEHAVIORAL|Concentration-controlled therapy|
48147261|NCT02458274|OTHER|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
48147262|NCT05076838|DRUG|Diazepam Nasal Spray [Valtoco]|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
48147263|NCT02107976|DIETARY_SUPPLEMENT|Vitamin E|400 IU per day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
48147264|NCT02107976|DIETARY_SUPPLEMENT|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
48358250|NCT01568983|DIETARY_SUPPLEMENT|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
48358251|NCT00002494|DRUG|cyclophosphamide|
48358252|NCT00002494|DRUG|cytarabine|
48358253|NCT00002494|DRUG|dexamethasone|
48669926|NCT03279653|PROCEDURE|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
48669927|NCT00002429|DRUG|Lamivudine/Zidovudine|
48669928|NCT00002429|DRUG|Nelfinavir mesylate|
48147265|NCT00519844|DRUG|somatropin|
48358254|NCT00002494|DRUG|doxorubicin hydrochloride|
48358255|NCT00002494|DRUG|etoposide|
48669929|NCT00002429|DRUG|Stavudine|
48147266|NCT06092177|PROCEDURE|Periodontal surgery with virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
48358256|NCT00002494|DRUG|ifosfamide|
48358257|NCT00002494|DRUG|leucovorin calcium|
48358258|NCT00002494|DRUG|mesna|
48358259|NCT00002494|DRUG|methotrexate|
48358260|NCT00002494|DRUG|prednisone|
48358261|NCT00002494|DRUG|therapeutic hydrocortisone|
48358262|NCT00002494|DRUG|vincristine sulfate|
48358263|NCT00002494|RADIATION|low-LET cobalt-60 gamma ray therapy|
48358264|NCT00002494|RADIATION|low-LET photon therapy|
48358265|NCT03770689|DRUG|Peposertib 50 mg|Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
48358266|NCT03770689|DRUG|Peposertib 100 mg|Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
48358267|NCT03770689|DRUG|Peposertib 150 mg|Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
48358268|NCT03770689|DRUG|Peposertib 250 mg|Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
48358269|NCT03770689|DRUG|Capecitabine|Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
48669930|NCT00002429|DRUG|Didanosine|
48669931|NCT02383160|DEVICE|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
48669932|NCT02383160|DEVICE|Sham device|Placebo device with no active therapy
48669933|NCT05746988|OTHER|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
48669934|NCT03224039|DRUG|Sufentanil|Intranasal for one dose (experimental)
48669935|NCT03224039|DRUG|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
48669936|NCT03224039|DRUG|Morphine|intravenous push for one dose (active comparator)
48669937|NCT03515161|DEVICE|closed-loop|Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
48669938|NCT03763578|OTHER|Licorice|Natural herbal product
48669939|NCT05325203|BIOLOGICAL|Ongericimab|Administered by subcutaneous injection
48669940|NCT05325203|DRUG|Placebo|Administered by subcutaneous injection
48506946|NCT03247192|DIETARY_SUPPLEMENT|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
48506947|NCT03247192|DIETARY_SUPPLEMENT|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
48669941|NCT06268470|DRUG|Desloratadine plus cilostazol and dipyridamole|Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
48147267|NCT06092177|PROCEDURE|Periodontal surgery without virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
48147268|NCT02929758|BEHAVIORAL|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
48669942|NCT06268470|DRUG|Desloratadine|Desloratadine 20 mg/day
48669943|NCT05951166|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure
48147269|NCT04896567|DIAGNOSTIC_TEST|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
48669944|NCT04946630|DEVICE|PreciseInhale|Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.
48669945|NCT04946630|OTHER|Seretide Evohaler forte|Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
48669946|NCT02842593|BEHAVIORAL|Lower-repetition, heavier-load|8-12 reps/set at \~80% 1 repetition maximum
48147270|NCT03249857|BEHAVIORAL|cognitive tasks + IQ + MINI|"Patients will perform different tasks:~* cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~* Intelligence Quotient (IQ) test (PM38, Raven, 1960)~* Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
48147271|NCT03249857|BEHAVIORAL|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
48669947|NCT02842593|BEHAVIORAL|Higher-repetition, lighter-load|20-25 reps/set at \~30% 1 repetition maximum
48147272|NCT02192632|DRUG|Epiduo once daily with detailed instruction for how to apply it|
48358270|NCT03770689|RADIATION|Radiotherapy (RT)|Participants received RT 50 to 50.4 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions up to 5.5 weeks.
48358271|NCT00457093|DRUG|glargine|
48358272|NCT00457093|DRUG|detemir|
48669948|NCT04637529|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuvix®
48669949|NCT04637529|DRUG|Ibuvix® - ibuprofen|Ibuvix® + placebo of S(+) - Ibuprofen
48669950|NCT05429619|OTHER|PeerOnCall|A mobile health peer-to-peer support platform that consists of two inter-connected apps: PeerOnCall and PeerOnCall Support. The apps were co-designed by and for the public safety community in Canada, with customized content for correctional workers, emergency communicators, firefighters, paramedics and police.
48147273|NCT02192632|DRUG|Epiduo- once daily, simple instruction for application|
48147274|NCT02192632|DRUG|BPO once daily|
48147275|NCT05438875|DRUG|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
48358273|NCT04249466|OTHER|Questionnaire|"During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage."
48358274|NCT04312061|DRUG|oral tramadol|oral tramadol tablet 5o mg given 1 hour before LNG-IUD insertion
48669951|NCT01918137|DIETARY_SUPPLEMENT|chocolate bar|
48669952|NCT01918137|DIETARY_SUPPLEMENT|Porridge|
48669953|NCT06010680|DRUG|[14C]SHR2554|Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
48669954|NCT00193024|DRUG|Docetaxel|
48669955|NCT00193024|DRUG|Epirubicin|
48358275|NCT04312061|DRUG|Placebo oral tablet|oral placebo tablet given 1 hour before LNG-IUD insertion
48358276|NCT05213689|BEHAVIORAL|Educational comic book|An educational comic book was developed with qualitative data collected from an earlier study phase involving focus groups with youth from Bidi Bidi. The comic book is focused on HIV testing information and decision making as it follows the story of youth in Bidi Bidi who are seeking out HIV testing. Each youth in the appropriate arm with receive a copy of the comic book and together with 5-10 other youth will meet with a PN to read through and discuss the comic book. The comic will also include blank pages so that the youth can participate in the dialogue of the comic book. The comic will be available in English, Bari and Juba Arabic.
48358277|NCT05213689|DIAGNOSTIC_TEST|HIV Self-testing|Participants will receive HIVST kits so that they can perform their HIV testing.
48358278|NCT03198884|DRUG|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
48358279|NCT04041258|PROCEDURE|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
48358280|NCT01339845|BIOLOGICAL|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
48147276|NCT05438875|DRUG|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
48358281|NCT01339845|BEHAVIORAL|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
48358282|NCT04638036|DRUG|Cetuximab-IRDye800|Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
48358283|NCT04638036|DEVICE|Fluorescent molecular endoscopy and surgery|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe can be inserted through the standard working channel of the standard clinical endoscope for fluorescent endoscopy. Fluorescence imaging will be performed post the chemoradiotherapy.
48358284|NCT02638740|PROCEDURE|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
48358285|NCT02638740|PROCEDURE|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
48358286|NCT05643170|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
48358287|NCT01688427|BEHAVIORAL|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
48358288|NCT01688427|BEHAVIORAL|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
48358289|NCT01790763|DEVICE|Keramatrix|Dressing for second degree burn
48358290|NCT01790763|DEVICE|Mepilex|Dressing for second degree wound
48358291|NCT02622802|DRUG|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
48669956|NCT05587491|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
48358292|NCT02622802|DRUG|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
48358293|NCT02622802|DRUG|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
48358294|NCT01001884|OTHER|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
48358295|NCT01937949|DEVICE|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the groin (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
48358296|NCT06039540|DRUG|Captopril Tablets|0.3mg/kg, tid
48358297|NCT06039540|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
48358298|NCT06039540|DRUG|Spironolactone Tablets|2-4mg/kg, bid
48358299|NCT06039540|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
48358300|NCT06039540|DRUG|Potassium citrate powder|0.06g/kg, tid
48688158|NCT04717271|OTHER|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
48358301|NCT02742155|BEHAVIORAL|Play2Sleep|Behavioral: Video self-modelling
48358302|NCT02742155|BEHAVIORAL|Comparison|Behavioral: Information only
48358303|NCT02692976|BIOLOGICAL|mDC vaccination|Intranodal mDC vaccination
48358304|NCT02692976|BIOLOGICAL|pDC vaccination|Intranodal pDC vaccination
48358305|NCT02692976|BIOLOGICAL|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
48358306|NCT06409442|OTHER|Standard Physiotherapy Program|Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
48669957|NCT05271006|BEHAVIORAL|Exercise|The mHealth platform to be used by the exercise group is Down Dog, which has a suite of apps for yoga, HIIT, barre, and running workouts. Down Dog has agreed to provide free memberships for one year to all participants in the study. To ensure participant de-identification on the Down Dog platform, each participant will receive a Participant ID which will be pre-registered by the study coordinator on the Down Dog platform. Randomized participants will be provided instructions for downloading the apps onto their phone or a link to the website to be used on their computer. Following randomization, participants in the exercise group will be asked to engage in physical activity (using any if the Down Dog apps), 4 days a week for 20 minutes a day for 12 weeks.
48669958|NCT06362109|BEHAVIORAL|Routine rehabilitation|"Routine rehabilitation consists of:~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48358307|NCT06409442|OTHER|Kinesio Taping|In addition to the standard physiotherapy program, kinesio taping (device) will be applied.
48358308|NCT06409442|OTHER|Local Vibration Therapy|In addition to the standard physiotherapy program, local vibration (device) will be applied.
48358309|NCT01041885|DEVICE|INSTRUCT|INSTRUCT PolyActive scaffold implantation
48669959|NCT06362109|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
48669960|NCT01900366|PROCEDURE|Fat Biopsy|Fat biopsy
48669961|NCT00265850|BIOLOGICAL|bevacizumab|Given IV
48669962|NCT00265850|BIOLOGICAL|cetuximab|Given IV
48669963|NCT00265850|DRUG|FOLFOX or|Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
48669964|NCT00265850|DRUG|FOLFIRI|Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
48669965|NCT03940560|DEVICE|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
48669966|NCT01183351|BEHAVIORAL|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
48669967|NCT00888147|DIETARY_SUPPLEMENT|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
48358310|NCT00875966|DRUG|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
48358311|NCT00875966|DRUG|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
48669968|NCT01371058|DRUG|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
48669969|NCT01371058|DRUG|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
48669970|NCT01371058|DRUG|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
48669971|NCT06011083|DRUG|Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm|using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
48669972|NCT06011083|DEVICE|Fractional carbon dioxide (CO2) laser|fractional CO2 laser sessions once per month for 3 months over a similar psoriatic plaque
48669973|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic CGRP|Immunoassay kit for the evaluation of CGRP in blood
48669974|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic SP|Immunoassay kit for the evaluation of SP in blood
48358312|NCT00740194|DRUG|Aromatase inhibition|Letrozole
48669975|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic enkephalins|Immunoassay kit for the evaluation of enkephalins in blood
48669976|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic VIP|Immunoassay kit for the evaluation of VIP in blood
48669977|NCT05958914|DIAGNOSTIC_TEST|Dosage of CGRP in follicolar fluid|Immunoassay kit for the evaluation of CGRP in follicolar fluid
48358313|NCT00740194|DRUG|Estradiol|Dermestril
48358314|NCT03479840|PROCEDURE|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
48358315|NCT05848752|BEHAVIORAL|psychophysics|Subjects will be shown a pair of jars each filled with the same absolute number but different ratios of red/blue balls. Three blocks of trials exist, short-term inference (subjects must identify which of the equally likely jars is currently in use), long-term inference (subjects must predict the subsequent jar in use on the next trial, where jar switches are correlated across trials), or multi-timescale inference (subjects must both report the current jar and predict the subsequent jar, combining the short and longterm inferences). Subjects will draw balls as many balls as they wish with replacement (free response) during the short-term and multi-timescale blocks but will know the current jar in use for long-term inference.
48358316|NCT02405091|DRUG|NBI-98854|
48358317|NCT06147544|DRUG|PB-718|Administered subcutaneously once a week
48358318|NCT06147544|DRUG|Placebo|Administered subcutaneously once a week
48506948|NCT00299286|DRUG|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
48506949|NCT00299286|DRUG|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
48669978|NCT05958914|DIAGNOSTIC_TEST|Dosage of SP in follicolar fluid|Immunoassay kit for the evaluation of SP in follicolar fluid
48147277|NCT05343936|OTHER|Active surveillance|"The active surveillance protocol involves a TRUS prostate biopsy at eligibility, at 12 months and then every two years. MRI with or without biopsy at eligibility and then every two years. Clinical evaluation with digital rectal examination and PSA every 6 months. Every year a quality of life and anxiety evaluation are planned.~A new prostate biopsy is indicated if biochemical progression by PSA or changes in multiparametric MRI. Triggers for definitive intervention are biopsy pathological reclassification with Gleason score greater than 6, clinical progression or patient's request."
48358319|NCT04835935|OTHER|microbiome pattern|microbiome pattern in neonatal period
48147278|NCT03980236|DEVICE|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
48147279|NCT02207140|DIETARY_SUPPLEMENT|HOWARU Restore|
48358320|NCT05301140|DEVICE|Vivistim System|VNS Paired with rehabilitation movements
48506950|NCT03813810|OTHER|Non|There would be no interventions. Only measurements will be performed.
48506951|NCT03349983|BIOLOGICAL|MVA-BN-Brachyury/ FPV-Brachyury|Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
48506952|NCT00719771|DEVICE|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
48358321|NCT05669144|BIOLOGICAL|mitochondria and MSC-derived exosomes|autologous mitochondria and MSC-derived exosomes
48506953|NCT06139406|DRUG|JNJ-87801493|JNJ-87801493 will be administered subcutaneously.
48506954|NCT06139406|DRUG|JNJ-80948543|JNJ-80948543 will be administered subcutaneously.
48506955|NCT06139406|DRUG|JNJ-75348780|JNJ-75348780 will be administered subcutaneously.
48506956|NCT04061525|PROCEDURE|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
48506957|NCT03574350|BEHAVIORAL|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
48669979|NCT05958914|DIAGNOSTIC_TEST|Dosage of enkephalins in follicolar fluid|Immunoassay kit for the evaluation of enkephalins in follicolar fluid
48669980|NCT05958914|DIAGNOSTIC_TEST|Dosage of VIP in follicolar fluid|Immunoassay kit for the evaluation of VIP in follicolar fluid
48669981|NCT02472249|RADIATION|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
48669982|NCT02472249|DRUG|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
48358322|NCT03928990|DEVICE|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
48358323|NCT06135506|PROCEDURE|free-hand ridge splitting|Midcrestal incision will be followed by reflection of full thickness flap. Midcrestal cut without vertical osteotomy will be done using piezosurgery unit, and then the cut will be extended deep to the implant length. The ridge will be expanded progressively using bone wedges. Dental implant fixtures will be placed stably with 1 mm minimal thickness of buccal bone plate. Surgical site will be completely closed, and wound edges will be sutured in a tension-free way.
48669983|NCT01623063|PROCEDURE|Hysteroscopy|hysteroscopy with guided biopsies
48688159|NCT04717271|OTHER|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
47989763|NCT05608044|DRUG|Standard of Care|Regorafenib or trifluridine and tipiracil.
47989764|NCT03890549|DIAGNOSTIC_TEST|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
48669984|NCT05589987|DEVICE|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
48669985|NCT02345733|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
47989765|NCT06120621|PROCEDURE|Arm 1 : VCST-phaco group , Arm 2 : phaco group.|Arm 1 : VCST-phaco group , Arm 2 : phaco group.
47989766|NCT03689803|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy.
48506958|NCT03574350|BEHAVIORAL|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
48506959|NCT06494462|OTHER|virtual reality training|students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses
48669986|NCT02345733|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
47989767|NCT03689803|PROCEDURE|gastric bypass|gastric bypass
48147280|NCT03147222|BEHAVIORAL|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
48147281|NCT02355106|DEVICE|PolarStart System|Atrial flutter Ablation
48147282|NCT00004731|DRUG|Coenzyme Q10|
48147283|NCT01029639|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
48147284|NCT00410150|DRUG|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
48147285|NCT00410150|DRUG|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
47989768|NCT05202418|BEHAVIORAL|Biofeedback Enhanced Treatment|The intervention involves biofeedback enhanced cognitive behaviorally based coping skills treatment. Treatment will consist of a 6-visit group intervention conducted online, via Emory zoom. Groups will include 5-8 patients each. Sessions will include brief, daily homework to facilitate mastery that is developmentally tailored to youth (e.g., practice skills with support from phone or tablet apps). Groups will meet approximately every week for 6 weeks. Advanced Ph.D. students in clinical psychology and Principal Investigator will deliver the treatment protocol. Participants will complete questionnaires before and after each session to measure autonomic reactivity, lifetime stress, depression, anxiety in response to stress induction, and coping strategies.
48147286|NCT00773344|DRUG|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
48147287|NCT03983642|DEVICE|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
48506960|NCT02121392|DEVICE|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
48669987|NCT05815914|OTHER|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
48669988|NCT05815914|OTHER|control group|Routine nutritional and dietary recommendations will be given.
48669989|NCT04593121|DRUG|BIIB107|Administered as specified in the treatment arm.
48358324|NCT06135506|PROCEDURE|AI/guided ridge splitting|"The patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial buccal mucosa.~A midcrestal cut will be performed on the crest of alveolar ridge guided by the guide slits. The cuts will be expanded progressively using bone wedges through the guide slits gradually lateralize and expand the labial alveolar plate of bone, so the labial cortex will move through the intentionally created micro gap till it touches the fitting aspect of the patient specific guide. Implant drills will be inserted through the guiding holes in the surgical guide and the implant osteotomy sites will be prepared. Finally, implants will be inserted in the osteotomy sites using torque-wrench in a self-tapping fashion engaging palatal and basal bone for primary stability."
48358325|NCT03099018|DIAGNOSTIC_TEST|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
48358326|NCT03844529|DEVICE|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
48358327|NCT00983944|BIOLOGICAL|bleomycin sulfate|Given IV
48358328|NCT00983944|BIOLOGICAL|rituximab|Given IV
48358329|NCT00983944|DRUG|EPOCH regimen|Given IV or orally
48358330|NCT00983944|DRUG|cyclophosphamide|Given IV or orally
48358331|NCT00983944|DRUG|doxorubicin hydrochloride|Given IV or orally
48358332|NCT00983944|DRUG|etoposide|Given IV or orally
48358333|NCT00983944|DRUG|prednisone|Given IV or orally
48358334|NCT00983944|DRUG|vincristine sulfate|Given IV or orally
48358335|NCT03823963|COMBINATION_PRODUCT|Mepilex® Border dressing|Soft silicone self-adherent dressing (5-layers)
48358336|NCT03823963|OTHER|Standard care|The control group will receive pressure ulcer prevention standard care
48358337|NCT00498706|BEHAVIORAL|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
47989769|NCT02507583|DRUG|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
48669990|NCT04593121|DRUG|Placebo|Administered as specified in the treatment arm.
48669991|NCT02353962|OTHER|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
48669992|NCT01853709|BEHAVIORAL|Education|
48669993|NCT01853709|OTHER|Fiber free diet|
48669994|NCT01853709|DIETARY_SUPPLEMENT|Adjuvants|
48669995|NCT01853709|DRUG|Polyethylene glycol (PEG)|
48358338|NCT00498706|BEHAVIORAL|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
48358339|NCT01927276|OTHER|Gluten Free Flour|
48358340|NCT01927276|OTHER|Wheat Flour|
48358342|NCT02460042|PROCEDURE|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
48358343|NCT02460042|DEVICE|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
48358344|NCT03089008|OTHER|Eccentric exercises|
48358345|NCT03089008|OTHER|Stretching exercises|
48358346|NCT02663206|PROCEDURE|peroral endoscopic myotomy|peroral endoscopic myotomy
48358347|NCT02663206|PROCEDURE|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
48358348|NCT03523403|OTHER|Apples|3 whole Ontario-grown Gala apples
48358349|NCT04288713|DRUG|Eculizumab|A distal complement inhibitor.
48358350|NCT00959829|OTHER|Music and message|Experimental group: music and message Control group: silence
48358351|NCT03560479|DRUG|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
48358352|NCT03560479|OTHER|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
48358353|NCT03560479|DRUG|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
48358354|NCT03560479|DRUG|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
48358355|NCT03068182|DEVICE|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
48669996|NCT01853709|DRUG|Bisacodyl|
48669997|NCT03448211|DRUG|Para-toluenesulfonamide Injection (PTS)|Intratumoral injection
48669998|NCT03961308|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
48669999|NCT04681989|BEHAVIORAL|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. Instructions on how to use the physical therapy-based education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
48670000|NCT01029535|DEVICE|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
48506961|NCT02121392|DEVICE|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
48147288|NCT06416540|OTHER|Theraband Exercises plus Conventional Physiotherapy and Rehabilitation Program|"Upper extremity, shoulder flexion, abduction, elbow flexion and wrist extension movements will be applied to the study group by the physiotherapist in combination with the breathing pattern. The program will start with yellow therabant and the difficulty level will be increased according to the patient's condition. Exercise training will be applied in a total of 3 sets, 30-60 min/session, 5 days/week, 8-10 repetitions/set, depending on the condition of each patient, during the patients' stay in the intensive care unit.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient."
48147289|NCT06416540|OTHER|Conventional Physiotherapy and Rehabilitation Program|Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.
48147290|NCT04038190|BEHAVIORAL|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
48147291|NCT00604461|DRUG|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
48147292|NCT04258891|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
48147293|NCT02769130|DRUG|Losartan|Losartan is given for 12 months
48147294|NCT04387773|DRUG|GOCOVRI|"Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group."
48147295|NCT04202263|DRUG|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
48147296|NCT04202263|DRUG|Placebos|Placement of minocycline cream 0%
48147297|NCT01063465|DEVICE|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
48147298|NCT00021333|BIOLOGICAL|filgrastim|
48147299|NCT00021333|DRUG|cisplatin|
48147300|NCT00021333|DRUG|paclitaxel|
48147301|NCT00021333|RADIATION|radiation therapy|
48147302|NCT02629575|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
48147303|NCT05693428|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
48147304|NCT05693428|DRUG|Isoflurane|isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
48358356|NCT03068182|DEVICE|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
48358357|NCT03068182|OTHER|Exercise|
48358358|NCT00065221|DRUG|Ginger|
48358359|NCT02959736|BEHAVIORAL|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
48358360|NCT01599585|BEHAVIORAL|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
48358361|NCT03261544|PROCEDURE|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
48358362|NCT04744311|OTHER|ObsQoR-11T Questionnaire|The ObsQoR-11T questionnaire consists of 11 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
47989770|NCT03456674|DEVICE|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
48506962|NCT02121392|DRUG|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
48358363|NCT02994199|OTHER|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
48358364|NCT01110889|DRUG|Agomelatine (AGO178C)|
48358365|NCT01110889|DRUG|Agomelatine (AGO178C)|
48670001|NCT06135584|DRUG|Pioglitazone metformin tablets|Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
48670002|NCT06135584|DRUG|Other drugs|Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
48670003|NCT06135584|OTHER|Drug-free|Drug-free
48670004|NCT02563782|BIOLOGICAL|Sub-retinal transplantation of MA09-hRPE cells|transplantation
48670005|NCT02563782|DRUG|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
48670006|NCT02563782|DRUG|Placebo tacrolimus and mycophenolate mofetil|placebo
48670007|NCT02563782|PROCEDURE|Sham Surgery|Sham surgery
48670008|NCT02947191|BIOLOGICAL|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
48670009|NCT06398873|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300mg/2 weeks
48670010|NCT04142489|OTHER|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
48670011|NCT06100757|DEVICE|Micra Transcatheter Pacing System (TPS°|Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
48670012|NCT06100757|DEVICE|Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR|Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
48670013|NCT03586947|DRUG|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
48358366|NCT01110889|DRUG|Placebo|
48358367|NCT04778228|DEVICE|mechanical ventilation|"critically ill patients requiring mechanical ventilation (MV) were ventilated using high tidal volumes (Vt) and high airway pressures, until the pivotal ARDS net randomized controlled trial (RCT) demonstrated that a lung-protective MV strategy using a Vt of 4-8 mL/kg predicted body weight (PBW) and moderate levels of positive end-expiratory pressure (PEEP) improved survival (2). Since then, limitation of Vt to 4-8 mL/kg PBW, plateau pressures (Pplat) to a maximum of 30 cm H2O, and application of PEEP 10 -16 cm H2O represent the standard for MV in ARDS patients."
48670014|NCT04052009|OTHER|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
48670015|NCT04052009|OTHER|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
48670016|NCT04052009|OTHER|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
48358368|NCT03853057|OTHER|body positions|positive pressure ventilation at different body positions
48358369|NCT02062099|DRUG|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
48670017|NCT05785208|DRUG|Osimertinib|Osimertinib will be administered at a dose of 80 mg daily until disease progression
48358370|NCT02053649|BEHAVIORAL|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
48506963|NCT03278392|BEHAVIORAL|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
48506964|NCT03278392|BEHAVIORAL|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
48670018|NCT04891029|DIAGNOSTIC_TEST|DOvEEgene test|Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers
48670019|NCT02359903|DRUG|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
48670020|NCT02359903|DRUG|Infliximab (Remicade)|
48688160|NCT04054206|DRUG|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
48688161|NCT02089009|OTHER|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
48688162|NCT02089009|OTHER|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
48688163|NCT02089009|OTHER|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
48147305|NCT05693428|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
48147306|NCT00078832|DRUG|anastrozole|aromatase inhibitor
48358371|NCT02053649|OTHER|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
48358372|NCT05639361|BEHAVIORAL|Repeated Exposure|Caregivers will be asked to offer a novel vegetable to their infant/toddler 10 times at home according to the schedule of repeated exposure to which they are randomized.
48358373|NCT06449794|DIAGNOSTIC_TEST|Anti Phospholipid antibodies|diagnosis of SLE
48358374|NCT06449794|RADIATION|EEG|EEG for Cases with seizures.
48358375|NCT04440306|PROCEDURE|Mini-Gastric Bypass - Original Technique|Mini-Gastric Bypass - Original Technique is widely used form of bariatric surgery and includes a tailored BPLL
48506965|NCT02212379|DRUG|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
48506966|NCT05279300|DRUG|CS5001|CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.
48506967|NCT00157924|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
48670021|NCT04244734|OTHER|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
48688164|NCT00709176|BEHAVIORAL|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
48147307|NCT00078832|DRUG|placebo|Arimidex placebo
48147308|NCT04267952|BEHAVIORAL|Hand hygiene intervention program developed according to planned behavior theory|The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).
48506968|NCT00157924|DRUG|atorvastatin|atorvastatin 10mg
48506969|NCT00813800|DRUG|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
48506970|NCT04011670|OTHER|200 mg caffeine tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
48506971|NCT04011670|OTHER|Non-active tablet|"* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~* Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
48506972|NCT05279313|DRUG|Centanafadine Hydrochloride|Capsule
48506973|NCT05250011|DRUG|Dapagliflozin|Dapagliflozin, prescribed as per approved indication and current medical practice. Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
48506974|NCT00351884|DRUG|Vildagliptin AM|
48506975|NCT00351884|DRUG|vildagliptin pm|
48506976|NCT00351884|DRUG|placebo|
48506977|NCT00143390|DRUG|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
48506978|NCT00143390|DRUG|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
48506979|NCT06632535|OTHER|Chiropractic care|Chiropractic treatment will involve a personalized treatment plan within the context of a general care protocol administered by a chiropractor at the Osher Clinical Center for Integrative Health. The treatment plan will be customized to the patient's clinical needs following the current evidence and clinical practice guidelines.
48506980|NCT06632535|OTHER|Group medical visits|Participants will simultaneously enroll in virtual group medical visits with group discussion, practice based learning, and curricular themes pertaining to chronic pain management, healthy aging, and pillars of lifestyle medicine.
48506981|NCT05817682|OTHER|Interprofessional education|"The study will be conducted among students of the Krakow Academy. The experimental group will consist of 35 students participating in the Interdisciplinary Circle of Medical Simulation from the following faculties: medicine, nursing and medical rescue.~Students will be divided into 7 interprofessional teams, in which they will take classes planned for small groups."
48506982|NCT02369991|PROCEDURE|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
48506983|NCT04177784|OTHER|Online Educational Videos|The videos were developed by the researchers based on a prior study to test if specific information about obesity and weight control influence weight bias.
48506984|NCT00735605|OTHER|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
48506985|NCT00735605|PROCEDURE|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
48506986|NCT00735605|OTHER|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
48506987|NCT05134337|DRUG|LOXO-305|Oral LOXO-305
48506988|NCT05134337|DRUG|Itraconazole|Oral itraconazole
48506989|NCT05134337|DRUG|Rifampin|Oral rifampin
48506990|NCT02573844|DRUG|Proklama|
48506991|NCT02573844|DRUG|Placebo|
48506992|NCT06075576|DIAGNOSTIC_TEST|Intervention|No test articles will be used in the study. However, while taking measurements, the subject's eye will be exposed to light or light flashes that are about the same or lesser intensity than those in a routine eye exam in an eye care provider's office.
48506993|NCT05786846|DRUG|Iodinated contrast agents|Patients who use iodinated contrast agents clinically
48506994|NCT05135403|DEVICE|Defibrillation|External defibrillation from a wearable cardioverter defibrillator
48147309|NCT04267952|BEHAVIORAL|Classical hand hygiene education|expression of hand hygiene with verbal presentation method in a 40-minute lecture
48147310|NCT00584909|DRUG|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
48147311|NCT05124210|BIOLOGICAL|Sotrovimab|Sotrovimab will be administered.
48147312|NCT00547456|DRUG|Oxygen|Oxygen 2-3L Nasal cannula
48358376|NCT03561844|OTHER|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
48358377|NCT01492660|DEVICE|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
48358378|NCT01492660|DEVICE|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
48506995|NCT05408585|OTHER|Regional Anesthesia Techniques|Fascial Plane Blocks
48506996|NCT05930457|DRUG|2.5-3.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.
48506997|NCT05930457|DRUG|3.5-4.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 3.5-4.5mCi 64Cu-FAPI-XT117 injection.
48506998|NCT05930457|DRUG|4.5-5.5mCi 64Cu-FAPI-XT117|64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.
48506999|NCT01528007|DRUG|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
48507000|NCT01528007|DRUG|Placebo|Placebo pill with no active ingredients.
48507001|NCT05736653|DEVICE|Task-specific PCMS|120 pairs of TMS and PNS volleys will be administered during electromyography-triggered functional electrical stimulation (FES)-assisted task-specific training (task-specific PCMS). In the task-specific PCMS, participants will first grasp a spherical ball when prompted by an auditory 'Ready' cue, and upon seeing a visual 'Go' cue will voluntarily extend the wrist and fingers to release the ball. After the 'Go cue', our customized stimulation delivery algorithm triggers the TMS and PNS only when the extensor digitorum communis (EDC) muscle activity exceeds a pre-determined threshold. The algorithm will then trigger FES to EDC after detecting EDC activity (\~2 ms after PNS) for the next 2 seconds, allowing the pairing of PCMS (TMS and PNS) with the voluntary movement of EDC without the confounding effects of FES.
48507002|NCT05736653|DEVICE|Task-specific sham-PCMS|120 pairs of sham-PCMS stimuli will be administered during task-specific practice. The TMS coil will be placed \~10 cm behind the participant's head, and PNS electrodes will be placed in the same position as for task-specific PCMS, but no stimulation will be delivered. Like the task-specific PCMS condition, participants will perform the same grasp and release a ball task in an identical manner. FES will be delivered after detecting voluntary EDC activity, similar to the task-specific PCMS condition.
48688165|NCT00709176|BEHAVIORAL|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
48688166|NCT04727450|BEHAVIORAL|Cognitive training|Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
48688167|NCT04727450|BEHAVIORAL|physical training|"Involves learning of preselected routines of line dancing taught by a line dance instructor."
47989771|NCT05394987|DEVICE|Spectacles|"Prescription of refractive error correction in spectacles. Refractive error to be determined as part of standard optometric eye exam (performed by registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group \[PEDIG\] amblyopia clinical trial protocols): Hypermetropia: not undercorrected by \>+1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia: full correction of the anisometropic difference. Astigmatism: cylinder power in each eye should be within ≤±0.50D of fully correcting the astigmatism for each eye. If cylinder power is ≥1.00D, the prescribed axis in both eyes should be within ≤±6 deg of the cycloplegic refraction axis.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., \>50% of waking hours) for the duration of the study."
48670022|NCT04244734|OTHER|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
48147313|NCT03955406|PROCEDURE|Conventional Low flow Anesthesia|During the initial wash-in period 4 L/min Fresh gas flow will be used.
48147314|NCT03955406|PROCEDURE|Low Flow Anesthesia with fixed fresh gas flow rate|Fresh gas flow rate will be 1 L/min throughout the procedure.
48147315|NCT06100354|OTHER|Answering preference|Patients will answer a questionnaire with two possible choices describing several scenario of used of customized and connected prosthesis
48147316|NCT05059145|DRUG|Chlorhexidine Gluconate|Vaginal cream 1%
48147317|NCT05059145|DRUG|Fluconazole|150 mg oral capsule
48147318|NCT01875016|PROCEDURE|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
48147319|NCT03659942|OTHER|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
48147320|NCT05007002|DEVICE|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
48358379|NCT01027065|DRUG|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
48147321|NCT05281588|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
48147322|NCT01231074|DRUG|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
48147323|NCT01593137|DRUG|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin \>1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
48147324|NCT01593137|DRUG|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin \>1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
48147325|NCT06506175|DRUG|HRS9531 tablets|HRS9531 tablets
48147326|NCT00570622|DRUG|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
48358380|NCT01027065|DRUG|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
48358381|NCT03884803|BEHAVIORAL|E-health website|Access to the e-health intervention (website)
48358382|NCT03884803|OTHER|Standard Care|Control group to continue with standard care
48147327|NCT00570622|DRUG|Placebo|Patients receive placebo once a day orally for 9 days
48358383|NCT03599284|DRUG|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
48358384|NCT03599284|DRUG|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
48358385|NCT03599284|DRUG|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
48358386|NCT03599284|DRUG|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
48358387|NCT06110091|BEHAVIORAL|Integrated Behavioral Therapy Program|Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
48670023|NCT06495957|OTHER|Electroacupuncture group|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes.
48670024|NCT06495957|OTHER|Micro-acupuncture group|After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes. Electrical stimulation is applied briefly for the first 30 seconds.
48670025|NCT06304155|DIAGNOSTIC_TEST|Diagnostic efficacy,SUV|"The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 18F-FAPI PET were calculated and compared to evaluate the diagnostic efficacy.~Standardized uptake value (SUV) of 18F-FDG and 18F-FAPI for each target lesion of subject or suspected primary tumor or/and metastasis."
48670026|NCT04265131|OTHER|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
48670027|NCT00154349|DRUG|Imatinib Mesylate|
48670028|NCT01657305|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
48670029|NCT01657305|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
48670030|NCT04179110|DRUG|Pembrolizumab and Ramucirumab|Patients will receive Pembrolizumab 200 mg \& Ramucirumab 10 mg/kg every 3 weeks.
48670031|NCT01792167|BEHAVIORAL|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
48670032|NCT05900076|DIAGNOSTIC_TEST|Curettage for the evacuation of the product of conception|The product of conception taken during the intervention will be recovered at Day 1
48670033|NCT01746290|OTHER|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
48670034|NCT01529229|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
48670035|NCT01529229|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
48670036|NCT00046072|DRUG|E5564|
47989772|NCT02596594|DEVICE|fetal nutrition port system|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
48147328|NCT05167578|BEHAVIORAL|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
48670037|NCT02076945|PROCEDURE|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
48670038|NCT06141928|OTHER|Functional recovery analysis|Functional recovery analysis with force evaluator \& tester
48147329|NCT02556697|DEVICE|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
48670039|NCT03504228|DEVICE|Roadsaver|Dual layer micromesh Roadsaver carotid stent
48670040|NCT02282748|OTHER|No intervention|
48358388|NCT06110091|BEHAVIORAL|Health Education Program|Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
48670041|NCT04972253|DRUG|Infigratinib|Oral, dosage per protocol
48670042|NCT02832414|BEHAVIORAL|Intensive weight loss program|behavioral and dietary supplement
48670043|NCT04513782|DIAGNOSTIC_TEST|Audiological Assessments|Participants will all undergo routine audiological assessments. The results from these assessments will be evaluated in order to advance understanding of central hearing loss.
48670044|NCT03766984|DRUG|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
48670045|NCT03766984|DRUG|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
48670046|NCT03766984|DRUG|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
48670047|NCT02184533|DRUG|sodium selenite|Given PO
48670048|NCT02184533|RADIATION|radiation therapy|Undergo radiation therapy
48670049|NCT02184533|OTHER|laboratory biomarker analysis|Correlative studies
48670050|NCT02184533|OTHER|pharmacological study|Correlative studies
48670051|NCT02184533|OTHER|questionnaire administration|Ancillary studies
48670052|NCT06005987|BEHAVIORAL|OneTouch Reveal application|Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
48670053|NCT05401981|OTHER|Story checklist|The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
48670054|NCT02827721|DEVICE|impulse oscillometry|
48670055|NCT02827721|DEVICE|multiple breath washout test|
47989773|NCT00196560|DEVICE|Immobilization in External Rotation|
47989774|NCT04723381|OTHER|web based education|Expert support and consultancy were received for the design and preparation of the web page.
48358389|NCT00284258|DRUG|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
48358390|NCT00284258|DRUG|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
48358391|NCT05649046|DEVICE|thoracic scan Low dose|within 3 months after the V0 visit
48358392|NCT05649046|BIOLOGICAL|BLOOD SAMPLE|within 3 months after the V0 visit
48670056|NCT02827721|DEVICE|body plethysmography|
48670057|NCT05455892|OTHER|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
48670058|NCT00380926|DRUG|polyunsatturated fatty acids (fish oil)|
48358393|NCT05649046|BIOLOGICAL|FECES SAMPLE|within 3 months after the V0 visit
48358394|NCT00243490|PROCEDURE|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
48358395|NCT00073515|DRUG|Alfimeprase|
48358396|NCT04765839|OTHER|Educational, culturally appropriate COVID-19 messages|Educational, culturally appropriate COVID-19 messages will be developed and shared by RHCP.
48358397|NCT01196091|DRUG|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
48358398|NCT01196091|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
48358399|NCT01196091|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
48358400|NCT01196091|DRUG|Standard of Care|
48358401|NCT02061540|DRUG|LUM001|LUM001 oral dose
48670059|NCT03560492|OTHER|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
48670060|NCT03560492|DEVICE|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
48147330|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~1. Normal result~2. Ultralow or Dysbiotic result~3. Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
48147331|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
48358402|NCT05344859|BEHAVIORAL|Weekly Automated Health Coaching|This intervention will involve health coaching delivered by Artificial intelligence (AI). The automated health coaching mechanism will be coupled with AI-based responses, and recent advancements have made the voices generated through the AI, almost human-like voices. Every week participants enrolled in automated health coaching intervention will receive a health coaching and goal-setting call that will help guide the participants in managing their Type 2 Diabetes Mellitus. This technology-driven study group will inform us whether trained human coaches are required or if the automated technologies are sufficient to create clinically meaningful HbA1c improvements.
48670061|NCT00656682|BEHAVIORAL|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
48670062|NCT00656682|BEHAVIORAL|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
48670063|NCT04982991|DRUG|RIPK1 inhibitor|Capsule Oral
48670064|NCT02553629|DRUG|Rocuronium|
48670065|NCT01758029|DRUG|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
48670066|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
48670067|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
48670068|NCT01923636|OTHER|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
48670069|NCT03589274|BEHAVIORAL|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
48670070|NCT03589274|BEHAVIORAL|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
48358403|NCT05344859|BEHAVIORAL|Weekly Human Health Coaching|Every week participants enrolled in human health coaching intervention will receive a health coaching call and goal-setting call from their respective health coaches to guide them in managing their Type 2 Diabetes Mellitus.
48670071|NCT00649350|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
48358404|NCT05344859|BEHAVIORAL|Adapted Reward Level|In the adapted reward (gamified) variation, participants will receive 25 cents per day for the first week of daily-monitoring calls, 50 cents per day in the second week, 75 cents per day in the third week, and a dollar per day from the fourth week until the end of the study (Aim 2). In the adaptive variation, missing one day of monitoring (in the past seven days), drops the reward value by one level (example: 75 cents becomes 50 cents), two days of missed calls drop the reward level by two levels, and similarly for three days. In the adaptive variation, participants have to continue to daily monitor their behavior to again build up their reward levels.
48358405|NCT05344859|BEHAVIORAL|Fixed Gamified Reward Level|In our fixed-reward arm, participants will be awarded 25 cents per day for answering the daily monitoring call - this serves simply as a reward for answering the daily calls. It is important that the rewards are for answering the calls and not for the actual values of the responses provided.
48358406|NCT02489656|DEVICE|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
48358407|NCT06360510|PROCEDURE|%5 dextrose injection|hydrodissection with %5 dextrose
48358408|NCT06360510|PROCEDURE|betamethasone injection|perineural betamethasone injection
48358409|NCT02933489|DIAGNOSTIC_TEST|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
48358410|NCT02933489|DIAGNOSTIC_TEST|Digital Tomosynthesis Mammography|Undergo DBT
48670072|NCT00649350|DRUG|Glucophage XR 750 mg|750mg, single dose fed
48670073|NCT03849105|RADIATION|4-L-[131I]iodo-phenylalanine (131I-IPA)|"Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"
48670074|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
48670075|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
48670076|NCT02447185|DRUG|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
48670077|NCT02447185|DRUG|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
48670078|NCT00300014|PROCEDURE|Intravitreal triamcinolone injection|
48670079|NCT00300014|PROCEDURE|Air-fluid exchange|
48670080|NCT04919434|OTHER|IRECO|During 5 days, women included in the study will have to only use personal care product distributed by the research team.
48670081|NCT04032821|DRUG|Alkotinib（300mg)|1. First empty stomach, after the meal.2. After eating first, after fasting.
48670082|NCT03569189|OTHER|High Fat Diet|"Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
48670083|NCT04391712|DEVICE|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
48147332|NCT00980538|DRUG|Etravirine|Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
48147333|NCT06192459|DEVICE|Modality physical therapy|Magnetotherapy, low-energy laser, electrotherapy, etc.
48358411|NCT02933489|OTHER|Quality-of-Life Assessment|Ancillary studies
48358412|NCT02933489|OTHER|Questionnaire Administration|Ancillary studies
48358413|NCT00605228|DRUG|MOVIPREP|2L Drug
48358414|NCT00605228|DRUG|COLOPEG|4L Drug
48358415|NCT06091202|BEHAVIORAL|CORPs Intervention|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
48670084|NCT04391712|OTHER|Regular Inpatient Medical Care|Regular inpatient medical care
48670085|NCT00146744|BIOLOGICAL|Mtb72F/AS02A|
48670086|NCT06159907|DIAGNOSTIC_TEST|the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors|"For the evaluation of patients affected by endometrial cancer, the correlations between semi-quantitative PET parameters (SUVmax, SUVmean, MTV and TLG calculated at different SUVmax thresholds) and histological data, such as for example myometrial invasion, will be investigated. lymph node invasion, tumor grade and type, risk level, probability of mutation of the p53 gene, etc.~In addition to traditional imaging parameters we will also investigate the usefulness of radiomic features, i.e. quantitative data extracted from PET images (PET/CT or PET/MRI), in predicting and explaining histological data"
48670087|NCT01868828|DRUG|PAD|Induction Therapy of PAD for 4 cycles.
48670088|NCT01868828|DRUG|VCD|Induction Therapy of VCD for 4 cycles.
48670089|NCT01868828|OTHER|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
48670090|NCT00611390|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
48670091|NCT00611390|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
48670092|NCT01317303|PROCEDURE|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
48670093|NCT01317303|PROCEDURE|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
48358416|NCT06091202|BEHAVIORAL|Minimally Enhanced Usual Care (MEUC)|"Participants will be randomly assigned to the intervention or to the comparator arm. The follow-up period is 12 months. The primary outcome is a change in pain interference.~After the baseline assessment, participants will complete a masked telephone assessments with research staff at 3-, 6-, 9-, and 12-months.~A subset of individuals may be invited to participate in a qualitative interview at 12-month follow-up."
48358417|NCT04735432|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
48670094|NCT01317303|PROCEDURE|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
48670095|NCT01317303|PROCEDURE|iTBS|190 seconds of intermittent theta-burst stimulation
48670096|NCT01286597|DIETARY_SUPPLEMENT|dietary restriction|restrict intake of lactose
48688168|NCT04727450|BEHAVIORAL|Combination of cognitive and physical training (CCPT)-BIGMAP|BIGMAP is a program engaging participants in specially designed cognitive/memory games together with physical training (Fu \& Chow, 2019).
48358418|NCT04735432|BIOLOGICAL|efgartigimod IV|Intravenous infusion of efgartigimod
48358419|NCT02203006|BIOLOGICAL|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
48670097|NCT06118645|DRUG|cadonilimab combined +paclitaxel (albumin-bound)|"1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase"
48670098|NCT00111072|DRUG|dexamethasone 0.01% solution|
48670099|NCT04494048|OTHER|Endoscopic Bariatric Therapies|Participation in this study will allow for data collection through medical chart review for at least 6 standard of care visits up to 1 year after consenting to participate in this registry study. The exposure of interest is total body weight loss, safety and efficacy
48670100|NCT02814656|DRUG|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
47989775|NCT03784404|PROCEDURE|Transvaginal aspiration|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
48670101|NCT02814656|DRUG|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
48670102|NCT05456529|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.
48670103|NCT01142440|BEHAVIORAL|behavioral intervention|"* Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups"
47989776|NCT03784404|PROCEDURE|transvaginal aspiration and surgicel injection|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
48358420|NCT01318291|BEHAVIORAL|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
48358421|NCT01318291|BEHAVIORAL|Control|Medical treatment alone
48358422|NCT04815915|OTHER|Graston technique|Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
48670104|NCT03097289|DEVICE|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
48670105|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
48670106|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
48670107|NCT00067561|DRUG|Alosetron|
48358423|NCT00250094|DRUG|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is \>1,500 and platelets \> 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
48670108|NCT04496479|BIOLOGICAL|LYG-LIV0001|Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
48670109|NCT03237806|DRUG|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
48670110|NCT03237806|DRUG|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
48670111|NCT00133627|DRUG|Ketotifen|
48358424|NCT03977506|DIAGNOSTIC_TEST|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
48358425|NCT01128855|DRUG|3 mg/kg GSK2402968|Weekly subcutaneous injection
48147334|NCT06192459|OTHER|Combined therapy:|Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
48358426|NCT01128855|DRUG|6 mg/kg GSK2402968|Weekly subcutaneous injection
48358427|NCT01128855|DRUG|9 mg/kg GSK2402968|Weekly subcutaneous injection
48358428|NCT01128855|DRUG|12 mg/kg GSK2402968|Weekly subcutaneous injection
48358429|NCT01128855|OTHER|Placebo|Weekly Placebo
48358430|NCT04771936|OTHER|Physiotherapy Exercises|All patients shall be randomly assigned to 3 groups: the control group who shall be awaiting surgery and not receiving a regular physiotherapy, the exercise group who shall be subject to a set of conventional exercises and a core exercise group who shall be performing the conventional exercises plus exercises aimed at the activation of core muscles. These exercises shall be carried out 3 times weekly for a period of 3 months. During the first 4 weeks, all sessions shall be supervised by a physiotherapist. From the 5th to the 8th week, patients shall attend 2 supervised sessions and complete the 3rd one at home. Between the 9th and the 12th week, patients shall then attend 1 supervised intervention and complete 2 sessions at home.Patients assigned to the control group shall be given a chance to enrol into the program upon completion of the study if they wish to do so.
48358431|NCT01584427|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
48358432|NCT04709406|DRUG|deep neuromuscular blockade in bariatric surgery|obese patients who underwent bariatric surgery
48358433|NCT05512195|RADIATION|New delineation approach|New delineation approach
48358434|NCT05761769|OTHER|no intervention|no intervention
48358435|NCT01273506|DRUG|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
48358436|NCT01273506|DRUG|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
48358437|NCT01276873|DEVICE|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
48358438|NCT00539825|DRUG|GSK704838|
48670112|NCT03544450|BEHAVIORAL|Psychosocial counselling|"Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support)."
48670113|NCT03544450|OTHER|Enhanced Usual Care|Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
48670114|NCT03507582|OTHER|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
47989777|NCT03784404|DRUG|Intracytoplasmic sperm injection|"Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance."
48507003|NCT05736653|DEVICE|PCMS-rest|120 pairs of TMS and PNS volleys will be administered with the EDC muscle at rest every 10 s (\~20 min, 0.1 Hz). TMS will be used to elicit motor-evoked potentials (MEPs). Antidromic activation of spinal motor neurons will be elicited by supramaximal peripheral nerve stimulation (PNS) applied to the radial nerve near the elbow. Volleys will be timed to arrive in the spinal cord based on central and peripheral conduction times calculated for each subject so that the pre-synaptic terminal is depolarized via TMS \~1-2 ms before spinal motor neurons are depolarized via PNS at a pulse duration of 200us. We will also perform stimulation of the cervical roots (C-root) by placing the coil behind the neck and stimulating the C-root (C6 and C7 vertebrae), which innervate the finger extensor muscles. Conduction times will be calculated from latencies of the primary motor area (M1) MEP, C-root, and M-wave.
47989778|NCT04102215|DEVICE|HEARO|Robotic system for otological procedures
48507004|NCT06233591|DRUG|LP-10 (Liposomal Tacrolimus)|Liposomal oral rinse formulation of Tacrolimus
48147335|NCT01921166|DRUG|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
48147336|NCT01921166|DRUG|Leuprolide flare|Leuprolide flare ovulation induction
48147337|NCT06236204|PROCEDURE|Arthroscopic Scapholunate Ligament Reconstruction|reconstruction of the SL ligament with palmaris tendon graft tunneled through the scaphoid and lunate as described by Corella et al.
48507005|NCT00976911|DRUG|Bevacizumab|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
48507006|NCT00976911|DRUG|liposomal doxorubicin|40mg/m2 iv every 4 weeks
48507007|NCT00976911|DRUG|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
48507008|NCT00976911|DRUG|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
47989779|NCT04102215|DEVICE|OTOPLAN|Otological surgical planning software
48147338|NCT00308308|DRUG|Technosphere Insulin|Inhalation, 15U/30U
48147339|NCT00308308|DRUG|Active comparator|sc injectable insulin
48147340|NCT04721483|PROCEDURE|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
48147341|NCT01594606|BEHAVIORAL|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
48507009|NCT02346591|BEHAVIORAL|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
48507010|NCT02346591|BEHAVIORAL|Online stress management information|Online educational information about stress management
48670115|NCT03507582|OTHER|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
48670116|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,25%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume."
48670117|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,16%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume"
48670118|NCT04384614|DIAGNOSTIC_TEST|Test PCR|Viral load (COVID+) testing by PCR
48670119|NCT04384614|GENETIC|TDR|IDR and blood sampling for testing DNA Cheque
48670120|NCT04384614|OTHER|Clinical Examination|COVID 19 symptoms and Physical Examination
48670121|NCT03069378|DRUG|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
48670122|NCT03069378|DRUG|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
48358439|NCT01815866|PROCEDURE|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
48507011|NCT04720131|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks.
48358440|NCT02559830|GENETIC|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10\^6 transduced CD34+ cells/Kg (maximum 20x10\^6) at bedside for infusion.
48358441|NCT03187795|DRUG|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
48507012|NCT04720131|DRUG|apatinib|"Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage."
48507013|NCT04720131|DRUG|Capecitabine|Capecitabine was administered 1000mg/m2 orally, b.i.d. every 3 weeks (Day 1-14 of a treatment cycle)
48507014|NCT04465695|DRUG|Interferon beta-1b|Subcutaneous injection of interferon β-1b 1mL (0.5mg; 16 million IU) for 3 days
48507015|NCT04465695|DRUG|Clofazimine|Oral 100mg twice daily on day 1, then 100mg daily for 2 days
48507016|NCT03883308|BEHAVIORAL|Multi-domain cognitive training|The cognitive exercises are designed to train executive functions and memory.
48507017|NCT03883308|BEHAVIORAL|Cross-word puzzle training|The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
48507018|NCT03604315|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
48507019|NCT03604315|PROCEDURE|Computed Tomography|Undergo \[18F\]FTT PET/CT
48507020|NCT03604315|RADIATION|Fludeoxyglucose F-18|Given IV
48507021|NCT03604315|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
48507022|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
48507023|NCT03604315|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET/CT
48670123|NCT06279611|DRUG|LY007|FC and LY007 infusion
48670124|NCT00003816|BIOLOGICAL|anti-thymocyte globulin|Given IV
48670125|NCT00003816|DRUG|busulfan|Given IV
48670126|NCT00003816|DRUG|carboplatin|Given IV
48670127|NCT00003816|DRUG|cyclophosphamide|Given IV
48670128|NCT00003816|DRUG|etoposide|Given IV
48670129|NCT00003816|DRUG|fludarabine phosphate|Given IV
48670130|NCT00003816|DRUG|melphalan|Given IV
48670131|NCT00003816|DRUG|thiotepa|Given IV
48670132|NCT00003816|RADIATION|total-body irradiation|Given twice daily for 3 days
48670133|NCT00497003|DRUG|Treatment with either metoprolol or carvedilol|
48670134|NCT05945888|DRUG|BI 3000202|BI 3000202
48670135|NCT05945888|DRUG|Placebo matching BI 3000202|Placebo matching BI 3000202
48670136|NCT00503984|DRUG|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
48358442|NCT03187795|DRUG|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
48358443|NCT05826431|DEVICE|Cubii elliptical|Low impact, portable, and compact elliptical for seated use.
48358444|NCT05644639|DEVICE|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
48358445|NCT05832008|BEHAVIORAL|Patient Nudge|Brief persuasive messaging to increase awareness about the importance of annual lung cancer screening and completion of recommended follow-up sent to patients via text message.
48358446|NCT05832008|BEHAVIORAL|Clinician Nudge|EHR-based Prompts - an pended order and message that alerts a clinician if a patient is due for screening or diagnostic follow-up.
48358447|NCT05008718|OTHER|38% SDF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
48358448|NCT05008718|OTHER|5% NaF group|Participants will be randomized and will receive either 38% SDF treatment or 5% NaF treatment
48358449|NCT02689089|DRUG|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
48358450|NCT04700891|DIAGNOSTIC_TEST|Olfactory identification test|"Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function."
48358451|NCT04700891|DIAGNOSTIC_TEST|Edmonton Frail Scale|The Edmonton Frail Scale (EFS) involves nine domains of frailty : functional performance, cognitive function, general health, functional independence, social support, used medications, nutrition, mood and continence. It has been validated with respect to comprehensive geriatric assessment and to other screening tools related to frail state. EFS test is considered most appropriate for use in routine preoperative screening and only requires 5 minutes.
48358452|NCT04700891|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength is a simple and reliable measurement technique for the assessment of maximal voluntary hand force. Handgrip strength is used as a reflect of nutritional status and muscle mass, physical function and health status. Measurement will be realized using a digital handgrip dynamometer. Patients will be asked to grip the dynamometer with the second finger node at 90° angle to the handle and to grab the handle as strongly as they can. Maximal grip strength will be checked with the forearm away from the body in standing position.
48358453|NCT05651412|OTHER|Dynamic gait index and 5 time sit to stand test|dynamic gait index and 5 time sit to stand test was administered to all sample size of 400
48358454|NCT01943396|PROCEDURE|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
48358455|NCT05285397|DRUG|Liraglutide Pen Injector [Saxenda]|Subcutaneous injection of GLP-1 agonist
48358456|NCT06282731|DRUG|Silodosin|Indications:Benign prostate hyperplasia
48670137|NCT00503984|DRUG|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
48670138|NCT00503984|DRUG|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
48670139|NCT00503984|GENETIC|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
48670140|NCT00503984|DRUG|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
48670141|NCT00503984|DRUG|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
48358457|NCT01931020|DRUG|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
48670142|NCT04578626|DEVICE|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
48507024|NCT06492278|BEHAVIORAL|SMART-3RP|The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
48507025|NCT06492278|BEHAVIORAL|Health Education Program|This is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team.
48507026|NCT01616030|OTHER|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
48507027|NCT03214393|DIAGNOSTIC_TEST|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
48507028|NCT03214393|DIAGNOSTIC_TEST|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
48670143|NCT05618444|BEHAVIORAL|Automated Management (AM)|A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
48670144|NCT03510273|DEVICE|Liger Medical Thermocoagulator|"Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)"
48670145|NCT05853354|BIOLOGICAL|Denosumab|Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
48358458|NCT01931020|DRUG|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
48358459|NCT00474552|DRUG|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
48358460|NCT00382044|DRUG|Eprex; Neorecormon; Aranesp|
48670146|NCT03305484|OTHER|No intervention|No intervention, observation only
48670147|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
48670148|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
48670149|NCT03015493|OTHER|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
48670150|NCT03015493|OTHER|Traction|Traction techniques for the cervical spine
48358461|NCT02283229|BEHAVIORAL|Newborns with preventive caring advices|Advices to prevent head molding
48358462|NCT02283229|OTHER|Newborns with normal caring advices|Normal handling
48507029|NCT02640690|BEHAVIORAL|Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)|(10) 1-hour sessions of trauma sensitive yoga
48358463|NCT01444989|OTHER|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
48507030|NCT02640690|BEHAVIORAL|Cognitive Processing Therapy|(12) 1.5 hour sessions of cognitive processing therapy
48670151|NCT03662282|DRUG|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
48670152|NCT06546085|BEHAVIORAL|Exercise|Supervised treadmill exercise at 85% VO2max, 3x/wk for 16 weeks. Exercise duration will be adjusted based on individual VO2-heart rate (HR) relationship so that \~400 kcals will be expended during each training session.
48670153|NCT04257019|OTHER|Lavender oil|Inhalation of Lavender oil
48670154|NCT04257019|OTHER|Almond oil|Inhalation of Almond oil
48670155|NCT04257019|OTHER|Water|Inhalation of water
48670156|NCT06086743|OTHER|Experimental Group|This group will perform 10 minutes of same warm up exercises. After warm up participants will perform 4 resistance exercises with induced EMS. The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises. the intensity of EMS would be 100A and it would remain same throughout training session. The current administered would be galvanic current. Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
48358464|NCT01444989|OTHER|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
48358465|NCT04051944|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
48507031|NCT04276922|BEHAVIORAL|Visual Arts|"Subjects meet for 90 minutes, once weekly, over 12 weeks for guided drawing/sketching sessions. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
48670157|NCT06086743|OTHER|Control Group|Group B (Control group)will perform 10 minutes of same warm up exercises (Arm swings, jogging on the spot, Walks on treadmill). Group B will perform same 4 resistance exercises without EMS. These 4 exercises include Bicep curls, Triceps dips, Quadriceps chair and squats.The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises and the participants will be instructed, not to perform any kind of exercise during this period.Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
48358466|NCT01134328|DRUG|AC-150 Combo|1 drop in each eye for up to 14 days
48358467|NCT01134328|DRUG|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
48358468|NCT01134328|DRUG|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
48358469|NCT01134328|DRUG|Vehicle|1 drop in each eye once per day for up to 14 days
48358470|NCT02557633|BIOLOGICAL|Grass MATA MPL 10200|
48358471|NCT02557633|BIOLOGICAL|Grass MATA MPL 18200|
48358472|NCT02557633|BIOLOGICAL|Placebo|
48670158|NCT03344341|DRUG|Dapagliflozin|Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
48670159|NCT03344341|DRUG|Acarbose|Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
48670160|NCT06423690|DEVICE|EAS1 System|tumor ablation system in IRE method
48670161|NCT00295789|DRUG|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
48670162|NCT00295789|DRUG|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
48670163|NCT00362492|PROCEDURE|Bilateral ultrasound examination 7+/- 2 after surgery|
48670164|NCT02402595|DRUG|AVP-923|
48670165|NCT02402595|DRUG|AVP-786|
48670166|NCT02402595|DRUG|Itraconazole|
48670167|NCT06389214|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
48670168|NCT06389214|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
48670169|NCT02818517|OTHER|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
48670170|NCT02818517|OTHER|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
48670171|NCT05544084|BEHAVIORAL|Patient Navigator Approach|Patient navigators in collaboration with community health workers will work with women eligible for cervical cancer screening to overcome intrapersonal and community level barriers to screening in order to engage early with the health system for cervical cancer screening and follow-up of positive screens. Their support can help patients get the cancer screenings and follow-up care they need, while addressing prevalent gender inequities and community-level stigma associated with cancer within the Senegal context.
48670172|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
48670173|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
48670174|NCT05881707|DRUG|CKD-828, D064, D702|QD, PO
48670175|NCT02996396|DEVICE|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
48670176|NCT04140617|BEHAVIORAL|Exposure to aerosol of electronic cigarette|Exposure to aerosol of electronic cigarette (30 min)
47989780|NCT05634551|BEHAVIORAL|Questionnaires|Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
47989781|NCT05634551|BEHAVIORAL|Interview|The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
47989782|NCT00898157|OTHER|laboratory biomarker analysis|
47989783|NCT03487861|DIAGNOSTIC_TEST|observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35\~50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
48147342|NCT02684994|BEHAVIORAL|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
48147343|NCT04345588|DRUG|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
48147344|NCT03996798|OTHER|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
48147345|NCT02565225|BEHAVIORAL|RheumaLive App use|
48147346|NCT04087239|OTHER|HIV|
48358473|NCT05138965|PROCEDURE|the mCP with alginates dressing|The method is to use gauzes folded onto the RVF wound surface to compact the deep wound so as to solid and durable,when the gauzes surface will be covered by alginates dressing.
48358474|NCT05138965|PROCEDURE|only alginates dressing|Only alginates dressing will be placed above the RVF wound without any pressure.
48358475|NCT06127108|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.
48670177|NCT05268757|BEHAVIORAL|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
48670178|NCT03064932|OTHER|Controlled feeding diet|Average American diet with different levels of spices
47989784|NCT00954902|DIETARY_SUPPLEMENT|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
48670179|NCT04461353|DRUG|Aerolized Hydroxychloroquine Sulfate|sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
48670180|NCT04461353|OTHER|Placebo|The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
48670181|NCT03118336|DRUG|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
48670182|NCT00871078|DEVICE|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
47989785|NCT00954902|BEHAVIORAL|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
48147347|NCT06439277|DRUG|Tirzepatide|Administered SC
48147348|NCT06439277|DRUG|Placebo|Administered SC
48147349|NCT06015659|DRUG|Zentalis|Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
48147350|NCT06015659|DRUG|Gemzar|Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
48147351|NCT05120505|DRUG|Metformin|The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
48147352|NCT05120505|DRUG|Placebo|The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
48358476|NCT05419284|OTHER|GAPP+Care|"standard physiotherapy 45 minutes per day, 5 day a week (GAPP)~+ 3 extra exercise sessions led by a caregiver (+Care)"
48670183|NCT00871078|DEVICE|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
48670184|NCT00308334|DRUG|Domperidone|10 mg po TID X 14 days
48358477|NCT05419284|OTHER|+Care|"3 extra exercise moments led by a caregiver: one physiotherapist-caregiver-patient exercise session: the physiotherapist will educate and train the caregiver on the exercises and hands-on skills.~Two caregiver-patient exercise sessions"
48670185|NCT00308334|DRUG|Placebo- Sugar pill|placebo po TID x 14 days
48670186|NCT03848455|DIAGNOSTIC_TEST|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
47989786|NCT00954902|OTHER|Placebo antioxidant concentrate|Placebo capsules
47989787|NCT00374881|DRUG|Morphine|Morphine
47989788|NCT00374881|DRUG|Morphine|Morphine low dose
47989789|NCT00374881|DRUG|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
47989790|NCT00374881|DRUG|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
47989791|NCT00374881|DRUG|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
47989792|NCT06054347|OTHER|VINELAND II|Standardised questionnaire filled by the investigator during an interview with the parents or with the patient himself if capable of it. Duration 1 hour to 1 hour and a half.
47989793|NCT03028831|DIETARY_SUPPLEMENT|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
47989794|NCT03028831|DIETARY_SUPPLEMENT|Resistant starch|70g high-amylose maize starch
47989795|NCT05487326|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound guidance
47989796|NCT05487326|PROCEDURE|cervical epidural injection|cervical epidural injection by fluoroscopy
47989797|NCT05023187|BEHAVIORAL|SCOT|"A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (\~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.)."
47989798|NCT05023187|BEHAVIORAL|CON|"A 8-week active control intervention consisting of 2 sessions (\~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics."
47989799|NCT02975219|DRUG|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
48358478|NCT05419284|OTHER|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
48358479|NCT01860131|BEHAVIORAL|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
48358480|NCT01835236|DRUG|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
48358481|NCT01835236|DRUG|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
48358482|NCT01835236|DRUG|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
48358483|NCT01835236|DRUG|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
48358484|NCT01835236|DRUG|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
48358485|NCT03588949|DIETARY_SUPPLEMENT|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
48358486|NCT03588949|DIETARY_SUPPLEMENT|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
48358487|NCT00002336|DRUG|Clarithromycin|
48358488|NCT05367921|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
48507032|NCT04276922|BEHAVIORAL|Music|"Subjects meet for 90 minutes, once weekly, over 12 weeks, for guided music-listening exercises (such as lyric analysis, patient-chosen, music for relaxation and/or visualization) and active music making. The 12 sessions follow a standard sequence, addressing three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards are completed at baseline, weekly and at completion to assess satisfaction, stress, and well-being. Qualitative focus groups, after the intervention, assess acceptability of intervention, outcomes, program development and implementation."
48670187|NCT00508092|PROCEDURE|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
48358489|NCT06141239|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
48358490|NCT06141239|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration
48358491|NCT06141239|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
48358492|NCT03983304|DEVICE|The ZELTIQ System|The EMS device will be used to perform the treatments.
48670188|NCT06019507|BIOLOGICAL|TCD601|Investigational Product
48670189|NCT06019507|BIOLOGICAL|Cyclophosphamide|Conditioning Regimen
48670190|NCT06019507|DRUG|TAC|Immunosuppression Therapy
48670191|NCT06019507|DRUG|MMF|Immunosuppression Therapy
47989800|NCT06144346|RADIATION|Stereotactic Ablative Radiation Therapy|SABR to all metastatic lesions
47989801|NCT06144346|PROCEDURE|Locoregional treatment|mastectomy or BCS for the primary tumor
47989802|NCT06144346|OTHER|Standard of Care|Systemic treatment and palliative treatment
47989803|NCT05847075|OTHER|Heat Therapy|Participants in the HT group will undertake whole body heat treatment according to previous methods. Participants will be housed in an environmental chamber initially set at 55.0oC on three non-consecutive days of the week during 12 weeks. Each session will last 60 min.
48358493|NCT03206606|DEVICE|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
48358494|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1|Patients will receive Lemborexant 5 mg per day on the first day of sleep test
48358495|NCT05763329|DRUG|Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2|Patients will receive Lemborexant 5 mg per day on the second day of sleep test
48358496|NCT05763329|DRUG|Placebo Day 1|Patients will receive placebo on the first day of sleep test
48358497|NCT05763329|DRUG|Placebo Day 2|Patients will receive placebo on the second day of sleep test
48358498|NCT00033293|OTHER|Clinical Observation|Undergo observation
48358499|NCT00033293|DRUG|Cyclophosphamide|Given IV
48358500|NCT00033293|OTHER|Laboratory Biomarker Analysis|Correlative studies
48358501|NCT00033293|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
48358502|NCT00033293|DRUG|Prednisone|Given orally
48358503|NCT00033293|BIOLOGICAL|Therapeutic Immune Globulin|Given IV
48358504|NCT05920655|DIAGNOSTIC_TEST|Optic coherence tomography|Eye examination of patients with optic coherence tomography test by an ophthalmologist
48358505|NCT00982267|DRUG|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
48358506|NCT02938975|OTHER|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
48670192|NCT06019507|DRUG|Corticosteroids|Immunosuppression Therapy
48670193|NCT01098747|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
48670194|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
48670195|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
48670196|NCT01098747|DRUG|Placebo|Single-dose of placebo
48670197|NCT01985022|BEHAVIORAL|Group-ESI|The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
48147353|NCT02735005|OTHER|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
48358507|NCT02938975|OTHER|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
48358508|NCT02938975|OTHER|Placebo lotion|A liposome lotion with no DEET
48670198|NCT01985022|BEHAVIORAL|Individual-ESI|The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
48147354|NCT05210985|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
48358509|NCT02938975|OTHER|Army combat uniform|Army combat uniform with no permethrin
48358510|NCT02114359|DRUG|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
47989804|NCT05847075|OTHER|StrengthTraining|Participants will perform supervised exercise in a gym on three non-consecutive days of the week. Each session will last \~60 min and will consist of a warm up, the resistance training and a cool down. All sessions will be conducted by qualified sport and exercise scientists for 12 weeks.
48358511|NCT02114359|DRUG|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
48358512|NCT02114359|DRUG|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
47989805|NCT05847075|OTHER|Sedentary Control|Participants will not receive any intervention during 12 weeks.
48358513|NCT02114359|DRUG|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
48358514|NCT02114359|DRUG|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)
48358515|NCT02114359|DRUG|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)
48147355|NCT05210985|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years."
48670199|NCT05034328|DEVICE|Healsea® Children|Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed
48670200|NCT05034328|OTHER|Conventional therapies for common cold|Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
48670201|NCT00402129|PROCEDURE|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
48670202|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
48670203|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
47989806|NCT03325075|BIOLOGICAL|VAL-181388|Escalating dose levels
48358516|NCT02114359|DRUG|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
48358517|NCT02018276|DRUG|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
48358518|NCT02018276|DRUG|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
48670204|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
48358519|NCT01711333|DRUG|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
48670205|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
48670206|NCT00565409|DRUG|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
47989807|NCT03325075|OTHER|Placebo|Saline
47989808|NCT01170754|DRUG|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
47989809|NCT01170754|DRUG|Golytely 4 liters|Golytely 4 liters
47989810|NCT01748981|OTHER|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
48147356|NCT05210985|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
48147357|NCT03602053|BIOLOGICAL|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
48147358|NCT03602053|BIOLOGICAL|ROTAVAC 5D|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
48147359|NCT03602053|BIOLOGICAL|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
48147360|NCT03350620|DRUG|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
48507033|NCT04276922|BEHAVIORAL|Dance/Movement|"Subjects will meet once weekly, and begin with a movement check-in, a gentle physical warm-up, and then either a structured or improvisational movement process. for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
48507034|NCT04276922|BEHAVIORAL|Writing/Poetry|"Subjects will meet once weekly, for writing workshops to encourage participants to tell the stories they need to tell, using integral elements of good writing, for a total of 12 weeks. Each session will last 90 minutes. The 12 sessions will follow a standard sequence that addresses three primary themes: creating safety, inviting vulnerability, and integrating into a transformative community.~Surveys, activity diary cards will be completed at baseline, weekly and at intervention completion to assess satisfaction, stress, and well-being. Qualitative focus groups will occur after the intervention to assess acceptability of intervention, outcomes assessments, program development and implementation."
48507035|NCT04276922|BEHAVIORAL|Control|Control Group will only complete surveys at baseline and 12 weeks later.
48670207|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
48670208|NCT05431647|OTHER|Sensory integration therapy|The individuals were divided into two as randomized controlled. Both physiotherapy and sensory integration therapy were applied to the intervention group. Each treatment was applied as 2 sessions per week, 2 days a week for 8 weeks. In the control group, only physiotherapy treatment was applied for 8 weeks, 2 days a week, 2 sessions per week.
48670209|NCT06131658|OTHER|Functional motor control excercise|This include functional motor control thrice a week for six weeks
48670210|NCT06131658|OTHER|convectional excercise|This include convectional exercise thrice a week for six weeks
48670211|NCT01727388|PROCEDURE|lateral decubitus|
48670212|NCT01727388|PROCEDURE|supine decubitus|
48507036|NCT04826692|DRUG|Metformin|Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
48670213|NCT02151929|DEVICE|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
48670214|NCT02151929|DEVICE|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
48670215|NCT03670160|DRUG|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
47989811|NCT01748981|OTHER|As usual|Controls, not training
47989812|NCT06502626|OTHER|Regular training|performed their routine programs
47989813|NCT06502626|OTHER|Sprint Interval Training|Sprint interval training will be given for 4 weeks. Each week consisted of three training sessions, separated by at least one resting day. Participants will complete a 15-minutes warm up before training session. The Sprint interval training group consisted of 30 s sprints at near maximal effort, with three minutes of rest between each sprint. The training intensity of Sprint interval training sessions was evaluated subjectively during sessions. During the first week, the Sprint interval training group performed five sprints per session. The number of sprints then increased gradually, until a total of 10 sprints per session. When the number of sprints reached seven, subjects were given six minutes of rest midway through the training session
48147361|NCT03350620|DRUG|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
48147362|NCT03350620|DRUG|Placebo|Vehicle (placebo) will be administered, once daily (QD)
48147363|NCT03196518|PROCEDURE|PET Imaging|PET/CT study immediately after injection
48147364|NCT03196518|OTHER|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes
48507037|NCT04826692|DRUG|Placebo|425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
48507038|NCT04707781|DIAGNOSTIC_TEST|chest CT|assessment of interstitial lung disease using chest CT
48507039|NCT01751737|PROCEDURE|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
48670216|NCT03670160|DRUG|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
48670217|NCT06333548|DIAGNOSTIC_TEST|Appropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM|No intervention
48670218|NCT02573948|OTHER|no intervention is assessed|
48670219|NCT05291754|DEVICE|PEEK Cranioplasty|3D printed PEEK skull implant
48147365|NCT01542502|DRUG|Anakinra|Anakinra 100 mg daily subcutaneous injection
48507040|NCT04810026|BEHAVIORAL|Education|Healthy-lifestyle and diabetes-related virtual education (text and videos)
48670220|NCT00905229|DRUG|Phytonadione|2.5 mg po
48670221|NCT00905229|DRUG|Phytonadione|0.5 mg IV
48358520|NCT03620292|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
48358521|NCT03620292|DEVICE|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
48358522|NCT03001726|PROCEDURE|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
48358523|NCT03001726|DRUG|oxaliplatin|oxaliplatin 100 mg/m2
48358524|NCT03001726|DRUG|S1|S1 40mg/m2
48358525|NCT03001726|DRUG|Docetaxel|docetaxel 40 mg/m2
48358526|NCT00198510|DRUG|Vitrase|7.5 IU of Vitrase
48670222|NCT00363584|DRUG|capecitabine|
48670223|NCT00363584|OTHER|clinical observation|
47989814|NCT01570374|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
47989815|NCT02724306|BEHAVIORAL|Active Lifestyle Programme|
47989816|NCT00350636|DRUG|Oxybutynin topical gel|1 application daily to skin for 12 weeks
47989817|NCT00350636|OTHER|Placebo topical gel|1 application daily to skin for 12 weeks
48147366|NCT01542502|DRUG|Placebo|Placebo daily subcutaneous injection
48358527|NCT00198510|DRUG|Vitrase|55 IU of Vitrase
48358528|NCT00198510|DRUG|Vitrase|75 IU of Vitrase
47989818|NCT04725760|DEVICE|BrainPort Vision Pro|"Ten hours of training over 3 to 5 days, followed by autonomous use of the device.~It will be recommended that the subject use the BrainPort® Vision Pro device for at least 5 hours per month for a period of 12 months."
48147367|NCT01223053|DRUG|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
48358529|NCT02346799|BEHAVIORAL|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
48507041|NCT04810026|BEHAVIORAL|Meal delivery|breakfast, lunch, and dinner adhering to the longevity diet macro-nutrient profiles
48507042|NCT04810026|BEHAVIORAL|Lifestyle coaching|calls with coach and/or nutritionist, access to Facebook community support group
48670224|NCT00363584|PROCEDURE|adjuvant therapy|
48670225|NCT03326245|DRUG|Methylphenidate Pill|Oral methylphenidate (60 mg) given 30 minutes prior to bolus \[11C\]raclopride
48670226|NCT03326245|DRUG|Oral Placebo|Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection
48670227|NCT03326245|DRUG|Intravenous Placebo|Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.
48670228|NCT03326245|DRUG|Intravenous methylphenidate|Intravenous methylphenidate 0.25 mg/kg in 3ml sterile saline given 30 minutes post bolus injection of \[11C\]raclopride.
47989819|NCT00002631|DRUG|chemotherapy|
47989820|NCT00002631|DRUG|cisplatin|
47989821|NCT00002631|DRUG|fluorouracil|
48358530|NCT02346799|BEHAVIORAL|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
48358531|NCT02346799|BEHAVIORAL|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
48358532|NCT02346799|BEHAVIORAL|Partner Assignment|"Participants will be required to have same workout window as partners."
48358533|NCT03602742|DEVICE|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
48358534|NCT03381703|DRUG|YH12852|YH12852 administration
48507043|NCT04919265|OTHER|No intervention - mother-infant cohort study|There are no interventions because it is a mother-infant cohort study
48507044|NCT04734405|DRUG|Prof-001|Prof-001 cream
48507045|NCT04734405|DRUG|Fluconazole 150 mg|Fluconazole capsule
48507046|NCT04734405|DRUG|Placebo cream|ointment base to mimic Prof-001
48670229|NCT00659282|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
48670230|NCT05090618|GENETIC|DNA analysis|GWAS
48670231|NCT05784181|DEVICE|bipolar transurethral resection and Laser enaculation by holmium: YAG laser|Laser enaculation by holmium: YAG laser
48670232|NCT00602693|BIOLOGICAL|umbilical cord blood transplantation|Infusion of umbilical cord blood
48670233|NCT00602693|DRUG|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
48670234|NCT00602693|DRUG|fludarabine phosphate|40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
48670235|NCT00602693|DRUG|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
48670236|NCT00602693|RADIATION|Total body irradiation|200 cGy on Day -1
48670237|NCT00602693|BIOLOGICAL|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.
48670238|NCT00602693|DRUG|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
48670239|NCT06254066|DRUG|Adebrelimab plus Fluzoparib|Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer
48670240|NCT01076010|DRUG|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
47989822|NCT00002631|RADIATION|low-LET electron therapy|
47989823|NCT00002631|RADIATION|low-LET photon therapy|
47989824|NCT01174927|DRUG|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
48147368|NCT01223053|DRUG|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
48147369|NCT05684809|OTHER|Post Isometric relaxation Technique (PIR)|In PIR intervention, the patients were requested to lie down in a supine position and their neck was in a lateral flexion to the opposite side so that the target upper Trapezius muscle fibers would be in a lengthened position. The therapist performed a moderate isometric contraction (approximately 75% of maximal) of upper Trapezius muscles, held it for 5 seconds, then relaxed for 3 seconds before moving the cervical spine into the new barrier. In each session, this technique was repeated for four times, on alternate days for three weeks.
48147370|NCT05684809|OTHER|Cervical Mobilization (CM)|Cervical Mobilization was delivered in prone lying with their foreheads resting comfortably on his hands, and the chin was tucked in.The treatment session was done on alternate days (3 days a week) for 3 weeks, hence the total number of sessions were 9.
48147371|NCT05684809|OTHER|conventional treatment|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10-second relaxation) were given, and isometric exercise of the neck((10 repetitions of two sets with 10 seconds hold) alternate days for three weeks.
48147372|NCT01702103|DRUG|Mometasone furoate|
48147373|NCT00966745|DRUG|milrinone|
48147374|NCT00966745|DRUG|placebo|
48147375|NCT01775878|DEVICE|Telemonitoring Device|Telemonitoring device was installed in patients' homes
48670241|NCT01076010|DRUG|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
48670242|NCT04936191|DEVICE|DynamX Bioadaptor|Patients received percutaneous coronary intervention in a similar way to a traditional DES. Patients first receive radial artery or femoral artery cannulation with anticoagulation during the intervention. All coronary angiograms are carefully measured by at least 2 orthographic views and performed under the same standard conditions. After adequate predilatation of the target lesion, the coronary stenting will be performed. All patients will receive a loading dose of acetylsalicylic acid and a P2Y12 inhibitor pre-procedure followed by dual antiplatelet therapy for at least 6 months.
48670243|NCT05104060|PROCEDURE|pectoralis minor intervention group|The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
48670244|NCT05104060|PROCEDURE|shoulder strengthening group|The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
48670245|NCT04585308|DEVICE|transShield Embolic Protection System|Used for embolic protection during TAVR.
47989825|NCT01174927|OTHER|Placebo|Saline
48147376|NCT04301713|OTHER|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
48147377|NCT02744105|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
48147378|NCT00825318|PROCEDURE|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
48147379|NCT04251325|OTHER|Basic Life Support Courses|4 hours basic life support courses for laypersons
48147380|NCT05755178|BEHAVIORAL|Music, feelings and relationships - music group for children at shelters|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
48358535|NCT03381703|DRUG|14C-labeled YH12852|14C-labeled YH12852 administration
48670246|NCT05829174|BEHAVIORAL|Psychoeducation and cognitive modules|Psychoeducation and cognitive modules: what is procrastination, role of rewards, work environment, belief identification, cognitive restructuring, relapse prevention.
48670247|NCT05829174|BEHAVIORAL|Behavioral module: Starting on Time and Planning Realistically|Learning of realistic planning, and timely starting of work.
48670248|NCT05829174|BEHAVIORAL|Behavioral module: Working Time Restriction|Restriction of allowed time for work, and gradual increase of allowed time, if previous time windows where effectively used.
48670249|NCT05829174|BEHAVIORAL|Behavioral module: Pomodoro Time Management Technique|Working in 25 minutes time intervals
48670250|NCT05282121|DRUG|Avenciguat (BI 685509)|Avenciguat (BI 685509)
48670251|NCT05282121|DRUG|Empagliflozin|Empagliflozin
48670252|NCT05194150|DEVICE|non-diffractive monofocal IOL|Rayone EMV
48670253|NCT05194150|DEVICE|standard EDOF IOL|Acrysof IQ Vivity
48670254|NCT00284635|PROCEDURE|Fast track vs conventional|
48670255|NCT05281913|OTHER|Psychoeducational Game|Psychoeducational Game
48670256|NCT02108886|DRUG|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
47989826|NCT05854589|DRUG|Sodium Chloride Granules|Sodium Chloride crystals
48670257|NCT02108886|DRUG|Placebo|empty capsule filled with sugar
48670258|NCT02108886|OTHER|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
48670259|NCT05378113|DRUG|Ondansetron|Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
48670260|NCT05378113|DRUG|Lidocaine|Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
47989827|NCT05854589|OTHER|Water|Plain distilled water
47989828|NCT03967392|DRUG|Xylocaine|TREATMENT
47989829|NCT00712829|DRUG|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
47989830|NCT00712829|DRUG|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
47989831|NCT04264637|DRUG|Azelastine hydrochloride (BAYR9258)|Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
47989832|NCT04264637|DRUG|Placebo|Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
47989833|NCT00914355|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
47989834|NCT01317745|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
48358536|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care + CARDIO|Combination of dietary supplement with clinical care
47989835|NCT01317745|DRUG|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
47989836|NCT01317745|BIOLOGICAL|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
47989837|NCT05251545|OTHER|Pulmonary vein isolation|Comparison of power levels in catheter ablation in regard of single procedure success rate (freedom of any atrial arrhythmia with a duration of more than 30 sec. 45 Watts versus standard power levels (30 Watts).
47989838|NCT02232542|DRUG|Duloxetine - low dose|
47989839|NCT02232542|DRUG|Duloxetine - high dose|
47989840|NCT02232542|DRUG|Placebo|
48670261|NCT03199183|RADIATION|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
48670262|NCT03199183|OTHER|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
48670263|NCT03199183|GENETIC|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
48670264|NCT02300233|DRUG|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
48670265|NCT02300233|DRUG|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
48670266|NCT06545032|PROCEDURE|lumbar fusion|Minimal Invasive Transforaminal Lumbar Interbody Fusion
48670267|NCT04683705|DIAGNOSTIC_TEST|Ultrasound|"1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
48670268|NCT00741078|DRUG|statin, amlodipine|
48670269|NCT00784121|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
48670270|NCT02374229|PROCEDURE|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
47989841|NCT00495170|DRUG|Carboplatin|2 area under curve (AUC) by vein Weekly
47989842|NCT00495170|RADIATION|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
47989843|NCT00495170|DRUG|Paclitaxel|50 mg/m\^2 by vein Weekly
47989844|NCT00425230|DRUG|Duloxetine|
47989845|NCT04018833|DRUG|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
47989846|NCT04018833|DRUG|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
47989847|NCT03667560|PROCEDURE|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
48670271|NCT02374229|PROCEDURE|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
48670272|NCT00534001|DRUG|bupropion hydrochloride|Given orally
48670273|NCT00534001|OTHER|placebo|Given orally
48670274|NCT04996329|OTHER|early health warning intervention|early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
48670275|NCT02343302|DEVICE|Jackson-Pratt Drain|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
48670276|NCT02343302|DEVICE|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
48670277|NCT02636647|BIOLOGICAL|Fecal transplant|
48670278|NCT06298227|OTHER|Postoperative analgesia management with Paracerol® and IV PCA with Talinat®|In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.
48670279|NCT06298227|OTHER|Erector spinae plane block|The block will be applied while the patient is in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed longitudinally 4 cm lateral to the T11 transverse process. The erector spinae muscle and the hyperechoic transverse process will be visualized. Using the in-plane technique, the 100 mm block needle (Stimuplex 360®) will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block location. Once the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
48670280|NCT06298227|OTHER|Quadratus lumborum plane block|QLB will be performed with the patient in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed at the level of the 12th rib, just above the iliac crest, in the parasagittal oblique plane, at the L1-L2 level. After the quadratus lumborum, erector spinae, and psoas major muscles are visualized, a 100 mm block needle (Stimuplex 360®) will be advanced in-plane anteriorly to QL, and the needle tip will be brought between the QL and PM muscles (Anterior QLB). The location will be confirmed by hydraulic dissection with 5 ml saline injection. After the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
48670281|NCT03381989|DEVICE|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
48670282|NCT01281111|DRUG|Dimethyl Fumarate (BG00012)|
48670283|NCT01281111|DRUG|Aspirin|
48670284|NCT01281111|DRUG|BG00012 matching placebo|
48670285|NCT01281111|DRUG|ASA matching placebo|
48670286|NCT03769688|DRUG|Cervicovaginal secretions|Same as arm descriptions
48670287|NCT03769688|DRUG|Metronidazole gel|5 day course of vaginal MetroGel will be used prior to VMT intervention.
48670288|NCT03769688|DIAGNOSTIC_TEST|Screening tests|Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
48670289|NCT03769688|BEHAVIORAL|Activities restriction|Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
48670290|NCT03769688|OTHER|Sterile Saline placebo|This will be administered as a placebo in place of cervicovaginal secretions
48670291|NCT00406861|DRUG|montelukast in treatment of ENL reaction|
48670292|NCT03044444|DIETARY_SUPPLEMENT|citrus extract|Participants will receive either a low or high dose citrus extract
48670293|NCT03044444|OTHER|placebo|participants will receive 500mg of maltodextrin
48670294|NCT05733689|DEVICE|ctDNA Blood Test|Blood will be collected for ctDNA testing
48670295|NCT05733689|COMBINATION_PRODUCT|FLOT|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Docetaxel 50 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 2600 mg/m2 continuous infusion over 24 hours daily on Day 1 Every 14 Days"
48670296|NCT05733689|COMBINATION_PRODUCT|FOLFOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
48670297|NCT05733689|COMBINATION_PRODUCT|FOLFIRI|"* Irinotecan 180 mg/m2 IV on Day 1~* Leucovorin 400 mg/m2 IV on Day 1~* Fluorouracil 400 mg/m2 IV Push on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 Days"
48670298|NCT05733689|COMBINATION_PRODUCT|FOLFIRINOX|"* Oxaliplatin 85 mg/m2 IV on Day 1~* Irinotecan 150 mg/m2 IV on Day 1~* Leucovorin 200 mg/m2 IV on Day 1~* Fluorouracil 1200 mg/m2 continuous infusion over 24 hours daily on Days 1 and 2 Every 14 days"
48507047|NCT04734405|DRUG|Placebo capsule|encapsulated lactose powder to mimic 150 mg fluconazole capsule
48670299|NCT05733689|COMBINATION_PRODUCT|PACLITAXEL with or without CARBOPLATIN|"* Paclitaxel 200 mg/m2 IV on Day 1~* Carboplatin AUC 5 IV on day 1 Every 21 Days~OR~- Paclitaxel 80mg/m2 IV on Days 1,8,15 Every 28 Days"
48670300|NCT05733689|COMBINATION_PRODUCT|DOCETAXEL and IRINOTECAN (alone or combined)|"* Docetaxel 35 mg/m2 IV on Days 1 and 8~* Irinotecan 50 mg/m2 IV on Days 1 and 8 Every 21 Days~* Docetaxel 75 mg/m2 IV on Day 1 Every 21 Days~* Docetaxel 150 mg/m2 IV on Day 1 Every 14 Days"
48670301|NCT05733689|DRUG|NIVOLUMAB (alone or when added to a regimen above)|"* 240 mg IV on Day 1 every 14 days, or~* 360 mg IV on Day 1 every 21 days, or~* 480 mg IV on Day 1 every 28 days"
48670302|NCT05733689|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|"* 200 mg IV on Day 1 every 21 days, or~* 400 mg IV on Day 1 every 42 days"
48670303|NCT02018120|PROCEDURE|connective tissue graft|
48670304|NCT02018120|PROCEDURE|platelet rich fibrin|
48670305|NCT04925141|DRUG|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
47989848|NCT03667560|PROCEDURE|FlexHD|Patient will be implanted with FlexHD.
47989849|NCT03793582|DIAGNOSTIC_TEST|ApneaLink Type III portable sleep study|Type III portable sleep study
47989850|NCT04699409|OTHER|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
47989851|NCT04699409|OTHER|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
47989852|NCT01974583|PROCEDURE|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
47989853|NCT01974583|PROCEDURE|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith \& Nephew)
47989854|NCT01974583|PROCEDURE|covered with paraffin gauze|Group C covered with paraffin gauze
48507048|NCT00603837|DEVICE|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
48507049|NCT00603837|DEVICE|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
48507050|NCT03583684|BEHAVIORAL|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
48507051|NCT02391129|PROCEDURE|Operation for Periprosthetic fractures of the hip with stem loosening|
48507052|NCT05014841|BEHAVIORAL|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
48507053|NCT06003296|PROCEDURE|Calcaneocuboid arthrodesis|Calcaneocuboid arthrodesis in triple arthrodesis
47989855|NCT04443504|BEHAVIORAL|The Connected Family Series|The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
47989856|NCT02771158|DRUG|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
48507054|NCT02759692|DEVICE|TEST Contact Lens|
48507055|NCT02759692|DEVICE|CONTROL Contact Lens|
48507056|NCT03571412|DEVICE|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
47989857|NCT02771158|DRUG|placebo|placebo will be administered to double blind the study
48507057|NCT04562155|DRUG|BAY1817080|Study drug BAY1817080 will be administered orally as tablet.
48507058|NCT04562155|DRUG|Placebo|Matching Placebo for BAY1817080 will be administered orally as tablet.
48507059|NCT04116762|DEVICE|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
48507060|NCT04116762|DEVICE|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
48507061|NCT03486691|OTHER|Routine measurement of left lobe|Routine preoperative measurement of left lobe
48147381|NCT00072670|DRUG|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
48358537|NCT04465513|DIETARY_SUPPLEMENT|Best Standard of Care|Combination of placebo with clinical care
48507062|NCT03486691|OTHER|control group|no routine preoperative measurement of left lobe
48507063|NCT00524732|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
48507064|NCT04286451|BEHAVIORAL|Sleep Restriction|Women will be undergo 4 nights of sleep restriction.
48507065|NCT04286451|BEHAVIORAL|Habitual Sleep|Women will be undergo 4 nights of habitual sleep.
48507066|NCT06633185|DRUG|phenytoin cream|application of the cream after internal anal sphincterotomy versus non application.
48507067|NCT06633185|DRUG|no phenytoin cream|Non application of the phenytoin cream
48670306|NCT01287494|DRUG|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
48670307|NCT06543485|PROCEDURE|intramedullary screw fixation of metacarpal fractures|intramedullary screw fixation of metacarpal fractures through limited open approach
48670308|NCT02755961|BEHAVIORAL|Dietary education|
48670309|NCT02755961|BEHAVIORAL|Education on phosphate binder use|
48507068|NCT04901988|DRUG|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
48147382|NCT04191863|OTHER|Clinical, EEG and laboratory assessment at presentation|"* The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG."
48147383|NCT04191863|DRUG|Valproate|valproate monotherapy
48147384|NCT01156675|DEVICE|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
48147385|NCT01156675|DEVICE|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
48358538|NCT01315873|DRUG|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
48507069|NCT01858272|DRUG|H5.020CMV.PDGF-b and limb compression bandage|
48507070|NCT04778488|DEVICE|Near-Infrared-Spectroscopy (NIRS)|Placement of 2 NIRS optodes on the patients' forehead, measurement of NIRS during cardiac arrest and up to 72h post return of spontaneous circulation
48507071|NCT00704847|DRUG|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
48507072|NCT00704847|DRUG|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
48507073|NCT02935621|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
48507074|NCT02935621|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
48670310|NCT03234634|PROCEDURE|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~1. Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~2. Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
48507075|NCT02643355|DRUG|Olanzapine|
48507076|NCT02643355|DRUG|Clonidine|
48507077|NCT02762461|PROCEDURE|IVF or ICSI|
48507078|NCT06633913|DEVICE|spTMS-TBS-spTMS|This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
48507079|NCT05871034|PROCEDURE|phacoemulsification|cataract extraction
48507080|NCT06494488|DRUG|EPA|Fish oil
48507081|NCT06494488|DRUG|DHA|Fish oil
48507082|NCT05349643|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
48507083|NCT05422625|DEVICE|PTNS Treatment|Patients will be placed in a comfortable position, sitting or supine. The treatment leg will be propped up comfortably on a footrest but draped and out of view from the patient. A 34-gauge needle electrode will be inserted at a 60-degree angle 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. A PTNS surface electrode will be placed on the ipsilateral calcaneus as well as 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the foot. When the PTNS lead set is connected to the Urgent PC stimulator, a current level of 0.5 to 9 mA at 20 Hz is selected based on each patient's foot and plantar motor and sensory responses. Treatment lasts 30 minutes and given once weekly for 12 consecutive weeks.
48670311|NCT01493414|DRUG|INC424|All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
48670312|NCT06482775|DRUG|dexmedetomidine|The dosing and administration will be implemented according to an algorithm based on pain scoring results
48670313|NCT03483389|DRUG|Alcohol, Ethyl|Randomized within-subjects design
48147386|NCT01997866|OTHER|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
48147387|NCT01997866|OTHER|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
48147388|NCT05116306|DRUG|Hyaluronic acid|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
48147389|NCT05116306|DRUG|Propylene glycol|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
48147390|NCT03971539|DRUG|BI 894416|BI 894416 film-coated tablet.
48147391|NCT03971539|DRUG|Placebo|Placebo film-coated tablet matching BI 894416.
48147392|NCT04453930|DRUG|Camrelizumab，an engineered anti-PD-1 antibody|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).
47989858|NCT04503759|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
47989859|NCT02158104|PROCEDURE|Deep dry needling|
48358539|NCT01315873|DRUG|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
48358540|NCT04850885|DRUG|inj dexamethasone 4mg/ml and inj lignocaine 20mg/ml|The modified technique of classical IANB was to be selected to avoid failure as described by Clark and Homes (1959). The patients were requested to keep their mouth wide open and an occlusal plane parallel to the floor. Palpation of anatomical landmarks was done properly and the guide finger was positioned at the retromolar fossa. A 5 ml syringe equipped with a 24 gauge needle length of 3.6 cm was used, it was been advanced from premolar on the opposite side into the tissue just above the fingernail until hitting the bone. The body of the syringe was redirected over the lower central incisors and kept parallel to the molars in a horizontal plane at the same time. The needle was inserted another 2 cm deep into the tissue and 3.5 ml of solution X was deposited 1 cm higher than the usual after multiple aspirations (90 degrees two planes). Further, 1 ml solution X was deposited after the withdrawn needle in pterygomandibular space.
48358541|NCT02897011|DRUG|Methotrexate|
48507084|NCT05422625|DEVICE|Sham PTNS Treatment|"Patients will be positioned similarly as PTNS patients. A Streitberger needle will be used at the tibial nerve insertion site as described above to simulate needle placement. Three electrodes will be placed on the patient's foot, two active TENS electrodes and one inactive TENS electrode. The TENS grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe. Another gel electrode will be placed on the top of the foot just above the small toe for conduction. These two electrodes will be connected to the TENS unit lead wires for sham stimulation. A third, inactive, gel electrode, will be placed near the medial aspect of the calcaneus to mimic the PTNS treatment. The TENS electrode will be connected by lead wires to the TENS unit set at 20 HZ. The TENS unit will be turned on and stimulation slowly increased to the patient's first sensory level and then turned off."
48507085|NCT06462560|OTHER|Vivo Online Exercise Program|Virtual online exercise programs conducted by the Vivo team consisting of multiple time a week group live programs
47989860|NCT02127242|PROCEDURE|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
47989861|NCT01330485|BEHAVIORAL|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
48358542|NCT04027842|DEVICE|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
48358543|NCT06016829|DIAGNOSTIC_TEST|Nutrition Risk Screening 2002 (NRS-2002)|Nutritional status assessment tool
48358544|NCT06016829|DIAGNOSTIC_TEST|Global Leadership Initiative on Malnutrition (GLIM)|Nutritional status assessment tool
48670314|NCT03483389|OTHER|Alcohol, Ethyl - placebo|Randomized within-subjects design
48670315|NCT00549159|DEVICE|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
48670316|NCT00549159|DEVICE|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
48670317|NCT05964894|OTHER|ergonomic training|ergonomic education \& exercise training
48358545|NCT06016829|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
48358546|NCT06016829|DIAGNOSTIC_TEST|Dietary inflammatory index (DII)|The Dietary Inflammatory Index (DII) is a scoring algorithm that indicates the inflammatory potential of the diet.
48358547|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Quality of life assessment tool
48358548|NCT06016829|DIAGNOSTIC_TEST|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer 29 (EORTC-QLQ-CR29)|Quality of life assessment tool
48670318|NCT03663192|DEVICE|strain echocardiography|strain echocardiography during septic shock
48670319|NCT01426802|DRUG|vildagliptin|Drug 50mg vildagliptin bid
48670320|NCT01877304|DEVICE|AKITA|
48670321|NCT05691933|PROCEDURE|Block group|Patient will be subjected to bilateral external oblique intercostal plane block
48670322|NCT05691933|PROCEDURE|Morphine infusion|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
48670323|NCT04005300|DIETARY_SUPPLEMENT|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
48670324|NCT04005300|DIETARY_SUPPLEMENT|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
48670325|NCT00845702|DRUG|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
48670326|NCT00845702|OTHER|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
48670327|NCT03130686|DEVICE|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
48670328|NCT00188214|PROCEDURE|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
48670329|NCT03744390|DRUG|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
48670330|NCT05167812|OTHER|Observation of pregnancies after intake|Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
48670331|NCT03156114|DRUG|BI 754111|Day 1 of 3 week cycle
48670332|NCT03156114|DRUG|BI 754091|Day 1 of 3 week cycle
48670333|NCT02189109|DRUG|NVX-108|0.2% emulsion administered i.v.
48670334|NCT04575519|DRUG|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
48670335|NCT04575519|DRUG|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
48670336|NCT04575519|DRUG|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
48670337|NCT04575519|DRUG|SoC TB|Standard of Care Tuberculosis treatment
48670338|NCT02162706|OTHER|Non intervention study|
48670339|NCT04038073|DIAGNOSTIC_TEST|Antistreptolysin O Test|Test to evaluate of any histories of streptococcal infections
48670340|NCT04038073|DIAGNOSTIC_TEST|Anti-Deoxyribonuclease B|Test to evaluate of any histories of streptococcal infections
48670341|NCT04038073|DIAGNOSTIC_TEST|TLR, MyD88, IRAK-4 polymorphism|Test to evaluate of the frequency and types of genetic alterations of innate immunity
48670342|NCT04038073|DIAGNOSTIC_TEST|Anti-Basal Ganglia Antibody|Test to evaluate the autoimmune component
48670343|NCT02379052|DRUG|Dupilumab|
48670344|NCT02379052|DRUG|Placebo|
48670345|NCT05772325|OTHER|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian
48670346|NCT05772325|OTHER|The brief standardized 4-minute heart healthy dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists
48670347|NCT01045369|DRUG|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
48670348|NCT04960670|OTHER|Evaluation of microbiome and maternal/infant lifestyle|Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.
48670349|NCT02297412|DRUG|Minocycline Hydrochloride|Given PO
48670350|NCT02297412|OTHER|Placebo|Given PO
48670351|NCT02297412|OTHER|Quality-of-Life Assessment|Ancillary studies
48147393|NCT04453930|DRUG|Platinum|"Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6)."
48147394|NCT04453930|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
48507086|NCT06462560|OTHER|Medbridge Home program|At home exercise program accessed through exercise descriptions and short vidoes
48670352|NCT02297412|OTHER|Questionnaire Administration|Ancillary studies
48670353|NCT02543775|PROCEDURE|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
48670354|NCT02892240|OTHER|No intervention. Observational study|
48670355|NCT00265915|BIOLOGICAL|rituximab|
48670356|NCT00265915|BIOLOGICAL|sargramostim|
48670357|NCT00104702|PROCEDURE|adjuvant therapy|
48670358|NCT00104702|PROCEDURE|conventional surgery|
48670359|NCT00104702|RADIATION|radiation therapy|
48670360|NCT02205320|BIOLOGICAL|DRL_PG|
48670361|NCT02205320|BIOLOGICAL|Pegfilgrastim Form A|
48670362|NCT02205320|BIOLOGICAL|Pegfilgrastim Form B|
48670363|NCT05739266|BEHAVIORAL|3 minutes step test|3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
48147395|NCT04453930|DRUG|Apatinib|Apatinib was administered at a dose of 250 mg during the maintenance phase.
48147396|NCT00430911|DRUG|Radiotherapy|
48358549|NCT06016829|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
48358550|NCT06016829|DIAGNOSTIC_TEST|Neutrophil-Lymphocyte Ratio (NLR)|The neutrophil-to-lymphocyte ratio (NLR) is calculated as the simple ratio between neutrophil and lymphocyte counts.
48358551|NCT04475029|DRUG|Methadone|One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
48358552|NCT04475029|DRUG|Morphine|One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
48358553|NCT03397199|DRUG|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA \<1.4, 60mg bid BSA\>1.4），bid,from day1-day 14.
48358554|NCT01884155|PROCEDURE|Allogeneic umbilical cord blood therapy|
48358555|NCT00106366|DRUG|insulin detemir|
48358556|NCT00106366|DRUG|insulin glargine|
48358557|NCT00106366|DRUG|insulin aspart|
48358558|NCT03420989|OTHER|Active snack food|snack enriched with seaweeds and carob
48358559|NCT03420989|OTHER|Control snack food|the same snack food without seaweeds and carob
48358560|NCT00527046|DRUG|CP-424,391|
48358561|NCT02403089|OTHER|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
48358562|NCT02403089|OTHER|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
48358563|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active high)|Higher dose of probiotic supplement
48358564|NCT01728610|DIETARY_SUPPLEMENT|Probiotic (Active low)|Lower dose of probiotic supplement
48358565|NCT01728610|DIETARY_SUPPLEMENT|Placebo|Placebo
48358566|NCT02367196|DRUG|CC-90002|
48358567|NCT02367196|DRUG|Rituximab|
48358568|NCT06125626|DIETARY_SUPPLEMENT|Probiotical|A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group
48358569|NCT06125626|OTHER|Placebo|A daily sachet of placebo will be given to this groups
48358570|NCT00105833|BEHAVIORAL|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
48670364|NCT05878574|DRUG|Low molecular weight heparin|Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
48670365|NCT05168761|PROCEDURE|partial nephrectomy|
48670366|NCT00678522|DRUG|Atorvastatin|80 mg atorvastatin daily on two following days
48358571|NCT02478658|OTHER|exercise training|high-intensity resistance training
48358572|NCT01412333|DRUG|Interferon beta-1a|
48507087|NCT06620133|OTHER|Pain education and patient-led goal setting|8 week program delivered via five, up to 1-hour telehealth sessions. The sessions will be scheduled at approximately fortnightly intervals. Participants will also be prescribed approximately 30 minutes of online activities with each session. Pain education will be based on Explain Pain and the curriculum will have specified learning objectives adapted for each individual participant. Participants will access the online education curriculum through Pathwright. For patient-led goal setting, the healthcare practitioner will take an initial history of the participants physical activity behaviours and problems related to their back pain. The participant will prioritise their problems according to impact in their life. Strategies will then be discussed, and the participant will, in collaboration with the healthcare practitioner, set goals and strategies to work on independently between sessions.
48507088|NCT06620133|OTHER|Supervised group exercise|Participants will be asked to attend 1-2 sessions of online supervised group exercise each week for 8 weeks. The sessions will be performed in small groups (up to 8 people) and be led by a trained healthcare practitioner. The prescribed exercises will be able to be performed at home with minimal equipment and will mostly involve bodyweight resistance training targeting the major muscle groups.
48507089|NCT03620968|OTHER|cognitive training|15 minutes day of brain training by an APP
48507090|NCT01008189|BEHAVIORAL|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
48507091|NCT01008189|BEHAVIORAL|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
48507092|NCT03626688|DRUG|Ralinepag|Active
48507093|NCT03626688|DRUG|Placebo|Placebo
48507094|NCT00985491|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
48507095|NCT03007238|BIOLOGICAL|Aldesleukin|Given SC
48507096|NCT03007238|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
48507097|NCT03007238|OTHER|Laboratory Biomarker Analysis|Correlative studies
48507098|NCT03007238|OTHER|Quality-of-Life Assessment|Ancillary studies
48507099|NCT00381914|DRUG|Vitamin D|400 IU vitamin D / day
48507100|NCT00381914|DRUG|Vitamin D|800 IU vitamin D / day
48507101|NCT00381914|DRUG|Vitamin D|1200 IU vitamin D / day
48507102|NCT01192607|DEVICE|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
48507103|NCT03747510|DEVICE|CarpX Device|Transverse carpal ligament release with CarpX Device
48507104|NCT01565057|OTHER|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
48507105|NCT01291771|PROCEDURE|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
48507106|NCT06587035|DRUG|Somatrogon|Long-acting growth hormone for pediatric growth hormone deficiency.
48670367|NCT04899765|BIOLOGICAL|BCG vaccine|It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
48670368|NCT04899765|BIOLOGICAL|Measles vaccine|It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
48358573|NCT01412333|DRUG|Ocrelizumab-matching placebo|
48358574|NCT01412333|DRUG|Ocrelizumab|
48358575|NCT01412333|DRUG|Interferon beta-1a-matching placebo|
48358576|NCT05940324|DRUG|Ketamine|Ketamine is an FDA-approved dissociative anesthetic.
48358577|NCT05940324|DRUG|Naltrexone Pill|Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
48358578|NCT05940324|OTHER|Placebo pill|An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
48358579|NCT00850135|DEVICE|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
48507107|NCT03585634|BEHAVIORAL|Dads in Gear Program|
48670369|NCT04899765|OTHER|Placebo|Saline
48670370|NCT01882465|DEVICE|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
48670371|NCT01882465|DEVICE|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
48507108|NCT04164472|BEHAVIORAL|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 14 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
48670372|NCT01882465|DEVICE|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
48358580|NCT06077123|DEVICE|Contigo Application|Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
48358581|NCT04310267|DEVICE|Petit typeface mask|(Intraoral) Hyrax expander for maxilary sutures disarticulation through expansion, (Extraoral) Face mask for generating maxillary protraction forces and head gear face-bow to act as a connector between both intra and extra oral parts.
48358582|NCT03702452|OTHER|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
48358583|NCT03702452|OTHER|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
48358584|NCT03013335|DRUG|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
48358585|NCT05839899|DRUG|Mifepristone plus one dose Misoprostol|Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later
48507109|NCT01956305|DRUG|DS-7309|DS-7309 powder in bottle
48507110|NCT01956305|DRUG|placebo|placebo to match DS-7309 powder in bottle
48507111|NCT01956305|DRUG|Metformin|Metformin 500mg tablet for Cohort F
48507112|NCT02938377|BEHAVIORAL|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
48507113|NCT02938377|BEHAVIORAL|CBT4CBT|9 computerized modules delivered at the participant's pace
48507114|NCT02938377|DRUG|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
48507115|NCT05691504|PROCEDURE|Biopsy|Undergo biopsy
48670373|NCT05129956|DEVICE|"Covidien Emprint Ablation System with Thermosphere Technology"|The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
48670374|NCT00281593|DRUG|Telmisartan|
48670375|NCT00281593|DRUG|Ramipril|
48507116|NCT05691504|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48507117|NCT05691504|DRUG|Cobimetinib|Given PO
48507118|NCT05691504|PROCEDURE|Computed Tomography|Undergo CT
48507119|NCT05691504|PROCEDURE|Echocardiography|Undergo ECHO
48507120|NCT05691504|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48507121|NCT05691504|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48507122|NCT05691504|DRUG|Pelcitoclax|Given IV
48507123|NCT00435812|BIOLOGICAL|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
48507124|NCT00435812|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
48507125|NCT01044264|DRUG|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
48507126|NCT01044264|DRUG|Placebo|Placebo
48507127|NCT01316315|DRUG|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
48507128|NCT01316315|DRUG|Placebo|Same as active
47989862|NCT01330485|BEHAVIORAL|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
47989863|NCT04511793|DEVICE|Medtronic Synchromed II pump|The pump will be placed during surgery and the pump will be filled with a combination of floxuridine (FUDR), dexamethasone, heparin, and saline.
47989864|NCT00146146|DRUG|testosterone undecanoate alone|1000 mg/12 weeks
47989865|NCT00146146|DRUG|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
48507129|NCT05801952|DEVICE|Aerobika* OPEP, PARI O-PEP (Flutter), PARI PEP® S System|The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices: Aerobika\* OPEP Device (Trudell Medical International), Flutter - PARI O-PEP Device (PARI Respiratory Equipment, Inc.) and PEP - PARI PEP® S System (PARI Respiratory Equipment, Inc.).
48507130|NCT03153449|DEVICE|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
48507131|NCT05158088|DEVICE|Borescope|Endotracheal intubation using borescope
48507132|NCT05158088|DEVICE|Video laryngoscope|Endotracheal intubation using video laryngoscope
48670376|NCT02261961|BIOLOGICAL|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
48670377|NCT02261961|OTHER|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
48358586|NCT05839899|DRUG|Mifepristone plus two doses Misoprostol|Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that
48507133|NCT03303209|OTHER|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
48507134|NCT02692144|OTHER|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
48507135|NCT06632548|DEVICE|telescopic overdenture|two implant retained mandibular overdenture with telescopic attachment
47989866|NCT00146146|DRUG|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
48358587|NCT03124524|DRUG|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
48358588|NCT03124524|DRUG|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
48358589|NCT04772287|DRUG|Toripalimab|Toripalimab: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
48358590|NCT04772287|DRUG|Toripalimab mimetic (placebo)|Placebo: 240mg, IV, q3w, 4 cycles in total; Platinum-containing dual-drug chemotherapy: The specific dose is based on the standard of the selected protocol, IV, q3w, a total of 4 cycles.
48507136|NCT00400595|DRUG|Mupirocin ointment|topical ointment (already in widespread clinical use)
48507137|NCT00400595|DRUG|Polysporin Triple|
48507138|NCT06323980|DEVICE|Reverse Total Shoulder|Uncemented Reverse Total Shoulder
48507139|NCT03741712|DRUG|SHR3680|Tablet. Specifications of 80mg
48507140|NCT03741712|DRUG|SHR2554|Tablet. Specifications of 50mg and 200mg
48507141|NCT05674851|OTHER|MRI|collection of MRI scans for mathematical model development
48507142|NCT03201445|DRUG|Filgotinib|200 mg tablet administered orally once daily
48507143|NCT03201445|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
48507144|NCT03201445|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
48507145|NCT05404334|DIAGNOSTIC_TEST|Androgen receptor status and BRCA mutation|Androgen receptor status by IHC and germ line BRCA mutation
48507146|NCT04149093|DIAGNOSTIC_TEST|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
48670378|NCT02261961|OTHER|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
48670379|NCT02261961|OTHER|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
48670380|NCT02261961|DIETARY_SUPPLEMENT|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
48670381|NCT02261961|DIETARY_SUPPLEMENT|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
48670382|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
48670383|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
48670384|NCT05354024|BIOLOGICAL|NDV-HXP-S 10μg|NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)
48670385|NCT05354024|BIOLOGICAL|BNT162b2 30μg|Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
48670386|NCT02160821|PROCEDURE|Caudal Epidural|Ultrasound Guided Caudal Block
48670387|NCT02160821|PROCEDURE|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
48670388|NCT01482858|DIETARY_SUPPLEMENT|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
48670389|NCT01482858|OTHER|Placebo|Gelatin capsules, each containing 500 mg \[comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose\] for oral use as placebo
48507147|NCT06634225|DIAGNOSTIC_TEST|Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test|Patients will receive the care they need, in line with HAS recommendations. They will be asked to perform two gait analysis tests on a three-dimensional platform, equipped with sensors (medical device).
48670390|NCT02462226|BEHAVIORAL|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
48670391|NCT02462226|BEHAVIORAL|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
48670392|NCT05227170|OTHER|Lactobacillus Plantarum 299v Freeze Dried Capsule|The intervention is a probiotic lactobacillus that is contained in food products in the US
48670393|NCT05227170|OTHER|Freeze Dried Potato Starch Capsule|The intervention is potato starch that is freeze dried designed to mimic the lp299v capsule.
48670394|NCT06110403|DRUG|TRIXEO AEROSPHERE|BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
48670395|NCT00781547|DRUG|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
48670396|NCT01058239|DRUG|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
48670397|NCT01058239|DRUG|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
48670398|NCT04042805|BIOLOGICAL|Sintilimab|200mg intravenously every 3 weeks
48670399|NCT04042805|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48358591|NCT00071604|BEHAVIORAL|Medication Adherence Therapy|
48507148|NCT05179876|DRUG|Macitentan|Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
48507149|NCT05179876|DRUG|Selexipag|Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms.
48507150|NCT05179876|DRUG|Macitentan/Tadalafil FDC|Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
48507151|NCT00457483|DRUG|hydrochlorothiazide|12.5 mg once-a-day
48670400|NCT03152123|DRUG|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
48670401|NCT03152123|DRUG|Placebos|tablets over-capsuled
48670402|NCT03152123|DRUG|Phentermine|Phentermine 60 mg (capsule over-capsuled)
48670403|NCT04841954|DIAGNOSTIC_TEST|hemp prick-test|hemp seed and flower prick-test
48358592|NCT00071604|BEHAVIORAL|Friendly Support Group|
48670404|NCT01453166|OTHER|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
47989867|NCT03628755|BEHAVIORAL|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
47989868|NCT03628755|BEHAVIORAL|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
47989869|NCT03628755|BEHAVIORAL|combination Group|combination group intervention of DMT + FST
47989870|NCT04798547|PROCEDURE|Short Myotomy|Evaluation of short length myotomy
47989871|NCT04798547|PROCEDURE|Standard Length Myotomy|Standard Length Myotomy
48507152|NCT00457483|DRUG|valsartan, 80 mg once-a-day|80 mg once-a-day
47989872|NCT00014677|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
47989873|NCT00014677|PROCEDURE|conventional surgery|
48507153|NCT03122977|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
47989874|NCT02756884|BIOLOGICAL|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
48507154|NCT03122977|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
48670405|NCT01453166|OTHER|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
48670406|NCT01453166|OTHER|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
48670407|NCT03006588|PROCEDURE|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
48670408|NCT01203709|DRUG|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
48670409|NCT04096417|DRUG|Pemigatinib|Given PO
47989875|NCT02756884|BIOLOGICAL|adipose derived stem cells|control arm will only received the adipose derived stem cells.
47989876|NCT00829543|PROCEDURE|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
48670410|NCT04096417|OTHER|Quality-of-Life Assessment|Ancillary studies
48670411|NCT00615576|DRUG|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
48670412|NCT00615576|DRUG|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
48670413|NCT01310010|DRUG|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
48670414|NCT04167527|DEVICE|Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device|"Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
48670415|NCT04167527|COMBINATION_PRODUCT|Initial medical management (iMM)|"Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
47989877|NCT04368819|DRUG|Allopurinol 300 MG|Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
47989878|NCT04368819|DRUG|Placebo oral tablet|Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
47989879|NCT01435109|BEHAVIORAL|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
47989880|NCT01435109|BEHAVIORAL|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
48507155|NCT01098630|OTHER|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
48670416|NCT01979614|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
48670417|NCT01979614|OTHER|Placebo|5% v/v glucose solution
48670418|NCT00120133|DRUG|Atorvastatin|
48670419|NCT01301677|DRUG|Hydrocortisone|Hydrocortisone liquid formulation
48670420|NCT01301677|DRUG|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
48670421|NCT01301677|DRUG|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
48670422|NCT02478489|DRUG|Oral naltrexone (PO-NTX)|oral naltrexone
48670423|NCT02478489|DRUG|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
48670424|NCT05748821|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
48670425|NCT05309044|BEHAVIORAL|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
48670426|NCT05309044|OTHER|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
48670427|NCT05309044|OTHER|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
48670428|NCT04907071|DEVICE|Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)|The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
48670429|NCT04016857|PROCEDURE|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
48670430|NCT04016857|PROCEDURE|Control|deflated cuff placed on the left arm for 40 min
48670431|NCT03101800|DRUG|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
47989881|NCT01435109|BEHAVIORAL|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
47989882|NCT01404325|DRUG|standard therapy|centre specific CNI-based triple drug immunosuppression
47989883|NCT01404325|DRUG|Everolimus|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
48507156|NCT01098630|OTHER|Questionnaire Administration|Ancillary studies
48670432|NCT03101800|DRUG|Azathioprine|Standard weight based azathioprine dosage
48670433|NCT02045784|DIETARY_SUPPLEMENT|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
48670434|NCT02045784|OTHER|Breast milk|Unlimited breast feeding
48670435|NCT04301648|OTHER|STAR Nurse|"This intervention will consist in that the nurse who is in the hemodynamic nurse's office will do the STAR Nurse's tasks and competences.~Although the intervention will be detailed through phase 1 (integrative review) and 2 (Delphy methodology).~It is expected that the main STAR nurse's competencies and tasks in the nurse's office will be:~1. To guarantee a comprehensive evaluation and appropriate triage to candidates for an interventional procedure of structural heart disease, coordinating the request for complementary tests and previous visits.~2. Make education to the patient and family.~3. Make communication bridge with cardiologists.~4. Establish specific patient-centered care processes.~5. Promote continuity of care after discharge, follow up after discharge, and reevaluate quality of life and fragility."
48670436|NCT04301648|OTHER|Common Practice|Common practice will consist in that the nurse who is in the hemodynamic nurse's office will do her usual task that is exclusively health education.
48670437|NCT01740869|OTHER|Stem cells|
48670438|NCT00002907|DRUG|bryostatin 1|
48670439|NCT02663310|PROCEDURE|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
48670440|NCT02663310|PROCEDURE|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
48670441|NCT03829111|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
48670442|NCT03829111|BIOLOGICAL|Ipilimumab|Given IV
48670443|NCT03829111|BIOLOGICAL|Nivolumab|Given IV
48670444|NCT02153489|DRUG|Aclidinium bromide|
48670445|NCT02153489|DRUG|Placebo|
48670446|NCT02731287|DRUG|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
48670447|NCT02731287|DRUG|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
48670448|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 15 opioid tablets for post-operative pain
48670449|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 25 opioid tablets for post-operative pain
48670450|NCT04278703|DRUG|oxycodone|Patients will be given a prescription for 35 opioid tablets for post-operative pain
48670451|NCT02252315|OTHER|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
48670452|NCT02252315|OTHER|Verbal education module|A structured in-person education module about mild traumatic brain injury.
48507157|NCT01520870|DRUG|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
48670453|NCT02053844|OTHER|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
48670454|NCT02053844|OTHER|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
48670455|NCT05562115|OTHER|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
48670456|NCT04554303|DRUG|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
48670457|NCT04554303|DRUG|Amlodipine 5mg|Oral administration, 1 tablet per day
48670458|NCT02441842|DRUG|atenolol|administered 60 minutes pre procedure
48670459|NCT02441842|DRUG|lisinopril|administered 60 minutes pre procedure
48670460|NCT02441842|OTHER|glucose|administered 60 minutes pre procedure
48358593|NCT05739890|OTHER|Embryo genome sequencing|This project proposes the testing of a cohort of research embryos to establish the key parameters for amplified trophectoderm biopsied embryos using minimum depth required for genome sequencing (\>depth of 30x per base).The remaining embryo tissue will be whole genome sequenced to validate the results of the biopsy.
48358594|NCT05739890|OTHER|Parents genome sequencing|Analysis will be performed using trio testing of each embryo in addition to the DNA from the genetic parent to facilitate the derivation of de novo mutation rate.
48358595|NCT05246228|OTHER|Peripheral blood sampling in order to evaluate changes in the circulating immune population|Eveluation: circulating T cells CD3+CD8+ and CD3+CD4+, absolute lymphocyte count (ALC) and neutrophil counts (ANC) and neutrophil/lymphocyte ratio (NLR), Treg lymphocytes, Naïve/Memory T lymphocytes CD4+ and CD8+,myeloid-derived suppressor cells, Plasmacytoid Dendritic Cells NK cells dimension and bright, NKT cells, Myeloid Dendritic cells, Monocytes subsets, B lymphocytes ,Analysis of plasma cytokines (TNFalpha, TGFbeta, IL-6, IL-10) by ELISA,FN signature: real-time PCR on mRNA from peripheral blood mononuclear cells (PBMCs)
48670461|NCT02668666|DRUG|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
47989884|NCT05196841|BEHAVIORAL|Anastatica Hierochuntica|During the sampling process, the researcher inquired through women who apply for pregnancy follow-up and contacted the mothers who had some inclusion criteria. Also, the researcher outlined the research plan and objectives. The participants were assessed based on the eligibility criteria and, if they were eligible and willing to participate in the study.
48358596|NCT03500419|DEVICE|RestoreX|PTT - Penile traction therapy in the straight position.
48358597|NCT03500419|OTHER|No treatment|Control group. No treatment will be given for the 6 months post-prostatectomy
48507158|NCT03079635|DIETARY_SUPPLEMENT|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
48507159|NCT03079635|DIETARY_SUPPLEMENT|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
48507160|NCT04096755|DIAGNOSTIC_TEST|Procedure|serum and urine samples will be taken for analysis
48507161|NCT06233903|DRUG|18F-mFBG|18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
48670462|NCT02668666|DRUG|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
48670463|NCT02320864|PROCEDURE|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
48670464|NCT05592301|DIAGNOSTIC_TEST|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI)|The Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) is used to diagnose perioperative stroke.
48670465|NCT05592301|DIAGNOSTIC_TEST|Transcranial Doppler (TCD)|Used to diagnose PFO
48670466|NCT05592301|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|Used to diagnose PFO.
48670467|NCT05636202|OTHER|No intervention|There was no intervention in the retrospective study
48670468|NCT06489366|DEVICE|Thulium Fiber laser (TFL) lithotripsy|Patients with proximal ureteral stones undergoing ureteroscopic lithotripsy using thulium laser lithotripsy.
48670469|NCT06489366|DEVICE|Ho: YAG lithotripsy|Ho:YAG laser lithotripsy was used in patients with proximal ureteral stones undergoing ureteroscopic lithotripsy.
48670470|NCT02539550|DRUG|Placebo|Placebo
48670471|NCT02539550|DRUG|PF-06266047|PF-06266047
48670472|NCT04120129|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.
48670473|NCT04120129|DEVICE|sham TMS coil|The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.
48670474|NCT06135948|DRUG|Extra dose of L-thyroxine, 25 mcg during Ramadan|Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
48670475|NCT00076440|DRUG|Leuprolide acetate|
48670476|NCT03564873|DRUG|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
48670477|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
48147397|NCT05804734|DRUG|Vitamin K Antagonist - Drug|"Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment."
48147398|NCT02770274|DRUG|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
48358598|NCT01072656|DEVICE|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
48147399|NCT02770274|DRUG|Aspirin|Monotherapy with aspirin 100 mg once daily
48147400|NCT05647941|DIAGNOSTIC_TEST|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
47989885|NCT02165436|OTHER|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
47989886|NCT02165436|OTHER|Control|No intervention will be assessed for this group.
48147401|NCT00605137|DRUG|insulin detemir|
48147402|NCT00605137|DRUG|insulin NPH|
48147403|NCT00505427|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|
48147404|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
48147405|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
48147406|NCT00831194|BEHAVIORAL|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
48507162|NCT04900519|BIOLOGICAL|STI-6643|Anti-CD47 human monoclonal antibody
48670478|NCT03564873|DRUG|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
48670479|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
48358599|NCT00779233|DRUG|Zidovudine tablets 300 mg|
47989887|NCT00015301|DRUG|Methylphenidate|
47989888|NCT00294073|PROCEDURE|Fascia Iliaca Block|
47989889|NCT00294073|PROCEDURE|Femoral Block (with stimulating catheter)|
48358600|NCT00000368|BEHAVIORAL|Cognitive behavior therapy|
48358601|NCT00000368|DRUG|Paroxetine or other medication - algorithm used|
48358602|NCT00877890|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
48358603|NCT00877890|DRUG|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
48358604|NCT03263169|BEHAVIORAL|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
48358605|NCT01590524|BEHAVIORAL|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
48507163|NCT00244478|DIETARY_SUPPLEMENT|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
48507164|NCT00244478|DIETARY_SUPPLEMENT|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
47989890|NCT00294073|PROCEDURE|Femoral Block (without stimulating catheter)|
47989891|NCT01080690|PROCEDURE|EGD|In this arm EGD will be performed before EUS.
47989892|NCT01080690|PROCEDURE|EUS|In this arm EUS will be performed before EGD.
47989893|NCT03605303|DEVICE|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
48507165|NCT05250648|DRUG|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
48507166|NCT05250648|PROCEDURE|complete cytoreductive surgery without HIPEC|in the arm without HIPEC, only complete cytoreductive surgery will be performed
47989894|NCT03605303|DEVICE|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
47989895|NCT04716387|OTHER|Standard LLIN|Long-lasting insecticidal net containing alphacypermethrin, a pyrethroid insecticide, and manufactured by Shobikaa Impex Private Limited.
47989896|NCT04716387|OTHER|Piperonyl butoxide ITN|Insecticide treated net containing permethrin, a pyrethroid, and piperonyl butoxide, an insecticide synergist, manufactured by Sumitomo Chemical.
47989897|NCT04716387|OTHER|Pyriproxyfen ITN|Insecticide treated net containing alpha-cypermethrin, a pyrethroid, and pyriproxyfen, an insect growth regulator, manufactured by Disease Control Technologies.
47989898|NCT04716387|OTHER|Chlorfenapyr ITN|Insecticide-treated nets containing two active ingredients: alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide, manufactured by BASF.
47989899|NCT02085785|BEHAVIORAL|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
48507167|NCT02931929|DRUG|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
48507168|NCT04170465|DRUG|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
47989900|NCT02085785|BEHAVIORAL|Self-directed control group|Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
48358606|NCT00171327|DRUG|valsartan, fluvastatin|
48358607|NCT02699047|DIETARY_SUPPLEMENT|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
48507169|NCT04170465|DRUG|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
48507170|NCT03972735|OTHER|Psychiatric interview|PANSS, MADRS, PSP, YMRS
48507171|NCT03972735|OTHER|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
48507172|NCT03972735|OTHER|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
48670480|NCT06007586|DRUG|Aprepitant Injection|Two antiemetic groups use placebo,Dexamethasone and Ondansetron, Three antiemetic groups use Aprepitant,Dexamethasone and Ondansetron.
48670481|NCT03132285|DEVICE|PrePex|Prepex is a non surgical male circumcision device
48670482|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
48670483|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
47989901|NCT02085785|OTHER|Screened only|Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
47989902|NCT05576493|PROCEDURE|phaco+MP-TSCPC|The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
47989903|NCT05576493|PROCEDURE|phaco+TSCPC|The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
47989904|NCT05576493|PROCEDURE|phaco+endocyclophotocoagulation|phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
47989905|NCT05576493|PROCEDURE|phaco GSL|phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
47989906|NCT03836196|RADIATION|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
47989907|NCT03928847|DRUG|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
47989908|NCT00099385|BEHAVIORAL|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg \& Kusche) curriculum.
47989909|NCT00013429|PROCEDURE|Visual|
47989910|NCT03945474|OTHER|Sham|See description in sham arm.
47989911|NCT03945474|OTHER|Osteopathic Manipulation, OMT|See description in OMT arm
47989912|NCT02164747|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
47989913|NCT06027853|DRUG|CLL1 CAR-NK cell injection|"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"
47989914|NCT04889339|DEVICE|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
47989915|NCT04889339|DEVICE|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
47989916|NCT03667365|PROCEDURE|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
47989917|NCT03667365|OTHER|strict clinical surveillance|strict clinical surveillance strategy
47989918|NCT00530933|PROCEDURE|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
48507173|NCT03972735|OTHER|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
48507174|NCT01168752|DRUG|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
48670484|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
47989919|NCT00530933|PROCEDURE|Transcutaneous tibial nerve stimulation|30 minutes once weekly
47989920|NCT00530933|PROCEDURE|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
47989921|NCT04859751|DRUG|VB4-845 Injection|Intravesical administration of VB4-845 Injection.
47989922|NCT04659850|OTHER|low fat, low AGE milkshake|low fat, low AGE milkshake given after an overnight fast
48507175|NCT01915758|DRUG|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
47989923|NCT04659850|OTHER|low fat, high AGE milkshake|low fat, high AGE milkshake given after an overnight fast
47989924|NCT04659850|OTHER|high fat, low AGE|high fat, low AGE milkshake given after an overnight fast
47989925|NCT04659850|OTHER|high fat, high AGE milkshake|high fat, high AGE milkshake given after an overnight fast
48147407|NCT04738370|OTHER|Sample collection|Bloods +/- urine +/- vaginal swabs taken
48507176|NCT01915758|DRUG|vehicle gel|vehicle gel
48507177|NCT01819610|DRUG|SPRIX|
48507178|NCT03485365|DRUG|GSK3858279 IV|GSK3858279 will be available as solution for injection to be administered via IV route.
48507179|NCT03485365|DRUG|GSK3858279 SC|GSK3858279 will be available as solution for injection to be administered via SC route.
48507180|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC or IV)|Placebo will be available as sodium chloride solution to be administered via SC or IV route.
48670485|NCT04097990|OTHER|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
48670486|NCT05810519|BEHAVIORAL|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
48670487|NCT05810519|BEHAVIORAL|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
48670488|NCT02113319|DRUG|dasatinib|dasatinib 50 mg and 20 mg During one year
48358608|NCT02699047|DIETARY_SUPPLEMENT|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
48670489|NCT04084041|DEVICE|Simeox|Airway clearance device
48670490|NCT04084041|OTHER|CCPT|Conventional chest physiotherapy
48670491|NCT04937192|OTHER|No intervention|No intervention
47989926|NCT04152603|BEHAVIORAL|BRIEF Educational Module|The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
48670492|NCT01049087|RADIATION|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
48670493|NCT01049087|RADIATION|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
48670494|NCT00287924|DRUG|methotrexate|
48670495|NCT00287924|PROCEDURE|adjuvant therapy|
47989927|NCT04990414|OTHER|Cognitive Behavioural Therapy|Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
48670496|NCT00210444|BIOLOGICAL|Botulinum toxin type A|
48670497|NCT02006186|BEHAVIORAL|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
48670498|NCT04303975|OTHER|clinical measurements|Only clinical parameters were recorded, no intervention was made.
48670499|NCT02167789|DEVICE|Paradym CRT 8770|
48670500|NCT03551782|DRUG|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
48670501|NCT03551782|DRUG|Apalutamide 240 mg|Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
48358609|NCT02943863|DEVICE|HFNC followed by conventional nasal cannula|
48507181|NCT03485365|DRUG|Placebo matching to GSK3858279 (SC)|Placebo will be available as sodium chloride solution to be administered via SC route.
48507182|NCT06525207|DEVICE|Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography|Global morpho-functional assessment of the anal sphincter complex using Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography
48507183|NCT04801381|PROCEDURE|Aquablation therapy|Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA
48670502|NCT05499026|DRUG|Chenodeoxycholic Acid|Bile acid
48670503|NCT00882024|DRUG|Tranilast|150 mg tranilast tablets, bid, 12 weeks
48670504|NCT00882024|DRUG|Tranilast|75 mg tablets, bid, 12 weeks
48670505|NCT00882024|DRUG|Placebo|Placebo tablets, bid, 12 weeks
48670506|NCT03239457|BIOLOGICAL|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
48670507|NCT01865487|BIOLOGICAL|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
48670508|NCT01865487|BIOLOGICAL|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
48670509|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
48670510|NCT00984503|DRUG|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
48670511|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
48670512|NCT00984503|DRUG|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
48670513|NCT01737866|DRUG|AMG 423|omecamtiv mecarbil
48358610|NCT02943863|DEVICE|Conventional nasal cannula followed by HFNC|
48358611|NCT01724164|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
48670514|NCT01472731|OTHER|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
48670515|NCT01472731|DRUG|GC1008|5 mg/kg intravenous use
48670516|NCT03667404|DIETARY_SUPPLEMENT|Resistant maltodextrin|Resistant maltodextrin powder
48670517|NCT03667404|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin powder
47989928|NCT05757661|OTHER|Focal Vibration|"A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%."
47989929|NCT05757661|OTHER|Sham Group|The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
47989930|NCT05303207|DIETARY_SUPPLEMENT|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
48358612|NCT01724164|BEHAVIORAL|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
48358613|NCT01724164|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
48358614|NCT01724164|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
48358615|NCT01724164|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
48358616|NCT01908335|DRUG|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
48358617|NCT01908335|DRUG|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
48670518|NCT05780879|DRUG|Venetoclax|Venetoclax administered orally once daily on days 3-16.
47989931|NCT00656409|DRUG|Conjugated pneumococcal vaccine (Prevenar)|
48358618|NCT01908335|DRUG|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
48358619|NCT01908335|DRUG|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
48358620|NCT03145857|DRUG|[68]Ga-HA-DOTATATE|All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
48358621|NCT00198406|PROCEDURE|diagnostic and therapeutic management|
48358622|NCT03713242|DRUG|ACT-541468 25 mg|Administered as a tablet.
48358623|NCT03713242|DRUG|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
48358624|NCT03154918|DRUG|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
48358625|NCT00519558|DRUG|somatropin|
48358626|NCT02691078|OTHER|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
48358627|NCT04151758|DRUG|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
48670519|NCT05780879|DRUG|FLAG or CLAG Protocol|FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
48670520|NCT02196753|OTHER|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV\> 40% of the background."
47989932|NCT05204654|OTHER|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
48358628|NCT04151758|OTHER|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
47989933|NCT05204654|DEVICE|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
47989934|NCT04039412|DRUG|Hybrid regimen|two-step (dual-quadruple) treatment
47989935|NCT04039412|DRUG|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
47989936|NCT04039412|DRUG|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
47989937|NCT03831347|BEHAVIORAL|Hatha Yoga|12 weeks of Hatha Yoga
47989938|NCT02391740|OTHER|Questionnaire|
47989939|NCT00644280|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
47989940|NCT02829463|RADIATION|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
47989941|NCT01116297|DEVICE|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
47989942|NCT01813539|DRUG|ARGX-110|ARGX-110 will be administered as an IV infusion.
47989943|NCT03384979|DRUG|Iopamidol|Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
47989944|NCT02675413|DRUG|Dimethyl Fumarate|Open-label
47989945|NCT06419387|DEVICE|Self-Therapy Mobile App|Self-Therapy Mobile App includes videos and guidelines for applying EMDR Flash Technique
47989946|NCT06419387|OTHER|Psycho-education Videos|Psycho-education Videos include guidelines for increasing emotion regulation skills.
48358629|NCT04151758|OTHER|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
47989947|NCT02075658|DEVICE|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
47989948|NCT02075658|DEVICE|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
47989949|NCT02985229|DRUG|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
47989950|NCT02985229|DRUG|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
47989951|NCT05029986|BEHAVIORAL|Socialization phase|Control condition: does not involve speech-related exercises
47989952|NCT05029986|BEHAVIORAL|Speech breathing intervention|Experimental condition: involves speech-related exercises
47989953|NCT05153512|PROCEDURE|MRI|Pelvic MRI without injection of contrast product and WITHOUT rectal or vaginal opacification
47989954|NCT04249037|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|A 30 day supply of Bictegravir 50mg/Emtricitabine 200mg/Tenofovir Alafenamide 25mg will be provided to the rapid start arm.
48358630|NCT00538486|DRUG|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
48358631|NCT00538486|DRUG|Telmisartan|Telmisartan 80mg 1/d
48670521|NCT03940716|BEHAVIORAL|IntERact|"This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (\~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
48147408|NCT06390345|OTHER|FOCuSEd Integrated Intervention|"Participants randomized to the intervention will receive an integrated telehealth-delivered, remote lifestyle intervention that promotes healthy eating and 150 minutes per week of moderate-intensity physical exercise. This intervention will include a core curriculum during the first 3 months that includes: 1) a 12-session video based program; 2) goal setting and self-monitoring using a Fitbit tracker and MyFitnessPal; 3) lifestyle coaching; and 4) three tele-pulmonary rehab sessions and an additional 60-75 minutes of gradually increasing self-directed exercise per week. At the end of 3 months, we will offer to enter a recommendation for weight loss medications to intervention participants with a BMI of ≥ 27 kg/m2. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach."
48147409|NCT06390345|OTHER|Enhanced Usual Care|"Participants in the enhanced usual care group will be referred to MOVE! (VA's weight loss management program) and pulmonary rehabilitation in coordination with their primary care provider."
48358632|NCT00538486|DRUG|Candesartan|Candesartan 8mg daily
48507184|NCT04801381|PROCEDURE|Transurethral laser enucleation|Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
48670522|NCT04052061|BIOLOGICAL|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
47989955|NCT04249037|DRUG|Standard initiation of antiretroviral therapy (ART)|Standard initiation of ART at the discretion of provider + new diagnosis package with laboratory evaluations and social work referral.
48670523|NCT02711501|PROCEDURE|Laser-assisted surgery.|laser-assisted surgery
48670524|NCT02711501|PROCEDURE|conventional surgery by blade|conventional surgery
47989956|NCT01947920|DRUG|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
48147410|NCT03688087|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
48147411|NCT03688087|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
48358633|NCT00538486|DRUG|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
48358634|NCT00538486|DRUG|Amlodipine|Amlodipine 5mg 1/d
48670525|NCT02128087|BEHAVIORAL|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
48670526|NCT02128087|BEHAVIORAL|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
48670527|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
47989957|NCT01947920|DRUG|Placebo|Size-matching capsules containing an appropriate inactive excipient
48358635|NCT00538486|DRUG|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
48358636|NCT05191615|BEHAVIORAL|Job crafting training|"Consists of two main parts. In the first part, both managers and employees will be trained in the principles of SDT and JD-R. For managers, particular attention will be paid to the provision of need support and work values. For employees, particular attention will be paid to employees' opportunities for job crafting and promoting their basic psychological need satisfaction at work.~In the second part of the intervention, participants will have the opportunity to discuss their current health status and receive preventive health recommendations from a preventive care specialist."
48507185|NCT05232266|DRUG|Caralluma Fimbriata|Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
48507186|NCT05232266|DRUG|Placebo comparator - Microcrystalline cellulose|Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
48507187|NCT03642639|DEVICE|MICRUSFRAME and GALAXY coils|MICRUSFRAME and GALAXY Coils
48507188|NCT00282919|DRUG|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
48147412|NCT03210025|DRUG|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
48147413|NCT03210025|DRUG|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
48507189|NCT01159080|DRUG|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
48507190|NCT01159080|DRUG|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
48507191|NCT06211491|OTHER|Urodynamic test|Urodynamic testing is performed using saline solution at the same temperature as body temperature (37 degrees) at two injection speeds of 10 mL/min and 100 mL/min, respectively.
48507192|NCT00567905|DIETARY_SUPPLEMENT|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
48147414|NCT01000207|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
48147415|NCT03556332|DRUG|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
48507193|NCT06028880|BEHAVIORAL|Free2Be|Free2Be is a manualized 13-week face-to-face group intervention for SM individuals with one pre-session and plus 12 intervention sessions. The themes of each session are: Human nature \& Relation with suffering (S1), Emotional regulation \& Multiple selves (S2), Creative hopelessness \& Values (S3), Compassionate attention (S4), Compassionate acceptance (S5), Self-criticism; Compassion \& Flows of compassion (S6), Compassionate imagination; Compassionate self (S7), Early experiences; Stigma and shame; \& Compassionate cognitive desfusion (S8), Compassionate thinking (S9), Difficult emotions: Shame \& Anger (S10), Coming out \& Compassionate behaviour (assertiveness) (S11), Positive emotions \& Preparing for the future (S2).
48507194|NCT02895828|OTHER|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
48507195|NCT02895828|OTHER|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
48507196|NCT03031886|OTHER|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
48507197|NCT03031886|OTHER|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
48670528|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+5
48670529|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
48670530|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+1
48670531|NCT03381118|BIOLOGICAL|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
48507198|NCT03601130|DEVICE|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
48507199|NCT03601130|DEVICE|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
48670532|NCT04392973|COMBINATION_PRODUCT|Favipiravir and Hydroxychloroquine|"Route of Administration: Oral (or through Nasogastric tube)~Dose:~Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)~Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily."
48670533|NCT02253043|DEVICE|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
48670534|NCT03703505|DRUG|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled \[14C\]AG-348.
48147416|NCT03556332|DRUG|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
48147417|NCT03556332|DRUG|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
48147418|NCT03556332|DRUG|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
48147419|NCT03556332|PROCEDURE|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine \>2mg/dL, they will receive 140 mg/m2.
48358637|NCT05608265|DEVICE|OSNAT 800 IO|Real-time, combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for retinal imaging
48670535|NCT03703505|DRUG|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
48147420|NCT03979352|DRUG|empagliflozin|Treatment with empagliflozin 25mg orally once a day
48147421|NCT03979352|DEVICE|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
48147422|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after phage treatment.
48147423|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after standard infection treatment.
48147424|NCT04507347|DRUG|TRC041266|TRC041266 sachet 1500 mg strengths
48147425|NCT04507347|DRUG|Placebo|TRC041266 sachet 1500 mg matching placebo
48147426|NCT03886207|OTHER|ginger powder footbath|38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
48147427|NCT03886207|OTHER|warm water only footbath|38-40° C warm water footbath without any additive reaching up to mid-calf level
48147428|NCT04424745|OTHER|Simultaneous Attention Bias Modification Training and Transcranial Direct Current Stimulation (tDCS)|Participants will receive 10 sessions of computerised attention bias modification training with either real or sham tDCS. Participants will self-administer tDCS at home, with research supervision, and complete attention bias modification training on a laptop or desktop computer while receiving stimulation. Sessions will be completed week daily for 2-3 weeks.
48147429|NCT01819857|DRUG|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
48358638|NCT02348931|DEVICE|Use of customized nasal brace (Nasella) for nose deformities|
48358639|NCT02348931|PROCEDURE|corrective surgery|
48147430|NCT01819857|DRUG|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
48147431|NCT01819857|DRUG|Zofran 8 mg|intravenous administration of 8 mg ondansetron
48147432|NCT03165825|DRUG|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
48147433|NCT03165825|DRUG|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
48507200|NCT05739149|DIAGNOSTIC_TEST|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
48507201|NCT05739149|PROCEDURE|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
48507202|NCT05324410|DRUG|VX-840|Solution for oral administration.
48507203|NCT05324410|DRUG|Placebo|Placebo matched to VX-840 for oral administration.
48147434|NCT04524676|PROCEDURE|Individualized Treatment|Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
48147435|NCT05230394|DIAGNOSTIC_TEST|Attended Polysomnography in the Lab|Using standard Level 1 polysomnography
48147436|NCT05230394|DIAGNOSTIC_TEST|Unattended Polysomnography in the Home|Using Cerebra's Prodigy system
48358640|NCT04852484|DRUG|local anesthetic-morphine|Before the operation, 19 mL of 0.5% Ropivacaine + 2 mg of morphine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 6 mg of morphine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
48507204|NCT01464931|DRUG|Denosumab|Adminstered by subcutaneous injection
48507205|NCT01872286|DEVICE|AKE-1|
48507206|NCT01872286|DEVICE|Pillcam SB2|
48507207|NCT02987452|OTHER|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
48147437|NCT01030263|OTHER|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
48147438|NCT01030263|OTHER|Random four-quadrant biopsies.|Random four-quadrant biopsies.
48147439|NCT02709200|DRUG|Dexmedetomidine|
48147440|NCT02416947|DIETARY_SUPPLEMENT|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
48147441|NCT02416947|DIETARY_SUPPLEMENT|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
48147442|NCT02416947|DIETARY_SUPPLEMENT|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
48147443|NCT01400997|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
48358641|NCT04852484|DRUG|local anesthetic-ketamine|Before the operation, 19 mL of 0.5% Ropivacaine + 50 mg of ketamine (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine + 200 mg of ketamine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
48358642|NCT04852484|DRUG|local anesthetic|Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
48358643|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg
48507208|NCT02987452|OTHER|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
48507209|NCT02987452|OTHER|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
48507210|NCT01897038|DRUG|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
48507211|NCT01897038|DRUG|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
48507212|NCT02414776|DRUG|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
48688169|NCT03571750|BEHAVIORAL|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
47989958|NCT02404285|DRUG|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
47989959|NCT02404285|DRUG|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
48147444|NCT01474759|BEHAVIORAL|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
48147445|NCT01474759|BEHAVIORAL|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
48147446|NCT01474759|OTHER|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
48147447|NCT01474759|BEHAVIORAL|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
48147448|NCT06014671|BEHAVIORAL|Interpersonal Psychotherapy|Intervention Group were took interpersonal psychotherapy
48147449|NCT01382706|DRUG|docetaxel|Given IV
48147450|NCT01382706|DRUG|lapatinib ditosylate|Given PO
48507213|NCT05895955|BIOLOGICAL|TetraFluvac TF vaccine|"The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus\] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
48358644|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 3000 mcg with aluminum hydroxide (alum)
48358645|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg
48147451|NCT01382706|OTHER|immunohistochemistry staining method|Correlative studies
48147452|NCT01382706|GENETIC|fluorescence in situ hybridization|Correlative studies
48358646|NCT05245838|BIOLOGICAL|Z-1018|contains gE at a dose of 100 mcg to be combined with a Toll-like receptor 9 agonist adjuvant, CpG 1018 at dose of 6000 mcg, with aluminum hydroxide (alum)
48358647|NCT05245838|BIOLOGICAL|Shingrix|a suspension for injection supplied as a single-dose vial of 50 mcg varicella zoster virus (VZV) glycoprotein E (gE) antigen and AS01B adjuvant
48358648|NCT04337112|DRUG|viltolarsen|Intravenous (IV) infusions, weekly, at 80mg/kg, once weekly (approximately every 7 days).
48358649|NCT00942292|DIETARY_SUPPLEMENT|Lipidem- fish oil emulsion BBraun UK|
48358650|NCT00942292|PROCEDURE|Digital Contrast MRI scan|
48358651|NCT04270890|DEVICE|Abdominal compression belt system|"The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position."
48358652|NCT02872090|DRUG|Indacaterol|inhalation
47989960|NCT00431210|BIOLOGICAL|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
47989961|NCT05302544|OTHER|Mixed Reality training|Mixed Reality training: Mixed Reality game with appearance of virtual balloons in the game area that the subject must find and pierce with finger
47989962|NCT05302544|OTHER|motor activities|motor activities usually performed
48147453|NCT01382706|OTHER|laboratory biomarker analysis|Correlative studies
48358653|NCT02872090|DRUG|Glycopyrronium|inhalation
48358654|NCT02872090|DRUG|Tiotropium|inhalation
48358655|NCT02872090|DRUG|Placebo|
48147454|NCT02721147|BEHAVIORAL|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
48507214|NCT05895955|BIOLOGICAL|Vaxigrip vaccine|"Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection."
48670536|NCT06255353|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48147455|NCT02721147|BEHAVIORAL|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
48670537|NCT06255353|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
48688170|NCT03571750|BEHAVIORAL|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
47989963|NCT01136850|DRUG|chloroquine, sulphadoxine pyrimethamine, LLIN|"\> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~\< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth."
47989964|NCT01136850|DRUG|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
47989965|NCT02416258|DRUG|LP0113 aerosol spray|
48358656|NCT02872090|PROCEDURE|photoplethysmography|inhalation
47989966|NCT02416258|DRUG|Aerosol spray vehicle|
47989967|NCT02416258|DRUG|LEO 90100 aerosol foam|
47989968|NCT02416258|DRUG|Betamethasone dipropionate aerosol spray|
47989969|NCT02416258|DRUG|Calcipotriol aerosol spray|
47989970|NCT02416258|DRUG|Daivobet® gel|
48147456|NCT02721147|BEHAVIORAL|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
48147457|NCT02721147|BEHAVIORAL|Behavioral, Psychological or Informational Intervention|Receive educational information and support
48147458|NCT01390753|DIETARY_SUPPLEMENT|Human donor milk|
48147459|NCT01721694|DRUG|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
48358657|NCT04659447|DRUG|Platelet-Rich Plasma|36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
48358658|NCT06283615|DRUG|Vitamin D|Vitamin D2 injection
47989971|NCT01405963|DRUG|Placebo|Administered in a 1-hour intravenous infusion
47989972|NCT01405963|BIOLOGICAL|Tezepelumab|Administered in a 1-hour intravenous infusion
47989973|NCT06218355|OTHER|Intensive Education|Intervention will consist of virtual education and communication through scheduled push notifications
47989974|NCT06218355|OTHER|Enhanced Virtual Care|"Intervention will utilize a telehealth model consisting of pull approach of patient engagement."
47989975|NCT04256785|DIETARY_SUPPLEMENT|VSL#3|sachets containing probiotic
47989976|NCT04256785|DIETARY_SUPPLEMENT|Placebo|sachets containing placebo
48147460|NCT01721694|DRUG|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
48147461|NCT05664776|DEVICE|Dynamic office chair|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
48358659|NCT00305266|DRUG|intravenous gammaglobulin|individual dose
48358660|NCT05841615|OTHER|Renal Denervation operation|RDN: Percutaneous renal artery sympathetic radiofrequency ablation for both sides. For each side, a total of 13 targets were ablated. The ablation power was 8W\~12W for 40 seconds
48147462|NCT04750902|DRUG|0.24% Sodium Fluoride Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
48147463|NCT04750902|DRUG|1.5% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
48358661|NCT05841615|OTHER|Pulmonary vein isolation|PVI: Pulmonary vein isolation was performed until the potential of each pulmonary vein disappeared under the guidance of the CARTO mapping system. Ablation of the top line and the bottom line of the left atrium was performed at the same time.
48358662|NCT00313742|DRUG|insulin detemir|
48358663|NCT00313742|DRUG|insulin glargine|
48507215|NCT03651830|DEVICE|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
48147464|NCT04750902|DRUG|4.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
48507216|NCT03651830|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
47989977|NCT04937296|BEHAVIORAL|Physical activity|Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
48688171|NCT04008303|PROCEDURE|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
47989978|NCT04937296|OTHER|Usual care|Usual care.
47989979|NCT03925740|DRUG|MI Varnish|Application of MI varnish material versus the standard 1.23% APF.
48507217|NCT05444530|BIOLOGICAL|VAC85135|Participants will receive VAC85135 as IM injection.
48507218|NCT05444530|DRUG|Ipilimumab|Participants will receive Ipilimumab as IV infusion.
47989980|NCT03925740|DRUG|PreviDent Varnish|Application of PreviDent Varnish material versus the standard 1.23% APF.
48507219|NCT03403075|BEHAVIORAL|ETAF|Therapeutic education and Physical activity
48147465|NCT04750902|DRUG|8.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
48688172|NCT05580601|DRUG|CIML-NK Cells|"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."
47989981|NCT03925740|DRUG|1.23% APF|Standard 1.23% APF application
48147466|NCT05950841|DRUG|Low dose IHAT|Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
48147467|NCT05950841|DRUG|High Dose IHAT|Twice daily dose of 1 capsule (100mg per capsule IHAT)
48147468|NCT05950841|DRUG|Carob flour|Twice daily dose of 1 capsule (carob flour)
48147469|NCT05558748|PROCEDURE|USG-guided Caudal block|USG-guided Caudal block after general anesthesia
48147470|NCT05558748|PROCEDURE|USG-guided Ilioinguinal/Iliohypogastric block|USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
48507220|NCT03403075|BEHAVIORAL|Usual care|Usual care
48147471|NCT06115070|DRUG|Alteplase|intravenous alteplase(0.9 mg/kg;maximum dose, 90mg; 10% administered as a 1-minute bolus,the remaining infused over 1 hour)
48147472|NCT04698694|DEVICE|Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)|The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
48507221|NCT04267029|DIAGNOSTIC_TEST|TADPOL battery (deep clinicolaboratory profile)|"profile dimensions:~* hemolytic~* allergic~* cardiorenal~* inflammatory~* leukoagglutinating~* exploratory bioarchive"
48147473|NCT04698694|DEVICE|Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)|The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
48358664|NCT00313742|DRUG|insulin NPH|
48688173|NCT01391689|DIETARY_SUPPLEMENT|diindolylmethane|Given PO
48688174|NCT01391689|DIETARY_SUPPLEMENT|placebo|Given PO
48507222|NCT05043441|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.
48507223|NCT05043441|BEHAVIORAL|Psychoeducation|The psychoeducation control group will receive care as usual with psychoeducation materials provided.
48507224|NCT03578367|DRUG|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
48507225|NCT03578367|DRUG|Imatinib|Imatinib 400 mg taken orally once daily
48670538|NCT06255353|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48670539|NCT02314442|DRUG|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
48507226|NCT03578367|DRUG|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
48507227|NCT03578367|DRUG|Asciminib single agent|Asciminib 80 mg taken orally once daily
48507228|NCT01793948|DRUG|metformin hydrochloride|Given PO
48507229|NCT01793948|OTHER|placebo|Given PO
48670540|NCT02314442|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
48670541|NCT05439733|OTHER|Questionnaire completion|Women will be asked to complete questionnaires 6 weeks after delivery
48670542|NCT05936424|OTHER|Unilateral Resistance Exercise Leg|One will perform unilateral resistance exercise
48670543|NCT05936424|OTHER|Non-Exercise Control Leg|One leg will serve as a non-exercise control
47989982|NCT04011501|PROCEDURE|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
47989983|NCT00999583|DRUG|EPOETINE ALPHA|5 injections of 40000 UI of EPO
47989984|NCT00999583|OTHER|Control arm|Usual take care of cardiac arrest
47989985|NCT02368795|DEVICE|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
47989986|NCT02368795|DRUG|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
47989987|NCT02368795|DRUG|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
47989988|NCT02368795|DRUG|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
47989989|NCT03773887|OTHER|collection of liver biopsies collection of blood samples|blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
47989990|NCT01665066|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
48507230|NCT01793948|OTHER|laboratory biomarker analysis|Correlative studies
48507231|NCT02572245|DEVICE|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
48507232|NCT02572245|DEVICE|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
48507233|NCT03004287|DRUG|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
48507234|NCT03004287|DRUG|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
48507235|NCT03004287|DRUG|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
48507236|NCT03004287|DRUG|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
48507237|NCT03004287|DRUG|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
48507238|NCT03004287|DRUG|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
48507239|NCT03004287|DRUG|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
48147474|NCT06425991|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
48507240|NCT03004287|DRUG|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
48670544|NCT03368066|DRUG|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
48147475|NCT04374981|DRUG|Celecoxib 100mg|Tablets
48147476|NCT04374981|DRUG|Montelukast 10mg|Tablets
48147477|NCT01802333|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
48147478|NCT01802333|DRUG|Cytarabine|Given IV
48147479|NCT01802333|DRUG|Daunorubicin Hydrochloride|Given IV
48147480|NCT01802333|DRUG|Idarubicin|Given IV
48147481|NCT01802333|OTHER|Laboratory Biomarker Analysis|Correlative studies
48147482|NCT01802333|DRUG|Vorinostat|Given PO
48147483|NCT00025376|DRUG|PS-341|
48147484|NCT00025376|PROCEDURE|Tumor Biopsy|
48147485|NCT01274156|DEVICE|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
48147486|NCT01274156|DEVICE|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
48147487|NCT01274156|DEVICE|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
48147488|NCT01274156|DEVICE|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
48147489|NCT06500910|OTHER|Physical Exercise|10 weeks of child-friendly physical exercise program
48147490|NCT01817491|OTHER|American Heart Association Diet|
48147491|NCT01817491|OTHER|Reduced Fat Vegan Diet|
48147492|NCT04311983|BEHAVIORAL|Tobacco Quitline|"Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back)."
48147493|NCT04311983|BEHAVIORAL|Smoke Free Home|The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
48507241|NCT03004287|DRUG|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
48507242|NCT03004287|PROCEDURE|ASCT|day 0 of Transplant(s)
48507243|NCT03004287|DRUG|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
48507244|NCT03004287|DRUG|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
48507245|NCT01145508|DRUG|Docetaxel|Given IV
48507246|NCT01145508|OTHER|Laboratory Biomarker Analysis|Correlative studies
48507247|NCT01145508|DRUG|Prednisone|Given PO
48507248|NCT01145508|BIOLOGICAL|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
48507249|NCT01145508|BIOLOGICAL|Rilimogene Galvacirepvec|Given SC
48507250|NCT04077918|DIETARY_SUPPLEMENT|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
48507251|NCT02985671|DRUG|orphenadrine, acetaminophen, caffeine and diclofenac sodium|orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
48670545|NCT01344148|DRUG|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
48670546|NCT05477654|DIAGNOSTIC_TEST|Extensive motor-cognitive testing protocol|Screening of their functional performance while monitoring brain and muscle activity
48670547|NCT00352300|PROCEDURE|Adjuvant Therapy|
48670548|NCT00352300|DRUG|Carboplatin|Given IV
48147494|NCT02301507|BEHAVIORAL|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
48507252|NCT02985671|DRUG|Diclofenac Sodium 50 MG|Voltaren (diclofenac sodium 50mg) tablet
48147495|NCT04330612|OTHER|Perioperative Updates|In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
48507253|NCT02985671|DRUG|Placebo (for experimental drug)|tablet without active substances, manufactured to mimic experimental product tablet
48507254|NCT02985671|DRUG|Placebo (for Voltaren)|tablet without active substances, manufactured to mimic Voltaren 50mg tablet
48507255|NCT02383810|DRUG|Elsiglutide|
48670549|NCT00352300|DRUG|Paclitaxel|Given IV
48670550|NCT00352300|BIOLOGICAL|Pegfilgrastim|Given IV
47989991|NCT01665066|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
48507256|NCT02383810|DRUG|Placebo|
48507257|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5421|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
48507258|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5424|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
47989992|NCT01665066|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
48507259|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5429|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection
47989993|NCT01665066|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
48147496|NCT05334433|PROCEDURE|Local anesthesia injection|Local anesthesia administration
47989994|NCT01665066|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
48147497|NCT02263859|DEVICE|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
48147498|NCT03945084|DRUG|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
48507260|NCT06361875|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection
48507261|NCT06361875|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection
48507262|NCT06361875|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection
48507263|NCT03261011|BIOLOGICAL|AK-104|Subjects will receive AK104 by intravenous administration.
48507264|NCT04395066|DIAGNOSTIC_TEST|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
48507265|NCT03596814|OTHER|No Interventional study|Retrospective data
48507266|NCT01178710|DRUG|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
48507267|NCT02518672|DIETARY_SUPPLEMENT|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
48507268|NCT02518672|DIETARY_SUPPLEMENT|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
48670551|NCT03827239|OTHER|Activity/Moderate Exercise|3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
48670552|NCT02013609|DRUG|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
48670553|NCT02366325|DRUG|EPO-018B|
48670554|NCT02901886|BEHAVIORAL|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
48670555|NCT01805284|DRUG|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
48670556|NCT02920320|OTHER|Internet-based self-help program|
48670557|NCT03561155|DEVICE|Robot assisted treatment (Amadeo®)|"The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon."
47989995|NCT05240560|DRUG|BP1.3656|Histamine H3 receptor antagonist/inverse agonist
47989996|NCT03686384|DRUG|SVT-15652|1 vial twice daily
47989997|NCT03686384|DRUG|Placebo|1 vial twice daily
47989998|NCT04424017|BIOLOGICAL|Specific anti-SARS-CoV-2 antibodies|"A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples.~All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA)."
47989999|NCT01730755|DRUG|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
48147499|NCT03945084|OTHER|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
48507269|NCT01216787|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
48507270|NCT01216787|OTHER|pharmacological study|
48507271|NCT01216787|PROCEDURE|therapeutic conventional surgery|
48147500|NCT02875704|OTHER|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
48147501|NCT02424305|DRUG|LEO 43204 gel 0.018%|
48670558|NCT03561155|OTHER|Conventional treatment|"The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control"
48147502|NCT02424305|DRUG|LEO 43204 gel 0.1%|
48147503|NCT02424305|DRUG|LEO 43204 gel 0.037%|
48147504|NCT04620265|OTHER|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
48147505|NCT04620265|OTHER|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
48147506|NCT04620265|OTHER|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
48147507|NCT04620265|OTHER|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
48147508|NCT04620265|OTHER|The conventional exercise program|This group received the conventional exercise program only.
48147509|NCT03187704|OTHER|HEPA air filtration|Air filters were placed in participant homes
48147510|NCT04296734|BEHAVIORAL|Mothers and Babies|Mothers \& Babies (MB) is a program that promotes healthy mood management by teaching pregnant women and new moms how to effectively respond to stress in their lives through increasing the frequency of thoughts and behaviors that lead to positive mood states. Designed as a perinatal depression prevention, the Mothers \& Babies targets three specific risk factors: limited social support, lack of pleasant activities, and harmful thought patterns.
48147511|NCT01196286|BEHAVIORAL|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
48147512|NCT01196286|BEHAVIORAL|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
48147513|NCT02108496|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
48147514|NCT02108496|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
48147515|NCT02108496|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
48147516|NCT02108496|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
48507272|NCT01216787|OTHER|laboratory biomarker analysis|Correlative studies
48670559|NCT05192421|BEHAVIORAL|Wellness Education|Receive wellness education through a weekly email and web portal content.
48670560|NCT05192421|BEHAVIORAL|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
48670561|NCT05192421|BEHAVIORAL|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
48147517|NCT00681226|DRUG|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
48507273|NCT01775449|BEHAVIORAL|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
48507274|NCT03484143|DEVICE|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
48507275|NCT03484143|DEVICE|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
48507276|NCT05062213|OTHER|Moisturizer Body Lotion|Moisturizer Body Lotion
48507277|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback|Participants will receive accurate feedback about their sleep data.
48507278|NCT06602960|BEHAVIORAL|Inflated Sleep Data Feedback|Participants will receive inflated feedback about their sleep data, suggesting better sleep quality than detected by Fitbit (actual sleep hours +10%).
48507279|NCT06602960|BEHAVIORAL|Deflated Sleep Data Feedback|Participants will receive deflated feedback about their sleep data, suggesting poorer sleep quality than detected by Fitbit (actual sleep hours -10%).
48670562|NCT06033625|PROCEDURE|CEMENTLESS TOTAL KNEE REPLACEMENT|CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
48670563|NCT01068184|DRUG|AZD6553|Single or multiple oral dose
48507280|NCT06602960|BEHAVIORAL|Accurate Sleep Data Feedback + Sleep-related Educational Information|Participants will receive accurate feedback about their sleep data along with sleep-related educational information.
48670564|NCT01068184|DRUG|Placebo|single or multiple oral dose
48670565|NCT05456048|DRUG|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
48147518|NCT05054556|DIAGNOSTIC_TEST|Labaratory tests|"Estimation of serum levels of the following parameters:~galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes"
48147519|NCT04721600|DEVICE|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
48507281|NCT03922776|PROCEDURE|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~* at diagnosis, before chemotherapy (pre-CT)~* after chemotherapy (post-ct) Collection of two blood samples (5mL),~* before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~* and then, after chemotherapy (post-CT), up to 3 months after enrollment"
48507282|NCT02817945|DRUG|68Ga-NOTA-3P-TATE-RGD|68Ga-NOTA-3P-TATE-RGD were injected into the patients before the PET/CT scans
48507283|NCT06463002|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring and Montreal Cognitive Assessment|Noninvasive tests to assess blood pressure control and cognition
48147520|NCT06034444|OTHER|interRAI LTCF|Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
48147521|NCT01853904|PROCEDURE|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
48507284|NCT02902367|OTHER|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
48147522|NCT01853904|PROCEDURE|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
48147523|NCT01942525|OTHER|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
48147524|NCT04019925|DEVICE|ADM/MDM hip|Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
48147525|NCT05830422|OTHER|nothing|Follow-up observation was conducted without any intervention in an outpatient setting.
48507285|NCT02902367|OTHER|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
48507286|NCT01625832|PROCEDURE|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
48670566|NCT05456048|DRUG|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
48670567|NCT04027647|DRUG|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
48670568|NCT03262805|DIETARY_SUPPLEMENT|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
48670569|NCT03262805|OTHER|Placebo|Microcrystalline cellulose
48670570|NCT01293812|DRUG|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
48367560|NCT03728647|BEHAVIORAL|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
48507287|NCT02769273|DEVICE|Percutaneous Transluminal Angioplasty|
48507288|NCT00124124|DRUG|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
48670571|NCT01293812|DRUG|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
48670572|NCT02669498|PROCEDURE|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
48670573|NCT01269684|DRUG|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
48670574|NCT02985411|BEHAVIORAL|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
47990000|NCT04321148|PROCEDURE|standard of care PCI|optimal medical care PCI
47990001|NCT04321148|PROCEDURE|Impella-protected PCI|Impella-protected PCI
48147526|NCT05836402|DIETARY_SUPPLEMENT|Low carbohydrate diet intervention|"Patients will receive a study kit. The kit will contain the following:~* Instruction sheet containing medical food instructions and food journal and a web link to the weekly online journal~* A 30-day supply of the medical food, KetoCitra, developed by Santa Barbara Nutrients, Inc. KetoCitra® is a ready-to-mix powder to be dissolved in water and taken twice per day with meals. KetoCitra® contains BHB, citrate, and a blend of minerals (potassium, calcium, magnesium) and is flavored with natural lemon flavor and stevia natural sweetener. KetoCitra® is sugar- and sodium-free and is intended to support the metabolic switch aimed for with the low-carbohydrate diet by providing exogenous BHB (Package insert)"
48147527|NCT01163929|DRUG|paclitaxel|"Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks"
48147528|NCT03802279|OTHER|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
48147529|NCT03802279|OTHER|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
48147530|NCT03071172|DRUG|Triptorelin for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
48147531|NCT03071172|DRUG|Recombinant Human Choriogonadotropin alfa Solution for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
48147532|NCT03071172|DRUG|Progesterone Soft Capsules|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
48358665|NCT06320964|BEHAVIORAL|TARANG|For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
48358666|NCT00818636|BEHAVIORAL|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
48358667|NCT05140694|DRUG|Empagliflozin|Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)
48358668|NCT05140694|DRUG|Dulaglutide|Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)
48670575|NCT02985411|OTHER|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
48670576|NCT04971928|DRUG|GSK3228836|GSK3228836 will be administered
48670577|NCT03820011|OTHER|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
48670578|NCT00655837|DRUG|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
48670579|NCT00655837|DRUG|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
48670580|NCT00655837|DRUG|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
48670581|NCT05874726|DIAGNOSTIC_TEST|Blood Collection|Blood collection via venipuncture
48670582|NCT05874726|DIAGNOSTIC_TEST|Urine Collection|Free catch urine sample collection
48670583|NCT05874726|DIAGNOSTIC_TEST|Tissue Sample Collection|Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
48670584|NCT02987257|DRUG|Harmonized supportive care|Harmonized supportive care with and etanercept placebo days 1 and 4
48670585|NCT02987257|DRUG|Etanercept 50 mg sc day 1 and day 4|Harmonized supportive care with placebo
48670586|NCT02918526|DEVICE|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
48670587|NCT00079313|DRUG|Imatinib|
48670588|NCT02098135|DEVICE|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
48507289|NCT00124124|DRUG|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
48670589|NCT03692403|DRUG|Quinagolide 360 µg|Vaginal ring containing quinagolide 360 µg for daily releases
48147533|NCT03921775|DRUG|Remimazolam Tosilate|For induction and maintenance of general anesthesia
48358669|NCT05140694|DRUG|Empagliflozin and Dulaglutide|Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
48358670|NCT02308709|RADIATION|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
48358671|NCT03604094|PROCEDURE|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
48358672|NCT00967863|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
48358673|NCT00967863|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
48358674|NCT05591573|DIETARY_SUPPLEMENT|Low glycemic index drink|Fruit flavoured drink with low glycemic index sugar (300 ml)
48358675|NCT05591573|DIETARY_SUPPLEMENT|High glycemic index drink|Fruit flavoured drink with high glycemic index sugar (300 ml)
48358676|NCT03704428|DRUG|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
48358677|NCT06264336|BEHAVIORAL|treadmill training|Participants will undergo 12 sessions (4 weeks, 3 sessions/week) of treadmill training. During each session, participants will walk for 40 min. with 5 min. of warmup and cooldown at 50% of maximal walking speed (tested each week) with 30 min. of training interposed. The type of training will be determined by the assigned treatment arm.
48358678|NCT00058318|DRUG|capecitabine|Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
48358679|NCT00058318|DRUG|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
48358680|NCT04772651|OTHER|Mediterranean Diet|Diet meeting the requirements for mediterranean style (rich in vegetables, fruit, olive oil, fish) (Davis et al., 2015)
48358681|NCT04772651|OTHER|Normal hospital diet|Normal hospital diet
48358682|NCT04772651|OTHER|dietary coaching|dietary coaching
48358683|NCT04772651|OTHER|Psychoeducation on depression|Psychoeducation on depression (50minutes once a week for 4 weeks)
48358684|NCT00638989|BIOLOGICAL|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
48358685|NCT00638989|BIOLOGICAL|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
48358686|NCT00638989|BIOLOGICAL|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
47990002|NCT01619683|DRUG|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
47990003|NCT01619683|DRUG|Placebo|1 placebo capsule per day, oral
47990004|NCT00768300|DRUG|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
47990005|NCT00768300|DRUG|Placebo|Placebo to match ambrisentan was administered orally once daily.
48147534|NCT03921775|DRUG|Propofol|For induction and maintenance of general anesthesia
48358687|NCT05305742|OTHER|Instrument Design|Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
48358688|NCT01662752|DRUG|Indocyanine green|Please see arm description
48358689|NCT05143294|BEHAVIORAL|Conectar Jugando Classroom Program|Modern Board Games Intervention in Elementary Classrooms
48358692|NCT02289144|DRUG|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
48507290|NCT02332837|BEHAVIORAL|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
48507291|NCT02332837|BEHAVIORAL|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
48507292|NCT02332837|BEHAVIORAL|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
48670590|NCT03692403|DRUG|Quinagolide 720 µg|Vaginal ring containing quinagolide 720 µg for daily releases
48670591|NCT03692403|DRUG|Quinagolide 1080 µg|Vaginal ring containing quinagolide 1080 µg for daily releases
48670592|NCT03692403|DRUG|Placebo|Matching placebo
48670593|NCT06097403|DIAGNOSTIC_TEST|Covid 19 swap|diagnostic tool
48670594|NCT06056180|OTHER|Balance Training|Participants will be given static and dynamic balance training with a balance platform game console (20 minutes) containing interactive video games based virtual reality for a total of 6 weeks.
48670595|NCT06056180|OTHER|Motor İmagery Training|For motor imagery training, two visualization scenarios will be created: anterior and posterior motor imagery. One of the visualization scenarios appropriate to each individual's needs will be used. Participants will be asked to perform kinesthetic or visual motor imagery in accordance with the scenario they listened to (10 minutes).
48670596|NCT06056180|OTHER|Action Observation Training|Action observation training will be done using video modeling method. The video content will include Nintendo Wii games in which the games that the person will play in that session are played by someone else and successful scores are achieved (10 minutes).
48670597|NCT01250054|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
48670598|NCT01250054|DEVICE|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
48670599|NCT03731403|OTHER|MI varnish|CPP- ACP with 5 % sodium fluoride GC
48670600|NCT02761642|DRUG|Epoetin Beta|All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
48670601|NCT01841996|DRUG|ME1111 solution|Once a day for 28 days
48670602|NCT01841996|DRUG|Vehicle Solution|Once a day for 28 days
48670603|NCT03100266|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamonosus GG
48670604|NCT03100266|OTHER|Inactive capsules|Placebo
48670605|NCT02367963|BEHAVIORAL|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
48670606|NCT02367963|BEHAVIORAL|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
48670607|NCT06194305|OTHER|CBIT|Participants will receive 8 sessions delivered weekly over 10 weeks. All sessions will be video recorded. CBIT components are: 1) Psychoeducation about tics, 2) Functional interventions, 3) Competing response (CR) training, 4) Social support: supportive people (e.g., parent, teacher) , 5) Motivational enhancements, 6) Homework: is assigned each session and typically involves self-monitoring and CR practice. Participants will complete a brief daily homework tracking log in REDCap.
48670608|NCT03263403|BIOLOGICAL|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
48688175|NCT05082012|DEVICE|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
48147535|NCT02664870|PROCEDURE|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
48147536|NCT02664870|PROCEDURE|Arthroplasty|Total hip, shoulder, or knee arthroplasty
48358693|NCT06231927|BEHAVIORAL|The Skills for Life Adjustment and Resilience (SOLAR) program|The SOLAR program is a 5-session intervention program that aims to introduce participants necessary recovery skills after a traumatic event resulting in a subclinical distress. During the program, participants will be given workbooks including the topics for skill development for recovery and adjustment. At each session, they will discuss these topics with the study coaches.
48358694|NCT05916794|OTHER|Modified Cervical Retraction Exercises (MCRE)|Group A includes Modified cervical retraction exercise The patient is in sitting OR standing position and faces the physical therapist. The MCRE program consisted of alternating head position( neutral, side bending and rotation) while pushing their chin backward patients maintained an upright posture and tried to pull back their shoulders while maintaining this retracted position patient side bend OR rotate their head respectively hold the position for 20 sec.subject performed 5 sets of 10 repetition for 3-4 days per week. Rest intervals of 30 seconds were provided after the completion of 10 repetitions for each pattern and between sets, respectively. The total duration of MCRE will be of approximately 15-20 minutes
48358695|NCT05916794|OTHER|Motor Control therapeutic exercise(MCTE)|Motor control therapeutic exercises will be guided for the retraining of cervical muscles.it include craniocervical flexor exercise,craniocervical extensor exercise, co-contraction of flexors and extensor, a synergy exercise for retraining the strength of the deep neck flexors. Each of these four exercises will be performed for 3 sets of 8 to 10 repetitions, taking an approximate total duration of 15-20 minutes for, 3 days a week
48358696|NCT02095028|BEHAVIORAL|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
48507293|NCT03482258|DIETARY_SUPPLEMENT|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
48147537|NCT04528602|PROCEDURE|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
48358697|NCT04474210|DRUG|JNJ-56136379|Participants will receive JNJ-56136379 tablets orally.
48358698|NCT03307395|PROCEDURE|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
48358699|NCT01416259|DRUG|Withdraw treatment|
48358700|NCT01694459|DRUG|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
48507294|NCT03482258|DIETARY_SUPPLEMENT|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
48507295|NCT06046794|OTHER|Analyze of GemCore status|Genomic analyze of GemCore status
48507296|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
48507297|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
48670609|NCT03263403|BIOLOGICAL|Quadri Meningo|Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo \[Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined\] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
48670610|NCT03157050|OTHER|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
48670611|NCT00686673|BEHAVIORAL|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
48670612|NCT00686673|BEHAVIORAL|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
48670613|NCT05511402|OTHER|Exercise training|People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.
48670614|NCT00736983|DRUG|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
48670615|NCT00736983|DRUG|ciprofloxacin|12 weeks; daily 2 x 500mg
48670616|NCT06179979|DIAGNOSTIC_TEST|PET/CT with 11C-PiB|Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
48670617|NCT00886730|BEHAVIORAL|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
48670618|NCT00886730|BEHAVIORAL|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
48670619|NCT00886730|BEHAVIORAL|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
48670620|NCT05685784|DEVICE|Bytelfies kit - sensor dot|"Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand"
48670621|NCT03351946|PROCEDURE|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
48670622|NCT03351946|PROCEDURE|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
47990006|NCT04251221|DRUG|Oral Alcohol Challenge|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
47990007|NCT00457600|PROCEDURE|patient-driven health IT product|
47990008|NCT06213168|OTHER|HFNC|Patients assigned to the control group will be continuously treated by HFNC. HFNC will be initiated within one hour following randomization
47990009|NCT06213168|OTHER|CPAP and HFNC|Patients assigned to the intervention group will receive high flow nasal oxygen plus CPAP sessions
47990010|NCT05482009|OTHER|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
48358701|NCT01694459|DRUG|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
47990011|NCT01486628|DRUG|ND0612|levodopa and carbidopa solution for subcutaneous administration
47990012|NCT01486628|DRUG|Placebo|Saline solution for SC continuous administration
47990013|NCT00100126|DRUG|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
47990014|NCT01239706|DRUG|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
47990015|NCT03808051|PROCEDURE|Physiological-based cord clamping|See Arm description.
47990016|NCT03808051|PROCEDURE|Time-based cord clamping|See Arm description.
47990017|NCT04898257|DIETARY_SUPPLEMENT|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
47990018|NCT02400502|BEHAVIORAL|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
48358702|NCT02382887|PROCEDURE|tracheal intubation|tracheal intubation with the Airtraq
48358703|NCT02382887|DEVICE|Airtraq|
48358704|NCT02382887|DEVICE|fiberscope|
48358705|NCT03065166|OTHER|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
47990019|NCT05793320|PROCEDURE|Carpal Tunnel Release Surgery|Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.
48358706|NCT03065166|OTHER|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
48358707|NCT02253173|DRUG|Estradiol|
48358708|NCT02253173|DRUG|Placebo|
48670623|NCT02913963|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
48670624|NCT02913963|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
48670625|NCT03130829|DIETARY_SUPPLEMENT|Oligo Fucoidan|Oral, twice daily
48670626|NCT03130829|DIETARY_SUPPLEMENT|Placebo|Oral, twice daily
48670627|NCT03680807|DIAGNOSTIC_TEST|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
48670628|NCT03367884|PROCEDURE|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
48670629|NCT03367884|RADIATION|Definitive radiotherapy|Definitive radiotherapy (70Gy)
48670630|NCT05348811|DRUG|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol."
48670631|NCT06157021|PROCEDURE|Rotary pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using (Fanta AF baby\* rotary files and Endo Radar\* rotary device).
48670632|NCT06157021|PROCEDURE|Manual pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using Manual H files, Mani\*)
48670633|NCT02481414|BIOLOGICAL|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
48670634|NCT02481414|BIOLOGICAL|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
48670635|NCT01577602|OTHER|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
48670636|NCT01577602|OTHER|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
48670637|NCT01577602|OTHER|Combined intervention|Combines the printed medication list with the open ended question
48670638|NCT00307957|DEVICE|Pillar Palatal Implants|
48670639|NCT00003929|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
48670640|NCT00003929|DRUG|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
48670641|NCT00003929|DRUG|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
48670642|NCT00003929|RADIATION|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
48670643|NCT02258802|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
48670644|NCT02714660|OTHER|none, observational study|
48670645|NCT05221866|BEHAVIORAL|Empowering patient to steer their pain management after surgery|Prior to discharge from the hospital, patients will be approached regarding interest in the study with an introductory letter that describes the content and purpose of the study. Following informed consent, patients will be randomized to receive the consumer health informatics app (UControlPain) versus provision of an app with only data collection function (no educational components) in an intent-to-treat design. Randomization will be implemented via REDCap by the study coordinators so that all investigators will remain blind to group assignment. Further, information on which type of app was installed will not be shared with providers or patients.
48670646|NCT05221866|BEHAVIORAL|Provider-facing prescription aid|Providers will be given information to inform a patient-centered post-discharge pain management plan.
48670647|NCT00244192|DRUG|infliximab (Remicade)|
48670648|NCT05351528|OTHER|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
48670649|NCT01044030|DRUG|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
48670650|NCT01044030|DRUG|Placebo|7.5 mL by mouth three times daily
48670651|NCT05736393|DEVICE|Back Exosuit|The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
48688176|NCT00263432|PROCEDURE|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
47990020|NCT03689998|DEVICE|immediate implant placement|immediate implant placement in freshly extraction socket
48507298|NCT05997732|DRUG|Norepinephrine Bitartrate|Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
48507299|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
48507300|NCT05997732|DRUG|Phentolamine Mesylate|Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
48670652|NCT00891150|DRUG|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
48670653|NCT05659849|OTHER|Manual therapy techniques|Passive joint mobilization techniques are applied to the affected knee joint. For the first week (three sessions), the joint mobilization exercises included grade I or II rhythmic oscillations. During the following weeks, grade III or IV oscillation techniques were applied, depending on the level of tolerance and pain of each patient. In knee distraction, the patients are in a prone position with 50° knee flexion, and the physical therapist applies the techniques. The dorsal and ventral glides was performed with the patient in a supine position.
48147538|NCT04528602|PROCEDURE|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~* Common procedure steps~* The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~* The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~* The infant's feet will be freed.~* The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~* The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~* Tapes of the clean diaper will be fastened.~* Hands will be washed after the procedure.~* Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
48670654|NCT05659849|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) therapy treats pain using low-voltage electric currents. A small device administers the electrical current to or near nerves. TENS treatment inhibits or changes pain perception.
48670655|NCT05805137|DEVICE|WoundWatch wound management system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch wound management system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
48147539|NCT03147586|DRUG|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
48147540|NCT03147586|DRUG|placebo|placebo
48358709|NCT00842504|DRUG|Micafungin|3 mg/kg IV once over 1 hour
48670656|NCT01758094|DRUG|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
47990021|NCT03689998|DRUG|Melatonin|topical application of melatonin
48358710|NCT05248776|DRUG|CPL207280|IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
48507301|NCT05997732|DRUG|Phenylephrine Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
48358711|NCT05248776|DRUG|Placebo|Matching placebo tablet.
48358712|NCT02021864|DRUG|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
48358713|NCT02021864|DRUG|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
48507302|NCT05997732|DRUG|Isoproterenol Hydrochloride|Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
48507303|NCT05997732|DRUG|Propranolol Hydrochloride|Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
48507304|NCT01015937|DRUG|Turmeric extract|turmeric 500 mg TID for 45 days
48507305|NCT01015937|DRUG|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
48670657|NCT02588157|DEVICE|Macintosh|Direct laryngoscopy
48670658|NCT02588157|DEVICE|Glidescope|Glidescope videolaryngoscope
48670659|NCT02588157|DEVICE|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
47990022|NCT06084546|DEVICE|geko™ X-W3|The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
48358714|NCT05166031|BIOLOGICAL|bOPV and nOPV2|Approximately 265 subjects will receive 2 doses of bOPV, nOPV2 or bOPV + nOPV2 per arm separated by 28 days between doses.
48358715|NCT02092142|BIOLOGICAL|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
48358716|NCT01017991|OTHER|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
48358717|NCT01017991|OTHER|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
48358718|NCT03802201|DRUG|PTG-300|Subcutaneous (SC)
48358719|NCT01032265|BEHAVIORAL|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
48670660|NCT04199585|DRUG|Lu AF95245|solution, single dose, orally
48670661|NCT04199585|DRUG|Lu AF95245 14C radiolabelled spiked dosage|solution, single dose, orally
48670662|NCT04199585|DRUG|Placebo|solution, single dose, orally
48670663|NCT01143220|OTHER|No specific interventions|Observational investigation, only procedures according to local hospital standard.
48670664|NCT04302025|DRUG|Alectinib|Participants will receive oral alectinib twice per day (BID)
48670665|NCT04302025|DRUG|Entrectinib|Participants will receive oral entrectinib daily
48670666|NCT04302025|DRUG|Vemurafenib (Enrollment closed)|Participants will receive oral vemurafenib BID
48670667|NCT04302025|DRUG|Cobimetinib (Enrollment closed)|Participants will receive oral cobimetinib daily
48670668|NCT04302025|DRUG|Pralsetinib (Enrollment closed)|Participants will receive oral pralsetinib daily
48670669|NCT04302025|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion
48670670|NCT04302025|DRUG|SBRT|Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
47990023|NCT03021850|PROCEDURE|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
47990024|NCT01894581|DIETARY_SUPPLEMENT|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
47990025|NCT01894581|DRUG|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
47990026|NCT01879241|DRUG|Rasagiline|
48507306|NCT01025453|DRUG|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
48670671|NCT04302025|PROCEDURE|Resection|Participants will receive surgical resection of the primary tumor along with selected lymph nodes
48670672|NCT04302025|DRUG|Chemotherapy|Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician
48670673|NCT04302025|DRUG|Divarasib|Participants in the KRAS G12C cohort will receive divarasib for approximately 8 weeks until the day before surgery.
48670674|NCT04077177|BEHAVIORAL|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
48670675|NCT04302116|DRUG|Combination therapy with vigabatrin and prednisolone|High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
48670676|NCT04302116|DRUG|Vigabatrin Tablets|Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
48670677|NCT01100112|DRUG|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
48670678|NCT00182143|DRUG|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
48670679|NCT00182143|DRUG|Unfractionated Heparin|5000 IU BID
47990027|NCT01879241|DRUG|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
48670680|NCT00905190|DRUG|Ondansetron|24 mg one time
48670681|NCT01638507|DEVICE|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
47990028|NCT02875860|DEVICE|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
48507307|NCT03523442|DRUG|Apalutamide|The participants will receive apalutamide 240 mg once daily orally.
48507308|NCT05743881|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
48507309|NCT05743881|BIOLOGICAL|mRNA-1365|Sterile liquid for injection
48507310|NCT05743881|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) solution for injection
48507311|NCT05743881|DRUG|Nimenrix|Solution for injection
48670682|NCT00565565|DRUG|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
48670683|NCT01088503|DRUG|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
48670684|NCT00776789|OTHER|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
48670685|NCT00776789|OTHER|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
48670686|NCT03568812|DRUG|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
48670687|NCT03568812|OTHER|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
48670688|NCT02250417|OTHER|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
48670689|NCT04832347|OTHER|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
48670690|NCT04832347|OTHER|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
48670691|NCT05227976|BEHAVIORAL|Patient education (Theory)|"Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks."
48670692|NCT05227976|BEHAVIORAL|Physical training|"Physical training group (1 hour/week)~Interventions given once weekly for 10 weeks."
48507312|NCT01422187|DRUG|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
48507313|NCT03047434|OTHER||
48670693|NCT05227976|BEHAVIORAL|Mindfulness and medical yoga in group|"Mindfulness/medical yoga in group (1hour/week)~Interventions given once weekly for 10 weeks."
48670694|NCT01987466|BIOLOGICAL|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
48670695|NCT00639951|BIOLOGICAL|A|20 vials up front in a Single Dose of Antivipmyn
48670696|NCT00639951|BIOLOGICAL|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
48670697|NCT02512380|DRUG|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
48670698|NCT02512380|DRUG|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
48670699|NCT02373618|OTHER|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
48670700|NCT02373618|OTHER|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
48670701|NCT02613195|DRUG|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
48670702|NCT01136369|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
48670703|NCT03667105|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
47990029|NCT02875860|DEVICE|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
47990030|NCT02875860|OTHER|Standardized postnatal care|After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
48358720|NCT01032265|BEHAVIORAL|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
48507314|NCT03253055|RADIATION|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are \~8uSv and \~4uSv respectively.
48507315|NCT03253055|RADIATION|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
48507316|NCT03253055|OTHER|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
48507317|NCT03253055|OTHER|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
48358721|NCT03952676|DEVICE|Moving cupping|"1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
48358722|NCT03952676|DEVICE|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
48358723|NCT03436095|OTHER|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
48358724|NCT00219310|DRUG|Famciclovir|
48670704|NCT03667105|OTHER|MC|Xenogenous graft placed in the surgical site.
48670705|NCT03667105|OTHER|XDM|Xenogenous dermal collagen graft placed in the surgical site.
48670706|NCT05960357|OTHER|To inform|It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
48670707|NCT00239603|DEVICE|OV-Watch|
48670708|NCT02828384|OTHER|low fodmap diet|dietary teaching
47990031|NCT03264287|PROCEDURE|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
47990032|NCT03264287|PROCEDURE|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
47990033|NCT00123591|DRUG|activated recombinant human factor VII|
48358725|NCT05273294|DEVICE|Portable color Doppler ultrasound system|In the ultrasound group, the catheter type was selected according to the results of ultrasonic measurement of transverse diameter of cricoid cartilage after induction of general anesthesia, and tracheal intubation was performed with ordinary laryngoscope after measurement
48358726|NCT05647928|OTHER|no intervention|no intervention
47990034|NCT00399360|DRUG|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
48358727|NCT04691622|BIOLOGICAL|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
48358728|NCT01931189|BIOLOGICAL|NI-071|100mg/vial
48358729|NCT01931189|BIOLOGICAL|Infliximab|100mg/vial
48358730|NCT05934929|OTHER|Circulating tumor DNA detection|biological assessment on operating bed to detect residual circulating tumor DNA
48358731|NCT01520675|PROCEDURE|surgery|Drainage procedure
48358732|NCT01520675|PROCEDURE|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
48367561|NCT03728647|BEHAVIORAL|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
47990035|NCT00399360|DRUG|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
47990036|NCT00399360|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
47990037|NCT05742438|DRUG|Lidocaine IV|Continuous intravenous infusion of lidocaine
47990038|NCT05742438|DRUG|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
47990039|NCT05742438|DRUG|intrathecal morphine|intrathecal morphine injection
47990040|NCT02988791|DIETARY_SUPPLEMENT|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
48367562|NCT00284726|DEVICE|Celsior Cold Storage Solution|
47990041|NCT02988791|DIETARY_SUPPLEMENT|Placebo|Placebo
47990042|NCT00003010|DRUG|marimastat|
47990043|NCT05891899|OTHER|observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
48367563|NCT03820388|DRUG|Propofol 2mg/kg|2 mg/kg
48670709|NCT02828384|DIETARY_SUPPLEMENT|Psyllium|7.1g of psyllium daily
48670710|NCT05948189|OTHER|exercise program|The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
48670711|NCT00546481|DRUG|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
48670712|NCT00546481|DRUG|Epoetin|As prescribed, iv, 3 times weekly
48670713|NCT01871441|RADIATION|Total-body irradiation|Undergo TBI
48670714|NCT01871441|BIOLOGICAL|Donor lymphocytes infusion (DLI)|Undergo DLI
48670715|NCT01871441|DRUG|Cyclophosphamide|Given IV
48670716|NCT01871441|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
48670717|NCT01871441|DRUG|Tacrolimus|Given IV
48670718|NCT01871441|DRUG|Mycophenolate mofetil|Given IV
48670719|NCT06165991|DRUG|Liposomal bupivacaine, Bupivacaine|"1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA"
48358733|NCT06085768|BEHAVIORAL|VRE intervention|Virtual reality exposure therapy is a new treatment technology developed in recent years. This technology combines virtual reality technology with traditional exposure therapy, and uses virtual reality technology to present the exposure scenes required for exposure therapy. Therefore, it can break through the limitations of time and space and more intuitively display some things that are difficult to simulate in the treatment room. Scenes do not require the client to undergo treatment through imaginary exposure, thereby increasing the immersion and reality of the treatment. Over the past two decades, numerous studies have explored and proven the effectiveness of virtual exposure therapy.
48358734|NCT03294343|PROCEDURE|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
48358735|NCT03294343|PROCEDURE|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
48670720|NCT06187324|DIAGNOSTIC_TEST|biomarkers|by th use of perio paper GCF was collected and Biomarkers level was estimated
48358736|NCT03294343|OTHER|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
48367564|NCT03820388|DRUG|Etomidate 0.3 mg/kg|0.3 mg/kg
48367565|NCT03820388|DRUG|Propofol 1 mg/kg|1 mg/kg Propofol
48367566|NCT03820388|DRUG|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
48367567|NCT01013116|BIOLOGICAL|modified allergen extract of house dust mites|subcutaneous injections
48507318|NCT03253055|OTHER|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
48670721|NCT02710539|DRUG|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
48670722|NCT02710539|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
48670723|NCT06413732|OTHER|Conventional physiotherapy|Conventional physiotherapy was applied for approximately 1 hour, 5 days a week.
48670724|NCT02549079|OTHER|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
48507319|NCT03253055|BIOLOGICAL|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
48507320|NCT03253055|OTHER|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
48507321|NCT06549712|GENETIC|identify genetic determinants of the predisposition to develop respiratory failure|To identify the main common genetic determinants of severe COVID-19 by conducting a GWAS: in first phase we will compare SARS-CoV-2 positive patients with severe lung affection to healthy controls from the same geographic area, in order to provide initial data informing the research in the field in a timely fashion. This will be conducted in close collaboration with the University of Kiel COVID-19 genomic initiative. Later on, we will proceed to assess objectives 1 and 2 in the full cohort, including also infected controls who did not developed clinically significant symptoms
48507322|NCT06549712|GENETIC|identify genetic determinants of the predisposition to develop respiratory failure|To provide extensive genetic characterization of all patients managed at the Fondazione in order to facilitate other groups working on specific projects (e.g. on candidate genes such as SERPINA1 and ACE2 by the Intensive Care and Cardiology Units and other that may emerge from upcoming projects), in a large population and in a very timely fashion, and without incurring in any additional expenses for the Fondazione research network, and coordinate research efforts.
48670725|NCT05253404|DEVICE|Ambu® AuraOnce™ Disposable Laryngeal Mask|Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
48670726|NCT04488133|DRUG|Nusinersen|Administered as specified in the treatment arm.
48670727|NCT04929964|PROCEDURE|MRM , Toilet Mastectomy , BCS|MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
48670728|NCT00956761|BIOLOGICAL|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
48688177|NCT04644198|BIOLOGICAL|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 \& 2.
48358737|NCT04087967|DRUG|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
48358738|NCT04087967|DRUG|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
48670729|NCT00527228|DRUG|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
48670730|NCT00527228|DRUG|placebo|
48670731|NCT04382443|DRUG|Colchicine|At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
48670732|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
48670733|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
48670734|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
48670735|NCT00473018|BEHAVIORAL|standard versus enhanced risk reduction counseling|
48670736|NCT00741169|DRUG|TMC435350|200 mg taken by mouth once daily for 7 days
48670737|NCT00741169|DRUG|Rifampin|600 mg taken by mouth once daily for 7 days
48670738|NCT00741169|DRUG|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
48670739|NCT02833883|DRUG|Enzalutamide|
48358739|NCT05040867|OTHER|Physical exercise program|"The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day."
48358740|NCT02833727|OTHER|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
48358741|NCT02750436|DEVICE|Ultrasound guided|This group will be treated using an ultrasound imaging device
48358742|NCT02750436|DEVICE|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
48367568|NCT01013116|BIOLOGICAL|placebo|subcutaneous injections
48670740|NCT02833883|DRUG|CC-115|
48367569|NCT06326658|OTHER|Bufei Yishen Prescription Granule|The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
48367570|NCT04331236|BEHAVIORAL|Cognitive Behavioral Therapy|CBT trains individuals to identify and reframe dysfunctional thoughts to help improve mood and behavior. CBT intervention also includes teaching relaxation and mindfulness strategies, as well as ways to help improve functioning through the use of behavioral goal setting.
48670741|NCT02790502|DEVICE|Food Photography Application©|Group testing RFPM as method of recording plate waste
48670742|NCT02136914|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
48670743|NCT02136914|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
48670744|NCT03271866|DRUG|metformin|metformin 1500mg per day
48670745|NCT01870869|DEVICE|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
48670746|NCT00765414|BIOLOGICAL|Myozyme|30 mg/kg qow f and 40 mg/kg qow
48670747|NCT00741065|PROCEDURE|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
48670748|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
48670749|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
48670750|NCT02751944|DIETARY_SUPPLEMENT|NEM|Dietary supplement for the support of joint health.
48670751|NCT02751944|DIETARY_SUPPLEMENT|Placebo|Placebo
48670752|NCT01302002|DRUG|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
48670753|NCT02404714|DEVICE|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
48147541|NCT03490006|PROCEDURE|Erector Spinae Plane Block|A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
48147542|NCT03490006|PROCEDURE|Paravertebral Block|Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
48147543|NCT06463314|DEVICE|INSTI Multiplex HIV/Syphilis Antibody Test|"The INSTI® Multiplex HIV-1/HIV-2 Syphilis Antibody Test (bioLytical Laboratories Inc., Richmond, BC), \[INSTI Multiplex Test\] is a single use, rapid, flow-through in vitro qualitative immunoassay for the detection of antibodies to HIV Type 1 and 2 and Treponema pallidum (Syphilis) in human fingerstick blood and serum. The test is intended to screen for HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and Syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than one minute. This test is licensed by Health Canada."
48147544|NCT03260452|PROCEDURE|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
48147545|NCT03073902|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
48147546|NCT04716517|OTHER|Alkasite bioactive restorative material.|"Alkasite restorative is a category of filling material, like compomer, and is essentially a subgroup~of the composite resin. Cention N is a urethane dimethacrylate (UDMA)-based, self-curing powder/liquid restorative with optional additional light curing. The liquid comprises of dimethacrylates and initiators, while the powder contains various glass fillers, initiators, and pigments. It is radio opaque and contains alkaline glass fillers capable of releasing fluoride, calcium, and hydroxide ions. Due to the sole use of cross-linking methacrylate monomers in combination with a stable, efficient self-cure initiator, Cention N displays a high polymer network density and degree of polymerization over the complete depth of the restoration."
48147547|NCT04716517|OTHER|Resin Modified Glass Ionomer|The resin-modified glass ionomer materials are hybrid materials of traditional glass ionomer cement with a small addition of light-curing resin, and hence exhibit properties intermediate to the two, with some characteristics superior to conventional glass ionomer materials
48367571|NCT04331236|OTHER|Yoga|Yoga consists of physical exercises, breathing techniques, and meditation designed to condition the physical body, calm the mind, and stabilize emotions.
48670754|NCT06219252|DEVICE|Intraoperative aberrometer|the patient intraocular lens will be optimized during the aphakic period after cataract extraction and before intraocular lens implantation, this will produce a possible change in the dioptric power of the intraocular lens
48670755|NCT06219252|OTHER|Preoperative intraocular lens calculation|the intraocular lens in this group will be calculated preoperatively with Barrett Universal II formula
48670756|NCT05158413|DIETARY_SUPPLEMENT|High dose|Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
48670757|NCT05158413|DIETARY_SUPPLEMENT|Low dose|Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
48670758|NCT01248325|DRUG|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
48670759|NCT01248325|DRUG|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
48670760|NCT05641402|OTHER|Text messages|Text messages based on behaviour change techniques
48670761|NCT00403130|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
48670762|NCT00403130|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
47990044|NCT05883930|OTHER|'Let's Move' program|"Students will complete data collection forms as part of the program. According to International Physical Activity Questionnaire (IPAQ), those who are low in activity and inactive will be assigned to the appropriate intervention program based on their sedentary lifestyle stage.~Students will enter the module system prepared according to the five different stages of change \[not thinking (1), thinking (2), preparing (3), acting (4), continuing (5)\] of sedentary living.~There are 12 different initiatives for each phase/module of the program. Summary and reinforcing questions are asked at the end of each trial. If participants do not answer the questions, they cannot continue with the next week's initiative.~Participants' daily step counts with the smart wristband are recorded in the program.~Daily alerts/reinforcement messages related to that week's initiative will be sent during all phases."
47990045|NCT05883930|OTHER|no intervention|No intervention will be applied to the control group.
48670763|NCT00403130|DRUG|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
48670764|NCT03787329|OTHER|Core decompression surgery with bone marrow concentration|Core decompression surgery with bone marrow concentration
48670765|NCT03787329|OTHER|Core decompression surgery|Core decompression surgery only
48670766|NCT05964569|OTHER|model-guided optimization of treatment plan|original treatmant plans are optimized based on model-based NTCP
47990046|NCT01865539|DEVICE|Custom Foot Orthotic|Custom foot orthotic with custom design pads
47990047|NCT01865539|DEVICE|Sham Orthotic|Leather insert without the custom design pads
48670767|NCT05964569|OTHER|standard treatment plan, no optimization|original treatment plans are not optimized
48147548|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
48147549|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
48507323|NCT06549712|GENETIC|identify genetic determinants of the predisposition to develop respiratory failure|"To provide a coordination to manage the collaboration with other research consortia in the field, e.g. the An anonymized GWAS to urgently query host genetic predisposition to severe COVID-19 (SARS-CoV-2 infection) lung disease, and the COVID-19 Host Genetic Initiative (https://www.covid19hg.org). Indeed, collaboration among large networks analyzing several thousand cases will be ultimately necessary to clarify the genetic basis of COVID-19 susceptibility, and large collaborative networks are essential instruments for conducting human genetic research."
48147550|NCT04769921|DEVICE|dental implants and abutments from Nobel Biocare|The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
48147551|NCT05150652|DRUG|Anastrozole 1mg|Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
48147552|NCT05150652|DRUG|Letrozole 2.5mg|Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
48147553|NCT05150652|DRUG|Exemestane 25 mg|Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
48147554|NCT05150652|DRUG|Tamoxifen|Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
48367572|NCT03893994|OTHER|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
48507324|NCT03259659|OTHER|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
48507325|NCT04880603|DEVICE|Restrata Graft|Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
48507326|NCT04880603|PROCEDURE|Standard of Care Skin Graft|Standard of Care Skin Graft
47990048|NCT02420054|BEHAVIORAL|Intermittent fasting|Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
48147555|NCT02894086|OTHER|database.|database
48670768|NCT05361265|OTHER|fetal movement counting|pregnant women were trained about fetal movements and fetal movement counting was taught. Pregnant women were asked to perform ten fetal movements by counting once a day. In the application of the study, it was ensured that the pregnant women in the experimental group performed fetal movement counting for at least four to six weeks. In this context, pregnant women were called every week to monitor and to motivate them to continue the counting.
48670769|NCT01720394|DEVICE|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
48670770|NCT01720394|DRUG|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
47990049|NCT02420054|OTHER|Time control|Time control period with no change in eating habits.
47990050|NCT06094673|OTHER|No intervention|No intervention
47990051|NCT02747706|BEHAVIORAL|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
48147556|NCT02837705|OTHER|blood draw|
48670771|NCT00002322|DRUG|Atevirdine mesylate|
47990052|NCT03109574|DEVICE|BioFlo DuraMax Chronic Hemodialysis Catheter|
47990053|NCT03109574|DEVICE|Standard of Care Catheter|
47990054|NCT05245760|DRUG|Intravenous Tislelizumab|Participants will receive 200mg, every three weeks for up to 51 weeks
47990055|NCT05245760|DRUG|Chemotherapy|Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
47990056|NCT05245760|RADIATION|Fractionated radiation|Concurrent with chemo, x5 weeks
47990057|NCT05245760|PROCEDURE|Esophagectomy|Surgical resection of cancer after chemoradiation therapy when no disease progression found.
48147557|NCT00952523|DRUG|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
48147558|NCT00952523|DRUG|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
48147559|NCT04640805|DIETARY_SUPPLEMENT|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
48147560|NCT04640805|OTHER|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
48507327|NCT05440123|OTHER|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
48147561|NCT00059527|BEHAVIORAL|Healthy Youth Places: a behavior change model|
48147562|NCT05100511|DEVICE|ERG electrode tests for fundus image-guided focal ERG|Investigate the patient comfort, usability and signal-to-noise ratio of different commercial CE marked ERG electrodes.
47990058|NCT03441633|DRUG|apixaban|current or new medication
47990059|NCT03441633|DRUG|dabigatran|current or new medication
47990060|NCT03441633|DRUG|VKA|current or new medication
47990061|NCT03441633|DRUG|rivaroxaban|current or new medication
47990062|NCT03721315|BEHAVIORAL|Intervention|"The health literacy enhancement will comprise of the following:~* Practical day to day information to help manage the disease~* Benefits of medication and adherence~* Tips to improve managing shortness of breath~* Proper use of inhalers (if applicable)~* Managing daily activities"
47990063|NCT03633487|DRUG|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
47990064|NCT01798199|OTHER|The training by Verve System|
48507328|NCT06256107|DEVICE|Virtual Reality Headset|Virtual Reality Headset
48507329|NCT02242045|DRUG|Idelalisib|150 mg tablet(s) administered orally twice daily
47990065|NCT02702505|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
47990066|NCT02702505|OTHER|ProRoot MTA|Control group
47990067|NCT03625245|OTHER|Control Yogurt|125 g/day
47990068|NCT03625245|OTHER|Yogurt Variety 1|125 g/day
47990069|NCT03625245|OTHER|Yogurt Variety 2|125 g/day
47990070|NCT04269980|OTHER|MAP|MAP
47990071|NCT04124289|OTHER|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
47990072|NCT02225990|OTHER|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
48507330|NCT03552068|DRUG|placebo|"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."
48670772|NCT00002322|DRUG|Zidovudine|
47990073|NCT02225990|OTHER|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
47990074|NCT02225990|OTHER|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
47990075|NCT02225990|OTHER|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
47990076|NCT03020407|PROCEDURE|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
47990077|NCT03020407|DRUG|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
47990078|NCT03020407|DRUG|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
47990079|NCT06242314|PROCEDURE|L_PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds
47990080|NCT06242314|PROCEDURE|A-PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds
47990081|NCT06242314|PROCEDURE|Palatal stent|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
47990082|NCT01076881|BEHAVIORAL|exercise training|
47990083|NCT02401880|DRUG|Linagliptin|22 subjects will receive Linagliptin for 30 days
47990084|NCT02401880|OTHER|Placebo|22 subjects will receive Placebo for 30 days
48147563|NCT05100511|DEVICE|Fundus image-guided focal ERG|Record focal ERG from a healthy retinal area and from an area with visible symptoms.
48507331|NCT03552068|DRUG|Clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
48507332|NCT06473012|BEHAVIORAL|Cognitive Behavioral Therapy for Caregivers of Older Adults|Cognitive Behavioral Therapy Intervention for Caregivers of Older Adults is designed to be implemented in a group setting with 12 to 15 caregivers in a group. It consists of 6 weekly sessions, and each session lasts for 90 minutes to 120 minutes. The content of the intervention is based on lifestyle intervention, CBT and effective communication skills. Home practices will be assigned to the participants in between each weekly session.
48507333|NCT06473012|BEHAVIORAL|Control intervention for Caregivers of Older Adults|The control group receives 6 weekly education sessions on useful healthcare information (mental health, physical health, health ageing and dementia). Each session lasts for 90 minutes to 120 minutes.
48688178|NCT06346509|DRUG|PORT-77|Healthy adult participants will receive a single oral dose of PORT 77.
48147564|NCT06012786|DIAGNOSTIC_TEST|Diagnostic Criteria of Myofascial Pain Syndrome|"Major criteria:~1. The patient's complaint of regional pain~2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point~3. Presence of palpable taut band~4. Presence of palpable and tender points along the length of the taut band~5. Restriction of ROM in the area of the affected muscle~Minor criteria:~1. Pain/sensory change with pressure palpation of the trigger point~2. Local twitch response with palpation/injection of the trigger point in the taut band~3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis"
48147565|NCT06012786|DIAGNOSTIC_TEST|The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer|Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
48507334|NCT03886415|DRUG|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
48507335|NCT00384930|DRUG|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
48147566|NCT06012786|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
48147567|NCT06012786|DIAGNOSTIC_TEST|VAS|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
48147568|NCT06012786|DIAGNOSTIC_TEST|Quick DASH|The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
47990085|NCT02401880|DRUG|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
48147569|NCT06012786|DIAGNOSTIC_TEST|Lymqol-Arm|Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
47990086|NCT03532919|DIAGNOSTIC_TEST|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
48358743|NCT05288049|BEHAVIORAL|Enhancing cognitive reserve|The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.
47990087|NCT02588170|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
48147570|NCT06012786|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
48147571|NCT00383812|DRUG|Intravitreal Bevacizumab|
48358744|NCT05288049|BEHAVIORAL|Support therapy|The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
48358745|NCT02842255|DEVICE|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
48358746|NCT02008981|DRUG|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
48358747|NCT02008981|DRUG|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
48507336|NCT00384930|DRUG|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
48507337|NCT00384930|DRUG|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
47990088|NCT02588170|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
47990089|NCT00591942|DEVICE|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
48507338|NCT00384930|DRUG|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
48507339|NCT00384930|DRUG|placebo|Placebo tablet taken by mouth one a day for twelve weeks
47990090|NCT00323518|DRUG|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
47990091|NCT00323518|DRUG|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
47990092|NCT03394482|DRUG|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
47990093|NCT03394482|DRUG|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
47990094|NCT03394482|DRUG|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
47990095|NCT03394482|DRUG|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
48688179|NCT06346509|DRUG|Placebo|Healthy adult participants will receive matching placebo on Day 1.
47990096|NCT03394482|DRUG|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
48507340|NCT02437903|DEVICE|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
48358748|NCT02008981|DRUG|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
48507341|NCT00005983|RADIATION|radiation therapy|
48507342|NCT00005983|PROCEDURE|surgery|surgery
48507343|NCT05597748|DEVICE|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
48507344|NCT05597748|DEVICE|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
48507345|NCT04733703|OTHER|questionnaire|assessment of postoperative quality of recovery with the QoR-15
48507346|NCT02648932|BIOLOGICAL|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
48507347|NCT02648932|PROCEDURE|Matched Unrelated Donor Transplant|
48507348|NCT02055664|DRUG|Ropivacaine 0.2%|
48670773|NCT05465525|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
47990097|NCT03394482|DRUG|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
47990098|NCT04322747|DIAGNOSTIC_TEST|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
47990099|NCT01163487|DRUG|Dichloroacetate|25-50mg/kg per day; oral
47990100|NCT01163487|DEVICE|EF5|21 mg/kg; IV
48358749|NCT02008981|DRUG|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
48670774|NCT05465525|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
48670775|NCT05465525|OTHER|No Block|The patients will receive general anesthesia.
48688180|NCT02758600|OTHER|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
48358750|NCT01854957|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
48358751|NCT05044715|BEHAVIORAL|Treatment as Usual|"Treatment as usual-TAU groups include:~1. Mood Groups - General Process Groups~2. Anxiety Groups - Cognitive Behavioral Therapy~3. Body Image and Eating Concerns Groups~4. Reconciling Faith and Sexuality Groups"
48358752|NCT05044715|BEHAVIORAL|Compassion-Focused Therapy (CFT)|The CFT protocol assumes that participants have no prior experience with meditation, mindfulness, and self-compassion and teaches principles of each as well as skills such as guided meditations.
48358753|NCT00665249|BEHAVIORAL|Motivational Interviewing|See MotivationalInterviewing.org
48358754|NCT00665249|BEHAVIORAL|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
47990101|NCT05248841|DRUG|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
47990102|NCT05248841|DRUG|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
47990103|NCT02883634|OTHER|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
47990104|NCT02883634|OTHER|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
47990105|NCT00230464|DRUG|LAF 237|
47990106|NCT03176992|DRUG|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
48147572|NCT05390710|COMBINATION_PRODUCT|LAE005 + Afuresertib + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
48670776|NCT03704493|DIAGNOSTIC_TEST|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
48670777|NCT01485848|DRUG|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
48670778|NCT01485848|DRUG|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
48147573|NCT02135666|PROCEDURE|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
48670779|NCT01313507|BIOLOGICAL|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
48358755|NCT00665249|OTHER|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
48358756|NCT04591340|DIETARY_SUPPLEMENT|dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition|All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
48358757|NCT04849429|BIOLOGICAL|Platelet rich plasma (PRP) with exosomes|Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
48358758|NCT04849429|DRUG|Normal Saline|placebo : 2 ml normal saline para discal administration
48670780|NCT01932788|DRUG|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
48358759|NCT00311012|DRUG|Aliskiren|
48358760|NCT06214039|BEHAVIORAL|Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety|A 3-hour one session exposure therapy for public speaking anxiety
48358761|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
48358762|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
48507349|NCT02055664|DRUG|Chlorure de sodium 0.9%|
48507350|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
48670781|NCT01932788|DRUG|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
48670782|NCT00557037|DRUG|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
48670783|NCT05714007|DRUG|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
48670784|NCT05714007|DRUG|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
48670785|NCT03846661|DEVICE|Physiomesh|difference in risk for recurrence and postoperative complication
48670786|NCT00196040|DEVICE|PFX Closure System|
48670787|NCT02719392|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
48670788|NCT02719392|DRUG|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
48670789|NCT02719392|OTHER|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
48670790|NCT00166127|DRUG|Levosimendan|
47990107|NCT02473354|DRUG|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
47990108|NCT02473354|DRUG|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
47990109|NCT02473354|DRUG|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
47990110|NCT00966173|DEVICE|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
47990111|NCT03556579|DEVICE|senofilcon A with new UV blocker|Test Lens
47990112|NCT03556579|DEVICE|senofilcon A|Control Lens
48358763|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
48358764|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
48358765|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
48358766|NCT00529113|DRUG|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
48358767|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
48507351|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
48507352|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
48507353|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
48507354|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
48147574|NCT04702594|BEHAVIORAL|Music therapy session via tools validated by MUSIC CARE|Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
48147575|NCT05832970|OTHER|Brief skin cooling|Brief skin cooling will be applied to the hand using the cold-bath immersion
48507355|NCT05256719|BIOLOGICAL|Placebo-1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
48670791|NCT06262438|DRUG|Quizartinib|"Quizartinib is a novel oral Class III receptor tyrosine kinase (RTK) inhibitor exhibiting highly potent and selective but reversible inhibition of FMS-like tyrosine kinase FLT3. The dose will be adjusted for the patient's body weight (BW) as measured at the start of each course. Quizartinib will be administered orally once daily and is taken for 14 consecutive days during induction and consolidation courses.~Induction course 1: Start on day 13; Induction course 2: Start on day 9; Consolidation course 1: Start on day 6; Consolidation courses 2 and 3 (only if no allo-SCT is done): Start on day 6.~Continuation courses 1-6: patients will receive quizartinib for six 28-day courses. For the first 15 days of course 1 a starting dose will be applicable. On course 1 Day 16, the dose will be increased if the average QTc of the triplicate Electrocardiograms is ≤450 msec on course 1 Day 15. Once the dose is increased, the patient may continue on this dose as long as dose reduction is not needed."
48670792|NCT06262438|DRUG|Etoposide|"Induction course 1: 150 mg/m2 once daily by Intravenous (IV) infusion over 2 hours (+/- 30 mins) on days 1-5 inclusive (total 5 doses).~Induction course 2: 150 mg/m2 once daily by IV infusion over 2 hours (+/- 30 mins) on days 6-8 inclusive (total 3 doses).~Consolidation course 2 (only if no allo-SCT is done): 100 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 1-5 inclusive (total 5 doses)."
48670793|NCT06262438|DRUG|Dexrazoxane|"Induction course 1: 250 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on day 6-10 inclusive (total 5 days), per investigator discretion and per institutional guidelines and availability.~Induction course 2: 600 mg/m2 once daily by 15 mins IV infusion shortly before daunorubicin on day 2,4,6 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability.~Consolidation course 1: 500 mg/m2 once daily by 15 mins IV infusion shortly before Mitoxantrone on 3-5 inclusive (total 3 does), per investigator discretion and per institutional guidelines and availability."
48670794|NCT06262438|DRUG|Mitoxantrone|"Induction course 1: 5 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 6-10 inclusive (total 5 doses). Please note that mitoxantrone and cytarabine should not be given concomitantly. Mitoxantrone should be completed before cytarabine is given.~Consolidation course 1: 10 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 3-5 inclusive (total 3 doses)."
48670795|NCT06262438|DRUG|Cytarabine|"Induction course 1: 200 mg/m2 once daily by IV infusion over 12 hours (+/- 1 hour) on days 6-12 inclusive (total 7 doses), following mitoxantrone. Induction course 2: 100 mg/m2 once daily by continuous IV infusion on days 1-2 inclusive. And 100 mg/m2 twice daily as a 30min (+/- 10 mins) IV infusion every 12 hours on days 3-8 inclusive (total 12 doses). Consolidation course 1: 1000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 min) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 2 (only if no allo-SCT is done): 3000 mg/m2 twice daily by IV infusion over 2 hours (+/- 30 mins) every 12 hours on days 1-3 inclusive (total 6 doses).~Consolidation course 3 (only if no allo-SCT is done): 2000 mg/m2 once daily by IV infusion over 3 hours (+/- 1 hour) starting 4 hours after fludarabine on days 1-5 inclusive (total 5 doses), following fludarabine."
48670796|NCT06262438|DRUG|Methotrexate|"Induction course 1: Methotrexate (MTX) Intrathecal therapy (IT) prophylaxis is age-adjusted. If MTX is given at diagnosis omit IT therapy on day 6 unless in case of CNS involvement (CNS3). For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently. For children with CNS2, CSF must be investigated on day 22; if leukemic cells persist, treat as CNS3.~Induction course 2, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 1, Day 1: MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently.~Consolidation course 2 and 3, Day 1 (only if no allo-SCT is done): MTX (IT) prophylaxis is age-adjusted. For children with initial CNS involvement (CNS3) MTX IT is replaced with triple IT and given more frequently."
48507356|NCT05256719|BIOLOGICAL|Placebo-2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
48507357|NCT05256719|BIOLOGICAL|Placebo-5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
48147576|NCT01644604|DEVICE|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
48147577|NCT03996577|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
48147578|NCT03996577|DRUG|placebo|the control group will be given the same volume of saline.
48147579|NCT05589831|DEVICE|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
48147580|NCT06311292|DEVICE|Volara System|Intrapulmonary percussive ventilation for mobilizing mucus.
48358768|NCT00529113|DRUG|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
48358769|NCT00529113|DRUG|Placebo|Placebo capsules x 28 days
48507358|NCT05256719|BIOLOGICAL|Placebo-7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
48507359|NCT05256719|BIOLOGICAL|Placebo-10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
48507360|NCT06589505|DEVICE|Software as a Medical Device|The subject will undergo treatment using the Software as a Medical Device
48507362|NCT03009773|OTHER|rehabilitation multitasking walking.|rehabilitation multitasking walking.
48507363|NCT03009773|OTHER|Traditional walking rehabilitation|Traditional walking rehabilitation
48507364|NCT05470205|DRUG|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
48670797|NCT06262438|DRUG|Daunorubicin|Induction course 2: 60 mg/m2 once daily by IV infusion over 1 hour (+/- 15 mins) on days 2,4,6 inclusive (total 3 doses).
48670798|NCT06262438|DRUG|Fludarabine|Consolidation course 3 (only if no allo-SCT is done): 30 mg/m2 once daily by IV infusion over 30 mins (+/- 10 mins) on days 1-5 inclusive (total 5 doses).
48670799|NCT06262438|OTHER|allo-SCT|The SCT procedure is left to the discretion of the investigator and not part of this protocol.
48670800|NCT06451354|OTHER|Erector spinae plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.
48670801|NCT06451354|OTHER|Posterior Quadratus lumborum plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
48507365|NCT05470205|DRUG|SHAPE measurement (Definity ultrasoud contrast agent)|Two vials with 3 mL of Definity will be mixed and diluted in 50 mL of normal saline, yielding a concentration of 49.4 μL/mL, and infused at a rate of at least 4 ml/min.
48507366|NCT01562561|DRUG|repaglinide|2 mg at each main meal
48507367|NCT01562561|DRUG|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
48507368|NCT03916783|BEHAVIORAL|Combination intervention|"The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use."
48670802|NCT06451354|OTHER|Lateral Transversus abdominis plane block (20 ml bupivacaine 0.25% in each side)|Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
48670803|NCT01624714|DRUG|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
48507369|NCT05396521|OTHER|Blood Flow Restriction|Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.
48670804|NCT01624714|DRUG|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
48507370|NCT05396521|OTHER|Standard of Care Physical Therapy|Group 1 (Control) will receive standard of care physical therapy.
48507371|NCT03944824|OTHER|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
48670805|NCT01643460|PROCEDURE|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size \& amount of fluid aspirated from the cyst.
48670806|NCT05525962|BEHAVIORAL|questionnaries, scales, cognitive tests|"A first interview is planned with a psycholgist in the weeks following the minor arrival in the structure (M0)~* M0: cognitive test, psychiatric classification and psychologic assessments~* M12 and M24: psychiatric classification and psychologic assessments"
48670807|NCT00002217|DRUG|Lamivudine/Zidovudine|
48670808|NCT00002217|DRUG|Abacavir sulfate|
48670809|NCT00002217|DRUG|Amprenavir|
48670810|NCT01913327|DRUG|Aripiprazole|
48358770|NCT00529113|DRUG|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
48670811|NCT01913327|DRUG|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
48670812|NCT01913327|DRUG|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
48670813|NCT06088329|BEHAVIORAL|Mindful Walking for Adults with Chronic Pain|Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
48670814|NCT01750125|DEVICE|measure ascending aortic blood flow with pulse wave Doppler|
48670815|NCT04709003|DIAGNOSTIC_TEST|Serologic test|A blood test to check antibodies type and amount
48670816|NCT04709003|DIAGNOSTIC_TEST|Respiratory swabs|PCR test to Covid-19
47990113|NCT00311623|DRUG|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
47990114|NCT00311623|DRUG|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
47990115|NCT00311623|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed on Day 15
48670817|NCT05870345|DEVICE|Butterfly IQ|Butterfly IQ is a pocket sized ultrasound device. Each participant will undergo a ultrasound exam of both elbows using a pocket sized ultrasound device.
48670818|NCT02740465|BEHAVIORAL|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
48670819|NCT02740465|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
48670820|NCT06360419|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
48670821|NCT06360419|DRUG|Placebo|Placebo tablets, taken once daily
48670822|NCT01641484|PROCEDURE|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
48670823|NCT02476448|DRUG|Normal saline|Used to distend the bladder for cystoscopic evaluation
48670824|NCT02476448|DRUG|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
48670825|NCT02476448|DRUG|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
48670826|NCT02476448|DRUG|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
48670827|NCT05874089|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billions/sachets
48670828|NCT05874089|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
48670829|NCT04596722|DIETARY_SUPPLEMENT|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
48670830|NCT04596722|OTHER|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
48670831|NCT04294355|DEVICE|Artificial intelligence-Assisted colonoscopy|Artificial intelligence-Assisted colonoscopy for detection of colonic polyp
48358771|NCT06103266|DRUG|Rivaroxaban|Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
48358772|NCT00162799|DRUG|Triflusal (DCI)|
48670832|NCT04294355|PROCEDURE|Conventional colonoscopy|Conventional colonoscopy
48670833|NCT00660803|DRUG|Fulvestrant|
48670834|NCT01392573|DRUG|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
48670835|NCT01392573|DRUG|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
48670836|NCT00685061|DRUG|Thymoglobulin|Induction
48358773|NCT02659839|OTHER|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
48358774|NCT03290586|DEVICE|Flower Cube|single use, sterile disposable fixation construct
48670837|NCT00685061|DRUG|Campath-1H|Induction
48670838|NCT00685061|DRUG|Daclizumab|Induction
48670839|NCT00069641|BIOLOGICAL|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
48670840|NCT00069641|BIOLOGICAL|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
48670841|NCT00069641|BIOLOGICAL|Placebo|Patients will receive weekly infusions of placebo.
48670842|NCT05579652|DIAGNOSTIC_TEST|Abdominal tension measurement|A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
48670843|NCT06048211|OTHER|Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals
48670844|NCT06160323|PROCEDURE|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
48670845|NCT05391230|OTHER|Permethrin-treated lesu|0.5% permethrin soaked baby wraps (lesus)
48670846|NCT05391230|OTHER|Untreated lesu|Water soaked baby wraps (lesus)
48670847|NCT00098995|DRUG|cisplatin|
48670848|NCT00098995|DRUG|tirapazamine|
48670849|NCT00098995|RADIATION|brachytherapy|
48670850|NCT00098995|RADIATION|radiation therapy|
48670851|NCT06361134|BEHAVIORAL|SAFE Early İntervention|As part of the intervention, sensory-based intervention was applied in an enriched environment. In the home setting, physiotherapists collaborated with the family to advance the intervention. The intervention was revised by making monthly home visits to infants with a corrected age of 42 weeks.
48670852|NCT06361134|BEHAVIORAL|NDT based therapy|Neuromotor evaluations of the babies were performed in a clinical setting. The rehabilitation program to be implemented was given to the family as a booklet. The programs of the children examined in the clinic every month were revised.
48670853|NCT04679454|RADIATION|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
48670854|NCT04679454|RADIATION|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
48670855|NCT04591119|PROCEDURE|Transversus Thoracic Muscle Plane Block|40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
48670856|NCT04591119|PROCEDURE|Parasternal Intercostal Plane Block|40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between pectoralis major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
48670857|NCT06033534|DEVICE|STIMULAN|"Procedures:~Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection."
48358775|NCT05807815|PROCEDURE|Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation|"FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
48670858|NCT03030456|DEVICE|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
48670859|NCT06101368|BEHAVIORAL|Phsical Activity|Combined Aerobic and Resistance Training
48670860|NCT06101368|DRUG|Medication|The drug will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
48670861|NCT02028845|DEVICE|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
48670862|NCT02028845|DEVICE|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
48358776|NCT02572869|OTHER|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
48358777|NCT02572869|BEHAVIORAL|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
47990116|NCT02402309|DRUG|Active topical NS2 1% dermatologic cream|
47990117|NCT02402309|DRUG|Vehicle placebo 0.0% NS2 dermatologic cream|
47990118|NCT03914560|OTHER|Burn injury|minor burn injury
48358778|NCT02172326|DRUG|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
48670863|NCT03431454|PROCEDURE|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
48670864|NCT03431454|PROCEDURE|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
48670865|NCT03431454|PROCEDURE|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
48670866|NCT01926743|PROCEDURE|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
48670867|NCT03586518|DIAGNOSTIC_TEST|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
48670868|NCT03586518|DIAGNOSTIC_TEST|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
47990119|NCT02935322|DRUG|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
47990120|NCT02935322|DRUG|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
47990121|NCT02935322|DRUG|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
48670869|NCT03586518|PROCEDURE|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
48670870|NCT03586518|DIAGNOSTIC_TEST|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
48147581|NCT02500433|OTHER|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
48147582|NCT02500433|OTHER|Conventional therapy|
48670871|NCT03586518|DIAGNOSTIC_TEST|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
48670872|NCT01941602|DRUG|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
48670873|NCT01941602|PROCEDURE|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
48670874|NCT04681144|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
48670875|NCT04699344|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
48670876|NCT04186585|DRUG|BP-C2|Oral daily intake
48147583|NCT04712032|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
48147584|NCT03953079|DRUG|Drug: GB-102|Intravitreal injection of GB-102
48147585|NCT03953079|DRUG|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
48147586|NCT02776124|DIETARY_SUPPLEMENT|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
48147587|NCT00873626|DRUG|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
48358779|NCT02237573|OTHER|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~1. a detailed report of the consultation (motive, case history, clinical examination, conclusion)~2. written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
48670877|NCT00490581|OTHER|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
48670878|NCT02982330|BEHAVIORAL|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing \<10% carbohydrate, \~75% fat, and 15% protein. Matched for calories to the active comparator arm.
48670879|NCT02982330|BEHAVIORAL|Guidelines Breakfast|A low fat breakfast containing \~55% carbohydrate, \<30% fat, and 15% protein. Matched for calories to the experimental arm.
48358780|NCT02237573|OTHER|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
48358781|NCT05981872|BEHAVIORAL|rehacom|"Rehacom was carried out at the cognition laboratory at Faculty of physical therapy, Cairo University for training of figural memory, attention concentration.~1. Attention concentration training consists of 24 levels of difficulties .~2. Figural memory training consists of 9 levels of difficulties. In the training session, every patient was starting training from level one and when the patient successfully finished the level, the training then Progress to the level of difficulty."
48358782|NCT04693091|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
48358783|NCT01696708|OTHER|31-Phosphorus RMN Spectroscopy|
48670880|NCT01027429|DRUG|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
48670881|NCT01027429|DRUG|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
48670882|NCT01027429|DRUG|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
48670883|NCT03375099|BEHAVIORAL|Lethal Means Counseling|Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
48670884|NCT03375099|BEHAVIORAL|Health and Stress Reduction|Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
48670885|NCT06324032|PROCEDURE|EUS Elastography (EUS-E)|All procedures will be performed with Olympus echoendoscopes (Olympus Europa SE \& CO. KG, Hamburg, Germany) or Pentax echoendoscopes in combination with dedicated elastography software
48670886|NCT04411303|BEHAVIORAL|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
47990122|NCT02935322|OTHER|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
47990123|NCT03849833|DIETARY_SUPPLEMENT|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
47990124|NCT05998200|OTHER|Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA|Participants will used the serum twice daily for 8 weeks
47990125|NCT03255382|DRUG|Fumaderm|Fumaderm tablet administered orally
47990126|NCT03255382|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
47990127|NCT02913391|OTHER|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
47990128|NCT02913391|OTHER|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
47990129|NCT05476341|DRUG|Bevacizumab injection|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
47990130|NCT05476341|DRUG|Bevacizumab injection（Avastin）|Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
47990131|NCT03625791|BIOLOGICAL|blood sample|1 tube with 4 ml of blood per patient
47990132|NCT02904551|PROCEDURE|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
47990133|NCT02904551|PROCEDURE|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
47990134|NCT06418841|PROCEDURE|Computer-Assisted Paramedian Approach Technique|Computer-Assisted Paramedian Approach Technique
48358784|NCT03088345|DRUG|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
48358785|NCT03088345|DRUG|Placebo|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
48358786|NCT02582619|OTHER|Focus groups, semistructured interviews and Delphi rounds|
48358787|NCT01968629|DRUG|Eovist|
48358788|NCT05201924|BEHAVIORAL|Bedtime routine|a regular routine conducted around bedtime includes brush, book reading and regular bedtime
48358789|NCT05201924|BEHAVIORAL|Control|a healthy control checklist
48358790|NCT02365272|DRUG|Amikacin|Amikacin administered in a single dose for critical care patients
48358791|NCT06091306|BEHAVIORAL|Psychotherapy|"Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department."
48358792|NCT03056209|DRUG|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
48358793|NCT03056209|DRUG|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
48358794|NCT03056209|DRUG|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
48358795|NCT03056209|DRUG|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
48670887|NCT04411303|BEHAVIORAL|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
48670888|NCT04411303|BEHAVIORAL|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
48670889|NCT04411303|BEHAVIORAL|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
48670890|NCT00240877|BIOLOGICAL|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
48670891|NCT00240877|OTHER|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
48670892|NCT01968122|DEVICE|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (\<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
48670893|NCT05768594|OTHER|Blood sample|After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
48670894|NCT05956002|DRUG|Estraimod Immediate Release (IR)|an immediate release tablet
48670895|NCT05956002|DRUG|Etrasimod Mini Tab in water|very small tablet mixed in water
48670896|NCT05956002|DRUG|Etrasimod Mini Tab in chocolate pudding|very small tablet mixed in chocolate pudding
48670897|NCT05956002|DRUG|Etrasimod Mini Tab in yogurt|Very small tablet mixed in yogurt
48670898|NCT05956002|DRUG|Etrasimod Mini Tab in applesauce|Very small tablet mixed in applesauce
47990135|NCT06418841|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
47990136|NCT03787628|DRUG|Cannabidiol (CBD) 600 mg|CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml od CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
48358796|NCT03056209|DRUG|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
48358797|NCT03056209|DRUG|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
48358798|NCT03056209|DRUG|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
48358799|NCT03056209|DRUG|Placebo|oral administration, placebo
48358800|NCT03316599|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
48358801|NCT03316599|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
48670899|NCT04017130|DRUG|MT-0169|MT-0169 intravenous infusion.
48358802|NCT03316599|DRUG|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
48358803|NCT03041493|BEHAVIORAL|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
48507372|NCT03944824|DIAGNOSTIC_TEST|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
48507373|NCT00364936|PROCEDURE|Palliative care service|
48670900|NCT00714948|DRUG|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) \> 2.1), after consultation with the Principal Investigator.
48670901|NCT03156218|DRUG|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
48507374|NCT06168630|OTHER|Manual lymph drainage|It consists of patients who will receive manual lymph drainage everyday for 5 days. The subject's position will be supine with their knees bent. Every session will be of 45 minutes. Manual lymph drainage will with abdominal lymph drainage, after which central lymph stimulation will be performed. Then, by stimulating the bilateral axillary lymph nodes, the flow of fluid over the right and left breasts will be directed toward the axillary lymph nodes. While the patients in the prone position, bilateral axillary lymph nodes will be stimulated, and each manual lymph drainage will be performed from the dorsum to the axillary lymph node .
48507375|NCT06168630|OTHER|Control group|The other group will receive massage for 20 minutes every day for 5 days from first day of treatment. Massage will be done using the index and middle fingers in a spiral motion towards the nipples.
48670902|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure and orthodontic treatment|subepithelial connective tissue graft and orthodontic tooth levelling and alignment
48670903|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure|subepithelial connective tissue graft procedure
48670904|NCT00005989|DRUG|tipifarnib|
48670905|NCT00097630|PROCEDURE|SAT: Spontaneous Awakening Trial|
48670906|NCT00097630|PROCEDURE|SBT: Spontaneous Breathing Trial|
48670907|NCT05910944|PROCEDURE|Shunt surgery|Shunt surgery according to each local centers routine
48670908|NCT02622789|OTHER|Pilates Exercises|Pilates method based stability exercise intervention
48670909|NCT04138095|DEVICE|Virtual Reality|Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
48670910|NCT00832013|DRUG|Propofol|See detailed description
48670911|NCT00832013|DRUG|Propofol|See detailed description
48670912|NCT04841993|DRUG|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
48670913|NCT04841993|DRUG|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
48670914|NCT04841993|DRUG|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
48670915|NCT06344637|DRUG|10 % lidocaine spray without adrenaline|Pateint with indication for manual vacuum aspiration aged between 20-60 years will received a standard injection of pethidine along with 1% lidocaine spray without adrenaline on cervical os to compare pain scores with placebo. Along with measuring side effects immediately and 30 minutes after receiving 1% lidocaine without adrenaline.
48670916|NCT06344637|OTHER|Placebo|4 puffs of normal saline apply on cervical os before manual vacuum aspiration
47990137|NCT03787628|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
48507376|NCT05524961|DEVICE|Bright light therapy|Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
48507377|NCT05524961|DEVICE|Inactivated negative ion generator|Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
48507378|NCT05524961|DEVICE|Inactivated negative ion generator|Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
48670917|NCT01074125|DRUG|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
48670918|NCT03262961|DRUG|Sildenafil 20 MG|
48670919|NCT03262961|DRUG|Placebo Oral Tablet|
48670920|NCT03703388|DIETARY_SUPPLEMENT|Arctigenin|Arctigenin capsule
48670921|NCT01840033|DEVICE|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
48688181|NCT04005469|DRUG|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
48358804|NCT03041493|BEHAVIORAL|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
48358805|NCT03041493|BEHAVIORAL|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
48507379|NCT00877162|BEHAVIORAL|Controlled crying and routines|Behavioural (teaching and support)
48670922|NCT01840033|DEVICE|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
48670923|NCT06146647|BEHAVIORAL|Positive body image TV show|This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.
48507380|NCT01188278|DRUG|Imatinib|Drug being observed but not provided
48670924|NCT06146647|BEHAVIORAL|Positive body image music video|This is a positive body image song with strong visual representation of diverse body sizes in the music video.
48670925|NCT06146647|BEHAVIORAL|Active control TV show about a visit to the dentist|14 minute tv show following a tv character as he visits the dentist.
47990138|NCT03032666|DRUG|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
47990139|NCT02414334|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|
48670926|NCT06146647|BEHAVIORAL|Active control music video about brushing teeth|Music video of a tv character singing about brushing teeth
47990140|NCT00048607|DRUG|aprepitant|
47990141|NCT00048607|DRUG|Comparator: paroxetine HCL|
47990142|NCT00048607|DRUG|Comparator: Placebo (Unspecified)|
48358806|NCT05994664|OTHER|Heartmath Intervention|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
48358807|NCT05994664|OTHER|Control Group|The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
48358808|NCT04004000|DRUG|Losmapimod|"The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination."
48358809|NCT05844592|DRUG|INV-101|subjects will be randomized 3:1 ratio
48358810|NCT03265431|DRUG|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
48358811|NCT05948722|BEHAVIORAL|Motivational Interview Group (MIG)|Brief MI intervention with the conventional treatment
48358812|NCT05948722|PROCEDURE|Conventional treatment group (CTG)|Conventional treatment
48358813|NCT03568513|DIETARY_SUPPLEMENT|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
48358814|NCT03568513|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
48358815|NCT02783261|OTHER|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
48358816|NCT02879435|DRUG|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
48358817|NCT02879435|OTHER|Placebo|pre-operative wound infiltration with 10 ml of sterile water
48358818|NCT00679354|DRUG|cilengitide|Given IV
48358819|NCT00679354|OTHER|laboratory biomarker analysis|Correlative studies
48358820|NCT00679354|OTHER|pharmacological study|Correlative studies
48358821|NCT01183130|DEVICE|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
48358822|NCT02453828|PROCEDURE|Non-cardiac surgery|patients having non-cardiac surgery
48358823|NCT05190328|OTHER|Muscle Energy Technique|"Experimental: Muscle Energy Technique Post isometric relaxation: Patient will perform isometrics on upper trapezius and levator scapulae one by one. Each isometric contraction will be held for 10 seconds and then participants will be asked to relax the contraction with exhalation. This will be repeated five times in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Muscle energy technique."
48507381|NCT05368311|OTHER|Dietary recommendations including protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
48507382|NCT05368311|OTHER|Dietary recommendations without protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations.
48507383|NCT05773248|PROCEDURE|ERAS protocol|The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
48670927|NCT04778150|DEVICE|VO 100 medical device from Mespere LifeSciences|The investigators want to show a positive relationship between SjvO2 and SvO2 in order to possibly use in the future SjvO2 measured by VO 100 as a noninvasive surrogate of SvO2 in patients undergoing liver transplantation surgery.
48670928|NCT02327767|DEVICE|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
48670929|NCT02393859|DRUG|Blinatumomab|15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
48670930|NCT02393859|DRUG|Dexamethasone|10 mg/m\^2/day intravenous (IV) on Days 1-6
48670931|NCT02393859|DRUG|Vincrisitne|1.5 mg/m\^2/day IV on Days 1 and 6
48670932|NCT02393859|DRUG|Daunorubicin|30 mg/m\^2 IV over 24 hours on Day 5
48670933|NCT02393859|DRUG|Methotrexate|1 g/m\^2 IV over 36 hours on Day 1
48670934|NCT02393859|DRUG|Ifosfamide|800 mg/m\^2 IV for 1 hour on Days 2-4
48670935|NCT02393859|DRUG|PEG-asparaginase|1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6
48670936|NCT02393859|DRUG|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
48670937|NCT02138825|DRUG|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
48670938|NCT02138825|DRUG|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
48670939|NCT02234349|PROCEDURE|pancreas kidney transplantation|
48670940|NCT02234349|PROCEDURE|kidney transplantation|
48670941|NCT00812955|DRUG|ABT-143|Once daily for 8 weeks
48670942|NCT00812955|DRUG|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
48507384|NCT05776251|DEVICE|taVNS|"Includes the use of Soterix Medical Device, which consists of a handheld smart-phone size device. There are two electrodes (designed for studies in infants) with small patches that the participant places on the external ear (the cymbals conchae and the tragus). The stimulation intensity is personalized for each participant based on perceptual threshold."
48507385|NCT06634173|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated Cancer associated fibroblasts as a marker of Tumor Micro-Environment and indirectly as a marker for malignancies.
48507386|NCT02904824|BIOLOGICAL|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
48507387|NCT02904824|BIOLOGICAL|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
48507388|NCT04762498|BIOLOGICAL|Pegloticase|IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate
48507389|NCT04762498|DRUG|Methotrexate (MTX)|15 mg oral dose methotrexate administered weekly
48507390|NCT03038841|DEVICE|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
48507391|NCT04336943|BIOLOGICAL|Durvalumab|Given IV
48507392|NCT04336943|DRUG|Olaparib|Given PO
48507393|NCT04336943|OTHER|Quality-of-Life Assessment|Ancillary studies
48507394|NCT04336943|OTHER|Questionnaire Administration|Ancillary studies
48507395|NCT02829151|DRUG|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
48670943|NCT04716894|DRUG|BI 474121|BI 474121 oral solution
48670944|NCT04716894|DRUG|Itraconazole|Itraconazole oral solution
48670945|NCT00203190|DRUG|Topiramate|
48670946|NCT00956293|DRUG|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
48670947|NCT00956293|DRUG|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
48670948|NCT00956293|DRUG|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
48670949|NCT00956293|DRUG|Cyclosporin A (CsA)|Dosage was based according to blood level
48670950|NCT00956293|DRUG|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
48670951|NCT01331759|DEVICE|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
48670952|NCT02351089|DIETARY_SUPPLEMENT|Capsules placebo|Capsules
48670953|NCT02351089|DIETARY_SUPPLEMENT|Capsules probiotic powder and corn starch|
48670954|NCT02315092|DEVICE|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
48670955|NCT03481348|DEVICE|Pharyngeal Electrical Stimulation|Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
48358824|NCT05190328|OTHER|Active Release Technique|"Experimental: Active Release Technique: Therapist will apply deep pressure on both sides of levator scapulae and upper trapezius muscles (over the area of tenderness) and the patient is instructed to actively move the muscle from the shortened to a lengthened position and thereby breaking adhesions. 1 set of 5 repetitions in one session.~Routine Physical Therapy including TENS, Hot Pack, Strengthening, and stretching exercises will also be delivered along with Active Release Technique."
48358825|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
48670956|NCT05654584|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
48670957|NCT02068144|DIETARY_SUPPLEMENT|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
47990143|NCT06202391|PROCEDURE|Autogenic Inhibition-MET|Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
48358826|NCT00983242|DRUG|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
48358827|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
48358828|NCT06319066|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
48507396|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
48670958|NCT02068144|OTHER|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
48670959|NCT05384314|DEVICE|RespiraSense|The use of continuous electronic monitoring of respiratory rate
48670960|NCT03781674|DRUG|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
48670961|NCT03781674|DRUG|progesterone 200mg|Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
48670962|NCT03781674|DRUG|placebo to progesterone 200mg|Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
48670963|NCT03781674|DRUG|placebo to progesterone 400mg|Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
48670964|NCT05016089|OTHER|The 16-style simplified Pilates exercise programme|The 16-style simplified Pilates exercise programme was developed by a group of experienced Pilates and rehabilitation experts from our completed pilot work.
48670965|NCT01656577|DRUG|Pexacerfont|
48670966|NCT02612311|BIOLOGICAL|Obinutuzumab|Obinutuzumab: IV infusion
48670967|NCT02612311|BIOLOGICAL|Ublituximab|Ublituximab: IV infusion
47990144|NCT06202391|PROCEDURE|Reciprocal Inhibition-MET protocol|Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
48670968|NCT02612311|DRUG|TGR-1202|TGR-1202: Oral daily dose
48670969|NCT02612311|DRUG|Chlorambucil|Chlorambucil: Oral dose
48358829|NCT06319066|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
48670970|NCT03613064|OTHER|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
48670971|NCT03433976|DRUG|spinal anesthesia|spinal anesthesia for planned cesarean sections
47990145|NCT03775980|DEVICE|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
47990146|NCT00488163|DRUG|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
48358830|NCT06172829|DEVICE|Advantage MX Module|no intervention will be provided.
48358831|NCT01023139|BEHAVIORAL|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
48358832|NCT01272245|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
48358833|NCT01272245|DRUG|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
48358834|NCT05713331|BEHAVIORAL|CLS-R|CLS-R Training includes school provider training in CLS via web platform and videoconferencing for workshops, consultation and coaching.CLS is a 10-12 week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom and home.
48358835|NCT03003429|OTHER|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
48358836|NCT05729165|DEVICE|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
48358837|NCT05729165|OTHER|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
48670972|NCT06274658|BEHAVIORAL|High-intensity interval exercise|Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.
48670973|NCT02747147|DEVICE|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
48670974|NCT04915716|OTHER|Peripheral blood glucose levels were monitored|Peripheral blood glucose levels were monitored
48670975|NCT02638909|DRUG|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
48670976|NCT03192098|DEVICE|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
48670977|NCT05050903|OTHER|Rhinovirus infection|Inoculation with rhinovirus-16
47990147|NCT04840238|DRUG|Cholecalciferol|30,000IU cholecalciferol
47990148|NCT04840238|DRUG|Placebo|Placebo tablets
47990149|NCT03375918|OTHER|CONSULT-BP Educational Intervention|"The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias."
48670978|NCT00145626|DRUG|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
48670979|NCT00145626|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
48670980|NCT00145626|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
48670981|NCT00332618|DEVICE|OXYGENATED GLYCEROL TRIESTERS|
48670982|NCT03366337|DRUG|Bardoxolone methyl capsules|Bardoxolone 5 mg capsules
48670983|NCT00796458|DRUG|docetaxel|Given IV
48358838|NCT00859144|BEHAVIORAL|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
48358839|NCT00859144|BEHAVIORAL|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
48507397|NCT02829151|DRUG|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
48507398|NCT05648188|BIOLOGICAL|Sample|Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
48670984|NCT00796458|DRUG|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
48670985|NCT02117102|OTHER|Bladder and lumbar stimulation technic|
48670986|NCT04268914|DEVICE|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
48507399|NCT00002282|DRUG|Clotrimazole|
48507400|NCT00002282|DRUG|Fluconazole|
48507401|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cemented Fixation|
48507402|NCT01194817|DEVICE|High-Flexion Knee Replacement System using Cementless Fixation|
48507403|NCT05705765|OTHER|Suspension training|Training with suspension devices. 12 sessions of 40-45 min in four weeks.
48507404|NCT05705765|OTHER|Instability training|Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
48507405|NCT04104802|DEVICE|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
48507406|NCT05008601|DEVICE|Wrist-word optical heart rate and ECG measurement device|Aino ECG: wrist-word optical heart rate and ECG measurement device
48507407|NCT06217211|DIETARY_SUPPLEMENT|Remolacha|BJ or PL will be administered 3 h before the start of the NO2- evaluation test since the peak in blood occurs 2-3 h after ingesting NO3-. Both drinks (BJ and PL) will be provided in an unlabeled 140ml maroon red plastic bottle. Participants will receive a randomly assigned bottle. containing 140 ml (\~ 12.8 mmol, \~ 808 mg NO3-) of BJ Beet-It-Pro Elite Shot concentrate (Beet IT; James White Drinks Ltd., Ipswich, United Kingdom) or PL.
48507408|NCT04126590|BIOLOGICAL|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
48670987|NCT04268914|DEVICE|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
48670988|NCT00734552|DIETARY_SUPPLEMENT|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
48670989|NCT00734552|DIETARY_SUPPLEMENT|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
48670990|NCT01707537|BIOLOGICAL|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
48670991|NCT06382051|DIAGNOSTIC_TEST|PEST Screening group|PEST Screening group
48670992|NCT04670809|DRUG|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
48670993|NCT04670809|DRUG|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
48670994|NCT01352429|RADIATION|Proton Therapy|
48670995|NCT01352429|RADIATION|IMRT|
48670996|NCT02301897|DRUG|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
48670997|NCT02301897|DRUG|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
48670998|NCT04470024|DRUG|INCAGN01876|agonistic antihuman GITR mAb
48670999|NCT04470024|DRUG|INCMGA00012|humanized, hinge-stabilized, IgG4κ mAb that recognized human PD-1
48671000|NCT04470024|BIOLOGICAL|DPV-001|autophagosome cancer vaccine
48671001|NCT02474979|DEVICE|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
48671002|NCT02474979|OTHER|Control|
48671003|NCT02464982|PROCEDURE|Tattoo|tattoo device with EC standards, and sterile single-use only needle
48507409|NCT04608110|DRUG|ASTX030|In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
48671004|NCT03722979|PROCEDURE|Cardiac surgery|The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
47990150|NCT00999557|DRUG|bimatoprost ophthalmic solution|Applied topically
48671005|NCT04225858|PROCEDURE|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
47990151|NCT00999557|DRUG|placebo|Applied topically
48358840|NCT00859144|BEHAVIORAL|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
48671006|NCT02431156|OTHER|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
48688182|NCT06292195|OTHER|Exposure|Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
47990152|NCT00867451|BEHAVIORAL|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
47990153|NCT00867451|DRUG|Melatonin|Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
48507410|NCT00828737|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
47990154|NCT06333769|RADIATION|Short-course Radiotherapy|Rectal lesions + metastatic lymph nodes, DT: GTV-P 30Gy/5Fx. Pelvic lymphatic drainage area, DT: CTV-P 22.5Gy/5Fx.
47990155|NCT06333769|DRUG|Tislelizumab|Tislelizumab：200mg，d1，q3w，2 cycles.
48358841|NCT02256150|DRUG|Mizoribine (MZR)|
48507411|NCT04617522|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
47990156|NCT06333769|DRUG|capecitabine|capecitabine：1000mg/m2， d1-14，2 cycles.
47990157|NCT06333769|DRUG|Oxaliplatin|oxaliplatin：130mg/m2 d1，q3w, 2 cycles
48358842|NCT02256150|DRUG|Cyclophosphamide (CTX)|
48507412|NCT06484699|PROCEDURE|open repair of perforated peptic ulcer|group (A) includes patients with perforated peptic ulcer that will be operated by open repair approach
48507413|NCT06484699|PROCEDURE|laparoscopic repair of perforated peptic ulcer|group (B) includes patients with perforated peptic ulcer that will be operated by laparoscopic repair approach
48507414|NCT06474208|DRUG|Formulation 1|Oral suspension of Vericiguat (BAY1021189) in single dose (SD).
48507415|NCT06474208|DRUG|Formulation 2|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose in SD.
48671007|NCT04670861|PROCEDURE|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
48671008|NCT05164471|GENETIC|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
48671009|NCT00278161|BIOLOGICAL|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
48671010|NCT00278161|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
48671011|NCT00278161|DRUG|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
48671012|NCT05430061|DIETARY_SUPPLEMENT|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
48671013|NCT04442893|BEHAVIORAL|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
48671014|NCT04442893|OTHER|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
48671015|NCT00317265|PROCEDURE|Coronary bypass surgery|
48671016|NCT03844308|BEHAVIORAL|Isha Kriya Meditation|Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
48671017|NCT02834819|DRUG|3% Nebulized Hypertonic Saline|
48671018|NCT03814135|DRUG|Hipnos 3|1 tablet, oral, once a day.
48358843|NCT05362825|DRUG|Neo-adjuvant Chemotherapy FOLFOXIRI Regimen|Oxaliplatin 85mg/m2 IV; Irrinotecan 165mg/m2 IV; Leucovorin 400mg/m2 IV; 5-Fluorouracil 2400mg/m2 continuous infusion in 46 hours - every 2-week cycle, up to 12 cycles.
48358844|NCT05362825|PROCEDURE|synchronous resection surgery|Patients undergoing colorectal primary and liver resection in a single operation or staged curative procedure or no surgery
48358845|NCT03593720|PROCEDURE|Measurement in Office|Penile length and glans size in 3 dimensions
48507416|NCT06474208|DRUG|Formulation 3|Oral suspension of Vericiguat (BAY1021189) with increased level of flavor in SD.
47990158|NCT01797003|OTHER|High tibial osteotomy|
48507417|NCT06474208|DRUG|Formulation 4|Oral suspension of Vericiguat (BAY1021189) with increased level of sucralose and flavor in SD.
48507418|NCT06474208|DRUG|Formulation 5 (placebo)|Matching placebo of formulation 1 in SD.
47990159|NCT05069766|OTHER|BioXmark™|During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
47990160|NCT05830487|BEHAVIORAL|Low AGE diet with reduced energy and fat|This group will be given a low AGE diet with reduced energy and fat,.
47990161|NCT05830487|BEHAVIORAL|Energy and fat-reduced normal diet|This group will be given a diet with reduced energy and fat, and AGE levels will not be interfered with
48507419|NCT06510205|DEVICE|Mentor Breast implants|"Mentor breast implants are circular or waterdrop-shaped devices with shells made of successive cross-linked layers of silicone elastomer. The shell is filled with Mentor's proprietary formulation of silicone gel.~Mentor breast implants are available in smooth and textured shells, both supplied in sterile form."
48507420|NCT05369728|OTHER|Coronary CT in 1st line compared to the strategy with functional test in 1st line in patient at Intermediate Risk of Developing Stable Coronary Disease:|Coronary CT in 1st line compared to the strategy with functional test in 1st line in Patients at Intermediate Risk of Developing Stable Coronary Disease:
48507421|NCT06634316|OTHER|Mediterranean diet|Mediterranean diet recommendations and daily physical exercise
48507422|NCT06634316|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral nutritional supplement|Hypercaloric, hyperproteic oral supplement combined with Mediterranean diet recommendations (2 per day) and daily physical exercise
48507423|NCT06634316|DIETARY_SUPPLEMENT|Protein module|Protein module (10g/day) combined with Mediterranean diet recommendations and daily physical exercise
48671019|NCT03814135|DRUG|Hipnos 5|1 tablet, oral, once a day.
48358846|NCT03593720|PROCEDURE|Measurement in OR|Penile length and glans size in 3 dimensions
48671020|NCT03814135|OTHER|Hipnos 5 Placebo|1 tablet, oral, once a day.
47990162|NCT03337074|OTHER|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
47990163|NCT03337074|OTHER|Questionnaire|Participants are asked to complete a questionnaire.
47990164|NCT03337074|OTHER|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
47990165|NCT00212732|DRUG|ONO-8025 (KRP-197)|
48358847|NCT05745506|OTHER||Not applicable, there is no intervention description in this study.
48507424|NCT06634316|COMBINATION_PRODUCT|Vitamin D supplementation|Calcifediol supplement administered orally in order to reach sufficiency levels (30 ng/ml)
48671021|NCT03814135|OTHER|Hipnos 3 Placebo|1 tablet, oral, once a day.
47990166|NCT05127447|DEVICE|ES application|Electrical stimulation (ES) application will be given to the ES group
48671022|NCT03973957|DEVICE|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
48671023|NCT03973957|DRUG|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
47990167|NCT05127447|OTHER|Sham application|Only vacuum was applied and no current was given from the applied device
47990168|NCT05302154|BEHAVIORAL|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
47990169|NCT05302154|BEHAVIORAL|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
47990170|NCT05302154|BEHAVIORAL|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
48358848|NCT00006037|DRUG|fluorouracil|
48358849|NCT00006037|DRUG|irinotecan hydrochloride|
48358850|NCT00006037|DRUG|oglufanide disodium|
48358851|NCT03962413|PROCEDURE|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
48358852|NCT01172561|BEHAVIORAL|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
48358853|NCT01172561|BEHAVIORAL|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
48358854|NCT01063361|DIETARY_SUPPLEMENT|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
48507425|NCT06634316|COMBINATION_PRODUCT|Physical exercise|Physical exercise adapted to patients with heart failure (Cardiac rehabilitation)
48507426|NCT06007924|DRUG|Avutometinib|Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
48507427|NCT06007924|DRUG|Defactinib|Defactinib 200 mg twice daily 3 weeks on/1 week off
48507428|NCT04775849|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed uni- or bilateral
48507429|NCT03792295|DRUG|acetominophen, ibuprofen, oxycodone|Multimodal pain treatment group
48507430|NCT03792295|DRUG|Oxycodone|Classic opiod pain treatment group
48671024|NCT03973957|DRUG|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
48671025|NCT03973957|DEVICE|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
48671026|NCT02750930|DRUG|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
48671027|NCT02750930|DEVICE|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
48671028|NCT04655157|DRUG|encorafenib|A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
48671029|NCT04655157|DRUG|nivolumab|A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
48671030|NCT04655157|DRUG|ipilimumab|A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
48671031|NCT04655157|DRUG|binimetinib|A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
48671032|NCT02373904|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
47990171|NCT02268786|OTHER|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
47990172|NCT00708539|DRUG|progesterone|90 mg, vaginal, once daily
47990173|NCT00708539|DRUG|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
47990174|NCT02649907|DIETARY_SUPPLEMENT|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
47990175|NCT02649907|OTHER|Nutritional counseling|nutritional counseling for healthy eating behaviour
47990176|NCT02649907|DIETARY_SUPPLEMENT|formula diet|formula diet to help weight loss
47990177|NCT01472250|DRUG|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
47990178|NCT00654173|DRUG|Rosuvastatin|
48358855|NCT01063361|DIETARY_SUPPLEMENT|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
48358856|NCT04184752|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
48358857|NCT03815955|BEHAVIORAL|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
48358858|NCT06381752|DEVICE|Continuous passive motion|Daily application of continuous passive motion
48358859|NCT06381752|OTHER|standard rehabilitation|standard rehabilitation program with group physiotherapy
48358860|NCT03586076|BIOLOGICAL|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
48358861|NCT03586076|BIOLOGICAL|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
48358862|NCT05780164|OTHER|Research readiness tool|Online/paper based tool containing information about lung cancer clinical trials
48358863|NCT01097733|OTHER|Randomization of Pre-knowledge of CT coronary venography|
48358864|NCT05944861|OTHER|Combined ultrasonography and flouroscopy guided injeciton|In the ultrasound+fluoroscopy group, the sacroiliac injection will be started under ultrasound guidance. With the help of ultrasound, when sacral 2 foramen is seen the needle will be advanced to the entrance of the sacroiliac joint under real-time in-plane view. After considering intra-articular placement, fluoroscopy guidance will be initiated. An anteroposterior image will be taken to confirm whether contrast material is within the joint. If intra-articular placement is not achieved after contrast medium infiltration, needle reposition will be performed under fluoroscopy for correct needle placement. After the intraarticular contrast pattern is seen, 1 ml of 40 mg methylprednisolone + 1 ml of 1% lidocaine mixture will be injected.
48671033|NCT02229617|DRUG|Subcutaneous testosterone|
48671034|NCT04170920|DEVICE|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
48671035|NCT01659450|OTHER|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
48671036|NCT01659450|OTHER|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
48671037|NCT01659450|OTHER|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
48671038|NCT02063256|DIETARY_SUPPLEMENT|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
47990179|NCT00654173|DRUG|Simvastatin|
47990180|NCT00654173|DRUG|Atorvastatin|
48671039|NCT02063256|OTHER|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
48671040|NCT02466724|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
48671041|NCT05344534|BEHAVIORAL|Leadership and Organizational Change for Implementation|LOCI is data driven leadership development and coaching for clinic managers and working with agency executives and middle managers to foster a strategic implementation climate
48507431|NCT06007833|BEHAVIORAL|Physical Therapy and Rehabilitation Modalities|In the experimental group, the subjects who were taken to the physical therapy modality in addition to conventional therapy. Total, each session was performed for 60 minutes, 8 weeks, 3 days a week, under the supervision of a physiotherapist, while the other days, the family member performed 3 times a day, each movement for 3 sets, 10-15 repetitions, for a total of 60 minutes. A rest interval of less than 2 minutes was given between each set. By making use of heat modalities before starting the exercises, the elongation ability of the warmed tense structure was increased and the risk of damage in stretching exercises was reduced. The cold application was applied to the soft tissues in the extended position for 1-2 minutes with a cold pack, as the application of cold immediately after the stretching would ensure the preservation of the range of motion. Progress in the exercise program; adjusted for strength, endurance, flexibility, balance and functionality parameters.
48671042|NCT06187857|BEHAVIORAL|Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)|Feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults
48671043|NCT02230982|DRUG|nintedanib|soft gelatin capsule
48671044|NCT05641610|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10\^12vg/kg, 5.0×10\^12vg/kg, 1.0×10\^13vg/kg.
48671045|NCT00374647|DRUG|mycophenolate mofetil|
48671046|NCT00374647|DRUG|sirolimus|
48671047|NCT01179230|OTHER|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
48671048|NCT01179230|OTHER|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
48671049|NCT04920318|COMBINATION_PRODUCT|tDCS + language therapy|In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.
48671050|NCT04920318|COMBINATION_PRODUCT|sham TDCS + language therapy|sham control will be applied with language therapy to the same regions as active TDCS.
48671051|NCT05210725|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
47990181|NCT02502539|PROCEDURE|Controlled physical activity|
48671052|NCT04524988|PROCEDURE|Laparoscopic Simulation Training|All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
48671053|NCT03800550|DRUG|Bedaquiline|Bedaquiline tablet will be administered, orally.
47990182|NCT00944450|DRUG|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
48671054|NCT03800550|DRUG|Clarithromycin|Clarithromycin tablet will be administered, orally.
48671055|NCT01935947|DRUG|Azacitidine|Given SC
48671056|NCT01935947|DRUG|Azacitidine|Given PO
48671057|NCT01935947|DRUG|Docetaxel|Given IV
48671058|NCT01935947|DRUG|Entinostat|Given PO
48671059|NCT01935947|DRUG|Gemcitabine Hydrochloride|Given IV
48671060|NCT01935947|DRUG|Irinotecan Hydrochloride|Given IV
48671061|NCT01935947|OTHER|Laboratory Biomarker Analysis|Correlative studies
48671062|NCT01935947|DRUG|Pemetrexed Disodium|Given IV
48671063|NCT02273089|DEVICE|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
48671064|NCT00570843|DRUG|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
48671065|NCT00570843|DRUG|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
48671066|NCT05298475|DRUG|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
48671067|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
48671068|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
48671069|NCT04155476|DRUG|Nitroglycerin Topical Product|application of NG topical to dorsals pedis and posterior tibial arteries.
48671070|NCT05239078|DRUG|local anaesthetic injection|Inferior alveolar nerve block
47990183|NCT00944450|DRUG|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
47990184|NCT05297825|BEHAVIORAL|Vegan diet|Healthy vegan diet.
47990185|NCT05297825|BEHAVIORAL|Omnivore diet|Healthy omnivore diet.
47990186|NCT02692781|DRUG|MOD-6031|
47990187|NCT02692781|OTHER|Placebo control|
47990188|NCT02785107|BEHAVIORAL|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
47990189|NCT06320730|OTHER|Observational study, records of blood glucose level after reperfusion|Analyzes blood glucose level after reperfusion by dividing it into two groups: those with blood glucose levels between 110 and 180 and those with blood glucose levels below 110 or above 180.
47990190|NCT04954612|OTHER|Questionnaire study (Cross-sectional analytical clinical research)|Questionnaire study (Cross-sectional analytical clinical research)
47990191|NCT01290640|DEVICE|DePuy fixed-bearing Total Condylar III (TC3) TKA|
48671071|NCT06053528|DRUG|Antibiotic|Effect if treatment
48671072|NCT01943760|DRUG|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
48671073|NCT01943760|DRUG|0.9% saline|
48671074|NCT05556434|DIAGNOSTIC_TEST|radiological evaluation|"All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases"
48671075|NCT05066412|OTHER|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
48671076|NCT04347421|DIETARY_SUPPLEMENT|Krill oil group|This group takes 500 mg/day Krill oil for 12 weeks.
48671077|NCT04347421|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks.
48671078|NCT05206903|OTHER|Questionnaires|Questionnaires about pandemia process
48671079|NCT00129857|DRUG|Dexanabinol|
48671080|NCT04908150|OTHER|Core training|A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
48671081|NCT01847443|DRUG|Nicotine (2 mg)|2 mg nicotine gum in two formulations
48671082|NCT01847443|DRUG|Nicotine (4 mg)|4 mg nicotine gum in two formulations
48358865|NCT05944861|OTHER|Flouroscopy guided injection|In the fluoroscopy group, the advancement of the needle into the sacroiliac joint will be performed by taking anteroposterior and lateral views. In the same way, the needle tip will be placed in the inferior of the sacroiliac joint, and contrast material distribution examination and injection of the drug will be performed as in the ultrasound + fluoroscopy group.
48358866|NCT05309499|DRUG|ferric carboxymaltose|ferric carboxymaltose is i.v. iron, 121 patiants will be randomised to this group
48671083|NCT01374425|DRUG|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m\^2) by IV bolus and subsequent 2400 mg/m\^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
47990192|NCT01290640|DEVICE|DePuy PFC Rotating Platform TC3 TKA|
47990193|NCT04576130|DEVICE|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
48671084|NCT01374425|DRUG|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
48671085|NCT01374425|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
48671086|NCT01374425|DRUG|Leucovorin|Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
48671087|NCT01374425|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
48671088|NCT01374425|DRUG|Capecitabine|Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
48671089|NCT00276419|DRUG|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
48671090|NCT00276419|DRUG|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
48671091|NCT04410861|PROCEDURE|Micropulse laser photostimulation|In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
48671092|NCT05293340|DIETARY_SUPPLEMENT|Avocado Vouchers|Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
48671093|NCT03605693|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
48671094|NCT04278248|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
48671095|NCT03953807|DRUG|Dexamethasone Intravitreal Implant|Implant 700 μg
48671096|NCT06310382|DRUG|GH55|GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
48671097|NCT03567694|DRUG|HA115|Test Drug
48671098|NCT03567694|DRUG|Placebo|Placebo
48671099|NCT04573855|BIOLOGICAL|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
48671100|NCT04949009|DRUG|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
48671101|NCT00946933|DIETARY_SUPPLEMENT|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
48671102|NCT00946933|DIETARY_SUPPLEMENT|placebo|0.025 g/kg/day of NaCl (sodium chloride)
48671103|NCT01846026|DRUG|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
48671104|NCT01846026|DRUG|placebo|
48671105|NCT00085748|DRUG|paliperidone ER|
48358867|NCT05309499|DRUG|ferrous sulphate|ferrous sulphate is oral iron, 121patiants will be randomised to this group
48671106|NCT02468830|DRUG|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
48671107|NCT04885101|PROCEDURE|LISWT Group|The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
48671108|NCT04885101|PROCEDURE|NARFT Group|The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
48671109|NCT04885101|PROCEDURE|Sham Group|In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
48671110|NCT04638478|OTHER|PRECODE-MRI|Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy
48671111|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab|Administration of Lilly Bamlanivimab to COVID positive patients
48358868|NCT00656799|DRUG|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
48671112|NCT04790786|BIOLOGICAL|Regeneron Casirivimab + Imdevimab|Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients
48671113|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab + Etesevimab|Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients
48671114|NCT04790786|BIOLOGICAL|Sotrovimab|Administration of Sotrovimab to COVID positive patients
48671115|NCT04790786|BIOLOGICAL|Bebtelovimab|Administration of Bebtelovimab to COVID positive patients
48358869|NCT00656799|DRUG|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
48358870|NCT04678349|DIETARY_SUPPLEMENT|PHGG|Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.
48358871|NCT04678349|OTHER|conventional care|follow low fibre diet and anti-diarrhea drugs
48358872|NCT05965999|DEVICE|EsoCheck|EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.
48358873|NCT00069251|DRUG|Bupropion|
48358874|NCT00003368|DRUG|irinotecan hydrochloride|
48358875|NCT04212611|DRUG|INFRA ORBITAL BLOCK|Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
48358876|NCT00952471|OTHER|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
48358877|NCT04733040|DRUG|MOR202|5 or 2 doses of MOR202 will be administered as an intravenous infusion
48358878|NCT02109939|GENETIC|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
48358879|NCT04328181|DEVICE|Spectral Photon Counting Computed Tomography (SPCCT)|"For the dual-layer spectral CT scanner (IQon®, Philips, Amsterdam, The Netherlands), the following parameters will be used for the acquisition:~* Tube potential 120 kVp;~* Tube current time product of 150 mAs;~* Gantry revolution time 0.33 s;~* Automatic exposure control (angular and longitudinal) combined xyz-axis;~* Beam collimation geometry 64 x 0.625 mm - scan field-of-view - 22 cm;"
48671116|NCT05236166|DRUG|Rapid withdrawal of antiepileptic|"Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
48671117|NCT05236166|DRUG|Slow withdrawal of antiepileptic|"Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
48671118|NCT02875470|DEVICE|Intensiv Perio Set|Diamond burs for root planing
48671119|NCT02875470|DEVICE|Gracey curette|
48671120|NCT02474121|DEVICE|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
48671121|NCT00770393|PROCEDURE|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
48671122|NCT00770393|PROCEDURE|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
48358880|NCT04328181|DEVICE|DECT (Dual Energy CT)|"The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field-of-view (FOV) of 168 mm in-plane, and a z-coverage of 20 mm. It is equipped with energy-sensitive photon-counting detectors relying on the direct conversion high band gap semiconductor of cadmium zinc telluride (CZT). The electronics comprises 5 rate counters with 5 different configurable energy thresholds. The SPCCT scanner has the following parameters:~* Base platform : iCT scanner~* Tube Voltage (kVp) : 120, capability for imaging at 80 and 100 kVp~* Tube current (mA) : 10 - 300~* Spatial Resolution : \> 30 lp/cm, ≤ 250 µm~* Z-coverage isocenter (mm) : 20 mm~* FOV (mm) : 500~* Minimum rotation time : 0.33 s/rotation~* Acquisition modes : Axial, Helical, Step \& Shoot"
48507432|NCT06007833|BEHAVIORAL|Conventional Group|As a conservative treatment in the control group, post-surgical plastering followed by orthoses and positioning was applied.
48507433|NCT03893565|DRUG|GSK2831781 - Double Blind Phase|GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
48671123|NCT03643835|DEVICE|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
48671124|NCT03643835|OTHER|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
48671125|NCT01544673|DRUG|linezolid|600 mg oral tablet twice daily for 4.5 days
48671126|NCT01544673|DRUG|Placebo|500 mg oral placebo twice daily for 4.5 days
48671127|NCT02149459|RADIATION|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
48671128|NCT02149459|DRUG|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
48671129|NCT02149459|BEHAVIORAL|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
48671130|NCT02131766|DEVICE|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
48671131|NCT02131766|OTHER|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
48671132|NCT02007941|DRUG|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
48671133|NCT00578097|BIOLOGICAL|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
48671134|NCT00578097|DRUG|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
48671135|NCT04616248|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
48671136|NCT04616248|DRUG|Poly ICLC|Given IT
48671137|NCT04616248|RADIATION|Radiation Therapy|Undergo radiation therapy
48671138|NCT04616248|BIOLOGICAL|Recombinant Flt3 Ligand|Given IT
48671139|NCT04616248|DRUG|Pembrolizumab|Given IV
48671140|NCT04616248|DRUG|Tocilizumab|Given SC
48671141|NCT03248323|RADIATION|dyna-pbv|
48671142|NCT02146443|OTHER|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
48671143|NCT02146443|OTHER|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
48358881|NCT05605691|DEVICE|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
48507434|NCT03893565|DRUG|Placebo|Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).
48507435|NCT03893565|DRUG|GSK2831781 - Open Label phase|GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
48507436|NCT02593253|OTHER|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
48507437|NCT02593253|OTHER|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
48507438|NCT03239223|DRUG|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
48507439|NCT03961490|OTHER|No interventional study|No interventional study
48507440|NCT02752087|DRUG|LY900014|Administered SC
48507441|NCT00004230|DRUG|captopril|
48507442|NCT00004230|DRUG|cyclophosphamide|
48507443|NCT00004230|PROCEDURE|autologous bone marrow transplantation|
48507444|NCT00004230|PROCEDURE|peripheral blood stem cell transplantation|
48507445|NCT00004230|RADIATION|radiation therapy|
48507446|NCT04563546|OTHER|Quality Improvement|A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
48507447|NCT03019159|DEVICE|Teleconsulting|
48507448|NCT01352780|BEHAVIORAL|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
48671144|NCT02146443|DEVICE|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
48507449|NCT01023048|OTHER|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
48507450|NCT04479553|DRUG|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
48507451|NCT00901212|DEVICE|Device programming|6-month period
48507452|NCT02563392|PROCEDURE|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
48507453|NCT02563392|PROCEDURE|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
48507454|NCT00929890|BEHAVIORAL|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
48507455|NCT00929890|BEHAVIORAL|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
48507456|NCT02154295|DEVICE|Infraredx Test Catheter|
48507457|NCT02002286|DRUG|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
48507458|NCT02002286|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
48507459|NCT03715504|DRUG|TP-3654|oral PIM inhibitor
48671145|NCT02812914|OTHER|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
48507460|NCT01420471|DRUG|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
48671146|NCT02812914|BEHAVIORAL|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
48671147|NCT02812914|BEHAVIORAL|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
48507461|NCT01420471|OTHER|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
48671148|NCT04001400|DRUG|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
48671149|NCT04001400|DRUG|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
48358882|NCT00421460|DRUG|Testosterone Undecanoate,1000mg|duration for 4 injections
48358883|NCT04203290|DRUG|Bupivacaine|%0.25 bupivacaine solution
48358884|NCT04203290|DRUG|Sevoflurane|End tidal sevoflurane concentration
48358885|NCT01962909|DRUG|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
48671150|NCT04487405|DEVICE|OVAnex|OVAnex is a multivarite index assay assessing ovarian cancer risk
48671151|NCT04025892|BEHAVIORAL|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
48671152|NCT02412670|DRUG|Methotrexate|Given IV
48671153|NCT02412670|DRUG|Vinblastine|Given IV
48671154|NCT02412670|DRUG|Doxorubicin|Given IV
48671155|NCT02412670|DRUG|Cisplatin|Given IV
48671156|NCT02412670|DRUG|Gemcitabine|Given IV
48671157|NCT02412670|DRUG|Carboplatin|Given IV
48671158|NCT02412670|DRUG|Pegfilgrastim|Administered subcutaneously
48671159|NCT02412670|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy and lymph node dissection
48671160|NCT03928925|OTHER|Bougie|disposable tracheal tube introducer of approximately 70 cm in length
48671161|NCT03928925|OTHER|Endotracheal Tube with Stylet|endotracheal tube preloaded with a removable, malleable stylet
48671162|NCT01554098|PROCEDURE|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
48671163|NCT01554098|PROCEDURE|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
48671164|NCT02089204|RADIATION|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
48671165|NCT02089204|RADIATION|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
48671166|NCT02089204|RADIATION|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
48671167|NCT03279107|OTHER|Soluble corn fiber|soluble corn fiber
48671168|NCT03279107|OTHER|maltodextrin|maltodextrin
48671169|NCT05699057|BEHAVIORAL|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
48671170|NCT01306695|BEHAVIORAL|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
48671171|NCT01306695|OTHER|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
48507462|NCT02656888|DRUG|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
48671172|NCT05781581|OTHER|no intervention|no intervention
48671173|NCT00830050|DRUG|Naproxen|500 mg BID 7 days
48671174|NCT00830050|DRUG|Placebo|BID 7 days
48671175|NCT02799589|DRUG|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
48671176|NCT02799589|DRUG|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
48671177|NCT02799589|DRUG|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
48671178|NCT00002766|BIOLOGICAL|dactinomycin|
48671179|NCT00002766|BIOLOGICAL|sargramostim|
48671180|NCT00002766|DRUG|carmustine|
48671181|NCT00002766|DRUG|cyclophosphamide|
48671182|NCT00002766|DRUG|cytarabine|
48671183|NCT00002766|DRUG|daunorubicin hydrochloride|
48671184|NCT00002766|DRUG|doxorubicin hydrochloride|
48671185|NCT00002766|DRUG|etoposide|
48671186|NCT00002766|DRUG|mercaptopurine|
48671187|NCT00002766|DRUG|methotrexate|
48671188|NCT00002766|DRUG|mitoxantrone hydrochloride|
48671189|NCT00002766|DRUG|pegaspargase|
48671190|NCT00002766|DRUG|prednisone|
48671191|NCT00002766|DRUG|vincristine sulfate|
48671192|NCT00002766|RADIATION|radiation therapy|
48147588|NCT05817513|OTHER|Myofascial release.|Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.
48147589|NCT05817513|OTHER|Traditional exercises for scoliosis treatment.|"The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises."
48671193|NCT01643681|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
48671194|NCT02886650|PROCEDURE|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
48671195|NCT01370876|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
48147590|NCT03032965|DRUG|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
48671196|NCT02917005|DRUG|Palbociclib|CDK 4/6 inhibitor
48507463|NCT02656888|DRUG|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
48507464|NCT05733221|DEVICE|3D Printed Model|3D Printed Model generated pre-operatively of the patients mandible.
48507465|NCT05549609|BIOLOGICAL|XSTEM-VLU|XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
48671197|NCT02917005|DRUG|Exemestane|Aromatase inhibitor
48507466|NCT05549609|OTHER|Vehicle|CryoStor CS10 cryomedium
48671198|NCT02917005|DRUG|Goserelin|LHRH agonist
48671199|NCT02003482|RADIATION|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
48671200|NCT02003482|DEVICE|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
48671201|NCT06000670|PROCEDURE|stromal vascular fraction injection in the osteoarthritic knee|stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
48671202|NCT06084364|DRUG|Injection of triamcinolone acetonide into the CMC-1 joint|intraarticular injection with triamcinolone acetonide
48671203|NCT06084364|BEHAVIORAL|Multimodal Occupational therapy for CMC-1 joint OA|Patient education, instructions about hand exercises, orthosis and training
48671204|NCT06084364|DRUG|Placebo|Intraarticular injection with saline
48507467|NCT00999323|DEVICE|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
48507468|NCT06077383|DIETARY_SUPPLEMENT|Weizmania Coagulans BC99|Probiotics group subjects take probiotics every day for 8 weeks.
48671205|NCT02932826|BIOLOGICAL|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml NS
48671206|NCT02932826|DRUG|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
48671207|NCT02024412|DRUG|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
48671208|NCT02024412|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
48671209|NCT05070130|DEVICE|dPR and FFR|OpSens non-hyperemic dPR and/or OpSens FFR
48671210|NCT06301503|DRUG|USG Guided Combined LPB-SNB with Isobaric Bupivacaine|Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)
48147591|NCT03032965|DRUG|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
48147592|NCT04316494|DRUG|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
48507469|NCT06633471|DRUG|Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).|Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
48507470|NCT03055650|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
48507471|NCT02950649|DEVICE|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
48507472|NCT02950649|DEVICE|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
48507473|NCT00226174|DRUG|Curcuminoids|
48507474|NCT04463797|OTHER|Square-stepping exercise|The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.
48507475|NCT04463797|OTHER|Stretching and strengthening|whole-body stretching and upper extremity strengthening
48507476|NCT05605015|BEHAVIORAL|ACTIVE-CR|The ACTIVE-CR intervention comprises three key components: a wrist-worn physical activity monitor, a web-based platform providing physical activity feedback, and three autonomy supportive online trainer sessions. Each component is grounded by multiple established behaviour change techniques consistent with the behaviour change taxonomy developed by Michie et al. (2013). The barriers to physical activity were identified in our previous work and are consistent with previous literature
48671211|NCT06301503|DRUG|Control|Local anesthetic infiltration of 2% lidocaine (3ml)
48671212|NCT06003439|BEHAVIORAL|Virtual Reality Program|Behavioral: Virtual Reality Program The VR Program will be pre-installed on Meta Quest 2 headsets, which will be donned by students as a class to experience the intervention for approximately the length of one school class period (approximately 30-40 minutes). Each participant will experience the program once a week for 3 weeks. Participants who missed a week will complete the program by the 4th or 5th week.
48671213|NCT06003439|BEHAVIORAL|VR Program|VR program participants will be able to download a mobile app that complements and reinforces the school-based VR session.
48671214|NCT05722587|OTHER|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
48671215|NCT04941690|OTHER|A questionnaire method was used.|The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.
48671216|NCT05759208|DRUG|OK-101|Ophthalmic Solution
48671217|NCT05759208|DRUG|Placebo|Placebo
48671218|NCT04631809|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
48671219|NCT04631809|PROCEDURE|CT-Coronary Angiography + Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
48671220|NCT06000930|DIAGNOSTIC_TEST|Troponin fragmentation|laboratory test from blood sample
48671221|NCT02722408|DRUG|Gemcabene|300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
48671222|NCT02553187|DRUG|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
48671223|NCT05704153|DEVICE|Parasym 1Hz|Transcutaneous auricular vagus nerve stimulation of 1Hz
48671224|NCT05704153|DEVICE|Parasym 30Hz|Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
48671225|NCT05704153|DEVICE|Sham Intervention|Sham stimulation
48671226|NCT00281970|DRUG|cisplatin|
48671227|NCT00281970|DRUG|docetaxel|
48671228|NCT00281970|PROCEDURE|adjuvant therapy|
48671229|NCT00959426|DRUG|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
48671230|NCT00959426|DRUG|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
48671231|NCT03264144|BEHAVIORAL|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
48147593|NCT04316494|DRUG|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
48671232|NCT06487871|DIETARY_SUPPLEMENT|Fucoidan extracted from Undaria pinnatifida (UPF)|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
48671233|NCT06487871|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
48671234|NCT03949023|PROCEDURE|Standard of Care Cerebral Angiogram Group|"Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration)."
48671235|NCT03971929|DRUG|SHR0532|once daily(QD) for 4weeks
48671236|NCT03971929|DRUG|SHR placebo|once daily(QD) for 4weeks
48147594|NCT06084988|BIOLOGICAL|Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
48507477|NCT05602883|BEHAVIORAL|music therapy|Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
48507478|NCT05769257|DRUG|IS-001|Intravenous injection of IS-001 investigational drug
48507479|NCT06104995|OTHER|Interventional video|The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.
48507480|NCT06104995|OTHER|Control video|The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
48507481|NCT06470282|DRUG|Enfortumab Vedotin|Given intravenously (IV)
48147595|NCT02007070|BIOLOGICAL|Pembrolizumab|Intravenous infusion
48507482|NCT06470282|BIOLOGICAL|Pembrolizumab|Given IV
48507483|NCT06470282|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Undergo standard of care, IMRT
48671237|NCT03971929|DRUG|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
48671238|NCT02227303|BEHAVIORAL|lifestyle modification instructional and motivational sessions|
48671239|NCT00998010|DRUG|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
48671240|NCT03842735|OTHER|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
48671241|NCT03842735|BEHAVIORAL|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
48507484|NCT06470282|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
48671242|NCT01306747|BEHAVIORAL|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
48671243|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
48671244|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
48147596|NCT05271045|DIETARY_SUPPLEMENT|fortified canola oil with vitamins A and D and γ-oryzanol|30 g fortified canola oil with vitamins A and D and γ-oryzanol
48147597|NCT05271045|DIETARY_SUPPLEMENT|Active comparator|30 g fortified canola oil with vitamins A and D
48147598|NCT05271045|DIETARY_SUPPLEMENT|Placebo|30 g fortified sunflower oil with vitamins A and D
48147599|NCT03422705|DEVICE|Optimised programming|Optimised programming to avoid RV pacing when possible.
48147600|NCT03422705|DRUG|Lisinopril|Uptitration of lisinopril
48147601|NCT03422705|OTHER|Standard care|No pacemaker adjustment or medical therapy
48147602|NCT06534918|OTHER|Fitbit|Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
48507485|NCT06470282|PROCEDURE|Cystoscopy (CS)|Undergo cystoscopy
48507486|NCT06470282|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
48507487|NCT06470282|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
48507488|NCT06470282|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET Scan, may be combined with CT (PET/CT)
48507489|NCT05229003|DRUG|Anlotinib|Anlotinib 8mg or 10mg, d1-9，q2w
48507490|NCT05229003|DRUG|Penpulimab|Penpulimab 200mg, d6, q2w
48507491|NCT05229003|DRUG|Irinotecan|Irinotecan 180mg/m2, d6, q2w
48507492|NCT04594317|DEVICE|low level laser therapy|buccal application of diode laser on non-contact mode
48507493|NCT06091540|BEHAVIORAL|Feasibility and Efficacy of Individual SH+ Intervention|The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
48671245|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
48671246|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
48671247|NCT01601184|DRUG|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
48147603|NCT06534918|BEHAVIORAL|Nutrition Course|The virtual, synchronous nutrition course will be a 30-60 minute group education class on nutrition information for cancer survivors. The class will be held once per week.
48147604|NCT06534918|BEHAVIORAL|Physical Activity Program|The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
48507494|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered.
48147605|NCT06534918|BEHAVIORAL|Weekly One on One Session with Registered Dietitian|Participants will be referred to weekly one on one sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
48507495|NCT06255665|DRUG|JNJ-79032421|JNJ-79032421 will be administered at RP2D regimen.
48507496|NCT05467696|DRUG|CTP-543|For each period, subjects will be dosed with CTP-543 12 mg (1 x 12 mg tablet)
48507497|NCT04421300|BEHAVIORAL|smile exercise|"Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day"
48507498|NCT04421300|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
48507499|NCT00209105|DRUG|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
48507500|NCT00209105|BEHAVIORAL|Psychosocial stress induction|Laboratory stress induction, no drug administration
48507501|NCT00209105|PROCEDURE|Brain imaging of sad mood , self-reference, reward|Brain imaging
48507502|NCT00209105|BEHAVIORAL|Acoustic startle|No drugs involved
48507503|NCT06359288|OTHER|Group receiving QR code supported training|During the training process, QR codes were integrated into the sections related to the care of the newborn in the guide to provide mothers with the opportunity to watch the video simultaneously while reading the guide in practices requiring skills related to hygienic care of the newborn and nutrition / communication / sleep, and to allow them to watch it repeatedly as long as they feel the need. In these videos, the application steps were shown one by one. When the code is scanned with a smartphone, it automatically redirects the user to the specified URL. The QR codes in the Implementation Guide on the Care of the Newborn consist of eight videos) that allow mothers to watch the hygienic care of the newborn in practice. After the end of this phase of the training, the questionnaires were re-administered to the mothers in both groups one month after discharge.
48507504|NCT00256399|DRUG|Alfuzosin 10 mg|
48507505|NCT04893018|BIOLOGICAL|Efineptakin alfa|Given IM
48507506|NCT05351671|DRUG|RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
48671248|NCT01601184|DRUG|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
48671249|NCT03583229|DRUG|Aspirin 75mg|7 days treatment with 75 mg aspirin daily.
48671250|NCT03583229|OTHER|Extracorporeal photopheresis|4 x ECP treatments in 60 days.
48507507|NCT05351671|DRUG|RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)|After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at a loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses.
48671251|NCT01822665|DRUG|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
48507508|NCT05351671|DRUG|Placebo (saline dosed every 8 hours for a total of 3 doses)|After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
48507509|NCT03563911|BEHAVIORAL|Brief Mindfulness-Based Intervention (BMBI)|The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 1 week (a handout and link to an online guided mindfulness practice will be provided).
48507510|NCT03563911|BEHAVIORAL|Control/Nutrition Education|The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 1 week (a handout and link to online resources will be provided).
48507511|NCT06312657|BEHAVIORAL|Drug Cue|Individualized drug cues paired with choice options reinforced by $0.25
48507512|NCT06312657|BEHAVIORAL|Money|Two money values will be tested ($0.25 and $4.00)
48147606|NCT06534918|BEHAVIORAL|Weekly One on One Session with an Exercise Physiologist|Participants will be referred to weekly one on one sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
48147607|NCT06534918|BEHAVIORAL|Nutrition Prescription|The nutrition prescription pad serves as a quick checklist designed to assist participants in effectively monitoring their dietary habits. Participants randomized to intervention group will each receive a one-time nutrition prescription in person during their first intervention week.
48147608|NCT06534918|BEHAVIORAL|Physical Activity Prescription|The physical activity prescription pad serves as a quick checklist designed to assist participants in effectively monitoring their exercise routines. Participants randomized to intervention group will each receive a one-time physical prescription in person during their first intervention week.
48507513|NCT06312657|DRUG|Withdrawal|Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal.
48507514|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
48671252|NCT01822665|DRUG|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
48671253|NCT01822665|OTHER|Placebo|Placebo tablets
48671254|NCT03898284|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry will be performed in addition to usual care
47990194|NCT04463095|PROCEDURE|PER ORAL ENDOSCOPY MYOTOMY (POEM)|Peroral endoscopic myotomy (POEM)combines thelong-term efficacy of a myotomy with the benefits of an endoscopic, minimally invasive procedure.Other therapeutic options include endoscopic balloon dilatation and surgical myotomy. Endoscopic balloon dilatation is still widely performed because of its relative non-invasiveness and simplicity, but it has a relatively lower success rate and often requires multiple treatment sessions. Surgical myotomy has been thought to be the curative therapeutic choice for symptomatic achalasia. However, it requires skin incisions and additional anti-reflux surgical intervention.Unlike surgical myotomy, POEM preserves the anatomical integrity of the LES and possibly minimizes postoperative reflux.
47990195|NCT06489652|DRUG|89Zr-Oxine-RY_SW01 Cell Injection|Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY_SW01 cells injection
48147609|NCT05081778|BEHAVIORAL|Obese patient following a medical course|Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg
48147610|NCT02106325|DRUG|Ketamine|IV of Ketamine (.25mg/kg)
48147611|NCT02106325|DRUG|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
48671255|NCT00299364|DRUG|Black Cohosh (iCR) or tibolone|
48671256|NCT02312648|OTHER|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
48671257|NCT02312648|OTHER|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
48671258|NCT00163644|PROCEDURE|aereobic plus resisted exercise|
48671259|NCT00163644|PROCEDURE|aerobic plus active exercise|
48671260|NCT00163644|OTHER|No formal exercise plus phone calls|
48671261|NCT05233514|OTHER|Aerobic exercise in addition to Metformin treatment|The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
48671262|NCT02054637|DRUG|Lanreotide|
48671263|NCT02684968|PROCEDURE|Colorectal surgery|
48671264|NCT04201639|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
48671265|NCT01101607|PROCEDURE|Distal Forearm Fracture Reduction|Fracture reduction
48671266|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
48671267|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
48671268|NCT05187260|DRUG|Nusinersen|SPINRAZA® (nusinersen) prescribed as part of standard of care
48671269|NCT02005744|DRUG|CKD-501|CKD-501 0.5mg, PO(per oral), once
48671270|NCT02221973|DIETARY_SUPPLEMENT|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
48671271|NCT05963438|PROCEDURE|anterior retraction|After placement of mini-implants and extraction of maxillary first premolar, retraction of anterior either simultaneously or separately depending on the allocated group will be done
48671272|NCT00204529|DRUG|pegylated interferon-alpha-2a|
47990196|NCT05389345|BEHAVIORAL|Transcranial direct current stimulation|Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
48147612|NCT00213317|PROCEDURE|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
48147613|NCT04838509|OTHER|no intervention|retrospective descriptive without intervention
48671273|NCT00204529|DRUG|interferon-alpha-2a|
48671274|NCT06388252|PROCEDURE|Electrochemotherapy with Intratumoral Cysplatin|ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
48671275|NCT06388252|PROCEDURE|Electrochemotherapy with Intravenous Bleomycin|ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
48671276|NCT05117996|OTHER|capsule endoscopy|capsule endoscopy
48671277|NCT05117996|OTHER|standard small bowel preparation|2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
48671278|NCT05117996|OTHER|Simplified small bowel preparation|Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
48671279|NCT00358111|DEVICE|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
48358886|NCT05150171|OTHER|e-self-management intervention|The app is developed based on a combination of behavioural change techniques informed by Social cognitive theory and the EULAR recommendations on management of hand osteoarthritis. The 12-week intervention consists of 25 short informational videos addressing the themes prioritized by the patient research partners. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The informational videos and exercise program are delivered in a progressive order across the 12 weeks. Encouragement and motivational messages are provided each week to enhance continued adherence to the intervention.
47990197|NCT05389345|BEHAVIORAL|Executive function training|The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
47990198|NCT05229120|BEHAVIORAL|Episodic Future Thinking|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
47990199|NCT03232281|DRUG|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
48358887|NCT01948089|BEHAVIORAL|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
48147614|NCT00251199|DRUG|VX-950|
48358888|NCT01948089|BEHAVIORAL|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
48358889|NCT06212518|OTHER|GENPOP ad libitum fluid intake|Unrestricted fluid intake.
48358890|NCT06212518|OTHER|GENPOP fluid restriction|In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).
48358891|NCT06212518|OTHER|ATHLETE ad libitum fluid intake|No restriction on fluid intake
48507515|NCT00642252|DRUG|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
48671280|NCT06464770|DRUG|Chlorhexidine Gluconate|Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
48671281|NCT00405288|DRUG|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
48671282|NCT00532844|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
48671283|NCT00532844|DRUG|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
48671284|NCT06350448|DRUG|Washed Microbiota Transplantation|Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
48147615|NCT00251199|DRUG|peginterferon|
48671285|NCT04636307|OTHER|Biomarkers|To identify biomarkers obtained using non-invasive procedures that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in NPDR.
48671286|NCT01814956|DRUG|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
48671287|NCT01814956|DRUG|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
48671288|NCT05698303|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
48671289|NCT00098800|DRUG|fenretinide|
48671290|NCT00712517|DRUG|propofol|propofol anesthesia 3-5mg/kg
48671291|NCT00712517|DRUG|sevoflurane|sevoflurane anesthesia
48358892|NCT06212518|OTHER|ATHLETE restricted fluid intake|Not permitted to drink during training session.
48358893|NCT01188785|DRUG|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
48358894|NCT00269685|DRUG|vasopressin|
48358895|NCT04211740|DRUG|OCH-NCNP1|OCH-NCNP1 3mg is supplied as granules and take orally once a week.
48358896|NCT04211740|DRUG|Placebo|Placebo is supplied as granules and take orally once a week.
48358897|NCT05663827|DRUG|Ruxolitinib|A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.
48358898|NCT04102657|OTHER|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
48671292|NCT00724100|DRUG|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
48671293|NCT02332928|DRUG|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
48671294|NCT02332928|DRUG|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
48358899|NCT04102657|OTHER|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
48358900|NCT04102657|OTHER|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
48358901|NCT04102657|OTHER|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
48507516|NCT05024864|DIAGNOSTIC_TEST|Urea breath test|"After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection. In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician."
48507517|NCT01236911|OTHER|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
48507518|NCT02837848|PROCEDURE|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
48507519|NCT02837848|PROCEDURE|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
48507520|NCT00767624|DRUG|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
47990200|NCT03232281|DRUG|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
47990201|NCT03296254|BEHAVIORAL|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
47990202|NCT03296254|BEHAVIORAL|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
47990203|NCT05376696|BEHAVIORAL|Set For Variability|This intervention will focus on training students to use a sound variation of grapheme correspondence rule in order to read an irregular spelling word correctly.
48358902|NCT00661362|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
48358903|NCT00661362|DRUG|Placebo|oral tablet, once daily for 24 weeks
48358904|NCT00661362|DRUG|Metformin|oral tablet, once daily for 24 weeks
48358905|NCT03224936|DEVICE|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
48358906|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
48358907|NCT00659009|OTHER|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
48358908|NCT00659009|OTHER|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
48358909|NCT05515653|GENETIC|Exposure to genetics (polygenic)|The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
48358910|NCT06502509|DIETARY_SUPPLEMENT|Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)|Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
48358911|NCT06502509|DIETARY_SUPPLEMENT|Lemon tea|Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
48358912|NCT04954976|OTHER|Orthodontic retention procedures survey|The survey was composed of eight parts, about sociodemographic status, retention system selection, choice of fixed and removable retention system, retention period, supervision, given instruction and needs for practice guidelines.
48358913|NCT00440232|DRUG|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
48358914|NCT00440232|DRUG|Placebo|Inert tab identical in appearance to Frovatriptan
48358915|NCT00657748|DRUG|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
48358916|NCT01172054|BIOLOGICAL|VAX128|one IM injection
48358917|NCT01172054|BIOLOGICAL|Placebo|One IM injection
48358918|NCT01633567|BEHAVIORAL|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
48358919|NCT01633567|BEHAVIORAL|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
48358920|NCT04581057|BIOLOGICAL|Specific blood sampling|"A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α"
48358921|NCT04450862|OTHER|Cognitive Behavioural therapy self help intervention for anxiety|"The intervention will involve five key components:~Psychoeducation - Increase awareness of how PH may affect emotional health, normalisation of difficulties, and discussion of how symptoms associated with anxiety may add to the burden of the disease.~Cognitions - Identify and challenge negative automatic thoughts associated with anxiety.~Coping skills - Educate and practice a range of behavioural coping methods to help participants better manage their physical symptoms associated with anxiety in PH.~Exposure - Replace avoidance of anxiety provoking situations and activities using graded exposure.~Relapse prevention - Focus on relapse prevention with implementation intentions and promotion of problem solving."
48358922|NCT00544193|DRUG|gemcitabine hydrochloride|
48358923|NCT00544193|GENETIC|polymerase chain reaction|
48358924|NCT00544193|OTHER|immunohistochemistry staining method|
48358925|NCT00544193|PROCEDURE|conventional surgery|
48358926|NCT00544193|RADIATION|intraoperative radiation therapy|
48358927|NCT00544193|RADIATION|radiation therapy|
48358928|NCT02422160|OTHER|No interventions are planned|No interventions are planned
48671295|NCT03627052|DRUG|Itacitinib|In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.
48671296|NCT03627052|DRUG|Placebo|Placebo administered orally twice daily in the double-blind period.
48671297|NCT01686113|OTHER|NEFA|
48147616|NCT01123005|PROCEDURE|PET Scan|radiation calculated per patient
48358929|NCT00327210|BEHAVIORAL|Blood Glucose Awareness Training|
48358930|NCT05786976|OTHER|Lotion BNO 3732|Crem body lotion twice daily
48358931|NCT05786976|OTHER|Body Lotion Benchmark product|Crem body lotion twice daily
48358932|NCT00027404|DRUG|Fluoxetine|
48358933|NCT03030092|OTHER|Maximal Strength Training|leg pres and abduction exercises
48358934|NCT04214470|OTHER|No intervention|There is no intervention for this study
48358935|NCT05956080|DIAGNOSTIC_TEST|Allergy testing|University Medicine Greifswald
48358936|NCT03703661|PROCEDURE|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
48358937|NCT03703661|PROCEDURE|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
48358938|NCT03484052|OTHER|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
48358939|NCT03272009|DRUG|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
48671298|NCT01686113|OTHER|Sucrose|
48671299|NCT03942224|DRUG|Bortezomib|Given SC
48671300|NCT03942224|BIOLOGICAL|Daratumumab|Given IV
48671301|NCT03942224|DRUG|Dexamethasone|Given IV and PO
48358940|NCT03272009|DRUG|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
48358941|NCT03272009|DRUG|Entecavir|Tablets administered orally
48358942|NCT03272009|DRUG|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
48358943|NCT03659695|DIETARY_SUPPLEMENT|Grape Powder|69 g/d freeze dried grape powder
48358944|NCT03659695|DIETARY_SUPPLEMENT|Placebo Powder|69 g/d placebo powder matched for taste and appearance
48358945|NCT01218061|OTHER|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):\* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)\* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
48671302|NCT03942224|DRUG|Ixazomib|Given PO
47990204|NCT05376696|BEHAVIORAL|Current Best Practices|This active control intervention will focus on training students to use grapheme-phoneme correspondence rules and sight words in the absence of set-for-variability component
47990205|NCT01371474|DRUG|Paroxetine|
48358946|NCT00111176|DEVICE|Endovascular repair|Endovascular repair.
47990206|NCT01358357|DRUG|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
47990207|NCT01358357|DRUG|Placebo|20-80 mg flexible dose
48358947|NCT00111176|PROCEDURE|Surgical|Surgical endovascular repair
48358948|NCT05750901|DEVICE|Fractional ablative laser|Fractional ablative laser used for treatment for skin laxity and tightening
48358949|NCT00654056|DRUG|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
48358950|NCT06005233|DEVICE|Smartwatch|Smartwatch with PPG- and 1-lead ECG derived analysis of cardiac arrhythmia. Analysis will be performed centrally at the Cardiology Core Lab at the Klinikum Rechts der Isar.
48358951|NCT04717856|OTHER|screening: HCV RNA test and risk factors questionaire|Screening by using a rapid finger prick test for HCV RNA and a questionnaire to assess risk factors.
48671303|NCT05385211|OTHER|Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency|Blood samplings; Glucose monitoring; CFTR variants
48358952|NCT00381706|BIOLOGICAL|cetuximab|given IV
48358953|NCT00381706|DRUG|ECF|epirubicin and 5-fluorouracil given IV
48358954|NCT00381706|DRUG|IC|cisplatin and irinotecan given IV
48358955|NCT00381706|DRUG|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
48358956|NCT01998854|DEVICE|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
48671304|NCT01881815|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
48671305|NCT06167226|DRUG|Personalized Ayurveda treatment protocol|The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
47990208|NCT06280573|COMBINATION_PRODUCT|Wim Hoff method|breathing exercises, cold exposure, and meditation
48147617|NCT01123005|DRUG|EF5|10 mCi, IV
48147618|NCT01123005|DRUG|Carbogen|Calculated per patient
48147619|NCT01123005|DRUG|Dichloroacetate|
48671306|NCT00110214|DRUG|docetaxel|Given IV
48671307|NCT00110214|OTHER|placebo|Given IV
48671308|NCT00110214|DRUG|prednisone|Given orally
48671309|NCT00110214|BIOLOGICAL|bevacizumab|Given IV
48671310|NCT00110214|OTHER|laboratory biomarker analysis|Correlative studies
48671311|NCT02268383|DRUG|Luspatercept|Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
48671312|NCT02343315|DEVICE|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~* Equipment- TENS (CEFAR Basic TENS Machine)~* Electrodes- Four channel electrode to cover the site of pain~* Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~* Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~* Frequency- 5 Hertz~* Duration- 30 minutes"
48147620|NCT01324648|BEHAVIORAL|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
48147621|NCT01324648|BEHAVIORAL|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
48147622|NCT01324648|OTHER|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
48147623|NCT00007306|DRUG|Parathyroid hormone ointment|
48147624|NCT05766566|PROCEDURE|Perianal fistula surgery|surgical treatment of the perianal fistula through curettage, closure with suture thread (vicryl 2/0) of the internal orifice and lipofilling of the passage with microfragmented autologous adipose tissue processed with the Lipogems® system.
48147625|NCT02060175|DEVICE|Cilotax drug-eluting stents implantation|
48358957|NCT03186079|DRUG|Xiaojidaozhi Decoction|Mixture of twelve Chinese herbal medicines granule
48147626|NCT02060175|DEVICE|DESyne drug-eluting stents implantation|
48147627|NCT03675282|DRUG|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
48147628|NCT03675282|DRUG|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
48358958|NCT03186079|DRUG|Placebo|Mixture of 10% Chinese herbal medicines granule and 90% artificial gum
48358959|NCT03186079|DRUG|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
48507521|NCT00767624|BEHAVIORAL|Desensitization Therapy for Insomnia|
48507522|NCT00767624|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|
48147629|NCT04557566|BEHAVIORAL|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
48507523|NCT03361930|DEVICE|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
48147630|NCT01470209|DRUG|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
48147631|NCT01470209|DRUG|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
48147632|NCT00038597|DRUG|SCH66336|
48358960|NCT03186079|BEHAVIORAL|Toilet training|Toilet training has been considered a routine method in treatment of constipation
48358961|NCT03862781|PROCEDURE|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
48507524|NCT05709535|DIAGNOSTIC_TEST|[18F]-PSMA-1007|\[18F\]PSMA-1007 is a diagnostic radiopharmaceutical for Positron Emission Tomography (PET) scan. The intervention involves single intravenous administration of \[18F\]PSMA-1007 for PET scan.
48507525|NCT04712981|BEHAVIORAL|HOPE|Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
48507526|NCT01716715|DRUG|Cabozantinib S-malate|Given PO
48507527|NCT01716715|OTHER|Laboratory Biomarker Analysis|Correlative studies
48507528|NCT01716715|DRUG|Paclitaxel|Given IV
48358962|NCT01700127|OTHER|Breastfeeding|breastfeeding encouraged versus withheld
48358963|NCT02705313|DRUG|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
48358964|NCT04056715|DEVICE|Zio XT|ambulatory cardiac monitoring device
48358965|NCT03725566|DRUG|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
48507529|NCT04249869|DRUG|VGH-AD1|VGH-AD1 includes Yi-gan-san 3.0g, Huan-shao-dan 1.0g, Danshen(Radix et Rhizoma Salviae Miltiorrhizae) 0.75g, Tian-ma(Rhizoma Gastrodiae) 0.75g, Gou-teng(Ramulus Uncariae Cum Uneis) 0.375g, and Ba-ji-tian(Radix Morindae Officinalis) 0.375g, two times per day, each serving a small packet of 7.5 grams of concentrated granules.
48507530|NCT02996487|DRUG|Vancomycin|
48507531|NCT02996487|OTHER|Placebo|
48507532|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 1
48358966|NCT02878135|PROCEDURE|fast application|
48358967|NCT02878135|PROCEDURE|slow application|
48358968|NCT01126385|DEVICE|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
48507533|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 2
48507534|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 3
48507535|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 4
48507536|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 5
48507537|NCT04187339|BIOLOGICAL|NGM395|NGM395 Dose 6
48507538|NCT04187339|OTHER|Placebo|Placebo
48507539|NCT06365918|DRUG|VG2025|Given by Intraperitoneal
48507540|NCT03471000|OTHER|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
48507541|NCT03471000|OTHER|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
48507542|NCT02750748|DRUG|Naltrexone|
48507543|NCT02750748|OTHER|Intravail|
48507544|NCT00002070|DRUG|Sargramostim|
48507545|NCT00002070|DRUG|Ganciclovir|
48507546|NCT04769414|DRUG|Gemcitabine fluorouracil|"chemotherapy protocol given as:~* Gemcitabine 1000mg/m2 IV short infusion~* Leucovorin 400 mg/m2 IV short infusion~* Flourouracil 400 mg/m2 direct IV shot~* Flourouracil 2000 mg/m2 contineous infusion over 46 hours~The whole regimen will be repeated bi-weekly"
48507547|NCT05113433|OTHER|conventional physical therapy|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session."
48507548|NCT05113433|OTHER|standing frame.|"muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty ."
48507549|NCT00620087|PROCEDURE|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
48671313|NCT02343315|OTHER|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
48507550|NCT00620087|PROCEDURE|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
48507551|NCT05316155|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
48507552|NCT02329535|DRUG|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
48507553|NCT06536140|OTHER|Home observations and interview|"If persons want to participate, the person will be invited one week before the first observation for a 'warm-up' phone call (W1) as a preparation for the three observations and follow-up interview.~During the observations, SH will be an active participant, offering to help with activities of daily life with the person, so opportunities are created to observe and ask questions (sensory ethnography). The person will be asked to take pictures or make drawings of important things in the house as the observer will be able to better understand how they feel about exercise and PA (visual ethnography). Six weeks after the last observation (W10), formal follow-up interviews (30-60 min) with questions based on the observations that took place, will be held to explore specific issues in-depth."
48507554|NCT05852561|OTHER|Group Superficial+Deep Serratus Anterior Plan Block|The block will be performed after induction of general anesthesia and surgical positioning. 15 ml of 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and latissimus dorsalis muscles. The same concentration of block fluid will be applied between the serratus anterior and the outer intercostal muscle.
48507555|NCT05852561|OTHER|Group Deep Serratus Anterior Plan Block|30 ml 0.375% Bupivacaine + epinephrine 5 µg/ml will be administered between the serratus anterior and outer intercostal muscle.
48507556|NCT00609999|DRUG|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected \& will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 \& at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib \& Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib \& Erlotinib given daily for 28 days for purpose of scheduling evaluations.
48507557|NCT04305353|OTHER|Diary (blank journal) plus PTSD psycho-education|A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
48507558|NCT04305353|OTHER|PTSD psycho-education alone|"We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015."
48507559|NCT06122376|DEVICE|U-shaped Power Toothbrush|Twice daily brushing for 30 seconds with fluoride toothpaste
48507560|NCT06122376|DEVICE|Soft Manual Toothbrush|Twice daily brushing for two minutes with fluoride toothpaste
48507561|NCT00235404|OTHER|Multicomponent treatment|Specialized care in preparing recharge to home
48507562|NCT00235404|OTHER|usual care|Usual recharge directly from hospital to home
48507563|NCT04154774|DRUG|Apalutamide|Apalutamide will be administered orally.
48507564|NCT05094089|DEVICE|Hernia repair with mesh|Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
48507565|NCT03490760|DRUG|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
48507566|NCT03490760|RADIATION|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
48507567|NCT04513366|DRUG|SEL-212 low-dose|IV infusion of SEL-212 low-dose every 28 days for a total of up to 12 infusions
48507568|NCT04513366|DRUG|SEL-212 high-dose|IV infusion of SEL-212 high-dose every 28 days for a total of up to 12 infusions
48507569|NCT04513366|OTHER|Normal Saline|IV infusion of Normal Saline every 28 days for a total of up to 12 infusions
48507570|NCT01040598|BIOLOGICAL|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
48507571|NCT05253963|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be used during the second night of polysomnography .
48507572|NCT01352416|DRUG|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
48507573|NCT01352416|DRUG|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
48671314|NCT02343315|OTHER|UHEP|"All the participants will receive the following treatments:~1. Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~2. Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~3. Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
48671315|NCT03431597|DIETARY_SUPPLEMENT|novel micronutrient|The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
48671316|NCT03431597|DIETARY_SUPPLEMENT|existing micronutrient supplement, UNIMMAP|UNIMMAP will be provided in tablet form and given one daily
48147633|NCT04947709|BEHAVIORAL|Physical Activity|The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
48147634|NCT04809701|PROCEDURE|Temporary implantation of defibrillation coils and pulse generator|Each subject will undergo temporary implantation of defibrillation coils and pulse generator according to the NV-ICD electrode configurations.
48147635|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration A first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration A. Then up to two defibrillation energies will be tested for Configuration B.
48147636|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration B first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration B. Then up to two defibrillation energies will be tested for Configuration A.
48147637|NCT04809701|PROCEDURE|Removal of defibrillation coils and pulse generator|Defibrillation coils and pulse generator will be removed from the subject after the defibrillation tests are completed.
48147638|NCT06344481|DEVICE|Surgical (Hyalex Cartilage Knee Implant)|Implantation of Hyalex Cartilage Knee Implant.
48147639|NCT02837419|BEHAVIORAL|Health related Quality of life EQ-5D|Quality of Care
48507574|NCT00191165|DRUG|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
48507575|NCT00191165|DRUG|Somatropin|In-label dosage
48507576|NCT02045589|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
48671317|NCT03256721|DRUG|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
48671318|NCT03256721|DRUG|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
48671319|NCT03294005|DIAGNOSTIC_TEST|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
48671320|NCT02194114|OTHER|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
48507577|NCT02045589|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
48507578|NCT02045589|DRUG|Abraxane®|125 mg/m2 intravenous administration
48507579|NCT00001110|PROCEDURE|Bronchoalveolar lavage|
48507580|NCT04410237|DEVICE|Med-Jet|"One half of each psoriasis plaque will be treated with a Med-Jet device and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using a conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
48507581|NCT04410237|OTHER|Traditional Syringe|"One half of each psoriasis plaque will be treated with a traditional syringe and Triamcinolone acetonide (TAC) while the control half will be untreated.~One side of the body will be treated using conventional syringe and the opposite side of the body will be treated using the Med-Jet needle-free injection device to verify efficacy, safety, and pain score"
48507582|NCT03390426|DRUG|Mepivacaine|An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
48358969|NCT04498585|OTHER|VR Stimulation|Participants in the intervention group will be provided with 30 minutes of relaxing, 360-degree virtual reality stimulation and corresponding sounds, three times a day (morning, midday, evening) everyday during their stay in the ICU, up to a maximum of 14 days.
48507583|NCT03390426|PROCEDURE|Perifemoral Injection of Local Anesthetic|An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
48507584|NCT03390426|DRUG|Saline|An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
48507585|NCT00516152|DRUG|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~  * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response"
48507586|NCT02667067|DEVICE|Simplify Disc|Simplify Disc at one level in the cervical spine.
48671321|NCT06185426|DRUG|Methyprednisolon and low level laser theraphy|All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.
48671322|NCT03952208|OTHER|Neurocognitive Testing|A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
48671323|NCT02663154|DRUG|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
48671324|NCT02663154|DRUG|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
48671325|NCT00901303|DRUG|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
47990209|NCT03852550|OTHER|e-health application|In the first part of this study, an e-health application (MyREADY Transition\[TM\] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
47990210|NCT03190161|BEHAVIORAL|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
47990211|NCT05175690|DIAGNOSTIC_TEST|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
47990212|NCT05243368|DIETARY_SUPPLEMENT|Personalized Nutritional Intervention|Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.
47990213|NCT03512314|DRUG|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
47990214|NCT01842256|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
47990215|NCT01842256|DRUG|atorvastatin 40mg|"* 1 Tablet (atorvastatin 40mg),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
48358970|NCT03870646|COMBINATION_PRODUCT|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
48147640|NCT05590026|DRUG|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
48671326|NCT04464551|DRUG|[14C]D-0316 suspension|Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
48507587|NCT02667067|DEVICE|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®\|C Disc trial."
48507588|NCT05151783|OTHER|conventional physiotherapy|"Control group receivewill routine physical therapy including modalities like ultrasound (3 MHz continuous type; duration 10 minutes), heat modalities (apply to the involved region of shoulder joint shoulder for 10 minutes), shoulder ROM exercises, capsular stretching, and joint mobilization 5 times per week for four weeks. Duration of session will be 40 minutes.~All Maitland mobilization will be given in supine position. After giving glenohumeral (GH) joint distraction, GH caudal glide, GH dorsal glide, and GH ventral glide were given at a rate of 2-3/second oscillations for 1-2 minutes to patients. Grade I or II rhythmic oscillations will be applied in pain free movement."
48507589|NCT05151783|OTHER|PNF technique|Group will receive scapular PNF techniques with routine physical therapy explained above For PNF techniques, patients will be lying on unaffected shoulder. In this group, 20 repetitions of diagonal scapular Pattern (Anterior Elevation and Posterior Depression and Posterior Elevation and Anterior Depression) with 20 sec rest period will be given to patients. Preparatory instructions for the desired movement will be given to patients at the start of procedure. PNF facilitation techniques of RI (Rhythmic initiation) \& repeated contractions will be used in all patterns
48147641|NCT02400528|BEHAVIORAL|quality of life questionnaires|
48671327|NCT03421184|OTHER|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
47990216|NCT04318990|PROCEDURE|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
47990217|NCT04318990|PROCEDURE|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
48671328|NCT03421184|OTHER|urine sample|10 ml
48671329|NCT03421184|OTHER|food questionnaire|dietary habit enquiry and a 48h dietary
47990218|NCT01447524|BEHAVIORAL|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
47990219|NCT04220008|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
47990220|NCT04220008|DRUG|Busulfan|Given IV
47990221|NCT04220008|DRUG|Clofarabine|Given IV
47990222|NCT04220008|DRUG|Cyclophosphamide|Given IV
47990223|NCT04220008|DRUG|Gemcitabine|Given IV
48147642|NCT00028600|BIOLOGICAL|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC \>= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC \> 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
48147643|NCT00028600|BIOLOGICAL|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
48147644|NCT00028600|DRUG|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
48147645|NCT00028600|DRUG|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
48671330|NCT03421184|OTHER|hair|lock of hair
48671331|NCT01606579|DRUG|PRI-724|PRI-724
48671332|NCT01606579|DRUG|PRI-724|PRI-724 in combination with dasatinib
48671333|NCT01606579|DRUG|PRI-724|PRI-724 in combination with low dose ara-C therapy
48671334|NCT04270422|OTHER|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
48671335|NCT04270422|OTHER|Usual physiotherapy|Usual evidence based physiotherapy
48671336|NCT00896012|PROCEDURE|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
48671337|NCT00896012|DRUG|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
48671338|NCT00896012|DRUG|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
48671339|NCT01445847|DRUG|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
48671340|NCT01445847|OTHER|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
48671341|NCT05221008|DRUG|SHR6508；Placebo|Group A:SHR6508 low dose
48671342|NCT05221008|DRUG|SHR6508；Placebo|Group B:SHR6508 medium dose
48671343|NCT05221008|DRUG|SHR6508；Placebo|Group C:SHR6508 high dose
48507590|NCT06360055|DRUG|Dabigatran Etexilate|Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
48507591|NCT06360055|DIETARY_SUPPLEMENT|D-mannose|Subjects will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
48507592|NCT00879411|DRUG|Micardis|
48671344|NCT05221008|DRUG|SHR6508；Placebo|Group D:SHR6508 high dose(single dose)
48671345|NCT00788814|BEHAVIORAL|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
48671346|NCT00735150|BEHAVIORAL|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
48671347|NCT03500211|DRUG|Lidoderm 5 % Topical Patch|Lidocaine patch after cesarean section delivery.
48671348|NCT03500211|OTHER|Sham Topical Patch|Sham patch after cesarean section delivery.
48671349|NCT04441697|DIAGNOSTIC_TEST|Multiple sleep latency tests|The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.
48671350|NCT05726149|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
48671351|NCT05726149|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
48671352|NCT05726149|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
48671353|NCT01132352|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
48671354|NCT05908162|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, subpopulation of monocytes and expression CD64 on neutrophils
47990224|NCT04220008|DRUG|Mycophenolate Mofetil|Given IV
47990225|NCT04220008|BIOLOGICAL|Rituximab|Given IV
48671355|NCT01165034|OTHER|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
47990226|NCT04220008|DRUG|Tacrolimus|Given IV
47990227|NCT04220008|DRUG|Vorinostat|Given PO
48147646|NCT00028600|DRUG|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
48147647|NCT00028600|DRUG|methotrexate|5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl
48147648|NCT00028600|DRUG|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
48147649|NCT00297713|DRUG|ALTU-238|
48147650|NCT04299022|OTHER|Vivigen Cellular Bone Matrix|Allograft bone matrix
48358971|NCT03870646|COMBINATION_PRODUCT|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
48358972|NCT05643287|PROCEDURE|Periodontal treatment|Non-surgical periodontal treatment
48507593|NCT03977714|DEVICE|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
48507594|NCT03977714|DEVICE|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
48507595|NCT03977714|DEVICE|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
48671356|NCT02972229|RADIATION|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
48671357|NCT02972229|RADIATION|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
48671358|NCT01459692|OTHER|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
48147651|NCT00325845|PROCEDURE|Synvisc viscosupplementation|
48671359|NCT06280248|PROCEDURE|Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst|"The technical success rates, clinical success rates, and potential complications of the different endoscopic ultrasound-guided techniques for the best drainage of pancreatic fluid collections (PFCs) as regard type, caliber, and number of plastic stents and the ideal timing for stent removal will be assessed.~Also compare early vs. late intervention for complete endoscopic necrosectomy of walled off pancreatic necrosis (WOPN ) as regard to technical success rates, clinical success rates, potential complications, and the number of sessions needed will be done.~In order to evaluate total resolution or a reduction in cyst diameters with clinically significant improvement in symptoms, patients will be monitored for one month and six months following the insertion of the stent."
48671360|NCT04734314|OTHER|conventional physical therapy|conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.
48358973|NCT00125268|DEVICE|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm\^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
48358974|NCT00125268|DEVICE|Sham Device|The sham device is non-active but otherwise identical to the study device.
48358975|NCT04912297|BIOLOGICAL|10-valent pneumococcal conjugate vaccine, PCV10|10-valent pneumococcal conjugate vaccine, PCV10
48358976|NCT01524094|DRUG|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
48358977|NCT01524094|PROCEDURE|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
48358978|NCT00837889|DRUG|diuretics, inotropica|
48358979|NCT03195231|DRUG|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
48358980|NCT03195231|DRUG|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
48358981|NCT06370065|DRUG|HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）|PD-1 inhibitor
48358982|NCT06326073|PROCEDURE|Non Surgical Periodontal Treatment|Phase 1 periodontal (full mouth debridement) treatment was applied to groups with periodontitis in one session.
48358983|NCT04851769|DRUG|PCSK9 inhibitor plus statin|Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).
48358984|NCT04851769|DRUG|standard statin therapy|Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.
48358985|NCT04851769|PROCEDURE|Coronary imaging follow-up|coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up
48671361|NCT04734314|OTHER|vojta therapy|"Vojta Dynamic Neuromuscular Stabilization (DNS) is a therapy used to manage neurological and musculoskeletal conditions each patient in the study group (group B) was instructed to lie prone on an examination table with the participant's shoulders abducted, elbows flexed approximately 80-90°, and the forearms hanging off the edge of the table. Pressure-like stimulation of the calcaneus and ASIS were performed in the postural position named by Vojta as reflex creeping.~Each patient received 12 sessions three session per week."
48671362|NCT00569933|BEHAVIORAL|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
48358986|NCT01985035|BEHAVIORAL|Diet|Reduction of energy intake in order to weight loss
48358989|NCT00492739|BIOLOGICAL|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
48358990|NCT06292429|OTHER|Complex Training|"Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw"
48671363|NCT03737552|OTHER|Polysomnography|Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
48671364|NCT02505425|BEHAVIORAL|Behavioral Support|"ENABLE CHF-PC includes:~1. In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~2. Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
48671365|NCT02505425|BEHAVIORAL|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
48358991|NCT06292429|OTHER|Conventional Training|"Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted"
48358992|NCT06292429|OTHER|Control Group|No intervention given
48671366|NCT06353503|PROCEDURE|autologous bone marrow aspirate concentrate|local knee joint injection of autologous bone marrow
48671367|NCT04781816|DRUG|SAR443122|Pharmaceutical form: Capsule Route of administration: Oral
48671368|NCT04781816|DRUG|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
48671369|NCT01345448|DRUG|Brimonidine|0.1% Brimonidine Lotion, dosed once.
48671370|NCT01345448|DRUG|Placebo Lotion|Placebo Lotion dosed once.
48671371|NCT01663311|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
48671372|NCT01663311|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
48671373|NCT02742129|DRUG|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
48671374|NCT02742129|DRUG|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
48671375|NCT02830243|DRUG|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
48671376|NCT02830243|DRUG|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
48671377|NCT04076332|OTHER|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
48671378|NCT04618588|PROCEDURE|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
48671379|NCT05687227|BEHAVIORAL|Online education and counseling|Online education and counseling regarding gynecological examination
48671380|NCT02280993|DRUG|DHAP|DHAP
48671381|NCT02280993|DRUG|Brentuximab Vedotin|Brentuximab Vedotin
48358993|NCT02668679|PROCEDURE|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
48671382|NCT02280993|OTHER|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
48671383|NCT02024854|BEHAVIORAL|skin-to-skin|
48671384|NCT02024854|BEHAVIORAL|standard care|
48671385|NCT05142306|BIOLOGICAL|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation
48671386|NCT03496168|DRUG|mavacamten|mavacamten capsules
48671387|NCT03010943|DEVICE|Virtual reality headset|Feasibility and tolerance
48671388|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
48671389|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
48671390|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
48671391|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
48671392|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
48358994|NCT02668679|DEVICE|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
48671393|NCT03206372|OTHER|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
48671394|NCT03206372|OTHER|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
48671395|NCT02554994|OTHER|Multifactorial intervention|"There are six components of intervention in this study.~* For all participants:~  1. Group exercise~ 2. Nutritional supplement(commercial liquid formula will be provided every day).~* For selected participants:~  1. Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~ 2. At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~ 3. Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
48671396|NCT02554994|OTHER|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
48671397|NCT03817489|BEHAVIORAL|Baduanjin qigong|The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.
48358995|NCT02668679|BIOLOGICAL|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
48358996|NCT02668679|OTHER|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
48358997|NCT02894606|DRUG|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
48671398|NCT03817489|BEHAVIORAL|Mindfulness meditation|The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
48671399|NCT05125744|DIAGNOSTIC_TEST|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
48671400|NCT00276432|DEVICE|iSTAT point of care analyzer|
48671401|NCT04280003|OTHER|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
48671402|NCT04280003|DRUG|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
48671403|NCT06332586|BEHAVIORAL|Diversified teaching|Diversified teaching (read and jointly mark the key points of the triage diagnosis teaching manual and read the TMS online course at any time, 1 triage diagnosis seminar/quarter, interactive teaching) for triage diagnosis nurses
48671404|NCT02116179|BEHAVIORAL|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
48671405|NCT02927444|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
48671406|NCT02927444|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
48671407|NCT06078475|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
48671408|NCT04236999|BEHAVIORAL|Yo Sé Lo Que Quiero (YSLQQ)|"This program is organized in 12 sessions around three themes:~* Knowledge and attitudes (sessions 1, 3, 5 and 9): Students reflect on their knowledge of legal and illegal drugs, using critical thinking to obtain an objective assessment of this knowledge.~* Intrapersonal skills (sessions 4, 6, 8, 10. 11. and 12): Activities are carried out where students can put themselves in everyday situations and develop skills such as assertiveness, problem solving, among others.~* Interpersonal skills (sessions 2 and 7): Students are instructed to practice refusal skills, assertiveness, and analyze coping strategies."
48507596|NCT03977714|DEVICE|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
48507597|NCT03977714|DEVICE|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
48671409|NCT00901225|DRUG|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
48671410|NCT02001129|BEHAVIORAL|Automated Telephone System|Participants receive automated reminder phone calls.
48671411|NCT02001129|BEHAVIORAL|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
48507598|NCT00735306|DRUG|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
48507599|NCT00735306|DRUG|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
48507600|NCT00735306|RADIATION|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
48507601|NCT04553874|OTHER||observational study without intervention
48671412|NCT02001129|BEHAVIORAL|Usual Care|Participants receive a standard reminder letter in the mail.
48671413|NCT01944020|DEVICE|CPAP|use of CPAP each night for 2 months
48671414|NCT06129019|BEHAVIORAL|Reiki|Reiki application will be done
48671415|NCT00519727|DRUG|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
48671416|NCT03156829|OTHER|Splint|Custom made splint
48671417|NCT03156829|DRUG|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
48671418|NCT03156829|COMBINATION_PRODUCT|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
48671419|NCT04161209|DRUG|Citalopram|Single dose administration of citalopram (20mg)
48671420|NCT04161209|OTHER|Placebo|Lactose placebo tablet
48671421|NCT06328842|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48671422|NCT06328842|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48671423|NCT03631264|DEVICE|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
48671424|NCT06375525|DEVICE|Janssen's icon Application (App)|
48671425|NCT04326062|OTHER|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
48671426|NCT04326062|OTHER|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
48671427|NCT05162690|DRUG|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
48671428|NCT05162690|OTHER|Placebo|Metformin DPP4 inhibitors
48671429|NCT04656405|OTHER|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
48671430|NCT04656405|OTHER|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
48671431|NCT04656405|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
48358998|NCT02894606|DRUG|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
48358999|NCT01176864|PROCEDURE|Double-balloon enteroscopy|Double-balloon enteroscopy
48507602|NCT00507130|BIOLOGICAL|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
48507603|NCT00507130|BIOLOGICAL|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
48507604|NCT00507130|BIOLOGICAL|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
48507605|NCT00507130|OTHER|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
48507606|NCT05352412|BEHAVIORAL|Shared Decision Making Aid|Patients will be randomized to the shared decision making aid intervention.
48359000|NCT01176864|PROCEDURE|Single-balloon enteroscopy|Single-balloon enteroscopy
48359001|NCT00333242|DRUG|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
48507607|NCT05352412|BEHAVIORAL|Baseline Counseling As usual|Patients will be randomized to the baseline counseling as usual.
48507608|NCT02226601|DRUG|Aprepitant|3 days perioperative Aprepitant once a day
48507609|NCT02226601|DRUG|Placebo|3 days perioperative Placebot once a day
48507610|NCT02877459|DEVICE|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
48671432|NCT04848402|DEVICE|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
48671433|NCT04848402|DEVICE|Single Auto Injector|Used to administer placebo SC.
47990228|NCT05938751|BEHAVIORAL|TEAm_YOUNG ADULTS program|The TEAm_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
48359002|NCT03040180|DRUG|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
48359003|NCT03040180|DEVICE|EndoVE|Electroporation using an endoscopic electroporation device
48359004|NCT02321163|DEVICE|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
48359005|NCT02321163|DEVICE|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
48359006|NCT02321163|DEVICE|NMES no stimulation|Placebo, electrode pad on, no stimulation
48507611|NCT06168123|BEHAVIORAL|Quality of life questionnaires will be assessed in addition to standard care|Quality of life questionnaires will be assessed in addition to standard care
48507612|NCT01143766|DRUG|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
48507613|NCT01143766|OTHER|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
48507614|NCT01723618|DRUG|CRD007|
48507615|NCT06174597|PROCEDURE|UCA-PSCs/bFGF or bFGF Intramuscular injection|After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
48507616|NCT01769560|BEHAVIORAL|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
48507617|NCT04130750|COMBINATION_PRODUCT|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
48507618|NCT00316095|DRUG|telmisartan|
48507619|NCT00316095|DRUG|simvastatin|
48507620|NCT06350916|BEHAVIORAL|SeamlessMD® Mobile Application|Mobile cloud-based applications (apps), such as SeamlessMD®, are readily accessible on smart phones and offer an innovative strategy to encourage and track patient adherence to recommended ERAS components pre- and postoperatively.
48507621|NCT01144247|DRUG|alloreactive CTL|cellular immunotherapy with alloCTL
48507622|NCT01814553|DRUG|afatinib|Daily treatment starting 40 mg per day
48507623|NCT01814553|DRUG|loperamide|Follow cohort assignment and diarrhea management guidelines
48507624|NCT04474444|OTHER|attendance by ambulance crew|hear, attendance, convey
48507625|NCT06633614|DEVICE|Supervised prehabilitation programme|Participants will receive standard preoperative physiotherapy education along with a Fitbit Aspire 3 wearable device to track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalized exercise program, supervised remotely by a physiotherapist via telemedicine twice a week. The program will include 20-minute sessions at least three times per week, focusing on strength training, aerobic exercises (at 40% of maximal heart rate), and flexibility exercises. Progress will be monitored through vital signs and workout data, with the physiotherapists adjusting the regimen as needed. Participants with low inspiratory pressure (MIP \&amp;lt;100 cmH₂O) will receive an Inspiratory Muscle Trainer (IMT). Additionally, some participants may be provided with a portable cycle pedometer featuring adjustable resistance. To ensure safety, both participants and caregivers will receive a safety briefing, and a 24-hour emergency hotline.
48507626|NCT06633367|OTHER|Increasing time in nature|This intervention includes requesting an increase in time spent outdoors, eligibility to receive a prize, and information on peer performance.
48507627|NCT01653301|DRUG|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
48507628|NCT01653301|DRUG|XELOX RT|"* Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
48671434|NCT04848402|DRUG|Placebo|Administered SC.
48671435|NCT03383042|DRUG|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
48671436|NCT03383042|DRUG|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
48671437|NCT03383042|DRUG|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
48671438|NCT03383042|DRUG|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
48671439|NCT03383042|DRUG|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
48671440|NCT03383042|DRUG|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
48671441|NCT03383042|DRUG|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
48359007|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
48359008|NCT03557801|BEHAVIORAL|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
48671442|NCT03383042|DRUG|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
48671443|NCT03383042|DRUG|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
48671444|NCT02764411|DRUG|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
48359009|NCT03557801|OTHER|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
48359010|NCT04034342|OTHER|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
48359011|NCT00153452|BEHAVIORAL|perpetration of intimate partner violence|
48359012|NCT05613244|OTHER|Phone call|Patients will be asked to complete a questionnaire via a phone call
48359013|NCT03961529|DRUG|0.3% OPA-15406 ointment|Twice daily
48359014|NCT03961529|DRUG|1% OPA-15406 ointment|Twice daily
47990229|NCT05318599|DEVICE|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
48359015|NCT02005679|BEHAVIORAL|application of the mini-mental state test|
48507629|NCT05927948|DEVICE|Laight therapy, NICE V3.1 device|Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
48671445|NCT03672149|DRUG|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
48671446|NCT02121509|DRUG|Linagliptin|1 x Linagliptin tablet
48671447|NCT02121509|DRUG|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
48671448|NCT02121509|DRUG|Metformin ER|3 x Metformin ER tablets
48671449|NCT02435654|DRUG|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
48671450|NCT01507701|DRUG|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
47990230|NCT05318599|DEVICE|Lung ultrasound|Lung ultrasonography
47990231|NCT05318599|OTHER|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
47990232|NCT05318599|DIAGNOSTIC_TEST|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
47990233|NCT03541018|PROCEDURE|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
48507630|NCT03414086|OTHER|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
48507631|NCT03414086|OTHER|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
48507632|NCT06413043|DRUG|Selenium|Add on Selenium (100mcg once daily) with Vitamin B Complex and Standard Treatment for Grave's Disease
48507633|NCT00183560|BEHAVIORAL|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
48507634|NCT00183560|DRUG|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
48507635|NCT00183560|DRUG|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
48507636|NCT05222698|PROCEDURE|Facial reanimation surgery by free muscle trasfer.|Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
48507637|NCT06075953|DRUG|Tamoxifen|For premenopausal women: 20 mg or 5 mg tamoxifen orally for postmenopausal women: For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (5 mg) or standard dose (20 mg) of tamoxifen
48507638|NCT06075953|DRUG|Exemestane|for postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
48507639|NCT06075953|DRUG|Letrozole|for postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily,
48507640|NCT06075953|DRUG|Anastrazole|for postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily;
48507641|NCT06075953|DRUG|Testosterone + Anastrazole|Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
48507642|NCT06075953|DRUG|Elacestrant|Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
48507643|NCT06075953|DRUG|Z-endoxifen|Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
48507644|NCT04416165|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
48507645|NCT06633653|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
48507646|NCT05044312|OTHER|Sleeping Disturbances|most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
48671451|NCT05007548|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
48671452|NCT05523284|DIAGNOSTIC_TEST|SonoPODography|SonoPODography (SPG) is a novel ultrasound-guided technique whereby saline is injected through the cervix and flushed into the POD, creating an acoustic window for diagnosing superficial endometriosis.
47990234|NCT04826146|DEVICE|Validation of qCON versus BIS|Correlation between qCON and BIS values (main outcome) and qNOX and MOAA/S scale are determined
47990235|NCT02220582|OTHER|MRI|Magnetic Resonance Imaging
47990236|NCT00708162|DRUG|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
47990237|NCT00708162|DRUG|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
47990238|NCT00708162|DRUG|EVG placebo|Placebo to match elvitegravir administered orally once daily
48507647|NCT04480021|BEHAVIORAL|MITHRA|A mobile based application (app) in CBOs to screen, track and treat mild to moderate depression among low income women using Healthy Activity Program (HAP),a WHO-recommended evidence-based intervention.
48507648|NCT04480021|BEHAVIORAL|EUC|Group education on depression by community health workers
48507649|NCT00492986|DRUG|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
48507650|NCT06548815|DRUG|GZR4|Ascending single doses - 4 dose levels.
48507651|NCT06548815|DRUG|Placebo|Ascending single doses - 4 dose levels.
48507652|NCT01335334|DRUG|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
48507653|NCT06246799|DRUG|Tirzepatide|Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
48507654|NCT06246799|DRUG|Pioglitazone|Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
48507655|NCT06246799|DRUG|Sitagliptin|Sitagliptin: will be administered as a 100mg dose once daily.
48147652|NCT05842330|DRUG|Concerta|"Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d).~The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.~The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release."
48147653|NCT05842330|DRUG|Placebo|"The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm."
48147654|NCT02035852|OTHER|MRI|3T MRI vs. 7T MRI
48359016|NCT02352181|PROCEDURE|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if fibrinogen \<1gram per liter~Platelet concentrate :~* if platelets \<50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~* if platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~* if prothrombin\<40% before transfusion at anhepatic phase or in case of bleeding.~* if prothrombin\<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
48507656|NCT06246799|DRUG|Metformin HCI XR|Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
48507657|NCT04207463|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
48507658|NCT04207463|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
48507659|NCT06260124|OTHER|Slow tempo|A single Greek traditional dance of slow tempo lasting 3-4 minutes.
48507660|NCT06260124|OTHER|Moderate tempo|A single Greek traditional dance of moderate tempo lasting 3-4 minutes.
48507661|NCT06260124|OTHER|Fast tempo|A single Greek traditional dance of fast tempo lasting 3-4 minutes.
48507662|NCT03803787|DRUG|Inhaled budesonide|Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
48507663|NCT04749238|DEVICE|NucleoCapture device|Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
48507664|NCT06369233|DEVICE|MegaShield®-SP|MegaShield®-SP application Lumbar discectomy or laminectomy
48507665|NCT06369233|DEVICE|Guardix-SP Plus|Guardix-SP Plus application Lumbar discectomy or laminectomy
48507666|NCT05297578|BIOLOGICAL|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
48147655|NCT03077958|PROCEDURE|Total Knee Replacement (2 different design)|Patients will randomely receive either Attune or PFC Sigma TKR
48147656|NCT03137732|DEVICE|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
48147657|NCT02362789|BIOLOGICAL|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
48147658|NCT02362789|BIOLOGICAL|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
48147659|NCT00003240|DRUG|cisplatin|
48147660|NCT00003240|DRUG|ifosfamide|
48147661|NCT00003240|DRUG|mitomycin C|
48147662|NCT00003240|DRUG|vinblastine sulfate|
48147663|NCT00003240|DRUG|vindesine|
48147664|NCT00003240|DRUG|vinorelbine tartrate|
48147665|NCT00003240|PROCEDURE|conventional surgery|
48147666|NCT00003240|RADIATION|radiation therapy|
48147667|NCT02386085|PROCEDURE|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
48147668|NCT06471153|BEHAVIORAL|Empowerment Program Based on BASNEF Model|Initially, the researcher established rapport with children of both groups and their gradians, screened them for the eligibility criteria, explained the aim of the study, the duration and nature of the training sessions, and obtained informed assent. The researcher established the session objectives and learning activities and prepared the learning materials. The researchers also prepared the learning environment. The Empowerment program is implemented in accordance with the BANCEF model for behavior transformation into four educational sessions. After the intervention, children's nail-biting knowledge, practice, attitude, and self-efficacy were reassessed.
48507667|NCT05297578|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
48507668|NCT01831401|PROCEDURE|Operating table position 0° head down (Horizontal)|
48147669|NCT06471153|BEHAVIORAL|Routine Health Education|Children in the control group received routine health education about the problems of nail-biting and routine advice to quit nail-biting.
48147670|NCT05351788|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
48147671|NCT05351788|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
48359017|NCT02352181|PROCEDURE|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin \<9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM \<8 mm~Platelet concentrate :~* If MCF EXTEM \<40mm or A10\<35 mm and MCF or A10 FIBTEM \>8mm.~* If platelets \<30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~  2 Fresh frozen plasma if CT EXTEM \>100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~* if fibrinolysis in EXTEM~* Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes \>15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
48359018|NCT00829010|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
48359019|NCT00829010|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
48359020|NCT00829010|BIOLOGICAL|measles|Intramuscular injection, 2 doses
48359021|NCT00829010|BIOLOGICAL|Rotarix|Oral, 2 doses
47990239|NCT00708162|DRUG|RAL placebo|RAL placebo administered orally twice daily.
48507669|NCT01831401|PROCEDURE|Operating table position 7° head down.|
48147672|NCT05351788|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
48147673|NCT05351788|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
48147674|NCT06405386|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
48359022|NCT00829010|BIOLOGICAL|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
48507670|NCT01831401|PROCEDURE|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
48507671|NCT01831401|DEVICE|Standard straight acetabular component introducer without alignment guide.|
48507672|NCT01831401|DEVICE|Modified 35° acetabular component introducer.|
48147675|NCT06405386|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
48147676|NCT06418919|PROCEDURE|Radiofrequency ablation treatment|RFA is used to ablate the entire thyroid gland
48507673|NCT01831401|DEVICE|Inclinometer-assisted acetabular component introducer.|
47990240|NCT00708162|DRUG|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
47990241|NCT04185246|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
48507674|NCT05194098|DEVICE|TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil|Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes
48359023|NCT01156246|DRUG|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
48359024|NCT01172795|BEHAVIORAL|Relaxation session|30 minutes relaxation session (audiotape)
48359025|NCT01172795|BEHAVIORAL|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
48359026|NCT00529152|DRUG|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
48507675|NCT05194098|DEVICE|SHAM (inactive) TMS stimulation|Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
48507676|NCT04842786|OTHER|Coconut oil|Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
48507677|NCT04208958|BIOLOGICAL|VE800|VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under Good Manufacturing Practice (GMP) conditions. These strains were selected for their ability to induce an immune response.
48507678|NCT04208958|DRUG|Nivolumab|Nivolumab is an approved medication that blocks antibodies for certain types of cancer.
47990242|NCT04185246|DIAGNOSTIC_TEST|Echocardiogram|Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
48507679|NCT04208958|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection.
48507680|NCT06412679|BEHAVIORAL|Life Skills Education|The RESETTLE-IDPs study compares two innovative delivery approaches for a culturally-adapted life skills education (LSE) intervention aimed at improving the mental health and well-being of internally displaced persons in Nigeria. The interventions are distinguished by their mode of delivery (in-person vs. WhatsApp-based), their focus on peer support and skill-building, and their tailoring to the specific needs and challenges of IDP populations.
48507681|NCT05189444|DRUG|Vonoprazan|20mg bid
48507682|NCT05189444|DRUG|Amoxicillin|0.75g tid
48147677|NCT04506047|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
48147678|NCT02033174|OTHER|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
48147679|NCT02033174|OTHER|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
48147680|NCT02793752|OTHER|Age|Maternal Age
48359027|NCT00412295|DEVICE|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
48359028|NCT03527927|DRUG|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
48507683|NCT05189444|DRUG|Esomeprazole|20mg bid
48147681|NCT00505024|BEHAVIORAL|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
48147682|NCT00505024|OTHER|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
48147683|NCT06593210|BIOLOGICAL|Adjuvant, non-live RSV vaccine|One dose of arexvy vaccine to transplant recipients.
48147684|NCT03845088|PROCEDURE|temporomandibular jont reconstruction with costochondral transplantation|temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
48359029|NCT04297124|DRUG|CC-90009|0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose
48359030|NCT04297124|RADIATION|[14C]|A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
48359031|NCT01048164|PROCEDURE|Massage|Chair Massage
48507684|NCT05189444|DRUG|Amoxicillin|1.0g bid
48507685|NCT05189444|DRUG|Clarithromycin|0.5g bid
48507686|NCT05189444|DRUG|Bismuth potassium citrate|0.22g bid
48507687|NCT02552303|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
48507688|NCT02552303|DRUG|Armodafinil|Active medication
48507689|NCT02552303|DRUG|Placebo|Placebo for Nuvigil (armodafinil)
48147685|NCT00375388|DRUG|Metformin on top of intensive insulin therapy|
48147686|NCT05901688|OTHER|Umbilical cord measurements & observations|"In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~1. Umbilical cord coiling index (UCI)~2. Transverse diameter of umbilical cord (UC)~3. Transverse diameter of umbilical vein (UV) and artery (UA)~4. Umbilical vein (UV) Doppler flow characteristics~5. Presence of nuchal cord"
48147687|NCT01792505|BIOLOGICAL|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
48147688|NCT06092736|DRUG|Compound Danshen Dropping Pills|Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
48147689|NCT06092736|DRUG|Placebo|placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
48147690|NCT06462989|DEVICE|ECHONEXT|ECHONEXT Artificial intelligence algorithm
48147691|NCT04210830|DIAGNOSTIC_TEST|Quantra-Device|Point of Care Coagulation Monitoring System
48147692|NCT02211872|DRUG|BI 2536 BS, intravenous|
48507690|NCT02335983|DRUG|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
48507691|NCT02335983|DRUG|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
48147693|NCT05463302|DEVICE|Active sleepgift blanket|Participants for group1 will be provided with real/active sleepgift blanket first for 10 consecutive nights and then cross over.
48147694|NCT05463302|DEVICE|Sham Sleepgift Blanket|Participants for group 2 will be provided with sham sleepgift blanket for 10 consecutive nights and then cross over.
48359032|NCT03103464|OTHER|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
48147695|NCT05553730|BEHAVIORAL|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
48147696|NCT02379975|PROCEDURE|Non-surgical Periodontal Therapy|
48147697|NCT05963113|BEHAVIORAL|Pharyngeal Swallowing Exercises|12-weeks of proactive pharyngeal swallowing exercises conducted 5 times per week. The exercise program will include the following four exercises: effortful saliva swallows, tongue-hold swallows, effortful pitch glides and posterior lingual resistance. Each exercise set will include 10 repetitions of each exercise (40 reps per set). The number of sets will be gradually increased as tolerance builds.
48147698|NCT05963113|DIETARY_SUPPLEMENT|Protein Supplementation|12-week supply of the commercially-available Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink). Participants will be asked to consume one drink per day for the 12-week intervention period.
48147699|NCT05963113|DEVICE|MRI|Participants will be scanned using a 3T MRI scanner and a 16-channel phased array neck coil.
48147700|NCT06073470|DRUG|methylphenidate|The patients with ADHD will receive 12-week treatment with methylphenidate.
48507692|NCT02335983|DRUG|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
48359033|NCT03103464|OTHER|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
48359034|NCT06102993|OTHER|Non-interventional study|The only intervention is to analyze serum molecules of patients with COPD and controls without COPD.
48507693|NCT03518801|BEHAVIORAL|Prolonged Exposure|psychotherapy
48507694|NCT03518801|DRUG|Cannabidiol|active medication
48507695|NCT03518801|DRUG|placebo|non-active medication
48507696|NCT01312571|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
48507697|NCT01312571|BEHAVIORAL|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
48507698|NCT03910387|DRUG|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
48507699|NCT03910387|DRUG|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
48507700|NCT03910387|DRUG|Telotristat Ethyl|Given PO
48507701|NCT01960049|PROCEDURE|ropivacaine + iv PCA|
48507702|NCT01960049|PROCEDURE|saline and IV PCA|
48671453|NCT02457026|DRUG|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
48671454|NCT02457026|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
48671455|NCT02457026|DRUG|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
48147701|NCT03483714|PROCEDURE|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
48671456|NCT05434819|PROCEDURE|Surgical Atrial Fibrillation Ablation|Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.
48147702|NCT00807079|DRUG|carboplatin|
48671457|NCT04221633|BEHAVIORAL|Enhancing Early Engagement (E3) webinar|Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
48147703|NCT00807079|DRUG|topotecan hydrochloride|
48507703|NCT06549855|DRUG|Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)|"1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day"
48671458|NCT04221633|BEHAVIORAL|Consultation for E3 training|10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
48671459|NCT00827957|DEVICE|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
48671460|NCT00827957|DEVICE|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
48671461|NCT01128569|DRUG|Fluticasone Furoate|FF
47990243|NCT06520930|BEHAVIORAL|breathing exercise therapy|Description: The breathing exercises to be applied were taught to each pregnant woman face to face with one-on-one training. The taught practice was then repeated by the pregnant woman and the researcher together. In the next step, pregnant women were asked to perform the application themselves. In this way, it was determined whether individual breathing exercise practices were performed correctly and effectively. After the one-on-one training was completed, the pregnant women were divided into groups of maximum six people and breathing exercise exercises were performed 7 days a week, once a day and once a week face-to-face for 8 weeks. Each session lasted approximately 45 minutes. For 8 weeks, a short reminder message was sent to pregnant women every morning to ensure that they did not interrupt their daily breathing exercise practices, and they were called in the evening to check whether they had performed the application correctly and whether they had any problems.
48147704|NCT00408109|DRUG|VRC-AVIDNA036-00-VP|
48671462|NCT01128569|DRUG|FF/Vilanterol (VI; GW642444M)|FF/VI
48147705|NCT02832830|RADIATION|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
48147706|NCT02832830|RADIATION|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
48147707|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
48147708|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
48507704|NCT05597150|DIETARY_SUPPLEMENT|Magnesium Citrate|Each participant should receive a high-magnesium diet for 1-3 weeks and take magnesium supplements for 4-6 weeks.
48671463|NCT01128569|DRUG|Placebo|Placebo Inhaler
48671464|NCT05791214|OTHER|score|Creation and validation of new nurse' score in ICU
48671465|NCT02197572|DRUG|Sapanisertib|Sapanisertib capsules.
48671466|NCT03358030|DRUG|ISIS 416858|Subcutaneous injection
48671467|NCT03358030|DRUG|Placebo|Subcutaneous injection
48671468|NCT03361488|OTHER|Trained anesthesiogist|
48671469|NCT05691387|BEHAVIORAL|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
48147709|NCT02841020|PROCEDURE|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
48507705|NCT04965077|DRUG|Recombinant Humanized Monoclonal Antibody MIL97 for Injection|"Dose escalation phase: The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL97 every 3 week on Day 1 of each cycle. Additional 1 or 2 dose cohorts will receive an intravenous infusion of MIL97 every 2 week on Day 1 of each cycle after last patient finishes DLT observation period.~Dose expansion phase: One or two recommended expansion doses (either Q3W or Q2W) will be selected from 6 dose groups (0.01mg/kg, 0.03mg/kg, 0.1mg/kg, 0.2mg/kg, 0.3mg/kg 0.45mg/kg) based on results of dose escalation phase. MIL97 will be administered via intravenous infusion for 60 to 90 minutes on Day 1 of each cycle."
48671470|NCT05691387|BEHAVIORAL|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
47990244|NCT03092531|BEHAVIORAL|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
47990245|NCT00994292|DRUG|YM150|oral
48147710|NCT03544047|DRUG|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
48147711|NCT02428595|DEVICE|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
47990246|NCT00994292|DRUG|Placebo|oral
48147712|NCT00924833|DRUG|placebo|placebo tablet BID
48671471|NCT01767896|BIOLOGICAL|ASP7374|subcutaneous (sc)
48671472|NCT01767896|BIOLOGICAL|approved egg-derived TIV|subcutaneous (sc)
48147713|NCT00924833|DRUG|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
48147714|NCT00924833|DRUG|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
48147715|NCT06103877|BIOLOGICAL|AZD1163|"In Part 1, Participants will receive AZD1163 through IV infusion or SC injection on Day 1.~In Part 2, participants will receive AZD1163 through SC injection on Days 1 and 15."
48147716|NCT06103877|OTHER|Placebo|"In Part 1, Participants will receive matching placebo through IV infusion or SC injection on Day 1.~In Part 2, participants will receive matching placebo through SC injection on Days 1 and 15."
48147717|NCT03867656|OTHER|GLP-2|GLP-2 injection
48147718|NCT03867656|OTHER|GIP|GIP injection
48147719|NCT03867656|OTHER|Placebo|Placebo injection
48147720|NCT05602272|PROCEDURE|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
48147721|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
48359035|NCT02365740|OTHER|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
48507706|NCT02810379|PROCEDURE|written informed consent|
48507707|NCT02810379|PROCEDURE|video+written informed consent|
47990247|NCT02630355|OTHER|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
48359036|NCT02365740|OTHER|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
48359037|NCT02365740|OTHER|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
47990248|NCT06005142|DIETARY_SUPPLEMENT|Eriomin|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day capsule of Eriomin for 12 weeks.
47990249|NCT06005142|DIETARY_SUPPLEMENT|Washout|After 12 weeks of treatment with the active component (Eriomin) or placebo, the participants will follow a washout for 2 weeks.
47990250|NCT06005142|DIETARY_SUPPLEMENT|Placebo|Pre-diabetic patients on oral biguanide (metformin) (1000 mg/day) will receive a 250 mg/day placebo capsule for 12 weeks.
47990251|NCT01882374|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
47990252|NCT03839212|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
48147722|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
48147723|NCT04028518|DRUG|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
48147724|NCT01297088|DRUG|BAY86-9596|One single dose administration of a diagnostic agent
48147725|NCT03998956|PROCEDURE|CPVI|Circumferential PV isolation only
48147726|NCT03998956|PROCEDURE|CPVI+BOX|Circumferential PV and BOX isolation
48147727|NCT03998956|PROCEDURE|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
48147728|NCT06585124|DIAGNOSTIC_TEST|Flow Cytometry|Study of t cell population in flow cytometry
48147729|NCT02973932|BEHAVIORAL|Cognitive-bahavioral psychotherapy|
48507708|NCT04840537|PROCEDURE|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP|endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure for exploration of an indeterminate biliary stenosis and biliary drainage
48507709|NCT03906578|DIETARY_SUPPLEMENT|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
48507710|NCT03906578|OTHER|Placebo|Placebo with similar appearance to probiotic
48507711|NCT05198518|DEVICE|Microcurrent TENS device|The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
48507712|NCT05198518|DEVICE|Sham Device|The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
48507713|NCT01655576|PROCEDURE|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
48507714|NCT02294461|DRUG|Enzalutamide|Oral
47990253|NCT03839212|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
48147730|NCT05495633|OTHER|Collection and evaluation of clinical (CROMs) and patient-reported outcomes (PROMs)|"The study uses a web-based German-language registry database called heartbeat ONE by heartbeat medical solutions GmbH (Berlin, Germany) that provides both clinical reported outcome measures (CROMs) and patient-reported outcome measures (PROMs). PROMs are investigated by validated questionnaires: IPSS/QoL, ICIQ-MLUTS, MSHQ, ICIQ-MLUTSsex, QoR-15GE, PROMIS Global Health 10, ICIQ-S, NRS, and by home urine flow measurement (iUFlow) as well as by self-designed questionnaires to assess patients´ preferences and expectations for Rezum and for surgical therapy of the prostate, satisfaction with the Rezum therapy, side effects of the Rezum therapy, (re)medication to treat BPO and LUTS, and reoperations after Rezum therapy."
48359038|NCT02365740|DRUG|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
48359039|NCT02365740|DRUG|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
48359040|NCT05008302|PROCEDURE|hand motor coordination in a sitting positin|Before each test, the patient was instructed on how the exercise should be done. The test consisted of two motor tasks, carried out in two different starting positions: sitting and lying down (supine). During the first examination, the subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction, with the elbow bent in the intermediate position between pronation and supination of the forearm. In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position).
48359041|NCT03820804|OTHER|Diet|A specific dietary treatment for patients with Phenylketonuria.
48507715|NCT02294461|DRUG|Placebo|Oral
48507716|NCT03796494|PROCEDURE|Straight abutment|This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
48507717|NCT03796494|PROCEDURE|Slim abutment|This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
48507718|NCT02724371|DEVICE|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
48671473|NCT03946969|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.
47990254|NCT03839212|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
47990255|NCT03839212|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
47990256|NCT03619187|DRUG|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
47990257|NCT05877794|DEVICE|central venous catheter insertion|All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
47990258|NCT00132184|DRUG|Vitamin D|
47990259|NCT00343200|DRUG|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
47990260|NCT00343200|DRUG|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
47990261|NCT05762003|DRUG|interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab|Administered as part of routine clinical practice.
47990262|NCT06250985|OTHER|Timing of reimplantation|Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
47990263|NCT02447081|DEVICE|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
48147731|NCT05495633|OTHER|Analysis of uroflowmetry data by Kesem Health iUFlow medical uroflowmetry device|If patients have a smartphone with app function (Android or Apple), they will be provided with a certified and approved home uroflowmetry medical device (iUFlow from Kesem Health) at study entry. This should enable patients to measure their urine flow conveniently from home and thus be independent of the medical consultation (automated home bladder monitoring solution). iUFlowTM is marketed by Kesem Health Pty Ltd, 5A Hartnett Cl, Mulgrave VIC 3170, Australia. The Device is FDA and CE approved and is approved to be used in the EU and Switzerland. Every time a patient is using the device urine flow measurement data and additional voluntary parameters entered by the patient (micturition protocol, drinking protocol) will be sent to the study database.
48147732|NCT03956927|OTHER|S-TPE|S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
48671474|NCT03946969|DRUG|Liposomal Paclitaxel + Cisplatin + S-1|Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
48147733|NCT03956927|OTHER|Questionnaires|Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
48147734|NCT05173766|OTHER|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
48147735|NCT04518306|DRUG|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg|Oral tablets
48147736|NCT04518306|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Oral tablets
48147737|NCT04518306|DRUG|Placebo|Placebo
48147738|NCT01117285|OTHER|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
48147739|NCT01117285|OTHER|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~* 3-day post-graduate course~* 2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~* Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~* Discussion platform~* Web-based registration system: Provides guidance in using the COTiD program for every individual client.~* Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~* Information on the COTiD program through a website and newsletters.~* Motivational reminders."
48671475|NCT03210701|OTHER|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
48147740|NCT00663429|DRUG|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
48147741|NCT00568087|DRUG|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
48147742|NCT00568087|DRUG|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
48147743|NCT05990556|PROCEDURE|interventional procedure to block bilateral meningeal blood supply|"The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging."
48671476|NCT04024826|BEHAVIORAL|EFP|This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
48671477|NCT04024826|BEHAVIORAL|LFP|This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
48671478|NCT04024826|BEHAVIORAL|ELP|This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
48671479|NCT04024826|BEHAVIORAL|LLP|This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase
48671480|NCT05809388|BEHAVIORAL|Parent training|"Parent Training program according to Ten steps of Barkley's program plus two additional follow-up sessions. This will be conducted by a trained psychologist; each session will last approximately 60 minutes and will includes exercises, discussions and role-playing."
48359042|NCT03820804|DRUG|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
48507721|NCT06218576|OTHER|None, purely observational study|None, purely observational study
48671481|NCT05809388|BEHAVIORAL|Virtual Reality-assisted PT sessions|"The experimental group will follow the same program of CG sample. Parent Training sessions will be conducted by a trained psychologist; each session will last approximately 60 minutes that include:~* 40 minutes of as usual PT session, with exercises, discussions and role-playing.~* 20 minutes of VR screen with which the parents may interact; VR screen will provides instructive, stimulating, interactive, and direct feedbacks exercises to enhance parenting strategies."
47914345|NCT04207619|OTHER|hyperinsulinemic-hypoglycemic clamp|An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.
48147744|NCT06415825|BEHAVIORAL|Standard advice and Preliminary muscle contraction|The maneuver groups will receive standard advice and an additional one - preliminary contraction of the muscles in the corresponding kinesiology segment. This advice will be embedded in all motor activities of daily living involving the relevant area.
48147745|NCT06415825|BEHAVIORAL|Standard advice|Standard advice includes avoiding heavy physical activity, sudden and unexpected loads, repetitive and prolonged overloads, and long periods of hypomobility.
48147746|NCT01480258|BIOLOGICAL|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis \[acellular, component\], hepatitis B \[recombinant DNA\], polio virus \[inactivated\], and Haemophilus influenza type b conjugate vaccine \[adsorbed\]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
48359043|NCT01796795|DRUG|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
48671482|NCT04095052|DIETARY_SUPPLEMENT|Methyl Folate|1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
48671483|NCT04095052|DIETARY_SUPPLEMENT|Placebo|Microcrystalline Cellulose capsule
48671484|NCT06546475|DRUG|N-Acetylcysteine|regular dose or high dose add-on
48671485|NCT04707092|DRUG|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
47990264|NCT01622699|DEVICE|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
47990265|NCT01622699|OTHER|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
47990266|NCT06021015|DEVICE|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
47990267|NCT06021015|DEVICE|Irinotecan and HepaSphere Microspheres|Irinotecan and HepaSphere Microspheres
48671486|NCT02268643|OTHER|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
48671487|NCT05989776|BEHAVIORAL|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
47990268|NCT03688750|OTHER|no intervention|
47990269|NCT02755324|BIOLOGICAL|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
47990270|NCT02607891|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
47990271|NCT02607891|DRUG|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
47990272|NCT04278547|DIAGNOSTIC_TEST|ELISPOT IFN-γ assay|"ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of low risk will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a high risk ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available."
47990273|NCT03980457|DEVICE|Indego Exoskeleton|Powered generated orthosis
48359044|NCT01796795|DRUG|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
48359045|NCT01796795|DRUG|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
48507722|NCT06379724|DRUG|Tranexamic acid|100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.
48507723|NCT06379724|DRUG|Thrombin JMI|The wound base is then sprayed with a film of Thrombin-JMI
48147747|NCT01480258|BIOLOGICAL|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
48507724|NCT06379724|PROCEDURE|skin graft|Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.
48671488|NCT02972710|OTHER|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
48147748|NCT01480258|BIOLOGICAL|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
48507725|NCT04034407|PROCEDURE|Damage control surgery|"All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis."
48507726|NCT03781401|DEVICE|Ambulatory blood pressure monitoring|
48507727|NCT03645707|BEHAVIORAL|CAR Training and Psychoeducational Sessions|"Participation in the CAR Training Program, a 1-day training program developed by the J\&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions."
48507728|NCT01893346|DRUG|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
48507729|NCT02794597|BEHAVIORAL|SHINE intervention group|Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
48671489|NCT02972710|OTHER|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
48507730|NCT03565679|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
48507731|NCT03565679|DEVICE|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
48147749|NCT01480258|BIOLOGICAL|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis \[DTaP\], Hepatitis B \[HepB\], Poliovirus \[IPV\] and Haemophilus influenzae type b \[Hib\] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
48147750|NCT01672242|DEVICE|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
48147751|NCT01672242|DEVICE|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
48147752|NCT04487717|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
48147753|NCT05198219|DEVICE|Ambu® aScope™ 4 Rhinolaryngo|Patient indication following a rhinolaryngoscopy
48147754|NCT05198219|DEVICE|Conventional reusable rhinolaryngoscope|Patient indication following a rhinolaryngoscopy
48147755|NCT04325737|DRUG|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
48147756|NCT04325737|DRUG|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
48507732|NCT06434623|OTHER|patient record|using patient record to construct AI models
48507733|NCT02813265|DRUG|KPI-121 0.25% Ophthalmic Suspension|
48147757|NCT04543669|BIOLOGICAL|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
48147758|NCT00680134|DRUG|AN2690|AN2690 1% Solution, once daily for 180 days
47990274|NCT03980457|OTHER|Standard Rehabilitation|Standard Rehabilitation
48147759|NCT00680134|DRUG|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
48147760|NCT03455725|DEVICE|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
48147761|NCT03455725|OTHER|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
48147762|NCT05186402|PROCEDURE|Total or subtotal gastrectomy|Gastric resection with digestive continuity according Roux or Bilroth
48147763|NCT03709225|BEHAVIORAL|Music-based meditation|The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
48147764|NCT00121589|DRUG|Lutein|
48147765|NCT03478072|DEVICE|trichoscopy|hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures
48507734|NCT02813265|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
48507735|NCT04972110|DRUG|RP-3500 (camonsertib)|RP-3500 (camonsertib, ATR inhibitor) in combination with niraparib or olaparib (PARP inhibitors)
48507736|NCT01860677|DEVICE|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
48507737|NCT05548738|DRUG|medthylprednisolone|a type of steroids injected in epidural space
47990275|NCT05312398|DRUG|Cetuximab|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
48147766|NCT01182272|DRUG|sorafenib tosylate|
48147767|NCT01182272|OTHER|laboratory biomarker analysis|
48147768|NCT01182272|PROCEDURE|neoadjuvant therapy|
48147769|NCT01182272|PROCEDURE|therapeutic conventional surgery|
48147770|NCT00009191|DRUG|Sertraline [Zoloft]|
48507738|NCT05548738|DRUG|prolotherapy|a type of hypertonic glucose
48507739|NCT04746794|BEHAVIORAL|Population-level screening|"The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A previvor plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified."
48671490|NCT02805140|BEHAVIORAL|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
48507740|NCT01824043|DRUG|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
47990276|NCT05312398|DRUG|FOLFIRI|"I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter"
48507741|NCT03140371|DIETARY_SUPPLEMENT|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
48507742|NCT00025259|BIOLOGICAL|Bleomycin Sulfate|Given IV or SC
48147771|NCT00321971|BEHAVIORAL|PST-MCI/AD Caregiving|The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
48147772|NCT00321971|BEHAVIORAL|NT-MCI/AD Caregiving|The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
48147773|NCT03824340|DRUG|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
48147774|NCT01643122|OTHER|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
48147775|NCT01643122|OTHER|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
48507743|NCT00025259|DRUG|Cisplatin|Given IV
48671491|NCT02805140|BEHAVIORAL|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
48147776|NCT03492177|DRUG|selexipag (Uptravi)|Film-coated tablets for oral administration
48507744|NCT00025259|DRUG|Cyclophosphamide|Given IV
47990277|NCT05312398|DRUG|FOLFOX regimen|"II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line"
47990278|NCT05312398|DRUG|Irinotecan|"III LINE:~- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
47990279|NCT04481633|DIAGNOSTIC_TEST|COVID 19 serology|Diagnosis of Covid-19 past infection will be made by serology
48147777|NCT06080802|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
48507745|NCT00025259|DRUG|Cytarabine|Given IV
48507746|NCT00025259|DRUG|Dexamethasone|Given IV
48507747|NCT00025259|DRUG|Doxorubicin Hydrochloride|Given IV
48507748|NCT00025259|DRUG|Etoposide|Given IV
48507749|NCT00025259|BIOLOGICAL|Filgrastim|Given SC
48507750|NCT00025259|RADIATION|Involved-Field Radiation Therapy|Undergo IFRT
48507751|NCT00025259|DRUG|Prednisone|Given orally
48507752|NCT00025259|DRUG|Vincristine Sulfate Liposome|Given IV
48507753|NCT00043628|PROCEDURE|Stem Cell Mobilization|
48507754|NCT01866046|BEHAVIORAL|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
48671492|NCT02805140|BEHAVIORAL|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
48671493|NCT01317992|DRUG|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
48147778|NCT05584306|DRUG|610 30mg group|610 30mg subcutaneous (SC) Q4W，8 times
48147779|NCT05584306|DRUG|610 100mg group|610 100mg subcutaneous (SC) Q4W，8 times
48147780|NCT05584306|DRUG|610 300mg group|610 300mg subcutaneous (SC) Q4W，8 times
48147781|NCT05584306|OTHER|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
48147782|NCT05584306|OTHER|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
48147783|NCT05584306|OTHER|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
48359046|NCT01593176|PROCEDURE|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
48507755|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with capsules containing rosemary and alkylglycerol|
48507756|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with control capsules|
48507757|NCT03523338|DRUG|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
48507758|NCT03523338|DRUG|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
48507759|NCT00767169|DEVICE|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
48507760|NCT00750581|DRUG|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
48507761|NCT02374138|BEHAVIORAL|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
48507762|NCT02374138|OTHER|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
48671494|NCT01317992|DRUG|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
48671495|NCT01493089|DRUG|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
48147784|NCT06211998|DEVICE|Group 1|Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1
48147785|NCT06211998|DEVICE|Group 2|Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2
48147786|NCT01314482|DRUG|Minocycline|200mg bd for 3 days before surgery
48359047|NCT03686579|RADIATION|chest trauma|clinical and radiological study
48507763|NCT04635527|DRUG|IBI318|before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W
48507764|NCT04635527|PROCEDURE|cTACE|conventional transarterial chemoembolization
48671496|NCT01493089|DRUG|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
48671497|NCT04209556|DRUG|PF-06826647 100 mg QD|Investigational Product
48671498|NCT04209556|DRUG|PF-06826647 300 mg QD|Investigational Product
47990280|NCT04481633|OTHER|COVID 19 Self-Questionnaire|COVID 19 Self-Questionnaire
47990281|NCT01356966|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
47990282|NCT01356966|DRUG|Placebo|2 placebo pills PO BID for12 weeks
47990283|NCT01356966|DIETARY_SUPPLEMENT|Folate|Folate 1 mg daily for 12 weeks
47990284|NCT03493009|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
47990285|NCT03566368|DIAGNOSTIC_TEST|Electrocardiogram|a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes
47990286|NCT03566368|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.
47990287|NCT03566368|DIAGNOSTIC_TEST|Cardiac enzyme - Troponin I Levels|Blood sample - venous collected to measure blood troponin - I levels.
47990288|NCT02063854|DRUG|NE-58095 IR|NE-58095 IR tablets
47990289|NCT02063854|DRUG|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
47990290|NCT02063854|DRUG|NE-58095 DR|NE-58095 DR tablets
47990291|NCT02063854|DRUG|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
47990292|NCT02155140|DIETARY_SUPPLEMENT|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
48359048|NCT04829591|OTHER|observational|Heart failure, non interventional
48359049|NCT00682292|DRUG|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
48359050|NCT00682292|DRUG|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
48359051|NCT00323479|DRUG|Anastrozole|1mg/Day oral
48359052|NCT06435455|DRUG|GH21|GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule
48507765|NCT04635527|DRUG|placebo|before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
48671499|NCT04209556|DRUG|PF-06826647 600 mg QD|Investigational Product
48671500|NCT04209556|DRUG|Placebo|Matched Placebo
48671501|NCT04209556|DRUG|PF-6826647 400 mg QD|Investigational Product
48507766|NCT03671616|BIOLOGICAL|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
48507767|NCT01582152|DRUG|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
48147787|NCT02501369|BEHAVIORAL|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
48147788|NCT01768585|DRUG|Ivabradine|Please see description of Intervention Arm
48507768|NCT01582152|DRUG|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
48147789|NCT01768585|DRUG|Placebo|
48147790|NCT05694286|PROCEDURE|Juvederm Volbella XC hyaluronic acid dermal filler injection|Infraorbital filler injection
48147791|NCT00605605|DRUG|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
48147792|NCT01123200|DEVICE|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
48359053|NCT06435455|DRUG|D-1553|D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet
48507769|NCT02388906|DRUG|Ipilimumab|Specified dose on specified days
48507770|NCT02388906|DRUG|Nivolumab|Specified dose on specified days
48507771|NCT02388906|OTHER|Placebo matching Ipilimumab|Specified dose on specified days
48507772|NCT02388906|OTHER|Placebo matching Nivolumab|Specified dose on specified days
48507773|NCT03661697|DEVICE|Laser Therapy|"Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face."
48507774|NCT03661697|OTHER|Basic Skin Care Regimen|Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
48507775|NCT03661697|OTHER|Lytera|cosmeceutical serum applied to face daily for 12 weeks
48507776|NCT04032249|BEHAVIORAL|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
48507777|NCT04032249|BEHAVIORAL|Intervention Group (IG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
48507778|NCT00866190|DRUG|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
48507779|NCT00866190|DRUG|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
48147793|NCT04119700|PROCEDURE|Muco-muscular endorectal advancement flap after fistulectomy|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
48507780|NCT00567684|DEVICE|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
48507781|NCT00567684|OTHER|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
47990293|NCT06449807|BEHAVIORAL|crossover point intensity exercise|crossover point intensity exercise
47990294|NCT02848183|DRUG|Cytarabine|
48147794|NCT04119700|PROCEDURE|Primary sphincter reconstruction after fistulectomy|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
48147795|NCT06056726|PROCEDURE|BIB positioning|BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy
48147796|NCT04245722|DRUG|FT596|Experimental Interventional Therapy
48507782|NCT06632327|PROCEDURE|Surgical Procedure|undergo surgery
48507783|NCT06632327|DRUG|Cisplatin|Give cisplatin
48507784|NCT06632327|DRUG|Carboplatin|Give Carboplatin
48507785|NCT06632327|DRUG|Pemetrexed|Give Pemetrexed
48507786|NCT06632327|DRUG|Gemcitabine|Give Gemcitabine
48507787|NCT06632327|DRUG|Docetaxel|Give Docetaxel
48507788|NCT06632327|DRUG|Vinorelbine|Give Vinorelbine
48507789|NCT06632327|DRUG|Nivolumab|Give Nivolumab
48507790|NCT06632327|DRUG|Pembrolizumab|Give Pembrolizumab
48507791|NCT06632327|DRUG|Atezolizumab|Give Atezolizumab
48507792|NCT06632327|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
48507793|NCT06632327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48507794|NCT06632327|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48507795|NCT06216678|OTHER|Healthy Dietary Pattern with Cottonseed Oil|Cottonseed Oil
48507796|NCT06216678|OTHER|Healthy Dietary Pattern with Fatty Acid-Matched Plant Oils|Plant oil blend fatty acid matched
48507797|NCT06216678|OTHER|Healthy Dietary Pattern with PUFA:SFA Ratio-Matched Plant Oil|Plant oil with matched PUFA to SFA ratio
48507798|NCT04060290|OTHER|Observational study|Observational study of this study, no interventions involved
48671502|NCT01901536|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
48147797|NCT04245722|DRUG|Cyclophosphamide|Lympho-conditioning agent
48147798|NCT04245722|DRUG|Fludarabine|Lympho-conditioning agent
48147799|NCT04245722|DRUG|Rituximab|Monoclonal Antibody
48147800|NCT04245722|DRUG|Obinutuzumab|Monoclonal Antibody
48147801|NCT04245722|DRUG|Bendamustine|Conditioning agent
48147802|NCT05272202|DRUG|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
48147803|NCT05272202|DEVICE|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
48147804|NCT05272202|DEVICE|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
48147805|NCT00368602|DRUG|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
48147806|NCT00368602|OTHER|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
48147807|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
48147808|NCT00603798|DRUG|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
48147809|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
48147810|NCT05485441|OTHER|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
48147811|NCT00786344|BEHAVIORAL|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
48147812|NCT05950594|RADIATION|Radiotherapy|Standard of care pre-operative radiotherapy
48147813|NCT05950594|OTHER|Surgery|Standard of care definitive surgery
48147814|NCT01577875|DEVICE|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
48359054|NCT05481190|BEHAVIORAL|Tele-Exercise Program|Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
48147815|NCT02053714|BEHAVIORAL|Diabetes self-management and education|
48147816|NCT00000284|DRUG|Cotinine fumarate|
48147817|NCT03046394|DEVICE|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
48507799|NCT01883349|PROCEDURE|Kidney Transplant|Kidney Transplant Surgery
48507800|NCT01883349|OTHER|No kidney transplant|The control group was made up of subjects without ESRD and were not on the renal transplantation waitlist.
48147818|NCT03046394|DEVICE|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
48507801|NCT03940625|DIAGNOSTIC_TEST|Cardiac MRI and echocardiography, laboratory parameters|Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)
48507802|NCT05740618|DRUG|Mannitol Inhalant Product|A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.
48507803|NCT02870010|BIOLOGICAL|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
48507804|NCT02870010|RADIATION|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
48147819|NCT03046394|DEVICE|A-DER|Triton by Otto Bock, advertised for activity category 3-4
48147820|NCT00910962|DRUG|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
48507805|NCT04829357|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures the subjects would receive as part of SOC.
48507806|NCT03749486|PROCEDURE|Cataract surgery|Cataract surgery will be done following ArcScan measurement
48507807|NCT04879680|PROCEDURE|sentinel node detection|Under general anesthesia 5 ml at 2.5mg/ml of Infracyanine ® (Laboratoire SERB; France) were injected circumferentially around the areola. Two ml of patent blue-V dye (Laboratoire Guerbet, Aulney-Sous-Bois, France) were injected in combination in the cohort of patients undergoing the procedure after primary chemotherapy. This was followed by a breast massage to facilitate absorption into the lymph vessels, then the surgical lights were turned off and image were obtained under near-infrared light using a first generation Near Infra Red (NIR) device \[K\]. Course of subcutaneous lymphatic drainage pathway fluorescence was followed up to where it disappeared to enter to deeper axilla and an incision was performed at that place. Lymphatic duct identification using the NIR camera allowed localization and removal of the sentinel lymph node(s).
48147821|NCT00910962|DRUG|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
48147822|NCT00910962|DRUG|Placebo|Placebo
48147823|NCT04619108|BIOLOGICAL|Thrombosomes®|
48147824|NCT04148885|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48147825|NCT04148885|DRUG|carboplatin|Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48147826|NCT02173756|DRUG|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
48147827|NCT02173756|DRUG|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
48147828|NCT01558999|DRUG|High concentration SI-614|1 drop in each eye 4 times a day
48147829|NCT01558999|DRUG|Low concentration SI-614|1 drop in each eye 4 times a day
48507808|NCT00109408|DRUG|Methotrexate|7.5-20mg po weekly
48507809|NCT00109408|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
48507810|NCT05524571|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
48507811|NCT05524571|DRUG|Placebo|Matching Placebo
48147830|NCT01558999|DRUG|Vehicle|1 drop in each eye 4 times a day
48147831|NCT00925548|BIOLOGICAL|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~\*calculated as mass of lipopeptide (antigen)"
48147832|NCT00925548|BIOLOGICAL|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
48147833|NCT00925548|DRUG|cyclophosphamide|300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
48147834|NCT00925548|DRUG|sodium chloride (NaCl)|NaCl 9 g/L infusion
48507812|NCT02882308|DRUG|Olaparib|50/25 mg BD split x 5 days
48507813|NCT02882308|DRUG|Cisplatin|60 mg/m\^2 d1-d5
48507814|NCT02882308|DRUG|Olaparib|300 mg BD x 21-28 days.
48147835|NCT04867044|OTHER|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
48507815|NCT02882308|DRUG|Durvalumab|1500 mg d1
48507816|NCT06582849|OTHER|Standard assistance|Standard assistance includes all community and institutional resources currently available for which the participant qualifies.
48507817|NCT06582849|OTHER|Enhanced assistance|Enhanced assistance includes gift cards and checks to support food, housing, utilities, transportation, pharmacy, and other non-medical costs
48507818|NCT03630107|OTHER|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
48507819|NCT05017961|DEVICE|Autograft|An autograft bone will be harvested from proximal tibia or posterior superior iliac crest. First the bony landmarks of the posterior iliac crest or proximal tibia are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. After 1 cm skin incision and gentle dissection of subcutaneous soft tissue, the bone harvesting device inserted through the skin and subcutaneous tissues until it reaches the cortical bone. Then, manual pressure is used to position the bone harvesting device against the dense cortical bone. A battery-powered power instrument is then will be used to drill the harvesting device into the medullary cavity. After the harvesting device insertion the cancellous strips of bone will be harvested and applied to the fracture site gap.At the conclusion of autograft bone harvesting procedure, the wound will be closed with 3-0 Nylon and a sterile dressing will be applied to the harvest site.
48507820|NCT05017961|DEVICE|Allograft only|The jar containing allograft tissue and cryopreservation solution will be placed in a sterile basin containing a warm (35°C to 39°C; 95°F to 102.2°F) sterile irrigant (Normal saline or 5% Dextrose in Lactated Ringer's Solution). The jar containing the allograft will remain in this solution until the contents of the jar flows freely upon inversion. The jar will be removed from the warm solution once free-flowing. Sterile gauze or the optional strainer will be used to decant the cryopreservation solution into a waste container. 5% Dextrose in Lactated Ringer's Solution will be added to the indicated fill line to immerse the allograft tissue. The cap will be replaced and inverted twice to suspend tissue until ready for use. 5% Dextrose will be decanted in Lactated Ringer's Solution prior to use. Implant will be used within 2 hours of thawing.
48507821|NCT05017961|DEVICE|Allograft combined with BMAC|A bone marrow aspiration kit will be used for bone marrow aspiration. First the bony landmarks of the posterior iliac crest and sacroiliac joint are palpated. The skin is then injected down to and including the periosteum with 1% lidocaine without epinephrine. Then, the bone marrow aspiration trochar and needle are percutaneously inserted through the skin and subcutaneous tis- sues until it reaches the posterior iliac crest. The trajectory of the needle will be parallel to the iliac crest, or perpendicular to the Anterior Superior Iliac Spine (ASIS) or Posterior Superior Iliac Spine (PSIS), depending on the harvest site used. After the trochar is inserted into the posterior iliac crest but prior to aspiration, 1 mL of heparin (1,000 U/mL) will be preloaded into the syringe. Approximately 60 mL of bone marrow will be aspirated, which requires the use of two 30-mL syringes. At the conclusion of BMAC harvesting, a sterile dressing will be applied to the harvest site.
48507822|NCT01130597|DRUG|patiromer|Active investigational drug
48507823|NCT01130597|DRUG|spironolactone|
48507824|NCT03172494|DRUG|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
48507825|NCT03172494|DRUG|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
48147836|NCT04867044|OTHER|Control|healthy woman volunteers
48147837|NCT05334225|OTHER|Training Program|An in-person urethral catheterization training program that utilizes training videos (demonstrating procedures, providing examples of ordinary and difficult cases, utilizing animation techniques as well)
48147838|NCT06505928|DRUG|hepalatide|hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
48147839|NCT04884256|DRUG|CBT-004|Dose response study
48507826|NCT03172494|DRUG|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
48507827|NCT03429400|DRUG|Morphine Sulfate|Morphine every 4 hours as needed for up to a maximum of 5 days
48147840|NCT00249366|DRUG|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
48147841|NCT00249366|DRUG|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
48147842|NCT05371002|BEHAVIORAL|Online group nonviolent communication (NVC) interventions|"The primary purpose of NVC as defined by Dr. Marshall Rosenberg is to resolve interpersonal conflict using empathic communication skills. Nonviolence does not refer to the mere absence of physical harm. It is a way of life that helps us to transform old patterns of defensiveness and aggressiveness into compassion and empathy and to improve the quality of all types of relationships. The basic model of NVC consists of four key principles: the separation of observation from evaluation (observation), exploring and expressing the feelings that emerge from observations (feeling), taking responsibility for one's feelings (need), and telling others the need to enrich lives (request). A book on NVC specifically targets parents to improve communication and connection with their children. The NVC model emphasizes the importance of observation and has similarities with the concept of mindful parenting, which refers to a non-judgmental and open parenting style."
47990295|NCT02848183|DRUG|Idarubicin|
47990296|NCT02848183|DRUG|Mitoxantrone|
47990297|NCT02848183|DRUG|Etoposide|
47990298|NCT02848183|PROCEDURE|Hematopoietic stem cell transplantation|
47990299|NCT04718142|DEVICE|vNEP|Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
47990300|NCT00047021|BIOLOGICAL|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
47990301|NCT00047021|DRUG|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
47990302|NCT00047021|DRUG|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
47990303|NCT03945396|DRUG|Homeopathic Medication|A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
48507828|NCT05167799|DEVICE|Cardiac Contractility Modulation (CCM)|Patients will be implanted with CCM device according to indications, to improve Heart Failure symptoms and then enrolled in the Registry if they fullfil Inclusion and Exclusion Criteria (First of all if they are diagnosed with TTR Amyloidosis)
48507829|NCT00843635|DRUG|Tadalafil|Given orally
48507830|NCT00843635|OTHER|Placebo|Given orally
48507831|NCT02942641|PROCEDURE|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
48507832|NCT02942641|PROCEDURE|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
48507833|NCT02942641|DEVICE|Foley|
48507834|NCT01807247|PROCEDURE|Intensive lower limbs muscles strengthening|
48507835|NCT04345913|PROCEDURE|Biopsy|Undergo biopsy
48507836|NCT04345913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48507837|NCT04345913|PROCEDURE|Computed Tomography|Undergo CT scan
48359055|NCT05481190|BEHAVIORAL|Just observation|Standard care was given to the children in the control group.
48359056|NCT03089489|DIAGNOSTIC_TEST|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
48359057|NCT04735289|OTHER|EPIC-COS Food Frequency Questionnaire diet Evaluation|Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
48359058|NCT04735289|OTHER|Metabolome, Microbiota, Lymphocytes subpopulations|"At diagnosis before any treatment for bone sarcoma will be obtained :~1. a blood sample for metabolomics analyses~2. a stool sample for microbiota analysis~3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples"
48507838|NCT04345913|DRUG|Copanlisib Hydrochloride|Given IV
48507839|NCT04345913|DRUG|Eribulin Mesylate|Given IV
48507840|NCT04345913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48507841|NCT05009511|BEHAVIORAL|Learning through feedback|The goal of this investigation is to examine the influence of feedback timing on learning and brain function.
48507842|NCT05776823|BEHAVIORAL|Pharmacist Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
48507843|NCT05776823|BEHAVIORAL|BIRT|BIRT participants will receive a 30-45-minute session delivered by the pharmacist to introduce and encourage treatment options, MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials), and a referral to treatment/linkage to service providers.
48507844|NCT05776823|BEHAVIORAL|SMC|SMS participants will receive a 5-10-minute counseling session delivered by the pharmacist providing MOUD information, OUD information, and treatment facility information (i.e., flyers (RDD study/CAST clinic/State Opioid Response III funded agencies) and educational materials).
48147843|NCT05371002|OTHER|Waitlist control group|Waitlist control, but included a short active intervention during the 2nd and 3rd assessments.
48359059|NCT03315676|DRUG|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
48359060|NCT03315676|DRUG|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
48507845|NCT05776823|BEHAVIORAL|Substance Use Counselor Narcan Training|A 20-45-minute didactic presentation conducted with a skills training component designed to demonstrate appropriate administration of the Narcan nasal spray.
48507846|NCT04974749|BIOLOGICAL|REPLAGAL|REPLAGAL IV infusion.
48507847|NCT03587324|DRUG|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
48671503|NCT00797719|OTHER|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
48671504|NCT05468502|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
48671505|NCT02392988|OTHER|acupuncture treatment|acupuncture treatment
48671506|NCT02392988|OTHER|Placebo Comparator|Placebo Comparator
48147844|NCT02074384|DEVICE|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
48359061|NCT03928106|OTHER|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
48359062|NCT00681902|DRUG|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
48359063|NCT00681902|DRUG|Placebo|Jet saline
48359064|NCT05042804|OTHER|Machine learning models predicting postoperative death and acute kidney injury|The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
48147845|NCT02074384|DEVICE|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
47990304|NCT03945396|OTHER|Multidisciplinary intervention (Exercise program, diet, motivational support)|"Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight."
48507848|NCT04201626|PROCEDURE|Adapted ERAS|"Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan."
48507849|NCT03844386|BIOLOGICAL|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
48507850|NCT03844386|BIOLOGICAL|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
48507851|NCT03844386|OTHER|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
48507852|NCT00154869|DRUG|Peginterferon Alfa-2a plus Ribavirin|
47990305|NCT03945396|DRUG|Homeopathic placebo|A 30 ml bottle of 30% alcohol-distilled water.
47990306|NCT01266460|BIOLOGICAL|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
47990307|NCT01266460|OTHER|Laboratory Biomarker Analysis|Correlative studies
48507853|NCT04159870|DRUG|Rifaximin|Rifaximin pills 400 mg x 3/day
48507854|NCT04159870|DRUG|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
48507855|NCT05856630|DRUG|Goserelin Acetate Sustained-Release Microspheres for Injection|10.8mg, Single dose, subcutaneously（SC）
48671507|NCT05123014|OTHER|relex smile|In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
48671508|NCT02213029|DRUG|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or \>150mg
48671509|NCT02213029|DRUG|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
48671510|NCT02213029|DRUG|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
48671511|NCT02213029|DRUG|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
48671512|NCT06033287|DRUG|Different treatment regimens following progression on CDK4/6 inhibitors.|This study is a single-arm, non-interventional study that evaluates the efficacy and safety of the first-line treatment regimen, which includes CDK4/6 inhibitors combined with endocrine therapy. After disease progression on first-line treatment, the second-line systemic treatment regimen (including but not limited to switching to another CDK4/6 inhibitor combined with endocrine therapy, other types of endocrine therapy, chemotherapy, targeted therapy, etc.) will be evaluated.
48671513|NCT02341066|DEVICE|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
48671514|NCT04281784|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
48671515|NCT04858399|DIAGNOSTIC_TEST|Evaluation|To examine the differences in respiratory functions, orofacial muscle tone changes, anxiety/ depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
48671516|NCT05584579|PROCEDURE|laparoscopic surgery|laparoscopic surgery
48671517|NCT00529360|DRUG|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
47990308|NCT05985850|DRUG|Aurora 1:1 Drops (Indica)|Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
48147846|NCT02074384|OTHER|Clinician|Survey of clinicians after study visits
48507856|NCT05856630|DRUG|Zoladex 10.8 MG Drug Implant|10.8mg, Single dose, subcutaneously（SC）
48507857|NCT04807647|OTHER|"Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player."|white noise will be played while breastfeeding
48507858|NCT03171974|DRUG|Dexamethasone|dexamethasone will be injected intracapsular under US
48507859|NCT03171974|DEVICE|US|dexamethasone will be injected intracapsular under US
48507860|NCT01243775|DRUG|Belotaxel|60 mg/m2 3 weekly (day 1)
48507861|NCT01243775|DRUG|Belloxa|70 mg/m2 3 weekly (day 2)
48507862|NCT03593018|DRUG|Oral azacitidine|Azacitidine tablets
48507863|NCT03593018|DRUG|Romidepsin|Romidepsin injection
48507864|NCT03593018|DRUG|Bendamustine|Bendamustine injection
48507865|NCT03593018|DRUG|Gemcitabine|Gemcitabine injection
48507866|NCT06408935|DRUG|Guselkumab|Guselkumab will be administered IV and SC.
48671518|NCT00529360|DRUG|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
48147847|NCT03340662|DRUG|CC-122|CC-122
48147848|NCT03340662|DRUG|Itraconazole|CYP3A Inhibitor
48147849|NCT03340662|DRUG|Fluvoxamine|CYP1A2 Inhibitor
48147850|NCT03340662|DRUG|Rifampin|CYP3A Inducer
48147851|NCT01166191|RADIATION|Radiotherapy|Radiotherapy
48147852|NCT02555397|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
48147853|NCT00629564|DRUG|Esomeprazole|20mg oral
48147854|NCT00629564|DRUG|Esomeprazole|15 minute intravenous infusion
48147855|NCT03276286|DEVICE|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
48147856|NCT05065840|BEHAVIORAL|CDC 4 Pillars Program|The CDC's 4 Pillars Transformation Program (4 Pillars Program) is a robust and empirically supported strategic approach that promotes the uptake of adult vaccinations and addresses facilitators and barriers at the patient, provider, and clinic level. This multi-level, evidence-based intervention has been successfully utilized to increase HPV vaccination in the general population and is primed to be tested in the high-risk HIV population, particularly PLWH in the rural South. This proposal seeks to expand the success of the 4 Pillars Program and tailor, refine, and implement in the HIV positive population who are at extraordinarily high risk for HPV-related cancers and can obtain the most benefit from the vaccine.
48147857|NCT00187356|PROCEDURE|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
48359065|NCT00065715|DIETARY_SUPPLEMENT|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = \< 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
48359066|NCT00065715|OTHER|Blinded placebo|Blinded placebo - Coated tablet
48359067|NCT04383691|DRUG|Lurasidone HCl|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.
48359068|NCT04383691|DRUG|Placebo|Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
48359069|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
48359070|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
48359071|NCT01547208|PROCEDURE|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
48359072|NCT01547208|PROCEDURE|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
48359073|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
48359074|NCT02509663|PROCEDURE|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
48359075|NCT02509663|DEVICE|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
48359076|NCT02509663|DEVICE|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
48359077|NCT00498927|DRUG|temozolomide|
48359078|NCT00498927|GENETIC|protein expression analysis|
48359079|NCT00498927|GENETIC|reverse transcriptase-polymerase chain reaction|
48671519|NCT04628130|OTHER|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
48671520|NCT04793516|OTHER|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
48671521|NCT06199414|DEVICE|Venous Closure|Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
48147858|NCT02754375|PROCEDURE|rTMS|
48147859|NCT00787176|DRUG|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
48147860|NCT00787176|DRUG|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
48147861|NCT00787176|DRUG|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
48147862|NCT00787176|DRUG|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
48147863|NCT03897491|DRUG|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
48507867|NCT01596309|DIETARY_SUPPLEMENT|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
48507868|NCT03629080|BIOLOGICAL|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
48507869|NCT03629080|BIOLOGICAL|placebo|Saline will be used for placebo.
47990309|NCT05985850|DRUG|Placebo|Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
48147864|NCT04514094|DRUG|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
48147865|NCT04514094|PROCEDURE|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
48147866|NCT01557439|DRUG|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
48147867|NCT00255749|BIOLOGICAL|epoetin alfa|
48147868|NCT03482999|DEVICE|TissuGlu Surgical Adhesive|
48147869|NCT05180175|DRUG|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
48147870|NCT01861041|DRUG|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
47990310|NCT01154218|DRUG|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
48147871|NCT01861041|DRUG|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
48147872|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Materials Only|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment."
48147873|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Direct Training|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers."
48359080|NCT00498927|OTHER|diagnostic laboratory biomarker analysis|
48359081|NCT00498927|OTHER|immunoenzyme technique|
48359082|NCT03377166|DIAGNOSTIC_TEST|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
48359083|NCT05051306|OTHER|High-load resistance exercise|Subjects in high-load trial performed 4 sets per exercise, 8 repetitions with load of 85%-8RM with 90 sec of rest between sets.
48359084|NCT05051306|OTHER|Low-load resistance exercise|Subjects in low-load trial performed 4 sets per exercise, 15 repetitions with load of 45%-8RM with 90 sec of rest between sets.
48359085|NCT03903861|OTHER|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
48359086|NCT03903861|OTHER|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
48359087|NCT03903861|OTHER|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
48359088|NCT05913401|BEHAVIORAL|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
48359089|NCT05913401|BEHAVIORAL|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
48359090|NCT03188003|OTHER|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
48507870|NCT06210919|BIOLOGICAL|TRTP-101|Intradermal injection of the each of four sites
48507871|NCT05992766|OTHER|Reformer Pilates|Reformer Pilates exercises activates the lumbopelvic muscles and supports functional movement. Activated muscles support the spine and reduce the load on the spine by correcting the posture, helping the core muscles such as the abdomen and spine stay healthier by attaching them to a neutral pelvis Pilates consists of a sliding platform working with the help of a pulley system specific to the use, allowing the individual to apply certain resistances, and providing the opportunity to exercise sitting, standing, or lying down.
48671522|NCT01471964|DRUG|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
47990311|NCT01073709|DRUG|Acetaminophen|
47990312|NCT03644745|BEHAVIORAL|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
48359091|NCT03188003|OTHER|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
48507872|NCT05992766|OTHER|Hammock Yoga|Hammock Yoga is performed with a silk hammock, which is an auxiliary equipment. The most distinctive characteristic that makes Hammock Yoga different from other exercises is the spine traction provided by the upside-down posture, and the smooth and shiny silk hammock allows strengthening exercises. The Hammock Yoga aims to reduce the load on the spine by upside-down postures that defy the laws of physics.
48359092|NCT03256123|DIETARY_SUPPLEMENT|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The biscuits for each subject will contain \~200 kcal with 10 g of red palm shortening/day (630 µg RE/day). This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 630 µg RE of vitamin A/day. This would fulfill \~70% of the RNI of vitamin A for children aged 7-11 years old.
48507873|NCT05992766|OTHER|Traditional mat exercises|The mat exercises help build core strength, stamina, and motor control of the abdominal and lumbar trunk musculature. The exercises focus on the re-education of a precise co-contraction pattern of local muscles of the spine. Also mat exercise increases the level of endorphins and the stimulation of mechanoreceptors, causing biomechanical stress to support healing in tissues.
48507874|NCT01775189|DRUG|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
48507875|NCT01775189|DRUG|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
48507876|NCT01775189|DRUG|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
48507877|NCT01775189|DRUG|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
48507878|NCT05412355|PROCEDURE|ERAS protocol|ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.
48507879|NCT00670202|DRUG|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
48671523|NCT01728142|DEVICE|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
48507880|NCT00670202|DRUG|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
48507881|NCT04140162|DRUG|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1"
48507882|NCT04140162|DRUG|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
48671524|NCT01728142|OTHER|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
48507883|NCT04140162|DRUG|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
48507884|NCT04140162|DRUG|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
48507885|NCT05232812|RADIATION|3-[11C]-OHB|The PET tracer 3-\[11C\]-OHB is used to quantify 3-hydroxybutyrate uptake
48671525|NCT00454116|DRUG|Vandetanib|once daily oral tablet two doses
48671526|NCT00454116|DRUG|FOLFIRI|Intravenous infusion
48671527|NCT02814188|OTHER|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
48671528|NCT02814188|OTHER|Placebo Beverage|750 ml of an artificially-sweetened beverage
48671529|NCT00008086|DIETARY_SUPPLEMENT|calcitriol|
48671530|NCT00008086|DRUG|carboplatin|
48671531|NCT01041261|DIETARY_SUPPLEMENT|BariatrX Essentials 360 Treatment|Medical food
48671532|NCT03912870|OTHER|Value of Flow Cytometry in Infectious Point of Care|"To validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.~This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers."
48671533|NCT05522686|OTHER|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
48671534|NCT05522686|OTHER|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
48359093|NCT03256123|DIETARY_SUPPLEMENT|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
48359094|NCT04173910|PROCEDURE|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
47990313|NCT04945785|OTHER|No intervention|no intervention
48507886|NCT01013558|DRUG|Remifentanil|0.15 microgram/kg/min continuous infusion.
48671535|NCT05522686|OTHER|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
48359095|NCT00840684|DRUG|amsacrine|
48359096|NCT00840684|DRUG|busulfan|
48507887|NCT01013558|DRUG|saline|continuous infusion
48507888|NCT06228599|OTHER|Treatment Plan|A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
48507889|NCT04819334|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
47990314|NCT02567955|BIOLOGICAL|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
48359097|NCT00840684|DRUG|cytarabine|
48359098|NCT00840684|DRUG|daunorubicin hydrochloride|
48359099|NCT00840684|DRUG|laromustine|
48359100|NCT00840684|DRUG|melphalan|
48359101|NCT00840684|DRUG|mitoxantrone hydrochloride|
48507890|NCT05521659|OTHER|Standardized oral care protocol|Standardized oral care protocol (3 times a day at certain hours (06-14-22) with oral care set including chlorhexidine gluconate)
48620088|NCT05149105|PROCEDURE|Argon plasma coagulation|On D0, in the operating room, argon plasma coagulation will be performed around the perimeter of the anastomosis for a period of 5 to 10 min under general anesthesia. The removal of the catheter and the endoscope will be carried out under control. Patients will be kept under surveillance the night following the procedure. A liquid diet will be prescribed for 10 days. The follow-up will be carried out on an outpatient basis with a control endoscopy at 2 months, followed by a new procedure in the event of an anastomosis larger than 1.5 cm. A new endoscopic check will be carried out at 4 months if an argon plasma coagulation was performed during the previous check, with a third and last argon plasma coagulation if an anastomosis of more than 1.5 cm persists. The number of procedures will therefore be a maximum of 3. A control endoscopy will be performed at one year for the final control of the anastomosis.
48671536|NCT05522686|OTHER|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
47990315|NCT02567955|BIOLOGICAL|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
47990316|NCT05892042|DRUG|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
47990317|NCT05023525|DRUG|HSK31858, tablet|Starting dose in single ascending dose: 5 mg
47990318|NCT05023525|DRUG|Placebo, tablet|Matching placebo
48359102|NCT00840684|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48359103|NCT00840684|PROCEDURE|autologous hematopoietic stem cell transplantation|
48359104|NCT00207493|BEHAVIORAL|Kit enhancement to referral|
48359105|NCT00207493|PROCEDURE|patient referral versus contract referral|
48359106|NCT00600665|BEHAVIORAL|PAINReportIt|A pain assessment data collection tool
48359107|NCT00600665|BEHAVIORAL|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
48359108|NCT00600665|BEHAVIORAL|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
48671537|NCT04314817|DRUG|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
48359109|NCT03435328|DEVICE|TENS|"* Duration of stimulation: 5 minutes.~* Frequency: will be fixed at 50 Hertz.~* Pulse duration: 250 µs.~* Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~* Sessions: only one session"
48359110|NCT04765306|DEVICE|Traditional Direct Fascial Closure|Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
48359111|NCT04765306|DEVICE|Fascial Closure Device|Fascial closure using a fascial closure device under direct laparoscopic guidance.
48671538|NCT01802788|DEVICE|St Jude Medical Portico replacement aortic valve|
48359112|NCT03164213|DEVICE|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
48359113|NCT03164213|DEVICE|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
48671539|NCT01802788|PROCEDURE|Transcatheter Aortic Valve Implant|
48671540|NCT00641108|DRUG|ADAM SPECT plus Cognitive Therapy|
48671541|NCT00641108|DRUG|ADAM SPECT plus No Therapy|
48671542|NCT01595087|DRUG|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
48620089|NCT00055146|DRUG|ONTAK|
48671543|NCT02332473|DRUG|Ypeginterferon alfa-2b|
48671544|NCT02332473|DRUG|Granulocyte-macrophage colony stimulating factor|
48359114|NCT02532829|OTHER|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
48671545|NCT03040128|DRUG|Minocycline|high-dose, intravenous minocycline
48671546|NCT03040128|OTHER|normal saline infusion|
48671547|NCT03563482|DIAGNOSTIC_TEST|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
48359115|NCT03453593|OTHER|No intervention|No intervention
48671548|NCT04684589|DRUG|Tadalafil 20 MG|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
48671549|NCT04684589|DRUG|Placebo|Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
47914346|NCT04207619|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
47914347|NCT02165098|DRUG|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
47914348|NCT02165098|DRUG|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
47914349|NCT02165098|DRUG|Cariprazine capsule|Cariprazine capsule - fasted
48671550|NCT05545748|BEHAVIORAL|Zero (0) Tolerance Program (SToP)|"1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~2. Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~3. Informative materials (information notes and brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~4. Informative telephone text messages: Reminder phone messages related to SHS and THS"
48671551|NCT05545748|BEHAVIORAL|Exposure Feedback Group|1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
48671552|NCT00219089|DRUG|aliskiren|
48671553|NCT02063451|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
47914350|NCT02165098|DRUG|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
47914351|NCT02165098|DRUG|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
47914352|NCT00951197|OTHER|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
48147874|NCT05890404|BEHAVIORAL|LGBTQ-Affirmative CBT Training: Local Supervision|"Participants will be provided a digital suite of online self-guided learning materials, including step-by-step treatment materials, client handouts, and how to instructions for delivering the treatment. In addition, participants will receive 12 weekly 1-hour live training webinars on delivering LGBTQ-affirmative CBT led by expert trainers. This arm will also receive one year of ongoing (at least monthly) supervision in LGBTQ-affirmative CBT from an expert supervisor at your center."
48147875|NCT02166723|DEVICE|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
48147876|NCT02166723|DEVICE|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
48507891|NCT05354739|DEVICE|The vibration cold device (BUZZY)|If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
48671554|NCT03071965|BIOLOGICAL|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
48147877|NCT06470152|PROCEDURE|Correction strategy in reference to our PI-dependent clustering of sagittal alignment|For type I patients (PI \< 39.56°), the target LL = -0.13\*PI2+9.36\*PI-134.08; for type II patients (39.56° ≤ PI \< 49.16°), the target LL = 0.45\*PI+26.57; for type III patients (49.16° ≤ PI \< 58.31°), the target LL = -0.15\*PI2+17.09\*PI-420.57; for type IV patients (PI \> 58.31°), the target LL = 0.06\*PI2-7.55\*PI+289.77. Prediction intervals of 95% confidence is adopted as the target LL range.
48359116|NCT03310879|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
48359117|NCT05246644|DRUG|acetaminophen|we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
48671555|NCT03071965|PROCEDURE|Surgery|Surgery to implant device for NT-501
48359118|NCT03315416|OTHER|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
48359119|NCT01293214|PROCEDURE|Limb transplantation|
48359120|NCT02114528|DRUG|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
48507892|NCT04537832|OTHER|No Intervention|No Intervention
48671556|NCT03071965|PROCEDURE|Surgery|Sham surgery
48671557|NCT03242226|DEVICE|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
48671558|NCT03242226|DEVICE|single vision spectacles|Wear single vision spectacle only
48671559|NCT02834455|DEVICE|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
48359121|NCT02114528|PROCEDURE|Catheter ablation|Ventricular tachycardia catheter ablation.
48507893|NCT06633094|OTHER|Educational videos|Internet will be used to deliver educational videos to subjects enrolled in the home management arm of the study which will be available on the Carilion Clinic Orthopaedic Education YouTube Channel. This will consist of a prerecorded video made by the three pediatric orthopaedic surgeons on this study explaining the nature of buckle fractures and treatment. Participants will be sent a link to the video over email (an example of a similar video in clinical use at Carilion Orthopaedics and the script of the video can be found in the study document attached).
48507894|NCT05289297|PROCEDURE|Karydakis Flap Procedure|Pilonidal sinus surgery will be performed with the Karydakis Flap procedure.
48671560|NCT02834455|DEVICE|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
48671561|NCT00318929|DRUG|Divalproex Sodium Extended-Release Tablets|Once a day dosing
48671562|NCT04966325|DRUG|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
48671563|NCT04966325|DRUG|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
48671564|NCT04966325|DRUG|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
48671565|NCT04966325|DRUG|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
48671566|NCT03487016|DRUG|Gemcitabine|Arm A
48671567|NCT03487016|DRUG|Nab-paclitaxel|Arm A
48671568|NCT03487016|DRUG|5-FU|Arm B Arm C
48671569|NCT03487016|DRUG|Irinotecan Liposomal Injection|Arm B Arm C
48671570|NCT03487016|DRUG|Oxaliplatin|Arm C
48671571|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
48359122|NCT00632372|DEVICE|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
48359123|NCT00632372|DEVICE|HeartPOD™ System|Left atrial pressure monitoring.
48507895|NCT05289297|PROCEDURE|Burow's Triangle Advancement Flap Procedure|Pilonidal sinus surgery will be performed with the Burow's Triangle Advancement Flap procedure.
48507896|NCT00721227|PROCEDURE|Reduction Gastroplasty|"* Subjects will undergo reduction gastroplasty by gastric plication~* Subjects are followed for 12 months to evaluate outcomes and potential complications."
48671572|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
48671573|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
48671574|NCT02422979|COMBINATION_PRODUCT|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
48671575|NCT02422979|COMBINATION_PRODUCT|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
48507897|NCT05142280|OTHER|Decision-aid for cardiovascular disease risk|The active choice intervention aims to promote an active choice regarding coping with an increased risk of cardiovascular disease. This means that individuals should (a) become aware of a discrepancy between the current and desired situation; (b) understand what the CVD risk means, and what its causes and consequences are; (c) evaluate the pros and cons of the different options to cope with the risk; and (d) are clear about their values regarding the choice.
48507898|NCT05142280|OTHER|Control|The control condition contains information that resembles usual care by a GP regarding CVD prevention
48671576|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
48359124|NCT02461576|DEVICE|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
48671577|NCT04381247|DIAGNOSTIC_TEST|Molecular diagnostics in HAP and VAP|Airway samples will be analyzed both by standard and molecular based microbiological analysis.
48671578|NCT03091361|OTHER|imaging, no intervention|no intervention
48671579|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
48671580|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
48671581|NCT01100281|BEHAVIORAL|Neuropsychological examination|Examination including especially concept formation
48671582|NCT01100281|OTHER|MRI|MRI performed in T1-weighted three dimensional sequence
48671583|NCT03089060|DEVICE|Silicone Finger cap|Treatment with silicone finger cap
48359125|NCT05370560|OTHER|Plasma transthyretin concentration|Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
48359126|NCT04560179|DRUG|Tobramycin solution for inhalation 78mg dose|Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
48359127|NCT04560179|DRUG|Tobramycin solution for inhalation 150mg dose|Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
48359128|NCT04560179|DRUG|Tobramycin solution for inhalation 216mg dose|Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
48671584|NCT03089060|DEVICE|Film Dressing|Treatment with conventional film dressing
48359129|NCT04560179|DRUG|Tobramycin solution for inhalation 300mg dose|Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
48359130|NCT00566475|OTHER|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
48359131|NCT06127394|PROCEDURE|Sacral ESP Block|Sacral ESPB median approach, 40 ml %0,25 Bupivacaine
48359132|NCT06127394|PROCEDURE|Pudendal Block|Bilateral pudendal block, 10 ml %0,25 bupivacaine
48507899|NCT04641078|DRUG|Darolutamide|600 mg BID
48507900|NCT04641078|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
48507901|NCT00551668|PROCEDURE|proximal patellar surgery|Initial proximal patellar surgery
48671585|NCT04994223|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
48671586|NCT04804124|BEHAVIORAL|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
48359133|NCT03818399|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
48507902|NCT00551668|PROCEDURE|Nonoperative|Nonoperative without surgery
48359134|NCT01092572|DRUG|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
48507903|NCT04215276|OTHER|Valsalva maneuver|pressure during Valsalva maneuver was measure using sphygmomanometer
47990319|NCT00935844|DRUG|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
47990320|NCT02542878|DEVICE|Foam roller|A bout of 60 seconds of myofascial release with foam roller
47990321|NCT04915755|DRUG|Niraparib|Niraparib will be administered.
47990322|NCT04915755|DRUG|Placebo|Matching placebo will be administered
47990323|NCT03098537|DRUG|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
47990324|NCT03098537|OTHER|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
47990325|NCT03821298|OTHER|Standard of Care Hand Therapy|8 sessions 2 times a week for 4 weeks
47990326|NCT05436847|OTHER|Proprioceptive Training|Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
48359135|NCT01092572|DRUG|placebo|placebo 1 tablet once daily for 12 weeks
48359136|NCT04333628|DRUG|chloroquine|oral treatment of chloroquine
48507904|NCT04215276|OTHER|Control|patient was not given any intervention
48507905|NCT03997851|DRUG|Acetaminophen|Topical acetaminophen gel
48507906|NCT03997851|DRUG|Carbomer 980|Topical vehicle gel
48507907|NCT04932161|PROCEDURE|Titanium Granules|After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
48507908|NCT04932161|PROCEDURE|Hydroxyapatite|After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
48507909|NCT00400699|OTHER|counseling intervention|
48507910|NCT00400699|OTHER|study of socioeconomic and demographic variables|
48507911|NCT00400699|PROCEDURE|psychosocial assessment and care|
48507912|NCT04720118|OTHER|No Intervention|There is no intervention for this study.
48507913|NCT02174289|DEVICE|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
48507914|NCT05304247|OTHER|questionnaire and clinical examination|Prevalence and Risk Factors of Black Tooth Stains and Their Relation With Caries Experience in Primary Teeth of A Group of Preschool Children
48507915|NCT04031755|DRUG|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
48507916|NCT04031755|DRUG|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
48671587|NCT02148588|DRUG|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
48671588|NCT00541112|BIOLOGICAL|cetuximab|
48671589|NCT00541112|DRUG|capecitabine|
48671590|NCT00541112|DRUG|fluorouracil|
47990327|NCT05436847|OTHER|Routine Physical Therapy|Neurodevelopmental treatment- age appropriate
47990328|NCT00565968|DRUG|melphalan|
47990329|NCT00565968|DRUG|sorafenib tosylate|
47990330|NCT00565968|GENETIC|gene expression analysis|
47990331|NCT00565968|GENETIC|protein expression analysis|
47990332|NCT00565968|GENETIC|western blotting|
47990333|NCT00565968|OTHER|pharmacological study|
47990334|NCT03678532|DRUG|Midazolam|
47990335|NCT06397898|OTHER|Educational video|Viewing an educational video before Novasure treatment
47990336|NCT02456142|DRUG|caudal bupivacaine|
47990337|NCT02456142|DRUG|intravenous morphine|
47990338|NCT05294172|DRUG|KL-A167|KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
48359137|NCT04333628|OTHER|standard care|Currently, there is no specific treatment for novel coronavirus. The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.
48359138|NCT05057377|DIAGNOSTIC_TEST|Standard Overground Assessment|The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
48507917|NCT06200324|OTHER|Ready-to-Use Parenteral Nutrition|"In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day."
48507918|NCT04204291|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
48671591|NCT00541112|DRUG|leucovorin calcium|
47990339|NCT05294172|DRUG|Gemcitabine|4-6 cycles for combined therapy
47990340|NCT05294172|DRUG|Cisplatin|4-6 cycles for combined therapy.
47990341|NCT05294172|DRUG|Placebo|4-6 cycles for combined therapy.Placebo maintenance.
48359139|NCT05057377|DIAGNOSTIC_TEST|Robotic Safety-Environment Assessment|The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
48359140|NCT04026633|BEHAVIORAL|CAA|Participants will write about the use of PBS and alcohol use.
48359141|NCT04026633|BEHAVIORAL|Control|Participants will write about eating and exercise.
48359142|NCT00592644|PROCEDURE|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
47990342|NCT04102592|OTHER|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
47990343|NCT04102592|OTHER|Untreated Lesu (baby wrap)|Matching untreated lesu
47990344|NCT03388060|PROCEDURE|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
47990345|NCT03388060|PROCEDURE|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
48359143|NCT00592644|PROCEDURE|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
48359144|NCT00475579|PROCEDURE|tube with subglottic drainage and polyurethane cuff|
48359145|NCT01749228|DRUG|Etodolac Capsules USP 300 mg|300 mg capsule once a day
48359146|NCT01749228|DRUG|Etodolac|500 mg tablet once a day
48359147|NCT03621111|BEHAVIORAL|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
47990346|NCT03388060|PROCEDURE|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
48359148|NCT03621111|BEHAVIORAL|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
48671592|NCT00541112|DRUG|oxaliplatin|
47990347|NCT05783362|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion. Conditioned pain modulation will be calculated as the average pain ratings of the second testing stimulus series minus the average pain ratings of the first testing stimulus series.
48147878|NCT06470152|PROCEDURE|Correction strategy in reference to the SAAS score|"This new score is composed of three sagittal parameters (PI-LL, PT and TPA). For these three parameters, points were assigned based on offset with age-adjusted targets 0 points if the parameter was within 10 years of the patient's age (Match). For each 20 years above the age-adjusted target, 1 point was added (e.g., + 1 point between + 10 and + 30, + 2 points between +30 and +50). Conversely, 1 point was subtracted for each 20 years below the age-adjusted target (e.g., -1 point between -10 and -30, -2 points between -30 and -50). SAAS was calculated by adding all 3 components, creating a discreet score that could have a negative value (under corrected) or positive value (over corrected). SAAS was sub-categorized into SAAS-Under if it was less than -1, SAAS-Match if it was between -1 and + 1 or SAAS-Over if it was greater than + 1."
48359149|NCT03621111|BEHAVIORAL|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
48359150|NCT03539900|DRUG|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
48359151|NCT03539900|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
48671593|NCT00541112|PROCEDURE|adjuvant therapy|
48671594|NCT00541112|PROCEDURE|conventional surgery|
48671595|NCT00541112|PROCEDURE|neoadjuvant therapy|
48671596|NCT00541112|RADIATION|radiation therapy|
48671597|NCT05595850|BEHAVIORAL|Mindfulness|Online non-meditation mindfulness program
48671598|NCT05595850|BEHAVIORAL|Mindful Learning|Online learning program
48671599|NCT03649802|DIETARY_SUPPLEMENT|Low dose vitamin D3|Low dose arm-800 IU given daily
48671600|NCT03649802|DIETARY_SUPPLEMENT|High dose vitamin D3|High dose arm-5000 IU given daily
48671601|NCT02550015|BEHAVIORAL|High intensity interval training|Uphill treadmill walking
48671602|NCT02550015|BEHAVIORAL|General information|Standard care
48671603|NCT06094504|OTHER|Spectral Lighting|Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
48671604|NCT04747262|BEHAVIORAL|SPACE|SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes \& Scahill, 2014)
48671605|NCT01149746|DRUG|Tamsulosin|Test 0.4 mg Capsule
48671606|NCT01149746|DRUG|Tamsulosin|Reference Listed 0.4 mg Capsule
48671607|NCT01642550|DRUG|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
48671608|NCT01642550|DRUG|Placebo|
48671609|NCT00099021|DRUG|pioglitazone hydrochloride|Given PO
48671610|NCT05988918|DRUG|ESK981|160 mg, PO, Once daily 5 days on and 2 days off
48671611|NCT05018494|OTHER|experimental treatment|This group will receive the common treatment and will be discharged with complete manual on life style modifications comprising education, exercise and diet with telerehabilitation monitoring.
48671612|NCT05018494|OTHER|common treatment|This group will receive the common treatment and will be discharged with home exercise plan without telerehabilitation monitoring.
48147879|NCT02003885|DRUG|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
48147880|NCT04794439|DRUG|Dentifrices|Dentifrice on plaque
48147881|NCT01169402|DRUG|Fluconazole|25mg/kg intravenously once weekly while on ECMO
48147882|NCT05844306|PROCEDURE|Computed Tomography|Undergo \[18F\]-FDG PET-CT
48147883|NCT05844306|OTHER|Fludeoxyglucose F-18|Given via injection
48147884|NCT05844306|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
48147885|NCT05844306|DEVICE|Positron Emission Tomography|Undergo \[18F\]-FDG PET-CT
48671613|NCT03249402|DRUG|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
48147886|NCT05123755|DRUG|AV-001 Injection|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
48147887|NCT05123755|DRUG|AV-001 Placebo Injection|D-PBS
48507919|NCT05917600|OTHER|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
48507920|NCT01708551|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48507921|NCT06632977|OTHER|Genetic testing|undergo genetic testing
48507922|NCT06632977|DRUG|Valemetostat Tosylate|Given PO
48507923|NCT06632977|PROCEDURE|Magnetic Resonance Imaging|undergo Magnetic Resonance Imaging
47990348|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
47990349|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
47990350|NCT05737212|RADIATION|500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq|Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
48147888|NCT02134626|DRUG|Simvastatin|40mg / pill, one pill orally once a day for three months
48147889|NCT02134626|DRUG|Placebo pill|
48147890|NCT04812977|DRUG|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
48147891|NCT04917185|OTHER|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
48147892|NCT04919369|BIOLOGICAL|Atezolizumab|Given IV
48147893|NCT04919369|DRUG|Tretinoin|Given PO
48507924|NCT06632977|PROCEDURE|Computed Tomography|undergo Computed Tomography
48507925|NCT06632977|PROCEDURE|Bone scan|undergo Bone scan
48507926|NCT06632977|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
48507927|NCT06632977|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
48671614|NCT03249402|DRUG|JNJ-42847922|Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
48671615|NCT02296476|DRUG|Birabresib|Administered orally in a fasted state once daily.
48147894|NCT01354288|OTHER|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
48147895|NCT05034237|DEVICE|ND;YAG 1064NM LASER|laser hair removal sessions
48507928|NCT06632977|PROCEDURE|Biospecimen Collection|undergo blood collection
48507929|NCT06632977|DRUG|Carboplatin|Given IV
48507930|NCT06632977|DRUG|Cabazitaxel|Given IV
48507931|NCT06632977|DRUG|Abiraterone Acetate|Given PO
48507932|NCT06632977|DRUG|Enzalutamide|Given PO
48507933|NCT06632977|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
48507934|NCT02520297|DRUG|TRV130|Drug
48507935|NCT04988087|DRUG|MHV370|MHV370 for 24 weeks
48507936|NCT04988087|DRUG|Placebo|Placebo for 24 weeks
48147896|NCT06443099|OTHER|Different methods used after intramuscular injection|Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.
48147897|NCT02400749|DRUG|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
48147898|NCT02400749|DRUG|Placebo|Placebo tablets will be provided to sites in blister cards.
48147899|NCT00002405|DRUG|Amprenavir|
48507937|NCT04440137|BEHAVIORAL|Bottle-feeding cessation program|Specific brochure and proper oral hygiene education emphasizing on the benefit of stopping bottle-feeding given to subject
48147900|NCT02764320|OTHER|Migraine Prophylactic Therapy Only|Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
48147901|NCT02764320|OTHER|Discontinuation of Overused Medication|Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
48507938|NCT04388553|PROCEDURE|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
48507939|NCT01186484|DRUG|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
48507940|NCT00946816|BEHAVIORAL|Nutritional Intervention|Nutritional Intervention
48507941|NCT01496300|PROCEDURE|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
48507942|NCT01496300|PROCEDURE|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
48507943|NCT02901548|DRUG|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
47990351|NCT06516887|DRUG|bemcentinib|Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
47990352|NCT06516887|DRUG|pacritinib|For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
47990353|NCT05153915|DRUG|Tacrolimus granules|Oral
47990354|NCT06136923|DEVICE|CT-100-D-004-A|Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
47990355|NCT06136923|DEVICE|CT-100-D-004-B|Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
47990356|NCT05826886|BEHAVIORAL|Emotional Writing|Participants complete four 20-minute sessions of emotional writing (at home) on four consecutive days. Instructions are provided online before each writing session.
47990357|NCT02283047|BEHAVIORAL|DIET|Lifestyle intervention through hypocaloric diet
48147902|NCT01499251|DRUG|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
48147903|NCT01499251|DRUG|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
48147904|NCT01499251|DRUG|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
48147905|NCT06498232|OTHER|Active Video Based Exercises|Warm-up and cool-down will consist of aerobic games (Step, Hula Hoop, Rhythm Parade Dance, Run) available in Nintendo Wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City, and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis, and Baseball will be included in the program. In all games, progress will be made by increasing the difficulty levels, and in balance games, the game will be made more difficult with an additional balance board and bosu.
48147906|NCT06498232|OTHER|Stabilization and Strengthening Exercises|Warm-up exercises will consist of active dynamic warm-up exercises. Stabilization and strengthening exercises; extremity movements will begin with teaching respiratory control in supine, prone, sitting, crawling, squat, and standing positions, and will be made more difficult with the addition of exercise tires and exercise balls. Balance exercises will start from static positions and move on to dynamic positions with the inclusion of different surfaces. In the cooling exercises, in addition to breathing exercises, stretching exercises will be performed for the trunk, upper and lower extremities.
48147907|NCT06498232|OTHER|Waiting List-Spine protection principles training|Participants will be placed on a waiting list. Following the initial evaluations, participants will be informed that they will be included in an exercise program at the end of 6 months. During this process, participants in the control group will be called by phone at the 6th, 12th, and 18th weeks to question their status and to remind them that they will start the exercise program after a while. It will be evaluated at the end of 6 months, and the end of the study, exercise training approaches in the intervention group will be applied to participants who wish to do so, with the same protocol and duration.
48147908|NCT02981953|DEVICE|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
48147909|NCT00244452|DRUG|Cetrorelix|
47990358|NCT02283047|BEHAVIORAL|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
47990359|NCT02283047|BEHAVIORAL|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
47990360|NCT02283047|BEHAVIORAL|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
47990361|NCT03863223|DRUG|Pyrotinib, Trastuzumab, Docetaxel|Pyrotinib 400mg orally daily until progressive disease
47990362|NCT03863223|DRUG|Placebo, Trastuzumab, Docetaxel|Placebo 400mg orally daily until progressive disease
47990363|NCT04478357|DRUG|4 mg Fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
48147910|NCT02354417|BIOLOGICAL|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
48147911|NCT00898313|GENETIC|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
48147912|NCT00898313|GENETIC|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
47990364|NCT04478357|DRUG|4 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
47990365|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Zwickau|Manufactured at Zwickau
47990366|NCT04478357|DRUG|8 mg fesoterodine ER tablet from Freiburg|Manufactured at Freiburg
47990367|NCT01561820|BEHAVIORAL|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5\[HRmax-HRrest\]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
47990368|NCT03899584|DRUG|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
48671616|NCT06101303|OTHER|Psychophysical assessment|"Thermal stimuli: The Thermal Sensory Analyzer will be used to deliver heat and cold stimuli. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water bath or an electronic electronic temperature-controlled water bath. Participants will be free to pull out of the water bath at any time.~Pressure stimuli: Pressure stimuli will be applied by using a handheld algometer. These devices have a round probe that allows quantifying the amount of pressure that is being applied by real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.~Mechanical stimuli: A set of standardised von Frey filaments (0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 and 256mN). The contact area of the hairs with the skin is of uniform size (\<1 mm²) and texture."
48359152|NCT03917576|OTHER|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
48359153|NCT03917576|OTHER|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
48147913|NCT00898313|GENETIC|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
48147914|NCT00898313|OTHER|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
48359154|NCT00173615|PROCEDURE|Extracorporeal membrane oxygenation|
48147915|NCT00898313|PROCEDURE|nasal brushing|Using a brush, superficial cells are removed from the nose.
48359155|NCT01920516|DRUG|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
48359156|NCT01271049|OTHER|Novel Food Product|Novel food product containing essential oil blend
48359157|NCT01271049|OTHER|Control Food Product|Control food product
48359158|NCT02271620|PROCEDURE|nasal allergen provocation test|nasal allergen provocation test
48359159|NCT03430726|OTHER|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
48359160|NCT06119828|BEHAVIORAL|breastfeeding education for family members|The first breastfeeding skills of mothers who gave birth in the delivery room and the first breastfeeding skills after birth were evaluated using BEDÖ. After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. After the mothers' 1-hour breastfeeding was evaluated in the delivery room, the training phase of family members began. CBT was administered to family members in the waiting room before the training, which lasted approximately 7-8 minutes. Then, breastfeeding training was given to family members for 20-25 minutes. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. On the 15th postpartum day, the family member was called by phone and reminded about breastfeeding education. At the first month postpartum,Checklist were administered to the mother via telephone conversation
47990369|NCT03899584|DRUG|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
47990370|NCT01991457|DRUG|Fludarabine|
47990371|NCT01991457|PROCEDURE|Total Body Irradiation|
47990372|NCT01563718|DRUG|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
47990373|NCT06196333|DEVICE|Non-contact specular microscopy|using specular microscope to do morphological examination of corneal endothelial cells
47990374|NCT00774228|DEVICE|I-ZIP Ocular Bandage|
48147916|NCT00898313|PROCEDURE|Blood draw|Venous blood will be collected
48147917|NCT00898313|PROCEDURE|Urine collection|Subjects will be asked to provide a urine specimen.
48147918|NCT00898313|PROCEDURE|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
48147919|NCT00898313|PROCEDURE|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
48147920|NCT00898313|PROCEDURE|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
48671617|NCT06101303|BEHAVIORAL|Psychophysical assessments of experimental pain|"Pain ratings- Pain intensity and pain unpleasantness ratings will be assessed~Pain thresholds to heat, cold and/or pressure will be tested and participants will be instructed to press a button the first moment they feel pain.~Temporal summation- participants will rate the pain evoked by a single pinprick stimulus and by a series of 10 identical pinprick stimuli.~Conditioned pain modulation (CPM) efficiency - CPM testing includes the application of a test stimulus without conditioning (heat or pressure stimuli) and a subsequent application of the same test stimulus together with a conditioning stimulus (cold stimulus).~Offset analgesia will be assessed using the three-temperature method (T1°C 5s, T1+1°C 5s, T1°C 20s). During the OA paradigm, real time pain intensity ratings will be obtained~Cold pain tolerance will be assessed by having participants immerse their hand or foot in a cold water bath. Tolerance will be defined by the time of hand/foot withdrawal."
48671618|NCT06101303|DIAGNOSTIC_TEST|Blood, urine and saliva samples|Blood (approximately 2 tablespoons), urine and saliva samples will be collected and sent to ZRT Laboratory, LabCorp, or internal Washington University lab for analyses of sex hormone levels (e.g., testosterone, estradiol, progesterone). Additional samples will be stored in a biobank for future processing.
48359161|NCT06119828|OTHER|receiving routine breastfeeding training|After giving birth, mothers were taken to the maternity ward after being kept under control in the delivery room for 2 hours. Mothers' breastfeeding was evaluated at the 1st hour in the delivery room. CBT was administered to family members in the waiting room. BBST was applied after the mother transferred to the maternity ward. Before the mother and the baby were discharged from the hospital, BEDÖ and BBTÖ were administered to the family member. At the first month postpartum, BBTÖ was administered to the family member, and BBTÖ and EÖY scale and Breastfeeding Checklist were administered to the mother over the phone.
48359162|NCT04005885|DEVICE|comfilcon A|Contact Lens
48507944|NCT02901548|PROCEDURE|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
47990375|NCT00774228|DEVICE|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
47990376|NCT06246318|OTHER|virtual reality|The virtual reality protocol here is based on perceptual-motor activities, supported by Nintendo Wii resources. The user will be able to control a game character in a virtual environment using a remote control with a motion sensor. Wii Fit Plus requires the use of the Wii Balance Board that the player stands on during gameplay. The Wii Balance Board is not a wobbly balance board, but is able to detect and track the user's center of balance, a feature used extensively in the game. Wii Fit Plus includes more than 40 activities including yoga, strength training, aerobics and balance games. During the virtual reality application, different games will be preferred in each session depending on the duration of the games. Virtual reality application will be carried out in a corner prepared for virtual reality application in the room where the conventional occupational therapy session is held. Families have the right to observe and attend all sessions whenever they wish.
48147921|NCT00898313|PROCEDURE|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
48359163|NCT04005885|DEVICE|somofilcon A|daily disposable contact lens
48507945|NCT02874885|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
48507946|NCT01959854|DEVICE|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
48507947|NCT01959854|DEVICE|xanthan gum|0.2% xanthan gum preservative free
48507948|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^7 pfu /2mL administered in each deltoid
48507949|NCT00083603|BIOLOGICAL|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
48507950|NCT00083603|BIOLOGICAL|Empty TBC-FPV|Empty FPV 10\^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
48507951|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^8 pfu /2mL administered in each deltoid
48359164|NCT04005885|DEVICE|stenfilcon A|daily disposable contact lens
48359165|NCT04766944|OTHER|No intervention|No intervention
48359166|NCT00852124|BIOLOGICAL|VSL#3|VSL#3 2 times daily
48507952|NCT00083603|BIOLOGICAL|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10\^9 pfu /2mL administered in each deltoid
48507953|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^7 pfu/2mL administered into each deltoid
48147922|NCT05576701|BEHAVIORAL|Laughter Therapy|In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
48147923|NCT05576701|OTHER|Control|The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
48147924|NCT04221321|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg
47990377|NCT06246318|OTHER|conventional occupational therapy|"Sensory integration and gross motor training approaches will be used in the conventional occupational therapy program. A manualized protocol based on Ayres sensory integration principles will be followed (Schaaf et al., 2012). The intervention will be carried out by a licensed occupational therapist trained in sensory integration.~This approach suggests that if a child engages in individually adapted sensorimotor activities, the nervous system is better able to modulate, organize, and integrate sensory information and is also more likely to use sensory information in adaptive ways (Ayres, 1972). Components of the intervention include a sensory-rich, playful, child-centered approach, providing a decision challenge, and facilitating increasingly complex adaptive behaviors by engaging the child in individually tailored, developmentally appropriate play interactions"
48671619|NCT06101303|PROCEDURE|Biopsy and surgery-related data.|During the surgery, biopsies will be collected from the endometriosis lesions as well as from a healthy peritoneum. If there are no endometriosis lesions, biopsies will be taken of two common locations where endometriosis lesion grows (the infra-ovarian fossa). The lesions will be characterized based on their appearance and invasiveness of the lesions (i.e., powder-burn lesions, nonclassical red or white lesions, and superficially or deeply infiltrating (\>5mm) lesions). In addition, surgery-related data such as the incision size, type of anesthesia, pain ratings after the surgery, analgesic medication after the surgery, and side effects will be documented. Blood, saliva, urine, and samples will be collected for hormonal analyses or stored in a Biobank for future analyses.
48671620|NCT05554276|COMBINATION_PRODUCT|neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
48147925|NCT04221321|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
48147926|NCT04221321|DRUG|RAPA114|RAPA114 tablet
48507954|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^8 pfu/2mL administered into each deltoid
48671621|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
48671622|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r ATLL
48671623|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL
48671624|NCT01492088|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
48671625|NCT06373211|DRUG|Immunoglobulins IV (CLAYRIG)|"Patients will be treated with cycles of :~- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles"
48671626|NCT06373211|DRUG|Cyclophosphamide IV|"Patients will be treated with cycles of :~- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles"
47990378|NCT01337219|DRUG|Tobramycin|
47990379|NCT04101903|DIAGNOSTIC_TEST|The 6-week Hip Checklist|Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
48147927|NCT02995447|OTHER|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
48507955|NCT00083603|BIOLOGICAL|TBC-MVA and TBC-FPV|Empty MVA 10\^9 pfu/2mL administered into each deltoid
48507956|NCT03350607|OTHER|Non interventional study|Non interventional study (collect of data)
48507957|NCT06625567|OTHER|Animated video|Patients will watch an educational video describing the procedure before hysteroscopy without anesthesia
48507958|NCT01801631|OTHER|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
48671627|NCT06373211|DRUG|Methylprednisolone IV|"Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles"
48671628|NCT04333615|BEHAVIORAL|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
48671629|NCT00419055|PROCEDURE|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
48671630|NCT02025374|DRUG|Hyperbaric levobupivacaine|
48671631|NCT02025374|DRUG|Hyperbaric bupivacaine % 0.5|
47990380|NCT01279551|DRUG|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
47990381|NCT01279551|DRUG|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
47990382|NCT05275764|PROCEDURE|primary or secondary intraocular lens implantation surgery|primary or secondary intraocular lens implantation surgery
48147928|NCT01124942|DEVICE|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
47990383|NCT02788968|OTHER|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
48671632|NCT05110326|OTHER|ERGON Technique|"* Hot pack for 15 minutes.~* Patient position: Prone with knee flexion approximately 45◦.~* Position of therapist: Standing at the affected side of patient.~* Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~* Strengthening exercises for quadriceps and hamstring will then be performed.~* Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Wall sits: For 10 seconds, 5 sets."
47990384|NCT06221904|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
47990385|NCT01550796|BEHAVIORAL|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
47990386|NCT03573479|OTHER|PICU Liber8 Bundle|Bundle of elements for quality improvement
48359167|NCT00852124|BIOLOGICAL|VSL#3 or placebo|1 packet 2 x daily of placebo
48359168|NCT00757289|BIOLOGICAL|PRP Injection|PRP Injection
47990387|NCT05181423|OTHER|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
47990388|NCT05077709|DRUG|IO102-IO103 in combination with pembrolizumab|The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
47990389|NCT05536258|OTHER|Fluid|The investigators will titrate fluid administration to maintain a RI \> 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI \> 90 over at least 85% of the intraoperative period.
48359169|NCT00757289|BIOLOGICAL|Corticosteroid Injection|Corticosteroid Injection
48359170|NCT05832866|OTHER|Clinical Based Isometric contraction strengthening Exercises using Thera band|Patients did isometric contraction exercises using thera band in the clinic physically. They did not need to be monitored by telephone
48359171|NCT05832866|OTHER|Telemonitored Home based Isometric Cntraction strengthening exercises using Thera band|Patients did isometric contraction exercises using thera band at home, they were monitored by telephone three times in a week for 8 weeks
47990390|NCT06201117|BEHAVIORAL|Preparatory information for ICU stay|Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
47990391|NCT06201117|BEHAVIORAL|Usual information|Preoperative information that is given to patients before having cardiac surgery
47990392|NCT02310945|OTHER|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
48671633|NCT05110326|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"* The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~* Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~* Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~* The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~* Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~* The procedure will be repeated 3 times in every session.~Strengthening Exercises:~* Same as ERGON Group"
48147929|NCT01124942|DEVICE|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
48359172|NCT06366685|BEHAVIORAL|Exercise and Psychological Intervention|To address the symptoms and severity experienced by esophageal cancer patients after surgery, providing them with exercise or psychological interventions to improve their rehabilitation outcomes.
48359173|NCT02354690|DRUG|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
48359174|NCT02354690|DRUG|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
48671634|NCT03443687|BEHAVIORAL|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
48671635|NCT03443687|DEVICE|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
48671636|NCT01989429|DRUG|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
47990393|NCT05230537|DRUG|Iptacopan (LNP023)|oral capsules
48359175|NCT02354690|DRUG|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
48359176|NCT02354690|DRUG|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
47990394|NCT05230537|DRUG|Placebo|oral capsules
47990395|NCT05025111|DEVICE|Entia Liberty|Home monitoring device
47990396|NCT01011660|DRUG|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
47990397|NCT05494242|OTHER|Surgical intervention|Pars-plana vitrectomy.
48147930|NCT04501588|BEHAVIORAL|Responsive training with no video feedback|Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.
48147931|NCT04501588|BEHAVIORAL|Responsive training with video feedback|Parents will receive responsive training and watch themselves on video to reflect on their strategy use.
47990398|NCT01305850|DRUG|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
48147932|NCT04187378|DEVICE|Surgical Underbody Blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
48147933|NCT04187378|DEVICE|Surgical access blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
48147934|NCT03419754|DIETARY_SUPPLEMENT|Glucose|Glucose
48147935|NCT03419754|BEHAVIORAL|Fidgetting|low intensity physical activity (fidgetting)
48147936|NCT01128439|OTHER|No intervention|No intervention
48359177|NCT03268057|DRUG|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
47990399|NCT01305850|DRUG|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
47990400|NCT01305850|DRUG|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
47990401|NCT01305850|DRUG|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
47990402|NCT04826705|DEVICE|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
47990403|NCT02394847|DRUG|propofol|
48147937|NCT03441464|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
48147938|NCT01526486|PROCEDURE|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
48147939|NCT01526486|PROCEDURE|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
48147940|NCT05197088|DRUG|Tamsulosin|1 week of tamsulosin
48147941|NCT00300339|DRUG|SL650472, Clopidogrel|
48147942|NCT06397989|DIETARY_SUPPLEMENT|Ready-to-use school food|80 grams of peanut paste-based food containing skim milk powder, cowpea, peanuts, vegetable oil, and multiple micronutrients
48147943|NCT06397989|DIETARY_SUPPLEMENT|Standard meal|300ml of porridge made with rice/millet flour
48147944|NCT03506802|RADIATION|18F-FHBG|Given IV
48147945|NCT03506802|BIOLOGICAL|Aldesleukin|Given SC
48671637|NCT06024187|PROCEDURE|Cold dissection|The subcutaneous flap dissection was performed with a scissor in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally. Our tumescent technique utilizes a solution made by mixing 0.2ml of epinephrine with 250 ml of 0.9% Sodium Chloride solution to create a 1‰ ratio. 150ml to 150ml of the solution was injected into the subcutaneous tissue of the operated breast with a 20-gauge spinal needle to establish a bloodless plane. The septa between the skin flap and parenchyma then was dissected using a scissor.
47990404|NCT01626807|BEHAVIORAL|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
47990405|NCT04743427|OTHER|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
47990406|NCT04743427|DEVICE|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
47990407|NCT04487639|DIAGNOSTIC_TEST|SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics|a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
47990408|NCT02546557|PROCEDURE|Coronary Artery Bypass Graft surgery|
47990409|NCT06209151|OTHER|monitor signs of infection|Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation \& mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.
47990410|NCT03301142|PROCEDURE|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
48147946|NCT03506802|BIOLOGICAL|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
48147947|NCT03506802|PROCEDURE|Computed Tomography|Undergo PET/CT
48147948|NCT03506802|BIOLOGICAL|Filgrastim|Given SC
48671638|NCT06024187|PROCEDURE|Electrocautery Dissection|The subcutaneous flap dissection was performed with electrocautery in this group. The boundary of mastectomy flap was defined as the edge of clavicle superiorly, the edge of sternum medially, the edge of inframammary fold inferiorly, and the edge of the latissimus dorsi laterally.
48147949|NCT03506802|OTHER|Laboratory Biomarker Analysis|Correlative studies
48359178|NCT02650804|DRUG|BPM31510 Nanosuspension Injection|
48359179|NCT02650804|DRUG|Gemcitabine|
48359180|NCT01664585|BEHAVIORAL|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
48359181|NCT01664585|BEHAVIORAL|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
48359182|NCT06095999|BEHAVIORAL|Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity|The intervention, delivered through a virtual coach, has a personalized duration and intensity, but will last on average 16 weeks. The intervention has three phases: preparation, execution (including \[re\]lapse) and closing. By having chat conversations with the Perfect Fit virtual coach (using the mobile application 'NiceDay'), the user will be guided through the different phases of the intervention. In each phase, the user has chat conversations with the virtual coach (e.g. about goal setting, weekly reflection) and, in addition, receives exercises and educational video material to support smoking cessation and PA promotion. Additionally, a smartwatch is used to objectively assess PA. It allows participants to monitor their PA and the data (on the number of steps) is used to give automatic, personalized PA advice to the user.
48147950|NCT03506802|DRUG|Lenalidomide|Given PO
48147951|NCT03506802|PROCEDURE|Leukapheresis|Undergo leukapheresis
48147952|NCT03506802|DRUG|Melphalan|Given IV
48147953|NCT03506802|DRUG|Plerixafor|Given SC
48147954|NCT03506802|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48147955|NCT04859062|DRUG|lidocaine gel 2%|assessing its efficacy in decreasing muscle traction pain,In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In the experimental group, we applied lidocaine gel 2% abundantly below both eyelids of the surgical eye for at least 3 minutes before the surgical incision, while nothing was applied to patients in the control group.
48147956|NCT04859062|OTHER|control group|In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In control group, we didn't apply lidocaine gel 2% to the operative eye .
48671639|NCT03099473|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
48671640|NCT03099473|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
48671641|NCT03099473|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
48671642|NCT04703140|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|2 nasopharyngeal swabs taken for PCR and COVIDISC
48671643|NCT02598141|BIOLOGICAL|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
48671644|NCT02598141|BIOLOGICAL|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
48671645|NCT01106989|DRUG|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
48671646|NCT02990650|BEHAVIORAL|Balance Task Training with therapist guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The therapist will provide guarding support"
48671647|NCT02990650|BEHAVIORAL|Balance task training with robotic guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
48671648|NCT02990650|BEHAVIORAL|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
48671649|NCT03111212|DRUG|Iloprost|Iloprost nebulized
48671650|NCT03111212|DRUG|control|sodium chloride 0,9% nebulized
48671651|NCT03893981|OTHER|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
48671652|NCT03893981|OTHER|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
48671653|NCT02042287|DEVICE|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
48671654|NCT02042287|DRUG|Metronidazole|Oral antibiotic
48671655|NCT01478932|BEHAVIORAL|diaphragmatic breathing retraining|In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
48147957|NCT03655366|OTHER|Questionnaire for Dog owners|Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
48147958|NCT03655366|OTHER|Questionnaire for Dog trainers|Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
48507959|NCT01801631|OTHER|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
48507960|NCT05754710|DRUG|Xeljanz|Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz
48507961|NCT00096603|DRUG|Raptiva (efalizumab)|
48507962|NCT05389631|OTHER|no intervention|no intervention
48507963|NCT00002737|BIOLOGICAL|recombinant interferon alfa|
48147959|NCT02705729|DEVICE|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
48147960|NCT02705729|DEVICE|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
48147961|NCT04518865|DEVICE|Herbst appliance|The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
48507964|NCT00002737|DRUG|chemotherapy|
48147962|NCT04776122|DEVICE|Therapy|Device-assisted breathing for relaxation
48147963|NCT04776122|OTHER|No device|Breathing platform without device
48359183|NCT05241470|DRUG|ST-100 Ophthalmic Solution|One drop in each eye twice a day
48359184|NCT05241470|DRUG|Placebo Ophthalmic Solution|One drop in each eye twice a day
48507965|NCT00002737|DRUG|isotretinoin|
48507966|NCT03330054|DEVICE|fundoscope|Fundoscope for eye examination
48507967|NCT01728129|DEVICE|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
48507968|NCT01728129|OTHER|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
48507969|NCT00577395|DRUG|placebo|oral tablet once a month for 12 months
48507970|NCT00577395|DRUG|risedronate|tablet, 150 mg once a month for 12 months
48507971|NCT03696225|BEHAVIORAL|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
48507972|NCT03696225|BEHAVIORAL|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
48671656|NCT01478932|BEHAVIORAL|Health Promotion|n-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
48671657|NCT03912363|OTHER|Rotating fluids protocol|"IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 100 mg/dL or less: IV fluids with 5% dextrose~* For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose~* For blood glucose \> 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)"
48671658|NCT03912363|OTHER|Insulin infusion protocol|"Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 80 mg/dL: No insulin AND IV fluids with 5% dextrose~* For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose~* For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose~* For blood glucose \> 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose"
48671659|NCT06151626|OTHER|virtual-reality based rhythmic skill training|Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.
48671660|NCT06151626|OTHER|rhythmic skill training with visual feedback|The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface
48671661|NCT06151626|OTHER|strengthening group|Participants receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.
48671662|NCT06151626|OTHER|breathing and muscle relaxation exercises|5 minutes of breathing and muscle relaxation exercises
48671663|NCT00664950|DEVICE|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
48671664|NCT00664950|DEVICE|IntertAn IM nail|interTAN IM nail
48671665|NCT00920556|DRUG|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
48671666|NCT00920556|DRUG|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
48671667|NCT01900665|DRUG|Solanezumab|Administered Intravenously (IV)
48671668|NCT01900665|DRUG|Placebo|Administered IV
48671669|NCT01808378|DRUG|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
48671670|NCT06086964|OTHER|therapeutic diet.|gluten and casein free diet.
48671671|NCT06086964|OTHER|physiotherapy|specific physiotherapy developmental program according to the pre evaluation of gross motor status.
48507973|NCT06358235|OTHER|Music Therapy|30-minute music therapy session.
48671672|NCT03388372|BIOLOGICAL|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
48671673|NCT03388372|DRUG|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
47990411|NCT03301142|PROCEDURE|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
47990412|NCT05098925|OTHER|Biological testing|Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
47990413|NCT05823623|DRUG|Inetetamab|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
48507974|NCT06358235|OTHER|No Music therapy|The practice where patients are simply fitted with headphones and rest quietly without listening to music.
48507975|NCT04735926|DRUG|Calcifediol 75mcg|Soft gelatin capsule. Oral administration once per week
48507976|NCT04735926|DRUG|Calcifediol 100mcg|Soft gelatin capsule. Oral administration once per week
48671674|NCT03388372|RADIATION|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
47990414|NCT05823623|DRUG|Pyrotinib|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
48507977|NCT04735926|DRUG|Calcifediol 125mcg|Soft gelatin capsule. Oral administration once per week.
48507978|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
48507979|NCT04735926|OTHER|Placebo|Soft gelatin capsule. Oral administration once per week.
48507980|NCT06633731|OTHER|Biocellulose Mask|Immediately after treatment, a Biocellulose Mask was applied to the subjects global face for 8 to 10 minutes.
48507981|NCT06633731|OTHER|Post Procedure Cream|Immediately after treatment and after Biocellulose Mask removal, the Post-Procedure Cream was applied to the subjects global face. Subjects were instructed to apply to the global face from days 1 - 3 post treatment.
48507982|NCT06633731|OTHER|Gentle Cleanser|Subjects were instructed to wash their face with the Gentle Foaming Cleanser twice daily for 12 weeks.
48671675|NCT03238989|OTHER|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
48671676|NCT02481258|DRUG|Ataciguat (HMR1766)|
48359185|NCT00641979|DRUG|budesonide|Current product
48507983|NCT06633731|OTHER|Facial Moisturizer|Subjects were instructed to apply the facial moisturizer twice daily to the global face from day 3 after treatment until next study visit.
48507984|NCT06633731|OTHER|sunscreen|Subjects were instructed to apply the bland sunscreen to the global face once daily in the morning, with re-application with extended sun exposure per FDA guidelines.
48507985|NCT03990610|PROCEDURE|Mammoplasty|Undergo standard of care breast reconstructive surgery
48507986|NCT03990610|PROCEDURE|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
48507987|NCT02908048|OTHER|Blood samples|Blood samples collected at varying intervals over a two to three year period.
48507988|NCT00522561|OTHER|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
48507989|NCT05767320|PROCEDURE|open repair(exploration)|repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration
48507990|NCT05767320|PROCEDURE|abdominal laparoscopy|repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
48507991|NCT06442787|DEVICE|conventional splints|only intermediate and final splint will be used during the surgery
48507992|NCT06442787|DEVICE|cutting guides and positioning guides|patient's specific manufacturing cutting guide and positioning guide related with orthognathic surgery
48507993|NCT06442787|DEVICE|cutting guides and fixation plates|patient's specific manufacturing cutting guide and fixation plates related with orthognathic surgery
48507994|NCT05249673|OTHER|global postural reeducation|"GPR interventions will last 9 sessions, 1 hour each, with one-to-one supervision, once or twice a week according to the participant's needs. All participants will receive advice to follow written ergonomic suggestions and to repeat the exercises in the first physical therapy session at home twice a week for 15 minutes. Each group will get a home exercise program, which will differ according to the type of treatment received. Participants in the GPR group will execute one posture routine."
48507995|NCT05249673|OTHER|neck stabilization training|"Each exercise session will be comprised 10-minute warm-up exercises, 40-minute stabilization exercises, and 10-minute cool-down and stretching exercises, including neck and shoulder girdle muscles. The whole program will be carried out 3 days per week for 4 weeks.~performed. The participants will be asked to maintain the positions and contractions during the exercises and throughout the day as much as possible. The combination and progression of the exercises will be designed according to condition of the patient."
48507996|NCT05908292|PROCEDURE|Pelvic Floor Scar Tissue Self-Scar Massage|Self scar-massage intervention of healed pelvic floor scar tissue for 5 minutes, 3x/week for 6 weeks.
48507997|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's Parent Toolkit 2.0|Parent Toolkit 2.0 is designed to equip parents and caregivers with skills to talk to their teens about sex and contraception and ultimately influence their teens' decision-making and behaviors around sex. The Georgia Campaign for Adolescent Power \& Potential (GCAPP) developed the Parent Toolkit intervention. Morehouse School of Medicine's (MSM) Health Promotion Research Center tested and adapted it through an OPA Innovation Network grant, creating Parent Toolkit 2.0.
48507998|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's General Health Guide|General Health Guide provides information to parents on how to promote health in their families.
48507999|NCT03745157|DRUG|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
48508000|NCT06628557|OTHER|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients
48508001|NCT03255174|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
48508002|NCT05452122|OTHER|Auditory and Electrical Stimulation|Electrical and auditory stimulation will be applied during sleep.
48508003|NCT03466268|DRUG|Gumarontinib Tablets|Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
48671677|NCT02481258|OTHER|Placebo Comparator: Matching Placebo|
48671678|NCT03424395|OTHER|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
48671679|NCT00001034|DRUG|Ganciclovir|
48671680|NCT02957513|BEHAVIORAL|Text Messaging (TM)|As specified in the arm description above
48671681|NCT02957513|BEHAVIORAL|Health Coaching (HC)|As specified in the arm description above
48671682|NCT02957513|BEHAVIORAL|Enhanced Usual Care (EC)|As specified in the arm description above
48671683|NCT05771532|BEHAVIORAL|Received the GS-SHEP|"The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy."
48359186|NCT00641979|DEVICE|Budesonide|New type device
48508004|NCT06444178|DRUG|Aspirin|Oral administration
48508005|NCT06444178|DRUG|REGN9933|Administered intravenous (IV)
48508006|NCT06444178|DRUG|REGN7508|Administered IV
48508007|NCT06444178|DRUG|Rivaroxaban|Oral administration
48671684|NCT02294032|DRUG|Immunosuppressive Agents|standard of care for patients post-transplant
48671685|NCT02283034|DEVICE|The CPRmeter|Feedback device - 1
48671686|NCT02283034|DEVICE|The PocketCPR|Feedback device - 2
48508008|NCT05495672|PROCEDURE|Local treatment|"Radical surgical resection, local radiotherapy, radiofrequency ablation (RFA) or interventional therapy (absolute alcohol or cryotherapy).~The equipment used for RFA of lung lesions consisted of the radiofrequency generator (CelonLab POWER), cold circulation pump (Celon Aquaflow Ⅲ), radiofrequency needle electrode (Celon proSurge: T20, T30 and T40 is an electrode length of 20, 30 and 40 mm respectively, and maximum output power of 20, 30 and 40 W; Olympus Surgical Technologies Europe, Hamburg, Germany)."
48508009|NCT00002926|DRUG|cytarabine|
48671687|NCT02283034|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
48671688|NCT02283034|DEVICE|The CPREazy|Feedback device - 3
48671689|NCT02283034|DEVICE|The CPR PRO APP|Feedback device - 4
48671690|NCT02283034|DEVICE|The CardioPump|Feedback devices - 5
48671691|NCT02283034|DEVICE|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
48671692|NCT00399035|DRUG|Cediranib|oral tablet
48671693|NCT00399035|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
48671694|NCT00399035|DRUG|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
48671695|NCT00399035|DRUG|Cediranib Placebo|oral tablet
48671696|NCT02338388|PROCEDURE|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
48671697|NCT02178800|DRUG|GSK1265744 Tablets|30-mg tablets, taken orally
48671698|NCT02178800|DRUG|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection"
48671699|NCT02178800|DRUG|Placebo for GSK1265744 Tablets|Taken orally
48147964|NCT01383785|OTHER|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
48147965|NCT01383785|OTHER|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
48147966|NCT01383785|OTHER|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
48147967|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
48147968|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
48147969|NCT03187249|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
48147970|NCT03187249|BEHAVIORAL|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
48147971|NCT03187249|BEHAVIORAL|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
48359187|NCT00641979|DRUG|Placebo|
48508010|NCT00002926|DRUG|etoposide|
48508011|NCT00002926|DRUG|idarubicin|
48508012|NCT00002926|PROCEDURE|allogeneic bone marrow transplantation|
48508013|NCT00002926|PROCEDURE|peripheral blood stem cell transplantation|
48671700|NCT02178800|DRUG|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
48671701|NCT05120050|DEVICE|ASP Health instrument|The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H\&E staining etc.
48671702|NCT02263014|BEHAVIORAL|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
48671703|NCT01114737|DRUG|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
48671704|NCT01114737|DRUG|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
48671705|NCT03249194|DRUG|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
48671706|NCT02817178|OTHER|Additional biological samples|blood and tumor tissue samples
48671707|NCT01305187|DEVICE|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
48671708|NCT01983007|PROCEDURE|High-intensity exercise|Performance of high-intensity exercise
48671709|NCT01983007|PROCEDURE|Low-intensity exercise|Performance of low-intensity exercise
48671710|NCT03766061|PROCEDURE|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
47990415|NCT05823623|DRUG|Oral Vinorelbine Tartrate|Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
48671711|NCT03766061|PROCEDURE|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
48359188|NCT04093401|OTHER|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
48359189|NCT02871232|OTHER|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
48359190|NCT00323804|BIOLOGICAL|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
48671712|NCT04769206|DRUG|Galantamine|4mg daily titrating up to 8mg twice a day
48671713|NCT04769206|DRUG|Placebo|1 pill a day for 4 weeks, 2 pills a day for 8 weeks
48671714|NCT02832570|DRUG|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
48671715|NCT02832570|DRUG|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
48671716|NCT01049373|DRUG|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
48671717|NCT01049373|DRUG|Placebo solution|10 drops, t.i.d, 15 weeks
48671718|NCT01336816|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
47990416|NCT01552252|DIETARY_SUPPLEMENT|apple juice|unaltered(0% POs-Ca) commercially available apple juice
47990417|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
47990418|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
47990419|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
47990420|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
47990421|NCT03702946|OTHER|oxytocin in abdominal myomectomy|Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
47990422|NCT00231335|DRUG|escitalopram|
47990423|NCT05266755|OTHER|Fracture Territorial Liaison Service afert a Hip fracture|Give a diferent than the current one way of follow up to the patients with hip fracture
48359191|NCT00323804|DRUG|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
48359192|NCT00323804|DRUG|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
48359193|NCT03102424|DEVICE|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
48359194|NCT03102424|DEVICE|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
48359195|NCT02023892|DRUG|atorvastatin|
48671719|NCT01336816|OTHER|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
48671720|NCT00233532|DRUG|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
48359196|NCT02023892|DRUG|placebo|
48359197|NCT00442611|DRUG|Abatacept|
48359198|NCT00442611|DRUG|Placebo|
48359199|NCT01161433|BEHAVIORAL|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system."
48359200|NCT04493229|DRUG|Oxytocin|IM Oxytocin
48359201|NCT04493229|DRUG|Placebo|Placebo IM
48671721|NCT02115321|DRUG|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
48671722|NCT02115321|DRUG|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
48671723|NCT02115321|DRUG|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
48671724|NCT04373421|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
47990424|NCT05434520|PROCEDURE|Preoperative biliary drainage (ERC og PTC-aided)|Placement of biliary stent (plastic, covered SEMS, uncovered SEMS) endoscopic by ERC or placement of plastic catheter by PTC
48359202|NCT04280185|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is a way of intraperitoneal chemotherapy
48359203|NCT05165186|OTHER|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video.
48359204|NCT00216086|DRUG|Capecitabine|"Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
48359205|NCT00216086|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
48147972|NCT04527679|DRUG|GC combined Lenvatinib|"1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg)."
48147973|NCT04768556|OTHER|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
48147974|NCT04768556|OTHER|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
48359206|NCT00216086|PROCEDURE|EUS|biopsy per EUS
48359207|NCT00216086|DRUG|Neoadjuvant Chemotherapy|"* Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
48359208|NCT00216086|PROCEDURE|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
48359209|NCT00216086|PROCEDURE|Surgery|Surgery within 8 weeks following chemoradiotherapy
47990425|NCT01207765|DRUG|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
48671725|NCT04373421|PROCEDURE|St. John's wort oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
48671726|NCT04373421|PROCEDURE|Virgin olive oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
47990426|NCT01207765|DRUG|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
47990427|NCT00412854|BIOLOGICAL|Infanrix™/Hib|
47990428|NCT00412854|BIOLOGICAL|Infanrix|
47990429|NCT00412854|BIOLOGICAL|Hiberix|
48359210|NCT00216086|PROCEDURE|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
47990430|NCT05363384|DRUG|CT-L01|FDC tablet, single dose, oral administration
48359211|NCT03281356|BEHAVIORAL|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
48359212|NCT05859776|DRUG|AXT107 Low Dose|Single suprachoroidal injection of AXT107 (0.125 mg/eye)
48359213|NCT05859776|DRUG|AXT107 Mid Dose|Single suprachoroidal injection of AXT107 (0.250 mg/eye)
48508014|NCT02052011|DRUG|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
48508015|NCT02052011|DRUG|Placebo|
48508016|NCT06634238|OTHER|Incremental shuttle walk test|Participants were recommended to wear comfortable clothing and appropriate shoes for the test. To minimize variability, one masked and one unmasked ISWT was performed on the same participant at the same time of day, one day apart
48508017|NCT02552732|DEVICE|NHF with or without Oxygen|NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
48508018|NCT04430309|BEHAVIORAL|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
48671727|NCT01211561|DRUG|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
47990431|NCT05363384|DRUG|Alogliptin Benzoate 25 mg|Alogliptin Benzoate 25 mg, oral administration
47990432|NCT05363384|DRUG|Metformin HCl XR 1,000 mg|Metformin HCl XR 1,000 mg, oral administration
48359214|NCT05859776|DRUG|AXT107 High Dose|Single suprachoroidal injection of AXT107 (0.500 mg/eye)
48359215|NCT02955446|DRUG|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
48359216|NCT00066716|DRUG|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
48508019|NCT04430309|BEHAVIORAL|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
48508020|NCT04510051|DRUG|Cyclophosphamide|Given IV
48508021|NCT04510051|DRUG|Fludarabine|Given IV
48508022|NCT04510051|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
48508023|NCT01121848|DRUG|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
48508024|NCT01121848|DRUG|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
48508025|NCT01121848|DRUG|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
48508026|NCT05695131|DEVICE|GlenXRose Virtual Reality Speech Therapies|Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
48508027|NCT04371094|DEVICE|a device to facilitate endotracheal intubation|a device to facilitate endotracheal intubation
48508028|NCT04141930|DRUG|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
48671728|NCT01211561|DRUG|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
48147975|NCT06019767|BEHAVIORAL|Cognitive Processing Therapy|CPT is a type of cognitive behavioral therapy recommended for the treatment of PTSD. Delivered over 12 sessions with an emphasis on addressing trauma-related cognitions and challenging trauma-related beliefs. Includes homework assignments. For this study, CPT will be conducted in groups.
48147976|NCT06092905|OTHER|Endoscopic clearance of common bile duct stones|Under general anesthesia, in left lateral decubitus, endoscopic clearance of common bile duct stones was done. Ultrasonography was used to ensure right positioning of the guide wire in the common bile duct, and ensure stone clearance.
48359217|NCT00066716|DRUG|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
48671729|NCT02757807|BEHAVIORAL|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
48671730|NCT02326727|DRUG|Ropivacaine|Epidural analgesia
48671731|NCT02326727|DRUG|Fentanyl|General Anesthesia
48671732|NCT02326727|DRUG|Propofol|General Anesthesia
48671733|NCT02326727|DRUG|Isoflurane|General Anesthesia
48671734|NCT02326727|DRUG|Nitrous Oxide|General Anesthesia
48671735|NCT04240431|DIAGNOSTIC_TEST|Probing /irrigation of lacrimal passages|Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
48671736|NCT00991809|DRUG|Alfentanil|15 mcg/kg IM
48359218|NCT00066716|DRUG|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
48359219|NCT00066716|PROCEDURE|adjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~4. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
48359220|NCT00066716|PROCEDURE|conventional surgery|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
48359221|NCT00066716|PROCEDURE|neoadjuvant therapy|"1. Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~2. Operation will be performed within 6-12 hours from the last dose of celecoxib.~3. Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
48359222|NCT00158275|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
48671737|NCT00991809|DRUG|Diphenhydramine|25 mg IM
47990433|NCT00598247|DRUG|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
47990434|NCT04888156|OTHER|Unchanged treatment|Treatment is the same pre- and post self-tonometry
48671738|NCT00300378|DRUG|desvenlafaxine 50 mg|
48671739|NCT00300378|DRUG|desvenlafaxine 100 mg|
48671740|NCT02636296|OTHER|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
48671741|NCT02636296|OTHER|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
48671742|NCT00216333|DRUG|combined fixed dose combination|
48671743|NCT01909544|OTHER|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
48671744|NCT04265794|BEHAVIORAL|H2GO!|Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
48671745|NCT02793661|DEVICE|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
48671746|NCT02793661|OTHER|Control|Hydration protocol following ESC Guidelines 2014
48671747|NCT00940550|DRUG|Prolonged-release melatonin|2 mg tablet, once.
48671748|NCT00940550|DRUG|Temazepam|20 mg capsule, once
48671749|NCT00940550|DRUG|Zolpidem|10 mg capsule, once
48359223|NCT00158275|DRUG|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
48359224|NCT00158275|BEHAVIORAL|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
48359225|NCT03927703|DRUG|SB206 12%|Topically once daily
48359226|NCT03927703|DRUG|Placebo|Topically once daily
48359227|NCT02995018|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-174)
48359228|NCT02995018|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
48359229|NCT02311634|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
48359230|NCT02311634|DEVICE|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
48359231|NCT05797727|DEVICE|LifeChamps Platform HCP|Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
48359232|NCT05797727|DEVICE|LifeChamps Platform|Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires
48359233|NCT01907750|DEVICE|biliary drainage tube|
48359234|NCT00268658|DEVICE|SmartStep(tm) biofeedback device|
48359235|NCT00901849|DRUG|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
48359236|NCT05488873|DRUG|WST-057 Active|WST-057 Topical Solution
48359237|NCT05488873|DRUG|Placebo|Matching Placebo Topical Solution
48508029|NCT06523660|BEHAVIORAL|CHUCK CHUCK SKILLS: CHild's Understanding of Cognitive sKills|The intervention will consist of an online EF training that will be delivered across 10 sessions (one 1 hour session per week for ten weeks). It will target core EF components including inhibitory control, attention shifting, and working memory in children with Autism Spectrum Disorder aged 5 to 7 years. It will also provide strategies (e.g., behavioral principles, compliance training) for promoting behavioral regulation and emotion regulation in these children. Accompanied parent coaching will be provided to enhance children's generalization of EF skill attainment.
48508030|NCT06523660|BEHAVIORAL|Parent Psychoeducation|Group-based parent psychoeducation, which consists of 10 sessions, 1-hour weekly program delivered via telehealth, will be provided to the control group.
47990435|NCT04888156|OTHER|Changed treatment|Treatment is changed post self-tonometry
48508031|NCT01476332|DRUG|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
48508032|NCT01476332|DRUG|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
48508033|NCT01476332|DRUG|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
48508034|NCT00237393|DRUG|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
48508035|NCT00237393|DRUG|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
48671750|NCT00940550|DRUG|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
48671751|NCT05067868|BIOLOGICAL|Replagal|Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
48671752|NCT04584047|PROCEDURE|Cell-based non-invasive prenatal testing|Blood sampling.
48671753|NCT03475602|DIAGNOSTIC_TEST|PLA2R|Determination of serum concentration of anti PLA2R antibody
47990436|NCT04237441|OTHER|number of participants with surgical complications|observation before and after multidisplinary team conference (MDT) was implemented
47990437|NCT05523661|DRUG|Dasatinib plus anti-CD19/CD22 CAR-T cells|Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy
47990438|NCT00017992|DRUG|Lopinavir/Ritonavir|
47990439|NCT00017992|DRUG|Emtricitabine|
47990440|NCT00017992|DRUG|Stavudine|
48508036|NCT05213039|OTHER|assessments|All of the children with cerebral palsy will be assessed by two different physiotherapist observers. The timed 360° turn test, Expanded and revised Gross Motor Function Classification System (GMFCS-E\&R) for functional motor levels of the subjects, lower extremity muscle tone will be measured with the Modified Ashworth Scale (MASH) at the beginning of the one-time study and recorded. Pediatric Berg Balance Scale, Timed Up and Go Test, Pediatric Functional Reaching test and Modified Four Square Stepping Test, 3m walking back test (3MGYT) will be performed.Evaluations will be made by two separate physiotherapists with at least 5 years of experience in this field. The time it took for individuals to complete activities during the tests with a stopwatch will be recorded.
48508037|NCT03133650|DRUG|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
48508038|NCT06282783|DRUG|Topiramate|Single dose of 400mg
48671754|NCT03475602|DIAGNOSTIC_TEST|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
48671755|NCT03888248|DEVICE|Whole-body vibration|Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
48671756|NCT03888248|OTHER|Muscle strengthening exercises|Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
48671757|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
48671758|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
48671759|NCT02745873|DRUG|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
48671760|NCT03893526|DRUG|Entresto|Single dose administration of entresto
48671761|NCT03893526|DRUG|Sitagliptin|Single dose administration of sitagliptin
48671762|NCT03893526|DRUG|Valsartan|single doses administration of valsartan
48359238|NCT01930487|DIETARY_SUPPLEMENT|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
48508039|NCT03133338|DEVICE|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
48508040|NCT00930163|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
48508041|NCT00930163|DRUG|placebo|Subcutaneous repeating dose
48508042|NCT05592548|DEVICE|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
48508043|NCT00626392|DRUG|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
48508044|NCT00626392|DRUG|aspirin (ASA)|325 mg tablets administered once daily
48508045|NCT00626392|DRUG|aspirin placebo (ASA Pbo)|Tablets administered once daily
48508046|NCT02925104|DRUG|INC280|
48508047|NCT03101644|DRUG|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
48508048|NCT02553447|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
48508049|NCT02553447|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48508050|NCT00528411|DRUG|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
48508051|NCT00528411|DRUG|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
48508052|NCT00528411|DRUG|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
48508053|NCT05965973|OTHER|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
48508054|NCT05965973|OTHER|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
48671763|NCT03893526|DRUG|Placebo|placebo day
48671764|NCT06134817|DEVICE|Embozene Color-Advanced Microspheres.|"Embozene Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer. The microspheres are intended to occlude vasculature for the purpose of blocking blood flow to a target tissue.~In the study, the abnormal vessels will be embolized with 100 μm Embozene Microspheres solution under direct fluoroscopic visualization to prevent reflux and non-target embolization. Multiple geniculate arteries may be embolized until neovascularity is no longer seen."
48671765|NCT02266303|OTHER|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
48671766|NCT02964377|DRUG|(+)- Epicatechin|
48671767|NCT01341743|DRUG|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
48671768|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
48671769|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
48671770|NCT03856866|DRUG|Hydroxychloroquine|Hydroxychloroquine: 4mg/kg/day, divided bid.
48671771|NCT03856866|DRUG|Placebo|Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
48671772|NCT00426803|DRUG|activated recombinant human factor VII|
48671773|NCT05292001|DRUG|Iron-Dextran Complex Injection [InFed]|single 1000mg dose
48671774|NCT05292001|OTHER|Saline Placebo|Normal saline
48671775|NCT03775993|DRUG|Human growth hormone|Administration of growth hormone
48671776|NCT03775993|OTHER|Placebo|Administration of placebo
47990441|NCT02680743|OTHER|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
47990442|NCT01736150|DRUG|Placebo|"* Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
47990443|NCT01736150|DRUG|Sevelamer carbonate|"* Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
48359239|NCT01930487|DIETARY_SUPPLEMENT|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
48359240|NCT05465785|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
48508055|NCT00086281|DRUG|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
48671777|NCT06405126|DIAGNOSTIC_TEST|Optiek predictive model|Patient data will be extracted to run the predictive model, which will estimate the probability of group 2 pulmonary hypertension. However the results of the model will have no diagnostic or therapeutic implications in this phase of the investigation.
47990444|NCT01438918|DRUG|SD-6010|200 mg tablets once a day for 2 years
47990445|NCT01438918|DRUG|SD-6010|50 mg tablets once a day for 2 years
47990446|NCT01438918|DRUG|Placebo|Placebo tablets once a day for 2 years
48359241|NCT00953784|PROCEDURE|standard operating management|As previously described
48359242|NCT00748449|PROCEDURE|Colonoscopy|1 Colonoscopy
48359243|NCT00748449|PROCEDURE|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
48359244|NCT00552006|BEHAVIORAL|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
48359245|NCT00552006|BEHAVIORAL|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
48359246|NCT01468389|DRUG|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
48359247|NCT01468389|DRUG|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
48359248|NCT02146885|OTHER|Weight Control|Weight Control
48508056|NCT00086281|DRUG|Zolpidem (Z)|Zolpidem 10 mg oral tablets
48508057|NCT00086281|DRUG|Modafinil (M)|Modafinil Oral Tablets
48508058|NCT00086281|DRUG|Placebo (P)|Placebo Oral Solution
48508059|NCT03497169|DRUG|Lisdexamfetamine Dimesylate|Patients are tested for their normal prescription lisdexamphetamine medication
48508060|NCT01492920|DIETARY_SUPPLEMENT|Acetyl-L-Carnitine Hydrochloride|Given orally
48508061|NCT01492920|OTHER|Placebo|Given orally
48508062|NCT01492920|OTHER|Questionnaire Administration|Ancillary studies
48508063|NCT01492920|OTHER|Quality-of-Life Assessment|Ancillary studies
48508064|NCT05976230|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
48508065|NCT06381557|DRUG|Zhengyuan Capsules|Zhengyuan capsules, 4 capsules at a time, 3 times per day;
48508066|NCT06381557|DRUG|Placebo contains 5%-10% Zhengyuan Capsule total mixed powder|Zhengyuan capsules simulator（Placebo contains 5%-10% Zhengyuan Capsule total mixed powder）, 4 capsules at a time, 3 times per day;
48508067|NCT02971098|PROCEDURE|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
48671778|NCT03070093|DRUG|gilteritinib|oral
48671779|NCT00529672|PROCEDURE|crossectomy and short stripping|under spinal or complete anaesthesia
48671780|NCT00529672|PROCEDURE|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein\>
47990447|NCT03063658|DRUG|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
47990448|NCT03063658|DRUG|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
47990449|NCT03022565|DRUG|Vorinostat|Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
47990450|NCT01669733|OTHER|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
47990451|NCT01669733|OTHER|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
48671781|NCT00529672|PROCEDURE|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
48359249|NCT05902533|RADIATION|Radiation (reduced elective nodal dose (30.6 Gy)|28-30 fractions Monday through Friday of intended chemoradiation depending on the total dose required (50.4-54 Gy) which will occur over approximately 5.5 to 6 weeks.
48359250|NCT05902533|DRUG|Capecitabine|825 mg/m2 BID (Oral Twice daily on days with RT)
47990452|NCT03986320|DEVICE|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
47990453|NCT03518385|DIAGNOSTIC_TEST|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
47990454|NCT04371887|OTHER|Local Tailoring|"The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants."
48147977|NCT05434507|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
48147978|NCT01565031|PROCEDURE|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
48359251|NCT05902533|DRUG|Mitomycin c|10 mg/m2 slow IV push Day 1 and 29
48359252|NCT02466906|DRUG|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.
48359253|NCT02466906|DRUG|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
48359254|NCT05290441|PROCEDURE|None involvement|No EGFR involvement
48359255|NCT02714894|DRUG|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
48359256|NCT00090324|DRUG|quetiapine fumarate tablets|
48359257|NCT01157585|DRUG|paliperidone ER|8 week prospective study
48508068|NCT01526473|BIOLOGICAL|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
48508069|NCT06484478|OTHER|Wearable technology monitoring|Observational study (no intervention delivered)
48508070|NCT05326048|OTHER|cytof analysis|cytof analysis of biological samples of CIS patients. Genomic analysis
48508071|NCT05110742|DRUG|Fludarabine Phosphate|Given by IV
48508072|NCT05110742|DRUG|Cyclophosphamide|Given by IV
48508073|NCT05110742|DRUG|CAR.5/IL15-transduced CB-NK cells|Given by IV
48508074|NCT01994291|DRUG|Ranibizumab|"Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks"
48671782|NCT03225482|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
48671783|NCT03225482|BEHAVIORAL|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
48508075|NCT01994291|DRUG|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
48508076|NCT01994291|DRUG|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
48671784|NCT03055091|OTHER|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
48671785|NCT03055091|OTHER|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
48671786|NCT02330614|OTHER|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
48671787|NCT02330614|OTHER|Nothing - control group|Only NEO-FFI test , data used as control
48508077|NCT01994291|DRUG|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
48508078|NCT04615650|PROCEDURE|Surgical treatment|Surgical treatment of suprasyndesmotic ankle fractures
47990455|NCT01685996|DRUG|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
47990456|NCT01685996|DRUG|placebo|
47990457|NCT03941431|DRUG|Jueyin granules|Jueyin granules p.o. once a day for 8 weeks.
47990458|NCT03941431|DEVICE|moving cupping therapy|Moving cupping therapy three times per week for 8 weeks.
47990459|NCT03941431|DEVICE|NB-UVB therapy|NB-UVB phototherapy three times per week for 8 weeks.
47990460|NCT03941431|DRUG|Jueyin placebo granules|Jueyin placebo granules p.o. once a day for 8 weeks.
47990461|NCT03941431|DEVICE|moving cupping placebo therapy|Moving cupping placebo therapy three times per week for 8 weeks.
48359258|NCT04467866|BEHAVIORAL|A Ride-on Car with a Standing Posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
48359259|NCT04467866|BEHAVIORAL|Regular Therapy Program|The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks. Each participant will have the opportunity to walk on the hallway/public space and interact with the therapist and caregivers depending on his/her motor abilities.
48359260|NCT04915209|OTHER|Narrative interviews|During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
48359261|NCT03137524|DEVICE|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
48359262|NCT05608694|OTHER|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
48359263|NCT03759444|OTHER|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
48359264|NCT05588011|DEVICE|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
48359265|NCT05588011|DEVICE|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
48359266|NCT04926870|OTHER|picture archiving and communication system|PACS administration during teaching
48359267|NCT04926870|OTHER|traditional|Clinical experience administration during teaching without PACS
48359268|NCT03970967|DEVICE|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
48359269|NCT02607735|DRUG|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
48359270|NCT02607735|DRUG|Placebo|Tablet administered orally once daily with food
48359271|NCT01933399|OTHER|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
48508079|NCT04615650|DEVICE|Ankle orthosis|Non-surgical treatment of suprasyndesmotic ankle fractures
48508080|NCT03587116|DRUG|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
48508081|NCT03587116|DRUG|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
48508082|NCT00636389|DEVICE|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
47990462|NCT03941431|DEVICE|NB-UVB placebo phototherapy|NB-UVB placebo phototherapy three times per week for 8 weeks.
47990463|NCT01618409|BEHAVIORAL|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
47990464|NCT00484211|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
47990465|NCT05132504|DRUG|Pembrolizumab|Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.
47990466|NCT05132504|DRUG|Folfirinox|Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
47990467|NCT03900767|OTHER|Electronic Health Record intervention|AAC
47990468|NCT03900767|BEHAVIORAL|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
47990469|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
47990470|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
48359272|NCT01933399|OTHER|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
48359273|NCT01933399|OTHER|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
48359274|NCT00532987|BEHAVIORAL|Questionnaire|Questionnaire form to be completed by patient
48359275|NCT03137433|DIETARY_SUPPLEMENT|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
48359276|NCT06095349|OTHER|inhalatory treatment with sulfureous aerosol|osteopenic patients are subject to a 12-days cycle of 30 minutes-long inhalatory treatment with sulfureous aerosol
48359277|NCT04146870|OTHER|not have|not have
48359278|NCT06402149|OTHER|dexamethasone|Use of dexamethasone in infraclavicular block
47990471|NCT00956904|DEVICE|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
47990472|NCT00422591|DRUG|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).
48147979|NCT05837689|DRUG|Blinatumomab|IV
48147980|NCT05876286|OTHER|Neurological examinations|Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.
48147981|NCT01350167|PROCEDURE|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
48147982|NCT04128956|DRUG|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
48359279|NCT06164418|PROCEDURE|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
48359280|NCT04679896|DEVICE|MagnetOs Putty|Procedure: Instrumented posterolateral spine fusion
48359281|NCT05584072|DIAGNOSTIC_TEST|Active pedal plantarflexion (APP) test|Active pedal plantarflexion (APP) test
48359282|NCT03705156|DRUG|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
48359283|NCT03705156|DRUG|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
48359284|NCT00267267|DRUG|torcetrapib/atorvastatin|
48359285|NCT00267267|DRUG|ezetimibe/simvastatin|
48359286|NCT01386749|PROCEDURE|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
48359287|NCT02089191|DEVICE|Nelfilcon A contact lenses|
48359288|NCT02089191|DEVICE|Stenfilcon A contact lenses|
48359289|NCT03356327|DRUG|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
48359290|NCT03356327|DRUG|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
48359291|NCT00755521|DRUG|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
48359292|NCT00758420|DRUG|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
48359293|NCT00758420|DRUG|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
48359294|NCT03909724|DRUG|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
48359295|NCT03909724|DRUG|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
48359296|NCT00887094|BEHAVIORAL|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
48359297|NCT00887094|BEHAVIORAL|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
48359298|NCT00216346|DRUG|Paromomycin sulfate|
48359299|NCT00216346|DRUG|Amphotericin B|
48508083|NCT00636389|DEVICE|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
48508084|NCT04278716|OTHER|Safe return to play checklist|this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
48508085|NCT04539912|DEVICE|angulated screw retained crown|ASC abutment was used in AG;
48359300|NCT02583828|DRUG|Cyclophosphamide 50mg|
48359301|NCT02583828|DRUG|Letrozole 2.5 mg|
47990473|NCT00422591|DRUG|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
48359302|NCT01694667|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
48359303|NCT01694667|OTHER|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
48359304|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48508086|NCT04539912|DEVICE|cemented crown|prefabricated Ti abutment was used in CG
48359305|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
48359306|NCT05600556|OTHER|Best Practice|Review imaging on standard computer screen
48359307|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
48359308|NCT05600556|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48359309|NCT05600556|PROCEDURE|Computed Tomography|Undergo CT
48508087|NCT00482781|BIOLOGICAL|Infanrix|
48508088|NCT00482781|BIOLOGICAL|Pediatrix|
48508089|NCT00236912|DRUG|levofloxacin; metronidazole|
48671788|NCT03293121|BEHAVIORAL|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength \& coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
47990474|NCT02551731|DRUG|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
47990475|NCT03896555|DEVICE|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
48359310|NCT05600556|OTHER|Virtual Technology Intervention|Review virtual reality images
48359311|NCT05600556|OTHER|Questionnaire Administration|Complete questionnaire
48359312|NCT01899729|DRUG|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
48359313|NCT01899729|DRUG|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
48359314|NCT01899729|DRUG|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
48359315|NCT01899729|DRUG|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
48359316|NCT01899729|DRUG|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
48359317|NCT04383743|DRUG|Cisplatin|Given IV
48359318|NCT04383743|DRUG|Doxorubicin|Given IV
48359319|NCT04383743|DRUG|Methotrexate|Given IV
48359320|NCT04383743|BIOLOGICAL|Pegfilgrastim|Given SC
48508090|NCT04314648|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|Embedding of a collaborative care team, called the Substance Use Treatment and Recovery Team (START), for inpatients with OAUDs within an existing hospital consultation liaison psychiatry service.
48508091|NCT05769010|DRUG|SHR-A1811|SHR-A1811: intravenous
48508092|NCT05769010|DRUG|Pyrotinib|Pyrotinib: oral
48671789|NCT03293121|BEHAVIORAL|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
48671790|NCT03322982|BEHAVIORAL|Low-fat diet|less than 20% calories from fat daily
48671791|NCT04985084|BEHAVIORAL|The intervention group|The intervention will last for four weeks and target six dietary behaviors related to gastric cancer. The intervention components include one session of face-to-face education prior to discharge and three sessions of telephone counselling after discharge. The face-to-face education will last for 20 to 30 minutes and each session of telephone counselling will last for 10 to 20 minutes. All the interventional sessions are individual based.
48359321|NCT04383743|BIOLOGICAL|Pembrolizumab|Given IV
48359322|NCT04383743|PROCEDURE|Radical Cystectomy|Undergo standard of care radical cystectomy
48359323|NCT04383743|DRUG|Vinblastine Sulfate|Given IV
48359324|NCT03549637|DIAGNOSTIC_TEST|Psychiatric population|Genetic and biological analysis of patients
48359325|NCT00120029|BEHAVIORAL|weight loss counseling|
48508093|NCT05769010|DRUG|Bevacizumab|Bevacizumab: intravenous
48508094|NCT05583305|DIAGNOSTIC_TEST|Imaging assessment|Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.
48359326|NCT04374526|BIOLOGICAL|COVID-19 Convalescent Plasma|ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
48359327|NCT04399993|OTHER|Intervention Protocol in Diaphragm|"The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements."
48359328|NCT04399993|OTHER|Sham technique|In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
48359329|NCT01041586|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
48359330|NCT06356441|DIAGNOSTIC_TEST|AI|An artificial intelligence model predicts the risk and contours of local recurrence for MR images and triages them before radiologists interpret them.
48359331|NCT00472823|DIETARY_SUPPLEMENT|Vitamin D3|Orally for one year
48359332|NCT00472823|DIETARY_SUPPLEMENT|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
48359333|NCT00005838|DRUG|shark cartilage extract AE-941|Given orally
48359334|NCT00005838|OTHER|placebo|Given orally
48359335|NCT00005838|DRUG|cisplatin|Given IV
48359336|NCT00005838|DRUG|vinorelbine tartrate|Given IV
48359337|NCT00005838|DRUG|carboplatin|Given IV
48359338|NCT00005838|DRUG|paclitaxel|Given IV
48359339|NCT00005838|RADIATION|radiation therapy|Undergo radiotherapy
48359340|NCT02330640|DRUG|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
48508095|NCT05583305|DIAGNOSTIC_TEST|Neurosonology assessment|Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.
48671792|NCT04985084|OTHER|Usual care|General dietary advice provided as routine by the ward nurses before discharge from the hospital.
48671793|NCT01643057|DEVICE|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
48671794|NCT06461039|DRUG|NNC0487-0111 A|NNC0487-0111 A will be administered subcutaneously.
48671795|NCT06461039|DRUG|NNC0487-0111 C|NNC0487-0111 C will be taken orally.
48671796|NCT06461039|DRUG|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)|Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.
48671797|NCT06461039|DRUG|Acetaminophen - 500 mg/15 ml|Acetaminophen - 500 mg/15 ml will be taken orally.
48671798|NCT05081921|DRUG|MesoCellA-Ortho administration|"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."
48671799|NCT05081921|DRUG|HA administration|"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."
48671800|NCT02569346|DRUG|Triumeq|Single-dose Triumeq as a whole tablet
48671801|NCT02569346|DRUG|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
48671802|NCT02569346|DRUG|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
48671803|NCT06000592|DEVICE|Digitimer|transcutaneous spinal cord stimulation for blood pressure control following spinal cord injury.
48671804|NCT01478984|PROCEDURE|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
48671805|NCT01478984|PROCEDURE|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
48671806|NCT02375074|BEHAVIORAL|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
48671807|NCT02375074|BEHAVIORAL|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
48671808|NCT01652781|DRUG|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
48671809|NCT05035238|BIOLOGICAL|Triple dose vaccination by inactivated Covid19 vaccine|triple dose intramuscular vaccine on Day 0, Day 28, and Day 120.
48671810|NCT04383093|DRUG|Tadalafil 5mg|Combination therapy of daily tadalafil plus tamsulosin
48671811|NCT00329030|DRUG|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
48508096|NCT05583305|DIAGNOSTIC_TEST|Blood Test|Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.
47990476|NCT05487482|OTHER|Ageing Safe from the Risk (ASRi) Model of safety culture|For the intervention groups, planning will be done to provide education and training. Families will be given modules on Safety Culture in the Elderly. Materials provided about the safety of the elderly include changes in the elderly, the concept of safety in the elderly, the type of danger to the elderly, how to prevent harm in the elderly, the first handling in case of accidents, and the role of the family in the efforts of elderly safety. The material will be delivered by experts in elderly health and patient safety (professionals from health centers, social services, and academics). In addition to education and training, families will also receive home visits to check and monitoring the condition of the elderly at home related to adverse events and the home environment. Measuring will be done every 4 weeks by using a monitoring book.
48508097|NCT02965963|DRUG|Dopamine|
48508098|NCT02965963|DRUG|Metoclopramide|
48508099|NCT02965963|DRUG|Placebos|
48508100|NCT02965963|OTHER|Rest|
48508101|NCT02965963|OTHER|Exercise - 60%|60% of VO2max
48508102|NCT02965963|OTHER|Exercise - 85%|85% of VO2max
47990477|NCT03016286|OTHER|vibration|Whole body vibration at 25Hz frequency
47990478|NCT01924312|BEHAVIORAL|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
47990479|NCT00001482|DRUG|Lamotrigine (Lamictal® (Registered Trademark)|
47990480|NCT00001482|DRUG|Gabapentin (Neurontin® (Registered Trademark))|
47990481|NCT03366376|RADIATION|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
47990482|NCT00295347|DRUG|Spironolactone|
48508103|NCT05892692|BEHAVIORAL|Ecological Momentary Intervention|Participants will receive hypothetical and real-time behavioral feedback using a smartphone application which provides ecological momentary responses to their current behaviors. By providing safety tips and advice, the intervention may decrease incidences of sexual assault and risky sex compared to a control group.
48508104|NCT00787059|DRUG|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
48671812|NCT00329030|DRUG|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
47990483|NCT00295347|DRUG|fludrocortisone|
47990484|NCT00295347|DRUG|escitalopram|
48508105|NCT00787059|DRUG|Sucrose (3%)|
48508106|NCT06299930|PROCEDURE|Neoadjuvant chemotherapy|Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy
48508107|NCT06299930|PROCEDURE|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
48508108|NCT04513288|DIETARY_SUPPLEMENT|Experimental treatment L-citrulline (Protéocit®)|Enteral administration of citrulline for 5 days.
48508109|NCT04513288|OTHER|Placebo treatment|Enteral administration of iso-nitrogenous placebo for 5 days.
48508110|NCT05424822|DRUG|JNJ-80948543|JNJ-80948543 will be administered as SC or IV injection.
48508111|NCT03444376|DRUG|GX-188E|GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
48508112|NCT03444376|DRUG|KEYTRUDA®|pembrolizumab(100mg/4mL/vial), Intravenous administration
48508113|NCT02652611|PROCEDURE|SI Screw Removal Surgery|
47990485|NCT02022098|DRUG|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
47990486|NCT02022098|RADIATION|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
47990487|NCT02022098|DRUG|Debio 1143|Debio 1143 solution
47990488|NCT02022098|DRUG|Placebo|Matching placebo solution
47990489|NCT00961844|BIOLOGICAL|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
47990490|NCT00961844|DRUG|Temozolomide|
47990491|NCT01894854|PROCEDURE|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
47990492|NCT06297733|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the inventory and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
47990493|NCT06297733|OTHER|Validity|The inventory will be applied by face-to-face technique and convergent validity will be evaluated. Construct validity will be evaluated through exploratory and confirmatory factor analysis. Coefficients of fit will be calculated.
48671813|NCT00587041|DIETARY_SUPPLEMENT|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
48671814|NCT00587041|DIETARY_SUPPLEMENT|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
48359341|NCT02330640|DRUG|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
48671815|NCT00587041|OTHER|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
48359342|NCT02330640|DRUG|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
48359343|NCT04999319|PROCEDURE|PVB|Paravertebral block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
48359344|NCT04999319|PROCEDURE|ESPB|Erector spinae plane block will be performed before the surgery with 20 mL of %0.5 bupivacaine at T4 level.
48359345|NCT03755037|DRUG|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
48671816|NCT01677260|DRUG|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
48671817|NCT01677260|DRUG|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
48671818|NCT03058133|OTHER|fMRI study|Functional brain activations of face-voice processing during a gender task
48671819|NCT04795401|DEVICE|FRAME FR IFU|The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
48359346|NCT00304681|DRUG|OROS*-Methylphenidate|
48359347|NCT01922466|PROCEDURE|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week"
48359348|NCT01922466|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
48359349|NCT05439200|DEVICE|Asynchronous 3D movies|3D movies streamed at home for viewing on a handheld lenticular 3D screen
48359350|NCT05439200|DEVICE|Patching|Adhesive patch to cover the fellow eye
48359351|NCT05456516|BEHAVIORAL|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
48359352|NCT06365957|OTHER|Ketone monoester supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate, and acetone).
48359353|NCT06365957|OTHER|High-intensity interval exercise|High-intensity interval exercise is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high-intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of lower-intensity movements. The exercise will be conducted on a computer-monitored cycle ergometer.
48359354|NCT06365957|OTHER|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise generally consists of 30-60 min of aerobic exercise at 64-76% peak heart rate, while interval training involves more intense bouts interspersed by recovery periods. The exercise will be conducted on a computer-monitored cycle ergometer.
48508114|NCT02652611|PROCEDURE|Non-screw removal treatment (non-operative management)|
48508115|NCT04328961|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy
48508116|NCT04328961|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.
48508117|NCT03645239|PROCEDURE|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
48508118|NCT03645239|OTHER|Preoperative pain assessment|"Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?)."
48508119|NCT03645239|OTHER|Questionnaires|Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.
48508120|NCT03645239|OTHER|Headspace|The mindfulness exercise mobile application, Headspace, will be downloaded into the patients' mobile devices. Patients will be asked to experience a mindfulness exercise for 10-30 minutes before delivery. HADS and pain score will be asked after the intervention.
48508121|NCT04144361|PROCEDURE|sleeve with plication|sleeve with plication
48508122|NCT04144361|PROCEDURE|sleeve without plication|sleeve without plication
48508123|NCT04618783|BIOLOGICAL|Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 7.5, 22.5, and 22.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
48508124|NCT04618783|BIOLOGICAL|Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 15, 45, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
48508125|NCT04618783|BIOLOGICAL|Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses|Antigen content: 22.5, 67.5, and 67.5 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
48508126|NCT04618783|BIOLOGICAL|Three doses of control wIPV, vaccinated within one-month interval between doses|Antigen content: 40, 8, and 32 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
48508127|NCT04618783|BIOLOGICAL|Three doses of control sIPV, vaccinated within one-month interval between doses|Antigen content: 30, 32, and 45 D-antigen unite for type 1, 2, and 3 in 0.5 ml diluent per dose
48508128|NCT04105127|DEVICE|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
48508129|NCT04105127|DEVICE|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
48508130|NCT01910012|DRUG|ADI-PEG 20|
48508131|NCT02506283|DEVICE|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
48508132|NCT02274831|OTHER|Email Reminder of need to follow up with primary physician|
48508133|NCT05938504|OTHER|ONS_320275|Subjects will consume two packs (165ml/pack) of placebo ONS (ONS_320275) orally daily at any time of day.
48508134|NCT05938504|OTHER|ONS_211567|Subjects will consume two packs (165ml/pack) of test ONS (ONS_211567) orally daily at any time of day.
48508135|NCT06625918|DEVICE|Ultraviolet B exposure to produce vitamin D synthesis|Exposure using a UV skin care device on vitamin D production and immune response in healthy adults
47990494|NCT06297733|OTHER|Reliability|The reliability of the items will be tested with Cronbach alpha. Test-retest reliability will be measured by ICC.
47990495|NCT01280214|DRUG|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
48508136|NCT01696058|DRUG|Tiotropium|marketed product
48508137|NCT01696058|DRUG|Placebo matching Olodaterol|one dose
48508138|NCT01696058|DRUG|Tiotropium|marketed product
48508139|NCT01696058|DRUG|Olodaterol|one dose
48671820|NCT00105534|DRUG|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
48671821|NCT00105534|OTHER|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
48671822|NCT05775900|DRUG|Cetuximab|Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
48671823|NCT05775900|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
48671824|NCT01779414|OTHER|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
48671825|NCT00501644|DRUG|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
48671826|NCT00501644|DRUG|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
48671827|NCT00501644|DRUG|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
48671828|NCT01979679|DRUG|Lurasidone 80 mg|
48671829|NCT01979679|DRUG|Lurasidone 120 mg|
48671830|NCT01979679|DRUG|Lurasidone 160 mg|
48671831|NCT06274983|DEVICE|IVR platform trial|8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform. Patients will receive device training and then use the VR device at home for 12 weeks. Physiotherapists will conduct pre (visit 1) and post (visit 2) assessments to assess changes using a Goniometer (measures ankle range of movement), PEDSQL quality of life data, GAD-7 anxiety questions and the NorthStar Ambulatory Assessment.
48671832|NCT02655887|DEVICE|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
48671833|NCT00089492|DRUG|Optimized Background ARVs|As prescribed
47990496|NCT02537054|DRUG|Aflibercept|Intravitreal injection
48359355|NCT06365957|OTHER|Placebo|The placebo will be the taste-matched water.
48508140|NCT04194294|DRUG|Lidocaine|Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.
48508141|NCT04194294|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
48671834|NCT00089492|DRUG|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
48671835|NCT00089492|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
48671836|NCT01196195|DRUG|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
48671837|NCT01196195|DRUG|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
48671838|NCT02150239|PROCEDURE|operation|
48671839|NCT03200002|DRUG|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
48359356|NCT02364999|DRUG|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
48359357|NCT02364999|DRUG|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
48359358|NCT02364999|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
47990497|NCT00775970|BEHAVIORAL|walking activity|
47990498|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in a day ight
47990499|NCT06332846|OTHER|oral examination|The oral health was assessed in each patient enrolled in the study. The examination was performed by using dental mirror and a calibrated periodontal probe in the artificial lightning
48359359|NCT02364999|DRUG|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
48359360|NCT03082768|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two \[18F\]MNI-968 injections and PET scans.
48508142|NCT02787408|DEVICE|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
48508143|NCT03875859|DRUG|Remetinostat|Topical 1% remetinostat gel
48508144|NCT01279083|DRUG|DE-112|Topical ocular solution
48508145|NCT01279083|DRUG|DE-112|Topical ocular solution
48508146|NCT01279083|DRUG|DE-112|Topical ocular solution
48508147|NCT01279083|DRUG|DE-112|Topical ocular solution
48671840|NCT03200002|DRUG|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count \<1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count \<1000/mm3.
48671841|NCT04020640|OTHER|no intervention|Measure human intake using stable isotope technique
48359361|NCT05135507|BEHAVIORAL|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
48671842|NCT02544854|DRUG|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended."
48671843|NCT06302023|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) 1000 mg|Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
48671844|NCT04861714|DEVICE|Regeneten|Augmentation of standard subscapularis repair with regeneten patch
48671845|NCT04861714|PROCEDURE|Standard repair|Standard subscapularis repair
48359362|NCT05502120|DEVICE|Laryngoscopy with Vie-Scope laryngoscope|Evaluation of laryngeal view using Vie-Scope laryngoscope, intubation efficacy, complications
48359363|NCT05502120|DEVICE|Laryngoscopy with Macintosh blade laryngoscope|Evaluation of laryngeal view using stnadard Macintosh blade laryngoscope
48508148|NCT01279083|DRUG|DE-112 Vehicle Solution|Topical ocular solution
47990500|NCT01214161|DRUG|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
48359364|NCT05609500|BEHAVIORAL|Warfarin dosage adjustment model|Warfarin dosage adjustment model use to predict the initiation and the maintenance dose of warfarin. Variation of warfarin dose during stable maintenance phase for the same patient might be influenced more by temporal factors such as modification of drug regimens that utilize the CYP450 pathway, or dietary vitamin K intake
48359365|NCT05980390|DIAGNOSTIC_TEST|IL 35 in tissue biopsy|Elisa testing
48359366|NCT01195636|DRUG|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
48359367|NCT01195636|DRUG|Placebo|Twice daily application of Placebo ointment
48359368|NCT05314699|BEHAVIORAL|resistance-aerobic exercise, RA|Participants conduct 5-min warm up, 13-min resistance exercise, 12-min aerobic exercise, and 5-min cool down.
48508149|NCT01279083|DRUG|Timolol Maleate Solution|Topical ocular solution
48508150|NCT00002825|BIOLOGICAL|filgrastim|
48508151|NCT00002825|DRUG|docetaxel|
48508152|NCT06619626|DEVICE|alveolar recruitment strategy applied group|the effect of alveolar recruitment strategy on the mechanical parameters of the patients
48508153|NCT06619626|DRUG|group without alveolar recruitment strategy|effect on mechanical parameters of patients without alveolar recruitment strategy
48508154|NCT04257149|DIAGNOSTIC_TEST|Hemorrhagic stroke group (group A)|Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
48508155|NCT04257149|DIAGNOSTIC_TEST|Ischemic stroke group (group B)|Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
48508156|NCT04257149|DIAGNOSTIC_TEST|Stroke mimic group (group C)|Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
48508157|NCT02195661|DIETARY_SUPPLEMENT|Melatonin|
48671846|NCT03835078|DEVICE|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
48671847|NCT03835078|DEVICE|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
48671848|NCT01378117|DRUG|Sitagliptin|Sitagliptin 50-100mg po once daily
48671849|NCT01378117|DRUG|glargine|glargine once daily
48671850|NCT01378117|DRUG|lispro|lispro before meals
48671851|NCT01847755|DRUG|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
48671852|NCT06020521|OTHER|Three spectrometry differents technics|"Collection of expired air as follows:~* For online mass spectrometry techniques (PTR-MS and SICRIT)~* For offline mass spectrometry (GCxGC-MS)~Performing volatolome analyses:~* By PTR-TOF-MS (Ionicon) and SICRIT-HRMS (SICRIT module (Plasmion) coupled to a Q-exactive instrument (Thermofisher)) for online analyzes~* By two-dimensional gas chromatography coupled with mass spectrometry (Pegasus BT-4D, Leco) for the desorption tubes."
48671853|NCT04676906|DRUG|NNC0113-6861|Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
48671854|NCT04676906|DRUG|NNC0113-6860|Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
48671855|NCT04676906|DRUG|NNC0113-6891|Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
48671856|NCT06206434|DIAGNOSTIC_TEST|Point of care ultrasonography|Transthoracic echocardiogrpahy followed spinal anesthesia and 5 ml/kg Ringers lactate fluid co-loading
48671857|NCT02873078|BEHAVIORAL|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
48671858|NCT02793583|BIOLOGICAL|Ublituximab|
48671859|NCT02793583|DRUG|Umbralisib|
47914353|NCT03699215|DRUG|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.
48508158|NCT02195661|DRUG|Chloral Hydrate|
48671860|NCT02793583|BIOLOGICAL|Bendamustine|
48671861|NCT03387956|DRUG|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
48671862|NCT03387956|DRUG|dexamethasone|intravenous 8 mg dexamethasone (2ml).
48671863|NCT06058962|DRUG|Suramin Sodium|Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
48671864|NCT00644839|DRUG|CP-945,598|Administration of CP-945,598 alone in period 1
48671865|NCT00644839|DRUG|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
48359369|NCT05314699|BEHAVIORAL|aerobic-resistance exercise, AR|Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cold down.
48671866|NCT00646126|DRUG|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
48671867|NCT00646126|DRUG|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
48671868|NCT01812057|DRUG|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
48671869|NCT01812057|DRUG|Placebo|Sodium Chloride 0.9% -5 ml
48671870|NCT03753022|OTHER|Group G5|Submitted to peep 5
48671871|NCT03753022|OTHER|Group G10|Submitted to peep 10
48508159|NCT04810065|OTHER|SingStrong: Strong lungs through Song|"Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.~The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.~Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,"
48508160|NCT01544179|DRUG|Gefitinib|Investigational Drug
48508161|NCT01544179|DRUG|Placebo|Matching placebo as comparator
48508162|NCT01544179|DRUG|Pemetrexed|Chemotherapy (concomitant therapy)
48671872|NCT03753022|OTHER|Group G15|Submitted to peep 15
48671873|NCT01227785|DEVICE|INCEPTA ICD or CRT-D|
48671874|NCT02142088|DEVICE|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
48671875|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Ultravision™ System|The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
48671876|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Airseal® iFS|The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
48671877|NCT05215002|OTHER|Telephone Call|Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
48671878|NCT05215002|OTHER|No telephone call|Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
48671879|NCT00403156|DRUG|Imatinib Mesylate /Ranibizumab|
48671880|NCT02590289|DRUG|BBI-5000|BBI-5000 low dose, middle dose, or high doses
48671881|NCT01342926|DRUG|GSK933776|GSK933776
48671882|NCT01342926|DRUG|Placebo|Placebo
48671883|NCT04256187|OTHER|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
48671884|NCT04271800|BIOLOGICAL|CD19 CAR-T cells|A single infusion of CD19-CAR-T cells will be administered intravenously.
48671885|NCT04276025|OTHER|Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
48359370|NCT04313894|BIOLOGICAL|Wharton Jelly Originated Mesencimal Stem Cell|In this study, the patient who has no systemic disease from Erciyes University, Obstetrics and Gynecology Department will be taken to the cord transport solution which will be medical waste after delivery. Samples for transport bacteriological tests from the transport solution to the laboratory shall be separated. They will be processed in a number of ways. The cells obtained will be administered intraarticularly at a dose of 1 x 100.000.000.
48359371|NCT03427528|BEHAVIORAL|Fathers and Babies (FAB)|The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
48359372|NCT03427528|BEHAVIORAL|MB 1-on-1 plus TXT|Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
48359373|NCT04718883|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
48359374|NCT06305169|DIAGNOSTIC_TEST|Gastropanel|Gastropanel is a commercially available blood test which given serum levels of pepsinogen I and II and gastrin 17 along with helicobacter pylori infection status
48359375|NCT02368158|OTHER|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
48359376|NCT00427739|PROCEDURE|Cardiac CT|64 slice spiral computerized tomography
48359377|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
48359378|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
48359379|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
48359380|NCT01138605|DRUG|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
48508163|NCT01544179|DRUG|Cisplatin|Chemotherapy (concomitant therapy)
48359381|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
48359382|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
48359383|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
48359384|NCT01138605|DRUG|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
48359385|NCT01138605|DRUG|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
48359386|NCT01138605|DRUG|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
48359387|NCT01138605|DRUG|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
48359388|NCT01138605|DRUG|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
48359389|NCT01138605|DRUG|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
48508164|NCT02790515|DRUG|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
48359390|NCT01138605|DRUG|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
48359391|NCT01138605|DRUG|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
48359392|NCT02840903|DRUG|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
48359393|NCT02610894|OTHER|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
48508165|NCT02790515|DRUG|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
48508166|NCT02790515|DRUG|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
48508167|NCT02790515|DRUG|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
48508168|NCT02790515|DRUG|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
48508169|NCT02790515|DRUG|Melphalan|Given IV prior to transplant on Days -2 and -1.
48508170|NCT02790515|DRUG|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
48508171|NCT02790515|DRUG|Rituximab|Given IV prior to transplant on Day -1.
48508172|NCT02790515|DRUG|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
48508173|NCT02790515|DRUG|Thiotepa|Given IV prior to transplant on Day -3.
48508174|NCT02790515|BIOLOGICAL|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
48147983|NCT02144883|BEHAVIORAL|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
48359394|NCT02610894|OTHER|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
48359395|NCT00934752|DEVICE|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
48359396|NCT00053482|BIOLOGICAL|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
48359397|NCT00053482|BIOLOGICAL|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
48359398|NCT04598100|BEHAVIORAL|FOCUS-EC|
48359399|NCT02975206|DRUG|Serlopitant High Dose|serlopitant tablets - high dose
48359400|NCT02975206|DRUG|Placebo Oral Tablet|placebo tablet
48508175|NCT02790515|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
48359401|NCT02975206|DRUG|Serlopitant Low Dose|serlopitant tablets - low dose
48508176|NCT02790515|DRUG|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
48508177|NCT04686552|DIETARY_SUPPLEMENT|cinnamon|6 g of ground cinnamon
48508178|NCT04627987|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.
48508179|NCT04627987|DIAGNOSTIC_TEST|Serum biomarkers (High sensitivity troponin, NT-proBNP|Blood tests looking evidence of cardiac structural remodelling and function.
48508180|NCT04627987|PROCEDURE|Implantable Loop Recorder|Determine post-AVR arrhythmia burden
48508181|NCT04627987|DIAGNOSTIC_TEST|6 minute walk test|Validated assessment of functional capacity - distance walked over 6 minute time frame.
48508182|NCT04627987|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
48508183|NCT05827614|DRUG|BBI-355|Oral CHK1 inhibitor
48359402|NCT05849740|DRUG|Daratumumab and corticosteroid treatment|Daratumumab and corticosteroid treatment
47990501|NCT01214161|OTHER|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
47990502|NCT04022447|DRUG|Dupilumab|retrospective data collection
47990503|NCT01631877|DRUG|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
48359403|NCT03267004|DEVICE|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\]."
48359404|NCT03267004|DEVICE|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\]."
48359405|NCT02223949|DEVICE|Cook double balloon catheter|
48359406|NCT02223949|DRUG|PGE1 tablet|
48359407|NCT00736385|DRUG|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
48359408|NCT00736385|DRUG|Placebo|placebo 2000 mg daily for 12 months
48359409|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 1mg once daily
48359410|NCT00256204|DRUG|Rasagiline Mesylate|tablet, 2mg once daily
48359411|NCT00256204|OTHER|Placebo|Placebo
48359412|NCT05658328|BEHAVIORAL|SHARP - Physical and social activity|Technology-enabled neighborhood walking 3x/week for 16 weeks with conversational reminiscence
48508184|NCT05827614|DRUG|Erlotinib|EGFR Inhibitor
48508185|NCT05827614|DRUG|Futibatinib|FGFR1-4 Inhibitor
48508186|NCT04609826|DRUG|JNJ-74856665|JNJ-74856665 will be administered orally.
48508187|NCT04609826|DRUG|AZA|AZA will be administered IV infusion or SC injection.
48508188|NCT04609826|DRUG|VEN|VEN tablet will be administered orally.
48508189|NCT06035809|BEHAVIORAL|SMART|A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
48508190|NCT00631657|DRUG|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
48508191|NCT00631657|DRUG|Placebo|One placebo tablet once a day
48508192|NCT05076240|PROCEDURE|FilmArray® analysis|FilmArray® multiplex PCR analysis to diagnose ventilator associated pneumonia in COVID-19 ARDS
48508193|NCT06149806|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|efficacy and tolerability of Sacubitril/Valsartan in the treatment of chronic heart failure on complex congenital cardiopathy
47990504|NCT01631877|OTHER|placebo|injection placebo will be given for 5 days along with placebo tablets
48359413|NCT03698370|DRUG|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
48359414|NCT03698370|DEVICE|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
48359415|NCT03058809|DEVICE|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
48359416|NCT00688649|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
48359417|NCT00688649|DIETARY_SUPPLEMENT|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
48359418|NCT00029666|DEVICE|Neopulse Magnetic Stimulator|
48359419|NCT03357328|OTHER|Therapy light room|See group description
47990505|NCT02545790|PROCEDURE|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
47990506|NCT02545790|BIOLOGICAL|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
47990507|NCT03264209|BEHAVIORAL|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
47990508|NCT01356745|DRUG|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
48359420|NCT03357328|OTHER|Standard light|See group description
48359421|NCT00305773|DRUG|vorinostat|Given orally once daily
48508194|NCT01307176|BEHAVIORAL|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
48508195|NCT00392912|DRUG|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
48508196|NCT03906552|OTHER|nonpharmalogocial methods|neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
47990509|NCT01356745|DRUG|medical air|inhalation gas for inhalation use
48359422|NCT00305773|DRUG|vorinostat|Given orally three times daily
47990510|NCT03125070|OTHER|Best Practice and Internet site with links to existing resources|Receive usual care
47990511|NCT03125070|OTHER|Internet, Mobile app and Telehealth Intervention|Receive INSPIRE and survivorship care plan
47990512|NCT03125070|OTHER|Survey Administration|Ancillary studies
47990513|NCT00845169|PROCEDURE|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
47990514|NCT02029833|OTHER|Regular Canola Oil|
48359423|NCT01181336|BIOLOGICAL|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
48359424|NCT01181336|BIOLOGICAL|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
48359425|NCT01429376|OTHER|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
48359426|NCT01429376|OTHER|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
48508197|NCT03598790|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
48508198|NCT00010426|DRUG|cysteamine hydrochloride|
48147984|NCT02144883|BEHAVIORAL|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
48671886|NCT06353477|DRUG|EPs® 7630|EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
48671887|NCT04753489|DRUG|Rivaroxaban film-coated tablet 10 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
48671888|NCT04753489|DRUG|Xarelto® film-coated tablet 10 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
48147985|NCT02706483|DRUG|Plecanatide|
48359427|NCT01429376|OTHER|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
48359428|NCT01429376|OTHER|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
48508199|NCT05913505|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
48359429|NCT04143828|BEHAVIORAL|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
48359430|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
48671889|NCT00794092|DRUG|Sinerem administration|Single dose
47990515|NCT02029833|OTHER|High Oleic Canola Oil|
48671890|NCT04258852|DRUG|Low strength nicotine e-liquid|Low strength nicotine e-liquid
48671891|NCT04258852|DRUG|High strength nicotine e-liquid|High strength nicotine e-liquid
48671892|NCT04286178|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
48671893|NCT04286178|DIETARY_SUPPLEMENT|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
48671894|NCT04286178|DIETARY_SUPPLEMENT|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
48671895|NCT04286178|DIETARY_SUPPLEMENT|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
47990516|NCT02029833|OTHER|Western Type Diet - Common Dietary Oils|
48359431|NCT00833066|BIOLOGICAL|Placebo|placebo entero-coated capsules
48359432|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
48359433|NCT00833066|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
47990517|NCT01531712|DRUG|Gemcitabine|1000mg/m2 / / 40mg/m2
47990518|NCT01531712|RADIATION|Radiotherapy|50.4 Gy
47990519|NCT01531712|DRUG|Tarceva|100mg/day
48359434|NCT00554229|DRUG|ZD4054|ZD4054 10 mg oral tablet once daily
48359435|NCT00554229|DRUG|Placebo|Matching placebo oral tablet once daily
48359436|NCT05753124|OTHER|Observational|This is an observational study
47990520|NCT01531712|DRUG|Oxaliplatin|100mg/m2 (only in QT)
47990521|NCT02806310|OTHER|Blood draw|blood sampling for biomarker levels
47990522|NCT06051188|DEVICE|Flow-controlled ventilation|Flow-controlled ventilation (FCV)
47990523|NCT02133950|PROCEDURE|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
47990524|NCT02133950|PROCEDURE|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
47990525|NCT04927390|DRUG|Mycophenolate Mofetil 500mg|Mycophenolate Mofetil oral tablet twice daily for up to 96 weeks
48147986|NCT05731440|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
48147987|NCT04520321|DRUG|TTHX1114(NM141)|engineered FGF-1 delivered intracamerally
48147988|NCT04520321|OTHER|Vehicle (placebo)|Placebo
48147989|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
48147990|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
48147991|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
48147992|NCT05642702|OTHER|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
48359437|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
48671896|NCT04286178|BEHAVIORAL|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
48671897|NCT03528317|OTHER|Alternate day fasting|Alternate day fasting with a high protein diet
48671898|NCT02350218|DRUG|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
48671899|NCT02382588|DRUG|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
48671900|NCT02382588|DRUG|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
47990526|NCT02130661|DRUG|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
47990527|NCT02130661|DRUG|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
47990528|NCT02130661|DRUG|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
47990529|NCT03163082|OTHER|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
47990530|NCT03163082|BEHAVIORAL|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
47990531|NCT03163082|OTHER|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
47990532|NCT03163082|OTHER|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
47990533|NCT04823637|DIAGNOSTIC_TEST|Ultrasonography vs Osteopathic manipulative medicine structural exam|Structural examination of the thoracic spine using ultrasound and osteopathic palpatory examination on skin.
48147993|NCT05642702|OTHER|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
48147994|NCT02359071|OTHER|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
48147995|NCT03391700|DRUG|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
48147996|NCT03391700|DRUG|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
48147997|NCT05661240|DEVICE|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
48147998|NCT05661240|DRUG|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
48359438|NCT01148836|DIETARY_SUPPLEMENT|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
48359439|NCT02774863|OTHER|Home passages|Three home passages between the 2nd and 3rd months of follow up.
48359440|NCT00597129|BIOLOGICAL|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
48359441|NCT05763472|GENETIC|Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).|Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.
48359442|NCT03481634|DRUG|Brolucizumab|Intravitreal injection
48359443|NCT03481634|DRUG|Aflibercept|Intravitreal injection
48359444|NCT05074160|DEVICE|OCS Liver|Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.
48359445|NCT01118039|DRUG|sunitinib malate|
48359446|NCT01118039|OTHER|immunohistochemistry staining method|
48359447|NCT01118039|OTHER|laboratory biomarker analysis|
48359448|NCT01118039|OTHER|pharmacological study|
48359449|NCT01118039|PROCEDURE|quality-of-life assessment|
48359450|NCT02095444|DRUG|Menstrual blood stem cells|10\*7 cells/kg, intravenous injection for 4 times during two weeks
48359451|NCT02084940|DRUG|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
48359452|NCT05684315|PROCEDURE|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
48359453|NCT03700424|DRUG|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
48671901|NCT03820830|DRUG|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
48671902|NCT03820830|DRUG|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
48671903|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
48671904|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
48671905|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
48147999|NCT01336842|DRUG|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
48671906|NCT02670902|BEHAVIORAL|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
48359454|NCT03700424|DRUG|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
48359455|NCT03309722|OTHER|biomarker study|
48359456|NCT05031494|DRUG|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
48359457|NCT05031494|DRUG|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
48359458|NCT05031494|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
48359459|NCT05031494|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
48671907|NCT02670902|BEHAVIORAL|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
48508200|NCT05913505|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
48359460|NCT03212209|DEVICE|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
48508201|NCT03121287|OTHER|Imaging Biomarkers|Whole lung volumetric CT scans
48508202|NCT03121287|OTHER|Pulmonary|Pulmonary Function Tests \& 6 minute hall walk
48508203|NCT03121287|OTHER|Imaging|Cardiac MRI
47990534|NCT06478537|DRUG|Hetrombopag Olamine|"Treatment period: 24-week Hetrombopag (2.5mg/d\~7.5mg/d) treatment.~* Two consecutive visits with PLT\>600 × 10\^9/L: daily dose reduction of 2.5mg; If the lowest dose has been used, extend the dosing interval.~* Two consecutive visits with PLT\<300 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached.~* Two consecutive visits with PLT\<50 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached; If PLT is still\<50 × 10\^9/L with7.5mg/d × 28d, the patient will be withdrawn.~Drug discontinuation period：8-week Hetrombopag (2.5mg/d\~7.5mg/d) reduction. Hetrombopag reduces by 2.5mg every 2 weeks, and after reducing to the minimum dose of 2.5mg/d x 2 weeks, it is changed to 2.5mg once every other day (Qod) treatment, with a maximum reduction time of 8 weeks. If the PLT during two consecutive visits is less than 30 × 10\^9/L, the patient will be withdrawn."
47990535|NCT06478537|DRUG|Aspirin|Aspirin 100mg, qd
47990536|NCT00278083|DRUG|Study drug administration|
47990537|NCT00278083|PROCEDURE|Tuberculin intradermal skin test|
48508204|NCT03121287|OTHER|Specimen Collection|Blood draw
48671908|NCT01889992|RADIATION|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 \>/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
48671909|NCT01889992|PROCEDURE|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
48671910|NCT01889992|OTHER|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
48671911|NCT01889992|DRUG|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
48671912|NCT01889992|PROCEDURE|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
48671913|NCT01889992|GENETIC|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
47990538|NCT00278083|PROCEDURE|Lung function test for FEV1|
48508205|NCT01178528|DRUG|ivabradine|7.5 mg bd
48508206|NCT01178528|DRUG|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
48508207|NCT01178528|DRUG|Carvedilol|25 mg bd
48508208|NCT00508131|OTHER|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
48508209|NCT05076019|DRUG|Atorvastatin 80mg|Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
48508210|NCT05076019|DRUG|Placebo|Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
47990539|NCT00278083|PROCEDURE|Asthma symptom scores diary|
47990540|NCT00278083|PROCEDURE|Quality of life diary|
47990541|NCT00278083|PROCEDURE|Breath nitric oxide|
47990542|NCT00278083|PROCEDURE|Breath condensate|
47990543|NCT00278083|PROCEDURE|Sputum induction|
47990544|NCT00278083|PROCEDURE|Blood sampling|
47990545|NCT00278083|PROCEDURE|Urinalysis|
47990546|NCT05211713|DEVICE|Opp|Opp is a universal mental health promoting mobile application for adolescents aged 13-25 years.
48508211|NCT02194348|DRUG|BIBN 4096 BS - in single rising doses|
48508212|NCT02194348|DRUG|Placebo|
48148000|NCT00246350|PROCEDURE|massage|8 light massage treatments and hot pack
48148001|NCT00246350|PROCEDURE|massage|16 light massage treatments and hot packs
48148002|NCT00246350|PROCEDURE|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
48671914|NCT01889992|OTHER|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
48671915|NCT01381770|BIOLOGICAL|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
48671916|NCT00408980|BEHAVIORAL|Fat and calorie controlled diet|
48671917|NCT04236271|DEVICE|connected objects|a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
48148003|NCT00246350|PROCEDURE|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
48148004|NCT00589628|DRUG|infliximab|5mg/kg/dose IV at 4 week intervals
48148005|NCT00589628|DRUG|infliximab|10mg/kg/dose IV at 4 week intervals
48359461|NCT05998902|PROCEDURE|Trophic enteral feeding combined with supplemental parenteral nutrition|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
48359462|NCT05998902|PROCEDURE|Full enteral feeding|The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
48359463|NCT05518994|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
48359464|NCT04768439|DRUG|Low Dose Vitamin D|Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
48359465|NCT04768439|DRUG|High Dose Vitamin D|Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
48359466|NCT05277194|BEHAVIORAL|KeepCalm app|The KeepCalm app is designed to help manage stress and prevent challenging behaviors in children with autism.
48508213|NCT06148415|BEHAVIORAL|Fetal Heartbeat Monitoring Group|Fetal Heartbeat Monitoring Group
48508214|NCT01458873|DRUG|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
48148006|NCT02855762|OTHER|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
48148007|NCT00091728|DRUG|Depo Medroxyprogesterone acetate|
48508215|NCT01458873|DRUG|diluted sodium bicarbonate 2.1%|50ml
48508216|NCT01458873|DRUG|normal saline|50ml
48508217|NCT02276950|PROCEDURE|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
48359467|NCT02375529|PROCEDURE|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
48359468|NCT02375529|PROCEDURE|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
47990547|NCT02917031|DRUG|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
48671918|NCT03251521|OTHER|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
48671919|NCT02160288|DRUG|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
48359469|NCT00286156|DRUG|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
48359470|NCT02088736|DEVICE|Intraosseous|
48359471|NCT02088736|DEVICE|Intravenous|
47990548|NCT02917031|DRUG|Sitagliptin|50 mg or 100 mg, gray capsule
48359472|NCT00671411|DRUG|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings \& Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 \& 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings \& energy w/i FDA guidelines. This will only be performed while imaging the kidney."
48359473|NCT00663533|DEVICE|Vas-X|mechanical vasectomy device
48359474|NCT05071794|DRUG|Propofol|Antiemetic effect of propofol
47990549|NCT02917031|DRUG|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
47990550|NCT02917031|DRUG|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
47990551|NCT02884596|DRUG|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
47990552|NCT01854905|OTHER|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
47990553|NCT06200727|PROCEDURE|PRF membrane tamponade surgery in macular hole|A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.
48671920|NCT02160288|DRUG|Normal Saline|Dispensed in a 5 cc syringe
48671921|NCT01441388|DRUG|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
48671922|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
47990554|NCT06200727|PROCEDURE|ILM peeling in macular hole|The treatment of the macular hole was ILM peeling.
47990555|NCT06200727|PROCEDURE|PRF membrane grafting in pterygium|Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.
48148008|NCT00091728|DRUG|Combined oral contraceptives|
48148009|NCT06088199|DRUG|Apremilast|Oral tablet
48671923|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
48671924|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
48671925|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
48671926|NCT01441388|DRUG|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
48671927|NCT01441388|DRUG|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
47990556|NCT06200727|PROCEDURE|Autologous conjunctival transplantation in pterygium|Used of autologous conjunctiva to cover exposed sclera after pterygium excision
47990557|NCT06200727|PROCEDURE|autologous PRF membrane grafting in trabeculectomy for glaucoma|Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.
47990558|NCT06200727|PROCEDURE|Amniotic membrane in trabeculectomy for glaucoma|Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.
48671928|NCT03401203|PROCEDURE|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
48671929|NCT03401203|PROCEDURE|Balloon angioplasty|Percutaneous coronary intervention
48359475|NCT05071794|DRUG|saline 0.9%|Placebo
48359476|NCT03000413|DRUG|Ketamine|Active treatment
48359477|NCT03000413|DRUG|Fentanyl|
48671930|NCT01162551|DRUG|Sirolimus and Methotrexate|"Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days."
48671931|NCT02603757|DIETARY_SUPPLEMENT|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
48671932|NCT00765219|BEHAVIORAL|CBT|10-12 weekly sessions of CBT in person or over the telephone.
48671933|NCT00765219|OTHER|Usual Care|Treatment as usual provided by participants' physician(s)
47990559|NCT06200727|PROCEDURE|PRF membrane grafting incorneal ulcer|After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
48359478|NCT02909504|DRUG|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
48508218|NCT02276950|PROCEDURE|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
48508219|NCT01199016|PROCEDURE|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
48508220|NCT01199016|PROCEDURE|Nose/throat swab|To be performed at every study visit
48508221|NCT01199016|BIOLOGICAL|Observational|Observational Study Only
48508222|NCT04823975|BEHAVIORAL|Health Insurance Education Program (HIEP)|\[See arm/group description\]
48508223|NCT01910246|DRUG|Metformin|
48508224|NCT02339662|DRUG|Gabapentin|muscles pain treatment
48508225|NCT02339662|DRUG|Amitriptyline|muscles pain treatment
48508226|NCT06634329|OTHER|Oro or Nasogastric tube feeding|Parental involvement in their premature baby's feeding
48508227|NCT01038362|OTHER|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
48508228|NCT01038362|OTHER|No Almonds|NCEP Step 1 diet without almonds
48508229|NCT03668392|DRUG|Asparaginase|Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
48508230|NCT05578183|DEVICE|theta burst stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
48508231|NCT05578183|DEVICE|sham stimulation|expect for the TBS, all patients get cognitive training alike on a training system in medical center.
48508232|NCT03677583|OTHER|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
48359479|NCT06000826|DEVICE|Celsi Warmer|During the study, research participants will receive thermal care via the Celsi Warmer. Aside from thermal treatment, research participants will receive the standard of care from the neonatal unit, and will also be closely monitored by study personnel throughout the study. The results from this study will allow the research team to determine if the Celsi Warmer is an effective tool for warming and monitoring newborns in wards of low-resource hospitals. The research team hopes to demonstrate that the Celsi Warmer is effective for the appropriate treatment of newborn hypothermia in hospitals in low-resource settings.
48671934|NCT02612493|OTHER|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
47990560|NCT06200727|PROCEDURE|Amniotic membrane in corneal ulcer|After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
48671935|NCT00459940|DRUG|Pioglitazone|
48671936|NCT04163939|OTHER|Vista Therapy Collar|The patient will wear the cervical collar
47990561|NCT02192918|BEHAVIORAL|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
47990562|NCT02192918|BEHAVIORAL|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
48671937|NCT04163939|OTHER|Placebo|The patient will not wear the cervical collar
48359480|NCT00276354|DRUG|PEG 4000 (Forlax ®)|
48359481|NCT02736149|DRUG|ubenimex|
48359482|NCT02629887|DEVICE|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
48359483|NCT02629887|DEVICE|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
48671938|NCT02452073|OTHER|Thyroid function tests|
48671939|NCT05490758|OTHER|sensorimotor training|sensorimotor training include activities like play with dough, peg games, puzzles for 5 days a week for 4 week.
48671940|NCT05490758|OTHER|constraint induced movement therapy|constraint induced movement therapy in which arm was constraint for 6 hours a day for 5 days a week for 4 week.
48671941|NCT03389308|DRUG|diacerein 1% ointment|"Topically apply study medication to lesions identified by the Investigator that require.~treatment"
48671942|NCT02185534|DRUG|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
48671943|NCT04402710|BEHAVIORAL|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
48671944|NCT04402710|BEHAVIORAL|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
47990563|NCT02192918|BEHAVIORAL|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
47990564|NCT05358171|OTHER|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
47990565|NCT05358171|OTHER|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
48148010|NCT03039556|BEHAVIORAL|Normal Daily Steps|Complete normal daily ambulation for one week
48508233|NCT03677583|OTHER|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
47990566|NCT01053819|DRUG|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
48359484|NCT02629887|DEVICE|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
48359485|NCT03696498|PROCEDURE|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
48508234|NCT06453850|DEVICE|Use of FLEXIGO delivery catheter|Use of FLEXIGO delivery catheter for implantation of ventricular pacing lead
48508235|NCT03016819|DRUG|AL3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
48359486|NCT03696498|PROCEDURE|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
48359487|NCT01784900|DRUG|Catumaxomab 100µg|
48359488|NCT01784900|DRUG|Catumaxomab 140µg|
48359489|NCT06459856|OTHER|Balloon blowing|Ask the patient to take in a deep breath; steadily and slowly blow up the huge balloon. See the balloon getting bigger, and bigger. Now ask the patient to close the eyes and imagine the balloon floating into the air. Let the patient continue blowing of balloons until he or she gets relaxed and calm.
48508236|NCT03016819|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
47990567|NCT03099044|OTHER|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
48508237|NCT03016819|DRUG|AL3818 or placebo|AL3818 or placebo 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
48508238|NCT01226407|DRUG|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
48508239|NCT02976285|PROCEDURE|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
48508240|NCT00006183|PROCEDURE|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
48508241|NCT00006183|PROCEDURE|Thoracic Surgery|
48671945|NCT02965638|OTHER|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
48359490|NCT06459856|OTHER|Percussion|Percussion is a technique involving rhythmic tapping or clapping on the chest or back, serves as a means to move and loosen retained secretions within the airways. This mechanical intervention helps in removing mucus from the bronchial walls, and facilitates its expectoration and clearance
48671946|NCT01809665|DEVICE|ICD/CRT-P therapy|
48671947|NCT01809665|OTHER|MRI|
48671948|NCT02448147|BEHAVIORAL|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
48148011|NCT03039556|BEHAVIORAL|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
48148012|NCT03039556|BEHAVIORAL|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
48148013|NCT03077256|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery
48671949|NCT02448147|BEHAVIORAL|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
48671950|NCT01864265|DRUG|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
48671951|NCT01864265|DRUG|Placebo|Placebo will be administered according to the label of the biological
48671952|NCT00003109|DRUG|irinotecan hydrochloride|
48359491|NCT02141854|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
48508242|NCT04362553|DEVICE|wearable vital signs sensor|vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
48508243|NCT00753857|OTHER|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
48508244|NCT00753857|OTHER|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
48508245|NCT01711892|BEHAVIORAL|Soccer training|
48671953|NCT00003109|DRUG|raltitrexed|
48148014|NCT00854594|BEHAVIORAL|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
48148015|NCT03556852|DRUG|Carbetocin|1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
48148016|NCT03556852|DRUG|Misoprostol|2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
48508246|NCT04093375|PROCEDURE|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
48671954|NCT05009095|DEVICE|The Listening Program® with bone conduction headphones|The Listening Program method of Music-Based Auditory Stimulation is enhanced with the addition of bone conduction technology with the ABT Bone Conduction System. Bone Conduction combines the experience of listening to music through modified headphones adding subtle, synchronized acoustic vibration of the skin and skeletal system, engaging the whole body and brain in the listening process. This multi-sensory approach accelerates and expands the benefits of The Listening Program.
48671955|NCT00540696|DRUG|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
48671956|NCT01794910|OTHER|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
48671957|NCT05884372|DRUG|Eldecalcitol|the same as arm descriptions.
48671958|NCT05884372|DRUG|Native Vitamin D|the same as arm descriptions.
48671959|NCT05884372|DRUG|Denosumab|the same as arm descriptions.
48671960|NCT05884372|DRUG|Calcium|the same as arm descriptions.
48671961|NCT05587660|PROCEDURE|Fully threaded cannulated screws|The most popular method in undisplaced neck of femur fracture include internal fixation by cannulated screws in which screws can be inserted relatively simply and atraumatically as compared to other methods. Screws can be used partially threaded or fully threaded; however studies on fully threaded screw fixation method are inconclusive.
48671962|NCT01459666|DRUG|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
48671963|NCT01459666|DRUG|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
48671964|NCT01015521|DRUG|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
47990568|NCT03099044|OTHER|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
48148017|NCT05898789|BEHAVIORAL|CaRE@Home intervention|participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
48148018|NCT00907959|DRUG|BZL101|Oral BZL101 20 grams/day (10 grams BID).
48148019|NCT02948309|DRUG|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
48148020|NCT02948309|DRUG|Placebo|1ml subcutaneous injection 3 times/week
48148021|NCT02254902|BEHAVIORAL|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
48359492|NCT02141854|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
48359493|NCT02141854|DRUG|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
48671965|NCT00770302|DRUG|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
48671966|NCT03758807|OTHER|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
48671967|NCT03758807|OTHER|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
47914354|NCT03699215|DRUG|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
47990569|NCT03099044|OTHER|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
47990570|NCT04309643|DRUG|CTP-543|Investigational Drug
47990571|NCT04309643|DRUG|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
48148022|NCT01973361|DEVICE|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
48148023|NCT01973361|DEVICE|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
48671968|NCT04275076|PROCEDURE|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
48671969|NCT03845829|PROCEDURE|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
48671970|NCT00998257|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
48671971|NCT01249001|DRUG|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
48671972|NCT01249001|DRUG|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
48671973|NCT01490034|BEHAVIORAL|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
47990572|NCT04899414|DRUG|Dexamethasone, azacytidine, Pegaspargase, Tislelizumab|Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
48671974|NCT01490034|BEHAVIORAL|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
48671975|NCT01490034|BEHAVIORAL|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
48671976|NCT01490034|BEHAVIORAL|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
48671977|NCT03314935|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
48671978|NCT03314935|DRUG|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
48671979|NCT03314935|DRUG|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
48671980|NCT03314935|DRUG|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
48671981|NCT03314935|DRUG|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
48359494|NCT02141854|DRUG|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
48671982|NCT03314935|DRUG|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
48671983|NCT03314935|DRUG|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
48671984|NCT00551096|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
48671985|NCT00551096|DRUG|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
48671986|NCT00551096|DRUG|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
48671987|NCT02962921|DRUG|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
48359495|NCT02859480|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
48359496|NCT02859480|DRUG|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
48671988|NCT01244711|DRUG|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
48671989|NCT01951664|OTHER|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
48671990|NCT01951664|BEHAVIORAL|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
48671991|NCT01951664|BEHAVIORAL|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
48671992|NCT01951664|BEHAVIORAL|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
48671993|NCT01951664|OTHER|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
48671994|NCT05412992|DRUG|DMTS Patch|DMTS applied before surgery and worn for 96 hours
48671995|NCT05412992|DRUG|Placebo Patch|Matching patches that have no active drug applied before surgery and worn for 96 hours
48671996|NCT05346328|DRUG|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
47990573|NCT00140647|DRUG|Ramipril|
47990574|NCT00140647|DRUG|Rosiglitazone|
47990575|NCT04967196|BIOLOGICAL|Ipilimumab|Given via DoseConnect device or IV
47990576|NCT04967196|BIOLOGICAL|Nivolumab|Given IV
47990577|NCT04967196|PROCEDURE|Lymph Node Assessment|Undergo lymphatic imaging with ICG
48671997|NCT04940728|OTHER|Creative thinking techniques intervention program|The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
48508247|NCT04093375|OTHER|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
48671998|NCT01025557|OTHER|Dietary intervention|Dietary treatments with beverages
48671999|NCT03815747|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
48672000|NCT01555866|DRUG|isavuconazole|IV
48672001|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with local anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.
48672002|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with placebo|Block performed with bilaterally inserted q-tips with isotone NaCl
47990578|NCT04967196|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47990579|NCT06258876|OTHER|PrEP in general practice|Prescription and follow-up of PrEP in general practice
47990580|NCT02824250|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
48672003|NCT05390684|OTHER|audit of complications, prospective data collection|Prospective colecction of data will be performed to create a predictive model of leak and major complication
48672004|NCT05081362|OTHER|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity during ten minutes in rest and ten minutes in orthostatic position
48672005|NCT00692003|DRUG|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg; \>= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
48672006|NCT00692003|DRUG|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
48672007|NCT06576466|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate. Guinama brand with CE marking. Code 89823.
48672008|NCT06576466|OTHER|Placebo|Dextrinomaltose. Guinama brand with CE marking. Code 91146.
48672009|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
48672010|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
47990581|NCT00000296|DRUG|Cotinine fumarate|
47990582|NCT04176900|OTHER|Ingeo Biopolymer (PLA)|Biopolymer used for 3D-printing of rigid bolus
48359497|NCT03177473|DEVICE|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
48359498|NCT05357586|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders is a manualized, evidence-based form of cognitive behavioral therapy aimed at targeting emotion regulation processes that underlie common forms of emotional disorders such as anxiety, depression, and commonly co-occurring mental health challenges.
48359499|NCT00916994|DEVICE|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
48672011|NCT01343745|DRUG|Placebo|pressurised metered dose inhaler
48672012|NCT00395473|DRUG|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
48672013|NCT03150381|BEHAVIORAL|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
48672014|NCT03150381|BEHAVIORAL|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
47990583|NCT04176900|OTHER|Ecoflex 030|Polymer used for the 3D-printed flexible bolus
48359500|NCT00581724|BEHAVIORAL|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
48508248|NCT03478527|DIETARY_SUPPLEMENT|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
48508249|NCT03478527|OTHER|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
48508250|NCT06322602|PROCEDURE|Intracranial Catheter Placement|Undergo Ommaya reservoir placement
47990584|NCT00456547|PROCEDURE|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
47990585|NCT02591147|DEVICE|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
47990586|NCT02591147|DEVICE|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
47990587|NCT04731168|DEVICE|Mandibular advancement device|Patients will have a mandibular advancement device during the first postoperative night
48508251|NCT06322602|PROCEDURE|Lumbar Puncture|Undergo LP
48508252|NCT06322602|PROCEDURE|Biopsy|Undergo biopsy
48508253|NCT06322602|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
48508254|NCT06322602|PROCEDURE|Computed Tomography|Undergo CT
48508255|NCT04874805|OTHER|Measurement of oxygen saturation|Measurement of oxygen saturation by pulse oximetry once a day, at 6 a.m., for a minimum of 3 days, thanks to three pulse oximeters (1 measurement point per device/day), in parallel with a synchronous sampling, programmed as part of the usual care, of arterial gasometry.
48148024|NCT05658900|OTHER|Enucleation with albumin PRF|"The protocol that will be used in the preparation of albumin PRF~1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~2. The venous blood sample will be centrifuged at 700 g for 8 minutes.~   \* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes."
48148025|NCT05658900|OTHER|Enucleation without albumin PRF|"The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst."
48148026|NCT05307302|DIAGNOSTIC_TEST|Force Sense|A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
48508256|NCT05343546|DEVICE|Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion|"Use of either copper T380A or Levonorgestrel LNG 52 IUS after medical management of first trimester incomplete abortion within seven days of giving Misoprostol Early insertion or 2-4 weeks after Misoprostol use Standard insertion"
48508257|NCT05351801|DRUG|THC (Syndros)|Participants will receive a target dose of 10mg per day of THC (Syndros).
48672015|NCT03150381|BEHAVIORAL|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
48672016|NCT02347085|DRUG|GFF MDI (PT003)|
48672017|NCT02347085|DRUG|Placebo MDI|
48672018|NCT03358602|RADIATION|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
48672019|NCT03358602|PROCEDURE|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
48672020|NCT05887791|DIETARY_SUPPLEMENT|Collagen hydrolysate|Single dose
48672021|NCT05887791|OTHER|Placebo|Single dose
48672022|NCT02558101|BEHAVIORAL|Control invitation materials|"In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~2. an invitation letter with a pre-scheduled appointment plus the same information booklet~3. a reminder re-invitation letter for those who miss their appointment without cancelling"
47990588|NCT01227772|BIOLOGICAL|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
47990589|NCT04696939|DRUG|Atezolizumab|Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.
47990590|NCT04696939|DRUG|Carboplatin|Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
47990591|NCT04696939|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
47990592|NCT02654535|OTHER|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
47990593|NCT02663609|OTHER|No intervention|No treatment (intervention) was administered.
47990594|NCT02341807|BIOLOGICAL|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
48672023|NCT02558101|BEHAVIORAL|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
48672024|NCT02156024|DRUG|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
47990595|NCT03559946|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
47990596|NCT03559946|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
48508258|NCT05351801|DRUG|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
48508259|NCT05351801|DRUG|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
48508260|NCT05351801|DRUG|Placebo|Placebo
48508261|NCT02121873|DEVICE|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
48148027|NCT05307302|DIAGNOSTIC_TEST|Joint Reproduction Sense|A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
47990597|NCT05130931|OTHER|Multimodal conservative treatment|"15 min of Pain education + 20 min of Specific mobilization of the forearm musculature, pronator teres, tendons of the palmar flexors of the wrist and fingers, transverse carpal ligament and palmar fascia through manual mobilization assisted by Diacutaneous Fibrolysis technique + 10min of self-management and explanation of home-based exercise.~3 sessions of 45 minutes will be taken to perform this protocol and the patient will be shown a self-treatment to be performed 3-5 times a day. The protocol will be carried out over 3 weeks (1 session per week)."
47990598|NCT06287333|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
48148028|NCT05307302|DIAGNOSTIC_TEST|Seated Medicine Ball Throw|A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.
48359501|NCT00890201|PROCEDURE|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
48359502|NCT04312815|DRUG|SM03|SM03: 600 mg intravenous (IV)
48359503|NCT04312815|DRUG|Placebo|Placebo: 600 mg intravenous (IV)
47914355|NCT05768607|PROCEDURE|Quality of Life QUESTIONNAIRE (SF36)|Units of a scale of the patients will be compared pre and postoperatively by using SF36
47990599|NCT01838031|OTHER|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
47990600|NCT00115856|PROCEDURE|Intravascular MRI|Arterial imaging of atherosclerosis
47990601|NCT01754844|DRUG|AZD7624|Single dose inhaled IMP via a nebulizer
48359504|NCT04312815|DRUG|MTX|Methotrexate: 7.5-20 mg/wk oral
48359505|NCT05364658|DEVICE|Juvene IOL|Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
48359506|NCT03642327|BEHAVIORAL|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
48359507|NCT03642327|OTHER|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
48359508|NCT04973722|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously
48359509|NCT04973722|DRUG|Prolia|60 mg/1 ml, once every 6 months administered subcutaneously
48359510|NCT00089206|BIOLOGICAL|incomplete Freund's adjuvant|
48359511|NCT00089206|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
48508262|NCT02121873|DEVICE|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
48672025|NCT04486690|DRUG|Ketofol (propofol to ketamine ratio 1:1)|"* Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min"
48672026|NCT04486690|DRUG|propofol|"Propofol infusion, 25-150 mcg/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min."
48672027|NCT01419119|DRUG|Cholecalciferol high dose at Vitamin D deficiency|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
48359512|NCT00089206|BIOLOGICAL|sargramostim|
48359513|NCT03008928|BEHAVIORAL|Alcooquizz|
47914356|NCT05768607|PROCEDURE|INCONTINENCE IMPACT QUESTIONNAIRE (IIQ-7)|Units of a scale of the patients will be compared pre and postoperatively by using IIQ-7
47914357|NCT05768607|PROCEDURE|UROGENITAL DISTRESS INVENTORY (UDI - 6)|Units of a scale of the patients will be compared pre and postoperatively by using UDI - 6
47914358|NCT03713346|OTHER|Lactose free milk|Single dose of lactose free milk
47914359|NCT03713346|OTHER|Jersey milk|Single dose of jersey milk
47914360|NCT03713346|OTHER|High A1 β-casein milk|Single dose of high A1 β-casein milk (commercial milk)
47914361|NCT03713346|OTHER|High A2 β-casein milk|Single dose of A2 β-casein milk
47914362|NCT05241977|PROCEDURE|anterior supra scapular nerve block|nerve block for postoperative pain
47914363|NCT03198624|DRUG|HTL0018318|Part A single dose Part B five doses
47914364|NCT03198624|DRUG|Placebo oral capsule|Part B only
47990602|NCT01754844|DRUG|Placebo to match|Single dose inhaled Placebo via a nebulizer
47990603|NCT06096220|PROCEDURE|Enucleation|Enucleation is complete removal of the cyst from the bony defect of the jaw affected by the lesion. Osteotomy is performed to allow access to the cyst, cystic wall is detached from the bone and removed completely.
47990604|NCT06096220|DIAGNOSTIC_TEST|incisional biopsy|Lesions clinically abd radiographically consistent with OKC will be submitted for histological examination to confirm the diagnosis of OKC
48359514|NCT06314308|BEHAVIORAL|CATCHES|At the baseline visit (T0), informed consent will be obtained, and baseline questionnaires and measurements completed. A physical activity monitor will be provided. After discharge, Task Specific Training guided by Cognitive Behavioral Therapy with Exposure delivered over 7 one-hour sessions including two intake sessions by specialists and five follow up sessions delivered by CHWs individually at home over 3 months. After the final session at 12 weeks (about 3 months), participants will complete a study end visit (T1) which will include follow up questionnaires and measurements.
48508263|NCT02121873|DEVICE|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
48508264|NCT02481362|OTHER|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
48508265|NCT02481362|OTHER|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
48508266|NCT02733380|DRUG|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
48672028|NCT01419119|DRUG|Cholecalciferol median dose at Vitamin D insufficiency|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
47990605|NCT06096220|DRUG|Application of 5-fluorouracil|5% 5-fluorouracil cream will be applied immediately after the enucleation to the cystic cavity for 24 hours
48672029|NCT01419119|DRUG|Cholecalciferol low dose at Vitamin D deficiency|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
48148029|NCT05307302|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.
48148030|NCT05307302|DIAGNOSTIC_TEST|Passing Accuracy|A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
48148031|NCT00749944|DRUG|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
48148032|NCT00749944|DRUG|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
48359515|NCT04562233|BEHAVIORAL|Online-delivered physical activity intervention.|Participants randomized to the intervention arm will engage in 12, weekly, supervised, exercise sessions using Zoom with the exercise trainer.
48359516|NCT04562233|BEHAVIORAL|Printed, individualized resistance-based physical activity program.|Without the supervision of an exercise trainer, participants will be given a printed, individualized resistance-based physical activity program to complete over the course of 12 weeks.
48359517|NCT06436170|DIAGNOSTIC_TEST|OCTA|OCTA is a non invasive diagnostic technique to visualize RPC
48359518|NCT05520489|DEVICE|Repetitive Transcranial Magnetic stimulation|"Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%."
48359519|NCT05520489|DEVICE|Robot Assisted Therapy|"This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle."
48672030|NCT01419119|DRUG|Cholecalciferol median dose at sufficient Vitamin D level|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
48508267|NCT02733380|DRUG|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
47990606|NCT06096220|DRUG|Application of Carnoy solution|Carnoy solution will be applied during the enucleation as described previously
48508268|NCT02733380|DRUG|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
48672031|NCT03440073|OTHER|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
48672032|NCT03440073|OTHER|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
47990607|NCT05084573|DRUG|Liposomal bupivacaine|Single bolus injection 10mL 1.33% LB
47990608|NCT05084573|DRUG|Standard bupivacaine|Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
48148033|NCT03305705|DRUG|Iron Carboxymaltose|Single intravenous infusion within 20 min
48148034|NCT03305705|DRUG|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
48148035|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
48148036|NCT01346722|OTHER|Diet- CR|conventional rice-based diet
48148037|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
48148038|NCT01346722|OTHER|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
48508269|NCT02733380|DRUG|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
48508270|NCT02733380|DRUG|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
48508271|NCT02645903|DRUG|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
48148039|NCT00082667|DRUG|gefitinib|
48148040|NCT00082667|PROCEDURE|Surgery|
48508272|NCT02645903|DRUG|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
48148041|NCT00309673|DRUG|lidocaine / Prilocaine|
48508273|NCT01137994|DRUG|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
48508274|NCT01137994|BIOLOGICAL|Trastuzumab|monoclonal antibody directed to HER2 receptor
48148042|NCT01521702|DRUG|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
48508275|NCT01137994|DRUG|Docetaxel|Taxane chemotherapy
48508276|NCT01137994|DRUG|Paclitaxel|Taxane chemotherapy
48148043|NCT01521702|PROCEDURE|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
48508277|NCT01137994|DRUG|Vinorelbine|Vinka alkaloid
48672033|NCT04946695|OTHER|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
48508278|NCT03597529|DRUG|Melatonin|melatonin
48508279|NCT00126282|BEHAVIORAL|behavior therapy|
48672034|NCT02701764|DRUG|Pregabalin|
47990609|NCT04812054|PROCEDURE|Hypothermic oxygenated machine perfusion|Hypothermic oxygenated perfusion using a Liver Assist device (Organ Assist, Groningen, the Netherlands). Temperature of the perfusate will be set to 12 degrees Celsius. Dedicated cannulas will be placed in the aorta for arterial perfusion and in the portal vein for portal perfusion. Pressure will be set at 25 mmHg for arterial line (pulsatile flow, 30 mmHg systolic pressure and 20 mmHg diastolic pressure, 60 beats per minute) and 3 mmHg for portal line (continuous flow). 100% oxygen will be supplied to the oxygenators with a flow of 500 ml / min or higher, in order to achieve pO2 of at least 450 mmHg.
48672035|NCT02701764|DRUG|Placebo|
48148044|NCT04678752|OTHER|Weight management care path|"* Documentation and data capture built in the Electronic Health Record~* Clinical data support that suggests weight loss approach(es)~* Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~* Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~* Evidence-based online training on weight management for clinicians~* Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~* Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
48359520|NCT05520489|OTHER|Enhanced upper limb therapy programme|Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
48359521|NCT00152997|DRUG|Pramipexole 0.125 mg tablets|
48672036|NCT01977222|DEVICE|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
47990610|NCT04812054|PROCEDURE|Simple cold storage|Following back-table preparation, the allograft will either be transferred to the operating room for implantation or stored in preservation solution at 4 degrees Celsius in a refrigerator
47990611|NCT01062282|DRUG|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
47990612|NCT03498625|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
47990613|NCT01909596|DEVICE|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
47990614|NCT01909596|DEVICE|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
47990615|NCT01909596|DEVICE|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
47990616|NCT00703612|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
47990617|NCT03016247|BEHAVIORAL|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
47990618|NCT03016247|BEHAVIORAL|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
48148045|NCT04678752|OTHER|Control|"Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit."
48359522|NCT00152997|DRUG|Pramipexole 0.125 mg tablets Placebo|
48359523|NCT01739192|DRUG|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
48359524|NCT02286336|OTHER|brachial plexus block|brachial plexus block with ropivacaine 40ml
48508280|NCT00126282|DRUG|D-Cycloserine|
48508281|NCT06626464|DRUG|[14C]MK-8189|Oral administration
48508282|NCT05386940|OTHER|PKN1 level|different PKN1 level after on-pump cardiac surgery
48508283|NCT05709197|PROCEDURE|Braun anastomosis|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
48508284|NCT05709197|PROCEDURE|Standard Child reconstruction|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
48508285|NCT05258448|OTHER|Chemoradiotherapy|Cardiac Magnetic Resonance scan and ECG
48508286|NCT06310304|DRUG|Ruxolitinib IR|Tablet
48508287|NCT06310304|DRUG|Ruxolitinib XR|Tablet
48672037|NCT03394989|DRUG|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
48508288|NCT01346787|DRUG|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
48148046|NCT01990183|DEVICE|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
48672038|NCT03394989|OTHER|Placebo|Placebo
48148047|NCT01990183|OTHER|Standard Care|Current care advices in the management of preterm infants in the first months of life
48148048|NCT00267865|DRUG|Methotrexate|6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
48359525|NCT00598884|BEHAVIORAL|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
48508289|NCT00150787|DRUG|LEVETIRACETAM|
48508290|NCT01860352|DIETARY_SUPPLEMENT|Fish OIl|
48672039|NCT03394989|DRUG|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
48148049|NCT00267865|DRUG|Rituximab|375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
48672040|NCT04249401|DRUG|Rivaroxaban (Xarelto)|NOAC, reduced dose
48672041|NCT04249401|DRUG|Apixaban|NOAC, reduced dose
48672042|NCT04249401|DRUG|Dabigatran|NOAC, reduced dose
48672043|NCT04249401|DRUG|Warfarin|VKA
48672044|NCT02189798|DEVICE|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
48672045|NCT02189798|DEVICE|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
48359526|NCT04623281|DEVICE|Sixty device|Prototype wearable hydration monitor to be worn by patient during dialysis and at night
48508291|NCT01062711|DIETARY_SUPPLEMENT|Whey or soy protein|Whey and casein are isolated milk proteins
48672046|NCT02616731|DRUG|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
48672047|NCT02616731|DRUG|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
48672048|NCT04124627|PROCEDURE|Ultrasound guidance in addition to radiographic guidance|Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
48672049|NCT00725088|BEHAVIORAL|Exercise training|Exercise training
48672050|NCT04426747|OTHER|No intervention|No intervention
48672051|NCT01240863|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
48148050|NCT00267865|DRUG|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
48148051|NCT00780078|PROCEDURE|extubation|extubation failure in patients intubated orotracheally
48148052|NCT05333835|DRUG|HR17031 injection|HR17031 injection
48359527|NCT03606889|DIAGNOSTIC_TEST|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
48148053|NCT05333835|DRUG|INS068 injection|INS068 injection
48148054|NCT05333835|DRUG|SHR20004 injection|SHR20004 injection
48508292|NCT03197181|DEVICE|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
48508293|NCT04583189|DIAGNOSTIC_TEST|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
48672052|NCT01240863|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
48672053|NCT02896309|DIETARY_SUPPLEMENT|Sodium bicarbonate|
48148055|NCT03941366|PROCEDURE|Standard of care chemotherapy with the change for avoidance of extensive surgery|All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
48148056|NCT04454723|PROCEDURE|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
48672054|NCT02896309|DIETARY_SUPPLEMENT|Sodium chloride|
48672055|NCT02375100|PROCEDURE|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
48672056|NCT02375100|PROCEDURE|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
48672057|NCT02375100|PROCEDURE|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
48672058|NCT02375100|DRUG|Bupivacaine %0.5 (hyperbaric)|
48672059|NCT02375100|DRUG|Bupivacaine %0.25 (isobaric)|
48148057|NCT04454723|PROCEDURE|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
48148058|NCT03950609|DRUG|Everolimus|Given PO
48148059|NCT03950609|DRUG|Lenvatinib|Given PO
48148060|NCT02915003|BEHAVIORAL|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
48148061|NCT00003634|BIOLOGICAL|oregovomab|
48148062|NCT00603278|DRUG|GW685698X|GW685698X
48148063|NCT00603278|DRUG|placebo|placebo
48148064|NCT06385483|DRUG|Afatinib|Given PO
48672060|NCT02375100|DEVICE|25G Quincke needle|
48672061|NCT02375100|DEVICE|Echogenic Needle with 30° bevel|
48672062|NCT02375100|DRUG|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
48672063|NCT02375100|DRUG|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
48672064|NCT05522738|DRUG|Combination: Fruquintinib + FOLFIRI|"Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w"
48672065|NCT05362994|DEVICE|Selution SLR™ sirolimus-eluting balloon|If the residual stenosis is ≤30% after initial plain old balloon angioplasty, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained. Technical success is defined as residual diameter stenosis ≤30% and adequate distal run-off. Bail-out stenting will be performed if residual stenosis is \>30%, either after plain old balloon angioplasty or angioplasty with Selution SLR. For lesions with residual stenosis \>30% but not suitable for stenting, repeat angioplasty will be performed for at most twice.
47990619|NCT02855437|DEVICE|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
47990620|NCT02855437|DEVICE|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
48359528|NCT03606889|DIAGNOSTIC_TEST|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
48508294|NCT05096832|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|"Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).~Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily"
48508295|NCT05096832|BIOLOGICAL|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
48508296|NCT02376816|BIOLOGICAL|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
48672066|NCT05362994|DEVICE|Plain old balloon angioplasty|The investigators routinely start with a balloon catheter with a diameter ≥0.5 mm smaller than the reference vessel and ended with a balloon catheter with the size approximately equal to the reference vessel diameter. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group.
48672067|NCT01951053|DRUG|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
47990621|NCT00292864|DRUG|SNS-032 Injection|
47990622|NCT04056442|DRUG|Cannabidiol , synthetic form|Cannabidiol ( synthetic form)
47990623|NCT04056442|DRUG|Placebo|Olive Oil Solution, 5%
48148065|NCT06385483|PROCEDURE|Biopsy|Undergo biopsy
48148066|NCT06385483|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48148067|NCT06385483|PROCEDURE|Computed Tomography|Undergo CT scan
48148068|NCT06385483|PROCEDURE|Echocardiography|Undergo ECHO
48148069|NCT06385483|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48148070|NCT06385483|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
48148071|NCT03307356|OTHER|Uterine Transplant|Transplant of a uterus from a donor, deceased or living
48148072|NCT04351243|DRUG|Gimsilumab|Gimsilumab is a fully human monoclonal antibody (mAb).
48148073|NCT04351243|DRUG|Placebo|Normal saline
48148074|NCT00587756|PROCEDURE|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
48148075|NCT05701176|DIAGNOSTIC_TEST|[18F]F-AraG PET scan|\[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
48359529|NCT03606889|DRUG|Bupivacaine|0.2 ml/kg bupivicaine
48359530|NCT01738568|BEHAVIORAL|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
48359531|NCT01738568|BEHAVIORAL|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
48672068|NCT01951053|DRUG|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
48672069|NCT01951053|DRUG|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
48672070|NCT05144789|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
48672071|NCT05144789|DEVICE|Active TBS-DMPFC|"Participants in the active stimulation group will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
48672072|NCT05144789|DEVICE|Sham TBS-DLPFC or DMPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
48672073|NCT03925363|DEVICE|Physical activity mobile-application|The active group will be given the feedback app and the control group the blind app
48359532|NCT00499161|BEHAVIORAL|New model of nursing care|
48359533|NCT04845581|PROCEDURE|Diagnostic tests: Determination of the gingival phenotype, measure gingival thickness and width of keratinized tissue|Gingival thickness was measured using UGTM method and CBCT/ CAD with PDIP technology at upper incisors and canines in three points localized midbucally : Free gingival thickness (FGT), supracrestal ( SGT) and crestal (CGT). Width of keratinized tissue was measured using periodontal probe calibrated for 1 mm. The gingival phenotype was determined by both methods according to the following criteria: GT ≤ 0,7 mm - thin gingival phenotype, GT \&gt; 0,7 mm ≤ 1,0 mm - medium gingival phenotype, GT \&gt; 1,0 mm - thick gingival phenotype. Toincrease the repeatability of the results, two researchers tested the same values twice on 2days interval between sessions.
48508297|NCT03523299|PROCEDURE|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
48508298|NCT01795911|BIOLOGICAL|Pegylated Interferon Lambda|
47990624|NCT04289246|DEVICE|Medication Ambient Display (MAD)|"MAD was implemented for Android tablets to provide the following external cues:~* Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~* Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken."
47990625|NCT00244946|BIOLOGICAL|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
47990626|NCT00244946|DRUG|carmustine|
47990627|NCT00244946|DRUG|cytarabine|
47990628|NCT00244946|DRUG|etoposide|
47990629|NCT00244946|DRUG|melphalan|
47990630|NCT00244946|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|
48508299|NCT01795911|DRUG|Ribasphere|
48508300|NCT01795911|DRUG|Daclatasvir|
48508301|NCT04380961|DRUG|Sirukumab|Participants will receive single dose infusion of sirukumab on Day 1.
48672074|NCT06251414|BEHAVIORAL|Exercise Intervention|Blood Flow Restriction (BFR) training, also known as occlusion training or restricted blood flow training, involves applying external pressure to a limb using inflatable cuffs or elastic bands. This pressure partially restricts arterial blood flow while occluding venous blood flow in the pressured limb. The goal is to increase muscle strength and size by creating metabolic stress and promoting physiological adaptations, such as muscle hypertrophy, with lighter loads than traditional resistance training.
48672075|NCT06251414|BEHAVIORAL|Instrument-Assisted Soft Tissue Mobilization|Instrument-Assisted Soft Tissue Mobilization (IASTM) is a therapeutic technique that involves the use of specially designed tools or instruments to apply controlled mechanical pressure to soft tissues in the body. These tools are typically made of stainless steel or other materials and have various shapes and edges. The primary aim of IASTM is to address musculoskeletal conditions by breaking down scar tissue, fascial restrictions, and adhesions in the soft tissues. Practitioners use the instruments to detect and treat areas of tissue dysfunction, promoting improved range of motion, reduced pain, and enhanced functional mobility.
48672076|NCT06251414|BEHAVIORAL|Tuinal|Tuinal, also known as Tui Na or Chinese therapeutic massage, is a traditional Chinese medicine (TCM) healing technique that involves manual manipulation of the body's soft tissues, including muscles and tendons. It is a form of bodywork that aims to balance the flow of vital energy (Qi) within the body and promote overall well-being. Tuina techniques may include kneading, rolling, pressing, and brushing, and they are applied to specific acupressure points or along the body's meridians. Tuina is used to address various health concerns, alleviate pain, improve circulation, and enhance the body's natural healing processes, making it an integral part of traditional Chinese medicine.
48672077|NCT06350422|OTHER|Head-Down tilt Bed Rest test|All of the volunteers underwent 60 days of the Head-Down tilt Bed Rest test.
48672078|NCT00499525|DRUG|paclitaxel|given IV
47914365|NCT05262049|OTHER|intermittent compression-decompression with glides|Patients in this group will be given only intermittent compression and decompression with glides. Traction (decompression applied at knee joint with anteroposterior glide followed by compression for about 6 minutes (30 glides, 10 seconds compression and vice versa), for the duration of 4 weeks (3 days a week, alternate days)
47990631|NCT05966324|DRUG|baxdrostat|Baxdrostat is an aldosterone synthase inhibitor
47990632|NCT03284996|DEVICE|Doppler ultrasonography|Examination of the whole cases \& controls by doppler ultrasound to measure renal resistive index.
47990633|NCT01912846|BEHAVIORAL|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
47990634|NCT01912846|BEHAVIORAL|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
48672079|NCT00499525|DRUG|sorafenib tosylate|given orallly
48672080|NCT00499525|OTHER|placebo|given orally
48148076|NCT06455605|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
48148077|NCT06455605|DRUG|2141 V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
48148078|NCT02301871|DEVICE|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
48672081|NCT03631693|PROCEDURE|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
48148079|NCT02301871|PROCEDURE|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
47990635|NCT00485407|DRUG|Atomoxetine Hydrochloride|
47990636|NCT04833621|DEVICE|NMES GROUP|The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
47990637|NCT03922451|DRUG|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
47990638|NCT03922451|DRUG|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
47990639|NCT04243187|OTHER|Chilean Native Beans|"In each visit the participant would have to:~1. Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~2. Fill a survey of food consumption~3. Bean plate intake~4. Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~5. Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey)."
47990640|NCT05322642|BEHAVIORAL|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
47990641|NCT05322642|BEHAVIORAL|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
47990642|NCT00525668|DRUG|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
47990643|NCT00525668|DRUG|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
48148080|NCT02301871|PROCEDURE|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
48148081|NCT01205126|DRUG|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
48148082|NCT01205126|DRUG|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
48148083|NCT01205126|DRUG|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
48148084|NCT01753440|PROCEDURE|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
48359534|NCT03845504|DEVICE|Intermittent Theta Burst Stimulation|Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
48359535|NCT02428387|BEHAVIORAL|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
48359536|NCT02198313|DRUG|BIIX 1 XX - D1|
48359537|NCT02198313|DRUG|BIIX 1 XX - D2|
48359538|NCT02198313|DRUG|BIIX 1 XX - D3|
48672082|NCT03631693|PROCEDURE|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
48148085|NCT06432023|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diagnostic and research scanning using magnetic resonance imaging.
48148086|NCT03730688|DEVICE|Conventional compartment pressure measurement|Compartment pressure will be measured using the conventional compartment pressure measurement system.
48148087|NCT03730688|DEVICE|Experimental compartment pressure measurement|Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
48148088|NCT03914586|DEVICE|oXiris filter|Continuous Renal Replacement Therapy with oXiris filter
48148089|NCT04012359|DIAGNOSTIC_TEST|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
48359539|NCT02198313|DRUG|Placebo|
48508302|NCT04380961|DRUG|Placebo|Participants will receive placebo IV single dose infusion on Day 1.
48508303|NCT04380961|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
48508304|NCT06487208|OTHER|Use of a digital cognitive aid in order to anticipate a critical situation|Use of a digital cognitive aid in order to anticipate a critical situation
47990644|NCT03101137|DRUG|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
48148090|NCT04012359|DIAGNOSTIC_TEST|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
48148091|NCT04012359|DIAGNOSTIC_TEST|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
48148092|NCT04012359|OTHER|Clinical examination|Standard clinical examination performed by investigating physician
48148093|NCT04050683|PROCEDURE|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
48148094|NCT04050683|PROCEDURE|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 1-3 days after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes."
48148095|NCT03103945|DEVICE|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
48148096|NCT04725032|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
48508305|NCT06487208|OTHER|Placebo|No intervention
48508306|NCT03219190|BEHAVIORAL|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
48508307|NCT04460560|DRUG|Terlipressin|"For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump"
48508308|NCT00005000|DRUG|Nelfinavir mesylate|
48508309|NCT00005000|DRUG|Efavirenz|
48508310|NCT00005000|DRUG|Lamivudine|
48508311|NCT00005000|DRUG|Keyhole-Limpet Hemocyanin|
48508312|NCT00005000|DRUG|Stavudine|
48508313|NCT00005000|DRUG|Zidovudine|
48508314|NCT00005000|DRUG|Didanosine|
48508315|NCT06377033|BEHAVIORAL|Behavioral nudge|Comparison of genetic rates among individuals for whom it may make a difference in their care across study arms.
48672083|NCT03874767|BEHAVIORAL|Patient Mobility|A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
48148097|NCT04725032|DRUG|Sevoflurane|Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
48148098|NCT03137459|BEHAVIORAL|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
48508316|NCT06002581|DEVICE|rTMS real stimulation stage1|In the first stage, the early treatment group use low-frequency rTMS real stimulation,
48672084|NCT02184065|DRUG|Meloxicam|
48672085|NCT04327440|BIOLOGICAL|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
48672086|NCT04327440|OTHER|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
48672087|NCT01060787|PROCEDURE|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
47990645|NCT03101137|DRUG|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
48672088|NCT01060787|PROCEDURE|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
48672089|NCT01043718|BEHAVIORAL|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
48148099|NCT03137459|OTHER|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
48148100|NCT05481008|DEVICE|transcatheter aortic valve implantation|All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
48148101|NCT01180959|DRUG|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
48148102|NCT01180959|DRUG|Erlotinib|150 mg by mouth once a day.
48148103|NCT01736488|DRUG|Fimasartan|Fimasartan 60mg
48148104|NCT01736488|DRUG|Atenolol|Atenolol 50mg
48148105|NCT06463509|OTHER|Establishment of an in-deepth tumor profiling platform|In-depth tumor profiling beyond genomics
48148106|NCT06604715|DRUG|JNJ-87562761|JNJ-87562761 will be administered.
48148107|NCT02751125|DRUG|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
48508317|NCT06002581|DEVICE|rTMS shame stimulation stage1|In the first stage, the control group (delayed treatment group) all use sham stimulation.
48148108|NCT04728035|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection
48148109|NCT04931498|OTHER|Questionnaire|Medical history, demographics and lifestyle factors will be assessed by the participant.
48148110|NCT04931498|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
48148111|NCT04931498|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
48148112|NCT04931498|PROCEDURE|Venepuncture (GMPR)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key erythroid markers~* Proteomic analysis of isolated erythrocytes using mass spectrometry"
48148113|NCT04931498|PROCEDURE|Venepuncture (SWAP70)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key markers~* Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~* Immunoglobulin isotype titre analysis in plasma~* Isolation of monocytes for subsequent use in phagocytosis assays"
48148114|NCT03946631|DIAGNOSTIC_TEST|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
48359540|NCT05232344|DRUG|Estradiol / Progesterone|Treatment with estradiol (Provames®, 3 mg morning and evening, or 6 mg per day) will start on the 1st or 2nd day of her period. This treatment is continued until the end of the study (discontinuation treatment after the blood test taken on Day 7). After ten days of minimum estradiol treatment (and up to 7 days later to be working days), vaginal progesterone treatment will start in the evening on Day 0 (400 mg, Progestan®, evening and morning, ie 800 mg per day).
48359541|NCT05232344|BEHAVIORAL|Sexual event|A sexual intercourse (protected or not protected by condoms) will take place in a pre-defined order for each participant within one hour of the administration of the progesterone ovum on the evening of Day 2 and Day 6.
48672090|NCT01043718|BEHAVIORAL|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
48672091|NCT02986074|DEVICE|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
47990646|NCT03101137|DRUG|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
48359542|NCT05140486|PROCEDURE|Rehabilitation: shortwave diathermy and perceptual training|All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
47990647|NCT02533947|BEHAVIORAL|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
47990648|NCT02533947|BEHAVIORAL|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
47990649|NCT00136305|BEHAVIORAL|Pictorial asthma action plan|
47990650|NCT00136305|BEHAVIORAL|Written asthma action plan|
47990651|NCT00842686|DRUG|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
47990652|NCT01688258|PROCEDURE|Diagnostic swab|
47990653|NCT04089059|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)"
48148115|NCT05956093|RADIATION|FAPI PET CT|the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
48148116|NCT01709630|DRUG|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
48148117|NCT04037072|DRUG|Mitomycin C|Topical application of Mytomycin C (MMC)
48148118|NCT04037072|OTHER|Control|Topical application of Normal Saline
48148119|NCT02418286|OTHER|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
48359543|NCT04476706|DRUG|canakinumab|canakinumab
48359544|NCT00155324|DEVICE|Extracorporeal Shock Wave Therapy (Device)|
48508318|NCT06002581|DEVICE|rTMS real stimulation stage 2|In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
48672092|NCT02986074|DEVICE|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
48672093|NCT00002139|DRUG|Azithromycin|
48148120|NCT05141409|DEVICE|Artificial Intelligence|Artificial Intelligence
48148121|NCT06187402|DRUG|LM-24C5|Administered intravenously
48148122|NCT06165133|OTHER|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
48508319|NCT01402635|DEVICE|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
48508320|NCT05523154|PROCEDURE|Biospecimen Collection|Undergo collection of bile samples
48148123|NCT06165133|OTHER|Mesh inguinal hernia repair performed by fully trained surgeons|Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
48148124|NCT01762397|DRUG|PMK-S005|
48148125|NCT00289952|DRUG|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
47990654|NCT03722550|OTHER|Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides|Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
48359545|NCT00979264|BEHAVIORAL|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
48359546|NCT00231972|BEHAVIORAL|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
48359547|NCT00231972|BEHAVIORAL|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
48359548|NCT04898036|DEVICE|Blue Light Therapy|This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.
48359549|NCT04898036|DEVICE|Sham Light Therapy|To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.
48359550|NCT00039104|DRUG|rebimastat|Given PO
48359551|NCT00039104|DRUG|zoledronic acid|Given IV
48359552|NCT00039104|OTHER|laboratory biomarker analysis|Correlative studies
48359553|NCT02098733|DRUG|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
48508321|NCT05523154|OTHER|Laboratory Procedure|Undergo routine laboratory testing
48508322|NCT05523154|DEVICE|Nanopore Sequencing|Undergo nanopore sequencing
48508323|NCT00520819|DRUG|Antioxidant-rich food items|
48508324|NCT04204538|OTHER|Dietary habits|Data collected using food frequency questionnaire
48508325|NCT04204538|OTHER|Risk factors associated with metabolic syndrome|Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome
48508326|NCT05403255|OTHER|evaluation of the quality of life with questionnaires|"Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France."
48508327|NCT05855122|DRUG|Tocilizumab|Pateients enrolled in Tocilizumab group will receive tocilizumab(8mg/kg) at day -7 before transfusion of stem cells.
48508328|NCT05636514|DRUG|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
48508329|NCT05636514|DRUG|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
48508330|NCT03307629|DRUG|NOX66|NOX66 delivered as rectal suppository.
48508331|NCT03307629|RADIATION|Irradiation Therapy|Radiation per selected tumour lesion.
48508332|NCT05604989|DRUG|Probiotic Combination Cap/Tab|The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus \& Bifidobacterium lactis.
48508333|NCT05604989|DRUG|intravitreal Anti-VEGF injection|Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
48508334|NCT05853744|DRUG|lavender essential oil inhaled using cotton balls|cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
48359554|NCT03515265|OTHER|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
48359555|NCT03515265|OTHER|Microhybrid resin composite restoration|a type of conventional resin composite
47990655|NCT03722550|OTHER|Breast-feeding|Exclusive Breast-feeding up to 4 months of age
47990656|NCT03722550|OTHER|Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk|Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
47990657|NCT05623267|DRUG|Sugemalimab|Recombinant anti-PD-L1 fully human monoclonal antibody
48148126|NCT00289952|DRUG|HAART|As per standard of care.
48148127|NCT04267549|DRUG|sintilimab|a checkpoint inhibitor via blocking PD-1 (programmed cell death-1) site of signaling.
48148128|NCT04267549|DRUG|apatinib|a multi-target anti-angiogenic tyrosine kinase inhibitor (TKI)
48508335|NCT05853744|DRUG|lavender essential oil inhaled using face mask|These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
48672094|NCT04616937|DIETARY_SUPPLEMENT|GOS|Prebiotic
48672095|NCT04616937|DIETARY_SUPPLEMENT|Placebo|Placebo
48508336|NCT05853744|DRUG|Distilled water|inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
48148129|NCT04267549|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).
48508337|NCT00220831|DRUG|Natural source Vitamin E 400IU/day|
48508338|NCT06584292|PROCEDURE|caudal block|Caudal Block (CB) Procedure: The sacral hiatus was identified using an out-of-plane transverse ultrasound view at the level of the sacral cornua. The probe was then rotated longitudinally to visualize the sacrococcygeal ligament and sacral bone. A block needle was inserted through the sacrococcygeal membrane into the sacral canal using the in-plane technique, and 0.125% bupivacaine was administered at a dose of 1 mL/kg, with a maximum limit of 20 mL per side.
47990658|NCT05623267|DRUG|Placebo|Placebo of Sugemalimab
48508339|NCT06584292|PROCEDURE|Retrolaminar block|Retrolaminar Block (RL) Procedure: The RL block was performed with the patient in a lateral decubitus position. The ultrasound probe was positioned at the L4 vertebral level in a paramedian sagittal plane. The probe was moved medially until the vertebral laminae were visualized. The needle was inserted using the in-plane technique, advancing from the cephalad to caudal direction until it contacted the L4 lamina. A dose of 0.1 mL/kg of 0.25% bupivacaine was then injected into the retrolaminar space.
48508340|NCT06106165|OTHER|In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered in-person, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
48672096|NCT01404650|DRUG|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
48148130|NCT04267549|DRUG|Nab paclitaxel|Nab paclitaxel is a albumin-bound well tolerated paclitaxel than traditional paclitaxel
48148131|NCT00857077|DRUG|Sulfadoxine-pyrimethamine|
48148132|NCT00857077|DRUG|Placebo|
48672097|NCT02656667|DEVICE|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
47990659|NCT00868075|PROCEDURE|Chest physiotherapy|Twice daily for 8 weeks
48148133|NCT00098735|DRUG|FTY720|
48148134|NCT05055804|DEVICE|ELG|"The effectiveness of ELG to standardized blood test methods (fingerstick) and comparison to AlcNOW + (or equivalence) and of laboratory test results.~Human subject requirements during ELG study will not challenge diabetics or non-diabetics glycemic event. For example, diabetes type 1, the subject will not have to adjust their insulin or glucose. For type 2 diabetes, the subject will not have to adjust their oral hypoglycemic agent or glucose, as well."
48148135|NCT00138814|PROCEDURE|Radiotherapy (boost versus no boost)|
48148136|NCT06341309|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
47990660|NCT00868075|PROCEDURE|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
47990661|NCT01172847|DRUG|oseltamivir [Tamiflu]|multiple oral doses
48148137|NCT06341309|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
47990662|NCT01172847|DRUG|rimantadine|multiple oral doses
48148138|NCT04209322|PROCEDURE|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
47990663|NCT05095987|PROCEDURE|Laparoscopic Appendectomy|Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
48359556|NCT02933411|OTHER|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
47990664|NCT02496832|DRUG|18F-Fluoroazomycin arabinoside|
47990665|NCT00388635|DRUG|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
47990666|NCT00388635|DRUG|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
47990667|NCT00388635|DRUG|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
48148139|NCT04209322|PROCEDURE|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
48148140|NCT06022653|OTHER|Treatment|EVAR,TEVAR,PTA
48148141|NCT01448928|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
48148142|NCT01742585|DRUG|ASP1585|oral
48148143|NCT01742585|DRUG|placebo|oral
48359557|NCT02933411|OTHER|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
48672098|NCT02656667|DEVICE|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
48672099|NCT02656667|OTHER|Conventional pulmonary rehabilitation|excercise training on treadmill
48148144|NCT05410717|BIOLOGICAL|Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells|"Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy."
48148145|NCT01595425|DRUG|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
48148146|NCT01595425|DRUG|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
48148147|NCT02868086|DEVICE|OCT B-scans|
48148148|NCT02868086|DEVICE|OCT angiography|
48148149|NCT02540915|OTHER|Standard of Care - Registry|Standard of Care - Registry
48508341|NCT06106165|OTHER|Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered online, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
48508342|NCT00013091|BEHAVIORAL|Self-management therapy; Psychoeducational group therapy|
48508343|NCT00264550|DRUG|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
48148150|NCT06440200|BEHAVIORAL|group gamed-based activity|Participants in interventional group will play the active-type software with Switch game console which develops by Nintendo company. Team building, cooperation, cohesion, sense of belonging and sense of achieving will be emphasized.
48148151|NCT01049633|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
48148152|NCT01049633|DRUG|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
48148153|NCT01049633|BIOLOGICAL|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
48148154|NCT01049633|DRUG|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
48148155|NCT01049633|DRUG|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
48508344|NCT00264550|DRUG|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
47990668|NCT02297828|DEVICE|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
47990669|NCT02297828|DEVICE|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
48148156|NCT01049633|DRUG|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
48148157|NCT01049633|DRUG|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
48148158|NCT01049633|DRUG|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
48508345|NCT00264550|DRUG|Methotrexate|Participants will receive methotrexate capsules weekly.
48508346|NCT00264550|DRUG|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
48508347|NCT00264550|DRUG|Placebo capsules|Participants will receive placebo capsules weekly
48508348|NCT02129608|DEVICE|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
48508349|NCT02129608|DRUG|Lorcaserin|10 mg pills twice daily for 12 weeks.
48508350|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
47914366|NCT05262049|OTHER|Conventional Physical Therapy|"In this group conventional therapy will be given according to below mentioned protocol for 4 weeks (3 days a week, alternate days).~* Hot pack /TENS for 10 minutes~* Stretching: Hamstring(10x) and calf (10x)~* Strengthening of periarticular muscles especially the quadriceps (straight leg raising, pillow squeeze-isometric and dynamic)"
47914367|NCT05262049|OTHER|conventional physical therapy and intermittent compression-decompression with glides|Patients in this group will receive the combination of conventional physical therapy and intermittent compression and decompression with glides, for 4 weeks (3 days a week, alternate days).
47914368|NCT04927169|DRUG|Interleukin-7|IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
47990670|NCT01977170|BIOLOGICAL|Hib/PRP-T vaccine|Hib liquid vaccine
47990671|NCT02760446|BEHAVIORAL|CAM-ICU.fr|Neuropsychological testing
47990672|NCT05337592|DRUG|BI 1815368 formulation 1|BI 1815368 formulation 1
47990673|NCT05337592|DRUG|Placebo|Placebo
48148159|NCT01049633|DRUG|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
48148160|NCT01049633|DRUG|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
48359558|NCT02933411|OTHER|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
48359559|NCT02933411|OTHER|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
48148161|NCT01049633|DRUG|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
48148162|NCT01049633|DRUG|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
48148163|NCT03240588|DEVICE|Neurostimulation System|Spinal cord stimulation
48148164|NCT03966456|DRUG|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
48148165|NCT04314206|DRUG|VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
48148166|NCT04314206|DRUG|Placebo for VNRX-5024|"Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)"
48359560|NCT01844414|BEHAVIORAL|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
48672100|NCT06017492|BEHAVIORAL|video assisted discharge teaching|Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
48672101|NCT05144828|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
48672102|NCT05144828|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
48672103|NCT00437398|BIOLOGICAL|Islet Transplant|Purified pancreatic islets
47990674|NCT05337592|DRUG|BI 1815368 formulation 2|BI 1815368 formulation 2
47990675|NCT05152888|DRUG|Evolocumab|Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.
47990676|NCT01199744|DRUG|zanamivir|zanamivir
47990677|NCT06488963|OTHER|NatraCure Cold Therapy gloves and socks|These gloves and socks will be adjusted and tied to the child's wrists and ankles. There are sizes suitable for all ages and the dimensions of the gloves and socks can be adjusted with a snap fastener. The gloves and socks contain a soft Lycra lining and four inner gel cold packs to ensure full length cold therapy treatments. When the children wear these gloves and socks, they can still move their fingers and toes easily. In addition, it is a great advantage that the iced gel packs do not touch the child's skin directly.
48672104|NCT05809089|DEVICE|High flow nasal cannula (HFNC)|"High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours."
47990678|NCT01375387|DRUG|Lacosamide|100 mg oral tablet, single dose
47990679|NCT01375387|DRUG|Lacosamide|Lacosamide 2 X 100 mg tablet
47990680|NCT01375387|DRUG|Lacosamide|Lacosamide 4 X 100mg tablet
48148167|NCT02619825|DEVICE|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
48672105|NCT05809089|DEVICE|Noninvasive ventilation (NIV)|Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
47990681|NCT01375387|OTHER|Placebo 3|Placebo - 3 tablets
47990682|NCT01375387|OTHER|Placebo 4|Placebo - 4 tablets
47990683|NCT01375387|OTHER|Placebo 2|Placebo - 2 tablets
47990684|NCT03800927|DEVICE|Long duration ultrasound|Low-intensity long duration ultrasound treatment
47990685|NCT03887000|OTHER|magnesium|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
47990686|NCT03887000|OTHER|placebo|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
47990687|NCT00134160|DRUG|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
47990688|NCT00134160|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
47990689|NCT01522755|DEVICE|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
47990690|NCT00518323|DRUG|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
47990691|NCT00518323|DRUG|Placebo|Once daily for 6 weeks
48148168|NCT02619825|DEVICE|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
48148169|NCT05297097|DIETARY_SUPPLEMENT|Trulacta breastmilk supplement|one supplement daily
48148170|NCT03486756|BEHAVIORAL|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
48148171|NCT02625025|PROCEDURE|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
48148172|NCT02625025|PROCEDURE|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
48148173|NCT02625025|PROCEDURE|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
48148174|NCT05576779|OTHER|Ofatunumab|All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
48148175|NCT00253552|BIOLOGICAL|filgrastim|
48148176|NCT00253552|DRUG|busulfan|
48359561|NCT01844414|BEHAVIORAL|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
48508351|NCT02140385|PROCEDURE|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
48508352|NCT02140385|DEVICE|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
48672106|NCT05814471|DEVICE|Cable fastening system and 3d printed straps|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
48148177|NCT00253552|DRUG|cyclophosphamide|
48148178|NCT00253552|DRUG|cyclosporine|
48148179|NCT00253552|DRUG|etoposide|
48148180|NCT00253552|DRUG|methotrexate|
48359562|NCT01844414|BEHAVIORAL|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
47990692|NCT00518323|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
47990693|NCT00518323|DRUG|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
47990694|NCT04377477|RADIATION|Single fraction whole lung radiotherapy|Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy
47990695|NCT01629368|DRUG|Carbamazepine|Multiple doses of carbamazepine
47990696|NCT01629368|DRUG|RO4917523|Single dose of RO4917523
48148181|NCT00253552|PROCEDURE|allogeneic bone marrow transplantation|
48359563|NCT01808911|DRUG|Steroid + cyclophosphamide|
48359564|NCT01808911|DRUG|Steroid + rituximab|
47990697|NCT02834533|DEVICE|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
48148182|NCT00253552|RADIATION|radiation therapy|
48359565|NCT01342627|DRUG|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
48508353|NCT02140385|DEVICE|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
48508354|NCT02140385|DEVICE|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
48508355|NCT04540679|OTHER|VIP4SCI|Technology-enabled self-management \& rehabilitation solution
48508356|NCT03834454|DRUG|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
48508357|NCT03834454|DRUG|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
48508358|NCT00789737|DRUG|Welchol|Welchol 625mg tablets
48508359|NCT00789737|DRUG|Placebo|placebo
48508360|NCT00015873|DRUG|asparaginase|
48508361|NCT00015873|DRUG|cytarabine|
48508362|NCT00015873|DRUG|mercaptopurine|
48508363|NCT00015873|DRUG|methotrexate|
48508364|NCT00015873|DRUG|prednisolone|
48508365|NCT00015873|DRUG|vincristine sulfate|
48508366|NCT00956800|OTHER|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
48672107|NCT05814471|DEVICE|Velcro straps system|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
48148183|NCT06506552|PROCEDURE|IMA preserving|Performing left hemicolectomy, sigmoidectomy or rectal resection the IMA was preserved ligating the sigmoids arteries close to the colonic wall
48148184|NCT06506552|PROCEDURE|IMA sectioning|Performing left emicolectomy, sigmoidectomy or rectal resection the IMA is sectioned after the origin of left colic artery.
48672108|NCT06005909|OTHER|Cawthorne-Cooksey Exercises|"A- Head and Eye Movements While Lying and Sitting:~1. While keeping your head still, look up and then down again.~2. Look from side to side while keeping your head still.~3. Extend your hand at arm's length, draw your fingers towards your nose while focusing your eyes on your fingers.~4. With eyes open, slowly turn your head from side to side.~5. Turn your head from side to side quickly.~6. With eyes open, slowly move your head up and down.~7. Move your head up and down quickly.~8. Repeat items 4,5,6 and 7 with your eyes closed.~B-Head and Body Movements While Sitting:~1. Place an object on the floor in front of your feet, reach out to pick it up, then upright return to your position. Looking down while picking up the item, then Remind you to look up when trying to fix it.~2. Lean forward and move the object forward and back under your knees. C- Standing Exercises~1-Get from a sitting position to a standing position and sit down again. 2-Repeat this with your eyes closed."
48672109|NCT06005909|OTHER|Mechanical Hippotherapy Exercises|"From the patient on the mechanical hippotherapy device;~* Maintaining trunk balance while raising both hands above head,~* Maintaining trunk balance while opening the arms next to the trunk,~* Maintaining trunk balance while extending the arms back and forth with successive movements,~* Maintaining trunk balance with hands clasped behind the waist,~* The arms are open to both sides, while transferring the weight ball from one hand to the other, it is requested to maintain the body balance."
48672110|NCT03925987|BEHAVIORAL|Exposure therapy|10 weekly sessions of group-based exposure therapy
48672111|NCT02935192|BIOLOGICAL|Vaccine|Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
48672112|NCT02935192|OTHER|Placebo|Phosphate buffered saline, 0.5 mL by IM injection
48148185|NCT05401188|OTHER|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.
47990698|NCT00459173|DRUG|rimonabant (SR141716)|
48508367|NCT00956800|OTHER|Normal care|Control group will receive 5 routine office visits in one year
48672113|NCT04479592|OTHER|Particle counter|Particle counter to measure the aerosol generated
47990699|NCT05903885|OTHER|On-site Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home based Fecal Immunochemical Test (FIT) kit directly at the DMV site by the research staff.
47990700|NCT05903885|OTHER|Onsite with social media advertising Fecal Immunochemical Test (FIT) Kit Distribution|Participants will receive home-based Fecal Immunochemical Test (FIT) kits directly at the DMV location through face-to-face contact, supplemented by exposure to targeted social media advertisements.
47990701|NCT03211949|PROCEDURE|axillary block|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
48148186|NCT05401188|OTHER|hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
48148187|NCT03014726|COMBINATION_PRODUCT|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
48508368|NCT06463522|PROCEDURE|Autologous Tumor-infiltrating Lymphocytes|Autologous Tumor-infiltrating Lymphocytes, 2.0\*10\^7/Kg, single intravenous infusion.
48508369|NCT05060744|DEVICE|Antacid|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
48672114|NCT02469220|DIETARY_SUPPLEMENT|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
48672115|NCT02469220|DIETARY_SUPPLEMENT|Standardized FODMAP|Blinded food supplements containing FODMAPs
48672116|NCT02095756|OTHER|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
48672117|NCT02095756|OTHER|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
48672118|NCT05173376|BEHAVIORAL|Portion size manipulation|The intervention was administered via changing portion sizes of foods served to participants.
48672119|NCT03026244|DIETARY_SUPPLEMENT|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
48672120|NCT03026244|DIETARY_SUPPLEMENT|Placebo product|3 periods of 3 weeks placebo product
48672121|NCT01630317|PROCEDURE|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
48672122|NCT01630317|PROCEDURE|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
48672123|NCT03017443|BEHAVIORAL|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
48672124|NCT03017443|BEHAVIORAL|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (\~50% kcal from carbohydrate, \~25% from protein, \~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
48672125|NCT03017443|BEHAVIORAL|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included \< 30% fat (\< 7% saturated fat), \< 150 mg/d of cholesterol, and \< 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu \[7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week\], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
48148188|NCT01147757|DRUG|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
48148189|NCT03218085|DRUG|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
48359566|NCT02808273|DRUG|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
48508370|NCT05060744|OTHER|Control|The tablets should be kept in the mouth without chewing or swallowing, allowing them to dissolve completely.
48508371|NCT03685422|OTHER|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Visual analog scale-anxiety (VAS-A), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
48508372|NCT05898165|OTHER|Development of an algorithm|Prospective verification of a developed algorithm to predict the risk of a new onset Atrial Fibrillation
48672126|NCT03017443|BEHAVIORAL|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
48672127|NCT01299389|DRUG|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
48672128|NCT01299389|DRUG|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
48672129|NCT03976297|OTHER|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
47990702|NCT03211949|DRUG|Scandicaine|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
48672130|NCT05541848|OTHER|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
48672131|NCT05541848|OTHER|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
48672132|NCT06127433|DRUG|Insulin Glargine|Insulin Glargine
48672133|NCT06127433|DRUG|Metformin|Metformin
48672134|NCT06127433|DRUG|Dapagliflozin|Dapagliflozin
48672135|NCT06127433|DRUG|Insulin aspart|Insulin aspart
48672136|NCT05065658|DRUG|Posaconazole|Intravenous posaconazole prophylaxis
48672137|NCT03889652|DIAGNOSTIC_TEST|Oct scans|Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
48672138|NCT05715060|PROCEDURE|Median sternotomy closure (sternal closure)|Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)
48672139|NCT04709510|DIAGNOSTIC_TEST|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
48672140|NCT03261921|DRUG|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
48672141|NCT03261921|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
48672142|NCT03261921|DRUG|Bupivacaine|local anesthetic agent
48672143|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
48672144|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
48672145|NCT02545439|DRUG|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
48672146|NCT06391892|PROCEDURE|Neoadjuvant chemotherapy instead of upfront surgery|"All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board.~If preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.~* Apart from blood collection (within the scope of clinical routine), there is no additional diagnostic intervention performed on the patient.~* The respective neoadjuvant chemotherapeutical drug will be selected and applied by the treating medical oncologist at physicians choice (unaffected by study participation), usually mFOLFIRINOX or Gemcitabine/nabPaclitaxel at standardized dosage recommended by NCCN and local guidelines.~FOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin."
48672147|NCT06391892|PROCEDURE|Upfront surgery|Standard of care as recommended by tumor board (not affected by study conditions).
48672148|NCT02475421|BIOLOGICAL|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
47914369|NCT04927169|DRUG|PLACEBO|IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
47990703|NCT01141881|DRUG|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
47990704|NCT02910076|DRUG|Hydroxychloroquine|200 MG Plaquenil three times a day
47990705|NCT03930888|DIETARY_SUPPLEMENT|Dietary supplement|Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
47990706|NCT06215404|OTHER|Liberal group|Fluid challage to keep stroke volume variation \< 10%
47914370|NCT02538354|DIETARY_SUPPLEMENT|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
47990707|NCT06215404|OTHER|restrictive group|Fluid challage to keep stroke volume variation \< 18%
48359567|NCT06042179|BEHAVIORAL|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
48359568|NCT06042179|BEHAVIORAL|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
48359569|NCT05892302|BEHAVIORAL|Access to Asma Guardian website/app|The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
48508373|NCT05615831|BEHAVIORAL|Resistance Training with Blood flow restriction|Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.
48359570|NCT05892302|BEHAVIORAL|Delayed Access to Asma Guardian website/app|Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
48359571|NCT03385629|BEHAVIORAL|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
48359572|NCT03385629|OTHER|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
48359573|NCT03385629|OTHER|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
48359574|NCT02619461|OTHER|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
48672149|NCT01173679|DRUG|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
48359575|NCT01880489|BEHAVIORAL|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
48359576|NCT02510885|DEVICE|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
48359577|NCT02621281|DEVICE|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
48508374|NCT06593639|OTHER|Prehabilitation before surgery|Prehabilitation multimodal program will start about 4 weeks before the surgery and will be continued until 2 weeks after the surgical intervention. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
48672150|NCT01173679|DRUG|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
48672151|NCT01173679|DRUG|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
47914371|NCT02837107|DIETARY_SUPPLEMENT|Mind Master|80ml Mind Master / day for 8 weeks
47990708|NCT03068273|DEVICE|Real-time CGM data|
47990709|NCT00844363|PROCEDURE|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
47990710|NCT02024867|DRUG|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
48672152|NCT02425397|GENETIC|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
48672153|NCT02425397|GENETIC|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
48672154|NCT04764526|OTHER|Protein-enriched ice cream|Offering two protein-enriched ice creams
48672155|NCT02576873|OTHER|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
48672156|NCT06065124|PROCEDURE|Bariatric surgery strategy|Bariatric surgery including an intensive pre- and postoperative treatment scheme
48672157|NCT02524249|DRUG|Caffeine|
48672158|NCT02524249|DRUG|Placebo (dextrose)|
47914372|NCT02837107|DIETARY_SUPPLEMENT|Placebo|80ml a look-alike Placebo / day for 8 weeks
47914373|NCT05317325|BIOLOGICAL|OCDC vaccine; NeoDC vaccine|OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.
48148190|NCT03218085|DRUG|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
48359578|NCT02621281|DEVICE|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
48359579|NCT01364948|OTHER|Coconut oil application|Four ml coconut oil application twice daily for first week
48359580|NCT01364948|OTHER|No oil application|Oil application was not done
48359581|NCT02287363|OTHER|No intervention involved|No interventions will be involved since it is an observational study
48508375|NCT06593639|OTHER|Prehabilitation before and during CRT|Prehabilitation multimodal program will start about 4 weeks CRT and will be continued in parallel until 2 weeks after the end. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
48508376|NCT05971940|DRUG|Orforglipron|Administered orally.
48672159|NCT00419692|DRUG|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
48672160|NCT00051077|DRUG|Adefovir dipivoxil|
48672161|NCT00051077|DRUG|Peginterferon-alfa-2A|
48672162|NCT00051077|DRUG|Ribavirin|
48672163|NCT00051077|PROCEDURE|Liver Biopsy|
48672164|NCT00001561|DRUG|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
48672165|NCT00001561|DRUG|GM-CSF|
48508377|NCT05971940|DRUG|Placebo|Administered orally
48508378|NCT03082144|DRUG|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
48672166|NCT06347913|RADIATION|ultrasound|Umbilical Artery Systolic/Diastolic Ratio and Amniotic Fluid Index in Prediction of Fetal Outcome in Term Pregnancies
48672167|NCT02328521|DRUG|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
48672168|NCT02328521|DRUG|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
48672169|NCT01101451|DRUG|Cisplatin|Given IV
48672170|NCT01101451|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
48148191|NCT00175253|DRUG|alemtuzumab|
48508379|NCT03082144|DRUG|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
48508380|NCT03082144|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
48672171|NCT01101451|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
48672172|NCT01101451|OTHER|Laboratory Biomarker Analysis|Correlative studies
48508381|NCT04020783|OTHER|NO Intervention|NO Intervention
48508382|NCT04333030|OTHER|questionnaire|Tobacco Use and Risk Questionnaire
48508383|NCT04239027|DRUG|RTH258/Brolucizumab|"Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye."
48508384|NCT03357718|DRUG|Precedex|2 µg/kg oral
48508385|NCT03357718|DRUG|Midazolam|0.5 mg/kg
48672173|NCT01101451|OTHER|Quality-of-Life Assessment|Ancillary studies
48672174|NCT01101451|OTHER|Questionnaire Administration|Ancillary studies
48672175|NCT06179680|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|"MRI Protocol: Uses advanced MRI sequences to examine brain structures and detect white matter issues.~WMH Assessment: Evaluates white matter health using various methods, including manual and automated tools.~Neuropsychological Testing: Subjects undergo comprehensive cognitive testing administered by IRCCS Policlinico San Donato's Clinical Psychology Service.~Follow-up: Patients are monitored for cognitive changes semiannually, with additional assessments for those showing signs of progression. After two years, all patients undergo examination and tests to assess their condition."
48672176|NCT02999607|OTHER|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
48672177|NCT04340518|DEVICE|Scleral lens|Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
48672178|NCT00994864|DRUG|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
48672179|NCT06414044|DRUG|Atogepant 60 mg|Patients using atogepant 60 mg tablet daily as migraine prevention
48672180|NCT04164069|BIOLOGICAL|Bevacizumab|Given IV
48672181|NCT04164069|DRUG|Dasatinib|Given PO
48672182|NCT04164069|DRUG|Fluorouracil|Given IV
48148192|NCT00175253|PROCEDURE|islet transplant|
48148193|NCT00301054|DRUG|Ferrous sulphate|
48148194|NCT00301054|DRUG|Sulphadoxine-Pyrimethamine|
48359582|NCT01885962|BEHAVIORAL|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
48359583|NCT05506813|OTHER|cognitive training and conventional training|cognitive training along with conventional therapy
48359584|NCT05506813|OTHER|motor dual task training along with conventional therapy|motor dual task training along with conventional therapy
48672183|NCT04164069|DRUG|Leucovorin|Given IV
48672184|NCT04164069|DRUG|Leucovorin Calcium|Given IV
48672185|NCT04164069|DRUG|Oxaliplatin|Given IV
48672186|NCT04164069|OTHER|Quality-of-Life Assessment|Ancillary studies
48672187|NCT06167486|DRUG|SG2918|The SG2918 will be administrated by intravenous infusion every 3 weeks
48672188|NCT01897532|DRUG|Placebo|placebo matching tablets
48672189|NCT01897532|DRUG|Linagliptin|
48359585|NCT04343612|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
48359586|NCT02409628|DEVICE|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
48359587|NCT03494946|PROCEDURE|Liver transplantation|
48359588|NCT03494946|DRUG|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
48359589|NCT04493736|BEHAVIORAL|MHSAFE app recording|Participants are asked a series of questions to elicit their feelings and emotions as part of an audio recorded interview along with their normal therapy session.
48508386|NCT02655705|DRUG|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
48508387|NCT02655705|DRUG|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
48508388|NCT04660240|DEVICE|Abluminus Sirolimus Eluting Stent System (ASES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
48508389|NCT04660240|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System (OSES)|"The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion."
48508390|NCT00099879|DRUG|BMS-275183|
48508391|NCT04478812|DIAGNOSTIC_TEST|Single Group Assignment|Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
48508392|NCT00306930|DEVICE|Acetabular cup|Acetabular cup replacement
48508393|NCT06633315|OTHER|low dos dexmedetomidine|received dexmedetomidine 2.5 μ g/kg nasal drops
48508394|NCT06633315|OTHER|high dos dexmedetomidine|received dexmedetomidine 3 μ g/kg nasal drops
48508395|NCT06633315|OTHER|dexmedetomidine and esketamine|received dexmedetomidine 2 μ g/kg nasal drops plus ketamine 0.5 mg/kg nasal drops
48508396|NCT06449144|OTHER|Mindfulness education|The mindfulness-based stress reduction method was examined and a two-step mindfulness education is planned. To reveal the experience of pain: It was planned to conduct interviews with the participants to realize what they think about the pain they have experienced before or what they think about the pain they have experienced here and now, what emotions they have, and their experiences related to their coping processes with pain. Participants will be encouraged to notice negative thoughts that could impact their coping with pain negatively, and they will be provided with education on the benefits of managing the process of changing these negative thoughts. Attempts will be made to establish positive thinking. Attention: Recognizing the relationship between pain sensation and attention and encouraging its expression is included in the intervention. Information on distraction was given and two exercises we planned to increase the level of awareness.
48508397|NCT05395286|BEHAVIORAL|Innovation Lab|An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.
48508398|NCT03426137|DRUG|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
48508399|NCT03426137|DRUG|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
48508400|NCT03426137|OTHER|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
48508401|NCT03647670|DRUG|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
48508402|NCT03647670|DRUG|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
48508403|NCT04482673|DRUG|Daily Vitamin D3|6000 IU vitamin D3 daily
48508404|NCT04482673|DRUG|Daily placebo|Placebo daily
48359590|NCT00645736|OTHER|No intervention|No intervention
48359591|NCT00984919|OTHER|high performance liquid chromatography|
48359592|NCT00984919|OTHER|laboratory biomarker analysis|
48359593|NCT00984919|OTHER|mass spectrometry|
48359594|NCT01795313|BIOLOGICAL|HLA-A2 restricted synthetic tumor antigen|
48359595|NCT01795313|DRUG|Imiquimod|
48359596|NCT01795313|OTHER|enzyme-linked immunosorbent assay|
48359597|NCT01795313|OTHER|flow cytometry|
48359598|NCT01795313|OTHER|immunohistochemistry staining method|
48359599|NCT01795313|OTHER|laboratory biomarker analysis|
48508405|NCT04482673|DRUG|Bolus vitamin D3|Bolus 20,000 IU vitamin D3 daily for 3 days
48508406|NCT04482673|DRUG|Bolus placebo|Bolus placebo daily for 3 days
48508407|NCT00952731|DRUG|oral placebo|Oral placebo taken daily for 4-10 weeks.
48508408|NCT00952731|DRUG|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
48508409|NCT00952731|DRUG|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
48508410|NCT00952731|DRUG|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
48508411|NCT01560650|DEVICE|CRRT|Difference dose of CRRT
48359600|NCT05474885|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
48359601|NCT04791241|OTHER|check-list including lung ultrasound|"The investigator will follow the checklist which includes the collection of anamnestic data and clinical signs, the performance of a pulmonary embolism clinical probability score and a cardiopulmonary ultrasound with count -standardized rendering. After completing this checklist, the investigator will note their diagnosis (list of proposals on the data collection sheet), the treatments started (closed list of therapeutic classes). If he orders other tests, he will write them down and then note the diagnosis made and the treatments prescribed after obtaining the results of these tests.~The therapeutic management of patients compared to the usual care in the respective departments may be modified depending on the results of the cardiopulmonary ultrasound . The emergency physician may initiate therapy before the results of additional examinations that he would have usually performed without cardiopulmonary ultrasound."
48148195|NCT03956771|BEHAVIORAL|Real neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
48148196|NCT03956771|BEHAVIORAL|Sham neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
48148197|NCT02142569|DRUG|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
48672190|NCT02031302|DEVICE|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
48672191|NCT06301646|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
47990711|NCT03139149|PROCEDURE|Adhesiolysis|"Method of video laparoscopic operation:~* Open access in the left upper quadrant of the anterior abdominal wall,~* Installation of trocars, depending on the prevalence of the adhesion process~* Assessment of the peritoneal adhesion index~* Detection of the asleep gut~* Detection of obstacle area~* Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
48508412|NCT04909229|DEVICE|PEAR-003b PDT Intervention|The PEAR-003b digital therapeutic delivers CBT-I via mobile devices as 6 treatment core modules over 9 weeks.
48508413|NCT04909229|DEVICE|Fitbit|Patients will receive a Fitbit and receive standard of care
48508414|NCT04909229|BEHAVIORAL|Sleep education materials|Patients will receive sleep hygiene and healthy sleep tips.
48148198|NCT02142569|DRUG|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
48508415|NCT04926831|DRUG|capmatinib|150 mg and 200 mg tablets for oral administration
48508416|NCT04108208|DRUG|Apalutamide|Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.
47990712|NCT03139149|RADIATION|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
47990713|NCT03139149|RADIATION|Computer tomography|Computer tomography of abdomen with iv contrast
47990714|NCT03139149|PROCEDURE|Ultrasound|Ultrasound of the abdomen (2 times)
48148199|NCT02142569|DRUG|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
48508417|NCT04108208|DRUG|Placebo|Matching placebo will be administered orally.
48508418|NCT04108208|DRUG|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
48672192|NCT06301646|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
47990715|NCT03139149|OTHER|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
48148200|NCT02142569|DEVICE|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
48148201|NCT03823690|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
48148202|NCT03823690|DEVICE|The pyloro-duodenal stent|As listed in the arms description
48148203|NCT02206906|BEHAVIORAL|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
47990716|NCT04215380|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks
48359602|NCT04896840|OTHER|Telerehabilitation İntervention, Motor learning|"Telerehabilitation İntervention:~Training videos will be sent to the families of the children in the tele-rehabilitation group before starting to work. With the training videos, it is aimed to teach the exercises to be done to the families. Treatment will be applied by their families for 8 weeks, 2 days a week, 40 minutes a day. Physiotherapist will attend the sessions by video conference method. Video conference calls will be made by phone over the WhatsApp application.~Motor learning:~The first 10 minutes will start with active stretching Functional lying in a sitting position, Functional lying with feet together in a standing position. rolling the pilates ball on the wall, walking on its side. Going up and down stairs at different heights. Walking across different surfaces and obstacles. Getting up from chairs of different heights, sitting and extending the object taken from the ground. Functional exercises suitable for the child's level."
48508419|NCT05656872|PROCEDURE|Transverse Abdominis Plane Block|Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
48508420|NCT05656872|PROCEDURE|Ilioinguinal-iliohypogastric block|Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
48508421|NCT02654119|DRUG|Cyclophosphamide|Given IV
48508422|NCT02654119|OTHER|Laboratory Biomarker Analysis|Correlative studies
48508423|NCT02654119|DRUG|Paclitaxel|Given IV
48508424|NCT02654119|BIOLOGICAL|Trastuzumab|Given IV
48508425|NCT05658458|DRUG|Vericiguat (Verquvo, BAY1021189)|The recommended starting dose of vericiguat is 2.5 mg once daily, taken with food. The dose of vericiguat would be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the participant.
48508426|NCT05464524|OTHER|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
48508427|NCT05464524|OTHER|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
48508428|NCT03143374|DRUG|18F-AV-1451|"The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain.~Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit.~The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
48508429|NCT00591981|BEHAVIORAL|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
48508430|NCT06633575|BEHAVIORAL|exercise intervention|Patients will participate in an 8-week supervised aerobic exercise program, the intensity was set at the moderate to vigorous intensity (≥150mins/week exercise on the treadmill).
48508431|NCT04429347|DRUG|Gabapentin|Friday night: 1 capsule of 300 mg, Saturday night: 2 capsule of 300 mg (total 600 mg), Sunday night: choice of 1 or 2 capsule of 300 mg (total of 300 or 600 mg)
48508432|NCT04429347|DRUG|Placebo|Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
48508433|NCT04429347|DRUG|Tizanidine|Friday night: 1 capsule of 2 mg, Saturday night: 2 capsule of 2 mg (total 4 mg), Sunday night: choice of 1 or 2 capsules of 2 mg (total of 2 or 4 mg)
48508434|NCT03656744|DRUG|HTD1801|HTD1801 tablets, 250mg
48508435|NCT03656744|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
48508436|NCT01009502|DRUG|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
48508437|NCT00794508|BIOLOGICAL|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
48508438|NCT06021626|DRUG|CRD3874|"Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~1. 0.1~2. 0.3~3. 0.9~4. 1.8~5. 2.7~6. 4.05"
48508439|NCT06630221|DRUG|Eltrombopag (EPAG)|100 mg, 28-day cycles, 3+ cycles
48508440|NCT01192048|OTHER|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
48359603|NCT01657903|DRUG|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
48359604|NCT01657903|DRUG|Potassium nitrate|All study treatments contain 5% w/w KNO3.
48672193|NCT06301646|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48148204|NCT04478552|PROCEDURE|Fascia iliaca compartment block|It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.
48148205|NCT04478552|PROCEDURE|Placebo injection|same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
48508441|NCT03912545|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
48148206|NCT06332118|OTHER|ice massage group|Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
48148207|NCT01190995|DRUG|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
48359605|NCT05070208|OTHER|NOT PROVIDED|NOT PROVIDED
48359606|NCT05926011|DEVICE|RGn600|RGn600 with a 10 Hz-pulsed wave mode light emission
48359607|NCT05926011|DEVICE|RGn600 Sham|RGn600 inactivated
48359608|NCT00278213|BIOLOGICAL|alemtuzumab|
48359609|NCT00278213|DRUG|cyclophosphamide|
48359610|NCT00278213|DRUG|fludarabine phosphate|
48359611|NCT00278213|DRUG|mitoxantrone hydrochloride|
48508442|NCT05186675|PROCEDURE|superselective adrenal arterial embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
48508443|NCT04494984|DRUG|INM005|The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
48359612|NCT03944811|PROCEDURE|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
48359613|NCT03944811|PROCEDURE|Summers technique|Summers technique
48359614|NCT04524013|OTHER|There is no intervention. It is an observational study.|There is not intervention
48359615|NCT05633290|DIAGNOSTIC_TEST|CMR|CMR Imaging 6-10 weeks post hospital discharge.
48508444|NCT04494984|DRUG|Placebo|Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
48359616|NCT05633290|DIAGNOSTIC_TEST|hs-troponin|Biomarker of myocardial injury
48508445|NCT05465954|PROCEDURE|Biospecimen Collection|Correlative studies
48359617|NCT05633290|DIAGNOSTIC_TEST|NT-pro BNP|Biomarker for heart failure
48508446|NCT05465954|BIOLOGICAL|Efineptakin alfa|Given IM
48508447|NCT05465954|BIOLOGICAL|Pembrolizumab|Given IV
48359618|NCT05633290|DIAGNOSTIC_TEST|CRP|Acute phase inflammatory marker
48359619|NCT05633290|DIAGNOSTIC_TEST|IL1-B|Inflammatory biomarker
48359620|NCT05633290|DIAGNOSTIC_TEST|IL-6|Inflammatory Biomarker
48359621|NCT05633290|DIAGNOSTIC_TEST|IL-10|Inflammatory Biomarker
48359622|NCT05633290|DIAGNOSTIC_TEST|TNF-alpha|Inflammatory Biomarker
48508448|NCT05465954|PROCEDURE|Biopsy|Undergo tumor biopsy
48508449|NCT00431483|BEHAVIORAL|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
48508450|NCT05517538|DEVICE|Electromyography-Needle Intramuscular Drug guidance|EMG-guided needle neurotoxin injection
48508451|NCT05517538|DRUG|Botulinum toxin type A|Botulinum toxin type A injection into the Corrugator Supercilii muscle
48508452|NCT04569669|DIAGNOSTIC_TEST|FFR and FFRCT|All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
48508453|NCT05243446|DRUG|Losartan|losartan treatment
48508454|NCT00950365|DRUG|Erlotinib Hydrochloride|Given PO
48508455|NCT00950365|OTHER|Laboratory Biomarker Analysis|Correlative studies
48508456|NCT00950365|DRUG|Pemetrexed Disodium|Given IV
48508457|NCT04605874|OTHER|Package Quantity (cigarillos)|After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack.
48359623|NCT00004569|PROCEDURE|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
48672194|NCT05758324|DIETARY_SUPPLEMENT|Nutri PNEA|4 sequences of 10 tablets (one intake)
48672195|NCT05758324|DIETARY_SUPPLEMENT|Placebo|4 sequences of 10 tablets (one intake)
48672196|NCT06216158|DRUG|Iberdomide|Iberdomide p.o. (1.0 mg, day 1-21 of each 29-days cycle)
48672197|NCT06216158|DRUG|Isatuximab|Isatuximab s.c. (1400 mg, cycle 1: day 1, 8, 15, 22; cycles 2-3: day 1 and 15; from C4: day 1)
48359624|NCT01758367|DRUG|Deciatbine(DAC)|
48359625|NCT02678702|BEHAVIORAL|CBT-I|CBT-I
48359626|NCT02678702|BEHAVIORAL|Treatment as usual|Treatment as usual
48359627|NCT00002625|DRUG|topotecan hydrochloride|
48359628|NCT00002625|RADIATION|low-LET electron therapy|
48359629|NCT00002625|RADIATION|low-LET photon therapy|
48359630|NCT00591786|DRUG|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
48359631|NCT00796172|BEHAVIORAL|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
48359632|NCT00796172|BEHAVIORAL|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
48359633|NCT02094339|PROCEDURE|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
48359634|NCT02094339|PROCEDURE|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
48359635|NCT02094339|PROCEDURE|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
48359636|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
48359637|NCT02094339|DRUG|ropivacaine|0.2% ropivacaine
48359638|NCT02094339|DRUG|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
48359639|NCT04678973|BEHAVIORAL|Self-compassion mindfulness practice|"Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey."
48359640|NCT02053597|DRUG|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
48359641|NCT02053597|DRUG|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
48359642|NCT00115622|DRUG|fluticasone furoate|
48672198|NCT06216158|DRUG|Dexamethasone|Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
48672199|NCT03151031|PROCEDURE|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
48672200|NCT02224534|DRUG|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
48672201|NCT02224534|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
48359643|NCT00003572|BIOLOGICAL|peripheral blood lymphocyte therapy|
48359644|NCT00003572|DRUG|mycophenolate mofetil|
48359645|NCT00003572|DRUG|tacrolimus|
48359646|NCT00003572|PROCEDURE|allogeneic bone marrow transplantation|
48672202|NCT01903005|DRUG|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
48672203|NCT06467630|PROCEDURE|Preserving alveolar bone volume after tooth extraction|"* Visit 1: A periodontal or dental implant surgery is done aiming to preserve alveolar bone volume after extraction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* V2bis (1 month +/- 1 week) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
48672204|NCT06467630|PROCEDURE|Alveolar crest reconstruction|"* Visit 1: A periodontal or dental implant surgery is done aiming to alveolar crest reconstruction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
48672205|NCT06467630|PROCEDURE|Covering bone defects during immediate implant placement.|"* Visit 1: A periodontal or dental implant surgery is done aiming to cover bone defects during immediate implant placement.~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (3 months ± 1 month) - Late post-surgery follow-up"
47990717|NCT04215380|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
48359647|NCT00003572|RADIATION|radiation therapy|
48359648|NCT04995042|DRUG|SHR7280|Drug: SHR7280 All participants receive SHR7280 alone.
48672206|NCT02091076|DEVICE|Silk fibroin with bioactive coating layer dressing|
48148208|NCT01190995|DRUG|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
48359649|NCT05445869|DEVICE|ProSomnus® EVO Sleep and Snore Device|The ProSomnus® EVO Sleep and Snore Device is an intraoral device for snoring and obstructive sleep apnea. It works by repositioning the mandible during sleep, thereby improving the flow of air through the patient's pharyngeal space. The ProSomnus® EVO Sleep consists of maxillary and mandibular device arches that are CAD/CAM designed with twin-mated posts and digitally milled to be patient-specific according to physician prescription. Prescribed advancements can be achieved by simply removing the current upper or lower device arch and inserting the next upper or lower device arch in the mandibular advancement series. The device does not have any adjustment mechanisms to modify or maintain the mandibular position such as pistons, screws, straps, or repositioning elastics. The device is supplied nonsterile.
48359650|NCT02205177|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
48508458|NCT02919592|DEVICE|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
48508459|NCT02919592|DEVICE|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. MemoryGel Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
48672207|NCT02091076|DEVICE|Bactigras wound dressing|
48672208|NCT00511758|PROCEDURE|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
48672209|NCT00748631|DEVICE|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
48672210|NCT03669796|DIETARY_SUPPLEMENT|Marine protein hydrolysate (mph)|Marine (Cod) protein hydrolysate
48672211|NCT03669796|DIETARY_SUPPLEMENT|Control|Maltodextrin/Casein
48672212|NCT04000061|OTHER|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
48672213|NCT04000061|OTHER|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
48508460|NCT02919592|PROCEDURE|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
48672214|NCT05486390|BEHAVIORAL|Nudge, health coaching and shared decision-making|"The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~1. Goal setting and action plan~2. After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making."
48508461|NCT06194760|PROCEDURE|Vitrectomy with ILM peeling|Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
48508462|NCT04986384|DRUG|Atoderm SOS spray Aerosol 200ml|A bottle of 200ml topical spray was used on the eczematous skin lesions for itch relief.
48508463|NCT01371812|DRUG|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
48672215|NCT03157895|BEHAVIORAL|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
48672216|NCT02418520|DEVICE|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
48508464|NCT01371812|DRUG|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
48508465|NCT00683345|DRUG|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
48148209|NCT04927507|BEHAVIORAL|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
48148210|NCT04413175|OTHER|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
48672217|NCT01178840|DEVICE|WC then FC2|4 uses of WC followed by 4 uses of FC2
48672218|NCT01178840|DEVICE|FC2 then WC|4 uses of WC followed by 4 uses of FC2
48672219|NCT04099277|DRUG|LY3435151|Administered IV
48672220|NCT04099277|DRUG|Pembrolizumab|Administered IV
48508466|NCT00683345|DRUG|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
48672221|NCT03319641|DIAGNOSTIC_TEST|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
48672222|NCT04660760|DRUG|Paclitaxel|Given IV
48672223|NCT04660760|OTHER|Quality-of-Life Assessment|Complete questionnaires
48672224|NCT04660760|BIOLOGICAL|Ramucirumab|Given IV
48508467|NCT06054165|OTHER|Clinical pathway|Evidence-based and expert-opinion-based clinical pathway regarding the diagnostic and treatment strategy
48508468|NCT01954745|DRUG|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
48508469|NCT06111352|DRUG|Pralidoxime|Inj. Pralidoxime 1 gm I/V will be given as first dose over 10-20 minutes. If no improvement of muscle weakness, then repeat the dose after one hour. Then 1 gram of Inj. Pralidoxime will be given at an 8-hour interval
48672225|NCT04660760|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
48672226|NCT06411301|DRUG|225Ac-DOTATATE|Two intravenous infusions every 6 weeks (Q6W)
48148211|NCT00835328|DRUG|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
48672227|NCT06159257|DIAGNOSTIC_TEST|Blood test|"Whenever possible, samples will be collected by the nurse in the patient's home, according to the study visit schedule. However, if this is not possible, patients will be asked to come in for sample collection at another mutually convenient time at the CERBA ALLIANCE LABORATORY closest to the patient's address.~Venous blood will be drawn on each visit."
48672228|NCT00100802|OTHER|Laboratory Biomarker Analysis|Correlative studies
48672229|NCT00100802|DRUG|Lomustine|Given PO
48672230|NCT00100802|RADIATION|Radiation Therapy|Undergo radiation therapy
48672231|NCT00100802|DRUG|Temozolomide|Given PO
48672232|NCT01644643|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
48672233|NCT01644643|DRUG|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
48672234|NCT01644643|DRUG|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
48672235|NCT02804061|BEHAVIORAL|NELIP|
48672236|NCT04442568|OTHER|ERAS|early mobilisation, early oral intake, early discharge
48672237|NCT02565992|BIOLOGICAL|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
48672238|NCT02565992|DRUG|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
48672239|NCT05150678|PROCEDURE|removal of ceserean section scar|we will remove the previous scar in group A
48672240|NCT05150678|PROCEDURE|non removal of cesearean section scar|we will open in the previous cesearean scar in group B
48672241|NCT02102243|DRUG|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
48672242|NCT02102243|DRUG|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
48148212|NCT00835328|DRUG|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
48148213|NCT02569294|BEHAVIORAL|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
48359651|NCT05431231|DIAGNOSTIC_TEST|Outcome Questionnaire-45|a questionnaire that evaluates the patient's level of distress. The questionnaire was developed by Lambert et al. in 1996 and was translated to Hebrew by Gross, Glasser, Elisha et al. in 2015. The questionnaire is composed of 45 statements that describe emotional states, assessing three main components: subjective discomfort, interpersonal relationships and performance of social roles. The participants are asked to rate how often they have felt the states described by each statement using a five-level Likert scale (0 - never, 4 - almost always). This questionnaire has been used extensively and has showed good internal consistence of 0.93 for its English version and 0.91 for its Hebrew version.
48359652|NCT05431231|DIAGNOSTIC_TEST|Hopkins symptoms checklist - short form|a questionnaire for assessing symptomatic distress. The questionnaire was developed by Lutz, Tholen, Schürch, and Berking in 2006. It is a short version of the SCL-90-R, that was developed by Derogatis in 1992. The checklist includes 11 items that describe negative feelings and thoughts. Participants are asked to rate the extent to which a given feeling or thought has troubled them in the past week using a four-level Likert scale (1 - not at all, 4 - very much). This tool is highly correlated with the Global Severity Index (r=.91) and has shown high internal consistency.
48508470|NCT06111352|DRUG|Atropine|Inj. Atropine (3 ampule) will be given in intravenous route as a first dose, rapidly. Then the dose will be doubled from the previous dose in every 5 minutes interval until the signs of atropinisation appeared. Then infusion of 10% of the total bolus dose (the dose that was given until the signs of atropinisation appeared) per hour, will be given with intravenous Normal saline/ 5% DNS(Dextrose and Sodium chloride) as a maintenance dose. The dose will be reduced for adjustment, based on clinical features/improvement
48672243|NCT02102243|DRUG|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
48148214|NCT02569294|BEHAVIORAL|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
48148215|NCT02569294|BEHAVIORAL|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
48148216|NCT04213768|PROCEDURE|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
48148217|NCT04213768|PROCEDURE|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
48148218|NCT03040453|DEVICE|Microwave ablation|
48148219|NCT03040453|DEVICE|Irreversible electroporation|
48148220|NCT06199011|DRUG|Esketamine hydrochloride|A standardized non-opioid anesthesia will be achieved by using continuous intraoperative infusion of esketamine.
48148221|NCT06199011|DRUG|Opioid|A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
48148222|NCT05852197|DRUG|anticoagulant or antiplatelet drugs|combination of anticoagulant or antiplatelet drugs
48148223|NCT04948866|BEHAVIORAL|ADRD-PC Program|Included in arm/group descriptions
48359653|NCT05431231|DIAGNOSTIC_TEST|Prodromal Questionnaire - Brief Version|a patient questionnaire that assesses the existence of a prodromal state or fully developed psychosis. It was developed by Ising et al. in 2012 and was translated to Hebrew by Koren et al. in 2016. The tool is based on a more extensive questionnaire - PQ-92 - that was developed by Loewy et al. in 2005 - and constitutes an attempt to create an improved shorter version. The PQ-16 includes 16 items that refer to thoughts, feelings and experiences that describe various symptoms, including abnormal perception (9 items), unconventional thinking and paranoia (5 items) and negative symptoms (2 items). For each item, first, the participant is asked to indicate whether he had experienced that phenomenon in the past month, and if he had, he is asked to describe the extent to which the phenomenon had caused him distress, using a four-level Likert scale (0 - no distress, 3 - severe distress). Ising et al. found that Kronbach's α was 0.774 for the whole questionnaire.
48359654|NCT05431231|DIAGNOSTIC_TEST|Manchester Short Assessment of Quality|a patient questionnaire that assesses quality of life. This questionnaire was developed by Priebe, Huxley, Knight and Evans in 1999. It is based on a longer questionnaire - Lancashire Quality of Life Profile (LQLP) - and was created as an attempt to form an improved shorter version. The questionnaire is composed of two parts: personal details that can change over time and 16 questions that assess objective and subjective quality of life. The objective items are presented as yes or no questions, while regarding the subjective items, participants are asked to describe, using a 7-level Likert scale, the extent to which they are satisfied with their lives. Priebe et al. reported an alpha internal consistency of 0.74.
48508471|NCT03155516|OTHER|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
48508472|NCT03155516|OTHER|Current practice procedure|Current practice clinical procedure for pain management
48508473|NCT05373628|DIAGNOSTIC_TEST|Gradient and pulse imaging|A novel diffusion-based magnetic resonance imaging method
48508474|NCT06474273|DRUG|Methylprednisolone|IV Methylprednisolone
48508475|NCT06474273|DRUG|Prednisone|Oral prednisone augmentation
48508476|NCT04529837|OTHER|Gauze|placement of gauze
48508477|NCT04529837|OTHER|No gauze|no gauze
48672244|NCT02102243|PROCEDURE|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
48148224|NCT03425175|OTHER|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
48148225|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
48148226|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
48508478|NCT02382861|DEVICE|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
48672245|NCT02102243|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
48148227|NCT05861232|BEHAVIORAL|Behavioral|fear and anxiety during inhalation therapy
48148228|NCT00255268|DRUG|Goserelin|
48148229|NCT00255268|DRUG|Bicalutamide|
48148230|NCT04904354|DEVICE|AcQBlate® Force Sensing Ablation System|Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.
48148231|NCT05179772|DRUG|Olanzapine|Olanzapine (2.5 mg to 20 mg)
48148232|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
48148233|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
48148234|NCT06012214|PROCEDURE|ROBOTIC-ASSISTED ESOPHAGECTOMY|Comparison between robotic and conventional minimally invasive esophagectomy
48148235|NCT01684540|OTHER|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
48148236|NCT01684540|DRUG|Sinupret forte|
48359655|NCT05431231|DIAGNOSTIC_TEST|Self-Stigma of Mental Illness Scale|a patient questionnaire that assesses internalized self-stigma. It was developed by Corrigan, Watson, and Barr in 2006. The questionnaire is composed of four dimensions. The questionnaire includes 40 items, 10 items for each dimension. The participant is asked to rate the extent to which he agrees with each item using a 9-level Likert scale. The questionnaire yields four separate scores for each dimension, and each dimension can be administered separately and independently. In the current study, only one 10-item dimension will be administered - the extent to which the participant has internalized stereotypes concerning mental illness. Corrigan et al (2006) reported an internal consistency alpha of 0.81 and a test-retest reliability ratio of 0.82 for this dimension.
48508479|NCT02382861|DEVICE|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
48508480|NCT00055042|DRUG|Vitamin E|
48148237|NCT04893759|DRUG|Pelcitoclax|Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
48148238|NCT02536534|OTHER|Correlation assessment|
48148239|NCT02817360|DRUG|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
48148240|NCT02817360|OTHER|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
48148241|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
48148242|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
48359656|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for patient|this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
48508481|NCT03541980|DRUG|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
48508482|NCT03541980|DRUG|Normal saline|Normal saline volume equivalent
48148243|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
48359657|NCT05431231|OTHER|Quality of service/satisfaction questionnaire|measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
48508483|NCT05436314|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.
48508484|NCT05436314|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
48508485|NCT05436314|OTHER|Sham Manual Lymphatic Drainage|Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.
48672246|NCT02102243|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
48672247|NCT02102243|PROCEDURE|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
48672248|NCT02522039|DRUG|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
47990718|NCT00462761|DRUG|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
48148244|NCT02643368|BIOLOGICAL|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
48148245|NCT03883178|PROCEDURE|Minimal-invasive endoscopic transgluteal approach|Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
48508486|NCT01365312|DRUG|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
48508487|NCT01365312|DRUG|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
48508488|NCT02053337|DEVICE|Self adhesive foam dressing|Self adhesive foam dressing
48672249|NCT02522039|DRUG|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
48672250|NCT02522039|DRUG|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
48672251|NCT01416961|RADIATION|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
48359658|NCT05431231|DIAGNOSTIC_TEST|Clinical decision-making style|a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
48508489|NCT05346926|DEVICE|3D-printed cast|The 3D-printed casts are produced using 3D print technology based on software by Belgian software company: The patient's forearm is scanned with a tablet (duration: approx. 5 min), whereupon the cast is printed overnight according to the scan (duration: approx. 4h) and adjusted to the patient during the next appointment.
48672252|NCT01416961|DRUG|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
48672253|NCT01416961|DRUG|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
47990719|NCT05749575|DRUG|Chidamide Plus Toripalimab Plus Paclitaxel|Each participant receives chidamide plus toripalimab plus paclitaxel
47990720|NCT00625976|BEHAVIORAL|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
48672254|NCT04167254|BEHAVIORAL|Sit Down and Play|Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
48672255|NCT05524831|OTHER|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
48672256|NCT05524831|OTHER|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
48148246|NCT04755309|BEHAVIORAL|Rhythmic intervention|"The rhythmic intervention consists in an ecological and non-invasive intervention based on enriched auditory and musical active experience. It is based on the most recent scientific evidence in the field and provides exposure to and active synchronization with complex musical rhythms. It is thought to promote the infant's ability to recognize and process the complex rhythms of spoken language. Importantly, it taps into and empowers early auditory processing skills. The intervention includes several tasks described in the literature, for example tapping and bouncing at the beat of complex musical rhythms.~The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks."
47990721|NCT00625976|BEHAVIORAL|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
48508490|NCT05346926|DEVICE|Conventional cast|A conventional plaster cast is applied for treatment of the distal radius fracture.
48508491|NCT03850548|OTHER|Prosthetic joint infection with Cutibacterium acnes|patients having a prosthesis infection with C.acnes identified by specific PCR
48672257|NCT04505761|DEVICE|Virtual Reality|Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
48672258|NCT03423602|DEVICE|PerQseal®|Large hole closure system
48672259|NCT01816048|DRUG|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
48672260|NCT01816048|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
48508492|NCT06234943|OTHER|Chlamydia trachomatis and Neisseria gonorrhea self-swab(s) and/or urine collection. Clinical assessment and prescribing of treatment for participants with positive test results|Participants will be tested by self-swab sample (pharyngeal, vaginal or rectal) and/or urine sample (urogenital) for Chlamydia trachomatis and Neisseria gonorrhea. Selection of swab(s) or urine-based testing will be determined by the individual's sexual risk factors. Participants who have positive CT and/or NG test results will undergo clinical assessment of the CT and/or NG infection by the pharmacist and a prescription will be issued for treatment as appropriate.
48508493|NCT04214626|DRUG|Rituximab|"Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles)."
48672261|NCT01816048|PROCEDURE|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
48672262|NCT01816048|PROCEDURE|Computed Tomography|Undergo 18F NaF PET/CT scan
48672263|NCT03076606|DIAGNOSTIC_TEST|ophthalmologist examination|ophthalmologist examination after geriatric consultation
48672264|NCT00628381|DIETARY_SUPPLEMENT|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
47914374|NCT05255809|OTHER|Alexander Technique + Routine Physical Therapy|Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
47914375|NCT05255809|OTHER|Routine Physical Therapy|Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
47990722|NCT01531374|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
47990723|NCT05309109|OTHER|Hemodialysis sessions|Patients will receive thrice weekly 4 hours hemodialysis sessions during 12 months.
47990724|NCT01591291|DRUG|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
48672265|NCT00628381|DIETARY_SUPPLEMENT|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
48672266|NCT04357899|DRUG|thrombolysis therapy|
48672267|NCT04357899|PROCEDURE|endovascular therapy|
48672268|NCT04357899|PROCEDURE|decompressive surgery|
48672269|NCT04357899|DIAGNOSTIC_TEST|multimodal imaging in acute ischemic stroke|
48672270|NCT04357899|PROCEDURE|transfer of acute stroke patients to tertiary stroke centers|
48672271|NCT04357899|DRUG|initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention|
48672272|NCT02961244|OTHER|Prewarming and perioperative warming with Forced Air Warming device and its blankets.|
48672273|NCT02961244|DEVICE|Forced Air Warming blanket|
48672274|NCT05341947|BIOLOGICAL|Activated T cells|Activated T cells (ATC) administered intravenously at one timepoint
48672275|NCT05845112|DIAGNOSTIC_TEST|Molecular Diagnostics|pooled sputum samples will be used at the site of sample collection on the EDGE platform using Xpert ULTRA cartridges
48359659|NCT05431231|DIAGNOSTIC_TEST|Global Assessment of Functioning Scale|a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
48359660|NCT05431231|DIAGNOSTIC_TEST|Session Alliance Inventory - for therapist|a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, \& Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
48672276|NCT05845112|DIAGNOSTIC_TEST|Qualitative C-Reactive Protein (CRP)|CRP qualitative (POC) rapid tests are immunochromatographic based assays for qualitative or semiquantitative determination of CRP circulating in blood, serum or plasma at the Point of Care with a time to result in 5 minutes.
47990725|NCT01591291|DRUG|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
48508494|NCT04214626|DRUG|Lenalidomide|Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
47990726|NCT01853046|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
47990727|NCT04714996|DRUG|ES-481|"Treatment Period Week 1 - 25 mg qd, Week 2 - 25 mg bid, Week 3 - 50 mg bid, Week 4 - 75 mg bid.~Step-down and Washout Period Day 1 - 125 mg, Day 2 - 100 mg, Day 3 - 75 mg, Day 4 - 50 mg, Day 5 - 50 mg, Day 6 - 25 mg, Day 7 - 25 mg, Days 8 to 14 - 0 mg"
47990728|NCT04714996|DRUG|Placebo|Placebo on Week 1, Week 2, Week 3 and Week 4
47990729|NCT04714996|DRUG|Open-Label Extension Study|Dosing will be at the discretion of the Investigator with a minimum dose of 25 mg/day (25 mg qd) to a maximum dose of 150 mg/day (75 mg bid).
47990730|NCT05501184|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
47990731|NCT05501184|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
47990732|NCT04400786|PROCEDURE|intermittent treatment|According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
47990733|NCT04400786|PROCEDURE|continuous treatment|The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
47990734|NCT03946384|OTHER|data collection|data collection on the history of the disease, hemophilia
48148247|NCT04755309|BEHAVIORAL|Passive auditory stimulation|The same auditory stimulation is provided to infants, but no active tasks are proposed. Children and caregiver are entertained with motor and cognitive tasks not related to the auditory stimuli presented. The intervention takes place in small groups of infant-caregiver pairs (N=4/5) for 1 hour/week for 6 weeks.
48148248|NCT02495402|BEHAVIORAL|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
48508495|NCT04214626|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48508496|NCT04214626|DRUG|Epirubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48508497|NCT04214626|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48508498|NCT04214626|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
48148249|NCT03242863|OTHER|Food proportionality|Proportions of high and low energy dense foods manipulated
48508499|NCT04214626|DRUG|Methotrexate|Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
48148250|NCT01058694|BEHAVIORAL|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
48148251|NCT01513005|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
48359661|NCT01096615|DIETARY_SUPPLEMENT|Placebo|"Description:~- capsule size 3~Composition of the product:~* 45 mg of microcristalline cellulose,~* 132 mg of maltodextrin,~* 3 mg of magnesium stearate.~Composition of the capsule:~* 46 mg of hypromellose,~* 1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
48359662|NCT01096615|DIETARY_SUPPLEMENT|Lactobacillus paracasei LP-33|"Description:~* minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~* capsule size 3 1 capsule daily together with a meal, with a glass of water."
48359663|NCT01146691|OTHER|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
48359664|NCT05260476|OTHER|Reablement|The service provider customizes a training plan and formulates training goals based on the patient's level of disability, family environment, and the needs of the patient and the caregiver.
48359665|NCT05883150|DRUG|Nebulized Midazolam|"All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern"
48359666|NCT05883150|DRUG|Intranasal Midazolam|All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
48359667|NCT06133790|GENETIC|PCR - Immunohistochemistry - Immunolabelling|Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
48359668|NCT04373616|BIOLOGICAL|ACI-24|injections
48359669|NCT04373616|BIOLOGICAL|Placebo|injections
48359670|NCT03066492|OTHER|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
48359671|NCT03066492|OTHER|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
48359672|NCT00155246|DRUG|pentoxifylline (drug)|
48148252|NCT00147394|DRUG|Risperidone|
48359673|NCT03706144|OTHER|Prodigy Math Training|https://www.prodigygame.com/
48359674|NCT04375007|OTHER|Routine care|Physiotherapy intervention in routine care
48359675|NCT02402920|DRUG|Carboplatin|Given IV
47914376|NCT01224990|PROCEDURE|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
47914377|NCT04235296|BIOLOGICAL|epidermal growth factor|Residual wounds from the same person were divided into control group and experimental group. The epidermal growth factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
48148253|NCT06231667|OTHER|Education|four training sessions were applied to the intervention group
48148254|NCT03489356|BEHAVIORAL|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
48148255|NCT01465399|BIOLOGICAL|Plasma Rich in Growth Factors PRGF-Endoret|
48148256|NCT01465399|PROCEDURE|Conventional closure of the lesion|
48148257|NCT06594497|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
48508500|NCT06172621|PROCEDURE|Spinal Cord Associative Plasticity (SCAP)|Paired non-invasive brain and spinal cord stimulation.
48148258|NCT06594497|OTHER|Conventional Physiotherapy + Kinesthetic motor imagery training|Conventional Physiotherapy + Kinesthetic motor imagery training
48148259|NCT05436041|BEHAVIORAL|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
48359676|NCT02402920|DRUG|Cisplatin|Given IV
48359677|NCT02402920|DRUG|Etoposide|Given IV
48359678|NCT02402920|OTHER|Laboratory Biomarker Analysis|Correlative studies
48359679|NCT02402920|BIOLOGICAL|Pembrolizumab|Given IV
48508501|NCT06172621|PROCEDURE|Upper extremity task-oriented exercise|Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
48508502|NCT05102227|DEVICE|Left bundle branch area pacing|A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
48672277|NCT05845112|DIAGNOSTIC_TEST|Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP|CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.
48672278|NCT05845112|DIAGNOSTIC_TEST|Urine lateral flow tests|The assay combines a pair of high affinity monoclonal antibodies directed towards largely Mycobacterium tuberculosis-specific lipoarabinomannan epitopes and a silver-amplification step that increases the visibility of test and control lines. This enables the detection of urinary lipoarabinomannan concentrations that are approximately 30 times lower than that detected by a previous test called AlereLAM and improved analytical specificity compared with AlereLAM.
48672279|NCT05845112|DIAGNOSTIC_TEST|Portable Chest X Ray Image Acquisition|Qure.ai (Qure.ai, New York, USA) is a computer aided detection (CAD) software for the automated screening of tuberculosis. Qure.ai is a mobile based interpretation software that screens chest X-Ray to detect TB in less than a minute. Qure.ai can distinguish abnormal scans from normal and detect abnormalities in the lungs, pleura, mediastinum, bones, diaphragm, and heart.
48672280|NCT02125955|DIETARY_SUPPLEMENT|Prebiotic fiber|Dissolved in water.
48148260|NCT02481011|DRUG|antithrombotic drugs|
48148261|NCT04998266|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
48148262|NCT04998266|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
48359680|NCT02402920|PROCEDURE|Radiation Therapy|Undergo radiation therapy
48359681|NCT06330649|DIETARY_SUPPLEMENT|Energy Drink|This is a commercially available energy drink
48359682|NCT06330649|OTHER|Water Control|This is a commercially available bottled water
48672281|NCT02125955|DIETARY_SUPPLEMENT|Placebo|Dissolved in water
48672282|NCT03978845|DRUG|Lidocaine|Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
48672283|NCT03794973|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
48672284|NCT03794973|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
47990735|NCT03239587|BEHAVIORAL|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
48359683|NCT00750867|DRUG|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
48359684|NCT02181335|DRUG|Respimat® Budesonide low dose|
47990736|NCT03239587|PROCEDURE|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
48359685|NCT02181335|DRUG|Respimat® Budesonide high dose|
48359686|NCT02181335|DRUG|Turbohaler® Budesonide|
48359687|NCT02181335|DRUG|Placebo|
48359688|NCT02327182|DRUG|MT-4666|
48359689|NCT01164267|DRUG|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
48508503|NCT00641069|DEVICE|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
48508504|NCT04197050|DRUG|Sacubitril / Valsartan Oral Tablet|After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
47990737|NCT03239587|BEHAVIORAL|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
48148263|NCT03788278|DEVICE|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
48148264|NCT04004754|DRUG|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
48148265|NCT02454556|DRUG|FOLITIME®|
48359690|NCT03792126|OTHER|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
48359691|NCT02147431|DRUG|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
48359692|NCT02147431|DRUG|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
48508505|NCT03071939|OTHER|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
48148266|NCT02454556|DRUG|Gonal-F®|
48359693|NCT02768636|DIETARY_SUPPLEMENT|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
48359694|NCT00004580|DRUG|Lopinavir/Ritonavir|
48359695|NCT00004580|DRUG|Nevirapine|
48672285|NCT05171153|OTHER|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
48359696|NCT04572464|OTHER|Mindfulness Based Guided Meditation|Mindfulness Based Guided Meditation will be practiced by nurses under the supervision of researcher for 15 min thrice a week for two weeks
48359697|NCT00417235|DEVICE|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
48359698|NCT00417235|BEHAVIORAL|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
48359699|NCT01435564|BEHAVIORAL|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
48672286|NCT05171153|OTHER|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
48672287|NCT05171153|OTHER|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
48672288|NCT01041430|OTHER|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
48672289|NCT01041430|OTHER|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
48672290|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
48672291|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
48672292|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
48672293|NCT03698279|BIOLOGICAL|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
47990738|NCT06389747|OTHER|BFR technique|For BFR application, Airbands brand, wireless, automatic training cuffs will be used. During application, it will be ensured that the device module faces forward and the cuff will be fixed in the correct position by wrapping the band around the metal ring. There will be a space between the skin and the cuff that can fit two fingers. The cuff will then be paired via Bluetooth with the Airbands app installed on the phone. BFR cuffs will be placed proximal to the biceps brachii muscle and pressure will be applied. The cuff will be inflated to automatically detect limb pressure. BFR application with 80% pressure to one group of participants and 20% pressure to the other group will be applied simultaneously with the exercise.
47990739|NCT03997149|BEHAVIORAL|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
47990740|NCT03997149|BEHAVIORAL|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
47990741|NCT05931679|DEVICE|VR Headset|A VR headset will be used for participants in the Interactive VR and 360 degree video groups.
47990742|NCT05931679|OTHER|Traditional Theatre-based simulation|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
47990743|NCT05426226|DEVICE|laser acupuncture|using laser acupuncture device on sleep acupoints during sleep
47990744|NCT05426226|DEVICE|sham device|using sham device on sleep acupoints during sleep
47990745|NCT01764009|BIOLOGICAL|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
47990746|NCT05969288|OTHER|Behavioral survey|"Behavioral survey by administering a short self-administered questionnaire (read more in the Detailed description section)."
48148267|NCT05434559|DRUG|Insulin Degludec|Switch during standard routine care to Insulin Degludec.
48359700|NCT01435564|BEHAVIORAL|pedometer only|Participants in this group will receive only a pedometer.
48359701|NCT04906733|PROCEDURE|Tumor biopsy|Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.
48359702|NCT04983004|BEHAVIORAL|tele-rehabilitation|According to the pre-arranged case service schedule, the researcher is asked to push the computer and cart to the case ward for installation, and use the communication software to interact with each other in real time. The intervention method directly plays the recorded video to demonstrate the action according to the action needs of the case. The therapist can observe the video demonstration and the actual action execution of the case at the same time from the screen.
48359703|NCT04983004|BEHAVIORAL|bedside rehabilitation|The bedside therapist and the case work together to set an activity schedule. The case is asked to establish and record daily routine activities, provide basic exercise and activity schedules to avoid degradation and reduce the lack of active participation in activities. The protection is to wear personal protective equipment, including protective clothing, gloves, masks, and face shields, and wash hands and disinfect before and after treatment.
48508506|NCT01284946|DRUG|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
48148268|NCT02978040|DRUG|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
48148269|NCT02978040|DRUG|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .
48508507|NCT03159338|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
48508508|NCT03159338|BIOLOGICAL|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
48148270|NCT02978040|DRUG|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
48508509|NCT06111261|DRUG|Albumin solution|200ml of 20% Human Serum Albumin
48148271|NCT05963802|OTHER|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
48148272|NCT06343636|DRUG|VG-3927|Dose Escalation
48148273|NCT06343636|DRUG|Placebo|Dose Escalation
48508510|NCT06111261|DRUG|Balanced crystalloid solution|Balanced crystalloid solution
48672294|NCT03698279|BIOLOGICAL|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
47990747|NCT05301296|DIAGNOSTIC_TEST|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
47990748|NCT04698733|DEVICE|BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device|"Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
48148274|NCT06343636|DRUG|VG-3927|One Dose Level
48148275|NCT03530735|OTHER|Finger-prick Autologous Blood (FAB)|"Patients will be instructed to use FAB therapy by:~1. Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~2. Use a diabetic lancet to prick their cleaned fingertip.~3. Squeeze 5 drops of blood form their finger into 10ml of saline.~4. Gargle the blood-saline mixture for 5 minutes.~5. Swallow the blood-saline mixture.~6. Repeat this 4 times per day."
48148276|NCT01600196|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
48148277|NCT05326685|OTHER|video with korotkoff sounds|The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
48508511|NCT04808180|OTHER|Biorepair Shock Treatment|Teeth from this group will undergo the application of Biorepair Toothpaste for the first 7 days of the month for 9 months (1 application per day that lasts 10 minutes).
48508512|NCT04808180|OTHER|No treatment|Teeth from this group will not be treated with the experimental toothpaste.
48508513|NCT04925193|DRUG|Selinexor|Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
48508514|NCT04925193|DRUG|Pomalidomide|Oral Table
48508515|NCT04925193|DRUG|Daratumumab|Injection
48508516|NCT04925193|DRUG|Carfilzomib|Injection
48508517|NCT04925193|DRUG|Dexamethasone|Oral tablet or injection
48508518|NCT06634355|DRUG|Sugammadex|In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
48508519|NCT04665466|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
48672295|NCT05068349|DRUG|Butylphthalide|Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
48672296|NCT01641107|DRUG|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
48672297|NCT01722929|DEVICE|Skin sensor|
48672298|NCT03363178|BIOLOGICAL|GC3107|BCG Vaccine, 0.1mL
48672299|NCT04389073|DRUG|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48672300|NCT04389073|BIOLOGICAL|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48672301|NCT04389073|BIOLOGICAL|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48672302|NCT04389073|DRUG|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48672303|NCT04389073|DRUG|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48359704|NCT06128642|DEVICE|Toe separator orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after the participants use the toe separation orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
48359705|NCT06128642|DEVICE|Dynamic orthosis|"The orthoses to be used during the study will be randomly distributed to the individuals participating in the study. Foot pressure analysis will be evaluated after participants use the dynamic orthosis for 8 hours a day, for a total of 1 month.~Plantar pressure analysis will be performed again without orthosis, with orthosis and 1 month after the use of orthosis. Additionally, patient orthosis satisfaction evaluation will be made at the end of the 1-month period during which the participants use the orthoses."
48359706|NCT03799523|OTHER|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
48359707|NCT03799523|OTHER|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
48359708|NCT04109066|BIOLOGICAL|nivolumab|Specified Dose on Specified days
48672304|NCT04389073|DRUG|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
48359709|NCT04109066|DRUG|paclitaxel (PTX)|Specified dose on Specified days
47914378|NCT04235296|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|Residual wounds from the same person were divided into control group and experimental group. The pleiotropic factor is used to control group. Then the foam wound dressing was selected to cover the residual wound, and the dressing was changed every 2 days.
47914379|NCT04416360|OTHER|Interview by psychologists|"Interviews for children / teenagers and parents :~* The questions encourage a narrative~* Repeated interviews: during confinement, at the end of confinement, and 3 months after the end of confinement~* Interviews carried out by videoconference, by trained psychologists not involved in the care process~Interview for referring caregivers: a single interview of approximately 45 minutes, 3 months post-confinement"
48359710|NCT04109066|OTHER|nivolumab placebo|Specified dose on Specified days
48359711|NCT04109066|DRUG|anthracycline|Specified dose on Specified days
48359712|NCT04109066|DRUG|cyclophosphamide|Specified dose on Specified days
48359713|NCT04109066|DRUG|Endocrine Therapy|Variable endocrine therapy of investigators choice
48359714|NCT04109066|PROCEDURE|Surgery|Surgery for breast cancer
48359715|NCT04016727|BIOLOGICAL|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
48359716|NCT00979004|DRUG|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
48359717|NCT01562327|DRUG|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
48148278|NCT03349476|DEVICE|MFAM|"Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy"
48148279|NCT03401099|PROCEDURE|Radiofrequency ablation of CTI|Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
48148280|NCT03401099|PROCEDURE|Cryoballoon PVI|Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
48148281|NCT00839085|DRUG|GSE|grape seed extract (100 mg/6h), PO
48148282|NCT00839085|DRUG|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
48148283|NCT01575704|OTHER|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
48148284|NCT01575704|OTHER|Mental Training|Memorial/ mental training and relaxation, 5 times per week
48148285|NCT06074354|BEHAVIORAL|Attention-control group|Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
48508520|NCT04772157|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.
48148286|NCT06074354|BEHAVIORAL|MY-RIDE group|MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
48148287|NCT04704856|BEHAVIORAL|Supervised exercise|Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
48359718|NCT02358863|DRUG|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
48359719|NCT02358863|DRUG|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
48359720|NCT02358863|DRUG|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
48359721|NCT02358863|DRUG|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
48508521|NCT03769961|OTHER|No intervention|No interventions - Observational study
48508522|NCT01208987|OTHER|Medication History was printed|
48359722|NCT02358863|DRUG|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
48359723|NCT02358863|DRUG|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
48359724|NCT02358863|DRUG|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
48359725|NCT02358863|DRUG|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
48359726|NCT02134912|DRUG|crizotinib|Given PO
48359727|NCT02134912|DRUG|pemetrexed disodium|Given IV
48359728|NCT02134912|OTHER|laboratory biomarker analysis|Correlative studies
48359729|NCT02134912|OTHER|pharmacological study|Correlative studies
48359730|NCT03010059|DRUG|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
48359731|NCT03010059|DRUG|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
48359732|NCT02576171|BEHAVIORAL|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
48508523|NCT04257045|OTHER|Interview|Participate in semi-structure, in-depth qualitative interviews
48508524|NCT04257045|OTHER|Questionnaire Administration|Complete questionnaires
48508525|NCT04257045|OTHER|Survey Administration|Complete survey
48672305|NCT04274595|DRUG|Generic antiretroviral|200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
48672306|NCT03212352|DRUG|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
48672307|NCT03212352|DRUG|Misoprostol|Regular treatment with Misoprostol 800 mcg.
48359733|NCT03268395|DIAGNOSTIC_TEST|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
48359734|NCT03161015|DRUG|GBT440|Oral
48359735|NCT03894501|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
48359736|NCT03894501|BEHAVIORAL|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
48508526|NCT04223557|DEVICE|focused power ultrasound treatment|Patients will be placed in the lateral decubitus position and receive treatment with sequential bilateral PRF ablation. Before the treatment, a professional sonographer will be responsible for the length, thickness, and width of PRF sac measurement and localisation, and utilise the ultrasonic diagnostic transducer to delineate the targeted region. The treatment will launch layer-by-layer. After confirming accurate localization of the treatment, layer-by-layer PRF ablation will be performed on the patients. The device generates and delivers a pattern of conic-shaped ultrasound energy to the PRF sac noninvasively. The treatment of FPU-mediated PRF ablation will be implemented once.
48508527|NCT04223557|DEVICE|Sham treatment|Participants will receive the same procedure as those in the FPU treatment including PRF ultrasonic measurement and localization and focused ultrasound treatment parameters setting, except that no energy will be delivered to the PRF.
48672308|NCT01226303|DRUG|ATRA|see the protocol
48672309|NCT01226303|DRUG|ATRA + IDA|see the protocol
48672310|NCT05746390|BEHAVIORAL|Home Alone|See Home Alone description.
48672311|NCT02805452|DRUG|Succinate of Solifenacin|
48672312|NCT02805452|DRUG|Placebo of Succinate of Solifenacin|
48672313|NCT06022094|OTHER|2 months of reduced carb menus|Participants will eat a reduced carb menu for 2 months
48672314|NCT05535114|OTHER|Yoga-resistance exercise|Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation \& meditation (10 minutes).
48672315|NCT00881894|DRUG|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
48672316|NCT04650295|OTHER|Household Remedy|If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.
48672317|NCT04650295|OTHER|Tap water|If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
48672318|NCT02434211|OTHER|Questionnaire and focus group|
48672319|NCT04317144|BEHAVIORAL|Web-based follow-up programme.|Participants who are randomized to the intervention-group will have access to web-based follow-up for one year. The programme includes short films of equipment used in intensive care e.g. ventilator, suction-device. Continous renal replacement therapy , central vein catheter among other things. About 15 short films with icu-staff talking and show how the equipment works and alarm sounds. The intervention also includes lectures about how the ICU works and what problems a critically ill patient can suffer from post-icu. There is a built-in conversation tool in the programme that can be used both by the participant and the staff who works with the follow-up programme. Questionnaires is sent out 2,6 and 12 month post-icu. The questions include PTSD, Depression, QoL and physical activity. At the end of the study, participants are sent a questionnaire asking for their experience using the web-based follow up programme.
48672320|NCT04317144|BEHAVIORAL|No follow-up|"Participants randomized to no follow-up receive e-questionnaires 2, 6 and 12 months post-ICU care. The questions are the same as in web-based follow-up intervention group and include PTSD, Depression, QoL and physical activity."
48672321|NCT04149496|COMBINATION_PRODUCT|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
48672322|NCT01152788|DRUG|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
48359737|NCT04050540|DRUG|Doxycycline|200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
48359738|NCT05286541|PROCEDURE|Lateralized buccal cortex with xenograft|the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
48359739|NCT05286541|PROCEDURE|Lateralized buccal cortex with autogenous particulate|lateralized buccal cortex with autogenous particulate
48672323|NCT01152788|DRUG|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
48672324|NCT02559973|DRUG|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
48672325|NCT02559973|DRUG|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
48672326|NCT00819429|DIETARY_SUPPLEMENT|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
48672327|NCT00819429|BEHAVIORAL|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
48672328|NCT00819429|OTHER|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
48672329|NCT04787003|DRUG|oncolytic virus (OVV-01) injection|intratumoral injection of OVV-01 with or without immune checkpoint inhibitors
48672330|NCT04061109|DRUG|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
48672331|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
48672332|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
48672333|NCT03768427|DRUG|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
48672334|NCT03768427|DRUG|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
48672335|NCT03768427|DRUG|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
48148288|NCT01820702|OTHER|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at \~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against \~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
48148289|NCT05037123|DRUG|Continuous ketamine infusion|Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
48148290|NCT05037123|DRUG|Ketamine + Saline|Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
48148291|NCT05037123|OTHER|Placebo|Placebo, Saline dose and infusion intraoperatively, then saline IV dose in post-anesthesia care unit plus 2 hours of saline administration after surgery
48148292|NCT06469931|OTHER|range of motion exercises|In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
48359740|NCT06371989|PROCEDURE|Image guided vacuum assisted biopsy|Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
48508528|NCT00970827|PROCEDURE|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
48508529|NCT02132858|OTHER|cytology specimen collection procedure|Correlative studies
48508530|NCT02132858|OTHER|laboratory biomarker analysis|Correlative studies
48508531|NCT04544410|DRUG|Tildacerfont/Placebo|Tablet, administered daily
48508532|NCT02851745|DRUG|Linagliptin|
48508533|NCT02851745|DRUG|Placebo|
48508534|NCT03399825|DEVICE|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
48508535|NCT06633172|PROCEDURE|laparoscopic ventral mesh rectopexy|performing ventral mesh rectopexy via laparoscopic surgery to correct the anterior rectocele.
48508536|NCT06633172|PROCEDURE|Trans vaginal repair|performing repair of the rectocele through the recto vaginal septum repair.
48672336|NCT03280368|OTHER|Bloodtest|
48672337|NCT03280368|OTHER|Questionnaires|
48672338|NCT01912573|DRUG|Intranasal (IN) naloxone|
48672339|NCT01912573|DRUG|Intravenous (IV) naloxone|
48508537|NCT03111771|PROCEDURE|carcinological surgery|carcinological surgery for Group K +
48508538|NCT03111771|PROCEDURE|cervical surgery|cervical surgery for Group K-
48508539|NCT01129843|DRUG|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
48508540|NCT02182635|DRUG|Ba253BINEB|
48508541|NCT02257697|DRUG|Mizoribine (MZR)|
48508542|NCT02257697|DRUG|Cyclophosphamide (CTX)|
48508543|NCT06634056|DRUG|Pentoxifylline|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
48508544|NCT06634056|OTHER|Placebo|One placebo orally three times a day and another placebo orally two times a day on day one of radiotherapy and continue treatment for 6 months.
48508545|NCT06634056|OTHER|α-Tocopherol|Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
48508546|NCT05706883|PROCEDURE|Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes|Patients with evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes suspected of being metastasis from lung cancer will be submitted to the biopsy from this location.
48672340|NCT01912573|DRUG|Intramuscular (IM) naloxone|
48672341|NCT01912573|DRUG|Intraosseus (IO) naloxone|
48672342|NCT05157087|DRUG|Omalizumab|"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."
48672343|NCT02015247|PROCEDURE|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
48672344|NCT04617080|PROCEDURE|SUPRACOR Regular|SUPRACOR algorithm with regular (100%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
48672345|NCT04617080|PROCEDURE|SUPRACOR Strong|SUPRACOR algorithm with strong (130%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
48672346|NCT03764111|DEVICE|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
48148293|NCT06469931|DEVICE|Extracorporeal shock wave therapy|Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercises for wrist and hand and splinting.
48359741|NCT04433936|DIAGNOSTIC_TEST|Pentacam tomography|The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
48359742|NCT02992054|OTHER|stimulating activities|
48672347|NCT03764111|DEVICE|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
48672348|NCT00689806|DRUG|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
48672349|NCT00689806|DRUG|Placebo|Placebo by mouth once daily for weeks 1-4.
48148294|NCT06469931|OTHER|ozone therapy|ozone therapy
48148295|NCT06500403|DIAGNOSTIC_TEST|liver and stiffness measurement|liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
48148296|NCT06356883|DRUG|IA Carboplatin + IA Caelyx|Intraarterial infusion of carboplatin combined with liposomal doxorubicin
48359743|NCT04854603|OTHER|Food|Dairy products with regular and reduced sugar content and water control.
48359744|NCT04013633|OTHER|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
48359745|NCT04013633|OTHER|Face-to-face training|Short face-to-face CPR training
48672350|NCT02034643|PROCEDURE|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
48672351|NCT06487299|DRUG|Ferrous Lactate|The injection solution was 3 ferrous lactate (10ml:0.1g iron) mixed with 20ml saline.
48359746|NCT02411994|DRUG|Pyronaridine-artesunate|
48359747|NCT02411994|DRUG|Artemether-lumefantrine combination|
48359748|NCT00135408|DRUG|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
48672352|NCT06487299|DRUG|Iron sucrose|The injection was 3 shots of ferrous lactate (5ml:100mg iron) mixed with 35ml saline.
48672353|NCT06487299|DRUG|0.9% NaCl solution|The same volume and color as Iron sucrose.
48359749|NCT00135408|DRUG|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
48359750|NCT03844581|DEVICE|interferential current|Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
48359751|NCT03844581|DRUG|Propiverine Hydrochloride|propiverine hydrochloride 20 mg/once per day in the morning
48359752|NCT05314530|BEHAVIORAL|ReTA-model|Validating the rehabilitation model ReTA
48359753|NCT04997564|DRUG|Tenofovir Alafenamide 25 MG|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .
48359754|NCT04997564|DRUG|Sofosbuvir / Velpatasvir|All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
47914380|NCT04593199|BEHAVIORAL|Gamified Smartphone App|The primary objective was to determine the acceptability and satisfaction of the Draco app among children. Secondary objective was to evaluate if the Draco app could improve physical activity levels (steps, and moderate-to-vigorous physical activity) and intrinsic motivation for physical activity in children. The gamified smartphone app, Draco, is a virtual pet simulator where you care for a pet by exercising, walking, and answering healthy lifestyle questions.
47914381|NCT04593199|BEHAVIORAL|Physical activity tracking app|Participants were asked to use the Fitbit app to track and sync their daily physical activity.
47914382|NCT04870580|DIAGNOSTIC_TEST|Fluorodopa PET tracer|PET/CT scan using fluorodopa tracer
47990749|NCT05700981|DIAGNOSTIC_TEST|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
48148297|NCT06356883|DRUG|IA Carboplatin + IA Etoposide Phosphate|Intraarterial infusion of carboplatin combined with etoposide phosphate
47990750|NCT05351242|OTHER|Thermotherapy/sauna bath|Thermotherapy/sauna bath
47990751|NCT03755986|DEVICE|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
47990752|NCT01170494|DRUG|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
47990753|NCT01170494|DRUG|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
47990754|NCT01170494|DRUG|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
48359755|NCT01476033|DIETARY_SUPPLEMENT|nutraceutical group|6 capsules of supplement or placebo for 8wk
48359756|NCT03175822|BEHAVIORAL|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements \[e.g., colour and line\] and principles \[e.g., proportion and balance\] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
48359757|NCT05750615|OTHER|Uncertain what intervention will be co-created|Uncertain what intervention will be co-created
48672354|NCT04343573|RADIATION|Involved-field Photon Radiation Therapy|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
48672355|NCT04343573|RADIATION|Proton Craniospinal Irradiation (CSI)|Proton CSI (30Gy \[RBE\] in 10 fractions)
48148298|NCT04459156|DIETARY_SUPPLEMENT|Fiber Inulin|Commercially available inulin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
48359758|NCT00496145|BEHAVIORAL|Spanish Diabetes Self-Management Program|small-group self management education program
48359759|NCT02196389|DEVICE|Nasal dilator Nasanita|Nasal Dilator
48359760|NCT02196389|DEVICE|Nasal dilator Nozovent|
48359761|NCT02196389|DEVICE|Nasal dilator Breath Right|
48359762|NCT02196389|DEVICE|Nasal dilator Airmax|
48359763|NCT05858567|DRUG|Envafolimab|"Drug: Envafolimab This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).~Other Names:~KN053 Drug: Oxaliplatin 130mg/m2，ivgtt，d1~Drug: Capecitabine 1000mg/m2，po，bid，d1-14~Radiation: Short-course Radiation Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.~Procedure/Surgery: Biopsy, local excision or TME surgery (total mesorectal excision) Biopsy can choose endoscopic or needle biopsy, colcal excision refers to excison of the local lession after total neoadjuvant therapy The total mesorectal excision can choose open, laparoscopic or robotic according to the specific condition of the patient."
48672356|NCT04343573|OTHER|Neurocognitive Assessment|All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
48672357|NCT04343573|OTHER|MDASI-BT and MDASI-SP|Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
47990755|NCT01170494|DRUG|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
47990756|NCT01170494|DRUG|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
47990757|NCT01170494|DRUG|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
48359764|NCT04885660|DRUG|compound lisinopril tablet|The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
48359765|NCT04885660|DRUG|compound lisinopril tablet(Lisonorm®)|The subjects randomly received single oral administration of compound lisinopril tablet(Lisonorm®)
48359766|NCT03433391|DEVICE|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
48359767|NCT03433391|OTHER|Surgery Only|Single level partial discectomy as per standard of care procedures.
48359768|NCT00490477|DEVICE|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
48359769|NCT05365984|DIAGNOSTIC_TEST|end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）|The measurement of end tidal carbon monoxide corrected for ambient carbon monoxide （ETCOc）is conducted in the process of risk evaluation.
47990758|NCT01170494|DRUG|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
47990759|NCT01170494|DRUG|placebo orally everyday|placebo orally everyday
47990760|NCT04341142|DIAGNOSTIC_TEST|Serological tests will be applied on patients blood sampling|Application of tests on patients' serum
47990761|NCT00524550|DIETARY_SUPPLEMENT|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
47990762|NCT04962061|OTHER|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
48359770|NCT05365984|OTHER|Internet Plus technology|The Internet Plus technology is applied in the process of follow-up management.
48359771|NCT02055872|DRUG|Intravenous albumin|
48359772|NCT02055872|DRUG|Normal saline|
48672358|NCT05261659|BEHAVIORAL|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
48672359|NCT05261659|BEHAVIORAL|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
48672360|NCT04960124|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
48508547|NCT05706883|PROCEDURE|Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes|Patients without evidence of enlarged and/or PET positive cervical and/or supraclavicular lymph nodes will be submitted to the biopsy considered less invasive and effective based on imaging data and clinical health status.
48508548|NCT04409314|DRUG|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
48508549|NCT04409314|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48508550|NCT04205305|DRUG|conventional blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
48508551|NCT04205305|DRUG|intensive blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
47990763|NCT04962061|OTHER|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
47990764|NCT04962061|OTHER|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
47990765|NCT04317911|OTHER|Catheter Ablation|Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.
47990766|NCT05264545|DEVICE|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
48508552|NCT03590054|DRUG|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
48508553|NCT03590054|BIOLOGICAL|Pembrolizumab|Given IV on day 1 of every 21 day cycle
48672361|NCT05236322|DEVICE|soft tissue laser|Surgical laser used in excision purpose
48672362|NCT04653974|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
48672363|NCT05753514|OTHER|ESWT|ESWT
48672364|NCT04926116|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
48672365|NCT04926116|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
48672366|NCT02093260|BIOLOGICAL|Vaccine|"Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly."
48672367|NCT02603679|DRUG|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
47990767|NCT04336982|DRUG|CC-90009|Injection
47990768|NCT04336982|DRUG|Venetoclax|Tablet
47990769|NCT04336982|DRUG|Azacitidine|Injection
47990770|NCT04336982|DRUG|Gilteritinib|Tablet
48508554|NCT00311324|BEHAVIORAL|Special Intervention|
48508555|NCT00311324|BEHAVIORAL|Delayed Intervention|
48672368|NCT02603679|DRUG|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
48672369|NCT02603679|DRUG|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
48672370|NCT02603679|DRUG|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
48672371|NCT04548206|OTHER|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
48359773|NCT05103540|BEHAVIORAL|Comprehensive SEM-Based Program|The SEM theorizes that there are multiple inter-related levels of influences on human behavior, and a successful preventive program should address factors at each stratum. My intervention addresses three levels; individual, interpersonal, and social. Firstly, the research will collaborate with relevant stakeholders to design and obtain a commitment from the schools to a suicidal behavior prevention policy and protocol document. Secondly, the intervention will train staff and students on best practices to improve students' connectedness thereby, creating a positive school environment. Thirdly, the study will identify and train gatekeepers on the proper response to suicidal thoughts and other suicidal behaviors; and serve as the link between the students and a school-linked mental health specialist. We will train the gatekeepers to use school-based screening tools. Lastly, this research will educate all students on suicidal behaviors.
48359774|NCT05198284|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
48359775|NCT05472506|DRUG|IK-175 + nivolumab|IK-175 + nivolumab
48359776|NCT03080506|DEVICE|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
48359777|NCT01787435|DRUG|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
48359778|NCT05860595|GENETIC|KL003 cell injection Drug Product|Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.
48672372|NCT04548206|OTHER|control|The program consisted of progressive relaxation exercises at home.
48672373|NCT03180229|DRUG|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
48672374|NCT03674983|BEHAVIORAL|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
48359779|NCT01873599|BEHAVIORAL|Positive Affect Journaling|
48359780|NCT02827773|OTHER|Talking Pill Bottle|Made by Talking Rx
47990771|NCT01485640|DRUG|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
48359781|NCT03276494|DEVICE|Intraosseous|Intraosseous administration of hypertonic saline
48359782|NCT03276494|DRUG|Hypertonic saline|Intraosseous administration of hypertonic saline
48359783|NCT04277429|DIAGNOSTIC_TEST|Cardiac function assessment|Echocardiography, cardiac enzymes analysis
48359784|NCT06331806|DIAGNOSTIC_TEST|Evaluation of myocardial fibrosis|echocardiogram with left ventricular ejection fraction (LVEF) evaluation (biplane method) and CMR with contrast media agent
48359785|NCT04840914|DRUG|LY3461767|Administered SC.
48359786|NCT04840914|DRUG|Placebo|Administered SC.
48672375|NCT04937725|DIAGNOSTIC_TEST|eye tracking|Eye tracker will be used to evaluate study parameters
48672376|NCT05564637|DRUG|Treprostinil|30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprostinil therapy for 3-months with gradual up titration to target dose as per standard clinical practice.
47990772|NCT02335164|BIOLOGICAL|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
47990773|NCT02335164|BIOLOGICAL|Advax1|Delta inulin adjuvant formulation 1
48359787|NCT00434876|DRUG|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
48359788|NCT00434876|DRUG|Placebo.|Inactive or inert pill which will be used as a comparator.
47990774|NCT02335164|BIOLOGICAL|Advax2|Delta inulin adjuvant formulation 2
48359789|NCT06025656|DIAGNOSTIC_TEST|Leg Lateral Reach Test|"To conduct the leg reach test, participants began by positioning themselves with their arms hanging at their sides. They were then guided to raise the leg under assessment and extend it across the opposite leg to make contact with a wooden bar, employing trunk rotation in the process. During each trial, participants were consistently motivated to ensure that both shoulders remained in contact with the floor and to stretch their tested leg as far as they could along the length of the wooden bar. If a participant was unable to sustain contact between their foot and the wooden bar for a duration of 5 seconds at the point of maximal reach, or if both shoulders lifted off the floor, that specific trial was considered invalid and not included in the analysis.~Each participant completed three repetitions of this test for both the right and left sides, and the average of their reach distances was subsequently calculated for assessment."
48359790|NCT00143728|DRUG|Lamivudine|See Detailed Description.
48359791|NCT00171964|DRUG|Zoledronic acid in combination with therapy|
48508556|NCT04366687|BEHAVIORAL|Smart Parents - Safe and Healthy Kids|Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.
48672377|NCT05564637|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC) while exercising|A procedure to measure how well or poorly your heart is pumping and to measure the pressures in the heart and lungs. A catheter will be inserted into a vein and artery in order to take the measurements and this will be conducted while exercising on a supine cycle ergometer. Various measurements will be taken during periods of rest and exercise.
48672378|NCT05564637|DIAGNOSTIC_TEST|Optional Muscle Biopsy|A sample of muscle tissue will be collected and analyzed for the ability of the cells to utilize oxygen.
48508557|NCT04366687|BEHAVIORAL|Parents as Teachers|Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
48672379|NCT04254146|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
47990775|NCT04119856|OTHER|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~* The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~* The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~* The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~* The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~* The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
47990776|NCT02258230|DEVICE|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
47990777|NCT02258230|DEVICE|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
47990778|NCT05774158|OTHER|Physiotherapy assessment|Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
47990779|NCT02542631|DEVICE|Bolus Insulin Patch (Calibra Finesse)|
47990780|NCT02542631|DEVICE|Insulin Pen (Novo-Nordisk FlexPen®)|
47990781|NCT05052099|DRUG|mFOLFOX6, Atezolizumab and Bevacizumab|"All study medication is administered by intravenous (IV) infusion on Day 1 of each 14-day cycle:~• mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form \[levo leucovorin\]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2~combined with~* Atezolizumab 840 mg and~* Bevacizumab 10 mg/kg"
47990782|NCT02084147|DEVICE|positron emission tomography|Undergo PET
47990783|NCT02084147|DEVICE|computed tomography|Undergo CT
48672380|NCT00392093|DRUG|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
48672381|NCT03653182|DIAGNOSTIC_TEST|Pulse, tongue image, and voice sound|They are four diagnosis methods of TCM
48672382|NCT03929003|BEHAVIORAL|Inspired|The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
47990784|NCT02084147|DEVICE|magnetic resonance imaging|Undergo MRI
47990785|NCT03011307|DRUG|Oxytocin|spinal injection of oxytocin
47990786|NCT03011307|DRUG|Placebo|spinal injection of placebo
47990787|NCT00822068|DEVICE|anodal tDCS|anodal transcranial direct current stimulation
47990788|NCT00822068|DEVICE|cathodal tDCS|cathodal transcranial direct current stimulation
48359792|NCT00000980|DRUG|Spiramycin|
48672383|NCT01466465|DRUG|Cholecalciferol|given orally, once daily, before grass pollen season
48672384|NCT01466465|OTHER|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
48672385|NCT06375083|BEHAVIORAL|Cognitive Behavioral Therapy|The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook. The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions.
48672386|NCT02869724|OTHER|Weekly divided delivery|
48672387|NCT02869724|OTHER|Monthly divided delivery|
48672388|NCT04500457|BEHAVIORAL|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
48672389|NCT03109405|DEVICE|Stimulation-assisted venous access|Stimulation-assisted venous access
48672390|NCT03109405|OTHER|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
48672391|NCT03390725|BEHAVIORAL|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
48672392|NCT03995160|PROCEDURE|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
48672393|NCT03995160|PROCEDURE|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
48672394|NCT02886130|DIETARY_SUPPLEMENT|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
48508558|NCT03136965|BIOLOGICAL|PRP|Injection of autologous platelet rich plasma (PRP)
48672395|NCT02886130|DIETARY_SUPPLEMENT|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
48508559|NCT03136965|PROCEDURE|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
48672396|NCT01760070|DEVICE|Hybrid knife|Use Hybrid knife in ESD procedure
48672397|NCT01760070|DEVICE|IT knife|Use IT knife in ESD procedure.
48672398|NCT03420144|DRUG|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
48148299|NCT04459156|DIETARY_SUPPLEMENT|Placebo Maltodextrin|Commercially available maltodextrin is provided as powder. The following doses will be administered twice daily (with breakfast and dinner): Day 1-2: 5-g; Day 3: 7.5-g; Day 4: 10-g; Day 5: 12.5-g; Day 6-7: 15-g. All supplements are commercially available.
48148300|NCT06432036|PROCEDURE|Angiogram|Undergo angiogram
48672399|NCT03420144|DRUG|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
48672400|NCT00328029|DRUG|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
48672401|NCT00328029|PROCEDURE|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
48148301|NCT06432036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48148302|NCT06432036|PROCEDURE|Computed Tomography|Undergo CT scan
48148303|NCT06432036|RADIATION|Radioembolization|Undergo radioembolization
48148304|NCT06432036|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
48508560|NCT03136965|PROCEDURE|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
48672402|NCT00328029|PROCEDURE|pharmacokinetics, done during the treatment|"12 blood collections :~* after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~* 3 hours after 2nd taken of Busulfan~* 3 hours after 3rd taken of Busulfan~* 3 hours after 4th taken of Busulfan~* 3 hours after 5th taken of Busulfan~* 3 hours after 6th taken of Busulfan."
48672403|NCT01400009|DRUG|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
48672404|NCT01400009|DRUG|Placebo|Standard Placebo made of Lactose 100 mg
48672405|NCT02239926|DRUG|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
48672406|NCT02239926|DRUG|Placebo|
48672407|NCT03374020|DEVICE|Notal OCT|Imaging using Notal OCT
48672408|NCT03048435|OTHER|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
48148305|NCT06432036|OTHER|Survey Administration|Ancillary study
48148306|NCT06432036|RADIATION|Yttrium Y 90 Glass Microspheres|Given intra-arterially
48148307|NCT02520336|BEHAVIORAL|Reminder|
47990789|NCT00822068|DEVICE|sham stimulation|sham stimulation
47990790|NCT03012347|DRUG|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
47990791|NCT03012347|DRUG|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
48508561|NCT06448806|OTHER|mobile health lifestyle intervention|You will be asked to record all dietary and physical activity log for 12 months on an application. Mobile sms reminders will be sent to you on regular basis. At day 0, at 6th and 12 months you will be asked to provide 3 ml of blood for the methylation and advance glycation level testing and your weight and body fat percentage will be measured. During this period you will have to follow the lifestyle and diet chart provided to you by the researchers.
48508562|NCT04163510|BEHAVIORAL|Behavioral: Parent/Child Reading Program|A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
48508563|NCT03831165|COMBINATION_PRODUCT|Melatonin 3 mg|melatonin and placebo
48508564|NCT03831165|DRUG|Acyclovir|Only acyclovir 200 mg twice a day
48508565|NCT00274118|DRUG|telmisartan|
48508566|NCT00274118|DRUG|enalapril|
48508567|NCT04836897|DEVICE|PrizValve® valve and transapical delivery system|Transcatheter aortic valve replacement system
48508568|NCT00576316|DRUG|Symbicort Turbuhaler 160/4.5|
48508569|NCT06626295|OTHER|exercise-snack group|Adolescents in the exercise-snacks group will perform 4 \&amp;amp;amp;#34;exercise-snacks\&amp;amp;amp;#34; sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity.
48508570|NCT02647385|DRUG|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
48508571|NCT00022334|BIOLOGICAL|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
48508572|NCT00338455|DRUG|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
48508573|NCT00338455|DRUG|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
48508574|NCT04462887|BEHAVIORAL|Nursing intervention program|The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
48508575|NCT01261091|PROCEDURE|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
47990792|NCT01867827|OTHER|Neurofeedback and Physical Exercise|
47990793|NCT01867827|OTHER|Physical Exercise|
48672409|NCT03048435|OTHER|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
48148308|NCT04710576|DRUG|Axatilimab|Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
48508576|NCT01261091|PROCEDURE|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
48508577|NCT03887494|DEVICE|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
48148309|NCT05581394|DEVICE|BabySat V3|Evaluation of Accuracy of BabySat V3
48148310|NCT01362309|DRUG|d-cycloserine.|50 mg administered on two occasions.
48508578|NCT04697095|OTHER|Blood samples|: The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
48359793|NCT03678766|BEHAVIORAL|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
48508579|NCT02916667|OTHER|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
48148311|NCT06012799|DIAGNOSTIC_TEST|continuous glucose monitoring|FreeStyle Libre Flash Glucose Monitoring System
48148312|NCT00483457|DRUG|enzyme inhibitor therapy|enzyme inhibitor therapy
48148313|NCT00483457|GENETIC|protein expression analysis|protein expression analysis
48508580|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
47990794|NCT01978587|DRUG|JTZ-951|
48148314|NCT00483457|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
48148315|NCT00483457|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
48148316|NCT00483457|PROCEDURE|biopsy|biopsy
48359794|NCT03678766|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
48508581|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
48508582|NCT02027428|DRUG|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
48508583|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
48508584|NCT02027428|DRUG|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
48508585|NCT02027428|DRUG|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
48672410|NCT03730584|DRUG|Ropivacaine|"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."
48672411|NCT03730584|BIOLOGICAL|Blood test|Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
48672412|NCT00371371|PROCEDURE|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
48672413|NCT00371371|PROCEDURE|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
48148317|NCT01381341|DRUG|linifanib|QD on Day 1 of Periods 1 and 2
48672414|NCT00371371|PROCEDURE|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
48672415|NCT00564109|PROCEDURE|retrospective Observation|retrospective Observation
48672416|NCT04818905|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
48672417|NCT04818905|OTHER|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
48672418|NCT02949011|DRUG|Baloxavir Marboxil|Tablets taken orally
48148318|NCT03361202|OTHER|blood sampling|"* atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~* control group:before coronary angiography and at hospital discharge."
48148319|NCT02529605|DIETARY_SUPPLEMENT|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
48148320|NCT02529605|DIETARY_SUPPLEMENT|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
48148321|NCT03941977|DEVICE|Percutaneous introduction of cannula|An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
48148322|NCT03941977|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
48672419|NCT02949011|DRUG|Placebo to Baloxavir Marboxil|Matching tablets taken orally
48148323|NCT03941977|BIOLOGICAL|Bone Grafting|A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
48672420|NCT02949011|DRUG|Oseltamivir|Capsules taken orally
48672421|NCT02949011|DRUG|Placebo to Oseltamivir|Matching placebo capsules taken orally
47990795|NCT00004984|DRUG|Parenteral Insulin|Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
48672422|NCT01263327|BIOLOGICAL|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
48672423|NCT02784392|DRUG|Ulimorelin|Active
47990796|NCT00004984|OTHER|Close Observation|Study visits every 6 months including an oral glucose tolerance test
47990797|NCT00004984|DRUG|Oral Insulin|Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
48148324|NCT05520411|DIETARY_SUPPLEMENT|HUM Flatter Me|Proprietary Enzyme Blend: Protease 3.0 Protease 4.5 Protease 6.0 Neutral Bacterial Protease Peptidase Bromelain Papain Lipase Amylase Glucoamylase Alpha-galactosidase Invertase Diastase Hemicellulase + Cellulase Beta-Glucanase Phytase Lactase Ginger Root Fennel Seed Peppermint Leaf
48672424|NCT02784392|DRUG|Metoclopramide|Comparator
48672425|NCT03888014|DEVICE|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
48672426|NCT03888014|DRUG|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
48672427|NCT02318017|DRUG|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
48672428|NCT02318017|DRUG|Placebo|
48508586|NCT02027428|OTHER|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
48672429|NCT03830580|OTHER|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
48672430|NCT04324892|DRUG|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
48148325|NCT05871502|DEVICE|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days). This device will be selected from those currently available on the market, with CE marking, and with previous studies documenting its safety and feasibility for radiological procedures.
48148326|NCT01566383|PROCEDURE|24-hr pH monitoring|"Visit 1~The following will be done:~* A medical history including review of your current drugs;~* Collection of demographic information;~* A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~* 24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~* The catheter will be removed from your nose; and~* You will return the recording device"
48148327|NCT02492126|OTHER|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
48148328|NCT04006015|OTHER|No intervention being delivered.|No interventions are being delivered.
48148329|NCT00407732|BEHAVIORAL|psychosocial intervention|motivational enhancing case management intervention
48148330|NCT01315418|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
48148331|NCT01315418|OTHER|2-Non fermented dairy product (control)|
48148332|NCT04703114|DIAGNOSTIC_TEST|Blood count|Blood count at each visit
48148333|NCT04703114|DIAGNOSTIC_TEST|Blood collection|Blood collection to understanding of the immunological profile at each visit
48148334|NCT04703114|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR at day 8 and day 15
48148335|NCT04703114|DIAGNOSTIC_TEST|Saliva samples|Research of SARS-CoV-2 infection in saliva samples at each visit (excepted inclusion)
48148336|NCT04703114|DIAGNOSTIC_TEST|Faeces samples|Research of SARS-CoV-2 infection in faeces samples at day 3, day 15 and day 90
48148337|NCT04703114|GENETIC|Genetic blood collection|Collection to further research at each visit
48148338|NCT04703114|OTHER|Data collection|Demographics, symptoms, biological constants
48148339|NCT02953756|RADIATION|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
48148340|NCT01843920|DRUG|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
48148341|NCT01843920|DRUG|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
48148342|NCT01795989|DEVICE|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
48148343|NCT03799588|DEVICE|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
48148344|NCT03447912|BEHAVIORAL|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
48148345|NCT02370953|DEVICE|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
48508587|NCT04385303|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
48508588|NCT04385303|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
48508589|NCT00340678|DRUG|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
48508590|NCT00340678|DRUG|Placebo|Treatment with placebo corresponding to each dose of losartan.
48508591|NCT04511598|DEVICE|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
47990798|NCT00004984|DRUG|Placebo|Placebo for oral insulin
47990799|NCT03134027|PROCEDURE|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
47990800|NCT03134027|PROCEDURE|Tumor biopsy|Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
48672431|NCT05508828|PROCEDURE|Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy|All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
48672432|NCT00112892|DIETARY_SUPPLEMENT|selenium|
48672433|NCT00112892|DRUG|irinotecan hydrochloride|
48672434|NCT06161480|DEVICE|Weighted Blanket|Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
48672435|NCT00149786|BEHAVIORAL|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
48148346|NCT02370953|PROCEDURE|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
48148347|NCT04607356|DEVICE|Blood Flow Restriction (BFR)|The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
48508592|NCT04511598|DEVICE|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
48508593|NCT01059344|DRUG|Mesalamin|4.8g/day, 800 mg tablets
48672436|NCT00149786|BEHAVIORAL|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
48672437|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
48508594|NCT06634277|BEHAVIORAL|NavSTAR (Philly adaptation)|Patient Navigation
48672438|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
48672439|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
48672440|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
48672441|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
48672442|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
48672443|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
48672444|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
48672445|NCT01309789|DRUG|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
48672446|NCT03493958|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
48672447|NCT00499200|DRUG|SRA-444|
48672448|NCT01977378|DRUG|Sustained-Release Desvenlafaxine Hydrochloride|
48672449|NCT01977378|DRUG|Sustained-Release Venlafaxine Hydrochloride|
47990801|NCT05076747|BEHAVIORAL|Cardiovascular training|8 weeks of cardiovascular training
48672450|NCT05771129|DEVICE|Pulse electric field ablation system developed by Zhouling (Shanghai) Medical Appliance Co., Ltd.|Pulsed electric field ablation instrument is a therapeutic instrument based on the irreversible electroporation (IRE) mechanism. The high frequency short duration energy is delivered via a disposable pulse ablation catheter through the bronchoscope and act on the bronchial mucosa, through which goblet cell hyperplasia and airway mucus secretion will be alleviated. The entire treatment consists of two procedure sessions that will be performed one month apart. The first treatment procedure consists of a baseline biopsy of the airway mucosa followed by the treatment of the right lung. The second procedure consists of a biopsy of the treated airway, followed by the left-side treatment. A third bronchoscopy will be performed three months following the first treatment and mucosa-biopsy will be conducted to evaluate the histopathological change in mucus producing cells after treatment. Subjects will also be required to fill questionnaire and complete several examinations during follow-up.
48508595|NCT05263830|OTHER|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
48672451|NCT04849637|DRUG|Virgin Coconut Oil|Oral supplementation of virgin coconut oil to COVID-19 patients
48672452|NCT00705705|BEHAVIORAL|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
48672453|NCT00705705|BEHAVIORAL|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
48672454|NCT04618029|OTHER|Home Modification|"Home Modification Intervention~Floor~Provide recommendations to:~* Fix the back of the rugs and mats with adhesive/heavy duty tape~* Buy non-slip mats~* Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~* Buy a torch light~* To replace worn light bulbs~* Buy a light switch~Bathroom~Provide recommendations to:~* Buy a non-slip mat~* Install a grab rail~* Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast"
48672455|NCT04618029|OTHER|Education|"Techniques Description Energy Conservation~* Take your time~* Go to the toilet more often, so you don't have to rush~* Use a nearby toilet: commode, different bathroom~* Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~* Adjust equipment before changing position~* Avoid transfers when tired~* Ask for help if you feel sick or especially tired~* Allow time for eyes to adjust to change in lighting~Task Simplification~* Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~* Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~* Proper positioning while doing tasks~* Safe mobility around the home"
48672456|NCT02866812|OTHER|questionnaires assessing the state of fatigue, depression and anxiety|
48672457|NCT04461496|PROCEDURE|Hybrid revascularization|The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area
48672458|NCT04461496|PROCEDURE|Full metall Jacket|The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.
48672459|NCT04851964|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
48672460|NCT04851964|OTHER|Placebo|Placebo subcutaneous injection
48672461|NCT01406600|DRUG|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
48672462|NCT02030821|DRUG|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
48672463|NCT02030821|DRUG|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
48672464|NCT00203385|DRUG|Divalproex|Depakote up to 2000mg/d
48672465|NCT00293163|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
48672466|NCT02984670|BEHAVIORAL|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
48672467|NCT02984670|BEHAVIORAL|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
48672468|NCT02984670|BEHAVIORAL|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
48672469|NCT05480228|DRUG|NRD135SE.1|The double-blind treatment phase is up to 13 weeks.
48672470|NCT05480228|OTHER|Placebo|A matching placebo will be taken for up to 13 weeks.
48672471|NCT02903290|OTHER|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|
48672472|NCT02903290|OTHER|walking track GAITRite,manual dynamometer, and treadmill|
48672473|NCT05626933|PROCEDURE|Buccinator myomucosal flap with Furlow palatoplasty|Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes
48508596|NCT06629844|OTHER|The VR dementia education group|The intervention group will receive the VR dementia education program, which will be conducted once for each participant, and each session will accommodate a maximum of 20 participants. The VR dementia education program will follow the flow below, integrating video dramatizations, VR experiences, lectures, and discussions. The program is designed to simulate real-life dementia care situations, encourage reflection, and enhance nursing students' understanding of dementia management. The following are the steps for intervention: Introduction (3 minutes), Pre-Program Questionnaire (10 minutes), Lecture Introduction (2 minutes), Bad Drama (Unfriendly Communication) (10 minutes), Bad VR (10 minutes), Discussion (5 minutes), Lecture 1: What is Dementia? (10 minutes), Good VR (10 minutes), Good Drama (10 minutes), Lecture 2: What Can We Do to Support PLWD? (5 minutes), N-impro (10 minutes), Post-Program Questionnaire (10 minutes), Conclusion (5 minutes).
48672474|NCT05232656|BEHAVIORAL|Pre-Discharge Checklist and Patient Safety Dashboard|Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
48672475|NCT03840213|BEHAVIORAL|Filling a questionnaire and interviewDescription|"The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey."
48148348|NCT04607356|OTHER|Evidence-informed care|Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
48672476|NCT00372957|DRUG|GW823093 15mg|White opaque capsule containing 15mg of GW823093 as free base
48672477|NCT00372957|DRUG|GW823093 placebo capsule|Matching placebo of GW823093 capsule or 15mg capsule
48672478|NCT00372957|DRUG|GW823093 30mg|White opaque capsule containing 15mg of GW823093 as free base
48672479|NCT03974269|PROCEDURE|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
48672480|NCT05973162|OTHER|Virtual Realty Training|"They would be receiving treatment as follow:~Virtual Reality is a technology that aims to completely immerse the user inside the computer generated world, giving the impression to the user that they have stepped inside the synthetic world. RA mobile phone , head mounted display (HMD) will be used and videos of patient's interest will be played on phone which will create a 3D world around the patient.~And while watching conventional physical therapy will be performed side by side.~Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
48672481|NCT05973162|OTHER|Transverse friction massage (TFM)|"They would be receiving treatment as follow:~Transverse friction massage (Soft tissue mobilization technique) on the surrounding burn region for 5-10min in intervals. Frequency: 3 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 10 mins Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
47990802|NCT05076747|BEHAVIORAL|Standard Therapy|8 weeks of Standard Therapy
48148349|NCT05917756|OTHER|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
48148350|NCT05917756|OTHER|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
48148351|NCT04613947|BEHAVIORAL|Informed consent|The style of informing patients about the procedure they will undergo
48508597|NCT06629844|OTHER|The control group|The intervention begins with an introduction to the VR dementia program, outlining its objectives and setting participant expectations. A pre-program questionnaire follows to assess baseline knowledge, attitudes, and intention to assist people with dementia. A brief lecture introduces a dramatization showing ineffective communication with a PLWD, followed by a VR scenario highlighting poor care practices. After discussing these observations, participants attend a lecture explaining dementia's symptoms and progression, with culturally adapted video content for Indonesian audiences. Next, a positive VR scenario demonstrates best practices in dementia care, followed by a video on supportive communication. A second lecture offers practical strategies for caregiving and communication, complemented by an N-impro session to deepen understanding. The session concludes with a post-program questionnaire and final reflection to encourage real-world application of the learned skills.
48508598|NCT02826538|DEVICE|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
48672482|NCT05419752|DRUG|bioceramic sealer|bioceramic based obturating sealer
48672483|NCT05419752|DRUG|MTA|MTA based obturating sealer
48672484|NCT05419752|DRUG|resin sealer|resin based obturating sealer
48508599|NCT02826538|DEVICE|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
48672485|NCT01684670|BEHAVIORAL|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
48672486|NCT01426061|OTHER|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
48672487|NCT01426061|OTHER|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
48148352|NCT04613947|PROCEDURE|Third molar surgery|Surgical extraction of the third molar tooth
48148353|NCT02091102|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
48148354|NCT05748808|BEHAVIORAL|Use of biofeedback and virtual reality in the treatment of aggressive outbursts|Participants are trained to identify their physiological response when they are relaxed and when an outburst is coming. They are treated with cognitive, behavioral and emotional self-regulation therapies for managing anger and learning positive coping skills. Biofeedback toghether with virtual reality help them to improve their recognition and control of emotions.
48672488|NCT01426061|OTHER|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
47990803|NCT00227903|BEHAVIORAL|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
47990804|NCT00227903|BEHAVIORAL|Brief Advice|Advice and education
47990805|NCT05546047|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
48672489|NCT01446874|DRUG|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
48672490|NCT02953184|DRUG|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
48672491|NCT02953184|DRUG|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
48359795|NCT04352244|PROCEDURE|Fat biopsy|"The fat biopsy is performed during a scheduled procedure at the Beth Israel Deaconess Medical Center (BIDMC). Routine preoperative procedures will be followed, including local anesthesia (numbing a particular region of the body) or general anesthesia (being put to sleep).~Adipose tissue will be sampled from different depots depending on the procedure. For example, the surgeon will collect adipose tissue from the neck and supraclavicular depots from cervical spine, thyroid, and parathyroid procedures; perinephric fat from adrenalectomies, omental fat from abdominal procedures, and paraspinal fat from lumbar spine procedures. Up to 5 pieces of fat tissue weighing about three to six grams will be removed. All other aspects of the surgical procedure will proceed as planned. Samples will be prepared for subsequent laboratory analysis."
48359796|NCT04352244|DIAGNOSTIC_TEST|Blood sampling|A blood sample will be collected in the fasting state either during preoperative testing or in the preoperative area on the day of planned procedure for measurement of adipose functional markers (leptin, adiponectin) and insulin resistance (insulin, C-peptide), and measures of glycemia (glucose, hemoglobin A1c).
48359797|NCT04352244|GENETIC|Blood sample for DNA analysis|Targeted resequencing of DNA to identify variants associated with adipose phenotypes will be performed.
48359798|NCT03701373|DRUG|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA\<1.25 m2), 50 mg (1.25≤BSA\<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
48359799|NCT03701373|OTHER|Observation|Observation without anti-tumor treatment
48359800|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 1|
48508600|NCT05881746|PROCEDURE|anatomical liver resection|Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
48508601|NCT05881746|PROCEDURE|nonanatomical liver resection|Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
48508602|NCT05962762|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|"The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group."
48508603|NCT05298761|DRUG|Lignocaine|Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
48672492|NCT02953184|DRUG|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
48672493|NCT02953184|DRUG|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
48672494|NCT02953184|DRUG|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
47990806|NCT00913367|DRUG|glimepiride + insulin glargine (Amaryl + Lantus)|"* Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
47990807|NCT00913367|DRUG|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"* Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
48359801|NCT00425594|DRUG|HalfLytely and Bisacodyl Tablets - Formulation 2|
48359802|NCT00425594|DRUG|NuLYTELY|
48359803|NCT00642824|DRUG|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
48672495|NCT02953184|DRUG|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
48672496|NCT02953184|PROCEDURE|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
48672497|NCT02953184|PROCEDURE|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
48672498|NCT02953184|PROCEDURE|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
48672499|NCT01012284|DRUG|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
48672500|NCT05275673|DRUG|sapanisertib|capsules for oral administration
48359804|NCT00642824|DRUG|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
47990808|NCT04463550|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
47990809|NCT03229668|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
47990810|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
48672501|NCT06521216|DRUG|Ferrous sulfate|all patients will receive 200 mg elemental iron (ferrous sulphate)
48672502|NCT02850588|PROCEDURE|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
48672503|NCT02850588|PROCEDURE|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
47990811|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
48148355|NCT03122444|DRUG|Imipramine|Imipramine will be given daily for 21-30 days.
47990812|NCT05042947|DEVICE|double-loop clips|a new ligation method using the double-loop clips (D-L clips) technique
48148356|NCT05602961|DRUG|GLB-COV2-043|COVID-19 vaccine, administered as a booster
48359805|NCT01292733|OTHER|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
48359806|NCT01292733|OTHER|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
47990813|NCT05042947|DEVICE|Titanium Clip|the Titanium Clip
48359807|NCT01292733|OTHER|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
48359808|NCT04775485|DRUG|DAY101|DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
48359809|NCT05299411|DRUG|iron (isomaltoside)|iron supplement through intravenous infusion
48359810|NCT05299411|DRUG|Dried Ferrous Sulfate|iron supplement through oral intake
47990814|NCT06110429|DRUG|Lactate, Sodium|Isovolemic and osmotic infusion Comparison of osmotic agent
47990815|NCT06110429|DRUG|Hypertonic saline|Isovolemic and osmotic infusion Comparison of osmotic agent
47990816|NCT06019637|OTHER|Onasemnogene Abeparvovec|Retrospective and prospective observational study. There is no treatment allocation.
47990817|NCT00654407|DRUG|Rosuvastatin|
48148357|NCT05602961|DRUG|BNT162b2/COMIRNATY®|active control
48359811|NCT02155660|DRUG|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
48359812|NCT02155660|DRUG|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
48359813|NCT02155660|DRUG|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
47990818|NCT00654407|DRUG|Atorvastatin|
47990819|NCT00654407|DRUG|Simvastatin|
47990820|NCT01237535|DRUG|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
48148358|NCT04274127|DIAGNOSTIC_TEST|early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)|completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
48148359|NCT04401943|OTHER|online fatigue intervention|on line teleconferencing fatigue intervention for 6 weeks on causes of fatigue, ways to protect joint and save energy, ways to manage stress, pain, good eating habits, and exercise.
48359814|NCT02155660|DRUG|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
48359815|NCT00423540|DRUG|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
48359816|NCT02220608|BIOLOGICAL|Bortezomib|
48359817|NCT02220608|DRUG|G-CSF|
48359818|NCT00000642|DRUG|CD4-IgG|
48359819|NCT05275309|OTHER|Exploration of optimal PEEP in supine and prone position|"1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again."
48359820|NCT05488327|DRUG|Lenalidomide|All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
48672504|NCT04144777|DIETARY_SUPPLEMENT|Solarplast|Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
48672505|NCT03335202|DIAGNOSTIC_TEST|analysis of microbiome|microbial profiling by next generation sequencing
48672506|NCT02633735|OTHER|Appy CDS|See description under arm/group section
48672507|NCT02987582|BEHAVIORAL|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
48672508|NCT01850953|DRUG|Varenicline|This is an approved smoking cessation medication.
48672509|NCT01850953|DRUG|Placebo|
48672510|NCT01709526|BEHAVIORAL|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
48672511|NCT06488924|DRUG|JR-446|IV infusion
48148360|NCT04820088|OTHER|Computer based role play trianing|Participants will train with a computer-based role-play simulation. They will interact with a lifelike video character on screen. They will interact with the character in one of four scenarios (i.e., patient intake, traditional needs, high-risk needs,and social and physical transition). They will receive real-time and after-action feedback in a safe, non-stressful environment. Their usage of the system will be monitored and transcripts will be collected.
48148361|NCT03054766|PROCEDURE|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
48148362|NCT03054766|DRUG|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
48359821|NCT01725724|PROCEDURE|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
48359822|NCT01725724|PROCEDURE|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
48359823|NCT00043199|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
48359824|NCT06482957|OTHER|Surveys|Complete surveys
48359825|NCT06482957|OTHER|Blood Collection|Undergo blood collection
48359826|NCT06482957|OTHER|Saliva Collection|Undergo salvia collection
48359827|NCT06482957|OTHER|Urine Collection|Undergo urine collection
48672512|NCT00185237|DRUG|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
48672513|NCT00185237|DRUG|Placebo|Placebo patch
48672514|NCT01873105|OTHER|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
48672515|NCT01248793|DRUG|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
47990821|NCT01237535|DRUG|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
48672516|NCT01248793|DRUG|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
48672517|NCT01248793|DRUG|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
47990822|NCT01237535|PROCEDURE|Insemination without luteal support|Routine insemination procedure without luteal support
47990823|NCT02850315|DEVICE|optimal coherence tomography|
47990824|NCT00183092|DRUG|Quinacrine|100mg by mouth three times a day
47990825|NCT00183092|DRUG|Placebo|100mg by mouth three times a day
47990826|NCT06320145|DEVICE|Cryotherapy|This device used at the first, second and third day of period to decrease pain for 20 min at first, second and third day
47990827|NCT06320145|OTHER|core stability exercises|core stability exercises
47990828|NCT01481233|DRUG|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
48148363|NCT03277456|BIOLOGICAL|MVA-NP+M1|Intramuscular injection of novel vaccine
48148364|NCT01735435|OTHER|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
48359828|NCT06482957|OTHER|Stool Collection|Undergo stool collection
48359829|NCT06482957|OTHER|Tissue collection|Undergo tissue collection
48359830|NCT06482957|OTHER|Physical Activity Monitoring|FitBit will be worn to track physical activity
48359831|NCT02438111|GENETIC|metagenome|metagenome
48359832|NCT06405256|RADIATION|magnetic resonance imaging-guided adaptive radiotherapy|Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
48359833|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
48359834|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
48359835|NCT00956046|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
48359836|NCT00562081|BEHAVIORAL|Education|24/7 access to a Certified Asthma Educator
48359837|NCT00562081|BEHAVIORAL|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
48359838|NCT02346955|BIOLOGICAL|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
48359839|NCT02346955|BIOLOGICAL|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
48359840|NCT03381144|DRUG|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
48359841|NCT03381144|DRUG|Placebo|Participants will receive GDC-0334-matching placebo.
48672518|NCT05747274|DEVICE|SRDK0921|SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
48672519|NCT02649764|DRUG|Cytarabine|Given IV
48672520|NCT02649764|DRUG|Fludarabine Phosphate|Given IV
48672521|NCT02649764|OTHER|Laboratory Biomarker Analysis|Correlative studies
48672522|NCT02649764|DRUG|Prexasertib|Given IV
48672523|NCT01175343|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
48672524|NCT01175343|OTHER|Laboratory Biomarker Analysis|Correlative studies
48672525|NCT00382174|DRUG|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
48672526|NCT00382174|DRUG|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
48672527|NCT06487780|BEHAVIORAL|Lifestyle-focused Occupational Therapy Intervention|The proposed intervention, led by trained occupational therapists, will focus on establishing sustainable self-care routines. It will consist of approximately 12 biweekly sessions, each lasting about an hour on average. Therapists will customize session timing and duration based on participant needs.
48672528|NCT06487780|OTHER|Education|Participants in the education group will receive standardized education materials on diabetic foot ulcers (DFUs), foot care, and offloading treatment to prevent foot ulcer recurrence.
48508604|NCT05127915|DEVICE|Adient absorbable filter + best practice VTE prophylaxis|Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
48672529|NCT00693888|BEHAVIORAL|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
48672530|NCT00022178|DRUG|cisplatin|
48672531|NCT00022178|DRUG|cyclophosphamide|
48672532|NCT00022178|DRUG|doxorubicin hydrochloride|
47990829|NCT02921776|OTHER|Aim 1 - VidaTalk - post-extubation|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~* Tell me you are tired~* Tell me you are having pain~* Rate this pain~* Tell me there is pain in your back~* Tell me your pain is sharp~* Ask to see the doctor~* Write your favorite color by drawing with your finger~* Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app."
48148365|NCT02598388|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).
48148366|NCT02598388|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units).
48148367|NCT02598388|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
48508605|NCT05127915|DEVICE|best practice VTE prophylaxis|Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
48508606|NCT02628886|BIOLOGICAL|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
48508607|NCT02628886|BIOLOGICAL|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
48508608|NCT02628886|OTHER|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
48508609|NCT03590769|DRUG|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
48508610|NCT00323466|PROCEDURE|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
48508611|NCT06006065|BEHAVIORAL|Upper limb somatosensory discrimination therapy|"Participants will receive three 45 minute sessions of upper limb somatosensory discrimination therapy per week for a period of 8 weeks.~Each session includes 30 minutes of component-based training, including graded practice of three components of somatosensation (i.e., tactile object recognition, texture discrimination and proprioception). Next, 15 minutes of occupation-based practice will be completed to enhance transfer to a functional context. This includes repetitive and structured practice of self-chosen activities of daily living, while attention is designated to the somatosensory aspects necessary for successful task completion (e.g., identification of button based on touch)."
48508612|NCT06006065|BEHAVIORAL|Upper limb motor therapy|Participants in the control group will receive an equal amount of motor training, including 30 minutes of unimanual motor tasks and 15 minutes of bimanual goal directed training. The unimanual motor tasks will be selected based on the main difficulties of the child (e.g., grip strength, supination). Bimanual goal directed training includes whole task practice of self-chosen activities of daily living. All therapy sessions will be performed under supervision of a trained physical and/or occupational therapist. Therapy adherence and progression will be closely monitored by the therapist.
48508613|NCT02720874|BEHAVIORAL|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
48508614|NCT02720874|BEHAVIORAL|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
48672533|NCT00022178|DRUG|epirubicin hydrochloride|
48672534|NCT00022178|DRUG|fluorouracil|
48672535|NCT00022178|DRUG|vincristine sulfate|
48359842|NCT03663361|OTHER|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
48359843|NCT03663361|OTHER|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
48359844|NCT05786404|DRUG|PRIM-DJ2727 - FROZEN|Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
48359845|NCT05786404|DRUG|PRIM-DJ2727 - CAPSULES|Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
48359846|NCT03782766|PROCEDURE|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
48359847|NCT00095836|DRUG|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
48359848|NCT04065464|DEVICE|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
48359849|NCT01522599|OTHER|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
48359850|NCT01522599|OTHER|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
48359851|NCT01100203|DRUG|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
48359852|NCT01216644|DRUG|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
48359853|NCT01216644|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
48359854|NCT01216644|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
48359855|NCT01216644|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
48359856|NCT01216644|DRUG|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
48359857|NCT01216644|DRUG|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
48359858|NCT01216644|DRUG|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
48672536|NCT04859998|BEHAVIORAL|dog-assisted therapy|It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
48508615|NCT02720874|BEHAVIORAL|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
48148368|NCT05054751|DRUG|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
48148369|NCT05054751|DRUG|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
48672537|NCT02831660|DRUG|idarucizumab|
48148370|NCT04814719|DRUG|Pentosan Polysulphate Sodium|Subcutaneous Injection (100mg/ml)
48148371|NCT04814719|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
48148372|NCT02025712|DRUG|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
48148373|NCT02025712|DRUG|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
48672538|NCT03488329|DIETARY_SUPPLEMENT|Individual nutritional therapy|"Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition."
48148374|NCT06390462|BEHAVIORAL|Interpersonal counseling|A structured psychotherapeutic intervention to prevent depression or treat mild to moderate depression. IPC-A is a brief, individual-based intervention (3-8 sessions). The focus is on interpersonal relations as a factor of resilience in depressive symptoms. IPC-A is a shorter form of IPT-A, developed by prof. Myrna Weissman and team.
48148375|NCT06390462|BEHAVIORAL|Treatment as usual|Any other behavioral or medical support or depression indicated by depressive symptoms or depression. This is based on adolescent, caretaker and professional's report.
48148376|NCT06390462|OTHER|No support, intervention or other treatment|The group will comprise those adolescents who report sustained depression but do not seek or receive support over 6 months of follow-up based on adolescent and caretaker's report
48359859|NCT05306860|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
48672539|NCT05200312|DRUG|Zanubrutinib|160 mg capsules administered by mouth twice daily (21-day cycles).
48672540|NCT05200312|DRUG|Lenalidomide|25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
48148377|NCT02411188|BEHAVIORAL|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
48359860|NCT01126528|DIETARY_SUPPLEMENT|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
48672541|NCT05200312|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
48672542|NCT05200312|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
47990830|NCT02921776|OTHER|Aim 2 - VidaTalk - intubated|Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
48359861|NCT01126528|DIETARY_SUPPLEMENT|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
48359862|NCT02795182|DRUG|Zanubrutinib|
48359863|NCT02795182|DRUG|Tislelizumab|
48359864|NCT02717026|DEVICE|Optical coherence tomography|Sections including the retinal vasculature will be taken.
48672543|NCT05200312|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
48672544|NCT05200312|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
48672545|NCT05200312|DRUG|Prednisone (or equivalent)|40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
48672546|NCT05579210|BEHAVIORAL|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
48508616|NCT02720874|BEHAVIORAL|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
48508617|NCT02720874|BEHAVIORAL|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
48508618|NCT02318303|DRUG|GSP 301-1 NS (QD)|GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
48508619|NCT02318303|DRUG|GSP 301-2 NS (BID)|GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
48148378|NCT00257894|DRUG|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
48148379|NCT00257894|DRUG|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
48148380|NCT02060071|OTHER|Blood test|Blood test
48148381|NCT03262389|DRUG|Fludeoxyglucose PET CT|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
48148382|NCT03262389|DRUG|Sodium Acetate C11 PET CT|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
48148383|NCT03262389|DRUG|Fludeoxyglucose PET MRI|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
48148384|NCT03262389|DRUG|Sodium Acetate C11 PET MRI|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
48148385|NCT01737398|DRUG|Inotersen|
48148386|NCT01737398|DRUG|Placebo|
48148387|NCT01619007|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
48148388|NCT01619007|DRUG|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
48148389|NCT02966197|PROCEDURE|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
48508620|NCT02318303|DRUG|GSP 301 Placebo NS|GSP 301 placebo NS administered as 2 sprays/nostril
48672547|NCT05579210|BEHAVIORAL|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
47990831|NCT02921776|DEVICE|Aim 3 - VidaTalk tablet app|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
47990832|NCT02921776|OTHER|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
48672548|NCT01394380|OTHER|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
47990833|NCT00304564|BEHAVIORAL|Music Listening|subjects listen to music
48148390|NCT02966197|DEVICE|Prophylactic internal iliac artery balloon|
48148391|NCT02966197|RADIATION|Radiology operation|
48359865|NCT02717026|DEVICE|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
48359866|NCT02717026|DEVICE|Fundus photography|30 and 50 degree fundus images
48508621|NCT02318303|DRUG|Olopatadine HCl-1 NS (QD)|Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
48508622|NCT02318303|DRUG|Olopatadine HCl-2 NS (BID)|Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
48508623|NCT02318303|DRUG|Mometasone Furoate-1 NS (QD)|Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
48508624|NCT02318303|DRUG|Mometasone Furoate-2 NS (BID)|Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
48508625|NCT03007992|DRUG|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
48508626|NCT04829994|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this study. The surgical procedures being performed within the study are identical to the surgical procedures subjects would receive as part of SOC.
48508627|NCT05645159|OTHER|Blended learning in heart disease|The intervention included face-to-face classes and online resources (Moodle, online syllabus, videos, websites, podcasts, activities, apps, forums, emails, tutoring).
48508628|NCT05293912|DRUG|SG2501|During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
48508629|NCT00293943|PROCEDURE|Pulmonary vein ablation|
48508630|NCT06632808|OTHER|Exercise|Deep cervical flexor muscle exercises target the deep neck muscles that play a crucial role in the stabilization of the cervical spine and the maintenance of proper posture. These muscles, particularly the longus colli and longus capitis, are responsible for the correct alignment of the head and neck. The exercises typically involve gentle flexion of the neck (bringing the chin towards the chest) with low-intensity, controlled movements. The goal is to strengthen these muscles, enhance spinal stability, and alleviate symptoms such as tension-type headaches. Additionally, these exercises support postural control and can reduce excessive strain on the neck.
48508631|NCT03039426|DRUG|Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
48508632|NCT03039426|DRUG|Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
48508633|NCT02268968|DRUG|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
48508634|NCT05092269|DRUG|Ustekinumab|Ustekinumab will be administered as a SC injection.
48508635|NCT02691143|OTHER|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
48672549|NCT00364169|PROCEDURE|Degree of constipation|
48359867|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played with a facilitator.
48508636|NCT00866879|DRUG|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
48508637|NCT00866879|OTHER|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
48508638|NCT00866879|PROCEDURE|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
48359868|NCT05637749|OTHER|Medical serious game intervention (educational)|Medical serious game designed to facilitate the rehearsal of diabetes management knowledge. Players are presented with a colony of individuals, all of whom have some form of diabetes, and are tasked to manage food, insulin, and medication intake throughout the day. The intervention may be played alone.
48359869|NCT02255240|BEHAVIORAL|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
48672550|NCT03914989|OTHER|olfactory enrichment (essential oils)|Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
48359870|NCT02579525|OTHER|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
48672551|NCT00869167|DRUG|Ramelteon|melatonin agonist
48672552|NCT01127919|BEHAVIORAL|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
48672553|NCT01127919|OTHER|Cognitive Component|Provide general information about health and fitness
48672554|NCT05021952|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
48672555|NCT02795494|BEHAVIORAL|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
48672556|NCT02795494|BEHAVIORAL|ASK-P questionnaire at baseline|Patient-reported activity level score
47990834|NCT00507442|DRUG|VELCADE (bortezomib)|bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
47990835|NCT00507442|DRUG|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
47990836|NCT00507442|DRUG|cyclophosphamide|cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
47990837|NCT00507442|DRUG|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
47990838|NCT05369845|OTHER|questionary|the patient will complete validated questionnaires, at three periods (at the time of the initiation of the CPAP, and during the 2 planned follow-up consultations: four months and at 1 year) The validated questionnaires are as follows: Illness Perception Questionnaire (IPQ-R), Beliefs about Medicines Questionnaire (BMQ), Morisky Medication Adherence Scale (MMAS), Hospital Anxiety and Depression Scale (HADS), Rollnick Scale.
47990839|NCT04105933|OTHER|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
47990840|NCT04105933|OTHER|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
48672557|NCT02795494|BEHAVIORAL|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
47990841|NCT03738891|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
47990842|NCT02190812|DEVICE|Forearm supporter|The forearm supporter be use in tennis elbow.
47990843|NCT02190812|DEVICE|Grip ball|
47990844|NCT05264077|DRUG|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
47990845|NCT01540656|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
48672558|NCT02928861|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
48672559|NCT00034021|DRUG|Ginkgo Biloba|
48672560|NCT00034021|BEHAVIORAL|Sex Therapy (genital focus)|
48672561|NCT04608877|BEHAVIORAL|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
48672562|NCT04608877|BEHAVIORAL|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
48672563|NCT06178367|DRUG|Low molecular weight hyaluronic acid|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
48672564|NCT06178367|DRUG|High molecular weight hyaluronic acid|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
48672565|NCT06178367|DRUG|Vehicle|Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
48672566|NCT03480984|OTHER|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
47990846|NCT01010308|DRUG|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
48672567|NCT03480984|OTHER|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
48672568|NCT05156411|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
48672569|NCT05149820|OTHER|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
48672570|NCT05149820|DRUG|Magnesium|Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L
48672571|NCT02592421|DRUG|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
48672572|NCT02592421|DRUG|Placebo|Placebo Comparator
48672573|NCT00987714|PROCEDURE|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
48672574|NCT01385592|DRUG|AFQ056|
48672575|NCT01385592|DRUG|Placebo|
48672576|NCT01657370|DRUG|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
48672577|NCT01657370|DRUG|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
48672578|NCT01657370|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
48672579|NCT06480201|DRUG|Ketamine|Ketamine infusion amount is dictated by BMI, sex, and age.
48672580|NCT06480201|OTHER|Saline|Saline infusion amount is dictated by BMI, sex, and age.
48672581|NCT04478903|OTHER|Questionnaire|Zarit Burden Inventory French version and SF12
48359871|NCT02579525|OTHER|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
48359872|NCT00062972|DRUG|donepezil|
48359873|NCT00062972|DRUG|glucose|
48359874|NCT06218238|OTHER|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
48359875|NCT06218238|OTHER|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
48359876|NCT03962127|OTHER|no intervention|no intervention
48359877|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
48508639|NCT00866879|PROCEDURE|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
48672582|NCT03423511|DEVICE|MiStent II coronary artery stent|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
47990847|NCT01866514|PROCEDURE|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
48672583|NCT03423511|DEVICE|Xience or Promus coronary artery stents|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
48672584|NCT06341881|BEHAVIORAL|Transitional Care Training Program|A nursing based transitional care training intervention would be carried out to prepare the family caregivers to take care of their elderly stroke survivors at home. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the family caregivers at their homes after hospitalization. The study participants would be evaluated after 8 weeks of the intervention. A structured, validated and literature based assessment checklist will be devised to assess the usefulness and feasibility of the intervention. Assistance of senior nurses and health professionals, specialized in stroke care will be taken during the training part of the program.
48672585|NCT02562781|DRUG|Oxygen|Oxygen in sufficient quantity to maintain SpO2 \> 98%
48672586|NCT02562781|OTHER|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 \> 90%
48672587|NCT05914194|DRUG|NLS-2|Participants will receive NLS-2 tablets orally.
48672588|NCT05914194|DRUG|Placebo|Participants will receive NLS-2 matching placebo tablets orally.
48672589|NCT00708409|PROCEDURE|Cardiac valve surgery|Different autograft implantation techniques.
48672590|NCT00583219|DRUG|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
48672591|NCT00583219|DRUG|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
48672592|NCT05710952|DEVICE|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
48672593|NCT00506038|PROCEDURE|fine needle technique|
48672594|NCT05570032|DEVICE|Virtual Reality Training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
48672595|NCT01176760|DRUG|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
47990848|NCT01866514|DRUG|2% preservative-free lidocaine|
47990849|NCT01866514|DEVICE|EZ-IO|
47990850|NCT02618174|BEHAVIORAL|Neutral Control Condition|Message about age of University of Birmingham
47990851|NCT02618174|BEHAVIORAL|Food-based Control Condition|Message about variety of vegetables in the world
48359878|NCT01406509|BIOLOGICAL|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
48359879|NCT01636050|OTHER|squat exercise training|Intervention may include squat exercise for 8 weeks
48359880|NCT04225104|BEHAVIORAL|Yogic breathing intervention|Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.
48359881|NCT00758394|DRUG|Fluoride|Brush two times a day for 4 days.
48508640|NCT00866879|PROCEDURE|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
48508641|NCT00866879|OTHER|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
48359882|NCT00758394|DRUG|Triclosan/Fluoride|Brush two times daily for 4 days
48359883|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
48359884|NCT00758394|DRUG|Triclosan/Fluoride|Brush twice daily for 4 days
48359885|NCT02681094|DRUG|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
48359886|NCT02681094|DRUG|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
48359887|NCT02681094|DRUG|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
48359888|NCT02681094|DRUG|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
48359889|NCT02987205|DEVICE|Revanesse Ultra|NLF correction
48672596|NCT01176760|OTHER|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
48672597|NCT03222674|BIOLOGICAL|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
47990852|NCT02618174|BEHAVIORAL|Health Condition|Message about the health benefits of eating vegetables
47990853|NCT02618174|BEHAVIORAL|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
47990854|NCT02618174|BEHAVIORAL|Liking Social Norm|Message suggesting most people like eating vegetables
47990855|NCT03120546|DEVICE|rigid video stylet intubation|intubation using rigid video stylet
47990856|NCT03120546|DEVICE|video laryngoscope intubation|intubation using video laryngoscope
47990857|NCT05751967|DRUG|Placebo Combined With Ursodeoxycholic Acid|1 tablet/ day
47990858|NCT05751967|DRUG|Fenofibrate Combined With Ursodeoxycholic Acid|200 mg/day
48359890|NCT02987205|DEVICE|Restylane|NLF Correction
48359891|NCT06159049|DIAGNOSTIC_TEST|68Ga-FAPI dimer(68Ga-LNC1013)|68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.
48508642|NCT00866879|PROCEDURE|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
47990859|NCT02968563|DRUG|Tirabrutinib|Tablets administered orally
47990860|NCT02968563|DRUG|Idelalisib|Tablets administered orally
47990861|NCT02968563|DRUG|Obinutuzumab|Administered intravenously
47990862|NCT00253474|BIOLOGICAL|PEG-interferon alfa-2a|
47990863|NCT05505357|PROCEDURE|Breast surgery omission|For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.
47990864|NCT00226954|DRUG|zoledronic acid|
48359892|NCT04806165|BEHAVIORAL|Repeated Administration|A discussion with the chatbot, including follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48359893|NCT04806165|BEHAVIORAL|Personalized Recommendation|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder.
48508643|NCT00273039|DRUG|paroxetine|
48508644|NCT06189976|DIAGNOSTIC_TEST|Rapid atrial pacing|Rapid atrial pacing after TAVI
48508645|NCT03138655|DRUG|Vedolizumab|Vedolizumab IV infusion.
48508646|NCT04787679|PROCEDURE|Hip replacement surgery|After hip replacement surgery the sponsor obtains femoral head samples for the study
48508647|NCT02627651|OTHER|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
48508648|NCT06259305|OTHER|Creation of a memory track combined with the baby's heartbeat|This is as described above
48508649|NCT06623474|DIAGNOSTIC_TEST|diagnosed by traditional diagnostic markers（such as AFP or CT etc.）|A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).
48508650|NCT06052280|OTHER|Telerehabilitation exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only."
48672598|NCT00467376|DRUG|Insulin Glulisine|3 times a day before each meal
48672599|NCT00467376|DRUG|Lispro|3 times a day before each meal
48672600|NCT00467376|DRUG|Insulin Glargine|once daily
48672601|NCT00959907|DRUG|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
48672602|NCT02878395|PROCEDURE|Ileocolic resection|
48672603|NCT01387750|OTHER|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
48672604|NCT01387750|OTHER|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
48672605|NCT04326790|DRUG|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
48672606|NCT04326790|DRUG|Standard treatment|Standard treatment
48672607|NCT01228214|DRUG|Placebo|Placebo 5mg/daily for 12 months
48672608|NCT01228214|DRUG|amiloride|5mg/daily for 12 months
48672609|NCT03985280|DEVICE|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
48672610|NCT03985280|DRUG|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
48148392|NCT01000935|OTHER|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
48359894|NCT04806165|BEHAVIORAL|Motivational Interviewing|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
48359895|NCT04806165|BEHAVIORAL|Core Modules Only|A discussion with the chatbot, including only the core modules.
48508651|NCT06052280|OTHER|Home self-exercise program|"After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them."
48508652|NCT06144632|DEVICE|THERMOCOOL STSF Bi- Directional Navigation Catheter|THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.
48359896|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48508653|NCT06144632|DEVICE|TRUPULSE Generator|TRUPULSE Generator will be used to deliver PF/RF ablation.
48508654|NCT03997617|DIAGNOSTIC_TEST|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
48508655|NCT04589663|DRUG|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
48508656|NCT04589663|DRUG|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
48672611|NCT04607629|BIOLOGICAL|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
48508657|NCT04589663|DRUG|Standard of Care (Soc)|Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
48508658|NCT01529710|DRUG|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
48508659|NCT05846646|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
47990865|NCT02548247|DIETARY_SUPPLEMENT|Orafti® Inulin|Dietary fiber
47990866|NCT02548247|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
47990867|NCT03492216|BEHAVIORAL|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
47990868|NCT03492216|BEHAVIORAL|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
47990869|NCT02532647|DRUG|Remimazolam|
48359897|NCT04806165|BEHAVIORAL|Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48359898|NCT04806165|BEHAVIORAL|Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder and identifying a personalized recommendation for accessing help for their eating disorder.
48359899|NCT04806165|BEHAVIORAL|Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including identifying a personalized recommendation for accessing help for their eating disorder and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48359900|NCT04806165|BEHAVIORAL|Psychoeducation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders.
48359901|NCT04806165|BEHAVIORAL|Psychoeducation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48508660|NCT05846646|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
48508661|NCT05846646|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
48508662|NCT02849938|DEVICE|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
48508663|NCT04659603|DRUG|tusamitamab ravtansine|"Pharmaceutical form:Concentrated solution for IV;~Route of administration: IV infusion"
48508664|NCT04659603|DRUG|Gemcitabine|"Pharmaceutical form: Lyophilized powder for reconstitution or as a solution for infusion;~Route of administration: IV infusion"
48672612|NCT04607629|BIOLOGICAL|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
48672613|NCT00947219|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
48672614|NCT00947219|DEVICE|Control device|Device is used 3 times a week on non-consecutive days
48672615|NCT01085526|BIOLOGICAL|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
48672616|NCT01085526|DRUG|Alutard phl prat|
48672617|NCT05604261|DRUG|Anaprazole sodium 40 mg|Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
48672618|NCT05604261|DRUG|Anaprazole sodium 60 mg|Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
48672619|NCT05604261|DRUG|Rabeprazole sodium 20 mg|Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
48672620|NCT01148667|DIETARY_SUPPLEMENT|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
48672621|NCT01148667|DIETARY_SUPPLEMENT|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
48672622|NCT01309061|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
48672623|NCT03457077|BEHAVIORAL|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
47990870|NCT02532647|DRUG|Midazolam|
47990871|NCT02532647|DRUG|Placebo|
47990872|NCT02090647|BEHAVIORAL|aesthetic outcome|
48359902|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and identifying a personalized recommendation for accessing help for their eating disorder.
48672624|NCT02184676|BIOLOGICAL|Analysis of early immune modifications|"* blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~* cord blood sampling~* stool sampling in mothers and newborns at birth (day 7)~* blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
48672625|NCT02184676|OTHER|Collection of clinical and socio-demographic data|"1. Questionnaire filled in by clinicians at enrollment and at birth~2. Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
48672626|NCT01413438|PROCEDURE|Craniotomy|
48508665|NCT06456034|BEHAVIORAL|Perinatal palliative care|Intervention group will receive specialized perinatal palliative care support from moment of severe perinatal diagnosis. This intervention is aimed at 5 major care components, namely 1. Support offered by a fixed perinatal palliative care team, 2. that team has received specialized perinatal palliative care training, 3. care is structured within a new perinatal palliative care approach or pathway, including fixed means of communication with team members, 4. psychological support is structurally being offered to parents and healthcare providers, and 5. debriefings after every perinatal death are being organized in the involved team.
48359903|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders and motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder.
48672627|NCT04975308|DRUG|Imlunestrant|Administered orally.
48672628|NCT04975308|DRUG|Exemestane|Administered orally.
48672629|NCT04975308|DRUG|Fulvestrant|Administered IM.
48672630|NCT04975308|DRUG|Abemaciclib|Administered orally.
48672631|NCT01366573|DRUG|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
48672632|NCT01366573|OTHER|Placebo|Placebo
48359904|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and identifying a personalized recommendation for accessing help for their eating disorder.
48359905|NCT04806165|BEHAVIORAL|Psychoeducation, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48359906|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48359907|NCT04806165|BEHAVIORAL|Psychoeducation, Motivational Interviewing, Personalized Recommendation, Repeated Administration|A discussion with the chatbot, including psychoeducational content to increase knowledge related to eating disorders, motivational interviewing techniques to help overcome barriers to seeking care for their eating disorder, identifying a personalized recommendation for accessing help for their eating disorder, and follow ups over the course of 2 weeks to encourage help seeking for their eating disorder.
48672633|NCT06446583|OTHER|Chewing sugar-free gum|Upon arrival at the preoperative preparation room, patients begin chewing sugar-free gum provided by the preoperative nurse. They continue chewing until they enter the operating room (for at least 15 minutes). Before entering the operating room, it is confirmed that the gum has been discarded.
48672634|NCT02070497|OTHER|case management|case management group will accept the case manager's service; the control group will just accept the routine care
48672635|NCT03905915|DEVICE|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
48672636|NCT00210847|DRUG|tramadol, acetaminophen|
48672637|NCT04846387|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"A T1-weighted Anatomical Image, Diffusion Weighted Image, and functional MRI (fMRI) of empty bladder image will be obtained.~Additionally, fMRI image during full bladder state and voiding/holding tasks will be obtained."
47990873|NCT03295253|PROCEDURE|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
47990874|NCT02430675|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
47990875|NCT02430675|DEVICE|NanoKnife|
48672638|NCT04846387|DIAGNOSTIC_TEST|Post-Void Residual|The patient's post-void residual is determined using a portable ultrasound machine after emptying the bladder just prior to entering the MRI scanner and immediately after the MRI scan.
48672639|NCT04846387|DIAGNOSTIC_TEST|Uroflowmetry|Patients will urinate into a funnel connected to an electric flow meter to record urine flow rates in mililters per second. This is used as part of the screening process.
48672640|NCT04846387|BEHAVIORAL|Questionaire - AUA Symptom Score|Subjects will fill out questionnaire asking about urinary symptoms. The range is 0-35.
48672641|NCT05575141|PROCEDURE|incisional hernia repair|Incisional hernia repair for the treatment of wide ventral incisional hernias.
48672642|NCT02213614|DIETARY_SUPPLEMENT|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
48672643|NCT02213614|DIETARY_SUPPLEMENT|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
48672644|NCT02213614|OTHER|natural spring water|A group will drink natural spring water for 4 months
48672645|NCT04168931|DRUG|Trastuzumab|The first-line standard treatment for gastric cancer is based on fluoropyrimidine and platinum-containing chemotherapy (FOLFOX). When the tumor expresses HER2 3+ on IHC or 2+ and is confirmed by FISH, trastuzumab at the standard dose of 8 mg / kg in D1 of the first cycle is added, followed by 6 mg / kg every 2 weeks for the remaining cycles until disease progression, unacceptable toxicity. (3) We will use the same doses of trastuzumab, but HER2 positivity is determined by immunocytochemical expression and FISH in CTCs for patients with negative expression in tissue biopsy.
48672646|NCT02756403|DRUG|Azithromycin|500 mg
48672647|NCT02756403|DRUG|Doxycycline|200 mg
48672648|NCT02756403|DRUG|Metronidazole|500 mg
48672649|NCT02756403|DRUG|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
48672650|NCT02782442|BEHAVIORAL|Structured Cognitive Training & PRIME|The treatment condition-- 30-35 hours of CT over 16 weeks (\~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application
48672651|NCT02782442|BEHAVIORAL|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (\~2 hours per week), combined with the personalized PRIME coaching application.
48672652|NCT04603001|DRUG|LY3410738|Oral LY3410738
48672653|NCT04603001|DRUG|Venetoclax|Oral venetoclax
48672654|NCT04603001|DRUG|Azacitidine|Subcutaneous or intravenous azacitidine
48672655|NCT05821660|OTHER|Five-day hypocaloric and ketogenic programme|Dietary intervention
48672656|NCT03654144|DRUG|Dienogest|oral tablets
48672657|NCT03654144|DRUG|Combined Oral Contraceptive|oral tablets
48672658|NCT01276106|DRUG|AC-201, 25mg|Capsule, 25mg BID
48672659|NCT01276106|DRUG|AC-201, 50mg|Capsule, 50mg BID
48672660|NCT01276106|DRUG|AC-201, 75mg|Capsule, 75mg BID
48672661|NCT01276106|DRUG|Placebo|Placebo BID
48672662|NCT05083078|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
48672663|NCT05083078|DRUG|Risankizumab|Risankizumab will be administered subcutaneously.
48672664|NCT04076267|OTHER|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
48672665|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
48672666|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
48672667|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
48672668|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
48672669|NCT02746302|DRUG|HS-20004|
48148393|NCT01921985|DRUG|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
48148394|NCT01921985|DRUG|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
48672670|NCT02746302|DRUG|Placebo|
48672671|NCT03495934|DRUG|pracinostat|\[14C\]-pracinostat
48359908|NCT00430924|DRUG|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
48672672|NCT00818493|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
48148395|NCT01377545|PROCEDURE|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
48508666|NCT04719455|BEHAVIORAL|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
48508667|NCT04719455|OTHER|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
48508668|NCT05830344|DEVICE|Placebo Multi Radiance Medical® Super Pulsed Laser|Placebo, without therapeutic dose.
48508669|NCT05830344|DEVICE|Active Multi Radiance Medical® Super Pulsed Laser|Active with a dose of 8.02 J per site.
48508670|NCT01616355|OTHER|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
48508671|NCT03741400|DEVICE|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
48508672|NCT04877457|DRUG|Ocrelizumab|The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
48508673|NCT04877457|OTHER|Placebo|Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
48508674|NCT03169231|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
47990876|NCT06415422|BIOLOGICAL|Biological samples|Biological samples are taken from the patient's catheter inserted upon admission (the usual access route for patients): A daily sample is collected into a dry tube for off-site analysis by VeriFyNow until platelet function normalizes (for example, if platelet function normalizes on Day 2, no further VeriFyNow analysis will be conducted on subsequent days).
48148396|NCT01377545|PROCEDURE|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
48359909|NCT03490123|DRUG|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
48359910|NCT03490123|DRUG|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
48359911|NCT03490123|DRUG|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
48359912|NCT03490123|DRUG|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
48359913|NCT03490123|DRUG|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
48359914|NCT03289676|COMBINATION_PRODUCT|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
48359915|NCT00191438|DRUG|gemcitabine|
48359916|NCT00191438|DRUG|capecitabine|
48359917|NCT00191438|DRUG|docetaxel|
48508675|NCT03169231|OTHER|Placebo|Intravenously delivered
48508676|NCT00753662|DEVICE|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
48508677|NCT00753662|DEVICE|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
48508678|NCT00753662|DEVICE|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
47990877|NCT03066674|OTHER|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
47990878|NCT03066674|OTHER|Control group|TENS,Exercises,Postural education ,Home exercises program.
48148397|NCT00512265|DRUG|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
48148398|NCT00512265|DRUG|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
48148399|NCT02327806|DEVICE|pulsed electromagnetic field therapy|
47990879|NCT00527943|DRUG|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
47990880|NCT00527943|DRUG|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
47990881|NCT01185938|DRUG|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
48672673|NCT00818493|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
48508679|NCT04558918|DRUG|LNP023|Taken Orally b.i.d. Dosage Supplied: 200 mg Dosage form: Hard gelatin capsule Route of Administration: Oral
48148400|NCT04603898|DIETARY_SUPPLEMENT|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
48672674|NCT00818493|DRUG|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
48672675|NCT04552002|DIETARY_SUPPLEMENT|Synbiotic group|Probiotics and prebiotics
48148401|NCT04603898|DIETARY_SUPPLEMENT|Carbon-13 Ascorbic Acid Oral Load|Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
48359918|NCT06204133|OTHER|Artificial intelligence model building|Using non-image medical data of cervical lesions and clinical pathology results in different medical institutions, machine learning is adopted to establish multiple multi-modal cervical cancer intelligent screening prediction models. This method was used to analyze the prediction performance of the multi-modal cervical cancer intelligent screening prediction and risk triage model, and to evaluate and optimize the self-learning ability of the established multi-modal cervical cancer intelligent screening prediction model.
48359919|NCT03870139|DEVICE|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
48359920|NCT03870139|DEVICE|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
48359921|NCT02143336|PROCEDURE|subcuticular suture|
48359922|NCT02143336|PROCEDURE|Skin staples|
48359923|NCT04250142|DEVICE|Self-etching Adhesive|A Self-etching adhesive will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
48359924|NCT04250142|DEVICE|Glass Ionomer|A conventional glass ionomer will be used to cover deep carious dentin after a selective removal of caries lesion to soft dentin procedure.
48359925|NCT01432236|DRUG|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
48359926|NCT01432236|DRUG|placebo|placebo capsules twice a day for 14 weeks
48359927|NCT05284604|DRUG|Mesenchymal Stem Cells (MSCs)|The MSCs are recovered from bone marrows of healthy donors. Each donor is carefully screened for pathogens to assure the product is safe. The MSCs are strictly compliant with FDA standards under Current Good Manufacturing Practice (cGMP) regulations.
48359928|NCT00570089|DRUG|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
48359929|NCT00570089|DRUG|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
48508680|NCT04558918|DRUG|Eculizumab|"Administered as intravenous infusion every 2 weeks as per the stable regimen, the maintenance dose is a fixed dose.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
48508681|NCT04558918|DRUG|Ravulizumab|"Administered as intravenous infusion every 8 weeks, the maintenance dose is based on body weight.~Dosage Supplied: 300 mg/30mL Dosage form: Concentrate solution for infusion"
48672676|NCT04464239|DRUG|TS-142|TS-142 tablets
47990882|NCT01662518|DEVICE|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
48508682|NCT04623086|DRUG|Insulin Degludec|Insulin Degludec injection
48672677|NCT04464239|DRUG|TS-142 Placebo|TS-142 matching placebo tablets
48672678|NCT01440361|DRUG|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
48672679|NCT01440361|DRUG|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
48672680|NCT05095298|DRUG|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
48672681|NCT02012218|DRUG|ADT|
48672682|NCT02012218|DRUG|Brexpiprazole|
48672683|NCT05587673|DRUG|Methylprednisolone|High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
48672684|NCT03406403|DEVICE|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
48148402|NCT03823794|OTHER|No intervention|Observational analysis of usual care only
48148403|NCT02805075|OTHER|Fructooligosaccharide|Given PO
48148404|NCT02805075|OTHER|Laboratory Biomarker Analysis|Correlative studies
48359930|NCT02862028|BIOLOGICAL|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
48148405|NCT05905068|DRUG|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
48508683|NCT04623086|DRUG|Insulin Glargine|Insulin Glargine injection
48508684|NCT04623086|DRUG|Placebo|9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
48508685|NCT02244814|BEHAVIORAL|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
48508686|NCT02244814|BEHAVIORAL|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
48508687|NCT00557089|DRUG|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
48148406|NCT02734784|PROCEDURE|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
48672685|NCT03406403|DRUG|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
48148407|NCT02734784|PROCEDURE|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
47990883|NCT04977076|OTHER|Uninterrupted NOAC use|Continuing NOAC use in advance of elective CAG or PCI.
47990884|NCT04977076|OTHER|Interrupted NOAC use|Usual care, interruption of NOAC prior to procedure.
47990885|NCT04103762|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
48148408|NCT06360367|BEHAVIORAL|HI-FLY Curriculum|Participants receive the standard HI-FLY Curriculum over 6 weeks.
48148409|NCT06360367|BEHAVIORAL|HI-FLY Curriculum + PortionSize Ed app|Participants receive the standard HI-FLY Curriculum over 6 weeks and the PortionSize Ed mobile app.
48508688|NCT00557089|OTHER|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
48508689|NCT06456853|OTHER|Pain assesment|We will ask patients about their pain and will try to asses their pain scores. Then we will ask them to which methot is more suitable for assesment.
48508690|NCT02341898|OTHER|Educational programme for all nurses|
48508691|NCT02341898|OTHER|Training and structured support for nominated key nurses|
48508692|NCT02341898|OTHER|Facultative train-the-trainer module for key nurses|
48508693|NCT02341898|OTHER|Printed study material|
48508694|NCT02341898|OTHER|Supportive material (poster, mugs etc.)|
48508695|NCT03276078|DRUG|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
48508696|NCT04628897|BEHAVIORAL|Exposures|"1. Total area of available floor space inside the home (m2)~2. Frequency that child plays outdoors~3. Total number of physical hazards in the home (presence of open stairwells, stove height)~4. Total number of fine-motor activity items available to the child~5. Presence of gross-motor activity items available to the child across each category (e.g., fixed, portable: ball equipment, push/pull equipment, riding equipment, rocking and twisting equipment)~6. Hemoglobin concentration (g/L)."
48508697|NCT04293796|PROCEDURE|Vacuum-assisted biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, after neoadjuvant systemic treatment on patients with clinical complete response on primary breast cancer management we recommend to take at least 12 biopsies with 7-10G needle sizes with sentinel lymph node biopsy.
48508698|NCT00890604|OTHER|Stepwise normothermia protocol|Use of standard care interventions in a protocolized/step-wise fashion instead of ad hoc based on nurse decision making which may include antipyretics, physical cooling measures.
47990886|NCT04103762|DIAGNOSTIC_TEST|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
47990887|NCT00495833|BEHAVIORAL|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
47990888|NCT00495833|BEHAVIORAL|Promotional gift|half of participants who go to a fire station will receive a gift card.
47990889|NCT00019396|DRUG|flt3 ligand|
47990890|NCT00019396|DRUG|gp100 antigen|
47990891|NCT00019396|DRUG|MART-1 antigen|
47990892|NCT00019396|DRUG|Montanide ISA-51|
47990893|NCT00019396|DRUG|tyrosinase peptide|
48148410|NCT00689195|DIETARY_SUPPLEMENT|Curcumin powder|oral capsules containing the investigational agent
48148411|NCT00689195|DIETARY_SUPPLEMENT|Ashwagandha extract|4.5% extract of ashwagandha
48148412|NCT03846817|OTHER|Physiotherapist-led treatment|12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
48148413|NCT03748056|BEHAVIORAL|Targeted incentives|Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
48148414|NCT03748056|BEHAVIORAL|Nominal loyalty card discount and nutrition education|All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
48672686|NCT03406403|OTHER|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
48148415|NCT04021277|DRUG|20 uL/kg PS101|20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
48148416|NCT04021277|DRUG|40 uL/kg PS101|40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
48148417|NCT04021277|DEVICE|Ultrasound|Ultrasound activation and enhancement
48148418|NCT03411408|DEVICE|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
48148419|NCT03411408|RADIATION|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
48148420|NCT00275314|DRUG|Valganciclovir|
48148421|NCT05588739|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
48148422|NCT01137682|DRUG|Pasireotide|"* Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
48148423|NCT01137682|DRUG|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
48148424|NCT01137682|DRUG|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
48148425|NCT00456235|DRUG|Mycophénolate Mofétil|
48359931|NCT05690581|DRUG|CM369|Specified dose on specified days.
48359932|NCT03840681|OTHER|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
48359933|NCT04328142|OTHER|Qigong group|Traditional Chinese Medicine exercise programme
48359934|NCT04328142|OTHER|Physiotherapy|Physiotherapy exercise programme
48359935|NCT05718011|DRUG|Dexmedetomidine|0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
48359936|NCT05718011|DRUG|Ketamine|0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
48359937|NCT00050440|DRUG|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
48359938|NCT00050440|DRUG|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
48359939|NCT03748654|DIAGNOSTIC_TEST|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
48359940|NCT03820518|DRUG|Calcitriol|
48359941|NCT04779476|OTHER|Socket Dressing|Following dental extraction immediately, the socket will be dressed with one of the materials tested
48359942|NCT05466604|DRUG|Hyaluronidase Injection mesomedica|injection of 150 IU hyaluronidase to perioperative region, submucosally.
48148426|NCT00456235|DRUG|Ciclosporine A|
48148427|NCT00456235|DRUG|Tacrolimus|
48148428|NCT05248217|BEHAVIORAL|healthcare workers|healthcare
48148429|NCT05863585|DRUG|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|100µg
48148430|NCT00486954|DRUG|Lapatinib|6 pills at 250 mg each once daily
48148431|NCT00486954|DRUG|Paclitaxel|Infusion at 80 mg/m2 weekly
48508699|NCT00890604|DRUG|Ibuprofen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
48148432|NCT00409903|DRUG|Eprosartan|
48359943|NCT05466604|DRUG|Dexamethasone dekort|injection of 8 mg dexamethasone to perioperative region, submucosally.
48359944|NCT00992706|DRUG|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
48359945|NCT00992706|DRUG|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
48359946|NCT01729806|BIOLOGICAL|Ipilimumab|Given IV
48359947|NCT01729806|OTHER|Laboratory Biomarker Analysis|Correlative studies
48359948|NCT01729806|BIOLOGICAL|Rituximab|Given IV
48359949|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.54g (3 capsules) each time, twice daily; placebo, 1 capsule, twice daily
48359950|NCT05459519|DRUG|Placebo|Placebo, 4 capsules each time, twice daily
48359951|NCT05459519|DRUG|Dengzhanxixin Capsule plus Placebo Capsule|Dengzhanxixin Capsule, 0.72g (4 capsules) each time, once daily; placebo, 4 capsules, once daily
48359952|NCT03076411|DRUG|Pepsin|
48359953|NCT05713513|OTHER|Leukapheresis|Leukapheresis to isolate 1x10e9 cells, examined for purity and specificity under Good Manufacturing Practice (GMP)
48508700|NCT00890604|DRUG|Acetominophen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
48672687|NCT05577026|BEHAVIORAL|Educational intervention and prescription feedback|Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.
48148433|NCT03788707|OTHER|Passive leg raising|After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
48148434|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
48148435|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
48148436|NCT02346409|DEVICE|tACS of the cerebellum|tACS of the cerebellum
48148437|NCT03442998|OTHER|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
48148438|NCT03442998|OTHER|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
48148439|NCT05556200|DRUG|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)
48148440|NCT05556200|DRUG|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
48148441|NCT03054506|DEVICE|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
48148442|NCT03054506|DEVICE|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
48148443|NCT03054506|DEVICE|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
48148444|NCT03379597|DRUG|Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)|Bifico 840mg Bid
48148445|NCT03379597|DIETARY_SUPPLEMENT|Dietary fiber|dietary fiber compound powder 30g bid
48148446|NCT03337022|DRUG|CC-90006|CC-90006
48359954|NCT05330806|PROCEDURE|Collagenase chemonucleolysis|"After local anesthesia, and the puncture point was 8-12cm on the side of the paraspinous process under C arm fluoroscopy. The needle was punctured though the skin with an angle of 45-60 to the posterior of the vertebral via safe entry zone to the herniated site outside the intervertebral disc under the epidural space. The syringe was drawn back to confirm that no blood or cerebrospinal fluid was flowing out, Contrast agents were injected to make sure no flows out of the spinal canal. 600 unit collagenase was dissolved in 2ml normal saline and injected slowly with rate of 1ml per minute. The needle was removed and keep the dorsal elevated position for 6-8 hours. Keep away from load bear of lumbar for 3 months."
48359955|NCT05330806|PROCEDURE|Percutaneous endoscopic lumbar discectomy (PELD)|For L1-L4 segment, percutaneous endoscopic transforaminal discectomy(PETD) will be performed. An 1cm length incision was made at 8-14cm lateral of the paraspinous process, where a needle puncture to the superior articular process of the lower involved vertebrae of the herniated disc. A series of conical rods are to be introduced, subsequently a reamer is to be introduced through the cannula. After removal of the disc herniation, the cannula and endoscope are to be removed. For L5/S1 segment, percutaneous endoscopic interlaminar discectomy(PEID) was performed. An incision of nearly 7 mm was made at the entry point of the skin, and a series of expansion channels were sequentially inserted into the surface of the ligamentum flavum.Then, the ligamentum flavum and soft tissue around it were removed. Then, the tongue of the working cannula was inserted and rotated into the lateral nerve root. Removed the prominent nucleus pulposus by various nucleus pulposus forceps.
48359956|NCT02180035|DIETARY_SUPPLEMENT|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
48359957|NCT02180035|DIETARY_SUPPLEMENT|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
48359958|NCT02180035|BEHAVIORAL|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
48148447|NCT03337022|OTHER|Placebo|Placebo
48148448|NCT02876653|OTHER|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
48148449|NCT05911841|DRUG|LY3454738|Administered SC
48148450|NCT05911841|DRUG|Placebo|Administered SC
48148451|NCT04552457|BEHAVIORAL|No activity restrictions|"Patients in the No activity restrictions group will be allowed to return to their normal activity immediately."
48148452|NCT04552457|BEHAVIORAL|Activity restrictions|"Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it."
48148453|NCT00169923|DRUG|rosiglitazone|
48148454|NCT01543789|PROCEDURE|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
48148455|NCT01543789|PROCEDURE|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
48148456|NCT04214093|DRUG|AZD0466|"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."
48508701|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
48508702|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
48508703|NCT00160069|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
48508704|NCT06022900|BEHAVIORAL|Online training group|online health education with video call
48508705|NCT06022900|BEHAVIORAL|Face-to-face training group|Face-to-face health education with home visit
48359959|NCT04922814|DRUG|muscle relaxation|They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
48359960|NCT05007236|DRUG|RP7214 + Standard of care (SOC)|RP7214 tablets will be administered orally twice a day for 14 days
48359961|NCT05007236|DRUG|Placebo + Standard of care (SOC)|Placebo will be administered orally twice a for 14 days
48359962|NCT04506073|DRUG|Mesenchymal Stem Cells|1 dose is 10 X 10\^6 MSC/kg
48359963|NCT04506073|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
48359964|NCT00000894|DRUG|Cidofovir|
48359965|NCT00000894|DRUG|Probenecid|
48508706|NCT02329626|DEVICE|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study."
48508707|NCT06137625|BEHAVIORAL|With regular rhythm|All children learn one dance choreographie with regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
48508708|NCT06137625|BEHAVIORAL|Without regular rhythm|All children learn one dance choreographie without regular rhythm music.The pre-recorded choreography is displayed on a large screen in front of the child. The child practices the choreography by imitating the models in order to learn the sequence movements.
48508709|NCT00788138|DIETARY_SUPPLEMENT|Vitamin D3|250,000 IU of vitamin D3
47990894|NCT01139450|DRUG|0417|Topical 0417 test product applied twice daily for 4 weeks
48359966|NCT00000894|DRUG|Ganciclovir|
48359967|NCT02683031|OTHER|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
48359968|NCT06303362|OTHER|Elastic band excercise|experimenatal group was given elastic band excercises along with stretching (pectoralis major, minor, trapezius, rhomboids and neck flexors) and conventional therapy. Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
48508710|NCT00788138|DIETARY_SUPPLEMENT|Placebo|Matching Placebo
48508711|NCT01613313|DRUG|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
48508712|NCT04751071|DRUG|Roflumilast 500Mcg Tab|Roflumilast 500µg tablet once daily for 6 weeks plus the standard therapy
48508713|NCT04751071|DRUG|Placebo|Placebo tablet once daily for 6 weeks plus the standard therapy
48508714|NCT04302714|PROCEDURE|Hysteroscopic injection|Hysteroscopic injection
48508715|NCT04302714|PROCEDURE|Cervical injection|Cervical injection
48508716|NCT00447993|COMBINATION_PRODUCT|Low Dose NT-501|Low Dose NT-501 Implanted in study eye and fellow eye received sham surgery
48508717|NCT00447993|COMBINATION_PRODUCT|High Dose NT-501|High Dose NT-501 Implanted in study eye and fellow eye received sham surgery
48508718|NCT01727726|DRUG|Brexpiprazole|tablet/capsule
48508719|NCT01727726|DRUG|Seroquel XR|tablet/capsule
48508720|NCT01727726|DRUG|Placebo|tablet/capsule
48508721|NCT03179215|DIAGNOSTIC_TEST|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
48508722|NCT03295981|DRUG|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
48508723|NCT04895982|BIOLOGICAL|BNT162b2|Intramuscular Injection
48508724|NCT01839318|DEVICE|Nelfilcon A contact lenses|
48508725|NCT01839318|DEVICE|Omafilcon A contact lenses|
48508726|NCT01839318|DEVICE|Etafilcon A contact lenses|
48508727|NCT06522633|DRUG|The intervention involves the discontinuation of the opioid.|Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
48508728|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 1|Brain training games with physical exercise component.
48508729|NCT05169632|DEVICE|Computerized Gaming Rehabilitation Program 2|Cognitive training games with physical exercise component.
48508730|NCT01982448|DRUG|Cisplatin|
48508731|NCT01982448|DRUG|Paclitaxel|
47990895|NCT01139450|DRUG|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
47990896|NCT01139450|DRUG|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
47990897|NCT02522286|BEHAVIORAL|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
47990898|NCT02522286|BEHAVIORAL|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
48359969|NCT06303362|OTHER|strengthening with conventional physical therapy|control group was given strengthening excercises and stretching (pectoralis major, minor, trapezius, rhomboids (Sessions will be given 3 days in a week for a period of 4 weeks. The assessment was done at baseline, after 2 weeks and at the end of 4 weeks.
48359970|NCT04597424|DRUG|Experimental: doxycycline|"2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days."
48359971|NCT04597424|BIOLOGICAL|Bexsero® vaccine|1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
48672688|NCT05577026|BEHAVIORAL|General information on treatment guidelines|Written information on guidelines and recommendations regarding prescription of opioids.
48672689|NCT04118829|DRUG|Perampanel|"For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day."
48672690|NCT05247203|BIOLOGICAL|Telitacicept|subcutaneous injection
48672691|NCT05247203|DRUG|standard therapy|A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
47990899|NCT02708147|OTHER|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
47990900|NCT02708147|OTHER|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
47990901|NCT00159250|DRUG|AVI-4658 (PMO)|morpholino antisense oligonucleotide
48148457|NCT02111499|DRUG|LAS41004-IMP1|daily topical application
48359972|NCT03683238|DIETARY_SUPPLEMENT|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
48359973|NCT03696576|DEVICE|EMST|Training of the respiratory system muscles using the EMST device.
48359974|NCT03696576|BEHAVIORAL|PhoRTE|Completing of PhoRTE voice therapy.
48359975|NCT00606021|DRUG|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
48359976|NCT00606021|DRUG|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
48359977|NCT00001343|DRUG|Humatrope|
48359978|NCT00001343|DRUG|Oxandrolone|
48672692|NCT06305208|DEVICE|Endoscopic gastric suturing|Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
48672693|NCT06305208|DEVICE|Endoscopic gastric plication|Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
48672694|NCT06305208|DEVICE|Revisional gastroplasty|Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
48359979|NCT01072500|BEHAVIORAL|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
48672695|NCT06305208|DEVICE|Transoral outlet reduction endoscopy (TORe)|Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
48359980|NCT01072500|BEHAVIORAL|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
47990902|NCT06454461|DRUG|Upadacitinib 15 MG|Upadacinib 15mg once daily for the 8 weeks after NECS
48359981|NCT00779597|BEHAVIORAL|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
48672696|NCT06305208|DEVICE|Duodenal mucosal resurfacing (DMR)|Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
48672697|NCT06305208|DEVICE|Intragastric balloon(s)|The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
48672698|NCT05672914|BEHAVIORAL|Tablet-based sustained care|A tablet-based motivational-interviewing intervention, tailored specifically to smokers with psychiatric disorders, to motivate the use of evidence-based tobacco treatment and cessation in cigarette smokers upon discharge from an inpatient psychiatric hospitalization. In addition, participants will receive standard hospital tobacco care (see Usual Care Arm).
48672699|NCT03322163|OTHER|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
48672700|NCT04855175|DEVICE|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
48672701|NCT04855175|OTHER|Autograft|Patients in this arm will use patient's own bone
48672702|NCT01282866|DEVICE|LightSheer Duet|LightSheer Duet HS handpiece
47990903|NCT05657678|DRUG|Vitamin D3 - 750 000 IU|a single administration of 750,000 IU of vitamin D3
48508732|NCT06588842|OTHER|Cluster Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets and 15-second rests after repetitions three and six.
48672703|NCT01308840|DRUG|Panitumumab|Day 1 and 15 = 6 mg/kg IV
48672704|NCT01308840|DRUG|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
48672705|NCT01308840|DRUG|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
48672706|NCT03321071|BEHAVIORAL|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
48148458|NCT02111499|DRUG|LAS41004 IMP2|daily topical application
48508733|NCT06588842|OTHER|Traditional Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets.
48508734|NCT05460481|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
48508735|NCT00685776|DRUG|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
48508736|NCT00685776|DRUG|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
48508737|NCT06113302|DRUG|Luspatercept|Given by SC or (Injection)
48148459|NCT02111499|DRUG|LAS41004 IMP3|daily topical application
48148460|NCT02111499|DRUG|LAS41004 IMP4|daily topical application
48508738|NCT06249815|COMBINATION_PRODUCT|Misoprostol 200mcg Tab|ranscervical Foley catheter (silicone, size 20F with 30ml balloon)+Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
48508739|NCT06249815|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
48148461|NCT02111499|DRUG|LAS41004 IMP6|daily topical application
48148462|NCT02111499|DRUG|LAS41004 IMP5|once daily, topical
48148463|NCT05172648|OTHER|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
48148464|NCT05172648|OTHER|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
48148465|NCT03917186|DRUG|Sevoflurane|administration of sevoflurane
48148466|NCT03917186|DRUG|Desflurane|administration of Desflurane
48148467|NCT06604754|OTHER|Assigned Intervention for VR Training|In VR training patients use VR headsets to engage in virtual environments for 8 weeks where they perform exercises designed to enhance balance, coordination, and strength. Simultaneously, the VR platform incorporate pulmonary exercises that focus on improving breathing techniques, lung capacity, and overall respiratory health. Patients will engage in 3 sessions per week with total time duration of 45 to 60 minutes. VR-based training provides real-time feedback and adapts to the patient's progress, offering a comprehensive approach to rehabilitation that addresses both balance and pulmonary function in a motivating and controlled manner.
48508740|NCT05486481|DRUG|Venetoclax|Given orally (PO)
48508741|NCT05486481|DRUG|Dexamethasone|Given PO
48508742|NCT05486481|DRUG|Daratumumab|Given Subcutaneously (SC)
48508743|NCT05486481|DEVICE|Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay|Lab test
48508744|NCT01455298|OTHER|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
48508745|NCT00115830|DRUG|Atorvastatin|
48508746|NCT00115830|DRUG|Rosuvastatin|
48508747|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
48508748|NCT02197910|OTHER|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
48508749|NCT00912613|OTHER|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
48508750|NCT02794870|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
48508751|NCT02794870|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
48508752|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Single pill
48508753|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg|Signle pill
48508754|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg .|oral tablet
48508755|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg|oral tablet
48508756|NCT04518293|DRUG|Telmisartan 20 mg/indapamide 1.25 mg|oral tablet
48508757|NCT04518293|DRUG|telmisartan 40 mg/indapamide 2.5 mg|oral tablet
48508758|NCT04518293|DRUG|Amlodipine 2.5 mg/indapamide 1.25 mg|oral tablet
48508759|NCT04518293|DRUG|amlodipine 5 mg/indapamide 2.5 mg|oral tablet
48672707|NCT03321071|BEHAVIORAL|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
48672708|NCT00201279|DRUG|13-cis Retino Acid|
48672709|NCT04161534|DEVICE|KT Tape|in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
48672710|NCT04161534|DEVICE|Arm Sling|An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
48672711|NCT02217618|DRUG|LY2409021|
48672712|NCT03160625|DEVICE|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
48672713|NCT06174207|OTHER|Oxygen|Standard supplemental Oxygen therapy (5l/min) will be applied with an oxygen concentrator via nasal cannula.
48359982|NCT00413231|DEVICE|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
48359983|NCT00298766|DRUG|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
48508760|NCT03450252|DEVICE|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
48508761|NCT03450252|DEVICE|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
48508762|NCT00501098|DRUG|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
48508763|NCT02547090|PROCEDURE|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
48508764|NCT04914455|DIAGNOSTIC_TEST|Echocardiography and transhepatic inferior vena cava assessment using ultrasound.|"For all participant :~* Inferior vena cava diameter will be measure before and after fluid expansion 'which administration will be decided by a physician other that the investigator).~* Stroke volume using primarily VTI in TTE or a cardiac output monitoring device (Swan ganz catheter (Edwards life science), EV 1000 (edwards life science), PiCCO(Getinge))~* Absence of significant pericardial effusion of hematoma~Whenever possible:~Subcostal measurement of IVC, ejection fraction, cardiac outcput, mitral E, A and E' waves, TAPSE, tricupid S' wave, Right ventricle fractional area change.~venous congestion assesment : hepatic vein, portal vein and renal vein Doppler to define the VEXUS Score;"
48672714|NCT03338985|GENETIC|Genetic analysis|Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
48672715|NCT05407103|OTHER|Cold Acupressure|For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
48672716|NCT05407103|OTHER|Warm Acupressure|For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
48672717|NCT03348124|BEHAVIORAL|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
48672718|NCT06054399|OTHER|educational program|Education resources in Spanish through social media directed to the targeted audience mentioned above. There will be at least three interventions along the study, one for each pregnancy trimester, including topics such as: Migraine criteria, management strategies, risks of medication overuse, alarm symptoms, etc. These educational interventions will be conducted by trained health care professionals, mainly using audio-visual media.
48672719|NCT01356394|OTHER|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
48359984|NCT02624661|DRUG|Glycerol|
48508765|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
48508766|NCT04731363|DIETARY_SUPPLEMENT|erythritol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
48508767|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 5g|Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
48508768|NCT04731363|DIETARY_SUPPLEMENT|glucose, 30g|Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
48672720|NCT04420676|DIETARY_SUPPLEMENT|Omnibiotic AAD|Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate
48672721|NCT04420676|DIETARY_SUPPLEMENT|Placebo|matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.
48672722|NCT02170844|DRUG|BIBR 1048 MS|
48672723|NCT02170844|DRUG|Placebo of BIBR 1048 MS|
48672724|NCT03789981|GENETIC|Immunogenic profile|RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
48672725|NCT02361671|OTHER|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
48672726|NCT00389753|DRUG|Application of Aruba Aloë formula F-BC-096 or control|
48672727|NCT04074564|COMBINATION_PRODUCT|MASCT-I, Camrelizumab,Apatinib|"Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2."
48672728|NCT04103021|DEVICE|Port-A-Cath|Totally implanted central venous access device
48672729|NCT02329743|DRUG|RX-10045|topical therapy
48672730|NCT05595746|PROCEDURE|dental implant placement|In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
48672731|NCT05660603|OTHER|control|patients will receive standard general anesthesia
48672732|NCT05660603|PROCEDURE|LSP|patients will receive standard general anesthesia followed by ultrasound-guided combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.
48672733|NCT05660603|PROCEDURE|CP|patients will receive standard general anesthesia followed by ultrasound-guided circum-psoas blocks with 40 ml of bupivacaine 0.25%.
48672734|NCT05660603|DEVICE|Ultrasound|ultrasound
48672735|NCT03532022|DRUG|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
48672736|NCT03532022|DRUG|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
48672737|NCT03833141|OTHER|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
48672738|NCT01977365|BEHAVIORAL|Growth promotion based on child centered approach|"- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
48672739|NCT03729843|RADIATION|CBCT and intraoral digital radiography|Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
48359985|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
48359986|NCT00103935|DRUG|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
48672740|NCT02107534|BEHAVIORAL|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
48672741|NCT04468373|DEVICE|WA-NG (NG-IMT) Telescope Prothesis|The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
48672742|NCT01497834|DRUG|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
48672743|NCT01497834|DRUG|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
48672744|NCT04067232|DIAGNOSTIC_TEST|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
48672745|NCT02172729|DRUG|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
48359987|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
47990904|NCT05657678|DRUG|Vitamin D3 - 500 000 IU|a single administration of 500,000 IU of vitamin D3
48359988|NCT00103935|DRUG|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
48359989|NCT05978063|DRUG|difelikefalin 2.0 mg tablets|Oral difelikefalin 2.0 mg administered twice daily
48359990|NCT05978063|DRUG|difelikefalin 1.0 mg tablets|Oral difelikefalin 1.0 mg administered twice daily
48508769|NCT02505308|OTHER|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
48508770|NCT05308082|BEHAVIORAL|Dance Movement Therapy (DMT)|The main Dance Movement Therapy (DMT) methods were dance-movement improvisations, body awareness exercises, and reflection through drawing/painting, writing, and verbalization. There was an orientation to personal space and body awareness, interaction in pairs, and interaction in the whole group. The themes included exploration of boundaries, somatic resources, symbols, pleasant and unpleasant emotions, mindfulness, and body awareness, enriched movement experiences, and safety and touch. In the present study, it consists of six sessions, including (1) Movement for Self-expression, (2) Movement for Emotional Health I, (3) Movement for Emotional Health II, (4) Movement for Connection \& Creativity, (5) Embracing your Dancing Child, and (6) Movement for Self-compassion.
48148468|NCT06604754|OTHER|Assigned Intervention for Traditional Physical Therapy Training|In Traditional physical therapy balance training for patients with chronic obstructive pulmonary disease (COPD) involves exercises designed to improve stability, strength, and coordination for duration of 8 weeks. These exercises, such as static balance tasks, dynamic movement drills, and strength training, help address the balance deficits often seen in COPD patients due to muscle weakness and reduced physical activity. Additionally, pulmonary effects are managed through breathing exercises such as deep breathing and pursed lip breathing that enhance respiratory functions, improve lung capacity and efficiency.
48148469|NCT01437540|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
48148470|NCT01437540|DRUG|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
48148471|NCT05497167|OTHER|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
48148472|NCT04261309|OTHER|Usual care|Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
48508771|NCT05063032|OTHER|Radiofrecuency ablation|Radiofrequency ablation to treat left atrial flutter, guided by high-density mapping versus linear ablation.
48508772|NCT00625053|PROCEDURE|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
48148473|NCT05597215|RADIATION|Tc-99m MDP and gamma camera|Injection of radioactive element (Tc-99m MDP) then imaging with gamma camera and low dose CT (SPECT/CT)
48148474|NCT04739306|BIOLOGICAL|CT-P42|2mg/0.05 mL by Intravitreal injection
48672746|NCT01135472|DRUG|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
48672747|NCT03674892|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|Subject will place the tips of the ITN into both nostrils simultaneously. Subject will be asked to apply it for 3 minutes \[could be modified if need be\], daily.
48672748|NCT00014729|DRUG|isotretinoin|
47990905|NCT01103687|BIOLOGICAL|Ad26.ENVA.01 (rAd26)|5 x 10\^10 virus particles (VP) vaccine delivered intramuscularly (IM)
47990906|NCT01103687|BIOLOGICAL|Placebo Vaccine|Placebo vaccine delivered IM
47990907|NCT03043625|OTHER|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
47990908|NCT03043625|OTHER|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
48148475|NCT04739306|BIOLOGICAL|Eylea|2mg/0.05 mL by Intravitreal injection
48672749|NCT01152307|BEHAVIORAL|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
48672750|NCT00050583|BEHAVIORAL|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
48672751|NCT00050583|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
48672752|NCT00000134|DRUG|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
48672753|NCT00000134|DRUG|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
48672754|NCT00994903|DRUG|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
48672755|NCT00994903|DRUG|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
48672756|NCT00761345|DRUG|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
48672757|NCT00761345|DRUG|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
48672758|NCT00761345|RADIATION|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
48672759|NCT03419429|DRUG|Simvastatin|Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
48148476|NCT03222232|BEHAVIORAL|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
48508773|NCT00625053|PROCEDURE|Open midline incisional hernia repair|"* Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~* Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
48148477|NCT05778253|DIAGNOSTIC_TEST|WES and ctDNA detection|WES and ctDNA detection
48148478|NCT01890954|DEVICE|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
48148479|NCT03720249|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
48148480|NCT03720249|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
48148481|NCT03230084|DEVICE|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
48148482|NCT05272254|DRUG|10% povidone iodine + FV|applied to children's teeth
48508774|NCT02558348|DRUG|AL3818|Administered orally
48508775|NCT03547037|DRUG|JNJ-63723283|JNJ-63723283 will be administered intravenously.
48672760|NCT03419429|OTHER|EDTA|EDTA is a demineralizing agent used for root surface conditioning.
48672761|NCT03419429|DEVICE|Occlusive membrane|Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.
48672762|NCT03419429|DEVICE|Modified perforated membrane|Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
48672763|NCT05398016|BEHAVIORAL|low-intensity intervention for anxiety|Brief (4-6 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
48672764|NCT06229691|BEHAVIORAL|30 minute treadmill walk|"Participants will walk on a treadmill at their preferred speed for 30 minutes. One minute challenge periods will occur at minutes 7, 17, and 27, when the treadmill speed will increase by 50%. This walk will induce a magnitude of muscle fatigue corresponding to an individual participant's fatigability."
48672765|NCT02700438|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
48672766|NCT02700438|PROCEDURE|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
47990909|NCT04407312|DRUG|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
47990910|NCT04407312|DRUG|placebo|Placebo, tablet, 200mg, once daily, 30 days.
47990911|NCT04407312|DRUG|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
48148483|NCT05272254|OTHER|Placebo +FV|applied to children's teeth
48508776|NCT03547037|DRUG|Erdafitinib|Erdafitinib will be administered orally.
48508777|NCT06453252|OTHER|we are aiming to develop a Scoring system based on certain variables derived from both groups|We are aiming to develop a Scoring system based on certain variables derived from both group
48508778|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
48508779|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
48508780|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
48508781|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
48508782|NCT01160172|DRUG|Saline placebo|intramuscular vaccination according to protocol schedule
48672767|NCT03581175|PROCEDURE|Colonoscopy|
48672768|NCT03581175|DRUG|Bowel cleansing regimen|
47990912|NCT04407312|DRUG|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
47990913|NCT03395912|DRUG|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
47990914|NCT00441844|DRUG|Simvastatin|
47990915|NCT02248610|OTHER|Non-interventional study|
48148484|NCT06505525|PROCEDURE|Extra-articular reconstruction with the Anterolateral Ligament|Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
48148485|NCT02214095|DRUG|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
48148486|NCT02214095|DRUG|lactose capsules|
48148487|NCT05886465|DRUG|Atezolizumab|1200 mg, iv.drip, Q3W
48148488|NCT05886465|DRUG|Bevacizumab|15mg/kg, iv.drip, Q3W
48148489|NCT05886465|PROCEDURE|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
48148490|NCT02716272|DRUG|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
48148491|NCT02716272|DRUG|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
48148492|NCT00869609|BEHAVIORAL|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
48148493|NCT00869609|BEHAVIORAL|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
48148494|NCT00889473|DRUG|Larazotide acetate|gelatin capsule
48148495|NCT00889473|DRUG|Placebo|gelatin capsule
48148496|NCT00889473|DIETARY_SUPPLEMENT|Gluten 900 mg|gelatin capsule
48148497|NCT01517282|BIOLOGICAL|MOR103|Anti-GM-CSF monoclonal antibody
48508783|NCT01499459|GENETIC|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
48508784|NCT01121562|DRUG|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
48508785|NCT02988128|DEVICE|Treatment for intracranial aneurysms|Embolization of aneurysms
48508786|NCT02988128|DEVICE|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
48672769|NCT00755170|DRUG|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
48508787|NCT05520515|OTHER|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
48508788|NCT05520515|OTHER|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
48508789|NCT05520515|OTHER|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
48672770|NCT00755170|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
48672771|NCT06389058|OTHER|Recommendation for the diagnoses and treatment of Severe Asthma|No intervention planned in this phase for the patients. Recommendations to be developed for healthcare and condition.
48672772|NCT01911455|DRUG|acamprosate|
48672773|NCT01911455|DRUG|Placebo|
48672774|NCT02039011|DRUG|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
48672775|NCT02039011|DRUG|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
48672776|NCT02807701|PROCEDURE|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~1. dissection~2. reconstruction"
48672777|NCT02807701|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
48148498|NCT01517282|OTHER|Placebo|Placebo to anti-GM-CSF monoclonal antibody
48148499|NCT06093451|DRUG|Dexmedetomidine|Moderate agitation: 120 mcg Severe agitation: 180 mcg
48148500|NCT06093451|DRUG|Lorazepam 2 MG/ML|2 mg
48148501|NCT01263522|OTHER|different training programs|two different endurance programs and one strength endurance program
48148502|NCT01263522|OTHER|control condition|unchanged lifestyle
48148503|NCT05722925|DRUG|Fluciclovine PET/CT|8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
48359991|NCT05978063|DRUG|difelikefalin 0.25 mg tablets|Oral difelikefalin 0.25 mg administered twice daily
48359992|NCT05978063|DRUG|Placebo tablets|Oral Placebo administered twice daily
48359993|NCT00343161|DRUG|esomeprazole|
48508790|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
48148504|NCT00488605|DRUG|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
48148505|NCT00488605|DRUG|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
48148506|NCT00853957|DRUG|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
48148507|NCT00853957|DRUG|Amlodipine|Amlodipine 5 mg titrated to 10mg
48148508|NCT05746026|BEHAVIORAL|Psycho-educational Program|"This program consisted of five (5) sessions during two weeks.~* Session 1: introduction and basic information about Climate Change~* Session 2: causes and factors that contribute to climate change by humans and nature~* Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being.~* Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~* Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes (e.g. emotion management, problem solving, and cognitive reframing responses) that influence reactions to (and preparations for) adverse impacts of climate change, including chronic environmental conditions and extreme events."
48359994|NCT00343161|DRUG|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
48359995|NCT03552614|DEVICE|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
48508791|NCT02022748|DRUG|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
48508792|NCT02022748|DRUG|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
48672778|NCT01474967|DRUG|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
48672779|NCT01474967|DRUG|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
48508793|NCT04790708|RADIATION|Lutetium-177 (177Lu)-DOTATOC|5 cycles of 3,7 e 5,55 gigabequerel (GBq) of 177Lu-DOTATOC every 8-10 weeks. Cumulative activity: 18,5 e 27,75 GBq
48508794|NCT04790708|RADIATION|Yttrium-90 (90Y)-DOTATOC|5 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks. Cumulative activity: 9,25 e 13,875 GBq
48508795|NCT04790708|RADIATION|177Lu-DOTATOC + 90Y-DOTATOC|"3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC alternated with 2 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks.~Cumulative activity: 18,5 e 27,75 GBq of 177Lu-DOTATOC and 9,25 e 13,875 GBq of 90Y-DOTATOC"
48672780|NCT00537537|DRUG|Telbivudine|
48672781|NCT05390164|DIAGNOSTIC_TEST|skin biopsy|skin biopsy to be analyzed by ELISA
48672782|NCT06181981|DIAGNOSTIC_TEST|MRI fingerprinting|This method allows to get quantitative magnetic resonance imaging for the simultaneous measurement of multiple tissue properties in a single, time-efficient acquisition
48672783|NCT01631968|PROCEDURE|Cement without antibiotic.|
48672784|NCT01631968|PROCEDURE|Cement with erytromycin and colistin.|
48672785|NCT02885142|PROCEDURE|Local excision for early rectal cancer|
48672786|NCT01069913|DRUG|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation."
48672787|NCT02485015|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
48672788|NCT02485015|DRUG|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
48672789|NCT04602091|OTHER|no intervention|no intervention
48672790|NCT01234493|PROCEDURE|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
48672791|NCT01234493|PROCEDURE|no fixation|No syndesmosis fixation.
48148509|NCT02670161|DRUG|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
48508796|NCT04790708|RADIATION|Re-treatment 177Lu-DOTATOC|3 cycles of 3,7 e 5,55 GBq of 177Lu-DOTATOC every 8-10weeks. Cumulative activity: 11,1 e 16,65 GBq of 177Lu-DOTATOC
48508797|NCT04790708|RADIATION|Re-treatment 90Y-DOTATOC|3 cycles of 1,85 e 2,775 GBq of 90Y-DOTATOC every 8-10 weeks Cumulative activity: 5,55 e 8,325 GBq of 90Y-DOTATOC
48508798|NCT04355065|BEHAVIORAL|Cognitive Traning with The Secret Trail of Moon|Patients are pharmacologically stable and receive a cognitive intervention with our videogame once a week in the hospital.
48672792|NCT02837718|PROCEDURE|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
47990916|NCT02492347|PROCEDURE|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
47990917|NCT02594839|DRUG|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
48148510|NCT04842006|DRUG|Total neoadjuvant therapy (TNT)|Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
48148511|NCT04842006|DIAGNOSTIC_TEST|Minimal residual disease (MRD)|Postoperative MRD on circulating cell-free DNA
48148512|NCT04842006|RADIATION|Long radiation therapy|Long-course 50.4 Gy radiation with capecitabine
48148513|NCT05533788|DRUG|ABSK091 tablet|ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
48148514|NCT04023266|DRUG|Intravenous N-Acetylcysteine|Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
48148515|NCT02704637|DEVICE|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
48148516|NCT03220815|PROCEDURE|Drilling at low speed|
48508799|NCT04355065|BEHAVIORAL|Cognitive Traning with Therapeutic Chess|This group is pharmacologically stable. This group performs cognitive training through a therapeutic chess protocol designed by a chess psychologist. The training is done from home and we contact them weekly to correct the exercises done and to follow up.
48508800|NCT04355065|DRUG|Control Group|"These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group."
48508801|NCT01027195|DEVICE|Bipolar Radiofrequency (Aquamantys 6.0)|
48508802|NCT01027195|DEVICE|Standard Bovie Electrocautery|
48508803|NCT00103714|DRUG|denufosol tetrasodium (INS37217)|
48508804|NCT04252092|OTHER|Sensory training|15 session,20 minutes sensory training program
48672793|NCT00066326|DRUG|imatinib mesylate|
48672794|NCT00066326|DRUG|tanespimycin|
48672795|NCT03807583|DRUG|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
48148517|NCT03220815|PROCEDURE|Conventional drilling at high speed|
48148518|NCT05981209|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48508805|NCT04252092|OTHER|Electrical stimulation|15 session,20 minutes electrical stimulation program
47990918|NCT02594839|DRUG|Placebo|intravenous infusion of 400 mL saline
47990919|NCT02885961|DRUG|Dabigatran|Anti-coagulant
47990920|NCT02885961|RADIATION|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
47990921|NCT03642223|OTHER|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
47990922|NCT06250231|OTHER|No intervention|No intervention
47990923|NCT05831761|DRUG|Comparison of analgesic efficacy protocol|Comparison of 4 possible analgesic protocols
47990924|NCT02825927|OTHER|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
48148519|NCT05981209|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48148520|NCT05981209|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48508806|NCT04839692|DRUG|Hyaluronic acid filler|Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.
48508807|NCT00873457|DRUG|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
48508808|NCT05365724|BIOLOGICAL|Omicron COVID-19 Vaccine (Vero Cell), Inactivated|2 doses of vaccine according to the immunization schedule of 0, 21-28 days
48508809|NCT02837614|DRUG|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
48508810|NCT02837614|DRUG|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
48508811|NCT02837614|PROCEDURE|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
48508812|NCT02837614|DRUG|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
48508813|NCT02072304|BEHAVIORAL|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
48148521|NCT05981209|PROCEDURE|Computed Tomography|Undergo CT
48148522|NCT05981209|DRUG|Dexamethasone|Given IV or PO
48508814|NCT02072304|BEHAVIORAL|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
48148523|NCT05981209|PROCEDURE|Echocardiography|Undergo ECHO
48508815|NCT03195335|OTHER|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
48508816|NCT03086759|PROCEDURE|platelet rich plasm|intra-articular infiltration with platelet rich plasm
48508817|NCT03086759|DRUG|Triamcinolone Hexacetonide|intra-articular infiltration withTriamcinolone Hexacetonide
48508818|NCT03086759|PROCEDURE|Isotonic Saline Solution|intra-articular infiltration with Isotonic Saline Solution
48148524|NCT05981209|BIOLOGICAL|Elotuzumab|Given IV
48508819|NCT01774708|DEVICE|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
48508820|NCT04854044|DRUG|Akt/ERK Inhibitor ONC201|Given orally
48148525|NCT05981209|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48148526|NCT05981209|BIOLOGICAL|Mezigdomide|Given PO
48508821|NCT04854044|RADIATION|Radiation Therapy|Undergo radiation therapy
48508822|NCT04854044|PROCEDURE|Resection|Undergo surgical resection
48508823|NCT04058067|DRUG|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
48148527|NCT05981209|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
48148528|NCT06163157|OTHER|Connective tissue massage(CTM)|CTM will be applied by a trained physiotherapist for 3 days/week for 4 weeks. Application time will be approximately 15-20 minutes.
48148529|NCT03576118|DRUG|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
48148530|NCT03576118|DRUG|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
48148531|NCT06080945|OTHER|pharmacist-led patient-centered medication therapy management|The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
48148532|NCT06116656|DIAGNOSTIC_TEST|blood leucocyte transcriptomics|the analysis of the RNA transcripts produced by the genotype at a given time that provides a link between the genome, the proteome, and the cellular phenotype.
48148533|NCT01435720|BIOLOGICAL|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
48148534|NCT01435720|BIOLOGICAL|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
48148535|NCT01435720|BIOLOGICAL|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
48148536|NCT01435720|BIOLOGICAL|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
48508824|NCT04058067|DRUG|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
48508825|NCT02191761|DRUG|SM04755|Escalating Doses
48508826|NCT06011707|BEHAVIORAL|OPT-IN|Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).
47990925|NCT00005888|BEHAVIORAL|Fortified Pasteurized Donor Human Milk supplement|
48148537|NCT06406777|DIAGNOSTIC_TEST|Spirometry|Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.
47990926|NCT00005888|BEHAVIORAL|Preterm Formula supplement|
47990927|NCT00661076|DRUG|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
47990928|NCT00661076|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
47990929|NCT05109507|BEHAVIORAL|Visitor Mindset|Single-session, self-guided intervention
47990930|NCT05109507|BEHAVIORAL|Relaxing with Nature|Single-session, self-guided intervention
48508827|NCT06011707|OTHER|Psychoeducational control|This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
47990931|NCT06171776|DRUG|RetroMTA|calcium silicate lining material work as dentin substitute
47990932|NCT06171776|DRUG|TheraCal|calcium silicat material light cured
47990933|NCT06171776|DRUG|Fuji IX|filling material bonded chemically to the tooth structure
47990934|NCT06301711|BEHAVIORAL|Rehabilitation therapy|"The study lasted 10 days for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided."
47990935|NCT06301711|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
47990936|NCT06301711|DRUG|Lidocaine Hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48508828|NCT03976544|DRUG|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
48148538|NCT06406777|DIAGNOSTIC_TEST|Contrast Lung Computed Tomography (CT) Scan|CT scan of the lungs using contrast
48508829|NCT03976544|DRUG|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
48672796|NCT03807583|DIETARY_SUPPLEMENT|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
48672797|NCT00707993|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
47990937|NCT06208059|OTHER|manual acupuncture|In manual acupuncture, the scalp motor area on the lesion side will be needled and left in place for 30 minutes after obtaining qi. During the needle retention, the needles will be twisted intermittently for 2 minutes twice, at a frequency of approximately 200 r/min.
48148539|NCT06406777|DIAGNOSTIC_TEST|Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan|MRI will be taken while subject is lying on their back breathing 100% oxygen.
48148540|NCT06406777|DIAGNOSTIC_TEST|129Xe MRI scans|MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.
48148541|NCT00286832|PROCEDURE|PET scan|One extra PET scan after 1 cycle of treatment.
48148542|NCT06277206|DIAGNOSTIC_TEST|18F-FAPI PET/CT|Enrolled patients underwent 18F-FAPI PET/CT at diagnosis. And preoperative 18F-FAPI PET/CT was completed in the patients met the criteria for conversion surgery after systemic treatment. The correlation between changes of parameters before and after treatment and pathologic response was analyzed.
48148543|NCT03243838|DRUG|Apatinib|All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
48508830|NCT01874353|DRUG|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
48508831|NCT01874353|DRUG|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
48148544|NCT06121778|OTHER|Home|There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
48508832|NCT03515590|OTHER|Emulsion with solid droplets|This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
48508833|NCT03515590|OTHER|Emulsion with liquid droplets|This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
48508834|NCT06277232|OTHER|Nutrition care|Nutrition care is designed to include nutrition assessment (e.g., malnutrition screening, monitoring weight changes, etc.), optimization of individual dietary patterns, and evaluation. Through the Diet4painrelief platform, a dietician will follow up the progress of each participant in different timepoints and also plan meetings with other professionals in IPRP. A dietitian together with a physician in rehabilitation are responsible for the administration of the procedure.
48672798|NCT00707993|DRUG|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
48672799|NCT03392181|DRUG|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
48672800|NCT03454230|PROCEDURE|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
48672801|NCT04736472|DEVICE|Pharmacogenetic test|Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
48672802|NCT02668289|OTHER|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
47990938|NCT06208059|OTHER|electroacupuncture|In electroacupuncture, the scalp motor area will be needled, and after obtaining qi, the treatment will involve applying electroacupuncture stimulation using a continuous wave with a frequency of 2 Hz. The intensity of the stimulation will be adjusted based on the patient's tolerance, and each treatment session will last for 30 minutes.
47990939|NCT03016962|DEVICE|cap-assisted colonoscopy|cap-assisted colonoscopy
47990940|NCT03016962|DEVICE|Standard colonoscopy|Standard colonoscopy
47990941|NCT04466540|DRUG|Hydroxychloroquine|Hydroxychloroquine pharmaceutical form will be tablets of 400 mg.
47990942|NCT04466540|DRUG|Placebo|Hydroxychloroquine placebo
47990943|NCT02695745|DRUG|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
47990944|NCT02695745|DRUG|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
47990945|NCT02695745|DRUG|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
47990946|NCT02695745|DRUG|Capsaicin|1% administered topically
48148545|NCT04866563|DRUG|AX-8, Part 1 of the study|orally disintegrating tablets, BID
48148546|NCT04866563|DRUG|Placebo, Part 1 of the study|orally disintegrating tablets, BID
48148547|NCT04866563|DRUG|AX-8, Part 2 of the study|orally disintegrating tablets, TID
48148548|NCT04866563|DRUG|Placebo, Part 2 of the study|orally disintegrating tablets, TID
48148549|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
48359996|NCT03552614|OTHER|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
48359997|NCT06193733|BIOLOGICAL|Autologous Dendritic Cell|Biological: Immunotherapy with dendritic cells
48359998|NCT04239807|DEVICE|Group 1 GALILEO WBV|3 month home based WBV training
48359999|NCT04239807|OTHER|Group 2 Control|Training on the floor without WBV
48672803|NCT02668289|OTHER|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
48672804|NCT02668289|OTHER|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
48672805|NCT02668289|OTHER|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
48672806|NCT02668289|OTHER|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
48672807|NCT02668289|OTHER|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
47990947|NCT04251598|BEHAVIORAL|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
48360000|NCT03345875|DIAGNOSTIC_TEST|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
48360001|NCT01314885|DRUG|PF-03715455|20mg, Inhaled, single dose
48360002|NCT01314885|DRUG|PH-797804|30mg, Oral, single dose
48360003|NCT01314885|DRUG|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
48360004|NCT01314885|DRUG|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
48360005|NCT05371249|DRUG|Vonoprazan-based triple therapy|vonoprazan 20mg+amoxicillin 1000 mg + clarithromycin 500 mg twice daily for seven days
48360006|NCT05371249|DRUG|Extended sequential therapy|Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
48360007|NCT06037499|DIAGNOSTIC_TEST|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
48360008|NCT05709470|OTHER|No-intervention|Observational cross-sectional study design with no intervention
48360009|NCT03163121|BIOLOGICAL|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
48360010|NCT03163121|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
48360011|NCT03163121|OTHER|Normal Saline|0.9% sodium chloride
48360012|NCT03163121|BIOLOGICAL|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
48672808|NCT02668289|OTHER|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
48672809|NCT02668289|PROCEDURE|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
48672810|NCT02668289|OTHER|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
48672811|NCT00346619|DRUG|Nelfinavir|
48508835|NCT06277232|BEHAVIORAL|Dialogue and education (part of Interdisciplinary Pain Rehabilitation Program)|Dialogue and education consists of patient education, training in wellness and healthy living habits, meetings with families, video feedback, and couples therapy and self-training (e.g., home lessons, activity diary, physical self-training, reflection time, and self-analysis. . In addition, lectures in basic pain science and pain management are offered for both patients as well as for relatives, friends, and colleagues.
48508836|NCT06277232|BEHAVIORAL|activity training (part of Interdisciplinary Pain Rehabilitation Program)|Activity training includes graded activity training, and exposure training, which are delivered by an interdisciplinary team (i.e., a physiotherapist, an occupational therapist, and a psychologist).
48148550|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
48672812|NCT03092479|BEHAVIORAL|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
48148551|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
47990948|NCT04251598|BEHAVIORAL|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
47990949|NCT01951339|DRUG|Sitagliptin|100 mg sitagliptin
47990950|NCT01951339|DRUG|Glimepiride|"Active Comparator~2mg glimepiride"
48672813|NCT06006871|BEHAVIORAL|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|Patients are pharmacologically stable and receive a cognitive intervention with our videogame twice a week in the hospital (10 sessions) and twice a week in their home with a computer video game (other 10 sessions).
48672814|NCT06006871|DRUG|Usual treatment for ADHD|All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
48148552|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
48148553|NCT00245505|DRUG|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
48508837|NCT06277232|BEHAVIORAL|meetings (part of Interdisciplinary Pain Rehabilitation Program)|The meetings consist of conferences with patients, rehabilitation team, vocational guidance, rehabilitation coordinator, goal-setting meetings, and meetings to check goal achievement.
48508838|NCT06277232|BEHAVIORAL|Cognitive behavioral therapy (part of Interdisciplinary Pain Rehabilitation Program)|Acceptance and Commitment Therapy (ACT, e.g., goal compass, training in ACT principles, and mindfulness) is mainly delivered by psychologist in a group-treatment (e.g., training in coping strategies). The cognitive behavioral principles are also used in physiotherapy, ergonomics, and education in pain management.
48508839|NCT06277232|BEHAVIORAL|Relaxation techniques (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist and psychologist in an interdisciplinary team.
48508840|NCT06277232|BEHAVIORAL|Physical exercise (part of Interdisciplinary Pain Rehabilitation Program)|This group-treatment is mainly format by a physiotherapist in an interdisciplinary team.
48672815|NCT04781348|PROCEDURE|Platelet Rich Plasma plus fat grafting|The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
48148554|NCT00546884|BEHAVIORAL|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
48148555|NCT00546884|BEHAVIORAL|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
48148556|NCT01728090|OTHER|hand sanitizer|alcohol-based, hydroalcoholic gel
47990951|NCT01951339|DRUG|Placebo|2 mg placebo once daily
47990952|NCT01951339|DRUG|Placebo|100 mg placebo once daily for three months
47990953|NCT01225575|DRUG|co.don chondrosphere®|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect"
47990954|NCT01952756|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
47990955|NCT01952756|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
48508841|NCT04312672|BIOLOGICAL|AAV5-hRKp.RPGR|Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.
48508842|NCT06421077|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular vagal nerve stimulation
48508843|NCT03704415|PROCEDURE|Extended endoscopic sinus surgery|ESS of all sinuses
48672816|NCT00003614|DRUG|estramustine phosphate sodium|
48672817|NCT00003614|DRUG|paclitaxel|
48672818|NCT00051714|BEHAVIORAL|Family-Based Preventive Intervention|
48148557|NCT03064906|DEVICE|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
48148558|NCT02282215|BIOLOGICAL|CLT-008|Single intravenous infusion
48148559|NCT02282215|BIOLOGICAL|G-CSF|Daily subcutaneous injections
48148560|NCT06519448|DRUG|Empagliflozin 10 miligrams (mg)|Use of empagliflozin 10 mg daily for 12 months.
48148561|NCT02391766|BEHAVIORAL|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
48148562|NCT02391766|BEHAVIORAL|usual care|
48148563|NCT04728282|PROCEDURE|RTSA with subscapularis repair|Lateralized reverse total shoulder arthroplasty with repair of subscapularis
48148564|NCT04728282|PROCEDURE|RTSA without subscapularis repair|Lateralized reverse total shoulder arthroplasty without repair of subscapularis
48148565|NCT02374372|DEVICE|conventional hemodialysis|
48148566|NCT02374372|DEVICE|hemodiafiltration On-line|
48672819|NCT01727934|DRUG|Miravirsen sodium|Subcutaneous injection
48360013|NCT02434250|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
48360014|NCT04923958|DIAGNOSTIC_TEST|Novel mycobacterial culture techniques|We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
48360015|NCT04923958|DIAGNOSTIC_TEST|Novel sputum smear microscopy techniques|We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
48360016|NCT04923958|DIAGNOSTIC_TEST|Sputum-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
48360017|NCT04923958|DIAGNOSTIC_TEST|Tongue swab-based molecular assays|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
47990956|NCT03927612|DEVICE|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
48360018|NCT04923958|DIAGNOSTIC_TEST|Urine LAM assays|We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
48360019|NCT04923958|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
48360020|NCT04923958|DIAGNOSTIC_TEST|Breath-based assays|We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
47990957|NCT03927612|DEVICE|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
47990958|NCT05855668|BEHAVIORAL|CBT|12 weeks of group CBT for AUD or CUD
47990959|NCT02067299|DRUG|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
47990960|NCT02067299|OTHER|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
47990961|NCT03741660|DIETARY_SUPPLEMENT|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ \[100kcal\] of glucommanan)
47990962|NCT03741660|DIETARY_SUPPLEMENT|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
47990963|NCT02590939|DEVICE|CEFALY Active|Active external trigeminal nerve stimulation
47990964|NCT02590939|DEVICE|CEFALY Placebo|Placebo external trigeminal nerve stimulation
47990965|NCT02662881|DEVICE|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
48148567|NCT03466775|DIAGNOSTIC_TEST|Anti-angiotensin II type 1 receptor antibody measurement|Anti-angiotensin II type 1 receptor antibodies are assessed using quantitative ELISA in stored serum samples obtained within the first year after transplantation
48148568|NCT03466775|DIAGNOSTIC_TEST|Measurement of ENDAT expression level allograft|Endothelial-associated transcript expression level is assessed using microarray in stored kidney allograft biopsies obtained within the first year after transplantation
48148569|NCT03466775|OTHER|Allograft survival|
48148570|NCT03466775|OTHER|Allograft rejection appearance|
48148571|NCT00239642|DRUG|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
48360021|NCT04923958|DIAGNOSTIC_TEST|Artificial intelligence-based digital health tools|We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
48360022|NCT04923958|DIAGNOSTIC_TEST|Phage-based assays|We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
48672820|NCT04780139|DIAGNOSTIC_TEST|Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area|Measuring the internal jugular vein cross section area and relate this to the incidence of hypotension after spinal anesthesia.
48672821|NCT05017064|DEVICE|Cryotherapy group|The use of intraoral ice pack during root canal treatment
48672822|NCT05017064|OTHER|Control group|No cryotherapy will be used
48672823|NCT03314610|OTHER|Gait speed|No intervention, only propose water and wait for need to void
48672824|NCT03445312|BEHAVIORAL|not processing urine cultures|microbiology lab will not process culture unless called
48672825|NCT05930080|DRUG|SKCPT|the randomly assigned subjects took the study drug for 12 weeks
48148572|NCT00239642|DRUG|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
48672826|NCT05930080|DRUG|Celebrex|the randomly assigned subjects took the study drug for 12 weeks
48672827|NCT01497197|DRUG|GONAL-f®|GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.
48672828|NCT01497197|DRUG|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
48672829|NCT01497197|BIOLOGICAL|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
48508844|NCT03704415|PROCEDURE|Limited endoscopic sinus surgery|Partial ethmoidectomy
48672830|NCT05045716|DRUG|Lecanemab|Lecanemab IV infusion.
48672831|NCT05045716|DRUG|Lecanemab|Lecanemab SC injection.
48672832|NCT04388007|OTHER|Thoracic spinal manipulation|High velocity, low amplitude force manipulation
47990966|NCT02662881|DEVICE|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
48672833|NCT02169648|DRUG|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
47990967|NCT01785979|DRUG|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
47990968|NCT01785979|DRUG|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
47990969|NCT04426331|BEHAVIORAL|Voucher Without Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free."
48148573|NCT00239642|DRUG|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
48148574|NCT00003049|DRUG|fluorouracil|
48148575|NCT00003049|DRUG|leucovorin calcium|
48148576|NCT00003049|PROCEDURE|conventional surgery|
48148577|NCT00003049|RADIATION|radiation therapy|
48148578|NCT03037827|PROCEDURE|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
48148579|NCT03037827|DEVICE|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
48148581|NCT00423215|DRUG|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
48148582|NCT00490906|DRUG|Copaxone|20 mg, subcutaneous injections, taken daily
48148583|NCT00490906|DRUG|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
48508845|NCT03093116|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
48672834|NCT01679483|DRUG|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
48672835|NCT03131908|DRUG|GSK2636771|"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."
48672836|NCT03131908|DRUG|Pembrolizumab|Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
48672837|NCT03606291|RADIATION|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
48672838|NCT02255929|RADIATION|Gamma Knife Radiosurgery|
48672839|NCT00159926|PROCEDURE|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
48672840|NCT00159926|PROCEDURE|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
48672841|NCT05713461|BEHAVIORAL|exercise training program|"Adapted Interval Training Intervention, three days a week, 10 weeks.~Warm-up 10': Joint mobility and cardiovascular activation~Main part:~Resistance training circuit for strengthening the main muscle groups.~Cool down Flexibility and CORE"
48148584|NCT00490906|DRUG|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
48672842|NCT05713461|BEHAVIORAL|Feeding training|Two workshops on healthy eating habits (Week 1 and week 5). Food Frequency Questionnaires (weekly). Feedback weekly. Mediterranean Diet Adherence Screener (MEDAS). The dietary intervention will be based on the nutritional recommendations based on the Mediterranean diet, according to the evidence from the PREDIMED trial.
48672843|NCT01385150|GENETIC|mutation analysis|
48672844|NCT01385150|GENETIC|protein analysis|
48672845|NCT01385150|OTHER|laboratory biomarker analysis|
48672846|NCT01385150|OTHER|liquid chromatography|
48672847|NCT01385150|OTHER|mass spectrometry|
48148585|NCT02936609|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
48148586|NCT00106405|DRUG|Memantine HCl|
48148587|NCT04371406|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
48148588|NCT04371406|DIETARY_SUPPLEMENT|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
48360023|NCT04923958|DIAGNOSTIC_TEST|Cartridge-based molecular assays for detecting drug resistance|We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
48672848|NCT03567707|BIOLOGICAL|C-section -Vaginal seeding|Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding.
48672849|NCT03567707|DRUG|C-section - Placebo Seeding|Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.
48672850|NCT03567707|OTHER|standard care|Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
48672851|NCT03980639|DRUG|patient treated with DMARD|Case report of cancer overall
48672852|NCT00017043|DRUG|ixabepilone|
48672853|NCT00268281|DEVICE|Left Ventricular Capture Management Software|
48672854|NCT01384318|OTHER|Manometer|Measuring cuff pressure
48672855|NCT00795028|OTHER|Standard Care for people after hip fracture|
48672856|NCT00795028|OTHER|Standard Care + exercise intervention|
48672857|NCT04255615|OTHER|AI to analyze 3 D ultrasound|AI to assess 3 D ultrasound to assess antral follicle count
48672858|NCT00981903|DRUG|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
48672859|NCT02405988|DRUG|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
48672860|NCT02405988|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
48672861|NCT02319486|DRUG|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
48672862|NCT02319486|DRUG|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
48672863|NCT06191484|BEHAVIORAL|WELL Behavioral Probe|Participant record the timing and regularity of sleep, meals, and social activity twice daily, for 3 months, using a digital diary. Participants also receive weekly motivational health coaching.
48672864|NCT03816189|DIAGNOSTIC_TEST|Blood test|Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
48148589|NCT05285592|OTHER|Fecal Transplantation|Fecal Transplantation
48148590|NCT05285592|DRUG|Standard Medical Treatment|Standard Medical Treatment
48360024|NCT04923958|DIAGNOSTIC_TEST|Sequencing-based assays for detecting drug resistance|We will evaluate targeted and whole genome sequencing assays.
48360025|NCT02200510|BEHAVIORAL|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
48360026|NCT02200510|BEHAVIORAL|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
48360027|NCT05119998|DRUG|IBI325 + sintilimab|IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation
48360028|NCT05119998|DRUG|IBI325|IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation
48148591|NCT05291403|OTHER|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
48148592|NCT05291403|OTHER|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
48148593|NCT05291403|OTHER|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
48148594|NCT00185692|PROCEDURE|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
48148595|NCT00185692|DRUG|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
48148596|NCT00185692|DRUG|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
48148597|NCT00185692|DRUG|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
48148598|NCT00185692|DRUG|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
48148599|NCT00185692|DRUG|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
48148600|NCT00185692|DRUG|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
48148601|NCT00185692|DRUG|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
48148602|NCT00185692|DRUG|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
48672865|NCT03816189|DIAGNOSTIC_TEST|Skin biopsies|In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
48672866|NCT03345303|DRUG|Bortezomib|Bortezomib Injectable Solution
48672867|NCT00144326|DRUG|Tiotropium Bromide|
48672868|NCT00144326|DRUG|Placebo|
47990970|NCT04426331|BEHAVIORAL|Voucher With Value Information|"Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free."
47990971|NCT02612935|DEVICE|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
48672869|NCT01653444|DRUG|GC1119|biweekly, IV infusion
47990972|NCT03554226|BEHAVIORAL|NeuroPsychiatric Inventory Clinician (NPI-C)|All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
47990973|NCT02092662|OTHER|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
47990974|NCT02092662|OTHER|Healthy controls|no treatment
47990975|NCT03407573|BIOLOGICAL|Administration of Red Cell|Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
48148603|NCT00870168|DRUG|chemotherapy|
48148604|NCT00870168|GENETIC|gene expression analysis|
48148605|NCT00870168|OTHER|laboratory biomarker analysis|
48148606|NCT00870168|PROCEDURE|breast biopsy|
48148607|NCT04362618|OTHER|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
48360029|NCT02733887|DEVICE|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
48148608|NCT04362618|BEHAVIORAL|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
48148609|NCT05242874|DRUG|Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.
48508846|NCT03218488|DRUG|Ustekinumab|Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.
48508847|NCT03268707|DEVICE|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
48508848|NCT03268707|OTHER|Conventional follow up|Conventional follow up at physician practice
48508849|NCT05184543|OTHER|Routine Exercise Program|8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
48148610|NCT05242874|DRUG|Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.
48148611|NCT04434872|PROCEDURE|Colonoscopy|Fecal microbiota transplantation through colonoscopy
48148612|NCT04434872|PROCEDURE|Gastroscopy|Fecal microbiota transplantation through gastroscopy
48148613|NCT04434872|DRUG|Fecal Microbiota|
48148614|NCT04434872|PROCEDURE|Enema|Fecal microbiota transplantation through enema
48148615|NCT06051721|DRUG|CYB004|CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
48148616|NCT06051721|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
48148617|NCT06288685|PROCEDURE|percutaneous A1 pulley release|Treatment trigger finger by release A1 pulley by percutaneous procedure
48148618|NCT06288685|DRUG|Triamcinolone|Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release
48148619|NCT03213587|DRUG|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
48508850|NCT05184543|OTHER|Core Stability Exercise Program|In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
48508851|NCT05184543|OTHER|Body Weight Neuromuscular Warm-Up Program|Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
48672870|NCT06201728|OTHER|Follow-up in a flare-up clinic|Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
48360030|NCT02733887|DEVICE|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
48360031|NCT02733887|RADIATION|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
47990976|NCT03717480|DEVICE|ClinicMACs|The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
47990977|NCT04919356|GENETIC|G2019S LRRK2|No cost genetic testing for G2019S LRRK2
47990978|NCT04608786|DRUG|ZKAB001 5mg/kg|ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
47990979|NCT04608786|DRUG|Capecitabine|Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
48508852|NCT01269931|PROCEDURE|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
48508853|NCT03086382|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
47990980|NCT04418986|PROCEDURE|opposite clear corneal incisions (OCCI)|"Coaxial small incision cataract surgery was performed for all cases using a 2.8 mm keratome placed at steep meridian and 1-mm paracentesis was made 90 degrees apart with a 20-gauge microvitrectomy blade. Surgery was performed with a 30-degree, 0.9-caliper phacoemulsification tip (microtip) with a divide and conquer technique.~In the OCCI group, a single penetrating incision was created with 2.8 mm keratome in the clear cornea, 1.5 mm anterior to limbal blood vessels, centered over the steep meridian and opposite the phacoemulsification incision."
48508854|NCT03086382|DRUG|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
48508855|NCT04307576|DRUG|Omitted Doxorubicin|Omission of IV Doxorubicin
48508856|NCT04307576|DRUG|Omitted Vincristine+Dexamethasone pulses|Omission of Vincristine+Dexamethasone pulses
47990981|NCT00048295|DRUG|Alicaforsen|
48672871|NCT02443701|OTHER|Exercise|Warmup program, maximum isometric strengthening, and jump training
47990982|NCT02024620|BEHAVIORAL|Behavioral activation plus mobile app|
48148620|NCT01144533|PROCEDURE|isotonic saline injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* isotonic saline 4ml + telebrix(contrast media) 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
48148621|NCT01144533|PROCEDURE|steroid injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
48360032|NCT03824704|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
48508857|NCT04307576|DRUG|Inotuzumab Ozogamicin+Standard Maintenance Therapy|Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
48508858|NCT04307576|DRUG|Imatinib|p.o. Imatinib
48508859|NCT04307576|DRUG|6-tioguanine+Standard Maintenance Therapy|Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
48508860|NCT04307576|DRUG|Blinatumomab|IV Blinatumomab
48508861|NCT02593110|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
48508862|NCT02593110|DRUG|Telmisartan|Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
48672872|NCT02443701|OTHER|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
47990983|NCT02024620|BEHAVIORAL|Standard behavioral activation|
48508863|NCT02593110|OTHER|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
48672873|NCT02443701|OTHER|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
48508864|NCT02593110|DRUG|Placebo|
47990984|NCT00148889|DEVICE|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
47990985|NCT03210610|DIAGNOSTIC_TEST|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
47990986|NCT04592029|DRUG|TACE combined with sintilimab and bevacizumab|Sintilimab and bevacizumab are administered at 3-7 days after the first TACE. The study includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then, Sintilimab 200mg/kg IV. q3w+ select specific dose of bevacizumab (7.5mg/kg or 15 mg/kg IV. q3w), expand to 36-39 patients for the further safety and efficacy study. The study treatment of sintilimab and bevacizumab lasts up to 24 months. TACE can be repeated when indicated clinically.
47990987|NCT01288911|DRUG|enzalutamide|capsules
47990988|NCT01288911|DRUG|bicalutamide|tablets
47990989|NCT02773927|DRUG|Metformin|Metformin in tablet presentation of 500 mg
47990990|NCT02773927|DIETARY_SUPPLEMENT|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
47990991|NCT02773927|OTHER|Placebo of agave inulin|Calcinated magnesia powder
47990992|NCT02773927|OTHER|Metformin placebo|Calcinated magnesia tablet
47990993|NCT05161598|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
48672874|NCT06351826|OTHER|ELLASI|A structured intervention for polytrauma patients
48508865|NCT05353387|OTHER|Motivational Interviewing|Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
48508866|NCT06634147|BEHAVIORAL|Exercise|"Multicomponent individualized exercise intervention As mentioned earlier, patients in the control group (G0) will receive the usual care currently provided to other patients, which includes a referral to physical therapy if needed.~The intervention for the multicomponent physical exercise intervention group (G1) will consist of a multicomponent physical training program that includes progressive and supervised aerobic endurance, strength, and balance training lasting 4-7 days during their hospitalization. This will be supervised by the research team from the Geriatrics Unit. Additionally, after hospital discharge, they will receive individualized guidelines to engage in multicomponent physical exercise for 3 months, along with individualized recommendations from the Nutrition and Dietetics Service of HUN.~The multicomponent physical training program will consist of chair squat exercises. The main part of the training will utilize machines for strength training for the lower extremit"
48508867|NCT04648202|DRUG|FS120|Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
48508868|NCT03451552|BEHAVIORAL|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
48508869|NCT03744429|OTHER|Mediterranean Diet|Participants will be provided with meals that follow a Mediterranean meal plan.
48508870|NCT02455518|DRUG|Oxycodone/acetaminophen|
48508871|NCT02455518|DRUG|Hydrocodone/acetaminophen|
48508872|NCT02455518|DRUG|Codeine/acetaminophen|
48148622|NCT01144533|PROCEDURE|sodium hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
48360033|NCT03824704|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
48672875|NCT06351826|OTHER|Standard|Unstructured interventions that are given in everyday practice (standard intervention)
48672876|NCT02194790|BEHAVIORAL|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
48508873|NCT02455518|DRUG|Ibuprofen/acetaminophen|
48508874|NCT00782405|DRUG|quetiapine|XR, 150-300mg
48508875|NCT00782405|DRUG|mirtazapine|30-45 mg
48508876|NCT00541879|BEHAVIORAL|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
48508877|NCT00541879|OTHER|comparison|
48508878|NCT04138823|DRUG|BI 891065|film-coated tablets
48508879|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
48508880|NCT02851693|DEVICE|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
48508881|NCT04521127|OTHER|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
48508882|NCT04521127|OTHER|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 \* 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
48508883|NCT02722915|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
48672877|NCT05857566|DRUG|RDX-002|A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
48672878|NCT00805584|DRUG|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
48360034|NCT01279954|DRUG|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
48148623|NCT01144533|PROCEDURE|steroid and hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
48672879|NCT01428219|DRUG|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
48508884|NCT02722915|BEHAVIORAL|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 \& 4; controls without AVH: Days 2 \& 3)
48148624|NCT00644501|DRUG|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
48508885|NCT02722915|OTHER|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
48508886|NCT02722915|OTHER|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
48672880|NCT03988426|BIOLOGICAL|Octanorm|Octanorm
48672881|NCT01929200|DRUG|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
48148625|NCT01505309|DEVICE|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
48148626|NCT04985903|BEHAVIORAL|Clinician Communication Intervention|The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
48148627|NCT04985903|OTHER|5A's lecture|a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
48508887|NCT02722915|OTHER|SF36|questionnaire about life quality after 1 week during a telephone interview
48508888|NCT06632223|OTHER|Sensory motor training|Each session will be composed of 10 minutes of warm-up, followed by 50-60 minutes of sensory motor exercises, followed by 5-10 minutes of cool down.
48672882|NCT01929200|DRUG|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
48508889|NCT06632223|OTHER|Traditional physical therapy|traditional physical therapy program in form of stretching exercises, strengthening exercises, scar management, and gait training
48508890|NCT03712878|RADIATION|Total-Body Irradiation|Undergo TBI
48148628|NCT05659836|DEVICE|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
48508891|NCT03712878|PROCEDURE|Donor Lymphocyte Infusion|Given IV
48508892|NCT03712878|DRUG|Cyclophosphamide|Given IV
48508893|NCT03712878|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
48508894|NCT03712878|DRUG|Tacrolimus|Given IV
48508895|NCT03712878|DRUG|Mycophenolate Mofetil|Given IV
48508896|NCT03876262|DRUG|Moxidectin|2mg tablets, encapsulated for blinding
48508897|NCT03876262|DRUG|Ivermectin|3mg tablets, encapsulated for blinding
48508898|NCT04077190|DEVICE|Adipose-derived stem cells|5cc adipose derived stem cells.
47990994|NCT04923204|DIAGNOSTIC_TEST|Pharmacogenomic-testing with NEUROPHARMAGEN|"This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information."
47990995|NCT05267652|OTHER|Preoxygenation with Non-Invasive Positive Pressure Ventilation|The delivery of oxygen and ventilation by non-invasive mechanical ventilation via a tight-fitting mask from the initiation of preoxygenation until the initiation of laryngoscopy. Trial protocol will not dictate the brand or type of mechanical ventilator that will be used to deliver non-invasive ventilation.
47990996|NCT05267652|OTHER|Facemask Oxygen|The delivery of supplemental oxygen via a non-rebreather mask or bag-mask device without manual ventilation from the initiation of preoxygenation until induction. Trial protocol will not dictate the brand or type of facemask. The decision between use of a non-rebreather mask and use of a bag-mask device will be made by treating clinicians. The decision of whether to provide manual ventilation with a bag-mask device between induction and laryngoscopy will be made by treating clinicians.
47990997|NCT06210490|DRUG|Disitamab Vedotin|Disitamab vedotin (RC48-ADC) is a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E via a cleavable linker. Two phase II studies, RC48-C005 (NCT03507166) and RC48-C009 (NCT03809013), have shown its significant antitumor potential in patients with la/mUC with HER2 overexpression (immunohistochemistry (IHC) 3+ or 2+). In 2022, RC48-ADC was approved for patients with HER2 overexpressing la/mUC who had received prior chemotherapy in China.
48148629|NCT01780272|OTHER|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
48148630|NCT01381549|DRUG|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
47990998|NCT06210490|RADIATION|Radiotherapy|Radiotherapy dose: 45-50 Gy/25f/5w to lymph node drainage area; 62.5 Gy/25f/5w to metastatic or suspected metastatic lymph nodes.
47990999|NCT06210490|OTHER|Standard of Care|Standard of Care
48508899|NCT04077190|DEVICE|cortisone injection|cortisone injection
48508900|NCT03706937|OTHER|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
48508901|NCT01324505|DRUG|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
48508902|NCT01324505|DRUG|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
47991000|NCT05478447|PROCEDURE|Vibration|whole-body vibration, and tendon vibrations will be applied to the human body
47991001|NCT04324060|DRUG|Danazol + rhTPO (recombinant human thrombopoietin injection)|subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased \>50×10e9/L, total course is 6 months
47991002|NCT04324060|DRUG|Danazol + sodium chloride|Danazol 0.2g tid po+ control (sodium chloride)
47991003|NCT02751515|OTHER|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
48508903|NCT01324505|DRUG|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
48508904|NCT04234932|DRUG|Netarsudil Ophthalmic|Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)
48508905|NCT05478577|OTHER|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
48508906|NCT01692366|DRUG|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
48508907|NCT04808310|DEVICE|Quantitative flow ratio|Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)
48148631|NCT01381549|DRUG|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
48148632|NCT01381549|OTHER|Placebo|saline placebo
48148633|NCT02315209|DEVICE|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
48148634|NCT06165497|BEHAVIORAL|Meditation practices|Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
48148635|NCT06165497|OTHER|Internet-as-usual|Participants will be instructed to use the internet as they typically do.
48148636|NCT00337246|BIOLOGICAL|rituximab|
48148637|NCT00337246|DRUG|cyclophosphamide|
48148638|NCT00337246|DRUG|fludarabine phosphate|
48508908|NCT04808310|DIAGNOSTIC_TEST|Assessment of angiographic severity of the stenosis|The indication to coronary stent intervention will be based on angiography
48672883|NCT01819272|DRUG|Met DR|metformin delayed-release tablets
48672884|NCT01819272|DRUG|Met XR|metformin extended-release tablets
48148639|NCT00337246|DRUG|mitoxantrone hydrochloride|
48148640|NCT02875730|PROCEDURE|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
48672885|NCT01819272|DRUG|Placebo|placebo delayed-release tablets
48148641|NCT02875730|PROCEDURE|CMRI|Cardiac Magnetic Resonance Imaging
48148642|NCT05771272|DIAGNOSTIC_TEST|Sit and Reach Test|To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
48508909|NCT00737763|DRUG|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
48508910|NCT00737763|DRUG|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
48508911|NCT05977036|DEVICE|DiviTum® TKa assay|Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
48148643|NCT05771272|DIAGNOSTIC_TEST|Weight Bearing Lunge Test|To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
47991004|NCT02751515|OTHER|Untreated skin|One site is patched without treatment as control
48148644|NCT02979678|OTHER|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
48148645|NCT03855514|OTHER|NuShield|NuShield® is a dehydrated placental allograft.
48508912|NCT05977036|DRUG|CDK4/6 + Endocrine therapy|FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
48508913|NCT03713632|DRUG|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
48508914|NCT03713632|DRUG|Placebo|Placebo 300mg every 2 or every 4 weeks
48508915|NCT05323279|DEVICE|artificial intelligence assistance system|The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
48508916|NCT04062266|DRUG|Azacitidine|Given SC or IV
48508917|NCT04062266|DRUG|Venetoclax|Given PO
47991005|NCT04971733|DRUG|E2814|E2814 intravenous infusion.
47991006|NCT02258126|OTHER|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
48508918|NCT03531138|OTHER|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
48672886|NCT04572334|OTHER|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
48672887|NCT00698828|DRUG|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
47991007|NCT00478985|BEHAVIORAL|Imatinib ending|Interruption of the treatment by Imatinib
47991008|NCT00116532|DRUG|Escitalopram|
48148646|NCT03541369|DRUG|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
48360035|NCT06430736|DRUG|Tocilizumab before CAR-T cell infusion|"Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, with completion of the infusion 1 hour prior to infusion of CAR-T cells.~Treatment of eventual subsequent CRS/ICANS will be identical as in patients in the standard arm."
48360036|NCT06430736|DRUG|Tocilizumab at emerging CRS|Tocilizumab will be given at the standard-dose of 8 mg/kg b.w. intravenously, and it will be repeated after 8 hours for a maximum of four administrations in patients with ongoing signs of CRS.
48508919|NCT01959295|DRUG|ASP2151|200 mg once daily
48508920|NCT01959295|DRUG|ASP2151 placebo|once daily
48508921|NCT01769456|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
48508922|NCT01769456|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
48508923|NCT00771459|DRUG|Ropivacaine 0.5 %|Local infiltration analgesia
48508924|NCT00771459|DRUG|Isotonic NaCl|Local infiltration analgesia
48508925|NCT03496610|DRUG|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
48508926|NCT03496610|PROCEDURE|QL Block|Patient will receive ultrasound guided QL Block
48672888|NCT00698828|DRUG|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
48148647|NCT01554332|DEVICE|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
48508927|NCT00045864|DRUG|Recombinant Human Interleukin-2 and Rituximab|
48148648|NCT00670852|PROCEDURE|X-rays and CT scan|CT Scan x-rays
48148649|NCT03823703|DRUG|Miricorilant|Tablets taken orally
48148650|NCT03823703|DRUG|Placebo|Placebo tablets
48508928|NCT04971187|DRUG|Bintrafusp Alfa|Given IV
48148651|NCT00211276|DRUG|ONTAK (denileukin diftitox)|
48148652|NCT06399939|BEHAVIORAL|Nap|Naps are common but promoted by soothing, lying the infant down, and/or rocking and massaging
48148653|NCT06399939|BEHAVIORAL|Wake|Wake is encouraged by keeping the infant upright, providing stimulation (e.g., reading books, handing toys)
48148654|NCT05603949|DEVICE|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
48148655|NCT04265872|DRUG|Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis|injection into a vein
48148656|NCT04115670|BEHAVIORAL|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~* 3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~* Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
48148657|NCT04115670|BEHAVIORAL|Control group|The control group will follow its normal course of activity
48148658|NCT00221988|DRUG|Levetiracetam (Keppra)|
48148659|NCT03305185|COMBINATION_PRODUCT|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
48508929|NCT04971187|DRUG|Pemetrexed|Given IV
48508930|NCT04971187|DRUG|Carboplatin|Given IV
48508931|NCT04971187|DRUG|Cisplatin|Given IV
48508932|NCT03803982|PROCEDURE|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
48672889|NCT00698828|DRUG|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
48672890|NCT04446403|PROCEDURE|Suprascapular Nerve Block|The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .
48672891|NCT04446403|PROCEDURE|Axillary Nerve Block|Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.
48672892|NCT04446403|PROCEDURE|posterior cord block|Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.
48508933|NCT03803982|DRUG|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
48508934|NCT00576108|DRUG|KD7040 Topical Gel|KD7040 topical gel
48508935|NCT00576108|DRUG|Placebo gel|Placebo gel
48508936|NCT00247780|PROCEDURE|Pulmonary vein isolation and cavotricuspid ishtmusblock|
48508937|NCT04595422|OTHER|Educational Intervention|Undergo training consisting of a 60-minute educational session
48508938|NCT04595422|OTHER|Educational Intervention|Receive lung cancer screening educational materials
48508939|NCT04595422|OTHER|Questionnaire Administration|Complete questionnaire
48508940|NCT04595422|OTHER|Survey Administration|Ancillary studies
48508941|NCT06354660|DRUG|Retatrutide|Administered SC.
48508942|NCT06354660|DRUG|Placebo|Administered SC.
48508943|NCT04207489|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
48360037|NCT04016506|OTHER|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
48360038|NCT03710460|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
48508944|NCT01393886|PROCEDURE|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
48508945|NCT04061148|DEVICE|NIRSIT|NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
48508946|NCT02889523|DRUG|Tazemetostat|Tablets 200 mg, to be administrated per os
48360039|NCT03710460|DRUG|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
48360040|NCT03710460|DRUG|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
48508947|NCT02889523|DRUG|Rituximab|375 mg/m²/dose, D1
48508948|NCT02889523|DRUG|Cyclophosphamide|750 mg/m²/dose, D1
48360041|NCT01959269|DRUG|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
48360042|NCT04352686|DRUG|Buspirone|Administration of buspirone to assess esophageal sensitivity
48508949|NCT02889523|DRUG|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
48148660|NCT03305185|DEVICE|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
48508950|NCT02889523|DRUG|Doxorubicin|50 mg/m²/dose, D1
48508951|NCT02889523|DRUG|Prednisolone|40 mg/m2 in the morning D1 to D5
48148661|NCT04249700|DEVICE|Curve Sauna Dome|All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
48148662|NCT02315014|OTHER|whey protein|whey protein.
48360043|NCT04352686|DRUG|Placebo|Administration of placebo to assess differences in esophageal sensitivity
48360044|NCT04467138|DRUG|Omegaven|Pure fish oil emulsion (Omegaven®, Fresenius Kabi) was used as the additional product along with the standard lipid emulsion to reach a fish oil dose of approx. 0.5 g fish oil/kg/d.
48508952|NCT02609074|PROCEDURE|Minimally invasive internal fixation surgeries|
48508953|NCT02609074|DEVICE|CPC/rhBMP-2 micro-scaffolds|
48148663|NCT02315014|OTHER|placebo|placebo.
48360045|NCT02976194|DRUG|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
48360046|NCT04258761|DRUG|10XB-101 Solution for Injection|Active test article
48360047|NCT01738724|DRUG|Dienogest|Dienogest 2mg pills daily during 6 months
48360048|NCT01738724|DRUG|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
48360049|NCT01738724|DRUG|Desogestrel|Desogestrel 75mcg pills daily during six months
48360050|NCT02918006|BIOLOGICAL|VXA-A1.1|Enteric coated oral vaccine tablet
48360051|NCT02918006|BIOLOGICAL|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
48360052|NCT02918006|OTHER|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
48360053|NCT02918006|OTHER|Saline Solution for Placebo IM Injection|
48360054|NCT02455596|DRUG|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
48360055|NCT02770872|OTHER|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
48360056|NCT01432756|BEHAVIORAL|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
48508954|NCT02609074|DEVICE|CPC paste|
48508955|NCT04326621|OTHER|Pressure Release Technique (PRT)|A pressure applied on muscles trigger points with the finger of a physiotherapist and exercises
48508956|NCT04326621|OTHER|Control|exercises
48508957|NCT05260580|OTHER|No Intervention: Routine care|
48508958|NCT03504683|BEHAVIORAL|Early TRE|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
48508959|NCT03504683|BEHAVIORAL|Mid-day TRE|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
48508960|NCT03504683|BEHAVIORAL|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
48508961|NCT03430388|BIOLOGICAL|Yellow Fever vaccine (17D)|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
48508962|NCT02598856|DRUG|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
48508963|NCT02598856|DRUG|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
48508964|NCT02598856|DRUG|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
48508965|NCT02598856|DRUG|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
48508966|NCT06633055|DRUG|JH013 injection|JH013 injection is a BAFF-R inhibitor monoclonal antibody
48508967|NCT06633055|DRUG|Placebo|JH013 injections placebo
48148664|NCT03575507|DEVICE|Treatment with BTL EMSCULPT device.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
48148665|NCT05440240|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
48148666|NCT05440240|DRUG|Corticosteroid injection|Depo-Medrol
48148667|NCT05440240|OTHER|Saline injection|Isotonic saline
48148668|NCT03236779|OTHER|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
48508968|NCT02496663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48148669|NCT05910788|DEVICE|high flow nasal cannula|"The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications."
48148670|NCT00164021|PROCEDURE|Physiotherapy, exercise, percutaneous gastrostomy feeds|
48148671|NCT00164021|DRUG|Anti-reflux pharmacotherapy|
48148672|NCT01264874|DRUG|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
48148673|NCT01264874|OTHER|placebo|For 3 years IU every 50 days
48148674|NCT01098409|DRUG|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
48148675|NCT01098409|DRUG|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
48148676|NCT06517576|DEVICE|Blood glucose monitor with Digital Platform and Health Coaching|Blood glucose monitors will be used daily to measure blood glucose measurements.
48148677|NCT06517576|DEVICE|Continuous glucose monitor|Continuous glucose monitors will be used daily to measure blood glucose measurements.
48148678|NCT06517576|OTHER|Usual Care|Usual care for type 2 diabetes
48148679|NCT00552461|DRUG|rituximab|IV, 1000 mg, two weeks, 2 times
48148680|NCT02291549|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
48148681|NCT02291549|DRUG|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
48148682|NCT02291549|PROCEDURE|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
48148683|NCT00996164|DRUG|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
48148684|NCT00996164|DRUG|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
48360057|NCT02500706|DRUG|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
48148685|NCT04927949|DRUG|cangrelor perfusion during PCI|Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer
48148686|NCT04927949|PROCEDURE|standard PCI|primary PCI without cangrelor
48148687|NCT03071523|PROCEDURE|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
48148688|NCT03071523|PROCEDURE|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
48360058|NCT02500706|DRUG|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
48360059|NCT02500706|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
48360060|NCT00238160|DRUG|cisplatin|
48360061|NCT00238160|DRUG|fluorouracil|
48360062|NCT00238160|PROCEDURE|adjuvant therapy|
48360063|NCT00238160|PROCEDURE|chemotherapy|
48360064|NCT00238160|PROCEDURE|conventional surgery|
48360065|NCT00238160|PROCEDURE|hepatic arterial infusion|
48360066|NCT00238160|PROCEDURE|surgery|
48360067|NCT03531918|DRUG|Cladribine|Given IV
48360068|NCT03531918|DRUG|Cytarabine|Given IV
48360069|NCT03531918|DRUG|Gemtuzumab Ozogamicin|Given IV
48360070|NCT03531918|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given SC
48360071|NCT03531918|OTHER|Laboratory Biomarker Analysis|Correlative studies
48360072|NCT03531918|DRUG|Mitoxantrone Hydrochloride|Given IV
48360073|NCT01277666|DRUG|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
48360074|NCT01277666|DRUG|GSK1605786A|500 mg once daily, administered orally for 12 weeks
48360075|NCT01277666|DRUG|Placebo|Placebo capsules, administered orally for 12 weeks
48508969|NCT02496663|PROCEDURE|Computed Tomography|Undergo CT scan
48508970|NCT02496663|PROCEDURE|Echocardiography|Undergo ECHO
48508971|NCT02496663|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
48508972|NCT02496663|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48508973|NCT02496663|BIOLOGICAL|Necitumumab|Given IV
48508974|NCT02496663|DRUG|Osimertinib|Given PO
48672893|NCT04446403|PROCEDURE|General anesthesia|General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
48672894|NCT04366856|BEHAVIORAL|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
48360076|NCT01802242|RADIATION|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
48360077|NCT01802242|OTHER|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice
48360078|NCT06071533|DRUG|Dandshen|Dandshen injection 20ml /day
48360079|NCT03819023|DIAGNOSTIC_TEST|Respilife monitor|Respilife monitor
48360080|NCT02129192|DRUG|Amlodipine 5mg capsule|Amlodipine 5mg capsule
48360081|NCT02129192|DRUG|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
48360082|NCT02129192|DRUG|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
48360083|NCT00079157|BIOLOGICAL|incomplete Freund's adjuvant|
48672895|NCT04366856|BEHAVIORAL|2: No instruction regarding positioning|group with no instruction regarding positioning (control group)
47991009|NCT03533192|BEHAVIORAL|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
47991010|NCT01677975|PROCEDURE|FNA (fine needle aspiration)|
47991011|NCT05678829|OTHER|Education|The trainings for the Virtual Reality group will continue in accordance with the training titles according to the weeks, using virtual reality glasses.
47991012|NCT00985842|DEVICE|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
47991013|NCT00985842|DEVICE|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
48360084|NCT00079157|BIOLOGICAL|sargramostim|
48360085|NCT00079157|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
48360086|NCT03230266|PROCEDURE|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
48360087|NCT01497899|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
48360088|NCT01497899|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
48360089|NCT01497899|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
47991014|NCT00985842|DEVICE|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
47991015|NCT00985842|DEVICE|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
47991016|NCT00985842|DEVICE|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
48148689|NCT04890626|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Main randomization
48148690|NCT04890626|DRUG|Baricitinib + dexamethasone|Rescue randomization
48148691|NCT04890626|DRUG|Dexamethasone|Rescue randomization
48148692|NCT03060785|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|
48360090|NCT01497899|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
48360091|NCT00904436|DRUG|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
48360092|NCT04873895|DRUG|Axitinib 5 MG|axitinib 5 mg po BID until progression or intolerance
48360093|NCT04873895|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 600 mg po BID until progression or intolerance
48360094|NCT04873895|PROCEDURE|trans arterial chemoembolization|segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.
48360095|NCT00656227|DRUG|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
48360096|NCT02133144|BEHAVIORAL|overeating fat|
48360097|NCT02133144|BEHAVIORAL|overeating carbohydrate|
48360098|NCT04306835|BEHAVIORAL|Cognitive behavioural therapy for insomnia|a technique for treating insomnia without medications
48360099|NCT00045019|OTHER|quality-of-life assessment|QLQ-C30 SAT32
48508975|NCT03929991|OTHER|Observational|To record social and clinical characteristics
48508976|NCT02461160|DRUG|TAK-915 suspension|TAK-915 oral suspension
48360100|NCT02511691|DRUG|18F-PSS232|Diagnostic PET Tracer
48360101|NCT04610827|DRUG|Ferrous sulfate|Guideline-recommended 3 mg/kg/day dosing
48508977|NCT02461160|DRUG|Midazolam|Midazolam oral solution
48508978|NCT02461160|DRUG|Placebo|Placebo-matching TAK-915 suspension
48508979|NCT02461160|DRUG|TAK-915 tablet|TAK-915 tablet
48672896|NCT01143402|DRUG|Dacarbazine|Given IV
48672897|NCT01143402|OTHER|Laboratory Biomarker Analysis|Correlative studies
48672898|NCT01143402|OTHER|Quality-of-Life Assessment|Ancillary studies
48672899|NCT01143402|DRUG|Selumetinib|Given PO
48148693|NCT05751720|DRUG|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
48148694|NCT02469324|BEHAVIORAL|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
48148695|NCT02469324|BEHAVIORAL|Compassionate Mind Training|see above
48508980|NCT01000558|OTHER|biologic sample preservation procedure|
48672900|NCT01143402|DRUG|Temozolomide|Given PO
48672901|NCT02527395|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
48148696|NCT02170207|DRUG|Lansoprazole|Lansoprazole 30 mg injection
48672902|NCT02527395|OTHER|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
48148697|NCT04889326|OTHER|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
48148698|NCT03214614|DRUG|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
48148699|NCT03214614|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
48148700|NCT03214614|DRUG|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
48148701|NCT03214614|DRUG|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
48508981|NCT06632951|DRUG|Livmoniplimab|Intravenous (IV) Infusion
48508982|NCT06632951|DRUG|Budigalimab|IV Infusion
48508983|NCT06632951|DRUG|Docetaxel|IV Infusion
48508984|NCT06632951|DRUG|Paclitaxel|IV Injection
48672903|NCT02527395|OTHER|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
48672904|NCT06237634|OTHER|splint and exercise and advices|A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
48672905|NCT06237634|OTHER|Triamsinolon Asetonid ozone|40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.
48672906|NCT06237634|OTHER|ozone|In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
48508985|NCT06632951|DRUG|Docetaxel|IV Injection
48508986|NCT06632951|DRUG|Paclitaxel|IV Infusion
48508987|NCT06632951|DRUG|Gemcitabine|IV Infusion
48508988|NCT01724450|DRUG|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
48672907|NCT04264039|BIOLOGICAL|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
48672908|NCT04264039|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
48672909|NCT04264039|DRUG|Cytoxan|300mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
48672910|NCT04264039|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
48508989|NCT01724450|DRUG|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
48508990|NCT02602444|DRUG|ticagrelor|180 mg loading dose
48508991|NCT05744141|PROCEDURE|Relaxation Exercises|"Relaxation exercises consist of voluntary, rhythmic and regular stretching and relaxation of large and small muscle groups until the whole body relaxes. For this exercise application, the Relaxation Exercises CD prepared by the Turkish Psychological Association will be used. The CD consists of 30 minutes and relaxation exercises are explained with the sound of a stream accompanied by verbal instructions. This exercise includes rhythmic breathing, muscle relaxation exercises and music (stream sound)."
48508992|NCT01534130|DEVICE|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
48148702|NCT03471442|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
48672911|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy)|We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative
48148703|NCT03471442|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
48508993|NCT01534130|DEVICE|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
48508994|NCT00036192|DRUG|FK614|
48672912|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy) - control|"usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group."
48148704|NCT03471442|DRUG|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
48672913|NCT01654939|DRUG|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
48672914|NCT02347592|DEVICE|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
48672915|NCT02347592|DEVICE|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
48672916|NCT05160948|OTHER|Informational Report|All EcoMAPPE participants and their caregivers will be invited to complete a questionnaire to assess their understanding of air pollution and attitudes and beliefs about science and research before and after receiving their individual study air pollution monitoring results collected as part of their participation in EcoMAPPE.
48672917|NCT06488274|DIETARY_SUPPLEMENT|New infant formula|The new formula will be given to infants during the 4-month study period.
48672918|NCT03509961|DIAGNOSTIC_TEST|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
48672919|NCT03509961|DRUG|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
48360102|NCT00572663|DRUG|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
48672920|NCT04310696|OTHER|Buteyko Breathing exercises|Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
48672921|NCT04310696|OTHER|Pursed lip breathing|Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
48672922|NCT04143230|OTHER|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
48672923|NCT03584906|PROCEDURE|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
48360103|NCT06419062|DEVICE|Frontier X2|Frontier X2 device will be used to measuring for physiological changes (breathing rate, heart rate, ECG, and heart rate variabilities) in people with COPD.
48360104|NCT00397527|DRUG|lactoserum|
48360105|NCT05891301|OTHER|Questionnaires set|The contents of the questionnaire included gender, age, BMI, previous operation history, previous medication history, smoking history,patient mobility in the hospital, etc.Questionnaire was completed on the first postoperative day.From the third day to the end of the seventh day, patients were evaluated daily for gastrointestinal dysfunction.Postoperative mobility was assessed daily.
48508995|NCT03653884|DIAGNOSTIC_TEST|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
48508996|NCT06156774|OTHER|Chimeric Antigen Receptor T-cells (CAR-T) therapy|Patients will be treated with CAR-T cell product as per routine clinical practice.
48508997|NCT01638585|DRUG|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
48508998|NCT02607267|OTHER|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
48508999|NCT01969786|OTHER|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
48360106|NCT00355381|BEHAVIORAL|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
48360107|NCT02752178|OTHER|MA|Monoaminergic antidepressant use
48360108|NCT02752178|OTHER|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
48672924|NCT03584906|PROCEDURE|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
48148705|NCT03471442|DRUG|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
48148706|NCT03471442|DRUG|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
48360109|NCT03812224|DRUG|Erenumab|Administered by subcutaneous injection once a month
48672925|NCT03584906|PROCEDURE|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
48672926|NCT03584906|PROCEDURE|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
48509000|NCT06501430|OTHER|Heating Therapy|Heating Therapy will be performed on subjects along with PNF Exercises.
48672927|NCT03584906|PROCEDURE|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
48672928|NCT05833711|DRUG|Froniglutide|SC Weekly Injection
48672929|NCT05833711|DRUG|Placebo|SC Weekly Injection
48672930|NCT01674504|DRUG|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
48672931|NCT05576025|OTHER|Lifestyle intervention (cold exposure)|Participants will undergo two cold exposures with different shivering intensities. Mild shivering is defined as energy expenditure increased by 1.5-fold compared to the resting metabolic rate. Moderate shivering is 2.5-fold increase in metabolic rate.
48148707|NCT06437158|DRUG|Bleomycin|To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
48360110|NCT03812224|DRUG|Placebo|Administered by subcutaneous injection once a month
48360111|NCT00590031|DRUG|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
48360112|NCT00590031|DRUG|Irinotecan|Irinotecan will be given 65 mg/m2
48360113|NCT00590031|RADIATION|External Beam Radiation Therapy|will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
48360114|NCT04354701|OTHER|Web-based REDCap survey|The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
48360115|NCT02638285|DRUG|LH|
48360116|NCT02638285|DRUG|HCG|
48360117|NCT02638285|DRUG|Clomiphene|
48360118|NCT02371980|DRUG|Vortioxetine|Vortioxetine capsules
48360119|NCT02371980|DRUG|Placebo|Vortioxetine placebo-matching capsules
48360120|NCT05524259|DIETARY_SUPPLEMENT|Myo-inositol and routinely recommended folic acid|Participants randomly allocated to the intervention group will receive 4 grams myo-inositol added to their routinely recommended 0.4 mg folic acid supplement, divided over two daily sachets of sugary powder throughout pregnancy.
48509001|NCT06501430|OTHER|Manual Soft tissue Release|Manual Soft tissue Release will be performed on subjects along with PNF Exercises.
48509002|NCT02156167|DEVICE|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
48509003|NCT02570594|OTHER|questionary|
48509004|NCT02845193|DEVICE|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
48672932|NCT03142919|BIOLOGICAL|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
48672933|NCT03142919|BIOLOGICAL|Placebo|Saline solution
48672934|NCT03978039|DRUG|Chemotherapy|treatment as per standard of care
48672935|NCT03978039|DRUG|Immunotherapeutic Agent|treatment as per standard of care
48672936|NCT03978039|DRUG|target treatment|treatment as per standard of care
48672937|NCT03978039|PROCEDURE|Surgery|treatment as per standard of care
48148708|NCT05537935|DRUG|Low Dose Naltrexone|Subjects will be started with 3mg LDN orally administered daily for one week with a planned increase to 4 mg/day beginning week two, if tolerated. They will be provided a 4 week supply of study medication. The most common side effects are difficulty sleeping and vivid dreams, which is seen more frequently with nighttime dosing, so LDN will be given as a daytime dose.
48148709|NCT05565898|DEVICE|positron emission tomography for exclusion of bone marrow infiltration in lymphoma|compare the diagnostic accuracy of PET/CT scan against Bone Marrow Biopsy in detection of bone marrow involvement for staging of lymphoma
48148710|NCT04703244|PROCEDURE|chemotherapy or endocrine therapy for breast cancer|Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
48509005|NCT02845193|DEVICE|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
48509006|NCT02845193|DEVICE|CAD/NAM|computer aided design NAM
48509007|NCT06581783|DRUG|Simethicone plus NAC|Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals
48672938|NCT03978039|RADIATION|Radiotherapy|treatment as per standard of care
48672939|NCT00327912|PROCEDURE|Laparoscopic Biliopancreatic diversion with Duodenal switch|
48672940|NCT00327912|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
48148711|NCT02717780|DRUG|Fentanyl and sevoflurane|
48672941|NCT01732536|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
48672942|NCT01732536|PROCEDURE|Sham procedure|In-office bilateral sham procedure
48672943|NCT01732536|DRUG|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
48672944|NCT01999933|RADIATION|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
48672945|NCT01999933|DRUG|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
48148712|NCT02717780|DRUG|Remifentanil and desflurane|
48672946|NCT01999933|DRUG|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
47991017|NCT03169673|DIAGNOSTIC_TEST|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
48148713|NCT03130946|DEVICE|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
48148714|NCT03130946|DEVICE|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
48148715|NCT04059575|OTHER|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
48360121|NCT05524259|DIETARY_SUPPLEMENT|Routinely recommended folic acid|The control group will receive similar looking sachets of supplements containing only the standard dose of 0.4 mg folic acid without the added myo-inositol supplement as part of the current standard-of-care recommendation.
48360122|NCT06250712|DEVICE|Continous ECG Patch|Using a continuous patch ECG for 1 week during 1 month
48360123|NCT06250712|DEVICE|Intermittent handheld ECG|Using a handheld ECG twice daily and when symptoms are present during 1 month
48509008|NCT02658799|DRUG|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
48672947|NCT01999933|DRUG|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
48672948|NCT00006356|DRUG|carboplatin|
48672949|NCT00006356|DRUG|cisplatin|
48672950|NCT00006356|PROCEDURE|conventional surgery|
48672951|NCT04160104|OTHER|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
48672952|NCT04160104|OTHER|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
48672953|NCT04739943|DEVICE|Mobile Monitoring Device|App for self monitoring device for respiratory symptoms
48672954|NCT05572879|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
48672955|NCT05572879|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
48672956|NCT03348293|PROCEDURE|3D printing|Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.
48672957|NCT00484783|PROCEDURE|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
48672958|NCT00484783|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
48672959|NCT01621178|DRUG|Dulaglutide|Administered SC
48672960|NCT01621178|DRUG|Insulin glargine|Administered SC
48672961|NCT01621178|DRUG|Insulin lispro|Administered SC
47991018|NCT00909779|DRUG|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
47991019|NCT00909779|DRUG|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
47991020|NCT05688241|DRUG|Donor-derived ex-vivo expanded EBV Tscm CTL|Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
48509009|NCT02658799|DRUG|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
48672962|NCT03433547|PROCEDURE|Buckle|Surgical procedures of macular buckling
48148716|NCT04059575|OTHER|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
48148717|NCT05868382|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
48148718|NCT05868382|BIOLOGICAL|mRNA-1010.4|Sterile liquid for injection
48148719|NCT05868382|BIOLOGICAL|mRNA-1010.6|Sterile liquid for injection
48148720|NCT05636306|DRUG|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
48148721|NCT05636306|DRUG|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
48148722|NCT03094442|DRUG|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
48509010|NCT05597319|PROCEDURE|Liver resection|Liver resection, different kind of according to pathology
48509011|NCT02012348|OTHER|Antibacterial soap with triclocarban|
48509012|NCT02012348|OTHER|Antibacterial soap + benzalkonium chloride|
48509013|NCT02012348|OTHER|Control soap|
48509014|NCT05174195|DRUG|Desogestrel 0.075 milligram|Inserted after 3 months use of DESOGESTREL
48509015|NCT05174195|DRUG|Implanon NXT® subdermal implant|Inserted immediately
48509016|NCT00451048|DRUG|sunitinib malate|Given orally
48509017|NCT03417687|DRUG|129Xe MRI|Evaluation of pulmonary function
48509018|NCT03417687|DRUG|133 Xe scintigraphy|Evaluation of pulmonary function
48509019|NCT06015763|PROCEDURE|Endoscopy|Endoscopic biopsy
48509020|NCT05498428|DRUG|Amivantamab|Amivantamab will be administered subcutaneously by manual injection.
48672963|NCT03433547|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy
48672964|NCT03433547|OTHER|Limbal paracentesis|Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
48672965|NCT03433547|OTHER|Gas injection|Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
48509021|NCT05498428|DRUG|Lazertinib|Lazertinib will be administered as an oral tablet.
48509022|NCT05498428|DRUG|Carboplatin|Carboplatin will be administrated by IV infusion.
48672966|NCT03433547|OTHER|Peeling internal limiting membrane|Peeling internal limiting membrane with forceps
48509023|NCT05498428|DRUG|Pemetrexed|Pemetrexed will be administered by IV infusion.
48509024|NCT05498428|DRUG|Direct Oral Anticoagulant (DOAC)|DOAC will be administered orally.
48672967|NCT03433547|OTHER|Gas tamponade|Filling the vitreous cavity with gas (C3F8, 14%)
48672968|NCT01804452|OTHER|Observational Study|
48672969|NCT04344730|DRUG|Dexamethasone injection|Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
48672970|NCT04344730|DRUG|placebo|Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
48672971|NCT04344730|PROCEDURE|conventional oxygen|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
48360124|NCT03620500|BEHAVIORAL|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
48509025|NCT05498428|DRUG|Low Molecular Weight Heparin (LMWH)|LMWH will be administered subcutaneously.
48672972|NCT04344730|PROCEDURE|CPAP|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
48672973|NCT04344730|PROCEDURE|HFNO|TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
48672974|NCT04344730|PROCEDURE|mechanical ventilation|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
48672975|NCT02579434|DRUG|Midazolam I.V.|Midazolam I.V. 1mg/ml
48672976|NCT02012803|PROCEDURE|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
48509026|NCT06089200|PROCEDURE|Transversus Abdominal Plane Block|20 cc of bupivacaine 0.2% was given to the transversus abdominis plane
48509027|NCT06089200|PROCEDURE|Spinal Morphine|100 µg was administered intrathecally preoperatively
48509028|NCT04874155|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode.
48509029|NCT04874155|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode.
48509030|NCT04874155|DEVICE|NTX100 Neuromodulation System - Open-Label|Noninvasive peripheral nerve stimulation device programmed to active mode.
48509031|NCT06349941|DEVICE|Movn app|Participants will receive a FitBit accelerometer to monitor physical activity. Participants will have a 2 week run-in period where physical activity levels will be monitored followed by a 12-week home-based exercise program delivered via a previously validated, commercially available smartphone platform called Movn (Moving Analytics, California)
48509032|NCT04097873|OTHER|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
48509033|NCT04097873|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
48509034|NCT06291415|DRUG|HMPL-523|Syk inhibitor
48509035|NCT00307918|DEVICE|acupuncture|
48509036|NCT06628804|DIETARY_SUPPLEMENT|Artemisia and green tea extracts|Artemisia and green tea extracts 700 mg/day for 8 weeks
48509037|NCT06628804|DIETARY_SUPPLEMENT|Placebo|Placebo 700 mg/day for 8 weeks
48509038|NCT04731246|OTHER|Video-oculography / Neuropsychological evaluations|Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
48509039|NCT03020537|BIOLOGICAL|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
48509040|NCT04311671|DRUG|Moxidectin|2 mg tablets, encapsulated for blinding
48509041|NCT04311671|DRUG|Ivermectin|3 mg tablets, encapsulated for blinding
48509042|NCT04311671|DRUG|Albendazole|400 mg tablets
48509043|NCT05458882|BEHAVIORAL|"living with food allergy educational booklet"|An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
48509044|NCT00776087|DEVICE|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
48509045|NCT00776087|DEVICE|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
48509046|NCT00003911|RADIATION|stereotactic radiosurgery|
48509047|NCT02603991|PROCEDURE|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
48509048|NCT02603991|DRUG|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
48509049|NCT03624309|DRUG|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
48509050|NCT03624309|DRUG|Docetaxel|Docetaxel (75mg/m2 IV d1)
48509051|NCT05443178|DRUG|Nivaquine ® (Chloroquine)|dose escalation and extension trial
48509052|NCT03909880|OTHER|Kinesio tape|"Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping."
48360125|NCT02425891|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
48360126|NCT02425891|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
48360127|NCT02425891|DRUG|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
48360128|NCT01778140|OTHER|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
48509053|NCT02635113|DEVICE|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
48672977|NCT02012803|OTHER|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
48672978|NCT04462601|OTHER|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
48672979|NCT03186768|BEHAVIORAL|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
48672980|NCT01711528|DRUG|Bortezomib|Given SC
48672981|NCT01711528|DRUG|Dexamethasone|Given PO
48672982|NCT01711528|DRUG|Dinaciclib|Given IV
48672983|NCT01711528|OTHER|Laboratory Biomarker Analysis|Correlative studies
48672984|NCT03004885|DEVICE|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
48672985|NCT04772209|DRUG|Sodium bicarbonate|Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.
48672986|NCT04772209|DRUG|Heparin|Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
48672987|NCT02781441|BEHAVIORAL|Question prompt list (QPL)|
48672988|NCT02781441|BEHAVIORAL|Education brochure of Groupe Français des Myélodysplasies|
48360129|NCT01778140|OTHER|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
48672989|NCT02734329|PROCEDURE|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
48672990|NCT02734329|PROCEDURE|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
48672991|NCT03059784|OTHER|APP-based multifaceted management|Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
48672992|NCT06376864|BEHAVIORAL|Activity Breaks|The Activity Breaks intervention is a 5-minute Activity Breaks programme that allows classroom teachers of all ages and ability levels to lead simple movement activities within their classrooms, negating the need for additional personnel or space.
48672993|NCT03709901|OTHER|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
48672994|NCT03709901|OTHER|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
48672995|NCT04970069|OTHER|Video on analgesic education|A four minute video informing the patient about opioids.
48672996|NCT04970069|OTHER|Video on general perioperative education|A four minute video informing the patient about general perioperative process.
48672997|NCT03809273|DRUG|Yangxinshi|Yangxinshi pill 3 pills /tid
48672998|NCT03809273|DRUG|Trimetazidine|Trimetazidine 20mg/tid
48672999|NCT03809273|DRUG|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
48673000|NCT03809273|DRUG|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
48673001|NCT04815798|COMBINATION_PRODUCT|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
48673002|NCT04815798|COMBINATION_PRODUCT|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
48673003|NCT04815798|PROCEDURE|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
48673004|NCT01585402|DRUG|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
48673005|NCT01585402|DEVICE|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
48360130|NCT06402240|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical behavior therapy (DBT) in its fully adherent form is a comprehensive intervention involving individual, group, and phone coaching sessions that addresses complex psychological conditions including suicidality, personality disorders, and post-traumatic stress disorder. Evidence for briefer formats incorporating the group skills training format have been successful for many types of conditions, which includes alcohol and substance use disorders. DBT skills training (DBT-ST) involves structured lessons for learning skills in 5 areas: mindfulness, emotion regulation, distress tolerance, interpersonal effectiveness, and addiction. The current intervention is an internet-delivered version of DBT-ST which aims to teach people the same 5 areas of skills in an online environment with a chatbot and interactive format.
48148723|NCT03094442|DRUG|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
48360131|NCT02487901|DEVICE|ultrasonic osteotome|making gutter with ultrasonic osteotome
48360132|NCT02487901|DEVICE|drill|making gutter with drill
48360133|NCT01773616|DRUG|Oral prednisolone|
48360134|NCT01773616|DRUG|Rituximab|
48360135|NCT01773616|DRUG|Mycophenolate mofetil|
48360136|NCT01773616|DRUG|Methyl prednisolone|
48360137|NCT01327586|BEHAVIORAL|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
48360138|NCT01327586|BEHAVIORAL|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
48360139|NCT02204267|OTHER|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
48360140|NCT02204267|DEVICE|ECG|
48360141|NCT04755751|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages
48673006|NCT05317598|OTHER|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
48673007|NCT02696603|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
48673008|NCT02696603|BEHAVIORAL|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
48673009|NCT02696603|BEHAVIORAL|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
48148724|NCT01944774|DRUG|Nemonoxacin 500 mg|IV Infusion, once daily for 7\~14 days
48360144|NCT03097666|DEVICE|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
48360145|NCT01442961|PROCEDURE|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
48360146|NCT01442961|PROCEDURE|vaginal : vaginal hysterectomy|Vaginal hysterectomy
48360147|NCT01219166|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
48360148|NCT01878786|DRUG|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
47991021|NCT05024058|DRUG|Ligelizumab|Ligelizumab treated groups and arms
48148725|NCT01944774|DRUG|Nemonoxacin 650 mg|IV Infusion, once daily for 7\~14 days
48148726|NCT01944774|DRUG|Moxifloxacin 400 mg|IV Infusion, once daily for 7\~14 days
48148727|NCT00390806|DRUG|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
48148728|NCT00390806|RADIATION|Radiation|Whole brain radiation
48360149|NCT01878786|DRUG|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
48360150|NCT01878786|DRUG|Mycophenolate mofetil (MMF/MPA)|Control Drug
48360151|NCT04885205|BEHAVIORAL|cognitive behavioral therapy for insomnia (CBT-I)|The CBT-I program is a 6-week, 1x/week, one-on-one program. The delivery of CBT-I will be done remotely over a secure teleconference service (Zoom) or phone. Participants will maintain a sleep diary during the course of the program to aid in tailoring the intervention. Each session lasts about 45-60min:
48360152|NCT03313752|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
48360153|NCT03313752|OTHER|Placebo|placebo
48360154|NCT04630561|BEHAVIORAL|Postural Intervention Program|Dynamic warmup program designed to target several areas of physical and mental wellbeing.
48360155|NCT00411606|PROCEDURE|Thermography|Subjects will have a picture of their face taken with a thermal camera
48360156|NCT04252872|DRUG|HCP0605|
48360157|NCT04252872|DRUG|HGP1405|
48360158|NCT04252872|DRUG|HCP1401|
48360159|NCT00497939|DRUG|Saw palmetto and sanmiaoshan capsule|
48360160|NCT00301236|DRUG|Dexmethylphenidate HCl extended-release capsules|
48509054|NCT05656261|GENETIC|Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys|On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
48509055|NCT05046743|OTHER|Colonic gas load|Colonic infusion of gas via an anal cannula
48509056|NCT05046743|OTHER|Sham load|Sham infusion of gas via an anal cannula
48148729|NCT01653106|PROCEDURE|cryotherapy|Receive shaved ice
47991022|NCT05024058|OTHER|Placebo|Placebo treated groups and arms
47991023|NCT01678092|BIOLOGICAL|omalizumab|
48148730|NCT01653106|OTHER|questionnaire administration|Participate in PROMS
48148731|NCT01653106|OTHER|pharmacological study|Correlative studies
48148732|NCT04184349|DRUG|LA group|In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
48148733|NCT04184349|DRUG|B Group|In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
48360161|NCT04627233|DRUG|Human Ezrin Peptide 1 (HEP1)|"HEP-1 will be administrated s.c. into the lower abdominal wall~1. induction dosage: 2 mg Ezrin in 2 ml physiological saline applied s.c.,one injection every 12 hours until symptoms disappear followed by~2. maintenance dosage: 0.2 mg Ezrin in 1 ml physiological saline solution s.c 1/day for 10 days"
48360162|NCT04627233|DRUG|Placebo|placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
48360163|NCT05488249|DIAGNOSTIC_TEST|Cardiac imaging tests|"* 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics."
48360164|NCT05488249|DIAGNOSTIC_TEST|Venous blood sample collection|Venous blood sample collection during CCTA image acquisition for evaluation of serum levels of hsCRP, IL-6, matrix metalloproteases - MMP9, Adhesion molecules (VCAM, ICAM, e-selectin, p-selectin) periostin.
48360165|NCT05869240|DRUG|BPB-101|Subjects will receive an intravenous infusion of BPB-101 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
48360166|NCT03575975|DEVICE|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
48148734|NCT04343274|DRUG|Tozuleristide|
48148735|NCT01634295|DRUG|CKD-828 2.5/40mg|"* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
48148736|NCT01634295|DRUG|CKD-828 5/40mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
48148737|NCT01634295|DRUG|CKD-828 5/80mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks."
48148738|NCT01634295|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks."
48148739|NCT01634295|DRUG|S-amlodipine 5mg|"* S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks."
48148740|NCT00567606|OTHER|Strength/Weight Training & Drug/Supplement|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
48360167|NCT01145833|OTHER|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
48360168|NCT01145833|OTHER|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
48360169|NCT01917136|DRUG|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
48360170|NCT01917136|DRUG|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
48360171|NCT01917136|OTHER|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
48360172|NCT00090844|DRUG|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
48360173|NCT00193856|DRUG|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
48360174|NCT00193856|DRUG|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
48360175|NCT00193856|RADIATION|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
48673010|NCT02696603|BEHAVIORAL|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test \[Corsi, P.M. (1972)\] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
48673011|NCT02696603|BEHAVIORAL|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
48148741|NCT00567606|COMBINATION_PRODUCT|Drug/Supplement only|G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.
48148742|NCT03507998|DRUG|CGX1321|CGX1321 capsules for oral administration
48148743|NCT06386354|DIAGNOSTIC_TEST|Train-of-four|Patients submitted to general anesthesia with neuromuscular block will be monitored at their arrival to the Post-Anesthesia Care Unit to assess the presence of residual neuromuscular block.
48148744|NCT04364399|BIOLOGICAL|Mumps vaccine|One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
48360176|NCT02712008|DRUG|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
48360177|NCT02712008|DRUG|Intravitreal Aflibercept Injection (IAI)|
48360178|NCT00001302|DRUG|PSC 833|
48360179|NCT00001116|DRUG|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
48360180|NCT05200468|OTHER|Ketogenic diet|Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
48360181|NCT05200468|OTHER|Caloric restriction diet|Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
48148745|NCT04364399|BIOLOGICAL|measles, mumps and rubella combined vaccine, live|One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
48360182|NCT05200468|OTHER|Intermittent fasting 16/8|Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
48148746|NCT04883515|DIETARY_SUPPLEMENT|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
48148747|NCT04883515|DIETARY_SUPPLEMENT|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
48673012|NCT02696603|BEHAVIORAL|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
48360183|NCT00504595|DRUG|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
48509057|NCT01738451|DRUG|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
48509058|NCT01738451|DRUG|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
48509059|NCT02986867|RADIATION|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
48509060|NCT01811316|OTHER|Probiotics|
48509061|NCT06456866|OTHER|interpretation|interpretation of blood gases samples
48509062|NCT05321368|BEHAVIORAL|LINKED-HEARTS Program|The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
48509063|NCT06634264|DEVICE|Soft Oral Appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
48509064|NCT06550700|PROCEDURE|laparoscopic hybrid surgery (LHS)|First performed the laparoscopic exploration of the entire abdominal-pelvic cavity to determine the resectability of the primary and metastatic lesions. After the blood vessel detachment and bowel detachment, the distal bowel of the tumor was severed and the pneumoperitoneum was closed. The liver metastases were then removed in both cohorts by open resection through the right subcostal incision.
48673013|NCT02696603|OTHER|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
48673014|NCT02289469|OTHER|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
48673015|NCT02856022|DEVICE|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1\~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
48360184|NCT00504595|DRUG|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
48360185|NCT05523648|DRUG|Chronic Hepatitis B|92 patients included in the study were randomly divided into 2 groups, 42 patients in the control group and 50 patients in the treatment group. Both groups of patients received conventional basic treatment such as liver protection. Moreover, in both groups, patients were instructed to change their dietary structure to control low-fat and low-sugar, and were instructed to perform appropriate aerobic exercise.
48360186|NCT04828304|DEVICE|PLASOMA|Treatment with cold plasma device
48360187|NCT01392079|DRUG|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
48360188|NCT01484522|BIOLOGICAL|FluMist|Administered at the manufacture's recommended dose
48360189|NCT01484522|BIOLOGICAL|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
48360190|NCT01484522|BIOLOGICAL|Fluzone|Vaccine administered at manufacturer's recommended dose
47991024|NCT05973383|BEHAVIORAL|LongLife Active- Basic|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars."
48509065|NCT05093764|DEVICE|VIV TAVR with BVF using TCEP|The insertion and retrieval of the SENTINEL device is performed at the time of the patients TAVR procedure in the same setting while they are sedated under moderate sedation or general anesthesia depending on the case. The device is inserted at the initiation of the procedure through 6F right radial artery access and the filters are positioned in the left common carotid artery and brachiocephalic artery. After deployment, the usual TAVR procedure is performed. At the conclusion of the procedure, the SENTINEL device is extracted and hemostasis is achieved at the radial access site in the usual fashion with patent hemostasis.
48673016|NCT02856022|PROCEDURE|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
48673017|NCT02431325|DRUG|Teduglutide|
48673018|NCT02431325|DRUG|Placebo|
48360191|NCT02306928|OTHER|Blood draw|
48360192|NCT04303091|BEHAVIORAL|Physical Activity for Advanced Cancer Treatment (PAACT)|12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
48360193|NCT01701531|DRUG|RBCPF|
48360194|NCT00131131|BEHAVIORAL|Exercise|
48509066|NCT03616145|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Experimental Condition
48509067|NCT03616145|OTHER|Light Touch|Comparator Arm
48509068|NCT00413881|PROCEDURE|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
48509069|NCT00413881|PROCEDURE|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
48673019|NCT04624100|PROCEDURE|Hernia repair|Primary or mesh repair of primary ventral or incisional hernia
48673020|NCT05289752|PROCEDURE|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
48148748|NCT04883515|PROCEDURE|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
48360197|NCT05780099|OTHER|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
48360198|NCT02036983|PROCEDURE|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
48360199|NCT02036983|PROCEDURE|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
48360200|NCT02036983|PROCEDURE|Opioid IV medications (Control)|Standard anesthetic technique.
48360201|NCT01276795|DIETARY_SUPPLEMENT|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
48360202|NCT03864029|DRUG|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
48360203|NCT02603939|PROCEDURE|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
48360204|NCT04134689|DEVICE|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
48360205|NCT04134689|OTHER|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
48360206|NCT05977569|OTHER|Prolonged Fasting|Participants are asked to refrain from caloric intake for 3 days following a period of habitual lifestyle assessment and metabolic assessment.
48509070|NCT03261492|BEHAVIORAL|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
48673021|NCT05289752|DEVICE|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
48673022|NCT01047189|DRUG|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
48673023|NCT01047189|DRUG|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
48673024|NCT01047189|DRUG|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
48673025|NCT05981326|PROCEDURE|Biopsy|biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment
48673026|NCT05981326|PROCEDURE|Blood samples|Centralized blood samples will be performed at inclusion + evaluation visits
48673027|NCT05981326|BEHAVIORAL|Questionnaires|Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
48360207|NCT03789864|DIAGNOSTIC_TEST|Biodynamic imaging (BDI) of mycosis fungoides|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
48360208|NCT03287726|DIETARY_SUPPLEMENT|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
48509071|NCT03261492|BEHAVIORAL|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
48509072|NCT02227511|DIETARY_SUPPLEMENT|Fruits|Randomization to extra fruit or nuts as snacks
48673028|NCT03861182|BIOLOGICAL|Biological functionalization of the prosthetic materials by PRF|The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
48673029|NCT03376516|DRUG|Wilate|von Willebrand factor / Factor VIII (plasma derived)
48673030|NCT02803203|DRUG|osimertinib|
48673031|NCT02803203|DRUG|Bevacizumab|
48673032|NCT04170088|DRUG|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
48673033|NCT04170088|DRUG|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
48673034|NCT05562505|OTHER|Venovenous ECMO|ECMO therapy for patients with hypoxic respiratory failure.
48673035|NCT00696878|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
48673036|NCT00696878|BIOLOGICAL|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
48673037|NCT00696878|BIOLOGICAL|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
48673038|NCT00696878|BIOLOGICAL|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
48673039|NCT00696878|DRUG|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
48673040|NCT02432430|BEHAVIORAL|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
48673041|NCT02432430|BEHAVIORAL|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
48673042|NCT03609424|DRUG|PDR001, Imatinib|"-Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested"
48360209|NCT03287726|DIETARY_SUPPLEMENT|placebo|Placebo 2 capsules/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
48509073|NCT02227511|DIETARY_SUPPLEMENT|Nuts|
48509074|NCT04409483|DRUG|Lopinavir-Ritonavir Drug Combination|400mg/100mg taken orally twice daily for 14 days.
48509075|NCT04409483|COMBINATION_PRODUCT|Standard Care|Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
48509076|NCT04181723|DRUG|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
48673043|NCT04044963|BEHAVIORAL|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
48673044|NCT01323985|DRUG|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
48509077|NCT04181723|OTHER|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
48509078|NCT05388513|PROCEDURE|Surgical Resection|Surgically treated patients included
48509079|NCT00476775|BEHAVIORAL|after school ethnic dance program - ballet folklorica|
48509080|NCT00476775|BEHAVIORAL|culturally-tailored, home-based screen time reduction|
48673045|NCT01323985|DRUG|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
48673046|NCT02945124|OTHER|K tape|Applying K tape to children to the lower limb muscles during motor activities.
48673047|NCT05236036|DRUG|Mycophenolate Mofetil|Given PO
48673048|NCT05236036|OTHER|Quality-of-Life Assessment|Ancillary studies
48509081|NCT00476775|BEHAVIORAL|culturally-tailored health and nutrition education|
48509082|NCT04049136|DIAGNOSTIC_TEST|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
48509083|NCT03167463|PROCEDURE|flap|Repair choanal atresia with using flap during surgery
48509084|NCT01056315|DRUG|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
48509085|NCT01056315|DRUG|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
48509086|NCT02558530|OTHER|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
48509087|NCT05498181|DRUG|Sacubitril-valsartan|sacubitril/valsartan
48509088|NCT05498181|DRUG|Placebo|Placebo
48673049|NCT05236036|RADIATION|Radiation Therapy|Receive radiation therapy
48673050|NCT05236036|DRUG|Temozolomide|Given Orally (PO)
48509089|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3|50,000 IU VD3 / week for 8 weeks
48673051|NCT06544044|BEHAVIORAL|Brief Mindfulness' Self compassion|session includes mindfulness exercises like breath awareness and body scans, self-compassion practices like self-kindness meditations, and emotional regulation strategies such as cognitive reappraisal and response modulation. Discussions focus on applying mindfulness and self-compassion to manage difficult emotions, improve interpersonal interactions, and reduce aggression. Home practice assignments encourage students to integrate mindfulness and self-compassion into their daily lives. The program curriculum is based on existing evidence-based interventions, including mindfulness-based stress reduction for teens.
48673052|NCT04174859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
48360210|NCT03941327|DEVICE|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
48360211|NCT05754736|DRUG|Ametinib combined with bevacizumab|Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
48509090|NCT04005612|DIETARY_SUPPLEMENT|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
48509091|NCT04005612|DIETARY_SUPPLEMENT|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
48509092|NCT04005612|OTHER|control|no intervention
48360212|NCT03086044|DRUG|Sofosbuvir/velpatasvir|2 weeks of treatment beginning on the day of transplant
48360213|NCT03086044|OTHER|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
48360214|NCT04071639|DRUG|Haloperidol 2Mg Tab|Haloperidol take 0.5mg\~2mg three time a day.
48360215|NCT04071639|DRUG|Risperidone 1Mg Tab|Risperidone take 1mg once at night.
48360216|NCT04071639|DRUG|Zoloft 50Mg Tablet|Zoloft take 50mg once in the morning.
48509093|NCT01767038|PROCEDURE|OCT Spectralis|
48509094|NCT01767038|PROCEDURE|microperimetry|
48509095|NCT03115268|BEHAVIORAL|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
48148749|NCT04883515|PROCEDURE|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
48148750|NCT02990494|BEHAVIORAL|STANDARD|Standard Internet-delivered behavioral weight loss
48360217|NCT04071639|DRUG|Idebenone|Idebebone take 30mg three times a day.
48673053|NCT03859076|BEHAVIORAL|MB-BP|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
48673054|NCT03859076|OTHER|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
48673055|NCT01760577|DRUG|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
48673056|NCT01760577|DRUG|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
48148751|NCT02990494|BEHAVIORAL|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
48148752|NCT02990494|BEHAVIORAL|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
48148753|NCT06207747|DIAGNOSTIC_TEST|additional PET/CT at 4 weeks, analysing using quantative analysis|Patient with metastatic melanoma will be monitored with additional PET/CT at 4 weeks, analysing using quantative analysis will be done.
48148754|NCT01027455|DEVICE|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
48148755|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
48148756|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
48148757|NCT01473459|PROCEDURE|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
48360218|NCT04071639|DRUG|Deutetrabenazine Oral Tablet [Austedo]|The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
48148758|NCT01473459|PROCEDURE|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
48360219|NCT05315531|DIETARY_SUPPLEMENT|Water Intake|Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
48360220|NCT03677440|BEHAVIORAL|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
48360221|NCT03677440|BEHAVIORAL|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
48673057|NCT00001937|DRUG|FK463|
48673058|NCT00001937|DRUG|Fluconazole|
48673059|NCT02267434|BIOLOGICAL|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
48673060|NCT02267434|BIOLOGICAL|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
48673061|NCT02267434|BIOLOGICAL|Adjuvant without active component|s.c. injection
48673062|NCT04580914|DEVICE|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
48673063|NCT05330871|BIOLOGICAL|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48673064|NCT05330871|BIOLOGICAL|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48360222|NCT01832051|DRUG|89Zr-trastuzumab injection|
48360223|NCT02293200|DEVICE|Standard BLS|basic life support without any feedback device
48360224|NCT02293200|DEVICE|TrueCPR|CPR with feedback device
48509096|NCT01857479|DRUG|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
48509097|NCT01857479|DRUG|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision."
48673065|NCT05330871|BIOLOGICAL|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48673066|NCT05330871|BIOLOGICAL|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48673067|NCT05330871|BIOLOGICAL|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
48673068|NCT05330871|BIOLOGICAL|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
48148759|NCT02765984|DEVICE|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
48148760|NCT02591082|DEVICE|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
48360225|NCT00086164|DRUG|edifoligide (E2F Decoy)|
48360226|NCT01309581|DRUG|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
48360227|NCT01309581|DRUG|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
48360228|NCT02195895|DRUG|Alendronate|Weekly oral alendronate 70 mg for 12 months
48360229|NCT02195895|DIETARY_SUPPLEMENT|Calcium|Daily oral 1000 mg Calcium
48673069|NCT05330871|BIOLOGICAL|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
48673070|NCT05330871|BIOLOGICAL|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
48360230|NCT02195895|DIETARY_SUPPLEMENT|Vitamin D|Daily oral 1000 IU
48360231|NCT04778696|PROCEDURE|PASO Pacemapping|Using the PASO pacemapping visualisation module of CARTO3
48360232|NCT04778696|PROCEDURE|Conventional Pacemapping|without visualisation in 3D mapping
48360233|NCT03466528|DRUG|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
48360234|NCT03466528|DRUG|Pabrinex|standard treatment
48360235|NCT01431794|DRUG|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
48360236|NCT01431794|DRUG|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
48360237|NCT01431794|DRUG|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
48360238|NCT01431794|DRUG|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
48673071|NCT05330871|BIOLOGICAL|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
48673072|NCT05330871|BIOLOGICAL|10 Intramuscular injection for booster groups|1 dose 0.5ml
48673073|NCT05330871|BIOLOGICAL|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48673074|NCT05330871|BIOLOGICAL|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48509098|NCT02480348|DEVICE|Polymer-free DES (Drug Eluting Stent)|
48360239|NCT01431794|DRUG|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
48360240|NCT01512849|DRUG|TA-7284 Low|Low
48360241|NCT01512849|DRUG|TA-7284 High|High
48360242|NCT04728789|DRUG|Avatrombopag 20 MG|Avatrombopag 20mg/week to 60mg/day, starting at 20mg/day and increased by 20 mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
48360244|NCT01816516|BEHAVIORAL|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
48360245|NCT01816516|BEHAVIORAL|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
48360246|NCT01697371|RADIATION|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
48360247|NCT01697371|RADIATION|Proton Radiation|
48360248|NCT01183299|OTHER|Dietary salt intake|
48360249|NCT01979003|DRUG|Fluorescein|
48360250|NCT00204763|DEVICE|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
48360251|NCT00204763|DEVICE|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
48509099|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
48673075|NCT05330871|BIOLOGICAL|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48148761|NCT01571440|DIETARY_SUPPLEMENT|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
48360252|NCT04686110|OTHER|angiographic optical coherence tomography|angiographic optical coherence tomography
48360253|NCT03389594|OTHER|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
48360254|NCT04205604|DRUG|18F-Fluoro Dopa Imaging|Imaging with 18F-Fluoro Dopa PET Imaging
48360255|NCT02429206|OTHER|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
48360256|NCT02429206|OTHER|standard moisturizing cream (Glaxal Base)|
48673076|NCT05330871|BIOLOGICAL|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
48673077|NCT05330871|BIOLOGICAL|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
48360257|NCT02295254|OTHER|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
48673078|NCT05330871|BIOLOGICAL|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
48673079|NCT05330871|BIOLOGICAL|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
48673080|NCT05330871|BIOLOGICAL|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
48673081|NCT05330871|BIOLOGICAL|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
48673082|NCT05330871|BIOLOGICAL|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
48360258|NCT00458601|DRUG|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
48673083|NCT05330871|BIOLOGICAL|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
47991025|NCT05973383|BEHAVIORAL|LongLife Active- Standard|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Standard are also offered a community with social support."
48673084|NCT05330871|BIOLOGICAL|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
48673085|NCT05330871|BIOLOGICAL|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
48673086|NCT05330871|BIOLOGICAL|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
48673087|NCT04754763|DRUG|Dentin-Bonding Agents|3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
48673088|NCT04754763|DRUG|Propolis|Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific \& Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
48148762|NCT01571440|DIETARY_SUPPLEMENT|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
48148763|NCT00048477|DRUG|L-NMMA and Sodium Nitrite|
48360259|NCT00458601|DRUG|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
48360260|NCT03459105|PROCEDURE|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
48360261|NCT03459105|PROCEDURE|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
48673089|NCT01889394|PROCEDURE|secondary wound healing|secondary wound healing
48673090|NCT01889394|PROCEDURE|primary wound closure using a limberg flap|primary wound closure using a limberg flap
48148764|NCT04644692|OTHER|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
48673091|NCT03759990|DEVICE|lean|Videolaryngoscope used in intubation
48148765|NCT03204773|DIAGNOSTIC_TEST|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
48148766|NCT03204773|DIAGNOSTIC_TEST|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
48148767|NCT03204773|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|Testing for pain
48148768|NCT03204773|DIAGNOSTIC_TEST|Becks Depression Inventory (BDI)|Screening for depression
48673092|NCT03759990|DEVICE|obese|Videolaryngoscope used in intubation
48673093|NCT00827177|DRUG|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If \< 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
48673094|NCT06353815|OTHER|4% articaine infiltration|Two injections using short needle and dental syringe will be given , the first injection is 1.5 ml out of 1.8 ml of 4% articaine with 1:100,000 epinephrine (ARTINIBSA 4% 1:100,000) in the mucobuccal fold adjacent to the mandibular first Molar, the second injection is 0.3 ml in the lingual side for lingual soft and hard tissues .
48673095|NCT02552576|BIOLOGICAL|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
48360262|NCT03459105|DRUG|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
48673096|NCT04635137|PROCEDURE|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
48673097|NCT05548764|PROCEDURE|Prevention Bundles for SSIs|10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
48673098|NCT02700672|OTHER|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
48673099|NCT04457986|DRUG|Erector spina plane block (ESP)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
48673100|NCT04457986|DRUG|Modified thoracolumbar interfacial plane block (MTI)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
48673101|NCT04457986|DRUG|Intravenous patient controlled analgesia (IV-PCA)|Patient will receive intravenous patient controlled analgesia with tramadol
48673102|NCT00834821|BEHAVIORAL|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
48673103|NCT00834821|BEHAVIORAL|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
48673104|NCT01033929|BIOLOGICAL|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
48148769|NCT03204773|DIAGNOSTIC_TEST|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
48360263|NCT00574340|OTHER|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
48360264|NCT01939067|DEVICE|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
48360265|NCT01939067|DEVICE|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
48673105|NCT03704350|DIETARY_SUPPLEMENT|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
48673106|NCT01469039|DRUG|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
48673107|NCT01469039|DRUG|Placebo|Placebo for IM injection, given monthly
48673108|NCT03119168|DRUG|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
48673109|NCT03119168|OTHER|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
48673110|NCT01302184|DEVICE|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
48673111|NCT01302184|DEVICE|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
48673112|NCT03461471|BEHAVIORAL|Exercise Intervention|Exercise intervention
48148770|NCT02133131|DRUG|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
48148771|NCT02133131|DRUG|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
48673113|NCT04364087|DIAGNOSTIC_TEST|Oral glucose tolerance test|Oral glucose tolerance test with 75 g glucose (75 g OGTT) will be performed to those with normal fasting glucose and HbA1C levels. Women will be recommended to have normal diet for 3 days and overnight fasting for at least 8 hours. The blood withdrawal will be performed twice: (i) fasting and (2i) 2 hours after solution administration. The volume of blood for each test is 2 ml. Impaired glucose tolerance will be diagnosed when two-hour glucose levels of 140 to 199 mg/dL (7.8 to 11.0 mmol/l) (American Diabetes Association, 2018).
48673114|NCT05117814|DRUG|Zanubrutinib|as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
48673115|NCT04781530|DEVICE|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)|BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus): Nasopharyngeal swab
48673116|NCT02011269|BIOLOGICAL|Trichuris Suis Ova|
48673117|NCT03089554|DRUG|Therapeutic Intervention|Therapeutic Intervention
48673118|NCT05778695|DIETARY_SUPPLEMENT|Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate|Ketone ester (KE) dietary supplement (KetoneAid)
48673119|NCT02351011|BIOLOGICAL|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
48673120|NCT02351011|BIOLOGICAL|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
48673121|NCT02351011|BIOLOGICAL|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
48673122|NCT04592341|DRUG|Gantenerumab|Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
48673123|NCT05724082|OTHER|Clean Air Intervention|"Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc."
48673124|NCT02117778|PROCEDURE|Continuous Nerve Block|
48673125|NCT05718817|DRUG|XEN1101|XEN1101 capsules
48673126|NCT00800800|DRUG|Rosuvastatin|40 mg, oral, single dose
48673127|NCT00800800|DRUG|Placebo|oral, single dose
48673128|NCT01790373|BEHAVIORAL|Suubi+Adherence|"* Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~* Financial education and workshops on asset-building, future planning, and protection from risks~* Mentorship from a young adult/near-peer~* Family-based microenterprise development training~* Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
48673129|NCT01790373|BEHAVIORAL|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
48673130|NCT04169464|DRUG|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
48673131|NCT00297869|PROCEDURE|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
48673132|NCT02234726|BEHAVIORAL|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
48673133|NCT05894057|OTHER|Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB|On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.
48673134|NCT01252082|PROCEDURE|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
48673135|NCT00894387|DRUG|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
48673136|NCT00894387|DRUG|Placebo|Placebo
48148772|NCT02002689|DRUG|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
48148773|NCT00994708|DRUG|esomeprazole|
48148774|NCT04894136|PROCEDURE|ICSI-TESE; embryo-transfer|The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.
48148775|NCT01578304|DRUG|Imidafenacin|Tablet, 12 weeks twice daily
48148776|NCT01578304|DRUG|Fesoterodine|Tablet, 12 weeks once daily
48360266|NCT01246024|DEVICE|ERG|scotopic and photopic ERG
48673137|NCT05246527|BEHAVIORAL|Physical Exercise|30 min of cycling on an ergometer, moderate or high intensity
48673138|NCT05246527|BEHAVIORAL|Control Intervention|30 min of watching a movie
48673139|NCT02448199|DRUG|Meloxicam and Glucosamine|Experimental
48673140|NCT02448199|DRUG|Meloxicam|Active Comparator
47991026|NCT05973383|BEHAVIORAL|LongLife Active- Premium|"The digital service LongLife Active with three core subjects:~1) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Premium are also offered a community with social support plus private on-line health consultations. The number of private health consultations is 3 for a 3 months subscription, 4 for a 6 months subscription, and 6 for a 12 months subscription."
48673141|NCT02448199|DRUG|Glucosamine|Active Comparator
48673142|NCT03423407|DEVICE|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
48673143|NCT05738330|BEHAVIORAL|Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)|Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
48673144|NCT05738330|BEHAVIORAL|Usual Care|Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
48673145|NCT03520309|PROCEDURE|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
48673146|NCT05158920|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)|MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
48673147|NCT00314821|DRUG|ropinirole|
48673148|NCT04037228|DEVICE|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
48673149|NCT03586271|PROCEDURE|trifocal lens|phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
48673150|NCT03586271|PROCEDURE|bifocal lens 1|phacoemusification +bifocal lens(Diff-aay) implantation
48673151|NCT03586271|PROCEDURE|bifocal lens 2|phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
48673152|NCT03586271|PROCEDURE|bifocal lens 3|phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
48673153|NCT00818090|DRUG|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
48148777|NCT06222086|OTHER|Calisthenic exercise training with telerehabilitation|The training group will be given calisthenic exercise training 30-45 minutes a day, 3 days a week, via video conference, accompanied by a physiotherapist, for 6 weeks. The training workload of aerobic exercise training will be applied at 60-80% of peak heart rate, with dyspnea 3-4 points or fatigue 4-6 points according to the Modified Borg Scale (MBS). Blood sugar measurement will be taken before exercise training. People whose blood sugar result is \>300 mg/dL will not be allowed to exercise that day.
48148778|NCT06222086|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
48148779|NCT05005247|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
48673154|NCT03940807|DRUG|11.25mg GnRH agonist|"Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
48148780|NCT05951335|OTHER|m-Health Transition Care Program|The m-Health supportive care transition program is a routine support program for caregivers of TBI patients. This program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, which consists of education about physical health, TBI medical problems, and how to treat TBI patients at home.
48148781|NCT04913194|BEHAVIORAL|ARFID-PTP|ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
48360267|NCT02581501|DRUG|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
48360268|NCT03316898|DRUG|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
48360269|NCT03316898|DRUG|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
48360270|NCT03316898|DRUG|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
48360271|NCT03316898|DRUG|Memantine|Memantine as prescribed by the physician as per standard of care.
48673155|NCT03940807|DRUG|0.1 mg GnRH agonist|"Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
48360272|NCT02331173|DRUG|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~* Topical dorzolamide 2% three times per day~* Topical brinzolamide 1% three times per day"
48360273|NCT04835389|BIOLOGICAL|AlloGen Liquid|Amniotic fluid
48360274|NCT04835389|DRUG|Placebo|0.9% normal saline
48360275|NCT02571829|DRUG|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
48673156|NCT03940807|DRUG|25 µg transdermal oestradiol|Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
48673157|NCT05761821|DEVICE|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
48673158|NCT06105918|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48673159|NCT06105918|PROCEDURE|Computed Tomography|Undergo rhPSMA-7.3 PET/CT and SPECT-CT
48148782|NCT04836871|COMBINATION_PRODUCT|DFPP combined with chemotherapy|Double filtration plasmapheresis combined with chemotherapy
47991027|NCT04171973|DEVICE|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
48509100|NCT05805215|COMBINATION_PRODUCT|Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus|"TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz."
48509101|NCT05805215|COMBINATION_PRODUCT|High-frequency stimulation (placebo) with Face-name association training task|High-frequency (\>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
48509102|NCT04001946|DEVICE|Button Huggie|low profile, external securement device for G-buttons
48509103|NCT02103504|DEVICE|DePuy Attune posterior stabilized fixed bearing total knee replacement|
48509104|NCT05422638|BEHAVIORAL|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
48673160|NCT06105918|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48673161|NCT06105918|OTHER|Flotufolastat F-18|Given IV
48673162|NCT06105918|DRUG|Lutetium Lu 177 PSMA-10.1|Given IV
48673163|NCT06105918|PROCEDURE|Positron Emission Tomography|Undergo rhPSMA-7.3 PET/CT
48673164|NCT06105918|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT scan
48673165|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
48673166|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
48673167|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
47991028|NCT04171973|DEVICE|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
47991029|NCT04415281|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
47991030|NCT04415281|DEVICE|sham THOR® laser system|sham THOR® laser system
48148783|NCT06562881|OTHER|Scheduling Navigation|Participants will be connected to a scheduler to schedule a surgical consultation visit at time of recruitment. Participation does not guarantee or require surgery.
48148784|NCT06562881|OTHER|Without Scheduling Navigation|Patients will work with clinic staff in the usual fashion for their treatment for primary hyperparathyroidism. They will not be connected directly to a scheduler to help schedule a surgical consultation visit at time of recruitment. With our crossover design, if patients have not yet received surgical consultation after 3 months, they will be called and connected with a scheduler at that time. Participation does not guarantee or require surgery.
48148785|NCT04440956|DRUG|64Cu-SARTATE|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."
48509105|NCT05422638|BEHAVIORAL|PCT|8-week health promotion group focused on providing support and facilitating problem solving
48509106|NCT06448260|OTHER|Questionnary|Data from theses patients will be collected in our personnal data base with ask of consent according to the law Then each patient alive will have questionnary to answer by phone or during a visit.
48509107|NCT06273267|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
48673168|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
48673169|NCT06354673|PROCEDURE|Stellate ganglion block|Sympathectomy by using combination of regional nerve block and systemic drugs
48673170|NCT06354673|DRUG|Dexmedetomidine|intravenous Dexmedetomidine infusion
48673171|NCT06354673|DRUG|Ketamine|intravenous ketamine infusion
48673172|NCT06266000|DRUG|Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
48673173|NCT06266000|DRUG|Commercial Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
48673174|NCT06266000|DRUG|Palm Oil capsule|Palm oil capsule
48673175|NCT04435743|DRUG|Lenalidomide|"Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles."
48673176|NCT01667341|BIOLOGICAL|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
48673177|NCT01667341|BIOLOGICAL|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
48673178|NCT01667341|BIOLOGICAL|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
48673179|NCT04016701|DEVICE|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
48360276|NCT05677906|OTHER|Walking only (Step It Up!)|Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.
48360277|NCT05677906|OTHER|Combined (Step It Up! plus Civic Engagement)|Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
48360278|NCT01335659|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
48509108|NCT02045147|BEHAVIORAL|Grp 1a Low Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
48509109|NCT02045147|BEHAVIORAL|Grp 2a Low Cognition, High Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
48509110|NCT02045147|BEHAVIORAL|Grp 3a Normal Cognition, Low Activation Intervention|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
48509111|NCT02045147|BEHAVIORAL|Grp 4a Normal Cognition, High Activation Intervention|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
48509112|NCT06489626|DRUG|Methylprednisolone 4 milligram Tab|6-day 4 milligram methylprednisolone oral taper
48673180|NCT04016701|BEHAVIORAL|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
48673181|NCT05812326|DRUG|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
48673182|NCT00577278|BIOLOGICAL|rituximab|Given IV
47991031|NCT05057442|OTHER|Proprioception assessment, functionality assessment|Proprioception assessment, functionality assessment
47991032|NCT06368960|RADIATION|Radiotherapy|Radiation： Hypofractionated radiotherapy
47991033|NCT06368960|DRUG|BM201 injection|BM201 injection：Dose escalation：24mg to 240mg
48148786|NCT06237621|DEVICE|SnapshotNIR imaging|SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
48360279|NCT01335659|DEVICE|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
48360280|NCT00979862|DRUG|Cediranib Maleate|Given PO
48360281|NCT00979862|DRUG|Cilengitide|Given IV
48360282|NCT00979862|OTHER|Laboratory Biomarker Analysis|Correlative studies
48360283|NCT03157752|BEHAVIORAL|Quality of life questionnaire|Quality of life questionnaire
48360284|NCT00547729|DEVICE|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
48360285|NCT01706744|OTHER|Intermediate care unit|
48509113|NCT06489626|DRUG|Dexamethasone injection|4 milligram intravenous dexamethasone will be administered intraoperatively
48509114|NCT01339338|PROCEDURE|warming the contrast media|warm the contrast media with 37℃ water-bathing
48509115|NCT05475327|OTHER|Conventional Physical Therapy|"Heating pad~A total of 3 sessions per week were given for 15 to 20 mins"
48673183|NCT00577278|DRUG|fludarabine phosphate|Given IV
48148787|NCT02214914|DRUG|BI 11634 drinking solution|
48148788|NCT02214914|DRUG|BI 11634 tablet|
48360286|NCT01706744|OTHER|Local health care 1|
48360287|NCT01706744|OTHER|Local health care 2|
48360288|NCT00682409|OTHER|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
48360289|NCT00544674|DRUG|PR104|administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks
48360290|NCT00544674|OTHER|F-18-fluoromisonidazole|administered intravenously prior to PET scan
48673184|NCT00577278|DRUG|melphalan|Given IV
48673185|NCT00577278|DRUG|sirolimus|Given PO
48673186|NCT00577278|DRUG|tacrolimus|Given PO or IV
48360291|NCT04950491|OTHER|Modified Dental Anxiety Score (MDAS) questionnaire|MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
48360292|NCT04950491|OTHER|Pain questionnaire|Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
48360293|NCT04950491|OTHER|Oral Health-Related Quality of Life (OHRQoL) questionnaire|The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
48360294|NCT06089772|OTHER|Comparing to Manipulation and Myofascial Release Techniques|Randomized Controlled Trials
48360295|NCT02883010|DEVICE|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
48360296|NCT02883010|OTHER|Standard Care|Care path normally used by the hospital
47991034|NCT02009046|BEHAVIORAL|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
47991035|NCT02009046|BEHAVIORAL|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
48360297|NCT06356649|PROCEDURE|extubation|Complications after extubation
48360298|NCT02961348|OTHER|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
48360299|NCT02961348|OTHER|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
48509116|NCT05475327|OTHER|Relaxation exercises|"The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins."
48509117|NCT03103516|PROCEDURE|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
48148789|NCT02214914|DRUG|Placebo|
48360300|NCT03572699|OTHER|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
48360301|NCT03925493|BEHAVIORAL|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
48148790|NCT00595764|BEHAVIORAL|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
48360302|NCT03925493|BEHAVIORAL|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
48360303|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
48509118|NCT03103516|PROCEDURE|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
48509119|NCT06593054|DRUG|Ceftibuten|Ceftibuten dihydrate, formulated in capsules
48509120|NCT06593054|DRUG|Avibactam prodrug|Avibactam prodrug, formulated in capsules
48673187|NCT00577278|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
48148791|NCT00595764|BEHAVIORAL|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
48509121|NCT06593054|DRUG|CTB-AVP in Tablet|ceftibuten and avibactam prodrug, in Tablet formulation
48509122|NCT04026386|BEHAVIORAL|Center Based or In Home Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
48509123|NCT00990860|DRUG|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
48148792|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
48148793|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
48509124|NCT00990860|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
48509125|NCT01296997|DIETARY_SUPPLEMENT|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
48673188|NCT00577278|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
48673189|NCT00577278|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
48673190|NCT00577278|OTHER|laboratory biomarker analysis|Correlative Studies
48673191|NCT01173510|DRUG|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
48673192|NCT01173510|DRUG|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
48673193|NCT06211699|PROCEDURE|Omentopexy with Laparoscopic Sleeve Gastrectomy|Patients with omentum sewed to the remnant gastric staple line during laparoscopic sleeve gastrectomy.
48673194|NCT06211699|PROCEDURE|Clips with Laparoscopic Sleeve Gastrectomy|Patients performed clips to the remnant gastric staple line during laparoscopic sleeve gastrectomy
48673195|NCT03401437|BEHAVIORAL|SF-36|Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
48673196|NCT03401437|BEHAVIORAL|HAD|Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
48673197|NCT03401437|OTHER|ANSM|Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
47991036|NCT02009046|BEHAVIORAL|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
47991037|NCT02009046|BEHAVIORAL|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
48509126|NCT01296997|OTHER|placebo|the subjects consumed a bread without pentacalcium phosphate
48509127|NCT05322109|DIAGNOSTIC_TEST|CMR|Clinically indicated cardiac magnetic resonance tomography executed according to international guideline recommendations.
48360304|NCT03062644|DRUG|MR308|four times daily; Mode of Administration:oral
48360305|NCT03062644|DRUG|MR308|two times daily; Mode of Administration:oral
48360306|NCT03062644|DRUG|MR308|given four times daily to maintain the blind; Mode of Administration:oral
48509128|NCT00709488|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
48509129|NCT00709488|PROCEDURE|Placement of device in prostate urethra|Placement of device in prostate urethra
48509130|NCT00709488|DEVICE|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
48509131|NCT04290195|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Intravitreal injection of 1.25 mg of ziv aflibercept in patients
48509132|NCT01243437|DRUG|ciprofloxacin|"* For adults and children aged \> 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
48509133|NCT01243437|DRUG|doxyxcycline|"* For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~* For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
48509134|NCT05150847|OTHER|Oxygenation|Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
48509135|NCT03548701|DIAGNOSTIC_TEST|Thromboelastometry testing|Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
48509136|NCT03307265|DEVICE|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
48509137|NCT03307265|DEVICE|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
48509138|NCT03685578|DEVICE|EmboTrap® Revascularization Device|EmboTrap® Revascularization Device
48509139|NCT03685578|DEVICE|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
48360307|NCT04568629|OTHER|Advice from the PiPS-B14 prognostic tool|"Participants were informed that prognostic advice came from the PiPS-B14 prognostic tool. PiPS-B14 is a validated prognostic algorithm that has been shown to be as accurate as an agreed multi-professional survival estimate.~Participants were further informed that in a previous study the PiPS-B14 risk categories for predicting two-week survival were as accurate as a doctor's or a nurse's prediction."
48360308|NCT04568629|OTHER|Advice from another clinician|"Participants were informed that prognostic advice came from another clinician.~Doctors were told that advice was from a nurse, whereas nurses or other types of HCPs were told that advice was from a doctor."
47991038|NCT00876954|PROCEDURE|Normothermia|Warming without increase in core temperature
48148794|NCT00279409|DRUG|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
48148795|NCT00279409|DRUG|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
48148796|NCT00842959|DEVICE|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
48148797|NCT00842959|DEVICE|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
48148798|NCT02820909|PROCEDURE|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
48509140|NCT03685578|DEVICE|CEREGLIDE 71 Intermediate Catheter|CEREGLIDE 71 Intermediate Catheter
48509141|NCT05056896|DRUG|Aspirin|Capsule taken orally
48509142|NCT05056896|OTHER|Placebo|Capsule taken orally
48148799|NCT02820909|PROCEDURE|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (\> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
48360309|NCT05243199|DRUG|Sacubitril/Valsartan|The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).
48509143|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
48509144|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
48673198|NCT01883024|OTHER|A decision support software|
48360310|NCT05243199|DRUG|Irbesartan|The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
48360311|NCT01294761|DRUG|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
48360312|NCT05662488|DIAGNOSTIC_TEST|[68Ga]FAPI PET/CT and [18F]FDG PET/CT|To perform \[68Ga\]FAPI PET/CT and \[18F\]FDG PET/CT in patients with advanced liver and biliary cancer before and after treatment with PD-1 Based Combination Therapy
47991039|NCT00876954|PROCEDURE|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
47991040|NCT04877470|OTHER|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
47991041|NCT05757921|DEVICE|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
48360313|NCT01888380|PROCEDURE|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
48360314|NCT01888380|PROCEDURE|Conventional autopsy|
48360315|NCT00880958|DIETARY_SUPPLEMENT|Mixture of various probiotics and fermentation products|
48360316|NCT00880958|DIETARY_SUPPLEMENT|Placebo|
48360317|NCT04229186|DIETARY_SUPPLEMENT|EVOO-C|Each patient will consume 10 mg total daily amount EVOO-C
48360318|NCT04229186|DIETARY_SUPPLEMENT|ROO|Each patient will consume 10 mg total daily amount ROO
48509145|NCT01898273|DRUG|I-124-CLR1404|single-dose, intravenous
48509146|NCT03122197|DRUG|Letrozole Oral Tablet|Administration: Letrozole will be given orally once daily.
48509147|NCT03122197|DRUG|Temozolomide|50 mg/m2 TMZ administered orally once daily
48509148|NCT05180916|DEVICE|TVNS|Cerbomed NEMOS
48509149|NCT06599580|BEHAVIORAL|Training caregivers to screen children for malnutrition relapse|Caregivers enrolled in the trial who are assigned to the two experimental arms, will be provided mid-upper arm circumference tapes and trained on how to screen their child for malnutrition relapse and asked to bring their child back to the clinic if relapse is detected.
48673199|NCT01883024|OTHER|Insulin Pump|
48673200|NCT01883024|OTHER|Continuous glucose monitoring|
48673201|NCT04902989|OTHER|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
48673202|NCT01783444|DRUG|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
48360319|NCT04121182|OTHER|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
48360320|NCT04121182|OTHER|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
48360321|NCT02411968|OTHER|111In-Girentuximab DOTA SPECT|
48673203|NCT01783444|DRUG|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
48673204|NCT01783444|DRUG|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
47991042|NCT05757921|OTHER|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
48360322|NCT00003716|BIOLOGICAL|rituximab|
48360323|NCT00561028|OTHER|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
48673205|NCT01900886|OTHER|Peginterferon alfa-2a|Treatment as usual clinical practice
48673206|NCT01900886|DRUG|Ribavirin|Treatment as usual clinical practice
47991043|NCT05799807|PROCEDURE|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
47991044|NCT05799807|PROCEDURE|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
47991045|NCT01057017|BIOLOGICAL|intervention|
48360324|NCT00264628|DRUG|GW679769|
48360325|NCT01024946|DRUG|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
48673207|NCT03910621|DRUG|Miglustat|capsule, oral use
48673208|NCT05262244|DRUG|Bevacizumab-IRDye800CW|Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
48673209|NCT05262244|DRUG|Vedolizumab-IRDye800CW|Vedolizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
48509150|NCT06599580|OTHER|Reduced follow-up schedule|Caregivers in one of the caregiver mid-upper arm circumference screening arms, will be asked to adhere to a reduced follow-up clinic visit schedule for when they bring their child to the clinic for planned visits. The standard of care includes monthly visits for the first 3 months post recovery, but those randomized to the reduced follow-up schedule arm, will not bring their child to the clinic for planned visits 1 month and 2 months after baseline.
48509151|NCT06349590|DIETARY_SUPPLEMENT|High-fiber/low-fat meals|Meals with Low fat/High fiber
48509152|NCT04274231|GENETIC|different effection|Analysis of the reasons for treatment
48509153|NCT00002678|DRUG|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
48509154|NCT00002678|DRUG|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
48148800|NCT04795999|BEHAVIORAL|Project With|There are 12 lessons in Project With, typically delivered in six weekly sessions, with each session having two one-hour long lessons and a meal with facilitators in between the two lessons. Each lesson includes a discussion of selected literary works, including poetry, short stories, and excerpts from films and other videos. The curriculum is intended to be delivered to groups of 8-12 youth. In ideal program delivery, participants also share a meal with each other and with the Youth Advocate. Shared mealtimes create group cohesion and allow Youth Advocates to connect with participants on a personal level, building trust. At the end of the Project With curriculum, youth will partake in an offsite day excursion to Camp Eaton, a wooded camp outside of Los Angeles. At Camp Eaton, Youth Advocates will lead a Project With session, lunch, bonding activities and games, and an opportunity to engage in an outdoor activity.
48148801|NCT03909074|BIOLOGICAL|36-71 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
48148802|NCT03909074|BIOLOGICAL|36-71 months old children-control EV71 vaccine.|Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
48509155|NCT00002678|DRUG|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
48673210|NCT05964179|BEHAVIORAL|time extended feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.
48673211|NCT05964179|BEHAVIORAL|time restricted feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
47991046|NCT06162442|DRUG|Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)|"The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria."
47991047|NCT05158868|DIAGNOSTIC_TEST|HiF-1 alpha measurement|HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
47991048|NCT05805982|BEHAVIORAL|Educational Video|Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
48673212|NCT00820989|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
48673213|NCT01634217|BIOLOGICAL|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
48673214|NCT00775268|PROCEDURE|Biopsy|Biopsy taken
48148803|NCT03909074|BIOLOGICAL|6-35 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
48509156|NCT00166582|DEVICE|electronic medication monitoring system|
48509157|NCT00166582|BEHAVIORAL|parent-adolescent communication and problem-solving skills|
48509158|NCT05640258|DIAGNOSTIC_TEST|rotatory chair testing in a velocity step protocol.|Tc was evaluated by the rotational velocity step test using the OtoaccessTM interface (Interacoustics Nydiag 200, Middlefart, Denmark). Subjects were seated on the rotatory chair wearing videonystagmography goggles with their heads supported and tilted 30° forward, thus bringing the horizontal semicircular canals plane perpendicular to the axis of rotation. Standard videonystagmography techniques were employed to record eye-movements. Subsequent to eye movements' calibration, the chair was accelerated about the yaw axis at 30°/sec2 to a maximal velocity of 90°/sec, followed by rotation at a constant velocity. After 57 seconds of constant velocity rotation, the chair was decelerated to zero velocity at 30°/sec2. The described velocity step was conducted both clockwise and counter-clockwise, giving a total run time of 4 minutes.
48673215|NCT00775268|DIAGNOSTIC_TEST|fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography|Imaging
48673216|NCT00775268|OTHER|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
48673217|NCT00775268|PROCEDURE|computed tomography|Undergo scans
48673218|NCT00775268|PROCEDURE|fine-needle aspiration|sample collected
48673219|NCT04601116|DRUG|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
48673220|NCT04601116|DRUG|Placebo oral tablet|Placebo 1 tablet per day for 2 years
48673221|NCT05882396|OTHER|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
48673222|NCT05882396|OTHER|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
47991049|NCT05805982|BEHAVIORAL|In person genetic cancer counseling|"Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts"
47991050|NCT00755131|OTHER|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
48148804|NCT04256421|DRUG|Tiragolumab|Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
48148805|NCT04256421|DRUG|Atezolizumab|Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
48360327|NCT04313595|DEVICE|RespirHó|"The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of noise that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject ."
48673223|NCT01595477|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
48673224|NCT01342731|DRUG|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
48360328|NCT05476094|DRUG|Polyene Phosphatidylcholine|AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
48360329|NCT02469506|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
48360330|NCT00346294|DRUG|Etanercept|Intervention type was to study the drug delivery method.
48360331|NCT05022693|DRUG|BIO89-100|Subcutaneous Injections
48360332|NCT02020564|BEHAVIORAL|Speed of Processing Training|
48360333|NCT02020564|BEHAVIORAL|Placebo Control|
48673225|NCT02292537|DRUG|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
48673226|NCT02292537|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
48673227|NCT06576427|DEVICE|Vertex Pulmonary Embolectomy System|Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
48673228|NCT01605357|DRUG|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
48673229|NCT01605357|DRUG|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
48148806|NCT04256421|DRUG|Carboplatin|Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
48148807|NCT04256421|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
48148808|NCT04256421|DRUG|Placebo|Placebo administered by IV infusion on Day 1 of each 21-day cycle.
48148809|NCT00587405|PROCEDURE|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
48148810|NCT00587405|PROCEDURE|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
48148811|NCT06086548|OTHER|metabolomic on plasma sample|metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
48148812|NCT02249156|BEHAVIORAL|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
48148813|NCT02930265|DRUG|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
48148814|NCT02912338|BEHAVIORAL|Resistant Training|
48148815|NCT02912338|OTHER|Control Group|
48148816|NCT00882050|DRUG|Exenatide 0.27 ng/kg/min|"Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
48148817|NCT00882050|DRUG|Exenatide 0.41 ng/kg/min|"Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
48509159|NCT05629975|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|"Each package contained L-arginine (750 mg), methionine (300 mg), glutamine (5 g), plant protein (10 g), vitamin B12 (1 ug), vitamin C (50 mg), vitamin D (2000 IU), vitamin A (300 mg), folic acid (5 mg), omega-3 fatty acid (1 g), zinc (20 mg), magnesium (400 mg), selenium (100 mcg), whole wheat fiber (5 g), carotenoid (3 mg), curcumin supplement (500 mg).~Probiotics included orally administration of clostridium butyricum\& bifidobacterium (500 mg) every day for 7 days."
48360334|NCT00137267|BEHAVIORAL|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
48360335|NCT00137267|BEHAVIORAL|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
48673230|NCT05245539|DRUG|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
48360336|NCT05158244|DRUG|PF-07081532|Study Drug, once daily for 42 days
48360337|NCT05158244|DRUG|Placebo|Placebo, once daily for 42 days
48673231|NCT03391999|OTHER|A questionnaire; CHU9D|Measuring Health Related Quality of Life
48360338|NCT03240666|OTHER|non applicable|non applicable
48360339|NCT02216227|DRUG|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
48360340|NCT02216227|DRUG|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
48360341|NCT02216227|DRUG|Cefazolin|All patients will receive Cefazolin during surgery
48360342|NCT02216227|DRUG|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
48509160|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice1|100% Orange Juice
48509161|NCT03685201|DIETARY_SUPPLEMENT|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
48673232|NCT02679378|DEVICE|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
48673233|NCT03310944|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
48673234|NCT00682149|DIETARY_SUPPLEMENT|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
48509162|NCT03685201|DIETARY_SUPPLEMENT|Raw Orange|Raw Orange
48509163|NCT00143247|DRUG|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
48509164|NCT00096837|DRUG|Motexafin Gadolinium Injection|
48509165|NCT01589289|DEVICE|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
48509166|NCT01589289|DEVICE|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
48509167|NCT01589289|DEVICE|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
48509168|NCT01589289|DEVICE|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
48509169|NCT01589289|DEVICE|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
48509170|NCT04226950|DRUG|Recombinant Interferon Alpha|Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers;
48509171|NCT04226950|DRUG|Pegylated interferon alfa-2b|Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
48509172|NCT00183911|DRUG|floxuridine, 5-Fluorouracil, leucovorin|
48509173|NCT00183911|PROCEDURE|External Beam Radiotherapy|
48509174|NCT00183911|PROCEDURE|Surgery|
48509175|NCT05227963|OTHER|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
48509176|NCT05227963|OTHER|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
48509177|NCT02988635|OTHER|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
48509178|NCT05727618|DRUG|Pituitrin|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
48509179|NCT05727618|DRUG|normal saline|Intravenous infusion of normal saline at the same dose and speed
48509180|NCT06361121|PROCEDURE|mid-point transverse process to pleura (MTP) block|"the T1-T12 thoracic spinal levels will be sonographically identified using a high frequency linear US probe (HFL_50, 15_6MHz). Then the probe will be placed vertically and nearly 3 cm lateral to the spinous process at the thoracic level T4/T5. The paraspinal muscles (erector spinae, trapezius, rhomboid), transverse processes , superior costo-transverse ligament (SCTL) and parietal pleura will be all identified under parasagittal scanning.~In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL."
48509181|NCT06361121|PROCEDURE|Thoracic Paravertebral Block|In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
48673235|NCT03070990|DRUG|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
48673236|NCT00948688|RADIATION|Radiation therapy|Once per day, 5 days a week for 6 weeks
48673237|NCT00948688|DRUG|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
48673238|NCT00948688|DRUG|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
48673239|NCT03470350|DRUG|Galunisertib|treatment with capecitabine and galunisertib
48360343|NCT02216227|DRUG|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
47991051|NCT01010906|DRUG|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
47991052|NCT01010906|DRUG|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
48360344|NCT02543762|PROCEDURE|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
48360345|NCT00519220|OTHER|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
48360346|NCT01462851|DRUG|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
48360347|NCT01462851|DRUG|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
48509182|NCT01390532|DEVICE|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
48509183|NCT06081179|DRUG|Psilocybin|Single dose of psilocybin (15mg), orally in form of capsules
48509184|NCT06081179|DRUG|3,4 Methylenedioxymethamphetamine|Single dose of MDMA (100mg), orally in form of capsules
48509185|NCT06081179|DRUG|Methylphenidate|Single dose of methylphenidate (60mg), orally in form of capsules
48509186|NCT06470438|DRUG|JNJ-88998377|JNJ-88998377 will be administered.
48509187|NCT04495036|OTHER|data collection (21-items-patient descriptive survey)|"Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~* Demographic data of telemedicine users and non-users~* Subjective disease perception of the dermatology patients~* Use of internet, telemedicine and telemedicine insurance model~* Patients´ willingness for additional features of telemedicine~* Advantages and disadvantages telemedicine and face-to-face consultation~* Suitable fields of dermatology for telemedicine from the patient's perspective~* Recommended structure of telemedical services by users and non-users"
48509188|NCT04495036|OTHER|data collection (23-items-physician descriptive survey)|"To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~* Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~* Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective"
48509189|NCT03583086|DRUG|Vorolanib|Given by mouth
48509190|NCT03583086|BIOLOGICAL|Nivolumab|Given by IV
48509191|NCT05720065|DRUG|Botulinum toxin type A|Randomized double-blind administration
48509192|NCT05720065|DRUG|Isotonic saline 0,9%|Randomized double-blind administration
48509193|NCT02735785|BEHAVIORAL|Harnessing Online Peer Education (HOPE) Social Media Intervention|
48673240|NCT03376932|DRUG|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
48673241|NCT03376932|DRUG|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
48673242|NCT03376932|DRUG|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
48673243|NCT03376932|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
47991053|NCT06496776|PROCEDURE|Choukroun's technique|Suturing will be done using the method described by Choukroun.
47991054|NCT02621411|DRUG|Substance use|Patients are found use of substances by preoperative screen
47991055|NCT05870033|DEVICE|Electromyography (EMG) measurement|Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
47991056|NCT05735392|OTHER|Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.|Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
47991057|NCT01951157|DRUG|Docetaxel|Powder for solution for infusion
47991058|NCT01951157|DRUG|Gemcitabine|Powder for solution for infusion
47991059|NCT01951157|DRUG|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
47991060|NCT04295512|BEHAVIORAL|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. UOT will be adapted for use in mental health service settings. Mental health therapists will be trained in UOT and deliver to youth and caregivers.
48360348|NCT01462851|DRUG|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
48360349|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
48148818|NCT00882050|DRUG|Placebo|"Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
48360350|NCT01462851|DRUG|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
48360351|NCT01729065|OTHER|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
48360352|NCT05422027|DRUG|Selinexor|"Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles"
48360353|NCT05422027|DRUG|Bortezomib|"The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone"
48509194|NCT02665104|DEVICE|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
48509195|NCT04167540|BIOLOGICAL|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
48509196|NCT03847298|OTHER|Physical activity and physical fitness assessment|Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
48360354|NCT05422027|DRUG|Lenalidomide|"The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
48360355|NCT05422027|DRUG|Dexamethasone|"The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone"
48360356|NCT02406599|DEVICE|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
48360357|NCT02406599|OTHER|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
48360358|NCT01333865|DRUG|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
48360359|NCT05248542|OTHER|Virtual Reality Usage on Oral Care Knowledge|Virtual Reality Usage on Oral Care Knowledge about independent older adults
48360360|NCT01223560|DRUG|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
48509197|NCT01097512|DRUG|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
48509198|NCT01097512|DRUG|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
48673244|NCT03376932|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
47991061|NCT05049070|DIAGNOSTIC_TEST|Mobile medical application to self administer a subjective refraction test|GoEyes is a software as a medical device and mobile medical application, which is downloaded to a smartphone and is a self-administered subjective refraction test that measures the refractive error of the user's eyes in the home environment without any contact or help from health care professionals
48148819|NCT03155035|DRUG|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
47991062|NCT05049070|DIAGNOSTIC_TEST|Standard of care refraction test|Standard of care subjective manifest refraction test performed by a healthcare professional
48148820|NCT03155035|DIETARY_SUPPLEMENT|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
48148821|NCT02607956|DRUG|DTG|50 mg tablets administered orally, once daily
48148822|NCT02607956|DRUG|F/TAF|200/25 mg tablets administered orally, once daily
48360361|NCT01223560|OTHER|Exercise|Exercise on tread mill
48360362|NCT01223560|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate intake
48148823|NCT02607956|DRUG|B/F/TAF|50/200/25 milligrams (mg) FDC tablets administered orally, once daily
48509199|NCT02462291|OTHER|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
48509200|NCT05321641|BEHAVIORAL|Mobile phone message reminders.|Utilising mobile messaging service to send reminders to people with epilepsy to take antiseizure medications and sending reminders to primary health facilities to restock anti-seizure medications.
48509201|NCT03838497|BIOLOGICAL|Prevenar13|Prevenar13 for both arms
48148824|NCT02607956|DRUG|DTG Placebo|Tablets administered orally, once daily
48673245|NCT03376932|DEVICE|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
48673246|NCT03376932|DEVICE|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
48673247|NCT03376932|DEVICE|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
48673248|NCT03376932|DEVICE|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
48673249|NCT04834726|BEHAVIORAL|Opt-In (Call-Back)|Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.
48673250|NCT04834726|BEHAVIORAL|Opt-in (In-Bound)|Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
48673251|NCT04834726|BEHAVIORAL|Standard Message|The message describes that the patient is eligible for the COVID vaccine.
48673252|NCT04834726|BEHAVIORAL|Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination.
48673253|NCT04834726|BEHAVIORAL|Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.
48673254|NCT04834726|BEHAVIORAL|Opt-Out Framing|This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.
47991063|NCT06023732|BEHAVIORAL|Behavioral activation and emotion-focused interventions|Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
47991064|NCT00613015|DRUG|Guanfacine|
47991065|NCT00613015|DRUG|Modafinil|
47991066|NCT00613015|DRUG|Placebo|
47991067|NCT02002364|PROCEDURE|tracheal intubation|
47991068|NCT03082599|DEVICE|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
47991069|NCT03594279|BEHAVIORAL|Community Mobilization|Community Mobilization
47991070|NCT03594279|BEHAVIORAL|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
47991071|NCT04145999|PROCEDURE|PRP application|The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
48148825|NCT02607956|DRUG|F/TAF Placebo|Tablets administered orally, once daily
48148826|NCT02607956|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
48673255|NCT04834726|BEHAVIORAL|Phone Call|The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.
48673256|NCT02133469|BIOLOGICAL|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
48673257|NCT02133469|BIOLOGICAL|Hib Vaccine|Single Dose
48673258|NCT01107639|BIOLOGICAL|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
48673259|NCT01107639|DRUG|cisplatin|"* Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5"
48673260|NCT01107639|DRUG|docetaxel|"* Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5"
48673261|NCT01107639|PROCEDURE|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
48673262|NCT01107639|PROCEDURE|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
48148827|NCT01583855|PROCEDURE|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
48509202|NCT06029179|DRUG|sodium zirconium cyclosilicate (SZC)|40 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.
48509203|NCT06029179|DRUG|sodium polystyrene sulfonate|40 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.
48673263|NCT01312480|OTHER|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~1. Ask if the patient smokes.~2. Advise every patient to quit.~3. Assess readiness to quit.~4. Assist in quitting and finding services.~5. Arrange for cessation services and follow-up."
48673264|NCT01312480|OTHER|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
48509204|NCT04880473|DEVICE|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
48509205|NCT06349174|PROCEDURE|bronchoscopic lung volume reduction surgery using endobronchial valve|The patients would undergo bronchoscopic lung volume reduction surgery using the self developed endobronchial valve.
47991072|NCT04145999|OTHER|Placebo PRP application|Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.
47991073|NCT04145999|RADIATION|Photobiomodulation|Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
47991074|NCT04145999|OTHER|Placebo Photobiomodulation|Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
48148828|NCT01583855|DEVICE|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
48360363|NCT00696644|DRUG|Teriparatide|20 mcg daily subcutaneous for 18 months.
48360364|NCT03287830|BEHAVIORAL|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
48360365|NCT04613791|BIOLOGICAL|Blood test|Collection of epidemio-clinical, biological, radiological and therapeutic patient data. Study samples collected from 154 patients to determine whether a particular immune profile could identify individuals prone to insulin resistance
48360366|NCT00585104|DRUG|levosimendan|10-minute infusion
48360367|NCT02940353|DEVICE|TREFOIL concept|
48360368|NCT06012266|DRUG|Dapagliflozin tablet|"Patients randomized to Group A will start with Dapagliflozin on Visit 1 and take Dapagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Dapagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose:~* participants ≤12 year old: 5mg once daily p.o. (commercially available tablet)~* participants \>12 year old: 10mg once daily p.o. (commercially available tablet)"
48360369|NCT06012266|DRUG|Empagliflozin Tablets|"Patients randomized to Group A will start with Empagliflozin on Visit 1 and take Empagliflozin once daily up to the day before Visit 3.~Patients randomized to Group B will start Empagliflozin once daily on the day of Visit 3, to be continued up to the day preceding Visit 4.~Dose: Empagliflozin 10mg once daily p.o. (commercially available tablet)"
48360370|NCT05892406|DEVICE|Static guide|A static guide will be designed and fabricated based on CBCT and intra-oral scan. Implant will be placed under the assistance of statistic guide through the whole procedure.
48509206|NCT01906515|DEVICE|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
47991075|NCT00003733|DRUG|carboplatin|
47991076|NCT00003733|DRUG|paclitaxel|
47991077|NCT00003733|DRUG|topotecan hydrochloride|
47991078|NCT04364308|OTHER|Fetal Echography|Fetal ultrasound and its parameters
47991079|NCT02066467|DEVICE|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
47991080|NCT06101199|OTHER|Acute Intermittent Hypercapnic Hypoxia|15 x \[1 min 9% O2, 4% CO2, and balance N2, followed by 1.5 min normoxia\];
47991081|NCT06101199|OTHER|Transcutaneous spinal cord stimulation|Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of \~25-35 mA and a pulse width of 400 µsec, using a biphasic symmetric waveform. Paired with Respiratory Resistance Training and Hand Grip Strength Training.
47991082|NCT06101199|OTHER|SHAM Acute Intermittent Hypercapnic Hypoxia|Normoxia for the amount of time AIHH is delivered.
47991083|NCT06101199|OTHER|SHAM Transcutaneous spinal cord stimulation|"Open-loop, continuous, high-frequency electrical stimulation at 150 Hz with a tolerable current amplitude of 0mA and a pulse width of 400 µsec,using a biphasic symmetric waveform.~Paired with Respiratory Resistance Training and Hand Grip Strength Training."
47991084|NCT02911181|OTHER|BIVA measurement|
47991085|NCT00838058|DRUG|CE-224,535|one 250mg tablet, once in the morning in fasted state
47991086|NCT00838058|DRUG|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
47991087|NCT00838058|DRUG|CE-224,535|4x250mg tablets, once in the morning, in fasted state
48148829|NCT03200509|OTHER|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
48148830|NCT03200509|OTHER|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
48148831|NCT00264654|DRUG|BRL29060A|
48148832|NCT00264654|DRUG|paroxetine hydrochloride hydrate|
48148833|NCT02491645|OTHER|Sensory interventions|"1. Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~2. Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~3. Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~4. Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~5. Auditory stimulation : Sound familiarisation and music time will be done."
48148834|NCT00692757|DRUG|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
48148835|NCT00692757|DRUG|Iodopovidone|Iodopovidone
48148836|NCT01641848|DEVICE|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
48148837|NCT02543307|PROCEDURE|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
48673265|NCT01783210|BEHAVIORAL|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
48360371|NCT05892406|DEVICE|Dynamic navigation|Implant will be placed under the assistance of dynamic navigation.
48360372|NCT05892406|DEVICE|Robotic system|Implant will be placed under robotic arm and human collaboration.
48148838|NCT04471298|DRUG|Qishenyiqi dripping pills, 6 bags|28 consecutive days
48148839|NCT04471298|DRUG|Qishenyiqi dripping pills, 9 bags|28 consecutive days
48148840|NCT04471298|DRUG|Qishenyiqi dripping pills, 12 bags|28 consecutive days
48148841|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 6 bags|28 consecutive days
48360373|NCT03297554|BEHAVIORAL|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
48509207|NCT05231278|DEVICE|nCLE aided RANB biospy|nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
48148842|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 9 bags|28 consecutive days
48360374|NCT02397980|BEHAVIORAL|Behavioral intervention|"* What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves"
48360375|NCT05610670|OTHER|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
48360376|NCT05949528|OTHER|no intervention|no intervention
48509208|NCT02264860|DIETARY_SUPPLEMENT|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
48509209|NCT06572111|DRUG|BI 1839100 (C-14) formulation 1|BI 1839100 (C-14) formulation 1
48360377|NCT05706610|BEHAVIORAL|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
48509210|NCT06572111|DRUG|BI 1839100|BI 1839100
48148843|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 12 bags|28 consecutive days
48360378|NCT05706610|BEHAVIORAL|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
48148844|NCT05404802|DEVICE|Experimental group intervention|"Training session~Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.~Free-play session~In these sessions, every participant can interact with one PARO without instructions but are under the safety supervision of a PARO facilitator."
48148845|NCT05404802|DEVICE|Control group intervention|Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.
48509211|NCT06572111|DRUG|BI 1839100 (C-14) formulation 2|BI 1839100 (C-14) formulation 2
47991088|NCT00838058|DRUG|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
47991089|NCT00838058|DRUG|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
47991090|NCT00838058|DRUG|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
47991091|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
47991092|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
48148846|NCT00361088|DRUG|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
48148847|NCT00361088|DRUG|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
48148848|NCT00671853|DRUG|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
48148849|NCT00671853|DRUG|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
48148850|NCT03743688|BIOLOGICAL|Influenza Vaccine Recipients|0.5 mL intramuscular injection
48148851|NCT06461949|DRUG|Dupilumab|Dupilumab (Dupixent) is a human monoclonal antibody administered via subcutaneous injection to treat various conditions such as Chronic Rhinosinusitis with Nasal Polyps, Asthma and Eosinophilic Esophagitis.
48148852|NCT04330573|OTHER|No intervention. Observational study|Observational study
48148853|NCT04748705|DRUG|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
48148854|NCT04748705|DRUG|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
48360379|NCT06169449|BEHAVIORAL|Weight management--diet|The diet structure adopts an energy-limited balanced diet. In this structure, the total daily energy intake is reduced by 500\~1000 kcal based on the target energy intake; however, the balance is maintained for the energy supply ratio of the three major nutrients (with carbohydrate, protein, and fat accounting for 55\~60%, 10\~20%, and 15\~30% of the total daily energy, respectively). Combined with the patient's eating habits, the food exchange portion method is used as a guide; each portion providing 90 kcal is considered as one portion. Specific recipes are formulated after calculating the ideal weight and the total daily calorie intake based on activity intensity, determining the number of six food exchange portions and the distribution of three meals according to the total calorie and diet structure, and combining the equivalent food exchange table based on individual tastes and preferences; this ensures patient acceptability and implementation.
48360380|NCT06169449|BEHAVIORAL|Weight management--exercise|Exercise goals are divided into four levels based on individual health conditions and personal preferences; these include: cultivating exercise habits, improving cardiopulmonary function, enhancing muscle strength, and improving flexibility. Individualized exercise prescriptions that specify the exercise type, intensity, time, and frequency are formulated.
48148855|NCT01274000|DRUG|YM060|oral
48148856|NCT01274000|DRUG|placebo|oral
48509212|NCT00620399|OTHER|lumbar corset|
48509213|NCT06353269|DRUG|Estring Vaginal Product|estradiol vaginal ring, exchanged every 12 weeks
48509214|NCT06353269|DRUG|Vagifem|vaginal estrogen tablet, used twice per week
48148857|NCT05303324|DRUG|ALXN1840|Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
48148858|NCT05141968|DIETARY_SUPPLEMENT|vitamin D supplements (2000 IU/day)|The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
48148859|NCT03070301|DRUG|LEE011|LEE011 200 mg daily
48509215|NCT06353269|DRUG|Estrace 0.01% Vaginal Cream|vaginal estrogen cream, used twice per week
48509216|NCT04529954|DRUG|Valproic Acid delivered to ICV|Valproic Acid delivered to ICV via an implantable pump and catheter system
48509217|NCT03975231|DRUG|Dabrafenib|Given PO
48509218|NCT03975231|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48509219|NCT03975231|DRUG|Trametinib|Given PO
48148860|NCT03070301|DRUG|everolimus|everolimus 5 mg daily or 2.5mg daily
48148861|NCT03410680|BEHAVIORAL|FUERTES|The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
48148862|NCT01613703|DRUG|ONO-2952|1 mg to 200 mg QD at a single descending dose
48509220|NCT03190031|OTHER|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
48509221|NCT03190031|OTHER|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
48509222|NCT05209165|DRUG|Semaglutide|weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
48509223|NCT05209165|DRUG|Placebo|Matching placebo and intake visit for VA MOVE
48509224|NCT01182376|DRUG|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
48509225|NCT01182376|DRUG|Placebo|Placebo will be administered by the patient's team according to established guidelines.
48360381|NCT06169449|BEHAVIORAL|Weight management--accompany|This component involves the inclusion of patients in online management. Online groups are established, daily feedback is obtained regarding weight management implementation, self-sharing is encouraged, and peer support is established; a total of 6 sessions of online health education are provided once every 4 weeks for 20-60 minutes at each session. This includes information regarding the risks associated with overweightness and obesity; weight management benefits; knowledge regarding diet and nutrition, exercise and sports, and behavioral styles; and problem exchange and sharing, among others. Professional support is provided by weekly communication with patients one-on one via WeChat or telephonic conversations. The patient's diet and exercise record sheet are checked, patients are asked questions regarding implementation of the current program and any discomfort or difficulties; corresponding guidance is provided as appropriate.
48509226|NCT02176785|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
48509227|NCT02594865|DIETARY_SUPPLEMENT|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
48509228|NCT02594865|DIETARY_SUPPLEMENT|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
48509229|NCT00776750|BIOLOGICAL|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
48509230|NCT05780476|BEHAVIORAL|Psychoeducation|6 sessions of 2 hours over 6 weeks
48509231|NCT05780476|BEHAVIORAL|Psychoeducation + virtual reality|6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
48509232|NCT03795038|DEVICE|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
48509233|NCT03795038|DEVICE|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
48509234|NCT05258383|OTHER|3D maps of physical doses|3D maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's CT image used by the treatment planning system (dosimetric calculation performed by Monte Carlo method).
48673266|NCT01783210|BEHAVIORAL|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
47991095|NCT00117247|DRUG|darbepoetin alfa|
47991096|NCT05348161|PROCEDURE|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
47991097|NCT05348161|PROCEDURE|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
47991098|NCT05348161|PROCEDURE|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
47991099|NCT05348161|PROCEDURE|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
47991100|NCT05348161|PROCEDURE|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
47991101|NCT05348161|PROCEDURE|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
47991102|NCT00459836|DRUG|PR-104|
47991103|NCT00459836|DRUG|docetaxel|
47991104|NCT00459836|DRUG|gemcitabine hydrochloride|
47991105|NCT00459836|OTHER|laboratory biomarker analysis|
47991106|NCT00459836|OTHER|pharmacological study|
47991107|NCT00694759|DRUG|pioglitazone|30 mg for 2 weeks, then 45 mg daily
47991108|NCT00694759|DRUG|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
47991109|NCT00694759|DRUG|placebo|capsule twice daily
47991110|NCT04498728|OTHER|Mobile Health Application for Remote Monitoring|The use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital.
47991111|NCT00982488|DRUG|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
47991112|NCT00982488|DRUG|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
47991113|NCT01983527|PROCEDURE|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
47991114|NCT01983527|DRUG|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
47991115|NCT04577937|DIAGNOSTIC_TEST|LAM patients underwent PSG|Patients with confirmed diagnosis of LAM underwent a whole-night polysomnography. The presence of either acute or chronic respiratory failure or the use of long-term oxygen therapy are considered exclusion criteria
47991116|NCT02101047|DRUG|Phenylephrine|
47991117|NCT04896710|DEVICE|SD Biosensor|Nasal swab SD biosensor to be self administered
47991118|NCT02762266|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
47991119|NCT02762266|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
47991120|NCT02762266|DRUG|embolic agent|". Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads"
47991121|NCT02762266|DRUG|lipiodol|
48148863|NCT00805792|DRUG|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
48148864|NCT05897307|DRUG|Ropivacaine|dexmedetomidine
48148865|NCT00603018|DRUG|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
48148866|NCT01455779|DEVICE|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
48148867|NCT01707563|PROCEDURE|skin punch biopsy and molecular biology|
48148868|NCT01707563|OTHER|fibroblast culture and molecular biology|
48148869|NCT02708498|BEHAVIORAL|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
48148870|NCT03775915|OTHER|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
48148871|NCT03775915|OTHER|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
48509235|NCT05795322|OTHER|Sound healing with tuning forks|"Over the course of a half-hour virtual session, a specially developed triple OM track created by tuning forks was played."
48509236|NCT03578575|DRUG|Danggui Buxue Tang|Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
48509237|NCT03578575|DRUG|Placebo|Placebo is a very low dose Danggui Buxue Tang powder.
48148872|NCT05329402|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
48148873|NCT05329402|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
48148874|NCT01948557|BEHAVIORAL|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
48148875|NCT04007445|BEHAVIORAL|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
48148876|NCT04007445|OTHER|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
48148877|NCT06418594|DRUG|Adebrelimab|Adebrelimab: 1200mg, ivgtt, administered on the first day of each cycle, with a cycle of 21 days
48148878|NCT06418594|DRUG|Apatinib|Apatinib: 250 mg, oral, once daily, continuous use, with a cycle of 21 days
48509238|NCT03883802|DRUG|Foxy-5|Lyophilized powder for solution for intravenous infusion
48509239|NCT03883802|DRUG|FOLFOX regimen|6 months treatment regimen
48509240|NCT03883802|PROCEDURE|Tumour resection (colon cancer surgery)|Surgical removal of patients colon cancer
48509241|NCT04135326|OTHER|Quality-of-Life Assessment|Ancillary studies
48509242|NCT04135326|OTHER|Questionnaire Administration|Ancillary studies
48509243|NCT04135326|PROCEDURE|Transcranial Direct Current Stimulation|Undergo tDCS
48509244|NCT05778903|OTHER|Nerve block|Suprazygomatic maxillary nerve block
47991122|NCT01165255|DRUG|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
47991123|NCT01165255|DRUG|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
48148879|NCT06418594|DRUG|Etoposide|Etoposide: 50mg/day, oral, administered on days 1-14 of each cycle, with a cycle of 21 days
47991124|NCT01165255|DRUG|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
47991125|NCT00696514|DIETARY_SUPPLEMENT|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
47991126|NCT00696514|DIETARY_SUPPLEMENT|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
47991127|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hib-MenAC|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
47991128|NCT00228917|BIOLOGICAL|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
48148880|NCT05935306|DRUG|Ibuprofen|All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
48148881|NCT05935306|OTHER|Photobiomodulation simulation|The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.
48360382|NCT06169449|BEHAVIORAL|Weight management--refresh|According to the dietary nutrition guidelines for Chinese residents, patients are advised to drink 2500 ml or more of water daily; they are also advised to work and rest regularly to ensure sufficient sleep time, ensure smooth bowel movements, take deep breaths when waking up in the morning, pay attention to the work-rest balance, avoid being sedentary, and stand up and move around at least once every 50 minutes, maintain physical vitality by adjusting daily living habits.
48360383|NCT06169449|BEHAVIORAL|Control group|The relationship between overweightness and obesity and endometrial cancer risk was explained to patients in the control group and their willingness for self-weight management was respected. Communication was maintained with patients from treatment initiation to 3 and 6 months after treatment; patients' questions regarding weight reduction were answered and suggestions were provided regarding nutrition, exercise, and lifestyle management.
48509245|NCT04881019|DEVICE|Continuous glucose monitoring|Continuous monitoring of blood sugar over a 10-day period.
48148882|NCT05935306|DEVICE|Photobiomodulation|. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.
48148883|NCT05935306|OTHER|Ibuprofen simulation|Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
48148884|NCT00924755|DEVICE|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
48509246|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
48509247|NCT00580515|BEHAVIORAL|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
48360384|NCT04951479|DEVICE|Gel-Bead embolization|OptiSphere is FDA approved for the embolization of hypervascular tumors. The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. In this study the Optispheres will be used for Geniculate artery embolization (GAE) which is a minimally-invasive procedure that has historically been performed for treatment of patients with recurrent knee hemarthrosis. Embolization is a procedure in which material is used to block small blood vessels. Angiogenesis, or growth of new vessels, has been implicated in the initiation and maintenance of joint inflammation. GAE has been applied to patients with moderate osteoarthritis-related pain refractory to maximal medical management with preliminary studies demonstrating a reduction in patient pain.
48360385|NCT00643851|DRUG|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
48360386|NCT00643851|DRUG|Metformin XR|Tablets, Oral, Once daily, 24 weeks
48360387|NCT02443311|DRUG|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
48360388|NCT02443311|DRUG|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
48360389|NCT03277651|DIAGNOSTIC_TEST|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
48360390|NCT01986166|DRUG|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
48360391|NCT01986166|DRUG|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
48360392|NCT05330429|DRUG|Magrolimab|Administered intravenously
48509248|NCT00580515|BEHAVIORAL|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
48509249|NCT02041065|DEVICE|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
48509250|NCT02041065|DEVICE|CUSA induced dissection|Ultrasound based destruction of the liver
48509251|NCT06329427|OTHER|Dragon Ambient eXperience (DAX) Copilot|The tool (DAX) listens to the conversation between a clinician and patient/caregiver during their visit, provides transcriptions between different speakers for the clinician to review, edit, and included in the final EHR notes.
48509252|NCT05496491|RADIATION|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
48673267|NCT00766519|OTHER|volume optimization|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~  + systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is \> 10%"
48673268|NCT00766519|OTHER|standard volume administration|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
48673269|NCT04547465|DIAGNOSTIC_TEST|Echocardiography|2D Speckle-tracking echocardiography
48673270|NCT06043336|DRUG|Dexamethasone, granisetron & palonosetron|. Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
48673271|NCT03783780|DEVICE|INVSENSOR00031|Noninvasive pulse oximeter sensor
48673272|NCT05850767|OTHER|Sleep deprivation|Participants will stay fully awake for 24 hours
48673273|NCT06007417|DRUG|GenSci004|GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
48673274|NCT06007417|DRUG|Genotropin|Genotropin
48673275|NCT05600413|DIETARY_SUPPLEMENT|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
48673276|NCT05600413|DIETARY_SUPPLEMENT|Placebo|4 weeks of Placebo (crystalline cellulose)
48673277|NCT01154452|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
48673278|NCT01154452|OTHER|Laboratory Biomarker Analysis|Correlative studies
48673279|NCT01154452|OTHER|Pharmacological Study|Correlative studies
47991129|NCT00228917|BIOLOGICAL|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
47991130|NCT02110342|DRUG|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of \[14C\] PF-04449913
48673280|NCT01154452|DRUG|Vismodegib|Given PO
48673281|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Maintenance Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Maintenance in Immunosuppression medication.
48360393|NCT05330429|DRUG|Bevacizumab|Administered intravenously
48509253|NCT05496491|DRUG|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
48673282|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Withdrawal Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Withdrawal of MMF immunosuppression medication.
48673283|NCT03051958|BEHAVIORAL|Internet mindfulness&exposure treatment|"See description under Arm."
48673284|NCT03051958|OTHER|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
48360394|NCT05330429|DRUG|Irinotecan|Administered intravenously
48360395|NCT05330429|DRUG|Fluorouracil|Administered intravenously
48360396|NCT05330429|DRUG|Leucovorin|Administered intravenously
48360397|NCT00862329|DIETARY_SUPPLEMENT|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
48360398|NCT00862329|DIETARY_SUPPLEMENT|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
48360399|NCT00862329|DIETARY_SUPPLEMENT|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
48360400|NCT00862329|DIETARY_SUPPLEMENT|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
48360401|NCT03845010|DRUG|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
48360402|NCT03845010|DRUG|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
48673285|NCT02122380|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
48148885|NCT06257563|OTHER|Isle of TEND Intervention|"The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers."
48148886|NCT00860301|OTHER|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
48673286|NCT02122380|DRUG|Placebo|1 placebo pill by mouth per day for 30 days
48673287|NCT05301543|BEHAVIORAL|Experimental: Behavioral approach 1|Includes changing sleep habits and cognitions around sleep from a mental level
48673288|NCT05301543|BEHAVIORAL|Comparator: Behavioral approach 2|Includes changing sleep habits and awarenes of sleep from a perception level
48673289|NCT00547963|BEHAVIORAL|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
48148887|NCT01492127|BIOLOGICAL|Blood test|Blood test
48360403|NCT03845010|PROCEDURE|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
48360404|NCT02497599|DRUG|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
48360405|NCT02497599|RADIATION|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
48360406|NCT02497599|PROCEDURE|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
48360407|NCT02216539|BEHAVIORAL|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
48360408|NCT02216539|PROCEDURE|Lung transplantation|
48148888|NCT05713136|DEVICE|Diagnostic Test: Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
48360409|NCT02216539|OTHER|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
48360410|NCT00847249|DRUG|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
48360411|NCT00847249|DRUG|Placebo|Each subject will receive a single-dose.
48360412|NCT04686539|DRUG|CBD|CBD oil not containing THC, to be administered sub-lingual.
48360413|NCT04686539|DRUG|Placebo|Placebo Oil
48148889|NCT06102278|OTHER|Peritoneal Metastasis|Patients experiencing postoperative peritoneal metastasis
48148890|NCT04753450|OTHER|No intervention|No intervention
48360414|NCT02094781|DIETARY_SUPPLEMENT|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
48360415|NCT02094781|DIETARY_SUPPLEMENT|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
48673290|NCT03278548|DRUG|Volulyte 6%|Solution for infusion
48673291|NCT03278548|DRUG|Ionolyte|Solution for infusion
48673292|NCT05172700|DRUG|Pirtobrutinib|Administered orally.
48673293|NCT01291966|BEHAVIORAL|Motivational interview|
48673294|NCT05610644|OTHER|isocaloric, isonitrogenous meals|Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
48673295|NCT01978483|DRUG|Denosumab|
48673296|NCT01978483|RADIATION|UVB exposure|
48673297|NCT01978483|DRUG|Diphenylcyclopropenone|
48148891|NCT05258929|OTHER|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
48360416|NCT02094781|DIETARY_SUPPLEMENT|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
48673298|NCT01978483|DRUG|Normal Saline|
48673299|NCT06550882|DRUG|OBIZUR|OBIZUR injection.
48148892|NCT00458510|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
48148893|NCT02558907|OTHER|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
48148894|NCT01780428|DRUG|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
48148895|NCT01780428|DRUG|Placebo|
48148896|NCT00259363|DRUG|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
48148897|NCT04584736|DRUG|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
48148898|NCT06296875|DIETARY_SUPPLEMENT|Vegetable oil|mixed vegetable oil
48148899|NCT06296875|DIETARY_SUPPLEMENT|Krill oil|Krill oil
48148900|NCT06226818|OTHER|completion of scales and questionnaires|"Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances."
48360417|NCT02939326|DRUG|EB-001 injection|
48360418|NCT02939326|DRUG|Placebo injection|
48360419|NCT03091569|OTHER|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
48360420|NCT03091569|OTHER|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
48509254|NCT05496491|DRUG|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
48148901|NCT06245902|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
48360421|NCT04265027|DRUG|50 mg BIA 9 1067|Hard Capsule; Oral
48360422|NCT04265027|DRUG|25 mg BIA9 1067|Hard Capsule; Oral
48360423|NCT04265027|DRUG|50 mg Ongentys|Hard Capsule; Oral
48360424|NCT04265027|DRUG|25 mg Ongentys|Hard Capsule; Oral
48360425|NCT00354627|DRUG|TMC125|200 mg b.i.d. till commercially available.
48360426|NCT03486951|PROCEDURE|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
48360427|NCT00145379|DRUG|Tablet Metformin 500 mg|
48360428|NCT00145379|DRUG|Placebo|
48360429|NCT00838968|DRUG|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
48360430|NCT03319329|DEVICE|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
48509255|NCT04130516|DRUG|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER|LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
48509256|NCT04130516|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|pembrolizumab- anti-PD-1 antibody
48509257|NCT05755347|OTHER|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
48148902|NCT06245902|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
48148903|NCT06245902|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
48148904|NCT06245902|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
48148905|NCT06245902|DRUG|Matching Placebo|Two Placebo capsules
48148906|NCT04718116|DRUG|Group tapentadol 50 mg|patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
48148907|NCT04718116|DRUG|group tapentadol 75 mg|patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
48509258|NCT05755347|OTHER|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
48509259|NCT05755347|OTHER|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
48509260|NCT05755347|OTHER|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
48509261|NCT05755347|OTHER|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
48509262|NCT00243412|DRUG|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
48673300|NCT04860115|PROCEDURE|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
48673301|NCT04410159|DRUG|Povidone-Iodine|Gargle
47991131|NCT06180447|BIOLOGICAL|Hepatitis B vaccine, rabies vaccine, HPV vaccine, influenza vaccine|Exposure was defined as use of the vaccine 90 days before the last menstrual period and during pregnancy.
47991132|NCT01524848|DRUG|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
48148908|NCT04718116|DRUG|group tramadol 100 mg|patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
48148909|NCT02049684|PROCEDURE|Patch|
48148910|NCT02132195|DRUG|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
48148911|NCT00937807|DRUG|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
48148912|NCT00937807|DRUG|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
48673302|NCT04410159|DRUG|Essential oils|Gargle
48673303|NCT04410159|OTHER|Tap water|Gargle
48673304|NCT05987124|DRUG|Defibrotide|HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
48509263|NCT00243412|DRUG|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
47991133|NCT00826800|DRUG|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
47991134|NCT02881242|OTHER|Laboratory Biomarker Analysis|Correlative studies
47991135|NCT02881242|OTHER|Quality-of-Life Assessment|Ancillary studies
47991136|NCT02881242|DRUG|Trametinib|Given PO
48509264|NCT00243412|DRUG|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
47991137|NCT03822676|DEVICE|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
48148913|NCT01985256|BIOLOGICAL|Toca 511|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
48148914|NCT01985256|DRUG|Toca FC|
48148915|NCT04967014|DRUG|HIP2101|Test drug
48148916|NCT04967014|DRUG|RLD2101|Reference drug
48148917|NCT06147115|OTHER|Assessment tool to determine severity of GI bleeding|The Rockall score is a validated mortality risk assessment for patients admitted with upper GI bleeding.
48148918|NCT06152497|DRUG|Placebo|Oral placebo
48148919|NCT06152497|DRUG|H1 blockade: Telfast: 180mg Fexofenadine|H1 blockade: oral blockade with 180mg Fexofenadine
48148920|NCT06152497|BEHAVIORAL|Resistance training|Resistance training: lower body exercise
48509265|NCT00243412|DRUG|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
48509266|NCT00243412|DRUG|Rituximab|500 mg or 1000 mg IV\*2.
48148921|NCT04309578|DRUG|Trastuzumab, Capecitabine and Cisplatin|"* Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
48509267|NCT06247371|BEHAVIORAL|Decision aid|The Singapore developed HF DA is a A3 sized one-page poster designed to convey information about HF medications options (ACEI and ARNI only) and their pros and cons. The DA contains informative attributes of both medications that are presented side by side for comparison. These attributes include subsidized cost, frequency of use, duration of use, route of administration, low blood pressure side effect rate and benefits such as non-hospitalization rate and survival rate.
48509268|NCT00865371|DRUG|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
48509269|NCT00865371|DRUG|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
48360431|NCT02984735|OTHER|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
48360432|NCT03813576|DIAGNOSTIC_TEST|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
48360433|NCT00056628|DEVICE|The COGNIShunt® System|
48360434|NCT03399331|DIETARY_SUPPLEMENT|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
48360435|NCT03399331|DIETARY_SUPPLEMENT|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
48360436|NCT03399331|COMBINATION_PRODUCT|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
48360437|NCT00090623|DRUG|rhuFab V2 (ranibizumab)|
48360438|NCT00436085|BEHAVIORAL|Cognitive behavioral stress management training|
48360439|NCT04549675|BEHAVIORAL|Sun Safe Partners Online|Sun Safe Partners Online has 4 individual-focused modules and 4 couple-focused modules focusing on skin cancer prevention education and sun protection.
48360440|NCT04549675|BEHAVIORAL|Generic Online Sun Safety Information intervention|4 links to sent to participants from (1) The Skin Cancer Foundation's Skin Cancer Prevention guidelines, (2) the Centers for Disease Control and Prevention's information on risk factors for skin cancer, (3) the American Academy of Dermatology's information on how to select an appropriate sunscreen, and (4) The Skin Cancer Foundation's information on sun protective clothing. Participants were emailed a link to one of the resources each week for 4 weeks.
48360441|NCT03427762|OTHER|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
48360442|NCT04303247|BIOLOGICAL|CD19 and CD22 targeted CAR-T cells|The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
48360443|NCT00015015|DRUG|Dichloroacetate|
48360444|NCT04185194|DRUG|Lidocaine|transmission of the drug molecules to the underlying muscles
48360445|NCT04185194|DEVICE|pulsed ultrasound|using thermogenic and cavitation effect of ultrasound to reduce tight muscles and relieve pain
48360446|NCT04185194|OTHER|especially designed physical therapy program|by myofascial trigger point release, stretching and strengthening exercises of upper trapezius muscle and infrared radiation by tungsten lamp for upper trapezius
48360447|NCT01681537|DRUG|Lenalidomide|
48360448|NCT01681537|DRUG|Mitoxantrone|
48360449|NCT01681537|DRUG|Etoposide|
48360450|NCT01681537|DRUG|Cytarabine|
48360451|NCT04157907|BEHAVIORAL|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
48360452|NCT02150785|DRUG|Streptokinase|
48360453|NCT02504424|DEVICE|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
48360454|NCT00352027|DRUG|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
48360455|NCT00352027|DRUG|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
48360456|NCT00352027|DRUG|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
48360457|NCT00352027|DRUG|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
48360458|NCT00352027|DRUG|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
48360459|NCT00352027|DRUG|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
48360460|NCT00352027|DRUG|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
48360461|NCT00352027|DRUG|Prednisone|Given PO every other day of weeks 1-12.
48360462|NCT00352027|BIOLOGICAL|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
48360463|NCT00352027|PROCEDURE|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
48673305|NCT05231824|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|Behavioral weight loss treatment is the current gold standard treatment for obesity.
47991138|NCT03630575|PROCEDURE|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
47991139|NCT05372848|DIAGNOSTIC_TEST|Manual toothbrush|volunteers who used manual toothbrush for at least 2 years
47991140|NCT05372848|DIAGNOSTIC_TEST|Electric toothbrush|volunteers who used electric toothbrush for at least 2 years
48360464|NCT05570747|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
48673306|NCT05231824|BEHAVIORAL|AI-optimized Behavioral Weight Loss Treatment|AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
48360465|NCT05570747|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
48360466|NCT04961125|GENETIC|germline variants|Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
48360467|NCT02023515|BEHAVIORAL|Emotional brain training|Stress management based program
48673307|NCT05916300|OTHER|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination."
48673308|NCT03246607|DEVICE|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
48673309|NCT03776630|OTHER|Blood sample|"Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample."
48673310|NCT05753462|DRUG|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
48673311|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
48673312|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
48673313|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
48673314|NCT05379699|OTHER|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
48673315|NCT05379699|OTHER|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
48673316|NCT05100134|DRUG|ceritinib|Patients receive ceritinib
48673317|NCT00487981|DEVICE|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
48673318|NCT04592406|OTHER|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR\<30mL/min/1.73m2 patients.
48673319|NCT00757068|BEHAVIORAL|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
48673320|NCT00757068|BEHAVIORAL|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
48673321|NCT02020590|DRUG|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
48673322|NCT02422329|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline and after intervention.
48673323|NCT02422329|BEHAVIORAL|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
48673324|NCT02422329|BEHAVIORAL|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
48673325|NCT01642446|PROCEDURE|Precise hepatectomy|Precise hepatectomy
48673326|NCT01642446|OTHER|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
48360468|NCT02023515|BEHAVIORAL|Behavioral weight loss|Standard behavioral weight loss
48509270|NCT05593419|DEVICE|TIIC signature|Collect tumor tissue of 300 gastric cancer patients at treatment baseline, samples will be transferred to central lab to detect the density and spatial proximity of certain immune cells infiltrated in tumor by multi complex immunohistochemistry, and evaluate patients' TIIC signature.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastaticorgan ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
48673327|NCT05271942|PROCEDURE|Tilt and Tumble|The Tilt and Tumble technique is used to remove the human lens.
48673328|NCT05271942|PROCEDURE|Divide and Conquer|The Divide and Conquer technique is used to remove the human lens.
48673329|NCT01547156|DEVICE|Intervention group|
48673330|NCT03266029|DEVICE|Cordio App|
48673331|NCT04927676|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, a hormone status is determined.
47991141|NCT04368286|BEHAVIORAL|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
47991142|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
47991143|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
47991144|NCT02225756|DRUG|Placebo|Oral administration for a short time of placebo
47991145|NCT00391989|DRUG|Dasatinib|
47991146|NCT02364544|BEHAVIORAL|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
47991147|NCT02364544|BEHAVIORAL|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
47991148|NCT02364544|BEHAVIORAL|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
47991149|NCT02364544|BEHAVIORAL|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
47991150|NCT02364544|OTHER|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
48673332|NCT05752656|OTHER|Clinical examinations|Clinical examinations and administration of clinical scales
48673333|NCT02273921|OTHER|EEG recording|EEG is recorded once for each participant
48673334|NCT01247623|BIOLOGICAL|GV1001|
48673335|NCT00947128|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
48673336|NCT00947128|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
48673337|NCT03745768|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
48673338|NCT03745768|DEVICE|sham stimulation|Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
48673339|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
48673340|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
48673341|NCT00608062|DRUG|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
48673342|NCT00608062|DRUG|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
48148922|NCT06374082|OTHER|WhatsApp message|"Participants in the intervention group will receive 3 WhatsApp messages per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205). These messages are about the core content of the course, including (1) Knowledge Themes: harmfulness of smoking and benefits of quitting, the fundamentals of nicotine addiction, smoking cessation counselling with the 5A model, and pharmacotherapy for smoking cessation; (2) Attitude Themes: nurses' role in smoking cessation and the importance of smoking cessation; and (3) Practice Themes: practical advice on counseling techniques, communication skills by motivational interviewing, local smoking cessation resources for referral.~Participants in the control group will receive 3 WhatsApp messages about generic mental health information per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205)."
48148923|NCT03543982|DIETARY_SUPPLEMENT|Oral probiotic product|Once per day (QD), 28 days
48148924|NCT06339788|DRUG|HD-P023|Single dose administration of HD-P023
48509271|NCT04279236|OTHER|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
48673343|NCT00608062|DRUG|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
48148925|NCT06339788|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
48148926|NCT06339788|DRUG|Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
48148927|NCT00914056|DRUG|lactulose|withdrawal of lactulose
48148928|NCT04862507|OTHER|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
48148929|NCT04862507|DIAGNOSTIC_TEST|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
48148930|NCT03880981|DRUG|Ibuprofen 600 mg|ibuprofen 600mg Po q 6 hours prn pain
48148931|NCT03880981|DRUG|Acetaminophen|acetaminophen 600mg po q6 hours prn pain
48148932|NCT00075699|DRUG|cisplatin|
48148933|NCT00075699|DRUG|mitomycin C|
48148934|NCT00075699|DRUG|vincristine sulfate|
48148935|NCT00075699|DRUG|vinorelbine tartrate|
48148936|NCT00075699|PROCEDURE|pain therapy|
48148937|NCT00075699|PROCEDURE|psychosocial assessment and care|
48148938|NCT00075699|PROCEDURE|quality-of-life assessment|
48148939|NCT05344742|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)
48148940|NCT05344742|DRUG|Capecitabine|The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.
48148941|NCT05344742|DRUG|Albumin-paclitaxel|The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks.
48148942|NCT00274196|PROCEDURE|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
48148943|NCT00274196|PROCEDURE|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
48148944|NCT03405480|OTHER|Rehabilitation|Rehabilitation
48148945|NCT00899795|GENETIC|cytogenetic analysis|
48673344|NCT03757429|OTHER|RS-virus infection|The intervention consists of lower respiratory tract infection due to RS-virus
48148946|NCT00899795|GENETIC|fluorescence in situ hybridization|
48148947|NCT00899795|OTHER|flow cytometry|
48148948|NCT00899795|PROCEDURE|biopsy|
48148949|NCT00355784|OTHER|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
48148950|NCT00355784|DRUG|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
48148951|NCT03374722|DRUG|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
48148952|NCT02245620|DRUG|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
48148953|NCT02245620|DRUG|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
48148954|NCT00119782|BEHAVIORAL|Diet|A dietary intervention that will promote lower calorie intake
48148955|NCT00119782|BEHAVIORAL|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
48148956|NCT00119782|BEHAVIORAL|Environment|Increase worksite access to both healthy foods and physical activity
48673345|NCT02950103|DRUG|Phosphoethanolamine|Phosphoethanolamine PO daily
48673346|NCT02097784|PROCEDURE|Echocardiography|
48148957|NCT03967457|DIAGNOSTIC_TEST|questionnaires survey|Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7)
48148958|NCT03967457|DIAGNOSTIC_TEST|Urodynamic testing|"Urodynamic testing consists of important urodynamic parameters including:~Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume"
48360469|NCT02983240|DEVICE|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
48360470|NCT03719716|OTHER|Anticipatory care planning letter|Patient letter to take to GP and GP literature
48509272|NCT04279236|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
48509273|NCT04279236|OTHER|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
48360471|NCT03717727|OTHER|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
48360472|NCT03717727|OTHER|Control|16-week home-based exercise by standard protocol and usual treatment.
48360473|NCT05853172|DRUG|AK104|Subjects will receive AK104 until disease progression or for up to 6 cycles.
48509274|NCT05418114|DRUG|Magnesium sulfate|. One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
48509275|NCT06239857|PROCEDURE|Epidural pulsed radiofrequency|The radiofrequency treatment is applied under sterile conditions in the operating room environment. The target epidural area is reached under fluoroscopy guidance using a radiofrequency needle. After control of the needle position, radiofrequency treatment is given. Radiofrequency parameters are set as maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
48360474|NCT05853172|DRUG|Apatinib|Subjects will receive apatinib until disease progression or for up to 6 cycles.
48673347|NCT04305977|BEHAVIORAL|WAVE-TW|The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
48360475|NCT05853172|DRUG|Paclitaxel|Subjects will receive paclitaxel until disease progression or for up to 6 cycles.
48360476|NCT05853172|DRUG|S-1|Subjects will receive S-1 until disease progression or for up to 6 cycles.
48360477|NCT01341574|PROCEDURE|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
47991151|NCT03683758|OTHER|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
48148959|NCT03967457|DIAGNOSTIC_TEST|Rectum dynamics testing|Rectum dynamics testing consists of important parameters of rectum activities
48360478|NCT01341574|PROCEDURE|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
48360479|NCT03544385|DRUG|Ringers Solution|Treatment vs Placebo
48360480|NCT03544385|DRUG|Placebo - Concentrate|treatment vs placebo
48360481|NCT03164031|DEVICE|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
48360482|NCT03164031|DEVICE|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
48148960|NCT03967457|DIAGNOSTIC_TEST|ovarian reserve function|"Testing for ovarian reserve function consists of:~Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B"
48509276|NCT04819763|OTHER|Physical therapy|"Coordination training for lateral movement of the mandible (spatula exercise):~1. A wooden spatula is loosely placed between the teeth of the upper and lower jaw; the head must be aligned with the body axis; the exercise should be performed in front of a mirror.~2. The lower jaw moves to the left and back to the center with little contact to the spatula~3. The lower jaw moves to the right and back to the center under contact with the spatula~Training of the left lateral pterygoid muscle:~1. The left palm is placed on the left temple region~2. Right hand forms a fist and is placed on the tip of the right chin~3. Both arms are aligned parallel to the surface of the floor~4. The lower jaw is moved to the right against a moderate resistance of the fist = concentric muscle work~5. With measured force of the fist, the lower jaw is brought back to the center = eccentric muscle work (Right lateral pterygoid muscle training with opposite hands.)"
48673348|NCT01749488|OTHER|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
48673349|NCT00093366|BIOLOGICAL|etanercept|
48148961|NCT04372732|DIAGNOSTIC_TEST|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
48673350|NCT00093366|DRUG|arsenic trioxide|
48673351|NCT00981721|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
48148962|NCT01794351|DIETARY_SUPPLEMENT|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
48148963|NCT01794351|OTHER|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
48148964|NCT02705885|DIETARY_SUPPLEMENT|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
48673352|NCT04955184|DEVICE|non-invasive monitoring|non-invasive measurements of cardiac output
48673353|NCT05198401|OTHER|covid-19|viral infection
48673354|NCT05655975|PROCEDURE|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
48673355|NCT01642303|OTHER|vodcasting|listening to downloaded vodcasting files
48148965|NCT02705885|DIETARY_SUPPLEMENT|Placebo IgY|Placebo IgY
48148966|NCT03316170|BEHAVIORAL|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
48673356|NCT01642303|OTHER|no intervension|Listen to student book listening files
48148967|NCT03316170|DRUG|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
48673357|NCT05272189|BEHAVIORAL|Simulated Second Reader AI|In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.
48673358|NCT05272189|BEHAVIORAL|Target Prevalence|The frequency with which targets are presented varies from 10% to 90%
48673359|NCT05159258|OTHER||
48673360|NCT00560300|DRUG|1 alpha D2|Vitamin D sterol
48148968|NCT04391439|DRUG|Intravenous Methylprednisolone|
48148969|NCT01373723|OTHER|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
48148970|NCT03139045|BIOLOGICAL|Venous puncture in elderly patients|Venous puncture in elderly patients
48673361|NCT00560300|DRUG|1,25 dihydroxy vitamin D3|Active vitamin D sterol
48673362|NCT00560300|DRUG|Sevelamer HCl|Phosphate binder
48673363|NCT00560300|DRUG|Calcium Carbonate|Phosphate binder
48673364|NCT04355650|OTHER|Clinical decision support tool|Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
48673365|NCT02073162|PROCEDURE|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
48673366|NCT04764695|DIAGNOSTIC_TEST|D2O dilution technique|Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.
48148971|NCT00312949|BEHAVIORAL|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
48509277|NCT04819763|OTHER|Appliance therapy|"Upper and lower jaw impressions are registered by using an intraoral scanner. The arbitrary hinge axis position is determined using a face bow.~The stabilization appliance with anterior canine guidance is manufactured in the Lexmann laboratory in Dresden.~The stabilization appliance is incorporated by the dentist and the static and dynamic occlusion is checked. A tension-free fit of the appliance on the lower jaw is necessary. Additionally, equal contacts in the side teeth area and incisors guidance in the case of mandibular protrusion are checked visually and by using occlusion foil. During mandibular lateral movement only the canine guidance takes place and is also registered optically and by using occlusion foil.Interference contacts should be adjusted.~The patient is instructed to wear the stabilization appliance while sleeping. The wearing rhythm is described as intermittent. (three nights - wearing the appliance, one night - not wearing the appliance)."
48673367|NCT04473001|OTHER|Continuous vital signs and glucose monitoring|"The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)"
48673368|NCT04824703|DRUG|Oxygen|"* Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1"
48148972|NCT00312949|BEHAVIORAL|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
48148973|NCT00824057|DRUG|AZD6280|oral
48509278|NCT03123276|DRUG|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
48509279|NCT03123276|DRUG|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
48509280|NCT04683029|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered intravenously.
48509281|NCT04683029|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered subcutaneously.
48509282|NCT04683029|DRUG|Placebo|Placebo will be administered intravenously or subcutaneously.
48509283|NCT05125965|OTHER|additional time for the MRI|3 additional minutes to perform the MRI
48673369|NCT03166930|BEHAVIORAL|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
48148974|NCT00824057|DRUG|Midazolam|oral
48148975|NCT00824057|DRUG|Caffeine|oral
48148976|NCT03120936|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
48148977|NCT03120936|BEHAVIORAL|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
48148978|NCT01062165|DRUG|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
48148979|NCT05687825|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
48673370|NCT03166930|BEHAVIORAL|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management from the manual.
48673371|NCT04677998|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
48673372|NCT05710250|BEHAVIORAL|6-week MBSR program|"Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
48148980|NCT02199444|DRUG|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
48148981|NCT02199444|DRUG|Placebo|
48148982|NCT04518397|BEHAVIORAL|Theatre|6-week participatory arts culturally-informed theatre program
48148983|NCT05245474|COMBINATION_PRODUCT|Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)|Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
48148984|NCT00263900|DEVICE|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
48148985|NCT06475326|DRUG|Adebrelimab|Adebrelimab ,20mg/Kg per time, Q4W
48509284|NCT02713555|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
48509285|NCT02713555|PROCEDURE|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
48509286|NCT05784441|DRUG|JNJ-90009530|JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
48509287|NCT02765763|DRUG|2-Minute Reveal Masque|
48509288|NCT02765763|DRUG|24/7 Barrier Repair Cream|
48509289|NCT02765763|DRUG|8-in-1 BioSerum|
48509290|NCT02765763|DRUG|Null Formula 2-Minute Reveal Masque|
48148986|NCT06475326|DRUG|Oxaliplatin 100 MG|Oxaliplatin: 60mg/m2, Q2W
48148987|NCT06475326|DRUG|Irinotecan liposome|Irinotecan Liposome: 50mg/m2, Q2W
48148988|NCT06475326|DRUG|Calcium Folinate|Calcium Folinate: 400mg/m2, Q2W
48148989|NCT06475326|DRUG|Fluorouracil|Fluorouracil: 2400mg/m2, Q2W
48148990|NCT02035345|DRUG|Carboplatin|
48148991|NCT01441596|DRUG|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
48148992|NCT01441596|DRUG|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
48148993|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
48148994|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
48148995|NCT03710850|DIETARY_SUPPLEMENT|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
48148996|NCT02239991|PROCEDURE|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
48509291|NCT02765763|DRUG|Null Formula 24/7 Barrier Repair Cream|
48509292|NCT02765763|DRUG|Null Formula 8-in-1 BioSerum|
48509293|NCT02478203|DEVICE|Airtraq|videolaryngoscope for difficult airway
48509294|NCT02478203|DEVICE|Glidescope|videolaryngoscope for difficult airway
48509295|NCT02478203|DEVICE|direct laryngoscopy|gold standart for intubation
48509296|NCT01987310|DRUG|atorvastatin|atorvastatin 20 mg per day for 6 months
48673373|NCT05710250|BEHAVIORAL|6-week muscular relaxation program|"Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily)."
48148997|NCT00413283|BIOLOGICAL|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
48509297|NCT01987310|BEHAVIORAL|lifestyle counseling|lifestyle modification by dietician counseling and follow up
48673374|NCT05365100|DRUG|BN102|oral tablets: BN102, BID
48673375|NCT03192137|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
48673376|NCT03192137|OTHER|Vehicle|Vehicle twice daily for 16 days
48673377|NCT03961802|OTHER|sessions of shoulder rehabilitation|3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
48673378|NCT03855943|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
48673379|NCT03855943|BEHAVIORAL|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
48673380|NCT04794738|DRUG|SHR8554|SHR8554 Injection; high dose
48673381|NCT04794738|DRUG|SHR8554|SHR8554 Injection; low dose
48673382|NCT04794738|DRUG|Saline Solution|Saline Solution
48148998|NCT00413283|DRUG|Placebo|Placebo subcutaneous injection.
48148999|NCT00413283|DRUG|Gemcitabine|Intravenous infusion
48149000|NCT00413283|DRUG|Carboplatin|Intravenous infusion
48149001|NCT00413283|DRUG|Cisplatin|Intravenous infusion
48509298|NCT06121934|DRUG|Carica Papaya Leaf Extract|Active drug: CPLE 500mg 2 capsule t.i.d for 5 dayseive CPLE or placebo once daily for 5 days.
48509299|NCT06121934|DRUG|Placebo|Placebo: visually matched placebo 2 capsule t.i.d for 5 days
48509300|NCT01004744|DRUG|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
48509301|NCT00097032|DRUG|risperidone; quetiapine|
48673383|NCT04794738|DRUG|Morphine|Morphine
48673384|NCT00114725|PROCEDURE|Laser-assisted intracytoplasmic sperm injection|
48673385|NCT00551889|DRUG|celecoxib|
48673386|NCT00551889|DRUG|cyclophosphamide|
48673387|NCT00551889|OTHER|laboratory biomarker analysis|
48673388|NCT04217018|DIAGNOSTIC_TEST|Prediction of molecular pathology|Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
48673389|NCT03154021|COMBINATION_PRODUCT|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
48673390|NCT03154021|COMBINATION_PRODUCT|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
48673391|NCT02971709|BEHAVIORAL|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
48673392|NCT01343888|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
48673393|NCT01343888|DRUG|BI 201335|BI 201335 once daily high dose
48149002|NCT00465114|PROCEDURE|Hemodynamic Monitoring|
48149003|NCT01199302|BIOLOGICAL|Brodalumab|Administered intravenously once every 4 weeks
48149004|NCT03853746|DRUG|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
48149005|NCT02680314|DRUG|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
48509302|NCT04268199|DRUG|Bortezomib Injection|Subcutaneous injection
48509303|NCT02361242|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
48509304|NCT05088811|DIAGNOSTIC_TEST|WRAP53, UCA-1|Diagnostic value of UCA-1 and WRAP53 in HCC
48509305|NCT04918485|OTHER|preoperative psychological intervention|including closing the relationship between nurse and patient , knowledge education,
48509306|NCT00606164|DRUG|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
48509307|NCT00606164|DRUG|Placebo|A single one-hour intravenous infusion of placebo on Day 1
48509308|NCT03458299|BEHAVIORAL|Motivational Interviewing|2 hours of motivational interviewing
48509309|NCT03458299|BEHAVIORAL|Psychoeducation|2 hours of DVD viewing and discussion
48673394|NCT01343888|DRUG|BI 201335|BI 201335 once daily low dose
48673395|NCT01343888|DRUG|Placebo|
48673396|NCT00972517|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Three intramuscular injections
48509310|NCT03743155|BIOLOGICAL|mesenchymal cells|Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
48673397|NCT06047132|DIAGNOSTIC_TEST|Salivaru biomarkers|C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
48149006|NCT05941988|PROCEDURE|pre grafting partial maxillary expansion with post grafting expansion|pre grafting partial maxillary expansion then anterior iliac grafting followed by 2 months period for consolidation then post grafting expansion till full arch alignment
48360483|NCT04586322|OTHER|No intervention, (observational study).|"From every participant the following information was recorded for further analysis:~* BEWE score- Basic erosive tooth wear examination (from 2 calibrated examiners) to diagnose the presence of erosive tooth wear.~* Their answer to a validated questionnaire assessing the dietary habits based in the frequency of acidic diet.~* 2 Intra oral scans (IOS): Baseline and follow up (1 year after baseline) to perform a quantification of tissue loss (in Volume loss per mm3) using Wearcompare software."
48360484|NCT05247736|DIAGNOSTIC_TEST|Infrared Thermography|Non-contact body thermometry
48360485|NCT00519415|OTHER|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
48360486|NCT00519415|OTHER|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
48360487|NCT02045615|PROCEDURE|Proposed technique for removal of the Wichita Fusion Nail|
48360488|NCT01308151|OTHER|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
48509311|NCT05998148|OTHER|virtual phone appointment visits|Patient will have post-operative appointments that place with telemedicine. The visits will will be virtual phone appointments scheduled at approximately 6 weeks, 12 weeks, and 6 months after surgery.
48673398|NCT04480229|BEHAVIORAL|Telenursing and Counseling|After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
48673399|NCT05221619|DRUG|Nipocalimab|Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.
48673400|NCT00353080|DRUG|risedronate (HMR4003)|
48673401|NCT00692887|DEVICE|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
48673402|NCT04097652|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
48673403|NCT04741932|OTHER|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
48673404|NCT02100293|DRUG|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
48673405|NCT02100293|DRUG|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
48673406|NCT01252615|BEHAVIORAL|patient only|education, behavioral strategies, psychological interventions
48149007|NCT04070521|OTHER|Observational EEG Monitoring|Subjects will be monitored with electroencephalogram (EEG) after arriving to the Emergency Department with suspected overdose
48149008|NCT05112302|OTHER|Virtual reality|Use of virtual reality goggles during procedure
48149009|NCT01160159|OTHER|Tests|Arterial parameters
48360489|NCT04565535|BEHAVIORAL|Novel donor lifestyle optimisation protocol|Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
48360490|NCT03042663|PROCEDURE|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
48360491|NCT02036476|DRUG|Cabozantinib|oral administration
48360492|NCT06322940|OTHER|250 mL serving size, 3.25% fat content|Milk
48360493|NCT06322940|OTHER|175 g serving size, ≥2% fat content|Yogurt
48360494|NCT06322940|OTHER|50 g serving size, ≥28% fat content|Cheese
48360495|NCT05416385|OTHER|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
48509312|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
48509313|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
48509314|NCT00506584|DIETARY_SUPPLEMENT|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
48509315|NCT00506584|DIETARY_SUPPLEMENT|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
48673407|NCT01252615|BEHAVIORAL|patient and partner intervention|education, psychological support, behavioral strategies
48360496|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
48360497|NCT01526928|DRUG|Rociletinib|Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
48360498|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
48673408|NCT03767543|DRUG|INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
48673409|NCT06218810|DRUG|Cadonilimab + bevacizumab + FOLFOX|Cadonilimab + bevacizumab + FOLFOX
48673410|NCT03988946|DEVICE|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
48509316|NCT00506584|DIETARY_SUPPLEMENT|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
48509317|NCT03628625|DRUG|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
48509318|NCT03628625|DRUG|Placebo|Folic acid for 3 days
48509319|NCT03628625|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
48673411|NCT03423121|DRUG|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
48673412|NCT03423121|DRUG|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
48673413|NCT01298336|DRUG|Clarithromycin|500 mg twice a day seven days a week
48673414|NCT01298336|DRUG|Moxifloxacin|400 mg per day seven days a week
48673415|NCT00441272|DRUG|Pioglitazone|
48673416|NCT00888914|DRUG|RT001|RT001
48673417|NCT00888914|DRUG|RT001|RT001
48673418|NCT00888914|DRUG|RT001|RT001
48673419|NCT00888914|DRUG|RT001|RT001
48673420|NCT00888914|OTHER|Vehicle Comparator|Vehicle Comparator
48149010|NCT01160159|OTHER|Healthy volunteers|Arterial parameters and blood test
48509320|NCT04759768|DRUG|Nalmefene Hydrochloride|3mg nasal spray
48509321|NCT04759768|DRUG|Nalmefene|1mg intramuscular injection
48509322|NCT03240263|PROCEDURE|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
48509323|NCT03240263|PROCEDURE|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
48673421|NCT01082848|DRUG|aripiprazole|10 mg QD during 26 weeks
48673422|NCT01082848|DRUG|placebo|QD during 26 weeks
48673423|NCT00678730|DRUG|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
48673424|NCT04630821|OTHER|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
48673425|NCT03345277|OTHER|Continuous Temperature monitoring|Residents in a long term care facility will wear a thermometer continuously for 3 months, measuring their body temperature
48673426|NCT04712747|PROCEDURE|Ophthalmological examinations|"* OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~* Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~* Color retinophotography~* Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
47991152|NCT03683758|OTHER|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
48673427|NCT04712747|PROCEDURE|Blood pressure measurement at rest|At the inclusion visit
48673428|NCT04482725|OTHER|Trial product 1|Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
48673429|NCT04482725|OTHER|Trial product 2|Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
48673430|NCT04482725|OTHER|Trial product 3|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
48673431|NCT04482725|OTHER|Trial product 4|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
48673432|NCT04482725|OTHER|Trial product 5|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
48673433|NCT04482725|OTHER|Trial product 6|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
48673434|NCT04482725|OTHER|Trial product 7|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
48673435|NCT04482725|OTHER|Trial product 8|Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
48673436|NCT04482725|OTHER|Trial product 9|Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
48673437|NCT04482725|OTHER|Trial product 10|Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
48673438|NCT04482725|OTHER|Trial product 10|Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
48673439|NCT04482725|OTHER|Trial product 12|Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
48673440|NCT04467814|BEHAVIORAL|Better Together|"Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (\~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3."
47991153|NCT01187927|BIOLOGICAL|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
47991154|NCT04242004|DRUG|Docosahexaenoic acid (DHA) capsules|Treatment was provided as 7 omega-3 fatty acid (Lovaza) capsules daily. Each capsule contained 1 g of omega-3 fatty acids with approximately 450 mg of docosahexaenoic acid (DHA).
47991155|NCT04242004|DIETARY_SUPPLEMENT|Soy oil capsules|The placebo was identical looking capsules that contained soy oil
48509324|NCT06500208|DRUG|Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide|Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles
48509325|NCT06633029|DEVICE|Prismaflex HF20|CRRT fluid management and reduction of uremic toxins.
48509326|NCT06633029|DEVICE|Prismaflex M60|CRRT fluid management and reduction of uremic toxins.
48673441|NCT04467814|BEHAVIORAL|Usual Care|Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
48673442|NCT00921050|DRUG|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
48673443|NCT00921050|DRUG|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
48673444|NCT01667250|DEVICE|GammaCore Active Device|
48673445|NCT01667250|DEVICE|GammaCore Sham Device|
48673446|NCT01451411|DRUG|Conivaptan hydrochloride|Intravenous
47991156|NCT06419972|OTHER|multimodal physiotherapy programme|The intervention to which the climacteric women will be subjected will consist of a combined program of education and general strength and pelvic floor muscles exercises of 8 weeks duration, at a rate of 2 sessions/week. Each of the sessions will last 60 min, except for the first one, which will be 90 min.
47991157|NCT02408393|DRUG|Saline|
47991158|NCT02408393|DRUG|Ropivacaine|
47991159|NCT05020496|DRUG|Diphenylcyclopropenone (DPCP)|Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
47991160|NCT03145025|DEVICE|Retisert|Intravitreal Implant
48509327|NCT00936247|DRUG|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
48509328|NCT00936247|DRUG|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
48509329|NCT01927198|DRUG|Placebo|
48509330|NCT01927198|DRUG|RDEA3170 5 mg|
48509331|NCT01927198|DRUG|RDEA3170 10 mg|
48509332|NCT01927198|DRUG|RDEA3170 12.5 mg|
48509333|NCT04368351|DIETARY_SUPPLEMENT|SivoMixx (200 billion)|Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
48509334|NCT04368351|DRUG|Azithromycin|dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
48509335|NCT04368351|DRUG|hydroxychloroquine|dose: 200 mg, 1 cp x 2 / day
48509336|NCT06380881|DRUG|SHR-2017|SHR-2017
48509337|NCT04220970|OTHER|BIA-ALCL|Observational : no intervention
48673447|NCT01451411|DRUG|Placebo|Intravenous
48673448|NCT01739894|DRUG|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
48673449|NCT04218812|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
48673450|NCT04218812|DIAGNOSTIC_TEST|Automated electrical source imaging (ESI)|"The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch."
48673451|NCT06104137|OTHER|course (MOOC) patient education|this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.
48673452|NCT06104137|OTHER|standard patient consent process|standard consenting and shared decision making in the clinic
48673453|NCT05042206|BIOLOGICAL|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
48673454|NCT05801913|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
48673455|NCT05801913|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48673456|NCT05801913|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48673457|NCT05801913|PROCEDURE|Computed Tomography|Undergo CT
48673458|NCT05801913|PROCEDURE|Leukapheresis|Undergo leukapheresis per SOC
48673459|NCT05801913|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion chemotherapy per SOC
48673460|NCT05801913|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48673461|NCT05801913|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
48673462|NCT05801913|PROCEDURE|Positron Emission Tomography|Undergo PET
48673463|NCT05801913|PROCEDURE|X-Ray Imaging|Undergo x-ray
48673464|NCT00180037|DRUG|Coenzyme Q10 Nanodispersion (Nanoquinone)|
47991161|NCT03145025|DRUG|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
48673465|NCT00180037|DRUG|Placebo|
48673466|NCT05174585|BIOLOGICAL|JAB-BX102 (anti-CD73 monoclonal antibody)|Administered by intravenous infusion (IV)
48673467|NCT05174585|BIOLOGICAL|pembrolizumab (anti-PD-1 monoclonal antibody)|Administered by intravenous infusion (IV)
48673468|NCT03997864|DRUG|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
48673469|NCT03997864|DRUG|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
48673470|NCT04093232|DRUG|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
47991162|NCT03060447|DRUG|Vesatolimod|Tablets Administered orally
47991163|NCT03060447|DRUG|Placebo|Tablets Administered orally
48360499|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
48673471|NCT03693495|DIAGNOSTIC_TEST|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
48360500|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
48673472|NCT03693495|DIAGNOSTIC_TEST|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
48360501|NCT01526928|DRUG|Rociletinib|"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
48673473|NCT03693495|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
47991164|NCT03060447|DRUG|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
47991165|NCT04035161|COMBINATION_PRODUCT|Investigational Product|2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
47991166|NCT04035161|OTHER|Reference Standard|60% (v/v) 1-propanol skin preparation
47991167|NCT04035161|COMBINATION_PRODUCT|Active Comparator|ChloraPrep® SEPP® skin preparation
47991168|NCT04035161|OTHER|Negative Control|0.9% Normal Saline skin preparation
48360502|NCT00326976|DRUG|FX06|400 mg as intravenous injection in two divided boluses
48360503|NCT00326976|PROCEDURE|Percutaneous coronary intervention|
48360504|NCT02908945|DRUG|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
48360505|NCT02908945|DEVICE|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
48673474|NCT04051177|BEHAVIORAL|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
48673475|NCT04051177|BEHAVIORAL|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
48673476|NCT04321616|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
48673477|NCT04321616|DRUG|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
47991169|NCT05634460|DRUG|potassium hydroxide|Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
47991170|NCT02081144|OTHER|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of \~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
48673478|NCT04321616|OTHER|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
48673479|NCT00412581|DRUG|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
48673480|NCT00412581|DRUG|Dacarbazine|600 mg/m\^2 intravenously on Day 1 of every study cycle.
48673481|NCT06323070|OTHER|Low-fat cookies|To determine the effects of low-fat cookie consumption on physiological indicators of wellness regarding sexual, skin, and gut health
48673482|NCT06323070|OTHER|Watermelon|To determine the effects of watermelon consumption on physiological indicators of wellness regarding sexual, skin, and gut health
47991171|NCT02081144|DRUG|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
47991172|NCT02081144|DRUG|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
47991173|NCT02081144|BEHAVIORAL|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
48509338|NCT04181606|DRUG|Esmolol infusion|The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
48509339|NCT04181606|DRUG|Saline infusion|Saline will be rate/volume matched to the calculated esmolol dose.
48673483|NCT01231789|PROCEDURE|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
48673484|NCT01231789|PROCEDURE|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
48360506|NCT04107935|BEHAVIORAL|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
48360507|NCT04107935|BEHAVIORAL|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
48673485|NCT00930449|OTHER|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
48673486|NCT00930449|OTHER|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
48673487|NCT00930449|OTHER|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
48673488|NCT03929666|DRUG|ZW25 (Zanidatamab)|"* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1"
48360508|NCT04828928|PROCEDURE|electromyogram|Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
48673489|NCT03929666|DRUG|Capecitabine|Administered orally twice daily (PO bid)
48673490|NCT03929666|DRUG|Cisplatin|Administered IV
48673491|NCT03929666|DRUG|Fluorouracil|Administered IV
48673492|NCT03929666|DRUG|Leucovorin|Administered IV
48673493|NCT03929666|DRUG|Oxaliplatin|Administered IV
48673494|NCT03929666|DRUG|Bevacizumab|Administered IV
48673495|NCT03929666|DRUG|Gemcitabine|Administered IV
48673496|NCT01160809|OTHER|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
48673497|NCT00286650|PROCEDURE|3rd molar teeth extraction|
48673498|NCT00198679|DRUG|Chlorhexidine|
48673499|NCT06250764|DIAGNOSTIC_TEST|Clinical periodontal measuremenets|The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G
48673500|NCT06250764|DIAGNOSTIC_TEST|ELISA test from gingival crevicular fluid (GCF)|GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively
48673501|NCT04418895|OTHER|Chemoradiation|Subjects will receive neoadjuvant chemoradiation per standard of care. This is typically comprised of radiotherapy of 5040 cGy (centigray) with concurrent capecitabine 825 mg/m2 by mouth (po) two times daily (bid) (typically rounded to the nearest 500 mg dose) or infusional 5-fluorouracil (5FU). However, dosing and administration are at the discretion of the treating medical and radiation oncologist.
48673502|NCT04418895|RADIATION|short course radiation therapy|An acceptable alternative approach is short-course radiation therapy per standard of care, which is typically comprised of radiotherapy of 25 Gy (gray) in 5 fractions, with surgery within 1 week of completion of therapy or delayed for 6-8 weeks. Selection of the optimal radiation therapy approach is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist. However, generally, short-course radiation therapy is not recommended for low-lying tumors less than 5 centimeters (cm) from the anal verge.
47914383|NCT02685982|DEVICE|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
48149011|NCT06307574|BEHAVIORAL|bpMedManage|In this 16-week RCT, a total of 100 older adults with MCI will be recruited. There are two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on the education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.
48149012|NCT05676372|PROCEDURE|CRC+HIPEC|Sample prelevation of cytoreductive surgery
48149013|NCT03989778|DRUG|Vitamin D|Vitamin D supplementation
48360509|NCT04247724|BEHAVIORAL|Recreational handball|
48360510|NCT04247724|BEHAVIORAL|Control|
48360511|NCT04021706|DRUG|Anamorelin Hydrochloride|Ghrelin receptor agonist
48360512|NCT04021706|DRUG|Placebo|placebo is a inert substance
48360513|NCT01970436|OTHER|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
48509340|NCT04181606|OTHER|Pre exercise baseline|Subject rests quietly while drug infusion begins (3 min loading dose followed by 10 min of maintenance dose) until heart rate and blood pressure stabilize.
48509341|NCT04181606|OTHER|Isometric handgrip exercise|The subject will grip at 40% of their maximum and maintain that grip for 90 seconds. Once at rest and once during heavy intensity cycling.
48509342|NCT04181606|OTHER|Semi-recumbent cycling|Subjects will pedal for 2-4 minutes at a very light intensity (20W), followed immediately by 5 minutes at a moderate intensity (at a workload intended to elicit 85% of the oxygen consumption observed at the lactate threshold), and 5 minutes of cycling at a heavy intensity (at a workload estimated to elicit oxygen consumption half way between those observed at the lactate threshold and respiratory compensation point). Subjects will then continue cycling at the heavy intensity for 90 seconds while performing isometric handgrip exercise.
48509343|NCT03403647|DIETARY_SUPPLEMENT|Vitamin D|Oral daily vitamin D
48509344|NCT00195338|DRUG|etanercept|
48509345|NCT06634368|BEHAVIORAL|Hospital GamePlan4Care|The Hospital GamePlan4Care intervention will include access to a written VA Care Transitions handbook, access to the GamePlan4Care website for skills training, 11 emails encouraging them to visit the website, and four phone calls with a dementia care specialist to tailor the training to the caregiver's needs over a 3-month period.
48509346|NCT06634368|OTHER|Health Education|Caregivers in the health education arm will receive a VA Care Transitions Handbook, 4 emails with a weblink to a general caregiving topic, and 4 phone calls to confirm that the emails were received over a 3-month period.
48673503|NCT04418895|DRUG|mFOLFOX6|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
47991174|NCT02287064|DRUG|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
48360514|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
48673504|NCT04418895|DRUG|CAPOX|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
48673505|NCT04418895|DRUG|fluoropyrimidine +/- oxaliplatin|possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
48673506|NCT03483454|OTHER|Exercise class|Same as above.
47991175|NCT03023969|DRUG|ozone oxygen mixture|receive 10 ml of ozone oxygen mixture under variable dosing
48509347|NCT01404286|BEHAVIORAL|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
48673507|NCT03483454|OTHER|Home exercise|Same as above.
48509348|NCT02937389|DIAGNOSTIC_TEST|Patients after esophagectomy|Endoscopic examinations are performed at 1 and 8 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
48673508|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
48673509|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
48673510|NCT00057564|DRUG|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
48509349|NCT05440890|OTHER|Best current rehabilitation protocol|Inflamation control and edema with physical agents, recover full pasive and active range of motion, normalize gait pattern, lower limb strengthening (specially quadriceps and hamstrings), neuromuscular control training, cycling, landings and running.
48673511|NCT00057564|DRUG|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
47991176|NCT03034421|BEHAVIORAL|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
47991177|NCT04213365|OTHER|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
48360515|NCT01193361|DRUG|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
48360516|NCT01193361|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
48509350|NCT05440890|OTHER|Cross-training protocol|Beginning on 2º week after ACLR, 3 times per week during 8 weeks, based on isotonic exercise at least to 80% of 1RM in leg extension. 5 sets o 6 repetions with 1,5 - 2 minutes between series.
48509351|NCT02583958|DEVICE|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
48509352|NCT02583958|DEVICE|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
48509353|NCT02052193|DRUG|Dabrafenib|Measurement of toxicity related to UV exposure
48509354|NCT02052193|DRUG|Vemurafenib|Measurement of toxicity related to UV exposure
48509355|NCT05410886|OTHER|Questionnaire|A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.
48509356|NCT00549679|DRUG|GSK256066|PDE4 inhibitor
48509357|NCT00549679|DRUG|Placebo|Placebo
48673512|NCT06452693|DRUG|TQA3038 injection/placebo|TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
48673513|NCT06452693|DRUG|Nucleotide drugs Control group|Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
48673514|NCT00089622|DRUG|Intravenous Levodopa|
48673515|NCT00089622|DRUG|Lisuride Transdermal System|
48673516|NCT04185350|DRUG|68Ga-NOTA-MAL-Cys39-exendin-4|After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
48673517|NCT02147821|PROCEDURE|No Pleural Chest Tube|
48673518|NCT03274765|DIAGNOSTIC_TEST|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
48673519|NCT00960544|DRUG|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
48673520|NCT01011114|DRUG|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
47914384|NCT01962324|RADIATION|SIB Dose-Escalation Radiotherapy|
47991178|NCT04096625|DEVICE|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
47991179|NCT04096625|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
47991180|NCT04096625|DEVICE|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
48360517|NCT01193361|DRUG|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
48360518|NCT01193361|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
48360519|NCT05542472|OTHER|Family Support Program Based on a Nurse-Led Case Management Model|A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
48673521|NCT01011114|DRUG|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
48673522|NCT03487094|OTHER|Infant formula|Multi-centered, prospective, randomized clinical trial
48673523|NCT03757507|DEVICE|MultiSpectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
48673524|NCT05814237|OTHER|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
48673525|NCT02514343|DRUG|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
48673526|NCT02514343|DRUG|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
48673527|NCT03041935|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
48673528|NCT03041935|PROCEDURE|Caudal-epidural nerve block|See arm description
48673529|NCT03041935|DRUG|Acetaminophen|See arm description
48673530|NCT03041935|DRUG|Sevoflurane|See arm description
48673531|NCT03041935|DRUG|Remifentanil|See arm description
48673532|NCT03041935|DRUG|Propofol|See arm description
48673533|NCT03041935|DRUG|Morphine|See arm description
48673534|NCT03041935|DRUG|Ondansetron|See arm description
48673535|NCT03041935|DRUG|Dexamethasone|See arm description
48673536|NCT03041935|DRUG|Ketorolac|See arm description
47991181|NCT02526940|PROCEDURE|rectal biopsies|6 rectal biopsies
47991182|NCT02526940|OTHER|Blood samples|Blood samples
48673537|NCT03041935|DRUG|Ropivacaine|See arm description
48673538|NCT05988736|DEVICE|MaCintosh Laryngoscope (DL)|A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.
48673539|NCT05988736|DEVICE|McGrath Laryngoscope (VL)|A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis
48673540|NCT00641693|DRUG|Budesonide|16mg Nasal Spray
48673541|NCT00641693|DRUG|Budesonide|32mg Nasal Spray
48673542|NCT00641693|DRUG|Budesonide|64mg Nasal Spray
48673543|NCT00641693|DRUG|Placebo|
48673544|NCT03522961|DRUG|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
48673545|NCT03522961|DRUG|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
48673546|NCT03826043|DIAGNOSTIC_TEST|Blood sample analysis|Thrombophilia, blood count and coagulation count
48673547|NCT03421886|DEVICE|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
48673548|NCT03421886|DEVICE|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
48673549|NCT02717650|OTHER|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
48673550|NCT02717650|OTHER|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
47914385|NCT03192371|BIOLOGICAL|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
47991183|NCT00196079|DEVICE|Coronary stent|
47991184|NCT02406651|DRUG|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
47991185|NCT02406651|DRUG|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
47991186|NCT05791045|PROCEDURE|single vs double|we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade
48673551|NCT02717650|OTHER|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
48673552|NCT05909137|RADIATION|IMRT+adjuvant immunotherapy|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT and the control group with CTV-delineated IMRT using a random number table.
48673553|NCT05880251|BEHAVIORAL|Operant Conditioning with Peripheral Stimulation|This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.
47991187|NCT02229136|DRUG|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
48360520|NCT04343027|BEHAVIORAL|Review|Physicians will review patient-reported outcome measurements with their patients during office visits.
48360521|NCT04340804|BEHAVIORAL|Kcal labelling|Real-time kcal counter synchronised with the food amount changes
48360522|NCT04340804|BEHAVIORAL|PACE labelling|Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
48673554|NCT05880251|BEHAVIORAL|Control Group with Peripheral Stimulation Only|This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
48673555|NCT02705092|OTHER|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
48673556|NCT02705092|OTHER|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
48673557|NCT01153204|BEHAVIORAL|Group Psychotherapy|
48673558|NCT01153204|OTHER|Group Psychotherapy plus Sildenafil citrate|
48360523|NCT02492789|BIOLOGICAL|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
48673559|NCT01153204|DRUG|Sildenafil citrate|
48673560|NCT03174327|DIAGNOSTIC_TEST|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
48673561|NCT05634486|BEHAVIORAL|Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)|Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment
48673562|NCT05634486|OTHER|Psychoeducation (Sham intervention)|Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
48673563|NCT01402960|DEVICE|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
48673564|NCT02826616|DRUG|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
48673565|NCT06362759|DRUG|TOUR006 - 50 MG|TOUR006 50 MG
48673566|NCT06362759|DRUG|TOUR006 - 25 MG|TOUR006 25 MG
48360524|NCT00794235|DRUG|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
48673567|NCT06362759|DRUG|TOUR006 - 15 MG|TOUR006 15 MG
48673568|NCT06362759|OTHER|Placebo|Placebo
48673569|NCT00202579|DRUG|Ivabradine|
48509358|NCT05299528|BEHAVIORAL|Direct Feedback|Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
48673570|NCT01288157|DRUG|Golimumab|Single dose of 100 mg subcutaneously
48673571|NCT01288157|DRUG|Golimumab|Single dose of 50 mg subcutaneously
47991188|NCT02229136|DRUG|Prednisolone|Prednisolone oral solution 15 mg/5 ml
47991189|NCT05852743|DEVICE|shear wave and strain elastography|shear wave elastography is a quantitative technique , while strain elastography is qualitative technique
48673572|NCT03739151|BEHAVIORAL|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
48673573|NCT02507154|DRUG|Cetuximab + NK cells|
48673574|NCT03630146|BEHAVIORAL|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
48673575|NCT03630146|OTHER|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
48673576|NCT01861665|DRUG|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
47991190|NCT05771142|DEVICE|Smart t-shirt|24h ECG Monitoring with the smart t-shirt under study
47991191|NCT05771142|DEVICE|ECG Holter|24h ECG Monitoring with ECG Holter
47991192|NCT05771142|DEVICE|Smartwatch|24h ECG Monitoring with a smartwatch
47991193|NCT04448405|BEHAVIORAL|Questionnaire for evaluation of confinement on deviant sexual fantasies|Questionnaire for evaluation of confinement on deviant sexual fantasies. Population already followed for deviant fantasies
47991194|NCT03287804|BIOLOGICAL|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
47991195|NCT02397421|DRUG|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
47991196|NCT02397421|DRUG|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
48509359|NCT06065215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that uses powerful magnets and radio waves to generate detailed images of the body's internal structures. The MRI intervention includes using a specialized MRI machine and lung imaging protocol.
48673577|NCT01861665|DRUG|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
48673578|NCT06151119|DIAGNOSTIC_TEST|68Ga FAPI PET/CT|68Ga FAPI PET/CT
48673579|NCT02982629|BEHAVIORAL|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
48673580|NCT06370039|DRUG|INV-102|INV-102 Ophthalmic Solution
47991197|NCT00416559|OTHER|clinical observation|
48673581|NCT06370039|DRUG|Vehicle|Vehicle Ophthalmic Solution
48673582|NCT05110573|PROCEDURE|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
47991198|NCT02254928|DRUG|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
47991199|NCT02069743|OTHER|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
48360525|NCT03098667|DEVICE|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
48360526|NCT03098667|DEVICE|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
48360527|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
48509360|NCT06065215|DIAGNOSTIC_TEST|Echocardiogram|"An echocardiogram, often called an echo, is a non-invasive medical test that uses high-frequency sound waves (ultrasound) to create real-time images of the heart's structure and function. It provides valuable information about the heart's size, shape, and function."
48509361|NCT06065215|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound is a non-invasive imaging technique that employs high-frequency sound waves (ultrasound) to visualize the structures and conditions of the lungs. It is particularly valuable for diagnosing and monitoring lung-related conditions, such as pneumonia, pleural effusions, and pulmonary edema. The lung ultrasound intervention involves using an ultrasound machine equipped with a specialized probe gently placed on the chest to capture detailed images of the lungs and adjacent structures.
48509362|NCT01061476|DEVICE|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
48509363|NCT01061476|OTHER|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
48509364|NCT01061476|OTHER|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
48509365|NCT02730299|DRUG|NiCord® (omidubicel)|
48509366|NCT02730299|OTHER|Cord Blood Unit|Cord blood unit
48509367|NCT03289273|DRUG|Regorafenib (Stivarga, BAY73-4506)|As per the treating physicians discretion
48673583|NCT01061385|DEVICE|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
48673584|NCT01061385|OTHER|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
48360528|NCT01567072|DRUG|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
48360529|NCT01567072|DRUG|Placebo|Only placebo treatment instead of NSAID painkillers
48360530|NCT00372944|DRUG|AZD6244|oral capsule
48360531|NCT00372944|DRUG|capecitabine|oral tablet
48360532|NCT01930396|DRUG|Tinzaparin|
48509368|NCT01716975|DRUG|EVP-6124|Arms 1, 2
48360533|NCT01930396|DRUG|Unfractionated Heparin|
48509369|NCT01716975|DRUG|Placebo|Arm 3
48509370|NCT05659212|DRUG|Dexmedetomidine|Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
48509371|NCT05659212|DRUG|Magnesium sulphate|Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
48673585|NCT04266522|OTHER|Informational Intervention|Receive printed materials
48360534|NCT01930396|DRUG|Placebo (for Tinzaparin)|0.9% Normal Saline
48360535|NCT01930396|DRUG|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
48360536|NCT00329992|BEHAVIORAL|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
48673586|NCT04266522|OTHER|Counseling|Receive direct physicist interactions to describe the technical aspects of the treatment
48673587|NCT04266522|OTHER|Questionnaire Administration|Ancillary studies
48360537|NCT04252560|PROCEDURE|Colectomy, CRS+HIPEC|No special interventions are going to be performed. Fecal samples are going to be taken and analysed
48360538|NCT01402206|BEHAVIORAL|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
48360539|NCT04052906|OTHER|Training|Planned Inhaler Medication Trainning
48360540|NCT01211366|OTHER|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
48360541|NCT01211366|OTHER|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
48360542|NCT03046329|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
48509372|NCT05659212|DRUG|Lidocaine|Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
48509373|NCT06499740|BEHAVIORAL|Adapted SAFETY-A for PC|This intervention is a suicide prevention intervention that will be adapted from the evidence-based SAFETY-Acute program. The specific intervention components will be determined from information gathered in this study but the investigators anticipate will include components such as safety planning, lethal means restriction, psychoeducation, motivation building, and care linkage.
48509374|NCT06499740|BEHAVIORAL|Treatment as Usual|Treatment as usual delivered in participating clinics.
48509375|NCT01670591|BEHAVIORAL|PS - Prevention in School|
48509376|NCT03443830|DRUG|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
48509377|NCT05751343|DRUG|TACE-HACI, plus atezolizumab-bevacizumab|transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
48509378|NCT05424458|PROCEDURE|Anterior Implant Treatment|Patients received routine examinations before surgery. The surgical procedures were performed by experienced experts. Immediate loading protocol was delivered if the insertion torque was over 35 N·cm; otherwise, removable restorations with submerged implants were applied. After a healing period of 3 to 6 months, a definitive screw-retained porcelain-fused-to-metal (PFM) or a CAD/CAM zirconia restoration were performed.
48509379|NCT03734315|DEVICE|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
48509380|NCT03502434|DRUG|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
48509381|NCT03502434|OTHER|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
48509382|NCT03502434|OTHER|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
48509383|NCT03502434|OTHER|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
48509384|NCT05440201|OTHER|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
48509385|NCT04657224|DRUG|JNJ-64264681|JNJ-64264681 capsules will be administered orally.
48509386|NCT04657224|DRUG|JNJ-67856633|JNJ-67856633 capsules or tablets will be administered orally.
48509387|NCT06323148|DRUG|Osimertinib|Adjuvant osimertinib for three years after radical surgery
48509388|NCT06323148|DRUG|No adjuvant therapy|No adjuvant therapy
48509389|NCT03391414|DRUG|hypertonic bicarbonate|8.4% sodium bicarbonate inhaled
48509390|NCT03391414|DRUG|sodium chloride|7% sodium chloride inhaled
48509391|NCT03513055|OTHER|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
48360543|NCT03406806|OTHER|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
48360544|NCT03406806|OTHER|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
48509392|NCT01322230|OTHER|Control|Multimedia Control
48673588|NCT04726891|BEHAVIORAL|Movement-2-Music + Social Networking Support|The primary goal of the proposed research is to conduct a 12-week pilot study of the SMART-HEALTH intervention in 30 individuals with SCI. There are several unique features of this study design, including a novel adapted exercise program (M2M), instructor-led, individualized training (M2M Live; described in D.2.1), individualized behavioral coaching, and social networking support.
48149014|NCT05563987|BEHAVIORAL|ACT-DE|The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
48149015|NCT05563987|BEHAVIORAL|DE|DE
48149016|NCT01645241|DRUG|gonadotropins plus GnRH antagonists|
48509393|NCT01322230|OTHER|WISEMD Original|Current WISEMD
48509394|NCT01322230|OTHER|Social Networking|Social networking feature
48509395|NCT01322230|OTHER|Social Networking plus Emotional Design|social networking features plus user interface enhancements
48509396|NCT04831359|DEVICE|Doppler ultrasound|Tissue Doppler ultrasound on pediatric patients
48509397|NCT03620045|BEHAVIORAL|Acute moderate physical activity|For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
48509398|NCT05306509|BEHAVIORAL|NiCE|Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family. The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs. Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary. If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better. If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
48509399|NCT05306509|OTHER|Routine PPC|Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
48673589|NCT05834049|BEHAVIORAL|Virtual Parental Presence on Induction of Anesthesia|Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room
48509400|NCT04349436|BIOLOGICAL|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
48509401|NCT01590277|DRUG|Active Ethanol|Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
48673590|NCT05834049|BEHAVIORAL|Midazolam|Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
48673591|NCT01186250|DRUG|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
48673592|NCT01186250|DRUG|Placebo|placebo taken daily for one year
48673593|NCT05035043|OTHER|Determination of the economic burden NAFLD patients|Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease
48673594|NCT02947633|DRUG|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
48149017|NCT01645241|DRUG|ganirelix|
48149018|NCT03431350|DRUG|Niraparib 200 mg|Participants will receive niraparib 200 mg orally.
48149019|NCT03431350|DRUG|Cetrelimab 240 mg|Participants will receive cetrelimab 240 mg IV every 2 weeks.
48149020|NCT03431350|DRUG|Cetrelimab 480 mg|Participants will receive cetrelimab 480 mg IV every 4 weeks.
48149021|NCT03431350|DRUG|Abiraterone acetate 1000 mg|Participants will receive AA 1000 mg orally.
48149022|NCT03431350|DRUG|Prednisone 5 mg|Participants will receive prednisone 5 mg orally.
48149023|NCT01826994|DEVICE|heart type fatty acid binding protein testing|
48149024|NCT03233997|OTHER|FT21018|An electronic cigarette
48149025|NCT03233997|OTHER|FT21033|An electronic cigarette
48149026|NCT03233997|OTHER|FT21034|An electronic cigarette
47991200|NCT02115711|BEHAVIORAL|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
48509402|NCT01590277|DRUG|Active Iomazenil|Active iomazenil, administered intravenously at a dose of 3.7 ug/kg. Administered over 10 minutes, beginning 10 minutes after the start of the ethanol/placebo clamp.
48509403|NCT01590277|DRUG|Placebo|Control: no alcohol, administered for a total of 90 minutes.
48673595|NCT02947633|DRUG|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
48673596|NCT04049500|OTHER|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
48673597|NCT03941847|OTHER|music|listening music
48673598|NCT02818465|OTHER|Vascular calcifications by Xray|
48673599|NCT02818465|OTHER|Vascular calcifications by tomodentimetry|
48673600|NCT02818465|BIOLOGICAL|Blood sample withdrawn|
47991201|NCT05881603|OTHER|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
47991202|NCT01482039|PROCEDURE|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
47991203|NCT01482039|PROCEDURE|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
47991204|NCT03198533|DEVICE|Triathlon PA|Implantation of Knee Prosthesis
47991205|NCT03198533|DEVICE|Triathlon Pressfit|Implantation of Knee Prosthesis
47991206|NCT06404632|BEHAVIORAL|Lev-g|Lev-g includes three sessions + a booster session using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev-g is done in groups to enable support and tips from others.
47991207|NCT01109199|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
47991208|NCT01109199|DIETARY_SUPPLEMENT|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
47991209|NCT04475679|DEVICE|Adhese Universal DC|Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth surface
48149027|NCT03233997|OTHER|FT21035|An electronic cigarette
48149028|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
48149029|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
48149030|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
48509404|NCT01590277|DRUG|Placebo|Control: no iomazenil, administered for a total of 10 minutes
48509405|NCT06393517|DRUG|PF-06954522 IR (Formulation 1)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
48509406|NCT06393517|DRUG|PF-06954522 MR (Formulation 2)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
48509407|NCT06393517|DRUG|PF-06954522 MR (Formulation 3)|Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
48673601|NCT00598650|DRUG|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
48673602|NCT01107067|DRUG|Sustanon|250 mg/21 days
48673603|NCT00639288|OTHER|modified CPT-C|modified CPT-C
48673604|NCT01776853|DIETARY_SUPPLEMENT|Glucose|
48673605|NCT01776853|DIETARY_SUPPLEMENT|Fructose|
48673606|NCT01776853|DIETARY_SUPPLEMENT|Fructans|
48673607|NCT03255889|DRUG|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
48673608|NCT03255889|OTHER|Placebo|Sunflower oil emulsion of equal calories.
48673609|NCT00497900|DRUG|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
48673610|NCT05783895|DIAGNOSTIC_TEST|Post screening diagnostic test|1) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
48673611|NCT04187131|BEHAVIORAL|augmented reality|The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
48360545|NCT03406806|OTHER|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
48360546|NCT05788718|DRUG|Sugammadex|As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
48360547|NCT03384394|DEVICE|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
48149031|NCT00657709|BIOLOGICAL|Infanrix Hexa|Routine vaccination
48149032|NCT00657709|BIOLOGICAL|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
48360548|NCT03384394|DEVICE|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
48360549|NCT03309865|DIETARY_SUPPLEMENT|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
48509408|NCT03527953|OTHER|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
48509409|NCT03527953|OTHER|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime\&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
48509410|NCT03527953|OTHER|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
48509411|NCT05620537|OTHER|observation|There are no interventions.
48509412|NCT03108053|PROCEDURE|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
48509413|NCT03108053|DEVICE|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
48509414|NCT05139810|DRUG|Donidalorsen|Donidalorsen will be administered by SC injection.
48509415|NCT05139810|DRUG|Placebo|Donidalorsen-matching placebo will be administered by SC injection.
48509416|NCT01703624|DRUG|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
48509417|NCT00437918|DRUG|nateglinide|
48509418|NCT00437918|DRUG|acarbose|
48509419|NCT03864016|DRUG|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
48509420|NCT03864016|DRUG|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
48509421|NCT03864016|DRUG|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
48509422|NCT03365557|PROCEDURE|Airway peak pressure|Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
48509423|NCT01258712|DRUG|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
48509424|NCT01258712|DRUG|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
48509425|NCT01635816|BIOLOGICAL|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
48509426|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
48509427|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
48509428|NCT01635816|BIOLOGICAL|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
48509429|NCT06470373|DRUG|RBS-001 Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
48509430|NCT06470373|DRUG|Eylea® Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
48360550|NCT03309865|DRUG|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
48673612|NCT02399644|BEHAVIORAL|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
48360551|NCT04779294|DIAGNOSTIC_TEST|STAN ( St wave analysis) and fetal blood sample-lactate|The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
48360552|NCT00510406|DRUG|tamsulosin hydrochloride|Alphablocker
48360553|NCT00510406|DRUG|solifenacin succinate|antimuscarinic
48360554|NCT00510406|DRUG|Placebo|Placebo
48673613|NCT02399644|OTHER|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
48360555|NCT02424708|DRUG|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
48360556|NCT02424708|DRUG|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
48149033|NCT00657709|BIOLOGICAL|Prevenar|Routine vaccination
48360557|NCT02424708|DRUG|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
48360558|NCT03115164|OTHER|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
48673614|NCT03719807|OTHER|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
48673615|NCT03719807|OTHER|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
48673616|NCT05285228|BEHAVIORAL|effect of choice on cooperation (pseudoalternative)|For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.
48673617|NCT05285228|BEHAVIORAL|given fluoride varnish (control)|For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.
48673618|NCT01428310|DIETARY_SUPPLEMENT|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
48360559|NCT03303131|OTHER|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
48360560|NCT05289999|DEVICE|Virtual reality headset for first injection|Performing the first ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
48360561|NCT05289999|DEVICE|Virtual reality headset for second injection|Performing the second ultrasound-guided epidural injection through the sacrococcygeal hiatus using the virtual reality headset
48360562|NCT00688194|DRUG|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
48360563|NCT00688194|DRUG|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
48673619|NCT01428310|DIETARY_SUPPLEMENT|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
47991210|NCT04475679|DEVICE|Adhese Universal|Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic to bond indirect restorations to the tooth
48149034|NCT01721109|DRUG|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
48149035|NCT03757767|OTHER|Fasting for 26-hours|"All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points."
48360564|NCT00688194|DRUG|fulvestrant|Given intramuscularly
48360565|NCT00688194|DRUG|lapatinib ditosylate|Given orally
48360566|NCT00688194|DRUG|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
48360567|NCT00688194|OTHER|placebo|Given orally
48509431|NCT05405582|COMBINATION_PRODUCT|Community-based differentiated HIV prevention incl.PrEP with SRH|Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).
48360568|NCT03419741|DEVICE|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
48509432|NCT05405582|OTHER|Primary Health Clinic based HIV prevention and care|Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.
48673620|NCT02654496|OTHER|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
48673621|NCT05260749|PROCEDURE|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
48673622|NCT05260749|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
48673623|NCT05238415|DIAGNOSTIC_TEST|Psychological and Physiological Assessments|About N = 60 patients admitted to the study receive a 3-day assessment (a further examination) at the Kiliani-Klinik Bad Windsheim which considers physical and psychological parameters relevant for the diagnosis of a Post-/ Long-COVID Syndrom.
48673624|NCT04530201|DEVICE|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
48673625|NCT00175929|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
48673626|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
48673627|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
48673628|NCT02246010|DIETARY_SUPPLEMENT|Lactose- free milk|Lactose- free milk
48673629|NCT05295628|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
48673630|NCT05295628|DEVICE|SENTINEL™ Cerebral Protection System|The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
48673631|NCT00710983|BIOLOGICAL|Oral polio vaccine|
48673632|NCT01952743|PROCEDURE|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
48509433|NCT00799825|BIOLOGICAL|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
48360569|NCT01326481|DRUG|TRC105|IV
48360570|NCT01326481|DRUG|Capecitabine|oral
48509434|NCT03170531|DIAGNOSTIC_TEST|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
48509435|NCT03170531|DIAGNOSTIC_TEST|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
48360571|NCT02603380|OTHER|No intervention|This is an observational study. No intervention will be given.
48673633|NCT01952743|PROCEDURE|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
48673634|NCT03288844|PROCEDURE|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
48509436|NCT04752059|DRUG|Trastuzumab deruxtecan|Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
48360572|NCT02589873|BEHAVIORAL|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
48360573|NCT02589873|BEHAVIORAL|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
48360574|NCT02058186|DRUG|oral vitamin D|
48509437|NCT03694899|BEHAVIORAL|phone contact|patients will be called prior to their outpatient appointment
48509438|NCT05105009|DRUG|Furosemide|"* Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine"
48509439|NCT02295540|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated IMRT
48360575|NCT02058186|DRUG|Placebo|
48360576|NCT01714336|DRUG|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
48360577|NCT01714336|DRUG|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
48509440|NCT02295540|RADIATION|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
48509441|NCT02295540|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48509442|NCT02295540|OTHER|laboratory biomarker analysis|Correlative studies
48509443|NCT01377012|BIOLOGICAL|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
48673635|NCT03288844|OTHER|Digital pictures|Digital pictures 2D to be taken at each visit
48673636|NCT03288844|OTHER|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
48673637|NCT03196830|BIOLOGICAL|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
48673638|NCT01800786|DEVICE|CPAP|
48673639|NCT04116593|BEHAVIORAL|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
48360578|NCT03187951|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
48360579|NCT03187951|BEHAVIORAL|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
48360580|NCT03187951|OTHER|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
48360581|NCT03187951|BEHAVIORAL|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
48360582|NCT03187951|BEHAVIORAL|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
48149036|NCT04212299|DEVICE|Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)|"The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA)."
48673640|NCT05572840|OTHER|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
48149037|NCT04641715|PROCEDURE|OAGB-MGB|One Anastomosis Gastric Bypass - Mini Gastric Bypass as both restrictive and malabsorptive bariatric procedure
48149038|NCT05080556|DRUG|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
48149039|NCT06005116|RADIATION|[68Ga]-NOTA-SGC8|Participants will be irrigated with \[68Ga\]-NOTA-SGC8 intravesically, with 0.05mCi/kg per person per time according to body weight, no more than 5mCi. The participants will be instructed to urinate cleanly before irrigation, and then irrigated \[68Ga\]-NOTA-SGC8 into the bladder via catheter for 30 minutes to make full contact between the injection and tumor. After 30 minutes, the injection will be withdrawn and 300ml normal saline will be injected into the bladder to maintain the shape of the bladder.
48149040|NCT04996654|BEHAVIORAL|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
48149041|NCT04996654|BEHAVIORAL|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
48149042|NCT01075854|DRUG|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
48360583|NCT03187951|BEHAVIORAL|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
48360584|NCT05393778|PROCEDURE|Measured Technique|Manual intra-operative checks and tools are used to aid in component placement during surgery.
48360585|NCT05393778|PROCEDURE|Navigated Technique|IntelliJoint® navigation is an imageless-based navigation system that utilizes a miniature infrared camera and microelectronics to measure hip center of rotation, acetabular inclination and version, leg length, and offset. The device provides accurate real-time data on implant positioning to aid in placement of the components during surgery.
48360586|NCT00935701|DEVICE|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
48360587|NCT01496924|OTHER|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
48360588|NCT00004166|DRUG|amifostine trihydrate|
48360589|NCT00004166|PROCEDURE|quality-of-life assessment|
48360590|NCT04547127|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT Plasma|Intravenous infusion.
48360591|NCT04547127|DRUG|Standard Medical Treatment|SMT
48360592|NCT02460120|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
48360593|NCT05297552|DRUG|RC48-ADC|Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
48360594|NCT05297552|DRUG|JS001|Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
48509444|NCT01377012|BIOLOGICAL|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
48149043|NCT03821285|PROCEDURE|Pulmonary Rehabilitation|Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training
48509445|NCT03935438|OTHER|Cardiac rehabilitation|The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
48149044|NCT05028257|BIOLOGICAL|COVID-19 Vaccines|Pursuit of vaccination in case of anaphylactic reaction
48360595|NCT04059354|BEHAVIORAL|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
48360596|NCT06358261|BEHAVIORAL|Diabetes Prevention Patient Activation Clinical Decision Support Tool|Diabetes Prevention Patient Activation Clinical Decision Support Tool will be used by the doctor during the visit to discuss lifestyle management
48360597|NCT01351415|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
48360598|NCT01351415|DRUG|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m\^2) on Day 1 every 21 days.
48360599|NCT01351415|DRUG|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
48360600|NCT01351415|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV over 10 minutes on Day 1 every 21 days.
48509446|NCT02865460|DRUG|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
48509447|NCT02865460|DRUG|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
48509448|NCT03893097|DRUG|Praziquantel|40 mg/kg at baseline
48509449|NCT03893097|DRUG|Artesunate + Mefloquine|4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
47991211|NCT06172764|DIETARY_SUPPLEMENT|Vitamin D supplements along with behavioral modification|"Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
47991212|NCT06172764|COMBINATION_PRODUCT|Topical fluoride application and Vitamin D supplements along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Vitamin D soft gel capsules of 50,000 IU/week for two months followed by a maintenance dosage of 5000 IU/day for one month.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
47991213|NCT06172764|PROCEDURE|Topical fluoride application along with behavioral modification|"Professional topical 5% sodium fluoride gel application for 5 minutes on the teeth having ICL.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling.~Behavior modification for dental caries with standard instructions of brushing teeth twice daily with regular fluoridated toothpaste and diet counseling."
47991214|NCT04315337|BEHAVIORAL|Virtual Kitchen Training|VR Training will include repeated practice of a single, everyday task in a non-immersive VR context (e.g., VR Breakfast) using a laptop with a touch-screen interface for four days over the course of one week.
48509450|NCT04150770|DRUG|infliximab|
48149045|NCT05949788|OTHER|No intervention|Retrospect study, no direct intervention
48149046|NCT00268697|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
48149047|NCT00268697|DRUG|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
48149048|NCT00268697|DRUG|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
48360601|NCT02219516|DRUG|RDEA3170|
48360602|NCT03677661|OTHER|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
47991215|NCT00690014|DRUG|probenecid|500 mg q 6 hrs
48149049|NCT05228834|DRUG|Voxelotor Only Product in Oral Dose Form|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
48360603|NCT03677661|OTHER|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
48360604|NCT03378284|DRUG|Tegoprazan|Tegoprazan QD for 7 days
48360605|NCT03378284|DRUG|Revaprazan|Revaprazan QD for 7 days
48360606|NCT02998931|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
48360607|NCT02998931|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
48360608|NCT04423224|OTHER|GDFM|Stroke volume variation fluid management
48360609|NCT04423224|OTHER|USUAL CARE - CONTROL|Usual care fluid management
48360610|NCT03710343|DRUG|Metformin|Single case ABA study design. Phase B (intervention period) with metformin administered orally (or by gastrostomy tube) for 16 weeks.
48360611|NCT03702023|DRUG|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
48360612|NCT03702023|DRUG|Placebo Oral Tablet|Control group will be given a placebo capsule.
48673641|NCT03586375|OTHER|Intensive Support Team Care|Intensive Support Teams (ISTs) are specialist teams which have been advocated for many years as the right services to help people with intellectual disabilities (ID) and challenging behaviour stay in their local communities. They may be staffed by one or more professions, e.g. psychology, nursing, psychiatry, and usually deliver interventions such as positive behaviour support and accept people with ID who are in a crisis when challenging behaviour emerges or provide support when a person is admitted to a local inpatient facility.
48673642|NCT00664482|BIOLOGICAL|AGS-006|Autologous Therapy for Pancreatic Cancer
48673643|NCT05111145|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
48149050|NCT05228834|DRUG|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
48149051|NCT05185089|DRUG|Orvepitant Maleate|Orvepitant tablets 30mg or 10mg
48149052|NCT05185089|DRUG|Placebo|Placebo tablets to match orvepitant 30mg and 10mg tablets
48360613|NCT00871468|PROCEDURE|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
48360614|NCT00871468|PROCEDURE|anterior-inferior plate|ORIF clavicle with anterior inferior plate
48360615|NCT06065410|OTHER|Baseline|Walking without any instruction or sound
48360616|NCT06065410|OTHER|Intrinsic focus|Walking focusing on ensuring equal step lengths and step durations on both sides and symmetry between both steps
48360617|NCT06065410|OTHER|White noise|Intrinsic focus accompanied by white noise
48360618|NCT06065410|OTHER|environmental sound|Intrinsic focus accompanied by environmental sound
48360619|NCT01174602|BEHAVIORAL|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
48673644|NCT05111145|DRUG|IVA|Tablets for oral administration.
48360620|NCT01174602|BEHAVIORAL|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
48360621|NCT02733276|OTHER|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
48360622|NCT02733276|OTHER|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
48673645|NCT02864264|DRUG|BMS-986184|
48673646|NCT02864264|DRUG|Placebo matching BMS-986184|
48360623|NCT02498340|DIETARY_SUPPLEMENT|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
48360624|NCT01548729|PROCEDURE|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
47914386|NCT03689686|DEVICE|Noninvasive Respiratory Support|"Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~1. Standard Oxygen therapy with mask~2. HFNC flow 2l/Kg~3. HFNC flow 3l/Kg~4. Helmet CPAP"
48149053|NCT05174026|OTHER|Fludeoxyglucose F-18|Given IV
48360625|NCT02525835|DIETARY_SUPPLEMENT|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
48360626|NCT02525835|DIETARY_SUPPLEMENT|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
48360627|NCT04330794|OTHER|NMFACT|caries index
48360628|NCT04330794|OTHER|DMF index|caries index chart to collect data about decayed missed filled teeth
48673647|NCT06307847|DRUG|SP5M001 inj|pre-filled syringe
48673648|NCT06307847|DRUG|Synovian inj|pre-filled syringe
48673649|NCT00029250|DRUG|Garlic powder standardized to allicin|
48673650|NCT02805543|DEVICE|Color doppler imaging|
48673651|NCT01254448|DRUG|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
48673652|NCT01254448|DRUG|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
48360629|NCT05606549|BEHAVIORAL|Marital self disclosure|Intervention time during hospitalization is the first day after chemotherapy, and intervene once per chemotherapy, a total of 4 times, 40-60 min each time. Interventions included verbal and written disclosure. The researcher will preside over the MSD process and introduce of MSD for gastric patients and their spouse，both patient and their spouse will receive a training or review on MSD skills, 5-10 minutes each time. Couples practice MSD skills through 4 revealing themes. Couples are encouraged to express their FCR, and when one partner disclosure, supporters should allow the speaker to fully express their feelings and respond positively to the speaker's message, showing empathy for them, and acknowledging their point of view.
48360630|NCT04044625|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
48360631|NCT04044625|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
48360632|NCT00303719|BIOLOGICAL|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
48360633|NCT00303719|DRUG|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
48360634|NCT00303719|DRUG|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of \>200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
48360635|NCT00303719|DRUG|fludarabine|Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.
48360636|NCT00303719|DRUG|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) \> 0.5 x 109 /L).
48360637|NCT00303719|PROCEDURE|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
48360638|NCT00303719|RADIATION|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
48360639|NCT00303719|DRUG|filgrastim|Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) \> 2500 for 2 consecutive days.
48360640|NCT04953663|BIOLOGICAL|it-hMSC|Different doses of it-hMSC
48360641|NCT01235767|OTHER|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
48360642|NCT05189535|DRUG|Pentoxifylline|Pentoxifylline 400 mg oral tablet twice daily for 12 weeks.
48149054|NCT05174026|PROCEDURE|Magnetic Resonance Imaging|Undergo 18F-FDG PET-MRI
48360643|NCT05189535|DRUG|Paclitaxel|Paclitaxel I.V 80 mg/m2 weekly
48360644|NCT05189535|DRUG|Placebo|placebo
48360645|NCT01676428|RADIATION|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions \<5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
48360646|NCT05046418|OTHER|Hypoallergenic formula containing synbiotics|An extensively hydrolysed formula containing synbiotics or an amino acid formula containing synbiotics.
48360647|NCT05535452|DEVICE|Photobiomodulation through LED board|The applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physiotherapists and physiotherapy students, through the sportllux LED plate equipment, medium size, which combines light emitters in two wavelengths: red (660nm) and infrared (850nm).
48360648|NCT05528159|PROCEDURE|Intraabdominal CO2 insufllation|Patients will receive intraabdominal CO2 insufflation and will be operated under trendelenburg position
48149055|NCT05174026|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET-MRI
48360649|NCT01796106|DEVICE|Resin infiltration|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth, the study lesions will be treated using the resin infiltrant Icon (DMG, Germany) according to manufactures´ instructions. Essentially, the treatment consists of the following parts: 1) isolating the tooth with a rubber dam and cleaning its surface; 2) removing/ conditioning the surface layer of the lesion (using Icon-Etch) to open the lesion body; 3) drying of the exposed porous enamel; 4) infiltrating the existing pore volume with the resin infiltrant (Icon Infiltrant); 5) light curing of the resin infiltrant; 6) repeating the infiltration step including light curing; followed by 7) finalizing using interproximal finishing/polishing strips.
48360650|NCT01796106|DEVICE|Fluoride varnish & Oral hygiene instruction|Up to two proximal early caries lesions (only if the second lesion is in a separate quadrant) per participant will be included. After radiographic and SFE imaging to assess lesion depth oral hygiene instruction and topical fluoridation therapy will be provided. For topical fluoridation Duraphat Fluoride Varnish (Colgate, USA) will be used according to manufactures´ instructions.
47914387|NCT01839604|DRUG|AZD9150|Intravenous infusion over 3 hours.
48509451|NCT05393479|BEHAVIORAL|Thinking Healthy Programme|The Thinking Healthy Programme (THP) is a psychological treatment recommended by the World Health Organization for perinatal depression. The THP is based on the basic tenets of cognitive behavioural therapy (CBT) that aims to identify unhealthy thoughts and the vicious effects it has on the emotions and behaviour of a person and transform to healthy thinking style that ultimately impacts one's emotions and behaviour, too. The intervention aims to bring positive outcomes in three areas - a) mother's health, b) the mother-baby relationship, and c) the mother's relationship with others. A randomized controlled trial (RCT) showed that the intervention was effective in reducing depressive symptoms and disability and improving functioning. Additionally, women receiving THP had higher rate of exclusive breastfeeding, and engaging more with their infants. Similarly, infants of these women were also less likely to have diarrhoeal episode and more likely to complete immunization.
48360651|NCT03866239|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
48360652|NCT03866239|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
48360653|NCT03866239|DRUG|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
48360654|NCT03866239|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
48360655|NCT04030351|OTHER|food - dried fruit|raisins, apricots, figs, and pineapple
48360656|NCT04698954|BEHAVIORAL|Adherence Improving self-Management Strategy|The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.
48360657|NCT04698954|OTHER|Treatment-as-usual|Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
48360658|NCT04605341|DEVICE|miniplate|comparison between k wires and miniplate in metacarpal fractures
48360659|NCT03839576|BEHAVIORAL|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
48360660|NCT03839576|BEHAVIORAL|Computerized training|Attention, memory, speed of processing, and executive functioning.
48360661|NCT04352049|PROCEDURE|Preoxygenation|
48673653|NCT05663463|DRUG|Fluzone High-Dose - 2 doses|2 doses of the High-Dose (HD) influenza vaccine separated by 4-6 weeks For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
48360662|NCT00304421|DRUG|rabeprazole|
48360663|NCT00304421|DRUG|pantoprazole|
48509452|NCT04748965|DIAGNOSTIC_TEST|Digital Subtraction Angiography|Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
48509453|NCT02366273|OTHER|PASI and HOMA index|
48360664|NCT00187733|OTHER|Fasting blood and urine collection|Not applicable no drugs dispensed
48360665|NCT06481605|DEVICE|C-REX|The C-REX is a CE-marked class IIa device consisting of an invasive surgical part, including two anastomotic rings, intended for short-term use, and surgical instruments LapAid and RectoAid for assisting the placement of the anastomotic ring to intestine. The device is supplemented with a catheter to monitor the anastomosis.
48360666|NCT02886442|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
48360667|NCT02886442|OTHER|New adhesive strip|This is a newly developed adhesive strip
48360668|NCT06354920|BEHAVIORAL|Bonding Bundle|Doctors in the intervention arm will be asked to use suggested approaches while meeting with their hospitalized patients. The goal of these strategies is to improve the relationship and interactions between patients and physicians.
48360669|NCT04306692|DRUG|Myo-inositol|2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).
48360670|NCT04306692|DRUG|Clomiphene Citrate|"Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days."
48360671|NCT04104893|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
48360672|NCT03098576|OTHER|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
48360673|NCT03098576|OTHER|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
48360674|NCT02009501|DEVICE|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
48673654|NCT05663463|DRUG|Fluzone High-Dose - 1 dose of HD|1 dose of the High Dose (HD) influenza vaccine, followed by a placebo injection 4-6 weeks later For 2023-2024 influenza season the influenza quadrivalent HD vaccine was used. For 2024 -2025 influenza season the influenza trivalent HD vaccine will be used.
48673655|NCT00046904|BIOLOGICAL|etanercept|
48673656|NCT01051037|RADIATION|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
48673657|NCT01051037|RADIATION|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
48360675|NCT02009501|DEVICE|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
47991216|NCT03989999|PROCEDURE|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.~If TCD is normal (FVd\>25 cm/sec and PI \<1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (\< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
47991217|NCT05562973|DRUG|Psilocybin|Participants will receive three psilocybin sessions, at least two weeks apart.
47991218|NCT00628433|DRUG|Placebo|Placebo
47991219|NCT00628433|DRUG|HE3286|daily for 28 days
47991220|NCT01985581|DRUG|Guanfacine extended release|
47991221|NCT01985581|DRUG|Placebo|
47991222|NCT01985581|DRUG|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
47991223|NCT01627821|DEVICE|Jarvik 2000 VAS|Jarvik 2000 LVAD
48673658|NCT06287372|OTHER|Cardioplegic solution|Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection
48673659|NCT04691921|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
47991224|NCT01627821|DEVICE|HeartMate II|HeartMate II LVAD
47991225|NCT02694237|BEHAVIORAL|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
47991226|NCT02694237|BEHAVIORAL|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
47991227|NCT02694237|BEHAVIORAL|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
47991228|NCT02475551|DRUG|IdeS|Intravenous infusion
47991229|NCT02320500|BEHAVIORAL|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
47991230|NCT02320500|OTHER|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
47991231|NCT06024421|DRUG|favipiravir|Light yellow, film-coated tablet, each containing 200 mg of favipiravir
48149056|NCT04402125|BEHAVIORAL|TargEted MAnageMent Intervention (TEAM)|"TEAM targets acquisition of self-management expertise and use of healthy behaviors that are intended to reduce stroke risk and burden. TEAM participants will continue in their regular medical care, supplemented by the TEAM intervention. Components are as follows:~1. A 60 minute initial session in which the nurse and the PED meet with the patient who has experienced stroke or TIA. The initial session will cover introductions, orientation, and logistic planning.~2. Five 60-minute group sessions with 6-10 stroke survivors (and their care partners as applicable) held approximately 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 week after enrollment. Sessions are co-lead by a nurse and a PED.~3. Six brief telephone sessions implemented after the conclusion of the 5 TEAM group sessions. Calls will be conducted every 2 weeks for 12 weeks. Calls will reinforce group session content, provide social support and facilitate linkage with other care providers."
48673660|NCT05402254|OTHER|Pharmacovigilance Program|Knowledge of the risks in the use of the drug, identification and notification of ADE
48673661|NCT06160141|OTHER|Resistance training|"Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises."
48673662|NCT04596683|PROCEDURE|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
48673663|NCT01486303|PROCEDURE|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
48673664|NCT02448134|BEHAVIORAL|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
47991232|NCT06024421|DRUG|Placebo|Light yellow, film-coated tablet
47991233|NCT02558257|BEHAVIORAL|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
48360676|NCT03718728|BEHAVIORAL|Mind&Life|Acceptance and mindfulness-based group intervention program.
48673665|NCT01166347|DEVICE|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
47991234|NCT04946357|RADIATION|Protons|proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
47991235|NCT04946357|RADIATION|carbon ions|carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
47991236|NCT05812976|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
47991237|NCT05812976|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
47991238|NCT02311738|OTHER|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
48509454|NCT06550258|OTHER|Equine-assisted therapy|Hippotherapy is a therapeutic intervention applied by physiotherapists that aims to improve impaired body functions. Hippotherapy is a therapy in which the rider receives stimuli from the horse that stimulate the sensory, neuromotor and cognitive systems during riding and exercise on the back of a horse. Hippotherapy is effective on posture control, balance, gross motor functions and functional performance in children with cerebral palsy.
48673666|NCT01166347|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
48673667|NCT00560508|DRUG|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
48673668|NCT00560508|DRUG|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
48673669|NCT01900067|DEVICE|BARRIER® EasyWarm Active Self-Warming Blanket|
48673670|NCT05498584|BEHAVIORAL|exercise based cardiac rehabilitation|The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
48509455|NCT06550258|OTHER|Traditional Pediatric Physiotherapy|In traditional pediatric physiotherapy, cushions of appropriate hardness were used for proprioceptive input. Stools of different heights were used for sitting, squatting, standing up by holding on and standing, Bobath balls and balance boards were used for balance reactions. Triangular and roll cushions of different hardness were used for weight transfer. Surfaces with different patterns were used for sensory input. The child's wishes and interests were taken into consideration in the selection of materials. The treatment was planned according to the activities that were difficult in daily life and the aim was to transfer the knowledge learned to daily life.
48673671|NCT02465931|OTHER|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
48673672|NCT02465931|OTHER|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
48360677|NCT03718728|BEHAVIORAL|Standard|Personalized diet and physical exercise recommendations.
47991239|NCT05880927|DRUG|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
47991240|NCT03370003|OTHER|Standard medical care|All children will receive nutritional treatment and standard medical care in accordance with the nutritional guidelines of the national protocol, with the exception of the routine distribution of antibiotics.
47991241|NCT00034333|DRUG|MTC-DOX for Injection|
48360678|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
48149057|NCT06557330|DRUG|Bendamustine|Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.
48360679|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
48360680|NCT02699840|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
48360681|NCT00124696|DRUG|Cocaethylene|
48360682|NCT00198042|PROCEDURE|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
48360683|NCT06272279|DEVICE|spinal stimulation-DCS|transcutaneous spinal stimulation by direct current stimulation
48673673|NCT04029207|PROCEDURE|Cesarean section|Abdominal, operative delivery of the fetus
48360684|NCT06272279|OTHER|spinal stimulation-sham DCS|sham transcutaneous spinal stimulation by direct current stimulation
48360685|NCT06272279|OTHER|spinal stimulation-EPS|transcutaneous spinal stimulation by electrical pulsed stimulation
48360686|NCT06272279|OTHER|sham spinal stimulation-EPS|sham transcutaneous spinal stimulation by electrical pulsed stimulation
48360687|NCT04763824|BEHAVIORAL|Telementoring with Practice Facilitation|We are attempting to provide education and encourage practice change
48360688|NCT03312075|OTHER|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
48360689|NCT01888367|DRUG|DFA-02 Antibiotic Gel|
48360690|NCT01888367|DRUG|DFA-02 Placebo Gel|
48360691|NCT02781246|DRUG|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
48673674|NCT00429182|DRUG|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
48360692|NCT01365468|DRUG|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
48673675|NCT00429182|DRUG|Cyclophosphamide|1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
47991242|NCT00002091|DRUG|Pentoxifylline|
48360693|NCT01713569|DEVICE|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
48360694|NCT04263129|PROCEDURE|Tracheal, carinal or bronchial transplantation using a stented cryopreserved aortic|Radical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.
48360695|NCT01625364|BEHAVIORAL|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
48360696|NCT01625364|BEHAVIORAL|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
48360697|NCT06150352|DEVICE|Continuous Positive Airway Pressure or other management for OSA per clinical indications.|PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
48509456|NCT05702229|DRUG|Rilvegostomig|an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
48509457|NCT05702229|DRUG|Volrustomig|an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
48509458|NCT05702229|DRUG|FOLFOX|5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
48509459|NCT05702229|DRUG|XELOX|capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
48509460|NCT05702229|DRUG|AZD7789|an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
48509461|NCT05702229|DRUG|AZD0901|an anti Claudin18.2 ADC; IV infusion
48509462|NCT05702229|DRUG|5-Fluorouracil|5-FU, IV infusion, Q3W
48509463|NCT05702229|DRUG|Capecitabine|Oral take, Q3W
48509464|NCT00318877|BEHAVIORAL|After school team sports program|
48509465|NCT00318877|BEHAVIORAL|After school health education program|
48673676|NCT00429182|DRUG|Thiotepa|120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
48673677|NCT00429182|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0.
48673678|NCT02868853|BEHAVIORAL|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
48673679|NCT02868853|BEHAVIORAL|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
48673680|NCT02868853|BEHAVIORAL|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
48673681|NCT01897493|DRUG|Evacetrapib|Administered orally
48673682|NCT01897493|DRUG|Digoxin|Administered orally
48360698|NCT02552537|DRUG|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
48360699|NCT02552537|DRUG|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
48360700|NCT00369564|DRUG|glutamic acid|Given orally 3 times daily
48360701|NCT00369564|OTHER|placebo|Given orally 3 times daily
48360702|NCT03753867|DRUG|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
48360703|NCT02079701|BIOLOGICAL|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
48360704|NCT02079701|BIOLOGICAL|Placebo|
48360705|NCT02178215|OTHER|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
48360706|NCT02178215|OTHER|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
48360707|NCT00004024|BIOLOGICAL|aldesleukin|
48360708|NCT00004024|BIOLOGICAL|autologous tumor cell vaccine|
48509466|NCT06583473|BEHAVIORAL|Interactive digital health application|The study program will provide an integrated interactive digital health application (LINE app on smartphones, incorporating information about biodata recording, health education, questionnaires, and online Q\&A)
48673683|NCT04725006|DEVICE|Spinal cord stimulation system|These systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain. Stimulation will be applied to the system using an external stimulator to see if sensations can be evoked in the participant's limb/foot.
48673684|NCT02423486|DEVICE|Electromagnetic stimulation therapy (BIOCON-2000)|
48673685|NCT02423486|DEVICE|Electromagnetic stimulation therapy with biofeedback|
48149058|NCT06557330|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
48673686|NCT02308761|DRUG|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
48360709|NCT00004024|BIOLOGICAL|muromonab-CD3|
48360710|NCT00004024|BIOLOGICAL|sargramostim|
48360711|NCT00004024|BIOLOGICAL|therapeutic autologous lymphocytes|
48360712|NCT00004024|PROCEDURE|surgical procedure|
48360713|NCT00004024|RADIATION|radiation therapy|
48360714|NCT03310476|OTHER|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
48360715|NCT03580902|BEHAVIORAL|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
48360716|NCT03580902|DRUG|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
48360717|NCT02485340|DRUG|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
48360718|NCT02485340|DRUG|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
48509467|NCT03296878|OTHER|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
48509468|NCT03296878|OTHER|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
48360719|NCT02485340|DRUG|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
48360720|NCT03716206|DEVICE|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
48360721|NCT03716206|OTHER|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
48360722|NCT04360889|DRUG|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)|Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
48360723|NCT04360889|DRUG|Tocopherol|patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
48360724|NCT04360889|OTHER|Elastic compression|patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
48360725|NCT03018028|DRUG|Semaglutide|Oral administration once daily
48360726|NCT03018028|DRUG|Placebo|Oral administration once daily
48360727|NCT03018028|DRUG|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
48360728|NCT04461457|COMBINATION_PRODUCT|211-astatine MX35 F(ab')2|Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
48360729|NCT04619563|DRUG|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
48360730|NCT04337203|BEHAVIORAL|SHARE-S Implementation Program|The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
48360731|NCT00468273|DRUG|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
48360732|NCT04057313|DIETARY_SUPPLEMENT|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
48360733|NCT04501419|PROCEDURE|US-guided breast biopsy|During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
48360734|NCT04501419|OTHER|Ultrasound-guided breast biopsy training program|This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
48360735|NCT00963469|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
48360736|NCT00963469|DRUG|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
48360737|NCT00963469|DRUG|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
48360738|NCT03087474|OTHER|Non-Interventional|Non-Interventional
48673687|NCT06420193|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
48673688|NCT03102983|OTHER|MRI functional|vowels records and MRI session
48673689|NCT01692288|BEHAVIORAL|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
48673690|NCT01949129|DRUG|VP16|60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
48673691|NCT01949129|RADIATION|TBI|2 x 2Gy/day , 3 days (total 12Gy)
48360739|NCT02646332|DRUG|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
48673692|NCT01949129|DRUG|Thiotepa|2x5 mg/kg BW, 1 day
48360740|NCT02646332|DRUG|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
48360741|NCT04899752|BEHAVIORAL|Motivational Interviewing|Participants will participate in three different communication styles to determine the effect of MI on cardiac rehab outcome measures.
48360742|NCT00207506|BEHAVIORAL|HoMBReS: A lay health advisor approach to STD prevention|
48360743|NCT02250586|BEHAVIORAL|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
48360744|NCT03264027|DRUG|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
48360745|NCT03264027|DRUG|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
48360746|NCT03264027|DRUG|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
48360747|NCT05972668|DEVICE|Smartphone Apps|The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
48360748|NCT01915355|DEVICE|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
48673693|NCT01949129|DRUG|Treosulfan|14g/m² BS, 3 days
48673694|NCT01949129|DRUG|Fludarabine|30 mg/m² BS, 5 days
48673695|NCT01949129|DRUG|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
48673696|NCT01949129|DRUG|ATG Thymoglobulin|MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
48673697|NCT01949129|DRUG|Cyclophosphamide|as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
48360749|NCT01321736|DIETARY_SUPPLEMENT|dietary fiber|mixture of fiber sources added to liquid nutrition product
48360750|NCT00209755|PROCEDURE|therapeutic drug monitoring of ribavirin and dose adaptation|
48360751|NCT01271608|DEVICE|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
48360752|NCT04522193|DEVICE|Glycemic Holter|Continuous glycaemia monitoring,
48673698|NCT01949129|DRUG|Grafalon|MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
48673699|NCT05341310|BEHAVIORAL|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
48673700|NCT05341310|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
48673701|NCT05725122|PROCEDURE|Extracorporeal shock wave lithotripsy|Extracorporeal shock wave lithotripsy will given to the patients
48673702|NCT05725122|PROCEDURE|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
48673703|NCT00352859|DRUG|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
48673704|NCT00352859|DRUG|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
48673705|NCT02785328|OTHER|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
48673706|NCT02785328|OTHER|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
48673707|NCT02785328|OTHER|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
48673708|NCT05370274|PROCEDURE|Strength training intervention|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
48673709|NCT05370274|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
48673710|NCT00119197|BIOLOGICAL|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~* Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~* Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~* Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~* Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart"
48673711|NCT00119197|BIOLOGICAL|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart"
48673712|NCT05038696|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
48673713|NCT05043948|DIAGNOSTIC_TEST|Blood samples|for evaluation of the genome-wide association study
48360753|NCT04522193|RADIATION|gastric emptying scintigraphy|Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.
48360754|NCT04522193|DEVICE|Holter ECG|continuous cardiac monitoring
48360755|NCT03922919|DRUG|Cefotaxime Injection|Systematic use of cefotaxime.
48360756|NCT03922919|PROCEDURE|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
48360757|NCT03922919|DRUG|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
48360758|NCT00001151|DRUG|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
48673714|NCT01436110|DRUG|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
48673715|NCT01436110|DRUG|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
48673716|NCT01436110|DRUG|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
48360759|NCT02798809|OTHER|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
48360760|NCT03020797|DRUG|Perampanel|
48360761|NCT03020797|DRUG|Placebo Oral Tablet|
48360762|NCT01550315|PROCEDURE|Pulsitile Arterial Tonometry (PAT) Protocol|"* A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
48360763|NCT01550315|DEVICE|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
48509469|NCT02113618|BEHAVIORAL|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
48673717|NCT04555174|DEVICE|Orsiro Mission DES|Percutaneous Coronary Intervention (PCI)
48673718|NCT01382914|OTHER|chlorhexidine 0.12%|twice daily, 10 ml, topical
48673719|NCT00962871|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
48673720|NCT00962871|DRUG|tenofovir|300mg po daily for 2 weeks
48673721|NCT00820547|BIOLOGICAL|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
48673722|NCT00820547|DRUG|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
48673723|NCT00820547|DRUG|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
48673724|NCT00820547|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
48149059|NCT03771300|BEHAVIORAL|Mindfulness|This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
48149060|NCT03771300|BEHAVIORAL|Mindfulness condition complemented by VR|"The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health."
48509470|NCT02113618|BEHAVIORAL|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
48509471|NCT02135471|DRUG|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
48509472|NCT02135471|DRUG|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
48509473|NCT01957735|DRUG|BP31510 monotherapy|
48509474|NCT01957735|DRUG|BP31510 in combination with chemotherapy|
48509475|NCT05379673|OTHER|Oxygen Gas for Inhalation|Oxyhemoglobin saturation (SpO2) higher than 96% vs SpO2 between 90% and 94%.
48673725|NCT00820547|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
48673726|NCT05816824|OTHER|Symptom monitoring software via visual feedback|With PhysioAnalyst software, individuals are evaluated using clinical tools (questionnaire, scale). These evaluations provide visual feedback to individuals in the form of tables and graphs. In this way, patients can observe the changes in their clinical status.
48673727|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
48673728|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
48673729|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
48673730|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
48673731|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
48673732|NCT01010672|DRUG|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
48673733|NCT00335166|DRUG|Pardaprunox|12-42 mg
48673734|NCT00335166|DRUG|pramipexole|1.5-4.5 mg
48673735|NCT00335166|DRUG|Placebo Comparator|Placebo
48673736|NCT06141551|PROCEDURE|total laminectomy decompression|Surgical decompression
48673737|NCT05065801|COMBINATION_PRODUCT|GABRINOX|Patients in the experimental arm received sequential treatment: 3 cycles of GEMBRAX followed by 2 cycles of FOLFIRINOX
48673738|NCT05065801|COMBINATION_PRODUCT|FOLFIRINOX|Patients in this arm received reatment: 3 cycles of FOLFIRINOX
48673739|NCT04846231|DIETARY_SUPPLEMENT|Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
48360764|NCT01550315|DEVICE|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
48149061|NCT03771300|BEHAVIORAL|Relaxation|This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
48149062|NCT00021099|DRUG|ixabepilone|Given IV
48149063|NCT03937752|OTHER|3D endodanal ultrasound|Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
48509476|NCT06251245|PROCEDURE|Oral Injector|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* • Experimental Group (Giving the medicine orally to the child with an Oral Injector)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
48673740|NCT04846231|DRUG|Rosuvastatin|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
48149064|NCT04515550|DIAGNOSTIC_TEST|lumbar puncture|Some participants will have an optional lumbar puncture
48149065|NCT04523909|DIAGNOSTIC_TEST|Trajectory of neuroinflammatory proteins in CSF and blood|Kinetics of neuroinflammatory markers in CSF and blood
48673741|NCT04846231|OTHER|Placebo|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
48673742|NCT02405299|OTHER|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
48149066|NCT00424476|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
48360765|NCT02142673|DEVICE|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
48673743|NCT06513533|OTHER|Placebo|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
48149067|NCT00424476|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
48360766|NCT02142673|DEVICE|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
48149068|NCT00424476|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
48149069|NCT00700557|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
48360767|NCT02142673|DEVICE|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
48360768|NCT00577421|DRUG|risedronate|5 mg tablet of risedronate once a day for 2 years
48360769|NCT00316212|DRUG|INS50589 Intravenous Infusion|
48360770|NCT05236257|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Pediatric patients with IFS harboring an NTRK gene fusion.
48360771|NCT05236257|DRUG|Standard of Care|Standard of care for the patients from the eligible external cohorts.
48149070|NCT00700557|DIETARY_SUPPLEMENT|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
48149071|NCT03196622|DEVICE|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
48149072|NCT00397098|DRUG|SR58611A|
48149073|NCT05031052|DEVICE|End-ischemic normothermic oxygenated machine perfusion|Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.
48149074|NCT05031052|PROCEDURE|Static cold storage|Immediate implantation of kidney allograft after conventional and static preservation on ice
48149075|NCT02275351|DRUG|SM04554|Topical solution, applied once a day
48149076|NCT02275351|DRUG|Vehicle|Topical solution, applied once a day
48149077|NCT05051709|PROCEDURE|Corrective osteotomy|First metatarsal distal corrective osteotomy
48149078|NCT05051709|PROCEDURE|Fusion of First ray|Fusion of first ray with soft tissue procedure
48149079|NCT03170440|OTHER|Transcutaneous nerve stimulation location 1|Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
48149080|NCT03170440|OTHER|Transcutaneous nerve stimulation location 2|Stimulation will be performed using electrodes placed in alternate location.
48149081|NCT05408845|DRUG|Docetaxel|Given IV
48360772|NCT02263742|BEHAVIORAL|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
48360773|NCT02263742|BEHAVIORAL|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
48360774|NCT03637504|BEHAVIORAL|MedActionPlan®|web-based, mobile medication management application \[MedActionPlan® (MAP)\]
48360775|NCT04541836|DIAGNOSTIC_TEST|18F-PMPBB3|single intravenous injection 5mCi 18F-PMPBB3 per scan
48360776|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
48360777|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
48360778|NCT01535638|DRUG|BI 207127|Medium dose film-coated tablet
48673744|NCT06513533|DRUG|Dimethyl fumarate|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
48673745|NCT02890277|DEVICE|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
48673746|NCT02890277|DRUG|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
48673747|NCT05983094|DRUG|Utidelone|Utidelone injection 30mg/m2, on days 1-5 of each cycle
48673748|NCT05983094|DRUG|Carboplatin|Carboplatin Area under curve(AUC)6, iv, was administered on day 1
48673749|NCT05983094|DRUG|Epirubicin|Epirubicin 75mg/m2 was administered on day 1
48673750|NCT05983094|DRUG|Trastuzumab|Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
48673751|NCT05983094|DRUG|Pertuzumab|Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
47991243|NCT02294344|OTHER|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35\~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
48149082|NCT05408845|OTHER|Questionnaire Administration|Ancillary studies
48149083|NCT05408845|BIOLOGICAL|Trastuzumab|Given IV
48673752|NCT03764969|BEHAVIORAL|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.
48149084|NCT05408845|BIOLOGICAL|Trastuzumab Emtansine|Given IV
48149085|NCT01077440|GENETIC|DNA analysis|DNA analysis will be performed on samples collected.
48149086|NCT01077440|GENETIC|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
48149087|NCT01077440|OTHER|flow cytometry|Flow cytometry will be done on the samples collected.
48149088|NCT01077440|OTHER|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
48149089|NCT00629447|DRUG|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
48149090|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po
48673753|NCT03764969|BEHAVIORAL|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
48673754|NCT03764969|BEHAVIORAL|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
48673755|NCT04231071|DEVICE|Onlay Mesh group|Primary suture repair with a small only mesh on the closed defect
48673756|NCT00733486|DEVICE|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
48673757|NCT02809885|BIOLOGICAL|Hepatitis E serology|
48673758|NCT04473781|PROCEDURE|Interstitial Radiation Therapy|Undergo interstitial brachytherapy
48149091|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
48149092|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
48149093|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
48149094|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
48149095|NCT00680654|DRUG|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
48149096|NCT06193915|DEVICE|Ultrasound guided hematoma block.|Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.
48673759|NCT05994768|OTHER|18F-FDG PET/CT|Patients who underwent an 18F-FDG PET/CT examination and a labeled leukocyte scintigraphy before and after antibiotic therapy in the case of management of an EO.
48673760|NCT02665533|DRUG|Dexamethasone|Dexamethasone 8 mg
48673761|NCT02665533|DRUG|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
48673762|NCT01871025|OTHER|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
48673763|NCT01871025|OTHER|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
48673764|NCT03362268|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
47991244|NCT02294344|DRUG|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count \<3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count \<3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
48360779|NCT04244773|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
48360780|NCT04244773|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
48360781|NCT03946592|DRUG|Normal saline|Inject the Drug into submental fat via subcutaneous
48360782|NCT03946592|DRUG|DWJ211|Inject the Drug into submental fat via subcutaneous
48673765|NCT03362268|DRUG|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
48673766|NCT05996393|DRUG|Ciclosporin|3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml
48673767|NCT05996393|DRUG|Avatrombopag|60 mg/d orally, 24 weeks
48673768|NCT05996393|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|rabbit anti-human thymocyte immunoglobulin (r-ATG 3mg/kg/d), intravenously, 5 days;
48673769|NCT01459809|DRUG|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
48673770|NCT01459809|DRUG|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
48673771|NCT01336244|DRUG|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
48673772|NCT01336244|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
48673773|NCT01298843|DRUG|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
48673774|NCT03388541|DRUG|Dexmedetomidine|Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
48673775|NCT03388541|DRUG|Placebo|A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
48673776|NCT05702814|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
48673777|NCT04940130|BIOLOGICAL|Sanaria® PfSPZ Vaccine|non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
48673778|NCT04940130|OTHER|Normal Saline|placebo control- saline
48673779|NCT02725905|BEHAVIORAL|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
48673780|NCT02725905|BEHAVIORAL|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
48673781|NCT03076281|DRUG|Metformin Hydrochloride|Given orally
48673782|NCT03076281|DRUG|Doxycycline|Given orally
48673783|NCT03076281|DRUG|Metformin +Doxycycline|Given orally
48673784|NCT02308293|BEHAVIORAL|High intensity exercise|3x30 seconds 'all out' sprints
48673785|NCT02308293|BEHAVIORAL|Lay down comfortably|rest
48673786|NCT00786162|OTHER|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
48149097|NCT06193915|PROCEDURE|Blind hematoma block|Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
48149098|NCT02802176|DEVICE|INVOcell device|intra-vaginal culture of embryos using INVOcell device
48673787|NCT00786162|OTHER|BP cuff at workplace|Provided BP cuff for communal use at the worksite
48673788|NCT02923154|DRUG|MT-3995|
48673789|NCT02923154|DRUG|Placebo|
48673790|NCT06282861|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Product to be used according to specifications. 1 inhalation daily for 12 months
48673791|NCT06282861|DRUG|Brimica|As per product specifications
48673792|NCT06282861|DRUG|Duaklir|As per product specifications
48673793|NCT06282861|DRUG|Ultibro|As per product specifications
48673794|NCT06282861|DRUG|Ulunar|As per product specifications
48673795|NCT06282861|DRUG|Xoterna|As per product specifications
48673796|NCT06282861|DRUG|Anoro|As per product specifications
48673797|NCT06282861|DRUG|Laventair|As per product specifications
48673798|NCT06282861|DRUG|Spiolto Respimat|As per product specifications
48673799|NCT06282861|DRUG|Yanimo|As per product specifications
48673800|NCT06282861|DRUG|Foradil|As per product specifications
48673801|NCT06282861|DRUG|Broncoral|As per product specifications
48673802|NCT06282861|DRUG|Formoterol stada|As per product specifications
48673803|NCT06282861|DRUG|Oxis|As per product specifications
48673804|NCT06282861|DRUG|Formatris|As per product specifications
48673805|NCT06282861|DRUG|Formoterol Aldo|As per product specifications
48360783|NCT01540110|DRUG|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
48360784|NCT00620672|DIETARY_SUPPLEMENT|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
48360785|NCT00620672|DIETARY_SUPPLEMENT|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
48360786|NCT03091920|DRUG|IW-1973|Oral Tablet
48360787|NCT03091920|DRUG|Placebo|Oral Tablet
48360788|NCT03723811|DRUG|SJP002 BID|1 drop b.i.d for 12 weeks
48673806|NCT06282861|DRUG|Onbrez|As per product specifications
48673807|NCT06282861|DRUG|Oslif|As per product specifications
48673808|NCT06282861|DRUG|Hirobriz|As per product specifications
48673809|NCT06282861|DRUG|Striverdi|As per product specifications
48673810|NCT06282861|DRUG|Beglan|As per product specifications
48673811|NCT06282861|DRUG|Betamican|As per product specifications
48673812|NCT06282861|DRUG|Inaspir|As per product specifications
48673813|NCT06282861|DRUG|Serevent|As per product specifications
48673814|NCT06282861|DRUG|Soltel|As per product specifications
48149099|NCT02802176|OTHER|Traditional IVF|traditional culture of embryos in-vitro
48149100|NCT03530644|DEVICE|WM3.4NR|The investigational medical device will collect spectral Raman data from tissue.
48149101|NCT03530644|DEVICE|P0.1|The investigational medical device will collect spectral Raman data from tissue.
48149102|NCT00777309|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
48149103|NCT00777309|DRUG|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
48149104|NCT00777309|DRUG|Placebo|The placebo is provided as a capsule
48360789|NCT03723811|DRUG|SJP002 QID|1 drop q.i.d for 12 weeks
48360790|NCT03723811|DRUG|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
48673815|NCT06282861|DRUG|Eklira|As per product specifications
48673816|NCT06282861|DRUG|Bretaris|As per product specifications
48673817|NCT06282861|DRUG|Seebri|As per product specifications
48673818|NCT06282861|DRUG|Tovanor|As per product specifications
48673819|NCT06282861|DRUG|Enurev|As per product specifications
48673820|NCT06282861|DRUG|Spiriva|As per product specifications
48673821|NCT06282861|DRUG|Tavulus|As per product specifications
48673822|NCT06282861|DRUG|Sirkava|As per product specifications
48673823|NCT06282861|DRUG|Braltus|As per product specifications
48673824|NCT06282861|DRUG|Gregal|As per product specifications
48673825|NCT06282861|DRUG|Incruse|As per product specifications
48673826|NCT06282861|DRUG|Rolufta|As per product specifications
48673827|NCT03117959|DEVICE|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
48673828|NCT03117959|DEVICE|Stryker Triathlon Custom Fit Knee|
48673829|NCT03440450|DRUG|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
48673830|NCT02448966|PROCEDURE|open esophagectomy|
48673831|NCT02448966|PROCEDURE|Minimally invasive esophagectomy|
48673832|NCT05567705|OTHER|The attitudes of doctors working in the surgical clinic of a university hospital for patient blood management: a survey-based study|No intervention required
48673833|NCT01296503|DRUG|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
48673834|NCT01296503|DRUG|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
48673835|NCT00839566|PROCEDURE|Ablation|AV-node ablation
48673836|NCT00839566|OTHER|Rate Control|Rate control by drug
48673837|NCT02393820|DRUG|pazopanib|treatment will be given until progression or unacceptable toxicity .
48673838|NCT00498043|DRUG|R-CHOP14 induction regimen|R-CHOP14 induction regimen
48673839|NCT00498043|DRUG|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
48673840|NCT02432573|BEHAVIORAL|Delayed rounds|
48673841|NCT00435630|OTHER|LapSim training|complete curriculum training on LapSim surgical simulator
48673842|NCT06246747|OTHER|In clinic physical therapy|Patients visit the clinic to receive traditional physical therapy treatment
48673843|NCT06246747|OTHER|Telerehabilitation only|Patients receive remote treatment using the Wizecare platform
48673844|NCT01535287|DRUG|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
48673845|NCT04039529|DEVICE|SCENERGY-guided Biopsy|Use of SCENERGY during a lung, liver or kidney biopsy
48673846|NCT03091088|OTHER|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
48673847|NCT03091088|OTHER|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
48673848|NCT00654537|DRUG|Rosuvastatin|
48673849|NCT00654537|DRUG|Atorvastatin|
48673850|NCT00654537|DRUG|Pravastatin|
48673851|NCT00654537|DRUG|Simvastatin|
48673852|NCT00224965|BEHAVIORAL|Behavior Therapy|
48673853|NCT04645173|DEVICE|CIED envelope|Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.
48673854|NCT04222530|DIAGNOSTIC_TEST|Linear EUS first|Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
48673855|NCT04222530|DIAGNOSTIC_TEST|ME-NBI first|Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
48673856|NCT03410069|DEVICE|IKORUS UP system|Continuous assessment of the urethral microcirculation
48673857|NCT05415488|OTHER|Online dietary group treatment|Dietary advice will be given during one 90 minute online group session
48673858|NCT04541082|DRUG|ONC206|ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
48673859|NCT00917319|OTHER|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
48673860|NCT04348071|DRUG|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
48673861|NCT02044679|OTHER|Water|
48673862|NCT02044679|OTHER|No intervention|
47991245|NCT06189222|DEVICE|virtual reality glasses|The population of the study consisted of children who were aged between 7- 12 and were on treatment using an intravenous catheter in the pediatric emergency unit of a state hospital in Turkey.Participants were divided into two groups, namely experimental and control groups, by using simple randomization software. The design and implementation of the study were based on the principles in the CONSORT list (Consolidated Standards of Reporting Studies). Descriptive data form for children,this form was prepared to collect information about the children included in the sample. It consists of seven questions on children's sociodemographic characteristics and previous intravenous catheter insertion experience.The Children's Emotional Manifestation Scale (CEMS), this scale was developed by Li \& Lopez (2005) to measure children's emotional responses during stressful medical procedures. The VR glasses we used in our study were connected to a mobile phone.
47991246|NCT03314155|DIAGNOSTIC_TEST|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer (\[18F\]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
47991247|NCT03929861|DRUG|Fluconazole (BAYT006267) 150 mg capsules|Fluconazole 150 mg
47991248|NCT03929861|DRUG|Fluconazole 150 mg capsules (DiflucanTM)|Fluconazole 150 mg
48360791|NCT03723811|DRUG|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
48673863|NCT03790644|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
48673864|NCT04601129|PROCEDURE|enhanced recovery after surgery program|practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
48673865|NCT04786054|DIAGNOSTIC_TEST|BED Questionnaire|BED Questionnaire
48673866|NCT01130337|DRUG|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
48673867|NCT01130337|DRUG|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
48673868|NCT01130337|DRUG|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
48673869|NCT04955067|DIAGNOSTIC_TEST|Diagnositic test|The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
48673870|NCT00363571|DRUG|GTN, Diamox|
48673871|NCT02812745|DEVICE|recording of cardiac output|
48673872|NCT02812745|DEVICE|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
48673873|NCT02588469|OTHER|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
48673874|NCT02588469|OTHER|Control group|Standard obesity care with physical activity program
48673875|NCT00811720|DRUG|Placebo|as-needed use, tablets, orally, 6 months
48673876|NCT00811720|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
48673877|NCT01612676|DRUG|FE 202158|
48360792|NCT00680966|BEHAVIORAL|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
48673878|NCT00894595|BEHAVIORAL|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
48360793|NCT02003586|DIETARY_SUPPLEMENT|plant-based ingredient|
48673879|NCT06348303|DRUG|Metaxalone m640 mg oral tablet|Metaxalone partially micronized 640 mg tablet
48673880|NCT06348303|DRUG|Metaxalone 800 mg oral tablet|Metaxalone non-micronized 800 mg oral tablet
48673881|NCT05590247|BEHAVIORAL|Intermittent Fasting Diet|Patients will follow the 16: 8 traditional intermittent fasting model, where they may only consume calories during 1 continuous 8-hour period of the day. Water may be consumed during fasting.
48673882|NCT04005586|DEVICE|Light Delivery Device (LDD)|Study eye will undergo Light delivery Device treatments
48360794|NCT02003586|DIETARY_SUPPLEMENT|No plant-based ingredient|
48360795|NCT05091840|OTHER|oximetry monitoring|monitoring oximetry in both groups using the INVOS™ system 5100C Oximeter
48360796|NCT04033029|DEVICE|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
48360797|NCT04033029|DRUG|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
48360798|NCT01728454|DRUG|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
48360799|NCT01728454|DRUG|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
48360800|NCT00928642|DRUG|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
48360801|NCT00928642|DRUG|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
48360802|NCT03364114|DEVICE|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
48360803|NCT03364114|DEVICE|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
48360804|NCT03347279|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
48673883|NCT02099396|DRUG|Docetaxel+lobaplatin|
48673884|NCT02099396|DRUG|Gemcitabine+lobaplatin|
48673885|NCT04708262|OTHER|Cognitive Analytic Therapy for Containing Self-Harm in Young People|The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
48673886|NCT06046248|DRUG|Belumosudil|200mg PO QD x 24 cycles (28-day cycle)
48360805|NCT03347279|OTHER|Placebo|Placebo subcutaneous injection
48360806|NCT03800758|BEHAVIORAL|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
48360807|NCT03800758|BEHAVIORAL|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
48360808|NCT06333535|OTHER|foot massage|foot massage
48360809|NCT06333535|OTHER|abdominal massage|abdominal massage
48360810|NCT06333535|OTHER|foot and abdominal massage|foot and abdominal massage
48360811|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single dose orally
48360812|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
48360813|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
48360814|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
48673887|NCT06046248|DRUG|Rituximab|375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
48673888|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor|Arm A
48673889|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
48673890|NCT01465035|BIOLOGICAL|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
48673891|NCT01465035|BIOLOGICAL|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
48673892|NCT00751478|DRUG|ALO-01|ALO-01 capsules
48673893|NCT00751478|DRUG|MSIR|immediate release morphine sulfate
48673894|NCT00751478|DRUG|Placebo|Placebo
47991249|NCT01768351|DRUG|Paricalcitol|Zemplar cp 1 mcg/day per os
47991250|NCT01768351|DRUG|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
48360815|NCT05263895|DRUG|PF-07321332|PF-07321332 will be administered as single oral dose orally.
48360816|NCT01643889|DRUG|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
48149105|NCT02935478|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
48149106|NCT02344706|DEVICE|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
48149107|NCT05652452|OTHER|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
48360817|NCT01643889|DRUG|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
48360818|NCT01643889|DRUG|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
48360819|NCT01643889|DRUG|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
48360820|NCT02473380|DEVICE|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
48360821|NCT02929836|PROCEDURE|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
48360822|NCT02929836|PROCEDURE|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
48360823|NCT02929836|PROCEDURE|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
48360824|NCT02929836|PROCEDURE|linear ablation|Right atrial CTI ablation was performed during SR.
48360825|NCT02929836|DEVICE|CARTO|3 dimensional mapping system
48673895|NCT00396617|DEVICE|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
48673896|NCT00396617|PROCEDURE|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
48673897|NCT01184976|BIOLOGICAL|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
48673898|NCT03257358|DRUG|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
48673899|NCT04152486|BIOLOGICAL|Ad26.ZEBOV, MVA-BN-Filo vaccine|"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
48673900|NCT05046626|OTHER|Nutritional counseling|Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
48673901|NCT06117007|DIETARY_SUPPLEMENT|Betalains|"Betalains extracted from red beetroot (Beta vulgaris) encapsulated in edible capsules.~(25 mg betalains per capsule)"
48673902|NCT06117007|OTHER|Placebo|Placebo capsules containing rice hulls. (0 mg betalains per capsule)
48673903|NCT04127526|OTHER|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
48673904|NCT02941614|BEHAVIORAL|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
48673905|NCT06320600|OTHER|no intervention|It's an observational study, no intervention included
48360826|NCT06341738|BEHAVIORAL|Video education about HPV and HPV vaccine|video animation in 8 minutes to promote about HPV and HPV vaccine. the video is played in front of class using LCD projector.
48360827|NCT06341738|BEHAVIORAL|Electronic reminder messages|Reseachers send reminder messages twice per vaccination event (e.g., 7 days and 1 day before vaccination event), with a total of four times sending reminder messages using the app on the smartphone.
48360828|NCT06341738|BEHAVIORAL|Usual Information Service|this usual information (e.g., the HPV vaccination event) was delivered face-to-face by staff in front of class
48360829|NCT05910489|OTHER|Biomonitoring of MNPLs in biological samples of greenhouse workers and controls|Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
48360830|NCT02652286|DEVICE|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
48673906|NCT02159625|DEVICE|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
48673907|NCT00498992|DIETARY_SUPPLEMENT|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
48673908|NCT03444324|BIOLOGICAL|BT524|BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinical condition.
48673909|NCT03444324|BIOLOGICAL|FFP/Cryo|FFP/Cryo was administered intravenously; dosage according to local standards in mL per kg body weight.
48673910|NCT03847831|BEHAVIORAL|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
48673911|NCT02008994|OTHER|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
48673912|NCT06139601|BEHAVIORAL|Virtual single session intervention|A single session, self-paced body empowerment program. The program consists of a single 45-minute self paced, interactive, virtual module.
48673913|NCT04028687|DEVICE|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
48673914|NCT02607410|DRUG|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
48673915|NCT02607410|DRUG|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
47991251|NCT05544786|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
47991252|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
48360831|NCT01070654|PROCEDURE|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
48360832|NCT01070654|DEVICE|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
48360833|NCT01353976|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
48360834|NCT01353976|OTHER|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
48360835|NCT02795871|BEHAVIORAL|Neuropsychological and cognitive assessment|
48360836|NCT01228084|DRUG|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
48360837|NCT01228084|OTHER|Laboratory biomarker analysis|Correlative studies
48360838|NCT01228084|OTHER|Pharmacological study|Correlative studies
48360839|NCT00041119|DRUG|AC regimen|Given IV
48360840|NCT00041119|DRUG|cyclophosphamide|Given IV
48360841|NCT00041119|DRUG|doxorubicin hydrochloride|Given IV
48360842|NCT00041119|DRUG|paclitaxel|Given IV
48360843|NCT06253624|PROCEDURE|All Arthroscopic ATFL Repair Surgery|The patients undergo surgery with spinal block, general anesthesia, or a combination of both. During the diagnostic arthroscopy, the anterior compartment is examined with a 4 mm 30-degree camera, and lateral ankle instability is diagnosed arthroscopically
48360844|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
48360845|NCT00984009|OTHER|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
48360846|NCT00984009|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
48360847|NCT02306291|DRUG|GMI-1271|E-selectin antagonist
48360848|NCT02306291|DRUG|Mitoxantrone|induction chemotherapy
48360849|NCT02306291|DRUG|Etoposide|induction chemotherapy
48360850|NCT02306291|DRUG|Cytarabine|induction chemotherapy
48360851|NCT02306291|DRUG|Idarubicin|induction chemotherapy
48673916|NCT03261895|BEHAVIORAL|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
48673917|NCT05922995|DRUG|Tasimelteon|20 mg capsules taken on a nightly basis
48673918|NCT04773548|OTHER|VR-JIT|Job interview with virtual interviewer
48673919|NCT00473109|PROCEDURE|Dialysis without systemic heparinization|Dialysis without systemic heparinization
48673920|NCT06406530|PROCEDURE|PRF|Patients blood is standardized centrifuged and split in to a red-phase (erythrocytes) and white-phase (PRF). The gained PRF is processed to a clot-fort and is inserted into the alveolus.
48673921|NCT06406530|PROCEDURE|Natural Healing|After the tooth extraction, natural healing is aimed by allowing a blood clot formation without any further intervention.
47991253|NCT05544786|DRUG|Nirmatrelvir/Ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
48149108|NCT05652452|OTHER|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
48149109|NCT06412432|OTHER|Exercise training (ET1+ET2)|Exercise training will consist of continuous aerobic training of moderate intensity on cycle ergometer/treadmill, with a frequency of 2-3 weekly sessions lasting 12 weeks, with exercise intensity of VO2 peak of 40% gradually increasing up to 50-60% of VO2 peak based on individual tolerability and improvement; 55-65% of heart rate at peak; 40-59% of heart rate reserve; 4-6 Metabolic equivalents (METS); the duration of the session will gradually increase from 15-30 min to 45-60 min.
48149110|NCT06412432|BEHAVIORAL|Optimal Medical Therapy (No-ET)|Patients will be handled according to optimal medical therapy
48673922|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
48673923|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP|1 x 10\^10 PU administered in deltoid
48673924|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
48673925|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
48673926|NCT04593550|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48149111|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 40 Gy
48149112|NCT06224244|RADIATION|Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost|Patients undergo BCS followed by ten-fraction adjuvant breast irradiation (34Gy) with a risk adapted SIB dose of 43 Gy
48673927|NCT04593550|BEHAVIORAL|BrainCheck Cognitive Assessment|Undergo cognitive function assessment BrainCheck
48149113|NCT04400045|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
48149114|NCT04148794|BEHAVIORAL|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
48149115|NCT04693598|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
48149116|NCT00068809|PROCEDURE|Short Cycle Antiretroviral Therapy|
48149117|NCT06153706|DRUG|Subgingival application of L-PRF loaded with metronidazole|After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
48673928|NCT04593550|PROCEDURE|Cognitive Assessment|Undergo 3D-Confusion assessment
48673929|NCT04593550|PROCEDURE|Electroencephalography|Undergo EEG
48673930|NCT03307538|RADIATION|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
48673931|NCT01892371|DRUG|Azacitidine|Given SC or IV
48673932|NCT01892371|DRUG|Cytarabine|Given SC
48673933|NCT01892371|DRUG|Quizartinib|Given PO
48673934|NCT01510873|OTHER|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
48673935|NCT00552071|DRUG|Octreotide LAR 30 MG Injection|Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
48673936|NCT01267786|PROCEDURE|Liver surgery|hepatectomy
48673937|NCT02249403|DRUG|Talsaclidine 6 mg|
47991254|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
47991255|NCT05544786|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
47991256|NCT01655017|PROCEDURE|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
48673938|NCT02249403|DRUG|Talsaclidine 12 mg|
48673939|NCT02249403|DRUG|Talsaclidine 24 mg|
48673940|NCT02249403|DRUG|Talsaclidine 36 mg|
48673941|NCT02249403|DRUG|Placebo|
48673942|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
48673943|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
48673944|NCT04240886|DRUG|fosmanogepix|IV and oral fosmanogepix
48673945|NCT02176629|OTHER|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
48673946|NCT02176629|OTHER|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
48673947|NCT02212665|BEHAVIORAL|High intense interval training|
48673948|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer|
48673949|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+HIIT|
48360852|NCT02929875|BEHAVIORAL|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
48360853|NCT04216628|OTHER|Amniotomy|Artificial rupturing of membranes and IV infusion of Oxytocin
48149118|NCT06153706|OTHER|Subgingival application of L-PRF|The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
48360854|NCT02205229|DRUG|Multi-ingredient, topical compounded medications|
48509477|NCT06251245|PROCEDURE|Spoon|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* Control Group (Giving the medicine orally to the child with an oral medication spoon)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
48509478|NCT03128021|DRUG|Escitalopram Pill|Double-blinded, randomly assigned
48509479|NCT03128021|OTHER|Placebo|Double-blinded, randomly assigned
48360855|NCT02581852|OTHER|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
48360856|NCT04131504|DRUG|Infliximab|No standard dosing regimen will be used and the dose will be determined by the treating physician
48673950|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+group intervention|
48360857|NCT04131504|DRUG|Adalimumab|No standard dosing regimen will be used and the dose will be determined by the treating physician
48673951|NCT03882281|DRUG|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
48673952|NCT06185790|OTHER|LCHF diet|Low-carb high-fat (LCHF) diet
48673953|NCT05799118|GENETIC|GWAS|The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
48673954|NCT04614844|BEHAVIORAL|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
48673955|NCT04614844|BEHAVIORAL|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
48673956|NCT05184335|DRUG|Brilaroxazine|RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
48149119|NCT06013124|OTHER|Work environment, well-being, customer satisfaction|Evaluation hospital work environment, staff well-being features and patients/caregivers satisfaction and perceived quality of care
48360858|NCT05569473|PROCEDURE|TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY|A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
48360859|NCT05818215|OTHER|NO intervention|NO intervention
48509480|NCT03128021|DRUG|Levomilnacipran Pill|Double-blinded, randomly assigned
48509481|NCT01290159|OTHER|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
48509482|NCT06214806|BEHAVIORAL|Grocery Vouchers|Participants will be given vouchers to buy groceries each month for five months.
48673957|NCT05184335|OTHER|Placebo|RP5063 matching Placebo
48673958|NCT00411489|PROCEDURE|endolumenal surgery|
48149120|NCT04674605|DEVICE|biomarkers|biomarkers
48360860|NCT00935766|DRUG|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
48360861|NCT00935766|DRUG|Placebo|
48360862|NCT00793715|PROCEDURE|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
48360863|NCT00793715|PROCEDURE|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
48360864|NCT04948840|BIOLOGICAL|Blood sampling|Blood sample of 7 mL whole venous blood in an EDTA citrate tube (4.5 mL) and a PAXgene Blood RNA tube (2.5 mL).
48360865|NCT01901809|DRUG|Furosemide|
48360866|NCT01901809|DRUG|Dopamine|
48673959|NCT01056614|DRUG|fludarabine phosphate|Given IV
48673960|NCT01056614|DRUG|busulfan|Given IV
48673961|NCT01056614|BIOLOGICAL|anti-thymocyte globulin|Given IV
48673962|NCT01056614|DRUG|tacrolimus|Given IV and orally
48673963|NCT01056614|DRUG|methotrexate|Given IV
48673964|NCT01056614|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
47991257|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients \>65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
48509483|NCT04167592|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
48673965|NCT01056614|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
48509484|NCT04167592|DRUG|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
48509485|NCT01693796|OTHER|blood and urine samples ; Echography|
48509486|NCT03698552|BIOLOGICAL|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
48509487|NCT04718948|DEVICE|Urinary Multimodal Fiber Optic Spectroscopy|"Approach based on a physical principle, mainly spectroscopy, which is rapid non-invasive and does not require the use of additional substances or contrast media in the diagnosis of urothelial neoplasms in urine samples.~It will be administered through a appositely designed device"
48509488|NCT04718948|DIAGNOSTIC_TEST|Urine Cytology|An expert cytopathologist will analyze urine samples to detect urinary tract cancer cells. It is the current golden standard to detect urothelial cancer in urine
48509489|NCT04718948|PROCEDURE|Surgery|It will provide a reliable information on the presence/absence of cancer in the urinary tract (from direct visualization to pathological analysis)
48509490|NCT00616070|DRUG|Difluprednate|Difluprednate
48509491|NCT00616070|OTHER|Placebo|Vehicle
47991258|NCT00741039|BIOLOGICAL|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
47991259|NCT06423144|PROCEDURE|TACE/HAIC|TACE/HAIC were performed within 1 month prior/after the first PD-1/PD-L 1 inhibitor/antiangiogenic drug treatment;
47991260|NCT06423144|DRUG|PD-1/PD-L1 inhibits and anti-angiogenic agents|Agents were administrated based on the instructions recommended
47991261|NCT05778786|DEVICE|Acuvue Oasys 1 Day for Astigmatism|CONTROL
47991262|NCT05778786|DEVICE|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
47991263|NCT01746927|OTHER|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
47991264|NCT00433823|DRUG|Atorvastatin, Ezetimibe|
47991265|NCT05202743|OTHER|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
47991266|NCT05045976|OTHER|Web-based interactive self-management support program|The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
47991267|NCT01032876|PROCEDURE|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (\>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
47991268|NCT01032876|PROCEDURE|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
48149121|NCT04151147|PROCEDURE|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
48509492|NCT04204057|DRUG|Tenalisib|Tenalisib 800 mg BID, Orally
48509493|NCT05029921|DRUG|Ustekinumab|Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
48509494|NCT06282146|PROCEDURE|transcranial magnetic stimulation|non-invasive form of brain stimulation
48509495|NCT04236882|OTHER|Focus Group|Attend focus group
48509496|NCT04236882|BEHAVIORAL|Health Education|Receive educational material on healthy homes
48509497|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based sleep intervention
48509498|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based health coaching sessions
48509499|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based counseling sessions
48509500|NCT04236882|OTHER|Interview|Complete interview
48673966|NCT01056614|OTHER|laboratory biomarker analysis|Correlative studies
48673967|NCT04123730|OTHER|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
48360867|NCT02054572|DRUG|[¹⁴C]Etelcalcetide|750 nCi of \[¹⁴C\]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
48360868|NCT00295152|BEHAVIORAL|community occupational therapy in dementia|
48360869|NCT04451369|OTHER|Prehabilitation program|physical, nutritional and psycho-social supports before surgery
48360870|NCT05724641|DIAGNOSTIC_TEST|MRI perfusion imaging using ASL's non-invasive technique|Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
48149122|NCT04151147|PROCEDURE|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
48149123|NCT03301597|BIOLOGICAL|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
48360871|NCT03132129|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
48360872|NCT03132129|DIAGNOSTIC_TEST|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
48360873|NCT03132129|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
48360874|NCT03132129|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
48360875|NCT03132129|DIAGNOSTIC_TEST|Manganese-enhanced magnetic resonance imaging (MEMRI)|A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
48360876|NCT03132129|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
48360877|NCT03132129|DIAGNOSTIC_TEST|Accelerometer watch|Watch worn to collect free living physical activity data for 7 days.
48149124|NCT03301597|DRUG|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
48360878|NCT03132129|DIAGNOSTIC_TEST|Blood tests|Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.
48360879|NCT00982111|DRUG|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
48360880|NCT00982111|DRUG|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
48360881|NCT00982111|BIOLOGICAL|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
48360882|NCT03132038|DRUG|Nivolumab|3 mg/kg, every two weeks, during a maximum of one year
48509501|NCT04236882|OTHER|Questionnaire Administration|Ancillary studies
48509502|NCT03337269|OTHER|Educational video|Approximately 7 minute video on the HPV vaccine
48509503|NCT03337269|OTHER|Educational handout|One page handout on the HPV vaccine
48509504|NCT03337269|OTHER|Control|Control
48509505|NCT01791270|DEVICE|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~1. - Respiratory Polygraphy~2. - Ambulatory Blood Pressure Monitoring~3. - Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~4. - ß1en subunit expression in peripheral blood leukocytes."
48509506|NCT00224289|DRUG|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
48509507|NCT04837131|DRUG|Ixazomib|Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
48509508|NCT03735004|DEVICE|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
48509509|NCT05350605|BEHAVIORAL|Breastfeeding position education with lactation simulation model|pregnant women will receive training with a lactation simulation model once in the last trimester.The pregnant woman will wear the lactation simulation model during the education period and show what she has learned practically on the model.Mothers who have given birth will be supported to practice the breastfeeding position in the postpartum service.
48149125|NCT05224388|DRUG|Enoxaparin|Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen
48149126|NCT05224388|DRUG|Heparin|Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
48673968|NCT05544435|BEHAVIORAL|Motivational İnterviewing|Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak \& Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller \& Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
47991269|NCT04951245|PROCEDURE|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
47991270|NCT04951245|PROCEDURE|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
48149127|NCT01090739|DEVICE|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
48149128|NCT05383586|OTHER|Creative Music Therapy|Creative Music Therapy is provided during kangaroo-care. It is an individualized, family- centered approach offering infant-directed humming and singing accompanied with the monochord.
48149129|NCT00631202|DRUG|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
48149130|NCT04550455|DRUG|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
48509510|NCT05237336|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences."
48509511|NCT05237336|BEHAVIORAL|Counselling as usual|Control group, Counselling as usual
48509512|NCT04338269|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
48509513|NCT04338269|DRUG|Cabozantinib|Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
47991271|NCT01067222|DRUG|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
47991272|NCT01067222|DRUG|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
47991273|NCT01067222|DRUG|Placebo|Placebo oral capsules, 4 capsules per day
48673969|NCT02126319|BEHAVIORAL|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
48673970|NCT02126319|BEHAVIORAL|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
48360883|NCT04806373|DRUG|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
48360884|NCT04806373|DRUG|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
48360885|NCT04628754|OTHER|Exercise and protein|Home based exercise regime and dietary protein guidance
48360886|NCT00640900|BEHAVIORAL|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
48360887|NCT00640900|BEHAVIORAL|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
48360888|NCT00004333|DRUG|NTBC|
48360889|NCT03906006|DRUG|ABP-671|Drug: ABP-671, single oral dose
48360890|NCT03906006|OTHER|Placebo|Other: Placebo, single oral dose
48360891|NCT03500315|OTHER|HIV D+/R+|Kidney from an HIV-infected deceased donor
48360892|NCT06318000|OTHER|Balance test, bilateral coordination test, fundamental motor skills test|Functional assessment
48360893|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
48360894|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
48360895|NCT02051257|OTHER|Laboratory Biomarker Analysis|Correlative studies
48360896|NCT04121637|OTHER|Aerobic Exercise|"Each exercise session;~* 5 min warm-up = 30% of VO2 max~* 20 min exercise = 50-60% of VO2 max~* 5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
48360897|NCT04121637|OTHER|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
48673971|NCT03478670|GENETIC|Strimvelis|"Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.~This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273."
48360898|NCT03070262|DRUG|CA|caffeic acid, 300mg, tid, po
48360899|NCT03070262|DRUG|placebo group|placebo tablet, 3 tablets, tid, po
48360900|NCT02350660|DIETARY_SUPPLEMENT|cow's milk|daily consumption of cow's milk
48360901|NCT02350660|DIETARY_SUPPLEMENT|peanut powder|peanut oral immunotherapy
48360902|NCT03589794|OTHER|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
48360903|NCT03589794|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
48360904|NCT03589794|BIOLOGICAL|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
48360905|NCT02215486|OTHER|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
48360906|NCT02215486|OTHER|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
48360907|NCT03822286|OTHER|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
48673972|NCT01205503|DRUG|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
48360908|NCT03822286|OTHER|Support group|A counseling master mix 8\~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40\~60 minutes each time.
48360909|NCT03822286|OTHER|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
48360910|NCT02790749|PROCEDURE|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
48360911|NCT02790749|PROCEDURE|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
48509514|NCT02487303|DRUG|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
48509515|NCT02487303|DRUG|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
48673973|NCT01205503|DRUG|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
47991274|NCT03078647|DEVICE|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
47991275|NCT06356181|DEVICE|Respiratory Maximus Training Device|Those in the intervention group will wear the respiratory training device for 3 days per week of high-intensity functional training over 6-weeks.
48509516|NCT05019443|DEVICE|Wedge Scoring Balloon|Scoring balloon
48509517|NCT05019443|DEVICE|Conventional Balloon|Conventional balloon
48509518|NCT03283384|DRUG|Letrozole|Letrozole 2.5 mg daily.
48509519|NCT03283384|DRUG|Chemotherapy|Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
48509520|NCT03283384|DRUG|Ribociclib plus letrozole|Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
48673974|NCT01205503|DRUG|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
48673975|NCT01205503|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
48673976|NCT01474304|DRUG|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
48509521|NCT00506701|DRUG|Tadalafil|40 mg tablet
48509522|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Intermediate Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
48509523|NCT04794101|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR Low Dose|Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
48509524|NCT05762692|DEVICE|High-flow nasal oxygenation device|The patients included will be oxygenated by HFNO device during the operation
48509525|NCT03960840|BIOLOGICAL|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
48509526|NCT03960840|DRUG|Ibrutinib|Tablets or capsules for oral daily use
48673977|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
48673978|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
48673979|NCT06439121|PROCEDURE|4-7-8 Breathing Technique|Patients will be instructed to practice the 4-7-8 breathing technique once per hour (4 breaths) post-surgery. Pain and nausea-vomiting will be monitored at 0, 2, 6, 12, and 24 hours during their 24-hour hospital stay.
48673980|NCT01973868|DRUG|Regorafenib (Stivarga, BAY73-4506)|
48673981|NCT01973868|DRUG|Cetuximab (ERBITUX)|
48673982|NCT02668341|OTHER|non-interventional|non-interventional survey study
48360912|NCT05179291|OTHER|Buzzy Group|The Buzzy device was placed 5-10 cm above the injection area and making sure that it was in contact with the skin. The ice pack was kept in the deep freezer and placed into the device before the application. Buzzy was introduced to the children pre-procedure. Cold application and vibration were started pre-procedure and maintained until the procedure was completed. Following the Buzzy application, the device was wiped with 70% alcohol and used for other children. The Buzzy devices were kept in the deep freeze and refrozen. The same person conducted the pain reduction methods during phlebotomy.
48360913|NCT05179291|OTHER|Virtual Realitiy-VR Group|VR glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses 2-3 minutes before starting the application and it continued until the end of the phlebotomy procedure (three minutes on average). 3D video suggestions (Space Experience, Blue Whale 360 VR Experience) were offered to the children before the phlebotomy procedure and they were asked to choose one of them.
48360914|NCT01591044|DRUG|Placebo|1 puff bid or 2 puffs bid
48360915|NCT01591044|DRUG|R940343 1mg|R343 1mg, 1 puff bid
48360916|NCT01591044|DRUG|R940343 2mg|R343 2mg, 2 puffs bid
48673983|NCT06168383|DRUG|HSK31679 80mg|once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
48673984|NCT06168383|DRUG|HSK31679 160mg|once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
48360917|NCT03474627|DEVICE|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
48360918|NCT03474627|DEVICE|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
48360919|NCT00229242|DRUG|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
48360920|NCT03968523|PROCEDURE|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
48360921|NCT03968523|PROCEDURE|TAP block|TAP block technique
48360922|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
48360923|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
48360924|NCT00621764|BIOLOGICAL|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
48509527|NCT06423807|DRUG|Ondansetron lozenge|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
48509528|NCT00000494|DRUG|indomethacin|
48360925|NCT00621764|BIOLOGICAL|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
48360926|NCT03660566|PROCEDURE|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
48360927|NCT03660566|PROCEDURE|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
48360928|NCT04130854|DRUG|APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days|"1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX~2. Short course radiation therapy 5 Gy x 5 days~3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~4. Leucovorin 400mg/m2 IV Day 1 of each cycle~5. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
48360929|NCT04130854|DRUG|mFOLFOX and Radiation Therapy 5Gy x 5 days|"1. Short course radiation therapy 5 Gy x 5 days~2. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~3. Leucovorin 400mg/m2 IV Day 1 of each cycle~4. 5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
47991276|NCT06356181|DEVICE|No Respiratory Training Device|Those in the control group will train for 3 days per week of high-intensity functional training over 6-weeks.
48360930|NCT04882930|PROCEDURE|Functional Near-Infrared Spectroscopy (fNIRS)|All participants will undergo Functional Near-Infrared Spectroscopy (fNIRS). The hemodynamic response in CPF will be measured using an Octomon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
48360931|NCT02454140|RADIATION|SBRT|Fixed five-fraction stereotactic radiotherapy
48360932|NCT01813630|DRUG|DA-3002|
48360933|NCT01813630|DRUG|Genotropin®|
48509529|NCT00000494|PROCEDURE|surgery, cardiovascular|
48509530|NCT06223386|BEHAVIORAL|Designed on-line course A with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.
48673985|NCT06168383|DRUG|Placebo|once daily, oral administration of placebo from Day 1 to Week 52.
48149131|NCT05223309|OTHER|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
48360934|NCT01943266|DIETARY_SUPPLEMENT|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
48673986|NCT04476667|BEHAVIORAL|e-Psychotherapy|Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
48360935|NCT03181672|PROCEDURE|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
47991277|NCT00805623|DIETARY_SUPPLEMENT|sucrose|1 cc of sucrose 33.5% with or without pacifier
48360936|NCT03181672|PROCEDURE|control group|Deltoid muscle injection with 1% lidocaine 10ml
48673987|NCT03323853|BEHAVIORAL|Computerized Assessment and Referral System (CARS) Self-Assessment Screener|Subjects will take the CARS-SA Screener.
48149132|NCT06168045|DIAGNOSTIC_TEST|Cerebral tissue oxygenation and blood pressure measurement|Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
48360937|NCT04494087|OTHER|Explanatory video|Links to explanatory videos handed out to patients to be watched at home after standard informed consent giving
48360938|NCT04494087|OTHER|Informed consent form|Links to a digital version of the informed consent form already discussed during the process of informed consent giving.
48360939|NCT04812236|DRUG|Wulingsan single decoction granules|Wulingsan single decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
48360940|NCT04812236|DRUG|Wulingsan co-decoction granules|Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
48360941|NCT04812236|DRUG|Wuling Powder|Wuling powder is composed of Alisma, Polyporus, Atractylodes, Poria, Guizhi. 2 times a day, 5g each time, take it with warm water
48360942|NCT04812236|DRUG|Wulingsan granule simulant|Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
48673988|NCT03323853|BEHAVIORAL|CARS-SA Summary Results|Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
48149133|NCT03031782|DRUG|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
48360943|NCT02422537|DIETARY_SUPPLEMENT|Unmodified wheat bran|
48360944|NCT02422537|DIETARY_SUPPLEMENT|Wheat bran with reduced particle size|
48360945|NCT02422537|DIETARY_SUPPLEMENT|Destarched pericarp-enriched wheat bran|
48360946|NCT02422537|DIETARY_SUPPLEMENT|No wheat bran fraction|
48360947|NCT04286737|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
48360948|NCT05670028|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or vasoactive drugs (noradrenaline or dopamine).
48360949|NCT03011606|PROCEDURE|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
48360950|NCT03976882|DRUG|Hetrombopag|Hetrombopag
48360951|NCT03976882|DRUG|Placebo|Placebo
48673989|NCT05964335|DRUG|nalbuphine ER 27 mg|Oral tablets
48673990|NCT05964335|DRUG|Placebo|Oral tablets
48673991|NCT05964335|DRUG|nalbuphine ER 54 mg|Oral Tablets
48673992|NCT05964335|DRUG|nalbuphine ER 108 mg|Oral tablets
48673993|NCT06209944|PROCEDURE|Cardiopulmonary resuscitation|cardiac compression, endotracheal intubation, defibrillation, and use of cardiovascular medications, to restore circulation in patients with cardiac arrest
48360952|NCT03008889|DRUG|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
48673994|NCT02838043|DIETARY_SUPPLEMENT|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
48673995|NCT02271061|DEVICE|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
48673996|NCT02271061|DEVICE|Control tape|Apply tape in same technique without tension.
48673997|NCT01624935|BEHAVIORAL|interpersonal psychotherapy|interpersonal psychotherapy
48673998|NCT04933292|DRUG|Methylprednisolone and Mycophenolate mofetil|Methylprednisolone combination of mycophenolate mofetil
48149134|NCT03031782|OTHER|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
48149135|NCT00484198|DRUG|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
48509531|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitian|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.
48149136|NCT00484198|DRUG|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
48673999|NCT04933292|DRUG|Methylprednisolone and azathioprine|Methylprednisolone combination of azathioprine
48674000|NCT01908140|DRUG|Aclidinium Bromide / Formoterol Fumarate|
48674001|NCT01908140|DRUG|Salmeterol / Fluticasone|
48674002|NCT05011253|OTHER|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
48149137|NCT00484198|DRUG|Rivoglitazone|1.0 mg tablet administered orally, once daily
48149138|NCT00484198|DRUG|Rivoglitazone|1.5 mg tablet administered orally, once daily
48360953|NCT03008889|DRUG|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
48360954|NCT03729128|DRUG|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
48360955|NCT03729128|DRUG|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
48360956|NCT04812821|OTHER|questionnaire|questionnaire post delivery
48360957|NCT00652964|DEVICE|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
48360958|NCT02014285|PROCEDURE|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
48360959|NCT03433599|OTHER|Repeated exposure to acute Intermittent Hypoxia (rAIH)|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
48509532|NCT06223386|BEHAVIORAL|Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.
48360960|NCT03433599|OTHER|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
48360961|NCT03433599|OTHER|Upper-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
48360962|NCT03433599|OTHER|Lower-limb Training by Research Staff|Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
48509533|NCT06223386|BEHAVIORAL|Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians|Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
48149139|NCT05689424|DRUG|HDV-Insulin Lispro|The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
48360963|NCT06497569|BEHAVIORAL|Dietitian Consultation|"Participants will meet with a dietitian who will provide individualized nutrition counseling and dietary goals for calorie and protein intake.~Bi-weekly, 30-minute dietitian telehealth visits will be conducted via ZOOM videoconferencing at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention."
48509534|NCT04079465|DEVICE|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
48509535|NCT02094911|BEHAVIORAL|Combined lifestyle intervention|"10-month intervention period with:~* weekly group-based sports lessons supervised by a physiotherapist~* individual dietary advice by a dietician~* case management by practice nurse~* maintenance programme to guide subjects to maintain lifestyle behaviour change"
48674003|NCT01981798|BEHAVIORAL|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
48149140|NCT06195332|PROCEDURE|open TAR|Participants will undergo open TAR repair according to the assigned treatment arm.
48360964|NCT06497569|BEHAVIORAL|Survey|"Surveys will be conducted using the PG-SGA short form19-21 and a brief symptom assessment tool that captures additional nutrition-impact symptoms not captured by the PG-SGA (e.g., swallowing difficulty) measured by the FACT Esophageal and Gastric Cancer scales and the FAACT anorexia/cachexia scales 22,23 through REDCap.~Surveys are completed at the pre-intervention baseline visit and monthly during the intervention period prior to the dietitian visits (up to 90 days), and at the 4 and 6 month timepoints post-intervention."
48360965|NCT06497569|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietitian during the 30-minute dietitian telehealth visits at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
48360966|NCT06497569|BEHAVIORAL|Referral to Dietitian|Usual Care condition referral to a dietitian based on physician discretion.
48149141|NCT06195332|PROCEDURE|endoscopic TAR|Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
48149142|NCT03466645|DRUG|Vancomycin|The 1st group receives vancomycin an hour before craniotomy
48360967|NCT06497569|BEHAVIORAL|Social Determinants of Health Survey (SDOH)|"Participants will complete a SDOH Survey that captures individual-level factors (insurance type, preferred language, educational attainment, annual household income, digital health literacy, financial toxicity, and self-reported barriers to care \[e.g., transportation\]) and structural-level factors (neighborhood disadvantage, rural residence).~Digital health literacy will be measured using the validated eHEALS scale, an 8-item measure assessing confidence with finding, evaluating, and applying electronic information to inform health decision-making (score ≤ 30 indicates low literacy)."
48149143|NCT03466645|DRUG|Cefazolin|The 2nd group receives cefazolin an hour before craniotomy
48509536|NCT02094911|OTHER|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
48509537|NCT00613886|DEVICE|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
48509538|NCT00613886|BEHAVIORAL|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
48149144|NCT02865109|DRUG|Nusinersen|Administered by intrathecal injection
48509539|NCT03021863|BEHAVIORAL|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
48509540|NCT03021863|BEHAVIORAL|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
48509541|NCT03021863|BEHAVIORAL|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
48674004|NCT03226847|PROCEDURE|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
48674005|NCT01220492|DRUG|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
48674006|NCT01220492|DRUG|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
48674007|NCT00889707|DRUG|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
48674008|NCT00889707|DRUG|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
48688183|NCT06422325|DEVICE|MPC closed-loop system in insulin only mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.
48360968|NCT05068726|DRUG|18F Fluoroestradiol Radiopharmaceutical with PET/CT|Administration of one dose of 18F FES for PET/CT imaging
48360969|NCT05852964|GENETIC|Molecular Immunology , gene expressions|Expression levels of inflammatory and anti-inflammatory genes
48360970|NCT03973775|DRUG|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
48360971|NCT01494727|DRUG|CJ Amlodipine/Valsartan 10/160mg|single dose
48509542|NCT03021863|BEHAVIORAL|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
48509543|NCT03021863|BEHAVIORAL|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
48509544|NCT03021863|BEHAVIORAL|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
48360972|NCT01494727|DRUG|Novartis Exforge 10/160mg|single dose
48360973|NCT02485405|OTHER|Trier social stress test|Volunteers perform Trier social stress test
48360974|NCT03653039|DEVICE|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
48360975|NCT03653039|DEVICE|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
48360976|NCT02067546|DEVICE|Experimental toilet seat|
48509545|NCT03021863|BEHAVIORAL|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
48509546|NCT03021863|BEHAVIORAL|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
48509547|NCT03021863|BEHAVIORAL|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
48509548|NCT01577771|BIOLOGICAL|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
48509549|NCT06550284|OTHER|Physical Therapy|The intervention will be physical therapy standard care.
48509550|NCT00645892|DRUG|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
48674009|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - OptiMA|"All children randomized to this arm will be treated with a RUTF, with weekly ration determined according to MUAC, weight and presence of nutritional edema. Ration will be adjusted weekly according to the change in MUAC and weight throughout the outpatient follow-up until the child achieves nutritional recovery.~RUTF dosage will 170 kcal/kg/d for the most severely wasted (MUAC \< 115 mm or edema) and reduced to 125 kcal/kg/d for children with MUAC 115-119mm and 75 kcal/kg/d for children with MUAC 120-124 mm.~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet nutritional recovery criteria, and then a monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition). Referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected)."
48674010|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - ComPAS|All children randomized to this arm will be treated with RUTF, with weekly ration determined according to MUAC and presence of nutritional edema. Children enrolled with MUAC \< 115 mm or edema will receive 1000 kcal/d (2 sachets/day) RUTF until MUAC has surpassed 115 mm and/or edema is resolved for 2 weeks at which time ration will be reduced to 500 kcal/d (1 sachet/day) until MUAC \> or = to 125 mm is achieved for 2 consecutive weeks. Children enrolled with MUAC 115-124 mm will receive 1 sachet/day until MUAC \> or = 125 mm is achieved for 2 consecutive weeks and clinically well. Following nutritional recovery, a study nurse will conduct monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition) with referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected) for the remainder of the 6 month period following inclusion.
47991278|NCT06392542|BEHAVIORAL|Whole Selves|Whole Selves is a brief online self-guided intervention addressing transgender/nonbinary young adults' experiences with alcohol use and romantic relationships. The intervention is delivered in a single session of approximately 40 minutes. Whole Selves employs principles of technology-adapted motivational interviewing (e.g., eliciting and strengthening participants' internal reasons for behavior change through interactive activities) as well as personalized feedback on participants' self-reported alcohol use and romantic relationship experiences. The intervention incorporates text and video narratives from transgender/nonbinary people sharing their own experiences with alcohol use and romantic relationships. Content will be tailored based on participants' current alcohol use and romantic relationship experiences.
47991279|NCT02105610|DRUG|desflurane, isoflurane, sevoflurane|
47991280|NCT02105610|DRUG|total intravenous anesthetics|
48360977|NCT02067546|DEVICE|Standard toilet seat|
48360978|NCT01560013|DRUG|Naltrexone|Naltrexone, oral 50 mg per day.
48360979|NCT05815576|BEHAVIORAL|Intrinsic foot muscle fatigue|"Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction)."
48360980|NCT03715036|DIAGNOSTIC_TEST|Point-of-care US|The intervention includes reassuring the AC and DVP
48360981|NCT04025749|BEHAVIORAL|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
48360982|NCT04025749|OTHER|Care as usual|Care as usual
48509551|NCT00645892|DRUG|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
48509552|NCT06342115|DRUG|Ceftolozane-Tazobactam|In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
48509553|NCT06342115|DRUG|Meropenem|The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
48509554|NCT03212248|DIAGNOSTIC_TEST|Thoracic Ultrasound (TUS)|
48509555|NCT05478252|DRUG|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
48509556|NCT05478252|DRUG|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
48509557|NCT02068703|BEHAVIORAL|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
48509558|NCT02068703|BEHAVIORAL|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
48509559|NCT04648800|DRUG|BCG-10 vaccine|"The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."
48509560|NCT04648800|DRUG|0.9% saline|0.9% saline
48509561|NCT02292173|DRUG|Trametinib|"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
48509562|NCT02292173|DRUG|Sorafenib|"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
48509563|NCT01933477|OTHER|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
48509564|NCT06130423|DRUG|Music intervention|Music therapy carried out with Music Care
48509565|NCT06130423|DRUG|Nicotine replacement|NRT: Nicotine Patch, Nicotine Gum
48149145|NCT03607851|DRUG|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
48149146|NCT03607851|DRUG|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
48509566|NCT05204082|DEVICE|Single Use Vein Entry Indicator Device|Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
48509567|NCT06539533|OTHER|pilates training|The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.
48149147|NCT03607851|DRUG|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
48509568|NCT05456958|OTHER|MRI Biofeedback|We will use state-of-the-art fMRI and neurofeedback of brain signals in order to teach patients with PTSD to self-regulate pathological brain activity that is associated with their symptoms. Indeed, feedback information is crucial for learning, where rt-fMRI-based neurofeedback makes information about brain activity accessible to our consciousness (Ros et al., 2014; Sitaram et al., 2017). It thus provides a reinforcement signal to induce personalized learning mechanisms, allowing individuals to search for appropriate cognitive strategies to voluntarily control brain activity. The feedback signal will come from activity within either the amygdala or PCC.
48509569|NCT05456958|OTHER|Sham-MRI Biofeedback|In the sham-control arm (N=20), individuals will receive fake neurofeedback signal, i.e., from a successful participant in one of the experimental arms.
48509570|NCT02953977|BEHAVIORAL|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
48509571|NCT00397514|PROCEDURE|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
47991281|NCT01465022|DRUG|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
48509572|NCT05896735|PROCEDURE|Ultrasound-guided axillary vein catheterization|All axillary vein catheterizations were performed according to standard central venous catheterization procedures, which were performed under ultrasound guidance at the bedside. Before the operation, patients were placed in a supine position with the upper limb placed in a natural position, and the ultrasound probe and wires were wrapped with a sterile protective sheath. Ultrasound pre-scanning the axillary artery and axillary vein, and pay attention to using the minimum pressure to control the ultrasound probe to avoid crushing the blood vessels. The operator holds the ultrasound probe and puncture needle to puncture the axillary vein under the guidance of ultrasound. After drawing out of the dark red blood, the guide wire was inserted and the puncture needle was withdrawn. The three-lumen CVC catheter was then inserted using the Seldinger technique.
48509573|NCT04614948|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
48509574|NCT04614948|OTHER|Placebo|Placebo will be administered as IM injection on Day 1 and Day 57.
48509575|NCT03765788|DRUG|Secukinumab 300 mg, s.c.|Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
48509576|NCT03765788|DRUG|Prednisolone|Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
47991282|NCT01465022|DRUG|Progestin-only pill|.35 mg norethindrone once a day orally
47991283|NCT03106155|DRUG|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
47991284|NCT01475331|DRUG|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
47991285|NCT01475331|DRUG|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
47991286|NCT01475331|DRUG|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
47991287|NCT02563678|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen therapy
47991288|NCT02563678|OTHER|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
48149148|NCT00276679|DRUG|temozolomide|
48149149|NCT02512315|DRUG|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
48149150|NCT02512315|DRUG|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
48149151|NCT02512315|RADIATION|Concurrent chemoradiation (CCRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
48674011|NCT04698070|OTHER|National nutritional Strategy (Niger)|"Different protocols for SAM and MAM comprise the Niger National Nutrition Protocol:~1. SAM: Children with MUAC\<115 or WHZ\<-3 or nutritional edema, will be treated with RUTF, according to a dosage table based on weight at each visit.~2. MAM: Children aged between 6-24 months with MUAC between 115 -124 mm and WHZ\>-3 will be treated with RUSF. Children with the same anthropometry but age 24-59 m will only receive supplementation if they develop criteria for SAM during the 6 month study period. They will be monitored via monthly home visits by a study nurse.~All children will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
48509577|NCT03765788|DRUG|Placebo|Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
48509578|NCT06581055|DRUG|Luspatercept|As per COMMANDS Trial (NCT03682536) study protocol
48509579|NCT06581055|DRUG|Epoetin Alfa|As per COMMANDS Trial (NCT03682536) study protocol
48149152|NCT04910711|DRUG|Dolutegravir|Dolutegravir-based antiretroviral therapy
48360983|NCT06217926|BEHAVIORAL|Experimental Group (Educational content; ChatGPT and Google Bard training)|"Educational content; ChatGPT and Google Bard training for senior students of the Faculty of Health Sciences who volunteered to participate in the study was provided by Dr. Lecturer It will be given by member Yasemin Özyer Güvener. After the training is completed, students will be asked to use generative artificial intelligence for educational purposes.~During the posttest implementation of the study (one week before the final exams), the Personal Information Form, Attitude Scale Towards Artificial Intelligence and Westside Exam Anxiety Scale will be re-administered to the 3rd and 4th year students of the Faculty of Health Sciences."
48360984|NCT05790499|DRUG|Atorvastatin|Patients are treated with atorvastatin for 2 weeks (40 mg/day), atorvastatin free for 2 weeks, atorvastatin treatment for 2 weeks, atorvastatin free for 2 weeks, a 4-week washout period (no treatment), and atorvastatin treatment for the last 4 weeks.
48674012|NCT00441766|DRUG|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
48674013|NCT00441766|DRUG|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
48674014|NCT00441766|DRUG|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
48674015|NCT00441766|DRUG|placebo|Part A: placebo capsule every 12 hours for 4 weeks
48674016|NCT05583344|DRUG|GSK4532990|GSK4532990 will be administered.
48674017|NCT05583344|DRUG|Placebo|Placebo will be administered.
48674018|NCT00716001|DRUG|N-acetylcysteine|
48674019|NCT04892030|BEHAVIORAL|Whole Food Plant-Based Behavioral Weight Loss Treatment|Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
48674020|NCT03533660|BEHAVIORAL|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
48674021|NCT03533660|BEHAVIORAL|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
48674022|NCT05091411|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
48674023|NCT02136225|BEHAVIORAL|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
48674024|NCT02227810|OTHER|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
47991289|NCT02563678|OTHER|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
48360985|NCT05978804|OTHER|Computerized Cognitive Training via BrainHQ|Computerized Cognitive training (BrainHQ)
48509580|NCT06147830|OTHER|None (Observational study)|Not Applicable since Observational Study
48509581|NCT03039270|OTHER|With sonic activation (SMART Device®)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
48674025|NCT02227810|OTHER|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
48674026|NCT02227810|OTHER|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
48674027|NCT02306811|DRUG|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
48674028|NCT00512278|DRUG|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
48674029|NCT00512278|DRUG|Placebo|Placebo
48674030|NCT01677871|DRUG|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
48674031|NCT01677871|DRUG|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
48149153|NCT04910711|DRUG|Levonorgestrel implant|Women initiating the levonorgestrel implant
48149154|NCT04910711|DRUG|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
48149155|NCT01868555|DRUG|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
48149156|NCT01868555|DRUG|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
48149157|NCT01868555|DRUG|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
48360986|NCT05978804|DEVICE|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
48360987|NCT04399434|OTHER|test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity|test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
48674032|NCT01677871|DRUG|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
48674033|NCT01677871|DRUG|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
48674034|NCT01597726|DRUG|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D\&E, repeated once 3 hours after the first dose if needed
48674035|NCT01597726|DEVICE|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D\&E
48674036|NCT03940079|DEVICE|computer-based cognitive game (including 3 training tasks)|"First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor."
48674037|NCT03420742|DRUG|Midazolam|Midazolam syrup.
48674038|NCT03420742|DRUG|Brigatinib|Brigatinib tablets.
48674039|NCT02039830|BEHAVIORAL|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
48149158|NCT01868555|DRUG|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
48360988|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
48360989|NCT00315640|DRUG|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
48360990|NCT00315640|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
48360991|NCT00315640|OTHER|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
48149159|NCT01270906|DRUG|CHIR-258 (TKI258)|
48360992|NCT04880642|DRUG|C21|C21
48360993|NCT04880642|DRUG|Placebo|Placebo
48674040|NCT02039830|BEHAVIORAL|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
48674041|NCT02035514|BIOLOGICAL|Bone marrow autologous mesenchymal stem cells transplantation|
48674042|NCT03121144|DEVICE|Masimo Centroid System|Noninvasive positional monitoring device
48509582|NCT03039270|OTHER|Control (Without sonic activation)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
48509583|NCT06202612|DRUG|SHR0302 quick release tablets|SHR0302 quick release tablets 8 mg
48509584|NCT06202612|DRUG|SHR0302 sustained-release tablets|SHR0302 sustained-release tablets 10 mg
48674043|NCT02077231|DRUG|Vitamin A|use one drop in the eye
48674044|NCT02077231|DRUG|carbomer eye gel|use one drop in the eye
48674045|NCT00066690|DRUG|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
48674046|NCT00066690|OTHER|Laboratory Biomarker Analysis|Correlative studies
48674047|NCT00066690|PROCEDURE|Oophorectomy|Undergo bilateral surgical oophorectomy
48674048|NCT00066690|OTHER|Quality-of-Life Assessment|Ancillary studies
48674049|NCT00066690|RADIATION|Radiation Therapy|Undergo ovarian irradiation
48674050|NCT00066690|DRUG|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
48674051|NCT00066690|DRUG|Triptorelin|3.75 mg by im injection q28 days for 5 years
48674052|NCT01450644|OTHER|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
48674053|NCT02965066|DEVICE|Coloplast Test Catheter|Newly developed intermittent catheter
48509585|NCT03516513|BEHAVIORAL|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
48509586|NCT03516513|BEHAVIORAL|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
48674054|NCT02965066|DEVICE|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
48674055|NCT04298619|DIAGNOSTIC_TEST|Standard cohort: Clinical lab follow-up|
48674056|NCT04298619|DIAGNOSTIC_TEST|Imaging cohort: integrated imaging follow-up|
48674057|NCT06154018|DRUG|Protamin|ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
48674058|NCT01349673|DRUG|Budesonide Foam|Topical
48674059|NCT00447798|BEHAVIORAL|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building \& strengths based case management
48674060|NCT02015403|DRUG|Standard Care + NAC (N -ACETYLCYSTEINE)|
48674061|NCT02015403|DRUG|Standard Care (in control arm)|
48674062|NCT02605408|DEVICE|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
48674063|NCT02605408|PROCEDURE|Phacoemulsification|Removal of the cataractous lens
48674064|NCT00509327|DRUG|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
48674065|NCT00509327|DRUG|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
48674066|NCT03841942|OTHER|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
48674067|NCT03841942|OTHER|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
48674068|NCT03289533|DRUG|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
48674069|NCT03289533|DRUG|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
48674070|NCT03710889|DRUG|Abaloparatide|Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].
48674071|NCT05230576|DIAGNOSTIC_TEST|Deep learning training cohort|train the deep learning model
48674072|NCT05230576|DIAGNOSTIC_TEST|Deep learning validation cohort|evaluate the model
48674073|NCT02471053|OTHER|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
48674074|NCT04063917|DEVICE|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
48674075|NCT05561842|PROCEDURE|mHealth US-breast biopsy|During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
48674076|NCT01745588|DRUG|Pomalidomide|
48674077|NCT01745588|PROCEDURE|stem cell|
48674078|NCT01745588|DRUG|Dexamethasone|
48360994|NCT06389994|DEVICE|Esophageal String Test|The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
48360995|NCT04337879|DRUG|AL2846|AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
48360996|NCT04337879|DRUG|Calcium folate|Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
48674079|NCT01745588|DRUG|Clarithromycin|
48674080|NCT05962281|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation which involves the use of low intensity currents propagated via the scalp, is widely implemented as both a fundamental and clinical neuroscientific tool. Over the last decades, tDCS showed significant therapeutic promise, as numerous studies revealed that it can result in improved attention and executive functions in patients with neurological disorders, through modification of neuronal excitability.
48674081|NCT03807388|DEVICE|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
48674082|NCT03807388|OTHER|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
48360997|NCT04337879|DRUG|5-FU|5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
48360998|NCT04337879|DRUG|Oxaliplatin|Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
48149160|NCT04829188|BEHAVIORAL|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
48360999|NCT04337879|DRUG|Irinotecan|Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
48509589|NCT05370469|OTHER|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
48674083|NCT00403325|DRUG|rhuFab V2 [ranibizumab] ( Lucentis )|
48674084|NCT05285579|BIOLOGICAL|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
48361000|NCT05758493|DIAGNOSTIC_TEST|124I-Evuzamitide|Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
48509590|NCT05370469|DEVICE|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
48674085|NCT05285579|OTHER|Tumour samples|reuse of tumour tissue collect in usual patient care
48674086|NCT05321329|DRUG|Capecitabine|Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
48509591|NCT05370469|DEVICE|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
48674087|NCT02606318|OTHER|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
48674088|NCT02606318|OTHER|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
48674089|NCT00246363|DRUG|Silymarin|Silymarin (milk thistle)
48674090|NCT00246363|DRUG|Placebo|Placebo
48674091|NCT03024424|BEHAVIORAL|Early disclosure|
48674092|NCT03024424|BEHAVIORAL|Late disclosure|
48674093|NCT03999580|DRUG|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
48509592|NCT05370469|OTHER|Surveys|Electronic and paper surveys will be administered throughout the study.
48509593|NCT00125112|BEHAVIORAL|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
48509594|NCT01741883|BEHAVIORAL|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
48674094|NCT02067507|BEHAVIORAL|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
48674095|NCT02067507|BEHAVIORAL|Staff training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
48674096|NCT02067507|BEHAVIORAL|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
48674097|NCT03793686|DRUG|PBCLN-003|Investigational drug
48509595|NCT01741883|BEHAVIORAL|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
48509596|NCT05238454|BIOLOGICAL|SCTV01C|intramuscular injection
48509597|NCT05238454|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|intramuscular injection
48509598|NCT05238454|BIOLOGICAL|Comirnaty|intramuscular injection
48509599|NCT05340829|BIOLOGICAL|ThisCART19A|ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
48509600|NCT04129671|GENETIC|No intervention was applied|No intervention was administered
48509601|NCT04128501|DRUG|Azacitidine|Given SC
48509602|NCT04128501|DRUG|Venetoclax|Given PO
48509603|NCT03766412|OTHER|High School start time|The time that the school starts
48674098|NCT03793686|DRUG|Placebo|Placebo
48674099|NCT06041022|OTHER|Exposure factors|Including demographical data, laboratory features and liver histological indicators.
48674100|NCT03087175|DEVICE|MGuard stent|MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
48674101|NCT03087175|DEVICE|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
48674102|NCT02438033|DEVICE|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
48674103|NCT05960487|OTHER|Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)|Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
48149161|NCT04829188|BEHAVIORAL|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
48149162|NCT04829188|BEHAVIORAL|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
48149163|NCT04829188|BEHAVIORAL|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
48149164|NCT04829188|BEHAVIORAL|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
48149165|NCT01458782|PROCEDURE|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
48674104|NCT01976299|DEVICE|AVERT|
48509606|NCT00315887|DRUG|Buprenorphine transdermal delivery system|
48509607|NCT01197144|DRUG|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
48674105|NCT04842968|OTHER|Methylene blue injection|Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
48674106|NCT04638751|DRUG|Immunotherapy|Checkpoint inhibitor
48674107|NCT04638751|DRUG|Chemotherapy|Any form of chemotherapy
48674108|NCT04638751|PROCEDURE|CRC surgical resection|Surgical resection to remove colorectal cancer
48674109|NCT04638751|PROCEDURE|Colonoscopy|Standard-of-care colonoscopy for CRC screening
48149166|NCT03392844|OTHER|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
48509608|NCT01197144|DRUG|Placebo|Subcutaneous, every other week for 4 weeks
48509609|NCT00049179|DRUG|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
48509610|NCT00049179|DRUG|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
48509611|NCT02483208|DRUG|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
48509612|NCT02483208|DRUG|Advate|Advate infusion to analyze pharmacokinetics.
48509613|NCT04223375|BEHAVIORAL|Nutrition Training|Postpartum women were educated on postpartum healthy and regular nutrition.
48509614|NCT06489535|OTHER|RETAIN|"There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC)."
48509615|NCT06489535|OTHER|Unrelated videos|These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
48509616|NCT03362606|BIOLOGICAL|OC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
48674110|NCT00263003|DRUG|Irbesartan/hydrochlorothiazide|
48674111|NCT00263003|DRUG|Irbesartan|
48674112|NCT04502862|DRUG|SAR231893|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
48674113|NCT04502862|DRUG|Placebo|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
48674114|NCT04115462|DRUG|Morphine|A 20 mg tablet of morphine
48674115|NCT04115462|DRUG|Placebo oral tablet|Matching tablet of placebo
48674116|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
48674117|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
48674118|NCT04115462|DRUG|isotonic saline|A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
48674119|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
48509617|NCT04809233|DRUG|Tipifarnib|
48509618|NCT00459901|DRUG|Erlotinib and capecitabine|
48509619|NCT04962152|DRUG|Nalbuphine Sebacate or Sesame oil (placebo)|ultrasound-guided intramuscular injection after the induction of anesthesia immediately
48509620|NCT05134857|DRUG|Zonisamide|The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
48149167|NCT05813522|DRUG|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
48149168|NCT02613767|OTHER|Protein meal|Ingestion of protein
48149169|NCT02613767|OTHER|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
48509621|NCT05134857|DRUG|Placebo|The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
48509622|NCT02723747|OTHER|myocardial perfusion with magnetic resonance imaging|
48149170|NCT01681563|DRUG|Pentostatin|Lyophilized powder for intravenous administration.
48509623|NCT04505956|DEVICE|Holmium laser lithotripsy with Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
48149171|NCT01681563|DRUG|Cyclophosphamide|IV
48149172|NCT01681563|DRUG|Ofatumumab|Liquid concentrate for solution for infusion.
48149173|NCT04229940|PROCEDURE|Peritoneal bridging|The defect is covered by peritoneal bridging
48509624|NCT04505956|DEVICE|Holmium laser lithotripsy without Moses Technology|Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
48509625|NCT04591223|BEHAVIORAL|Competency-based physical training (CbM)|The intervention to be added to online social work treatment as usual (OSW) is a well-designed, one-on-one structural physical workout module which will be offered by a licensed senior physical trainer in public sports ground or gymnasium. The aim is to strengthen participants' sense of competence, improve their physical fitness, self-confidence and self-image through an outcome-driven Circuit training. One of the chief advantages of Circuit training is its adaptability. Circuit training can be performed with gym equipment and/or bodyweight exercises which is deemed to be suitable for beginner and easy to practice at home on oneself. Participants can continue to replicate the exercise with or without any equipment. The program will be delivered in six one-hour sessions, including face-to-face and online mode, over one month.
48149174|NCT04229940|PROCEDURE|No peritoneal bridging|The defect is left without bridging
48149175|NCT00071188|DRUG|ZD6474|
48674120|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
48674121|NCT03309982|DIETARY_SUPPLEMENT|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
48149176|NCT00071188|DRUG|Paclitaxel|
48149177|NCT00071188|DRUG|Carboplatin|
48149178|NCT02605876|DEVICE|Whole body vibration|
48149179|NCT02605876|DEVICE|Local muscle vibration|
48149180|NCT00139360|DRUG|Bevacizumab|Anti angiogenesis treatment
48674122|NCT03309982|OTHER|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
48674123|NCT04470388|DRUG|EDP-514|Oral Capsule
48674124|NCT04470388|DRUG|Placebo|Placebo to match EDP-514
48674125|NCT04446312|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
48674126|NCT06002009|RADIATION|MRI|MRI of shoulder
48361001|NCT05282667|PROCEDURE|Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)|"A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure"
48674127|NCT06002009|OTHER|Nerve conduction study|Nerve conduction study
48674128|NCT01716364|BIOLOGICAL|Anti-LeY- scFv-CD28-ζ vector,.|
48674129|NCT02710877|DEVICE|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
48674130|NCT02710877|OTHER|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
48674131|NCT02710877|DRUG|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
48674132|NCT02710877|DRUG|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
48674133|NCT02710877|DRUG|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
48674134|NCT02793687|DRUG|MEXIDOL® (ethylmethylhydroxypyridine succinate)|
48674135|NCT02793687|OTHER|Placebo|
48149181|NCT00878904|DRUG|epirubicin hydrochloride|
48149182|NCT00878904|DRUG|panobinostat|
48674136|NCT06438198|OTHER|Pre-specified switch from controlled to assisted ventilation when PaO2/FiO2-ratio > 200 mmHg|A pre-specified switch from controlled to assisted ventilation will be initiated when PaO2/FiO2-ratio \> 200 mmHg. The moment of switch is pre-specified but patient management and ventilator settings are up to the clinical team. Switch is complete when the patient triggers all breaths spontaneously. Switch success is defined if patient reaches 72 hours on assisted ventilation. Switch failure is defined if patient switches back to controlled ventilation for more than 2 hours before 72 hours.
48674137|NCT02746588|OTHER|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
48674138|NCT02681653|DRUG|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
48361002|NCT04477668|DEVICE|Helmet non-invasive ventilation|Patients will be allocated to helmet non-invasive ventilation
48509626|NCT03047330|DRUG|Estradiol withdrawal|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
48509627|NCT03047330|OTHER|Fragmented sleep|Fragmented sleep will be experimentally induced.
48509628|NCT02875691|DIETARY_SUPPLEMENT|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
48509629|NCT02875691|DIETARY_SUPPLEMENT|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
48674139|NCT02681653|DRUG|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
48361003|NCT04072796|BEHAVIORAL|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
48361004|NCT03099811|BEHAVIORAL|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
48361005|NCT03099811|BEHAVIORAL|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
48361006|NCT05122442|OTHER|Patients with inherited retinal disease|Patients with inherited retinal disease
48361007|NCT04754568|OTHER|Virtual reality instructional design|60 minute immersive VR experience with branching method information delivery, physical therapy assessment, and diagnosis.
48361008|NCT04754568|OTHER|Role-playing instructional design|60 minute traditional role-playing with standardized patient
48361009|NCT02912793|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
48361010|NCT01053806|DRUG|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
48361011|NCT00951912|DIETARY_SUPPLEMENT|Placebo|10g soy protein isolated per day
48509630|NCT06242821|OTHER|Observation|Patients who chose to be part of the study, but do not wish to participate in PT or Yoga, will be monitored with routine imagine, and survey follow up.
48674140|NCT01508208|OTHER|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
48149183|NCT00878904|GENETIC|gene expression analysis|
48149184|NCT00878904|GENETIC|protein expression analysis|
48509631|NCT06242821|OTHER|Physical Therapy|Patients will either be randomized or self select to participate in Physical Therapy as per standard of care for non-operative AIS.
48509632|NCT06242821|OTHER|Yoga|Patients will either be randomized or self select to participate in the Yoga intervention. This will consist of online 20 min yoga classes, 2 times per week for 6 months. The class will be a set protocol, and patients will be given the protocol to do at home if desired.
48509633|NCT03651882|DRUG|Oxytocin|Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
48509634|NCT03651882|DRUG|Carbetocin|Carbetocin is given 0.1mg intravenously as a bolus after delivery.
48674141|NCT00488514|DRUG|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
48674142|NCT04067492|DRUG|RPH - 104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
48674143|NCT04067492|DRUG|Voltaren®|Enteric-coated tablets, 25 mg and 50 mg
48361012|NCT00951912|DIETARY_SUPPLEMENT|Daidzein|50mg daidzein +10g soy protein isolated per day
48509635|NCT05095571|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
48509636|NCT03709979|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
48674144|NCT05781152|DRUG|Anti-TNF therapy|Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
48149185|NCT00878904|GENETIC|western blotting|
48149186|NCT00878904|OTHER|immunologic technique|
48361013|NCT00951912|DIETARY_SUPPLEMENT|Genistein|50mg genistein +10g soy protein isolated per day
48361014|NCT03516227|BEHAVIORAL|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
48361015|NCT04193228|DEVICE|Carbon Fibre Ankle Foot Orthosis|Off teh shelf carbon fibre ankle foot orthoses worn bilaterally
48361016|NCT04193228|BEHAVIORAL|Exercise|Ankle muscle strength training
48509637|NCT03597464|DRUG|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg twice daily (BID)
48509638|NCT03597464|DRUG|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
48509639|NCT00383305|DEVICE|Cool-Cap|
48509640|NCT04566289|DEVICE|PiCSO|Percutaneous coronary intervention
48509641|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Low Dose|
48509642|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Medium dose|
48509643|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) High dose|
48509644|NCT01123915|OTHER|Dimethyl Sulfoxide|
48509645|NCT05101343|BEHAVIORAL|Breathing meditation|Daily, 5-minute breathing meditation for one week.
48674145|NCT05915611|OTHER|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
48674146|NCT05915611|OTHER|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
48674147|NCT02619838|DEVICE|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
48674148|NCT05458518|PROCEDURE|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
48674149|NCT01138475|DRUG|Paricalcitol|1 microgram by mouth daily for 6 weeks
48509646|NCT04556851|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
48509647|NCT04556851|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
48509648|NCT04556851|DRUG|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
48509649|NCT06385548|DRUG|Lurbinectedin|participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.
48509650|NCT06385548|DRUG|Dostarlimab|participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
48509651|NCT06330363|OTHER|Laser therapy|The Cube plus30 from Eltech K-Laser s.r.l. (Italy, www.k-laser.com) will be used for LLLT. The laser devices from Eltech K-Laser s.r.l. have been used in (clinical) studies with a variety in patient populations (38-41) and clinical practice (https://resources.k-laser.com.au/medical-laser-clinical-applications). The device is a registered medical device in the EU confirmed by Kiwa Cermet Italia.
48509652|NCT06330363|OTHER|Sham|The laser device has sham light option that will be used.
48509653|NCT05151289|BIOLOGICAL|Blood test at time of inclusion for sFlt-1/PlGF ratio|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
48361017|NCT02068391|BEHAVIORAL|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
48361018|NCT02068391|BEHAVIORAL|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at \~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
48361019|NCT03928249|DIETARY_SUPPLEMENT|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
48361020|NCT06282081|DIAGNOSTIC_TEST|Serum Neurofilament Light|The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.
48361021|NCT02660073|DEVICE|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
48674150|NCT01138475|DRUG|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
48674151|NCT01138475|DRUG|Placebo|Inactive substance, one capsule daily for 6 weeks
47991290|NCT00481195|DRUG|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day \[2 tablets\]) was allowed. The dosage could not be increased after it was decreased.
48674152|NCT06220877|PROCEDURE|Buccal Pad of Fat|surgical procedure
48674153|NCT06220877|PROCEDURE|A-PRF|blood sample
48674154|NCT06220877|PROCEDURE|fibrin glue|procedure
48674155|NCT06220877|PROCEDURE|oxidized cellulose|procedure
48674156|NCT04446221|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
48674157|NCT05367869|PROCEDURE|Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy|General anaesthesia ,supine position with hyperextension to the neck Low collar incision to the neck , incision to the skin and platysma muscle and fascia ,upper and lower flaps are developed ,separation of strap muscles and identification of the thyroid gland after freeing of investing fascia Ligation of the middle thyroid vein and ligation and separation of the superior pedicle away from the external laryngeal nerve At this point of operation and before ligation of inferior pedicle methylene blue 0.05% spraying is applied to the field the amount varies according to size of the thyroid lobe and variation in population and neck size Thyroid gland stained by bluish color , recurrent laryngeal nerve not stained or minimally stained so we can avoid injury to it parathyroid glands get red of the stain after about 3 minutes so we can avoid injury to it thyroid gland lose its stain in about 15 minutes so we can remove any residual and decrease residual tissue or recurrence
48674158|NCT03730610|BEHAVIORAL|Exercise training|Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
48674159|NCT03751397|OTHER|blood test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein, beta-2 microglobulin, uromodulin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
48674160|NCT03751397|OTHER|urine test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein beta-2 microglobulin, uromodulin, albumin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
48674161|NCT05887037|DIAGNOSTIC_TEST|mNGS|mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time
48674162|NCT05887037|DIAGNOSTIC_TEST|The traditional microbiological cultures|Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.
48149187|NCT00878904|OTHER|laboratory biomarker analysis|
48149188|NCT00878904|OTHER|pharmacological study|
48361022|NCT02660073|DEVICE|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
48361023|NCT00923806|BIOLOGICAL|PG13-CEA_TCR (Anti-CEA TCR PBL)|
48361024|NCT00923806|DRUG|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
48361025|NCT00375596|DRUG|Ketotifen/vasoconstrictor|
48361026|NCT00722410|DIETARY_SUPPLEMENT|VSL#3|A probiotic preparation.
48361027|NCT00722410|DRUG|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
48361028|NCT01824524|DRUG|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
48361029|NCT06065787|DEVICE|NeuroGlove|The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development.
48361030|NCT03236935|DRUG|L-NMMA|pan-nitric oxide synthase inhibitor
48361031|NCT03236935|DRUG|Pembrolizumab|PD-1 inhibitor
48361032|NCT03529162|PROCEDURE|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
48361033|NCT06000462|DRUG|Dapagliflozin 10mg Tab|Mentioned in detailed description.
48361034|NCT04065516|PROCEDURE|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
48361035|NCT02672982|OTHER|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
48361036|NCT02672982|OTHER|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
48361037|NCT00969735|DEVICE|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
48361038|NCT00969735|DEVICE|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter \> 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
48361039|NCT05156697|DIETARY_SUPPLEMENT|Capsinoids + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
48361040|NCT05156697|OTHER|Placebo + Exercise|60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
48361041|NCT01332006|PROCEDURE|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
48361042|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|
48361043|NCT01332006|BIOLOGICAL|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
48361044|NCT02967965|OTHER|Imagery|MRI at year 3
48149189|NCT05453435|DRUG|Entecavir|All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
48361045|NCT00556309|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
48361046|NCT01197976|DEVICE|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
48361047|NCT01197976|DEVICE|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
48361048|NCT06457529|DIAGNOSTIC_TEST|conventional treatment with Prolotherapy|"Group A got prolotherapy along with conven¬tional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Prolotherapy is an injection treatment used to relieve pain. Your healthcare provider will inject a small amount of an irritant into your body. Dextrose (sugar) solution is the most commonly injected irritant. Proponents of prolotherapy claim it relieves pain by jumpstarting your body's natural healing abilities."
48361049|NCT06457529|OTHER|Dry Needling and conventional treatment|"Group B Subjects in Group B will get Dry Needling along with conventional treatment, which includes ultrasonic therapy for 10 minutes. The intensity will be 3MHz at 1.0 watts/cm2.~Trigger-point dry needling is an invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle"
48361050|NCT02275949|DEVICE|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
48674163|NCT00578032|BEHAVIORAL|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
48674164|NCT06213207|OTHER|Simulator based training to manage asphyxia and essential newborn care using neonatalie|The intervention, HBB training package will be used which was applied to train the hospitals staff in Nepal (Chaulagain et al., 2021) and Laerdal Global Health (Laerdal Global Health, 2021) to enhance the competencies on the resuscitation to newborn using NeoNatalie. Health workers will receive 5 days simulation training by expert pediatrician and pediatric nurse who have prior working experience in Neonatal Intensive Care Unit (NICU) or Special Neonatal Care Unit. After the training, mentoring and coaching will be provided experienced newborn coach/trainer on a monthly basis for six months.
48674165|NCT00196209|PROCEDURE|catheter ablation|catheter ablation to treat persistent atrial fibrillation
48361051|NCT02275949|DEVICE|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
48361052|NCT02275949|DEVICE|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
48361053|NCT02275949|DEVICE|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
48361054|NCT02275949|DEVICE|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
48361055|NCT00684073|DRUG|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
47991291|NCT00481195|DRUG|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
47991292|NCT04628676|DRUG|tranexamic acid|Tranexamic acid is added to the irrigation fluid used in arthroscopic shoulder surgery.
48361056|NCT00684073|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
48361057|NCT05284383|BEHAVIORAL|Closed-label nocebo conditioning|"Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials)."
48509654|NCT05151289|BIOLOGICAL|Follow-up blood test 2 to 4 weeks after inclusion|As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
48509655|NCT05151289|DIAGNOSTIC_TEST|Placenta analysis for all included patients, even in case of normal birthweight|"After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as vascular IUGR or nonvascular IUGR."
48509656|NCT05250973|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
47991293|NCT04628676|DRUG|Epinephrine|Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
48509657|NCT05250973|DRUG|Cyclophosphamide|Cyclophosphamide will be administered either orally or IV.
48509658|NCT05250973|DRUG|Bortezomib|Bortezomib will be administered by SC injection or IV.
48509659|NCT05250973|DRUG|Dexamethasone|Dexamethasone will be administered orally or IV.
48509660|NCT03245866|OTHER|Observational/ no intervention|
48509661|NCT02147964|DRUG|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months \[all subjects\]
48509662|NCT02147964|DRUG|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]
48509663|NCT02147964|DRUG|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
48509664|NCT02147964|DRUG|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
48509665|NCT02147964|DRUG|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
48509666|NCT02147964|DRUG|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
48509667|NCT02147964|DRUG|placebo ketoconazole|placebo ketoconazole daily for 4 months
48509668|NCT01006018|DRUG|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
48361058|NCT05284383|BEHAVIORAL|Closed-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
48361059|NCT05284383|BEHAVIORAL|Open-label counterconditioning|"Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful)."
48361060|NCT05284383|BEHAVIORAL|Closed-label extinction|"Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials)."
48361061|NCT05932160|OTHER|5% glucose|Patients in the experimental group were infused intravenously with 5% dextrose (500 ml/h) in the PACU.
48361062|NCT05932160|OTHER|lactated ringers|Patients in the control group were infused intravenously with lactated ringers (500 ml/h) in the PACU.
48361063|NCT01064973|DRUG|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
48361064|NCT05890131|OTHER|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
48361065|NCT03202641|PROCEDURE|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
48361066|NCT03202641|PROCEDURE|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
48361067|NCT02840760|DEVICE|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
48361068|NCT03188133|OTHER|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
48361069|NCT04338542|GENETIC|Tumor biobsies analysis|Analysis on archived tumor biopsies
48674166|NCT00196209|PROCEDURE|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
48674167|NCT02398526|DRUG|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
48674168|NCT01963988|PROCEDURE|Transurethral Coagulation (TUC)|
48674169|NCT01963988|PROCEDURE|Transurethral Resection(TUR)|
48361070|NCT00845299|DRUG|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
48361071|NCT00845299|DRUG|artificial tears preserved with Benzalkonium Chloride|
48361072|NCT02705339|DRUG|Rociletinib|
48361073|NCT02705339|PROCEDURE|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
48361074|NCT02705339|PROCEDURE|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
48674170|NCT01093313|BEHAVIORAL|Cognitive therapy|
48361075|NCT03112343|DEVICE|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
48674171|NCT01093313|BEHAVIORAL|attention training|
48509669|NCT01006018|DRUG|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
48674172|NCT00558636|DRUG|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
48674173|NCT00558636|DRUG|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
48674174|NCT02568722|OTHER|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization."
48674175|NCT02568722|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
48674176|NCT06270238|DEVICE|High-Frequency1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
48674177|NCT06270238|DEVICE|cTBS1|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
48674178|NCT06270238|DEVICE|High-Frequency2|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral premotor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
48674179|NCT06270238|DEVICE|cTBS2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
48674180|NCT06270238|DEVICE|High-Frequency3|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
48674181|NCT06270238|DEVICE|cTBS3|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
48674182|NCT01466491|DRUG|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
48674183|NCT04719221|DRUG|Evolocumab|The maximum dose of combined cholesterol therapy (Statin + Ezetimibe) is prescribed for 2 months, and a cholesterol test is performed in an outpatient clinic to ensure that LDL-Cholesterol \<70mg/dL is met. Patients who do not meet the criteria are randomized to maintain current treatment or receive additional Evolocumab according to randomization.
48674184|NCT04719221|DEVICE|NIRS IVUS|near-infrared spectroscopy
48674185|NCT03539757|DEVICE|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
48361076|NCT03112343|DEVICE|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
48361077|NCT01896596|BIOLOGICAL|Menjugate|Administered with routine vaccinations at 3 months of age
48361078|NCT01896596|BIOLOGICAL|Menitorix|Administered with routine vaccinations at 3 months
48361079|NCT01896596|BIOLOGICAL|NeisVac-C|Administered with routine vaccinations at 3 months
48361080|NCT04005781|DRUG|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
48361081|NCT04005781|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
48149190|NCT04927806|DEVICE|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~* Staphyloccus epidermis~* Pseudomonas aeruginosa~* Klebsiella pneumoniae~* Acinetobacter calcoaceticus~* Escherichia coli"
48149191|NCT00848952|OTHER|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
48361082|NCT05681533|PROCEDURE|CT scan|coronary calcium score measurement by CT scan
48509670|NCT01006018|DRUG|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
48361083|NCT02155712|DEVICE|Triathlon Tritanium Knee|Cementless
48509671|NCT01233739|DRUG|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
48509672|NCT01233739|DRUG|Placebo|Administration of 2 capsules of placebo orally.
48509673|NCT02568839|DRUG|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
48509674|NCT02568839|DRUG|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
48509675|NCT06019598|OTHER|Licorice|Ecologic sweet licorice pastilles made from Glycyrrhiza glabra grown in Calabria, Italy, with a GA content of 29.9 ±2.0 mg/g.
48509676|NCT03760185|DRUG|Brimonidine Tartrate|All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
48149192|NCT01787409|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
48149193|NCT01787409|OTHER|Laboratory Biomarker Analysis|Correlative studies
48149194|NCT04170634|OTHER|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
48149195|NCT05022953|OTHER|Education, dijital storytelling|Digital story
48149196|NCT02400645|PROCEDURE|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
48149197|NCT02400645|PROCEDURE|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
48149198|NCT02400645|DRUG|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
48149199|NCT02400645|DRUG|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
48361084|NCT02155712|DEVICE|Triathlon Knee|Cemented
48361085|NCT01537458|PROCEDURE|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
48361086|NCT05183594|DIETARY_SUPPLEMENT|TSupport (a Traditional Chinese Medicine)|TSupport is made up of 11 Chinese medicinal herbs.
48361087|NCT01063114|RADIATION|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
48509677|NCT05511311|PROCEDURE|Resistance Training|Resistance training developed by the researcher (SCR-RSCM) for 12 weeks
48509678|NCT05511311|PROCEDURE|Standard Therapy|Standard therapy for 12 weeks
48509679|NCT03324295|DIAGNOSTIC_TEST|cortical cataract|Blood urea
48509680|NCT02974712|DRUG|Fentanyl|
48509681|NCT02974712|DRUG|Saline|
48509682|NCT01886079|DRUG|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
48509683|NCT01886079|DRUG|Saline|0.4 mcg/kg/h, IV
48509684|NCT01884337|DRUG|Apixaban|
48509685|NCT06174467|BEHAVIORAL|SEELearning Training|"This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions."
48509686|NCT06174467|BEHAVIORAL|Waiting list group of the intervention|The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
48509687|NCT04867174|BEHAVIORAL|Financial incentives|Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
48509688|NCT04867174|BEHAVIORAL|Convenient scheduling link|In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
48509689|NCT04867174|BEHAVIORAL|Race concordant|Randomized to a messenger who is race concordant with the participant
48509690|NCT04867174|BEHAVIORAL|Gender concordant|Randomized to a messenger who is gender concordant with the participant
48674186|NCT04046640|DEVICE|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
48674187|NCT01781884|DRUG|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
48674188|NCT01781884|DRUG|Placebo|
48674189|NCT02896257|OTHER|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
48674190|NCT00636181|DEVICE|Auto AFlex|Positive pressure therapy treatment
48674191|NCT00636181|DEVICE|Auto CPAP|Positive pressure therapy treatment
48674192|NCT00636181|DEVICE|CPAP|Positive pressure therapy treatment
48674193|NCT03601390|DEVICE|PET/CT and EBV DNA|PET/CT and EBV DNA will be proformed after the IMRT treatment
48674194|NCT02706925|DRUG|BI 443651|
48674195|NCT02706925|DRUG|Placebo|
48674196|NCT00298636|DRUG|adenosine|
48674197|NCT01605669|OTHER|Tranthoracic Echocardiogram|standard measurement
48509691|NCT01091324|DRUG|Dextromethorphan|60 mg, bid
48509692|NCT01091324|DRUG|Silymarin|150 mg , tid
48509693|NCT01091324|DRUG|sugar pill|placebo
48509694|NCT00487968|DRUG|eltrombopag|
48509695|NCT04302038|DIETARY_SUPPLEMENT|Protein|Additional daily protein provided by potato protein.
48509696|NCT04302038|DIETARY_SUPPLEMENT|Placebo control|No additional dietary protein (outside of 0.8 g/kg/day as provided by diet)
48509697|NCT04283019|DRUG|CBD|CBD will be orally ingested
48509698|NCT04283019|DRUG|THC|THC will be orally ingested
48509699|NCT02811432|OTHER|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
48509700|NCT02811432|OTHER|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
48509701|NCT01509703|PROCEDURE|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
48509702|NCT03912597|DEVICE|Virtual Reality|The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.
48509703|NCT03912597|DEVICE|Brochure|Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.
48509704|NCT03912597|DEVICE|Standard Video Control|The 4-minute standard video depicts a similar storyline as was shown in the VR video. The standard video is filmed from a third-party perspective with multiple takes edited into a final video, following the standard filming style of these videos. The standard video will be viewed from a laptop with headphones attached.
48509705|NCT04075591|DEVICE|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
48674198|NCT01605669|DEVICE|Cardiac Ascultation Recordings with Electronic stethoscope|3M device
48674199|NCT03538093|OTHER|Experimental: Local Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus a. activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase:4th-6th week: hot compress + electrotherapy IFT (fr: 4kHz, AMF 100Hz, modulation 20Hz, 20 mins), stabilizer training. Hamstring, quadriceps, gluteus maximus and psoas stretching, stationary bicycle without load. 7th-9th week: stabilizer training elevating a leg, stationary bicycle low load. 10th-12th week: 1kg to elevated leg on stabilizer training, stationary bicycle moderate load."
48674200|NCT03538093|OTHER|Experimental: Global Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: add obliques cross exercises in supine with contralateral leg, lumbopelvic bridge exercises, sitting on the edge of the bed. Day 3: add bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase: physiotherapy: 4th-6th week: hot compress + electrotherapy IFT, lumbopelvic bridge exercises, obliques cross exercises. Hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, stationary bicycle low load. 10th-12th week: physiotherapy, side plank, unilateral bridge, stationary bicycle moderate load."
48509706|NCT02354014|DRUG|Bedaquiline (TMC207)|TMC207 oral tablet adult formulation (containing 100 mg TMC207 per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg TMC207. Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of TMC207 8 mg/kg qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3.
48674201|NCT03538093|OTHER|Experimental: Mixed Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus abdominis activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~4th-6th week: hot compress + electrotherapy IFT, stabilizer training, hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, change stationary bicycle load to low load. 10th-12th week: physiotherapy, advanced global exercise (side plank), unilateral bridge,stationary bicycle moderate load."
48674202|NCT02725333|PROCEDURE|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
48674203|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
48509707|NCT02354014|DRUG|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
48509708|NCT02074618|OTHER|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
48509709|NCT04614753|OTHER|Dealcoholized Muscadine Wine|300 ml of Dealcoholized Muscadine Wine
48509710|NCT04614753|OTHER|Control Beverage|300ml of Sugar Water and Acid Content
48509711|NCT06192056|BEHAVIORAL|RNT Focused Web- Based Self-Help Program|This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
48509712|NCT03190902|BEHAVIORAL|Attention Processing Training program (APT)|
48509713|NCT03190902|BEHAVIORAL|nonspecific computer training (n-ST)|
48674204|NCT02487966|BEHAVIORAL|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
48674205|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
48674206|NCT02487966|BEHAVIORAL|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
48674207|NCT03895294|OTHER|Health care under the strategic purchase-Clinical pathway|1) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
48674208|NCT03895294|OTHER|Usual care process prior strategic purchase-clinical pathway|1) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
48674209|NCT06466525|DRUG|LBT-3627|Synthetic peptide
48674210|NCT06466525|DRUG|Placebo|Vehicle
48674211|NCT03557866|DIAGNOSTIC_TEST|running|individuals will be asked to run for 5 km in self selected speed
48674212|NCT02340884|BEHAVIORAL|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
48674213|NCT04180098|BEHAVIORAL|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
48674214|NCT04180098|OTHER|No intervention|Participants in the control group are placed on a waiting list.
48674215|NCT02625181|PROCEDURE|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
48674216|NCT02625181|PROCEDURE|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
48674217|NCT02625181|PROCEDURE|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
48674218|NCT02625181|PROCEDURE|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
48674219|NCT02625181|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
48149200|NCT02400645|DRUG|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
48509714|NCT06403280|DIETARY_SUPPLEMENT|Alcoholic drink|Participants will receive vodka with rum flavored orange juice with a target blood alcohol of 0.4 ‰ 30 minutes after alcohol consumption. The required amount of vodka will be calculated with the Widmark formula.
48149201|NCT05920538|DRUG|Nicardipine|Subcutaneous infiltrate drug at puncture site by ultrasound-guided
48149202|NCT05920538|OTHER|Normal saline|Subcutaneous infiltrate NSS at puncture site by ultrasound-guided
48674220|NCT02625181|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
48674221|NCT02625181|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
48674222|NCT02625181|PROCEDURE|Elective surgery|Surgical procedures that are scheduled and not an emergency.
48674223|NCT02625181|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
48674224|NCT02625181|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
48674225|NCT02625181|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
48361088|NCT05472051|OTHER|Community-based healthcare offer provided by an the ARCAD Santé PLUS NGO and integrated into the activities of the ADDAD NGO|"In the framework of the current activities of the ARCAD Santé PLUS a team formed by a doctor, a nurse and laboratory assistant will provide prevention and medical activities during the community-based activities organized by the housekeepers ADDAD NGO. The medical consultation will propose:~* HIV screening, including pre- and post- counseling~* Hepatitis B and hepatitis C screening, including pré- and post- counseling. The HBV vaccine will be proposed to housekeepers with negative results to both HBV and HCV testing~* Tuberculosis screening will be proposed to housekeepers with symptoms suggesting the possibility of TB~* For housekeepers sexually active, the medical team will propose a gynecological test in order to screen for genital infections. Furthermore, a pregnancy test will be proposed.~Medicines for current diseases (headache, diarrhea, etc. will be provided by the medical staff)."
48149203|NCT05513729|DRUG|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
48361089|NCT02842333|OTHER|Additional biological samples|Blood samples
48509715|NCT06403280|DIETARY_SUPPLEMENT|Placebo drink|Participants will receive a non-alcoholic rum flavored orange juice.
48149204|NCT05513729|DRUG|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
48149205|NCT04645303|DRUG|hyaluronic acid (20 mg/2 mL)|A1-Pulley infiltration for trigger finger
48149206|NCT04645303|DRUG|Triamcinolone acetonide 10mg/ml|A1-Pulley infiltration for trigger finger
48361090|NCT04555876|DEVICE|high tone external muscle stimulation- stationary bicycle|high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
48509716|NCT03687411|PROCEDURE|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
48674226|NCT02625181|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
48674227|NCT02625181|DRUG|Scopolamine|Prophylactic antiemetic
48674228|NCT02625181|DRUG|Droperidol|Prophylactic antiemetic \& rescue antiemetic
48674229|NCT02625181|DRUG|Haloperidol|Prophylactic antiemetic \& rescue antiemetic
48674230|NCT02625181|DRUG|Dexamethasone|Prophylactic antiemetic \& rescue antiemetic
48674231|NCT02625181|DRUG|Promethazine|Prophylactic antiemetic \& rescue antiemetic
48674232|NCT02625181|DRUG|Meclizine|Prophylactic antiemetic \& rescue antiemetic
48674233|NCT02625181|DRUG|Aprepitant|Prophylactic antiemetic \& rescue antiemetic
48674234|NCT02625181|DRUG|Metoclopramide|Rescue antiemetic
48674235|NCT02625181|DRUG|Fentanyl|Analgesic drug / Opioid
48674236|NCT02625181|DRUG|Sufentanil|Analgesic drug / Opioid
48674237|NCT02625181|DRUG|Alfentanil|Analgesic drug / Opioid
48674238|NCT02625181|DRUG|Remifentanil|Analgesic drug / Opioid
48674239|NCT02625181|DRUG|Morphine|Analgesic drug / Opioid
48674240|NCT02625181|DRUG|Meperidine|Analgesic drug / Opioid
48674241|NCT02625181|DRUG|Hydromorphone|Analgesic drug / Opioid
48674242|NCT02625181|DRUG|Methadone|Analgesic drug / Opioid
48674243|NCT02625181|DRUG|Oxycodone|Analgesic drug / Opioid
48674244|NCT02625181|DRUG|Oxymorphone|Analgesic drug / Opioid
48674245|NCT02625181|DRUG|Hydrocodone|Analgesic drug / Opioid
48674246|NCT02625181|DRUG|Ketamine|Analgetic / Analgesic drug
48674247|NCT02625181|DRUG|Ondansetron|Prophylactic antiemetic \& rescue antiemetic
48674248|NCT02625181|DRUG|Granisetron|Prophylactic antiemetic \& rescue antiemetic
48674249|NCT02625181|DRUG|Dolasetron mesylate|Prophylactic antiemetic \& rescue antiemetic
48674250|NCT02625181|DRUG|Palonosetron|Prophylactic antiemetic \& rescue antiemetic
48674251|NCT02625181|DRUG|Tropisetron|Prophylactic antiemetic \& rescue antiemetic
48674252|NCT02625181|DRUG|Ramosetron|Prophylactic antiemetic \& rescue antiemetic
48674253|NCT01361984|DRUG|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
48674254|NCT01361984|DRUG|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
48674255|NCT03848416|BIOLOGICAL|Ixekizumab|Administered SC
48674256|NCT03593174|DEVICE|Ossur Rigid Dressing|Removable Rigid Dressing
48674257|NCT03593174|DEVICE|Elastic Bandage|Usual modality: Elastic bandage
48149207|NCT05837728|BEHAVIORAL|Health promoting assessment of older adults living at home|Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
48361091|NCT03691649|DRUG|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
48361092|NCT03691649|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
48509717|NCT04315571|DEVICE|Gore® Viatorr® Endoprosthesis with controlled expansion|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.
48509718|NCT04315571|PROCEDURE|Large Volume Paracentesis with albumin infusion|For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
48509719|NCT00627510|OTHER|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
48674258|NCT05378412|BEHAVIORAL|3Cs|The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
48674259|NCT01245725|DRUG|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
48674260|NCT01245725|DRUG|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
48674261|NCT04581785|BIOLOGICAL|hLB-001|hLB-001 via IV infusion
48674262|NCT04344184|DRUG|L-ascorbic acid|50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
48674263|NCT04344184|OTHER|Placebo|Dextrose 5% Water
48674264|NCT04236089|DEVICE|robotic hand|mirror therapy with robotic hand
48674265|NCT02969070|DIETARY_SUPPLEMENT|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
48674266|NCT02969070|DIETARY_SUPPLEMENT|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
48674267|NCT02752347|DEVICE|Surface EMG device|measuring the muscles activity using surface EMG device
48674268|NCT00975520|OTHER|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
48674269|NCT00975520|RADIATION|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
48674270|NCT01159093|BEHAVIORAL|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
48674271|NCT01159093|BEHAVIORAL|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
48509720|NCT05154461|OTHER|Alginate|BHB covered in alginate will be realised in stomach-duodenum
48674272|NCT01159093|OTHER|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
48674273|NCT01159093|OTHER|Control|Usual care
48674274|NCT06460870|OTHER|Mojzisova method|The home based regular exercises stretching and strengthning exercises twice daily along with hot pack. Manual therapy was applied in the first half of the menstrual cycle, once a month, for one hour. It includes mobilization of ribs, lumbar spine, and sacroiliac joints as well as coccygeal treatment, and internal rectal work. The patient was received 2 sessions per month for 3 months, for 45 minutes.
48674275|NCT06460870|OTHER|Stretching exercises|Stretching exercises was performed such as cobra pose, cat/cow pose and baby pose along with hotpack for 2 sessions per month for 45 min for 3 months.
48674276|NCT06414083|DEVICE|Diathermy|Diathermy will be used to ablate the randomized sample.
48149208|NCT00000178|DRUG|Prednisone|
48361093|NCT06218290|DRUG|Oxylanthanum Carbonate|Phosphate Binder to Reduce Hyperphosphatemia
48509721|NCT05154461|OTHER|Pea-protein|BHB covered in pea-protein will be released in ileum-colon
48509722|NCT06600269|PROCEDURE|Cycling Training|Cycling combined with priming strategies to enhance motor learning tasks. Each session will last for 15 minutes, conducted three times per week, over a period of two weeks.
48674277|NCT06414083|DEVICE|CO2 Laser|CO2 Laser will be used to ablate the randomized sample.
48674278|NCT06414083|DEVICE|Argon Beam Coagulator|Argon Beam Coagulator will be used to ablate the randomized sample.
48674279|NCT05261828|BEHAVIORAL|Education and rehabilitation associated with personalized follow-up|short multidisciplinary program including education and rehabilitation and a personalized follow-up for patients with subacute and chronic low back pain
48674280|NCT05261828|BEHAVIORAL|Reassuring messages and advices|Reassuring messages and advices in agreement with current recommendations
48674281|NCT05960838|DEVICE|Ultrasling® Quadrant|Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
48674282|NCT05960838|DEVICE|Bledsoe ARC®|Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
48674283|NCT01149330|DRUG|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
48674284|NCT00672594|DRUG|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
48674285|NCT04919720|BEHAVIORAL|FRAM Model and Human Factors/Quality Improvement Intervention|The group will use semi-structured interviews and ethnographic observations to inform development of a Functional Resonance Analysis Method (FRAM) model of the process for rescue of deteriorating patients in EGS, using information from 3 hospitals. A focus group approach will be used in co-designing reform of the system for responding to post-operative deterioration, working with small groups of frontline clinical staff from relevant areas in the three Trusts involved.
48674286|NCT05827289|DEVICE|Cancer Patients Better Life Experience (CAPABLE)|The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
48674287|NCT04704024|DRUG|Tenofovir Disoproxil Fumarate|oral TDF medication 300 mg daily
48674288|NCT04704024|DRUG|Lamivudine Oral Solution|Oral lamivudine with weight-based dosing BID from birth until 6 months of age
48674289|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
48674290|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
48149209|NCT01439399|DRUG|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
48361094|NCT06404476|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
48361095|NCT00409149|BEHAVIORAL|CALM Approache|
48361096|NCT00409149|BEHAVIORAL|DASH approach|standard dietary DASH approach in hypertensive patients
48361097|NCT03010358|DRUG|Entospletinib|Given PO
48361098|NCT03010358|OTHER|Laboratory Biomarker Analysis|Correlative studies
48361099|NCT03010358|BIOLOGICAL|Obinutuzumab|Given IV
48509723|NCT01661062|OTHER|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
48509724|NCT02224157|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
48509725|NCT02224157|DRUG|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
48509726|NCT03591497|OTHER|Virtual Reality|As described in Experimental arm description.
48509727|NCT01924559|OTHER|standard clothing|
48509728|NCT01924559|OTHER|Biohazard gear|
48509729|NCT01924559|DEVICE|Direct Laryngoscopy|
48509730|NCT01924559|DEVICE|Glidescope|
48509731|NCT01924559|DEVICE|Supraglottic Airway|
48509732|NCT03638544|DIETARY_SUPPLEMENT|Reduced gluten bread and Pasta compared o normal gluten bread and Pasta|Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
48509733|NCT05547841|DEVICE|Echocardiography acquisition|Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
48509734|NCT03550001|PROCEDURE|Injection CNP before NAT|Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
48509735|NCT03105102|DRUG|Placebo for Risankizumab SC|Placebo for Risankizumab SC Subcutaneous (SC) Injection
48509736|NCT03105102|DRUG|Risankizumab IV|Risankizumab IV Intravenous (IV) infusion
48361100|NCT03010358|OTHER|Pharmacological Study|Correlative studies
48674291|NCT02835144|OTHER|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
48674292|NCT02835144|OTHER|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
48674293|NCT02193997|OTHER|Fiber|
48674294|NCT02193997|OTHER|Fiber|
48674295|NCT02193997|OTHER|Placebo|
48361101|NCT05734586|OTHER|EAT-10 (Eating assessment Tool) screening questionnaire|After inclusion, issuance of the EAT-10 screening questionnaire for swallowing disorders by the healthcare team
48361102|NCT05734586|PROCEDURE|Protective measures for the upper airways|"In the event of an EAT ≥2 score, immediate implementation or within three days by the healthcare team of protective measures for the upper airways in 3 sectors:~1: Postural maneuvers; 2: Hygienodietetic rules; 3: Food textures"
48361103|NCT01428479|DRUG|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
48361104|NCT01428479|DRUG|Placebo|Placebo solution will be administered intravenously.
48361105|NCT05926895|DRUG|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
48361106|NCT03699501|OTHER|Questionnaires|"* A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~* A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~* A validated depression scale: the Beck scale~* A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~* A validated self-assessment questionnaire for coping: The Brief cope)"
48361107|NCT03699501|PROCEDURE|Oral examination|"* An evaluation of dental health using the CAO index~* An evaluation of oral hygiene with the IHO-S index"
48361108|NCT03699501|OTHER|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
48361109|NCT00424463|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
48361110|NCT00424463|DRUG|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
48361111|NCT04815226|DEVICE|Peristeen Transanal Irrigation|Using Peristeen Transanal Irrigation twice per week for 12 weeks
48361112|NCT03655015|PROCEDURE|Lung Tumor Resection|Lung Tumor Resection
48361113|NCT01135368|DRUG|Lansoprazole|Lansoprazole capsules
48361114|NCT04193982|DRUG|Saroglitazar|Patient receives Saraglitazar 4mg once daily
48674296|NCT05935956|DEVICE|Magnetic Peripheral Nerve Stimulation|Magnetic Peripheral Nerve Stimulation
48674297|NCT03733938|OTHER|endodontic microsurgery|teeth with failed root canal treatment will be treated by endodontic microsurgery
48674298|NCT04831671|OTHER|Surgical Approach - Infra-patella nailing|The intra-medullary nail will be introduced via an infra-patella incision.
48674299|NCT04831671|OTHER|Surgical Approach - Supra-patella nailing|The intra-medullary nail will be introduced via a supra-patella incision.
48674300|NCT02848092|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
48674301|NCT02848092|OTHER|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
48674302|NCT03387215|DRUG|ITI-214|Oral
48674303|NCT03387215|OTHER|Placebo|Oral
48149210|NCT01439399|DRUG|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
48361115|NCT04193982|DRUG|Vitamin E|Patient receive Vitamin E 400mg twice daily after food for 6 months
48361116|NCT04193982|DRUG|Combination drug|Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months
48361117|NCT04193982|BEHAVIORAL|Lifestyle Changes|Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months
48361118|NCT05124327|OTHER|QI project- usage of RPM|close monitoring through RPM to analyze feasibility and compare readmission rates
48361119|NCT00072098|BIOLOGICAL|adenovirus vector|
48361120|NCT00072098|BIOLOGICAL|interleukin-12 gene|
48361121|NCT05950373|OTHER|Education video|six minute long education video focusing on protein and energy meals for older adults.
48509737|NCT03105102|DRUG|Placebo for Risankizumab IV|Placebo for Risankizumab IV Intravenous (IV) infusion
48509738|NCT03105102|DRUG|Risankizumab SC|Risankizumab SC Subcutaneous (SC) injection
48674304|NCT01152801|DRUG|Everolimus (RAD001)|
48674305|NCT02169011|PROCEDURE|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
48674306|NCT02169011|PROCEDURE|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
48674307|NCT05016258|DEVICE|KONTACT MB|Dental implant surgery
48674308|NCT02735018|DRUG|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
48674309|NCT02735018|DRUG|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
48674310|NCT06547034|DEVICE|Ultrasound|Breast Ultrasound
48674311|NCT02852798|DRUG|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
48674312|NCT04281498|DRUG|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
48674313|NCT04281498|DRUG|Enasidenib|50mg -100mg daily
48674314|NCT04283188|BEHAVIORAL|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
48674315|NCT01263457|DEVICE|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
48361122|NCT03481296|BEHAVIORAL|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
48509739|NCT03105102|DRUG|Risankizumab On-Body Injector (OBI)|Subcutaneous (SC) injection; on-body injector (OBI)
48674316|NCT00038844|DRUG|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
48674317|NCT00038844|DRUG|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
48674318|NCT00038844|DRUG|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
48674319|NCT00038844|DRUG|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
48674320|NCT05775302|OTHER|IASTM of Gastrocnemius + Conventional therapy|The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
48674321|NCT05775302|OTHER|IASTM of AchillesTendon + Conventional Therapy|Participants will receive a maximum of 60 seconds\<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
48674322|NCT01971684|DRUG|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
48674323|NCT06159504|DRUG|sofosbuvir/velpatasvir (SOF/VEL)|400mg of SOF and 100mg of VEL self administered daily as a tablet.
48674324|NCT06159504|DIAGNOSTIC_TEST|Shortened read time of rapid diagnostic test for hepatitis C virus.|Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
48674325|NCT00105664|PROCEDURE|Collaborative care model|
48674326|NCT00105664|PROCEDURE|Group interventions|
48674327|NCT00105664|PROCEDURE|Facilitated consultation|
48674328|NCT00059631|DRUG|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
48674329|NCT00059631|DRUG|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
48674330|NCT03395028|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
48361123|NCT03481296|BEHAVIORAL|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
48361124|NCT00743613|BEHAVIORAL|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
48361125|NCT00743613|PROCEDURE|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
48361126|NCT03890029|BEHAVIORAL|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups for 60 minutes/week over eight weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After eight weeks, all participants will be post-tested.
48361127|NCT03890029|BEHAVIORAL|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
48361128|NCT01531764|DRUG|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 \& 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
48361129|NCT01719718|PROCEDURE|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
48361130|NCT01719718|PROCEDURE|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
48361131|NCT05223374|DEVICE|Canvas Dx|Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only)
48361132|NCT02306525|PROCEDURE|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
48361133|NCT04842942|PROCEDURE|TOETVA|Transoral Endoscopic Thyroidectomy Vestibular Approach
48361134|NCT03104686|OTHER|Short pasta (dry)|50g available carbohydrate of penne pasta
48361135|NCT03104686|OTHER|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
48361136|NCT03104686|OTHER|Bread|50g available carbohydrate of bread
48361137|NCT03104686|OTHER|Glucose|50g available carbohydrate of glucose monohydrate
48361138|NCT01048736|BEHAVIORAL|Exercise Only|4 d/wk of aerobic exercise
48361139|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
48361140|NCT01048736|BEHAVIORAL|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
47991294|NCT02255721|BEHAVIORAL|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
48361141|NCT03665129|BIOLOGICAL|IPH5401 and Durvalumab|IPH5401 and durvalumab
48674331|NCT02515344|OTHER|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
48361142|NCT01397331|DRUG|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
48674332|NCT02515344|OTHER|Providing general information about CRC sreening|
47991295|NCT02255721|BEHAVIORAL|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
48674333|NCT01310530|RADIATION|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
47991296|NCT05939375|BEHAVIORAL|FCC educational training|An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
47991297|NCT00256698|DRUG|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
47991298|NCT00256698|DRUG|Anastrozole|1 mg oral tablet
48674334|NCT06498115|DRUG|Norepinephrine|Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
48674335|NCT02171689|DRUG|[14C]- BIBW 2992 MA2|
47991299|NCT02280772|DIETARY_SUPPLEMENT|Glucomannan|
47991300|NCT02280772|DIETARY_SUPPLEMENT|Maltodextrin|
47991301|NCT04675294|DRUG|evorpacept|IV Q3W
47991302|NCT04675294|DRUG|pembrolizumab|IV Q3W
47991303|NCT03889158|BIOLOGICAL|Typhoid Vaccine|All participants will receive the typhoid vaccine.
47991304|NCT03889158|DIETARY_SUPPLEMENT|Ascorbic Acid|All participants will receive ascorbic acid.
47991305|NCT02167607|DIETARY_SUPPLEMENT|Active Comparator|Purple Potato
47991306|NCT02167607|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Comparator
47991307|NCT05058300|DEVICE|CT Thorax|CT Thorax (GE Revolution with chest pain algorithm)
47991308|NCT02175420|BIOLOGICAL|BCG|
47991309|NCT02175420|BIOLOGICAL|TFV|
48361143|NCT01397331|DRUG|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
48361144|NCT00917553|DRUG|doxycycline monohydrate|50 mg
48361145|NCT00917553|DRUG|Placebo|Cellulose Placebo Capsule
48361146|NCT00171691|DRUG|Diclofenac Topical Sodium Gel 1%|
48361147|NCT04134949|BEHAVIORAL|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
48361148|NCT04134949|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
48361149|NCT03756636|PROCEDURE|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
48674336|NCT06322667|OTHER|No Intervention|This is a non-interventional study.
48361150|NCT04241627|BEHAVIORAL|Cell Phone Support|Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
48674337|NCT04416243|BEHAVIORAL|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
48674338|NCT05439980|OTHER|Knowledge questionnaire|Completion of a questionnaire at baseline
47991310|NCT05280067|DEVICE|ZetaFuse™ Bone Graft|The ZetaFuse™ Bone Graft will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.
48674339|NCT05439980|OTHER|Focus groups|structured interviews
48674340|NCT05925348|DIAGNOSTIC_TEST|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
48674341|NCT06230484|DEVICE|Invisalign first palatal expander|Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.
48674342|NCT06230484|DEVICE|Conventional rapid maxillary expansion|Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
47991311|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 \[13mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
47991312|NCT00629837|BIOLOGICAL|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 \[22mg of liposomes/kg\] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
47991313|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 \[13mg of liposomes/kg\]
47991314|NCT00629837|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 \[22mg of liposomes/kg\]
47991315|NCT04571580|DRUG|Normal Saline|intracoronary infusion with normal saline
48674343|NCT00538057|DRUG|GW685698X & GW642444M|study drug
47991316|NCT04571580|DRUG|Reteplase Injection 9mg|low-dose intracoronary fibrinolytic therapy with reteplase 9mg
47991317|NCT04571580|DRUG|Reteplase Injection 18mg|low-dose intracoronary fibrinolytic therapy with reteplase 18mg
48361151|NCT02212249|BIOLOGICAL|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
48361152|NCT02825745|DIETARY_SUPPLEMENT|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
48361153|NCT04244227|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
48674344|NCT04847440|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
47991318|NCT03238404|PROCEDURE|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
48509740|NCT06040151|DEVICE|Digizorg mobile app (quality evaluation study)|Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
48509741|NCT02054689|RADIATION|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
48361154|NCT01833351|DRUG|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
48509742|NCT01564264|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
48509743|NCT04484259|DRUG|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
48509744|NCT04484259|DRUG|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
48509745|NCT04484259|DRUG|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
48509746|NCT00026299|DRUG|ZD1839|
48509747|NCT00026299|DRUG|oxaliplatin|
48509748|NCT03461731|DEVICE|Control|laser beam only
48509749|NCT03461731|DEVICE|800 nm laser|800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
48674345|NCT04847440|DRUG|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
48674346|NCT04847440|DRUG|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
48674347|NCT03108521|DRUG|Sitagliptin|100mg.QD for 3 months
48674348|NCT02768285|PROCEDURE|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
47991319|NCT03238404|PROCEDURE|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
48674349|NCT02388880|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
48674350|NCT03965403|DEVICE|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
48674351|NCT01749527|BEHAVIORAL|minimal activity|Pad test with minimal activity
48674352|NCT04379674|OTHER|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
48361155|NCT01833351|DRUG|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
48361156|NCT02648867|DEVICE|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
48361157|NCT03395704|DRUG|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
48361158|NCT03395704|DRUG|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
48361159|NCT05785949|PROCEDURE|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.
48361160|NCT05785949|DEVICE|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
48361161|NCT03369925|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
48361162|NCT03369925|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin
48361163|NCT05763836|DRUG|Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]|Intravenous ibuprofen infusion
48361164|NCT05763836|PROCEDURE|Scalp nerve block|Scalp nerves blocked by using local anesthetics
48509750|NCT03461731|DEVICE|combination laser|800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
48509751|NCT03461731|DEVICE|905 nm laser|905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
48509752|NCT06173271|DIETARY_SUPPLEMENT|multi-intervention program and protein foods supplementation|This study aimed to investigate the effects of a multi-intervention program (protein-rich food supplement, nutrition education, and exercise) on reducing the risk of sarcopenia.
48509753|NCT05096429|BEHAVIORAL|PROVIDENT|Each of the state's 39 municipalities will be randomised to the intervention (PROVIDENT) or comparator condition. An interactive, web-based tool will be developed to visualize the PROVIDENT model predictions. Municipalities assigned to the treatment arm will receive neighborhood risk predictions from the PROVIDENT model, and state agencies and community-based organizations will direct resources to neighborhoods identified as high risk. Municipalities assigned to the control arm will continue to receive surveillance information and overdose prevention resources, but they will not receive neighborhood risk predictions from this study.
48509754|NCT05634408|DEVICE|ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management (A1D)|TEST Lens
48509755|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
48509756|NCT02191644|DIETARY_SUPPLEMENT|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
48674353|NCT04379674|OTHER|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
48674354|NCT04379674|OTHER|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
47991320|NCT00768144|DRUG|Sunitinib|
47991321|NCT01857349|OTHER|Chlora Prep|Surgical Scrub skin preparation
47991322|NCT01857349|OTHER|Dura Prep|Surgical Scrub skin preparation
48674355|NCT02770066|DEVICE|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~* Antiplatelet therapy (usually standard)~* Cholesterol-lowering drugs (usually standard)~* Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~* Smoking cessation, diet and physical activity (usually standard)"
48674356|NCT00005903|DRUG|GDNF & Synchro Med Infusion System|
48674357|NCT05924139|DIETARY_SUPPLEMENT|Omega-3 fatty acid|6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
48674358|NCT05924139|DIETARY_SUPPLEMENT|Placebo|4 capsules per day of coconut oil
48674359|NCT02575443|DRUG|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
48674360|NCT02575443|DRUG|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
48674361|NCT03574961|BEHAVIORAL|e-Support group|Online (remote), web-based support group via private video link.
48674362|NCT03574961|BEHAVIORAL|e-Journaling placebo|Online journaling activity.
48674363|NCT00054522|DIETARY_SUPPLEMENT|calcitriol|
48674364|NCT00054522|DRUG|dexamethasone|
48674365|NCT05376722|DRUG|pamiparib|pamiparib 40 mg orally, twice a day
48674366|NCT05376722|DRUG|abiraterone|biraterone acetate 1000 mg orally, once a day
48674367|NCT05376722|DRUG|prednisone|prednisone acetate tablets (prednisone) 5 mg, once a day
48674368|NCT05357833|DRUG|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
48674369|NCT05357833|DRUG|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
48674370|NCT05357833|DIAGNOSTIC_TEST|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
48674371|NCT02058979|DRUG|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
48674372|NCT02058979|DRUG|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
48674373|NCT00527618|DRUG|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
48674374|NCT00527618|DRUG|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
48674375|NCT05067881|PROCEDURE|Pulmonary resection|Resection of pneumohematocele
48674376|NCT01984047|DRUG|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
48674377|NCT01984047|DRUG|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
48674378|NCT02026011|DRUG|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
48674379|NCT02026011|DRUG|Placebo|Sugar pill, matched to the active study medication in capsule size and color
48674380|NCT04812431|BIOLOGICAL|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
48674381|NCT05775211|BIOLOGICAL|Intrauterine administration of PBMC immunomodulated with IFNt|Standard density gradient centrifugation will be performed to obtain autologous PBMC from patients' peripheral blood (9 ml). Isolated cells will be suspended in RPMI 1640 supplemented with 10% HSA (human serum albumin) and incubated in the presence of 500 IU/ml IFNt for 24 h at 37˚C. The cultured cell suspension will be introduced into the uterine cavity via a catheter.
48674382|NCT05526053|OTHER|Lung volume preservation|Extubate the patient connected to the ventilator and PEEP of 5 cmH2O after a successful SBT also using PEEP.
48674383|NCT03053778|OTHER|Early follow-up|Early follow-up until 4 weeks after discharge
48674384|NCT03111316|DRUG|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
48674385|NCT03111316|DEVICE|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
48674386|NCT01135225|DEVICE|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
48674387|NCT01135225|DEVICE|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
48674388|NCT04945486|OTHER|Peer-mentor intervention|Peer-mentor support for up to 6 months
48674389|NCT04923243|PROCEDURE|hip/knee replacement|hip/knee replacement
48674390|NCT05921617|OTHER|No intervention|Routine care
48674391|NCT01102595|DRUG|Temozolomide|"* Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
48674392|NCT01102595|DRUG|Bevacizumab|"* 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis."
48674393|NCT01102595|RADIATION|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
48674394|NCT01070342|DEVICE|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
48674395|NCT03517670|OTHER|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
48674396|NCT03517670|OTHER|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
48674397|NCT03517670|OTHER|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
48674398|NCT03517670|OTHER|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
48674399|NCT03396887|OTHER|U Control Drink Smartphone Application|The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
48674400|NCT03396887|OTHER|Control group|The control group will receive treatment as usual.
48674401|NCT00005852|BIOLOGICAL|anti-thymocyte globulin|
48509757|NCT05191537|OTHER|Sustained Natural Apophyseal Glides|The patient sits well supported in a chair. The cervical spine and head are set in a neutral position. A painless passive posterior to anterior (PA) glide is applied in the plane of the facets on either the spinous process or the articular pillar/cervical lamina. While the glide is sustained the patient actively moves their neck in the direction that previously produced the symptoms. If symptom-free, the patient applies over-pressure further into the movement restriction. 3-6 repetitions are performed
48509758|NCT05191537|OTHER|shoulder Mobilization with arm movement|The patient is seated. The therapist contacts the length of the spinous process with the medial aspect of the thumb. A transverse glide is applied by the therapist's index finger against the thumb contacting the spinous process. The direction of the glide is to the contralateral side of the pain. While the mobilisation is sustained the patient moves their arm through a pain-free abduction range. 3-5 sets of 6-10 repetitions may be performed.
48361165|NCT01077193|PROCEDURE|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
48509759|NCT01017796|DRUG|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
48509760|NCT04322565|DRUG|Colchicine|Cochicine 1mg/day
48674402|NCT00005852|BIOLOGICAL|filgrastim|
48674403|NCT00005852|BIOLOGICAL|muromonab-CD3|
48674404|NCT00005852|DRUG|cyclophosphamide|
48361166|NCT00006025|DRUG|irinotecan hydrochloride|
48509761|NCT04063150|BIOLOGICAL|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
48509762|NCT04063150|BIOLOGICAL|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
48674405|NCT00005852|DRUG|cyclosporine|
48674406|NCT00005852|DRUG|methylprednisolone|
48674407|NCT00005852|PROCEDURE|allogeneic bone marrow transplantation|
48674408|NCT03110029|DRUG|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
48674409|NCT03110029|OTHER|Application of Nail Polish|Application of Nail Polish
48674410|NCT04740580|DIETARY_SUPPLEMENT|Glycine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
48361167|NCT00006025|DRUG|temozolomide|
48361168|NCT03714451|DIETARY_SUPPLEMENT|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
48509763|NCT04063150|BIOLOGICAL|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
48509764|NCT04063150|BIOLOGICAL|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
48509765|NCT05358080|DRUG|Entelon Tab. 50mg|twice daily for 24months
48509766|NCT05358080|DRUG|Placebo|twice daily for 24months
48509767|NCT04166565|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
48509768|NCT04166565|DRUG|Bortezomib|Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
48149211|NCT01439399|DRUG|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
48149212|NCT01439399|DRUG|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
48509769|NCT04166565|DRUG|Cyclophosphamide|"Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
48509770|NCT04166565|DRUG|Dexamethasone|Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
48674411|NCT04740580|DIETARY_SUPPLEMENT|N-acetylcysteine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
48674412|NCT04740580|DIETARY_SUPPLEMENT|Alanine|The placebo arm will supplement Alanine
48674413|NCT03302143|PROCEDURE|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
48674414|NCT03302143|PROCEDURE|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
48674415|NCT01014702|DEVICE|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
48674416|NCT01014702|DEVICE|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
48674417|NCT04892186|DRUG|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g + folic acid 200mcg twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
48674418|NCT04892186|DRUG|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin 850 mg twice a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
48674419|NCT02710188|DRUG|HTL0009936 modified release|HTL0009936 modified release
48674420|NCT02710188|DRUG|HTL0009936 immediate release|HTL0009936 immediate release
48674421|NCT04096105|DRUG|CC-93538|a single dose CC-93538 SC
48674422|NCT02843412|PROCEDURE|choose two tumor tissue paraffin blocks|
48674423|NCT01576783|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
48674424|NCT01576783|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
48674425|NCT03931187|BEHAVIORAL|Cognitive progressive muscular relaxation therapy|This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 28-30 days during IVF-ET.
48149213|NCT01285167|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
48361169|NCT03714451|DIETARY_SUPPLEMENT|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
48361170|NCT00144456|DRUG|ED-71|0.75μg/day(p.o.)for 144 weeks
48361171|NCT00144456|DRUG|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
48509771|NCT05921552|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo surgery. Exercises will be performed using resistance tubes (Bodylastics Inc) and the included accessories (handles and anchor straps) to perform resistance exercises. During Zoom sessions, certified exercise trainers will guide participants to utilize equipment to perform resistance exercises with proper form. Each groups resistance training session will span approximately 1 hour, including a brief warm-up, stretching, and 2 sets of ≥12 repetitions for each of 5 exercises: single arm chest press, single arm row, lateral raise, squat (or chair stand), and resistance tube deadlift.
48509772|NCT05921552|BEHAVIORAL|Aerobic Training|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
48509773|NCT05042258|DRUG|Dupilumab|12 week dupilumab administration
48509774|NCT01499433|DRUG|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
48149214|NCT01852175|DRUG|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
48149215|NCT01852175|DRUG|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
48361172|NCT00144456|DRUG|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
48509775|NCT00385008|DRUG|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
48509776|NCT00385008|DRUG|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
48149216|NCT03761979|DIETARY_SUPPLEMENT|Strontium L-lactate|The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
48361173|NCT00144456|DRUG|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
48361174|NCT04854226|DIETARY_SUPPLEMENT|Macronutrients_CARB|Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
48361175|NCT04854226|DIETARY_SUPPLEMENT|Macronutrient_FAT|Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL
48361176|NCT00286234|DRUG|omega-3 acid ethyl esters|4 q qd
48361177|NCT00286234|DRUG|extended release niacin|2 g qpm
48361178|NCT00286234|DRUG|placebo|omacor placebo plus niaspan placebo
48361179|NCT00286234|DRUG|omega-3 acid ethyl esters|4 g qd
48361180|NCT00286234|DRUG|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
48361181|NCT03513575|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
48674426|NCT03187509|DRUG|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
48674427|NCT03187509|OTHER|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
48674428|NCT01938261|DRUG|paracetamol|
48674429|NCT01938261|DRUG|0.45 % saline solution|Placebo
48674430|NCT05985707|DRUG|KN026|KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
48674431|NCT05985707|DRUG|KN046|KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
48674432|NCT05985707|DRUG|XELOX|XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
48674433|NCT03679390|DRUG|Ketamine|With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
48674434|NCT05784818|BEHAVIORAL|Up To Me Intervention + No Booster|Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.
48674435|NCT05784818|BEHAVIORAL|Up To Me Intervention + Booster|In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
48509777|NCT05265273|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
47991323|NCT04471389|OTHER|Incidence and risk factors of hypertension|During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
47991324|NCT00482235|DRUG|MK0359|
48674436|NCT04460781|BIOLOGICAL|Flublok Quadrivalent influenza vaccine RIV4|Route of administration: Intramuscular
48674437|NCT04460781|BIOLOGICAL|Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4|Route of administration: Intramuscular
48674438|NCT02162654|PROCEDURE|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
48674439|NCT02162654|PROCEDURE|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
48674440|NCT01180283|DRUG|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
48674441|NCT03313414|DRUG|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
48674442|NCT04564235|GENETIC|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
47991325|NCT02493608|DEVICE|scalpel|used to cut the abdominal wall.
47991326|NCT02493608|DEVICE|Diathermy|Diathermy used to cut , coagulate the tissue
47991327|NCT05433961|DRUG|MagniXene Hyperpolarized Xenon MRI|Magnetic Resonance Imaging of lung function using Hyperpolarized Xenon as a contrast agent.
47991328|NCT00600938|DRUG|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
47991329|NCT00600938|DRUG|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
47991330|NCT00600938|DRUG|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
48149217|NCT03481153|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention
48674443|NCT04564235|GENETIC|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
48674444|NCT04330209|OTHER|weight loss diets|The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
48674445|NCT04904172|DEVICE|Masimo O3 Regional Oximetry|wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
48674446|NCT05908838|DRUG|Modified Banxia Xiexin Decoction|The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
48674447|NCT05908838|DRUG|combination chemotherapy with Placebo granules|combination chemotherapy with Placebo granules
48674448|NCT05257382|PROCEDURE|ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy|After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
48674449|NCT02838641|DEVICE|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
48674450|NCT05895994|DRUG|RD13-02 cell infusion|CAR-T cells
48674451|NCT00846846|DEVICE|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
48674452|NCT03502564|BEHAVIORAL|CBT for ED|Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
48674453|NCT03502564|BEHAVIORAL|Concurrent CBT for ED and PTSD|The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
48674454|NCT05879952|BEHAVIORAL|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
48674455|NCT05879952|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
48674456|NCT06455722|DRUG|[68Ga]Ga-P15-041|Intravenous injection of one dose of 111-148 MBq (3-4 mCi) \[68Ga\]Ga-P15-041. Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.
48674457|NCT00318669|DRUG|Paroxetine hydrochloride hydrate|
48674458|NCT01830348|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
47991331|NCT00600938|DRUG|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
48149218|NCT04167852|BEHAVIORAL|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
48674459|NCT01830348|DRUG|placebo vehicle gel|
47991332|NCT00600938|DRUG|Deferasirox|
47991333|NCT00600938|DRUG|Deferoxamine|
47991334|NCT01761214|DRUG|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
47991335|NCT01761214|DRUG|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
48674460|NCT04532515|DEVICE|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
48674461|NCT04532515|DEVICE|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
48674462|NCT02343770|OTHER|blood sample for identifying biomarkers|
48674463|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
48674464|NCT03668964|DIETARY_SUPPLEMENT|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
48674465|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
48674466|NCT03668964|DIETARY_SUPPLEMENT|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
48361182|NCT03513575|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
48361183|NCT03513575|OTHER|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
48361184|NCT03513575|OTHER|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
48361185|NCT03513575|OTHER|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
48361186|NCT03513575|OTHER|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
48361187|NCT06313658|PROCEDURE|Total brachial plexus exploration and reconstruction|In the adopted strategy, anatomical reconstruction was always performed when feasible and the lower trunk was considered the primary reinnervation target. Anatomical reconstruction of the plexus was attempted in the presence of at least three available roots; the best quality root stump (usually C5) was used for hand reanimation, while the lower ruptured roots were directed towards the upper and middle trunks. If one or more of the remaining root stumps were of doubtful quality, the compromised roots were grafted to the posterior divisions of the upper and middle trunks, while elbow flexion could be restored by transferring the intercostal nerves (T3-5) to the lateral cord. The lateral root of the median nerve was also included in the intercostal nerve transfer to restore hand sensations. In all cases, the spinal accessory nerve was directly sutured to the suprascapular nerve to restore rotator cuff function.
48361188|NCT03184805|DRUG|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
48361189|NCT03184805|DRUG|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
48674467|NCT03668964|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
48674468|NCT03668964|DIETARY_SUPPLEMENT|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
48674469|NCT03668964|DIETARY_SUPPLEMENT|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
48674470|NCT03819257|DIAGNOSTIC_TEST|Endoanal ultrasound|For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
48674471|NCT03819257|DIAGNOSTIC_TEST|High-resolution anorectal manometry|"1. rest - basal anal pressures at rest over 60 s~2. squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~3. cough - anorectal pressure changes during cough~4. push - anorectal pressure changes during simulated defecation~5. rectoanal inhibitory reflex - reflex anal response to rectal distension~6. rectal sensation - assessment of rectal sensitivity to distension."
48361190|NCT03280186|PROCEDURE|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
48361191|NCT00615420|DIETARY_SUPPLEMENT|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
48361192|NCT00615420|DIETARY_SUPPLEMENT|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
48361193|NCT06228365|DEVICE|use of a device incorporating virtual reality software|use of a device incorporating virtual reality software
48361194|NCT06228365|DRUG|Neuroleptanalgesia|Usual neuroleptanalgesic treatment
48361195|NCT05703789|PROCEDURE|Dental rehabilitation with either composite resin of crown therapy|Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns.
48509778|NCT00812448|DIETARY_SUPPLEMENT|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
47991336|NCT05423028|PROCEDURE|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
48149219|NCT04167852|BEHAVIORAL|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
48361196|NCT05703789|OTHER|Waiting list|Waiting list. Patients randomized to this group will not receive any intervention but answer questionnaires after 4 months on waiting list
48509779|NCT05984186|DEVICE|High Velocity Therapy|FiO2=100% with Flow=5LPM FiO2=21% with Flow=25-35LPM FiO2=100% with Flow=25-35LPM FiO2=21% with Flow=5LPM
48674472|NCT03819257|DIAGNOSTIC_TEST|Balloon expulsion test|A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
48674473|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
47991337|NCT03204305|DRUG|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
47991338|NCT03204305|DRUG|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
48149220|NCT02694107|OTHER|Proprioceptive exercises|
48674474|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
48674475|NCT00000413|BEHAVIORAL|Psychoeducational program|
48674476|NCT02580877|DRUG|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
48674477|NCT02580877|DRUG|500mg oral insulin crystals every other week|human insulin crystals in capsules
48674478|NCT04708886|DRUG|Romosozumab|Year 1 study drug
48674479|NCT04708886|DRUG|Alendronate|Year 2 study drug
48674480|NCT03425916|OTHER|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
48674481|NCT03654274|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
48674482|NCT03654274|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
48674483|NCT05531500|DRUG|Injection|Injection of local anesthetic + steroids
48674484|NCT05531500|DEVICE|Radiofrequency|Application of radiofrequency on the diseased nerve
48674485|NCT05046392|BEHAVIORAL|Face-to-Face ART Adherence Intervention|All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.
48674486|NCT05046392|BEHAVIORAL|Carium Mobile Health Platform|Participants assigned to the experimental condition will receive access to a mobile health app, called Carium, for 12 months. The app will be used to facilitate continued coaching from the adherence coach. The app incorporates automated medications reminders with interactive adherence coaching via a secure messaging feature. Participants will receive custom medication reminders as push notifications that will ask them to indicate if they have taken their medication or not. This will allow adherence coaches to monitor self-reported adherence in the app. Adherence coaches will use the secure messaging feature to check-in with participants and reach out to participants who appear to be struggling with adherence and offer assistance.
48674487|NCT00835458|PROCEDURE|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
48361197|NCT02939456|OTHER|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
48361198|NCT03513432|DIETARY_SUPPLEMENT|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
48674488|NCT02135068|DEVICE|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
48674489|NCT02135068|OTHER|Snacking|Up to 45 g of oral glucose via Gatorade
48674490|NCT03129542|DRUG|Midodrine Hydrochloride 10 milligrams|Three doses taken every 8 hours.
48509780|NCT06571513|BEHAVIORAL|Written Exposure Therapy|During session one of the written exposure therapy intervention, the therapist will provide psychoeducation about PTSD and the rationale for the proposed intervention. Psychoeducation and treatment rationale are scripted to ensure consistency. The therapist will provide the participant with instructions for writing about the same trauma memory (their recent sexual assault) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
48509781|NCT06571513|BEHAVIORAL|Unemotional Writing|During the unemotional writing sessions, the therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did the day before the session from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. The participant will self report Subjective Units of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session.
48509782|NCT00004315|DRUG|ursodiol|
48674491|NCT03129542|DRUG|Placebo capsule|Three doses taken every 8 hours.
48149221|NCT02694107|OTHER|Control|
48149222|NCT00452894|DRUG|varenicline tartrate|
48149223|NCT00721097|OTHER|spirometry, and blood taken|each month during one year
48361199|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
48361200|NCT03513432|DIETARY_SUPPLEMENT|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
48361201|NCT03233308|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
48361202|NCT03233308|OTHER|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
48361203|NCT04611204|OTHER|Descriptive cohort|NT-proBNP assay, electrocardiogram and transthoracic echocardiography before CTS surgery release. Pathological analysis for amyloid deposits of transverse carpal ligament of patients included.
48674492|NCT02112643|DRUG|Sodium selenate|A 100 microgram pill will be orally administered twice a day for 6 months.
48674493|NCT02112643|DIETARY_SUPPLEMENT|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
48674494|NCT03445767|OTHER|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
48674495|NCT06014307|BEHAVIORAL|Diet order: PBMA, Animal|Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.
48674496|NCT06014307|BEHAVIORAL|Diet order: Animal, PBMA|Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.
48674497|NCT03240107|PROCEDURE|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
48674498|NCT03240107|PROCEDURE|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
48674499|NCT04298489|DIAGNOSTIC_TEST|Personalized drug sensitivity test|"The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay.~The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software."
48674500|NCT02961036|OTHER|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
48674501|NCT02961036|OTHER|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
48674502|NCT02961036|OTHER|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
48674503|NCT02961036|OTHER|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
48674504|NCT02961036|OTHER|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
48361204|NCT01691937|PROCEDURE|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
48674505|NCT02961036|OTHER|Group A Reminder|One survey reminder at 14 days
48674506|NCT02961036|OTHER|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
48674507|NCT05125003|BEHAVIORAL|FITBI|parents learn to identify high probability cues in the environment that can elicit RRBI symptoms and teach their child to inhibit repetitive behaviors and instead replace them with alternative and flexible play behaviors; and (b) teach parents how to embed this FITBI approach into their child's everyday routines
48509783|NCT05992857|PROCEDURE|Pancreaticoduodenectomy without retromesenteric omental flap|Resection of the pancreatic head, duodenum, distal common bile duct and gallbladder followed by reconstruction using pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy performed on the first jejunal loop.
48509784|NCT05992857|PROCEDURE|Pancreaticoduodenectomy with retromesenteric omental flap|All exposed peripancratic arteries should be covered with a retromesentric omental flap
48509785|NCT01739660|DRUG|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
48509786|NCT05248165|DEVICE|PCI|Percutaneous coronary intervention
48509787|NCT01777230|PROCEDURE|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
48509788|NCT01777230|PROCEDURE|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
48674508|NCT05125003|BEHAVIORAL|Parental Education|Sessions will cover relevant information on young children with ASD, including understanding the ASD diagnosis, developmental changes in ASD, educational planning, advocacy, and treatment options.
48149224|NCT05651802|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
48361205|NCT01691937|PROCEDURE|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
48361206|NCT01691937|PROCEDURE|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
48149225|NCT05651802|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
48361207|NCT01157962|PROCEDURE|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
48361208|NCT05536934|DRUG|Nω-hydroxy-nor-arginine|
48361209|NCT01196065|DRUG|RO5313534|single oral dose
48361210|NCT01196065|DRUG|memantine|multiple doses to steady state
48509789|NCT01777230|PROCEDURE|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
48149226|NCT05651802|DRUG|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
48149227|NCT03773432|OTHER|Probe meal|The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
48509790|NCT06632301|DEVICE|Primary hip replacement with cementless stem|Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
48509791|NCT02198183|DEVICE|Casmed Fore-Sight Elite|
48509792|NCT02198183|DEVICE|Non-invasive Cardiac Output Monitor (NICOM)|
48509793|NCT02322203|DIETARY_SUPPLEMENT|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
48361211|NCT02243163|BEHAVIORAL|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
48361212|NCT01959594|DRUG|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
48361213|NCT01959594|DRUG|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
48361214|NCT01959594|DRUG|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
48509794|NCT00606346|BIOLOGICAL|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
48674509|NCT06448975|PROCEDURE|Deep cervical Lymphovenous Bypass|Deep cervical lymph-vein bypass surgery, connecting deep cervical lymph input vein vessel
48361215|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
48361216|NCT01959594|DRUG|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
48674510|NCT06069609|DEVICE|Kalifilcon a Contact Lens for Astigmatism|Kalifilcon A Daily Disposable Toric Contact Lens for Astigmatism
48674511|NCT06069609|DEVICE|Acuvue Oasys 1-Day for Astigmatism|Commercially available contact lenses: Acuvue Oasys 1-Day for Astigmatism
48509795|NCT00606346|DRUG|No Biologics|Treatments will be prescribed according to investigator judgement.
48149228|NCT03779945|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
48361217|NCT01688479|DRUG|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
48361218|NCT01688479|DRUG|Essex® cream (Schering-Plough), aqueous cream without parabens|
48361219|NCT04108598|OTHER|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
48361220|NCT03607435|DEVICE|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
48361221|NCT03513835|DIAGNOSTIC_TEST|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
48361222|NCT05681169|OTHER|School-based HPV-counselling and HPV-vaccination.|"1. Scholl-based parental HPV-counselling~2. Scholl-based pupil HPV-counselling~3. Scholl-based HPVV"
48361223|NCT01070186|DRUG|Sunitinib|50mg/day for 4 weeks
47991339|NCT02556333|DRUG|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
48361224|NCT01070186|OTHER|Tumor biopsy|Conducted prior to administration of sunitinib therapy
47991340|NCT00437554|DRUG|Glimepiride|
48149229|NCT03779945|PROCEDURE|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
48361225|NCT01070186|PROCEDURE|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
48361226|NCT01070186|OTHER|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
48361227|NCT04972097|DEVICE|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
48361228|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)
48361229|NCT01064986|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
48361230|NCT01064986|BIOLOGICAL|Placebo|Saline vehicle (placebo)
48509796|NCT01559389|DRUG|Solifenacin|Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
48509797|NCT05985135|PROCEDURE|Muscle Biopsy|Needle muscle biopsy of the outer thigh muscle
48509798|NCT05985135|OTHER|Jell-O with Amino acids|An amino acid mixture containing 13C6 Lysine isotope label
48674512|NCT04884607|OTHER|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"* Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~* Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
48674513|NCT06170567|OTHER|The effect of puzzles on students' course success|The effect of puzzles on students' course success
47991341|NCT01968590|DRUG|Cholecalciferol|DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
47991342|NCT04612556|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
47991343|NCT04187560|DRUG|LB-102|(N-Methyl amisulpride)
48361231|NCT01064986|BIOLOGICAL|Hydrocortisone|Hydrocortisone
48361232|NCT04553796|DEVICE|fibroscan|Fibroscan is a non-invasive test that helps assess the health of your liver. Specifically, it uses ultrasound technology to determine the degree of fibrosis or scarring that may be present in your liver from various liver diseases or conditions
48509799|NCT05985135|DIETARY_SUPPLEMENT|Dextrose|Intravenous form of sugar
48509800|NCT05015452|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
48149230|NCT05569018|BEHAVIORAL|Blended group transversal protocol (BLGr-TP)|It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,...) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
48149231|NCT05569018|BEHAVIORAL|Face-to-face group transversal protocol (FFGr-TP)|It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
48149232|NCT01288729|DEVICE|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
48361233|NCT06286735|DIETARY_SUPPLEMENT|cinnamomum|60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.
48361234|NCT06286735|OTHER|Placebo|60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
48361235|NCT01904760|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
48361236|NCT01904760|DRUG|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
48149233|NCT01288729|DEVICE|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
48361237|NCT01641029|OTHER|No intervention|There is no intervention
47991344|NCT02345811|DEVICE|Sapphire|silicone-hydrogel contact lens
48149234|NCT03136588|DEVICE|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
48361238|NCT04529525|DRUG|Ivermectin|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
48361239|NCT04529525|DRUG|Placebo|Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.
48361240|NCT01256957|DEVICE|HEPA filter|
48361241|NCT04038437|DRUG|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
48361242|NCT04038437|DRUG|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
48361243|NCT05376241|BEHAVIORAL|Decision aid|Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
48361244|NCT01440231|DRUG|Placebo|Matching placebo administered by subcutaneous injection, once weekly
48361245|NCT01440231|DRUG|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
48361246|NCT01440231|DRUG|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
48361247|NCT01440231|DRUG|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
47991345|NCT02345811|DEVICE|senofilcon A|contact lens
47991346|NCT01992861|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
48674514|NCT06213272|BEHAVIORAL|Phono-Motor Therapy|The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
48361248|NCT01440231|DRUG|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
48361249|NCT06092411|BEHAVIORAL|Cognitive Behavioural Therapy for Depression|Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
48674515|NCT06213272|BEHAVIORAL|Aerobic Exercise Training (AET)|Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
47991347|NCT01992861|PROCEDURE|Diffusion Weighted Imaging|Undergo DW MRI
47991348|NCT01992861|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
47991349|NCT01992861|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
48361250|NCT06092411|DEVICE|Bright Light Therapy|Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
48509801|NCT03927014|OTHER|thiol/disulfide levels|Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
48361251|NCT04194086|DRUG|posaconazole oral suspensions|posaconazole oral suspensions（5mg/kg/d,tid) will be administered specially febrile neutropenia patients four times a day and blood samples will be taken any hours after the first dose at least Day 7.
48674516|NCT06213272|BEHAVIORAL|Stretching|Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
48361252|NCT04284033|DEVICE|Extended Wear Infusion Set|For two of the 4 weeks, the Extended Wear insulin infusion set will be used
48361253|NCT04284033|DEVICE|Standard Infusion Set|For two of the 4 weeks, the standard insulin infusion set will be used
48361254|NCT01287858|DRUG|AC430|Healthy volunteers will either receive AC430 or placebo.
48361255|NCT00347685|DRUG|tramadol ER|
48361256|NCT04843527|DEVICE|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
48361257|NCT04843527|DEVICE|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
48509802|NCT05575076|DRUG|Simufilam|simufilam 100 mg oral tablet, twice daily
48509803|NCT01958073|DRUG|Conjugated Estrogen Vaginal Cream|
48509804|NCT01958073|DRUG|Estradiol Ring|
48509805|NCT01958073|DRUG|Placebo|
48674517|NCT05073939|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
48674518|NCT05073939|DRUG|Oral Placebo|Administration of placebo orally
48674519|NCT01730872|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
48674520|NCT01730872|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
48674521|NCT06416228|DIETARY_SUPPLEMENT|Beetroot juice|Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations
48674522|NCT04556344|BEHAVIORAL|Emotional skills|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
48674523|NCT04556344|BEHAVIORAL|Short free talk and relaxation|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
47991350|NCT01992861|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
47991351|NCT01992861|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
47991352|NCT03430596|DRUG|Pramipexole|The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
47991353|NCT03430596|DRUG|Trihexyphenidyl hydrochloride|he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
48361258|NCT02218346|DRUG|AG221|AG221 in fed and fasted conditions
48361259|NCT03960294|OTHER|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
48361260|NCT02963194|DRUG|Oxytocin|
48361261|NCT02963194|DRUG|Placebo|
48361262|NCT03031873|DEVICE|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
48509806|NCT02954991|DRUG|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
48509807|NCT02954991|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
48674524|NCT02525640|DEVICE|Hearing Aid|Hearing aid comparison
48674525|NCT04799002|DRUG|Topotecan|Topotecan intraocular injection for chemotherapy in retinoblastoma
48674526|NCT04799002|DRUG|Melphalan|Melphalan intraocular injection for chemotherapy in retinoblastoma
48674527|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
48361263|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Normal Aging|Using software developed for this purpose, a current photograph of the subject will be aged and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
48361264|NCT04754867|BEHAVIORAL|Future Self Virtual Reality Image - Smoking Consequences Aging|Using software developed for this purpose, a current photograph of the participant will be aged showing the results of continued smoking and presented through a visual medium. The image (face) will be rendered as a 3D virtual reality avatar.
48361265|NCT04754867|BEHAVIORAL|Current Self Virtual Reality Image|Using software developed for this purpose, a current photograph of the participant will be rendered as a 3D virtual reality avatar.
48674528|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
48361266|NCT04754867|BEHAVIORAL|Letter - 20 years|"Participants will write a 200-300 word letter to the self they see in that image in 20 years' time. The instructions will read: Think about who you will be in 20 years from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
48361267|NCT04754867|BEHAVIORAL|Letter - 3 months|"Participants will write a 200-300 word letter to the self they see in that image. The instructions will read: Think about who you will be in 3 months from now, and write about the person you are now. What things are important and dear to you, and how do you see your life?"
48361268|NCT04770701|DRUG|Ahah Drug|"- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
48361269|NCT04770701|DEVICE|Ahah Placebo|"- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg)~-Take 1tablet x 2 times / 24 hours. Maintained for 9 months."
48509808|NCT02954991|DRUG|Mocetinostat|Mocetinostat is an HDAC inhibitor.
48509809|NCT02954991|DRUG|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
48509810|NCT06632587|PROCEDURE|Early cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Early cranioplasty is defined as being performed within 8 weeks following the decompressive hemicraniectomy.
48509811|NCT06632587|PROCEDURE|Standard-of-care cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Standard-of-care cranioplasty is defined as being performed after 3 months following the decompressive hemicraniectomy.
48509812|NCT05351658|DEVICE|KronoSafe® System|All patients included in the study will have a temporary pacemaker with active fixation leads, held by the KronoSafe® fixation system.
48509813|NCT04430894|DRUG|Carfilzomib|"* Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~* Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
48509814|NCT04430894|DRUG|Isatuximab|"* Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  -- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity"
48509815|NCT04430894|DRUG|Lenalidomide|- Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
48509816|NCT04430894|DRUG|Dexamethasone|Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
48674529|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
48674530|NCT05865301|OTHER|Questionnaire for patients receiving therapy|Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.
48674531|NCT01680926|DIETARY_SUPPLEMENT|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
48674532|NCT01504295|DRUG|Metadoxine|Improve Liver Function and Reduce ALcohol Use
48674533|NCT01169480|BEHAVIORAL|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
48361270|NCT05872243|DEVICE|active rTMS|Each participant will receive two 1800 pulse active rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
48674534|NCT03037125|PROCEDURE|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
48361271|NCT05872243|DEVICE|sham rTMS|Each participant will receive two 1800 pulse sham rTMS in each session, with a 50-minute break in between. Participants will receive two separate sessions daily (a sum of 7200 pulses per day). The intervention will take place for 15 continuous days.
48149235|NCT03159494|OTHER|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
48674535|NCT03037125|PROCEDURE|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
48361272|NCT01098435|DRUG|RDC-0313 (ALKS 33)|Capsules for daily oral administration
48361273|NCT01098435|DRUG|Placebo|Capsules containing lactose and no active drug for daily oral administration
48149236|NCT00789971|DRUG|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
48149237|NCT00789971|DRUG|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
48149238|NCT03989232|DRUG|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
48361274|NCT02527031|OTHER|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
48361275|NCT02527031|OTHER|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
48361276|NCT00856336|DRUG|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
48361277|NCT00271076|PROCEDURE|IVUS|
48361278|NCT00271076|DEVICE|CAS|
48361279|NCT00271076|PROCEDURE|CEA|
48361280|NCT05610228|OTHER|NO intervention|No intervention
48361281|NCT03596307|DIETARY_SUPPLEMENT|Ashwagandha extract|Shoden 180 mg capsule.
48674536|NCT05196750|OTHER|Behavioural questionnaires and assessments on mother and child|Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
48674537|NCT03782064|DRUG|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
48674538|NCT03782064|BIOLOGICAL|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
48674539|NCT04815200|DEVICE|Copper Nickel titanium arch wire|Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
48674540|NCT02905578|DRUG|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
48674541|NCT02905578|DRUG|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
48674542|NCT02905578|DRUG|Pharmacological ascorbate|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~* given 3 times weekly~* given for 4 weeks out of the 4 week cycle~* no dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"
48674543|NCT00848419|DRUG|Epidural administration of bolus|
48674544|NCT00305448|DRUG|Fulvestrant|250 intramuscular injection
48674545|NCT00305448|DRUG|Fulvestrant|500 mg intramuscular injection
48674546|NCT04188132|OTHER|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
48674547|NCT01600404|DRUG|antimuscarinic treatment|
48674548|NCT02869165|DRUG|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
48674549|NCT02869165|DRUG|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
48674550|NCT02965989|PROCEDURE|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
48674551|NCT01176877|BEHAVIORAL|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
48674552|NCT00526539|OTHER|Total hip replacement, Spectron and Taperloc|
48674553|NCT06133881|DRUG|prilocaine|intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
48674554|NCT06133881|DRUG|bupivacaine|intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
48674555|NCT03589287|BIOLOGICAL|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
48674556|NCT00060671|DRUG|rituximab|
48674557|NCT00060671|DRUG|Pixantrone (BBR 2778)|
48674558|NCT01840943|DRUG|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
48674559|NCT01840943|DRUG|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
48674560|NCT04222192|OTHER|Epidural block|Epidural catheter insertions
48674561|NCT06460038|DRUG|Tenapanor|Inhibitor of NH3
48149239|NCT03989232|DRUG|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
48149240|NCT01451840|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
48674562|NCT06460038|DRUG|Placebo|Placebo drug
48674563|NCT02636387|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
48674564|NCT04240106|DRUG|Niraparib|Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
48674565|NCT04240106|DRUG|Aromatase Inhibitors|Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
48674566|NCT05246202|BEHAVIORAL|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
48674567|NCT05246202|BEHAVIORAL|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
48674568|NCT03186430|BEHAVIORAL|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
48509817|NCT04129229|DEVICE|LinguaFlex Tongue Retractor (LTR)|The LinguaFlex Tongue Retractor (LTR) is a small, flexible, implanted tongue retaining device that lessens the backward movement of the tongue during sleep. The LTR's flexible shaft and a nubbed tether passes through the center of the tongue beneath the tongue blade (frenulum area) and connects to a disc (head) that rests on the external surface of the tongue base mucosa. Underneath the tongue, on the external surface of the frenulum, a small anchor secures the shaft that can be adjusted to tension the LTR to maximize therapeutic effect and maintain comfort.
48361282|NCT03596307|DIETARY_SUPPLEMENT|Placebo|Placebo 180 mg (Sucrose) capsule.
48361283|NCT04631757|DRUG|Camrelizumab + SOX + Radiotherapy|Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
48361284|NCT00266149|DRUG|Oral contraception|
48509818|NCT03062163|OTHER|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
48361285|NCT00266149|DRUG|Lamotrigine|
48361286|NCT05588076|OTHER|no intervention|no intervention
48509819|NCT03062163|OTHER|Placebo|Transdermal patch loaded with normal saline
48674569|NCT00041028|DRUG|EF5|
48674570|NCT00041028|OTHER|flow cytometry|
48674571|NCT00041028|OTHER|immunohistochemistry staining method|
48674572|NCT04003298|DEVICE|Electric toothbrush|Electric toothbrush and power interdental device
48674573|NCT04003298|DEVICE|Control|Oscillating-rotating
48674574|NCT01147393|DRUG|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over \~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
48361287|NCT02481440|BIOLOGICAL|human umbilical cord mesenchymal stem cells (hUC-MSCs)|Four times of intrathecal administrations of hUC-MSCs
48361288|NCT02086760|OTHER|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
48361289|NCT02086760|RADIATION|Scintigraphy|
48361290|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
48361291|NCT05212623|BIOLOGICAL|quadrivalent influenza split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
48509820|NCT04521972|DEVICE|Room light/light bulb|Room light will be ON/OFF or red light used in the room. Reducing/eliminating light in the room in the evening and night is expected to allow the natural release of melatonin, which is thought to promote uterine contractions in late pregnancy.
48509821|NCT00841828|DRUG|Epirubicin|
48509822|NCT00841828|DRUG|Cyclophosphamide|
48361292|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
48361293|NCT05212623|BIOLOGICAL|Influenza virus split vaccine|This vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection.
48361294|NCT00126763|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
48361295|NCT01029691|DEVICE|Positive Airway Pressure|Women will use positive airway pressure until delivery
48361296|NCT05224856|BIOLOGICAL|CT-P63 and CT-P66 / Placebo|Inhalation
48509823|NCT00841828|DRUG|Docetaxel|
48509824|NCT00841828|DRUG|Lapatinib|
48509825|NCT00841828|DRUG|Trastuzumab|
48509826|NCT06142318|DRUG|Pirfenidone|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
48509827|NCT06142318|DRUG|Placebo|Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
48674575|NCT01147393|BIOLOGICAL|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
48509828|NCT04521387|PROCEDURE|injection therapy|The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
48674576|NCT00939107|PROCEDURE|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
48674577|NCT00939107|PROCEDURE|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
48509829|NCT04521387|DRUG|Platelet Rich Plasma|Platelet rich plasma injection in the painful area of humeral epicondyle.
48674578|NCT00006132|DRUG|acyclovir|
48361297|NCT01207336|DEVICE|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
48509830|NCT04521387|DRUG|Corticosteroid Injection|Corticosteroid injection in the painful area of humeral epicondyle.
48509831|NCT04521387|DRUG|Hyaluronic Acid Injection|Hyaluronic acid injection in the painful area of humeral epicondyle.
48509832|NCT04521387|OTHER|Placebo Injection|Saline injection in the painful area of humeral epicondyle.
48509833|NCT02806024|DRUG|Tranexamic Acid|
48509834|NCT02806024|DRUG|Placebo Drug|50 cc Normal Saline IV
48149241|NCT01451840|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
48149242|NCT00266305|BEHAVIORAL|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
48361298|NCT05132140|DEVICE|adaptive optics system|the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).
48361299|NCT04302363|OTHER|Fecal microbiota detection and exfoliated cell gene detection|Fecal microbiota detection and exfoliated cell gene detection
48361300|NCT06323863|PROCEDURE|stapedectomy|stapes removal and replacement by a prosthesis
48361301|NCT06323863|RADIATION|ultra high resolution CT|imaging study
48361302|NCT00696774|DRUG|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
48361303|NCT01797302|DIETARY_SUPPLEMENT|Vitamin D3|Tablet form
48361304|NCT03958409|DIAGNOSTIC_TEST|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
48361305|NCT03958409|DIAGNOSTIC_TEST|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
48361306|NCT00572858|PROCEDURE|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
48509835|NCT00742118|PROCEDURE|Colic biopsies|colic biopsies and analysis
48674579|NCT02151656|DRUG|F17464|
48674580|NCT02151656|DRUG|Placebo|
48674581|NCT04283656|DRUG|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
48674582|NCT04283656|DRUG|Spironolactone 100mg|200mg orally for two doses, twice-daily
48674583|NCT04283656|DRUG|Estradiol 2mg|4mg orally for two doses, twice-daily
48674584|NCT04283656|OTHER|Placebo|Placebo for one dose, daily
48674585|NCT03824392|BIOLOGICAL|Efzofitimod 1.0 mg/kg or Placebo|Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
48674586|NCT03824392|BIOLOGICAL|Efzofitimod 3.0 mg/kg or Placebo|Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
48674587|NCT03824392|BIOLOGICAL|Efzofitimod 5.0 mg/kg or Placebo|Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
48674588|NCT04316559|OTHER|Placebo|Placebo capsule
48674589|NCT04316559|DRUG|TRV734|biased agonist at mu opioid receptors
48674590|NCT03912610|DIAGNOSTIC_TEST|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
48674591|NCT03665259|PROCEDURE|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
48674592|NCT03665259|PROCEDURE|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
48149243|NCT00923078|BEHAVIORAL|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
47991354|NCT06403735|DRUG|QLC1101|QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
47991355|NCT02373787|DEVICE|creos xenoprotect|Implant placement with simultaneous bone augmentation
47991356|NCT02373787|DEVICE|Bio-Gide|resorbable collagen membrane
48149244|NCT00923078|BEHAVIORAL|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
48361307|NCT00572858|GENETIC|Blood test|Blood test for genetic testing
48361308|NCT00572858|PROCEDURE|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
48509836|NCT04003896|DRUG|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
48509837|NCT05096260|BEHAVIORAL|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
48361309|NCT00572858|PROCEDURE|Saliva test|Saliva test for cotisol levels
48674593|NCT03412825|DIETARY_SUPPLEMENT|Egg supplementation|Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
47991357|NCT03459742|BEHAVIORAL|Gamification strategy|"The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity."
48149245|NCT01615614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
48361310|NCT01906489|DRUG|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
48361311|NCT01906489|DRUG|Placebo|Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
48149246|NCT01615614|DRUG|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
48149247|NCT05236218|OTHER|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
48149248|NCT05236218|OTHER|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
48361312|NCT05341609|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
48361313|NCT05341609|DRUG|Paxlovid|Day 1\~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
48361314|NCT01488175|PROCEDURE|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
48361315|NCT01488175|PROCEDURE|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
48361316|NCT01191190|DRUG|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
48674594|NCT06073197|PROCEDURE|erector spinae plane block|Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
48674595|NCT06073197|PROCEDURE|combined deep and superficial serratus anterior plane block|Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
48361317|NCT04925466|DEVICE|CPAP at pressure of 10 cmH2O|Patients used CPAP with the pressure of 10 cmH2O during overnight polysomnography
48361318|NCT04925466|DEVICE|CPAP at minimal effective pressure|Patients with OSA will be treated with CPAP at minimal effective pressure derived from manual titration during sleep.
48149249|NCT03400059|DEVICE|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
48149250|NCT03400059|DEVICE|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
48509838|NCT06632366|OTHER|Sexual Dysfunction in the Postpartum Period|The experimental group will receive mindfulness-based self-compassion training. The control group will not receive any intervention.
48509839|NCT04054154|DEVICE|Shear Wave Elastography|Undergo shear wave elastography
48509840|NCT04054154|PROCEDURE|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
48509841|NCT04391504|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
48674596|NCT03161210|OTHER|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
48674597|NCT03161210|OTHER|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
48674598|NCT03161210|OTHER|Saline|Saline is a control group
48674599|NCT00000226|DRUG|Buprenorphine|
48674600|NCT02065934|OTHER|cardio-pulmonary resuscitation|
48674601|NCT03332121|BIOLOGICAL|B001|4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
48674602|NCT02487953|DRUG|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
48674603|NCT02487953|OTHER|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
48674604|NCT02487953|OTHER|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
47991358|NCT03946033|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
48149251|NCT00595725|OTHER|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
48674605|NCT02487953|OTHER|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
48674606|NCT06084351|DRUG|Convalescent Plasma|"Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:"
48361319|NCT00842829|DRUG|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
48361320|NCT02337855|OTHER|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
48361321|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
48509842|NCT01397643|OTHER|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
48509843|NCT01397643|OTHER|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
48674607|NCT06084351|OTHER|Standard of Care|Standard of care treatment for hospitalized COVID-19 patients
48674608|NCT04188249|DRUG|Golimumab|This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.
48674609|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water|
48674610|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate|
48509844|NCT00308880|DRUG|Transamin|
48361322|NCT02337855|BIOLOGICAL|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
48509845|NCT02538965|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
48674611|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate + protein|
48674612|NCT02691026|DRUG|Pembrolizumab|
48509846|NCT01767324|DEVICE|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
48509847|NCT01767324|DEVICE|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
48674613|NCT02248896|DRUG|Telmisartan|
48674614|NCT02248896|DRUG|Other angiotensin-receptor blockers (ARBs)|
48674615|NCT02248896|DRUG|Angiotensin-converting enzyme inhibitors (ACEIs)|
48674616|NCT02248896|DRUG|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
47991359|NCT05413707|PROCEDURE|Fixation of the posterior malleolus fractures|Fixation of the posterior malleolus fracture with screws and or plating.
47991360|NCT05413707|PROCEDURE|Fixation of lateral and/or medial malleolus fractures|Fixation with screws and/or plating
47991361|NCT05413707|PROCEDURE|Syndesmotic fixation|Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
47991362|NCT04562285|DIAGNOSTIC_TEST|Serologic immunoassays to SARS-CoV-2 antibodies|Detect and characterize antibodies to SARS-CoV-2
48149252|NCT00498797|DRUG|Zactima (vandetanib)|
48149253|NCT00498797|DRUG|Docetaxel|
48149254|NCT00498797|DRUG|Prednisolone|
48149255|NCT00780988|BIOLOGICAL|Autologous tumor cell + CpG vaccine|
48674617|NCT04073901|OTHER|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
48674618|NCT00569322|PROCEDURE|BG Test|
48509848|NCT01767324|DEVICE|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
48509849|NCT02686736|BEHAVIORAL|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
48674619|NCT05350540|OTHER|ICG dye|Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
47991363|NCT06160973|OTHER|Feed the Household|Medically tailored meals will be provided for the enrolled individual, with additional meals provided as needed for others living the same household
48361323|NCT01607996|PROCEDURE|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
48149256|NCT00780988|PROCEDURE|Autologous hematopoietic and immune cell rescue (transplantation)|
48149257|NCT06157099|DRUG|Atorvastatin|Given PO
48674620|NCT03402100|DRUG|eye drops|children who received daily eye drops for myopia
48674621|NCT02971319|DEVICE|Tc-99M-Tetrofosmin SPECT|
48149258|NCT06157099|DRUG|Placebo Administration|Given orally (PO)
48361324|NCT01607996|DRUG|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
48149259|NCT06157099|PROCEDURE|Computed Tomography|Undergo CT
48361325|NCT00219531|BEHAVIORAL|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
48361326|NCT00609089|BEHAVIORAL|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
48361327|NCT00609089|BEHAVIORAL|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
48509850|NCT03223844|DRUG|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
48509851|NCT04208750|DEVICE|Vision R-800 Phoropter|Refraction utilizing the Vision R-800 Phoropter with resulting glasses
48509852|NCT04208750|DEVICE|Standard Phoropter|Refraction utilizing the standard phoropter with resulting glasses
48674622|NCT02971319|DEVICE|F-18 FDG PET|
48674623|NCT03930589|PROCEDURE|Remote Ischemic conditioning|BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
48674624|NCT03930589|OTHER|Standard of care|Standard of care
48149260|NCT06157099|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48149261|NCT06157099|OTHER|Electronic Health Record Review|Ancillary studies
48149262|NCT06412809|OTHER|Combined Land- and Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented both on land and in water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~Land-based exercise:~1. Plank exercise~2. Russian twist~3. Push-up~4. Goblet squat~5. Kettle bell swing~Water-based exercise:~1. Flutter kicks~2. Isometric core crunches~3. Jump lunges~4. Kicks~5. Resisted knee flexion"
48149263|NCT06412809|OTHER|Land-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented on land. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Plank exercise~2. Russian twist~3. Dead bug~4. Push-up~5. Goblet squat~6. Nordic hamstring curl~7. Lunges~8. Kettle bell swing~9. Calf raises~10. Bird dog"
48361328|NCT06330727|DIETARY_SUPPLEMENT|Coffee capsule|Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
48361329|NCT06330727|DIETARY_SUPPLEMENT|Corn starch capsule|Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
48361330|NCT02217046|PROCEDURE|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
48361331|NCT00417248|DRUG|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
48361332|NCT00417248|DRUG|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
48361333|NCT00417248|PROCEDURE|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
48361334|NCT00417248|DRUG|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
48361335|NCT00417898|DRUG|Aspirin|
48509853|NCT01326650|DRUG|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
48509854|NCT01326650|DRUG|placebo|daily oral placebo supplement for three years
48509855|NCT05327231|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
48674625|NCT04796038|DEVICE|Balloon dilatation|Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
48674626|NCT01482195|BIOLOGICAL|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
48674627|NCT01261975|PROCEDURE|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
48674628|NCT01261975|PROCEDURE|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
48361336|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
48509856|NCT05327231|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
48509857|NCT02205190|DRUG|Fimasartan|
48361337|NCT00808132|DRUG|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
48361338|NCT00808132|DRUG|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
48361339|NCT00808132|DRUG|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
48361340|NCT00808132|DRUG|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
48361341|NCT00003855|PROCEDURE|axillary lymph node dissection|
48361342|NCT00003855|RADIATION|whole breast irradiation|
48361343|NCT06070831|DEVICE|Inspiratory muscle training|"Respiratory training, performed through IMT, was carried out with a pressure threshold device (Treshold IMT, Philips-Respironics, Pittsburg, PA, USA). Threshold IMT offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the inspiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
48361344|NCT06070831|DEVICE|Expiratory muscle training|"Respiratory training, performed through PEP, was carried out with a pressure threshold device (Treshold PEP, Philips-Respironics, Pittsburg, PA, USA). Threshold PEP offers a constant and specific pressure for strength and endurance training of the respiratory muscles, regardless of the strength or speed with which patient breathes. A flow-independent one-way valve ensures constant resistance and allows you to specifically adjust workload (in cmH2O). The training must be supervised by a healthcare professional. During the expiration, a spring-loaded valve resists to stimulate the training of the respiratory muscles. Before training began, the participants and primary caregivers completed one-session familiarization with a specialist to know the operation of the device.~Adult people with acquired brain injury carried out the training program for 8 weeks, 1 session every day, 5 days a week. The participants performed 5 series of 1 minute with 1-minute rest between them."
48361345|NCT01455064|DEVICE|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
48509858|NCT02205190|DRUG|Rosuvastatin|
48674629|NCT00004927|DRUG|ixabepilone|
48361346|NCT03272672|OTHER|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
48509859|NCT02205190|DRUG|Fimasartan/Rosuvastatin combination|
48509860|NCT04358952|DIAGNOSTIC_TEST|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
48509861|NCT03918460|DEVICE|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
48509862|NCT06622642|PROCEDURE|Transoral technique for mandibular angle fracture reduction|In transoral technique approach inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. A 5-hole 2mm miniplate with 2 holes anterior and 2 holes posterior to fracture line will be screwed to external oblique ridge and MMF will be removed and incision line will be closed.
48674630|NCT02370472|OTHER|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
48674631|NCT02996422|BEHAVIORAL|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
48674632|NCT02996422|BEHAVIORAL|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
48674633|NCT00286377|DRUG|prosaptide|
48674634|NCT03122938|DIETARY_SUPPLEMENT|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
48674635|NCT03122938|DIETARY_SUPPLEMENT|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (\<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
47991364|NCT06160973|OTHER|Dedicated Driver|Medically tailored meals will be delivered each week by a driver who is an employee of Community Servings
48674636|NCT03115918|DEVICE|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
48674637|NCT03115918|OTHER|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
47991365|NCT06160973|OTHER|Feed the Individual|Medically tailored meals will be provided for the enrolled individual
47991366|NCT06160973|OTHER|Commercial Shipper|Meals will be delivered by a commercial shipping organization
47991367|NCT04626232|PROCEDURE|N-SLEEVE technique|The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
47991368|NCT04626232|PROCEDURE|SLEEVE|SLEEVE Technique : Removal of 2/3 of the stomach
48674638|NCT01890096|RADIATION|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
48674639|NCT01890096|RADIATION|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
48674640|NCT01937520|DEVICE|acupuncture|One half of subjects will receive a standardized acupuncture regiment
48674641|NCT01937520|DEVICE|no acupuncture|placebo
48674642|NCT02214069|DEVICE|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
48674643|NCT00161889|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
48674644|NCT00403143|PROCEDURE|cataract surgery|
48149264|NCT06412809|OTHER|Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented in the water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Core pulls~2. Flutter kicks~3. Water cycling~4. Isometric core crunches~5. Seated push-up~6. Jump squats~7. Jump lunges~8. Kicks~9. Ankle jumps~10. Resisted knee flexion"
48149265|NCT03188887|DRUG|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
48149266|NCT03188887|DRUG|Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)|treatment with Renin angiotensin system (RAS) blockade or SGLT2i
48149267|NCT06462378|RADIATION|Proton therapy|External beam proton therapy combined with standard cisplatin and brachytherapy
48674645|NCT02332187|DEVICE|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
48361347|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride|Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
48674646|NCT02332187|DEVICE|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
48674647|NCT01332214|DRUG|AZD2820|Subcutaneous Injection in abdomen or Thigh
48674648|NCT01332214|DRUG|Placebo|Subcutaneous Injection in abdomen or Thigh
48674649|NCT03810846|BEHAVIORAL|Walking football exercise program|Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
48674650|NCT04414293|RADIATION|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
48674651|NCT04396821|DRUG|TST001|TST001 is a humanized IgG1 monoclonal antibody.
48674652|NCT04396821|DRUG|Nivolumab Injection [Opdivo]|Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
48149268|NCT00079222|DRUG|itraconazole|
48149269|NCT00079222|DRUG|voriconazole|
48674653|NCT04396821|DRUG|mFOLFOX6|mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
48674654|NCT04396821|DRUG|Gemcitabine|Chemotherapy medication
48361348|NCT04868513|DRUG|Pregnant women to whom applied silane fluoride + 1% chlorhexidine|Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
48674655|NCT04396821|DRUG|Albumin-Bound Paclitaxel|Chemotherapy medication
48674656|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-discordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
48149270|NCT00166075|PROCEDURE|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
48149271|NCT00007826|BIOLOGICAL|BCG vaccine|
48361349|NCT00212667|DRUG|ONO-5920|
48361350|NCT05814107|DRUG|CT-996|Capsule of CT-996
48361351|NCT05814107|DRUG|Placebo|Capsule of Placebo
48361352|NCT02416466|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells.
48361353|NCT02416466|DEVICE|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
48509863|NCT06622642|PROCEDURE|Transbuccal technique for mandibular angle fracture reduction|In transbuccal technique inferior alveolar nerve block and buccal nerve block will be given by 2% xylocaine with 1:100000 adrenaline. Incision will be made with surgical blade no 15 from gingival crevices of molars to ascending ramus. Fracture segments will be reduced alongwith MMF. extraorally a stab incision will be made with scalpel blade parallel to relaxed resting skin tension lines through which the cannula with a trocar will be inserted through facial tissue down to bone. Transbuccal instrument system will cionsist of transbuccal guide, mountable retractor, drill sleeve, drill guide, and 2mm drill bit. A 2mm titanium miniplate will be placed along buccal cortex and screwed through trocar system. MMF will be removed and incision line closed
48149272|NCT00007826|BIOLOGICAL|monoclonal antibody 105AD7 anti-idiotype vaccine|
48149273|NCT00007826|DRUG|alum adjuvant|
48149274|NCT04126993|DRUG|Camrelizumab,|Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
48361354|NCT05231694|DRUG|Nerver growth factor (NGF) injection|The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
48361355|NCT05231694|DRUG|Placebo injection|The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
48509864|NCT00002231|BIOLOGICAL|APL 400-003|
48509865|NCT03364543|OTHER|Access to the Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs.
48509866|NCT03364543|OTHER|Access to social worker and a community worker|Access to social worker and a community worker, but no systematic process for addressing health-harming legal needs.
48509867|NCT04550923|COMBINATION_PRODUCT|Z-Brace interbody fusion device|Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
48674657|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-concordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
48509868|NCT04550923|COMBINATION_PRODUCT|PEEK interbody fusion device|Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
48674658|NCT01622296|DRUG|Sodium bicarbonate|8.4% neutralizing solution
48674659|NCT01622296|DRUG|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
48674660|NCT04474639|DEVICE|echocardiographic examination|conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
48674661|NCT05112848|BIOLOGICAL|NVX-CoV2373|"Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70)."
48674662|NCT00495703|BEHAVIORAL|Exercise|6-months of regular aerobic exercise
48674663|NCT00495703|BEHAVIORAL|Usual Care|6-months of behavioral strategies to aid memory/cognition
48674664|NCT06151470|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
48674665|NCT06151470|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
48674666|NCT02681081|OTHER|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
48674667|NCT02681081|OTHER|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
48674668|NCT02681081|OTHER|Control|Normal food intake
47991369|NCT00298181|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
48149275|NCT04126993|DRUG|Apatinib|Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
48149276|NCT02464215|PROCEDURE|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
48149277|NCT02464215|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
48509869|NCT01547130|DRUG|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
48361356|NCT05231694|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hua Tuo brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), 28 days as a course of treatment, once a day."
48361357|NCT05231694|DEVICE|sham EA intervention|The only difference between sham EA intervention and EA intervention is that the stimulator is connected to the needle handle without power for 40 min intervention.
48361358|NCT04414150|DRUG|SHR-1802|This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
48361359|NCT06137235|OTHER|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
48361360|NCT06137235|OTHER|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
48361361|NCT06308289|OTHER|Global Posture Re-education|Focusing on postural correction and movement patterns
48674669|NCT05923697|BEHAVIORAL|AF-EMDR|"Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol."
48674670|NCT00005579|DRUG|dolastatin 10|
48674671|NCT03110705|BEHAVIORAL|sport|recreaational sport : diving or multisport
48674672|NCT02394626|PROCEDURE|Surgery followed by adjuvant second-line therapy|"Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
48361362|NCT06308289|OTHER|Active Cycle of Breathing Technique|Emphasizing breathing control, thoracic expansion, and mucus clearance techniques
48361363|NCT06135558|DIAGNOSTIC_TEST|MAI detection|to detect the presence of marginal acute inflammation
48361364|NCT03049891|OTHER|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
48361365|NCT03049891|OTHER|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
48361366|NCT03049891|OTHER|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
48361367|NCT04643769|DRUG|ORIN1001|Oral tablet - ORIN1001
48361368|NCT04643769|DRUG|Placebo|Oral tablet - placebo
48674673|NCT02394626|PROCEDURE|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
47991370|NCT00720057|DRUG|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
47991371|NCT00720057|DRUG|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
48361369|NCT00764530|DEVICE|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
48361370|NCT00764530|DEVICE|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
48361371|NCT03656315|OTHER|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
48361372|NCT04335552|OTHER|Standard of care|Standard of care
48361373|NCT04335552|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5
48361374|NCT04335552|DRUG|Azithromycin|Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5
48509870|NCT01547130|DRUG|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
48674674|NCT01796288|RADIATION|simultaneous radiotherapy|
48674675|NCT01796288|DRUG|Erlotinib|
48674676|NCT00436436|DRUG|O6-benzylguanine|
48674677|NCT00436436|DRUG|temozolomide|
48361375|NCT06268366|OTHER|Exercise|Three exercises consisting of stretching and strengthening specific to the movement pattern dysfunction scored by Symmio will be prescribed to the participants. The exercises are standardized and assigned within the Symmio application with video instruction and guidance.
48149278|NCT01239641|PROCEDURE|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
48149279|NCT01607697|BEHAVIORAL|Mindfulness Training|Mindfulness Training
48509871|NCT06230406|PROCEDURE|surgery for artherial and/or venous diseases|collection of vascular samples from surgery and blood samples
48361376|NCT01567254|BEHAVIORAL|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
48361377|NCT01567254|BEHAVIORAL|music ONLY|music. It will be equal in length to the auditory guided imagery disk
48361378|NCT03950505|DRUG|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks|All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
48361379|NCT02997111|DEVICE|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
48361380|NCT02860676|DRUG|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
48361381|NCT02727452|OTHER|Skin-to-skin contact|
48361382|NCT01208025|OTHER|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
48361383|NCT02134340|DRUG|[I-124]-CPD-1028 Injection|A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
48361384|NCT02134340|BIOLOGICAL|CPD-1061|\[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
48361385|NCT05580081|BEHAVIORAL|i-CAN|online support and consultation to providers
48361386|NCT04416074|BEHAVIORAL|An online 5-week professional identity group psychotherapy|This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.
48361387|NCT04416074|OTHER|Message push|Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
48361388|NCT05673057|DRUG|MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)|"Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated."
48361389|NCT04524130|DRUG|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
48361390|NCT04524130|DRUG|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
48149280|NCT04725552|BEHAVIORAL|'Change' - an e-health intervention|The aim of the e-health intervention is to support the patient's change process and facilitate the doctor's ability to help. We plan for a web-application instead of a native application. A web-application enables use from mobile devices and from computers and is thus not dependent on a specific mode or system. Before including patients (postponed to September 2020 because of the Corona-virus pandemic), about 30 members of the general public have tested the e-health intervention.
48361391|NCT04524130|DRUG|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
48361392|NCT04314258|DIETARY_SUPPLEMENT|Moringa oleifera tea|4 grams of Moringa oleifera tea twice daily
48361393|NCT02612194|DRUG|Crizotinib|Crizotinib was administered orally at 250mg twice daily
48361394|NCT03440606|BEHAVIORAL|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
48509872|NCT05705076|DRUG|catheter induced thromboprophylaxis|Direct oral anticoagulation for catheter induced thromboprophylaxis
48509873|NCT04539652|DRUG|Experimental|Experimental group are treated with TenofoBell®
48509874|NCT04660331|OTHER|Communication Intervention|Undergo communication strategy intervention
48674678|NCT05837221|DIAGNOSTIC_TEST|Metagenomic sequencing|Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
48149281|NCT05085678|DEVICE|Co'moon (online website to support women with AET)|"The tool contains three parts:~1. e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~2. serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~3. a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals ."
48149282|NCT06245317|DEVICE|Mechanical Ventilation Mode|Each arm will have a different ventilation mode according to the allocation.
48361395|NCT00670098|PROCEDURE|Bariatric surgery|patients receive either gastric bypass or lap-band
48361396|NCT00670098|BEHAVIORAL|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
48361397|NCT03908723|OTHER|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
48509875|NCT04660331|OTHER|Communication Skills Training|Undergo communication training sessions
48361398|NCT02493075|BEHAVIORAL|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
48361399|NCT00424736|PROCEDURE|whole body CT scan|
48361400|NCT05270876|DEVICE|Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique|Experimental: The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
48361401|NCT05270876|DEVICE|Standard of care fitting or diagnostic measurement of Cochlear Implant and sound processor|The comparator will be the standard of care fitting or diagnostic or measurement approach.
48509876|NCT04660331|BEHAVIORAL|Healthcare Activity|Participate in interview
48509877|NCT04660331|BEHAVIORAL|Healthcare Activity|Undergo environmental scan
48509878|NCT04660331|OTHER|Survey Administration|Complete survey
48509879|NCT06044012|PROCEDURE|Double layer of buccal myomucosal Flap and buccal pad of fat|The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
48361402|NCT04296344|OTHER|Acupuncture Therapy Treatments|10 consecutive weekly group acupuncture therapy treatments
48361403|NCT04296344|OTHER|Yoga Therapy Sessions|8 consecutive yoga therapy sessions that occur immediately following in a room adjacent to acupuncture therapy.
47991372|NCT00566150|DRUG|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
47991373|NCT00566150|DRUG|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
48149283|NCT00051753|DRUG|levofloxacin; amoxicillin/clavulanate|
48149284|NCT01739738|DEVICE|Ureteral Stent|patients who need to receive stent as per standard of care
48674679|NCT05837221|DIAGNOSTIC_TEST|Metabolic analysis|Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
48361404|NCT05297240|DRUG|Belantamab mafodotin|At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
48509880|NCT01131468|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
48509881|NCT03580486|OTHER|The squares test|The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
48674680|NCT05844228|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
48674681|NCT02157428|DRUG|Flumazenil|
48149285|NCT01707914|DIETARY_SUPPLEMENT|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
48361405|NCT03602209|PROCEDURE|Removal of infected implant|
47991374|NCT03307720|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
47991375|NCT03307720|DRUG|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
47991376|NCT04127786|BIOLOGICAL|Purified vero rabies vaccine - serum free - VRVg-2|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
48149286|NCT01707914|DIETARY_SUPPLEMENT|placebo|
48509882|NCT00660907|DRUG|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
48509883|NCT00660907|DRUG|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
48509884|NCT00660907|DRUG|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
48509885|NCT01404078|DRUG|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
48509886|NCT01404078|DRUG|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
48509887|NCT00727597|DRUG|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
47991377|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Verorab®|Pharmaceutical form:Freeze-dried Route of administration: Intramuscular
47991378|NCT04127786|BIOLOGICAL|Purified inactivated rabies vaccine - Imovax® Rabies|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
48149287|NCT05990868|DRUG|Tylenol|Rectal tylenol will be placed at the time of oocyte retrieval
47991379|NCT05393141|BEHAVIORAL|diet and biopsychosocial exercise intervention|dietary intervention: biopsychosocial exercise intervention:
48509888|NCT00727597|DRUG|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
48149288|NCT00490113|DRUG|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
48149289|NCT00976053|PROCEDURE|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
48509889|NCT04820660|OTHER|Task orientated strengthening training|"1. Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~2. Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~3. Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~4. Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~5. forward step-up onto blocks of various heights to strengthen the lower limb muscles;~6. heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy."
48509890|NCT04820660|OTHER|Balance training exercises|"1. Stepping forward, backward, and sideways on the exercise step;~2. Stepping over blocks of various heights;~3. Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~4. Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~5. From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~6. Arms; bending the trunk forward and side to side);~7. Performing double-legged stance for 10 s;~8. Performing tandem stance for 10 s;~9. Rising from a chair without the use of the arms;~10. Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~11. Performing single- legged stance for 10 s."
48361406|NCT03602209|DRUG|Antibiotic durations|
48361407|NCT05504928|OTHER|School nurse program|School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
48361408|NCT02777008|DRUG|CTP-543|
48509891|NCT05296863|COMBINATION_PRODUCT|Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|"Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
48361409|NCT02777008|DRUG|Placebo for CTP-543|
48361410|NCT03783221|OTHER|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
48509892|NCT05296863|COMBINATION_PRODUCT|Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil|Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
48509893|NCT05296863|COMBINATION_PRODUCT|Placebo and 5% Minoxidil|"Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night."
48674682|NCT02157428|DRUG|saline|
47991380|NCT03045887|DRUG|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
47991381|NCT03045887|DRUG|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
47991382|NCT03045887|DRUG|Placebo|Lactose as powder for inhalation
47991383|NCT01788670|DIETARY_SUPPLEMENT|Ethanol|
48361411|NCT03783221|OTHER|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
47991384|NCT01788670|OTHER|Water|
47991385|NCT05482633|OTHER|Inspiratory muscle training (IMT)|Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
47991386|NCT05149846|PROCEDURE|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
47991387|NCT00410644|DRUG|OROS Hydromorphone HCI|
47991388|NCT02974296|DEVICE|transcranial magnetic stimulation|non invasive brain stimulation approach
47991389|NCT01761838|OTHER|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
48149290|NCT02110914|BEHAVIORAL|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
48149291|NCT03619044|OTHER|2 FES-PET Imaging will be performed:|"* before treatment initiation~* before treatment cycle 3 initiation"
48361412|NCT02059174|DRUG|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
48361413|NCT02059174|DRUG|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
48361414|NCT02059174|DRUG|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
48149292|NCT03928743|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
48509894|NCT02091466|DEVICE|pre-warming|warming patients 30 minutes prior to anesthesia
47991390|NCT01761838|OTHER|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
47991391|NCT01761838|OTHER|Low back pain participants without SMT|No treatment
47991392|NCT03857984|OTHER|Blood sampling|blood sample before and after a single HD
48361415|NCT01650610|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
48361416|NCT01013636|PROCEDURE|Blood sampling|"* Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
47991393|NCT02192255|BEHAVIORAL|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted \< than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
47991394|NCT04208594|DRUG|Ivabradine|comparing between both drugs for the effect of hypotensive anesthesia
47991395|NCT04208594|DRUG|Propranolol|comparing between both drugs for the effect of hypotensive anesthesia
47991396|NCT01057420|DRUG|oxygen inhalation|Inhalation of 80% oxygen via face mask
47991397|NCT04600674|PROCEDURE|Delayed cord clamping|DCC performed at 60 sec after birth
48509895|NCT02793505|DRUG|metformin|This is not an intervention but an observed exposure.
48509896|NCT02793505|DRUG|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
48509897|NCT04766164|BEHAVIORAL|Survey|Data will be obtained via self-report from participants via a one-time Qualtrics survey.
48509898|NCT05274555|OTHER|Assessment|"The Upper Limb Short Questionnaire was administered by the researcher in face-to-face sessions with the children and their caregivers.~The lower extremity functions and ambulation levels of the children were evaluated by the researcher using the Vignos Scale.~The Brooke Upper Extremity Functional Rating Scale and ABILHAND-Kids were used to evaluate children's upper extremity functions."
47991398|NCT04600674|PROCEDURE|Early cord clamping|ECC performed at 15 sec after birth
47991399|NCT05451862|DEVICE|Holmium-166 treatment|Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
47991400|NCT05451862|DEVICE|Holmium-166 work-up|Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
47991401|NCT02211001|OTHER|Pilates Group|The exercises were applied once a week during eight weeks.
47991402|NCT02211001|OTHER|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
47991403|NCT02211001|OTHER|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
47991404|NCT04225299|DRUG|TOOKAD®|TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
47991405|NCT01498718|BIOLOGICAL|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
47991406|NCT01498718|BIOLOGICAL|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
47991407|NCT04800211|OTHER|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
48149293|NCT03928743|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
48149294|NCT02090205|PROCEDURE|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
48149295|NCT02090205|PROCEDURE|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
48361417|NCT04896606|OTHER|Standard of Care|Patients will receive standard of care for COVID-19.
48509899|NCT05184881|OTHER|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
48509900|NCT05184881|OTHER|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
48674683|NCT05364710|DIETARY_SUPPLEMENT|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
48674684|NCT01550601|PROCEDURE|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
47991408|NCT04800211|OTHER|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
48149296|NCT02090205|PROCEDURE|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
48674685|NCT04145076|DRUG|Placebo|Two oral doses of placebo.
48509901|NCT05978947|DEVICE|ZyMōt Multi 850µL device|The ZyMōt Multi 850µL device is a laboratory tool designed for use in assisted reproductive technology (ART) procedures such as intrauterine insemination (IUI) and in vitro fertilization (IVF). It is a sperm preparation device that uses a proprietary patented technology to isolate and select motile sperm from semen samples for use in ART procedures.
48509902|NCT05978947|DEVICE|Density Gradient Centrifugation Method|Density gradient centrifugation is a laboratory technique used to separate and isolate different types of cells or particles based on their density. It is commonly used in various applications, including cell biology, immunology, and assisted reproductive technology (ART).
48674686|NCT04145076|DRUG|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
48149297|NCT02090205|DEVICE|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
48149298|NCT02090205|DEVICE|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
48361418|NCT04896606|BIOLOGICAL|SARS-CoV2-CTLS|Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.
48361419|NCT02807376|DEVICE|Surgeon's 'standard of care' stapler|
48674687|NCT04145076|DRUG|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
48674688|NCT02268110|OTHER|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
48509903|NCT04069338|PROCEDURE|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
48509904|NCT04005352|BIOLOGICAL|Brolucizumab 6 mg|Intra-vitreal injection
48674689|NCT02268110|OTHER|Abdominal binding|Wearing an abdominal binder for 12 weeks
48674690|NCT03273686|PROCEDURE|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
48149299|NCT01064778|OTHER|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
48361420|NCT02807376|DEVICE|Ethicon Powered Vascular Stapler|
48509905|NCT04005352|BIOLOGICAL|Aflibercept 2 mg|Intra-vitreal injection
48509906|NCT06632821|OTHER|No intervention will be used.|University students' health literacy, physical activity, back pain and posture habits will be evaluated.
48509907|NCT01350570|OTHER|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
47991409|NCT06053073|DEVICE|Cervical rippening at home|The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
47991410|NCT06053073|DEVICE|Cervical rippening in the hospital|The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
47991411|NCT00861146|BEHAVIORAL|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
47991412|NCT03647865|PROCEDURE|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
48361421|NCT05064449|DRUG|Soticlestat|Soticlestat tablets.
48361422|NCT05064449|DRUG|Itraconazole|Itraconazole oral solution.
48361423|NCT05064449|DRUG|Mefenamic acid|Mefenamic acid capsule.
48361424|NCT06204003|DRUG|Cannabis/Hemp Isolate Extract|Formulation: CBD (99%; 0.1% THC isolate)
48361425|NCT02616172|GENETIC|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
48361426|NCT01266876|DRUG|Alirocumab|Alirocumab two SC injections in the abdomen only.
48361427|NCT01266876|DRUG|Placebo|Placebo two SC injections in the abdomen only.
48509908|NCT01350570|OTHER|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
48509909|NCT01350570|OTHER|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
48509910|NCT01350570|DRUG|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
48674691|NCT04896853|BIOLOGICAL|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
48674692|NCT05361850|PROCEDURE|Extubation|Removal of the endotracheal tube
48674693|NCT01402869|DRUG|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
48674694|NCT01402869|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
48674695|NCT03027674|DRUG|10% nifedipine cream|Topical treatment for Raynaud
48674696|NCT03027674|DRUG|5% sildenafil cream|Topical treatment for Raynaud
48149300|NCT01064778|OTHER|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
48149301|NCT05168345|OTHER|Course and web information|"The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~1. Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~2. An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker."
48674697|NCT02724241|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
48674698|NCT02724241|OTHER|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
48674699|NCT02724241|OTHER|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
48674700|NCT00305877|BIOLOGICAL|cetuximab|Given IV
48674701|NCT00305877|DRUG|gemcitabine hydrochloride|Given IV
47991413|NCT03191760|BEHAVIORAL|Behavioral Activation|Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
47991414|NCT02360592|DRUG|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
47991415|NCT02360592|DRUG|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
48361428|NCT03273933|DEVICE|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
48361429|NCT03273933|DEVICE|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
48361430|NCT04899167|OTHER|MRI 1.5T and 3.0T|Magnetic Resonance Imaging for Renal Fibrosis
48361431|NCT01759095|DEVICE|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
48361432|NCT03693391|DRUG|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
48361433|NCT03693391|DRUG|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) \[18F\]JNJ-64511070 will be administered.
48509911|NCT02077361|GENETIC|rAAV2.REP1 vector|No additional details needed.
48509912|NCT03353883|DRUG|Triptorelin SR|GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
48509913|NCT06629038|BEHAVIORAL|observation alone|observation of maximal mouth opening and range of motion of shoulder abduction
48509914|NCT04667286|PROCEDURE|Prone Position (PP)|Prone the patients on oxygen for at least 10 hrs a day
48509915|NCT05331807|DIETARY_SUPPLEMENT|Omega-3 FA|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA)
48674702|NCT00305877|DRUG|capecitabine|Given orally
47991416|NCT02360592|DRUG|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
47991417|NCT02360592|DRUG|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
47991418|NCT02493673|DEVICE|Continuous positive airway pressure device|(ResMed Spirit S8)
48509916|NCT05331807|DIETARY_SUPPLEMENT|Vitamin D|one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
48509917|NCT05331807|COMBINATION_PRODUCT|Combined Omega-3 and Vitamin D Supplementation|Two capsules of 1000mg fish oil daily (Each soft gel capsule contains 180mg EPA and 120 mg DHA) and one capsule of vitamin D3 weekly (one D3 capsule contains 50,000 IU)
48509918|NCT00950131|OTHER|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
48509919|NCT00115427|DRUG|Liatermin (r-metHuGDNF)|
48674703|NCT00305877|RADIATION|radiation therapy|Undergo radiation therapy
48674704|NCT00305877|BIOLOGICAL|bevacizumab|Given IV
48674705|NCT00305877|OTHER|laboratory biomarker analysis|Correlative studies
48674706|NCT03767439|DRUG|Vismodegib|150 mg PO daily
48674707|NCT03767439|DRUG|Nivolumab|480 mg IV every 4 weeks
48674708|NCT03767439|DRUG|Ipilimumab|1 mg/kg IV every 6 weeks
48674709|NCT03758261|DRUG|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
48674710|NCT03758261|DRUG|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
48674711|NCT04877327|PROCEDURE|Ablation|Cryotherapy and radiofrequency
48361434|NCT01738672|DRUG|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
48509920|NCT02343783|OTHER|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
48361435|NCT03815201|DIETARY_SUPPLEMENT|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
48361436|NCT03815201|OTHER|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
48674712|NCT00369837|DRUG|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
48674713|NCT02266563|DRUG|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
48674714|NCT02266563|DRUG|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
48674715|NCT03098563|DRUG|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
48674716|NCT03511001|OTHER|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
48674717|NCT05745766|OTHER|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
48509921|NCT00638053|GENETIC|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
48509922|NCT00000108|BEHAVIORAL|Exercise|
48509923|NCT00656266|DRUG|mycophenolate mofetil|immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
48509924|NCT00656266|OTHER|placebo medication|medication that looks like mycophenolate mofetil
47991419|NCT01394679|DRUG|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
47991420|NCT01394679|DRUG|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
47991421|NCT03420651|OTHER|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
48361437|NCT05150925|OTHER|Cast treatment|Dorsal cast placed in OR
48361438|NCT05150925|OTHER|Immediate mobilization|Immediate mobilization postoperatively without casting
48361439|NCT05150925|PROCEDURE|Volar plating|Volar plating of distal radius fracture
48509925|NCT05645705|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
48509926|NCT05645705|OTHER|LISTERINE Cool Mint Antiseptic Mouthwash|Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
48509927|NCT05645705|OTHER|Listerine Advanced Gum Alcohol|Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
48674718|NCT05745766|OTHER|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
48674719|NCT05745766|OTHER|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
48361440|NCT04056962|DRUG|Tacrolimus ointment|topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
48361441|NCT03721406|DRUG|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
48361442|NCT06000891|DRUG|ZP7570|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
48361443|NCT06000891|DRUG|Placebo|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
48361444|NCT00287976|DRUG|irinotecan hydrochloride|
48361445|NCT04306627|DRUG|Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment|comparative antihypertensive antilipidemic treatment assessment on carotid intima media thickness in both study groups
48361446|NCT01515813|DRUG|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
48361447|NCT01515813|DRUG|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
48361448|NCT01515813|DRUG|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
48361449|NCT02200549|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
48361450|NCT02200549|DEVICE|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
48674720|NCT05802277|DIAGNOSTIC_TEST|Hamstring muscles function assessment|Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
48149302|NCT00916318|BEHAVIORAL|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
48149303|NCT03143036|DRUG|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days)."
48509928|NCT05645705|OTHER|Listerine Advanced Gum Zero|Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
48509929|NCT05645705|OTHER|LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint|Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
48509930|NCT04112186|BEHAVIORAL|Behavioral group therapy #1|Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
48149304|NCT03837015|DRUG|Estring Vaginal Ring|Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
47991422|NCT03420651|OTHER|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
47991423|NCT02803151|RADIATION|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
47991424|NCT06268561|OTHER|Visual acuity analysis|Collection of information on visual acuity from the medical file concerning the surgery
47991425|NCT06268561|OTHER|Intraocular pressure analysis|Collection of information on intraocular pressure from the medical file concerning the surgery
48149305|NCT03837015|OTHER|RepHresh Pro-B|Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
48361451|NCT02200549|DEVICE|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
48509931|NCT04112186|BEHAVIORAL|Behavioral group therapy #2|Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
48509932|NCT03103841|PROCEDURE|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
48509933|NCT04794036|OTHER|Asynchronous telerehabilitation programme|Home-based physical rehabilitation programme using a telerehabilitation platform
48509934|NCT04794036|OTHER|Rehabilitation programme|Home-based physical rehabilitation programme by means of an explanatory booklet
48674721|NCT02808429|DRUG|Placebo|Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
48361452|NCT03397095|COMBINATION_PRODUCT|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
48674722|NCT02808429|DRUG|Atacicept 25 mg|Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
48674723|NCT02808429|DRUG|Atacicept 75 mg|Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
48674724|NCT05495438|OTHER|Hypothetical AI|n/a - There is no intervention. Clinicians will review the suggestions of a hypothetical AI
48149306|NCT06010173|DRUG|Gadopiclenol|Dose/volume of gadopiclenol to be administered will be calculated based on patient's weight at the dose of 0.05 mmol/kg BW
48149307|NCT06010173|DRUG|Comparator|Dose/volume of comparator to be administered will be calculated based on patient's weight at the dose of 0.1 mmol/kg BW
48509935|NCT00858481|DRUG|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
47991426|NCT06268561|OTHER|Analysis of optical coherence tomography (OCT) images|Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery
48509936|NCT00858481|DRUG|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
48509937|NCT00858481|DRUG|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
48509938|NCT00858481|DRUG|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
48674725|NCT03694951|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
47991427|NCT06268561|OTHER|Analysis of retinograms|Collection and analysis of retinography images of the medical file concerning the surgery
48674726|NCT03984721|DIAGNOSTIC_TEST|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
48361453|NCT03397095|DEVICE|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
48149308|NCT01317914|OTHER|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
48361454|NCT04152109|OTHER|Without laying on of hands subgroup|The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or count during 5 minutes, around 8 weeks.
48509939|NCT06324435|DRUG|Apremilast|60mg/day
48361455|NCT04152109|OTHER|Laying on of hands without Spiritual connection|Participants included in this subgroup will be exposed to the laying on of hands with healing intent by volunteers. The patients will be blindfold in the supine bed during 5 minutes, around 8 weeks.
48361456|NCT04152109|OTHER|"Laying on of hands by Spiritual Passe"|"The participants will be subjected application of the laying on of hands by the volunteer who will give the Spiritist passe. Patients remain in the supine bed blindfolded for 5 minutes, around 8 weeks."
48361457|NCT01523613|DEVICE|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
48361458|NCT01523613|DEVICE|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
48361459|NCT04084444|DRUG|T8 tablet 0.5mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
48361460|NCT04084444|DRUG|T8 tablet 1mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
48361461|NCT04084444|DRUG|Placebo|Blank control.
48361462|NCT00356434|DEVICE|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
48361463|NCT00356434|DEVICE|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
47991428|NCT04212260|BEHAVIORAL|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
47991429|NCT04212260|BEHAVIORAL|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
47991430|NCT03760120|DEVICE|PEP-MASK|
48361464|NCT05060003|DRUG|Atezolizumab|Atezolizumab is provided by Genentech.
48361465|NCT05060003|DRUG|Tiragolumab|Tiragolumab is provided by Genentech.
48361466|NCT05060003|DEVICE|Signatera Assay|"* To detect residual disease or to determine cancer recurrence with ctDNA~* Step 2 screening (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)"
48361467|NCT04383041|OTHER|No intervention|Completing questionnaires via ePRO app from their own mobile devices
48361468|NCT01682694|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
48361469|NCT01682694|DIETARY_SUPPLEMENT|placebo|
47991431|NCT05023226|PROCEDURE|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
47991432|NCT05023226|PROCEDURE|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
47991433|NCT00320983|DRUG|Topotecan|Topotecan
47991434|NCT00320983|DRUG|Cisplatin|Cisplatin
47991435|NCT04639609|OTHER|Characterization of Neuromuscular Function and Fatigue|at inclusion
47991436|NCT04851678|OTHER|None - observational study|None - observational study
47991437|NCT01819454|DEVICE|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
48361470|NCT04115605|DEVICE|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
48361471|NCT03637959|DEVICE|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
48361472|NCT00384969|DRUG|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
48361473|NCT02723474|DEVICE|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
48361474|NCT06250192|OTHER|Virtuel education|Randomization to virtuel education based on a tool of small videos accessible via smartphones
48509940|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
48509941|NCT01586793|DEVICE|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
48509942|NCT02497638|DRUG|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
48509943|NCT02497638|DRUG|Atorvastatin|Atorvastatin 20 mg once daily until progression.
48361475|NCT04704206|OTHER|Children will perform activities on interactive tablet|"The main difference between the types of interventions is the mode of use and the level of interactivity of the interactive media, where the AIMG actively performs activities, that is, there is user interaction with the equipment through touch or verbal response and the performance of activities like rotating an object, dragging and zooming. PIMG is not the same, the user is just a spectator, having contact with the equipment only when switching on / off, choosing the content, performing activities such as increasing / decreasing the volume and touching certain specific objects such as giving play / pause . Both groups will have a total of 48 intervention sessions."
48361476|NCT05774886|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan"
48361477|NCT00136461|DRUG|All-trans retinoic acid|
48361478|NCT00136461|DRUG|Bryostatin 1|
48361479|NCT05902611|BEHAVIORAL|BMI determination, Eruption Time Assessment, Caries Assessment|BMI determination, Eruption Time Assessment, Caries Assessment
47991438|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
48674727|NCT02717325|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
48361480|NCT01901679|DRUG|Celebrex|200 mg PO BID
48361481|NCT01641523|DEVICE|CustomBone Service|customized hydroxyapatite cranial prosthesis
48361482|NCT02993731|DRUG|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
48674728|NCT03928041|DEVICE|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
47991439|NCT00947973|BEHAVIORAL|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
47991440|NCT05481515|DEVICE|Pulse oximetry|Pulse oximeters will be evaluated against routine arterial blood gas measurements
48361483|NCT02993731|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
48674729|NCT02047448|PROCEDURE|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
48509944|NCT02497638|DRUG|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
48509945|NCT02497638|DRUG|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
48509946|NCT06551584|DRUG|ORCA-T|On Day 0, participants will receive an infusion of Orca-T HSPCs and Orca-T Tregs. On Day +2 or +3 (between approximately 48 to 72 hours of Day 0), patients will receive an infusion of the Orca-T Tcons. There is no dose escalation or de-escalation planned for the Orca-T investigational product.
48509947|NCT01305044|BEHAVIORAL|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
47991441|NCT05481515|DEVICE|Spectrophotometry|Spectrophotometry will be used to measure skin tone
47991442|NCT03104114|BEHAVIORAL|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
47991443|NCT03104114|BEHAVIORAL|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
48361484|NCT02993731|DRUG|Gemcitabine|Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
48361485|NCT00892879|DEVICE|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
47991444|NCT01620710|RADIATION|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
47991445|NCT01620710|RADIATION|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
48361486|NCT03480529|DRUG|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
48509948|NCT01305044|BEHAVIORAL|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
48361487|NCT04310995|DRUG|Nicorandil 5mg tid|oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
48361488|NCT04310995|DRUG|Diltiazem 180mg qd|oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
48509949|NCT01386983|DRUG|5ARI|Dutasteride or Finasteride
48509950|NCT01386983|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
48361489|NCT04310995|DRUG|Isosorbide Mononitrate 50mg qd|oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
48509951|NCT05881525|BIOLOGICAL|TC-N201 cells|T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
48509952|NCT05881525|DRUG|IL-2|Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
48509953|NCT05881525|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
48509954|NCT05881525|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
48509955|NCT05881525|DRUG|Nab-paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
48674730|NCT06243614|DRUG|Buagafuran capsules, 15mg/ capsule|Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
48674731|NCT06243614|DRUG|Buspirone tablets, 5mg/ tablet|Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
48674732|NCT06243614|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
48674733|NCT06243614|DRUG|Buspirone tablets mimic, 0mg/ tablet|Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
48674734|NCT05447689|BEHAVIORAL|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
48674735|NCT04230967|BEHAVIORAL|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
48674736|NCT04230967|BEHAVIORAL|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
48674737|NCT01769053|OTHER|Variable Ventilation|
48674738|NCT02385006|BIOLOGICAL|Blood sample|
48674739|NCT05022173|DEVICE|Helmet Non-Invasive Ventilation|The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.
48674740|NCT05022173|DEVICE|Facemask Non-Invasive Ventilation|The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.
48674741|NCT05313763|OTHER|conventional physical therapy|A hotpack will be applied to the neck area for 15 minutes in the prone position of the patients. Conventional type Tens with a frequency of 50 Hz and a pulse duration of \<150 microseconds will be applied for 20 minutes, taking the painful area to the center. Ultrasound will be applied to the patients for 5 minutes with a dosage of 1-1.5 watts/cm2. Cervical joint range of motion exercises, stretching exercises for trapezius, scalenia, rhomboid, levator scapulae, pectoral and suboccipital muscles will be applied, then cervical isometric strengthening exercises and stabilization exercises will be carried out in a controlled manner. Conventional physical therapy will be applied by the same physiotherapist 5 days a week for 3 weeks.
48361490|NCT04589260|DRUG|TD-1058|Study drug to be administered by oral inhalation
48361491|NCT04589260|DRUG|Placebo|Placebo to be administered by oral inhalation
47991446|NCT06541015|DEVICE|InTENSity 10 TENS Stimulator|InTENSity 10 TENS stimulator is a portable electrotherapy device featuring Transcutaneous Electrical Nerve Stimulation (TENS) therapeutic device. The stimulator sends a gentle electrical current to underlying nerves and muscle group via electrodes applied on the skin. The parameters of device are controlled by the buttons.
47991447|NCT06300242|BEHAVIORAL|Reminders|Reminders
48509956|NCT04302012|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and/or after administration of mydriatic agent
48509957|NCT04302012|DRUG|Mydriatic Agent|Subjects may be administered mydriatic medication to dilate their pupils.
48509958|NCT05940012|OTHER|Manual Therapy|Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.
48509959|NCT03301571|OTHER|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
48509960|NCT03301571|OTHER|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
47991448|NCT06300242|BEHAVIORAL|Financial Incentive|$50 financial incentive for getting vaccinated within 1-week
47991449|NCT06300242|OTHER|Placebo|No special messages or incentives
47991450|NCT00257647|OTHER|SV40 vectors carrying siRNA|in vitro only use of gene therapy
47991451|NCT06523504|DEVICE|DIMS|wear DIMS ,and use placebo,once nightly, both eye
47991452|NCT06523504|DRUG|The 0.02% ATP Group|wear SP, and use 0.02%ATP eye drops, once nightly, both eye
47991453|NCT06523504|DRUG|The 0.04% ATP Group|wear SP, and use 0.04%ATP eye drops, once nightly, both eye
48149309|NCT02980432|OTHER|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
47991454|NCT06523504|COMBINATION_PRODUCT|0.02%ATP+DIMS|wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
47991455|NCT06523504|COMBINATION_PRODUCT|0.04%ATP+DIMS|wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
48149310|NCT01073722|DEVICE|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
47991456|NCT00994240|PROCEDURE|Electrodessication & Curettage|Electrodessication \& Curettage 1 or 3 cycles
48149311|NCT01073722|DEVICE|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
48149312|NCT02634593|BEHAVIORAL|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
48361492|NCT04491045|OTHER|Workshop Training on Multicomponent Collaborative Care for Depression|Hybrid Workshop Trainings on Stepped collaborative care model for depression that involves using a team-based approach to integrating depression care components (screening, psychoeducation, Behavior Activation therapy, and antidepressant medications) into primary care settings. This integration involves task-shifting mental health tasks from mental health specialist to community providers at the commune health stations.
48674742|NCT05313763|OTHER|Active Kinesiotaping|For kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, and the application will be started from the midline of the upper thoracic vertebrae. Initially, 4-5 cm stretching will be applied, and the arms of the Y strip will be adhered to the cervical paravertebral muscles without stretching. I strip will be applied to the painful area with the area correction technique, with maximum stretching in the middle and without stretching the ends. The applications will be made by the same physiatrist with 7 years of clinical experience.
48674743|NCT05313763|OTHER|Sham Kinesiotaping|For Sham kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, the application will be started from the midline of the upper thoracic vertebrae, and the Y and I bands will be applied without stretching. The applications will be made by the same physiatrist with 7 years of clinical experience.
48674744|NCT02824523|DRUG|aspirin|
47991457|NCT01569958|OTHER|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
47991458|NCT01569958|OTHER|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
47991459|NCT04935112|DRUG|Sitravatinib|100 mg sitravatinib on Day 1
47991460|NCT04935112|DRUG|Pantoprazole|40 mg QD on Day 1 to Day 7 of Period 2 in Group 1
47991461|NCT04935112|DRUG|Famotidine|40 mg PO 2 hrs after sitravatinib in Period 2 of Group 2
47991462|NCT02259361|DRUG|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
47991463|NCT02259361|DRUG|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
47991464|NCT04038515|DRUG|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
47991465|NCT04038515|DRUG|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
48674745|NCT02524561|DRUG|CEE pill|Conjugated equine estrogens 0.45 mg/day
48674746|NCT02524561|DRUG|Estradiol patch|Climara 50 mcg/day
47991466|NCT04038515|DRUG|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
47991467|NCT04038515|DRUG|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
47991468|NCT04038515|OTHER|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
47991469|NCT04038515|OTHER|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
47991470|NCT04038515|OTHER|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
47991471|NCT04038515|OTHER|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
48149313|NCT05660811|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
48149314|NCT05660811|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
48149315|NCT05660811|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
48149316|NCT05660811|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
48149317|NCT04403815|PROCEDURE|vascular access for coronary procedures|comparison of x-rays exposition of interventional cardiologist according to vascular access used
48509961|NCT03301571|OTHER|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
48509962|NCT01797237|DEVICE|PFNA|
48149318|NCT05512299|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
48149319|NCT01115309|DEVICE|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
48149320|NCT00001895|DRUG|FDG|
48149321|NCT00001895|DRUG|NH(3)|
48509963|NCT01797237|DEVICE|InterTAN|
48674747|NCT02524561|DRUG|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
48674748|NCT02524561|OTHER|Placebo tablet|Placebo tablet
48361493|NCT04491045|OTHER|Supervision|Ongoing supervision and coaching is provided to community health providers by local mental health specialist from the provincial psychiatric hospital for 6-9 months
48361494|NCT04491045|OTHER|Community-Engaged Learning Collaborative|The CELC group will receive support for continuous quality improvement using a province-wide learning collaborative that will meet monthly for 3 months, followed by bi-monthly meetings for 12 months.
48674749|NCT02524561|OTHER|Placebo patch|placebo patch
48674750|NCT02524561|OTHER|Placebo progesterone|placebo progesterone
48361495|NCT02670395|DRUG|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
48361496|NCT02670395|DRUG|Placebo|Placebo solution will be administered orally.
48509964|NCT05162508|OTHER|Nasopharyngeal swab|Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)
48509965|NCT04717557|DRUG|Hyperbaric Oxygen|Hyperbaric oxygen (HBO2) 1-2 times daily for up to 10 times after amputation
48674751|NCT06320704|DEVICE|Digital occlusal adjustment using Occulosense digital device|Digital occlusal adjustment of mandibular complete denture using Occulosense digital device
48674752|NCT00429754|DRUG|Aprepitant|
48674753|NCT05278026|OTHER|guideline recommended routine treatment|
48149322|NCT02349802|DRUG|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
48509966|NCT06634433|BEHAVIORAL|Health Personnel Attitude|The intervention consists of a two-phase Training of Trainers Program (TTP) designed for health professionals aimed at enhancing interprofessional education (IPE) skills. Phase 1 includes three days of online theoretical training, focusing on topics such as interprofessional collaboration, communication, and conflict resolution. Phase 2 involves two days of face-to-face practical sessions, where participants engage in scenario-based learning and small group discussions to apply IPE concepts. The effectiveness of the program is assessed through pre-test and post-test evaluations, measuring changes in participants\&#39; knowledge, attitudes, and competencies in interprofessional education.
48509967|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
48509968|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
48509969|NCT00961402|BEHAVIORAL|Wellness Control|6-month wellness control
48509970|NCT00961402|BEHAVIORAL|Exercise Intervention|6 month exercise intervention
48674754|NCT00586794|DRUG|Sildenafil|3x per day 20 mg TID
48674755|NCT00586794|DRUG|Placebo|3x per day, 20 mg TID
48149323|NCT02349802|DRUG|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
48149324|NCT05983939|DRUG|PIPE-791|Single and multiple ascending oral doses of PIPE-791 tablets.
48149325|NCT05983939|DRUG|Placebo|Single and multiple ascending oral doses of matching placebo tablets.
48149326|NCT04449822|PROCEDURE|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
48149327|NCT04449822|PROCEDURE|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
48149328|NCT01351675|DRUG|Placebo|Oral, once daily
48361497|NCT05246735|DIAGNOSTIC_TEST|MR-guided Near Infrared optical tomography|
48361498|NCT00650715|DEVICE|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
48361499|NCT00650715|DEVICE|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
48509971|NCT00159237|PROCEDURE|blood test|
48509972|NCT00197288|BIOLOGICAL|Influenza|
48509973|NCT05297773|BEHAVIORAL|Aerobic Training Group|The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to a maximum of 64% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
48509974|NCT05297773|BEHAVIORAL|Resistance Training Group|Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
48149329|NCT01351675|DRUG|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
48361500|NCT03933254|DIAGNOSTIC_TEST|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
48361501|NCT05450133|OTHER|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
48674756|NCT05505461|DRUG|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
48674757|NCT00577694|DRUG|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
48361502|NCT05450133|OTHER|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
48361503|NCT05450133|OTHER|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
48361504|NCT05450133|OTHER|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
48509975|NCT05297773|OTHER|Control group|The control group will perform a weekly stretching/relaxation session for 45 minutes.
48509976|NCT03931525|DEVICE|Fractitional Radiofrecuency with Drug Delivery|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug
48361505|NCT05450133|OTHER|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
48361506|NCT02337075|BEHAVIORAL|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
48361507|NCT02337075|DEVICE|Activity Mentor|
48361508|NCT03646812|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
48361509|NCT03646812|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
48361510|NCT03646812|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
48509977|NCT03931525|DEVICE|Fractitional Radiofrecuency|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
48361511|NCT03646812|OTHER|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
48674758|NCT00577694|DRUG|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
47991472|NCT04038515|OTHER|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
48361512|NCT03646812|OTHER|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
48361513|NCT03646812|OTHER|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
48361514|NCT03646812|OTHER|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
47991473|NCT02608268|DRUG|MBG453|Anti human TIM-3 monoclonal antibody. MBG453 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
47991474|NCT02608268|DRUG|PDR001|Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).
47991475|NCT02608268|DRUG|Decitabine|commercially available chemotherapy
48361515|NCT03646812|OTHER|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
48361516|NCT03646812|OTHER|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
48149330|NCT01668355|OTHER|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
48361517|NCT00760994|BEHAVIORAL|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).
48361518|NCT00760994|BEHAVIORAL|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
48361519|NCT00760994|OTHER|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
48361520|NCT05502276|PROCEDURE|Endoscopic Full-Thickness Resection (EFTR)|Full Thickness Endoscopic Resection using the FTRD Ovesco Device
48361521|NCT05502276|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
48361522|NCT04187586|OTHER|Extracorporeal shock wave therapy|ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 6 sessions.
48149331|NCT00778609|DRUG|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
48149332|NCT00778609|DRUG|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
48361523|NCT00763373|OTHER|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
48361524|NCT05617599|DEVICE|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
48361525|NCT01619436|DRUG|Clonidine|bolus, clonidine 2 mg/kg IV
48361526|NCT01619436|DRUG|Ringer lactato|1 ML ringer lactato IV, as placebo
48361527|NCT03443921|PROCEDURE|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
48361528|NCT03443921|DRUG|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
48361529|NCT00121459|DEVICE|Ortho All-Flex diaphragm and Replens lubricant gel|
48509978|NCT03417635|BEHAVIORAL|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
48509979|NCT03417635|BEHAVIORAL|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
48509980|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
48509981|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
48509982|NCT04095312|PROCEDURE|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
48509983|NCT03680612|DRUG|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
48509984|NCT03680612|DRUG|cefepime 1 g or cefepime 2 g|cefepime monotherapy
48361530|NCT05421676|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
48361531|NCT01866839|DEVICE|Graft Manipulation (CD34+ Selection)|
48361532|NCT04960332|DEVICE|Prevena|RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
48509985|NCT05886868|DRUG|BL0020|"Dose Escalation Stage: BL0020 will be administered via intravenous infusion on days 1 of a 21-days treatment cycle.~Dose Expansion Stage: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation Stage."
48509986|NCT02650843|OTHER|DAT SPECT imaging|
48509987|NCT00751556|DRUG|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
48509988|NCT00751556|DRUG|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
48509989|NCT03915509|DEVICE|Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis|Lasak Impladent Implants (sandblasted)
48509990|NCT06338124|DIAGNOSTIC_TEST|Triglyceride glucose index|To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.
48509991|NCT05782881|BEHAVIORAL|phone calls and encouraging patients' lifestyle change and medication adherence|Use some methods to strictly intervene blood glucose , blood pressure and blood lipids for protocol treatment group people.
48509992|NCT05782881|DRUG|Statin|Treatment and management according to the guidelines
48509993|NCT04191850|PROCEDURE|Single Port Video-Assisted Thoracoscopic Surgery|Single Port Video-Assisted Thoracoscopic wedge resection was performed for primary spontaneous pneumothorax.
48509994|NCT00399633|DRUG|sumatriptan|
48674759|NCT01213082|DRUG|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
48674760|NCT01213082|DRUG|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
48509995|NCT04928079|PROCEDURE|deep brain stimulation|performing deep brain stimulation if needed
47991476|NCT02587065|DRUG|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
47991477|NCT03559322|DEVICE|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
47991478|NCT00271089|PROCEDURE|PBSC Collection|
47991479|NCT00271089|PROCEDURE|Bone Marrow Harvest|
47991480|NCT00271089|DEVICE|CliniMacs Cell Selection System|
47991481|NCT04665921|DRUG|SGN-STNV|Given into the vein (IV; intravenously)
47991482|NCT01382017|DRUG|Lacosamide|Lacosamide 200 or 400 mg
47991483|NCT01382017|DRUG|Placebo|Placebo
47991484|NCT01382017|DRUG|Carbamazepine|Carbamazepine 600 mg
47991485|NCT06482021|DEVICE|Low-intensity extracorporeal shock wave|Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.
47991486|NCT03872089|OTHER|Infrared Thermography|Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
48509996|NCT04928079|DRUG|Anti-Parkinsonian Drugs|Using anti-parkinsonian drugs if needed
48509997|NCT00073710|DRUG|Zemplar|
48509998|NCT00073710|PROCEDURE|42 Ca carbonate absorption via single tracer method|
48509999|NCT00073710|DRUG|Calcijex|
48510000|NCT05713851|DRUG|Dapagliflozin|dapagliflozin is given for 21 days vs standard of care
48510001|NCT05443568|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
48510002|NCT02123810|OTHER|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
48510003|NCT04693416|OTHER|Intrapersonal Stigma Reduction|Brief intervention for stigma reduction
48510004|NCT04693416|OTHER|Interpersonal Stigma Reduction|Brief intervention for support persons of intrapersonal intervention participants.
48361533|NCT04470349|DEVICE|LITOS|Patients who received a LITOS dynamic distraction system after 31.12.2017
48361534|NCT04470349|DEVICE|Ligamentotaxor|Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
48361535|NCT00266799|DRUG|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
47991487|NCT02123355|DRUG|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
48361536|NCT00266799|DRUG|Capecitabine|capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
48361537|NCT02915133|PROCEDURE|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
48361538|NCT00003874|BIOLOGICAL|monoclonal antibody CD19|
48361539|NCT00003874|BIOLOGICAL|monoclonal antibody CD20|
48361540|NCT00003874|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48361541|NCT05751915|DEVICE|CardioFlux|CardioFlux MCG is a process that observes incremental changes in the heart's electrical activity by the magnetic fields generated by these currents. These magnetic fields have been used for decades via electrocardiogram to help diagnose and treat both acute and chronic cardiac pathology. The CardioFlux device reaches the potential of this phenomenon by sensing a complete magnetic field map. It is equipped with a magnetic shielding chamber and can attenuate magnetic field noise by a factor of nearly 1500 which maximizes signal to noise ratio. CardioFlux is an easy to operate, noninvasive modality that can detect the presence of ischemic cardiac tissue in symptomatic patients in a less than 5-minute scan. The device uses the proprietary software called Faraday which processes MCG scans, create diagnostic functional images, and run analytics.
48361542|NCT02876315|DIETARY_SUPPLEMENT|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
48361543|NCT02876315|DIETARY_SUPPLEMENT|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
48361544|NCT05560412|DIETARY_SUPPLEMENT|Zein nanocapsules|1 g of Zein nanoencapsulated daily
48361545|NCT05560412|DIETARY_SUPPLEMENT|control|1 g of Zein non-encapsulated daily
48361546|NCT02449694|DEVICE|OCS Liver|OCS Liver will be used to preserve the donor liver
48361547|NCT00405795|DEVICE|Envision® Patient Support System|
48510005|NCT06633380|BEHAVIORAL|Standard Physical Activity - Fasted|30 minutes of walking at a self-selected pace that they must have completed 15 minutes prior to consumption of first meal in the morning.
48510006|NCT06633380|BEHAVIORAL|Standard Physical Activity - Post-Meal|30 minutes of walking at a self-selected pace to start 30 minutes after the start of the first meal in the morning.
48510007|NCT06633380|BEHAVIORAL|Dispersed Physical Activity|10 minutes of walking at a self-selected pace to start 30 minutes after the start of each main meal throughout the day (i.e., three bouts total).
48510008|NCT06633380|BEHAVIORAL|Physical Activity Snacks|2 minutes of walking or marching on the spot at a self-selected pace every 30 minutes throughout the day for 7.5 waking hours.
48510009|NCT06633380|BEHAVIORAL|Muscle Strengthening|30 minutes of muscle strengthening exercises targeting the major muscle groups of the whole body, to start 30 minutes after the start of the first meal in the morning.
48510010|NCT00001526|DRUG|Daclizumab (Zenapax)|
48510011|NCT04575311|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
48510012|NCT04575311|OTHER|Placebo|Matching Placebo
47991488|NCT02123355|PROCEDURE|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.
47991489|NCT02123355|DRUG|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
47991490|NCT02123355|DRUG|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
48361548|NCT03356301|DEVICE|Cardiac MRI|Non injected cardiac MRI exam
48361549|NCT03356301|DEVICE|Applanation tonometry|Applanation tonometry and ECG
48361550|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
48510013|NCT01357148|DRUG|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
48510014|NCT04363827|DRUG|Hydroxychloroquine|Hydroxychloroquine
48510015|NCT04015908|DRUG|Celecoxib|Celecoxib 100mg
48510016|NCT04015908|DRUG|Acetaminophen|Acetaminophen 325mg
48510017|NCT04015908|DRUG|Pregabalin|Pregabalin 50 mg
48510018|NCT04015908|DRUG|Oxycodone|oxycodone 5-10 mg
48510019|NCT04015908|DRUG|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
48510020|NCT04683679|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses
48510021|NCT04683679|DRUG|Olaparib|Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.
48149334|NCT03624114|PROCEDURE|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
48149335|NCT00255242|DRUG|Simvastatin treatment for 28 days|40 mg / day
48361551|NCT03679572|PROCEDURE|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
48674761|NCT01213082|DRUG|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
48361552|NCT00946829|DRUG|telmisartan|
48361553|NCT06482086|DRUG|Anlotinib|8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
48361554|NCT06482086|DRUG|Lenvatinib|8/12 mg qd, po.
48361555|NCT06482086|DRUG|Sorafenib|0.4 g bid, po.
48361556|NCT06482086|DRUG|Donafenib|0.3 g bid, po.
48674762|NCT01500317|DRUG|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
48361557|NCT06482086|DRUG|Everolimus|10 mg qd, po.
48361558|NCT06482086|DRUG|Apatinib|500 mg qd, po.
48361559|NCT06482086|DRUG|Dabrafenib + Trametinib|Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
48674763|NCT01500317|DRUG|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
48674764|NCT01500317|DRUG|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
48674765|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (1RDA+CoQ10)|
48674766|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (3RDA)|
48674767|NCT02381964|DIETARY_SUPPLEMENT|Placebo|
48149336|NCT00689637|DRUG|AZD3480|AZD3480 capsules qd, 12 days
48361560|NCT06482086|DRUG|Cabozantinib|Cabozantinib 60mg qd, po.
48361561|NCT06482086|DRUG|Vandetanib|Vandetanib 300mg qd, po.
48361562|NCT06482086|DRUG|Entrectinib|Entrectinib 600mg qd，po.
48361563|NCT06482086|DRUG|Pralsetinib|400mg qd, po.
48361564|NCT06482086|DRUG|Larotrectinib|100mg qd，po
48361565|NCT02475564|DRUG|Placebo|40mg of starch
48361566|NCT02475564|DRUG|Resveratrol|40mg of resveratrol (powder)
48149337|NCT00689637|DRUG|Placebo|Placebo capsules qd, 12 days
48149338|NCT00689637|DRUG|Warfarin|Warfarin: single dose on day 6
48149339|NCT01441336|PROCEDURE|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
48149340|NCT05350709|OTHER|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
48149341|NCT01653925|OTHER|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
48149342|NCT01653925|DRUG|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
48361567|NCT01990339|DRUG|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
48510022|NCT04683679|RADIATION|Radiation|The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
48361568|NCT01853397|DEVICE|Liposonix System (Model 2)|
48361569|NCT04166136|OTHER|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
48361570|NCT04166136|OTHER|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
48510023|NCT00875797|DIETARY_SUPPLEMENT|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
48510024|NCT00875797|DIETARY_SUPPLEMENT|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
48510025|NCT03387566|DRUG|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
48510026|NCT02764151|DRUG|PF-06840003|Daily Oral PF-06840003
48510027|NCT02180737|DRUG|Dexmeditomedine|
48510028|NCT04352868|DEVICE|Intelliwave multifocal, toric, soft contact lens|This is a quarterly disposable, multifocal, toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
48510029|NCT04352868|DEVICE|Intelliwave toric, soft contact lens|This is a quarterly disposable toric soft contact lens commercially available from Art Optical Contact Lens, Inc.
48149343|NCT04765046|DEVICE|Bispectral (BIS™) Complete Monitoring System|The BIS™ Complete Monitoring System is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS technology converts raw EEG data acquired from the frontal cortex into a single number to measure the level of consciousness, called the BIS index. A bilateral sensor is to be placed on the patient's forehead to collect the EEG signals and transmit them back to the system.
47991491|NCT02123355|DRUG|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
48149344|NCT04201275|DRUG|HEC74647PA capsule|Capsule administered orally once daily
47991492|NCT00484939|DRUG|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
48149345|NCT04201275|DRUG|placebo|HEC74647PA capsule matching placebo administered orally once daily
48149346|NCT05557838|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
48149347|NCT05557838|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
48149348|NCT00554814|DRUG|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
48149349|NCT00554814|DRUG|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
48149350|NCT00554814|DRUG|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
48149351|NCT02268253|DRUG|SL-401|
48149352|NCT00537914|DRUG|Omnitrope|All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
48149353|NCT05233904|DIAGNOSTIC_TEST|Diagnostic-CT-enabled Planning|Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease
48149354|NCT05233904|DIAGNOSTIC_TEST|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice
48149355|NCT00966706|DRUG|capecitabine|Given systemically
48149356|NCT00966706|DRUG|cisplatin|Given systemically
48149357|NCT00966706|DRUG|docetaxel|Given systemically
48149358|NCT00966706|DRUG|epirubicin hydrochloride|Given systemically
48149359|NCT00966706|DRUG|gemcitabine hydrochloride|Given systemically
48149360|NCT00332852|DRUG|Letrozole|2.5 mg/day - oraly
48149361|NCT05652114|BEHAVIORAL|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
48149362|NCT03924362|PROCEDURE|PCNL|Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
47991493|NCT00484939|DRUG|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
47991494|NCT01185119|DRUG|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
47991495|NCT06044376|COMBINATION_PRODUCT|Formula milk with triple Bifidobacterium probiotic strain|Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10\^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10\^7 CFU/serving), Bifidobacterium longum subsp. infantis M-63 (6.9 x 10\^7 CFU/serving).
47991496|NCT06044376|OTHER|Formula milk|Formula milk without any addition of probiotic strain
47991497|NCT00070187|BIOLOGICAL|aldesleukin|Given IV
47991498|NCT00070187|BIOLOGICAL|filgrastim|Given IV
48149363|NCT00514670|OTHER|Alcohol-based hand sanitizer & quaternary ammonium wipes|
48149364|NCT04704557|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
48149365|NCT02056379|DRUG|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
48149366|NCT02056379|DRUG|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
48149367|NCT02871726|DEVICE|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy.
48149368|NCT02871726|OTHER|TRUS biopsy|Uronav for prostate biopsy.
48149369|NCT02109172|DRUG|TD-4208|
48510030|NCT02008812|DEVICE|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
48510031|NCT03423186|DRUG|SOBI003|Weekly i.v.infusion
48510032|NCT02029157|DRUG|ARQ197|
48149370|NCT02109172|DRUG|Placebo|
48149371|NCT02418065|OTHER|training on ergonomic bicycle|
48149372|NCT02418065|DRUG|Testosterone|
48149373|NCT02418065|DRUG|Oral nutritional supplementation|
48149374|NCT02418065|DRUG|n3 polyunsaturated fatty acid|
48510033|NCT02029157|DRUG|Placebo|
48361571|NCT04166136|OTHER|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
48361572|NCT02297620|DRUG|Suglat®|oral
48149375|NCT01728857|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
48149376|NCT01581320|DRUG|Test group|Once a month, administration of DP-R206 \& placebo for 16 weeks
48149377|NCT01581320|DRUG|Reference group|Once a month, administration of Bonviva \& placebo for 16 weeks
48674768|NCT04256239|BEHAVIORAL|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
48361573|NCT00483600|DRUG|fondaparinux|injections of 2.5mg every other day for 4 weeks
48361574|NCT05146531|DEVICE|McCoy laryngoscope|Patients scheduled for general anesthesia were intubated with McCoy laryngoscope.
48361575|NCT05146531|DEVICE|C-MAC D-blade video laryngoscope|Patients scheduled for general anesthesia were intubated with C-MAC D-blade video laryngoscope.
48361576|NCT04515849|DRUG|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
48361577|NCT04515849|DRUG|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
48361578|NCT04515849|DRUG|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
48361579|NCT04515849|DRUG|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
48361580|NCT04515849|DRUG|Placebo|Placebo administered subcutaneously
48674769|NCT01836289|DRUG|High-dose Cyclophosphamide|
48674770|NCT02311803|PROCEDURE|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
48674771|NCT02311803|PROCEDURE|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
48674772|NCT00718536|DRUG|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
48149378|NCT06285578|DIETARY_SUPPLEMENT|Probiotics supplementation|Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.
48149379|NCT06285578|BEHAVIORAL|HIIT training|HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.
48149380|NCT06285578|DIETARY_SUPPLEMENT|Placebo supplementation|Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
48361581|NCT01482338|DRUG|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
48510034|NCT01085357|PROCEDURE|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
48149381|NCT00000250|DRUG|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
48149382|NCT00000250|DRUG|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
48149383|NCT00103857|DRUG|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
48510035|NCT01085357|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
48510036|NCT02977897|DRUG|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
48510037|NCT01061268|DRUG|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
48510038|NCT01061268|DRUG|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
48510039|NCT02108093|PROCEDURE|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
48510040|NCT01093092|DIETARY_SUPPLEMENT|Calcitriol|Given PO
48510041|NCT01093092|DRUG|Cisplatin|Given IV
48510042|NCT01093092|DRUG|Gemcitabine Hydrochloride|Given IV
48510043|NCT01093092|OTHER|Pharmacological Study|Correlative studies
48510044|NCT00464438|DRUG|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
48510045|NCT00464438|DRUG|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
48361582|NCT01482338|DRUG|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
48361583|NCT02764931|OTHER|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
48361584|NCT02940158|OTHER|1/4 cup- Small red lentil|
48361585|NCT02940158|OTHER|1/4 cup- Small green lentil|
47991499|NCT00070187|BIOLOGICAL|recombinant interferon gamma|Given IV
47991500|NCT00070187|DRUG|carmustine|Given IV
47991501|NCT00070187|DRUG|cyclosporine|Given IV
47991502|NCT00070187|DRUG|cytarabine|Given IV
48149384|NCT00103857|DRUG|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
48149385|NCT00103857|DRUG|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
48149386|NCT00103857|DRUG|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
48149387|NCT00103857|DRUG|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
48149388|NCT00103857|DRUG|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
48149389|NCT02008214|DRUG|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
48149390|NCT02008214|DRUG|Placebo|Placebo matching pentoxifylline dosage
48149391|NCT05396573|BIOLOGICAL|RQ3013|A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL
48149392|NCT05396573|BIOLOGICAL|Comirnaty|A single dose of 30 μg/0.3 mL
48361586|NCT02940158|OTHER|1/4 cup- corn|
48361587|NCT02940158|OTHER|1/4 cup- macaroni|
48361588|NCT02940158|OTHER|1/4 cup- white potato|
48361589|NCT02940158|OTHER|1/4 cup- white rice|
48361590|NCT02940158|OTHER|1/2 cup- small red lentil|
48361591|NCT02940158|OTHER|1/2 cup- small green lentil|
48361592|NCT02940158|OTHER|1/2 cup- corn|
48361593|NCT02940158|OTHER|1/2 cup- macaroni|
48361594|NCT02940158|OTHER|1/2 cup- white potato|
48361595|NCT02940158|OTHER|1/2 cup- white rice|
48361596|NCT02561273|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
48361597|NCT02561273|DRUG|Cyclophosphamide|Given IV
48361598|NCT02561273|DRUG|Doxorubicin Hydrochloride|Given IV
48361599|NCT02561273|DRUG|Etoposide|Given IV
48361600|NCT02561273|OTHER|Laboratory Biomarker Analysis|Correlative studies
47991503|NCT00070187|DRUG|etoposide|Given IV
47991504|NCT00070187|DRUG|melphalan|Given IV
47991505|NCT00070187|PROCEDURE|autologous bone marrow transplantation|
47991506|NCT00070187|PROCEDURE|bone marrow ablation with stem cell support|
47991507|NCT00070187|PROCEDURE|peripheral blood stem cell transplantation|
47991508|NCT05577585|DRUG|Ketamine 50 MG/ML|See also Arm description
47991509|NCT05577585|DRUG|Midazolam|See also Arm description
47991510|NCT05577585|DRUG|Ketamine 50 MG/ML|Open Label Follow Up (up to 8 Infusions)
47991511|NCT04142021|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Surgery planning done based solely on coronary computed tomography angiography.
47991512|NCT05028439|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
48361601|NCT02561273|DRUG|Lenalidomide|Given PO
48361602|NCT02561273|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
48361603|NCT02561273|DRUG|Prednisone|Given PO
48361604|NCT02561273|DRUG|Vincristine Sulfate|Given IV
48361605|NCT05814406|DRUG|JW0201|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
48510046|NCT01686230|OTHER|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
48510047|NCT01686230|DRUG|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
48510048|NCT06107803|DRUG|Roluperidone 64 mg|64 mg/day oral
48510049|NCT06107803|DRUG|Olanzapine 10 MG|10 mg/day oral
48361606|NCT05814406|DRUG|Placebo|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
48361607|NCT02142075|DRUG|Daptomycin|
48361608|NCT00000175|DRUG|Estrogen|
48674773|NCT02739958|DRUG|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
48361609|NCT00000175|DRUG|Testosterone|
48361610|NCT02139709|DIETARY_SUPPLEMENT|Ganglioside|
48674774|NCT02739958|DRUG|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
48674775|NCT03333694|DRUG|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
48361611|NCT02139709|DIETARY_SUPPLEMENT|Placebo|
48361612|NCT00967343|BIOLOGICAL|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
48361613|NCT03647059|DIAGNOSTIC_TEST|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
48674776|NCT03333694|DRUG|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
48674777|NCT03842046|PROCEDURE|phenylephrine infusion|In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
48674778|NCT03842046|PROCEDURE|norepinephrine infusion|In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
48674779|NCT01544348|OTHER|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
48361614|NCT01924793|DRUG|DAS181-F02 Dry Powder in Bulk|Administered via DPI
48510050|NCT01453179|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
48510051|NCT01453179|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
48510052|NCT01180426|DRUG|CHR-2797|120mg once daily oral for 48 weeks
48510053|NCT04392427|DRUG|Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :|"Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days"
48510054|NCT04935229|DRUG|SD-101|SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device
48674780|NCT01544348|BIOLOGICAL|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
48674781|NCT01544348|BIOLOGICAL|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
48674782|NCT01544348|BIOLOGICAL|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
48674783|NCT01544348|BIOLOGICAL|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
48361615|NCT01924793|DRUG|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
48361616|NCT01985152|DRUG|Azilsartan Trimethylethanolamine|
48361617|NCT01985152|DRUG|Placebo|
48361618|NCT03061617|OTHER|VCV mode|set fixed 6ml/kg tide volume
48361619|NCT03061617|OTHER|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
48361620|NCT03757026|OTHER|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
48149393|NCT00975078|PROCEDURE|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
48149394|NCT00975078|DRUG|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
48149395|NCT01555892|BIOLOGICAL|EBV-specific T cells: A|Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
48149396|NCT01555892|BIOLOGICAL|EBV-specific T cells: B|Dose Level 3: 1 x 10\^8 cells/m2 + 2 x 10\^8 cells/m2
48149397|NCT00046488|DRUG|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
48149398|NCT02064335|BEHAVIORAL|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
48510055|NCT04935229|BIOLOGICAL|Nivolumab|During Cohort B, nivolumab will be administered together with SD-101 and during Cohort C, it will be administered with ipilimumab and SD-101
48510056|NCT04935229|BIOLOGICAL|Ipilimumab|During Cohort C, ipilimumab will be administered together with nivolumab and SD-101
48149399|NCT00391651|DRUG|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
48149400|NCT00391651|DRUG|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
48510057|NCT04935229|BIOLOGICAL|Nivolumab and Relatlimab|During optional Cohort C1, nivolumab and relatlimab will be administered with SD-101
48674784|NCT01544348|BIOLOGICAL|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
48149401|NCT05771285|OTHER|Cold application|To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
48361621|NCT03757026|OTHER|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
48674785|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
48674786|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
48510058|NCT05966662|DEVICE|IVL with Shockwave C2+ 2Hz Coronary IVL Catheter|Lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
48510059|NCT03245112|DRUG|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
48149402|NCT01929616|DRUG|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
48149403|NCT05107453|DRUG|Levobupivacaine|"The Investigational Medical Product (IMP) is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
48510060|NCT00187993|DRUG|Growth hormone|
48510061|NCT06163391|DRUG|SOT201|intravenous infusion
48510062|NCT05489666|DIETARY_SUPPLEMENT|Nature Made Vitamin D3 5,000 IU, 125mcg|Taking a 5,000 IU oral supplement of Vitamin D3, daily, for 8 weeks, may improve strength performance in women who have and are continuing a resistance trained workout regimen. After blood vitamin D levels have been raised to an optimal range, a lower dosage may be assigned as needed from 5,000 IU per day to 1,000-2,000 IU per day.
48510063|NCT05489666|DIETARY_SUPPLEMENT|Placebo|Resistance trained women may not improve their strength performance with low levels of vitamin D in the blood.
48149404|NCT04048226|DRUG|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
48149405|NCT04048226|DRUG|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
48149406|NCT04577599|OTHER|Mobile Low-dose Computed Tomography (LDCT) Screening|Low Dose CT Scan of the Chest
48149407|NCT03964272|DEVICE|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
48149408|NCT05588297|DRUG|CapOx(Capecitabine+ Oxaliplatin)|CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
48149409|NCT05588297|DRUG|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
48510064|NCT04554940|BIOLOGICAL|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
48361622|NCT03757026|OTHER|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
48361623|NCT04022109|DEVICE|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
48361624|NCT04022109|PROCEDURE|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
48361625|NCT04022109|DIAGNOSTIC_TEST|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
48361626|NCT04022109|DIAGNOSTIC_TEST|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
48361627|NCT03508206|DIETARY_SUPPLEMENT|SBRP|SBRP capsules
48361628|NCT03508206|DIETARY_SUPPLEMENT|PLACEBO|Placebo capsules
48361629|NCT06332274|DRUG|Tislelizumab|"Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
48361630|NCT06332274|OTHER|Blood sampling|Blood sampling for analyses of MRD (Molecular Residual Disease)
48361631|NCT06332274|DRUG|Placebo|"Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
48149410|NCT05588297|DRUG|Nivolumab|Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
48510065|NCT06355102|OTHER|Conventional treatment and care|Conventional treatment and care
48510066|NCT06129305|OTHER|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography|Comparison of the distance of the Erector Spina muscle from the skin at different thoracal levels and different posıtıons under ultrasonography
48674787|NCT01035502|DRUG|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
48510067|NCT01761760|BEHAVIORAL|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
48674788|NCT01273571|DRUG|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
48674789|NCT05407805|OTHER|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
48674790|NCT02099825|DRUG|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
48674791|NCT03479489|OTHER|Human dehydrated amnion chorion allograft|Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
48674792|NCT03569943|DEVICE|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
48674793|NCT02529683|DRUG|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
47991513|NCT05028439|DRUG|Chemotherapy drug|Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
47991514|NCT00803868|DRUG|varenicline|up to 1mg po bid for 9 weeks
47991515|NCT00803868|DRUG|placebo|placebo matching study drug up to 1mg po bid
47991516|NCT00734279|DRUG|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
47991517|NCT00734279|DRUG|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
47991518|NCT00734279|DRUG|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
47991519|NCT00734279|DRUG|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
47991520|NCT02064166|DRUG|Intranasal Insulin|"1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks."
47991521|NCT03384550|BEHAVIORAL|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
48149411|NCT03662698|BEHAVIORAL|Guided Imagery|GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
48510068|NCT01902225|DRUG|Istodax|
48510069|NCT01902225|DRUG|Doxil|
48510070|NCT05608473|OTHER|Posture Exercises|A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
48510071|NCT02032797|DRUG|Progesterone|
48510072|NCT00811928|DRUG|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
48674794|NCT06299592|COMBINATION_PRODUCT|PET/MRI using [18F]FEPPA tracer|PET/MRI scans with \[18F\]FEPPA radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia
48674795|NCT05670327|OTHER|Diaphragmatic ultrasound assessment|TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters
48361632|NCT04759391|OTHER|Exercise|Pelvic floor muscle training program planned under the supervision of a physiotherapist was applied and followed to the exercise group, using the digital application.
48361633|NCT04759391|OTHER|Lifestyle recommendations|Information was given within the scope of lifestyle recommendations (fluid intake, diet, constipation, weight control, smoking related to lower urinary system symptoms
48361634|NCT02985385|OTHER|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
48361635|NCT05151549|DRUG|Camrelizumab|200mg/3weeks
48361636|NCT05151549|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
48674796|NCT00143559|DRUG|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
48361637|NCT02908815|DEVICE|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
48361638|NCT02908815|DEVICE|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
48361639|NCT00303290|DRUG|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
47991522|NCT03384550|BEHAVIORAL|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
48361640|NCT00303290|DRUG|Ara-C (cytosine arabinoside)|10 mg under the skin daily
48361641|NCT00391443|DRUG|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)
48361642|NCT00391443|DRUG|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
48361643|NCT02804386|DRUG|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
48361644|NCT01926366|DRUG|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
48361645|NCT01926366|DRUG|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
48361646|NCT00003649|BIOLOGICAL|Ad5CMV-p53 gene|
48361647|NCT04622878|PROCEDURE|thrombectomy and PTA|open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
48361648|NCT01809158|DRUG|minocycline|
48361649|NCT01809158|DRUG|placebo|
48361650|NCT05563441|PROCEDURE|laparoscopic surgery|Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
48361651|NCT00723515|DRUG|sodium fluoride|sodium fluoride 5%
48361652|NCT00723515|DRUG|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
48361653|NCT06496698|PROCEDURE|Simple Interrupted Suture|In the control group, simple interrupted sutures will be used for wound closure after surgical repair of ankle fractures.
48510073|NCT00811928|DRUG|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)"
48510074|NCT06633289|OTHER|Experimental formula|New hydrolyzed rice protein-based formula
48674797|NCT00143559|PROCEDURE|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
48674798|NCT00143559|DEVICE|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
48674799|NCT02459561|DEVICE|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
48674800|NCT02459561|OTHER|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
48361654|NCT06496698|PROCEDURE|Subcuticular Suture|In the experimental group, subcuticular sutures will be used for wound closure after surgical repair of ankle fractures.
48361655|NCT03369340|OTHER|P3P 1|2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
48361656|NCT03369340|OTHER|P3P 2|2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
48361657|NCT03369340|OTHER|P3P 3|1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
48361658|NCT03369340|OTHER|P3P 4|2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
48361659|NCT04079322|OTHER|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
48510075|NCT06633289|OTHER|Control formula|Commercially available amino acid-based formula.
48510076|NCT00735618|OTHER|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
48674801|NCT04824014|DIAGNOSTIC_TEST|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
48674802|NCT01866748|DRUG|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
48361660|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
48361661|NCT03807336|BEHAVIORAL|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
48361662|NCT03969589|BEHAVIORAL|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
48361663|NCT03969589|OTHER|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
48361664|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
48361665|NCT01584115|BIOLOGICAL|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
48361666|NCT04528433|BEHAVIORAL|Medical-education-community Collaborated Intervention|The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
48361667|NCT04528433|BEHAVIORAL|routine clinical care|Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
48361668|NCT04369742|DRUG|Hydroxychloroquine (HCQ)|HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)
48361669|NCT04369742|DRUG|Placebo: Calcium citrate|Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
48674803|NCT01866748|DRUG|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
47991523|NCT03384550|BEHAVIORAL|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
47991524|NCT03384550|BEHAVIORAL|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
47991525|NCT03136003|DRUG|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
48149412|NCT03662698|OTHER|Treatment as Usual|This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
48149413|NCT03370588|DRUG|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
48149414|NCT03370588|DRUG|Normal saline|Group B: Saline infusion during same time period.
48149415|NCT04222400|DIAGNOSTIC_TEST|Frailty Assessment|Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
48149416|NCT04349709|BEHAVIORAL|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus \& Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
48149417|NCT04251845|DIETARY_SUPPLEMENT|topical melatonin|Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
48149418|NCT04251845|OTHER|PLACEBO|Topical application of placebo once daily for 6 weeks with a follow up for 3 months
48149419|NCT05466760|RADIATION|PET/MR|Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
48361670|NCT05389865|PROCEDURE|Surgery on the proximal aorta (aortic root +/- ascending aorta)|Surgery involving replacing, repairing or reinforcing the proximal aorta (root and ascending aorta)
48149420|NCT05860894|DEVICE|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
48149421|NCT05624814|DEVICE|Spinal Cord Stimulation|Spinal Cord Stimulation consists of the transcutaneous or surgical implantation of different types of electrodes in the epidural space; electrodes are then connected to an Implanted Pulse Generator that generates stimulating currents.
48361671|NCT05389865|OTHER|Patients diagnosed with thoracic aortopathy but not operated upon|Radiological size criteria or Genetic mutations associated with aortopathies
48361672|NCT00702949|DRUG|pregabalin|Given orally
48361673|NCT00702949|OTHER|placebo|Given orally
48361674|NCT03033290|DRUG|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
48674804|NCT01866748|DRUG|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
48149422|NCT05624814|OTHER|Standard therapies|Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
48149423|NCT04292795|DEVICE|Therapeutic Ultrasound|The Intervention will be provided according to the set protocols used in previous literature.
48149424|NCT04292795|DEVICE|Short wave diathermy|The Intervention will be provided according to the set protocols used in previous literature.
48149425|NCT05947071|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
48149426|NCT05947071|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
48510077|NCT00641225|DRUG|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
48149427|NCT00600366|DRUG|biphasic insulin aspart|
48149428|NCT00547326|PROCEDURE|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
48361675|NCT03033290|DRUG|placebo|placebo control
48361676|NCT00133640|DRUG|cholecalciferol|
48674805|NCT01866748|DRUG|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
48674806|NCT05123300|DIAGNOSTIC_TEST|18F-PSMA-1007|18F-PSMA-1007 is a tracer for a PET/CT. Prostate cancer often has marked uptake of PSMA, hence PSMA-PET/CT is in the guidelines in the European Union for detecting relapse. But we will use it for staging primary prostate cancer.
47991526|NCT03136003|BEHAVIORAL|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
47991527|NCT04123288|DRUG|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
48361677|NCT00133640|BEHAVIORAL|Physiotherapy|
48361678|NCT04930133|DRUG|Gilotrif|This is non-interventional, multi-center, multi-cohort study based on existing data from EGFR sensitizing mutation-positive NSCLC patients treated with afatinib as the first-line treatment. Enrolled patients will be categorized into four cohorts (cohort A, B, C and D) according to the type of second line treatment with biopsy results before start of second line treatment.
48361679|NCT03026556|DRUG|Dabigatran vs. Rivaroxaban|observed for 6 years
48361680|NCT03026556|DRUG|Dabigatran vs. Apixaban|Observed for 6 years
48674807|NCT01539447|DRUG|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
48674808|NCT01539447|DRUG|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
48674809|NCT01381367|BIOLOGICAL|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
48149429|NCT00547326|PROCEDURE|Treatment with placebo|Treatment with placebo
48149430|NCT05164926|OTHER|perineal massage with St. John's Wort oil|perineal massage with St. John's Wort oil during labor
48149431|NCT01371227|DRUG|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
48149432|NCT00016042|BIOLOGICAL|lymphokine-activated killer cells|
48149433|NCT00016042|BIOLOGICAL|recombinant interferon alfa|
48149434|NCT00016042|BIOLOGICAL|sargramostim|
48149435|NCT00016042|DRUG|fluorouracil|
48149436|NCT04024709|PROCEDURE|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
48149437|NCT02727998|DRUG|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
48149438|NCT02727998|DRUG|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
48149439|NCT01848132|DRUG|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
48149440|NCT01848132|DRUG|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
48149441|NCT01848132|DRUG|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
48361681|NCT02245295|PROCEDURE|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
48361682|NCT02245295|PROCEDURE|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
48510078|NCT01507766|DRUG|early enteral nutrition|The enteral nutrition was started within 48h after admission
48510079|NCT01507766|DRUG|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
48510080|NCT02466841|PROCEDURE|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
48510081|NCT04284540|RADIATION|Adjuvant hypofractionation|15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.
48674810|NCT01381367|DRUG|Normal Saline|normal saline, 0.5ml given subcutaneously
48674811|NCT02057926|DRUG|The effect of tetracycline in degradation and permeability of collagen membranes.|
48674812|NCT02611102|DIETARY_SUPPLEMENT|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
48674813|NCT03986125|BEHAVIORAL|Emotional Awareness & Expression Therapy|emotion-focused
48674814|NCT03986125|BEHAVIORAL|Mindfulness Meditation Training|meditation training and practice
48149442|NCT01848132|DRUG|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
48361683|NCT00890851|PROCEDURE|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
48361684|NCT03519815|DEVICE|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
48361685|NCT03519815|DEVICE|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
47991528|NCT04123288|DRUG|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
47991529|NCT03022344|RADIATION|Cardiac CT|
47991530|NCT05953454|OTHER|Pain neuroscience Education|A pain neuroscience education session geared towards fear-avoidance beliefs
47991531|NCT01907672|PROCEDURE|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
47991532|NCT05317533|PROCEDURE|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
47991533|NCT01271920|DRUG|AUY922|
47991534|NCT01271920|DRUG|Trastuzumab|
48149443|NCT01848132|DRUG|Prednisone|Prednisone: oral, 100 mg, days 1-5
48149444|NCT01848132|DRUG|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
48510082|NCT04284540|RADIATION|Definitive Hypofractionation|15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
48510083|NCT05071976|DIAGNOSTIC_TEST|ICG-NIR angiography|Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
48510084|NCT00551018|DRUG|Vicriviroc|one 30 mg tablet QD
48510085|NCT00551018|DRUG|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
48510086|NCT05980572|DRUG|Glenohumeral joint and subacromial space triamcinolone injections|"All patients will receive both glenohumeral joint and subacromial space injections. The injections will consist of a solution containing 1 ml of 40 mg/ml triamcinolone acetonide and 1 ml of 1% lidocaine in each site. The glenohumeral joint injection will be performed blindly using an anterior approach. The needle will be inserted medially to the head of the humerus, located approximately 1 cm lateral to the coracoid process, and directed posteriorly at a slight superior and lateral angle.~Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds."
48674815|NCT04301323|DRUG|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
48674816|NCT04301323|DRUG|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
48674817|NCT04301323|DRUG|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
47991535|NCT05127889|DRUG|curodont|"* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
47991536|NCT02197507|DEVICE|Digitized sensor|Measure of grip strength of the dominant hand
47991537|NCT01003509|PROCEDURE|modified shouldice and double|one arm modified shouldice, other one is double repair
47991538|NCT03491995|DRUG|Quadruple therapy|Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
47991539|NCT03491995|DRUG|Classic treatment|Omeprazole, amoxycillin, clarithromycin
47991540|NCT03169582|DRUG|Avanafil|Drug administration (Avanafil)
48149445|NCT05060406|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
48149446|NCT00116233|DEVICE|REPEL-CV|
48149447|NCT04347889|DRUG|Hydroxychloroquine|Oral loading dose followed by once weekly dosing
48361686|NCT01281592|DRUG|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
48361687|NCT00422955|DRUG|rosiglitazone|
48361688|NCT02251574|OTHER|Low Calorie Diet|Weight management program designed around a low calorie diet.
48674818|NCT05582681|DIAGNOSTIC_TEST|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
48674819|NCT05582681|OTHER|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
48674820|NCT05582681|DRUG|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
48361689|NCT02251574|OTHER|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
48361690|NCT02251574|OTHER|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
48149448|NCT04347889|OTHER|Vitamin C|Once daily vitamin C 1 gm
48149449|NCT01691404|DIETARY_SUPPLEMENT|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
48361691|NCT01741285|DRUG|Beclomethasone (QVAR)|Small particle treatment
48361692|NCT01741285|DRUG|Beclomethasone (Clenil)|Course particle beclomethasone
48361693|NCT01741285|DRUG|Fluticasone|Course particle treatment
48361694|NCT03206190|OTHER|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
48361695|NCT03206190|BEHAVIORAL|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
48361696|NCT03206190|DIAGNOSTIC_TEST|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
47991541|NCT03169582|DRUG|Sildenafil|Drug administration (Sildenafil)
47991542|NCT04052048|DIAGNOSTIC_TEST|Subtraction Normalized Expression of Phagocytes Blood Test|Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness
48149450|NCT01691404|DIETARY_SUPPLEMENT|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
48149451|NCT01691404|DIETARY_SUPPLEMENT|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
48361697|NCT03206190|DIAGNOSTIC_TEST|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
48361698|NCT03206190|DIAGNOSTIC_TEST|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
48149452|NCT02090478|OTHER|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
48149453|NCT02090478|OTHER|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
48361699|NCT03206190|DIAGNOSTIC_TEST|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
48361700|NCT03206190|DIAGNOSTIC_TEST|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
48674821|NCT00602524|DRUG|Pilocarpine|
48674822|NCT05295264|OTHER|Moderate exercise program|"Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy."
48674823|NCT04817202|DRUG|hzVSF-v13 (intravenous, single dose)|Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)
47991543|NCT03873389|DRUG|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
47991544|NCT03209427|DRUG|Morphine 100 μg|Intrathecal injection of morphine100 μg
47991545|NCT03209427|DRUG|Morphine 200 μg|Intrathecal injection of morphine 200 μg
47991546|NCT04349488|DEVICE|Anodal Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
47991547|NCT00621894|DRUG|LGD-4665|LGD-4665 Thrombopoietin mimetic
47991548|NCT00621894|DRUG|Placebo|Placebo
47991549|NCT00547742|PROCEDURE|PET/CT Scan|
48149454|NCT00977678|OTHER|open access gastroscopy|access to gastroscopy without preceding appointment
48149455|NCT00977678|OTHER|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
48149456|NCT04344886|PROCEDURE|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
48149457|NCT04344886|PROCEDURE|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
48361701|NCT05855382|OTHER|Persistent COVID-19|To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
48361702|NCT02122302|DEVICE|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
48361703|NCT04974853|COMBINATION_PRODUCT|Cardio-complement|Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
48361704|NCT06043895|DEVICE|EpiFaith CV|The conducting physician will localize the central vein using EpiFaith CV and assess if there is arterial puncture.
48674824|NCT04817202|DRUG|hzVSF-v13 (subcutaneous, single dose)|Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
48674825|NCT04817202|DRUG|hzVSF-v13 (intravenous, multiple dose)|Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
48510087|NCT05980572|DEVICE|App-assisted exercise|Patients will be educated on how to perform the 7 sets of frozen shoulder exercise. Subjects will be advised to perform all the exercises to a point that they may feel tightness but not painful and hold to the point for 2-3 seconds. Then the APP group will suggest performing the exercise from APP education The APP intervention group will be guided through the exercises using the mobile app, while the conventional group will be provided with a printed pamphlet illustrating the exercises.. Each set exercise will have 10 repetitions and investigators recommend 4 sessions per day.
48149458|NCT04344886|PROCEDURE|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
48149459|NCT04344886|PROCEDURE|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
48510088|NCT05980572|DRUG|Nonsteroidal anti-inflammatory drugs (aceclofenac)|All patients will be prescribed two weeks of nonsteroidal anti-inflammatory drugs (aceclofenac) .
48674826|NCT04817202|DRUG|Placebo (intravenous, single dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)
48149460|NCT05763732|BEHAVIORAL|Rhythmic Auditory Stimulation (RAS)|"Rhythmic auditory stimulus (RAS) is a Neurologic Music Therapy (NMT) technique that utilizes an auditory rhythmic cue to entrain gait to a specific rhythm.~RAS, as an anticipatory time cue, can be used as both an immediate entrainment stimulus, providing rhythmic cues during movement, and as a facilitating stimulus for planning and executing a movement to achieve more functional gait patterns. Cadence, gait velocity, and stride length are the commonly used parameters to monitor changes in a patient's gait."
48149461|NCT05776134|BIOLOGICAL|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
48149462|NCT04636515|DRUG|F520|200mg，Q3W
48149463|NCT02395692|OTHER|Treatment|Correlative studies
48149464|NCT02395692|DRUG|Methoxyamine|Given PO
48149465|NCT02395692|DRUG|Temozolomide|Given PO
48149466|NCT05052398|DRUG|PSP NEURO SERUM|PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.
48674827|NCT04817202|DRUG|Placebo (subcutaneous, single dose)|Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
48149467|NCT05052398|DRUG|Placebo PSP NEURO SERUM|Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
48149468|NCT01945086|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
48149469|NCT01945086|DRUG|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
48149470|NCT01945086|OTHER|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
48149471|NCT02472808|OTHER|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
48149472|NCT02472808|OTHER|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
48674828|NCT04817202|DRUG|Placebo (intravenous, multiple dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
47991550|NCT00547742|PROCEDURE|phlebotomy|
48149473|NCT02472808|OTHER|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
48149474|NCT02472808|OTHER|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
48149475|NCT01074528|BEHAVIORAL|mindfulness based stress reduction program|8-week mindfulness training program
48149476|NCT05902572|OTHER|No intervention|Observational data collection only.
48510089|NCT06235684|OTHER|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion|During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
48510090|NCT01051947|DRUG|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
47991551|NCT02984033|RADIATION|Head and Neck patients|Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
48361705|NCT06043895|DEVICE|Conventional|The conducting physician will localize the central vein using Raulerson syringe and assess if there is arterial puncture.
48510091|NCT01051947|DRUG|Metoprolol|dosage prescribed prior to starting on study
48510092|NCT05439083|BIOLOGICAL|9-valent HPV vaccine|All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
48361706|NCT01999205|BEHAVIORAL|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
48510093|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention + IVR booster calls|1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
48510094|NCT01125371|BEHAVIORAL|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
48510095|NCT01125371|BEHAVIORAL|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
48674829|NCT02479880|DRUG|Tenofovir DF|300 mg tablet administered orally once daily for up to 96 weeks
48674830|NCT02479880|RADIATION|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
48674831|NCT01732991|DEVICE|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
48674832|NCT05086861|DEVICE|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
47991552|NCT04623918|OTHER|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
47991553|NCT04623918|OTHER|Control rice|Control rice (C4), identical in appearance
47991554|NCT01948817|DRUG|Deferasirox|Deferasirox 20mg/kg taken BID
47991555|NCT00303498|DRUG|Sitexsentin sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
47991556|NCT00303498|DRUG|Placebo|placebo identical to the study drug in description, dose and duration
48510096|NCT03237507|DRUG|S-1|40-60mg/m\^2 bid, days 1-14, oral，every 3 weeks.
48510097|NCT03237507|DRUG|oxaliplatin|100mg/m\^2 days 1，intravenous infusion, every 3 weeks.
48510098|NCT03237507|DEVICE|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
47991557|NCT02729974|PROCEDURE|ROTEM|rapid testing of blood clot formation
47991558|NCT02729974|PROCEDURE|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
47991559|NCT02083731|BIOLOGICAL|MSCs|
47991560|NCT05569850|OTHER|Brushing|Brushing the teeth 2x a day for 4 weeks.
47991561|NCT05196009|BEHAVIORAL|mHealth peer navigation and social support|Peer navigation, asynchronous support via SMS, Motivational Interviewing, virtual social support group focused on mental health and substance use, linkage and follow-up
47991562|NCT05133219|OTHER|Occupational Therapy|Occupational therapy is the only profession that helps people across the lifespan to do the things they want and need to do through the therapeutic use of daily activities (occupations). Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent-or live better with-injury, illness, or disability.
47991563|NCT06067542|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
48361707|NCT05870891|OTHER|Food|Food
48361708|NCT03474380|BEHAVIORAL|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
48510099|NCT03237507|DRUG|Paclitaxel|intraperitoneal perfusion
48510100|NCT00822978|DRUG|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
48510101|NCT03484546|PROCEDURE|laparoscopic endometrioma cyst excision|laparoscopic resection of ovarian endometrioma
48510102|NCT04094727|DRUG|Presumptive treatment with Artemether-lumefantrine (AL)|All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
48149477|NCT01839032|DRUG|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
48149478|NCT04937309|DEVICE|non invasive auricular vagal stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
48149479|NCT04937309|DRUG|usual medical treatment|Standard anti emetic treatments to prevent emesis due to chemotherapy
48149480|NCT04937309|DEVICE|sham stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
48149481|NCT06506279|DEVICE|CorTec Brain Interchange (BIC) System|Surgical implantation of the BIC System. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients.
48149482|NCT02097316|DEVICE|JewelPump|
48149483|NCT02097316|DEVICE|usual insulin pump|
48149484|NCT06341504|BEHAVIORAL|Prevention pop-up messages|"Messages are shown full screen on the EGM's play screen on a fixed presentation schedule. Clock of the gambling session starts the first time the participant puts money in the EGM. From this event, messages are shown at those timepoints: \[1\] +10 minutes; \[2\] +40 minutes; \[3\] +70 minutes; \[4\] +100 minutes. Messages block the screen for 15 seconds before automatically closing. Up to 4 different messages are presented during the gambling session. Order is determined by sortition without replacement.~Messages have a warning heading Caution!. Content is, from top to bottom: (a) time spent gambling from beginning; (b) warning that gambling could lead to serious monetary loss; (c) 1 of 4 self-appraisal phrases about current gambling behaviour; (d) advice to the participant that a break could help choose what is best for them; (e) countdown before the message closes itself; (f) Health department logo is shown in the lower right corner as a more neutral endorsement of the messages."
48674833|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
48149485|NCT06341504|BEHAVIORAL|Mandatory time limit|Activated either when (a) the previous time limit is up; or (b) the player bank meter reaches $0. When the previous time limit is up, a pop-up takes up the upper third of the play screen and requires the player to set a new time limit using one of five choice buttons (four firsts buttons: 15, 30, 45 or 60 minutes; fifth button: cash out, which prints a receipt and ends the gambling session). As the EGM cannot track who is playing, there are no limits on consecutive gambling sessions. When the player's bank meter reaches $0, the the pop-up described above appears as soon as new money is inserted in the EGM, no matter if the previous time limit is up or not.
48149486|NCT06341504|BEHAVIORAL|Responsible gambling information|Located in a submenu accessed through a button on the main touch screen. This open a window which contains basic information on randomness and responsible gambling advice. The information is presented in small white font on a black background.
48149487|NCT06341504|DEVICE|Electronic gambling machine (model IGT GL20)|"EGM model currently in use in Quebec, Canada, the location where this study is conducted. The EGMs used in this study are fully functional and unaltered except for the presentation of prevention pop-up messages in the experimental arm of this study. These machines are equipped with basics responsible gambling features, the two main ones described in this section (i.e. Mandatory time limit; Responsible gambling information). Wins/losses sequence is fully randomized and not determined beforehand."
48149488|NCT06341504|DEVICE|Square terminal|This terminal allows for buying non-alcoholic beverages (soft drinks or coffee) and chips during the experimentation. This is done to enhance the realism of the bar setting. It also allows for real cash withdrawal from bank account during gambling session. Quebec's code of conduct for EGMs commercialization prohibits retailers from having an ATM near their EGMs, and prohibits them from lending money to consumers or withdrawing cash for them to gamble. However, this rule is not always followed in practice. For this study, participants will be allowed to withdraw from their bank account, at the bar counter, if they ask for it. However, this will not be offered to them upfront.
48149489|NCT00113529|DRUG|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
48674834|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
48149490|NCT03584282|BEHAVIORAL|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
48149491|NCT03584282|BEHAVIORAL|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
48149492|NCT01662232|DIETARY_SUPPLEMENT|Green tea beverage|
48149493|NCT01662232|DIETARY_SUPPLEMENT|Green tea extract|
48149494|NCT01662232|DIETARY_SUPPLEMENT|EGCG|
48149495|NCT01662232|OTHER|Placebo|
47991564|NCT02276729|OTHER|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
47991565|NCT00891722|OTHER|biologic sample preservation procedure|
48149496|NCT04671251|DRUG|AEVI-007|50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
48149497|NCT00936065|DRUG|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
48510103|NCT04094727|OTHER|Enhanced vector control|"The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round."
48149498|NCT00936065|DRUG|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
48149499|NCT00936065|DRUG|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
48149500|NCT05939830|PROCEDURE|Stained region Lymph Node Biopsy (SrLNB)|Before NST, positive lymph nodes would be marked with localized titanium clips under ultrasound guidance, and carbon nanoparticles suspension would be injected into the cortex of the marked lymph nodes and surrounding suspicious lymph nodes for staining. Marked and stained lymph nodes will be removed and biopsied after NST.
48674835|NCT03210857|OTHER|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
48674836|NCT02859974|BEHAVIORAL|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
48149501|NCT05939830|RADIATION|Regional lymph node radiotherapy (RNI) including the axilla|RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
48149502|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
48149503|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
48149504|NCT00141271|DRUG|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
48674837|NCT00891696|DRUG|Rapamycin|Single 16-mg oral dose
48510104|NCT02346266|OTHER|SMART Education|
48674838|NCT00891696|OTHER|Amino acid supplementation|Nutritional drink containing essential amino acids
48149505|NCT01287832|DRUG|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
48149506|NCT01287832|DRUG|Daptomycin|
48149507|NCT03056170|DEVICE|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
48149508|NCT00234585|DEVICE|Renal Artery Stent with Protective Device/Drug|
48149509|NCT01566552|DRUG|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
48149510|NCT04766996|BEHAVIORAL|Guided mindfulness exercises|Guided Meditation twice daily
48149511|NCT04766996|OTHER|Self-administered aromatherapy|Self-administered aromatherapy every 6 hours and at bedtime
48149512|NCT04766996|DRUG|Baby aspirin|Baby aspirin 81mg: Twice daily for 6 weeks after surgery
48149513|NCT04766996|DRUG|Tylenol/Acetaminophen|Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery
48149514|NCT04766996|DRUG|Pregabalin|"Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery"
48149515|NCT04766996|DRUG|Prednisone|Prednisone 5mg: Daily for three weeks after surgery
48674839|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
48674840|NCT00891696|DRUG|Sodium nitroprusside|Variable rate for 3 hours
48674841|NCT00891696|DEVICE|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
48149516|NCT04766996|DRUG|Meloxicam|"Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery"
48674842|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
48149517|NCT04766996|DRUG|Prilosec|"Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery"
48149518|NCT04766996|DRUG|Tramadol|Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
48149519|NCT04766996|DRUG|Voltaren|Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
48674843|NCT04720378|BIOLOGICAL|ST266|1X ST266
48149520|NCT04766996|DRUG|Zofran|Zofran 4 mg pre-operative
48674844|NCT05510518|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
48674845|NCT04979806|DRUG|Cefepime-zidebactam (FEP-ZID)|3 g (2 g FEP + 1 g ZID) IV q8h
48674846|NCT04979806|DRUG|Meropenem|1 g IV q8h
48674847|NCT04818957|DIETARY_SUPPLEMENT|Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)|Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
48674848|NCT04582006|PROCEDURE|Bariatric surgery|Surgical treatment of morbid obesity.
48674849|NCT01569412|BIOLOGICAL|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
48674850|NCT01065025|DRUG|4SC-205|Repeated ascending oral doses of 4SC-205.
48674851|NCT05162638|PROCEDURE|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
48674852|NCT01355614|DRUG|QAX576|
48674853|NCT01355614|DRUG|Infliximab|
48674854|NCT01273038|DEVICE|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
48674855|NCT01273038|DEVICE|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
48674856|NCT05556486|DEVICE|GlioStem|GlioStem is an oligothiophene derivative which can penetrate physiological cell membranes and selectively binds to structures inside the GSCs. GlioStem is conveniently administered ex-vivo onto the investigated tissue or cell culture by a pipette. After only a few minutes, the GSCs will emit green light from GlioStem molecules under blue illumination.
48674857|NCT04198883|COMBINATION_PRODUCT|Protheracytes|Intramyocardiac (LV) injection of stem cells with a dedicated catheter
48674858|NCT02592278|DRUG|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
48674859|NCT02592278|DRUG|Control Group|Twice a day brush with fluoride toothpaste.
48674860|NCT01852643|PROCEDURE|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
48674861|NCT01852643|PROCEDURE|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
48149521|NCT04766996|DRUG|Pepcid|Pepcid 20 mg pre-operative
48149522|NCT04766996|DRUG|Reglan|Reglan 10 mg pre-operative
48149523|NCT04766996|DRUG|Versed|Versed 2 mg pre-operative
48149524|NCT04766996|DRUG|Lidocaine|Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
48149525|NCT04766996|DRUG|Propofol|Propofol 10-125 mcg/kg/min intraoperative
48149526|NCT04766996|DRUG|Ancef|Ancef 2-3 gm weight-based dosing intraoperative
48149527|NCT04766996|DRUG|Tranexamic Acid (TXA)|Tranexamic Acid (TXA) 2 gm intraoperative
47991566|NCT00891722|OTHER|laboratory biomarker analysis|
48149528|NCT04766996|DRUG|Decadron|Decadron 10 mg intraoperative
48149529|NCT04766996|DRUG|Bupivacaine hydrochloride|Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
48149530|NCT04766996|DRUG|Toradol|Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
48149531|NCT00108407|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|
48149532|NCT00108407|BEHAVIORAL|Twelve Step Facilitation Therapy|
48149533|NCT00623714|DRUG|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
48149534|NCT00623714|DRUG|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
47991567|NCT00891722|OTHER|questionnaire administration|
48361709|NCT04929314|BEHAVIORAL|Systematic Interactive Communication Model to Strengthen Self-Care Regardless of Health Literacy Level|The central element of the intervention is the interactive communication model. A website that contains easy-to-understand knowledge and material about various chronic diseases such as chronic obstructive pulmonary disease, diabetes, heart failure, as well as knowledge and material about wound care, compression treatment and prevention of infections has been developed. Information within each topic is given based on the interactive communication model. The idea is that community nurses should not themselves assess what characterizes an easy-to-understand level or the amount of information for each individual citizen, which seeks to ensure a systematic and uniformity in the work with self-care and more self-sufficient citizens. At the same time, the model makes it possible to take into account the individual citizen's knowledge and competencies (level of HL). Further, the nurses receive specialised education regarding HL to complement their use of the interactive communication model.
48361710|NCT02439424|DEVICE|Reactive ATP|"Reactive ATP turned to on"
48361711|NCT00381810|DRUG|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
48361712|NCT00381810|DRUG|Methylprednisolone|
48361713|NCT00381810|DRUG|Acetaminophen|
48361714|NCT00381810|DRUG|Diphenhydramine|
48361715|NCT04509024|BEHAVIORAL|Incidental training|Training involving non-speech sounds embedded in a video-game.
48361716|NCT04509024|BEHAVIORAL|Explicit training|Training involving explicit sound and category information
48510105|NCT03577782|BIOLOGICAL|Entyvio (Vedolizumab)|"1. Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~2. Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
48674862|NCT05962255|DRUG|Furosemide intravenous infusion|"At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics."
48674863|NCT05962255|DRUG|Continous intravenous infusion of 0.9% Sodium Chloride solution|Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
48674864|NCT05962255|DRUG|Continous intravenous infusion of 5% Glucose solution|Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
48674865|NCT02709720|DRUG|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
48674866|NCT02709720|DRUG|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
48674867|NCT02709720|DRUG|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
47991568|NCT01558752|DEVICE|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
47991569|NCT01558752|DEVICE|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
47991570|NCT03130166|PROCEDURE|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
48361717|NCT04509024|BEHAVIORAL|Classroom training|Structured adult classroom language training.
48361718|NCT04509024|BEHAVIORAL|Classroom and incidental training|Both classroom and incidental training.
48361719|NCT04509024|BEHAVIORAL|Classroom and explicit training|Both classroom and explicit training.
48361720|NCT03851315|DEVICE|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
48361721|NCT02275559|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
48361722|NCT02275559|BEHAVIORAL|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
48361723|NCT05987709|DIAGNOSTIC_TEST|GuardantSHIELD Blood Test|The GuardantSHIELD CRC screening test is a commercially available test which works by finding signs of colorectal tumor in the blood of patients at average risk for CRC
48361724|NCT05327309|DRUG|Bleomycin|
48674868|NCT02709720|DRUG|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
48674869|NCT02709720|RADIATION|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
48674870|NCT02737501|DRUG|Brigatinib|Brigatinib tablets
48674871|NCT02737501|DRUG|Crizotinib|Crizotinib tablets
48674872|NCT00696033|DRUG|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
48674873|NCT00696033|DRUG|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
48674874|NCT00696033|DRUG|placebo|lorazépam placebo or Diazépam placebo
48674875|NCT02797314|OTHER|Bone biopsies|Bone biopsies
48510106|NCT01205984|DRUG|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
48510107|NCT02143076|BEHAVIORAL|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
48674876|NCT04883255|DRUG|10 mg Δ9-tetrahydrocannabinol (THC)|5-day course of orally-administered THC (dronabinol), 10 mg
48674877|NCT04883255|DRUG|600 mg cannabidiol (CBD)|5-day course of orally-administered CBD, 600 mg
48674878|NCT04883255|DRUG|Placebo|5-day course of orally-administered placebo
48510108|NCT02143076|BEHAVIORAL|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
48510109|NCT02143076|BEHAVIORAL|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
48510110|NCT01920022|DRUG|Mifepristone|Day one of medical abortion
48510111|NCT01920022|DRUG|etonorgestrel|
48510112|NCT02698033|DRUG|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
48510113|NCT02698033|OTHER|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
48510114|NCT03837002|OTHER|foot care protocol|foot assesment, foot care, foot care education
48510115|NCT05842174|DRUG|Hydroxychloroquine|Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure
48674879|NCT05157061|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
48674880|NCT05157061|DIETARY_SUPPLEMENT|Maltodextrine|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
48510116|NCT05842174|DRUG|Lipiodol|Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.
48510117|NCT05842174|DRUG|Placebo|Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
48674881|NCT03983330|BEHAVIORAL|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
47991571|NCT03130166|PROCEDURE|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
47991572|NCT04500834|BIOLOGICAL|Metal Panel T.R.U.E. Test|Diagnostic patch test
47991573|NCT03885141|DRUG|Zolpidem|Zolpidem or Placebo if there is a wake up during the night
47991574|NCT06135727|DEVICE|Maestro2 OCT|3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
48510118|NCT04647565|OTHER|interviews|interviews (human and social sciences)
48510119|NCT06409208|BEHAVIORAL|mHealth intervention (video and reminder SMSs)|intervention includes educational video related to postnatal care and reminder SMSs related to postnatal visits, family planning adoption and exclusive breast feeding practice.
48510120|NCT04007653|OTHER|Observation|No intervention
48149535|NCT05792683|DEVICE|lumbar drain|"Patient will be placed in the lateral decubitus position; catheter will be inserted by using a Tuohy needle in the interspinous area of lumbar spine. The LD catheter will reach the lumbar subarachnoid space.The remaining part of the drainage kit will be placed along the back of the patient. The catheter insertion site will be sutured and treated with povidone-iodine ointment. Sterile drape will be used to cover the entire external part of the LD.~The CSF will be collected within the closed beg. CSF drainage through LD will be around 10 ml per hour or 200-250 ml/day."
48149536|NCT05968885|PROCEDURE|Intradetrusor Botox® (onabotulinumtoxinA) injection|The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.
48510121|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
48510122|NCT06006390|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
48149537|NCT05968885|DRUG|Combine Mirabegron and Solifenacin.|Combination pharmacotherapy
48149538|NCT02713594|BEHAVIORAL|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
48149539|NCT02713594|OTHER|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
48149540|NCT00376324|DRUG|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
48149541|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 2 capsules
48149542|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 1 capsule
48149543|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch B Ultibro Breezhaler 85/43 μg 2 capsules
48149544|NCT04856098|DRUG|Ultibro Breezhaler with oral charcoal|Activated charcoal suspension, granules 50 g / bottle
48149545|NCT02411175|OTHER|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
48149546|NCT02411175|DRUG|20% ethanol|
48361725|NCT04810429|DRUG|Incobotulinumoxin A|"XEOMIN® (incobotulinumtoxinA) is an approved medication that inhibits the release of acetylcholine and muscle blockage. Xeomin is indicated for the symptomatic treatment of blepharospasm and hemifacial spasm, cervical dystonia of a predominantly rotational type (spasmodic torticollis), spasticity of the upper limbs and chronic sialorrhea due to neurological changes. Xeomin comes as a white powder for solution for injection. When dissolved Xeomin is a clear, colorless solution that does not contain particles. Xeomin is reconstituted before use with sterile sodium chloride 9 mg / ml (0.9%) solution, without preservatives, for injections.~The active substance is Clostridium botulinum type A neurotoxin (150 kD), without complexing proteins. The other components are human albumin and sucrose."
48149547|NCT06100406|OTHER|Biofield tuning|Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected.
48361726|NCT04810429|PROCEDURE|TMJ surgical arthroscopy|TMJ arthroscopy is a minimal invasive surgical technique for different types of temporomandibular joint (TMJ) internal derangements. Besides the acceptable outcomes of TMJ arthroscopy, the authors believe that adding to this treatment a single injection of BTXA into the temporalis and masseter muscles could reduce joint loading, improving TMJ arthroscopic results.
48361727|NCT04681742|BEHAVIORAL|CO-OP Group|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
48361728|NCT03432819|BEHAVIORAL|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
48361729|NCT06048627|DRUG|Amine/zinc lactate/fluoride system|Amine/zinc lactate/fluoride system (250 ppm F), meridol®, Colgate-Palmolive
48361730|NCT06048627|DRUG|negative control|Sodium fluoride mouthwash 250 ppm
48361731|NCT00962780|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
48510123|NCT00002200|DRUG|Abacavir sulfate|
48510124|NCT04585880|OTHER|Virtual Collaborative Care Clinic|The vCCC will operate under a collaborative care agreement with the Primary Care Physicians as an extension (and not a replacement) of their care. Trained clinical pharmacists will monitor blood pressure and prescribe and adjust medications under the license of, and in communication with, the patient's Primary Care Physician. As part of the Primary Care Physician's team and per Primary Care Physician's directions, the pharmacists may coordinate blood pressure management with other clinicians such as cardiologists or nephrologists co-managing patients blood pressure.
48149548|NCT02221011|DEVICE|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
48149549|NCT06404736|DRUG|Bispecific antibody (bsAb) targeting PD-1 and CLTA-4|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
48149550|NCT06404736|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
48510125|NCT05593497|DRUG|Capivasertib|400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
48510126|NCT05593497|DRUG|abiraterone acetate|"Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib."
48510127|NCT05816538|PROCEDURE|Paravertebral nerve block (PVB)|PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
48149551|NCT06404736|DRUG|Carboplatin|Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
48149552|NCT03561870|DRUG|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
48149553|NCT04780685|BIOLOGICAL|hMSC|IV administration
48149554|NCT00158847|DRUG|fluticasone 500 mcg|
48149555|NCT00158847|DRUG|fluticasone 500 mcg + salmeterol 50 mcg|
48149556|NCT00383994|DRUG|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
48149557|NCT00383994|DRUG|Rituximab|375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.
48149558|NCT00383994|BIOLOGICAL|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
48149559|NCT02043652|DRUG|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
48149560|NCT02043652|DRUG|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
48149561|NCT03645213|DEVICE|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
48149562|NCT03645213|DEVICE|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
48149563|NCT00264576|BIOLOGICAL|Influenza Virus Vaccine|
48149564|NCT04009109|DRUG|Lenalidomide|Induction and Maintenance
48510128|NCT05816538|PROCEDURE|Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|Pectoralis and Serratus Plane Nerve blocks (PECS 2) is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
48510129|NCT05816538|DEVICE|Regional anesthetic technique with ultrasound guidance|The device that will be used is an ultrasound with an 8 Hz ultrasonic linear probe for both regional anesthetic techniques.
48510130|NCT05816538|DEVICE|Regional anesthetic technique with peripheral nerve stimulation.|The 22G neurostimulator needle (Stimuplex D®, B. Braun Melsungen AG)\], and neurostimulator (Stimuplex HNS 12, B. Braun, Melsungen AG, Germany) will be used for both regional anesthesias.
48149565|NCT04009109|DRUG|Ixazomib|Induction and Only Maintenance Arm B
48510131|NCT05816538|DRUG|Levobupivacaine 0.5%|Local anesthetic levobupivacaine 0.5% will be used for regional anesthetic technique with ultrasound guidance and peripheral nerve stimulation. For the paravertebral block at a dose of 0.3ml/kg total, applied at the thoracic (Th) level of Th2, Th3, and Th4 and divided into levels. For the PECS 2 block levobupivacaine 0.5% 10 ml will be applied in the space between the large and small pectoral muscles and 15 ml in the space between the small pectoralis muscle and the serratus anterior muscle.
48510132|NCT05816538|PROCEDURE|General anesthesia|In both groups for induction of general anesthesia we will use 1% propofol 2 - 2.5 mg/kg (10 mg/ml, Fresenius), sufentanil (Sufentanil® Altamedics) 0.2 μg / kg, rocuronium \[Zemuron®, Schering - Plow\] 0.8 mg/kg. We will use a laryngeal mask (I - gel supraglottic airway) of appropriate sizes for airway maintenance. All subjects will be ventilated by controlled mechanical ventilation with a volume of 8 ml/kg, a frequency of about 12 breaths per min with a mixture of oxygen and air in a 40: 60% ratio. Maintenance of anesthesia and sedation in group 1 will be performed with continuous infusion of 1% propofol (10 mg / ml, Fresenius) (25 - 150 mcg / kg / min.) and rocuronium \[Zemuron®, Schering - Plow\] 0.01 mg / kg / min per perfusor.
48149566|NCT04009109|DRUG|Daratumumab Injection|Induction and Only Maintenance Arm B
48510133|NCT04360538|OTHER|Quality of Life|Physical disability assessment tool
48510134|NCT04360538|OTHER|Impact Event Score|Psychological Sequelae assessment tool
48510135|NCT04360538|OTHER|Hospital anxiety and depression scale|Psychological Sequelae assessment tool
48149567|NCT04009109|DRUG|Dexamethasone|Induction and Only Maintenance Arm B
48149568|NCT00236470|DRUG|risperidone|
48361732|NCT00962780|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
48361733|NCT00962780|PROCEDURE|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
48510136|NCT04219826|DRUG|CK-3773274 (5 - 15 mg)|CK-3773274 tablets administered orally
48361734|NCT00962780|PROCEDURE|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
48361735|NCT03866824|DRUG|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
48361736|NCT03866824|DRUG|injection of corticosteroids|intra-articular injection
48361737|NCT03866824|DEVICE|RMI|A CONTROL RMI at 1 year follow-up.
48361738|NCT02367157|PROCEDURE|Kenzo Kase Method|
48149569|NCT02935673|DRUG|lumicitabine|Oral administration of lumicitabine as tablet.
48149570|NCT02935673|DRUG|Placebo|Oral administration of matching placebo.
48149571|NCT05749562|DEVICE|Cheneau-Toulouse-Munster brace|Full length, orthogonal anteroposterior and lateral X-rays will be taken with the Cheneau-Toulouse-Munster brace.
48149572|NCT02162823|PROCEDURE|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
48149573|NCT01017159|DRUG|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
48149574|NCT05964309|OTHER|supine group|after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
48149575|NCT05964309|OTHER|sitting group|after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
48361739|NCT02367157|DEVICE|Kinesio Taping|
48361740|NCT02584660|DRUG|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
48361741|NCT02584660|DRUG|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
48361742|NCT06110962|DEVICE|Sleeptracker-AI|The Sleeptracker-AI Monitor (Fullpower Technologies, California, USA) is a commercially available, unobtrusive, and non-wearable home sleep monitoring device. It is either pre-installed in a mattress or can be purchased separately by consumers where it is placed under the mattress. The device uses piezo-electric sensors that register the forces exerted through the mattress by features such as the subject's motion, respiration, heartbeats, and snoring vibrations.
48361743|NCT00069654|PROCEDURE|Forearm blood flow study|
48361744|NCT00069654|PROCEDURE|Brachial artery reactivity study|
48361745|NCT00069654|PROCEDURE|Treadmill exercise test|
48361746|NCT06444724|PROCEDURE|APP|Patients in the application group communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
48361747|NCT06292026|DEVICE|ProgenaMatrix Keratin graft|place ProgenaMatrix graft on the wound
48361748|NCT06292026|OTHER|standard of care|apply non adherent dressing
48149576|NCT00210145|BEHAVIORAL|Aesthetic care|
48361749|NCT01302535|OTHER|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
48361750|NCT01302535|OTHER|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
48149577|NCT00785499|BEHAVIORAL|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
48149578|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
48149579|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
48149580|NCT05351411|OTHER||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
48149581|NCT04361240|RADIATION|Proton vs Photon Radiation|Assignment to proton vs photon by randomization on RadComp parent study.
48361751|NCT02243189|DRUG|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
48361752|NCT02243189|DRUG|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
48361753|NCT02243189|DRUG|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
48361754|NCT00307736|DRUG|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
48361755|NCT00307736|DRUG|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
48361756|NCT00307736|DRUG|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
48361757|NCT00307736|PROCEDURE|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
48510137|NCT04219826|DRUG|CK-3773274 (10 - 30 mg)|CK-3773274 tablets administered orally
48510138|NCT04219826|DRUG|Placebo for CK-3773274|Placebo administered orally
48674882|NCT03983330|BEHAVIORAL|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
48361758|NCT04834375|DRUG|Weight-based dexamethasone dose|Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
48361759|NCT05030506|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
48361760|NCT05030506|BIOLOGICAL|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
48361761|NCT05030506|DRUG|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
48361762|NCT00889031|OTHER|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
48361763|NCT01825759|DRUG|danshen dripping pill|
48361764|NCT05489276|DRUG|TQB2825 injection|TQB2825 injection is a bi-specific, humanized antibody against CD3×CD20, with the structure ratio of anti-CD3 to anti-CD20 of 1:2. It has two asymmetric Fab ends and a complete Fc end, and is a natural IgG4 subtype with weak antibody-dependent cell-mediated cytotoxicity or complement dependent cytotoxicityfunction. By bridging CD3 and CD20, TQB2825 injection induces T cell activation to promote T cell proliferation/expansion, promote the formation of cytolytic synapses, and cause cytotoxic T cells to release perforin and granase, thereby killing CD20 positive tumor cells. Therefore, TQB2825 injection is intended for the treatment of CD20 positive hematologic tumors, including but not limited to lymphoma, leukemia and myeloma.
48361765|NCT03651011|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
48361766|NCT03651011|PROCEDURE|Navigated laser photocoagulation|Navigated laser photocoagulation planned from flourscein angiography.
48361767|NCT04879511|DRUG|metformin|Oral hypoglycemic drug metformin
48361768|NCT04879511|DRUG|Basal/bolus insulin|Basal/bolus insulin
48510139|NCT00920790|BIOLOGICAL|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
48510140|NCT03939715|BIOLOGICAL|DermaPure®|Surgical intervention using DermaPure®
48510141|NCT03939715|PROCEDURE|native tissue|Surgical intervention using native tissue
48510142|NCT06505798|PROCEDURE|Catheter Ablation|Participants randomised to the catheter ablation arm will undergo Pulmonary Vein Isolation (PVI) which is the essential ablation intervention. The technique used will be at the discretion of the treating physician but may include Cryoballoon (Medtronic/Boston Scientific), Radiofrequency: CARTO (Biosense), pulsed field radiofrequency ablation, or Precision (Abbott Medical) electro-anatomical mapping systems. Additional ablation lesions may be delivered as preferred by the operator and will be documented. Electro-anatomical voltage maps will be collected (in SR/AF) and stored for later analysis.
48361769|NCT05425537|OTHER|Drowning incident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
48361770|NCT00732199|OTHER|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
48361771|NCT00863031|BEHAVIORAL|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
48361772|NCT00863031|BEHAVIORAL|Video-viewing|Three sessions of viewing health educational videos.
48361773|NCT05536544|OTHER|IBDMED|The IBDMED program will be applied for 8 weeks and include education on MED diet and lifestyle components, focused on increasing and diversifying dietary fiber intake, reduction of ultra-processed food intake and promoting an active lifestyle. This intervention is digitally supported by an interactive website application and step trackers to monitor lifestyle parameters.
48361774|NCT05536544|OTHER|Control|Dietary counseling according to the local dietary guidelines for patients with IBD
48361775|NCT00582764|OTHER|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
48361776|NCT00266604|DRUG|Topiramate|
48361777|NCT04604015|DIAGNOSTIC_TEST|NeuralBot Investigational System|The NeuralBot Investigational System when used with the Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.
48361778|NCT04604015|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|A test that uses ultrasound to create a hemodynamic assessment for major cardiovascular events.
48361779|NCT03943004|DRUG|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
48361780|NCT04787744|PROCEDURE|PET-directed Local Therapy using Surgery|Surgery will be used to treat metastases.
48361781|NCT04787744|RADIATION|PET-directed Local Therapy using Radiation|"Radiation therapy will be used to treat metastases.~Radiation options include:~1. Stereotactic body radiotherapy (SBRT) using 1-10 fractions~2. Conventionally fractionated radiotherapy using elective nodal radiotherapy and a simultaneous integrated boost to involved nodes~The selection of the form of metastasis-directed radiotherapy for each metastasis will be determined using shared decision-making between the treating physician and the Veteran."
48361782|NCT04787744|OTHER|Salvage Local Therapy for locally recurrent disease|For Veterans who have a local recurrence in addition to oligorecurrent metastatic lesions, they will undergo salvage local therapy using brachytherapy, SBRT, surgery, cryotherapy or HIFU. The selection of modality of salvage local therapy will be determined using shared decision-making between the treating physician and Veteran.
48361783|NCT04787744|DRUG|Goserelin, Histrelin, Leuprolide & Triptorelin|Androgen deprivation therapy (ADT) using an LHRH agonist
48361784|NCT04787744|DRUG|ADT + Nilutamide, Flutamide, & Bicalutamide|ADT adding anti-androgen therapy to an LHRH agonist
48361785|NCT04787744|DRUG|Degarelix & Relugolix|ADT using an LHRH Antagonist.
48361786|NCT04787744|DRUG|ADT + Docetaxel +/- prednisone|Enhanced SST using chemohormonal therapy
48361787|NCT04787744|DRUG|ADT + Abiraterone + Prednisone|Enhanced SST using Abiraterone + Prednisone
48674883|NCT01016132|DEVICE|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
48361788|NCT04787744|DRUG|ADT + Abiraterone + Methylprednisolone|Enhanced SST using Abiraterone + Methylprednisolone
48674884|NCT02673944|DEVICE|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
48361789|NCT04787744|DRUG|ADT + Apalutamide|Enhanced SST using ADT + Apalutamide
48361790|NCT04787744|DRUG|ADT + Enzalutamide|Enhanced SST using ADT + Enzalutamide
48361791|NCT04787744|RADIATION|Prostate-directed Radiation for De novo oligometastatic prostate cancer|"Veterans in ARM 1 will receive prostate-directed RT only and NO treatment to any nodal or distant metastatic sites.~Acceptable dose/fractionations include 55 Gy in 20 fractions and 36 Gy in 6 fractions.~Veterans in ARM 2 should receive prostate-directed local therapy using radiotherapy or radical prostatectomy in addition to PET-directed local therapy to metastases."
48361792|NCT00000529|DRUG|tamoxifen|
48361793|NCT03171142|DRUG|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
48361794|NCT03171142|DRUG|Air|Air 21% via nasal cannula 2 litter per minutes
48361795|NCT00836199|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
48674885|NCT04110106|OTHER|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H\&Y scale by a neurologist.
48674886|NCT00432393|DRUG|levodopa-carbidopa|
48674887|NCT03557125|OTHER|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
48674888|NCT03557125|OTHER|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
48674889|NCT02429817|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
48510143|NCT06048263|BEHAVIORAL|interpersonal psychotherapy (IPT)|The ROSE intervention is a five-session intervention developed to build communication skills, improve social support, and improve stress management. It is easy to learn and does not require a healthcare professional or mental health specialist to deliver. For this study, the investigators plan to deliver to individuals during inpatient visits, in-person appointments or via telemedicine (phone or videoconference), as appropriate or per participant preference. The first four sessions are approximately 60 minutes in length.
48510144|NCT06048263|DRUG|Ketamine|During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg \~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
48510145|NCT05013437|DRUG|Evomela|16 mg/m\^2 Evomela administered one time via a central line
48510146|NCT05013437|DEVICE|Next Generation Sequencing|Next Generation Sequencing
48510147|NCT05013437|DRUG|Prochlorperazine|10mg once intravenous (IV) within 30 minutes before Evomela
48149582|NCT03888807|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
48149583|NCT03888807|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
48361796|NCT00836199|BIOLOGICAL|Placebo vaccine|Placebo vaccine given 6 times over 6 months
48674890|NCT02429817|DEVICE|Aeroneb Solo|
48674891|NCT02429817|DEVICE|Jet Nebulizer|
48674892|NCT02429817|OTHER|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
48149584|NCT00838448|BEHAVIORAL|Exercise|Exercise performed on a treadmill for 20-30 minutes
48149585|NCT03119051|BEHAVIORAL|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
48361797|NCT02698917|OTHER|Low normal PaCO2|4.5-4.7 kPa
48361798|NCT02698917|OTHER|High normal PaCO2|5.8-6.0 kPa
48361799|NCT02698917|OTHER|Low normal PaO2|10-15 kPa
48361800|NCT02698917|OTHER|High normal PaO2|20-25 kPa
48361801|NCT02698917|OTHER|Low normal MAP|65-75 mmHg
48361802|NCT02698917|OTHER|High normal MAP|80-100 mmHg
48149586|NCT03119051|BEHAVIORAL|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
48149587|NCT03720028|BEHAVIORAL|Observation|Describe communication and sensory profile using standardized tests and observations.
48361803|NCT02611037|DRUG|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
48674893|NCT02429817|OTHER|Spirometry|FEV1, FVC assessment
48674894|NCT00742625|DRUG|daunorubicin hydrochloride|Given IV
48674895|NCT00742625|DRUG|cytarabine|Given IV
48149588|NCT03720028|BEHAVIORAL|Parental experiences|Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
48361804|NCT02611037|DRUG|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).
48361805|NCT02611037|DRUG|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
48361806|NCT02611037|OTHER|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
48361807|NCT03756805|DEVICE|upper airway stimulation|One group of patients with UAS
48510148|NCT05013437|DRUG|Acetaminophen|650 mg once orally within 30 minutes before Evomela
48510149|NCT05013437|DRUG|Diphenhydramine|50 mg once intravenously within 30 minutes before Evomela
48510150|NCT03293316|DEVICE|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
48674896|NCT00742625|DRUG|bortezomib|Given IV
48674897|NCT01251302|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
48674898|NCT04123301|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
48674899|NCT04123301|DEVICE|Sham Theta Burst Stimulation (TBS)|The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
48674900|NCT03521700|DRUG|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.
48149589|NCT00722865|DRUG|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
48149590|NCT02558543|DRUG|Stromal Vascular fraction|
48149591|NCT02558543|DRUG|Ringer lactate|
48361808|NCT03756805|DEVICE|continuous positive airway pressure|One group of patients with CPAP
48361809|NCT05875272|PROCEDURE|interchangeability of arterial or venous hemostasis|Paired arterial and venous blood sampling respectively on the radial arterial catheter and on the central venous catheter before the extracorporeal circulation, and on the sampling ramp during the extracorporeal circulation. Point of care biology exams are performed on two HSE devices simultaneously. Controls carried out, routinely, every 20 minutes according to the service protocol, before the CPB (starting ACT without heparin), during the CPB (ACT objective ≥400 seconds), after protamine reversal of heparin. On average, 10 samples are taken during heart surgery.
48674901|NCT02255669|DEVICE|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
48674902|NCT02255669|DEVICE|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
48674903|NCT04838184|DEVICE|Dental Implants (Straumann Roxolid® / SLActive®)|"In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.~In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation."
47991575|NCT04188522|DIAGNOSTIC_TEST|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
47991576|NCT04727229|DRUG|Bupivacaine Hydrochloride|Injection of Bupivacaine near the stellate ganglion
47991577|NCT04727229|DRUG|Normal Saline|Injection of Normal Saline near the stellate ganglion
48149592|NCT02209376|BIOLOGICAL|CART-EGFRvIII T cells|
48149593|NCT02834559|DRUG|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
48149594|NCT02834559|DRUG|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
48149595|NCT02900937|DEVICE|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
48149596|NCT00060502|DRUG|Infliximab; Gemcitabine|
48149597|NCT02125409|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
48149598|NCT02125409|PROCEDURE|Screening colonoscopy|
48149599|NCT03406507|BIOLOGICAL|Ravulizumab|Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
48361810|NCT03671434|BEHAVIORAL|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
48361811|NCT03671434|BEHAVIORAL|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
48674904|NCT03030898|DIAGNOSTIC_TEST|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
48674905|NCT02909088|DRUG|Ecopipam 50mg|
48674906|NCT02909088|DRUG|Ecopipam 100mg|
48149600|NCT06275256|PROCEDURE|Rezum|The Rezum device is inserted, a needle is deployed, and vapor is injected into the prostate for nine seconds. This vapor disperses between cells, then cools, releases heat, and gently disrupts the prostate's cells. Because of the initial swelling, a catheter is then inserted, which will remain for two to five days.
48149601|NCT06275256|DEVICE|iTind|The iTind device is temporarily placed inside the prostatic urethra (the narrowed portion of the prostate), where it slowly expands and exerts gentle pressure at three precise points. The effect of the iTind is to widen the prostatic urethral opening through which urine can now flow more easily.
48510151|NCT05342779|PROCEDURE|stripping of great saphenous vein|"I will make 2 or 3 small cuts in your leg. The cuts are near the top, middle, and bottom of your damaged vein. One is in your groin. The other will be farther down your leg, either in your calf or ankle.~I will then thread a thin, flexible plastic wire into the vein through your groin and guide the wire through the vein toward the other cut farther down your leg.~The wire is then tied to the vein and pulled out through the lower cut, which pulls the vein out with it.~I will close the cuts with stitches. Patient will wear bandages and compression stockings on leg after the procedure."
48510152|NCT03277924|DRUG|Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48510153|NCT03277924|DRUG|Nivolumab 100 MG/10 ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48510154|NCT03277924|DRUG|Epirubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48510155|NCT03277924|DRUG|Ifosfamide|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48510156|NCT03277924|DRUG|Doxorubicin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48510157|NCT03277924|DRUG|Dacarbazine|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48510158|NCT03277924|DRUG|Cisplatin|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48510159|NCT03277924|DRUG|Methotrexate|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
48674907|NCT04347343|PROCEDURE|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
48674908|NCT02213068|DRUG|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
48674909|NCT02213068|DRUG|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
48149602|NCT02592902|PROCEDURE|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
48149603|NCT02592902|PROCEDURE|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
48149604|NCT04224597|DIAGNOSTIC_TEST|ultrasonography|all participants will be determined by ultrasonography.
48149605|NCT05130099|OTHER|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
48510160|NCT00905710|PROCEDURE|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
48510161|NCT03999749|DRUG|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
48510162|NCT03999749|DRUG|Nivolumab|Nivolumab (3 mg/kg) will be administered IV on Days 1 and 22 of each 42-day induction treatment cycle. Nivolumab will continue to be administered IV at 240 mg flat dose every 2 weeks; i.e., at Days 1, 15, 29, 43, 57, and 71 of the 84-day treatment cycle for the first maintenance cycle until week 24, then nivolumab will be administered at 480 mg flat dose every 4 weeks to a maximum of 2 years
48674910|NCT02213068|DRUG|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
48674911|NCT01820806|DRUG|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
48674912|NCT04651205|DIETARY_SUPPLEMENT|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
48674913|NCT01291108|DRUG|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
48510163|NCT03999749|DRUG|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle. After 12 weeks of therapy, starting at Week 13, subjects enter the maintenance phase. Tocilizumab will be administered intravenously every 6 weeks during the first 84 day maintenance treatment cycle only at 4 mg/kg
48510164|NCT00550030|RADIATION|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
48149606|NCT00142532|PROCEDURE|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (\~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (\~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
48149607|NCT00142532|PROCEDURE|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
48674914|NCT01291108|DRUG|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
48361812|NCT05776706|DIAGNOSTIC_TEST|AR-based navigation|"The surgeon will perform all surgical planning and operations with reference to the existing navigation. In this process, the errors of the existing navigation and the newly developed navigation are measured and compared in 3D at several points, and the points are as follows.~1. Fiducial markers~2. Nasion~3. Tumor's margin (anterior, posterior, superior, inferior)"
48149608|NCT04255251|DRUG|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
48149609|NCT04255251|DRUG|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
48361813|NCT04880499|DIETARY_SUPPLEMENT|Iron plus folic acid, vitamin B2, B6, B12, C, and E|A number of 30 subjects are supplemented with iron plus folic acid, vitamin B2, B6, B12, C, and E daily for 60+/-15 days before orthopedic surgery.
48674915|NCT01291108|DRUG|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
48674916|NCT03165786|BEHAVIORAL|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
48674917|NCT01732614|PROCEDURE|Topcon Endpoint Management laser|
48674918|NCT00648037|DRUG|Rituximab|Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given.
48674919|NCT01126190|BIOLOGICAL|Neugranin|Neugranin will be administered per dose and schedule specified in the arm description.
48361814|NCT06119061|DRUG|Telavancin Injection|Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
48361815|NCT02961049|PROCEDURE|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
48361816|NCT02961049|PROCEDURE|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
48361817|NCT02961049|PROCEDURE|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
48361818|NCT02961049|PROCEDURE|Wash and dry|Wash and dry with absorbent paper.
48361819|NCT02961049|DEVICE|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
48510165|NCT00550030|OTHER|No treatment|no UV exposure
48510166|NCT05856006|OTHER|upper trapezius stretching plus neck isometrics|upper trapezius stretching plus neck isometrics
48510167|NCT05856006|OTHER|upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics|"Mid-Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
48510168|NCT02467478|DRUG|Linagliptin|5 mg tablet once daily for 12 weeks
48510169|NCT02467478|DRUG|Placebo|1 tablet daily for 12 weeks
48674920|NCT01126190|BIOLOGICAL|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
48674921|NCT01126190|DRUG|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
48674922|NCT04507906|DRUG|Nivolumab Combined with Anlotinib|In combination dose finding phase, Phase 1b will begin with Dose Level 1; anlotinib 12 mg/day orally (from days 1 to 14 in a 21-day cycle) and nivolumab (360mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (anlotinib 10 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously) and Dose Level 3 (anlotinib 8 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously).If RP2D was reached in Part A, eligible patients would be enrolled and receive nivolumab (360mg q3w, intravenously) plus anlotinib (RP2D, QD from day 1 to 14 of a 21-day cycle) .
48674923|NCT00049361|DRUG|temozolomide|
48674924|NCT00049361|DRUG|thalidomide|
48674925|NCT00049361|RADIATION|radiation therapy|
48149610|NCT04053491|PROCEDURE|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
48149611|NCT02327975|OTHER|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
48149612|NCT02327975|OTHER|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
48674926|NCT01567033|BEHAVIORAL|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
48674927|NCT04568603|DRUG|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
48674928|NCT00928187|DRUG|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
48149613|NCT02327975|OTHER|Control group|No received intervention.
48149614|NCT02753075|DEVICE|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
48674929|NCT00928187|DRUG|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight \< 60 kg, 400 mg if weight \> 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
48674930|NCT00928187|DRUG|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
48674931|NCT03001661|DEVICE|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
48674932|NCT03001661|DRUG|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
48674933|NCT02559648|DRUG|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
48674934|NCT02559648|DRUG|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
48149615|NCT02753075|DEVICE|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
48149616|NCT02753075|OTHER|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
48149617|NCT02753075|DRUG|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
48361820|NCT02961049|DEVICE|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
48674935|NCT04485845|DRUG|Vildagliptin|to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
48361821|NCT02961049|PROCEDURE|Photoactivated|Photoactivated for 20 seconds
48361822|NCT03040063|PROCEDURE|Combined endovascular approach (EVAR)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Heparin 70-80 IU/kg i.a.~5. implantation of peripheral stent graft VIABAHN~6. implantation of peripheral stent SUPERA into stent graft~7. insertion of strait flush catheter for local thrombolysis~8. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~9. control angiography in 12 hrs or earlier according to clinical status and symptoms~10. repeated angiography in 24 hrs"
48674936|NCT04485845|DRUG|Captopril Tablets|used to treat hypertension in metabolic syndrome patients and as a renal protector
48674937|NCT04485845|DRUG|MetFORMIN 500 Mg Oral Tablet|antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
48361823|NCT03040063|PROCEDURE|Standard optimal therapy (OPT)|"1. puncture of SFA in orthograde position if possible~2. DSA through 4F dilator, proof of occlusion~3. wire test~4. Unfractionated heparin 70-80 IU/kg i.a.~5. insertion of strait flush catheter for local thrombolysis~6. administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~7. control angiography in 12 hrs or according to clinical status and symptoms~8. repeated angiography in24 hrs~9. Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
48149618|NCT04379310|DRUG|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
48510170|NCT01590303|DRUG|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
48149619|NCT00193102|DRUG|Thalidomide|Thalidomide
48149620|NCT00193102|DRUG|Capecitabine|Capecitabine
48149621|NCT04502459|PROCEDURE|Tourniquet|A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
48149622|NCT06307054|DRUG|anti-CLL-1 CAR NK cells|Eligible patients enrolled in the study after screening will receive lymphocyte collection(from the patient or a donor ) and receive single dose CLL-1 CAR NK cells infusion after a successful cell production. There are a total of four cell dose level:5×10\^6 CAR-NK cells/kg,1×10\^7CAR-NK cells/kg,2×10\^7CAR-NK cells/kg,4×10\^7CAR-NK cells/kg
48361824|NCT00750360|BIOLOGICAL|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
48361825|NCT04267939|DRUG|Elimusertib (BAY1895344)|Elimusertib will be administered in 28-day cycles.
48361826|NCT04267939|DRUG|Niraparib|Niraparib will be administered in 28-day cycles.
48674938|NCT04118725|DIAGNOSTIC_TEST|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
48149623|NCT05832489|DRUG|Placebo|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
48149624|NCT05832489|DRUG|Methylphenidate immediate release 25mg|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
48674939|NCT05257928|BEHAVIORAL|CARE-CITE Gait|The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
48149625|NCT05024266|DRUG|Tislelizumab|Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
48149626|NCT04851197|OTHER|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
48674940|NCT02603276|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
47991578|NCT03586388|OTHER|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
48149627|NCT03503188|DEVICE|Littmann ®|electronic stethoscope
48510171|NCT01590303|DRUG|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
48149628|NCT03528356|BEHAVIORAL|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
48149629|NCT02827110|DEVICE|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
48149630|NCT02827110|DEVICE|pentax-airway scope|Tracheal intubation using pentax-AWS
48361827|NCT01913275|PROCEDURE|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
48510172|NCT00215280|DRUG|ivermectin and albendazole|
48510173|NCT06377514|DEVICE|Test IOL Model DEN00V|Eligible subjects will be randomized in a 1:1 ratio to receive the Test IOL Model DEN00V in both eyes for the duration of the study
48510174|NCT06377514|DEVICE|Control IOL Model DCB00|Eligible subjects will be randomized in a 1:1 ratio to receive the control IOL Model DCB00 in both eyes for the duration of the study
48510175|NCT00053183|PROCEDURE|conventional surgery|
48674941|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
48674942|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
48674943|NCT05739825|OTHER|FMT from healthy donors|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through FMT
48674944|NCT03675113|OTHER|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
47991579|NCT01517269|BEHAVIORAL|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
48149631|NCT02827110|PROCEDURE|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
48674945|NCT03675113|OTHER|Control Group|Deep breathing exercises combinated with arm movements
48149632|NCT01472796|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
48149633|NCT01472796|DRUG|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
48149634|NCT00224913|PROCEDURE|Neuromuscular electrical stimulation|
48510176|NCT00053183|RADIATION|brachytherapy|
48510177|NCT00053183|RADIATION|radiation therapy|
48510178|NCT04688892|DEVICE|Cupping|dynamic cupping
48510179|NCT03328975|DRUG|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
48510180|NCT03328975|OTHER|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
48149635|NCT00224913|PROCEDURE|Voluntary exercise|
48149636|NCT00774826|DRUG|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
48361828|NCT01913275|PROCEDURE|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
48361829|NCT01671176|DEVICE|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
48361830|NCT02700932|DEVICE|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
48149637|NCT00774826|DRUG|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
48674946|NCT05835310|BIOLOGICAL|Anifrolumab|Participants will receive a single dose of Anifrolumab via IV infusion.
48674947|NCT05835310|DRUG|Placebo|Participants will receive matching placebo via IV infusion
48674948|NCT01464749|BEHAVIORAL|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
48674949|NCT01464749|BEHAVIORAL|usual care|no specific rehabilitation
48674950|NCT04086355|OTHER|oromotor exercises and neuromuscular electrical stimulations|treatment study group with occupational exercises and electrical stimulation
48510181|NCT02930759|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-096)
48674951|NCT03281629|DEVICE|Active TMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
48674952|NCT03281629|DEVICE|Sham TMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
48674953|NCT02481193|DRUG|Cisatracurium|Different doses of cisatracurium pretreatment
48149638|NCT00774826|DRUG|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
48149639|NCT03140709|DRUG|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
48674954|NCT05444738|DRUG|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
48674955|NCT05444738|DRUG|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
48149640|NCT06287671|PROCEDURE|Colorectal resection or stoma closure|Elective open or minimally invasive resection for colorectal cancer, IBD or other benign colorectal disorder, or stoma closure
48149641|NCT01941706|BEHAVIORAL|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
48149642|NCT04135872|OTHER|strengthened nuitritional treatment|improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
48149643|NCT00457314|BEHAVIORAL|Exercise|Regular exercise training
48149644|NCT05792176|BEHAVIORAL|Music Training Intervention|The Music Training Intervention (MTI) entails 12-weeks of online instruction to learn to play the ukulele. Participants will be taught the basic information on how to handle and hold the ukulele, musical chords, and popular songs. They will be instructed to play at least 30-minutes a day, five days a week.
48149645|NCT05792176|BEHAVIORAL|Music Listening|Participants randomized to this arm will be asked to listen to their preferred music for at least 30 minutes, 5 days a week. A member of our research team will call them every week to answer any questions they have about the ML protocol. They will be asked to record their experience in a practice log.
48674956|NCT04421404|BIOLOGICAL|COVID-19 Convalescent Plasma (CCP)|COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.
47991580|NCT01517269|BEHAVIORAL|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
48149646|NCT03677986|BEHAVIORAL|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
48149647|NCT01330953|DRUG|Placebo|Single intravenous placebo dose.
48149648|NCT01330953|DRUG|LY2928057|Single intravenous dose.
48149649|NCT05095077|DRUG|Tadalafil 40 MG|Single dose on study day 1/2
48149650|NCT05095077|DRUG|Placebo|Identical to active IMP
48149651|NCT00004250|BIOLOGICAL|dactinomycin|
48149652|NCT00004250|DRUG|isolated limb perfusion|
48149653|NCT00004250|DRUG|melphalan|
48361831|NCT04152538|OTHER|not intervention but investigation|possible differences in quadriceps muscular activity
48361832|NCT02853318|BIOLOGICAL|Bevacizumab|Given IV
48361833|NCT02853318|DRUG|Cyclophosphamide|Given PO
48361834|NCT02853318|OTHER|Laboratory Biomarker Analysis|Correlative studies
48510182|NCT00387556|DRUG|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
48510183|NCT03005912|DEVICE|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
48510184|NCT03005912|DEVICE|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
48510185|NCT03005912|DEVICE|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
48510186|NCT03005912|DEVICE|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
48149654|NCT03612388|PROCEDURE|use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation|use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
48149655|NCT00363090|BIOLOGICAL|alemtuzumab|
48149656|NCT00363090|DRUG|cyclophosphamide|
48361835|NCT02853318|BIOLOGICAL|Pembrolizumab|Given IV
48510187|NCT05498779|PROCEDURE|Ablation therapy|Radiofrequency or microwave ablation
48361836|NCT02948244|DIETARY_SUPPLEMENT|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
48361837|NCT02948244|DIETARY_SUPPLEMENT|Placebo|Placebo
48361838|NCT04390217|DRUG|LB1148|LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
48361839|NCT04390217|DRUG|Placebo|Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
48510188|NCT06505070|BEHAVIORAL|Recreational Games|"40 individuals in the intervention group were introduced to 15 games. Researchers conducted these sessions and provided participants with instructions and rules for the games. Then, they were asked to rate the games from 1 to 10. In this form, the elderly individuals evaluated the games by determining the minimum 1 and maximum 10 points according to their interest and willingness to play. Thus, it was ensured that individuals freely choose the games they want to play. As a result, bingo, matching pairs, word challenges and hot-cold games, which received the highest scores from the participants, were selected to be played."
48674957|NCT04421404|BIOLOGICAL|Placebo|Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
48674958|NCT00572598|DRUG|4- [F-18] fluoropaclitaxel|4- \[F-18\] fluoropaclitaxel, \<84 micrograms, \<10 mCi, IV followed by PET/CT imaging
48674959|NCT04118543|OTHER|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
48674960|NCT04118543|OTHER|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
48674961|NCT04405440|BEHAVIORAL|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
48674962|NCT06373003|OTHER|Diagnostic accuracy|To assess the diagnostic accuracy of non-criteria aPL (anti-vimentin/cardiolipin and anti-phosphatidylserine/prothrombin) in identifying APS in patients with thrombosis/ recurrent adverse pregnancy outcomes
48674963|NCT00192543|BEHAVIORAL|diet of fish and fruit|fish and fruit in specified quantities
48674964|NCT00192543|BEHAVIORAL|fruit and fish|no drugs
48674965|NCT00192543|BEHAVIORAL|diet only|Fish and fruit
48674966|NCT00192543|BEHAVIORAL|regular diet|no change in regular diet
48674967|NCT02267889|PROCEDURE|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
48674968|NCT02267889|DEVICE|D-SPECT dedicated cardiac nuclear camera|
47991581|NCT00762242|PROCEDURE|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
48149657|NCT00363090|DRUG|doxorubicin hydrochloride|
48149658|NCT00363090|DRUG|prednisone|
48149659|NCT00363090|DRUG|vincristine sulfate|
48510189|NCT03277118|DEVICE|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
48510190|NCT04123626|DRUG|QR-1123|unilateral IVT injection
48510191|NCT04123626|OTHER|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
48149660|NCT00363090|OTHER|flow cytometry|
48149661|NCT00363090|OTHER|pharmacological study|
48149662|NCT00677742|OTHER|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
48149663|NCT00677742|OTHER|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
48149664|NCT05177835|DRUG|ABX464|All subjects will receive ABX464 given at 25 mg QD.
48510192|NCT06570187|DRUG|Dexmedetomidine|Dexmedetomidine will be administered with an initial dose of 0.2 μg/kg/hour, infusion rate is to be titrated based on response for at least 24 hours.
48510193|NCT06570187|DRUG|Propofol|Propofol will be administered as the comparator sedative with the standard treatment of sepsis and septic shock.
48674969|NCT00148863|DRUG|Peg-interferon alpha 2a (drug)|
48149665|NCT01049815|DRUG|sevelamer hydrochloride|800-3200 mg with each meal
48149666|NCT01049815|DRUG|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
48510194|NCT03494101|OTHER|Blood samples|Blood samples will be collected and analyzed at different study time points
48510195|NCT03494101|OTHER|Stool samples|Stool samples will be collected and analyzed at different study time points
48510196|NCT03494101|OTHER|Clinical information|Clinical information will be collected at different study time points using questionnaires
48674970|NCT00148863|DRUG|Ribavirin (drug)|
48674971|NCT00148863|DRUG|Interferon gamma (drug)|
48674972|NCT06082804|OTHER|APN and medical management|Patients are followed by the advanced practice nurse and the hematologist.
48674973|NCT06082804|OTHER|Medical management|Patients are followed by the hematologist only (standard of care).
48149667|NCT05639556|DIAGNOSTIC_TEST|BMI and lean mass index from DXA|Estimate and compare correlation between lean mass index from DXA and BMI
48674974|NCT06082804|BEHAVIORAL|Quality of life assessment|EORTC-QLQ-C30 questionnaire
48674975|NCT06082804|BEHAVIORAL|Treatment compliance assessment|GIRERD questionnaire
48674976|NCT00950651|DRUG|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
48674977|NCT00950651|DRUG|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
48674978|NCT04021290|DRUG|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
48674979|NCT04021290|DRUG|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
48674980|NCT02132286|DRUG|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
48674981|NCT01444911|DEVICE|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
48149668|NCT05639556|DIAGNOSTIC_TEST|Anthropometric Measurements|Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
48149669|NCT05639556|DIAGNOSTIC_TEST|Hand-grip strength|A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
48149670|NCT05639556|DIAGNOSTIC_TEST|Six-minute walk Test|This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
48149671|NCT05639556|DIAGNOSTIC_TEST|Sit-to-Stand Test|This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
48674982|NCT01444911|DEVICE|Vaginal Dilator|Still vaginal dilator with lubricant.
48674983|NCT05922618|DEVICE|I-One|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
48674984|NCT04933500|DEVICE|Whitacre spinal needle|25G Whitacre spinal needle
48674985|NCT01848093|OTHER|sputum collection|collecting of spontaneous sputum from the patient
48149672|NCT05639556|DIAGNOSTIC_TEST|Short physical performance battery (SPPB)|This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
48674986|NCT00607802|BIOLOGICAL|leukocyte therapy|
48674987|NCT00607802|GENETIC|polymerase chain reaction|
48674988|NCT01647698|BEHAVIORAL|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
48510197|NCT06016738|DRUG|Palazestrant|Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.
48510198|NCT06016738|DRUG|Fulvestrant|Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle
48149673|NCT05639556|DIAGNOSTIC_TEST|BIA Sub-study|A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
48149674|NCT05639556|DIAGNOSTIC_TEST|Accelerometry to assess physical activity|Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
48149675|NCT05639556|OTHER|Gastrointestinal (GI) and nutrition questionnaires:|Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
48361840|NCT06309368|DRUG|Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation|An elliptical transverse incision will be made extending 1-2 cm lateral and medial to the mucocutaneous junction. The mobilization, anastomosis and fascial closure will be performed as in the pursestring closure group. The incision will then be irrigated using direct stream into the wound with 350cc of Prontosan. After one minute the wound will be suctioned dry. The subcutaneous fat will be mobilized and approximated with interrupted 2-0 Vicryl. The skin will be approximated with deep dermal 3-0 Vicryl and a running subcuticular 4-0 Monocryl suture and Dermabond will be applied.
48510199|NCT06016738|DRUG|Anastrozole|Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle
48510200|NCT06016738|DRUG|Letrozole|Participants will be treated with letrozole once daily on a 4 week (28 day) cycle
48361841|NCT06309368|PROCEDURE|Pursestring Closure|A circular incision will be made at the mucocutaneous junction of the ileostomy. After complete mobilization of the ileal limbs off the fascia and a stapled side to side functional end to end anastomosis, the fascia including the external and posterior rectus sheath will be closed with two running #0 PDS (Polydioxanone) suture. The wound will then be irrigated with saline and partially closed in the subcuticular plane with a 2-0 Monocryl suture in a pursestring fashion and packed in the middle with plain packing.
48510201|NCT06016738|DRUG|Exemestane|Participants will be treated with exemestane once daily on a 4 week (28 day) cycle
48510202|NCT03902730|OTHER|Traditional Back Squat|Participants will complete traditional back squat in this four treatment crossover design.
48510203|NCT03902730|OTHER|Barefoot Back Squat|Participants will complete barefoot back squat in this four treatment crossover design.
48510204|NCT03902730|OTHER|Box Squat|Participants will complete box squat in this four treatment crossover design.
48674989|NCT01647698|BEHAVIORAL|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
48149676|NCT05639556|OTHER|Psychosocial questionnaire: PHQ-8|This is an 8-item scale that measures depressive symptoms over the past two weeks.
48149677|NCT05639556|OTHER|Psychosocial questionnaire: GAD-7|This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
48674990|NCT01647698|BEHAVIORAL|No training|No training during the experiment.
48674991|NCT01842672|DRUG|Clofarabine|Dose Escalation of Clofarabine
48510205|NCT03902730|OTHER|Traditional Back Squat with Chains|Participants will complete traditional back squat with chains in this four treatment crossover design.
48510206|NCT02075307|DIETARY_SUPPLEMENT|Blueberry Powder|
48510207|NCT02075307|DIETARY_SUPPLEMENT|Placebo|
48510208|NCT01469078|DRUG|Monofer®|Single Bolus Injections
48510209|NCT00000620|DRUG|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control \<6%; standard control 7.0-7.9%).
48510210|NCT00000620|DRUG|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control \<120 mm Hg; standard control \<140 mm Hg).
48510211|NCT00000620|DRUG|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR \<50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
48510212|NCT03173287|PROCEDURE|Quantification of liver fibrosis|Procedure MRI and liver biopsy
48510213|NCT02012426|BEHAVIORAL|Weight management program|
48510214|NCT02354794|DIETARY_SUPPLEMENT|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
48510215|NCT02354794|DIETARY_SUPPLEMENT|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
48674992|NCT01842672|DRUG|Mitoxantrone|
48674993|NCT05065593|OTHER|resistance and aerobic exercise|Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
48674994|NCT05065593|OTHER|physical activity recommendation|Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
48674995|NCT06026150|OTHER|Ultrasound scanning of inguinal area for femoral nerve and artery|ultrasound scanning of inguinal region is done in femoral fracture patient to identify femoral artery and nerve
48674996|NCT00643942|OTHER|No intervention required|
48674997|NCT00652275|BIOLOGICAL|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
48361842|NCT06477432|DEVICE|mesofiller® mesotox|The investigated product mesofiller® mesotox was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. Both sessions were conducted within 14-day intervals.
48361843|NCT01688362|BIOLOGICAL|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
48674998|NCT00652275|BIOLOGICAL|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
48674999|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
48675000|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
48675001|NCT06476288|OTHER|Low-intensity resistance exercise training|The intervention protocol will consist of 60 minutes of low-intensity resistance exercise training 3x/week for 6 weeks.
48675002|NCT06476288|OTHER|High-Dose Remote ischemic conditioning (RIC)|Treatment dose of RIC- the RIC cuff will be inflated to 20 mmHg over the participant's systolic blood pressure. The treatment dose of RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
48675003|NCT06476288|OTHER|Low-Dose Remote ischemic conditioning (RIC)|This dose will be the control for the study. Low-dose RIC- the RIC cuff will be inflated to 10 mmHg below the participant's diastolic blood pressure. The low-dose RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
48675004|NCT02774434|DEVICE|JM-105|Measurement of TcB via the JM-105 device
48675005|NCT06113003|DIETARY_SUPPLEMENT|Prebiotic|Wheat dextrin fiber
48675006|NCT06113003|DIETARY_SUPPLEMENT|Probiotic|Probiotic packet
48675007|NCT00456573|PROCEDURE|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
48675008|NCT05500651|OTHER|Dance and Movement Therapy (DMT)|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
48675009|NCT01470222|OTHER|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
48675010|NCT05781243|DRUG|Lactated Ringer Solution|Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
48675011|NCT05781243|DRUG|Normal saline|Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
48675012|NCT02579811|DRUG|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
48675013|NCT03100448|DEVICE|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
48675014|NCT06123611|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
48675015|NCT00284180|DRUG|Vinflunine|Novel second generation vinca alkaloid
48675016|NCT00284180|DRUG|Trastuzumab|Anti-HER2 monoclonal antibody
48675017|NCT05545943|OTHER|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
48675018|NCT05545943|OTHER|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
48675019|NCT05545943|OTHER|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
48675020|NCT05545943|OTHER|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
48675021|NCT02546882|BIOLOGICAL|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
48675022|NCT02546882|DRUG|saline|1 ml saline was injected for 1 cm2 area.
48675023|NCT02002988|PROCEDURE|endomyocardial BT injection|
48510216|NCT06381713|BEHAVIORAL|High intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 5 times 30' per week for 2 times 4 weeks."
48510217|NCT06381713|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 2 times 30' per week for 20 weeks."
48510218|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
48510219|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
48510220|NCT02394093|DRUG|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
48510221|NCT00710866|BIOLOGICAL|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
48510222|NCT02709291|BEHAVIORAL|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
48510223|NCT02709291|BEHAVIORAL|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
48510224|NCT05010616|DEVICE|Fixed orthodontic appliances|"Visual presentation of patient's predicted teeth alignment at the end of orthodontic treatment:~Presenting predicted teeth alignment after orthodontic treatment to patients before treatment starts, by using photos and videos of dental digital set-up.~Predicted teeth alignment can be described as: well-leveled and aligned patient's dental arches, well engaged posterior teeth and normal frontal teeth relationships."
48361844|NCT01688362|DRUG|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
48361845|NCT06227689|OTHER|Vaccine chatbot that offering HPV vaccine-related information|The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
48361846|NCT03803176|PROCEDURE|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
48149678|NCT05639556|OTHER|Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
48149679|NCT05639556|OTHER|Psychosocial questionnaire: CF Fatalism Scale|The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
48149680|NCT05639556|OTHER|Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
48510225|NCT05838196|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
48361847|NCT01008098|DRUG|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
48361848|NCT01521494|DRUG|PA21|
48361849|NCT01521494|DRUG|PA21|
48361850|NCT01521494|DRUG|PA21|
48361851|NCT01521494|DRUG|PA21|
48361852|NCT01521494|DRUG|Placebo|
48361853|NCT02545686|BEHAVIORAL|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
48361854|NCT02545686|BEHAVIORAL|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
48361855|NCT02545686|PROCEDURE|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
48510226|NCT03108885|OTHER|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
48510227|NCT02227446|DRUG|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
48149681|NCT05639556|OTHER|12-month Questionnaire|A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.
48149682|NCT05639556|OTHER|Oral glucose tolerance testing (OGTT)|For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.
48149683|NCT05639556|DEVICE|Continuous glucose monitoring (CGM)|Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.
48149684|NCT05639556|DIAGNOSTIC_TEST|Chest CT scans (When available within the past 6 months in medical records)|Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.
48361856|NCT02545686|PROCEDURE|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
48510228|NCT02754856|BIOLOGICAL|Durvalumab|Given IV
48510229|NCT02754856|OTHER|Laboratory Biomarker Analysis|Correlative studies
48510230|NCT02754856|PROCEDURE|Therapeutic Conventional Surgery|Undergo liver surgery
48510231|NCT02754856|BIOLOGICAL|Tremelimumab|Given IV
48675024|NCT05410418|DRUG|Mosunetuzumab|"Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg."
48675025|NCT05410418|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
48510232|NCT05437315|BIOLOGICAL|bi-4SCAR GD2/PSMA T cells|Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV
48510233|NCT05314088|BEHAVIORAL|RISE+|The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
48510234|NCT05314088|BEHAVIORAL|Stress Reduction Control|Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
48510235|NCT00151346|DRUG|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
48510236|NCT00151346|DRUG|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
48510237|NCT05329324|OTHER|Questionnaire for study group|Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
48361857|NCT00212615|DRUG|Oxaliplatin (Eloxatin)|
48361858|NCT00212615|DRUG|Capecitabine (Xeloda)|
48361859|NCT01634087|DRUG|Itacitinib|Itacitinib administered orally
48361860|NCT01634087|DRUG|Placebo|Placebo administered orally
48510238|NCT05329324|OTHER|Questionnaire for control group|Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
48149685|NCT05639556|DIAGNOSTIC_TEST|Hologic Dual X-Ray Absorptiometry (DXA)|DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.
48675026|NCT04814953|OTHER|questionnaires|EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
48675027|NCT05533632|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
48675028|NCT04924621|DEVICE|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
48361861|NCT00443794|DRUG|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
48675029|NCT04924621|DEVICE|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
48675030|NCT04924621|DRUG|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
48675031|NCT04924621|DRUG|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
48361862|NCT00443794|DRUG|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
48510239|NCT05976126|OTHER|Determination of dioxins (PCDD/Fs), polychlorinated biphenyls (PCBs) and trace elements|Peripheral blood (about 100 mL in several aliquots) was collected from the volunteers, in the early morning, in blood collection tubes (SST II Advance Tubes, BD Vacutainer). The samples were left for approximately 50 min, then the serum was separated from whole blood by centrifugation at 2,000 rcf for 10 min at 4 °C and then aliquots were stored at -80°C until analysis.
48361863|NCT00443794|DRUG|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
48675032|NCT04924621|DRUG|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
48149686|NCT05639556|DIAGNOSTIC_TEST|Ultrasound Sub-study of assessment of appendage muscles using ultrasound|A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.
48510240|NCT04625244|OTHER|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
48510241|NCT02296931|OTHER|Saline|Standard IV Saline Fluids
48361864|NCT00443794|DRUG|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
48361865|NCT00443794|DRUG|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
48361866|NCT00443794|DRUG|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
48361867|NCT00443794|DRUG|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
48510242|NCT02296931|DRUG|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
48510243|NCT03337958|DEVICE|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
48510244|NCT06621446|OTHER|Comprehensive intervention model|A dry eye intervention strategy: including health education, the use of eye drops, and regular review.
48675033|NCT04924621|DRUG|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
48675034|NCT04924621|DRUG|Drug use target(T group)|Make BIS \< 60 .
48675035|NCT04924621|DRUG|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
48675036|NCT04924621|DRUG|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
48675037|NCT04924621|DRUG|Propofol|Propofol 1-2ug/ml, intravenous injection
48149687|NCT05639556|DIAGNOSTIC_TEST|Psychosocial questionnaire: Hunger Vital Sign questionnaire|Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.
48149688|NCT05639556|OTHER|Respiratory symptom questionnaire: CRISS|Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.
48361868|NCT00443794|DRUG|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
48361869|NCT00443794|DRUG|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
48361870|NCT01266811|DRUG|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
48361871|NCT01266811|BIOLOGICAL|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
48361872|NCT02400593|BEHAVIORAL|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
48361873|NCT02033824|OTHER|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
48361874|NCT02033824|PROCEDURE|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
48675038|NCT04924621|DRUG|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
48675039|NCT04924621|DRUG|Drug use target|Make the BIS between 70 and 80.
48675040|NCT02664519|BEHAVIORAL|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
48675041|NCT01111227|DRUG|Propofol and isoflurane|Comparison of two anesthetic drugs
48675042|NCT04851574|DRUG|Sugammadex Injection|Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.
48675043|NCT02129712|BEHAVIORAL|Cognitive training|
48361875|NCT03594422|DRUG|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
48361876|NCT05992051|BEHAVIORAL|Exercise Therapy|Exercise therapy is considered as the integral component of interventions for chronic non-specific neck pain. It includes different type resistance training, range of motion exercises and stretching exercises to improve neck condition and release symptoms.
48510245|NCT04490616|OTHER|rTMS treatment|"A two-site rTMS stimulation delivered by a Magstim unit featuring a double 70 mm cooled coil will be applied.~MCI patients will be randomly assigned to one of the two study groups:~1. RR-Gr will receive 4 weeks of rTMS stimulation of the right temporo-parietal junction (RTPJ) and medial prefrontal cortex (MPFC);~2. PL-Gr will receive sham stimulation of the RTPJ and MPFC during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment will consist of five sessions (50 min, one per day).~For each area target, a total of 2000 pulses at 20Hz, 3-s train duration, and 28-s inter-train interval at 100% motor threshold (MT) will be delivered per session. A fixed intensity of MT will ensure a more consistent spatial spread of TMS effects in subjects' brains not influenced by differences in individual MT. In the sham condition, a sham coil will be used.~Each session lasted for about 60 min including time for set up and 50 min of stimulation."
48510246|NCT05272150|DRUG|Guselkumab|Participants will receive guselkumab as subcutaneous injection.
48510247|NCT05272150|DRUG|Placebo|Participants will receive placebo as subcutaneous injection.
48510248|NCT04528407|OTHER|Observation without intervention|This study is a follow-up study without intervention.
48510249|NCT02218801|OTHER|Evaluation of treatment for liver metastasis|
48675044|NCT03521154|DRUG|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
48675045|NCT03521154|DRUG|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
48675046|NCT06271824|BEHAVIORAL|Self-Compassion Based Resilient Caregiving Course|The Resilience Habits for Caregivers Course is a live, online, weekly 6 session program lasting 1.5 hours per session. The structure contains didactics, group discussions, guided exercises, and practices facilitated by a certified self-compassion instructor. Topics covered include: (1) noticing and accepting emotions (including conflicting emotions); (2) cultivating curiosity and self-compassion; (3) relating skillfully to difficult thoughts; (4) savoring and gratitude practices.
48675047|NCT03789292|BIOLOGICAL|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
48675048|NCT03789292|BIOLOGICAL|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
47991582|NCT03543592|DIAGNOSTIC_TEST|3 dimensional ultrasonography and Doppler|Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
48510250|NCT04187417|DRUG|topical tetracaine hydrochloride 1%|topical ophthalmologic anesthestic
48510251|NCT04187417|DRUG|Placebo|Placebo
48510252|NCT05703360|DEVICE|Audiovisual Stimulation|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
48510253|NCT01596660|DRUG|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
48510254|NCT01596660|DRUG|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
48510255|NCT04010474|PROCEDURE|Modified Surgical APGAR Score|"Four intraoperative factors~1. Lowest heart rate (HR),~2. Lowest mean arterial pressure (MAP)~3. Estimated blood loss~4. Operation time"
48510256|NCT02448368|DRUG|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
48675049|NCT05173974|DEVICE|Super Poligrip Free|A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.
48675050|NCT05173974|DEVICE|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
48675051|NCT05173974|DEVICE|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
48675052|NCT01080417|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
47991583|NCT03889769|DIAGNOSTIC_TEST|OSNA test|Analysis of lymph node with OSNA
48361877|NCT00297284|DRUG|Modafinil|
48361878|NCT01978548|DRUG|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
48510257|NCT02448368|DRUG|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
48510258|NCT02448368|DRUG|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
48510259|NCT02448368|DRUG|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
48510260|NCT02448368|DRUG|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
48510261|NCT02143921|BEHAVIORAL|Training intervention|Intervention group service providers received intervention training
48361879|NCT01978548|DRUG|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
48675053|NCT05534893|DIETARY_SUPPLEMENT|Blueberry powder group|Participants in the blueberry powder group will receive freeze dried blueberries in form of a powder
48675054|NCT05534893|DIETARY_SUPPLEMENT|Placebo powder group|Participants in the placebo powder group will receive an isocaloric placebo powder
48675055|NCT03215043|DIETARY_SUPPLEMENT|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
48510262|NCT05256394|BEHAVIORAL|Pain Manager + tailored implementation support|Individualized training, technical assistance, and workflow assessments.
48510263|NCT01413607|DEVICE|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
47991584|NCT03518333|DEVICE|Injection of adipose derived cells into penis|Injection of Icellator-derived cells
48361880|NCT01978548|DRUG|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
48361881|NCT01909635|BEHAVIORAL|Food Feelings|
48361882|NCT01909635|BEHAVIORAL|Other Feelings|
48361883|NCT03960164|COMBINATION_PRODUCT|Dermal regeneration photosynthetic matrix (DRPM)|"Primary Procedure: DRPM implantation~1. Wound bed preparation and cleaning.~2. DRPM implantation.~3. Illumination with LED device.~Secondary Procedure: Autologous partial skin graft"
48361884|NCT06201585|DEVICE|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)|SHURUI Endoscopic Surgical Robotic System (SR-ENS-600)
48361885|NCT03366935|OTHER|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
48361886|NCT03366935|OTHER|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
48510264|NCT01413607|DEVICE|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
48510265|NCT00438217|DRUG|Triptorelin (GnRH agonists)|
48510266|NCT00438217|DRUG|Leuprolide (GnRH agonists)|
48510267|NCT00198250|DRUG|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
48675056|NCT03215043|OTHER|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
48675057|NCT01424943|BEHAVIORAL|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
48675058|NCT01424943|OTHER|BabyNet Services As usual|BabyNet services as usual based on IFSP
48675059|NCT05517486|DRUG|GTX-101|Bupivacaine HCl metered spray
48675060|NCT05517486|DRUG|Bupivacaine HCl subcutaneous injection|Bupivacaine HCl, 50 mg/10 mL
48675061|NCT06026280|BEHAVIORAL|DRIVEN Application|Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
48149689|NCT05639556|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.
48361887|NCT03366935|OTHER|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
48361888|NCT05464849|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
48361889|NCT02068261|BEHAVIORAL|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
48510268|NCT02252406|DRUG|Ranolazine|Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
48510269|NCT02252406|OTHER|Placebo|Matching placebo tablets daily for 24 weeks.
48510270|NCT02304133|OTHER|Education|
48510271|NCT06632574|DRUG|paclitaxel cationic liposomes|Paclitaxel cationic liposomes is a modified new drug. In this study, administration is performed through arterial catheter infusion.
48510272|NCT02422134|OTHER|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
48510273|NCT01740245|DEVICE|Chlorhexidine vaginal suppositories|
48510274|NCT01740245|DEVICE|Polyhexamethylene biguanide vaginal suppositories|
48675062|NCT06026280|OTHER|Career Resources|Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
48675063|NCT02910141|DEVICE|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
48361890|NCT02068261|BEHAVIORAL|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
48361891|NCT04129138|OTHER|Survey Administration|Complete survey
48510275|NCT04924257|DRUG|Esketamine nasal spray|Patients will receive two treatments per week for four weeks (maximum of eight treatment sessions) or until clinical remission (MADRS \<10).
48510276|NCT04924257|PROCEDURE|Electroconvulsive therapy|Patients will receive three treatments per week for four weeks (maximum of 12 ECT treatments) or until clinical remission (MADRS \<10).
48510277|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for > 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
48675064|NCT02908581|DRUG|Placebo|Administered orally once daily
48675065|NCT02908581|DRUG|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
48675066|NCT06547762|OTHER|Hybrid approach (in-person and remote) to pediatric rehabilitation: A look beyond the COVID-19 crisis|Hybrid rehabilitation. Out patients will receive one day a week of remote therapy and the remaining (1-4 days) in person at rehabilitation hospital
48675067|NCT01887405|DRUG|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
48675068|NCT00988793|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
48675069|NCT00988793|PROCEDURE|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
48675070|NCT04180111|DEVICE|CATS Tonometer|CATS Tonometer Prism
48675071|NCT01646814|DRUG|PL2200|PL2200, containing 325 mg aspirin active ingredient
48510278|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for < 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
48510279|NCT06278480|DEVICE|MegaCarti®|Medical devices containing allogeneic cartilage
48510280|NCT06278480|PROCEDURE|microfracture|microfracture
48675072|NCT01646814|DRUG|Aspirin tablets|325 mg aspirin tablets (USP)
48675073|NCT02593058|BEHAVIORAL|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
48675074|NCT02593058|BEHAVIORAL|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
48675075|NCT01038505|DRUG|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
48675076|NCT03334838|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
48675077|NCT04398576|BEHAVIORAL|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T\&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
48675078|NCT04398576|BEHAVIORAL|Community actions|There will be embedded community-based actions within a local strategy.
48675079|NCT03054714|DEVICE|catheter replacement|catheter removal and delayed replacement, versus exchange over a guidewire
48675080|NCT01881789|DRUG|Oprozomib|Extended release (ER) tablets administered orally
48675081|NCT01881789|DRUG|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
48361892|NCT02349841|DRUG|Meropenem|To administer 2g daily 8 hourly for 14 days
48361893|NCT02349841|DRUG|Faropenem|To adminster 600mg 8 hourly daily for 14 days
48361894|NCT02349841|DRUG|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
48361895|NCT02349841|DRUG|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
48361896|NCT01071772|DRUG|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
48510281|NCT01666392|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
48510282|NCT01666392|DIETARY_SUPPLEMENT|Placebo|Placebo
48510283|NCT02125877|DRUG|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
48361897|NCT03481933|DEVICE|Transcranial stimulation|"1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
47991585|NCT04622839|OTHER|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
47991586|NCT01815125|DRUG|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
48510284|NCT02125877|DRUG|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
48675082|NCT01881789|DRUG|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.
48675083|NCT01881789|DRUG|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
48675084|NCT05749640|OTHER|Precontoured sectional matrix EZ COAT|All teeth will be treated with (Palodent ® plus sectional matrix system) (sectional matrix, biting ring, plastic diamond wedge)
48361898|NCT02106845|DRUG|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
48510285|NCT00902317|PROCEDURE|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
48675085|NCT05749640|OTHER|PerForm™|Treated with (PerForm™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
48510286|NCT00902317|PROCEDURE|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
48510287|NCT00902317|PROCEDURE|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
48675086|NCT05749640|OTHER|AdDent Trimax™|Treated with (AdDent Trimax™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
48675087|NCT05749640|OTHER|Contact Pro™|Treated with (Contact Pro™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
48675088|NCT00421148|DRUG|Sugammadex 0.5 mg/kg|IV infusion
48675089|NCT00421148|DRUG|Sugammadex 1 mg/kg|IV infusion
48675090|NCT00421148|DRUG|Sugammadex 2 mg/kg|IV infusion
48675091|NCT00421148|DRUG|Sugammadex 4 mg/kg|IV infusion
48675092|NCT00421148|DRUG|Placebo|IV infusion
47991587|NCT01815125|DRUG|PLacebo|placebo
48361899|NCT02106845|DRUG|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
48510288|NCT00902317|DEVICE|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
48675093|NCT00421148|DRUG|Rocuronium bromide|IV infusion
48675094|NCT05031143|DRUG|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
48675095|NCT03420937|DRUG|Sugammadex|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
48675096|NCT03420937|DRUG|Neostigmine, Atropin Biotika|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
48675097|NCT03568747|DEVICE|noninvasive ventilation|dual-limb circuit NIV were given on maquet servo i apparatus
48675098|NCT03568747|DEVICE|oxygen therapy|oxygen therapy were introduced to the side port of the facemask
48675099|NCT01201551|DRUG|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
48675100|NCT01201551|DRUG|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
48675101|NCT01201551|DRUG|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
48361900|NCT02106845|DRUG|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
48361901|NCT01684085|BEHAVIORAL|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
48675102|NCT04674267|OTHER|Phase 2 Intervention - Geriatric Co-Management|"Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year."
48675103|NCT00533429|DRUG|enzastaurin|1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
48675104|NCT00533429|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
48675105|NCT00533429|DRUG|carboplatin|Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
48675106|NCT00533429|DRUG|bevacizumab|15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
48675107|NCT00533429|DRUG|Placebo|oral, daily
48510289|NCT00902317|PROCEDURE|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
48510290|NCT04952909|DEVICE|ShortCut™|Splitting bioprosthetic aortic valve leaflets
48149690|NCT05639556|OTHER|Psychosocial questionnaire: Additional Health Questionnaire|Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.
48149691|NCT02470312|PROCEDURE|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
48510291|NCT00717379|DRUG|Tacrolimus|oral
48510292|NCT00717379|DRUG|Mycophenolate Mofetil|oral
48510293|NCT00717379|DRUG|Methylprednisolone or equivalent|oral
48510294|NCT00717379|DRUG|Prednisone|oral
48510295|NCT03161340|DRUG|Rapamycin|Patients will take Rapamycin 2 days before IVF until 15 days after IVF
48510296|NCT04951986|DRUG|Rifampin|Rifampicin up to 35 mg/kg/day for 14 days
48510297|NCT04951986|DRUG|Levofloxacin|Levofloxacin 750mg daily (for weight \<50kg) or 1 g daily (for weight \>50 kg) daily for 14 days
48510298|NCT04951986|DRUG|Rifampicin, Pyrazinamide, Ethambutol and Isoniazid|Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
48510299|NCT04951986|DRUG|Prednisone|Prednisone 1.5mg/kg/day for 14 days
48510300|NCT04951986|DRUG|Placebo|Placebo identical to Prednisone
48675108|NCT00137059|DRUG|acetaminophen sustained-release|
48675109|NCT04658927|DRUG|Dexamethasone, 0.4mg|iLUX + dextenza
48675110|NCT04658927|DRUG|Prednisone acetate|Prednisolone acetate 1% and iLux
48675111|NCT04658927|OTHER|Control|iLUX alone.
48675112|NCT01634230|DRUG|OCR-002|daily dose: 10 g infused over 24 hours
48675113|NCT05556889|PROCEDURE|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
48675114|NCT05556889|PROCEDURE|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
48510301|NCT00275574|PROCEDURE|acupuncture|acupuncture
48675115|NCT01983592|OTHER|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
48149692|NCT02470312|DEVICE|MediGuide|
48149693|NCT02470312|PROCEDURE|EP|
48675116|NCT01983592|OTHER|Unmedicated lactose/sucrose globule|
48675117|NCT03852784|OTHER|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
48149694|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
48149695|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
48361902|NCT01684085|BEHAVIORAL|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
48361903|NCT01684085|DRUG|Lorazepam|Lorazepam 1 mg
48510302|NCT01324531|PROCEDURE|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
48510303|NCT01324531|PROCEDURE|Bankart repair|Bankart repair based on surgeon's preference
48510304|NCT00916760|BIOLOGICAL|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
48510305|NCT00916760|BIOLOGICAL|Placebo|Subcutaneous monthly treatment
48510306|NCT04191499|DRUG|Inavolisib|Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.
48510307|NCT04191499|DRUG|Placebo|Participants will receive oral placebo on Days 1-28 of each 28-day cycle.
48675118|NCT00518050|BEHAVIORAL|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~* Screening, skin self-examination, sun protection, and other cancer preventive practices;~* Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~* Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
48675119|NCT00518050|BEHAVIORAL|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
48675120|NCT00374114|PROCEDURE|cervical conization|
48361904|NCT03223129|OTHER|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
48361905|NCT03223129|OTHER|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
48149696|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
48149697|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
48510308|NCT04191499|DRUG|Palbociclib|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
48510309|NCT04191499|DRUG|Fulvestrant|Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
48510310|NCT05434637|OTHER|Physical Therapy|Individuals randomized to this intervention will receive physical therapy, personalized for the participant's specific needs, and include exercises to be performed at home.
48149698|NCT02168855|DRUG|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
48149699|NCT02168855|BEHAVIORAL|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
48675121|NCT00374114|PROCEDURE|ultrasonic surgical aspiration of the cervix|
48675122|NCT04868344|DRUG|MRG003|Administered intravenously
48149700|NCT01827748|DEVICE|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
48510311|NCT05434637|OTHER|Sound-based Therapy|Individuals randomized to this intervention will receive sound-based therapy, consistent with an audiology-based standard of care treatment.
48510312|NCT05434637|OTHER|Combination Therapy|Individuals randomized to this intervention will receive both individualized physical therapy and sound-based therapy.
48510313|NCT03391726|OTHER|CART-19 cells|CART-19 cells treat
48510314|NCT01799369|BEHAVIORAL|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
48675123|NCT00521677|PROCEDURE|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
48675124|NCT00521677|PROCEDURE|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
48675125|NCT04422431|DRUG|Bis-Choline Tetrathiomolybdate|Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
48675126|NCT04240340|OTHER|semi-structured interview|Semi-structured, face-to-face interviews will be carried out with participants.
48675127|NCT03092310|DEVICE|Artificial Pancreas Device|Artificial Pancreas Device
48675128|NCT02171143|DRUG|ASP2409|intravenous (IV)
48675129|NCT02171143|DRUG|Placebo|intravenous (IV)
48675130|NCT00151450|DRUG|Pregabalin|
48675131|NCT00151450|DRUG|Venlafaxine XR|
48361906|NCT03049839|BEHAVIORAL|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
48361907|NCT03049839|BEHAVIORAL|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
48361908|NCT03049839|BEHAVIORAL|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
48510315|NCT06551870|OTHER|Physical activity|The complexity of the games will increase as the levels of the sports games advance, which leads to faster movements with greater demands to progress in the sequence of the games, which allows reaching increases in intensity.
48149701|NCT01827748|DEVICE|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
48361909|NCT02828202|OTHER|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
48361910|NCT02828202|OTHER|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
48361911|NCT02828202|OTHER|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
48510316|NCT03086551|DEVICE|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
48675132|NCT00873925|BIOLOGICAL|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
48675133|NCT00873925|DIETARY_SUPPLEMENT|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
48675134|NCT00873925|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
48675135|NCT02172014|DRUG|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
48675136|NCT02172014|DRUG|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
48361912|NCT03735186|BEHAVIORAL|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
48361913|NCT03136809|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
48361914|NCT00738322|DRUG|AZD1305|Solution for iv infusion, single dose
48361915|NCT00738322|DRUG|Placebo|NaCl solution for iv infusion, single dose
48361916|NCT04517825|DIAGNOSTIC_TEST|Cepheid Xpert HIV-1 Viral Load Assay|Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling
48361917|NCT03822689|DEVICE|Ventilator breathing tube F2220|M: Folding D: 22mm; L: 2.0M
48361918|NCT03822689|DEVICE|Ventilator breathing tube F2216|M: Folding; D: 22mm; L:1.6M
48675137|NCT03435068|DEVICE|Ceramic rotary bur|Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
48675138|NCT03435068|DEVICE|Diode laser|The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
48510317|NCT03086551|DEVICE|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
48510318|NCT03086551|BEHAVIORAL|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
48361919|NCT03822689|DEVICE|Ventilator breathing tube F1520|M: Folding; D: 15mm; L:2.0M
48510319|NCT06187805|DEVICE|OSSIX Volumax|OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
48510320|NCT05333731|DRUG|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
48510321|NCT04210050|DEVICE|Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.|"In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time.~For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring."
48675139|NCT03435068|DEVICE|Scalpel|Scalpel surgery were performed as control group (conventioanl group).
48675140|NCT01055145|DRUG|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
48675141|NCT00003873|DRUG|fluorouracil|Given IV or orally
48675142|NCT00003873|DRUG|eniluracil|Given orally
48675143|NCT01160133|OTHER|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
48675144|NCT01160133|OTHER|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
48361920|NCT03822689|DEVICE|Ventilator breathing tube F1516|M: Folding; D: 15mm; L:1.6M
48361921|NCT03822689|DEVICE|Ventilator breathing tube U1016|M: Unfolding; D: 10mm; L:1.6M
48361922|NCT03822689|DEVICE|Ventilator breathing tube U1516|M: Unfolding; D: 15mm; L:1.6M
48361923|NCT03822689|DEVICE|Ventilator breathing tube CA20|M: Co-axis; L:2.0M
48361924|NCT03822689|DEVICE|Ventilator breathing tube CA16|M: Co-axis; L:1.6M
48361925|NCT04890028|RADIATION|F-DOPA PET/CT|"All subjects will be imaged~1 time injection of 2 MBq/kg of 18F-DOPA"
48361926|NCT01728194|DRUG|Escitalopram|20 mg target dose for 12 weeks
48361927|NCT01728194|OTHER|Magnetic Resonance Imaging|Structural and functional MRI of the brain for research purposes.
48675145|NCT05746858|OTHER|no intervention (observational study)|No intervention (observational study)
48675146|NCT01060254|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
48675147|NCT01060254|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
48361928|NCT03243201|DRUG|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
48361929|NCT03243201|OTHER|Purified Water|Purified water will be given as placebo
48675148|NCT03534050|RADIATION|postoperative adjuvant RT|
48675149|NCT04794348|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Autologous units of fresh frozen plasma collected from the subject by plasmapheresis
48361930|NCT04586920|DRUG|LY3509754|Administered orally
48361931|NCT04586920|DRUG|Placebo|Administered orally
48361932|NCT04586920|DRUG|Itraconazole|Administered orally
48361933|NCT04586920|DRUG|Midazolam|Administered orally
48361934|NCT00799370|PROCEDURE|Early weight bearing|Weight bearing performed immediately after surgery
48361935|NCT00799370|PROCEDURE|Delayed weight bearing|Weight bearing performed 2 months after surgery
48361936|NCT00082628|DRUG|Placebo|Placebo matched to serostim® as subcutaneous injection.
48361937|NCT00082628|DRUG|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
48361938|NCT00082628|DRUG|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
48361939|NCT03770663|DRUG|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
48361940|NCT03770663|DRUG|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
48361941|NCT06403358|DIETARY_SUPPLEMENT|YOVIS BIMBI|42 male and female subjects, aged between 3 and 14 years with acute diarrhea will be treated with Yovis BAMBINI. The 42 subjects will be recruited with a competitive enrolment at the involved study sites.
48361942|NCT00078715|DRUG|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
48361943|NCT00078715|DRUG|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
48675150|NCT04794348|BIOLOGICAL|Freeze Dried Plasma (FDP)|Autologous units of freeze dried plasma manufactured from plasma collected from the subject by plasmapheresis
48361944|NCT05230992|DEVICE|Cryoprobes First|In this experimental group, the Cryoprobe is used in first and the classic biopsy forceps in a second time. This medical device under study is the flexible, single-use Cryoprobe, supplied in sterile condition, 1.1 mm in diameter, 1150 mm long, with extraction tube, 817 mm long (reference 20402-401), or 757 mm long (reference 20402-402) marketed. These cryoprobes are covered by a CE marking. Cryoprobes must be used in conjunction with the Erbecryo®2 device and its accessories.
48361945|NCT05230992|DEVICE|Cryoprobes Second|In this second experimental group, the same medical devices are used but in the other order.
48510322|NCT04210050|DIAGNOSTIC_TEST|Arterial blood gas (ABG) and serum bicarbonate level|Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
48675151|NCT03201640|BEHAVIORAL|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
48675152|NCT03201640|BEHAVIORAL|virtual|Participants will be shown an immersive virtual reality preparation for surgery
48361946|NCT02798172|DRUG|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
48361947|NCT06178107|DIETARY_SUPPLEMENT|LP-LDL Probiotic|LP-LDL a dietary food supplement probiotic
48361948|NCT06178107|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo comparator Maltodextrin
48361949|NCT00952133|DRUG|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
48361950|NCT00952133|DRUG|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
48675153|NCT00411424|DRUG|ASK8007|IV
48675154|NCT00411424|DRUG|Placebo|IV
48361951|NCT05238324|BIOLOGICAL|Genetic HMI-203|HMI-203 delivered intravenously
48361952|NCT03812198|DRUG|LEO 32731 modified release tablet|At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
48361953|NCT03812198|DRUG|LEO 32731 blend, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
47991588|NCT06200077|PROCEDURE|Modified Ridge-Splitting|Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.
47991589|NCT04751825|BEHAVIORAL|I-EAET|See information in arm description.
47991590|NCT03340025|DEVICE|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
47991591|NCT03340025|DEVICE|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
48149702|NCT03368105|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy."
48510323|NCT04210050|DIAGNOSTIC_TEST|Overnight home oximetry and transcutaneous CO2 monitoring|will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.
48510324|NCT03938285|OTHER|Theranova 400 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
48510325|NCT03938285|OTHER|FxCordiax 120 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
48510326|NCT00609180|BEHAVIORAL|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
48510327|NCT00609180|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
48510328|NCT00609180|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
48510329|NCT00609180|DIETARY_SUPPLEMENT|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
48510330|NCT01242722|DEVICE|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
48510331|NCT04811560|DRUG|Bleximenib|Bleximenib is administered orally.
48510332|NCT06633809|OTHER|Immediate endovascular therapy|The best medical therapy includes intravenous fibrinolysis, anticoagulants or antiplatelet, but NOT any immediate endovascular therapies.
48510333|NCT04981327|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|Apixaban 5 MG BID versus Apixaban 2.5 MG BID
48510334|NCT03734939|OTHER|None intervention is planned.|None intervention is planned, just a survey.
48510335|NCT01753557|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
48510336|NCT01753557|DRUG|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
48510337|NCT01753557|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
48510338|NCT04540796|DRUG|JNJ-75348780|Participants will receive JNJ-75348780 by subcutaneous (SC) administration.
48675155|NCT01452477|DRUG|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
48149703|NCT05496829|BEHAVIORAL|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
48149704|NCT05496829|OTHER|Usual Care|Receipt of usual care from providers
48149705|NCT05888285|PROCEDURE|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
48149706|NCT05888285|PROCEDURE|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
48149707|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
48361954|NCT03812198|DRUG|LEO 32731 API, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
48675156|NCT01452477|DRUG|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
48675157|NCT02589288|PROCEDURE|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
48675158|NCT02589288|PROCEDURE|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
48675159|NCT04095065|BEHAVIORAL|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking.
48675160|NCT04095065|BEHAVIORAL|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing \& treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse \& sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
48675161|NCT04095065|BEHAVIORAL|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
48149708|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
48149709|NCT03169855|DIAGNOSTIC_TEST|Slit lamp (LOCS III Score)|Diagnostic procedure only
48149710|NCT01029925|DRUG|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
48361955|NCT03812198|DRUG|LEO 32731 soft capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
48361956|NCT03812198|DRUG|LEO 32731 gastro-resistant capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
48361957|NCT03812198|DRUG|LEO 32731|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
48361958|NCT03812198|OTHER|Placebo|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
48361959|NCT03793010|DRUG|FX006|Single Intra-articular injection
48361960|NCT03793010|DRUG|Normal saline|Single Intra-articular injection
48510339|NCT05576077|BIOLOGICAL|TBio-4101|TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.
48510340|NCT05576077|DRUG|Pembrolizumab|Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
48149711|NCT01535261|DRUG|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
48149712|NCT06505863|PROCEDURE|Transanal total mesorectal excision|Transanal approach in surgical treatment of rectal cancer along the anatomical and embryological planes, called total mesorectal excision, as described in 1988 by Heald et al.
48149713|NCT00024245|DRUG|pralatrexate|
48149714|NCT00024245|DRUG|probenecid|
48149715|NCT03080337|OTHER|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
48675162|NCT04095065|BEHAVIORAL|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
48149716|NCT04558021|DRUG|Niclosamide suspension|200mg/10ml
48149717|NCT04558021|OTHER|Placebo|10ml placebo(absent of niclosamide)
48149718|NCT03610984|OTHER|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
48675163|NCT05030584|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
48675164|NCT05030584|DRUG|Placebo|Matching placebo orally once daily.
48361961|NCT04441658|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
48361962|NCT04441658|BIOLOGICAL|saline|saline containing human albumin will be infused to the control group
48361963|NCT03167866|BEHAVIORAL|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
48361964|NCT03167866|BEHAVIORAL|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
48361965|NCT03480620|OTHER|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
48149719|NCT04411771|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
48361966|NCT03480620|OTHER|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
48361967|NCT00000970|DRUG|Foscarnet sodium|
48361968|NCT00000970|DRUG|Ganciclovir|
48675165|NCT02779868|DIETARY_SUPPLEMENT|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
48361969|NCT01603628|BIOLOGICAL|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
48361970|NCT01603628|DRUG|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
48361971|NCT00997906|DRUG|carboplatin,|Given IV
48361972|NCT00997906|DRUG|cisplatin|Given IV
48361973|NCT00997906|DRUG|gemcitabine hydrochloride|Given IV
48361974|NCT00997906|DRUG|paclitaxel|Given IV
48361975|NCT00997906|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
48361976|NCT03860181|PROCEDURE|Subcuticular Sutures - Surgeon 1|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
48510341|NCT05007821|DRUG|Linezolid 600 mg|One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26
48510342|NCT05007821|DRUG|Linezolid 1200 mg (QD)|Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4
48510343|NCT05007821|DRUG|Linezolid 1200 mg (TIW)|Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26
48675166|NCT02779868|DIETARY_SUPPLEMENT|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
48675167|NCT04203589|BEHAVIORAL|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
48675168|NCT04203589|OTHER|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
48675169|NCT00548834|DRUG|CDP870|
48675170|NCT04046393|DEVICE|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
48675171|NCT04046393|DEVICE|Meridian Energy Analysis Device(MEAD)|measure meridian energy
48675172|NCT04046393|PROCEDURE|bacteria culture|use culture swab to culture nasal discharge
48675173|NCT04046393|PROCEDURE|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
48675174|NCT04046393|COMBINATION_PRODUCT|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
48361977|NCT03860181|PROCEDURE|Metal Staples - Surgeon 2|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
48361978|NCT03860181|DEVICE|PRINEO - Surgeon 1|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
48675175|NCT05246969|OTHER|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
48675176|NCT05993793|DEVICE|Fototherapy|The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
48675177|NCT02609425|DEVICE|Stratafix PGA Suture|Subject leak Stricture rates post procedure
48675178|NCT00122889|DRUG|Garlic powder with high allicin content|
48675179|NCT00122889|DRUG|Garlic powder with low allicin content|
48675180|NCT00122889|DRUG|Garlic oil|
48675181|NCT00122889|DRUG|Aged garlic|
48675182|NCT04092114|OTHER|Control|Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
48675183|NCT04092114|BEHAVIORAL|CHARISMA Intervention|"SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning"
48675184|NCT00766116|DRUG|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
48675185|NCT00766116|DRUG|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
48675186|NCT00287781|DRUG|Lidocaine|
48675187|NCT06154616|DIETARY_SUPPLEMENT|Control Product|Lactose-free skimmed milk
48361979|NCT03860181|DEVICE|PRINEO - Surgeon 2|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
48675188|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250|Lactose-free skimmed milk enriched with 250 mg aswaghanda
48675189|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250 + TRP|Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan
48675190|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 600|Lactose-free skimmed milk enriched with 600 mg aswaghanda
48675191|NCT00057057|BEHAVIORAL|Telephone Care|
48675192|NCT00272220|BEHAVIORAL|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
48675193|NCT00466180|BEHAVIORAL|Nevirapine from twice-a-day to once-a-day|
48675194|NCT01757665|DEVICE|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
48675195|NCT03172143|PROCEDURE|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
48675196|NCT03172143|PROCEDURE|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
48675197|NCT05265546|DRUG|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
48675198|NCT04802603|RADIATION|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
48361980|NCT06205459|PROCEDURE|deep marginal acquisition using thermacut bur|thermacut bur is a tool which doesn't contain any abrasives so it is much safer on the root surface of both prepared and adjacent teeth, and yields better treatment outcome in cases when exposing deep margins is needed.
48361981|NCT03055806|DRUG|IX-01 400 mg|IX-01 400 mg caplet
48675199|NCT02273102|DRUG|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
48675200|NCT02273102|DRUG|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
48675201|NCT04197284|DEVICE|Biofeedback, Myomed 632|"Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses."
48675202|NCT04197284|DEVICE|device for electrical stimulation, BTL 4000 Smart|Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.
48675203|NCT04197284|OTHER|kinesitherapy|isometric exercise of the quadriceps muscle
48675204|NCT05865951|OTHER|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
48675205|NCT05865951|OTHER|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
48361982|NCT03055806|DRUG|Placebo|Placebo caplet(s)
48361983|NCT03055806|DRUG|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
48675206|NCT00750230|DIETARY_SUPPLEMENT|NEM|see Treatment Arm
48149720|NCT04411771|BEHAVIORAL|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
48361984|NCT03055806|DRUG|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
48361985|NCT02530281|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
48361986|NCT02530281|OTHER|Vehicle|Vehicle (placebo) topical wipes
48675207|NCT03012334|DRUG|Lasmiditan|Dose is based on treatment sequence in 5-way crossover
48675208|NCT03012334|DRUG|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
48675209|NCT03012334|OTHER|Placebo|Placebo comparator based on treatment sequence in 5-way crossover
48361987|NCT05291429|DEVICE|OVR Health's VR experience|Virtual reality experience
48675210|NCT00290810|BIOLOGICAL|bevacizumab|Given IV
48675211|NCT01861847|DRUG|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
48675212|NCT01861847|DRUG|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
48675213|NCT04734262|DRUG|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
48361988|NCT03724799|DEVICE|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
48361989|NCT00141297|DRUG|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
48675214|NCT04734262|DRUG|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
48361990|NCT05791357|DIAGNOSTIC_TEST|PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA|Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
48361991|NCT00693524|DRUG|tacrolimus|oral
48675215|NCT04734262|DRUG|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
48361992|NCT00693524|DRUG|Anti-IL2R AB|i.v.
48675216|NCT01322256|PROCEDURE|Bone scintigraphy|Bone scintigraphy of the affected area
48675217|NCT01322256|PROCEDURE|Leukoscan|Scintigraphy with labeled neutrophils
48675218|NCT01322256|PROCEDURE|PET / CT|PET / CT of the affected area
48149721|NCT06210555|PROCEDURE|Renal transplantation|Operative procedure - receipt of a kidney
48149722|NCT06210555|PROCEDURE|Living kidney donation|Operative procedure - donation of a kidney
48361993|NCT00693524|DRUG|Mycophenolate mofetil|oral
48361994|NCT00693524|DRUG|prednisone|oral
48361995|NCT03672721|DRUG|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
48361996|NCT05507190|OTHER|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
48361997|NCT02962973|DEVICE|CARMAT TAH|
48675219|NCT01322256|PROCEDURE|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
48675220|NCT01322256|BIOLOGICAL|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
48675221|NCT01731795|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
48675222|NCT00948077|DRUG|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)"
48675223|NCT06132945|DRUG|Cabozantinib|Cabozantinib (40 mg PO daily)
48675224|NCT06132945|DEVICE|Nivolumab|Nivolumab (480 mg IV Day 1)
48675225|NCT06132945|RADIATION|Stereotactic Radiosurgery (SRS)|Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
48675226|NCT04335968|DRUG|Melatonin 4 mg|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
48675227|NCT04335968|DRUG|Placebo oral tablet|placebo of this drug with the same schedule, during the same period of time.
48675228|NCT01421966|BIOLOGICAL|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
48361998|NCT02962973|PROCEDURE|Surgical intervention|
48361999|NCT00460499|DRUG|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
48362000|NCT00460499|DRUG|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
48362001|NCT00460499|DRUG|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
48362002|NCT00327834|DRUG|atomoxetine|
48362003|NCT01408862|OTHER|venous puncture|Blood for in vitro studies will be drawn
48362004|NCT01849289|DRUG|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
48362005|NCT01849289|DRUG|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
48362006|NCT04606810|OTHER|multidisciplinary educational intervention|At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
48362007|NCT01177826|PROCEDURE|Sample collection|Stool sample
48362008|NCT05170581|DRUG|Sintilimab Combined with Platinum-containing Chemotherapy|Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
48362009|NCT04537364|DIAGNOSTIC_TEST|combined diagnosis of renal parenchymal damage|"This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity \>1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time."
48675229|NCT01421966|BIOLOGICAL|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
48675230|NCT01478022|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
48149725|NCT04447586|OTHER|Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer|"Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study."
48149726|NCT04447586|OTHER|Pressure measurement during exhalation through an alternative PEP device/soft drink straw.|"Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets."
48362010|NCT01097057|DRUG|Carboplatin|Given IV
48510344|NCT05007821|DRUG|Bedaquiline 200 mg|Two 100mg tablets taken orally once daily in the morning during weeks 1-8
48675231|NCT01478022|DRUG|Ibuprofen|Ibuprofen 200 mg daily, capsules
48149727|NCT01843049|RADIATION|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
48149728|NCT01843049|DRUG|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
48362011|NCT01097057|DRUG|Etoposide|Given IV
48362012|NCT01097057|BIOLOGICAL|Filgrastim|Given SC
48362013|NCT01097057|DRUG|Ifosfamide|Given IV
48362014|NCT01097057|PROCEDURE|Leukapheresis|Given through catheter
48510345|NCT05007821|DRUG|Bedaquiline 100 mg|One 100mg tablet taken orally once daily in the morning during weeks 9-26
48675232|NCT01478022|OTHER|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
48510346|NCT05007821|DRUG|Delamanid 300 mg|Six 50mg tablets taken orally once daily in the morning during weeks 1-26
48510347|NCT05007821|DRUG|Clofazimine 300 mg|Three 100mg capsules taken orally once daily in the morning during weeks 1-2
48510348|NCT05007821|DRUG|Clofazimine 100 mg|One 100mg capsule taken orally once daily in the morning during weeks 3-26
48510349|NCT00022282|DRUG|shark cartilage extract AE-941|
48510350|NCT06633627|OTHER|Recording of brain activity using electroencephalography (EEG)|Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared
48510351|NCT04611529|DRUG|Ibuprofen 400 mg|Ibuprofen 400mg
48510352|NCT04611529|DRUG|Topical diclofenac|Diclofenac 1% gel 4gm
48510353|NCT03624907|RADIATION|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
48362015|NCT01097057|DRUG|Plerixafor|Given SC
48362016|NCT01097057|BIOLOGICAL|Rituximab|Given IV
48510354|NCT03624907|RADIATION|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
48510355|NCT04022408|DIAGNOSTIC_TEST|Liquid based cytology|Liquid based cytology
48510356|NCT04022408|DIAGNOSTIC_TEST|Conventional cytology|Conventional cytology
48510357|NCT04600258|DIETARY_SUPPLEMENT|Dark Chocolate|The patients will receive 40g per day of dark chocolate for 2 months
48510358|NCT01475097|DRUG|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
48510359|NCT01475097|DRUG|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
48510360|NCT01014793|DRUG|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
48510361|NCT04241926|DIAGNOSTIC_TEST|transpolmonary thermodilution|Thermodilution was attempted via PICC and via CICC in the same patient
48362017|NCT04862689|DEVICE|Ringer Perfusion Balloon Catheter|Non-emergent Percutaneous Coronary Intervention (PCI) for treatment of a coronary artery lesion with Ringer Perfusion Balloon Catheter.
48362018|NCT00963742|DEVICE|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
48675233|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube plus bougie|"Use of a straight, malleable, semirigid bougie on first-attempt intubation. The required bougie is at least 60cm length, a coudé tip is recommended but not required. Operator may choose whether to bend the bougie prior to intubation.~During laryngoscopy, the operator will insert the bougie into the trachea under direct or indirect visual control. If the bougie is successfully placed in the trachea, an assistant will load the endotracheal tube directly over the bougie while the operator will manually stabilize the bougie. Once the bougie has reached the mouth, the assistant will then stabilize the bougie, and the operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube. Then, the assistant will withdraw the bougie from the endotracheal tube.~The use of a stylet is not permitted."
47991592|NCT03099447|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
47991593|NCT03099447|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
47991594|NCT03099447|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
48362019|NCT05824611|OTHER|collect movement data from epileptic seizures|non-invasive recording of movement data during care as usual
48362020|NCT03449186|OTHER|Saliva collection|
48362021|NCT03449186|OTHER|GCF collection|
48362022|NCT01454531|DRUG|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
48675234|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube alone|"During laryngoscopy, the operator will insert the endotracheal tube alone into the trachea under direct or indirect visual control. The operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube.~The use of a stylet is not permitted."
48675235|NCT01267474|OTHER|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
48675236|NCT01267474|OTHER|Control|The control group received only three one-hour general sessions on health issues.
48675237|NCT02071771|DEVICE|Nelfilcon A toric contact lenses|
47991595|NCT04595513|DRUG|TAVT-18 (sirolimus)|The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
48510362|NCT03507647|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"MBCT is a manualised group skills-training program (Segal, Williams \& Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently."
48675238|NCT02071771|DEVICE|Etafilcon A toric contact lenses|
48675239|NCT03099122|BIOLOGICAL|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder~Route of administration: intravenous"
48675240|NCT03099122|DRUG|Tacrolimus|"Pharmaceutical form: tablet~Route of administration: oral"
48675241|NCT03099122|DRUG|Methylprednisolone|"Pharmaceutical form: powder~Route of administration: intravenous"
48675242|NCT03099122|DRUG|Mycophenolate mofetil|"Pharmaceutical form: capsule~Route of administration: oral"
48675243|NCT03099122|DRUG|Mycophenolate Na|"Pharmaceutical form: capsule~Route of administration: oral"
48149729|NCT03779776|OTHER|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
48510363|NCT03507647|OTHER|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
48510364|NCT01590797|DRUG|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
48675244|NCT03099122|DRUG|prednisone|"Pharmaceutical form: tablet~Route of administration: oral"
48675245|NCT00806260|DRUG|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
48675246|NCT00806260|DRUG|Placebo|Placebo daily for 4 weeks
47991596|NCT00118976|DRUG|Lisinopril|
47991597|NCT04432051|BEHAVIORAL|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
48149730|NCT03779776|OTHER|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
48149731|NCT01540019|DRUG|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
48149732|NCT03635801|DEVICE|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
48149733|NCT00244426|DRUG|indobufen|Indobufen capsules 100 and 200mg
48675247|NCT00806260|OTHER|Alcohol|
48675248|NCT00806260|OTHER|alcohol placebo|fruit juice
48675249|NCT02797756|PROCEDURE|Esophago-gastro-duodenoscopy (EGD) with biopsy|
48675250|NCT02797756|PROCEDURE|Esophageal Impedance Monitoring (EIM)|
48675251|NCT03083782|DRUG|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
48675252|NCT03083782|DRUG|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
47991598|NCT03485820|BEHAVIORAL|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
47991599|NCT03485820|BEHAVIORAL|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
47991600|NCT00991055|DRUG|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
47991601|NCT05970757|DIAGNOSTIC_TEST|Extended MRI|Extension of the brain tumor MRI-protocol
47991602|NCT04417920|PROCEDURE|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
48149734|NCT00244426|DRUG|aspirin|Acetylsalicylic acid capsules 300mg
48149735|NCT00412178|DEVICE|telecommunication based glucose monitoring system|
48149736|NCT05686967|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
48149737|NCT05686967|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
48149738|NCT05686967|BEHAVIORAL|Aerobic exercise|Moderate intensity aerobic exercise on the treadmill
48362023|NCT04030806|OTHER|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
48362024|NCT04759729|COMBINATION_PRODUCT|Probiotic and vitamin D|"Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements."
48510365|NCT01590797|DRUG|Placebo|Matching placebo once daily for 24 weeks
48675253|NCT03083782|DRUG|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
48675254|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
48362025|NCT04759729|DIETARY_SUPPLEMENT|placebo and vitamin D|Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
48362026|NCT01385098|DIETARY_SUPPLEMENT|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
48362027|NCT02429076|DRUG|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
48362028|NCT02429076|DRUG|Placebo|normal saline
48362029|NCT02429076|DRUG|Sevoflurane|Inhaled anesthetic
48510366|NCT01590797|BIOLOGICAL|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
48510367|NCT01590797|DRUG|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
48510368|NCT03095638|DRUG|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
48675255|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
48675256|NCT02015039|DRUG|BoNT Injections|
48675257|NCT02015039|PROCEDURE|Occupational Therapy|
48675258|NCT02533310|OTHER|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
48675259|NCT02533310|OTHER|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
48362030|NCT02429076|DRUG|Propofol|IV anesthetic
48362031|NCT03687229|DIAGNOSTIC_TEST|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
47991603|NCT01536379|DRUG|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
47991604|NCT01536379|DRUG|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
47991605|NCT01680718|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
47991606|NCT01680718|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
47991607|NCT01680718|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
47991608|NCT03904433|OTHER|Coconut oil|Coconut oil given in coffee with cream
48362032|NCT03687229|DIAGNOSTIC_TEST|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
48362033|NCT04737551|OTHER|Follow-up only|Only routine follow-up but no treatment
48362034|NCT04737551|DRUG|Adjuvant chemotherapy|Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
48362035|NCT04737551|RADIATION|Adjuvant chemoradiotherapy|"Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion."
48510369|NCT03095638|DRUG|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
48675260|NCT05230511|DRUG|Lactobacillus RhamnosusGG|LGG® (Culturelle Probiotic LGG®) will be used. This is the product we have used in the past and for which we have demonstrated safety, tolerability, and preliminary efficacy. For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG® capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG® mixture into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will be asked to return any remaining capsules at the end of the study. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
48675261|NCT05230511|DRUG|Saline bladder wash|Participants will draw up the 45cc of normal saline into a 60cc syringe and instill via the intermittent catheter after the last catheterization prior to going to bed after trigger symptoms occur. Participants will be instructed to complete the USQNB-IC at the time of symptoms (in real time), and then continue completing the USQNB-IC at the determined frequency for the phase.
48675262|NCT01583673|OTHER|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
48675263|NCT01583673|OTHER|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
48675264|NCT00598819|DEVICE|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
48675265|NCT06028828|DRUG|Fludarabine|Given Day-5, Day-4, Day-3, Day-2
47991609|NCT03904433|DIETARY_SUPPLEMENT|Caprylic acid|Caprylic acid given in coffee with cream
48510370|NCT03095638|DRUG|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
48510371|NCT03095638|DRUG|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
48675266|NCT06028828|DRUG|Melphalan|Given Day-5
48675267|NCT06028828|RADIATION|Total Body Irradiation|Given Day-1
48675268|NCT01904721|DRUG|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
48675269|NCT01904721|DRUG|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
47991610|NCT03904433|OTHER|Sunflower oil|Sunflower oil given in coffee with cream
47991611|NCT03904433|OTHER|Glucose|Glucose dissolved in water
48362036|NCT04737551|RADIATION|Adjuvant chemoradiotherapy + Adjuvant chemotherapy|See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
48675270|NCT01904721|DRUG|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
48675271|NCT06091358|DEVICE|PrO2|"The intervention arm will receive a handheld PrO2 device and will participate in two unsupervised sessions and one supervised via Microsoft teams sessions per week.~Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6 x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day each week."
48675272|NCT01207206|DRUG|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
48675273|NCT03776084|DEVICE|Continuous Positive Airway Pressure|CPAP indication
48675274|NCT04739111|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)|In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
48675275|NCT04494685|DEVICE|Intervention group (Robotic rehabilitation)|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland). The training protocol has a progression of the board inclination up to 90º associated with flexion/extension movements of the knees and hips, with time evolution of up to 40 minutes. Such equipment is associated with electrostimulation of the quadriceps, hamstrings, sural triceps and anterior tibialis.
47991612|NCT01916356|OTHER|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
47991613|NCT05375695|OTHER|Time-restricted eating|"The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care."
47991614|NCT03504696|OTHER|Non-interventional|Non-interventional
48362037|NCT00087594|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
48362038|NCT00087594|DRUG|ribavirin|1000/1200mg (\< or \>= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
48675276|NCT04494685|OTHER|Control group (Conventional physiotherapy)|Knee and hip flexion and extension movements, hip adduction, and abduction, respecting the articular physiology of each joint. Weight transfer will also be performed in the sitting and standing position, mini squat, and gait training. All exercises will have a total of 10 repetitions in three sets. In the end, stretching of the upper and lower limbs will be performed.
47991615|NCT02710045|BIOLOGICAL|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
47991616|NCT02710045|BIOLOGICAL|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
48362039|NCT06093321|DEVICE|SYB PDO Thread|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
48362040|NCT06093321|DEVICE|MINT lift®|Apply the test device (SYB PDO Thread) and the control device (MINT lift®) with 7±1 lines on each side of the nasolabial fold.
48362041|NCT00382382|OTHER|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
48362042|NCT06107387|BEHAVIORAL|Binge Eating Self-help for Teens|Guided self-help intervention
48362043|NCT00208572|DRUG|Citalopram|
48362044|NCT00977366|OTHER|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
48675277|NCT01587248|DEVICE|Harmonic|Dissection with harmonic scalpel
48149739|NCT01308879|BEHAVIORAL|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
48362045|NCT00977366|OTHER|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
48510372|NCT05551871|DRUG|Simvastatin|the patient will receive Simvastatin for 7 days
48510373|NCT05551871|DRUG|Placebo drug|the patient will receive Placebo drug for 7 days
48510374|NCT05410587|DEVICE|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
48510375|NCT06109311|DRUG|Orforglipron|Administered orally.
48510376|NCT06109311|DRUG|Placebo|Administered orally.
48510377|NCT00805961|RADIATION|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
48675278|NCT01587248|PROCEDURE|electrocautery|Dissection in modified radical mastectomy
48675279|NCT03250143|DRUG|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
48675280|NCT03034707|DIETARY_SUPPLEMENT|biotin|
48675281|NCT00146861|DEVICE|sensor programming|
48675282|NCT01888861|DIETARY_SUPPLEMENT|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
48675283|NCT01888861|DRUG|placebo|the patients in this arm were received 900mg placebo through NG tube.
48675284|NCT05834985|PROCEDURE|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
48149740|NCT05789134|OTHER|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
48510378|NCT00805961|DRUG|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
48510379|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
48510380|NCT00805961|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
48510381|NCT00805961|DRUG|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
48675285|NCT02539186|BIOLOGICAL|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
48149741|NCT06186063|OTHER|Pramlintide|At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
48510382|NCT03414476|OTHER|Hair follicles sampling|The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
48510383|NCT04999891|OTHER|Neurocognitive tests|Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
48510384|NCT05503511|DRUG|NPT 2042 (bumetanide analog) or Matching Placebo|Soft gelatin capsules
48510385|NCT05746832|PROCEDURE|Endoscopic stenting Retrograde Cholangiopancreatography (ERCP)|Assessment of the differences in stone size and the largest CBD diameter before and after stenting in one or two sessions. Stone clearance and complications were also determined with the ERCP, and factors associated with complete clearance were evaluated in patients with difficult CBD stones (a large \[≥ 20 mm\] or multiple \[≥ 3 sized ≥ 15 mm\] CBD stones). And also compared the outcomes with conventional procedure of open surgery.
48510386|NCT03063918|OTHER|Informational Intervention|Receive a workbook
48510387|NCT03063918|OTHER|Quality-of-Life Assessment|Ancillary studies
48510388|NCT03063918|OTHER|Questionnaire Administration|Ancillary studies
48510389|NCT03063918|OTHER|Survey Administration|Ancillary studies
48510390|NCT03063918|BEHAVIORAL|Telephone-Based Intervention|Receive personalized dietary intervention
48675286|NCT02539186|DEVICE|splint|
48675287|NCT04211454|OTHER|No intervention|There is no intervention for this study.
48675288|NCT04038294|DIETARY_SUPPLEMENT|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
48675289|NCT04038294|DIETARY_SUPPLEMENT|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
48149742|NCT06186063|OTHER|Placebo (saline) infusion|At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
47991617|NCT02710045|BIOLOGICAL|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
48510391|NCT01119365|OTHER|Bright light|Light is administered through a custom designed mask with LED lights.
48510392|NCT03069326|DRUG|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
48510393|NCT03069326|DRUG|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
48510394|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 500 mg|500 mg tablet taken orally with one meal daily
48510395|NCT04036110|DIETARY_SUPPLEMENT|Vitamin C 1000 mg|1000 mg tablet taken orally with one meal daily
48510396|NCT04036110|OTHER|Placebo|1 tablet taken orally with one meal daily
48510397|NCT00530218|DRUG|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
48510398|NCT02234219|PROCEDURE|Heart-shape anastomosis|a new operation approach for Hirschsprung disease
48510399|NCT02234219|PROCEDURE|Soave anastomosis|traditional approach for Hirschsprung disease
48675290|NCT06199024|DIETARY_SUPPLEMENT|Oral cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
48675291|NCT03289143|DRUG|Semorinemab|Participants will receive Semorinemab intravenously (IV).
48510400|NCT05107596|DRUG|64Cu-DOTA-ECL1i|Inject PET Radioisotope for imaging
47991618|NCT02905682|DRUG|Desmopressin|
47991619|NCT02905682|DRUG|Placebo|
47991620|NCT01782859|DRUG|Prednisone|
47991621|NCT01782859|DRUG|Hydrocortisone|
48149743|NCT01033123|DRUG|BSI-201|IV infusion, 5.6 mg/kg
48149744|NCT00608959|DRUG|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
48149745|NCT00608959|DRUG|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
48510401|NCT06498167|DRUG|Upadacitinib|Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).
48510402|NCT03138590|DEVICE|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
48510403|NCT02032680|BEHAVIORAL|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
48510404|NCT02032680|BEHAVIORAL|In-persons Multi-Family Group Psycho-Education treatment|This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.
48510405|NCT02032680|OTHER|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
48510406|NCT03991676|BEHAVIORAL|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
47991622|NCT01782859|DRUG|Placebo (for Prednisone)|
47991623|NCT06537154|PROCEDURE|Active Surveillance|Participant found to have a cCR will be randomized to either standard of care or investigational active surveillance.
47991624|NCT06537154|PROCEDURE|Control arm - Definitive bladder treatment|Standard of care, consisting of radical cystectomy or chemo-radiation of the bladder
47991625|NCT01824407|DEVICE|Electrohydraulic-generated shock wave|
47991626|NCT01824407|DEVICE|Sham device plus standard of care|
47991627|NCT00367081|DRUG|TMX-SMX (Bactrim(R))|
47991628|NCT00367081|DRUG|Pyrimethamine plus Sulfadiazine plus leucoverin|
47991629|NCT01462721|DEVICE|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
47991630|NCT00000586|DRUG|hydroxyurea|
47991631|NCT00991666|PROCEDURE|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
47991632|NCT02202642|PROCEDURE|collagenase|Cultured limbal stem cells transplantation
47991633|NCT02307357|BEHAVIORAL|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
47991634|NCT06095323|DEVICE|compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg)|The intervention group will wear compression sleeves for upper limbs with a pressure level of 1 (15-20mmHg) during the day for 12 months.
47991635|NCT04490720|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
47991636|NCT04490720|DIETARY_SUPPLEMENT|Buckwheat husk extract|consume 1 sachet per day for 2 months
47991637|NCT00853723|DRUG|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
48510407|NCT03002701|BEHAVIORAL|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
47991638|NCT00853723|DRUG|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
48149746|NCT06284694|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|See experimental arm description
48149747|NCT00882375|DRUG|Nicotine|Nicotine administered using novel NRT user instructions
48149748|NCT00882375|DRUG|Placebo|Placebo administered using novel NRT user instructions
48149749|NCT00460434|DEVICE|TVT|Prophylactic TVT
48149750|NCT00460434|OTHER|Sham|Sham TVT
48510408|NCT06197165|OTHER|Targeted Shiatsu|"demonstrate the beneficial impact targeted Shiatsu compared with a comfort Shiatsu"
48510409|NCT05616637|DIAGNOSTIC_TEST|Navicular Drop Test|While participants in sitting position, the navicular tuberosity (NT) will be palpated.The most distal protruding portion of the medial NT will be marked. Participants will be asked to stand with equal weight on both feet. The new distance will be measured. The navicular drop test (NDT) results will then be obtained by comparing the measured values between the sitting and standing positions. Each measurement will be repeated three times and the average of the 3 measurements will be calculated. The expression in mm of the distance between the two marks will be considered the amount of ND. The amount of navicular fall of 10 mm or more will be interpreted as pes planus. Measurements will be made on both extremities. As a result of the measurements, if pes planus is present in a single extremity, that extremity, if it is present in both extremities, the extremity with higher NDT or if it is equal on both sides, the dominant extremity will be tested.
48510410|NCT05616637|OTHER|Lower Extremity Length Measurement|Lower extremity length will be recorded to normalize dynamic balance test data. The person will lie in the supine position. The distance between the umbilicus and the anterior superior of the spina iliaca will be measured in cm with the help of a tape measure. If there is no asymmetry, it will be assumed that there is no rotation in the pelvis, and it will be started to measure the length of the lower extremity. If pelvic asymmetry is detected, the pelvic position will be corrected manually. Then, the most inferior point of the spina iliaca anterior superior and the most distal point of the medial malleolus will be marked and measured and recorded. Lower extremity length and data in 3 different directions will be used in cm. The purpose of using formulas is to easily provide comparisons with other studies using the same type of data. The data obtained from the formula is expressed as a percentage of the length of the limb.
48510411|NCT05616637|OTHER|Y Balance Test|While the individual tries to balance on one bare foot at the midpoint of the assembly, the individual will also be asked to reach as far as possible with the other foot in the anterior, posteromedial and posterolateral directions, touch the tip of the toe, and then immediately return to the starting position without disturbing the balance. The test will be evaluated for 3 repetitions. Situations where the participant will be requested to repeat the test: the foot on the ground passes the reference point or the heel lifts off the ground, perturbations caused by the environment, contact of the foot with the ground, and loss of balance when returning to the starting position. 10 seconds between 3 repetitions during testing will be given. Each participant will be given the right to try 6 times before starting the test in order to eliminate the possible learning parameter. The test will be repeated 3 times in each direction and the closest distance in cm will be recorded.
48675292|NCT03289143|DRUG|Placebo|Matching placebo doses of Semorinemab given intravenously (IV).
48675293|NCT03289143|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
48675294|NCT04244266|OTHER|NO INTERVENTION, it is an observational study|No intervention
48675295|NCT05190679|OTHER|None/Observational Studies|This is an observational study and there is no intervention.
47991639|NCT00853723|DRUG|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
47991640|NCT02127567|OTHER|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
47991641|NCT02127567|OTHER|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
48149751|NCT05577182|DRUG|INCA32459-101|solution for infusion
48149752|NCT01267188|DRUG|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
48149753|NCT05000359|BEHAVIORAL|text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
48149754|NCT06085859|DEVICE|Routine nasal catheter group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide
48149755|NCT06085859|DEVICE|Mask group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
48149756|NCT05612113|BEHAVIORAL|Live Supervision + Session Goal Formulation|"Read under Arms"
48149757|NCT05612113|OTHER|Session Goal Formulation|"Read under Arms"
48149758|NCT05320133|DRUG|JWC containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
48510412|NCT05446259|OTHER|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
48149759|NCT05320133|DRUG|Bismuth-containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
48149760|NCT03075475|BEHAVIORAL|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
48510413|NCT00786409|BIOLOGICAL|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
48510414|NCT05322122|DEVICE|Side-to-side anastomosis duodeno-ileostomy diversion procedure|Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.
48510415|NCT06170697|DRUG|Camrelizumab|200mg, iv, d1, q3w
48675296|NCT05940311|DEVICE|Affinity Mediated Transport Amplification (AMT)|Rich format single-molecule detection powered by plasmotic nanostructures of the opto-fluidific chip and proteogenomics digital readout integrated into single biotech platform.
48149761|NCT03778606|DIETARY_SUPPLEMENT|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
48675297|NCT04702386|BEHAVIORAL|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
48675298|NCT04702386|BEHAVIORAL|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
48675299|NCT00613431|DRUG|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
48675300|NCT00613431|DRUG|Placebo|Some subjects will receive matching placebo instead of CS-8080.
48675301|NCT04451759|OTHER|MRI exploration|ultra high field (7T) magnetic resonance imaging
47991642|NCT03294733|PROCEDURE|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
48149762|NCT05234476|BEHAVIORAL|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
48149763|NCT05234476|BEHAVIORAL|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
48149764|NCT02274116|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
48149765|NCT02274116|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
48149766|NCT00091676|BIOLOGICAL|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
48149767|NCT00091676|BIOLOGICAL|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
48149768|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
48149769|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
48510416|NCT06170697|DRUG|Cisplatin|80-100mg/m2, iv, q3w, 2-3 cycles in total
48510417|NCT06170697|DRUG|Carboplatin|AUC 2, iv, q1w, 5-7 cycles in total
48510418|NCT06170697|DRUG|Lobaplatin|30mg/m2, iv, q3w, 2-3 cycles in total
48510419|NCT06170697|DRUG|Nedaplatin|25-30 mg/m2, iv, q1w, 5-7 cycles in total
48510420|NCT06170697|RADIATION|Radiotherapy|PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
48510421|NCT01531439|DRUG|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
48510422|NCT01531439|DRUG|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
48675302|NCT00087984|BIOLOGICAL|MB-002|Dendritic Cell Immunotherapy
48675303|NCT05739292|BIOLOGICAL|EuNmCV-5|0.5mL single intramuscular dose on Day 0
48675304|NCT05739292|BIOLOGICAL|Menveo|0.5mL single intramuscular dose on Day 0
48675305|NCT06341361|DIAGNOSTIC_TEST|OCT-based machine learning FFR|OCT-based machine learning FFR and wire-based FFR
48675306|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 1|\[¹⁴C\] BI 685509 formulation 1
48675307|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 2|\[¹⁴C\] BI 685509 formulation 2
48675308|NCT05515328|DRUG|BI 685509 formulation 3|BI 685509 formulation 3
48675309|NCT04227327|DRUG|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
48675310|NCT04227327|DRUG|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
48675311|NCT02847169|DEVICE|filcon IV1 toric lens|toric contact lens
48675312|NCT02847169|DEVICE|ocufilcon D toric lens|toric contact lens
48675313|NCT02540590|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
48675314|NCT02540590|DEVICE|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
47991643|NCT06340646|OTHER|Return of Genetic Results: Biomarker information from cancer cells|Participants will receive a novel return of results report that is tailored to their choices.
48362046|NCT01763099|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
48510423|NCT04556071|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.
48510424|NCT04556071|DRUG|Bevacizumab|The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
48510425|NCT04774497|OTHER|Oxygen inhalation treatment group|Oxygen inhalation group: oxygen inhalation was started on the first day of chemotherapy, and the oxygen inhalation volume was 2 L / min, 8 hours / day for 3 consecutive days.
48510426|NCT04774497|OTHER|Control group|The control group was not given oxygen inhalation.
48510427|NCT00186940|DRUG|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
48510428|NCT00256113|DRUG|Saredutant succinate (SR48968C)|
48510429|NCT02836691|DEVICE|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
48510430|NCT01653717|PROCEDURE|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
48510431|NCT01653717|DRUG|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
48510432|NCT01653717|DRUG|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
48510433|NCT01653717|PROCEDURE|T-cell Infusion|Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
48510434|NCT04198259|PROCEDURE|interventional devascularization|Interventional devascularization (BRTO and its variations) is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral.
48510435|NCT04198259|PROCEDURE|TIPS|TIPS is very effective in the treatment of bleeding GV, with more than a 90% success rate for initial hemostasis. It frequently requires additional embolization of spontaneous collaterals feeding the varices. The incidence of encephalopathy was higher after TIPS.
48510436|NCT06257251|OTHER|Histological slides digitization|Histological slides of the capsule samples taken during surgery will be collected for analysis and digitized. Using the NDPview2 software, the investigators will manually count the silicone particles present in the peri-prosthetic capsule and measure the surface area of the capsule to estimate the silicone particle density.
48510437|NCT02290457|BEHAVIORAL|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
48510438|NCT00948324|DRUG|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
48510439|NCT03098082|DEVICE|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
48510440|NCT04507841|DRUG|Niraparib|Niraparib was used as 100mg capsules once a day since cycle 1 / day 1. The daily dose (e.g. 200 mg is 2 capsules of 100 mg) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors (the best in the morning). The patient must swallow all the capsules completely and do not chew the capsules. You may drink water or eat when taking medicine.
48510441|NCT04228835|DIAGNOSTIC_TEST|Fluorescence Cholangiography|Administration of ICG for fluorescence cholangiography
48510442|NCT06633926|BEHAVIORAL|Nutrition Education|Given nutrition education
48510443|NCT06633926|BEHAVIORAL|Lifestyle Counseling|Given lifestyle recommendations
48510444|NCT06633926|OTHER|Yoga|Participate in yoga
48510445|NCT06633926|PROCEDURE|Marma therapy|Participate in marma therapeutic touch
48510446|NCT06633926|OTHER|Educational Intervention|Attend online HEI sessions
48510447|NCT06633926|OTHER|Quality of Life Questionnaire Administration|Self-reported questionnaires are given to participants to complete
48510448|NCT04032717|DRUG|Q-Griffithsin (Q-GRFT) enema|Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
48510449|NCT04032717|OTHER|Placebo enema|Approximately 125mL of 0.9% sodium chloride solution
48510450|NCT03131804|OTHER|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
47991644|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to cancer|Participants will receive a novel return of results report that is tailored to their choices.
48149770|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
48675315|NCT04828135|DRUG|Hyperpolarized 129Xenon gas|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
48510451|NCT05510284|OTHER|Doula-coordinated, midwife-delivered postpartum care|A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
48149771|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
48149772|NCT01515202|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
48362047|NCT01763099|BIOLOGICAL|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10\^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
48362048|NCT02381795|DRUG|Nasal Carbon Dioxide|
48362049|NCT06077682|DRUG|Cyclopentolate|Well-known eye drop used for cycloplegic refraction among children.
48510452|NCT03340974|DRUG|GC4419|90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
48510453|NCT03340974|DRUG|Placebo|Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
48510454|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 50 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
48510455|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 55 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
48675316|NCT03662061|OTHER|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
48675317|NCT01123343|DEVICE|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
48675318|NCT05911971|OTHER|Experimental|specific reeducation (not detailed to maintain blinding of participants)
48149773|NCT03431649|DRUG|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
48362050|NCT06077682|DRUG|Tropicamide|Well-known eye drop used for cycloplegic refraction among children.
48510456|NCT02137876|PROCEDURE|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
48510457|NCT03041428|DEVICE|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
48510458|NCT03132779|DRUG|Intralipid|Adose of intralipid given and rechecking NKcells activity
48510459|NCT00352417|DRUG|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
48510460|NCT00352417|DRUG|Placebo|oral dosing, 1 time daily for 12 weeks
48510461|NCT02971020|OTHER|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
48510462|NCT05102812|BEHAVIORAL|Breakfast Group Intervention|An actionable toolkit encompassing an assessment, a personalised care plan and a range of outcome measures.
48510463|NCT03983915|DRUG|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
48510464|NCT03983915|DRUG|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
48510465|NCT03983915|DEVICE|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
48149774|NCT03431649|DRUG|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
48362051|NCT02401945|DRUG|DE-120|
48362052|NCT02401945|DRUG|Aflibercept|
48510466|NCT01137071|BIOLOGICAL|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
48675319|NCT05911971|OTHER|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
48675320|NCT04877678|DRUG|Bepotastine|10 mg Bepotastine, twice a day
48675321|NCT04877678|DRUG|Placebo|Identical looking placebo, twice a day
48675322|NCT05935059|DRUG|Pregabalin|Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)
48675323|NCT05935059|DRUG|Tianeptine|Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
48675324|NCT03672214|PROCEDURE|Without placement of indwelling catheter|No placement of indwelling catheter prior to Caesarean section
48510467|NCT01184443|DRUG|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
47991645|NCT06340646|OTHER|Return of Genetic Results: Inherited mutations related to other medical issues|Participants will receive a novel return of results report that is tailored to their choices.
47991646|NCT01852942|DRUG|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
47991647|NCT01852942|DRUG|Placebo|one tablet by mouth daily
48362053|NCT01116726|BEHAVIORAL|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
48362054|NCT01116726|BEHAVIORAL|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
48362055|NCT00999882|DRUG|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
47991648|NCT01619345|DRUG|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
48362056|NCT02841254|OTHER|Non interventional study|
48510468|NCT05884684|OTHER|Reviewing Imaging with Participant|Post-operatively, the images taken during the procedure will be reviewed with the participant.
48510469|NCT01820975|DIETARY_SUPPLEMENT|High protein intake|
48510470|NCT01820975|OTHER|Placebo comparator|No protein intake
48510471|NCT04616430|DRUG|Topical endoxifen|topical solution
48675325|NCT03672214|PROCEDURE|With placement of indwelling catheter|Placement of indwelling catheter prior to Caesarean section
48675326|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Original doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
47991649|NCT05104034|BEHAVIORAL|Osteoporosis screening and treatment as needed|All residents underwent screening using the Fracture Risk Assessment Tool (FRAX) and Mobile dual-energy X-ray absorptiometry (DXA) (Horizon Wi, Hologic Inc., Bedford, MA). Our study nurses actively assisted osteoporosis treatment if indicated.
47991650|NCT05104034|BEHAVIORAL|Sarcopenia|Sarcopenia assessment adhered to the 2019 Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia guideline. Following screening, individuals identified with sarcopenia underwent tailored interventions involving exercise and nutrition as deemed necessary.
48362057|NCT03469206|PROCEDURE|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
48675327|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Monkey doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush monkey doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
48675328|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Dog without velcro doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush dog doll, without velcro in palms. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
48675329|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Bear doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush smiling bear doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
48675330|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Rabbit doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush rabbit doll, with a neutral expression. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
48675331|NCT05840835|DRUG|IMX-110 combined with Tislelizumab|Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
48675332|NCT00200967|DRUG|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
48675333|NCT00200967|DRUG|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
48675334|NCT03911856|OTHER|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
48675335|NCT03911856|OTHER|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
48675336|NCT05000307|DIAGNOSTIC_TEST|Blood sample|Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
48675337|NCT00827814|DRUG|Dutasteride|Dutasteride 0.5 mg od.
48675338|NCT03218774|BEHAVIORAL|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
48675339|NCT03218774|BEHAVIORAL|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
48675340|NCT04268069|DRUG|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
47991651|NCT05104034|BEHAVIORAL|Exercise|TheraBand (resistance band) was utilized as the exercise tool within the community. T
48362058|NCT03469206|DRUG|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
48675341|NCT04268069|DRUG|Placebo Ophthalmic Solution|Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
48362059|NCT05170516|PROCEDURE|4 °C colled saline irrigation|In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery
48362060|NCT05170516|PROCEDURE|10 °C cooled saline irrigation|Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
48362061|NCT05170516|PROCEDURE|Room temperature saline irrigation|In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
48362062|NCT00004937|DRUG|acridine carboxamide|
48362063|NCT01108068|DRUG|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
48362064|NCT01160458|DRUG|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
48510472|NCT04616430|DRUG|Placebo|topical
48510473|NCT01843296|DRUG|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
48510474|NCT01843296|PROCEDURE|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
48510475|NCT01843296|DRUG|Bupivacaine|
48675342|NCT03101319|DRUG|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
48675343|NCT03101319|DRUG|B Complex Oral Tablet|As mentioned in the description of the study arm
48675344|NCT02639247|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
48675345|NCT02639247|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
48675346|NCT01410929|PROCEDURE|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
48675347|NCT04082130|PROCEDURE|(XCM)+(CAF)|The description of this intervention has been already given before.
48675348|NCT04082130|PROCEDURE|(SCTG)+(CAF)|The description of this intervention has been already given before.
48675349|NCT03388892|DEVICE|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
48362065|NCT00523744|DRUG|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
48362066|NCT00523744|DRUG|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
48362067|NCT00523744|DRUG|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
48362068|NCT00523744|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
48362069|NCT02952027|BEHAVIORAL|Use-recording, patient-reminder alarm for incentive spirometry|
48510476|NCT01843296|DRUG|Fentanyl|
48510477|NCT00309803|DEVICE|FiberNet Embolic Protection Device|
48510478|NCT06500169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48510479|NCT06500169|PROCEDURE|Discussion|Ancillary studies
48510480|NCT06500169|OTHER|Exercise Intervention|Complete golf related exercises
48510481|NCT06500169|OTHER|Interview|Ancillary studies
48510482|NCT06500169|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
48510483|NCT06500169|PROCEDURE|Physical Examination|Ancillary studies
48510484|NCT06500169|OTHER|Physical Performance Testing|Ancillary studies
48510485|NCT06500169|OTHER|Questionnaire Administration|Ancillary studies
48510486|NCT06500169|OTHER|Recreational Therapy|Participate in golf program
48510487|NCT04731792|OTHER|Virtual Reality|a bronchial fibroscopy with a virtual reality helmet
48510488|NCT00922740|DRUG|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
48510489|NCT00922740|DRUG|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
48510490|NCT03946852|DEVICE|Abdominal Regional Perfusion|Abdominal Regional Perfusion
48510491|NCT03857269|OTHER|Acupoint Massage|The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.
48510492|NCT03857269|OTHER|lavender essential oil|Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.
48149775|NCT04135183|PROCEDURE|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
48149776|NCT04878809|OTHER|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
48149777|NCT04878809|OTHER|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
48149778|NCT03493282|DRUG|Active Treatment- CT1812 100 mg|CT1812
48149779|NCT03493282|DRUG|Active Treatment- CT1812 300 mg|CT1812
48149780|NCT03493282|DRUG|Placebo|Matching Placebo
48149781|NCT00005971|DRUG|alvocidib|
48149782|NCT01956396|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
48149783|NCT03420729|PROCEDURE|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
48510493|NCT03857269|OTHER|Acupoint Massage and lavender essential oil|At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
48510494|NCT03848390|BEHAVIORAL|Conventional diet|The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
48510495|NCT03848390|BEHAVIORAL|Modified Time-restricted Feeding|The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
48510496|NCT03848390|BEHAVIORAL|Physical activity|At least 30 minutes of physical activity per day 5 times per week.
48510497|NCT03848390|BEHAVIORAL|Restricted consumption of sweetened beverages|Restricted consumption of juice, soda, and other sweetened beverages.
48362070|NCT01872273|OTHER|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
48149784|NCT03420729|DEVICE|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
48149785|NCT02464072|PROCEDURE|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
48362071|NCT04657406|DRUG|Zofin|Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.
48362072|NCT04417166|DRUG|Pembrolizumab|50 mg powder for concentrate for solution for infusion
48362073|NCT04417166|RADIATION|Involved Field Radiation Therapy|"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."
48510498|NCT02443987|OTHER|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
48510499|NCT05419011|BIOLOGICAL|Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5|Given SC
48675350|NCT03388892|DEVICE|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
48675351|NCT04941105|DRUG|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
48675352|NCT04941105|DRUG|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
48362075|NCT04900714|PROCEDURE|Decremental PEEP|High PEEP to low PEEP.
48362076|NCT04900714|DIAGNOSTIC_TEST|Lung ultrasound score|lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
48362077|NCT04900714|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analysis to determine arterial oxygen tension
48510500|NCT05419011|PROCEDURE|Biopsy|Undergo biopsy
48675353|NCT04286152|DRUG|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
48675354|NCT04286152|DRUG|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
48675355|NCT01224236|DRUG|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
48675356|NCT01224236|DRUG|control|multivitamin solution without iron
48149786|NCT02464072|PROCEDURE|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
48149787|NCT02464072|PROCEDURE|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
48149788|NCT01763502|OTHER|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
48149789|NCT01763502|OTHER|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
48675357|NCT03061292|PROCEDURE|Pectoral Nerve Block|
48675358|NCT03061292|PROCEDURE|Without Pectoral Nerve Block|
48675359|NCT02132403|DRUG|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
48675360|NCT02132403|DRUG|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
48675361|NCT02132403|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
48675362|NCT04217109|DIAGNOSTIC_TEST|Odour sampling|"Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample."
48675363|NCT00532701|DRUG|Peg-IFN + WB RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 5-16"
48675364|NCT00532701|DRUG|Peg-IFN + LD RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-6~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
47991652|NCT05104034|DIETARY_SUPPLEMENT|Nutrition|Nutrition Nutritional education programs aim to increase protein food serving and the choice of those with insufficient dietary intake. Protein supplement was added if indicated.
47991653|NCT05104034|BEHAVIORAL|Pharmaceutical care|We collected drug information of the elderly. Detailed and real-time prescription drug information was retrieved from the National Health Insurance PharmaCloud System. A pharmaceutical care team performed patient-centered drug review and discussion every three to six months.
48149790|NCT04327349|BIOLOGICAL|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
48149791|NCT06319924|DRUG|Simethicone combined with Macrogol 4000 (PEG)|bowel preparation product for colonoscopy as part of CRC screening
48149792|NCT02131792|PROCEDURE|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
48149793|NCT00648466|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
48149794|NCT00648466|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fasting
48149795|NCT02223078|BIOLOGICAL|G17DT|
48675365|NCT00532701|DRUG|Peg-IFN + WB RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
48149796|NCT02223078|BIOLOGICAL|Placebo Comparator|
48149797|NCT06173167|DEVICE|Crowns self-adhesively luted|After cavity preparation, the zirconia chairside crown will be placed using SpeedCEM Plus. The excess will be light cured with Bluephase G4 in PreCure mode (950 mW/cm\^2). After removal of the excess, the luting material margins will be light-cured again for 20s (1200 mW/cm\^2).
48149798|NCT06173167|DEVICE|Crowns conventionally cemented|After cavity preparation, the zirconia chairside crown will be placed using ZirCAD Cement. The excess cement will be removed in the gel phase, either following light curing (5 - 10 seconds per segment) or following self-curing (approximately 2 min after placement). The restoration will be held in position during final curing that is complete 4 min 30 s after placement.
48149799|NCT04097314|DRUG|Zibotentan|10mg OD Zibotentan
48149800|NCT04097314|DRUG|Placebo oral tablet|Placebo
48362078|NCT04900714|DIAGNOSTIC_TEST|Registration of respiratory mechanics|Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
48675366|NCT00532701|DRUG|Peg-IFN + WB RBV for 48 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
48675367|NCT00532701|DRUG|Peg-IFN + LD RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
48675368|NCT05986266|DRUG|Carbetocin|To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
48675369|NCT03952403|DRUG|HLX10, an engineered anti-PD-1 antibody|HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
48675370|NCT03952403|DRUG|HLX04, a bevacizumab biosimilar|HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
48675371|NCT03952403|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
48675372|NCT03952403|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
48675373|NCT04451005|OTHER|0|Elderly patients with sarcopenia
48675374|NCT04865289|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
48675375|NCT04865289|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
48675376|NCT04865289|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
48675377|NCT04865289|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
48675378|NCT05116956|OTHER|non interventional|Multinational prospective, standard care data collection, non-interventional, study not involving human subjects
48675379|NCT01337778|BEHAVIORAL|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
48675380|NCT01337778|BEHAVIORAL|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
48149801|NCT05470465|DRUG|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
48149802|NCT05470465|DRUG|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
48675381|NCT00295646|DRUG|tamoxifen|20 mg/d
48675382|NCT00295646|DRUG|anastrozole|1 mg/d
48675383|NCT00295646|DRUG|zoledronic acid|4 mg q6m
48675384|NCT00295646|OTHER|goserelin|3.6 mg goserelin subcutaneously every 28 days
48675385|NCT03736148|OTHER|Manual Manipulation|Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
48675386|NCT03736148|OTHER|Instrument-assisted Manipulation|The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
48675387|NCT03736148|OTHER|Placebo|Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
48149803|NCT05470465|DRUG|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
48149804|NCT05583331|PROCEDURE|Cataract surgery|Cataract surgery will be performed as per local practice and standard guidelines.
48149805|NCT05583331|PROCEDURE|Vitrectomy|Vitrectomy will be performed as per local practice and standard guidelines.
48149806|NCT00731692|DRUG|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
48675388|NCT02699697|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48675389|NCT02699697|RADIATION|Palliative Radiation Therapy|Undergo EBRT
48675390|NCT02699697|OTHER|Quality-of-Life Assessment|Ancillary studies
48675391|NCT02699697|OTHER|Questionnaire Administration|Ancillary studies
48675392|NCT00414570|DRUG|[18]F-FLT PET scan|Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
48362079|NCT04900714|DIAGNOSTIC_TEST|Evaluation of dead space|Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
48510501|NCT05419011|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48362080|NCT02555722|DEVICE|fanfilcon A (test)|silicone hydrogel lens
48675393|NCT03291132|OTHER|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
48675394|NCT00186628|PROCEDURE|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
48675395|NCT00186628|DRUG|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
48675396|NCT00186628|DRUG|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
48675397|NCT00186628|DRUG|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates \> 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
48675398|NCT00186628|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
48675399|NCT00186628|DRUG|Filgrastim|Filgrastim provided as needed for neutrophil support
48675400|NCT00186628|DRUG|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
48675401|NCT00186628|DRUG|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
48675402|NCT00186628|DRUG|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
47991654|NCT01798472|PROCEDURE|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
48149807|NCT00731692|DRUG|Placebo|Matching placebo capsules were administered orally once daily
48149808|NCT04153357|DEVICE|airtraq|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
48362081|NCT02555722|DEVICE|enfilcon A (control)|silicone hydrogel lens
48362082|NCT04765449|DRUG|Cytotoxic T Lymphocytes|Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.
48362083|NCT02835391|DEVICE|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
48362084|NCT02835391|DEVICE|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
48362085|NCT02835391|PROCEDURE|Electrocautery/Diatermy|Procedure for the control of bleeding
48362086|NCT05594966|DIAGNOSTIC_TEST|multimodal MRI|patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
48362087|NCT01558206|OTHER|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
48510502|NCT05419011|PROCEDURE|Colonoscopy|Undergo SOC colonoscopy
48510503|NCT05419011|DRUG|Nogapendekin Alfa|Given nogapendekin alfa inbakicept (N-803) SC
48510504|NCT05419011|DRUG|Placebo Administration|Given SC
48510505|NCT05419011|OTHER|Questionnaire Administration|Ancillary studies
48510506|NCT01917916|DRUG|Placebo|Solution for subcutaneous (s.c.) injection.
48510507|NCT01917916|DRUG|BI 655064|Solution for subcutaneous (s.c.) injection.
48510508|NCT05950178|DIAGNOSTIC_TEST|Apnea test under high-flow oxygenation|Apnea test under high-flow oxygenation in patients with a confirmed clinical brain death by a standard apnea test (under standard oxygen therapy)
48510509|NCT04612751|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
48510510|NCT04612751|DRUG|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
48675403|NCT00186628|DRUG|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
48675404|NCT00186628|DRUG|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
48675405|NCT01326299|OTHER|Carbohydrate placebo|dissolve in water and consume with meal
48675406|NCT01326299|OTHER|Nutritional ingredient|Dissolve in water and consume with meals
48362088|NCT01558206|OTHER|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
48362089|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil|20 g of coconut oil
48510511|NCT04612751|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
48510512|NCT04612751|DRUG|AZD2936|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
48510513|NCT04612751|DRUG|MEDI5752|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
48510514|NCT04612751|DRUG|AZD7789|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
48510515|NCT01406587|DRUG|PP4001|50 mg, 1 dose every 12 hours x 4 doses
48510516|NCT01406587|DRUG|PP4001|100 mg, 1 dose every 12 hours x 4 doses
48675407|NCT01326299|OTHER|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
48675408|NCT01326299|OTHER|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
48675409|NCT01326299|OTHER|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
48675410|NCT02055950|PROCEDURE|Storage of kidney in refrigerated solution|
48675411|NCT02055950|PROCEDURE|Kidney perfused by pulsatile machine|
48675412|NCT04495686|BEHAVIORAL|Telehealth-delivered Care Coordination Program|"Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform."
48675413|NCT00054743|PROCEDURE|Blood draw|
48675414|NCT04137367|BEHAVIORAL|Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
48675415|NCT04137367|BEHAVIORAL|Sham Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
48675416|NCT04942431|BEHAVIORAL|Rebirth active SCHOOL 2.0 movement program|60 Minutes of physical activity per day integrated in every school-day.
48675417|NCT05932173|BIOLOGICAL|Anti-CD19 Autologous CAR-T Cell Infusion|Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
48675418|NCT02126163|BEHAVIORAL|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
48675419|NCT04350801|DIAGNOSTIC_TEST|home-based cognitive monitoring|a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)
48675420|NCT03366363|OTHER|acupuncture|acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
48675421|NCT06632782|BEHAVIORAL|Breath Awareness using pyramid|Participants are provided 1-2 hr training for 6 weeks on bringing breath awareness to the present moment using a pyramid
48149809|NCT04153357|DEVICE|c-mac|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
48362090|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + MCT|10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
48362091|NCT02679222|DIETARY_SUPPLEMENT|MCT|20 g of MCT (60 of C8+40 of C10)
48362092|NCT02679222|DIETARY_SUPPLEMENT|Coconut oil + tricaprylin|10 g coconut oil + 10 g tricaprylin
48362093|NCT02679222|DIETARY_SUPPLEMENT|Tricaprylin|20 g tricaprylin
48362094|NCT02679222|DIETARY_SUPPLEMENT|Tricaprin|20 g tricaprin
48362095|NCT02679222|DIETARY_SUPPLEMENT|Control|No supplement taken on this visit
48510517|NCT01406587|DRUG|PP4001|200 mg, 1 dose every 12 hours x 4 doses
48510518|NCT01406587|DRUG|Placebo|Placebo, 1 dose every 12 hours x 4 doses
47991655|NCT01798472|PROCEDURE|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
47991656|NCT01798472|PROCEDURE|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
48510519|NCT03804814|BEHAVIORAL|Motivational Interviewing Training|"Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers."
48362096|NCT04832633|DIAGNOSTIC_TEST|Different contrast media injection methods|Different contrast media injection methods
48510520|NCT01423123|DRUG|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
48510521|NCT01423123|BIOLOGICAL|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
48362097|NCT01379404|DEVICE|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
48362098|NCT00004842|DRUG|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
48362099|NCT01314261|DRUG|ABT-267|5 mg or 25 mg tablets
47991657|NCT01798472|PROCEDURE|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
47991658|NCT03495323|DRUG|LY3300054|LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
47991659|NCT03495323|DRUG|Prexasertib|Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
47991660|NCT06135155|DRUG|PEG-rhGH with new preparation|A single subcutaneous injection of PEG-rhGH with new preparation
47991661|NCT06135155|DRUG|PEG-rhGH with present preparation|A single subcutaneous injection of PEG-rhGH with present preparation
48362100|NCT01314261|DRUG|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
48362101|NCT01314261|DRUG|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
48362102|NCT01314261|OTHER|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
48362103|NCT00551200|DRUG|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
48510522|NCT01423123|DRUG|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
48510523|NCT06328179|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；|VHEA -Induction Phase Regimen/Consolidation therapy after remission
48675422|NCT03771339|PROCEDURE|Continuous Epidural analgesia|Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
48675423|NCT03771339|PROCEDURE|Bilateral Quadratus Lumborum block|Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
47991662|NCT01285245|DRUG|kineret|once daily 100 mg of kineret subcutaneously for 8 days
47991663|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (one day)|Participants will engage in 40 minutes of cycling at 70-75% maximum heart rate (MHR).
47991664|NCT05972265|BEHAVIORAL|Placebo - Light Intensity Exercise (one day)|Control participants will engage in 40 minutes cycling at 40-50% maximum heart rate (MHR).
47991665|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (9 wks)|Participants will be asked to engage in moderate-intensity activity four days each week, 40 minutes each time, and will wear an activity monitoring device to assess their fidelity to the intervention.
48362104|NCT00551200|DRUG|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
48362105|NCT04126876|DRUG|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
48510524|NCT04233073|DRUG|andexanet alfa|Andexanet is a recombinant version of human FXa
48510525|NCT05624398|DEVICE|Vivity IOL|Cataract surgery with implantation of the Vivity IOL along with concurrent implantation of the Hydrus Microstent
48510526|NCT04521101|OTHER|VAST Course|Educational course to teach non-technical skills
48675424|NCT04402307|OTHER|Chin Tuck Against Resistance|Training in 6 weeks 3 times a day.
48675425|NCT01824290|DRUG|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
48675426|NCT01824290|DRUG|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
48675427|NCT01824290|DRUG|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
48675428|NCT03134326|DEVICE|R1-25 and R2-25 Pulse Oximeter Sensor|
48675429|NCT00700648|DRUG|insulin aspart|Intravenous NovoRapid dose \& frequency as decided by treating physician
47991666|NCT05972265|OTHER|Day 1 Assessments|Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), Life Events Checklist (LEC-5), and neuropsychological testing: approximately 1.50 hours
48362106|NCT04126876|DRUG|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
48362107|NCT06160531|DRUG|CC-42344|Anti-influenza A agent
48362108|NCT06160531|DRUG|Placebo|Matching placebo
48362109|NCT02993640|DRUG|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
48362110|NCT02159911|DRUG|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
48362111|NCT00805142|DRUG|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
48675430|NCT05951647|DRUG|Chamomile extract mouthwash|5% chamomile extract mouthwash in a dose of 15 ml twice daily.
48675431|NCT05951647|DRUG|Pomegranate peel extract mouth wash|5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
48675432|NCT05951647|DRUG|Combination of 5% chamomile extract and pomegranate peel extract mouthwash|Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
48675433|NCT05951647|PROCEDURE|Scaling|Patients will be managed by scaling
48675434|NCT05951647|DRUG|Scaling and Chlorohexidine mouthwash|scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
48675435|NCT03150537|BIOLOGICAL|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
48362112|NCT01018069|DRUG|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
48675436|NCT01808469|BIOLOGICAL|Monoclonal antibody|
48675437|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
48675438|NCT05144672|OTHER|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
48675439|NCT05144672|PROCEDURE|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
48675440|NCT05144672|OTHER|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
48675441|NCT05144672|OTHER|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
48675442|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
48675443|NCT05144672|RADIATION|Abdominal ultrasound.|It will be performed for patients only.
48675444|NCT00451399|DRUG|metformin|
48675445|NCT00451399|BEHAVIORAL|lifestyle intervention|
48362113|NCT03973827|DRUG|ProTrans|Single infusion of 25, 100 or 200 million cells per patient.
48362114|NCT03973827|DRUG|Placebo|Placebo Comparator: Sham transplantation (placebo) Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)
48362115|NCT00784316|DRUG|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
48362116|NCT01882036|PROCEDURE|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
48675446|NCT03407092|OTHER|ADAPT cohort|Thrombectomy with distal aspiration technique
48675447|NCT03407092|OTHER|Stentriever Cohort|Thrombectomy with stent retriever
48675448|NCT00251836|PROCEDURE|Laparoscopic hand-assisted donor nephrectomy|
48675449|NCT00670930|DRUG|omalizumab at a dose of 0.016mg/kg/IU/mL|
48675450|NCT00670930|DRUG|Placebo|
48675451|NCT00107276|DRUG|capecitabine|
48675452|NCT00107276|DRUG|cyclophosphamide|
48675453|NCT02582827|DRUG|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
48362117|NCT01882036|OTHER|Hypocaloric diet|Hypocaloric liquid diet for 10 days
48362118|NCT02206958|BEHAVIORAL|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
48362119|NCT01651676|OTHER|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
48362120|NCT01017211|OTHER|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
48362121|NCT04830293|PROCEDURE|Carotis Doppler Ultrasound|Neck was rotated about 30-45 ° to the opposite side of the image. The common carotid artery and internal jugular vein were viewed transversely on the B Mode USG image. Then, the probe was rotated approximately 90 ° and the carotid artery was visualized in the longitudinal plane. The probe and guide line were adjusted so that the Doppler angle was 60 °. The image was created with the guiding line parallel to the blood flow. After imaging of the carotid artery bifurcation, measurements were made 1 cm distal to this level.
48362122|NCT06154460|PROCEDURE|Laterjet Surgery|The laterjet procedure is an operation in which the coracoid process is transferred to the glenoid rim with a screw.
48362123|NCT06154460|PROCEDURE|Reimplissage Surgery|"Reimplissagge operation, which means to fill, is an open procedure designed to limit the engagement of Hill-Sachs deformity by passing the infraspinatus into the Hill-Sachs defect."
48362124|NCT06154460|PROCEDURE|Capsular Reconstruction|Allografts or autografts are used for capsular reconstruction. In the procedure performed with capsular repair and grafts, the capsule is strengthened and stabilization is attempted
48362125|NCT01791088|DRUG|sirolimus|Given PO
48362126|NCT01791088|OTHER|pharmacological study|Correlative studies
48362127|NCT01791088|OTHER|laboratory biomarker analysis|Correlative studies
48362128|NCT03428230|DRUG|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
48362129|NCT03428230|DRUG|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
48362130|NCT03428230|DRUG|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
48362131|NCT03428230|DRUG|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
48675454|NCT03623438|BEHAVIORAL|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
47991667|NCT05972265|OTHER|Symptom Measures and Neuropsychological Tests|Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and neuropsychological testing: approximately 1.25 hours
48149810|NCT04306081|DRUG|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
48149811|NCT04306081|OTHER|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
48510527|NCT05852223|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200mg Q3W will be administered via IV infusion for 2 courses from the date of randomization until to the date of thyroidectomy.
47991668|NCT05972265|OTHER|Day 36 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
47991669|NCT05972265|OTHER|Day 57 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
48362132|NCT03428230|DRUG|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
47991670|NCT05972265|OTHER|Day 78 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
47991671|NCT03616899|DRUG|KPI-121 Ophthalmic Suspension|KPI-121 Ophthalmic Suspension
47991672|NCT03616899|DRUG|Vehicle|Vehicle for KPI-121 0.25% ophthalmic suspension
47991673|NCT04552392|OTHER|No intervention|No intervention
48362133|NCT03949816|OTHER|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
48362134|NCT03949816|OTHER|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
48510528|NCT05385549|DRUG|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
48510529|NCT03300583|BEHAVIORAL|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
48675455|NCT03623438|BEHAVIORAL|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
48675456|NCT02088125|OTHER|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
47991674|NCT00227305|DRUG|quetiapine fumarate|Oral dosing, flexible dosing
47991675|NCT03251508|DRUG|Peanut OIT|Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
48149812|NCT03883217|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
48149813|NCT05516758|DRUG|Peresolimab|Administered subcutaneously (SC)
48149814|NCT05516758|DRUG|Placebo|Administered SC
47991676|NCT04318509|DIETARY_SUPPLEMENT|GMPOWER|(casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
48362135|NCT02183792|DRUG|Tolvaptan|
48362136|NCT02183792|DRUG|Furosemide|
48362137|NCT03244189|BEHAVIORAL|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
48362138|NCT03244189|BEHAVIORAL|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
48362139|NCT03244189|BEHAVIORAL|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
48362140|NCT02779621|PROCEDURE|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
48362141|NCT02779621|PROCEDURE|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
48510530|NCT03300583|BEHAVIORAL|Semi-structured interviews|1:1 semi-structured interviews led by the PI
48510531|NCT06546774|DIETARY_SUPPLEMENT|Melatonin|In the study group, patients will receive melatonin supplementation for at least two months prior to IVF cycles
48510532|NCT06223087|OTHER|winter swimming|Intervention involves bathing/swimming in cold water during the winter months in open waters
48510533|NCT03909269|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
48510534|NCT03909269|DIAGNOSTIC_TEST|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
48510535|NCT03909269|RADIATION|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
48510536|NCT03909269|DEVICE|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
48510537|NCT05698225|OTHER|Streptococcus pneumoniae serotype 6B|A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
48362142|NCT03136029|DIETARY_SUPPLEMENT|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
48362143|NCT03136029|DIETARY_SUPPLEMENT|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
48362144|NCT03136029|OTHER|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
48362145|NCT00642122|DRUG|Budesonide|0.5mg once daily
48362146|NCT00642122|DRUG|Budesonide|1mg once daily
48362147|NCT00642122|DRUG|Budesonide|1mg twice daily
48362148|NCT00642122|DRUG|Budesonide|2mg once daily
48362149|NCT00642122|DRUG|Budesonide|4.00mcg twice daily
48362150|NCT01743066|DIETARY_SUPPLEMENT|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
48362151|NCT04717154|BIOLOGICAL|Ipilimumab|4 courses of 1mg/kg q3w
48362152|NCT04717154|BIOLOGICAL|Nivolumab|4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)
48362153|NCT03349840|DRUG|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
48510538|NCT06632405|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
48675457|NCT02088125|OTHER|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
47991677|NCT03888872|DEVICE|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
47991678|NCT03888872|OTHER|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:"
47991679|NCT03057665|DEVICE|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
48362154|NCT03349840|DRUG|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
48362155|NCT03986671|DEVICE|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
48362156|NCT03615586|OTHER|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone.
48362157|NCT03615586|OTHER|Without Chaperone|Female patients examined by male physicians without the presence of a female (nurse) chaperone.
48362158|NCT05399823|OTHER|Exercise|Strecthing exercises will given for 15-20 minutes everyday for four weeks
48362159|NCT01721668|BEHAVIORAL|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
48362160|NCT01721668|BEHAVIORAL|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
48362161|NCT00031109|BIOLOGICAL|gp160 MN/LAI-2|
48675458|NCT03853044|DRUG|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
47991680|NCT01826487|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
48362162|NCT00031109|BIOLOGICAL|Aluminum hydroxide|
48362163|NCT01488994|BIOLOGICAL|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
48362164|NCT00271362|BEHAVIORAL|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
48362165|NCT00271362|PROCEDURE|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
48362166|NCT05895422|PROCEDURE|pyeloplasty|repair of the uPJO
48362167|NCT05109728|DRUG|[177Lu]Lu-DOTA-TATE|"Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed."
48362168|NCT05109728|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
48362169|NCT05109728|OTHER|Temozolomide|"Concomitant Phase: Temozolomide 75mg/m2/d p.o until last day of EBRT.~Maintenance Phase: Temozolomide p.o 150 mg/m2/d during cycle 1 then 200 mg/m2/d for the following cycles if tolerated well in Cycle 1. 6 cycles total (1 cycle = every 28 days)"
48362170|NCT05109728|OTHER|Radiotherapy|2 Gy/day, 5 days per week followed by 2 days of rest, for 6 consecutive weeks
48362171|NCT05539742|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
48362172|NCT05539742|DIETARY_SUPPLEMENT|Palm oil|Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
48362173|NCT02827084|DEVICE|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
48362174|NCT02827084|DEVICE|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
48362175|NCT04450394|DRUG|LY3209590|Administered SC
48362176|NCT04450394|DRUG|Insulin Degludec|Administered SC
48362177|NCT00208715|DRUG|Provigil|
48362178|NCT02757651|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
48510539|NCT06632405|DRUG|Nab paclitaxel|Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.
48510540|NCT06632405|DRUG|Levocetirizine Hydrochloride|5mg daily, start 3 days before the 1st administration
48510541|NCT06632405|DRUG|Placebo|5mg daily, start 3 days before the 1st administration
48510542|NCT05848947|DRUG|99mTc-Macro Albumin Aggregate|Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
48510543|NCT03482115|RADIATION|PET examination with radiopharmaceutical drug [18F] DPA-714|Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
48510544|NCT03482115|DIAGNOSTIC_TEST|MRI examination|MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
48362179|NCT06202313|BIOLOGICAL|Cadonilimab|Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
48362180|NCT06202313|DRUG|Eribulin|Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
48362181|NCT04251949|PROCEDURE|LED photobiomodulation|1 PLED session before each radiotherapy session, until the end of the radio or radio-chemotherapy treatment. Each session will last 7 minutes. The light delivered will be preset on the lamp which will deliver a red light of a wavelength of 630nm, at a fluence of 37J/cm².
48510545|NCT03482115|BIOLOGICAL|Blood samples|Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
48510546|NCT05746598|DRUG|Cisplatin injection|Cisplatin 75mg/m2
48510547|NCT02985216|DRUG|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
48510548|NCT02985216|DRUG|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
48510549|NCT05164783|COMBINATION_PRODUCT|Sanacoach Parkinson (SCP)|A web-based monitoring tool for patients with PD, using questionnaires. It includes nine parts: 1) A 89-question, quarterly questionnaire about PD-symptoms. 2) Questionnaire responses are converted to scores on 16 PD-related domains. Both the current score and the score's change compared to the previous questionnaire are visible. 3) An interim evaluation is sent after 6 weeks with questions on any domains where a patient indicated problems. 4) A medication monitor can be initialized by the treating physician to evaluate the effect of a therapeutic change. 5) A consultation preparation module allows patients to indicate which topics they want to discuss during an outpatient visit. 6) Patients can ask for 'calling advise' if they are unsure whether to contact their physician. 7) Patients and healthcare providers can send each other text messages. 8) Interactive learning modules about PD. 9) Annual evaluation regarding patient satisfaction, self-management and healthcare consumption.
48510550|NCT05317338|BEHAVIORAL|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
48510551|NCT05628727|OTHER|Time Restricted Feeding|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
48510552|NCT05628727|OTHER|5:2 Fasting|This group will use the 5:2 method and fast for two non-consecutive days of the week.
48510553|NCT02600533|PROCEDURE|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
48510554|NCT04611633|COMBINATION_PRODUCT|Trimbow|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
48510555|NCT03933215|DRUG|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
48510556|NCT02286687|OTHER|Laboratory Biomarker Analysis|Correlative studies
48675459|NCT03853044|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
47991681|NCT01826487|DRUG|Placebo|Placebo will be administered as per the schedule specified in the arm.
47991682|NCT05077592|DRUG|10% Povidone Iodine|Povidone-iodine is a topical antiseptic agent used for the treatment and prevention of infection in wounds.
48362182|NCT03437811|DEVICE|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
48362183|NCT02026193|PROCEDURE|oocyte vitrification|
48362184|NCT02026193|PROCEDURE|embryo freezing|
48510557|NCT02286687|OTHER|Pharmacological Study|Correlative studies
48510558|NCT02286687|DRUG|Talazoparib|Given PO
48510559|NCT04860609|OTHER|Conventional Physiotherapy|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Bed Rest with lumbar Sacral Support~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
48675460|NCT03853044|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
48675461|NCT03853044|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
48675462|NCT03853044|DRUG|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
48675463|NCT00853892|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
48675464|NCT00853892|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
48675465|NCT02274961|DRUG|S-pantoprazole 10mg|
48675466|NCT02274961|DRUG|Placebo|
48675467|NCT05171972|DRUG|Ofatumumab|This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
48675468|NCT00499668|DRUG|aprepitant|125 mg orally for 7 days
48675469|NCT00499668|DRUG|ondansetron hydrochloride|24 mg orally for 7 days
48675470|NCT00720694|DEVICE|Duolith SD1|
48675471|NCT00720694|DEVICE|Sham Duolith SD1|
48675472|NCT04285697|OTHER|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
48675473|NCT02969642|DEVICE|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
48675474|NCT03313830|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
48675475|NCT03313830|DIETARY_SUPPLEMENT|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
48675476|NCT02250976|DRUG|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
48675477|NCT02250976|DRUG|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
48675478|NCT02250976|DRUG|Livaro tab. 2mg|Pitavastatin Ca 2mg
48675479|NCT03980392|OTHER|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
48675480|NCT01802099|OTHER|Enteral nutrition|
48675481|NCT01802099|OTHER|Parenteral nutrition|
48675482|NCT04544735|BEHAVIORAL|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
48149815|NCT01867879|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
48675483|NCT01742884|OTHER|Thealoz|Instillation of 1 drop of Thealoz
48510560|NCT04860609|OTHER|Lumber Spinal Decompression|"The treatment will be given in the following way.~1. Tens~2. Infrared/Moist Heat heat for 10 minutes at low back region.~3. Lumbar Mobilization (Maitland) CPA 3 sets of 10 reps~4. Stretching Exercises (Calf, Hams, Back Extensors) 3 sets of 8-10 reps~5. Strengthening Exercises (Back Extensors) 3 sets of 8-10 reps~6. Postural Education~7. Home Plan~8. Decompression therapy session lumbar spinal decompression therapy for 30 minutes.~9. Home plan:~Exercises Posture Correction Precautions Contra indication"
48510561|NCT04303780|DRUG|AMG 510|21 day cycles
48510562|NCT04303780|DRUG|Docetaxel|21 day cycles
48675484|NCT01742884|OTHER|Vehicle|1 drop of the vehicle will be instillated in the eye
48149816|NCT01867879|DRUG|Placebo|Placebo tablets, orally, single dose.
48149817|NCT00866541|DEVICE|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
48149818|NCT03790098|BEHAVIORAL|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
48510563|NCT00755443|DEVICE|Drug eluting stent|Drug eluting stent implantation
48510564|NCT00755443|DEVICE|Bare metal stent|
48675485|NCT00361465|OTHER|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
48675486|NCT05342298|OTHER|prediction model|Data will be pre-processed prior to final analysis, including data cleaning, imputation of missing values, dimensionality reduction, and removal of outliers. Data will be utilized as Xi and Yi where Xi presents input (features) and Yi presents dependent variables (outcomes). Different classification algorithms will be tested for accuracy to build the final model including logistic regression, SVM, XGboost and random forest algorithms. Data will be split at 0.8:0.2 for model training and testing, respectively.
48675487|NCT00997854|OTHER|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
48675488|NCT03533088|OTHER|Hospitalized rehabilitation|Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks
48675489|NCT03533088|OTHER|Home-based rehabilitation|Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
48675490|NCT06028698|OTHER|Inducing positive emotion music|listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
48149819|NCT05700656|DRUG|Galunisertib plus capecitabine|Combination therapy with galunisertib plus capecitabine
48149820|NCT04407442|DRUG|Azacitidine|Given IV
48149821|NCT04407442|BIOLOGICAL|Daratumumab|Given SC
48149822|NCT04407442|DRUG|Dexamethasone|Given IV or PO
48149823|NCT05431426|DRUG|CH6001|CHF6001 will be administered using the NEXThaler® DPI device
48149824|NCT00494416|OTHER|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
48149825|NCT02893618|DRUG|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
48149826|NCT02297464|OTHER|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
48149827|NCT02297464|OTHER|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
48149828|NCT03593590|DRUG|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
48149829|NCT03237026|OTHER|No intervention required|No intervention required
48149830|NCT03110783|BIOLOGICAL|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
48149831|NCT02287571|DEVICE|Derotation splint|This group is the actual intervention group.
48149832|NCT02287571|DEVICE|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
48510565|NCT01171755|DRUG|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
48510566|NCT06550570|BEHAVIORAL|QEVA questionnaire|QEVA questionnaire administered at 2 days pospartum (in hospital) and 4 weeks postpartum (phone call). (specific for the study)
48510567|NCT01987479|DRUG|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
48510568|NCT01987479|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
48510569|NCT01987479|DRUG|Methotrexate|Methotrexate will be administered per investigator's discretion.
48675491|NCT04141319|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
48675492|NCT04141319|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
48675493|NCT04141319|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
48675494|NCT02433912|PROCEDURE|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
48675495|NCT02433912|PROCEDURE|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
48675496|NCT02433912|DRUG|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
48149833|NCT00334438|BIOLOGICAL|rituximab|250mg/m2, IV, Days 1 and 8
48149834|NCT00334438|DRUG|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
48149835|NCT00334438|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
48149836|NCT00334438|RADIATION|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
48149837|NCT03473665|DRUG|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
48149838|NCT03473665|DRUG|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
48149839|NCT03473665|DRUG|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
48149840|NCT03473665|DRUG|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
48149841|NCT01745445|OTHER|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
48149842|NCT01894620|DEVICE|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
48510570|NCT01119781|DRUG|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
48675497|NCT02433912|DRUG|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
48675498|NCT02315222|DIETARY_SUPPLEMENT|Regenium|
48675499|NCT02315222|DIETARY_SUPPLEMENT|Placebo|
48675500|NCT02315222|PROCEDURE|Full Mouth Disinfection|
48510571|NCT05866419|DEVICE|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
48510572|NCT00506792|DRUG|QAU145|
48510573|NCT00506792|DRUG|Placebo|
48510574|NCT04817020|OTHER|%2 Klorheksidin|Effect on phlebitis
48510575|NCT01254383|DRUG|Sildenafil Tablet|Tablet, 50 mg, Single Dose
48510576|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
48675501|NCT06269510|BEHAVIORAL|ENGAGE-ALD Application (APP)|"Participants randomized to this will complete the app at the time of enrollment.~If in-person, will complete the app on a research laptop or iPad. The ENGAGE-ALD app consists of two modules developed based on preliminary data: 1) a misconception correction module and 2) a treatment matching module designed to match patients to participant's preferred form of alcohol treatment based on preferences for 19 different dimensions of alcohol treatment. The intervention will consist of administering a single session of the ENGAGE-ALD app."
48675502|NCT06269510|BEHAVIORAL|Treatment Facilitation bundle|Participants will complete a survey. The module includes motivational interviewing-informed content tailored to address and assist in overcoming barriers. After taking the survey, participants will receive a virtual coaching session (either via phone or online virtual platform). Sessions will focus on identifying participant goals with respect to alcohol use and liver health, providing education on risks of alcohol use to liver health and risks of relapse, reviewing participants individually identified barriers to alcohol treatment, exploring benefits of and these barriers to alcohol treatment, and performing collaborative goal-setting, among other topics.
48510577|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
48510578|NCT00990925|BEHAVIORAL|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
48510579|NCT00990925|OTHER|Usual Care|Care as usual
48675503|NCT06269510|BEHAVIORAL|Enhanced Usual Care|This group will receive standard hepatology care, and an educational pamphlet defining alcohol treatment resources available within Michigan Medicine and giving information on how participants can access these resources. This information will be given directly to participants that enroll in person or e-mailed to participants or sent via postal mail for those that enroll remotely.
48510580|NCT00247494|DRUG|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
48510581|NCT06611280|OTHER|No Interventions|No delivered intervention.
48510582|NCT05083182|DRUG|Ustekinumab|Ustekinumab will be administered as subcutaneous injection.
48510583|NCT05083182|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
48510584|NCT04412278|OTHER|Online Survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess physical activity level (International Physical Actvity Questionairre) and Exercise Benefits and Barriers (Exercise Benefits and Barriers Scale).
48510585|NCT02132793|BEHAVIORAL|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
48510586|NCT02132793|BEHAVIORAL|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
48362185|NCT06116474|BEHAVIORAL|Web-Based Physical Fitness Intervention|The exercise program has been designed according to the progressive overload method. Therefore, the volume of the exercise program increased as the weeks progressed. Exercise videos were uploaded to YouTube on Mondays, Wednesdays and Fridays send to participants via a message group to follow the program. The videos featured the experts' explanations of the movements for each exercise.. The equipment that the participants should use in the training sessions was selected from the materials available at home (eg., use of water bottles instead of weight dumbbells). The exercise sessions is divided into 3 parts: warm-up (2-4 min. average), main part (14-19 min. average), cool-down (3-5 min. average). The warm-up includes movements to increase the heart rate and warm up the muscles to be worked on for that session. The main part of the exercise program also included rest breaks when the participants were asked to move and stretch.
48675504|NCT04245709|DRUG|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
47991683|NCT03318250|DEVICE|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
48675505|NCT06505746|OTHER|No intervention|No investigational drug will be administered to participants in this study.
48675506|NCT01884363|OTHER|Once ounce per day of walnuts|
48675507|NCT06191042|DRUG|si-544|Subcutaneous injection in the abdomen
47991684|NCT00293696|DRUG|bicalutamide (Casodex), goserelin (Zoladex)|
47991685|NCT01135758|DRUG|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
48510587|NCT03226535|DEVICE|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
48510588|NCT05506150|BEHAVIORAL|Interviews|"Focused conversations to understand features of a GI bleed that are important to patients and families.~Patients and family members are invited to participate in focused conversations. For interviews and focus groups, criterion sampling will be used. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data includes self-reported demographic characteristics of the patient and family members. Qualitative data about participants will be obtained through individual interviews and focused groups and project team field notes."
48510589|NCT02110784|DRUG|Eurartesim tablets|dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
48510590|NCT05501678|DRUG|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
48675508|NCT06191042|DRUG|Placebo|Subcutaneous injection in the abdomen
48675509|NCT01518387|DRUG|Lanthanum Carbonate (BAY77-1931)|
48675510|NCT01425476|DRUG|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
48675511|NCT01425476|DRUG|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
48675512|NCT01425476|DRUG|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
47991686|NCT04521465|DEVICE|NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)|Eye drops
47991687|NCT06005922|OTHER|physiotherapy|ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises
48675513|NCT05040646|OTHER|Delphi exercise|"During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached."
48675514|NCT05249686|OTHER|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
48675515|NCT05249686|OTHER|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
48510591|NCT05501678|DRUG|Placebo|Matching Placebo given orally
48510592|NCT01727037|PROCEDURE|Bronchoscopic intrabullous autologous blood instillation|
48510593|NCT06037005|OTHER|Cognitive Behavioral Therapy Group|Group intervention program based on cognitive behavioral approach of ten sessions; It was completed in approximately one and a half months (May-June 2022) in the Faculty of Nursing, by dividing the experimental group into two separate groups, two days a week for each group. Each session was held for approximately one hour. The last measurement was made three months after the last therapy session (September 2022).
48510594|NCT02201277|DEVICE|Filter Placed|
48510595|NCT03560180|DIAGNOSTIC_TEST|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
48510596|NCT03560180|DIAGNOSTIC_TEST|Serum C-reactive Protein|see study protocol
48675516|NCT04528238|OTHER|Relaxing Visual Immersion|During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
48675517|NCT01339936|DEVICE|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
48149843|NCT01894620|DEVICE|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
48149844|NCT03230981|DEVICE|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
48362186|NCT04046666|DEVICE|Functional near infrared spectroscopy|Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
48510597|NCT03560180|DIAGNOSTIC_TEST|serum Procalcitonin|see study protocol
48675518|NCT03714438|DRUG|Medicago Sativa|Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
48675519|NCT03714438|DIETARY_SUPPLEMENT|Placebo|Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
48675520|NCT04416113|PROCEDURE|photobiomodulation and photodynamic therapy|antiviral treatment
48510598|NCT01912378|DRUG|Oxytocin|
48510599|NCT01912378|DRUG|Placebo nasal spray|
48149845|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
48149846|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
48149847|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
48510600|NCT04538625|DRUG|Crofelemer 125 MG [Mytesi]|Randomized, Double-blind, Placebo-controlled, two arm trial
48510601|NCT04538625|DRUG|Placebo|Matching placebo tablets
48510602|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL ECT)|
48510603|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL LAP ECT)|
48510604|NCT04939220|PROCEDURE|TEE with SGA|SGA Placement and maintenance with inhalational anesthetic or propofol
48510605|NCT04939220|PROCEDURE|TEE with Deep Sedation|Deep sedation with propofol and natural airway
48510606|NCT02901977|DRUG|Ramipril|Antihypertensive therapy
48510607|NCT02901977|DRUG|Doxazosin|Antihypertensive therapy
48510608|NCT04717492|OTHER|Observational|Observational
48675521|NCT03991910|DRUG|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
48675522|NCT03991910|DRUG|Ramipril 5Mg Oral Capsule|the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
48675523|NCT03323684|OTHER|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
48675524|NCT03323684|OTHER|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
48675525|NCT03323684|OTHER|Control group (C)|No intervention will be done
48675526|NCT03323684|DRUG|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
48675527|NCT03323684|DRUG|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
48675528|NCT03323684|DRUG|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
48675529|NCT01964183|DRUG|tolterodine|Oral
48675530|NCT01964183|DRUG|mirabegron|Oral
48675531|NCT00551083|OTHER|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR\*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
48675532|NCT00551083|OTHER|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
48675533|NCT04199065|OTHER|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
48675534|NCT00954161|OTHER|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
48675535|NCT00954161|OTHER|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
48675536|NCT05713071|PROCEDURE|Bariatric Endoscopic Antral Myotomy|BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
48675537|NCT03984773|BEHAVIORAL|Nudge|Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
48675538|NCT05926063|OTHER|Comparison short vs extended EBAT treatment group|This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
48675539|NCT05855018|DRUG|Atropine sulfate eye drops|One drop once daily
48510609|NCT02454855|DRUG|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
48675540|NCT01914250|DRUG|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
48675541|NCT05592821|PROCEDURE|dental implant placement|In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
48675542|NCT02604459|DEVICE|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
48675543|NCT02604459|DEVICE|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
48675544|NCT02604459|PROCEDURE|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
48675545|NCT02604459|PROCEDURE|General anesthesia|General anesthesia will be used in both groups
48675546|NCT02604459|DRUG|propofol|propofol per protocol
48675547|NCT02604459|DRUG|fentanyl|fentanyl per protocol
48675548|NCT02604459|DRUG|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
48675549|NCT04624516|OTHER|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
48675550|NCT02629926|OTHER|GH Replacement (NutropinAq®)|GH Replacement continued.
48362187|NCT04046666|PROCEDURE|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm."
48510610|NCT02454855|DRUG|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
48510611|NCT03551288|DRUG|SUVN-911|Tablet
47991688|NCT06005922|OTHER|TMJ exercises|tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
48362188|NCT01306240|PROCEDURE|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
48510612|NCT02724228|DRUG|BMN 111|BMN 111 will be administered subcutaneously daily.
48510613|NCT00010530|PROCEDURE|Meditation|
48675551|NCT02629926|OTHER|No additional treatment|GH Replacement not continued.
48675552|NCT03754322|DIAGNOSTIC_TEST|LAMP|LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
48675553|NCT03754322|DIAGNOSTIC_TEST|Microscopy/RDT|Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
48675554|NCT01936233|DRUG|Aspirin|Aspirin 0.1 QD po
48675555|NCT01936233|DRUG|Lamivudine|LAminvudine 0.1 QD po
48675556|NCT00535418|DRUG|Letrozole|
48675557|NCT02257749|OTHER|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
48675558|NCT02257749|OTHER|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
48149848|NCT02633228|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
48675559|NCT02078752|DRUG|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
48675560|NCT02078752|DRUG|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
48675561|NCT05937529|OTHER|Cream containing madecassoside and 5 % panthenol|Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
48675562|NCT05937529|OTHER|Daylight PDT|Daylight PDT performed with 2 hours of artifical indoor light.
48675563|NCT03126643|BIOLOGICAL|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
48675564|NCT06512532|OTHER|fireworks eye injury|patients presented with eye injury during festivals due to fireworks
48675565|NCT00407719|DRUG|Bevacizumab|
48675566|NCT00368524|BEHAVIORAL|contingency management and behavioral day treatment|
48675567|NCT05832892|DRUG|surufatinib|"In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib."
48675568|NCT05832892|DRUG|KN046|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
48675569|NCT05832892|DRUG|gemcitabine|Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
48675570|NCT05832892|DRUG|Nab paclitaxel|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
48675571|NCT00394264|PROCEDURE|Soft Tissue|
48675572|NCT00394264|PROCEDURE|Myofascial release|
48675573|NCT00394264|PROCEDURE|Counterstrain|
48675574|NCT00394264|PROCEDURE|Muscle energy|
48675575|NCT00394264|PROCEDURE|Sacro-iliac articulation|
48362189|NCT01306240|PROCEDURE|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
48675576|NCT00394264|PROCEDURE|High-velocity, low amplitude|
48675577|NCT03894891|DRUG|Nivolumab|Nivolumab is a type of immunotherapy.
48675578|NCT03894891|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
48675579|NCT03894891|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
47991689|NCT05601986|OTHER|Physiotherapy and Rehabilitation Program|"The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board."
48675580|NCT03894891|RADIATION|Intensity-modulated radiotherapy|IMRT is definitive treatment for head and neck cancer.
48675581|NCT01459094|DRUG|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
48675582|NCT01459094|DRUG|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
48675583|NCT04753619|DRUG|Niclosamide Oral Tablet|"* NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding."
48675584|NCT00181844|DRUG|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children \<12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
48149849|NCT01036932|DRUG|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
48149850|NCT01036932|DRUG|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
48675585|NCT01379807|DRUG|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
48675586|NCT01781377|DRUG|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
48675587|NCT01781377|DRUG|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
48675588|NCT01781377|DRUG|PLACEBO|SALINE INFUSION
48675589|NCT02473471|DEVICE|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
48675590|NCT00375466|DRUG|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
48675591|NCT00375466|DRUG|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
48362190|NCT01790633|OTHER|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
48362191|NCT01790633|OTHER|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
48362192|NCT06117644|DRUG|Furmonertinib|Furmonertinib 40 mg/tablet, 4 tablets, QD
48675592|NCT04375436|DRUG|NTRX-07-SDD|NTRX-07-SDD for oral administration
48675593|NCT00003645|DRUG|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
48675594|NCT00003645|DRUG|Leuprolide Acetate|50 mg tablet orally daily for 12 months
48149851|NCT02301286|DRUG|Acetylsalicylic acid|
48675595|NCT03744338|OTHER|questionnaire|"The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest."
48675596|NCT03707886|BEHAVIORAL|Pain SMART|Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
48675597|NCT03707886|OTHER|minimally enhanced usual care|The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
48675598|NCT03571932|BEHAVIORAL|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
48675599|NCT04775550|DRUG|Daratumumab|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
48149852|NCT02301286|DRUG|Placebo Acetylsalicylic acid|
48149853|NCT02304445|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
48362193|NCT00757159|DEVICE|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
48362194|NCT00757159|DEVICE|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
48362195|NCT03524664|BEHAVIORAL|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior."
48675600|NCT04775550|DRUG|Bortezomib|Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
48149854|NCT02304445|RADIATION|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
48149855|NCT00911716|BIOLOGICAL|bevacizumab|
48149856|NCT00911716|DRUG|cyclophosphamide|
48149857|NCT00911716|DRUG|docetaxel|
48149858|NCT00911716|PROCEDURE|adjuvant therapy|
48362196|NCT00372905|DRUG|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
48362197|NCT00372905|DRUG|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
48149859|NCT01668498|DRUG|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
48149860|NCT01668498|DRUG|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
48149861|NCT03323502|BEHAVIORAL|ACP Specialist Program|New structured role with responsibility for ACP
48675601|NCT04775550|DRUG|Lenalidomide|Oral, dosage per protocol, days 1-21 per cycle
48149862|NCT04459949|DEVICE|Sharkskin|Use of Sharkskin ILM forceps
48149863|NCT04459949|DEVICE|Grieshaber|Use of Grieshaber ILM forceps
48149864|NCT06542614|DRUG|TQH3906 capsules|To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
48149865|NCT06542614|DRUG|Placebo of TQH3906 capsules|Placebo without drug substance.
48149866|NCT00911391|DEVICE|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
48149867|NCT00911391|PROCEDURE|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
48362198|NCT00372905|DRUG|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
48362199|NCT05748366|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
48362200|NCT05748366|DRUG|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
48362201|NCT00416572|BEHAVIORAL|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
48149868|NCT01992497|DIETARY_SUPPLEMENT|Probiotic|
48149869|NCT00375323|DRUG|NovoSeven|
48510614|NCT06452901|OTHER|Progression and structured surgical training.|Participants will be exposed to different amounts of open vascular surgical training, but only group I will receive the complete structured and progressive training program. This ensures that all participants have access to the potential benefits derived from the intervention. Current evidence supports this approach, which supports the benefits of medical simulation in the training process of surgical residents.
48510615|NCT03819894|DIAGNOSTIC_TEST|Introduction of a lower female hs-cTn threshold|The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
48510616|NCT02803658|BEHAVIORAL|smoking behavior|
48510617|NCT02803658|BIOLOGICAL|Sperm collection|
48510618|NCT05786664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48149870|NCT04044885|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
48149871|NCT05220813|DRUG|Lidocaine|local infiltration by lidocaine in the surgical site
48149872|NCT05220813|DRUG|Bupivacain|44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
48149873|NCT05192902|DEVICE|Computer-controlled Local Anaesthesia (CCLA)|The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
48149874|NCT05192902|DEVICE|Conventional Local Anaesthesia|Conventional dental local anaesthetic injections.
48149875|NCT05889832|DIAGNOSTIC_TEST|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
48510619|NCT05786664|OTHER|Electronic Health Record Review|Review of records
48675602|NCT04775550|DRUG|Dexamethasone|Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
48675603|NCT00997789|DRUG|Rebamide|Rebamipide 100 mg Tablet, three times a day
48675604|NCT02746406|DEVICE|Peritron+|Peritron+ device to measure intravesical pressure
48149876|NCT03308500|BEHAVIORAL|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
48149877|NCT03308500|BEHAVIORAL|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
48149878|NCT03000829|OTHER|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
48149879|NCT03000829|OTHER|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
48149880|NCT02382185|OTHER|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
48149881|NCT02382185|DRUG|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
48149882|NCT02382185|DEVICE|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
48149883|NCT03498456|DRUG|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
48149884|NCT03498456|DRUG|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
48149885|NCT00153374|BEHAVIORAL|Women's health|
48149886|NCT03799757|DRUG|40ml of 0.25% bupivacaine|
48149887|NCT03799757|DRUG|40ml of 0.9% normal saline|
48362202|NCT00416572|BEHAVIORAL|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
48362203|NCT06225830|DEVICE|Eksobionics Eksoskeleton NR|During treatment sessions, the therapist will guide the participant's progress using a specific plan. The therapist will set a trajectory for each leg, determining the appropriate step height and length, and program it into the Ekso device. The Ekso will then assist the participant by following this trajectory, with varying levels of assistance for each step. As the participant improves, the therapist will gradually reduce the assistance provided until the participant reaches a point where they no longer require assistance or reach a plateau. In the final phase, the trajectory will be removed, and the participant will walk using their own movements. The therapist may add resistance or assistance based on the participant's needs, but it will be in line with their self-generated movements rather than a predetermined path.
48510620|NCT05786664|OTHER|Quality-of-Life Assessment|Complete quality-of-life questionnaires
48510621|NCT05786664|OTHER|Survey Administration|Complete surveys
48149888|NCT02786277|OTHER|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
48149889|NCT06509269|PROCEDURE|intraoral scanning|Intraoral Scanning of edentulous Jaw
48362204|NCT01059955|DRUG|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
48362205|NCT01059955|DRUG|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
48510622|NCT01665326|OTHER|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
48149890|NCT06509269|PROCEDURE|Desktop scanning|Desktop scanning of definitive impression
48149891|NCT00401050|PROCEDURE|chiropractic manipulative therapy|
48149892|NCT00401050|PROCEDURE|knee exercises|
48149893|NCT00401050|PROCEDURE|Graston Instrument Soft Tissue Mobilization (GISTM)|
48149894|NCT01569399|OTHER|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
48149895|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
48149896|NCT01757288|DRUG|PACLITAXEL|
48149897|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
48149898|NCT05458544|DRUG|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
48149899|NCT05847114|OTHER|Stres ball|Stress ball compression for 15 minutes during surgery
48510623|NCT05857852|DEVICE|Low-Intensity Focused Ultrasound|Low-Intensity Focused Ultrasound administration to right dorsal anterior insula, in one of two sessions
48510624|NCT05857852|DEVICE|Sham LIFU device|Sham LIFU device administered in one of two sessions
48510625|NCT05178342|DRUG|CA-4948|"Patients will be treated orally with CA-4948 at 300 mg BID (2x200mg) over 4 cycles. One cycle consists of 28 days, 21 of which are treatment days, followed by 7 days off.~Patients with erythroid response (HI-E) after 4 cycles who tolerate CA-4948 may continue to receive CA-4948 until loss of HI-E response."
48675605|NCT05927116|OTHER|Mobile phone app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD)|TRIP is a mobile app-based intervention comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
48362206|NCT03225027|BEHAVIORAL|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
48362207|NCT03225027|BEHAVIORAL|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
48362208|NCT03225027|BEHAVIORAL|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
48362209|NCT03225027|BEHAVIORAL|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
48362210|NCT03225027|OTHER|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
48362211|NCT03225027|DIAGNOSTIC_TEST|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
48362212|NCT03225027|DIAGNOSTIC_TEST|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
48362213|NCT03225027|OTHER|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
48510626|NCT05745597|OTHER|Follow up|Four samples of cervical exfoliated cells and fornix secretions were collected from all subjects at enrollment, 6 months, 12 months and 24 months for HPV integration status and vaginal microbiota diversity sequencing, and two additional samples of peripheral blood (whole blood + serum) were collected at enrollment.
48510627|NCT02003950|OTHER|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
48510628|NCT04813783|OTHER|Mucositis care training to be given in line with MASCC / ISOO 2019|Mucositis care training to be given in line with MASCC / ISOO 2019
48510629|NCT02193217|DRUG|MT-1303-Low|
48510630|NCT02193217|DRUG|MT-1303-High|
48510631|NCT02193217|DRUG|Fingolimod|
48510632|NCT02193217|DRUG|Placebo|
48675606|NCT00878267|BEHAVIORAL|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
48675607|NCT05999331|OTHER|initial aspartate aminotransferase (AST) to platelet (PLT) ratio index|All eligible patients were given antibiotics therapy, actively control infection source, as well as other supportive therapy to maintain organ function.
48675608|NCT02799550|BIOLOGICAL|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
48675609|NCT02954458|DRUG|TED|0.05 mg/kg SC injection once daily.
48675610|NCT02954458|OTHER|SOC|Standard safety assessments and adjustments in nutritional support.
47991690|NCT05601986|OTHER|Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program|The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
47991691|NCT02598427|DRUG|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
47991692|NCT02598427|DRUG|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
48362214|NCT03117686|DIAGNOSTIC_TEST|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
48362215|NCT03919760|BEHAVIORAL|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~1. individualized medication management using a decision support tool;~2. a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~3. supported employment and education (SEE);~4. a family education program"
48362216|NCT06421363|DRUG|Inclisiran|Implementation of a follow-up program that incorporates Inclisiran treatment in patients with a history of chronic coronary syndrome
48362217|NCT04389931|OTHER|Lactose tab|Two tablets containing lactose Procedure: Periodontal treatment Scaling and root planning
48362218|NCT04389931|DRUG|Omega 3|Two tablets containing 1g Omega 3. Procedure:Periodontal treatment Scaling and root planning
48675611|NCT02954458|DEVICE|Syringe|Teduglutide will be administered using syringe.
48510633|NCT00493415|DRUG|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
48149900|NCT04278690|OTHER|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent. Instruction sheets include optimized instructions (mL-only, doses appropriately rounded, visuals of recommended tool (e.g. 1-mL syringe best for doses of \<1 mL), explicit frequency information (e.g. 'morning and night' instead of '2x/day') reinforced by pictograms (e.g. sun/moon icons)). For each medication, staff will: 1) review the dose (refer to the pictographic dose diagram, which illustrates optimal dosing tool filled to correct amount), 2) demonstrate the dose using optimal dosing tool, 3) ask parent to 'teachback'/'showback' dose (e.g. parent shows provider how much they would give by pulling back plunger on syringe to right level), 4) provide optimal dosing tool for the parent to take home. We anticipate this process will take \~5-10 minutes.
48149901|NCT04278690|OTHER|HELPix+Tech|After parent receives usual care and HELPix , trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app. For each medicine: A. Dosing module with optimized instructions (c/w HELPix); parent teachback/showback of dose B. Frequency module supports simplified, explicit intervals (e.g. 'morning and night'), parent chooses convenient times (text reminders sent based on preferences). Time for TECH depends on # medicines and parent baseline knowledge; structured protocol used to see # teachback rounds needed .
48149902|NCT04471805|DEVICE|Sham transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
48149903|NCT04471805|DEVICE|Transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
48149904|NCT00391794|BEHAVIORAL|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
48149905|NCT00391794|BEHAVIORAL|Educational Seminar|4 hour education session led by trained facilitators
48149906|NCT03507452|DRUG|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
48149907|NCT03507452|DRUG|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
48149908|NCT02037568|BEHAVIORAL|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
48149909|NCT05747872|BEHAVIORAL|Buerger Allen Exercises|"These exercises are specific exercises aimed at improving circulation in the feet and legs.~While doing the exercises, first of all;~1. The legs are raised at an angle of 45 degrees and supported in this position for 1-3 minutes until the skin turns white.~2. Sit on the edge of the bed and let your legs hang down (make sure there is no pressure behind the knees). In this position, move your foot left and right and up and down for 3 minutes.~3. Lie on your back for 5 minutes keeping your legs warm with a blanket.~Performing all three of these exercises in sequence means 1 session. Exercises are done 2 times a day, at least 3 sessions each time."
48362219|NCT05512039|DRUG|Botox 50 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
48362220|NCT05512039|DRUG|Botox 100 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
48362221|NCT03459794|DRUG|Ivermectin|150 mcg/kg ivermectin, by mouth.
48510634|NCT00493415|DRUG|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
48362222|NCT03459794|OTHER|Placebo|An oral placebo will be administered, once
48362223|NCT05113849|BIOLOGICAL|IN-B009 (Low-dose)|Two doses, intramuscular injection
48362224|NCT05113849|BIOLOGICAL|IN-B009 (High-dose)|Two doses, intramuscular injection
48362225|NCT05650528|DRUG|QG101-23-0 capsules|Single and Multiple Dose for oral
48510635|NCT00194701|BEHAVIORAL|Walking exercise|
48510636|NCT02218554|GENETIC|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
48510637|NCT01111825|DRUG|Temsirolimus|"28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
48510638|NCT01111825|DRUG|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
48510639|NCT04890912|RADIATION|Conventional Fractionation|Dose prescribed is 45 Gy in 25 fractions (1.8 Gy per fraction) delivered daily over 5 weeks.
48510640|NCT04890912|RADIATION|Hypofractionation|Dose prescribed is 30 Gy in 5 fractions (6 Gy per fraction) delivered every other day over 11 days. There will be a minimum of 36 hours and maximum of 96 hours between fractions. The entire course of treatment should be completed within no less than 10 days.
48675612|NCT02954458|DEVICE|Needle|Teduglutide will be administered using needle.
48675613|NCT05269459|DRUG|Cannabidiol (CBD) as Nantheia ATL5|Gel caps containing 100mg of Nantheia ATL5. Subjects will take 4 capsules twice daily.
48675614|NCT05269459|DRUG|Placebo|Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
48675615|NCT04390399|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48675616|NCT04390399|DRUG|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
48675617|NCT04390399|BIOLOGICAL|PD-L1 t-haNK|PD-L1 t-haNK suspension for infusion
48675618|NCT04390399|DRUG|Nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
48675619|NCT04390399|DRUG|Gemcitabine|2', 2'-difluoro 2'deoxycytidine, dFdC
48675620|NCT04390399|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48675621|NCT04390399|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48675622|NCT04390399|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
48675623|NCT04390399|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
48149910|NCT01245699|BEHAVIORAL|scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing|scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
48149911|NCT04565288|DRUG|Atomoxetine|Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
48149912|NCT04565288|DRUG|Placebo|Matching placebo (sugar pill)
48510641|NCT06348615|DEVICE|Anti-cellulite cream-gel Medical Device (DEFBODY)|one bottle of 400 ml, twice a day
48510642|NCT02072603|OTHER|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
48675624|NCT04390399|DRUG|Irinotecan liposome|Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
48675625|NCT05579730|DRUG|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo|Brimonidine tartrate 0.025% / ketotifen fumarate 0.035% combo
48675626|NCT05579730|DRUG|Ketotifen fumarate ophthalmic solution 0.035%|Ketotifen fumarate ophthalmic solution 0.035%
48675627|NCT05579730|DRUG|Brimonidine tartrate ophthalmic solution 0.025%|Brimonidine tartrate ophthalmic solution 0.025%
48675628|NCT05579730|DRUG|Vehicle ophthalmic solution|Vehicle ophthalmic solution
47991693|NCT04919954|DRUG|Tebipenem Pivoxil Hydrobromide|Tebipenem 300 mg or 600 mg will be administered orally every 8 hours for total of 3 to 7 doses
47991694|NCT02211573|OTHER|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
47991695|NCT03961607|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
48149913|NCT05980078|OTHER|Interactive consent|They were randomized to complete an interactive consent.
48675629|NCT02061475|DRUG|Lidocaine Patches|
48675630|NCT01628068|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
48675631|NCT02785692|RADIATION|Radiation|preoperative Radiotherapy/ IMRT
48675632|NCT00971282|DRUG|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
48675633|NCT00971282|OTHER|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
48675634|NCT00776360|DRUG|oxytocin|80mIE/min as continuous infusion for 70 minutes
48149914|NCT05980078|OTHER|Standard consent|They were randomized to complete a standard written consent.
48149915|NCT02804074|OTHER|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
48149916|NCT02804074|OTHER|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
48675635|NCT00776360|DRUG|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
48675636|NCT02977338|OTHER|Retrospective review|
48675637|NCT04044014|DEVICE|Gellan sheet|Gellan sheet.
48675638|NCT04044014|DEVICE|Gellan fluid gel|Gellan fluid gel.
48675639|NCT04044014|DEVICE|Mepitel One|Control dressing-- Mepitel One.
48675640|NCT02112539|OTHER|platelet aggregation measurement|
48675641|NCT03678545|DRUG|Dupilumab (blinded)|Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.
48675642|NCT03678545|DRUG|Placebo (blinded)|Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
48149917|NCT01482091|DRUG|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
48149918|NCT01482091|DRUG|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
48149919|NCT02699619|DEVICE|Pinloc|3 hook pins interlocked in plate.
48675643|NCT03678545|DRUG|Dupilumab (open-label)|After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
48675644|NCT03606486|OTHER|Biospecimen Collection|Undergo collection of tumor sample and blood draw
48510643|NCT02072603|OTHER|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
48675645|NCT03606486|OTHER|Laboratory Biomarker Analysis|Correlative studies
48675646|NCT03606486|DEVICE|Lavage|Undergo uterine lavage
48675647|NCT03606486|OTHER|Pap Smear|Undergo pap smear
48675648|NCT00328718|DRUG|montelukast (5mg QD)|
48675649|NCT00328718|DRUG|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
48675650|NCT02261207|DRUG|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
48675651|NCT06170151|DIAGNOSTIC_TEST|Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.
48675652|NCT02560220|BIOLOGICAL|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
48675653|NCT06468787|DEVICE|Kosmos Anatomical Object Labeling and View Identification Algorithms|Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is compared to majority opinion of 5 radiologists.
48675654|NCT03265444|BIOLOGICAL|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
47991696|NCT06057792|DEVICE|negative pulsed pressure AeroFlow system|"For the application of pulsatile negative pressure, the AeroFlow® equipment will be used, carried out by one of the researchers participating in the project.The application will be carried out addressing the structure of interest (scar), following the protocol established by INDIBA to release adhesions between the different depth planes. The work will consist of an application of pulsed negative pressure using suction cups, which will work automatically at a frequency and intensity tolerable by the patient.~Treatment protocol in 2 phases Total application time 15min~1. Static cup: preparation: Prepare the tissue surrounding the scar. 5min~2. Dynamic Cup: work: Lock the tissue around the scar and the scar itself.10min Suction mode: continuous with continuous sliding of the cup The number of treatment sessions will consist of a total of 6 sessions, so there will be two sessions over 3 weeks."
48149920|NCT02699619|DEVICE|2 Hansson pins|2 isolated hook pins.(Without plate)
48149921|NCT01964586|DRUG|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
48149922|NCT01964586|DRUG|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
48149923|NCT01964586|DRUG|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
48149924|NCT06407141|BEHAVIORAL|transcranial pulse stimulation|Participants in the experimental arm will receive six sessions of Transcranial Pulse Stimulation (TPS) over a two-week period, using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). Each session will involve delivering 6,000 ultrasound pulses at an energy level of 0.2-0.25 mJ/mm² and a frequency of 4-5 Hz, targeting specified brain regions based on MRI navigation.
48149925|NCT06407141|BEHAVIORAL|Sham TMS|Participants in the sham control group will undergo six sessions over a two-week period, utilizing the same NEUROLITH® TPS system (Storz Medical AG, Switzerland) as used in the experimental group. The key difference lies in the standoff device attached to the handpiece: while the experimental arm uses a standoff filled with silicone oil to transmit ultrasound pulses, the sham group\&#39;s standoff is filled with air. This design ensures that the sham device replicates the appearance, feel, and sound of the active treatment without transmitting any therapeutic pulses, effectively maintaining the blinding aspect of the study.
48149926|NCT02488733|PROCEDURE|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
48362226|NCT05650528|DRUG|Placebo|Single and Multiple Dose for oral
48510644|NCT03532373|OTHER|Preference Elicitation tool|A preference elicitation tool for carpal tunnel syndrome
48675655|NCT05554458|BEHAVIORAL|ChildTaks+ intervention|The ChildTalks+ Intervention ChildTalks+ is a preventive intervention originally developed in the Netherlands, targeting children up to 18 years of age. It has been implemented in Norway, Italy, and Portugal. It has a clear and well-described theoretical basis focusing on psychoeducation. Its key strategy is to provide feasible and replicable interventions to improve the quality of life of families where parents are affected by a mental disorder.
48675656|NCT04677491|DRUG|Ospemifene 60 mg|Ospemifene vs placebo
48675657|NCT04677491|BEHAVIORAL|fMRI experiments|Participants will see sexually explicit video clips that alternate with non-sexual clips and neutral color projection and b) smell alternate pheromones with clear air and pine aroma.
47991697|NCT00829374|DRUG|Dimebon|5 mg orally three times daily
48675658|NCT03308682|DRUG|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
48675659|NCT02374125|DEVICE|Diacutaneous Fibrolysis|Applied only around teres major muscle.
48675660|NCT02374125|OTHER|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
48675661|NCT02374125|OTHER|Protocolized physiotherapy|Exercises, TENS and cryotherapy
47991698|NCT00829374|DRUG|Dimebon|20 mg orally three times daily
48149927|NCT02488733|DRUG|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
48149928|NCT01781923|BEHAVIORAL|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
48149929|NCT01781923|BEHAVIORAL|Small group social skills training|Meet once per week for duration of 40 weeks.
48510645|NCT00221377|DEVICE|Intubation using tracheal tubes with or without cuff|
48510646|NCT01239108|DRUG|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
48510647|NCT04936035|DRUG|Placebo|Placebo administered by SC injection
48510648|NCT04936035|DRUG|ALN-AGT01|ALN-AGT01 administered by SC injection
48510649|NCT00001705|DRUG|GP100 peptide|
48510650|NCT00001705|DRUG|IL-2|
48510651|NCT04389892|DIAGNOSTIC_TEST|Contrast enhanced harmonic endoscopic ultrasound|"During the echoendoscopy the image was fixed on the region of interest (pancreatic cyst) and the extended pure harmonic detection mode was selected. 2,4ml contrast enhancement (Sonovue-Bracco Italy) was injected in the right antecubital vein of the participants followed by a flush of 5ml 0.9% saline solution to ensure that the entire quantity of the agent goes in to the blood flow.~After the administration the pancreatic cyst was observed for at least 120 seconds.We followed the enhancing behavior of the cyst wall, the septa and the solid components. Arterial enhancement (contrast uptake) was considered the first 25-30 seconds after injection and the venous phase (wah-out) 30-45 seconds after injection.~EUS-FNA was performed in all patients without contraindications"
48510652|NCT06185881|PROCEDURE|restoration of cervical carious teeth|restoration of carious cervical lesions by glass ionomer
48510653|NCT05102552|DRUG|SPN-817, Treatment B|SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
48510654|NCT05102552|DRUG|SPN-817, Treatment C|SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
48510655|NCT05102552|DRUG|BIS-001, Treatment A|BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
48510656|NCT00281957|DRUG|sorafenib tosylate|Given orally
48510657|NCT00281957|DRUG|tipifarnib|Given orally
48510658|NCT00281957|DRUG|temsirolimus|Given IV
48510659|NCT05547620|DEVICE|LIFUS Online Real|Stimulation using NeuroFUS device while standing
48510660|NCT05547620|DEVICE|LIFUS Online Sham|Stimulation using NeuroFUS device while standing
48510661|NCT05547620|DEVICE|LIFUS Offline|Stimulation using NeuroFUS device prior to standing
48510662|NCT03763357|DEVICE|Heat Therapy (HT)|Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
48510663|NCT03122925|DEVICE|MR|MR
47991699|NCT00829374|DRUG|Placebo comparator|Placebo orally three times daily
47991700|NCT04085133|DIAGNOSTIC_TEST|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
48149930|NCT02081976|BEHAVIORAL|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
48510664|NCT05465109|OTHER|TBI-AD/ADRD Caregiver Support Intervention (TACSI)|The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
48510665|NCT06501677|BEHAVIORAL|WBI|"The WBI will comprise of four sessions focusing on CRAFT principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to the DP (PPR; i.e., actively listening, showing understanding, expressing interest in what their DP is thinking and feeling, and trying to see where the DPs is coming from), (3) understanding the DP's drinking reinforcers, and (4) supporting the DP if they want help and engaging in positive, healthy activities with the DP. ' partner.~Each module will take \~20-30 minutes and each session will: (1) instill optimism in CPs, (2) be solution-focused, (3) emphasize that the CP is not responsible for the DP's behaviors, and (4) use a nonjudgmental, non-confrontational, empathetic style. The WBI intervention is focused on reduced drinking in the DP and improved CP wellness."
48510666|NCT04554446|PROCEDURE|T-MSAT(Motion style acupuncture treatment using traction)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. T-MSAT(Motion style acupuncture treatment using traction) is a kind of MSATs, and a treatment that improves musculoskeletal problems by pulling the patient's body through the device and giving instructions for walking while being acupuncture.
48362227|NCT01173874|DRUG|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
48510667|NCT04554446|PROCEDURE|Korean medicine treatment|acupuncture, chuna, pharmacoacupuncture and Korean herbal medicine.
48510668|NCT03632018|BEHAVIORAL|HEART-PLAY|Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
48675662|NCT02905279|BEHAVIORAL|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
48675663|NCT02905279|BEHAVIORAL|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
47991701|NCT01096810|DRUG|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
47991702|NCT02635828|DRUG|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
47991703|NCT02635828|DRUG|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
47991704|NCT02635828|DRUG|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
47991705|NCT00568750|DRUG|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
48362228|NCT01574118|BEHAVIORAL|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
48510669|NCT03632018|BEHAVIORAL|Standard Cardiac Rehabilitation|During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
48675664|NCT02905279|BEHAVIORAL|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
48362229|NCT01574118|BEHAVIORAL|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
48362230|NCT01574118|BEHAVIORAL|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
48362231|NCT01574118|BEHAVIORAL|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
48362232|NCT01574118|BEHAVIORAL|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
48362233|NCT01574118|BEHAVIORAL|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
48362234|NCT01574118|BEHAVIORAL|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
48362235|NCT01574118|BEHAVIORAL|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
48362236|NCT01309646|BIOLOGICAL|Infanrix™-IPV+Hib|Intramuscular, 3 doses
48510670|NCT04637555|DRUG|sacubitril/valsartan|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
48510671|NCT05339334|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir will be given by mouth two times a day for 10 days
48510672|NCT01279720|BIOLOGICAL|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
48675665|NCT02905279|BEHAVIORAL|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
47991706|NCT06323460|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47991707|NCT06323460|DRUG|Carboplatin|Given IV
47991708|NCT06323460|DRUG|Cisplatin|Given IV
47991709|NCT06323460|PROCEDURE|Computed Tomography|Undergo PET/CT
47991710|NCT06323460|RADIATION|External Beam Radiation Therapy|Undergo external beam radiotherapy
47991711|NCT06323460|DRUG|Paclitaxel|Given IV
47991712|NCT06323460|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
47991713|NCT06323460|OTHER|Questionnaire Administration|Ancillary studies
47991714|NCT01802723|DRUG|Drug: salmeterol xinafoate|
47991715|NCT01802723|DRUG|Drug: Placebo|
47991716|NCT03664947|OTHER|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
47991717|NCT03441841|DRUG|Lidocaine + Prilocaine|Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
47991718|NCT03441841|DRUG|Lidocaine|Single topical dose of 2g lidocaine 2.5 % formulation.
47991719|NCT03441841|DRUG|Prilocaine|Single topical dose of 2g prilocaine 2.5 % formulation.
48362237|NCT01309646|BIOLOGICAL|Infanrix™ IPV|Intramuscular, 3 doses
48362238|NCT01309646|BIOLOGICAL|Hiberix™|Intramuscular, 3 doses
48362239|NCT01309646|BIOLOGICAL|Synflorix™|Intramuscular, 3 doses
48675666|NCT05595200|DIAGNOSTIC_TEST|Level III portable sleep study|Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
48675667|NCT06255405|BEHAVIORAL|Self-compassion|The dyadic parent-child self-compassion program is designed by the research team and validated by a panel of experts. It includes 5 weekly sessions. Each session lasts for 60 minutes. The dyads will be guided to do self-compassion practices (e.g. affectionate breathing, compassionate letters to oneself etc). Didactic topics, inquiry, and home practices are also involved.
48675668|NCT01775527|OTHER|blood test|
48362240|NCT01309646|BIOLOGICAL|Rotarix™|Oral, 2 doses
48149931|NCT02081976|OTHER|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
48149932|NCT01859689|RADIATION|brachytherapy|Undergo image-guided HDR brachytherapy
48362241|NCT04438642|PROCEDURE|shoulder finishline|tooth will be prepared having shoulder finishline.
48149933|NCT01859689|RADIATION|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
48362242|NCT04438642|PROCEDURE|butt joint with bevel|tooth will be prepared having butt joint with bevel finishline.
48362243|NCT02288793|OTHER|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
48362244|NCT03011164|PROCEDURE|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
48362245|NCT05205161|DRUG|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
48362246|NCT05779280|OTHER|THDA + Acetyl Zingerone Topical Product|A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily
48362247|NCT05779280|OTHER|THDA|A skin care product with THDA (VitaSynol® C) used twice daily
48362248|NCT04720027|DIAGNOSTIC_TEST|Duplex imaging|Completion of AVVQ and EQ5D questionnairs
48362249|NCT00919828|DEVICE|Avivo System|Non invasive external monitoring device
48149934|NCT01859689|OTHER|laboratory biomarker analysis|Correlative studies
48149935|NCT00807053|DRUG|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
48149936|NCT00807053|DRUG|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
48362250|NCT05626959|DRUG|NTI164|Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
48362251|NCT04993144|DEVICE|continuous theta burst stimulation|stimulatory protocol
48362255|NCT04385667|DEVICE|levonorgestrel intrauterine system (LNG-IUD)|progestin delivery for regression of atypical endometrial hyperplasia
48149937|NCT00807053|DRUG|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
48149938|NCT00807053|DRUG|Placebo|Placebo
48149939|NCT03043339|OTHER|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
48362256|NCT04385667|DRUG|Oral Megesterol 160 mg daily|progestin delivery for regression of atypical endometrial hyperplasia
48362257|NCT01049789|BEHAVIORAL|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
48510673|NCT03309527|BEHAVIORAL|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
48510674|NCT03309527|BEHAVIORAL|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
48149940|NCT03043339|OTHER|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
48149941|NCT03043339|OTHER|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
48149942|NCT03043339|OTHER|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
48510675|NCT03593538|DRUG|Metformin|Metformin capsule
48510676|NCT03593538|DRUG|Placebo|Sucrose filler in gel capsules
48149943|NCT01285882|OTHER|Representations|"1. A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~2. To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~   * 1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~  * 2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~3. Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
48510677|NCT04642404|DRUG|Epidiolex 100 mg/mL Oral Solution|Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
48510678|NCT04642404|DRUG|Placebo|Placebo drug will be a solution with the same taste, texture and color as the drug.
48149944|NCT04376788|BIOLOGICAL|exchange blood transfusion from normal donor|IV method
48149945|NCT04376788|BIOLOGICAL|plasma from convalescent patients with COVID-19|IV method
48510679|NCT02943135|DRUG|lidocaine in-situ gel|lidocaine in-situ gel
48149946|NCT04376788|DRUG|Methylene Blue 5 MG/ML|IV method
48149947|NCT00547885|DRUG|Dihydrocodeine|"Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting"
48149948|NCT00047684|BEHAVIORAL|Brief Integrative Therapy|
48149949|NCT01427816|DRUG|KCT-0809|
48149950|NCT01427816|DRUG|KCT-0809|
48149951|NCT01427816|DRUG|Placebo|
48149952|NCT04929444|OTHER|Training on vertigo|"Online training on vertigo management in primary care with a face-to-face session.~On the one hand, the course will contain theoretical content and clinical cases will be used as the methodology of the course, with feedback paths for each correct or incorrect answer from the students and videos recorded expressly for the course. In addition, there will be a face-to-face session where all participants must perform the diagnostic and therapeutic maneuvers proposed in the course, to evaluate the use of the training and also to standardize the way of doing them for the study"
48149953|NCT05825105|BIOLOGICAL|Platelet-Rich Plasma|The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
48149954|NCT00818519|DRUG|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
48149955|NCT00818519|DRUG|Placebo|Inert tablet
48149956|NCT03771261|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
48149957|NCT03771261|DIETARY_SUPPLEMENT|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
48149958|NCT03397147|BEHAVIORAL|Sleep Coach Jr.|A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
48149959|NCT06503991|BEHAVIORAL|Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP)|Clinic-based hypertension educational intervention delivered by a Community Health Worker.
48149960|NCT06503991|BEHAVIORAL|Control of Blood Pressure and Risk Attenuation (COBRA)|Multi-component counseling program addressing patient education, provider training, coordination of care, and subsidizing care costs.
48149961|NCT02122042|BIOLOGICAL|HBOT|
48149962|NCT03343041|DIETARY_SUPPLEMENT|low-carbohydrate nutrition|low-carbohydrate enteral nutrition
48510680|NCT02943135|DRUG|placebo in-situ gel|placebo in-situ gel
48510681|NCT02051062|BIOLOGICAL|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
48510682|NCT03474458|DRUG|Doxycycline|Doxycycline
48510683|NCT03474458|DRUG|Standard of care therapy|Standard of care therapy
48510684|NCT00238355|DRUG|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
48510685|NCT00238355|DRUG|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
48510686|NCT03249831|DRUG|Cyclophosphamide|Orally daily
48510687|NCT03249831|DRUG|Pentostatin|Intravenous
48510688|NCT03249831|DRUG|Rabbit anti-thymocyte globulin|Intravenous
48675669|NCT05321459|OTHER|Neurological prognosis|"In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool."
48675670|NCT02921295|DEVICE|Sidekick Stubbies|
48675671|NCT01823380|PROCEDURE|Blood test|Blood test
48675672|NCT06121648|OTHER|hydrotherapy|30 degrees temperature pool balance and breathing therapy
48675673|NCT06121648|OTHER|neurological physiotherapy|Balance and neurological physiotherapy on land
48675674|NCT04403308|BIOLOGICAL|ONO-7913|ONO-7913 will be administered by intravenous continuous infusion during the designated time.
48675675|NCT05575544|PROCEDURE|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
48675676|NCT04361500|DEVICE|Seraph 100|Seraph 100 therapy during a COVID-19 infection
48362258|NCT01049789|BEHAVIORAL|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
48362259|NCT01008228|PROCEDURE|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
48362260|NCT01008228|PROCEDURE|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
48510689|NCT03249831|DRUG|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
48675677|NCT00123825|DRUG|Gemcitabine|
48675678|NCT00123825|DRUG|Cisplatin|
48675679|NCT05497661|OTHER|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
48675680|NCT05497661|OTHER|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
48675681|NCT03975153|BIOLOGICAL|guselkumab|Treatment at the FDA-approved psoriasis dosing for 20 weeks
48675682|NCT00989976|BEHAVIORAL|normal sleep times|8.5 h bedtimes
48675683|NCT00989976|BEHAVIORAL|bedtime restriction|4.5 h restricted bedtimes
48675684|NCT04535089|DRUG|Dexmedetomidine injection|receive IV bolus dose of 0.5 ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5 ug/kg/h
48675685|NCT04535089|DRUG|Lidocaine Iv|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
48675686|NCT04068454|DEVICE|Virtual reality device|Functional exercises will be done by virtual reality group
48675687|NCT04068454|OTHER|EBM rehabilitation exercises|scapular exercises will be done
47991720|NCT03350854|BEHAVIORAL|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
48149963|NCT03343041|DIETARY_SUPPLEMENT|Standard enteral nutrition|standard enteral nutrition
48149964|NCT04619823|OTHER|Blood sample collection|Blood sample collection Mosquito collection at home
48149965|NCT01389791|DRUG|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
48149966|NCT01389791|DRUG|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
48149967|NCT01389791|DRUG|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
48149968|NCT06360120|DRUG|Atorvastatin 40 Mg Oral Tablet|The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
48149969|NCT06360120|DRUG|Rosuvastatin 20mg|The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
48149970|NCT02947880|DRUG|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
48510690|NCT03249831|DRUG|Mycophenolate mofetil|IV or oral
48510691|NCT03249831|BIOLOGICAL|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
48149971|NCT02947880|DRUG|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
48510692|NCT06338462|DEVICE|Chatbot|The chatbot is a WhatsApp-based, artificial-intelligence powered customer service agent adapted for TB outreach. The objective of the Chatbot is to facilitate information gathering, education, and support throughout TB contact evaluation, ensuring accessible assistance on-demand during and after contact tracing procedures. It operates in a secure data environment that includes end-to-end encryption and has been reviewed and approved by the data protection team within the information technology unit at the Cali Secretariat of Public Health (SoPH) for the study purposes.
48510693|NCT06338462|DIAGNOSTIC_TEST|Oral testing|Oral testing involves collection of a saliva sample or use of a nylon swab to collect material from the tongue and oral mucosa that is then tested with a molecular test for Mycobacterium tuberculosis
48510694|NCT02630979|BEHAVIORAL|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
48510695|NCT00261781|BEHAVIORAL|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
48510696|NCT06148584|BEHAVIORAL|General, status-neutral HIV education|General, status-neutral HIV education
48510697|NCT06148584|DIAGNOSTIC_TEST|HIV self-test kits|HIV self-test kits
48510698|NCT06148584|OTHER|Information about where to receive HIV prevention services|Information about where to receive HIV prevention services
48510699|NCT06148584|BEHAVIORAL|Barber-led peer support group education|Barber-led peer support group education
48675688|NCT05856955|BEHAVIORAL|mHealth Coaching Intervention|The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.
48675689|NCT05856955|BEHAVIORAL|Enhanced Usual Care|Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
48149972|NCT03469089|DRUG|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
48149973|NCT03469089|DRUG|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
48149974|NCT03469089|DRUG|Modafinil|Modafinil tablet 100 mg placed in a capsule
48149975|NCT03469089|DRUG|Placebo for ketamine|0.9 % NaCl infusion solution
48149976|NCT03469089|DRUG|Placebo for modafinil|Placebo capsule for modafinil capsule
48149977|NCT02836184|DRUG|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
48362261|NCT04701801|DIAGNOSTIC_TEST|MoCA test|Preoperative MoCA test and State-Trait Anxiety Inventory Test (STAI FORM ) questionnaire form will be filled in female patients between the ages of 18-65 by making a one-on-one interview with the patient and the MoCA test will be applied in the early postoperative period (1st week) to ensure its relationship with POCD will be checked.
48362262|NCT01287507|DIETARY_SUPPLEMENT|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
48510700|NCT06148584|BEHAVIORAL|Facility-based HIV risk reduction counseling|Facility-based HIV risk reduction counseling
48510701|NCT06148584|DIAGNOSTIC_TEST|Facility-based HIV testing|Facility-based HIV testing
48510702|NCT06148584|OTHER|Information about facility distributed HIV self-test kits|Information about facility distributed HIV self-test kits
48510703|NCT06148584|DIAGNOSTIC_TEST|STI testing|STI testing
48510704|NCT05461196|BEHAVIORAL|CPMRx|Patients use a mobile application to track pain medication usage and pain scores.
48149978|NCT02836184|DRUG|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
48149979|NCT03153423|PROCEDURE|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
48149980|NCT05187520|DEVICE|Patient-controlled epidural analgesia (PCEA)|Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
48149981|NCT05187520|DRUG|Naldebain®|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
48149982|NCT02759406|DEVICE|coronary stent|
48510705|NCT06128070|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48510706|NCT06128070|PROCEDURE|Chest Computed Tomography|Undergo chest CT
48510707|NCT06128070|PROCEDURE|Echocardiography|Undergo ECHO
48510708|NCT06128070|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
48510709|NCT06128070|DRUG|Methotrexate|Given IV
48510710|NCT06128070|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48675690|NCT05404971|OTHER|Joint integrity exercises|patients with three strokes followed by 3 sec rest period. Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set.
48149983|NCT06470685|BEHAVIORAL|Qualitative Research Interviews|Research Interviews
48149984|NCT05223725|BIOLOGICAL|AdKCNH2-G628S|adenovirus containing the transgene KCNH2-G628S
48149985|NCT03717233|DEVICE|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
48149986|NCT04114279|PROCEDURE|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
48149987|NCT02617459|DRUG|Levobetaxolol eye drops|one drop per time; twice daily
48149988|NCT02617459|DRUG|Betaxolol eye drops|one drop per time; twice daily
48149989|NCT01778803|DRUG|defactinib|
48510711|NCT06128070|DRUG|Ruxolitinib Phosphate|Given PO
48510712|NCT06128070|DRUG|Tacrolimus|Given IV
48510713|NCT04862910|OTHER|Kinect Based Virtual Reality Training|The participant will receive the game instructions from the examiner.Protocol will be implemented 3 steps Warm Up phase Activity phase and cool down phase. The games will be played under the supervision and guidance of the therapist.Games are selected from Kinect games Kinect Sports Kinect Adventures and Your Shape Fitness Evolved. Three treatment sessions per week will be given to each participant. Total duration of each treatment session will be 45 Minutes.Participants will be instructed to walk outdoors for 30 Minutes daily. Routine Medication and routine diet will be continued.
48510714|NCT04862910|OTHER|Control Group|"* They will be instructed to walk outdoors daily for 30 Minutes.~* They will continue their daily activities with a routine diet and routine Medication"
48510715|NCT05721976|BEHAVIORAL|"With Love, Grandma (Con Cariño, Abuelita)"|"Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
48510716|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
48510717|NCT01313585|DRUG|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
48510718|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
48149990|NCT01778803|DRUG|Paclitaxel|
48149991|NCT02474004|PROCEDURE|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
48149992|NCT02153697|DEVICE|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
48149993|NCT02153697|DRUG|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
48362263|NCT00104299|DRUG|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m\^2 infusions once weekly for 4 week
48362264|NCT00104299|DRUG|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
48362265|NCT00104299|DRUG|Azathioprine|2 mg/kg/day orally for months 4-6
48362266|NCT00104299|DRUG|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
48362267|NCT00104299|DRUG|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
48510719|NCT01313585|DRUG|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
48510720|NCT00855907|OTHER|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
48510721|NCT06550466|OTHER|Breakfast only|Participants will attend a breakfast-only arm without the exercise protocol.
48149994|NCT04054856|DEVICE|Body Sensor Network|"The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person."
48149995|NCT00233142|BEHAVIORAL|Expressive writing|Writing as therapeutic intervention
48675691|NCT05404971|OTHER|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
48675692|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Eurofarma)|
48675693|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Zodic)|
48149996|NCT00233142|BEHAVIORAL|Neutral writing|Non-expressive writing
48675694|NCT03594110|DRUG|Empagliflozin|Taken daily with or without food
48675695|NCT03594110|DRUG|Matching placebo|Taken daily with or without food
48675696|NCT02171026|DRUG|Dabigatran etexilate|
48149997|NCT05603442|PROCEDURE|Thoracic intervertebral foramen block|The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
48149998|NCT03529006|PROCEDURE|Sequent Please inflation|PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
48149999|NCT03529006|PROCEDURE|Absorb BVS implantation|PCI procedure for treatment of ISR with Absorb BVS implantation
48150000|NCT06593275|PROCEDURE|Protection of the palatal donor area with flowable resin|Use of fluid resin for protection of the palatal donor area to assess postoperative pain generated during14 days
48150001|NCT06593275|PROCEDURE|Protection of the palatal donor area with a self-adhesive dressing|Use of a self-adhesive dressing for protection of the palatal donor area to evaluate postoperative pain generated for 14 days
48675697|NCT02171026|DRUG|Amiodarone|
48675698|NCT01382771|DRUG|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
48362268|NCT00211692|DRUG|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
48362269|NCT00211692|DRUG|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
48362270|NCT05458674|DRUG|Tucatinib|taken orally
48362271|NCT05458674|DRUG|Eribulin|taknen intravenously
48362272|NCT05458674|DRUG|Trastuzumab|taken intravenously
48510722|NCT06550466|OTHER|FAST|Participants will be exercised for 90 minutes following a 12-hour overnight fast
48510723|NCT06550466|OTHER|FED|Participants will be exercised 90 minutes after a breakfast
48510724|NCT05056623|BEHAVIORAL|Dyadic pain management program|"Face-to-face part: The DPM will start with 20-30 minutes of physical exercise supervised by research assistant, followed by 20-minutes of pain management education. Communication skills regarding the practice of various pain management techniques by the participants and their caregivers will be taught. At the end of the session, the caregiver and research assistant will help the older adults to make portfolio entries on the activities of the day, to help them recall the various pain-relief methods learned in each class.~Home-based part: An exercise book will be given to guide them in performing exercises at home. It is recommended to perform 30 minutes of exercise, 3 times a week, at home and the more frequent the exercise time, the better.~All participants will join a WhatsApp group to receive teaching materials and videos of the physical exercises learned, for practice at home. The team will produce compact disc (CD) with the exercise video clips to the dyads for revision."
48510725|NCT05056623|OTHER|Usual care and pain management pamphlet|Usual care and pain management pamphlet
48675699|NCT01382771|DRUG|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
48675700|NCT00004227|BIOLOGICAL|cetuximab|
48675701|NCT00004227|PROCEDURE|conventional surgery|
48675702|NCT00004227|RADIATION|radiation therapy|
48675703|NCT01768949|DEVICE|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
48675704|NCT01111643|DEVICE|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
48675705|NCT01541865|DEVICE|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
48675706|NCT04315558|DRUG|Revefenacin Inhalation Solution [Yupelri]|nebulized drug comparison
48675707|NCT04315558|DRUG|Ipratropium Bromide|nebulized drug comparison
48675708|NCT01639469|BEHAVIORAL|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
48675709|NCT01639469|BEHAVIORAL|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
48675710|NCT00444925|DRUG|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
48150002|NCT01164319|PROCEDURE|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
48150003|NCT03529435|BEHAVIORAL|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
48150004|NCT03529435|BEHAVIORAL|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
48150005|NCT06421376|DRUG|Cardonilizumab|Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
48150006|NCT06421376|RADIATION|Chemoradiotherapy ±immunotherapy|"Chemoradiotherapy ± immunotherapy：~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles"
48510726|NCT06633978|DEVICE|MediTrain|Participants will engage with a digital meditation app for 30m/day for 6wks. MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
48675711|NCT00444925|DRUG|placebo|once daily (OD)for 12 weeks
48675712|NCT00444925|DRUG|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
48675713|NCT06443892|PROCEDURE|Pericapsular Nerve Block (PENG)|Evaluation of postoperative analgesic efficacy of PENG block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
48675714|NCT06443892|PROCEDURE|Suprainguinal Fascia Iliaca Compartment Block (SFICB)|Evaluation of postoperative analgesic efficacy of SFICB block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
48675715|NCT02960425|DIETARY_SUPPLEMENT|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
48675716|NCT02960425|DIETARY_SUPPLEMENT|Placebo|Topical placebo
48675717|NCT02356536|DEVICE|Agilitas|WCD trial
48675718|NCT01518790|DRUG|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
48675719|NCT05518006|DIETARY_SUPPLEMENT|PreMama Balance|Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
48675720|NCT05518006|DIETARY_SUPPLEMENT|Placebo Drink|Blended Placebo drink
48675721|NCT00202696|DRUG|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
48675722|NCT00202696|OTHER|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
48675723|NCT02049411|DRUG|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
48150007|NCT06421376|PROCEDURE|Radical surgery|Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
48150008|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in plasma|
48675724|NCT02049411|DRUG|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
48675725|NCT00041340|DRUG|imatinib mesylate|Given orally
48675726|NCT00041340|OTHER|laboratory biomarker analysis|Correlative studies
48675727|NCT00183014|BEHAVIORAL|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
48675728|NCT00183014|BEHAVIORAL|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
48510727|NCT06633978|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
48150009|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in human albumin|
48150010|NCT02578004|OTHER|biochemical and molecular analysis|
48150011|NCT05398484|DRUG|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
48362273|NCT01231620|DRUG|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
48362274|NCT01231620|DRUG|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
48362275|NCT01231620|DRUG|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
48362276|NCT01231620|DRUG|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
48510728|NCT06633978|DEVICE|Sleep monitor|Sleep Profiler devices are FDA-cleared reduced-montage EEG recording devices that will be used in accordance with its FDA clearance. They are completely non-invasive and are designed to be comfortable enough to wear all night without interfering with normal sleep. These devices enable quality sleep recordings in the comfort of people's homes, rather than required an overnight stay at a sleep lab at UCSF.
48510729|NCT06633835|BIOLOGICAL|protein subunit: Novavax COVID-19 vaccine|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
48510730|NCT06633835|BIOLOGICAL|Pfizer mRNA COVID-19 vaccine|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
48362277|NCT02461342|OTHER|not intervention|This is a cross-sectional study, no intervention was performed.
48362278|NCT00117520|DRUG|Caffeine|
48510731|NCT06538415|OTHER|Pulse Diet|Participants will consume cooked pulse (112 calories -lentils, red kidney beans, black beans, and pinto beans) during 14 weeks.
48362279|NCT01903096|BEHAVIORAL|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
48362280|NCT01903096|DRUG|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
48150012|NCT05398484|DRUG|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
48150013|NCT05398484|BEHAVIORAL|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
48362281|NCT01143818|DRUG|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
48362282|NCT01388114|DEVICE|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
48362283|NCT04205513|DEVICE|Medly|Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
48362284|NCT02532998|DRUG|AZD9977 oral suspension|AZD9977 oral suspension, single dose
48362285|NCT02532998|DRUG|AZD9977 placebo oral suspension|oral suspension, single dose
48362286|NCT02532998|DRUG|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
48510732|NCT06538415|OTHER|Control Rice Diet|Participants will consume cooked rice (112 calories) during 14 weeks.
48362287|NCT02532998|DRUG|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
48362288|NCT05237713|DRUG|Canakinumab Injection|Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
48150014|NCT06017557|DIAGNOSTIC_TEST|Artificial Intelligence|With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.
48150015|NCT00223769|DRUG|Oxandrolone|
48362289|NCT03187626|DRUG|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
48362290|NCT03187626|DRUG|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
48362291|NCT04778995|OTHER|Structured online training program for effective management of nursing services|"An online structured training program was prepared to reach out to manager nurses for increasing their knowledge regarding the effective management of nursing services in crisis periods. A web page was structured with the support of a professional computer engineer.~Participant manager nurses could log into the system via a personal username and password on the main login screen of the site. In this page, there is an Informed Consent Form.~In the Download Training Documents link; the educational content prepared in sections was presented. Educational content consisted of the issues such as: Management of Crises and Emergency Situations, Leadership in Crisis, Planning and Managing Nurse Human Power in Crisis, Supervision and Management of Patient Care, Logistics and Support Services, Communication in Extraordinary Situations, Motivation Tools Used in Extraordinary Situations, Stress Management During Crisis and Employee Adaptation and Training in Crisis."
48675729|NCT06432686|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is a safe, relatively cheap, and non-painful stimulation of the peripheral sensory and motor nerves. The stimulator is easy to operate and pwMS can apply the stimulation themselves at home. This makes TENS an interesting tool to augment sensory input. A high frequency and long pulse duration is used.
48362292|NCT02363322|DRUG|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
48362293|NCT02363322|OTHER|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
48362294|NCT02117024|DRUG|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
48362295|NCT02117024|DRUG|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
48510735|NCT03068039|OTHER|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
48510736|NCT03068039|OTHER|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
48510737|NCT05576246|DIAGNOSTIC_TEST|airway pressure occlusion measurement|Flow, airway pressure (Paw), and esophageal pressure (Pes) will be recorded for 10 minutes on different NIV settings: during each one, three end-expiratory airway occlusions will be applied at random intervals. Each occlusion was maintained for the duration of a single breath deflection in Paw from PEEP, confirmed by the return of Paw to baseline.
48675730|NCT06432686|BEHAVIORAL|Movement|Participants are instructed to perform plantar- and dorsi-flexion contraction in a relatively slow tempo. The movement of the ankle is measured by an MRI-compatible potentiometer and participants receive feedback of this movement on the screen inside the scanner.
48150016|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
48510738|NCT00810511|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel contact lens
48510739|NCT00810511|DEVICE|Comfilcon A contact lens|Silicone hydrogel contact lens
48510740|NCT05503576|DEVICE|reminder mobile application|After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
48675731|NCT01723969|GENETIC|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
48675732|NCT01526941|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
48150017|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
48150018|NCT01765023|DRUG|Period I : atorvastatin, Period II : atorvastatin and metformin|
48150019|NCT01765023|DRUG|Period I : metformin, Period II : atorvastatin and metformin|
48675733|NCT01526941|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
48675734|NCT03584815|PROCEDURE|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
48675735|NCT03584815|OTHER|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
48675736|NCT03644719|BEHAVIORAL|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
48675737|NCT05637177|BEHAVIORAL|Anging Wisely|The program includes 11 meetings of two hours in a group of up to eight people. The sessions are held weekly. Each lesson is given a homework assignment. A total of 10 groups will take place.
48675738|NCT05637177|BEHAVIORAL|Music therapy|Music therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 12. A total of 10 groups will be implemented.
48675739|NCT05637177|BEHAVIORAL|Reminiscence therapy|Reminiscence therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 10. A total of 5 groups will be implemented.
48675740|NCT05637177|BEHAVIORAL|Cognitive training|"Intervention cognitive training will take place once a week for 45 minutes for 20 weeks. Seniors can choose from two options: 1. group training full-time or home training (online) using the comprehensive training program MENTEM."
48675741|NCT05637177|BEHAVIORAL|Educational activities|Interventions in educational activities will run for one academic year. In total, seniors will attend 16 lectures in each educational module. The lectures will run 1 x 14 days for 90 minutes.
48675742|NCT06110559|DEVICE|Active transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received 1.5 mA stimulation for 30 minutes."
48675743|NCT06110559|DEVICE|Sham transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation."
48675744|NCT00287950|DRUG|carboplatin|
48675745|NCT00287950|DRUG|cisplatin|
48675746|NCT00287950|DRUG|cyclophosphamide|
48675747|NCT00287950|DRUG|etoposide|
48675748|NCT00287950|DRUG|vincristine sulfate|
48675749|NCT00287950|PROCEDURE|adjuvant therapy|
48675750|NCT00287950|PROCEDURE|conventional surgery|
48150020|NCT01406899|BEHAVIORAL|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
48150021|NCT05851521|DEVICE|Temporary prostatic stent (Exime®)|Placement of temporary prostatic stent (Exime®) following the procedure described in the product information
48675751|NCT00287950|PROCEDURE|neoadjuvant therapy|
48675752|NCT00287950|RADIATION|radiation therapy|
48675753|NCT02745496|PROCEDURE|TRUS Biopsy|Standard of Care Treatment
48675754|NCT02745496|PROCEDURE|TRUS/FUSION Biopsy|Interventional Treatment
48675755|NCT04210492|RADIATION|45 Gray (Gy) regimen|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
48675756|NCT06395701|RADIATION|radioteraphy and chemotherapy after RTU --trimodality therapy--|TMT ( trimodality treatment) consists of complete and maximal TURBT of the bladder tumor, followed by definitive radiotherapy combined with a radiosensitizing agent.
48675757|NCT05689879|DRUG|STOP arm|TNF-alpha antagonists withdrawal
48675758|NCT02951637|DRUG|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
48675759|NCT02951637|DRUG|Gefitinib|Gefitinib (250mg daily)
48675760|NCT05356273|PROCEDURE|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
48150022|NCT05851521|DEVICE|Indwelling catheter|Placement of indwelling catheter
48150023|NCT05107232|OTHER|MRI|MRI
48675761|NCT03553537|DRUG|Decitabine|10mg/m² iv on day 1-5
48675762|NCT03553537|DRUG|Cyclophosphamide|750mg/m² iv on day 6
48675763|NCT03553537|DRUG|Doxorubicin|DOX
48675764|NCT03553537|DRUG|Vincristine|1.4mg/m² iv on day 6
48675765|NCT03553537|DRUG|Prednisone|100mg/m² po on day6-10
48510741|NCT04663191|PROCEDURE|anatomical resection|Anatomical resection with systematic lymph-node dissection
48150024|NCT00704548|DRUG|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
48510742|NCT06398275|DRUG|Remimazolam 20 MG Injection [Byfavo]|Remimazolam 0.1 mg/kg intravenous injection
48510743|NCT06398275|DRUG|NaCl 0.9%|NaCl 0.9% 0.04 mL/kg
48150025|NCT00704548|DRUG|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
48362296|NCT02117024|DRUG|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed"
48362297|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 5µg|
48362298|NCT04421105|DRUG|Lysergic acid diethylamide (LSD) 10µg|
48362299|NCT04421105|DRUG|Lysergic acid diethylamide (LSD)20 µg|
48362300|NCT04421105|DRUG|Placebo|
48362301|NCT00537251|DRUG|Insulin glargine|
48362302|NCT03556644|RADIATION|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
48362303|NCT04036006|BEHAVIORAL|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
48362304|NCT04036006|BEHAVIORAL|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
48510744|NCT02592317|DRUG|JNJ 56021927|JNJ 56021927 will be administered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
48510745|NCT02592317|DRUG|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
48510746|NCT02592317|DRUG|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
48510747|NCT02592317|DRUG|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
48510748|NCT04275986|PROCEDURE|Intensity modulated radiotherapy (IMRT)|Intensity-modulated radiation therapy (IMRT) with a total dose of 45Gy in 25 fractions
48510749|NCT04275986|DRUG|Chemotherapy|Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
48510750|NCT01577940|PROCEDURE|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
48150026|NCT00211042|OTHER|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
48150027|NCT02642640|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
48150028|NCT02642640|DRUG|placebo|
48150029|NCT02294994|DRUG|tirofiban|
48150030|NCT03067870|BIOLOGICAL|Stem Cell Transplantation|"* Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~* Transplantation of autologous bone marrow derived stem cells in joints."
48150031|NCT03733574|DRUG|LY03005|Drug: LY03005 80 mg, oral tablets, single dose
48150032|NCT03733574|DRUG|Pristiq|Drug: Pristiq 50 mg, oral tablets, single dose
48510751|NCT01577940|PROCEDURE|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
48510752|NCT02186288|OTHER|High-flow nasal cannula oxygen|
48510753|NCT06198166|OTHER|Cuevas Medek|Group A: will receive Cuevas Medek (CME) In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. The materials that will be used consists of three wooden boxes with the same dimensions (20cm x 40cm x 60cm), a bigger box, a wooden plate and two planks with the same dimensions (17cm x 80cm). Boxes
48675766|NCT04454060|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
48675767|NCT04902209|PROCEDURE|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
48675768|NCT00003365|DIETARY_SUPPLEMENT|curcumin|
48675769|NCT00003365|DIETARY_SUPPLEMENT|rutin|
48675770|NCT00003365|DRUG|quercetin|
48675771|NCT00003365|DRUG|sulindac|
48675772|NCT05359939|DIAGNOSTIC_TEST|18F-FDGal PET/CT versus 18F-choline PET/CT|Fifty patients with known HCC are investigated with two PET/CT-scans with 18F-FDGal and 18F-choline. In some of the cases one of the CT-scans will be altered to a contrast-enhanced MRI scan. A contrast-enhanced CT scan will be performed as part of the standard diagnostic work-up. We include patients with known HCC as the aim is to compare the diagnostic performance of the two tracers. Images will be analyzed for focal lesions and compared to other modalities by an experienced specialist in PET and an experienced radiologist.
48362305|NCT02907866|DEVICE|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
48675773|NCT00934583|BEHAVIORAL|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
48675774|NCT03795649|DRUG|Tranexamic Acid|Imunomodulatory effect
48675775|NCT05680493|PROCEDURE|Manual pressure release|lengthens the muscle up to the increasing resistance, then gradually applies gentle pressure on MTrp until fingers feels a definite increase in tissue resistance (first barrier). Pressure would maintain until clinician sense relief of tension
48675776|NCT05680493|PROCEDURE|Dry needling|A filiform needle is inserted at 45 degree in to trigger point and then twirl the needle up and down to release trigger point
48675777|NCT05680493|PROCEDURE|Heat therapy|Hydro collator pack will be placed on affected area for relaxation and pain relief for 15 min
48675778|NCT03224364|PROCEDURE|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
48675779|NCT03224364|PROCEDURE|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
48675780|NCT04406103|BEHAVIORAL|Sleepwell|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
48675781|NCT04406103|BEHAVIORAL|Empower|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
48675782|NCT04523584|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo MR imaging of the liver. Liver PDFF will be measured.
48675783|NCT04523584|DEVICE|Ultrasound Imaging|Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
48675784|NCT04312477|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
48675785|NCT00517699|DRUG|rituximab [MabThera/Rituxan]|750mg/m2 iv
48675786|NCT00517699|DRUG|Methotrexate|8g/m2 iv
48362306|NCT00299091|DRUG|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
48362307|NCT03263767|DRUG|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
48362308|NCT03263767|DRUG|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
48675787|NCT00517699|DRUG|Cytarabine|2g/m2 iv
48675788|NCT05141838|DRUG|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
48675789|NCT05141838|DIETARY_SUPPLEMENT|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
48675790|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
48362309|NCT03263767|RADIATION|Full body irradiation|2 grays at Day-1
48362310|NCT03263767|DRUG|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
48362311|NCT03263767|DRUG|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
48362312|NCT03263767|OTHER|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
48362313|NCT03263767|OTHER|nuclear cells|CD3+ cells if needed after transplantation
48362314|NCT03263767|DRUG|Thymoglobulin Injectable Product|At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
48675791|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
48675792|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
48675793|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
48675794|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
48675795|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
48675796|NCT01406132|DRUG|ASP015K|oral
48675797|NCT00524121|DRUG|erlotinib hydrochloride|Oral
48675798|NCT00524121|OTHER|immunohistochemistry staining method|Correlative Study
48675799|NCT00524121|RADIATION|radiation therapy|Radiation Treatment
48675800|NCT05850143|DRUG|Dexamethasone|Oral Dexamethasone a longer and potent corticosteroid with lesser sideffects and good compliance
48675801|NCT05850143|DRUG|Prednisolone|Oral Multidose Prednisolone
48150033|NCT02443532|BEHAVIORAL|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
48150034|NCT02443532|BEHAVIORAL|Individual education|Usual care (individual consultations as routinely performed)
48675802|NCT05630781|DRUG|Belsomra|randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional \~7 days and then scanned a final time.
48675803|NCT05630781|DRUG|Placebo|comparator taken for \~10 days
48362315|NCT03005691|RADIATION|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
48362316|NCT03005691|OTHER|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
48675804|NCT05630781|DRUG|Methylphenidate|Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
48362317|NCT03005691|PROCEDURE|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
48362318|NCT02816255|DEVICE|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
48362319|NCT02816255|DEVICE|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
48362320|NCT00805194|DRUG|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
48362321|NCT00805194|DRUG|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
48675805|NCT03197610|PROCEDURE|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
48675806|NCT00142792|DEVICE|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
48675807|NCT06131905|DRUG|Magnesium Sulfate|40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
48150035|NCT02416102|DRUG|Losartan 50 mg|50 mg Losartan taken orally once daily for 4 consecutive weeks.
48150036|NCT02416102|DRUG|Losartan 100 mg|50 mg Losartan taken orally twice daily for 4 consecutive weeks.
48150037|NCT05128799|OTHER|3 Wishes Program (3WP)|"The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds."
48362322|NCT04418752|OTHER|Psychological therapy|"The National Institute for Health and Care Excellence (2018) specifies NET as a psychological intervention for the treatment of PTSD or prominent symptoms of PTSD in adults. NET is a short-term treatment which incorporates elements of CBT exposure therapy and testimonial therapy. In exposure therapy, clients are encouraged to repeatedly discuss traumatic experiences in detail, including emotions and sensory experiences (Schauer, Elbert, \& Neuner, 2011).Testimonial therapy involves the construction of a detailed and coherent report of the survivor's biography including an explicit description of the traumatic events (Neuner, Schauer, Roth \& Elbert, 2002, pp.5-6). Therefore, NET aims to embed the traumatic experience within the context of the person's life and the mechanisms of change are theorised to be exposure and habituation to the traumatic experience and the reconstruction of autobiographical memory."
48362323|NCT04035356|DEVICE|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
48150038|NCT01906073|DRUG|intranasal fentanyl spray|
48150039|NCT01906073|DRUG|slow release morphine|
48675808|NCT06131905|DRUG|Propofol|An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
48675809|NCT01552837|DRUG|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
48675810|NCT03902795|DIAGNOSTIC_TEST|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
48675811|NCT03902795|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
48675812|NCT01206829|BEHAVIORAL|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
48675813|NCT01206829|BEHAVIORAL|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
48675814|NCT01471821|DRUG|antiretroviral treatment|antiretroviral treatment
48675815|NCT01490918|DRUG|Acarbose|Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.
48675816|NCT01490918|DRUG|Placebo acarbose|acarbose placebo
48675817|NCT01490918|DRUG|placebo metformin|metformin placebo
48675818|NCT00395109|DEVICE|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
48675819|NCT01152125|OTHER|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
48675820|NCT06465784|PROCEDURE|Retrograde and Antegrade Ureteroscopic Laser Lithotripsy|Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study
48675821|NCT00841061|DIETARY_SUPPLEMENT|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
48675822|NCT00841061|DIETARY_SUPPLEMENT|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
48675823|NCT01293136|PROCEDURE|Femoral nerve block|Ropivacaine
48675824|NCT01293136|DRUG|Intravenous opioids|Whatever opioids prescribed
48150040|NCT05452408|DRUG|Antitumor B KAC|ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.
48150041|NCT04733573|DEVICE|Two different occlusal splints|Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)
48675825|NCT05799391|DRUG|SJC|Soothing cream jel
48675826|NCT05799391|OTHER|Placebo|Placebo cream jel
48675827|NCT05173012|DRUG|SAGE-324|SAGE-324 oral tablets.
48675828|NCT05173012|DRUG|SAGE-324 Matched Placebo|SAGE-324 matched placebo oral tablets.
48675829|NCT00746525|OTHER|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
48150042|NCT02541292|OTHER|No intervention, observational|
48150043|NCT03627156|BEHAVIORAL|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
48675830|NCT00746525|OTHER|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
48675831|NCT00746525|OTHER|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
48675832|NCT01720030|DRUG|Levosimendan|Verum therapy
48675833|NCT01720030|DRUG|Conventional therapy|Placebo therapy to safeguard blinding
48675834|NCT05609357|DEVICE|Head-up Cardiopulmonary Resuscitation|Elevate patient's head to 30 degrees by EleGARD System during cardiopulmonary resuscitation
48675835|NCT00800982|PROCEDURE|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
48675836|NCT00800982|DRUG|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
48675837|NCT03443635|BEHAVIORAL|Treatment|The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
48675838|NCT01111162|BIOLOGICAL|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
48675839|NCT04778748|DIAGNOSTIC_TEST|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
48675840|NCT02184598|BEHAVIORAL|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
48675841|NCT02184598|BEHAVIORAL|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
48675842|NCT02439905|DRUG|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
48675843|NCT02439905|DRUG|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
48675844|NCT03918382|OTHER|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
48675845|NCT04904367|PROCEDURE|Deep tissue massage|The amount of pressure during the massage was adjusted by the physiotherapist with reference to muscle tissue palpation in the patients. During the massage, olecranon, pisiform bone protrusion, metacarpophalangeal and proximal interphalangeal joint faces forearm, wrist and fingers were used during the massage to reach deep tissue. As a massage technique, compression and stretching techniques are used in combination.
48150044|NCT06153589|OTHER|Musicotherapy|"Musicotherapy will be offered to patients who meet the eligibility criteria, and have been randomized to the experimental arm.~Patients will only be seen once during the study. Patients are placed in individual rooms. Hifi audio headphones (equipped with hygienic earcups) and a tablet equipped with the Music Care application will be offered to patients in the experimental group and the investigators will help them choose the style of music, which respects the U-shaped sequence.~The Music Care application has proven that the use of headphones allows the patient to be isolated and therefore to obtain less parasitic care. He will be told at the start of the session that he can ask to interrupt it if he wishes to communicate with the team, particularly regarding possible pain.~The musicotherapy session begins before the act of debridement (10 minutes before), lasts during the act (40 minutes maximum), and continues for 10 minutes after the end of the debridement."
48150045|NCT05148949|BIOLOGICAL|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
48150046|NCT05148949|BIOLOGICAL|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
48150047|NCT05183802|DRUG|Setmelanotide, administered subcutaneously [SC], once daily.|Dosing based on age, and titrated from starting dose to target dose.
48150048|NCT01809444|DRUG|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
48150049|NCT01809444|DRUG|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
48675846|NCT04904367|PROCEDURE|Conventional physiotherapy|For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
48675847|NCT02960633|DEVICE|Corail with collar.|
48675848|NCT02960633|DEVICE|Corail without collar.|
48150050|NCT06493448|OTHER|observation|This is an observational study.
48150051|NCT04187456|DRUG|Savolitinib|Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
48150052|NCT04187456|DRUG|Midazolam|Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.
48150053|NCT00087724|DRUG|FK962|
48675849|NCT02255539|DEVICE|Geelong Prototype Mask|A nasal pillows prototype mask to be trialled with a PAP therapy device for a period of 6 weeks. Participants will wear the mask in place of their current mask for the duration of the trial.
48675850|NCT01761513|DRUG|YH4808|"Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks"
48675851|NCT01761513|DRUG|YH4808|"Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks"
48150054|NCT00104442|DRUG|Rivastigmine|
48510754|NCT06198166|OTHER|Standard kinetic programs|Group B: will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
48675852|NCT01761513|DRUG|YH4808|"Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks"
48675853|NCT01761513|DRUG|YH4808|"Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks"
48675854|NCT03738722|DRUG|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
48675855|NCT02575144|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
48675856|NCT02575144|DRUG|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min
48675857|NCT02575144|DRUG|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
48675858|NCT01789242|DRUG|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
48675859|NCT01789242|DRUG|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
48150055|NCT06351800|BEHAVIORAL|Predictplusprevent intervention|The intervention is based on validated risk algorithms to predict depression and anxiety and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps participants to develop their own personalized plans to prevent (PPP) depression and/or anxiety; 3) eight intervention modules (the core of the system) including activities to prevent depression and anxiety, to be proposed and monitoring by the DSS. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6, 9 and 12 months.
48362324|NCT03343990|PROCEDURE|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
48362325|NCT03343990|PROCEDURE|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
48362326|NCT05850429|DIETARY_SUPPLEMENT|Seaweed protein|Novel protein extracted from seaweed
48150056|NCT06351800|OTHER|Psychoeducational intervention|To know the level of risk of experiencing depression and/or anxiety in the next 12 months. In addition, participants assigned to this intervention will have free access to the 24 self-help pamphlets for preventing depression and anxiety.
48150057|NCT02011789|DIETARY_SUPPLEMENT|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
48150058|NCT02011789|DIETARY_SUPPLEMENT|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
48150059|NCT03206398|DEVICE|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
48150060|NCT01189045|BEHAVIORAL|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
48150061|NCT01189045|BEHAVIORAL|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
48150062|NCT04527965|OTHER|Customized diet to reduce liver fat|"Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided"
48362327|NCT01679964|DRUG|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
48362328|NCT00497744|DRUG|Intraperitoneal Cefepime|
48510755|NCT06041789|DRUG|Donepezil|10 mg tablet
48675860|NCT00087698|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
48510756|NCT06041789|DRUG|Placebo|Donepezil placebo tablet
48510757|NCT02125721|DRUG|Tiopronin 1g per day|500mg PO BID x 7 days
48510758|NCT02125721|DRUG|Tiopronin 2g per day|1g PO BID x 7 days
48510759|NCT02125721|DRUG|Tiopronin 3g per day|1.5g PO BID x 7 days
48510760|NCT05284266|PROCEDURE|Liposuction early|Liposuction 6-9 months after inclusion
48510761|NCT05284266|PROCEDURE|Liposuction late|Liposuction 18-21 months after inclusion
48510762|NCT05284266|OTHER|Standard conservative treatment|"Standard Conservative treatment consisiting of:~Physical therapy, including compression garment and exercise program, Self-care program"
48675861|NCT00087698|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
48675862|NCT01514721|DRUG|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
48675863|NCT04803474|DIAGNOSTIC_TEST|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
48675864|NCT02132897|DRUG|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
48675865|NCT02132897|DRUG|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
48675866|NCT02043990|DEVICE|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
48150063|NCT04527965|OTHER|Healthy Nordic diet|"Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided"
48150064|NCT04527965|OTHER|Control|"Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided"
48150065|NCT04989023|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
48150066|NCT06022003|DRUG|AzaCITIDine Oral Tablet|AML study treatment
48150067|NCT06022003|DRUG|Xospata|R/R FLT3-mutated AML standard treatment
48150068|NCT00001998|DRUG|Nystatin|
48150069|NCT03191097|DRUG|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
48150070|NCT03191097|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
48675867|NCT02271529|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
48675868|NCT00776529|OTHER|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
48675869|NCT00776529|OTHER|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
48675870|NCT06569121|BEHAVIORAL|Group Lifestyle Balance for People Post Stroke (GLB-CVA)|12-month healthy lifestyle and weight loss program modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB)
48675871|NCT00544856|BEHAVIORAL|complex cognitive training|
48675872|NCT04904107|DIAGNOSTIC_TEST|modified HEART score (including POC hs cTnI analysis)|"The modified HEART score was developed in 2007 and has been validated to stratify the risk of short-term adverse cardiac events in patients with chest pain at the ED. Negative predictive value (NPV) of the modified HEART score for ACS as well as positive predictive value (PPV) for major adverse cardiac events (MACE) within 6 weeks after presentation is high.~The modified HEART score is an acronym for history, ECG, age, risk factors and troponin at arrival.The components can be rated 0,1 or 2 points each and result in a total score between 0 and 10."
48675873|NCT04904107|OTHER|Standard care and triage according to the local (EMT)protocol.|Standard care and triage of chest pain patients according to the local (EMT)protocol.
48150071|NCT05568277|BEHAVIORAL|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
48150072|NCT03436563|BIOLOGICAL|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
48150073|NCT03403153|BEHAVIORAL|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
48150074|NCT02663297|DRUG|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)"
48150075|NCT05973864|DRUG|Pembrolizumab injection|On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
48150076|NCT05973864|DRUG|Capecitabine tablets|1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
48150077|NCT05973864|RADIATION|Local radiotherapy|Local radiotherapy will be performed as per standard practice if indicated.
48150078|NCT04634994|DRUG|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
48675874|NCT05394610|DEVICE|Sana Device|Audio Visual Stimulation patterns intended to produce a therapeutic benefit.
48150079|NCT02474745|PROCEDURE|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
48362329|NCT04984252|BEHAVIORAL|Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice|This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
48362330|NCT04984252|BEHAVIORAL|Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.|This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
48362331|NCT04984252|BEHAVIORAL|Distraction group|Participants will be asked to listen recording on irrelevant topic.
48675875|NCT05394610|DRUG|Sana Device (Control)|A control device that mimics the physcial appearance of the Sana device.
48675876|NCT00140023|DRUG|Azithromycin microspheres 2.0 single dose|
48675877|NCT01334554|DRUG|Sildenafil|20 mg three times a day.
48675878|NCT01334554|DRUG|Placebo|No active drug
48362332|NCT05043194|DRUG|Ursodeoxycholic Acid 250 Mg Oral Capsule|prevention
48675879|NCT03089047|BIOLOGICAL|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
48675880|NCT03089047|BIOLOGICAL|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
48675881|NCT04685213|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
48675882|NCT04685213|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
48675883|NCT03440866|DRUG|Administration of drugs concomitantly.|Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
48675884|NCT04934267|OTHER|Eccentric Exercise for subjects with JHS|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
48675885|NCT04934267|OTHER|Eccentric Exercise for Controls|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
48675886|NCT02146131|DEVICE|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
48675887|NCT02146131|DEVICE|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
48675888|NCT03273907|DEVICE|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
48675889|NCT03273907|PROCEDURE|Cataract surgery|Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
48675890|NCT01482130|BEHAVIORAL|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
48675891|NCT01482130|BEHAVIORAL|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~* Weight bearing activities (walking, jogging or strength training)~* 30 - 60 minutes, 3 - 5 times each week~* A total of 2 - 3 hours each week should be achieved"
48675892|NCT04589897|DEVICE|Manuka honey sinus rinse|Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
48675893|NCT04589897|DEVICE|Standard sinus rinse|will follow the standard NHS nasal rinse protocol
48675894|NCT00443118|DEVICE|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
48362333|NCT00411229|DRUG|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
48362334|NCT00411229|DRUG|Oxaliplatin|IV infusion, 130mg/m²
48362335|NCT02114099|DRUG|Atorvastatin|10 mg qd x1 year
48362336|NCT00958230|DEVICE|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
48362337|NCT00124384|BEHAVIORAL|CBT-I|
48362338|NCT00124384|DRUG|modafinil|
48362339|NCT03216564|DRUG|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
48362340|NCT00721136|DRUG|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
48510763|NCT05284266|OTHER|Standard conservative treatment with Intermittent Pneumatic Compression (IPC)|Physical therapy, including compression garment and exercise program, Self-care program and Intermittent Pneumatic Compression (IPC)
48510764|NCT05794503|DRUG|Neostigmine|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.
48510765|NCT05794503|DRUG|Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex
48510766|NCT05422794|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
48510767|NCT05422794|PROCEDURE|Biopsy|Undergo biopsy
48510768|NCT05422794|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48675895|NCT00443118|DEVICE|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
48675896|NCT00443118|DEVICE|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
48675897|NCT01336348|DRUG|Prasugrel|60 mg loading dose given orally at presentation
48675898|NCT01336348|DRUG|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
48675899|NCT00413439|DRUG|Isavuconazole|Intravenous solution or oral capsules
48675900|NCT06319781|OTHER|Observational|The study is a prospective non-interventional, observational study.
48675901|NCT04419467|BIOLOGICAL|CSL346|VEGF-B antagonist monoclonal antibody
48675902|NCT04419467|DRUG|Placebo|Normal saline
48675903|NCT06263036|OTHER|Men|Laryngeal cartilages
48675904|NCT06263036|OTHER|Women|Laryngeal cartilages
48675905|NCT01122979|DRUG|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
48675906|NCT01122979|DRUG|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
48675907|NCT01122979|DRUG|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
47991721|NCT02838680|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
47991722|NCT01288794|DRUG|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
47991723|NCT01288794|DRUG|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
47991724|NCT03679780|DRUG|BQ-788|This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
47991725|NCT03679780|DRUG|BQ-123|This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
48510769|NCT05422794|PROCEDURE|Computed Tomography|Undergo CT
48675908|NCT01122979|DRUG|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
48675909|NCT05386342|DEVICE|TufTex Over-the-Wire Embolectomy Catheter|The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
48675910|NCT06316726|COMBINATION_PRODUCT|full bed silicone mattress plus other measures|full bed silicone mattress plus put silicone pads on the head and shoulders, cotton rolls wraps bony prominence (elbows and heels), petrissage every two hours on shoulders to fingers and lower legs to heels, change location of ankle pads, use round gel full of air sit pad, a pillow on the knees
48675911|NCT02358408|DEVICE|Blood glucose monitoring systems for self-testing|
48675912|NCT05165095|DEVICE|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
48675913|NCT03465722|DRUG|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
48675914|NCT03465722|DRUG|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
47991726|NCT03679780|DRUG|L-Arginine|A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
48510770|NCT05422794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48675915|NCT01070979|DRUG|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
48675916|NCT01070979|DRUG|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
48675917|NCT01070979|DRUG|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
48675918|NCT02311881|DRUG|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
48675919|NCT02311881|DRUG|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
47991727|NCT03679780|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
47991728|NCT03679780|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
47991729|NCT03679780|DRUG|Lactated Ringer's|Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
47991730|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
47991731|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
47991732|NCT04829565|DRUG|Botulinum toxin|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of botulinum toxin 50 IU
48510771|NCT05422794|DRUG|Nab-paclitaxel|Given IV
48510772|NCT05422794|BIOLOGICAL|Pembrolizumab|Given IV
48510773|NCT01118065|DRUG|everolimus|
48510774|NCT04309617|PROCEDURE|nephrectomy|Surgery performed within the study period
48510775|NCT01830790|DRUG|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
48150080|NCT02474745|PROCEDURE|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
48150081|NCT06201000|DRUG|SGLT2 inhibitors (Dapagliflozin and Empagliflozin)|10 mg of dapagliflozin or empagliflozin
48150082|NCT05082948|OTHER|Suture fixation of stent|Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
48150083|NCT05082948|OTHER|Non suture|Standard placement of stent without suture fixation
48150084|NCT02216448|OTHER|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
48150085|NCT02216448|OTHER|OR Training|Training on diagnostic knee arthroscopy in the OR
48150086|NCT02954276|DRUG|Omexa Sublingual Sumatriptan tablet|75 mg
48675920|NCT02311881|DRUG|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
48675921|NCT01405183|OTHER|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
48675922|NCT06632626|OTHER|Task oriented training exercises|Task oriented training is a type of exercises in form of tasks using papers, pens, scissors, clips, coins, screws and clay
48675923|NCT06632626|OTHER|Traditional physical therapy|Traditional physical therapy inform of mobilization, strengthening exercises of hand and streching exercises.
48675924|NCT01506024|PROCEDURE|Total hip arthroplasty direct lateral approach|
48675925|NCT01506024|PROCEDURE|Total hip arthroplasty posterior approach|
47991733|NCT04829565|DRUG|Placebo|echo-guided injection into the trapezo-medial-phalangeal jointof 0.5 ml of placebo
47991734|NCT05548842|DIETARY_SUPPLEMENT|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill 1,000 mg/day for 4 weeks
47991735|NCT05548842|DIETARY_SUPPLEMENT|Placebo group|Placebo 1,000 mg/day for 4 weeks
47991736|NCT00982709|BEHAVIORAL|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
47991737|NCT03668938|OTHER|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
47991738|NCT03668938|OTHER|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
47991739|NCT04375189|OTHER|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
48675926|NCT01506024|PROCEDURE|Total hip arthroplasty, anterior approach|
48150087|NCT02954276|DRUG|Imitrex Oral Product|100 mg
48150088|NCT03684499|OTHER|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
48150089|NCT03684499|OTHER|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.(Bandyopadhyay et al, 2017)
48150090|NCT02875444|OTHER|Angio-CT|
48150091|NCT00674609|DRUG|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
48675927|NCT04872569|BEHAVIORAL|Decision-making tool|"Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support."
47991740|NCT00571987|DEVICE|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
47991741|NCT03994692|DEVICE|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
47991742|NCT03994692|PROCEDURE|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
47991743|NCT06234501|DIETARY_SUPPLEMENT|Pyridoxal 5'-Phosphate (100 mg)|100 mg Pyridoxal 5'-Phosphate tablet once daily with food
47991744|NCT06234501|OTHER|Placebo|Placebo tablet once daily
47991745|NCT00152750|DRUG|APO-clonidine|
47991746|NCT04002596|DEVICE|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
48150092|NCT00674609|DRUG|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
48150093|NCT00674609|DRUG|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
48150094|NCT01918943|DEVICE|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
48150095|NCT04480957|BIOLOGICAL|ARCT-021 Dose 1|ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)
48150096|NCT04480957|BIOLOGICAL|ARCT-021 Dose 2|ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
48150097|NCT04480957|BIOLOGICAL|ARCT-021 Dose 3|ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
48150098|NCT04480957|BIOLOGICAL|ARCT-021 Dose 4|ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
48150099|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 1|ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
48150100|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 2|ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
48150101|NCT04480957|OTHER|Placebo|Sterile 0.9% saline
48150102|NCT01403922|DRUG|TC-5214|Tablet oral bid days 1 to 7
48150103|NCT01403922|DRUG|TC-5214|Tablet oral bid days 8 to 14
48150104|NCT01872104|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
48150105|NCT03028961|OTHER|Stanford Letter|Receive and complete the Stanford Letter
48150106|NCT03028961|OTHER|Interview|Undergo semi-structured, research staff-led interview
48150107|NCT03028961|OTHER|Questionnaire Administration|Ancillary studies
48150108|NCT03028961|OTHER|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
48150109|NCT02731950|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
48150110|NCT02256826|DRUG|BILR 355 BS|
48150111|NCT02256826|DRUG|Ritonavir (RTV)|NORVIR®
48150112|NCT02256826|DRUG|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
48150113|NCT00949234|DRUG|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance \<30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
48150114|NCT01900015|DRUG|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
48150115|NCT01900015|DRUG|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
48150116|NCT06266676|OTHER|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
48150117|NCT06266676|OTHER|slide presentation|Provide online presentations.
48150118|NCT03840993|DRUG|MT-2990|over 16 weeks
48150119|NCT03840993|DRUG|Placebo|over 16 weeks
48150120|NCT01779089|DRUG|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
48150121|NCT01779089|DRUG|placebo|
48150122|NCT02529176|BEHAVIORAL|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
48150123|NCT00856453|BEHAVIORAL|Home yoga practice|training for and tracking of patient's practice of yoga at home
48150124|NCT00856453|BEHAVIORAL|yoga classes|organized out of home classes for yoga
48150125|NCT01759459|DRUG|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
48150126|NCT01759459|DRUG|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
48150127|NCT01759459|DRUG|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
48362341|NCT00721136|DRUG|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
48150128|NCT00461656|DRUG|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
47991747|NCT00031889|DRUG|Exemestane|Exemestane
48150129|NCT04964037|OTHER|No intervention|No intervention
48150130|NCT05792475|DIAGNOSTIC_TEST|Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software|TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
48150131|NCT02961283|DRUG|ASN003 ascending doses|
48150132|NCT02961283|DRUG|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
48150133|NCT00005635|BIOLOGICAL|trastuzumab|
48150134|NCT00005635|DRUG|paclitaxel|
48150135|NCT05051488|PROCEDURE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
48150136|NCT05051488|DEVICE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
48150137|NCT05062226|DIETARY_SUPPLEMENT|PKU/TYR GMP Protein Substitute|After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
48150138|NCT02632630|DRUG|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
48150139|NCT02632630|DIETARY_SUPPLEMENT|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
48150140|NCT02632630|DRUG|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
48150141|NCT02632630|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
48150142|NCT04669119|DIETARY_SUPPLEMENT|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
48510776|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
48510777|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
47991748|NCT00031889|DRUG|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
47991749|NCT05958355|OTHER|Functional postural control training|All participants will receive functional postural control training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
47991750|NCT05958355|OTHER|Treadmill training|All participants will receive treadmill training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
47991751|NCT03809507|OTHER|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
47991752|NCT00300859|BEHAVIORAL|brief motivational intervention|
48150143|NCT04669119|DIETARY_SUPPLEMENT|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
48150144|NCT04669119|DIETARY_SUPPLEMENT|Placebo|Placebo
48150145|NCT06201754|OTHER|Measure air quality|Measure air quality, including PM2.5、PM10
48150146|NCT01558765|OTHER|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
48150147|NCT06157294|PROCEDURE|Intra-articular pulsed radiofrequency|Intra-articular pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the intra-articular joint, which is the target tissue, is reached with the help of fluoroscopy images, pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
48362342|NCT00721136|DRUG|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
47991753|NCT06365268|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
47991754|NCT02004028|DRUG|VS-6063|
47991755|NCT02443012|DRUG|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
47991756|NCT02443012|PROCEDURE|Laser|Grid/Focal Laser Photocoagulation
47991757|NCT02576288|DRUG|Sitagliptin|anti-inflammatory properties
47991758|NCT02576288|DRUG|Placebo|No anti-inflammatory properties
47991759|NCT01018368|DRUG|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
47991760|NCT01018368|DRUG|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
47991761|NCT06427811|DRUG|Asciminib|Film-coated tablets with 40 mg dose strength taken orally
48362343|NCT01772017|DEVICE|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
48150148|NCT06157294|PROCEDURE|Median branch pulsed radiofrequency|Median branch pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the median branch region, which is the target area, is reached with the help of fluoroscopy images, location confirmation will be provided by giving sensory and motor stimulation. Pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
48362344|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
48362345|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
48362346|NCT03654638|OTHER|Questionnaire Administration|Ancillary studies
48362347|NCT04981236|PROCEDURE|Pericapsular nerve group block|A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.3% will be injected.
48362348|NCT04981236|PROCEDURE|Periarticular block|The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
48510778|NCT05649137|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
48510779|NCT01181570|DRUG|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
48510780|NCT01181570|DRUG|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
48510781|NCT05523791|DIETARY_SUPPLEMENT|Fortiral|Twice a day, patients took 10 g of powder containing 92.5% whey protein with 2.7% cysteine; emulsifier: soy lecithin, lactose free to be reconstituted with 150-200 ml of water.
48675928|NCT03330444|PROCEDURE|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
48675929|NCT02878083|DRUG|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
48675930|NCT02878083|DRUG|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
48675931|NCT01530373|DRUG|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
48675932|NCT01530373|DRUG|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
48675933|NCT01615744|PROCEDURE|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
48675934|NCT01615744|PROCEDURE|Non-surgical management|Early active exercises and elevation to decrease swelling
47991762|NCT02722850|BEHAVIORAL|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
47991763|NCT01410045|PROCEDURE|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
47991764|NCT00966602|DRUG|VX-809|VX-809 capsule, once daily for 14 days
47991765|NCT00966602|DRUG|VX-770|VX-770 tablet, once every 12 hours for 14 days
47991766|NCT00966602|DRUG|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
47991767|NCT00966602|DRUG|Placebo|Matching Placebo
48150149|NCT04123119|BIOLOGICAL|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 \& 10 weeks.
48362349|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
48510782|NCT05523791|DIETARY_SUPPLEMENT|Mg++|Twice a day, patients took 2.250g of magnesium pidolate (=184 mg of Magnesium++ ione) powder twice a day to be reconstituted with 150-200 ml of water
48510783|NCT04153903|OTHER|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
48675935|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
48675936|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - medium|
48675937|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
48675938|NCT01706653|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
48675939|NCT01790607|DRUG|ONO-2745 /CNS 7056|
48675940|NCT00888537|OTHER|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
48675941|NCT00888537|OTHER|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
48675942|NCT00700622|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
48675943|NCT00700622|DRUG|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
48675944|NCT00700622|DRUG|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
48675945|NCT04242706|DEVICE|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
48675946|NCT04242706|DEVICE|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
48362350|NCT00050505|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
48362351|NCT03043300|OTHER|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
48675947|NCT01730612|DRUG|TF2 - 68 Ga-IMP-288:|ImmunoTEP
47991768|NCT04355325|DEVICE|modified monolithic zirconia crowns|outcomes and complications of implant restoration
47991769|NCT04355325|DEVICE|Metal Ceramic crowns|outcomes and complications of implant restoration
47991770|NCT03575312|DRUG|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
47991771|NCT04882228|DRUG|Entelon Tab.150mg|twice daily for 8 weeks
47991772|NCT04882228|DRUG|Venitol Tab.|twice daily for 8 weeks
48362352|NCT03043300|OTHER|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
47991773|NCT04882228|DRUG|Placebo of Venitol Tab.|twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
47991774|NCT04882228|DRUG|Placebo of Entelon Tab.150mg|twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
47991775|NCT05352893|DRUG|Imsidolimab high dose|intravenous
47991776|NCT05352893|DRUG|Imsidolimab low dose|intravenous
48362353|NCT03043300|OTHER|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
48362354|NCT03043300|OTHER|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
48675948|NCT06242847|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|Participants ingest 75 g of glucose in 10 fl oz aqueous solution (fruit flavored) after an overnight fast. Blood is drawn at baseline (t = 0 min) and at 120 min after ingestion. This test is non-experimental.
47991777|NCT05352893|OTHER|Placebo|intravenous
48675949|NCT06242847|PROCEDURE|Skin punch biopsy|Punch biopsies are taken from lesional (psoriatic) and non-lesional skin after an overnight fast and at 120 min after ingestion of glucose during OGTT. This procedure is non-experimental.
48675950|NCT04935255|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
48675951|NCT02811822|DRUG|GMI-1271|
48675952|NCT05039788|OTHER|Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements|"Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements At D30 and D90~Measurement of systolic and diastolic blood pressure, impedancemetry, weight, 3 times a week between D30 and D90 post-transplant,"
48675953|NCT01399112|BEHAVIORAL|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
48675954|NCT06292767|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
47991778|NCT05225142|PROCEDURE|Modified minimally invasive surgery|Surgical intervention alone
47991779|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative|Surgical intervention with local application of regenerative biomaterial
48675955|NCT06486766|BEHAVIORAL|Norwegian SMS|Individuals receive a SMS in Norwegian language at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is applicable to all three populations (general population, immigrants born in Poland, immigrants born in Ukraine)
48675956|NCT06486766|BEHAVIORAL|Polish/Ukrainian SMS|Individuals receive an SMS in the official language of their native country (i.e., Polish or Ukrainian) at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is only applicable to the two immigrant populations (immigrants born in Poland, immigrants born in Ukraine)
48675957|NCT05707338|PROCEDURE|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
48150150|NCT03850847|OTHER|Step 1: Semi-structured Interviews|"1. Cover SDMs' experience around:~   * withdrawal of life sustaining therapies~  * organ donation among those who were approached (including with the medical team and the organ donation organisation)~  * understanding of the situation~  * views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~2. Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached)."
48150151|NCT03850847|OTHER|Step 2: National Telephone Survey|Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
48150152|NCT00502359|DEVICE|capillary blood glucose measurement|
48362355|NCT03043300|OTHER|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
48362356|NCT03043300|OTHER|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
48362357|NCT03043300|OTHER|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
48362358|NCT03558503|DRUG|UGN-102|"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
48362359|NCT05713344|OTHER|Clinical history|Detailed clinical history including demographic details, pain details (character, pattern, location, change in character, involvement of new areas), duration of disease, co-morbidities, family history, adverse life events, sleep details, details of stress/anxiety.
48675958|NCT01202240|DRUG|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
48675959|NCT03549741|DRUG|Clomiphene Citrate 50mg|oral tablets
48675960|NCT03549741|DRUG|Cabergoline Oral Tablet|oral tablets
48675961|NCT03549741|DRUG|Placebo Oral Tablet|oral tablets
48675962|NCT03368781|DEVICE|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
47991780|NCT05225142|PROCEDURE|Modified minimally invasive surgery with enamel matrix derivative and bone replacement graft|Surgical intervention with local application of regenerative biomaterial and bone replacement graft
47991781|NCT03411681|OTHER|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
47991782|NCT00140569|PROCEDURE|CHVP + interferon|
47991783|NCT00140569|DRUG|fludarabine|
47991784|NCT00140569|PROCEDURE|CHOP + TBI and autotransplant|
47991785|NCT00009854|DRUG|carmustine in ethanol|
47991786|NCT00009854|PROCEDURE|conventional surgery|
47991787|NCT03316885|DEVICE|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
47991788|NCT03316885|PROCEDURE|Cataract Surgery|Routine small incision cataract surgery with unilateral IOL implantation
48675963|NCT00704067|BEHAVIORAL|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
48675964|NCT00704067|BEHAVIORAL|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
48675965|NCT05807399|DRUG|BTZ-043|BTZ-043 1,000mg once daily.
47991789|NCT00993291|PROCEDURE|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
47991790|NCT00993291|PROCEDURE|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
47991791|NCT05256667|COMBINATION_PRODUCT|RCT-SV|Group 1- Endodontic treatment in a single visit using chemomechanical preparation and passive ultrasonic irrigation, followed by obturation and final restoration.
47991792|NCT05256667|OTHER|RCT-TVWD|Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
47991793|NCT05256667|OTHER|RCT-TVWOD|Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
47991794|NCT04518514|DEVICE|TAPE-Software|Telemedical Risk Assessment and Preoperative Evaluation prior to anaesthesia via personal computer
48150153|NCT02691702|DRUG|BIIB118|Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
48150154|NCT02691702|DRUG|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
48150155|NCT05280509|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
48150156|NCT05280509|DRUG|Ruxolitinib|Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
48150157|NCT02481934|PROCEDURE|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
48150158|NCT02481934|DRUG|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
48150159|NCT02481934|DRUG|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
48150160|NCT04887857|DRUG|CC-486|Specified dose on specified days
48150161|NCT04887857|DRUG|Venetoclax|Specified dose on specified days
48510784|NCT01908907|DIETARY_SUPPLEMENT|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
48510785|NCT01908907|DIETARY_SUPPLEMENT|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
48675966|NCT05807399|DRUG|Rifampicin|Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.
48675967|NCT05807399|DRUG|Isoniazid|Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
48675968|NCT05807399|DRUG|Pyrazinamide|Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.
47991795|NCT00827970|BEHAVIORAL|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
48150162|NCT01159314|PROCEDURE|Baerveldt Device surgical Procedure|Implant surgery
48150163|NCT01379677|DRUG|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
48150164|NCT01379677|DRUG|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
48150165|NCT00101296|DRUG|tipifarnib|Given orally
48150166|NCT00101296|OTHER|pharmacological study|Correlative studies
48150167|NCT00101296|OTHER|laboratory biomarker analysis|Correlative studies
48150168|NCT02292056|BEHAVIORAL|1-on-1 counseling|"1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~4. 10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
48150169|NCT02919059|DRUG|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
48150170|NCT02919059|DRUG|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
48150171|NCT04464499|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
48150172|NCT00903214|DRUG|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
48150173|NCT00903214|GENETIC|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
48150174|NCT00903214|PROCEDURE|axillary lymph node biopsy|
48150175|NCT00903214|PROCEDURE|digital image analysis|
48150176|NCT00903214|PROCEDURE|needle biopsy|
48675969|NCT05807399|DRUG|Moxifloxacin|Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2:.
48675970|NCT02404168|DRUG|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
48675971|NCT02404168|DRUG|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
48675972|NCT06447766|BEHAVIORAL|Feeding Families Your Way Program|Feeding Families Your Way is a video-based education program delivered by the University of Rhode Island Supplemental Nutrition Assistance Program - Education (SNAP-Ed).
48675973|NCT00000857|DRUG|Interleukin-12|
48675974|NCT03670849|DEVICE|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
48150177|NCT00903214|PROCEDURE|sentinel lymph node biopsy|
48150178|NCT00903214|PROCEDURE|therapeutic conventional surgery|
48150179|NCT00636168|DRUG|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
48150180|NCT00636168|DRUG|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
48150181|NCT03689452|DEVICE|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
48150182|NCT03689452|DRUG|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
48150183|NCT05711433|PROCEDURE|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
48150184|NCT06106776|DRUG|Chimeric Antigen Receptor|This study will evaluate the incidence of cardiac dysfunction at 7 days and 1 month after chimeric antigen receptor-T cell infusion (tisagenlecleucel, axicabtagene ciloleucel e brexucabtagene autoleucel).
48150185|NCT04880135|OTHER|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
48510786|NCT05052047|OTHER|Brisk Walking Group|Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
47991796|NCT05878054|OTHER|Proactive, integrated and personalised care|During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
47991797|NCT05364723|OTHER||no intervention
48675975|NCT05055076|DEVICE|PODEYE TORIC|Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
48675976|NCT00143000|DRUG|Peginterferon alfa-2a 40KD and Ribavirin|
48675977|NCT03530150|DRUG|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
48675978|NCT02164344|DIETARY_SUPPLEMENT|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
48675979|NCT03938051|OTHER|Experimental group|Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
47991798|NCT01039233|DRUG|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
47991799|NCT06539559|DRUG|Eribulin|Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
48150186|NCT04880135|OTHER|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
48150187|NCT04382053|DRUG|DFV890|DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
48675980|NCT03938051|OTHER|Control group|20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
48675981|NCT05634330|OTHER|exercise treatment|core stabilization exercise
48150188|NCT04382053|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
48150189|NCT06452914|DEVICE|Semiconductor Embedded Therapeutic Socks|Semiconductor Embedded Therapeutic Socks
48150190|NCT06452914|DEVICE|Placebo Socks|Socks not containing the Semiconductor Embedded Therapeutic fabric
48362360|NCT05713344|OTHER|Clinical examination|Thorough clinical examination, anthropometric measurement, assessment of pain (Izbicki score, Visual analog scale, modified brief pain inventory, pain catastrophising score, painDetect)
48362361|NCT05713344|OTHER|Evaluation of quality of life|Use of the EORTC QLQ c30 with PAN 28 to evaluate quality of life
48362362|NCT05713344|OTHER|Evaluation of mental state|Use of Beck depression inventory and Hospital Anxiety Depression score to evaluate depression and anxiety
48362363|NCT05713344|DIAGNOSTIC_TEST|Pancreatic quantitative sensory testing|Pancreatic quantitative sensory testing will be performed to evaluate temporal summation, pain detection threshold, pain tolerance threshold, and conditioned pain modulation.
48362364|NCT04901286|BEHAVIORAL|Exercise Only|Cycling in a lab environment
48362365|NCT04901286|BEHAVIORAL|Exercise + Non-Immersive Virtual Reality|Cycling with an environment simulated by non-immersive virtual reality
48362366|NCT04901286|BEHAVIORAL|Exercise + Immersive Virtual Reality|Cycling with an environment simulated by immersive virtual reality
47991800|NCT06539559|DRUG|Bevacizumab|Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
48362367|NCT02749643|DEVICE|Vibrotactile feedback system|
48362368|NCT05610865|OTHER|Control; Standard-of-care management|Patients will undergo conventional wound care management.
48362369|NCT05610865|BIOLOGICAL|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
48150191|NCT02188745|DRUG|17B-estradiol|Anti-estrogen
48150192|NCT02188745|DRUG|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
48150193|NCT02188745|DRUG|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
48150194|NCT02188745|DRUG|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
48362370|NCT05610865|BIOLOGICAL|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
48362371|NCT05610865|BIOLOGICAL|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
48362372|NCT01813136|DRUG|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
48362373|NCT01813136|DRUG|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
48362374|NCT02394457|DRUG|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
48362375|NCT02394457|PROCEDURE|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
48510787|NCT05052047|OTHER|Conventional Breathing Exercise Group|"Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed"
48675982|NCT05439551|DIAGNOSTIC_TEST|MeMed BV®|Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
48675983|NCT05734664|DEVICE|Pulsify sensor|A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.
48675984|NCT05734664|DEVICE|State-of-the-art ultrasound equipment|A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
48675985|NCT05243628|BIOLOGICAL|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
48675986|NCT05243628|BIOLOGICAL|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48150195|NCT06443736|PROCEDURE|Standardized perineal massage|Patients in this arm will be educated in the perineal massage proposed by the authors; the training will be performed during a group session, (organized bimonthly) conducted by obstetrical staff specialists, in the presence of the principal investigator and/or co-authors. In these sessions, a brief lecture on aspects of primary prevention related to pelvic floor structures (healthy diet, body weight control, moderate physical activity avoiding excessive exertion, posture control, therapy minctional education) and then screened an explanatory video regarding the three-step perineal massage proposed by the authors. The adequately prepared patient should then apply such perineal massage at home from the 34th gestational week until delivery according to the procedural methods provided.
48150196|NCT06443736|BEHAVIORAL|Primary prevention|Patients in this arm will be offered a group meeting in which aspects of primary prevention related to the structures of the pelvic floor (healthy diet, body weight control, moderate physical activity avoiding exertion excessive exertion, posture control, micturition educational therapy); participation in this meeting will be on a voluntary basis, and patients randomized to that group will have free choice in educating the pelvic floor pelvic floor in pregnancy.
48150197|NCT04464148|DRUG|Pregnenolone 250 mg|Pregnenolone 250 mg capsule BID (500 mg QD total)
48150198|NCT04464148|DRUG|Pregnenolone 400 mg|Pregnenolone 400 mg capsule BID (800 mg QD total)
48150199|NCT00209053|PROCEDURE|Coronary Artery Bypass|
48362376|NCT05331144|DRUG|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine)|Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine) will be used to treat high blood pressure. Additional antihypertensive medications may be used if needed.
48675987|NCT05243628|DEVICE|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
48675988|NCT05017870|DRUG|KSR-001|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
47991801|NCT03693079|PROCEDURE|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~1. Primary suction; cups are left attached to the skin for 5 minutes.~2. Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~3. Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~4. Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~5. Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
47991802|NCT00587483|DRUG|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
47991803|NCT00587483|DRUG|Amiodarone|300 mg
47991804|NCT00587483|DRUG|Placebo|Saline
47991805|NCT00632255|DRUG|Imatinib|Conventional therapy with imatinib
48150200|NCT02349815|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
48150201|NCT06130605|OTHER|Data collection|Data collection
48150202|NCT04471415|DRUG|DRP-104|"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"
48150203|NCT04471415|BIOLOGICAL|atezolizumab|atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
47991806|NCT00480597|DRUG|gemcitabine|
48150204|NCT05244954|DRUG|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
47991807|NCT00480597|DRUG|cisplatin|
47991808|NCT00480597|DRUG|vinorelbine|
47991809|NCT00480597|DRUG|capecitabine|
48150205|NCT05244954|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
48150206|NCT01383590|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
48150207|NCT00941447|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
48150208|NCT00941447|BEHAVIORAL|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
48362377|NCT05331144|OTHER|PCP|Participants will follow their PCP's recommendations for BP control.
48362378|NCT01060150|DRUG|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
48510788|NCT03903211|DRUG|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
48675989|NCT05017870|DRUG|KSR-004|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
48675990|NCT05017870|DRUG|KSR-001-02|KSR-001-02
48675991|NCT05017870|DRUG|KSR-001-03|KSR-001-03
48675992|NCT04527055|DRUG|Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
48675993|NCT04527055|DIETARY_SUPPLEMENT|Lactobacillus acidophilus and Bifidobacterium lactis Bb12|"The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
48675994|NCT04527055|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
48150209|NCT00941447|BEHAVIORAL|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
48150210|NCT05873504|DEVICE|High Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
48675995|NCT04527055|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
47991810|NCT04508842|BIOLOGICAL|CD19/CD22-Dual-STAR-T|Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
47991811|NCT00642239|DRUG|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
47991812|NCT00642239|DRUG|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
48150211|NCT05873504|DEVICE|Low Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
48150212|NCT03602807|DEVICE|Extracorporeal Shockwave Therapy|"2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra"
48150213|NCT03060525|BEHAVIORAL|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
48150214|NCT03884478|BEHAVIORAL|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
48150215|NCT03166215|DRUG|TAK-935|TAK-935 tablets.
48150216|NCT03166215|DRUG|Placebo|TAK-935 placebo-matching tablets.
48150217|NCT04153994|PROCEDURE|Erector Spinae Plane Blockade|The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
48150218|NCT02808676|DIETARY_SUPPLEMENT|Vitamin D3|Dose: 10000 IU, three times per week, orally.
48150219|NCT02808676|OTHER|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
47991813|NCT00302874|BEHAVIORAL|Implementation of a protocol for treatment of hyperglycemia|
47991814|NCT03975855|DEVICE|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
48675996|NCT04527055|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
47991815|NCT05371574|DRUG|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
47991816|NCT03541265|DRUG|Exparel|long-acting Bupivacaine extended release liposome compound
47991817|NCT03541265|PROCEDURE|Adductor block protocol|Adductor block using Exparel
47991818|NCT03541265|PROCEDURE|peri-articular injection protocol|peri-articular injection using Exparel
47991819|NCT06253611|DRUG|Nivolumab|Nivolumab 240 mg IV; every 2 weeks
47991820|NCT06253611|DRUG|FOLFOX regimen|Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks
48150220|NCT02808676|OTHER|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
48150221|NCT02808676|OTHER|placebo D3|matching placebo for Vitamin D3
48150222|NCT02808676|OTHER|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
48675997|NCT04763434|DRUG|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
48675998|NCT02538120|OTHER|Microvascular assessment|Microvascular assessment
48675999|NCT00503425|DRUG|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
48150223|NCT02808676|OTHER|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
48150224|NCT02676778|DRUG|E7777|
48150225|NCT02346786|DIETARY_SUPPLEMENT|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
47991821|NCT06253611|BIOLOGICAL|EXL01|Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
48150226|NCT02346786|DIETARY_SUPPLEMENT|tap water|
48150227|NCT02652455|DRUG|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
48362379|NCT02030795|OTHER|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
48510789|NCT06634134|BEHAVIORAL|Adjusting training advice|Based on discomfort related to the menstrual cycle the female cyclist can choose to adjust the suggested training.
48510790|NCT06001593|DEVICE|YPS-201b|electrical stimulation device.
48510791|NCT06001593|DRUG|betahistine|Relieve symptoms of balance disorders or dizziness
48676000|NCT02240121|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
48676001|NCT02240121|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
48150228|NCT02652455|PROCEDURE|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
48150229|NCT02652455|DRUG|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
48150230|NCT02652455|DRUG|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
48150231|NCT02652455|DRUG|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
48150232|NCT02652455|BIOLOGICAL|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
48676002|NCT02861287|OTHER|Economic evaluation|
47991822|NCT03720496|BIOLOGICAL|CD19-TriCAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10\^6 CAR+ T cells/kg body weight.
47991823|NCT00893750|BEHAVIORAL|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
47991824|NCT00893750|BEHAVIORAL|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
47991825|NCT00893750|BEHAVIORAL|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
47991826|NCT06120036|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
48150233|NCT02652455|DRUG|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
48150234|NCT03848741|BEHAVIORAL|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
48150235|NCT03848741|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
48150236|NCT03848741|DIETARY_SUPPLEMENT|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
48150237|NCT03848741|DIETARY_SUPPLEMENT|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
48150238|NCT00847977|DRUG|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
48150239|NCT00847977|DRUG|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
48150240|NCT00801606|DRUG|Zinc|Zinc 20 mg/day
48150241|NCT00801606|DRUG|Micronutrient without zinc|Multimineral 2 RDA
48150242|NCT00801606|DRUG|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
48150243|NCT00801606|DRUG|Placebo|Placebo
48150244|NCT03898999|OTHER|Overall status|An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
48362380|NCT02030795|OTHER|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
48362381|NCT03708029|OTHER|Revita Allograft|Human placental allograft
48362382|NCT05042531|DRUG|Azacitidine|Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days
48510792|NCT06001593|DEVICE|YPS-201b|sham electrical stimulation device.
48510793|NCT00702988|DRUG|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
48510794|NCT00702988|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
48510795|NCT03545230|PROCEDURE|":Four Not Techniques"|":Four Not Techniques~1. Not enter posteriorly~2. Not too much dissection the muscle around the lateral condyle during surgery~3. Not perfect anatomical reduction~4. Not using bone graft."
48676003|NCT02164526|OTHER|Routine therapy|Routine therapy
48676004|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
48676005|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
48676006|NCT01997645|PROCEDURE|LIFT|
48676007|NCT01997645|PROCEDURE|RAF|
48676008|NCT00374517|DRUG|Pimonidazole hydrochloride|
48150245|NCT01597999|RADIATION|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
48150246|NCT03019432|BEHAVIORAL|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
48150247|NCT01745835|DRUG|2L Coolprep®|\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
48150248|NCT01745835|DRUG|1L Coolprep® and Bisacodyl|"1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
48150249|NCT00222209|BEHAVIORAL|Experimental heat pain model|
48150250|NCT06215326|BEHAVIORAL|moderate-intensity continuous training|Participants in MICT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a warm-up of 5 minutes at 50% at peak WR, the patient start exercising at 60%-70% peak WR for 30-40 minutes (four 5-8 minutes sets, with a 2-min rest in between), and then the patients cooled down for 5 minutes at 50% peak WR. Moderate-intensity exercise training intensity control at 55-74% HRmax or 40-69% VO2peak or PRE12-13 as recommended by guidelines.
48150251|NCT06215326|BEHAVIORAL|high-intensity interval training|Participants in HIIT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a 5-minute warm-up at 50% at peak WR, the patients complete 20 series of vigorous-intensity sprint (80%-100% peak WR for 30-60s) separated by a low-intensity recovery (30% peak WR or completely rest for 15s), and then the patients cooled down for 5 minutes at 50% peak WR. Participants will begin training at a relatively moderate intensity (60%-65% peak WR) for the first 3 sessions and gradually increase to the target intensity beginning on the 4th session. Intensity control of high-intensity exercise training at 75-90% HRmax or 70-85% VO2peak or PRE14-16 as recommended by guidelines.
48150252|NCT04014452|PROCEDURE|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
48150253|NCT04014452|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
48150254|NCT05536440|DRUG|PF-07261271|IV or SC
48150255|NCT05536440|DRUG|Placebo|IV or SC
48150256|NCT03805789|BIOLOGICAL|Alpha-1 antitrypsin (AAT)|Alpha-1 antitrypsin is a lyophilized product for intravenous administration.
48150257|NCT03805789|BIOLOGICAL|Placebo|Albumin solution administered intravenously
48150258|NCT01790100|DRUG|VX-135|12 weeks of VX-135
48150259|NCT01790100|DRUG|Ribavirin|12 weeks of ribavirin
48510796|NCT05173441|BIOLOGICAL|Human COVID-19 immunoglobulin (pH4) for intravenous injection|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.
48510797|NCT05173441|DRUG|Placebo|The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
48510798|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention face-to-face|
48510799|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention delivered via DVD|
48510800|NCT03145389|PROCEDURE|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
47991827|NCT06120036|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
48510801|NCT02046486|DRUG|Ticagrelor 180mg whole tablets|
48510802|NCT02046486|DRUG|Ticagrelor 180mg crushed and dispersed|
48362383|NCT05042531|DRUG|Dasatinib|dasatinib,20mg,po,qd,treatment cycles every 28 days
48362384|NCT02223533|DEVICE|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
48362385|NCT02223533|DRUG|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
48362386|NCT00902473|DRUG|Topiramate|25mg tablets
48362387|NCT05430230|DRUG|Naproxen 500 Mg|naproxen tablets
48676009|NCT01718899|BIOLOGICAL|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
48362388|NCT05430230|DRUG|Placebo|lactose NF
48362389|NCT04887012|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
48362390|NCT06021912|DRUG|Immunotherapy|Sublingual immunotherapy
48362391|NCT05979857|DRUG|SP-3164|SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
48362392|NCT01064518|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines
48362393|NCT01064518|DRUG|Placebo (Dose B)|Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
48510803|NCT01338870|DRUG|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
48510804|NCT01338870|DRUG|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
48676010|NCT00208065|DRUG|almotriptan or pseudoephedrine|
48676011|NCT06016322|DIETARY_SUPPLEMENT|Dried Chicory Root|"Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose)."
47991828|NCT04723940|DRUG|Bactrim|Bactrim will be given for 6 weeks to treat joint infection
48676012|NCT01948479|DEVICE|Optimised instant offloading insole|
48676013|NCT02764996|DEVICE|Acupuncture|
48676014|NCT05796388|DEVICE|Virtual Reality|Both groups will receive standard of care linaclotide 290 mcg.
48676015|NCT02523287|BIOLOGICAL|Fluad|Randomized assignment
48676016|NCT02523287|BIOLOGICAL|Saline|Randomized assignment
48676017|NCT05874141|DIAGNOSTIC_TEST|HBA1C|blood sample on EDTA
48676018|NCT05874141|DIAGNOSTIC_TEST|Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides|serum sample
48676019|NCT05874141|DIAGNOSTIC_TEST|Urine analysis and urinary albumin-to-creatinine ratio|Morning urine sample
48676020|NCT05874141|DIAGNOSTIC_TEST|Serum creatinine and estimated glomerular filtration rate|serum sample
48676021|NCT05874141|DIAGNOSTIC_TEST|Complete blood count|blood sample on EDTA
48676022|NCT05874141|DIAGNOSTIC_TEST|Thyroid-stimulating hormone|serum sample
48676023|NCT05874141|DIAGNOSTIC_TEST|Serum iron, TIBC, Transferrin saturation and serum ferritin if needed|serum sample
48676024|NCT05874141|PROCEDURE|Electrocardiography (ECG)|by electrocardiogram
47991829|NCT04723940|DRUG|Cefadroxil|Cefadroxil will be given for 6 weeks to treat joint infection
47991830|NCT04723940|DRUG|Doxycycline Hcl|Doxycycline HCl will given for 6 weeks to treat joint infection
47991831|NCT04723940|DRUG|Clindamycin|Clindamycin will given for 6 weeks to treat joint infection
47991832|NCT05387655|BIOLOGICAL|BCG|BCG vaccination
47991833|NCT05387655|BIOLOGICAL|Placebo vaccine|Placebo vaccination
47991834|NCT03238638|DRUG|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
47991835|NCT03238638|DRUG|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
48362394|NCT03245372|PROCEDURE|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
48362395|NCT03245372|PROCEDURE|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
48362396|NCT02041533|BIOLOGICAL|Nivolumab|
48362397|NCT02041533|DRUG|Gemcitabine|
48362398|NCT02041533|DRUG|Cisplatin|
48362399|NCT02041533|DRUG|Carboplatin|
48362400|NCT02041533|DRUG|Paclitaxel|
48362401|NCT02041533|DRUG|Pemetrexed|
48362402|NCT05129917|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 14 day
48362403|NCT05129917|DIETARY_SUPPLEMENT|Gojinsen® drinks|consume 1 sachet per day for 14 day
48362404|NCT03515499|BEHAVIORAL|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
48362405|NCT03515499|BEHAVIORAL|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
48510805|NCT01338870|DRUG|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
48510806|NCT01338870|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
48510807|NCT01338870|DRUG|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
48510808|NCT01338870|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
48676025|NCT05874141|PROCEDURE|Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound|imaging
48676026|NCT05874141|PROCEDURE|Arterial duplex ultrasound of both lower limbs|imaging
48676027|NCT05874141|DIAGNOSTIC_TEST|Random blood glucose|serum sample
48676028|NCT05874141|DIAGNOSTIC_TEST|AST, ALT, albumin|serum sample
48676029|NCT00790049|DRUG|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
47991836|NCT00887354|DRUG|Teriparatide|Administered subcutaneously
47991837|NCT00887354|DRUG|Risedronate|Administered orally
47991838|NCT00887354|DRUG|Placebo|"Weekly: Administered orally~Daily: Administered subcutaneously"
48150260|NCT05758532|BIOLOGICAL|Measles-Mumps-Rubella vaccine (MMR)|0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
48150261|NCT04898582|OTHER|Mineral 89 Probiotic Fractions|The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions
48362406|NCT04228666|BIOLOGICAL|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
48362407|NCT02050256|OTHER|continuing medical education and electronic decision support|
48362408|NCT02050256|OTHER|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
48362409|NCT03146195|OTHER|Dynamic Magnetic resonance imaging|
48362410|NCT01378156|BIOLOGICAL|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
48362411|NCT01333020|OTHER|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
48362412|NCT03725709|PROCEDURE|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
48362413|NCT01496781|PROCEDURE|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
48362414|NCT01496781|PROCEDURE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
48362415|NCT04557696|OTHER|REFLECT Curriculum|Annual quarterly workshops will consist of guest lecturers, role playing, patient panels, coaching, knowledge assessments, Standardized Patient (SP) simulations and debriefing/feedback sessions.
48362416|NCT00202267|DEVICE|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
48362417|NCT00202267|DEVICE|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
48676030|NCT00790049|DRUG|Placebo; oral|matching placebo
48676031|NCT03048773|DEVICE|shockwave therapy|Intervention with shockwave therapy
48676032|NCT03048773|OTHER|PT|Physical therapy 3 times per week for 3 weeks
48676033|NCT03048773|OTHER|placebo|sham shockwave therapy
47991839|NCT00887354|DIETARY_SUPPLEMENT|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
47991840|NCT00887354|DIETARY_SUPPLEMENT|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
47991841|NCT05757531|DRUG|[¹⁴C]-LY3437943|Administered SC.
47991842|NCT02071888|DRUG|CB-839|Glutaminase inhibitor
47991843|NCT02071888|DRUG|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
47991844|NCT02071888|DRUG|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
47991845|NCT03755687|OTHER|Art Therapy Intervention|Standardized mixed media art directives.
47991846|NCT05196542|PROCEDURE|patients with apical prolapse who will do Sacro hysteropexy using mersilene tape|comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
48362418|NCT01747928|OTHER|dual-chamber syringe|dual-chamber syringe for mock injection
48362419|NCT05178563|PROCEDURE|IPT+PDT|The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
48362420|NCT05178563|PROCEDURE|IPT+Placebo|IPT+Placebo
48362421|NCT02260791|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
48676034|NCT01881282|DRUG|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
48676035|NCT01881282|DRUG|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
48676036|NCT03376464|DEVICE|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
48676037|NCT01562886|DRUG|Rilpivirine|Rilpivirine 26mg
48676038|NCT05450835|PROCEDURE|OGT group|In OGT group,the nasogastric tube was pulled out 3 cm from the oesophagal lumen to connect with the OGT. Meanwhile, the OGT was sleeved on anvil fork extracorporeally and the linear stapler was put into abdomen through trocar on the right side and then cartridge fork was inserted through jejunum opening towards the oral side of the lumen. Next, the anvil fork sleeved with OGT insert into the oesophageal mucosa canal by movement of the connection of fork -OGT -gastric tube.
48676039|NCT05450835|PROCEDURE|Overlap group|In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al.
48676040|NCT04377503|DRUG|Tocilizumab 180 MG/ML|Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
48676041|NCT04377503|DRUG|Methylprednisolone Sodium Succinate|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
48676042|NCT00366210|BEHAVIORAL|Constraint-Induced Movement (CI) Therapy|
48676043|NCT00366210|BEHAVIORAL|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
48676044|NCT00952705|BIOLOGICAL|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
48676045|NCT00952705|BIOLOGICAL|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
48676046|NCT00952705|BIOLOGICAL|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
48676047|NCT01440764|DRUG|Furosemide|
48676048|NCT01440764|DRUG|Saline|
48676049|NCT02274220|DIETARY_SUPPLEMENT|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
48676050|NCT02274220|DIETARY_SUPPLEMENT|Standard advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
48676051|NCT03771040|DRUG|Masitinib|
48676052|NCT03771040|DRUG|Placebo|
48676053|NCT00746187|DEVICE|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
48676054|NCT00746187|DEVICE|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
48676055|NCT03173014|DEVICE|EEG|EEG monitoring
48676056|NCT06451874|BEHAVIORAL|Functional Power Training (FPT)|Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.
48676057|NCT06451874|BEHAVIORAL|Music-Based Digital Therapy (MBDT)|Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.
48676058|NCT06451874|BEHAVIORAL|FPT + MBDT|For non-responders who were randomized to augment treatment, they will receive combined FPT and MBDT treatment.
47991847|NCT05950789|OTHER|Virtual reality application|"During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over."
47991848|NCT00494832|DRUG|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
48676059|NCT03101189|DRUG|ACT-541468|Capsule
48676060|NCT03101189|DRUG|placebo|Matching placebo capsule
48676061|NCT03323138|PROCEDURE|Ex-PRESS and phacoemulsification|
48676062|NCT03046836|DRUG|Oxytocin|40 IU oxytocin nasal spray
48676063|NCT03046836|DRUG|Placebo|Saline
48676064|NCT00672230|DIETARY_SUPPLEMENT|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
48676065|NCT04189835|DIAGNOSTIC_TEST|EBV DNA in whole blood and plasma|Consecutive measurements of EBV DNA in whole blood and plasma
48676066|NCT03855566|BEHAVIORAL|Intensive behavioral therapy for obesity|Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
48676067|NCT01946334|DEVICE|anorectal manometry and high-resolution three-dimensional|
48676068|NCT02587832|DEVICE|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
47991849|NCT00494832|DRUG|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
47991850|NCT00499018|DRUG|Rituximab|375 mg/m2 day 1
48676069|NCT02587832|DEVICE|NCPAP|Bubble CPAP System.
48676070|NCT00381654|DRUG|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
48676071|NCT00283946|DRUG|Zolpidem MR|Oral
48676072|NCT00283946|DRUG|Zolpidem|Oral
48676073|NCT04282850|PROCEDURE|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
48676074|NCT02874443|OTHER|Knowledge Translation of labor management guidelines|
48676075|NCT04750486|DEVICE|Sequential compression devices|Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
48676076|NCT01724216|DEVICE|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
48676077|NCT03565172|DIAGNOSTIC_TEST|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
48362422|NCT02260791|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
48362423|NCT03646916|DRUG|Dexamethasone|Gluco-corticosteroid
48362424|NCT03646916|OTHER|No dexamethasone|Nothing
48362425|NCT04075240|DRUG|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
48676078|NCT03565172|OTHER|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
48676079|NCT03565172|DIAGNOSTIC_TEST|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
48676080|NCT02098304|DEVICE|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
48676081|NCT03856736|OTHER|MIAT|Moderated aerobic exercise
48676082|NCT03856736|OTHER|Control|Weekly body relaxation and sham group
48676083|NCT04277624|DRUG|fezolinetant - test formulation|Administered orally
48676084|NCT04277624|DRUG|fezolinetant - reference formulation|Administered orally
48676085|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (full intervention)|The full ENRICH pilot intervention will consist of content related to diet, physical activity, stress/mental health, sleep, tobacco cessation, and child health. The investigators will use an adapted version of the Mothers and Babies stress management intervention to address mental health, an adapted version of the HEALTH curriculum to address diet/physical activity, and an adapted version of the INSIGHT curriculum to address child health.
48676086|NCT05856162|BEHAVIORAL|ENRICH pilot intervention (partial intervention: only diet and physical activity)|The partial ENRICH intervention will focus only on diet and physical activity.
48676087|NCT00600067|DRUG|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
48676088|NCT00600067|DRUG|Placebo|Oral placebo capsules, once daily, 28 weeks
48362426|NCT04075240|DRUG|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
48362427|NCT03797391|DRUG|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks).~Participants may continue to receive study drug until discontinuation criteria are met."
48676089|NCT01674790|BEHAVIORAL|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
48676090|NCT01674790|BEHAVIORAL|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
48676091|NCT01674790|BEHAVIORAL|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
48362428|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
48362429|NCT01028794|BIOLOGICAL|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
48362430|NCT04067076|OTHER|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
48362431|NCT01190280|PROCEDURE|Cholecystectomy operation|Cholecystectomy after randomization
48676092|NCT01674790|BEHAVIORAL|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
47991851|NCT00499018|DRUG|Ciclofosfamide|1200 mg/m2 day 1
48510809|NCT03796052|OTHER|Avena Sativa Skincare Regimen|Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
48510810|NCT05645952|OTHER|Clinical follow up of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
47991852|NCT00499018|DRUG|Doxorubicina|70 mg/m2 day 1
48362432|NCT00003556|BIOLOGICAL|ALVAC-hB7.1|
48362433|NCT00003556|BIOLOGICAL|canarypox-hIL-12 melanoma vaccine|
48676093|NCT02156193|PROCEDURE|Prophylactic clip|Prophylactic clipping
48676094|NCT02156193|PROCEDURE|No prophylactic management|No prophylaxis
48676095|NCT04460183|DRUG|RESP301, a Nitric Oxide generating solution|Product application requires inhalation using a standard handheld nebulizer.
48676096|NCT04460183|OTHER|Standard of Care|Participants will receive institutional SOC for the treatment of COVID-19.
48676097|NCT06453031|PROCEDURE|Gastric Ischemic Preconditioning Before Esophagectomy|Does embolization of the left gastric artery prior oesophagectomy reduce postoperative complications, particularly anastomotic leaks and ischemia of the gastric conduit?
48676098|NCT06288425|OTHER|Non interventional|Non interventional. Review of clinical, biopsy (histopathological and molecular) features associated with rejection and non-rejection pathology diagnosis
48676099|NCT01212029|BEHAVIORAL|Behavioral measures|Behavioral tasks/ questionnaires
48676100|NCT01212029|DEVICE|fNIRS Devices &amp; Application|Device 1- fNIRSoft and Device 2 - NIRScout
48676101|NCT01212029|OTHER|Physiological measures|A set of tasks.
48676102|NCT04100408|OTHER|Biospecimen Collection|Undergo saliva or buccal mucosa collection
48676103|NCT04100408|OTHER|Laboratory Biomarker Analysis|Correlative studies
47991853|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
48150262|NCT03989609|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
48150263|NCT03989609|DRUG|Midazolam|midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
48150264|NCT06053983|DEVICE|Turbox CRP kit|Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.
48150265|NCT06053983|DRUG|rosuvastatin 20 mg,|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
48676104|NCT04100408|OTHER|Questionnaire Administration|Ancillary studies
48676105|NCT02051478|OTHER|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
48676106|NCT02051478|OTHER|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
48676107|NCT03381287|DRUG|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
48150266|NCT06053983|DRUG|atorvastatin 40 mg|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
48150267|NCT01279447|DRUG|0.25% Bupivacaine|10cc, single dose, US guided injection
48150268|NCT01279447|DRUG|Normal Saline|10cc, single dose, US guided injection
48150269|NCT06031493|COMBINATION_PRODUCT|Multimodal intervention on sexual dysfunction and quality-of-life|Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
48150270|NCT01002586|OTHER|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
47991854|NCT00499018|DRUG|Prednisone|100 mg day g 1-5
48150271|NCT01002586|OTHER|Walking exercise program|walking exercise program
48150272|NCT04794465|DIAGNOSTIC_TEST|Colorectal cancer screening|Patients with IBP diagnosed during the colorectal cancer screening
48150273|NCT00403845|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
48676108|NCT03381287|DRUG|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
48676109|NCT03381287|DRUG|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
47991855|NCT00499018|DRUG|Pegfilgrastim|6 mg day +1
47991856|NCT00499018|DRUG|Mitoxantrone|8 mg/m2/days 1-3
47991857|NCT00499018|DRUG|ARA-C|2000 mg/m2/12h day 1 - 3
47991858|NCT00499018|DRUG|Lenograstim|5 μg/Kg/days +2
48150274|NCT00403845|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
48150275|NCT00403845|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
48150276|NCT01942772|DEVICE|Ankle-Foot Orthosis|
48150277|NCT03810300|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
48150278|NCT03810300|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
48150279|NCT03810300|OTHER|Food and cash transfer|15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
47991859|NCT00499018|DRUG|BCNU|300 mg/m2 day -7
47991860|NCT00499018|DRUG|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
47991861|NCT00499018|DRUG|VP-16|100 mg/m2/12h days -6,-5,-4,-3
47991862|NCT00499018|PROCEDURE|ASCT|PBSC Reinfusion
47991863|NCT00499018|DRUG|Ciclofosfamide|750 mg/m2 day 1
48150280|NCT03810300|BEHAVIORAL|Nutrition behavior Communication Change (BCC)|Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
48150281|NCT03810300|OTHER|Control|No transfer, no behavior change communication
48150282|NCT05675748|DRUG|Azvudine|Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
48362434|NCT00600639|DEVICE|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
47991864|NCT00499018|DRUG|Doxorubicina|50 mg/m2 day 1
47991865|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
47991866|NCT02949492|DRUG|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
48676110|NCT03381287|DRUG|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
48676111|NCT03381287|DRUG|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
48676112|NCT03381287|DRUG|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
48150283|NCT01952002|OTHER|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
48150284|NCT04247256|DRUG|FOLFIRI Protocol|FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
48150285|NCT04247256|DRUG|SCO-101|Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
48676113|NCT03842267|DRUG|Gemigliptin 50mg|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
48676114|NCT03842267|DRUG|Gemigliptin Placebo|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* - The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
48676115|NCT01328743|BEHAVIORAL|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
48676116|NCT02329093|PROCEDURE|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
48676117|NCT00360958|PROCEDURE|ultrafiltration|
48676118|NCT03017105|OTHER|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
48676119|NCT03017105|OTHER|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
48150286|NCT03742297|DRUG|Lenalidomide.|Lenalidomide
48362435|NCT00600639|DRUG|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
48362436|NCT00600639|DRUG|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
48362437|NCT03163290|OTHER|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
48510811|NCT00360087|DRUG|Bosentan|
48676120|NCT04074083|BEHAVIORAL|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
48676121|NCT04074083|BEHAVIORAL|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
48676122|NCT03248388|DEVICE|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
48676123|NCT03248388|DEVICE|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
48676124|NCT06405490|DRUG|Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab|Use the above medications on a regular basis
48676125|NCT01655186|DRUG|Bardoxolone Methyl|
48150287|NCT03742297|DRUG|Carfilzomib|Carfilzomib
48150288|NCT03742297|DRUG|Bortezomib|Bortezomib
48150289|NCT03742297|DRUG|Daratumumab|Daratumumab
48150290|NCT03742297|DRUG|Dexamethasone|Dexamethasone
48150291|NCT03742297|DRUG|Prednisone|Prednisone
48676126|NCT01655186|DRUG|Placebo|
48150292|NCT03742297|DRUG|Melphalan|Melphalan
48150293|NCT03927118|PROCEDURE|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
48510812|NCT04474990|DRUG|Tradipitant|NK-1 Receptor antagonist
47991867|NCT01715311|DRUG|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
47991868|NCT01715311|DRUG|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
48150294|NCT01118156|OTHER|Education|75-minute training teaching utilization of new standardized suicide nomenclature
48150295|NCT01919489|DRUG|Liraglutide + OADs|Liraglutide subcutaneously daily
48150296|NCT01919489|DRUG|Glargine + OADs|Glargine once daily subcutaneously
48150297|NCT01115153|OTHER|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
48150298|NCT01115153|OTHER|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
48362438|NCT03163290|OTHER|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
48362439|NCT01017289|DEVICE|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
48362440|NCT04955236|DRUG|Partial scalp block|"Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.)."
47991869|NCT01715311|DRUG|Tiotropium|Tiotropium capsules for inhalation once daily
47991870|NCT01715311|DRUG|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
48362441|NCT04955236|DRUG|Fentanyl|1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
48362442|NCT02766309|OTHER|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker \& Gandeck, 2002).
48676127|NCT02563730|PROCEDURE|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
48676128|NCT02850978|DRUG|Spiolto|
48150299|NCT00795639|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
48150300|NCT00795639|DRUG|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
48150301|NCT00195988|DRUG|tacrolimus, steroids, mycophenolate mofetil|
48150302|NCT03680768|OTHER|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
48150303|NCT00096278|BIOLOGICAL|Bevacizumab|Given IV
48150304|NCT00096278|DRUG|Fluorouracil|Given IV
48676129|NCT05465070|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
48676130|NCT05465070|DEVICE|Sham Control|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
48676131|NCT02525926|PROCEDURE|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
48150305|NCT00096278|DRUG|Leucovorin Calcium|Given IV
48150306|NCT00096278|DRUG|Oxaliplatin|Given IV
48150307|NCT00505986|PROCEDURE|endometrial biopsy|
48150308|NCT05253066|DRUG|Chidamide combined with exemestane (+/- goserelin)|Chidamide combined with exemestane (+/- goserelin)
48150309|NCT05253066|DRUG|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
48150310|NCT00425971|DRUG|BMEC-1217B|
48150311|NCT05776056|DRUG|Methylphenidate|Methylphenidate 10mg will be taken twice daily.
48150312|NCT05776056|DRUG|Placebo|An inactive pill (placebo) will be taken twice daily.
48676132|NCT02525926|PROCEDURE|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
48676133|NCT02186483|DRUG|Metformin|Metformin,1000mg, once daily
48676134|NCT02186483|DRUG|Rosuvastatin|Rosuvastatin, 20 mg, once daily
48676135|NCT02186483|DRUG|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
48676136|NCT03657836|DIETARY_SUPPLEMENT|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
48676137|NCT03657836|DRUG|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
48676138|NCT02574793|DEVICE|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
48676139|NCT02207543|OTHER|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
48362443|NCT03434860|DIETARY_SUPPLEMENT|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
48362444|NCT03434860|DIETARY_SUPPLEMENT|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
48362445|NCT06497231|OTHER|Beautifil II LS|Beautifil II LS is a low shrinkage bioactive giomer resin composite.
48362446|NCT06497231|OTHER|Nanohybrid resin composite material|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component.
48362447|NCT05079724|PROCEDURE|Cardiac Surgery|About 3.5-31.0% of Patients undergoing cardiac surgery Complains from Postoperative Acute renal injury (AKI) that is a severe complication increasing the risk factor for mortality about 8-folds, The occurrence of AKI in patients undergoing cardiac surgery raises the mortality rate from 0.4-4.4% to 1.3-22.3%; when those same patients require dialysis.
48362448|NCT05838586|BEHAVIORAL|prolonged SB|4 hours of prolonged SB
48362449|NCT05838586|BEHAVIORAL|SB broken 1|4 hours of SB broken up by 5 minutes of self-paced walking every hour
48362450|NCT05838586|BEHAVIORAL|SB broken 2|4 hours of SB with one 20-minute bout of self-paced walking
47991871|NCT02440477|OTHER|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
48150313|NCT06119256|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.
48150314|NCT01223014|DRUG|AZD2423|AZD2423
48362451|NCT03914924|BEHAVIORAL|Exercise Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
48510813|NCT05845502|BIOLOGICAL|SZ003 CAR-NK|Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.
47991872|NCT02182531|DRUG|Epinastine|
47991873|NCT02182531|DRUG|Pseudoephedrine|
47991874|NCT02182531|DRUG|Epinastine + Pseudoephedrine combination|
47991875|NCT06146933|DIAGNOSTIC_TEST|Glucometer Test|blood glucose measurement using finger tip capillary blood using BGM
47991876|NCT06146933|DIAGNOSTIC_TEST|Refernce Measurement|blood glucose measurement using finger tip capillary blood using reference method
47991877|NCT03761381|DEVICE|Optical Coherence Tomography Angiography (OCTA) Imaging|Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
47991878|NCT03761381|DEVICE|Noninvasive Retinal Amyloid Imaging (NRAI)|The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
47991879|NCT04178187|DRUG|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
47991880|NCT04178187|DRUG|Caps Placebo|Caps Placebo
47991881|NCT05885074|DRUG|Empagliflozin Arm|The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months
47991882|NCT05885074|OTHER|Control Arm|The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months
47991883|NCT05885074|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
47991884|NCT05885074|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
47991885|NCT01147705|DRUG|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
47991886|NCT01147705|DRUG|Placebo|Same appearance/dosing as active drug.
47991887|NCT02015780|DRUG|Fasiglifam|Fasiglifam tablets
47991888|NCT02015780|DRUG|Placebo|Fasiglifam placebo-matching tablets
47991889|NCT02015780|DRUG|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
48150315|NCT04211194|PROCEDURE|Upper GI Endoscopy|Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
48150316|NCT00895076|DRUG|dexamethasone|iontophoretic patch and injection
47991890|NCT01764568|BEHAVIORAL|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz \& Woodward 2007a; Moritz \& Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8-module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
48150317|NCT00549666|DRUG|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
48150318|NCT00549666|DRUG|Placebo 40 mg|Placebo 40 mg once daily during treatment period
48150319|NCT00549666|DRUG|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
48150320|NCT01074281|DRUG|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
48150321|NCT04184609|OTHER|Control|In this condition, the participants will not receive any medications or drugs before exercise
48150322|NCT04184609|DRUG|Albuterol|180 mcg of Albuterol will be administered before exercise
48150323|NCT06598891|PROCEDURE|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
48150324|NCT06598891|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
47991891|NCT01764568|BEHAVIORAL|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
47991892|NCT05488691|BEHAVIORAL|EMDR|The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.
47991893|NCT05488691|BEHAVIORAL|TAU|treatment as usual for substance use disorders
47991894|NCT04941456|OTHER|Open Tracheostomy|Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
47991895|NCT04941456|DEVICE|PMV in place|Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.
47991896|NCT03159481|BEHAVIORAL|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
47991897|NCT05955118|DEVICE|Hydrus Microstent|Hydrus Microstent placed at the time of cataract surgery
47991898|NCT03345667|DRUG|lucentis|Use of lucentis and other anti-vegf in patients with diabetic retinopathy
47991899|NCT04001881|OTHER|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
47991900|NCT04001881|DRUG|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
47991901|NCT02133287|DEVICE|AVI® Arsenic trioxide drug eluting stent delivery system|
48150325|NCT02175017|DRUG|ONO-4538|
48150326|NCT04543188|DRUG|PF-07284890|PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
48150327|NCT04543188|DRUG|Binimetinib|Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
48150328|NCT04543188|DRUG|Midazolam|Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
48150329|NCT01185340|DRUG|LY2216684|
48150330|NCT01185340|DRUG|Placebo|
48150331|NCT01185340|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
48150332|NCT01406041|BIOLOGICAL|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
48150333|NCT06299540|BEHAVIORAL|Individual Physical Activity Intervention (IPAI)|No drug will be administered as a part of this study. The intervention will consist in an IPAI provided to participants for 6 months to practice physical activity in addition to their medical treatment in routine clinical practice settings. IPAI will be an adaptive program and will comprise two periods, the first period consisting in a supervised 4-month program and the second one in an unsupervised 2-month program to achieve greater autonomy.
48150334|NCT06299540|DRUG|Ibrutinib|No drug will be administered as a part of this study. Participants received ibrutinib as per their routine clinical practice settings.
48150335|NCT01752816|BEHAVIORAL|exercise training|
48150336|NCT00043459|DRUG|intravenous T900607-sodium|
48150337|NCT05190289|OTHER|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
48676140|NCT01103856|BEHAVIORAL|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
47991902|NCT02133287|DEVICE|Firebird2® sirolimus eluting stent system|
48150338|NCT01653392|BIOLOGICAL|Observational Intervention|This is an observational study, therefore no interventions are specified.
48150339|NCT05780957|OTHER|MCED|multi-cancer early detection (MCED) test
48150340|NCT04515576|DRUG|LY3493269|Administered SC
48150341|NCT04515576|DRUG|Dulaglutide|Administered SC
48150342|NCT04515576|DRUG|Placebo|Administered SC
48150343|NCT02465632|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
48150344|NCT02465632|DRUG|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
48150345|NCT02465632|DRUG|Placebo|
47991903|NCT05459922|DEVICE|Wearable bright light therapy device|Light treatment glasses (Re-timer®) will be used to deliver bright light therapy. This device is available commercially and allows participants to freely move around while receiving light from LEDs positioned below the eyes. Re-timer® can be worn over glasses and does not interfere with vision, reading, or computer work.
48150346|NCT03162835|OTHER|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
48150347|NCT01175980|OTHER|Laboratory Biomarker Analysis|Correlative studies
48150348|NCT01175980|DRUG|Vorinostat|Given PO
48362452|NCT03914924|BEHAVIORAL|Lifestyle Education Program|"On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week."
48362453|NCT05818202|OTHER|Questionannire|The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
48150349|NCT05549713|PROCEDURE|Upper blepharoplasty|Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
47991904|NCT05459922|DEVICE|Wearable placebo light therapy device|The placebo Re-timer® emits light intensity to a level that will not impact sleep and circadian timing and appears identical to the original Re-timer®.
48150350|NCT02779127|OTHER|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
48150351|NCT02779127|OTHER|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
48150352|NCT02779127|OTHER|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
48150353|NCT02779127|OTHER|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
48150354|NCT02779127|OTHER|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
48150355|NCT04099576|OTHER|physiotherapy and education|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
48510814|NCT05128760|DIAGNOSTIC_TEST|characterization of aPL|characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
47991905|NCT01696994|OTHER|Laboratory Biomarker Analysis|Correlative studies
48150356|NCT04099576|OTHER|Physiotherapy alone|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
48150357|NCT04610606|BEHAVIORAL|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of \>1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
48362454|NCT06123962|PROCEDURE|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
48362455|NCT00863135|DEVICE|CPAP|continuous positive airways pressure
48362456|NCT00863135|DEVICE|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
48362457|NCT06477523|DRUG|AK104|IV infusion
48676141|NCT01103856|BEHAVIORAL|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
48676142|NCT03632096|RADIATION|Photobiomodulation|The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
48676143|NCT03632096|RADIATION|Sham|The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
48676144|NCT06036199|DEVICE|Focused Ultrasound Pallidotomy|Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
48676145|NCT05214066|DRUG|Rabbit ATG|ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
48676146|NCT00606489|DRUG|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
48676147|NCT00606489|DRUG|Placebo|Placebo
48676148|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;
48676149|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
48676150|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
48676151|NCT02143349|DIETARY_SUPPLEMENT|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
48676152|NCT02143349|OTHER|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
48676153|NCT03816787|PROCEDURE|Negative pressure therapy|Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
48676154|NCT00783432|DRUG|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
48676155|NCT00783432|DRUG|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
48676156|NCT00002348|DRUG|Mitoguazone|
48676157|NCT04559061|DEVICE|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
48362458|NCT06477523|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
48676158|NCT00514930|DEVICE|Hexablate|
48676159|NCT00272792|DRUG|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
48676160|NCT00272792|DRUG|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
48676161|NCT01192126|DEVICE|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
47991906|NCT01696994|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
47991907|NCT01696994|PROCEDURE|Ultrasound Imaging|Undergo TVU
47991908|NCT02139527|DEVICE|Total Disc Replacement|
48362459|NCT06477523|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
48362460|NCT06477523|RADIATION|low-dose radiotherapy|"The subjects will receive LDRT, from C1D1-C1D5, once a day for 3Gy, until the target dose of 15Gy is achieved (Cycles 1).~LDRT treatment for primary/mediastinal positive lymph nodes/metastatic lesions during maintenance therapy (C1D1-C1D5, 15Gy)."
48362461|NCT01393561|DRUG|Group 1|Brompheniramine + phenylephrine
48362462|NCT01393561|DRUG|Group 2|Placebo
48510815|NCT06633705|DRUG|Vaginal Cream with Applicator|Vaginal Cream that contains estriol (1mg estriol in 1 g cream)
47991909|NCT00463749|DRUG|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
47991910|NCT00463749|DRUG|Placebo|NaCl as placebo
47991911|NCT04353154|DIAGNOSTIC_TEST|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
47991912|NCT03935373|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing.
47991913|NCT03935373|DIAGNOSTIC_TEST|Oral microbiome|The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome.
48676162|NCT01192126|DEVICE|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
48676163|NCT02269696|DRUG|Metoprolol|Intraoperative metoprolol infusion.
48676164|NCT02269696|DRUG|Normal saline|Equal of volume compared to metoprolol.
48676165|NCT05322278|OTHER|Data collection|No interventions
48676166|NCT02394158|DRUG|Metformin|
47991914|NCT03935373|DIAGNOSTIC_TEST|Proteomics|The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics.
47991915|NCT03935373|DIAGNOSTIC_TEST|RNA sequencing|The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing.
47991916|NCT03935373|DIAGNOSTIC_TEST|Cytokine|The serum of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
48362463|NCT03281239|DIAGNOSTIC_TEST|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~* laser doppler~* blood tests~* Holter ECG. No drug and no placebo were used in this arm."
48676167|NCT02394158|DRUG|placebo|
48676168|NCT03637491|DRUG|Avelumab|IV treatment
48676169|NCT03637491|DRUG|Binimetinib|Oral treatment
48676170|NCT03637491|DRUG|Talazoparib|Oral treatment
48676171|NCT05749471|DIAGNOSTIC_TEST|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of \> 19, any one item with a score of \> 5, or any three items with a score of \> 4 would have sexual dysfunction.
48676172|NCT00728156|DRUG|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
48676173|NCT00728156|DRUG|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
48676174|NCT03645538|OTHER|Parkinson's disease patients|"The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
48676175|NCT03645538|OTHER|No drug|The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
48150358|NCT02181179|BEHAVIORAL|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
48150359|NCT03740386|DRUG|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
48676176|NCT05634473|DRUG|Methacholine Chloride|Cholinergic agonists
48676177|NCT05970926|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the extremity arteries, which is non-invasive, and the parameters of arterial structure and blood flow will be measured.
48676178|NCT02062515|DRUG|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
48676179|NCT04093960|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
48676180|NCT02844985|OTHER|No Intervention|
48676181|NCT05035459|DIAGNOSTIC_TEST|lung ultrasound|drug adjustment based on lung ultrasound results
48159922|NCT04560192|BEHAVIORAL|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"1. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~2. Waiting period with TAU."
48362464|NCT05529030|BEHAVIORAL|Salience of Omicron variant|The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster
48362465|NCT05529030|BEHAVIORAL|Self-protection message|The message makes a reference to protecting one's self
48362466|NCT05529030|BEHAVIORAL|Other-protection message|The message makes a reference to protecting others (patients)
48362467|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
48362468|NCT00636116|BIOLOGICAL|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
48362469|NCT00636116|BIOLOGICAL|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
48362470|NCT04408716|PROCEDURE|Ablation Index Guided High-Power Short-Duration Strategy|Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
48676182|NCT05035459|DIAGNOSTIC_TEST|Lung ultrasound|drug adjustment independent on lung ultrasound results
48676183|NCT02701205|BIOLOGICAL|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
48676184|NCT02701205|BIOLOGICAL|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
48676185|NCT02701205|DRUG|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
48676186|NCT05411107|PROCEDURE|Biospecimen Collection|Undergo collection of sputum sample
48676187|NCT05411107|PROCEDURE|Bronchial Brush Biopsy|Undergo bronchial brush biopsy
48676188|NCT05411107|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
48676189|NCT05411107|DRUG|Iloprost|Given PO
48676190|NCT05411107|DRUG|Placebo Administration|Given PO
48362471|NCT04408716|PROCEDURE|Standard Radiofrequency Ablation Technique|Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
48362472|NCT01063699|PROCEDURE|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
48362473|NCT03814876|BEHAVIORAL|Group session psycho-education|Active comparator - control group
48362474|NCT03814876|BEHAVIORAL|FITS|Manualized family intervention
48676191|NCT05411107|OTHER|Questionnaire Administration|Ancillary studies
48676192|NCT00224081|DRUG|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
48676193|NCT01252589|OTHER|HRQOL questionnaire|
48676194|NCT03172273|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
48676195|NCT03172273|PROCEDURE|paracentesis|paracentasis plus albumine invision
48676196|NCT00852410|DRUG|1% lidocaine with 1:100,000 adrenaline|high dose
48150360|NCT03555656|BEHAVIORAL|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
48150361|NCT03555656|BEHAVIORAL|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
48150362|NCT00321555|DRUG|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
48150363|NCT04607889|OTHER|Survey|Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
48150364|NCT05448794|OTHER|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
48150365|NCT03853941|BEHAVIORAL|Intervention|Theory-based communication training programme delivered to healthcare professionals
48150366|NCT01654198|RADIATION|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
48150367|NCT01846156|DRUG|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
48362475|NCT01643109|OTHER|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
48362476|NCT03348644|DIETARY_SUPPLEMENT|Phosphate tablets.|
48676197|NCT00852410|DRUG|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
48676198|NCT01087593|DRUG|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
48676199|NCT01352286|GENETIC|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
48676200|NCT05910515|OTHER|Debriefing|Structured debriefing in non-technical skills. (This is an educational study)
48676201|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate venous blood sampling
48676202|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
48676203|NCT04608019|OTHER|Immediate Antibiotics|increase airway clearance/start oral antibiotics right away
48510816|NCT02204228|DEVICE|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
48676204|NCT04608019|OTHER|Tailored Treatment|increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
48150368|NCT03696563|DEVICE|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
48676205|NCT01057537|DRUG|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
48676206|NCT01057537|DRUG|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
48676207|NCT03423433|BEHAVIORAL|Heel raise intervention|A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
48676208|NCT00844103|DRUG|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
48676209|NCT00844103|DRUG|Placebo|10ml oral solution administered once a day over 10 days.
48150369|NCT03696563|OTHER|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
48362477|NCT03348644|DIETARY_SUPPLEMENT|High cheese intake.|
48362478|NCT03348644|DIETARY_SUPPLEMENT|High milk intake.|
48362479|NCT04063059|BEHAVIORAL|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
48676210|NCT01856322|DRUG|Sulindac|one tablet 150mg twice daily
48676211|NCT01856322|DRUG|Placebo|One tablet twice daily
48676212|NCT01856322|OTHER|Validate assays and shipping methods|
48676213|NCT01649713|DRUG|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
48510817|NCT00863772|BIOLOGICAL|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
48510818|NCT00863772|BIOLOGICAL|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
48150370|NCT01424345|DRUG|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
48150371|NCT01424345|DRUG|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
48150372|NCT00416858|DRUG|cisplatin|
48510819|NCT00863772|OTHER|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
48510820|NCT02047734|DRUG|Ozanimod|Oral capsule, daily for 24 months
48150373|NCT00416858|DRUG|fluorouracil|
48150374|NCT00416858|PROCEDURE|adjuvant therapy|
48510821|NCT02047734|DRUG|Ozanimod placebo|Oral capsule, daily for 24 months
48150375|NCT00416858|PROCEDURE|conventional surgery|
48150376|NCT00416858|PROCEDURE|neoadjuvant therapy|
48150377|NCT00416858|RADIATION|radiation therapy|
48510822|NCT02047734|DRUG|Interferon beta-1a|Intramuscular injection, 30 µg, weekly for 24 months
48510823|NCT02047734|DRUG|Interferon beta-1a placebo|Intramuscular injection, weekly for 24 months
48510824|NCT03283267|DRUG|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
48676214|NCT01070134|BEHAVIORAL|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
48362480|NCT01678469|OTHER|blood sample|
48362481|NCT05619939|DIETARY_SUPPLEMENT|Protein isolate|The indicated protein isolates will be given to subjects as their major protein source
48362482|NCT01986049|DRUG|Bupivicaine|
48362483|NCT01531244|BIOLOGICAL|dactinomycin|Given via ILI
48362484|NCT01531244|DRUG|melphalan|Given via ILI
48362485|NCT01531244|BIOLOGICAL|Conditionally replicative adenovirus 3/5-delta|Given via ILI
48362486|NCT00350610|OTHER|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
48362487|NCT00350610|BEHAVIORAL|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
48362488|NCT00025194|DRUG|estramustine phosphate sodium|
48362489|NCT00025194|DRUG|ixabepilone|
48362490|NCT05504811|DEVICE|FitMi AD|Exercise using the motion sensing devices and a tablet computer
48362491|NCT05504811|OTHER|Conventional exercise program|Exercise following printed sheets or booklet
48362492|NCT01229592|DRUG|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
48362493|NCT01229592|DRUG|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
48150378|NCT04243772|OTHER|Data extraction|Data extraction from medical files
48362494|NCT00028015|DRUG|SarCNU|
48362495|NCT04498949|BEHAVIORAL|UP|"The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)"
48676215|NCT01070134|BEHAVIORAL|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
48676216|NCT01773928|BIOLOGICAL|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
48676217|NCT01773928|BIOLOGICAL|VCIV manufactured with the current manufacturing process (VCIV current)|
48676218|NCT01773928|BIOLOGICAL|Fluzone®, licensed trivalent influenza vaccine (TIV)|
48362496|NCT04498949|OTHER|Treatment as usual|Diagnostic test. Psychoeducation Supoortive care
48362497|NCT05577351|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System paired with a single-use, disposable tubing set specific for use with the RapidPulseTM Aspiration System
48676219|NCT02800733|DIETARY_SUPPLEMENT|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
48676220|NCT02800733|DIETARY_SUPPLEMENT|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
48676221|NCT03457714|BEHAVIORAL|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
48676222|NCT03457714|OTHER|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
48362498|NCT04613687|DEVICE|Compression bandage|Compression bandage URGO BD001 for the management of venous leg ulcers with ABPI (Ankle Brachial Pressure Index) ≥ 0.8, venous
48362499|NCT04514705|OTHER|Exercise|Exercise with treadmil and weight training station
48676223|NCT05002348|DEVICE|Laser acupoint stimulation(Laser pen)|Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
48676224|NCT04764721|DEVICE|18F-FDG PET-CT|Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
48362500|NCT01696396|DRUG|Abrilumab|Administered by subcutaneous injection.
48510825|NCT06050343|DRUG|Humulin® Regular|subcutaneous injection at a dose of 0.3 IU / kg
48510826|NCT06050343|DRUG|Rinsulin® R|subcutaneous injection at a dose of 0.3 IU / kg
48510827|NCT04831424|BEHAVIORAL|Trier social stress test|The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.
48510828|NCT05607745|OTHER|FMT and placebo|Similar healthy diet counseling is given to all participants in both FMT and placebo group. FMT to placebo is given in 2:1.
48676225|NCT00888225|PROCEDURE|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
48676226|NCT00888225|PROCEDURE|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
47991917|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pattern.
47991918|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine tongue diagnosis.
48150379|NCT05072795|BEHAVIORAL|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
48150380|NCT02408978|DRUG|OXP005|
48150381|NCT02408978|DRUG|Naproxen|
48676227|NCT05017623|DRUG|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
48676228|NCT02870465|PROCEDURE|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
48676229|NCT01525823|DRUG|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
48676230|NCT01525823|DRUG|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
48676231|NCT03596671|DEVICE|RENOVA iStim™ System|Tibial implantable neuromodulation device
48676232|NCT05057013|DRUG|HMBD-001|Participants with advanced solid tumours will receive their assigned dose level of HMBD-001 diluted in 0.9% sodium chloride, administered once a week as a 120-minute intravenous (IV) infusion. Cycles are 28 days with no break in between; administration may continue for up to 6 cycles but may continue for longer if the participant is deemed to be benefitting.
48676233|NCT05057013|DRUG|HMBD-001 and enzalutamide|Participants with metastatic castration resistant prostate cancer (mCRPC) confirmed as HER3 positive with no PTEN loss or with a NRG1 fusion rearrangement will receive the HMBD-001 recommended Phase 2 dose (RP2D) as determined in Part A, diluted in 0.9% sodium chloride and administered once a week as a 120-minute IV infusion, in combination with enzalutamide administered at a fixed dose of 160 mg once daily, in 28-day cycles with no break between cycles. Immediately before commencing combination therapy, participants may receive one 28-day cycle of enzalutamide monotherapy to confirm that their disease does not respond to enzalutamide alone. HMBD-001 may be administered for up to 6 cycles; enzalutamide may be continued until disease progression or unacceptable toxicity.
48676234|NCT06169163|OTHER|Exhaled breath sampling|Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
48676235|NCT03706365|DRUG|Abemaciclib|Administered orally.
48676236|NCT03706365|DRUG|Abiraterone Acetate|Administered orally.
48676237|NCT03706365|DRUG|Prednisone|Administered orally.
48676238|NCT03706365|DRUG|Placebo|Administered orally.
48676239|NCT00445094|DRUG|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
48676240|NCT00445094|DRUG|Comparator: amikacin / Duration of Treatment: 3 Days|
48676241|NCT00445094|DRUG|Comparator: tazocin / Duration of Treatment: 3 Days|
48676242|NCT00445094|DRUG|Comparator: vancomycin / Duration of Treatment: 3 Days|
48150382|NCT05188248|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
48676243|NCT02131311|DEVICE|disposable, single-use pessary|
48676244|NCT05180513|BEHAVIORAL|Teleconference Mindfulness Intervention|The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.
48150383|NCT04314102|OTHER|No intervention will be made.|No intervention will be made. Only checks will be made
47991919|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pulse diagnosis.
48150384|NCT03829566|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
48150385|NCT03829566|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
48510829|NCT00006348|DRUG|ondansetron|
48676245|NCT05180513|BEHAVIORAL|Smartphone App Mindfulness Intervention|The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
48150386|NCT03829566|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
48150387|NCT03829566|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
48676246|NCT00012441|PROCEDURE|hemodialysis|
48676247|NCT05452252|DIAGNOSTIC_TEST|functional mandibular evaluation|Active mandibular movements including depression, protrusion, and left-right deviation, facial anthropometry was measured on facial shape on photograph, and phenotype and asymmetry
48676248|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
48676249|NCT02829996|DRUG|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
48676250|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
48676251|NCT02829996|DRUG|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
48150388|NCT03829566|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
48676252|NCT02829996|DRUG|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
48676253|NCT05074225|OTHER|Electrodesiccation and Curettage vs Excision|"Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS)."
48676254|NCT00002593|DRUG|fluorouracil|Given IV as described in Arm Description
48150389|NCT03829566|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
48676255|NCT00002593|DRUG|leucovorin calcium|Given IV as described in Arm description.
48150390|NCT03829566|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
48362501|NCT01696396|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
48510830|NCT00006348|OTHER|placebo|
48676256|NCT00002593|DRUG|levamisole hydrochloride|Given as described in arm description
48150391|NCT03829566|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
48676257|NCT06021808|PROCEDURE|Thoracoscopic LAA clipping|The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.
48150392|NCT01180400|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
48150393|NCT01180400|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
48150394|NCT04127513|DRUG|Ammonium Lactate|12% ammonium lactate moisturizing cream
48150395|NCT04127513|DRUG|Urea|10% urea moisturizing cream
48362502|NCT01766401|DRUG|Placebo|
48362503|NCT01766401|DRUG|Vilazadone|Viibryd
48362504|NCT00039546|DRUG|cyclophosphamide|
48362505|NCT00039546|DRUG|epirubicin hydrochloride|
48362506|NCT00039546|DRUG|gemcitabine hydrochloride|
48362507|NCT00039546|DRUG|paclitaxel|
48362508|NCT00039546|PROCEDURE|adjuvant therapy|
48362509|NCT03524586|PROCEDURE|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
48362510|NCT03524586|PROCEDURE|Contralateral rotation of head|Contralateral rotation of head against fixed tube
48510831|NCT00396565|DRUG|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
48676258|NCT06021808|DRUG|Novel oral anticoagulant|For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
48150396|NCT01857245|OTHER|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
48150397|NCT02288572|DIETARY_SUPPLEMENT|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
48150398|NCT02288572|DIETARY_SUPPLEMENT|Placebo|Taking dietary supplement on a daily basis for 3 months.
48676259|NCT03246087|DEVICE|Acupunture|"acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
48150399|NCT01707277|OTHER|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
48676260|NCT03246087|OTHER|Standard of care|standard of care home exercise program
48676261|NCT04419545|DIAGNOSTIC_TEST|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
48676262|NCT04676893|DRUG|D418 Tab.|1T
48676263|NCT04676893|DRUG|CKD-388 Tab.|1T
48676264|NCT00752492|OTHER|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
48676265|NCT04087356|GENETIC|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
48676266|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
48676267|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
48676268|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
48676269|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
48676270|NCT03714607|DEVICE|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
48676271|NCT04317235|DRUG|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
48150400|NCT01707277|OTHER|Usual care|Usual pahramacological treatment
48150401|NCT02028390|DEVICE|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
48150402|NCT02028390|DEVICE|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
48150403|NCT02028390|DEVICE|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
48676272|NCT04300387|BEHAVIORAL|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
48676273|NCT02656836|OTHER|Home tonometry, diagnostic study|Evaluating intraocular pressure
48676274|NCT02471313|DRUG|[18F] FMISO|\[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
48676275|NCT02282228|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
48510832|NCT00396565|DRUG|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
48510833|NCT00396565|DRUG|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
48676276|NCT02136043|DEVICE|PBASE system 1.1 (active treatment)|
48676277|NCT00710944|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
48676278|NCT02339805|OTHER|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
48150404|NCT02028390|DEVICE|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
48150405|NCT02028390|DEVICE|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
48510834|NCT04934059|DRUG|Yuxuebi tablet|0.5g/ tablet
48676279|NCT02339805|DEVICE|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
48510835|NCT04934059|DRUG|Placebo tablet|0.5g/ tablet
48510836|NCT02836314|OTHER|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
48676280|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
48676281|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
48676282|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
48676283|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
48676284|NCT02101398|DEVICE|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
48362511|NCT02409966|PROCEDURE|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
48362512|NCT02409966|PROCEDURE|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
48510837|NCT02836314|OTHER|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
48510838|NCT02216097|DRUG|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
48676285|NCT01685814|DRUG|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
47991920|NCT03935373|DIAGNOSTIC_TEST|Heart rate variability|Sjögren's syndrome patients and health subjects will take the heart rate variability.
48676286|NCT01685814|BIOLOGICAL|autologous stem cell transplant|
47991921|NCT03935373|DIAGNOSTIC_TEST|Schirmer's test|Sjögren's syndrome patients will take the Schirmer's test.
48676287|NCT01685814|BIOLOGICAL|allogeneic stem cell transplant|
48676288|NCT04679038|BIOLOGICAL|SHR-1701|Intravenous (IV) on Day 1 of each cycle
48676289|NCT04679038|DRUG|Famitinib|Famitinib, po, qd
48676290|NCT06042426|DRUG|Dexamethasone|Two 8 mg doses. One dose applied prior to incision and the other at POD1
48150406|NCT03991052|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
48676291|NCT06042426|DRUG|Morphine|Morphine 0.1 mg per kg intravenous every 6 hours
48676292|NCT06042426|DRUG|Oxycodone and acetaminophen|2 tabs of oral oxycodone combined with acetaminophen every 6 hours (the same pill includes both drugs)
47991922|NCT03935373|DIAGNOSTIC_TEST|Blood function test, liver function test, kidney function test, and immune function test|Sjögren's syndrome patients and health subjects will take the blood function test (WBC, RBC, Hb, HCT, Platelet, MCV, MCH, and MCHC), liver function test (AST and ALT), kidney function test (BUN and Cre), and immune function test (RF, Anti-SSA, Anti-SSB Ab, ESR, and CRP)
48150407|NCT03991052|DEVICE|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
48150408|NCT03117218|DIAGNOSTIC_TEST|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
48150409|NCT03458416|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
48510839|NCT02216097|DRUG|Placebo|Matching placebo tablet taken once daily for 7 days.
48676293|NCT00670566|DRUG|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
48676294|NCT02494154|DEVICE|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
48510840|NCT00796107|DRUG|RG1507|R1507 was administered at a dose 16 mg/kg every 3 weeks.
48510841|NCT00796107|DRUG|Letrozole|Letrozole was administered orally at a dose 2.5 mg daily.
48510842|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
48676295|NCT02494154|DEVICE|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
48676296|NCT02946346|OTHER|vaginal sampling|
48150410|NCT01074996|DRUG|S-1|40-60mg bid , days 1-14, every 3 weeks
48150411|NCT01074996|DRUG|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
48150412|NCT01448993|DRUG|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
48150413|NCT01448993|DRUG|Placebo|
48362513|NCT03241485|DRUG|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
48362514|NCT03241485|DRUG|Placebo|Saline intrathecal given in the same manner as the intervention groups.
48362515|NCT06355024|DRUG|Inosine|oral inosine 200mg tid
48362516|NCT06355024|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
48362517|NCT03576456|DRUG|Alprazolam 0.5 mg|receive alprazolam prior to angio
48676297|NCT05847647|OTHER|Retrograde Filling Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
48676298|NCT05847647|OTHER|Retrograde Filling+L-PRF Group|2. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
47991923|NCT01640483|OTHER|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
47991924|NCT04087707|DRUG|Step 1: TS-142|Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
47991925|NCT04087707|DRUG|Step 2: TS-142|Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
48362518|NCT03576456|DRUG|Placebo Oral Tablet|receive placebo prior to angio
48362519|NCT04060589|OTHER|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
48362520|NCT04060589|OTHER|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
48676299|NCT05847647|OTHER|(Orthograde Filling Group / OG Group).|3. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
48510843|NCT00817518|DRUG|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
48676300|NCT05847647|OTHER|(Orthograde Filling+L-PRF Group|4. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
47991926|NCT04087707|DRUG|Step 2: Placebo|Elderly participants will receive placebo once daily for 7 consective days
47991927|NCT00006028|DRUG|cisplatin|
48510844|NCT03006302|DRUG|Epacadostat|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Epacadostat (100, 300, or 600 mg) is taken by mouth twice a day, every day.
48510845|NCT03006302|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on day 1 of Cycles 1-6.
48510846|NCT03006302|BIOLOGICAL|CRS-207|CRS-207: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 10\^9 CFU) will be administered IV on Day 2 of Cycles 3-6.
48676301|NCT00198471|DRUG|Vitrase|
47991928|NCT00006028|DRUG|gemcitabine hydrochloride|
47991929|NCT02730325|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
47991930|NCT02730325|OTHER|Placebo|
48362521|NCT04060589|OTHER|Urine Donation|Urine will be collected prior to prostate biopsy
47991931|NCT03747432|DRUG|Propofol|Procedural sedation during TAVR procedure using propofol
47991932|NCT03747432|DRUG|Dexmedetomidine|Procedural sedation during TAVR procedure using dexmedetomidine
48362522|NCT04060589|OTHER|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
48362523|NCT02197351|PROCEDURE|White light biopsy|Endoscopy with biopsies guided by high definition white light
48150414|NCT03697018|OTHER|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
48150415|NCT06035627|OTHER|Prevention hypothermia|Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
48676302|NCT04836442|OTHER|Alcohol-PTSD-PFI (AP-PFI)|Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
48676303|NCT04836442|OTHER|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
48676304|NCT05305898|DRUG|Metformin|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
48676305|NCT04470297|DRUG|Ramelteon 8mg|Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
47991933|NCT01059474|DRUG|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
47991934|NCT05982054|PROCEDURE|core decompression with local bone marrow mononuclear cells injection|under local anesthesia ,anterior approach, with ultrasound and fluoroscopy guide
48150416|NCT03861884|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessment and MRI at 3T and/or 7T
48150417|NCT05795283|DRUG|Citalopram i.v. and p.o|"Citalopram:~i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28"
48150418|NCT05795283|DRUG|Citalopram p.o|"Citalopram:~p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28"
48150419|NCT04823156|DIETARY_SUPPLEMENT|Calcium|Daily calcium food supplement.
48150420|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
48150421|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
48150422|NCT05974631|BEHAVIORAL|Prolonged Exposure therapy|Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
48150423|NCT05974631|BEHAVIORAL|Suicide risk management|Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
48150424|NCT01659697|BEHAVIORAL|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
48150425|NCT04535440|OTHER|No intervention|No intervention
48362524|NCT02197351|PROCEDURE|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
48510847|NCT03006302|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m\^2) will be administered IV on day 1 of Cycles 1 and 2.
48676306|NCT02712996|DRUG|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
48676307|NCT02712996|DRUG|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
48150426|NCT00545922|BEHAVIORAL|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
48150427|NCT00545922|BEHAVIORAL|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
48150428|NCT03988855|DRUG|DNV3837|Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
48362525|NCT02197351|PROCEDURE|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
48362526|NCT02249377|OTHER|Platelets-Rich-Plasma|Platelet-Rich Plasma
48676308|NCT02321605|BEHAVIORAL|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
48676309|NCT02321605|BEHAVIORAL|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
48676310|NCT00641732|DRUG|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
48362527|NCT02249377|DRUG|Corticosteroid|Corticosteroid
47991935|NCT01820754|DRUG|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
48362528|NCT00758316|OTHER|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
48362529|NCT00758316|PROCEDURE|Thoracoscopy|Talc poudrage
48362530|NCT03770936|DRUG|Candesartan|Candesartan 8 mg/day
48362531|NCT03770936|DRUG|Ramipril|ramipril 1.25 mg/day
48362532|NCT05011110|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
48362533|NCT01359813|DRUG|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
48362534|NCT04005924|OTHER|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
48362535|NCT00743041|BEHAVIORAL|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
48362536|NCT05940051|DRUG|Zanubrutinib, Polatuzumab vedotin and Rituximab|Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m2 ivgtt D1
48362537|NCT00540228|BIOLOGICAL|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
48362538|NCT00540228|BIOLOGICAL|Fluarix™|Single dose, Intramuscular injection
48362539|NCT03700866|PROCEDURE|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
48362540|NCT05564364|DEVICE|Recumbent Bike|The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
48362541|NCT05564364|DEVICE|Upright Bike|The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
48362542|NCT03362827|OTHER|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
48362543|NCT03362827|OTHER|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
48362544|NCT05326672|DRUG|Benvitimod Cream|Benvitimod cream, 1%, applied twice daily for 8 weeks after enrolment.
48362545|NCT05326672|DRUG|Placebo|Placebo, applied twice daily for 8 weeks after enrolment.
47991936|NCT01820754|DRUG|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
48362546|NCT06317298|DRUG|Fruquintinib and Everolimus|Fruquintinib and Everolimus
48362547|NCT04823858|PROCEDURE|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
48362548|NCT02215915|PROCEDURE|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
48362549|NCT02215915|PROCEDURE|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
47991937|NCT00001053|BIOLOGICAL|HIV p17/p24:Ty-VLP|
48362550|NCT02215915|PROCEDURE|DES implantation|
48362551|NCT05280223|DRUG|Dexmedetomidine|injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydrodissection
48362552|NCT05280223|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
48362553|NCT06042764|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
48362554|NCT02268942|DEVICE|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
48362555|NCT02268942|PROCEDURE|Thoracotomy|Thoracotomy implant technique
48362556|NCT02677506|PROCEDURE|Supraclavicular|Brachial plexus block with supraclavicular approach
48676311|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
47991938|NCT00001053|BIOLOGICAL|Aluminum hydroxide|
47991939|NCT00605813|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
48362557|NCT02677506|PROCEDURE|Infraclavicular|Brachial plexus block with infraclavicular approach
48362558|NCT00993694|DRUG|chemotherapy|
48150429|NCT06473194|PROCEDURE|general anesthesia drug (like Propofol, esmeron, and ketamin, .effects of pneumoperitoneum|this research will involve the selection of elective cases with ASA class I or II and assessment of patients with respiratory cardiovascular parameters and hematology perioperative
48150430|NCT03493906|OTHER|Patient Ambassador Support|Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
48150431|NCT00955097|DRUG|Definity®|Definity® injections given both pre-ablation and post-ablation
48362559|NCT00993694|DRUG|dapsone|
48150432|NCT06340191|OTHER|Pilates with cueing|"The Pilates with a cueing component of the intervention involved a specialized approach to Pilates training. Participants in this group underwent an initial phase of training before the main sessions began, which consisted of two smaller group sessions focused on learning explicit verbal and tactile cues. These cues were designed to assist participants in maintaining proper body alignment, engaging specific muscle groups more effectively, and refining their movement techniques to enhance the overall efficacy of the Pilates exercises.~During the actual Pilates sessions, the instructors, who were certified and brought extensive experience to the program, provided real-time feedback to the participants. This feedback was based on the cueing instructions, aiming to optimize the execution of the Pilates exercises."
48150433|NCT06340191|OTHER|Pilates without cueing|"The Pilates without cueing portion of the study involved participants following the same comprehensive Pilates program as the Pilates with cueing group, with a significant distinction: they did not receive any additional training on cueing. This group engaged in 60-minute Pilates sessions twice a week for 8 weeks, under the supervision of certified and highly experienced Pilates instructors. The program included a variety of exercises, both mat-based and utilizing props, designed to improve participants\&#39; physical condition and wellness.~However, unlike their counterparts in the first group, these participants were not given explicit instructions on how to enhance their body alignment, muscle engagement, or movement techniques through verbal and tactile cues. They performed the Pilates exercises following the standard regimen, without the nuanced guidance and real-time feedback focused on optimizing exercise execution through cueing."
48150434|NCT00623844|BEHAVIORAL|physical activity|activity program at kindergarten 5 \* 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
48362560|NCT00993694|OTHER|medical chart review|
48362561|NCT00993694|PROCEDURE|assessment of therapy complications|
48362562|NCT01917799|DRUG|Aspirin|75mg tab of LDA once daily for 7 months
48362563|NCT01917799|DRUG|Heparin|0.4 mL/day of the Enoxaparin
48362564|NCT05511636|OTHER|Oxygen therapy|This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
48362565|NCT00001126|DRUG|Cidofovir|
48362566|NCT05231551|PROCEDURE|Placental tissues|Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
47991940|NCT05851859|OTHER|Cardiac coherence|Use of Cardiac coherence (complementary respiratory training) during 6 month
47991941|NCT05780333|PROCEDURE|TAP block|Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
48362567|NCT00656981|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
47991942|NCT05780333|PROCEDURE|ESP block|Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
48362568|NCT00656981|DRUG|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
48362569|NCT02365311|PROCEDURE|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
48362570|NCT00959192|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
48362571|NCT00959192|OTHER|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
48362572|NCT00959192|OTHER|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
48510848|NCT03006302|BIOLOGICAL|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). GVAX will be administered on Day 2 of Cycles 1 and 2.
48510849|NCT05341830|BEHAVIORAL|Recovery housing|Recovery housing provides housing and other services to individuals who are recovering from substance-use disorders. They provide a substance-free living environment, as well as services to assist residents with life in recovery. These services include connections to employment and educational opportunities, help obtaining documentation such as a driver's license, connection to mutual aid, and assistance building life skills.
47991943|NCT00364884|DRUG|ketoaminoacid|
47991944|NCT03179995|DRUG|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
47991945|NCT03179995|OTHER|Placebo|Normal saline will be administered in the same fashion as Octreotide
47991946|NCT03019939|DRUG|Isavuconazole|Given PO or IV
47991947|NCT02738333|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
47991948|NCT02738333|DRUG|SOF|400 mg tablet administered orally once daily
48362573|NCT01944462|BEHAVIORAL|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
48362574|NCT03445780|DRUG|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
48362575|NCT03445780|PROCEDURE|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
48362576|NCT03445780|PROCEDURE|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
47991949|NCT02738333|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
47991950|NCT00014209|DRUG|cisplatin|
47991951|NCT00014209|DRUG|dexamethasone|
47991952|NCT00014209|DRUG|gemcitabine hydrochloride|
47991953|NCT05306301|DRUG|Ponatinib|Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
47991954|NCT01103609|DRUG|Warfarin|Oral tablet od on Day 4
47991955|NCT01103609|DRUG|Placebo|Oral tablet bd, stepwise increased
48150435|NCT05796271|DRUG|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
48150436|NCT04103476|COMBINATION_PRODUCT|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
48150437|NCT04103476|OTHER|Placebo|Placebo
48150438|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Test drug|oral, once
48150439|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug|oral, once
48362577|NCT03389659|DRUG|vitamin D3|vitamin D3 400IU\*5pills po. qd continue to disease progression
48362578|NCT03389659|DRUG|Placebo|placebo 5 pills po. qd continue to disease progression
48362579|NCT06166394|DRUG|Spinal hypobaric Mepivacaine Local Anesthetic Injection|• Administration of a hypobaric spinal mixture for Day-Surgery patients: 3.4ml of 1.5% mepivacaine created by 3ml 2% mepivacaine with 1ml sterile water, and then discarding 0.6ml
48362580|NCT06166394|DRUG|Spinal hypobaric Bupivacaine Local Anesthetic Injection|"Administration of a hypobaric spinal mixture for In-patients:~3ml of 0.33% bupivacaine created by 2ml 0.5% bupivacaine with 1ml sterile water"
48362581|NCT03059576|OTHER|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~* Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~* Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~* Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
48362582|NCT01297621|PROCEDURE|reduction mammaplasty|conventional reduction mammaplasty
48362583|NCT01297621|OTHER|control|follow up, questionnaire responses
48362584|NCT04327245|OTHER|Intervention ingest a 5000 mg of D-tagatose|"Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids."
48676312|NCT00641732|DRUG|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
48676313|NCT00641732|DRUG|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
48676314|NCT00641732|DRUG|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
48676315|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
47991956|NCT01103609|DRUG|AZD1656|Oral tablet bd, stepwise increased
47991957|NCT03371992|DRUG|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
47991958|NCT03371992|DIAGNOSTIC_TEST|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
47991959|NCT03371992|OTHER|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
47991960|NCT00483808|DEVICE|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
47991961|NCT03697668|DRUG|Imatinib|triple combination for the treatment of malaria
47991962|NCT03697668|DRUG|Dihydroartemisinin-piperaquine|standard malaria treatment
47991963|NCT05194618|DIETARY_SUPPLEMENT|Valerian - lavender|1 tablet per day, half hour before bedtime, day 1 to day 28
47991964|NCT05194618|DIETARY_SUPPLEMENT|Placebo|1 tablet per day, half hour before bedtime, day 1 to day 28
48362585|NCT04327245|OTHER|Intervention ingest a 15,3 mg of stevia|"Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
48676316|NCT00641732|DRUG|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
48676317|NCT01082614|DEVICE|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV \> 12%.
48676318|NCT03068897|DRUG|Metaxalone|Metaxalone 400-800mg
48676319|NCT03068897|DRUG|Tizanidine|Tizanidine 2-4mg
48676320|NCT03068897|DRUG|Baclofen|Baclofen 10-20mg
48676321|NCT03068897|DRUG|Ibuprofen 600 mg|Ibuprofen
48676322|NCT03068897|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
48676323|NCT00504439|DRUG|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
48676324|NCT00504439|DRUG|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
48676325|NCT00504439|DRUG|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
48150440|NCT02830893|DEVICE|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
48150441|NCT02830893|BEHAVIORAL|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
48150442|NCT00883272|DIETARY_SUPPLEMENT|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
48150443|NCT05125614|OTHER|No adjuvant chemotherapy|There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.
48510850|NCT01617252|DEVICE|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
48676326|NCT00410189|DRUG|ZD6474|300 mg by mouth daily for 28 Days.
48676327|NCT04877860|OTHER|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement."
48676328|NCT04877860|OTHER|Multimodal rehabilitation program + traditional biomedical information|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment."
48676329|NCT04877860|OTHER|Control group|Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
48676330|NCT05489211|DRUG|Datopotamab deruxtecan (Dato-DXd)|Intravenous (IV) Antibody drug conjugate
48676331|NCT05489211|DRUG|Capecitabine|Administered orally
48676332|NCT05489211|DRUG|5-Fluorouracil|Administered as an IV
48676333|NCT05489211|DRUG|Volrustomig|Administered as an IV
48676334|NCT05489211|DRUG|Carboplatin|Administered as an IV
48150444|NCT01911819|PROCEDURE|Sinus augmentation|
48150445|NCT01911819|DRUG|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
48676335|NCT05489211|DRUG|Leucovorin LV|Administered as an IV
48676336|NCT05489211|DRUG|Bevacizumab|Administered as an IV
48676337|NCT05489211|DRUG|Rilvegostomig|Administered as an IV
48150446|NCT01911819|DRUG|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
48150447|NCT01911819|DRUG|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
48150448|NCT03037736|DRUG|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
48150449|NCT03037736|DRUG|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
48150450|NCT03037736|DRUG|Normal saline|Normal saline will be used as the placebo.
48150451|NCT05196256|PROCEDURE|Dural puncture|Dural puncture with a 25 Gauge needle without injection of local anesthetics into the dural space
47991965|NCT02986568|PROCEDURE|Cervical cancer|"If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size \< 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
48362586|NCT03943394|OTHER|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
48362587|NCT06284772|OTHER|Questionnaire and fecal sampling|The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
48362588|NCT06284772|OTHER|Health examination|This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.
48362589|NCT03365531|OTHER|Alternate Daily Fasting (ADF)|See ADF arm for details
48362590|NCT03365531|OTHER|Caloric Restriction (CR)|See CR arm for details
48362591|NCT05871008|OTHER|Assessment tool IA3-CP with SDoH|Each patient randomly assigned to IA3-CP with SDoH study arm will complete a pre-visit assessment tool including SDoH. Feedback is provided to provider and patient.
48362592|NCT05871008|OTHER|Assessment tool IA3-CP without SDoH|Each patient randomly assigned to IA3-CP only study arm will complete a pre-visit assessment tool excluding SDoH. Feedback is provided to provider and patient.
48362593|NCT05455723|PROCEDURE|Tracheal Intubation|Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
48362594|NCT04963738|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a single SC injection.
48362595|NCT04390334|DRUG|Daridorexant|Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.
48676338|NCT05489211|DRUG|Prednisone/ prednisolone|Administered orally
48676339|NCT05489211|DRUG|Cisplatin|Administered as an IV
48676340|NCT05085483|DIETARY_SUPPLEMENT|Nutritional Ketogenic Supplement|This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
48676341|NCT05085483|DIETARY_SUPPLEMENT|Isocaloric placebo supplement|Isocaloric placebo supplement
47991966|NCT02986568|PROCEDURE|Uterine cancer|"Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
47991967|NCT02986568|PROCEDURE|Cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy."
48150452|NCT05196256|PROCEDURE|Combined spinal epidural analgesia|Standard epidural preceded by a dural puncture with a 25G sequential needle and intrathecal injection of 2.5 ug of Sufentanil and 2.5 mg of normobaric Levobupivacaine
48676342|NCT04991493|DRUG|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
48150453|NCT05196256|PROCEDURE|Epidural analgesia|Epidural analgesia
48150454|NCT05196256|DRUG|Sufentanyl/Levobupivacaine|Epidural analgesia
48150455|NCT00041639|DRUG|hMN14 (labetuzumab)|
48150456|NCT00939211|DRUG|AZD9164|Solution for inhalation through nebulization, single dose
48150457|NCT00939211|DRUG|Tiotropium|Dry powder for inhalation, single dose
48150458|NCT00939211|DRUG|Placebo|Placebo
48362596|NCT04390334|DRUG|Famotidine|Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.
48362597|NCT04390334|DRUG|Efavirenz|Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
48362598|NCT01373294|DRUG|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
48362599|NCT01373294|DRUG|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
48676343|NCT04991493|OTHER|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
48676344|NCT02881775|DEVICE|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
48676345|NCT02881775|DEVICE|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
48362600|NCT04193137|DIAGNOSTIC_TEST|Oral sodium loading test,Seated saline infusion test and Captopril challenge test|"Oral sodium loading test : Patients received 6g oral sodium every day for 3 days.~Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Captopril challenge test: Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 2 h. Blood samples were drawn at time zero and 2 h after the challenge."
48362601|NCT00396266|DRUG|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
47991968|NCT02986568|PROCEDURE|Non-cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type."
48362602|NCT00998933|DRUG|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
48362603|NCT03026764|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
48362604|NCT03026764|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
48362605|NCT02269709|DEVICE|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
48510851|NCT02859142|DRUG|Chantix|Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
48510852|NCT02859142|BEHAVIORAL|Behavioral Counseling Sessions|One-to-one behavioral counseling sessions with a trained therapist
48510853|NCT02859142|DRUG|NicodermCQ|Nicotine patches provided over 12 week participation
47991969|NCT02109614|DRUG|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
47991970|NCT02109614|DRUG|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
47991971|NCT03068247|DRUG|Duloxetine|10 week treatment
47991972|NCT03068247|DRUG|Placebo|10 week treatment
47991973|NCT00067366|BEHAVIORAL|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
47991974|NCT00067366|BEHAVIORAL|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
47991975|NCT02955979|OTHER|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
47991976|NCT02423538|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
47991977|NCT02423538|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
47991978|NCT04760366|OTHER|fascial- muscular lengthening therapy|"Patients in this group will receive interventional therapy~To perform this technique:~1. Have the patient in side lying position~2. Hip is maximally flexed to shorten the iliopsoas muscle.~3. Therapist fingers should be on to the targeted area.~4. Apply gentle pressure in upward direction.~5. While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~6. Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~   * Hot pack for 15 minutes.~  * Myofascial release of iliopsoas.~  * TENS for 15 minutes."
47991979|NCT04760366|OTHER|Stretching's of iliopsoas muscle|"Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~1. modified lunge position.~2. The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~* Hot pack for 15 minutes.~* Myofascial release of iliopsoas~* TENS for 15 minutes."
47991980|NCT04760366|OTHER|the conventional therapy|the conventional therapy
47991981|NCT02711046|PROCEDURE|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
47991982|NCT03128346|PROCEDURE|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
47991983|NCT03128346|DRUG|Hydromorphone Hydrochloride|IV, Hydromorphone
47991984|NCT03128346|DRUG|Aspirin|Oral Aspirin
47991985|NCT03128346|DRUG|Acetaminophen|Oral acetaminophen
48510854|NCT02859142|DRUG|Placebo|Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
48510855|NCT00224471|BIOLOGICAL|GSK208141 vaccine|3 IM doses
48676346|NCT06378437|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
48510856|NCT06632886|DIAGNOSTIC_TEST|AI-Assisted Non-Contrast CT for Multi-Cancer Screening|Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
48676347|NCT03460652|DRUG|KP415 oral capsule|Once-daily oral dose
48676348|NCT01816425|DEVICE|Thermoplastic partial denture|
48676349|NCT01816425|DEVICE|CoCr partial denture|
48676350|NCT06487234|DEVICE|Functional band|Participants will wear the functional band for 1-hour electroacupuncture stimulation
48676351|NCT06487234|DEVICE|Placebo band|Participants will wear the nonfunctioning band for 1-hour with no electroacupuncture stimulation
48676352|NCT04691037|DIAGNOSTIC_TEST|CCTA|All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
48676353|NCT02566811|PROCEDURE|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
48676354|NCT02566811|PROCEDURE|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
48676355|NCT06111638|GENETIC|Single dose intravenous injection of BBM-H803|Single dose intravenous infusion of BBM-H803, an adeno-associated viral (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII transgene in liver. The dose of BBM-H803 will be calculated according to participant's weight.
48676356|NCT00836394|DEVICE|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
48676357|NCT00856323|DRUG|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
48676358|NCT00856323|BEHAVIORAL|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
48676359|NCT03828760|BEHAVIORAL|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
48676360|NCT03128489|BIOLOGICAL|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
48676361|NCT03935178|DIAGNOSTIC_TEST|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
48676362|NCT03280693|DIAGNOSTIC_TEST|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
48676363|NCT04646577|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
47991986|NCT03128346|DRUG|Fentanyl|IV, fentanyl
47991987|NCT03899376|RADIATION|Volumetric modulated arc therapy|VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk
47991988|NCT03899376|RADIATION|conventional radiotherapy|Radiotherapy focus on pelvis area
47991989|NCT05128877|OTHER|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
48510857|NCT04521738|DRUG|SAR441255|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
48676364|NCT04646577|DEVICE|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
48676365|NCT01537315|DRUG|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
48676366|NCT01537315|OTHER|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
48676367|NCT05741723|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
48676368|NCT03134859|BEHAVIORAL|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
48676369|NCT05547386|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48676370|NCT05547386|DRUG|Gallium Ga 68 Gozetotide|Given IV
48676371|NCT05547386|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48676372|NCT03659110|BIOLOGICAL|HPV 4|1000 subjects will be received the HPV 4 vaccine
48676373|NCT04143581|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg/die for 28 days
48676374|NCT02868424|DRUG|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
48676375|NCT05807373|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
48676376|NCT03745638|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
48676377|NCT03745638|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
48676378|NCT00394576|BEHAVIORAL|Internet-based nutrition module along with usual care|usual care plus Internet-based nutrition module
48676379|NCT00394576|BEHAVIORAL|usual care|usual care
47991990|NCT01978665|DRUG|prednisone|similar size tablets
48150459|NCT01688388|PROCEDURE|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
48150460|NCT06375317|DRUG|PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets|"PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses."
48150461|NCT00576485|PROCEDURE|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
48362606|NCT01422395|PROCEDURE|Freezing|Vitrification
48676380|NCT00648648|DRUG|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
48676381|NCT00648648|DRUG|gemcitabine|Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
48676382|NCT00648648|DRUG|cisplatin|Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
48676383|NCT00648648|DRUG|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
48676384|NCT05820048|DRUG|Lansoprazole 15 mg|"1. Short-term treatment of active duodenal ulcer~2. Short-term treatment of active benign gastric ulcers~3. Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~4. Maintain duodenal ulcer after treatmentLaw~5. Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~6. Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~7. Short-term treatment of gastroesophageal reflux disease~8. Short-term treatment of erosive reflux esophagitis~9. Post-treatment maintenance therapy for erosive reflux esophagitis~10. Pathological hyperdivision, including Zolinger Ellison syndrome"
48362607|NCT04703712|PROCEDURE|Lens extraction combined with goniosynechialysis|The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.
48362608|NCT04703712|PROCEDURE|Trabeculectomy surgery|The patients enrolled underwent trabeculectomy surgery
47991991|NCT03233958|BEHAVIORAL|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation \[Hunger, Weinhold, Bornhäuser, Link, \& Schweitzer, 2015\].
47991992|NCT03366402|DIAGNOSTIC_TEST|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
47991993|NCT04011527|PROCEDURE|Rotational Atherectomy in Coronary Lesion/s|
48362609|NCT03497975|DRUG|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
48362610|NCT03497975|OTHER|Matching Placebo Tablets|Matching Tablets with no active substance
48362611|NCT03497975|DRUG|Nalbuphine ER Tablets|Open Label Extension
48362612|NCT01539720|DRUG|Ulipristal acetate|30 mg tablet
48362613|NCT01539720|DEVICE|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
48362614|NCT02522091|DEVICE|functional brain MRI|
48362615|NCT02522091|OTHER|Neuropsychology tests|
48676385|NCT02597530|DEVICE|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
48676386|NCT06093399|DEVICE|System ON|The DBS system will be turned on, and the individual's stutter will be assessed.
48676387|NCT06093399|DEVICE|System OFF|The DBS system will be turned off, and the individual's stutter will be assessed.
48676388|NCT05521009|OTHER|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
48676389|NCT05066126|BEHAVIORAL|Mixed-Presentation of Content|Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
48676390|NCT03082677|DRUG|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
48362616|NCT04706715|OTHER|89Zr-DFO-REGN3767|Anti-LAG-3 PET imaging tracer
48362617|NCT04706715|DRUG|Cemiplimab|Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
48362618|NCT06148181|DRUG|ABBV-141|Infusion; intravenous (IV)
48362619|NCT06148181|DRUG|Placebo for ABBV-141|Infusion; IV
48362620|NCT06148181|DRUG|ABBV-141|Injection; subcutaneous (SC)
48362621|NCT06148181|DRUG|Placebo for ABBV-141|Injection; SC
48362622|NCT02763605|OTHER|no intervention|
48362623|NCT05998603|DIETARY_SUPPLEMENT|High protein intake|The participants received a 60g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
48362624|NCT05998603|DIETARY_SUPPLEMENT|Moderate protein intake|The participants received a 20g whey protein bolus each evening prior to sleep pre and post a military load carriage test.
48362625|NCT05998603|DIETARY_SUPPLEMENT|Carbohydrate maltodextrin placebo|The participants received an isocaloric carbohydrate bolus each evening prior to sleep pre and post a military load carriage test.
48362626|NCT05998603|OTHER|Control no supplementation|Control group, no supplementation, only basic training
48676391|NCT03634111|PROCEDURE|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
48676392|NCT03634111|DRUG|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
48676393|NCT03634111|DRUG|Ropivacaine|Ropivacaine 0.25% 20 ml each side
48362627|NCT05379621|OTHER|COVID-19 infection|All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
48362628|NCT00426842|DRUG|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
48362629|NCT04747028|DIAGNOSTIC_TEST|Dmf score|A chart to calculate the caries index
48362630|NCT02671786|OTHER|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories \& 15-17 gms of proteins.
48362631|NCT06376201|DRUG|Amphotericin B cholesterol-sulfate complex for injection|"Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition)."
48362632|NCT01485185|DRUG|Gabapentin lower dose|Repeat, oral dose
48362633|NCT01485185|DRUG|Donepezil|Repeat, oral dose
48362634|NCT01485185|OTHER|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
48362635|NCT01485185|OTHER|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
48150462|NCT02575014|DRUG|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
48150463|NCT06299345|OTHER|Motor imagery training|MI for this study took the form of non-guided first-person mental practice. First-person imagery was explained to each participant where they imagined performing the target skill through their own eyes rather than if they were a bystander watching someone else do the task (third person).
48150464|NCT06299345|OTHER|NO motor imagery training|The participants performed the physical task only. It is a mirror tracing game that requires participants to trace a star shape viewed through a mirror, going as fast as possible while staying within the lines.
48150465|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
48150466|NCT06049758|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
48150467|NCT06049758|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
48150468|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
48150469|NCT02888353|DEVICE|Device: MRI|Perform MRI in patients with cardiac devices
48150470|NCT03686176|OTHER|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
48150471|NCT03694145|OTHER|In-Person Eye Examination|Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
48150472|NCT03665675|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
48150473|NCT03665675|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given intravenously
48150474|NCT05629806|DRUG|Metformin plus pioglitazone|After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
48150475|NCT05629806|DRUG|Acarbose|After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
48150476|NCT04583293|OTHER|No intervention|This study does not involve any intervention or new treatment.
48676394|NCT03051802|DEVICE|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
48676395|NCT02264743|DRUG|Femoston Conti|Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
48676396|NCT02264743|DRUG|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
48676397|NCT00110045|DRUG|caspofungin acetate|
48150477|NCT01605084|DRUG|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
48150478|NCT01605084|DRUG|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
48150479|NCT01605084|DRUG|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
48150480|NCT01605084|DRUG|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~* Didanosine + Stavudine~* Zidovudine + Stavudine~* Lamivudine + Emtricitabine"
48150481|NCT05387629|BEHAVIORAL|Education|Nursing students will be trained through social media.
48362636|NCT01485185|DRUG|Gabapentin higher dose|Repeat, oral dose
48676398|NCT02534883|DRUG|Misoprostol|To be place vaginally
48676399|NCT02534883|DRUG|Placebo|To be placed vaginally
48676400|NCT01165125|DRUG|FF / GW642444|200mcg/25mcg Novel DPI
48676401|NCT01165125|DRUG|ketoconazole|400mcg overencapsulated tablets
48676402|NCT01165125|DRUG|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
47991994|NCT00302042|BEHAVIORAL|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
48676403|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
48676404|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
48676405|NCT03578250|OTHER|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
48676406|NCT01265017|DRUG|Estradiol, medroxyprogesterone, hydrocortisone, GH|"* Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,"
48676407|NCT01265017|DRUG|Matching placebo|matching placebo
48676408|NCT04902391|OTHER|Health Services|The Acute Mental Health Care Bundle consists of 3 core elements, including: (1) ED triage, (2) ED assessment and care, and (3) follow-up care.
48676409|NCT03475342|DRUG|Tranexamic Acid|Ampoules and packaging for both arms will be identical in appearance.
48676410|NCT03475342|OTHER|Placebo|Ampoules and packaging for both arms will be identical in appearance.
48676411|NCT06351839|BEHAVIORAL|Sleep-Well despite persistent pain|The Sleep-Well program covers four overarching topics stretched over 7 group sessions (each lasting \~1.5 hours): 1) providing information about sleep physiology, causes of sleep problems, sleep habits and hygiene and use of sleep assessment methods (i.e., sleep diaries) for deciding sleep restriction schedules; 2) behavioural strategies through the application of stimulus control and sleep restriction; , 3) mental strategies by addressing and changing unhelpful (meta)cognitions that commonly occur in sleep and persistent pain conditions; and 4) strategies related to maintenance of good sleep and prevention of relapse. The program has been developed by Diakonhjemmet hospital in Oslo and includes a guideline for therapist and a workbook for patients (that includes home tasks for the participant).
47991995|NCT00302042|BEHAVIORAL|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
47991996|NCT01001507|PROCEDURE|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
48150482|NCT05730192|DEVICE|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
48150483|NCT01070199|BEHAVIORAL|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
48150484|NCT01070199|BEHAVIORAL|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
48362637|NCT04636333|BIOLOGICAL|Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
48676412|NCT06351839|BEHAVIORAL|TAU (treatment-as-usual)|The treatment-as-usual arm represents an active waiting-list arm as subjects receive standard care, which may involve some sleep assessment, rudimentary advice/education about sleep, and possibly also sleep medication. The type of sleep treatment this group receives during the waiting-list period will be recorded from the patients' journal.
48676413|NCT02765399|DRUG|Liraglutide|
48676414|NCT02765399|DRUG|Placebo|
48676415|NCT00815386|DEVICE|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
48676416|NCT05818826|DRUG|normal saline solution|Prepare 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group.
48676417|NCT05818826|DRUG|Hydrocortisone and normal saline solution|Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
48676418|NCT01495325|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
48362638|NCT04636333|BIOLOGICAL|Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
48510858|NCT04521738|DRUG|placebo|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
48676419|NCT01495325|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
48676420|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
48676421|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
48676422|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
47991997|NCT03669692|BEHAVIORAL|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
47991998|NCT03669692|BEHAVIORAL|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
47991999|NCT01328821|DRUG|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
48362639|NCT04636333|BIOLOGICAL|Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
48676423|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
48362640|NCT04636333|BIOLOGICAL|Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
48676424|NCT03420365|BEHAVIORAL|Aerobic exercise|30 minutes of either aerobic, or balance and coordination, or reading magazines
48676425|NCT00644826|BEHAVIORAL|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
47992000|NCT01328821|DRUG|CTP-499|400 mg immediate release capsule
47992001|NCT03540966|COMBINATION_PRODUCT|CapulinTM|a kind of camouflage agent
48362641|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
48362642|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
48676426|NCT03765047|BEHAVIORAL|Intervention Arm|"The physical activity intervention consists of:~1. School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~2. Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~3. PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~4. Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
47992002|NCT03540966|OTHER|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
47992003|NCT04294511|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
48362643|NCT04636333|BIOLOGICAL|Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Two doses of placebo (0.5ml) at the schedule of day 0, 14.
48150485|NCT01070199|BEHAVIORAL|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
48362644|NCT04636333|BIOLOGICAL|Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#|Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
48510859|NCT05986695|BEHAVIORAL|Alert|Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note
48510860|NCT05986695|BEHAVIORAL|Peer comparison report|Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.
48510861|NCT03656588|DRUG|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
48510862|NCT03656588|DRUG|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
48510863|NCT01593046|DRUG|GSK1265744 Oral|30mg tablet
48510864|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
48510865|NCT01593046|DRUG|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
48510866|NCT01593046|DRUG|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
48510867|NCT01593046|DRUG|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
48510868|NCT01593046|DRUG|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
48510869|NCT01593046|DRUG|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
48510870|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
48510871|NCT04206969|BEHAVIORAL|Transcultural psychotherapy|In addition to usual care, the participants receive transcultural psychotherapy
48510872|NCT02538380|PROCEDURE|EUS-B-FNA followed by EUS-FNA for LAG analysis|
48510873|NCT04602546|DEVICE|BIS Complete Monitoring System|The BIS™ EEG complete monitoring system is intended for use under the direct supervision of a licensed healthcare practitioner or by personnel trained in its proper use. The system and its associated parameters are intended for use on adult patients within a hospital or medical facility, providing patient care to monitor the state of the brain by data acquisition of EEG signals.
48510874|NCT04769531|OTHER|Hip Joint Mobilizations|i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
48676427|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
48676428|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
47992004|NCT04130230|DRUG|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
47992005|NCT04130230|DRUG|Standard therapy|Standard therapy for sepsis and septic shock
47992006|NCT05321615|DEVICE|Palpator|Palpator for tumor localization
48150486|NCT01070199|BEHAVIORAL|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
48150487|NCT05049174|BEHAVIORAL|Nuse-led interview and referral to municipal healthy life-centres|Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
48150488|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
48150489|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
48150490|NCT01739972|DRUG|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
48150491|NCT01739972|DRUG|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
47992007|NCT05321615|DEVICE|Grasper|Atraumatic lung grasper
47992008|NCT05321615|DEVICE|Ultrasound|VATS ultrasound
47992009|NCT05321615|OTHER|Finger palpation|Palpation of the lung/tumour using the surgeon's finger
47992010|NCT02385084|DRUG|LY2409021|Administered orally
47992011|NCT00957073|DEVICE|Rheos® system|Implant procedure
48150492|NCT05610878|BIOLOGICAL|Cultured ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat
47992012|NCT03970733|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
47992013|NCT03970733|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
47992014|NCT03205410|PROCEDURE|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
47992015|NCT03205410|PROCEDURE|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
47992016|NCT00507754|OTHER|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
47992017|NCT03343873|DRUG|Midazolam|Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
47992018|NCT03343873|DRUG|Propofol|Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
47992019|NCT03343873|DRUG|Dexmedetomidine|Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
47992020|NCT05507255|OTHER|Relaxation training|Relaxation training in the form of deep breathing exercises
48362645|NCT00006242|DRUG|BMS-214662|Given IV
48676429|NCT00439335|DRUG|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
48676430|NCT00439335|DRUG|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
48676431|NCT05730881|PROCEDURE|ECMO|VA-ECMO is a life support measures, we need to estimate the survival by different techniques to allocate therapeutic interventions properly
48676432|NCT00190736|DRUG|Atomoxetine Hydrochloride|
48676433|NCT00190736|DRUG|placebo|
48676434|NCT03785184|DRUG|venetoclax|tablet; oral
48676435|NCT03785184|DRUG|lenalidomide|capsule; oral
48676436|NCT03785184|DRUG|dexamethasone|tablet; oral
48676437|NCT06106893|BIOLOGICAL|CD19 Universal CAR-γδ T Cells|Intravenous infusion of CD19 Universal CAR-γδ T Cells
48676438|NCT00295607|DRUG|Tacrolimus|immunosuppression
48676439|NCT00295607|DRUG|steroids, monoclonal anti-IL2R antibody|immunosuppression
48676440|NCT00066339|DRUG|gefitinib|
48150493|NCT05610878|BIOLOGICAL|Curcumin-preconditioned ASCs enrichment fat grafting|Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat
48150494|NCT05610878|OTHER|Conventional fat grafting|Patients will undergo conventional fat harvesting and grafting of fat into recipient site
48510875|NCT04769531|OTHER|Hip joint Muscle strength training|i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
48676441|NCT04088968|BEHAVIORAL|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
47992021|NCT05507255|OTHER|An aerobic exercise program|An aerobic exercise program of a moderate intensity, based on the target heart rate (THR) that will be calculated in accordance with Karvonen's equation, using resting heart rate (HRrest), maximal heart rate (HRmax) and training fraction. THR = HRrest (bpm) + (HRmax (bpm) - HRrest (bpm)) × training fraction.The exercise session will have three phases, warming up, active phase and cooling down.
47992022|NCT03343808|PROCEDURE|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
47992023|NCT00183300|BEHAVIORAL|Prolonged Exposure Therapy|
47992024|NCT02059850|BIOLOGICAL|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
47992025|NCT02059850|DRUG|Cyclophosphamide|Given IV
47992026|NCT02059850|OTHER|Laboratory Biomarker Analysis|Correlative studies
48150495|NCT01017055|OTHER|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
48150496|NCT03717935|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) Supplement|Powder supplement
48150497|NCT03717935|OTHER|Placebo|Powder that will be similar to the essential amino acid supplement
48150498|NCT04532814|OTHER|Exercise|Cycling 60% VO2 max
48150499|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
48150500|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
48150501|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
48150502|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
48362646|NCT00006242|OTHER|laboratory biomarker analysis|Correlative studies
48362647|NCT00006242|OTHER|pharmacological study|Correlative studies
48676442|NCT00373607|DRUG|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
48676443|NCT00373607|DRUG|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
48676444|NCT03018158|DEVICE|denture wear.|MR Imaging was collected with or without denture wear.
48676445|NCT04179305|BEHAVIORAL|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
48362648|NCT00408031|DRUG|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
48362649|NCT03180268|OTHER|Clinical Observation|Undergo observation
48676446|NCT04179305|BEHAVIORAL|Usual Care Arm|Oncologists will provide care in non-specific manner.
48676447|NCT01082627|DRUG|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
48676448|NCT01082627|OTHER|common daily practice|common daily practice
48150503|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
48150504|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
48150505|NCT05634161|OTHER|Cognitive improvement software|Cognitive improvement software
48150506|NCT04182217|OTHER|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
48362650|NCT03180268|RADIATION|Radiation Therapy|Undergo radiation therapy
48362651|NCT03515031|DEVICE|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
48150507|NCT03204175|OTHER|FIT Plus|"* Group handwashing facilities~* Daily group handwashing and toothbrushing activities~* Sanitation operation and maintenance manuals for school officials~* Toilet cleaning consumable~* Toilet and handwashing station maintenance kits~* Soap, toothbrushes, and toothpaste"
48362652|NCT03515031|DEVICE|Venturi Mask Oxygenation|delivery of high flow oxygen
48362653|NCT05254964|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hour on every working 20 days (4 weeks) during the subacute stroke phase
48362654|NCT02372539|OTHER|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
48362655|NCT02372539|OTHER|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
48362656|NCT03307408|OTHER|blood collection|Standard routine practice clinico-biological data will be collected
48362657|NCT05897996|DEVICE|creation of vascular access for hemodialysis|endo-AVfs created with Wavelinq
48362658|NCT05384509|DIAGNOSTIC_TEST|solid organ malignancies treatment|Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Target therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
48676449|NCT03247634|BEHAVIORAL|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
48676450|NCT05647499|BEHAVIORAL|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
48676451|NCT01590368|DEVICE|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
48676452|NCT01590368|DEVICE|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
48676453|NCT03576261|OTHER|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
48676454|NCT03576261|DIAGNOSTIC_TEST|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
48676455|NCT05115435|BEHAVIORAL|neuro linguistic programming|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
48676456|NCT04289558|DRUG|Sodium Nitrite|Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
48676457|NCT05573139|DIAGNOSTIC_TEST|Assessment of muscle strength by manual dynamometry|The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
48676458|NCT06209489|OTHER|White cover|"* A white cover will be covered over the incubator during phototherapy.~* Baby massage will be applied during phototherapy."
48676459|NCT02869321|DRUG|Fentanyl|
48676460|NCT02869321|DRUG|Morphine Sulfate|
48510876|NCT04769531|OTHER|knee strengthening and flexibility exercises|"i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:"
48676461|NCT02869321|DRUG|Fentanyl placebo|
48362659|NCT00154986|PROCEDURE|immunohistochemical staining, transfection, invasion assay|
48676462|NCT02869321|DRUG|Morphine Sulfate placebo|
48362660|NCT00792324|DRUG|Etravirine|Four 100mg tablets daily for 12-24 weeks
48362661|NCT00792324|DRUG|Efavirenz|One 600mg tablet daily
48362662|NCT06131294|DEVICE|Fluoride Application (Experimental Fluoride Application)|Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.
48362663|NCT06131294|DEVICE|Fluor Protector S|Fluor Protector S is applied on white spot lesions.
48510877|NCT00338728|DRUG|Imatinib Mesylate|Given PO
48510878|NCT00338728|DRUG|Letrozole|Given PO
48510879|NCT00086593|DRUG|lamotrigine|
48676463|NCT02869321|PROCEDURE|Gastrostomy|
48676464|NCT02054975|DRUG|Vitamin D2 + vitamin D3|higher dose vitamin D
48676465|NCT02054975|DRUG|Vitamin D3|lower dose vitamin D
48510880|NCT01722422|DRUG|oxygen and saline|
48510881|NCT05096650|PROCEDURE|mesotherapy of platelet rich plasma and platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
48676466|NCT01326806|BEHAVIORAL|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
48676467|NCT01326806|BEHAVIORAL|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
48676468|NCT01709552|BEHAVIORAL|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
48150508|NCT03204175|OTHER|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
48362664|NCT00430703|BEHAVIORAL|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
48362665|NCT05482958|DEVICE|HOP watch|Prospective observational study
48362666|NCT02087085|DRUG|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
48676469|NCT01709552|BEHAVIORAL|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
48150509|NCT00554905|PROCEDURE|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
48150510|NCT00554905|PROCEDURE|TACE|TACE first, then RFA within 2 weeks
48676470|NCT00719992|PROCEDURE|coronary angiography|effect of level of HS-CRP
48150511|NCT04756986|DRUG|malic acid|1% malic acid spray
48150512|NCT06090760|BEHAVIORAL|Mindfulness|"Mindfulness is paying attention in a particular way: on purpose, in the present moment, and non-judgmentally (Kabat-Zinn 1994, 4) and has five facets: awareness, nonjudgement, nonreactive, observe, and describe (Baer et al., 2006)."
48150513|NCT00670449|DRUG|Fingolimod|Fingolimod was supplied in capsules.
48150514|NCT04692441|DIETARY_SUPPLEMENT|Heavy Cream|100 ml of dairy cream with 40.4g of total fat, to ingest orally
48150515|NCT05597033|BEHAVIORAL|Exercise|walking and handgrip exercise
48150516|NCT05597033|BEHAVIORAL|Control|seated rest
48150517|NCT00882323|DRUG|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
48150518|NCT05248672|DRUG|CT1812|Study Drug
48150519|NCT02784145|DIETARY_SUPPLEMENT|Resistant starch|
48150520|NCT02784145|OTHER|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
48150521|NCT00538499|DRUG|Fentanyl citrate|
48150522|NCT00538499|DRUG|Bupivacaine hydrocloride|
48150523|NCT00538499|PROCEDURE|videothoracoscopy|
48150524|NCT00637559|DRUG|Esomeprazole Magnesium|
48150525|NCT04651426|DEVICE|The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1|"The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm."
48150526|NCT03427177|BEHAVIORAL|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
48150527|NCT01637194|DRUG|everolimus|Given PO
48150528|NCT01637194|BIOLOGICAL|cetuximab|Given IV
48150529|NCT01637194|OTHER|pharmacological study|Correlative studies
48150530|NCT01637194|OTHER|laboratory biomarker analysis|Correlative studies
48150531|NCT06430606|PROCEDURE|Tint Time|Arterial blood gas was obtained immediately after intubation(Tint) in supine position. Ventilator parameters and hemodynamic parameters were recorded.
48150532|NCT06430606|PROCEDURE|T0 Time|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
48150533|NCT06430606|PROCEDURE|T1|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
48150534|NCT04462159|BEHAVIORAL|Risk Reduction Program|Education, exercise, teaching kitchen and nutrition, and psychological support
48150535|NCT01863082|OTHER|exercise|practice of physical exercise
48150536|NCT01783379|DRUG|micafungin|100mg/day infusion in 1 hour
48150537|NCT01599221|DEVICE|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
48150538|NCT03937089|OTHER|Data collection|Data collection from medical file
48150539|NCT02026583|DRUG|Simvastatin|
48150540|NCT01236898|DRUG|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
48150541|NCT06598774|OTHER|Assessment of head posture:|Head posture was assessed using photographic methods and craniovertebral angle
48150542|NCT06598774|OTHER|Assessment of Cervical Pain Pressure Threshold|The cervical PPTs were assessed using a mechanical pressure algometer (Baseline Force Gauge Model 12-0304; Baseline, NY, USA).
48150543|NCT06598774|OTHER|Assessment of general cervical mobility|Cervical mobility was assessed using the CROM (Cervical Range of Motion) deluxe device.
48150544|NCT06598774|OTHER|Assessment of upper cervical mobility|It will be assessed using the CROM device and the flexion-rotation test.
48150545|NCT06598774|OTHER|Assessment of Body Awareness|Body awareness will be assessed using a questionnaire designed to determine normal or abnormal sensitivity levels in body composition.
47992027|NCT06363656|DEVICE|Wears the smartwatch during the sleep time to capture sleep characteristics and answer questionaires|"* Synchronization of smartwatch with smartphone (internet connection) to send sleep characteristics captured by the application~* Weight~* Height~* Body measurements (circumferences)~* Questionnaires about overall health status~* Pittsburgh Sleep Quality Index questionnaire~* Insomnia Severity Index~* Sleep Hygiene Index~* Epworth Sleepiness Scale~* NoSAS score (Neck, Obesity, Snoring, Age, Sex)"
48150546|NCT02499991|BEHAVIORAL|memory|keep track of social events in diary for memory recall. Used by treatment group
48362667|NCT02087085|OTHER|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
48362668|NCT05534594|DRUG|18F-PSMA-1007|As explained under 'Arms'.
48362669|NCT00352794|DRUG|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
48362670|NCT00352794|DRUG|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
48362671|NCT04436406|DIAGNOSTIC_TEST|[99mTc]-NM-01 SPECT/CT|Technetium labelled anti-PD-L1 single-domain antibody (NM-01) single-photon emission computed tomography (SPECT)/CT
48362672|NCT01238757|OTHER|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
48362673|NCT01238757|OTHER|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
48362674|NCT00845533|DRUG|Dihydroartemisinin-Piperaquine|
48362675|NCT04998175|PROCEDURE|ventriculo-peritoneal shunt|A ventriculoperitoneal shunt is a tube that drains excess cerebrospinal fluid into abdomen
48362676|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
48362677|NCT03098992|DEVICE|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
48362678|NCT01852591|BIOLOGICAL|PCV 13|
48510882|NCT05146648|DEVICE|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
48510883|NCT04906421|DRUG|TVB-2640|Oral dose, tablet
47992028|NCT04265274|DRUG|Disulfiram|dosing 400mg daily
47992029|NCT04265274|DRUG|Vinorelbin|25mg/m2 day 1 and 8,
48150547|NCT00634348|DRUG|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
48150548|NCT00634348|DRUG|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
48362679|NCT00601510|DRUG|capecitabine|
48362680|NCT00601510|DRUG|cisplatin|
48510884|NCT04906421|OTHER|Placebo|Oral dose, tablet
48510885|NCT06236841|DRUG|XH-S004 tablet|XH-S004 tablets will be administered orally as per assigned treatment regimen on schedualed days.
48676471|NCT05726331|OTHER|Chiropractic Care|Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.
48676472|NCT05726331|OTHER|Tai Chi|Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.
48362681|NCT00601510|DRUG|imatinib mesylate|
48362682|NCT01795716|DRUG|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
48362683|NCT01795716|DRUG|Glivec|Single and multiple oral Glivec 400mg qd
48362684|NCT03273868|OTHER|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
48510886|NCT06236841|DRUG|XH-S004 placebo tablet|XH-S004 placebo tablet (matched) will be administered orally as per assigned treatment regimen on schedualed days.
47992030|NCT04265274|DRUG|Cisplatin|75mg/m2 day 1
48150549|NCT00353106|BEHAVIORAL|Interview|30-minute interviews of participating patients and their caregiver(s).
48362685|NCT03273868|OTHER|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
48362686|NCT04380480|COMBINATION_PRODUCT|Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy|"One or two weeks before CCRT, all patients will undergo a percutaneous endoscopic gastrostomy (PEG) to be administered enteral nutrition support(30-35 kcal/kg of energy, 1.2-1.5g/kg of protein and electrolyte supplementation each day). Nutritional supplements will be administered till 1 month after CCRT.~All patients will receive definitive radiotherapy combined with three cycles of S-1 (40mg/2, BID, po) on D1-14, D22-35, D43-56."
48510887|NCT05454670|PROCEDURE|Two-flap palatoplasty|Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
48510888|NCT01484327|DRUG|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
48510889|NCT05264129|DRUG|Atogepant|Oral Tablet
48510890|NCT05264129|DRUG|Ubrogepant|Oral Tablet
48510891|NCT04659759|OTHER|COVID-19 exposure|COVID-19 exposure during pregnancy
48510892|NCT04659759|BIOLOGICAL|COVID-19 vaccine|Receipt of any COVID-19 vaccine
47992031|NCT04265274|DRUG|Copper|2 mg of elementary Copper daily
47992032|NCT04098224|DEVICE|smART+ System|Utilizing the smART+ System to provide feeding optimization to the patient
47992033|NCT00671307|DRUG|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
47992034|NCT00671307|DRUG|Placebo|Vehicle control given as IV infusion over 1 hour
47992035|NCT00415909|DRUG|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
47992036|NCT00415909|DRUG|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
48510893|NCT03298217|DEVICE|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
48676473|NCT05726331|OTHER|Enhanced Usual Care|Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
47992037|NCT01557296|DIETARY_SUPPLEMENT|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
48150550|NCT00353106|BEHAVIORAL|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
48510894|NCT02695810|DRUG|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
47992038|NCT01557296|RADIATION|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
47992039|NCT01557296|OTHER|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
47992040|NCT01557296|BIOLOGICAL|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
47992041|NCT00002233|DRUG|Indinavir sulfate|
47992042|NCT00002233|DRUG|Abacavir sulfate|
47992043|NCT00002233|DRUG|Amprenavir|
47992044|NCT00002233|DRUG|Lamivudine|
47992045|NCT04244513|DEVICE|Deep brain stimulation|the HD-DBS arm will be routinely activated after surgery and then stimulated for 6 months(6 months stimulation). The HD-shamDBS arm will be re-launched 3 months after surgery, continued stimulation for 3 months(3 months stimulation), and then entered the open study.
47992046|NCT01173718|DEVICE|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
48150551|NCT01940913|DIETARY_SUPPLEMENT|Probiotic capsules|
48150552|NCT01940913|DIETARY_SUPPLEMENT|Placebo capsules|
48510895|NCT02695810|DRUG|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
48510896|NCT02695810|BEHAVIORAL|Exercise|Interval training, 5 times per week, 30 min per session
48510897|NCT04963153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48510898|NCT04963153|PROCEDURE|Bone Scan|Undergo bone scan
48510899|NCT04963153|PROCEDURE|Computed Tomography|Undergo CT
48510900|NCT04963153|PROCEDURE|Echocardiography|Undergo echocardiography
48676474|NCT04831437|RADIATION|Hypofractionated EBRT|EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
48676475|NCT04831437|RADIATION|Standard EBRT|EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
48676476|NCT03800030|DEVICE|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
48676477|NCT03800030|DEVICE|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
47992047|NCT00005010|DRUG|Irbesartan|
47992048|NCT00005010|DRUG|Pravastatin|
47992049|NCT04804943|DEVICE|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
47992050|NCT00039754|DRUG|Holmium-166-DOTMP|
47992051|NCT05188209|DRUG|MRG003|Administered intravenously
47992052|NCT00778011|DRUG|Ondansetron|dosage
47992053|NCT00778011|DRUG|Ondansetron|4 mg
47992054|NCT00778011|DRUG|Metoclopramide|10 mg IV
47992055|NCT01818076|DRUG|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
47992056|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with rhubarb root|TeTrimTeas welsh Herbal tea with green tea and rhubarb root
47992057|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with senna|TeTrimTeas welsh Herbal tea with green tea and senna
48150553|NCT05843149|BEHAVIORAL|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
48150554|NCT05843149|BEHAVIORAL|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
48150555|NCT01434355|OTHER|Laboratory Biomarker Analysis|Correlative studies
48676478|NCT03800030|DEVICE|Sham tACS|NeuroConn technologies, direct current-stimulator plus
48676479|NCT06391580|DEVICE|Poly-L-lactin Acid (PLLA) Based Facial Injectable|Poly-L-lactin Acid (PLLA) Based Facial Injectable
48676480|NCT02599480|DRUG|mirabegron|50 mg daily during 12 months
48676481|NCT02599480|PROCEDURE|Echocardiography|Echocardiography
47992058|NCT05862532|DIETARY_SUPPLEMENT|TeTrimTeas welsh Herbal tea with green tea|TeTrimTeas welsh Herbal tea with green tea
48150556|NCT01434355|OTHER|Questionnaire Administration|Ancillary studies
48150557|NCT04429672|BEHAVIORAL|The Right to your Sexual Health|which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
48150558|NCT04429672|BEHAVIORAL|Friendly sexual health services and reproductive for adolescents|consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
48150559|NCT05726097|DRUG|polyethylene glycol|colonic preparation
48150560|NCT05726097|DRUG|sodium phosphate|colonic preparation
48150561|NCT05726097|DRUG|polyethylene glycol + ascorbic acid|colonic preparation
48510901|NCT04963153|DRUG|Enfortumab Vedotin|Given IV
48510902|NCT04963153|DRUG|Erdafitinib|Given PO
48510903|NCT04963153|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48510904|NCT03829787|DEVICE|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
48510905|NCT04428450|DEVICE|Deprexis|CBT-based, integrative online self-help program
48510906|NCT00448383|BIOLOGICAL|adalimumab|40mg every other week
48510907|NCT01392625|BIOLOGICAL|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
48510908|NCT01392625|BIOLOGICAL|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
48510909|NCT04585230|DRUG|CBD|CBD oil Roll-On Stick
48676482|NCT02599480|PROCEDURE|Cardiac MRI|Cardiac MRI
48676483|NCT02599480|PROCEDURE|Maximal exercise capacity|Maximal exercise capacity
48676484|NCT02599480|PROCEDURE|Blood sampling|Blood sampling for study assessments and future exploratory studies.
48676485|NCT02599480|PROCEDURE|Endothelial function measurement|EndoPAT assessment
48676486|NCT02599480|RADIATION|18FDG-PET|PET scanning for beige/brown fat activation
48676487|NCT00560092|DRUG|intrathecal magnesium sulfate|intrathecal magnesium sulfate
48676488|NCT05480176|OTHER|Comprehensive intervention and management Ⅰ|Mainly health advisory.
48676489|NCT05480176|OTHER|Comprehensive intervention and management Ⅱ|Health advisory and regular follow-ups.
48676490|NCT05480176|OTHER|Comprehensive intervention and management Ⅲ|Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
48150562|NCT05726097|DRUG|gastrografin|colonic preparation
48150563|NCT05726097|DRUG|magnesiumoxid + sodium picosulfate|colonic preparation
47992059|NCT01709851|DEVICE|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
47992060|NCT01709851|DEVICE|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
47992061|NCT05715008|OTHER|Kefir|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
47992062|NCT05715008|OTHER|Placebo|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
47992063|NCT04508192|OTHER|Exercise|Both interventions are simple strength exercises without technical equipment
47992064|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
47992065|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
47992066|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
48510910|NCT04585230|DRUG|Mineral Oil|Mineral Oil- Roll on Stick
48510911|NCT04585230|DRUG|Placebo|Roll- On stick with no CBD and no Mineral Oil
48510912|NCT02740114|DRUG|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
48510913|NCT02740114|DRUG|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
48510914|NCT02740114|DRUG|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
48676491|NCT02235571|BEHAVIORAL|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
48676492|NCT00473889|DRUG|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
48676493|NCT00473889|DRUG|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
48676494|NCT00473889|DRUG|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
48676495|NCT00473889|DRUG|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
48150564|NCT05726097|DRUG|prucalopride|colonic preparation
48362687|NCT04439708|OTHER|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
48150565|NCT04996186|OTHER|Clinical interviews|Semi-qualitative interviews and questionnaire STAR-Q
48150566|NCT06600490|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
48150567|NCT02374294|DEVICE|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of \~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
48150568|NCT00237705|DRUG|metoclopramide|
48150569|NCT02813733|PROCEDURE|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
48150570|NCT01074229|DRUG|Placebo|placebo injection
48150571|NCT01074229|DRUG|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
48150572|NCT01074229|DRUG|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
48362688|NCT03226743|OTHER|collaborative and stepped care model|"Including elements:~* collaborative and stepped care of patients with mental disorders~* treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~* initial training of participating health care providers~* formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~* formalized ICD-diagnostics~* guideline-oriented treatment recommendations~* bibliotherapy or internet-based self-help for patient with mild to moderate disorders~* online referral platform~* case management for patients with severe disorders~* systematic and regular monitoring~* regular quality circles for participating health care providers"
48362689|NCT05110495|DRUG|Xentuzumab|The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
48362690|NCT00741910|DRUG|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
48510915|NCT02740114|BEHAVIORAL|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
48150573|NCT04864106|DEVICE|Endoscopic Examination|Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
48150574|NCT00323778|DRUG|Hyalgan|
48150575|NCT03699761|PROCEDURE|Closure of the pelvic peritoneum|Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
48362691|NCT00114400|DRUG|folic acid|
48362692|NCT00114400|DRUG|vitamin B12|
48510916|NCT02740114|BEHAVIORAL|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
48510917|NCT05954286|DRUG|Upamostat|Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
48150576|NCT03699761|PROCEDURE|Nonclosure of the pelvic peritoneum|Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
48150577|NCT06501508|DEVICE|Stratafix Symmetric|Use of Stratafix Symmetric for primary fascial closure
48150578|NCT00011102|BEHAVIORAL|Weight Gain Prevention for Women Project|
48150579|NCT05333757|OTHER|Questionnaire|Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
48150580|NCT05928494|OTHER|Scenario-based high-fidelity simulation method|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
48150581|NCT03543540|BIOLOGICAL|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
48150582|NCT03543540|BIOLOGICAL|Placebo|Placebo injections: 14 in total at twice weekly intervals
48150583|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
48150584|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
48150585|NCT06393855|PROCEDURE|single-step Trans-PRK|Both eyes were treated consecutively in each patient by single-step Trans-PRK performed by SCHWIND Amaris 500 S excimer laser platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Topical Proparacaine Hydrochloride Eye Drops 0.5% (Alcaine, Alcon, Fort Worth, TX, USA) were used to anesthetize the eyes, and use povidone-iodine to disinfect the eyelid skin. After a lid speculum had been inserted, and the other eye was blocked. Epithelial and stromal ablations were performed using a single continuous laser shooting session on an excimer laser platform. After the appeals step, Mitomycin C 0.02 % was applied to the stromal surface for 20 s, then rinse with cold salt water.
48362693|NCT00114400|DRUG|vitamin B6|
48362694|NCT03770078|DEVICE|Test Product A|The test product is a newly developed ostomy product
48362695|NCT04852809|OTHER|No intervention|This is an observational study
48362696|NCT04378049|PROCEDURE|Total knee arthroplasty|Surgeon will perform a total knee arthroplasty procedure according to local standard of care
48510918|NCT05954286|DRUG|Placebo (PO)|Oral Capsules
48510919|NCT03889080|DIAGNOSTIC_TEST|functional MRI|functional MRI scan of the brain
48510920|NCT01221389|DRUG|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
48510921|NCT04204473|DRUG|TY-9591(10mg,40mg) qd. po|Increased dose cohorts from low dose to MTD(20mg Cohort1, 40mg Cohort2, 80mg Cohort3,120mg Cohort4, 160mg Cohort5, 200mg Cohort6)
48510922|NCT03571386|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
48362697|NCT04378049|PROCEDURE|Robot-assisted partial knee arthroplasty|Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
48676496|NCT01476540|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
48676497|NCT03415503|DRUG|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
48676498|NCT05822154|OTHER|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
48676499|NCT05723744|DEVICE|ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias|"For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline"
48362698|NCT06428175|BEHAVIORAL|Focused Dose Hospital-to-Home Transitional Care Interventions|Focused dose H2H-TCIs will consist of a one-time post-discharge phone call completed within 72 hours post-hospital discharge by a clinical interventionist (e.g., nurse care coordinator or care manager). Calls will follow a structured template that provides empirically supported core H2H-TCI functions (follow-up care access, contingency planning, medication review, family education). The interventionist will also conduct a pre-hospital discharge clinical needs assessment with the parent.
48362699|NCT06428175|BEHAVIORAL|Extended Dose Hospital-to-Home Transitional Care Interventions|Extended dose H2H-TCIs will include a pre-discharge clinical needs assessment and initial phone call within 72 hours post-discharge, similar to the focused arm. After the initial contact, the dose of the extended H2H-TCI will increase as subjects receive high-intensity support during weekly post-discharge phone contacts through 30 days post-discharge. All contacts in the extended dose arm will be completed by a transition coach interventionist (e.g., nurse care coordinator or care manager) who will be formally trained on pillars of the Care Transitions Intervention© (CTI), a multi-faceted H2H-TCI that is the basis for the extended dose arm.
48362700|NCT00462657|GENETIC|polymerase chain reaction|
48510923|NCT03571386|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
48510924|NCT06125730|OTHER|DIME Beauty Eyelash Boost Serum|The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
48510925|NCT05554081|DEVICE|Peezy urine collection device|use peezy collection to obtain urine sample
48510926|NCT03961659|DRUG|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
48510927|NCT03961659|DRUG|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
48510928|NCT03961659|DRUG|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
48510929|NCT01510782|DRUG|Placebo to BI 655064|intravenous infusion of escalating doses
48510930|NCT01510782|DRUG|Placebo to BI 655064|subcutaneous injection of escalating doses
48510931|NCT01510782|DRUG|BI 655064|intravenous infusion of escalating doses
48676500|NCT05087498|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
48676501|NCT05087498|BIOLOGICAL|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
48676502|NCT05217459|DEVICE|Self-expanding intracranial drug stent system|All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
48676503|NCT04098302|DRUG|Dutasteride Capsules|1 mg/day oral dutasteride (2 x 0.5 mg capsules)
48676504|NCT04098302|DRUG|Placebo Capsules|Placebo capsules with matching appearance as Dutasteride Capsules
48676505|NCT01896830|BIOLOGICAL|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
48676506|NCT01896830|BIOLOGICAL|0.9% normal saline|0.5 mL, intramuscular
48676507|NCT03069508|DRUG|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
48676508|NCT04161690|DRUG|Dexketoprofen Trometamol|intravenous dexketoprofen 50mg or intrathecal
48676509|NCT04161690|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|Local Infiltration Analgesia
48676510|NCT01896687|DEVICE|Scrambler|Electrotherapy
48676511|NCT04412681|DIAGNOSTIC_TEST|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
48676512|NCT00165789|DRUG|E2007|
48676513|NCT04176107|BEHAVIORAL|Informative video|Exposure to informative video before cesarean delivery
48676514|NCT02644824|DEVICE|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
48676515|NCT05816746|DRUG|Low-Dose Decitabine plus anti-PD-1|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
48676516|NCT03506620|DRUG|Ropivacaine injection|Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
48150586|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.
48150587|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea,A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.
48510932|NCT01510782|DRUG|BI 655064|subcutaneous injection of escalating doses
48510933|NCT05418504|DRUG|Dental anesthesia|Dental anesthesia, used to do any dental procedure
48510934|NCT00111553|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
48510935|NCT02506829|BEHAVIORAL|Smoking cessation counseling (Quitline)|
48510936|NCT02506829|BEHAVIORAL|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
48150588|NCT04432909|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
48150589|NCT02865083|DEVICE|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
48510937|NCT02506829|BEHAVIORAL|Financial incentives|
48510938|NCT06323447|DIAGNOSTIC_TEST|PointCheck|Binary classification of severe neutropenia
48510939|NCT06387524|PROCEDURE|McConnell Taping|Begin with the patient in supine lying with the knee slightly bent. The knee should be completely relaxed and a foam roller or rolled up towel under the knee. Start the tape in line with the middle of the knee cap at the outer aspect of the knee. Using your thumb on top of the sports tape, gently push the patella towards the inner aspect of the knee whilst simultaneously using your fingers to pull the skin at the inner aspect of the knee towards the patella. Finish this taping technique at the inner aspect of the knee ensuring you have created some wrinkling of the skin at the inner aspect of the knee.
48676517|NCT03506620|DRUG|Saline Solution for Injection|20 cc of saline will be injected in the form of a QL block as a placebo.
48676518|NCT05896943|DRUG|Ustekinumab|Patients with ulcerative colitis treated with ustekinumab
48676519|NCT04578756|DRUG|Cariprazine Flexible Dose|1 capsule to be taken orally at approximately the same time of day (morning or evening)
48676520|NCT04578756|DRUG|Cariprazine Flexible Dose|Dose solution (in milliliters) to be taken orally at approximately the same time of day (morning or evening)
48676521|NCT01215656|DIETARY_SUPPLEMENT|Lactobacillus fermentum|
48676522|NCT01215656|DIETARY_SUPPLEMENT|Follow on formula without probiotics|
48676523|NCT05843331|PROCEDURE|implants|Four implants in the maxilla with locator attachments
48676524|NCT01206517|DRUG|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
48676525|NCT01206517|DRUG|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
48676526|NCT01206517|DRUG|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
48150590|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
48676527|NCT05249205|BEHAVIORAL|REHIT1|This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
48676528|NCT05249205|BEHAVIORAL|REHIT2|This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
48676529|NCT02666313|BEHAVIORAL|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.~Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
48676530|NCT04096586|OTHER|Red juice|To determine the effects of red juice on satiety and gut health
48676531|NCT04096586|OTHER|Watermelon juice|To determine the effects of watermelon juice on satiety and gut health
48676532|NCT05504759|OTHER|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
48676533|NCT05504759|OTHER|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
48676534|NCT05504759|OTHER|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
48676535|NCT03117114|DEVICE|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
48362701|NCT00462657|OTHER|bronchoalveolar lavage|
48362702|NCT00462657|OTHER|immunoenzyme technique|
48362703|NCT00462657|OTHER|laboratory biomarker analysis|
48362704|NCT00462657|PROCEDURE|bronchoscopy|
48362705|NCT00462657|PROCEDURE|management of therapy complications|
48362706|NCT01442545|DRUG|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
48362707|NCT00963820|DRUG|Ixazomib citrate|Ixazomib citrate capsules
48362708|NCT01782976|DRUG|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
48362709|NCT01782976|DRUG|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
48362710|NCT01782976|BEHAVIORAL|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
48362711|NCT00006493|DRUG|Rosiglitazone|
48362712|NCT01296464|DRUG|Carbidopa|Capsules
48676536|NCT03117114|OTHER|Standard polypectomy|Absence of an EVD, standard polypectomy
48676537|NCT05254756|DEVICE|Bouquet speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
48150591|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
48362713|NCT00464841|PROCEDURE|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
48362714|NCT00464841|PROCEDURE|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
48676538|NCT05254756|DEVICE|Traditional plastic 2-blade disposable speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
47992067|NCT02977988|BEHAVIORAL|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
47992068|NCT02977988|BEHAVIORAL|Brain and Recovery (B&R)|B\&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B\&R group will receive didactic education on the neurobiology of addiction. B\&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
47992069|NCT04179695|OTHER|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
47992070|NCT04179695|OTHER|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
47992071|NCT03348345|BEHAVIORAL|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
48362715|NCT05167955|BEHAVIORAL|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy|An online mindfulness-based cognitive intervention is used as a proposed treatment intervention for erectile dysfunction among African- Caribbean men based in the United Kingdom.
47992072|NCT02951156|BIOLOGICAL|Avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
47992073|NCT02951156|BIOLOGICAL|Utomilumab|Investigational, fully human IgG2 CD 137/4-1BB agonist
48362716|NCT02465957|BIOLOGICAL|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
48362717|NCT02465957|BIOLOGICAL|aNK (NK-92) + N-803|aNK - A natural killer cell line recovered from a patient with large granular lymphoma and N-803 - Recombinant human super agonist interleukin-15 (IL-15) complex
48510940|NCT06387524|PROCEDURE|ECCENTRIC EXERCISES:|"Performed for 6 weeks, in 3 sets of 10-12 repetitions each day. Detailed protocol is as under:~Warm up phase (5 minutes) It will comprise of following components 5 minutes warm up exercise protocol: Marching in place while swinging your arm, rotating toe touching, walking jacks, leg swings, arm circles, shoulder shrugs Eccentric exercises: Each of the following exercise will be performed for 30 seconds, repetitions and hold time will increase with increasing weeks according to patient's stamina.~Straight leg raise, side lying hip abduction, single leg bridging, supported double leg squatting, hip hikes,supported single leg squatting Following is the detailed description of Cool down phase: Hip stretch, cat cow stretch, oblique stretch, lower back stretch, calf stretch, cross body shoulder stretch"
48510941|NCT06010186|OTHER|Ultrasound measurement of the diaphragm and intercostals|"The specific research procedures correspond to the addition of :~* Two additional ultrasound examinations, i.e. at discharge from intensive care and 3 months after hospital discharge: non-invasive examination (duration 20 minutes). Ultrasound is a risk-free, painless procedure involving the placement of an ultrasound probe on the body part under investigation, without the need for a radius or puncture.~* Questionnaires to assess quality of life (SF-36) and functional impact (LCADL) of dyspnea, carried out at discharge from hospital and at 3 months (duration 15 minutes)."
48510942|NCT05959252|DRUG|Unfractionated heparin|Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
48510943|NCT05959252|DRUG|Bivalirudin|Bivalirudin protocol with target aPTT 50-70 seconds
48676539|NCT02619747|DRUG|Compound Sodium Alginate Oral Suspension sachet|
48676540|NCT02619747|DRUG|Matched placebo|
48676541|NCT01731847|PROCEDURE|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
48676542|NCT00955474|DRUG|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
48150592|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
48362718|NCT03639064|DRUG|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
48362719|NCT02738073|DRUG|Control: Saline|
48362720|NCT02738073|DRUG|Tranexamic Acid|
48362721|NCT05573204|DRUG|Obeticholic Acid Oral Tablet|Obeticholic acid used as 10 mg tablet once daily for 6 months
48362722|NCT05573204|DRUG|Vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
48510944|NCT05360485|BEHAVIORAL|MOV'D (Move Often eVery Day)|The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.
48510945|NCT05360485|BEHAVIORAL|Fitbit Self-Monitoring|All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
48510946|NCT03909282|PROCEDURE|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
48676543|NCT00955474|DRUG|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
48676544|NCT00955474|DRUG|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
48676545|NCT00955474|DRUG|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
48676546|NCT04196725|OTHER|Physical therapy treatment|Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging
48676547|NCT04196725|BEHAVIORAL|Lifestyle treatment|Two weeks rehabilitation programme focusing on physical activity
47992074|NCT02951156|BIOLOGICAL|Rituximab|CD20-directed cytolytic antibody
47992075|NCT02951156|OTHER|Azacitidine|Antimetabolite antineoplastic agent and demethylation agent.
47992076|NCT02951156|DRUG|Bendamustine|Alkylating drug
47992077|NCT02951156|DRUG|Gemcitabine|Nucleoside analogue
47992078|NCT02951156|DRUG|Oxaliplatin|Platinum-based drug
47992079|NCT03698747|DEVICE|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
47992080|NCT03309358|DRUG|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
47992081|NCT03309358|DRUG|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
47992082|NCT02963337|DRUG|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
47992083|NCT02963337|DRUG|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
47992084|NCT00882193|DRUG|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
47992085|NCT00882193|DRUG|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
47992086|NCT00882193|DRUG|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or \> 75mg in 2 divided doses
47992087|NCT01988831|DRUG|Propranolol hydrochloride|This intervention apply to Propranolol group
47992088|NCT01988831|DRUG|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
47992089|NCT03812887|DIAGNOSTIC_TEST|Photopatchtesting|Photopatchtesting to the sunscreen series and extended series, irradiated at both 24 and 48 hours
47992090|NCT02419742|DRUG|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams\*milliliter/minute \[mg\*mL/min\]) multiplied by (Glomerular Filtration Rate \[GFR\] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
47992091|NCT02419742|DRUG|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
47992092|NCT02419742|DRUG|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m\^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
47992093|NCT02419742|DRUG|Doxorubicin|Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
47992094|NCT02419742|DRUG|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m\^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
48676548|NCT00440817|OTHER|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
48676549|NCT04734158|OTHER|corneal imaging|corneal imaging using AS-OCT
48676550|NCT00570713|DRUG|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
48676551|NCT00570713|DRUG|Placebo|As per package insert.
48676552|NCT00570713|DRUG|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
47992095|NCT02419742|DRUG|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
47992096|NCT05336474|DIAGNOSTIC_TEST|Ultrasonographic upper airway measurements|Ultrasonographic upper airway measurements: Epiglottis-skin distance, Hyoid bone-skin distance, Anterior commissure-skin distance and Thickness of tounge
47992097|NCT01069146|PROCEDURE|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
47992098|NCT01148745|DRUG|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
48362723|NCT06366035|DEVICE|LoVE4MUM mobile application|LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
47992099|NCT03200496|DRUG|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
47992100|NCT03200496|DRUG|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
47992101|NCT03200496|DRUG|TALION®|Reference drug : Talion®
48362724|NCT02468076|DEVICE|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
48362725|NCT01143116|DEVICE|"Silver-nitrate coated catheter (Catheter A)"|Catheter A releases silver ions into the urethra and urinary bladder upon catheterization.
48362726|NCT01143116|DEVICE|"Degradable silver particle-coated catheter (Catheter B)"|Catheter B releases both silver ions and degradable silver particles into the urethra and urinary bladder upon catheterization.
48362727|NCT01811693|DRUG|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
48362728|NCT01811693|DRUG|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
48676553|NCT01123226|PROCEDURE|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
47992102|NCT04052984|PROCEDURE|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
48150593|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
48150594|NCT00150852|DRUG|Vancomycin|
48150595|NCT05728372|DRUG|Copper Cu 64-DOTA-pembrolizumab|Given IV
48150596|NCT05728372|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48150597|NCT05728372|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48150598|NCT01692652|DRUG|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
48362729|NCT01811693|DRUG|Glycerly Trinitrate|0.4 mg sublingual single metered spray
48676554|NCT01123226|PROCEDURE|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
48676555|NCT03982017|OTHER|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
48676556|NCT03982017|OTHER|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
48676557|NCT03286192|BEHAVIORAL|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
48676558|NCT04187261|PROCEDURE|hip fracture surgeries|fixation or replacement
48676559|NCT03579758|DRUG|Capecitabine|Given PO
48676560|NCT03579758|DRUG|Cisplatin|Given IV
48676561|NCT03579758|DRUG|Gemcitabine|Given IV
48676562|NCT02234440|DRUG|Metformin|
48676563|NCT02234440|DRUG|Insulin|
47992103|NCT00289809|DRUG|combination of TLC D-99 and Ifosfamide|"* TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~* Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
47992104|NCT05068128|OTHER|Flow MRI|"4 flow acquisitions based on the 2D cine phase contrast sequence (present on all MRI systems) will be performed.~This sequence requires a cardiac synchronization by a plethysmograph put on the patient's finger.~32 cardiac phases are reconstructed per acquisition. The processing of the flow MRIs and the analysis of the flow curves of the LCS and blood during the cardiac cycle will be performed using the Amiens software.~Parameters measured via flow MRI are:~- Cerebral vascular flow, intracranial LCS dynamic volume, extracranial LCS dynamic volume"
47992105|NCT05068128|OTHER|PERFUSION TEST|"The test will be performed will include:~* Inserting a needle into the lumbar space, Ommaya reservoir or valve pre-chamber, as appropriate~* Connect the needle to the pressure transducer via saline filled manometer lines connected via a 3-way valve. The other end of the 3-way connection will be connected to a saline~* Recording of the opening pressure for 10 minutes~* The infusion test is terminated either when the pressure stabilizes again on a new plateau, or when the average pressure exceeds 40 mmHg, or in case of adverse effects or symptoms such as headache, nausea/vomiting or visual disturbances.~* At the end of the test, a depletion of 30 to 50 mL of CSF will be performed.~* The pressure recording during the test is then used to calculate the parameters of the mechanical properties of the CSF circulation and reported to the neurosurgeon ordering the test."
47992106|NCT04059679|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
47992107|NCT04059679|DRUG|Aspirin 81 mg|EC aspirin 81 mg qd
47992108|NCT02802592|DRUG|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
47992109|NCT02802592|DRUG|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
47992110|NCT03094845|BIOLOGICAL|Placebo solution|15 injections over 7 weeks
47992111|NCT03094845|BIOLOGICAL|hdmASIT+TM|15 injections over 7 weeks
47992112|NCT01351844|BEHAVIORAL|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
48150599|NCT01692652|OTHER|warm compress only group|
48362730|NCT00551681|DEVICE|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
48676564|NCT05494268|DRUG|Carbohydrate|Preoperative Carbohydrate Loading Drink
48676565|NCT03186625|DRUG|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
48676566|NCT03186625|DRUG|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
48676567|NCT03901638|DRUG|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
48676568|NCT03901638|DRUG|Placebo|Placebo
48676569|NCT05613907|OTHER|CLTI Clinic|This is a specialist clinic designed to assess and manage patients with CLTI.
48150600|NCT00535626|DEVICE|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
48676570|NCT00529269|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
48676571|NCT03500289|DRUG|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
48676572|NCT03500289|DRUG|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
48362731|NCT00551681|DEVICE|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
48676573|NCT01738061|BEHAVIORAL|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
48676574|NCT05853588|OTHER|training|On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
48676575|NCT02622477|DRUG|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
48676576|NCT02862977|DRUG|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
47992113|NCT01351844|BEHAVIORAL|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
48510947|NCT03909282|RADIATION|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
48676577|NCT02862977|DRUG|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
48676578|NCT02125344|DRUG|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
47992114|NCT03885713|BIOLOGICAL|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)) per clinical practice or tofacitinib (oral 5mg bid)
47992115|NCT04358848|DEVICE|X-PLO2R|Portable Oxygen Concentrator (POC)
47992116|NCT03479307|DRUG|Bilastine Ophthalmic Solution 0.6%|1 drop in each eye at 2 separate times during an 8 day period.
47992117|NCT03479307|DRUG|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|1 drop in each eye at 2 separate times during an 8 day period.
47992118|NCT03479307|DRUG|Vehicle of Bilastine Ophthalmic Solution|1 drop in each eye at 2 separate times during an 8 day period.
48362732|NCT03995979|OTHER|4 Day Protein Restricted Diet|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
48362733|NCT01957033|BEHAVIORAL|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
48362734|NCT01957033|BEHAVIORAL|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
47992119|NCT03852303|DRUG|ivermectin|evaluate effect of ivermectin on frequency of seizures
47992120|NCT03816085|OTHER|Shoes|Shoes with different heel heights
47992121|NCT01517009|DRUG|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
48676579|NCT02125344|DRUG|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
48676580|NCT02125344|DRUG|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
48676581|NCT02125344|DRUG|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
48676582|NCT02125344|DRUG|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
48676583|NCT02125344|DRUG|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
48676584|NCT02125344|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
47992122|NCT01517009|DRUG|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
47992123|NCT01517009|DRUG|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
48676585|NCT02125344|DRUG|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
48150601|NCT05555199|RADIATION|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
48150602|NCT05555199|DRUG|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
48150603|NCT03677271|BEHAVIORAL|Physical Activity|
48150604|NCT04945044|DEVICE|Computed adenoma detection system (CADe)|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps
48150605|NCT04945044|BEHAVIORAL|Control group (regular colonoscopy)|It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
48150606|NCT02791308|DRUG|Pimecrolimus Cream 1% (Valeant)|
48150607|NCT02791308|DRUG|Vehicle cream|
48150608|NCT02791308|DRUG|Pimecrolimus Cream, 1%|
48150609|NCT00915629|DIETARY_SUPPLEMENT|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
47992124|NCT01517009|PROCEDURE|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
47992125|NCT00159055|BIOLOGICAL|CMV vaccine|
48150610|NCT03583034|PROCEDURE|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
48150611|NCT02649478|DRUG|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
48150612|NCT02649478|DRUG|Placebo|
48150613|NCT02649478|DRUG|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
48150614|NCT04113226|DRUG|Rituximab|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
48150615|NCT04113226|DRUG|Lenalidomide 20 MG|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
48150616|NCT04113226|OTHER|Comprehensive Geriatric Assessment (CGA)|A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,...) on which treatment may impact.
47992126|NCT04563169|OTHER|Video consultation|The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (\>6 hours per night); 2) rest AHI \< 5 (or \<10 if age \>70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
48362735|NCT01957033|BEHAVIORAL|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
48150617|NCT04113226|OTHER|Activities of daily living (ADL) scale|Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
48150618|NCT01698567|DRUG|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
48362736|NCT01957033|OTHER|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
48150619|NCT01698567|DRUG|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
48150620|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
48150621|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
48676586|NCT05345548|DIAGNOSTIC_TEST|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
48676587|NCT06312189|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
48676588|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
47992127|NCT04023448|PROCEDURE|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
48150622|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
48150623|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
48150624|NCT01092325|DRUG|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
48150625|NCT01092325|DRUG|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
48150626|NCT03874091|PROCEDURE|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
48676589|NCT00938613|DRUG|Placebo|nasal spray, one spray per nostril at time 0
48676590|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
48150627|NCT03874091|PROCEDURE|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
48150628|NCT03874091|DRUG|Morphine PCA pump|Morphine given postoperatively.
48676591|NCT06543615|DEVICE|Ultrasonography|Ultrasound assessment of residual gastric volume
48676592|NCT00080574|PROCEDURE|Skin Biopsy|
48362737|NCT01957033|OTHER|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
47992128|NCT03434847|OTHER|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
47992129|NCT03790839|DRUG|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
47992130|NCT03790839|DRUG|Dorzagliatin|Glucokinase activator currently under development
47992131|NCT01661192|DRUG|AAT( Alpha 1 Antitrypsin)|
47992132|NCT04415632|OTHER|low glycemic index diet|• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
47992133|NCT04415632|OTHER|High glycemic index diet|Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
47992134|NCT02074995|BIOLOGICAL|BVS857|Group 1A\&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
47992135|NCT02074995|OTHER|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
47992136|NCT04690543|PROCEDURE|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
47992137|NCT04690543|PROCEDURE|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
48150629|NCT01581333|DRUG|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
48676593|NCT01312519|DEVICE|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
48676594|NCT01312519|DEVICE|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
48676595|NCT04130412|PROCEDURE|open release|Open release of lateral retinaculae
48676596|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (monoacylglycerol form)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
48676597|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (ethyl ester)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
48676598|NCT06617286|BIOLOGICAL|CD30 CAR T-cell|After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.
48676599|NCT01558596|PROCEDURE|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
48676600|NCT01558596|PROCEDURE|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
48676601|NCT02922946|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
48676602|NCT03982277|DRUG|Rifampin 300 Mg Oral Capsule|High dose rifampicin at 35mg/kg
48676603|NCT02462031|DRUG|KD101|200mg, 400mg, 800mg, 1400mg
48676604|NCT02462031|DRUG|placebo|200mg, 400mg, 800mg
48676605|NCT00835289|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids|Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
48676606|NCT00835289|OTHER|Placebo|3 capsules of matching corn oil placebo
48676607|NCT00002170|DRUG|Nelfinavir mesylate|
48676608|NCT00364247|DRUG|CG5503 IR;tapentadol|
48676609|NCT00983034|DRUG|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
48676610|NCT05302310|OTHER|integrated care|"i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed."
48362738|NCT01957033|OTHER|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
48676611|NCT04595643|OTHER|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
48676612|NCT05529251|RADIATION|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~* 20 Gy if no more disease is visible (node \< 1 cm in large diameter)~* 24 Gy for nodes \<= 2 cm~* 30 Gy for nodes \> 2 cm"
48676613|NCT05529251|DRUG|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
48676614|NCT05529251|DRUG|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
48676615|NCT03886467|OTHER|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
48150630|NCT01581333|DRUG|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
48150631|NCT02010086|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
48676616|NCT03929432|DEVICE|Active Transcranial Direct Current Stimulation with SLT|"Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS \[excitatory\]left target; C-tDCS \[inhibitory\]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment"
48676617|NCT03929432|DEVICE|Sham Transcranial Direct Current Stimulation with SLT|Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
48676618|NCT04212078|DRUG|Levofloxacin Ophthalmic|0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
48676619|NCT04212078|DRUG|Cefuroxime|The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
48676620|NCT05372393|PROCEDURE|Local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.
48676621|NCT05372393|PROCEDURE|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
48676622|NCT01787383|DRUG|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
48676623|NCT01787383|DRUG|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
48676624|NCT02781961|OTHER|cellvizio|pCLE during gastroscopy
48676625|NCT01365793|DRUG|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
48676626|NCT01365793|DRUG|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
48676627|NCT01365793|DRUG|0.45% saline intravenous fluid|0.45% saline fluid
48676628|NCT01365793|DRUG|0.9% saline Intravenous fluid|0.9% saline fluid
48676629|NCT01354522|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
48150632|NCT02010086|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
48150633|NCT05201625|DIAGNOSTIC_TEST|real time PCR|real time PCR
48150634|NCT00507702|PROCEDURE|phlebotomy|Standard of care
48150635|NCT04664179|BIOLOGICAL|Dose Level 1A: 2 x 10^7 cells/m2|2 x 10\^7 cells/m2
48150636|NCT04664179|BIOLOGICAL|Dose Level 2A: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
48150637|NCT04664179|BIOLOGICAL|Dose Level 2B: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
48150638|NCT04664179|BIOLOGICAL|Dose Level 3B: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
48150639|NCT04664179|BIOLOGICAL|Dose Level 3A: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
48150640|NCT03647800|BIOLOGICAL|APVO436|APVO436
48150641|NCT03107156|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
48150642|NCT06091709|OTHER|Multimodal Exercises and Education delivered through tele rehabilitation|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
48510948|NCT01740726|BEHAVIORAL|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
48676630|NCT01354522|DRUG|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
48676631|NCT05074823|DRUG|Ketamine 0.1 mg|Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
48676632|NCT05074823|DRUG|Ketamine 0.2 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
48150643|NCT06091709|OTHER|Selafcare|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
48150644|NCT00457834|DEVICE|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
48150645|NCT06390176|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG powder|Lactobacillus rhamnosus GG powder (PROBIOTICS Powder, USA) contained no less than 5×10\^8 CFU viable cells of Lactobacillus rhamnosus GG as the active ingredient.
48150646|NCT06390176|DIETARY_SUPPLEMENT|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus rhamnosus GG powder
48510949|NCT01740726|DRUG|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
48510950|NCT05138991|PROCEDURE|Echocardiogram Recording|Undergo assessment via echo
48510951|NCT05138991|OTHER|Questionnaire Administration|Ancillary Studies
48510952|NCT05138991|PROCEDURE|Stress Cardiac Magnetic Resonance Imaging|Undergo assessment via CMR
48510953|NCT05138991|DEVICE|Wireless Synchronized Cardiac Function Monitoring Device|SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
48510954|NCT00827437|OTHER|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
48510955|NCT03083652|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
48510956|NCT03083652|OTHER|Sham|Conventional physiotherapy with NMES device NOT activated
48676633|NCT05074823|DRUG|Ketamine 0.3 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
48676634|NCT03293303|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
48676635|NCT01718158|BIOLOGICAL|Peginterferon Lambda-1a|
48676636|NCT01718158|BIOLOGICAL|Peginterferon Alfa-2a|
48676637|NCT01718158|DRUG|Ribavirin|
48676638|NCT01718158|DRUG|Daclatasvir|
48676639|NCT01718158|DRUG|Telaprevir|
48510957|NCT03718650|DRUG|Pimonidazole|Patients will take a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
48510958|NCT03718650|PROCEDURE|Surgical Resection|Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
48510959|NCT01919788|DRUG|Insulin (Insuman Rapid)|
48510960|NCT01919788|DRUG|Glucose|
48510961|NCT01919788|OTHER|Saline|
48510962|NCT04825340|BIOLOGICAL|Nasal Spray Lyophilized Live Attenuated Influenza Vaccine|0.2 ml/vial, 0.2ml/dose/per person
48510963|NCT03951324|OTHER|Interobserver agreement or Interrater agreement|Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
48676640|NCT00784368|DRUG|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
48676641|NCT00784368|DRUG|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
48676642|NCT05609825|DRUG|LY3875383|Administered SC.
48676643|NCT05609825|DRUG|Placebo|Administered SC.
48676644|NCT06475768|DIAGNOSTIC_TEST|Stress Echocardiogram|Exercise testing via treadmill with simultaneous gas exchange analysis and pre- and post-exercise transthoracic echocardiography.
48676645|NCT06475768|DIAGNOSTIC_TEST|Cardiovascular Magnetic Imaging (cMRI)|Non-invasive imaging scan used to examine function and structure of the heart
48676646|NCT06475768|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Elastography (cMRE)|Non-invasive imaging scan used to measure myocardial stiffness
48676647|NCT06457477|DRUG|Sintilimab|100mg/10ml/1bottle
48676648|NCT06457477|DRUG|NAs|tablets
48676649|NCT06457477|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
48150647|NCT06390176|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
48150648|NCT01212809|DEVICE|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
48150649|NCT01212809|DEVICE|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
48150650|NCT04288661|PROCEDURE|No drain placement|The need of perianastomotic drain placement after Roux-en-Y reconstruction in total gastrectomy operations is investigated. As intervention, no drain placement is considered
48150651|NCT04280978|DIAGNOSTIC_TEST|ABI ABC|"The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes."
48676650|NCT03917030|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the toot.
48676651|NCT03917030|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade II defect with open flap debridement only.
48676652|NCT00563758|DRUG|tegaserod|
48676653|NCT00680628|DRUG|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: \<60Kg=30mg; ≥60Kg to \<70Kg=35mg; ≥70Kg to \<80Kg=40mg; ≥80Kg to \<90Kg=45mg; ≥90Kg=50mg"
48676654|NCT00680628|DRUG|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
48676655|NCT01001351|DRUG|PRT-201|Applied topically during surgery.
48676656|NCT01001351|DRUG|Placebo|Applied topically during surgery
48676657|NCT06307249|GENETIC|SNP|Diagnostics of patients' carriers or not of the risk allele(s)
48676658|NCT06307249|DRUG|Palbociclib 125mg|Palbociclib 125mg/day/os over 21 days every 28 days
48676659|NCT06307249|DRUG|Bevacizumab|10mg/kg every 21 days
48676660|NCT01736033|DRUG|Tamsulosin|1 tablet(0.2mg) orally q.d.
48676661|NCT01736033|DRUG|Finasteride|1 tablet(5mg) orally q.d.
48676662|NCT01736033|DRUG|Placebo|1 tablet(0.2mg) orally q.d.
48150652|NCT00821093|DRUG|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
48150653|NCT00821093|DRUG|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
48362739|NCT01957033|OTHER|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
48362740|NCT01957033|OTHER|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
48676663|NCT03245346|DRUG|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
48676664|NCT03245346|DRUG|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
48676665|NCT03245346|DRUG|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
48676666|NCT03245346|DRUG|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
48676667|NCT01899430|DRUG|liraglutide|
48676668|NCT01899430|DRUG|metformin|
48676669|NCT04512118|DIAGNOSTIC_TEST|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
48676670|NCT01188941|BEHAVIORAL|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
48676671|NCT05176951|DRUG|Treprostinil Palmitil|Oral inhalation using a capsule-based dry powder inhaler device.
48676672|NCT05176951|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
48676673|NCT01955460|BIOLOGICAL|Aldesleukin|Given IV
48676674|NCT01955460|DRUG|Cyclophosphamide|Given IV
48676675|NCT01955460|DRUG|Fludarabine Phosphate|Given IV
48676676|NCT01955460|OTHER|Laboratory Biomarker Analysis|Correlative studies
48676677|NCT01955460|BIOLOGICAL|NGFR-transduced Autologous T Lymphocytes|Given IV
48676678|NCT01955460|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
48676679|NCT02651116|DRUG|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
48676680|NCT02651116|DRUG|Placebo|10 mL Placebo
48676681|NCT02651116|DEVICE|Cough recording device|FDA approved device validated for use in adults and children
48676682|NCT05270148|OTHER|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
48676683|NCT05270148|OTHER|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
48676684|NCT00638729|DRUG|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
47992138|NCT00529854|OTHER|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
48676685|NCT00638729|DRUG|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
48676686|NCT00638729|DRUG|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
48676687|NCT04980469|OTHER|Vitex negundo + Zingiber officinale|200 mg/ Capsule
48676688|NCT04980469|OTHER|Placebo (MCC)|200 mg/ Capsule
48676689|NCT00784862|DRUG|Anastrozole|1mg, orally, once daily
48676690|NCT00784862|DRUG|Tamoxifen|20mg, orally, once daily
48676691|NCT01029912|DEVICE|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
48676692|NCT06012539|OTHER|Qualitative (interviews)|Interviews were held with participants at three different time points, approximately six months apart. Interviews were taped and analyzed for common themes.
48676693|NCT05007327|OTHER|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
48676694|NCT03129464|DEVICE|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
48676695|NCT04915508|DRUG|Hormone Therapy|Receive hormonal therapy
47992139|NCT00775931|PROCEDURE|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
47992140|NCT00775931|DRUG|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
48676696|NCT04915508|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
47992141|NCT00775931|RADIATION|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
47992142|NCT00775931|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
48150654|NCT00821093|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
48676697|NCT04122846|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
48676698|NCT03130998|BEHAVIORAL|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
48676699|NCT03130998|BEHAVIORAL|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
48362741|NCT01957033|OTHER|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
48676700|NCT03519997|DRUG|Pembrolizumab|Pembroluzumab 200mg IV once every 3 weeks
48676701|NCT03519997|DRUG|Bavituximab|Bavituximab 3mg/kg IV weekly
48676702|NCT02230189|BIOLOGICAL|Segmental airway allergen challenge|
48676703|NCT02230189|PROCEDURE|Bronchoscopy|
48676704|NCT02230189|DIAGNOSTIC_TEST|Methacholine challenge test|
48362742|NCT04390360|PROCEDURE|Protective ventilation implementation|In this condition, we will implement the protective ventilation related with gender and height . A blood gas will be performed at before protective ventilation implementation and at the end of this condition.Time condition 30 minutes
48676705|NCT02230189|DIAGNOSTIC_TEST|Spirometry|
48676706|NCT02230189|DIAGNOSTIC_TEST|Allergen skin prick test|
47992143|NCT00775931|DRUG|Busulfan|patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
47992144|NCT00775931|DRUG|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
47992145|NCT00775931|PROCEDURE|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
47992146|NCT02207790|DRUG|E2609|
48362743|NCT04390360|PROCEDURE|Protective ventilation with HME|In this condition, the patient will received protective ventilation with a Heat Moisture Exchanger (HME). A blood gas will be performed at the end of this condition.Time condition 30 minutes
48362744|NCT04390360|PROCEDURE|Protective ventilation with Heated humidifier|In this condition, the patient will received protective ventilation with a Heated humidifier. A blood gas will be performed at the end of this condition.Time condition 30 minutes
47992147|NCT02207790|DRUG|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
47992148|NCT03585179|DRUG|Oral Tranexamic Acid|Participants will take a pill of 250 mg bid for 12 weeks
47992149|NCT03585179|DRUG|5% topical tranexamic acid|Participants will apply a layer of gel on the affected skin bid for 12 weeks
48362745|NCT04390360|PROCEDURE|Tidal Volume reduction|n this condition, we will reduce Tidal volume (with smartphone application calculation) to obtain the same alveolar ventilation (PaCO2) obtained on the HME condition
48362746|NCT00158301|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
48676707|NCT04186325|PROCEDURE|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
48676708|NCT06507579|DEVICE|Hydra transcatheter aortic valve (THV) series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
48676709|NCT02192567|DRUG|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."
48676710|NCT00421512|DRUG|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
48676711|NCT00553631|BIOLOGICAL|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
48676712|NCT00553631|BIOLOGICAL|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
48676713|NCT06184178|OTHER|Socio-health care|Socio-health care under TEC-MED model and an integral assessment
48676714|NCT02563145|BEHAVIORAL|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
48676715|NCT02563145|BEHAVIORAL|Treatment as usual|Psychoeducation, general counselling
48676716|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide test|Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
48676717|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide placebo|collagen peptide placebo
48676718|NCT06100146|DIETARY_SUPPLEMENT|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
48676719|NCT06100146|OTHER|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
48676720|NCT05312606|OTHER|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
48676721|NCT05312606|OTHER|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
48676722|NCT01684839|DEVICE|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
48676723|NCT02678754|OTHER|No intervention required, purely observational|
48362747|NCT00158301|DRUG|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
48362748|NCT03920046|BEHAVIORAL|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
48676724|NCT03194399|BEHAVIORAL|Personalized health care service|Physical activity coaching, other functional outcome observation
48362749|NCT03124329|PROCEDURE|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
48676725|NCT01119287|DRUG|Dexamethasone 0.1% ophthalmic suspension|Maxidex
48676726|NCT01119287|DRUG|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
48676727|NCT01119287|OTHER|Inactive ingredients, used as placebo|Tears Naturale II
48676728|NCT01537471|DRUG|Placebo|Placebo
48676729|NCT01537471|DRUG|Meclizine|Meclizine 12.5 mg
47992150|NCT03585179|DRUG|4% hydroquinone|Participants will apply a layer of cream on the affected skin once at night
47992151|NCT01559896|DIETARY_SUPPLEMENT|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
48150655|NCT00821093|DRUG|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
48150656|NCT04804371|DRUG|F18-FDG|Evaluate FDG uptake
48510964|NCT00735397|DRUG|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
48676730|NCT01537471|DRUG|Meclizine|Meclizine 25 mg
48676731|NCT05353413|DEVICE|Neuroimaging|Magnetic resonance diffusion tensor imaging of the brain
48676732|NCT05353413|DIAGNOSTIC_TEST|VEP - visual evoked potential|Electrophysiology of the visual pathway.
48676733|NCT05353413|DIAGNOSTIC_TEST|Ophthalmology examination.|Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
48676734|NCT00198328|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
48676735|NCT00198328|PROCEDURE|Surgical Excision|Patients have their tumor surgically removed.
48676736|NCT06103344|BEHAVIORAL|4-7-8 Breathing Exercise Training|Participants in the intervention group will be taught 4-7-8 breathing exercises collectively, and the training will be repeated on specified days (twice a week for a total of 4 weeks). During the training, it will be checked whether each participant in the intervention group can perform the breathing exercise correctly and feedback will be given. Participants who fail to implement the exercise will be excluded from the study. 4-7-8 breathing exercise training, prepared in accordance with the literature, will be given by the assistant researcher who has training and certification in breathing exercises. Training will be planned in an empty classroom, for approximately 20 minutes and at the students' end time. Thus, educational activities in the institution will not be disrupted.
48676737|NCT01335126|OTHER|Emulsion type artificial tear|2 types of artificial tears
48676738|NCT01467336|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
48510965|NCT01649960|DRUG|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
48676739|NCT02802293|DEVICE|repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
48676740|NCT02802293|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
48676741|NCT04927481|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
48676742|NCT04576910|BIOLOGICAL|vaccinated with Sabin IPV|the 4th dose of polio vaccination
48676743|NCT04576910|BIOLOGICAL|vaccinated with bOPV|the 4th dose of polio vaccination
48676744|NCT00211289|BEHAVIORAL|Education by community pharmacist|
48676745|NCT05677100|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy.
48676746|NCT03661840|BEHAVIORAL|Acceptance and Commitment Therapy|Intervention group participants will attend eight weekly, 90-minute, in person, group-based ACT sessions. Groups will be initiated with no more than 10 participants and no fewer than 6 participants. Sessions will include key theoretical ACT constructs and strategies as they relate to chronic pain. A licensed clinical psychologist or licensed clinical social worker trained in ACT will facilitate all sessions. Participants in the ACT intervention group will also continue to receive medication management and other behavioral management interventions that they would get as usual treatment.
48676747|NCT03661840|OTHER|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management. This includes continued medication management for cancer related chronic pain by prescribing providers, and access to supportive oncology services. It may also include other behavioral pain management such as physical therapy, acupuncture, or massage.
48676748|NCT02054065|OTHER|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
48676749|NCT02448355|DEVICE|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
47992152|NCT01974375|DRUG|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing \<40 kg)
48150657|NCT03883984|DRUG|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
48150658|NCT03883984|DRUG|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
48150659|NCT03657641|BIOLOGICAL|Pembrolizumab|Given IV
48150660|NCT03657641|DRUG|Regorafenib|Given PO
48676750|NCT04602143|DRUG|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
48676751|NCT03166852|OTHER|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
48150661|NCT01377844|DRUG|EGT0001442|
48150662|NCT01377844|DRUG|Placebo|
48510966|NCT00815360|DRUG|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
48676752|NCT03960879|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
48676753|NCT03960879|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cervical cytology
47992153|NCT01974375|DRUG|Fluconazole|Fluconazole 100\~200mg/day, IV care until oral medication becomes possible
47992154|NCT01857934|DRUG|cyclophosphamide|Given intravenously (IV)
47992155|NCT01857934|DRUG|topotecan|Given IV
47992156|NCT01857934|BIOLOGICAL|hu14.18K322A|Given IV
48150663|NCT00891709|DRUG|LEO 29102|First-in-man. Healthy volunteers
48150664|NCT05323643|DEVICE|Ultrasound|"musculoskeletal US will be performed using commercially -available equipment, with high frequency linear -array transducers and a standard gel interface. The higher frequency transducers provide better spatial resolution, while the lower frequency transducers provide a greater depth of tissue penetrance. Colour Doppler US is also performed in most cases as it plays an important role in supporting and confirming diagnoses, by providing valuable information about the pathophysiology of the abnormality.~The patients will be seated with hands placed on a table, to permit examination of both volar and dorsal aspects, in longitudinal and transversal axis. Examination of the hands and fingers usually requires a large amount of transmission gel, in order to avoid compression and to permit dynamic evaluation. When acute trauma with skin lesions is investigated, sterile transmission gel, or sterile acoustic standoff pads can be used"
48150665|NCT05415072|DRUG|DYP688|Single agent DYP688
48150666|NCT05945979|DIETARY_SUPPLEMENT|A power supplement with biotin|A power dietary supplement containing aminoacids and vitamins
48150667|NCT05885334|OTHER|control|Caregivers will not receive any educational solution different than what is done by routine in centers. After six months, performance in caregivers tasks will be video recorded.
48150668|NCT05885334|OTHER|Virtual Reality|Caregivers will receive a educational solution of virtual reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
48510967|NCT00815360|PROCEDURE|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
48676754|NCT03960879|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
48676755|NCT03392428|OTHER|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
48676756|NCT03392428|DRUG|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
48676757|NCT04154605|DEVICE|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
48676758|NCT04154605|DEVICE|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
48676759|NCT01734824|DRUG|Denosumab|sc RANKL-inhibitor
48676760|NCT01734824|DRUG|Teriparatide|daily subcutaneous injection of teriparatide
48676761|NCT01734824|DRUG|Placebo Denosumab|one subcutaneous injection denosumab placebo
47992157|NCT01857934|PROCEDURE|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
48362750|NCT03124329|PROCEDURE|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
48510968|NCT00815360|DRUG|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
48510969|NCT00815360|PROCEDURE|macular laser|macular laser to areas of retinal thickening or leakage
48510970|NCT03597919|BIOLOGICAL|Sabin IPV|We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
48510971|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3 + bracket|
48510972|NCT02132806|PROCEDURE|Piezosurgery with biomaterial mp3|
48510973|NCT02132806|PROCEDURE|Piezosurgery|
48510974|NCT03372291|OTHER|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
48510975|NCT03372291|OTHER|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
48510976|NCT06547411|DEVICE|PC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group I received pressure control ventilation (PC).
48510977|NCT06547411|DEVICE|VC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group II received volume control ventilation (VC).
48676762|NCT01734824|DRUG|Placebo Teriparatide|daily subcutaneous placebo injection
48676763|NCT05075889|DRUG|Indocyanine Green|Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
48676764|NCT02735603|DRUG|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
48676765|NCT02735603|OTHER|Placebo|Naltrexone/bupropion placebo-matching tablets.
48676766|NCT02735603|DRUG|Moxifloxacin|Moxifloxacin tablet.
48676767|NCT05399966|DIETARY_SUPPLEMENT|Monarda Didyma extract|Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
48676768|NCT05399966|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
48676769|NCT00446329|DRUG|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
47992158|NCT01857934|PROCEDURE|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
47992159|NCT01857934|DRUG|cisplatin|Given IV
47992160|NCT01857934|DRUG|etoposide|Given IV
47992161|NCT01857934|DRUG|doxorubicin|Given IV
48676770|NCT01502514|PROCEDURE|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
48676771|NCT00666081|DRUG|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
48676772|NCT01059357|DEVICE|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
48676773|NCT00196677|DRUG|Vitamins, minerals and medical herbs|
48676774|NCT02490397|OTHER|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
48676775|NCT02490397|OTHER|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
48676776|NCT00645840|DRUG|Anakinra|Patients will receive daily anakinra therapy for 28 days
48676777|NCT05011149|DRUG|Ibuprofen|"Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent."
48676778|NCT05842486|OTHER|Anti-C5 antibody treatment|Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
48150669|NCT05885334|OTHER|Augmented reality|Caregivers will receive a educational solution of augmented reality videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
48510978|NCT06547411|DEVICE|PRVC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group III received pressure-regulated volume control ventilation (PRVC).
48510979|NCT01179711|DEVICE|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
48510980|NCT02637531|DRUG|IPI-549 (eganelisib)|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
48510981|NCT02637531|DRUG|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
48510982|NCT06574360|DRUG|S1RA plus NMDAE|Use of an S1R agonist plus an NMDA enhancer for the treatment of treatment-resistant schizophrenia.
48510983|NCT06574360|DRUG|S1RA plus Placebo Cap|Use of an S1R agonist plus placebo as a comparator
48510984|NCT04263324|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care.
48510985|NCT05489614|DRUG|Olpasiran|Participants will receive olpasiran by subcutaneous (SC) injection.
48510986|NCT04502420|DIAGNOSTIC_TEST|Lung function before and after surgery|A diagnostic test
48510987|NCT05368064|OTHER|observational|collection of phenotype data
48510988|NCT05639075|OTHER|Peripheral vision|A gait analysis test will be performed in each patient after cataract surgery to test peripheral vision
48510989|NCT05501990|BEHAVIORAL|Health intervention based on intelligent applet|Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.
48510990|NCT00839553|PROCEDURE|Intrapleural Minocycline application|
48510991|NCT03706014|BEHAVIORAL|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
48510992|NCT03706014|BEHAVIORAL|Control|Contact-equivalent attention control program in which students play educational games
48510993|NCT06088030|DRUG|Arsenic trioxide|Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
48510994|NCT02068092|DRUG|Hydroxytyrosol|
48510995|NCT05931978|OTHER|CKD dashboard|Online dashboard that visualizes patients' individual PROM- and clinical data related to their kidney disease.
48510996|NCT06290908|PROCEDURE|RPE-P/TLIF|patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with RPE-P/TLIF
48510997|NCT04771975|BEHAVIORAL|Exercise Counselling|Phase 1: See previous description for MatchQEP (Intervention) group. Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants had the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner. The 8-week program was open to all participants from Phase 1 who choose to continue in the study, regardless of initial randomization status. Behavioural and exercise counselling were offered to phase 2 participants.
48510998|NCT04771975|BEHAVIORAL|Partner Matching|"Phase 1: All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants were rematched with different partner for this phase of the trial.~Participants will be matched based on personal and cancer-related characteristics."
48510999|NCT04771975|BEHAVIORAL|Resistance training sessions led by a QEP|Phase 2: participants were offered the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner.
48511000|NCT01736969|DEVICE|RD047-023|Experimental hydrogel
48511001|NCT01736969|DEVICE|Predicate Device|
48511002|NCT02581722|DEVICE|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
48511003|NCT03168230|PROCEDURE|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
48511004|NCT02279108|DRUG|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
48511005|NCT02279108|DRUG|isotope|One injection, 20 MBq techntium99, intradermal use
48676779|NCT03814928|BEHAVIORAL|Caregivers eCourse|Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
48150670|NCT05885334|OTHER|360 videos|Caregivers will receive a educational solution of 360 degrees videos with care situations simulations for 1h. After six months, performance in caregivers tasks will be video recorded.
48676780|NCT03372161|DRUG|SP-102|injection
48676781|NCT03372161|DRUG|Placebo|injection
48511006|NCT05969249|DEVICE|Upper limb in vibration training|"The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move."
48676782|NCT05504512|OTHER|No intervention|No intervention
48676783|NCT00989508|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
48511007|NCT01154361|DRUG|Icatibant (subcutaneous) and plazebo (intravenous)|
47992162|NCT01857934|DRUG|vincristine|Given IV
47992163|NCT01857934|DRUG|busulfan|Given IV
48511008|NCT01154361|DRUG|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
48511009|NCT04704570|OTHER|Exercise|Spinal stabilization exercise
48511010|NCT04704570|OTHER|Remotely and face to face evaluation of Functional Capacity Level|Quality of life assessment (SF-36), and cognitive assessment ((Montreal Cognitive Assessment Scale (MOCA)) will be administered face to face. Functional capacity assessment tests will be administered both face-to-face and remotely. All participants will be administered both remotely and face-to-face. The order of the remote and face-to-face evaluations will be determined by the closed envelope randomization method. The remote evaluation will be done by video interview method under the direction of the researcher. During the remote evaluation, the necessary equipment for the participant will be prepared in the unit in advance. There will be a 10-30 minute rest interval between each evaluation.This application will only be applied at the beginning of the exercise program.After the 8-week program, only face-to-face evaluation will be made.
48511011|NCT00555152|OTHER|Laboratory Biomarker Analysis|Correlative studies
47992164|NCT01857934|DRUG|melphalan|Given IV
48511012|NCT00555152|DRUG|Lapatinib Ditosylate|Given PO
48511013|NCT00555152|OTHER|Placebo|Given PO
48511014|NCT06630000|BEHAVIORAL|FACT|Two 90-minute FACT sessions led by a trained interventionist.
48511015|NCT06630000|BEHAVIORAL|Control|Two 90-minute sessions individually with a study interventionist, 2-weeks apart (focused on nutrition education).
48511016|NCT06598241|DEVICE|Borate-base Bioactive Glass Fiber Matrix (BBGFM)|Bioactive glass materials are biocompatible water-soluble inorganic ceramic materials that release their constituent ions when immersed in body fluids.
48511017|NCT00408746|BEHAVIORAL|palatal development|Impressions of preterm and term palates.
48511018|NCT00365313|DRUG|celecoxib, esomeprazole|
47992165|NCT01857934|BIOLOGICAL|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
47992166|NCT01857934|BIOLOGICAL|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
47992167|NCT01857934|RADIATION|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
48511019|NCT05603403|DRUG|Probiatop|1 sachet orally, 2 times a day, for 42 days
48511020|NCT05603403|OTHER|Placebo|1 sachet orally, 2 times a day, for 42 days
48511021|NCT04647903|DRUG|ADAIR 10 mg IR tablets|manipulated ADAIR 3x10mg
48511022|NCT04647903|DRUG|d-amphetamine sulfate|crushed d-amphetamine sulfate 3x10mg
48511023|NCT04647903|DRUG|Placebo|placebo for oral and intranasal administration
48676784|NCT00989508|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
48676785|NCT02964806|DIETARY_SUPPLEMENT|Ordinary Diet|
47992168|NCT01857934|BIOLOGICAL|GM-CSF|Given subcutaneously (SQ)
47992169|NCT01857934|BIOLOGICAL|G-CSF|Given subcutaneously (SQ)
47992170|NCT01857934|DRUG|mesna|Given IV
47992171|NCT01857934|DRUG|levetiracetam|Given IV
47992172|NCT01857934|BIOLOGICAL|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
47992173|NCT01857934|DRUG|Isotretinoin|Given orally (PO)
48511024|NCT03901976|DEVICE|bed exit detection|bed exit detection to avoid patients fall
48511025|NCT03637387|DRUG|BIIB074|Administered as specified in the treatment arm
48676786|NCT02964806|DIETARY_SUPPLEMENT|Modified Atkin's Diet|
48676787|NCT02964806|DIETARY_SUPPLEMENT|Ketogenic Diet|
48676788|NCT04868383|BEHAVIORAL|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
47992174|NCT01857934|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
48362751|NCT03124329|BIOLOGICAL|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
48362752|NCT03124329|DEVICE|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
48362753|NCT05914480|OTHER|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
48150671|NCT00630409|DRUG|Gemcitabine|800 mg IV day 1 and 8
48362754|NCT00374764|DRUG|Risperidone|
48362755|NCT00374764|BEHAVIORAL|ABA|
48362756|NCT02354599|DRUG|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
48511026|NCT03637387|DRUG|Placebo|Administered as specified in the treatment arm.
48150672|NCT00630409|DRUG|Doxil|24 mg/m2 every 21 days IV
48150673|NCT04655833|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
48150674|NCT06483698|OTHER|Sublobar resection|Sublobar resection is a series of surgical approaches for lung cancer.
48150675|NCT06483698|OTHER|Lobectomy|Lobectomy is the surgical approach for lung cancer.
48150676|NCT03366571|DRUG|Nucleos(t)ide Analogues|Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
48150677|NCT02107235|DRUG|oral rigosertib|
48511027|NCT02352935|DEVICE|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
48511028|NCT00237653|DRUG|Valganciclovir|
48511029|NCT06550427|DIAGNOSTIC_TEST|ctDNA analyzed by phased variant|this observational cohort study is to investigate the correlation between ctDNA analyzed by phased variant and the early outcome of the disease.
48511030|NCT03443271|PROCEDURE|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
48511031|NCT03443271|PROCEDURE|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
48511032|NCT03775044|DEVICE|Medherent Device|The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
48511033|NCT00216138|DRUG|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
48511034|NCT00216138|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
48511035|NCT00216138|DRUG|Premedication|Dexamethasone and antiemetic premedication
47992175|NCT00003799|DRUG|fluorouracil|Given IV
47992176|NCT00003799|DRUG|oxaliplatin|Given IV
47992177|NCT00003799|RADIATION|radiation therapy|Undergo radiotherapy
47992178|NCT00003799|DRUG|leucovorin calcium|Given IV
47992179|NCT00003799|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48150678|NCT02107235|DRUG|cisplatin|
48150679|NCT02107235|RADIATION|Radiotherapy|
48150680|NCT00476151|DRUG|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
48150681|NCT00476151|DRUG|placebo cream|inactive placebo cream applied two times daily
48676789|NCT03815149|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
47992180|NCT04599374|OTHER|no intervention|This study collected data only without any intervention.
48362757|NCT02354599|DRUG|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
48676790|NCT06224569|OTHER|Black tea flavoured, tea drink|Black tea powder containing 50.0 mg of caffeine and 11.5 mg of theanine, to be dissolved in 200 ml boiling water.
48511036|NCT06388499|OTHER|TECC (Telerehabilitation and Exercise for Chronic Conditions)|"Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing."
47992181|NCT05951387|DRUG|dexmedetomidine plus ketamine|titrating the dose of dexmedetomidine mixed with ketamine (staring dose 0.5ug/kg/hr, 0.5mg/kg/hr respectively)to achieve full sedation
48511037|NCT05792111|DRUG|Trigger point injection (lidocaine)|trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
48511038|NCT05792111|DRUG|Caudal epidural Group (bupivacaine + triamcinolone + NaCl)|It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
48511039|NCT04408235|DRUG|Enoxaparin|Low-Dose LMWH: enoxaparin 4000 IU daily; High dose LMWH: 70 IU/kg twice daily
48511040|NCT06304168|OTHER|Non-Interventional Study|Non-interventional study
48511041|NCT00554190|DEVICE|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
48511042|NCT00554190|DEVICE|Merogel Injectable|Bioresorbable hyaluronic acid product
48676791|NCT06224569|OTHER|Black tea flavoured, caffeine-only drink|50.0 mg of caffeine in a black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
47992182|NCT05951387|DRUG|Dexmedetomidine|starting intravenous infusion with dexmedetomidine starting at dose 0.5ug/kg//hr and titrate the dose to achieve full sedation
48676792|NCT06224569|OTHER|Black tea flavoured, placebo drink|A black tea-like powder i.e., matched to the 'black tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
48676793|NCT06224569|OTHER|Green tea flavoured, tea drink|Green tea powder containing 30.6 mg of caffeine and 11.1 mg of theanine, to be dissolved in 200 ml boiling water.
47992183|NCT01319812|DEVICE|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
47992184|NCT01319812|DEVICE|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
47992185|NCT05533047|PROCEDURE|TURP|Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
47992186|NCT00403247|DIETARY_SUPPLEMENT|Capsule with folate, Vitamin B12 & pyridoxine|
47992187|NCT00403247|OTHER|placebo|placebo capsule
47992188|NCT05397054|BEHAVIORAL|Education|- Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients
47992189|NCT05397054|BEHAVIORAL|Reformulation|- Reformulation: Dietary recommendation in low sodium intake
47992190|NCT05397054|BEHAVIORAL|Environmental change|- Environmental change: Encourage about low sodium intake in community
47992191|NCT05397054|DEVICE|Salt meter|- Used salt meter: at least 3 times/wk
47992192|NCT05397054|BEHAVIORAL|standard treatment|standard treatment
48362758|NCT02354599|DRUG|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
48362759|NCT06019351|DEVICE|OrthoAnalyzer™ software|OrthoAnalyzer™ software module from 3Shape Software
48362760|NCT04301349|DRUG|vaginal dinoprostone|two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
48362761|NCT04301349|DRUG|vaginal misoprostol|two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
48362762|NCT04301349|DRUG|placebo|two tablets of placebo given 3 hours prior to IUD insertion
48362763|NCT04902573|OTHER|Non-interventional|As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.
48362764|NCT00515866|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
48362765|NCT00515866|DRUG|Gemcitabine|intravenous injection
48676794|NCT06224569|OTHER|Green tea flavoured, caffeine-only drink|30.6 mg of caffeine in a green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, to be dissolved in 200 ml boiling water. Caffeine is the only biologically active ingredient in this intervention.
47992193|NCT03253107|DRUG|Chemotherapy|"Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
48150682|NCT01249378|OTHER|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
47992194|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
47992195|NCT01682902|DRUG|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
47992196|NCT01682902|DRUG|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
47992197|NCT01012687|DRUG|perindopril erbumine|8 mg tablet
48362766|NCT04810806|PROCEDURE|Immediate coronary angiography within 2 hours after randomization|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
48511043|NCT04684043|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
48676795|NCT06224569|OTHER|Green tea flavoured, placebo drink|A green tea-like powder i.e., matched to the 'green tea' intervention for flavour and appearance, containing no biologically active ingredients, to be dissolved in 200 ml boiling water.
47992198|NCT00914862|DRUG|Ramelteon|Ramelteon tablets, orally for one day only.
47992199|NCT02036502|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
47992200|NCT02036502|DRUG|Lenalidomide|Oral capsule
48150683|NCT04206618|DRUG|Teriparatide|1 subcutaneous injection daily for 12 months
48511044|NCT02351141|OTHER|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
48511045|NCT01128179|DRUG|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
47992201|NCT02036502|DRUG|Dexamethasone|Oral tablet IV infusion
47992202|NCT02036502|DRUG|Carfilzomib|IV infusion
47992203|NCT00537381|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
47992204|NCT00537381|DRUG|Prednisone|Prednisone 5 mg orally twice daily.
47992205|NCT00537381|BIOLOGICAL|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
48150684|NCT04206618|DRUG|Denosumab|1 subcutaneous injection every 6 months for 12 months
48150685|NCT03248076|DRUG|Fentanyl Citrate|1γ/Kg fentanyl
48676796|NCT05719207|DEVICE|Balloon dilation of eustachian tube (Stryker XprESS LoProfile ENT dilation system)|Patients in the intervention group would undergo balloon dilation of the eustachian tube under local anesthetic in clinic. The Stryker XprESS LoProfile ENT dilation system will be used. Participants may undergo dilation under general anesthesia if a contraindication to in-clinic dilation exists.
48676797|NCT05719207|OTHER|Sham procedure|Patients in the sham group will undergo the motions of an in-office dilation of the eustachian tube, without actually dilating the eustachian tube.
48676798|NCT04407338|DEVICE|B-DYN|The surgical technique for placement of the B-Dyn device is performed under general anaesthesia. The procedure begins with the insertion of the first upper polyaxial screw which is screwed in with the polyaxial screwdriver. The use of the phantom (Trial 10) is necessary in order to position the second screw. Once the screws are positioned, the B-Dyn is taken between the jaws of the gripping forceps in order to insert it into the heads of the polyaxial screws. The movable rod of the B-Dyn is then placed in the head of the upper screw. The positioning mark of the fixed rod must be placed facing the operator and in the center of the lower screw head. Finally the cap of the lower polyaxial pedicle screw is tightened. A final tightening of the two plugs on the polyaxial pedicle screw heads is performed to fix the assembly.
48676799|NCT04407338|DEVICE|Conventional Bolted fusion (with or without cage)|The surgeon will complete his gesture by placing 2 screws in the upper vertebra and 2 screws in the lower vertebra; the screws will be connected to each other to stabilize the assembly. This type of surgery is done via posterior approach and under general anaesthesia.
48676800|NCT02472912|BIOLOGICAL|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
47992206|NCT00537381|DRUG|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
47992207|NCT03071978|DEVICE|CRT with LV-only pacing / bi-ventricular pacing|LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
48150686|NCT03500809|PROCEDURE|Aqueous release of the wound|"1. Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~2. This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye."
48150687|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
48150688|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
48511046|NCT01128179|DRUG|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
48676801|NCT02472912|BIOLOGICAL|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
48676802|NCT02472912|BIOLOGICAL|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
47992208|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
47992209|NCT00708942|DRUG|Placebo|Placebo suppository, for 3-7 hours application
47992210|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
47992211|NCT00708942|DRUG|Placebo|Placebo ointment for 5 hours application
47992212|NCT00035464|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
47992213|NCT00035464|DRUG|Placebo|placebo tablets, twice a day for 6 months
47992214|NCT01669915|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
47992215|NCT01669915|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
47992216|NCT01669915|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
47992217|NCT01669915|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
47992218|NCT02467569|DRUG|Hemay020|
47992219|NCT00430560|BEHAVIORAL|cognitive rehabilitation|computer training
48511047|NCT05329259|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
48511048|NCT05518188|BIOLOGICAL|MELPIDA|MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene
48511049|NCT00048737|DRUG|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
48511050|NCT00048737|DRUG|Rituximab|250 mg/m\^2 on day 1 and day 8
48511051|NCT00048737|DRUG|Fludarabine|30 mg/m\^2/day for 3 days
48511052|NCT00048737|DRUG|Cyclophosphamide|750 mg/m\^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
48150689|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
48150690|NCT05976672|OTHER|PRSS (Peer Recovery Support Specialist)|Upon receiving an alert through a study dashboard, the PRSS (who is blinded in not knowing whether the alert was caused by data anomaly or a random generation), the PRSS will be able to access identifiable contact details and contact the participant by phone and provide the necessary support assistance (e.g., locations of AA/NA meetings, sleep and/or relaxation techniques, etc).
48150691|NCT05925751|DIAGNOSTIC_TEST|CT/PET/WSI-based Deep Learning Signature|CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
48150692|NCT06428799|DEVICE|Carebot AI MMG|"Carebot AI MMG is a software solution that utilizes artificial intelligence methods, specifically deep learning and computer vision algorithms, to evaluate and localize suspicious regions of potential lesions during the interpretation of digital breast x-rays as part of standard mammography screening procedures. The Carebot AI MMG medical device is not intended for use in diagnostic mammography. The Carebot AI MMG is intended for use in women over the age of 18.~The predictive outputs of the Carebot AI MMG medical device are intended to aid decision-making in screening clinical practice, always in conjunction with other relevant patient information and based on the professional judgment of the examining clinician. The Carebot AI MMG is specifically designed to provide a supporting layer of analysis that helps in evaluating or prioritizing mammography images with additional patient information and the professional judgment of the examining physician."
48150693|NCT03816878|BIOLOGICAL|H5N1 pISV|Administered as an intramuscular (IM) injection
48150694|NCT05109832|DRUG|14C-IMP4297|14C marked IMP4297
48150695|NCT05726994|BIOLOGICAL|exhaled breath collection|Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
48150696|NCT05726994|OTHER|Data collection|Clinical data will be collected in order to seek correlations with the exhaled breath profile.
47992220|NCT00430560|PROCEDURE|work therapy|opportunity to work in carefully supervised hospital job
48150697|NCT00065247|BEHAVIORAL|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
48150698|NCT01428609|PROCEDURE|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
48150699|NCT06498323|DRUG|tenecteplase|Intravenous thrombolytic agents administration
48150700|NCT05512598|DRUG|HB0034|HB0034, a single dose
48150701|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
48676803|NCT03141255|DEVICE|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
47992221|NCT00430560|BEHAVIORAL|work therapy|work therapy
48150702|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
48150703|NCT03769090|DRUG|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
47992222|NCT00245206|DRUG|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
47992223|NCT00245206|DRUG|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
47992224|NCT00245206|DRUG|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
47992226|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
47992227|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
47992228|NCT04501367|DRUG|Prednisone acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
48150704|NCT02482324|DRUG|ALZT-OP1a|Mast cell stabilizer
48150705|NCT02482324|DRUG|ALZT-OP1b|anti-inflammatory
48150706|NCT02482324|DEVICE|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
48150707|NCT03272815|DEVICE|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
48150708|NCT03272815|DEVICE|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
48362767|NCT04810806|PROCEDURE|Delayed coronary angiography after stabilization of heart failure|After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
48362768|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube
47992229|NCT04164615|DRUG|GB221|"GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
48150709|NCT01308099|DEVICE|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours."
48150710|NCT01171950|DEVICE|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
48150711|NCT02451553|DRUG|Afatinib Dimaleate|Given PO
48150712|NCT02451553|DRUG|Capecitabine|Given PO
48676804|NCT03141255|DEVICE|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
48676805|NCT00209937|DRUG|Gaboxadol|
48150713|NCT02451553|OTHER|Laboratory Biomarker Analysis|Correlative studies
48150714|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
48150715|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
48676806|NCT04819113|BIOLOGICAL|Nimenrix|MenACWY-TT vaccine
48676807|NCT00152204|DRUG|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
48676808|NCT00152204|DRUG|IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
48676809|NCT02112305|DRUG|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
48150716|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
48150717|NCT01996514|DIETARY_SUPPLEMENT|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
48150718|NCT01996514|DIETARY_SUPPLEMENT|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
48150719|NCT01996514|BEHAVIORAL|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
48150720|NCT01996514|BEHAVIORAL|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
48362769|NCT04695444|DEVICE|nasotracheal tube (Ring-Adair-Elwin)|different materials for nasotracheal intubation conventional PVC tube with rubber suction catheter
48362770|NCT04695444|DEVICE|nasotracheal tube (portex)|different materials for nasotracheal intubation velvet soft PVC tube.
48362771|NCT03459976|DIAGNOSTIC_TEST|evaluate serum level HE4 in endometrial cancer|"1. HE4 in beignin endometrial diseases~2. HE4 in endometrial cancer"
48511053|NCT00048737|PROCEDURE|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
48676810|NCT02112305|DRUG|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
48676811|NCT04160312|DIETARY_SUPPLEMENT|Mitopure™ (Proprietary Urolithin A)|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
48676812|NCT04160312|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice (approximately 1 glass equivalent)
48676813|NCT04306562|DIETARY_SUPPLEMENT|enteral nutrition supplement|enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
48676814|NCT05860348|DEVICE|Barostim™ System|Implantation of the Barostim™ System
48150721|NCT05063175|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
48150722|NCT05063175|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
48362772|NCT05309785|DRUG|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
48362773|NCT05862675|DIAGNOSTIC_TEST|RNA sequencing of blood samples|Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
48362774|NCT00747942|BEHAVIORAL|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
48676815|NCT00253916|BEHAVIORAL|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
48676816|NCT00253916|BEHAVIORAL|Resistance Exercise Program|Resistance Exercise Program
48676817|NCT01063790|BEHAVIORAL|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
48511054|NCT05210010|DEVICE|CA-4F|"The study intervention is the CA-4F algorithm developed by Ensho Health.~The algorithm is a process for converting input parameters to a CA-4F Risk Score intended to facilitate clinical prioritization of patients suitable for follow-up investigation for ATTR-CM.~The algorithm is applied using the CA-4F Likelihood Estimator which encodes it in software and records its outputs. The CA-4F Likelihood Estimator is controlled through a graphical user interface called the CA-4F Controller.~The CA-4F Likelihood Estimator and its Controller are Class I medical devices in Canada registered under the Medical Device Establishment License of Ensho Health (license 16208)."
48511055|NCT02766283|DRUG|iodinated contrast agents|Intravascular application
48511056|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
48676818|NCT05998486|DIAGNOSTIC_TEST|EMG in wrist flexor-pronators and extensor-supinators|The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.
48511057|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
48511058|NCT00229177|DRUG|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
48511059|NCT01630070|DEVICE|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
48511060|NCT00740012|OTHER|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
48511061|NCT00740012|OTHER|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
48511062|NCT00740012|OTHER|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
48511063|NCT00740012|OTHER|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
48511064|NCT00740012|OTHER|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
48511065|NCT00740012|OTHER|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
48676819|NCT06183489|DRUG|Elranatamab|Elranatamab will be administered via a subcutaneous injection (SC)
48676820|NCT05575700|DRUG|Ibuprofen|400 mg tablet three times daily
48676821|NCT05575700|DRUG|Placebo|tablet three times daily
48676822|NCT06387069|DRUG|HMPL-306 Regimen|Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
48676823|NCT06387069|DRUG|Salvage Chemotherapy Regimen|"Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:~* MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).~* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).~* LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).~* Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7)."
47992230|NCT04164615|DRUG|Placebo control|"Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
47992231|NCT02604524|DEVICE|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
48150723|NCT01697982|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
48362775|NCT05713929|OTHER|Recruitment maneuver (RM)|performance of a recruitment maneuver of 30 cm H20 for 30 seconds and measurement of electrical impedance
48362776|NCT05713929|OTHER|Reverse Trend (REV TREND)|Place the patient in the reverse trendelenburg position and measuring the electrical impedance after 5 minutes
48676824|NCT02271893|DRUG|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
48362777|NCT04785781|OTHER|without masks|apply a bicycle ergometer test protocol to individuals without a mask
48362778|NCT04785781|OTHER|Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)|apply a bicycle ergometer test protocol to individuals with a surgical mask
48362779|NCT04785781|OTHER|FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)|apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
48676825|NCT05255302|DRUG|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
48676826|NCT05255302|DRUG|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
47992232|NCT02604524|OTHER|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
47992233|NCT04150276|PROCEDURE|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
48362780|NCT05990257|PROCEDURE|HHB+TAPB+and LA|Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)
48150724|NCT01697982|BEHAVIORAL|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
48150725|NCT02267122|PROCEDURE|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
48362781|NCT05990257|PROCEDURE|HHB+LA|Hepatic Hilar Block (HHB) and Local Anesthesia (LA)
48362782|NCT05990257|PROCEDURE|TAPB+LA|Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
48150726|NCT02267122|PROCEDURE|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
48362783|NCT05278611|DRUG|EP-9001A|The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
48362784|NCT05278611|DRUG|placebo|placebo
48362785|NCT00149227|DRUG|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
48362786|NCT00149227|DRUG|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
48362787|NCT00060333|RADIATION|radiation therapy|
48362788|NCT05032391|BIOLOGICAL|The pentavalent rotavirus vaccine (live attenuated oral, freeze-dried)|Three times orally in a volume of 2.5 ml (1 dose)
48362789|NCT05032391|DRUG|Placebo|Three times orally in a volume of 2.5 ml (1 dose)
48511066|NCT00362466|DRUG|Dasatinib|Tablets, Oral, Once daily, 5-7 years
48676827|NCT05255302|DRUG|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
48676828|NCT05255302|DRUG|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
48676829|NCT00038948|DRUG|Sirolimus|Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
47992234|NCT04150276|PROCEDURE|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
48362790|NCT06201936|BEHAVIORAL|Preliminary information on neuroaxial procedures|Pre-existing information of pregnant women on neuroaxial pain-relieving procedures for childbirth and their informative sources
48150727|NCT03315195|DIETARY_SUPPLEMENT|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
48150728|NCT00529529|DRUG|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
48150729|NCT00529529|DRUG|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
48150730|NCT00529529|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
48150731|NCT00529529|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
48362791|NCT00004728|DRUG|Warfarin|
48676830|NCT00038948|DRUG|tacrolimus|
48362792|NCT00004728|DRUG|Aspirin|
48511067|NCT00362466|DRUG|Imatinib|Tablets, Oral, Once daily, 5-7 years
48676831|NCT00038948|DRUG|Cyclosporine A|
48676832|NCT00484796|PROCEDURE|MED-SEP|intraoperative neurophysiological monitoring
48676833|NCT00484796|PROCEDURE|TRI-SEP|intraoperative neurophysiologic monitoring
48676834|NCT00484796|PROCEDURE|neuropsychological tests|neurological short- and longterm outcome
48676835|NCT05361174|BIOLOGICAL|IOV-4001|A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
47992235|NCT05118451|PROCEDURE|3 d visualization technology|3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
48676836|NCT02916069|DEVICE|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
47992236|NCT00491010|PROCEDURE|radiofrequency catheter ablation|
47992237|NCT00104455|DRUG|activated recombinant human factor VII|
47992238|NCT01578395|RADIATION|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
47992239|NCT01578395|RADIATION|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
47992240|NCT01578395|OTHER|No radiation exposure|Subjects not undergoing any radiation exposure
47992241|NCT01679379|PROCEDURE|Absorbable suture group|Skin is closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\]
47992242|NCT01679379|PROCEDURE|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
47992243|NCT01253759|PROCEDURE|TTT + ICG-based PDT|
47992244|NCT04297137|DIETARY_SUPPLEMENT|Protein ingestion|Ingestion of various sustainable non-animal derived protein sources compared to animal-based milk protein.
47992245|NCT05339503|OTHER|enamel microabrasion|It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.
47992246|NCT02583776|DEVICE|Unblinded - CGM|Data from device will be readable and alarms on
47992247|NCT02583776|DEVICE|Blinded - CGM|Data from device will be blinded and alarms off
47992248|NCT00446407|OTHER|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
47992249|NCT00446407|OTHER|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
48676837|NCT02916069|DEVICE|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
48362793|NCT05272969|DIAGNOSTIC_TEST|Beck depression inventory fast screen (Questionnaire)|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
48362794|NCT05272969|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI) (Questionnaire)|Validated questionnaire for pain.
48362795|NCT05272969|DIAGNOSTIC_TEST|German Pain Inventory (Questionnaire)|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
48362796|NCT05272969|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS) (Questionnaire)|Validated questionnaire for perceived fatigue
48362797|NCT05272969|DIAGNOSTIC_TEST|Rotterdam Handicap Scale (RHS) (Questionnaire)|validated questionnaire to assess a patient's functional ability and level of handicap
48676838|NCT02916069|DEVICE|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
48676839|NCT04541485|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
48676840|NCT04541485|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
48676841|NCT06379828|OTHER|Please note that this is an observational study; not applicable|Please note that this is an observational study; not applicable
47992250|NCT05446402|COMBINATION_PRODUCT|Geologie Acne Regimen - one side of face|"Geologie is an over-the-counter cosmetic acne regimen with three products. The regimen also has three levels over the course of three months, in which the nighttime lotion is switched to a stronger formula each month. The Geologie Clear System regimen for acne prone skin includes:~1. Clarifying Gel Cleanser - SA Formula (2% Salicylic Acid)~2. Brightening Day Cream - SPF 15 (5% Azelaic Acid, 2% Hyaluronic Acid, 1%Niacinamide)~3. Repairing Night Cream -~   1. Level 1 (0.05% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  2. Level 2 (0.2% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)~  3. Level 3 (0.3% Retinol, 3% Niacinamide, 2% Hyaluronic Acid)"
48150732|NCT04018521|BEHAVIORAL|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
47992251|NCT05446402|COMBINATION_PRODUCT|Proactive Acne Regimen - other side of face|"ProActiv is an over-the-counter cosmetic regimen with three products. The~Proactiv Solution 3-Piece System regimen includes:~1. Renewing Cleanser (Active ingredient: 2.5% Benzoyl Peroxide)~2. Revitalizing Toner (Glycolic Acid)~3. Repairing Treatment (Active ingredient: 2.5% Benzoyl Peroxide)"
48150733|NCT04018521|BEHAVIORAL|CSC Usual Care|standard of care provided to youth following first episode of psychosis
48150734|NCT01305837|DRUG|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
48150735|NCT02017509|PROCEDURE|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
48362798|NCT05272969|DIAGNOSTIC_TEST|R-PAct (Questionnaire)|The R-PAct scale is designed specifically for Pompe disease, which consists of 18 items addressing daily life activities with three response options.
48362799|NCT05272969|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
48362800|NCT05272969|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
48362801|NCT05272969|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. If a six-minute-walk-test was performed within the last 3 months within the routine treatment, no additional test will be performed and the distance walked in meters as well as borg scale will be recorded in the study CRF, including the date of the assessment. If not performed within the last six months, a six-minute-walk test will be performed once.
48362802|NCT05272969|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
48362803|NCT05272969|DIAGNOSTIC_TEST|Muscle ultrasound|Muscle ultrasound is an ideal imaging modality that allows for atraumatic, noninvasive, radiation-free point-of-care neuromuscular imaging. Muscular diseases are typically associated with an increase in the echogenicity from the muscle substance, distal attenuation of muscle echo and a corresponding loss of bone echo. A measurement on both sides deltoid, biceps and triceps brachii muscle, quadriceps femoris muscle, tibialis anterior muscle, rectus abdominis muscle and paravertebral muscles of cervical (C5-7), thoracic (Th4-6) and lumbar (L4-5) muscles. Muscle tissue alterations will be classified using the Heckmatt scale I-IV, describing muscle echogenicity. For muscle ultrasound, a linear 17MHz probe will be used. The muscle ultrasound assessment usually takes 15-20 minutes.
48511068|NCT00117832|DRUG|Azelastine nasal spray|
48511069|NCT05327673|OTHER|questionnaire|"* quality of life score: FACT-BMT~* decisional conflict scale~* Discreet Choice Experiment questionnaire"
48511070|NCT06188624|DRUG|TQB2922 for injection|TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
48676842|NCT01131897|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
48676843|NCT03513315|BEHAVIORAL|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
48362804|NCT05272969|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
48362805|NCT05272969|DIAGNOSTIC_TEST|Borg Scale|The Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
48362806|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Creatine kinase|CK-Level assessment in peripheral blood (peripheral venous blood draw)
48362807|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: Vitamin D Level|Vitamin D Level in peripheral blood (peripheral venous blood draw)
48362808|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: calcium|calcium level in peripheral blood (peripheral venous blood draw)
48362809|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: magnesium|magnesium level in peripheral blood (peripheral venous blood draw)
48362810|NCT05272969|DIAGNOSTIC_TEST|Laboratory assessment: phosphate|phosphate level in peripheral blood (peripheral venous blood draw)
48150736|NCT02017509|PROCEDURE|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
48150737|NCT02017509|PROCEDURE|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
48362811|NCT05272969|GENETIC|Genetic test: ACE polymorphism|peripheral venous blood draw for genetic analysis of ACE polymorphism
48362812|NCT05272969|GENETIC|Genetic test: ACTN3 polymorphism|peripheral venous blood draw for genetic analysis of ACTN3 polymorphism
48362813|NCT05272969|GENETIC|Blood draw for optional genetic exome sequencing|"Optionally, upon additional informed consent, exome sequencing from peripheral blood will be performed in a second step to assess whether polymorphisms or pathogenic mutations in genes that are associated with chronic pain syndromes contribute to increased pain. This analysis will be performed collectively after enrollment is complete by the Genetikum Neu-Ulm. The selection of the genes is based on the Human Phenotype Ontology (HPO) search terms myalgia, muscle pain, chronic pain, musculoskeletal pain, pain, and nociceptive pain."
48362814|NCT01547494|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
48150738|NCT02017509|GENETIC|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
48150739|NCT00035256|DRUG|teriparatide|
48150740|NCT00035256|DRUG|raloxifene HCl|
48150741|NCT00035256|DRUG|placebo|
48150742|NCT01912521|BEHAVIORAL|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
48150743|NCT05177029|DRUG|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
48362815|NCT01547494|DIETARY_SUPPLEMENT|mixture of omega3 and vitamins|mixture of omega3 and vitamins
48362816|NCT03929614|OTHER|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
48362817|NCT01952041|BEHAVIORAL|Device: Smartphone|
48362818|NCT01952041|BEHAVIORAL|Treatment as usual|
48362819|NCT06188403|PROCEDURE|Orthognathic surgery (lefort1)|Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
48362820|NCT04087824|DEVICE|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
48362821|NCT01552408|DRUG|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
48676844|NCT03513315|BEHAVIORAL|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
48676845|NCT03825757|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
48676846|NCT03825757|DRUG|Acetyl Salicylic Acid|Primaspan 250 mg tablet Acetyl Salicylic Acid
48150744|NCT05177029|DRUG|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
48150745|NCT02179086|RADIATION|3-dimensional conformal radiation therapy|Undergo standard-dose 3D-CRT
48150746|NCT02179086|RADIATION|intensity-modulated radiation therapy|Undergo standard-dose IMRT
48150747|NCT02179086|RADIATION|photon beam radiation therapy|Undergo dose-escalated and -intensified photon IMRT
48362822|NCT01552408|PROCEDURE|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
48362823|NCT01813149|DRUG|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
48362824|NCT01813149|OTHER|punch biopsy|
47992252|NCT05328128|BEHAVIORAL|Toilet training|As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
48511071|NCT04302636|DIETARY_SUPPLEMENT|Low glycemic index diet|The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
47992253|NCT05190731|OTHER|Osteopathic cranial manipulative medicine|Osteopathic cranial manipulative medicine technique using compression of 4th ventricle technique
48150748|NCT02179086|RADIATION|intensity-modulated radiation therapy|Undergo dose-escalated and -intensified photon IMRT
48150749|NCT02179086|RADIATION|proton beam radiation therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
48150750|NCT02179086|DRUG|temozolomide|Given PO
48511072|NCT01015469|PROCEDURE|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
48150751|NCT02179086|OTHER|laboratory biomarker analysis|Correlative studies
48150752|NCT00539604|PROCEDURE|MDCT and Coronary Angiography|
48362825|NCT04312958|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
48362826|NCT00756223|DRUG|Arm A|Dose escalation Arm A (4 weeks)
48362827|NCT00756223|DRUG|Arm B|Dose escalation Arm B (3 weeks)
48511073|NCT01015469|PROCEDURE|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
48511074|NCT03491657|BEHAVIORAL|virtual reality distraction (Yes VR)|
48150753|NCT01789593|OTHER|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
48511075|NCT03491657|BEHAVIORAL|music distraction (No VR)|
48362828|NCT03819504|PROCEDURE|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
48362829|NCT01017640|OTHER|Laboratory Biomarker Analysis|Correlative studies
48362830|NCT01017640|DRUG|Mitomycin|Given IV
48362831|NCT01017640|DRUG|Veliparib|Given PO
48676847|NCT03567889|DRUG|Daromun|Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
48676848|NCT03567889|PROCEDURE|Surgery|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
47992254|NCT05190731|OTHER|Sham|Touch only, no osteopathic cranial manipulation
47992255|NCT05632549|DRUG|Placebo|Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
47992256|NCT05632549|DRUG|L-Carnitine 500Mg Oral Tablet|Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
48150754|NCT00632736|DRUG|Ropinirole XL (formerly CR)|
48150755|NCT04255823|OTHER|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
48150756|NCT04255823|OTHER|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
48150757|NCT01156194|DRUG|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
48150758|NCT01156194|DRUG|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
48150759|NCT01156194|DRUG|Placebo|globule identical to true homeopathy comparators
48362832|NCT05879380|DIAGNOSTIC_TEST|MRPA|patients will receive an extra MRPA, on top of the standard CTPA
48362833|NCT05879380|DIAGNOSTIC_TEST|CPTA|patients will receive an extra MRPA, on top of the standard CTPA
48676849|NCT03567889|DRUG|Adjuvant therapy|Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
48676850|NCT04384471|OTHER|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
48676851|NCT01144143|DRUG|Infliximab|the study drug will be injected into the joint through a needle
48676852|NCT01144143|DRUG|Placebo|the placebo will be injected into the joint through a needle
48676853|NCT01144143|DRUG|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
48150760|NCT02201992|OTHER|Clinical Observation|Undergo observation
48150761|NCT02201992|DRUG|Crizotinib|Given PO
48676854|NCT01726543|PROCEDURE|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
48676855|NCT01726543|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
48511076|NCT04928768|OTHER|Questionnaire|A validated questionnaire (five-point Likert scale) through 10 items developed by Lee et al 2018 is employed to measure the level of orthodontic treatment satisfaction in 10 items; overall satisfaction, tooth alignment, facial appearance, eating and chewing, confident smile and self-image, retention state, treatment duration, treatment costs, intention to recommend, and relief of previous concerns. Total satisfaction is calculated by averaging the Likert scores from the 10 items
48511077|NCT02028741|OTHER|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
48362834|NCT05638529|DRUG|Pregnyl (1,500) IU|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of hCG (Pregnyl 1,500 IU) on their assigned trigger day.
48362835|NCT05638529|DRUG|1.5 mL of normal saline|Patients will self-administer a subcutaneous injection of a GnRH agonist (Suprefact 0.5 mg) and a separate intramuscular injection of normal saline (1.5 mL - sham placebo) on their assigned trigger day.
48150762|NCT02201992|OTHER|Laboratory Biomarker Analysis|Correlative studies
48150763|NCT01249144|DEVICE|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
48150764|NCT02955225|DEVICE|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
48362836|NCT04846634|DRUG|Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
48511078|NCT01059578|DRUG|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
48150765|NCT02955225|DEVICE|Passive shoe insole|A deactivated insole measures shoe pressure only.
48150766|NCT04389086|DRUG|Combination drug|"Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI."
48150767|NCT04389086|RADIATION|Chemoradiotherapy|"Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy."
48150768|NCT04389086|PROCEDURE|Surgery locally recurrent rectal cancer|"Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional."
48150769|NCT03185143|DRUG|Naltrexone and Acetaminophen Combination|Treat a single Qualified Migraine attack.
48150770|NCT03185143|DRUG|Sumatriptan 100 mg|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
48150771|NCT03185143|DRUG|Placebo|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
48150772|NCT03100851|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.
48150773|NCT06416345|DEVICE|Cue2Walk|24 weeks of using of the Cue2Walk device in the own living environment + 8 weeks of naturalistic follow-up
48150774|NCT06416345|OTHER|Usual Care|24 weeks of receiving usual care + 8 weeks of using of the Cue2Walk device in the own living environment
48150775|NCT00006214|DRUG|flutamide|
48150776|NCT00006214|OTHER|placebo|
48150777|NCT02207777|PROCEDURE|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose approximately 16-18% (with a range of 16-25%) of their body weight.
48150778|NCT02207777|BEHAVIORAL|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 6 months to lose approximately 16-18% (with a range of 16-25%) of their body weight.
48150779|NCT05236868|DRUG|Seltorexant|Seltorexant will be administered orally as a tablet and as an intravenous infusion of 14C-seltorexant.
48150780|NCT05396755|PROCEDURE|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
48150781|NCT04371445|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
48150782|NCT04371445|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
48150783|NCT03385226|DRUG|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
48150784|NCT03385226|RADIATION|Radiotherapy|12Gy in 3 fractions
48150785|NCT05941156|BIOLOGICAL|Anti-CD56 CAR T|CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
48150786|NCT05852509|BEHAVIORAL|TPA4You|TPA4You integrates technology components in the form of video-conferencing (e.g., Zoom) with a health coach, wearable sensor (e.g., Fitbit), and personalized text messaging into a package to (a) tailor physical activity (PA) prescriptions based on the family care partners of persons with heart failure (HF-FCP)'s feedback and individual wearable sensor data, (b) provide tailored PA coaching sessions using video-conferencing, and (c) motivate daily exercise using text messages.
48511079|NCT01059578|DRUG|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
48150787|NCT05852509|BEHAVIORAL|Attention control group|Participants will be given booklets, provided by the NIA, AHA, and National Alliance for Caregiving, that include content about self-care for FCPs' health and well-being, but not specific to PA or exercise. Participants will receive text messages every other day to encourage them to wear the Fitbit device, and to provide friendly greetings and reminders of upcoming survey data collection.
48150788|NCT06388824|DRUG|normal saline|Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
48150789|NCT06388824|DRUG|Esketamine|Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery
48150790|NCT05986851|DRUG|Azeliragon|Oral capsule
48150791|NCT05546021|PROCEDURE|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
48150792|NCT03785756|DRUG|Ibuprofen 300 mg Oral Tablet|2 × 300 mg tablets at Hours 0 and 12
48150793|NCT03785756|DRUG|Ibuprofen 200 mg Oral Tablet|2 × 200 mg tablets at Hours 0, 8, and 16
48150794|NCT03785756|DRUG|Placebo of PR tablet|2 tablets up to four times in 24 hours
48150795|NCT03785756|DRUG|Placebo of IR tablet|2 tablets up to four times in 24 hours
48150796|NCT03063021|DRUG|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
48150797|NCT03044756|DRUG|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
47992257|NCT05632549|DRUG|Biotin Capsules|Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
47992258|NCT00010465|PROCEDURE|Craniosacral Osteopathic Manipulative Treatment|
47992259|NCT00010465|DRUG|Botanicals|
47992260|NCT05089682|DEVICE|DBS Stimulation during sleep|Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
48150798|NCT06378320|OTHER|App access and Text message|Access to App and Text messages with app related breastfeeding related question
48150799|NCT06378320|OTHER|App access only|Access to App without Text messages with app related breastfeeding related question
48150800|NCT03968276|OTHER|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
48150801|NCT00188747|PROCEDURE|Thromboelastograph, Point of Care|
48150802|NCT06128356|DRUG|Dexmedetomidine Sublingual|Dexmedetomidine 120 mcg on two thin dissolvable films for sublingual administration
48150803|NCT06147440|OTHER|Dietary intervention|Participants receive diets following different dietary patterns for 1 week.
48150804|NCT00621842|DRUG|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
48676856|NCT03729986|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
47992261|NCT00103181|RADIATION|3-dimensional conformal accelerated partial breast irradiation|
47992262|NCT00103181|RADIATION|brachytherapy|
47992263|NCT00103181|RADIATION|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
47992264|NCT00103181|RADIATION|MammoSite or other single-entry intracavitary device|
47992265|NCT04902456|PROCEDURE|Power chain and Crimpable hook fro En-masse Retraction|"Retraction will start on a 0.017x0.025 stainless steel wire using elastomeric chain ( for applied will be 212 g per side ) extending between the cripmable hooks and the miniscrew"
47992266|NCT04902456|PROCEDURE|T-loop|closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine.
47992267|NCT05667038|DRUG|Probiotic|"The probiotics sachet contains a granular powder with 6 microorganism strains (30 × 109 CFU/gram): Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, and Bifidobacterium longum BCMC®02120.~The drug is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
48150805|NCT00621842|DRUG|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
48150806|NCT03741634|OTHER|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (\~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
48150807|NCT03669419|DIAGNOSTIC_TEST|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
48150808|NCT02237456|PROCEDURE|Comparison of OCT scans|
47992268|NCT05667038|DIETARY_SUPPLEMENT|Placebo|"Placebo:~Subjects in the placebo group will receive the placebo consisting of only the carrier of the probiotic product, that is maize starch and maltodextrins.~The sachet is consumed orally, two sachets per day, by dissolving the sachet content in a glass of room-temperature water, one before breakfast and one before the last meal, for three months length."
47992269|NCT03608579|DRUG|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
48150809|NCT02237456|PROCEDURE|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
48150810|NCT03306329|DRUG|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
48150811|NCT03306329|DRUG|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
48150812|NCT03306329|DRUG|Placebo|Placebo tablets administered once daily
48150813|NCT05620199|PROCEDURE|Upfront resection|Resection of the primary tumor
48150814|NCT03945409|DEVICE|OPTIVENT|OPTIVENT (SIDAM SRL, Mirandola, Italy) is a new fully automated and self-calibrating system that allows a real-time monitoring and recording of airway pressure and esophageal pressure during mechanical ventilation. The system required the insertion of an esophageal balloon catheter and an airway pressure transducer.
48150815|NCT04468737|BEHAVIORAL|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
48150816|NCT05926557|PROCEDURE|Spermidine gel|First step: Non-surgical mechanical debridement (NSMD) Second step: application of spermidine gel
48150817|NCT05926557|PROCEDURE|NSMD|Only mechanical debridement with curettes and scaler peek tips
48362837|NCT04846634|DRUG|Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel|A cycle of treatment is defined as 21 days of once daily treatment.
47992270|NCT03879382|BIOLOGICAL|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
47992271|NCT03879382|DRUG|Fludarabine|30mg/m2/d
47992272|NCT03879382|DRUG|Cyclophosphamide|300mg/m2/d
47992273|NCT03832582|DRUG|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
47992274|NCT01316276|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
47992275|NCT05547074|PROCEDURE|pancreatic cancer surgery|Surgical resection of pancreatic cancer，including radical or palliative surgery
47992276|NCT03900000|OTHER|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
48150818|NCT01531699|DRUG|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
48150819|NCT01531699|OTHER|saline control|single application for up to 6 hours
48150820|NCT01531699|DRUG|Betadine ophthalmic prep solution|single application for up to 6 hours
48150821|NCT02734394|BEHAVIORAL|Exercise|Cardiovascular and resistance exercise training
48150822|NCT04099186|PROCEDURE|catheter directed hydro-mechanical fragmentation of pulmonary embolism|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
48362838|NCT04846634|DRUG|Penpulimab+Anlotinib|A cycle of treatment is defined as 21 days of once daily treatment.
48511080|NCT01059578|RADIATION|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
48511081|NCT04779554|DRUG|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
48511082|NCT04779554|DRUG|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
48150823|NCT01861509|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
48150824|NCT02936401|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
48150825|NCT03858556|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
48150826|NCT03858556|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
48150827|NCT03858556|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48150828|NCT03858556|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48150829|NCT03858556|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48150830|NCT03858556|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48676857|NCT02287194|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
47992277|NCT04811170|OTHER|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
48150831|NCT03858556|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
47992278|NCT02503332|DRUG|Pegcetacoplan|
48150832|NCT03858556|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
48150833|NCT00243568|DRUG|Vicriviroc|
48511083|NCT05976165|OTHER|Breath Testing|Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
48511084|NCT04774744|OTHER|Educational Intervention|Receive digital health coaching program
48511085|NCT04774744|OTHER|Questionnaire Administration|Ancillary studies
47992279|NCT02503332|OTHER|Sham Procedure|
47992280|NCT04250571|OTHER|"information about No treatment group"|Participants will receive no pills and will be told that they are in the no treatment group
47992281|NCT04250571|OTHER|imaginary pill technique|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
47992282|NCT04250571|OTHER|open label placebo|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders."
47992283|NCT05749302|DRUG|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
47992284|NCT02205333|BIOLOGICAL|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
47992285|NCT02205333|BIOLOGICAL|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
47992286|NCT02205333|BIOLOGICAL|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
47992287|NCT02205333|BIOLOGICAL|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
47992288|NCT03084588|DRUG|methadone|Patients will be given methadone at induction of anesthesia
47992289|NCT03084588|PROCEDURE|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
48511086|NCT04774744|OTHER|Supportive Care|Receive standard of care support services
48511087|NCT01141205|BIOLOGICAL|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
48511088|NCT01141205|DRUG|Saline|1.2 ml saline intramuscularly
48676858|NCT02906410|OTHER|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
48676859|NCT02906410|OTHER|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
47992290|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Standard dose|"Standard Dose - (30ug in 0.3ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
47992291|NCT05387317|BIOLOGICAL|AstraZeneca Standard dose|"Standard Dose (5xE10vp in 0.5ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
47992292|NCT05387317|BIOLOGICAL|Pfizer-BioNTech Fractional dose|"Fractional Dose - (15ug in 0.15ml)~The Pfizer-BioNTech COVID-19 vaccine, BNT162b2, encodes a P2 mutant spike protein and is formulated as an RNA-lipid nanoparticle (LNP) of nucleoside-modified mRNA (modRNA)."
48676860|NCT03417466|DEVICE|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
47992293|NCT05387317|BIOLOGICAL|AstraZeneca Fractional dose|"Fractional Dose (2.5E10vp in 0.25ml)~ChAdOx1 nCoV-19 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 spike (S) surface glycoprotein"
48676861|NCT03523689|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
48150834|NCT06502067|DRUG|Analgesia mangement group A,B|1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
48150835|NCT01351896|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48150836|NCT01351896|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48150837|NCT01351896|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48511089|NCT06160219|DRUG|Hydroxycobalamin|prophylactic use of hydroxycobalamin in vasoplegia in high risk patients undergoing cardiac surgeries
48511090|NCT02623985|DEVICE|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
48511091|NCT02623985|DEVICE|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
48511092|NCT02623985|DEVICE|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
48511093|NCT00259233|DRUG|peripheral Peptide YY administration|
48676862|NCT03523689|PROCEDURE|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
47992294|NCT05387317|BIOLOGICAL|Moderna Standard dose|Standard dose (50ug in 0.25ml)
47992295|NCT05387317|BIOLOGICAL|Moderna Fractional dose|Fractional dose (20ug in 0.1ml)
47992296|NCT05103215|DRUG|Lidocaine HCl 2%|Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
47992297|NCT05103215|DRUG|Normal saline|Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
48150838|NCT01351896|PROCEDURE|Computed Tomography|Undergo CT
48150839|NCT01351896|DRUG|Lenalidomide|Given PO
48511094|NCT00459043|DRUG|ZD6474|Taken orally once every morning
48511095|NCT00459043|DRUG|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
48676863|NCT04609605|DEVICE|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
48676864|NCT03155763|PROCEDURE|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
48676865|NCT05812352|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
48676866|NCT05812352|BEHAVIORAL|Instructional flashcard|Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
48676867|NCT05812352|BEHAVIORAL|In-person training|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
48676868|NCT00609752|DRUG|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
48676869|NCT00609752|DIETARY_SUPPLEMENT|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
48150840|NCT01351896|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
48676870|NCT02621437|OTHER|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
48676871|NCT02621437|OTHER|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire"
47992298|NCT01142310|DRUG|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
48150841|NCT04063449|DRUG|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
48150842|NCT04063449|DRUG|endostar|Antiangiogenic therapy plus chemotherapy
48150843|NCT01798537|DRUG|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
48150844|NCT03149484|DEVICE|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
48150845|NCT03149484|OTHER|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
48150846|NCT03933098|BIOLOGICAL|Test Vaccine Vi-DT Typhoid conjugate|"* Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial"
48150847|NCT03933098|BIOLOGICAL|Control Vaccine Typbar TCV®|"* Manufacturer: Bharat Biotech~* Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~* Dose: 0.5 ml"
48150848|NCT01680315|BEHAVIORAL|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
48150849|NCT01680315|BEHAVIORAL|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
48150850|NCT01652014|DRUG|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
48676872|NCT00903422|DRUG|eltrombopag olamine|thrombopoietin receptor agonist
48676873|NCT00903422|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
48676874|NCT05252286|OTHER|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
48676875|NCT05252286|OTHER|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
48676876|NCT05252286|OTHER|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
48676877|NCT02840279|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
48676878|NCT02840279|DRUG|Placebo|
47992299|NCT01142310|DRUG|Placebo|
48150851|NCT01652014|DRUG|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
48150852|NCT01652014|DRUG|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
48150853|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
48150854|NCT01652014|PROCEDURE|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
48150855|NCT01652014|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
48150856|NCT01652014|RADIATION|total-body irradiation|Undergo TBI
48150857|NCT01652014|DRUG|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
48150858|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
48150859|NCT01652014|PROCEDURE|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
48150860|NCT00694902|DRUG|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
48362839|NCT01491711|DRUG|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
48511096|NCT01297985|BEHAVIORAL|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
48511097|NCT05329662|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency|"* Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~* Dose: 1.0 x 106 cells/kg patient bodyweight.~* Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10\^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"
48676879|NCT06252844|BEHAVIORAL|Resistance exercise training|Supervised PRT will consist of leg extension, leg curl, leg press, and calf raises. Initially participants will start with a 4 weeks adaptation with low loads at 15 (repetition maximum, RM) conducting for 1-3 sets. Further on subjects will continue with a 5 month of PRT with intensity increasing every 2 weeks from 12 to 6 RM. Each exercise will be done for 3 sets with 2 min rest periods between sets. After the 2 weeks at 6 RM, 1 week of rest will be applied. After the rest week, the same cycle starting from 12 RM will be repeated until the end of intervention.
48676880|NCT06252844|BEHAVIORAL|Active control|Supervised static stretching exercises will be performed without causing an unpleasant feeling of stretching, up to pain, maintaining the stretching position for at least 30 s. Exercises will be performed slowly so that heart rate (HR) does not exceed 50% maximum. Subjects will calculate their HR before training, in the middle and after the training measuring the pulse for 10 s. Exercises will be repeated 3-5 times for each side of the body. The duration of the training will be match to PRT group and will take around 40 min. In order to keep the subjects interested and motivated, two of the stretching exercises will be changed every two weeks.
48150861|NCT00694902|DRUG|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
48150862|NCT04680559|BEHAVIORAL|MCBI|The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
48150863|NCT04680559|BEHAVIORAL|Active Comparator|Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
48150864|NCT06383507|DRUG|CHT101|After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
48150865|NCT05542004|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
48150866|NCT05587907|DEVICE|FitLight Trainer|Evaluation of the reaction time before and after special training program using visual stimuli.
48150867|NCT01277679|PROCEDURE|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
48150868|NCT01237600|PROCEDURE|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
48150869|NCT06119802|DIAGNOSTIC_TEST|atrial fibrillation|ECG of atrial fibrillation last more than 30 seconds.
48362840|NCT01491711|DRUG|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
48676881|NCT04084535|OTHER|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
48676882|NCT04084535|OTHER|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
48150870|NCT06180109|DRUG|Empagliflozin film coated tablets|1 film coated tablet of 25 mg Empagliflozin
48150871|NCT06180109|DRUG|Jardiance film-coated tablets|1 film coated tablet of 25 mg Empagliflozin
48150872|NCT00832650|DRUG|fesoterodine fumarate|8 mg OD for 14 days
48150873|NCT00832650|DRUG|placebo|OD for 14 days
48150874|NCT00832650|DRUG|solifenacin|10 mg OD for 14 days
48150875|NCT00732498|DRUG|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
48150876|NCT00732498|DRUG|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
48362841|NCT04164264|DRUG|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS \<60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
48150877|NCT00732498|DRUG|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
48150878|NCT00732498|DRUG|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
48362842|NCT00245869|PROCEDURE|Contrast-enhanced Ultrasound|
48150879|NCT00732498|DRUG|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
48150880|NCT00732498|DRUG|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
48150881|NCT00732498|DRUG|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
48150882|NCT02429973|DRUG|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
48150883|NCT00753896|DRUG|exenatide|subcutaneous injection, 2.0mcg, once weekly
48150884|NCT00441168|DRUG|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
48150885|NCT00441168|DRUG|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
48150886|NCT00441168|DRUG|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
48150887|NCT00441168|DRUG|vincristine|vincristine: 0.4mg IV push on days 1 to 4
48150888|NCT05912998|PROCEDURE|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
48362843|NCT05733468|DRUG|Theracal LC|After hemorrhage control , 1-1.5mm of TheraCal LC will be placed on the radicular pulp stumps followed by light curing, followed by the placement of IRM and composite restorative material after 2 weeks
48362844|NCT05733468|DRUG|MTA|After hemorrhage control , a small ball like consistency of 2-3mm of MTA will be placed on the radicular pulp stumps, followed by the placement of IRM and composite restorative material after 2 weeks
48676883|NCT05118113|PROCEDURE|Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers|Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5
48676884|NCT02948764|DEVICE|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
48362845|NCT00483067|DRUG|2-CdA|12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days
48362846|NCT00483067|DRUG|Ara-C|1 gm/m\^2/day IV Over 2 Hours x 5 Days
48362847|NCT00483067|DRUG|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
48150889|NCT02082639|BIOLOGICAL|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
48150890|NCT02082639|BIOLOGICAL|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
48150891|NCT02718456|BEHAVIORAL|Expedited CD4 testing|
48362848|NCT04417816|OTHER|Exercise training intervention with ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
48362849|NCT04417816|OTHER|Exercise training intervention without ultrasound induced adipose tissue cavitation|Exercise training intervention with ultrasound induced adipose tissue cavitation
48362850|NCT02896998|PROCEDURE|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
48362851|NCT02896998|PROCEDURE|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
48362852|NCT03579004|DRUG|Paclitaxel|Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
47992300|NCT05695924|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
47992301|NCT05695924|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
47992302|NCT00739037|DRUG|Placebo|
47992303|NCT00739037|DRUG|PAZ-417|
47992304|NCT02659527|DRUG|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
47992305|NCT02659527|DEVICE|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
47992306|NCT01510379|DEVICE|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
47992307|NCT01510379|DRUG|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
47992308|NCT01510379|DRUG|IV promethazine 25 mg q 6 hours prn|
47992309|NCT01510379|DRUG|Elixir promethazine 25 mg q 6 hours prn after discharge|
48362853|NCT03579004|DRUG|Cisplatin|Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
48676885|NCT04305626|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
48676886|NCT02748681|DEVICE|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
47992310|NCT02164305|OTHER|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
47992311|NCT02164305|OTHER|Neuromuscular group|Closed-chain exercise for shoulder muscles
47992312|NCT02164305|OTHER|Control|No exercise training
47992313|NCT04851886|DEVICE|BURT|Robot-assisted upper-limb individual (i.e. one-on-one) rehabilitation will be delivered using the BURT system by Barrett Technology
47992314|NCT04851886|DEVICE|BURT + PostureCheck|Robot-assisted upper-limb group (i.e. up to three subjects) rehabilitation will be delivered using the BURT system by Barrett Technology + PostureChek (a camera-based system to track the quality of the exercises)
47992315|NCT02344680|DRUG|Anti-HIV Agents|
47992316|NCT04165512|COMBINATION_PRODUCT|bupivacaine and triamcinolone|a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
47992317|NCT02478554|OTHER|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
47992318|NCT03331146|DRUG|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
47992319|NCT03331146|DRUG|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
47992320|NCT02434731|DEVICE|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
48150892|NCT02718456|BEHAVIORAL|Supplemental peer counseling|
48150893|NCT04093050|DRUG|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
48150894|NCT05822791|DIAGNOSTIC_TEST|Prolonged cardiac monitoring|Prolonged cardiac monitoring
48150895|NCT05822791|DIAGNOSTIC_TEST|ECG|Electrocardiogram
48676887|NCT03619993|DEVICE|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
48150896|NCT05971615|OTHER|peripheral venous blood gases|peripheral venous blood gases
48362854|NCT03579004|DRUG|Fluorouracil|Fluorouracil is used in two cycles of neoadjuvant chemotherapy
48362855|NCT03579004|RADIATION|chemoradiotherapy|Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
48362856|NCT03579004|PROCEDURE|Ivor Lewis esophagogastrectomy|Open Ivor Lewis esophagogastrectomy
48362857|NCT02500901|DRUG|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
48362858|NCT02500901|DRUG|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
48362859|NCT03040479|DRUG|lasmiditan 200 mg|single dose
48511098|NCT01332292|DRUG|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
48150897|NCT01694147|DEVICE|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
48150898|NCT01625494|DRUG|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
48150899|NCT01625494|DRUG|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
48150900|NCT01625494|DRUG|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
48676888|NCT03619993|DEVICE|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
48362860|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
48362861|NCT02666118|PROCEDURE|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
48362862|NCT02666118|PROCEDURE|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
48511099|NCT01332292|DRUG|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
48511100|NCT01853800|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|
48676889|NCT02307448|PROCEDURE|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
48676890|NCT02307448|PROCEDURE|Standard of Care|Patients will receive weekly standard of care.
48150901|NCT01625494|DRUG|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
48150902|NCT01528605|DIETARY_SUPPLEMENT|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
48150903|NCT01528605|DIETARY_SUPPLEMENT|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
48150904|NCT01528605|DIETARY_SUPPLEMENT|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
48150905|NCT01528605|DIETARY_SUPPLEMENT|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
48150906|NCT01528605|DIETARY_SUPPLEMENT|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
48676891|NCT03775317|PROCEDURE|Video Laryngoscopy|The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
48676892|NCT03775317|PROCEDURE|Direct Laryngoscopy|The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
48676893|NCT02115035|DRUG|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
48150907|NCT01528605|DIETARY_SUPPLEMENT|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
48676894|NCT01652313|DRUG|Rasagiline|1 mg/day, tablets for 7 days, orally
48150908|NCT04618653|OTHER|assessment only|Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
48150909|NCT01318356|BEHAVIORAL|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
48150910|NCT01318356|DRUG|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
48150911|NCT01318356|DRUG|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
48150912|NCT01432223|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
48150913|NCT02745509|OTHER|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
48150914|NCT02964234|BEHAVIORAL|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
48150915|NCT02964234|BEHAVIORAL|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
48150916|NCT03518450|PROCEDURE|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
48362863|NCT02666118|PROCEDURE|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
48362864|NCT00331058|PROCEDURE|Bronchoscopsy|Healthy and Asthmatic Volunteers
48362865|NCT00331058|PROCEDURE|Prednisolone|Asthmatic Volunteers
48676895|NCT02178319|PROCEDURE|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
48676896|NCT02178319|PROCEDURE|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
48676897|NCT05373212|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
48676898|NCT05373212|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
48676899|NCT00343564|DRUG|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
47992321|NCT05792228|OTHER|nurse-led standardized intervention|Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
47992322|NCT04528745|DIAGNOSTIC_TEST|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
47992323|NCT01897012|DRUG|Alisertib|Given PO
47992324|NCT01897012|OTHER|Laboratory Biomarker Analysis|Correlative studies
47992325|NCT01897012|DRUG|Romidepsin|Given IV
47992326|NCT05162547|DEVICE|NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA
47992327|NCT02337907|DRUG|Placebo|for blinding purposes
47992328|NCT02337907|DRUG|Placebo|
47992329|NCT02337907|DRUG|BI 409306|
47992330|NCT02337907|DRUG|Donepezil|
47992331|NCT04444414|OTHER|Manual therapy|bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.
47992332|NCT04444414|OTHER|Control group|The control group received no treatment, they only attended the evaluations.
47992333|NCT01318447|RADIATION|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
47992334|NCT02750592|DRUG|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
47992335|NCT04615611|DRUG|salbutamol|inhalation of salbutamol
47992336|NCT04615611|DRUG|Placebo|administration of placebo
47992337|NCT02081690|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
47992338|NCT00123539|DRUG|Estrogen Replacement Therapy|
47992339|NCT00123539|PROCEDURE|Surgery|
48150917|NCT03518450|PROCEDURE|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
48150918|NCT03518450|PROCEDURE|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
48150919|NCT03975361|OTHER|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
48150920|NCT05500261|DRUG|Dexmedetomidine|intranasal administration of dexmedetomidine
48150921|NCT01590056|OTHER|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~1. listening to nonverbal affect bursts corresponding to emotions~2. applying a simple go-no-go auditory test"
48150922|NCT00307489|DRUG|tenofovir DF|300 mg tablet, once daily (QD)
48150923|NCT00307489|DRUG|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
48676900|NCT00343564|DRUG|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
48676901|NCT04579666|DRUG|Pegcetacoplan (APL-2)|Complement (C3) Inhibitor
48676902|NCT04579666|OTHER|Placebo|Sterile solution of equal volume to active arm
48150924|NCT00705172|DRUG|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
48150925|NCT03639545|DRUG|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
48150926|NCT03639545|DRUG|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
48150927|NCT03639545|DRUG|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
48150928|NCT03639545|DRUG|Placebos|The patients receive for 12 weeks.
48362866|NCT03180320|BEHAVIORAL|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~1. Baduanjin exercise;~2. evaluations of exercise capacity and clinical conditions;~3. consultations on exercise prescription and management of symptoms/signs during exercise;~4. education covering topics related to the CHF and exercise; and~5. a series of adherence strategies."
48362867|NCT03180320|DRUG|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
48150929|NCT05140499|DRUG|Liposomal bupivacaine|Popliteal nerve block
48150930|NCT05140499|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution|Continuous nerve catheter
47992340|NCT06081127|OTHER|MOve-ABC|"The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~1. Three in-person visits for clinical measurements~2. Enhanced usual care (EUC)~3. Pre-hab ((Pre-Treatment) PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~4. Teach Back (HEP, post-op movement precautions)~5. Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals."
47992341|NCT06081127|OTHER|Enhanced Usual Care|"All patients will receive EUC. However, half of our sample will have only EUC consisting of~1. Three in-person visits for clinical measurements~2. Planned oncology treatment (surgery, chemotherapy, radiation)~3. Nursing education on surgical site and drain care, post-operative movement precautions, pain management~4. If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~5. Monthly monitoring with Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) surveys beginning at baseline with alerts from scores = or \< 45 (indicating moderate or severe impairment) for physical therapy referral"
47992342|NCT05819333|OTHER|Exercise Program + Respiratory Strength Training|Strength, Flexibility, Cardiovascular exercise + respiratory strength training
47992343|NCT05819333|OTHER|Exercise Program + Respiratory Relaxation Training|Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
47992344|NCT04878523|DIETARY_SUPPLEMENT|multi berries juice|Testing product
47992345|NCT04878523|DIETARY_SUPPLEMENT|Placebo drink|Blank
47992346|NCT03630809|BIOLOGICAL|HER2 DC1 Vaccine|Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
48150931|NCT01648049|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein \& Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, \& Dick, 1995).
48150932|NCT01648049|BEHAVIORAL|Treatment as usual|Standard Care - Treatment as usual
48362868|NCT01299636|DRUG|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
48362869|NCT04342572|DRUG|Melphalan|-The drug is commerically available
48362870|NCT02083822|PROCEDURE|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
48362871|NCT01140646|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
48362872|NCT01140646|OTHER|questionnaire administration|Ancillary studies
47992347|NCT00415233|BIOLOGICAL|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
47992348|NCT00415233|RADIATION|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
48362873|NCT01140646|PROCEDURE|quality-of-life assessment|Ancillary studies
48362874|NCT05911893|DIETARY_SUPPLEMENT|high caloric oral nutritional supplements|High caloric oral nutritional supplements (which can supplement 30% of the energy requirement) is given daily, and the recommended amount of energy and protein is referred to the 2013 Chinese Dietary Nutrient Reference Intake Table. At 6 months of enrollment, participants will be asked to evaluate whether to continue feeding according to the experimental group protocol or to stop to ensure proper nutritional intake.
48362875|NCT05911893|BEHAVIORAL|nutritional education|After enrollment,health education information is pushed approximately every 4 weeks through the WeChat platform or/and short text messages to parents.
48150933|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols and fish oil|4 weeks intervention, 3 times daily
48150934|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols|4 weeks intervention, 3 times daily
48150935|NCT01313988|DIETARY_SUPPLEMENT|Placebo|4 weeks, 3 times daily
48150936|NCT01352026|DRUG|Metformin|
48150937|NCT02493556|DEVICE|LLLT before muscle damage|
48150938|NCT02493556|DEVICE|Placebo LLLT before muscle damage|
48150939|NCT02493556|DEVICE|LLLT after muscle damage|
48150940|NCT02493556|DEVICE|Placebo LLLT after muscle damage|
48150941|NCT02618876|DRUG|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
48150942|NCT02618876|DRUG|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
48150943|NCT02883985|RADIATION|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
48150944|NCT04554615|DRUG|Insulin|insulin infusion to control postoperative hyperglycemia
47992349|NCT01380509|DRUG|Metronidazole|Capsules, single-dose, fasting
48676903|NCT02374541|BEHAVIORAL|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
48676904|NCT02025998|DRUG|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
47992350|NCT01380509|DRUG|Flagyl|Capsules, single-dose, fasting
47992351|NCT01899534|OTHER|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
48150945|NCT05206552|OTHER|Questionnaire|Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
48150946|NCT01718223|DRUG|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
48150947|NCT01718223|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
48676905|NCT02025998|OTHER|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
48676906|NCT02796833|DRUG|SMOFlipid20%|
48676907|NCT01936883|RADIATION|HDR|High dose rate brachytherapy
48676908|NCT01936883|RADIATION|LDR|Low dose rate brachytherapy boost
48676909|NCT01774773|DRUG|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
48676910|NCT01774773|DRUG|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
47992352|NCT04965545|DIETARY_SUPPLEMENT|low copper diet|All patients with wilson disease should receive low copper diet
47992353|NCT01975909|DEVICE|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
47992354|NCT00003679|DRUG|cyclophosphamide|
48362876|NCT05911893|BEHAVIORAL|dietary guidance|At follow-up visits at 0, 1, 2, 3, 6,and 12 months after enrollment, a professionally trained pediatrician give the participant's guardian dietary instructions appropriate to the age stage and physical condition of the child. Each session lasts approximately 10 minutes.
48362877|NCT04824118|DIAGNOSTIC_TEST|Thromboelastometry|Point of Care Test for clotting parameters (ClotPro device)
47992355|NCT00003679|DRUG|docetaxel|
47992356|NCT00003679|DRUG|doxorubicin hydrochloride|
47992357|NCT00003679|DRUG|tamoxifen citrate|
47992358|NCT00003679|PROCEDURE|conventional surgery|
48362878|NCT04824118|DIAGNOSTIC_TEST|Clotting Studies|"Standard laboratory tests for clotting:~* International normalised ratio (INR)~* Prothrombin time (PT)~* adjusted partial thromboplastin time (aPTT)~* fibrinogen"
48362879|NCT04824118|DIAGNOSTIC_TEST|Full Blood Count|For platelet count
47992359|NCT00003679|RADIATION|radiation therapy|
47992360|NCT00878709|DRUG|neratinib|
47992361|NCT00878709|OTHER|placebo|
47992362|NCT02316067|OTHER|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
48150948|NCT01718223|OTHER|laboratory biomarker analysis|Correlative studies
48150949|NCT01718223|DRUG|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
48150950|NCT03150004|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|"Subjects will be started on CLAG-M regimen, which consists of the following:~* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 2 gm/m\^2 IV over four hours on days 1-5~* Mitoxantrone 10 mg/m\^2 IV on days 1-3;~* G-CSF at a dose of 300 μg on days 0-5."
48150951|NCT03150004|DRUG|Cladribine and Cytarabine (CLLDAC) Regimen|"* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 20 mg/m\^2 subcutaneous injection on days 1-10;"
48362880|NCT04824118|DIAGNOSTIC_TEST|Quantitative hCG|Serum human chorionic gonadotrophin
48362881|NCT04824118|DIAGNOSTIC_TEST|Pregnancy Test|Point of care urinary pregnancy test
48362882|NCT01404689|DRUG|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
48150952|NCT04694053|PROCEDURE|surgical debridement|The surgical team performed an extended surgical debridement to healthy tissue of external genital, as well as perineal, perianal, and infrapubic regions.
48150953|NCT01411683|DEVICE|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
48150954|NCT06453759|PROCEDURE|Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei|"The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes; up to 6 additional electrodes may be added but, where possible, existing electrode trajectories will be extended to facilitate recording.~At the beginning of the recording process, usually within the first 24-48 hours of implantation, we will conduct 2 study-specific stimulation experiments:~1. Single pulse electrical stimulation (SPES):~2. N-of-1 trials of simulated DBS: We will simulate high (130Hz) and low (6Hz) frequency DBS currents from each pair of thalamic nuclei (always bilateral) and record spontaneous interictal neuronal activity in all other cortical contacts for 15 minutes. We will also record SPES from each of the cortical contacts."
48150955|NCT02995707|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
48150956|NCT06467240|PROCEDURE|hybrid rapid maxillary expander assisted with Micro-osteo perforation (MOPs)|patients with constricted maxillary will applied for hybrid expansion and group of them will assisted by Micro-osteo perforation (MOPs)
48362883|NCT01404689|OTHER|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
48362884|NCT02745093|DRUG|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
48676911|NCT01774773|DRUG|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
48676912|NCT00945659|DEVICE|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
48676913|NCT00945659|OTHER|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
48676914|NCT00945659|BEHAVIORAL|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
48676915|NCT01072136|OTHER|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
47992363|NCT03849859|DEVICE|Single plastic stent|Deployment of single plastic stent
47992364|NCT03849859|DEVICE|Multiple plastic stents|Deployment of multiple plastic stents
48676916|NCT01072136|DRUG|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
47992365|NCT02400879|DRUG|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
48150957|NCT01862224|DRUG|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
48150958|NCT01862224|DRUG|Placebo|Matching placebo once daily (Week 0 to Week 12).
48150959|NCT01862224|DRUG|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
48676917|NCT01072136|DRUG|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
47992366|NCT02400879|DRUG|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
48150960|NCT05978089|DRUG|Yangxinshi tablet|The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
48150961|NCT05978089|DRUG|Yangxinshi tablet simulants|The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
48150962|NCT00965471|DRUG|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
48150963|NCT00965471|DRUG|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
48362885|NCT02745093|DRUG|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
48362886|NCT03732040|OTHER|miswak stick|miswak stick use as preventive hygiene measures
48362887|NCT03732040|OTHER|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
48150964|NCT02397902|DIETARY_SUPPLEMENT|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
48150965|NCT02397902|DIETARY_SUPPLEMENT|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
48150966|NCT01706055|BIOLOGICAL|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
48362888|NCT03732040|OTHER|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
48362889|NCT04998344|BIOLOGICAL|Inactivated influenza vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
48362890|NCT04998344|BIOLOGICAL|Inactivated polio vaccine|Vaccines will be administered as a single dose regimen for the pregnant women and two doses for children at 28-day interval as recommended by the vaccine manufacturers.
48150967|NCT04847908|OTHER|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
48150968|NCT06087159|BEHAVIORAL|mHealth Toolkit for Wellness & Empowering Lives of School Community (mWEL)|mWEL-App is a preventive intervention tool for teachers and parents as a self-help support. It integrates three key mental health presentive service functions: i) comprehensive screen to assess mental health (anxiety, depression), stress, and related contextual risks; ii) a tailored strength and weakness profile/report with recommendations to promote self-awareness and mental health knowledge; and iii) tailored evidence-based strategies and additional support and clinical resources to improve skills in stress management, emotion regulation, and maintain mental wellness. mWEL will be designed as a self-administered tool. Participating parents and teachers can access to mWEL app after they sign up for an account. Intervention participants will have access to the App anytime within a 3-5 month study period.
48150969|NCT01596894|DRUG|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
48150970|NCT01596894|DRUG|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
48150971|NCT00930319|OTHER|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
48362891|NCT04176016|DRUG|OTSA101-DTPA-111In|single IV injection, 185MBq/body
48362892|NCT04176016|DRUG|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
48362893|NCT02194699|BIOLOGICAL|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
48150972|NCT00444730|PROCEDURE|Radical Prostatectomy|Surgical procedure for prostate cancer.
48150973|NCT00444730|PROCEDURE|InterStim Implantation|surgical placement of the interstim
48150974|NCT00444730|PROCEDURE|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
48362894|NCT02194699|OTHER|Placebo|Placebo subcutaneous injection
48362895|NCT00082238|OTHER|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
48362896|NCT03431467|DEVICE|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
48511101|NCT03543189|DRUG|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
48511102|NCT03543189|RADIATION|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
48511103|NCT03543189|RADIATION|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
48362897|NCT00784160|DRUG|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
48362898|NCT02934282|DRUG|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
48362899|NCT04286724|BEHAVIORAL|"Brief behavioural procedure including a computerized visuospatial task (computer game Tetris)"|"Brief behavioural procedure including a computerized visuospatial task (the computer game Tetris) preceded by a reactivation of the traumatic memory of childbirth"
48362900|NCT06299150|OTHER|IPS e.max CAD|CAD CAM Restoration
48511104|NCT03543189|DRUG|Androgen Deprivation Therapy|Standard of care.
48150975|NCT01714947|DRUG|[^14C]-alisertib|\[\^14C\]-alisertib oral solution
48676918|NCT03717623|DRUG|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
48150976|NCT01714947|DRUG|alisertib|Alisertib enteric coated tablets
48150977|NCT05793489|OTHER|Silibinin|"WBRT will be concomitant to Silibinin. Silibinin at dose of 500 mg must be administrated twice a day for the first month, after once a day continuously.~Total dose and fractionation of WBRT: 30 Gy in 10 fractions."
48362901|NCT05956223|DEVICE|Virtual Reality measurement of essential tremor and dystonia|"1. The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~   Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~2. Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
48362902|NCT01434498|DRUG|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
48362903|NCT01434498|DRUG|GS-9451 tablet|GS-9451 tablet, 200 mg QD
48676919|NCT01333410|DRUG|tacrolimus ointment|2 applications per days for 6 months
48676920|NCT01333410|DRUG|Mometasone furoate|2 applications per day for 6 months
48676921|NCT03569124|OTHER|Teaching tool for identification of colorectal polyps|This is a teaching session on how to identify the colorectal polyps shot in blue light imaging.
47992367|NCT03896243|DIAGNOSTIC_TEST|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
48150978|NCT04421456|DRUG|GWP42003-P|oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
48150979|NCT04421456|DRUG|Placebo|oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
48150980|NCT05310292|BIOLOGICAL|Oral glucose tolerance test|Consumption of 75 grams of glucose, diluted in water, added 1,5 g of acetaminophen.
48362904|NCT01434498|DRUG|tegobuvir capsule|tegobuvir capsule, 30 mg BID
48362905|NCT01434498|DRUG|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
48362906|NCT01434498|DRUG|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
48362907|NCT01434498|DEVICE|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
48362908|NCT03474172|DEVICE|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
48362909|NCT03474172|DEVICE|Cloak Shape Device for Genuine Tuina|The Cloak Shape Device for Genuine Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a genuine Tuina will be manipulated.
48511105|NCT03020589|DRUG|Tacrolimus|See description in arm/group sections
48676922|NCT01397227|BIOLOGICAL|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
48150981|NCT05310292|BIOLOGICAL|Mixed meal test|Consumption of a standardized liquid meal, with caloric and dietary content equal to a standard meal.
48150982|NCT04110392|DIETARY_SUPPLEMENT|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
47992368|NCT01466387|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
47992369|NCT01466387|BIOLOGICAL|Yellow Fever Vaccine|One dose of yellow fever vaccine.
47992370|NCT01466387|BIOLOGICAL|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
47992371|NCT01466387|BIOLOGICAL|Rabies Vaccine|Three doses of Rabies vaccine.
47992372|NCT01466387|BIOLOGICAL|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
48511106|NCT05577195|DEVICE|Impella|To provide active left ventricular unloading in the experimental arm
48676923|NCT01397227|BIOLOGICAL|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
48676924|NCT01397227|BIOLOGICAL|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
48676925|NCT02626169|DRUG|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
47992373|NCT04167007|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
48150983|NCT04864353|BEHAVIORAL|RestDep: Internet-delivered intervention targeting residual cognitive symptoms|The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
48150984|NCT00134056|DRUG|atrasentan hydrochloride|Given orally
48150985|NCT00134056|DRUG|docetaxel|Docetaxel given IV and prednisone given orally
48150986|NCT00134056|DRUG|prednisone|Docetaxel given IV and prednisone given orally
48150987|NCT00134056|OTHER|placebo|Given orally
48150988|NCT03539237|OTHER|Video demonstration of physical activity intensity levels|In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
48150989|NCT01878955|GENETIC|AMH level difference between patient with PCOS and multicystic ovaries.|
48150990|NCT05329142|DIAGNOSTIC_TEST|Surplus sample toxicology analysis|Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.
48150991|NCT05213585|DRUG|Ivermectin cream|Topical application of ivermectin cream to eyelashes of treatment eye.
48150992|NCT04943614|OTHER|Biodex balance system|BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy
48150993|NCT04943614|OTHER|conventional exercises|balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
48150994|NCT04907344|DRUG|Camrelizumab|IV infusion
48150995|NCT04907344|DRUG|Nab-Paclitaxel|IV infusion
48150996|NCT04907344|DRUG|Carboplatin|IV infusion
48150997|NCT05278117|PROCEDURE|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
48150998|NCT03199456|DEVICE|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
48150999|NCT03199456|DEVICE|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
48151000|NCT04213235|BEHAVIORAL|Physical activity|The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
48151001|NCT04990037|DRUG|CAN04|Administered intravenously
48151002|NCT04990037|DRUG|FOLFIRINOX|Administered intravenously
48151003|NCT06455072|DRUG|Nituzumab|EGFR monoclonal antibody
48151004|NCT06455072|DRUG|Serplulimab|PD-1 (programmed death receptor 1) monoclonal antibody
48151005|NCT04117386|DIAGNOSTIC_TEST|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
48151006|NCT04117386|DIAGNOSTIC_TEST|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
48151007|NCT03867396|DEVICE|CROS|Advanced Bionics CROS
48151008|NCT03867396|DEVICE|Hearing Aid|Advanced Bionics Naida hearing aid
48151009|NCT03867396|OTHER|Cochlear Implant Alone|No hearing device on contralateral ear
48151010|NCT03001141|OTHER|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
48151011|NCT03468348|DRUG|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
48151012|NCT01151397|DRUG|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
48151013|NCT01151397|DRUG|Peg + Ribavirin|Peg+ Ribavirin for 6 months
48151014|NCT01736722|DEVICE|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
48151015|NCT04412174|BIOLOGICAL|GC022F|GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg.
48151016|NCT01404702|DRUG|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
48151017|NCT01404702|BIOLOGICAL|Aldesleukin|"Dose Level 1: 3 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
48151018|NCT05586763|DRUG|Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)|Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication, post medication at 30 and 60 mins posts anti-vertigo medication and at time of disposition. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
48151019|NCT03780634|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
48676926|NCT02626169|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
48676927|NCT05233124|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15mg
47992374|NCT04167007|DRUG|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
47992375|NCT03249311|DRUG|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
47992376|NCT03249311|DRUG|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
47992377|NCT03249311|DRUG|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
47992378|NCT05220579|DEVICE|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
47992379|NCT05220579|DEVICE|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
47992380|NCT02016482|BIOLOGICAL|Adalimumab|
47992381|NCT02016482|OTHER|Placebo|
47992382|NCT03388294|BEHAVIORAL|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
48676928|NCT05233124|DRUG|Acetylsalicylic acid 100mg|Acetylsalicylic acid 100mg
48151020|NCT03780634|DRUG|PD-1 antibody|200mg intravenously every 3 weeks
48362910|NCT03534466|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
48676929|NCT05233124|DRUG|Clopidogrel 75 Mg Oral Tablet|Clopidogrel 75mg
48676930|NCT00553566|PROCEDURE|medical chart review|
48676931|NCT00553566|PROCEDURE|questionnaire administration|
47992383|NCT02007876|BEHAVIORAL|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
47992384|NCT02064010|DRUG|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
47992385|NCT02064010|DRUG|Placebo|Placebo tablet, administered orally for 4 weeks
47992386|NCT01369979|PROCEDURE|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
47992387|NCT00735787|BIOLOGICAL|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
47992388|NCT00735787|BIOLOGICAL|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
47992389|NCT01170182|DRUG|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
47992390|NCT01170182|DEVICE|Prilosec® 40 mg|Prilosec® 40 mg
48151021|NCT03780634|DRUG|Sorafenib|400 mg Bid Po
48676932|NCT00553566|PROCEDURE|study of socioeconomic and demographic variables|
48676933|NCT05160363|DRUG|Pyronaridine Tetraphosphate|A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.
48676934|NCT05160363|DRUG|Piperaquine tetraphosphate|A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.
48676935|NCT05160363|DRUG|Placebo|Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
48676936|NCT02032576|DEVICE|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
48676937|NCT03138785|DRUG|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
48676938|NCT03138785|RADIATION|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
48151022|NCT05118867|BEHAVIORAL|iPREPARED|iPREPARED is a mobile health technology that can be accessed via the web, tablet, or phone. It contains a preparatory video that outlines what to expect during the hospitalization. Instructional videos and examples are provided for the patient and their recovery partner to use to do their own reorientation, distraction techniques, physical activity, and sleep hygiene.
48151023|NCT05161247|OTHER|Zona pellucida sperm selection|Sperm selection for ICSI based on the spermatozoa ability to adhere to immobilized zona pellucida proteins.
48151024|NCT05161247|OTHER|Conventional sperm selection|Sperm selection for ICSI based on the sperm morphology.
48151025|NCT05161247|OTHER|Intracytoplasmic Sperm Injection (ICSI)|Normal ICSI procedure.
48151026|NCT06105099|BEHAVIORAL|Motor-phonetic intervention|"Children will receive phonetic articulation therapy treating consonants in a phoneme-by-phoneme basis, emphasizing phonetic placement and shaping techniques.~Phonetic articulation therapy includes a progression of the target consonant from isolated level, syllable level, word level, sentence level, spontaneous speech level in five different steps:~identification of the target consonant using visual, tactile, and auditory feedback techniques, discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 90% of the time with minimal cues from the therapist."
48151027|NCT06105099|BEHAVIORAL|Phonological intervention|"The phonological approach consists of two phases. In the first phase, the child's attention is drawn to the contrastive features of the speech sound system which are relevant to the target consonants. Terms that describe the sound features will be introduced using words on the child's level, e.g. in the case of active nasal fricatives the words 'nose' and 'mouth' will be used. Child-friendly games will be played to illustrate the contrast between the concepts followed by activities that focus on the contrasts in non-speech sounds, in which child and therapist will alternate between being listener and speaker. At the end of this phase, minimal word pairs (e.g. tap/cap), only produced by the therapist, will be used to facilitate the child's awareness of sounds in words and meaningful differences based on distinctive features.~In the second phase, the child will produce minimal pairs providing the opportunity to monitor his/her speech and to make self-corrections."
48151028|NCT06105099|BEHAVIORAL|Combined phonetic-phonological intervention|Children will receive motor-phonetic articulation therapy supplemented with phonological principles. Therapy will be provided following the same five steps as the 'motor-phonetic group'. However, articulation errors will not be treated in a phoneme-by-phoneme basis. In contrast, multiple errors will be targeted simultaneously by focusing on a process. For example, if the child produces glottal stops for the /t/ and the /p/, these sounds will be treated simultaneously as sounds requiring oral front placements. Exercises will be embedded in meaningful language contexts such as minimal pairs
48151029|NCT01964547|DRUG|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
48151030|NCT01964547|DRUG|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
48151031|NCT00015132|DRUG|Sertraline|
48151032|NCT06557733|PROCEDURE|Biopsy|Undergo biopsy
48151033|NCT06557733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48151034|NCT06557733|DRUG|EP2/EP4 Antagonist TPST-1495|Given PO
48151035|NCT06557733|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
48151036|NCT06557733|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
48151037|NCT06557733|OTHER|Questionnaire Administration|Ancillary studies
48151038|NCT03708744|DRUG|A: M207 3.8mg, 30 min, upper arm|A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
48362911|NCT03534466|BEHAVIORAL|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
48362912|NCT04168775|DEVICE|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
48362913|NCT01663298|PROCEDURE|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
48362914|NCT03493204|OTHER|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
48362915|NCT03493204|OTHER|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
48151039|NCT03708744|DRUG|B: M207 3.8 mg, 30 min, thigh|B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
48151040|NCT03708744|DRUG|C: M207 3.8 mg, 1 hr, upper arm|C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
48151041|NCT03708744|DRUG|D:zolmitriptan nasal spray|D: 2.5 mg/0.1 mL intranasal zolmitriptan
48151042|NCT00027209|DRUG|prempro|
47992391|NCT03388229|BEHAVIORAL|not an intervention|it was observation not intervention
47992392|NCT00679263|DRUG|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
47992393|NCT00679263|DRUG|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
47992394|NCT00679263|DRUG|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
47992395|NCT00783445|BEHAVIORAL|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
47992396|NCT00783445|BEHAVIORAL|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
47992397|NCT01237873|DRUG|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
47992398|NCT04286607|DRUG|Topical roflumilast|Active treatment
47992399|NCT01203228|OTHER|Reduced Intensity Conditioning|"Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
47992400|NCT01203228|OTHER|Myeloablative conditioning|"Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
47992401|NCT02378363|OTHER|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
47992402|NCT04518501|DRUG|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
47992403|NCT03647228|DRUG|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
47992404|NCT03647228|DRUG|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
47992405|NCT06029634|DIAGNOSTIC_TEST|T-bet B cell|The frequency, function, and phenotype of T-bet B cells was tested
47992406|NCT05860283|DEVICE|Core stabilization exercise using pressure biofeedback unit|"From crook lying:~* 1st and 2nd weeks LEVEL 1: ADIM and hold for 10 seconds LEVEL 2 : Hold for 5 sec. Repeat 10 times. Opposite lower extremity on plinth; bent leg fall out.~* 3rd and 4th week LEVEL 3 : Opposite lower extremity on plinth a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~* 5th and 6th weeks LEVEL 4 : Hold opposite lower extremity at 90˚ of hip flexion a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~From prone lying:~Extension of each lower extremity. The exercise progression each week will be evaluated.Each exercise session lasted 20 min. The patients had to hold each exercise for 10 seconds, three sets per session and each set 10 repetitions."
48362916|NCT01066819|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
48362917|NCT01066819|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
48362918|NCT00210067|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
48362919|NCT00193726|DRUG|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
48511107|NCT05577195|DEVICE|VA-ECMO|To provide circulatory support in both arms
47992407|NCT05860283|PROCEDURE|Diaphragmatic release technique|This technique will be given 3 days per week for 6 weeks with total technique duration of 45 minutes. The maneuver will be repeated in 4 sets per session, each set will consist of 5 deep breaths with 2-min intervals in between sets.
47992408|NCT00366600|DRUG|neratinib|HKI-272
47992409|NCT05669560|COMBINATION_PRODUCT|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
47992410|NCT01477060|DRUG|Lapatinib|1250 mg/ die, os
47992411|NCT01477060|DRUG|Metformin|1500 mg/die, os
48151043|NCT03923556|DRUG|Sugammadex|Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
48151044|NCT03923556|DRUG|Neostigmine|Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
48362920|NCT00193726|DRUG|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
48362921|NCT05408676|DEVICE|electric stimulation therapy|Transcutaneous electrical acupoint stimulation (TEAS) was achieved by an electrical neuromuscular stimulation device (JNR2; designed by the Department of Hand Surgery, Huashan Hospital, Fudan University, manufactured by Energy Conservation and Environment Protection Technology Company, Jiatong University, Shanghai,China)
48362922|NCT02830295|OTHER|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
48362923|NCT03062631|DRUG|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
48362924|NCT05804344|DEVICE|Anodal speech motor tDCS|tDCS montage set for Anode: C5; Cathode: Fp2
48362925|NCT05804344|DEVICE|Cathodal speech motor tDCS|tDCS montage set for Anode: Fp2; Cathode: C5
48511108|NCT06408506|PROCEDURE|Re-Entry Surgery|Re-entry surgery 4 months after the insertion of the implants to reveal implants after osseointegration
48362926|NCT05804344|DEVICE|Anodal IFG tDCS|tDCS montage set for Anode: F3; Cathode: Fp2
47992412|NCT01893554|BIOLOGICAL|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
48362927|NCT05804344|DEVICE|Cathodal IFG tDCS|tDCS montage set for Anode: Fp2; Cathode: F3
48362928|NCT05804344|DEVICE|Sham tDCS|tDCS device set in Sham mode
48151045|NCT00798837|RADIATION|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions~* A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
48362929|NCT04155190|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
48362930|NCT04155190|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
48362931|NCT01611558|BIOLOGICAL|Ipilimumab|
48362932|NCT03740516|DRUG|CC-10004|CC-10004 will be administered orally
48362933|NCT01212627|DRUG|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
48362934|NCT02192190|DRUG|LY2951742|Administered subcutaneously (SC)
48362935|NCT02192190|OTHER|Placebo- oral|Administered orally
48362936|NCT02192190|OTHER|Placebo - SC|Administered SC
48362937|NCT02192190|DRUG|Celecoxib|Administered orally
48362938|NCT04371757|DRUG|α1-adrenergic block|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
48362939|NCT04371757|OTHER|Placebo|Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
48362940|NCT03145428|DIAGNOSTIC_TEST|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
48362941|NCT02388750|DRUG|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
48362942|NCT02388750|RADIATION|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
48362943|NCT00106626|DRUG|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
48362944|NCT05384873|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
48362945|NCT05384873|OTHER|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
48511109|NCT06408506|PROCEDURE|Probing peri-implant bone|Probing peri-implant bone with Dental Probe during surgery
48511110|NCT06408506|PROCEDURE|Scanning peri-implant bone|Scanning peri-implant bone during surgery
48511111|NCT06408506|PROCEDURE|Conventional Impressions|Conventional Impressions during surgery
47992413|NCT01893554|BIOLOGICAL|Placebo|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
47992414|NCT01739582|DRUG|Androxal|
47992415|NCT03302013|PROCEDURE|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
48362946|NCT01085149|DRUG|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
48362947|NCT00673140|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
48362948|NCT00673140|RADIATION|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
48362949|NCT01062516|DRUG|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
48362950|NCT01062516|DRUG|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
48362951|NCT03958461|PROCEDURE|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
48511112|NCT06408506|PROCEDURE|Implant Surgery|Placement of 6 implants in the edentulous mandible
48676939|NCT00936663|DRUG|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
48151046|NCT01846078|DEVICE|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
48151047|NCT02314000|DEVICE|Precision or Precision Spectra Spinal Cord Stimulator System|
48362952|NCT04622163|OTHER|Secondary Mentor|Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.
48362953|NCT04622163|OTHER|Career Development Resources|Subjects will receive career development resources.
48362954|NCT06381310|DEVICE|asus-handheld-ultrasound LU710L|Ultrasound-guided group:The nurse uses ultrasound-guide injection. control group: After physical assessment by the nurse, the injection will be carried out according to the conventional injection plan.
48362955|NCT04980300|BEHAVIORAL|Expanded Intervention|Participants in the Expanded Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
48362956|NCT04980300|BEHAVIORAL|Brief Intervention|Participants in the Brief Intervention arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
48362957|NCT03676712|DEVICE|scoliosis brace|Wear at least 18 hours a day
48362958|NCT04006431|OTHER|embolization|Retrospective, observational collection with division of patients into two groups according to unilateral or bilateral embolization of the porstatic arteries.
48511113|NCT06408506|PROCEDURE|Healing procedure|"All 6 Implants in all patients are let to heal for 4 Months under the same conditions:~The most distal implants are left submerged. The most mesial implants are left transgingival and the Implants in the middle are immediately loaded using gold bar retained dentures"
48511114|NCT00231543|PROCEDURE|Laparoscopic fundoplication|
48511115|NCT00231543|PROCEDURE|open Nissen fundoplication|
48676940|NCT00936663|DRUG|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
48676941|NCT01055613|DEVICE|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
48676942|NCT01055613|DEVICE|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
48676943|NCT03489044|DRUG|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
48676944|NCT03489044|DRUG|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
48676945|NCT06090058|DIAGNOSTIC_TEST|Measurement of neurofilament light chain|Serum samples will be collected into a serum gel with clotting activator tube (Sarstedt). After delivery to the laboratory, the serum samples were centrifuged at 2500 × g for 6 min at 4 Celsius degree, then aliquoted into at least three vials (0.3 mL per vial) and stored at -70 Celsius degree until the analysis.
48676946|NCT01626573|DRUG|Itacitinib|
48676947|NCT01626573|DRUG|Itacitinib Placebo|
48676948|NCT04339413|DRUG|Gantenerumab|Gantenerumab was administered as SC injection Q4W.
48676949|NCT04795375|BEHAVIORAL|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
48676950|NCT00249587|DRUG|Methadone|dosed to effect, every six hours
48676951|NCT03484728|BEHAVIORAL|placebo manipulation|application of nonactive body cream on forearm
48676952|NCT01586689|BEHAVIORAL|Oxford House|community-based recovery home for participants recovering from substance dependency
48676953|NCT01586689|BEHAVIORAL|Safe Haven|professionally-staffed treatment facility
47992416|NCT03302013|PROCEDURE|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
48362959|NCT03092141|OTHER|Physical training|
48676954|NCT01586689|BEHAVIORAL|Usual aftercare|control group - participants may or may not seek treatment on their own
48362960|NCT00514241|DEVICE|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
48362961|NCT05810415|DIAGNOSTIC_TEST|Renin levels and lactic acid levels|Sampling of blood for measuring renin and lactate
48362962|NCT02008461|PROCEDURE|radiofrequency ablation|
48676955|NCT03679104|PROCEDURE|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
48362963|NCT02008461|DRUG|botulinum toxin injection|
48362964|NCT02827747|OTHER|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
48362965|NCT02827747|OTHER|Placebo|Placebo pill
48362966|NCT02827747|DIETARY_SUPPLEMENT|Centrum|Centrum
48362967|NCT02827747|COMBINATION_PRODUCT|Dietary Sources|From dietary sources of vitamins.
48362968|NCT02683330|BEHAVIORAL|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
48362969|NCT01200251|DRUG|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
48362970|NCT02610231|DRUG|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
48362971|NCT02071342|PROCEDURE|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
48676956|NCT03679104|PROCEDURE|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
48676957|NCT00000389|DRUG|Fluvoxamine|
48362972|NCT02523742|DEVICE|IMRf|
48676958|NCT00212836|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
48676959|NCT00212836|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
48676960|NCT00003312|RADIATION|iodine I 125|
48676961|NCT01545765|DRUG|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
48151048|NCT05301725|OTHER|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
48362973|NCT02523742|OTHER|language task and a reference task (rest and Tamil)|
48362974|NCT04465240|OTHER|Virtual reality|Participants are immersed in a neighborhood environment in virtual reality
48362975|NCT02246309|DEVICE|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
48362976|NCT02246309|DEVICE|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
48362977|NCT02791841|BEHAVIORAL|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
48362978|NCT02791841|BEHAVIORAL|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
48511116|NCT03509857|DEVICE|BUZZY(tm)|"Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager)."
48362979|NCT02791841|BEHAVIORAL|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
48362980|NCT03894111|OTHER|decesased patients|mortality ratio
48511117|NCT03509857|OTHER|No Intervention|No intervention
48511118|NCT05805410|BEHAVIORAL|robotic hippotherapy|A custom designed cable-driven robotic system that mimics horseback movement during walking was used in this study.
48511119|NCT05805410|BEHAVIORAL|Conventional physical therapy|Stretching of trunk and leg muscles, followed by sitting and standing balance training, and conventional treadmill walking.
48151049|NCT05301725|OTHER|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
48362981|NCT05972343|DEVICE|Cryoablation|Takes place at single time point.
48151050|NCT02074709|DRUG|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
48151051|NCT02074709|DRUG|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
48151052|NCT02821572|BIOLOGICAL|blood sample|
48362982|NCT04748159|OTHER|Prone position/ Abdominal position|Standardized positioning of the infant in the prone position respectively abdominal position. Depending on age and size, one or two rolled towels are placed lengthwise under the baby. Both arms are placed cranially in U-position towards the head. Since the position of the head has no significant influence on lung ventilation, the head is placed according to the infant's tolerance.
48676962|NCT05018689|OTHER|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
48676963|NCT05018689|OTHER|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
48676964|NCT02431546|BEHAVIORAL|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
47992417|NCT00496756|DRUG|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
47992418|NCT04178746|DEVICE|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
47992419|NCT01132547|DRUG|cyproheptadine hydrochloride|Given orally
48151053|NCT02821572|PROCEDURE|spleen sample|
48151054|NCT04493307|DIAGNOSTIC_TEST|Phlebotomy|Serial assessment of hemostasis by blood and urine collection
48151055|NCT06277245|DRUG|LNK01001|Capsule; Oral
48151056|NCT06277245|DRUG|Placebo|Capsule; Oral
48151057|NCT03562702|OTHER|Standard IV Rehydration Therapy|IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
48151058|NCT03562702|OTHER|Oral Rehydration Therapy (ORT)|Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
48151059|NCT05773872|OTHER|Questionary|"In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)"
48151060|NCT02547974|BIOLOGICAL|Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
48151061|NCT02547974|BIOLOGICAL|Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
48362983|NCT03838692|DRUG|Ponatinib|A daily oral dose at 30 mg.
48362984|NCT02599740|OTHER|Natural fruit extract|Natural fruit extract consumed with rice
48362985|NCT02599740|OTHER|Assumed active|Assumed key active consumed with rice
48362986|NCT02599740|OTHER|Placebo|Rice only
47992420|NCT01132547|OTHER|placebo|Given orally
47992421|NCT05559255|OTHER|Counterstrain manual manipulative treatment|"The steps required to perform counterstrain in any region of the body are as follows:~1. Find the tender point.~2. Assess the tenderness using a pain scale.~3. Passively and gently place the patient in a position-of-comfort that results in the greatest reduction of tenderness at the tender point. Approximate the position first, then fine-tune through small arcs of movement. Aim to achieve at least 70% tenderness reduction, with the goal of 100%.~4. Maintain the position for 90 seconds while continuing to monitor the patient's tender point.~5. Passively return the patient to a neutral position.~6. Re-test for tenderness at the tender point."
48151062|NCT02547974|BIOLOGICAL|Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
48151063|NCT02547974|DRUG|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
48151064|NCT01962402|DRUG|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
48151065|NCT01962402|BEHAVIORAL|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
48151066|NCT04769219|OTHER|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
48151067|NCT01554345|DRUG|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
48151068|NCT00233545|DRUG|miltefosine|
48151069|NCT00233545|DRUG|antimony|
48151070|NCT04448613|OTHER|MRI|"Patients with optic disc swelling diagnosed by a fundus and included in the study will have a brain MRI and visual pathways lasting 30 minutes.~Two additional 10-minute sequences will be added to the standard protocol."
48151071|NCT03810911|DRUG|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
48362987|NCT00681772|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
48362988|NCT04588298|DRUG|AZD9833|AZD9833 tablets will be administered orally.
48362989|NCT04449185|DRUG|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days|Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days
48362990|NCT01935622|DRUG|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
48362991|NCT01935622|DRUG|placebo|Placebo 1 tablet every 12 hours for 14 days
48362992|NCT03523390|DRUG|Avelumab 3 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
48676965|NCT00751712|DEVICE|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
48676966|NCT04915638|DIETARY_SUPPLEMENT|Experimental intervention group with enriched cookies|Enriched cookies containing a micronutrients formula (vitamins, minerals, antioxidants, and omega-3 fatty acids) each day (Monday to Friday).
47992422|NCT05864300|BEHAVIORAL|Neurocheck frequency|Randomized to hourly or every-other-hour examinations
47992423|NCT04335279|OTHER|SPIN-CHAT Program|Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.
47992424|NCT01075698|DRUG|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
47992425|NCT01075698|DRUG|ARB (Telmisartan)|Telmisartan 20-80 mg/day
47992426|NCT05418192|OTHER|Enriched Environment|Enriched Environment (EE) consisted of motor and sensory enriched play environment to promote participant's self-generated movements, exploration and task success. EE also included positioning in a graded manner. Visual stimulus and level appropriate vestibular stimulus was also given. Dosing of positioning and sensory inputs was done throughout the therapy. Primary Intervention will be given for 20 to 25 minutes intermittently for period of 4-5 hours a day, 5 days a week for 24 weeks.
47992427|NCT05418192|OTHER|Traditional Physcial Therapy|Participants of this group received traditional physical therapy based NDT. No additional dosing guidance was given to this group. No home program was specifically assigned to this group. No specific environmental modifications were made for this group.
48151072|NCT00409500|DRUG|AQW051|
48151073|NCT05894551|OTHER|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
48362993|NCT03523390|DRUG|Avelumab 10 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
48676967|NCT00207220|PROCEDURE|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
48676968|NCT00207220|PROCEDURE|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
48151074|NCT05894551|OTHER|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
47992428|NCT00017147|DRUG|carmustine|"40 mg/m\^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m\^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
47992429|NCT00017147|RADIATION|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
48151075|NCT05894551|OTHER|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
48151076|NCT05823766|BEHAVIORAL|In-Person Outcome Assessment|Assessments will be administered to evaluate participant outcome status
48151077|NCT05823766|PROCEDURE|3T Magnetic Resonance Imaging (MRI)|Participants will be asked to complete a 3T MRI
48151078|NCT05823766|BEHAVIORAL|Clinical Visit|Patients who screen positive for PTE will have an in-depth clinical visit
48151079|NCT05823766|PROCEDURE|Blood Draw|Blood Draw for Plasma, DNA, Serum, RNA
48151080|NCT05823766|PROCEDURE|EEG|An EEG will be performed on patients who screen positive for PTE at the clinical visit
48151081|NCT05823766|BEHAVIORAL|Telephone Outcome Assessment|Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
48151082|NCT05702190|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
48151083|NCT05702190|DRUG|Placebo|Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
48151084|NCT05256836|OTHER|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
48151085|NCT02480283|PROCEDURE|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
48151086|NCT02480283|RADIATION|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
48151087|NCT02480283|PROCEDURE|Venipuncture|To collect blood cells and serum for analyses.
48151088|NCT02480283|PROCEDURE|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
48151089|NCT03068741|DRUG|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
48151090|NCT03068741|DRUG|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
47992430|NCT00017147|DRUG|O6-Benzylguanine|120 mg/m\^2 IV over 1 hour on day 1 of each cycle
47992431|NCT03627819|DIETARY_SUPPLEMENT|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
47992432|NCT03627819|DIETARY_SUPPLEMENT|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
47992433|NCT03627819|DIETARY_SUPPLEMENT|Control margarine|Margarine without any addition
47992434|NCT04674046|DEVICE|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
47992435|NCT04674046|PROCEDURE|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
48151091|NCT03068741|DRUG|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
48151092|NCT03068741|DRUG|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is \<90mmHg and continued until systolic blood pressure is \>=100mmHg.
48151093|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
48151094|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
48151095|NCT01201278|DRUG|Insulin LISPRO|Subcutaneous insulin lispro 8 U
48151096|NCT03189550|PROCEDURE|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
48676969|NCT04992468|DRUG|Ovulation triggering with GnRH-a+rhCG|recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
48511120|NCT03260725|BEHAVIORAL|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
47992436|NCT04674046|BEHAVIORAL|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
48676970|NCT04992468|DRUG|Ovulation triggering with GnRH-a|rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)
48676971|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
48676972|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
48676973|NCT00893841|DRUG|placebo|placebo
48676974|NCT00893841|DRUG|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
48676975|NCT01154491|DRUG|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
48676976|NCT01154491|DRUG|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
48676977|NCT01154491|DRUG|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
48676978|NCT04865666|DEVICE|movr mHealth App|The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
48511121|NCT03260725|BEHAVIORAL|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
48676979|NCT03646760|BEHAVIORAL|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
48362994|NCT03523390|DRUG|Avelumab 20 mg/kg Q2W|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
48362995|NCT03523390|DRUG|Avelumab 10 mg/kg QW|Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
48362996|NCT04422951|BEHAVIORAL|Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment|Addition of two wise wise social psychological interventions-growth mindset and self-affirmation-to a 6-month usual care behavioral intervention for weight control in children with obesity
48676980|NCT03646760|BEHAVIORAL|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
47992439|NCT02034955|RADIATION|Post-operative Adaptive Radiation Therapy|
47992440|NCT05086887|DIAGNOSTIC_TEST|Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases|All individuals are tested. Individuals with demonstrated parasitic disease are referred to the Infectious diseases or Pediatric clinic for evaluation and treatment.
48362997|NCT04422951|BEHAVIORAL|Education plus usual care behavioral treatment|6-month health education plus usual care behavioral intervention for weight control in children with obesity
48362998|NCT02168816|DRUG|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
48151097|NCT03189550|PROCEDURE|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
48151098|NCT03189550|PROCEDURE|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
47992441|NCT06427356|BEHAVIORAL|PREVAIL Interdisciplinary Team|Patient meets simultaneously with an interdisciplinary team (IDT) five pain specialists and develops an individualized treatment plan based on Whole Health. Participants receive five months of coaching calls then return six months later for a follow-up visit with the IDT.
48151099|NCT00316121|DEVICE|HEALOS and Leopard Cage|Placement in interbody space
48362999|NCT02168816|DRUG|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
48363000|NCT03949894|DRUG|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
48363001|NCT00730665|DRUG|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
48363002|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
48363003|NCT00730665|DRUG|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
48363004|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
48363005|NCT00730665|DRUG|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
48363006|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
48676981|NCT06511687|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study
48676982|NCT04830943|DRUG|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
47992442|NCT06301815|DIAGNOSTIC_TEST|Scale for Contraversive Pushing|Lateropulsion will be assessed using the Scale for Contraversive Pushing (SCP). It involves observation of the posture of the participant in sitting and standing. Scores are assessed in sitting and standing giving a maximum score of 6.
47992443|NCT06301815|DIAGNOSTIC_TEST|Catherine Bergego Scale|Neglect will be assessed using the Catherine Bergego Scale. The scale is a 10-point scale with each item scored between 0 (no neglect) and 3 (severe neglect). It involves observation of a participant completing daily activities such as eating, dressing and walking.
48676983|NCT03320187|DRUG|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
48676984|NCT03320187|DRUG|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
48151100|NCT00316121|DEVICE|Leopard Cage and Autograft|Placement in the interbody space
48151101|NCT02384122|DRUG|Octreotide|Two injections of 20 mg will be given monthly.
48363007|NCT00730665|DRUG|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
48363008|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
48363009|NCT00730665|OTHER|Placebo|Capsule, Placebo, every 12 hours (twice a day)
48511122|NCT00610610|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
48511123|NCT00610610|DRUG|Placebo|Same shape Placebo
48676985|NCT00539240|DRUG|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
48676986|NCT00539240|DRUG|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
48676987|NCT00539240|DRUG|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
48151102|NCT04177849|PROCEDURE|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
48676988|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Screening-2002|Nutritional Risk Screening-2002
48676989|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Index|Nutritional Risk Index
48676990|NCT05417672|DIAGNOSTIC_TEST|Mini Nutritional Assessment|Mini Nutritional Assessment
48676991|NCT05417672|DIAGNOSTIC_TEST|Glasgow Prognostic Score|Glasgow Prognostic Score
48363010|NCT00730665|DRUG|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
48363011|NCT02499380|DEVICE|PneumRx Coil System|
48363012|NCT03604159|DRUG|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
48363013|NCT03604159|DRUG|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
48363014|NCT04437524|OTHER|therapeutic exercises|Treatment that will continue 3 days a week for 6 weeks in female patients with fibromyalgia.
48363015|NCT00352833|DRUG|catumaxomab|
48363016|NCT03958695|DEVICE|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
48363017|NCT03958695|DEVICE|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
48363018|NCT02347124|BEHAVIORAL|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
48363019|NCT02347124|BEHAVIORAL|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
48363020|NCT00453635|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles
48363021|NCT00453635|DRUG|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
48363022|NCT00453635|DRUG|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
48363023|NCT00453635|DRUG|Vinorelbine|Vinorelbine at the dose of 60mg/m\^2 per os,weekly
48363024|NCT04252924|OTHER|lifestyle characteristics|Exposures of interest: Mediterranean diet, orthorexia nervosa, smoking, physical activity, sleep duration, stress level
48363025|NCT05153252|BEHAVIORAL|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
48363026|NCT05153252|BEHAVIORAL|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
48363027|NCT03027180|DEVICE|Noninvasive positive airway pressure with different levels|
48363028|NCT03917394|DRUG|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
47992444|NCT06301815|DIAGNOSTIC_TEST|Bucket Test|"The bucket test involves the patient being sat upright and looking into a translucent bucket with the bucket covering their complete field of vision. On the inside of the bucket on the bottom is a dark straight line. On the outside of the bottom of the bucket is a matching dark line, the bottom of the bucket is divided into degrees with the zero-degree line being equivalent to the line inside the bucket. For measurement the bucket will be randomly rotated right or left by the examiner to 45 degrees and then slowly rotated back to the zero-degree position. Patients will signal when they estimate the inside bottom line to be truly vertical by saying stop or by raising their non-paretic hand."
48151103|NCT04177849|PROCEDURE|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
48363029|NCT03917394|DRUG|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
48363030|NCT03965234|DRUG|Cisplatin|Given via infusion
48363031|NCT03965234|PROCEDURE|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
48363032|NCT03965234|PROCEDURE|Metastasectomy|Undergo metastasectomy
48363033|NCT05321264|BEHAVIORAL|Educational nursing intervention|Four weekly individualized intervention sessions, with a duration of 40 minutes.
48363034|NCT04419558|DRUG|Pamrevlumab|Sterile solution for injection
48363035|NCT04419558|DRUG|Placebo|Sterile solution for injection
48363036|NCT00751335|DEVICE|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
48363037|NCT00751335|DEVICE|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
47992445|NCT06115408|DRUG|Dienogest 2 MG|Clinical trial
47992446|NCT06115408|DRUG|N-acetyl cysteine|Clinical trial
48363038|NCT04306003|OTHER|ERAS pathway|See ERAS pathway arm description.
48363039|NCT04306003|OTHER|Standard Perioperative Care|See control arm description.
48676992|NCT05417672|DIAGNOSTIC_TEST|Prognostic Nutritional Index|Prognostic Nutritional Index
48676993|NCT05417672|DIAGNOSTIC_TEST|Anthropometric measurements|middle arm circumference
48676994|NCT05417672|DEVICE|Handgrip strength test|Handgrip strength test
48151104|NCT00668746|DRUG|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
48676995|NCT05979961|RADIATION|IMRT and concurrent cisplatin|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)
48363040|NCT03218943|DEVICE|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
48363041|NCT03218943|DEVICE|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
48363042|NCT03472339|DRUG|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
48363043|NCT03861832|DIETARY_SUPPLEMENT|KB220Z|Acts to enhance dopamine
48363044|NCT03861832|DIETARY_SUPPLEMENT|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
48363045|NCT03832712|PROCEDURE|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
48363046|NCT03832712|DRUG|Best Medical Treatment|Unselective β-blockers such as Propanolol
48363047|NCT02935023|RADIATION|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
48363048|NCT05528965|PROCEDURE|Perpendicular Group|Radiofrequency ablation was applied to the perpendicular group by placing the tip of electrode perpendicularly to contact the genicular nerves.
48363049|NCT05528965|PROCEDURE|Parallel Group|Radiofrequency ablation was applied to the parallel group by placing the electrode lay parallel to contact the genicular nerves.
48363050|NCT04694079|PROCEDURE|Group 1, CMR-guided/aided VT ablation|"Ablation of the anatomical channels of heterogeneous tissue within the scar"
48363051|NCT04694079|PROCEDURE|Group 2, CMR-aided VT ablation|"Ablation of the electrical conduction channels within the scar"
48363052|NCT04694079|PROCEDURE|Group 3, Electroanatomical guided ablation|Ablation guided by an electro-anatomical system without the aid of CMR
48363053|NCT05811143|DEVICE|Spinal Cord Stimulator|SOC Implantation of Spinal Cord Stimulator for Lipomatosis and Low Back Pain.
48363054|NCT05047601|DRUG|PF-07321332|PF-07321332
48363055|NCT05047601|DRUG|Placebo for PF-07321332|Placebo
48363056|NCT05047601|DRUG|Placebo for Ritonavir|Placebo
48363057|NCT05047601|DRUG|Ritonavir|Ritonavir
48363058|NCT00372580|PROCEDURE|blood test|
48363059|NCT00651911|DRUG|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
48363060|NCT02263924|DIETARY_SUPPLEMENT|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
48363061|NCT02263924|DIETARY_SUPPLEMENT|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
48363062|NCT05231291|OTHER|hand grip strength|Observational study
48363063|NCT01577446|PROCEDURE|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
48363064|NCT00808184|DRUG|CPT-11, Raltegravir (Isentress®), Midazolam|
48363065|NCT03918356|DEVICE|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
48363066|NCT03918356|OTHER|healthy control group|healthy control
48363067|NCT01807442|OTHER|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
48363068|NCT01493024|DRUG|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
48363069|NCT01493024|DRUG|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
48363070|NCT04561739|DEVICE|Paclitaxel coated balloon|"The Paclitaxel coated balloon is a paclitaxel-eluting rapid exchange balloon catheter for PTCA. Paclitaxel is the pharmacologically active substance for anti-neointima, whereas iopromide, a well-tolerated nonionic x-ray contrast agent, acts as a release-supporting additive.~The active drug coating is located on the surface of the balloon, which contains 3 μg Paclitaxel per 1 mm2. The spray coating of the mixture of paclitaxel and iopromide of the Swide is via ultrasound, with the crystal size\<2um."
48363071|NCT04561739|DEVICE|Sirolimus eluting stents|The device has a backbone of L605 cobalt chromium. The stent has a open cell, in-phase, peak-to-valley design. The strut thickness is 86 μm and has a stent profile less than 1.12mm. The polymer coating of the stent is a styrene-butadiene block copolymer. The antiproliferative drug concentration is at 9 ug/mm, which 80% of the drug is released by 30 days.
48363072|NCT03435289|DRUG|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
48363073|NCT01667731|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
48363074|NCT01667731|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
48363075|NCT02698176|DRUG|Birabresib|Administered as an oral capsule in a fasted state
48363076|NCT00002362|DRUG|Abacavir sulfate|
48363077|NCT00002362|DRUG|Efavirenz|
48363078|NCT00002362|DRUG|Emtricitabine|
48363079|NCT00002362|DRUG|Stavudine|
48363080|NCT05322759|OTHER|aquatic exercises|aquatic polymetric exercises for 30 min including hip abduction/adduction, knee flexion/extension, hip flexion/extension, holding pool from sides, bending forward and picking up objects, shoulder flexion/extension kangroo jumpes, jumping to sides.
48511124|NCT02101580|DRUG|ADI-PEG 20|
48363081|NCT05322759|OTHER|halliwick exercise programme|Halliwick exercise programme for 30 min include sagittal rotations, transversal rotations, longitudnal rotations and combined rotations.
48363082|NCT00159146|DRUG|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
48363083|NCT04930627|DRUG|Empagliflozin|dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
48363084|NCT05979727|DRUG|RE02|Low, medium or high dose of RE02
48363085|NCT05979727|DRUG|Manitol|Placebo Comparator
48363086|NCT05964296|OTHER|The MAURISSE application use|"* Exchanges with the care team via the messaging system,~* Postponement of consumption,~* Monitoring of consumption,~* Access to information on the To Do List,~* Access to personal content to help with management (Socio-professional situation, type of life, personal history..).~* Postponement of a feeling of boredom,~* Access to proposals to fight against this feeling."
48363087|NCT05964296|OTHER|Usual care|The usual care within the center will consist of appointments with doctors; regular follow-up meetings with nurses, psychologists, social workers, therapeutic groups depending on the evaluation.
48363088|NCT00073541|DRUG|EMD 72000|
48363089|NCT02409576|BIOLOGICAL|Expanded , Activated NK cells|"1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
48363090|NCT04101994|DEVICE|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
48363091|NCT04101994|DEVICE|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
48363092|NCT04101994|DEVICE|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
48676996|NCT05979961|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
48676997|NCT05547412|DEVICE|NovaGuide 2 Intelligent Ultrasound System|The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
48676998|NCT02881736|OTHER|electroencephalographic,magnetic resonance imaging|
48676999|NCT03801928|DRUG|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
48677000|NCT01288625|DRUG|Amifostine|500 mg sc, qod, 3 times per week
48677001|NCT01288625|RADIATION|Amifostine|500mg rinsing wash, qod, 3 times per week
48677002|NCT03132558|DRUG|Radiopaque Media|
48677003|NCT02399787|OTHER|blastocyst biopsy|Performed on day 5
48677004|NCT03371199|DRUG|Sodium chloride|Sodium chloride tablets, 250 mg
48677005|NCT03371199|DRUG|Placebo Oral Tablet|Starch tablets
48677006|NCT05889325|PROCEDURE|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
48677007|NCT01705340|DRUG|Akt inhibitor MK2206|Given PO
48363093|NCT00754312|DRUG|SNDX-275|
48363094|NCT01633398|GENETIC|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
48363095|NCT04312737|DEVICE|Self-Collecting Devices|FLOQSwab (Copan) Colli-Pee (Novosanis)
48363096|NCT04312737|DIAGNOSTIC_TEST|In Vitro Diagnostic Assays|Papilloplex (GeneFirst) HPV Oncopredict DNA (Hiantis) HPV Oncopredict RNA (GeneFirst)
48363097|NCT04169126|DRUG|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
48363098|NCT02561026|BIOLOGICAL|Frozen plasma|patients randomized to receive frozen plasma transfusions
48363099|NCT01914042|DRUG|Morphine|
48363100|NCT01914042|DRUG|Milnacipran|
48363101|NCT00034697|DRUG|temozolomide|
48363102|NCT01192139|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
48677008|NCT01705340|BIOLOGICAL|trastuzumab|Given IV
48363103|NCT01192139|DRUG|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
48363104|NCT01192139|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
48363105|NCT02899026|DRUG|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
48363106|NCT02899026|DRUG|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
48677009|NCT01705340|DRUG|lapatinib ditosylate|Given PO
48677010|NCT01705340|OTHER|laboratory biomarker analysis|Optional correlative studies
48677011|NCT01979718|DEVICE|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
48363107|NCT02899026|DRUG|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
48677012|NCT05680467|OTHER|Manual Therapy|"The protocol will last 30 minutes and will include the application of the following manual techniques:~* Lumbar soft tissue and joint cranial and lateral mobilization with the patient in the supine position~* Bilateral medial lumbar soft tissue mobilization~* Functional massage on the quadratus lumborum muscle with the patient in a lateral position on both sides~* Extension with coupled sidebending mobilization of the thoracic area with the patient in a lateral position on both sides~* Soft tissue lateral mobilization of the thoracic area with the patient in a lateral position on both sides"
48363108|NCT02539680|PROCEDURE|endoscopy|duodenal biopsies
48677013|NCT05680467|OTHER|Manual Therapy plus TECAR|The participants of this group will be given the same manual protocol as the first group in combination with the application of high frequency current. Soft tissue mobilization manipulations will be applied in combination with a capacitive conventional electrode and with a special electrode bracelet that makes the therapist's own hand as an antistatic electrode. The frequencies of the high frequency current will be 300khz, 500khz, and 1MHz, while as a reference electrode a flexible self-adhesive ground will be used placed on the abdomen
47992447|NCT06214650|OTHER|Radiofrequency|"Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A.~It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session.~The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week."
47992448|NCT06214650|OTHER|Control|Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.
47992449|NCT01393808|DRUG|Paricalcitol|1-month Paricalcitol 2mcg/day
47992450|NCT01393808|OTHER|placebo|1-month Placebo Treatment
47992451|NCT00625859|DRUG|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
47992452|NCT00625859|DRUG|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
47992453|NCT00625859|DRUG|Placebo|Placebo tablets will be given to subjects.
47992454|NCT03832621|DRUG|Temozolomide|temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
47992455|NCT03832621|DRUG|Nivolumab|nivolumab 480 mg i.v. every 4 weeks
47992456|NCT03832621|DRUG|Ipilimumab|low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
47992457|NCT03318354|DRUG|Torrent's Olmesartan Medoxomil Tablets 40 mg|
47992458|NCT03318354|DRUG|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
48151105|NCT00224198|PROCEDURE|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
48363109|NCT03618433|OTHER|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
48511125|NCT00769938|DEVICE|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
48677014|NCT05680467|OTHER|Control|Participants in this group will only receive general instructions about managing their back pain and counseling about avoiding activities that may worsen their symptoms.
48677015|NCT02041299|DRUG|Deferiprone|
48677016|NCT02041299|DRUG|Deferoxamine|
48677017|NCT00811954|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
48677018|NCT00811954|DRUG|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
48677019|NCT00811954|DRUG|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
48677020|NCT00811954|DRUG|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
48677021|NCT00811954|DRUG|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
48677022|NCT04666974|BEHAVIORAL|iCBT|Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.
48677023|NCT04666974|BEHAVIORAL|In-Person CBT|Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
48677024|NCT04111705|DRUG|Lorlatinib|100 mg once daily
47992459|NCT06362434|DEVICE|Audiovisual stimulation|The MOT IVR audiovisual stimulation task involves the 3D multiple-object-tracking paradigm composed of 6-8 high-contrast spheres which features are adapted to the visual ability of individuals with low-vision (luminosity = 80 nits, size = 1° to 3° visual angle). The spheres move for 20s. following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. The participant, comfortably seated, is asked to track the moving cued target among moving distractors for 20s. A spatial sound is correlated to the movement of the cued target. After 20s., the movement stops and the participant is asked to select, using a laser pointer, the cued sphere among the distractors (mark-all procedure). Speed of the spheres is regulated by a staircase 1:1 procedure. The stimulation can here be stopped by the participant if required. After 3 blocks of 15x20s., the system stops and goes on stand-by mode until the next session. Data are collected in real time.
48677025|NCT04169516|DIAGNOSTIC_TEST|index of microcirculatory resistance|Physiological parameters of the culprit artery after PCI were determined with the restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Aortic pressure (Pa), distal intracoronary pressure (Pd), fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) were measured using a 0.014 coronary temperature and pressure-sensing guidewire (PressureWireCertus, ST. Jude Medical, MN, USA).
48677026|NCT02527473|OTHER|Dispatcher-Assisted Basic Life Support CPR Education|"The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.~The one hour training session is split into four parts:~1. Video self-instruction manikin practice (30 min), including a brief introduction to AED.~2. Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer~3. Debriefing (15 min): Questions, answers and reflection~4. Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone"
48151106|NCT00383500|DEVICE|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
48151107|NCT00383500|DEVICE|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
48151108|NCT02212275|DRUG|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
48677027|NCT01189786|DEVICE|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
48677028|NCT04125329|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
48677029|NCT03370211|OTHER|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
48677030|NCT05623345|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
48677031|NCT05623345|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
48677032|NCT05125146|BEHAVIORAL|e-CBTi|See arm/group description
48677033|NCT05125146|DRUG|Trazodone|See arm/group edescription
48363110|NCT03618433|OTHER|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
48363111|NCT00694265|PROCEDURE|Decompression|Surgical decompression of the median nerve
48677034|NCT04632394|DIAGNOSTIC_TEST|Generation of computational model from cardiac MRI.|Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
48151109|NCT01858909|DRUG|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
48151110|NCT05742646|BEHAVIORAL|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
48151111|NCT05742646|BEHAVIORAL|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
48151112|NCT05786911|OTHER|nutritional score|correlation between a food habit and nutritional status score of the parturient and a postpartum fatigue (FSS) and pain (ENA) score
48363112|NCT00694265|PROCEDURE|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
48363113|NCT01694966|DRUG|Methylene Blue MMX®|
47992460|NCT00329407|DRUG|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM \& 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM \& 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM \& 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
48151113|NCT04992494|BEHAVIORAL|MBCT-Telephone|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
48151114|NCT04992494|BEHAVIORAL|MBCT-Video|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
48363114|NCT01694966|DRUG|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
48677035|NCT04632394|PROCEDURE|VT ablation|Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (\~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
48677036|NCT02583347|DEVICE|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
48151115|NCT03987815|DRUG|Nivolumab|Nivolumab
48363115|NCT04858516|DRUG|palbociclib and exemestane plus trastuzumab and pyrotinib|Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer
48363116|NCT01494909|DIETARY_SUPPLEMENT|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
48363117|NCT03191604|OTHER|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
48363118|NCT04801615|OTHER|Surgery|All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections
48363119|NCT05784558|DEVICE|UroLift System|The UroLift System is a procedure that utilizes tiny implants to lift and hold the enlarged prostate tissue out of the way so it no longer blocks the urethra.
48677037|NCT03773003|DIETARY_SUPPLEMENT|Probiotics|"The administered probiotics are readily available on the market and contain~* Bifidobacterium breve, B. infantis, B. lactis, B. longum~* Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~* Streptococcus thermophilus"
48677038|NCT03773003|DIETARY_SUPPLEMENT|Placebo|Identically looking to verum, containing corn starch.
48677039|NCT00876707|DEVICE|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
48677040|NCT00876707|DEVICE|ReSTOR implant|Implant of multifocal IOL ReSTOR
48677041|NCT00876707|DEVICE|ReZoom implant|Implant of multifocal IOL ReZoom
48677042|NCT06440252|DRUG|Grape Seed Extract|One daily dose of 1 capsule containing 600mg grape seed extract
48677043|NCT06440252|DRUG|Maltodextrin|One daily dose of 1 capsule
48677044|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
48677045|NCT00932035|DRUG|isosulfan blue based lymphatic mapping|
48677046|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo standard axillary lymph node dissection
48677047|NCT00932035|PROCEDURE|quality-of-life assessment|Ancillary studies
48677048|NCT00932035|OTHER|Questionnaire administration|Ancillary studies
48677049|NCT03469167|DEVICE|CEGP003|Application of CEGP003 to peptic ulcer bleeding
48677050|NCT03469167|DEVICE|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
48677051|NCT01239771|DRUG|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
48677052|NCT01239771|DRUG|Placebo|Two subjects in each cohort will be given placebo.
48677053|NCT06486181|OTHER|Thrombolysis/Thrombectomy|"Endovascular interventions will be either catheter directed thrombolysis or mechanical thrombectomy procedures both of which have been cleared by FDA for the treatment of acute DVT.~Catheter-directed thrombolysis involves the use of a catheter to deliver thrombolytic agents directly to the site of the clot, effectively dissolving the thrombus. Mechanical thrombectomy, on the other hand, employs specialized devices to physically remove the clot from the vessel. These procedures have been cleared by FDA as they are targeted approaches to safely and effectively restore blood flow and reduce the risk of complications associated with acute DVT."
48677054|NCT02628444|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
48677055|NCT02628444|BIOLOGICAL|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
48677056|NCT03595735|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
48677057|NCT04357184|OTHER|Blood flow restriction training|BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
48677058|NCT03102294|OTHER|inspiratory muscle training|inspiratory muscle training with 50% of MIP
48677059|NCT03102294|OTHER|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
48677060|NCT00696124|BIOLOGICAL|VM202 2 mg|2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
48677061|NCT00696124|BIOLOGICAL|VM202 4 mg|4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
48677062|NCT00696124|BIOLOGICAL|VM202 8 mg|8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
48677063|NCT00696124|BIOLOGICAL|VM202 16 mg|16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
48677064|NCT00100737|DRUG|interleukin-2|
48677065|NCT00100737|DRUG|rituximab|
48363120|NCT05784558|OTHER|Watchful Waiting or BPH Medications|Subjects for whom the physician decides the best course of therapy to be either watchful waiting or new or continuing BPH medications.
48363121|NCT05784558|DEVICE|Other Surgical Intervention|Physician decides the best course of therapy to be a surgical intervention other than the UroLift System.
48363122|NCT05901142|BEHAVIORAL|Exercise-based multi-phasic, multi-modal intervention|"Pre-op: 2\*60min supervised; 1\*30min unsupervised walking sessions per week Supervised session: Aerobic: 8\*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2\*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1\*60min supervised exercise; unsupervised walking \[2\*30min weeks 1-2; 3\*30min week 3; 4\*30min weeks 4-6\] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3\*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1\*10reps in week 1, to 2\*10reps in weeks 2-4, and 3\*10reps in weeks 4-6"
48363123|NCT03763292|BEHAVIORAL|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
48363124|NCT03313440|OTHER|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
48363125|NCT03313440|OTHER|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
48363126|NCT04613804|DRUG|Toripalimab Injection|"Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle."
48363127|NCT03309215|OTHER|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of \>99 wt.% nickel one consist of \>99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
48363128|NCT02081664|BEHAVIORAL|lifestyle intervention|
47992461|NCT02197806|DRUG|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
48363129|NCT03953794|DEVICE|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
48363130|NCT03907943|PROCEDURE|carotid endarterectomy|Surgical treatment of ICA stenosis.
48363131|NCT02548091|OTHER|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
48363132|NCT02548091|PROCEDURE|Non invasive ventilation|
48363133|NCT02548091|PROCEDURE|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
48363134|NCT02548091|PROCEDURE|Computed tomography (CT)|
47992462|NCT02197806|DRUG|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
48363135|NCT00000721|DRUG|CD4 Antigens|
47992463|NCT02197806|DRUG|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
47992464|NCT02653560|DRUG|Potassium chloride powder|
47992465|NCT02653560|DRUG|Potassium magnesium Citrate (KMgCit)|
47992466|NCT02653560|DRUG|Potassium citrate powder|
47992467|NCT02653560|DRUG|Placebo|
48363136|NCT02185040|DRUG|CC-220|0.3 mg oral capsules once every other day with or without food
48363137|NCT02185040|DRUG|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
47992468|NCT02144233|PROCEDURE|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
47992469|NCT02144233|PROCEDURE|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
47992470|NCT05471479|DRUG|Activated Charcoal|Activated charcoal administered as per Clinical Toxicology Recommendations Collaborative or as per current practices
47992471|NCT02258321|DRUG|PPI-668 tablet|
47992472|NCT02258321|DRUG|PPI-668 capsule|
48363138|NCT02185040|DRUG|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
48363139|NCT02185040|DRUG|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
48363140|NCT02185040|DRUG|Placebo|Matching oral placebo daily
48363141|NCT02716532|DIETARY_SUPPLEMENT|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
48677066|NCT03011749|OTHER|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
48363142|NCT02728804|OTHER|Quality-of-Life Assessment|Complete questionnaire
48677067|NCT03318445|DRUG|Rucaparib|All participants will take rucaparib by mouth
48677068|NCT03318445|DRUG|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
48677069|NCT01170234|DEVICE|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
48677070|NCT06117345|BEHAVIORAL|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
48677071|NCT02854995|PROCEDURE|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
48677072|NCT02854995|PROCEDURE|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
48151116|NCT00956527|BEHAVIORAL|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
48151117|NCT02173457|DRUG|Chiglitazar|Take orally
48363143|NCT02728804|OTHER|Questionnaire Administration|Complete questionnaires
48363144|NCT01222767|DRUG|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
48363145|NCT02941861|OTHER|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
48511126|NCT03450044|BIOLOGICAL|Dendritic cells|Adoptive transfer of autologous DCs
48511127|NCT04740697|OTHER|Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.|"Each included patient will be referred to the health care staff for a blood sample:~* for the determination of the residual plasma concentration of tamoxifen and its active metabolites,~* for the constitution of a biobank.~Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...)."
47992473|NCT04390945|DRUG|Camrelizumab|Camrelizumab combined with concurrent radiotherapy and chemotherapy
48151118|NCT02173457|DRUG|Sitagliptin|Take orally
48151119|NCT03640078|OTHER|acquisition imaging|The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
48363146|NCT02941861|OTHER|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
48511128|NCT06206135|DRUG|the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)|The initial dose of Nephoxil capsules for the subjects participating in this study shall be determined at the investigator's discretion, and subjects shall be classified into either the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) according to the initial dose. It will be conducted with 13 visits over 48 weeks.
48363147|NCT02865278|OTHER|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
48363148|NCT02113891|DRUG|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
48363149|NCT03034746|OTHER|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
48511129|NCT00579566|OTHER|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
48363150|NCT03034746|OTHER|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
48677073|NCT03149146|OTHER|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
48677074|NCT03149146|OTHER|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
48363151|NCT02897830|DRUG|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
48677075|NCT02526303|DRUG|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
47992474|NCT06245291|DRUG|Imdusiran|subcutaneous injection
47992475|NCT06245291|DRUG|Durvalumab|intravenous injection
47992476|NCT02968303|DRUG|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
47992477|NCT05228145|GENETIC|NGN-101|Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.
47992478|NCT06114355|PROCEDURE|EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)
47992479|NCT04327232|DRUG|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
47992480|NCT04327232|DRUG|Placebo oral tablet|Placebo
48151120|NCT04819204|DRUG|Cetrorelix Acetate|GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.
48151121|NCT04819204|DRUG|Testosterone gel|Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
48677076|NCT05143333|OTHER|DANA app|The Defense Automated Neurobehavioral Assessment (DANA) is a battery of cognitive tests delivered via an electronic tablet or smartphone. The platform allows higher temporal precision and frequency of measurement than traditional neuropsychological methods while including previously standardized cognitive tests and allowing individuals to repeatedly self-administer the battery in their own homes without examiner supervision. Hence, the DANA battery bypasses several of the major limitations associated with in-person cognitive exams.
47992481|NCT02732483|DRUG|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
48677077|NCT01964378|DRUG|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
47992482|NCT04432311|BEHAVIORAL|Binge Focused Therapy (BFT)|The BFT group will be provided Binge Focused Therapy, a group-based, guided-self help intervention. Participants in this group will attend three online group sessions spread over six weeks (Week 1, Week 2, and Week 6) and complete homework between sessions. Following Session 3, there is a four week period where participants complete self-guided check-ins once per week to monitor continued progress and/or signs of relapse.
47992483|NCT04432311|BEHAVIORAL|CBT Unguided Self Help (CBT USH)|The CBT USH group will be provided with the book, Overcoming Binge Eating by C. Fairburn, which is a well-established self-help book used to help individuals understand binge eating and control binge eating behaviours. After participants receive the book, they will have 10 weeks to read it and work through the exercises provided in the book.
48151122|NCT01864980|PROCEDURE|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
48151123|NCT01864980|PROCEDURE|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
48151124|NCT03622372|PROCEDURE|Operative repair of Zone 2 FDP tendon lacerations|Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
47992484|NCT01768481|DRUG|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
47992485|NCT01768481|DRUG|sugar pill|placebo controlled arm receives similarly looking placebo.
47992486|NCT01112852|DRUG|pantoloc 40 mg|pantoloc iv. infusion per day
47992487|NCT01112852|DRUG|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
48677078|NCT01964378|DRUG|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
47914388|NCT01660958|DIETARY_SUPPLEMENT|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
47992488|NCT05262530|BIOLOGICAL|BNT142|Intravenous bolus/infusion
48151125|NCT03622372|DEVICE|CoNextions TR Implant System|The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).
48151126|NCT03622372|DEVICE|4-strand locked cruciate repair|A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
48151127|NCT00993278|DIETARY_SUPPLEMENT|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
48363152|NCT02897830|DRUG|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
48363153|NCT02897830|DRUG|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
48677079|NCT00106041|BEHAVIORAL|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
48677080|NCT05763680|DIAGNOSTIC_TEST|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
48677081|NCT03856359|DRUG|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
48677082|NCT04455828|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
48677083|NCT02613520|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
48677084|NCT02613520|OTHER|Normal Saline|0.9% Sodium chloride
48677085|NCT02613520|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
48677086|NCT02154516|DEVICE|ODH Hip System|
48677087|NCT03919565|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
48677088|NCT03919565|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
48677089|NCT03919565|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
48677090|NCT02118519|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
48677091|NCT00334568|DRUG|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
48677092|NCT00334568|DRUG|Placebo|Placebo
48677093|NCT04862559|DEVICE|NovaCross|A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
48677094|NCT01880151|DEVICE|EEG|EEG recorded during a resting condition and during an episodic memory task condition
48677095|NCT01082081|DRUG|Paracetamol 1000 mg|Paracetamol 1000 mg
48677096|NCT01082081|DRUG|Paracetamol 500 mg|Paracetamol 500 mg
48677097|NCT01082081|DRUG|Placebo|Placebo
48677098|NCT02642211|PROCEDURE|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
48677099|NCT03637283|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
48677100|NCT03637283|PROCEDURE|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
47992489|NCT01471379|DRUG|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
48677101|NCT04361292|PROCEDURE|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
48677102|NCT01757301|OTHER|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
48677103|NCT01757301|OTHER|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
48677104|NCT03056833|DRUG|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
48677105|NCT03056833|DRUG|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
48677106|NCT03056833|DRUG|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
48677107|NCT00286897|DRUG|E2007|
48677108|NCT06513065|DRUG|Mitomycin c|"Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy."
48677109|NCT04725019|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.
48363154|NCT06017349|DEVICE|Non-invasive glucose meter|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
48363155|NCT06017349|DEVICE|EKF analyzer|Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
48363156|NCT06017349|DEVICE|Accu-Chek Guide|Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
48363157|NCT03552172|OTHER|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
48363158|NCT03552172|OTHER|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
48363159|NCT02885506|DRUG|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
48511130|NCT04421235|BEHAVIORAL|Childbirth support|"There are 5 program components that women may receive as a part of childbirth support:~Prenatal education - consists of up to 8 sessions of education on pregnancy, childbirth, and postpartum health and wellness.~Support group - semi-structured group which provides time for women to process their pregnancy and postpartum-related experiences with other women facing similar challenges. Integrates mindfulness exercises, cognitive-behavioral skills, and special topics as requested by group members.~Lactation program - program for women who wish to provide breastmilk for infants from which they are separated.~Doula support program - 2 prenatal and 2 postnatal individual visits with a doula who will also provide continuous childbirth support and support during separation from infants.~Parenting classes - group classes focused on helping women learn parenting skills and (if applicable) meet state requirements for reunification with children"
48511131|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
48511132|NCT06633783|DRUG|Semaglutide|The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
48511133|NCT04712279|DRUG|Ivermectin 0.6mg/kg/day|Use of ivermectin 0.6m/kg/day q.d.for 05 days
48511134|NCT04712279|DRUG|Ivermectin 1.0mg/kg/day|Ivermectin 1.0mg/kg/day q.d. for 05 days
48511135|NCT04712279|DRUG|Placebo|Placebo q.d.for 05 days
48511136|NCT04712279|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg/day q.d. for 05 days
48511137|NCT04948892|OTHER|Prescence of the father during cesarean section in general anesthesia|The father is now present in the OR during cesarean section category 1, instead of waiting outside
48677110|NCT04725019|BEHAVIORAL|Motor training|Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
48677111|NCT06000969|DEVICE|Lung Recruitment Conventional|the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
48677112|NCT06000969|DEVICE|Lung Recruitment Ultrasound|the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
48677113|NCT04859101|OTHER|Gum|2 minutes of gum chewing prior to procedure
48677114|NCT04859101|OTHER|Control|2 swallows prior to procedure
48677115|NCT04570306|DRUG|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
48677116|NCT00066053|PROCEDURE|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
48677117|NCT00066053|PROCEDURE|Referral|
48677118|NCT03920241|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
48677119|NCT03920241|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
48677120|NCT03920241|OTHER|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
48677121|NCT03783598|BEHAVIORAL|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
48677122|NCT00771212|OTHER|Observational pain control study|Observational pain control study
48677123|NCT03364231|DRUG|Umbralisib|Oral Daily Dose
47992490|NCT01471379|DRUG|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
47992491|NCT01471379|DRUG|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
48151128|NCT00993278|DIETARY_SUPPLEMENT|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
48677124|NCT04892719|DIAGNOSTIC_TEST|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
48677125|NCT02117011|OTHER|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
48677126|NCT00659841|DRUG|Ciclesonide|200µg Ciclesonide versus placebo
48677127|NCT00659841|DRUG|Placebo|placebo
48151130|NCT00901459|DEVICE|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
48151131|NCT00901459|DEVICE|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
48151132|NCT00901459|DEVICE|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
48677128|NCT01503814|OTHER|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
48677129|NCT05160506|DRUG|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
48677130|NCT05160506|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
48677131|NCT05004844|DIAGNOSTIC_TEST|Viscoelastic assays and aggregometry tests|Viscoelastic assays and aggregometry tests performed with ROTEM will allow us to characterize the clot forming abilities and platelet functions of our patients. ROTEM is used routinely for aiding clinicians in choosing the appropriate blood products for patients ROTEM requires samples of whole blood in an amount that does not entail additional burden or risk for patients. In our study, viscoelastic assays and aggregometry will be performed upon arrival, and 24-,48-,72-hours post-admission.
48677132|NCT06009822|OTHER|Postoperative outcome measurements|"Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index."
48677133|NCT03305952|BEHAVIORAL|CBCT|
48677134|NCT03305952|OTHER|TAU|
48677135|NCT00355030|DRUG|somatropin|0.05 mg/kg/day
48151133|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
48151134|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
48151135|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
48677136|NCT00355030|DRUG|leuprorelin|11.25 mg/3 months
48677137|NCT00383071|BIOLOGICAL|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
48677138|NCT00383071|PROCEDURE|Apheresis|Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.
48151136|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
48151137|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
48151138|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
48151139|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
47992492|NCT01471379|DRUG|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
48151140|NCT01428622|DRUG|Olodaterol|aqueous solution
48151141|NCT01428622|DRUG|Olodaterol|aqueous solution
48151142|NCT01428622|DRUG|Olodaterol|aqueous solution
48151143|NCT01428622|DRUG|Olodaterol|aqueous solution
48151144|NCT01428622|DRUG|Olodaterol|aqueous solution
48151145|NCT01428622|DRUG|Olodaterol|aqueous solution
48151146|NCT01428622|DRUG|Olodaterol|aqueous solution
48151147|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
48151148|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
48151149|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
48151150|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
48151151|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
48151152|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
48151153|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
48151154|NCT01428622|DRUG|BI54903|ethanolic solution
48151155|NCT01428622|DRUG|BI54903|ethanolic solution
48151156|NCT01428622|DRUG|BI54903|ethanolic solution
48151157|NCT01428622|DRUG|BI54903|ethanolic solution
48151158|NCT01428622|DRUG|BI54903|ethanolic solution
48151159|NCT01428622|DRUG|BI54903|ethanolic solution
48151160|NCT01428622|DRUG|BI54903|ethanolic solution
48151161|NCT00674765|DRUG|Seroquel|400 mg/day
48151162|NCT00674765|DRUG|Placebo|400 mg/day
48677139|NCT05604443|OTHER|retrospective analyze|retrospective analyze of MS39 and Pentacam images
48677140|NCT05555342|PROCEDURE|Irreversible electroporation (IRE) ablation|IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.
48677141|NCT05555342|RADIATION|Radiation Therapy|Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.
48677142|NCT05228405|OTHER|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
48677143|NCT00132301|DRUG|Docetaxel|Chemotherapy agent
47992493|NCT02496247|OTHER|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
47992494|NCT03160742|DEVICE|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
48151163|NCT04034732|BEHAVIORAL|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
48151164|NCT04034732|BEHAVIORAL|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
48677144|NCT00132301|DRUG|Prednisone|steroid in combination with chemotherapy agent
48677145|NCT01369043|DIETARY_SUPPLEMENT|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
48677146|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
48677147|NCT01581684|DRUG|Placebo|Solution for oral administration
48677148|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
48677149|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
47992495|NCT03626220|PROCEDURE|acupuncture|manually manipulate acupuncture at CV6 and three acupoints on each arms and legs
47992496|NCT01369576|DRUG|Placebo|3.75-7.5mg 14 doses 4 weeks
47992497|NCT01369576|DRUG|Zopiclone|3.75-7.5mg 14 doses 4 weeks
47992498|NCT03283423|DEVICE|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
47992499|NCT00110058|BIOLOGICAL|recombinant interferon alfa|
47992500|NCT00110058|BIOLOGICAL|therapeutic allogeneic lymphocytes|
47992501|NCT00110058|DRUG|cyclosporine|
47992502|NCT00110058|DRUG|fludarabine phosphate|
47992503|NCT00110058|DRUG|imatinib mesylate|
48677150|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
48677151|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
47992504|NCT00110058|DRUG|mycophenolate mofetil|
48677152|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
47992505|NCT00110058|PROCEDURE|peripheral blood stem cell transplantation|
48677153|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
48677154|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
48677155|NCT05837039|BEHAVIORAL|Healthcare Provider|Questionnaires
48677156|NCT05837039|BEHAVIORAL|Caregiver Perception|Questionnaires
48677157|NCT00729443|DRUG|AZD3241|single oral dose
47992506|NCT00110058|RADIATION|radiation therapy|
48677158|NCT00729443|DRUG|Placebo|
47992507|NCT05537077|OTHER|Prolotherapy|DPT was applied as a total of 3 sessions at 0, 3 and 6 weeks. In each session, intra-articular 5 ml and periarticular 10 ml dextrose injections were administered to the knee. Periarticular injection was applied to 10 points as 1 ml in each region. The regions were determined as medial and lateral coronary ligaments, proximal and distal medial and lateral collateral ligaments, pes anserinus region, proximal and distal patellar tendon, quadriceps tendon attachment area.
47992508|NCT05537077|OTHER|Home based exercise program|Knee ROM, isometric and isotonic quadriceps strengthening exercises were given as 2 sets of 10 repetitions per day for 12 weeks.
47992509|NCT05537077|OTHER|Hotpack therapy|Hotpack treatment was applied for 20 minutes at 0, 3 and 6 weeks.
47992510|NCT03968302|DRUG|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
47992511|NCT03968302|DRUG|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
47992512|NCT04342039|DRUG|Budesonide Nasal|budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
47992513|NCT04342039|OTHER|Placebo|2 sprays each nostril daily on days as indicated in the timeline
47992514|NCT00454987|BIOLOGICAL|Menitorix|Menitorix was only administered to subjects of the group Meningitic+Hiberix group at 40 to 43 months of age.
48151165|NCT01034774|DRUG|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
48151166|NCT01034774|DRUG|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
48151167|NCT04271813|DRUG|Anlotinib plus Sintilimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
48151168|NCT04508829|DRUG|Anti-EGFR monoclonal antibody|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
48151169|NCT01399905|DRUG|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
48151170|NCT05025553|DIETARY_SUPPLEMENT|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
48151171|NCT05931224|DRUG|D064, D702, placebo of D660|Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660
48151172|NCT05931224|DRUG|D660, placebo of D064, placebo of D702|Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
48151173|NCT00572494|DEVICE|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
48151174|NCT00572494|DEVICE|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of \>50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
48151175|NCT05503550|DRUG|Talquetamab|Talquetamab will be administered subcutaneously (SC).
48151176|NCT03577054|BEHAVIORAL|HBB Prompt|Mobile app developed through user-centred design in phase 1 of this study
48363160|NCT02885506|DRUG|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
47992515|NCT00454987|BIOLOGICAL|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
48151177|NCT03577054|BEHAVIORAL|Low-Dose High Frequency training|Participants will be encouraged to practice their HBB skills daily
48151178|NCT03826056|BEHAVIORAL|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
48151179|NCT03826056|BEHAVIORAL|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
48151180|NCT01714479|OTHER|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
48151181|NCT01714479|OTHER|Placebo|
48151182|NCT04122820|DIAGNOSTIC_TEST|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
48151183|NCT02970578|PROCEDURE|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
47992516|NCT03571542|OTHER|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
47992517|NCT01946373|DRUG|Cyclophosphamide|
47992518|NCT01946373|DRUG|Fludarabine|
47992519|NCT01946373|BIOLOGICAL|T cells|
47992520|NCT01946373|BIOLOGICAL|Interleukin-2|
47992521|NCT01946373|BIOLOGICAL|Dendritic cell vaccine|
48511138|NCT06632964|BIOLOGICAL|Recombinant oncolytic adenovirus injection solution of VT-101|Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion
48511139|NCT06630533|OTHER|Baduanjin Exercise Group|Baduanjin exercises (Eight-Part Exercises or Eight-Part Brocades), an important part of Qigong, consist of eight postures (1-holding the hands high with palms up, 2- posing as an archer shooting, 3- holding one arm aloft, 4- looking backwards, 5- swinging the head and lowering the body, 6- moving the hands down the back and legs and touching the feet, 7- thrusting the fists and making the eyes glare, and 8- raising and lowering the heels).
48511140|NCT02730663|DEVICE|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
48151184|NCT05123118|BEHAVIORAL|Integrated intervention of smoking cessation and breastfeeding|The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
48363161|NCT04778215|OTHER|A progressive specific lumbar stabilization program|The aim of these programs is to optimize the stabilization and control of segmental motion of the lumbar spine. It is based on the draw-in action, hereafter called the abdominal hollowing, presented by Richardson and Jull (1995). The training program consists of three levels. Level 1 introduces the abdominal hollowing exercise in the prone and four-point kneeling position. Level 2 is a progression of these exercises and the gymnasts are also instructed to perform the abdominal hollowing standing on a balance board with slightly flexed knees while slowly moving the arms. Level 3 takes the training into sports specificity and the abdominal hollowing are to be held during three different basic trampette jumps with emphasis on good trunk and body control during jumping and landing.
48363162|NCT04864197|BIOLOGICAL|platelet rich fibrin|prf membrane placement over implant site for gingival thickening
48363163|NCT03769792|DIAGNOSTIC_TEST|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
48363164|NCT03769792|DEVICE|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
48363165|NCT03769792|DIAGNOSTIC_TEST|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
48363166|NCT03769792|DIAGNOSTIC_TEST|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
48363167|NCT03769792|DIAGNOSTIC_TEST|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
48363168|NCT03577028|BIOLOGICAL|HPN424 Fixed IV 1.3 to 150 ng/kg|Fixed dose IV cohorts at doses from 1.3 to 150 ng/kg
48363169|NCT03577028|BIOLOGICAL|HPN424 Prime Step IV 36 ng/kg Target|Step-dosing IV cohort at a single Prime Dose followed by the Target Dose (12/36 ng/kg)
48151185|NCT05123118|BEHAVIORAL|Attention placebo control|Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
48511141|NCT06370481|OTHER|Telemedicine|Routine care administered via telemedicine
48151186|NCT02338505|DEVICE|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
48151187|NCT04785794|BIOLOGICAL|Sing2016 M2SR H3N2 influenza vaccine|This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
48363170|NCT03577028|BIOLOGICAL|HPN424 1 Prime Step IV 225-300 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (100/300 ng/kg and 75/225 ng/kg)
48363171|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 300 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (50/150/300 ng/kg with prior chemotherapy and 50/150/300 ng/kg no prior chemotherapy)
48363172|NCT03577028|BIOLOGICAL|HPN424 2 Prime Step IV 450 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (100/300/450 ng/kg and 50/150/450 ng/kg)
48363173|NCT03577028|BIOLOGICAL|HPN424 Fixed SC|Fixed subcutaneous dose 120 ng/kg
48511142|NCT06370481|OTHER|Standard of care|Standard of care, as received in HIV clinic settings
48511143|NCT05725863|OTHER|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
48511144|NCT03408379|OTHER|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~* A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~* A Tissue sample will be taken during the surgery~* Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
48363174|NCT01362062|DRUG|Tocilizumab|
48363175|NCT02058966|DRUG|Entacapone|Entacapone 200 mg oral dose
48363176|NCT02058966|DRUG|Methamphetamine|Methamphetamine 20 mg oral dose
48363177|NCT02058966|DRUG|Placebo|capsules compounded to be of similar appearance to the active drugs
48511145|NCT06257095|BEHAVIORAL|Stepped-care social and mental health engagement|Each student will be matched to an older adult and the students will make one call o the older adult which lasts upto 1 hour each week for 8 weeks. Ending each call, the student will assess symptoms of depression anxiety through questionnaires. If the participant responds yes on two consecutive calls to any of these questions, they will be asked if they would like to receive a call from the University of Texas Health Science Center Trauma and Resilience Center to discuss free counseling services.
48511146|NCT06257095|BEHAVIORAL|APS Usual care|Participants will receive a phone call for data collection. Then they will be offered to receive an abbreviated version of the stepped-care social and mental health engagement intervention, lasting only 6-weeks with the option to continue calls if agreeable between the student and older adult.
48151188|NCT04785794|OTHER|Placebo|This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
48511147|NCT00381160|BEHAVIORAL|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
48511148|NCT01650584|DRUG|ISTA Tears|sterile ophthalmic solution
48677159|NCT05762042|OTHER|dietary supplement|"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."
48677160|NCT01778959|DEVICE|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
48677161|NCT01778959|DEVICE|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
48677162|NCT01778959|DEVICE|standard OVD|use of a standard cohesive OVD during cataract surgery
48677163|NCT01778959|DEVICE|OVD|use of a highly cohesive OVD during cataract surgery
47992522|NCT03571581|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
47992523|NCT01950923|DRUG|sildenafil citrate|Given PO
47992524|NCT01950923|OTHER|placebo|Given PO
48151189|NCT01858649|PROCEDURE|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
48151190|NCT01858649|DRUG|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
48151191|NCT01858649|DRUG|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
48151192|NCT01858649|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
48151193|NCT01858649|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
48151194|NCT02637999|DRUG|PEG IFN alfa-2a|
48151195|NCT02637999|DRUG|Myrcludex B|
48151196|NCT02825550|DEVICE|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
48151197|NCT03556059|OTHER|Role of EOSS|The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
48151198|NCT04014686|OTHER|No exercise intervention group|no exercise intervention
48151199|NCT04014686|BEHAVIORAL|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
48151200|NCT00564447|DRUG|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
48677164|NCT02949024|DRUG|IVT Aflibercept|IVT aflibercept \[2 mg (50 µL)\]
48151201|NCT00564447|DRUG|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
48151202|NCT02212626|DEVICE|Rotarex S|
48151203|NCT02282137|DRUG|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
48511149|NCT01650584|DRUG|Systane|Sterile ophthalmic solution
48677165|NCT02949024|DRUG|SC CLS-TA|\[4 mg (100 µL)\]
48677166|NCT06364917|DRUG|Pembrolizumab|The dosing regimens for Pembrolizumab (200 mg Q3W), are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
48677167|NCT06364917|DRUG|Carboplatin|The combination therapy dosages for Carboplatin are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
47992525|NCT01950923|PROCEDURE|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
48511150|NCT06509503|DRUG|Combined oral contraceptive|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
47914389|NCT01660958|BEHAVIORAL|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
47914390|NCT04976907|DEVICE|Contactless vital sign information collection|Collection of facial blood flow and temperature information via conventional and infrared/thermal video of the face for the purpose of estimating vital signs using machine learning-based computational models.
47992526|NCT00837707|DRUG|aripiprazole|Flexible dose: 5-30 mg/day
48151204|NCT01042132|PROCEDURE|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
48363178|NCT01446744|RADIATION|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
48151205|NCT01042132|PROCEDURE|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
48151206|NCT03202056|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
48363179|NCT01446744|RADIATION|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
48363180|NCT05807646|OTHER|Vein ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric vein ligated first.
48363181|NCT05807646|OTHER|Artery ligation first|During this procedure, patients undergo laparoscopic rectal cancer surgery with the inferior mesenteric artery ligated first.
48363182|NCT05032131|BIOLOGICAL|ADSVF|Group 1 and 2 : Escalating dose of ADSVF injection (5 millions of cells, 10 millions of cells and 20 millions of cells).
48363183|NCT05614362|DIETARY_SUPPLEMENT|Channa Striatus extract|Channa Striatus extract given with a dose of 500 mg three-times-daily for each patient
48363184|NCT05614362|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin given three-times-daily for each patient
48363185|NCT06207864|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, saliva, and stool samples
48363186|NCT06207864|PROCEDURE|Return of Results|Receive results
48511151|NCT06509503|DRUG|Vaginal Ring|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
48511152|NCT01403857|OTHER|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
48511153|NCT01403857|OTHER|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
48511154|NCT06452095|DEVICE|Hyperbaric Oxygen therapy|The SECHRIST INDUSTRIES Models 3600 and 4100 (H/HR) Hyperbaric Chambers are Monoplace Pressure Chambers designed to administer oxygen at near 100% concentration as the hyperbaric treatment gas, up to 3.0 atmospheres absolute (ATA) of pressure (29.4 psig). This study will utilize the 3600 and 4100 (H/HR) Hyperbaric Chambers located at Toronto General Hospital, Rouge Valley Hyperbaric Medicine Unit and Restore Hyperbaric Oxygen \& Medical Centre.
48511155|NCT00769873|DRUG|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days
48511156|NCT03827720|DEVICE|SENSE Device|Non-invasive radiofrequency (RF) sensor
48511157|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
48511158|NCT04977479|OTHER|Placebo|Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
48511159|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine, Bivalent|mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
48511160|NCT05755971|OTHER|Combination taping|Elastic and rigid tapes applied together for six weeks
48511161|NCT04743492|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
48511162|NCT06157190|OTHER|Unsupervised monitoring|"This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data."
48511163|NCT03300843|BIOLOGICAL|Peptide loaded dendritic cell vaccine|On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between intravenous (IV) and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
48511164|NCT00516373|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
48511165|NCT03997279|DRUG|Saccharomyces boulardii|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
48677168|NCT06364917|DRUG|Paclitaxel|The combination therapy dosages for Paclitaxel are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
48677169|NCT06364917|DRUG|Pemetrexed|The combination therapy dosages for Pemetrexed are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
48677170|NCT06364917|DRUG|Nivolumab|The dosing regimens for Nivolumab (360 mg Q3W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
48151207|NCT03202056|OTHER|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
48151208|NCT02181881|BEHAVIORAL|DuoPACT|Intervention sessions are administered weekly by a counselor.
48151209|NCT02181881|BEHAVIORAL|Life Steps|Intervention sessions are administered weekly by a counselor.
48151210|NCT03635242|OTHER|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
48151211|NCT03635242|OTHER|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
48511166|NCT03997279|DRUG|Placebo|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
47992527|NCT06134479|DRUG|150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5|On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
48151212|NCT02313194|DEVICE|Epidural Stimulation|Determine if epidural stimulation can improve motor function
48151213|NCT02313194|DRUG|Buspirone|Determine if the pharmacological agent in combination with the stimulator can improve motor function.
48151214|NCT03455751|GENETIC|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
48151215|NCT00470756|OTHER|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
48151216|NCT03473652|OTHER|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
48151217|NCT01250717|DRUG|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
48511167|NCT03107221|BEHAVIORAL|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
48511168|NCT05289947|OTHER|Placebo|Caramel, chocolate brown, flavor (E_1982648), dextrin
47914391|NCT02457104|PROCEDURE|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
47914392|NCT02457104|BEHAVIORAL|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
48151218|NCT01250717|DRUG|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
48151219|NCT01250717|DRUG|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
48151220|NCT01250717|DRUG|Zoladex|Given subcutaneously for 4 doses every three months
48151221|NCT01250717|DRUG|Casodex|Taken orally once a day for 6 months
48151222|NCT01250717|PROCEDURE|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
48151223|NCT01624532|BIOLOGICAL|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
48151224|NCT05986630|DEVICE|TEOSYAL® TPVM|"Injection of TEOSYAL® TPVM at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
48363187|NCT06207864|OTHER|Survey Administration|Surveys and Interviews
48363188|NCT02230644|OTHER|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
48677171|NCT06364917|DRUG|Ipilimumab|The dosing regimens for Ipilimumab (1 mg/kg Q6W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
48677172|NCT02782845|DRUG|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
48677173|NCT02782845|DRUG|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
48363189|NCT02230644|OTHER|Other distraction|Such as newspaper, magazine or the news on television
48151225|NCT05986630|DEVICE|COMPARATOR|"Injection of a COMPARATOR at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
48151226|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia® bitter|"* ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein"
48151227|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia®|"* ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein"
48151228|NCT04876261|DIETARY_SUPPLEMENT|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"* extra virgin olive oil~* 5 mg hydroxytyrosol"
48511169|NCT05289947|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
48151229|NCT02784834|DRUG|dimethyl fumarate|
48151230|NCT02669056|OTHER|5-HT measurement|
48151231|NCT02669056|OTHER|cerebral MRI|
48363190|NCT03862729|PROCEDURE|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
48677174|NCT02782845|DRUG|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
48677175|NCT06285045|DRUG|Roujin Formula|48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
48677176|NCT00087087|DRUG|pemetrexed disodium|
48677177|NCT02733003|BEHAVIORAL|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
48677178|NCT03956173|OTHER|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
48151232|NCT02669056|OTHER|Video recording|
48151233|NCT02669056|OTHER|EEG|
48151234|NCT02669056|OTHER|growth curves|
48151235|NCT02669056|OTHER|ASQ questionnaire|
48151236|NCT02167191|BEHAVIORAL|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
48151237|NCT03324048|OTHER|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
48151238|NCT04604899|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
48677179|NCT06521814|PROCEDURE|REFLECT scoliosis correction system|(i.e. purpose of research) The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.
48677180|NCT05578989|DEVICE|Virtual reality glasses|watching a video with music with virtual reality glasses.
48151239|NCT03448302|RADIATION|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time \& permeability surface measurements will be obtained.
48151240|NCT04468659|DRUG|Lecanemab|IV infusion.
48151241|NCT04468659|DRUG|Placebo|IV infusion.
48151242|NCT05866289|OTHER|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
48151243|NCT04004832|DIAGNOSTIC_TEST|there is not any intervention procedure|there is not any intervention procedure
48151244|NCT05619991|OTHER|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
48151245|NCT05619991|OTHER|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
48151246|NCT02152111|DIETARY_SUPPLEMENT|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
48151247|NCT02152111|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months.
48677181|NCT04153695|OTHER|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
48677182|NCT02981056|OTHER|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
48677183|NCT02981056|OTHER|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
48677184|NCT02981056|OTHER|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
48677185|NCT02827812|OTHER|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
48677186|NCT02827812|OTHER|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
48677187|NCT02827812|OTHER|Home-Based telemedicine program|"1. A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~2. A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
48151248|NCT04693013|DEVICE|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
48151249|NCT03264222|OTHER|Security screening procedure|Screening procedure with security device (model QPS 100)
48151250|NCT01248663|PROCEDURE|antecolic reconstruction|see study arm description
48151251|NCT01248663|PROCEDURE|retrocolic reconstruction|see study arm description
48363191|NCT03862729|PROCEDURE|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
48363192|NCT04657003|DRUG|Tirzepatide|Administered SC
48363193|NCT04657003|OTHER|Placebo|Administered SC
48677188|NCT02777086|BEHAVIORAL|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
48677189|NCT03039387|DEVICE|anodal transcranial direct current stimulation|
48151252|NCT03252210|PROCEDURE|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
48151253|NCT05771402|DRUG|Anti-PD-1 antibody|Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
47914393|NCT02616588|BEHAVIORAL|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
48151254|NCT05771402|DRUG|NAs|Once/day, 1 capsule/time, oral
48151255|NCT05771402|DRUG|Peg-IFNα|Once/week, 180μg/time, subcutaneous injection
48151256|NCT01928888|DRUG|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
47992528|NCT06134479|DRUG|150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger|On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
48151257|NCT01928888|DRUG|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
48151258|NCT01928888|DRUG|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
48151259|NCT00062478|DRUG|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
48151260|NCT01420328|DRUG|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks
48151261|NCT01420328|DRUG|Placebo|Placebo treatment for 6 weeks
48151262|NCT00576550|DRUG|Urea|Urea cream applied twice daily up to six months
48151263|NCT00576550|DRUG|betamethasone valerate|Application once daily for two weeks
48151264|NCT00576550|DRUG|betamethasone valerate|Application twice daily for two weeks
48151265|NCT03807934|OTHER|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
48151266|NCT00741923|OTHER|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
48151267|NCT00065663|GENETIC|GAM501|
47914394|NCT05856136|DRUG|Fentanyl Injection|Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
47992529|NCT02906774|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
47992530|NCT02255500|DRUG|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
47992531|NCT02255500|DRUG|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
48151268|NCT02364674|RADIATION|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
48151269|NCT03327025|BEHAVIORAL|Health education counseling|Health education counseling
48151270|NCT05760417|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
48151271|NCT01748058|BEHAVIORAL|Exercise based on active video gaming|
48151272|NCT00553813|DRUG|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
48151273|NCT04937049|OTHER|EMAeHealth digital tool|eHealth intervention to support Maternal Education
48151274|NCT04223674|DIAGNOSTIC_TEST|Serological screen and treat|Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
48151275|NCT00476957|DEVICE|Stent|Stent implantation
48151276|NCT00476957|DEVICE|Stent|Stent implantation
48151277|NCT00021996|DRUG|valdecoxib|
48151278|NCT02151994|DRUG|BIA 5-1058|oral administration
48151279|NCT02151994|DRUG|Placebo|oral administration
48151280|NCT05049265|BIOLOGICAL|JS007|JS007 only
48151281|NCT05530239|OTHER|Blood sample collection|Blood sample collection
48151282|NCT03376763|DRUG|Abilify maintena|Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
48363194|NCT03224442|PROCEDURE|PRF|soft tissue augmentation by prf
48363195|NCT03224442|PROCEDURE|Palatal Pedicle|soft tissue augmentation by palatal pedicle
48677190|NCT03039387|DEVICE|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
48677191|NCT04587037|PROCEDURE|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
48677192|NCT04587037|PROCEDURE|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
48677193|NCT05501639|DRUG|tiotropium|tiotropium
48151283|NCT02757456|BEHAVIORAL|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
48151284|NCT02757456|OTHER|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
48677194|NCT05501639|DRUG|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
48677195|NCT05501639|DRUG|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
48677196|NCT06152198|DEVICE|Treatment|Allocation to hip arthroplasty or internal fixation. The choice between hemi- or total hip arthroplasty in the arthroplasty group and type of osteosynthesis are the surgeon preference.
48677197|NCT01344798|BIOLOGICAL|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
48677198|NCT01297283|OTHER|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
48677199|NCT01297283|OTHER|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
47992532|NCT00097799|DRUG|Tipranavir|500 mg twice daily
47992533|NCT00097799|DRUG|Ritonavir|200 mg twice daily
47992534|NCT06431854|BEHAVIORAL|ED-MINERVA Program|ED-MINERVA Program aims to improve ED symptoms and related difficulties of the patient and provide tools to enhance the family's management (nutritionally, emotionally, and behaviorally) in their natural environment. The treatment consists of four phases with a gradually decreasing therapeutic intensity, ranging from total hospitalization, family treatment apartment, to home treatment and subsequent linkage with specialized local facilities. The ED-MINERVA program uses various aspects of family-based treatment, cognitive behavioral therapy, dialectical behavioral therapy, and systemic family therapy.
47992535|NCT01930851|PROCEDURE|Gastric bypass operation|
48151285|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
48511170|NCT04848727|OTHER|Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)|"The EIT system will be placed at the subject's bedside to collect EIT measurements: Ventilation distribution%, changes in regional aeration in arbitrary units (AU), dependent and non-dependent silent spaces. A data acquisition cart will also be placed at the subject's bedside to collect hemodynamic and respiratory parameters measurements including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices.~The LuMon belts for neonates are disposable single-patient use belts that are adhesive-free. EIT measurements and data will be collected on each timeperiods (t1 and t2) for approximately 15-30 minutes on invasive or non-invasive ventilatory support."
48511171|NCT05609630|DRUG|Upadacitinib|Oral tablet or Oral solution
48511172|NCT05609630|DRUG|Tocilizumab|Subcutaneous injection or Intravenous infusion
48511173|NCT03115216|PROCEDURE|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
48511174|NCT03115216|PROCEDURE|CEIOL|Manual cataract extraction and intraocular lens placement
48511175|NCT06251050|DRUG|lithium-containing mouthwash|The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
48511176|NCT06251050|DRUG|Plcacebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
48511177|NCT06251050|DRUG|lithium-containing mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
48511178|NCT02643667|DRUG|Ibrutinib|-Ibrutinib will be supplied by Pharmacyclics Inc.
48511179|NCT02643667|PROCEDURE|Radical prostatectomy|-Standard of care
48511180|NCT00144157|DRUG|Nevirapine|
48511181|NCT00144157|DRUG|Zidovudine|
48511182|NCT00144157|DRUG|3TC|
48677200|NCT05197400|DIAGNOSTIC_TEST|preoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
48677201|NCT05197400|DIAGNOSTIC_TEST|postoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
48677202|NCT04435314|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days
48677203|NCT04435314|DRUG|Placebo|Subjects will receive placebo TID for 7 days.
48677204|NCT02898922|BIOLOGICAL|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
47992536|NCT02045576|DEVICE|sleep position trainer|
47992537|NCT02045576|DEVICE|Oral Appliance Therapy|
47992538|NCT00854074|DEVICE|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
48151286|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
48151287|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
48151288|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
48151289|NCT05209256|DRUG|Chemotherapy|Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
48151290|NCT05209256|DRUG|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
48151291|NCT04180072|DRUG|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
48151292|NCT04180072|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
48151293|NCT03522909|OTHER|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~1. Primary outcome variable.~   - Hospital length of stay~2. Secondary outcome variables.~   * Number of admissions from outside hospitals~  * Adverse outcomes~  * Intensive Care Unit admissions~  * Opioid use~  * NICU admissions~  * Patient satisfaction~  * Cost of inpatient admission~  * Cost of outpatient care~  * Hospital readmissions rate"
48677205|NCT02246491|OTHER|A-T iPS cell line|Reprogramming A-T patients iPS cell line
48151294|NCT04312425|PROCEDURE|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
48151295|NCT04312425|PROCEDURE|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
48151296|NCT03535545|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
48151297|NCT03535545|DIAGNOSTIC_TEST|PET Imaging|All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
48151298|NCT02985476|OTHER|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
48151299|NCT06139419|RADIATION|definitive radiotherapy|Participants were treated with definitive thoracic radiotherapy
48151300|NCT06139419|DRUG|induction chemo-immunotherapy|All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
48511183|NCT05690490|PROCEDURE|Endoscopic mucosal resection with circumferential incision|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision will be made around the lesion with an offset of 2-5 mm. Then there will be a one-stage electro excision of the neoplasm using an endoscopic loop.
48677206|NCT02246491|OTHER|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
48677207|NCT06059677|DRUG|Active smoked cannabis|Assessment of active cannabis smoking and driving impairment
48677208|NCT06059677|DRUG|Placebo smoked cannabis|Assessment of placebo cannabis smoking and driving impairment
48677209|NCT03541499|BIOLOGICAL|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.
48677210|NCT03541499|OTHER|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
48151301|NCT06139419|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
48151302|NCT06139419|DRUG|Immunotheapy consolidation|Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
48363196|NCT02699489|PROCEDURE|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
47992539|NCT06536777|OTHER|Plyometric Exercises|This include Plyometric Training for 8 weeks
48363197|NCT02699489|PROCEDURE|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
48677211|NCT06078527|DEVICE|Cheung-Bearelly Aesthesiometer|The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
48677212|NCT06078527|PROCEDURE|Transnasal Laryngoscopy|A procedure to examine your larynx (voice box)
48677213|NCT06078527|OTHER|Questionnaires|Patient-reported health and behavioral outcomes measures will be administered
48677214|NCT03938831|DRUG|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
48363198|NCT04395924|DIAGNOSTIC_TEST|Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta|"During labor and delivery~1. Sample of amniotic fluid~2. 2 samples of blood cord after the birth of the new born~3. 2 samples of placenta~These samples will be tested with A RT-PCR COVID-19 test and / or serology's A sample of blood cord and placenta will be frozen at -80 degree C and studied for PCR and viral proteome, cytokines , D-dimers and others inflammatory markers in the PRIMMO Laboratory (Prof. TOUMI and LESPESSAILLES) and after in the Centre of molecular biophysics of CNRS of Orleans (Prof. PICHON)"
48677215|NCT03938831|DRUG|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
48677216|NCT01484457|DEVICE|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose \< 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
47992540|NCT06536777|OTHER|Blood Flow Restriction Training|This include Blood Flow Restriction Training for 8 weeks
47992541|NCT03580850|OTHER|No intervention in this restrospective study|This study is an obervational study
47992542|NCT04057404|DEVICE|Alivecor Heart Monitor|
47992543|NCT05659810|DRUG|Gabapentin 300mg|Preoperative gabapentin before spinal anesthesia
47992544|NCT05295927|DRUG|EPI-7386|EPI-7386 will be administered orally once daily.
47992545|NCT05295927|DRUG|Abiraterone Acetate|Abiraterone Acetate will be administered orally once daily.
47992546|NCT05295927|DRUG|Prednisone or Prednisolone|Prednisone or Prednisolone will be administered orally twice daily.
47992547|NCT05295927|DRUG|Apalutamide|Apalutamide will be administered orally once daily.
47992548|NCT02723084|DRUG|ABT-493/ABT-530|Co-formulated tablet
47992549|NCT02723084|DRUG|sofosbuvir (SOF)|Tablet
47992550|NCT02723084|DRUG|ribavirin (RBV)|Capsule
48363199|NCT01481259|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
48363200|NCT01481259|OTHER|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
48677217|NCT06136143|PROCEDURE|Group 1: Autogenous bone graft|The maxillary sinus will be grafted with the autogenous bone graft.
48677218|NCT06136143|PROCEDURE|Group 2: Plenum® Osshp|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.
48677219|NCT06136143|PROCEDURE|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.
48677220|NCT06136143|PROCEDURE|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
47914397|NCT04201808|DRUG|Tenofovir Alafenamide 25 MG|All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
47914398|NCT01189019|DRUG|ranibizumab|2mg intravitreal injection monthly
47914399|NCT01189019|DRUG|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
47914400|NCT00629889|DRUG|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
47914401|NCT00629889|DRUG|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
47914402|NCT03705013|OTHER|Cologuard|Observational
47914403|NCT04280237|OTHER|Blood samples|Blood samples
47914404|NCT01417013|OTHER|Systane Ultra|Lubricant Eye Drops
47914405|NCT01417013|OTHER|Optive|Lubricant eye drops
47992551|NCT01828892|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
47992552|NCT01828892|PROCEDURE|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
48151303|NCT06139419|DRUG|Thymosin Alpha1|"Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months."
47992553|NCT01828892|DRUG|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
48151304|NCT02710669|DRUG|(R)-propafenone|
48151305|NCT02710669|DRUG|(S)-Propafenone|
48151306|NCT02710669|DRUG|Placebo|
48363201|NCT05311358|DEVICE|The engineer-built system, video-game based Kinect sensor|There are 3 computer games using Kinect sensor to detect movement of trunk and upper extremities of the children.
48511184|NCT05690490|PROCEDURE|Endoscopic submucosal dissection|The endoscope will be passed into the intestine to the site of the tumor. Using an endoscopic needle, the solution will be injected into the submucosa to create a pillow. Then, using an endoscopic knife (insulated tip knife, Olympus or Water Jet, Erbe), a circular incision is made around the lesion. Then dissection will be performed in the submucosal layer.
48511185|NCT06359639|BEHAVIORAL|Cognitive restructuring|Five 50-60-minute videoconferencing sessions of cognitive restructuring based on Mind Over Mood: Second Edition (MOM2) (Greenberger \& Padesky, 2016) and The Clinician's Guide to CBT Using MOM2 (Padesky \& Greenberger, 2019) as guides. The sessions will consist of understanding the cognitive model, filling in Thought Records, and complementary coping strategies of looking for evidence, action planning, and acceptance.
47992554|NCT01828892|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
47992555|NCT02206425|DRUG|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
47992556|NCT02206425|DRUG|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
48151307|NCT01019824|DRUG|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
48151308|NCT02376062|OTHER|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~* On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~* Weekly case conferences~* Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
48151309|NCT00963105|DRUG|lenalidomide|"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
48151310|NCT00447109|DEVICE|Closed system suction|
48363202|NCT01533285|BIOLOGICAL|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
47992557|NCT02206425|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
47992558|NCT02206425|DRUG|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
48363203|NCT01533285|BIOLOGICAL|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
48677221|NCT01122446|OTHER|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
48677222|NCT01122446|DRUG|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
47992559|NCT02206425|DIETARY_SUPPLEMENT|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
47992560|NCT02206425|DRUG|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
48151311|NCT04930263|BEHAVIORAL|Aerobic exercise|The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
48363204|NCT05340179|PROCEDURE|Interlaminar cervical epidural injection|Fluoroscopy-guided interlaminar cervical epidural injection
48363205|NCT05340179|PROCEDURE|Cervical selective nerve root block|Ultrasound-guided cervical selective nerve root block
48363206|NCT05223478|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
48363207|NCT05223478|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
48151312|NCT04930263|BEHAVIORAL|control group|control group received routine care and a manual on healthy living
48677223|NCT04898478|BEHAVIORAL|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
48677224|NCT01086696|DRUG|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
47992561|NCT02206425|DRUG|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
47992562|NCT02206425|DRUG|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
48151313|NCT00749840|BEHAVIORAL|Questionnaire|Questionnaire taking 60-90 minutes.
48151314|NCT01870895|DRUG|YM060|oral
48151315|NCT01870895|DRUG|Placebo|oral
48151316|NCT04434222|DEVICE|Compressive stockings|Compressive stockings with built in Orthotimer Sensor
47992563|NCT02408939|DRUG|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
48151317|NCT01923935|DRUG|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)
48151318|NCT01923935|DRUG|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)
47992564|NCT00652236|OTHER|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
48151319|NCT04168437|OTHER|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
48151320|NCT05281809|DRUG|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
48151321|NCT00002409|DRUG|Lamivudine/Zidovudine|
48151322|NCT00002409|DRUG|Abacavir sulfate|
48151323|NCT02854982|PROCEDURE|therapeutic management of the prostate Cancer as usual|
48151324|NCT00943371|DRUG|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
48151325|NCT00943371|DRUG|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
48151326|NCT02659176|PROCEDURE|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
48363208|NCT04841928|BEHAVIORAL|Mindful attention|The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
48363209|NCT04841928|BEHAVIORAL|Decentering|The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
48363210|NCT04841928|BEHAVIORAL|Value-based action|The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
48363211|NCT03506464|PROCEDURE|Myofascial Release Technique|The same described in the arm description
48363212|NCT00214942|DRUG|ORAVESCENT Fentanyl Citrate|
47992565|NCT01480076|DRUG|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
47992566|NCT05516342|BEHAVIORAL|LEAD IT! Programming|LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.
47992567|NCT00293644|DRUG|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
47992568|NCT02051946|DEVICE|Retroject Device|
47992569|NCT02051946|DRUG|ethacrynic acid injection|
47992570|NCT02051946|DRUG|balanced salt solution|
48151327|NCT02659176|PROCEDURE|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
48151328|NCT04618211|DRUG|Deucrictibant|deucrictibant soft capsules for oral use
48151329|NCT04618211|DRUG|Placebo|Matching placebo capsules for oral use
48151330|NCT00019344|DRUG|alvocidib|
48363213|NCT01329822|BEHAVIORAL|Caloric restriction|Caloric restriction
48677225|NCT02581436|OTHER|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
47992571|NCT05543941|DEVICE|XPERIENCE Advanced Surgical Irrigation|The patient will undergo THA, TKA, or HR with irrigation of the deep wound prior to fascial closure consisting of XPERIENCE Advanced Surgical Irrigation (XP). XP solution will be applied prior to fascial closure and left to soak for up to 3 minutes. Remaining product will be suctioned away throughout the procedure. No rinsing should take place after irrigation and surgical site will be closed according to site standard operating procedures.
47992572|NCT05543941|DEVICE|Dilute Betadine|The patient will undergo THA, HR or TKA with irrigation of the deep wound prior to fascial closure consisting of Dilute Betadine (DB). DB concentration will be standardized at 0.3% povidone-iodine. DB will be prepared by combining 30 mL of sterile 10% povidone-iodine (from a sterile catheter pack) with 1 L of 0.9% saline in a sterile splash basin. Solution will be left to soak for up to 3 minutes and remaining povidone-iodine solution will be suctioned away. Area will then be rinsed with 1L of normal saline. Surgical site will be closed according to site standard operating procedures.
47992573|NCT00358566|BIOLOGICAL|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
47992574|NCT00358566|DRUG|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
47992575|NCT00368056|DRUG|Eszopiclone|eszopiclone 3 mg
47992576|NCT00368056|DRUG|Placebo|Placebo tablet
48151331|NCT01289834|DEVICE|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH \& Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
47992577|NCT02087475|DRUG|Irinotecan|
47992578|NCT02087475|DRUG|5-fluorouracil|
47992579|NCT02087475|RADIATION|Local radiotherapy|
47992580|NCT02087475|PROCEDURE|R0 resection|
47992581|NCT04824131|DRUG|Oral cabotegravir (CAB)|30 mg tablets
47992582|NCT04824131|DRUG|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
47992583|NCT04824131|DRUG|Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)|300 mg/200 mg fixed-dose combination tablets
47992584|NCT02081482|RADIATION|18F-FDG PET|
47992585|NCT02517996|DRUG|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
47992586|NCT02517996|DRUG|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
47992587|NCT00941044|DEVICE|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
48363214|NCT03562728|DEVICE|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
48363215|NCT03562728|OTHER|Standard of Care|Patients in the control group are going to receive standard of care
47992588|NCT04746703|RADIATION|Magnetic Resonance Imaging|Pancreatic MRI will be performed in severe-obese patients with a planned bariatric surgery, before and 6 months after bariatric surgery.
48363216|NCT00701181|PROCEDURE|Laser Treatment|Necessity of laser treatment is assessed every three months.
48363217|NCT00701181|DRUG|PF-04523655 high|3 mg intravitreal injection
48363218|NCT00701181|DRUG|PF-04523655 middle|1 mg intravitreal injection
48363219|NCT00701181|DRUG|PF-04523655 low|0.4 mg intravitreal injection
47992589|NCT04479956|PROCEDURE|Varicose vein surgery|sapheno-femoral junction (SFJ) incompetence, GSV reflux from the groin to below the knee
47992590|NCT00520975|BIOLOGICAL|Bevacizumab|Given IV
47992591|NCT00520975|DRUG|Carboplatin|Given IV
47992592|NCT00520975|DRUG|Paclitaxel|Given IV
47992593|NCT00520975|OTHER|Placebo|Given IV
47992594|NCT00520975|BIOLOGICAL|Trastuzumab|Given IV
47992595|NCT05402150|BEHAVIORAL|Behavioral Activation|"* instruction to create a list of individual positive activities.~* instruction to include daily positive activities and fill out a mood protocol, which covers the time period shortly before, during and after the activity."
47992596|NCT05402150|BEHAVIORAL|Mindulness and Gratitude|"* instruction to fill out a mindfulness diary: reflection of daily pleasant situation, instructing the participants to revisit the impressions of their 5 senses during this situation, in addition they should specify how long they have actually dealt with these pleasant impressions of the situation they reflected upon~* instruction to do a gratitude exercise and name one or more things they are generally grateful for each day."
47992597|NCT05402150|BEHAVIORAL|Combination of Behavioral Activation and Mindfulness and Gratitude|This group will do a combination of the two intervention types.
47992598|NCT02347267|BEHAVIORAL|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
47992599|NCT02347267|BEHAVIORAL|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
47992600|NCT00072618|DRUG|Exisulind|
47992601|NCT04460820|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2,IV on Day 1 of each cycle
47992602|NCT02532244|OTHER|sample collection|collection of blood
48677226|NCT02581436|OTHER|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine \>25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
48677227|NCT00913510|DEVICE|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
48677228|NCT00913510|DRUG|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
47992603|NCT03836547|BEHAVIORAL|Coaching and Weight Loss for patients with dyspnea|Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
47992604|NCT03836547|BEHAVIORAL|Active Control|Participants will receive usual care for 12 weeks followed by the active intervention.
47992605|NCT02784821|DRUG|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
47992606|NCT02784821|OTHER|Gastric fluid|Microbiome evaluated using gastric aspirate.
47992607|NCT02784821|OTHER|Breast milk|Microbiome will be evaluated using mother's breast milk.
47992608|NCT02784821|OTHER|Stool samples|Microbiome will be evaluated using infant's stool.
47992609|NCT02784821|DRUG|Antibiotics|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
47992610|NCT00150072|DRUG|imatinib|
47992611|NCT05840146|OTHER|Kinesiotaping|"Two I-strips were used:~1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension."
47992612|NCT05840146|OTHER|Sham taping|A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
47992613|NCT03902912|DRUG|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
47992614|NCT03479476|DRUG|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
47992615|NCT03479476|DRUG|Metformin|Active medication.
47992616|NCT03204981|DEVICE|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
47992617|NCT03204981|PROCEDURE|Ablation|standard ablation
47992618|NCT06186765|DEVICE|Axonics SNM System (Model 4101)|Safety and performance/effectiveness assessment of the recharge free Axonics SNM System (Model 4101 in participants with overactive bladder (OAB) or fecal incontinence (FI).
47992619|NCT01295515|DRUG|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
48151332|NCT01289834|DEVICE|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
48363220|NCT01736176|DRUG|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
48363221|NCT01736176|PROCEDURE|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
48677229|NCT04550897|DRUG|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
48677230|NCT05871619|PROCEDURE|Remin Pro|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
48363222|NCT01736176|DRUG|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
48151333|NCT00629993|BEHAVIORAL|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
48363223|NCT00129220|DRUG|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
48363224|NCT00129220|DRUG|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
48363225|NCT00129220|DRUG|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
47992620|NCT02749812|DEVICE|Constant Continuous Positive Airway Pressure|
48363226|NCT04264260|DRUG|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
48677231|NCT05871619|PROCEDURE|X Pur Remin|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
47992621|NCT02749812|DEVICE|Automatic continuous Positive Airway Pressure|
48363227|NCT00809627|DRUG|Caffeine|Caffeine 500 mg IV
47992622|NCT00310128|DRUG|cisplatin|
47992623|NCT00310128|DRUG|cytarabine|
47992624|NCT00310128|DRUG|etoposide|
47992625|NCT00310128|DRUG|methylprednisolone|
47992626|NCT00310128|DRUG|rituximab|
48363228|NCT00809627|DRUG|saline|Normal saline
48363229|NCT01729481|DRUG|Gemcitabine|1000 mg/m² iv weekly
48363230|NCT01729481|DRUG|Erlotinib|100mg, once per day
48363231|NCT01729481|DRUG|Oxaliplatin|85mg/m², q2weeks
48363232|NCT01729481|DRUG|Folinic Acid|400 mg/m², q2weeks
48363233|NCT01729481|DRUG|Irinotecan|180 mg/m², q2weeks
47992627|NCT00310128|DRUG|yttrium Y 90 ibritumomab tiuxetan|
47992628|NCT00310128|PROCEDURE|antibody therapy|
47992629|NCT00310128|PROCEDURE|biological therapy|
47992630|NCT00310128|PROCEDURE|chemotherapy|
47992631|NCT00310128|PROCEDURE|monoclonal antibody therapy|
47992632|NCT00310128|PROCEDURE|radiation therapy|
48363234|NCT01729481|DRUG|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
48363235|NCT05836428|OTHER|no intervention|no intervention
48363236|NCT01265628|PROCEDURE|perimetry|automated static perimetry with adapted GATE strategy
48363237|NCT00686894|PROCEDURE|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
48363238|NCT00686894|DRUG|Infliximab|"* 5 mg/kg~* IV~* Frequency : weeks 0,2,6"
48363239|NCT03389490|DRUG|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
48363240|NCT03389490|DRUG|Neutral protamine hagedorn insulin|Self titration of NPH insulin
48363241|NCT00579527|BIOLOGICAL|Cultured Thymus Tissue for Implantation (CTTI)|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
47992633|NCT00310128|PROCEDURE|radioimmunotherapy|
48363242|NCT00579527|OTHER|Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation|For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
48363243|NCT00579527|PROCEDURE|Blood Draw|Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
47992634|NCT00310128|PROCEDURE|radioisotope therapy|
47992635|NCT05872581|BEHAVIORAL|Hand scanner instant feedback|Participants will be informed about their hand scanner results of the first hand washing attempt to get individualized feedback about their hand wash performance.
47992636|NCT05872581|BEHAVIORAL|Video training|Participants will watch a training video about the 7 steps of hand washing after the first hand washing attempt.
47992637|NCT05719805|DRUG|Mavacamten|Specified dose on specified days
48151334|NCT04037592|DEVICE|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
47992638|NCT05492565|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Pre-exposure prophylaxis with coformulated Tenofovir Disoproxil Fumarate 300mg/Emtricitabine 200mg oral QD to prevent HIV infection
47992639|NCT03375411|DEVICE|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
47992640|NCT03465592|DRUG|Nivolumab|Administered IV
48151335|NCT04037592|DEVICE|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
48363244|NCT00579527|DRUG|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
48151336|NCT04037592|DEVICE|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
48151337|NCT00265252|DRUG|Alendronate|
48151338|NCT05993247|COMBINATION_PRODUCT|Probiotics capsule|Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs
48677232|NCT05871619|PROCEDURE|Fluoride varnish|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
48677233|NCT03369366|DEVICE|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
48151339|NCT05993247|COMBINATION_PRODUCT|Placebo capsule|Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
48151340|NCT04923685|OTHER|Trier Social Stress Test|The TSST is a standardized test to induce acute psychological stress in humans. Participants will abstain from caffeine for 12 hours and nicotine for 2 hours prior to the test. An IV butterfly catheter will be placed in an arm vein and flushed with saline. Participants will rest for 15 minutes. A 10ml baseline blood sample will be drawn. They will perform the TSST task and then have 10ml of blood drawn at 0, 15, 30, 60, and 90 minutes post-TSST.
48511186|NCT06359639|BEHAVIORAL|Supportive counselling|Five 50-60-minute videoconferencing sessions of supportive counselling consisting of psychoeducation on breakup effects, validation of breakup experiences and emotions, introduction to deep breathing and progressive muscle relaxation, and identification of existing coping strategies.
48511187|NCT05070026|OTHER|uni-portal VATS group|patients received pulmonary lobectomy under general anesthesia by using uni-portal VATS method
48677234|NCT03369366|DEVICE|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
48677235|NCT02043145|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
47992641|NCT04425395|BEHAVIORAL|Cold pressor task (CPT)|"The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order."
47992642|NCT04425395|BEHAVIORAL|Acoustic Recordings|During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
47992643|NCT04425395|DIAGNOSTIC_TEST|Index measurement NOL™|Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
47992644|NCT04425395|DIAGNOSTIC_TEST|Video pupillometry|This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
48151341|NCT03686917|OTHER|CHAT-P|Survey
48151342|NCT02506322|BEHAVIORAL|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~1. psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~2. Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~3. dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~4. behavior changes, (social, problem solving) skill training, communication skills, crisis management"
48151343|NCT02506322|BEHAVIORAL|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
48151344|NCT01026441|DEVICE|Vela100 (Aesthetic)|6 treatments once a week
48151345|NCT06606769|OTHER|Exercise|supervised exercise training; twice a week for 12 months
48677236|NCT05542459|DRUG|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
48677237|NCT04871477|OTHER|Communication Intervention|Audio record part of clinic visit
47992645|NCT05473273|DRUG|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
48151346|NCT03981549|BIOLOGICAL|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
48151347|NCT03981549|BIOLOGICAL|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does penetrate the bone followed by sham intravitreal injection without penetration of the eye
48151348|NCT04425252|DRUG|Brequinar|DHODH inhibitor, 100 mg daily x 5 days
48151349|NCT04425252|OTHER|Standard of Care|Standard of Care per institutional guidelines for COVID-19 patients
48151350|NCT02416297|PROCEDURE|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
47992646|NCT05473273|DRUG|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
47992647|NCT05772520|DRUG|TLL018 tablets|oral tablets administered BID for 12weeks
47992648|NCT03013439|DRUG|Iron Isomaltoside|The trial is a dose escalating trial.
47992649|NCT00000806|DRUG|Telinavir|
47992650|NCT03636347|DRUG|Placebo Oral Tablet|twice daily administration
47992651|NCT03636347|DRUG|Alvelestat oral tablet - dose 1|twice daily administration
47992652|NCT03636347|DRUG|Alvelestat oral tablet - dose 2|twice daily administration
48151351|NCT02462278|DEVICE|TempuRing|
48151352|NCT00238745|DRUG|Bazedoxifene|
47992653|NCT02812316|DEVICE|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
48151353|NCT00238745|DRUG|Placebo|
48511188|NCT05070026|OTHER|three port VATS group|patients received pulmonary lobectomy under under general anesthesia by using three port VATS method
48511189|NCT04378738|BEHAVIORAL|survey|all people in the cohort
48511190|NCT00641615|BIOLOGICAL|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
48677238|NCT04871477|OTHER|Questionnaire Administration|Ancillary studies
48677239|NCT03509818|OTHER|plyometric exercise|acute plyometric exercise
48677240|NCT03509818|OTHER|Aerobic exercise|acute aerobic exercise
48677241|NCT05858177|DRUG|Temozolomide capsule|Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
48677242|NCT04477460|DIETARY_SUPPLEMENT|Thickened feeds|Thickened feeds directed by medical team
48677243|NCT04477460|DIETARY_SUPPLEMENT|Non-thickened feeds|Non-thickened feeds directed by medical team
48677244|NCT00326599|DRUG|carboplatin|Given IV
48677245|NCT00326599|DRUG|cediranib maleate|Given orally
48363245|NCT00579527|DRUG|Cyclosporine|"In addition to RATGAM, subjects with typical cDGA with PHA responses \>50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol."
48363246|NCT00579527|DRUG|Tacrolimus|If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
48363247|NCT00579527|DRUG|Methylprednisolone or Prednisolone|Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells \>4,000cumm. Steroids are weaned as per protocol.
48363248|NCT00579527|DRUG|Daclizumab|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
48363249|NCT00579527|DRUG|Mycophenolate mofetil|In addition, subjects with Atypical DiGeorge with PHA responses \>75,000cpm while on no immunosuppression or PHA responses \>40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
48363250|NCT05908422|DEVICE|Alvision™ Interventional Cardiology Diagnostic Catheter|The Alvision™ Interventional Cardiology Diagnostic Catheter is a single use only, thin, flexible single lumen tube, with a proximal hub, sterilized with ethylene oxide (EO) gas, non-pyrogenic. The product is defined as a catheter to inject a contrast medium into selected blood vessels.
48363251|NCT02073149|DIETARY_SUPPLEMENT|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
48363252|NCT02073149|DIETARY_SUPPLEMENT|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
48363253|NCT02073149|DIETARY_SUPPLEMENT|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
48363254|NCT02768428|OTHER|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
48363255|NCT06482905|BIOLOGICAL|Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103|3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells
48363256|NCT02804581|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
48363257|NCT01344213|DRUG|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
48363258|NCT01344213|DRUG|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
48363259|NCT01344213|DRUG|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
48363260|NCT01344213|DRUG|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
48363261|NCT01483378|OTHER|Choosing to receive the vaccine|
48363262|NCT05004363|DRUG|Lokelma Oral Product|Potassium binder
48363263|NCT02908841|DEVICE|Surgicel Snow|
48677246|NCT00326599|DRUG|gemcitabine hydrochloride|Given IV
48677247|NCT01103440|DRUG|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
48677248|NCT01103440|DRUG|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
48677249|NCT03540420|DRUG|Atezolizumab|atezolizumab 1200 mg intravenous every 3 weeks in 12 months
48677250|NCT05754476|OTHER|Low-dose GBCA levels|MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
48677251|NCT03924492|DRUG|ZULRESSO (brexanolone) injection|ZULRESSO
48677252|NCT00525434|DEVICE|Seraffix LTB|wounds closure by using laser and albumin
48677253|NCT04144114|DIETARY_SUPPLEMENT|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
48677254|NCT04144114|DIETARY_SUPPLEMENT|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
48677255|NCT04144114|DIETARY_SUPPLEMENT|Placebo|Placebo
48363264|NCT02908841|OTHER|Standard of Care|
48363265|NCT00072215|DRUG|cisplatin|given IV
48363266|NCT00072215|DRUG|ifosfamide|given IV
48677256|NCT03931226|DRUG|Drug consumption|number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
48677257|NCT05086965|OTHER|Playing the virtual game simulation|The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
48677258|NCT05175274|DRUG|Colchicine|Colchicine 0.5mg/tablet
48677259|NCT05175274|DRUG|Placebo|matching placebo
48677260|NCT01370304|OTHER|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
48151354|NCT06454578|DRUG|Adebrelimab + Apatinib|"the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years"
48151355|NCT01742832|DRUG|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
48151356|NCT01742832|DRUG|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
48151357|NCT05053035|DRUG|AL001|Administered via intravenous (IV) infusion
48151358|NCT05053035|DRUG|Placebo|Administered via intravenous (IV) infusion
48151359|NCT02918045|DEVICE|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
48151360|NCT02918045|DEVICE|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
48151361|NCT02713776|DRUG|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
48151362|NCT02713776|DRUG|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
48151363|NCT05486988|DRUG|Immunotherapy|PD-1/PD-L1 inhibitors
48677261|NCT01370304|OTHER|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
48677262|NCT01370304|OTHER|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
48677263|NCT02546583|DRUG|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
48151364|NCT05486988|DRUG|Chemotherapeutic Agent|2 cycles
48151365|NCT05486988|DRUG|Chemotherapy|4\~6 cycles
48151366|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
48151367|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
48363267|NCT00072215|DRUG|paclitaxel|given IV
48677264|NCT02546583|DRUG|IV Chlorothiazide|
48677265|NCT00237237|DRUG|vildagliptin|
48677266|NCT00107731|DRUG|quetiapine fumarate|
48677267|NCT00107731|DRUG|lithium|
48151368|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
48151369|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
48151370|NCT02938286|DEVICE|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
48151371|NCT02938286|DRUG|AHES|Topical application at test region I-IV under occlusion for 15 minutes
48151372|NCT00997152|DRUG|JTT-654|Tablets
48151373|NCT00997152|DRUG|JTT-654 Placebo|Tablets
48151374|NCT02788708|DRUG|Lenvatinib Mesylate|Given PO
48151375|NCT02788708|DRUG|Paclitaxel|Given IV
48151376|NCT02788708|OTHER|Pharmacological Study|Correlative studies
48151377|NCT02973035|DRUG|Amlodipine|
48363268|NCT00072215|DRUG|vinblastine|given IV
48363269|NCT00876759|RADIATION|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
48511191|NCT05631197|OTHER|Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment|Domiciliary use twice a day
48677268|NCT00107731|DRUG|divalproex|
48677269|NCT04357561|BEHAVIORAL|Exercise group (Schroth best practice)|Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
48363270|NCT00876759|RADIATION|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
48151378|NCT02973035|DRUG|Valsartan|
48151379|NCT01282918|DEVICE|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
48151380|NCT01282918|DEVICE|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
48151381|NCT03209336|RADIATION|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
48151382|NCT02942771|DRUG|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
48363271|NCT05116904|OTHER|Assessment|Pupil reflex and melatonin profile, circadian profile assessment
48363272|NCT02286622|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
48363273|NCT04907942|DEVICE|EMA + Automated Text Message Intervention|Intervention includes 3 weeks of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of automated text messages delivered twice a day, which content follows constructs from The Transactional Model of Stress and Coping.
48363274|NCT04907942|BEHAVIORAL|EMA Alone|Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate momentary affects.
48363275|NCT05910242|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
48363276|NCT05910242|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
48363277|NCT05791487|OTHER|Ulcerative colitis Exclusion Diet|a limited whole food diet (UCED)
48363278|NCT05791487|OTHER|Partial enteral nutrition (PEN)|"The diet will be supplemented by 3 glasses a day (750 ml) of the formula developed for UC using the UCED principles."
48363279|NCT05791487|OTHER|free diet|oral Budeosnide for 6 weeks + free diet
48363280|NCT05791487|DRUG|Oral Budesonide|Oral Budesonide 9 mg
48677270|NCT04948112|DEVICE|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
48677271|NCT04948112|DEVICE|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
48677272|NCT01837680|DRUG|Insulin|
48677273|NCT00409955|PROCEDURE|Lamellar transplant with lyophilized corneas|
48677274|NCT00997984|DRUG|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
48677275|NCT00997984|DRUG|placebo|dosed in the AM or PM
48151383|NCT02942771|DRUG|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
48151384|NCT02942771|DRUG|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
48151385|NCT02942771|DRUG|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
48151386|NCT02942771|DRUG|Placebo|0.9% sodium chloride
48151387|NCT02975609|RADIATION|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
48151388|NCT02975609|RADIATION|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
48151389|NCT05982847|DIAGNOSTIC_TEST|Blood pressure screening|Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
48363281|NCT01549327|OTHER|Oncology Interactive Navigator|
48677276|NCT00997984|DRUG|extended-release guanfacine hydrochloride|Dosed in the PM
48677277|NCT02504372|BIOLOGICAL|Pembrolizumab|IV infusion
48677278|NCT02504372|OTHER|Placebo|IV infusion
48677279|NCT00310375|DRUG|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
48363282|NCT01549327|OTHER|Routine Care|
48363283|NCT06203028|BEHAVIORAL|Cyberbullying Awareness Training|The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
48363284|NCT01227694|OTHER|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
48363285|NCT02628262|PROCEDURE|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
48511192|NCT05631197|OTHER|Sensodyne Repair & Protect|Domiciliary use twice a day
48511193|NCT06632938|DRUG|ABBV-382|Subcutaneous (SC) Injection
48511194|NCT06632938|DRUG|ABBV-382|Intravenous (IV) Infusion
48677280|NCT02647476|DIETARY_SUPPLEMENT|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
48677281|NCT02647476|DIETARY_SUPPLEMENT|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
48677282|NCT04800393|DRUG|Sevoflurane|induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
48677283|NCT04800393|DRUG|Propofol|propofol-based total intravenous anesthesia during breast cancer surgery
48363286|NCT03939858|PROCEDURE|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
48151390|NCT04843956|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided biopsy|"Capillary with suction (puncture with gradual withdrawal of the stylet, applying dry suction with a 10 ml air vacuum syringe after removing the stylet)~Capillary without suction (puncture with removal of the stylet gradually, without suction after removing the stylet)~wet suction (Prior to puncture, the stylet is removed from the needle and irrigated with 1-2 ml saline solution to replace the air column with liquid, then the solid lesion is punctured and suction is placed with a 10 ml vacuum syringe of air)"
48151391|NCT05045456|DEVICE|Cardiologs Platform|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
48151392|NCT03109210|BEHAVIORAL|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
48151393|NCT03109210|BEHAVIORAL|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
48151394|NCT00896740|GENETIC|microarray analysis|
48151395|NCT00896740|PROCEDURE|biopsy|
48151396|NCT00202228|DRUG|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
48151397|NCT05313477|DRUG|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If \<10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If \>20 ng/mL, 20000U of Ergocalciferol capsule per week
48677284|NCT05461586|DEVICE|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
48677285|NCT05461586|DEVICE|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
48677286|NCT01058252|COMBINATION_PRODUCT|INVOCell, Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~* Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~* Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst \> 10 mm).~* Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~* On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~* Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
48151398|NCT05313477|DRUG|Calcium carbonate|1000mg of Calcium carbonate daily
48151399|NCT06225063|OTHER|Pilates|The application of pilates aims to correct real-time deviations observed in the body during movement, to maintain stability, to maintain stability, to gradually form proper sensorimotor ability and improve cervical dysfunction. Pilates is an important part but also a primary point in the stages of rehabilitation, since through it the execution of movement is encouraged earlier thus providing help for the later stages of rehabilitation. Pilates exercises concern movements at all levels of body movement and in various positions.
48151400|NCT06225063|OTHER|Cognitive Functional Therapy|Cognitive component: Educating patients about their perceptions of pain, explaining diagnosis and diagnostic findings, answering questions about their problem and symptoms, progressively challenge their customers in a non-judgmental way, education for multifactorial and biopsychosocial spectrum of pain, encouraging participants to movement and for active participation in daily activities, if receiving a self-management plan participation in activities with a degree of difficulty 2-3/10, tips for more effective sleep Specific functional training: Understanding pain modification through relaxation exercises, awareness and body control, modified body positions for better control of the cervical spine with parallel relaxation of the thoracic spine to participate in fearful or painful activities, engaging in movements of daily activities Lifestyle changes: Gradual increase in physical activity based on patient preferences, stress management and social interaction
48151401|NCT06189898|DIAGNOSTIC_TEST|Re Staging FDG-PET|Additional interim FDG-PET during week four of preoperative or definitive chemoradiation for esophageal carcinomas. Evaluation of standardized uptake ratio (SUR) and increased uptake of non tumor affected esophagus (Delta NTO).
48151402|NCT06459869|DRUG|NG-350A IV administration|a tumour-selective anti-CD40-expressing adenoviral vector
48363287|NCT03939858|DIAGNOSTIC_TEST|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
48511195|NCT06632938|DRUG|Placebo for ABBV-382|IV Infusion
48511196|NCT06632938|DRUG|Placebo for ABBV-382|SC Injection
48511197|NCT03348735|DRUG|Lidocaine patch 5%|Application of Lidocaine 5% patch for 12 hours.
48151403|NCT06459869|DRUG|Capecitabine oral administration|chemotherapy
48151404|NCT06459869|RADIATION|Radiotherapy|long-course intensity-modulated radiotherapy
48363288|NCT03939858|DIAGNOSTIC_TEST|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
48363289|NCT02216630|DRUG|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
48363290|NCT02949544|OTHER|water immersion|warm water immersion
48363291|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
48363292|NCT00708344|DRUG|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
48363293|NCT04778722|DIETARY_SUPPLEMENT|Oral probiotics|containing four Lactobacillus strains (Lactobacillus crispatus -Lbv88, Lactobacillus rhamnosus -Lbv96, Lactobacillus jensenii -Lbv116, and Lactobacillus gasseri -Lbv150)
48363294|NCT02447393|DRUG|levocetirizine|levocetirizine
48363295|NCT02447393|DRUG|cetirizine|cetiridine
48363296|NCT02447393|DRUG|placebo|placebo
48363297|NCT02363699|DRUG|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
48363298|NCT02363699|DRUG|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
48363299|NCT02189239|DRUG|Zeller Entspannung film coated tablet|
48363300|NCT02189239|DRUG|Placebo|
48363301|NCT02189239|OTHER|No Treatment|
48677287|NCT01058252|PROCEDURE|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
48677288|NCT01058252|PROCEDURE|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~* E2 level is over 150 pg/ml/per mature follicle (\> 15 mm)~* Domminent follicle is greater than 18 mm in mean diameter~* LH Remains as Baseline, OR~* The day when Urinary LH Surge is positive"
48677289|NCT01058252|PROCEDURE|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~* Poor patient compliance~* Premature Ovulation~* Premature LH Surge~* Endometrium \< 7 mm~* Poor Follicular Development~* E2 Level \> 2,500 pg/ml"
48677290|NCT01058252|PROCEDURE|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
48151405|NCT03633318|DEVICE|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
48363302|NCT05916534|BEHAVIORAL|WeCAB Intervention|The WeCAB intervention will use a dedicated WeCAB community health worker who will administer a social determinants of health (SDOH) tool and use digital care navigation to monitor closed loop referrals.
48677291|NCT03484429|DEVICE|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
48363303|NCT01825811|BIOLOGICAL|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
48677292|NCT03484429|OTHER|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
48677293|NCT00577369|OTHER|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
48363304|NCT01825811|BIOLOGICAL|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
48363305|NCT04689399|DIAGNOSTIC_TEST|Standard Q COVID-19 Ag - test, produced by SD Biosensor INC.|Alle Danish citizens tested for infection with SARS-CoV-2 by swabs in the oropharynx, and subsequently analysis of the specimens by RT-PCR test at Testcenter Danmark's test centers will be included in the study. Participants will, in addition to the oropharyngeal swab they are already schedule for, be examined by a rapid antigen test.
48363306|NCT00695318|DRUG|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
48363307|NCT00695318|DRUG|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
48511198|NCT03348735|DRUG|Capsaicin 8% Patch|Application of Capsaicin 8% patch for
48363308|NCT06220227|PROCEDURE|vitrification and thawing procedures|"Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst."
48363309|NCT05363787|OTHER|therapeutic touch|Therapeutic Touch (TT) is an evidence-based holistic treatment method in which universal energy is used intentionally and with compassion for a specific purpose, in order to contribute to one's balance and recovery.In a world dominated by technology, one can lose touch with our inner self. We lose our intuitive abilities for beautiful everyday sensations of nature, the surrounding environment, and various visual and auditory elements. The Therapeutic Touch is an ancient Ayurvedic self-massage technique that connects your body to your soul.It is also used in therapeutic communication. Therapeutic communication is the process of influencing and being influenced by one another. It consists of individual-centered, purposeful, planned, effective and satisfying actions.
48677294|NCT04878393|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
48363310|NCT00336986|DRUG|recombinant interleukin-21|
48363311|NCT06464276|OTHER|No intervention|No intervention
48677295|NCT05323890|DRUG|Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy|Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
48677296|NCT01456130|DRUG|Alogliptin|Alogliptin tablets
48677297|NCT01456130|DRUG|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
48677298|NCT05859139|OTHER|DA Scaling Strategies|For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
48363312|NCT03955211|DRUG|HTX-011|300 mg
48363313|NCT03955211|DRUG|HTX-011|400 mg
48363314|NCT03955211|DEVICE|Luer Lock Applicator|Applicator for instillation.
48677299|NCT00836771|DIETARY_SUPPLEMENT|Infant Formula|
48677300|NCT00003869|DRUG|carboxyamidotriazole|Given PO
48363315|NCT03955211|DRUG|Ibuprofen|400 mg
48363316|NCT03955211|DRUG|Acetaminophen|975 mg to 1 g
48363317|NCT00671190|DRUG|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
48363318|NCT00671190|DRUG|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
48363319|NCT00671190|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
48363320|NCT00671190|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
48363321|NCT00671190|DRUG|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
48363322|NCT00132405|DRUG|ALGRX 3268|
48363323|NCT05931575|DRUG|Fasudil hydrochloride|Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
48511199|NCT03348735|DRUG|Pregabalin|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
48677301|NCT00003869|OTHER|placebo|Given PO
48677302|NCT00003869|PROCEDURE|quality-of-life assessment|Ancillary studies
48677303|NCT00003869|OTHER|laboratory biomarker analysis|Correlative studies
48677304|NCT01177124|BEHAVIORAL|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
48677305|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
48151406|NCT00728325|BEHAVIORAL|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
48677306|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
48677307|NCT01331681|PROCEDURE|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
48151407|NCT00728325|BEHAVIORAL|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
48363324|NCT05931575|DRUG|Placebo|0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
48363325|NCT01211067|PROCEDURE|Lichtenstein hernioplasty|"* Mesh hernioplasty~* Ultrapro mesh (Ethicon, Johnson \& Johnson)"
48363326|NCT05578040|PROCEDURE|Auricular acupressure|To conduct this intervention, we used adhesive patches without Vaccaria seed to sham auricular acupressure at the cervical vertebra acupoint in the first trial phase and auricular acupressure at the cervical vertebra acupoint in the other two trial phases in 2 groups of auricular acupressure acupoints of the left and right cervical vertebra.
48363327|NCT03185637|PROCEDURE|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
48511200|NCT05308628|DIAGNOSTIC_TEST|Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA etc.)|Liver biopsies will be performed at 3 months, 6 months and 12 months post-transplant. Fibrosis was evaluated using the liver allograft fibrosis score (LAFSc) staging system. Liver Allograft Fibrosis by Using Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA)or (FBLN3,YKL40,LECT2 etc.)
48151408|NCT00610194|DRUG|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
48151409|NCT06337045|BEHAVIORAL|Complex prevention and rehabilitation intervention|The complex intervention started and ended with individual consultations with health professionals and furthermore included physical exercise, smoking cessation, alcohol treatment, dietary interventions, AF specific patient education, MediYoga, and/or psychosocial support.
48363328|NCT01278966|OTHER|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
48363329|NCT00188162|DEVICE|CT|
48511201|NCT01370447|DRUG|EPI-743|EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.
48511202|NCT03640416|DEVICE|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
48363330|NCT04301492|DRUG|Vortioxetine|16 weeks for each participant. During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed. After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml). All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day. After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day. At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
48363331|NCT04927611|PROCEDURE|Biopsy, open or laparoscopic surgery|Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.
48363332|NCT04488406|OTHER|No Intervention|Not applicable to these subjects. There is no study-related intervention
48677308|NCT03688919|BEHAVIORAL|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
48677309|NCT04340492|OTHER|Education to Adapted Physical Activity|4 group sessions (5 patients) aiming at promoting physical activity, the first three focusing respectively on endurance, posture and balance and power re-enforcement at one-week interval. A fourth session, 3 months latter is a consolidating session aiming at identify and overcome obstacles to practice physical activity in everyday life.
48677310|NCT04340492|OTHER|Standard care|Standard care concerning Parkinson's disease and physical activity
47992654|NCT05889598|OTHER|Ballistic Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40%1RM, the ballistic training group will complete eccentric phase hack squat exercise in approximately 3 seconds and the concentric phase as fast as possible with throwing type contractions. If participants can, participants will be allowed to take off in the concentric phase. To maintain high velocity in this group, lower loads will be used compared to the conventional group. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
48151410|NCT04759378|DIAGNOSTIC_TEST|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
48151411|NCT02233075|DRUG|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
48151412|NCT01330745|OTHER|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
48151413|NCT01299324|DEVICE|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
48363333|NCT05386979|PROCEDURE|Opioid free anesthesia technology|We have adopted a variety of methods to replace the use of opioids in the process of balanced anesthesia.
48151414|NCT03643445|BEHAVIORAL|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
48151415|NCT03643445|BEHAVIORAL|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
48151416|NCT01276080|DRUG|Donepezil|10 mg tablets
48363334|NCT03111810|DRUG|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
48363335|NCT03111810|DRUG|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
48363336|NCT02776904|OTHER|Immediate Post-concussion Assessment and Cognitive Testing|Computerized assessment that provides information related to visual reaction time and visual memory.
48363337|NCT02776904|OTHER|Gait with single and dual task|Walking alone and then walking while performing a memory task on a tablet.
48511203|NCT04264676|DRUG|Metronidazole Oral Tablet|Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
48511204|NCT04264676|DRUG|Placebo oral tablet|Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
47992655|NCT05889598|OTHER|Conventional Resistance Lower Body Strength Training|The exercise programme involves two supervised sessions per week at Loughborough University. Each session will involve 30-40 minutes of exercise, comprising warm-up , two main exercises: a hack squat and calf raise using a hack squat machine, and core exercises. After a warm-up period involving 5 minutes cycling and one set of 5 conventional repetitions at 40% of 1RM, the conventional training group will complete eccentric and concentric phases of hack squatting exercises for approximately 3 seconds each, with appropriate breathing techniques. The load will be decided according to regular maximal muscular strength test (1RM) to use of the correct weight for training (in proportion to the strength). Participants will start off using light weights and these will increase as participants become stronger.
47992656|NCT03471195|DIAGNOSTIC_TEST|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
47992657|NCT04877379|DRUG|VNRX-7145|β-lactamase inhibitor
47992658|NCT04877379|DRUG|VNRX-5024 (ceftibuten)|β-lactam antibiotic
47992659|NCT04877379|DRUG|Placebo|Placebo
47992660|NCT00631527|DRUG|Leuprolide|Injections given through a needle in the muscle every 3 months.
47992661|NCT00631527|DRUG|Goserelin|Subcutaneous injections given once every 3 months.
47992662|NCT00631527|DRUG|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
47992663|NCT00631527|DRUG|Casodex|Once a day by mouth for 2 weeks.
47992664|NCT00631527|RADIATION|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
47992665|NCT04372680|DIAGNOSTIC_TEST|CTUS examination|fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
47992666|NCT01376271|DRUG|Paroxetine|
47992667|NCT03488654|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
47992668|NCT01608659|DRUG|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
47992669|NCT02146547|DRUG|Aripiprazole|Administration in once-a-day schedule without regard to meals.
47992670|NCT02146547|DRUG|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
47992671|NCT02146547|DRUG|Paliperidone|Administration once a day orally standardised in relation to food intake.
47992672|NCT02146547|DRUG|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
47992673|NCT03887364|OTHER|Group A-Diaphragmatic breathing|Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
48363338|NCT02776904|OTHER|Y-Balance test|Dynamic balance test measuring reaching of the leg to the anterior,postero- lateral, and postero-medial directions.
48363339|NCT02776904|OTHER|Psychomotor Vigilance Task|Assessment measuring reaction time based on auditory cues.
48151417|NCT04704986|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|"Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
48151418|NCT04704986|DRUG|PVI using the PolarX Cryoballoon (Boston Scientific)|"Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
48151419|NCT03213379|DEVICE|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
48677311|NCT00985647|DRUG|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
48677312|NCT01770743|BIOLOGICAL|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
48677313|NCT01770743|BIOLOGICAL|BioThrax|
48677314|NCT03763734|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
48677315|NCT04663594|OTHER|WofB|Online experience designed to reduce anxiety and depression and support mental health and wellbeing
48677316|NCT04663594|OTHER|Ashmolean Website|A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
48677317|NCT04021446|OTHER|Exercise|personalized exercise prescription
48677318|NCT00178971|DRUG|adjunctive treatment with buspirone|buspirone 15-30 mg qd
48677319|NCT00178971|DRUG|placebo|placebo
48677320|NCT05703217|PROCEDURE|classical physical therapy with physiotherapy.|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds. In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
48677321|NCT03461939|OTHER|ePRIME symptom monitoring tool|ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
48677322|NCT03541278|PROCEDURE|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
48677323|NCT03541278|PROCEDURE|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
48151420|NCT04565873|DIAGNOSTIC_TEST|TSH|retrospective TSH level
48151421|NCT00286013|DRUG|Association of gemcitabine, oxaliplatin and radiotherapy|
48151422|NCT06281639|DEVICE|RAPID|test the clinical screening potential for congenital heart disorders using a single ECHO image taken by the RAPID device
48151423|NCT03905928|OTHER|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
48151424|NCT03905928|OTHER|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
48151425|NCT03905928|OTHER|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
48151426|NCT03905928|OTHER|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
48677324|NCT04580043|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
48677325|NCT04580043|DEVICE|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
48677326|NCT04580043|BEHAVIORAL|Sham Training|Computer-based task practice in a non-active/inert task.
48677327|NCT04580043|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
48677328|NCT05502003|OTHER|High Intensity Interval Training|Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.
48677329|NCT05502003|OTHER|Moderate Exercise Training|The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
48363340|NCT00925522|DEVICE|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
48363341|NCT05613933|OTHER|Improved practices|A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc...
48677330|NCT05566938|OTHER|Tailored nutritional recommendations for each metabotype|Tailored nutritional recommendations for each metabotype detected (at the group level), that will be delivered through a mobile application. Moreover, each volunteer will recieve individualized nutritional recommendations.
48151427|NCT01686724|BEHAVIORAL|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
48677331|NCT00833027|DRUG|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
48677332|NCT01444430|DRUG|Symbicort pMDI|Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
48677333|NCT01444430|DRUG|budesonide pMDI|Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
48677334|NCT05211180|BEHAVIORAL|Vida Sana|Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.
48363342|NCT02871024|DEVICE|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
48677335|NCT05211180|BEHAVIORAL|Vida Sana y Completa|Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
48151428|NCT01686724|OTHER|Business As Usual|
48363343|NCT06401538|DRUG|BMB-101|BMB-101 liquid administered orally twice a day for 3 months
48363344|NCT00308659|PROCEDURE|FOB protected distal microbiological samplings|
48363345|NCT01054794|DEVICE|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
48511205|NCT05382585|OTHER|Next generation Sequencing|Next generation sequencing for 161 genes
48677336|NCT06295380|BEHAVIORAL|Virtual environment practiced on the Caren|The virtual environment practised on the Caren will make the scenario totally immersive and allow the subject to perform the motor task by recruiting muscles according to a motor coordination scheme different from the traditional one.
48677337|NCT06295380|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy
48677338|NCT06049550|OTHER|no intervention|no intervention
48677339|NCT06283277|DEVICE|Obstetric Ultrasound|Measuring fetal clavicular length and estimated fetal weight using Hadlock IV formula and Youssef's formula.
48677340|NCT02057965|DRUG|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight
48151429|NCT01363206|BIOLOGICAL|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
48151430|NCT01363206|BIOLOGICAL|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
48151431|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；
48151432|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
48151433|NCT04945616|DRUG|Aspirin、ticagrelor、placebo or SHR2285|groupC： Aspirin + ticagrelor + placebo or SHR2285
48151434|NCT01394406|DRUG|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
48151435|NCT01394406|DRUG|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
48151436|NCT05723484|DEVICE|GIFT Device|The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
48151437|NCT00002094|DRUG|Atevirdine mesylate|
48151438|NCT06197100|OTHER|Supportive care training|The program includes breastfeeding teaching, baby massage, managing gas issues (shaking, white noise), and nutrition for mothers.
48151439|NCT06197100|OTHER|control grups|Mothers in this group will be given an educational brochure containing information about colic.
48151440|NCT02869308|DRUG|stannous pyrophosphate|Injection of 1ml Angiocis
48151441|NCT02869308|DRUG|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
48151442|NCT02869308|DEVICE|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
48151443|NCT02869308|DEVICE|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
48511206|NCT03696953|BIOLOGICAL|Florajen3|Probiotic combination product One capsule daily by mouth.
48511207|NCT04190017|OTHER|Cranial MRI|Cranial MRI
48151444|NCT02776917|DRUG|Cirmtuzumab + Paclitaxel|Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
48151445|NCT03773770|DRUG|Triheptanoin|Liquid for oral (PO) or enteral tube administration
48151446|NCT03022747|DRUG|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
48151447|NCT03022747|DRUG|Standard treatment|Oral 6-mercaptopurine and methotrexate
48151448|NCT02991456|DRUG|Rolapitant|single 180 mg dose by mouth
48151449|NCT02991456|DRUG|Ondansetron|8 mg by mouth daily
48151450|NCT02736175|DRUG|Dexamethasone|
48151451|NCT02736175|OTHER|Placebo Vehicle|
48151452|NCT02473549|DEVICE|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
48151453|NCT02473549|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
48363346|NCT02609529|OTHER|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
48363347|NCT02609529|OTHER|Placebo|
48363348|NCT03162302|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
48363349|NCT01568957|BEHAVIORAL|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
48363350|NCT03029494|DEVICE|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
48363351|NCT03029494|DRUG|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
48511208|NCT05163392|DEVICE|Silverlon|SIlver-plated biopatch
48511209|NCT05163392|DEVICE|Control|Tegaderm without biopatch
48151454|NCT02473549|DEVICE|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
48677341|NCT06405295|OTHER|no intervention|Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
48677342|NCT06459596|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
48677343|NCT03974074|DRUG|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
48677344|NCT06075875|DIETARY_SUPPLEMENT|mixed animal and vegetable proteins|"mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group) and continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm)."
48677345|NCT06075875|DIETARY_SUPPLEMENT|pure vegetable proteins|pure vegetable proteins continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
47992674|NCT03887364|OTHER|Group B-Icing and Airflow Stimulation|"Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek \& nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers)."
48151455|NCT02473549|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
48677346|NCT01771874|DRUG|MDMA|125 mg per os, single dose
48151456|NCT03118609|OTHER|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
48151457|NCT05114499|DRUG|Donepezil|Donepezil 5mg qd
48151458|NCT05114499|DRUG|GV-971|GV-971 450mg bid
48363352|NCT03029494|DEVICE|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
48363353|NCT03029494|DIETARY_SUPPLEMENT|Vitamin C|1000 mg
48363354|NCT04968327|OTHER|Micro-osteoperforations (MOPs)|MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
48511210|NCT01161134|DRUG|Meloxicam|Meloxicam Tablets 15 mg
48511211|NCT06633146|BEHAVIORAL|Therapies in nature|Therapeutic tasks in nature specifically designed for the study
47992675|NCT01734330|BEHAVIORAL|Cognitive behavioral therapy in group|
47992676|NCT01734330|DRUG|Nicotine replacement|
48363355|NCT04968327|OTHER|Conventional canine retraction|using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
48363356|NCT04097925|DRUG|Doravirine|Doravirine 100 mg tablet
48363357|NCT04097925|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
48363358|NCT04412226|DEVICE|aerosol box|The aerosol box is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cube that covers the patient's head during the endotracheal intubation. Operator can intubate the patient through the two holes for arms.
48511212|NCT00303459|DRUG|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
48511213|NCT00303459|DRUG|placebo|Matching bosentan placebo/b.i.d.
48511214|NCT01328379|DRUG|Dalfampridine-ER 5mg|5mg, twice daily
48677347|NCT01771874|DRUG|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
48677348|NCT01771874|DRUG|Placebo|per os
47992677|NCT05508763|GENETIC|Genetic test for 14 pharmacogenes|Genotyping with the Global Diversity Array-8 v1.0 BeadChip with enhanced PGx
48151459|NCT06387940|OTHER|nEB Diet, followed for 36 hours|nEB diet first, then LC25 and LCEB in random order with a 5 days washout between each diet
48151460|NCT06387940|OTHER|LC25 Diet, followed for 36 hours|LC25 diet first, then nEB and LCEB in random order with a 5 days washout between each diet
48151461|NCT06387940|OTHER|LCEB Diet, followed for 36 hours|LCEB diet first, then LC25 and nEB in random order with a 5 days washout between each diet
48151462|NCT03936725|OTHER|1 year phone call : data collection|"Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up."
48151463|NCT02453269|BEHAVIORAL|Transdisciplinary program|
48151464|NCT01429168|DRUG|Etoricoxib|One 60-mg tablet orally daily
48151465|NCT01429168|DRUG|Placebo for etoricoxib|One 60-mg tablet orally daily
48151466|NCT03386344|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
48511215|NCT01328379|DRUG|Dalfampridine-ER 10mg|10mg, twice daily
48511216|NCT01328379|OTHER|Placebo|placebo, twice daily
48677349|NCT04635202|BEHAVIORAL|exercise training on elliptical device|This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
48677350|NCT04635202|BEHAVIORAL|group B (control group)|this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
48677351|NCT00754689|DRUG|Rimonabant|Tablet, oral administration
48677352|NCT00754689|DRUG|Metformin|Tablet, oral administration
48677353|NCT00754689|DRUG|placebo|Tablet, oral administration
48677354|NCT03492047|DIETARY_SUPPLEMENT|low dose N-acetylcysteine|N-acetylcysteine 600mg twice daily
48677355|NCT03492047|DIETARY_SUPPLEMENT|high dose N-acetylcysteine|N-acetylcysteine 1200mg twice daily
48511217|NCT04760496|DRUG|Oxytocin 4 mIU/mL|Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
48511218|NCT04760496|DRUG|Oxytocin 2 mIU/mL|Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
48677356|NCT03492047|DRUG|Paclitaxel|Paclitaxel 80mg /m2 IV
48677357|NCT05120700|BIOLOGICAL|Synovial Tissue and Fat Pad Stromal Vascular Fraction|Treatment of cartilage injury with a tissue engineering construct. It will be composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold
48677358|NCT00803361|DRUG|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
48677359|NCT00803361|DRUG|Placebo|placebo capsules, oral, once a day for 15 weeks
48677360|NCT04749147|OTHER|Black and White Printed Survey|This survey will feature black and white text and graphics.
48677361|NCT04749147|OTHER|Red Printed Survey|This survey will feature red text and graphics.
48677362|NCT03328832|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
48677363|NCT03328832|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
48511219|NCT04795596|PROCEDURE|secondary cytoreductive surgery|resection of isolated recurrent ovarian carcinoma in platinum resistant disease
48677364|NCT03328832|DRUG|rivaroxaban (10mg)|Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
47992678|NCT03695510|DRUG|Afatinib Oral Tablet|40mg oral, daily, continuously
48151467|NCT03386344|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
48151468|NCT04873986|DIAGNOSTIC_TEST|Scoliosis Tele-Screening Test|Scoliosis Tele-Screening test will be applied to children by parents at home. Participants with moderate and high risks will be invited to the physical examination to the centers or virtual assessment via e-mail. The researchers will be evaluated the TRACE and Adams' test from the photo and sent their opinions to the parents via e-mail.
48151469|NCT01549171|DRUG|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
48151470|NCT01549171|OTHER|normal saline|Supplement with vehicle only no Iloprost.
48511220|NCT04795596|DRUG|Chemotherapy|second line chemotherapy according to investigator's choice
48511221|NCT02908087|DRUG|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
48677365|NCT00626535|DRUG|Esomeprazole|20mg Oral Once Daily
48677366|NCT00626535|DRUG|Matching placebo|Oral Once Daily
48677367|NCT05260320|OTHER|Standardized Anesthetic Course from Premedication to Induction|See information in intervention group description
48677368|NCT00593060|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
48677369|NCT00593060|DRUG|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
48677370|NCT05922605|DRUG|S-ketamine & Ropivacaine|The experiment group (Group E) will receive a mixture of ropivacaine 0.2% 0.7 ml／kg and preservative-free S-ketamine 0.5 mg/kg caudally for postoperative analgesia.
47992679|NCT03695510|DRUG|Pembrolizumab Injection|200mg, intra-venous injection, every 3 weeks, for 35 cycles
47992680|NCT03403959|DEVICE|light therapy|6 weeks morning treatment with bright light therapy in own home.
48151471|NCT01630239|PROCEDURE|Laser ablation|Laser ablation of hepatic tumors
48151472|NCT05333276|DRUG|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
48511222|NCT02908087|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
48511223|NCT00478244|DRUG|busulfan|Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if \> 12 kg.
48511224|NCT00478244|DRUG|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
48511225|NCT00478244|DRUG|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
48511226|NCT00478244|PROCEDURE|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
48511227|NCT01062347|BIOLOGICAL|Zinc|
47992681|NCT00783601|DRUG|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
48151473|NCT00763919|BEHAVIORAL|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
48363359|NCT04412226|DEVICE|transparent sheet|The transparent sheet is a barrier that protects the staff against the aerosols during the aerosol generating procedures like endotracheal intubation. It is a transparent cover that covers the patient's head and body during the endotracheal intubation. Operator can intubate the patient through the space under the cover
48363360|NCT03459963|DEVICE|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
48363361|NCT03212872|DIAGNOSTIC_TEST|Endoscopy|
47992682|NCT00783601|DRUG|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
47992683|NCT00783601|DRUG|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
47992684|NCT00783601|DRUG|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
47992685|NCT06547866|DRUG|zanubrutinib + BGB-11417|"The investigational medicinal products (IMP) are Zanubrutinib (BGB- 3111) and BGB-11417.Treatment will be administered for a total of twenty 28 day cycles:~Cycle 1 with zanubrutinib only~Cycle 2 with zanubrutinib plus BGB-11417 ramp-up cycle 2, day 1 : 10mg cycle 2, day 2 : 20 mg cycle 2, day 3 : 40mg cycle 2, day 4-7 : 80md daily cycle 2, day 8 and beyond : 160 mg daily~Cycles 3-20 with zanubrutinib plus BGB-11417 full dose"
47992686|NCT04487054|OTHER|Pro-active palliative care|Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
47992687|NCT03190655|DEVICE|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
48363362|NCT06208410|DRUG|JS105|JS105 is administered once daily, orally
48363363|NCT06208410|DRUG|Fulvestrant injection|Fulvestrant intramuscularly,The first cycle was injected once in D1 and D15, and then once in each cycle D1, and 28 days was 1 cycle
48363364|NCT06208410|DRUG|Dalpiciclib Isetionate Tablets|Dalpiciclib Isetionate Tablets, QD, oral, taken continuously for 21 days, then stopped for 7 days, 28 days for a cycle
48363365|NCT06208410|DRUG|Toripalimab Injection|Toripalimab Injection,Intravenous infusion, once every 3 weeks, 21 days for 1 cycle
48363366|NCT06208410|DRUG|Paclitaxel for Injection (Albumin Bound)|Paclitaxel for Injection (Albumin Bound),Intravenous infusion, D1, 8, 15 infusion, every 28 days for a cycle
48363367|NCT06208410|DRUG|Fluzoparib Capsules|Fluzoparib Capsules is administered once daily, orally
48363368|NCT06208410|DRUG|Pyrotinib Maleate Tablets|Pyrotinib Maleate Tablets is administered once daily, orally
48363369|NCT06208410|DRUG|Capecitabine Tablets|Capecitabine Tablets is administered once daily, orally
48677371|NCT05922605|DRUG|Ropivacaine|The experiment group (Group C) will receive ropivacaine 0.2% 0.7 ml／kg plain and equial volume saline caudally for postoperative analgesia.
47992688|NCT03190655|DEVICE|Hydrogel|Hydrogel based wound dressing
48151474|NCT00763919|BEHAVIORAL|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
48151475|NCT00763919|BEHAVIORAL|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
48677372|NCT00328796|PROCEDURE|acupuncture in 6 specific points|
48677373|NCT00328796|DRUG|lidocaine 10mg/ml|
47992689|NCT04100304|DIAGNOSTIC_TEST|resection|CT volumetry,liver function,biopsy before resection
47992690|NCT01948973|DEVICE|Subsensory|The stimulation is here set to 90% of the sensory threshold
47992691|NCT01948973|DEVICE|OFF|The stimulation is here turned OFF
47992692|NCT01948973|DRUG|Suprasensory|The stimulation is here set suprasensory
48151476|NCT00763919|BEHAVIORAL|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
48151477|NCT02835196|DEVICE|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
48511228|NCT04414774|DEVICE|GG-Suicide-Ideation|GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
48151478|NCT02835196|OTHER|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
48151479|NCT06060847|PROCEDURE|Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome|Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
48151480|NCT06060847|PROCEDURE|Liver resection for HCC induced by metabolic syndrome|Patients in the active comparator arm will undergo liver resection for HCC
48151481|NCT00589745|OTHER|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
48151482|NCT05507372|DRUG|Pimozide 1 MG|Dopamine Receptor Antagonist - Oral Pimozide
48151483|NCT06000202|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 21 days. She receives 3 sessions, in total. Each session consists of application of PS03 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 6 passes followed by R11 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 3 passes.
48363370|NCT04734249|DRUG|Surufatinib(HMPL-012)|"1. Cohort 1:Surufatinib(250mg ,qd,po)+mFOLFOX6/FOLFIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~   Cohort 2:Surufatinib(250mg ,qd,po)+FOLFOXIRI,14 days for a cycle.The curative effect was evaluated every 4 cycles.~2. if the first-line chemotherapy was used FoLFOX ,the second-line is FOLFIRI,or the first-line chemotherapy was used FOLFIRI ,the second-line is FoLFOX.~3. Second-line Surufatinib Combined With Chemotherapy in Advanced CRC."
48363371|NCT04464876|DEVICE|SATURN TA System|SATURN TA TMVR Device implanted
48363372|NCT06421194|OTHER|Investigational meal 1 - Commercial animal-based protein foods [Siew mai (6 pieces) and Ngoh hiang (2 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
48363373|NCT06421194|OTHER|Investigational meal 2- Commercial animal-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of commercial animal-based protein foods (steamed Gyoza and oven-baked Luncheon meat) in a fasted state.
48363374|NCT06421194|OTHER|Investigational meal 3- Formulated plant-based protein foods [Siew mai (6 pieces) and Ngoh hiang (1 piece cut into 2)]|Participants consume a meal consisting of formulated plant-based protein foods (steamed Siew mai and oven-baked Ngoh hiang) in a fasted state.
48677374|NCT04749745|DRUG|L-theanine|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
48363375|NCT06421194|OTHER|Investigational meal 4- Formulated plant-based protein foods [Gyoza (11 pieces) and Luncheon meat (5 pieces)]|Participants consume a meal consisting of formulated plant-based protein foods (Gyoza and Luncheon meat) in a fasted state.
47992693|NCT01004588|DIETARY_SUPPLEMENT|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
47992694|NCT01004588|DIETARY_SUPPLEMENT|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
47992695|NCT00885716|BEHAVIORAL|patient training in shared decision making|
47992696|NCT00885716|BEHAVIORAL|cognitive training|
47992697|NCT04162028|DRUG|Nebutlized Ketamine|The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
48677375|NCT04749745|DRUG|Placebo|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
48677376|NCT00817934|DRUG|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
48677377|NCT04445792|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
47992698|NCT05085275|DRUG|Ferric Citrate 1 GM Oral Tablet [AURYXIA]|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
48151484|NCT06000202|DEVICE|Sham|Er:YAG laser is applied with sham handpiece.
48151485|NCT04184271|DRUG|38% silver diamine fluoride|Topical application of SDF to teeth
48151486|NCT01720407|DRUG|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
48151487|NCT01720407|DRUG|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
48363376|NCT02924311|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
48677378|NCT04445792|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
48677379|NCT00761488|DEVICE|AcrySof® Toric IOL|Implanted into the study eye
47992699|NCT05085275|DRUG|Placebo|All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
47992700|NCT02981823|PROCEDURE|hip replacement|The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
47992701|NCT02046408|OTHER|Computer Tablet|
47992702|NCT06069687|BIOLOGICAL|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
48151488|NCT00984334|DRUG|Naloxone SR 5 mg capsules|
48151489|NCT00984334|DRUG|Placebo|
48151490|NCT00984334|DRUG|Naloxone SR 10 mg capsules|
48151491|NCT00984334|DRUG|Naloxone SR 20mg capsules|
48151492|NCT00984334|DRUG|Naloxone SR 2.5 mg capsules|
48151493|NCT05390515|DRUG|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
48151494|NCT00579020|DRUG|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
48151495|NCT00579020|DRUG|Moxifloxacin ophthalmic solution 0.5%|
48151496|NCT00579020|DRUG|Dexamethasone phosphate solution, 0.1%|
48363377|NCT00075634|DRUG|decitabine|Given IV
48363378|NCT00075634|DRUG|doxorubicin hydrochloride|Given IV
48363379|NCT00075634|DRUG|cyclophosphamide|Given IV
48363380|NCT00075634|BIOLOGICAL|filgrastim|Given SC
48363381|NCT00075634|BIOLOGICAL|pegfilgrastim|Given SC
48363382|NCT00075634|OTHER|laboratory biomarker analysis|Correlative studies
48151497|NCT02705456|PROCEDURE|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
48151498|NCT02705456|PROCEDURE|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
48151499|NCT03335722|BEHAVIORAL|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
48151500|NCT03335722|DEVICE|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
48151501|NCT03335722|DEVICE|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
48363383|NCT00075634|OTHER|pharmacological study|Correlative studies
48363384|NCT02400281|DRUG|Crenolanib besylate|
48363385|NCT02400281|DRUG|Idarubicin|
48363386|NCT02400281|DRUG|Cytarabine|
48363387|NCT02400281|DRUG|Azacytidine|
48363388|NCT02400281|DRUG|Mitoxantrone|
48677380|NCT04944615|PROCEDURE|The guidewire successfully passed the CTO lesion|"The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery."
48677381|NCT01023152|PROCEDURE|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
48677382|NCT06199765|OTHER|Needlestick Injury Prevention|this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
48363389|NCT02400281|DRUG|Etoposide|
48363390|NCT02400281|DRUG|Fludarabine|
48363391|NCT02400281|DRUG|G-CSF|
48363392|NCT02543879|DRUG|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
48363393|NCT02543879|DRUG|Azacitidine|Azacitidine will be administered per site's standard of care
48363394|NCT06170359|PROCEDURE|robotic surgery under general anaesthesia|During robotic surgery, the standard 45-degree upright Trendelenburg position and for postoperative analgesia, 0.06 mg/kg morphine, 1 gram (g) paracetomol and 8 mg onasetron are administered iv to all patients 30 minutes before the end of the operation. At the end of surgery and after extubation, patients are taken from the recovery unit to the service. In the service, all patients are given paracetamol 1g every 8 hours and tenoxicam 20 mg every 24 hours for pain treatment. Tramadol 1 mg/kg iv is administered as rescue analgesic to patients with a VAS score \>4.
48677383|NCT04346511|OTHER|Acupuncture|Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
48677384|NCT03534882|OTHER|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
48677385|NCT06122103|DEVICE|Clareon Monofocal|Clareon Monofocal Intraocular Lens (toric and non-toric)
48363395|NCT02651038|DRUG|Micafungin|Measurement of PK
48363396|NCT05860166|OTHER|Test Scale|Developing an Neurodevelopment Test for evaluating infants in their neonatal period.
48363397|NCT00000322|BEHAVIORAL|Tyrosine|
48363398|NCT04669106|OTHER|laboratory clinical trial study|The research stage consisted of two stages, the first stage was the initial screening of the primary data of the research subjects, namely by analyzing food intake including mineral intake data, the diet of the research subjects, mineral and enzyme levels, and data on soil conditions in the area. The second stage was to analyze the relationship between the existing variables so that the most significant relationship was seen between the differences in diet, mineral content, enzyme levels, and soil content between the two groups.
48151502|NCT01259219|DRUG|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
48151503|NCT04304014|DIETARY_SUPPLEMENT|L. reuteri|(10\^8 CFU) once a day
48151504|NCT04304014|DIETARY_SUPPLEMENT|B. longum and P. Pentosaceus|(10\^9 CFU) once a day
48151505|NCT06296784|OTHER|e-health psychoeducation|e-health psychoeducation intervention provides information about BD clinical condition and symptoms, as well as identifying effective coping strategies to manage symptoms and the dysregulation of biological rhythms. The content covered the impact of the pandemic and its related restrictions on mental health, particularly on anxiety and depressive symptoms. The intervention comprised one session per week for two months, and each session lasted approximately an hour and a half. It was conducted by healthcare professionals.
48151506|NCT04323514|DIETARY_SUPPLEMENT|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
48151507|NCT00925327|OTHER|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
48151508|NCT06335667|DIAGNOSTIC_TEST|mpMRI + Diagnostic TURBT|mpMRI in addition to the TURBT surgical procedure
48151509|NCT05992584|DRUG|Lenvatinib, sintilimab plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
48151510|NCT00000497|BEHAVIORAL|diet, sodium-restricted|
48151511|NCT00000497|BEHAVIORAL|diet, reducing|
48151512|NCT00649402|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
48151513|NCT00649402|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
48151514|NCT05270096|OTHER|Advice|non-interventional study
48363399|NCT01486992|DRUG|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
48363400|NCT04822389|DEVICE|Telerehablitation using heart rate monitor|Eligible participants will undergo 12 weeks of physical exercise using a heart rate monitor and internet platform at home. The participants will regularly (minimum once per week) upload the exercise data from the heart rate monitor into the internet platform. An exercise telerehabilitation session consists of the warm-up phase, aerobic phase (30 - 50 minutes gradually increasing exercise duration; heart rate zone based on baseline cardiopulmonary exercise test) and cool-down phase. The exercise training period is set to 3 times a week for 12 weeks. Study participants will receive user guides developed by research team with detailed instructions regarding equipment set-up, training protocol, and contact information. Also, participants will receive weekly phone calls from week 0 to week 12 to monitor adverse events, encourage compliance and adherence to the study protocol, address any subject questions or concerns, and collect information regarding participants' current symptomatology.
48363401|NCT05471453|DIETARY_SUPPLEMENT|DHEA|75 mg DHEA supplementation per day for 3 months before IVF
48363402|NCT05471453|DIETARY_SUPPLEMENT|DHEA+CoQ10+Tocotrienol|75 mg DHEA supplementation + 30 mg CoQ10 + 300 mg Tocotrienol per day for 3 months before IVF
48151515|NCT04834167|DEVICE|OneDoc Picopulse|Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.
48151516|NCT01602900|DRUG|GSK356278|Investigational Medicinal Product
48151517|NCT01602900|DRUG|Rolipram|Challenge Agent
48151518|NCT02291861|DRUG|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
48151519|NCT02291861|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
48151520|NCT05714774|DEVICE|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
48151521|NCT00582920|RADIATION|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
48151522|NCT03029156|DEVICE|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
48151523|NCT03029156|DEVICE|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
48151524|NCT05957822|DRUG|TXA|Tranexamic acid injection 8-10mg/kg
48677386|NCT06122103|DEVICE|Light-Adjustable Lens|Light-Adjustable Lens (Intraocular Lens)
48677387|NCT00225914|DRUG|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
48151525|NCT05957822|DIAGNOSTIC_TEST|TEG6|performing thromboelastography (TEG6)
48151526|NCT02143713|DRUG|Elagolix|Elagolix tablets administered orally
48151527|NCT03157414|DRUG|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
48151528|NCT03157414|OTHER|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
48151529|NCT02568202|OTHER|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment."
48151530|NCT02400398|OTHER|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
48151531|NCT04705779|BEHAVIORAL|HARMONY|The HARMONY intervention will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
48151532|NCT04705779|BEHAVIORAL|Nutrition and Exercise Education (NEEW)|The Nutrition and Exercise Workgroup (NEEW) group will be delivered over 8 every-other-week sessions and 6 monthly booster sessions. Each session will have three components; an exercise sampler, cool down and tailored education on cardiometabolic prevention and risk reductions.
48151533|NCT03687554|DRUG|Venglustat GZ/SAR402671|Pharmaceutical form: Hard Capsule Route of administration: Oral
48151534|NCT01803958|RADIATION|partial breast irradiation|
48151535|NCT01803958|RADIATION|whole breast irradiation|
48151536|NCT00833599|DRUG|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
48151537|NCT01838707|DRUG|0.125% Bupivacaine HCL @ 4-5 ml/h|
48151538|NCT01838707|DRUG|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
48151539|NCT01838707|DRUG|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
48151540|NCT05497804|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48151541|NCT05497804|DRUG|Carfilzomib|Given IV
48151542|NCT05497804|PROCEDURE|Computed Tomography|Undergo CT
48151543|NCT05497804|BIOLOGICAL|Daratumumab|Given SC
48151544|NCT05497804|DRUG|Dexamethasone|Given IV/PO
48151545|NCT05497804|DRUG|Lenalidomide|Given PO
48151546|NCT05497804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48151547|NCT05497804|PROCEDURE|Positron Emission Tomography|Undergo PET
48151548|NCT05497804|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48151549|NCT05509881|DEVICE|Continuous glucose monitoring (CGM)|"Patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices."
48151550|NCT05509881|DEVICE|Usual care (Self-monitored blood glucose)|Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.
48151551|NCT02001467|OTHER|Simulation-based training|
48677388|NCT00225914|DRUG|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
48677389|NCT00726128|DEVICE|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
48151552|NCT00641797|DRUG|Meclizine|medication administration 25mg PO one time
48151553|NCT00641797|OTHER|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
48151554|NCT00641797|DRUG|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
48151555|NCT00641797|DRUG|Diphenhydramine|25 - 50mg PO/IV once prn
48151556|NCT00641797|DRUG|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
48151557|NCT06232005|DRUG|Mitomycin c|injection of antifibrotic drugs in urethral strictures after internal urethrotomy
48151558|NCT00110422|DRUG|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
48151559|NCT00110422|DRUG|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
48151560|NCT04527926|BEHAVIORAL|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
48151561|NCT04527926|BEHAVIORAL|Usual Care|Standard of Care
48151562|NCT03671356|OTHER|risk score|risk score
48151563|NCT02660086|BEHAVIORAL|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
48151564|NCT00312546|DRUG|Enfuvirtide|90 mg subcutaneously twice daily
48151565|NCT00312546|DRUG|Valproic acid|500 to 750 mg, taken orally twice daily
48151566|NCT02912104|BIOLOGICAL|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
48151567|NCT01883297|BIOLOGICAL|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10\^7 TILs (with maximum 3x10\^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10\^8 TILs (with maximum 1x10\^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10\^8 TILs (with maximum 3x10\^8 autologous dendritic cells)
48151568|NCT01883297|BIOLOGICAL|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
48151569|NCT01883297|DRUG|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
48151570|NCT05671055|OTHER|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
48151571|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised CARE program
48151572|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised TARE program
48151573|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo home-based stretching program
48151574|NCT03091842|OTHER|Informational Intervention|Receive instructional DVD and booklet of the flexibility exercises
48151575|NCT03091842|OTHER|Laboratory Biomarker Analysis|Correlative studies
48151576|NCT03091842|OTHER|Quality-of-Life Assessment|Ancillary studies
48151577|NCT03091842|OTHER|Questionnaire Administration|Ancillary studies
48151578|NCT01145326|DRUG|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
48151579|NCT01145326|DRUG|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
48151580|NCT03430362|DRUG|Hyoscine N Butylbromide|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
48151581|NCT03430362|DRUG|Normal Saline 0.9%|Group B, will receive 2 ml of normal saline single intravenous dose
48363403|NCT00788801|DRUG|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
48363404|NCT04120025|BEHAVIORAL|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
48363405|NCT00270816|DRUG|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
48363406|NCT00270816|DRUG|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
48677390|NCT04032925|DEVICE|PICSO|"PICSO therapy is delivered through the PICSO Impulse System, which consists of the PICSO Impulse console and PICSO impulse catheter. The PICSO therapy is delivered in each patient for a minimum of 20 minutes to a maximum of 45 minutes.~The PICSO Impulse catheter is automatically activated by the PICSO Impulse console. It is inserted in the coronary sinus via femoral vein access. The PICSO Impulse Console cyclically inflates and deflates the balloon at the tip of the PICSO Impulse catheter, generating transient increase in coronary sinus pressure."
48677391|NCT05554302|DRUG|18F-Fluciclovine|Patients will receive 5-mCi dose (+/- 20%) of 18F-Fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-Fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-Fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
48677392|NCT05197465|OTHER|Questionnaires|Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
48677393|NCT00339040|BIOLOGICAL|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
48677394|NCT00339040|OTHER|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
48151582|NCT04436965|OTHER|Standardized nutrition therapy|Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
48151583|NCT04436965|DRUG|Cisplatin|Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
48151584|NCT04436965|RADIATION|Intensity Modulated Radiation Therapy|Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
48151585|NCT03612102|BEHAVIORAL|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
48151586|NCT06188949|DIETARY_SUPPLEMENT|Dolichos biflorus (Horsegram) seed extract|1 capsule twice a day (Before breakfast \& dinner)
48363407|NCT02967042|DEVICE|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
48363408|NCT02458989|PROCEDURE|Scalpel|Use of a scalpel as a first incision during thyroid operation
48363409|NCT02458989|PROCEDURE|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
48677395|NCT02315703|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
48677396|NCT02315703|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
48677397|NCT02315703|BIOLOGICAL|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
48151587|NCT06188949|DIETARY_SUPPLEMENT|Carica papaya leaves extract|1 capsule twice a day (Before breakfast \& dinner)
48151588|NCT06188949|DIETARY_SUPPLEMENT|Placebo (MCC)|1 capsule twice a day (Before breakfast \& dinner)
48151589|NCT02407288|DEVICE|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
48151590|NCT02407288|DEVICE|Sham tDCS|
48677398|NCT02315703|BIOLOGICAL|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
48677399|NCT02315703|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
48151591|NCT05456061|DRUG|3% diquafosol eyedrops|Diquas® (Santen, Osaka, Japan), six times per day.
48151592|NCT05456061|PROCEDURE|Silicone punctal plug insertion|a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
48151593|NCT04964206|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.
48151594|NCT04964206|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
48151595|NCT02449902|DRUG|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
48151596|NCT02449902|DRUG|placebo|1 placebo capsule inserted vaginally for 14 days.
48151597|NCT03833765|PROCEDURE|CAF+XCM|After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
48151598|NCT03833765|PROCEDURE|CAF alone|Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
48151599|NCT02226029|OTHER|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions"
48151600|NCT04610125|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
48151601|NCT04610125|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
48151602|NCT04610125|PROCEDURE|Leukapheresis|Leukapheresis
48151603|NCT01850888|DRUG|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
48363410|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a high total daily dose
48363411|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
48151604|NCT01850888|DRUG|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
48151605|NCT01850888|DRUG|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000).
48151606|NCT01850888|PROCEDURE|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum \> 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum \>2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
48363412|NCT00779181|DRUG|ADX415|ADX415 taken three times a day to achieve a low total daily dose
48363413|NCT00779181|DRUG|Placebo|Placebo taken three times a day
48363414|NCT00498784|DRUG|Mirena|Mirena 52mg during 1 year
48151607|NCT06037577|DRUG|CM-101|Anti-human CCL24 monoclonal antibody (CM-101)
48363415|NCT02993133|DRUG|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
48151608|NCT06037577|DRUG|Placebo|Placebo Comparator
48151609|NCT02344602|DRUG|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
48363416|NCT04459858|OTHER|data analysis|"Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined."
48363417|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg I.V.
48363418|NCT00699361|DRUG|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
48363419|NCT03037489|DRUG|MIV-711|MIV-711 administered orally once daily
48363420|NCT02565303|PROCEDURE|Intervertebral space|
48363421|NCT02565303|DRUG|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
48151610|NCT01779492|DRUG|GL2907|once a day
48151611|NCT01779492|DRUG|Oxycontine CR 10mg|twice a day
48363422|NCT04795752|DEVICE|TearCare System|TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.
48363423|NCT04795752|DRUG|Restasis|Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
48511229|NCT00001797|DRUG|Recombinant human interleukin-10|
48511230|NCT06490185|OTHER|Clinical data collection|Clinical significance of peri-appendiceal abscess and phlegmon in acute complicated appendicitis patients undergoing emergency appendectomy
48511231|NCT04280926|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
48363424|NCT02297295|OTHER|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
48363425|NCT05720936|PROCEDURE|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach"
48363426|NCT02017366|OTHER|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
48677400|NCT03053934|BEHAVIORAL|Online video-based counselling|Videoconferencing facilitates communication between individuals (i.e., the counsellor and the client) in different geographical locations enabling them to interact simultaneously with each other on a computer monitor in real time. In other words, both the client and the therapist communicate live using both visual and audio aids simulating in-person therapy albeit from two separate geographical locations.
48677401|NCT03053934|BEHAVIORAL|Traditional in-person counselling|"Traditional in-person counselling is often referred to as face-to-face and can be loosely defined as any mental health intervention, whereby the clinician is in the same room with a client. The terms in-person and same room are used less frequently, but it has been argued that these terms are more descriptive (since in videoconferencing, clients are also seen face-to-face on screen). Therefore, the current study uses the term in-person to describe traditional, face-to-face counselling."
48677402|NCT01719848|OTHER|Measurements of parameters related with physical examinations for difficult airway prediction|
48677403|NCT05006105|DEVICE|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
48677404|NCT05006105|DEVICE|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
48677405|NCT05006105|OTHER|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
48677406|NCT05006105|OTHER|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
48363427|NCT00455780|BEHAVIORAL|Weight Loss Phase|Weight loss using CBT and meal replacements
48363428|NCT00455780|BEHAVIORAL|Continued CBT|Using CBT during weight loss maintenance
48363429|NCT00455780|BEHAVIORAL|reduced energy density education|Additional nutritional learning
48363430|NCT00455780|BEHAVIORAL|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
48151612|NCT00251147|PROCEDURE|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
48151613|NCT00251147|PROCEDURE|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
48151614|NCT04492085|OTHER|Questionnaire survey|A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
48363431|NCT01513460|DRUG|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
48363432|NCT01513460|DRUG|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
48363433|NCT01513460|DRUG|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
48363434|NCT01513460|DRUG|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
48363435|NCT02260609|OTHER|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
48363436|NCT00402662|DRUG|everolimus|
48363437|NCT00402662|DRUG|Imatinib|
48363438|NCT01982942|DRUG|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
48677407|NCT05006105|DEVICE|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
48363439|NCT01982942|DRUG|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
48363440|NCT01388205|BEHAVIORAL|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
48363441|NCT00245726|DEVICE|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
47992703|NCT01983358|DRUG|JPI-289|PARP-1 inhibitor
47992704|NCT01983358|OTHER|Placebo|Placebo
48151615|NCT02316171|BIOLOGICAL|CVA21|CAVATAK is a purified preparation of CVA21
48363442|NCT00245726|DEVICE|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
48363443|NCT00245726|DEVICE|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
48363444|NCT00138892|PROCEDURE|Waiting time (access time to Total joint replacement)|See Detailed Description.
48677408|NCT04743713|OTHER|UWRI-Tr|Questionnaire
48151616|NCT02316171|DRUG|Mitomycin C|Chemotherapy
48151617|NCT00022399|DRUG|celecoxib|400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
48151618|NCT00022399|DRUG|Placebos|Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
48151619|NCT05976828|DRUG|IBRX-042|"* Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"
48151620|NCT05928520|DRUG|Tramadol 5%|Topical tramadol 5%
48151621|NCT05928520|DRUG|Lidocaine 2%|Topical Lidocaine 2%
48363445|NCT05653115|PROCEDURE|Bariatric surgery|Bariatric surgery
48363446|NCT05779501|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution."
48363447|NCT05779501|BEHAVIORAL|Waiting-list|"The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program."
48363448|NCT03975816|DEVICE|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
48363449|NCT05419596|PROCEDURE|Urologic Surgery|Patients undergoing major urologic surgery will be examined with blood samples that will be taken preoperatively and postoperatively. Accordingly several gene variants and proteins will be examined for patients with or without postoperative cognitive dysfunction. These proteins consist of APOE, phosphatidyl-inositol-binding clathrin assembly protein, CR1 - complement receptor 1 , ATP-binding cassette transporter, IL6, Triggering receptor expressed on myeloid cells2 (TREM2).
48677409|NCT03067792|DRUG|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
48677410|NCT03067792|DRUG|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
48677411|NCT00156325|DRUG|Escitalopram (Lexapro)|
48677412|NCT05705479|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
48677413|NCT05705479|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
48151622|NCT04889820|DRUG|Neoadjuvant chemotherapy|In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
48151623|NCT04889820|DRUG|Adjuvant chemotherapy|After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
48151624|NCT04889820|PROCEDURE|Curative resection|After successful SEMS placement, curate resection will be performed for all enrolled patients regardless of neoadjuvant chemotherapy.
48151625|NCT05298709|OTHER|Hyperventilation and CO2 challenge|Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
48363450|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate and vitamin C|28 mg iron; 240 mg vitamin C
48363451|NCT04477018|DIETARY_SUPPLEMENT|Iron bis-glycinate chelate|28 mg iron only
48363452|NCT04477018|DIETARY_SUPPLEMENT|Placebo|Matched placebo
48511232|NCT05972148|OTHER|Digital scanning|Five intraoral scans, one for each arch before the insertion of scanbodies, were obtained. The implant locations were then marked, and the software trimmed a 6mm diameter circular section of the scan from the implant locations to allow the scanbodies to be added. Abutment-level polyetheretherketone (PEEK) scanbodies were hand-tightened onto each implant and not moved for the remainder of the scans. Scanbodies were scanned using a circular scan path, and scanning was finalized.
48511233|NCT05972148|OTHER|Photogrammetry|Rectangular-shaped titanium photogrammetry scanbodies were hand-tightened onto the Implants. Scanbodies were not moved before completing all scans for each arch. A total of five scans of each arch were obtained using a photogrammetry device. Measurements were successfully recorded by turning them green on the computer screen.
48511234|NCT05873933|OTHER|Hemptress Oil|Full ingredient list of the test product: Rubus occidentalis (Black raspberry) seed oil\*, Carica papaya (Papaya) seed oil\*, Bixa orellana (Annatto) seed oil\*, Orbignya oleifera (Babassu) seed oil\*, Borago officinalis (Bourrache) seed oil\*, Daucus carota (Carrot) seed oil\*, Hibiscus sabdariffa (Hibiscus) seed oil\*, Aronia melanocarpa (Chokeberry) seed oil\*, Vaccinium macrocarpon (Cranberry) seed oil\*, Moringa oleifera (Moringa) seed oil\*\*, Persea americana (Avocado) oil\*, Ribes nigrum (Black currant) seed oil\*, Copaifera officinalis (Copaiba) resin\*, Canabis sativa (Hemp) seed oil\*, Moringa peregrina seed oil extract \& Caprylic/Capric Triglyceride\*\* (Moringa peregrina extract), Ascorbyl tetraisopalmitate (Vitamin C), Proprietary full-spectrum blend of Cannabis sativa (Hemp) extract, Silica (Algica), Ergocalciferol (Vitamin D2), Menaquinone (Vitamin K2), Tocopherol (Vitamin E)\* Organic Ingredient\* Wild Crafted/Regenerative\*\*
48511235|NCT04218578|DIAGNOSTIC_TEST|speckle tracking analysis of transthoracic echocardiogram|analysis at workstation with 2D strain-Speckle tracking echocardiography of transthoracic cardiac echo at baseline and one-year follow up examination
48511236|NCT05668585|DRUG|CFT1946|Specified oral dose on specified day
48511237|NCT05668585|DRUG|Trametinib|Specified oral dose on specified day
48511238|NCT05668585|DRUG|Cetuximab|Specified intravenous dose on specified day
48151626|NCT06505382|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous neuromodulation|Percutaneous ultrasound-guided neuromodulation of the saphenous nerve in subjects with patellofemoral pain to assess its positive effects on pain and functionality.
48151627|NCT02363153|OTHER|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
48151628|NCT02183402|DRUG|Digoxin|
48151629|NCT02183402|DRUG|BI 1356|
48151630|NCT06173622|BEHAVIORAL|Fetal Positioning|In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
48151631|NCT05198557|DRUG|Inebilizumab|Participants will receive IV inebilizumab.
48151632|NCT05198557|DRUG|Placebo|Participants will receive IV placebo matched to inebilizumab.
48151633|NCT05111340|BEHAVIORAL|Perioperative score|Creation and validation of a perioperative walk score. The patient has to answer different items.
48151634|NCT04113187|DRUG|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
48151635|NCT04113187|DRUG|Placebo|per os, twice a day (morning and evening) during three months
48511239|NCT04803305|DRUG|PF-06946860|subcutaneous injection
48151636|NCT06096727|BEHAVIORAL|Energize!|Energize! is 3 month online physical activity program which consists of weekly physical activity goals, video lessons, action planning, and homework.
48151637|NCT05817292|DIETARY_SUPPLEMENT|Probiotics|Assumption of commercial probiotics
48151638|NCT05817292|OTHER|No intervention|No assumption of probiotics
48151639|NCT03657745|DEVICE|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
48151640|NCT00438048|PROCEDURE|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
48151641|NCT00438048|DRUG|Artificial Saliva|5ml 3 times daily
48151642|NCT01508117|DRUG|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
48151643|NCT01508117|RADIATION|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
48363453|NCT04313660|DRUG|Anlotinib In Combination With PD-1/L1 Inhibitor|"At the end of chest radiotherapy (c2d1), the simultaneous administration of androtinib hydrochloride capsule and PD-1 / L1 inhibitor was started. L~Arotinib hydrochloride capsule, 12 mg, Po, QD, was taken orally for two weeks, one week, three weeks as a cycle, completed in the first 14 days until the disease progress;~Durvalumab injection, 1500mg, IV, once every three weeks, completed on the first day until the disease progresses.~Tetraprizumab injection, 240mg, IV, once every three weeks, completed on the first day until the disease progresses.~The choice of durvalumab / trepril mAb was at the discretion of the researchers."
48151644|NCT03563989|DEVICE|Implantation of Stent (PCI)|Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
48151645|NCT03398902|BEHAVIORAL|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
48151646|NCT03398902|OTHER|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
48151647|NCT00010959|DRUG|Cimicifuga racemosa|
48151648|NCT00010959|DRUG|Trifolium pratense|
48151649|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
48677414|NCT03071861|DRUG|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
48677415|NCT03071861|DRUG|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
48677416|NCT02669589|DRUG|Heparin|
48151650|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
48151651|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
48151652|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
48151653|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
48151654|NCT04553627|DEVICE|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
48151655|NCT06280599|BEHAVIORAL|Transitional care model|In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
48151656|NCT03616522|OTHER|a novel mobile phone-based intervention for automated electronic PRO collection|Over the three-month study period, patients will be prompted weekly via text message to self-report up to eleven common symptoms, as well as their performance status and quality of life.
48151657|NCT03701022|DRUG|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
48151658|NCT00513123|PROCEDURE|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
48151659|NCT03039322|DIAGNOSTIC_TEST|Serum Golgi Protein 73|Serum test
48151660|NCT02092909|DRUG|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
48151661|NCT04520620|DRUG|Lovenox 40 MG in 0.4 mL Prefilled Syringe|"Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours"
48151662|NCT04520620|DEVICE|Ultrasound of the lower limbs|A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
48151663|NCT06585163|DRUG|Hydrocodone Bitartrate|Hydrocodone bitartrate oral suspension
48151664|NCT06585163|DRUG|Doxapram Hydrochloride|Doxapram hydrocholoride oral suspension
48151665|NCT05656937|PROCEDURE|internal jugular venous cannulation|internal jugular venous cannulation
48363454|NCT01244971|DRUG|Acarbose|100mg, 3 times daily
48363455|NCT01244971|BEHAVIORAL|Exercise|Moderate combined exercise, 50 minutes 3 times per week
48363456|NCT01244971|OTHER|Exercise + Acarbose|See respective monotherapy description
48511240|NCT04803305|DRUG|Placebo for PF-06946860|subcutaneous injection
48511241|NCT04839484|DEVICE|Study Product|up to 2cc per injection of filler placed into nasolabial fold.
48511242|NCT04839484|DEVICE|Active Control|up to 2cc per injection of filler placed into nasolabial fold.
48511243|NCT00375895|DRUG|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
48511244|NCT05990985|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
48511245|NCT05990985|DRUG|RiTUXimab Injection|RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.
48511246|NCT05990985|DRUG|Cyclophosphamid|Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
48511247|NCT05990985|DRUG|Vincristine|Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
48511248|NCT05990985|DRUG|Prednisolone|Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
48511249|NCT04445597|OTHER|Sampling of tissue|In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed
48677417|NCT02669589|DRUG|Citrate|
48677418|NCT01220102|DRUG|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
48677419|NCT00270127|DRUG|Epoetin alfa|
48677420|NCT06286332|OTHER|Music Therapy|30 minutes of self-selected music playback every day.
48677421|NCT03734822|OTHER|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
48677422|NCT03734822|DEVICE|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
47992705|NCT05257811|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device includes custom-fit earbuds with biometric sensors to detect EEG, motion (via tri-axial accelerometers), and heart rate. A ring laser scanner is used to capture the unique geometry of each participant's ear and external auditory canal. Digital models of the individual ear scans are generated and used to create custom fit, 3D-printed earbuds. This design process allows for consistent contact with the inner surface of the ear canal, providing high quality signal capture of brain activity, cardiac activity, and eye movements.
47992706|NCT00002384|DRUG|Cidofovir|
47992707|NCT05711225|BEHAVIORAL|smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse.|Smoking cessation videos prepared according to the Web-Based Transtheoretic model A module was created on the web, with 5 sections, prepared by the researcher according to the Web-Based Transtheoretic model, for quitting smoking or for pregnant women who quit smoking to maintain this behavior. The modules are prepared in the form of animated videos in which the researcher is educational. Each module is arranged for an average of 5-10 minutes. Theoretical information about the content has been added under each video.
48151666|NCT02627586|OTHER|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
48151667|NCT02627586|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
48151668|NCT00801905|DRUG|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
48151669|NCT00801905|OTHER|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
48151670|NCT05614141|DEVICE|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
48677423|NCT03734822|DIAGNOSTIC_TEST|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
48677424|NCT03734822|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
48677425|NCT05949918|BEHAVIORAL|Stage-matched interventions|"The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."
48677426|NCT05288023|DRUG|Azithromycin for Oral Suspension|"Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g).~Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program."
48677427|NCT00476320|PROCEDURE|Magnetic Resonance Imaging|
48677428|NCT00476320|PROCEDURE|Revascularization|
47992708|NCT03413813|DEVICE|Magmaris|Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.
47992709|NCT04300855|DRUG|Sunphenon|The study agent will be administered in divided doses with food, three capsules twice a day (405 mg) for 24 months
47992710|NCT04300855|DRUG|Placebo|Matching placebo
47992711|NCT03684512|BEHAVIORAL|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
47992712|NCT03684512|BEHAVIORAL|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
48151671|NCT05614141|OTHER|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
48677429|NCT00476320|PROCEDURE|Echocardiography with myocardial deformation imaging|
48677430|NCT00205764|DRUG|Melphalan|
48677431|NCT02155101|DRUG|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
48677432|NCT02155101|DRUG|ART with 2 NRTIs plus LPV/r (or ATV/r)|Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
48677433|NCT02494635|OTHER|Laboratory Biomarker Analysis|Biomarker analysis
48677434|NCT03243773|OTHER|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
47992713|NCT03684512|BEHAVIORAL|Facebook Group|Facebook group for parents to provide additional support and education
48151672|NCT05709886|DEVICE|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
48677435|NCT02789462|PROCEDURE|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
48677436|NCT01079325|DRUG|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
48677437|NCT01079325|OTHER|Saline|
48677438|NCT02343848|DEVICE|smart bracelet.|Physical activity will be evaluated using smart bracelet.
48677439|NCT04069312|DRUG|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
48677440|NCT04069312|DRUG|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
48151673|NCT00880724|DEVICE|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
48151674|NCT02182245|DRUG|BIBF 1120|
48151675|NCT02182245|DRUG|Paclitaxel|
48151676|NCT02182245|DRUG|Carboplatin|
48151677|NCT00001806|OTHER|Genetic Education and Counseling|Group Education and Counseling
48151678|NCT00001806|OTHER|Genetic Education and Counseling|Individual Education and Counlseing
48151679|NCT04800263|DRUG|SHR-1905|SHR-1905 will be injected subcutaneously
48151680|NCT04800263|DRUG|Placebo|Placebo will be injected subcutaneously
48151681|NCT05319756|DRUG|gabapentin 600 mg|Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
48151682|NCT05319756|DRUG|gabapentin 1200 mg|Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
48511250|NCT06206629|DIAGNOSTIC_TEST|blink reflex evaluation|A blink reflex evaluation will be performed in all subjects
48677441|NCT04319250|OTHER|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
48677442|NCT04319250|OTHER|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
47992714|NCT02494427|DEVICE|CAD/CAM manufactured fixed unitary dental prostheses|
47992715|NCT02494427|DEVICE|Conventionally manufactured unitary dental prostheses|
47992716|NCT01379742|DEVICE|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
47992717|NCT01379742|DEVICE|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
47992718|NCT06240156|OTHER|3D arch pad design Insole group|3D three-dimensional design that is already available on the market (patent number I315187). Its arch support principle is designed using 3DBS (Three-Dimensional Biomechanics System - 3DBS), which can conform to the user's feet.
48511251|NCT05567185|DRUG|Erdafitinib Intravesical Delivery System|Erdafitinib intravesical delivery system will be administered.
48511252|NCT00122759|DRUG|ketamine|
47992719|NCT06240156|OTHER|flat Insole group|General Insole without any special features
47992720|NCT06279689|OTHER|Ultrasound scans|Ultrasound scans connected with an application enabling the measurement of the force applied.
47992721|NCT03371628|DEVICE|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
48151683|NCT05319756|DRUG|gabapentin 600 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
48151684|NCT05319756|DRUG|gabapentin 1200 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
48151685|NCT05319756|DRUG|oxycodone HCl 20 mg|Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
48151686|NCT05319756|DRUG|placebo|Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
48151687|NCT04783389|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
48363457|NCT06089226|OTHER|Assessment Group|In our prospectively planned study, patients who meet the inclusion criteria will be evaluated by the researcher via face-to-face interview method and the evaluations specified in the outcome measurements. Patients participating in the study will first be given a general explanation about the purpose of the study and evaluation methods, and their written consent will be obtained.
48363458|NCT04436042|DEVICE|MyHand Device|These subjects may be asked to attend 1-40 sessions (approximately 90 mins) to trial a variety of device controls and/or components.
48363459|NCT02063932|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
48363460|NCT02667262|OTHER|Algorithm to identify patients experiencing opioid abuse/addiction|
47992722|NCT00946712|BIOLOGICAL|Bevacizumab|Given IV
48363461|NCT00469443|DRUG|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
48511253|NCT00589927|DRUG|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
48511254|NCT00589927|DRUG|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
48511255|NCT04588025|DEVICE|Point-of-care Portable Perfusion Phantom, P4|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
47992723|NCT00946712|DRUG|Carboplatin|Given IV
47992724|NCT00946712|BIOLOGICAL|Cetuximab|Given IV
47992725|NCT00946712|OTHER|Laboratory Biomarker Analysis|Correlative studies
47992726|NCT00946712|DRUG|Paclitaxel|Given IV
47992727|NCT03911414|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
47992728|NCT03911414|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
48151688|NCT04783389|DRUG|Placebo|Placebo subcutaneous (SC) injection.
48151689|NCT00986661|DRUG|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
48151690|NCT04760028|PROCEDURE|Adjusting the depth of anesthesia|After the main procedure, the depth of anesthesia can be adjusted as needed
48151691|NCT06197035|PROCEDURE|Coping With and Caring for Infants With Special Needs|The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
48151692|NCT06197035|PROCEDURE|Standard Physiotherapy|Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
48151693|NCT02301299|BEHAVIORAL|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
48151694|NCT03723902|OTHER|Heavy-load strength training|Three weekly sessions of heavy-load strength training for 10 weeks
48151695|NCT03723902|DIETARY_SUPPLEMENT|Protein supplementation|Daily supplementation of 2 x 17 grams of milk protein
48151696|NCT05843526|DEVICE|Experimental healing abutment|"Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment"
48151697|NCT05121376|GENETIC|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
48151698|NCT05121376|GENETIC|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
48151699|NCT05121376|GENETIC|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
48151700|NCT05121376|GENETIC|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
48511256|NCT03270878|DRUG|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
47992729|NCT04025658|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
47992730|NCT00668941|DRUG|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
47992731|NCT00668941|DRUG|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
48151701|NCT05121376|GENETIC|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
48151702|NCT05121376|GENETIC|Dose 6 of BMN 331|BMN 331 AAV Gene Therapy
48151703|NCT05121376|GENETIC|Dose 7 of BMN 331|BMN 331 AAV Gene Therapy
48151704|NCT02256553|BIOLOGICAL|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
48511257|NCT03270878|DRUG|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
48511258|NCT04800679|DRUG|receive 4 monthly IVB injections and then rescue IVB|IVB group that receive 4 monthly IVB injections and then rescue IVB
48511259|NCT04800679|DRUG|PRP group|PRP group that undergo full PRP in 2 or 3 sessions and then rescue IVB
47992732|NCT00668941|DIETARY_SUPPLEMENT|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
47992733|NCT00668941|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
47992734|NCT03698474|DRUG|Natrium picosulfate / Magnesium citrate|bowel preparation formula
47992735|NCT03698474|DRUG|Polyethylene glycol / Ascorbic acid|bowel preparation formula
48511260|NCT04800679|DRUG|IVB injections and a modified laser|Combination group that receive 2 bimonthly IVB injections and a modified laser (1 session anterior to the equator) and then rescue IVB or laser
48511261|NCT01871571|BIOLOGICAL|bevacizumab|Given IV
48511262|NCT01871571|DRUG|oxaliplatin|Given IV
48511263|NCT01871571|DRUG|leucovorin calcium|Given IV
47992736|NCT03698474|DRUG|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
47992737|NCT03134560|DEVICE|Vein Display Instrument|
47992738|NCT04681170|DRUG|Lomitapide|2mg,5mg, 10mg and 20mg capsules
47992739|NCT05132959|DIAGNOSTIC_TEST|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
47992740|NCT00763347|DRUG|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
48151705|NCT02256553|BIOLOGICAL|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
48151706|NCT02256553|DRUG|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
48151707|NCT02574910|DRUG|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
48511264|NCT01871571|DRUG|fluorouracil|Given IV
47992741|NCT00763347|DRUG|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
47992742|NCT00763347|DRUG|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
48151708|NCT04706442|OTHER|Supportive Parenting Application|The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
48151709|NCT01767025|DRUG|Oxytocin|
48151710|NCT01767025|DRUG|Sea water|
48151711|NCT03057197|PROCEDURE|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
48151712|NCT02635698|OTHER|Optifast|medically-supervised weight management program
48151713|NCT02635698|OTHER|Food-Based|low-energy, low-fat diet
48151714|NCT05174871|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
48511265|NCT01871571|OTHER|laboratory biomarker analysis|Correlative studies
48511266|NCT03352258|RADIATION|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
48151715|NCT05174871|BEHAVIORAL|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
48151716|NCT05147207|PROCEDURE|Superpath Approach|This is a minimally invasive surgical approach for THA.
48151717|NCT05967377|DRUG|Sorafenib - Period 1|Sorafenib (Nexavar®) Tablet, 200 mg
48151718|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 1|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
48151719|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 1|XS005 Sorafenib Tablet A, 100 mg
48151720|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 2|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
48151721|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 2|XS005 Sorafenib Tablet A, 100 mg
48151722|NCT05967377|DRUG|Sorafenib - Period 2|Sorafenib (Nexavar®) Tablet, 200 mg
48151723|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 3|XS005 Sorafenib Tablet A, 100 mg
48151724|NCT05967377|DRUG|Sorafenib - Period 3|Sorafenib (Nexavar®) Tablet, 200 mg
48677443|NCT04319250|OTHER|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
48677444|NCT05886153|DEVICE|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
48677445|NCT00537043|DRUG|SK&F-105517 (COREG CR FDC)|
48677446|NCT02491177|BEHAVIORAL|cMM|Home visits from community mentor mothers
48677447|NCT02491177|BEHAVIORAL|Text Messaging|Text messages received on mobile phone
48677448|NCT01563900|DEVICE|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
48677449|NCT01563900|DEVICE|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
47992743|NCT00763347|DRUG|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
48151725|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 3|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
48151726|NCT04733417|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
48151727|NCT04733417|DRUG|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
48151728|NCT03345199|OTHER|Inspiratory Muscle Trainer (IMT)|During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
48151729|NCT00038376|DRUG|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
48151730|NCT00038376|DRUG|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
48151731|NCT04460937|DRUG|Adavosertib|Given PO
48151732|NCT04460937|RADIATION|Radiation Therapy|Undergo radiation therapy
48151733|NCT04155372|PROCEDURE|Different Fluid Ingestion Rate|The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
48151734|NCT00378456|DRUG|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
48151735|NCT00378456|DRUG|Folinic acid|
48151736|NCT00378456|DRUG|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
48677450|NCT03725956|PROCEDURE|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
48677451|NCT01951898|DRUG|Montelukast|10mg/day, once a daily after dinner, for 28dyas
47992744|NCT00763347|DRUG|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
47992745|NCT00763347|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
48677452|NCT03962959|DEVICE|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
48677453|NCT03618667|DRUG|GC1118|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
48677454|NCT01842373|DRUG|LMX4|
48677455|NCT01842373|DRUG|BLT|
47992746|NCT00114465|DRUG|VSL#3|VSL#3 1 sachet twice a day
47992747|NCT00114465|OTHER|Placebo|Placebo 1 sachel twice a day
48151737|NCT00378456|DRUG|Placebo|
48151738|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
48151739|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
48151740|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
48151741|NCT01291524|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
48151742|NCT03747575|DRUG|MSTT1041A|Participants will receive subcutaneous (SC) MSTT1041A
48151743|NCT03747575|DRUG|Placebo|Participants will receive SC placebo
48151744|NCT02935894|DRUG|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
48151745|NCT02935894|OTHER|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
48151746|NCT02935894|DRUG|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
48151747|NCT00990132|DEVICE|Home mechanical ventilation|Nocturnal non-invasive ventilation
48151748|NCT00990132|DEVICE|Long term oxygen therapy|LTOT established as per national guidelines
48677456|NCT02132572|DEVICE|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
48677457|NCT02819531|DEVICE|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
48677458|NCT02819531|DEVICE|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
48677459|NCT02819531|DEVICE|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
48677460|NCT04530305|DRUG|Upadacitinib <15 MG [Rinvoq]|Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
48677461|NCT04244240|BEHAVIORAL|BEARNI Tool|"BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available."
48677462|NCT04912544|DEVICE|Noninvasive Ventilation Mask Microphone|Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
48677463|NCT01761708|PROCEDURE|primary ventral hernia repair with mesh|
48677464|NCT05731271|DRUG|TST003|IV humanized anti-GREM1 monoclonal antibody
47992748|NCT01733446|OTHER|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
47992749|NCT01108133|DRUG|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
48677465|NCT06259318|BEHAVIORAL|Kanasina Gulabi|Kanasina Gulabi is a theory-driven, educational-behavioral intervention designed to improve the quality of life and diabetes management among young adults living with type 2 diabetes in Mysore district, South India. In this intervention, young adults with type 2 diabetes were matched to non-specialist peer navigators -- trained young adult peers who were also managing type 2 diabetes -- and developed action plans to improve their physical and mental health outcomes. Intervention components included group education, mindfulness activities, self care activity tracking, and phone follow-ups to address knowledge gaps and misinformation about type 2 diabetes, build self-efficacy for type 2 diabetes-related self care activities, and provide emotional support for diabetes management.
48677466|NCT03345446|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
48677467|NCT02270281|DRUG|Dexmedetomidine 0.7 Mcg/kg/h|CIF 0.7mcg/kg/h
48677468|NCT02607124|DRUG|Ribociclib|
48677469|NCT01337193|OTHER|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
48677470|NCT01337193|OTHER|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
47992750|NCT01108133|DRUG|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
47992751|NCT01108133|DRUG|Placebo|Placebo
47992752|NCT01763424|DRUG|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
47992753|NCT01763424|DRUG|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
48363462|NCT00469443|DRUG|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
48677471|NCT03211819|PROCEDURE|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
48677472|NCT00618007|DRUG|PF-00734200 30 mg QD|30 mg QD
48677473|NCT00618007|DRUG|PF-00734200 20 mg QD|20 mg QD
48677474|NCT00618007|DRUG|Placebo|Placebo
48677475|NCT05495880|PROCEDURE|Laryngoscopy with forearm-support|forearm-supported head extension during direct laryngoscopy
48677476|NCT05495880|PROCEDURE|Laryngoscopy without forearm-support|without forearm-support for head extension during direct laryngoscopy
48677477|NCT05223998|PROCEDURE|Full-thickness skin microcolumns implantation|Surgical harvest and implantation of FTSM on an open wound requiring coverage.
48151749|NCT06479499|OTHER|Pilates Exercises|Group A will undergo Pilates exercise training, scheduled three times weekly over an 8-week period, for elderly individuals with COPD the duration and time interval time for Pilates exercise can vary depending on their overall health, fitness level, and tolerance. It begins with warm-up with 10-15 minutes which may include gentle stretches and deep breathing Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The exercise sessions lasting around 10-15 minutes and then gradually progressing to 20-30 minutes as the participants become more comfortable and their endurance improves. Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The rest interval will be 1-2 minutes between exercise and then gradually reducing it to 30 seconds or less. Pilates session ends with a cool-down which may involve stretching and relaxation with duration of about 5-10 minutes.
48677478|NCT00102986|DRUG|Lopinavir/ritonavir|
48151750|NCT06479499|OTHER|Aerobic Exercises|Group B will engage in Aerobic exercise plan, following the same frequency and duration as the Pilates exercise program-three sessions per week for 8 weeks, It begins with a warm-up of 5-10 minutes to prepare body for exercise it includes gentle movements, stretching, or a few minutes of low-intensity aerobic activity. It includes main exercise with moderate intensity like brisk walking or jogging with duration of 5-10 minutes and increase to 20-30 minutes as participants improves their endurance. The short interval begins with 1-2 minutes than gradually reducing it to 30 seconds or less as a person builds up stamina and fitness. The cool-down duration at end of exercise will be 5-10 minutes.
48151751|NCT02467673|DRUG|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
48151752|NCT02467673|DRUG|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
48151753|NCT06049719|OTHER|NIH Task Force's Recommended Multidimensional Minimal Dataset|Questionnaire
48151754|NCT03161509|DRUG|Paracetamol|single dose of 1 gr paracetamol
48677479|NCT03770858|DRUG|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
47992754|NCT06451042|DIAGNOSTIC_TEST|FET-PET/MRI|Radiation planning target volume (PTV) when planned with FET-PET/MRI to PTV when planned with conventional (Standard of Care) MRI only. 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) 180-200 megabecquerel (MBq) administered intravenously prior to PET/MRI imaging.
47992755|NCT00279890|DRUG|Topical SR-01|
47992756|NCT05947682|OTHER|Adipose tissue harvesting|Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
47992757|NCT03559153|OTHER|Shiatsu massage|The shiatsu massage will be during the rest break by 15 minutes.
47992758|NCT03559153|OTHER|Physical Exercise|The Physical Exercise will be during the rest break by 15 minutes.
47992759|NCT06446765|BEHAVIORAL|mindfulness-based Neurofeedback|Participants will complete one session of mindfulness-based fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
48151755|NCT03161509|DRUG|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
48151756|NCT00993434|BEHAVIORAL|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
48151757|NCT00993434|BEHAVIORAL|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
48151758|NCT01005563|OTHER|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
48151759|NCT01005563|OTHER|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
48151760|NCT00042939|BIOLOGICAL|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
48151761|NCT00042939|DRUG|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
48363463|NCT00469443|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
48677480|NCT03770858|DEVICE|Scratch sensor|advanced, flexible and wearable skin sensor
48677481|NCT01603043|DRUG|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
48677482|NCT01603043|DRUG|Sham injection|Mock injection administered as an empty hub without needle
48677483|NCT01479764|DRUG|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
48677484|NCT01479764|DRUG|Neostigmine|neostigmine, per usual practice
48677485|NCT01479764|DRUG|Glycopyrrolate|glycopyrrolate per usual practice
48677486|NCT02214901|DRUG|BIBW 2948 BS for oral inhalation|
48677487|NCT02214901|DRUG|Placebo|
47992760|NCT06446765|OTHER|control Neurofeedback|Participants will complete one session of control fMRI neurofeedback prior to 20 weeks of remote online weekly DBT skills group.
47992761|NCT04049851|DRUG|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
47992762|NCT04049851|DRUG|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
47992763|NCT04049851|DRUG|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
47992764|NCT05747729|DRUG|Surufatinib and Serplulimab|"Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks."
47992765|NCT02601742|OTHER|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
47992766|NCT02601742|OTHER|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
48677488|NCT05922345|DRUG|TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules|"AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1)."
48677489|NCT05922345|DRUG|TQB2450 matching placebo, docetaxel injection, AL2846 matching placebo|Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
48363464|NCT00469443|DRUG|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
48363465|NCT00469443|DRUG|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
48677490|NCT01163396|DRUG|Bevacizumab|
48677491|NCT01163396|DRUG|Irinotecan|
48677492|NCT01163396|DRUG|Oxaliplatin|
48677493|NCT01163396|DRUG|5-fluorouracil/leucovorin|
48677494|NCT02990975|DRUG|ketamine|
48677495|NCT05644717|DRUG|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
48677496|NCT02569567|PROCEDURE|Smart-Shear Wave(SSW) imaging|"1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
47992767|NCT03297385|DRUG|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
48363466|NCT00469443|DRUG|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
48363467|NCT00469443|DRUG|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
48363468|NCT01520727|DRUG|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
48363469|NCT01520727|DRUG|Placebo|single-dose
48677497|NCT02569567|PROCEDURE|Transient elastography(TE)|"1. Using the M probe in patients with BMI \<30 kg/m2.~2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
48677498|NCT00399074|DRUG|sulfadoxine pyrimethamine|Monthly SP
48363470|NCT00187148|BIOLOGICAL|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
48363471|NCT01503528|PROCEDURE|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
48363472|NCT01503528|PROCEDURE|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
48677499|NCT03234647|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
47992768|NCT00149487|BEHAVIORAL|Tailored Problem Solving Intervention|
47992769|NCT00149487|BEHAVIORAL|Family Education Intervention|
47992770|NCT00837655|DRUG|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of \<1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of \<1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
48363473|NCT06154044|BIOLOGICAL|CD34+ stem cell therapy|After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
48363474|NCT04736966|DRUG|Guselkumab 30mg|30mg of Guselkumab administered by subcutaneous injection
48363475|NCT04736966|DRUG|Guselkumab 70mg|70mg of Guselkumab administered by subcutaneous injection
48363476|NCT04736966|DRUG|Guselkumab 100mg|100mg of Guselkumab administered by subcutaneous injection
48363477|NCT06212349|OTHER|therapeutic-educational physiotherapy and pain education program|The EG will carry out a total of 24 sessions, at a rate of 3 weekly sessions of 30 minutes each. The first session of each month will be in person and the rest will be done at home following video tutorials with an App (https://fisiotrack.com). The face-to-face sessions will be conducted by a women's health physiotherapist, and will consist on therapeutic exercises based on body awareness, motor control and respiratory awareness.They will also receive a pain education program with indications on pain education, as well as basic information and general advice on the positive effects of physical activity and a healthy lifestyle for endometriosis. In addition, biweekly supervision will be carried out via telephone or video conference by a specialized physiotherapist.
48363478|NCT06212349|OTHER|pain education program|They will receive instructions on pain education, as well as basic information and general advice about the positive effects of physical activity and a healthy lifestyle for your endometriosis, in writing via email. In addition, they will receive biweekly supervision via telephone or video conference by a specialized physical therapist.
48677500|NCT03202212|PROCEDURE|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
48677501|NCT03202212|PROCEDURE|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
48677502|NCT05743374|OTHER|Normal diet|These patients will be given advice about a normal healthy diet.
48677503|NCT05743374|DIETARY_SUPPLEMENT|E400 elimination|Patients in the intervention group will be given advice how to eliminate E440 additives with regard to carragenan, CMC and polysorbates.
48677504|NCT01484496|BIOLOGICAL|Placebo|Placebo
48677505|NCT01484496|BIOLOGICAL|Belimumab 200 mg SC|Belimumab 200 mg SC
47992771|NCT00837655|DRUG|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration \<1.8 mmol/l.
47992772|NCT00862810|BIOLOGICAL|Received HPV vaccine first|
47992773|NCT00862810|BIOLOGICAL|Received concomitant vaccines first|
47992774|NCT00945139|DRUG|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
48151762|NCT00042939|DRUG|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
48151763|NCT03927963|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
48151764|NCT03927963|DRUG|Propofol|Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
48151765|NCT05681390|DRUG|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
48151766|NCT05881213|DRUG|CKD-378 (low-dose)|Quaque day (QD), PO
48151767|NCT01150305|BIOLOGICAL|blood sample|Peripheral whole blood sample, 5 ml
48151768|NCT01085253|OTHER|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
48151769|NCT06602206|OTHER|Conventional Treatment|Hot pack,TENS, ultrasound and exercises
48151770|NCT06602206|OTHER|shoulder mobilization|In the glenohumeral joint mobilization technique, distraction, anterior-posterior gliding, and inferior gliding movements will be applied.
48677506|NCT01484496|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
48677507|NCT05363488|DRUG|Bosutinib|Patients receiving bosutinib treatment
48151771|NCT06602206|OTHER|neck mobilization|Bridge, lateral flexion movement combined with traction, anterior-posterior gliding with traction, and lateral gliding techniques will be applied in neck mobilization.
48677508|NCT06538662|DRUG|FID 123320 Ophthalmic Solution|Investigational sterile aqueous solution
48677509|NCT06538662|DRUG|Vehicle|FID 123320 Ophthalmic Solution inactive ingredients
48677510|NCT00977483|DRUG|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
48677511|NCT00977483|DRUG|Placebo|1 tablet once daily 4 years double-blind treatment period
47992775|NCT00945139|DRUG|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
47992776|NCT01980355|DRUG|Tranexamic Acid|
47992777|NCT01980355|OTHER|Placebo|
47992778|NCT04640090|BEHAVIORAL|Smartphone app (Wysa)|The commercially available smartphone application, Wysa, offers evidence-based wellness tools such as supportive listening, deep breathing techniques, guided meditation, yoga, and more. Users can communicate via text to a virtual artificial intelligence (AI) chatbot and/or a human well-being coach.
48151772|NCT02697136|DRUG|CER-001|Recombinant human apoA-I/phospholipid complexes
48151773|NCT02697136|DRUG|Placebo|0.9% Sodium Chloride Injection, USP
48151774|NCT05745259|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
48151775|NCT05745259|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
48151776|NCT05867992|OTHER|Type of trauma|Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
48151777|NCT01484015|DRUG|cefepime hydrochloride|Given IV
48151778|NCT05779254|DRUG|Neomycin Sulfate|Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
48151779|NCT03596775|DRUG|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
48363479|NCT01711190|PROCEDURE|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
48363480|NCT02813681|PROCEDURE|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
48677512|NCT01110057|DRUG|Placebo|Placebo to match GW856553
48677513|NCT01110057|DRUG|GS856553|GW586553 7.5mg bid
48677514|NCT01294852|OTHER|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).
48677515|NCT02354261|DRUG|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
47992779|NCT05624437|OTHER|data record|data record
47992780|NCT05338892|OTHER|Non-Interventional|No study treatment will be administered on this study.
48151780|NCT03596775|DRUG|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
48151781|NCT03471637|OTHER|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]"
48151782|NCT05206916|PROCEDURE|cryotherapy|Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
48151783|NCT01365546|BIOLOGICAL|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
48677516|NCT04469205|OTHER|Coaching sessions|There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
48151784|NCT02548585|DRUG|MEDI0382|MEDI0382 administered subcutaneously.
48151785|NCT02548585|DRUG|Placebo|Placebo administered subcutaneously.
48151786|NCT02771561|PROCEDURE|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
48151787|NCT01195402|PROCEDURE|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
48151788|NCT01491100|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
48151789|NCT02649725|BEHAVIORAL|patient's satisfaction|Questionnaire based measurement.
48151790|NCT04301947|OTHER|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
48151791|NCT04301947|OTHER|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
48363481|NCT02813681|PROCEDURE|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
48363482|NCT02813681|PROCEDURE|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
48151792|NCT05500872|OTHER|Cross-education and blood flow restriction training|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
48151793|NCT05500872|OTHER|Cross-education|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
48151794|NCT01355692|DEVICE|Nd: YLF laser treatment|grid selective retinal treatment
48151795|NCT05362279|OTHER|Training|"One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training."
48151796|NCT04566120|DRUG|cinnamon extract mouthwash|cinnamon extract mouthwash
48151797|NCT04566120|DRUG|chlorohexidine based mouthwash|chlorohexidine based mouthwash
48151798|NCT00796575|DRUG|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
48363483|NCT06337656|DEVICE|Galileo WBV|Side-Alternating Whole-Body Vibration Training
48363484|NCT05007912|PROCEDURE|Esophagojejunostomy type|Use of either circular or linear stapler
48363485|NCT00281359|DEVICE|With heat|heat pad followed by dynamic splinting
48363486|NCT00281359|DEVICE|No heat|No heat added to tissue prior to dynamic splinting
48363487|NCT04144257|DRUG|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
48363488|NCT04144257|DRUG|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
48363489|NCT02334813|DRUG|Prednisone|Continuous daily therapy
48677517|NCT04345484|BEHAVIORAL|Goal-management training|9-week goal-management program
48677518|NCT04345484|BEHAVIORAL|Control|Healthy Lifestyle Program
47992781|NCT05387733|DRUG|10 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (2 mL each); total of 10 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (2 mL each); total of 20 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (2 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (2 mL each); total of 50 mg CBL-514."
48151799|NCT00796575|DRUG|placebo tablets|placebo tablets matching active
48677519|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
48677520|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
48677521|NCT00777595|DRUG|Placebo|Inhaled solution, single dose of placebo
48677522|NCT00777595|DRUG|Moxifloxacin|Tablet, oral, 400mg, single dose
48677523|NCT00429143|RADIATION|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
48151800|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
48151801|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
48151802|NCT01699178|DRUG|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
48151803|NCT01699178|DRUG|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
48151804|NCT03726502|PROCEDURE|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
48151805|NCT03726502|PROCEDURE|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
48151806|NCT03726502|PROCEDURE|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
48151807|NCT03726502|PROCEDURE|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
48677524|NCT00429143|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
48677525|NCT00429143|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
48677526|NCT00429143|DRUG|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
48677527|NCT00429143|DRUG|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
48151808|NCT05423171|OTHER|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
48151809|NCT00731913|OTHER|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
48151810|NCT05689177|BIOLOGICAL|Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)|Booster dose administration
48151811|NCT03019809|BIOLOGICAL|G-CSF for Conditioning before HSCT.|Mobilization of hematopoietic stem (HSC) into circulation
48151812|NCT03019809|BIOLOGICAL|Plerixafor for Conditioning before HSCT.|Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
48363490|NCT02334813|DRUG|Dexamethasone|4-day pulses every 3 weeks
48363491|NCT04657302|DRUG|Obinutuzumab|Participants will receive 1000 mg of intravenous (IV) obinutuzumab on Cycle 1 Day 1.
48363492|NCT04657302|DRUG|Glofitamab|Participants will receive 2.5 mg of IV glofitamab Cycle 1 Day 8, 10 mg at Cycle 1 Day 15, and 30 mg on Day 1 of Cycles 2-12 Q3W (cycle length = 21 days).
48363493|NCT04657302|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
48677528|NCT00429143|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
48677529|NCT03957863|BIOLOGICAL|Plasma collection for EPO assay|Plasma collection for EPO assay
48677530|NCT03569358|DEVICE|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
48677531|NCT03569358|DEVICE|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
48677532|NCT03510130|OTHER|Routine leg movement|Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
48677533|NCT01603225|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
48677534|NCT00803595|DRUG|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
48677535|NCT00803595|DRUG|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
48677536|NCT00803595|DRUG|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
48677537|NCT04013776|DIETARY_SUPPLEMENT|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
48677538|NCT01658085|DEVICE|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
48677539|NCT01658085|DEVICE|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
48677540|NCT04983771|DEVICE|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
48677541|NCT02722213|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
48677542|NCT01828840|DRUG|epidural morphine via PCEA|
48677543|NCT01828840|DRUG|epidural fentanyl via PCEA|
48677544|NCT01828840|DRUG|epidural methadone via PCEA|
48677545|NCT01828840|DRUG|intravenous morphine via PCA|
48677546|NCT02067143|DRUG|Prephase PDN + CY|
48151813|NCT03567356|OTHER|"MAT-PLUS Helping Hands"|"1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
48677547|NCT02067143|DRUG|Cycle 1 Induction|
48677548|NCT02067143|DRUG|Cycle 2 Induction / Early consolidation|
48677549|NCT02067143|DRUG|Cycle 3 Early consolidation|
48677550|NCT02067143|DRUG|Cycle 4 Consolidation|
48677551|NCT02067143|DRUG|Cycle 5 Consolidation|
48677552|NCT02067143|DRUG|Cycle 6 Consolidation|
48677553|NCT02067143|DRUG|Cycle 7 Consolidation|
48677554|NCT02067143|DRUG|Cycle 8 Reinduction|
48677555|NCT02067143|DRUG|Maintenance|If MRD negative MRD u/k SR
48677556|NCT02067143|PROCEDURE|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
48677557|NCT03110484|DRUG|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
48677558|NCT03110484|DRUG|Erlotinib|Erlotinib 100mg once daily
48677559|NCT04157699|DRUG|TDF tablet|TDF tablet 300mg QD
48677560|NCT04157699|DRUG|QL-007|QL-007 tablet
48677561|NCT01818843|OTHER|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
48677562|NCT04762836|DRUG|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
48677563|NCT04762836|BEHAVIORAL|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
48677564|NCT04762836|BEHAVIORAL|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
48677565|NCT04762836|OTHER|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
48151814|NCT04065685|OTHER|serious game named Go Wish|"The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences."
48151815|NCT04065685|OTHER|usual care|Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
48151816|NCT03066986|DRUG|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
48151817|NCT03066986|BIOLOGICAL|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely \<20mcg. Therefore minimum effective maintenance dose not yet defined."
48151818|NCT02619578|OTHER|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
48151819|NCT02619578|OTHER|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
48151820|NCT02619578|DRUG|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
48151821|NCT02619578|OTHER|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
48151822|NCT02158845|DRUG|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
48151823|NCT02158845|DRUG|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
48151824|NCT02271841|DEVICE|PVI|Pleth Variability Index
48151825|NCT05082545|DRUG|SHR-2002 and SHR-1316|Cohort study
48151826|NCT02398539|DRUG|Silver Nitrate|Silver Nitrate Sticks
48151827|NCT02398539|DRUG|Triamcinolone|0.5% cream
48511267|NCT02390024|DEVICE|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
48677566|NCT04762836|DRUG|Placebo|Placebo control in oral form
47992782|NCT05387733|DRUG|15 mg CBL-514 per injection|"The total injection volume per lipoma will be based on the lipoma size, as determined by ultrasound. Dosing sceme is presented as below:~Lipoma diameter of ≥1.0cm and ≤2.0cm - 1 injection (3 mL each); total of 15 mg CBL-514.~Lipoma diameter of \>2.0cm and ≤3.5cm - 2 injections (3 mL each); total of 30 mg CBL-514.~Lipoma diameter of \>3.5cm and ≤5.0cm - 3 injections (3 mL each); total of 45 mg CBL-514.~Lipoma diameter of \>5.0cm and ≤6.0cm - 5 injections (3 mL each); total of 75 mg CBL-514."
47992783|NCT00300950|BIOLOGICAL|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
47992784|NCT00300950|DRUG|Gemcitabine|Chemotherapy
47992785|NCT00402961|OTHER|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
47992786|NCT00402961|OTHER|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
47992787|NCT00501293|DRUG|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
47992788|NCT04337983|DEVICE|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
47992789|NCT04337983|DEVICE|Echocardiography|Daily echocardiography evaluation
47992790|NCT03534154|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging
47992791|NCT03534154|DIAGNOSTIC_TEST|Blood Sampling|Sampling of serum
48363494|NCT05290389|OTHER|SMART AMI APPLICATION|"SMART AMI allows real-time sharing and review of patient history and ECG between Emergency Department physicians and Interventional Cardiologists to allow for immediate decision-making regarding the need for percutaneous coronary intervention.~Participant physicians will use a smartphone application to communicate, transmit the ECG, and activate the STEMI team. This application enables calling and transmission of up to three images of ECGs, which can be reviewed immediately by the Interventional Cardiologist when communicating with the referring physician."
48363495|NCT01450566|DRUG|Lidocaine|Use of lidocaine
48363496|NCT01450566|DRUG|Saline|Saline
48151828|NCT06335888|DRUG|AzaFol|AzaFol-PET/CT imaging
48363497|NCT06033495|DEVICE|Coronary sinus reduction stent|Percutaneous stent implantation to reduce the dimension of the coronary sinus
48151829|NCT06335888|DRUG|FDG|FDG-PET/CT imaging
48151830|NCT04366895|OTHER|conventional single implant overdenture|conventional manufactured implant overdenture
48151831|NCT04366895|OTHER|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
48151832|NCT03639649|DIAGNOSTIC_TEST|STHLM3|
48151833|NCT04497818|OTHER|Cross Sectional study using scientifically validated psychometric Scales|Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale \& Modified Dental Anxiety 5 item Likert Scale).
48151834|NCT03615547|DRUG|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
48151835|NCT03615547|OTHER|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
48151836|NCT01280721|DRUG|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
48363498|NCT00694239|BEHAVIORAL|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
48363499|NCT03491501|OTHER|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
48363500|NCT00000799|DRUG|Cidofovir|
48363501|NCT00000799|DRUG|Probenecid|
48363502|NCT05485779|DRUG|AQ280|"Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral"
48363503|NCT05485779|DRUG|Placebo|"Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral"
48363504|NCT01842334|BEHAVIORAL|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
48151837|NCT02303509|DRUG|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
48363505|NCT01842334|DRUG|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
48363506|NCT02612558|DRUG|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
48363507|NCT05013476|COMBINATION_PRODUCT|Butterfly handheld ultrasound machine|Both arms of study will utilize the Butterfly ultrasound machine. Only the virtual learners will utilize zoom for their virtual education
48363508|NCT04454281|DRUG|Naloxone Hydrochloride 0.4 MG/ML|Drug will be topically applied to the corneal surface then study evaluations will ensue.
48363509|NCT02424136|OTHER|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
48363510|NCT02424136|OTHER|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
47992792|NCT03534154|DIAGNOSTIC_TEST|Microdialysis|Monitoring of cerebral fluid protein levels
47992793|NCT03534154|DIAGNOSTIC_TEST|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
48151838|NCT02303509|DRUG|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
48151839|NCT02303509|OTHER|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
48363511|NCT02424136|OTHER|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
48363512|NCT02424136|OTHER|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
48363513|NCT02424136|OTHER|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
48363514|NCT02424136|OTHER|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
48677567|NCT00894777|OTHER|Clinical record review|
47992794|NCT03534154|DIAGNOSTIC_TEST|MRI (advanced)|Advanced MRI
48363515|NCT02424136|OTHER|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
48363516|NCT06300866|DRUG|Test|test toothpaste containing 0.45% stannous fluoride
48677568|NCT04858113|OTHER|Blephaclean|Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
48677569|NCT04858113|OTHER|Baby Shampoo|Conventional baby shampoo
48677570|NCT05576324|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
48151840|NCT02287948|DEVICE|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.~1) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
48151841|NCT02985086|DRUG|Cefoxitin|
48151842|NCT02985086|DRUG|oxytocin/misoprostol|
48151843|NCT03277391|PROCEDURE|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
48151844|NCT03277391|DEVICE|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
48151845|NCT04430153|OTHER|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
48511268|NCT04975191|BEHAVIORAL|Resources|Participants will be provided a list of resources available at VCU that are intended to support student success
48677571|NCT05977218|OTHER|FoodSwitch|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
48677572|NCT02102958|BEHAVIORAL|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
48151846|NCT01821599|OTHER|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
48151847|NCT01821599|OTHER|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
48151848|NCT01245998|DRUG|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
48677573|NCT02102958|BEHAVIORAL|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
48677574|NCT04577911|OTHER|Basic Science Experiment|participants complete cognitive tasks while undergoing functional magnetic resonance imaging (fMRI)
48677575|NCT02820844|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
48677576|NCT02820844|DRUG|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
48677577|NCT02820844|DRUG|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
48151849|NCT01245998|DRUG|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
48363517|NCT06300866|DRUG|Control|toothpaste containing 0.76% sodium monofluorophosphate
48363518|NCT04524507|BIOLOGICAL|High-titer Convalescent COVID-19 Plasma (CCP1)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
48363519|NCT04524507|BIOLOGICAL|Standard-titer Convalescent COVID-19 plasma (CCP2)|At least two units of CCP transfused 4-24 hours apart on Study Day 0. A third unit may be administered, if available.
48511269|NCT04975191|BEHAVIORAL|Personalized Feedback Program (PFP)|Participants will complete an interactive online program that explores their personality-related traits to provide personalized recommendations for success
48511270|NCT04975191|BEHAVIORAL|Substance Use Feedback Program (BMI)|Participants will complete an online program based on brief motivational intervention (BMI) content/principles that explores their current substance use patterns to make personalized recommendations for success
48151850|NCT03095261|BEHAVIORAL|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
48151851|NCT03095261|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
48151852|NCT03095261|BEHAVIORAL|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
48151853|NCT03095261|BEHAVIORAL|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
48151854|NCT03961178|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
48151855|NCT03961178|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
48151856|NCT00742560|BIOLOGICAL|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
48151857|NCT00742560|DRUG|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
48151858|NCT00742560|DRUG|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
48151859|NCT00742560|DRUG|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
48151860|NCT00136851|DRUG|amlodipine besylate/benazepril hydrochloride|
48151861|NCT05511389|OTHER|Anterolateral electrode position|As described previously
48151862|NCT05511389|OTHER|Anteroposterior electrode position|As described previously
48151863|NCT05511389|OTHER|Manual pressure|Manual pressure applied to the anterior electrode
48677578|NCT02820844|OTHER|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
48151864|NCT02255006|DEVICE|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
48151865|NCT02255006|DEVICE|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
48151866|NCT02255006|DRUG|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
48151867|NCT02255006|DRUG|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
48151868|NCT00416442|DRUG|RSV604|
48363520|NCT01822912|OTHER|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
48363521|NCT01822912|OTHER|Heart Failure Usual Care|Subjects will receive standard of care.
48511271|NCT01437488|DRUG|Cabazitaxel|"* Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
48363522|NCT01475227|DRUG|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
48511272|NCT01437488|DRUG|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
48511273|NCT01437488|PROCEDURE|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
48151869|NCT02581826|DRUG|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
48151870|NCT02581826|DRUG|Placebo|No column specified.
48151871|NCT04780906|OTHER|Wrist taping|Wrist taping as used as standard in CrossFit practice
48151872|NCT00447356|DRUG|recombinant interferon alfa|
48151873|NCT03209492|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
48151874|NCT05415722|DRUG|TERN-501|Investigational drug
48151875|NCT05415722|DRUG|TERN-101|Investigational drug
48151876|NCT05415722|OTHER|Placebo|Matching placebo
48151877|NCT05377372|BEHAVIORAL|Breastfeeding support group|community-based breastfeeding support group aimed to increase exclusive breastfeeding success rates among Black women
48151878|NCT05377372|OTHER|Observation|Observe prospectively for breastfeeding initiation, duration and longitudinal health of child with sickle cell disease
48151879|NCT02822092|DRUG|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
48151880|NCT02463292|OTHER|no intervention|no intervention
48151881|NCT03680781|DEVICE|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
47992797|NCT04853342|DRUG|Drug: Furmonertinib 80 mg|The initial dose of Furmonertinib 80 mg once daily
48151882|NCT02896556|DEVICE|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
48151883|NCT03270098|BEHAVIORAL|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
48151884|NCT03270098|BEHAVIORAL|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
47992798|NCT04853342|DRUG|Furmonertinib 80 mg placebo|The initial dose of Furmonertinib 80 mg once daily
48151885|NCT03811743|BEHAVIORAL|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
48151886|NCT03811743|BEHAVIORAL|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
48151887|NCT03811743|BEHAVIORAL|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
48363523|NCT01475227|DRUG|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
48363524|NCT03901742|OTHER|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
48511274|NCT01437488|BIOLOGICAL|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
48363525|NCT03901742|DIETARY_SUPPLEMENT|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
48363526|NCT03901742|OTHER|Standard Enteral Nutrition|Cow's milk based infant formula.
48363527|NCT03878420|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
48363528|NCT03878420|DEVICE|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
48511275|NCT04294628|PROCEDURE|Biopsy|Undergo biopsy
48511276|NCT04294628|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48511277|NCT04294628|PROCEDURE|Computed Tomography|Undergo CT scan
48151888|NCT00253851|DRUG|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
48151889|NCT00903981|DRUG|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
48151890|NCT00903981|DRUG|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
48151891|NCT00903981|DRUG|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
48151892|NCT03344458|DRUG|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
48151893|NCT01368549|OTHER|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
48151894|NCT02992496|DRUG|Ketamine|1mg/kg, 6 applications over 2 weeks
48151895|NCT02992496|DRUG|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
48151896|NCT01285856|OTHER|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling."
48151897|NCT03824743|DRUG|Lactate Ringer|Patients managed with Lactate Ringer and obstetric hemorrhage
48151898|NCT03824743|DRUG|Plasma-lyte|Patients managed with Plasma-Lyte and obstetric hemorrhage
48151899|NCT03183856|DEVICE|Morning walk|a end-effector typed gait robot with a saddle
48151900|NCT03183856|OTHER|no Morning walk|ambulation voluntary or with a help of walker
48151901|NCT00440037|BIOLOGICAL|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
48151902|NCT02765204|DRUG|Dapagliflozin|
48151903|NCT02765204|DRUG|Saxagliptin|
48151904|NCT02765204|DRUG|Glucose|
48151905|NCT02217098|PROCEDURE|GIC Restorations|Restorations using Glass Ionomer Cement
48151906|NCT02217098|PROCEDURE|Carbomer Restorations|Restorations using Glass Carbomer
48151907|NCT02217098|PROCEDURE|Compomer Restorations|Restorations using Compomer
48363537|NCT00146458|PROCEDURE|18F-fluorodeoxyglucose positron emission tomography|
48363538|NCT00180349|DEVICE|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
48363539|NCT00495508|DRUG|Quinine|
48511278|NCT04294628|PROCEDURE|Echocardiography|Undergo ECHO
48511279|NCT04294628|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48511280|NCT04294628|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48151908|NCT02420509|DRUG|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
48151909|NCT03868202|DRUG|Estradiol Transdermal Product|Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
48151910|NCT01039506|DRUG|CPT-11 based regimens|
48363540|NCT00495508|DRUG|artemether / lumefantrine|
48363541|NCT01212666|PROCEDURE|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
48363542|NCT01212666|PROCEDURE|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
48363543|NCT01579383|BIOLOGICAL|ALD403|Single Dose IV infusion on Day 1
48363544|NCT01579383|BIOLOGICAL|ALD403|Single Dose subcutaneous injection on Day 1
48363545|NCT01579383|BIOLOGICAL|Sumatriptan|Single Dose subcutaneous injection on Day 1
48363546|NCT00697424|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
48363547|NCT01485003|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
48151911|NCT03042572|DRUG|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
48151912|NCT03042572|OTHER|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
48151913|NCT00336375|DRUG|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
48151914|NCT03576625|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
48151915|NCT03576625|DIETARY_SUPPLEMENT|Buglossoides Oil|Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
48151916|NCT04463485|PROCEDURE|Delayed Clamping|Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
48151917|NCT02674867|OTHER|Blood draw|
48151918|NCT04086342|DRUG|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
48151919|NCT04086342|DRUG|Placebo|Placebo is a vehicle oil that will match CHI-902.
48151920|NCT02286245|OTHER|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
48151921|NCT02286245|OTHER|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
48363548|NCT01844310|DRUG|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
48363549|NCT01844310|DRUG|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
48511281|NCT04294628|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
48511282|NCT03414684|DRUG|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
48511283|NCT03414684|DRUG|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
48151922|NCT01400945|DRUG|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
48151923|NCT05967793|OTHER|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
48151924|NCT01430299|DEVICE|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
48151925|NCT01430299|DEVICE|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
48151926|NCT05667909|DRUG|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
48151927|NCT03014024|OTHER|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
48151928|NCT03014024|OTHER|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
48151929|NCT05516511|DIAGNOSTIC_TEST|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
48151930|NCT00857909|DRUG|Amiloride|1 tablet twice a day
48151931|NCT00857909|DRUG|Spironolactone|1 tablet twice a day
48511284|NCT04107766|DEVICE|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
48511285|NCT02122692|DRUG|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
48151932|NCT00857909|DRUG|Placebo|Placebo
48151933|NCT00857909|DRUG|Placebo and spironolactone|5mg twice daily
48151934|NCT00857909|DRUG|Spironolactone|25mg twice daily
48151935|NCT03161665|OTHER|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
48151936|NCT05031065|RADIATION|Breast Cancer Radiotherapy|4000-4250 cGy in 15-16 daily fractions
48151937|NCT06185452|DRUG|Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.
48151938|NCT06185452|DRUG|Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
48151939|NCT01961934|DRUG|Sodium Acetate C11 PET/CT Imaging|
48151940|NCT05567848|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day)."
48151941|NCT03395197|DRUG|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
48151942|NCT03395197|DRUG|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
48151943|NCT06584734|OTHER|Not exercise|Patients were withdrawn from the exercise they had previously been doing during their hemodiafiltration sessions.
48151944|NCT06584734|OTHER|Exercise during hemodiafiltration session|Exercise with cycle ergometers during hemodiafiltration session, intensity was measure with power meters in Watts units.
48151945|NCT03145909|DRUG|ABBV-176|Intravenous infusion
48151946|NCT01732757|DRUG|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
48363550|NCT03602521|OTHER|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
48363551|NCT02893332|RADIATION|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
48363552|NCT02893332|DRUG|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
48511286|NCT02122692|DRUG|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
48511287|NCT02122692|DRUG|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
48511288|NCT05195801|DEVICE|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
47992799|NCT06528522|DIAGNOSTIC_TEST|Clinical Measurements and Saliva Sample Collection|"Saliva samples will be collected from all participants, and comprehensive clinical parameters will be meticulously documented. The Plaque Index (PI) and Gingival Index (GI) will be measured at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be recorded in detail for each tooth at six sites. The percentage of bleeding areas will be assessed within 20 seconds post-probing using a binary scoring system to indicate presence or absence. All clinical parameters will be recorded by a calibrated periodontologist utilizing manual probing techniques.~Following collection, saliva samples will be stored at -80°C until subsequent analysis. Concentrations of IL-39, IL-41, IL-1β, and TNF-α in the saliva samples will be quantified using specific enzyme-linked immunosorbent assay (ELISA) kits."
48511289|NCT02656407|DEVICE|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
48511290|NCT01068262|DRUG|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
48511291|NCT01068262|DRUG|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
48511292|NCT05511779|DRUG|Brincidofovir|BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
47992800|NCT06210854|DRUG|pBI-11|HPV16/18 vaccine
48151947|NCT01732757|DRUG|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
48151948|NCT01732757|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
48151949|NCT00004080|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
48151950|NCT00004080|PROCEDURE|conventional surgery|
48151951|NCT04321096|DRUG|Camostat Mesilate|Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2
48151952|NCT04321096|DRUG|Placebo oral tablet|Placebo
48151953|NCT05438745|OTHER|Copenhagen Burnout Inventry|Questionnaire
48151954|NCT02885376|DEVICE|Dentoxol|Mouthrinse
48151955|NCT02885376|DEVICE|Placebo|Mouthrinse
48151956|NCT01077284|DRUG|Febuxostat|Febuxostat capsules
48151957|NCT01077284|DRUG|Allopurinol|Allopurinol capsules
48151958|NCT01077284|DRUG|Placebo|Placebo-matching capsules
48151959|NCT00860509|OTHER|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
48151960|NCT02033915|OTHER|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
48151961|NCT02691884|PROCEDURE|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
48151962|NCT02142218|DRUG|Nivolumab|
48151963|NCT02122484|DRUG|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
48151964|NCT06172777|DIAGNOSTIC_TEST|suspected asthma|enrollment 200 asthma patients
48511293|NCT01639157|DRUG|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
48511294|NCT01639157|DRUG|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
48677579|NCT02820844|OTHER|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
48151965|NCT06172777|DIAGNOSTIC_TEST|suspected COPD|enrollment 200 COPD patients
48151966|NCT06172777|DIAGNOSTIC_TEST|confirmed asthma|enrollment 200 patients
48151967|NCT06172777|DIAGNOSTIC_TEST|confirmed COPD|enrollment 200 patients
48151968|NCT02703519|PROCEDURE|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
48151969|NCT04118998|BEHAVIORAL|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
48151970|NCT04118998|BEHAVIORAL|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
48151971|NCT00950235|BEHAVIORAL|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
48151972|NCT00950235|OTHER|Usual Care|Standard nutrition counseling from Health Plan
47992801|NCT00951665|DRUG|paclitaxel|Intravenous repeating dose
48151973|NCT05601167|DRUG|nirmatrelvir/ritonavir|Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
48151974|NCT05601167|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study
48151975|NCT03943771|OTHER|Anxiety, renal anatomy and surgery questionnaires|"The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file."
48677580|NCT02820844|OTHER|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
47992802|NCT00951665|DRUG|pertuzumab [Perjeta]|Intravenous repeating dose
47992803|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
48151976|NCT04117659|OTHER|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
48151977|NCT02147652|OTHER|Personalized music|
47992804|NCT00951665|DRUG|paclitaxel|Intravenous escalating dose
47992805|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
47992806|NCT02436551|OTHER|Observation|
48151978|NCT00274287|DRUG|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
48151979|NCT02767037|DEVICE|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
48151980|NCT02767037|GENETIC|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
48151981|NCT00959634|DRUG|ABT-126|Dose administered twice daily on Study Days 1-10
48151982|NCT00959634|DRUG|Placebo|Dose administered twice daily on Study Days 1-10
48151983|NCT01417923|DRUG|vitamin D|P.O.4000 units Vit D per day for 6 weeks
48151984|NCT03331978|BEHAVIORAL|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
48151985|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLActive® (hydrophilic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLActive® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
48151986|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLA® (hydrophobic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLA® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
48151987|NCT04727099|DEVICE|PicoWay Laser System|The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
48151988|NCT00711022|DEVICE|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
48151989|NCT05067816|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program (MSLP) is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a southeastern US population and includes support for increased physical activity. To promote healthy dietary intake and increased physical activity, the intervention incorporates theory-based behavioral approaches targeting self-efficacy, self-regulation, and internal motivation. The MSLP is delivered in 4 monthly counseling sessions with 3 interim phone follow-up contacts. A maintenance phase lasting 6 months follows the 4-month MSLP and includes 2 phone contacts about 2 months apart. Participants are counseled individually, with 2 in-person counseling visits (at the 1st and 4th counseling visit) and 5 total phone contacts. Each participant is provided with program materials in a participant manual, a cookbook, and a local resource manual identifying community resources to support making targeted behavior changes.
48151990|NCT04580732|DEVICE|MiniStim PNS|MiniStim PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
48151991|NCT01916447|DRUG|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
47992807|NCT06127992|DEVICE|Cold stimulation tests / critical temperature threshold|ICT was performed following a standard protocol. Briefly, a melting ice cube in thin plastic bag was placed on the volar surface of the patient forearm for 5 min, with macroscopic assessment of the test site 10 min later. TempTest® CSTs were done with TempTest® 4.0 (Courage \& Khazaka, Cologne, Germany), which has a single Peltier element (length: 350 mm, width: 2 mm) that provides a continuous temperature gradient from 4°C to 44°C. The use of TempTest® allows for reproducible and standardized cold (and heat) provocation tests and the identification of CTTs. TempTest® CST results were also assessed 10 min after the end of cold exposure.
48151992|NCT01916447|DRUG|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
48151993|NCT01916447|DRUG|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
47992808|NCT01525043|DRUG|Naproxen|Naproxen 500mg BID for the first 2 weeks
48151994|NCT04774198|DIAGNOSTIC_TEST|blood sample|Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)
48151995|NCT00368823|DEVICE|Electronic point-of-care delivery system|
48151996|NCT01028976|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
48151997|NCT01028976|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
48151998|NCT06242184|PROCEDURE|Group A(Nano-fortified Adhesive)|Nano-fortified dentin adhesive
48151999|NCT06242184|PROCEDURE|Group B(Adhesive without nanoparticles)|Conventional adhesives without nanoparticles
47992809|NCT01525043|DRUG|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
48152000|NCT01773707|DRUG|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
47992810|NCT01525043|DRUG|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
48152001|NCT01773707|DRUG|Placebo|Saline given as 30 minute IV infusion
47992811|NCT01525043|DRUG|Naproxen|500mg bid
47992812|NCT01525043|DRUG|Synera|Topical appication of single patch to elbow for 12hrs/day
47992813|NCT01525043|DRUG|Synera|Single patch applied to elbow for 4hrs/twice daily
47992814|NCT02227342|BIOLOGICAL|Fecal Microbiota Transplant|serial FMT
48152002|NCT03370094|DIAGNOSTIC_TEST|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
48152003|NCT06584877|OTHER|sample collection|Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).
48152004|NCT06584877|OTHER|Seeking consent and assent|Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
48152005|NCT04258306|DIETARY_SUPPLEMENT|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
47992815|NCT03897179|DEVICE|INVSENSOR00032 and INVSENSOR00033|Investigational pulse oximeter device
47992816|NCT06063395|PROCEDURE|open surgery on the abdominal aorta by laparotomy|Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
48152006|NCT04258306|DIETARY_SUPPLEMENT|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
48152007|NCT03258034|DRUG|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
48511295|NCT01644630|PROCEDURE|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
47992817|NCT00164190|PROCEDURE|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
48677581|NCT02820844|OTHER|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
48152008|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
48152009|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
48152010|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
48152011|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
48152012|NCT02423707|DRUG|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
48152013|NCT02423707|DRUG|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
48152014|NCT06076317|BEHAVIORAL|Telemedicine session|The content of telemedicine session is semi-standardized and includes: (1) evaluation of the tolerance and efficacy of drug treatment; (2) evaluation of depressive symptoms (PHQ9 scale); (3) identification of the daily difficulties; (4 ) personalized advice and orientation towards appropriate care pathways. Among the personalized advice, investigators will use the digital tools available to maintain remission, psychoeducation and monitoring tools (for example, application to learn mindfulness meditation, conversational chatbot coupled with artificial intelligence, etc.). Support on the use of these tools can be provided during telemedicine sessions.
47992818|NCT01014520|DRUG|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
47992819|NCT05270655|OTHER|Cognitive-behavioural intervention|Participants in the experimental group will receive five sessions of cognitive-behavioural intervention. Each session will be conducted face-to-face for 30-35 minutes a week and supplemented by home-based practices. The first session is an introductory to cognitive-behavioural intervention, the second session includes identifying, evaluating and challenging maladaptive thoughts, beliefs and behaviour, the third session includes behavioural activation, the fourth session is deep breathing, and the last session includes treatment evaluation and relapse prevention. The interventions will be delivered before chemotherapy sessions to avoid fatigue and to increase the patient's engagement with the interventions. To establish a strong therapeutic alliance and enhance intervention delivery and family support, parents will be invited to attend the introduction of the first session and the summary of each session (the last five minutes).
48152015|NCT01257724|OTHER|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence"
48152016|NCT06213363|DRUG|TCR1672 tablet|All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
48152017|NCT03843333|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.
48152018|NCT03843333|BEHAVIORAL|Behavioral Activation|BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.
48152019|NCT03843333|OTHER|Resource Navigation|CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.
48152020|NCT03843333|OTHER|Enhanced Usual Care|Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
48363553|NCT06428929|OTHER|The musical and lighted baby crib mobile:|The musical and lighted baby crib mobile: It measures 43.5x33x9.5 cm and is made of plastic. It is recommended for use in infants 0-12 months. It has music that makes it easier for babies to fall asleep by reducing stress. This baby mobile has a projection and music function. In addition, the mobile has a 360° flexible swivel bracket that can be adjusted as desired. The surface of the apparatus of the mobile, which is designed to be environmentally and baby friendly, is smooth. There are four rattles on the mobile
48152021|NCT05185102|OTHER|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
48152022|NCT00635323|DRUG|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
48152023|NCT01405508|DRUG|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
48152024|NCT01405508|DRUG|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
48152025|NCT01405508|DRUG|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
48152026|NCT01405508|OTHER|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
48152027|NCT04623996|DRUG|TP-0184|Oral dose
48152028|NCT04526171|BEHAVIORAL|Vaparshun|Participants in the intervention clusters were encouraged to improve their existing toilets.
48152029|NCT05971199|DRUG|Fruquintinib|Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；
48152030|NCT05971199|DRUG|Sintilimab|Sintilimab: 200 mg i.v. every 3 weeks
48152031|NCT05971199|DEVICE|Transcatheter arterial chemoembolization（TACE）|Transcatheter arterial chemoembolization（TACE）
48152032|NCT06008665|OTHER|Action Observation Therapy and Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~Training Session Duration: Each session lasts for 35-40 minutes. Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session."
48677582|NCT06513039|DRUG|Erythropoietin carried on chitosan carrier|Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing
48677583|NCT06513039|OTHER|chitosan carrier|inert scaffold agent
48152033|NCT06008665|OTHER|Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs."
48152034|NCT03588195|OTHER|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
48152035|NCT03588195|DEVICE|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
48152036|NCT02913898|BEHAVIORAL|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
48152037|NCT02913898|BEHAVIORAL|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
48152038|NCT00907933|DRUG|SB-705498|0.5mg intranasal SB-705498
48152039|NCT00907933|DRUG|SB-705498|1.5mg intranasal SB-705498
48152040|NCT00907933|DRUG|SB-705498|3mg intranasal SB-705498
48152041|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498
48152042|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498
48152043|NCT00907933|DRUG|Placebo|Placebo '498
48152044|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498 for 14 days bid
48152045|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498 14 days bid
48511296|NCT01644630|PROCEDURE|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
48511297|NCT04297319|PROCEDURE|Laser diiodo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks It is an outpatient procedure, not anesthesia required.
48677584|NCT03800277|DIETARY_SUPPLEMENT|Cranberry|Supplementation of polyphenols from cranberry extract
48677585|NCT03800277|DIETARY_SUPPLEMENT|Agaves|Supplementation of inulin from Agaves powder
48511298|NCT04297319|PROCEDURE|Laser Placebo|3 laser diiodo procedures of 5-10 minutes at intervals of 4 weeks. It is an outpatient procedure, not anesthesia required.
48511299|NCT05914688|DRUG|LY3209590 (Formulation 1)|Administered SC.
48511300|NCT05914688|DRUG|LY3209590 (Formulation 2)|Administered SC.
48677586|NCT03800277|DIETARY_SUPPLEMENT|Placebo|Supplementation with placebo
48677587|NCT02276742|BEHAVIORAL|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
48152046|NCT00907933|DRUG|Placebo|Placebo
48152047|NCT06019715|BEHAVIORAL|Postpartum Remote Physical Activity Intervention|Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
48152048|NCT05487209|DIAGNOSTIC_TEST|MRI,SCC-Ag|Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
48152049|NCT01430416|DRUG|AEB071|
48152050|NCT00084825|DRUG|Docetaxel|30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days
48152051|NCT00084825|DRUG|Imatinib mesylate|600 mg orally daily
48363554|NCT05743439|BEHAVIORAL|Early Augmentative and Alternative Communication (AAC) Intervention|Caregivers will receive 24, 50 min intervention sessions twice a week for three months. During each intervention session, the therapist provides instruction and coaching on using AAC and a set of evidence-based language support strategies. Strategies are taught sequentially in three phases: (1) Responding to all Communication, (2) Teaching Words, and (3) Creating Communication Opportunities. Caregivers practice using the AAC intervention strategies during three, five-minute routines with their children. Therapists coach the caregiver on using the targeted strategies during these routines, encouraging caregivers to reflect on their implementation, and developing a plan to use the AAC strategies during activities not practiced during the intervention session. The AAC intervention is provided to families using an evidence-based service delivery model, Family Guided Routines Based Intervention.
48152052|NCT03153566|BIOLOGICAL|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
48363555|NCT03363126|PROCEDURE|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
48677588|NCT02276742|OTHER|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
48152053|NCT03153566|DEVICE|cryotherapy|10 sec 1 cycle into all genital warts
48152054|NCT00828139|BIOLOGICAL|ziv-aflibercept|Given IV
48677589|NCT03558646|OTHER|There is no intervention planned (observational)|There is no intervention planned (observational)
48677590|NCT02994966|DEVICE|Surrosense|
48677591|NCT02994966|OTHER|Standard care|
48677592|NCT03566472|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
48677593|NCT01130181|DRUG|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
48677594|NCT01130181|DRUG|Placebo|Matching placebo
48363556|NCT01102816|OTHER|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
48677595|NCT00710892|BIOLOGICAL|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
48677596|NCT05335252|DRUG|Dronabinol|5mg 2x daily for 7 days
48677597|NCT05335252|DRUG|Placebo|1 caplet 2x daily for 7 days
48677598|NCT04452123|PROCEDURE|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
48677599|NCT04452123|PROCEDURE|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
48677600|NCT06393803|DRUG|2mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
48677601|NCT06393803|DRUG|5mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
48677602|NCT06393803|DRUG|10mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
48677603|NCT06393803|DRUG|20mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
48677604|NCT06393803|DRUG|30mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
48677605|NCT06393803|DRUG|40mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
48677606|NCT06393803|DRUG|50mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
48677607|NCT06393803|DRUG|60mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
48677608|NCT03133585|DEVICE|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
48677609|NCT03727971|DRUG|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
48152055|NCT00828139|DRUG|topotecan hydrochloride|Given IV
48363557|NCT01102816|OTHER|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
48363558|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
48511301|NCT00832156|BIOLOGICAL|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
48677610|NCT03727971|DRUG|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
48677611|NCT00439101|DRUG|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
48677612|NCT00439101|OTHER|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
48677613|NCT01516632|BEHAVIORAL|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
47992820|NCT02512432|DEVICE|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
48152056|NCT05944666|PROCEDURE|Multimodal technology (MT)|"Only fo the patients of the Main group. It will be different programms depending on severety of UL or LL paresis. Patients will receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, in moderate paresis of the upper limb, the neurointerface Exokist-2 with EEG registration will be used. The program for IS patients includes 10 sessions in inpatient stage every day 15-30 min for the method, 15 sessions with the MT in outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
48363559|NCT01305616|PROCEDURE|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
48363560|NCT00807456|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
48363561|NCT00996385|DRUG|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
48363562|NCT00461851|DRUG|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
48363563|NCT00461851|DRUG|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
48363564|NCT00461851|DRUG|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
48511302|NCT05160584|OTHER|No intervention|There is no interventional treatment component for participants with RRMM in this study.
48511303|NCT06328062|DRUG|Mirogabalin|Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
48511304|NCT06328062|DRUG|Pregabalin|Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
48511305|NCT03907878|BIOLOGICAL|Ligelizumab|Liquid in vial
48677614|NCT02861339|DEVICE|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
48677615|NCT04262479|DRUG|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
48677616|NCT04262479|DRUG|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
48677617|NCT03153501|DIAGNOSTIC_TEST|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
48677618|NCT00199615|PROCEDURE|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
48677619|NCT01807325|PROCEDURE|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
47992821|NCT05353127|DIAGNOSTIC_TEST|CPET/Cardiopulmonary Exercise Test|During CPET, a patient exercises against a progressively increasing work rate until volitional exhaustion, while breath-by-breath respiratory gasses are analyzed.
47992822|NCT00071760|DRUG|GW433908|Fosamprenavir suspension bid
47992823|NCT00071760|DRUG|ritonavir|Ritonavir solution bid
47992824|NCT03024723|DEVICE|nasal mask CPAP|CPAP and ventilation administered via nasal mask
48152057|NCT05944666|PROCEDURE|Conventional rehabilitation|It will be different programms depending on severety of UL or LL paresis. Conventional rehabilitation (CR) includes physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients consists of 10 sessions of every day trainings for inpatients stage, 15 sessions with the CR for outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
48152058|NCT05149716|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
48152059|NCT05149716|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
48152060|NCT03074968|DRUG|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
48152061|NCT03074968|DRUG|Normal saline|normal saline application
48152062|NCT03618888|OTHER|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
48152063|NCT03618888|OTHER|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
48152064|NCT03778788|OTHER|App group|Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
48152065|NCT03778788|OTHER|Booklet group|The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
48152066|NCT03778788|OTHER|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
48152067|NCT00242086|PROCEDURE|CT, PET and MRI|
48152068|NCT05771545|OTHER|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
48152069|NCT03850678|DEVICE|Hearing Aid|Hearing Aid
48152070|NCT04995497|DRUG|Intravenous Administration of Lidocaine Post Cardiac Surgery|Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
48152071|NCT04995497|DRUG|Administration of Lidocaine Post Cardiac Surgery via ESP Catheter|Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
48152072|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
48363565|NCT01497002|DRUG|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
48511306|NCT05097365|DIETARY_SUPPLEMENT|Vitamin B12 + folic acid supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.
48677620|NCT02336815|DRUG|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
48363566|NCT01497002|BIOLOGICAL|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
48152073|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 48 weeks
48152074|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
48152075|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 24 weeks
48152076|NCT05235815|PROCEDURE|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
48511307|NCT05097365|DIETARY_SUPPLEMENT|Placebo supplementation|A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.
48677621|NCT02336815|DRUG|Dexamethasone|20 mg was given with each dose of Selinexor.
48677622|NCT01109186|OTHER|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
48677623|NCT01129492|DEVICE|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
47992825|NCT03051321|DEVICE|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
48152077|NCT00753155|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
48152078|NCT04505215|OTHER|Mulligan Technique|"First, the painless application angle was determined for each patient. The lateral condyle of the humerus was fixed by the web range of the physiotherapist. The elbow joint was glided until the elbow joint and the hand tightening position were not able to cause pain.~The patients were asked to repeat the motion of the elbow joint and the ball squeezing motion given to their hands 10 times without pain. For pain control, the same procedure was performed with three sets, each containing 10 repetitions of the exercise. The interval between sets was 15 to 20 seconds, and the interval between repetitions within each set was 30 seconds."
48152079|NCT04505215|OTHER|Muscle Energy Technique|Firstly, 5-7 sec opposite isometric muscle contraction was requested from the patient in the barrier by passively stretching by the physiotherapist until the barrier of the related muscle or dysfunctional joint. After a short rest period of 2-3 seconds, the physiotherapist continued to stretch passively until the second barrier. The application continued until the tension of the muscle or dysfunction of the joint disappeared.
48152080|NCT04505215|OTHER|Only Exercise (Control)|Eccentric training for the extensor Carpi Radialis Brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercise for the EKRB muscle were given as home exercise program. The best stretching position for the EKRB tendon is provided when the elbow joint is in extension, forearm pronation, when the wrist is flexed with ulnar deviation (Mills maneuver). Each exercise was taught to patients in 10 repetitions and 10 seconds, and one day of the week, participants in the control group performed their exercises under the supervision of a physiotherapist.
48152081|NCT05333133|DIETARY_SUPPLEMENT|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
48152082|NCT04271254|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
48152083|NCT03267797|OTHER|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
48677624|NCT02521974|BIOLOGICAL|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
47992826|NCT01206647|DRUG|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
47992827|NCT00780325|DRUG|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
47992828|NCT00780325|DRUG|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
47992829|NCT00780325|DRUG|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
47992830|NCT00780325|DRUG|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
47992831|NCT00780325|DRUG|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
47992832|NCT00780325|DRUG|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
48511308|NCT03229135|DEVICE|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
48677625|NCT03859037|OTHER|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
48677626|NCT01117194|DEVICE|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
48677627|NCT01923766|DRUG|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
47992833|NCT05114616|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
47992834|NCT05114616|DEVICE|Ellcie Healthy Glasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
47992835|NCT03694860|OTHER|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
47992836|NCT03558243|PROCEDURE|Patent Hemostasis arm|Patent hemostasis with TR BAND
48152084|NCT03267797|OTHER|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
48152085|NCT02952170|OTHER|MRI|MRI to assess hepatic steatosis
48152086|NCT04264156|COMBINATION_PRODUCT|Lucinactant for Inhalation|A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).
48152087|NCT04264156|OTHER|nCPAP Only|Nasal continuous positive airway pressure (nCPAP) alone
48152088|NCT00794274|DRUG|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
48152089|NCT02693665|BEHAVIORAL|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
48152090|NCT03955341|DEVICE|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
48152091|NCT03955341|OTHER|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
48152092|NCT04914520|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
48152093|NCT04914520|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
48152094|NCT06171126|DIETARY_SUPPLEMENT|Faeces|Faeces from donor selected based on European guidelines, compared to own faeces (placebo)
48152095|NCT04727463|PROCEDURE|Sphincteroplasty|Overlapping sphincteroplasty
48152096|NCT00246389|DRUG|cyclobenzaprine hydrochloride|
48152097|NCT04891497|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
48152098|NCT04891497|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
48677628|NCT00756275|DRUG|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
48152099|NCT05851170|OTHER|The use of warm compresses and almond oil on the perineum during second stage|"Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes."
48152100|NCT05851170|OTHER|Use of almond oil use (routine care) during second stage|Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
48152101|NCT04249115|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.
48152102|NCT05718492|PROCEDURE|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
48152103|NCT05718492|DRUG|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
48152104|NCT00988845|DIETARY_SUPPLEMENT|Indole-3-carbinol|200 mg bid po X 8 weeks
48152105|NCT06207383|DEVICE|Conduction system pacing|Conduction system pacing (either His bundle pacing or left bundle branch area pacing)
48152106|NCT06207383|PROCEDURE|Atrioventricular nodal ablation|Catheter ablation of the atrioventricular node
48152107|NCT06207383|PROCEDURE|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
48152108|NCT03231579|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
48152109|NCT06211751|DRUG|TQB3909 tablets|TQB3909 is a protein inhibitor.
48152110|NCT06211751|DRUG|TQB3702 tablets|TQB3702 is a kinase inhibitor.
48152111|NCT03362853|DRUG|Nemonoxacin 500Mg Capsule|Receive a single dose in a fasting state
48152112|NCT03362853|DRUG|Moxifloxacin 400Mg Tablet|Receive a single dose in a fasting state
48152113|NCT03362853|DRUG|Nemonoxacin 750Mg Capsule|Receive a single dose in a fasting state
48152114|NCT03362853|DRUG|Placebo oral capsule|Receive a single dose in a fasting state
48677629|NCT00756275|DRUG|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
48677630|NCT00756275|BEHAVIORAL|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
48677631|NCT04210661|OTHER|prediction software with spell checker|test with prediction software with spell checker
48677632|NCT01476410|DRUG|brentuximab vedotin|Given IV
47992837|NCT03558243|PROCEDURE|ULTRA arm|Patent hemostasis protocol plus ipsilateral ulnar compression
47992838|NCT03558243|DEVICE|Hemostatic disc arm|StatSeal disc plus TR Band
48152115|NCT05773599|OTHER|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
48511309|NCT03564392|BEHAVIORAL|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
48511310|NCT06551974|BEHAVIORAL|Guided self-help plus IPT|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours. Participants will also attend a weekly online forum with interactional materials, and an online interpersonal group session.
48511311|NCT06551974|BEHAVIORAL|Guided self-help|The participants allocated in the intervention GSH arm will have access to self-help materials (workbook and videoclips), forum groups (interactional materials), online interpersonal group sessions for 8 weeks. The proposed online GSH will be adapted from two online interventions developed and tested with people with eating disorders by the Eating Disorders Research Unit team at King's College London, with a cooperation of the University of Palermo research team (Cardi et al., 2020). The GSH will include self-help materials, i.e. a written workbook and a library of 74 brief video-clips with the goal of providing psychoeducation about eating disorders and interpersonal difficulties and describing and modelling the use of helpful strategies to reverse abnormal eating behaviours.
48511312|NCT06551974|BEHAVIORAL|TAU|The Treatment as Usual is the usual or routine care provided to participants in the outpatient setting.
48511313|NCT02006329|DEVICE|acupuncture|
48511314|NCT00255554|BEHAVIORAL|Dialectical Behavioral Therapy|
48511315|NCT00255554|DRUG|Escitalopram|
48511316|NCT04435184|DRUG|Crizanlizumab|Crizanlizumab 5.0 mg/kg in 100 ml IV once.
48511317|NCT04435184|OTHER|0.9% saline|0.9% saline 100 ml IV once.
48677633|NCT01476410|DRUG|doxorubicin hydrochloride|Given IV
48677634|NCT01476410|DRUG|vinblastine|Given IV
48677635|NCT01476410|DRUG|dacarbazine|Given IV
48677636|NCT01476410|PROCEDURE|quality-of-life assessment|Ancillary studies
48677637|NCT01476410|GENETIC|DNA analysis|Optional correlative studies
47992839|NCT01265849|BIOLOGICAL|LI|LI 400 IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 consecutive weeks administered as neoadjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100 mg/m\^2 intravenously x3) to determine if LI plus CIZ affects the 3-5 year overall survival.
48152116|NCT03062124|PROCEDURE|SpyGlass pancreatoscopy|During the SpyGlass pancreatoscopy procedure visually guided biopsies and flushing liquid are collected from the pancreatic duct
48152117|NCT00501111|DRUG|AZD3480|3 oral doses
48152118|NCT00501111|DRUG|Donepezil|
48152119|NCT03029689|DRUG|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
48677638|NCT01476410|GENETIC|RNA analysis|Optional correlative studies
48677639|NCT01476410|RADIATION|fludeoxyglucose F 18|Correlative studies
48677640|NCT01476410|PROCEDURE|positron emission tomography|Correlative studies
48677641|NCT01476410|OTHER|laboratory biomarker analysis|Optional correlative studies
48677642|NCT01476410|OTHER|immunohistochemistry staining method|Optional correlative studies
48677643|NCT01476410|GENETIC|polymorphism analysis|Optional correlative studies
48152120|NCT03029689|DRUG|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
48152121|NCT03029689|DRUG|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
48152122|NCT03930173|DRUG|18F-fluciclovine|A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
48152123|NCT03930173|DEVICE|PET/CT of the brain|Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
48152124|NCT03528447|OTHER|Pulmonary Rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band."
48152125|NCT00761332|DRUG|teriparatide|treatment will be prescribed according to usual standard of care
48152126|NCT00761332|DRUG|antiresorptives|treatment will be prescribed according to usual standard of care
48152127|NCT06402201|BIOLOGICAL|CDR404|IV infusions
48677644|NCT01193452|DRUG|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
48152128|NCT03363009|DEVICE|Optimized group|The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
48152129|NCT03363009|DEVICE|Control group|Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
48152130|NCT04884282|DRUG|Tedopi|TEDOPI is a T-specific immunotherapy was designed to induce cytotoxic T-lymphocytes against five five tumor associated antigens (ie CEA, p53, HER-2/neu, MAGE2 and MAGE3)
48152131|NCT04884282|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.
48152132|NCT04884282|DRUG|Docetaxel|Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
48677645|NCT01193452|DRUG|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
48677646|NCT05409469|PROCEDURE|surgery|surgery on patients with aortic dissection
48677647|NCT01697085|DIETARY_SUPPLEMENT|Sea buckthorn oil|
48511318|NCT05055583|DRUG|Toripalimab in Combination With Platinum-based Chemotherapy|Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.
48511319|NCT05055583|PROCEDURE|Surgical treatment stage|After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.
48152133|NCT02183961|OTHER|Restech|
48152134|NCT02183961|OTHER|Peptest|
48152135|NCT02183961|OTHER|Detection of pepsin in adenoid specimen|
48152136|NCT05267379|DIAGNOSTIC_TEST|Take blood samples|Blood samples are used to check for polymorphisms in NSAID metabolization genes and to determine the diclofenac levels.
48152137|NCT00318591|DEVICE|SpeediCath|hydrophilic coated urinary intermittent catheter
48152138|NCT00318591|DEVICE|Conveen Uncoated|Uncoated urinary intermittent catheter
48152139|NCT05018065|BEHAVIORAL|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
48511320|NCT05055583|DRUG|Adjuvant treatment stage|Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.
48511321|NCT00098358|DRUG|Zileuton|
48511322|NCT00997204|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
48152140|NCT04362722|DRUG|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
48677648|NCT01697085|DIETARY_SUPPLEMENT|Placebo oil|
48677649|NCT04403919|DEVICE|Conventional Closure: Knee|Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson \& Johnson) and Dermabond advanced.
48152141|NCT02037009|OTHER|Health care organization (anesthetic surveillance)|
48152142|NCT02391714|PROCEDURE|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
48152143|NCT02391714|DRUG|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
48152144|NCT02391714|DRUG|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
48152145|NCT02391714|OTHER|Oxygen|100% oxygen via nasal mask.
48152146|NCT02391714|OTHER|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
48152147|NCT03451903|DRUG|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
48152148|NCT03451903|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
48152149|NCT04047303|DRUG|CC-90010|CC-90010
48152150|NCT03556267|DEVICE|spinal needle|It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
48152151|NCT00004171|DRUG|busulfan|
48677650|NCT04403919|DEVICE|Barbed suture closure: Knee|The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
48152152|NCT00004171|DRUG|cyclophosphamide|
48152153|NCT00004171|PROCEDURE|peripheral blood stem cell transplantation|
48152154|NCT05107921|DRUG|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
48152155|NCT01572896|BEHAVIORAL|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
48152156|NCT01572896|BEHAVIORAL|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
48152157|NCT05540639|BEHAVIORAL|Modified Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by video, by a leaflet and at a website.
48152158|NCT01261793|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
48152159|NCT01261793|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
48152160|NCT01261793|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
48152161|NCT05651035|OTHER|oral feeding|"In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made."
48152162|NCT01998334|OTHER|CVVH 6h|CVVH 6h for first three days
48152163|NCT01998334|OTHER|CVVH 10h|CVVH 10h for first three days
48152164|NCT01998334|OTHER|CVVHDF 6h|CVVHDF 6h for first three days
48152165|NCT01328223|RADIATION|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
48152166|NCT01411605|BEHAVIORAL|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
48677651|NCT04403919|DEVICE|Conventional Closure: Hip|"1. The capsule will be closed with Vicryl Plus number 1~2. Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~4. Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson \& Johnson)~5. followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson \&Johnson)."
48677652|NCT04403919|DEVICE|Barbed suture closure: Hip|"1. The capsule will be closed with stratafix symmetric PDS Plus~2. Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson \& Johnson, Somerville, NJ)~4. Subcuticular suture with stratafix spiral monocryl plus, Ethicon~5. followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson \&Johnson)."
48152167|NCT05007600|OTHER|Online Interactive Courses|In the experimental group, after consensus was reached in the expert meeting (consisting of a doctor specializing in occupational therapy, a doctor specializing in nursing, and a doctor specializing in public health), a 5-days-per-week (Monday to Friday) 8-week intensive online interactive course was designed. The course was made accessible to the participants through a social network app (Line) from 12:00 to 20:30.
48363567|NCT05507294|DRUG|Glumetinib|"Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration."
48511323|NCT06634095|BEHAVIORAL|Moulage group|The experimental group is trained with a moulage-supported standardized patient simulation. Participants in the experimental group practice during the specified moulage-supported standardized patient simulation. Moulage-supported simulations regarding pressure ulcers will be created and training will be provided.
48511324|NCT01410656|BEHAVIORAL|Telephone Implementation Intention|Telephone implementation intention counseling
48677653|NCT05468281|OTHER|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
48677654|NCT03128983|DEVICE|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
48511325|NCT01410656|BEHAVIORAL|Self-completed implementation intention|Self-administered implementation intention intervention
48511326|NCT00851435|BIOLOGICAL|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
48511327|NCT00720382|DRUG|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
48511328|NCT00720382|DRUG|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
48511329|NCT00745550|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
48511330|NCT04185623|PROCEDURE|denudation time lag|The time between ovum pickup and denudation of oocyte
48511331|NCT04131348|PROCEDURE|botulinum toxin type A|From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
48511332|NCT05418244|OTHER|Inhaled Isopropyl Alcohol|Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
48511333|NCT05418244|DRUG|Oral Ondansetron|4 mg oral disintegrating ondansetron tablet once
48511334|NCT05418244|OTHER|Inhaled Placebo|Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
48677655|NCT02512445|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
48677656|NCT02512445|BEHAVIORAL|Supportive Care Therapy|Supportive therapy
48677657|NCT02714491|OTHER|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
47992840|NCT01265849|DRUG|Cyclophosphamide|Cyclophosphamide was administered IV bolus (one time only) at a dose of 300mg/m\^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) for higher risk subjects (subjects determined at surgery to have adverse features per the National Comprehensive Cancer Network (NCCN) guidelines, such as, positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread, etc. that would pre-dispose them for higher risk of recurrence) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m\^2 intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
47992841|NCT01265849|DRUG|Indomethacin|One 25mg capsule of indomethacin was self administered orally (BID) beginning on day one of LI treatment daily until the day before surgery.
47992842|NCT01265849|DIETARY_SUPPLEMENT|Zinc|One capsule daily self administered beginning on day one of treatment with LI until one day before surgery
47992843|NCT01265849|PROCEDURE|Surgery|Excise tumor and nodes
47992844|NCT01265849|DRUG|Cisplatin|Cisplatin was administered 100mg/m\^2 IV concurrent with radiotherapy. The chemotherapy agent (cisplatin 100mg/m\^2) was administered intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
47992845|NCT01265849|RADIATION|Radiotherapy|Total 60 to 70 Gy (2Gy per day) in 30 to 35 fractions over 6 to 7 weeks to subjects determined at surgery to be at lower risk for recurrence (per NCCN guidelines). For subjects determined at surgery to be at higher risk for recurrence due to having positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread etc. (per NCCN guidelines), radiotherapy (as above) is combined with concurrent chemotherapy (cisplatin 100 mg/m\^2) intravenously on day 1 of weeks 1, 4 and 7 of radiotherapy.
47992846|NCT05283798|DEVICE|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
47992847|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
47992848|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
47992849|NCT01092182|DRUG|EPOCH-R|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
47992850|NCT01092182|DRUG|EPOCH-RR|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
47992851|NCT05633693|BEHAVIORAL|Counterpressure Maneuvers|Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).
47992852|NCT05633693|BEHAVIORAL|Baseline Stand|Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
47992853|NCT04248608|PROCEDURE|serratus plane block|ultrasound guided block
47992854|NCT04248608|PROCEDURE|erector spinae block|ultrasound guided block
47992855|NCT04248608|DRUG|Morphine Sulfate|intravenous morphine sulfate 0.1 mg/kg
47992856|NCT03195114|DIAGNOSTIC_TEST|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
48677658|NCT02714491|OTHER|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
48677659|NCT02714491|OTHER|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
48677660|NCT06257225|PROCEDURE|Guided Bone regeneration|After local anesthesia, a crestal incision will be performed followed by full-thickness mucoperiosteal flap elevation Flap advancement will be attained through periosteal scoring of the buccal; The resorbable collagen membrane (Bio Gide, Geistlich AG) will be trimmed to the defect size. Xenograft (Bio-Oss) together with scrapped autogenous bone will be mixed and placed at the surgical site. The membrane will positioned over the graft and tucked into the lingual flap. Patient allocation concealment will be broken and the patients will be randomly assigned into two groups Patients receiving horizontal bone augmentation with resorbable collagen membrane stabilized with no tacks. The first layer will be closed with horizontal mattress sutures placed 4 mm from the incision line, and single interrupted sutures are used to close the edges of the flap. Vertical incisions are closed using single interrupted sutures and mattress suture should remain in place for at least 2 to 3 weeks
48677661|NCT03069066|DEVICE|Bioresorbable vascular scaffold. Absorb GT1 (Abbott)|
47992857|NCT04341909|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
48511335|NCT00040131|DRUG|IL-10|
48511336|NCT01680107|DRUG|d-cycloserine|
48511337|NCT01680107|DRUG|placebo|
48511338|NCT01680107|BEHAVIORAL|cognitive-behaviour therapy|
48152168|NCT03988309|DIAGNOSTIC_TEST|Cxbladder|"The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care."
48152169|NCT00472082|DRUG|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
48511339|NCT04169152|PROCEDURE|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
48511340|NCT06451211|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants
48511341|NCT06451211|DRUG|Oxaliplatin|Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants
48511342|NCT06451211|DRUG|S-1|S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants
47992858|NCT06490029|DIAGNOSTIC_TEST|Auditory, vestibular and electrophysiological investigations|otoacoustic emissions, electrocochleography, vocal audiometry in noise and high-frequency tonal audiometry, impedancemetry
48511343|NCT06451211|DRUG|Capecitabine|Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
48511344|NCT06055829|DRUG|Insulin injection and blood glucose|The FreeStyle Libre sensor continuously measures glucose every minute and saves the glucose data. Scan the sensor at least every 8 hours for a full glycemic profile. The below data is displayed after a typical 1-second scan of the FreeStyle LibreLink app or FreeStyle Libre reader via the sensor:
48511345|NCT06495112|OTHER|Soft contact lens with lathe cut technique Lathe|athe cut technique Lathe cutting involves shaping a solid block of lens material into the desired form using precision machinery. This method allows for customized lens designs but may result in a less smooth surface compared to cast molding. Cast molding, on the other hand, uses a liquid monomer that is cured in a mold to form the lens. This technique typically results in a smoother and more uniform lens surface.
48511346|NCT06495112|DIAGNOSTIC_TEST|Soft contact lens with cast molding technique|Participants in this arm would receive Cast molding soft contact lenses and would wear them according to the study protocol, also likely for a specified duration.The cast molding technique for soft contact lenses involves creating lenses by polymerizing a liquid monomer mixture within a mold that forms the desired lens shape. Here's a brief overview of the steps involved in the cast molding process
48677662|NCT05915585|DEVICE|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
48677663|NCT03853967|OTHER|Low dose CT scan|low dose CT scan
48677664|NCT06106906|BIOLOGICAL|CD19 CAR-T cell infusion|CD19 CAR-T cell intravenous infusion
47992859|NCT06490029|DIAGNOSTIC_TEST|Biologic investigations; seric proteins|seric proteins
47992860|NCT00002173|BIOLOGICAL|HIV-1 Immunogen|
47992861|NCT01902342|DRUG|Oseltamivir 75 mg 1 cap|
47992862|NCT01338831|DRUG|LFA102|
47992863|NCT00045279|BIOLOGICAL|PEG-interferon alfa-2b|
47992864|NCT04902716|BEHAVIORAL|Design course|Precision nursing is a new trend in nursing in recent years. It is based on individual differences in disease type, gender, lifestyle, family, race, social and cultural factors, etc., to provide the most suitable empirical-based nursing treatment.Diverse courses include music, breathing exercises, cognitive training, hand-made knitting, etc.
47992865|NCT03342287|OTHER|questionnaires|Questionnaires rating IBS symptoms, constipation, anxiety and depression
47992866|NCT03342287|OTHER|cognitive evaluation|Administration of online cognitive battery
48677665|NCT04853914|DEVICE|HIFU treatment|HIFU treatment of Benign Prostatic Hyperplasia
48677666|NCT03573245|DRUG|Tranexamic Acid|Tranexamic acid effect on perioperative bleeding in orthopedic surgery
48677667|NCT00442416|DRUG|Epoetin alfa|As prescribed, SC
47992867|NCT03342287|OTHER|Blood|Measurement of cytokines/inflammatory biomarkers
48152170|NCT01796834|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
47992868|NCT03342287|OTHER|Fecal sample|Measurement of the gut microbiome
47992869|NCT01216579|OTHER|mannitol (an airway challenge agent)|
48152171|NCT00512473|DRUG|Saline infusion|0.9 % NaCl
48152172|NCT00512473|DRUG|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
48152173|NCT00512473|DRUG|Pegvisomant|30 mg Somavert administered at t = - 36 hours
48152174|NCT03616314|DEVICE|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
48152175|NCT03616314|DEVICE|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
48152176|NCT03616314|OTHER|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
48152177|NCT03638700|DEVICE|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
48152178|NCT03638700|DEVICE|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
48152179|NCT03638700|DEVICE|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
48152180|NCT03638700|DEVICE|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
48152181|NCT01075672|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
48152182|NCT00419172|DRUG|Deferasirox|
48511347|NCT03287843|PROCEDURE|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
48511348|NCT03287843|PROCEDURE|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
48511349|NCT06432374|BEHAVIORAL|WET|"The five weekly WET sessions were delivered online via Canvas. Five session modules were created, each containing writing instructions for the respective session and an assignment feature for participants to upload their narratives. All sessions included 30 minutes of writing. Following instructions, participants wrote about a specific work-related trauma event in detail and described the emotions and thoughts experienced during the event. While all sessions were self-paced, participants were advised to complete each subsequent session within one week. Participants had the option to self-administer sessions or participate in Zoom office hours for live writing sessions with a facilitator who had completed WET training providing the writing instructions."
48511350|NCT03174379|PROCEDURE|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
48152183|NCT00419172|DRUG|Rifampicin|
48152184|NCT02525497|DEVICE|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
48152185|NCT02525497|DEVICE|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
48363568|NCT02390323|PROCEDURE|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
47992870|NCT02295033|RADIATION|Boost irradiation|
47992871|NCT00918658|OTHER|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
47992872|NCT00918658|OTHER|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
47992873|NCT00918658|OTHER|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
48152186|NCT04002856|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
48152187|NCT01821222|DEVICE|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
48152188|NCT04707885|DEVICE|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at \~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
48152189|NCT01092689|DRUG|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP
48152190|NCT00360035|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
48152191|NCT06046209|DEVICE|Control Contact Lens|Daily disposable contact lens for 90 minutes
48677668|NCT00442416|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
48677669|NCT02091635|DRUG|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
48677670|NCT02091635|DRUG|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
48677671|NCT03228862|DRUG|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
48152192|NCT06046209|DEVICE|Test Contact Lens|Monthly replacement contact lens for 90 minutes
48152193|NCT03852771|DEVICE|Cirvo(TM) therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
48677672|NCT02663336|OTHER|Comparison ABPM with OBPM|No interventions
48152194|NCT06200909|OTHER|Mindfulness Meditation|8-week mindfulness meditation program, based on Kabat-Zinn's MBSR program and modified for caregivers. The intervention will be led by MBSR-trained facilitators.
48152195|NCT06200909|OTHER|Psychoeducation|"A lecture-style program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. The program will be delivered by a facilitator experienced in delivering similar content."
48152196|NCT06200909|OTHER|Wait list control|Participants will receive two hours of respite from their caregiving responsibilities per week, for eight weeks. They will be given the opportunity to participate in either the MM or the PSY condition following completion of testing.
48152197|NCT00071929|DRUG|oxaliplatin|
48152198|NCT01989845|DRUG|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
48152199|NCT05501340|DRUG|Serplulimab|PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
48152200|NCT05501340|DRUG|Molgramostim|200ug qd subcutaneous injection for 7 days
48511351|NCT03174379|PROCEDURE|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
48511352|NCT02193334|DRUG|KP-100IT|
48511353|NCT02193334|DRUG|Placebo|
48511354|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
48677673|NCT01008618|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
48677674|NCT01008618|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
48677675|NCT03983447|BEHAVIORAL|School-based intervention to promote PA and reduce ST|"This intervention was realized with all the children (1st grade-5th grade) and involved :~1. Physical (Environmental) adaptation of playgrounds~2. Time adaptation of lunch breaks~3. Curriculum-based program for children~4. Workshops and newsletters for parents~5. Meetings for teachers"
48511355|NCT00682357|DRUG|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
48152201|NCT05501340|RADIATION|Hypofractionated radiotherapy/Sterotactic body radiotherapy|8Gy\*3f
48511356|NCT00682357|DRUG|Placebo and Lidocaine|Placebo and lidocaine 20 mg
48511357|NCT02037386|DEVICE|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
48677676|NCT03063606|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
48677677|NCT03063606|DRUG|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
48677678|NCT00131521|DRUG|mucomyst|
48677679|NCT00131521|DRUG|sodium chloride (saline)|
48511358|NCT05153525|DRUG|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
48511359|NCT05153525|DRUG|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
48677680|NCT04023760|DRUG|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
48152202|NCT01628263|OTHER|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
48152203|NCT03034772|DRUG|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
48152204|NCT03034772|OTHER|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
48152205|NCT06389071|DEVICE|Fractional 2940 nm Laser|Fractional 2940 nm Laser
48152206|NCT02342275|DRUG|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
48152207|NCT02342275|DRUG|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
48152208|NCT06560411|DEVICE|Non-Invasive Ventilation|Provide continuous or intermittent ventilatory support for the care of individuals who require mechanical ventilation
48152209|NCT04414865|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
48152210|NCT06160375|DIAGNOSTIC_TEST|pain assessment after video assisted thoracoscopic lung surgeries|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
48152211|NCT04173000|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
48152212|NCT04173000|OTHER|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
48152213|NCT02994329|DEVICE|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
48152214|NCT02350426|OTHER|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
48152215|NCT02350426|OTHER|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
48363569|NCT02390323|DEVICE|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
48363570|NCT05179564|DIAGNOSTIC_TEST|iohexol administration|IV injection of weight-dependent low dose of iohexol at time 0
48677681|NCT01451749|DRUG|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
48363571|NCT05179564|DIAGNOSTIC_TEST|iohexol blood sampling|Blood sampling will be performed through an arterial (preferred) or venous line, other than the iohexol infusion line. In the first 30 minutes after iohexol injection, a blood sample of 2 ml will be obtained for iohexol concentration measurement and determination of renal biomarkers serum creatinine, cystatin C, betatrace protein. Subsequently, 2 up to 5 additional blood samples of 0,5 ml will be obtained for iohexol determination at 60,120 ,180, 240 and 360 minutes after iohexol injection to calculate iohexol plasma clearance from the plasma disappearance curve
48511360|NCT05840679|DRUG|Irrigation Solution|Different concentrations of NaOCl are being used as the endodontic irrigant.
48511361|NCT06379685|DRUG|PRO-190|Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.
48511362|NCT06379685|DRUG|Systane Ultra®|Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
48511363|NCT00562523|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
48152216|NCT02350426|OTHER|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
48152217|NCT03490188|BEHAVIORAL|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
48152218|NCT00472368|DRUG|LBH589|
48152219|NCT01658176|DRUG|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
48152220|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
48152221|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
48152222|NCT03623776|DRUG|JS001|JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
48152223|NCT03623776|DRUG|Pemetrexed|Subjects receive pemetrexed of 500 mg/m\^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
48152224|NCT03623776|DRUG|Carboplatin|Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
48152225|NCT03623776|PROCEDURE|Thoracic Surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
48152226|NCT04449445|DIETARY_SUPPLEMENT|Isocaloric and iso-nitrogenous standard enteral tube feeds|Dietary supplement
48677682|NCT01451749|DRUG|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
48677683|NCT02822053|PROCEDURE|US-guided laser ablation for refractory neoplasms|
48152227|NCT04449445|DIETARY_SUPPLEMENT|Nestle IMPACT AR|Dietary supplement
48152228|NCT00157209|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
48677684|NCT04389866|DEVICE|JUVÉDERM VOLUMA™ XC|Injectable gel
48152229|NCT00157209|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
48152230|NCT00157209|OTHER|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
48152231|NCT05836753|DRUG|Sarecycline Tablet|Each tablet contained 100 mg of Sarecycline.
48152232|NCT05836753|DRUG|Placebo tablets of Sarecycline tablets|Each tablet contained 0 mg of Sarecycline.
48152233|NCT05722821|OTHER|Hypopressive intervention|"Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~* A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~* There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible."
48677685|NCT03965182|DRUG|PEG|2 sachets of PEG will be used as the bowel prep regimen.
48677686|NCT03965182|DRUG|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
48152234|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
48152235|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
48152236|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
48677687|NCT03965182|DRUG|SPMC|2 sachets will be administered as the bowel prep regimen.
48677688|NCT05795270|OTHER|Treatment|Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
48677689|NCT01616277|BIOLOGICAL|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
48677690|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
48677691|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
48677692|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
48677693|NCT01616277|BIOLOGICAL|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
48677694|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
48677695|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
48677696|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
48152237|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
48152238|NCT03338491|BEHAVIORAL|Induction of Implemental Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
48152239|NCT03338491|BEHAVIORAL|Induction of Deliberative Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required."
48152240|NCT01271361|PROCEDURE|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
48152241|NCT01271361|PROCEDURE|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
48152242|NCT01512355|DRUG|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
48152243|NCT01512355|DRUG|placebo group|normal saline_02mcg/kg/hr
48152244|NCT04344236|DRUG|Saline oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
48677697|NCT01616277|BIOLOGICAL|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
48152245|NCT04344236|DRUG|0.5% Povidone/Iodine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
48152246|NCT04344236|DRUG|0.12% Chlorhexidine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
48152247|NCT00874393|DRUG|Dopamine|Dopamine
48152248|NCT00874393|DRUG|Hydrocortisone|Hydrocortisone
48152249|NCT00874393|DRUG|Infusion Placebo|Dextrose (D5W)
48152250|NCT00874393|DRUG|Syringe Placebo|Normal saline
48152251|NCT01562275|DRUG|Ipatasertib|multiple doses
48152252|NCT01562275|DRUG|Cobimetinib|multiple doses
48677698|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
48677699|NCT01616277|BIOLOGICAL|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
48677700|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
48152253|NCT02077114|BIOLOGICAL|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
48152254|NCT02462447|DRUG|11C-sarcosine|Radiotracer injection for PET/CT scan
48152255|NCT02462447|DRUG|11C-choline|Radiotracer injection for PET/CT scan
48677701|NCT01616277|BIOLOGICAL|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
48677702|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
48677703|NCT04539834|OTHER|electrolytes|measuring level of electrolytes
48677704|NCT00363311|DRUG|Dutasteride|Dutasteride 0.5mg
48677705|NCT00363311|DRUG|Matching placebo|Matching placebo
48677706|NCT03596788|DIETARY_SUPPLEMENT|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
48677707|NCT03596788|DIETARY_SUPPLEMENT|Placebo Beverage|The placebo beverage will contain aspartame.
48677708|NCT02491281|DRUG|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
48677709|NCT02491281|DRUG|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
48677710|NCT04918147|DRUG|elotuzumab|Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
48677711|NCT04918147|DRUG|placebo for elotuzumab|The placebo for elotuzumab is 0.9% sterile normal saline for injection.
48152256|NCT03603275|DRUG|New FVIII products|Kovaltry or Jivi prescribed by the treating Physician
48152257|NCT02501876|OTHER|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
48152258|NCT01555879|DRUG|Abatacept|As prescribed by a doctor for patient medical care.
48152259|NCT01701089|DRUG|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
48152260|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for 14 days
48152261|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for up to 17 days
48152262|NCT00004806|GENETIC|Cystic fibrosis transmembrane conductance regulator|
48152263|NCT02699398|BEHAVIORAL|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
48152264|NCT02699398|BEHAVIORAL|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
48152265|NCT02185586|PROCEDURE|laparoscopic cholecystectomy|
48152266|NCT01331278|PROCEDURE|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
48363572|NCT06462079|DRUG|Sacituzumab Govitecan|Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
48363573|NCT06462079|RADIATION|Radiotherapy|Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
48363574|NCT03963076|OTHER|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
47992874|NCT03169647|BEHAVIORAL|Listening-based intervention|Participants will listen to pre-specified material on a CD
47992875|NCT01511523|DIETARY_SUPPLEMENT|RGMA001|3 capsules administered BID once a day.
48152267|NCT01331278|PROCEDURE|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
48363575|NCT05250999|OTHER|Skin stretch sensory stimuli|Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
48363576|NCT05250999|OTHER|Transcutaneous Electrical nerve stimulation|TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
47992876|NCT01511523|DIETARY_SUPPLEMENT|Sugar Pill|Placebo
47992877|NCT00003573|BIOLOGICAL|filgrastim|
47992878|NCT00003573|DRUG|cisplatin|
48152268|NCT05159037|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
48152269|NCT05159037|BEHAVIORAL|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
48152270|NCT01241448|DRUG|LY2409021|Administered Orally
48152271|NCT01241448|DRUG|Placebo|Administered Orally
48152272|NCT00074932|BIOLOGICAL|Myozyme|20 mg/kg
48152273|NCT06046976|PROCEDURE|piesosurgical extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
48152274|NCT06046976|PROCEDURE|conventional extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
48152275|NCT05857163|DRUG|Rifasutenizol capsules|400 mg, BID
47992879|NCT00003573|DRUG|cyclophosphamide|
47992880|NCT00003573|DRUG|etoposide|
47992881|NCT00003573|DRUG|vincristine sulfate|
47992882|NCT00003573|RADIATION|radiation therapy|
47992883|NCT00175721|PROCEDURE|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
47992884|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
47992885|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
47992886|NCT05663307|DRUG|Aspirin|plus aspirin at a dose of 100 mg per day for 90 days.
47992887|NCT02578654|OTHER|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
47992888|NCT03613935|OTHER|Product 1|Comparison with products 2, 3, and 4
47992889|NCT03613935|OTHER|Product 2|Comparison with products 1, 3, and 4
47992890|NCT03613935|OTHER|Product 3|Comparison with products 1, 2, and 4
47992891|NCT03613935|OTHER|Product 4|Comparison with products 1, 2, and 3
48152276|NCT05857163|DRUG|Rabeprazole sodium enteric-coated tablets|20 mg, BID
48152277|NCT05857163|DRUG|Amoxicillin Capsules|1 g, BID
48152278|NCT05857163|DRUG|Clarithromycin placebo tablets|BID
48152279|NCT05857163|DRUG|Bismuth potassium citrate placebo capsules|BID
48363577|NCT05250999|OTHER|Control Group|This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
48363578|NCT00611351|BIOLOGICAL|anti-thymocyte globulin|
48363579|NCT00611351|DRUG|busulfan|
48363580|NCT00611351|DRUG|cyclophosphamide|
48363581|NCT00611351|DRUG|mycophenolate mofetil|
48363582|NCT00611351|DRUG|tacrolimus|
48363583|NCT00611351|GENETIC|polymerase chain reaction|
48363584|NCT00611351|GENETIC|polymorphism analysis|
48363585|NCT00611351|OTHER|flow cytometry|
48677712|NCT04918147|DRUG|methylprednisolone|Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
48152280|NCT05857163|DRUG|Clarithromycin tablets|500 mg, BID
47992892|NCT06022120|BEHAVIORAL|An integrated health literacy intervention|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish contexts among students at risk of poorer health outcomes compared to their peers with stronger literacy skills.
48152281|NCT05857163|DRUG|Bismuth potassium citrate capsules|240 mg, BID
48152282|NCT05857163|DRUG|Rifasutenizol placebo capsules|BID
48152283|NCT02450747|DEVICE|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
48152284|NCT00123500|BEHAVIORAL|Diet|Diet
48152285|NCT00123500|BEHAVIORAL|Physical Activity|Physical Activity
48152286|NCT00123500|BEHAVIORAL|Environment|Environment
48152287|NCT00123500|OTHER|Control Group|Control Group
48152288|NCT05609864|OTHER|Quantification of injectable drugs wastage|Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
48152289|NCT03444298|DRUG|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
48363586|NCT00611351|OTHER|laboratory biomarker analysis|
48363587|NCT00611351|OTHER|pharmacogenomic studies|
48677713|NCT04918147|DRUG|diphenhydramine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
47992893|NCT02469428|OTHER|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
47992894|NCT02469428|OTHER|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
47992895|NCT02601287|BIOLOGICAL|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
48363588|NCT00611351|OTHER|pharmacological study|
48677714|NCT04918147|DRUG|acetaminophen|Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
48677715|NCT04918147|DRUG|famotidine|Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
48677716|NCT04918147|DRUG|prednisone|Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
48677717|NCT05819476|PROCEDURE|OLP-injection|Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
47992896|NCT03796780|DIETARY_SUPPLEMENT|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
47992897|NCT03796780|DIETARY_SUPPLEMENT|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
47992898|NCT03344042|DRUG|Fentanyl|100mcg Fentanyl
47992899|NCT03344042|DRUG|Sufentanil|10mcg sufentanil
47992900|NCT03359642|OTHER|blood sample|14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
47992901|NCT03359642|OTHER|stool samples|Study of the fecal microbiota
47992902|NCT03359642|OTHER|food questionnaire|food questionnaire on the seven days before the collection
47992903|NCT03359642|OTHER|colonoscopy|Only for patients with ulcerative colitis (in routine care)
48152290|NCT03444298|DRUG|Placebo|Each dose consists of two capsules by mouth once daily for a total of 7 days.
48152291|NCT04231175|DIAGNOSTIC_TEST|DWI MRI of the pelvis, abdomen and thorax|Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
48152292|NCT05665348|DRUG|Ipilimumab Injection|Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
48152293|NCT05665348|DRUG|Atezolizumab Injection|One of the standard treatment's product for HCC management
48152294|NCT05665348|DRUG|Bevacizumab|One of the standard treatment's product for HCC management
48152295|NCT01341106|DRUG|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
48363589|NCT00611351|PROCEDURE|allogeneic bone marrow transplantation|
48363590|NCT00611351|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48363591|NCT00611351|PROCEDURE|peripheral blood stem cell transplantation|
48363592|NCT02182505|DRUG|Berodual® Respimat®, low dose|
48363593|NCT02182505|DRUG|Berodual® Respimat®, high dose|
48363594|NCT02182505|DRUG|Berodual® MDI|
48363595|NCT03585829|DRUG|Hydrocortisone|at a substitutive dosage
48363596|NCT03585829|DRUG|Prednisolone|at a substitutive dosage
48363597|NCT00724789|DRUG|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
48363598|NCT00724789|DRUG|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
48363599|NCT04039295|PROCEDURE|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
48363600|NCT03941041|BEHAVIORAL|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
48152296|NCT01533896|BEHAVIORAL|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
48152297|NCT01653509|DEVICE|Acyclovir patch|Patch containing acyclovir
48152298|NCT01653509|DEVICE|Placebo patch|Patch without acyclovir
48152299|NCT00913445|PROCEDURE|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
48152300|NCT04590625|DRUG|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
48152301|NCT04590625|DRUG|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
48152302|NCT04590625|DRUG|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
48152303|NCT04590625|DRUG|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
47992904|NCT03359642|OTHER|VOCs profile|Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
48152304|NCT05064475|DIAGNOSTIC_TEST|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
48152305|NCT04743999|OTHER|Quality of life questionnaire|We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
47992905|NCT02395900|DIETARY_SUPPLEMENT|Flaxseed|
47992906|NCT02395900|OTHER|control|
48152306|NCT04421534|DRUG|Lactoferrin|adding lactoferrin to standard of care treatment regimens
48152307|NCT03720717|DRUG|Baclofen 10mg|Baclofen administration pre-operatively
48152308|NCT03720717|OTHER|Placebo|Placebo administration
48152309|NCT00234832|DRUG|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
48152310|NCT00234832|DRUG|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
48152311|NCT00234832|DRUG|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
48152312|NCT00135200|DRUG|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
48152313|NCT03046888|PROCEDURE|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
48152314|NCT05324748|DRUG|Methylprednisolone|Injection with prednisolon
47992907|NCT02604212|DRUG|ARC-520|
48363601|NCT03704233|PROCEDURE|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
48363602|NCT02122965|OTHER|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
48363603|NCT00459680|DEVICE|Laser acupoint treatment|Laser
48363604|NCT00459680|PROCEDURE|Acupuncture|Needle acupuncture on ST36 and LI11.
47992908|NCT02604212|OTHER|Placebo|
47992909|NCT02604212|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
47992910|NCT02604212|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
48152315|NCT05324748|DRUG|Saline solution|0,9%
48152316|NCT01892982|BEHAVIORAL|Problem Solving Education tailored to NICU|
48152317|NCT02646878|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
48152318|NCT02855892|OTHER|Placebo|
48152319|NCT02855892|DRUG|GV1001|
48152320|NCT05540951|DRUG|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
48152321|NCT05540951|DRUG|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
48152322|NCT05705245|OTHER|recruitment|Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
48152323|NCT02838888|DEVICE|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
48363605|NCT03270631|OTHER|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
48363606|NCT03270631|OTHER|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
47992911|NCT02604212|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
48363607|NCT03270631|OTHER|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
48363608|NCT03270631|OTHER|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
48677718|NCT05819476|OTHER|Scripted Evidence-based treatment rationale|As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
47992912|NCT04754737|OTHER|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
48152324|NCT01543945|DRUG|Dexamethasone|4 mg iv before induction for high and extremely high risk
48152325|NCT01543945|DRUG|Ondansetron|4 mg iv before ended surgery 30 min
48152326|NCT01543945|DRUG|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
48152327|NCT03663049|DRUG|discontinue statin|Discontinue statin as prescribed for 12 weeks
48152328|NCT00663923|PROCEDURE|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
48152329|NCT02365402|DRUG|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
48152330|NCT04095338|OTHER|traditional rehabilitation|Each session will include 50 minutes of traditional physical rehabilitation therapy
48152331|NCT04095338|OTHER|virtual reality games intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Tymo system (Tyromotion, Austria), a wireless platform for the balance and the postural control training that simulates floor walking and stairs climbing. Tymo system is connected to a screen and provides virtual reality games, adaptable to the functional capacity of the patient. Through the games proposed, the physiotherapist will decide to work in a dimension (antero-posterior or medio-lateral dimension) or in two dimensions (combining the antero-posterior and medio-lateral movements).
48363609|NCT02179216|OTHER|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
47992913|NCT04754737|OTHER|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
48152332|NCT04095338|OTHER|robotic treadmill intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Walker view (TecnoBody, Italy), a treadmill equipped with a sensorized belt with eight load cells and a 3D camera.to detect length, speed and symmetry of the pace and load, range of the trunk, hips and knees. Patients will be asked to walk at a comfortable speed, while the physiotherapist will be able to work on different parameters such as step length, load distribution, and step height. The setting will take place taking into account the clinical conditions of each patient, customizing the intervention. The Walker View will offer visual and auditory feedback to the patient, so as to correct gait in real time.
48152333|NCT01071720|DRUG|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
48152334|NCT02272608|OTHER|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
48152335|NCT04694859|DEVICE|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
48152336|NCT01727193|DRUG|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
48152337|NCT01727193|DRUG|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
48152338|NCT03353649|BEHAVIORAL|Now vs. Later Cue|"As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus."
48677719|NCT05819476|OTHER|Experimental model of acute pain|Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
48677720|NCT01571622|DIETARY_SUPPLEMENT|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
48677721|NCT01571622|DIETARY_SUPPLEMENT|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
48677722|NCT03762161|DRUG|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
48677723|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
48677724|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
48677725|NCT00484341|DRUG|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
47992914|NCT04754737|PROCEDURE|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
47992915|NCT01433679|BEHAVIORAL|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
47992916|NCT02941445|DRUG|sitagliptin and metformin|
47992917|NCT02941445|DRUG|Metformin|
47992918|NCT02914652|DRUG|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
47992919|NCT02914652|DRUG|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
47992920|NCT02616042|OTHER|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
47992921|NCT02616042|OTHER|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
47992922|NCT01940809|DRUG|Dabrafenib|Given PO
47992923|NCT01940809|BIOLOGICAL|Ipilimumab|Given IV
47992924|NCT01940809|OTHER|Laboratory Biomarker Analysis|Correlative studies
47992925|NCT01940809|BIOLOGICAL|Nivolumab|Given IV
47992926|NCT01940809|DRUG|Trametinib|Given PO
47992927|NCT05766930|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 2-4 minutes on the participant's diseased area until half a bottle (20-40ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The relief genital itching evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
48363610|NCT02179216|OTHER|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
48363611|NCT03108989|DRUG|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
48363612|NCT03108989|DRUG|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
48363613|NCT04539444|BIOLOGICAL|CD19/22 CART|CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.
48363614|NCT04539444|DRUG|Tislelizumab|Patients will receive Tislelizumab 200mg/dose every 3 weeks.
48677726|NCT00484341|DRUG|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
48677727|NCT00484341|DRUG|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
48677728|NCT03680885|DRUG|Lidocaine gel|Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
48677729|NCT03680885|DRUG|Placebo|PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
48363615|NCT04781946|PROCEDURE|Endoscopic pneumatic balloon dilation|Using endoscopy, pneumatic balloon dilation may be used to treat stenosis of the gastric sleeve.
48363616|NCT04781946|PROCEDURE|Gastric peroral endoscopic myotomy (G-POEM)|Gastric per-oral endoscopic myotomy (G-POEM) is a recent innovation offering a minimally invasive endoscopic approach. G-POEM allows for the creation of a tunnel and subsequent myotomy from the gastric cardia to the gastric pylorus.
48677730|NCT03680885|DRUG|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
48677731|NCT06059807|DEVICE|maxillary expansion|Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
48677732|NCT04595786|DRUG|Tranexamic acid|20mg/kg TXA was prepared in a 50ml syringe for intravenous pump
48677733|NCT04595786|DRUG|0.9% saline|0.9% saline was prepared in a 50ml syringe for intravenous pump
48677734|NCT04735653|BEHAVIORAL|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
48677735|NCT04735653|BEHAVIORAL|Enhanced Standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
48677736|NCT01521598|DRUG|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
48677737|NCT01521598|DRUG|Placebo|This is the placebo. Patients will be randomized the placebo.
47992928|NCT00000766|DRUG|Foscarnet sodium|
47992929|NCT00000766|DRUG|Ganciclovir|
47992930|NCT01746979|DRUG|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
47992931|NCT01746979|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
47992932|NCT01746979|DRUG|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
48152339|NCT03353649|DEVICE|fMRI|Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
48363617|NCT04781946|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|The Roux-en-Y gastric bypass is a type of weight-loss surgery that involves creating a small pouch from the stomach and connecting the newly created pouch directly to the small intestine.
48363618|NCT00252798|DRUG|Gefitinib|
48363619|NCT00252798|DRUG|Carboplatin|
48363620|NCT00252798|DRUG|Paclitaxel|
48363621|NCT00252798|PROCEDURE|Radiation|
48363622|NCT02412826|DEVICE|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
48363623|NCT05553886|DRUG|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug|To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug
48152340|NCT05214248|OTHER|a multimedia admission orientation|A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
48152341|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
48152342|NCT05570344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support|"rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.~Text4Support:~Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation \[80\]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns."
48152343|NCT01207453|DRUG|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
48152344|NCT01207453|DRUG|Placebo|
48152345|NCT06255132|DEVICE|Automated pupillometer NPi-200|"Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS\>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS \> 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon)."
48677738|NCT05511012|OTHER|motion control fault tests|Patients make 6 motion control fault tests, in the same order. Each test is performed three times
48677739|NCT04062084|DEVICE|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
48152346|NCT03512041|BEHAVIORAL|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
48152347|NCT03512041|BEHAVIORAL|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
48152348|NCT03512041|BEHAVIORAL|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
48677740|NCT04458740|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
48677741|NCT04165863|PROCEDURE|total knee replacement surgery|total knee replacement surgery
48677742|NCT00507585|DRUG|Fluorouracil|300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
48677743|NCT00507585|DRUG|Avastin|10 mg/m\^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
48677744|NCT00507585|DRUG|Leucovorin|200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
47992933|NCT06162156|OTHER|Back massage|For the intervention group, massage will be given to the participant's back area by the researcher for 20 minutes, 12 hours after the cesarean birth. Preliminary data forms will be filled out by the participant before the massage. One hour after the massage, 'Visual Analog Scala' and 'Physiological Parameter Form' data will be filled in again. The final data forms will be filled out by the participant 24 hours after the cesarean birth, that is, 12 hours after the back massage.
47992934|NCT03687203|DIAGNOSTIC_TEST|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
47992935|NCT03009929|OTHER|Observational study|No intervention, observational only
47992936|NCT04067557|DIAGNOSTIC_TEST|molecuar test of BV|diagnosis of BV
47992937|NCT00716911|DRUG|ganciclovir|
47992938|NCT00716911|GENETIC|polymerase chain reaction|
47992939|NCT00716911|OTHER|flow cytometry|
47992940|NCT00716911|OTHER|immunologic technique|
47992941|NCT00716911|PROCEDURE|allogeneic bone marrow transplantation|
47992942|NCT00716911|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
47992943|NCT00716911|PROCEDURE|assessment of therapy complications|
47992944|NCT00716911|PROCEDURE|peripheral blood stem cell transplantation|
47992945|NCT03948256|PROCEDURE|Control intervention|Prompt closure of EVD with subsequent observation period
47992946|NCT03948256|PROCEDURE|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
47992947|NCT06362187|DEVICE|Gut Directed VR|The VR experiences follow a protocolized gut-directed therapy
47992948|NCT06362187|DEVICE|Sham Control VR|The same Oculus Quest 2 device as the active treatment group but will use distractive therapy
47992949|NCT00616460|DRUG|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
47992950|NCT05245708|DRUG|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
47992951|NCT05245708|DRUG|intranasal placebo|Each subject will be assigned to intranasal placebo.
47992952|NCT03403816|BEHAVIORAL|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
47992953|NCT02171260|DRUG|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
47992954|NCT01050257|DRUG|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
47992955|NCT01050257|DRUG|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
47992956|NCT00078026|DRUG|Apomine|
47992957|NCT05283187|BEHAVIORAL|Mindfulness Based Cognitive Therapy Group|Mindfulness Based Cognitive Therapy
47992958|NCT03294395|DRUG|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
48677745|NCT00507585|DRUG|Oxaliplatin|60 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
48677746|NCT02126046|GENETIC|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
48677747|NCT00368030|DRUG|Eszopiclone|Eszopiclone 3 mg QD
47992959|NCT03294395|DRUG|Fosfomycin Oral Suspension|single dose 6g oral suspension
47992960|NCT03294395|DRUG|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
47992961|NCT03294395|DRUG|Ceftriaxone|single dose 500mg intramuscular injection
47992962|NCT00777647|OTHER|Sugar-sweetened soft drink|One litre a day for six months.
47992963|NCT00777647|OTHER|Aspartame-sweetened soft drink|One litre a day for six months.
47992964|NCT00777647|OTHER|Semi-skimmed milk|One litre a day for six months
47992965|NCT00777647|OTHER|Water|One litre a day for six months.
47992966|NCT01424423|DRUG|Placebo|Placebo
47992967|NCT01424423|DRUG|GSK1223249|I.V. Infusion
47992968|NCT04352855|DRUG|Ceftolozane/tazobactam|Administration
47992969|NCT04404855|OTHER|NGS + Antibiotic Recommendation|NGS results in addition to recommended antibiotic therapy made by infectious disease pharmacist
47992970|NCT04404855|PROCEDURE|Standard of Care treatment|Subjects will have a standard of care urine culture and prophylactic antibiotic prescribed per routine care.
47992971|NCT05919303|RADIATION|CT Scan|CT scan study of abdomen
48677748|NCT00368030|OTHER|Placebo|Placebo tablet
48677749|NCT02991339|DRUG|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
48677750|NCT04892706|DRUG|IDP-126 Gel|Gel applied to face once daily in the evening.
48677751|NCT04892706|DRUG|IDP-126 Vehicle Gel|Gel applied to face once daily in the evening.
48677752|NCT04892706|DRUG|Epiduo® Forte Gel|Gel applied to face once daily in the evening.
48152349|NCT03512041|BEHAVIORAL|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
48152350|NCT03512041|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
48152351|NCT03512041|BEHAVIORAL|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
48677753|NCT06390956|DRUG|Pirtobrutinib|Administered once daily as an oral medication.
48152352|NCT03512041|BEHAVIORAL|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
48363624|NCT03140150|DEVICE|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
48677754|NCT02911142|DRUG|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
48677755|NCT02911142|DRUG|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
48677756|NCT02911142|DRUG|Prednisone|During cycle 1, Prednisone 60 mg/m2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m2 /day PO days 1-5.
48677757|NCT02911142|DRUG|Etopside|During cycle 1, Etoposide 50 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m2/day continuous intravenous infusion days 1 to 4.
48677758|NCT02911142|DRUG|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
48677759|NCT02911142|DRUG|Vincristine|During cycle 1, Vincristine 0.4 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
48677760|NCT02911142|DRUG|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
48677761|NCT02449941|DRUG|PPI (proton pump inhibitor)|"1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI."
48677762|NCT01899547|PROCEDURE|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
48677763|NCT01899547|PROCEDURE|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
47992972|NCT05741515|OTHER|Vestibular Balance Therapy|see intervention arm description
47992973|NCT05741515|OTHER|Sham Intervention|see sham intervention arm description
47992974|NCT03674918|DIAGNOSTIC_TEST|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
47992975|NCT02266459|DEVICE|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is \< 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
47992976|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
47992977|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
48363625|NCT03140150|OTHER|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
48677764|NCT00976716|DRUG|Celecoxib|"Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily"
48677765|NCT03429738|DRUG|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
48677766|NCT03429738|DRUG|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
48677767|NCT04968392|DRUG|Dexmedetomidine Hydrochloride|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
48677768|NCT04968392|DRUG|Levobupivacaine|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
48677769|NCT02022709|DRUG|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
48677770|NCT02022709|DRUG|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
48677771|NCT02022709|DRUG|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
48677772|NCT02022709|DRUG|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
48677773|NCT02022709|DRUG|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
48677774|NCT02022709|BEHAVIORAL|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
48677775|NCT05695170|BEHAVIORAL|PreventT2 (Individual intervention)|"PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National Diabetes Prevention Program (DPP), which has full recognition from the CDC based on outcome data over the course of a number of years."
48677776|NCT05695170|BEHAVIORAL|PreventT2 Together (Couple-based intervention)|PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
48677777|NCT01237431|DIETARY_SUPPLEMENT|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
48363626|NCT01005875|DRUG|Sorafenib|Nexavar in bottles of 120 tables
48363627|NCT01005875|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT
48677778|NCT00848263|PROCEDURE|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
48677779|NCT00848263|PROCEDURE|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
48677780|NCT00337038|DRUG|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
48677781|NCT05005221|BEHAVIORAL|Automated text messages|Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
48677782|NCT04954534|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
47992978|NCT00665353|DRUG|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
47992979|NCT00665353|DRUG|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
47992980|NCT00665353|DRUG|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
47992981|NCT02032966|PROCEDURE|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
48363628|NCT00862927|OTHER|Breath Sample|Breathe into machine measuring carbon monoxide.
48363629|NCT00862927|OTHER|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
48363630|NCT00862927|BEHAVIORAL|Questionnaire|6 surveys, taking approximately 30 minutes total.
48677783|NCT01531998|DRUG|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
48677784|NCT01531998|DRUG|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
48677785|NCT01531998|DRUG|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
48677786|NCT01531998|DRUG|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
47992982|NCT02032966|PROCEDURE|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
47992983|NCT03038815|DEVICE|VACOped|restriction of ankle joint motion
47992984|NCT03038815|DEVICE|Ortho Tri|restriction of ankle joint motion
47992985|NCT01153243|DRUG|Ergocalciferol|"Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
48677787|NCT01531998|BEHAVIORAL|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
47992986|NCT01153243|DRUG|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
47992987|NCT00813085|OTHER|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
48677788|NCT04451408|DRUG|LY3372993|Administered IV or SC.
47992988|NCT05243225|PROCEDURE|Laparoscopic versus open surgical management of post cholecystectomy bile duct injury|Comparison between laparoscopic and open surgical management of post cholecystectomy bile duct injury.
47992989|NCT05930210|DRUG|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
47992990|NCT05930210|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
47992991|NCT05361317|DEVICE|Nexis® PECA Bunion device|Hallux valgus correction with percutaneous chevron and Akin osteotomy.
47992992|NCT04626947|BIOLOGICAL|Bezlotoxumab|Bezlotoxumab infusion
47992993|NCT05696912|GENETIC|Ex-vivo approach concerning 25 patients|Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis
47992994|NCT05696912|GENETIC|In-vitro approach concerning 25 patients|In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay
48677789|NCT04451408|DRUG|Placebo|Administered IV or SC.
48677790|NCT00572416|BEHAVIORAL|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
48677791|NCT00572416|BEHAVIORAL|Healthy Eating Control|Equal time and attention and information about healthy eating
48677792|NCT00418704|DRUG|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
48677793|NCT00418704|DRUG|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
48677794|NCT05446935|PROCEDURE|HITOC|Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
48677795|NCT04133025|OTHER|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
47992995|NCT05275647|DRUG|BOTOX 100U in normal saline|LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
47992996|NCT05275647|DRUG|Normal saline|LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
47992997|NCT01782261|DRUG|Liraglutide|once daily subcutaneous injection
47992998|NCT01782261|DRUG|Saxagliptin|once daily tablet
47992999|NCT02971267|OTHER|Observational|None, observational only
47993000|NCT01092533|DRUG|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
47993001|NCT01092533|DRUG|Decortin|Maintenance dose 5 mg/d
47993002|NCT01912417|OTHER|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
47993003|NCT02659709|DEVICE|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
47993004|NCT03613051|BEHAVIORAL|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
47993005|NCT01763437|DRUG|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
48677796|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
48363631|NCT00862927|BEHAVIORAL|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
48363632|NCT03336164|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
48677797|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
48677798|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
48677799|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
48677800|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
48677801|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
48677802|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
48677803|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
48677804|NCT02574559|BEHAVIORAL|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
48677805|NCT01969539|DRUG|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
48677806|NCT01969539|DRUG|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
48677807|NCT01102920|BEHAVIORAL|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician."
47993007|NCT03720470|DRUG|PF-04965842 100 mg|"PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20."
47993008|NCT03720470|DRUG|PF-04965842 200 mg|"PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20."
48363633|NCT05275140|OTHER|Physical activity|Combat sports and exercise
48677808|NCT01102920|DEVICE|CPAP|CPAP-treatment as usual (during nights)
48677809|NCT01534481|BIOLOGICAL|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
48677810|NCT01534481|DIETARY_SUPPLEMENT|Preterm Formula|Preterm Formula determined by center practice.
48677811|NCT05663008|PROCEDURE|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
48677812|NCT05614661|BEHAVIORAL|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
48677813|NCT04014426|OTHER|Blood sample|"Exposed group:~* 15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~* 2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
48677814|NCT04014426|OTHER|Urinary sample|"Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)"
48677815|NCT00856609|DRUG|Byetta (exenatide)|Exenatide is an injectable medication
48677816|NCT00856609|BEHAVIORAL|Weight loss|Because response to weight loss
48677817|NCT00856609|OTHER|Metabolic Chamber|The subject stays in the small room
48677818|NCT00856609|DRUG|Placebo|
48677819|NCT06342765|DEVICE|Pedicle fixation surgery|Pedicle fixation surgery indicates a surgical approach in the thoracic spine down to sacral spine to either support interbody fusion (fusion of the discal space between two vertebrae) , or to correct spinal deformity.
48677820|NCT05113654|DIAGNOSTIC_TEST|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
48677821|NCT00362882|DRUG|docetaxel|Given IV
48677822|NCT00362882|DRUG|bortezomib|Given IV
48677823|NCT00362882|OTHER|laboratory biomarker analysis|correlative study
47993009|NCT03720470|DRUG|Dupilumab|Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
47993010|NCT03720470|DRUG|Oral Placebo|"Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16."
47993011|NCT03720470|DRUG|Injectable Placebo|Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
47993012|NCT00419198|PROCEDURE|Postconditioning|Postconditioning during angioplasty
47993013|NCT00419198|PROCEDURE|standard angioplasty|standard angioplasty without postconditioning
47993014|NCT00204347|DRUG|risperidone|
47993015|NCT03205059|BEHAVIORAL|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
47993016|NCT03205059|BEHAVIORAL|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
47993017|NCT03828812|BEHAVIORAL|Breakfast promotion|Recommendation of having breakfast daily
47993018|NCT03828812|BEHAVIORAL|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
47993019|NCT04130451|DRUG|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
47993020|NCT04025996|DIAGNOSTIC_TEST|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~* transthoracic echocardiography~* computed tomography of coronary arteries~* position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~* pupil dilation~* retinal photography~* dynamic vessel analyser~* IOL master"
47993021|NCT05643040|OTHER|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
47993022|NCT05643040|OTHER|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
47993023|NCT05643040|OTHER|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
48363634|NCT04851041|OTHER|Potato|Controlled human intervention trial to evaluate the impact of boiled potato intake as part of a healthy dietary patterns on cardiometabolic health
48363635|NCT04851041|OTHER|Pasta/rice|Since potatoes, white rice and white pasta are all products with a high glycemic index and concomitant relatively steep glucose excursions after intake, this intervention group helps to compare the effect of potato vs another high glucemic index food.
48677824|NCT00362882|OTHER|immunoenzyme technique|correlative study
48677825|NCT00362882|OTHER|immunohistochemistry staining method|correlative study
48677826|NCT00362882|OTHER|pharmacological study|correlative study
48677827|NCT02560727|DEVICE|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
48677828|NCT02560727|DEVICE|colonoscope|FMT via colonoscope is the most common approach.
48677829|NCT06246305|OTHER|conventional physical therapy training|conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance, and scapular stabilization exercises. The intervention is done 3 times per week for 12 weeks.
48363636|NCT04723342|DRUG|Blinatumomab|"Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment"
48677830|NCT06246305|DEVICE|Virtual Reality (VR) training|During the on-brace phase (0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. this program involves warming up and down stretching exercises and exercise training that includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. The intervention is done 3 times per week for 12 weeks.
47993024|NCT04989400|DRUG|Ulipristal Acetate|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
48363637|NCT00840931|DRUG|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
48677831|NCT01950728|DEVICE|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.
48677832|NCT01950728|DEVICE|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.
47993025|NCT04989400|DRUG|Misoprostol|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
48677833|NCT01950728|DEVICE|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
48677834|NCT02682459|DRUG|Lisinopril|
48677835|NCT01769976|OTHER|Periodic fasting|
48677836|NCT01769976|OTHER|Energy restriction|
48677837|NCT01769976|OTHER|Energy balance diet|
48677838|NCT06046066|DRUG|NM6603|NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
48677839|NCT04414540|DRUG|Metformin Extended Release Oral Tablet|Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
48677840|NCT04414540|DRUG|Pembrolizumab|Pembrolizumab q 3 weeks
48677841|NCT02849002|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
48677842|NCT05262413|DRUG|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
48677843|NCT01664754|DRUG|exemestane|Given PO
48677844|NCT01664754|DRUG|pemetrexed disodium|Given IV
47993026|NCT04098107|DEVICE|Throwing Device|The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
48363638|NCT00840931|BIOLOGICAL|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
48677845|NCT01664754|DRUG|carboplatin|Given IV
47993027|NCT02959047|DRUG|Alirocumab|150mg SQ every 2 weeks
47993028|NCT02959047|DRUG|Matching placebo|SQ every 2 weeks
47993029|NCT05771207|DIETARY_SUPPLEMENT|soy protein|The intervention is made up of soy protein supplements (30g/d) and dietary pattern modification.
48677846|NCT01664754|OTHER|laboratory biomarker analysis|Correlative studies
48677847|NCT01664754|OTHER|pharmacological study|Correlative studies
48363639|NCT01833299|PROCEDURE|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
48677848|NCT01664754|OTHER|questionnaire administration|Ancillary studies
48677849|NCT01664754|PROCEDURE|quality-of-life assessment|Ancillary studies
48677850|NCT03100318|DRUG|FYU-981|Oral daily dosing for 14 weeks
48677851|NCT03100318|DRUG|Benzbromarone|Oral daily dosing for 14 weeks
48677852|NCT00002286|DRUG|Zidovudine|
48677853|NCT01127932|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
48677854|NCT01127932|BEHAVIORAL|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
48677855|NCT01179269|DRUG|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
48677856|NCT01327235|DRUG|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
48677857|NCT01327235|DRUG|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
48677858|NCT03729635|PROCEDURE|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
48677859|NCT05353686|DRUG|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
48677860|NCT05353686|DRUG|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
48677861|NCT03712774|OTHER|EORTC QLQ C30|standardized questionaire
48677862|NCT03712774|OTHER|EORTC QLQ OES-18|standardized questionaire
48677863|NCT03712774|OTHER|EORTC OG-25|standardized questionaire
48677864|NCT03116425|DEVICE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
48152353|NCT05935072|BEHAVIORAL|Exercice and meal|The participants will carry out four experimental visits in a randomized order: CON_Calibré: control condition with a calibrated test meal; CON_AdLib: control condition with an ad libium test meal; EX_Calibré: exercise condition with a calibrated test meal; EX_AdLib: exercise condition with an ad libitm test meal. During each of the conditions, the participants will join the laboratory at 8:00 a.m. and will receive a calibrated breakfast. They will be asked at 11:00 a.m. either to rest in a semi-recumbent position for 30 minutes (CON conditions) or to perform a pedaling exercise on an ergocycle at 65% of their estimated aerobic capacity for 30 minutes. A test meal will be served to participants at 12:00 p.m., either ad libitum or calibrated. Appetite sensations will be assessed at regular intervals during each condition and their food reward preferences and ratio assessed 15 minutes before and 15 minutes after the test meals.
48363640|NCT01833299|PROCEDURE|TACE|
48363641|NCT01602627|DRUG|Hsp90 inhibitor AUY922|Given IV
48677865|NCT03116425|DEVICE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
48677866|NCT03116425|DEVICE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
48677867|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
48677868|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
48677869|NCT03116425|PROCEDURE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
48677870|NCT00894699|DRUG|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
48677871|NCT00894699|DRUG|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
48677872|NCT05389748|OTHER|Placebo|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to placebo in association with standard of care
48677873|NCT05389748|BIOLOGICAL|dodecafluoropentane emulsion (DDFPe)|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to DDFPe in association with standard of care
47993030|NCT05771207|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (30g/d) and dietary pattern modification.
48363642|NCT01602627|OTHER|pharmacological study|Correlative studies
47993031|NCT05771207|DIETARY_SUPPLEMENT|placebo|The intervention is made up of maltodextrin (30g/d) and dietary pattern modification.
47993032|NCT03459378|OTHER|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
48363643|NCT01602627|OTHER|laboratory biomarker analysis|Correlative studies
48363644|NCT00068549|DRUG|Gemcitabine Hydrochloride|Given IV
48677874|NCT04966234|DRUG|Posaconazole 100 MG [Noxafil]|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
48677875|NCT04966234|DRUG|Posaconazole 40 MG/ML|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
48677876|NCT03723980|DRUG|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
48677877|NCT03723980|DRUG|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
48677878|NCT02281656|PROCEDURE|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
48677879|NCT02281656|PROCEDURE|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
48677880|NCT00833443|DRUG|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
48677881|NCT04126018|DIAGNOSTIC_TEST|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
48677882|NCT04126018|DIAGNOSTIC_TEST|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
47993033|NCT03149107|DRUG|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
47993034|NCT03149107|DRUG|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
47993035|NCT03149107|BEHAVIORAL|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician \& rater)
48363645|NCT00068549|DRUG|Cisplatin|Given IV
48677883|NCT06322030|DIETARY_SUPPLEMENT|FOCUS-15 Lifestyle Management Program|15 week weight management program
48677884|NCT06322030|BEHAVIORAL|Exercise Training|15 weeks of progressive exercise training
48677885|NCT03154671|OTHER|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
47993036|NCT03149107|BEHAVIORAL|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician \& rater).
47993037|NCT04867265|PROCEDURE|Mout-to-mouth ventilation|we will record the visibility of chest rising
47993038|NCT04867265|PROCEDURE|Mout-to-mouth ventilation with quantitative analysis|we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
47993039|NCT02596269|DRUG|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
48363646|NCT00068549|RADIATION|Radiation Therapy|Undergo whole pelvis radiotherapy
48363647|NCT00068549|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
48677886|NCT04271358|BEHAVIORAL|Peer Health Coaching|The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
47993040|NCT02596269|DRUG|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
47993041|NCT03170128|PROCEDURE|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
47993042|NCT03170128|BEHAVIORAL|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
47993043|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of anemia.
48677887|NCT04665804|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
48677888|NCT04665804|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
47993044|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of fatigue.
47993045|NCT04474951|DIETARY_SUPPLEMENT|Peppermint|Eligible patients will take 40 drops TID of Fluid Extract of Peppermint for control of nausea.
48677889|NCT04665804|OTHER|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
48677890|NCT04665804|OTHER|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
48677891|NCT04665804|PROCEDURE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
48677892|NCT04665804|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
48677893|NCT00127881|DRUG|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
48677894|NCT03160456|DEVICE|Transcutaneous electrical stimulation|The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
47993046|NCT01879774|OTHER|Neuropsychological and motoric tests|"1. Neuropsychological tests~   * Mini Mental Status Test~  * Dem-Tect~  * Rey-Osterrieth Complex Figure Test~  * Trailmaking Test~  * Beck Depression Inventory~  * d2-R (optional)~2. Motoric tests~   * modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~  * Timed-up-and-go Test~  * Halstead Fingertapping Test~  * AIMS (Abnormal involuntary movement scale)~3. EEG (only in patients with hyponatremia)~4. MRI (only in patients with hyponatremia)"
47993047|NCT01888796|DRUG|Linagliptin|
47993048|NCT01888796|DRUG|placebo|
47993049|NCT02447133|DEVICE|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
47993050|NCT03599050|BEHAVIORAL|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
47993051|NCT01429272|DRUG|Minocycline|100 mg po bid for 6 weeks
47993052|NCT01429272|DRUG|Aspirin|81 mg po bid for 6 weeks
47993053|NCT01429272|DRUG|placebo|placebo for minocycline and/or aspirin
47993054|NCT05221333|DEVICE|Sorrel Wearable Injector|Use of Sorrel Wearable Injector in pilot study
47993055|NCT01312090|BIOLOGICAL|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
47993056|NCT01312090|BEHAVIORAL|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
47993057|NCT00445965|GENETIC|DNA analysis|
47993058|NCT00445965|OTHER|immunologic technique|
47993059|NCT00445965|OTHER|pharmacological study|
47993060|NCT00445965|RADIATION|iodine I 131 monoclonal antibody 3F8|
48677895|NCT03160456|DEVICE|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
47993061|NCT00445965|RADIATION|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
47993062|NCT02664909|DRUG|Tranexamic Acid|
47993063|NCT02664909|DRUG|Placebo (saline)|
47993064|NCT00598663|DEVICE|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
47993065|NCT00598663|DEVICE|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
47993066|NCT02563795|DRUG|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
47993067|NCT02563795|DRUG|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
47993068|NCT03629821|OTHER|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
47993069|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for NON-SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
47993070|NCT06042309|OTHER|SLS|Exposure to SLS on a randomized arm
48677896|NCT00772278|PROCEDURE|carotid artery stenting|carotid artery angiography, angioplasty and stenting
48677897|NCT00772278|PROCEDURE|carotid endarterectomy|open surgery including endarterectomy
48677898|NCT01059006|PROCEDURE|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
48677899|NCT01369199|DRUG|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
47993071|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.
48677900|NCT05465005|BEHAVIORAL|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
48677901|NCT05189210|DRUG|GV1001 Placebo|0.9% normal saline
48677902|NCT05189210|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
48677903|NCT05189210|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
48677904|NCT01285024|DEVICE|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
48677905|NCT05696847|DRUG|Tirzepatide|Administered SC
48677906|NCT05696847|DRUG|Placebo|Administered SC
48677907|NCT00000792|DRUG|Hypericin|
48677908|NCT00871663|DRUG|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
48677909|NCT06183151|DEVICE|Entia Liberty System|See arm/group description
48677910|NCT06094309|DRUG|Botulinum toxin type A injection|The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
48677911|NCT04524221|DRUG|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
48677912|NCT04524221|DRUG|Placebo|Placebo taken twice daily in capsule form for 42 days
48677913|NCT05955664|DIAGNOSTIC_TEST|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
48677914|NCT05955664|DIAGNOSTIC_TEST|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
48677915|NCT04619667|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
48677916|NCT04619667|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
48677917|NCT02060786|DRUG|generic clopidogrel (Plavitor® )|
48677918|NCT02060786|DRUG|original clopidogrel (Plavix® )|
48677919|NCT01172444|DRUG|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
48677920|NCT01172444|DRUG|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
48677921|NCT01172444|DRUG|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
48677922|NCT00994825|DRUG|Levosimendan|
48677923|NCT00994825|DRUG|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
48511364|NCT05076214|BEHAVIORAL|Aerobic exercise in group|"The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
48511365|NCT05076214|BEHAVIORAL|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
48677924|NCT01591265|PROCEDURE|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
48677925|NCT01591265|PROCEDURE|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
48677926|NCT02359006|DRUG|Minocycline|Minocycline will be compared with placebo
48677927|NCT02359006|DRUG|Placebo|Placebo will be compared with minocycline
48677928|NCT04188990|DIETARY_SUPPLEMENT|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
48677929|NCT04188990|DIETARY_SUPPLEMENT|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
48677930|NCT04188990|DIETARY_SUPPLEMENT|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
48677931|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
48677932|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
48677933|NCT00932074|DRUG|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
48677934|NCT01527422|DRUG|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
48677935|NCT04735315|OTHER|Preterm birth|The study compares young adult subjects born premature (\< 29 weeks) versus term \> 37-41 weeks)
48677936|NCT05270018|DRUG|Bacterial Lysates|14mg once a day
48677937|NCT05270018|OTHER|normal saline|14.0ml once a day
48677938|NCT00028158|DRUG|G207, an oncolytic virus|
48677939|NCT00980148|DRUG|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
48677940|NCT00980148|DRUG|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
48677941|NCT03888378|DRUG|0.3% Topical Minocycline Ointment|0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
48677942|NCT03888378|DRUG|1% Topical Minocycline Ointment|1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
48677943|NCT03888378|OTHER|Topical Vehicle Ointment|Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction
48677944|NCT00693927|PROCEDURE|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
47993072|NCT06042309|OTHER|Patch test on back|Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
47993073|NCT04483908|DIAGNOSTIC_TEST|blood draw|2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)
47993074|NCT04483908|DIAGNOSTIC_TEST|fingertip tests for POC assays|performing POC test by taking two blood drops from the fingertip
47993075|NCT04483908|DIAGNOSTIC_TEST|saliva collection|saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.
48363648|NCT05853289|OTHER|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
48677945|NCT00693927|PROCEDURE|CD8-depleted PBSC after nonmyeloablative conditioning|
48677946|NCT00258908|BIOLOGICAL|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
48677947|NCT04982705|DRUG|[Part 1.1] IDG-16177|\[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
48677948|NCT04982705|DRUG|[Part 1.1] Placebo of IDG-16177|\[Part 1.1\] subjects will receive a single oral dose of IMP.
48677949|NCT04982705|DRUG|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
48677950|NCT04982705|DRUG|[Part1.2] IDG-16177|\[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
48363649|NCT02981745|DRUG|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
48511366|NCT01308424|DRUG|BTL TML HSV|Sublingual micro-dosing for 7 days
48677951|NCT04982705|DRUG|[Part 2] IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
48677952|NCT04982705|DRUG|[Part 1.2] Placebo of IDG-16177|\[Part 1.2\] Administration once daily for 14 days.
48677953|NCT04982705|DRUG|[Part 2] Placebo of IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
48677954|NCT03336190|BEHAVIORAL|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
48677955|NCT03678051|BEHAVIORAL|Treatment as Usual (TAU)|Standard of care residential treatment
48677956|NCT03678051|BEHAVIORAL|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
48677957|NCT01762683|OTHER|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
48677958|NCT02605356|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
48511367|NCT01308424|DRUG|Matching placebo|sublingual dosing for 7 days
47993076|NCT04483908|DIAGNOSTIC_TEST|collection of swabs|collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)
47993077|NCT03503786|DRUG|Carboplatin|Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
47993078|NCT03503786|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
48511368|NCT06629831|OTHER|group with complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
48511369|NCT06629831|OTHER|group without complications|Complications in patients undergoing cytoreduction surgery for ovarian cancer
48677959|NCT02605356|DRUG|Placebo|
47993079|NCT03503786|DRUG|Avelumab|Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
47993080|NCT00496093|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
47993081|NCT00982475|PROCEDURE|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
47993082|NCT01132482|DRUG|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
47993083|NCT01132482|DRUG|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
47993084|NCT03731520|DIAGNOSTIC_TEST|Assessing exercise behavior|11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
47993085|NCT02938689|OTHER|Exercise|
47993086|NCT00590447|DRUG|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
48677960|NCT02605356|DRUG|Bortezomib|
48677961|NCT02605356|DRUG|Dexamethasone|
48677962|NCT01494324|OTHER|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
48677963|NCT05312840|DRUG|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
47993087|NCT00590447|DRUG|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
48152354|NCT02168153|OTHER|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
48152355|NCT02168153|OTHER|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
48152356|NCT00379210|BEHAVIORAL|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
48152357|NCT00379210|BEHAVIORAL|Nutrition Education course|8-week course in nutrition
48152358|NCT01123356|DRUG|Ofatumumab|"* Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles"
48511370|NCT06456905|BEHAVIORAL|Contingency Management|Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.
48511371|NCT03179423|DRUG|GNbAC1|Monthly IV repeated dose
48511372|NCT03179423|DRUG|Placebo|Monthly IV repeated dose
48677964|NCT05595343|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
48677965|NCT02938247|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
48677966|NCT02332785|OTHER|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
48677967|NCT04074512|DRUG|Copper Histidinate|Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.
48677968|NCT00633763|DRUG|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
47993088|NCT04500210|DIETARY_SUPPLEMENT|Placebo|Placebo in gelatin capsules
47993089|NCT04500210|DIETARY_SUPPLEMENT|Turmeric|Turmeric in gelatin capsules
48677969|NCT00633763|DRUG|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
48677970|NCT02390492|DRUG|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
48677971|NCT02390492|DRUG|Period 2 treatment|200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
48677972|NCT04463940|OTHER|No intervention|No intervention
47993090|NCT04306874|DIETARY_SUPPLEMENT|Ensure Max Protein|Liquid shake with 30 g protein per serving
47993091|NCT02608554|BEHAVIORAL|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
47993092|NCT02608554|BEHAVIORAL|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
47993093|NCT01990495|OTHER|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
48152359|NCT01123356|DRUG|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
48152360|NCT03031223|RADIATION|low-level laser therapy|low-level laser therapy
48152361|NCT03384342|DEVICE|Narrow-band UV-B therapy|"* Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~* For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
48152362|NCT05428215|DRUG|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
48152363|NCT04151888|DEVICE|Foley catheter|Thin sterile tube will be inserted in choana
48677973|NCT01022970|DRUG|QAX576 placebo|
48677974|NCT01022970|DRUG|QAX576|
48677975|NCT04155528|OTHER|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
48677976|NCT00898170|PROCEDURE|myoma removal|surgical removal of myoma by hysterectomy
48677977|NCT00606645|BIOLOGICAL|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
48677978|NCT01840488|DRUG|Irosustat (BN83495)|"Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
48152364|NCT01469884|DRUG|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
48152365|NCT01469884|DRUG|Cyclosporine|Trough level should be between 100 and 200ng/ml.
48152366|NCT01469884|DRUG|Tacrolimus|Trough level should be between 5 and 10ng/ml.
48363650|NCT04114266|OTHER|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
48363651|NCT00743639|PROCEDURE|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10\[7\] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
48363652|NCT04173169|DRUG|Elagolix 200 MG|Elagolix tablet
48363653|NCT04173169|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
48363654|NCT02343991|DEVICE|Transcranial ExABlate|MR Guided Focused Ultrasound
48363655|NCT00485615|DRUG|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
47993094|NCT01990495|OTHER|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
47993095|NCT05064033|OTHER|Pragmatic Set of intervention and posterior capsular stretch|Group 1 will receive a pragmatic set of interventions, including Serratus Anterior Stretch,Rotator Cuff Facilitation,Acromilcalavicular joint Mobilization,Stretch of Pectoralis Major and Minor,Thoracic Manipulation and posterior capsular stretch.
47993096|NCT05064033|OTHER|Pragmatic Set of intervention and Sleeper Stretch|Group 2 will receive a pragmatic set of interventions, including Serratus Anterior Stretch, Rotator Cuff Facilitation, Acromilcalavicular joint Mobilization, Stretch of Pectoralis Major and Minor, Thoracic Manipulation and sleeper stretch.
48363656|NCT05121129|DEVICE|iTBS|25 active iTBS sessions (5 sessions of 9.5 minutes/day, 1,800 pulses per session, 90% of resting motor threshold, placed over the left DLPFC)
48363657|NCT05585801|DEVICE|Dexcom G6 continuous glucose monitor|"Continuous glucose monitor will be used to measure interstitial glucose and aid in guiding the insulin therapy to achieve target blood glucose range of 6-10 mmol/l.~In the control group, blood glucose will be measured according to standards of care and a blinded continuous monitor will be used to compare the time i range between the arms."
48363658|NCT05585801|DIAGNOSTIC_TEST|Blood glucose measurements according to standards of care|Blood glucose will be measured using point of care glucose meter and standard biochemistry methods. Blinded CGM will be applied to obtain continuous glucose values for post-hoc comparison.
48363659|NCT02896972|PROCEDURE|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
48363660|NCT01680835|DEVICE|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.
48677979|NCT05225883|GENETIC|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
48677980|NCT03110718|DEVICE|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
48677981|NCT01545596|BEHAVIORAL|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
48677982|NCT04336241|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
48677983|NCT04336241|BIOLOGICAL|nivolumab|Programmed death receptor (PD-1) blocking antibody
48677984|NCT04965298|DRUG|Lansoprazole|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
47993097|NCT03429179|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
47993098|NCT03429179|OTHER|Physiological saline|intravenous infusion of the same volume of 0.9% saline
47993099|NCT00963287|DRUG|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
47993100|NCT04886986|DRUG|225Ac-J591|30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I\&T. Intravenous administration.
47993101|NCT04886986|DRUG|177Lu-PSMA-I&T|6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
47993102|NCT04886986|DRUG|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
47993103|NCT04853745|DEVICE|AIR-FLOW® Master Piezon|AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
47993104|NCT03745937|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
47993105|NCT03745937|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
47993106|NCT01522365|DEVICE|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
47993107|NCT01522365|DEVICE|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
47993108|NCT05957796|DEVICE|"Novel Snaps Eye Shield"|"Using a novel eye shield, Snaps manufactured in Morgantown, WV by Intermed Labs after cataract surgery that has a different adhesive mechanism that utilizes adhesive and snap-on attachments to the shield."
47993109|NCT05957796|OTHER|Standard Alcon Eye Shield|Use normal Alcon eye shield with tape to adhere to shield to eye postop.
47993110|NCT03768596|BEHAVIORAL|Nudge|Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.
47993111|NCT03768596|OTHER|vaccination form|a form about vaccination
47993112|NCT02290509|BIOLOGICAL|Flublok Quadrivalent|Intramuscular injection of study vaccine
47993113|NCT02290509|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
47993114|NCT00352846|DRUG|Zoledronic Acid|4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.
47993115|NCT00352846|DRUG|Vitamin D|400 mg by mouth daily
47993116|NCT00352846|DRUG|Calcium Carbonate|1200 mg by mouth daily
47993117|NCT03830944|DIAGNOSTIC_TEST|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
47993118|NCT03830944|DIAGNOSTIC_TEST|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
47993119|NCT03830944|DIAGNOSTIC_TEST|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
48363661|NCT05632705|OTHER|Closing pack|A closing pack, new sterile gloves and new sterile drapes will be used when commencing closure of the sheath and skin
47993120|NCT03830944|DIAGNOSTIC_TEST|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
48363662|NCT04873323|DRUG|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
48363663|NCT04873323|DRUG|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
48363664|NCT04873323|DRUG|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
47993121|NCT02994160|OTHER|Fast electrode|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
48677985|NCT04965298|OTHER|Matched placebo|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
48677986|NCT05346276|DIAGNOSTIC_TEST|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
48677987|NCT04312503|DRUG|Lurasidone|Patients are treated with dosages according clinical practice
48677988|NCT04312503|DRUG|aripiprazole, olanzapine, quetiapine or risperidone|Patients are treated with dosages according clinical practice
48677989|NCT05182450|OTHER|Mango leaf extract capsule|Single dose
48677990|NCT05182450|OTHER|Placebo capsule|Single dose
47993122|NCT01214018|OTHER|Questionnaires and interview|Questionnaires and interview
47993123|NCT06371742|OTHER|Liquid ingestion during labour|An assessment of the volume capacity of the water glasses was carried out using duly certified 50mL syringes in order to calibrate and control the correct measurement of the amount of water ingested. Water is measured using a graduated cup, which is pre-existing in the BP service, since its water intake policy is governed by the formula 1ml/kg/h of clear liquids (water or tea).
47993124|NCT06065579|OTHER|Well-Being Promotion Program|the well-being promotion program (Suldo,2016) , an intervention designed to improve subjective well-being. It was postulated that this intervention will eventually assist in managing emotional and behavioural problems among adolescents enrolled in the program.
47993125|NCT03816059|DIAGNOSTIC_TEST|Respiratory virus testing|All patients will be tested for respiratory viruses
47993126|NCT01423487|DRUG|Metformin|0.5g bid 26 weeks
47993127|NCT01423487|OTHER|Starch tablets|0.5g bid 26 weeks
47993128|NCT00208962|PROCEDURE|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
47993129|NCT05020314|BEHAVIORAL|Healthy Weight Clinic|Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
47993130|NCT00460031|DRUG|ketoconazole|400 tid
47993131|NCT00460031|DRUG|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
47993132|NCT00460031|DRUG|therapeutic hydrocortisone|20mg qam 10mg qhs
47993133|NCT05861037|OTHER|Video-Assisted Thoracoscopy with blebectomy and pleural abrasion|Thoracoscopic management of pneumothorax
47993134|NCT03096327|DRUG|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
47993135|NCT03096327|DRUG|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
47993136|NCT02859051|DEVICE|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
47993137|NCT03144882|DRUG|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
48677991|NCT00051207|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|
48677992|NCT00051207|BEHAVIORAL|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
48677993|NCT01027650|DRUG|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
48677994|NCT01027650|DRUG|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
47993138|NCT03144882|DRUG|Placebo|placebo
47993139|NCT04033601|BEHAVIORAL|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
47993140|NCT02788981|DRUG|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
47993141|NCT02788981|OTHER|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
47993142|NCT02788981|DRUG|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
47993143|NCT01548131|BEHAVIORAL|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
47993144|NCT00002627|BIOLOGICAL|filgrastim|
47993145|NCT00002627|DRUG|carboplatin|
47993146|NCT00002627|DRUG|cyclophosphamide|
47993147|NCT00002627|DRUG|mesna|
47993148|NCT00002627|DRUG|paclitaxel|
47993149|NCT00002627|PROCEDURE|peripheral blood stem cell transplantation|
47993150|NCT03025542|DRUG|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
47993151|NCT03025542|OTHER|Placebo|Subjects will receive injections of Placebo.
47993152|NCT01793727|DEVICE|Glidescope videolaryngoscope|
47993153|NCT01695694|BEHAVIORAL|supporting positive and healthy relationships|
47993154|NCT01695694|BEHAVIORAL|community support group|
48677995|NCT00548197|DRUG|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
48677996|NCT05120583|OTHER|Pilates exercises|Side kick internal/ external rotation with Pilate's band
48677997|NCT05120583|OTHER|Traditional physical therapy program|strength, flexibility
48363665|NCT05188560|OTHER|Action observation therapy|Subject is asked to observe videos with motor contents
48363666|NCT05188560|OTHER|motor imagery|mental simulation of a motor task
48677998|NCT03774797|OTHER|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
48677999|NCT04631315|DRUG|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
48363667|NCT04171752|DRUG|elafibranor|elafibranor 120mg is a coated tablet for oral administration
48363668|NCT05204901|DEVICE|Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position|In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
48678000|NCT04631315|DRUG|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
48678001|NCT06536543|OTHER|Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)|Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
48678002|NCT02931838|DRUG|BMS-986165|
48678003|NCT02931838|DRUG|Placebo for BMS-986165|
48678004|NCT05384834|BEHAVIORAL|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
48678005|NCT05527600|DIAGNOSTIC_TEST|intensity of acute pain evaluation|the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
47993155|NCT01370226|BEHAVIORAL|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
47993156|NCT01370226|BEHAVIORAL|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
47993157|NCT02280564|BEHAVIORAL|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
47993158|NCT05346809|DRUG|Isatuximab|Isatuximab in IV form 10 mg/kg doses
47993159|NCT05346809|OTHER|Standard Procedures|Standard procedures (standard of care) for transplant
47993160|NCT04979741|OTHER|No interventions|Observational study, no intervention is required
47993161|NCT05827926|BIOLOGICAL|Influenza Vaccine 1|quadrivalent seasonal influenza vaccine
48678006|NCT04015011|COMBINATION_PRODUCT|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
48678007|NCT00375674|DRUG|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
48678008|NCT00375674|OTHER|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
48678009|NCT04848480|DRUG|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
48678010|NCT04848480|DRUG|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
48678011|NCT04848480|DRUG|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
47993162|NCT05827926|BIOLOGICAL|mRNA-1083.1|Sterile liquid for injection
47993163|NCT05827926|BIOLOGICAL|mRNA-1083.2|Sterile liquid for injection
47993164|NCT05827926|BIOLOGICAL|mRNA-1083.3|Sterile liquid for injection
47993165|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 1|Sterile liquid for injection
48152367|NCT06505252|PROCEDURE|enoscopic Myringoplasty|"general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization~* the previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally in patients group A: 0.5 mL of HA vial will be injected directly over the fat graft and the TM remnant. After 5 minutes small gelfoam pieces soaked in 0.5 mL of HA vial will applied over the fat in patients group B PRPG was inserted into the external auditory canal on the outer face of the TM remnant and fat"
47993166|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 1|Sterile liquid for injection
48152368|NCT03426709|BEHAVIORAL|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
48152369|NCT01912599|DEVICE|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
48152370|NCT01912599|DEVICE|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
48152371|NCT00231166|DRUG|HCD122|
48152372|NCT02531997|BEHAVIORAL|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
48152373|NCT02531997|BEHAVIORAL|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
48152374|NCT05064566|DEVICE|caries assessment|clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
48678012|NCT02370992|RADIATION|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
47993167|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 1|Sterile liquid for injection
47993168|NCT05827926|BIOLOGICAL|Investigational Influenza Vaccine 2|Sterile liquid for injection
47993169|NCT05827926|BIOLOGICAL|Influenza Vaccine 2|quadrivalent seasonal influenza vaccine
48152375|NCT06233422|OTHER|No intervention involved|No intervention involved
47993170|NCT05827926|BIOLOGICAL|mRNA-1083|Sterile liquid for injection
48678013|NCT05370365|PROCEDURE|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
48678014|NCT02379195|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
48678015|NCT02379195|DRUG|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
48678016|NCT02379195|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
47993171|NCT05827926|BIOLOGICAL|Investigational COVID-19 Vaccine 2|Sterile liquid for injection
47993172|NCT05827926|BIOLOGICAL|COVID-19 Vaccine 2|Sterile liquid for injection
47993173|NCT01436981|PROCEDURE|CABG|Preparation of artery mammaria interna
47993174|NCT01054781|DRUG|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
48152376|NCT06341998|DRUG|sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children|The oral dose of sirolimus is 1mg/m2 daily (maximum 2 mg). Sirolimus whole blood trough concentration is measured 5 days after administration, with blood collected within half an hour before morning administration. Dose adjustment occurs weekly until the target range of 10-15ng/ml is achieved, followed by review every 21 days. Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
48363672|NCT04806334|DIAGNOSTIC_TEST|MRI imaging of the pelvis/bladder|The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
48363673|NCT04806334|DIAGNOSTIC_TEST|genomic analysis of tumor|Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
48678017|NCT02379195|DRUG|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
48678018|NCT02379195|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
48363674|NCT02290990|BEHAVIORAL|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
48363675|NCT04327505|DRUG|Hyperbaric oxygen|1.6- 2.4 ATA, 30-60 min (excluding compression/recompression)
48363676|NCT00464126|OTHER|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
48363677|NCT00464126|OTHER|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
48363678|NCT00000528|BEHAVIORAL|diet, sodium-restricted (Phase III) diet, sodium-restricted|
47993175|NCT05440279|DEVICE|digital patient support|"Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~1. electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~2. possibility to set personal adherence goals every week,~3. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~4. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
47993176|NCT01772303|DRUG|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
47993177|NCT04309656|DRUG|Pretomanid|"1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered."
48152377|NCT00130026|DRUG|Caffeine|500 mg IV
48152378|NCT00455104|OTHER|No intervention|This is an observational, voluntary registry.
48363679|NCT00000528|BEHAVIORAL|diet, reducing (Phase III)|
48363680|NCT00298285|DRUG|enoxaparin|
48363681|NCT00535236|BIOLOGICAL|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
48363682|NCT00535236|BIOLOGICAL|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
48363683|NCT02665273|PROCEDURE|Greater occipital nerve block|Bilateral greater occipital nerve block
48363684|NCT02665273|DRUG|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
48363685|NCT02292615|OTHER|Medical Imaging|
48363686|NCT00052494|DRUG|cisplatin|
48363687|NCT00052494|DRUG|imatinib mesylate|
48363688|NCT00052494|DRUG|irinotecan hydrochloride|
48363689|NCT00664729|BEHAVIORAL|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
48363690|NCT00664729|BEHAVIORAL|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
48363691|NCT00664729|BEHAVIORAL|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
48363692|NCT01817218|DRUG|Platelet Rich Plasma|
48678019|NCT04190823|DRUG|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
48678020|NCT05771714|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
48678021|NCT02251496|OTHER|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
48678022|NCT02251496|OTHER|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
48678023|NCT00702832|BEHAVIORAL|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
48678024|NCT00702832|OTHER|standard treatment|treatment as usual
48678025|NCT02228161|BEHAVIORAL|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
48678026|NCT01901484|DRUG|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
48678027|NCT04718350|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
48678028|NCT04718350|DRUG|milrinone at a dose of 50 mcg/kg|milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
48678029|NCT05110781|BIOLOGICAL|Atezolizumab|Given IV
48678030|NCT05110781|RADIATION|Radiation Therapy|Undergo radiation therapy
48678031|NCT05110781|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48678032|NCT05219253|BIOLOGICAL|HZ/su|Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.
48678033|NCT05219253|DRUG|Placebo|Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
48678034|NCT01722344|BEHAVIORAL|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
48678035|NCT01722344|BEHAVIORAL|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
48363693|NCT01817218|DEVICE|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
48363694|NCT00151723|PROCEDURE|treatment with 131I|
48678036|NCT05134610|DEVICE|AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE|Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
48363695|NCT03452059|DEVICE|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
48678037|NCT04335448|OTHER|No intervention is planed|No intervention is planed
48678038|NCT01862081|DRUG|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
48678039|NCT01862081|DRUG|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
48678040|NCT01862081|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
48678041|NCT04532840|DEVICE|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
48678042|NCT04532840|OTHER|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
48678043|NCT00973336|DRUG|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
48152379|NCT02545426|OTHER|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
48678044|NCT04486547|BEHAVIORAL|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
48678045|NCT04432922|OTHER|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
48678046|NCT01187654|BIOLOGICAL|AC133|intra coronary injection of bone marrow derived AC133+ cells
48678047|NCT01187654|BIOLOGICAL|MNC|intra coronary injection of bone marrow derived MNC
48678048|NCT01187654|BIOLOGICAL|CONTROL|autologous serum injection
48152380|NCT03536637|DRUG|DMT310|Topical Powder
48152381|NCT03536637|DRUG|Hydrogen Peroxide|Liquid Diluent
48678049|NCT00660972|DRUG|Raltegravir|400 mg tablet taken orally twice daily
48678050|NCT00660972|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
48678051|NCT00291031|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
48678052|NCT01235663|BEHAVIORAL|advisory support|regular advisory support to the prolong breast-feeding period
48678053|NCT03341637|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
48678054|NCT03341637|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
48678055|NCT05659914|DRUG|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
48678056|NCT01947335|DEVICE|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
47993178|NCT01906710|OTHER|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
48363696|NCT01709240|DEVICE|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
47993179|NCT03976063|DRUG|Nifedipine|Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
48363697|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
48678057|NCT02135744|BEHAVIORAL|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
48678058|NCT02263872|DRUG|Minocycline|Minocycline 200mg perday
48678059|NCT01847092|DRUG|AZD1722|
48678060|NCT01847092|DRUG|Placebo|Placebo for AZD1722
48678061|NCT01883700|OTHER|Boiled Pasta|
48678062|NCT01883700|OTHER|Boiled Chickpeas with Oil|
48678063|NCT01883700|OTHER|Instant Mashed Potatoes|
48678064|NCT01883700|OTHER|Instant Mashed Potatoes with Egg Whites|
47993180|NCT03976063|DRUG|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
47993181|NCT01086540|BIOLOGICAL|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
48152382|NCT03536637|DRUG|Placebo|Placebo Topical Powder
48363698|NCT01183611|BIOLOGICAL|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
48363699|NCT01183611|BIOLOGICAL|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
48363700|NCT01183611|BIOLOGICAL|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
48678065|NCT02661152|DRUG|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
48678066|NCT01408277|BIOLOGICAL|Santyl|2 mm Santyl applied once daily
48678067|NCT01408277|PROCEDURE|Control|Standard Care
48678068|NCT05015478|DEVICE|Tailored Rhythmic Lighting Intervention|40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
48678069|NCT05015478|DEVICE|Placebo Rhythmic Lighting Intervention|Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered with a random interval determined by a Poisson process with an average interval of 40 hertz (Hz). The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
48678070|NCT00000325|BEHAVIORAL|Gonadorelin|
48678071|NCT00412191|DRUG|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
48678072|NCT06404268|DEVICE|Motor relearning training|Ankle motor control relearning training under real-time feedback
48678073|NCT06404268|DEVICE|Passive stretching|Passive stretching under intelligent robotic control
48678074|NCT06404268|DEVICE|Gamed-based active movement training|Active movement training through movement games with robotic assistance
48678075|NCT06404268|DEVICE|Passive movement|Passive movement in the joint middle range of motion
48678076|NCT06404268|DEVICE|Active movement training|Active movement training without robotic assistance
48678077|NCT06404268|DEVICE|Ankle torque and motion measurement|Ankle torque and motion measurement with no real-time feedback
47993182|NCT01086540|OTHER|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
48678078|NCT03661177|OTHER|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
48678079|NCT02175277|DRUG|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
48678080|NCT05074017|DEVICE|3 nasopharyngeal swab|3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
47993183|NCT01086540|DIAGNOSTIC_TEST|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
47993184|NCT01086540|DRUG|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
48152383|NCT03385109|DEVICE|Surgery|Patients are approached surgically with the Senhance Surgical System
48152384|NCT01681394|DIETARY_SUPPLEMENT|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
48678081|NCT01184677|DEVICE|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
48678082|NCT01184677|DEVICE|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
48678083|NCT02253095|DRUG|Albendazole|
47993185|NCT01086540|DRUG|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
47993186|NCT01086540|DRUG|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
48152385|NCT01681394|DIETARY_SUPPLEMENT|Chocolate cream|
48678084|NCT02253095|DIETARY_SUPPLEMENT|Zinc|
48678085|NCT02253095|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|
48678086|NCT02253095|DRUG|Placebo|
48678087|NCT02778984|DEVICE|QuadraLite masks|The intervention is identical in the two group
48678088|NCT02778984|OTHER|standard mask|
48678089|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
48678090|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
48678091|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
48678092|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
48678093|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
48678094|NCT04845594|BEHAVIORAL|MySmileBuddy (MSB)|The technology-based MSB program equips community health workers (CHWs) with an iPad-based app that facilitates assessment of a child's early childhood caries (ECC).
48678095|NCT05135598|OTHER|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
48678096|NCT02988726|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
48678097|NCT02523989|OTHER|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
48678098|NCT02653092|DRUG|Insulin|
48678099|NCT02653092|DRUG|Intralipid|
48363701|NCT01183611|BIOLOGICAL|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
47993187|NCT01086540|DRUG|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
47993188|NCT00727753|DRUG|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
48152386|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
48152387|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
48152388|NCT04243954|DRUG|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
48152389|NCT02518802|DRUG|Gefitinib|Gefitinib 250mg per day for 2 years.
48152390|NCT02518802|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
48678100|NCT02653092|DRUG|Dextrose|
48678101|NCT02653092|DRUG|Heparin|
48678102|NCT02653092|DRUG|GnRH|
48678103|NCT02653092|PROCEDURE|Hyperinsulinemic Euglycemic Clamp|
48678104|NCT04230616|PROCEDURE|total knee arthroplasty|total knee arthroplasty
47993189|NCT00727753|DRUG|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
47993190|NCT00727753|OTHER|No treatment|No treatment
47993191|NCT03895281|DIAGNOSTIC_TEST|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
48152391|NCT04409132|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
48152392|NCT04430400|DIAGNOSTIC_TEST|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level \<500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
48152393|NCT06309745|PROCEDURE|retroperitoneal lymph node dissection|retroperitoneal lymph node dissection
48363702|NCT03220594|PROCEDURE|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
48678105|NCT04230616|RADIATION|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
48678106|NCT04704713|DRUG|Afamelanotide|
48678107|NCT04704713|DRUG|Placebo|
48678108|NCT05878977|DRUG|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
48678109|NCT04621994|OTHER|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
48678110|NCT04621994|OTHER|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
48678111|NCT05067205|PROCEDURE|Carpal tunnel release surgery|Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
48678112|NCT00297739|DRUG|Risperidone|
48678113|NCT00002372|DRUG|Indinavir sulfate|
48678114|NCT00002372|DRUG|Amprenavir|
48678115|NCT00002372|DRUG|Nelfinavir mesylate|
48678116|NCT00002372|DRUG|Saquinavir|
48678117|NCT05238519|BEHAVIORAL|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
48678118|NCT05496361|DEVICE|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
48678119|NCT05496361|DEVICE|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
48678120|NCT03810014|OTHER|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
48678121|NCT03810014|OTHER|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
48152394|NCT06309745|DRUG|Carboplatin AUC10|Carboplatin AUC10
48363703|NCT01078181|PROCEDURE|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
48678122|NCT03810014|OTHER|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
48678123|NCT03810014|OTHER|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
48678124|NCT00943631|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
48678125|NCT04406207|OTHER|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
48678126|NCT04231097|OTHER|MBCT intervention for ACS patients|The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
48678127|NCT04661605|DIAGNOSTIC_TEST|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
48678128|NCT03346083|DRUG|Betrixaban|Factor Xa inhibitor.
48678129|NCT00705770|DRUG|Anecortave Acetate|"Low dose~Sustained release depot suspension"
48678130|NCT00705770|DRUG|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
48678131|NCT00705770|DRUG|Anecortave Acetate|"High dose~Sustained release depot suspension"
48678132|NCT00705770|DRUG|Placebo|Placebo treatment with vehicle
48363704|NCT04047342|BEHAVIORAL|Welcome email|Email
48363705|NCT04047342|BEHAVIORAL|Loss frame|Email
48363706|NCT02612168|DEVICE|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
48152395|NCT04683900|OTHER|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
48152396|NCT04683900|OTHER|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
48678133|NCT04504630|DEVICE|High Definition Transcranial Direct Current Stimulation|This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).
48678134|NCT04504630|DEVICE|Sham HD-tDCS|Sham HD-tDCS
47993192|NCT03892460|DEVICE|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
47993193|NCT01829555|BEHAVIORAL|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
47993194|NCT02636868|DRUG|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
47993195|NCT02636868|DRUG|nCPAP|Nasal CPAP
47993196|NCT05575063|DEVICE|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
47993197|NCT05575063|DEVICE|Control Healon EndoCoat|Ophthalmic Viscoelastic device
48152397|NCT01862679|OTHER|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
48152398|NCT01862679|PROCEDURE|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
48678135|NCT02718235|OTHER|Overall survival|Observation of overall and disease free survival
48678136|NCT00616642|DRUG|rosiglitazone maleate|Given orally
48678137|NCT04832529|PROCEDURE|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
48678138|NCT00292526|DRUG|Enalapril|enalapril orally administered
48152399|NCT05989386|PROCEDURE|0.9% saline solution|During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.
48152400|NCT05989386|PROCEDURE|Povidone-iodine Swab|No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
48678139|NCT03693144|OTHER|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
48678140|NCT03693144|OTHER|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
48678141|NCT03693144|OTHER|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
48678142|NCT05412264|BEHAVIORAL|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
47993198|NCT05045144|COMBINATION_PRODUCT|RSVPreF3(120 μg)|A single dose of RSVPreF3(120 μg) combined with Sodium Chloride (NaCl) was administrated intramuscular (IM). There were used 3 different lots of RSVPreF3(120 μg), one for each individual group (RSV lot1 Group, RSV lot2 Group and RSV lot3 Group) considered under RSV pooled Group.
47993199|NCT05045144|COMBINATION_PRODUCT|Flu Quadrivalent influenza vaccine (15 μg HA)|A single dose of Flu Quadrivalent influenza (15 μg HA) vaccine was administrated intramuscular (IM).
47993200|NCT05045144|COMBINATION_PRODUCT|Placebo|One dose of placebo, administered intramuscularly in the deltoid region of the right arm, at Day 1.
48678143|NCT02140021|PROCEDURE|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
48678144|NCT02140021|OTHER|Laboratory Biomarker Analysis|Correlative studies
48152401|NCT01107171|DRUG|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
48152402|NCT01107171|DRUG|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
48152403|NCT01107171|DRUG|Placebo|Tang-min-Ling pills analogue 6g,tid,po
48152404|NCT06470945|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
48152405|NCT06470945|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
48152406|NCT00111865|BEHAVIORAL|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
48152407|NCT03669965|DRUG|KRT-232|KRT-232, administered by mouth
48152408|NCT03669965|DRUG|Ruxolitinib|Ruxolitinib per approved prescribing label
48152409|NCT01062776|BIOLOGICAL|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
48152410|NCT01062776|BIOLOGICAL|Placebo|No dehydration is induced
48152411|NCT03522844|OTHER|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
48152412|NCT03522844|DRUG|Escitalopram|Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
48152413|NCT06212596|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
48678145|NCT06319404|OTHER||
48678146|NCT06024551|OTHER|Telerehabilitation|Patients in this arm will be given telerehabilitation three times a week, for four weeks.
48678147|NCT06024551|OTHER|home exercise program|Patients in this arm will receive home exercise program for four weeks
48678148|NCT04532125|BIOLOGICAL|ARGX-117|Subjects treated with ARGX-117
47993201|NCT01950533|PROCEDURE|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
48678149|NCT04532125|OTHER|Placebo|Subjects treated with placebo
48678150|NCT04532125|BIOLOGICAL|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
48678151|NCT04532125|OTHER|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
48678152|NCT04532125|BIOLOGICAL|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
48678153|NCT04532125|OTHER|Placebo PH20 SC|Subjects treated with placebo PH20 SC
48678154|NCT05140356|DEVICE|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
48678155|NCT05140356|DEVICE|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
47993202|NCT01555268|BIOLOGICAL|trebananib|Given IV
47993203|NCT01555268|DRUG|cytarabine|Given SC
47993204|NCT01555268|OTHER|laboratory biomarker analysis|Correlative studies
48678156|NCT05593705|OTHER|observation|photograph for maxillary labial frenum and measurements with a periodontal probe
48678157|NCT04011735|DRUG|Respimat|Soft Mist Inhaler product
48678158|NCT00417768|DRUG|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
48678159|NCT00417768|OTHER|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
48678160|NCT03005730|OTHER|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
48678161|NCT03005730|OTHER|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
48678162|NCT02116842|DRUG|0.1% bupivacaine|Epidural block in early labour.
48678163|NCT02116842|DRUG|0.075% bupivacaine|Epidural block in early labour.
48678164|NCT02116842|DRUG|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
48678165|NCT03358420|DIAGNOSTIC_TEST|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
47993205|NCT01555268|OTHER|pharmacological study|Correlative studies
47993206|NCT06358105|PROCEDURE|Simulator-based training|A two-day training program will be performed before starting their cath lab period as interventional cardiology fellows
47993207|NCT06358105|PROCEDURE|Standard training|Standard master-apprentice training interventional cardiology fellows' program during their cath lab period
47993208|NCT00974012|DRUG|Divalproex Sodium|500 mg ER Tablet
47993209|NCT00974012|DRUG|Depakote®|500 mg ER Tablet
47993210|NCT03013556|DRUG|Group A, TDF|TDF for 96 weeks
48363707|NCT04484610|DRUG|Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain|Pharmacist eLearning modules, support tools and resources to promote assessing and dispensing appropriate opioid quantities for acute pain.
48363708|NCT02444611|DRUG|BCG Vaccine|intradermal vaccination
48363709|NCT02444611|DRUG|Hepatitis B Vaccine|intramuscular vaccination
48678166|NCT02559635|PROCEDURE|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
48678167|NCT02559635|DRUG|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
48363710|NCT04006821|DRUG|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
48363711|NCT04006821|DRUG|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
48363712|NCT02303730|DRUG|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
48363713|NCT02303730|DRUG|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c \>8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) \> 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%."
47993211|NCT03013556|DRUG|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
48363714|NCT03677752|OTHER|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
48678168|NCT00131352|DEVICE|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
48678169|NCT00131352|OTHER|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
48678170|NCT04321512|OTHER|There is no intervention given to the subjects|Not appicable
47993212|NCT03013556|DRUG|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
47993213|NCT04283006|DRUG|CD20/CD22 dual Targeted CAR T-cells|Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
47993214|NCT03424174|DEVICE|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
47993215|NCT03424174|DEVICE|Standard Total Knee Arthroplasty|Implantation StandardTotal Knee Arthroplasty
47993216|NCT01091389|PROCEDURE|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
47993217|NCT04536155|OTHER|questionnary SF36|"This is a validate questionnary:~Ware et al,1992, McHorney et al, 1993, McHorney et al, 1994 French version : Author : Alain Leplège; et coll. En 2001"
47993218|NCT04536155|OTHER|Hospital Anxiety and Depression Scale|this is a validate scale: author: Zigmond A.S., Snaith R.P. in 1983
47993219|NCT04536155|OTHER|Chronic Pain Acceptance Questionnaire|"This is a validate questionnaire:~Fish, R., McGuire, B.E., Hogan, M., Stewart, I. \& Morrison, T. (2010)."
48678171|NCT02264613|DRUG|ALRN-6924|ALRN-6924 will be administered as an IV infusion
47993220|NCT04536155|OTHER|digital pain scale|this is a validate scale A.N.A.E.S. February 1999
47993221|NCT01154621|DRUG|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
47993222|NCT01154621|DRUG|Placebo|Sterile 5% dextrose solution
48678172|NCT06069830|DRUG|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
48678173|NCT06069830|DRUG|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
48678174|NCT06069830|DRUG|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
48678175|NCT01941927|DRUG|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
48678176|NCT01941927|DRUG|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
48678177|NCT00042237|BEHAVIORAL|Schema Therapy|
48363715|NCT02137902|BEHAVIORAL|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
48678178|NCT00173017|DEVICE|wearing N95 masks|
48678179|NCT04660175|OTHER|non-resistance therapy|The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
48678180|NCT04660175|OTHER|acupuncture|According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
48678181|NCT04660175|OTHER|chuna|Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
48678182|NCT04660175|OTHER|pharmacoacupuncture|This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
48678183|NCT04660175|DRUG|Korean herbal medicine|Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
48678184|NCT03073525|BIOLOGICAL|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
48678185|NCT03073525|DRUG|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
48678186|NCT02503085|DRUG|Nurofen for Children®|
48678187|NCT02503085|DRUG|Algifor Dolo Junior®|
48678188|NCT03584126|DIAGNOSTIC_TEST|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
48678189|NCT00402844|DEVICE|Transvaginal mesh- PROLIFT®-system|
48678190|NCT03710265|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
48678191|NCT00825695|DIETARY_SUPPLEMENT|cocoa|two servings of cocoa daily for one month
48678192|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
48678193|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
48678194|NCT02407743|BEHAVIORAL|Surgical patients' clinical progression|Study the dynamic nature of pain
47993223|NCT02909452|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
47993224|NCT02909452|DRUG|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
47993225|NCT01825382|DEVICE|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
48678195|NCT02407743|GENETIC|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
48678196|NCT03794440|DRUG|Sintilimab|200mg IV d1， Q3W
47993226|NCT00622479|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
47993227|NCT00453921|DRUG|Methylphenidate|Dosage dependent on weight
47993228|NCT00453921|BEHAVIORAL|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
47993229|NCT00453921|OTHER|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
47993230|NCT05804175|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
47993231|NCT05185960|OTHER|ALLSWEET®|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.
48678197|NCT03794440|DRUG|IBI305|15mg/kg IV d1， Q3W
48678198|NCT03794440|DRUG|Sorafenib|400mg PO BID
48678199|NCT02890459|OTHER|Prize incentive - Low|Low expected prize value.
47993232|NCT05185960|OTHER|ALLSWEET® and sucrose|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.
47993233|NCT05185960|OTHER|Sucrose|Table sugar. It will be consumed by diluting it in water.
48678200|NCT02890459|OTHER|Prize incentive - High|High expected prize value.
48152414|NCT06212596|DRUG|Cyclophosphamide|Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
48152415|NCT06212596|DRUG|Prednisone|Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
48152416|NCT05803122|OTHER|Uniform Data Set (UDS) neuropsychological battery|Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
48152417|NCT02290353|DEVICE|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
48363716|NCT02137902|BEHAVIORAL|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
48363717|NCT02094794|DRUG|etoposide|Given IV
48678201|NCT02890459|OTHER|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
48678202|NCT02890459|OTHER|Travel Voucher|Travel voucher to assist with linkage to care.
48678203|NCT02890459|OTHER|Standard care|Includes HIV viral load and treatment adherence counseling.
48363718|NCT02094794|DRUG|cyclophosphamide|Given IV
48678204|NCT02890459|BEHAVIORAL|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
48678205|NCT02890459|BEHAVIORAL|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
48678206|NCT02890459|BEHAVIORAL|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
48678207|NCT02890459|BEHAVIORAL|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
48678208|NCT02890459|BEHAVIORAL|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
48678209|NCT02959788|OTHER|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
48678210|NCT00881985|DEVICE|continuous positive airway pressure|Use CPAP whenever sleep
48678211|NCT04195490|PROCEDURE|feminizing genitoplasty|feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
48678212|NCT04945525|OTHER|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
48678213|NCT02638714|BIOLOGICAL|Stem Cells|Intervention: Transplantation of autologous purified stem cells
48678214|NCT00174850|DRUG|Gaitril|
47993234|NCT05721833|DEVICE|Non-invasive high-frequency oscillatory|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
47993235|NCT05721833|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation.
47993236|NCT01927406|DRUG|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
48152418|NCT04755907|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions or liver metastases.
48152419|NCT04755907|OTHER|adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
48678215|NCT00047502|DRUG|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
48511373|NCT03546127|GENETIC|Next Generation Sequencing (NGS): exome, RNA seq|"Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~* Data from each cancer and normal genome will be analysed for the presence of somatic variants.~* DNA and RNA sequencing results will be integrated.~* Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest."
47993237|NCT01927406|DRUG|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
47993238|NCT03341832|DRUG|NVP-1203|oral dose for 7 days
47993239|NCT03341832|DRUG|NVP-1203-R|oral dose for 7 days
47993240|NCT03341832|DRUG|NVP-1203 placebo|oral dose for 7 days
47993241|NCT03341832|DRUG|NVP-1203-R placebo|oral dose for 7 days
47993242|NCT05023811|DRUG|[14C]RIST4271|\[14C\]RIST4271 oral solution
48511374|NCT05144490|OTHER|Exercise|A single session of bodyweight exercise
48511375|NCT02800642|DRUG|Aflibercept (Eylea, BAY86-5321)|The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
48511376|NCT01767948|DRUG|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
48511377|NCT00627861|DRUG|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
47993243|NCT00163475|DRUG|Roflumilast|
47993244|NCT03342547|PROCEDURE|Duodenal biopsy|Two duodenal biopsy samples will be collected from each participant
47993245|NCT03342547|PROCEDURE|Saliva|Saliva (1-2 mL) will be collected from each participant for secretor status testing
48363719|NCT02094794|RADIATION|total marrow irradiation|Undergo TMLI
48363720|NCT02094794|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
48363721|NCT02094794|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
48511378|NCT00627861|DRUG|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
48678216|NCT00047502|DRUG|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
47993246|NCT06541184|DRUG|Ziconotide [Prialt]|Intrathecal injection of ziconotide, using an internal pump, surgically inserted by a trained neurosurgeon or anesthesiologist, under general anesthesia.
47993247|NCT01042704|DRUG|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
47993248|NCT01042704|DRUG|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
47993249|NCT01042704|DRUG|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
48152420|NCT04755907|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
48363722|NCT03845842|BEHAVIORAL|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
48363723|NCT01226134|DRUG|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
48363724|NCT01226134|DRUG|Placebo|placebo capsules,thrice a day for four weeks
48363725|NCT00612456|DRUG|Pazopanib|Pazopanib eye drops formulation
48363726|NCT05939336|DIETARY_SUPPLEMENT|Mannooligosaccharides yeast extract|15 g per day of mannooligosaccharide yeast extract.
48678217|NCT05912491|DIAGNOSTIC_TEST|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
47993250|NCT01042704|DRUG|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
48152421|NCT03249272|DRUG|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
48152422|NCT03249272|DRUG|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
48152423|NCT02283632|PROCEDURE|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
48152424|NCT05739409|BIOLOGICAL|LILRB4 STAR-T cells injection|The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
48152425|NCT02529735|OTHER|efficiency study|Blood pressure values measured for comparative lower limb and arm
48152426|NCT02687841|DRUG|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
47993251|NCT01042704|DRUG|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
47993252|NCT01042704|DRUG|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
48152427|NCT02687841|DRUG|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
48152428|NCT03684772|DRUG|ICVT Topical Gel|Digoxin and Furosemide (0.125%)
48152429|NCT03684772|DRUG|Furosemide Topical Gel|Furosemide (0.125%)
48152430|NCT03684772|DRUG|Digoxin Topical Gel|Digoxin (0.125%)
48152431|NCT03684772|DRUG|Vehicle Topical Gel|Vehicle Gel
48678218|NCT04828707|DEVICE|Nerivio active device|Nerivio neurostimulator of conditional pain modulation (CPM)
48678219|NCT04828707|DEVICE|Nerivio sham device|Nerivio neurostimulator with an electrical output not intended for neurostimulation
48678220|NCT00968773|DEVICE|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
48152432|NCT02694198|OTHER|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
48152433|NCT00406276|DRUG|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
48152434|NCT00406276|DRUG|Docetaxel|In combination with RAD001
48152435|NCT04493125|DRUG|Mosapride citrate|Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.
48152436|NCT04493125|DRUG|Placebo|Placebo
48152437|NCT00551954|DRUG|acarbose|100 mg (tablets) t.i.d.
48152438|NCT00551954|DRUG|placebo|one tablet t.i.d.
48152439|NCT04617145|OTHER|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
48152440|NCT01075815|DRUG|Recombinant human luteinizing hormone (rhLH)|
48152441|NCT01075815|DRUG|Recombinant follicle-stimulating hormone (rFSH)|
48152442|NCT03958305|PROCEDURE|RADICAL HYSTERECTOMY|Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
48152443|NCT01979211|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
48152444|NCT01979211|RADIATION|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
48152445|NCT03242239|BIOLOGICAL|ALT02|
48152446|NCT03242239|BIOLOGICAL|EU-licensed Herceptin|
48152447|NCT03242239|BIOLOGICAL|US-licensed Herceptin|
48152448|NCT01705444|DEVICE|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
48152449|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac Acumen IQ® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management. It incorporates predictive parameters such as the hypotension prediction index and decision support parameters such as dynamic arterial elastance and maximum dP / dT.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
48152450|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
48152451|NCT03527329|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
48152452|NCT00560209|DRUG|ONO-1101|placebo for 1 minute IV
48152453|NCT00560209|DRUG|ONO-1101|0.06 mg/kg for 1 minute IV
48152454|NCT00560209|DRUG|ONO-1101|0.125 mg/kg for 1 minute IV
48152455|NCT00782353|DRUG|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
48152456|NCT00782353|DRUG|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
48152457|NCT00782353|DRUG|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
48152458|NCT05851144|BEHAVIORAL|Bienestar/Neema Coordinated School Health Program (BN CSHP)|Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
48152459|NCT03627299|DRUG|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
48511379|NCT04701164|DRUG|ANX005|Solution for intravenous infusion
48511380|NCT04701164|DRUG|Placebo|Solution for intravenous infusion
48511381|NCT03430765|BEHAVIORAL|Acceptance and Commitment Therapy|Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
48511382|NCT00240565|DRUG|Tositumomab 450 mg|Unlabeled TST
48511383|NCT00240565|DRUG|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
48363727|NCT01329991|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
48152460|NCT02169089|DRUG|Spironolactone|Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
48363728|NCT01329991|DRUG|Placebo|Matching placebo for PLX5622
48363729|NCT05986409|OTHER|light cover|10 wards were randomly selected as the intervention group (opaque black tape covering part of the light source), and another 10 wards were selected as the control group (no intervention).
48363730|NCT04343937|PROCEDURE|retrolaminar block|local anesthetic injection on the between the lamina of the vertebra and the paraspinous muscle
48363731|NCT00596622|DRUG|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
48363732|NCT03765554|DRUG|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
48363733|NCT03765554|DRUG|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
48363734|NCT06323629|BEHAVIORAL|Adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. It adapts the complexity of the treatment tasks.
48363735|NCT06323629|BEHAVIORAL|Non-adaptive recursive self-feedback procedure|The intervention uses self-feedback alone to improve speech production. However, it does not adapt the complexity of the treatment tasks.
48363736|NCT04060706|RADIATION|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
48363737|NCT00852358|DRUG|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
48363738|NCT04008160|DEVICE|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
48363739|NCT03463720|OTHER|Infected|Extremity wound, infected
48363740|NCT03463720|OTHER|Not infected|Extremity wounds, non-infected
48678221|NCT00968773|DEVICE|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
48152461|NCT02169089|DRUG|Placebo|Placebo
48152462|NCT00795392|OTHER|ASA scale|ASA scale evaluation before operation
48152463|NCT00795392|OTHER|Full-scale psychological assessment|Full-scale psychological evaluation before operation
48152464|NCT04168593|PROCEDURE|Acupuncture|20 min of Acupuncture section follow by 10 min of cupping around the knee
48152465|NCT03636958|DRUG|Perampanel|Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
48152466|NCT03636958|DRUG|conventional antiepileptic treatment|choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
48152467|NCT00796835|DRUG|ER OROS Paliperidone|
48363741|NCT05717413|DEVICE|metatarsophalangeal joint endoprosthesis|arthroplasty of 1 metatarsophalangeal joint
48363742|NCT03470506|OTHER|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
48363743|NCT02288416|OTHER|educational intervention|Undergo video-based intervention
48363744|NCT02288416|OTHER|questionnaire administration|Ancillary studies
48363745|NCT02288416|OTHER|quality-of-life assessment|Ancillary studies
48363746|NCT02288416|OTHER|Best Practice|
48363747|NCT03243981|DEVICE|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
48363748|NCT00312390|PROCEDURE|Flicker|
48363749|NCT00312390|PROCEDURE|Retinal Vessel Diameter|
48363750|NCT00312390|PROCEDURE|Retinal Blood Flow|
48363751|NCT04346368|BIOLOGICAL|BM-MSCs|Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).
48363752|NCT04346368|BIOLOGICAL|Placebo|Placebo
48363753|NCT00564759|DRUG|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
48363754|NCT03671811|DRUG|Megestrol Acetate|Given PO
48363755|NCT03671811|BIOLOGICAL|Pterostilbene|Given PO
48511384|NCT04244383|DIAGNOSTIC_TEST|interleukin IL-1beta and interleukin IL-18|pro-inflammatory cytokines measured in the serum
48678222|NCT04649216|DRUG|PCO371|PCO371 Capsule
48678223|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Oral solution
48678224|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Solution for infusion
48678225|NCT06432400|OTHER|Patient questionnaires|Patients questionnaires, on paper and data collection on patients medical file
48678226|NCT03811522|OTHER|carbon dioxide insufflation|Receives CO2 insufflation
48678227|NCT03811522|OTHER|Air insufflation|Receives air insufflation
48678228|NCT00129285|DRUG|Low Dose Modafinil|modafinil 200 mg/day
48678229|NCT00129285|DRUG|High Dose Modafinil|modafinil 400 mg/day
48363756|NCT05798299|BEHAVIORAL|Arm 1: Transdiagnostic intervention|The UP-C/C consists of 15 weekly sessions for children, each lasting 90 minutes. It is also composed by three sessions for parents and a meeting with the family prior to the exposure sessions. Parents have access to weekly psychoeducational material (in written and in video format) and help the children with homework completion.
48363757|NCT05798299|BEHAVIORAL|Arm 2: Anxiety-focused intervention|The Coping Cat in group format is a cognitive-behavioral evidence-based intervention for anxiety problems. It is composed by 16 90-minute sessions for children and two parenting sessions.
48363758|NCT00526227|DEVICE|Secura ICD|Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
48363759|NCT06045936|DRUG|Lidocaine|2 teaspoons of 2% lidocaine injection
48363760|NCT06045936|DRUG|Placebo|Saline injection
48363761|NCT04019860|BEHAVIORAL|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
48678230|NCT00129285|DRUG|Placebo|placebo 400 mg/day
48363762|NCT04019860|BEHAVIORAL|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
48363763|NCT01835964|PROCEDURE|Glucose Variability Observation|On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
48363764|NCT04282499|PROCEDURE|combined exercise|Patients will be undergone to aerobic exercises in addition to the resistance training.
48363765|NCT04282499|PROCEDURE|aerobic exercise|Patients will be trained through the aerobic exercises only.
48678231|NCT03395496|DRUG|Biodentine|Biodentine pulpotomy agent
48678232|NCT03395496|DRUG|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
47993253|NCT01042704|OTHER|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
48363766|NCT02917161|DEVICE|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
48363767|NCT05768360|DRUG|Savolitinib|The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
48511385|NCT05018312|BEHAVIORAL|Modified Collaborative Assessment (MCA)|The Modified Collaborative Assessment (MCA) will be assessment of the patients that Is more thoroughly-done, and which will be inspired by the school of Therapeutic Assessment and Collaborative Assessment. It will include the EASE, SCID-interview, PSE, ADOS and SCIP-interviews.
48511386|NCT05018312|BEHAVIORAL|Assessment as Usual (AAU)|Assessment as usual is the standard assessment the patients will receive in the clinic. It includes one or more interviews with a mental health professional in the clinic.
47993254|NCT01042704|OTHER|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
47993255|NCT01042704|OTHER|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
48363768|NCT05768360|DRUG|Digoxin|The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
48363769|NCT05768360|DRUG|Metformin Hydrochloride|The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
48511387|NCT06634303|DEVICE|Brain cooling|Brain cooling intervention in acute ischemic stroke patients post mechanical thrombectomy
48678233|NCT01133665|DRUG|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
48678234|NCT00730756|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
48678235|NCT00730756|OTHER|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
48678236|NCT01607125|DRUG|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
48678237|NCT01607125|DRUG|Placebo|capsules, orally, once daily for 13 to 14 days
48363770|NCT05768360|DRUG|Rosuvastatin|The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
48363771|NCT05768360|DRUG|Furosemide|The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
48678238|NCT00002343|DRUG|Ethambutol hydrochloride|
48678239|NCT00002343|DRUG|Rifabutin|
48678240|NCT00442923|DRUG|Coreg|
48678241|NCT02903823|DRUG|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
48678242|NCT06197152|OTHER|Nasopharyngeal swabs and biological collection|"* Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection"
48678243|NCT00915889|BEHAVIORAL|telephone-based intervention|Either 6 or 8 telephone educational sessions
48678244|NCT00915889|OTHER|counseling intervention|counseling and communications studies
47993256|NCT01042704|OTHER|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~* Physical exam~* Performance status (check of ability to perform daily functions)~* Recording of any new symptoms and any new medications being taken~* Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~* Urine test (24hr urine)~* Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~* A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
47993257|NCT04048642|BEHAVIORAL|DASH|7 days of a DASH diet
47993258|NCT04048642|BEHAVIORAL|Whole-Food, Plant-Based|7 days of a WFPB diet
48152468|NCT04516980|OTHER|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
48152469|NCT00785798|DRUG|Vorinostat|200mg to 400 mg twice daily on days 1-7
48152470|NCT00785798|DRUG|Pegylated Liposomal Doxorubicin (PLD), Doxil|IV 30mg/m2 on day 3 of a 21-day cycle
47993259|NCT04733365|OTHER|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
47993260|NCT06322329|OTHER|Dynamic MRI|Subjects receive a study-specific dynamic MRI scan. If the hypothesis of the study is confirmed, this examination can be used to inform future patients' treatment planning, replacing the use of 4D CT.
47993261|NCT02608931|DRUG|Dronabinol|
47993262|NCT02608931|OTHER|Placebo|placebo
47993263|NCT04120974|BEHAVIORAL|Optimal insulin injection|subjects receive training in optimal injection technique.
47993264|NCT03727503|OTHER|PPV from the capstesia|we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
48152471|NCT03015753|BEHAVIORAL|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
48152472|NCT03015753|OTHER|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
48152473|NCT05793580|DEVICE|Vibrant Soundbridge active middle ear implant|active middle ear implant
48152474|NCT04102605|DEVICE|Nunap Vision|Participants receive visual perceptual training using the Nunap Vision software
48152475|NCT04102605|DEVICE|Nunap Vision-C|Participants receive sham training using the Nunap Vision-C software
48152476|NCT00593983|BEHAVIORAL|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
48152477|NCT00593983|BEHAVIORAL|Time-matched health education|Health education and standard of care treatment
48152478|NCT05472883|PROCEDURE|blood samples|- Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
48152479|NCT05472883|PROCEDURE|collection of body tissues|removal of intra-abdominal fat and muscle tissue
48152480|NCT05472883|PROCEDURE|routine care procedure|"* Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~* clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~* dosage of ß HCG for womens."
48511388|NCT04112316|DRUG|liothyronine or placebo|Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
48511389|NCT01119664|DRUG|SCH 721015|
48678245|NCT00915889|OTHER|questionnaire administration|Ancillary studies
48678246|NCT00915889|OTHER|study of socioeconomic and demographic variables|Ancillary Studies
48678247|NCT00915889|PROCEDURE|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
48678248|NCT00856635|DRUG|Glatiramer Acetate|20 mg injected daily subcutaneously
48678249|NCT00856635|DRUG|placebo|injected daily subcutaneously
48678250|NCT06169618|OTHER|cervical radiculopathy|this group will have patients with cervical radiculopathy
48678251|NCT06169618|OTHER|normal group|this group will have normal subjects
48678252|NCT04294225|DRUG|Anastrozole|Given PO
48678253|NCT04294225|DRUG|Letrozole|Given PO
48678254|NCT01405404|BEHAVIORAL|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
48678255|NCT01405404|OTHER|Parent Training|12-session group on parenting skills and child behavior management
47993265|NCT04879004|DRUG|Ropivacaine injection|Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
48152481|NCT05721898|DIAGNOSTIC_TEST|Cortical Bone Mechanics Technology|Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
48152482|NCT00583349|DRUG|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
48152483|NCT04443556|DRUG|Tramadol|Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
48152484|NCT04443556|OTHER|IV PCA|An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
48363772|NCT04531345|DIAGNOSTIC_TEST|Flow cytometric analysis|IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
48363773|NCT02608099|DRUG|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
48678256|NCT01198574|DIETARY_SUPPLEMENT|Iron group|Ferrous fumarate, 60 mg, weekly dose
48678257|NCT01198574|DIETARY_SUPPLEMENT|Vitamin A group|Retinol, weekly dose, 15,000 IU
48678258|NCT01198574|DIETARY_SUPPLEMENT|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
48678259|NCT01198574|DIETARY_SUPPLEMENT|Placebo group|folic acid only as placebo group
48678260|NCT02491047|DEVICE|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
48678261|NCT02491047|OTHER|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
48678262|NCT02945163|DRUG|Tenofovir|Tenofovir Disoproxil Fumarate
48678263|NCT02945163|DRUG|Lamivudine|Lamivudine
48678264|NCT02945163|DRUG|Efavirenz|Efavirenz
48678265|NCT05340998|PROCEDURE|Transradial access for percutaneous coronary procedures|Transradial approach for percutaneous coronary procedures. The modality of radial puncture (needle vs cannula), the choice of radial sheath (long vs short; hydrophilic vs non hydrophilic), the type of catheters employed, the use of spasmolytic agents and the choice of secondary vascular access will be left to the operator discretion
48678266|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
48678267|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
48678268|NCT04610983|DIETARY_SUPPLEMENT|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
48511390|NCT00200044|DEVICE|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score \>15.
48511391|NCT04545320|BEHAVIORAL|Usual care control group|Health education
48511392|NCT04545320|BEHAVIORAL|HIIT group|Once-a-week HIIT
48511393|NCT04545320|BEHAVIORAL|MICT group|Once-a-week MICT
48678269|NCT03806530|DRUG|Gabapentin|100 mg capsule
48678270|NCT03806530|DRUG|Ropinirole|0.50 mg capsule
48678271|NCT03806530|DRUG|Placebo Gabapentin|Placebo capsule
48678272|NCT03806530|DRUG|Placebo Ropinirole|Placebo capsule
48678273|NCT04232982|PROCEDURE|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
48678274|NCT04232982|PROCEDURE|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
48678275|NCT01904929|OTHER|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
48678276|NCT06437847|OTHER|Questionnaire|Questionnaire assessing the use of cognitive tests.
47993266|NCT04739631|OTHER|acupuncture|use disposable sterile needles to insert to the acupuncture point
47993267|NCT04739631|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
47993268|NCT04945629|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
47993269|NCT04945629|DRUG|Blood clot and simple suture|Filling the alveolus with blood clot
47993270|NCT01046682|DRUG|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
48152485|NCT01092585|DRUG|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.~In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
48152486|NCT03796585|BEHAVIORAL|Immunization Registry Training|Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
48152487|NCT03796585|BEHAVIORAL|Informational flyer|Informational flyer with ImmPRINT contact information
48152488|NCT01962376|DRUG|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
48152489|NCT01962376|DRUG|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
48152490|NCT06541795|DEVICE|AcrySof IQ Vivity Extended Vision IOL|UV-absorbing, with or without blue light filtering, foldable IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients from whom a cataractous lens has been removed. The IOL mitigates the effects of presbyopia by providing an extended depth of focus. The toric models in addition reduce residual refractive astigmatism in patients with pre-existing corneal astigmatism.
48152491|NCT02299011|DEVICE|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
48152492|NCT02299011|DRUG|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
48363774|NCT02608099|DRUG|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
48363775|NCT00005089|BIOLOGICAL|rituximab|375 mg/m\^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
48511394|NCT03857282|OTHER|Aerobic Exercises|5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
48511395|NCT03857282|OTHER|Tai Chi Exercises|5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
48678277|NCT01623167|DRUG|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
48678278|NCT01623167|DRUG|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
48678279|NCT01623167|DRUG|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
48678280|NCT01623167|DRUG|Extension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
48678281|NCT01465386|DRUG|bortezomib|Given SC
48678282|NCT06257446|BEHAVIORAL|Task Instructions|Participants will be given cued instructions as to whether they are in a high or low motivation condition
48678283|NCT03924544|DRUG|Decorin|Antifibrotic agent
47993271|NCT02446236|DRUG|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
47993272|NCT02446236|DRUG|Ibrutinib|560 mg PO daily
47993273|NCT02446236|DRUG|Rituximab|375 mg/m2 IV Day 1
47993274|NCT02007564|BEHAVIORAL|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
47993275|NCT01811927|DEVICE|PRO-Kinetic Energy Stent|Bare-metal stent
47993276|NCT00326443|BIOLOGICAL|CVD 909|5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
47993277|NCT00326443|DRUG|Placebo|Buffer placebo administered on Day 0.
47993278|NCT00326443|BIOLOGICAL|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
47993279|NCT00815438|PROCEDURE|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
47993280|NCT00913809|DRUG|Desipramine HCL 100 mg Tablets Cord Laboratories|
47993281|NCT00913809|DRUG|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
47993282|NCT02157155|BIOLOGICAL|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
47993283|NCT04085198|PROCEDURE|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
47993284|NCT04085198|PROCEDURE|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
47993285|NCT03525210|BIOLOGICAL|9-valent HPV vaccine|Vaccination
47993286|NCT01366339|DRUG|Oral methylnaltrexone|
47993287|NCT01366339|DRUG|Oral placebo|
47993288|NCT02515045|DRUG|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
48152493|NCT06452888|BEHAVIORAL|Clinical decision support system.|The clinical decision support system includes evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures. Patients in the intervention group will receive the organizational management based on the guidelines and conduct intervention management for patients with actue ischemic stroke. The clinical decision system will classify the patients into risk factors, automatically generate treatment measures according to the guidelines, in order to standardize the treatment of physicians. Such as the management of complications after stroke, the treatment of antiplatelet, anticoagulation, antihypertensive and hypoglycemic.
48152494|NCT06452888|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
48152495|NCT04119778|BEHAVIORAL|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
48152496|NCT05230056|BEHAVIORAL|PG|Shoulder Digital therapy
48152497|NCT05230056|BEHAVIORAL|CTRL|Shoulder non-digital therapy
48152498|NCT04389684|OTHER|Psycho-Social Questionnaire|Patients, after enrollmenet in the study, receive a paper questionnaire during the month following COVID19 related confinement and all the material to send it back to the institution. They receive the same questionnaire 3 months later with all the material to send it back to the institution. The intervention is the same for all patients wether their treatment was modified or not.
48152499|NCT01002209|PROCEDURE|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
48152500|NCT01002209|PROCEDURE|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
48152501|NCT03572907|OTHER|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
48152502|NCT04175938|DEVICE|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
48363776|NCT00005089|DRUG|cyclophosphamide|750 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
48363777|NCT00005089|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
48678284|NCT03924544|DRUG|Mitomycin c|Antifibrotic agent
48678285|NCT02276430|OTHER|Vena punction|Once 90 ml
48678286|NCT06419439|DRUG|Ketamine hydrochloride|Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
48363778|NCT00005089|DRUG|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
48363779|NCT00005089|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
48511396|NCT01555671|DRUG|Meperidine|0.5 ml meperidine injection intravenously injected in randomly selected patients
48511397|NCT01555671|DRUG|Saline|0.5 ml saline solution injection intravenously injected in randomly selected patients
48511398|NCT00282451|DRUG|biphasic insulin aspart|
48678287|NCT06419439|BEHAVIORAL|Minimally Enhanced Usual Care|Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
48678288|NCT06419439|BEHAVIORAL|Brief narrative intervention|"Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention."
48678289|NCT02989116|BEHAVIORAL|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
48678290|NCT02989116|BEHAVIORAL|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
48678291|NCT02989116|BEHAVIORAL|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
48678292|NCT02989116|BEHAVIORAL|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
47993289|NCT02515045|DRUG|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
47993290|NCT02515045|DRUG|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
47993291|NCT02515045|DRUG|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
47993292|NCT05431959|OTHER|balneotherapy|immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
47993293|NCT06516276|DEVICE|Mobile App M.I.O|This mobile app provides patients with access to various resources and therapies focused on nutrition, exercise, and emotional well-being. The main objective is to measure the quality of life of the app users through validated questionnaires in a randomized health education study to evaluate whether a substantial improvement in their well-being is achieved.
48511399|NCT00282451|DRUG|insulin aspart|
48678293|NCT02989116|GENETIC|Saliva collection|Collection of a saliva sample for genotyping
48678294|NCT02989116|PROCEDURE|Brain Magnetic Resonance Imaging|Structural and functional MRI
48678295|NCT02989116|BEHAVIORAL|Cognitive testing|Battery of cognitive and academic tasks on executive functions
48152503|NCT05997420|BEHAVIORAL|STAR Program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
48152504|NCT05997420|BEHAVIORAL|Usual Care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
48678296|NCT02826408|DRUG|Rabeprazole sodium|WIll study effect of the medication on palpittions
48152505|NCT01709045|OTHER|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
48152506|NCT01709045|RADIATION|Dual-Energy Computed Tomography (DECT)|
48152507|NCT01709045|OTHER|Ultrasound|
48152508|NCT01709045|OTHER|Transcranial doppler|
48152509|NCT02845557|OTHER|OGTT and IVGTT tests|
48678297|NCT02826408|DRUG|Pacebo|Placebo comparison to active treatment
48678298|NCT05084248|DRUG|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
48678299|NCT02337894|DIETARY_SUPPLEMENT|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
48678300|NCT02337894|DIETARY_SUPPLEMENT|Placebo|Flavored drink without essential amino acids plus arginine.
48678301|NCT03536325|DRUG|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
48678302|NCT03536325|DRUG|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
47993294|NCT00629499|DRUG|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
47993295|NCT00629499|DRUG|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
47993296|NCT00629499|DRUG|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
47993297|NCT01094496|BIOLOGICAL|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
47993298|NCT01094496|DRUG|Chemotherapy|
48152510|NCT00409747|DRUG|Minocycline|
48152511|NCT06585735|DIETARY_SUPPLEMENT|Proteolytic enzyme fortified protein supplement|Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
47993299|NCT01758185|BIOLOGICAL|recombinant hepatitis b vaccine|0.5ml intramuscular
47993300|NCT01758185|BIOLOGICAL|Aleph influenza vaccine|0.5ml intramuscular
48152512|NCT03557307|BIOLOGICAL|Benralizumab|Benralizumab subcutaneous injection
48152513|NCT03571100|DRUG|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
48678303|NCT03536325|DRUG|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
48678304|NCT03536325|DRUG|Placebo|Participants will receive matching placebo on Day 1.
48678305|NCT01179984|DEVICE|Bard® LifeStent® Vascular Stent System|Stent Implantation
48678306|NCT05177042|DRUG|ARV-110 in Combination with Abiraterone|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles
48678307|NCT04509570|PROCEDURE|Biopsy|5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
48678308|NCT04584398|DEVICE|Respiratory muscle training with steam inhalation|
48678309|NCT06549465|BIOLOGICAL|In-111 rosopatamab tetraxetan|A single dose of 148 ± 37 MBq In-111 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes.
48678310|NCT06549465|BIOLOGICAL|45 KBq/kg Ac-225 rosopatamab tetraxetan|45 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
48678311|NCT06549465|BIOLOGICAL|55 KBq/kg Ac-225 rosopatamab tetraxetan|55 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
48678312|NCT06549465|BIOLOGICAL|60 KBq/kg Ac-225 rosopatamab tetraxetan|60 KBq/kg Ac-225 rosopatamab tetraxetan will be administered as an IV infusion over a period of 10 minutes. Doses will be given two weeks apart for a total of two doses.
48678313|NCT04845672|OTHER|2% chlorhexidine gluconate|Children in 2% chlorhexidine gluconate group , which is the routine practice of the hospital, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
47993301|NCT02140099|BEHAVIORAL|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
47993302|NCT02140099|BEHAVIORAL|Control Condition (Classroom Activities)|
47993303|NCT03451149|DEVICE|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
47993304|NCT05259007|DIETARY_SUPPLEMENT|propolis solved in lactic acid solvent|propolis given as a dietary supplement which was solved in a lactic acid solvent.
47993305|NCT05259007|DRUG|Amoxicillin-Clarithromycin-Lansoprazole|H pylori eradication treatment
47993306|NCT05259007|OTHER|IV saline 0.9%|Physiological serum solution is given as a placebo
47993307|NCT05259007|OTHER|Lactic acid|given to determine if the improvement of the symptoms are due to propolis or the solvent
47993308|NCT02556268|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
47993309|NCT02556268|DRUG|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
47993310|NCT02556268|DRUG|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
47993311|NCT02556268|DRUG|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
47993312|NCT02556268|DRUG|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
47993313|NCT02556268|DRUG|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
47993314|NCT03621852|DEVICE|Endoultrasound guided FNB|EUS FNB with Aquire TM device
47993315|NCT01801150|DEVICE|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
47993316|NCT05463510|DIAGNOSTIC_TEST|Videodermoscopy|Patients who had records for at least twice with videodermoscopy every 3 months were included.
47993317|NCT03103997|PROCEDURE|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
47993318|NCT01454869|DRUG|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
47993319|NCT01454869|DRUG|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
47993320|NCT00854945|DRUG|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
47993321|NCT05954624|DRUG|Digoxin|oral
47993322|NCT05954624|DRUG|Rosuvastatin|oral
47993323|NCT05954624|DRUG|ZSP1273|oral
47993324|NCT05954624|DRUG|Itraconazole|oral
47993325|NCT05954624|DRUG|Probenecid|oral
47993326|NCT03326492|DRUG|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
47993327|NCT02003131|BIOLOGICAL|Trophic factors from umbilical cord mesenchymal stem cells|
47993328|NCT03336775|PROCEDURE|acupuncture|Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
47993329|NCT01871116|BEHAVIORAL|POWER-remote|Web-based weight loss program.
47993330|NCT01871116|BEHAVIORAL|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
47993331|NCT03878745|DEVICE|Terumo Nanopass® 34G pen needle|Insulin pen needle
47993332|NCT03878745|DEVICE|BD Nano™ PRO 32G pen needle|Insulin pen needle
47993333|NCT00144209|DRUG|pramipexole|
47993334|NCT00144209|DRUG|levodopa in combination with benserazide|
47993335|NCT04324801|OTHER|Homeostatic plasticity induction using transcranial direct current stimulation|Homeostatic plasticity will be induced in the left primary motor cortex using tDCS applied for 7 minutes followed by an interval of 3 minutes and another block of 5 minutes of stimulation
47993336|NCT04784221|RADIATION|Radiation by protontherapy associated to nanoparticles injection|"Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles.~Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26.~The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy"
47993337|NCT06429462|DIAGNOSTIC_TEST|smartphone camera sensor tool|The study will involve the development and validation of a computer vision-based approach (using cameras to assess movements) to monitor knee flexion and extension, and a walking pattern assessment.
47993338|NCT00060476|DRUG|rofecoxib|
47993339|NCT00060476|DRUG|Comparator: placebo (unspecified)|
47993340|NCT05195723|DRUG|WP1122|Oral solution
47993341|NCT05195723|DRUG|Placebo|Oral solution
47993342|NCT00945009|BIOLOGICAL|Dactinomycin|Given IV
47993343|NCT00945009|DRUG|Doxorubicin Hydrochloride|Given IV
47993344|NCT00945009|RADIATION|Radiation Therapy|Undergo radiation therapy
47993345|NCT00945009|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48678314|NCT04845672|OTHER|soap-free body cleaning solution|Children in a wiping bath with soap-free body washing solution group, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
48152514|NCT03571100|DRUG|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
48363780|NCT00005089|RADIATION|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
47993346|NCT00945009|DRUG|Vincristine Sulfate|Given IV
47993347|NCT02235142|OTHER|Blood sample|
47993348|NCT00002504|BIOLOGICAL|aldesleukin|
47993349|NCT00002504|BIOLOGICAL|recombinant interferon alfa|
48363781|NCT03933553|OTHER|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
47993350|NCT00376909|OTHER|educational intervention|
48363782|NCT01920061|DRUG|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
48678315|NCT02795299|DRUG|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
48678316|NCT02795299|DRUG|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
47993351|NCT00376909|OTHER|study of socioeconomic and demographic variables|
47993352|NCT03098173|PROCEDURE|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
47993353|NCT03098173|PROCEDURE|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
47993354|NCT00171223|DRUG|STI571|STI571 oral capsules or tablets.
47993355|NCT00540345|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
47993356|NCT00540345|DRUG|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
48152515|NCT03472118|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
48152516|NCT03394508|DRUG|ALK Alutard birch or 5-grasses|Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.
48152517|NCT03394508|DRUG|ALK diluent 0,3% human albumin|Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
48363783|NCT01920061|DRUG|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
48363784|NCT01920061|DRUG|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
48363785|NCT01920061|DRUG|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
48363786|NCT03613766|OTHER|Physical activity program|
48363787|NCT00824746|DRUG|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
48363788|NCT00183976|DRUG|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
48363789|NCT00002176|DRUG|Hydroxyurea|
48363790|NCT00002176|DRUG|Nelfinavir mesylate|
48363791|NCT00002176|DRUG|Stavudine|
48363792|NCT00002176|DRUG|Didanosine|
48363793|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
48363794|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
48363795|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
48363796|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
48152518|NCT00163748|DRUG|gemcitabine, vinorelbine|
48152519|NCT00267774|DEVICE|Fractional flow reserve|
48152520|NCT00267774|PROCEDURE|Angio-guided PCI|
48152521|NCT06399198|PROCEDURE|Free gingival graft|After adequate local anesthesia is achieved, a horizontal incision will be placed at mucogingival junction level to prepare the recipient bed. A split-thickness flap will be raised without disturbing the periosteum. A free gingival graft will be obtained from the palate. The graft will be shaped and sutured to the recipient surface.
48152522|NCT02677688|BIOLOGICAL|Autologous EBV specific CTL infusion|
48152523|NCT06328296|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48152524|NCT06328296|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
48363797|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
48363798|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
48363799|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
48363800|NCT01105429|DRUG|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
48363801|NCT01105429|DRUG|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
48363802|NCT01105429|DRUG|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
48363803|NCT01105429|DRUG|Placebo|Capsule, Oral, (TBD), once daily, 2 days
48363804|NCT03474991|DRUG|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
48363805|NCT00315692|DEVICE|Biomarker Assay (CA125 and HE4)|
48363806|NCT06148025|BIOLOGICAL|BCG vaccine|0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
48363807|NCT06148025|BIOLOGICAL|Yellow Fever vaccine|0.5ml injected subcutaneously
48363808|NCT06148025|DRUG|Vancomycin Oral Capsule|500mg every 6 hours for 3 days
48363809|NCT06148025|DRUG|Neomycin Oral Product|1000mg every 6 hours for 3 days
48363810|NCT01959087|PROCEDURE|single port surgery|Single port surgery can be converted in multiport surgery if necessary
48363811|NCT01959087|PROCEDURE|Multiport surgery|
48678317|NCT02795299|DRUG|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
48678318|NCT02795299|DRUG|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
48678319|NCT03816722|DEVICE|Airvo2|Treatment with HighFlow through the Airvo2 device, 8 hours per day
47993357|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
47993358|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
47993359|NCT01061242|BEHAVIORAL|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
48678320|NCT03816722|OTHER|Usual care|"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"
48678321|NCT02655718|OTHER|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
48678322|NCT02655718|DEVICE|MRI|
47993360|NCT02489344|DRUG|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
47993361|NCT04160364|OTHER|qualitative study|qualitative research via guided interview
47993362|NCT05289011|OTHER|Interviews and questionnaires|"* Evaluation of inflammatory rheumatism~* Dietary survey~* International Physical Activity Questionnaire IPAQ~* BASDAI self-questionnaire~* Assessment of quality of life by ASQol questionnaire~* Assessment of fatigue by FACIT questionnaire~* Assessment of digestive symptoms~* Collection of demographic and general data~* Collection of treatment"
48363812|NCT01934166|DRUG|Nalmefene 18 mg|One single oral dose of 18 mg
48363813|NCT03338335|DRUG|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
48363814|NCT00986817|DRUG|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
48678323|NCT01541488|DRUG|BI 1021958|tablet
48678324|NCT01541488|DRUG|BI 1021958|drinking solution / tablet
48678325|NCT01541488|DRUG|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
48678326|NCT01027858|BEHAVIORAL|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
48152525|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
48152526|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
47993363|NCT00977132|DRUG|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
47993364|NCT00977132|DRUG|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
47993365|NCT02530450|DEVICE|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
48152527|NCT04967677|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
48152528|NCT04859465|DRUG|Abraxane combined with liposomal doxorubicin|Patients with advanced or unresectable angiogenic sarcoma who met the criteria of treatment failure received abraxane combined with liposomal doxorubicin regimen. Administration regimen: abraxane 220 mg / m2 D1 plus liposomal doxorubicin 35 mg / m2 D1, IV drip, 3 weeks as a cycle, until the disease progression or intolerable toxicity. Up to 8 cycles.
48152529|NCT05293093|OTHER|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
48152530|NCT04047355|DRUG|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
47993366|NCT02301273|OTHER|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
48363815|NCT00986817|DRUG|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
48363816|NCT01218477|DRUG|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia \[CML\]-chronic phase; 140 mg for those with CML-advanced phase)
48363817|NCT01218477|DRUG|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
47993367|NCT02301273|OTHER|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (\>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
47993368|NCT03251820|DRUG|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
47993369|NCT01855633|DEVICE|Traditional Theta burst stimulation (TBS)|
48678327|NCT01027858|BEHAVIORAL|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
48678328|NCT02499627|DRUG|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
48678329|NCT02499627|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
48678330|NCT03284060|BEHAVIORAL|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min)."
47993370|NCT01855633|DEVICE|Modified TBS rTMS|
47993371|NCT01855633|DEVICE|Sham rTMS|
47993372|NCT00857220|DRUG|eszopiclone|One 2 mg tablet per day for 12 months
48152531|NCT05809856|DEVICE|GrOwnValve - novel heart valve replacement approach|The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
48152532|NCT06416605|PROCEDURE|Maxillary Alveolar Ridge Augmentation|using tooth graft or bone graft to increase alveolar ridge width to be able to insert dental implant
48152533|NCT02967822|GENETIC|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
48152534|NCT02967822|GENETIC|Biological samples for healthy relatives|Blood samples.
48152535|NCT05444374|DRUG|Serplulimab|Recombinant anti-PD-1 humanized monoclonal antibody injection
48152536|NCT05444374|DRUG|Bevacizumab|Humanized anti-VEGF monoclonal antibody injection
48152537|NCT02724423|DRUG|NRL-1|
48152538|NCT04657718|DEVICE|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
48152539|NCT03425500|PROCEDURE|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
48152540|NCT03425500|PROCEDURE|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
48152541|NCT03425500|DEVICE|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
48678331|NCT03663309|DIAGNOSTIC_TEST|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~* Bring 4-day food diary (attached)~* Fill symptoms and complaints questionnaire (attached)~* Provide 24 h diet recall in case a food diary absents~* Fill Biagi score questionnaire (attached)~* Perform blood test of TTG~* Provide stool and urine samples"
48152542|NCT04372706|DRUG|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
48152543|NCT04372706|DRUG|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
48152544|NCT02604199|DRUG|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
48678332|NCT03310359|DIETARY_SUPPLEMENT|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
48678333|NCT03310359|OTHER|Placebo|Matching placebo pill
48678334|NCT01970228|DIAGNOSTIC_TEST|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
48678335|NCT05289089|BEHAVIORAL|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
48152545|NCT02604199|OTHER|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
48678336|NCT03123770|DRUG|Pegylated liposomal doxorubicin|a new kind of doxorubicin
48152546|NCT02604199|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
48152547|NCT02604199|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
48152548|NCT02604199|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
48152549|NCT02203513|DRUG|LY2606368|105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
48152550|NCT05982756|DRUG|DAG pre-excitation regimen with Bortezomib|Bortezomib+DAG pre-excitation regimen: Bortezomib (specification 3.5mg, intravenous injection, 4 times a course of treatment, 1.3mg/m2, d1, 4, 8, 11; doxorubicin liposome injection 5 mg/ m2, intravenous infusion, once every other day, 5 times in total; cytarabine 10 mg/m2 every 12 hours, subcutaneous injection, d1-14; G-CSF 200 μg/m2 daily, subcutaneous injection, d1-14 Days, WBC \>10×109/L during chemotherapy, postpone the use until it falls below this value;
48678337|NCT03123770|DRUG|Cyclophosphamide|traditional chemotherapy drug
48152551|NCT03245996|DEVICE|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
48678338|NCT03123770|DRUG|Epirubicin|traditional chemotherapy drug used in breast cancer
48678339|NCT03123770|DRUG|Docetaxel|traditional chemotherapy drug used in breast cancer
47993373|NCT00857220|DRUG|eszopiclone|one 3mg tablet per day for 12 months
47993374|NCT03475966|OTHER|Exercise|A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
47993375|NCT03475966|OTHER|Nutrition|Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
48678340|NCT00361972|DRUG|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
48678341|NCT00361972|DRUG|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
48678342|NCT06004154|DIAGNOSTIC_TEST|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries added to the usual follow-up at 1, 3, 6 and 12 months
48152552|NCT03245996|DEVICE|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
48152553|NCT03245996|DEVICE|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
48152554|NCT03245996|DRUG|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
48152555|NCT03245996|DRUG|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
48152556|NCT03245996|DRUG|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
48152557|NCT00966641|DRUG|Naproxen|Single orally administered dose of 500 mg naproxen
48152558|NCT00966641|DRUG|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
48152559|NCT01748851|DRUG|XELOX|capecitabine 1000mg/m2 bid po D1-D14
48152560|NCT01748851|DRUG|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
48152561|NCT05710627|DEVICE|TENEX|Use of TENEX device for sectioning of the gluteus medius and ITB tendons.
48152562|NCT03807947|PROCEDURE|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
48152563|NCT03807947|PROCEDURE|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
48678343|NCT04987827|OTHER|No intervention|No intervention
48678344|NCT04042454|OTHER|milk based anti-regurgitation infant formula|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
48678345|NCT04042454|OTHER|Milk based infant formula|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
48678346|NCT04543916|DRUG|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
48678347|NCT04543916|DRUG|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
48678348|NCT04543916|DRUG|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
48678349|NCT04543916|DRUG|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
48678350|NCT04543916|DRUG|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
48678351|NCT04543916|DRUG|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
47993376|NCT03475966|BEHAVIORAL|Relaxation techniques|Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
47993377|NCT04923503|BEHAVIORAL|diurnal fasting|subject conduct fasting in Ramadan for 30 days
47993378|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-087|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
47993379|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-088|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
47993380|NCT01589757|OTHER|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
47993381|NCT01589757|OTHER|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
47993382|NCT02981719|PROCEDURE|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment
47993383|NCT02981719|PROCEDURE|irreversible electroporation|percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
47993384|NCT03777007|DEVICE|SPARTA force plate|The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
47993385|NCT01123109|PROCEDURE|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
47993386|NCT03905122|DEVICE|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
47993387|NCT05319795|BEHAVIORAL|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
47993388|NCT05326594|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
47993389|NCT05326594|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
47993390|NCT05326594|DEVICE|Inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
47993391|NCT05326594|PROCEDURE|Heat Therapy|superficial heating for 20 minutes
47993392|NCT04263701|OTHER|Therapeutic exercises|Conventional physiotherapy exercises for children with cerebral palsy
47993393|NCT04263701|OTHER|Dual Task Training|Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
47993394|NCT01620073|OTHER|HIV counseling and testing|Male partner HIV counseling and testing
47993395|NCT02994732|DRUG|[14C]-BVD-523|\[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
48152564|NCT00104845|BIOLOGICAL|human gp100 plasmid DNA vaccine|
48152565|NCT00104845|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
48152566|NCT00992693|DRUG|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
48152567|NCT03449485|DRUG|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
48152568|NCT06266390|DEVICE|Transcranial Magnetic Stimulation (TMS)|The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.
48152569|NCT00905255|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48152570|NCT00905255|DEVICE|Pen auto-injector|
48152571|NCT05612256|DIAGNOSTIC_TEST|Electrical impedance tomography (EIT)|EIT is the measurement of impedance changes of the lung against the flow of alternating electrical currents applied to the thorax. The signal of the electrodes is transmitted to a monitor, which enables real-time assessment of lung aeration and changes in lung volume. EIT is able to reconstruct impedance changes with a high temporal resolution and allows calculation of tidal volumes, relative stretch of lung tissue and areas of poor ventilation. Areas with impedance changes of \< 10 % of the maximum impedance changes are called 'Silent Spaces'.
48152572|NCT05612256|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|FOT enables non-invasive assessment of lung mechanics using sound waves to inform about the respiratory impedance of the respiratory system (Zrs). Reactance of the respiratory system (Xrs) as part of Zrs is a surrogate measure of compliance of the respiratory system. Xrs was previously used to identify optimal PEEP level, i.e., the PEEP at highest compliance equivalent, in newborn infants using a setup requiring research-specific hardware and software. The FOT module integrated in the commercially available neonatal ventilator is routinely used. FOT measurements are performed twice at each PEEP level to assess the reproducibility of the measurements.
48152573|NCT05612256|DIAGNOSTIC_TEST|Saturation oxygenation pressure index (SOPI)|SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
48152574|NCT01217645|RADIATION|150 mg [14C] AZD6765|
48152575|NCT05811000|DRUG|PM012|PM012 650 mg tablet drug
48152576|NCT05811000|DRUG|PM012 Placebo|PM012 tablet placebo
48152577|NCT05811000|DRUG|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
48152578|NCT05811000|DRUG|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
48152579|NCT01079117|DRUG|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
48152580|NCT01079117|DRUG|Slow release oral morphine|
48152581|NCT01079117|DRUG|Methadone|
48152582|NCT01769729|BEHAVIORAL|PEPP|
48152583|NCT01769729|BEHAVIORAL|Care management|
48678352|NCT04543916|DRUG|Venetoclax (RP2D)|orally, once per day
48678353|NCT00363142|DRUG|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
48678354|NCT00363142|DRUG|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
48152584|NCT05627622|BEHAVIORAL|WhatsApp health education message|stone-prevention information on a monthly basis, using personal WhatsApp messages
47993396|NCT02065232|DRUG|Tilmanocept|
48152585|NCT02066454|DRUG|Apixaban|2.5mg x 2 per day during 6 months
47993397|NCT02065232|DRUG|Sulfur Colloid|
47993398|NCT01799499|DEVICE|TC-3 hydrogel|
47993399|NCT01799499|DEVICE|TC-3 hydrogel|
47993400|NCT01799499|DEVICE|TC-3 hydrogel|
47993401|NCT01455012|DRUG|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
47993402|NCT01455012|DRUG|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
48152586|NCT03853525|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
48152587|NCT03853525|OTHER|Semisolid vaseline|Product is applied to one side of the inguinal region.
48152588|NCT04150419|OTHER|Group 1|Attentional training to avoid threatening, negative or pain-related information.
48152589|NCT04150419|OTHER|Group 2|Attention training for vigilance for positive emotional information.
48152590|NCT04150419|OTHER|Group 3 (control group)|Neutral attentional training (control group).
48152591|NCT02700009|BEHAVIORAL|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
48152592|NCT02700009|OTHER|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
48678355|NCT04782349|OTHER|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
47993403|NCT00001960|DEVICE|Pacemaker therapy|
47993404|NCT04117347|DEVICE|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
48152593|NCT00559871|DRUG|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
47993405|NCT04117347|DEVICE|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
48152594|NCT01328483|PROCEDURE|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
48152595|NCT05615506|PROCEDURE|Suction Diathermy Adenoidectomy|suction diathermy adenoidectomy
48152596|NCT03851809|DRUG|Wendan decoction combination in acute brain injury|In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
48152597|NCT06226623|DIETARY_SUPPLEMENT|Coconut|Participants in the intervention group, unlike participants in the control group, were asked to consume 50 g of fresh coconut daily for four weeks.
48152598|NCT04521647|DRUG|Nicotine|Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
48152599|NCT00003731|DRUG|temozolomide|
48152600|NCT01241032|DRUG|Udenafil|200mg Single Oral Dose of
48152601|NCT01241032|DIETARY_SUPPLEMENT|Alcohol|Alcohol 39g / 240ml
48152602|NCT00118937|DRUG|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
48152603|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
48152604|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
48152605|NCT00426218|DRUG|ACZ885|
48152606|NCT05884671|DRUG|Sulpiride 400 MG|All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
48152607|NCT05884671|DRUG|Placebo|All participants will receive placebo during one of the sessions.
48152608|NCT04288440|PROCEDURE|Surgery|Removal of epiretinal membrane and ILM
48152609|NCT04288440|DEVICE|Vitrectomy machine|Pars plana vitrectomy
48152610|NCT03347084|DEVICE|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
48152611|NCT03347084|DEVICE|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
48152612|NCT04626128|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI)
48152613|NCT04626128|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
48152615|NCT02104375|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
48152616|NCT05472532|PROCEDURE|Patient sampling.|"One or several bio-specimens will be sampled depending on the cohort :~* Blood (40 ml)~* Pleural Fluid (40 ml)~* Peritoneal liquid (40 ml)~* Solid tumors"
48152617|NCT01256814|BEHAVIORAL|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
48152618|NCT01102426|DRUG|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
47993406|NCT04117347|DEVICE|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
48152619|NCT01102426|DRUG|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
48152620|NCT04397185|DEVICE|Breast Cancer Locator (BCL) guided partial mastectomy|The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
48152621|NCT04397185|DEVICE|Wire Localized (WL) partial mastectomy|Standard of care procedure
48152622|NCT04800978|BIOLOGICAL|BAVC-C+Durvalumab|"* Durvalumab Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for infusion after dilution.~* BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion"
48152623|NCT05360771|DEVICE|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
48152624|NCT05360771|DEVICE|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
48152625|NCT02714244|OTHER|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
48152626|NCT05591937|BEHAVIORAL|Self-Guided Online Prevention|An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
48152627|NCT05591937|BEHAVIORAL|Coach-Guided Online Cognitive Behavioral Therapy|An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
48152628|NCT05591937|BEHAVIORAL|Clinician-Delivered Psychological and Psychiatric Care|Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
48152629|NCT04276649|DRUG|Caltrate|Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
48152630|NCT01024023|DEVICE|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
48152631|NCT04315545|DIAGNOSTIC_TEST|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
48152632|NCT02255526|DEVICE|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
48152633|NCT05606809|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
48152634|NCT05506319|OTHER|Norepinephrine|"The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).~Interruption means suspension for at least 24 hours."
48152635|NCT05506319|OTHER|Vasopressin|"The patients will be randomized for the initial suspension of vasopressin (vasopressin group).~Interruption means suspension for at least 24 hours."
48152636|NCT05044286|OTHER|no intervention|no intervention
48152637|NCT06505785|OTHER|The creative drama group|"10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development."
48152638|NCT01320683|DRUG|oxaliplatin|Given IV
48152639|NCT01320683|DRUG|leucovorin calcium|Given IV
47993407|NCT03185728|OTHER|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
47993408|NCT03573947|DRUG|Nivolumab|360 mg intravenously every 3 weeks
47993409|NCT03573947|DRUG|Ipilimumab|1 mg/kg intravenously over 30 minutes
48152640|NCT01320683|DRUG|fluorouracil|Given IV
48152641|NCT01320683|BIOLOGICAL|bevacizumab|Given IV
48363818|NCT05230693|BEHAVIORAL|Sarcoidosis Patient Assessment and Resource Companion App|"The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day"
48363819|NCT05230693|BEHAVIORAL|Enhanced Standard Care|Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
48363820|NCT05572489|DIAGNOSTIC_TEST|visual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale|evaluation of pain, fatigue, mood, quality of life, cognitive status
48363821|NCT05879848|OTHER|VR|virtual reality scenario synchronized with the uterine contractions
48363822|NCT04098172|DEVICE|Pressure Guidewire|Fractional Flow Reserve measurement
47993410|NCT03573947|DRUG|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
47993411|NCT01914185|OTHER|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
47993412|NCT04421911|DRUG|Ketoprofen topical|Ketoprofen topical for 21days
47993413|NCT04421911|DRUG|Diclofenac Topical|Diclofenac topical for 21days
47993414|NCT00006240|BIOLOGICAL|sargramostim|
47993415|NCT00006240|DRUG|dexamethasone|
47993416|NCT00006240|DRUG|oral sodium phenylbutyrate|
47993417|NCT01797289|OTHER|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
48152642|NCT01320683|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
48152643|NCT01320683|OTHER|laboratory biomarker analysis|Correlative studies
48152644|NCT01320683|OTHER|pharmacological study|Correlative studies
48152645|NCT01320683|DRUG|irinotecan hydrochloride|Given IV
48363823|NCT04470960|BEHAVIORAL|Training course for the community center health coordinators|"These community centers who have volunteered to join the project will receive a 12 week training session which includes the values and principles of health promotion and the principles of building a health promotion project.~The participants will be requested to build a health promotion project within their community. Building and implementing the project will be assisted by a health promotion specialist. Each health promotion project will be evaluated according to the principles of health promotion."
48363824|NCT02662374|DRUG|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
47993418|NCT02389998|OTHER|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
47993419|NCT02389998|DRUG|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
47993420|NCT06455397|BEHAVIORAL|The Building Emotional Awareness and Mental Health (BEAM) Program|"The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol.~Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required."
47993421|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
47993422|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
47993423|NCT04988347|COMBINATION_PRODUCT|Spirulina platensis|Active treatment with Spirulina platensis in capsules containing 530 mg, 1 capsule orally each 8 hours, for 60 days
47993424|NCT04988347|OTHER|Placebo comparator|Placebo in capsules, 1 capsule orally each 8 hours, for 60 days
47993425|NCT05584150|OTHER|Deep Cleansing Gel|daily use
47993426|NCT02770586|DIAGNOSTIC_TEST|Breast PET|imaging of the breast using the Breast PET system
47993427|NCT01523886|DRUG|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
47993428|NCT01523886|DRUG|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
47993429|NCT03933787|DRUG|Saxagliptin 5mg|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
47993430|NCT03933787|DRUG|Placebo oral capsule|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
47993431|NCT03933787|OTHER|ergometric test in healthy volunteers|The volunteers will undergo an ergometric test in each session
47993432|NCT02331147|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment
47993433|NCT02331147|OTHER|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
47993434|NCT02515955|DRUG|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
47993435|NCT02515955|DRUG|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
47993436|NCT02515955|DRUG|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
47993437|NCT02515955|DRUG|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
47993438|NCT02515955|DRUG|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
48152646|NCT03849300|OTHER|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
48152647|NCT03849300|OTHER|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
48152648|NCT03849300|OTHER|Land-based walking exercise group|12 week land-based walking exercise program
48363825|NCT02662374|DRUG|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
48152649|NCT01655199|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
48152650|NCT05316649|OTHER|Measurement of external blood loss|Measurement of external blood loss
48678356|NCT04782349|OTHER|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
48678357|NCT04782349|OTHER|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
48678358|NCT00661830|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
48678359|NCT00661830|DRUG|Placebo|Placebo
47993439|NCT01271088|DRUG|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
48152651|NCT05316649|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|Serum Hemoglobin concentration
48152652|NCT04050722|DRUG|Sensodyne Repair and Protect|Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
48678360|NCT00661830|DRUG|Sorafenib|Sorafenib 400 mg bid orally continuously
48678361|NCT06008262|OTHER|Cold Application|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
48678362|NCT03467256|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
48678363|NCT03467256|DRUG|Fludarabine|given IV
48678364|NCT03467256|DRUG|Cyclophosphamide|given IV
48678365|NCT03467256|DRUG|Tocilizumab|given IV
48678366|NCT03467256|DRUG|Cytarabine|given IV
48678367|NCT03467256|DRUG|Etoposide|given IV
48678368|NCT03467256|DRUG|Dexamethasone|given IV
48678369|NCT04680624|PROCEDURE|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
48678370|NCT01163305|DRUG|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
48678371|NCT03007030|DRUG|Brentuximab Vedotin|Given IV
48678372|NCT03007030|OTHER|Laboratory Biomarker Analysis|Correlative studies
48152653|NCT04050722|DRUG|Colgate Cavity Protection|Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
48152654|NCT02122822|BIOLOGICAL|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
48678373|NCT04762082|DRUG|Tadalafil 10 MG|comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
48678374|NCT01569815|DRUG|LCZ696|LCZ696 400 mg once daily
48678375|NCT02140970|DRUG|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
48678376|NCT02140970|DRUG|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
48678377|NCT05545410|OTHER|MRI calibration|Non-injected thoracic aorta MRI calibration
48678378|NCT05135572|DIAGNOSTIC_TEST|Fibromiyalgia and foot pain|Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
48678379|NCT00808392|BIOLOGICAL|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
48678380|NCT00808392|BIOLOGICAL|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
48678381|NCT04001439|DRUG|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
48678382|NCT04692012|OTHER|FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION|VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
48678383|NCT04803513|DRUG|Galcanezumab|Galcanezumab according to clinical indication in real life
48678384|NCT04684940|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
48678385|NCT00000553|DRUG|simvastatin|
48678386|NCT00000553|DRUG|niacin|
48678387|NCT00000553|DRUG|antioxidants|
48678388|NCT04880239|PROCEDURE|Posterior colpoperineorrhaphy|Patients having a sacralcolpopexy will be randomized to ultra lightweight mesh (Coloplast Restorelle) with posterior colpoperineorrhaphy or the same procedure without the posterior colpoperineorrhaphy
48678389|NCT00753948|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
48678390|NCT05715658|DRUG|Dabigatran etexilate capsule|Adult healthy subjects and elderly healthy subjects only take one 110 mg dabigatran etexilate capsule (low-dose specification in the instruction manual) orally. Elderly patients with atrial fibrillation take dabigatran etexilate according to routine medical treatment.
48678391|NCT05003908|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48152655|NCT02442102|BEHAVIORAL|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
48152656|NCT00681135|DEVICE|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
48152657|NCT00681135|DEVICE|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
48678392|NCT04570618|DEVICE|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
48678393|NCT04570618|OTHER|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
48678394|NCT02590536|DRUG|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
48678395|NCT02590536|DRUG|placebo|
48678396|NCT03512574|DRUG|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
48678397|NCT03512574|DRUG|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
48678398|NCT03512574|OTHER|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
48678399|NCT03512574|DRUG|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
48678400|NCT02173405|DRUG|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
48678401|NCT02173405|DRUG|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
48678402|NCT01730911|OTHER|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
48678403|NCT05771805|OTHER|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
48678404|NCT05771805|OTHER|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
48678405|NCT02747758|DEVICE|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
48678406|NCT02747758|DEVICE|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
48678407|NCT02747758|DEVICE|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
48678408|NCT05461339|DRUG|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
48678409|NCT05461339|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
48678410|NCT04487197|PROCEDURE|blood sample for seroepidemiological investigation|blood sample for seroepidemiological investigation
48678411|NCT06007677|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
48678412|NCT01361217|DRUG|Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan|"1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water."
48678413|NCT05225519|DEVICE|long-sleeved white shirt impregnated with a long-infrared irradiation|Usage of an experimental shirt for a period of 12 weeks.
48678414|NCT05225519|DEVICE|long-sleeved white shirt|Usage of an experimental shirt for a period of 12 weeks.
48678415|NCT00133341|DRUG|Goldnatriomthiosulphate, MDBGN, parthenolide|
48678416|NCT04380623|BEHAVIORAL|Mobile Phone-Based Web-Page: HPV vaccine|Website to be accessed via mobile phone to deliver tailored educational material
48152658|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
48152659|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
48152660|NCT02254200|OTHER|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
48363826|NCT02662374|DRUG|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
48678417|NCT01845246|DEVICE|Prospective TDM Arm of colistin|
48678418|NCT05522283|DIAGNOSTIC_TEST|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
48678419|NCT00506779|DRUG|Imatinib Mesylate|Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily
48678420|NCT00506779|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 Hours every 21 Days
48678421|NCT04168567|DIAGNOSTIC_TEST|Microbiome analysis|Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.
48678422|NCT02225652|DRUG|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
48678423|NCT02250872|DRUG|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
48678424|NCT02250872|DRUG|Placebo|100mg in 2 divided doses plus cisplatin
48678425|NCT02250872|DRUG|Cisplatin|All patients will receive intravenous cisplatin
48678426|NCT03908203|PROCEDURE|Minimally invasive one-level lumbar deformity correction|The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
48678427|NCT02394821|DRUG|Polihexanide 2%|
48678428|NCT02394821|DRUG|Metronidazole 0.8%|
48678429|NCT03584347|BEHAVIORAL|Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.
48678430|NCT00161044|DRUG|Galantamine|
48678431|NCT06275828|DEVICE|slow beat mesic listening by headphone|classic slow beat type from researcher
48678432|NCT00348946|DRUG|androgen oxandrolone|Oxandrolone ,06 \>mg/kg/day, orally, for 2 years
48678433|NCT00348946|OTHER|placebo|an inactive substance
48678434|NCT05340530|DRUG|The injectable TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibatam.
48678435|NCT05340530|DRUG|meropenem|Meropenem is a carbapenem antibiotic
48678436|NCT05340530|DRUG|Avibactam Sodium|Avibactam is beta-lactamase inhibitor.
48678437|NCT05340530|DRUG|Placebo|It is a placebo.
48152661|NCT02254200|OTHER|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of \~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
48152662|NCT06021002|DRUG|R848|Nasal R848 administration
48152663|NCT06021002|DRUG|Saline|Nasal saline administration
48152664|NCT01000415|OTHER|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
48152665|NCT01305551|DRUG|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
48152666|NCT01305551|DRUG|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
48152667|NCT01305551|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
48152668|NCT04007822|BEHAVIORAL|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
48152669|NCT00593528|DEVICE|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
48152670|NCT00593528|DEVICE|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
48152671|NCT00593528|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
48152672|NCT01176409|DRUG|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
48678438|NCT05257486|DEVICE|Xoft eBx|The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source
48678439|NCT05188638|DRUG|SoftOx Inhaled Solution (SIS)|SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
48678440|NCT05188638|DRUG|Placebo|Sterile isotonic saline
48678441|NCT05298943|OTHER|walking in 4 situations|Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
48678442|NCT02209935|OTHER|Early Rehabilitation Protocol|
48152673|NCT01176409|DRUG|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
48678443|NCT02209935|OTHER|Usual care|
48152674|NCT00324363|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
48152675|NCT00324363|DRUG|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
48152676|NCT00763087|BEHAVIORAL|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
48152677|NCT00763087|BEHAVIORAL|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
48678444|NCT03855345|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
48152678|NCT00763087|BEHAVIORAL|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
48152679|NCT00889863|DRUG|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
48152680|NCT00889863|DRUG|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
48678445|NCT03855345|RADIATION|aPDT|aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
48678446|NCT05498740|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
48678447|NCT04144283|BEHAVIORAL|NAP|"For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold during stage 2 and stage 3 of NREM sleep."
48678448|NCT04144283|BEHAVIORAL|WAKE|For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.
48678449|NCT04176393|DRUG|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
48678450|NCT05357768|OTHER|data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue|"Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification."
48678451|NCT02897115|BIOLOGICAL|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
48678452|NCT02897115|OTHER|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
48678453|NCT00848458|OTHER|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
48678454|NCT00848458|OTHER|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
48678455|NCT02516501|DIETARY_SUPPLEMENT|MyAmino|MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
48678456|NCT02516501|DIETARY_SUPPLEMENT|betaquik|betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.
48678457|NCT02516501|RADIATION|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
48152681|NCT03583944|DRUG|Eribulin Mesylate|Eribulin mesylate IV infusion.
48678458|NCT06512506|OTHER|non-intervention|non-intervention
48152682|NCT02831088|DRUG|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
48678459|NCT06525038|OTHER|All groups were observed for clinical end-points described in the study protocol|All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.
48152683|NCT02831088|DRUG|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
48152684|NCT02831088|DRUG|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
48152685|NCT04109651|OTHER|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
48363827|NCT02662374|DEVICE|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
48363828|NCT02662374|DRUG|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
48678460|NCT05047133|DRUG|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
48678461|NCT04726995|OTHER|CHOP and BFM regiments|used CHOP and BFM regiments
48678462|NCT02620475|DEVICE|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
48678463|NCT00323531|PROCEDURE|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
48678464|NCT00323531|PROCEDURE|VATS decortication|thoracoscopic decortication
48678465|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
48678466|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
48678467|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
48678468|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
48363829|NCT03225833|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
48363830|NCT03225833|DRUG|Placebo|0.9% Sodium Chloride
48363831|NCT01673373|DEVICE|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
48363832|NCT02926690|DRUG|OTS167PO|Single arm, no competitor
48678469|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
48678470|NCT00413660|DRUG|CP-690,550|Oral tablets
48678471|NCT00413660|OTHER|placebo|Placebo
48678472|NCT05196373|DRUG|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
48678473|NCT03577262|OTHER|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
48678474|NCT03650868|PROCEDURE|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
48678475|NCT05101811|DRUG|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
48678476|NCT05101811|DEVICE|Vitamin D level assessment|Using lIAISON DEVICE
48678477|NCT05601440|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
48678478|NCT05601440|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
48678479|NCT05601440|OTHER|Observation|Monitoring arm
48678480|NCT05601440|DRUG|Niraparib|Dose and schedule will be assigned at enrolment
48678481|NCT05601440|DRUG|Fulvestrant|Dose and schedule will be assigned at enrolment
48678482|NCT03886948|DRUG|LY3074828|Administered subcutaneously (SC)
48678483|NCT03886948|DEVICE|Pre-filled syringe (PFS)|PFS used to administer LY3074828
47993440|NCT03788096|BEHAVIORAL|Peer Support with Motivational Interviewing|Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
47993441|NCT03788096|BEHAVIORAL|Usual Care Group|Usual care.
47993442|NCT02861703|BEHAVIORAL|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
47993443|NCT03742609|OTHER|ii) the reminder|Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
48678484|NCT03886948|DEVICE|Autoinjector (AI)|AI used to administer LY3074828
48678485|NCT02993627|DIETARY_SUPPLEMENT|Spirulina|2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis
47993444|NCT03742609|OTHER|ii) written behavioural plan|Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
47993445|NCT03742609|OTHER|iv) all materials|i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
47993446|NCT02208856|DRUG|BIBR 796 BS|
47993447|NCT02208856|DRUG|Placebo|
47993448|NCT02208856|OTHER|high fat standardized breakfast|
47993449|NCT01955161|DRUG|Placebo|Once daily, matching placebo capsules, orally
47993450|NCT01955161|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
47993451|NCT05184114|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Blood Tests|Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
47993452|NCT05665790|RADIATION|radiotherapy|radiotherapy
47993453|NCT05665790|PROCEDURE|palliative surgery|palliative surgery
47993454|NCT01424254|DEVICE|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
47993455|NCT01424254|PROCEDURE|Push-Enteroscopy|currently recommended standard
47993456|NCT00888095|PROCEDURE|deep brain stimulation|electrode implantation in either STN or cZI
48678486|NCT02993627|OTHER|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
48678487|NCT05461599|DEVICE|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
48678488|NCT01123148|DEVICE|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
48678489|NCT01037998|DRUG|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
48678490|NCT05809427|DEVICE|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
48678491|NCT04729348|DRUG|Pembrolizumab|Oral, daily, dosage per protocol
48678492|NCT04729348|DRUG|Lenvatinib|Oral, daily, dosage per protocol
48678493|NCT04686344|DRUG|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
48678494|NCT04686344|DRUG|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
48678495|NCT02118948|BEHAVIORAL|Abuse-focused intervention|
48678496|NCT02118948|BEHAVIORAL|Sexual behavior-focused intervention|
48678497|NCT02308267|OTHER|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
48363833|NCT03264976|DIAGNOSTIC_TEST|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
48363834|NCT04628585|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
48363835|NCT04382209|PROCEDURE|Erector spinae plane block|The transducer was placed vertically 3cm lateral to the midline to visualize the muscles of the back, transverse process and the pleura in between the two transverse processes. Bilateral ultrasound guided erector spinae plane block with 20 mL of 0.375% bupivacaine each using an in-plane, cranial-to-caudad approach to contact the bony shadow of the transverse process (TP) with the tip deep to the fascial plane of the erector spinae muscle. The correct location of the needle tip was confirmed by injecting 0.5-1 cc of normal saline 0.9% and observing linear fluid spread lifting the erector spinae muscle off the tip of the TP.
48363836|NCT04382209|DEVICE|Intravenous meperidine patient controlled analgesia device|Intravenous meperidine patient controlled analgesia device will be given to the patients postoperatively and 24 hour meperidine consumption will be recorded
48363837|NCT01632527|DRUG|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
48363838|NCT04647929|DEVICE|Santen PRESERFLO MicroShunt|the PRESERFLO MicroShunt will be implanted to increase aqueous humor outflow
48363839|NCT04647929|PROCEDURE|Trabeculectomy|a fornix-based trabeculectomy with a 3x4mm flap will be performed to increase aqueous humor outflow
48363840|NCT04796454|DRUG|Cisplatin|Cisplatin IV 25 mg/m² on d1 and d8 - always combined with Gemcitabine; maximum treatment 2 years
48363841|NCT04796454|DRUG|Gemcitabine|Gemcitabine IV 1000 mg/m² on d1 and d8 if in combination with Cisplatin; Gemcitabine IV 1000 mg/m² on d1 and d15 if in combination with Oxaliplatin; maximum treatment 2 years
48363842|NCT04796454|DRUG|Oxaliplatin|Oxaliplatin IV 100 mg/m² on d1 and d15 - always combined with Gemcitabine; maximum treatment 2 years
48678498|NCT02308267|OTHER|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
48678499|NCT02308267|PROCEDURE|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
48678500|NCT04774380|DRUG|Durvalumab|Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
48678501|NCT04774380|DRUG|Cisplatin|Participants will receive cisplatin via IV administration on Day 1 of each cycle.
48678502|NCT04774380|DRUG|Carboplatin|Participants will receive carboplatin via IV administration Day 1 of each cycle.
48678503|NCT04774380|DRUG|Etoposide|Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
48678504|NCT02839278|BIOLOGICAL|Blood sample|
48678505|NCT02625350|OTHER|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
48678506|NCT02625350|OTHER|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
48678507|NCT02625350|OTHER|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
48678508|NCT02824692|DEVICE|heart lungs and abdomen ultrasound|
48678509|NCT05807412|DRUG|PrabotulinumtoxinA-Xvfs|"All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
48363843|NCT04796454|DRUG|Pamiparib|Pamiparib 60 mg PO twice a day from d1 to day28 in a 4-week cycle - always combined with Temozolomide; until progression or maximum treatment 2 years
48363844|NCT04796454|DRUG|Temozolomide|Temozolomide 60 mg PO once a day from d1 to d7 in a 4-week cycle - always combined with Pamiparib; until progression or maximum treatment 2 years
48363845|NCT04145310|DRUG|BOL-DP-o-04 + SCO|sublingual drops
48363846|NCT04145310|DRUG|Placebo + SCO|sublingual drops
48363847|NCT06092866|BEHAVIORAL|Digital triage|A registered nurse assesses the symptoms reported by the patient on the online platform and gives appropriate advice for further care using chat.
48152686|NCT03662737|DIAGNOSTIC_TEST|Visuomotor adaptation task|We will measure performance of the subjects of each group on the visuomotor adaptation task, especially in the rotation condition, in which a perturbation will be induced between the anticipated location of the hand and the provided visual feedback, and in the washout condition, in which the rotation will be removed. We expect that subjects with cannabis use disorder will not show the expected implicit motor adaptation to the perturbation and consequently no deterioration of performance on the task, due to cannabis-induced cerebellar damage. In other words, we want to show that this visuomotor task is a cheap and quick biomarker of cerebellar dysfunction in chronic cannabis users.
48152687|NCT05890781|PROCEDURE|Skin biopsy|Skin biopsy
48152688|NCT05890781|PROCEDURE|Fresh tumor sample|Fresh tumor sample
48152689|NCT05890781|BIOLOGICAL|Blood sample|Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
48152690|NCT05890781|PROCEDURE|Healthy tissue from the tumor|Healthy tissue from the tumor site whenever possible
48152691|NCT05890781|PROCEDURE|Spinal cerebrospinal fluid (SCF)|Spinal cerebrospinal fluid (SCF) whenever possible
48363848|NCT03238209|DIAGNOSTIC_TEST|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
48363849|NCT00000515|BEHAVIORAL|diet, reducing|
48363850|NCT04715958|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
48678510|NCT05807412|DRUG|OnabotulinumtoxinA|"All subjects will receive one injection of 4 units or 0.1 cc of onabotulinumtoxinA into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of onabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
48678511|NCT03841851|PROCEDURE|sub epithelial connective tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate"
48678512|NCT00378638|DRUG|bevacizumab combined with dose dense chemotherapy|
48678513|NCT04232943|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (IPV)|"IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units"
48678514|NCT04232943|BIOLOGICAL|E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|"LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules."
48152692|NCT06095778|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
48152693|NCT02782273|DRUG|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
48152694|NCT02782273|DRUG|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
48152695|NCT06018233|OTHER|New proposal for regime creation|Interviews and building of proposals in the light of the information obtained and desk based research
48152696|NCT05612009|COMBINATION_PRODUCT|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
47993457|NCT01288950|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
48363851|NCT04715958|DRUG|Perflutren Lipid Microspheres|Given IV
48363852|NCT04715958|PROCEDURE|Ultrasound|Undergo unenhanced baseline ultrasound
48363853|NCT04045314|OTHER|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
48363854|NCT00784836|DRUG|BG9418 (interferon beta 1-a)|
47993458|NCT00772707|DEVICE|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI-FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
48363855|NCT05751850|DRUG|HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate|HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate
48678515|NCT04232943|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|"Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3."
48678516|NCT00742521|PROCEDURE|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
48678517|NCT00742521|PROCEDURE|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
48678518|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
48678519|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
48678520|NCT02365181|PROCEDURE|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
48678521|NCT02365181|PROCEDURE|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
47993459|NCT00772707|DEVICE|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
47993460|NCT00060931|DRUG|carvedilol|
47993461|NCT00060931|DRUG|metoprolol|
48152697|NCT06277011|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
48363856|NCT05751850|DRUG|nab-paclitaxel; gemcitabine|nab-paclitaxel in combination with gemcitabine
48511400|NCT03106987|DRUG|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
48678522|NCT02365181|DRUG|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
47993462|NCT03338426|DRUG|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
48511401|NCT03106987|DRUG|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
48152698|NCT05449756|OTHER|Self-administered questionnaires|Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
48152699|NCT03456778|DEVICE|Shear Wave Elastography|An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.
48152700|NCT02907489|OTHER|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
48152701|NCT06420752|DEVICE|Calf Plantar flexion|Daily passive calf stretching
48152702|NCT06420752|DIETARY_SUPPLEMENT|Dietary nitrate|Weekday 140 ml dietary nitrate consumption two hours prior to passive stretching
48152703|NCT04816435|DIAGNOSTIC_TEST|Ultrasound test|Ultrasound evaluation of airway
48152704|NCT04416100|DIAGNOSTIC_TEST|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
48152705|NCT04416100|DIAGNOSTIC_TEST|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
48511402|NCT05786209|OTHER|Whole-body Balm|Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
48511403|NCT05786209|OTHER|Wash and Shampoo|"Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method."
48678523|NCT05302427|BEHAVIORAL|Infant Massage|The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
48678524|NCT00921726|DRUG|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
48678525|NCT00921726|DRUG|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
48678526|NCT05741892|DEVICE|Fracture reposition with 3D printed patient specific repositions guides|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
47993463|NCT03338426|DRUG|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
47993464|NCT03338426|DRUG|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
47993465|NCT03338426|DRUG|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
47993466|NCT03002012|DRUG|Sertraline|sertraline 400mg/day
47993467|NCT03002012|DRUG|Placebo Oral Tablet|matched placebo tablet
48152706|NCT04416100|BIOLOGICAL|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
48511404|NCT03986411|OTHER|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
48152707|NCT04577391|OTHER|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
48152708|NCT04577391|OTHER|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
48152709|NCT03550014|PROCEDURE|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
48511405|NCT03986411|OTHER|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
48678527|NCT06287021|DEVICE|Jump System Traser® cup|Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup
48678528|NCT06287021|DEVICE|Jump System HAX-Pore® cup|Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup
48678529|NCT03645278|DRUG|SHR0532|Ascending dose oral adminstration
48678530|NCT03645278|DRUG|Placebo|Ascending dose oral administration
48678531|NCT01043744|DRUG|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)"
48363857|NCT06481046|BIOLOGICAL|Platelet Rich Plasma (PRP)|Platelet Rich Plasma (PRP) prepared from patient blood, spun twice to concentrate platelets. 45 cc of initial blood resulting in 4cc of injectable PRP.
48511406|NCT03986411|OTHER|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
48511407|NCT05603533|OTHER|Music and video-based group exercise therapy|Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
48511408|NCT03981692|OTHER|Consecutive dual task|8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.
48511409|NCT03981692|OTHER|Integrated dual task|8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
48511410|NCT05124886|OTHER|Moderately High Oxalate (MOx) Diet|Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
48511411|NCT01249573|OTHER|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
48678532|NCT01345929|DRUG|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
48678533|NCT01345929|DRUG|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
48678534|NCT04500119|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried), apply intermittent electrical stimulation (Blackrock Cerestim)
48678535|NCT01763333|DRUG|BI 1026706 Placebo|Placebo to BI 1026706
48678536|NCT01763333|DRUG|BI 1026706|different dose formulations
48678537|NCT03367169|PROCEDURE|minimally invasive method|type of surgical technique
48678538|NCT03367169|PROCEDURE|open reduction method|type of surgical technique
48678539|NCT01198821|DRUG|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
48678540|NCT01198821|DRUG|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
48152710|NCT03550014|PROCEDURE|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
48678541|NCT05842525|DRUG|intensive treatment|Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）
48678542|NCT05842525|DRUG|Maintenance treatment|Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
48678543|NCT04893512|DRUG|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
48152711|NCT05243602|DRUG|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
48678544|NCT02135627|DRUG|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
48678545|NCT02135627|OTHER|Current standard therapy|
48678546|NCT03646058|DRUG|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
47993468|NCT03002012|DRUG|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
47993469|NCT05746442|BEHAVIORAL|Smartphone-delivered Automated Messaging|An interactive smartphone based intervention will provide weekly smoking-related assessments and personalized automated messages designed to increase motivation, self-efficacy, use of coping skills, social support and to reduce nicotine withdrawal symptoms and stress for a 26 week period.
48152712|NCT05243602|DRUG|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
48152713|NCT03656822|DIAGNOSTIC_TEST|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
48152714|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
48152715|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
48678547|NCT03646058|DRUG|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
48152716|NCT03656822|DIAGNOSTIC_TEST|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
48678548|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
48678549|NCT04951102|BEHAVIORAL|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
48678550|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
48363858|NCT01083615|DRUG|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
48678551|NCT04951102|BEHAVIORAL|Standard Care|Standard Care for asthma.
48678552|NCT02082964|OTHER|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
48678553|NCT02082964|OTHER|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
48678554|NCT04037098|DIETARY_SUPPLEMENT|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
48678555|NCT04037098|DIETARY_SUPPLEMENT|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
47993470|NCT05746442|DRUG|Nicotine patch|Participants will be provided with a 8 week supply of nicotine patches
47993471|NCT05746442|BEHAVIORAL|Brief Advice to Quit and Smoking Cessation Self Help Materials|Participants will receive self-help materials from Khmer Quit Now, a national smoking cessation campaign in Cambodia
47993472|NCT05746442|BEHAVIORAL|Diet Assessment|Participants will be asked to complete brief weekly smartphone assessments about their diet for a 26-week period
47993473|NCT00238121|DRUG|sorafenib tosylate|Given orally
48363859|NCT01083615|DRUG|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
48363860|NCT01083615|DRUG|docetaxel|
48363861|NCT01083615|DRUG|cabazitaxel|
48363862|NCT01083615|DRUG|prednisone|
48363863|NCT02399189|DRUG|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
48363864|NCT00003016|DRUG|tamoxifen citrate|
48363865|NCT00003016|PROCEDURE|adjuvant therapy|
48363866|NCT04020224|DEVICE|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
47993474|NCT01178593|OTHER|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
48678556|NCT05406128|OTHER|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
48678557|NCT05406128|OTHER|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
48152717|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
48152718|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
48152719|NCT03044834|OTHER|PPB|Global current care
48152720|NCT02162927|DIETARY_SUPPLEMENT|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
48152721|NCT02162927|DIETARY_SUPPLEMENT|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
48152722|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy|
48152723|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
48152724|NCT02412345|OTHER|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
48152725|NCT04088305|DRUG|Individualized therapy|Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
48511412|NCT06229457|BEHAVIORAL|Girls PLAY program|Girls PLAY program (8-12 weeks) will include 1) a series of in-person sessions, led by Boys and Girls Clubs staff at the Boys and Girls Club sites, and 2) take-home activities. In-person sessions (60-75 min; 2-3x/week) will center around a different developmentally appropriate sport each week. Lesson plans will outline games/activities in which youth engage in fundamental, sport-specific movement skills. Lesson plans will be delivered by Boys and Girls Club leaders using acts of instruction derived from Self-Determination Theory. Take home activities will 1) summarize and add on to the week's in-person sessions and 2) be adapted for delivery by parents and/or self-guided participation by youth. Take-home activities will provide information for engaging in the past week's activities as well as additional activities that parents and youth can participate in together.
48511413|NCT06632314|DIETARY_SUPPLEMENT|Enteral feeding|Enteral feeding will be withheld or continued in very low birthweight neonates during packed red blood cell transfusion. Regional cerebral and splanchnic oxygenation will be measured using near-infrared spectroscopy (NIRS) for 48 hours. Cerebral and splanchnic oxygenation parameters, including cerebral regional oxygen saturation (crSO2), splanchnic regional oxygen saturation (srSO2), the ratio of crSO2 to srSO2 (CSOR), cerebral fractionated tissue oxygen saturation (cFTOE) and splanchnic fractionated tissue oxygen saturation (sFTOE) will be measured immediately before PRBCT (baseline) and at the first, sixth, 12th, 24th, and 48th hours after PRBCT using near-infrared spectroscopy.
48511414|NCT00438061|BEHAVIORAL|Weight loss by dietary restriction|
48678558|NCT03468777|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
47993475|NCT01627054|DRUG|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
47993476|NCT02555033|OTHER|Resistance training|traditional resistance training
47993477|NCT02555033|OTHER|Instability resistance training|training under unstable conditions
47993478|NCT02121483|DRUG|empagliflozin medium dose|
47993479|NCT02121483|DRUG|empagliflozin high dose|
47993480|NCT02121483|DRUG|empagliflozin low dose|
47993481|NCT03724409|DRUG|[90]Y-DOTATOC|Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
47993482|NCT04731376|OTHER|Best Practice|Receive standard peri-operative care
47993483|NCT04731376|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
47993484|NCT04731376|OTHER|Questionnaire Administration|Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
47993485|NCT04731376|DRUG|Testosterone Cypionate|Given IM
47993486|NCT03637803|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
47993487|NCT03637803|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
47993488|NCT02848014|BEHAVIORAL|Writing task|
48152726|NCT05240729|PROCEDURE|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
48152727|NCT03573375|BEHAVIORAL|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
48152728|NCT03704363|DRUG|Biosimilar Infliximab|Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
48363867|NCT04020224|DEVICE|Standard of Care|Red Blood Cell Component or whole blood
48678559|NCT03468777|DRUG|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
48363868|NCT01990001|OTHER|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
48678560|NCT03468777|DRUG|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
48678561|NCT02477527|DRUG|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
48511415|NCT03376061|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
48511416|NCT01194063|DRUG|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
48678562|NCT05585073|OTHER|Whether lymph node dissection is qualified or not|Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
48678563|NCT02743767|PROCEDURE|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
48678564|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
48678565|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
48678566|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
48678567|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
48678568|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
48678569|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
48678570|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
48678571|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
48678572|NCT02733744|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
48678573|NCT02478112|DEVICE|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
48678574|NCT03349255|BIOLOGICAL|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
48678575|NCT04149171|DRUG|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
48678576|NCT04149171|DRUG|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
48678577|NCT06406244|DEVICE|TEAS group|Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30 min before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
48678578|NCT06406244|DEVICE|sham group|Patients in the sham group will receive electrode attachment but without stimulation.
48152729|NCT03704363|OTHER|Placebo|Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
48678579|NCT04620889|DEVICE|AV Access|Arteriovenous shunting for blood access.
48363869|NCT01480193|OTHER|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
48363870|NCT01480193|OTHER|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
48678580|NCT04620889|DEVICE|PVP|Bypass or reconstruction of diseased or occluded blood vessels
48678581|NCT03972618|BEHAVIORAL|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
48678582|NCT00098033|DRUG|clofarabine|
48678583|NCT03591731|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
48678584|NCT03591731|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
48678585|NCT02901600|OTHER|Detection of the expression of DMTB1 by immunohistochemistry|
48678586|NCT00958477|BIOLOGICAL|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
48678587|NCT02154165|OTHER|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
48678588|NCT02694601|DIETARY_SUPPLEMENT|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
48678589|NCT02694601|DIETARY_SUPPLEMENT|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
48678590|NCT02694601|DIETARY_SUPPLEMENT|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
47993489|NCT02635516|DEVICE|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
48678591|NCT00573391|DRUG|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
48678592|NCT00573391|DRUG|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
48678593|NCT01626781|DEVICE|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
47993490|NCT06387992|OTHER|Three-dimensional dental acquisition|Consultation with a trained nurse who will perform a three-dimensional dental acquisition using a 3D intraoral camera
48363871|NCT00673075|DRUG|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
48363872|NCT00673075|DRUG|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
48363873|NCT03143855|DRUG|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
48363874|NCT03143855|DRUG|Placebo|Placebo will be administered twice daily for for 5 days
47993491|NCT04490161|OTHER|intravenous reinstallation of cerebrospinal fluid|10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
47993492|NCT01327300|DRUG|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
48363875|NCT01756482|DRUG|GS-5806|GS-5806, powder for oral solution
48363876|NCT01756482|DRUG|Placebo|
48363877|NCT01117428|DRUG|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
48363878|NCT03673631|DEVICE|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
48363879|NCT03673631|DEVICE|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
48363880|NCT01875731|BEHAVIORAL|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
48363881|NCT01875731|BEHAVIORAL|Guideline|Strategy based on enforced guideline guided antibiotic use
48363882|NCT02514629|DRUG|Placebo|
48363883|NCT02514629|DRUG|Metformin|
48363884|NCT02514629|DRUG|Testosterone Undecanoate|
48363885|NCT02514629|DRUG|Metformin + Testosterone Undecanoate|
48363886|NCT01724021|DRUG|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
48363887|NCT01724021|DRUG|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
48363888|NCT01724021|DRUG|Bendamustine|Standard chemotherapy
48363889|NCT01724021|DRUG|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
48363890|NCT01724021|DRUG|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
48363891|NCT01724021|DRUG|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
48363892|NCT01724021|DRUG|Rituximab|1400 mg SC, Day 1 Cycles 5-8
48511417|NCT01654003|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
48511418|NCT01654003|OTHER|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
48511419|NCT02265926|DEVICE|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
48511420|NCT04150263|PROCEDURE|Intraocular lens (IOL) ab externo scleral suture fixation|traditional IOL scleral suture fixation
48511421|NCT04150263|PROCEDURE|Modified IOL ab externo scleral suture fixation|Modified IOL scleral suture fixation
48511422|NCT01360463|BEHAVIORAL|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
48511423|NCT01360463|BEHAVIORAL|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
48511424|NCT06416046|DEVICE|Gemini laser|Photobiomodulation (810 + 980 nm, 15s/point, 11.8J/cm²) to evaluate healing and pain relief in recurrent aphthous stomatitis. A 0.7mm intraoral tip will be used - spot 0.38cm2 on the extent of the lesion.
48511425|NCT06416046|OTHER|Placebo|Examination and follow-up until the lesion heals spontaneously. The laser will not be activated.
48511426|NCT04251572|OTHER|Blood sampling|Blood sampling
48678594|NCT01626781|OTHER|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
48363893|NCT03494764|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
48678595|NCT02746328|DRUG|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
48678596|NCT02645565|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
48678597|NCT02645565|DRUG|Azathioprine|azathioprine will be given at 2 mg/kg.
48678598|NCT02645565|DRUG|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
48678599|NCT03353662|OTHER|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
48678600|NCT03353662|OTHER|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
48363894|NCT04249076|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05% is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
48511427|NCT04251572|OTHER|questionaires|Included participants will complete a baseline questionnaire at end of treatment (EOT) and a follow-up questionnaire throughout the follow-up period (Table 1). The questionnaires collect information on socio-demographics (age, gender, ethnicity, employment status, education level, housing status, incarceration, medical history and OST), injecting drug use (drugs injected, injection frequency and sharing of needle/syringe, cookers, cotton/filter or water). Details on the received DAA regime including mode of administration (direct observed therapy, pill box, etc.) and self-reported data on treatment adherence will also be recorded.
48511428|NCT05319210|PROCEDURE|Venous catheter application|To examine the effect of virtual reality glasses and buzzy application on pain management during venous catheter insertion in children.
48678601|NCT03353662|OTHER|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
48678602|NCT03353662|OTHER|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
48678603|NCT03353662|OTHER|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
48678604|NCT03353662|OTHER|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
48678605|NCT03613155|OTHER|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
48511429|NCT04655001|BEHAVIORAL|MORPH|A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.
48511430|NCT02565212|DRUG|Montelukast,mometazon froat|
48511431|NCT04546724|BIOLOGICAL|VLA1553|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
48363895|NCT04249076|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
48363896|NCT00001658|DRUG|Amoxicillin|
48363897|NCT05076981|DRUG|human chorionic gonadotropin|once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
48363898|NCT02501486|OTHER|ACTH stimulation test|An ACTH stimulation test will be done
48363899|NCT01116895|DRUG|LEO 22811|Oral solution
48511432|NCT04546724|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
48363900|NCT01116895|DRUG|Placebo|Placebo
48511433|NCT06057402|DRUG|Elranatamab|Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
48511434|NCT01730924|PROCEDURE|Pulmonary vein isolation using contact force sensing catheter|
48363901|NCT01722552|BEHAVIORAL|adherence feedback|
48678606|NCT05573698|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
48678607|NCT05573698|DRUG|Placebo|Matching Placebo will be administered by intravenous (IV) injection
48678608|NCT01116388|OTHER|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
48363902|NCT01722552|BEHAVIORAL|standard of care|
48363903|NCT01070511|DRUG|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
48363904|NCT01070511|DRUG|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
48363905|NCT05312528|PROCEDURE|endometriosis surgery|Laparoscopy was performed in the follicular phase of the woman's menstrual cycle and all recognizable endometriotic lesions were treated by bipolar coagulation, resection of endometriotic nodules and ovarian cystectomy.
48363906|NCT05312528|PROCEDURE|other benign condition surgeries|ovarian cystectomy, bilateral tubal ligation, myomectomy etc.
48363907|NCT02020811|DEVICE|Sentinel|
48363908|NCT02369757|BEHAVIORAL|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
48363909|NCT04694820|OTHER|Text Message-Based Navigation Intervention|Receive txt4TKI
48363910|NCT04694820|OTHER|Survey Administration|Ancillary studies
48363911|NCT03286114|DRUG|Pembrolizumab|200mg IV every 21 days
48363912|NCT01199913|OTHER|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
48363913|NCT06234891|DRUG|Nsaid|Medical treatment
48363914|NCT06234891|OTHER|Phsiotheraphy|Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
48363915|NCT00558961|DRUG|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
48363916|NCT02554916|BEHAVIORAL|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
48363917|NCT02554916|BEHAVIORAL|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
48363918|NCT02554916|OTHER|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
48363919|NCT02554916|DEVICE|Dual-Belt Treadmill|
48363920|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
48363921|NCT01049360|DRUG|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
48363922|NCT01049360|DRUG|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
48363923|NCT01049360|DRUG|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
48363924|NCT01049360|DRUG|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
48363925|NCT03958149|DEVICE|spinal collar|cervical collar to immobilise the cervical spine
48363926|NCT00568399|DRUG|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
48363927|NCT01617356|OTHER|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
48363928|NCT01617356|OTHER|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
48363929|NCT03942536|OTHER|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
48363930|NCT04401488|BIOLOGICAL|Prevenar 7 and Prevenar 13|pneumococcal conjugate vaccines
48511435|NCT00328848|BEHAVIORAL|Behavioral|Group Treatment(patient education, self management support, caregiver support)
48363931|NCT00720291|DRUG|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
48363932|NCT00720291|DRUG|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
48363933|NCT02918136|BIOLOGICAL|Adipose derived regenerative cells|
48363934|NCT02918136|DRUG|Cortisone Injectable|
48363935|NCT03843567|OTHER|Endoscopic characterisation training|"Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour."
48363936|NCT00507312|DEVICE|HD medical device (ViScope)|Device
48678609|NCT01116388|OTHER|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
48678610|NCT03457610|BEHAVIORAL|Speech and language intervention|Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
48678611|NCT01151020|DEVICE|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
48678612|NCT01119144|DEVICE|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
48678613|NCT01119144|DEVICE|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
48363937|NCT00507312|DEVICE|CSIRO device|device
48363938|NCT02184520|DEVICE|TRANSITION|
48363939|NCT02184520|DEVICE|REVERE|
48363940|NCT02719028|DRUG|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
48363941|NCT02719028|DRUG|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
48363942|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
48363943|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
48363944|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
48363945|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
48511436|NCT00328848|BEHAVIORAL|behavioral|patient education, self management support, caregiver support
48511437|NCT06352918|OTHER|Palmar grasp reflex stimulation|This initiative is stimulated by applying gentle pressure to the palm of the baby's palm while he or she is awake, lying on a flat surface in a symmetrical supine position.
48511438|NCT02315274|OTHER|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
48511439|NCT02492659|PROCEDURE|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
48511440|NCT02492659|PROCEDURE|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
48511441|NCT06297954|DRUG|Metoclopramide|Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
48511442|NCT06297954|DRUG|Placebo|Patients will receive placebo 10 ml IV in a single dose prior to randomization.
48511443|NCT00153972|DRUG|Cabergoline|
48511444|NCT00153972|DRUG|Levodopa|
48511445|NCT05233111|BEHAVIORAL|Brief Prolonged Exposure Therapy|Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
48511446|NCT05233111|BEHAVIORAL|Treatment as Usual|This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
48511447|NCT01589497|DRUG|Rifampicin|Participants with body weight \</= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight \>50kg were administered one 600 mg tablet orally once daily.
48678614|NCT04878601|OTHER|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
48678615|NCT04878601|OTHER|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
48678616|NCT02065323|DRUG|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
48152730|NCT06187155|OTHER|INR self-management|will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
48678617|NCT02065323|DRUG|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
48152731|NCT03770715|DEVICE|Respiratory polygraphy|The respiratory polygraphy consisted of continuous polygraphical recordings for a whole night from 22:00 h to 07:00 h with standardised equipment
48152732|NCT00035919|GENETIC|Mx-dnG1 Retroviral Vector|
48152733|NCT02222649|DIETARY_SUPPLEMENT|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
48152734|NCT02222649|DIETARY_SUPPLEMENT|Placebo|Capsules of starch, no therapeutic action
47993493|NCT01327300|OTHER|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
47993494|NCT00493584|PROCEDURE|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
48152735|NCT04150900|DRUG|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
48152736|NCT04150900|DRUG|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
48152737|NCT04908800|DRUG|KRP-A218|KRP-A218 tablet
48363946|NCT00620815|BIOLOGICAL|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
48363947|NCT00620815|BIOLOGICAL|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
48363948|NCT02828982|DEVICE|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
48152738|NCT04908800|DRUG|Placebo|Placebo tablet
48152739|NCT04908800|DRUG|itraconazole|10 mg/mL oral solution
48678618|NCT04590053|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
48678619|NCT04295837|OTHER|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
48678620|NCT04295837|OTHER|Usual Care|Standard occupational therapy
48678621|NCT02003443|BEHAVIORAL|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
48678622|NCT02573571|OTHER|Development of biomarkers|Blood sampling
48678623|NCT04930315|DRUG|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
48678624|NCT04930315|DRUG|Camrelizumab|200mg, iv, d1, q2w, both in two groups
48678625|NCT04967066|DIAGNOSTIC_TEST|Serum Levels of Adipocytokines|Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
48678626|NCT04563767|PROCEDURE|Infinitome|Added sequence of rs-fMRI.
48152740|NCT05725447|OTHER|Validity and reliability study|Face-to-face questionnaire study
48363949|NCT02828982|DEVICE|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
48678627|NCT05117151|DIAGNOSTIC_TEST|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
48678628|NCT04363242|BIOLOGICAL|SYN125|Administered by IV infusion
48152741|NCT05722756|OTHER|craniosacral therapy|subtle form of applied touch, type of osteopathy
48152742|NCT02612285|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
48152743|NCT06264999|DEVICE|Journey II CR|Implantation of Journey II CR Crucite Retaining Knee
48152744|NCT06264999|DEVICE|Journey II XR|Implantation of Journey II XR Bi Cruciate Retaining Knee
48152745|NCT00748098|DRUG|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
48152746|NCT00748098|DRUG|Placebo|Placebo
48363950|NCT05365256|BEHAVIORAL|Standard distraction during chemotherapy treatment period|habitual distraction of patients during chemotherapy sessions authorized as part of routine care
48363951|NCT05365256|BEHAVIORAL|Virtual distraction during chemotherapy treatment period|A virtual reality headset will be worn for 15 minutes per hour of treatment
48678629|NCT04363242|BIOLOGICAL|SYN004|Administered by IV infusion
48678630|NCT00614419|DEVICE|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
48678631|NCT00614419|DEVICE|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
48678632|NCT00556803|PROCEDURE|radiofrequency ablation|radiofrequency ablation
48678633|NCT00556803|PROCEDURE|TACE after RFA|TACE after RFA within one month
48678634|NCT03455894|DEVICE|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
48678635|NCT05973708|OTHER|Clamshell Exercise|Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
48678636|NCT05973708|OTHER|Frog pump exercise|Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
48678637|NCT06292663|DEVICE|Virtual Reality|The subjects get a supplement of information via. a Vitual Reality (VR) headset. The information they get through the VR headset is about their course on the day of their surgery.
48678638|NCT05026151|OTHER|Nutrition therapy according to ICU protocol|The study aims a verifying adherence to the ICU nutrition protocol
48678639|NCT03961243|BIOLOGICAL|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
48152747|NCT04596917|BEHAVIORAL|Preferred music listening|The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.
48363952|NCT05510999|OTHER|Placebo|One capsule of placebo will be taken twice daily for 24 weeks.
48363953|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction|Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.
48511448|NCT01589497|DRUG|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
48511449|NCT01589497|DRUG|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
48152748|NCT04596917|BEHAVIORAL|Relaxation breathing narrative over hypnotic music listening|The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
48363954|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction + water soluble pollen extract fraction|Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
48363955|NCT05510999|DIETARY_SUPPLEMENT|Lipid soluble pollen extract fraction|Each capsule contains 9 mg of lipid soluble pollen extract fraction. One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
48363956|NCT05510999|DIETARY_SUPPLEMENT|Water soluble pollen extract fraction + cranberry powder|Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder. One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
48363957|NCT05661500|OTHER|Creative Darama Group|Postmortem care training given by creative drama method
48363958|NCT05661500|OTHER|Classical Education Group|Postmortem care training given by classical education method
48363959|NCT02151045|PROCEDURE|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
48363960|NCT02151045|PROCEDURE|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
48678640|NCT06163196|OTHER|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
48678641|NCT03446898|OTHER|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
48678642|NCT02681367|OTHER|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
48678643|NCT06332976|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
48363961|NCT03725904|DIAGNOSTIC_TEST|Progesterone analysis in saliva|Analysis of salava progesterone
48152749|NCT04232410|DIAGNOSTIC_TEST|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
48363962|NCT03581032|DEVICE|Active reprogam|Reprogram Changes in AV/PV delays
48363963|NCT05521828|DRUG|Follitropin delta (Rekovelle)|12 mcg/day will be used for ovarian stimulation in both arms
48678644|NCT06119516|OTHER|Esophageal pressure-guided strategy,|A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
48678645|NCT02528942|RADIATION|Radiation therapy|Radiation therapy will be given to study patients.
48678646|NCT02879513|DRUG|Paclitaxel|
48678647|NCT02879513|DRUG|Cisplatin|
48678648|NCT02879513|DRUG|Epirubicin|
48678649|NCT02879513|DRUG|Cyclophosphamide|
48678650|NCT02879513|DRUG|5-fluoruracil|
48678651|NCT02994745|DRUG|Fimasartan, Atorvastatin|
48678652|NCT02903693|OTHER|cross sectional|
48678653|NCT05369364|DRUG|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
48363964|NCT05521828|DRUG|Duphaston|20 mg/day will be used for pituitary suppression in both arms
48363965|NCT05521828|DRUG|GnRH agonist (Gonapeptyl)|(2 ampules:0.2 mg) will be used for ovulation triggering in both arms
48363966|NCT06083376|OTHER|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
48363967|NCT06083376|OTHER|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
48363968|NCT05182034|BIOLOGICAL|SMUP-IA-01(low dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
48363969|NCT05182034|BIOLOGICAL|SMUP-IA-01(mid dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
48363970|NCT05182034|DRUG|Active Control Group Sodium chloride|A single knee administration of Sodium chloride
48363971|NCT04035408|OTHER|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
48363972|NCT00464854|DRUG|Glargine and insulin aspart or lispro|
48363973|NCT05342376|DRUG|Dexmedetomidine Hydrochloride|The parturients will receive 10 micro-gram Dexmedetomidine diluted in 02 ml normal saline to be administered intravenously over 10 minutes after umbilical cord is clamped..
48511450|NCT01589497|DRUG|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
48511451|NCT01589497|DRUG|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
48511452|NCT00436865|BEHAVIORAL|Weight loss|
48511453|NCT03900598|DRUG|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
48678654|NCT05369364|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
48678655|NCT00703742|DRUG|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
48678656|NCT02477917|BIOLOGICAL|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
48678657|NCT04005495|BEHAVIORAL|Teaching kitchen program|The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
48678658|NCT01361659|PROCEDURE|shockwave treatment|9 treatments in 3 months
48678659|NCT03335150|BEHAVIORAL|CogSMART-PD|Cognitive Rehabilitation for persons with PD-MCI
48678660|NCT03335150|BEHAVIORAL|Supportive Care|Support Group for persons with PD-MCI
48363974|NCT05342376|DRUG|Normal Saline|The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
48678661|NCT02063685|DRUG|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
48678662|NCT02063685|DRUG|Observation|not maintenance therapy and followed-up with MRD monitoring.
48678663|NCT02063685|DRUG|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
48678664|NCT02063685|DRUG|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
48678665|NCT02063685|DRUG|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
48678666|NCT02278315|DRUG|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
48678667|NCT02278315|DRUG|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
48678668|NCT02278315|DRUG|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
48678669|NCT02060929|DRUG|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
48511454|NCT04543890|RADIATION|Hyperfractionated radiotherapy|Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
48511455|NCT04543890|RADIATION|Hypofractionated radiotherapy|Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
48511456|NCT04543890|DRUG|Etoposide|Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
48511457|NCT04543890|DRUG|Cisplatin|Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
48511458|NCT00683579|DRUG|Early Treatment with HAART|HAART with possibility of de-intensification
48678670|NCT00581022|PROCEDURE|Polysomnography|Overnight Sleep Study
48678671|NCT02961270|DRUG|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
48678672|NCT03683810|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin in tablets 4g/daily
48511459|NCT00683579|OTHER|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
48511460|NCT00683579|DRUG|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA \>100,000 copies/ml
48678673|NCT03683810|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
48678674|NCT00983866|BEHAVIORAL|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
48511461|NCT00396643|DRUG|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
48678675|NCT06070818|OTHER|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
48678676|NCT05528406|DRUG|HLX208|900mg bid po
48678677|NCT05010083|BEHAVIORAL|diet and lifestyle program|See description of main arm.
48678678|NCT05772403|DIAGNOSTIC_TEST|CEUS|CEUS for atypical liver nodules
48678679|NCT01480726|PROCEDURE|Surgery|
48678680|NCT00589797|DEVICE|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
48678681|NCT00589797|DEVICE|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
48678682|NCT04150289|DRUG|Farydak|non-interventional study
48363975|NCT06454227|PROCEDURE|Subcutaneous washing|subcutaneous washing with chlorhexidine gluconate prior to skin closure
48678683|NCT01580410|DRUG|mitomycin C|Given by HIPEC
48678684|NCT01580410|DRUG|oxaliplatin|Given by HIPEC
48678685|NCT01580410|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48363976|NCT06454227|PROCEDURE|no subcutaneous washing|no washing
48363977|NCT02657109|OTHER|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
48363978|NCT00153699|DRUG|Topiramate|
48363979|NCT02583399|DRUG|Ibuprofen|Ibuprofen, 10 mg/kg
48363980|NCT05129618|DIETARY_SUPPLEMENT|MHS 1031|prebiotic syrup in individual sachets containing 1g (1.4 ml) of panosyl-isomaltooligosaccharides
48363981|NCT05129618|OTHER|placebo|liquid combination formulation of Neotame 7.92 mcg/g, phosphoric acid, and sterile water, designed to have the same degree of sweetness as the test material, provided in individual sachets containing 1.4 ml.
48363982|NCT02201199|DRUG|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48363983|NCT02201199|DRUG|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48363984|NCT02201199|DRUG|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48363985|NCT02430298|DRUG|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
48363986|NCT02430298|DRUG|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
48363987|NCT04054050|OTHER|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
48363988|NCT06334380|OTHER|Virtual Reality Modules Only|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team.
48363989|NCT06334380|OTHER|Virtual Reality Modules + Live Physical Therapist Support|Participants will complete self-paced VR modules prior to and after surgery (prehab/rehab) and will be provided with technical assistance from the study team. Participants will also have access to up to three live PT sessions via Zoom where they can ask questions and complete modules with PT feedback.
48363990|NCT01977573|DRUG|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
48152750|NCT04232410|DIAGNOSTIC_TEST|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
48363991|NCT01977573|DRUG|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
48363992|NCT06015269|DRUG|DC cells|At a single arm, 1x107cells dose
48363993|NCT03498911|PROCEDURE|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
48363994|NCT03080389|PROCEDURE|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10\^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
48363995|NCT06345287|RADIATION|radical radiotherapy (60Gy)|concurrent chemoradiotherapy (60Gy) after induction therapy
48363996|NCT06345287|RADIATION|radical radiotherapy (66Gy)|concurrent chemoradiotherapy (66Gy) after induction therapy
48363997|NCT06345287|RADIATION|radical radiotherapy (70Gy)|concurrent chemoradiotherapy (70Gy) after induction therapy
48363998|NCT06345287|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy
48363999|NCT02582008|DRUG|Bupropion Hydrochloride|Given PO
48364000|NCT02582008|OTHER|Laboratory Biomarker Analysis|Correlative studies
48364001|NCT02582008|DRUG|Nicotine Replacement|Given NRT
48364002|NCT02582008|OTHER|Quality-of-Life Assessment|Ancillary studies
48511462|NCT05403086|DRUG|Psilocybin|Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.
48364003|NCT02582008|OTHER|Questionnaire Administration|Ancillary studies
48511463|NCT05403086|DRUG|Ketamine|ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
48152751|NCT00257309|DRUG|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
48364004|NCT02582008|DRUG|Varenicline|Given PO
48364005|NCT05977777|DIAGNOSTIC_TEST|Contrast- enhanced ultrasound|Contrast- enahnched ultrasound is performed on target pancreatic lesion
48364006|NCT01834040|OTHER|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
48364007|NCT02945072|PROCEDURE|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
48364008|NCT02945072|PROCEDURE|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
48364009|NCT01905241|DEVICE|Anatomic TSA using RTI|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Real Time Instrumentation (RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
48511464|NCT02112487|DRUG|Macitentan|10 mg once daily
48511465|NCT03905720|PROCEDURE|Acupuncture|A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol. Treatments will provided daily for up to four hospital days.
48364010|NCT01905241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same with the exception of the instrumentation used to place the guide pin for placement of the glenoid implant.
48364011|NCT04854122|BEHAVIORAL|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate \[43\], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
48364012|NCT04854122|BEHAVIORAL|Usual care / Sham intervention|The control condition consists of usual activities.
48364013|NCT03489460|BEHAVIORAL|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
48152752|NCT00257309|PROCEDURE|Primary angioplasty|
48152753|NCT01236144|DRUG|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
48152754|NCT01236144|DRUG|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
48152755|NCT01236144|DRUG|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
48364014|NCT03489460|BEHAVIORAL|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
48678686|NCT01580410|OTHER|quality-of-life assessment|Ancillary studies
48678687|NCT01580410|DRUG|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
48678688|NCT04875494|BEHAVIORAL|Counseling/support group therapy|6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
47993495|NCT00493584|PROCEDURE|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
47993496|NCT05734079|OTHER|Standard of care|A written hand out containing all information required for bowel preparation
47993497|NCT05734079|OTHER|Standard of care + Video call|Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
47993498|NCT05734079|OTHER|Standard of care + Video call + Educational video film|Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
47993499|NCT05250037|PROCEDURE|Home spirometry|Undergo spirometry measurements
47993500|NCT05250037|PROCEDURE|Biospecimen Collection|Undergo nasal and/or oral swabs, and blood collection
47993501|NCT05250037|OTHER|Questionnaire Administration|Complete questionnaires
47993502|NCT04016376|DRUG|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
47993503|NCT04016376|DRUG|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
48152756|NCT00690534|DRUG|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
48152757|NCT00690534|DRUG|L-NMMA|variable rate for 3 hours
48364015|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
48364016|NCT00864968|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
48678689|NCT04875494|BEHAVIORAL|Physical Exercise|6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
48678690|NCT05298059|RADIATION|Laser of low frequncy|Apply the laser at three points on each tooth.
48678691|NCT05298059|DRUG|CPP-ACPF|Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.
48152758|NCT00690534|DRUG|Sodium Nitroprusside|variable rate for 3 hours
48152759|NCT00690534|OTHER|mixed meal|mixed meal
48364017|NCT04384952|OTHER|Parent-administered reading therapy.|Parent-administered reading therapy program: 15min each day, 5 days a week during 6 weeks during the summer break. Repeted reading with feedback from the parent and time control.
48364018|NCT04384952|OTHER|Dyslexic's Holiday Workbook|Use of a special Dyslexic's holiday book, no parent-guided training.
48152760|NCT06088082|DRUG|Bupivacaine Hydrochloride|Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
48152761|NCT03805698|DEVICE|Platelet-rich Plasma (PRP)|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
48364019|NCT00848172|DRUG|Octanoic Acid|4mg/kg
48364020|NCT00848172|DRUG|Placebo|identical capsules
48152762|NCT03805698|OTHER|Standard Arthroscopic Debridement|Standard arthroscopic debridement. No PRP injection.
48364021|NCT03088995|DIAGNOSTIC_TEST|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
48364022|NCT03487562|DRUG|DWP14012 Amg|DWP14012 Amg
48364023|NCT03487562|DRUG|DWP14012 Bmg|DWP14012 Bmg
48364024|NCT03487562|DRUG|Clarithromycin|Clarithromycin 500 mg
48152763|NCT05903820|DRUG|Estradiol patch|Transdermal patch of estradiol
48364025|NCT03487562|DRUG|Amoxicillin|Amoxicillin 1 g
48364026|NCT03487562|DRUG|Lansoprazole|Lansoprazole 30 mg
48364027|NCT04461899|BIOLOGICAL|Blood test|additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
48364028|NCT02793531|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
48364029|NCT05138731|OTHER|treatments according guidelines|different group intervened with different treatment following guidelines/consensuses accordingly
48364030|NCT03115021|DEVICE|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
48511466|NCT03905720|BEHAVIORAL|Pain Counseling|Participants will receive sessions with a counselor trained in pain management. The pain counselor will explain, review, and discuss the contents of a Pain Control booklet. Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
48678692|NCT03390517|DEVICE|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
48678693|NCT03369015|DRUG|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
48678694|NCT03369015|DRUG|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
48678695|NCT03369015|DRUG|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
48678696|NCT01417221|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
48364031|NCT03115021|DEVICE|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
48364032|NCT03115021|DEVICE|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
48364033|NCT03115021|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
48364034|NCT04549766|OTHER|calculate PRECISE DAPT score using clinical data|calculate PRECISE DAPT score using clinical data in STEMI patients after PPCI
48364035|NCT04749303|PROCEDURE|Large Screen|Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
48511467|NCT02694328|DRUG|ALKS 3831|Daily dosing
48511468|NCT02694328|DRUG|Olanzapine|Daily dosing
48511469|NCT01970800|DRUG|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
48364036|NCT03688841|DEVICE|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
48364037|NCT03688841|DEVICE|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
48364038|NCT01636674|OTHER|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
48364039|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 300mg for 12 weeks
48364040|NCT05442827|DRUG|SHR7280 tablets|SHR7280 tablets 400mg for 12 weeks
48678697|NCT03644810|DIAGNOSTIC_TEST|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
48678698|NCT03644810|DIAGNOSTIC_TEST|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
48678699|NCT03644810|PROCEDURE|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
48678700|NCT02462187|DRUG|NVN1000 8% Gel|once and twice daily
48678701|NCT02462187|DRUG|NVN1000 16%|once daily
48364041|NCT05442827|DRUG|PlaceboSHR7280 tablets blank preparation|Placebo group: SHR7280 tablets blank preparation for 12 weeks
47993504|NCT04016376|DRUG|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
47993505|NCT03311659|BIOLOGICAL|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
47993506|NCT00641862|DIETARY_SUPPLEMENT|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
47993507|NCT00641862|OTHER|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
47993508|NCT03311503|BIOLOGICAL|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
47993509|NCT06117384|GENETIC|Biomolecular profiling|Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
48152764|NCT05903820|DRUG|Progesterone|Oral progesterone capsules 100mg/day
48364042|NCT03163277|DRUG|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
48364043|NCT00931515|DEVICE|NuBac|NuBac device implanted at the L4/5 level.
48364044|NCT00931515|DEVICE|Prodisc-L|Prodisc-L implanted at the L4/5 level.
48364045|NCT01371721|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
48364046|NCT03374059|OTHER|Exercise program|
48364047|NCT03374059|OTHER|Life modification|
48511470|NCT01554319|DRUG|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
48678702|NCT02462187|DRUG|Vehicle|placebo comparator
48678703|NCT02462187|DRUG|NVN1000 24%|once daily
48678704|NCT06319209|OTHER|Preoperative resolved COVID-19|We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
48678705|NCT00892008|DRUG|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
48678706|NCT06337981|DRUG|(AJU-S56 5% and placebo)|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
47993510|NCT03999190|DRUG|NPA radiotracer|"\[11C\]NPA radiotracer, 2 injection per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
48678707|NCT06337981|DRUG|AJU-S56 5%|(AJU-S56 5%), 1drop/1times, 6times in a day
48678708|NCT06337981|DRUG|Placebo(Vehicle)|Placebo(Vehicle), 1drop/1times, 6times in a day
48678709|NCT04824664|OTHER|survey|survey among surgeon
48678710|NCT06183281|BEHAVIORAL|CBT, Mindfulness, and Movement|Blended CBT, mindfulness, and movement delivered through a mobile app and supported by a weekly telehealth pain management coach.
48364048|NCT01475513|DRUG|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
48364049|NCT01032057|DRUG|capecitabine|
48152765|NCT03855384|DRUG|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
48364050|NCT01032057|DRUG|gemcitabine hydrochloride|
48364051|NCT01032057|PROCEDURE|quality-of-life assessment|
48364052|NCT01032057|RADIATION|3-dimensional conformal radiation therapy|
48364053|NCT01176422|GENETIC|Blood sample|Blood samples will be collected before and after treatment completion.
48364054|NCT02558595|DIETARY_SUPPLEMENT|Niacinamide|
48364055|NCT02558595|OTHER|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
48364056|NCT04882839|COMBINATION_PRODUCT|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
48364057|NCT05761158|OTHER|questionnaire|patients are asked to complete a questionnaire
48364058|NCT02812550|PROCEDURE|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
48364059|NCT05273203|BEHAVIORAL|FIM-1|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
48364060|NCT05273203|BEHAVIORAL|FIM-2|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
48364061|NCT05273203|BEHAVIORAL|FIM-3|A football group (12 participants/session) will participate in 60 minutes football training that will contain warm-up, football technical drills and exercises, fitness exercises and football game.
48364062|NCT05273203|BEHAVIORAL|Control|No football training will be performed during 6 months period. Participation only in measurements at baseline and at 6 months.
48364063|NCT05434728|OTHER|20 ml venous blood collection|participant blood sample will be divided between sample EDTA sample tubes for thrombin generation testing and viscoelastic (ROTEM) testing of impaired hemostasis
48364064|NCT02987166|RADIATION|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
48364065|NCT02987166|DRUG|Pembrolizumab|200 mg
48364066|NCT00718887|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
48364067|NCT00718887|DRUG|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
48678711|NCT05309681|OTHER|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
48678712|NCT00495235|BEHAVIORAL|Questionnaire|Questionnaire taking about 20 minutes to complete.
48678713|NCT06235918|DRUG|Tislelizumab|Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
48364068|NCT01012700|DRUG|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
48678714|NCT06235918|DRUG|Nab-paclitaxel|260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
48364069|NCT04129931|DRUG|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
48364070|NCT04129931|DRUG|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
48364071|NCT04129931|DRUG|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
48364072|NCT04129931|DRUG|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
48364073|NCT04129931|DRUG|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
48364074|NCT04129931|OTHER|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
48364075|NCT00036816|BIOLOGICAL|MART-1 antigen|
48364076|NCT00036816|BIOLOGICAL|NA17-A antigen|
48364077|NCT00036816|BIOLOGICAL|gp100 antigen|
48364078|NCT00036816|BIOLOGICAL|tyrosinase peptide|
48364079|NCT00300794|DRUG|Ketamine|
48364080|NCT01203566|PROCEDURE|LESS appendectomy|See under arms description
48364081|NCT01203566|PROCEDURE|Conventional 3-port laparoscopic appendectomy|See under arms description
48364082|NCT02505789|OTHER|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
48364083|NCT00412360|BIOLOGICAL|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
48678715|NCT06235918|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
48678716|NCT00135616|DEVICE|surgical placement of a suburethral sling tvt or tvt-o|
48678717|NCT00876252|BIOLOGICAL|IC43|
48678718|NCT00876252|DRUG|Placebo|NaCl
48678719|NCT05036161|OTHER|Nasal high flow|Newborns with respiratory distress treated with NHF.
48678720|NCT05036161|OTHER|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
48678721|NCT04032886|OTHER|kinesio tape|This is a taping method used for correction of rounded shoulders.
48678722|NCT04032886|OTHER|exercise|Exercises include basic postural exercises.
48678723|NCT05042648|DRUG|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
48678724|NCT04054336|BEHAVIORAL|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
48678725|NCT04054336|BEHAVIORAL|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
48678726|NCT04054336|BEHAVIORAL|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
48678727|NCT02985177|DRUG|INF2.0 + IBU|Analgesics
48364084|NCT00412360|BIOLOGICAL|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
48678728|NCT02985177|DRUG|INF1.0 + IBU|Analgesics
48678729|NCT01773954|DRUG|Intravitreal Aflibercept Injection|Increased or decreased time between visits
48678730|NCT00592631|DEVICE|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
48678731|NCT00592631|DEVICE|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
48678732|NCT04375956|DRUG|Pembrolizumab|Experimental
48678733|NCT04630925|OTHER|isCGM|As previously described
48678734|NCT06011265|DRUG|Myrbetriq 25Mg Extended-Release Tablet|Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
48678735|NCT06011265|DRUG|Placebo|Participants take empty capsule orally
48678736|NCT05163301|BEHAVIORAL|Relapse Prevention Intervention|2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
48678737|NCT02295462|OTHER|Person-centered Care|Medication Review + Person-centered Care
48678738|NCT02295462|OTHER|Optimised Treatment|Medication Review only
48678739|NCT04270344|DRUG|Pitavastatin 4mg|combination therapy with pitavastatin/valsartan (LivaloV)
48678740|NCT01962428|DRUG|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
48678741|NCT00415870|BEHAVIORAL|Printed Material|Printed Material
48678742|NCT00415870|BEHAVIORAL|Weekly Weighing|Weekly Weighing
48678743|NCT00415870|BEHAVIORAL|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
48678744|NCT00415870|DEVICE|Text Message|Text Message
48678745|NCT00415870|BEHAVIORAL|Diet Goals via Cell Phone|Diet Goals via Cell Phone
48678746|NCT00415870|BEHAVIORAL|Food Monitoring|Food Monitoring
48678747|NCT05711927|DEVICE|SNOO Smart Sleeper|"Infants will be secured in the SNOO Sleep Sack. They will be placed in the center of the SNOO Smart Sleeper. The SNOO will be powered on and will start playing white noise and rocking from side-to-side. The SNOO's movement and sound settings will automatically ramp up and down as needed in response to the infant's sensed level of fussiness or crying per the manufacturer's programming. The preemie mode will be enabled, which caps motion at level 2 out of 5."
48364085|NCT00412360|RADIATION|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
48511471|NCT01554319|DRUG|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
48678748|NCT05711927|DEVICE|Traditional bassinet|Infants will be swaddled using a standard hospital blanket. They will be placed in the center of the SNOO Smart Sleeper, but the SNOO will be left powered-off. No white noise will be played. No side-to-side rocking motions will occur.
48678749|NCT02775266|OTHER|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
48678750|NCT02775266|PROCEDURE|Scaling and Root planing|Scaling and root planing will be done at baseline.
48678751|NCT02377414|DRUG|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
48678752|NCT02377414|DRUG|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
48364086|NCT00412360|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
48364087|NCT00412360|DRUG|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
48364088|NCT00412360|DRUG|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
48364089|NCT00412360|DRUG|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if \> 50 kg or 15 mg/kg IV q 8 hours if \< 50 kg beginning the morning of Day -3.
48364090|NCT05117580|DEVICE|telemedicine lifestyle guidance|Telemedicine lifestyle advices are given during 3 months, based on telemonitoring system data.
48364091|NCT00101790|DRUG|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
48678753|NCT06121726|OTHER|Ilioinguinal-Iliohypogastric nerve block|local anesthetic will be administered near ilioinguinal-iliohypogastric nerves under ultrasound guidance. Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
48678754|NCT06121726|DRUG|Local anesthetic|Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
48678755|NCT06440603|DIAGNOSTIC_TEST|PCR|"Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System"
48511472|NCT04614415|DEVICE|Autocrosslinked Hyaluronic aid|IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel. In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
48511473|NCT04614415|OTHER|placebo|The placebo consists in an isotonic saline solution (NaCl 0.9%)
48678756|NCT01992224|OTHER|early mechanical Ventilation|"Fulfillment of three or more criteria below:~respiratory rate \> 28 per minute serum lactate \> 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation"
48678757|NCT01992224|OTHER|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate \> 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
48678758|NCT04793282|BEHAVIORAL|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
48678759|NCT02543853|OTHER|direct trocar entry|direct trocar entry to provide pneumoperitoneum
48678760|NCT02543853|OTHER|veres needle entry|veres needle entry to provide pneumoperitoneum
48678761|NCT03413904|PROCEDURE|transanal TME|transanal approach to TME in rectal cancer
48678762|NCT03413904|PROCEDURE|laparoscopic TME|laparoscopic approach to TME in rectal cancer
48678763|NCT06462287|DRUG|Aprepitant 125 and 80Mg Oral Capsule|Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
48678764|NCT06462287|DRUG|Placebo|Placebo:1 oral capsule time a day for 4 days
48678765|NCT05964491|OTHER|No intervention|No intervention studied
48678766|NCT03177538|DRUG|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
48678767|NCT03177538|DRUG|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
48678768|NCT05358743|OTHER|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
48678769|NCT05358743|OTHER|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
48678770|NCT04556526|BIOLOGICAL|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
48678771|NCT04556526|BIOLOGICAL|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
48678772|NCT00899418|GENETIC|gene expression analysis|
48678773|NCT00899418|GENETIC|polymerase chain reaction|
48364092|NCT06186674|DIAGNOSTIC_TEST|sorensen test for back endurance|• Biering-Sorensen test will be utilized to gauge the trunk extensor muscles' isometric endurance. The patient will be lying on a treatment couch, prone. The top half of the body will be permitted to rest on a chair prior to the test starting. The patient will be told to elevate their upper trunks off of the chair at the start of the test. the examiner determined how long the individual could hold this position.
48511474|NCT04785755|DRUG|Oral standard diuretics therapy|Oral standard diuretics therapy (furosemide 40 mg tablet plus spironolactone 100 mg tablet with a dose increase in 40 mg:100 mg ratio) given once daily in the morning for 38 days (from the first day of the study to the end of the study).
48511475|NCT04785755|DRUG|Hypertonic saline solution|Hypertonic saline solution (150ml, 1.4% - 4.6%) infused slowly over one hour peripherally once daily from the first day of the study for eight days.
48511476|NCT04785755|DRUG|Etilefrine|Etilefrine 5 mg tablet given by mouth three times daily for 38 days (from the first day of the study to the end of the study).
48678774|NCT00899418|GENETIC|polymorphism analysis|
48678775|NCT00899418|OTHER|immunohistochemistry staining method|
48678776|NCT02791347|OTHER|Nutrition Intervention|
48678777|NCT00570323|DRUG|Arimidex|Aromatase inhibitors
48678778|NCT00570323|DRUG|Faslodex|Hormone Receptor
48678779|NCT01603173|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
48678780|NCT01603173|DRUG|Quetiapine Fumarate|25 mg tablet once a day
48678781|NCT05712980|DEVICE|Implanted pulse generator for SCS with different programming modalities|"Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization"
48678782|NCT02797912|OTHER|No intervention|
48678783|NCT03542019|DEVICE|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
48678784|NCT03542019|DEVICE|Dental crown|Replacement og missing tooth structure using monolithic zirconia
48678785|NCT03542019|DEVICE|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
48152766|NCT03855384|DRUG|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
48678786|NCT06145971|BEHAVIORAL|brief Cognitive Behavioural Therapy for Insomnia (bCBTi)|Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
48678787|NCT05895097|DEVICE|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
48678788|NCT05895097|DEVICE|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF \< 40 %
48678789|NCT01775553|DRUG|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
48678790|NCT03359369|DIAGNOSTIC_TEST|level of serum cholesterol and triglyceride|other
48678791|NCT04698239|DEVICE|LASER MILESMAN 445 NM|Laser application
48152767|NCT06476496|PROCEDURE|Acupuncture|A licensed acupuncturist will insert sterile disposable acupuncture needles in the selected body and ear acupoints aiming to alleviate long COVID related pain symptoms. Needles will be removed after 20 minutes of retention. After all the needles are removed, the acupuncturist will insert Pyonex press tack needles (0.3mm) in the participants' left ears and suggest the participants retain them in their ears for up to 5 days.
48364093|NCT06186674|DIAGNOSTIC_TEST|6 minute walk test|"It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace.~It gauges how far a person can go while walking for a total of six minutes on a level, hard surface. Cones will be used to mark turns at the start and end of the 30-meter border and every three meters throughout the corridor or walkway that was utilized for the test. The patient's objective is to cover the most distance in six minutes at a reasonable pace."
48511477|NCT06501326|DRUG|Liraglutide|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
48364094|NCT06186674|DIAGNOSTIC_TEST|c7-s1 SVA|Subjects will obtain standardized lateral views radiographs in a neutral standing position for the whole spine. The C7- S1 SVA will be measured as the distance from the plumb line dropped from the center of the C7 vertebral body to the most posterior edge of the upper sacral endplate surface.
48152768|NCT06411054|DEVICE|Acu-TENS|After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).
48511478|NCT06501326|DRUG|Orlistat|After randomization, the control group was treated with lifestyle intervention + orlistat until the end of follow-up. Trial group 1 was treated with lifestyle intervention + liraglutide. Trial group 2 was treated with lifestyle intervention + liraglutide + orlistat for a total treatment and follow-up period of 3 months.
48511479|NCT02965586|DRUG|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
48511480|NCT04108624|OTHER|Screening Phase|This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.
48678792|NCT04040062|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
48678793|NCT01907607|DRUG|PD 0332991|"PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.~PD-0332991 was dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
48678794|NCT04949945|BEHAVIORAL|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
48678795|NCT03358810|DEVICE|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
48678796|NCT05409703|BEHAVIORAL|reiki therapy|reiki therapy for nurses
48678797|NCT04105959|DRUG|RIST4721|RIST4721 oral solution
48364095|NCT01992900|DRUG|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
48511481|NCT04108624|DEVICE|Discontinuation Phase|Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing
48511482|NCT02564887|DEVICE|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
48511483|NCT05587348|BEHAVIORAL|Best Practice Advisory|Provider will get Best Practice Advisory or Message from DCE in intervention practices
48678798|NCT04105959|DRUG|Placebo|Placebo oral solution
48678799|NCT03355248|OTHER|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
48152769|NCT06411054|DEVICE|Sham acu-TENS|"After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair.~In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current. The pads will be stuck on the acupoints for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed)."
48152770|NCT00958971|DRUG|TKI258|All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
48152771|NCT02594267|DRUG|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone"
48152772|NCT01092715|PROCEDURE|Spinal mobilization|Non thrust mobilization to the cervical spine
48152773|NCT01092715|PROCEDURE|Massage|Sedative massage to cervical paraspinal muscles
48152774|NCT01092715|PROCEDURE|Neck exercises|Range of motion exercises to include foraminal opening
48152775|NCT06585644|DRUG|Furmonertinib in combination with Anrotinib and chemotherapy|The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
48152776|NCT05090904|DRUG|Brensocatib|Oral tablet
48152777|NCT05090904|DRUG|Placebo|Oral tablet
48152778|NCT03274934|BEHAVIORAL|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
48152779|NCT03274934|BEHAVIORAL|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
48152780|NCT03274934|BEHAVIORAL|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
48152781|NCT04167150|DIETARY_SUPPLEMENT|tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)|Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
48364096|NCT01992900|DRUG|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
48364097|NCT02519777|DRUG|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
48364098|NCT02519777|DRUG|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
48678800|NCT01276548|DRUG|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
48511484|NCT05587348|BEHAVIORAL|Peer Support|Patients referred to DSMES classes will be randomized to get a peer supporter
48678801|NCT01276548|DRUG|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
48678802|NCT03138525|OTHER|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
48678803|NCT03138525|OTHER|Blood sampling (controls)|Blood samples will be collected once at enrollment.
48152782|NCT01116700|DRUG|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
48152783|NCT03284840|DIAGNOSTIC_TEST|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
48152784|NCT03284840|DIAGNOSTIC_TEST|Thyroid size|Thyroid size by ultrasound.
48152785|NCT03892265|OTHER|Observational Study|No intervention is included in this observational study.
48152786|NCT03737188|DEVICE|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
48152787|NCT05778799|OTHER|Balance test|10 second left- or right-leg stance with eyes open, and single 10 second left- or right-leg stance with eyes closed
48152788|NCT02732470|OTHER|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
48152789|NCT02406859|BEHAVIORAL|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
48152790|NCT02406859|BEHAVIORAL|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
48678804|NCT00104988|DRUG|temozolomide|75 mg/m\^2/day PO daily for 6 weeks followed by a 2-week break
48678805|NCT00104988|DRUG|thalidomide|200 mg/day PO daily
48678806|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
48152791|NCT04255004|DEVICE|Pall Celeris System, point of care device for human cell therapy|Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
48152792|NCT01131325|DRUG|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
48152793|NCT04554199|DEVICE|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
48152794|NCT04184622|DRUG|Tirzepatide|Administered SC
48152795|NCT04184622|DRUG|Placebo|Administered SC
48152796|NCT05555121|DRUG|Progesterone Effervescent Vaginal Tablet|On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
48152797|NCT02413645|BIOLOGICAL|TriMix_100|100 μg of TriMix in
48152798|NCT02413645|BIOLOGICAL|TriMix_300|300 μg of TriMix in
48152799|NCT02413645|BIOLOGICAL|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
48152800|NCT02413645|BIOLOGICAL|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
48152801|NCT02413645|BIOLOGICAL|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
48152802|NCT05473130|DEVICE|Breethe Oxy-1 System|To pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass with Breethe Oxy-1 System
48152803|NCT01717625|DRUG|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
48152804|NCT06293794|OTHER|Personalized Clinical Decision Support (CDS)|The personalized CDS intervention evaluates clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. This is done through a nudge in the electronic health record that addresses common prescribing misconceptions for heart failure.
48152805|NCT06293794|OTHER|Traditional Clinical Decision Support (CDS)|The traditional CDS is the usual care intervention, which is patient-specific but are not clinician-specific.
48152806|NCT02542202|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
48152807|NCT01599078|DRUG|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
48152808|NCT01599078|DRUG|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
48152809|NCT01293201|DRUG|STAHIST|STAHIST dosed one tablet, BID
48152810|NCT01293201|DRUG|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
48152811|NCT00751088|PROCEDURE|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
48678807|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
48678808|NCT02953561|DRUG|Avelumab|Given IV
48678809|NCT02953561|DRUG|Azacitidine|Given SC or IV
48678810|NCT02953561|OTHER|Laboratory Biomarker Analysis|Correlative studies
48678811|NCT03526094|OTHER|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
48678812|NCT03526094|OTHER|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
48678813|NCT03526094|OTHER|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
48678814|NCT03526094|OTHER|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
48678815|NCT03526094|OTHER|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
48678816|NCT03526094|OTHER|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
48678817|NCT03526094|OTHER|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
48678818|NCT03526094|OTHER|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
48678819|NCT03526094|OTHER|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
48678820|NCT03526094|OTHER|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
48678821|NCT00965289|DRUG|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
48678822|NCT00893854|DRUG|Diclophenac|
48678823|NCT00893854|DRUG|Triamcinolone|
48678824|NCT02695914|DRUG|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
48678825|NCT00257569|DRUG|Cetirizine Dry Syrup|
48678826|NCT02444507|DRUG|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
48678827|NCT02444507|DRUG|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
48678828|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
48678829|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
48678830|NCT04748692|PROCEDURE|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
48678831|NCT04748692|PROCEDURE|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
48678832|NCT01945996|BEHAVIORAL|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
48678833|NCT01945996|BEHAVIORAL|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
48152812|NCT00751088|PROCEDURE|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
48678834|NCT04003844|DRUG|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
48678835|NCT04003844|DRUG|Acetylsalicylic acid|Coadministration
48364099|NCT02519777|DRUG|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
48511485|NCT05373004|DRUG|Empagliflozin 25 MG|It is the experimental drug in this trial. this drug has an approved efficacy in delaying kidney deterioration based on the results of (the EMPA-REG OUTCOME) trial. it is also recommended based on the ADA/EASD 2019 consensus, as the SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD. However, the previous trials where always add it to a patient already on an ACE inhibitor (in most cases). In this trial, it will be compared head to head with the gold standard treatment of CKD which is Enalapril 20 mg (ACE inhibitor).
48511486|NCT05373004|DRUG|Enalapril Maleate 20 mg|It is an ACE inhibitor, the active comparator in this trial, and is considered the gold standard for the treatment of diabetic kidney disease.
48511487|NCT04036838|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
48511488|NCT04036838|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
48511489|NCT04036838|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
48678836|NCT02564588|DRUG|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
48678837|NCT02564588|DRUG|Placebo|Placebo once daily
48678838|NCT05287776|DEVICE|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
48678839|NCT03368196|DRUG|DS-8201a|An antibody drug conjugate
48364100|NCT02519777|DRUG|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
48678840|NCT04318054|OTHER|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
48678841|NCT03008070|DRUG|IVA337|1200mg
48678842|NCT03008070|DRUG|IVA337|800mg
48678843|NCT03008070|DRUG|Placebo|Placebo to match
48364101|NCT05603481|DEVICE|Continuous Glucose Monitor|Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
48364102|NCT03550976|BEHAVIORAL|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
48364103|NCT01861158|BEHAVIORAL|Parenting Wisely|Computer-based, online, interactive parenting intervention
48511490|NCT04036838|DIAGNOSTIC_TEST|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
48678844|NCT04545879|DIETARY_SUPPLEMENT|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
48678845|NCT01384851|DRUG|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
48678846|NCT01384851|DRUG|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
48678847|NCT01384851|DRUG|Refresh Contacts|One drop both eyes four times daily for two weeks
48678848|NCT01446887|OTHER|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
48678849|NCT01668160|PROCEDURE|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
48678850|NCT01230320|PROCEDURE|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases."
48678851|NCT02099084|DRUG|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
48678852|NCT02099084|DRUG|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
48678853|NCT00933439|DRUG|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
48678854|NCT05794880|DEVICE|Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)|Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
48678855|NCT03243565|BIOLOGICAL|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
48678856|NCT03243565|BIOLOGICAL|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
48678857|NCT05207111|DRUG|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
48678858|NCT04288856|DRUG|BIIB078|Administered as specified in the treatment arm.
48152813|NCT00751088|PROCEDURE|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
48364104|NCT01226186|BEHAVIORAL|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
48364105|NCT01226186|BEHAVIORAL|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
48364106|NCT04369599|DEVICE|V/Q System|With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
48364107|NCT01279421|BEHAVIORAL|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
48511491|NCT04011605|PROCEDURE|Biological Sample of Carious Dentin|Dental patient volunteers will have either areas of decayed tooth structure or recurrent caries defective fillings removed using conventional, routine procedures, which will include: local anesthesia; tooth isolation using rubber dam; removal of superficial decay, weakened tooth structure or defective filling materials with rotary tooth cutting instruments; and then removal of softened dentin using sterile sharp spoon excavators, by hand. The limit of dentin removal will be determined by the clinician's estimate of tooth hardness, that is, using present conventional and ethical practice.
48678859|NCT00740753|DEVICE|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
48678860|NCT06493045|DRUG|IRL757|IRL757 capsule
48678861|NCT06493045|DRUG|Placebo|Placebo capsule
48678862|NCT03819387|DRUG|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
48678863|NCT02973997|OTHER|Laboratory Biomarker Analysis|Correlative studies
48678864|NCT02973997|DRUG|Lenvatinib|Given PO
48678865|NCT02973997|DRUG|Lenvatinib Mesylate|Given PO
48678866|NCT02973997|BIOLOGICAL|Pembrolizumab|Given IV
48678867|NCT01741493|DRUG|ABT-494|Oral administration of ABT-494 capsules
48678868|NCT01741493|DRUG|Placebo|Oral administration of placebo capsules
48678869|NCT01741493|DRUG|Tofacitinib|Oral administration
48678870|NCT03137953|PROCEDURE|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
48678871|NCT03137953|DIAGNOSTIC_TEST|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
48678872|NCT05681338|OTHER|the medium intensity coughing technique|The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
48678873|NCT05608954|OTHER|Bobath Concept|Handling of the Bobath Concept
48678874|NCT05608954|OTHER|Pediasuit|Pediasuit
48678875|NCT05608954|OTHER|Locomotor training|Locomotor training
48678876|NCT05608954|OTHER|Stretching|Active, passive, active-assisted stretching
48678877|NCT05608954|OTHER|Psychomotricity|Psychomotor skills
48678878|NCT05608954|OTHER|Virtual reality|Virtual reality
48678879|NCT01651286|PROCEDURE|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
48678880|NCT01651286|PROCEDURE|full face mask|using a standard full face mask during the induction of general anesthesia.
48678881|NCT00872274|DRUG|sumatriptan 100mg|
48152814|NCT00751088|PROCEDURE|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
48152815|NCT02962076|DRUG|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
48678882|NCT05789459|DEVICE|Stapler|Stapler
48678883|NCT05789459|OTHER|Suture|Suture
48678884|NCT04067089|PROCEDURE|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
48678885|NCT04067089|PROCEDURE|Surgical aortic valve replacement|Surgical aortic valve replacement
48678886|NCT04190680|BEHAVIORAL|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
48678887|NCT06515015|DEVICE|Endobronchial Silicon Spigots|The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
48152816|NCT03338829|BEHAVIORAL|Positive incentive|Compensation is paid for each glucose test completed
48152817|NCT03338829|BEHAVIORAL|Loss aversion|Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
48152818|NCT04054245|DRUG|LOXL2 Inhibitor PAT-1251|Given PO
48364108|NCT01279421|BEHAVIORAL|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
48152819|NCT04054245|OTHER|Quality-of-Life Assessment|Ancillary studies
48511492|NCT01038297|DRUG|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
48678888|NCT05043181|BIOLOGICAL|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
48678889|NCT00878592|BEHAVIORAL|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
48678890|NCT03284983|OTHER|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
48678891|NCT04068948|DRUG|Meperidine|This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
48678892|NCT04068948|DRUG|Hydroxyzine|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
48678893|NCT04068948|DRUG|Midazolam|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
48678894|NCT05827705|OTHER|need for Ephedrine hydrochloride|ephedrine dose in hypotension
48678895|NCT05173844|OTHER|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
48678896|NCT01419600|DRUG|AZD8683|Single Dose Inhaled IMP via Turbuhaler
48678897|NCT01419600|DRUG|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
48678898|NCT00384215|DRUG|insulin glargine [rDNA origin] injection|
48678899|NCT04754269|BEHAVIORAL|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
48152820|NCT04054245|OTHER|Questionnaire Administration|Ancillary studies
48152821|NCT00783185|BEHAVIORAL|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
48678900|NCT04754269|BEHAVIORAL|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
48152822|NCT00783185|BEHAVIORAL|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
48152823|NCT05546177|OTHER|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
48152824|NCT05546177|OTHER|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
48152825|NCT04950010|BEHAVIORAL|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be \~30 minutes in length. Indoor cycling is the primary mode of exercise.
48152826|NCT04950010|BEHAVIORAL|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
48152827|NCT01255709|DRUG|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
48152828|NCT01255709|DRUG|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
48152829|NCT01255709|DRUG|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
48152830|NCT02721849|BEHAVIORAL|Yoga for adolescents|12 week hatha yoga course for adolescents
48152831|NCT02721849|BEHAVIORAL|Yoga for parents|12 week hatha yoga course
48152832|NCT05357599|DIAGNOSTIC_TEST|EUS|The decision to start a beta-blocker will be made at the conclusion of the EGD based on the endoscopic findings (presence of esophageal varices)
48152833|NCT02195180|DRUG|ERY001|
48152834|NCT02195180|DRUG|Gemcitabine|
48152835|NCT02195180|DRUG|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
48152836|NCT02791685|BEHAVIORAL|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
48152837|NCT02791685|BEHAVIORAL|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
48152838|NCT02791685|BEHAVIORAL|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
48152839|NCT05374967|BEHAVIORAL|Lifestyle intervention: Live with IBD|"A digital lifestyle intervention divided into two phases:~1. An intensive phase lasting six months~2. a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks."
48152840|NCT05374967|OTHER|Control group|The standard of care for patients with IBD suffering from chronic fatigue.
48152841|NCT04361617|BEHAVIORAL|Daily consumption of tree nuts and extra virgin olive oil|All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
48152842|NCT02903602|BEHAVIORAL|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
48152843|NCT02903602|BEHAVIORAL|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
48152844|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection Alone|participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
48152845|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction|participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
48152846|NCT01880359|DRUG|Cisplatin|
48152847|NCT01880359|RADIATION|Radiotherapy|
48152848|NCT01880359|DRUG|Placebo|
48152849|NCT01880359|DRUG|Nimorazole|
48152850|NCT01381185|DRUG|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
48364109|NCT01047631|BEHAVIORAL|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Exercise classes \& activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
48364110|NCT01047631|BEHAVIORAL|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~* Measure general fitness levels such as walking, strength and balance.~* Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~* Blood and urine tests and a heart ultrasound.~* Questionnaires \& activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
48364111|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with FibriCheck®|Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.
48152851|NCT05483556|DEVICE|Real tDCS|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
48152852|NCT05483556|DEVICE|Sham tDCS|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
48364112|NCT06028893|DIAGNOSTIC_TEST|Heart rhythm measurements with Kardia Mobile®|Measurements are performed immediately before and after every FibriCheck® measurement.
48364113|NCT05286034|BEHAVIORAL|Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms|"Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms.~ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels."
48364114|NCT04353739|BEHAVIORAL|Self-Management for HIV-positive Asian Pacific Americans|Developed upon the results of our prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program.
48364115|NCT02174406|PROCEDURE|breast ultrasound|
48678901|NCT06041009|DIAGNOSTIC_TEST|Pancreatic elastase-1 in blood serum|Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
48678902|NCT02804490|DIETARY_SUPPLEMENT|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
48678903|NCT02804490|DIETARY_SUPPLEMENT|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
48678904|NCT02804490|DIETARY_SUPPLEMENT|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
48678905|NCT00652171|DRUG|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
48678906|NCT00652171|DIETARY_SUPPLEMENT|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
48678907|NCT02709512|DRUG|ADI-PEG 20 plus Pem Platinum|Investigational Drug in combination approved standard of care treatment for this indication
48678908|NCT02709512|OTHER|Placebo plus Pem Platinum|Placebo in combination approved standard of care treatment for this indication
48678909|NCT02701309|DEVICE|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
48364116|NCT02174406|PROCEDURE|DBT (Full field digital mammography + tomosynthesis)|
48364117|NCT04645628|OTHER|MRI examination|All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
48364118|NCT00557362|DRUG|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
48511493|NCT01038297|DRUG|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
48511494|NCT00138554|DRUG|vildagliptin|
48511495|NCT00138554|DRUG|pioglitazone|pioglitazone 45 mg qd
48678910|NCT06193564|OTHER|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) A constant current of 2 mA was applied to the experimental group for 20 minutes.
48678911|NCT06193564|OTHER|Cervical Stabilization Exercises|"Before initiating the stabilization exercises, individuals included in the study were instructed on correct postural alignment. Cervical chin tuck movement was taught during the exercise along with postural alignment and craniocervical flexion movement was requested. After teaching craniocervical flexion exercises in all positions (supine, lying on the side, prone, crawling, sitting, and standing), participants were instructed to perform the movement slowly.~The purpose of this phase was to establish the relationship between vision and motor learning using the Pressure Biofeedback Stabilizer device. The device was positioned on the neck area and inflated to 20 mmHg. The pressure level gradually increased in 2-mmHg increments from 20 to 30 mmHg. For each pressure value (22, 24, 26, 28, 30 mmHg), participants were asked to maintain craniocervical flexion for 10 seconds, and this exercise was repeated ten times."
48364119|NCT00557362|DRUG|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
48364120|NCT00557362|PROCEDURE|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
48364121|NCT06261216|OTHER|Interview|"* International Physical Activity Questionnaire (IPAQ-SF)~* interviewer-administered modified Lifetime Total Physical Activity Questionnaire (LTPAQ) form"
48364122|NCT02822274|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70_R84-064)
48511496|NCT06633120|OTHER|IVM|Immature oocytes will be retrieved from small ovarian follicles and matured overnight in the laboratory prior to undergoing fertilization and embryo culture.
48678912|NCT06193564|OTHER|Sham-Transcranial Direct Current Stimulation (tDCS)|tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) (Figure 2). As shown in the figure, a constant current of 2 mA was applied to the experimental group for 20 minutes. For the sham group, electrodes were placed in the same areas and a current of 0 mA was applied.
48364123|NCT03102073|DIAGNOSTIC_TEST|Radner test|"* The A5 reading booklet is held by the subject~* The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~* The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~* One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~* Stop criterion: reading time longer than 20 seconds or severe errors."
48678913|NCT05871580|RADIATION|Low frequency laser activated photobiomodulation|"Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~* apex tongue: 3 points~* lateral edge of the tongue: 4 points~* tongue dorsum: 10 points~* jugal mucosa: 8 points~* labial mucosa: 5 points~* hard palate: 8 stitches~* soft palate: 3 stitches~* gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point."
48678914|NCT05871580|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
48678915|NCT01809886|DRUG|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
48678916|NCT01809886|DRUG|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
48678917|NCT02377557|DRUG|Topical Steroids|
48678918|NCT05282875|DRUG|management of immunosuppressive therapy|"3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents"
48678919|NCT04328896|OTHER|CGM-Tele-monitoring|"Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
48678920|NCT01963767|DRUG|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
48678921|NCT01963767|DIETARY_SUPPLEMENT|Placebo|
48678922|NCT04114916|DIETARY_SUPPLEMENT|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
48678923|NCT04114916|DIETARY_SUPPLEMENT|maltodextrina|Two capsules daily at breakfast and dinner.
48678924|NCT06184191|OTHER|Robotic hand rehabilitation|Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
48678925|NCT01198782|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
48678926|NCT02574728|DRUG|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
48678927|NCT02574728|DRUG|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
48678928|NCT02574728|DRUG|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
48678929|NCT02574728|DRUG|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
48678930|NCT00083980|DRUG|Venlafaxine ER|75 to 225 mg daily
48511497|NCT04357080|PROCEDURE|Urethroplasty|Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
48678931|NCT00083980|DRUG|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
48678932|NCT00083980|DRUG|Kava|140 to 280 mg per day
48511498|NCT03377101|DRUG|Copanlisib|Given IV
48511499|NCT03377101|DRUG|Fulvestrant|Given IM
48364124|NCT00561964|DRUG|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
48511500|NCT03377101|OTHER|Laboratory Biomarker Analysis|Correlative studies
48678933|NCT01135992|DRUG|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
48678934|NCT01135992|DRUG|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
48678935|NCT02599311|DEVICE|transvaginal synthetic mesh|transvaginal synthetic mesh
48678936|NCT02599311|DRUG|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
48678937|NCT00414323|DRUG|Duloxetine|
48678938|NCT00414323|DRUG|Escitalopram|
48678939|NCT00414323|DRUG|Placebo|
48678940|NCT06112470|OTHER|Interview|Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.
48678941|NCT04451200|DRUG|Busulfan Injection|injections doses will be personalized by PK at days -7 and -4
48678942|NCT04078269|BIOLOGICAL|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
48678943|NCT04078269|BIOLOGICAL|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
48364125|NCT00561964|DRUG|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
48364126|NCT06187519|DEVICE|Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch|The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
48364127|NCT03365401|PROCEDURE|decompression surgery|undertake decompression surgery
48364128|NCT03365401|PROCEDURE|nonsurgical treatment|complete on bed with prevention of complication
48511501|NCT03377101|DRUG|Palbociclib|Given PO
48511502|NCT04082156|DEVICE|electrical stimulation|electrical stimulation
48511503|NCT04082156|DEVICE|Sham|no stimulation
48511504|NCT00486031|DRUG|Balsalazide Disodium|
48511505|NCT03953326|BEHAVIORAL|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
48678944|NCT04078269|BIOLOGICAL|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
48678945|NCT03218280|DRUG|Vitamin C|
48678946|NCT05252208|OTHER|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
48678947|NCT05252208|OTHER|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
48678948|NCT04767672|DIETARY_SUPPLEMENT|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
48678949|NCT04767672|DIETARY_SUPPLEMENT|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
48152853|NCT03214471|BEHAVIORAL|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
48678950|NCT04368377|DRUG|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
48152854|NCT04548778|DIAGNOSTIC_TEST|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
48152855|NCT02817685|OTHER|3 months|
48678951|NCT04368377|DRUG|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
47993511|NCT03999190|DRUG|Raclopride radiotracer|"\[11C\]raclopride radiotracer, 2 injections per subject~Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
48152856|NCT02817685|OTHER|6 months|
48152857|NCT02817685|OTHER|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
48152858|NCT03152409|DRUG|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
48152859|NCT03152409|DRUG|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
47993512|NCT03999190|DRUG|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist (\[11C\]raclopride) and agonist (\[11C\]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
48678952|NCT04368377|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
48678953|NCT04368377|DRUG|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
48678954|NCT00709150|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
47993513|NCT02942446|DEVICE|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
47993514|NCT01180673|BEHAVIORAL|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
48152860|NCT03834909|DRUG|Standard dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
48152861|NCT03834909|DRUG|Pregnancy-adjusted dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
48364129|NCT04531436|OTHER|Brief mindful eating intervention|Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
48364130|NCT06334237|OTHER|personalized treatment|According to the condition of each individuals, the study continues their routine clinical care. The study does not offer anything more than a routine clinical care. It is named personalized treatment because the condition of each individual varies, so the doctor may prescribe or offer clinical advice accordingly. .
48152862|NCT05306483|PROCEDURE|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
48511506|NCT03953326|DRUG|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
48511507|NCT03953326|DRUG|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
48511508|NCT03953326|DRUG|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
48511509|NCT02006225|DRUG|Plerixafor|
48511510|NCT01897805|DRUG|Heart-protecting Musk Pill|
48511511|NCT01897805|DRUG|Placebo|
48511512|NCT01783912|BEHAVIORAL|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
48511513|NCT01783912|BEHAVIORAL|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
48511514|NCT01783912|DRUG|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
48511515|NCT01783912|BEHAVIORAL|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
48511516|NCT00695305|DRUG|rilapladib|250 mg oral dose once daily
48511517|NCT00695305|DRUG|placebo|placebo
48511518|NCT00695305|OTHER|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
48511519|NCT00900835|OTHER|educational intervention|
48511520|NCT00900835|OTHER|questionnaire administration|
48511521|NCT00900835|OTHER|study of socioeconomic and demographic variables|
48511522|NCT00900835|PROCEDURE|assessment of therapy complications|
48511523|NCT00900835|PROCEDURE|fatigue assessment and management|
48511524|NCT00900835|PROCEDURE|quality-of-life assessment|
48511525|NCT00900835|PROCEDURE|standard follow-up care|
48678955|NCT00709150|BEHAVIORAL|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
48678956|NCT01538576|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
48678957|NCT02869542|OTHER|Data collection|
48678958|NCT00720577|DRUG|Simvastatin|40 Mg. tablet, 1 tablet daily
48678959|NCT00720577|DRUG|Losartan|50 mg., tablets, 1 tablet once daily
48678960|NCT00720577|DRUG|Pioglitazone|30 mg, tablet, 1 tablet once daily
48678961|NCT02648009|DRUG|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
48678962|NCT02648009|DRUG|Gadolinium|MRI with Gadolinium
48678963|NCT00443703|DRUG|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
48678964|NCT00443703|DRUG|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
48678965|NCT00443703|DRUG|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
47993515|NCT01180673|BEHAVIORAL|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
47993516|NCT05481177|DRUG|Ivabradine|Ivabradine is a drug approved to treat tachycardia in volunteers with heart failure. This study is to determine benefit of ivabradine treatment in postural orthostatic tachycardia syndrome (POTS) in participants with Long haul Covid.
47993517|NCT00108160|DRUG|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
47993518|NCT00108160|DRUG|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
48678966|NCT00443703|DRUG|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
47993519|NCT00206947|DRUG|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
47993520|NCT00206947|DRUG|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
47993521|NCT00279734|DRUG|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
47993522|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
47993523|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
47993524|NCT00279734|DRUG|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
47993525|NCT04669587|DRUG|ZB716|Pharmaceutical form: capsule Route of administration: oral
47993526|NCT04669587|DRUG|Palbociclib|Pharmaceutical form: capsule Route of administration: oral
47993527|NCT00927433|BEHAVIORAL|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
47993528|NCT01877629|DRUG|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
47993529|NCT01877629|DRUG|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
48678967|NCT06172816|OTHER|SARS-CoV-2|a virus infection
47993530|NCT05083793|DRUG|Pregabalin 150mg|The effect of pregabalin on post-operative pain
47993531|NCT05083793|OTHER|Placebo|patients will receive placebo one hour before operation
47993532|NCT00912990|DRUG|Cisatracurium|One intravenous dose: 0.2mg/kg/dose
47993533|NCT00912990|DRUG|Normal saline|One Intravenous dose
47993534|NCT05215301|DIAGNOSTIC_TEST|Multidimensional Voice Program|"MDVP (Multidimensional Voice Program) is a computerized acoustic analysis used to analyze sound quality using various parameters. Multidimensional Voice Program (MDVP) 4500 produced by Kay Elemetric Corp was used for voice evaluation.~Research subjects were asked to make a vowel sound /a/ using the same tone and intensity as the subject's daily speech. The researcher will give an example before letting the research subject tries. Voice recording was done using a microphone connected to a computer with the MDVP program. Voice recording was done in a quiet room for at least 3 seconds with a microphone distance of 10 cm from the mouth of the research subject. The recorded sound will be directly analyzed with the MDVP program. Sound recording was done 3 - 5 times, and the best sound acoustic analysis results were used for the study."
48678968|NCT02309658|DRUG|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
48678969|NCT02309658|DRUG|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
48678970|NCT02309658|RADIATION|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
48678971|NCT01251562|DRUG|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
48678972|NCT04973358|OTHER|buccotherm mouthwash|twice a day for 14 weeks
48678973|NCT04973358|OTHER|placebo mouthwash|twice a day for 14 weeks
48678974|NCT01024348|DRUG|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
48678975|NCT01024348|DRUG|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
48678976|NCT02840305|OTHER|Evaluation of visual function|
48678977|NCT02840305|OTHER|Magnetic Resonance Imaging|
48364131|NCT02769689|DRUG|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
48678978|NCT00167375|DRUG|eszopiclone 3 mg qHS|
48678979|NCT00167375|BEHAVIORAL|General cognitive/behavioral interventions for insomnia|
48678980|NCT04336657|OTHER|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
48678981|NCT04336657|DIAGNOSTIC_TEST|IgG|Measure the past immunity of the disease (if possible)
48678982|NCT00619944|DRUG|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
47993535|NCT06376682|PROCEDURE|CT-guided bone percutaneous procedure|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures (thermal ablation, bone consolidation, biopsy procedures).
47993536|NCT00128947|DRUG|Mycophenolic Acid|
47993537|NCT00128947|DRUG|Mycophenolate 7-O-Phenolic Glucuronide|
48364132|NCT02769689|DRUG|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
48364133|NCT02769689|DRUG|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
48678983|NCT00619944|DRUG|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
48678984|NCT02393339|DRUG|paracetamol|Pre-operative administration of Paracetamol syrup
48678985|NCT02393339|DRUG|placebo|Pre-operative administration of placebo syrup
48678986|NCT02461199|BIOLOGICAL|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
48678987|NCT03943576|DRUG|GXCPC1|The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
48678988|NCT03943576|DEVICE|HA|Hya Joint Plus synovial fluid supplement 3mL
48152863|NCT05306483|PROCEDURE|Ventricular septal defect closure catheter|Catheter closure of VSD
48678989|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^8 vp/mL administered on Day 0
48152864|NCT06270199|BIOLOGICAL|Control|Standard treatment
48152865|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|3 doses of 5 million MSC will be administered
48152866|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|6 doses of 5 million MSC will be administered
48152867|NCT06432959|BEHAVIORAL|Psychotherapy, Positive Affect Promoting Activities|"The specific activities that constitute the positive affect interventions will be determined by the therapist and participant collaboratively. Some examples of positive affect promoting activities are:~* Watch videos of animals and babies~* Eat a piece of candy~* Recall and describe a past positive experience~* Describe the positive attributes of the participant~* Engage in gratitude practice~* Do something nice for someone~The in-session positive affect activities will last approximately five minutes. For the first four weeks, the positive affect activities will be completed at the beginning of the session. After that, therapists will look for opportunities to incorporate positive affect activities at stuck points or before learning a new skill in-session. Additionally, therapists will work with participants to identify ways in which the participants can incorporate positive affect activities into their lives between sessions."
48152868|NCT06432959|BEHAVIORAL|Psychotherapy|Meet with treatment providers individually or in group to learn skills to address symptoms associated with depression and emotion dysregulation
48152869|NCT00002045|DRUG|Zidovudine|
48152870|NCT02269072|DRUG|Testosterone|Testosterone cream applied daily for two weeks
48152871|NCT02269072|DRUG|Nesiritide|Administered IV once during the study
48152872|NCT02269072|DRUG|Leuprolide|Administered twice during the study by injection
48152873|NCT02269072|DRUG|Anastrozole|Daily pill for 8 weeks
48678990|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^9 vp/mL administered on Days 0, 28, and 56
48678991|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^10 vp/mL administered on Days 0, 28, and 56
48678992|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^11 vp/mL administered on Days 0, 28, and 56
47993538|NCT01809873|BEHAVIORAL|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
47993539|NCT01907503|PROCEDURE|Evaluation of the balance of force platform|
48152874|NCT02269072|DRUG|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
48152875|NCT03819647|DRUG|stiripentol (Diacomit)|Administration of stiripentol per os
48152876|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19
48152877|NCT04324606|BIOLOGICAL|MenACWY|Standard single dose of MenACWY vaccine delivered intramuscularly
48152878|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 full boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
48152879|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 half boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10\^10vp of ChAdOx1 nCoV-19
48678993|NCT01509846|BIOLOGICAL|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
48364134|NCT02769689|DRUG|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
48364135|NCT02694562|DEVICE|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
48511526|NCT05858112|DIAGNOSTIC_TEST|SuperTROPO novel assay to measure the long forms of cTnT|SuperTROPO novel assay to measure the long forms of cTnT
48511527|NCT01537939|BEHAVIORAL|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
48511528|NCT00894829|BIOLOGICAL|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
48678994|NCT05473455|PROCEDURE|Experimental: Follicular aspiration with addition of follicular flushing.|Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
48678995|NCT06470516|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA.
48364136|NCT00465894|DRUG|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
48364137|NCT00465894|DRUG|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
48364138|NCT03427203|DEVICE|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
48364139|NCT03427203|DEVICE|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
48364140|NCT03427203|DEVICE|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
48364141|NCT03427203|DEVICE|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
48511529|NCT00894829|BIOLOGICAL|heparin sodium - APP|Heparin sodium APP 5.000 USP
48511530|NCT01446328|DRUG|Amisulpride|Tablets, dose range 50-1200 mg/ day
48511531|NCT01446328|DRUG|Aripiprazole|Tablets, dose range 5-30 mg/ day
48511532|NCT01446328|DRUG|Olanzapine|Tablets, dose range 2.5-20 mg/ day
48678996|NCT06470516|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
48511533|NCT02447146|OTHER|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
48511534|NCT02447146|OTHER|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
48511535|NCT04108026|DRUG|Durvalumab|1500 mg IV every 4 weeks
48511536|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using Polypropylene mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
48678997|NCT05674812|DIAGNOSTIC_TEST|Comprehensive evaluation|Non-ultrasound parameters:oxygenation index;arterial blood gas analysis;Type of surgery;ultrasound parameters:Diaphragmatic displacement, Mitral Annular Plane Systolic Excursion,Triscuspidal annular Plane Systolic Excursion, Lung score
48511537|NCT06430931|PROCEDURE|Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh|All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).
48511538|NCT00366366|BIOLOGICAL|Infanrix-Hexa|
48511539|NCT04202055|OTHER|Biomarker analysis|Detection of biomarker in cerebrospinal fluid
48511540|NCT06469502|PROCEDURE|Stretching Exercises|Group 1 will be included in the program consisting of stretching exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of stretching exercises (3 times a week) under the supervision of a physiotherapist.
48678998|NCT01107964|DRUG|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
48678999|NCT01107964|DRUG|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
48679000|NCT02153437|DRUG|BMS-919373|
48679001|NCT02153437|DRUG|Sotalol|
48511541|NCT06469502|PROCEDURE|Strengthening Exercises|Group 2 will be included in the program consisting of strengthening exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of strengthening exercises (3 times a week) under the supervision of a physiotherapist.
48679002|NCT02153437|DRUG|Placebo for BMS-919373|
48679003|NCT01898286|DRUG|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
48679004|NCT00976157|PROCEDURE|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
48679005|NCT02076854|BEHAVIORAL|Text-Message Intervention|
48679006|NCT05329337|DIAGNOSTIC_TEST|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
48679007|NCT02389465|DRUG|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
48152880|NCT04324606|BIOLOGICAL|MenACWY boost|A standard dose of MenACWY followed by a boost dose of MenACWY
48364142|NCT05547828|DRUG|Tislelizumab combined with chemoradiotherapy|"Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)"
48511542|NCT03132233|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
48679008|NCT02389465|DRUG|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
47993540|NCT05781295|DEVICE|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
47993541|NCT05781295|DEVICE|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
47993542|NCT05851430|DEVICE|PEF ablation|Pulsed Electric Field (PEF) Ablation per institutional standard of care
48152881|NCT04324606|DRUG|Paracetamol|1g every 6 hours for 24 hours
48152882|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp)
48152883|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of 5x10\^10vp of ChAdOx1 nCoV-19
48364143|NCT02590627|DRUG|Artemether-lumefantrine|Artemether-lumefantrine
48364144|NCT02590627|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
48364145|NCT05157178|BIOLOGICAL|Covid-19 (recombinante) vaccine|Administration of the Covid-19 (recombinante) vaccine
48511543|NCT03132233|OTHER|placebo powder|matched placebo powder to the IMP.
48511544|NCT04052620|DRUG|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
48511545|NCT04052620|DRUG|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
48679009|NCT00283543|DRUG|Gliadel Wafer|
48679010|NCT00283543|DRUG|Temozolomide|
48679011|NCT00283543|PROCEDURE|Limited field radiation|
48679012|NCT06364397|PROCEDURE|ERCP|Participants will undergo ERCP and indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place.
48511546|NCT04052620|OTHER|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
48511547|NCT04397263|DRUG|Guselkumab|Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
48511548|NCT01697553|OTHER|home automation pack coupled to teleassistance service|
48511549|NCT01697553|OTHER|Home without automation pack coupled to teleassistance service|
48511550|NCT01146756|DRUG|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
48679013|NCT06364397|COMBINATION_PRODUCT|Health education and conservative management of clinical routines|Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
48511551|NCT02365116|BEHAVIORAL|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
48679014|NCT01778998|PROCEDURE|MICS-group|Micro incision cataract surgery is done
48679015|NCT01778998|PROCEDURE|SICS-group|small incision cataract surgery is done
48679016|NCT01778998|PROCEDURE|SICS pre-cut|Small incision cataract surgery with pre-cut is done
48679017|NCT01778998|PROCEDURE|SICS stab-incision|Small incision cataract surgery with stab-incision is done
48679018|NCT06116981|OTHER|High Induction Magnetic Field Therapy|High Induction Magnetic Field Therapy is a method that has no side effects, is non-invasive and easy to apply, and is used to increase circulation in tissues.
48679019|NCT06116981|OTHER|Conservative Treatment|Shoulder exercises, transcutaneous electrical nerve stimulation, stretching.
48679020|NCT04164810|OTHER|Hydrotherapy|All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
48679021|NCT04164810|OTHER|Physical Therapy|All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
48679022|NCT01628913|DRUG|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
47993543|NCT04007523|BEHAVIORAL|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
47993544|NCT04007523|BEHAVIORAL|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
48152884|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later
48679023|NCT01628913|DRUG|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
48679024|NCT03685981|OTHER|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
48679025|NCT00190333|DRUG|escitalopram|escitalopram
48679026|NCT05598905|DRUG|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
48679027|NCT05598905|DRUG|Oxycodone 10mg|one 10mg tablet
48679028|NCT05598905|DRUG|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
48679029|NCT06400628|BEHAVIORAL|Self-management education|The base line data will be taken and used as control, while the final result will be utilized as the case
48679030|NCT00124930|DRUG|Olanzapine|
48679031|NCT00124930|DRUG|Haldol|
48679032|NCT00658489|BEHAVIORAL|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
48679033|NCT05833412|DIAGNOSTIC_TEST|Septicyte Rapid ®|SeptiCyte RAPID is based on the measurement of two gene expression biomarkers in peripheral blood (PLAC8 and PLA2G7) using quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Based on the results obtained in 1 hour from whole blood (100 mcl), the device issues a report with a sepsis probability scale according to 4 bands (1 low probability, 2-3 intermediate probability and 4 high probability).
48679034|NCT05833412|DIAGNOSTIC_TEST|FilmArray® blood culture identification (BCID2®)|After 6 to 8 hours of blood culture incubation, BCID2 will be performed on each of the 4 bottles. The BCID2 assay is an approved molecular test for the direct identification of pathogens causing bloodstream infections from blood cultures. The BCID2 Panel analyzes 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeasts and 10 antimicrobial resistance genes, all with a single test and with results available in approximately one hour from the blood culture. In addition, the BCID2® Panel menu includes seven additional resistance genes, including carbapenemases, colistin resistance genes and a MREJ assay that enables more speciﬁc MRSA identiﬁcation.
47993545|NCT04477811|DRUG|Vitamin K1|vitamin k1 tablets
47993546|NCT04477811|DRUG|Vitamin k2|vitamin k2 45 ug tablets twice daily
47993547|NCT04477811|OTHER|placebo|placebo tablets
48511552|NCT02365116|BEHAVIORAL|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
48511553|NCT03190811|BIOLOGICAL|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
48679035|NCT04092777|BEHAVIORAL|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
48679036|NCT04092777|OTHER|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
48679037|NCT04861272|BEHAVIORAL|Survey|Online survey
48679038|NCT05214352|OTHER|co-design in the intervention manual elaboration to increase the participation in the community|"It will co-design an intervention manual between all participants (families, young people with cerebral palsy and therapists) and researchers, using the involvement matrix to increase the participation of young people in the community.~Different focus grous will be created to work together and various online meetings, masterclass, workshops to increase the knowlodge in all groups."
48679039|NCT00104390|BIOLOGICAL|Grass MATA MPL|
48679040|NCT04224922|DRUG|Paclitaxel|
48679041|NCT04224922|DRUG|Carboplatinum|
48679042|NCT04224922|DRUG|Epirubicin|
48679043|NCT04224922|DRUG|Cyclophosphamide|
48679044|NCT01669746|BIOLOGICAL|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
48679045|NCT04528589|OTHER|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
48679046|NCT04522934|BEHAVIORAL|Pain Neuroscience Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
48679047|NCT04522934|BEHAVIORAL|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
48679048|NCT05504681|OTHER|Observational study|It takes the patient on average 15 minutes to complete the Brainlab Cognition app.
48679049|NCT04590599|DRUG|IBI310|IBI310 3 mg/kg,Q3W, for a total of 4 cycles
48679050|NCT04590599|DRUG|Placebo|Placebo Q3W, for a total of 4 cycles
48679051|NCT04590599|DRUG|Sintilimab|Sintilimab 200mg,Q3W
48679052|NCT02930707|DRUG|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
48152885|NCT02416349|OTHER|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
48679053|NCT02930707|DRUG|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
48679054|NCT03291106|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
48679055|NCT03291106|DIAGNOSTIC_TEST|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
48152886|NCT02416349|OTHER|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
48152887|NCT03256305|DEVICE|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
48679056|NCT03291106|DIAGNOSTIC_TEST|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
48679057|NCT03291106|DIAGNOSTIC_TEST|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
48152888|NCT03256305|DEVICE|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
48152889|NCT05134233|DEVICE|Low-intensity Focused Ultrasound|LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
48679058|NCT03167138|BIOLOGICAL|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
48679059|NCT03167138|DEVICE|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
48679060|NCT01233024|DIETARY_SUPPLEMENT|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
48679061|NCT01233024|DIETARY_SUPPLEMENT|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
48679062|NCT01233024|DIETARY_SUPPLEMENT|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
48679063|NCT01233024|DIETARY_SUPPLEMENT|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
48679064|NCT01233024|DIETARY_SUPPLEMENT|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
48679065|NCT02982655|PROCEDURE|Individualized BP lowering|
48152890|NCT02747459|BEHAVIORAL|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
48364146|NCT01916733|DRUG|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
48679066|NCT03019887|DRUG|reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
48679067|NCT03382912|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Nivolumab
48679068|NCT03382912|DRUG|Nivolumab|Nivolumab Alone
48679069|NCT01087983|DRUG|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
48679070|NCT01087983|DRUG|Sirolimus|Starting oral dose 1 mg daily.
48679071|NCT01087983|DRUG|Metformin|Starting oral dose 1000 mg daily.
48679072|NCT01424358|OTHER|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
48679073|NCT00622921|BEHAVIORAL|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
48679074|NCT02520492|DEVICE|noninvasive method of ICP measurements (Elios)|
48679075|NCT02414516|DRUG|OBP-801|OBP-801 will be administered IV
48152891|NCT01351597|DRUG|docetaxel/ oxaliplatin|"1. docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~2. oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
48679076|NCT00286299|OTHER|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
48679077|NCT00286299|OTHER|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
48679078|NCT00286299|OTHER|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
48679079|NCT06164691|DEVICE|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
48679080|NCT06164691|DEVICE|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
48152892|NCT04362059|DEVICE|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
48152893|NCT04362059|OTHER|Standard of Care|Standard of care treatment for respiratory illness
48152894|NCT02174315|BEHAVIORAL|Contingency Management|
48679081|NCT06164691|OTHER|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
48679082|NCT04169178|DRUG|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
48679083|NCT05975346|DRUG|Ketamine|description
48679084|NCT05975346|OTHER|saline nebulization|description
48152895|NCT06449599|DEVICE|ultrasound|local anesthesia 400 mg prilocaine (priloc 2%, 20 ml, Vemilac,Türkiye) to surgical field and additionally ultrasound-guided rhomboid intercostal plane block 0,25% bupivacaine 20 ml (Buvasin 0,5%, 20 ml, Vemilac, Türkiye) will be applied to the patients who will be inserted implantable cardioverter defibrillator.
48152896|NCT06449599|PROCEDURE|parenteral local anesthesia|only local anesthesia 400 mg prilocaine (priloc 2%, 20 ml, Vemilac,Türkiye) to surgical field will be applied to the patients who will be inserted implantable cardioverter defibrillator.
48152897|NCT00547716|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
48152898|NCT00547716|DRUG|Placebo comparator|
48152899|NCT02611193|PROCEDURE|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
48152900|NCT02611193|PROCEDURE|Simulated manipulative treatment|Simulated Manipulative Treatment
48364147|NCT05233319|OTHER|There is no intervention|There is no intervention
48679085|NCT06057805|DEVICE|Blinded Dexcom G7 CGM|CGM that records blood glucose but not visible to patient or provider in real time
48679086|NCT02441101|DEVICE|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
48679087|NCT02441101|DEVICE|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
48679088|NCT00006261|BIOLOGICAL|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
48679089|NCT00006261|DRUG|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
48679090|NCT00006261|DRUG|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
48679091|NCT00006261|DRUG|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
48679092|NCT00006261|DRUG|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
48679093|NCT00006261|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
48679094|NCT02840253|DEVICE|NIRS|
48679095|NCT00456625|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 dose
48679096|NCT06071598|OTHER|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
48679097|NCT00535769|DEVICE|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
48679098|NCT00535769|DEVICE|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
48511554|NCT03190811|BIOLOGICAL|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
48679099|NCT05211089|OTHER|Optical Coherence Tomography imaging of choroid|A single expert retinal specialists used a Topcon DRI-1 SS-OCT to do the Choroidal Thickness measurements. A 12, 9-mm radial line scan procedure was performed. Each radial line was automatically scanned 32 times in the same spot, followed by the creation of 12 high-resolution average B-scan images. Each scan was double-checked to confirm that it was centred on the fovea. Only scans of good quality were included. The perpendicular distance between the outer border of the RPE and the junction of the choroid and sclera was used to calculate CT. It was calculated automatically using the mapping software incorporated into the device and displayed as a colourful topographic map with nine subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) style grid.
48679100|NCT01138085|DRUG|GSK1120212|MEK inhibitor
48679101|NCT01138085|DRUG|GSK2141795|AKT Inhibitor
48679102|NCT01558284|DRUG|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
48679103|NCT01558284|DRUG|Placebo|Placebo
48679104|NCT05793359|DRUG|Methylprednisolone|methylprednisolone applied as intravenous infusions or intramuscularly
48679105|NCT03954912|PROCEDURE|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
47993548|NCT04713774|DEVICE|High-resolution peripheral quantitative CT scanner (HRpQCT)|HR-pQCT images of the distal radius and distal tibia (non-dominant, non-fractured limb) will be obtained using the XtremeCT device with standard protocols. HR-pQCT images wil be analysed with standard software and extended cortical measures software. This software identifies the periosteal and endosteal boundaries, enabling assessment of cortical micro- structural bone properties, including apparent cortical thickness (Ct.Th, mm), cortical tissue mineral density (TMD, mgHA/cm3) and cortical porosity (Ct.Po, %).
47993549|NCT06460064|BIOLOGICAL|fH1 2 ug|2 administrations at 3-week intervals.
47993550|NCT06460064|BIOLOGICAL|fH1 8 ug|2 administrations at 3-week intervals.
48679106|NCT03954912|PROCEDURE|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
48679107|NCT01623505|DRUG|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
48679108|NCT01623505|DRUG|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter."
48511555|NCT05198258|OTHER|Implementation strategy - experimental group|On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
48511556|NCT05198258|OTHER|Implementation - control group|Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
48679109|NCT01623505|DRUG|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
48679110|NCT01389986|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
48679111|NCT05124353|DRUG|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
48679112|NCT05529407|DEVICE|Simple Vaginal Tampon|Use of single use vaginal tampons
48679113|NCT05529407|DEVICE|Glass Vaginal Trainer|Use of glass vaginal trainers
48679114|NCT01306643|DRUG|Idelalisib|Tablet(s) administered orally twice daily
48679115|NCT05292690|DEVICE|Powered Wheelchair Obstacle Alerting System|Evaluation of an Obstacle Alerting System
48679116|NCT01953211|DRUG|combined oral contraceptives|
48679117|NCT03103854|BEHAVIORAL|BURST physical activity|BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
48679118|NCT03103854|BEHAVIORAL|Text Message Reminders|Patients were sent daily text message reminders to remind them to exercise.
48679119|NCT03103854|BEHAVIORAL|Moderate Intensity Continuous Training|This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
48679120|NCT00572182|DRUG|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
48364148|NCT01871428|DRUG|aleglitazar|150 mcg orally daily
48511557|NCT01776255|BEHAVIORAL|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
48511558|NCT01776255|BEHAVIORAL|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
48679121|NCT04995484|DRUG|Belzutifan|Two 40 mg tablets given as a single oral 80 mg dose.
48364149|NCT01871428|DRUG|placebo|matching aleglitazar placebo orally daily
48364150|NCT06479577|OTHER|ultrasound|ultrasound 1 MHZ continuous for 20 minute with routine physical therapy 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
48364151|NCT06479577|OTHER|high intensity laser therapy|905 nm super pulsed laser 40 minute session 3 days /week 150 minutes/ week resistance training 5-10 exercises involving major muscles of leg and foot 3-4 sets per exercise and 10- 15 repetition per set
48364152|NCT03119428|DRUG|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
48679122|NCT04450030|DRUG|Methyl Prednisolonate|2000mg intravenous methyl prednisolone per day for five consecutive days
48679123|NCT04450030|PROCEDURE|Immunoadsorption|6 courses of tryptophane-based immunoadsorption within up to 12 days
48679124|NCT06302465|DRUG|narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide|Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
48679125|NCT06302465|DRUG|doxorubicin、cisplatin、methotrexate、ifosfamide|doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
48679126|NCT04304079|DEVICE|ARssist system|As stated in ARssist system arm description
48679127|NCT03756116|PROCEDURE|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
48679128|NCT03756116|PROCEDURE|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
48679129|NCT02485587|BEHAVIORAL|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
48679130|NCT02485587|BEHAVIORAL|Treatment as usual|counseling, psychoeducation
48679131|NCT04831905|DEVICE|Micro-wave ablation|Micro-wave ablation
48679132|NCT03886493|DRUG|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
48679133|NCT02692963|BIOLOGICAL|BCG vaccination|BCG vaccine InterVax
47993551|NCT06460064|BIOLOGICAL|DSP-0546LP 2.5 ug|2 administrations at 3-week intervals.
47993552|NCT06460064|BIOLOGICAL|DSP-0546LP 5 ug|2 administrations at 3-week intervals.
47993553|NCT06460064|BIOLOGICAL|DSP-0546LP 10 ug|2 administrations at 3-week intervals.
47993554|NCT06460064|BIOLOGICAL|Placebo|2 administrations at 3-week intervals.
47993555|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 100mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 1
48679134|NCT05976659|DEVICE|Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)|Transcranial electrical stimulation (tES), via direct and alternating current, will be administered to the participants in their home by trained caregivers/study companions administrators. All training and intervention sessions will take place in the participant's home.
48152901|NCT04194671|BIOLOGICAL|Mesenchymal stem cells|In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7
48152902|NCT04194671|OTHER|Saline|In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
48152903|NCT02465866|DRUG|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
48152904|NCT02465866|DRUG|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
48152905|NCT02465866|DRUG|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
48152906|NCT02465866|DRUG|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
48364153|NCT03119428|DRUG|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
48364154|NCT02809872|OTHER|Diagnostic Thoracic Ultrasound|
48364155|NCT01265511|DRUG|Placebo|Oral tablets given bid for 28 days
48511559|NCT04556227|BEHAVIORAL|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
48511560|NCT06633601|DEVICE|MR-Guided Focused Ultrasound Technology|MRI Guidance for use with High-intensity-focused ultrasound (HIFUS)
48511561|NCT06633601|DRUG|Definity Suspension for Injection|Microbubble contrast agents for ultrasound
48511562|NCT05349045|DRUG|an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor|This is an observational study
48679135|NCT01016067|DEVICE|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
47993556|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 800mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 2
47993557|NCT06229496|COMBINATION_PRODUCT|Gemcitabine 1000mg/m2 + Nab-paclitaxel 125mg/m2 + S-1 (dose according to BSA)|Dose escalation study-dose level 3
48511563|NCT06235827|DIETARY_SUPPLEMENT|Green tean group|Patients in Group A will have to consume two cups (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes. They are only allowed to consume as hot drink, not for iced tea. Any sweetener or sugar is not allowed to mix in the drink. The green tea bag will be distributed to patient at beginning of research and at every visit. Patient will be reminded weekly using text messages or phone call by a research assistant for green tea consumption.
48511564|NCT06235827|DIETARY_SUPPLEMENT|Control group|Patients in Group B will not be consuming green tea during 6 months of study period.
47993558|NCT03161431|DRUG|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
47993559|NCT03161431|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
48152907|NCT04967092|DRUG|Modified Xiao-Feng Powder + Antiallergics|Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
48511565|NCT04892537|DEVICE|Coronary Sinus Reducer|Coronary Sinus Reducer implantation according to standard clinical protocols
48679136|NCT01016067|PROCEDURE|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
48679137|NCT00355368|DRUG|Succinylcholine|1mg/kg iv
48679138|NCT00355368|DRUG|Rocuronium|0.6mg/kg iv
48152908|NCT04967092|OTHER|Placebo + Antiallergics|Placebo granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
48364156|NCT01265511|DRUG|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
48364157|NCT01265511|DRUG|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
48364158|NCT01265511|DRUG|Copegus|tablets given bid for up to 48 weeks
48679139|NCT01864083|PROCEDURE|Positron Emission Tomography (PET)|
48679140|NCT01864083|DRUG|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
48364159|NCT01302340|DRUG|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
48679141|NCT01864083|PROCEDURE|Positron emission mammography (PEM) When available|
48679142|NCT01864083|PROCEDURE|MR|
48679143|NCT06426446|DEVICE|Withings Body Comp Pro|Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)
48511566|NCT04892537|PROCEDURE|Placebo Procedure|A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation
48679144|NCT05412043|BEHAVIORAL|Dance therapy|The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.
48511567|NCT05056038|PROCEDURE|Lateral Quadratus Lumborum block|Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.
48152909|NCT05839743|OTHER|Aerobic Exercise|The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.
48511568|NCT05056038|PROCEDURE|Posterior Quadratus Lumborum Block|In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
48511569|NCT00073697|DRUG|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
48511570|NCT00073697|BEHAVIORAL|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
48511571|NCT00073697|OTHER|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
48511572|NCT00549744|DRUG|GSK256066|
48511573|NCT06551766|DEVICE|Photosensitive hydrogel|In the photosensitive hydrogel group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by photosensitive hydrogel.
48511574|NCT06551766|DEVICE|6-0 absorbable stitches|In the suture fixation group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by two stitches using 6-0 absorbable wire.
48511575|NCT01741168|OTHER|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
48511576|NCT01741168|OTHER|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
48511577|NCT04429308|PROCEDURE|Photodynamic Therapy|Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)
48511578|NCT04429308|DRUG|Chemical Peels|Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
48511579|NCT03150407|DEVICE|VR101 Device (Efficacy)|Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days
48679145|NCT05412043|OTHER|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability|The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
48679146|NCT00000906|DRUG|Ritonavir|
48511580|NCT03150407|OTHER|Sham Control Ring|Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days
47993560|NCT02461225|DEVICE|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
48679147|NCT00000906|DRUG|Saquinavir|
47993561|NCT02461225|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
47993562|NCT00229255|OTHER|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
47993563|NCT00229255|OTHER|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
47993564|NCT00539578|DRUG|MK0777|Duration of Treatment: 4 weeks
47993565|NCT00539578|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
47993566|NCT00425867|BEHAVIORAL|PAR1 polymoprhisms and placental invasion|
47993567|NCT06372015|OTHER|Nutritional Approach|Nutritional Approach
47993568|NCT06372015|OTHER|Surgery Approach|Bariatric surgery
48679148|NCT00000906|DRUG|Methadone hydrochloride|
48679149|NCT02737319|DRUG|Rosuvastatin|40 mg of rosuvastatin before angioplasty
48679150|NCT03417583|OTHER|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
48679151|NCT00227084|DRUG|Arista AH hemostasis powder|
48679152|NCT02314676|BIOLOGICAL|PEG-somatropin|
48679153|NCT00052910|DRUG|cisplatin|Given IV
48679154|NCT00052910|DRUG|epirubicin hydrochloride|Given IV
48679155|NCT00052910|DRUG|fluorouracil|Given IV
48679156|NCT00052910|DRUG|leucovorin calcium|Given IV
48679157|NCT00052910|RADIATION|radiation therapy|Given 5 days a week for 5 weeks
48679158|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
48679159|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
48679160|NCT06139809|PROCEDURE|Intubation|Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
48679161|NCT02457247|DRUG|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
48679162|NCT02457247|DRUG|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
48679163|NCT02457247|DRUG|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
47993569|NCT04537000|DIAGNOSTIC_TEST|clinical condition score|A score is firstly identified using a clinical condition scale including the concentration of inspired oxygen to maintain the percutaneous oxygen saturation (SPO2)≧95%, the fusion rate of catecholamine drugs to maintain normal blood pressure, the nasopharyngeal temperature and the oxygen saturation of central venous blood. The score was graded as 0, 1 and 2 points according to the patient's clinical condition. The score identified from the scale plus 7 finally makes the clinical condition score. If the score is higher than 10, it will be replaced with 10. That is to say, the highest clinical condition score is 10. If the clinical condition score≦Hb, blood red cell transfusion will not be started. If the clinical condition score\>Hb, blood red cell transfusion will be started, and the volume will be calculated using the following formulation, transfusion volume(ml)=(clinical condition score - Hb)\*body weight \*5.
48679164|NCT00937495|DRUG|vorinostat|400 mg given PO
48679165|NCT00937495|DRUG|bortezomib|1.3 mg/m\^2 given IV
48679166|NCT04649658|BEHAVIORAL|Prone position|Prone position maintained at least 3 hours/day
47993570|NCT01653496|PROCEDURE|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
47993571|NCT02250755|OTHER|MRI T1 T2 sequences|MRI
47993572|NCT03444922|OTHER|Placebo|Ingestion of Placebo
47993573|NCT03444922|OTHER|BPA 4 ug/kg BW|Oral BPA ingestion of 4 ug/kg BW
47993574|NCT03444922|OTHER|BPA 50 ug/kg BW|Oral BPA ingestion of 50 ug/kg BW
48679167|NCT01280786|DRUG|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
48679168|NCT06167967|DIAGNOSTIC_TEST|ctDNA methylation|A blood-based circulating tumor DNA methylation assay that uses 6 different methylation markers, SEPT9 region1, SEPT9 region2, BCAT1, IKZF1, BCAN and VAV3.
48679169|NCT06167967|DIAGNOSTIC_TEST|standard treatment|This group was treated according to standard procedure
48679170|NCT05632237|BEHAVIORAL|Family strengthening program|"Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting."
48679171|NCT00118274|BIOLOGICAL|incomplete Freund's adjuvant|Given intradermally and subcutaneously
48679172|NCT00118274|BIOLOGICAL|melanoma helper peptide vaccine|Given intradermally and subcutaneously
48679173|NCT00118274|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
48679174|NCT00118274|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally and subcutaneously
48679175|NCT00118274|DRUG|cyclophosphamide|Given IV
48679176|NCT00330369|DRUG|Darusentan|Darusentan administered orally once daily
48679177|NCT00330369|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
48679178|NCT03436498|DRUG|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
48679179|NCT03436498|DRUG|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
48679180|NCT01728285|DEVICE|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
48679181|NCT00222976|DRUG|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
47993575|NCT06129721|PROCEDURE|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
47993576|NCT05750355|DRUG|TPN171H 10 mg Group|6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
47993577|NCT05750355|DRUG|TPN171H 30 mg Group|6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
47993578|NCT05750355|DRUG|TPN171H 40 mg Group|6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
48364160|NCT01302340|DRUG|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
48364161|NCT01302340|DRUG|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
48364162|NCT05976711|DEVICE|Magnetic resonance imaging (with PROUD software)|Philips Ingenia 3.0T MR system with in-house developed PROUD software
47993579|NCT05750355|DRUG|TPN171H 50 mg Group|6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
48679182|NCT02336061|BEHAVIORAL|Evaluation of gender differences on the psychosocial and economic impact.|
47993580|NCT05990101|BEHAVIORAL|Awake prone position (APP)|Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
47993581|NCT02526888|DRUG|ACT-541468|Oral capsule (25 mg) as single dose
47993582|NCT02526888|DRUG|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
47993583|NCT01312818|DRUG|Bortezomib|1.3 mg/m\^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
47993584|NCT01312818|DRUG|Vorinostat|180 mg/m\^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
47993585|NCT01312818|DRUG|Dexamethasone|6 mg/m\^2 by mouth (PO) divided twice a day (BID) on days 4-15.
47993586|NCT01312818|DRUG|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
47993587|NCT01312818|DRUG|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for \>18 years on Days 1-16."
47993588|NCT02177279|OTHER|Visit A high wheat bran|
47993589|NCT02177279|OTHER|Visit B normal wheat bran|
47993590|NCT02177279|OTHER|Follow up normal (8days) and high (1day) bran consumption|
48152910|NCT05839743|OTHER|Balance Exercise|Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.
47993591|NCT00847457|BEHAVIORAL|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
47993592|NCT00847457|BEHAVIORAL|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
47993593|NCT05783687|DIAGNOSTIC_TEST|NCC-Sp Assay|Orphalan has developed a new NCC speciation assay (NCC-Sp) using liquid chromatography inductively coupled plasma mass spectroscopy (LC-ICP-MS) to measure serum copper and ceruloplasmin bound copper from which non ceruloplasmin bound copper (NCC) is estimated.
47993594|NCT01760512|PROCEDURE|Gastric bypass|Gastric bypass
47993595|NCT04843748|DEVICE|cataract surgery and intraocular lens implantation - both eyes|cataract surgery and intraocular lens implantation for both eyes
47993596|NCT02225743|OTHER|Observation Of Temperature|Participants temperature will be recorded perioperatively.
47993597|NCT01048021|PROCEDURE|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
48152911|NCT05839743|OTHER|Combined Exercise|In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
48152912|NCT05088122|OTHER|no intervention|no intervention, not applicable
48364163|NCT02996162|DEVICE|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
48364164|NCT02996162|DEVICE|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
48679183|NCT04603469|OTHER|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
48679184|NCT00755807|DRUG|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
48679185|NCT00755807|DRUG|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
48679186|NCT00825994|DRUG|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]
48679187|NCT00134615|BEHAVIORAL|RQP patient health education module|
48679188|NCT01798381|DIETARY_SUPPLEMENT|Essential fatty acids|
48679189|NCT06397378|OTHER|short videos related to HPV vaccines|We will develop 4 new videos and revise 2 existing videos and hope to increase college students\&#39; intention to receive HPV vaccines.
48679190|NCT06397378|OTHER|CDC HPV Fact Sheet|This intervention is an educational information that CDC provided to explain why you should receive HPV vaccines. https://www.cdc.gov/std/hpv/stdfact-hpv.htm
48152913|NCT05172843|PROCEDURE|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
48152914|NCT05172843|BEHAVIORAL|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
47993598|NCT03822247|PROCEDURE|Multidisciplinary Recovery Program|"Preoperative care:~* Patient's education~* Providing respiratory training~* Assessment of nutritional status~* Application of compression stockings~* Thromboembolism prophylaxis by low molecular weighted heparin~* Induction of hemodynamic support 12 hours before the surgery~* Oral carbohydrate solution loading until 2 hours before the surgery~Intraoperative care:~* Maintaining normothermia~* Multimodal prevention of postoperative nausea and vomiting~* Use of spinal anesthesia~* Prevention of excessive blood loss~* Local anesthetic infiltration~Postoperative care:~* Active pain control~* Early mobilization~* Early onset of oral nutrition~* Early delirium detection~* Application of compression stockings"
48152915|NCT03999294|OTHER|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
48364165|NCT03942029|DRUG|LY3154207 Capsule|Administered orally as capsule
48364166|NCT03942029|DRUG|LY3154207 Tablet|Administered orally as tablet
48364167|NCT03942029|DRUG|Placebo|Administered orally as tablet
48364168|NCT03942029|DRUG|Fluconazole Tablet|Administered orally as tablet
48679191|NCT00153595|DRUG|EWO1|
48679192|NCT00331916|DRUG|quinolone|
48679193|NCT06251622|OTHER|Volumetric ultrasound of the quadriceps and fitting of an accelerometer|The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
48679194|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
48679195|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
48679196|NCT06292377|DIAGNOSTIC_TEST|ECG|An electrocardiogram (ECG) is a simple, non-invasive test that records the electrical activity of the heart.
48364169|NCT00273715|PROCEDURE|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
48679197|NCT06292377|DIAGNOSTIC_TEST|Transthoracic echography (TTE)|A transthoracic echocardiogram (TTE) is a test that uses ultrasound (sound waves) to create images of the heart.
48679198|NCT06292377|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will include: complete blood count, serum creatinine and electrolytes, liver enzymes, fast lipid profile, glucose, HbA1C, thyroid-stimulating hormone (TSH), CRP, iron status, cardiac troponin (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP).
48679199|NCT01247064|DRUG|Nebulized 3% saline|4 mL of nebulized 3% saline once
48679200|NCT01247064|DRUG|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
48679201|NCT06338930|OTHER|Remote monitoring|The intervention group will enroll in the remote monitoring programme. In the standard of care patients visit the outpatient clinic every six months. Patients in the control group will remain in the six-monthly follow-up programma, whereas patients in the intervention group will only visit the outpatient clinic two-yearly. The latter group will be monitored remotely via questionnaires, calprotectin analysis (using CalproSmart) and blood analyses. An IBD nurse will evaluate all incomming data and undertake action if necessary.
48679202|NCT02574039|DIETARY_SUPPLEMENT|Oat bran|66g oat bran made up in 350ml skimmed milk
48679203|NCT02574039|DIETARY_SUPPLEMENT|refined grain|refined grain product and 350ml skimmed milk
48679204|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
48679205|NCT00429871|DRUG|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
48679206|NCT00429871|DRUG|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
48679207|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
48679208|NCT04794868|DIAGNOSTIC_TEST|CCTA-derived high risk plaque characteristics|Presence of CCTA-derived high risk plaque characteristics
48679209|NCT04794868|DIAGNOSTIC_TEST|CFD-derived hemodynamic parameters|CFD-derived hemodynamic parameters
48679210|NCT00736112|OTHER|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
48679211|NCT00736112|PROCEDURE|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
48679212|NCT00736112|PROCEDURE|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
48679213|NCT05938348|BEHAVIORAL|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
48152916|NCT04162977|BEHAVIORAL|Personality-targeted Interventions|The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
48679214|NCT03175731|DRUG|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
48679215|NCT03175731|DRUG|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
48152917|NCT05848102|DRUG|dapagliflozin|FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
48679216|NCT04677543|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
48364170|NCT00273715|PROCEDURE|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
48679217|NCT04677543|DRUG|Azithromycin|Oral tablet
48679218|NCT04677543|DRUG|Ethambutol|Oral tablet
48679219|NCT04677543|DRUG|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
48679220|NCT02544347|OTHER|gingival crevicular fluid|gingival crevicular fluid was collected
48679221|NCT02544347|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
48679222|NCT03116997|DRUG|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
48679223|NCT03116997|DRUG|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
48679224|NCT00153413|BEHAVIORAL|Cookin' Up Health|A brief nutrition intervention designed to improve dietary habits
48364171|NCT06376942|DRUG|Glycopyrronium|Nebulized glycopyrronium 50 mcg
48679225|NCT04157881|DRUG|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
48679226|NCT04157881|DRUG|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
48679227|NCT02955888|DRUG|PBI4050|Investigational Medicinal Product
48679228|NCT02955888|DRUG|Placebo|Comparator
48679229|NCT04750863|OTHER|diagnosis criteria performance|
48679230|NCT01650948|DEVICE|RetnaGene AMD LDT|
48679231|NCT05068986|BEHAVIORAL|Asthma education|All the study participants were subjected to an educational asthma program for 3 months for providing parents and children with information and skills to manage their asthma ,which was presented from the the first session, through providing a written asthma action plan, information about avoiding triggers, training in the correct use of medicines, including inhaler technique, information and support to maximize adherence . All patients were followed up by a phone call every 2 weeks and follow up visit monthly to confirm compliance to the educational program
48679232|NCT00561522|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
48679233|NCT00561522|OTHER|No other preventive treatment|No other preventive treatment
48679234|NCT03704038|PROCEDURE|PEEP level|Patients will have variable PEEP levels and will be monitored
48679235|NCT01101672|PROCEDURE|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
48679236|NCT01101672|PROCEDURE|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
48679237|NCT00648258|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
48679238|NCT00648258|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
48511581|NCT03150407|DEVICE|VR101 Device (Safety)|Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
48364172|NCT06376942|DRUG|Ipratropium|Nebulized iptratropium 500 mcg
48364173|NCT06376942|OTHER|Saline|0.9% saline 2 ml
48364174|NCT01734967|DEVICE|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
48511582|NCT00003627|DRUG|cisplatin|
48511583|NCT00003627|DRUG|fluorouracil|
48511584|NCT00003627|RADIATION|radiation therapy|
48511585|NCT03513133|BEHAVIORAL|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
48511586|NCT04023227|DRUG|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
48511587|NCT04023227|DRUG|Enalapril|5 mg and 10 mg will be available for dose adjustments.
48511588|NCT05320887|OTHER|Normal Nicotine Content Vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
48511589|NCT05320887|OTHER|Normal nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
48511590|NCT05320887|OTHER|Low nicotine content vape with all flavor e-liquids|Participants are randomly assigned to the order of each marketplace Group
48511591|NCT05320887|OTHER|Low nicotine content vape with tobacco e-liquids|Participants are randomly assigned to the order of each marketplace Group
48511592|NCT06632678|OTHER|behavior, procedure, diet, exercise, device, education, and any other|Any type of intervention except pharmacological interventions (drugs, biologicals, genetics)
48511593|NCT02932410|DRUG|Macitentan|Dispersible tablet; Oral use
48511594|NCT02932410|OTHER|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and IV/SC prostanoids.
48511595|NCT03552848|BIOLOGICAL|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
48679239|NCT06199128|DIETARY_SUPPLEMENT|carboxymethyl β-glucan|It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
48679240|NCT04855630|DEVICE|DREEM 2 Headband|Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).
48679241|NCT04855630|OTHER|Exercise Routine|Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.
48679242|NCT06239038|PROCEDURE|total knee arthroplasty|total knee arthroplasty surgery with Police Arthroplasty joint academy center(PAJAC) Subvastus Approach
48679243|NCT00700908|BEHAVIORAL|automated telephone intervention vs. usual care|
48679244|NCT06424821|DRUG|Cadonilimab|Cadonilimab + chemotherapy
48679245|NCT04624308|DRUG|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
48679246|NCT02727322|DRUG|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
48679247|NCT02727322|DRUG|Placebo|Placebo
48679248|NCT05415553|PROCEDURE|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
48679249|NCT05415553|PROCEDURE|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
48511596|NCT01325844|PROCEDURE|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
48679250|NCT02065492|DRUG|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
48511597|NCT05435937|BEHAVIORAL|Partnering for change (P4C-Swe)|"P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation."
48511598|NCT05435937|BEHAVIORAL|Treatment as usual|Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
48679251|NCT02065492|DRUG|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
48679252|NCT02081313|OTHER|Biopsy|
48679253|NCT02081313|OTHER|Blood sample|
48679254|NCT06250608|DEVICE|Pulse oximeter, NIRSITX|It is a device that non-invasively continuously monitors blood oxygen saturation (rSO2) in localized areas of the brain. This device is attached to patients with symptoms suspected of stroke or diagnosed with stroke to continuously monitor the level of oxygen supply to the brain.
48679255|NCT02770027|DRUG|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
48679256|NCT02770027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
48679257|NCT03941418|DIETARY_SUPPLEMENT|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
48679258|NCT03941418|DIETARY_SUPPLEMENT|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
48679259|NCT03751826|OTHER|Incentivised network delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
48679260|NCT03751826|OTHER|Peer navigator delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
48679261|NCT03751826|OTHER|standard of care|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
48679262|NCT02955238|BEHAVIORAL|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
48679263|NCT02789085|DEVICE|ULF TENS stimulation|
48679264|NCT03154476|DRUG|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
48679265|NCT03154476|DRUG|Placebo|Placebo capsules matching study drug
48679266|NCT04313738|OTHER|Assigned Interventions|Home visit, health education
48679267|NCT00222144|DRUG|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
48679268|NCT03759600|DRUG|Niraparib|Niraparib capsule
48679269|NCT05155124|DRUG|Cetuximab + trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
48679270|NCT02358993|DRUG|methenamine hippurate|A urinary antiseptic used for prevention of UTI
48679271|NCT02358993|DRUG|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
48679272|NCT00002237|DRUG|Peldesine|
48679273|NCT02869672|BIOLOGICAL|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
48152918|NCT02674971|BEHAVIORAL|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
48364175|NCT01734967|PROCEDURE|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
48679274|NCT02869672|BIOLOGICAL|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
48679275|NCT05745649|OTHER|Resistance exercises|Resistance exercises
48679276|NCT05745649|OTHER|Ankle weights|Ankle weights
48679277|NCT03271164|DEVICE|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
48679278|NCT03271164|OTHER|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
48679279|NCT03486782|DEVICE|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
48679280|NCT03486782|DEVICE|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
48679281|NCT03486782|BEHAVIORAL|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
48679282|NCT05029310|DRUG|Patiromer Oral Product|interaction study
48511599|NCT01115478|DIETARY_SUPPLEMENT|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
48679283|NCT01158443|BEHAVIORAL|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
48679284|NCT01158443|BEHAVIORAL|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
48679285|NCT00992056|DRUG|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
48679286|NCT00992056|DRUG|Metoprolol|Metoprolol 50 mg titrated to 100 mg
48679287|NCT00886418|DRUG|muscle relaxant|muscle relaxant administration throughout anesthesia
48679288|NCT00886418|DRUG|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
48679289|NCT05618756|DIETARY_SUPPLEMENT|Acute oral CBD supplementation|1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
48679290|NCT05618756|DIETARY_SUPPLEMENT|Acute oral placebo supplementation|1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
48679291|NCT04868942|OTHER|Assisting to the event|"Participant will attend a concert respecting the Following measures :~* Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~* Health mediation, information on barrier measures~* Physical distancing (sitting participation)~* Person flow management"
48679292|NCT04495946|BEHAVIORAL|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
48679293|NCT04495946|BEHAVIORAL|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
48679294|NCT05274412|OTHER|hypotension prediction index(HPI)|Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI \< 85; pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
48152919|NCT01648699|DRUG|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
48152920|NCT01177644|DRUG|PDS 1.0|
48152921|NCT01589211|BEHAVIORAL|Brief advice|Brief advice of about 10 min accompanied by self-help material
48152922|NCT01589211|BEHAVIORAL|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
48152923|NCT01589211|BEHAVIORAL|Standard cessation course|Cessation course over 6 dates. Group setting.
48152924|NCT03957759|DIAGNOSTIC_TEST|Structured self-monitoring during an altitude ascent and stay at high altitude|Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
48152925|NCT01740284|DRUG|Grazax + Aerius|
48152926|NCT01740284|DRUG|Grazax + placebo|
48152927|NCT00427544|DRUG|PRA-027|
48679295|NCT05274412|OTHER|ordinary goal-directed hemodynamic therapy|Keep pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
48152928|NCT02707302|DEVICE|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
48152929|NCT02707302|PROCEDURE|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
48152930|NCT06451705|DRUG|PECS II block|Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg
48152931|NCT06451705|DRUG|LIA|Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
48679296|NCT03814356|DRUG|Methylphenidate|IV MPH
48679297|NCT01074073|DRUG|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
48679298|NCT04937634|DRUG|Melphalan|The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes.
48679299|NCT06004297|PROCEDURE|ACL reconstruction|performed arthroscopically
48679300|NCT04797377|BIOLOGICAL|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
48679301|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula A|
48679302|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets|
48152932|NCT00014235|DRUG|fludarabine phosphate|Given IV
48152933|NCT00014235|RADIATION|total-body irradiation|Undergo TBI
48152934|NCT00014235|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
48364176|NCT04542525|DEVICE|ACRYSOF IQ PanOptix Toric Trifocal IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism
48679303|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula B|
48364177|NCT04542525|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use
48679304|NCT00001964|DRUG|Cyclosporine A|Cyclosporine A
48679305|NCT00001964|DRUG|ATG|ATG
48364178|NCT03045497|DRUG|Perflutren Lipid Microspheres|Given IV
48364179|NCT03045497|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
48679306|NCT00001964|DRUG|MMF|MMF
48679307|NCT04821934|OTHER|TR|"TR is a specific remote tele rehabilitation program on exercise activity managed by the physiotherapist (PT) at home, this is the experimental group. PT will explain the rehabilitation program at hospital discharge by the use of a brochure and videos. TR will include an early exercise re-conditioning program \[aerobic exercise at the free body (with or without tools), cyclette and walking with a pedometer\] comprising 20 sessions of 60 minutes/day, 6 out of 7 days to be performed at home, for one month after discharge. The sessions will be self-managed by the patients 4 times a week and an expert PT will remotely supervise 2 times a week through a dedicated platform. The program will be progressively incremental and divided into 4 different levels of intensity (0- 3).~In addition to this specific rehabilitation program, the patients will be followed by a nurse tutor once a day for two weeks and once a week for a further two weeks in a program of Telesurveillance."
47993599|NCT05419076|RADIATION|Stereotactic Radiosurgery|All participants will undergo MSK standard SRS. A CT simulation will be performed per institutional standards, typically with contrast unless a contraindication exists. A contrast-enhanced MRI with 1mm slices will be fused to the CT simulation scan for the purposes of SRS planning. The SRS GTV will be considered the visible tumor on MRI and CT contrast enhanced studies. An expansion of 1-2mm will be used to create the PTV. Radiation dose may be between 16Gy and 30Gy in 1 to 5 fractions, per the discretion of the treating radiation oncologist. Participants with multiple lesions may receive different doses to each lesion per the discretion of the treating radiation oncologist. Concurrent treatment to other body sites is permitted.
48152935|NCT00014235|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
48152936|NCT00014235|DRUG|cyclosporine|Given PO or IV
48152937|NCT00014235|DRUG|mycophenolate mofetil|Given IV or PO
48152938|NCT00014235|OTHER|laboratory biomarker analysis|Correlative studies
48152939|NCT05541185|BIOLOGICAL|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
48152940|NCT05541185|BIOLOGICAL|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
48364180|NCT03045497|DEVICE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
48364181|NCT01719042|DRUG|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
48364182|NCT01719042|DIETARY_SUPPLEMENT|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
48364183|NCT01293123|DRUG|Raltegravir|raltegravir 400 mg PO twice daily
48364184|NCT01293123|DRUG|Efavirenz|efavirenz 600 mg PO once daily
48364185|NCT02683135|BEHAVIORAL|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
48364186|NCT02683135|BEHAVIORAL|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
48679308|NCT04821934|OTHER|TSu|"The patients of this group will perform a usual Telesurveillance and will be considered as control group.~All patients, at discharge from the hospital, will be provided with a finger pulse oximeter and a dedicated application (app) on their personal smartphone and will be advised on free physical activity to be performed at home. The nurse will check through scheduled calls (once a day for two weeks and once a week for a further two weeks) the patient's health condition, vital parameters and drugs administration. Patients will be able to contact the nurse at each time, in case of specific need, out of the scheduled call, 7/7 days.~A follow up by phone will be planned by nurse tutor at 2 months from the end of the study."
48679309|NCT04475159|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)|Pressurized Intraperitoneal Aerosol Chemotherapy will be delivered to the abdominal cavity by means of laparoscopy.
48679310|NCT03037866|BEHAVIORAL|LifeSkills Training for College|The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
48152941|NCT05541185|BIOLOGICAL|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
47993600|NCT05419076|PROCEDURE|Cerebrospinal fluid collection|All participants will undergo lumbar puncture for CSF collection at study enrollment.. Lumbar punctures will be performed by clinical staff in neurology or neuroradiology, per the discretion of the treating radiation oncologist, as dictated by scheduling limitations and expected clinical difficulty in obtaining a sample (e.g. requiring fluoroscopic guidance), with input from the PI, neurology, and/or neuroradiology as necessary. Participants will be encouraged to undergo repeat lumbar puncture for CSF collection at 3 months (+/- 4 weeks), and at the time of CNS disease progression, though these latter timepoints are not required. CSF cytology will be evaluated.
47993601|NCT05819762|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab LS screening panel on a specified Flow Cytometry
48364187|NCT02683135|BEHAVIORAL|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning \~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
48364188|NCT05135494|OTHER|Inspiratory Muscle Training|"The Experimental Group will perform IMT which includes training of the inspiratory muscles with the PowerBreath Medic Plus regulated at 75% of the subjects' maximal inspiratory pressure (MIP) values, five times/week over five weeks 5 sets of 5 repetitions with 1 set increasing each week.~They will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA."
48364189|NCT05135494|OTHER|Control|The control group will participate of the rehabilitation program that will consist of an average of 8 weekly sessions of physiotherapy and speech therapy, totaling 40 sessions. They will also perform 150 to 180 minutes of aerobic exercise of their choice and guidance on behavioral measures to manage OSA.
48364190|NCT02373176|DRUG|[14C]PRC 4016 (Icosabutate)|Single oral dose
48152942|NCT04992884|DEVICE|Gastric Alimetry|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
48152943|NCT04186819|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
48364191|NCT02119780|DEVICE|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
48364192|NCT02119780|DEVICE|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
48364193|NCT00515021|DRUG|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
48364194|NCT00515021|DRUG|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
48364195|NCT01710215|OTHER|FIT Screening Strategy|"* Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~* Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
47993602|NCT03879655|DRUG|VTS-270|Administered IT via LP infusion of VTS-270
47993603|NCT01578889|BIOLOGICAL|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
48679311|NCT03111004|OTHER|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
48679312|NCT03317743|DRUG|NOV140101 (IDX-1197)|The dose levels will be escalated following a 3+3 dose escalation scheme.
48679313|NCT06224907|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
48679314|NCT00682175|OTHER|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
48679315|NCT05124717|DRUG|Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
48679316|NCT05124717|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orallyn with 240 mL of water.
48679317|NCT02887157|DEVICE|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
48679318|NCT02887157|OTHER|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
48511600|NCT01115478|DIETARY_SUPPLEMENT|Zinc|Daily oral dose of 25 mg from enrollment until delivery
48511601|NCT01115478|OTHER|Placebo|Daily oral dose from enrollment until delivery
48152944|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
48679319|NCT02887157|OTHER|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
48679320|NCT03215498|DRUG|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
48679321|NCT03215498|DRUG|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
48679322|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 1|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
48364196|NCT01710215|OTHER|Colon Screening Strategy|"* Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~* Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~* Centralized processes to promote guideline-based follow up."
48364197|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
48364198|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
48364199|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
47993604|NCT01578889|BIOLOGICAL|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
47993605|NCT01578889|BIOLOGICAL|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10\^8 plaque-forming units (PFUs) administered as 5x10\^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
47993606|NCT01578889|BIOLOGICAL|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
47993607|NCT01578889|DEVICE|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
47993608|NCT03876964|DEVICE|Transcatheter Aortic Valve Replacement|Minimally invasive replacement of the aortic valve through a catheter.
48364200|NCT00642343|BEHAVIORAL|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
48364201|NCT04833972|OTHER|Survey questionnaire|Each version of the questionnaire has the same questions about perceived norms about substance use in the community but differs in how the response options are offered.
48364202|NCT04914091|OTHER|Semi-structured interviews and self-administered questionnaires|Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
48152945|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
48152946|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
48364203|NCT05875909|PROCEDURE|corneal flap transplantation|Patients with macular holes underwent a 25-gauge, 3-port pars plana vitrectomy . Fluid-air exchange was performed in patients with pathologic myopia suffering from macular holes with retinal detachment. We used a flute needle to drain the subretinal fluid. A corneal flap was obtained by small incision lenticule extraction (SMILE). Stripping pliers were applied to spread corneal flap over the macular hole. A drop of fresh autologous whole blood was dripped over the corneal flap to immobilise it. The vitreous cavity was filled with 14% perfluoropropane (C3F8) for macular holes with retinal detachment . The surgical incision was self-closed or sutured with a 6-0 polyglactin 910 suture . The patients were instructed to maintain a prone position for 2 weeks postoperatively.
48364204|NCT01787123|DRUG|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
48679323|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 2|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
48152947|NCT06505499|OTHER|Gait Profile Score|Gait Profile Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009).
48364205|NCT01787123|DRUG|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
48364206|NCT00005066|DRUG|O6-benzylguanine|
48364207|NCT00005066|DRUG|carmustine|
48364208|NCT02815475|DIETARY_SUPPLEMENT|Placebo comparator|
48679324|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 3|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
48679325|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 4|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
48679326|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 5|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
48679327|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 1|Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
48364209|NCT02815475|DIETARY_SUPPLEMENT|Curcumin|
47993609|NCT01245270|DIETARY_SUPPLEMENT|Bilberry capsule first, then control cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
47993610|NCT01245270|DIETARY_SUPPLEMENT|Control capsule first then bilberry cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
47993611|NCT03492255|DRUG|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
48152948|NCT06505499|OTHER|Gait Visual Score|Gait Visual Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009)
48152949|NCT02848898|DEVICE|Equistasi|
48152950|NCT02848898|OTHER|Placebo|
48364210|NCT02815475|DIETARY_SUPPLEMENT|Turmeric powder|
48364211|NCT01683058|DRUG|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
48364212|NCT00531310|DRUG|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
48364213|NCT03915782|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of \[5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
48511602|NCT02594670|OTHER|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
48511603|NCT02594670|OTHER|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
48679328|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 2|Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
48679329|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 3|Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
48679330|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 4|Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
48679331|NCT06393842|DEVICE|Cardiopulmonary Management Wearable Device|Fluid status and congestion can be determined by the CPM wearable device and correlates with non-invasive measures and biochemical markers of congestion and changes in congestion.
48679332|NCT05563662|PROCEDURE|Cardiac surgery|Patients with infective endocarditis undergoing open heart surgery
48679333|NCT04408677|DEVICE|Zilia Ocular|Measurement of the oxygen saturation in the eye fundus
48679334|NCT05186935|DEVICE|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
48679335|NCT01411423|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
48679336|NCT01559415|OTHER|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
48679337|NCT01559415|OTHER|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
48679338|NCT02852967|DRUG|Belumosudil|
48679339|NCT02852967|DRUG|Placebo|Placebo tablets matching belumosudil
48679340|NCT06312163|DEVICE|The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.|The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).
48679341|NCT01128725|OTHER|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~* psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~* Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
48679342|NCT00644943|DRUG|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
48679343|NCT00644943|DRUG|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
48679344|NCT01321853|OTHER|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
48679345|NCT01321853|OTHER|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
48679346|NCT00005590|DRUG|levofloxacin|
48679347|NCT04301661|OTHER|Blood collection|Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
48679348|NCT04301661|DRUG|Abacavir/lamivudine|Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.
48679349|NCT04301661|DRUG|Tenofovir alafenamide/emtricitabine|Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
48679350|NCT04301661|DRUG|Switch|Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
48679351|NCT04944771|DRUG|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
48679352|NCT04944771|DRUG|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
48679353|NCT01658553|DRUG|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
48679354|NCT03680534|PROCEDURE|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
48511604|NCT02594670|OTHER|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
48679355|NCT05211349|OTHER|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
48679356|NCT05211349|OTHER|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
48679357|NCT05211349|OTHER|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
47993612|NCT03492255|DRUG|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
47993613|NCT03492255|DRUG|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
48364214|NCT03915782|DEVICE|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of \[5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation\] started as soon as possible after Magnetic Resonance Imaging (MRI).
48679358|NCT05211349|OTHER|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
48679359|NCT05211349|OTHER|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
48679360|NCT00781638|DEVICE|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
47993614|NCT03492255|DRUG|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
48679361|NCT03272555|OTHER|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
48679362|NCT03938818|BEHAVIORAL|Tu'Washindi intervention|"The intervention includes the following components:~1. PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~2. Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~3. Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
47993615|NCT04283162|DRUG|Calcium Dobesilate|use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
47993616|NCT04283162|OTHER|conventional treatment|maintain lifestyle habits and the usual treatment
47993617|NCT02687984|DRUG|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
48511605|NCT00364000|DRUG|Calcium acetate|Calcium acetate in 240 chronic HD patients
47993618|NCT06291051|DEVICE|Electrical spinal cord stimulation|electrical spinal cord stimulation in Parkinson's patients presenting with painful camptocormia
47993619|NCT00082654|PROCEDURE|psychosocial assessment and care|
47993620|NCT03822208|BIOLOGICAL|AL003|"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"
48152951|NCT02033343|RADIATION|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
47993621|NCT03822208|OTHER|Saline Solution|Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
47993622|NCT00212823|DRUG|almotriptan malate|
47993623|NCT00000999|DRUG|Zidovudine|
47993624|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
47993625|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
47993626|NCT01486654|DEVICE|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
48364215|NCT02811367|DEVICE|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
48364216|NCT03270527|OTHER|High SFA diet (Diet 1)|'Diet 1' will contain \~18% of its total energy as SFA .
48364217|NCT03270527|OTHER|Low SFA diet (Diet 2)|'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
48364218|NCT01365104|DRUG|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
48364219|NCT03907072|DRUG|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
48511606|NCT00364000|DRUG|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
48679363|NCT03938818|OTHER|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
48679364|NCT00469833|DRUG|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
48679365|NCT01737762|BIOLOGICAL|HP802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
48679366|NCT01737762|BIOLOGICAL|Vehicle|
48679367|NCT04739930|PROCEDURE|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
48679368|NCT04739930|PROCEDURE|Control group incision|0.5cm sham incision over the iliac crest
48679369|NCT04064476|DRUG|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
48679370|NCT02907658|BEHAVIORAL|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
48679371|NCT00020150|DRUG|O6-benzylguanine|
48679372|NCT00020150|DRUG|temozolomide|
48679373|NCT04256473|DRUG|mutant pro-urokinase|Intravenous administration
48679374|NCT04256473|DRUG|Alteplase|Intravenous administration
48679375|NCT00967681|DIETARY_SUPPLEMENT|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
48679376|NCT00967681|DIETARY_SUPPLEMENT|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
48679377|NCT04972188|DRUG|ZYIL1 Capsule|NLRP3 inflammasome inhibitor
48679378|NCT05866692|DRUG|TY-2699a|"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"
48679379|NCT00953810|OTHER|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
48679380|NCT06176846|BEHAVIORAL|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
48679381|NCT06176846|BEHAVIORAL|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
48679382|NCT03218839|DEVICE|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
48679383|NCT01791517|OTHER|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
48679384|NCT01791517|OTHER|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
48679385|NCT01791517|OTHER|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
48679386|NCT01791517|OTHER|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
47993627|NCT04777708|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given by intratumoral injection
47993628|NCT04777708|BIOLOGICAL|Pembrolizumab|Given IV
48364220|NCT03907072|DRUG|Placebo|Buffered saline solution
48511607|NCT05790603|DEVICE|Intervention group with PHD-Band|The initial compression pressure was systolic blood pressure plus 10mmHg. Pressure will be released by 20mmHg and 40mmHg 1 hour and 2 hours respectively after the surgery and then the band will be removed after 3 hours if no bleeding occurs. The compression will continue if bleeding occurs.
48364221|NCT01969227|DRUG|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
48364222|NCT04470362|DEVICE|Isokinetic dynamometer|an isokinetic strengthening program for the quadriceps muscles. Twenty-four strengthening session will be performed using an isokinetic device. The exercise program begins with 60% of the mean peak torque, and the patient reaches this intensity by auditory biofeedback. An increasing dose program will be used in the first 5 sessions (1 set to 5 sets), and a dose of 6 sets will be applied from the sixth to twenty-fourth sessions, with the density rising from 60% to 80% of the mean peak torque according to the patient tolerance. Each set consisted of 5 repetitions of concentric (Con/Ecc) contraction in angular velocities of 30°/second and 120°/second for extensors. This program accomplished significant results in increasing the quadriceps power and strength.
48679387|NCT03961555|BIOLOGICAL|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
48679388|NCT03961555|BIOLOGICAL|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
48679389|NCT03961555|BIOLOGICAL|Rabies vaccine|it should be administered in deltoid muscle
48679390|NCT03037762|PROCEDURE|Flexible Endoscopic Evaluation of Swallowing|
48679391|NCT06551675|DIETARY_SUPPLEMENT|Silkworm pupa tablets|Participants will begin taking the silkworm pupa tablets immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
48679392|NCT06551675|DIETARY_SUPPLEMENT|Control product|The sham comparator contains 0.5% of the active ingredient of the study product, indistinguishable in appearance. Participants will begin taking the control immediately upon enrollment, 1200mg/tablet, two tablets a time, twice a day (BID), with a treatment duration of three months.
48679393|NCT06063681|DRUG|SR-8541A|orally administered ENPP1 inhibitor
48679394|NCT06003777|DRUG|PF-06954522|PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
48679395|NCT06003777|DRUG|Placebo|Placebo will be administered as oral suspensions as escalating single doses to be determined.
48679396|NCT05624983|DIAGNOSTIC_TEST|acoustic otoemisions|TOAE and DPOAE
48679397|NCT05624983|DIAGNOSTIC_TEST|Otoscopy|presence of earwax checked by video otoscop
48679398|NCT05624983|DIAGNOSTIC_TEST|Audiometry|Hearing Threshold will be measured with the AD528 interacoustics
48511608|NCT05790603|DEVICE|Control group with TR-Band|TR-Band will be inflated with 15 mL of air The band will be deflated with 1 mL of air hourly for the following 2 hours after the procedure. After 3 hours, the band will be removed if no bleeding occurs. If rebleeding occurs, the band will be inflated with appropriate volume of air until bleeding stops .
48679399|NCT05624983|DIAGNOSTIC_TEST|Tympanometry|Tympanic mobility will be measyred with the Titan interacoustics
48679400|NCT04764240|PROCEDURE|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
48679401|NCT04173182|DIAGNOSTIC_TEST|Probe-based confocal laser endomicroscopy evaluation|Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
48679402|NCT06308601|OTHER|Laughter yoga|Laughter is an innate, most natural, sincere and universal response to humorous stimuli. Philosophically, it is explained by relief theory, conflict theory and superiority theory (Öztürk \& Tezel, 2021). The emergence of laughter yoga was made by Dr., an Indian medical doctor, in 1995. It was created by combining breathing exercises and unconditional laughter with the work of Madan Kataria and his wife Madhuri Kataria. In laughter yoga, the individual can laugh in a simulated way with the interaction of group members, without a funny situation, joke or joke. The body cannot distinguish between real and unreal laughter, and fake laughter begins to turn into real laughter (Kataria, 2011).
48679403|NCT00004049|DRUG|apomine|
48679404|NCT00243139|DEVICE|Mandibular advancement device (activator)|
48679405|NCT05687981|DRUG|Bupivacaine|the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia
48679406|NCT05687981|DRUG|Dexamethasone|2 mg dexamethasone
48679407|NCT02272946|DRUG|Canakinumab|150mg Canakinumab received subcutaneously
48679408|NCT02272946|DRUG|Placebo|150mg Placebo received subcutaneously
48679409|NCT01582334|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
48679410|NCT04451135|DIAGNOSTIC_TEST|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
48679411|NCT04451135|DIAGNOSTIC_TEST|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
48679412|NCT04451135|DIAGNOSTIC_TEST|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
48679413|NCT04451135|DIAGNOSTIC_TEST|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
48679414|NCT04451135|DIAGNOSTIC_TEST|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
48679415|NCT04451135|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
48679416|NCT01266889|DEVICE|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
48679417|NCT04888988|BEHAVIORAL|Exercise Intervention|Participate in the Exercise for Cancer Patients (EXCAP) intervention
48679418|NCT04888988|OTHER|Tactile Sensitivity Test|Participants undergo tactile sensitivity test
48679419|NCT04888988|OTHER|Questionnaire Administration|Participants complete questionnaires
48679420|NCT04888988|PROCEDURE|Brain Magnetic Resonance Imaging|Participants may have options to complete brain MRI scans
48679421|NCT00255905|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|
48679422|NCT00255905|BEHAVIORAL|Clinician monitoring|
48679423|NCT04718740|DRUG|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
48679424|NCT04420858|BEHAVIORAL|Enhanced (experimental) education|See arm description.
48679425|NCT04420858|BEHAVIORAL|Standard (control) education.|See arm description.
48152952|NCT05576233|PROCEDURE|disinfection of the surface that the blood culture is taken|lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.
48152953|NCT01117532|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
48152954|NCT02741921|DEVICE|VivaSight DL|intubation using VivaSight DL tube
48364223|NCT03501394|OTHER|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
48511609|NCT03263897|DEVICE|insufflation|mobile interface driven insufflation of the ear canal
48679426|NCT04010097|OTHER|chewing gum|The test involves chewing a chewing gum for 4 minutes
48679427|NCT01908543|DRUG|Ferrous sulphate 200mg oral tablet|Administration by mouth
48679428|NCT04410965|DRUG|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
48679429|NCT00689897|PROCEDURE|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
48679430|NCT00689897|PROCEDURE|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
48152955|NCT02741921|DEVICE|conventional double-lumen tube|intubation using conventional double-lumen tube
48511610|NCT03263897|DEVICE|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
48511611|NCT05068154|DIAGNOSTIC_TEST|Myovista® WavECG™|The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired 12-lead ECG signal which is then analysed using artificial intelligence to provide information relating to left ventricular relaxation abnormalities
47993629|NCT01801644|DRUG|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
48152956|NCT02861716|DRUG|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
48364224|NCT03501394|OTHER|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
48679431|NCT00465972|DRUG|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
48679432|NCT00465972|DRUG|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
48679433|NCT00465972|DRUG|Placebo|Placebo capsule nightly for duration of study
48679434|NCT03564574|COMBINATION_PRODUCT|Lipid Emulsion|All patients in the 'Study group' received a single dose of 100 ml of 20 percent Lipid emulsion as an infusion over 1 hour along with routine treatment as per institution protocols. Atropine was administered to patients by doubling dose method, which comprised of administering atropine starting from 2mg and to double the dose and administer till complete atropinization. Following this an infusion of 10 percent of the atropinizing dose was given every hour. Patients were evaluated using a standardized clinical interview, physical examination, laboratory tests.
48679435|NCT01168843|OTHER|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
48679436|NCT04716608|OTHER|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
47993630|NCT03784885|BIOLOGICAL|AD07010|A protein based adjuvant
47993631|NCT03784885|BIOLOGICAL|Inactivated trivalent influenza vaccine|Inactivated trivalent seasonal influenza vaccine
47993632|NCT03389009|DIAGNOSTIC_TEST|Ultrasound Biomicroscopy of anterior segment of the eye|5150 Vumax (Sonomed, USA) under standard illumination
48152957|NCT02861716|DRUG|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
48364225|NCT03501394|OTHER|Health Questionnaire|Health and demographic information will be collected.
48364226|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
48364227|NCT00195702|BIOLOGICAL|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
48364228|NCT00195702|DRUG|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
47993633|NCT00874354|DRUG|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
47993634|NCT02834104|DEVICE|RMI|
47993635|NCT02834104|OTHER|myocardial biopsy|
48364229|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
48679437|NCT04716608|OTHER|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
48679438|NCT06074237|OTHER|Immersive resident education|Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
47993636|NCT02834104|BIOLOGICAL|blood sample|
48152958|NCT02861716|DRUG|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
48511612|NCT00576446|BIOLOGICAL|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
48511613|NCT00766779|PROCEDURE|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
48511614|NCT00766779|DRUG|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
48511615|NCT01720888|OTHER|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
48679439|NCT06074237|OTHER|Standardized patient (SP) encounter|"After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter."
48679440|NCT01760616|DRUG|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
47993639|NCT05147909|DIETARY_SUPPLEMENT|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
47993640|NCT05147909|DIETARY_SUPPLEMENT|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
47993641|NCT03583138|DRUG|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
47993642|NCT02747420|DEVICE|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
47993643|NCT02747420|DEVICE|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
47993644|NCT04273646|BIOLOGICAL|UC-MSCs|4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
47993645|NCT04273646|DRUG|Placebo|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
47993646|NCT03779464|DRUG|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
47993647|NCT00087711|DRUG|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
47993648|NCT00087711|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
47993649|NCT00087711|DRUG|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
47993650|NCT03559140|PROCEDURE|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
48679441|NCT00572429|DIETARY_SUPPLEMENT|l-carnitine|3 gram daily dose
48152959|NCT03249961|DEVICE|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
47993651|NCT03559140|PROCEDURE|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
47993652|NCT03559140|PROCEDURE|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
47993653|NCT00536107|DRUG|Gefitinib|250 mg oral
47993654|NCT00536107|PROCEDURE|CT or MRI|performed at screening and every 6 weeks
47993655|NCT00536107|DRUG|Docetaxel|60mg/m2 intravenous infusion
48511616|NCT02886624|DRUG|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
48511617|NCT02058329|OTHER|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
48511618|NCT04829175|DEVICE|Intervention|There is no intervention, beyond necessary clinical care, in this registry. The surgical procedures being performed within the registry are identical to the surgical procedures patients would receive as part of SOC.
48511619|NCT02056912|GENETIC|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
48679442|NCT05756023|PROCEDURE|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
47993656|NCT04010123|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.
48679443|NCT03440554|DIAGNOSTIC_TEST|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
48679444|NCT04916392|DRUG|Liposomal bupivacaine|5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
47993657|NCT04318236|BEHAVIORAL|HERMES (Online Self-Help Intervention based on problem-solving therapy)|"The Online Self-Help Intervention is an online program based on the problem-solving therapy (an evidence based approach of psychotherapy). All participants will receive the exact same intervention.~However, what will be experimentally varied are the four listed interventions."
47993658|NCT01650038|OTHER|treatment with faecal transplantation (donor faeces)|faecal transplantation
47993659|NCT01650038|OTHER|treatment with faecal transplantation (own faeces)|faecal transplantation
47993660|NCT04969549|OTHER|Theta burst stimulation|It consists of 20 sessions of iTBS over the dlPFC.
47993661|NCT06297447|OTHER|PNE4Adults - pain science education|Is formerly described under arm descriptions
47993662|NCT06297447|OTHER|Usual care|Is formerly described under arm descriptions
48679445|NCT06450015|DEVICE|Vacuum Assisted Closure|VAC applied after debridement and saline packing
48679446|NCT06450015|OTHER|Saline Dressing|Wound was managed by saline dressing
48152960|NCT03249961|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
48152961|NCT03249961|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
48511620|NCT02056912|BIOLOGICAL|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
48511621|NCT02925039|OTHER|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
48511622|NCT02925039|OTHER|Treatment as usual|Treatment as usual
48679447|NCT00373048|DRUG|mefloquine|tablet, once weekly
48679448|NCT00373048|DRUG|placebo|tablet, once weekly
48679449|NCT00858325|DRUG|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
48679450|NCT00130039|DRUG|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
48679451|NCT00130039|DRUG|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
48679452|NCT00761982|PROCEDURE|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
48679453|NCT03531814|BEHAVIORAL|Medication Event Monitoring System (MEMS^TM)|A computerized method of tracking the dates and times of a pill bottle being opened.
48679454|NCT03531814|OTHER|Questionnaires|Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
48679455|NCT02253082|DRUG|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
48679456|NCT02253082|BIOLOGICAL|Fresh frozen plasma|Standard FFP from the Blood Bank
48679457|NCT03951610|DEVICE|Test lens|contact lens
48679458|NCT03951610|DEVICE|Control lens|contact lens
48679459|NCT00006695|DRUG|carmustine|300 mg/m2 IV on Day -6
48679460|NCT00006695|DRUG|cytarabine|100 mg/m2 BID on Days -5 through -2
48679461|NCT00006695|DRUG|etoposide|100 mg/m2 BID on Days -5 through -2
48679462|NCT00006695|DRUG|melphalan|140 mg/m2 IV on Day -1
48679463|NCT00006695|PROCEDURE|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
48679464|NCT00006695|RADIATION|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
48679465|NCT05722366|OTHER|Active video game|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
48511623|NCT01792687|DRUG|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
48511624|NCT01792687|DRUG|Abiraterone acetate|1,000 mg, oral, daily
48679466|NCT05722366|OTHER|aerobic exercise|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
48679467|NCT04163653|DIAGNOSTIC_TEST|Non-contrast MRI|Classification and characterization of the lymphatic vasculature using non-contrast MRI.
48679468|NCT04163653|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Cardiopulmonary exercise test, measurement of VO2 and heart rate.
48679469|NCT05558488|OTHER|Meatless, restrictive ketogenic diet|"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes."
48679470|NCT04650230|DEVICE|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
48679471|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
48679472|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
48679473|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
48679474|NCT02621476|BEHAVIORAL|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
48511625|NCT01792687|DRUG|Prednisone|5 mg, oral, daily
48511626|NCT06412783|DIAGNOSTIC_TEST|blood test|performing blood tests on the participants for specific markers.
48511627|NCT04005365|DRUG|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
48679475|NCT02621476|BEHAVIORAL|Usual care|Usual care
48679476|NCT03843151|DRUG|BI 1358894|tablet
48679477|NCT03843151|DRUG|Itraconazole|oral solution
48679478|NCT05238350|PROCEDURE|Acupressure|Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
48679479|NCT01715389|OTHER|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
48679480|NCT05531006|OTHER|retrospective cohort study|retrospective patient file review
48364230|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
47993663|NCT06325007|DIETARY_SUPPLEMENT|Induction of labor|The study group only will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, in both groups, an extraamniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
48364231|NCT00195702|BIOLOGICAL|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
48364232|NCT05909618|DRUG|Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]|5 mg/kg solution for injection
48364233|NCT05909618|DRUG|Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]|3 mg/mL solution for injection
48364234|NCT05207371|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)
48364235|NCT03670056|DRUG|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
48364236|NCT04293081|DRUG|Preemptive chlorepheniramine maleate intravenous injection|Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes
48364237|NCT04293081|DRUG|normal saline|participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
48364238|NCT05798286|OTHER|Quantra|The study plans to collect 2 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts.
48364239|NCT05798286|OTHER|Control|The study plans to collect 1 additional 3 mL citrate tubes of venous blood in addition to the platelet and blood counts at each time.
48511628|NCT00125515|DRUG|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
48511629|NCT00125515|DRUG|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
48679481|NCT04280991|OTHER|Moderate intensity exercise under mild normobaric hypoxia and normoxia|The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
48679482|NCT03151122|BEHAVIORAL|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
48679483|NCT03151122|PROCEDURE|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
48679484|NCT02409433|DRUG|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
48679485|NCT02409433|DRUG|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
48679486|NCT03396302|OTHER|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
47993664|NCT06528704|DEVICE|Ventilation feedback device|Device showing delivered ventilation frequency and volume.
48364240|NCT04372173|DIAGNOSTIC_TEST|analysis of the concentration of the clotting factors in patients who underwent primary hip arthroplasty|"Blood samples were taken before surgery, 6 hours, two, four, and six days after the procedure. Venous blood samples were taken from peripheral veins.~All analyzed parameters (fibrinogen, factor II, factor VIII, factor X, D-dimer) were determined using an ACL TOP 500 CTS automated coagulation analyzer.~All patients were operated on by a single surgical team, with cementless hip replacements implanted, and without tranexamic acid administered in the perioperative period. All patients underwent venous thromboembolic complications prophylaxis.~The following data were collected: age, body mass index, gender, perioperative risk assessment scale according to the American Society of Anesthesiologists score, blood transfusions, hemoglobin levels before surgery and two days post-surgery, instances of thromboembolic complications. Because of the observational nature of this study no changes in the treatment of patients were made."
48364241|NCT01365195|DRUG|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
48364242|NCT01365195|DRUG|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
48364243|NCT01365195|DRUG|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
48511630|NCT06624644|BIOLOGICAL|LNS8801|G protein-coupled estrogen receptor (GPER) agonist
48511631|NCT06624644|BIOLOGICAL|Pembrolizumab|Recombinant monoclonal antibody (anti-PD1)
48364244|NCT04197999|DRUG|GMI-1359|Injection 10 mg/mL
48364245|NCT03654963|PROCEDURE|Medication reconciliation|Medication reconciliation is the systematic process described above.
48364246|NCT03757936|DRUG|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
47993665|NCT05952063|DIAGNOSTIC_TEST|Digital Psychological Test: Schema Scale|Thirty-five questionnaire, 5-point likert scale
47993666|NCT01037387|DRUG|Control|Current treatment according to the ATS/ERS guidelines
48364247|NCT03757936|DRUG|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
48364248|NCT00551629|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
48364249|NCT00551629|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
48511632|NCT06624644|DRUG|Chemotherapy (dacarbazine or temozolomide)|chemotherapy (dacarbazine, temozolomide)
47993667|NCT01037387|DEVICE|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
48679487|NCT03110224|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
47993668|NCT00878007|DRUG|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
47993669|NCT00878007|BEHAVIORAL|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness \& vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
47993670|NCT00878007|OTHER|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
47993671|NCT03394287|DRUG|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
47993672|NCT03394287|DRUG|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
47993673|NCT05373420|OTHER|Education level|Educational level was classified using the International Standard Classification of Education (ISCED) : ISCED0 (less than primary education), ISCED1 (primary education), ISCED2 (lower secondary school), ISCED3 (upper secondary school), ISCED4 (post-secondary non tertiary education), ISCED5 (short-cycle tertiary education), ISCED6 (bachelor's or equivalent level), ISCED7 (master's or equivalent level), ISCED8 (doctoral or equivalent level). We merged these different categories into three main education level : low (ISCED0 to ISCED2), middle (ISCED3 to ISCED4) and high (ISCED5 to ISCED 8). This information is provided by STATBEL.
47993674|NCT05373420|OTHER|Household net income|Income information is available as deciles of the net income of the whole household. This indicator is further categorized into low income (deciles 1 to 4), middle income (deciles 5 to 7), and high income (deciles 8 to 10). This information is provided by STATBEL.
48152962|NCT05322447|DRUG|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
48152963|NCT05322447|DRUG|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
48152964|NCT04791917|BEHAVIORAL|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
48152965|NCT04791917|BEHAVIORAL|Concentric Biceps Flexion|Muscle shortening biceps exercise
48364250|NCT00551629|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
48364251|NCT00551629|BIOLOGICAL|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
48364252|NCT00650975|DEVICE|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
48364253|NCT00650975|DEVICE|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
48364254|NCT05067387|DRUG|Placebo|Oral placebo
48364255|NCT05067387|DRUG|THC|Oral THC (20 mg)
48364256|NCT05067387|DRUG|CBD|Oral CBD (20 mg)
48364257|NCT05067387|DRUG|THC + CBD|Oral THC (20 mg) + CBD (20 mg)
48364258|NCT05217004|OTHER|Dementia Talk mobile application|The app includes features for caregivers such as medication management, behavior symptom management and monitoring, stress management tips and strategies, and task management with other care providers.
48364259|NCT05217004|OTHER|CLEAR Dementia Care mobile application|The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
48364260|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
48364261|NCT04069026|DRUG|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
48364262|NCT03726099|DRUG|esomeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing esomeprazole 40mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
48364263|NCT01832753|DRUG|Levothyroxine|
48364264|NCT02856295|DRUG|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
48679488|NCT05001971|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
48679489|NCT04855240|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
48679490|NCT04855240|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
48679491|NCT04855240|DRUG|Placebo|Oral dose of placebo
48364265|NCT01409642|BEHAVIORAL|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
48364266|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
47993675|NCT05373420|OTHER|Gender|Male or female. This variable is obtained from the Belgian national registry.
47993676|NCT05373420|OTHER|Migration background|Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.
48364267|NCT01409642|BEHAVIORAL|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
48364268|NCT06152367|BIOLOGICAL|TAPCells vaccine|Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
48364269|NCT04115020|DRUG|Naltrexone|Naltrexone 4.5 mg oral suspension
47993677|NCT05373420|OTHER|Household type|Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.
48364270|NCT04115020|DRUG|Placebo|Placebo oral suspension
48364271|NCT04118127|DRUG|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
47993678|NCT05373420|OTHER|Health literacy|Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
47993679|NCT05533931|OTHER|Resistive Breathing Training group|The patients performed two sessions each of 15 minutes session of resistive breathing for four days a week for six weeks using an inspiratory resistive device. Ask patient to take long slow inspirations while breathing through the resistive device
47993680|NCT05533931|OTHER|inspiratory hold technique|With the patient in a comfortable position such as side lying or reclined, the therapist may assist the patient by placing both hands on abdominal area to provide proprioceptive feedback. Then in a relaxed tone of voice therapist instructs the patient to sniff quickly through the nose three times with slow, relaxed exhalations
47993681|NCT00704535|DRUG|Ezetimibe|1 tablet of 10 mg once daily
48364272|NCT01591577|OTHER|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
48364273|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 300mg
48364274|NCT01719627|DRUG|TVD 300/200 QD|TVD 300/200 QD during 7 days
48511633|NCT06624644|BIOLOGICAL|Immunotherapy (Pembrolizumab)|pembrolizumab
48679492|NCT05468645|DRUG|[14C]Hemay005|Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
48679493|NCT03048201|DEVICE|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
48679494|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
48679495|NCT03048201|DEVICE|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
48364275|NCT01719627|DRUG|Maraviroc|Unique dose of Maraviroc 600mg
48679496|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System with LMC Liner|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
48152966|NCT01266837|DRUG|Everolimus|10 mg p.o once daily
48511634|NCT06624644|BIOLOGICAL|Immunotherapy (nivolumab and relatlimab)|nivolumab and relatlimab
48511635|NCT06624644|BIOLOGICAL|Immunotherapy (ipilimumab and nivolumab)|ipilimumab and nivolumab
48511636|NCT03946280|PROCEDURE|conventional X-ray based Fluoroscopy|catheter tracking via conventional X-ray based Fluoroscopy
48511637|NCT03946280|PROCEDURE|low X-ray 3D navigation technique|catheter tracking via low X-ray 3D navigation technique
48511638|NCT03585920|BEHAVIORAL|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
48511639|NCT00650208|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
48511640|NCT00650208|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
48511641|NCT03446807|DRUG|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
48679497|NCT05276128|DIETARY_SUPPLEMENT|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
48679498|NCT01746446|OTHER|Care team|Provides additional support to patients, family, and friends.
47993682|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
47993683|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
47993684|NCT00849160|DRUG|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
47993685|NCT00614315|DEVICE|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
47993686|NCT02657707|DEVICE|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
47993687|NCT02657707|DEVICE|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
47993688|NCT02935608|DRUG|BIIB074|Administered as specified in the treatment arm
47993689|NCT02935608|DRUG|Placebo|Matched placebo
47993690|NCT05774587|BEHAVIORAL|mHealth control group|Cardiac rehab control group
47993691|NCT05774587|BEHAVIORAL|mHealth technology assisted exercise counselling (mHealth)|Exercise and counselling through mHealth technology
47993692|NCT02120950|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
47993693|NCT02120950|OTHER|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
47993694|NCT00988507|DRUG|Ferroquine (SSR97193)|"Pharmaceutical form: capsule~Route of administration: oral"
47993695|NCT00988507|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
47993696|NCT00988507|DRUG|artesunate|"Pharmaceutical form: tablets~Route of administration: oral"
47993697|NCT06387914|DEVICE|Stimulation ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus at a level with potential to provide pain relief
47993698|NCT06387914|DEVICE|Stimulation Pseudo-ON|Neurostimulation of the periaqueductal gray matter and sensory thalamus S at a low level, not designed to provide pain relief
47993699|NCT02046460|DRUG|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
47993700|NCT02046460|DRUG|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
47993701|NCT02382458|BEHAVIORAL|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
47993702|NCT02382458|BEHAVIORAL|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
47993703|NCT01356654|DEVICE|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
48152967|NCT03917342|DEVICE|EEG measure|Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
47993704|NCT01356654|DEVICE|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
47993705|NCT03963115|DRUG|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
47993706|NCT03240679|DEVICE|Acell MatriStem® Surgical Matrix|Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
47993707|NCT02418923|OTHER|Procedure: Blood specimen collection|Blood specimen collection
47993708|NCT02393833|PROCEDURE|Blood samples collection|"Blood samples to be collected at the following time points:~1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~2. Months 12, 18 and 36 after start of induction chemotherapy~3. At time of confirmatory evidence of progression"
47993709|NCT03605797|OTHER|follow up of cases fixed by posterior tension band plate|Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
47993710|NCT00641407|DRUG|NPL insulin|Starting dose 10 IU bedtime and then titration
47993711|NCT00641407|DRUG|Insulin glargine|10 IU bedtime and then titration
47993712|NCT01413555|OTHER|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
47993713|NCT00149747|BEHAVIORAL|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
47993714|NCT00149747|BEHAVIORAL|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
47993715|NCT03551912|PROCEDURE|Surgery|All patients coming for elective surgery
47993716|NCT02982967|OTHER|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
47993717|NCT02411292|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
48152968|NCT04161976|DRUG|LY900027|LY900027 administered to participants with T1DM using CSII.
47993718|NCT04357015|DRUG|intravenous tranexamic acid|The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
48152969|NCT04161976|DRUG|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
48152970|NCT00451906|DRUG|Platinum-based chemotherapy|As prescribed
48152971|NCT00451906|DRUG|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
48152972|NCT05143580|BEHAVIORAL|Cognitive therapy|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education.~* Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~* Use gamification to evaluate: pain relief skills, lung expansion skills."
48152973|NCT05143580|BEHAVIORAL|Routine care|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education."
48152974|NCT00241475|DRUG|Gefitinib|
48152975|NCT00463957|DRUG|sildenafil|
48152976|NCT00463957|DRUG|tadalafil|
48152977|NCT00463957|DRUG|placebo|
48364276|NCT05002049|BEHAVIORAL|Intervention Group|Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
48364277|NCT01883596|DRUG|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
48364278|NCT01883596|DRUG|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
48364279|NCT04279509|PROCEDURE|Tumor Core Biopsy|"Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses."
48511642|NCT03446807|DRUG|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
48511643|NCT06295692|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
48511644|NCT05231629|DRUG|Dara-VRd intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
47993719|NCT04357015|DRUG|intravenous carbetocin|The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
47993720|NCT04357015|DRUG|placebo|the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
47993721|NCT05448651|DRUG|UPB-101|Subcutaneous injection
47993722|NCT05448651|DRUG|Placebo|Subcutaneous injection
48152978|NCT02917434|DIETARY_SUPPLEMENT|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
48679499|NCT06196996|PROCEDURE|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
48152979|NCT04650763|BIOLOGICAL|PRP injection|PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
48152980|NCT04650763|DEVICE|Automated blood cell separator to extract PRP|Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
48152981|NCT06441214|DRUG|Zanubrutinib|Patients will be treated with Zanubrutinib as per routine clinical practice.
48152982|NCT01461434|DEVICE|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
48152983|NCT03763409|DRUG|Losartan Potassium|active drug
48152984|NCT03763409|OTHER|placebo|placebo
48152985|NCT01479842|DRUG|BTK inhibitor PCI-32765|Given PO
48152986|NCT01479842|BIOLOGICAL|rituximab|Given IV
48152987|NCT01479842|DRUG|bendamustine hydrochloride|Given IV
48152988|NCT01479842|OTHER|pharmacogenomic studies|Correlative studies
48152989|NCT01479842|OTHER|pharmacological study|Correlative studies
48152990|NCT01479842|OTHER|laboratory biomarker analysis|Correlative studies
48152991|NCT04127747|DRUG|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
48679500|NCT00376636|DRUG|SPP635 (drug)|
48679501|NCT04895371|OTHER|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
48679502|NCT04895371|OTHER|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
48152992|NCT04127747|DRUG|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
48152993|NCT02659059|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
48152994|NCT02659059|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
48152995|NCT02659059|DRUG|Platinum Doublet Chemotherapy|
48152996|NCT06495463|DRUG|Trifluridine/tipiracil|"Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days."
48152997|NCT03981120|PROCEDURE|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
48152998|NCT05881005|DIAGNOSTIC_TEST|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
48152999|NCT00587171|DEVICE|Patching|2 hours daily patching
48153000|NCT00587171|PROCEDURE|Near activities|30 minutes daily near activities at home
48153001|NCT00587171|PROCEDURE|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
48153002|NCT00587171|PROCEDURE|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
48153003|NCT02558803|BEHAVIORAL|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
48153004|NCT04933188|DIAGNOSTIC_TEST|Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure|Baseline and follow-up examination of echocardiography is to be performed on study subjects.
48153005|NCT01094665|PROCEDURE|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
48153006|NCT01647802|DEVICE|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
48153007|NCT01647802|DEVICE|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
48153008|NCT01647802|DEVICE|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
48153009|NCT06035601|DEVICE|EHR-integrated texting platform (Urotrust)|"* An evidence-based algorithm that provides symptom triage and clinical guidance during an episode of acute UTI~* Evidence-based prevention education material on recurrent UTIs~* 5 standing orders for urinalysis and urine culture in the EHR upon enrollment~* Standard-of-care management for recurrent UTI"
48153010|NCT06035601|OTHER|Usual care|• Standard-of-care management of recurrent UTI (phone calls and/or secure EHR messages for acute symptoms) and follow up visits as determined by patients and their providers.
48679503|NCT03627949|BEHAVIORAL|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
48679504|NCT06029062|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
48679505|NCT06029062|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
48679506|NCT06029062|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
48679507|NCT03301337|DIETARY_SUPPLEMENT|Meat protein absorption|Meat protein absorption when digested together with a full meal.
48679508|NCT01201928|DRUG|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
48679509|NCT01201928|DRUG|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
48679510|NCT00420381|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
48679511|NCT01745653|DEVICE|Low level laser therapy|
48679512|NCT01745653|PROCEDURE|sham procedure|
47993723|NCT05552677|OTHER|Multicomponent Training|Participants will perform a multicomponent training that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 12 weeks
47993724|NCT03209063|DIAGNOSTIC_TEST|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene and methylenetetrahydrofolate reductase gene polymorphisms
47993725|NCT00930579|DRUG|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
47993726|NCT03402685|DEVICE|ClearSight|Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
47993727|NCT02444260|DRUG|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
47993728|NCT02444260|DRUG|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
47993729|NCT02444260|DRUG|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
48153011|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Astus©|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
48679513|NCT04889248|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
48679514|NCT00921115|DRUG|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
48679515|NCT00921115|DRUG|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
48364280|NCT04279509|PROCEDURE|Blood sampling|Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
48679516|NCT06360653|RADIATION|Stereotactic Post-operative Radiotherapy for Endometrial Cancer|Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
48364281|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
48511645|NCT05231629|DRUG|AHCT intensification, Dara-R maintenance|"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort~• MRD negative cohort - Patients will be randomized between arm A (3 cycles of Dara-VRd intensification followed by 13 cycles of Dara-R maintenance) and arm B (AHCT intensification followed by 13 cycles of Dara-R maintenance) for intensification and maintenance"
48511646|NCT05231629|DRUG|AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
48679517|NCT03565341|DEVICE|PiQo4|PiQo4 Laser System for treatment of Melasma
48679518|NCT04642521|DEVICE|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
47993730|NCT02444260|DRUG|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
47993731|NCT04156776|OTHER|Muscle Energy Technique|Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
47993732|NCT04156776|OTHER|Active Isolated Stretching|"The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session."
47993733|NCT04156776|OTHER|Conventional Treatment|Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
47993734|NCT05271955|DEVICE|"e-GOLIAH"|"Usual care plus electronic tablet with games application e-GOLIAH (Gaming Open Library for Intervention in Autism at Home)"
47993735|NCT05271955|BEHAVIORAL|Usual care|Usual care which combines speech therapy, psychomotor, educational or psychological care with a developmental and / or behavioral orientation and a school life support during schooling.
47993736|NCT04571775|DEVICE|Qi-Shield user group|real device Qi-Shield (treatment)
48153012|NCT03430609|DIAGNOSTIC_TEST|AMH Level|"The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery."
48153013|NCT03430609|DIAGNOSTIC_TEST|Transvaginal ultrasound for antral follicle count|The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
48153014|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Vicryl®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
48364282|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
48364283|NCT01248923|DRUG|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
48679519|NCT03243227|OTHER|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
48679520|NCT03243227|OTHER|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
48679521|NCT04204850|DRUG|Cabozantinib|Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
48679522|NCT02967679|DRUG|MD1003|
48679523|NCT01673659|DRUG|Mometasone furoate|
48679524|NCT01673659|DRUG|Nasonex Nasal Spray|
48679525|NCT01673659|DRUG|Placebo nasal spray|
48679526|NCT04690218|DIAGNOSTIC_TEST|Hospital anxiety and depression scale|Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.
47993737|NCT04571775|DEVICE|Sham Qi-Shield user group|sham device (placebo)
47993738|NCT06496503|BEHAVIORAL|Physical activity Protocol|The children included in the experimental group will undergo 12 weeks of physical activity sessions, and it is mandatory that all children complete a minimum of two weekly sessions of physical activity for 50-60 minutes. The activities will consist of content such as motor and cognitive games, sports, dance, and gymnastics. The intensity of the sessions will be checked using accelerometry. The physical activity protocol is adapted from a previously described protocol (CMSP, 2021; Klem, Filha, Monteiro, 2017; Mazzoccante et al.; 2020; Paiano, 2019; Rodrigues, 2018; Rosini et al., 2014). Acceptance of the exercise program in the pediatric population has been previously observed in a pilot study.
47993739|NCT06037720|DEVICE|Coaguchek testing|Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.
47993740|NCT04382833|OTHER|HOT APPLICATION|HOT APPLICATION
47993741|NCT04382833|OTHER|MASSAGE|
47993742|NCT05200754|OTHER|Convalescent/Vaccine-boosted Plasma (CP/PVP)|"Plasma from apheresis obtained from donors, who have recovered from SARS-CoV-2 infection or received a successful vaccination against SARS-CoV-2.~CP/PVP infusion is administered on two following days. Each CP/PVP bag contains approx. 238 - 337 ml anti-SARS-Cov-2 CP/PVP for infusion."
47993743|NCT00981955|DIETARY_SUPPLEMENT|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
47993744|NCT05023746|DIAGNOSTIC_TEST|Genetron lung cancer panel|Follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron lung cancer panel and comparison methods. The detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the Sanger sequencing method, when the site detection results compared with Sanger sequencing method are inconsistent, Sanger's detection results are recognized. The results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of Genetron lung cancer panel.
47993745|NCT00713336|DRUG|ZD4054|ZD4054 10mg Tablet
47993746|NCT00713336|DRUG|Moxifloxacin|400 mg capsule
47993747|NCT00713336|DRUG|ZD4054 Placebo|3 tablets
48679527|NCT04690218|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|Self assessment scale for public community. Applying the scale does not require any specially trained personnel.
48153015|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Surgicel®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
48153016|NCT05700279|PROCEDURE|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
48364284|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
48679528|NCT04690218|BEHAVIORAL|Nutritional Status Questionnaire|It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.
48679529|NCT01991483|DRUG|LY2928057|Administered intravenously
48679530|NCT01991483|DRUG|Placebo|Administered intravenously
48679531|NCT06513611|DIAGNOSTIC_TEST|Serum cortisol.|Serum cortisol levels obtained on admission.
48679532|NCT01261364|BEHAVIORAL|GeneSightRx|Multi-genetic pharmacogenomic panel
48679533|NCT01261364|BEHAVIORAL|Treatment as usual|Treatment as usual
48679534|NCT01699126|DEVICE|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
48679535|NCT01699126|DRUG|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
48679536|NCT04679961|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
48679537|NCT02615977|BEHAVIORAL|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
48679538|NCT02615977|BEHAVIORAL|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
48679539|NCT05863403|DIAGNOSTIC_TEST|Neuromuscular Training|Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk
47993748|NCT00713336|DRUG|Moxifloxacin placebo|1 capsule
47993749|NCT00713336|DRUG|ZD4054 Placebo|2 tablets
47993750|NCT00713336|DRUG|ZD4054|30mg tablet
47993751|NCT00713336|DRUG|ZD4054|10mg tablet
47993752|NCT01591876|OTHER|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
47993753|NCT01591876|OTHER|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
47993754|NCT06421389|DRUG|Tranexamic Acid Powder|2g of sucralfate powder, 1g of tranexamic acid powder, and 1g of barium will be sprayed through the endoscopy precisely on the bleeding site
48153017|NCT05700279|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
48153018|NCT01755130|PROCEDURE|Photoacoustic Imaging|Undergo LOUISA 3D
48153019|NCT04910399|DIETARY_SUPPLEMENT|Blue fish hydrolysate|"The experimental product is a dietary supplement composed of a hydrolysate of fatty blue fish containing low molecular weight peptides and n-3 polyunsaturated fatty acids.~One of the two study groups (28 volunteers) will take 4 capsules of the active product (blue fish hydrolysate), for 90 days.~Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
48364285|NCT01248923|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
48364286|NCT01248923|DRUG|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
48364287|NCT01248923|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
48364288|NCT00631228|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
48364289|NCT04803656|OTHER|Assessment of COPD patients|Assessments explained in the arm section were made as described in one session.
48679540|NCT05863403|DIAGNOSTIC_TEST|Traditional Exercise|Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
48511647|NCT05231629|DRUG|AHCT intensification, Dara-R consolidation, Dara-R maintenance|Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd. Upon confirmation of adequate hematopoietic cell collection and result of MRD1 patients will undergo 1:1 randomization according to the MRD-assigned cohort. MRD positive cohort - Patients will be randomized between arm C (AHCT intensification, 3 cycles of Dara-Tec consolidation and 13 cycles of Dara-Tec maintenance) and arm D (AHCT intensification, 3 cycles of Dara-R consolidation and 13 cycles of Dara-R maintenance) for intensification, consolidation and maintenance.
48511648|NCT05231629|DRUG|Dara-VRd induction|Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone
48511649|NCT02695537|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
48511650|NCT02849483|DRUG|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
48511651|NCT02849483|DRUG|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
48511652|NCT02695784|DIETARY_SUPPLEMENT|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
48511653|NCT05099250|DRUG|Bupivacain|local anesthetic agent
48511654|NCT05099250|DRUG|magnesium sulfate|In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines
48511655|NCT05099250|OTHER|saline|medical solution
48511656|NCT02814890|PROCEDURE|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
48511657|NCT02814890|PROCEDURE|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
48511658|NCT03915418|PROCEDURE|Connected tools|At home, parents will record their child's sleep for 1night Then, on the date scheduled for the inclusion of the children and after the recording of the 1 night at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
48511659|NCT04368689|OTHER|Floatation-based reduced environmental stimulation therapy|Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart
48511660|NCT05228028|PROCEDURE|fascia iliaca compartement block|Ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
48511661|NCT05228028|PROCEDURE|quadratus lumborum block|Ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery.
48511662|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"Placebo-controlled crossover design:~* Dietary Supplement: Antrodia Cinnamomea Products~* Dietary Supplement: Placebo"
47993755|NCT01374087|DRUG|Triptorelin 22.5 mg|Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
47993756|NCT01374087|RADIATION|Brachytherapy|Brachytherapy: Low or high dose rate.
48511663|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"A arm :~Stage I :~• Dietary Supplement: Antrodia Cinnamomea Products~Stage II:~• Dietary Supplement: Placebo~B arm :~Stage I :~• Dietary Supplement: Placebo~Stage II:~• Dietary Supplement: Antrodia Cinnamomea Products"
48511664|NCT06468436|DRUG|Dexmedetomidine-Esketamine Combination|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
48679541|NCT00537472|DRUG|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
48679542|NCT00537472|DRUG|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
48679543|NCT06209294|DRUG|AK104|AK104(10 mg/kg) d1,22
48679544|NCT06209294|DRUG|Carboplatin|AUC=2 d1,8,15,22, 29, 36
47993757|NCT02541747|BEHAVIORAL|massage|massage
48679545|NCT06209294|DRUG|Nab paclitaxel|125mg／m2 d1,8,15,22,29,36
48679546|NCT02383862|OTHER|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
48679547|NCT05362357|BEHAVIORAL|iSTART Web-app|30-day substance prevention web-app for students at a Hispanic Serving Institution.
48679548|NCT01023217|DRUG|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
48679549|NCT01023217|DRUG|Entecavir|Entecavir 1 mg/day orally
48679550|NCT01023217|DRUG|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
48679551|NCT04177537|DEVICE|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
48679552|NCT03725072|DRUG|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
48679553|NCT06413147|DEVICE|PFO closure|Surgery of PFO closure
48679554|NCT06029114|DIAGNOSTIC_TEST|Magnetic Resonance Elastography (MRE)|Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
48679555|NCT03306433|DEVICE|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
48679556|NCT00259844|BIOLOGICAL|TroVax|
48679557|NCT03402932|OTHER|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
48679558|NCT03402932|OTHER|Visual|The cognitive test will be administered visually by using timed computer slides.
48679559|NCT03402932|OTHER|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
47993758|NCT05968807|BEHAVIORAL|iParent2Parent Program|iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer support and mentorship.
47993759|NCT00660582|DRUG|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
48364290|NCT06030531|OTHER|Measures of spasticity, connectivity and analysis of single nucleotide polymorphisms and biomarkers of inflammation|We will test for presence of biological markers in blood that may correlate with levels of spasticity or neurological recovery and functional improvement, including the presence or absence of neuroplastic genetic polymorphisms (e.g. BDNF Val66Met polymorphism), as well as circulating levels of neuroplastic(e.g. BDNF) or inflammatory factors (e.g. interleukins, TNF) that may affect neuronal growth and functional restoration.
48364291|NCT06030531|OTHER|Analysis of biomarkers|We will test for the presence of biological markers in the blood to compare the distribution of polymorphisms and biomarkers with the spinal cord injury patient population.
48153020|NCT04910399|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~One of the two study groups (28 volunteers) will take 4 capsules of placebo per day, for 90 days.Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
48679560|NCT03610854|DEVICE|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
48153021|NCT01393964|DRUG|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
48153022|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
48679561|NCT06300177|DRUG|D-1553 Tablet|D-1553 is a KRAS inhibitor.
48679562|NCT06300177|DRUG|Docetaxel injection|Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
48153023|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
48153024|NCT01393964|DRUG|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
48679563|NCT01435174|DRUG|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
48679564|NCT01435174|PROCEDURE|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
48679565|NCT01435174|PROCEDURE|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
48679566|NCT02382991|DEVICE|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
48679567|NCT02382991|DEVICE|NMPK-3C60|1 month with NMPK - 3 months with 3C60
48679568|NCT02808923|OTHER|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
47993760|NCT00660582|DRUG|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
48153025|NCT01393964|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
48153026|NCT03131271|OTHER|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
48364292|NCT01442142|BEHAVIORAL|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
48679569|NCT02808923|OTHER|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
48679570|NCT04406402|BEHAVIORAL|Acute dietary protocols and lifestyle modification|The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
48153027|NCT03981328|DEVICE|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
48153028|NCT03981328|DEVICE|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
48153029|NCT06376006|BEHAVIORAL|EMR STAT - Survey|Surveys are completed before and after Advanced Fellow Training.
48153030|NCT04430673|OTHER|Home-School based VR system trial|Commercially available VR games operated Raspberry pi micro computer and Oculus Quest VR headsets provided for 2 weeks at dose and intensity selected by participants.
48153031|NCT02326194|BIOLOGICAL|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
48153032|NCT02326194|BIOLOGICAL|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
48153033|NCT02326194|BIOLOGICAL|placebo (one dose)|placebo, one doses
48153034|NCT02326194|BIOLOGICAL|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
48153035|NCT01219400|DRUG|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
48153036|NCT05491837|OTHER|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
48153037|NCT05491837|OTHER|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
48153038|NCT06485947|BIOLOGICAL|Dinutuximab beta|Combination of immunotherapy with standard chemotherapy
48153039|NCT06485947|DRUG|chemotherapy treatment called GPOH|chemotherapy treatment called GPOH
48153040|NCT06485947|DRUG|chemotherapy treatment called rapid COJEC|chemotherapy treatment called rapid COJEC
48153041|NCT04676763|DRUG|Substance P|Participants will receive Substance P
48153042|NCT04676763|DRUG|Normal Saline|Participants will receive normal saline as Negative control
47993761|NCT00396045|DRUG|Revlimid (CC-5013)|
47993762|NCT05326477|BEHAVIORAL|Behavioral weight loss treatment|The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
47993763|NCT03806959|OTHER|Pan Capsule and colonoscopy in patients with IBS|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
47993764|NCT01831154|DRUG|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
47993765|NCT01831154|DRUG|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
47993766|NCT01831154|DRUG|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
47993767|NCT04777695|OTHER|Decibel Monitor|Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
47993768|NCT05155007|DRUG|Rilematovir|Rilematovir will be administered orally as per assigned treatment sequence.
47993769|NCT05155007|DRUG|Ciclosporin|Ciclosporin will be administered orally as per assigned treatment sequence.
47993770|NCT04777162|DRUG|Tislelizumab|For included participants, tislelizumab would be administrated 200mg q3w iv.
47993771|NCT04777162|DRUG|Anlotinib|Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
47993772|NCT05027412|DEVICE|En bloc TURBT Collins Loop|En bloc TURBT Collins Loop
47993773|NCT05027412|DEVICE|Conventional TURBT|Conventional TURBT
47993774|NCT06397703|DRUG|Leuprolide, Degarelix or Relugolix|Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
47993775|NCT06397703|RADIATION|Stereotactic body radiation therapy/radiosurgery (SBRT)|SBRT will be directed to the prostate and delivered with a prescription dose of 40 Gy in 5 fractions prescribed to the 95% isodose line encompassing the planning target volume. Inter-fraction motion targeting and target position corrections will be utilized for each of the 5 treatment fractions.
47993776|NCT00452829|DRUG|Folic Acid and inositol|Folic Acid and inositol
47993777|NCT00452829|DRUG|Folic acid and placebo|Folic acid and placebo
48153043|NCT04676763|DRUG|Histamine|Participants will receive histamine as Positive control
48153044|NCT06244888|BEHAVIORAL|Intervention Targeting Stress and Emotion Regulation|This intervention involves learning and practicing relaxation exercises and setting aside time for pleasurable activities.
48153045|NCT06244888|BEHAVIORAL|Intervention Targeting Motivation and Self-efficacy for Weight Management|This intervention involves identifying values related to weight, lifestyle, and health; identifying barriers to value-consistent living; exploring the consequences of letting barriers drive behavior; and 4) setting goals that are small, specific, attainable, and values-consistent.
48679571|NCT05198076|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
48679572|NCT01694433|DRUG|Calcipotriene|1g daily BID
48679573|NCT01694433|DRUG|Placebo|1g daily BID
48364293|NCT01442142|BEHAVIORAL|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
48364294|NCT01442142|BEHAVIORAL|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
47993778|NCT03670303|BEHAVIORAL|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~1. Lectures on importance of spectacles use including visual materials such as pictures and videos.~2. An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~3. Posters~4. Brochures"
47993779|NCT04780854|DRUG|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
47993780|NCT04780854|DRUG|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
48364295|NCT02300922|DRUG|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
48679574|NCT01053533|DRUG|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
48364296|NCT02300922|DRUG|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
47993781|NCT02344030|DEVICE|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
47993782|NCT02344030|DEVICE|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
48364297|NCT02300922|DRUG|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
48364298|NCT03178591|DRUG|vildagliptin|
48364299|NCT03178591|DRUG|Dapagliflozin|
48364300|NCT05862740|PROCEDURE|Laparoscopic Debulking Surgery in advanced ovarian cancer|Laparoscopic debulking will be conducted until the surgical target is achieved or the operation is converted to laparotomy.
47993783|NCT03993197|BEHAVIORAL|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~* First week a session of Body Strategy ©~* Second week a psychological session with group of speech (Photolanguage ©).~* Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
48364301|NCT05862740|PROCEDURE|Standard laparotomic Debulking Surgery in advanced ovarian cancer|Debulking by laparotomy in patients when debulking could not be accomplished by laparoscopy.
48364302|NCT03730870|DIAGNOSTIC_TEST|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
48364303|NCT02238509|DRUG|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
48364304|NCT02238509|DRUG|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
48679575|NCT01053533|DRUG|western therapy|supportive therapy and antivirus therapy when necessary
48679576|NCT04554459|DRUG|Ponatinib 15 MG Oral Tablet|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
48679577|NCT01490255|DRUG|Ranolazine|os, 750 mg, twice per day, for 15 days
48679578|NCT01490255|DRUG|Amlodipine|os, 10 mg, once daily, 15 days
48153046|NCT06244888|BEHAVIORAL|Intervention for Normalization of Eating|This intervention involves dietary self-monitoring with the goal of staying within a calorie goal ranging from 1,200 kcal/day to 1,800 kcal/day. Participants are also provided with meal planning tools and encouraged to addresses hunger and cravings by promoting feelings of satiety via consumption of foods that are high in volume but low in calories.
48153047|NCT06244888|BEHAVIORAL|Intervention Targeting Physical Activity and Sleep|This simple intervention prompts participants at the start of the day to schedule up to 30 minutes of moderate-to-vigorous intensity physical activity; brisk walking is encouraged. Participants also set a bedtime and wake time and are encouraged to set a reminder alarm to ensure at least 8 hours of sleep.
48153048|NCT06337799|BEHAVIORAL|Research Pharmacist|The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
48153049|NCT03542721|DRUG|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
47993784|NCT05190380|OTHER|HIGH INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
48153050|NCT03542721|DRUG|Placebo of DA-5515|Placebo (three times a day)
48153051|NCT04944589|PROCEDURE|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
48364305|NCT03117192|DRUG|Zinc Sulfate|Zinc supplementation in syrup form
48364306|NCT03117192|DRUG|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
48364307|NCT00861627|BIOLOGICAL|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
48511665|NCT06468436|DRUG|Dexmedetomidine|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
47993785|NCT05190380|OTHER|LOW INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
47993786|NCT05849181|DEVICE|Moona Device|Moona Device pillow pad
47993787|NCT05849181|DEVICE|Inactive Moona Device|Inactive Moona Device pillow pad
47993788|NCT01870583|DRUG|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
48679579|NCT06393777|DIETARY_SUPPLEMENT|honey|analgesic effect of honey
47993789|NCT01870583|DRUG|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
47993790|NCT01870583|DRUG|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
47993791|NCT02334007|DRUG|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
47993792|NCT02334007|OTHER|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
47993793|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
48153052|NCT03623308|OTHER|Fiber cereal|Whole grain and bran cereal
48153053|NCT01452204|OTHER|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
48153054|NCT04650919|PROCEDURE|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~* Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~* Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
48153055|NCT03529942|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
48153056|NCT00082576|DRUG|Azithromycin/Chloroquine|
48153057|NCT00082576|DRUG|Mefloquine|
48364308|NCT00861627|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
48364309|NCT00861627|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
48364310|NCT01353521|PROCEDURE|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
48679580|NCT05854836|BEHAVIORAL|CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances)|CHOICES-PLEAS includes four manual-guided motivational interviewing sessions delivered by a trained counselor and one family planning counseling session delivered by a family planning clinician. The intervention is based on the Transtheoretical Model (TTM) of behavior change and motivational interviewing that includes a decisional balance exercise, goal self-selection, self-monitoring, self-generated plans, and importance and confidence scales. By using a patient-centered approach based on the TTM that meets patients where they are, counselors can have a more effective impact on patient behaviors. This adaptation from the original CHOICES intervention contains unique features focused on the incarcerated setting, illicit polysubstance use, and risky sexual behaviors most common among women with illicit polysubstance use.
48679581|NCT03573388|DEVICE|Optical coherence tomography (OCT)|Lesion OCT assessment
48679582|NCT05830318|OTHER|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
48679583|NCT00912782|DRUG|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
48679584|NCT00912782|DRUG|Placebo|Placebo one time per week for 3 weeks
48679585|NCT01977898|DRUG|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
48679586|NCT01977898|DRUG|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
48679587|NCT05596734|BIOLOGICAL|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
48679588|NCT05596734|BIOLOGICAL|qIRV (22/23)|Intramuscular injection
48679589|NCT05596734|BIOLOGICAL|QIV|Intramuscular injection
48679590|NCT05596734|BIOLOGICAL|bIRV|Intramuscular injection
48679591|NCT05596734|BIOLOGICAL|tIRV|Intramuscular injection
48364311|NCT03817814|BEHAVIORAL|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
48364312|NCT03578211|BEHAVIORAL|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
48679592|NCT01918865|DRUG|ISIS-PTP1BRx|
48679593|NCT01918865|DRUG|Placebo|
48679594|NCT01918865|DRUG|daily OAD (metformin and/or sulfonylurea)|
48679595|NCT00618735|DRUG|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
48679596|NCT00618735|DRUG|BIIB021|Twice daily dosing
48679597|NCT02776683|DRUG|BI 695502|
48679598|NCT02776683|DRUG|Avastin|
48364313|NCT00002075|DRUG|Flucytosine|
48153058|NCT05776329|BEHAVIORAL|AIA-D|"The total energy contribution (1800 kcal/d) is 20% from protein, 25% from lipids, and 55% from carbohydrates. The recommendations include increasing protein intake primarily from plant sources, limiting the intake of red and processed meat, reducing refined sugar, and moderating dairy consumption. It also includes a list of locally produced and seasonal fruits and vegetables and a list of selected ingredients with anti-inflammatory properties to elaborate their foods. Participants will attend 3 motivational sessions of 1 h every two weeks. Besides nutrition and health, the motivational talks focused on the environmental impact of sustainability. Session 1: Planetary healthy diet. The inflammatory potential of diet. Explanation of the program. Session 2. Effect of ultra-processed food on health. Session 3. Healthy diets.~Follow-up information, recipes, and pictures of dishes that meet the given recommendations will be sent once a week through closed social media groups."
48153059|NCT05776329|BEHAVIORAL|CONV-D|"CONV-D is based on general healthy diet recommendations. The total energy contribution (1800 kcal/d) was 20% from protein, 25% from lipids, and 55% from carbohydrates.~Among the recommended food groups are fruits (5 times a day), vegetables (5 times a day), cereals (3 times a day), legumes (3 times a day), dairy products (2 times a day), food of animal origin (3 times per day).~Participants in the CONV-D group will attend one motivational and nutritional orientation session on day 1 of the intervention.~Session 1. Food and nutrition. Obesity and diet. General healthy diet recommendations. Delivery of material (table of food equivalents).~Follow-up information will be sent once a week through closed social media groups."
48153060|NCT02465606|DRUG|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
48153061|NCT02465606|DRUG|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
48153062|NCT05893693|OTHER|Biological|CT0594CP
48153063|NCT01237509|DEVICE|Hypo device|
48153064|NCT03979144|BEHAVIORAL|Observational study|This was an observational study of a medical device, through the usability assessment, for the registration of a self-test for the immunodeficiency virus (HIV) screening.
48153065|NCT02700386|COMBINATION_PRODUCT|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
48153066|NCT04737889|DRUG|Rituximab|Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
48153067|NCT04737889|DRUG|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
48153068|NCT04737889|DRUG|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
48153069|NCT04737889|DRUG|Temozolomide|Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
48153070|NCT01526850|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
48153071|NCT01526850|DRUG|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
48153072|NCT00729170|DIETARY_SUPPLEMENT|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
48364314|NCT00002075|DRUG|Fluconazole|
48364315|NCT00002075|DRUG|Amphotericin B|
48364316|NCT05003687|DRUG|Lu AG06474|solution, orally (Parts A and B)
48364317|NCT05003687|DRUG|Placebo|solution, orally (Part A only)
48364318|NCT04621474|DIAGNOSTIC_TEST|Narrow band imaging (NBI)|Narrow-band imaging uses specific light wavelengths of 415 nm (blue) and 540 nm (green) due to a special filter which is electronically activated by a switch in the endoscope.
48364319|NCT00749866|DRUG|Gentamicin|Nebulised 80mg twice daily
48153073|NCT05197504|DRUG|atezolizumab plus bevacizumab|1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
48153074|NCT05959226|BEHAVIORAL|Exercise Intervention|"1. Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~2. Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;"
48153075|NCT05959226|DIETARY_SUPPLEMENT|Nutrition Intervention|(1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
48153076|NCT00091520|DRUG|Nesiritide|
48153077|NCT00158236|DRUG|Buprenorphine|
48153078|NCT00158236|DRUG|Buprenorphine and Naloxone|
48153079|NCT00158236|DRUG|Hydromorphone|
48153080|NCT03536520|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
48153081|NCT03536520|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
48364320|NCT00749866|DRUG|Saline|Nebulised 4mls 0.9% Saline twice daily
48153082|NCT05467267|PROCEDURE|TURBT|Patients with known bladder tumor undergoing TURBT - A biopsy from the tumor tissue will be taken. Peri operation a urine sample will be taken.
48153083|NCT03114592|OTHER|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
48153084|NCT04168450|OTHER|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
48153085|NCT04168450|OTHER|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
48153086|NCT00104364|DRUG|MK0731|
48153087|NCT04975386|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram will be performed before the operation and at certain time intervals during the operation.
48153088|NCT03424187|DIETARY_SUPPLEMENT|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
48364321|NCT04278846|DRUG|Depofoam bupivacaine|The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
48364322|NCT04278846|DRUG|Bupivacaine hydrochloride (HCl)|The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
48364323|NCT00453349|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
48364324|NCT00453349|DRUG|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
48364325|NCT04568382|OTHER|CI-PVP (context-informed pre-visit planning)|may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit
48364326|NCT04568382|OTHER|Standard PVP (pre-visit planning)|standard clinic staff chart review, email and/or phone call prior to diabetes office visit
48679599|NCT03400046|DRUG|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
47993794|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
48364327|NCT02090140|PROCEDURE|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
48679600|NCT03018860|PROCEDURE|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
48679601|NCT03018860|PROCEDURE|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
48679602|NCT01290146|DRUG|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
48153089|NCT05888272|BEHAVIORAL|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
48153090|NCT05001802|PROCEDURE|transverse scan, in-plane, posterior- anterior quadratus lumborum block|transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
48364328|NCT02090140|PROCEDURE|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
48679603|NCT01290146|DRUG|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min"
48153091|NCT05001802|PROCEDURE|paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
48511666|NCT01823601|BEHAVIORAL|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
48364329|NCT04927585|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid
48679604|NCT03391986|DEVICE|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
48679605|NCT03391986|PROCEDURE|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
48679606|NCT04420052|OTHER|Osteopathic manipulative treatment|"Osteopaths will executed several high velocity low amplitude (HVLA) techniques on the upper thoracic spine and cervical spine. These techniques are assumed to modulate the sympathetic cervical ganglia and reduce inflammation in chronic rhinosinusitis.~This procedure takes around 15 minutes."
48679607|NCT04420052|OTHER|Placebo manipulation|"The osteopath will lay hands without movement on the nose, the throat and the thorax of patients.~This procedure takes around 15 minutes."
48679608|NCT00418093|DRUG|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
48679609|NCT00418093|DRUG|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
48153092|NCT03676400|OTHER|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
48153093|NCT03676400|OTHER|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
48364330|NCT04927585|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid
48364331|NCT04927585|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
48153094|NCT03462771|DRUG|Fish oil|4g of fish oil daily for 14 weeks
48679610|NCT00418093|DRUG|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
48679611|NCT04299386|DEVICE|NeoPhylaxis|NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.
48679612|NCT04299386|DEVICE|ImplanTreat|ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
48679613|NCT01042067|OTHER|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
48153095|NCT03462771|DRUG|sunflower oil|4g of sunflower oil daily for 14 weeks
48153096|NCT01280656|DRUG|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
48364332|NCT04927585|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
48511667|NCT01823601|BEHAVIORAL|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
48511668|NCT06076460|OTHER|Early Total Enteral Feeding|This group will receive enteral feeding volumes at a rate of 80 ml/kg/day starting within the first two hours after birth. Volumes will increased by 20 ml/kg/day till day 4 (total 140 ml/kg/d) and then 150ml/kg/day on day 5.
48679614|NCT05767788|OTHER|Movement with Mobilization (MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
48679615|NCT05767788|OTHER|Sham Movement with Mobilization (Sham MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
48679616|NCT06205446|BEHAVIORAL|Healthy subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
48153097|NCT01280656|DRUG|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
48153098|NCT01280656|DRUG|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
48153099|NCT01280656|DRUG|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
48153100|NCT05815693|BEHAVIORAL|mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)|Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
48153101|NCT01050699|DRUG|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
48153102|NCT01050699|DRUG|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
48153103|NCT05145634|OTHER|Patient education related oral anticoagulants (OACs)|The interventions administered to the experimental group were one-on-one instruction and Health Belief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. Patient education related oral anticoagulant: each subject in the experimental group was taught individually according to investigators' App in the outpatient department (OPD) by researchers. Every months, participants received a follow-up phone call to clarify any questions related to the knowledge of anticoagulants. The contents of the teaching material consisted of: the purpose of taking anticoagulant, side effects, adjustments to daily diet, and precautions (i.e.how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure and medical card after pretest and routine care in the OPD. All participants completed posttest at 3-month follow-up.
48153104|NCT03800563|DEVICE|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
48153105|NCT01537263|DEVICE|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
48153106|NCT02161588|DRUG|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
48364333|NCT05728528|DRUG|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis|combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis
48364334|NCT05728528|DRUG|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone|pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
48364335|NCT04974931|DEVICE|PREVENA Incision Management System|Eligible participants, i.e. participants meeting inclusive criteria, will be randomised in equal proportions and divided into two arms. The PREVENA dressings will be applied to the
48364336|NCT05850637|RADIATION|adjuvant ultra-hypofractionated radiotherapy|adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
48364337|NCT00990522|PROCEDURE|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
48153107|NCT02161588|DRUG|placebo|Once-daily oral administration as tablets.
48153108|NCT00090558|DRUG|nitroglycerin|
48679617|NCT06205446|BEHAVIORAL|Laryngopharyngeal reflux disease subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
48364338|NCT04046029|DRUG|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
48679618|NCT06205446|BEHAVIORAL|Dyspepsia subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
48153109|NCT04178876|PROCEDURE|ethanol sclerotherapy|Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
48364339|NCT04046029|DRUG|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
48364340|NCT03384316|BIOLOGICAL|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
48364341|NCT03384316|BIOLOGICAL|ETBX-061; adenoviral Mucin-1 (MUC1) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
48153110|NCT04178876|PROCEDURE|stripping technique|Endometrioma laparoscopic cystectomy
48153111|NCT02005484|DRUG|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
48153112|NCT04132999|BEHAVIORAL|Family-informed intervention|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team
48153113|NCT04132999|BEHAVIORAL|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
48153114|NCT05850286|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, double infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
48153115|NCT05850286|DRUG|VRD-based Regimen|Bortezomib, Lenalidomide and Dexamethasone
48153116|NCT04293718|OTHER|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
48153117|NCT06185101|BEHAVIORAL|STEP-UP|The STEP-UP chronic pain self-management intervention (Support, Training, and Education for Pain Self-Management - Using Podcasts) will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care (PPC) approach to help them identify their values and priorities and develop goals that reflect these.
48153118|NCT01358201|DRUG|vINCRISTINE|
48153119|NCT01358201|DRUG|Dexamethasone|
48153120|NCT01358201|DRUG|Methotrexate|
48153121|NCT01358201|DRUG|Cytosine arabinoside|
48364342|NCT03384316|BIOLOGICAL|ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
48679619|NCT06205446|BEHAVIORAL|Irritable bowel disorder : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
48679620|NCT02103127|DEVICE|755nm Alexandrite laser with lens array|
48679621|NCT05593315|OTHER|Mindfulness and Buteyko techniques|Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
48679622|NCT03112291|PROCEDURE|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
48364343|NCT02857049|OTHER|Oral nutritional supplements (ONS) degustation|
48364344|NCT02241460|DRUG|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
48153122|NCT00761241|DRUG|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
48364345|NCT02241460|DRUG|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
48364346|NCT06399458|DIAGNOSTIC_TEST|For hypermobility; Beighton score and Brighton revised 1998 Criteria|Beighton score and Brighton revised 1998 Criteria
48364347|NCT02256956|DRUG|Amitriptyline|25 mg / day for 10 days
48679623|NCT03762460|OTHER|Online eHealth tool|Mobile-optimized online eHealth tool to support MBC.
48364348|NCT02256956|DRUG|Tolterodine|Placebo 1 mg / day for 10 days
48679624|NCT03762460|OTHER|Informational website|Participants randomized to this group will receive information about online resources for mental health
47993795|NCT05755009|RADIATION|High- and Low-dose radiotherapy|High- and Low-dose radiotherapy combined with immunotherapy and maintain immunotherapy. Immunotherapy (Envafolimab) once every week (maintain a total of two years). Continuous high-(8Gy×5F) and low-dose (1.33Gy×5F) Radiotherapy starts at the second week after immunotherapy.
48364349|NCT05429528|BEHAVIORAL|Implicit Tax|This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).
48364350|NCT05429528|BEHAVIORAL|Explicit Tiered Tax|This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
48364351|NCT03244111|BEHAVIORAL|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
48364352|NCT01540006|OTHER|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
48364353|NCT03490929|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
48679625|NCT06438185|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction.
47993796|NCT05762900|RADIATION|Ultra-fractionated radiation therapy|5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
47993797|NCT02706509|DRUG|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
47993798|NCT02706509|BEHAVIORAL|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
47993799|NCT02706509|DEVICE|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
47993800|NCT00893087|DEVICE|Triggering mode of the ventilator|10 min of each triggering mode
47993801|NCT00893087|DEVICE|Triggering method of the ventilator|Flow triggering
48364354|NCT03490929|DEVICE|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
47993802|NCT00893087|DEVICE|Triggering method of the ventilator|Pressure triggering
48364355|NCT01731951|DRUG|Imetelstat|Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
48364356|NCT04361695|PROCEDURE|Hemorrhoidectomy|The patient receives spinal anaesthesia and is placed in lithotomy position. A complex of external and internal haemorrhoid or internal haemorrhoid only is excised with monopolar electrocautery or bipolar electrosurgery device. Haemorrhoid pedicle is tied with absorbable polyfilament suture. One, two or three nodes can be removed per a procedure.
48364357|NCT04361695|DRUG|Ketoprophenum|Ketoprophenum
48364358|NCT04361695|DRUG|Placebo|Placebo
48364359|NCT02254876|OTHER|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
48364360|NCT02254876|OTHER|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
48364361|NCT00921973|BIOLOGICAL|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
48364362|NCT00921973|BIOLOGICAL|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
48364363|NCT02160509|DEVICE|IPhone based realtime remote ultrasound interpretation|
48364364|NCT03648047|DEVICE|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
48364365|NCT03648047|OTHER|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
47993803|NCT00893087|DEVICE|Triggering method of the ventilator|NAVA triggering
47993804|NCT06454409|DRUG|Azacitidine|Given IV
47993805|NCT06454409|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47993806|NCT06454409|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
47993807|NCT06454409|DRUG|Regorafenib|Given PO
47993808|NCT06454409|DRUG|Venetoclax|Given PO
48364366|NCT03648047|OTHER|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
48364367|NCT02517606|OTHER|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
47993809|NCT02392962|PROCEDURE|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
47993810|NCT02392962|PROCEDURE|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
47993811|NCT03409926|DIETARY_SUPPLEMENT|Acacia Gum|dietary supplement will be added to the participant's usual diet
47993812|NCT02258100|OTHER|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
47993813|NCT00101114|DRUG|sorafenib tosylate|Given PO
47993814|NCT00101114|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
47993815|NCT00101114|OTHER|laboratory biomarker analysis|Optional correlative studies
47993816|NCT05184374|DRUG|Gonadorelin|GnRH pump pulse subcutaneous injection of gonadorelin in a month
47993817|NCT00521768|BEHAVIORAL|Prolonged exposure|
47993818|NCT04816695|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
47993819|NCT00714519|DRUG|Xenaderm® Ointment|Topical, BID or as needed
47993820|NCT00714519|DRUG|Placebo Comparator|Topical, BID or as needed
47993821|NCT06316531|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
48364368|NCT02517606|OTHER|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
48364369|NCT02254694|OTHER|high heeled shoes|see detailed study description
48153123|NCT00761241|BIOLOGICAL|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
48153124|NCT00761241|RADIATION|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
48153125|NCT00761241|PROCEDURE|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
48153126|NCT06292247|BEHAVIORAL|Cognitive behavioral therapy|CBT aims to treat anxiety by restructuring unfavorable beliefs and controlling negative thoughts so as to reduce dental anxiety.
48153127|NCT06292247|BEHAVIORAL|Auricular plaster therapy|APT involves the application of plaster with seeds on specific points of the outer ear, known as auricular points (acupoints). This process is believed to restore balance and harmony within the body's system and achieve a therapeutic effect (e.g. reduce anxiety)
48153128|NCT06292247|BEHAVIORAL|Tell Show Do|TSD is composed of 3 phases. The Tell phase involves an age-appropriate explanation of the procedure. The Show phase is used to demonstrate a procedure up to the point where the instrument is performed. The Do phase is then initiated, and the treatment is performed.
48153129|NCT06250374|PROCEDURE|Bilateral trans-cranial Doppler ultrasound|Velocity measurements in the middle cerebral artery are made using an ultrasound probe applied to the patient's temple during surgery.
48153130|NCT05749315|OTHER|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
48153131|NCT05749315|OTHER|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
48153132|NCT03696342|DRUG|Pazufloxacin|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
48153133|NCT03696342|DRUG|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
48153134|NCT00666913|OTHER|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
48153135|NCT06584786|COMBINATION_PRODUCT|Jing Si herbal tea (JSHT)|JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).
48153136|NCT06584786|OTHER|Placebo|Placebo of JSHT
48153137|NCT01134497|DRUG|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
48153138|NCT01134497|DRUG|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
48153139|NCT04127695|DRUG|ABBV-0805|ABBV-0805 administered by IV infusion.
48153140|NCT04127695|DRUG|Placebo ABBV-0805|Placebo ABBV-0805 administered by IV infusion.
48153141|NCT05828654|BEHAVIORAL|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
47993822|NCT06316531|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
47993823|NCT03281954|DRUG|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
47993824|NCT03281954|DRUG|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
47993825|NCT05670392|DEVICE|laser and High intensity Tesla magnetic stimulation|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals followed by Eight (8) HITS therapies) Patients will receive two (2) HITS treatments per week for four (4) weeks(.
48679626|NCT03922464|DEVICE|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
48364370|NCT05196074|OTHER|Acute hypoxemic respiratory failure patients on VV-ECMO|To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
48679627|NCT06012630|DIAGNOSTIC_TEST|Ultarsound|Median nerve evaluation of participants with ultrasound
48679628|NCT04728646|DRUG|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
48679629|NCT04728646|DEVICE|Regular dissolvable intracanalicular plug|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
48679630|NCT01308359|DRUG|IV glucose 5%|500 ml glucose 5% within 30 minutes
48679631|NCT01308359|DRUG|saline|saline
48679632|NCT01825330|DEVICE|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
48679633|NCT01825330|DEVICE|sham|
48679634|NCT01302327|DRUG|Exenatide|Exenatide
48679635|NCT05908981|OTHER|sandalwood aromatherapy (Santalum album)|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
48679636|NCT03495726|BEHAVIORAL|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
48679637|NCT01595529|DRUG|Cefixime|Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
48679638|NCT01595529|DRUG|Cephalexin|Cephalexin 50mg/kg/day in 3 divided doses
48679639|NCT01595529|OTHER|Placebo|Placebo to match the other four active treatments
48364371|NCT03641599|DIAGNOSTIC_TEST|echocardiography|echocardiographic assessment of the RV and LV systolic function
48364372|NCT00556283|DEVICE|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
48679640|NCT01595529|DRUG|Trimethoprim/Sulfamethoxazole|8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
48679641|NCT01056081|OTHER|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
48679642|NCT05792163|DRUG|SNP318 (A)|Capsule for oral administration
48679643|NCT05792163|DRUG|Placebo (B)|Placebo capsules matching the SNP318 capsules
48679644|NCT01279876|DRUG|Melatonin|3mg oral, daily, one hour before sleep
47993826|NCT05670392|DEVICE|laser (without HITS treatment)|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals as described above.
48364373|NCT00556283|BEHAVIORAL|Biofeedback|electromyographic-based treatment sessions
47993827|NCT02981342|DRUG|Abemaciclib|Administered orally
47993828|NCT02981342|DRUG|LY3023414|Administered orally
47993829|NCT02981342|DRUG|Gemcitabine|Administered IV
48364374|NCT03341091|OTHER|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
48364375|NCT05507840|DEVICE|Valeda machine|Photobiomodulation treatment with Valeda machine will be applied every six months for 2 years in patients with dry age related macula degeneration.
48679645|NCT02640027|PROCEDURE|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
48679646|NCT00088491|DRUG|Intramuscular Olanzapine Depot|
48679647|NCT00088491|DRUG|Oral Olanzapine|
48679648|NCT02065011|DRUG|Blood draw for the laboratory assessment|
48679649|NCT02556281|BIOLOGICAL|Blood sampling|Blood sampling is done for patient with colorectal cancer
48679650|NCT03456219|OTHER|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
48679651|NCT03456219|OTHER|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
48679652|NCT00794846|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
48679653|NCT00794846|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
48679654|NCT02453893|DRUG|Iloperidone|
48153142|NCT05828654|BEHAVIORAL|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
48364376|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
48679655|NCT02453893|DRUG|Risperidone|
47993830|NCT02981342|DRUG|Capecitabine|Administered orally
47993831|NCT04804397|DIETARY_SUPPLEMENT|Sucrose|Sucrose sweetened soft drinks
47993832|NCT00923559|OTHER|Treatment as Usual at Child Health Centre|Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.
47993833|NCT00923559|OTHER|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
48679656|NCT00377897|PROCEDURE|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
48679657|NCT01041950|PROCEDURE|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
47993834|NCT05133518|DRUG|MELT-300|Sublingual tablet
48153143|NCT01922102|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
48679658|NCT00480740|DRUG|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
48679659|NCT01543919|DRUG|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
48679660|NCT01543919|DRUG|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
48679661|NCT01543919|DRUG|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
48679662|NCT01543919|DRUG|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
48679663|NCT01543919|DRUG|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
48679664|NCT01543919|DRUG|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
48679665|NCT01396590|DRUG|Perampanel|6 x 2 mg perampanel once per day
48679666|NCT01396590|DRUG|Perampanel|12 mg perampanel once per day
48679667|NCT04538131|DEVICE|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
48679668|NCT04538131|DEVICE|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
48679669|NCT00267306|DRUG|Visilizumab|
48679670|NCT02446821|DEVICE|VeraCept|IUD placement of VeraCept
48679671|NCT04404101|PROCEDURE|1). EUS-FNA plus MFB|The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.
48679672|NCT04404101|PROCEDURE|2). EUS-FNA Alone|The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
48153144|NCT01922102|DRUG|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
48153145|NCT01922102|DRUG|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
48153146|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fed state
48153147|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fasted state
48153148|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as oral solution
48153149|NCT03260270|DIAGNOSTIC_TEST|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
48153150|NCT03364803|OTHER|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
48679673|NCT01433042|DEVICE|capsule endoscopy|capsule endoscopy procedure
48153151|NCT03364803|OTHER|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
48153152|NCT03364803|OTHER|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
48153153|NCT03364803|OTHER|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
48153154|NCT03364803|OTHER|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
48153155|NCT03364803|OTHER|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
48153156|NCT03364803|OTHER|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
48153157|NCT03364803|OTHER|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
48153158|NCT03364803|OTHER|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
48679674|NCT06499103|DEVICE|Transcutaneous electrical nerve stimulation|The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
47993835|NCT05133518|DRUG|Midazolam alone|Sublingual tablet
47993836|NCT05133518|DRUG|Ketamine alone|Sublingual tablet
47993837|NCT05133518|DRUG|Placebo|Sublingual tablet
47993838|NCT05947201|DRUG|Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil|If the addition of Cadonilimab to neoadjuvant chemotherapy further improve the efficiency for locally advanced esophageal squamous cell carcinoma
48153159|NCT03364803|OTHER|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
48679675|NCT02505373|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
48153160|NCT03364803|OTHER|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
48153161|NCT00135226|DRUG|Aspirin|
48153162|NCT00135226|DRUG|Omega-3 Ethyl Esters|
48153163|NCT00135226|DRUG|Placebo Aspirin|
48153164|NCT00135226|DRUG|Placebo Omega-3 Ethyl Esters|
48153165|NCT03782545|DEVICE|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
48153166|NCT04441983|DIAGNOSTIC_TEST|7 Tesla MRI of the foot|7 Tesla MRI
48153167|NCT04158323|DEVICE|Airway Management in patients with a anticipated difficult airway|survey of anesthesists and intensive care physician of the perfomans with the flexible endoscope in patients with a anticipated difficult airway
48153168|NCT02648659|DRUG|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
48153169|NCT02648659|DRUG|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
48153170|NCT02648659|DRUG|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
48153171|NCT02648659|DRUG|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
48153172|NCT03385447|BEHAVIORAL|Physical Activity|Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
48153173|NCT00739388|DRUG|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
48679676|NCT02505373|BEHAVIORAL|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
47993839|NCT02574130|DRUG|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
48153174|NCT04617847|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
48153175|NCT00003996|DRUG|carmustine|
48153176|NCT00003996|DRUG|chemotherapy|
48153177|NCT00003996|DRUG|cisplatin|
48153178|NCT00003996|DRUG|etoposide|
48153179|NCT00003996|RADIATION|radiation therapy|
48153180|NCT03665714|OTHER|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
48153181|NCT03665714|OTHER|Enteral Nutrition Emulsion(TPF-T)|TPF-T
48153182|NCT01648491|PROCEDURE|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
48153183|NCT01648491|BIOLOGICAL|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
48153184|NCT04072809|OTHER|No intervention|This study does not involve any interventions.
48153185|NCT04528680|DEVICE|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
48153186|NCT04528680|DRUG|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
48153187|NCT04528680|DRUG|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
48153188|NCT02301117|DRUG|TAS-102|
48153189|NCT04955886|DRUG|Surufatinib(HMPL-012)|Surufatinib(250mg) will be orally administered within 1 hour after breakfast once a day (QD) , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met .
48153190|NCT04320433|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
48679677|NCT01141998|DRUG|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
48679678|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. Week 0-10.
47993840|NCT02574130|DRUG|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
47993841|NCT03388619|RADIATION|Prostate bed with integrated boost|Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.
47993842|NCT03388619|RADIATION|Prostate bed irradiation only|Radiation will be delivered to the prostate bed only.
47993843|NCT03388619|DIAGNOSTIC_TEST|Whole Body Bone Scan|At screening, if required by clinician.
47993844|NCT03388619|DIAGNOSTIC_TEST|18F-NaF PET Imaging|At screening, if required by clinician.
47993845|NCT03388619|DIAGNOSTIC_TEST|CT|Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.
47993846|NCT03388619|DIAGNOSTIC_TEST|mpMRI|mpMRI of the prostate bed at screening and 6 month follow up.
47993847|NCT03388619|DRUG|ADT|After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
47993848|NCT00785109|DIETARY_SUPPLEMENT|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
47993849|NCT01828047|DEVICE|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
48153191|NCT00884806|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
48153192|NCT00884806|DEVICE|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
47993850|NCT02261714|BIOLOGICAL|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
47993851|NCT02261714|BIOLOGICAL|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
47993852|NCT06449313|DRUG|Cemiplimab-Rwlc|350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.
47993853|NCT01299623|BEHAVIORAL|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
48153193|NCT00884806|DEVICE|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
48153194|NCT00884806|DEVICE|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
48153195|NCT00884806|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
48153196|NCT06490497|OTHER|Interview|individual interviews semi-directive
48153197|NCT03713229|DIAGNOSTIC_TEST|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
48153198|NCT01529372|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
48153199|NCT04485975|DEVICE|Therapeutic plasma exchange|Therapeutic plasma exchange filtrates plasma and decreases thyroid hormone concentration in the blood
48153200|NCT02607176|DRUG|Heweizhixie capsule|3 #, Tid, Oral for 3 days
48153201|NCT01727076|OTHER|Laboratory Biomarker Analysis|Correlative studies
48153202|NCT01727076|OTHER|Pharmacological Study|Correlative studies
48153203|NCT01727076|BIOLOGICAL|Recombinant Human Interleukin-15|Given SC
47993854|NCT05217251|OTHER|frontal alpha asymmetry in EEG|frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
48153204|NCT04254965|OTHER|Music therapy|Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
48153205|NCT04254965|DEVICE|Biosignal analysis|Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
48153206|NCT04828668|DIETARY_SUPPLEMENT|Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)|Hemp seed oil
48153207|NCT00297089|DRUG|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
48153208|NCT00297089|DRUG|pemetrexed|Standard pemetrexed every 21 days
47993855|NCT03498742|OTHER|NO Intervention|Routine clinical data; asthma control test and spirometry
47993856|NCT01718847|DRUG|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
47993857|NCT01200654|DRUG|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
48153209|NCT00297089|DRUG|placebo|Placebo daily for 14 days every 21 days
48153210|NCT03838159|DRUG|Paclitaxel|"Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected."
48153211|NCT03838159|DRUG|Carboplatin|Carboplatin must be administered at the end of the Paclitaxel infusion
48153212|NCT03838159|DRUG|Nivolumab|"Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation."
48153213|NCT01755598|BIOLOGICAL|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
48153214|NCT01755598|BIOLOGICAL|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
48153215|NCT04277273|OTHER|Questionnaire|Questionnaires WHOQOL-BREF and GOHAI
48153216|NCT05602571|OTHER|ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months."
47993858|NCT01920919|DRUG|Dexamethasone|
47993859|NCT01920919|DRUG|Placebo|
47993860|NCT05213923|PROCEDURE|ED Sepsis Tracking Sheet|Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
48153217|NCT05602571|PROCEDURE|PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
48153218|NCT05602571|PROCEDURE|Sham PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
48153219|NCT05667740|BIOLOGICAL|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
48153220|NCT05667740|BIOLOGICAL|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
48153221|NCT05667740|BIOLOGICAL|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
48153222|NCT05667740|DRUG|Placebo|Saline
48153223|NCT00006229|DRUG|carboplatin|
48153224|NCT00006229|DRUG|paclitaxel|
48679679|NCT01141998|RADIATION|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
48679680|NCT01141998|RADIATION|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
47993861|NCT05660564|PROCEDURE|DIGU Dorsal inlay preputial graft urethroplasty|"Using a scalpel, a midline incision is made from the meatus to the end of the plate .~The edge of the distal glans should not be incised to avoid meatal stenosis. The depth of this relaxing incision depends on the plate's width and depth, but in all cases, it extends down to the corpora cavernosa. Degloving of the penile skin to the penoscrotal junction If a minimal chord is present, it should be corrected.~From the inner prepuce, a free graft was measured, harvested, defatted, and stitched to the UP. With interrupted 6/0 polyglactin sutures running from the old meatus to the tip of the glans, the graft was secured to the medial edges of the incised plate. Depending on the location of the meatus, the characteristics of the UP, and the depth of the midline incision, the graft width and length varied in each case."
48153225|NCT00006229|DRUG|rebimastat|
48153226|NCT05114811|PROCEDURE|Self-provided perineal massage|External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.
48364377|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
48153227|NCT05114811|PROCEDURE|Physiotherapist perineal massage: manual and instrumental (with EPI-NO)|"The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device."
48511669|NCT06076460|OTHER|Conventional Enteral Feeding|This group will receive enteral feeding volumes at a rate of 20 ml/kg/day starting within the first two hours after birth and rest of the daily requirement as Total parenteral nutrition. Volumes will be increased by 20 ml/kg/day till day 3 and thereafter by 30 ml/kg/d till 150ml/kg/day on day 6.
48679681|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. From week 14 to 52.
48679682|NCT06032858|DRUG|Apremilast 30mg|Apremilast 30mg twice daily
48679683|NCT01744067|DRUG|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
48679684|NCT01744067|DRUG|Placebo|Placebo capsules 3 times a day (oral administration)
48679685|NCT02596139|OTHER|No Interventions|
48153228|NCT06029595|DRUG|Experimental: CHF6001 3200 μg|800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg
48153229|NCT06029595|DRUG|Placebo Comparator: CHF6001 Placebo|2 inhalations of CHF6001 matching placebo BID
48153230|NCT02769390|DRUG|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
48153231|NCT02769390|DRUG|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
48364378|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
48364379|NCT01508182|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
48511670|NCT01747746|DRUG|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
48511671|NCT01747746|DRUG|Warfarin and Enoxaparin|Historical Control
48511672|NCT05251610|DRUG|20mg oral propranolol and oxytocin|Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
48511673|NCT05251610|DRUG|Oxytocin only|Participants will have outright augmentation or induction of labor with oxytocin
48679686|NCT05530902|OTHER|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
48679687|NCT03977545|DIAGNOSTIC_TEST|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
48679688|NCT02059564|DRUG|HM11260C|doses of 6 mg, 16 mg
48679689|NCT02059564|DRUG|Placebo|Normal saline solution
48679690|NCT02059564|DRUG|Victoza|doses of 1.8 mg
48679691|NCT02549989|DRUG|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
48679692|NCT06379633|BEHAVIORAL|In vivo exposure|Exposure in vivo involves the confrontation with fear-evoking situations in real life.
48153232|NCT02769390|DRUG|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
47993862|NCT00971347|OTHER|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
47993863|NCT00971347|BEHAVIORAL|nutrition brochure|one-time at baseline visit
48153233|NCT01662804|DRUG|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
48153234|NCT03655704|DRUG|Apabetalone|A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
48153235|NCT01426217|DEVICE|Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt|Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
48153236|NCT00079235|DRUG|temsirolimus|Given IV
48153237|NCT00079235|OTHER|laboratory biomarker analysis|Correlative studies
48153238|NCT02069379|DRUG|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
48153239|NCT02069379|DRUG|Placebo|Placebo capsules prepared identically to Metformin capsules
48153240|NCT00389285|DRUG|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
48153241|NCT00389285|DRUG|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
48153242|NCT06501521|DIAGNOSTIC_TEST|Diagnostic test|No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
48153243|NCT00179478|DRUG|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
48153244|NCT03219216|DRUG|Glecaprevir/Pibrentasvir|Film-coated tablet
48153245|NCT06564077|OTHER|Eldoa technique with conventional therapy|"is myofascial stretching technique of the cervical spine. Patients were asked to adopt desired position to target intervertebral segments. Breathing is also important factor in ELDOA stretch. Patients were instructed to not to hold or strain breathing through promoting diaphragmatic breathing.~* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
48153246|NCT06564077|OTHER|conventional therapy|"* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
48153247|NCT06381388|DEVICE|cTBS|A single cTBS session delivered to the contralesional primary motor cortex.
48153248|NCT02769754|DEVICE|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
48153249|NCT02769754|OTHER|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
48153250|NCT01072071|DRUG|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
48153251|NCT00327314|PROCEDURE|Transplantation|
47993864|NCT03809442|DRUG|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
48153252|NCT00327314|PROCEDURE|Hematopoietic cell transplantation|
48153253|NCT06506630|DIETARY_SUPPLEMENT|coenzyme Q10|300 mg capsule twice a day
48153254|NCT06506630|DIETARY_SUPPLEMENT|placebo|300 mg capsule twice a day
48153255|NCT03042156|RADIATION|Palliative Radiation Therapy|
48153256|NCT04555694|DRUG|Cyclosporine|Used to increase tear production in patients who have dry eye caused by inflammation
48153257|NCT04555694|DRUG|Loteprednol Etabonate|Used to treat inflammation of the eye
48153258|NCT04555694|DRUG|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
48153259|NCT03312972|RADIATION|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
48153260|NCT00324571|DRUG|Sevelamer hydrochloride|
48153261|NCT00324571|DRUG|Calcium-based phosphate binder|
48153262|NCT01133678|DRUG|Everolimus|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
48679693|NCT06379633|BEHAVIORAL|(Virtual reality) exposure|Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
47993865|NCT03809442|DRUG|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
47993866|NCT03809442|DRUG|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
48364380|NCT01508182|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
48511674|NCT03164538|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
47993867|NCT03809442|DRUG|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
47993868|NCT03809442|DRUG|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
47993869|NCT03809442|DRUG|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
48511675|NCT03164538|BEHAVIORAL|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
48679694|NCT04379453|PROCEDURE|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
48679695|NCT04149665|DEVICE|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
48679696|NCT00712478|DRUG|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48679697|NCT03044275|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
48679698|NCT03044275|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
48679699|NCT01905189|PROCEDURE|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
47993870|NCT04319042|PROCEDURE|Immediate Loading|The implant receives an artificial tooth the same day as it is placed.
48679700|NCT06059612|PROCEDURE|injection|steroid injection into superior cluneal nerve
48679701|NCT02288299|DEVICE|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
48679702|NCT06219915|DRUG|Carbidopa 25 mg|Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
48679703|NCT06219915|DRUG|Carbidopa-Levodopa 25/100 mg|Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
48679704|NCT06219915|DRUG|Placebo 1|Participants will take one 25mg placebo tablet 3 times a day for 10 days.
48679705|NCT06219915|DRUG|Placebo 2|Participants will take one 100mg placebo tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.
47993871|NCT04319042|PROCEDURE|Early Loading|The implant receives an artificial tooth 4 weeks after placement.
47993872|NCT02233244|DRUG|CTX-4430|
47993873|NCT02233244|DRUG|Midazolam|
48153263|NCT01133678|DRUG|Placebo|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
48679706|NCT00466947|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
48679707|NCT00466947|BIOLOGICAL|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
48679708|NCT00466947|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
47993874|NCT02143609|DRUG|oxygen|Nocturnal nasal oxygen during stay at 2048 m
48153264|NCT00149565|DRUG|IFN-α2b|
48153265|NCT06075433|DEVICE|Genoss DES stent|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
48679709|NCT00466947|BIOLOGICAL|Infanrix hexa|Intramuscular injection,3 doses
48679710|NCT00466947|BIOLOGICAL|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
47993875|NCT02143609|DRUG|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
47993876|NCT03533452|DRUG|Ropivacaine|Local anesthetic injection
47993877|NCT03533452|DRUG|Normal saline|Sham injection
47993878|NCT01984008|DRUG|Picosulfate sodium, magnesium oxide, citric acid|
47993879|NCT05874752|DIAGNOSTIC_TEST|Transthoracic echocardiography|noninvasive myocardial work
47993880|NCT00561756|BIOLOGICAL|plasmid DNA vaccine therapy|
48153266|NCT00817739|DRUG|Leuprorelin|Leuprorelin injection
47993881|NCT00561756|OTHER|flow cytometry|
47993882|NCT00561756|OTHER|immunoenzyme technique|
48153267|NCT00817739|DRUG|Flutamide|Flutamide tablets
48153268|NCT02213094|DRUG|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
48153269|NCT02213094|DRUG|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
48153270|NCT00850954|OTHER|Informational Intervention|Receive information on secondhand smoke and supporting smoker in quitting
48153271|NCT00850954|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation materials based on TTM
48364381|NCT01508182|DRUG|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
48679711|NCT04426773|DEVICE|High-Definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
48679712|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
48679713|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
48153272|NCT00850954|OTHER|Survey Administration|Ancillary studies
48153273|NCT00230009|BEHAVIORAL|Brief motivational intervention|
48153274|NCT00002761|BIOLOGICAL|filgrastim|
48153275|NCT00002761|BIOLOGICAL|recombinant interferon gamma|
48511676|NCT01533012|PROCEDURE|Pressure difference|Peak inspiratory pressures difference between two lungs
48679714|NCT05490316|DRUG|IBI353 (Orismilast)|dose 1 or dose 2
48679715|NCT05490316|DRUG|placebo|placebo
48153276|NCT00002761|DRUG|busulfan|
48153277|NCT00002761|DRUG|cyclophosphamide|
47993883|NCT02786147|OTHER|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
48511677|NCT03700385|DEVICE|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
48679716|NCT02432781|DIETARY_SUPPLEMENT|Carbohydrate-rich drink|
47993884|NCT02786147|OTHER|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
47993885|NCT02786147|OTHER|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
47993886|NCT02786147|OTHER|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
47993887|NCT02136576|DEVICE|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
47993888|NCT02136576|DEVICE|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
48153278|NCT00002761|DRUG|cyclosporine|
48153279|NCT00002761|DRUG|cytarabine|
48153280|NCT00002761|DRUG|idarubicin|
48153281|NCT00002761|PROCEDURE|peripheral blood stem cell transplantation|
48153282|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
48153283|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
48679717|NCT02432781|DIETARY_SUPPLEMENT|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
48679718|NCT05280821|DIETARY_SUPPLEMENT|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
48679719|NCT05280821|DIETARY_SUPPLEMENT|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
48679720|NCT04787731|DRUG|Bupivacaine Local Anesthetic|Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
48679721|NCT01798888|PROCEDURE|Implantation of Deep Brain Stimulation|
48679722|NCT05334472|OTHER|Kesimpta|There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
48679723|NCT00094562|DRUG|Fish oil supplement|
48679724|NCT01393795|DRUG|Qutenza|8% patch
48679725|NCT01393795|DRUG|Tegaderm|No active drug
48679726|NCT02378285|DEVICE|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
48153284|NCT04513041|PROCEDURE|Pinhole surgical technique and tunnel technique in a split mouth design|Each subject will have the each surgical procedure which are both considered routine minimally invasive clinical care for gingival recession. Gum recession on one side will receive Pinhole surgical technique (test procedure). The other side will receive Tunnel technique (control procedure), Research component involved is the capture of digital impression using intra-oral scanner in the baseline (preoperative) and the final visit (6 months postoperative).
48153285|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
48153286|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
48153287|NCT06222671|DRUG|Placebo|Placebo subcutaneous (SC) injection.
48153288|NCT05744505|PROCEDURE|1565nm Non-ablative Fractional Laser|Every 3 weeks
48153289|NCT05744505|PROCEDURE|placebo|Every 3 weeks
48679727|NCT02378285|OTHER|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
48153290|NCT02219529|DEVICE|MCE|
48153291|NCT02219529|DEVICE|Standard gastroscopy|
48153292|NCT02033668|DRUG|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
48153293|NCT02033668|DRUG|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
48153294|NCT02033668|DRUG|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
48153295|NCT05208021|BEHAVIORAL|Intervention group (Motivational Interviewing)|The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
48153296|NCT06056219|DEVICE|Mirror therapy|30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
48153297|NCT06056219|DEVICE|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
48153298|NCT06056219|OTHER|Task-oriented training|20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
48153299|NCT00825513|DEVICE|Akreos Toric IOL|Lens implant following cataract surgery
48153300|NCT00825513|DEVICE|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
48153301|NCT02862158|DEVICE|FDT visual field|
48153302|NCT02862158|DEVICE|Standard HVF|
48153303|NCT02440256|OTHER|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
48153304|NCT06527833|PROCEDURE|Non Packing of perianal abscess cavity after drainage|"* All patients will undergo incision and drainage under general anaesthesia.~* In Group (A \[Non-Packing group\]), The surgery will be performed by making a cruciate incision over the abscess and incision widened using forceps to allow complete drainage of the cavity containing, without any catheter drainage and packing avoided. The lesion will be left open to heal by secondary intention. The patient was advised to have a sitz bath and apply a dressing over the cavity."
48679728|NCT02270658|DEVICE|CPAP|
48679729|NCT05207748|DIAGNOSTIC_TEST|Bone mineral density|Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
48679730|NCT06348641|OTHER|baby massage|The infant massage to be applied before the examination will be applied by a single nurse=researcher. Video recordings will be taken before and during the ROP examination and evaluations will be made by two neonatal nurses other than the researcher.
48679731|NCT03042429|DRUG|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
48679732|NCT03042429|DRUG|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
48153305|NCT06527833|PROCEDURE|Packing of perianal abscess cavity after drainage|an elliptical incision will be made, and the abscess will be fully drained then packing the cavity will be done with sterile gauze with a change of dressing every 24 hours until it is completely healed.
48153306|NCT03337204|BEHAVIORAL|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
48153307|NCT03337204|BEHAVIORAL|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
48153308|NCT05038319|PROCEDURE|EUS|The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
48153309|NCT01529853|DRUG|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48679733|NCT00405249|DRUG|elvucitabine|
48679734|NCT05685420|DRUG|Herombopag|Thrombopoietin receptor agonist
48679735|NCT02492243|DEVICE|PCI|
48679736|NCT02492243|DEVICE|ILR implantation|
48679737|NCT03135431|PROCEDURE|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
48679738|NCT03135431|PROCEDURE|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
48679739|NCT00604552|DEVICE|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
48153310|NCT01529853|DRUG|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48679740|NCT00451061|DRUG|Alfuzosin|
48679741|NCT00451061|DRUG|Tamsulosin|
48153311|NCT04977089|DIAGNOSTIC_TEST|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
48153312|NCT02512107|DIETARY_SUPPLEMENT|Juice Plus+|Dried fruit and vegetable juice capsule.
48153313|NCT02512107|OTHER|Placebo|Placebo capsule
48679742|NCT00315510|DRUG|Rosuvastatin|
48679743|NCT03174626|BEHAVIORAL|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
48679744|NCT03174626|OTHER|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
48679745|NCT06443333|OTHER|Data collection and follow-up observation|At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.
48679746|NCT06443333|OTHER|Data collection|Collect demographic and genetic information from healthy volunteers upon enrollment.
48153314|NCT01803945|DRUG|AVE8112|
48153315|NCT01803945|DRUG|Placebo|
48153316|NCT03373188|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
48153317|NCT03373188|BIOLOGICAL|Ipilimumab|Given IV
48153318|NCT03373188|BIOLOGICAL|Nivolumab|Given IV
48679747|NCT05214430|OTHER|3 months exclusive enteral nutrition after surgery|patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
48679748|NCT06107985|OTHER|Structured exercise program|This intervention will be based on shoulder kinetic control, load modification exercises and lumbopelvic stabilization with core stability exercises which is not a part of conventional exercise program for shoulder impingement syndrome patients.
48153319|NCT03373188|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
48153320|NCT05786768|DRUG|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
48153321|NCT05786768|DRUG|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
48153322|NCT04999800|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
48153323|NCT04999800|DRUG|Anlotinib|Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor
47993889|NCT02136576|DEVICE|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
47993890|NCT02807350|DEVICE|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
48153324|NCT02319304|DRUG|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
48153325|NCT02319304|RADIATION|Low dose fractionated radiation therapy (LDFRT)|see arm description
48153326|NCT03060356|BIOLOGICAL|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
48153327|NCT04428619|DEVICE|Peripheral Electrical Nerve Field Stimulation (PENFS) Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
48266824|NCT05666557|OTHER|self-myofascial release technique|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After self mobilization by roller, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
48364382|NCT04929782|DEVICE|Resin-based sealant|Etching with 37% phosphoric acid for 30 s (i-GEL N, i-dental, Lithuania), rinsing for 30 s with air-water spray and drying with oil-free air for 15 s, resin sealant (Conceal F, SDI, Australia) application into the occlusal and buccal/palatal pits and fissures with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20s on each surface.
48364383|NCT04929782|DEVICE|Giomer sealants|Self-etch primer (BeautiSealant Primer, Shofu, Japan) application to the occlusal and buccal/palatal pits and fissures with fine microbrush and waiting for 5 s, homogenizing the bond layer with gentle air stream for 5 s, giomer sealant application (BeautiSealant Paste, Shofu, Japan) with direct placement syringe system and light curing with 460-500 nm wavelength halogen light unit (Hilux Dental Curing Light Unit 250, Benlioğlu Dental Inc, Turkey) for 20 s on each surface.
48364384|NCT00669253|PROCEDURE|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
48364385|NCT00669253|PROCEDURE|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
48679749|NCT06107985|OTHER|Conventional Exercise Program|Conventional exercise program for shoulder impingement syndrome patients
48679750|NCT03190499|OTHER|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
48679751|NCT03667989|DIAGNOSTIC_TEST|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
48679752|NCT05459441|BIOLOGICAL|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
48153328|NCT04428619|DEVICE|Sham Device|Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
48153329|NCT04232202|DEVICE|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
48153330|NCT04232202|PROCEDURE|Standard extraction|Standard extraction procedure
48153331|NCT04552184|OTHER|GPOEM|gastric per oral endoscopic pyloromyotomy
48364386|NCT00669253|PROCEDURE|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
48364387|NCT02695758|PROCEDURE|Interscalene brachial plexus block|
48364388|NCT02695758|PROCEDURE|bupivacaine extended-release liposome injection|
47993891|NCT02807350|DEVICE|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
47993892|NCT01224847|DRUG|Tetracaine|1 gtt
47993893|NCT01224847|DRUG|Cocaine|1 gtt
48153332|NCT04552184|OTHER|SHAM Procedure|intrapyloric injection of saline solution
48153333|NCT05028322|DRUG|IMIQUIMOD cream|Cream to apply before intra-dermal vaccine injection
48679753|NCT05459441|DRUG|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
48679754|NCT00178074|BEHAVIORAL|total sleep deprivation|
48679755|NCT00178074|PROCEDURE|PET imaging|
48679756|NCT04791293|OTHER|MELD-Na score|MELD-Na scores will be compared between the groups
48679757|NCT00343005|BIOLOGICAL|AMA1-C1|
48153334|NCT05028322|BIOLOGICAL|HEPATITIS B SURFACE ANTIGEN|HBV Vaccine
48153335|NCT05908136|OTHER|restorative materials|two types of composite with strip crown in primary molars
48153336|NCT04415580|OTHER|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~* Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~* Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
48153337|NCT04415580|OTHER|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
48153338|NCT05281419|OTHER|Intralesional triamcinolone injection|Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week
48679758|NCT00343005|DRUG|AMA1-C1/alhydrogel Malaria Vaccine|
48679759|NCT02002507|OTHER|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
48679760|NCT02113774|OTHER|antimicrobial treatment according to in-vitro susceptibility|
48679761|NCT02904174|BEHAVIORAL|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question \& answer session were included in the group education.
48679762|NCT05496985|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
48679763|NCT04244071|DEVICE|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
48679764|NCT04244071|OTHER|routine hospital care|routine hospital care
48679765|NCT00790582|DRUG|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
47993894|NCT01224847|DRUG|Lidocaine|Lidocaine soaked pledget
47993895|NCT03811431|PROCEDURE|Contrast enhanced ultrasound guided liver biopsy|Conventional liver biopsy
47993896|NCT03040466|DEVICE|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
47993897|NCT03040466|DEVICE|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
47993898|NCT04796376|PROCEDURE|combined partial fistulectomy or fistulotomy and cutting seton procedure|Partial excision of fistulous tract or just fistulotomy plus cutting seton procedure which is a rubber band or threads put through fistulous tract
47993899|NCT01718652|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
47993900|NCT01718652|DRUG|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
48153339|NCT05281419|OTHER|No intralesional triamcinolone injection|No intralesional triamcinolone injection
48364389|NCT02359500|DRUG|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
48364390|NCT00578331|DRUG|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
48364391|NCT00578331|DRUG|Placebo Nasal Spray|2 sprays each nostril twice daily
48679766|NCT05746182|DIAGNOSTIC_TEST|Hereditary Cancer Panel|UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes
47993901|NCT05590689|DRUG|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
47993902|NCT05590689|RADIATION|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
47993903|NCT03826862|RADIATION|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
47993904|NCT00002670|DRUG|chemotherapy|
47993905|NCT00002670|DRUG|cisplatin|
47993906|NCT00002670|RADIATION|low-LET cobalt-60 gamma ray therapy|
47993907|NCT00002670|RADIATION|low-LET electron therapy|
47993908|NCT00002670|RADIATION|low-LET photon therapy|
48153340|NCT02389894|DEVICE|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
48153341|NCT02389894|DEVICE|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
48679767|NCT04643847|DRUG|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
48679768|NCT03269773|BIOLOGICAL|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
48679769|NCT03269773|OTHER|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
48153342|NCT06012877|BEHAVIORAL|Health Friendly Program|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
48153343|NCT04451720|DRUG|Risankizumab|Subcutaneous (SC) injection
48153344|NCT04451720|DRUG|Placebo|Subcutaneous (SC) injection
48153345|NCT04893824|DEVICE|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
48153346|NCT00296686|DRUG|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
48153347|NCT00296686|DRUG|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
48153348|NCT00296686|DRUG|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
48153349|NCT04995601|DEVICE|RF Health MAC|The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
48153350|NCT04489914|DEVICE|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
48153351|NCT04454125|BEHAVIORAL|AQI intervention|The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).
48364392|NCT02404324|OTHER|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
48364393|NCT03379324|BIOLOGICAL|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
48364394|NCT03379324|BIOLOGICAL|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
48364395|NCT05158127|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48364396|NCT01598831|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
48364397|NCT01598831|DRUG|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
48364398|NCT04601194|BEHAVIORAL|Coaching and Virtual Provider Program Practice|4 weekly goal setting/coaching sessions, coupled with Virtual Provider program training and practice
48364399|NCT05815004|DRUG|Gene therapy|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
48679770|NCT03611218|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
48679771|NCT03506139|RADIATION|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
48679772|NCT01021176|OTHER|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
48153352|NCT04454125|OTHER|Routine care|The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
48153353|NCT03733756|PROCEDURE|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
48153354|NCT03733756|PROCEDURE|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
48153355|NCT02637466|DRUG|Vortioxetine|
47993909|NCT00623727|BIOLOGICAL|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
48364400|NCT05815004|DRUG|Enzyme Replacement Agent|A hydrolytic lysosomal glucocerebrosidase-specific enzyme
48153356|NCT00801528|DRUG|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
48153357|NCT01541176|OTHER|Absence of corticotherapy post-transplantation|No study treatment
48153358|NCT01541176|DRUG|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~* D1 to D14 : 20 mg/day,~* D15 to M1 : 15 mg/day,~* M1 to M3 : 10 mg/day,~* M3 to M12 : 5 mg/day."
47993910|NCT00623727|BIOLOGICAL|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
47993911|NCT04076995|OTHER|Water Intake|Increased water intake during the 11 h protocol
47993912|NCT03696810|DIAGNOSTIC_TEST|Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
47993913|NCT00511615|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
47993914|NCT04045678|DRUG|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
47993915|NCT04045678|DRUG|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
48153359|NCT04366648|DRUG|JK-1201I|malignant solid tumor that has been confirmed by histopathology and/or cytology
48153360|NCT06359483|OTHER|Meal Frequency Manipulation|The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.
48153361|NCT03594045|DRUG|Apixaban|Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
48153362|NCT00447499|DRUG|Somatuline Autogel (lanreotide acetate)|Injections
48153363|NCT00447499|BEHAVIORAL|Home administration|Questionnaire
48153364|NCT01249794|PROCEDURE|non invasive ventilation|continuous positive airways pressure
48153365|NCT04004923|PROCEDURE|Monopolar hysteroscopy|Unipolar resectoscopes are used in this group and the distention fluid is mannitol
48364401|NCT02477631|DRUG|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
48364402|NCT02138552|DRUG|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
48153366|NCT04004923|PROCEDURE|Bipolar hysteroscopy|Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
48153367|NCT01469819|DRUG|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
48153368|NCT05457647|DEVICE|Riboflavin/UV-A corneal cross-linking|Corneal cross-linking procedure will be performed using the theranostic software module of the C4V CHROMO4VIS™ system in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop will be done for 15 minutes for the EpiOFF CXL treatment and 20 minutes for the EpiON CXL treatment. Estimates of riboflavin concentration into the cornea will be monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A irradiation of the cornea with 5.4 J/cm2 total energy dose and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score will be performed by the C4V CHROMO4VIS™ system during UV-A irradiation.
48153369|NCT05607147|DEVICE|Testing for SARS CoV2 Antigen and Antibody|Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
48364403|NCT02138552|DRUG|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
48679773|NCT01021176|DRUG|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
48679774|NCT01015755|BEHAVIORAL|combined therapy treatment|mouth care
48679775|NCT02578160|PROCEDURE|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
48679776|NCT06522477|OTHER|Virtual reality gait training|Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.
47993916|NCT03337100|BEHAVIORAL|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
47993917|NCT02373020|OTHER|colonoscopic biopsies|
48364404|NCT01632345|DRUG|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
48511678|NCT03316547|OTHER|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises \[passive range of motion (PROM), gentle stretching\]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
48153370|NCT02572986|DRUG|Permethrin|
48679777|NCT02341651|OTHER|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
47993918|NCT03593265|OTHER|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
48511679|NCT03203850|DRUG|Deferasirox FCT|Taken orally once per day (QD) as a film coated tablet (FCT)
47993919|NCT01191580|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
48153371|NCT00508183|PROCEDURE|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
48153372|NCT00508183|PROCEDURE|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
48153373|NCT05058547|DEVICE|SWEPPE|In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
48153374|NCT04019301|OTHER|Baduanjin Qigong, Community-based|The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.
48153375|NCT04019301|OTHER|Baduanjin Qigong, Internet-based|The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
48153376|NCT02976363|RADIATION|Radiotherapy breast cancer|
48153377|NCT02976363|OTHER|Evaluation Maximal Respiratory Pressures|
48153378|NCT02085824|DRUG|Enoxaparin|
48364405|NCT01632345|DRUG|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
48364406|NCT01632345|DRUG|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
48511680|NCT03203850|PROCEDURE|Phlebotomy|according to investigator's decision
48511681|NCT01589718|DRUG|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
48511682|NCT01589718|DRUG|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
48511683|NCT04898530|OTHER|NO INTERVENTION|There is no intervention for this study.
48679778|NCT03339310|DEVICE|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
48679779|NCT01662739|BEHAVIORAL|Questionnaire|
48679780|NCT05442567|DRUG|Vedolizumab IV|Vedolizumab IV infusion
48679781|NCT05442567|OTHER|No Intervention|Participants will not receive any intervention in the Observational Cohort.
48679782|NCT05765058|OTHER|Group A|Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
48153379|NCT02085824|DRUG|rivaroxaban|
48153380|NCT02085824|DRUG|dabigatran|
48364407|NCT01632345|DRUG|Placebo for Doravirine|Placebo tablets matching doravirine
48364408|NCT01632345|DRUG|Placebo for Efavirenz|Placebo tablets matching efavirenz
48364409|NCT02206230|RADIATION|Hypofractionated radiation therapy|
48364410|NCT02206230|RADIATION|Standard radiation therapy|
48364411|NCT02802527|PROCEDURE|Percutaneous Tracheostomy|
48364412|NCT00153322|BEHAVIORAL|Nurtition and Physical Activity Education|
48364413|NCT06183060|PROCEDURE|endotracheal intubation|all patients will receive laryngoscopy and endotracheal intubation
48364414|NCT05023239|OTHER|UG-SZM Group|The patients will be receive Ultrasound-Guided Suprazygomatic Maxillary Nerve Blocks 10 mL of a local anesthetic mixture composed of 0.25% plain bupivacaine .
48679783|NCT05765058|OTHER|Group B|Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
48153381|NCT01263223|DRUG|LY2216684|Administered orally
48679784|NCT05765058|OTHER|Group C|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
48679785|NCT05765058|OTHER|Group D|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
48679786|NCT01797757|DIETARY_SUPPLEMENT|Fish oil enriched with EPA|
48679787|NCT01797757|DIETARY_SUPPLEMENT|MAG-EPA oil|
48679788|NCT01797757|DRUG|Orlistat|
48679789|NCT01968538|RADIATION|Radiation Therapy|
48679790|NCT06512870|DIAGNOSTIC_TEST|Near infrared spectroscopy (NIRS)|A technique that relies on differential absorption of infrared light to provide relative estimation of tissue oxygenation, has been successfully used to monitor perfusion of various tissues, including muscle tissue of the lower extremity.
48153382|NCT01263223|DRUG|Placebo|Administered orally
48153383|NCT04818918|DEVICE|Absolute coronary flow measurement|Absolute coronary flow will be measured.
48153384|NCT04818918|DEVICE|Microvascular resistance measurement|Microvascular resistance will be measured.
48679791|NCT03722381|DRUG|Amlodipine Besylate|Pharmacokinetics
48679792|NCT03079531|DRUG|Secukinumab|Secukinumab 300 mg administered subcutaneously.
47993920|NCT01191580|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
47993921|NCT01191580|BEHAVIORAL|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
47993922|NCT04174287|DRUG|F-18-AV45|The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
47993923|NCT02808130|OTHER|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
47993924|NCT00862446|DRUG|Omegaven|1 gram/kg/day daily until on feeds
48153385|NCT04818918|OTHER|Cardiac MRI|Cardiac MRI will be performed to evaluate myocardial viability.
48153386|NCT00237718|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
48153387|NCT00237718|DRUG|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
48153388|NCT00237718|DRUG|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
48153389|NCT00237718|DRUG|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
48153390|NCT02361983|DEVICE|DLT versus bronchial blockers|Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
48153391|NCT05500313|BEHAVIORAL|Hypno-breastfeeding Education|The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.
48266825|NCT03416231|DRUG|Apatinib|apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
48679793|NCT05959317|OTHER|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
48679794|NCT05959317|OTHER|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
48679795|NCT02990715|DEVICE|C-Scan System|"1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
48679796|NCT04921852|PROCEDURE|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
48679797|NCT04921852|PROCEDURE|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
47993925|NCT03774433|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
47993926|NCT00859235|DRUG|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
47993927|NCT00859235|OTHER|Plain water|Mouth wash prior to procedure
48153392|NCT05500313|BEHAVIORAL|Experimental: Standart Breastfeeding Education|The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
48679798|NCT05139927|BEHAVIORAL|Motivational interviewing (MI) counseling|Those assigned to receive Component A will engage in a MI single session lasting approximately 30-45 minutes. The overall goal of the session is to increase participants' motivation and readiness to test for COVID-19 in various circumstances.
47993928|NCT05657691|DRUG|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
47993929|NCT05657691|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
47993930|NCT03608514|DRUG|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
47993931|NCT06327958|OTHER|Cormack-Lehane (C&L)|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
47993932|NCT06327958|OTHER|POGO score|There is no distinguishing feature of the C\&L and POGO scores required to provide the best laryngoscopic view from other interventions in this or any other clinical trial.
47993933|NCT00731770|DRUG|Advair 250|1 puff bid inhaled
47993934|NCT00731770|DRUG|Placebo- matched|1 puff bid inhaled
47993935|NCT00731770|DRUG|Placebo|Placebo 1 puff bid inhaled
47993936|NCT00731770|DRUG|Advair 250 - matched|i puff bid inhaled
47993937|NCT04700358|OTHER|Blood sampling|"Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)"
47993938|NCT01577147|OTHER|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
47993939|NCT02450032|BIOLOGICAL|G17DT|
47993940|NCT06069479|PROCEDURE|craniofacial surgery|Surgical treatment, either stripcraniectomy or fronto-orbital advancement
47993941|NCT05398432|OTHER|motivational interview|"After the pre-test data were applied to all patients, before starting the motivational interview seans, the patients were informed about the interview intervals, duration, and how many times they would be held. In the second week, motivational interview seans were started with the patients. seans with patients took place during the hemodialysis seans. A total of 6 seans were held, one seans per week. After the first seans of the self-care supported motivational interview, the Self-Care and Adaptation to Disease Training Guide prepared by the researcher in line with the literature was given to the experimental group. Self-care training was given in the first, second and third seans. Motivational interviews were conducted in the fourth, fifth and sixth seans. Motivational interviewing techniques were used for patients to realize their self-care activities. seans were held individually with the patients and each seans lasted approximately 15-20 minutes."
47993942|NCT02168010|DRUG|Analgecine|Analgesic drug under test
48153393|NCT01301183|DRUG|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
48364415|NCT04920305|DIETARY_SUPPLEMENT|Phosphatidylserine|subjects in the treatment group oral the PS (600mg/d, q.d.) for 6 months.
47993943|NCT02168010|DRUG|Neurotropin|Analgesic drug as positive control
47993944|NCT02168010|DRUG|Placebo|Blank tablet as placebo.
47993945|NCT06032247|BEHAVIORAL|Resistance exercise program- UL|"Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
47993946|NCT06032247|BEHAVIORAL|Resistance exercise program- BL|"Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
48266826|NCT03416231|DRUG|Docetaxel|Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.
48364416|NCT04920305|DIETARY_SUPPLEMENT|Bean powder|Subjects in the control group were given a placebo, which was the same shape of bean powder(600mg/d, q.d.).
48364417|NCT04201444|DIAGNOSTIC_TEST|Patient group|Patients with Cushing Disease (CD) receiving a medical treatment: n = 30 Plasmatic cortisol UFC Urine biocollection Salive biocollection
47993947|NCT06146946|PROCEDURE|Dissection of the No.253 lymph node|The range of the No.253 lymph node is as follows: medially, it extends from the root of the inferior mesenteric artery to the starting section of the left colonic artery; caudally, from the starting point of the left colonic artery to the intersection with the inferior mesenteric vein; laterally, it is bordered by the outer margin of the inferior mesenteric vein; and cranially, from the horizontal section of the duodenum to the beginning of the jejunum. In the controlled group, the surgery is performed with dissection of the No.253 lymph node.
47993948|NCT06146946|PROCEDURE|Omitting the dissection of the No.253 lymph node|In the experimental group, the surgery is performed without dissection of the No.253 lymph node.
47993949|NCT04483713|BEHAVIORAL|Educational Workshop|"The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires."
47993950|NCT04483713|BEHAVIORAL|Educational Workshop plus J. H. N. EBP Guide Tools|"In addition to the workshop. It will follow the same molds as the case of group Educational Workshop plus the Johns Hopkins Nursing Evidence-based Practice guide tools since the beginning of this practical class, when the participant will receive a description of a problem as a basis for elaborating their clinical question, and thus, move on to the next stage.~The tools will be offered in the case of this group: question development, evidence level and quality guide, research evidence assessment tool, individual evidence tool, evidence synthesis and recommendation tool, action planning tool and tool dissemination."
47993951|NCT06344754|OTHER|Gamified education|Training will be provided with gamification method. Data will be collected with \&#34;Introductory Information Form\&#34; and \&#34;Family Planning Attitude Scale\&#34;. The family planning attitude scale will be administered as both pre and post test.
47993952|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
47993953|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
47993954|NCT00192504|BIOLOGICAL|Motavizumab|Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
47993955|NCT00192504|OTHER|Placebo|Single dose of placebo administered intravenously (in the vein) on Day 0
47993956|NCT04665050|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
47993957|NCT04665050|BIOLOGICAL|PNEUMOVAX™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
47993958|NCT04726345|DRUG|Fexofenadine Hcl 180Mg Tab|Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
47993959|NCT04726345|DRUG|Placebo|Placebo tablet to be taken orally once a day until stent removal.
47993960|NCT05551494|DIAGNOSTIC_TEST|Urinary sample|"At study entry, we will collect urinary samples from women. Participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).~In addition, women will be asked to report about their habits about consumption of plastic"
47993961|NCT00605475|DRUG|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
47993962|NCT00605475|DRUG|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
47993963|NCT00605475|DRUG|Metformin|Participants continued on their stable daily dose of metformin throughout the study
47993964|NCT04345575|DEVICE|PainCare VR|Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.
47993965|NCT04345575|OTHER|Audio content|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
47993966|NCT04657614|OTHER|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
48679799|NCT05139927|BEHAVIORAL|Text messages (TMs) and quiz questions (QQs)|"This intervention lasts 6 weeks. This component is grounded in principles of behavioral economics. Its main goal is to add interest and excitement to the goal of COVID-19 testing, serve as a reminder that COVID-19 testing is recommended in a number of scenarios, and nudge participants toward testing and creating a habit of serial screening and COVID-19 testing as needed. Participants first receive a brief orientation to the component (15 min.), and the participant will put the study phone number into his/her phone and a test TM and QQ will be sent. TMs and QQs are programmed into the Telerivet program and sent automatically. Twice a week participants will receive a TM with information about COVID and COVID-19 testing followed by a true/false question about that TM two days later, for which they earn 10 points for a correct answer, and 5 points for an incorrect answer. Participants earn modest prizes based on their points."
48679800|NCT05139927|BEHAVIORAL|Peer education|This component has two aspects: Participants are trained to educate their peers on core messages about the importance of COVID-19 testing that address social norms about COVID-19 testing and highlight COVID-19 testing as an altruistic act (15-20 min. training). Then, participants are given the opportunity to educate three peers who are Black and Latino/Hispanic frontline essential workers on the core messages. These peers contact the study directly and receive a brief assessment and referrals to testing, but are not enrolled in the study.
48679801|NCT05139927|BEHAVIORAL|Access to COVID testing|Component D is an adaptive intervention component that avoids unnecessary costs; it is only provided if needed. Level 1: Over a 2-3 week period, navigation includes a brief needs assessment and guidance to assist participants in prioritizing, accessing, and completing COVID-19 testing sequences in a timely fashion and resolving barriers such as transportation or the possible need to take off work if diagnosed with COVID-19. Level 2: 1 month after enrollment, participants will be contacted by phone. If they have not been tested, we will provide them with a BinaxNOW test kit which can be picked up or mailed to them.
48679802|NCT02589197|DEVICE|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
48679803|NCT02589197|DEVICE|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
48679804|NCT04091191|DIETARY_SUPPLEMENT|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
48679805|NCT04276194|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo intensity modulated proton therapy
48153394|NCT01301183|DRUG|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
48153395|NCT03263117|DRUG|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
47993967|NCT04657614|OTHER|Anterior Alignment|Alignment that is anterior displaced pylon.
47993968|NCT04657614|OTHER|Posterior Alignment|Alignment that is posteriorly displaced pylon.
48266827|NCT06545487|OTHER|BLOOD SAMPLE|BLOOD ANALYTICS IN SEVERAL PARAMETERS
47993969|NCT00678119|BIOLOGICAL|AGS-003|Dendritic cell Immunotherapeutic
47993970|NCT00678119|DRUG|Sunitinib|An approved drug for the treatment of RCC
47993971|NCT02002923|PROCEDURE|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
48266828|NCT05762328|BEHAVIORAL|Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia|Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
48511684|NCT02777398|PROCEDURE|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
48511685|NCT02777398|PROCEDURE|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
48511686|NCT00368017|DRUG|pioglitazone|30 mg once a day for 12 weeks
48511687|NCT00368017|DRUG|placebo|1 pill once a day for 12 weeks
48679806|NCT04276194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48679807|NCT00169702|BEHAVIORAL|weight management program|12 sessions, psychoeducation
48679808|NCT00169702|BEHAVIORAL|weight management program|2 weekly, 12 sessions, psychoeducational weight management
48679809|NCT03345355|DIAGNOSTIC_TEST|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
48679810|NCT00610259|BEHAVIORAL|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
48153396|NCT03263117|DRUG|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
48153397|NCT03263117|PROCEDURE|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
48153398|NCT06063915|DEVICE|Isoinertial training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using isoinertial machines
48153399|NCT06063915|OTHER|Strength Training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using classic exercises
48153400|NCT00215943|DRUG|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
48153401|NCT00215943|DRUG|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
48153402|NCT00215943|DRUG|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
48153403|NCT00215943|DRUG|vincristine|As outlined in VAD Treatment Arm
48153404|NCT00215943|DRUG|adriamycin|As outlined in VAD Treatment arm
48153405|NCT00005867|BIOLOGICAL|bleomycin sulfate|
48153406|NCT00005867|DRUG|CHOP regimen|
48153407|NCT00005867|DRUG|cyclophosphamide|
48153408|NCT00005867|DRUG|doxorubicin hydrochloride|
48153409|NCT00005867|DRUG|etoposide|
48153410|NCT00005867|DRUG|mitoxantrone hydrochloride|
48153411|NCT00005867|DRUG|prednisolone|
48153412|NCT00005867|DRUG|vincristine sulfate|
48153413|NCT01292005|DRUG|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
48153414|NCT01292005|DRUG|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
48364418|NCT04201444|DIAGNOSTIC_TEST|Remission control group|Patients in remission of CD and having recovered a normal pituitary function for at least 12 months following pituitary surgery (normal UFC associated to: cortisol suppression following dexamethasone suppression test, or normal LNSC, or midnight serum cortisol \< 200 nmol/L) n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
48364419|NCT04201444|DIAGNOSTIC_TEST|Bilateral surrenalectomy control group|Patients with previous CD, treated with bilateral adrenalectomy and receiving weight adjusted doses of hydrocortisone for at least 6 months. Last daily dose of Hydrocortisone should be administered no later than 5 pm. n = 15 Plasmatic cortisol UFC Urine biocollection Salive biocollection Haircortisol
48364420|NCT03464162|BEHAVIORAL|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
48511688|NCT06354634|OTHER|Resin polymer (NuSmile Bioflx) crown|Resin polymer (NuSmile Bioflx)crown
48511689|NCT06354634|OTHER|Stainless steel crown|Stainless steel crown
48153415|NCT06348160|BEHAVIORAL|iHERO Toolkit Resource|iHERO Toolkit consists of micro-videos and supplemental online resources. Participants will have access to the toolkit housed on pathfactory for 30 days.
48364421|NCT05732740|BEHAVIORAL|Empower@Home:Connected|Cognitive behavioral therapy
48153416|NCT05583474|DRUG|OPC-1085EL|one drop for each eye, once per day
48153417|NCT05583474|DRUG|0.005% Latanoprost|one drop for each eye, once per day
48153418|NCT03754686|DRUG|Oseltamivir|Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
48153419|NCT03754686|DRUG|Paracetamol|Best medical care and oral paracetamol twice daily for five days
48153420|NCT04639752|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
48153421|NCT04639752|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
48153422|NCT01384916|BEHAVIORAL|Yoga|2x weekly
48153423|NCT01384916|BEHAVIORAL|Healthy Living Workshop|2x weekly
48153424|NCT03467802|BIOLOGICAL|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
48364422|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
48511690|NCT02483546|DEVICE|Laerdal®|simulation- based educational intervention
48679811|NCT00610259|OTHER|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
48679812|NCT03968692|DIAGNOSTIC_TEST|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
48153425|NCT03467802|DEVICE|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
48153426|NCT06332885|DEVICE|Zephyr Endobronchial Valve|Zephyr Valve provides an alternative technique to achieve bronchoscopic lung volume reduction (BLVR) using a minimally invasive approach. Zephyr Valve is a tiny unidirectional valve. During BLVR, multiple valves are placed to occlude a hyperinflated lobe of the lungs, allowing air to escape while blocking airflow into the treated lobe. This is intended to result in a reduction in lung volume and hyperinflation in the targeted area. Consequently, the remaining lobes can expand more fully, the overall lung works more efficiently, with resultant improvement in overall lung function in patients with hyperinflation associated with severe emphysema.
48153427|NCT03873038|DRUG|MK-2060|"Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22."
48364423|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
48364424|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
48364425|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
48364426|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
48364427|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
48364428|NCT00634933|DRUG|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
48364429|NCT00634933|DRUG|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
48364430|NCT00634933|DRUG|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
48364431|NCT05078268|BEHAVIORAL|HRV biofeedback training and self-help CBT-I|Participants will receive a booklet with content related to both self-help CBT-I and HRV biofeedback per week for 6 consecutive weeks. Participants are required to use around 1 hour to read through the content and perform the HRV biofeedback practice for around 20 minutes a day, 5-7 days a week and record their practice.
48364432|NCT05078268|BEHAVIORAL|Self-help CBT-I only|Participants will receive a booklet with content related to self-help CBT-I only per week for 6 consecutive weeks. Participants are required to use 30 to 40 minutes to read through the content.
48364433|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
48364434|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
48364435|NCT03490734|DIETARY_SUPPLEMENT|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
48364436|NCT03490734|DIETARY_SUPPLEMENT|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
48364437|NCT03490734|OTHER|Water|Three mL administered per associated logo presentation only during MRI procedure.
48364438|NCT03977363|DRUG|Anticoagulant drugs|Anticoagulant drugs
48364439|NCT05953896|COMBINATION_PRODUCT|Hyaluronic acid gel|For the Hyaluronic acid gel group: HA gel was injected 2-3mm apical to the coronal tip of the involved papillae and the needle was directed coronally with an angulation of 45° to the long axis of the tooth, and the bevel directed apically until papilla became blanched. The injection was given at each papilla at the following intervals baseline, one week and two weeks.
48364440|NCT05953896|COMBINATION_PRODUCT|Multilayer L-PRF membranes|For the multilayer L-PRF group: A single semilunar incision is made in the buccal vestibule, apical to the muco-gingival junction in the mid interproximal area of the papilla to be treated.Tunneling of the incisions has maintained the full height and thickness of the gingiva. Multilayer L-PRF membranes were prepared according to Pinto's protocol immediately prior to the surgery and placed in the tunnel then incision was closed with simple interrupted sutures.
47993972|NCT02002923|DRUG|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
47993973|NCT03550703|BIOLOGICAL|V3-Myoma|Once daily oral pill of V3-Myoma
48153428|NCT03873038|DRUG|Placebo|Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
47993974|NCT02735551|DRUG|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
47993975|NCT02735551|OTHER|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
47993976|NCT02735551|OTHER|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
48153429|NCT05449145|DIETARY_SUPPLEMENT|Vitamin D|1st week: Vitamin D 82285.71 IU per day (total dose: 576000IU per week); 2th to 4th week: Vitamin D 41142.86 IU per day (total dose: 288000IU per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
48153430|NCT05449145|DIETARY_SUPPLEMENT|Non-Vitamin D|1st week: 95% MCT oil 5.71 ml per day (total dose: 40 ml per week); 2th to 4th week: 95% MCT oil 2.86 ml per day (total dose: 20 ml per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
48153431|NCT04851288|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
48153432|NCT04851288|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
48153433|NCT00928265|DEVICE|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
48153434|NCT02422355|DEVICE|FNS|Surgical intervention using the FNS
48679813|NCT03446963|BEHAVIORAL|Groups for Health|Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
48153435|NCT02774876|DEVICE|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
48153436|NCT02774876|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
48679814|NCT02584712|OTHER|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
48679815|NCT05617118|DRUG|Baclofen 10mg|Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
48679816|NCT05617118|DRUG|Botulinum toxin type A|Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
48679817|NCT05407207|DEVICE|Tennant Biomodulator ®|Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
48679818|NCT01042158|DRUG|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
48679819|NCT06513390|DEVICE|Exoskeleton of default mode|Default mode: A standard control system offering a conventional assistive function of Exo-H3.
47993977|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Other Week dosing
48153437|NCT02774876|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
48153438|NCT02774876|OTHER|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
48153439|NCT00292409|DRUG|Aripiprazole|
47993978|NCT00409617|BIOLOGICAL|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
48153440|NCT06234449|PROCEDURE|Vaginal pessary before surgery for pelvic organ prolapse|use of vaginal pessary for patients waiting for gynecological surgery for stage III and IV pelvic organ prolapse
48364441|NCT01914900|DRUG|docetaxel, cisplatin, 5 fluorouracil|
48153441|NCT02124304|DEVICE|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
48153442|NCT03599440|OTHER|Pressure line extensions|"Two types of extension lines are connected:~* Perfusor® line 150cm (polyethylene)~* conventional arterial extension line"
48153443|NCT01913444|DRUG|Recombinant Antithrombin|
48679820|NCT06513390|DEVICE|Exoskeleton of Intelligent mode|Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
48153444|NCT05670678|DIETARY_SUPPLEMENT|a2 growing up stage 3 formula puls lactoferrin supplement|The participants in this group will consume 4-5 scoops (8.5g/scoop) of the assigned formula each time, and 4 times per day
48153445|NCT05670678|DIETARY_SUPPLEMENT|Enfinitas growing up stage 3 formula|The participants in this group will consume 4 scoops (10g/scoop) of the assigned formula each time, and 3 times per day
48153446|NCT05860218|OTHER|advices|"The following advice will be given to the patients :~1. Walking as flexibly (normally) as possible~2. Advise when lifting ;~   * avoid twisting and bending.~  * for heavy objects use thighs with a vertical back.~  * at other times, use the back and flex it.~3. Heat application for 20 mins twice /day .~4. Avoid sitting or standing for prolonged period and change position every 15 mins.~5. Sitting: Sit with a back support~6. Driving: Use a back support (lumbar roll) at the curve of your back.~7. Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary."
48153447|NCT05860218|OTHER|exercises plus advices|"In addition to the same advice of group A, a suggested functional exercise will be performed for this group.~1. Sidestepping against band resistance:~2. The quadriped opposite arm leg aganist resistance .~3. Squat row on a balance board with band resistance:~4. Front raise single leg support with band resistance:~5. The Advanced Prone Bridge:~6. Side sliding on a fitter board (lateral lunge with band):"
48153448|NCT01786915|DRUG|Bendavia 10mg|
48364442|NCT05427084|DRUG|Canagliflozin|Canagliflozin tablet 300mg PO daily
47993979|NCT00001442|DRUG|paclitaxel concurrent with radiation therapy|
47993980|NCT01028157|BEHAVIORAL|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
48153449|NCT01786915|DRUG|Bendavia 50mg|
48153450|NCT01786915|DRUG|Placebo|
48153451|NCT01215253|DRUG|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
48153452|NCT05652985|BEHAVIORAL|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
48364443|NCT05427084|DRUG|Placebo|Placebo tablet
48364444|NCT00391911|DRUG|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
48364445|NCT00391911|OTHER|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
48511691|NCT02483546|BEHAVIORAL|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
48679821|NCT02445014|DEVICE|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
48679822|NCT01692106|PROCEDURE|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
48679823|NCT03045588|OTHER|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
48679824|NCT06374888|DRUG|Neratinib maleate in combination with capecitabine|Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
48679825|NCT05580354|DRUG|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
48679826|NCT03413033|OTHER|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
47993981|NCT01028157|BEHAVIORAL|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
48511692|NCT02483546|BEHAVIORAL|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
48679827|NCT03413033|OTHER|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
48679828|NCT02653339|DRUG|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
48679829|NCT02653339|DRUG|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
48679830|NCT02606071|DEVICE|CRT-D|HF patients treated in clinical practice with a CRT-D device
48679831|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
48679832|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
48679833|NCT00099502|DRUG|Copaxone|20 mg administered s.c. once daily.
48679834|NCT05205616|DEVICE|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
48679835|NCT05205616|DEVICE|Reciprocating saw|See above description
48679836|NCT02537730|DEVICE|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
48679837|NCT02537730|DEVICE|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
48679838|NCT02537730|DEVICE|comfilcon A|contact lens
48679839|NCT04593368|OTHER|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
48679840|NCT00953953|DEVICE|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
48679841|NCT04799457|OTHER|Suture technique|We wil apply additional sutures to classical caesarean procedure.
48679842|NCT04090957|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
48679843|NCT04090957|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
48679844|NCT05640362|OTHER|Natural enzymes mouthwash|Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
48679845|NCT05640362|OTHER|Benzydamine mouthwash|Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
47993982|NCT01277952|DEVICE|Deep Brain Stimulation|Brain pace maker, implanted in the brain
47993983|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 6 and 9 months|Arm A will receive MR vaccine dose at 6 and 9 months of age
47993984|NCT03071575|BIOLOGICAL|Measles-rubella (MR) vaccine at 9 months|Arm A will receive MR vaccine dose at 9 months of age
48511693|NCT05231005|BIOLOGICAL|BNT162b2 vaccine|fourth dose of the BNT162b2 vaccine (30 microgram) adminstered IM
48679846|NCT05318495|DEVICE|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
48679847|NCT05318495|DEVICE|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
47993985|NCT03061110|BIOLOGICAL|Stromal Vascular Fraction|Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
48679848|NCT05318495|DEVICE|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
47993986|NCT03061110|OTHER|Usual Care|Usual care will include over-the-counter and prescription methods to treat xerostomia.
47993987|NCT01324388|BIOLOGICAL|LY2189265|Administered subcutaneously
47993988|NCT01324388|DRUG|Metoprolol|Administered orally
47993989|NCT01324388|DRUG|Lisinopril|Administered orally
47993990|NCT01324388|DRUG|Placebo|Administered subcutaneously
47993991|NCT06059911|DIETARY_SUPPLEMENT|Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)|Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids
47993992|NCT06059911|DIETARY_SUPPLEMENT|Placebo dietary supplement (97% maltodextrin)|Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin
47993993|NCT02308462|BEHAVIORAL|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid \& Plass, 2011)."
47993994|NCT04428996|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.
47993995|NCT02162290|OTHER|Interval exercise training|Exercise bouts in low and high intensities
47993996|NCT02162290|OTHER|Continuous exercise training|
47993997|NCT00392431|DRUG|amiodarone|
47993998|NCT01012011|DRUG|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
48511694|NCT04473066|PROCEDURE|Adenotonsillectomoy +/- turbinate reduction|Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
48511695|NCT06132932|DRUG|WX390|Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
48511696|NCT06219278|DEVICE|Profound Matrix|The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
48511697|NCT06158555|DRUG|250 ML NaCl 4.5 MG/ML Injection|Bolus 250 ml crystalloid. Usually 0.9% saline or compound sodium lactate solution at discretion of attending clinician
48511698|NCT04663230|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|right atrial late gadolinium enhancement in % and cm2
48511699|NCT02111603|DRUG|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
48511700|NCT02990780|RADIATION|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
47993999|NCT01198054|DRUG|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
47994000|NCT03739112|BIOLOGICAL|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
47994001|NCT03739112|BIOLOGICAL|Fluarix Quadrivalent® Comparator Vaccine|Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
47994002|NCT04120532|BEHAVIORAL|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
47994003|NCT06490328|DRUG|DKF-MA102|Administered twice at 12-week intervals
47994004|NCT03322033|DEVICE|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
47994005|NCT00973024|DRUG|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
48364446|NCT00391911|OTHER|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
48364447|NCT00391911|OTHER|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
48364448|NCT00954356|DRUG|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
47994006|NCT00973024|DRUG|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
47994007|NCT00973024|DRUG|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
48364449|NCT00954356|DRUG|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
48364450|NCT03683680|OTHER|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
48364451|NCT03683680|OTHER|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
48364452|NCT02138864|RADIATION|18F-FP-(+)-DTBZ|no available
48364453|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
48364454|NCT03984916|DIETARY_SUPPLEMENT|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
48679849|NCT05248178|BEHAVIORAL|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
48679850|NCT05248178|DEVICE|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
48364455|NCT03984916|DIETARY_SUPPLEMENT|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
48364456|NCT01957904|DEVICE|ArterX Surgical Sealant|
48679851|NCT05248178|BEHAVIORAL|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
48679852|NCT05248178|DEVICE|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
48679853|NCT00737724|DRUG|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
48364457|NCT01919749|OTHER|treated recommended|Treatment will be recommended after reviewing the profiling analysis
48364458|NCT02384629|DEVICE|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
48511701|NCT02990780|RADIATION|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
47994008|NCT00973024|DRUG|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
48511702|NCT05052476|DIETARY_SUPPLEMENT|Bactecal® D Liquid|The patients will be randomized into two arms, A and B, in function of the intervention dose
48511703|NCT02171871|OTHER|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
47994009|NCT00973024|DRUG|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
48364459|NCT02384629|DEVICE|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
48364460|NCT02384629|DEVICE|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
47994010|NCT05384067|BEHAVIORAL|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
47994011|NCT05595681|DRUG|Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)|"The investigational product is a C2C_ASC cell product (Cell2Cure®, Cell2Cure ApS, Denmark).~C2C_ASC is an advanced therapy investigational medicinal product (ATIMP) manufactured from abdominal adipose tissue derived mesenchymal stromal cells (ASC) from healthy donors. C2C_ASC is aseptically procured and manufactured according to tissue law and GMP by Cell2Cure ApS or Cardiology Stem Cell Center, Rigshospitalet, Copenhagen, Denmark, using manual isolation of cells from abdominal fat tissue, xeno-free cell expansion in automated closed bioreactor systems and cryopreservation of the final product.~The active substance is the in vitro expanded ASCs. The final product, C2C_ASC, is provided as a cryopreserved suspension of 50 million ASCs per ml with a total volume of 1,3 ml per vial. The exipient is CryoStor10 (Biolife Solutions), holding 10% DMSO."
47994012|NCT00177528|DRUG|venlafaxine-XR|
47994013|NCT04749953|PROCEDURE|Maxillary sinus floor augmentation|The sinus membrane of the maxillary sinus is elevated to create a space for the grafting material and placement of dental implants in the posterior maxilla
48364461|NCT02384629|DEVICE|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
48511704|NCT05232188|PROCEDURE|Percutaneous nephrolithotomy|percutaneous nephrolithotomy surgery, 22F amplatz sheath is used in one group, while 28F amplatz sheath is used in the other group.
47994014|NCT02983383|PROCEDURE|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
48511705|NCT05642845|DRUG|Atorvastatin film-coated tablet 40 mg|Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
48511706|NCT05642845|DRUG|Liprimar® film-coated tablet 40 mg|"Liprimar® is manufactured by Pfizer Pharmaceuticals LLC, Puerto Rico, LLC Polysan Scientific and Technological Pharmaceutical Firm; RU holder: Pfizer Inc, USA. Each tablet contains 40 mg of atorvastatin."
48511707|NCT02293980|DRUG|MK-3795|Oral administration
48511708|NCT02293980|DRUG|Nivolumab|IV infusion
48511709|NCT02293980|DRUG|Cabozantinib|Oral administration
48511710|NCT02293980|DRUG|Bezlutifan|Oral administration
48511711|NCT01461447|BIOLOGICAL|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
48511712|NCT06398119|OTHER|Traditional Treatment Program|Traditional Treatment Program for improving hand function
48511713|NCT06398119|OTHER|Virtual Reality Program|Virtual Reality Program for improving hand function
48511714|NCT05456230|DRUG|Midazolam|Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
48511715|NCT03389815|DRUG|WX-0593 Tablets|tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
48511716|NCT05927597|DRUG|INS1007|Oral tablets.
48511717|NCT05927597|DRUG|Placebo|Oral tablets.
48511718|NCT06633588|DRUG|Polyhexanide|Participants will apply Prontoderm® Nasal Gel and perform whole-body wash with Prontoderm® Foam daily for 5 days before surgery.
48679854|NCT00737724|DRUG|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
48364462|NCT00735163|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
48511719|NCT06633588|DRUG|Mupirocin and Chlorhexidine|Participants will apply Bactroban® Nasal ointment and perform whole-body wash with Lifo-Scrub® daily for 5 days before surgery.
48511720|NCT06418347|DRUG|Alpha lipoic acid|"Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects."
48679855|NCT03579693|DIETARY_SUPPLEMENT|CoQ10|CoQ10 tablet
48679856|NCT03579693|DIETARY_SUPPLEMENT|Nicotinamide riboside|NR tablet
48679857|NCT03579693|DIETARY_SUPPLEMENT|Placebo|Sugar pill designed to mimic coQ10 and NR
47994015|NCT02983383|PROCEDURE|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
47994016|NCT02402985|OTHER|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
47994017|NCT02402985|OTHER|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
47994018|NCT02867709|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
47994019|NCT02867709|DRUG|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
47994020|NCT04588649|DRUG|THK-5351|\[18F\]THK-5351 PET Imaging
47994021|NCT04588649|DRUG|AV-45|\[18F\]AV-45 PET Imaging
47994022|NCT03189615|DRUG|Lu AF35700|Single oral dose of 10 mg Lu AF35700
47994023|NCT02287558|DRUG|Pomalidomide|
47994024|NCT04244188|OTHER|Collection of datas|Collection of datas: pre- and postoperative scanner and endoprosthesis characteristics
47994025|NCT03432546|OTHER|Non-interventional|Non-interventional
47994026|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
47994027|NCT00477672|DRUG|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
47994028|NCT00477672|DRUG|Placebo|tablet, once daily by mouth, 6 weeks
47994029|NCT05883904|DRUG|Fedratinib|Fedratinib administered after AIFA reimbusement approval
47994030|NCT01765153|BEHAVIORAL|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
47994031|NCT01765153|BEHAVIORAL|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
47994032|NCT04588402|BIOLOGICAL|The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.|"Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse.~A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection."
47994033|NCT05044455|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|A 9 week CBT group, 2 hours weekly, is delivered by trained Peer facilitators to mothers randomized to this arm.
47994034|NCT04532099|DEVICE|Lehfilcon A contact lenses|Investigational soft contact lenses for daily wear worn in Part A of the study
47994035|NCT04532099|DEVICE|Senofilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part A of the study
47994036|NCT04532099|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part B of the study
47994037|NCT04532099|DEVICE|Hydrogen peroxide-based cleaning and disinfecting solution|For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
47994038|NCT03463889|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
47994039|NCT03463889|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI in combination with PET
48364463|NCT00154895|DRUG|intrapleural minocycline instillation|
48364464|NCT02010489|OTHER|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
48364465|NCT01647477|BEHAVIORAL|interview|25 minutes of semi directive interview
48364466|NCT01647477|BEHAVIORAL|questionnaires|questionnaires to answer at baseline 45 minutes
48679858|NCT01033084|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
48679859|NCT01033084|DRUG|Sertraline|Patient will receive sertraline 50mg/day.
48679860|NCT01033084|OTHER|double placebo|double placebo arm (sham stimulation/placebo pill)
48153453|NCT01322347|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
48153454|NCT01322347|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
48153455|NCT05581108|DIETARY_SUPPLEMENT|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
48153456|NCT05581108|DIETARY_SUPPLEMENT|Placebo|matched placebo (2 capsules)
48153457|NCT03406299|DRUG|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
48153458|NCT03406299|DRUG|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
48153459|NCT03406299|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
48153460|NCT03406299|DRUG|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
48511721|NCT06418347|DRUG|Letrozole|Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
48153461|NCT03406299|DRUG|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
48153462|NCT03800602|DRUG|Metformin|Given PO
48153463|NCT03800602|BIOLOGICAL|Nivolumab|Given IV
48153464|NCT04043663|DEVICE|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
48153465|NCT04043663|PROCEDURE|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
48153466|NCT04907877|DIETARY_SUPPLEMENT|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
48153467|NCT04907877|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
48153468|NCT05052151|OTHER|Low dialysate temperature|35°C
48511722|NCT06548997|DRUG|GZR18|5 μg/kg-maximum tolerated dose (MTD), single dose or two doses
48511723|NCT06548997|OTHER|Placebo|administered the same volume as GZR18
48511724|NCT02428439|DRUG|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
48153469|NCT05052151|OTHER|High dialysate temperature|37°C
48153470|NCT05052151|OTHER|Low dialysate bicarbonate concentration|30 mmol/L
47994040|NCT03463889|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
47994041|NCT00424138|RADIATION|FDG|
48511725|NCT04968184|DRUG|Placebo|Participants will orally receive placebo matching to KBP-5074 tablets QD.
48153471|NCT05052151|OTHER|High dialysate bicarbonate concentration|38 mmol/L
48153472|NCT06384859|DEVICE|ESWT|Receive ESWT once a week for 4 weeks
48153473|NCT06384859|BIOLOGICAL|PRP|Receive PRP injection at week 5
48153474|NCT02028650|BIOLOGICAL|the first donor's stem cell|HLA-matched stem cell infusion
48153475|NCT02028650|BIOLOGICAL|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
48153476|NCT03148353|PROCEDURE|Subacromial injection|"1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection"
48153477|NCT05494346|DEVICE|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
48153478|NCT06227897|DRUG|Aumolertinib|Aumolertinib 110 mg per day orally for 3 years.
48153479|NCT01469442|PROCEDURE|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
48153480|NCT04363645|OTHER|Multicontext (MC) approach|The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
48153481|NCT04722471|DRUG|Vaginally administered progesterone|The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
48511726|NCT04968184|DRUG|KBP-5074|Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
47994042|NCT02232425|DRUG|IX-01|
48153482|NCT01489163|BEHAVIORAL|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
48153483|NCT03063983|DRUG|Cyclophosphamide|Continuous oral cyclophosphamide
48153484|NCT03063983|DRUG|Methotrexate|Continuous oral methotrexate
48153485|NCT01107795|PROCEDURE|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
48153486|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 20mg
48153487|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 40mg
48364467|NCT04656769|PROCEDURE|Peridural analgesia|We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.
48511727|NCT06414226|DIETARY_SUPPLEMENT|Krill and Fish Oil vs. Placebo|Participants were prescribed to take a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at an appropriate temperature during the 8-week treatment period. The patients were informed to take 2 of the capsules in the bottle to be taken orally daily in the morning before breakfast and the other 2 capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil or placebo (empty capsule) capsules. The daily intake of EPA+DHA from krill and fish oil was determined as 520 mg and 600 mg, respectively. Krill and fish oil were obtained from Aniqnaturals Superba and Orzax Ocean company, respectively.
48153488|NCT04503629|DRUG|Rabeprazole sodium|Rabeprazole sodium 10mg
47994043|NCT02232425|DRUG|Placebo|
47994044|NCT01838993|DRUG|Lidocaine inhalation|Lidocaine inhalation before intubation
48153489|NCT02249429|DRUG|bimiralisib|60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
48153490|NCT05640245|DRUG|Sonelokimab|randomized treatment; parallel group
48153491|NCT05640245|DRUG|Placebo|randomized treatment; parallel-group
48364468|NCT00752518|DRUG|bortezomib|
48364469|NCT04939441|DRUG|Tenofovir alafenamide|Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
48364470|NCT02230501|DIETARY_SUPPLEMENT|stringent diet regimen|
48364471|NCT02230501|DIETARY_SUPPLEMENT|moderate diet regimen|
48364472|NCT02587845|DRUG|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
48364473|NCT02587845|DRUG|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
48364474|NCT06085404|PROCEDURE|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
48364475|NCT04277286|BEHAVIORAL|survey|"Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)"
48364476|NCT04509206|BEHAVIORAL|Nutritional education|The curriculum for the four classes include understanding MyPlate guidelines, learn basic knife skills, meal prep, and plan, home farming and no-cook cooking.
48364477|NCT05032196|DRUG|WVE-003|WVE-003 is a stereopure antisense oligonucleotide (ASO)
48364478|NCT00459329|BEHAVIORAL|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
48364479|NCT04012866|BEHAVIORAL|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
48364480|NCT04012866|BEHAVIORAL|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
48364481|NCT04012866|BEHAVIORAL|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
48364482|NCT02276274|DRUG|SYR-322-MET|Oral administration of SYR-322-MET
48364483|NCT04981886|DRUG|Netarsudil Ophthalmic|Subjects will be randomly assigned to this group
48364484|NCT04981886|DRUG|Bimatoprost Ophthalmic|Subjects will be randomly assigned to this group
48511728|NCT03460080|DIAGNOSTIC_TEST|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
48679861|NCT00180557|DEVICE|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
47994045|NCT01838993|DRUG|Placebo|
47994046|NCT02725047|OTHER|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
48153492|NCT05640245|DRUG|Adalimumab|randomized treatment; parallel-group
47994047|NCT02725047|OTHER|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
48153493|NCT00575081|DEVICE|Stereotactic brain procedures|Stereotactic brain procedures
48153494|NCT05159726|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
48266829|NCT01698957|OTHER|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
47994048|NCT05293756|BEHAVIORAL|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~1. Six weekly web-based education sessions on hypertension management.~2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
48679862|NCT00876863|DRUG|CERE-110: Adeno-Associated Virus injection Surgery|Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.
48679863|NCT00876863|PROCEDURE|Placebo Surgery|Placebo Surgery
47994049|NCT00464568|DRUG|GSK256066|
47994050|NCT00101907|DRUG|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
48153495|NCT00722514|BEHAVIORAL|patient education|"* complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* Patient education 6 x 90 Minutes"
48364485|NCT03023436|PROCEDURE|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
48364486|NCT03023436|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
47994051|NCT00101907|BIOLOGICAL|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
48679864|NCT05474456|OTHER|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
47994052|NCT00101907|DRUG|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
47994053|NCT00101907|DRUG|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
47994054|NCT04852458|DRUG|Intravenous (IV) hydrocortisone|"Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg."
48153496|NCT00722514|BEHAVIORAL|Standard Care|"* complex individual antiinflammatory rehabilitation program during inpatient~* complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
48153497|NCT01099878|DEVICE|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
48364487|NCT03023436|DRUG|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
48511729|NCT02443597|OTHER|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
48679865|NCT05474456|OTHER|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
48679866|NCT06512610|OTHER|Middle Eastern or North Coast of Africa patients with newly AML|Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients
48679867|NCT01533441|DIETARY_SUPPLEMENT|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
48364488|NCT03023436|DRUG|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
48364489|NCT02781662|BEHAVIORAL|Pharmacist Home-Visit|
48364490|NCT06006676|OTHER|Near Apnoeic ventilation|Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation
48364491|NCT06006676|OTHER|Crossover standardised ECMO weaning trials|"When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially"
48364492|NCT04205188|OTHER|therapeutic exercises|aerobic- balance -stretching and strengthening exercises
48364493|NCT04802226|OTHER|self exclusion procedure|self exclusion procedure( responsible gambling tool)
48364494|NCT05129644|DRUG|P1101 (24 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.
48153498|NCT01099878|DEVICE|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
48364495|NCT05129644|DRUG|P1101 (48 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
48364496|NCT05129644|DRUG|P1101 (90 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.
48364497|NCT05129644|DRUG|P1101 (180 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.
48364498|NCT05129644|DRUG|P1101 (225 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.
48364499|NCT05129644|DRUG|P1101 (270 mcg)|P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
48511730|NCT01708967|PROCEDURE|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
48511731|NCT00775125|DRUG|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
48511732|NCT00852722|OTHER|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
48511733|NCT01374269|OTHER|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
48511734|NCT01374269|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
48153499|NCT04203225|DRUG|LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel|Topical anesthetic
48153500|NCT01741207|DRUG|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
48153501|NCT00540800|DRUG|docetaxel|given in combination with epirubicin or capecitabine
48511735|NCT03778073|DRUG|Cosibelimab|Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
47994055|NCT00278954|BIOLOGICAL|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
48153502|NCT00540800|DRUG|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
48153503|NCT00540800|DRUG|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
48364500|NCT05129644|DRUG|Pegasys|Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
48364501|NCT00000291|DRUG|Labetalol|
48364502|NCT04851522|DRUG|Di-Dak-Sol|Topical solution applied externally.
48364503|NCT04851522|OTHER|White Petrolatum|Topical ointment applied externally
48364504|NCT02265575|DRUG|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
48364505|NCT05685537|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
48364506|NCT01711931|DEVICE|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
48364507|NCT01711931|DEVICE|Implantation of everolimus-eluting stents|
48364508|NCT01711931|DEVICE|Implantation of biolimus-eluting stents|
48364509|NCT04838678|DRUG|Neuropeptide Y|intra-arterial infusion of neuropeptide Y
48364510|NCT04126187|DEVICE|Panoptix|Panoptix trifocal intraocular lens (IOL)
48364511|NCT01773057|OTHER|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
47994056|NCT05441527|DEVICE|MI Paste, then, Biotene Dry Mouth Gel|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
48364512|NCT04071899|OTHER|Scale vaidation|It's just filling a scale in order to validate it in French
48364513|NCT02527291|OTHER|Blood test|Blood test for CMV PCR and IL28
48364514|NCT03181776|OTHER|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
48679868|NCT04233528|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
47994057|NCT05441527|DEVICE|Biotene Dry Mouth Gel, then, MI Paste|1 milliliter of product will be applied daily to the intaglio (i.e., underside) of the patient's removable prosthesis and seated intraorally.
47994058|NCT00789893|DEVICE|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis \& assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st \& 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, \& the 2nd will be one month ± 2 weeks from last day of radiation.
47994059|NCT00990496|DRUG|Fludarabine|30 mg/m2
48153504|NCT02144116|OTHER|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
48153505|NCT02144116|OTHER|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
48153506|NCT03840278|DEVICE|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
48153507|NCT03840278|DEVICE|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
48153508|NCT03840278|DRUG|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
48153509|NCT03760809|DRUG|Dexmedetomidine 0.5μg／kg|Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
48153510|NCT03760809|DRUG|Dexmedetomidine 1μg／kg|Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
48153511|NCT03562117|DRUG|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
48679869|NCT04902430|PROCEDURE|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
48679870|NCT04902430|PROCEDURE|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
48679871|NCT05653401|DRUG|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
48679872|NCT05653401|DRUG|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
47994060|NCT00990496|DRUG|Cyclophosphamide|600 mg/m2
47994061|NCT00990496|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
47994062|NCT04972084|DEVICE|Powerscope group|Treatment of Class II malocclusions using Powerscope appliance
47994063|NCT01593488|DRUG|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
48679873|NCT05653401|DRUG|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
47994064|NCT04426591|DRUG|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of \~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
48153512|NCT01923870|DRUG|Androxal 25 mg|
48153513|NCT01525888|PROCEDURE|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
48153514|NCT06181019|DRUG|50 mg of mirabegron|Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
48153515|NCT06181019|COMBINATION_PRODUCT|acupuncture combined with mirabegron.|Patients in the treatment group were treated with acupuncture combined with mirabegron.
48153516|NCT00993590|BEHAVIORAL|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
48153517|NCT02699437|OTHER|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
48679874|NCT01296750|OTHER|Early Physiotherapy start|Physiotherapy starting at one day post op
48153518|NCT00547300|DRUG|Metoprolol ER|Metoprolol ER once daily, oral administration
48153519|NCT00547300|DRUG|Nebivolol|Nebivolol once daily, oral administration
48364515|NCT03181776|OTHER|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
48679875|NCT00895362|DRUG|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
47994065|NCT04426591|DEVICE|INTERCEPT Blood System|In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
48153520|NCT03650972|OTHER|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
48153521|NCT00005713|BEHAVIORAL|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
48153522|NCT00992849|DRUG|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
48153523|NCT03918187|DRUG|Bupivacaine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
48153524|NCT03918187|DRUG|Nalbuphine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
48153525|NCT03918187|DRUG|Midazolam|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
48153526|NCT05077046|OTHER|Ergonomic handwriting pen|An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
47994066|NCT01741181|DRUG|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
48153527|NCT06414213|BEHAVIORAL|Motor Imagery (MI)|Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.
48153528|NCT06414213|DEVICE|Active tDCS|"The participants received a 20-minute active session of tDCS at a 2-milliamp current."
48153529|NCT06414213|DEVICE|Sham tDCS|"The participants received a 20-minute session of sham tDCS."
48153530|NCT00509314|BEHAVIORAL|melanocyte self-assembly and functional analysis|
48153531|NCT04531007|DIAGNOSTIC_TEST|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
48153532|NCT00582855|DRUG|AQW051|
47994067|NCT01741181|DRUG|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
47994068|NCT05135520|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo Transvaginal NOSE
48153533|NCT00582855|DRUG|Placebo|
48153534|NCT03576378|DRUG|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
48153535|NCT03956147|OTHER|Munich Shoulder Questionnaire|Validation and Reability study
48153536|NCT05196958|OTHER|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
48153537|NCT00754533|OTHER|Continuous versus interval training|Influence of different exercise training programs
48153538|NCT01518517|DRUG|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
48153539|NCT01518517|DRUG|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
48153540|NCT03503500|OTHER|Laid-back breastfeeding|"At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided"
47994069|NCT05135520|PROCEDURE|Transabdominal specimen extraction|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo transabdominal specimen extraction with incision elongation
48153541|NCT03503500|OTHER|Standard care|"2. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast"
48153542|NCT06374407|BEHAVIORAL|Dietary intervention based on the MIND diet|A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.
48153543|NCT01161953|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
48153544|NCT01924468|DRUG|Oral methylphenidate and Oral haloperidol|
48364516|NCT03181776|OTHER|supine position|The mother will be placed in standard supine position
48364517|NCT05551195|DEVICE|WB001|WB001 is a digital therapeutic for postpartum depression.
48364518|NCT05551195|DEVICE|ED001|ED001 is a digital therapeutic for postpartum depression.
47994070|NCT05856123|DEVICE|SimPull Lateral Transfer Device|Automated lateral transfer device
48153545|NCT06607315|OTHER|physical properties of soft tissue|Using the Myoton Pro device, the physical properties such as elasticity and viscosity of the Achilles tendon, patellar tendon, gastrocnemius, quadriceps, and hamstring muscles will be measured.
48153546|NCT06607315|OTHER|Analysis of Running Form|High-speed camera systems will be used to analyze biomechanical parameters in detail, such as angular movements of the lower extremity joints (tibia, ankle, knee, hip), step length, and ground contact time during running. These analyses will allow us to objectively characterize different running forms.
48153547|NCT05473468|DRUG|Famitinib|a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
47994071|NCT01433510|DRUG|Grazax|1 tablet/day - pre and co-seasonal
48153548|NCT02954809|DEVICE|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
48153549|NCT02954809|DEVICE|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
48153550|NCT06406361|BEHAVIORAL|stress management training|"-Nurses should have an idea about stress management training Awareness develops about the importance of attending sessions regularly. Nurses have information about the training program. Joint session dates are determined. The educator makes statements about himself and education. The benefits of education for nurses are explained. Nurses are informed about the general rules of education. The importance of regular attendance at sessions is emphasized. Privacy rules and limits are determined. The necessity of completing homework is explained. Nurses are enabled to share their feelings and thoughts. Ensuring that nurses are able to recognize stress and reactions to stress and identify sources of stress in individual and business life.~Being informed about the effects of stress and workload perception Being able to recognize the tension created by stress in the body Learning breathing and deep relaxation techniques to reduce or eliminate symptoms of stress"
48153551|NCT06565416|BEHAVIORAL|Implementation Strategies|Culturally centering screening and brief intervention for chronic pain and opioid misuse/opioid use disorder among American Indian/Alaska Native clients
48153552|NCT05349630|DRUG|Ferrous sulfate 325mg|Participants will take one tab of ferrous sulfate 325 mg (equivalent to 65 mg elemental iron) daily for 30 days.
48153553|NCT04081818|OTHER|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
48153554|NCT01709071|DRUG|IPV|
48153555|NCT01709071|DRUG|Low dose Sabin-IPV|
48364519|NCT05370235|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
48364520|NCT04287673|OTHER|Rehabilitation involving strongly the trunk|The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
48364521|NCT00544154|DRUG|CDP870|
48364522|NCT00056472|DRUG|Olanzapine|10-20mg/day
47994072|NCT06093412|PROCEDURE|unilateral epidural anesthesia|The patients received unilateral epidural anesthesia
47994073|NCT06093412|PROCEDURE|combined lumbar and epidural anesthesia|The patients received combined lumbar and epidural anesthesia
47994074|NCT01232920|DRUG|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
48153556|NCT01709071|DRUG|Low dose adjuvanted Sabin-IPV|
48364523|NCT00056472|DRUG|Sertraline|150-200mg/day
48364524|NCT00056472|OTHER|placebo|tablet that ressembles sertraline but contains no medication
48511736|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
48679876|NCT00895362|DRUG|Cetuximab|Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
48153557|NCT01709071|DRUG|Middle dose Sabin-IPV|
48153558|NCT01709071|DRUG|Middle dose adjuvanted Sabin-IPV|
48153559|NCT01709071|DRUG|High dose Sabin-IPV|
48153560|NCT01709071|DRUG|High dose adjuvanted Sabin-IPV|
48153561|NCT05512988|BIOLOGICAL|UC-MSC|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person."
48364525|NCT05514093|DEVICE|Beyond Silence App|"The Beyond Silence app is designed to be a mental health coach in your pocket for healthcare workers. It provides opportunities to build mental health literacy and reduce barriers to seeking support, including access to peer support either within or outside the organization."
48364526|NCT00676468|OTHER|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
48364527|NCT00676468|OTHER|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
48364528|NCT00676468|OTHER|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
47994075|NCT01232920|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
47994076|NCT02062333|DRUG|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
48153562|NCT05512988|BIOLOGICAL|Saline solution|"Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course"
48153563|NCT00067808|DRUG|Decitabine|10 mg/m\^2 by vein over 1 hour daily for 10 days
48153564|NCT00067808|DRUG|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
48153565|NCT00067808|DRUG|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
48153566|NCT04998825|DIETARY_SUPPLEMENT|Proteoglycan F|Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.
48153567|NCT04998825|OTHER|Placebo product|The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
48153568|NCT01478256|DRUG|Erythromycin|Topical erythromycin ointment twice a day
48153569|NCT01478256|DRUG|Besifloxocin|Topical Besifloxocin twice a day
48153570|NCT04475874|OTHER|supervised stretching exercises|30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
48153571|NCT04475874|OTHER|non-supervised active stretching home program|non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
48153572|NCT01182506|BEHAVIORAL|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
48153573|NCT03596697|DRUG|CRV431|Single or multiple dose(s) of CRV431
48153574|NCT03596697|DRUG|Placebo|Single Placebo dose
48153575|NCT03596697|DRUG|TDF|Single or multiple dose(s) of TDF
48679877|NCT05174338|OTHER|Registry|Observational, data collection
48679878|NCT02536144|PROCEDURE|magnetic-controlled capsule endoscopy system|"1. A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~2. The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~3. While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~4. The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
48679879|NCT02536144|PROCEDURE|Colonoscopy|"1. Bowel preparation should be well done before the examination.~2. A tube with illumination and camera system would insert into colon from anus.~3. From the pictures captured by the camera ,the doctor would see the mucous of the colon."
48679880|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
48679881|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
48679882|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
48679883|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
48679884|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
48679885|NCT02948582|DRUG|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
48679886|NCT04891913|DRUG|SY-007/ Placebo 15mg|15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
48153576|NCT04887597|DRUG|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
48153577|NCT04785261|DRUG|Methylhydroxypropylcellulose|1-2 drips each time, every 4 hours, for 12 weeks.
48153578|NCT04785261|DRUG|Carbomer|1 drip each time, at bedtime, for 12 weeks.
48153579|NCT04785261|DRUG|TCM Formula|6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
48153580|NCT04779047|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
48153581|NCT04779047|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
48153582|NCT04779047|DRUG|Tocilizumab|Tocilizumab 800 mg once.
48153583|NCT04779047|DRUG|Lopinavir/ Ritonavir|Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
48153584|NCT04779047|DRUG|Ivermectin|Ivermectin 36 mg at day 1,3 and 6.
48364529|NCT04325490|DRUG|Liquid powder|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
48364530|NCT04325490|DRUG|Hydrocortisone cream 1%|apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
48364531|NCT04105231|DRUG|Cannabidiol|Cannabidiol oral suspension
48679887|NCT04891913|DRUG|SY-007/ Placebo 30mg|30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
48679888|NCT04891913|DRUG|SY-007/ Placebo 60mg|60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
48364532|NCT04105231|DRUG|Risperidone|Risperidone, encapsulated tablet.
48364533|NCT04555993|PROCEDURE|lower abdominal surgery|Patients will undergo lower abdominal surgery under general anesthesia.
48364534|NCT04555993|OTHER|Erector spinae plane block|patients will receive erector spinae plane block using 20 mL levobupivacaine (0.25%).
48153585|NCT05959837|OTHER|Adaptive Rowing Exercise|Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
48364535|NCT04555993|OTHER|Transversus abdominis plane block|patients will receive transversus abdominis plane block using 20 mL levobupivacaine (0.25%).
48364536|NCT04306575|OTHER|Trans-venous lead extraction|Patients with a dysfunction or infection of a cardiac pacemaker or a defibrillator are indicated for extraction of these devices, so lead extraction is done transvenously to remove these leads
48364537|NCT02242305|DRUG|Hyoscine Butylbromide - Tablet|
48364538|NCT02242305|DRUG|Hyoscine Butylbromide - Capsule|
48364539|NCT02242305|DRUG|Placebo|
48364540|NCT00348686|DRUG|Candesartan|16 mg once daily in oral tablet form
48364541|NCT00348686|DRUG|Candesartan|32 mg once daily in oral tablet form
48364542|NCT00348686|DRUG|Felodipine|5 mg once daily in oral tablet form
48364543|NCT00348686|DRUG|Felodipine|10 mg once daily in oral tablet form
48679889|NCT03843528|DRUG|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
48679890|NCT03843528|DRUG|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
47994077|NCT02062333|DRUG|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
47994078|NCT02684266|DRUG|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
47994079|NCT00174655|DRUG|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
47994080|NCT00174655|DRUG|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
47994081|NCT00174655|DRUG|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
47994082|NCT00174655|DRUG|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
47994083|NCT05240404|DRUG|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
47994084|NCT05240404|PROCEDURE|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
47994085|NCT03860428|DRUG|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
47994086|NCT03860428|DRUG|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
47994087|NCT03860428|OTHER|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
47994088|NCT05693285|OTHER|No intervention|No intervention
48153586|NCT05353062|PROCEDURE|Hemostatic therapy|Bipolar hemostatic forceps
48364544|NCT05692427|DEVICE|Cryopen - Cryotherapy|Cryotherapy with N20
48364545|NCT03824756|OTHER|NGO supported GMP program|An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.
48364546|NCT03824756|OTHER|Non-supported GMP program|This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
48364547|NCT02924129|DEVICE|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
48364548|NCT00733096|DRUG|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
47994089|NCT03042052|DRUG|detrusor infection of Botulinum toxin|detrusor injection
48364549|NCT00733096|DRUG|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
48364550|NCT00733096|DRUG|normal saline|Two transforaminal epidural saline injections, two weeks apart
48364551|NCT06080529|OTHER|Sandbag exercise|Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
48364552|NCT02529358|BEHAVIORAL|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
48364553|NCT02529358|BEHAVIORAL|Personalized text messages|Patients write their own messages
48364554|NCT02529358|BEHAVIORAL|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
48364555|NCT05541380|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
48364556|NCT00519597|DEVICE|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
48153587|NCT05353062|PROCEDURE|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
48153588|NCT01807234|DRUG|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
47994090|NCT04690504|OTHER|dim light melatonin onset (DLMO)|A series of saliva samples will be collected and assayed for melatonin so that the timing of melatonin secretion onset can be determined.
48364557|NCT04921111|DRUG|SCT1000|Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
48511737|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
48511738|NCT02000765|DRUG|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
48511739|NCT02000765|DRUG|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
47994091|NCT03145168|OTHER|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
47994092|NCT03145168|OTHER|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
48153589|NCT01807234|DRUG|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
48364558|NCT04921111|DRUG|Gardasil®9|Recombinant 9 or 4 valent human papillomavirus vaccine
48364559|NCT04921111|DRUG|placebo|aluminium phosphate
48364560|NCT04921111|DRUG|Gardasil®|Recombinant 4 valent human papillomavirus vaccine
48364561|NCT04455958|DRUG|Lopinavir/Ritonavir|Given PO
48364562|NCT04455958|DRUG|Placebo Administration|Given PO
48364563|NCT04455958|OTHER|Questionnaire Administration|Ancillary studies
48511740|NCT03101865|DEVICE|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
48511741|NCT05870618|BIOLOGICAL|vaccinate with DTap|vaccinate with DTap
48511742|NCT05870618|BIOLOGICAL|vaccinate with DT|vaccinate with DT
47994093|NCT03815097|PROCEDURE|Mapleson circuit and nasal trumpet|The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
47994094|NCT05210166|DEVICE|Active tSCS and Lokomat|"A symmetrical biphasic 30 Hz current of 1 ms pulse-width with an electro-stimulator will be applied.~For the stimulation intensity, the maximum intensity tolerated by the patient will be selected. The intensity will be increased in case of habituation to the current."
47994095|NCT05210166|DEVICE|Sham tSCS and Lokomat|The protocol and device of sham tSCS combined with Lokomat will be the same as active tSCS except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 seconds and then slowly will be decreased to zero, being this intensity maintained for the remaining 20 minutes of stimulation.
47994096|NCT00049439|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
48153590|NCT01807234|DRUG|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
48153591|NCT05293691|BEHAVIORAL|Body, Breath & Mind|"The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
48153592|NCT05293691|BEHAVIORAL|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
48511743|NCT05952674|DEVICE|Vagus Nerve Stimulation (VNS)|The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
48511744|NCT05952674|OTHER|Best Medical Treatment|Best Medical Treatment for resistant depression.
47994097|NCT00049439|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
47994098|NCT00049439|DRUG|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
47994099|NCT00049439|DRUG|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
47994100|NCT00049439|DRUG|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
48679891|NCT05715138|PROCEDURE|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
48679892|NCT05715138|PROCEDURE|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
48679893|NCT05715138|DEVICE|GPi-DBS devices|"1. DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
48679894|NCT05715138|DEVICE|STN-DBS devices|"1. DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
48511745|NCT04593576|OTHER|Physical activity protocol/out door sports|"Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week."
47994101|NCT00919776|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
47994102|NCT00919776|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
48511746|NCT04593576|OTHER|Intensive table teaching speech therapy|Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
48511747|NCT00270907|DRUG|CT-2103|135 mg/m\^2 IV on Day 1.
48511748|NCT00270907|DRUG|Gemcitabine|1000 mg/m\^2 IV on Day 1 and 8.
47994103|NCT00817115|DEVICE|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
47994104|NCT05048121|OTHER|Cosmetic Active Ingredient CLS02021|Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days
48153593|NCT02896673|PROCEDURE|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
48153594|NCT06173063|DEVICE|Mobility+ Enteral Feeding System|Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
48511749|NCT04962386|DRUG|Hormone replacement therapy|HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
47994105|NCT05048121|OTHER|Placebo PLC01021|Topical, face application of the cream base, two times a day in a period of 30 days
48679895|NCT05115565|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
48679896|NCT04888806|DRUG|Camrelizumab|d1，200mg, iv, q3w
48679897|NCT04888806|PROCEDURE|ablation|the 37 enrolled patients received ablation of liver/lung metastases ，If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.
48679898|NCT04888806|DRUG|chemotherapy|standard treatment plan for mCRC, determined by the investigator
47994106|NCT02730572|DRUG|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
48153595|NCT01790659|DRUG|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
48153596|NCT01790659|DRUG|Paromomycin|Paromomycin alone
48153597|NCT01835847|DRUG|Tipepidine Hibenzate|
47994107|NCT02730572|DRUG|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
47994108|NCT02730572|DRUG|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
48153598|NCT04095897|PROCEDURE|Pecs II Block|Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
48153599|NCT00596960|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
48153600|NCT00596960|BEHAVIORAL|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
48153601|NCT00003376|DRUG|carboplatin|
48153602|NCT00003376|DRUG|cisplatin|
48153603|NCT00003376|DRUG|doxorubicin hydrochloride|
48153604|NCT00003376|DRUG|methotrexate|
48153605|NCT00003376|DRUG|paclitaxel|
48153606|NCT00003376|DRUG|vinblastine|
48153607|NCT01502241|DRUG|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
48153608|NCT01502241|RADIATION|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
48153609|NCT00819078|DRUG|Bupropion|300 mg/d
48153610|NCT00819078|DRUG|Placebo|no dosage
48679899|NCT06488690|OTHER|All patients who were pregnant and underwent cesarean section|Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.
48679900|NCT00540592|BIOLOGICAL|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
48679901|NCT00540592|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
48679902|NCT03491033|DRUG|chemotherapy|All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
48679903|NCT00843336|BEHAVIORAL|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
48679904|NCT00843336|BEHAVIORAL|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
48511750|NCT03777163|BIOLOGICAL|Butantan Institute Trivalent Seasonal Influenza Vaccine|Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
48511751|NCT03777163|BIOLOGICAL|Sanofi Trivalent Seasonal Influenza Vaccine|VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (\> 60 years),11,12 children (six months to three years) 13 and pregnant women.
48679905|NCT02897687|BEHAVIORAL|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
48679906|NCT02897687|BEHAVIORAL|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
48679907|NCT01354223|DEVICE|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
48679908|NCT01354223|DEVICE|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
48679909|NCT01072721|OTHER|Elastometry|Fibrosis detection with FIBROSCANN
48679910|NCT05254353|PROCEDURE|Analyses of proximal and distal samples|Evaluate the difference between proximal and distal CSF samples
48511752|NCT02420912|DRUG|Ibrutinib|Given PO
48679911|NCT04122989|OTHER|MS-SUPPORT|MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
48679912|NCT04789720|BEHAVIORAL|Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS)|Participants will complete a 9-item SyMon-SAYS symptom assessment checklist every week during the intervention phase (Intervention Group: weeks 1-16; Waitlist Control: weeks 9-16) through Epic MyChart via mobile app, computer or tablet. Patients' symptom scores will be monitored and reported to their oncology care providers. When a patient symptom score trigger threshold is met, the system will generate an email alert through Epic (electronic medical record system) messaging to the provider. The provider will take appropriate actions using his/her clinical judgement, including contacting patients and families when needed. Symptom scores overtime will be available in MyChart (patient-facing component of the Epic electronic medical record system) for patients and parents to review and to discuss with the child's provider during clinical visits.
48153611|NCT03382535|BEHAVIORAL|Voice therapy|Voice therapy with direct and indirect therapy elements.
48153612|NCT03382535|BEHAVIORAL|Voice therapy with carryover strategies|Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
48153613|NCT03382535|OTHER|Control group|No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
48153614|NCT01946256|DRUG|Amoxicillin|
48511753|NCT02420912|OTHER|Laboratory Biomarker Analysis|Correlative studies
48511754|NCT02420912|BIOLOGICAL|Nivolumab|Given IV
48511755|NCT06067503|DRUG|18F-fluorofuranylnorprogesterone|The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
48511756|NCT06067503|DEVICE|Liquid Biopsy|20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology
48679913|NCT04853771|BEHAVIORAL|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
48153615|NCT01946256|DRUG|Erythromycin|
48679914|NCT05989139|PROCEDURE|NPPV/HFNC|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each. NPPV will be delivered through a full-face mask with a FiO2 starting at 100% and then titrated to achieve an SpO2 of 92-98%. Expiratory positive airway pressure (PEEP) will be firstly set to 5 cmH2O and then increased to a maximum of 15 cmH2O based on SpO2. Pressure support (PS) will be set to an initial value of 10 cmH2O and then increased if signs of respiratory distress persisted or worsened to a maximum value of 20 cmH2O. After 40 minutes, patient is shifted to HFNC ventilation support for 40 minutes.~At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
48679915|NCT05989139|PROCEDURE|HFNC/NPPV|"Enrolled patients will receive NPPV and HFNC oxygen therapy in a randomized, cross-over fashion, for 40 minutes each.~HFNC oxygen therapy will start at a flow rate of 60 L/min and will be gradually decreased by 5 cmH2O at time if the patient experienced discomfort. FiO2 will be started at 100% and then titrated to maintain a peripheral oxygen saturation of 92%-98%. Active heating and humidification were provided using MR850, Fisher and Paykel, with a temperature chamber of 37°C. After 40 minutes, patient is shifted to NPPV ventilation support for 40 minutes At the end of the protocol, the patient will receive the treatment that will be shown as more appropriate for the patient, according to the attending physician, who will be informed about the results of the study on the individual patient."
48153616|NCT00003245|DRUG|irinotecan hydrochloride|
48153617|NCT04223141|PROCEDURE|SIA|As indicated by arm description
48153618|NCT01129375|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
48153619|NCT01129375|DRUG|placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
48153620|NCT01129375|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
48153621|NCT04031534|DRUG|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
48153622|NCT02936258|PROCEDURE|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
48153623|NCT02936258|PROCEDURE|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
48153624|NCT02936258|PROCEDURE|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
48679916|NCT03599518|DRUG|DS-1205c|DS-1205c 200 mg capsule for oral administration
48679917|NCT03599518|DRUG|Gefitinib|Gefitinib 250 mg tablet for oral administration
48153625|NCT02450786|DRUG|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
48153626|NCT00942188|DRUG|LY2189102|Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
48153627|NCT00942188|DRUG|Placebo|Participants received 2 SC injections weekly for 12 weeks.
48153628|NCT00409006|DRUG|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
48153629|NCT00409006|DRUG|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
48153630|NCT00409006|DRUG|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
47994109|NCT02508493|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
48153631|NCT00700999|DRUG|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
48153632|NCT00504101|DRUG|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
48153633|NCT00504101|DRUG|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
48153634|NCT00504101|DRUG|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
48153635|NCT00504101|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
48511757|NCT06067503|DEVICE|Positron Emission Tomography/Computed Tomography|FFNP drug in combination with PET/CT scans to image participant
48153636|NCT05457296|DRUG|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
48153637|NCT03307993|DRUG|Idalopirdine|Idalopirdine 60-120 mg daily dose
48153638|NCT03062488|DRUG|IV acetaminophen|multi-modal analgesia with IV acetaminophen
48153639|NCT03062488|DRUG|Fentanyl|single modal analgesia
48153640|NCT03062488|DRUG|PO acetaminophen|multi-modal analgesia with PO acetaminophen
48511758|NCT03645863|DRUG|MT-6548|Oral tablet
48511759|NCT03645863|DRUG|Iron supplement A|Oral tablet
48679918|NCT03181971|BEHAVIORAL|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
48364564|NCT00915226|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
48679919|NCT03882593|PROCEDURE|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
48679920|NCT02705612|DRUG|Cisplatin|
48679921|NCT02705612|RADIATION|External Beam Radiation Therapy|
48679922|NCT02705612|RADIATION|Internal Radiation Therapy|
48364565|NCT00915226|PROCEDURE|Squatting|Squatting
48679923|NCT02705612|DRUG|nimotuzumab|
48679924|NCT01520467|DRUG|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
48364566|NCT00665002|BIOLOGICAL|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
48364567|NCT00665002|DRUG|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
48679925|NCT01520467|DRUG|Placebo|1 placebo tablet /day administered orally for 18 months.
48364568|NCT00665002|DRUG|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
48364569|NCT00955682|BIOLOGICAL|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
48364570|NCT00955682|BIOLOGICAL|Meningitec™|One intramuscular dose (Booster)
47994110|NCT02508493|OTHER|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool"
48364571|NCT03367091|OTHER|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
48364572|NCT03367091|OTHER|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
48364573|NCT03367091|OTHER|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
48364574|NCT00207363|DRUG|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
48364575|NCT00207363|DRUG|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
48364576|NCT01354964|DRUG|Vitamin D|
48364577|NCT01354964|DRUG|Placebo|
48364578|NCT04256642|PROCEDURE|Erector Spinae Plane Block|A nerve block that injects local anesthetic in the Erector Spinae Plane
48364579|NCT04256642|DRUG|Intrathecal morphine|Intrathecal morphine at the time of spinal anesthesia
47994111|NCT02488655|DEVICE|Echopulse|HIFU Under ultrasound guidance
48153641|NCT03020914|DEVICE|Audiovisual Distraction|watching a movie using video glasses and headphones
47994112|NCT04807192|RADIATION|stereotactic body radiotherapy|one administration of SBRT 8 Gy at D1
48153642|NCT03627572|OTHER|No intervention|Not applicable (no intervention)
48153643|NCT06092684|DRUG|BT-KTM-I|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
48153644|NCT06092684|DRUG|Ketanest®S|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
48153645|NCT04988958|PROCEDURE|hydatid cyst resection|radical resection of hydatic cyst
48153646|NCT05859529|DRUG|JS002|The drug was administered by a single subcutaneous injection
48153647|NCT04246905|DRUG|sulforaphane|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
48364580|NCT05961761|DRUG|Propranolol|propranolol 40 mg x2 daily
48511760|NCT03645863|DRUG|Iron supplement B|Oral tablet
48511761|NCT03645863|DRUG|Iron supplement C|Oral tablet
48511762|NCT03645863|DRUG|Iron supplement D|Oral tablet
48511763|NCT02268578|DEVICE|Transcranial Direct Current Stimulation|2mA tDCS
47994113|NCT04807192|DRUG|CMP-001|4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
47994114|NCT01085097|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
48153648|NCT04246905|OTHER|placedo|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
48153649|NCT04246905|DRUG|selective 5 - HT reuptake inhibitors (SSRI)|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
48153650|NCT04474691|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
48153651|NCT04474691|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
47994115|NCT01085097|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be administered per dose and schedule specified in the arm description.
47994116|NCT01085097|DRUG|Prednisolone/Prednisone|Prednisolone/Prednisone will be administered per dose and schedule specified in the arm description.
47994117|NCT01085097|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
47994118|NCT01085097|DRUG|Methylprednisolone|Methylprednisolone (MP) will be administered per dose and schedule specified in the arm description.
48153652|NCT00003697|DRUG|vadimezan|
48153653|NCT05142553|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive one injection of COVID-19 Vaccine HIPRA
48153654|NCT05142553|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive one injection of Cominarty Vaccine
48153655|NCT02197494|DRUG|Valsartan|320mg tablets
48153656|NCT00513292|DRUG|Cyclophosphamide|Given IV
48364581|NCT05961761|DRUG|Pembrolizumab|pembrolizumab 2 mg/kg every 3 weeks
48364582|NCT03550508|BIOLOGICAL|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
48364583|NCT03795324|OTHER|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
48364584|NCT03795324|OTHER|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
48511764|NCT02268578|PROCEDURE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
48511765|NCT00948155|DRUG|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
48511766|NCT02505087|DRUG|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout."
47994119|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol low dose|1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
48153657|NCT00513292|DRUG|Epirubicin Hydrochloride|Given IV
48153658|NCT00513292|OTHER|Laboratory Biomarker Analysis|Correlative studies
48153659|NCT00513292|DRUG|Paclitaxel|Given IV
48153660|NCT00513292|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48153661|NCT00513292|BIOLOGICAL|Trastuzumab|Given IV
48153662|NCT05250362|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
48153663|NCT04392856|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
47994120|NCT04851899|DIETARY_SUPPLEMENT|Phaeosol high dose|2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
47994121|NCT04851899|DIETARY_SUPPLEMENT|Placebo|2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
47994122|NCT06243887|OTHER|Enhanced Recovery After Surgery (ERAS) protocol in minimal invasive esophagectomy|Enhanced Recovery After Surgery (ERAS) refers to patient-centered, evidence-based, multidisciplinary team developed pathways for a surgical specialty and facility culture to reduce the patient's surgical stress response, optimize their physiologic function, and facilitate recovery.
47994123|NCT06243887|OTHER|standard of care approaches in minimal invasive esophagectomy|standard of care approaches other than ERAS
47994124|NCT01623323|DRUG|Fluticasone Propionate|Fluticasone Propionate 400 μg
47994125|NCT01614990|DRUG|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
47994126|NCT01614990|DRUG|Placebo|placebo (Powerade®) daily for 7 days.
48153664|NCT04392856|BEHAVIORAL|Same than experimental condition (UP), after it finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
48153665|NCT04572425|OTHER|Guided imagery|10 minutes of guided imagery experience delivered on tablet
48153666|NCT04572425|OTHER|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
48153667|NCT05852379|DEVICE|active taVNS|Transcutaneous auricular vague nerve stimulation
48153668|NCT05852379|DEVICE|sham taVNS|Scham transcutaneous auricular vague nerve stimulation
48153669|NCT00801749|BEHAVIORAL|sleep|
48153670|NCT02962622|OTHER|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
47994127|NCT00006202|DRUG|Lutein|
47994128|NCT04558931|DRUG|CellProtect|In vitro expanded and activated autologous NK cells
47994129|NCT04558931|DRUG|Isatuximab|Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
48679926|NCT02377843|BEHAVIORAL|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
47994130|NCT04028752|BIOLOGICAL|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
47994131|NCT02410954|DEVICE|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
47994132|NCT05705284|OTHER|Structured multidisciplinary medication review|Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.
47994133|NCT02183831|DEVICE|Insertion of the capsular tension ring|
47994134|NCT04459312|DIAGNOSTIC_TEST|Antibody test (SARS-CoV2)|Antibody test
48153671|NCT03966599|DIAGNOSTIC_TEST|Pain|Patient's pain in order to VAS
48153672|NCT03966599|DIAGNOSTIC_TEST|Hemodynamic changes|changes in hemodynamic states
48153673|NCT05146479|PROCEDURE|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
48153674|NCT05104684|OTHER|chest physical therapy|The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
48511767|NCT02505087|DRUG|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
47994135|NCT01094691|PROCEDURE|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
48364585|NCT03795324|OTHER|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
48364586|NCT00626327|BIOLOGICAL|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
48679927|NCT02377843|BEHAVIORAL|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
47994136|NCT02684643|OTHER|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
47994137|NCT02684643|OTHER|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
47994138|NCT02684643|OTHER|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
47994139|NCT04361981|OTHER|Deep Venous Disease Diagnostic|Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
48153675|NCT05104684|OTHER|routine medical treatment|medical treatment
48153676|NCT04614688|BEHAVIORAL|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
48153677|NCT01373359|DRUG|Misoprostol|400 µg sublingual misoprostol
48153678|NCT01373359|DRUG|Oxytocin|10 IU IM
48153679|NCT04479137|DIAGNOSTIC_TEST|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
48153680|NCT01234025|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
48153681|NCT01234025|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
48511768|NCT05863169|DEVICE|fNIRS-Neurofeedback|Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
47994140|NCT03869450|DEVICE|Restylane Volyme|Hyaluronic based filler
47994141|NCT03869450|DEVICE|Restylane Defyne|Hyaluronic based filler
48679928|NCT06000488|BEHAVIORAL|Reflective Writing Workshop Sessions|Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
48679929|NCT05679349|OTHER|Survey Administration|Complete survey
47994142|NCT03869450|DEVICE|Restylane Lyft Lidocaine|Hyaluronic based filler
47994143|NCT06250023|OTHER|Early shift til oral antibiotic treatment for osteomyelitis|To investigate whether early transition to oral AB treatment after one week of IV treatment is non-inferior to the current national guideline of continued IV AB treatment for two to four weeks followed by oral AB treatment for PVO.
47994144|NCT03561623|OTHER|magnetic resonance (MR) Imaging|MRI of spinal cord and brain
47994145|NCT03561623|OTHER|quantitative muscle force assessment|quantitative assessment of muscle force
47994146|NCT02232581|DRUG|Alovudine - low|
47994147|NCT02232581|DRUG|Alovudine - medium|
47994148|NCT02232581|DRUG|Alovudine - high|
47994149|NCT02232581|DRUG|Placebo|
47994150|NCT03864874|DIAGNOSTIC_TEST|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
47994151|NCT01650207|PROCEDURE|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
48511769|NCT06418516|DEVICE|Capsule-sponge|The capsule-sponge is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
48679930|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
48679931|NCT05679349|OTHER|Survey Administration|Complete survey
48679932|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
48679933|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
47994152|NCT01650207|PROCEDURE|TENS|
48679934|NCT05679349|OTHER|Counseling|Undergo shared decision making counseling
48679935|NCT05679349|OTHER|Survey Administration|Complete survey
48153682|NCT01234025|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
48153683|NCT01234025|DRUG|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
48153684|NCT01234025|DRUG|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
47994153|NCT01650207|PROCEDURE|sham acupuncture|
47994154|NCT02112669|DEVICE|VasQ|
47994155|NCT02786628|OTHER|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
47994156|NCT03181854|BEHAVIORAL|Telephone coaching|Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
47994157|NCT03181854|BEHAVIORAL|Consultation with PCT doctor|Consultation with PCT physician every 3 weeks.
47994158|NCT03704961|BEHAVIORAL|music and audiobook listening|
47994159|NCT04430933|DRUG|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
47994160|NCT04430933|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
47994161|NCT04430933|DRUG|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
48153685|NCT02781233|OTHER|Progressive resistance training|Progressive resistance training program
48153686|NCT02781233|OTHER|Normal daily activities|Usual daily activities
48153687|NCT01483131|OTHER|Exercise training|12 weeks of resistance training twice a week.
48511770|NCT04974203|DEVICE|AptameX|DNA aptamer-based test using patient's saliva
48511771|NCT04577209|DEVICE|Disposable oxygen face tent|Disposable oxygen face tent used to minimize aerosol particles (through suction) during aerosol generating anesthesia procedures.
48511772|NCT04258033|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
48679936|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
48679937|NCT05773495|OTHER|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
48679938|NCT05773495|OTHER|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
48679939|NCT03056235|DEVICE|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
48679940|NCT03056235|DEVICE|Saline|Saline control
48679941|NCT00777959|DRUG|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
47994162|NCT04430933|DRUG|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
47994163|NCT03772847|DRUG|ginkgolide|ginkgolide plus alteplase
47994164|NCT02741700|BEHAVIORAL|Gout Storytelling Video Intervention|The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
47994165|NCT03849885|DRUG|Benzoyl peroxide gel|Skin prep with Chlorohexidine wipes and BPO.
47994166|NCT03911895|DEVICE|Stent more than 26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
47994167|NCT03911895|DEVICE|Stent equal to or less than26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
47994168|NCT02879409|DRUG|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
47994169|NCT02879409|DRUG|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
48153688|NCT01483131|OTHER|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
48364587|NCT00626327|BIOLOGICAL|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
48364588|NCT00626327|BIOLOGICAL|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
48364589|NCT01296321|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
48364590|NCT01296321|BEHAVIORAL|Waitlist|Passive waitlist during 8-10 weeks.
48364591|NCT06148805|OTHER|pilates exercise and diaphragm manual technique|pilates exercises
48679942|NCT00777959|DRUG|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
48679943|NCT00777959|DRUG|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
47994170|NCT02879409|DRUG|Sitagliptin|Oral: 100 mg once daily
47994171|NCT02879409|DRUG|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
47994172|NCT02879409|DRUG|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
48153689|NCT02958826|OTHER|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
48364592|NCT03891199|PROCEDURE|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
48364593|NCT00216827|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
48364594|NCT02957500|DEVICE|Mediclore® (adhesion barrier)|
48364595|NCT04982276|BIOLOGICAL|AK109|Subjects will receive AK109 by intravenous administration.
48364596|NCT04982276|DRUG|paclitaxel|Subjects will receive AK109 in combination with paclitaxel.
48364597|NCT04982276|DRUG|paclitaxel|Subjects will receive AK104 and AK109 in combination with paclitaxel.
48364598|NCT04982276|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
48364599|NCT00460642|DRUG|GnRH Antagonist (Cetrotide)|
48364600|NCT01513824|BEHAVIORAL|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
48364601|NCT06198946|DEVICE|External diaphragm pacing（EDP）|After the skin is disinfected, place the small electrode pads on the lower 1/3 of the outer edges of the sternocleidomastoid muscles on the left and right sides, and place the large electrodes on the surface of the pectoralis major muscles on both sides, and fix them with medical tape. Adjust the pacing according to the patient's tolerance. Frequency and stimulation intensity, each treatment time is 20 minutes, treatment is once a day, 5 days a week, and the treatment course is 4 weeks.
48511773|NCT04168008|BEHAVIORAL|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
48511774|NCT04168008|BEHAVIORAL|WISH Parenting|The educational sessions will focus on parenting and baby care.
48364602|NCT06198946|OTHER|Routine rehabilitation treatment|Participants received comprehensive rehabilitation treatments such as muscle strength training, hemiplegic limb comprehensive training, balance function training, limb neuromuscular electrical stimulation, acupuncture and other comprehensive rehabilitation treatments. Each project was 30 minutes/time, once a day, 5 days a week, and the treatment course was 4 weeks.comprehensive rehabilitation treatments, each item is 30 minutes/time, once a day, 5 days a week, and the treatment course is 4 weeks.
48364603|NCT02751606|DRUG|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
48364604|NCT02751606|DEVICE|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
48153690|NCT02848586|OTHER|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
48364605|NCT02751606|DEVICE|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
48153691|NCT02848586|BEHAVIORAL|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
48153692|NCT02848586|OTHER|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
48364606|NCT05261321|DRUG|Cannabis oil with a high ratio of THC to CBD|In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.
48364607|NCT05261321|DRUG|Cannabis oil with a high ratio of CBD to THC|In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.
48364608|NCT05261321|DRUG|Placebo|In the control condition, the placebo will be administered to participants.
48364609|NCT03810599|OTHER|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
48364610|NCT00114894|OTHER|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
48364611|NCT00114894|OTHER|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
48364612|NCT01486979|DRUG|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
48364613|NCT01486979|DRUG|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
47994173|NCT02879409|DRUG|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
47994174|NCT02879409|DRUG|human insulin|insulin dosage and administration according to physician
47994175|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (oral fluid HCVST)|"The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits."
48153693|NCT03417375|PROCEDURE|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
48153694|NCT00160537|DRUG|Levocetirizine|
48153695|NCT06523686|PROCEDURE|Guided bone regeneration|Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.
48153696|NCT03879252|DEVICE|Toothbrush|Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
48153697|NCT03879252|DRUG|Mouthwashes|Mouthwashes three times a day with a 1.4% baking mouthwash solution.
48153698|NCT01477177|DEVICE|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
48153699|NCT03734172|DIAGNOSTIC_TEST|Sample collection|Specimen collection
48364614|NCT05611281|DRUG|GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication|The dosage was calculated according to body weight and dose group once a day according to the assigned group.
48364615|NCT00741624|OTHER|Bandage|one application for one week
48364616|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT with intravenous contrast|Abdominal or body CT with intravenous contrast
48364617|NCT04196244|DIAGNOSTIC_TEST|Abdominal or body CT without intravenous contrast (native CT)|Abdominal or body CT without intravenous contrast (native CT)
48364618|NCT04605133|DEVICE|Electrical impedance tomography|Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
48364619|NCT03942991|DRUG|articaine|infiltration injection of 4%artpharmadent
48364620|NCT03942991|DRUG|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
48511775|NCT01289379|PROCEDURE|High Frequency Jet Ventilation|
48511776|NCT01289379|PROCEDURE|HFJV|
48511777|NCT04573114|PROCEDURE|Verticalization|Progressive levels of verticalization
48511778|NCT01850251|DIETARY_SUPPLEMENT|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
48679944|NCT02576548|BIOLOGICAL|MEDI4276|MEDI4276 is an investigational product
48511779|NCT01850251|DIETARY_SUPPLEMENT|Standard nutritional supplement|High protein, high calorie nutritional supplement.
48511780|NCT05044559|OTHER|Continuous Positive Air Way Group|CPAP between 10 and 12 cmH2O
48153700|NCT02079402|DRUG|Isotonic crystalloids|
48153701|NCT04711018|DIAGNOSTIC_TEST|Laryngoscopy|The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.
48153702|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring and weight loss|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
48153703|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
48153704|NCT04770909|BEHAVIORAL|Incentives for weight loss|Participants can earn up to $300 during the trial for achieving weight loss
48153705|NCT06585436|PROCEDURE|partial caries removal|removal of all cavity caries except last layer related to the pulp
48153706|NCT04882956|DRUG|intravitreal injection|Brolucizumab-Dbll intravitreal injection
48153707|NCT04882956|DRUG|intravitreal injection|Aflipercept intravitreal injection
48153708|NCT04004806|DEVICE|Hill Rom tracking device|Location tracking devices from Hill Rom company.
48153709|NCT02097056|DRUG|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
48153710|NCT06518811|OTHER|Video-Based Exercise Programme|The asynchronous video-based telerehabilitation programme had a duration of eight weeks. The participants were instructed to perform the exercises on a regular basis, three days a week, with a time interval of 24 hours between each session. The exercises were to be performed using the instructional videos and recorded in the exercise diaries provided. The participants were used exercise balls and resistance bands distributed by the researchers according to exercise programme.
48153711|NCT05644067|BIOLOGICAL|SumayaVac-1(SUM-101)|One immunization every 4 weeks for 3 months (total 3 immunizations)
48153712|NCT05644067|BIOLOGICAL|Verorab|One immunization every 4 weeks for 3 months (total 3 immunizations)
48153713|NCT00729261|PROCEDURE|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
48153714|NCT00729261|PROCEDURE|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
48364621|NCT03347461|DRUG|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
48364622|NCT03347461|DRUG|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
48679945|NCT02046018|OTHER|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
48364623|NCT05353881|OTHER|No intervention|No intervention
48679946|NCT02046018|OTHER|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
48679947|NCT02046018|OTHER|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
48679948|NCT05312684|PROCEDURE|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
48679949|NCT04062747|DEVICE|I-gel|After standard anesthesia i-Gel was placed into the patient
48679950|NCT04062747|DEVICE|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
48153715|NCT03508830|DRUG|Liposomal bupivacaine|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
48153716|NCT03508830|DRUG|Bupivacaine Injection|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
48153717|NCT01622023|PROCEDURE|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
48153718|NCT03402399|OTHER|Molecular analysis|Blood test
48153719|NCT00422162|DRUG|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
48511781|NCT05044559|OTHER|Control Group|"Day 1: Bed mobility chest physiotherapy, active assistive ROM 5 repetitions of upper and lower limb, ACBT cycle. ABGS was analyses at first minute of exercise and vital was record after exercise.~Day 2: Active range of motion exercise progress with 5 repetitions bed to chair mobility. same exercise progress with 5 repetition and 5 minute walk( day 3rd ).walking time will increase with 10 min at 4 day and at 5th day stair climbing the ABGS was record in ICU 3 days."
48511782|NCT04584762|DEVICE|Automated Variable Pressure Insufflation|Acute migraine treatment
48511783|NCT05024357|DRUG|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
48511784|NCT00451646|DRUG|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
48511785|NCT05167097|OTHER|ASSIST-linked Brief Intervention|WHO's ASSIST-linked Brief Intervention (with and without Steps 6-9, the decisional balance element)
48511786|NCT05167097|OTHER|Mindset Intervention|Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues
48511787|NCT01449370|DRUG|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
48511788|NCT04859452|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
48511789|NCT04859452|DRUG|Metformin hydrochloride tablets|Drug: Metformin hydrochloride, tablet, oral
48364624|NCT01146158|PROCEDURE|Axillary dissection for breast carcinomas|surgery Axillary dissection
48679951|NCT00625534|PROCEDURE|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
48679952|NCT00625534|PROCEDURE|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
48679953|NCT00925002|DRUG|Tafamidis|20 mg oral Fx-1006A daily
48679954|NCT03768089|DRUG|Placebo (matched to VX-121 suspension)|Placebo matched to VX-121 suspension for oral administration.
48153720|NCT00422162|DRUG|Placebo|placebo capsule by mouth
48153721|NCT02885610|BIOLOGICAL|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
48364625|NCT01116661|DRUG|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
48364626|NCT00237146|DRUG|Zoledronic acid|
48364627|NCT00531466|DRUG|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
48364628|NCT00531466|DRUG|Placebo|One tablet orally three times a day for 28 days
48364629|NCT04944966|DRUG|Maytenus Senegalensis|"* Maytenus senegalensis (Malherbal) has a very long history of safe medicinal use in Africa in adult as well as infants and children. It will be administered orally at a dose of 800mg 8 hourly for 4 days.~* Artemether 20mg/lumefantrine 120mg"
48364630|NCT02948998|DRUG|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
48364631|NCT05376163|OTHER|Survey Study|Headache Disabilty Index (HDI) will be applied.
48364632|NCT01711359|DRUG|Baricitinib|Administered orally
48511790|NCT04859452|DRUG|Glibenclamide tablets|Drug: Glibenclamide, tablet, oral
48511791|NCT04859452|DRUG|Valsartan Capsules|Drug: Valsartan, capsule, oral
48679955|NCT03768089|DRUG|VX-121 (Suspension)|Suspension for oral administration.
48679956|NCT03768089|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
48679957|NCT03768089|DRUG|IVA|Tablet for oral administration.
48679958|NCT03768089|DRUG|Placebo (matched to TEZ/IVA)|Placebo matched to TEZ/IVA for oral administration.
48679959|NCT03768089|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
48679960|NCT03768089|DRUG|VX-121 (Tablet)|Tablet for oral administration.
48679961|NCT03768089|DRUG|Placebo (matched to VX-121 tablet)|Placebo matched to VX-121 tablet for oral administration.
48679962|NCT00183144|BEHAVIORAL|Contingency management|
48679963|NCT00502580|BEHAVIORAL|Interview|Interview taking about 10 minutes to complete.
48153722|NCT02885610|BIOLOGICAL|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
48153723|NCT02885610|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
48364633|NCT01711359|DRUG|Methotrexate|Administered orally
48364634|NCT01711359|DRUG|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
48364635|NCT01711359|DRUG|MTX Placebo|MTX placebo administered orally once weekly.
48364636|NCT01711359|DRUG|Folic Acid|Administered orally every day
48364637|NCT03525912|DRUG|Ketamine|continuous infusion of low dose ketamine for postoperative pain
48364638|NCT03109418|DRUG|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
48364639|NCT03109418|PROCEDURE|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
48511792|NCT04859452|DRUG|Simvastatin tablets|Drug: Simvastatin, tablet, oral
48511793|NCT05847803|OTHER|No intervention, questionnaire survey|No intervention, questionnaire survey
48511794|NCT00457548|BEHAVIORAL|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
48511795|NCT00408083|DRUG|MultiHance|0.5 mmol/kg as a single dose administration
48511796|NCT00408083|DRUG|Magnevist|0.5 mmol/kg as a single dose administration
48679964|NCT02550444|DRUG|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
48679965|NCT02550444|DRUG|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
48679966|NCT02550444|DRUG|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
48679967|NCT01736267|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
48679968|NCT06447155|DIETARY_SUPPLEMENT|Bolus feeding|The babies fed with bolus feeding during TH composed this group
48679969|NCT06447155|DIETARY_SUPPLEMENT|Continuous feeding|The babies fed with continuous feeding during TH composed this group
48679970|NCT06447155|DIETARY_SUPPLEMENT|Placebo|The babies who were not fed during TH composed this group
48679971|NCT06156852|OTHER|Mindfulness-based stress reduction group|Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
47994176|NCT06203925|DIAGNOSTIC_TEST|Hepatitis C virus self-test (blood-based HCVST)|The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
48511797|NCT06035978|DRUG|Nebivolol|Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
48511798|NCT06035978|DRUG|Valsartan and Sacubitril|Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
47994177|NCT04530006|DIAGNOSTIC_TEST|Amantadine Hydrochloride|"Patients who are eligible for the study will be administered a regular 200 mg dose of FDA approved drug amantadine. This will be done at the following timepoints:~1. Within 4 weeks of the start of treatment; but as close to commencement of treatment (Day 1 of radiotherapy) as possible for newly diagnosed patients.~2. Cycle 1, Day 1 of chemotherapy (temozolomide or lomustine) +/- 7 days~3. Day 1 +/- 7 days for each visit where MRI is obtained (typically every 8-12 weeks - pre-cycles 4, 7, 10, for temozolomide or pre-cycles 3, 5, and 7 for lomustine)"
47994178|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv BID
47994179|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv TID
48511799|NCT06035978|DRUG|Carvedilol|Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
48679972|NCT06156852|OTHER|Cognitive behavioral-based stress reduction group|Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
48679973|NCT02342353|DRUG|Pacritinib|
48679974|NCT02342353|DRUG|Erlotinib|
48679975|NCT01456793|BEHAVIORAL|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
48679976|NCT02194946|DRUG|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
48511800|NCT06035978|DRUG|Bisoprolol|Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
48679977|NCT02194946|DRUG|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
47994180|NCT02514837|DEVICE|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
47994181|NCT04682626|DIETARY_SUPPLEMENT|Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.|Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
47994182|NCT05481567|OTHER|Questionnaire|A series of 14 questions about with the impact of periodontitis on quality of life.
47994183|NCT01012622|DRUG|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
47994184|NCT01170806|DRUG|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
47994185|NCT05279820|PROCEDURE|Partial pulpotomy|Partial pulp tissue amputation
47994186|NCT05279820|PROCEDURE|Full Pulpotomy|Full Pulpotomy
47994187|NCT00000954|DRUG|Bleomycin sulfate|
48511801|NCT06035978|DRUG|Metoprolol|Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
48511802|NCT06035978|DRUG|Spironolactone|Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
48511803|NCT01422980|OTHER|1- Test dairy product containing specific ingredients|
48679978|NCT00886769|DRUG|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
48679979|NCT00886769|DRUG|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
47994188|NCT00000954|DRUG|Vincristine sulfate|
47994189|NCT00000954|DRUG|Doxorubicin hydrochloride|
47994190|NCT00000954|DRUG|Zalcitabine|
47994191|NCT00000954|DRUG|Didanosine|
47994192|NCT05634252|BEHAVIORAL|Education|All conditions will receive education on skin cancer and strategies to prevention skin cancer, including sun protection strategies and avoidance of intentional and unintentional tanning.
47994193|NCT05634252|BEHAVIORAL|Action Plan|Participants will be guided through a worksheet for creating a personalized action plan for creating individualized sun protection and tanning plans for situations in which they receive UVR exposure. For the tanning worksheet, participants who report any tanning identify the locations at or activities during which they tan, select a tanning behavior to plan for, and then are guided through the steps of making a specific plan for an alternate activity that meets their goals while minimizing tanning and using sun protection.
48511804|NCT01422980|OTHER|2- Control dairy product without specific ingredients|
48511805|NCT05416788|OTHER|cervical manipulation|high-velocity, low-amplitude cervical manipulation
48679980|NCT04714866|BEHAVIORAL|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
48679981|NCT05742412|DEVICE|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
48679982|NCT05742412|DEVICE|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
48679983|NCT05015647|DIETARY_SUPPLEMENT|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
48679984|NCT05015647|OTHER|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
48679985|NCT00219596|DRUG|Xalacom|
48679986|NCT00219596|DRUG|unfixed Latanoprost and Timolol|
48679987|NCT04343365|OTHER|Evolutionary Tumor Board (ETB)|The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
48679988|NCT00375427|DRUG|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
48679989|NCT00209144|DRUG|Intensive insulin therapy|
48679990|NCT05481983|OTHER|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
48679991|NCT05481983|OTHER|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
47994194|NCT05634252|BEHAVIORAL|UV Photo|Participants will receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system. Participants will receive a handout of their photos accompanied by an explanation of UV light, its harmful effects on skin, and that using sun safe behaviors early in life will have the greatest impact and help to decrease risk for skin cancer.
47994195|NCT05634252|BEHAVIORAL|MC1R Test|Participants will provide a saliva sample using an Oragene® clinical-grade saliva kit. Once sequenced, participants will receive their MC1R testing results via web as well as a standardized booklet that addresses personal risk level and population risk level, strategies to reduce skin cancer risk, and number to call or email for further information.
48511806|NCT05416788|OTHER|Sham intervention|lateral flexion and cervical rotation without manipulation
47994196|NCT01083212|DRUG|AZD1656|Single dose,oral tablet
47994197|NCT01083212|DRUG|Gemfibrozil|Oral tablet bid on day 1 - 5.
47994198|NCT01083212|DRUG|Placebo|Oral tablet bid on day 1-5
47994199|NCT01618552|BEHAVIORAL|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
47994200|NCT01618552|OTHER|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
47994201|NCT02276872|DRUG|oral treprostinil|
47994202|NCT00070265|DRUG|oxaliplatin|Given IV
48511807|NCT05408975|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
48679992|NCT00360178|DRUG|Valsartan plus Hydrochlorothiazide|
48679993|NCT00360178|DRUG|Candesartan plus Hydrochlorothiazide|
48679994|NCT00360178|DRUG|Amlodipine|
48679995|NCT04722341|BEHAVIORAL|Time-Restricted Eating (TRE)|8-hour daily eating period, starting 1-3 hours after waking up
48679996|NCT04722341|BEHAVIORAL|Control|More than equal to a 12-hour daily eating period
48679997|NCT05524519|DRUG|Basic treatment|"1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
47994203|NCT00070265|DRUG|capecitabine|Given orally
47994204|NCT00070265|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
47994205|NCT00070265|OTHER|laboratory biomarker analysis|Correlative studies
47994206|NCT00032643|DRUG|DITPA|
47994207|NCT03886220|DRUG|Elagolix|Oral; Tablet
48679998|NCT05524519|PROCEDURE|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
48679999|NCT05524519|PROCEDURE|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
47994208|NCT03886220|DRUG|Placebo|Oral; Tablet
47994209|NCT02874742|DRUG|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
47994210|NCT02874742|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
47994211|NCT02874742|DRUG|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
47994212|NCT02874742|DRUG|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
47994213|NCT03226431|DRUG|Ascorbic Acid|ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
47994214|NCT04130399|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
48153724|NCT02885610|BIOLOGICAL|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
47994215|NCT04130399|DRUG|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
48153725|NCT02645578|DEVICE|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
48153726|NCT02163499|DRUG|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
47994216|NCT01799616|DRUG|Pamidronate|
47994217|NCT01799616|OTHER|Placebo|
47994218|NCT00004733|DRUG|levodopa|
47994219|NCT03662984|DRUG|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
47994220|NCT03662984|DRUG|Placebo Oral Tablet|To compare ciprofibrate
48153727|NCT00872404|DRUG|CP-751,871|20mg/kg/3 weeks
48153728|NCT03095378|PROCEDURE|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
48153729|NCT03095378|PROCEDURE|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
48680000|NCT05524519|PROCEDURE|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20\*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20\*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
48680001|NCT00002798|DRUG|asparaginase|
48153730|NCT03095378|PROCEDURE|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
48153731|NCT05000593|OTHER|normal saline|Intra-articular injection of normal saline
48680002|NCT00002798|DRUG|daunorubicin hydrochloride|
47994221|NCT05409144|PROCEDURE|Thoracic epidural infusion|Upon locating the desired site spot, lidocaine 1% must be injected into the skin and underlying tissues to decrease the discomfort with the advancement of the epidural needle. Once achieving local anesthesia, the epidural needle advanced with its stylet in place and with its bevel point cephalad; this will ultimately contribute to the proper location of the epidural catheter. The epidural needle must be advanced through the skin, subcutaneous tissue, supraspinous, and interspinous ligaments. Once there, the stylet must be removed, and the Loss of Resistance syringe (filled up with saline, air, or both) must be attached to the needle. The needle must be advanced while applying pressure to the plunger. Once the ligamentum flavum is pierced, a loss in resistance will be noted; this is the epidural space, and 5 to 10 cc of saline is injected to expand the epidural space; this may decrease the risk of vascular injury.
48153732|NCT05000593|OTHER|Cord Blood Mononuclear Cells (UCB-MNCs)|Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
48680003|NCT00002798|DRUG|fludarabine phosphate|
48680004|NCT00002798|DRUG|therapeutic hydrocortisone|
48680005|NCT00002798|PROCEDURE|allogeneic bone marrow transplantation|
48680006|NCT00002798|RADIATION|3-dimensional conformal radiation therapy|
48680007|NCT00002798|BIOLOGICAL|filgrastim|Given SC
48680008|NCT00002798|DRUG|cytarabine|Given IV or IT
48680009|NCT00002798|DRUG|idarubicin|Given IV
48680010|NCT00002798|DRUG|dexamethasone|Given PO
48680011|NCT00002798|DRUG|thioguanine|Given PO
48680012|NCT00002798|DRUG|etoposide|Given IV
48153733|NCT05033158|OTHER|Blood sampling|Blood sampling before and after COVID-19 vaccination
48153734|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.|Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
48153735|NCT05029089|DEVICE|Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)|Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
48680013|NCT00002798|DRUG|methotrexate|Given IT
48680014|NCT00002798|DRUG|cyclophosphamide|Given IV
48680015|NCT00002798|BIOLOGICAL|aldesleukin|
48680016|NCT00002798|DRUG|busulfan|
48680017|NCT03073863|DRUG|Atorvastatin|Analysis
48680018|NCT03948893|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
48680019|NCT03948893|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
48680020|NCT02122146|DRUG|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
48680021|NCT02122146|DRUG|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
48680022|NCT03554018|DRUG|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
48680023|NCT03554018|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
48680024|NCT03554018|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)
48680025|NCT03554018|DRUG|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
48680026|NCT05901571|OTHER|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
48680027|NCT05901571|OTHER|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
48680028|NCT05901571|OTHER|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
48680029|NCT05901571|OTHER|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
48680030|NCT06288204|DIETARY_SUPPLEMENT|Propolis + Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis, for 2 months.
48680031|NCT06288204|DIETARY_SUPPLEMENT|Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
48680032|NCT06288204|DIETARY_SUPPLEMENT|Placebo|The participant will consume 4 capsules a day of placebo, for 2 months.
48680033|NCT00589173|BEHAVIORAL|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
48680034|NCT00589173|BEHAVIORAL|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
48680035|NCT04554732|DRUG|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
48680036|NCT01836536|DRUG|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
48680037|NCT02202967|DRUG|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
48680038|NCT02202967|DRUG|Placebo|Placebo contains lactose granules
47994222|NCT05409144|DEVICE|Erector Spinae Plane Block|The block-level will be at T5. The ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle and T5 transverse process. 3ml lidocaine 1% will be used on skin and subcutaneous fat, Echogenic block needle will be inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process.
47994223|NCT05409144|DEVICE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions. Arm abduction is preferred. The ultrasound probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, then, 3ml lidocaine 1% will be used for skin and subcutaneous fat, using ultrasound guidance, a 38-mm 22-gauge regional block needle is going to be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep into the serratus anterior muscle.
48153736|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
48153737|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
48153738|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
48153739|NCT05408156|OTHER|Insoles|semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
48153740|NCT05591456|RADIATION|adjuvant radiotherapy|Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
48153741|NCT01851694|DRUG|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
48153742|NCT01851694|DRUG|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
48153743|NCT00407485|BIOLOGICAL|ziv-aflibercept|Given IV
48153744|NCT00407485|OTHER|pharmacological study|Correlative studies
48364640|NCT04812457|DRUG|Hialucic|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the intervention group, an ointment with hyaluronic acid (hyalucic ®) will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
48680039|NCT06525610|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
48680040|NCT04939038|PROCEDURE|Revascularization|Depending on the condition of the patients, patients will have either endovascular or surgical revascularization
48680041|NCT04939038|PROCEDURE|Standard wound care|Standard wound care according to guidelines
48680042|NCT03211663|DEVICE|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
48680043|NCT04763889|BEHAVIORAL|CBT|CBT for those with an allergy and anxiety
48680044|NCT02904369|DRUG|Emtricitabine|
48680045|NCT02904369|DRUG|Tenofovir alafenamide|
48680046|NCT02904369|DRUG|Tenofovir disoproxil|
48680047|NCT04651465|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
48680048|NCT01242631|DRUG|Everolimus|Everolimus 10 mg orally per day.
48680049|NCT03598049|DEVICE|densah burs osseo densification drills|osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
48680050|NCT03598049|DEVICE|conventional surgical burs drilling|conventional implant osteotomy site drilling with implant surgical kit
48680051|NCT02782585|OTHER|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
48680052|NCT02782585|OTHER|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
47994224|NCT03680950|DEVICE|Upper Gastrointestinal Monitoring System|Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
48153745|NCT03890692|PROCEDURE|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~* Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\\ septum\\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
48153746|NCT04408495|PROCEDURE|Intervention group_MRA|"Tidal Volume (Vt) =6-8 mL/kg of predicted body weight (PBW), Peep=8 cmH2O, recruitment maneuvers=30cm H2O every 30 min after intubation (except during CPB), after any disconnection and at the admission in ICU.~Recruitment maneuvers are performed in accordance with the surgical team an if SAP≥90 mmHg or MAP≥65 mmHg.~Ventilation is maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O"
48153747|NCT04408495|PROCEDURE|Control group|Vt=6-8 mL/kg of PBW, Peep=5 cmH2O , No recruitment maneuvers. Ventilation maintained during CPB Vt=2.5 mL/kg, Peep= 5 cmH2O.
48153748|NCT01277302|DRUG|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
48153749|NCT00800917|DRUG|Temsirolimus|25 mg weekly IV
48153750|NCT00800917|DRUG|Bevacizumab|10 mg/kg every 2 weeks
48511808|NCT05408975|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
48680053|NCT02782585|OTHER|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
47994225|NCT03989440|DRUG|AXER-204|human NoGo Trap fusion protein
47994226|NCT03989440|DRUG|Placebo|Phosphate buffered saline formulation
47994227|NCT04067128|BEHAVIORAL|Health coaching|Brief telephonic intervention consisting of up to three phone calls
47994228|NCT04504799|DEVICE|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
47994229|NCT01834287|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
47994230|NCT01834287|BEHAVIORAL|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
47994231|NCT02146573|BEHAVIORAL|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
48153751|NCT01768572|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
48153752|NCT01768572|DRUG|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
48680054|NCT04365686|DRUG|Ketofol as induction agent|Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
48153753|NCT01768572|DRUG|hydroxychloroquine|Dispensed according to local practice.
48153754|NCT01768572|DRUG|methotrexate|Dispensed according to local practice.
48511809|NCT01406444|DRUG|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
48511810|NCT01406444|DRUG|Risedronate|Risedronate 35mg PO one time weekly
48511811|NCT01406444|DRUG|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
48680055|NCT04365686|DRUG|Propofol as induction agent|Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
48153755|NCT01768572|DRUG|sulfasalazine|Dispensed according to local practice.
48153756|NCT01768572|DRUG|leflunomide|Dispensed according to local practice.
48153757|NCT01768572|DRUG|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
48680056|NCT01062698|DRUG|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
48680057|NCT01062698|PROCEDURE|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
48680058|NCT06128850|OTHER|disease|compare to diseases
48680059|NCT06260605|OTHER|Education|Nursing students learning about diabetes complications
48680060|NCT05849090|DRUG|Cephalosporin or clindamycin/vancomycin antibiotics..|Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
48680061|NCT05849090|DRUG|Vancomycin and Tobramycin antibiotics.|Vancomycin (1 gram) and tobramycin (1.2 grams).
48680062|NCT01602263|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
48153758|NCT01768572|DRUG|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
48153759|NCT03234049|OTHER|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
48680063|NCT00000763|DRUG|TNP-470|
48153760|NCT02851394|DRUG|Levobupivacaine|
48153761|NCT02851394|DRUG|levobupivacaine|
48153762|NCT02851394|DRUG|tramadol|
48680064|NCT04712123|OTHER|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
48680065|NCT00572104|OTHER|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
48153763|NCT01991678|DRUG|145 mg/m2 NKTR 102|
48680066|NCT00572104|OTHER|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
48680067|NCT05242601|OTHER||no intervention
48680068|NCT04961138|PROCEDURE|Transhepatic Arterial Chemotherapy And Embolization (TACE)|Receiving TACE and lenvatinib before surgery.
48680069|NCT04961138|PROCEDURE|Surgery|Removing tumor by surgery.
48680070|NCT02982811|DEVICE|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
48680071|NCT02625220|DEVICE|Prototype toric lens senofilcon A|Investigational prototype
48680072|NCT05851885|DIAGNOSTIC_TEST|AI-based reporting system|AI-based reporting system is a software platform for real-time analysis and records of abnormalities and landmarks during endoscopy.
48680073|NCT05940064|DRUG|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1
48153764|NCT01991678|DRUG|120 mg/m2 NKTR 102|
48153765|NCT01991678|DRUG|50 mg/m2 NKTR 102|
48153766|NCT04057300|DRUG|Ticagrelor 90mg|Ticagrelor tablet
48153767|NCT04057300|DRUG|Clopidogrel 75mg|Clopidogrel tablet
48153768|NCT04057300|DRUG|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
48153769|NCT04734236|DIAGNOSTIC_TEST|New technique vs Xpert|New technique vs Xpert
48153770|NCT00674791|BIOLOGICAL|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
48153771|NCT03740919|DRUG|LY900014|Administered SC
48153772|NCT03740919|DRUG|Insulin Lispro|Administered SC
48153773|NCT03740919|DRUG|Insulin Glargine|Administered SC
48153774|NCT03740919|DRUG|Insulin Degludec|Administered SC
48680074|NCT01882335|BEHAVIORAL|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
48680075|NCT05730946|DIAGNOSTIC_TEST|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
48680076|NCT04858542|BEHAVIORAL|Educational Vocal Health Modules|We have developed four educational health modules (total duration of approximately 30 minutes). First, these modules explain how masks impact communication and voice, then they describe health strategies to improve communication and voice, and finally, they give real-life examples of how the strategies can be implemented into the work setting.
48680077|NCT00987285|BEHAVIORAL|CASM +|Computer Assisted Self Management plus Social Support
47994232|NCT02146573|BEHAVIORAL|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~* CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~* Help patients/families navigate decisions in concert with preferences and beliefs~* Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~* Serve as point person for active intensivists on service and other specialists~* Help resolve conflict when multiple providers have different opinions on course of action"
47994233|NCT03893136|BIOLOGICAL|Tocilizumab|The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
47994234|NCT03893136|DRUG|Leflunomide|The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
48680078|NCT00987285|BEHAVIORAL|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
47994235|NCT01163708|DEVICE|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
47994236|NCT01163708|DEVICE|Navigation System|
47994237|NCT03168152|RADIATION|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
48153775|NCT02142478|BEHAVIORAL|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~* Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~* Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~* Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
48680079|NCT00777348|DRUG|Combination DSCG and Reproterol|1:
48680080|NCT02487160|DEVICE|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
48680081|NCT02487160|DEVICE|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
48680082|NCT04951011|DIAGNOSTIC_TEST|Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy
48680083|NCT05842746|DRUG|Elemene|Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
48680084|NCT05842746|DRUG|Placebo|Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
48680085|NCT02663427|DEVICE|serological examination and gastroscope|
48680086|NCT05875844|DIAGNOSTIC_TEST|Wrist Splint|Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
47994238|NCT03168152|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
47994239|NCT01997515|DRUG|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
47994240|NCT01997515|DRUG|placebo|Group P (placebo) will receive the same amount of saline.
47994241|NCT02451228|OTHER|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
48680087|NCT05875844|DIAGNOSTIC_TEST|Occupational Therapy|Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
47994246|NCT00374296|DRUG|MGCD0103|MGCD0103 administered orally three-times per week
47994247|NCT03935009|BEHAVIORAL|Manual toothbrush Curaprox 5460 ultra soft|Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
47994248|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°1|Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.
48680088|NCT00234130|PROCEDURE|nocturnal vs conventional dialysis|
47994249|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°2|Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
47994250|NCT06265116|OTHER|One-step universal adhesive|Each patient will receive a class II restoration using the corresponding group adhesive
48680089|NCT00003631|BIOLOGICAL|filgrastim|
48680090|NCT00003631|DRUG|carboplatin|
48680091|NCT00003631|DRUG|carmustine|
48680092|NCT00003631|DRUG|cyclophosphamide|
48680093|NCT00003631|DRUG|cytarabine|
48680094|NCT00003631|DRUG|etoposide|
48680095|NCT00003631|DRUG|ifosfamide|
48680096|NCT00003631|DRUG|melphalan|
48680097|NCT00003631|PROCEDURE|bone marrow ablation with stem cell support|
48680098|NCT00003631|PROCEDURE|peripheral blood stem cell transplantation|
47994251|NCT05487742|DRUG|Dexmedetomidine|dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
47994252|NCT05487742|DRUG|placebo salin infusion|salin infused as aplacebo for 72 hours
47994253|NCT05422599|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
47994254|NCT05422599|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
47994255|NCT04070131|OTHER|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
47994256|NCT05825937|DEVICE|ClearSight System|Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
47994257|NCT00369512|DRUG|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
47994258|NCT06110442|DEVICE|IbexBH Software|A software application applied to radiographs
48680099|NCT00003631|RADIATION|radiation therapy|
48680100|NCT06285552|BEHAVIORAL|Positive parenting PAIF program|Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences
48680101|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
48680102|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
48680103|NCT05137691|OTHER|Adapted NHS weight management 1:1 programme|Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
48680104|NCT05137691|OTHER|NHS 1:1 weight management programme|NHS 1:1 weight management programme
48680105|NCT04652804|BEHAVIORAL|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
48680106|NCT04652804|BEHAVIORAL|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
48680107|NCT04652804|BEHAVIORAL|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
48680108|NCT00972023|DRUG|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
48680109|NCT00972023|PROCEDURE|Surgical resection|Surgical procedure of the invasive breast cancer
48680110|NCT06363695|BEHAVIORAL|SafeCare Kenya|Adapted from SafeCare, this is a strengths-based program for parents with children ages 18 months through age 5, teaching parents skills and knowledge in three areas: 1) parent-child interactions, 2) child health, and 3) home safety.
47994259|NCT02273895|DRUG|Scopolamine|0.3 mg/mL, intravenously, once
47994260|NCT00046696|DRUG|NM-3|
47994261|NCT03147365|BEHAVIORAL|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
48680111|NCT06363695|OTHER|Care as Usual by Community Health Volunteers|Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
47994262|NCT03147365|BEHAVIORAL|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
47994263|NCT00715325|DEVICE|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
48153776|NCT02142478|BEHAVIORAL|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
48153777|NCT06023771|PROCEDURE|Invasive intervention for acute pancreatitis|Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
48153778|NCT00472199|DRUG|Pramipexole|
48153779|NCT00472199|DRUG|Placebo|
48153780|NCT00051740|BEHAVIORAL|Cognitive Adaptation Therapy (CAT)|
48153781|NCT00051740|BEHAVIORAL|Minimal Environmental Supports (MES)|
48511812|NCT04431765|OTHER|Eye Movement Desensitization Reprocessing therapy|The Eye Movement Desensitization Reprocessing therapy uses bi-alternating (right-left) sensory stimulation through eye movements. The patient follows the therapist's fingers from right to left in front of his eyes and also by auditory stimuli. The patient wears a helmet that alternately makes him hear a sound to the right, then to the left or touch the patient holds in his hands buzzers that alternately vibrate from right to left, or alternatively the therapist taps the patient's knees or the back of his hands.
48680112|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
48680113|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
48680114|NCT01530529|DRUG|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
47994264|NCT04748133|DEVICE|acupuncture needles|"Site of acupuncture points:~* Du 26: At junction of the upper and middle third of philtrum.~* Ren 17: On the midline level with the 4th intercostal space midway between the nipples.~* LI4 (Large Intestine 4): On the dorsum of the hand, between the 1st and 2nd metacarpal bones~* HT7 (Heart 7): On the ulnar end of the transverse crease of the wrist, in the small depression between the pisiform and ulna bones~* LV3 (Liver 3): On dorsum of the foot in a depression distal to the junction of the 1st and 2nd metatarsal bones.~* ST36 (Stomach 36): Antero-lateral leg, 1 middle-finger breadth next to the anterior crest of tibia, 3 cun under the depression lateral to the patellar ligament.~* PC6 (Pericardium 6): Palmar aspect of the forearm, between the tendons, 2 cun away from the transverse crease of the wrist"
47994265|NCT04748133|OTHER|placebo|no treatment
48680115|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
47994266|NCT02952339|BIOLOGICAL|RSV LID ΔM2-2 1030s vaccine|10\^5.0 PFU; administered as nose drops
47994267|NCT02952339|BIOLOGICAL|Placebo|Administered as nose drops
48153782|NCT06462768|OTHER|Blood sample|Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
48364641|NCT04812457|DRUG|Betadine gel|A professional not present at the intervention (researcher 2) will proceed to carry out the postoperative cures 48 hours after the intervention. The bandage will be removed, the area will be washed with physiological saline and the drug will be applied according to the group to which it belongs. In the control group, Betadine Gel will be used together with a non-stick dressing and a semi-compression bandage to prevent bleeding.
48680116|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
48364642|NCT02718131|DEVICE|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
48364643|NCT02718131|PROCEDURE|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
48364644|NCT06008522|DRUG|Bevacizumab-800CW|Imaging of fluorescently labeled Bevacizumab-800CW using OCT.
48364645|NCT02934919|DRUG|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
48364646|NCT01337440|DRUG|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
48364647|NCT01337440|DRUG|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
48153783|NCT05076578|DEVICE|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
47994268|NCT00819468|DRUG|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
47994269|NCT04127331|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
47994270|NCT00455507|DRUG|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
47994271|NCT00455507|DRUG|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
47994272|NCT00455507|DRUG|Placebo|Two placebo tablets orally once daily for 12 weeks
47994273|NCT01540708|DRUG|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
47994274|NCT01540708|DRUG|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
47994275|NCT03839511|PROCEDURE|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
47994276|NCT02804984|GENETIC|ICUS|
48153784|NCT04160871|BEHAVIORAL|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
48364648|NCT05359328|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
48680117|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
48680118|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
47994277|NCT04375488|OTHER|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
48680119|NCT03033680|DRUG|[F-18]PBR06|PET radiopharmaceutical
47994278|NCT04375488|OTHER|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
47994279|NCT01844609|BEHAVIORAL|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
47994280|NCT01844609|BEHAVIORAL|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
47994281|NCT01548612|DRUG|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
48680120|NCT01211392|OTHER|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
48680121|NCT00638300|DEVICE|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
48680122|NCT00638300|OTHER|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
48680123|NCT00638300|OTHER|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
48680124|NCT04942132|BEHAVIORAL|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
48680125|NCT00465608|DRUG|propranolol|propranolol by mouth (per os)
48680126|NCT04103112|DEVICE|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
48680127|NCT05807152|DEVICE|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
48680128|NCT02415244|PROCEDURE|TEE|Spinal cord segments will be imaged using the TEE
48680129|NCT00003846|BIOLOGICAL|filgrastim|
48680130|NCT00003846|DRUG|carboplatin|
48680131|NCT00003846|DRUG|cyclophosphamide|
48680132|NCT00003846|DRUG|thiotepa|
47994282|NCT01548612|DRUG|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
48680133|NCT00003846|DRUG|vincristine sulfate|
48680134|NCT00003846|PROCEDURE|bone marrow ablation with stem cell support|
48680135|NCT00003846|PROCEDURE|peripheral blood stem cell transplantation|
48680136|NCT00003846|RADIATION|radiation therapy|
48680137|NCT01189344|DRUG|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
48680138|NCT05123989|BEHAVIORAL|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
48680139|NCT05123989|BEHAVIORAL|Constant move goals|Static move goal delivered by the Welltory mobile app
48680140|NCT01485796|BIOLOGICAL|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
48680141|NCT01485796|BIOLOGICAL|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
48680142|NCT05063929|OTHER|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
48680143|NCT05063929|OTHER|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
48680144|NCT02385903|OTHER|Flammacerium|
48680145|NCT02385903|OTHER|Standard dressing procedure|
48680146|NCT03653806|OTHER|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
48680147|NCT05088044|OTHER|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
48680148|NCT01900522|DRUG|ITI-214 Dose A|ITI-214 Dose A Oral Solution
48680149|NCT01900522|DRUG|ITI-214 Dose B|ITI-214 Oral Solution Dose B
48680150|NCT01900522|DRUG|ITI-214 Dose C|ITI-214 Dose C Oral Solution
48680151|NCT01900522|DRUG|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
47994283|NCT04928677|DRUG|Codrituzumab|For Phase A (Dose Escalation), the starting dose (dose level 1) will be 10 mg/kg with 1 planned dose escalation to 20 mg/kg (dose level 2) if dose level 1 is determined to be safe and tolerable. Once a RP2D/MTD is identified in Phase A, then Phase B (hepatoblastoma expansion cohort) will open and allow for enrollment of up to 10 additional patients.For both phases, patients will receive codrituzumab IV once per week for a period of 21 days per cycle. Patients will be eligible for up to 25 cycles.
47994284|NCT01464346|DEVICE|Enlite Sensor|This is the Enlite sensor (all subjects)
47994285|NCT02653456|DEVICE|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
48680152|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
48680153|NCT01900522|DRUG|ITI-214 Dose E|ITI-214 Dose E Oral Solution
48680154|NCT01900522|DRUG|ITI-214 Dose F|ITI-214 Dose F Oral Solution
48680155|NCT01900522|DRUG|ITI-214 Dose G|ITI-214 Dose G Oral Solution
48680156|NCT01900522|DRUG|ITI-214 Dose H|ITI-214 Dose H Oral Solution
48680157|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
48680158|NCT04453826|DRUG|Camrelizumab plus chemo-radiotherapy|"1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
48680159|NCT04453826|DRUG|Chemo-radiotherapy alone|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
48680160|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
47994286|NCT06146582|BEHAVIORAL|Laguna Coach and App Intervention Group|Behavioral, mental and contextual support was delivered through personal interactions with Laguna Coaches via mobile app, phone, video, or web chat. Care interventions were individualized to best match each participant's needs and strengths. Support will be provided to participants through interactions over approximately 90 days.
48153785|NCT04160871|BEHAVIORAL|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
48680161|NCT04750343|BIOLOGICAL|GBP510 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
48680162|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
47994287|NCT04400903|DEVICE|Activity Monitor|Undergo HRV monitoring via WHOOP device
48680163|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
48680164|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
48680165|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
48680166|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
47994288|NCT04400903|OTHER|Quality-of-Life Assessment|Ancillary studies
47994289|NCT04400903|OTHER|Questionnaire Administration|Complete questionnaires
47994290|NCT05525156|DRUG|aspirin enteric coated tablet 75 mg|blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
47994291|NCT05303584|BIOLOGICAL|Ad5-nCoV-IH|The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.
47994292|NCT05303584|BIOLOGICAL|Ad5-nCoV-IM|The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.
47994293|NCT05303584|BIOLOGICAL|CoronaVac|CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
47994294|NCT05218018|DIETARY_SUPPLEMENT|Lipid drink|100 mls of heavy cream
48680167|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
48680168|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
48680169|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
47994295|NCT03144674|DRUG|Parsaclisib|Parsaclisib at the protocol-defined dose.
48680170|NCT00763256|DRUG|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
48680171|NCT00763256|DRUG|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
48680172|NCT02088853|DIETARY_SUPPLEMENT|high fat diet (hfd)|Sixty % of the energy content is based on fat.
48680173|NCT02088853|DIETARY_SUPPLEMENT|high carb diet|Sixty % of the energy content is based on carbohydrates.
48680174|NCT02455102|OTHER|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
48680175|NCT02988544|PROCEDURE|Artificial shrinkage|Artificial shrinkage of blastocyst
48680176|NCT04430361|DRUG|Megestrol|160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
48680177|NCT04430361|DRUG|5-HT3 receptor antagonist|5-HT3 receptor antagonist 2.5mg/iv
47994296|NCT05643261|OTHER|Muscle and technique training|The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.
47994297|NCT03644199|OTHER|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
47994298|NCT03644199|OTHER|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
48511813|NCT04431765|BEHAVIORAL|Trauma-Centred Cognitive and Behavioural Therapy|A CBT is a short, scientifically validated therapy that focuses on the interactions between thoughts, emotions and behaviours. These therapies focus on the current problems of the person, while taking into account their historical causes. They help gradually overcome disabling symptoms and aim to strengthen adaptive behaviours. A CBT relies on different techniques that help the patient to identify the mechanisms at the origin of his difficulties, to experiment with new behaviors and thus to gradually come out of vicious circles that perpetuate and aggravate the psychic suffering.
48511814|NCT04102189|DRUG|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
48680178|NCT04430361|DRUG|dexamethasone|dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
48680179|NCT01889108|BEHAVIORAL|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
48680180|NCT02920307|PROCEDURE|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
47994299|NCT01565109|DRUG|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
47994300|NCT01565109|RADIATION|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
48680181|NCT02920307|PROCEDURE|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
47994301|NCT00230698|DRUG|topiramate|
47994302|NCT02174068|DRUG|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
48680182|NCT02920307|PROCEDURE|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
48680183|NCT02920307|PROCEDURE|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
48680184|NCT01980199|DRUG|Fexinidazole|"600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days"
48680185|NCT03180112|GENETIC|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
48680186|NCT03939637|DRUG|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~* Children 1 to 5 years: Initial: 25 mg once daily~* Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity \[e.g., Chinese, Japanese, Korean, Taiwanese\])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
47994303|NCT01683981|DRUG|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
47994304|NCT06039423|PROCEDURE|The M-TAPA block|A high frequency (6-12 MHz) US linear probe was placed in the sagittal plane on the 10 th costal margin in the midline. The probe was then angulated deeply to visualize the lower surface of the costal cartilage. Via in plane technique, a 21 gauge Tuohy needle was inserted cranially between the lower fascia of the costal cartilage and upper fascia of the transversus abdominis muscle by moving the needle tip towards the posterior aspect of the 10 th costal cartilage and 20 mL bupivacaine (0.25 %) was injected.
47994305|NCT06039423|DRUG|Ketorolac|conventional general anaesthesia receiving multimodal analgesia
48511815|NCT04102189|OTHER|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
48511816|NCT06021418|DEVICE|DKB-119|Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
48680187|NCT03939637|DRUG|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
48680188|NCT03939637|DRUG|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
48680189|NCT03939637|DRUG|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
48680190|NCT00049322|BIOLOGICAL|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
48680191|NCT01478464|OTHER|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
47994306|NCT03568357|PROCEDURE|Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
48153786|NCT06241677|DRUG|alteplase or tenecteplase|Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
48153787|NCT03799965|OTHER|ERAS (Enhanced Recovery After Surgery ) are evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
48680192|NCT03183765|DRUG|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
48153788|NCT03799965|OTHER|ERAS are not evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
48153789|NCT03476954|OTHER|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
48153790|NCT02720705|DRUG|Dexmedetomidine|oral dexmedetomidine
48153791|NCT02720705|DRUG|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
48153792|NCT02261519|DRUG|NaBen®|500 mg twice daily (1000 mg total)
48364649|NCT06425185|OTHER|Single-leg stance under different instability conditions|"Participants will perform three attempts of 20 seconds of single-leg stance on the floor and on the 7 selected configurations of the BB. The order of measurement will be randomized. The description of the chosen configurations can be found in the Detailed Description section. In all cases, the participant's objective is to ensure that the edges of the BB are not in contact with the floor.~The position of the participant on the BB will be a single-leg stance on the randomly chosen foot, with the contralateral knee slightly flexed and hands placed on the hips. Participants will look at a fixed point placed 3 meters in front of them.~A rest period of 30 seconds will be allowed between trials. The physiotherapist responsible for supervising the measurements will be the one to adjust the BB configurations when needed."
47994307|NCT02740166|DRUG|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
47994308|NCT00002304|DRUG|Ketoconazole|
47994309|NCT00002304|DRUG|Fluconazole|
47994310|NCT01983579|PROCEDURE|Intraocular anti-VEGF injection|
47994311|NCT01983579|DEVICE|SENSIMED Triggerfish|
47994312|NCT06456333|DEVICE|High-density surface electromyography|Electromyographic signals were acquired from the paravertebral muscles in apical vertebral in patients with AIS using SAGA High Density Myoelectrics (TMSi International, New Zealand)
47994313|NCT03456596|OTHER|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
47994314|NCT05031182|PROCEDURE|Laparoscopy|The hysterectomy is performed by laparoscopy as described in the EMC.
47994315|NCT05031182|PROCEDURE|vNOTES|The hysterectomy is performed by vNOTES as described Dr BAEKELANDT and this team.
47994316|NCT02410382|DRUG|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
47994317|NCT02410382|DRUG|Placebo|oral placebo
47994318|NCT03402009|BEHAVIORAL|Apps|Apps and weblinks to coach self-guided meditation.
47994319|NCT03402009|BEHAVIORAL|EEG neurofeedback|Device provides feedback based on EEG readings.
48153793|NCT02261519|OTHER|Placebo|0 mg twice daily (0 mg total)
48153794|NCT05287178|BEHAVIORAL|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
48153795|NCT02834624|DRUG|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
48153796|NCT02834624|DRUG|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
48153797|NCT04551469|BEHAVIORAL|music|Music intervention for 30 minutes
48364650|NCT05858645|DRUG|deucravacitinib|Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment
48364651|NCT00027846|BIOLOGICAL|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \>1500/μl given subcutaneously or intravenously.
48364652|NCT00027846|DRUG|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.
48680193|NCT03183765|PROCEDURE|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
48680194|NCT00483054|DRUG|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
48680195|NCT00483054|DRUG|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
48680196|NCT04715841|OTHER|gait assessment|gait assessment were done using 3DMA system
48680197|NCT05557994|OTHER|Method|treatment of mature teeth with apical periodontitis
48680198|NCT04041232|DRUG|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
48680199|NCT03685058|DEVICE|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
48680200|NCT03685058|OTHER|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
48680201|NCT02172391|DRUG|Tiotropium inhalation powder capsules|
47994320|NCT05920421|PROCEDURE|diaghragm affection by ultrasound before and after the blocks|the participant will assess diaphragm sparing in each block and evaluate effectiveness of infraclavicular subomohyoid blocks and subomohyoid subscapularis blocks according to intraoperative and postoperative analgesia and diaphragm affection and comparing them with interscalen and with each others
48680202|NCT02172391|DRUG|Placebo inhalation powder capsules|
48680203|NCT05509062|PROCEDURE|Pressure|Subjects are randomized to one of three treatment groups
48680204|NCT01433406|DRUG|TAK-875|
47994321|NCT06291142|DEVICE|Observation - Nailfold capillaroscopy|Nailfold capillaroscopy examination
47994322|NCT00574054|RADIATION|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
47994323|NCT00335972|DRUG|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
47994324|NCT00335972|DRUG|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
47994325|NCT06067945|OTHER|microleakage|prevention of microleakage and secondary carries
47994326|NCT06036420|DEVICE|Flashed Light Therapy|Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
47994327|NCT06036420|BEHAVIORAL|Videoconference-delivered Cognitive Behavioral Therapy|Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
47994328|NCT01556581|PROCEDURE|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
47994329|NCT01556581|PROCEDURE|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
48680205|NCT01433406|DRUG|TAK-875|
48680206|NCT01470131|DRUG|Masitinib|Masitinib 6 mg/kg/day
48680207|NCT01470131|DRUG|Placebo|Matching placebo
48680208|NCT01470131|DRUG|Bortezomib|Standard therapy (cycles of bortezomib)
48680209|NCT01470131|DRUG|Dexamethasone|Standard therapy (cycles of dexamethasone)
48680210|NCT01316458|DRUG|STI571 (Glivec®)|
48680211|NCT05229809|DRUG|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
48680212|NCT05229809|DRUG|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
48680213|NCT00295282|DRUG|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
48680214|NCT00500461|DRUG|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
48680215|NCT02391324|PROCEDURE|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
48680216|NCT02391324|PROCEDURE|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
48680217|NCT02391324|PROCEDURE|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
48680218|NCT05525039|DEVICE|Low-magnitude High-frequency Vibration|0.3g, 35Hz, 20mins/day, at least 3 times/week
48680219|NCT05525039|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB) supplement|Oral nutritional HMB supplement at 3g/day
48680220|NCT05525039|DIETARY_SUPPLEMENT|Protein supplement|Daily protein supplement intake
48680221|NCT03710356|DRUG|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
48680222|NCT05079347|DIAGNOSTIC_TEST|HIV rapid test|Using a rapid test to assess a patient's HIV status
48680223|NCT02750046|PROCEDURE|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
48680224|NCT03462758|DEVICE|IUD|Postpartum IUD placement
48680225|NCT01431898|DRUG|GS-9669 tablets|
48680226|NCT01431898|DRUG|Placebo to Match GS-9669 tablet|
48680227|NCT06084000|DEVICE|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"* Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~* Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
48680228|NCT06084000|DEVICE|Drug-eluting stent|"* Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~* Special consideration:~  1. Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~ 2. The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~ 3. If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
48680229|NCT01803971|OTHER|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
48680230|NCT04088799|OTHER|No intervention|No intervention
48680231|NCT01121055|DRUG|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
48680232|NCT01121055|DRUG|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
48680233|NCT02708316|GENETIC|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
48680234|NCT01877681|PROCEDURE|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
48680235|NCT01877681|PROCEDURE|Active comparator|Usual care as specified in the PU practice guideline
48680236|NCT04952428|BEHAVIORAL|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted."
48680237|NCT05845619|BEHAVIORAL|Enhanced virologic monitoring|"The pilot intervention will include the following components:~1. More frequent viral load collection: Participants who enroll in the first 3 months of the pilot study period will be eligible for a 3-month follow-up visit and will have viral load assessed again at that time.~2. Rapid return of viral load results: Mentor mothers (peer counselors) will be trained to return viral load results to patients. Viral loads will will be processed with GeneXpert point of care technology.~3. Enhanced viral load counseling: Mentor mothers will reinforce adherence with all patients with undetectable levels via scripted messaging to reward and encourage healthy behavior. For those with any detectable levels, mentor mothers will be trained to provide targeted counseling with scripted messaging according to viral load level (undetectable, low-level viremia (50-1000), high viral load (\>1000))."
48680238|NCT03139032|DRUG|APD334|APD334 active treatment for 12 weeks.
48680239|NCT03877003|OTHER|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
47994330|NCT05948202|BEHAVIORAL|Pivotal Response Treatment|Group-based parent training to teach parents behavioral strategies based on principles of learning to motivate their child.
47994331|NCT01969903|DRUG|Precedex injection|
48511817|NCT04638101|BEHAVIORAL|Mindfulness-based intervention|Mindfulness-based intervention: The proposed MBI was designed based on well-known MBI programs including Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy and adapted to adolescents' needs and language. The program consisted of 8 weekly sessions in groups of up to 8 participants, lasting 1h30. Two MBI groups were offered per week (Wednesdays and Fridays) and participants had the possibility to choose the most convenient day for them. Two instructors were present for each group throughout the intervention.For each session one theme was addressed, such as attention and the stabilisation of the focus of attention, bodily sensations, breath, emotions, thoughts, compassion, stress, stress reactivity and coping strategies.
48511818|NCT03672045|DRUG|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
48680240|NCT05041998|DEVICE|Trans-femoral prosthetic socket|"Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis~1. Soft socket (Socket made from softer material than unmodified original)~2. Stiff socket (Socket made from stiffer material than unmodified original)~3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)~4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)~5. Oversized socket (The socket volume is 6% larger than the unmodified original)~6. Undersized socket (The socket volume is 6% smaller than the unmodified original)~7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))~8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)"
48680241|NCT01466283|GENETIC|DNA methylation analysis|
48680242|NCT01466283|GENETIC|fluorescence in situ hybridization|
48680243|NCT01466283|GENETIC|gene expression analysis|
48680244|NCT01466283|GENETIC|reverse transcriptase-polymerase chain reaction|
48680245|NCT01466283|OTHER|laboratory biomarker analysis|
48680246|NCT00852579|DRUG|Azithromycin|Daily dose 250mg
48680247|NCT00852579|DRUG|Placebo|Placebo
48680248|NCT06287255|BEHAVIORAL|EIM+|The Exercise is Medicine (EIM) program involves a personalized exercise prescription and wellness coaching component. At the first 1:1 session, participants are provided with a Fitbit and onboarded with Fitabase, allowing for documentation of baseline health behaviors. Over the course of the program, the EIM fitness specialist reviews Fitbit data and progress towards goals, sending push notifications for encouragement and reminders. A personal training session is conducted, followed by sixteen group sessions including up to eight participants. The final session includes updating goals, incorporating Fitbits, and providing an updated exercise prescription. Upon program completion, participants will attend monthly webinars and health coaching sessions at 6- and 12-months post-program. The program aims to help individuals overcome barriers and maintain long-term exercise self-efficacy.
48680249|NCT00358033|BEHAVIORAL|Counseling|
48680250|NCT00358033|BEHAVIORAL|Interactive Education|
48680251|NCT00358033|BEHAVIORAL|Group Support|
48680252|NCT00358033|PROCEDURE|Pharmacologic case management|Provided by clinical pharmacists
48680253|NCT02871817|OTHER|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
48680254|NCT04202666|DEVICE|convex skin barrier|Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
48680255|NCT01882387|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
48680256|NCT03880045|DRUG|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
48680257|NCT03880045|DRUG|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
48680258|NCT03880045|OTHER|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
48680259|NCT04037891|DRUG|rVA576|"19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial."
48364653|NCT00027846|DRUG|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
48364654|NCT00027846|DRUG|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
48364655|NCT00027846|DRUG|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.
48364656|NCT00027846|RADIATION|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
48511819|NCT00003643|BIOLOGICAL|bleomycin sulfate|
48511820|NCT00003643|BIOLOGICAL|filgrastim|
48511821|NCT00003643|DRUG|cisplatin|
48511822|NCT00003643|DRUG|etoposide|
48511823|NCT00003643|DRUG|paclitaxel|
48511824|NCT06161779|OTHER|Surgical reconstruction|submental artery island flap (SMAIF) for the reconstruction of laryngeal and hypopharyngal defects after the surgical resection of hypopharyngeal cancer
48511825|NCT04142112|DEVICE|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
48153798|NCT04479176|PROCEDURE|Transnasal Sphenopalatine Ganglion Block|In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.
48153799|NCT05812209|PROCEDURE|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
48153800|NCT03426332|OTHER|No intervention|No intervention
48153801|NCT01064180|DRUG|Carvedilol|Carvedilol Tablets 25 mg
48153802|NCT03809858|OTHER|Klue App|The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
48153803|NCT03670771|DIAGNOSTIC_TEST|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
48153804|NCT04217798|DRUG|Niraparib|Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
48153805|NCT02846142|DRUG|PTI-428|
48153806|NCT02846142|OTHER|Placebo|
48153807|NCT02846142|DRUG|ethinyl estradiol and levonorgestrel|
48153808|NCT05483478|COMBINATION_PRODUCT|mobile health combined Multi-course Program|mobile health combined Multi-course Program
48153809|NCT05264506|DRUG|NOMAC-E2 COC|"Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed."
48153810|NCT06387576|BEHAVIORAL|Behaviorally informed pre-discharge iPad video scheduling|The iPad video scheduling process will occur prior to patient discharge from the hospital. This intervention harnesses behavioral principles, such as commitment (patient committing to scheduled appointment), social accountability (patients feeling more accountable after scheduling their appointment via the video visit), and social support (patients feeling more supported after engaging in this conversation with a scheduler via video).
48153811|NCT03387592|DRUG|CPT-11|180 mg/m2
48153812|NCT03387592|DRUG|Calcio levofolinate|200 mg/m2
48153813|NCT03387592|DRUG|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
48153814|NCT03387592|DRUG|Capecitabine|1500 mg/m2
48153815|NCT03387592|DRUG|Temozolomide|200 mg/m2
48153816|NCT05018455|OTHER|Fall prevention program training based on Otago principles|balance and strength exercises
48153817|NCT02261675|DRUG|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
48511826|NCT04142112|DEVICE|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
48153818|NCT01973478|DEVICE|DBS|
48153819|NCT01973478|DEVICE|SHAM|
48153820|NCT04136249|DIETARY_SUPPLEMENT|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
48153821|NCT00804765|OTHER|Therapeutic education|Intensive training individual and collective teaching
48153822|NCT00804765|OTHER|Follow-up|classical follow-up with two individual consultations
48153823|NCT01125956|BEHAVIORAL|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
48153824|NCT01125956|BEHAVIORAL|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
48153825|NCT06055478|PROCEDURE|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block|"Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine or saline.~Low fixed dose patient controlled analgesia (PCA) were done in the two group."
48153826|NCT02303613|OTHER|Mapping|Mapping of current triage situation regarding 30 days mortality
48153827|NCT05186493|PROCEDURE|robot-assisted total pelvic exenteration|Patients with locally advanced pelvic cancer that require pelvic exenteration considered eligble, are operated minimmally invasive robot-assisted
48153828|NCT05248659|DRUG|Sibeprenlimab 400 mg s.c. Q4weeks|Sibeprenlimab 400 mg s.c. q 4 weeks
48153829|NCT04056598|DIAGNOSTIC_TEST|Study of humoral immunity|Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
48511827|NCT02404766|OTHER|C0-C1 dorsal glide manual mobilization|
48680260|NCT04037891|OTHER|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
48153830|NCT05181839|DRUG|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
48153831|NCT05487937|OTHER|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
48153832|NCT01299441|DEVICE|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
48511828|NCT02404766|OTHER|C7-T1 ventral cranial glide manual mobilization|
48680261|NCT00005739|BEHAVIORAL|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
48680262|NCT00005739|BEHAVIORAL|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
48680263|NCT02822742|DRUG|DE-117 ophthalmic solution|
48153833|NCT04617197|DEVICE|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
48153834|NCT01855672|DEVICE|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
48153835|NCT03778957|DRUG|Durvalumab|Durvalumab IV (intravenous)
48153836|NCT03778957|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
48153837|NCT03778957|OTHER|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
48153838|NCT03778957|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
48153839|NCT06475690|OTHER|Psychological interventions|Psychological interventions is used for intervention group
48153840|NCT01837199|DRUG|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
48364657|NCT00027846|DRUG|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
48364658|NCT00027846|PROCEDURE|therapeutic conventional surgery|
48364659|NCT05441124|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
48364660|NCT04994015|DEVICE|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by site clinician/physician/genetic counselor.
48364661|NCT03851302|OTHER|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
48364662|NCT03851302|OTHER|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
48364663|NCT03851302|OTHER|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
48364664|NCT01259388|DRUG|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
48364665|NCT03775733|DIETARY_SUPPLEMENT|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
48364666|NCT03775733|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
48511829|NCT05689502|DEVICE|Treatment|Subjects will participate in 6 hours of therapy a day, 5 days a week, for 3 consecutive weeks. These sessions will include 2 hours of occupational therapy, 2 hours of physical therapy, and 2 hours of guided individual work. Some of these sessions will be in a group setting. The therapy sessions will be individualized to the subject's personal goals and will focus on improving the function of the arm most affected by the stroke. Sessions may include electrical stimulation of the muscles, if it is determined to be safe. At the end of each week, the therapists will recommend exercises for the subjects to continue to work on at home on the weekend.
48364667|NCT02155725|DRUG|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
48511830|NCT01117493|BEHAVIORAL|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
48680264|NCT02822742|DRUG|Latanoprost ophthalmic solution 0.005%|
48153841|NCT05224596|DIAGNOSTIC_TEST|Blood draw and blood-based biomarkers analyses|blood-based biomarkers analyses
48153842|NCT06177067|DRUG|Revumenib|Given by mouth (capsule or liquid solution) or liquid solution by Nasogastric tube (NG) or Gastrostomy tube (G-tube)
48153843|NCT06177067|DRUG|Venetoclax|Given by mouth (tablet)
48153844|NCT06177067|DRUG|Azacitidine|Given intravenously (IV) infusion
48153845|NCT06177067|DRUG|intrathecal (IT) chemotherapy|Given intrathecal (IT)
48153846|NCT06177067|DRUG|Cytarabine|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
48153847|NCT06177067|DRUG|Methotrexate|Given intrathecal (IT) as part of intrathecal (IT) chemotherapy.
48153848|NCT00871494|DRUG|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
48153849|NCT05588661|OTHER|Perturbation Exercises|"Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients."
48153850|NCT05588661|OTHER|Whole Body Vibration|"It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks"
48364668|NCT02155725|DRUG|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
48364669|NCT04730739|DEVICE|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
48153851|NCT03726528|DIAGNOSTIC_TEST|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
48153852|NCT03465670|DEVICE|CHX|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
48153853|NCT03465670|DEVICE|CHX+HA+ADS|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
48153854|NCT02640326|OTHER|No Foley Urinary Catheter|No Foley urinary catheter will be put in place during the operation
48153855|NCT02640326|OTHER|Standard of care Foley urinary catheter insertion|A Foley urinary catheter will be put in place during the operation
48153856|NCT05440578|DRUG|olaparib plus bevacizumab maintenance therapy|First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
48153857|NCT00755716|DRUG|Placebo (sugar pill)|patients receive
48153858|NCT00755716|DRUG|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
48153859|NCT00755716|DRUG|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
48153860|NCT01695993|DEVICE|Acupressure bands|Bilateral acupressure wrist bands
48153861|NCT01695993|OTHER|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
48153862|NCT01695993|BEHAVIORAL|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
48153863|NCT01695993|OTHER|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
48153864|NCT01695993|BEHAVIORAL|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
48153865|NCT00683371|PROCEDURE|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
48511831|NCT01117493|BEHAVIORAL|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
48680265|NCT03003754|BEHAVIORAL|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
48511832|NCT01291394|DEVICE|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
48680266|NCT03003754|BEHAVIORAL|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
48680267|NCT01096108|BEHAVIORAL|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
48680268|NCT01096108|BEHAVIORAL|Motivational and Problem-Solving|Counseling phone calls
48680269|NCT01096108|BEHAVIORAL|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
48680270|NCT01349205|DRUG|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
48680271|NCT01349205|DRUG|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
48680272|NCT01349205|DRUG|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
48153866|NCT00683371|PROCEDURE|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
48364670|NCT02943577|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
48364671|NCT02943577|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
48364672|NCT05947968|OTHER|Scapular PNF|"Scapular proprioceptive neuromuscular facilitation exercise: will be applied in two diagonals:~1. anterior elevation and posterior depression~2. posterior elevation and anterior depression for 3 sets of 10 repetitions, The rest interval between sets will be 20 seconds.~Patients will lay on the unaffected side while the therapist stands in the line of desired motion. Firstly, the therapist will give preparatory instructions. In the beginning of the pattern, the therapist pulls the scapula to the elongated position and then gives instructions for the desired movement."
48153867|NCT05075135|DEVICE|Swibrace 3D-splint|"The Swibrace 3D splint is a custom-made splint. For scanning of the forearms, the investigators will use the scanner HandySCAN300 and the therewith delivered software VXElements, the latter being necessary to create an accurate scan on the computer.~Printing of the splint will be done by Materialise, Belgium."
48153868|NCT05075135|DEVICE|Plaster cast|The conservative gold standard treatment of distal radius and scaphoid fractures is applying a plaster cast. Therefore, patients in the control group follow standard therapy procedures.
48153869|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Naive-patients|Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
48153870|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Tolerant-patients|Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
48153871|NCT04005248|DIAGNOSTIC_TEST|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
48153872|NCT00557518|DRUG|Alagebrium|200 mg bid
48153873|NCT00557518|DRUG|Placebo|bid
48153874|NCT05935982|BEHAVIORAL|Virtual reality exercise|During school special physical education, participants will be asked to exercise using a virtual reality exercise headset, that will be adapted for arm use. Participants will asked to be seated during gameplay. Heart rate will be monitored and recorded during exercise.
48153875|NCT03108222|OTHER|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
48153876|NCT04973176|DEVICE|Standard Bougie|Standard Bougie for endotracheal intubation
48364673|NCT05947968|OTHER|Shoulder strengthening exercises|"Shoulder strengthening exercises:~The following four exercises will focus on shoulder and scapular strengthening. Before starting the program, the patients will be thoroughly instructed in the four exercises, and illustrations with specific exercise instructions will be provided. All subjects will perform the exercises with the affected side for three sets of 10 repetitions for each exercise, with a 1-minute rest between sets.~1. Standing shoulder external rotation with elastic resistance.~2. Bilateral external rotation with scapular retraction exercise.~3. Resisted scapular retraction with shoulder external rotation (Middle trapezius muscle).~4. Weighted scapular retraction and downward rotation Y-shape (lower trapezius muscle)."
48364674|NCT04001699|OTHER|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
48364675|NCT01716585|DRUG|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
48364676|NCT01716585|DRUG|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
48364677|NCT01716585|DRUG|Placebo for ABT-450/r/ABT-267|Tablet
48364678|NCT01716585|DRUG|Placebo for ABT-333|Tablet
48364679|NCT01716585|DRUG|Placebo for ribavirin|Capsule
48364680|NCT01230489|BIOLOGICAL|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
48680273|NCT05540626|DEVICE|Cala Trio|transcutaneous afferent patterned stimulation (TAPS)
48680274|NCT05460897|BEHAVIORAL|Health behaviour change|weekly sessions addressing strategies to tackle behavioural risk factors for chronic disease
48364681|NCT00391820|DRUG|TD-5108|
48680275|NCT06493175|DIAGNOSTIC_TEST|Application of large language model in emergency chest pain triage.|The large language model MedGuide-V5 is able to quickly extract key information from a patients description, and by analyzing these descriptions, it provides physicians with a possible initial diagnosis to help them quickly prioritize the treatment of patients.
48680276|NCT06493175|DIAGNOSTIC_TEST|According to the normal procedures to receive medical treatment|After the artificial intelligence system evaluation, the patients will receive the diagnosis and treatment according to the normal procedure. The overall time of artificial triage, the triage of patients, and other data will be recorded. Patient visits should not be delayed by the use of artificial intelligence systems for evaluation.
48364682|NCT02180854|OTHER|Control group|
48364683|NCT02180854|OTHER|Increased monitoring frequency|
48153877|NCT04973176|DEVICE|Flexi-tip Bougie (P3 Medical Bristol,UK)|Flexi-tip Bougie for endotracheal intubation
48153878|NCT03127475|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
48680277|NCT05600829|BEHAVIORAL|BWLT+CR|Patients will attend twelve 2-hour group-based weekly sessions (over Zoom) in addition to their twice-weekly CR exercise sessions, followed by biweekly follow-up sessions alternating between individual phone-based sessions with a facilitator, and group-based sessions for an additional 12 weeks. The empirically validated ASPIRE BWLT was recently adapted for an AF population with obesity. Briefly, the BWLT was modified to incorporate education and practical strategies requested by patients, including AF risk factor management, pathophysiology, medications, and disease course; exercising with AF; and coping with difficult emotions regarding AF. Weekly treatment goals focus on nutrition and moderate calorie reduction while emphasizing adherence to an individualized CR exercise prescription. The BWLT program will be delivered by senior clinical psychology PhD students and supervised by a registered Clinical Health Psychologist.
48680278|NCT05600829|BEHAVIORAL|CR-Only|The CR program consists of education, medication management, risk factor modification and 12 weeks of twice-weekly supervised cardiovascular exercise sessions. Patients with AF undergo a symptom-limited graded exercise stress test at intake, 12-weeks, 24-weeks, and 1-year post-randomization, where cardiorespiratory fitness (i.e., peak metabolic equivalents \[METS\]) and cardiometabolic risk factors (blood pressure, blood lipid profile, BMI, waist circumference, depression and anxiety symptoms, tobacco use, and exercise volume) are assessed.
48680279|NCT00470262|DRUG|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
48680280|NCT00470262|DRUG|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
48153879|NCT00003588|BIOLOGICAL|Ad5CMV-p53 gene|
48364684|NCT03491527|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
48364685|NCT03491527|PROCEDURE|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
48364686|NCT03491527|PROCEDURE|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
48364687|NCT03491527|PROCEDURE|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
48364688|NCT03491527|PROCEDURE|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
48364689|NCT03491527|PROCEDURE|Dental impression|Dental impression whith silicone.
48364690|NCT03491527|PROCEDURE|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
48364691|NCT03491527|PROCEDURE|Occlusal adjustment|Analysis of the occlusion with carbon paper.
48511833|NCT04669561|DRUG|Lifitegrast 5% Ophthalmic Solution|Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
48364692|NCT00692159|DRUG|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
48364693|NCT06188039|DIAGNOSTIC_TEST|Superior vena cava collapsibility index|"After induction of general anaesthesia following interventions will be performed.~1. Insertion of a tranesophageal echocardiography probe~2. Measurement of SVC-CI~3. Measurement of LVOT-VTI prior to fluid bolus~4. Fluid bolus (250ml of crystalloid)~5. Measurement of LVOT-VTI after fluid bolus~Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped."
48364694|NCT06188039|OTHER|PEEP elevation|"A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP.~A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated."
48511834|NCT06359028|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2
48511835|NCT06359028|DRUG|Crest cavity protection toothpaste|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
48153880|NCT00003588|PROCEDURE|laparoscopic surgery|
48153881|NCT06157840|DEVICE|mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity
48153882|NCT06157840|DEVICE|Simplified mHealth application and sleep health education|Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.
48153883|NCT04233411|OTHER|Mycoprotein ingestion|
48153884|NCT00840788|PROCEDURE|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
48364695|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
48364696|NCT03731065|DIETARY_SUPPLEMENT|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
48680281|NCT06045065|OTHER|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
48680282|NCT03259243|DRUG|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
48153885|NCT00840788|PROCEDURE|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
48153886|NCT00171652|DRUG|Diclofenac sodium gel 1%|
48153887|NCT01544309|DRUG|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society \[JAS\] Guidelines \[GL\] after 3 months, had the atorvastatin \[ATV\] dose of 20 mg.)"
48153888|NCT01544309|DRUG|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)"
48153889|NCT06198452|PROCEDURE|Vision Improvement|Laser Vision Improvement for Patients with Age-Related Macular Degeneration
48153890|NCT00004045|DRUG|exatecan mesylate|
48153891|NCT06585059|DRUG|TQB2928 injection + Almonertinib Mesilate Tablets|"TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects.~Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug."
48153892|NCT05850858|DIAGNOSTIC_TEST|ascetic fluid study|ascetic fluid study parameter in diagnosis of spontaneous bacterial peritpnitis
48153893|NCT03404440|OTHER|L.Reuteri|
48153894|NCT05404178|OTHER|Type 2 diabetes group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
48680283|NCT03884153|DEVICE|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
48680284|NCT06090955|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
48680285|NCT06090955|DRUG|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
48680286|NCT06090955|DRUG|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
48153895|NCT04844294|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
48364697|NCT03731065|DIETARY_SUPPLEMENT|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
48364698|NCT04951882|BIOLOGICAL|human derived umbilical cord derived mesenchymal stem cells|intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
48364699|NCT05954273|PROCEDURE|Osseodensification crestal sinsus graft|Osseodensification Mediated Maxillary Sinus Crestal Grafting
48364700|NCT02483715|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
48364701|NCT02483715|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
48364702|NCT03776331|DIAGNOSTIC_TEST|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
48364703|NCT02519127|OTHER|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
48364704|NCT02519127|OTHER|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
48153896|NCT04844294|BEHAVIORAL|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
48153897|NCT02080143|DEVICE|Thermal Adhesion Patch|
48153898|NCT02080143|DEVICE|Thermal Adhesion Patch|
48153899|NCT06577376|DRUG|DP303c|DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
48153900|NCT06577376|DRUG|Simmitinib tablets|A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
48153901|NCT06577376|DRUG|Irinotecan liposomes|A chemotherapy
48153902|NCT06577376|DRUG|Paclitaxel or docetaxel or irinotecan|Paclitaxel or docetaxel or irinotecan is used as a control.
48153903|NCT06430151|DEVICE|CUE1|Sternal worn focused vibrotactile stimulation and cueing device
48153904|NCT02335242|DRUG|Sildenafil 20 mg tablets|
48153905|NCT02335242|OTHER|Placebo tablets (resembling Revatio)|
48153906|NCT04547101|DRUG|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
48364705|NCT04004026|OTHER|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
48364706|NCT03223649|OTHER|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
48364707|NCT03223649|OTHER|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
47994332|NCT04868279|BEHAVIORAL|Web-Based Interactive Nurse Support Program Based on Health Promotion Model|Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
47994333|NCT00725218|DRUG|Saline|Saline 5 ml injection 10 min prior to propofol administration.
48153907|NCT02127892|BIOLOGICAL|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
48153908|NCT02127892|BIOLOGICAL|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
48153909|NCT02127892|BIOLOGICAL|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
48153910|NCT02127892|DEVICE|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
48153911|NCT04232488|PROCEDURE|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
48364708|NCT04076865|DRUG|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
48680287|NCT01145781|PROCEDURE|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
48680288|NCT02015481|DRUG|Cabaletta|
47994334|NCT00725218|DRUG|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
48153912|NCT04232488|PROCEDURE|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
48153913|NCT05088733|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
48153914|NCT05088733|OTHER|Routine medical care|Routine medical care
48153915|NCT00042510|BIOLOGICAL|Treatment group|
48153916|NCT03800745|DRUG|Colace 100Mg Capsule|Prescribed to Arm B
48153917|NCT03800745|DRUG|Miralax|Prescribed to Arm C
48153918|NCT04364035|BIOLOGICAL|ChAdOx1.HTI|ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
48153919|NCT04364035|BIOLOGICAL|MVA.HTI|MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
48153920|NCT04364035|DRUG|GS-9620|GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
48153921|NCT04364035|BIOLOGICAL|Placebo|Saline placebo delivered as one 0. 5 mL IM injection
48153922|NCT04364035|DRUG|Placebo Oral Tablet|Unit-dose placebo tablet delivered as two 3-mg placebo tablets
48153923|NCT03254524|OTHER|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
47994335|NCT03254186|DRUG|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
47994336|NCT03254186|DRUG|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
47994337|NCT05337215|BEHAVIORAL|kangaroo father care|The effect of postpartum kangaroo father care on paternal attachment
47994338|NCT01759108|DRUG|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
47994339|NCT04684381|DRUG|L-glutamine|Pharmacokinetic study
47994340|NCT05114135|DEVICE|Osteo3 ZP Putty|Transforminal Interbody Fusion at one spinal level (L2-S1) with instrumented posteriorlateral fusion on at least the contralateral side to the TLIF approach.
47994341|NCT03323346|DRUG|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
47994342|NCT01751386|DRUG|Baclofen|
47994343|NCT01751386|OTHER|Placebo|
47994344|NCT05169723|BEHAVIORAL|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
47994345|NCT00001437|DRUG|pentoxifylline|
47994346|NCT02940288|OTHER|Auricular Acupuncture|Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
47994347|NCT02940288|OTHER|Sham Acupuncture|Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
47994348|NCT03350360|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
47994349|NCT03350360|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
47994350|NCT04510779|DEVICE|Apple Watch|Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
48153924|NCT01474265|DRUG|Varenicline|0.5-2 mg per day, oral use
47994351|NCT03686410|BEHAVIORAL|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
47994352|NCT03686410|OTHER|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
47994353|NCT02775344|DEVICE|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
47994354|NCT04588987|BIOLOGICAL|PD-1|Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
47994355|NCT00939809|BIOLOGICAL|Urokinase-Derived Peptide A6|Given SC
47994356|NCT00939809|OTHER|Laboratory Biomarker Analysis|Correlative studies
47994357|NCT03263208|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
47994358|NCT03263208|DRUG|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
47994359|NCT03263208|BIOLOGICAL|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
47994360|NCT00426582|DRUG|Patupilone|
47994361|NCT02266420|PROCEDURE|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
48153925|NCT01474265|DRUG|Placebo|1-2 tablets per day, oral use
48153926|NCT01474265|DRUG|Nicorette TX|10-15 mg per day, transdermal use (patches)
48680289|NCT02538536|DRUG|PBI4050|
48153927|NCT05991947|OTHER|No intervention|No intervention measures are needed.
48680290|NCT03700164|OTHER|Temperature|Water-perfused suit.
48153928|NCT01330875|OTHER|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
48680291|NCT01820650|DEVICE|iTotal G2 CR Knee Replacement System|Total Knee replacement
47994362|NCT04901494|DRUG|SSRI|Selective serotonin reuptake inhibitor
48153929|NCT05530434|OTHER|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
48153930|NCT05530434|OTHER|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
48153931|NCT05269004|DRUG|Ocrelizumab|Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
48153932|NCT02889809|DRUG|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
48153933|NCT02889809|DRUG|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
48153934|NCT02889809|DRUG|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)
48153935|NCT02889809|DRUG|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
48680292|NCT05065073|DRUG|Iodixanol|Iso-osmolar Contrast Media
48680293|NCT05065073|DRUG|Iohexol|Low-Osmolar Contrast Media
48680294|NCT05024253|DRUG|Tranexamic acid injection|. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
48680295|NCT05024253|OTHER|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
47994363|NCT04225169|OTHER|Breathing exercises|The patient was taken to a quiet room and asked to lie on the bed. For the first 5 minutes, the researchers explained how the exercise is done with pictures and demonstrated it to the patient. The patient was asked to perform the exercise for 5 minutes under supervision by the researchers. If the patient performed DBE correctly, practice was discontinued. If not, the patient was asked to practice for another 5 minutes. If the patient still could not perform the exercise correctly at the end of this time, they were excluded from the sample. DBE was performed according to the Cleveland Clinic guideline as follows:
48680296|NCT02707965|DRUG|Oxcarbazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
47994364|NCT00139828|DRUG|human coagulation Factor IX|
48364709|NCT05262842|DRUG|JS001+IMP4297|"Phase I: Dose Escalation The primary endpoints are the safety and tolerability of the combination, including the incidence and nature of DLTs and the determination of the MTD and RP2D. A 3 + 3 dose-escalation (60mg,80mg,100mg)design will be used. Patient in each dose level will be treated with toripalimab 240mg in combination with senaparib.~Phase Ib: Dose Expansion This part will commence after the RP2D is determined and will further evaluate the safety and anti-tumor activity of toripalimab and senaparib in patients with specific types of advanced solid tumors. Patients will be enrolled concurrently into 5 exploratory cohorts with approximately 20 patients each cohort."
48680297|NCT02707965|DRUG|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
48680298|NCT02707965|DRUG|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
47994365|NCT05812521|PROCEDURE|Paravertebral block with methylene blue|The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
47994366|NCT05812521|PROCEDURE|Thoracic Epidural Anesthesia|The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
47994367|NCT04147455|BEHAVIORAL|Adapted RealConsent|The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men
47994368|NCT04147455|BEHAVIORAL|Health Education Control Condition|Participants will view six 30-minute web-based serial drama modules designed to promote health.
47994369|NCT00657007|BIOLOGICAL|belimumab|"1. 1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~2. 1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
47994370|NCT00657007|BIOLOGICAL|belimumab|"1. 4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~2. 4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
47994371|NCT00657007|BIOLOGICAL|belimumab|"1. 10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~2. 10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
47994372|NCT00657007|BIOLOGICAL|belimumab|"1. 20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~2. 20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
47994373|NCT00657007|BIOLOGICAL|Placebo|"1. IV (in the vein) on Day 0 (Cohorts 1-4).~2. IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
47994374|NCT04371679|OTHER|No interventions planned|No interventions planned. Observational.
47994375|NCT04176276|OTHER|no interventions required.|The study does not require any interventions.
47994376|NCT00651755|DRUG|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
48680299|NCT02707965|DRUG|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
48680300|NCT02707965|DRUG|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
48680301|NCT02707965|DRUG|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
48153936|NCT02223299|DIETARY_SUPPLEMENT|L-tyrosine|6g/d daily for 30 days
48153937|NCT02223299|DIETARY_SUPPLEMENT|L-Tryptophan|2g/d daily for 30 days
48153938|NCT02223299|DRUG|deplin|15mg daily for 30 days
48153939|NCT02223299|OTHER|Placebo A|a sugar-pill that looks like a real medication
48364710|NCT03797781|OTHER|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
48364711|NCT02457130|DRUG|Ticagrelor|
47994377|NCT00651755|DRUG|Cyclophosphamide|750 mg/m\^2 By Vein On Day 1
48364712|NCT02457130|DRUG|Clopidogrel|
48364713|NCT03049189|DRUG|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
48364714|NCT03049189|DRUG|Everolimus|Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
48364715|NCT03049189|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
48364716|NCT01996956|OTHER|volume expansion|fluid loading of 10 ml/kg colloid or blood product
48153940|NCT02223299|OTHER|Placebo B|a sugar-pill that looks like a real medication
48680302|NCT02707965|DRUG|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
48153941|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
48680303|NCT02707965|DRUG|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
48680304|NCT02474303|DRUG|Truvada|Demonstration Study
47994378|NCT00651755|DRUG|Doxorubicin|25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
47994379|NCT00651755|DRUG|Vincristine|2 mg By Vein On Day 1
47994380|NCT00651755|DRUG|Prednisone|100 mg PO for 5 Days
48153942|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose \[2x10\^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose\] by intradermal (ID) route on Days 0 and 28.
48153943|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
47994381|NCT00651755|DRUG|Rituximab|375 mg/m\^2 By Vein On Day 1.
47994382|NCT00651755|DRUG|Ondansetron|8 mg daily for 2 days
47994383|NCT05350319|RADIATION|A low-dose CT scan of the shoulder|Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
48153944|NCT06138587|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
48153945|NCT06138587|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
48153946|NCT02200016|PROCEDURE|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
48153947|NCT02200016|PROCEDURE|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
48364717|NCT02264327|BEHAVIORAL|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
48153948|NCT02200016|DEVICE|B Braun Contiplex S catheter|
48153949|NCT00049751|DRUG|Adalimumab|
48153950|NCT02450279|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
48364718|NCT02264327|BEHAVIORAL|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
48680305|NCT01162252|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
48680306|NCT01162252|BEHAVIORAL|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
48680307|NCT00860626|DRUG|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
48680308|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
48680309|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
48680310|NCT05822037|BIOLOGICAL|CT0594CP|Cell injection
48680311|NCT03263065|DIETARY_SUPPLEMENT|Bran|220g rice pudding meal with raspberry jam with added bran flakes
48364719|NCT02264327|BEHAVIORAL|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
48364720|NCT06028763|PROCEDURE|Injection of biocomposite hydrogel into ankle's cartilage lesion under arthroscopic control|Surgical treatment involves the use of an injectable biocomposite hydrogel containing autologous mesenchymal stem cells (MSCs), adipose tissue-derived cells, and chondroinductive growth factors (TGF-β1 and BMP-4) under arthroscopic control
48680312|NCT03263065|DIETARY_SUPPLEMENT|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
47994384|NCT04751149|PROCEDURE|Removal of Urinary Catheter|Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
47994385|NCT05174039|DRUG|Miglustat 100Mg Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
47994386|NCT02068222|DRUG|ABT-450/ritonavir (r)|Tablet
47994387|NCT02068222|DRUG|ABT-530|Tablet
47994388|NCT02068222|DRUG|Ribavirin (RBV)|Tablet
48680313|NCT03263065|DIETARY_SUPPLEMENT|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
48680314|NCT04968626|RADIATION|PI-LL|The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
48153951|NCT02450279|DEVICE|Vibrating-mesh nebulizer|
48153952|NCT02450279|DEVICE|Jet Nebulizer|
48153953|NCT02450279|OTHER|Planar scintigraphy|
48153954|NCT02450279|OTHER|Preoperative spirometry|
48153955|NCT01648075|DIETARY_SUPPLEMENT|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
48364721|NCT06028763|PROCEDURE|Microfracture of ankle's cartilage lesion under arthroscopic control|Microfracture involves creating tiny perforations in the damaged cartilage, exposing the underlying bone. This encourages the formation of a healing response, where blood and bone marrow cells fill the holes, forming a repair tissue known as fibrocartilage. This newly formed tissue aims to improve joint function and alleviate symptoms associated with cartilage damage. The procedure is performed under arthroscopic guidance, allowing for precise targeting of the lesion while minimizing trauma to the surrounding tissues.
48364722|NCT02155166|DRUG|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
47994389|NCT01321125|BIOLOGICAL|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
48680315|NCT02476604|BEHAVIORAL|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
48153956|NCT03928821|BIOLOGICAL|PGT121|20 mg/kg administered intravenously
48680316|NCT05745610|DRUG|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
48680317|NCT05745610|DRUG|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
48680318|NCT00463086|DRUG|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
48680319|NCT00463086|DRUG|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
48680320|NCT00459641|DRUG|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
48680321|NCT00459641|OTHER|Standard of Care|Bone marrow aspirate or steroids
48680322|NCT03502915|DRUG|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
48680323|NCT03502915|OTHER|Placebo|100% oxygen via Nitronox delivery device
48680324|NCT05115370|OTHER|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
48680325|NCT01277822|DRUG|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
48680326|NCT01277822|DRUG|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
48680327|NCT01277822|DRUG|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
48153957|NCT03928821|BIOLOGICAL|PGDM1400|20 mg/kg administered intravenously
48153958|NCT03928821|BIOLOGICAL|10-1074|20 mg/kg administered intravenously
48364723|NCT02155166|DRUG|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
48364724|NCT04284579|DEVICE|IV cannula|We measure the time duration needed for IV cannulation
48364725|NCT04762420|OTHER|Dose of sugammadex according to SSD and QSD|At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.
48153959|NCT03928821|BIOLOGICAL|VRC07-523LS|20 mg/kg administered intravenously
48364726|NCT01933542|DRUG|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
48364727|NCT01933542|DRUG|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
48364728|NCT01933542|DRUG|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
48680328|NCT01277822|DRUG|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
48680329|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
48680330|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
48680331|NCT02245321|OTHER|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
48680332|NCT02245321|OTHER|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
48680333|NCT02245321|DIETARY_SUPPLEMENT|Placebo|Receive pills to take daily that contain 0 mg iron.
48680334|NCT01224327|BIOLOGICAL|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
48680335|NCT01224327|DRUG|Conserved therapy|Oral or intravenous administration
48680336|NCT06273566|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the AdT-Physio, Brief Cope and GSES questionnaires in random order.
48680337|NCT06512779|OTHER|Control Group|sleep hygiene education
47994390|NCT01321125|OTHER|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
48153960|NCT01241994|OTHER|AASD dialysis technique|
48153961|NCT00702871|DRUG|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
48153962|NCT00702871|DRUG|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
48153963|NCT04182451|DEVICE|Meso Wound Matrix|"Subjects who meet eligibility criteria will receive standard of care and Meso Wound Matrix.~The standard of care therapy in this study is offloading of the DFU, appropriate sharp or surgical debridement, and aggressive infection management with the use of appropriate dressings. Total contact casting or fixed ankle walker will be used for off-loading. Wound Matrix is an acellular scaffold to reinforce and repair soft tissue defects. Subjects may receive up to eight applications of Meso Wound Matrix. Subjects whose study ulcer does not heal after eight applications will receive only SOC treatment for 4 additional weeks."
47994391|NCT01321125|BIOLOGICAL|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
47994392|NCT04026607|DIETARY_SUPPLEMENT|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
47994393|NCT05934682|PROCEDURE|Surgery|All children submitted to surgery will be followed until hospital discharge or 30 days postoperatively.
47994394|NCT01971450|DRUG|Iloprost (Ventavis, BAYQ6256)|
47994395|NCT02034786|PROCEDURE|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
47994396|NCT02034786|BIOLOGICAL|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
47994397|NCT02034786|PROCEDURE|Transdermal injection|Transdermal injection of hyaluronic acid only.
48680338|NCT06512779|PROCEDURE|Surgical Intervention|Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.
47994398|NCT00206414|DRUG|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
47994399|NCT00206414|DRUG|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
47994400|NCT02617823|PROCEDURE|lateral position|patients placed on their left side after epidural catheter insertion
47994401|NCT05266092|OTHER|Observational study|Observational study
48153964|NCT05542589|OTHER|Phenytoin phonophoresis|Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
48364729|NCT01933542|DRUG|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
47994402|NCT03563417|PROCEDURE|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
47994403|NCT03563417|OTHER|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
47994404|NCT03345589|DRUG|18-22mg/kg/d Ursodeoxycholic|18-22mg/kg/d Ursodeoxycholic
47994405|NCT03345589|DRUG|13-15mg/kg/d Ursodeoxycholic|13-15mg/kg/d Ursodeoxycholic
48364730|NCT04129736|DRUG|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
48364731|NCT05818176|DEVICE|NAVIRFA® Navigation System|radiofrequency ablation by NAVIRFA® Navigation System.
48364732|NCT05818176|DEVICE|ultrasound|radiofrequency ablation by ultrasound
48364733|NCT03537417|PROCEDURE|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
47994406|NCT03515772|DRUG|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
47994407|NCT00087451|DRUG|AP23573|ridaforolimus
48153965|NCT05542589|OTHER|Sham phenytoin phonophoresis|Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
48364734|NCT02389868|DRUG|Lovastatin|
48680339|NCT06512779|OTHER|Oropharyngeal Training (face-to-face)|Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
48680340|NCT06512779|OTHER|Oropharyngeal Training (telerehabilitation)|Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
48680341|NCT06512779|DEVICE|Continuous Positive Airway Pressure|Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
48680342|NCT05034809|DRUG|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
48680343|NCT05750108|DEVICE|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
48680344|NCT05750108|DEVICE|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
48680345|NCT05369598|DEVICE|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
48680346|NCT05369598|DEVICE|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
48680347|NCT05434494|DRUG|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
48680348|NCT05434494|DRUG|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
47994408|NCT00405873|DRUG|AMT2003|
47994409|NCT00363779|DRUG|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
47994410|NCT00363779|GENETIC|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
47994411|NCT00363779|GENETIC|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
47994412|NCT00363779|OTHER|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
47994413|NCT06308120|DEVICE|Ion Endoluminal System|Participants in the test arm will undergo a diagnostic bronchoscopy with ION™ Endoluminal System.
47994414|NCT06308120|DEVICE|superDimension Navigation System and Accessories|Participants in the control arm will undergo a diagnostic bronchoscopy with superDimension Navigation System and Accessories.
47994415|NCT04645407|DRUG|Fuzheng Huayu tablet|Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
47994416|NCT02044133|OTHER|Dosage Vitamine D|
47994417|NCT06104358|DRUG|HU6|HU6 is being evaluated for its effect on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function
47994418|NCT01848756|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
47994419|NCT04059731|DIETARY_SUPPLEMENT|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
47994420|NCT05757947|PROCEDURE|Сoronary bypass surgery according to the I-graft method|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and the formation of an anastomosis of the stump of the right internal mammary artery and end-to-end saphenous vein graft."
48153966|NCT03442309|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
48680349|NCT03313635|DIAGNOSTIC_TEST|Men presenting with low-T|Evaluation of prealbumin levels.
48680350|NCT01946633|DEVICE|magnetic-controlled capsule endoscopy(Navicam)|
48680351|NCT04326218|OTHER|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~* anti-PLA2R1 and anti-THSD7A antibodies~* anti-PLA2R1 and anti-THSD7A epitopes~* HLA typing"
48680352|NCT06092112|DRUG|CD-801|The subjects with advanced HCC will be treated by 100 μg CD-801 through the hepatic artery injection at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks.
48680353|NCT02056028|PROCEDURE|Hepatic resection|
48680354|NCT01899638|DRUG|UMEC/VI 125/25 mcg|Combination in high dose
48680355|NCT01899638|DRUG|UMEC/VI 62.5/25 mcg|Combination in low dose
48680356|NCT01899638|DRUG|UMEC 125 mcg|LAMA mono in high dose
48680357|NCT01899638|DRUG|UMEC 62.5 mcg|LAMA mono in low dose
48680358|NCT01899638|DRUG|VI 25 mcg|LABA mono
48680359|NCT05264415|BEHAVIORAL|Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)|Trauma-informed, family-centered, skill-building preventive intervention for families with preschool-aged children.
48680360|NCT05264415|OTHER|Parenting Education Website|A website providing parenting education resources in four primary domains relevant for families with preschool-aged children (parenting, child development, transitions, and self-care).
48680361|NCT04858438|PROCEDURE|Insufflation during surgery|This is the amount of insufflation using during the surgical procedure.
48680362|NCT06159283|DRUG|Immunoglobulins|Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.
48680363|NCT05329753|DEVICE|Mobile health application|Health intervention through a smartphone application that favors the process of learning
48680364|NCT05877560|DEVICE|Anodal-Transcranial Direct Current Stimulation|Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
48680365|NCT05877560|BEHAVIORAL|Office-Based Vergence/Accommodative Therapy|Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
48680366|NCT05877560|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.
48680367|NCT00400517|BIOLOGICAL|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
48680368|NCT00400517|DRUG|thalidomide|doses up to 400 mg/day
48680369|NCT00400517|PROCEDURE|conventional surgery|SOC care surgery
48680370|NCT00400517|PROCEDURE|neoadjuvant therapy|post radical prostatectomy
48680371|NCT03976505|OTHER|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
48680372|NCT03976505|OTHER|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
48680373|NCT03976505|OTHER|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
48680374|NCT03976505|OTHER|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
48680375|NCT03976505|OTHER|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
48680376|NCT00288548|DRUG|Metoprolol|
48680377|NCT06425510|BEHAVIORAL|Viviendo las Ventajas de la Asistencia Tecnológica|It comprises 2-hours small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected ATDs. The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals, providing information on ATDs, resources, and services, reflection on the advantages and disadvantages of using these ATDs, hands-on practice with selected ATDs, goal setting, and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.
48680378|NCT06425510|OTHER|Attention calls|Ten minutes attention calls, once a week for six weeks to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
48680379|NCT00742170|DEVICE|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
48680380|NCT01534286|DRUG|Theramine|Theramine 2 capsules 3 times per day
48680381|NCT01534286|DRUG|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
48680382|NCT06107543|DRUG|Nebulized Lidocaine|Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
48680383|NCT06107543|DRUG|Iv Lidocaine|Intravenous %2 lidocaine was administered before induction of anesthesia.
48680384|NCT06302803|BEHAVIORAL|Intermittent fasting plus time-restricted eating|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
48153967|NCT03442309|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
48153968|NCT03442309|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
48680385|NCT06302803|BEHAVIORAL|Calorie restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
48680386|NCT01673646|DRUG|Pasireotide LAR|Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
48680387|NCT03115372|OTHER|Educational Intervention|Attend CRC education session
48680388|NCT03115372|OTHER|Educational Intervention|Attend healthy nutrition session
48680389|NCT03115372|OTHER|Informational Intervention|Receive CRC screening brochure
48680390|NCT03115372|OTHER|Survey Administration|Ancillary studies
48680391|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about CRC screening
47994421|NCT05757947|PROCEDURE|Сoronary bypass surgery by the method of free conduit|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and anastomosis of the saphenous vein graft to aorta."
47994422|NCT01060033|DEVICE|MR Spectroscopy|
48680392|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
47994423|NCT01060033|DEVICE|Fat-Saturation and Diffusion-Weighted Imaging|
47994424|NCT01060033|DEVICE|Dynamic Contrast Enhancement MRI (MR-DCE)|
47994425|NCT01060033|DEVICE|Diffusion Tensor Imaging (DTI)|
48364735|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
47994426|NCT04668950|DRUG|Fluvoxamine|Up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days
47994427|NCT04668950|DRUG|Placebo|Will take 2 capsules per day as tolerated for approximately 15 days
48153969|NCT01219751|DRUG|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
48153970|NCT01094600|DRUG|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
48153971|NCT04017598|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
48364736|NCT02207413|BIOLOGICAL|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
48364737|NCT02508012|OTHER|Immuno monitoring|treatment optimization
48364738|NCT01335360|DRUG|Nevirapine|200mg twice daily of nevirapine
48364739|NCT06440876|BEHAVIORAL|Music and Imagery|See music and imagery arm description.
48680393|NCT00643890|GENETIC|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10\^12 vector genomes in 35 uL.
48680394|NCT01079364|DRUG|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
48680395|NCT01079364|DRUG|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
48680396|NCT01079364|DRUG|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
48680397|NCT02781571|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
48680398|NCT02558062|OTHER|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
48680399|NCT06284239|OTHER|Tell me about the game.|It is a game played with playing cards. On the game cards, there will be the word that the narrator student must explain to his group friends and five prohibited words right below this word. Prohibited words are synonyms, antonyms or close meanings of the word to be explained. According to the game rules, the student narrator will explain the word on the cards to his group friends without using prohibited words.
48680400|NCT04379154|DEVICE|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
48680401|NCT00364650|DRUG|Probiotic Supplement|2 capsules twice daily
48680402|NCT00364650|OTHER|Placebo|placebo
48153972|NCT04017598|DIETARY_SUPPLEMENT|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
48680403|NCT05710003|BEHAVIORAL|breathing exercises|"A-breathing exercises: 20 times per hour. While setting down, deep breathing is taken from the nose while mouth is closed, breath holding for at least ten seconds, then slow maximal exhalation for at least 10 seconds.~B-Upper Limb Endurance Exercises (low weight and high repetition) : Study participants will be educated to perform upper limb exercises every 4 hours. Three exercises will be repeated 10×3 times with 1 minute rest in between.~Breathing exercise and upper limb endurance exercises is explained in the reminder in details"
48680404|NCT00921388|OTHER|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
48680405|NCT00921388|BEHAVIORAL|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
48680406|NCT05939752|OTHER|ophthalmological examination|OCT-retinal angiography At inclusion, 3 months and 6 months
48364740|NCT04550234|DRUG|Verinurad prolonged release HPMC capsule|Randomized subjects will receive oral dose of verinurad HPMC capsule.
48153973|NCT04017598|DIETARY_SUPPLEMENT|Placebo of microcrystalline cellulose|placebo
48153974|NCT03423992|BIOLOGICAL|chimeric antigen receptor T cells|chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
48680407|NCT05939752|BIOLOGICAL|blood test|"a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion"
48153975|NCT03438968|BEHAVIORAL|Exercise training|Cardiac Rehabilitation exercise training
48153976|NCT01733199|OTHER|questionnaires|Summons of patients and filling questionnaire.
47994428|NCT05190198|OTHER|Proprioceptive neuromuscular facilitation|"* Weight shifting in each direction (anteriorly, posteriorly, and lateral side) combined with side-to-side head movements (5 times for each direction).~* One-legged stance with slight knee flexion of another leg for 15 seconds (5 times for each leg).~* One-legged stance with increasing knee flexion of the other leg for 15 seconds (5 times for each leg).~* Standing on a balance pad with shifting weight (anteriorly, posteriorly, and lateral side) 10 times in each direction.~* In standing position, moving the weight left and right maximally.~* In standing position, moving the weight forward and backward maximally.~* In standing position, moving both heels of feet up and down.~* In standing position, bending and stretching both knees by squatting as much as possible."
48153977|NCT05307653|PROCEDURE|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
48153978|NCT05307653|PROCEDURE|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
48680408|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
48153979|NCT05307653|PROCEDURE|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
48153980|NCT00310050|DRUG|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
48153981|NCT00310050|DEVICE|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
48364741|NCT04550234|DRUG|Allopurinol Tablet|Randomized subjects will receive oral dose of allopurinol tablet.
48364742|NCT04550234|DRUG|Verinurad/Allopurinol FDC Capsule|Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.
48364743|NCT04550234|DRUG|Verinurad prolonged release gelatin Capsule|Randomized subjects will receive oral dose of Verinurad gelatin capsule.
48364744|NCT01000233|DIETARY_SUPPLEMENT|Phytine (phytate)|300 mg tid \* 24 months
48364745|NCT01000233|DIETARY_SUPPLEMENT|Placebo|Phytine (Phytate)
47994429|NCT05190198|OTHER|conventional therapy|"(Dorsiflexion, planter flexion, eversion and inversion) 10 repetitions for each movement.~(A) Sit to stand (5 times). (B) Standing with shifting Weight anteriorly, posteriorly, and sideway (5 times for each direction). (C) Functional reach sideway and anterior for touching targets set by the therapist (5 times for each direction). (D) Standing on heels for 20 seconds (5 times). (E) Standing on toes for 20 seconds (5 times).~(A) Spot marching (2 min). (B) Walking over the heels, toes, lateral border of feet with the preferred speed (6 min). (C) Tandem walking in a straight line (2 min)."
47994430|NCT01741922|DRUG|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
47994431|NCT01741922|DRUG|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
47994432|NCT01741922|DRUG|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
47994433|NCT01741922|DRUG|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
47994434|NCT05568654|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Eligible patients in hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT testing. A CDSS-based alert will be generated in real time. If the patient is not being admitted to the intensive care unit, the form will append orders for viral pathogen and UAT testing.
47994435|NCT05568654|OTHER|Pharmacist-led de-escalation|A CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for greater than 48 hours and generate a list for the antimicrobial stewardship pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities (temperature, heart rate, oxygen saturation, blood pressure and respiratory rate) b) normal mental status and c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page. The de-escalation recommendations made by the pharmacist will be based on a protocol developed by the research team.
48153982|NCT03587272|DRUG|Alemtuzumab, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on Days -5 to -3) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
48153983|NCT02240810|DEVICE|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
48153984|NCT04783272|DIAGNOSTIC_TEST|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
48153985|NCT05781984|PROCEDURE|Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy
48153986|NCT00396409|DRUG|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
48153987|NCT00396409|DRUG|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
48153988|NCT00396409|DRUG|Placebo|Placebo given during the 2006 core study
48364746|NCT05240573|OTHER|SKI App|"The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information."
48364747|NCT00250601|DRUG|Saredutant succinate (SR48968C)|
48364748|NCT00389909|DRUG|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
48680409|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
48153989|NCT05356065|OTHER|survey administration|Outcome Measures
48680410|NCT02748499|OTHER|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
48680411|NCT02748499|OTHER|Control|Participants maintain their daily acitvities.
48153990|NCT01670942|OTHER|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
48153991|NCT05770206|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
48680412|NCT02360852|DRUG|A4250|A4250 once daily
48680413|NCT01515579|DRUG|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
48680414|NCT01515579|DRUG|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
48680415|NCT01310946|OTHER|Database|Database
48680416|NCT00769795|DRUG|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
48680417|NCT00769795|DRUG|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
48680418|NCT00769795|DRUG|Goserelin|10.8 mg subcutaneous once
48153992|NCT05770206|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
48153993|NCT00470990|DRUG|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
48153994|NCT05341713|BIOLOGICAL|inactive SARS-Cov-2 vaccine|We included epilepsy patients who were vaccinated with inactive SARS-CoV-2 vaccines
48153995|NCT00002878|DRUG|dexamethasone|
48364749|NCT06088511|BEHAVIORAL|e-Health System with nutritional advice|"A 12-week intervention consisting of a 4-weekly group-based, face-to-face supervised sessions, and an 8-week self-management phase will be arranged to the experimental group. The features of the System will be introduced to the users and their family members in the first two face-to-face sessions. The users and their family members will then be able to start using the System with the mobile app. In the other two sessions, all participants in the experimental group will learn how to accurately complete their dietary records in the e-Health System and will be provided with nutritional advice.~For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants are required to fill in their dietary record in the e-Health System every day, and will be provided with nutritional advice to improve high-quality protein and leucine intake, which is essential for muscle building."
48364750|NCT06088511|BEHAVIORAL|The Exercise Training|For the 8-week self-management phase, the participants will be recommended to follow the lifestyle interventions to relieve their problems related to sarcopenia. The participants in the experimental group will also be suggested to continually practise exercise training at home for 30 minutes at least 5 times per week. Participants can review the self-learning exercise videos embedded in the System. The exercise trainings include: a) progressive resistance training to improve muscle strength; and b) brisk walking exercise to maintain walkability.
48364751|NCT00495963|PROCEDURE|bronchoaleolar lavage|
48364752|NCT00495963|PROCEDURE|Bronchoscopy|
48680419|NCT02969915|BEHAVIORAL|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
48680420|NCT02969915|BEHAVIORAL|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
48680421|NCT05484466|DRUG|ZM-H1505R|There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
48680422|NCT05484466|OTHER|ZM-H1505R placebo|There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
47994436|NCT01678963|DRUG|Squalamine lactate|Ophthalmic solution 0.2%
47994437|NCT01678963|DRUG|Vehicle control|Ophthalmic solution vehicle control
47994438|NCT04139954|OTHER|There is no intervention in the study|There is no intervention in the study
48153996|NCT00002878|DRUG|doxorubicin hydrochloride|
48153997|NCT00002878|DRUG|valspodar|
48153998|NCT00002878|DRUG|vincristine sulfate|
48153999|NCT01621087|OTHER|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
48154000|NCT03479502|DRUG|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
48364753|NCT02637869|OTHER|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
48364754|NCT03338608|PROCEDURE|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
48154001|NCT03479502|DRUG|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
48154002|NCT01918852|DRUG|Capecitabine|
48154003|NCT01918852|DRUG|Teysuno|
48154004|NCT01918852|DRUG|Bevacizumab|
48154005|NCT05621096|RADIATION|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
48154006|NCT05621096|BIOLOGICAL|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
48154007|NCT05621096|RADIATION|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
48154008|NCT05536895|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
48154009|NCT05536895|DIAGNOSTIC_TEST|Multi-detector Computed Tomography|Conventional, standard of care perfusion imaging for AIS
48680423|NCT05484466|COMBINATION_PRODUCT|Baraclude|All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
47994439|NCT02595086|PROCEDURE|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
48154010|NCT05655689|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48154011|NCT05655689|DRUG|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48154012|NCT05655689|DRUG|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48154013|NCT05655689|DRUG|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48364755|NCT03338608|PROCEDURE|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
48680424|NCT02962245|DRUG|berberine|
48680425|NCT02962245|DRUG|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
47994440|NCT02595086|PROCEDURE|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
47994441|NCT04693507|DRUG|teverelix TFA 120 mg|Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
47994442|NCT04693507|DRUG|teverelix TFA 180 mg|Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
47994443|NCT04865354|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
47994444|NCT04865354|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
47994445|NCT00988754|BEHAVIORAL|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
47994446|NCT03492099|DRUG|buprenorphine|Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
47994447|NCT03604042|COMBINATION_PRODUCT|Protein fortifier|Protein Fortifier to be added to Fortified human milk according to feeding regimen
47994448|NCT01291056|OTHER|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
47994449|NCT01291056|DRUG|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
47994450|NCT00665977|DRUG|Thermosmart & placebo|a Fisher \& Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
48154014|NCT05655689|DRUG|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48154015|NCT05655689|DRUG|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48364756|NCT03338608|PROCEDURE|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
48364757|NCT06050707|RADIATION|Radiotherapy - Low risk group|20 fractions completed in 4 weeks
48364758|NCT06050707|RADIATION|Radiotherapy - Standard risk group|25 fractions completed in 5 weeks
48364759|NCT06050707|RADIATION|Radiotherapy - Intermediate risk group|30 fractions completed in 6 weeks
48364760|NCT06050707|RADIATION|Radiotherapy - High risk group|35 fractions completed in 7 weeks
48680426|NCT02652910|DRUG|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
48680427|NCT00296218|DRUG|Irbesartan|
48680428|NCT01704508|DRUG|Artemether-lumefantrine|
48680429|NCT01704508|DRUG|Dihydroartemisinin-piperaquine|
48680430|NCT01542463|DRUG|insulin detemir|Prescribed at the discretion of the physician
48680431|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
48680432|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
48154016|NCT05655689|DRUG|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48154017|NCT05655689|DRUG|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
48364761|NCT01979029|PROCEDURE|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
48364762|NCT01979029|PROCEDURE|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
48364763|NCT01201291|OTHER|Normobaric oxygen|Fraction of inspired oxygen
48364764|NCT02809963|DRUG|Eplerenone|50 mg tablets, oral use.
48364765|NCT02809963|DRUG|Placebo|50 mg tablets, oral use
48680433|NCT03487484|BEHAVIORAL|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
47994451|NCT00665977|DRUG|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher \& Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
47994452|NCT00665977|DEVICE|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher \& Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
47994453|NCT04238351|DEVICE|Transnasal humidified rapid insufflation ventilator exchange|applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.
48680434|NCT00737932|DRUG|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
48680435|NCT00737932|OTHER|placebo|Matching placebo for 8 weeks of treatment
47994454|NCT04238351|DEVICE|Conventional face mask|applying oxygen using usual face mask
47994455|NCT02395718|OTHER|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
47994456|NCT02395718|OTHER|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
48154018|NCT00275418|DRUG|beta carotene from Dunaliella algae|
48364766|NCT01320774|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
48680436|NCT04662931|DRUG|crizanlizumab|Crizanlizumab will be taken by IV infusion, at Week 1 Day 1, Week 3 Day 1, and Day 1 of every 4-weeks cycle until Week 51 Day 1
48680437|NCT01822769|OTHER|Cardiopulmonary rehabilitation|See Arm Description
48680438|NCT01822769|OTHER|Standard of care|See Arm Description
48680439|NCT02578446|DEVICE|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
48680440|NCT02578446|DEVICE|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
48680441|NCT03386435|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
48680442|NCT00337831|PROCEDURE|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
48680443|NCT02100930|BIOLOGICAL|Anti-GD2 3F8 Monoclonal Antibody|
48680444|NCT02100930|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
48680445|NCT02100930|DRUG|oral isotretinoin|
48154019|NCT02097420|DEVICE|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
48364767|NCT03535337|BEHAVIORAL|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
48680446|NCT03751371|DEVICE|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
48680447|NCT03751371|OTHER|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
48680448|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
48680449|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
48680450|NCT01145963|OTHER|Control pasta|control pasta
48680451|NCT01145963|OTHER|Experimental pasta B|experimental pasta
48680452|NCT01145963|OTHER|Experimental pasta C|experimental pasta
48680453|NCT04757571|DRUG|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
47994457|NCT05447754|OTHER|Combined RAGT and TBT|Combined RAGT and TBT: Participants will be treated with Lokomat for 40 minutes, twice a week for 5 weeks, and RAGT with a body weight support system and combined TBT for 40 minutes each session 3 times a week. During RAGT, 30-40% of each participant's body weight will be taken with the body weight support system. In patients without drop foot and knee instability in the sessions after the first session, the body weight will be reduced by 10% and progression will be achieved. The speed of the treadmill will be adjusted between 1.2-2.6 km/h and the maximum speed tolerated by the patient will be reached during the sessions. TBT exercises 3 times a week for 40 minutes (weight transfer to the paretic leg during sitting and standing, weight transfer during sitting and standing with or without an assistive device) will be personalized according to the patient. Progression of exercises will be provided by adding upper extremity and trunk activities in addition to exercises.
48680454|NCT04757571|DRUG|Placebo|Placebo tablet plus standard therapy
48680455|NCT02631291|BEHAVIORAL|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
47994458|NCT05447754|OTHER|balance exercises|TBT
47994459|NCT03156478|BEHAVIORAL|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
48154020|NCT01072149|DRUG|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
48364768|NCT03535337|BEHAVIORAL|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
48154021|NCT01072149|DEVICE|placebo|placebo
48154022|NCT03555617|DRUG|TD-1473|oral capsule/tablet, QD
48154023|NCT03555617|DRUG|Itraconazole|oral solution, QD
48154024|NCT00282061|DRUG|Melatonin|
48364769|NCT06151743|DRUG|three cycles (toripalimab + cetuximab + platinum)|Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).
48364770|NCT06151743|PROCEDURE|Radical surgery|The attending physician should select the appropriate surgical treatment and try to perform radical laryngeal preservation surgery for patients with tumor retraction after induction therapy. Patients who cannot preserve laryngeal function due to tumor load need to undergo total laryngeal resection. According to the scope of pharyngectomy, the surgical treatments include partial laryngopharyngectomy, total laryngectomy and partial pharyngectomy, total laryngopharyngectomy, and total pharyngo-laryngo-esophagectomy. Cervical lymph node dissection was performed when necessary.
48680456|NCT02631291|BEHAVIORAL|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
48680457|NCT03909412|DRUG|Carfilzomib|Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
48154025|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
48154026|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
48154027|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
48154028|NCT05990088|DEVICE|Heat Cured Conventional Polymethylmethacrylate Complete Removable Dentures based on neutral zone concept|The patients will receive complete removable dentures designed based on neutral zone concept and manufactured by heat cured conventional technique of polymethylmethacrylate
48680458|NCT03909412|DRUG|Cyclophosphamide|Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
48680459|NCT03909412|DRUG|Dexamethasone|Dexamethasone 40mg IV/PO to be administered as a premedication.
48680460|NCT03909412|DRUG|Granulocyte Colony-Stimulating Factor|On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
48680461|NCT05309967|OTHER|GLUMA DESINSITIZER|GLUTARALDEHYDE
47994460|NCT03156478|BEHAVIORAL|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
48680462|NCT05309967|OTHER|PLACEBO|DESTILLED WATER
48680463|NCT01232439|DRUG|opioid receptor kappa antagonist|"Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg"
48680464|NCT03007420|DRUG|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
47994461|NCT05595889|DRUG|Surufatinib|250 mg/day p.o. QD
47994462|NCT05595889|DRUG|Irinotecan|Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
48154029|NCT05990088|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
48154030|NCT00765791|PROCEDURE|Selective Neck Dissection Excluding Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is not dissected.
48154031|NCT00765791|PROCEDURE|Selective Neck Dissection Including Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is also dissected.
48154032|NCT04395196|DIETARY_SUPPLEMENT|Choline bitartrate|Provided in beverage form
48154033|NCT04395196|DIETARY_SUPPLEMENT|Placebo|Provided in beverage form
48154034|NCT06361056|BEHAVIORAL|Survey|All participants will complete a brief questionnaire.
48680465|NCT03007420|DRUG|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
48680466|NCT06349824|DRUG|injection Dextrose water|dextrose will be injected around median nerve in wrist
48680467|NCT06349824|DEVICE|USG machine|usg guided nerve hydrdissection
48680468|NCT00705874|DRUG|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
48680469|NCT00705874|DRUG|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
48680470|NCT00705874|DRUG|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
48680471|NCT00705874|DRUG|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
47994463|NCT06328153|DEVICE|Fu's Subcutaneous Needling|Operation of the FSN will follow the KOA's Fu's Subcutaneous Needling Treatment Code of Practice24. After routine disinfection, a disposable Fu's subcutaneous needle ( Nanjing-Paifu Medical Technology Co., Ltd., Jiangsu, China ) is inserted parallel into the subcutaneous loose connective tissue of the pathological tight muscles ( gastrocnemius muscle, tibial anterior muscle and quadriceps femoris muscle ). The FSN needle is operated in a swaying movement. The fan angle is approximately 60°; perform a total of 45 round trips in 30 seconds. Swaying is accompanied by reperfusion approach: 20 sweeps with 10 seconds of reperfusion approach as a group, 3 groups for each pathological tight muscle. The reperfusion approach requires active, short and sharp contractions of the pathological tight muscle. The muscle alternates contraction and relaxation. The FSN group is treated 3 times a week for 2 weeks.
48154035|NCT06361056|BEHAVIORAL|mHealth app|Eighty Black women with newly diagnosed breast cancer (inclusive of all stages) and who have access to a mobile device or computer will be recruited to the study intervention.
48154036|NCT03829371|DRUG|Velcade|Subcutaneous use
48680472|NCT00705874|DRUG|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
48680473|NCT00705874|DRUG|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
48680474|NCT00705874|DRUG|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
48680475|NCT02954224|OTHER|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
48680476|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 0.76 g|
48154037|NCT03829371|DRUG|Melphalan|Oral use
48154038|NCT03829371|DRUG|Prednisone|Oral use
48680477|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.15 g|
48680478|NCT02244372|DIETARY_SUPPLEMENT|Placebo|
48680479|NCT02250469|DEVICE|Treatment with the Axium SCS system|
48680480|NCT02250469|DEVICE|Treatment with the Medtronic SCS System|
48680481|NCT03417310|DEVICE|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
48680482|NCT03417310|PROCEDURE|Common reduction methods|Manual reduction methods without the assistance of any devices
48680483|NCT06017882|OTHER|Partial sleep deprivation|
48680484|NCT00506454|DRUG|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
48680485|NCT00506454|DRUG|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
48680486|NCT01810900|DEVICE|Protescal|
48680487|NCT05278845|DRUG|SLC-391|SLC-391 is an AXL inhibitor
48680488|NCT05247450|DEVICE|Functional electrical stimulation therapy (FES-t)|Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).
48680489|NCT05247450|OTHER|Conventional physiotherapy|Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
48680490|NCT00786305|DRUG|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
48680491|NCT00786305|DRUG|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
48680492|NCT05144776|DIAGNOSTIC_TEST|GeneXpert HBV DNA Viral Load Assay|The Xpert venous blood HBV DNA viral load assay will be adapted to operate using fingerstick capillary blood samples.
48680493|NCT05144776|DIAGNOSTIC_TEST|Dried Blood Spot HBV DNA test|HBV DNA viral load will be measured from a fingerstick capillary dried blood spot sample using a gold standard HBV DNA viral load assay
47994464|NCT06328153|DRUG|Celecoxib|Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
47994465|NCT00195247|DRUG|TTI-237|
47994466|NCT02275481|DRUG|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
48154039|NCT03829371|DRUG|Lenalidomide|Oral use
48680494|NCT06487637|BEHAVIORAL|CardioCare Quest|CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
48680495|NCT04373343|BEHAVIORAL|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
48680496|NCT06085235|BEHAVIORAL|exercise|cycling exercise for 15min, with 5min warm up
48154040|NCT03829371|DRUG|Dexamethasone|Oral use
48154041|NCT03829371|DRUG|Daratumumab|Subcutaneous Injection
48154042|NCT02548052|DRUG|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
47994467|NCT02275481|DRUG|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
47994468|NCT01962129|BIOLOGICAL|Sampling of blood|
48154043|NCT02548052|DRUG|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
48154044|NCT02548052|DRUG|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
48680497|NCT06082167|DRUG|Zanzalintinib|Specified doses on specified days
48154045|NCT02548052|DRUG|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
48154046|NCT02548052|DRUG|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
48154047|NCT02548052|DRUG|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
48154048|NCT06068803|DIETARY_SUPPLEMENT|Ketone drink|Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
48154049|NCT06068803|DIETARY_SUPPLEMENT|Placebo|Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
48154050|NCT02516202|DRUG|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
48154051|NCT02516202|DEVICE|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
48154052|NCT02516202|OTHER|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
48680498|NCT06082167|DRUG|Zanzalintinib-matched Placebo|Specified doses on specified days
48680499|NCT06082167|BIOLOGICAL|Pembrolizumab|Specified doses on specified days
48680500|NCT06554249|PROCEDURE|Vulsellum group|"The patients are asked to empty the bladder before IUD insertion. The vulsellum is applied on the cervix, sounding of the uterus is done and the IUD is inserted according to the standard technique of IUD insertion.~Pain intensity is assessed after the procedure using a visual analogue scale."
48680501|NCT06554249|PROCEDURE|Ultrasound group|"During the two hour period before IUD insertion, the patients are asked to drink about one liter of water and to avoid micturition.~Abdominal ultrasound is used to obtain a sagittal view of the uterus and the IUD is introduced into the uterine cavity under ultrasound guidance.~The vulsellum and uterine sound are not used during IUD insertion. Pain intensity is assessed after the procedure using a visual analogue scale.."
47994469|NCT00901758|DRUG|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
47994470|NCT00901758|DRUG|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
47994471|NCT02518867|OTHER|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
48154053|NCT02516202|OTHER|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
47994472|NCT02518867|OTHER|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
47994473|NCT02518867|OTHER|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
48154054|NCT01309802|DRUG|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
48154055|NCT06438549|BEHAVIORAL|HCP-CHW Integration into Prenatal Care for Smoking Cessation|CHWs will be integrated into primary care, and subjects will receive CHW home visits (up to 8) that will provide brief behavioral smoking cessation interventions before, during, and after a quit date. This brief behavioral intervention will include watching a video and reviewing self-help materials.
48680502|NCT02902445|BIOLOGICAL|rotavirus rapid screen test|According to routine care
48680503|NCT02902445|GENETIC|polymorphism exploration|from an oral swab collected after parents consent
47994474|NCT04824170|OTHER|Neural Glide|hot pack and cervical traction is applied for 10-15 min.Group A received Neural mobilization of median nerve which includes gliding and sliding was given,therapist stood on the patient \& affected side besides the patient, patient'S shoulder was depressed with one hand and elbow was moved in 90 degree flexion, forearm supination, extend the wrist and fingers with other hand. Then patient arm was moved into 90 degree abduction and then sliding or gliding of nerve was applied. Sliding was applied with elbow extension and wrist flexion and elbow flexion with wrist extension. 6 sets were performed. Each set was performed for 60 seconds, for alternative days in week for 4 weeks and then progressed to gliding/tensioning technique when symptoms improved
47994475|NCT04824170|OTHER|Rhythmic stabilization technique|"This group was receiving (PNF) Rhythmic stabilization technique with base line treatment.~Subject was lying in spine position on the treatment table and therapist resist an isometric contraction of agonist muscle group.pt maintain this position for 10 sec without trying to move and 12-15 repetitions were performed with 30 sec rest. Each therapeutic session treatment was focused on facilitation of neck stabilizers, improving neck stability, coordination, decreasing pain and improving postural control"
48680504|NCT02775630|PROCEDURE|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
48680505|NCT00984594|OTHER|Primary injury site|Autograft will be placed in the primary defect site.
48680506|NCT00984594|OTHER|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
47994476|NCT03560531|DRUG|ZN-c5|ZN-c5 is a study drug
47994477|NCT03560531|DRUG|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
47994478|NCT03285971|OTHER|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
47994479|NCT00002259|DRUG|Mitoxantrone hydrochloride|
47994480|NCT05133687|DRUG|Bupivacaine Hydrochloride|Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
47994481|NCT04572607|DIETARY_SUPPLEMENT|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
47994482|NCT02180412|BIOLOGICAL|Panhematin|Glucose loading
48680507|NCT03443089|DRUG|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
47994483|NCT02180412|OTHER|Glucose|Glucose is administered to both groups as routine care.
47994484|NCT00385996|DRUG|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
48680508|NCT03443089|DRUG|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
47994485|NCT04455269|DEVICE|AIRFLOW® with PLUS® powder and PIEZON® scaler|Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling
48680509|NCT05922007|OTHER|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
48680510|NCT05922007|OTHER|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
47994486|NCT04455269|DEVICE|PIEZON® scaler and rubber cup with abrasive paste|Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing
47994487|NCT04131634|RADIATION|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
48680511|NCT01611740|PROCEDURE|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships."
48680512|NCT06191692|DRUG|Isoniazid|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
48680513|NCT06191692|DRUG|Rifapentine|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
48680514|NCT06191692|DRUG|Rifampicin|This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
48680515|NCT03763695|OTHER|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
48680516|NCT03763695|OTHER|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
48680517|NCT06524271|DIETARY_SUPPLEMENT|Fermented Soybean|Same as described earlier
48680518|NCT06524271|DIETARY_SUPPLEMENT|Supplement without fermented soybean|Same as described earlier
48680519|NCT00002186|DRUG|Crofelemer|
48680520|NCT00002186|DRUG|Acyclovir|
48680521|NCT05542446|DRUG|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
48680522|NCT01440673|DRUG|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
48680523|NCT03719963|DEVICE|Cochlear implant|Cochlear implant for hearing process by surgical intervention
48680524|NCT06084533|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
48680525|NCT05782985|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
48680526|NCT01170273|DIETARY_SUPPLEMENT|vitamin D|cholecalciferol
48680527|NCT01170273|DIETARY_SUPPLEMENT|placebo|placebo tablet
48680528|NCT05536882|DRUG|Benzoyl peroxide|See arm description
47994488|NCT03369054|BEHAVIORAL|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
47994489|NCT03369054|BEHAVIORAL|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
48680529|NCT05536882|DRUG|Adapalene Gel|See arm description
47994490|NCT00411164|DRUG|OROS hydromorphone HCI (slow release)|
48680530|NCT06305585|OTHER|Primal Reflex Release Technique (PRRT)|Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
48680531|NCT05439343|OTHER|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
48680532|NCT05439343|OTHER|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
48680533|NCT03849664|DRUG|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
47994491|NCT06326294|DEVICE|Thermal ablation|Thermal ablative uses heat (100°C to 120°C) to cause localized tissue damage at the cervical transformation zone and destroy the abnormal epithelium.
48154056|NCT06438549|OTHER|Control Arm|Standard of Care which provides referrals to community-based smoking cessation resources.
48154057|NCT06549270|DRUG|MAbs|Monthly or quarterly mAbs administration
48154058|NCT03398889|DIAGNOSTIC_TEST|Plasma levels of metabolites|plasma levels of metabolites
48154059|NCT03398889|BEHAVIORAL|Dietary questionnaire|Harvard food frequency questionnaire
48154060|NCT03398889|DIAGNOSTIC_TEST|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
48154061|NCT02885714|PROCEDURE|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
48154062|NCT02885714|PROCEDURE|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
48154063|NCT03946345|DRUG|Iohexol Inj 300 MG/ML|"* Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~* Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~* Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations"
48680534|NCT03849664|DRUG|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
48680535|NCT03849664|DRUG|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
48680536|NCT03849664|DRUG|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
48680537|NCT03225391|BEHAVIORAL|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
48680538|NCT03225391|BEHAVIORAL|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
48154064|NCT00988130|OTHER|laboratory biomarker analysis|
48154065|NCT00988130|OTHER|questionnaire administration|
48154066|NCT00988130|PROCEDURE|assessment of therapy complications|
48154067|NCT00988130|PROCEDURE|high-intensity focused ultrasound ablation|
48154068|NCT00988130|PROCEDURE|quality-of-life assessment|
48154069|NCT02762786|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
48154070|NCT00874172|DRUG|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
48680539|NCT04765566|DEVICE|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
48154071|NCT00874172|DRUG|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
47994492|NCT06326294|PROCEDURE|LOOP ELECTROSURGICAL EXCISION PROCEDURE|Cervical tissue excision
47994493|NCT03904758|DIAGNOSTIC_TEST|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
48364771|NCT06151743|RADIATION|Radiotherapy or chemoradiotherapy|"1. Using intensity-modulated radiotherapy (IMRT) technology, the dose of radiotherapy is determined according to whether there are adverse prognostic factors in the postoperative pathology, including positive margins, extracapsular invasion of lymph nodes, primary pT3 or T4, N2 lymph node lesions, peripheral nerve invasion, vascular/lymphatic infiltration.~   Primary site: residual GTV or tumor bed dose 60-70Gy: 1.8-2.12 Gy / fraction. Cervical lymph nodes or lymphatic drainage area: 56-70 Gy: 1.7-2.12 Gy / fraction.~2. Postoperative adjuvant concurrent chemotherapy regimen:~Cisplatin 25mg/m2 i.v. d1-3, d22-24 or Carboplatin AUC 5 i.v. d1, d22 (if cisplatin contraindications)."
48680540|NCT05956847|PROCEDURE|gastroscopy|When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
48680541|NCT05060692|DIAGNOSTIC_TEST|Bloot testing|NFL measruments in serum
47994494|NCT02838056|DRUG|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
47994495|NCT01827657|DRUG|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
47994496|NCT00325754|DEVICE|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
48680542|NCT00039169|DRUG|ortataxel|
48680543|NCT01179308|OTHER|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
47994497|NCT00325754|DEVICE|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
47994498|NCT05070065|DEVICE|Cognitive remedy intervention with virtual reality (CEREBRUM)|Cognitive Remedial method Virtual Reality (CEREBRUM)
47994499|NCT05957783|OTHER|Cerebral palsy Gait analysis technique|Visual gait analysis in cerebral palsy new technique
47994500|NCT06462651|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
47994501|NCT06462651|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
47994502|NCT06264206|DIAGNOSTIC_TEST|Killer-cell immunoglobulin-like receptors (KIRs) testing|patients were tested for KIRs, and based on the divided in the 2 arms. Patient from ARM KIR AA received immunomuodulatorc treatment.
47994503|NCT00862186|BEHAVIORAL|'Fatigue Facts & Fixes'|"'Fatigue Facts \& Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
47994504|NCT02856633|DEVICE|Vitaliti|
47994505|NCT03375021|DRUG|CX717 200 mg|CX717 200 mg capsules BID
47994506|NCT03375021|DRUG|CX717 800 mg|CX717 4 X 200 mg capsules BID
47994507|NCT03375021|DRUG|Placebo|Placebo 200 mg or 800 mg capsules BID
47994508|NCT02196792|DEVICE|E-Poly liner|E-Poly liner with a titanium cup
47994509|NCT02196792|DEVICE|ArComXL liner|ArComXL liner with a titanium cup
47994510|NCT02196792|DEVICE|32 mm femoral head|Stem with a 32 mm CoCr femoral head
47994511|NCT02196792|DEVICE|36 mm femoral head|Stem with a 36 mm CoCr femoral head
47994512|NCT01421758|BEHAVIORAL|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
47994513|NCT01421758|BEHAVIORAL|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
47994514|NCT06514963|DRUG|HRS-9813|Specified dose on specified days
47994515|NCT06514963|DRUG|Placebo|Specified dose on specified days
48680544|NCT01179308|OTHER|Balanced general anesthesia and postoperative opioids|General anesthesia alone
48680545|NCT00870480|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
48680546|NCT00870480|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
48680547|NCT01853462|OTHER|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
48680548|NCT01853462|OTHER|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
48680549|NCT02248766|DEVICE|somofilcon A|somofilcon A lens
48680550|NCT04456478|PROCEDURE|pH at 7.38 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
48364772|NCT05233956|DEVICE|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
48680551|NCT04456478|PROCEDURE|pH at 7.22 ± 0.02|In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
48680552|NCT05572736|DEVICE|Conduction system pacing|Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).
47994516|NCT05818579|OTHER|Virtual reality experience|The VR experience is launched on the participants using all-in-one VR head-mount devices. Tablet computers are used to optimize the settings by the intervention facilitators. Each session lasts for approximately one hour with 10 minutes spent on the briefing, 20 minutes spent on the VR experience, and 30 minutes spent on the post-VR group discussion. There are two sessions per week. The whole course lasts for six weeks and there are a total of 12 sessions.
47994517|NCT01914406|OTHER|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
47994518|NCT01914406|OTHER|continuous moderate training|Continued exercise 45 min.
47994519|NCT04390477|DIETARY_SUPPLEMENT|Probiotic|Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
47994520|NCT01969812|DEVICE|Evie Slow-release Insemination Device|
47994521|NCT01969812|OTHER|Traditional Intrauterine Insemination|
47994522|NCT00006181|BEHAVIORAL|Team-based intervention|
47994523|NCT00006181|BEHAVIORAL|One-on-one intervention|
47994524|NCT01023646|OTHER|Carbohydrate + Protein|Light Tuna Packed in water.
48364773|NCT05233956|DRUG|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
47994525|NCT01023646|OTHER|Carbohydrate + Fat|Butter
47994526|NCT01023646|OTHER|Fiber|Unrefined Carbohydrate
48364774|NCT03188991|DRUG|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
48680553|NCT05572736|DEVICE|Biventricular pacing|Pacing from the coronary sinus and right ventricular leads.
48680554|NCT02691416|DRUG|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
48680555|NCT02691416|DRUG|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
48680556|NCT04833335|OTHER|MRI perfusion sequence|Quantitative analysis
47994527|NCT01023646|OTHER|Carbohydrate load|Carbohydrate
48680557|NCT03190798|DRUG|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
48680558|NCT03190798|DRUG|Placebo|Placebo for Canagliflozin
48680559|NCT05208008|OTHER|With service dog|No intervention
48680560|NCT01986894|DRUG|Placebo|Single oral dose of Placebo
48680561|NCT01986894|DRUG|Pomalidomide|Single oral dose of 4 mg pomalidomide
48680562|NCT01986894|DRUG|Pomalidomide|Single oral dose of 20 mg pomalidomide
48680563|NCT01986894|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
48680564|NCT00358059|BEHAVIORAL|Behavioral Family Systems Therapy for Diabetes|
48680565|NCT00327925|PROCEDURE|Find Cancer Associated Antibodies|
48680566|NCT03724279|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
48680567|NCT03015155|PROCEDURE|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
48680568|NCT05863390|BEHAVIORAL|McKenzie exercise|routine simple McKenzie exercise
48680569|NCT05863390|DIAGNOSTIC_TEST|Trochanteric belt|Trochanteric belt with conventional physical therapy
48680570|NCT02054039|DEVICE|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
48680571|NCT02054039|DEVICE|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
48680572|NCT00286091|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
48680573|NCT00286091|BIOLOGICAL|Placebo|Same volume subcutaneous injection
48680574|NCT00356070|DRUG|Strattera|
48680575|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
47994528|NCT01166477|DRUG|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
48364775|NCT04065412|PROCEDURE|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
48364776|NCT04065412|PROCEDURE|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
48680576|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
48680577|NCT03150147|OTHER|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
48680578|NCT03150147|OTHER|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
48680579|NCT03436901|DIAGNOSTIC_TEST|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
48680580|NCT04973995|BEHAVIORAL|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
48680581|NCT05165732|BIOLOGICAL|Experimental vaccine 1|Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
48680582|NCT05165732|BIOLOGICAL|Experimental vaccine 2|Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
48680583|NCT05165732|BIOLOGICAL|Experimental vaccine 3|Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
48364777|NCT06076863|OTHER|Pharmacist Care|Management of Paxlovid e-visits per regional protocol
48364778|NCT06076863|OTHER|AFM Pool Care|Management of Paxlovid e-visits per regional and local protocols
48364779|NCT02701933|DRUG|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
48680584|NCT02655276|OTHER|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
48680585|NCT02655276|OTHER|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
48680586|NCT03699566|OTHER|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
48364780|NCT02701933|DRUG|Saline|Saline, intravenous infusion
48364781|NCT00470223|DRUG|cisplatin|
48364782|NCT00470223|DRUG|doxorubicin hydrochloride|
47994529|NCT01166477|DRUG|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
47994530|NCT03646682|PROCEDURE|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
47994531|NCT01702701|DRUG|Montelukast|montelukast 10mg po pill q day for 12 weeks
48364783|NCT00470223|DRUG|etoposide|
48364784|NCT00470223|DRUG|ifosfamide|
48364785|NCT00470223|DRUG|methotrexate|
48364786|NCT00470223|DRUG|zoledronic acid|
48364787|NCT00470223|PROCEDURE|conventional surgery|
48364788|NCT04354870|DRUG|Hydroxychloroquine (HCQ)|Loading dose: 600 mg, oral, 1 day Maintenance dose: 200 mg, oral, daily, for 90 days
48680587|NCT03699566|OTHER|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
48680588|NCT03699566|OTHER|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
48680589|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum precipitated autoclaved L. major
48680590|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
48680591|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG
48680592|NCT04298294|OTHER|injectable platelet rich fibrin|biologic activator
48680593|NCT02235792|DEVICE|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
48680594|NCT04011592|DRUG|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
48680595|NCT04011592|DRUG|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
48364789|NCT02624713|BEHAVIORAL|obesity treatment|"1. Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~2. Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~3. Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
48364790|NCT01207427|DRUG|Placebo|
48680596|NCT00382317|DRUG|Iobitridol|
48680597|NCT02895516|DEVICE|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
48680598|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
48680599|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
48680600|NCT03950258|PROCEDURE|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
48364791|NCT01207427|DRUG|ADL5945 0.1 mg|
48364792|NCT01207427|DRUG|ADL5945 0.25 mg|
48680601|NCT02075086|DRUG|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
48680602|NCT04744948|DEVICE|Treadmill exercise|high intensity interval training
48364793|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab|Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
48680603|NCT04744948|OTHER|low caloric diet|low caloric diet (1200ca/lday)
48680604|NCT01720303|DRUG|repaglinide|2 mg (tablets) before each main meal
48680605|NCT01720303|DRUG|isophane human insulin|Injection s.c. (under the skin) at bedtime
48680606|NCT01720303|DRUG|insulin|Injection s.c. (under the skin) twice daily
48680607|NCT04144738|DIAGNOSTIC_TEST|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
48680608|NCT04144738|DIAGNOSTIC_TEST|FIT test|Stool samples will be collected by the subject for the FIT test.
48680609|NCT04144738|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
48680610|NCT02798744|DRUG|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
48680611|NCT02798744|BEHAVIORAL|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
48680612|NCT02798744|DRUG|Placebo|Placebo once daily for the duration of the study (24 weeks)
48680613|NCT00355355|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
48680614|NCT00355355|DEVICE|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
48680615|NCT00355355|PROCEDURE|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
48154072|NCT02765347|DRUG|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
48154073|NCT02765347|DRUG|Insulin|For arm 2, just accept insulin for 24 weeks
48680616|NCT00355355|PROCEDURE|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
48680617|NCT02059629|DEVICE|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
48154074|NCT02990845|DRUG|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
48680618|NCT02059629|DEVICE|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
48680619|NCT03182283|BEHAVIORAL|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
47994532|NCT01702701|DRUG|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
48154075|NCT02959866|OTHER|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
48154076|NCT06455527|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
48154077|NCT06455527|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).
48680620|NCT05882760|DRUG|Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Etch \& Rinse Tetric - N - Bond (Ivoclar)
48680621|NCT05882760|DRUG|Self Etch Tetric N Bond Universal®|Cavities will be restored with Conventional Hybrid Composite Restoration bonded with Self Etch Tetric N Bond Universal®
48154078|NCT04873544|PROCEDURE|ERAS protocols for TKA|ERAS protocols for TKA
48154079|NCT03736265|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
47994533|NCT04354207|DIAGNOSTIC_TEST|Peripheral vein punction|Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood
48154080|NCT03481725|DEVICE|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
48364794|NCT06169410|DRUG|nab-paclitaxel, lobaplatin, and S-1|Patients will be given lobaplatin (30 mg/m2) and nab-paclitaxel (100mg/m2) by intravenous drip on the first day of each cycle, 3 weeks a cycle, together with oral S-1 (patients with a body surface area less than 1.25 m2, will give 40 mg each time. Patients with a body surface area between 1.25 and 1.5 m2; will give 50 mg each time; patients with a body surface area greater than 1.5 m2, will give 60 mg each time), 2 weeks on and 1 week off.
48364795|NCT01129219|OTHER|Strength training|Strength training for 24 weeks
48680622|NCT05882760|DRUG|GC Fuji IX, GC, Japan®|Cavities will be restored with GC Fuji IX, GC, Japan®
48680623|NCT05882760|DRUG|Activa TM Bioactive Restorative ®|Cavities will be restored with Activa TM Bioactive Restorative ®
48680624|NCT04428255|DRUG|HBM9161 Dose A|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
48680625|NCT04428255|DRUG|HBM9161 Dose B|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
47994534|NCT04354207|DIAGNOSTIC_TEST|Stool collection|Gut microbiome will be investigated in stool samples.
47994535|NCT00265343|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
48680626|NCT04428255|DRUG|Placebo|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
47994536|NCT00265343|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
47994537|NCT05375552|DEVICE|Transcranial direct current stimulation|Participants will experience two repeated 20 minute sessions of tDCS (1.2 mA), with a 10-minute break.
48680627|NCT04364815|DRUG|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
48680628|NCT04364815|DRUG|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
48680629|NCT03464513|DEVICE|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
48680630|NCT03464526|DRUG|Orvepitant|Tablet, once daily, oral
48680631|NCT03464526|DRUG|Placebo|Tablet, once daily, oral
48680632|NCT01722994|DEVICE|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
48680633|NCT01722994|DEVICE|Chromic Gut Sterile absorbable Suture (Ethicon)|
48680634|NCT00004891|DRUG|chemotherapy|
48680635|NCT00004891|PROCEDURE|computed tomography|
48680636|NCT00004891|PROCEDURE|conventional surgery|
48680637|NCT00004891|PROCEDURE|neoadjuvant therapy|
47994538|NCT03412084|BEHAVIORAL|Stand up and move more|4 week behavioral intervention involving the development and implementation of action plans
48680638|NCT00004891|PROCEDURE|positron emission tomography|
47994539|NCT01113762|DEVICE|articular surface replacement ASR, DePuy|posterolateral incision
47994540|NCT01113762|DEVICE|ReCap/Magnum modular head, Biomet|posterolateral incision
47994541|NCT01113762|DEVICE|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
47994542|NCT01113762|DEVICE|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
47994543|NCT00003901|OTHER|immunohistochemistry staining method|
47994544|NCT00003901|PROCEDURE|biopsy|
48680639|NCT00004891|PROCEDURE|radionuclide imaging|
48680640|NCT00004891|RADIATION|fludeoxyglucose F 18|
48680641|NCT00004891|RADIATION|radiation therapy|
48680642|NCT05934383|DEVICE|Paradise® ultrasound renal denervation system.|Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
47994545|NCT00003901|PROCEDURE|surgery|
48680643|NCT03571360|OTHER|PD-L1 positive vs PD-L1 negative NSCLC patients|Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
48680644|NCT06425653|OTHER|Exercise Program|"In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"
48154081|NCT03481725|DEVICE|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
48154082|NCT04585048|BEHAVIORAL|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
48680645|NCT04780529|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
48680646|NCT03230318|DRUG|derazantinib|Derazantinib was administered orally at 300 mg once daily
48680647|NCT01324960|DRUG|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
48680648|NCT01324960|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
48680649|NCT00038090|DRUG|Thalidomide|100 mg capsules by mouth daily each evening
48680650|NCT00038090|DRUG|Dexamethasone|20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
48680651|NCT05778994|DEVICE|INTORUS|Exercise protocol with intorus
48680652|NCT00922246|DEVICE|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
48680653|NCT04422691|DIAGNOSTIC_TEST|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
47994546|NCT04409743|BEHAVIORAL|Remote Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
48680654|NCT05140135|BEHAVIORAL|Recovery Oriented Cognitive Therapy (CT-R)|The CT-R that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. In CT-R, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.
48680655|NCT05140135|OTHER|Treatment as Usual|All patients enrolled in the study who are randomized to the continued care as usual condition will continue to receive the treatments from their physician/treatment team at the Community Mental Health Center; however, they will not receive the adjunctive CT-R treatment.
48680656|NCT04963075|DEVICE|multisensory rehabilitation paradigm|"In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed."
48680657|NCT01393899|DRUG|Placebo|oral tablets twice daily
48680658|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
48680659|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
48680660|NCT02479204|DRUG|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
48680661|NCT02479204|DRUG|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
48680662|NCT02479204|DRUG|Placebo|ACT-33441-matching placebo
48680663|NCT02479204|DRUG|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
48364796|NCT00899626|GENETIC|protein analysis|
48364797|NCT00899626|GENETIC|proteomic profiling|
47994547|NCT03951194|BIOLOGICAL|Autologous Platelet Rich Plasma (PRP) intra ovarian infusion|Autologous PRP intra ovarian infusion
48680664|NCT02479204|DRUG|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
48680665|NCT04132414|DIAGNOSTIC_TEST|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
48680666|NCT02228044|BEHAVIORAL|Prevention program|
48680667|NCT05216939|OTHER|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
47994548|NCT03951194|OTHER|Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion|Autologous PFP intra ovarian infusion
47994549|NCT01972737|BIOLOGICAL|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
47994550|NCT02701647|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
48364798|NCT00899626|OTHER|biologic sample preservation procedure|
48364799|NCT00899626|OTHER|laboratory biomarker analysis|
48364800|NCT00899626|OTHER|medical chart review|
48364801|NCT00899626|PROCEDURE|diagnostic colonoscopy|
48364802|NCT00899626|PROCEDURE|diagnostic endoscopic procedure|
48364803|NCT00899626|PROCEDURE|diagnostic endoscopic surgery|
48364804|NCT00899626|PROCEDURE|diagnostic surgical procedure|
48364805|NCT00899626|PROCEDURE|endoscopic surgery|
48364806|NCT00899626|PROCEDURE|screening colonoscopy|
48364807|NCT00013689|DRUG|Fansidar (pyrimethamine and sulfadoxine)|
48364808|NCT01403415|DRUG|Dexamethasone|Given PO or IV
48364809|NCT01403415|OTHER|Laboratory Biomarker Analysis|Correlative studies
48364810|NCT01403415|DRUG|Methotrexate|Given IT
48680668|NCT05216939|OTHER|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
48364811|NCT01403415|DRUG|Mitoxantrone Hydrochloride|Given IV
48364812|NCT01403415|DRUG|Pegaspargase|Given IV
47994551|NCT02701647|OTHER|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
47994552|NCT02618434|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
48154083|NCT03839355|DRUG|Apixaban|Dosage either 5mg or 2.5mg for 2 years
48154084|NCT03839355|DRUG|Warfarin|Dosage assessed by your treating physician for 2 years
48364813|NCT01403415|OTHER|Pharmacological Study|Correlative studies
48364814|NCT01403415|DRUG|Temsirolimus|Given IV
48364815|NCT01403415|DRUG|Vincristine Sulfate|Given IV
48364816|NCT04309175|DEVICE|base rate programming of a permanent cardiac pacemaker|Base rate of a subject's pacemaker is set to a slower, and after wash-out, to a faster pacing rate (Slow-Fast Arm) or to a faster, and after wash-out, to a slower pacing rate (Fast-Slow Arm)
48364817|NCT00417495|BEHAVIORAL|Sentinel Lymph Node Technique|
48364818|NCT04882579|DIAGNOSTIC_TEST|Point-of-care-ultrasound examination|"The intervention consists of three ultrasound modalities:~1. Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology.~2. Deep venous ultrasound assessing presence of a deep venous thrombus~3. Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome."
48364819|NCT00513331|PROCEDURE|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
48364820|NCT00513331|PROCEDURE|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
48680669|NCT05216939|OTHER|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
48680670|NCT05216939|OTHER|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
48680671|NCT05716867|BIOLOGICAL|Measurement of salivary cystatin S protein levels in saliva|The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
48680672|NCT03130725|PROCEDURE|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
48680673|NCT03130725|PROCEDURE|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
48680674|NCT00142337|DRUG|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
48154085|NCT01497678|DEVICE|Extracellular Matrix|Extracellular Matrix
48364821|NCT00513331|PROCEDURE|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
48364822|NCT02275052|DRUG|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
48364823|NCT02275052|DRUG|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
48364824|NCT02275052|DRUG|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
48364825|NCT06035666|OTHER|Your World|Your World consists of a vitality session and use of the Your World app
48364826|NCT06035666|OTHER|Control app|Control app, no effect on stress/vitality
48364827|NCT04918524|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
48364828|NCT04918524|DRUG|Hydroxychloroquine|100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
47994553|NCT02618434|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
47994554|NCT02618434|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
47994555|NCT02369341|BIOLOGICAL|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
47994556|NCT05584865|OTHER|Digital occluar prosthesis|Each patient will receive the full digital fabricated ocular prosthesis. DICOM data from the Computerized Tomography (CT) will be imported into Materializes Interactive Medical Image Control System (MIMICS) software++++ tool for visualizing and segmenting medical images (such as CT and MRI)
47994557|NCT05584865|OTHER|Conventional occluar prosthesis|An accurate impression of the patient's eye socket will be obtained to prepare a suitable wax mod. The wax model will be flasked and processed into heat cured acrylic resin of the same colour of the sclera of the other healthy eye of the patient
47994558|NCT04708938|OTHER|High voltage electrical stimulation+exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
47994559|NCT04708938|OTHER|Exercise therapy|The effect of high voltage electrical stimulation on temporomandibular disorders
48680675|NCT00142337|DRUG|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight \>60 kg) once daily, starting at the onset of labor and for one month postpartum
48680676|NCT05844163|OTHER|observation|observation
47994560|NCT01644175|DRUG|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
47994561|NCT01644175|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
47994562|NCT01644175|DRUG|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
47994563|NCT01352988|DRUG|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
47994564|NCT05828199|DRUG|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
47994565|NCT05828199|DRUG|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
47994566|NCT03175328|PROCEDURE|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
48364829|NCT04918524|DRUG|Aspirin|100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.
47994567|NCT06238232|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
48364830|NCT04918524|DRUG|low molecular weight heparin Enoxaparin|40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
48680677|NCT03780751|BEHAVIORAL|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
47994568|NCT02820896|DRUG|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
47994569|NCT02820896|DRUG|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
47994570|NCT03747965|BIOLOGICAL|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
48680678|NCT03780751|BEHAVIORAL|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
47994571|NCT05773547|DEVICE|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
47994572|NCT02809690|DEVICE|CAT|Undergo 18F-FMAU PET/CT
47994573|NCT02809690|DRUG|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
47994574|NCT02809690|OTHER|Laboratory Biomarker Analysis|Correlative studies
47994575|NCT02809690|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
48364831|NCT03861442|DEVICE|Audio processor SONNET|AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
48364832|NCT03861442|DEVICE|SONNET 2: Configuration 1|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild
47994576|NCT02809690|DEVICE|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
47994577|NCT02809690|DEVICE|Ultrasound|Undergo TRUS-guided biopsy
47994578|NCT03962153|DIAGNOSTIC_TEST|Obstetric Ultrasonography|Obstetric Ultrasonography
47994579|NCT04430777|DRUG|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
47994580|NCT01277523|DRUG|tiotropium high dose|2 actuations once daily
48680679|NCT03749824|DIETARY_SUPPLEMENT|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
47994581|NCT01277523|DRUG|placebo|2 actuations once daily
47994582|NCT01277523|DRUG|tiotropium low dose|2 actuations once daily
47994583|NCT06063577|DEVICE|Stratafix suture|Stratafix symmetric suture
47994584|NCT06063577|DEVICE|Standard of care suture|Standard of care suture
47994585|NCT03849404|BIOLOGICAL|Adalimumab|Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
47994586|NCT05934877|BEHAVIORAL|PrEP navigation + text messaging|Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support services, according to their unique barriers, with the ultimate goal of PrEP initiation, adherence, and persistence; services may include mental healthcare, counseling for intimate partner violence, food insecurity, housing instability, hormone therapy. Text-messaging support includes once weekly text message.
47994587|NCT05934877|BEHAVIORAL|Standard of Care|The SOC arm provides PrEP education, information, and referrals. Those randomized to the SOC arm receive an approximate 20-30-minute educational session on PrEP, and will be given a PrEP pamphlet and list of clinics that provide PrEP in LAC.
48154086|NCT04015050|OTHER|milk based infant formula|Cows milk ased infant formula
48154087|NCT05809635|OTHER|Natural History Study|Longitudinal assessment of participants with BEST1 Vitelliform Macular Dystrophy
48154088|NCT00039052|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
48364833|NCT03861442|DEVICE|SONNET 2: Configuration 2|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong
47994588|NCT05934877|BEHAVIORAL|Contingency Management|Non-responders in the ASK-PrEP arm will be stepped and re-randomized (1:1) to Contingency Management (CM), either in concert with ASK-PrEP or alone. CM is a progressive contingency schedule. Participants submit a thrice weekly urine sample. Participants will receive a voucher-based escalating reinforcement schedule. Successive urine samples that are nonreactive for the metabolites of their identified SUD will escalate their voucher point value. Each three consecutive nonreactive urine samples will receive bonus voucher points. A reactive urine sample will place the participant at the initial voucher point value; however, a rapid reset procedure allows participants to return to their place in the escalating schedule following three consecutive nonreactive urine samples. Voucher points can be redeemed at any time during the study for goods or services that promote a pro-social and healthy lifestyle.
47994589|NCT04694677|DRUG|women receiving tranexamic acid|women receiving tranexamic acid during myomectomy
48680680|NCT03749824|DIETARY_SUPPLEMENT|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
47994590|NCT04694677|DRUG|women receiving misoprostol|women receiving misoprostol in myomectomy
47994591|NCT01066988|OTHER|ORB Ocular Emulsion|lubricant eye drop
47994592|NCT01066988|OTHER|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
47994593|NCT03041246|PROCEDURE|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
47994594|NCT01886807|DEVICE|TrueView PCD Video Laryngoscope|
47994595|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of right HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
47994596|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of left HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
47994597|NCT03403465|OTHER|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
47994598|NCT00245674|DRUG|amisulpride|
47994599|NCT03274986|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL.
47994600|NCT03274986|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
47994601|NCT03274986|PROCEDURE|Cataract surgery|IOL bilateral implantation
48364834|NCT03861442|DEVICE|SONNET 2: Configuration 3|AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)
48364835|NCT03861442|DEVICE|SONNET 2: Configuration 4|AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
47994602|NCT03010111|OTHER|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
47994603|NCT02589782|DRUG|Bedaquiline|
47994604|NCT02589782|DRUG|Pretomanid|
47994605|NCT02589782|DRUG|Moxifloxacin|
48364836|NCT03861442|DEVICE|SONNET 2: OPUS 2 configuration|AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
47994606|NCT02589782|DRUG|Linezolid|
47994607|NCT02589782|DRUG|Clofazimine|
47994608|NCT02589782|DRUG|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
48364837|NCT03861442|DEVICE|SONNET 2: SONNET configuration|AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
48364838|NCT01960036|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|
48364839|NCT01960036|BEHAVIORAL|Womens Health Education|
48680681|NCT03632707|RADIATION|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
48680682|NCT03632707|PROCEDURE|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
48680683|NCT06181838|PROCEDURE|Lesion extraction|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
48680684|NCT06181838|DRUG|Tretinoin|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
48680685|NCT02664480|OTHER|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
48680686|NCT04342676|DEVICE|k ras|K ras
48680687|NCT04342676|DRUG|Panitumumab|vectibex in stage iv
48680688|NCT05321017|BEHAVIORAL|MEP Operant Up-conditioning of the Wrist Extensor|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the wrist extensor (extensor carpi radialis), the muscle the bends the wrist back.
48680689|NCT02242058|OTHER|Quantitative sensory testing|
48680690|NCT02824393|BIOLOGICAL|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
47994609|NCT02816840|RADIATION|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
47994610|NCT02816840|RADIATION|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
48680691|NCT05671523|PROCEDURE|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
48680692|NCT05671523|OTHER|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
48680693|NCT04062188|OTHER|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
48680694|NCT00808522|DRUG|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
48680695|NCT02085421|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
48680696|NCT02232971|DRUG|Glucagon|Glucagon is given in three different doses according to three research days.
48680697|NCT02232971|OTHER|Isotonic saline solution|Placebo
48680698|NCT01214473|DIETARY_SUPPLEMENT|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
48680699|NCT01214473|DIETARY_SUPPLEMENT|Maltodextrin|Only maltodextrin as placebo
48680700|NCT02634242|OTHER|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
48680701|NCT02634242|OTHER|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
48680702|NCT06149923|GENETIC|quantitative Real-time PCR|: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
48680703|NCT05531552|DRUG|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
48680704|NCT05985837|DEVICE|KalobaGOLA spray (1)|Oral spray, 2-4 spray, till 8 times per day
48680705|NCT05985837|DEVICE|KalobaGOLA spray (2)|Oral spray, 2-4 spray, till 4 times per day
48680706|NCT05985837|DEVICE|KalobaGOLA tablets|1 tablets, 6 times per day
47994611|NCT00001893|DRUG|TNFR:Fc|
47994612|NCT04475133|OTHER|Ultrasound guided percutaneous neuromodulation|It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
47994613|NCT04910009|OTHER|Four sessions of practical privacy education|Two sessions of theoretical, four sessions of practical privacy education
47994614|NCT03745144|DRUG|Cladribine|Participants received cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
48364840|NCT01070381|DEVICE|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
48680707|NCT04106128|DIAGNOSTIC_TEST|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
48680708|NCT02325570|DEVICE|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
48680709|NCT02325570|PROCEDURE|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
48680710|NCT02970591|OTHER|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
48680711|NCT02970591|OTHER|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
48680712|NCT02970591|OTHER|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
47994615|NCT03745144|DRUG|Placebo|Participants received placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
47994616|NCT03745144|DRUG|Microgynon®|Participants received Microgynon® tablet once daily for 21 days in treatment period 1 and 2. Participants received Microgynon® for 21 days, starting on the first day of the menstrual cycle in Run-in period.
48680713|NCT04906031|DRUG|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
48680714|NCT05597540|DRUG|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
48680715|NCT05597540|DRUG|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
48680716|NCT00126152|BEHAVIORAL|Exercise, education and medical management|
48680717|NCT00912626|BEHAVIORAL|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
48680718|NCT00699413|DRUG|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
48680719|NCT00699413|DRUG|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
48680720|NCT00003935|DRUG|etoposide|
48680721|NCT00003935|DRUG|vincristine sulfate|
48680722|NCT00003935|RADIATION|radiation therapy|
48680723|NCT05402007|OTHER|Pulmonary rehabilitation exercises at the Rehabilitation Center|Face-to-face intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will prescribe pulmonary rehabilitation exercises that will be performed at the pulmonary rehabilitation center.
48680724|NCT05402007|OTHER|Home Intervention|Home Intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will provide a portfolio of self-explanatory exercises, and guide participants on safety precautions.
48680725|NCT05945498|BIOLOGICAL|TB/Flu-05E vaccine|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis
48680726|NCT05945498|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of placebo buffer solution
47994617|NCT02890979|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
47994618|NCT02890979|OTHER|Laboratory Biomarker Analysis|Correlative studies
47994619|NCT02890979|OTHER|Quality-of-Life Assessment|Ancillary studies
48364841|NCT01070381|DEVICE|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
48680727|NCT01154335|DRUG|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
47994620|NCT02890979|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
47994621|NCT06310330|DIAGNOSTIC_TEST|Comprehensive echocardiographic follow-up|Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients
47994622|NCT06310330|DIAGNOSTIC_TEST|Simplified echocardiographic follow-up|Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
47994623|NCT02540460|DRUG|LCB01-0371 800mg|LCB01-0371 800mg
47994624|NCT02540460|DRUG|LCB01-0371 800mg BID|LCB01-0371 800mg BID
47994625|NCT02540460|DRUG|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
47994626|NCT02540460|DRUG|Placebo|Placebo
47994627|NCT03410589|OTHER|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
47994628|NCT01923454|PROCEDURE|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
48364842|NCT03169842|DEVICE|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
48364843|NCT06137027|DRUG|Cannabidiol Oil|Cannabidiol oil will be administered sublingually 2-3 hours preoperatively
48364844|NCT06137027|DRUG|Placebo|Placebo will be administered sublingually 2-3 hours preoperatively
48680728|NCT01154335|DRUG|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
48680729|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
47994629|NCT01923454|DRUG|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
47994630|NCT01923454|PROCEDURE|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
47994631|NCT03205618|OTHER|Non-Interventional|Non-Interventional
47994632|NCT02921048|DIETARY_SUPPLEMENT|omega-3 fatty acids|
47994633|NCT03645655|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
47994634|NCT00006209|DRUG|Tucaresol|
47994635|NCT01425554|OTHER|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
47994636|NCT01425554|OTHER|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
47994637|NCT01425554|OTHER|Air-plethysmography of the neck|Air-plethysmography of the neck
48364845|NCT02792569|PROCEDURE|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
48364846|NCT00004911|PROCEDURE|bowel obstruction management|
48364847|NCT00004911|PROCEDURE|quality-of-life assessment|
47994638|NCT01425554|OTHER|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
47994639|NCT03713203|DEVICE|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
47994640|NCT03134482|PROCEDURE|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
47994641|NCT03134482|PROCEDURE|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
47994642|NCT04780763|OTHER|Milk product fermented by lactic bacteria or not fermented|2 bottles of 100g consumed daily during 28 days
47994643|NCT00931749|DEVICE|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
47994644|NCT00931749|DEVICE|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
47994645|NCT05447364|DRUG|Pregabalin 75mg|1 tab of Pregabalin Brillior 75 mg and 1 tab of Placebo
47994646|NCT05447364|DRUG|Pregabalin 150mg|2 tabs of Pregabalin Brillior 75 mg
47994647|NCT01782807|PROCEDURE|Salpingectomy or Fimbriectomy|
47994648|NCT05824533|DEVICE|onlay patella button|Total knee arthroplasty (TKA) with a patella onlay button placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
47994649|NCT05824533|PROCEDURE|Conventional procedure; NO onlay patella button|Total knee arthroplasty (TKA) placed with a CORI Robotics System based on pre-operative 4DCT-imaging.
47994650|NCT06414967|OTHER|Music Intervention|Music therapy carried out with Music Care
47994651|NCT01524861|DRUG|Placebo|a placebo tablet bis in die for 12 months
47994652|NCT01524861|DRUG|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
47994653|NCT01524861|DRUG|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
47994654|NCT05106244|OTHER|Real-Time Guidance of Home Care for Patients with PICC or PORT|the experimental group adopted the family self-nursing mode, mainly by the patients' family members to observe the catheter and do regular nursing, and the specialist nurses provided remote real-time online guidance to monitor the family nursing of central venous catheter. The procedures are as follows: (1) make nursing videos recorded by central venous catheter specialist nurses; (2) evaluate the nursing operation ability of the patients' family members and carry out relevant training and health education, repeat until they are qualified; (3) distribute nursing guidance prescriptions and maintenance manuals for central venous catheters; (4) provide online simulated realistic nursing video materials; (5) provide real-time telephone audio and video connection to complete remote nursing guidance. (6) set up a home nursing volunteer service group, establish a doctor-patient exchange group by using Wechat and other media.
47994655|NCT01541137|DRUG|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
47994656|NCT01541137|DRUG|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
47994657|NCT01541137|DEVICE|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
47994658|NCT03103789|DIAGNOSTIC_TEST|single catheter mucosal impedance testing|
47994659|NCT03103789|DIAGNOSTIC_TEST|balloon assembly mucosal impedance testing|
47994660|NCT02436421|OTHER|Best Practice Alert based in the Electronic Medical Record|
48364848|NCT01114191|DRUG|ABT-869|2.5mg \[5 mg days 1, 8 and 12. 17.5 mg on days 13 and after\]
48364849|NCT01114191|DRUG|ketoconazole|400 mg days 6-11
48364850|NCT01974414|DRUG|orally administered cedar honey|
48364851|NCT00622310|BEHAVIORAL|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (\~6.8 kg) during the 6 month intervention.
48364852|NCT01756209|DRUG|Magnesium 400Mg|magnesium 400 mg + conventional treatment
48364853|NCT01756209|DRUG|Ibuprofen 10 mg/kg|ibuprofen 10 mg/kg oral single dose
48364854|NCT01756209|DRUG|acetaminophen 15 mg/kg|Acetaminophen 15 mg/kg oral single dose
48364855|NCT04426227|OTHER|Gaze training|A training module in gaze training for peripheral nerve blockade
48680730|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
48680731|NCT01698931|DRUG|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
48680732|NCT01698931|DRUG|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
48680733|NCT01698931|DRUG|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
48680734|NCT00883948|BEHAVIORAL|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
48680735|NCT00883948|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
48680736|NCT04263766|OTHER|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
48680737|NCT00976638|OTHER|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
48680738|NCT00976638|OTHER|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
48680739|NCT01738633|BEHAVIORAL|nutritional counseling|
48364856|NCT04426227|OTHER|Discovery learning|A phase of discovery learning guided by novice operators themselves
48680740|NCT01738633|BEHAVIORAL|respirology counseling|
48680741|NCT00599352|DIETARY_SUPPLEMENT|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
48680742|NCT01978145|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
48364857|NCT03220620|OTHER|GDT|individualized fluid therapy
48364858|NCT00816712|DRUG|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 300 mg, Intramuscular injection."
48364859|NCT00816712|DRUG|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 \& 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Testosterone 100 mg, Intramuscular injection."
48364860|NCT00816712|DRUG|Comparator: Placebo given by Intramuscular Injection|"Day 1 \& 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 \& 7 - Placebo given as intramuscular injection."
48364861|NCT01403324|DRUG|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
48680743|NCT01978145|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
48680744|NCT05508646|BEHAVIORAL|Music therapy intervention|The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
48680745|NCT05508646|BEHAVIORAL|Personalized music CD|Participants will receive a personalized music CD that they keep and can listen to as they wish.
48680746|NCT02837471|DEVICE|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
48364862|NCT02049385|DRUG|Diazoxide|A nondiuretic vasodilator thiazide-related agent
48364863|NCT02049385|DRUG|Placebo|Placebo
47994661|NCT02500784|DRUG|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
47994662|NCT02500784|OTHER|Formoterol B (placebo)|2mL, BID inhaler for 12 months
47994663|NCT02336022|DEVICE|Respiratory Motion Inc|
47994664|NCT00232258|DRUG|Nolpitantium besylate|
47994665|NCT01062555|DRUG|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
47994666|NCT01062555|DRUG|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
47994667|NCT01062555|DRUG|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
47994668|NCT01062555|DRUG|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
47994669|NCT01017237|DRUG|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
47994670|NCT01017237|DRUG|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
47994671|NCT01017237|DRUG|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
47994672|NCT00345137|DRUG|Ng-monomethyl-L-arginine (drug)|
47994673|NCT05864911|DEVICE|the Gastric Bypass Stent System|The Gastric Bypass Stent System is a newly designed endoscopic duodenal-jejunal bypass liner for the treatment of obesity by Hangzhou Tangji Medical Technology Co., Ltd.. It consists of three main parts: a 60-cm polyethylene sleeve fixed into the duodenal bulb by anchors with barbs, a delivery system and a retrieval system. Compared to the Endobarrier, it has several technical adjustments. First, it improved sleeve materials to provide better barrier properties and reduce the breeding of bacteria resulting in hepatic abscess. Second, the barbs on the anchoring system have been modified to reduce duodenal injury. Third, the delivery and retrieval system have been optimized to eliminate the need of fluoroscopic guidance during implantation and explantation.
47994674|NCT01179477|DEVICE|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
47994675|NCT02591355|DEVICE|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
47994676|NCT02591355|DEVICE|Saline solution injection|Placebo is a saline solution
47994677|NCT01820455|DRUG|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
47994678|NCT01820455|DRUG|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
48680747|NCT01774812|DIETARY_SUPPLEMENT|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
47994679|NCT03539835|OTHER|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
47994680|NCT03539835|BEHAVIORAL|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
48680748|NCT01774812|DIETARY_SUPPLEMENT|Ergocalciferol|50,000IU 1x per week for 6 weeks
48680749|NCT06401499|DRUG|etoricoxib 60mg|investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
47994681|NCT03210870|BEHAVIORAL|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
47994682|NCT03809520|RADIATION|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
47994683|NCT02487238|BIOLOGICAL|Fecal Microbiota Enema|Active intervention.
47994684|NCT02487238|BIOLOGICAL|Normal Saline Enema|Placebo comparator.
47994685|NCT03305328|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
47994686|NCT05272904|PROCEDURE|Quilting|Following mastectomy and/or axillary lymph node dissection, the subcutaneous tissue is sutured to the pectoralis muscle placing multiple rows of running sutures. The suture starts at either end of the scar, running back and forth, creating rows of quilting stiches. The rows are placed transversely from the cranial to the caudal end of the wound with 2-3 cm between them, totalling some three to ﬁve rows for the cranial ﬂap. The caudal ﬂap is quilted with 2-3 rows in a caudal to cranial fashion. A subcutaneous suture followed by a intracutaneous running suture is used to close the skin.
47994687|NCT05272904|PROCEDURE|Conventional wound closure|Following mastectomy, skin is closed using subcutaneous sutures followed by intracutaneous running suture. Depending on the surgeons discretion a vacuum closed suction drain was placed beneath the skin flaps.
48154089|NCT03443739|OTHER|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
48680750|NCT04212130|OTHER|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
48680751|NCT01462929|DRUG|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
48680752|NCT01462929|DRUG|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
48154090|NCT05690178|OTHER|Deep Tissue Massage|The Deep Tissue Massage lasted 45 minutes. The entire therapy included 4 treatments over a period of 2 weeks. The interval between treatments was 3 days. The conducted therapy included techniques for: quadratus lumborum muscle, erector spinae muscle, thoracolumbar fascia, iliopsoas muscle. All techniques were performed on both sides of the patient's body.
48364864|NCT04255329|OTHER|Montessori reading roundtable|Such book is written in a way to adaptate to people with cognitif and sensory impairments. Indeed, text is written in large characters and structured to not involve episodic memory. Each person read one page aloud in his turn. After the reading phase, the participants discuss the questions about their opinions and distant memories.
47994688|NCT05933928|OTHER|Simulation-based electronic fetal monitoring training|"Practices will be carried out with the students in the intervention group with the NOELLA Birth Simulator, which is a high-reality simulator located in the Simulation laboratory of the Department of Midwifery of the Faculty of Health Sciences of Hamidiye. A simulator will be practiced with a separate scenario including early, late, variable deceleration, reactive, sinusoidal and non-reactive trace interpretation and intervention."
47994689|NCT00299260|BIOLOGICAL|CMV gB vaccine|20 micrograms
47994690|NCT00299260|DRUG|Placebo|normal saline
47994691|NCT02030379|BEHAVIORAL|QPL-CT|Use the QPL-CT to prioritize questions
47994692|NCT06529770|OTHER|NMP-e|"The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience."
47994693|NCT00077103|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
47994694|NCT00077103|BIOLOGICAL|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
47994695|NCT00077103|DRUG|cisplatin|cisplatin IV over 30-60 minutes on day 1
47994696|NCT00077103|DRUG|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
47994697|NCT00077103|DRUG|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
47994698|NCT00077103|RADIATION|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
47994699|NCT02374645|DRUG|Volitinib|600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
47994700|NCT02374645|DRUG|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
48680753|NCT01462929|DRUG|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
48680754|NCT04592471|DEVICE|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
48680755|NCT00579969|DRUG|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
48680756|NCT00579969|DRUG|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
48680757|NCT02616939|OTHER|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
47994701|NCT06167993|BEHAVIORAL|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy; It consists of manual therapy, skin care, compression therapy and therapeutic exercise.
47994702|NCT01415063|PROCEDURE|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
47994703|NCT01415063|PROCEDURE|TACE-RFA|TACE first, then RFA within 2 weeks
47994704|NCT00638313|BIOLOGICAL|Placebo|Subjects will be given either Placebo or PF-04603629.
47994705|NCT00638313|BIOLOGICAL|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
47994706|NCT00644969|DRUG|placebo|Randomization 2:1 treatment to placebo
47994707|NCT00644969|DRUG|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
48154091|NCT04597047|DIAGNOSTIC_TEST|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
48680758|NCT01590745|DEVICE|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
48680759|NCT03107728|DEVICE|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
48364865|NCT04255329|OTHER|Usual reading|The readen text is a normal, currently used in a everyday life support such as a journal article.
48364866|NCT01858675|OTHER|Biomarkers, red blood cells and plasma assessment|
48364867|NCT04725734|OTHER|Pregnant women|The patients will complete a questionnaire for each quarter
48680760|NCT03107728|DEVICE|Conventional orthotic brace|Participants will use the standard of care orthosis
48680761|NCT00392977|DIETARY_SUPPLEMENT|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
48680762|NCT04303429|DRUG|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
48364868|NCT03388450|DRUG|Omega 3|Enteral 1000 mg omega 3 fatty acid.
48680763|NCT02130674|DRUG|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
48680764|NCT02615119|DRUG|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
48680765|NCT02615119|DRUG|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
48680766|NCT01941771|DRUG|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
48680767|NCT01941771|DRUG|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
48680768|NCT04826783|DEVICE|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
48680769|NCT02013349|DEVICE|coronary intervention|
48680770|NCT01030120|DRUG|etanercept|etanercept 50mg BIW S.Q.
48680771|NCT01030120|DRUG|placebo|placebo
48680772|NCT00725686|DRUG|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
48680773|NCT03199677|DRUG|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
48680774|NCT03186105|OTHER|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
48680775|NCT02092727|BEHAVIORAL|Behavioral Interventions for Dialysis Facilities|"1. Educational seminars and monthly educational webinars~2. Peer-to-peer mentoring program~3. Bulletin boards about transplantation~4. Facility-specific feedback reports detailing transplant referral data for their center compared to state average~5. Formulate a facility-specific improvement plan to increase transplant referrals.~6. Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~7. Monthly monitoring and reporting of patient referrals to ESRD Network~8. Conduct a patient and family education session about transplantation~9. Host a movie day to show Living ACTS (About Choices in Transplantation \& Sharing) video"
48680776|NCT03672851|DRUG|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
48680777|NCT02375373|OTHER|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
47994708|NCT05891678|RADIATION|doppler study of central retinal artery|pulsed wave Doppler after decreasing the sample volume to fit inside the center of CRA. We will measure the peak systolic velocity (PSV), end diastolic velocity (EDV), and the resistivity index which equal PSV-EDV/PSV, we will measure 3 times and the expected normal value is less than 0.7.
48154092|NCT04597047|DIAGNOSTIC_TEST|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
48154093|NCT00126620|DRUG|erlotinib hydrochloride|
48154094|NCT00126620|DRUG|sorafenib tosylate|
48364869|NCT03388450|DRUG|Placebo|Enteral nutrition without omega 3 fatty acid.
48364870|NCT05476965|COMBINATION_PRODUCT|induction therapy; surgery; radiotherapy|Radiotherapy: de-escalation radiotherapy or standard radiotherapy
48364871|NCT01730768|DRUG|AQW051|
48364872|NCT01730768|DRUG|Placebo|
48364873|NCT00303602|DRUG|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
48364874|NCT00303602|DRUG|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
48680778|NCT04708808|BEHAVIORAL|music therapy|cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
48680779|NCT03479450|DRUG|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
48680780|NCT00269607|DRUG|Implantation of naltrexone implants|
48364875|NCT05102734|DRUG|Nitroglycerin Topical Product|Topical nitroglycerin solution
48364876|NCT05845554|DIAGNOSTIC_TEST|The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.|The extracted gDNA from bile sample will be analyzed by BileCAD to determine the level of CINs.
48364877|NCT03302923|BEHAVIORAL|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
48680781|NCT04280016|BEHAVIORAL|Exercise|Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
47994709|NCT03213821|OTHER|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (\>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
47994710|NCT00973739|DRUG|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
47994711|NCT02862431|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
47994712|NCT02862431|DRUG|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
47994713|NCT00428896|DRUG|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
47994714|NCT04745403|DRUG|mRNA HBV/TCR T-cells|"Study Infusion~The first dose of mRNA HBV-TCR T-cells at dose 1x10e5/kg BW will be infused on Day 0, and subsequently incremental doses on Day 14 and 28, up to the dose of 5-10x10e6/kg BW."
48680782|NCT04226625|DRUG|Propofol|Intravenous administration
48680783|NCT04226625|DRUG|Desflurane|Volatile administration
48680784|NCT04587882|BEHAVIORAL|Telehealth|Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
48680785|NCT04587882|BEHAVIORAL|Control|Participants will get usual care and wear a smartwatch.
48680786|NCT03673540|BEHAVIORAL|CBT+ application|Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
48680787|NCT00157963|DRUG|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
48680788|NCT03432494|DEVICE|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
48680789|NCT00158626|BEHAVIORAL|pelvic floor muscle training|
48154095|NCT03578744|PROCEDURE|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
48154096|NCT03751761|DRUG|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
48154097|NCT05813145|DRUG|Placebo|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
48154098|NCT05813145|DRUG|Fenofibrate 160mg|25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week in addition to 160mg fenofibrate once daily for 3 month.
48154099|NCT03899844|OTHER|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
48364878|NCT05631873|OTHER|Assistance with implementing Epic Smartlist|A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
48364879|NCT02409017|PROCEDURE|Insulin drip|
48364880|NCT05789823|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 5 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
48364881|NCT05789823|PROCEDURE|Mechanical thrombectomy alone|Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
48364882|NCT00852735|DIETARY_SUPPLEMENT|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
48680790|NCT02014805|RADIATION|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
48680791|NCT01885650|OTHER|Airway Clearance Techniques|
48680792|NCT05545592|OTHER|Low oestrogen dosage|From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
48680793|NCT05163314|DRUG|Soticlestat|Soticlestat mini-tablets or tablets
48364883|NCT02441387|DRUG|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
48680794|NCT01619761|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
48680795|NCT01619761|DRUG|Cyclophosphamide|Given IV
48680796|NCT01619761|DRUG|Fludarabine Phosphate|Given IV
48680797|NCT01619761|OTHER|Laboratory Biomarker Analysis|Correlative studies
48680798|NCT01619761|DRUG|Lenalidomide|Given PO
48680799|NCT01619761|DRUG|Melphalan|Given IV
48680800|NCT01619761|DRUG|Mycophenolate Mofetil|Given IV or PO
48680801|NCT01619761|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
47994715|NCT05237479|PROCEDURE|Suprainguinal fascia ilica block|Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
47994716|NCT05237479|OTHER|Placebo|The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
47994717|NCT00873509|DRUG|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
48154100|NCT03180086|OTHER|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
48154101|NCT05820451|DEVICE|Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.
48680802|NCT01619761|BIOLOGICAL|Rituximab|Given IV
48680803|NCT01619761|DRUG|Tacrolimus|Given IV or PO
48680804|NCT01619761|RADIATION|Total-Body Irradiation|Undergo TBI
48680805|NCT01619761|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
48680806|NCT06511895|DRUG|AZD4205|AZD4205 capsules administered at 150 mg orally, once daily, in 28-day cycle.
48680807|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
48680808|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
48680809|NCT00649285|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
48680810|NCT00649285|DRUG|Macrobid® Capsules 100 mg|100mg, single dose fed
48680811|NCT04963023|OTHER|Physical examinations|BPCO physical examinations
48680812|NCT04963023|DIAGNOSTIC_TEST|blood test|blood test in order to study immunologic markers
48680813|NCT05892419|OTHER|No intervention|There is no intervention
47994718|NCT00873509|DRUG|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
48680814|NCT05757180|BEHAVIORAL|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
48680815|NCT05757180|BEHAVIORAL|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus\*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (\*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
48680816|NCT00411385|DRUG|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
48680817|NCT00411385|DRUG|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
48680818|NCT00411385|DRUG|Ribavirin|800mg/day for 24 weeks
48680819|NCT05749367|DRUG|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
48680820|NCT05749367|DRUG|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
48680821|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
47994719|NCT00873509|DRUG|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
47994720|NCT04093388|DIAGNOSTIC_TEST|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
48364884|NCT02441387|OTHER|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
48364885|NCT02441387|OTHER|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
48364886|NCT03458429|DRUG|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
48680822|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
47994721|NCT04093388|DIAGNOSTIC_TEST|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
47994722|NCT04809220|DRUG|Dulaglutide|Administered SC
47994723|NCT04809220|DRUG|Oral antihyperglycemics|Administered orally
48154102|NCT05820451|DEVICE|Impella RP with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.
47994724|NCT04241497|BEHAVIORAL|Home-based rehabilitation|1 supervised exercise session at the hospital; 3 weeks of supervised home-based exercise training (3x/week); 9 weeks of unsupervised home-based exercise training (3x/week)
47994725|NCT02448238|OTHER|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (\~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
47994726|NCT05759442|DRUG|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
47994727|NCT05759442|DIETARY_SUPPLEMENT|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
47994728|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
47994729|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
47994730|NCT00979888|OTHER|educational intervention|
47994731|NCT00979888|OTHER|informational intervention|
47994732|NCT00979888|OTHER|psychosocial support for caregiver|
47994733|NCT00979888|OTHER|questionnaire administration|
47994734|NCT00979888|PROCEDURE|dyspnea management|
47994735|NCT00979888|PROCEDURE|management of therapy complications|
47994736|NCT06391736|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
47994737|NCT02363725|DRUG|Colchimax®|
47994738|NCT02363725|DRUG|Conventional treatment|
47994739|NCT04930848|OTHER|Euphorbia hirta (Dudhiya)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
47994740|NCT04930848|OTHER|PBO(Combined powder of Terminalia arjuna and Terminalia bellerica)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
47994741|NCT05352009|OTHER|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
47994742|NCT05352009|OTHER|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
47994743|NCT00105703|BEHAVIORAL|Case management using advanced nurse practitioners|
47994744|NCT03930706|OTHER|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
47994745|NCT00950547|DEVICE|CARDIOPAT|Cell Saver System at bedside for ICU stay
47994746|NCT00950547|DEVICE|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
47994747|NCT03034720|BEHAVIORAL|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
47994748|NCT02053753|DRUG|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
47994749|NCT02053753|DRUG|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
47994750|NCT02424929|PROCEDURE|Sedation|Propofol anesthesia administered during entire surgery.
47994751|NCT02424929|PROCEDURE|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
47994752|NCT03171987|DRUG|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
47994753|NCT03171987|DRUG|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
47994754|NCT01625455|DRUG|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
47994755|NCT01625455|DRUG|Placebo|Placebo will be given orally for a total of 7 days.
47994756|NCT01774786|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
47994757|NCT01774786|DRUG|Capecitabine|Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
47994758|NCT01774786|DRUG|Cisplatin|Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.
48154103|NCT05465187|OTHER|Non applicable|Non applicable
48154104|NCT00459849|PROCEDURE|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
48680823|NCT02863393|OTHER|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
48680824|NCT03475069|OTHER|Custom Designed Exercises|
48680825|NCT03475069|OTHER|Plates Exercises|
48680826|NCT03475069|OTHER|Calisthenics Exercises|
48680827|NCT01891981|DRUG|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
48680828|NCT03149159|DRUG|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
48680829|NCT03149159|DRUG|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
48680830|NCT03149159|RADIATION|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
48680831|NCT05429580|DRUG|Tranexamic acid|given intravenous tranexamic acid
48680832|NCT05429580|OTHER|5% Dextrose|given placebo.
48680833|NCT01000506|BIOLOGICAL|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
48680834|NCT01000506|BIOLOGICAL|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
48680835|NCT01000506|BIOLOGICAL|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
48680836|NCT01000506|DRUG|Placebo saline|Placebo saline every four weeks by i.v.
48680837|NCT06295900|OTHER|Intervention 1 Group|20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.
48680838|NCT06295900|OTHER|Intervention 2 Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
48680839|NCT06295900|OTHER|Placebo Control Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
48154105|NCT06585761|DRUG|SGLT2 inhibitor|patients with HF are subjected to regular dose of SGLT2I member according to patient status.
48154106|NCT06585761|DEVICE|echo cardiogram|the patients are subjected to ECHO to determine their EF prior to and post the study
48680840|NCT02131662|DRUG|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
48154107|NCT03321175|OTHER|subcutaneous saline irrigation|200 cc saline irrigation
48154108|NCT01181193|OTHER|Surgery|Craniotomy with total or partial removal of the brain tumor
48154109|NCT01181193|RADIATION|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
48680841|NCT02131662|DRUG|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
48680842|NCT02131662|DRUG|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
48680843|NCT02131662|DRUG|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
48680844|NCT02131662|DRUG|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
48680845|NCT04342091|DEVICE|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
48680846|NCT01916486|BEHAVIORAL|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
48680847|NCT01916486|BEHAVIORAL|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
48680848|NCT01916486|BEHAVIORAL|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
48680849|NCT05614752|DRUG|Fexuprazan|Fexuclue Tablet 40mg
48680850|NCT02870985|DEVICE|Coronary Stent|
48680851|NCT04256278|OTHER|Spermotrend|oral administration of antioxidants for three months
48680852|NCT06555341|BEHAVIORAL|Experimental: Six Thinking Hats Group|"2. Subcutaneous insulin administration was explained with the traditional training model.~3. The Six Thinking Hats technique and how it is used was then explained in detail to the students. Any points that were not fully understood were explained again so that the technique was thoroughly reinforced.~4. The researchers had made hats from different coloured card. All the students wore all the hats in turn and were asked the questions related to that colour hat as stated above (semi-structured questionnaire 1-6).~5. The responses given by the students to the questions were audio-recorded. Each interview lasted 30 mins."
48680853|NCT06555341|BEHAVIORAL|Other: Video Group|"2. Subcutaneous insulin administration was explained with the traditional training model.~3. Then by scanning the QR code from the nursing practice skills textbook(Aylaz \&amp; Yakıncı, 2024), the researchers provided the link for the students to watch the insulin application video.~4. Without mentioning hat colours or the Six Thinking Hats method to this group, the questions on the semi-structured questionnaire were asked, and the interviews, each lasting 30 mins, were audio-recorded.~5. After completing the video training, the mid-test data were collected by applying the Subcutaneous Insulin Application Skill Level Observation Form during administration of insulin to a dummy."
48680854|NCT04095702|OTHER|Weighted Pacifier|The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.
48680855|NCT04095702|OTHER|Non-Weighted Pacifier|The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
48680856|NCT01558115|DRUG|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
48680857|NCT01558115|OTHER|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
48680858|NCT05165069|DRUG|Mecobalamin 5 MG Disintegrating Oral Tablet|Mecobalamin 0.5mg / time, 3 times / day,was taken continuously for 6 months
48680859|NCT05165069|DRUG|placebo|placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
48680860|NCT02753478|OTHER|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
48680861|NCT03826459|PROCEDURE|Non-Locking Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& non-locking technique. The second layer cannot be of a locking technique.
48154110|NCT01181193|DRUG|Temozolomide|"1. 75 mg/m2/day for entire period of radiotherapy~2. 150-200 mg/m2/day for 5 days every 28 days, 6 cycles total"
48680862|NCT03826459|PROCEDURE|Locked Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& locking technique. The second layer can be locking or non-locking.
48680863|NCT02909660|OTHER|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
48680864|NCT00710398|BEHAVIORAL|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
48680865|NCT00710398|BEHAVIORAL|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
48680866|NCT06301308|DRUG|Intraurethral lidocaine gel alone|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
48680867|NCT06301308|DRUG|Intraurethral lidocaine gel + lidocaine 2% injection|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
48680868|NCT06301308|DRUG|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
48680869|NCT04369456|OTHER|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
48680870|NCT00401843|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
48680871|NCT00401843|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
48680872|NCT00401843|DRUG|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
48680873|NCT00401843|DRUG|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
48680874|NCT05607602|OTHER|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
48680875|NCT03971175|PROCEDURE|Forceps biopsy|Endobronchial biopsy with the forceps
48680876|NCT03971175|PROCEDURE|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
48154111|NCT01181193|DRUG|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
48680877|NCT02215057|DRUG|topical anesthesia|topical anesthetic drops and Group 2
48154112|NCT00933634|PROCEDURE|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
48154113|NCT00933634|DRUG|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
48364887|NCT03479424|OTHER|Observational|The MYIA in-home suite of devices.
48680878|NCT02215057|DRUG|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
48680879|NCT02804633|DRUG|IV Acetaminophen|1 gram every 6 hours
48680880|NCT02804633|DRUG|Placebo|100 ml of normal saline every 6 hours
47994759|NCT01774786|DRUG|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
47994760|NCT01774786|DRUG|Placebo|Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
47994761|NCT01774786|DRUG|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
47994762|NCT03265249|DEVICE|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
47994763|NCT04116138|DIETARY_SUPPLEMENT|Salovum|Egg yolk powder enriched for anti secretory factor
47994764|NCT06388395|PROCEDURE|Accuracy of full-arch surgical guides|The accuracy of the surgical guides will be assessed by superimposing the pre and post-treatment CBCT scans.
47994765|NCT06388395|PROCEDURE|Survival and complications of the prostheses|Two different prostheses will be assessed (conventional and PEEK). All complications will be recorded for a period of 3 years
48364888|NCT04384120|DEVICE|Blood Flow Restriction Therapy|Blood flow restriction cuffs which are FDA approved will be provided to patients randomized into the BFR group. Patients will be provided video instruction and training on how to conduct the traditional therapy exercises with the use of BFR.
48364889|NCT04384120|PROCEDURE|Traditional Therapy|Patients will be provided video instruction and training on how to conduct the traditional therapy exercises.
48680881|NCT00243191|DRUG|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
48680882|NCT04572646|OTHER|NRT proposition and exhaled CO measurement|"Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy."
48680883|NCT04475107|DRUG|Pyronaridine-Artesunate|Pyramax
48680884|NCT04475107|DRUG|Placebo|Placebo
48680885|NCT04284501|BEHAVIORAL|Non|questionnaire
48680886|NCT01484145|DRUG|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
48680887|NCT05431361|OTHER|Prehabilitation|A Registered Kinesiologist (RKin) will provide the exercise prescription, consisting of 4-5 days of aerobic exercise training and 2-3 days of resistance exercise training of major muscle groups, during a remotely delivered familiarization session using Microsoft Teams. The 60-minute remote program introduction will include a description and demonstration of all of the exercises that will follow the baseline assessment. Patients will be prescribed an individualized exercise program considering: (1) their exercise preferences, (2) their current physical capacity, (3) previous medical history, and (4) presence of underlying comorbidities, mobility, and skeletal fragility concerns \[NOTE: the location/impact of a tumour is not applicable for PROPELLER as it was in REB#5901, and is thus not included here\]. The participant will have an opportunity to execute the exercises in the remote presence of the RKin who will provide corrective feedback where applicable.
47994766|NCT06388395|PROCEDURE|Survival and complications of the implants|The effect of the two different prostheses on implants will be assessed in terms of survival and success rates.
47994767|NCT06388395|PROCEDURE|Conventional (metal-resin) implant-supported prosthesis|Full-mouth implant-supported conventional prosthesis will be constructed and evaluated for up to 3 years.
47994768|NCT06388395|PROCEDURE|PEEK implant-supported prosthesis|Full-mouth implant-supported PEEK prosthesis will be constructed and evaluated for up to 3 years.
47994769|NCT01894789|DRUG|Ticagrelor|Blinded administration of ticagrelor for 10 days
47994770|NCT01894789|DRUG|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
47994771|NCT04076774|DEVICE|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
48364890|NCT05937503|OTHER|manual therapy|The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.
48364891|NCT05937503|OTHER|conventional physiotherapy|Control group will only receive conventionel physiotherapy intervention.
48680888|NCT04971967|COMBINATION_PRODUCT|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
48680889|NCT01194245|DRUG|Insulin lispro|
48680890|NCT01194245|DRUG|recombinant human hyaluronidase PH20|
48680891|NCT01194245|DRUG|Insulin aspart|
48680892|NCT01194245|DRUG|Insulin glulisine|
48680893|NCT01194245|DRUG|Insulin glargine|
48680894|NCT03118505|DEVICE|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
48680895|NCT03118505|DEVICE|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
48680896|NCT01266330|DIETARY_SUPPLEMENT|Low Dairy|Less than 0.5 standard servings of dairy products per day
48680897|NCT01266330|DIETARY_SUPPLEMENT|Adequate Dairy|3.5 standard servings of dairy foods per day
48680898|NCT04684212|DEVICE|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
48680899|NCT04684212|DRUG|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
48680900|NCT01616212|OTHER|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
48680901|NCT01616212|OTHER|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
48680902|NCT01616212|OTHER|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
48680903|NCT01616212|OTHER|Drug Education for adolescents|Drug Education for adolescents
48680904|NCT04074226|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
47994772|NCT04076774|DEVICE|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
47994773|NCT03668626|OTHER|Family-centered intervention program (FCIP)|This program included in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention emphasized modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
47994774|NCT05270681|OTHER|Movement to Music|Participants will be educated on how to access prerecorded Move to Improve classes conducted by a professional dance instructor which will be accessible by computer or tablet 24/7 via a hyperlink. Classes last 45 minutes, and participants will be instructed to participate in the activity at least twice weekly, for 12 weeks. Each class uses movement to music combinations across different dance genres that build in intensity and sequence complexity, accompanied by music with faster beats, to encourage participants to achieve a moderate-vigorous level of physical and cognitive activity. Care partners will be present during each class to ensure safety and will also participate in the Move to Improve exercise program. The care partner and participant will be instructed to stand at a counter or behind a chair for safety during exercise.
47994775|NCT05891483|DRUG|SHR-1905 Injection|SHR-1905 Injection
47994776|NCT05891483|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
47994777|NCT00142571|DRUG|Gemcitabine|
47994778|NCT00142571|DRUG|Docetaxel|
48511836|NCT01947998|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
48511837|NCT01947998|DRUG|Warfarin|For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.
48511838|NCT01947998|DRUG|Antiplatelet drugs|For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
47994779|NCT01393340|DRUG|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
47994780|NCT01393340|DRUG|Placebo|Placebo
47994781|NCT02319005|DRUG|Revusiran (ALN-TTRSC)|
47994782|NCT02319005|DRUG|Sterile Normal Saline (0.9% NaCl)|
47994783|NCT06181890|OTHER|Motivational Interview|The data of the research will be collected between October 2023 and June 2024. Each meeting will last approximately 15-30 minutes.
48511839|NCT03561324|DEVICE|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
47994784|NCT05011864|BEHAVIORAL|Behavioral Activation|In BA, depressive symptoms are viewed as depressive behaviors. Compared to those without depression, people with depression engage in fewer overt behaviors that provide positive reinforcement and pleasure/enjoyment and in more behaviors that function to escape or avoid aversive stimuli (e.g., staying in bed all day).55-59 Thus, BA is aimed at increasing and reinforcing meaningful, healthy, and enjoyable behaviors while decreasing depressive behaviors and is well-suited to help depressed, disabled older adults increase mood-enhancing activities, self-care management skills, and social connectedness.
47994785|NCT05011864|BEHAVIORAL|Fall Prevention|Following FP psychoeducation based on the Centers for Disease Control and Prevention (CDC)'s STEADI tool kits, lay coaches will assist clients in implementing evidence-based FP strategies that have been adapted for low-income homebound seniors. These include referrals to healthcare providers as needed, home safety checks, practice of safe ambulation/transfer and mobility aid use, medication review, and in-home exercise routines with an innovative, gamified tablet-based exercise app for balance and strength building.
48511840|NCT04194645|DRUG|BI 474121 tablet|BI 474121 tablet
48511841|NCT04194645|DRUG|Placebo tablet|Placebo tablet
48511842|NCT04194645|DRUG|BI 474121 oral solution|BI 474121 oral solution
48511843|NCT04194645|DRUG|Placebo solution|Placebo solution
47994786|NCT05011864|OTHER|Telephone support|Subjects in this arm will receive 9 weekly support calls last 30 minutes each. These calls are intended to provide an opportunity for social support and check safety.
48511844|NCT02490280|BEHAVIORAL|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
48511845|NCT01864395|PROCEDURE|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
48511846|NCT01864395|PROCEDURE|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
47994787|NCT04121260|DRUG|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
47994788|NCT00945581|OTHER|Experimental Nutritional Powder Formula|Powder twice a day
48511847|NCT01864395|PROCEDURE|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
47994789|NCT00945581|OTHER|Placebo comparator|Powder twice a day
47994790|NCT03048656|OTHER|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
47994791|NCT00366158|DEVICE|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
48511848|NCT06091670|OTHER|No intervention|There is no intervention. The research is cross-sectional-descriptive type.
47994792|NCT00366158|DEVICE|Ventricular Intrinsic Preference|Programming of pacemaker
47994793|NCT02310464|DRUG|OBI-833/OBI-821|
47994794|NCT05039710|DRUG|JNJ-75220795|JNJ-75220795 will be administered as SC injection.
47994795|NCT05039710|OTHER|Placebo|Matching placebo will be administered as SC injection.
47994796|NCT01769833|DRUG|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
48511849|NCT01862484|DIETARY_SUPPLEMENT|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
47994797|NCT01769833|DRUG|Nucleosides|
48364892|NCT05215106|DRUG|Durvalumab|Following preparation of durvalumab, the entire contents of the IV bag should be administered as an IV infusion over approximately 60 minutes (±5 minutes), using a 0.2μm in-line filter (or add-on filter).
48511850|NCT01862484|DIETARY_SUPPLEMENT|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
48511851|NCT05513391|BIOLOGICAL|Recombinant influenza vaccine (RIV4)|Pharmaceutical form: solution for injection Route of administration: intramuscular
48511852|NCT05513391|BIOLOGICAL|Quadrivalent influenza vaccine (IIV4)|Pharmaceutical form: suspension for injection Route of administration: intramuscular
47994798|NCT02916563|DEVICE|Blood Glucose Monitoring System Altitude Performance|Performance as assessed against a reference method at an altitude of approximately 10,000 feet.
47994799|NCT03467113|DRUG|ZX008 0.2 to 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
47994800|NCT03467113|DRUG|Cannabidiol|Cannabidiol
47994801|NCT03510286|DIAGNOSTIC_TEST|Test-it™ PrCr Urinalysis Strips|The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
47994802|NCT02661360|BEHAVIORAL|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
48364893|NCT04210141|BIOLOGICAL|lyophilized BPI viper antivenom|Antivenom
48364894|NCT02619942|PROCEDURE|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
48364895|NCT02619942|PROCEDURE|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
48364896|NCT01332422|DRUG|Salmeterol and Fluticasone|Collection of safety data
48364897|NCT00242658|BEHAVIORAL|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
48364898|NCT03907085|OTHER|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
47994803|NCT02661360|BEHAVIORAL|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
48364899|NCT03907085|OTHER|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
48364900|NCT05006404|DEVICE|Pulmonary Valve Replacement Surgery|Pulmonary valve replacement surgery with the Autus Valve
48364901|NCT00005627|DRUG|carboplatin|
47994804|NCT00939913|DRUG|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
47994805|NCT00939913|DRUG|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
48364902|NCT00005627|DRUG|docetaxel|
47994806|NCT00939276|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
48364903|NCT00005627|DRUG|estramustine phosphate sodium|
48364904|NCT01509066|OTHER|Diet|Dietary approaches for PCOS
48364905|NCT03514394|BEHAVIORAL|Usual Care|The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).
48364906|NCT03514394|BEHAVIORAL|Modified Behavioral Activation (Task Sharing)|This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
48364907|NCT01593566|DRUG|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
48364908|NCT01593566|DRUG|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
48364909|NCT02730234|DEVICE|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
47994807|NCT00939276|DRUG|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
47994808|NCT03394768|OTHER|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
48364910|NCT00002276|DRUG|Ibuprofen|
48364911|NCT00002276|DRUG|Zidovudine|
47994809|NCT03322215|DRUG|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
48364912|NCT01473108|DRUG|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
48364913|NCT01473108|DRUG|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
48364914|NCT01473108|DRUG|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
48364915|NCT01473108|DRUG|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
47994810|NCT03322215|DRUG|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
48154114|NCT06426511|DRUG|Toripalimab+Chemotherapy|After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
48364916|NCT02486263|OTHER|Study Arm - acid suppression plus feeding bundle|"* Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds"
48364917|NCT02486263|OTHER|Conventional arm - acid suppression only|-Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
48364918|NCT02887508|BEHAVIORAL|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
48364919|NCT02887508|BEHAVIORAL|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
47994811|NCT03322215|DRUG|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
47994812|NCT03451877|GENETIC|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
47994813|NCT05572112|DEVICE|Venous access port implantation|Venous access port implantation
48511853|NCT05357066|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
48364920|NCT06336109|OTHER|Hypertonic saline knee and shoulder injection|"0.25 mL injection with hypertonic saline (7%) in the infrapatellar fat pad.~1.2 mL injection with hypertonic saline (7%) in the deltoid muscle."
48511854|NCT05357066|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
48511855|NCT01442688|DRUG|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
48511856|NCT01442688|DRUG|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
48511857|NCT03493256|OTHER|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
48511858|NCT00043810|PROCEDURE|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10\^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
48680905|NCT04074226|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
48680906|NCT02872870|BEHAVIORAL|auditory lexical decision task|
48680907|NCT02872870|DEVICE|electroencephalogram|
48680908|NCT06160596|GENETIC|Long term survival multimodal analysis|"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
48364921|NCT05423600|PROCEDURE|BES + TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
48364922|NCT05423600|PROCEDURE|Experimental: BES+sham TS|Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
48680909|NCT04149483|DRUG|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
48364923|NCT03219996|OTHER|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
48364924|NCT00003389|DRUG|Doxorubicin|given IV
48511859|NCT00043810|DRUG|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
47994814|NCT01984775|DRUG|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).
48364925|NCT00003389|DRUG|Bleomycin|given IV
48511860|NCT00043810|DRUG|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
48511861|NCT02735538|PROCEDURE|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
48680910|NCT04149483|DRUG|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
48680911|NCT05394506|PROCEDURE|Skin Biopsy|The skin biopsy is performed in the consultation outclinic room. A local anaesthetic (anaesthetic patch to be applied to the skin) is required for this procedure. The skin biopsy is usually performed on the front of the forearm (but can be performed on the arm, thigh or leg). After disinfection, a fragment of 3 to 4 mm in diameter is removed with a biopsy-punch (single-use device). If necessary, a suture can be placed. Otherwise, the wound is covered with Steristrip and a sterile dressing. The skin sample, intended for a fibroblast culture, will be placed in a flask to be kept at room temperature. It will be labelled with specific labels and sent to the local biological resource centre.
47994815|NCT01984775|DRUG|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
47994816|NCT01984775|DRUG|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
48364926|NCT00003389|DRUG|Vinblastine|given IV
48364927|NCT00003389|DRUG|Dacarbazine|given IV
48364928|NCT00003389|DRUG|Vincristine|given IV
48364929|NCT00003389|DRUG|Mechlorethamine|given IV
48364930|NCT00003389|DRUG|Etoposide|given IV
48364931|NCT00003389|DRUG|Prednisone|taken orally
48511862|NCT02735538|PROCEDURE|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
48511863|NCT02939625|DEVICE|muscle training|
48511864|NCT02939625|DEVICE|Continue Positive Airway Pressure|
48511865|NCT02939625|DEVICE|bilevel positive airway pressure|
48511866|NCT02668588|DRUG|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
47994817|NCT01984775|DRUG|Negative control|Negative control contains petrolatum.
48364932|NCT00003389|DRUG|Cyclophosphamide|given IV
48364933|NCT00003389|RADIATION|Radiotherapy|
48680912|NCT05394506|PROCEDURE|Muscle biopsy|The muscle biopsy is performed in a sterile room. A local anaesthetic is required for this procedure. After selecting the muscle from which the sample will be taken (usually from the deltoid muscle at the shoulder stump), placing a sterile field and disinfecting, a small incision is made in the skin until the selected muscle is exposed. A bundle of muscle fibres of approximately 1 cm x 0.5 cm is removed. The skin is then sutured and covered with a sterile dressing. The procedure takes about 30 minutes (including patient set-up). The muscle sample will be divided into 2 fragments, one for myoblast culture, the other for frozen tissue. The 2 vials will be labelled with specific labels and then sent to the local biological resource centre
48680913|NCT00731861|DRUG|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
48680914|NCT04219449|DIAGNOSTIC_TEST|PT|measuring PT drawn on citrated blood sample
48680915|NCT04219449|DIAGNOSTIC_TEST|Protein C|measuring protein C drawn on citrated blood sample
48680916|NCT04219449|DIAGNOSTIC_TEST|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
48680917|NCT02141165|DEVICE|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
48680918|NCT00711152|OTHER|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
48680919|NCT00711152|OTHER|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
48680920|NCT06270446|OTHER|Community based physiotherapy|Physiotherapy at community rehabilitation center
48680921|NCT06270446|OTHER|Outpatient physiotherapy|Physiotherapy at hospital
48364934|NCT04900961|OTHER|Resistance Exercise|The exercise regimens are generic and designed not to require expert physiotherapy input, therefore, the availability of NHS physiotherapists, which may be at times limited, will not be a barrier to implementation
48680922|NCT04895930|DRUG|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
48364935|NCT04000412|DEVICE|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
48364936|NCT04919889|OTHER|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
48364937|NCT03760562|DRUG|Glucocorticoids|Oral Glucocorticoids.
48364938|NCT03359382|OTHER|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
48364939|NCT06403605|DEVICE|Mirragen Wound Matrix|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
48364940|NCT06403605|DEVICE|Fibracol|"Offloading- patient will be offloaded in a diabetic CAM boot after treatment, or total contact cast if patient cannot be fit in a diabetic boot. Other names; pressure relief.~Additional outer dressing application-application of outer moisture retentive dressing, and a multilayer compression dressing. Other names; outer protective dressing.~Mirragen Wound Matrix-application of Mirragen to wound site along with standard of care treatment."
48680923|NCT04895930|DRUG|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
48680924|NCT03168893|DEVICE|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
48680925|NCT03168893|DEVICE|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
48680926|NCT03804242|BEHAVIORAL|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
48680927|NCT05039866|BIOLOGICAL|ST-920|No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
48680928|NCT01508910|BIOLOGICAL|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
48680929|NCT01508910|BIOLOGICAL|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
48680930|NCT01508910|OTHER|Standard of care|Standard of care for refractory angina
48680931|NCT04758286|PROCEDURE|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
48680932|NCT00017069|DRUG|arsenic trioxide|
48680933|NCT00017069|DRUG|dexamethasone|
48680934|NCT02353858|OTHER|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
48680935|NCT02353858|RADIATION|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
48680936|NCT02353858|DRUG|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
48680937|NCT00986791|OTHER|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
48680938|NCT03547908|DRUG|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
48680939|NCT03547908|DRUG|Placebo to match DTG|Tablet administered orally once daily, without regard to food
48680940|NCT03547908|DRUG|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
47994818|NCT06284226|DRUG|Allogeneic NK（CCT-ANK-11)|allogeneic natural killer cells
47994819|NCT01290666|DEVICE|Fistula Plug|Bioabsorbable fistula plug
47994820|NCT04834479|DEVICE|Ankle US and Ankle MRI|Ankle US and Ankle MRI
48511867|NCT02668588|DRUG|extended release of placebo|1 intramuscular injection of extended release of placebo
48511868|NCT06526624|DRUG|HS-20093|Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
48680941|NCT03547908|DRUG|DTG|50 mg tablet administered orally once daily, without regard to food
48680942|NCT03547908|DRUG|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
48680943|NCT03547908|DRUG|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
47994821|NCT05047081|BEHAVIORAL|Scoring Your College Goals Workshop|A two-hour virtual college readiness workshop.
47994822|NCT05047081|OTHER|Placebo|Placebo Treatment-As-Usual Group which does not receive the workshop intervention
47994823|NCT01296256|DRUG|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
47994824|NCT05921019|DEVICE|laser acupuncture|This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.
47994825|NCT05921019|DEVICE|sham laser acupuncture|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, Germany,and without any laser beam delivering
47994826|NCT05024500|OTHER|ARDSNet table|The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.
47994827|NCT05024500|OTHER|Driving Pressure|The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.
47994828|NCT05024500|OTHER|Electrical Impedance Tomography|The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
47994829|NCT04518254|BIOLOGICAL|Blood collection|A blood sample will be collected before and after treatment administration
47994830|NCT04518254|DRUG|L-Tyrosine 500 Mg|The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route
48680944|NCT04868305|PROCEDURE|Intramedullary nail|"Intertan nail (Smith \& Nephew)\* or Gamma 3 nail (Stryker)\*~\* All of the above-mentioned products are subjects to change into an equivalent product"
48680945|NCT04868305|PROCEDURE|Hip arthroplasty|"Total hip arthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~* Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)\*~Hemiarthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~  * All of the above-mentioned products are subjects to change into an equivalent product"
48680946|NCT01132703|DRUG|Glyburide for Injection|Administered as specified in the Treatment Arm.
48680947|NCT01132703|DRUG|Placebo|Administered as specified in the Treatment Arm.
48680948|NCT03235882|DIAGNOSTIC_TEST|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
48680949|NCT06512688|OTHER||This is a cross-sectional study without intervention.
48680950|NCT00390897|DRUG|Glivec|
48680951|NCT00390897|DRUG|Interferon|
48680952|NCT00120627|BEHAVIORAL|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
48680953|NCT00120627|OTHER|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
47994831|NCT04518254|DRUG|Placebo|The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
47994832|NCT04518254|BEHAVIORAL|Cognitive tasks|The participants will perform cognitive decision-making tasks: Simon task and masking task after treatment administration
47994833|NCT04518254|OTHER|Stress exposure|Unpleasant but not painful skin stimulations will be administered to the participants at variable intervals on the left leg during the cognitive tasks
47994834|NCT04518254|BEHAVIORAL|Anxiety scale|Spielberger's State Trait Anxiety Inventory (STAI) will be filled by the participants before and after cognitive tasks
47994835|NCT04518254|DEVICE|Electromyography (EMG)|Electromyography measurements will be performed during cognitive tasks.
47994836|NCT04518254|DEVICE|Electroencephalography (EEG)|Electroencephalography measurements will be performed during cognitive tasks.
47994837|NCT01210365|DRUG|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
47994838|NCT01210365|DRUG|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
47994839|NCT05963087|DRUG|Cetuximab Dabrafenib Tislelizumab|Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
47994840|NCT00721786|BEHAVIORAL|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
47994841|NCT04139707|DEVICE|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
47994842|NCT04139707|OTHER|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
47994843|NCT01220258|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
47994844|NCT03921931|OTHER|White light stimulation|Stimulation of the retina with white light
48364941|NCT02801487|RADIATION|Carbon ion radiotherapy (CIRT)|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
48364942|NCT02801487|DRUG|Cisplatin|Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
48364943|NCT06281171|OTHER|SkillTalk for Autistic Young Adults|A Microskills video training library on communication skills for autistic young adults.
48364944|NCT06281171|OTHER|Flyer Library|A collection of existing online resources on relationship skills
48364945|NCT05896605|DRUG|Azathioprine|Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
48364946|NCT05281146|DIETARY_SUPPLEMENT|Chickpeas and crushed peanuts fortified biscuit|This group received one daily pack of three fortified biscuits as snakes between breakfast and lunch on daily basis for four months. The chickpeas and crushed peanuts fortified biscuit consisted of wheat flour (extract 72%), Chickpea flour, crushed peanuts, wheat germ, Skimmed milk, corn oil, egg, sugar, Cinnamon, baking powder, salt, and vanilla.
48364947|NCT05281146|OTHER|Cognitive stimulation for the mothers|"I. Sessions for mothers~* Informing mothers about the most common causes of poor school achievement~* Clarification of mother's and family roles in improving student's cognitive abilities~* Defining cognitive functions needed for learning and school achievement~  o Attention, perceptive reasoning, memory, problem solving, proper use of language~* Identifying sensory functions necessary for the growth of cognitive functions~* Explaining factors that assist in academic excellence"
48364948|NCT05281146|OTHER|Cognitive stimulation for students|"* Activities to improve focus and visual attention~* Activities to improve visual memory~* Activities to improve vigilance and auditory attention~* Explaining types of memory Causes of weak memory Factors helping in improving memory Nutritional elements improving memory~* Training on skills of problem-solving"
48364949|NCT04226365|DRUG|Nortriptyline|10mg capsule Nortryptyline
48364950|NCT04226365|DRUG|Placebo|10mg capsule Thick-It filler
48364951|NCT00205010|PROCEDURE|Lymphoscintigraphy|
48364952|NCT00639600|PROCEDURE|human pancreatic islet transplantation|human pancreatic islet transplantation
48364953|NCT06172205|DRUG|intravenous FOLFOX7 plus Camrelizumab and apatinib|"Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
48511869|NCT02758639|BEHAVIORAL|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
47994845|NCT06114147|DEVICE|trans thoracic echocardiography measure|The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.
48511870|NCT05826535|DRUG|IMPT-314|CAR T-cell therapy
47994846|NCT06114147|DEVICE|ICON measure|The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.
47994847|NCT06114147|DEVICE|USCOM|Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
47994848|NCT06020560|DRUG|Dalteparin Prefilled Syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
47994849|NCT06020560|DRUG|Tinzaparin profiled syringe|Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
47994850|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) short burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the medial orbitofrontal regions over long periods of time.
47994851|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) long burst paradigm|The CBOT device is designed to stimulate intensive neural activity in the lateral orbitofrontal regions and networks over long periods of time.
47994852|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training plus beta caryophyllene (CBOT-Plus)|CBOT device enhanced with BCP.
48680954|NCT01637896|DEVICE|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
48680955|NCT01637896|DEVICE|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
48680956|NCT03949868|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
48680957|NCT03949868|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
48680958|NCT03949868|BEHAVIORAL|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
48680959|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
48680960|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
48680961|NCT04297150|DRUG|Apixaban|Drug indicated for the treatment of NVAF
48680962|NCT04297150|DRUG|Edoxaban|Drug indicated for the treatment of NVAF
48364954|NCT06172205|DRUG|HAIC-FOLFOX plus Camrelizumab and apatinib|"2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days"
48364955|NCT00186121|DRUG|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
48364956|NCT00186121|DRUG|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
48364957|NCT04141098|DEVICE|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
48364958|NCT05162495|DEVICE|BioStation T101 and TeraTube|Rapid detection of the novel SARS-CoV-2 (COVID-19) virus in breath samples.
48364959|NCT05588622|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
48364960|NCT04506606|PROCEDURE|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
48364961|NCT01074060|DRUG|plerixafor|Given IV
48680963|NCT04297150|DRUG|Rivaroxaban|Drug indicated for the treatment of NVAF
48680964|NCT04297150|DRUG|Dabigatran|Drug indicated for the treatment of NVAF
47994853|NCT06218407|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactory stimuli (i.e., not programmed for short or long burst), and without BCP enhancement.
48364962|NCT01074060|BIOLOGICAL|filgrastim|Given SC
48364963|NCT01074060|DRUG|cyclophosphamide|Given IV
48364964|NCT01074060|PROCEDURE|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
48511871|NCT06588296|DRUG|Ixekizumab|Administered SC
48511872|NCT06588296|DRUG|Tirzepatide|Administered SC
48511873|NCT04087434|DEVICE|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
48680965|NCT05219708|DIETARY_SUPPLEMENT|Calorie protein supplement|Participants assigned to the intervention group will receive the calorie and protein supplement (i.e. Ensure Original) to be consumed twice daily between meals for 30 days in addition to standard of care for heart failure
48680966|NCT05219708|OTHER|Control|Standard of care for heart failure
48680967|NCT00066612|DRUG|irinotecan hydrochloride|Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
48680968|NCT04644510|DEVICE|Lung ultrasonography|Standardized eight-point Lung ultrasonography
48680969|NCT06164522|OTHER|Abdominal ultrasound|Abdominal ultrasound to detect sliding sign
48680970|NCT06363474|PROCEDURE|Decompressive Craniectomy|Patients allocated to this arm will undergo decompressive craniectomy, which involves the surgical removal of a section of the skull (bone flap). This procedure is performed to alleviate intracranial pressure (ICP) by providing additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. After the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
48364965|NCT01074060|OTHER|laboratory biomarker analysis|Correlative studies
48364966|NCT06163144|OTHER|lab investigation|"Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.~\*Automated cell counters~* Advia 2120 8 difference~* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected."
48364967|NCT01766024|DRUG|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
47994854|NCT03273881|DRUG|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
47994855|NCT03273881|DRUG|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
47994856|NCT00918021|DRUG|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
47994857|NCT00918021|DRUG|placebo|placebo
47994858|NCT03197233|OTHER|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
47994859|NCT02293226|DEVICE|CoopDech|Video-laryngoscopy 1
47994860|NCT02293226|DEVICE|CoPilot|video-laryngoscopy 2
47994861|NCT02293226|DEVICE|Intubrite|Video-laryngoscopy 3
47994862|NCT02293226|DEVICE|Vividtrack|video-laryngoscopy 4
47994863|NCT03710655|DRUG|Apitox - pure honeybee toxin|Intradermal injection of 0.01 microliters
47994864|NCT03710655|DRUG|Placebo|Intradermal injection of 0.01 microliters
47994865|NCT06226779|BEHAVIORAL|Baduanjin exercsie|The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
47994866|NCT06226779|BEHAVIORAL|Brisk walking|The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
47994867|NCT06226779|BEHAVIORAL|Health education|Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
47994868|NCT02420691|OTHER|Laboratory Biomarker Analysis|Correlative studies
47994869|NCT02420691|OTHER|Pharmacological Study|Correlative studies
47994870|NCT02420691|DRUG|Ribociclib|Given PO
47994871|NCT03320564|DIAGNOSTIC_TEST|F-18 FDG PET|Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
47994872|NCT01757119|DRUG|Tardyferon 80 mg|Oral administration (2 tablets)
47994873|NCT05886296|BEHAVIORAL|Evaluation of the impact of a pre-surgical information session for people who must undergo shoulder rotator cuff surgery on empowerment for their functional rehabilitation process.|To evaluate the effect of the implementation of an information session for people who have to undergo rotator cuff surgery of the shoulder on the post-operative evolution of functionality, quality of life, empowerment and self-efficacy in the three months of the surgical intervention.
48680971|NCT06363474|PROCEDURE|Cisternostomy|Patients allocated to this arm will undergo cisternostomy, a microsurgical technique used in neurosurgery. Cisternostomy involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Following the procedure, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
48154115|NCT06426511|DRUG|Toripalimab+Chemotherapy followed by consolidation toripalimab|"After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles.~Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians."
48154116|NCT05450159|BEHAVIORAL|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
48154117|NCT05450159|BEHAVIORAL|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
48154118|NCT06032416|RADIATION|Preoperative CT Scan|Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
48154119|NCT04564222|DIETARY_SUPPLEMENT|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
48154120|NCT04564222|DIETARY_SUPPLEMENT|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
48154121|NCT06506578|RADIATION|Radiation|Radiation
48154126|NCT05256355|OTHER|musculoskeletal ultrasound|The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
48680972|NCT00889850|DRUG|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
48680973|NCT00889850|DRUG|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
48680974|NCT02776046|DRUG|High FiO2|High FiO2 with a perioperative open lung strategy
48680975|NCT02776046|DRUG|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
48680976|NCT00625586|BIOLOGICAL|RAV12|RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
48680977|NCT00625586|DRUG|Gemcitabine|1000 mg/m2 weekly, intravenously
48154127|NCT02602002|DRUG|Remifentanil|IV
48154128|NCT02602002|DRUG|Placebo|Placebo
48154129|NCT03276806|BEHAVIORAL|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
48154130|NCT03276806|BEHAVIORAL|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
48154131|NCT03276806|OTHER|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
48154132|NCT03276806|OTHER|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
48680978|NCT04546919|OTHER|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
48680979|NCT01158755|DRUG|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
48680980|NCT04009239|BEHAVIORAL|Time Restricted Feeding|Consuming energy during a short interval during the day
48680981|NCT01284959|DRUG|risperidone|risperidone 3mg, PO, 3 times
48680982|NCT01284959|DRUG|paliperidone ER|paliperidone ER 6mg, PO,3 times
48680983|NCT01284959|DRUG|placebo|lactose PO, 3times
48680984|NCT03123900|BEHAVIORAL|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
48680985|NCT03123900|BEHAVIORAL|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
48680986|NCT03123900|BEHAVIORAL|Combined training|Subjects included in this group receive both types of intervention.
48680987|NCT03084705|DEVICE|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
48680988|NCT01442337|DRUG|ASP8597|one time IV dose
48680989|NCT01442337|DRUG|Placebo|one time IV dose
48680990|NCT05619120|DRUG|Mexiletine|Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
48680991|NCT05619120|OTHER|Conventional therapy|Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
48680992|NCT00537160|BEHAVIORAL|Behavior modification, Nutrition Education, Exercise|
48680993|NCT01880190|OTHER|Ringer's Lactate|
48680994|NCT01880190|OTHER|HES 130/0.4 and Ringer's Lactate|
47994874|NCT05591014|DEVICE|Novel ROTEM interpretation software|Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
48154133|NCT04540952|DEVICE|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
47994875|NCT04903327|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
47994876|NCT04903327|DRUG|Placebo|Excipient solution
47994877|NCT04222569|PROCEDURE|T-piece|Spontaneous breath trial with a T-piece
47994878|NCT04222569|PROCEDURE|PSV 7 and PEEP 0|Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
48154134|NCT04540952|DEVICE|Standard Hysteroscopy Drape|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
48154135|NCT05670600|OTHER|foot and ankle exercise|"Foot and Ankle Exercise Phase~1. Pulling the foot upwards from the ankle~2. Bending the foot down from the ankle~3. Spreading the feet like a fan, moving the toes in and out to the right and left~4. Circle drawing exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)"
48511874|NCT05012826|OTHER|Osteopathic Manipulative Treatment in addition to Physiotherapy|Participants in this group will receive OMT in addition to the same interventions of PT group. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).
48511875|NCT05012826|OTHER|Physiotherapy|Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.
48511876|NCT06172634|DRUG|dentritic cell infusion and immunecheckpoint inhibitor|dentritic cell infusion and immunecheckpoint inhibitor
48511877|NCT04604795|DRUG|GSK3915393 Capsules|GSK3915393 capsules will be given orally.
48511878|NCT04604795|DRUG|GSK3915393 Solution for Infusion|GSK3915393 solution for infusion will be administered intravenously.
48511879|NCT04604795|DRUG|Placebo capsules|Placebo matching GSK3915393 capsules will be given orally.
48511880|NCT04604795|DRUG|Itraconazole|Participants will be administered with GSK3915393 along with ITZ orally
48511881|NCT04604795|OTHER|Water|Participants will be administered with GSK3915393 along with water orally
47994879|NCT04222569|PROCEDURE|PSV 0 and PEEP 0|Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
48154136|NCT06200818|PROCEDURE|Diode laser|
48680995|NCT02138812|DRUG|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
47994880|NCT01002833|BIOLOGICAL|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
48154137|NCT06200818|PROCEDURE|Er:CrYSGG|
48154138|NCT06200818|PROCEDURE|Formocresol|
47994881|NCT02990208|BEHAVIORAL|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens \& Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
48364968|NCT05205681|DIAGNOSTIC_TEST|Pre-operative imaging|Use of pre-operative imaging or the diagnosis of acute appendicitis
48364969|NCT06462391|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|Psychotherapy group (delivered virtually)
47994882|NCT02990208|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)
48364970|NCT03767309|PROCEDURE|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
47994883|NCT01756495|DRUG|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
47994884|NCT01756495|DRUG|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
47994885|NCT01756495|DRUG|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
48364971|NCT03767309|PROCEDURE|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
47994886|NCT01756495|DRUG|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
47994887|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
48154139|NCT05431543|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
48154140|NCT05431543|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
48154141|NCT05431543|DRUG|Vehicle proprietary ophthalmic solution|Proprietary Vehicle ophthalmic solution
48364972|NCT04881682|DEVICE|Immunoadsorption|see arm/group description
48364973|NCT04881682|BIOLOGICAL|Immunoglobulins|see arm/group description
48364974|NCT04850066|BEHAVIORAL|Equine-assisted intervention|Usual care including an equine-assisted intervention carried out on foot, next to the horse, in 3 sessions of 3 hours each, spread over 4 weeks. This program is based on self-awareness, communication, assertiveness and adaptability.
47994888|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
48154142|NCT04528368|BIOLOGICAL|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
48154143|NCT04874493|OTHER|Electronic Health Record Review|Review of medical records
48154144|NCT04874493|OTHER|Questionnaire Administration|Complete questionnaire
48154145|NCT04530721|OTHER|no intervention|we don't do any intervention
48154146|NCT00291928|DRUG|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
48154147|NCT00291928|DRUG|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
48154148|NCT00304278|DRUG|Erlotinib (Tarceva)|150 mg daily X 7 weeks
48154149|NCT00304278|DRUG|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
48154150|NCT00304278|RADIATION|Radiation Therapy (RAD)|5 days per week X 7 weeks
48364975|NCT05330728|OTHER|Suggestions for lifestyle changes+ Abdominal massage|Suggestions for lifestyle changes+ abdominal massage will be applied. Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Abdominal massage will be applied 3 times a week for 4 weeks.
48364976|NCT05330728|OTHER|Suggestions for lifestyle changes+ Kinesio taping|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once. Kinesio taping will be applied 3 times a week for 4 weeks.
48364977|NCT05330728|OTHER|Suggestions for lifestyle changes|Suggestions including regular and balanced diet, fluid consumption, regular walking and abdominal exercises and correct toilet habits will be given once.
48154151|NCT05134922|DRUG|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
48154152|NCT06415071|OTHER|No intervention|Exposures of interest would be clearly defined according to a specific research question and identified from the database
48154153|NCT06081972|DIETARY_SUPPLEMENT|Maltodextrin|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing placebo powder with a breakfast item on a daily basis.
48154154|NCT06081972|DIETARY_SUPPLEMENT|Chicory RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing chicory RG-I with a breakfast item on a daily basis.
48154155|NCT06081972|DIETARY_SUPPLEMENT|Carrot RG-I|During the feeding period (4 weeks) two capsules/ day will be administered to subjects randomized in this group containing carrot RG-I with a breakfast item on a daily basis.
48154156|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
48154157|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
48154158|NCT04536779|OTHER|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
48154159|NCT01668992|BEHAVIORAL|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
48154160|NCT00083473|DRUG|Pivanex|
47994889|NCT01988103|DRUG|Placebo|Placebo tablet BID for 16 weeks
47994890|NCT03754894|DEVICE|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
47994891|NCT03754894|PROCEDURE|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
47994892|NCT01068509|BIOLOGICAL|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
48154161|NCT05717725|PROCEDURE|Pulsed-field ablation|Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy
48154162|NCT05717725|PROCEDURE|Sham procedure|Patients will receive sham procedure, no ablation.
48364978|NCT03919682|OTHER|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
48364979|NCT03919682|OTHER|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
48364980|NCT04331314|DEVICE|Use of Symbios Bone Graft Material|Patients will receive Symbios Bone Graft Material according to randomization Group.
48364981|NCT04331314|DEVICE|Algipore Bone Substitution Material|Patients will receive Algipore Bone Substitution Material according to randomization Group.
48364982|NCT04434703|PROCEDURE|Platelet rich fibrin (PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 3000 rpm for 10 minutes then criss horizontal mattress suture will be applied to close the extraction wound
48364983|NCT04434703|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|following atraumatic extraction of the tooth using periotomes , 10 ml of patient's blood will be drawn by vein puncture of the antecubital vein and prepared in a centrifuge at 1300 rpm for 8 minutes then criss horizontal mattress suture will be applied to close the extraction wound
48364984|NCT04434703|PROCEDURE|blood clot|following atraumatic extraction of the tooth using periotomes, no bio-addative will be added and criss horizontal mattress suture will be applied to close the extraction wound
47994893|NCT01808430|PROCEDURE|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
47994894|NCT01816893|OTHER|Hypoglycemic hyperinsulinemic clamp|
47994895|NCT01816893|OTHER|Euglycemic hyperinsulinemic clamp|
47994896|NCT03760146|BIOLOGICAL|20vPnC|20vPnC
47994897|NCT03760146|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
47994898|NCT03760146|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
47994899|NCT03760146|OTHER|Saline|Placebo
47994900|NCT04139967|RADIATION|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
47994901|NCT05959239|DRUG|TB006|TB006 will be provided as single-use injectable glass vials.
47994902|NCT04846803|BIOLOGICAL|ABU bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)
47994903|NCT04846803|BIOLOGICAL|Saline bladder lavage|Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
48154163|NCT00001280|DRUG|itraconazole|
48154164|NCT02933645|DRUG|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
48154165|NCT02933645|DRUG|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
48154166|NCT02933645|RADIATION|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
48154167|NCT02933645|DRUG|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
48154168|NCT01852851|BEHAVIORAL|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
48154169|NCT06351397|BEHAVIORAL|Mixed Reality (MR)|"Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario"
48154170|NCT00087516|DRUG|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
48154171|NCT00087516|DRUG|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
48154172|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
48154173|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
48154174|NCT00087516|DRUG|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
48154175|NCT01072058|DRUG|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
48154176|NCT04026555|OTHER|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
48154177|NCT04026555|OTHER|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
48154178|NCT02092285|DRUG|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
48364985|NCT02062749|DRUG|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
48154179|NCT06431360|OTHER|hyperthermia|hyperthermia (using a heater, 44℃for 15 min)
48154180|NCT03293147|OTHER|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
48154181|NCT03293147|OTHER|Standard care|Standard care for hypertensive patients
48154182|NCT04728347|BIOLOGICAL|ARCT-021|ARCT-021 single dose
48154183|NCT00908193|DEVICE|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
48154184|NCT00908193|PROCEDURE|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
48154185|NCT03933735|DRUG|TNB-383B|Intravenous (IV) Injection
48154186|NCT04288414|DIAGNOSTIC_TEST|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
48154187|NCT03474978|DEVICE|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
48154188|NCT03473275|DIAGNOSTIC_TEST|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
48154189|NCT03473275|DIAGNOSTIC_TEST|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
48364986|NCT06227429|DRUG|Nitisinone|According to prescription
48364987|NCT03449342|DRUG|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
48364988|NCT02445768|OTHER|Cognitive multisensory rehabilitation|
48511882|NCT04604795|OTHER|Grape fruit juice|Participants will be administered with GSK3915393 along with GFJ orally
48511883|NCT04621019|DEVICE|BTL-785F|Treatment with study device.
48511884|NCT04639804|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
48511885|NCT04639804|DRUG|Naproxen|Naproxen 500 mg tablet
48511886|NCT04639804|DRUG|Aceclofenac|Aceclofenac 100 mg tablet
48511887|NCT04639804|DRUG|Celecoxib|Celecoxib 200 mg capsule
48154190|NCT05149976|DIAGNOSTIC_TEST|Voice recording before and after dietary intake|"* A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test."
48154191|NCT00370747|DRUG|Ecabet|ophthalmic solution 2.83%
48154192|NCT00370747|DRUG|Ecabet|ophthalmic solution 3.70%
48154193|NCT00370747|DRUG|Placebo|
48154194|NCT06079047|PROCEDURE|group Dexamethasone|Adductor canal block with dexamethasone
48154195|NCT06079047|PROCEDURE|group Controle|Adductor canal block with saline solution
48364989|NCT05730049|DEVICE|Transcutaneous auricular vagus nerve stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA(3). Pulse width will be set at 100μs and frequency will be set at 25Hz as performed in a previous protocol in stroke patients(3). The control group will receive the same stimulation parameters but will have the earpiece placed in the sham position such that stimulation is applied to the earlobe and does not activate the vagus nerve(4).
48364990|NCT00724243|DRUG|Infliximab|Infliximab given in accordance with the local summary of product characteristics
48364991|NCT00365872|BIOLOGICAL|Dendritic Cell (DC) Injections|"* DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
48364992|NCT00365872|PROCEDURE|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
48364993|NCT00365872|PROCEDURE|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
48680996|NCT02138812|DRUG|Paclitaxel|75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
47994904|NCT01140321|DRUG|Neridronate|"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
48154196|NCT00703365|DRUG|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
48154197|NCT05802498|DEVICE|IRMA|For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
48154198|NCT05618509|DEVICE|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
48154199|NCT05618509|OTHER|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
48154200|NCT05618509|OTHER|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
48154201|NCT05618509|DEVICE|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
48154202|NCT00267956|DRUG|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
48154203|NCT00267956|DRUG|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
48154204|NCT03672188|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
48154205|NCT03672188|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
48154206|NCT00538629|OTHER|no intervention|no intervention
48154207|NCT00538629|OTHER|no intervention|no intervention
48154208|NCT06291935|DRUG|VG901|"Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)"
48154209|NCT00328120|DRUG|Fulvestrant|500 mg intramuscular injection
48154210|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (60 perturbations)|The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
48154211|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (150 perturbations)|The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
48154212|NCT02854657|BEHAVIORAL|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
48154213|NCT06500117|OTHER|eMind application|learning phase accompanied by application for 8 weeks, then independent practical application phases
48154214|NCT06500117|OTHER|questionnaires|"Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F"
48154215|NCT06500117|OTHER|focus groupe|Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
48154216|NCT02054000|DRUG|Tirofiban|Intracoronary administering of Tirofiban
48154217|NCT02054000|OTHER|Placebo|Intracoronary serum physiologic
48154218|NCT05293379|OTHER|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
48154219|NCT03460132|DEVICE|Tomas® Anchorage System - DENTAURUM|self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
48154220|NCT05363839|DRUG|ACH-000029|ACH-000029 will be administered orally via a capsule.
48154221|NCT05363839|DRUG|Placebo|Placebo will be administered orally via a capsule.
48154222|NCT02531061|DEVICE|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
48154223|NCT02814461|DRUG|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
48154224|NCT02814461|RADIATION|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
48154225|NCT00003732|DRUG|carboplatin|
48154226|NCT00003732|DRUG|paclitaxel|
48154227|NCT00003732|DRUG|topotecan hydrochloride|
48154228|NCT03358485|DRUG|Aolanti Weikang tablets|Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
48154229|NCT03358485|OTHER|Placebo|Placebo
48154230|NCT02112799|DRUG|NVR 3-778|
48154231|NCT02112799|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
48154232|NCT02112799|DRUG|Pegasys|
48154233|NCT03852485|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
48154234|NCT05147545|OTHER|Moderate intensity physical effort|Pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer
48154235|NCT05147545|OTHER|Low intensity physical effort|Pedaling 3 minutes at the 30 Watt level of the ergometer
48154236|NCT05147545|OTHER|Hyperlipidic meal|Eating an hyperlipidic meal 60 minutes after a physical effort
48154237|NCT05147545|DIAGNOSTIC_TEST|Measure of circulating DNA|"Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort."
48154238|NCT00376935|DRUG|Palifermin|Keratinocyte growth factor administered via injection
48154239|NCT00376935|DRUG|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
48154240|NCT03317509|PROCEDURE|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
48154241|NCT04512456|BEHAVIORAL|Exercise training|Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
48154242|NCT04566276|BIOLOGICAL|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
48154243|NCT04566276|OTHER|Placebo|Saline
48154244|NCT00293085|DRUG|Docetaxel|
48154245|NCT00293085|DRUG|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
48154246|NCT00002723|DRUG|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
48154247|NCT00002723|DRUG|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
48154248|NCT00002723|DRUG|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
48154249|NCT02275806|DRUG|Irinotecan|
48154250|NCT02275806|DRUG|Cisplatin|
48154251|NCT05286242|BIOLOGICAL|COVID19 vaccine|All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
48154252|NCT04360928|DEVICE|Graymont X ERIS Knee Splint|Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.
48154253|NCT04360928|DEVICE|Standard Hinge Knee Brace|Standard knee brace used postoperatively after ACL reconstruction.
48154254|NCT06480500|DRUG|Ketamine hydrochloride|55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
48154255|NCT06480500|BEHAVIORAL|i-CBT (Internet-based Cognitive Behavioural Therapy)|Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
48154256|NCT06480500|DRUG|Midazolam Hydrochloride|55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.
48154257|NCT05256758|DRUG|Fenofibrate Capsules|49 patients randomised to receive fenofibrate for 6 months.
48154258|NCT05256758|DRUG|Placental Lactogen|13 patients randomised to receive placebo for 6 months.
48154259|NCT03366727|DEVICE|drug-coated balloon catheter （Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
48154260|NCT03366727|DEVICE|plain balloon catheter (Admiral, medtronic)|After predilation, using plain balloon catheter to cover the whole treated segment
48154261|NCT04685434|OTHER|Shriners Hospital for Children Upper Extremity Evaluation|The interventions are evaluating tools for the functional performance of the upper extremity.
48154262|NCT02259959|DRUG|Single rising doses of BI 1744 CL, solution for oral inhalation|
48154263|NCT02259959|DRUG|Tiotropium, fixed dose, solution for oral inhalation|
48154264|NCT02259959|DRUG|Placebo|
48154265|NCT00957918|DRUG|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
48154266|NCT00957918|OTHER|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
48154267|NCT03932253|OTHER|FCN-159|Administered orally once a day
48154268|NCT01657552|DRUG|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
48154269|NCT01657552|DRUG|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
48154270|NCT01657552|DRUG|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
48154271|NCT05534854|GENETIC|Gene test|Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
48154272|NCT02655536|DRUG|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
48154273|NCT02655536|DRUG|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
48154274|NCT05365230|OTHER|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
48154275|NCT05365230|OTHER|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
48154276|NCT03639194|DRUG|ABBV-011|Intravenous
48154277|NCT03639194|DRUG|Budigalimab|Intravenous
48154278|NCT05788536|GENETIC|DB-OTO|"DB-OTO will be administered as a single intracochlear injection into one ear (Part A).~* LD Cohort (starting dose)~* HD Cohort (high dose)"
48364994|NCT03559595|BEHAVIORAL|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
48364995|NCT01488227|DIETARY_SUPPLEMENT|Vitamin D|4000 IU of Vitamin D daily for 6 months
48511888|NCT06155695|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be administered using the Starstim system. We will use the freely available Simulation of Non-Invasive Brain Stimulation (SimNIBS) software to optimally target the rVLPFC and left TPJ in each subject. Finite element models will be generated using T1 and T2 scans. We will generate multiple models to maximize on-target stimulation and minimize off-target stimulation, as determined by ratio of the summed current density within and beyond target regions of interest (ROIs). tDCS current in the active stimulation condition will be maintained at 2.0 milliamps (mA) for the first 45 minutes of each one-hour training session. Sham stimulation the same current, only the current will be ramped down to 0 mA after 30 seconds. Our previous research has shown this method to produce indistinguishable skin sensation. During tDCS, patients will be monitored for possible negative side effects.
47994905|NCT06092099|DEVICE|TENA SmartCare Change Indicator|The TENA SmartCare Change Indicator is an accessory to absorbent incontinence products, intended for use on individual(s) with urinary incontinence who are dependent on one or more caregivers to change the absorbent incontinence product. The TENA SmartCare Change Indicator estimates the degree of urine saturation in the absorbent incontinence product and notifies the caregivers. This facilitates the caregiver's decision regarding when to change the absorbent incontinence product. As the current study is needed to validate the updated device, the full system will not be used, only the sensor part.
47994906|NCT03725007|DRUG|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
47994907|NCT04828889|DEVICE|Anal dilators|Anal sphincter training for relaxation
47994908|NCT04828889|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy is a firmly established method for treating anal fissures.
47994909|NCT02086864|DRUG|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
47994910|NCT02086864|DRUG|Placebo lactose/sucrose pill|
47994911|NCT02086864|BEHAVIORAL|Homeopathic consultation|
47994912|NCT00155337|PROCEDURE|photodynamic therapy|
47994913|NCT04662801|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will receive twelve weeks of BWL treatment.
47994914|NCT04662801|BEHAVIORAL|Early Responder: BWL continued|Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
47994915|NCT04662801|COMBINATION_PRODUCT|Early Non-responder: BWL continued with medication added|Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.
47994916|NCT00178035|DRUG|paroxetine|
47994917|NCT00178035|BEHAVIORAL|One night of Total Sleep Deprivation|
47994918|NCT05945277|BEHAVIORAL|Critical Time Intervention - Peer Support|CTI-PS is a time-limited, 9-month long intervention, provided at the critical time when a person is discharged from an inpatient psychiatric treatment facility.
47994919|NCT04552587|BEHAVIORAL|Heart APP|The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
47994920|NCT03921697|DEVICE|Werable sensors|Parkinson Disease Patients monitored by werable sensors
48154279|NCT05788536|GENETIC|DB-OTO|DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
48154280|NCT00814554|BEHAVIORAL|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
48364996|NCT01488227|DIETARY_SUPPLEMENT|Placebo|Acts as a control for the Vitamin D intervention
48364997|NCT01970384|DEVICE|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
48364998|NCT01970384|DEVICE|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
47994921|NCT03030573|PROCEDURE|Reconstruction of the bile duct with the round ligament|In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
47994922|NCT05449054|PROCEDURE|Anterior colporrhaphy|All patients will be operated by the vaginal route. They are prepared under strict aseptic conditions in the dorsal lithotomy position. The bladder is emptied preoperatively with a thin disposable catheter and antibiotic prophylaxis (cefazolin) is administered before incision. A vasoconstricting solution (combination of vasopression and NaCl) is administered and a vertical anterior vaginal incision is made from the apex to two centimeters short of the external urethral meatus using an electric cautery or a scalpel. The vaginal epithelium is grasped on both sides and the fibromuscular layer of the anterior vaginal wall is sharply dissected laterally to the inferior pubic ramus. The bladder is completely dissected from the apex and up to 4 to 6 cm from the pubic ramus. The anterior colporrhaphy is defined as a native tissue repair and rows of absorbable sutures (2/0 vicryl) are used.
47994923|NCT05863637|OTHER|Intensive Short-Term Dynamic Psychotherapy|A dynamic and intensive psychotherapy with eight therapeutic sessions
47994924|NCT03987061|DEVICE|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
47994925|NCT01357265|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
47994926|NCT01242956|BEHAVIORAL|verum group|video-based training after stroke
47994927|NCT01242956|BEHAVIORAL|Placebo group|non-video group
47994928|NCT03745092|DEVICE|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
47994929|NCT03745092|DEVICE|room air|The patient had a rest with lying, sitting or walking, did not performed with NBO intervention.
47994930|NCT03149692|OTHER|Penile allograft transplantation|Proof of concept of surgical procedure
47994931|NCT04076735|PROCEDURE|Distal femoral replacement|The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
47994932|NCT04076735|PROCEDURE|Surgical Fixation (ORIF)|A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
47994933|NCT05793528|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone. The injection site is cleaned with povidone-iodine 3 times and a sterile drape was applied. Short-acting local anesthesia (3 mL of 2% prilocaine) is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is inserted just below the pedicle. It is advanced into the subpedicular space using the coaxial technique under the intermittent guidance of fluoroscopy. The needle position is confirmed through a lateral view. Using lateral views, the needle is placed at the posterior one-third of the foramen. Using the anteroposterior view, one to 2 mL of the contrast agent (300 mg/50 mL iohexol) is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 8 mg (two mL) of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
47994934|NCT05793528|PROCEDURE|Ultrasound Guided Transforaminal Epidural Steroid Injection|The patients are positioned prone placed. Following the provision of aseptic conditions, the spinous process of the vertebral midline is visualized using a low-frequency convex ultrasound probe. The lateral edge of the relevant vertebral lamina is visualized by sonographic scanning in the horizontal plane. Local anesthesia is applied to the skin and subcutaneous tissue. A 3.5-inch, 22-gauge spinal needle is advanced to the lateral edge of the relevant vertebral lamina under ultrasound image guidance. Then, anteroposterior imaging is performed with fluoroscopy to confirm needle localization when the lamina margin is reached, and the needle is guided into the foramen under the guidance of fluoroscopy. The contrast agent is given and the distribution pattern is visualized. Once the epidural distribution of the contrast agent is confirmed without vascular flow, a mixture of 2 mL of dexamethasone, 1 mL of physiological saline, and 1 mL (0.5%) of bupivacaine hydrochloride is injected.
47994935|NCT01334723|DRUG|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
48364999|NCT04033328|DRUG|ORIC-101|ORIC-101 once daily in each 28-day cycle
48365000|NCT04033328|DRUG|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
48154281|NCT00814554|BEHAVIORAL|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
48154282|NCT00814554|OTHER|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
48154283|NCT05835856|DEVICE|Virtual coach with NAO robot|The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
48154284|NCT05835856|DEVICE|Virtual coach with Google Nest Hub (2e generation) group|The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
48154285|NCT05835856|DEVICE|Virtual coach with Gatebox device|The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.
48154286|NCT05835856|DEVICE|virtual coach with CelesTE robot|"The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers."
48680997|NCT00854789|BIOLOGICAL|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
48680998|NCT05672368|DEVICE|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
48680999|NCT02458872|BEHAVIORAL|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
48154287|NCT05835856|OTHER|booklet|Participant in the control group will receive a booklet containing information and activities on well-being
48154288|NCT03219788|DRUG|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
48154289|NCT03219788|DRUG|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
48154290|NCT03219788|DRUG|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
48154291|NCT04282863|PROCEDURE|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
48154292|NCT04282863|PROCEDURE|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
48365001|NCT05899127|DRUG|Lidocaine|1.5mg/kg induction，1.5 mg/kg/h maintenance
48681000|NCT03216720|PROCEDURE|CABG|"* Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds"
48154293|NCT06212180|DEVICE|mask|patients will be their own comparator. Patients will try both mask for 10 min and then decide which mask they want for the rest of the ventilation
48154294|NCT01493388|DRUG|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
48154295|NCT03463122|DEVICE|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
48154296|NCT03463122|OTHER|conventional therapy|conventional therapy for stroke rehabilitation
48154297|NCT02240836|OTHER|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
48154298|NCT04642495|DIAGNOSTIC_TEST|"Visual acuity testing with SW , Landolt-C and Tumbling-E symbols"|Establish prediction intervals for acuity tests
48154299|NCT05554991|DIETARY_SUPPLEMENT|HMO|Composition comprising of HMO
48154300|NCT05554991|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation having the same appearance and dosing regimen as the intervention
48154301|NCT05554991|BEHAVIORAL|Parental reassurance and support|Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
48154302|NCT06027216|DEVICE|Multiplexing Prism|"Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye."
48681001|NCT03216720|PROCEDURE|Miniaturized extracorporeal circulation|"* Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism"
48681002|NCT03216720|PROCEDURE|Conventional extracorporeal circulation|"* Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia"
48681003|NCT05325762|DRUG|Propofol|At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
48681004|NCT05325762|DRUG|Dexmedetomidine|Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
48681005|NCT05325762|DRUG|Saline|At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
47994936|NCT01334723|DRUG|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
47994937|NCT06496009|DRUG|PD-1 Inhibitors|advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
47994938|NCT00437593|PROCEDURE|ppVE, MP, ICG|surgery with ILM staining
47994939|NCT00437593|PROCEDURE|ppVE, MP, MB|Surgery with ERM staining
47994940|NCT04739007|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation (VA-ECMO)|VA-ECMO used for resuscitation after cardiac arrest
47994941|NCT04739007|DEVICE|Electrical Impedance Tomography (EIT)|EIT used to demonstrate ventilation and perfusion distribution in intubated patients on VA-ECMO
47994942|NCT02380664|DEVICE|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
47994943|NCT02380664|BEHAVIORAL|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
47994944|NCT05524181|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
47994945|NCT00199355|DRUG|Istradefylline (KW-6002)|
48154303|NCT05795309|DEVICE|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
48154304|NCT02379078|OTHER|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
48154305|NCT02379078|OTHER|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
48681006|NCT02895178|BEHAVIORAL|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
48681007|NCT06231706|OTHER|Prebiotic-like nut and seed mix|A mixture of nuts, seeds and other plant based ingredients.
48681008|NCT06231706|OTHER|Bread Crouton|A commercially available bread crouton product.
47994946|NCT03642392|OTHER|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
47994947|NCT06271252|DRUG|OriCAR-017|Anti-GPRC5D CAR-T cell product
47994948|NCT02641769|BIOLOGICAL|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
47994949|NCT05150353|PROCEDURE|MRI|Wrist MRI
47994951|NCT00735774|DRUG|11C-ORM-13070|Single dose of i.v. solution
48154306|NCT02379078|OTHER|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
48681009|NCT06231706|DIETARY_SUPPLEMENT|Probiotic capsule|Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule.
48681010|NCT06231706|OTHER|White bread and low fat spread|Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
48681011|NCT00244868|OTHER|counseling intervention|
48681012|NCT00244868|OTHER|educational intervention|
48365002|NCT05899127|DRUG|0.9%NaCl|2mg/kg induction，1.5 mg/kg/h maintenance
48681013|NCT02484443|BIOLOGICAL|Dinutuximab|Given IV
47994952|NCT03830554|OTHER|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
47994953|NCT04404647|PROCEDURE|Irreversible electroporation|The IRE procedure will be carried out as ultrasound guided technique either percutaneously or during laparotomy. Needle spacing and electrical pulse delivery will be performed in a standardized way.
47994954|NCT05814367|DRUG|Blink® Tears eye drops in a multidose bottle|Control
47994955|NCT05814367|DRUG|Preservative-free investigational lubricating eye drops in a Novelia® eyedropper|Test
47994956|NCT00012142|DRUG|temsirolimus|
48154307|NCT01086514|PROCEDURE|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
48154308|NCT06327997|BIOLOGICAL|Fast CAR T cells|This study designed three dose groups, each with a dosage of 5.0 × 10\^5/kg、1.0×10\^6/kg、5.0×10\^6/kg
48154309|NCT04035733|DRUG|rVA576|BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
48154310|NCT02525744|DRUG|LY900014|Administered SC
48154311|NCT02525744|DRUG|Insulin Lispro (Humalog)|Administered SC
48154312|NCT04179799|DEVICE|Diaphragm Pacing|"Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller."
48154313|NCT03602547|DRUG|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
48154314|NCT04362111|DRUG|Anakinra|The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
48681014|NCT02484443|OTHER|Laboratory Biomarker Analysis|Correlative studies
48681015|NCT02484443|OTHER|Pharmacological Study|Correlative studies
48154315|NCT04362111|DRUG|Normal saline|The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
48365003|NCT00425165|DRUG|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
48365004|NCT05582382|OTHER|logistic regression of known prognostic markers of severity of COVID19|"An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \& ALKA and compared with the currently proposed clinical risk assessment scoring system~The utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:~1. Hospital admission on the first encounter to ED~2. Admission to ICU for the duration of the COVID-19 hospitalization~3. In hospital and out of hospital mortality~4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)"
48365005|NCT00783822|OTHER|RGCT|rapid genetic counseling and testing
48365006|NCT03730987|BEHAVIORAL|HoMBReS intervention|Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
48681016|NCT02484443|BIOLOGICAL|Sargramostim|Given SC
48681017|NCT02052869|PROCEDURE|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
48681018|NCT00331877|PROCEDURE|family conference with bereavement information leaflet|
48681019|NCT01144325|PROCEDURE|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
48681020|NCT05006976|OTHER|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
48681021|NCT05006976|OTHER|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
48681022|NCT04887194|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
48681023|NCT04887194|DRUG|Warfarin|CYP2C9 probe substrate
48681024|NCT04887194|DRUG|Dextromethorphan|CYP2D6 probe substrate
48681025|NCT04887194|DRUG|Midazolam|CYP3A4 probe substrate
47994957|NCT05972499|OTHER|task-oriented training with pretend play|"Pretend play: Children engage in pretend play by acting out themes, taking on roles, assigning attributes to inanimate objects, and using objects as if they were something else Props will be added to hold the child interest. Role play costumes, or occupation props (police officer's suit), stimulate pretending elements.~Task-oriented training: It is involving the active, repetitive practice of functional activities to learn or relearn a motor skill. Training implies that the behavioral experiences are not just repetition of the same sensorimotor skill but involves progressive challenges to a participant's capabilities and involves tasks that are meaningful to the participant. It is based on the following principles: functional goal-directed training focus on practicing specific activities of importance to the child during daily activities; planning activity-focused interventions by adapting knowledge of motor learning ; and allowing for the interest and participation of the children."
47994958|NCT02206555|DRUG|emtricitabine/tenofovir disoproxil fumarate|
47994959|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
47994960|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
47994961|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
47994962|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
47994963|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
48154316|NCT04562714|DEVICE|FreeStyle Libre Flash Glucose Monitor|The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
48154317|NCT04562714|OTHER|Diabetes self-management education|"The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."
48154318|NCT00234299|DRUG|Aspirin|325mg, one tablet orally, six months
48154319|NCT00234299|DRUG|Placebo|325mg, one tablet orally every day, 6 months
48681026|NCT04887194|DRUG|Digoxin|P-gp probe substrate
48681027|NCT04887194|DRUG|Rosuvastatin|BCRP probe substrate
48154320|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
48154321|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
48154322|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
48154323|NCT02556606|DRUG|Midazolam|single 40 min infusion of MID 0.03mg/Kg
48681028|NCT04887194|DRUG|Nivolumab|Nivolumab is a programmed death receptor (PD-1) blocking antibody
48681029|NCT03864146|BEHAVIORAL|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
48681030|NCT01484652|DRUG|COV795|2 tablets taken every 12 hours
48681031|NCT01484652|DRUG|Placebo|2 tablets taken every 12 hours
48681032|NCT02345655|PROCEDURE|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
48681033|NCT02345655|OTHER|no test|normal procedure decided by the general practitioner
48681034|NCT05045859|BEHAVIORAL|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
47994964|NCT00817895|DRUG|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
47994965|NCT00817895|DRUG|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
48154324|NCT03939871|DRUG|fluvestrant + oral vinorelbine|Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
48154325|NCT05450822|DRUG|Levetiracetam|"Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models."
48154326|NCT05450822|DRUG|Levetiracetam Tablets|Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
48154327|NCT05450822|DRUG|Lamotrigine tablet|Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
48681035|NCT04463537|PROCEDURE|Body Temperature Measurements|"measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form."
48154328|NCT05881161|BEHAVIORAL|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
48154329|NCT05881161|BEHAVIORAL|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
48154330|NCT02857686|PROCEDURE|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
48154331|NCT02857686|PROCEDURE|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
48154332|NCT04932083|DRUG|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
48154333|NCT04932083|DRUG|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
48154334|NCT04932083|DRUG|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
48154335|NCT04932083|DRUG|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
48154336|NCT01093976|DRUG|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
48154337|NCT05166317|OTHER|This is an observational study|This is an observational study
48154338|NCT04295499|DEVICE|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
48154339|NCT00338325|BEHAVIORAL|Reading program|Reading of children's story/picture books preoperatively
48154340|NCT06261515|PROCEDURE|Active periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets; periodontal surgery if needed (residual probing pocket depths ≥ 6 mm).
48154341|NCT02747056|OTHER|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
48154342|NCT02747056|OTHER|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
48154343|NCT02747056|OTHER|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
48154344|NCT02489799|BEHAVIORAL|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
48154345|NCT02489799|BEHAVIORAL|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
48681036|NCT02811120|OTHER|venepuncture only|single venepuncture
48154346|NCT01807845|DIETARY_SUPPLEMENT|enriched skimmilk with VD|enriched skimmilk with VD
48154347|NCT01807845|DIETARY_SUPPLEMENT|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
48154348|NCT01807845|DIETARY_SUPPLEMENT|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
48154349|NCT04878861|BEHAVIORAL|Training in the blind field|Participants will complete visual training at two locations in the blind field. These two locations of training will be determined at the baseline study visit (0 months) and will be located within the perimetry-defined blind field. The training programme involves discriminating the direction of motion in a small circle of moving dots. The computer software and a chin-rest will be loaned to each participant to complete training at home. Participants will perform 300 trials at each location in their blind field, 5 days a week for at least 24 weeks (40-60 minutes in total). The computer programme will automatically generate a record of participant performance after each home training session.
48154350|NCT06286319|DEVICE|Angel Cooler|Device that provides cooled oxygen (between 4-8°C) directly to the lung airways along with external cooling to lung surfaces using cold preservation solutions.
48154351|NCT03792945|DRUG|local injection|In addition to the local injection, carpal tunnel brace will be given.
48154352|NCT03792945|DEVICE|extracorporeal shock wave therapy|In addition to all ESWT participants, carpal tunnel brace will be given.
48154353|NCT05071105|RADIATION|Stereotactic Body Radiation Therapy|In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.
48154354|NCT02289885|DEVICE|SonoScape|Ultrasonography device
48154355|NCT03145142|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
48154356|NCT03145142|PROCEDURE|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
48154357|NCT04802954|OTHER|Video acquisition|One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
48154358|NCT01844063|GENETIC|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
48154359|NCT01844063|GENETIC|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
48154360|NCT01844063|DRUG|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
48154361|NCT03554200|DRUG|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
48154362|NCT03554200|DRUG|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
47994966|NCT00817895|PROCEDURE|TACE|All patients will accept TACE one month after tumor was resected.
47994967|NCT05876273|DEVICE|Neural-net Artificial Pancreas|NAP is a neural-net implementation of the previously tested UMPC algorithm (below).
47994968|NCT05876273|DEVICE|University of Virginia Model Predictive Control|A previously tested artificial pancreas control algorithm, based on a differential-equation model of the human metabolic system in diabetes.
48154363|NCT01072734|DRUG|Vaccine|Influenza vaccine
48154364|NCT04999722|BEHAVIORAL|Traditional mode of management|Traditional model management of Diabetes Mellitus patients
48154365|NCT04999722|BEHAVIORAL|Mobile APP management|Management of diabetic patients with mobile phone APP
48154366|NCT04745338|DEVICE|3max cool shaping device|cryolipolysis sessions are applied on abdomen area each session for 40 min. each
48154367|NCT04745338|DIETARY_SUPPLEMENT|low calolric diet|low caloric diet (1200cal/day)
48154368|NCT01458288|DRUG|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
48154369|NCT05658484|DRUG|Dimethyl fumarate|Administered as specified in the treatment arm.
48154370|NCT04916847|OTHER|blood collection|"Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~1. Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~2. Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~3. SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay."
48154371|NCT06458296|OTHER|Control Group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
48154372|NCT06458296|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
48154373|NCT02297945|DRUG|metyrapone|Single arm study
48154374|NCT06388889|DRUG|Dexpramipexole Dihydrochloride|Oral administration of dexpramipexole tablet
48154375|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
48681037|NCT03837990|DRUG|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
48154376|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 18F-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
48154377|NCT03593798|OTHER|Lifestyle|Lifestyle intervention an effect on weight and physical capacity
48154378|NCT03240471|PROCEDURE|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
48154379|NCT03240471|PROCEDURE|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
48154380|NCT00755794|DRUG|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
48154381|NCT02468882|DIETARY_SUPPLEMENT|Watercress|100g of watercress daily during radiation therapy
48681038|NCT02810795|OTHER|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
47994969|NCT05738941|PROCEDURE|radiofrequency ablation|17-G length-adjustable electrode (RITA RF Electrode;) a 200-W RF generator is going to be used,under CT fluoroscopic guidance. The type of the electrode and the length of the active tip will be selected according to the size, location, and shape of the tumor, as well as the operator preference.ablation will be performed with 100 W energy for 30 seconds. The number of electrodes placed, ablation time per electrode, total ablation time, and total energy delivered to targets, as well as the temperature of the lesions, will be recorded. For lesions less than 3 cm, surgery was performed with one electrode , and for lesions of 3 cm or more, two or more electrodes were used . The procedure may be followed by injection of bone cement through the same working cannula, and a long working time will be delivered (STABILIT, Merit Medical Systems, Inc.) for the optimal filling of the bone lesion
48154382|NCT05185674|OTHER|Exposure: Coronavirus disease 2019 (COVID-19)|Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
48154383|NCT05459974|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
48154384|NCT05459974|DRUG|Placebo|Placebo pill once daily for 30 days after the atrial fibrillation ablation
48681039|NCT00329576|BIOLOGICAL|Hepatitis B vaccine|
48681040|NCT02163577|BIOLOGICAL|burosumab|solution for SC injection
48688184|NCT06422325|DEVICE|MPC closed-loop system in insulin/pramlintide mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.
48688185|NCT04224441|DRUG|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
48688186|NCT04852055|BEHAVIORAL|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
48154385|NCT01823458|BEHAVIORAL|Lottery Insurance|
48154386|NCT01823458|BEHAVIORAL|Standard Lottery|
48154387|NCT04653987|PROCEDURE|Percutaneous biliary drainage|
48154388|NCT02607293|DRUG|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
48154389|NCT02607293|DRUG|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
48154390|NCT02607293|DRUG|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
48154391|NCT04303858|DRUG|Eciskafusp Alfa|Participants will be administered eciskafusp alfa in different schedules.
48154392|NCT04303858|DRUG|Atezolizumab|Participants will be administered 1200 mg of atezolizumab once every 3 weeks.
48154393|NCT04807452|OTHER|Strength and balance training|Passive ROM to possible level of knee (flexion and extension), ankle (dorsiflexion and plantar flexion), forefoot (inversion and eversion) and toe (flexion and extension, adduction and abduction) joints.Resisted flexion and extension of knee, dorsiflexion and planter flexion of ankle, inversion and eversion of foot, flexion/extension, and abduction/adduction of toe with help of thera-band.The exercise prescription for strength training was made at approximately 50% of the estimated 1-RM. Exercise progression was achieved by instructing participants to increase the weight lifted in a specific exercise when they could perform 2 sets of 10-12 repetitions without maximal exertion on 2 consecutive training days. On basis of Borg Rating of Perceived Exertion of 10 to 13.Tandem leg stance for first 2 weeks and then it was progressed to Single leg stance toe and heel stance.For dynamic balance:backward walk Tandem walk and sideways walk.
48154394|NCT04807452|OTHER|Aerobics training|"After the baseline assessment, the participant in the Group B received Aerobic exercise with routine medical care.~All patients were followed for 3 days a week for 8 weeks treatment. Control Group received aerobic training. Control group received stretching exercise for 10 minutes and then treadmill walk for 10 minutes and then stationary bicycle for 10 minutes, and steppers for 10 minutes and 5 minute cool down ."
48154395|NCT06547775|DRUG|KN069|Solution for SC injection
48154396|NCT05248425|OTHER|Nurse Monitoring|Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
48154397|NCT06360445|DRUG|Olaparib Tablet test formulation 100mg|A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.
48154398|NCT06360445|DRUG|Olaparib Tablet reference formulation 100mg|Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
48681041|NCT01770405|DEVICE|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
48681042|NCT03856463|BEHAVIORAL|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
48681043|NCT03856463|OTHER|Usual Care|Usual care as provided by local oncologists
48681044|NCT01718522|DEVICE|sensor augmented pump (SAP)|
47994970|NCT05738941|PROCEDURE|angioembolization|"Use a 4- or 5-French diagnostic catheter for the initial angiogram and either continue to use this catheter for embolization where the feeding vessel is large or add a standard 2.3- to 2.5-French microcatheter as a coaxial technique .~- Injection of embolizing material in the feeding vessels using gel foam , PVA or histoacryl according to the nature of the bony lesion"
47994971|NCT03559179|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
47994972|NCT01991158|DRUG|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
48154399|NCT06360445|DRUG|Olaparib Tablet test formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
48154400|NCT06360445|DRUG|Olaparib Tablet reference formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
48154401|NCT02320045|DRUG|ITCA 650 (Exenatide in osmotic mini pump)|
48154402|NCT05308342|PROCEDURE|transplantation of human UC-MSCs into ovaries of POI patients|UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
48681045|NCT05631171|BEHAVIORAL|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
48681046|NCT02406521|DRUG|Pazopanib|
48681047|NCT02406521|DRUG|Sorafenib|
48681048|NCT02406521|DRUG|Radium-223|
48681049|NCT04494828|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
48681050|NCT04494828|DRUG|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
48681051|NCT03929354|BEHAVIORAL|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
48681052|NCT03929354|BEHAVIORAL|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
48681053|NCT04878107|DRUG|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
47994973|NCT01991158|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
47994974|NCT01991158|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
47994975|NCT01991158|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
48154403|NCT05308342|DRUG|hormone replacement treatment|Routine estrogen progesterone replacement periodic therapy
47994976|NCT02225522|OTHER|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
48154404|NCT00083148|DRUG|capecitabine|
48154405|NCT00083148|DRUG|irinotecan hydrochloride|
48154406|NCT03630432|BEHAVIORAL|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
48154407|NCT03630432|OTHER|Usual Care|Usual Care
48154408|NCT04802967|DRUG|Ketoprofen Lysine Salt combined with Gabapentin|KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
48154409|NCT04802967|DRUG|Ketoprofen Lysine Salt|KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
48154410|NCT04802967|DRUG|Gabapentin|300 mg
48154411|NCT04802967|OTHER|Placebo|2 capsules to maintain the blind
47994977|NCT04445428|BIOLOGICAL|oral polio vaccine + information|Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
48154412|NCT02297854|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
48154413|NCT03795792|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
48154414|NCT03795792|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Will be provided in capsules.
48681054|NCT04878107|DRUG|Apatinib|Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
48681055|NCT04878107|DRUG|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
47994978|NCT04445428|BEHAVIORAL|Information|Advice regarding how to protect oneself from COVID-19
47994979|NCT05689307|DEVICE|SIVA-MVP|Participants receive a small, wearable data recorder, wear it during the day and charge it on the nightstand during sleep for 14x24 hours. The encrypted, recorded segments are uploaded to a server. The server provides a secure environment where the segments are decrypted after receiving the required keys from the patient's SIVA smartphone application. The decrypted segments are then classified as cough by a machine learning algorithm. Participants respond to questions on a smartphone once a day for additional context data. The audio data from the first 24 hours after the patient started wearing the device are used for the validation of the performance of the cough detection algorithm.
47994980|NCT03398031|DRUG|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
47994981|NCT03398031|DRUG|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
48154415|NCT03969251|DEVICE|Transcranial Magnetic Stimulation (rTMS)|active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
48154416|NCT03969251|DEVICE|Sham (SS)|repetitive sham rTMS
48154417|NCT01587703|DRUG|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
48154418|NCT03414515|DEVICE|Endovascular intervention|Endovascular treatment with stent or balloon according to current practice
48154419|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
48154420|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
48154421|NCT00507845|DRUG|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
48688187|NCT02319460|BIOLOGICAL|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
48154422|NCT06185699|DIAGNOSTIC_TEST|standard superficial skin biopsy (SSSB)|standard superficial skin biopsy (SSSB) was applied to the face that was wiped with dry sterile gauze after dropping cyanoacrylate by marking 1 cm2 area on the slide that was wiped with dry sterile gauze from 3 areas of the face, right cheek, nose and the mid-forehead. After the slide was left for 60 seconds and slowly removed from the face, immersion oil was dripped onto the slide and covered with a coverslip, and Demodex mites were counted first under the light microscope at x10 and then x20 magnification (Demodex foliculorum and brevis were not differentiated). The process was repeated for each region.
48154423|NCT03621683|PROCEDURE|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
48154424|NCT03621683|DIETARY_SUPPLEMENT|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
48154425|NCT01292499|BEHAVIORAL|Psychotherapy|10 sessions (50 min)
48154426|NCT01292499|BEHAVIORAL|Psychoeducation|7 sessions + 7 phone calls
48154427|NCT01292499|BEHAVIORAL|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
48154428|NCT04552444|DRUG|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
48154429|NCT03574649|DRUG|Nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
48154430|NCT03574649|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
48681056|NCT04878107|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
48154431|NCT03574649|DRUG|5Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48154432|NCT03574649|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48154433|NCT03574649|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
48154434|NCT03574649|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
48154435|NCT03574649|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
48154436|NCT03574649|BIOLOGICAL|GI-4000|RAS yeast vaccine
48154437|NCT03574649|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
48681057|NCT04878107|RADIATION|LDRT|low dose radation therapy
48681058|NCT04099498|BEHAVIORAL|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
48681059|NCT04099498|BEHAVIORAL|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
48154438|NCT03574649|DRUG|Aldoxorubicin|INNO-206
48154439|NCT03574649|DRUG|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
48681060|NCT01823081|DRUG|Intravitreal injection of bevacizumab (Avastin)|
48681061|NCT01823081|DRUG|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
48681062|NCT03516578|OTHER|Cardiac magnetic resonance imaging|
48681063|NCT02877576|PROCEDURE|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
48681064|NCT02877576|BEHAVIORAL|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter...). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
48154440|NCT03574649|DRUG|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
48154441|NCT03574649|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
48154442|NCT03574649|DRUG|Docetaxel|Docetaxel
48681065|NCT02877576|BEHAVIORAL|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
48154443|NCT03574649|DRUG|carboplatin|carboplatin
48154444|NCT00483171|DRUG|CP-945,598|CP-945,598
48154445|NCT00483171|BEHAVIORAL|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
48154446|NCT00483171|BEHAVIORAL|Low Calorie Diet|Low calorie diet
48154447|NCT06162611|DRUG|Etonogestrel implant with Oral Levonorgestrel emergency contraception 1.5mg|Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion
48154448|NCT06162611|DEVICE|Etonogestrel implant with oral placebo|Single pill of placebo same day as contraceptive implant insertion
48681066|NCT00524888|PROCEDURE|suturing laceration|suturing simple lacerations of the hand
48681067|NCT00524888|PROCEDURE|bioadhesive|using bioadhesive on simple lacerations of the hand
48688188|NCT02319460|BIOLOGICAL|Plasma|
48154449|NCT00003934|DRUG|tretinoin|Given orally
48154450|NCT00003934|DRUG|daunorubicin hydrochloride|Given IV
48154451|NCT00003934|DRUG|cytarabine|Given IV
48154452|NCT00003934|DRUG|mercaptopurine|Given IV
48154453|NCT00003934|DRUG|methotrexate|Given IV
48154454|NCT00003934|DRUG|arsenic trioxide|Given IV
48154455|NCT01540474|BIOLOGICAL|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
48154456|NCT01540474|BIOLOGICAL|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
48154457|NCT01540474|BIOLOGICAL|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
48154458|NCT01540474|OTHER|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
48154459|NCT04352894|DIAGNOSTIC_TEST|Fluorescence guided peritoneal exploration|Intravenous injection of ICG
48154460|NCT04441073|DRUG|Lignocaine|preoperative nebulization of lignocaine
48154461|NCT04441073|DRUG|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
48681068|NCT02636504|DEVICE|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
48681069|NCT05493878|DIAGNOSTIC_TEST|mRNA expression|Tumor educated platelets ITGA2b and SELP mRNA by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
48154462|NCT02574234|OTHER|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
48154463|NCT02574234|OTHER|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
48154464|NCT02574234|OTHER|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
48154465|NCT02574234|OTHER|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
48154466|NCT02574234|OTHER|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
48154467|NCT02797899|DEVICE|Platelet Rich Fibrin|Native growth factors
48154468|NCT01895868|OTHER|Simulation-based ultrasound training|
48154469|NCT02167230|PROCEDURE|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
48154470|NCT02167230|PROCEDURE|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
48154471|NCT04968249|OTHER|Observational|Observational Cohort to understand risk factors for early COPD.
48154472|NCT01461967|DRUG|Placebo|Single ascending doses
48365007|NCT03730987|BEHAVIORAL|Families Talking Together (FTT)|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
48681070|NCT05814718|DRUG|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
48681071|NCT05814718|DRUG|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
48681072|NCT03463837|OTHER|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
48365008|NCT03730987|BEHAVIORAL|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
48365009|NCT03232151|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
48365010|NCT06018402|OTHER|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
48365011|NCT06018402|OTHER|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
48365012|NCT03672474|DEVICE|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
48365013|NCT03672474|DEVICE|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
48681073|NCT03463837|OTHER|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
48681074|NCT03463837|OTHER|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
48154473|NCT01461967|DRUG|RO5508887|Single ascending doses
48154474|NCT01461967|DRUG|RO5508887|Single doses
48154475|NCT04543032|OTHER|sensorimotor training|Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
48154476|NCT06336642|BEHAVIORAL|SPOT-ON Early Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
48154477|NCT06336642|BEHAVIORAL|SPOT-ON Delayed Start|Participants will start treatment within 3 days of enrollment, which may include: receiving information on breathing techniques, relaxation techniques, posture techniques, and distraction techniques, and/or trying different oxygen-based therapies, such as high-flow nasal cannula, low-flow supplemental oxygen, and non-invasive ventilation with a respiratory therapist.
48681075|NCT03463837|OTHER|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
48154478|NCT05075005|OTHER|Treatment Cohort|Subjects will walk on a specified University of Florida Natural Area Teaching Laboratory's (NATL) nature trail for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Time, distance, and GPS walking route will be recorded utilizing the MapMyRun smartphone application, which is free to download and easy to use. The study team will assist each subject with downloading the application onto their smartphone and provide a brief training on app use at their pre-trial visit. Subjects will be asked to save each training session within the app to report to the study team upon completion of the 8-week training protocol. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
48154479|NCT05075005|OTHER|Control Cohort|Subjects will walk on hardscapes (e.g. sidewalk, asphalt, track, etc) for approximately 30 minutes, three times per week for 8 weeks while wearing the minimalist shoes provided by the study team. Similarly to the treatment group, subjects will be asked to utilize the MapMyRun smartphone application to record their training sessions. Subjects will be instructed to walk at a comfortable pace and to stop if they begin experiencing increased pain or discomfort.
48154480|NCT01242345|DEVICE|Capnography|Monitoring of the capnography curve for early detection of apnea
48154481|NCT03876678|OTHER|Lactobacillus salivarius AP-32|Taking 1 probiotic capsule two times everyday for 7 days.
48154482|NCT03876678|OTHER|Bifidobacterium animalis subspecies lactis CP-9|Taking 1 probiotic capsule two times everyday for 7 days.
48154483|NCT03876678|OTHER|Placebo|Taking 1 placebo capsule two times everyday for 7 days.
48154484|NCT00473031|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
48154485|NCT00473031|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
48154486|NCT00473031|BEHAVIORAL|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
48154487|NCT01550822|OTHER|HEALS|
48154488|NCT04371029|OTHER|PSG|Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
48154489|NCT05346484|BIOLOGICAL|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
48154490|NCT05346484|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
48681076|NCT03463837|OTHER|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
48681077|NCT03463837|OTHER|Smoking Cessation|No smoking for 5-days in confinement.
48681078|NCT05968248|PROCEDURE|MLR-DBS|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
48688189|NCT02415049|OTHER|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
47994982|NCT03942354|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
47994983|NCT03942354|DRUG|Pretomanid|Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
47994984|NCT03942354|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
47994985|NCT03942354|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
48154491|NCT02722278|DRUG|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
48365014|NCT01791543|DEVICE|Intramural Needle Ablation Catheter|
48154492|NCT02722278|DRUG|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
48681079|NCT05968248|PROCEDURE|Conventional rehabilitation group|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
48154493|NCT00183209|BEHAVIORAL|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
48154494|NCT04009902|BEHAVIORAL|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
48154495|NCT03636295|DRUG|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
48154496|NCT02241980|OTHER|Patient survey|
48154497|NCT02241980|OTHER|Physician survey|
48681080|NCT03862612|PROCEDURE|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
48681081|NCT02069873|BEHAVIORAL|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
48681082|NCT00457678|DRUG|Visudyne|
48681083|NCT00457678|DRUG|Lucentis|
47994986|NCT03942354|DRUG|Clofazimine|Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
48154498|NCT04455542|OTHER|LMND-ALS|in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.
48154499|NCT04455542|OTHER|UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
48154500|NCT04455542|OTHER|FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
48154501|NCT03591263|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
48154502|NCT05398042|DIETARY_SUPPLEMENT|Ketone ester|A daily dose of 3x20g of ketone ester supplementation during a six week intervention period
48154503|NCT05398042|DIETARY_SUPPLEMENT|Medium Chain Triglyceride (MCT) oil|A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
48154504|NCT01317771|PROCEDURE|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
48154505|NCT05683639|OTHER|warming of the follicular aspiration needle|the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
48154506|NCT02125799|DEVICE|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
48154507|NCT00620230|DRUG|NVP-VAK694|
48154508|NCT00620230|DRUG|NVP-VAK694|
48154509|NCT05910359|DIAGNOSTIC_TEST|Ultrasound|transabdominal and transperineal ultrasound by expert sonographers
48154510|NCT03439800|OTHER|Mental and Physical Practice|"1. Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~2. They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~3. From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~4. From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~5. From 9th to final training session: both mental and physical practice of the dual task gait."
48681084|NCT00457678|DRUG|Dexamethasone|
48681085|NCT02524145|OTHER|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
48681086|NCT02524145|DRUG|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
47994987|NCT03942354|DRUG|Directly observed therapy (DOT)|Standard therapy
47994988|NCT02817165|DIETARY_SUPPLEMENT|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
48688190|NCT02415049|OTHER|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
48154511|NCT03439800|OTHER|Physical Practice|"1. Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~2. Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~3. From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~4. From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
48154512|NCT04491370|DRUG|Polatuzumab vedotin|All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.
47994989|NCT02817165|OTHER|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
48154513|NCT01801202|DEVICE|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
48154514|NCT06090487|DIAGNOSTIC_TEST|myocardial function after surgery|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation. transthoracic echo will be done before and after surgery, also total dose if inoptropic drugs will be noted
48154515|NCT03770156|BEHAVIORAL|Questionnaires|Overall Impression of the current state and evolution since the attacks
48154516|NCT04608357|DIAGNOSTIC_TEST|Needle Core Biopsies|Not an interventional study
48681087|NCT02524145|DRUG|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
48681088|NCT02524145|DRUG|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
48681089|NCT02177630|OTHER|Endomyocardial Biopsy|
48681090|NCT02941328|DRUG|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
48681091|NCT02941328|DRUG|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
48681092|NCT05940506|DRUG|KX-826-2.5 mg (0.25%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
48681093|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL QD|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
48681094|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
48681095|NCT05940506|OTHER|Placebo|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
48681096|NCT04169646|OTHER|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
48681097|NCT04169646|OTHER|Control|No intervention takes place during the control phase.
47994990|NCT01750008|PROCEDURE|Global Fibroid Ablation|
48154517|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules|Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
47994991|NCT01750008|PROCEDURE|Myomectomy|
47994992|NCT03169465|PROCEDURE|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
47994993|NCT03169465|PROCEDURE|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
47994994|NCT06406673|DRUG|Cadonilimab+EC/ET+RT|Cohort_1 patients with no history of previous systemic treatment for ES-SCLC received cadonilimab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative RT and two cycles of cadonilimab with EC/EP (combination phase). Afterward they received cadonilimab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase).
47994995|NCT06406673|DRUG|Cadonilimab+vorolanib|Cohort_2 patients with recurrent SCLC and after at most one systemic treatment received cadonilimab plus vorolanib, until disease progression or unacceptable toxicity.
48154518|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)|Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
47994996|NCT04079478|OTHER|AI|Artificial intellignece colonoscopy
47994997|NCT04996459|DRUG|Tislelizumab|Tislelizumab 200mg iv q3w
47994998|NCT01457885|DRUG|Clofarabine/Busulfan x 4|"* Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
48154519|NCT04062279|DIAGNOSTIC_TEST|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
47994999|NCT01457885|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
47995000|NCT03807011|DRUG|fentanyl group|fentanyl 2 μg/kg
47995001|NCT03807011|DRUG|remifentanil group|remifentanil 0.2 μg/kg/min
47995002|NCT02726074|DRUG|Perampanel|
47995003|NCT04846790|BEHAVIORAL|Nature Only|See above for description.
48154520|NCT03292744|DRUG|Alfacalcidol|alfacalcidol 0,5 mcg
47995004|NCT04846790|BEHAVIORAL|Nature+Mindfulness|See above for description.
47995005|NCT03214159|DRUG|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
48681098|NCT03998800|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
47995006|NCT03214159|DRUG|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
48154521|NCT05182242|OTHER|Collection of clinical data|family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
48154522|NCT05182242|BIOLOGICAL|Collection of samples|"Collected during fetal and blood sampling performed as part of care for ACPA:~* 4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~* 1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents"
48681099|NCT03998800|BEHAVIORAL|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
47995007|NCT02647086|DRUG|Dupilumab|
47995008|NCT02647086|DRUG|Midazolam|Cytochrome P450 substrate
47995009|NCT02647086|DRUG|Omeprazole|Cytochrome P450 substrate
47995010|NCT02647086|DRUG|Warfarin|Cytochrome P450 substrate
47995011|NCT02647086|DRUG|Caffeine|Cytochrome P450 substrate
47995012|NCT02647086|DRUG|Metoprolol|Cytochrome P450 substrate
47995013|NCT00005828|DIETARY_SUPPLEMENT|green tea extract|
47995014|NCT00819338|DIETARY_SUPPLEMENT|Efamax|5g daily as capsules for 3 months
47995015|NCT01517672|BEHAVIORAL|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
47995016|NCT03842384|BEHAVIORAL|iENDURE|The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
47995017|NCT03591016|OTHER|Recording number of IV attempts|Recording number of IV attempts in the operating room
47995018|NCT00005831|BIOLOGICAL|trastuzumab|Given IV
47995019|NCT00005831|DRUG|paclitaxel|Given IV
47995020|NCT00005831|DRUG|carboplatin|Given IV
48154523|NCT05182242|OTHER|Questionnaires|within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
48681100|NCT03345511|PROCEDURE|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
47995021|NCT00005831|DRUG|gemcitabine hydrochloride|Given IV
47995022|NCT00005831|OTHER|laboratory biomarker analysis|Correlative studies
47995023|NCT02629341|DIETARY_SUPPLEMENT|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
47995024|NCT02629341|DIETARY_SUPPLEMENT|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
47995025|NCT00149123|DRUG|hydrocortisone 200 mg/day|
47995026|NCT02428881|DRUG|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
47995027|NCT01315756|DEVICE|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
48681101|NCT05325229|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.
48154524|NCT05182242|OTHER|Parent interviews|as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
48154525|NCT05182242|OTHER|Professional interview and focus groups|Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
48154526|NCT00005771|DEVICE|Visual utrasound feedback|
48154527|NCT00005771|PROCEDURE|Abdominal Hollowing Exercise|
48154528|NCT02006914|DIETARY_SUPPLEMENT|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
48154529|NCT00420498|DRUG|Atomoxetine (Strattera™)|
48365015|NCT03558230|BEHAVIORAL|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
47995028|NCT01315756|DEVICE|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
47995029|NCT03754712|DIETARY_SUPPLEMENT|Vitamin D3|Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
48365016|NCT03558230|BEHAVIORAL|Vibration|Vibration applied to the wrist.
48365017|NCT03558230|BEHAVIORAL|Placebo (for vibration)|No vibration applied to the wrist.
48365018|NCT03507049|PROCEDURE|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
48681102|NCT05325229|DRUG|Bevacizumab|Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
48681103|NCT01396187|DRUG|PF-05231023|5 mg IV twice a week for 4 weeks
48681104|NCT01396187|DRUG|PF-05231023|25 mg IV twice a week for 4 weeks
47995030|NCT03911440|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
47995031|NCT03911440|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
47995032|NCT05278078|OTHER|psychological support|psychological support will be given to the patients in the experimental group.
47995033|NCT05278078|OTHER|nutritional education|nutritional education will be given to the patients in the experimental group.
48154530|NCT03236818|DRUG|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
48154531|NCT04870905|DRUG|Tis-U-Sol|Tislelizumab 200mg will be given every 3 weeks for 12 cycles
48154532|NCT01864200|BIOLOGICAL|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
48681105|NCT01396187|DRUG|PF-05231023|100 mg IV twice a week for 4 weeks
48681106|NCT01396187|DRUG|PF-05231023|200 mg IV twice a week for 4 weeks
48681107|NCT01396187|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
48154533|NCT01864200|BIOLOGICAL|Placebo|Saline placebo
48154534|NCT02192645|DRUG|Sanfujiu|
48365019|NCT03507049|PROCEDURE|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
48365020|NCT03507049|RADIATION|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
48365021|NCT03531099|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
48365022|NCT03531099|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
48365023|NCT03531099|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
48365024|NCT03531099|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
48365025|NCT03531099|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
48681108|NCT02593903|DRUG|Septra|
48688191|NCT03389412|DRUG|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
48688192|NCT03389412|DEVICE|Conditional alarm|Eight weeks of treatment.
48688193|NCT03275090|DRUG|Smoflipid ®|
48688194|NCT03850093|DRUG|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
48681109|NCT04430608|DEVICE|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
48154535|NCT02192645|DRUG|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
48154536|NCT00640354|DEVICE|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
48681110|NCT00344175|DRUG|pitavastatin|
48681111|NCT00344175|DRUG|simvastatin|
48681112|NCT05701553|DRUG|Anti-PD-1/PD-L1|Intravenous injection at indicated dose for at least 6 months
48681113|NCT05701553|DRUG|S-Adenosyl-Methionine|Taken orally at indicated dose for at least 6 months
47995034|NCT05278078|OTHER|psychological support and nutritional education|psychological support and nutritional education will be given to the patients in the experimental group.
47995035|NCT05278078|OTHER|no intervation|No intervention will be applied to the control group
47995036|NCT05110456|BEHAVIORAL|Telephone support|"Participants will receive 10 telephone counseling calls by trained coaches: 9 during pregnancy (one call/week) and 1 at 6 weeks postpartum. We have included individual telephone calls by a trained coaches aimed to :~1. encourage the use of online material;~2. identify strategies for overcoming obstacles;~3. help apply content to real-life settings; and~4. underscore the participants' success in using effective coping strategies"
47995037|NCT01817725|BIOLOGICAL|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those \<= 20 years old and 40μg in those \> 20 years old.
47995038|NCT01340092|OTHER|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~1. Help family identify key issues they need to address to get their child autism-specific services~2. Help family address barriers to obtaining these services and strategize approaches to overcome them."
48154537|NCT00640354|DEVICE|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
48154538|NCT05203822|DRUG|Tepotinib (HydroChloride hydrate)|Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
48154539|NCT05203822|DRUG|Itraconazole|Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
48154540|NCT01803828|DRUG|Tadalafil|20 mg/die (1 capsule)
48154541|NCT01803828|DRUG|Placebo|Placebo 20 mg/die (1 capsule)
48681114|NCT04965792|OTHER|Screening|Blood test
48681115|NCT03606148|DIAGNOSTIC_TEST|SurePathTM|In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
48681116|NCT03579069|OTHER|Ductus venosus Doppler|Ductus venosus Doppler
48681117|NCT03020004|DRUG|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
48681118|NCT03020004|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
48681119|NCT03020004|DRUG|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
47995039|NCT04759872|OTHER|Hyperinsulinemic-euglycemic Clamp|Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
47995040|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260
47995041|NCT04400838|BIOLOGICAL|MenACWY vaccine|Standard single dose of MenACWY vaccine
48154542|NCT06247267|DRUG|Fortesta|Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.
48154543|NCT06247267|DRUG|Estradiol|Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
48154544|NCT06247267|DRUG|Fortesta|Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.
48681120|NCT03020004|DRUG|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
48681121|NCT03240562|PROCEDURE|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
48681122|NCT03240562|DRUG|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
47995042|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later
48681123|NCT06198062|OTHER|Paraffin wax bath therapy|this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks
48681124|NCT06198062|OTHER|Paraffin Wax Bath Therapy and Muscle Energy Techniques|This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
48681125|NCT00964951|BIOLOGICAL|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
47995043|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine|Two standard doses of MenACWY vaccine 4-6 weeks apart
48681126|NCT00964951|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
48681127|NCT02918669|RADIATION|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
48681128|NCT05123339|OTHER|Questionnaire|Questionnaire
47995044|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (qPCR)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR
47995045|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL prime plus boost|Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)
47995046|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine min. 4 weeks apart|Two standard doses of MenACWY vaccine minimum 4 weeks apart
47995047|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart
48365026|NCT04329273|OTHER|Sliding leg curl|The exercise protocol consists of the following sets and repetitions Week 1- 2 sessions with 2 sets of 6 repetitions Week 2- 2 sessions with 3 sets of 6 repetitions Week 3- 2 sessions with 4 sets of 6 repetitions Week 4- 2 sessions with 4 sets of 8 repetitions Week 5- 2 sessions with 4 sets of 10 repetitions Week 6- 2 sessions with 4 sets of 10 repetitions Week 7- 2 sessions with 4 sets of 8 repetitions Week 8- 2 sessions with 4 sets of 8 repetitions
48688195|NCT03850093|DRUG|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
47995048|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
48688196|NCT03850093|DRUG|placebo|patients received oral placebo 2 hrs preoperative
48688197|NCT01234480|DEVICE|BD SurePath Plus Pap test|BD SurePath Plus Pap test
48688198|NCT01234480|DEVICE|BD SurePath Pap test|BD SurePath Plus Pap test
47995049|NCT00260858|DRUG|Test Meal: Reference food (glucose or white bread)|
47995050|NCT00260858|DRUG|Test Meal: Pirate's Booty|
47995051|NCT00260858|DRUG|Test Meal: Ceaprove wafer|
47995052|NCT00260858|DRUG|Test Meal: Stretch Island Strawberry Fruit Leather|
47995053|NCT04369794|BIOLOGICAL|BCG|0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose
47995054|NCT04369794|BIOLOGICAL|Placebo|0.9% saline in the same volume as the BCG vaccine in a single dose
48154545|NCT00816816|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
47995055|NCT03257553|DIAGNOSTIC_TEST|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
48154546|NCT00474409|DRUG|Merislon|
48154547|NCT00543049|DRUG|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
48154548|NCT00543049|DRUG|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
48154549|NCT06320171|DEVICE|Non-Invasive neuromodulation|This program involves changes in stimulus times and frequencies, varying from 192 Hz to 1429 Hz, generating symmetrical positive and negative polarity impulses. The intensity for all sessions is set to low, following the Arndt-Schulz law. A maximum total time of 10 minutes is considered for connecting the patient to the device at the beginning and for removing the device at the end of the session.
48154550|NCT00559195|BIOLOGICAL|epoetin beta|
48154551|NCT00559195|PROCEDURE|quality-of-life assessment|
48154552|NCT01504178|DRUG|duloxetine|administration during 28 days
48154553|NCT01504178|DRUG|placebo of duloxetine|administration during 28 days
48154554|NCT01504178|DRUG|injection of apomorphine|injection performed at D28
48154555|NCT01504178|DRUG|injection of placebo of apomorphine|performed at D28
48154556|NCT01504178|DRUG|L-Dopa|performed at D28
48154557|NCT01504178|DRUG|injection of placebo of L-Dopa|performed at D28
48154558|NCT05832320|DRUG|Etoposide|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
48511889|NCT06155695|BEHAVIORAL|Auditory Cognitive Control Training (ACCT)|ACCT incorporates a subset of components from Cognitive Enhancement Therapy found to have early benefits on the cognitive deficits of interest to the proposed studies and can be conducted more time-efficiently to achieve our specific goals. ACCT involves approximately 3 hours of computerized neurocognitive training using cognitive control and processing speed training software developed by Ben-Yishay and colleagues. Deficits in cognitive control are addressed with computer training exercises containing simple stimuli with little inherent emotional or motivational salience. ACCT requires individuals to be vigilant, inhibit irrelevant stimuli, and shift attention between auditory and visual modalities. Computer training exercises facilitate reaction time in a temporal mode using auditory cues (The Attention Reaction Conditioner), spatial focusing with visual cues (the Zero Accuracy Conditioner), and temporal vigilance with auditory and visual cues (Time Estimates).
48511890|NCT05114278|DRUG|Ferinject|Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
47995056|NCT04484454|DIETARY_SUPPLEMENT|ProdromeNeuro Omega 3 Oil Nutritional Supplement|ProdromeNeuro is an algae-derived Omega 3 oil nutritional supplement product comprised of naturally occurring alkylglycerol and natural fatty acids. ProdromeNeuro functions as a natural plasmalogen precursor which can be administered orally.
47995057|NCT01047956|DRUG|Methadone; NAC|Methadone NAC
47995058|NCT01047956|DRUG|Methadone|Methadone
47995059|NCT00233051|DRUG|Salmeterol or Salmeterol/Fluticasone|
47995060|NCT00387478|BIOLOGICAL|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~1. 600 SU/0.5 ml~2. 1600 SU/0.5 ml~3. 4000 SU/0.5 ml~4. 4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
47995061|NCT02570061|BEHAVIORAL|telephone|information given at the primary contact by phone, or at a scheduled later time
48154559|NCT05832320|DRUG|Daunorubicin|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
48154560|NCT03694210|DEVICE|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
48154561|NCT00393185|BIOLOGICAL|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
48154562|NCT06585332|OTHER|Assessment of respiratory paramenters (Maximal inspiratory pressure, maximal expiratory pressure, and voluntary peak cough flow))|"The voluntary peak cough flow is measured using a pneumotachograph (BTL cardiopoint Spiro, BTL industries), which meets the recommendations of the American Thoracic Society and the European Respiratory Society for range and accuracy in forced expiratory maneuvers.~Maximal expiratory and inspiratory pressures assessments were performed using a flanged rubber mouthpiece connected to a pressure manometer (Micro RPM, Vyaire Medical). Assessments are conducted according to the statements on respiratory muscle testing of the American Thoracic Society and the European Respiratory Society.~Hand grip strength Grip strength is measured using DHD-1 digital hand dynamometer (SAEHAN®,Seahan Corporation), assessment follows recommendation of The American Society of Hand Therapists."
48154563|NCT06204237|DRUG|[89Zr]Zr-DFO-APAC|All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
48154564|NCT06204237|RADIATION|PET/CT scan|The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.
48154565|NCT01391234|RADIATION|STAT RT planning and delivery workflow|"* Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~* Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~* Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
48154566|NCT02595788|OTHER|Change from supine to prone position|Change from supine to prone position
48154567|NCT01057888|OTHER|Autodialer|Autodialer telephone calls
48154568|NCT01057888|OTHER|Letters|Mailed reminder letters
48154569|NCT06552897|PROCEDURE|Intervention 1: Adductor Canal Block (ACB)|"For the Interventions section, you should describe the specific procedures or treatments administered in each arm of your study. Here's how you might present the interventions:~Intervention 1: Adductor Canal Block (ACB) Name: Adductor Canal Block (ACB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block. Dose and Administration: 20 ml of 0.25% bupivacaine is injected to target the saphenous nerve within the adductor canal.~Objective: To provide analgesia to the anterior and medial aspects of the knee, preserving motor function to facilitate early mobilization."
47995062|NCT02570061|BEHAVIORAL|consultation face-to-face|information given at a scheduled consultation at the hospital
48154570|NCT06552897|PROCEDURE|Intervention 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB)|"Name: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block followed by a selective tibial nerve block.~Dose and Administration:~Adductor Canal Block (ACB): 20 ml of 0.25% bupivacaine. Selective Tibial Nerve Block (STNB): 20 ml of 0.25% bupivacaine. Objective: To provide comprehensive analgesia to both the anterior and posterior aspects of the knee, aiming to enhance pain relief and reduce opioid consumption."
48154571|NCT02332525|DEVICE|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
48154572|NCT02951702|DRUG|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
48154573|NCT02135445|DRUG|TAK-385|TAK-385 tablet
48154574|NCT02135445|DRUG|Degarelix|Degarelix injection
48154575|NCT03423537|DRUG|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
48681129|NCT04884503|DRUG|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
48154576|NCT03423537|DRUG|Placebo|100IU per day containing N/S 0.9% will be injected
48154577|NCT01786551|DRUG|Eplerenone|50 mg daily for 14 days
48154578|NCT04315428|BEHAVIORAL|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
48154579|NCT04315428|BEHAVIORAL|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
48154580|NCT05386706|BEHAVIORAL|Digital Intervention|This study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.
48154581|NCT05386706|DRUG|Metformin|Traditional metformin monotherapy.
48154582|NCT05940805|PROCEDURE|Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|"1. Low-frequency transcranial electrical stimulation (2/100 Hz) applied through 0.3-mm-diameter and 40-mm-long needles placed subcutaneously on the scalp at the projection of Penfield's motor homunculus and sensory and frontal supplementary motor associative areas.~2. Paraspinous block at the levels of the C5, C6 and C7 vertebrae concordant with spasticity laterality.~3. Dry needling of spastic upper limb muscles, as identified through a thorough physical examination, using 0.3-mm-diameter and 40-mm-long needles.~4. Muscular functional electrical stimulation (FES) in the antagonists of the upper limb muscles with spasticity with the following parameters: 20-Hz frequency, 300-µs pulse width, zero-second ramp time, 5-second stimulation time, and 5-second resting time."
48154583|NCT05940805|PROCEDURE|SHAM Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used.
48681130|NCT04884503|DEVICE|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
47995063|NCT01420289|DEVICE|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
48154584|NCT02020200|DRUG|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg.
48154585|NCT02020200|DRUG|Placebo|
48154586|NCT00604344|DRUG|insulin detemir|
48511891|NCT05114278|DRUG|oral iron|All patients will receive an oral iron supplementation (100mg/day).
48511892|NCT05456503|DRUG|FPI-2620|Radiotracer
48681131|NCT01474785|DRUG|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
48681132|NCT01474785|OTHER|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
48681133|NCT01474785|PROCEDURE|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
47995064|NCT01420289|BEHAVIORAL|Excercise|Treadmill walking 45 minutes once daily
47995065|NCT03501758|DIAGNOSTIC_TEST|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
48681134|NCT01648023|DEVICE|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
48681135|NCT01648023|DRUG|Gem-Cis or Gem-Carbo|
48681136|NCT05393999|BIOLOGICAL|BMS-986414|Broadly neutralising antibodies BMS-986414
47995066|NCT03501758|DIAGNOSTIC_TEST|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
47995067|NCT01630512|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
47995068|NCT01630512|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
47995069|NCT03114228|DRUG|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
48154587|NCT00604344|DRUG|insulin NPH|
47995070|NCT03890770|DRUG|BMS-986165|Oral administration
48681137|NCT05393999|BIOLOGICAL|BMS-986413|Broadly neutralising antibodies BMS-986413
48681138|NCT00912574|DRUG|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
48154588|NCT02862288|DEVICE|Microwave ablation with Acculis Accu2i pMTA Applicator|
48154589|NCT02368288|DRUG|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
47995071|NCT00000751|DRUG|Anti-HIV Immune Serum Globulin (Human)|
47995072|NCT00000751|DRUG|Globulin, Immune|
47995073|NCT00000751|DRUG|Zidovudine|
47995074|NCT02901535|OTHER|Spirometry|Spirometry in baseline
47995075|NCT02901535|OTHER|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
47995076|NCT02901535|OTHER|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
48154590|NCT05163678|OTHER|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
48511893|NCT02159079|OTHER|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
48154591|NCT01167816|DRUG|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
48154592|NCT00001848|DRUG|Raloxifene|
48154593|NCT05237856|DEVICE|Capnometry Monitorization|After spinal anesthesia, a non-invasive nasal cannula will be applied to the patient, ETCO2 and IPI values will be continuously measured and recorded from this cannula with a capnometry device.
48154594|NCT04317872|DRUG|High dose of peri-operative intravenous dexamethasone|25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
48154595|NCT04317872|DRUG|Low dose of peri-operative intravenous dexamethasone|10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
48154596|NCT04348799|OTHER|BPD|It is a observation research.we didn't intervene anything.
48511894|NCT06548178|DRUG|T-DXd|T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.
48511895|NCT06548178|DRUG|THP|Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.
48681139|NCT00912574|DRUG|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
47995077|NCT02901535|OTHER|Spirometry - 20 weeks|Spirometry (20 weeks)
47995078|NCT00112502|DRUG|Celecoxib|400 mg orally twice a day continuous dosing
47995079|NCT00112502|DRUG|Isotretinoin|40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.
47995080|NCT00112502|DRUG|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
47995081|NCT00112502|DRUG|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
47995082|NCT01344187|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
47995083|NCT01344187|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
47995084|NCT01344187|DEVICE|KXL System|30 mW/cm2
47995085|NCT05188651|BEHAVIORAL|face masks|wearing face masks
47995086|NCT01625143|OTHER|laboratory biomarker analysis|Correlative studies
47995087|NCT03449160|DEVICE|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
47995088|NCT03449160|OTHER|physical therapy|routine physical therapy
47995089|NCT01353417|OTHER|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
47995090|NCT02877277|DIETARY_SUPPLEMENT|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
47995091|NCT02877277|DIETARY_SUPPLEMENT|Placebo|Oral intake of placebo tablet daily for 56 days
47995092|NCT02694406|DEVICE|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
48154597|NCT03677856|PROCEDURE|Paravertebral blockade|Type of anaesthesia
48154598|NCT03677856|PROCEDURE|Thoracic epidural block|Type of anaesthesia
48511896|NCT05057806|DRUG|Empagliflozin 25 MG|Empagliflozin 25MG will be administered orally once per day for 3 months
48511897|NCT05057806|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
48511898|NCT05551663|OTHER|Isometric exercise training|Participants randomised to the intervention will perform a 4-week programme of isometric exercise training.
48154599|NCT05345041|BEHAVIORAL|Keep it Movin'|Individual participants in churches randomized to the intervention arm will participate in the Keep it Movin' multi-component PA education program, as well as be encouraged by their church and study interventionist to participate in the church-wide walking program. Individuals enrolled in Keep It Movin' will attend weekly 90-minute sessions for 24 weeks. All sessions will include the structured physical activity component from the LIFE study intervention, with the following components, which were added to address needs of the target community: functional education, social support and problem-solving. To increase the functional gains seen in the LIFE pilot study and add content addressing self-management and PA with multiple chronic conditions (MCCs), the number of sessions in the proposed trial has been increased from 16 to 24 weeks.
48154600|NCT05345041|BEHAVIORAL|Go 4 Life Self Guided Education|Individual participants in churches randomized to the comparator arm will receive the church-wide walking program and the Go4Life Your Everyday Guide to Exercise and Physical Activity which was developed by the National Institutes of Health National Institute on Aging to promote physical activity in older adults. This includes an evidence-based exercise guide and motivational tips to help older adults start and sustain an exercise program. The Go4Life guide will add individual level education and encouragement to the interpersonal and community levels of intervention provided by the church-wide walking program.
48154601|NCT02674295|DRUG|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
48154602|NCT02674295|DRUG|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
48681140|NCT00912574|BIOLOGICAL|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
48681141|NCT00912574|DRUG|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
47995093|NCT03131440|BEHAVIORAL|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
47995094|NCT03131440|BEHAVIORAL|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
48681142|NCT03198091|DRUG|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
48681143|NCT03744195|OTHER|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~1. The skin will be cleaned properly with alcohol~2. The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~3. A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10\~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
47995095|NCT03131440|BEHAVIORAL|App+|"Participants will receive deluxe version of smartphone app with additional features."
47995096|NCT03131440|BEHAVIORAL|Online gym|Participants will receive access to online exercise videos.
47995097|NCT03131440|BEHAVIORAL|App notifications|Participants will receive motivational app notifications
47995098|NCT03131440|BEHAVIORAL|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
47995099|NCT04231786|PROCEDURE|Breast ultrasonography findings|Breast ultrasonography findings in patients over 30 years of age diagnosed with polycystic ovary syndrome.
47995100|NCT05165615|DEVICE|Insulin Pump t:slim X2 with Control-IQ technology|Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
48154603|NCT01942551|DRUG|Tadalafil|
48154604|NCT01942551|DRUG|Dutasteride|
48154605|NCT02054442|DRUG|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
47995101|NCT03685084|DRUG|AAI101 i.v.|600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
47995102|NCT03685084|DRUG|Saline 0.9% infusion|Vehicle infusion
47995103|NCT03685084|DRUG|Piperacillin i.v.|piperacillin 3 g i.v.
47995104|NCT03685084|DRUG|Cefepime i.v.|cefepime 1 g i.v.
47995105|NCT01467947|BIOLOGICAL|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
47995106|NCT03637465|BEHAVIORAL|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
48154606|NCT02054442|DRUG|Methotrexate|
48154607|NCT05129592|BEHAVIORAL|Coherent corrective messages|Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
48154608|NCT01598454|DRUG|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
48154609|NCT01989156|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
48154610|NCT01989156|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
48154611|NCT01989156|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
48154612|NCT02610413|OTHER|Laboratory Biomarker Analysis|Correlative studies
48154613|NCT04405089|DEVICE|Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with 2 milliamperes (mAmps) of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.
48154614|NCT04405089|DEVICE|Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
48154615|NCT06121739|BEHAVIORAL|Child Mental Health Literacy Program|The workshop has a participant-oriented character, seeking to apply the more theoretical contents to the local school context. It has four units and a total of nine modules, each lasting 90 or 120 minutes, with reference material on an educational platform. The topics are : 1) the person behind the role of educator; 2) the school community and its influence on the healthy development of students; 3) the expected development and its alterations in the different evolutionary stages; 4) common and differential factors of child and adolescent mental health disorders; 5) Stigma in Mental Health; 6) screening, the first care, and use of devices for the prevention and treatment of mental health disorders in children and adolescents.
48154616|NCT06270004|OTHER|nonsurgical periodontal therapy|sonic scaler for scaling and polishing. Graces curettes numbers(1-2,3-4,5-6,7-8,9-10,11-12,13-14)for root surfaces debridement(RSD), instructions and motivation for dental arch
48511899|NCT05171608|PROCEDURE|Ultrasound-based protocol based fluid therapy|"Protocol of the interventional group according to the ultrasonographic findings:~Ultrasound scan 2 hours before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate intravenous (IV) fluid therapy: 8 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy.~A 2nd ultrasound scan at 30 minutes before surgery:~IVCCI\>40 percent and absence of symmetric anterior 'B-profile' on the lung ultrasound indicate further IV fluid therapy: 5 ml/kg of isotonic, balanced crystalloid infusion.~IVCCI≤40 percent AND/OR symmetric anterior 'B-profile' contraindicates further IV fluid therapy."
48681144|NCT03744195|OTHER|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10\~30 reps)
48154617|NCT05799040|DEVICE|Self-developed pulmonary lobar ventilation detector|The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
48154618|NCT05799040|DEVICE|Chartis detection system|The participants would evaluated by the Chartis detection system.
48154619|NCT06062147|BEHAVIORAL|Teacher training|Training for teachers in the intervention arm in the learning process, SLLD and early warning signs, with an identification grid. Observation of identified pupils and implementation of educational and environmental adjustments.
48681145|NCT00608049|BEHAVIORAL|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
48154620|NCT05825456|PROCEDURE|endoprosthetic reconstruction|This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.
48154621|NCT05825456|PROCEDURE|Intramedullary nailing|This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
48154622|NCT05825456|PROCEDURE|Open reduction internal fixation with plate and screws|This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
48154623|NCT01684345|DRUG|Placebo|Solution for subcutaneous injection
48154624|NCT01684345|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
48154625|NCT01684345|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
48154626|NCT03479671|DRUG|Intralipid, 20% Intravenous Emulsion|Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
48154627|NCT04389554|OTHER|Blood D-dimer assay|Blood samples will be taken from the patients and will be examined by the ELISA method.
48681146|NCT00608049|BEHAVIORAL|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
48154628|NCT03612258|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
48154629|NCT02998658|DEVICE|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
48154630|NCT02998658|DEVICE|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
48154631|NCT05523388|OTHER|Collection of health-related data|A multimodal set of data including experimental, clinical, functional, radiological and biomechanical data is compiled before and after routine surgical intervention at baseline and at one-year follow-up.
48154632|NCT05057078|BEHAVIORAL|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
48154633|NCT01636258|BEHAVIORAL|Stress Management|Every other week
48154634|NCT01636258|BEHAVIORAL|Diet|Every other week
48154635|NCT01636258|BEHAVIORAL|Exercise|Every week
48154636|NCT01636258|BEHAVIORAL|Culinary education|Every other week
48154637|NCT06023745|GENETIC|genotyping|Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
48154638|NCT01815255|DRUG|tenofovir (TDF)|
48154639|NCT03419806|DRUG|Infudopa i.v.|"Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
48154640|NCT03419806|DRUG|Infudopa s.c.|"A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
48365027|NCT04329273|OTHER|Balance training|"The exercise protocol consists of 2 sessions/week with 4 sets of 30'' single stance.~Week 1 and 2- 1 set of 30'' single leg stance and 3 sets of 30'' single leg stance and ball kicks with contralateral foot Week 3 and 4- 2 sets of 30'' single leg stance while moving the ball around the leg with the contralateral foot and 2 sets of 30'' single leg stance, moving a ball around the knee with hands and kicking a ball with contralateral foot Week 5 and 6- 2 sets of 30'' single leg stance while giving and receiving hand passes with medicine ball (in couples) and 2 sets of 30'' single leg stance with perturbations (in couples) Week 7 and 8- Same as week 5 and 6 with extra 15 in each repetition"
48511900|NCT05689957|DRUG|Deep neuromuscular block using intravenous rocuronium induction at 1.2mg/kg and maintainance of 8-12mcg/kg/min for deep neuromuscular block|both arm are using low pressure pneumoperitoneum in laparoscopic surgery, moderate and deep neuromuscular block are monitor with neuromuscular monitoring. if surgical condition is inadequate, surgeon are allowed to increase intraabdominal pressure as per standard care
48511901|NCT02646761|DEVICE|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
48511902|NCT02646761|OTHER|Standard of Care Physical Therapy|Physical therapy rehabilitation program
48681147|NCT00608049|BEHAVIORAL|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
48681148|NCT00608049|BEHAVIORAL|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
48681149|NCT01715363|DRUG|Oxaliplatin|
47995107|NCT02255370|DRUG|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
47995108|NCT01511575|GENETIC|RNA analysis|
48511903|NCT02750826|OTHER|Health Education Program|
48511904|NCT02750826|OTHER|Weight Loss Intervention|
48681150|NCT01715363|DRUG|Folinic Acid|
48681151|NCT01715363|DRUG|Fluorouracile|
48681152|NCT04295811|DEVICE|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
48681153|NCT04295811|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
47995109|NCT01511575|GENETIC|reverse transcriptase-polymerase chain reaction|
47995110|NCT01511575|OTHER|laboratory biomarker analysis|
47995111|NCT02052921|PROCEDURE|Rectal resection|Surgical rectal resection
47995112|NCT02052921|OTHER|Observation|
47995113|NCT06278246|RADIATION|PET Scan|PET scan using the novel \[11C\]MK-6884 tracer to measure M4R during the antipsychotic-free state
47995114|NCT05497492|DRUG|propofol|single administration of propofol
48154641|NCT03419806|DRUG|LCIG (Duodopa)|"Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg."
48154642|NCT01581476|DRUG|Statin|10mg daily for a minimum period of 2 years
48154643|NCT01581476|DRUG|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
48154644|NCT01581476|DRUG|Placebo|Participants receive statin placebo and ACEI placebo
48154645|NCT01581476|DRUG|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
48154646|NCT02454647|DRUG|Induction chemotherapy|
48154647|NCT02454647|RADIATION|Radiotherapy with concurrent chemotherapy|
48154648|NCT02454647|PROCEDURE|Salvage surgery|
48154649|NCT06437327|PROCEDURE|Electrotherapy|Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes
48154650|NCT06437327|PROCEDURE|Active release technique|Active release technique is applied (patient is prone lying with knee flexed, Pressure is applied on taut band and patient is asked to move the leg in internal rotation to achieve maximal lengthening) Repetitions 5 to 7 times hold for 5 to 20 seconds
47995115|NCT05497492|DRUG|propofol and sufentanil|administration of propofol and sufentanil in combination
48365028|NCT04329273|OTHER|Core stability|"The exercise protocol consists of the following sets and repetitions Week 1 and 2- 3 sets of 30'' front plank, 3 sets of 20'' side plank, 2 sets of 30'' superman, 2 sets of 30'' supine bridge and 2 sets of 10 repetitions leg lowering exercise Week 3 and 4- increasing difficulty in 2 of the sets Week 5 and 6- adding 1 more set at each exercise Week 7 and 8- adding 15 in each repetition"
48511905|NCT05949411|OTHER|Screening visit|Subjects will be invited to perform the screening visit to sign the informed consent and then to ensure that they are able to participate in this study.
47995116|NCT05497492|DRUG|propofol and esketamine|administration of propofol and esketamine in combination
47995117|NCT05497492|DRUG|propofol and lidocaine|administration of propofol and lidocaine in combination
47995118|NCT03760796|DEVICE|Corrie Health Digital Platform|The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
48511906|NCT05949411|OTHER|Lactulose test|Fasted subjects (at least 10 hours) will receive on oral load of 10 g of lactulose. Then, exhaled H2 will be measured every 30 minutes during 4 hours.
48154651|NCT06437327|PROCEDURE|Hold relax technique|This technique is applied while the patient is in supine lying with one leg crossed over the other Patient is instructed to contract the piriformis against the manual resistance for 5 to 10 secs Then 15 secs of passive stretch is given repetitions x 5 times
48154652|NCT05630794|PROCEDURE|Biopsy|Undergo biopsy
47995119|NCT02299557|DRUG|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
48154653|NCT05630794|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48154654|NCT05630794|PROCEDURE|Colonoscopy|Undergo colonoscopy
48681154|NCT00285285|DEVICE|Point of Care Device; i-Stat Analyzer|
48681155|NCT03948802|DIAGNOSTIC_TEST|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
47995120|NCT02299557|DRUG|Placebo gel|Placebo gel applied intra-anally once daily
47995121|NCT02989350|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
47995122|NCT02989350|DIETARY_SUPPLEMENT|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
47995123|NCT01430481|DIETARY_SUPPLEMENT|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
47995124|NCT01807897|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
48154655|NCT05630794|DRUG|Dordaviprone|Given PO
48154656|NCT05630794|OTHER|Questionnaire Administration|Complete questionnaire
48154657|NCT05630794|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
48154658|NCT03287947|DRUG|nintedanib|Oral nintedanib, taken twice daily
48154659|NCT04567745|DIAGNOSTIC_TEST|Retinal fundus photography|Fundus photographs
48154660|NCT02665624|DRUG|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
48365029|NCT00103831|DRUG|Oral Taxane|
48511907|NCT05949411|OTHER|Administration of standardized meals with characterized dietary fiber content|Subjects will receive standardized breakfasts and lunches characterized in terms of dietary fiber content. Urine, saliva, feces samples will be collected. Breath test and gastrointestinal symptoms will be followed during maximum 8h. Subjects will also complete SF36 questionnaire, food diary and stool/transit questionnaire.
48511908|NCT05013307|OTHER|CASE|The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
48511909|NCT00484640|DRUG|Coumadin|
48511910|NCT05753995|DIAGNOSTIC_TEST|PET imaging|The evaluation of PET imaging using PET ligand \[18F\]JNJ-64413739 or a \[18F\] labeled equivalent in vivo in patients.
48511911|NCT00348504|DRUG|levosimendan|
48511912|NCT00348504|DRUG|dobutamine|
48154661|NCT02665624|DRUG|Senna alone|comparison of bowel cleansing and patient comfort.
48154662|NCT01662661|DRUG|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
48154663|NCT01662661|DRUG|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
48154664|NCT00037934|DEVICE|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
48154665|NCT00037934|OTHER|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
48154666|NCT04937920|BIOLOGICAL|DBI-002 probiotic gel|Topical application on skin affected with tinea versicolor
48154667|NCT04937920|BIOLOGICAL|Aqueous gel|Topical application on skin affected with tinea versicolor
48154668|NCT00401791|BEHAVIORAL|Exercise|"* Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period~* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer."
48681156|NCT01080924|DEVICE|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
48681157|NCT04082650|DRUG|vitamin D|4000IU per day
48154669|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC|Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type
48154670|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type
48154671|NCT06203756|DEVICE|Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision|Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
48681158|NCT04082650|OTHER|Placebo|The same doses with vitamin D
48681159|NCT06281977|DRUG|Dexmedetomidine|Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
48154672|NCT02896153|OTHER|Questionnaire|
48154673|NCT00794573|DRUG|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
48365030|NCT01500538|DRUG|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
48365031|NCT01551043|BIOLOGICAL|CART-19|
48681160|NCT06281977|DRUG|Normal saline|Programed as dexmedetomidine on infusion pump.
48154674|NCT00794573|OTHER|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
48365032|NCT02961153|OTHER|death|
48365033|NCT00786058|DRUG|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
48365034|NCT04318015|DRUG|Hydroxychloroquine|All treatment will be administered orally.
48681161|NCT04436445|COMBINATION_PRODUCT|dry cupping|represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
48681162|NCT04436445|OTHER|Life style modification|Life style modification
48681163|NCT02073812|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
48681164|NCT02039765|DRUG|Brimonidine tartrate|
48681165|NCT04114175|OTHER|Exercise BE|Basic exercises related to amputation will be applied
48154675|NCT04542551|PROCEDURE|Dilation 60-Fr non stricture|Dilation of patients with subjective dysphagia and normal endoscopy
48154676|NCT04542551|PROCEDURE|Sham|Sham dilator for patients with subjective dysphagia and normal endoscopy
48154677|NCT04542551|PROCEDURE|Non severe stricture - dilation with 60-Fr|Dilation of non severe stricture with 60-Fr dilator
48154678|NCT04542551|PROCEDURE|Non severe stricture - dilation with 46-Fr|Dilation of non severe stricture with 46-Fr dilator
48154679|NCT04542551|PROCEDURE|Severe stricture - dilation with 51-Fr|Dilation of a severe stricture with 51-Fr dilator
48154680|NCT04542551|PROCEDURE|Severe stricture - dilation with 42-Fr|Dilation of a severe stricture with 42-Fr dilator
48154681|NCT01699802|OTHER|Inhaled anaesthetic agent|
48511913|NCT06060431|OTHER|Pain Science Education|The Pain Science Education program consists of two workshops, 90 and 60 minutes in length, one week apart. The content of the workshops aims to provide students with information about the contemporary pain paradigm and to re-conceptualize pain.
48681166|NCT04114175|OTHER|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
48681167|NCT00161915|DRUG|Fibrin Sealant|
48681168|NCT05789498|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
48154682|NCT03729999|DEVICE|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
48154683|NCT01287624|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
48154684|NCT01287624|DRUG|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
48154685|NCT05762172|OTHER|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
48154686|NCT05486819|DRUG|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
48681169|NCT00642707|DRUG|PRO 140 (humanized monoclonal antibody to CCR5)|
48681170|NCT00642707|DRUG|Placebo Comparator|
48154687|NCT05650437|DEVICE|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
48681171|NCT04392674|DEVICE|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
48681172|NCT05183074|DEVICE|MR-linac|1.5-Tesla MR-linac based SBRT
48681173|NCT02315040|DEVICE|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
48154688|NCT05650437|BEHAVIORAL|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
48154689|NCT05650437|DIETARY_SUPPLEMENT|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A\&B)
48154690|NCT00155662|BEHAVIORAL|work-hardening program|
48154691|NCT05980247|DEVICE|Thimble Application|Use of of thimble application to practice mindfulness before needle procedure.
48154692|NCT03547648|PROCEDURE|peak airway pressure|Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
48681174|NCT02315040|OTHER|Standard Intrauterine Insemination|standard intrauterine insemination procedure
48681175|NCT05833035|DRUG|BI 1291583 mixed with [C-14] BI 1291583|BI 1291583 mixed with \[C-14\] BI 1291583
48681176|NCT04163523|DRUG|Zanubrutinib|
48154693|NCT05257642|OTHER|REThink Game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
48365035|NCT04318015|DRUG|Placebo oral tablet|All placebo will be administered orally
48365036|NCT03943524|DEVICE|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
48365037|NCT01345162|DRUG|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
48681177|NCT05669040|OTHER|Pharmacological education|Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
48681178|NCT05669040|OTHER|Training in the use of MyPlan Aplication|Review of the use of the aplication
48681179|NCT05669040|OTHER|Patient Experience|"* How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind"
48681180|NCT02944838|BEHAVIORAL|Senior Change Makers Advocacy Program|see description
48681181|NCT02944838|BEHAVIORAL|Senior Change Makers Physical Activity Program|see description
48681182|NCT04071431|OTHER|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
48688199|NCT01234480|PROCEDURE|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
48365038|NCT01345162|DRUG|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
48365039|NCT01345162|DRUG|intraoperative analgesia|ketorolac 30 mg iv
47995125|NCT01807897|DEVICE|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
47995126|NCT01807897|BEHAVIORAL|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
48365040|NCT01345162|DRUG|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
48365041|NCT03154424|PROCEDURE|External fixation in treatment the distal radius fracture|Compare two techniques
48365042|NCT03762785|DRUG|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
48365043|NCT03550040|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
48365044|NCT02195349|BIOLOGICAL|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
47995127|NCT00115973|DEVICE|pump|
47995128|NCT00115973|DRUG|insulin aspart|
47995129|NCT01505608|DRUG|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
48154694|NCT06181123|OTHER|Cardiorespiratory Assesments|The following were evaluated to make comparisons between the two groups: Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
48154695|NCT06142799|PROCEDURE|root canal treatment|The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week
48365045|NCT02195349|BIOLOGICAL|Placebo|Commercial saline solution administered by IV over approximately 2 hours
48365046|NCT04204967|DRUG|Fentanyl Transdermal System|in the experimental arm transdermal fentanyl will be administered with a starting dose of 50 mcg/hr simultaneously with the preexistent remifentanil continue infusion. Remifentanil infusion rate will be increased or decreased based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit. After randomization, the transdermal fentanyl dose can be modified every 24 hours according to the study protocol to achieve the desired effect in terms of PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected
48365047|NCT04204967|DRUG|Remifentanil|"In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl"
48365048|NCT05038306|DRUG|Chinese medicine WT|The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
48365049|NCT00266331|DRUG|Reduced glutathione|
48365050|NCT04997291|DRUG|Dexrazoxane|Twelve enrollees will be consecutively assigned to a dosing regimen of 400 mg/m2/dose. The medication will be administered in the operating room 30 minutes prior to starting cardiopulmonary bypass (dose #1), prior to aortic cross clamp removal (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3).
48511914|NCT00253721|DRUG|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
47995130|NCT01505608|DRUG|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
47995131|NCT01505608|DRUG|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
47995132|NCT03836963|BEHAVIORAL|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
47995133|NCT03836963|BEHAVIORAL|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
47995134|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
47995135|NCT03836963|BEHAVIORAL|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
47995136|NCT02325011|DRUG|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
48154696|NCT06037109|DEVICE|Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test|Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
48154697|NCT00000499|DRUG|chlorthalidone|
48154698|NCT00000499|DRUG|reserpine|
48154699|NCT00000499|DRUG|hydralazine|
48154700|NCT00000499|DRUG|metoprolol|
48154701|NCT03500796|PROCEDURE|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
48681183|NCT05670639|BEHAVIORAL|CAPABLE Care Partner|The CAPABLE Care Partner intervention consists of three components: 1) up to 3 sessions with a Care Partner Support person focused on developing action plans for self-care goals of the care partner 2) educational materials provided in a folder at the beginning of the program 3) inclusion in the CAPABLE clinician visits as deemed appropriate by the client, CAPABLE clinicians, and care partner
47995137|NCT02325011|DRUG|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
48681184|NCT03882437|BIOLOGICAL|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
47995138|NCT03503721|PROCEDURE|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
47995139|NCT03503721|PROCEDURE|bipolarTURP|the prostate will transurethrally resected using a bipolar current
47995140|NCT05782751|PROCEDURE|GROUPI|10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
47995141|NCT05782751|PROCEDURE|GROUP II|10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
47995142|NCT01527279|DRUG|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
47995143|NCT01527279|DRUG|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
48154702|NCT03500796|PROCEDURE|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
48681185|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 1.
48681186|NCT03974932|DRUG|Ibuprofen|NSAID.
48681187|NCT03974932|DRUG|Acetaminophen|Analgesic.
47995144|NCT01236937|DEVICE|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
47995145|NCT06256042|PROCEDURE|Occlusal splint|a stabilizing maxillary acrylic occlusal splint was made, flat, total and adjusted in central relation (RC).
48154703|NCT00755248|PROCEDURE|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
48154704|NCT02076802|BEHAVIORAL|physical exercises|
48681188|NCT03974932|DRUG|Celecoxib|NSAID.
48681189|NCT03974932|DRUG|+/- Bupivacaine HCl|Local anesthetic.
48681190|NCT03974932|DEVICE|Luer Lock Applicator|Applicator for instillation.
48681191|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 2.
47995146|NCT06256042|PROCEDURE|Arthrocentesis|The patient then underwent arthrocentesis of the temporomandibular joint itself, following the Nitzan technique.
48154705|NCT06286956|DEVICE|Treatment of rectal lesions with UNI-VEC|Polyp resections
48681192|NCT01187095|BEHAVIORAL|Expressive writing|3 consecutive days of writing
48154706|NCT05727878|DRUG|KPI-012|KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
48154707|NCT05727878|DRUG|KPI-012 Vehicle|KPI-012 formulation with no active drug
48511915|NCT01447277|PROCEDURE|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
48511916|NCT01447277|PROCEDURE|Femoral Block only|Performing a preoperative sciatic nerve block only
48681193|NCT01187095|BEHAVIORAL|Active ctrl|Control
48681194|NCT06170190|BIOLOGICAL|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
48681195|NCT00595296|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
48681196|NCT04300660|OTHER|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
48511917|NCT03183167|OTHER|No intervention|
48681197|NCT05042401|DRUG|SHR-1703|SHR-1703 low dose
47995147|NCT04931433|DRUG|Lignocaine|Group A will receive 1.5mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion will be halved to 1mg/kg/hour until the end of surgery. The same rate will be infused in the recovery room for another half an hour before participant is discharge.
47995148|NCT04931433|DRUG|Normal saline|Group B will receive saline of similar volume and rate as Group A
47995149|NCT01356797|DRUG|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
47995150|NCT01356797|DRUG|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
47995151|NCT03560050|BEHAVIORAL|Nutrition assistance|Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
47995152|NCT03560050|BEHAVIORAL|Children's environmental health|Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
48365051|NCT05564962|DIAGNOSTIC_TEST|Quality and Independence of Gait Classification Scale for Duchenne Muscular Dystrophy (QIGS-DMD)|MFM is a valid and reliable measure to evaluate the severity of the motor deficit of both ambulatory and non-ambulatory children with neuromuscular diseases. MFM consists of 32 items in 3 dimensions and is scored as a percentage of the maximum possible score which higher scores indicate better functional status. VLERS is a 10-item ordinal scale that identifies the functional status of the lower limbs. According to VLERS, level 1 indicates that the patient can walk independently and climb stairs without assistance while level 10 indicates is the patient is bedridden.
47995153|NCT05129878|PROCEDURE|scaling and OHI|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions
47995154|NCT05129878|PROCEDURE|oral Hygiene instructions|patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only
47995155|NCT05129878|PROCEDURE|Scaling and oral hygiene instruction|Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and Scaling
47995156|NCT02514356|BEHAVIORAL|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
47995157|NCT02514356|BEHAVIORAL|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
47995158|NCT01400516|DRUG|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
47995159|NCT01400516|DRUG|calcium citrate|1000 mg of calcium citrate
48365052|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
48365053|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
48365054|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
48365055|NCT02427412|DRUG|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
48365056|NCT02427412|DRUG|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
47995160|NCT01400516|DRUG|Vitamin D|800 IU of Vitamin D
47995161|NCT01400516|DRUG|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
47995162|NCT01145768|DRUG|TC-5214|4 mg tablet, oral, BID, group 1
48365057|NCT00719693|DRUG|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
48365058|NCT00719693|DRUG|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
48365059|NCT06296602|OTHER|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.|A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
48681198|NCT05042401|DRUG|placebo|placebo low dose
48681199|NCT05042401|DRUG|SHR-1703|SHR-1703 high dose
48681200|NCT05042401|DRUG|placebo|placebo high dose
48681201|NCT00890435|OTHER|questionnaire administration|
48681202|NCT00890435|PROCEDURE|psychosocial assessment and care|
48688200|NCT01234480|DEVICE|HPV DNA test|digene HC2 HPV DNA test
48688201|NCT01248988|OTHER|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
47995163|NCT01145768|DRUG|TC-5214|TBD tablet, oral, BID, groups 2-6
47995164|NCT01145768|DRUG|Placebo|
47995165|NCT06155591|OTHER|Community Nurse Case Manager (CNCM)|"Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~* Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~* Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~* Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~* Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~* Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~* Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history."
47995166|NCT03691064|DRUG|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.
47995167|NCT00798538|OTHER|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
47995168|NCT00798538|OTHER|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
47995169|NCT04260737|OTHER|Decision Aid for Men with Localized Prostate Cancer|The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
47995170|NCT06127459|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma).
47995171|NCT06127459|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
47995172|NCT03506750|DRUG|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
48365060|NCT06205212|OTHER|high-flow nasal oxygen|preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min
48365061|NCT06205212|OTHER|facemask|preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
48365062|NCT00638651|DEVICE|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
48365063|NCT00638651|DRUG|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
48365064|NCT00386529|DRUG|Aspirin enteric coated pellests 100mg|
48681203|NCT01416740|PROCEDURE|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
48681204|NCT01416740|DRUG|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
48681205|NCT02867228|OTHER|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
48681206|NCT04089852|DRUG|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
48365065|NCT03635645|DEVICE|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
48511918|NCT04646005|DRUG|Cemiplimab|Administered intravenously (IV) every three weeks (Q3W)
48365066|NCT03635645|DEVICE|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
48365067|NCT04179266|DRUG|Ketamine|One Cluster headache attack is treated with intranasal ketamine
48511919|NCT04646005|BIOLOGICAL|ISA101b|Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
48511920|NCT00161863|BIOLOGICAL|FSME-IMMUN NEW 0.25 ml|
48365068|NCT02931357|DEVICE|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
48365069|NCT02931357|DRUG|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
48511921|NCT01191944|DRUG|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
48511922|NCT01191944|DRUG|pramipexole extended release tablet|0.375mg-4.5mg, once a day
48511923|NCT05681715|DRUG|Rozanolixizumab|Rozanolixizumab self-administration via Syringe Driver or Manual Push.
48511924|NCT03267901|OTHER|food|45 g of walnut / iso-caloric white bread
47995173|NCT03506750|PROCEDURE|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
48511925|NCT05651607|DRUG|Cannabidiol|Oral solution, taken 3 times a day (morning, noon and evening), 5 mg/kg/day from day D0 to day D4. If not effective and well tolerated, dose increase : 10 mg/kg/day from day D5 to day D9, then 20 mg/kg/day from day D10 to day D29, maximum 800 mg/day
47995174|NCT03506750|PROCEDURE|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
47995175|NCT03506750|PROCEDURE|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
47995176|NCT03486093|DEVICE|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
47995177|NCT03486093|BEHAVIORAL|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
47995178|NCT01958775|DRUG|GLP-2|single subcutaneous dose of 1500mcg
47995179|NCT01958775|DRUG|Placebo|
47995180|NCT00205426|DRUG|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
47995181|NCT00199927|DRUG|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
47995182|NCT00199927|DRUG|standard therapy|standard therapy
47995183|NCT01708174|DRUG|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
48365070|NCT05280691|OTHER|Family Support Intervention (FSI)|In addition to usual care, families in the intervention group will receive (1) specialist nurse support along the patient pathway at defined time-points, from admission to discharge including follow-up care, and (2) nurse-coordinated liaison and structured, interprofessional communication by the ICU team. The intervention is grounded in a family systems approach and guideline-based strategies for family engagement in the ICU and has been pilot-tested in one ICU.
48365071|NCT01169233|DEVICE|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
48511926|NCT03295682|DEVICE|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
48681207|NCT04089852|DRUG|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
48681208|NCT03355950|PROCEDURE|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
48681209|NCT03355950|PROCEDURE|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
47995184|NCT01708174|DRUG|TMZ|Temozolomide capsules were obtained locally by the Investigator
47995185|NCT01637974|DRUG|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
47995186|NCT05287633|DRUG|Esomeprazole|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
47995187|NCT05287633|DRUG|Placebo|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
47995188|NCT00304356|DRUG|Nitazoxanide|500 mg bid
47995189|NCT02229318|DIETARY_SUPPLEMENT|FruitiVits|Daily administration of FruitiVits dietary supplement
47995190|NCT03463746|DEVICE|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
47995191|NCT03463746|DEVICE|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
47995192|NCT03891420|DRUG|Galidesivir|Galidesivir IV infusion
48365072|NCT01645449|DRUG|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
47995193|NCT03891420|DRUG|Placebo|Placebo IV infusion
47995194|NCT05126147|DRUG|Hydroxychloroquine|Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.
47995195|NCT02159664|OTHER|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
48365073|NCT04036214|DEVICE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
48511927|NCT00456300|DRUG|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
48681210|NCT00885183|PROCEDURE|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
47995196|NCT00852709|DRUG|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
47995197|NCT00852709|DRUG|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
47995198|NCT03229824|DEVICE|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
47995199|NCT05858346|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
47995200|NCT05858346|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
47995201|NCT02443142|DRUG|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
47995202|NCT02443142|DRUG|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
47995203|NCT03165110|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
47995204|NCT04429893|DRUG|magnesium sulphate|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
47995205|NCT04429893|DRUG|bupivicaine|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
47995206|NCT01176266|DRUG|asfotase alfa|
47995207|NCT01669447|BIOLOGICAL|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
47995208|NCT04000204|DEVICE|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
47995209|NCT04000204|DEVICE|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
48681211|NCT04781556|OTHER|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
48681212|NCT03933683|DEVICE|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
48681213|NCT04292197|DRUG|18-MC Compound|18-MC
47995210|NCT02417688|DEVICE|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
48511928|NCT00456300|DRUG|Insulin|Each subject received a baseline study with insulin alone
48681214|NCT05551156|BEHAVIORAL|Animal-assisted interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
48154708|NCT05951556|DEVICE|Use of BCI|Clients will utilize BCI with training to communicate wants and needs
48511929|NCT01049646|DRUG|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
48511930|NCT01049646|DRUG|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
48511931|NCT04617912|DEVICE|Long AFOV PennPET Explorer|A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
48688202|NCT05281237|DEVICE|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
47995211|NCT02790970|DEVICE|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
47995212|NCT02790970|OTHER|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
47995213|NCT05324540|OTHER|Cool therapy|Application of cool therapy. A chilled (between 5C and 10C) instrument will be applied to the oblique sinus while the patient is in atrial fibrillation.
47995214|NCT02607436|DRUG|Sarpogrelate|Sarpogrelate
47995215|NCT02607436|DRUG|Aspirin|Aspirin
47995216|NCT05298748|OTHER|Womb sound recordings|"Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al."
47995217|NCT04525950|PROCEDURE|Navio|New generation computer navigation with haptics and robotics
47995218|NCT04525950|PROCEDURE|Conventional|Total knee arthroplasty using conventional instruments
47995219|NCT04103632|DIAGNOSTIC_TEST|EVH test|"* Spirometry~* Skin prick test~* Peripheral blood test~* FeNO measurement"
47995220|NCT04738344|DEVICE|Percutaneous Coronary Intervention and Stent Implantation|Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
48154709|NCT03018288|DRUG|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
48365074|NCT05308420|PROCEDURE|Pericapsular nerve group (PENG) block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and 20ml 0.5% levobupivacaine with 2mg (0.5ml) dexamethasone injected (total volume of injectate 20.5ml) between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
48681215|NCT05551156|BEHAVIORAL|Conversational interaction|Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
48681216|NCT04771689|DRUG|Buprenorphine/Naloxone|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
48681217|NCT01658605|DRUG|GSK1605786|500 mg twice daily administered orally
48681218|NCT01658605|OTHER|Placebo|500 mg twice daily administered orally
47995221|NCT04287712|DIAGNOSTIC_TEST|Plasma lipids|Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.
47995222|NCT03853447|DIAGNOSTIC_TEST|Diagnostic imaging|MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
48365075|NCT05308420|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed at the level of the presumed interspace in-between the third and fourth lumbar vertebrae by introducing a 27 gauge pencil-point spinal needle and 15mg of levobupivacaine (3ml) injected intrathecally
48681219|NCT00690430|DRUG|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
48681220|NCT00690430|DRUG|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
48681221|NCT01786681|PROCEDURE|Positive pressure|
48681222|NCT00945373|DRUG|calcium dobesilate|2.5% gel
48681223|NCT00945373|PROCEDURE|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
48681224|NCT02648594|DEVICE|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
47995223|NCT01163279|BEHAVIORAL|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
48154710|NCT03018288|BIOLOGICAL|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
48681225|NCT04944576|DEVICE|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
48681226|NCT02018029|OTHER|cardiac resynchronisation therapy|
48681227|NCT01799486|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
48681228|NCT01799486|DRUG|Enecavir|0.5 mg monotherapy supplied in tablets.
47995224|NCT01163279|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
47995225|NCT06099977|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
47995226|NCT06099977|PROCEDURE|Placebo|Only headphone without sound will be applied.
47995227|NCT04434365|DRUG|Berberine|Berberine 100 mg twice daily for 4±1 weeks (Stage 1); then, 200 mg twice daily for 4±1 weeks (Stage 2); then, 300 mg twice daily for 4 weeks (Stage 3).
47995228|NCT04434365|DRUG|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
47995229|NCT04434365|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
47995230|NCT04434365|DRUG|Statin|Statins once daily for 12±1 weeks.
47995231|NCT04703439|BEHAVIORAL|Medication-taking reminders & educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
47995232|NCT04703439|BEHAVIORAL|Educational materials|The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
47995233|NCT03079609|PROCEDURE|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
47995234|NCT03079609|PROCEDURE|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
47995235|NCT04819555|GENETIC|Blood|a blood sample will be taken during hospitalisation for diagnostic confirmation or during the quarterly multidisciplinary consultations scheduled as part of the standard follow-up set up for these patients in the ALS centres of the FILSLAN network. If the genetic status is not yet known, this sample will be taken (1 tube of 7mL EDTA) and then sent within 24-48 hours at room temperature to one of the 3 participating molecular biology laboratories according to the criteria defined in the manual of samples being taken in the 3 laboratories.
47995236|NCT01420445|DRUG|YHD001 dose level 1|three times daily / 7 days
47995237|NCT01420445|DRUG|YHD001 dose level 2|three times daily / 7 days
47995238|NCT01420445|DRUG|Pelargonium sidoides extract|6-9mL three times daily / 7 days
47995239|NCT01420445|DRUG|placebo|three times daily / 7 days
47995240|NCT04902755|OTHER|Questionnaire|validation of the French linguistic version and the cross-cultural adaptation of the NBSS-SF.
47995241|NCT02372851|DEVICE|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
47995242|NCT03726008|BEHAVIORAL|Perinatal health promotion program and regular prenatal care|Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
47995243|NCT00930150|BEHAVIORAL|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
47995244|NCT00930150|BEHAVIORAL|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
47995245|NCT00930150|BEHAVIORAL|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
47995246|NCT00930150|BEHAVIORAL|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
47995247|NCT04476979|DRUG|Tocilizumab|Tocilizumab 8mg/kg D1 and if no response (No decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at D3
48365076|NCT05308420|DRUG|Intrathecal morphine|100 micrograms of preservative free morphine diluted to a volume of 0.5ml is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
48681229|NCT01799486|DRUG|Adefovir|10 mg monotherapy supplied in tablets.
48681230|NCT00654225|DRUG|Rosuvastatin|
48681231|NCT00654225|DRUG|Atorvastatin|
47995248|NCT04476979|DRUG|Dexamethasone|Dexamethasone : 10 mg once daily for the first five days (day 1 to day 5) then 5 mg per day for up to 5 days, 2.5mg per day for up to 4 days (or until oxygen supply independency if sooner)
47995249|NCT00017303|DRUG|carboplatin|
47995250|NCT00017303|DRUG|oglufanide disodium|
47995251|NCT00017303|DRUG|paclitaxel|
47995252|NCT00017303|PROCEDURE|conventional surgery|
47995253|NCT02034461|DEVICE|Utah Slanted Electrode Array|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations or peripheral nerve trauma.
47995254|NCT00116051|DEVICE|Acetabular implant, Monoblock cup|
47995255|NCT05188092|OTHER|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~1. LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~2. LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~3. LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
48681232|NCT05533944|OTHER|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
48688203|NCT00371202|PROCEDURE|keratoplasty|
48511932|NCT06471855|DEVICE|Multidisciplinary Conventional and Technology-based Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. According to their individualized rehabilitation project, patients will undergo non-immersive VR-based rehabilitation. VR-based rehabilitation will consist of one daily session (3 weeks) and will be conducted by the implementation of a single non-immersive VR device among the D-WallTM (TechnoBody SRL, Italy), the Walker ViewTM (TechnoBody SRL, Italy). Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants.
48681233|NCT02468440|OTHER|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
48681234|NCT02402803|OTHER|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
48681235|NCT03687242|DRUG|SPR001|Open label SPR001
48681236|NCT02832102|PROCEDURE|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
47995256|NCT02158390|BEHAVIORAL|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
47995257|NCT04577287|DEVICE|Transcranial direct current stimulation|Cathodal/Anodal tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
48154711|NCT03018288|DRUG|Temozolomide|Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
48681237|NCT06315972|DRUG|clemastine (8 mg/day)|add-on clemastine (8 mg/day) + aerobic exercise training
48681238|NCT06315972|DRUG|Placebo|add-on placebo + aerobic exercise training
48154712|NCT03018288|OTHER|Placebo|One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
48681239|NCT00276406|DRUG|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
48681240|NCT00276406|DRUG|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
47995258|NCT00181961|DRUG|Maca Root|
48154713|NCT03018288|PROCEDURE|Surgery|Tissue for vaccine production and neo-epitope monitoring.
48154714|NCT03152474|DRUG|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
48681241|NCT01312727|OTHER|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
48681242|NCT05982912|DIAGNOSTIC_TEST|breath sampling|We collect a breath sample of exhaled air and analyse the VOC profile in this sample
47995259|NCT02999256|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|
47995260|NCT02999256|OTHER|Placebo|
47995261|NCT02716558|OTHER|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
47995262|NCT02716558|OTHER|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
47995263|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
48154715|NCT03152474|DRUG|Vitamin A 100,000 IU|Dosed Intramuscular once daily
48681243|NCT02575729|DRUG|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
48681244|NCT00930917|DEVICE|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
48681245|NCT00930917|DEVICE|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
48681246|NCT00930917|OTHER|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
48681247|NCT01253083|BEHAVIORAL|mobility training with dynamic body weight support|
48681248|NCT02649452|OTHER|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
48681249|NCT02560090|BEHAVIORAL|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
48681250|NCT02560090|BEHAVIORAL|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
48681251|NCT02560090|BEHAVIORAL|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
48681252|NCT03133494|OTHER|ABG analysis|ABG analysis was performed and compared between two groups
48681253|NCT06199908|DRUG|AMT-562|Administered AMT-562 for injection intravenously
48681254|NCT04994639|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
48681255|NCT04575051|OTHER|Consult Model|The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
48681256|NCT04575051|OTHER|Engage Model|The Engage Model is a chronic care approach to supportive hearing loss self-management of ARHL. Engage includes (a) hearing screening for all residents, (b) an individualized communication plan for those with an identified hearing loss (e.g., one-to-one, group, telephone, television plans, hearing aid trouble shooting, communication strategies, etc.), (c) provision of simple, non-custom amplifiers, (d) referral to audiology if needed, and (e) ongoing support provided by trained personnel (Communication Facilitator) under the supervision of the audiologist.
48681257|NCT00014274|DRUG|carboplatin|
48681258|NCT00014274|DRUG|gemcitabine hydrochloride|
48681259|NCT00014274|DRUG|methotrexate|
48681260|NCT00014274|DRUG|vinblastine sulfate|
48681261|NCT03783962|BEHAVIORAL|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
48681262|NCT03783962|BEHAVIORAL|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
48681263|NCT02097628|PROCEDURE|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
48681264|NCT02097628|PROCEDURE|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
48365077|NCT05308420|PROCEDURE|Sham PENG block|A 22 gauge 120mm nerve block needle will be introduced under ultrasound guidance in plane from superolateral to posteromedial to position the needle tip posterolateral to the ileopsoas tendon in-between the anterior inferior iliac spine and the ileopubic (ileopectineal) eminence and a placebo solution consisting of 20.5ml 0.9%NaCl injected between the tendon and the inferior pubic ramus just proximal to the attachment of the anterior hip capsule
48154716|NCT03152474|OTHER|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
48154717|NCT04823078|OTHER|Activity base therapy|"activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching."
48365078|NCT05308420|DRUG|Intrathecal placebo|0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
47995264|NCT02637778|DIETARY_SUPPLEMENT|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, \> 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
48681265|NCT00271908|BEHAVIORAL|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
48681266|NCT06186583|DRUG|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
48681267|NCT00162214|DRUG|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
47995265|NCT04009421|DIAGNOSTIC_TEST|Coronary artery plaque assessment by CT coronary angiography QAngio CT RE|Assessment of segmental plaque volume and composition
47995266|NCT01085799|BEHAVIORAL|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
48681268|NCT00964483|BEHAVIORAL|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
47995267|NCT04528979|OTHER|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
47995268|NCT04528979|OTHER|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
47995269|NCT03287167|DRUG|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
47995270|NCT03287167|DRUG|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
47995271|NCT04404738|PROCEDURE|MicroPort® robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System
47995272|NCT04404738|PROCEDURE|da Vinci robot-assisted laparoscopic surgery|In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System
47995273|NCT05071183|DRUG|TPX-0005|Oral TPX-0005 capsules
47995274|NCT05071183|DRUG|Trametinib|Oral trametinib tablets
47995275|NCT00847288|OTHER|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
47995276|NCT00847288|OTHER|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
47995277|NCT00464425|PROCEDURE|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
48681269|NCT00964483|BEHAVIORAL|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
48681270|NCT04665427|OTHER|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
48681271|NCT04089527|DRUG|CC-95775|CC-95775
48681272|NCT05895123|DRUG|Rosuvastatin 20 mg|patients will receive one tablet rosuvastatin 20 mg every night
48681273|NCT05895123|DRUG|Atorvastatin 40mg|patients will receive one tablet Atorvastatin 40 mg every night
47995278|NCT00464425|PROCEDURE|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
48511933|NCT06471855|OTHER|Multidisciplinary Conventional Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to the patient's medical diagnosis, disability severity, and to consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
47995279|NCT00464425|OTHER|No Acupuncture|Control
47995280|NCT06050499|DEVICE|Microdialysis catheter + biosensor|"Microdialysis catheter from linton instrumetal 63 MD Catheter"
47995281|NCT05992597|DRUG|ZR2 RDHAP|ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
47995282|NCT00643422|DEVICE|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
47995283|NCT04630951|OTHER|Blood Flow Restriction Strength training with low load|Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
47995284|NCT04630951|OTHER|High Load Strength Training|High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
47995285|NCT05464459|PROCEDURE|Novel elbow procedure|A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
47995286|NCT06086028|OTHER|Wrist worn sensor|Biostrap collects biometrics such as the following: (1) sleep pattern/ quality; (2) steps, activity, calories; (3) heart rate/ HRV; (4) respiratory rate. Participants will be randomly assigned to one of two groups.
47995287|NCT01482793|PROCEDURE|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
47995288|NCT02195076|OTHER|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
47995289|NCT00733746|DRUG|erlotinib hydrochloride|oral administration
47995290|NCT00733746|DRUG|gemcitabine hydrochloride|Intravenous administration
47995291|NCT00733746|PROCEDURE|therapeutic conventional surgery|
48681274|NCT03074201|PROCEDURE|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
48681275|NCT03074201|DEVICE|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
47995292|NCT06523894|RADIATION|SBRT|Adapted to tumor volume BC SBRT
47995293|NCT02782533|DEVICE|Deep Brain Stimulation V3|
47995294|NCT06088550|DIETARY_SUPPLEMENT|BCAA|a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).
47995295|NCT06088550|OTHER|home-based graded exercise program|home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
47995296|NCT01474044|DRUG|Gastropylor Complex Capsules|3 pills, three times a day, after meal
47995297|NCT01474044|OTHER|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
48154718|NCT04823078|OTHER|Strength training|Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
48154719|NCT01876719|DRUG|AR08|
48154720|NCT01876719|DRUG|Placebo|
48154721|NCT04747496|DRUG|Edoxaban|This is a non-interventional, observational study.
48154722|NCT06119386|DEVICE|Rexon-Eye|In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
48154723|NCT05959447|DRUG|Camlipixant + Gemfibrozil|Camlipixant will be administered alone as well as in co-administration with gemfibrozil
48154724|NCT05959447|DRUG|Dabigatran etexilate + camlipixant|Dabigatran etexilate will be administered alone as well as in co-administration with camlipixant
48154725|NCT04618575|DRUG|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
47995298|NCT03795311|DRUG|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
48154726|NCT04618575|DRUG|Ursodeoxycholic acid only|Ursodeoxycholic acid only
48154727|NCT01361789|DRUG|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
48365079|NCT03778476|OTHER|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
48365080|NCT00617994|DRUG|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
48365081|NCT02812602|DRUG|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
48365082|NCT02812602|DRUG|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
48511934|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
47995299|NCT00418132|DRUG|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
47995300|NCT00418132|DRUG|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
47995301|NCT00485238|PROCEDURE|Argon laser Iridoplasty|
48154728|NCT01361789|DRUG|Dexamethasone|8 mg IV
48154729|NCT01361789|DRUG|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
48154730|NCT05746585|BEHAVIORAL|The Talk Web-based resources|Educational videos and podcasts for parents and their sons
48365083|NCT05202249|PROCEDURE|muscle layer fixation of thoracic drainage tube|The thoracic drainage tube is fixed on the muscle layer of the uniport
48365084|NCT01640704|BEHAVIORAL|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
48365085|NCT00019331|BIOLOGICAL|aldesleukin|
48365086|NCT00019331|BIOLOGICAL|ras peptide cancer vaccine|
48365087|NCT00019331|BIOLOGICAL|sargramostim|
48365088|NCT00019331|DRUG|DetoxPC|
48154731|NCT05567029|DRUG|Risankizumab Dose A|Prefilled Syringe
48154732|NCT05567029|DRUG|Risankizumab Dose B|Prefilled Syringe
48365089|NCT03390049|DEVICE|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
48365090|NCT03390049|DEVICE|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
48365091|NCT00183027|BEHAVIORAL|Dietary composition and energy intake|
48365092|NCT01071902|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
48511935|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
47995302|NCT00485238|DRUG|Intravenous acetazolamide|
48154733|NCT01016275|DEVICE|Misago (stent placement)|Misago iliac stent
48154734|NCT05791305|BEHAVIORAL|double duty intervention packages|The intervention employed in this study will serve as double-duty interventions. The WHO policy short report from 2017 and Hawkes et al2020 .'s were amended and used as the basis for the DDIs packages. The main components of the intervention packages are the promotion of a minimum level of dietary diversity, avoiding unwarranted harm from high-energy foods, and controlling market foods from the perspective of the consumer. The following central criteria will be used to evaluate the study's intervention packages.
48154735|NCT04374435|PROCEDURE|MKTP with Surgical blade|In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
48154736|NCT04374435|DEVICE|MKTP with Negative Pressure Instrument|In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
48154737|NCT04374435|DEVICE|Suction blister grafting without cell dissociation|In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
48154738|NCT02114502|DRUG|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
48681276|NCT04819529|BEHAVIORAL|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: daily visits by trained family members and health staff about the intervention process"
48681277|NCT04035343|BEHAVIORAL|Face down positioning|See description of the face down positioning group
48681278|NCT04035343|BEHAVIORAL|Supine positioning|See description of the supine positioning group
48681279|NCT00140712|DRUG|Ropinirole Immediate Release|Ropinirole Immediate Release
48681280|NCT00000277|DRUG|Mazindol|
47995303|NCT06341972|BEHAVIORAL|Cognitive behavioral therapy based self-management for anxiety|Evidenced based approach for educating patients about how to manage anxiety after respiratory failure.
47995304|NCT01822080|DRUG|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
48154739|NCT02114502|DRUG|SAHA|1,000 mg by mouth on Days -8 to -3.
48154740|NCT02114502|DRUG|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
48154741|NCT02114502|DRUG|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
48154742|NCT02114502|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
48154743|NCT02114502|PROCEDURE|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
48154744|NCT02114502|DRUG|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
48154745|NCT02114502|DRUG|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
48681281|NCT00382265|DRUG|tamsulosin|tamsulosin 0.4mg po qd for 28 days
48681282|NCT00382265|OTHER|Placebo|placebo po qd for 28 days
48681283|NCT03302403|GENETIC|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
48681284|NCT03302403|GENETIC|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
48681285|NCT03302403|GENETIC|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
48681286|NCT03302403|GENETIC|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
47995305|NCT01822080|DRUG|Placebo|Matching placebo once daily by mouth
47995306|NCT00791518|DRUG|No intervention|No intervention
48154746|NCT02114502|DRUG|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
48154747|NCT02114502|DRUG|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
48154748|NCT02114502|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
47995307|NCT02621242|PROCEDURE|Upper endoscopy|Upper endoscopy with biopsies
47995308|NCT02621242|PROCEDURE|Anoscopy|Anoscopy with biopsies
47995309|NCT02621242|DRUG|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
48154749|NCT02630927|DRUG|AG-519|AG519 will be tested.
48154750|NCT02630927|DRUG|Placebo|Placebo will be tested.
48365093|NCT01071902|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
48681287|NCT03302403|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
48681288|NCT03302403|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
47995310|NCT05046041|DRUG|Mifepristone + Misoprostol|A single 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally (buccal) every three hours until the abortion is achieved.
47995311|NCT00930566|DRUG|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
48154751|NCT00992030|DRUG|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
48154752|NCT00992030|RADIATION|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
48365094|NCT01071902|OTHER|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
48365095|NCT01071902|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
48365096|NCT00635804|DRUG|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
48365097|NCT00635804|DRUG|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
48365098|NCT06075251|BEHAVIORAL|I-InTERACT-North|I-InTERACT-North is a virtual stepped-care positive parenting program. It comprises online psychoeducational modules as well as live therapy and coaching sessions. The program lasts anywhere from 1 to 16 weeks depending on parents' progress.
48681289|NCT00453869|OTHER|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
48681290|NCT03238703|DRUG|Anastrozole|Given PO
48681291|NCT03238703|DRUG|Exemestane|Given PO
48681292|NCT03238703|OTHER|Laboratory Biomarker Analysis|Correlative studies
48681293|NCT03238703|DRUG|Letrozole|Given PO
48681294|NCT03238703|OTHER|Quality-of-Life Assessment|Ancillary studies
48681295|NCT03238703|OTHER|Questionnaire Administration|Ancillary studies
48681296|NCT03238703|DRUG|Tamoxifen Citrate|Given PO
48681297|NCT03238703|DRUG|Toremifene Citrate|Given PO
48681298|NCT01721486|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
47995312|NCT00930566|PROCEDURE|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
47995313|NCT04829877|BEHAVIORAL|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
47995314|NCT04829877|BEHAVIORAL|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
48154753|NCT03368300|OTHER|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
48511936|NCT01783886|PROCEDURE|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
48511937|NCT06578143|OTHER|Placebo|Placebo is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
47995315|NCT05752110|DRUG|Ketamine|0,5mg/kg single dose Ketamine (0.05ml/kg) intravenously administered
48681299|NCT01721486|DRUG|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
48681300|NCT00804050|DRUG|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
47995316|NCT05752110|OTHER|Saline|0.09% Saline (0.05ml/kg) intravenously administered
47995317|NCT03395158|DIAGNOSTIC_TEST|Implementation of new alert criteria|The intervention is when the prior alert criteria are replaced by the present alert criteria
47995318|NCT02937519|DEVICE|Chrono-chemotherapy pump:Melodie|
47995319|NCT02937519|DEVICE|Routine intravenous drip|
47995320|NCT02937519|DRUG|induction Chrono-chemotherapy|
47995321|NCT02937519|DRUG|induction Routine-chemotherapy|
48154754|NCT02403414|DEVICE|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
48154755|NCT05478564|OTHER|Intraoperative fluids and vasoactive drugs management protocol|Limitation of hypotensive events during open surgery for abdominal aorta repair
48365099|NCT03873259|DEVICE|Burst Wave Lithotripsy|Fragment upper urinary tract stones
48511938|NCT06578143|OTHER|Synbiotics|Synbiotics is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
48511939|NCT02558439|DRUG|CNTX-4975|
47995322|NCT02937519|DRUG|cisplatin chrono-chemotherapy|
47995323|NCT02937519|DRUG|cisplatin routine-chemotherapy|
48511940|NCT02558439|OTHER|Placebo|
48511941|NCT05970666|DRUG|TACE with adebrelimab and bevacizumab|TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
48511942|NCT01246310|DIETARY_SUPPLEMENT|Inositol|
48511943|NCT01246310|DIETARY_SUPPLEMENT|Placebo|
48681301|NCT00804050|DRUG|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
48688204|NCT04644146|GENETIC|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
47995324|NCT02937519|RADIATION|intensity-modulated radiation therapy|
47995325|NCT05041296|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
47995326|NCT01592929|RADIATION|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
47995327|NCT01592929|OTHER|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
47995328|NCT01592929|RADIATION|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
47995329|NCT01592929|RADIATION|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
47995330|NCT01592929|OTHER|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
47995331|NCT01020279|DRUG|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
47995332|NCT01020279|DRUG|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
48365100|NCT03689114|DRUG|Low dose carbamazepine|Carbamazepine, 300 mg/die
48681302|NCT03497039|DRUG|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
48681303|NCT03497039|OTHER|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
47995333|NCT03274531|BEHAVIORAL|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
48154756|NCT01672255|DRUG|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
48365101|NCT03689114|DRUG|Standard dose carbamazepine|Carbamazepine 600 mg/die
48365102|NCT03689114|DRUG|Low dose levetiracetam|Levetiracetam 500 mg/die
48511944|NCT01065402|DIETARY_SUPPLEMENT|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
48681304|NCT01654874|DRUG|99mTc-MIP-1404|
48681305|NCT06448130|DRUG|Henagliflozin 5mg|Henagliflozin 5mg + lifestyle intervention
48681306|NCT06448130|DRUG|Henagliflozin 10mg|Henagliflozin 10mg+ lifestyle intervention
48681307|NCT06448130|DRUG|Placebo|Placebo+ lifestyle intervention
48681308|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
48681309|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
48681310|NCT00394329|DRUG|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
47995334|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 400|dose 400 UNT/day for 12 months
47995335|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 800|dose 800 UNT/day for 12 months
47995336|NCT03691896|DRUG|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
47995337|NCT01625247|PROCEDURE|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
47995338|NCT02475577|DEVICE|Peripherals with HealthInterlink technology|home remote monitoring
47995339|NCT01434238|OTHER|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
48154757|NCT01672255|DRUG|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
48154758|NCT01125345|PROCEDURE|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
48365103|NCT03689114|DRUG|Standard dose levetiracetam|Levetiracetam 1000 mg/die
48365104|NCT03689114|DRUG|Low dose valproate|Valproate 300 mg/die
48365105|NCT03689114|DRUG|Standard dose valproate|Valproate 600 mg/die
48365106|NCT03689114|DRUG|Low dose zonisamide|Zonisamide 150 mg/die
48365107|NCT03689114|DRUG|Standard dose zonisamide|Zonisamide 300 mg/die
48511945|NCT01065402|DIETARY_SUPPLEMENT|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
48511946|NCT00324220|DRUG|MGCD0103|MGCD0103 Oral administration 3 times per week.
48154759|NCT03722602|OTHER|Standard rehabilitation after stroke|The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
48154760|NCT05531149|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
48154761|NCT05531149|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
48154762|NCT05543759|DIETARY_SUPPLEMENT|Ready-To-Use Therapeutic Food (RUTF)|"* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets RUTF/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
48681311|NCT02199093|OTHER|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
48365108|NCT03689114|DRUG|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
48511947|NCT00612664|DRUG|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
48511948|NCT04109729|DRUG|Nivolumab|"Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total"
48681312|NCT02199093|OTHER|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
48681313|NCT05673824|DRUG|Huaier Granule|"Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher."
48681314|NCT05673824|DRUG|VEGFR-TKIs|Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
48681315|NCT05629455|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
48681316|NCT03366025|DIAGNOSTIC_TEST|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
48681317|NCT01621984|OTHER|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
48681318|NCT00868829|DEVICE|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
48681319|NCT05353114|OTHER|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
48681320|NCT06138938|OTHER|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
48681321|NCT00008801|DRUG|hOKT3gamma1 (Ala-ala)|
48154763|NCT02577315|DRUG|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
48154764|NCT02577315|DRUG|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
48365109|NCT03689114|DRUG|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
48681322|NCT02065349|DRUG|ASP8477|oral
48681323|NCT02065349|DRUG|Placebo|oral
48365110|NCT03689114|DRUG|Low dose topiramate|Topiramate 100 mg/die
48365111|NCT03689114|DRUG|Standard dose topiramate|Topiramate 200 mg/die
48365112|NCT03689114|DRUG|Low dose lamotrigine|Lamotrigine 100 mg/die
48681324|NCT02452385|DRUG|CM082 tablet|CM082 tablets taken orally
48365113|NCT03689114|DRUG|Standard dose lamotrigine|Lamotrigine 200 mg/die
48365114|NCT03689114|DRUG|Low dose gabapentin|Gabapentin 450 mg/die
48365115|NCT03689114|DRUG|Standard dose gabapentin|Gabapentin 900 mg/die
48365116|NCT05905692|DRUG|L Carnitine|L carnitine will be given to group 1 (20 mg/kg/day) 3 times per week
48365117|NCT00526760|DRUG|Dexmedetomidine|
48365118|NCT03398187|DEVICE|cardiac catheterization|diagnostic and interventional cardiac catheterization
48511949|NCT06296485|BEHAVIORAL|SAGE Group Sessions|Participants enroll in 3 educational group sessions and receive CGMs
48511950|NCT06296485|OTHER|Usual Care|Participants continue to receive usual care (Control Arm)
48511951|NCT03132155|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
48511952|NCT03915405|DRUG|KHK2455|orally, once daily.
48511953|NCT03915405|DRUG|Avelumab|IV Administration
48511954|NCT00030706|DRUG|ixabepilone|
48511955|NCT05377060|BEHAVIORAL|Plasma p-tau risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.
47995340|NCT03503903|PROCEDURE|Wet Cupping|CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
47995341|NCT06143670|DRUG|Stannous fluoride toothpaste|0.454% w/w SnF2
47995342|NCT06143670|DRUG|Sodium fluoride toothpaste|0.243% w/w Sodium fluoride
48365119|NCT03773510|DRUG|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
47995343|NCT04748315|OTHER|SEMT(1:1)|Soccer trainning protocolo will be performed on an work to rest ratio 1:1 and the trainning volume will consist of 1 set and 6 repetitions per set
47995344|NCT04748315|OTHER|SEMT (1:3)|Soccer trainning protocolo will be performed on an work to rest ratio 1:3 and the trainning volume will consist of 1 set and 6 repetitions per set
47995345|NCT03624712|DIAGNOSTIC_TEST|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
47995346|NCT01324349|DEVICE|Veriset Hemostatic Patch|Topical hemostat
47995347|NCT01324349|DEVICE|Fibrin Sealant (TachoSil®)|Topical hemostat
47995348|NCT06297174|DRUG|Racecadotril 100 mg Capsules|Racecadotril 100 mg Capsules (test drug)
48511956|NCT05377060|BEHAVIORAL|Standard risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
48688205|NCT00832598|RADIATION|[18F]FACBC PET and [18F]FLT PET imaging|\[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
47995349|NCT06297174|DRUG|HIDRASEC®|HIDRASEC® (reference drug)
47995350|NCT03137693|OTHER|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
47995351|NCT03137693|PROCEDURE|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
47995352|NCT04819087|BEHAVIORAL|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
47995353|NCT04467879|DEVICE|Zona Plus Device|Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device
47995354|NCT04467879|DEVICE|Control Device|Zona Plus control sham device, with a nominal weaker grip
47995355|NCT04734509|DEVICE|Silhouette breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
47995356|NCT05414279|DIAGNOSTIC_TEST|Sodium determination|Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
47995357|NCT04652479|DRUG|Avexitide|Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
47995358|NCT05039008|OTHER|Blood flow restriction|The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
47995359|NCT04781673|DRUG|Ketamine|Will receive titratable infusion.
47995360|NCT04781673|DRUG|Lidocaine|Will receive titratable infusion, will have daily lidocaine level labs drawn daily.
47995361|NCT01367158|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
47995362|NCT01367158|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
47995363|NCT01367158|BIOLOGICAL|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
47995364|NCT01813084|DRUG|RV1729 single dose|Safety and tolerability of single escalating doses
47995365|NCT01813084|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
47995366|NCT01813084|DRUG|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
47995367|NCT01813084|DRUG|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
47995368|NCT02323230|BIOLOGICAL|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
47995369|NCT02323230|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
47995370|NCT05571605|BEHAVIORAL|Exercise|Participants randomized to this arm will exercise on a stationary bicycle.
48511957|NCT00620685|DRUG|Placebo|Tablet, once daily for 4 weeks
48511958|NCT00620685|DRUG|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
47995371|NCT05571605|BEHAVIORAL|Stretching|Participants randomized to this arm will perform stretching and balance exercise.
47995372|NCT05465551|COMBINATION_PRODUCT|Stress Management Toolkit|The toolkit will be a home-based, dyadic tangible toolkit comprised of simple tools to help people living with dementia (PLWD) and their care partners manage stress at home. Potential tools for the toolkit includes low burden, high safety tools such as weighted blankets, robotic pets and baby dolls, guided journals, aromatherapy and bright light therapy devices, and massage and acupressure tools. The tookit will also include user-safety guidelines and directions on how to use each tool. Tools will be included for participants with dementia and care partners.
48511959|NCT00620685|DRUG|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
48511960|NCT06006429|OTHER|Numerical dental impression by intraoral scanner|Intervention consists in an 3D intra oral representation of the oral cavity
47995373|NCT04366037|OTHER|Routine training|Training will be defined by each club coach
48681325|NCT06493643|OTHER|Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb|The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
48154765|NCT02577315|DRUG|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
48681326|NCT03930381|OTHER|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
48681327|NCT03689569|DIETARY_SUPPLEMENT|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
48681328|NCT03689569|BEHAVIORAL|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
48681329|NCT03689569|BEHAVIORAL|Starch|Patients will be given 30 grams of corn starch
48681330|NCT04365426|DEVICE|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
48681331|NCT04365426|PROCEDURE|Thermal (cold) stimulus|Water cold bath
48681332|NCT04365426|OTHER|Oral contraceptive (OC)|Oral contraceptive (OC)
48681333|NCT04365426|OTHER|No oral contraceptive (No OC)|No oral contraceptive (No OC)
48681334|NCT01789359|OTHER|Blueberry Juice|Dietary intervention
48681335|NCT03926377|PROCEDURE|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
48681336|NCT03926377|BIOLOGICAL|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
48681337|NCT03926377|PROCEDURE|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
48365120|NCT03773510|DRUG|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
48365121|NCT06026137|PROCEDURE|eFisioTrack Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity using the efisioTrack system without supervision by the physiotherapist.
48681338|NCT03926377|PROCEDURE|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
48681339|NCT01633840|OTHER|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
48681340|NCT01633840|OTHER|Elemental E028|Elemental E028 with no added food allergens
48681341|NCT03439644|OTHER|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
48681342|NCT01212471|DRUG|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
48681343|NCT01212471|DRUG|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
48681344|NCT01212471|DRUG|Placebo Comparator|sterile ophthalmic solution
48681345|NCT03277001|DRUG|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
48681346|NCT03277001|DRUG|Enoxaparin|Enoxaparin 40mg IH
48681347|NCT04310319|DIETARY_SUPPLEMENT|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
47995374|NCT04366037|OTHER|Routine training + proprioceptive exercise in warm-up|"Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
48154766|NCT02577315|DRUG|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
48154767|NCT05747352|OTHER|closed-loop hybrid insulin administration|observational non-interventional study
48681348|NCT04310319|DIETARY_SUPPLEMENT|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
48681349|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
48681350|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
48681351|NCT01135459|DRUG|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
48681352|NCT01135459|DRUG|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
48681353|NCT05242835|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
48681354|NCT05242835|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
48681355|NCT04796558|OTHER|AVAS Classification|Validation of AVAS classification
48681356|NCT05850442|DIAGNOSTIC_TEST|Questionary|Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
48681357|NCT05596318|DEVICE|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
48681358|NCT05596318|DEVICE|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
48681359|NCT01010451|PROCEDURE|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
48681360|NCT01010451|PROCEDURE|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
48681361|NCT01144624|DRUG|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
48681362|NCT01144624|DRUG|Placebo|Intravenous infusion of a saline solution
47995375|NCT04366037|OTHER|Routine training + proprioceptive exercise in cool-down|"Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds"
48365122|NCT06026137|PROCEDURE|Excercises Group|Application of manual therapy and physical modalities together with completion of the exercise program for functional recovery of the upper extremity supervised by the physical physiotherapist in a hospital room.
47995376|NCT05817019|DRUG|Sugammadex Sodium|Sugammadex Sodium 2mg/kg when TOF \>= 2, postoperative period
47995377|NCT05817019|DRUG|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg|neostigmine 50µg/kg + glycopyrollate 0.01mg/kg when TOF \>= 2, postoperative period
47995378|NCT01361438|OTHER|Total therapy approach|Total therapy approach
48365123|NCT01976403|BEHAVIORAL|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
48365124|NCT04846543|OTHER|MRI Scan|MRI scan
48681363|NCT01475643|DRUG|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
48681364|NCT01475643|DRUG|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
48681365|NCT05145699|DEVICE|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
48681366|NCT01486355|BIOLOGICAL|Measles vaccine|Edmonston-Zagreb measles vaccine
47995379|NCT04741828|DRUG|Vi-DT Typhoid Conjugate Vaccine|Typhoid Conjugate Vaccine
48365125|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
48681367|NCT00841243|DIETARY_SUPPLEMENT|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
48681368|NCT05359315|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
48365126|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
48365127|NCT01201902|BIOLOGICAL|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
48365128|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
48365129|NCT01201902|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
48365130|NCT01594424|DRUG|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
48365131|NCT01594424|DRUG|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
48365132|NCT05657301|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
48681369|NCT06227533|PROCEDURE|Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin|regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
48681370|NCT02977910|PROCEDURE|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
48681371|NCT00394758|PROCEDURE|CO2 laser surgery|
48681372|NCT00394758|PROCEDURE|ultrasonic surgical aspiration|
48681373|NCT03565822|OTHER|Interview|individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
48681374|NCT03542266|DRUG|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
48681375|NCT03542266|DRUG|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
48365133|NCT04421430|OTHER|Distraction cards|The distraction cards contain various hidden pictures and patterns which are visible only when looked at carefully. During a procedure, the child is expected to focus on the cards and answer the questions asked about what they see in them. Just before the venipuncture, the researcher showed the distraction cards participants the distraction cards and asked them to check them and then asked them questions about what they saw on the cards and kept asking questions until the end of the venipuncture. The distraction cards intervention and venipuncture were terminated at the same time.
48365134|NCT04421430|OTHER|Virtual reality|The virtual reality participants put on the virtual reality glasses and headsets about two minutes before the venipuncture and watched the 3D Dinosaur Animation movie throughout the procedure. The virtual reality intervention and venipuncture were terminated at the same time.
48511961|NCT05139888|DEVICE|Single wavelength light (red) only|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy red light (640-660 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months.
48681376|NCT00496431|DRUG|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
48681377|NCT02025634|DRUG|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
48681378|NCT02025634|DRUG|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
48681379|NCT03251027|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
48681380|NCT03251027|OTHER|Quality-of-Life|Ancillary studies
48681381|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep is crucial for processing emotional memories and consolidating implicit memories. By using targeted memory reactivation (TMR), a known method where sound S1 and sound S2 are associated with a waking experience(i.e.negative emotional words is associated with alcohol-related cues and positive emotional words is associated with healthy lifestyle cues) and strengthened during REM sleep, the investigators aim to augment the control of craving levels in patients with Alcohol Use Disorder.
48681382|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification|These patients will receive the treatment of emotional attention bias modification (EABM) without association with the sound S1 and sound S2.
48681383|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
47995380|NCT02625090|DRUG|UCB0942|"* Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral"
48681384|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
48681385|NCT00427011|DRUG|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
48681386|NCT02449811|DRUG|Perindopril|
48681387|NCT02449811|DRUG|Olmesartan|
48681388|NCT02449811|DRUG|Amlodipine|
48681389|NCT02449811|DRUG|Hydrochlorothiazide|
48681390|NCT01466205|DRUG|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
47995381|NCT06418503|OTHER|Balance Training|Participants will complete 16 sessions of balance training (30 min. each) over one month.
48681391|NCT01466205|DRUG|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
48681392|NCT00792311|PROCEDURE|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
48681393|NCT03093948|PROCEDURE|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
48681394|NCT02870062|OTHER|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
48681395|NCT02870062|OTHER|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
48681396|NCT05658718|PROCEDURE|refractive surgery|refractive surgery
48681397|NCT02094118|BIOLOGICAL|Point-of-care washed red blood cell transfusion.|
48681398|NCT02094118|BIOLOGICAL|Standard of care red blood cell transfusion.|
48365135|NCT04421430|OTHER|Buzzy|Buzzy® applies high frequency vibration and concentrated cold at injection site for procedural pain management and distraction before the shot in children and adults. Buzzy® was placed on the injection site (antecubital fossa) of the Buzzy® participants, and cold application and vibration was turned on 60 seconds before the procedure. After the 60 seconds, the nurse moved Buzzy® about 3 cm above the injection site and applied a tourniquet and performed the procedure. Buzzy® was on throughout the procedure. The Buzzy® intervention and venipuncture were terminated at the same time.
48681399|NCT03456700|DRUG|Auranofin|Given PO
48681400|NCT03456700|OTHER|Laboratory Biomarker Analysis|Correlative studies
48681401|NCT03456700|DRUG|Sirolimus|Given PO
48681402|NCT05498532|DIAGNOSTIC_TEST|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
48681403|NCT00002548|BIOLOGICAL|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
48681404|NCT00002548|DRUG|carmustine|20 mg/m2 I.V. day 1 q 35 days
47995382|NCT06418503|OTHER|EMG-Biofeedback Training|Participants will complete 16 sessions of EMG-biofeedback balance training (30 min. each) over one month.
48154768|NCT05785975|OTHER|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
48365136|NCT02760420|DRUG|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
48365137|NCT02760420|DRUG|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
48365138|NCT02573142|BEHAVIORAL|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
48681405|NCT00002548|DRUG|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
48681406|NCT00002548|DRUG|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
48681407|NCT00002548|DRUG|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
48681408|NCT00002548|DRUG|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
48681409|NCT00002548|DRUG|prednisone|40 mg/m2 PO days 1-7 q 35 days
48681410|NCT00002548|DRUG|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
48681411|NCT00002548|PROCEDURE|allogeneic bone marrow transplantation|day 0
48681412|NCT00002548|PROCEDURE|autologous bone marrow transplantation|day 0
48681413|NCT00002548|PROCEDURE|peripheral blood stem cell transplantation|day 0
48681414|NCT00002548|RADIATION|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
48681415|NCT01244035|DRUG|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
47995383|NCT04429737|DIETARY_SUPPLEMENT|clam protein capsules|The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
48154769|NCT00227422|BIOLOGICAL|Mencevax ACWY|
48681416|NCT01244035|DRUG|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
48681417|NCT01244035|DRUG|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
48681418|NCT01244035|DRUG|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
48681419|NCT01244035|DRUG|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
48681420|NCT01244035|DRUG|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
47995384|NCT04429737|DIETARY_SUPPLEMENT|Clam peptide plus Chlorella capsules|The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
47995385|NCT04429737|DIETARY_SUPPLEMENT|Placebo|The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
48154770|NCT05033054|DRUG|SGLT2 inhibitor|Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
48154771|NCT02167334|DEVICE|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
48154772|NCT02167334|PROCEDURE|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
48154773|NCT01848483|BEHAVIORAL|AIDS EPC Package plus MI|"1. Motivational Interviewing: In MI session #1, the nurse will set the agenda \& ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 \& 4, the nurse will also introduce advance care planning.~2. EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic \& conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation \& coordination of care."
48154774|NCT01848483|OTHER|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
48154775|NCT02199171|DRUG|carboplatin|Given via HIPEC
48154776|NCT06155123|DRUG|Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)|Monthly or quarterly mAbs administration for a year
48154777|NCT02084576|DRUG|Nepafenac|One drop in the study eye 3 times daily for 30 days
48154778|NCT02084576|DRUG|Ketorolac|One drop in the study eye 4 times daily for 30 days
48154779|NCT01064856|BIOLOGICAL|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
48681421|NCT02398201|DRUG|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
48365139|NCT02573142|BEHAVIORAL|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
48681422|NCT04361448|OTHER|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
48681423|NCT01191515|DEVICE|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
48681424|NCT06418737|BEHAVIORAL|Sleep HygieneTraining|"Training Content~* Importance of Sleep: The vital importance of sleep for physical and mental health.~* Benefits of Adequate and Quality Sleep: The numerous benefits of sufficient and good quality sleep.~* Sleep Stages: The different stages of sleep and their characteristics.~* Sleep Hygiene: The concept of sleep hygiene and its importance for improving sleep quality.~* What to Do?~* What to Avoid for Better Sleep?"
48365140|NCT05768776|PROCEDURE|HoLEP patients without MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, without using MOSES technology
48681425|NCT03410719|OTHER|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).
47995386|NCT05879107|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
48365141|NCT05768776|PROCEDURE|HoLEP patients with MOSES(TM) 2.0 effect (open label)|HoLEP surgery for the treatment of Benign Prostate Hyperthrophy, with the use of MOSES technology
48365142|NCT01250236|DRUG|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
48681426|NCT05317026|PROCEDURE|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
48154780|NCT01064856|BIOLOGICAL|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
48154781|NCT03803488|DEVICE|DropSafe safety pen needle|
48365143|NCT01250236|DRUG|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
48365144|NCT04126759|DEVICE|P0.3|Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
48365145|NCT02046213|DRUG|E2006|Single oral 10mg dose of 100 uCi \[14C\]E2006
48365146|NCT04187612|DEVICE|Bioelectrical Impedance Analysis (BIA)|BIA will be used to determine total body water
48365147|NCT05407168|OTHER|Best Practice|Receive standard of care
48365148|NCT05407168|OTHER|Health Promotion and Education|View decision aid
48365149|NCT05407168|OTHER|Questionnaire Administration|Ancillary studies
48365150|NCT03629834|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Maintenance Wakefulness Test
48365151|NCT05597189|DIETARY_SUPPLEMENT|Experimental product|Botanical extract
48365152|NCT05597189|OTHER|Control product consumption|Product with identical characteristics to the experimental product.
48681427|NCT05317026|PROCEDURE|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
48681428|NCT00260728|DEVICE|vascular access graft implantation|vascular access graft implantation
48681429|NCT05694663|DEVICE|Vivistim|After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
48681430|NCT04867083|DRUG|ARV bitherapie|"1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day"
48365153|NCT02612129|DRUG|arimoclomol|
48681431|NCT00076089|DRUG|Roflumilast|
48681432|NCT00610844|PROCEDURE|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
47995387|NCT05879107|BIOLOGICAL|PCV20|One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
48154782|NCT00208832|PROCEDURE|Graphic medication schedule (Pill card)|
48154783|NCT00208832|PROCEDURE|Refill reminder postcard|
48154784|NCT03896971|DRUG|Combination of thrombopoietin mimetic and cyclosporin A|This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
48154785|NCT00045201|DRUG|Erlotinib Hydrochloride|Given orally
48365154|NCT02612129|DRUG|Placebo|
48365155|NCT00380601|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
48365156|NCT02709239|DIETARY_SUPPLEMENT|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
48365157|NCT02709239|DIETARY_SUPPLEMENT|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
48365158|NCT03794856|OTHER|Functional and Structural Magnetic Resonance Imaging (research grade)|Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
48681433|NCT04356300|BIOLOGICAL|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
48681434|NCT02288000|DRUG|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
48681435|NCT02288000|DRUG|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
48681436|NCT01849315|BEHAVIORAL|AKIDS II|Physically active intervention
48681437|NCT03549338|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
48681438|NCT03549338|DRUG|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
48681439|NCT03549338|DRUG|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
48154786|NCT00045201|DRUG|Irinotecan Hydrochloride|Given IV
48365159|NCT03794856|OTHER|Cognitive Function Testing (non-diagnostic)|Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
48511962|NCT05139888|DEVICE|Dual wavelength light (red/blue)|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy dual wavelength light (640-660 nm and 405-450 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months..
47995388|NCT03044405|DIAGNOSTIC_TEST|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
48681440|NCT05433701|RADIATION|Stereotactic Body Radiotherapy|"* Verify the setup position and respiration of patients as in the simulation CT image.~* To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~* The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment."
47995389|NCT03044405|DIAGNOSTIC_TEST|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
47995390|NCT02482103|PROCEDURE|Renal denervation|Catheter based renal nerve ablation
48154787|NCT03364556|OTHER|No intervention|
48154788|NCT02400372|DEVICE|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
48154789|NCT01613456|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
48365160|NCT03794856|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Participants will fill out asthma and psychological questionnaires (non-diagnostic)
48681441|NCT05433701|PROCEDURE|Radiofrequency Ablation|- RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
48681442|NCT00235183|OTHER|plasma|transfusion of more than 15 mL/Kg of plasma
48681443|NCT05177419|DRUG|Lysergic Acid Diethylamide|100 micrograms LSD base
48511963|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
48681444|NCT05177419|DRUG|Lysergic Acid Diethylamide|Low dose of LSD base
48681445|NCT04923334|BEHAVIORAL|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
47995391|NCT00301210|DRUG|Tramadol|oral doses four times per day
47995392|NCT06008509|PROCEDURE|Gastric echography preoperative|Patients with acute abdomen that are going to surgery, are going to recieve a gastric echography in the surgery room before the start of anesthesia. This procedure include vision of the stomach during supine position and lateral position with curve transductor.
47995393|NCT01113632|DRUG|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
47995394|NCT00486694|DRUG|Sulfadoxine-pyrimethamine + artesunate|
47995395|NCT00486694|DRUG|Chloroquine|
48154790|NCT01613456|DIETARY_SUPPLEMENT|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
48154791|NCT02852499|OTHER|Urine sampling|
48154792|NCT02852499|OTHER|Carry a GPS and BET|
48154793|NCT02852499|OTHER|Carry pollution sensor|
48154794|NCT02852499|OTHER|Sampling at the maternity|
48154795|NCT02852499|OTHER|Self-questionnaires|
48154796|NCT02852499|OTHER|Sampling in partum period|Meconium and a strand of hair.
48681446|NCT04923334|BEHAVIORAL|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
48681447|NCT00581048|DRUG|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
47995396|NCT02794662|PROCEDURE|Oxygen Environment|FiO2 delivered by servo-controlled incubator
47995397|NCT02794662|PROCEDURE|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
47995398|NCT02628795|BEHAVIORAL|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
48154797|NCT04647409|OTHER|screening|The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
48154798|NCT03255785|DEVICE|Cataract surgery plus one iStent and one iStent Supra implanted|Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
48154799|NCT00708799|OTHER|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
48154800|NCT06169878|DEVICE|Adjustable lower limb abduction apparatus|"To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking."
48154801|NCT00578929|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
48154802|NCT00578929|DRUG|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
48154803|NCT05820542|OTHER|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
48154804|NCT05820542|OTHER|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
48365161|NCT06427616|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus push-ups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, feet will be placed flat on the ground. Participants will then move their heels up and down continuously.~Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till their 60-80% of their maximum heart rate is achieved and maintained"
48365162|NCT06427616|BEHAVIORAL|Sustained Soleus Push-ups|"Participants will start soleus push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and feet will be placed flat on the ground. Participants will then move their heels up and down continuously for.~Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum of 4 min break time after every 90 mins intervention. In the meantime, their blood sample will be collected"
48365163|NCT00038116|PROCEDURE|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
48365164|NCT00038116|PROCEDURE|placebo|sham surgery
48681448|NCT00838812|DRUG|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
48681449|NCT00539123|BEHAVIORAL|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
47995399|NCT02628795|OTHER|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
47995400|NCT01648855|OTHER|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
47995401|NCT04930354|DRUG|ECP-1014|Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
47995402|NCT03737747|PROCEDURE|induced hypothermia|
48154805|NCT01153997|DRUG|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
48154806|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
48365165|NCT00166803|DRUG|Rosiglitazone|Rosiglitazone , 4 mg daily
48365166|NCT02277418|DEVICE|VAVL|Videolaryngoscope
48365167|NCT02277418|DEVICE|MIL|Direct laryngoscopy
48511964|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
48154807|NCT01153997|DRUG|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
48154808|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
48154809|NCT01525875|DRUG|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
48154810|NCT01525875|DRUG|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
48365168|NCT02748018|DEVICE|670G and 770G Insulin Pump|Medtronic 670G and 770G Hybrid Closed Loop Systems
48365169|NCT02748018|DEVICE|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
48154811|NCT01840124|PROCEDURE|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
48365170|NCT04804111|DRUG|arm 0|placebo group
48681450|NCT00539123|BEHAVIORAL|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
48365171|NCT04804111|DRUG|arm 1|3 mg of the URC102 group
48681451|NCT05064046|BEHAVIORAL|LuCa + Health Disparity module|"The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making."
48365172|NCT04804111|DRUG|arm 2|6 mg of the URC102 group
48511965|NCT02928055|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
48511966|NCT01263938|DRUG|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
48511967|NCT02220062|PROCEDURE|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5\~10cc ethanol would be performed as bilateral injections at the celiac trunk.
48511968|NCT02220062|PROCEDURE|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2\~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
48511969|NCT06035835|COMBINATION_PRODUCT|Lacticaseibacillus rhamnosus|Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
47995403|NCT06523036|PROCEDURE|Combined chiropractic care and Tai Chi|Chiropractic will be personalized to the patients clinical needs within the scope of chiropractic practice in the Commonwealth of Massachusetts including: posture correction/spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation/mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports. Chiropractic will be administered by one of two chiropractors at the Osher Clinical Center. Tai Chi will take place at one of two schools used in prior NIH funded trials.
48365173|NCT04804111|DRUG|arm 3|9 mg of the URC102 group
47995404|NCT00379626|DRUG|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
48365174|NCT04804111|DRUG|arm 4|Febuxostat 80 mg
48365175|NCT04703959|OTHER|polysomnography|polysomnography is already done for all patients
48365176|NCT01626599|DEVICE|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~* is not implantable and no surgical procedure is required for a human subject to use the devices;~* is not for use in supporting or sustaining a human life; and~* is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~* Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
48511970|NCT06035835|COMBINATION_PRODUCT|Lactobacillus acidophilus + Bifidobacterium bifidum|Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
47995405|NCT05004155|DIAGNOSTIC_TEST|24 hour pH & impedance monitoring|24 hour pH impedance monitoring will be done on healthy subjects so that normative data specific to indian population can be generated.
47995406|NCT04177602|COMBINATION_PRODUCT|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
47995407|NCT04177602|COMBINATION_PRODUCT|Capecitabine based chemoradiation|Capecitabine based chemoradiation
47995408|NCT04926532|DRUG|Toripalimab|Toripalimab is a humanized anti-PD-1 monoclonal antibody
47995409|NCT04926532|DRUG|Sorafenib|Sorafenib is a multi-kinase inhibitor
47995410|NCT00471848|DRUG|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
47995411|NCT02141282|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
48154812|NCT00561678|DRUG|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
48154813|NCT00561678|DRUG|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
48154814|NCT01671371|OTHER|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
48511971|NCT05529446|DEVICE|Combination therapy (CT)|Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
48511972|NCT06467396|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of blood biomarkers (FABP+NT-proBNP) associated to Large Vessel Occlusion in blood samples used in combination with an APP.
48681452|NCT03527511|OTHER|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
48681453|NCT06090123|DRUG|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
48681454|NCT06090123|DRUG|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
47995412|NCT04308837|DRUG|Paclitaxel|50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
48154815|NCT02250911|OTHER|webcasts|
48154816|NCT02250911|BEHAVIORAL|Assessments|
48154817|NCT02250911|OTHER|Usual care|
47995413|NCT04308837|DRUG|Carboplatin|Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.
47995414|NCT04308837|DRUG|Dexamethasone|All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)
47995415|NCT04308837|DRUG|Diphenhydramine|All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)
48154818|NCT02502188|DRUG|CC-90005|
48154819|NCT02502188|DRUG|Placebo|
48681455|NCT06090123|DRUG|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
48681456|NCT01783197|DRUG|Paclitaxel|
48681457|NCT01783197|DRUG|Carboplatin|
48681458|NCT01783197|DRUG|Selumetinib|
48681459|NCT01783197|DRUG|Pemetrexed|
48681460|NCT01783197|DRUG|Cisplatin|
48681461|NCT03666338|OTHER|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
48681462|NCT05621122|OTHER|This is an observational study|This is an observational study. The control group (omnivours) will be compared with all otgher groups
48681463|NCT04871828|DRUG|Leukotriene Receptor Antagonist|Zafirlukast
48681464|NCT04871828|OTHER|Placebo|Placebo
48681465|NCT04081662|BEHAVIORAL|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
48681466|NCT01640015|OTHER|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
48681467|NCT02514291|BEHAVIORAL|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
48681468|NCT04514731|DRUG|Magnesium sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.
48681469|NCT04514731|DRUG|Isotonic Saline|Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
48681470|NCT03961191|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
48681471|NCT03961191|DIAGNOSTIC_TEST|high-risk HPV|High-risk HPV testing for the cervical cytology
48681472|NCT03961191|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
48681473|NCT01973010|OTHER|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
48681474|NCT01973010|DRUG|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
48681475|NCT05963243|OTHER|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
47995416|NCT04308837|DRUG|Famotidine|All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)
48154820|NCT05219747|OTHER|Mucoadhesive film containing Acmella oleracea extract|Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours
48154821|NCT05219747|OTHER|Mucoadhesive film without Acmella oleracea extract|Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
48154822|NCT03204318|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
48365177|NCT01208376|OTHER|Fibroscan|Fibroscan and Serum Fibrose-marker
48365178|NCT00948389|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
48681476|NCT05918965|DEVICE|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
48681477|NCT02213497|RADIATION|18F-FDG (Fluorodeoxyglucose) PET|
48681478|NCT02213497|DRUG|Carboplatin|
47995417|NCT04308837|DRUG|Palonosetron|All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)
48365179|NCT00948389|DRUG|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
48511973|NCT02658942|PROCEDURE|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
48511974|NCT02658942|PROCEDURE|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
48681479|NCT02213497|DRUG|Paclitaxel|
48681480|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
48681481|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
48681482|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
48681483|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
48681484|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
48681485|NCT05991583|DRUG|IBB0979|IBB0979 should be subcutaneous injected，qw
48511975|NCT03554434|BIOLOGICAL|AM0010|AM0010
47995418|NCT04308837|RADIATION|3D conformal or intensity modulated radiotherapy|Treatment will be given 5 days per week. Photon beams \>6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.
48681486|NCT01296971|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
48681487|NCT01296971|DRUG|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
48511976|NCT05349552|RADIATION|stereotactic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
48511977|NCT04382287|PROCEDURE|Remin Pro® and MI Paste Plus®|Te toothastes were applied at home twice a day over the six anterior upper primary teeth
48511978|NCT02715570|DRUG|PC945 - single doses|Safety and tolerability of single doses
48511979|NCT02715570|DRUG|Placebo - single doses|Safety and tolerability of single doses
48511980|NCT02715570|DRUG|PC945 - repeat doses|Safety and tolerability of repeat doses
48511981|NCT02715570|DRUG|Placebo - repeat doses|Safety and tolerability of repeat doses
48511982|NCT01860274|DEVICE|External Mesh for vein grafts|
48511983|NCT02248883|DRUG|TPV low|
48365180|NCT00182364|DRUG|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
48365181|NCT02561572|OTHER|Acupuncture|Yintang point acupuncture
48365182|NCT02517502|DRUG|DHA|4 capsules of 400 mg DHA daily
48365183|NCT02517502|DRUG|Placebo|Matched, blinded placebo
48365184|NCT01880320|DRUG|CD0271 0.3% / CD1579 2.5%|
48365185|NCT01880320|DRUG|CD0271 0.1% / CD1579 2.5%|
48365186|NCT01880320|DRUG|Topical Gel Vehicle|
48511984|NCT02248883|DRUG|Placebo|
48511985|NCT02248883|DRUG|Moxifloxacin|
48511986|NCT02248883|DRUG|TPV high|
48511987|NCT02248883|DRUG|RTV|
48511988|NCT06210022|DIAGNOSTIC_TEST|Neuropsychological Assessment|Cognitive evaluation and clinical monitoring of seizure frequency
48681488|NCT01296971|DRUG|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
48681489|NCT00945568|DRUG|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
48681490|NCT00413673|PROCEDURE|PRK|PRK
48681491|NCT05386147|DEVICE|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
48681492|NCT04021316|OTHER|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
48681493|NCT04021316|OTHER|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
48511989|NCT04277962|DEVICE|Triton L and D system for estimation of blood loss at time of vaginal delivery|The Triton L\&D system (Gauss Surgical, Inc., Menlo Park, CA) is an FDA-cleared mobile application on a tablet computer (iPad) that facilitates quantification of blood loss (QBL) by providing an easy to use process and user interface. Dry weights of all potential blood containing substrates are built-in to the device allowing batch weighing with automatic subtraction of dry weights. There is also a V-drape simulator accounting for collected fluids with automatic subtraction of a measured amount of amniotic fluid.
48511990|NCT00611624|RADIATION|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
48511991|NCT01851330|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
48511992|NCT01851330|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48511993|NCT02944773|PROCEDURE|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
48511994|NCT03981913|BEHAVIORAL|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
48511995|NCT05847829|DEVICE|T-REEX algorithm|Phase locked transcranial stimulation.
48511996|NCT03092973|DIAGNOSTIC_TEST|Ultrasound|
48511997|NCT01992718|PROCEDURE|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included."
48511998|NCT01992718|PROCEDURE|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
48681494|NCT03706768|OTHER|Glycocalyx|Measure Degradation of the Glycocalyx
48681495|NCT05604573|DIAGNOSTIC_TEST|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
47995419|NCT04308837|PROCEDURE|Surgical resection|Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.
48681496|NCT00097929|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
48681497|NCT01993134|PROCEDURE|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
48681498|NCT01993134|PROCEDURE|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
48681499|NCT04695353|PROCEDURE|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
48681500|NCT01990976|DEVICE|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
48681501|NCT01990976|PROCEDURE|Biopsy|biopsy of the vastus lateralis muscle
47995420|NCT04308837|RADIATION|Adjuvant Chemotherapy|The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
47995421|NCT00579956|DRUG|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
47995422|NCT00579956|DRUG|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
47995423|NCT04136392|DEVICE|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
48154823|NCT03204318|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
48154824|NCT03204318|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
48511999|NCT06331767|BEHAVIORAL|mSYNC|mSYNC in an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. Taking a behavioral medicine approach, mSYNC simulates hospital-based consultation \& liaison psychology service by intervening on interrelated health risk behaviors, mental health issues, and structural/treatment needs. The mHealth app includes modules with motivational interviewing for HIV/drug use risk behaviors, cognitive behavioral therapy for transdiagnostic psychological coping skills, referral system for needed hospital-based services (mental health/drug use treatment; HIV prevention; social services), and access to geolocated resources.
48681502|NCT00773643|OTHER|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
48681503|NCT04804696|DRUG|Toripalimab|Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
47995424|NCT00528723|DRUG|salbutamol 100 mcg|To be used as needed for symptom relief
47995425|NCT00528723|DRUG|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
47995426|NCT00528723|DRUG|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
47995427|NCT00491387|DRUG|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
48154825|NCT03204318|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
48154826|NCT04195334|DEVICE|internal fixation by IMN|using retrograde or antegrade IMN for femooral fractures fixation using a fit nail to the femoral intramedullary canaland follow up for union
48154827|NCT05056207|OTHER|Cohort I (patients receiving annual lymphedema screening|patientns who previously underwent preoperative perometer lymphedema screening
48154828|NCT05056207|OTHER|Cohort II (patients followed intensively for lymphedema)|patients who have recently undergone ALND
48154829|NCT04453137|BIOLOGICAL|Adalimumab originator|Subcutaneous injection every other week
48154830|NCT04453137|BIOLOGICAL|Adalimumab biosimilar|Subcutaneous injection every other week
48512000|NCT06273501|DRUG|Magtrace|Patients will receive superficial and interstitial injection with a 23 G needle with of a total volume of 0.1 - 1 ml Magtrace at four sites in or near the tumor in vulva, the same localization as the injections of Technetium99m and Patent blue for tracing SLNs performed at the surgery. The injection is performed by one of the gynecologic cancer surgeons participating in this study.The time of migration of SPIO to the groin nodes is not known for vulvar cancer. Transportation by dynamic MRI, with selective sequences repeated during a time span of 1- 60 minutes after the injection.
48681504|NCT04804696|DRUG|Paclitaxel|Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
48681505|NCT04804696|DRUG|Cisplatin|Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
48681506|NCT06511960|OTHER|Astaxanthin (12 mg/day) intervention|12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
48154831|NCT00026078|DRUG|docetaxel|
48154832|NCT00026078|DRUG|ifosfamide|
48512001|NCT00000978|DRUG|Zidovudine|
48681507|NCT06511960|OTHER|36 mg/day astaxanthin intervention|36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
48681508|NCT06511960|OTHER|Placebo|12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
48154833|NCT02948686|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
48154834|NCT02948686|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
48681509|NCT04796129|OTHER|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
48681510|NCT05071612|DRUG|AD109|Oral administration at bedtime
48681511|NCT05071612|DRUG|AD504|Oral administration at bedtime
48512002|NCT00000978|DRUG|Zalcitabine|
48512003|NCT05906524|DRUG|KD6001|KD6001 will be administered intravenously.
48512004|NCT05906524|DRUG|Tislelizumab|Tislelizumab will be administered intravenously.
48512005|NCT05906524|DRUG|Bevacizumab|Bevacizumab will be administered intravenously.
48681512|NCT05071612|DRUG|Atomoxetine Hydrochloride|Oral administration at bedtime
48681513|NCT05071612|DRUG|Placebo|Oral administration at bedtime
48681514|NCT02110485|OTHER|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
48681515|NCT04760483|DEVICE|SoracteLite(TM) TPLA for BPH|see prior section
48681516|NCT02849834|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
48681517|NCT02588417|DRUG|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
48681518|NCT02588417|DRUG|Levobupivacaine|levobupivacaine 2.5 mg
48681519|NCT01102491|DRUG|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
48681520|NCT06095869|OTHER|progressive relaxation exercise|Breastfeeding mothers in the progressive relaxation exercise group were applied gradual relaxation exercise before going to bed 3 days a week and for 4 weeks, under the supervision of the researcher, accompanied by a training CD prepared by the Turkish Psychologists Association.
48681521|NCT06095869|OTHER|relaxation background music|In the relaxation background music group, breastfeeding mothers were listened to relaxation background music on the Progressive Relaxation Exercise CD before going to bed 3 days a week and for 4 weeks.
48681522|NCT06095869|OTHER|control group|Mothers in this group received routine care practices in the clinic. No intervention was made to the mothers in the control group, only data collection tools were applied.
47995428|NCT01733407|DRUG|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
48681523|NCT03971162|DRUG|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
48681524|NCT03971162|DRUG|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
48681525|NCT05050292|OTHER|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
48681526|NCT05050292|OTHER|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
48681527|NCT05497739|DRUG|Intraperitoneal chemotherapy|5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
48681528|NCT05497739|DRUG|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
48681529|NCT03040089|DEVICE|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
48681530|NCT03040089|DRUG|Neoquine Cream 2%|2% hydroquinone cream
47995429|NCT01733407|DRUG|placebo|400mg/kg/d divided TID for year 1 only.
48681531|NCT03069833|DIAGNOSTIC_TEST|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
48681532|NCT01048398|DRUG|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
48681533|NCT01048398|DRUG|paracetamol|Control group: intravenous paracetamol 1g
47995430|NCT05595512|BEHAVIORAL|Naser Al-Husban|depressive symptoms within 6 months of delivery
47995431|NCT03332576|BIOLOGICAL|DPX-Survivac|SubQ injection
47995432|NCT03332576|BIOLOGICAL|DPX-Survivac(Aqueous)|SubQ injection
48681534|NCT03641807|OTHER|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
48681535|NCT03641807|OTHER|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
48681536|NCT02466477|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
47995433|NCT03332576|DRUG|Cyclophosphamide|PO BID
47995434|NCT01787227|DEVICE|xTAG RPP|
47995435|NCT04356690|DRUG|Etoposide|Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
48681537|NCT02466477|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
48681538|NCT02466477|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
47995436|NCT01571258|BEHAVIORAL|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
48681539|NCT04345692|DRUG|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
48681540|NCT01918241|DRUG|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
48681541|NCT01918241|DRUG|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
48681542|NCT01918241|DRUG|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
48681543|NCT01918241|DRUG|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
48681544|NCT04625400|DIAGNOSTIC_TEST|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
47995437|NCT03837873|DRUG|Rituximab|rituximab 750mg/m2 i.v. on day 0
47995438|NCT03837873|DRUG|Etoposide|50mg/m2, continuous i.v. on day 1-4
47995439|NCT03837873|DRUG|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
48681545|NCT05740046|DEVICE|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
48681546|NCT00255216|DRUG|Policosanol supplement (oral capsule) vs. placebo|
48681547|NCT01234181|PROCEDURE|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
48681548|NCT04476381|PROCEDURE|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
48681549|NCT05836831|DRUG|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
48681550|NCT05096637|OTHER|PreventiPlaque App|PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
48681551|NCT02547103|OTHER|Chlorhexidine gluconate-soaked cloths|
47995440|NCT03837873|DRUG|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
47995441|NCT03837873|DRUG|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
47995442|NCT03837873|DRUG|Cyclophosphamide|750mg/m2, i.v. on day5
47995443|NCT03837873|DRUG|Lenalidomide|25mg/day, p.o. on day 0-9
47995444|NCT03837873|DRUG|Cisplatin|100mg/m2 continuous i.v. on day 1
47995445|NCT03837873|DRUG|Cytarabine|2g/m2 q12h, i.v. on day 2
47995446|NCT04611763|DRUG|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
47995447|NCT04611763|DRUG|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
47995448|NCT00099554|DRUG|Etanercept|
47995449|NCT01865279|DRUG|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
47995450|NCT01865279|DRUG|placebo|Ascending single doses - 5 dose levels
47995451|NCT01865279|DRUG|insulin degludec|A single dose corresponding to that of isophane human insulin
47995452|NCT01865279|DRUG|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
47995453|NCT00559520|DIETARY_SUPPLEMENT|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
47995454|NCT00559520|DIETARY_SUPPLEMENT|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
47995455|NCT02574247|PROCEDURE|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
47995456|NCT03329495|PROCEDURE|SMA-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
47995457|NCT03329495|PROCEDURE|SMV-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
47995458|NCT04713475|BIOLOGICAL|PBGM01|AAVhu68 viral vector
48681552|NCT02547103|OTHER|Normal saline|
48681553|NCT02547103|OTHER|mupirocin ointment|
48681554|NCT05195086|DRUG|endoxan|Immunosuppressant
48681555|NCT05195086|DRUG|cellcept|Immunosuppressant
48681556|NCT05752097|DEVICE|[18F]AlF-NOTA-FAPI-04 PET/CT examination|The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
48681557|NCT05752097|PROCEDURE|Renal puncture biopsy|The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
48681558|NCT01340664|DRUG|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
48681559|NCT01340664|DRUG|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
48681560|NCT01340664|DRUG|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
48681561|NCT01340664|DRUG|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
47995459|NCT04064918|OTHER|Netarsudil 0.02% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
47995460|NCT04064918|OTHER|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
47995461|NCT03774277|BEHAVIORAL|Packed Promise for a Healthy Heart|"Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app"
47995462|NCT00056030|BIOLOGICAL|cetuximab|
48154835|NCT02948686|OTHER|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
48512006|NCT02018380|OTHER|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
48681562|NCT04119765|BIOLOGICAL|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
48681563|NCT04119765|BIOLOGICAL|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
47995463|NCT00056030|DRUG|fluorouracil|
47995464|NCT00056030|DRUG|leucovorin calcium|
47995465|NCT00056030|DRUG|oxaliplatin|
47995466|NCT01566955|PROCEDURE|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
48681564|NCT04119765|PROCEDURE|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
47995467|NCT00940212|DRUG|AZD2423|oral, single administration
47995468|NCT00940212|DRUG|Placebo|oral administration and single dose
47995469|NCT04327219|OTHER|CDED diet|examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
47995470|NCT02132767|DRUG|Amiodarone|"Amiodarone Initial Dose~* Oral: 400 mg po TID for 3 days is recommended~* For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~* Oral: at least 200 mg/day to be continued until 60 days after randomization~* If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
47995471|NCT02132767|PROCEDURE|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
47995472|NCT02132767|DRUG|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
47995473|NCT05339620|PROCEDURE|implant driver facilitated micro-osteoperforations|"3 micro-osteoperforations(in a vertical pattern) are done on the randomly allocated experimental side , distal to canine under local anesthesia. the other side of the mouth is used as a control.~alginate impression is taken before the intervention ."
48681565|NCT04119765|PROCEDURE|central pressure measurement|central pressure will be measured thank to the Complior® device
47995474|NCT04287777|DRUG|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
47995475|NCT04287777|DRUG|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
47995476|NCT04287777|DRUG|Placebo|Topical administration of Placebo (ointment) TID during 7 days
47995477|NCT05700435|BEHAVIORAL|Stress Management and Resilience Training|The Stress Management and Resilience Training (SMART) program focuses on improving the practices of gratitude, mindful presence, kindness, and developing a resilient mindset. In this proposed study, SMART will be provided via either a two-hour, video teleconference (VTC) or in-person training or by completion of a self-paced, on-line version completed over a period of four to eight weeks. The modalities VTC and in-person are the two intervention conditions.
47995478|NCT02548520|OTHER|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
48681566|NCT05761808|OTHER|exercises|Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.
48681567|NCT05761808|OTHER|neuromuscular electrical stimulation|NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
48681568|NCT00347932|DRUG|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
48681569|NCT00347932|DRUG|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
48681570|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
48681571|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
48154836|NCT02948686|OTHER|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
48154837|NCT05563961|DRUG|Panadol®|Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
48154838|NCT05563961|DRUG|SafeTynadol®|"Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)"
48154839|NCT03563170|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
48512007|NCT01772485|BEHAVIORAL|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
47995479|NCT02979145|OTHER|No intervention involved|
48154840|NCT03563170|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
48154841|NCT03563170|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
48154842|NCT03563170|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
48154843|NCT03563170|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
48154844|NCT03563170|DRUG|Cyclophosphamide|anhydrous
48154845|NCT03563170|DRUG|5-Fluorouracil|5-FU; Fluorouracil
48154846|NCT03563170|DRUG|Leucovorin|Leucovorin calcium salt
48154847|NCT03563170|DRUG|nab-Paclitaxel|ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
48512008|NCT01772485|BEHAVIORAL|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
48512009|NCT01128309|BEHAVIORAL|Stress Reduction Intervention|eight week group program, plus daily homework practice
48512010|NCT01128309|BEHAVIORAL|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
48512011|NCT03960125|DEVICE|Photodynamic Therapy|Blue Light Therapy Exposure
48512012|NCT03960125|DRUG|4% Imipramine|A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
48512013|NCT03960125|DRUG|Base Cream|Control to 4% Imipramine
48512014|NCT01887171|DRUG|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
48512015|NCT02130115|DEVICE|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
48512016|NCT05473143|OTHER|Protocol-based fluid management|"Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components. Fluid removal will be prescribed using a standardized template updated at least once per working day, before noon of each day, by the attending care team. This protocolized prescription will contain three components.~The first component of this prescription will be to define the 24h-fluid balance target either aiming for a negative fluid balance of 2 to 3% body weight (1.4-2.1 liters in a 70 Kg participant) (Option 1) or by aiming to avoid fluid accumulation by targeting a neutral fluid balance within 0.5% of body weight variation (-350 to +350 mL in a 70 Kg participant) (Option 2).~The second component is to pre-specify a prescription for fluid removal using KRT.~The third component is to prompt a daily re-evaluation of fluid intake by the attending care team."
48681572|NCT03329625|BEHAVIORAL|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
48681573|NCT03329625|BEHAVIORAL|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
48681574|NCT02014662|OTHER|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
48681575|NCT01084343|BIOLOGICAL|MYM-V101|"* Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
48154848|NCT03563170|DRUG|Sorafenib|NEXAVAR® tablets, for oral use
48154849|NCT03563170|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
48154850|NCT03563170|BIOLOGICAL|Aldoxorubicin hydrochloride|HCl
48154851|NCT03563170|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
48154852|NCT03563170|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
48154853|NCT03563170|BIOLOGICAL|GI-6207|CEA yeast vaccine
48154854|NCT03563170|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
48681576|NCT01564251|DRUG|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
48681577|NCT01564251|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
48681578|NCT01575808|DEVICE|GP1101|Endovascular stent graft implantation
48681579|NCT00714506|BEHAVIORAL|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
48681580|NCT00714506|OTHER|Physical activity control|physical activity plus successful aging health education
48681581|NCT03188263|OTHER|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
48154855|NCT03563170|DRUG|Cetuximab|ERBITUX® injection, for IV infusion)
48681582|NCT03188263|OTHER|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
48681583|NCT01356498|BIOLOGICAL|pegloticase|8 mg intravenous infusion
48681584|NCT05427123|OTHER|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
48681585|NCT02146053|DIETARY_SUPPLEMENT|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
48681586|NCT02146053|DIETARY_SUPPLEMENT|Placebo|placebo capsules: methyl cellulose
48681587|NCT02278341|DRUG|Roxadustat|Participants received initial dose of roxadustat orally as a tablet in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
48681588|NCT02278341|DRUG|Epoetin alfa|Participants received epoetin alfa via intravenous or subcutaneous injection, once a week, twice a week, or three times a week (TIW). Epoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of epoetin alfa was per UK SmPC of Eprex®. Participants received IV iron supplementation according to the standard of care.
48681589|NCT02278341|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa via intravenous or subcutaneous injection, once a week or once every other week. Darbepoetin alfa dosage was adjusted to maintain Hb level within the target range. Dosing of darbepoetin alfa was per EU SmPC of Aranesp®. Participants received IV iron supplementation according to the standard of care.
48681590|NCT02278341|DRUG|Iron|Oral iron treatment was recommended for supplementation to support erythropoiesis and as first-line treatment for iron deficiency, unless participant was intolerant to this treatment. For participants receiving roxadustat the recommended daily dose was 200 mg of elemental iron. Participants were advised to take roxadustat at least 1 hour before or 1 hour after oral iron. Intravenous iron supplementation for participants receiving roxadustat was allowed if all of the following criteria were met: The participant's Hb level had not responded adequately to roxadustat following two consecutive dose increases or reached the maximum dose limit, and participant's ferritin was \< 100 ng/mL (\< 220 pmol/L) or TSAT \< 20%, or the participant was intolerant of oral iron therapy. For participants treated with epoetin alfa or darbepoetin alfa, IV iron supplementation was given according to standard of care.
48681591|NCT03343340|OTHER|Early CRRT|Continous Renal Replacement Therapy
48681592|NCT03343340|OTHER|Late CRRT|Continous Renal Replacement Therapy
48681593|NCT03343340|OTHER|Standard Medical Therapy|Standard Medical Therapy
48154856|NCT03563170|BIOLOGICAL|N-803|Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
48154857|NCT04789616|DRUG|Maraviroc|Half of the participants will take maraviroc for a period of 8 weeks.
48512017|NCT05473143|OTHER|Usual care|The net fluid removal and the rate of net fluid removal will not be protocolized and will be prescribed and adjusted according to the attending care team without any specific guidance. The use of the documents provided for the intervention group will not be permitted in the control arm.
48512018|NCT02208739|PROCEDURE|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
48681594|NCT04914156|OTHER|Genetic based dietary advice|Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.
48681595|NCT04914156|OTHER|Personalised population based dietary advice|Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
48512019|NCT02208739|PROCEDURE|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
48681596|NCT01206634|PROCEDURE|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
48681597|NCT01206634|BEHAVIORAL|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
48681598|NCT00370266|DRUG|Triamcinolone|
48365187|NCT01489332|DRUG|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
48365188|NCT03341728|BEHAVIORAL|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
48365189|NCT03341728|BEHAVIORAL|Normal walking|Usual treadmill walking without optical flow perturbations
48365190|NCT05384821|DRUG|Vincristine|IV, D1-D22-D43 and D64
48365191|NCT05384821|DRUG|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
48365192|NCT05384821|DRUG|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
48365193|NCT05384821|DRUG|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
48365194|NCT05384821|DRUG|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
48154858|NCT04789616|BEHAVIORAL|Exercise Program|"All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program."
48154859|NCT04789616|OTHER|Placebo|Half of the participants will take a placebo for a period of 8 weeks.
48154860|NCT04789616|DEVICE|Activity Sensor|"Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study."
48154861|NCT04789616|BEHAVIORAL|Motor Learning|Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
48681599|NCT06192290|BEHAVIORAL|Home-based transitional Cardiac Telerehabilitation|This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
48154862|NCT03872661|DRUG|IBI308|IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.
48154863|NCT03872661|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.
48154864|NCT03872661|DRUG|Pemetrexed|Pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.
48154865|NCT03872661|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.
48154866|NCT03872661|PROCEDURE|Thoracic surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
48154867|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
48154868|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
48154869|NCT02501616|DRUG|Metformin|
48154870|NCT02501616|DRUG|Dapagliflozin|
48512020|NCT03729726|BEHAVIORAL|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
48512021|NCT04464070|DIETARY_SUPPLEMENT|niacin|induce biosynthesis of PGD2
48681600|NCT02480088|DRUG|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
48681601|NCT02480088|DRUG|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
48154871|NCT00801151|DRUG|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
48154872|NCT04123938|OTHER|Pea Protein|Soluble pea protein
48154873|NCT04123938|OTHER|Whey Protein|Whey protein concentrate
48154874|NCT04123938|OTHER|Maltodextrin|Non-protein isocaloric comparator
48365195|NCT02950168|PROCEDURE|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
48365196|NCT02935010|DRUG|Esomeprazole|proton pump inhibitor
48512022|NCT04464070|DRUG|aspirin|inhibition of cyclooxygenase
48365197|NCT02935010|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
47914326|NCT05239780|PROCEDURE|Brain stimulation|Brain stimulation will be performed after collection of clinical seizure data. Bipolar stimulation to one or several adjacent electrodes will be applied. Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments. Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e. 6Hz for θ, 11Hz for α, 20Hz for β, etc.). Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e. outcome evaluation). Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
47995480|NCT02831166|PROCEDURE|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
48154875|NCT01654289|OTHER|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
48154876|NCT01654289|OTHER|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
48154877|NCT05151016|DRUG|mifepristone|Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
48154878|NCT05151016|DRUG|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
48154879|NCT04707287|OTHER|No Intervention|No intervention used. This is observational study
48154880|NCT02067000|BEHAVIORAL|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
48681602|NCT02722005|BEHAVIORAL|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
48154881|NCT02458794|PROCEDURE|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
48154882|NCT02458794|DEVICE|LMA SupremeTM|
48154883|NCT02458794|DEVICE|Ambu-Aura GainTM|
48154884|NCT05673772|RADIATION|short-course radiotherapy|25 Gy in 5 fractions for 5 days
48154885|NCT05673772|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
48154886|NCT05673772|RADIATION|Chemoradiotherapy|45\~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)
48681603|NCT02722005|BEHAVIORAL|Access to referral to social services|Access to referral to a host of social services.
48154887|NCT05673772|PROCEDURE|TME surgery|TME surgery
48154888|NCT03935152|DRUG|Dydrogesterone|dydrogesterone capsule
48154889|NCT03935152|DRUG|placebo|placebo capsule
48681604|NCT00000696|DRUG|Interferon alfa-2a|
48681605|NCT00000696|DRUG|Zidovudine|
48681606|NCT04566939|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
48681607|NCT04566939|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
48681608|NCT04566939|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
48681609|NCT04566939|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48512023|NCT04464070|OTHER|PGD2|labeled precursor
48681610|NCT04566939|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48681611|NCT04566939|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
48154890|NCT01894750|BEHAVIORAL|group-based skill building self-care program|
48154891|NCT01025921|DRUG|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
48681612|NCT04566939|PROCEDURE|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48681613|NCT04566939|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
48681614|NCT04566939|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
48154892|NCT01025921|OTHER|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
48154893|NCT05274906|OTHER|Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat|Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)
48512024|NCT05176444|BEHAVIORAL|Music therapy|Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
48512025|NCT05133934|OTHER|Observational|A cohort study will be used to collect patient data, analyze the clinical characteristics, TCM syndromes, and treatment of knee osteoarthritis in China
48512026|NCT06061068|PROCEDURE|Hernia belt compression|Use the hernia belt to compress the inguinal region
47995481|NCT02831166|PROCEDURE|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
48681615|NCT02948699|DIETARY_SUPPLEMENT|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
47995482|NCT02242708|BEHAVIORAL|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
47995483|NCT02469454|DRUG|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
47995484|NCT02469454|DRUG|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
47995485|NCT04426682|DIAGNOSTIC_TEST|urodynamics parameters|"Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure."
48154894|NCT06367426|DRUG|DDN-A-0101 (SAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
48154895|NCT06367426|DRUG|DDN-A-0101 (MAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
48154896|NCT06367426|DRUG|Placebo (SAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
48365198|NCT02935010|DRUG|Amoxicillin|antibiotic for H. pylori eradication
48365199|NCT02935010|DRUG|Clarithromycin|antibiotic for H. pylori eradication
48365200|NCT02935010|DRUG|Metronidazole|antibiotic for H. pylori eradication
48681616|NCT06266559|OTHER|Chang Geng Healthy Drink|Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
48681617|NCT02522169|DRUG|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year."
47995486|NCT01425879|DRUG|Akt Inhibitor MK2206|Given PO
47995487|NCT01425879|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
47995488|NCT01425879|OTHER|Pharmacological Study|Correlative studies
48365201|NCT02935010|DRUG|Levofloxacin|antibiotic for H. pylori eradication
48681618|NCT01958255|BEHAVIORAL|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
48681619|NCT01146613|DRUG|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
48681620|NCT01146613|DRUG|Placebo|identical matched placebo x 2, 2xday, 13 weeks
48681621|NCT00881530|DRUG|BI 10773|BI 10773 high dose once daily
48681622|NCT00881530|DRUG|Metformin|open label comparator
47995489|NCT01109225|BIOLOGICAL|blood sample|
47995490|NCT01109225|PROCEDURE|MRI|
47995491|NCT01109225|PROCEDURE|echocardiography|
47995492|NCT01109225|BIOLOGICAL|urine sample|
47995493|NCT01109225|PROCEDURE|pulmonary echography|
47995494|NCT01109225|PROCEDURE|vascular check|
47995495|NCT01109225|PROCEDURE|renal echography|
47995496|NCT01487590|OTHER|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
48365202|NCT00444639|DRUG|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
48681623|NCT00881530|DRUG|BI 10773|BI 10773 low dose once daily
48681624|NCT00881530|DRUG|Sitagliptin|open label comparator
48681625|NCT01202201|OTHER|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
48681626|NCT04434547|BIOLOGICAL|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
48681627|NCT02548910|PROCEDURE|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
48681628|NCT02548910|DEVICE|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
48681629|NCT02659813|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
48681630|NCT03807050|DIETARY_SUPPLEMENT|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
48681631|NCT00833469|DRUG|Escitalopram|Once daily by mouth
48681632|NCT01672086|DEVICE|Stelkast Surpass Acetabular System implant|
48681633|NCT00792740|DRUG|ITF2357|ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
48681634|NCT00792740|OTHER|Placebo|Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
48681635|NCT02919163|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
47995497|NCT01487590|OTHER|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
48681636|NCT04194879|DIAGNOSTIC_TEST|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
48681637|NCT00752921|DRUG|etoricoxib|120 mg
48681638|NCT00752921|DRUG|placebo|placebo
48681639|NCT03184883|PROCEDURE|single conventional denture|mandibular conventional denture with soft liner
47995498|NCT02049333|PROCEDURE|Phacoemulsification|
48681640|NCT03184883|PROCEDURE|single flexible denture|mandibular flexible compete denture
48681641|NCT03474263|BIOLOGICAL|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
47995499|NCT02049333|PROCEDURE|Endoscopic Cycloplasty (ECPL)|
48681642|NCT00252512|BEHAVIORAL|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
48681643|NCT00252512|OTHER|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
48681644|NCT02901691|OTHER|musical rhythmic stimulation|
47995500|NCT00245141|BIOLOGICAL|dactinomycin|
47995501|NCT00245141|DRUG|cyclophosphamide|
47995502|NCT00245141|DRUG|vincristine sulfate|
47995503|NCT00245141|RADIATION|radiation therapy|
47995504|NCT05362747|BEHAVIORAL|Behavioral weight loss and produce vouchers|Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
47995505|NCT00546611|DRUG|PEP005|
47995506|NCT02441933|DRUG|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
47995507|NCT02441933|DRUG|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses"
47995508|NCT05931328|DRUG|thiotepa combined with pomalidomide|thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
48154897|NCT06367426|DRUG|Placebo (MAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
47995509|NCT05277844|RADIATION|Local Consolidative Radiation Therapy|Local consolidative radiation therapy to loco-regional disease and all Oligometastatic sites in addition to TKI
47995510|NCT05277844|DRUG|TKI|TKI
48154898|NCT00274976|BIOLOGICAL|alemtuzumab|
48154899|NCT01871597|DEVICE|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
48154900|NCT04677985|COMBINATION_PRODUCT|Menthol based topical analgesic|Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
48681645|NCT00848237|DEVICE|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
48681646|NCT02134301|DRUG|Oritavancin|
48681647|NCT03399864|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
48681648|NCT03399864|OTHER|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
48681649|NCT02517398|DRUG|MSB0011359C|Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
48681650|NCT06511947|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
48681651|NCT02735421|DRUG|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
48681652|NCT02735421|DRUG|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
48154901|NCT06290453|DIAGNOSTIC_TEST|micro RNA 27- FLP1 gene expression|"From each participant, 2 mL of blood will be drawn and store at 25-degree C. The expression of miRNA-27 and FLP1 gene will be measured using real time PCR.~Relative expression values will be normalised to the housekeeping gene GAPDH. The comparative cycle threshold (Ct) approach will be used to measure the relative expression of miRNA 27 and FLP1 gene. Then, using the equation -ΔΔCT, the fold change of each gene will be determined"
48681653|NCT01219101|DRUG|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
48681654|NCT01219101|DRUG|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
48681655|NCT05920811|OTHER|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
48154902|NCT06290453|DIAGNOSTIC_TEST|The Expanded Disability Status Scale (EDSS)|"The Expanded Disability Status Scale (EDSS) is a way of measuring how much someone is affected by their MS. Neurologists use it to monitor changes in the level of someone's disability over time. The EDSS has a range from 0 to 10.~Zero points is normal neurological examination. 10 points shows the MS-related death cases. Patients with EDSS score up to 5 are fully ambulatory patients."
48512027|NCT06402760|OTHER|TCM comprehensive treatment|"1. Taodan Granules (TCM formulation for promoting blood circulation and removing blood stasis): The granules consist of the following herbal components: milkvetch, licorice, angelica, rhizoma chuanxiong, peach seed, Salvia miltiorrhiza, Curcuma zedoaria, Achyranthes bidentata, and sarsaparilla. Patients will take it orally in two divided doses after breakfast and dinner.~2. Fish Oil: Patients will take 1g of fish oil orally twice daily. Patients will be instructed to purchase fish oil under the guidance of the researchers.~3. Exercise Plan: Researchers will design an exercise plan for patients, who will be required to engage in at least 150 minutes of moderate-intensity aerobic exercise per week.~Patients will undergo a 16-week treatment period followed by a 24-week follow-up period. During the follow-up, patients will continue taking fish oil and adhering to the exercise regimen, while other treatment modalities will be unrestricted."
48512028|NCT06402760|DRUG|Western medicine|The treatment methods prescribed in the guidelines.
48154903|NCT06290453|DIAGNOSTIC_TEST|Electrophysiological assessment:|Electromyography and nerve conduction velocity will be performed for all MS patients.
48681656|NCT05920811|OTHER|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
48681657|NCT03159468|BEHAVIORAL|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
48681658|NCT03159468|BEHAVIORAL|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
48681659|NCT03159468|OTHER|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
48681660|NCT04588636|BEHAVIORAL|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
48681661|NCT04588636|DEVICE|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
48681662|NCT04588636|DEVICE|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
48154904|NCT06290453|DIAGNOSTIC_TEST|MRI examination MRI brain:|will be done on all MS patients to detect the number, the site, and the enhancement of lesions
48154905|NCT05327270|DRUG|Nivolumab|Given by IT
48154906|NCT05995275|BIOLOGICAL|mRNA-1769|Sterile liquid for injection
48154907|NCT05995275|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
48154908|NCT01082354|DRUG|recombinant somatropin|as per standard practice
48512029|NCT00212680|DRUG|ONO-1101|
48512030|NCT06202729|OTHER|Questionnaire|GAD-7, VAS-A, NRS
48154909|NCT03527758|DEVICE|Flo TracIQ with HPI software|Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
47995511|NCT03164343|DEVICE|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
48154910|NCT05942183|DIAGNOSTIC_TEST|ONSD|ultrasound measurement of the optic nerve sheath diameter
48681663|NCT04588636|DEVICE|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
48681664|NCT03632460|DRUG|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
47995512|NCT03712319|BEHAVIORAL|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
47995513|NCT03712319|BEHAVIORAL|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
47995514|NCT00165893|DEVICE|Accu-Spina Device/IDD therapy|
48681665|NCT01913847|DRUG|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
48681666|NCT01913847|DRUG|Placebo|Oral placebo TID for 12 weeks
47995515|NCT00165893|PROCEDURE|Physical Therapy|
47995516|NCT03330431|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|"All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation."
47995517|NCT00089349|BIOLOGICAL|alemtuzumab|Given IV
47995518|NCT00089349|DRUG|methotrexate|Given IV
47995519|NCT00089349|DRUG|mercaptopurine|Given PO
47995520|NCT00108056|DRUG|Enzastaurin (LY317615) monohydronchloride|
47995521|NCT02746211|BIOLOGICAL|High Titre Influenza virus|High Titre Influenza virus
48365203|NCT01749930|DRUG|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
47995522|NCT02746211|BIOLOGICAL|Medium - High Influenza virus|Medium - High Influenza virus
48365204|NCT01749930|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening.
48365205|NCT01749930|DRUG|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
48365206|NCT02966912|DIETARY_SUPPLEMENT|400 mg of Magnesium Oxide twice daily for 24 weeks|
48365207|NCT02966912|OTHER|Open label (none)|
48681667|NCT05532228|PROCEDURE|Adenotonsillectomy|adenotonsillectomy by cold dissection
48681668|NCT06512077|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
48681669|NCT04549558|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
47995523|NCT02746211|BIOLOGICAL|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
48365208|NCT02902276|OTHER|additional blood sample|Two blood samples will be taken at ICU admission
48365209|NCT03896334|BEHAVIORAL|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
48365210|NCT03896334|BEHAVIORAL|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
48681670|NCT03686878|DRUG|Lifitegrast|Lifitegrast used twice a day
48365211|NCT02690506|DRUG|Placebo|
48365212|NCT02690506|DRUG|Pregabalin|
48365213|NCT03046069|OTHER|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
48681671|NCT01714323|BEHAVIORAL|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free \& Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
47995524|NCT02746211|BIOLOGICAL|Low titre|Low titre
47995525|NCT03862274|OTHER|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
47995526|NCT05832333|BIOLOGICAL|VaxigripTetra®|Suspension for injection Injection intramuscular
48681672|NCT01714323|BEHAVIORAL|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
48681673|NCT03578107|BEHAVIORAL|improvement of quality of stroke care|"1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams"
47995527|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)
47995528|NCT00371254|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)
47995529|NCT03295708|DIETARY_SUPPLEMENT|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
47995530|NCT03295708|DIETARY_SUPPLEMENT|soybean oil capsule|placebo capsule
47995531|NCT03075917|OTHER|Self Questionnaire|self questionnaire for allergic rhinitis control
48512031|NCT03097991|BEHAVIORAL|Focused Coparenting Consultation|Six 90-minute sessions completed within 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
48512032|NCT05850598|DEVICE|sham rTMS|The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
48681674|NCT03858517|DEVICE|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
48681675|NCT02598869|DRUG|Triamcinolone Acetonide|injection of triamcinolone acetonide
48681676|NCT02243683|DRUG|AX-024.HCl|
48681677|NCT02243683|OTHER|Placebo|
47995532|NCT00119392|BIOLOGICAL|rituximab|Given IV
47995533|NCT00119392|DRUG|cyclosporine|Given orally
47995534|NCT00119392|DRUG|fludarabine phosphate|Given IV
48512033|NCT05850598|DEVICE|active rTMS|Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
48512034|NCT02349867|DRUG|Gemcitabine|Given IV
48512035|NCT02349867|DRUG|Sorafenib|Given PO
47995535|NCT00119392|DRUG|mycophenolate mofetil|Given orally
47995536|NCT00119392|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
47995537|NCT00119392|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
47995538|NCT00119392|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
47995539|NCT00119392|RADIATION|total-body irradiation|Undergo TBI
47995540|NCT01048723|DRUG|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
47995541|NCT00657241|DRUG|Carvedilol CR|
47995542|NCT00657241|DRUG|Valsartan|
48512036|NCT02349867|DRUG|Vorinostat|Given PO
48681678|NCT03191162|DRUG|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
48681679|NCT02877069|DEVICE|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
47995543|NCT04199299|DEVICE|Heart rate and respiration rate sensors|The use of sensors to monitor physiological variables (e.g. heart rate, sleep). The design is a before-and-after comparison with respect to whether the use of sensors has changed the caregivers' practice and their (perceived) understanding of the participant. The frequency of participants' self harm or aggressive behavior after as compared to before the introduction of pulse- and respiration monitors will also be charted.
47995544|NCT04758377|PROCEDURE|Magnetic resonance imaging (MRI)|Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
47995545|NCT04009655|OTHER|music|music selected by musician
47995546|NCT01207518|BEHAVIORAL|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
47995547|NCT01207518|BEHAVIORAL|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
47995548|NCT03837561|DRUG|Cunox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
47995549|NCT03837561|DRUG|Botox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
48154911|NCT01141985|DEVICE|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
48681680|NCT04393662|DIAGNOSTIC_TEST|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
48154912|NCT05757622|DRUG|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
48681681|NCT04393662|DIAGNOSTIC_TEST|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
48154913|NCT05757622|DRUG|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
48154914|NCT04733950|OTHER|Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)|"Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target."
48681682|NCT04393662|DIAGNOSTIC_TEST|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
48681683|NCT04847570|OTHER|Music session|Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
48681684|NCT04209374|DEVICE|THA with SYMBOL CUP DM HA|
48681685|NCT02848456|PROCEDURE|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
48681686|NCT02848456|PROCEDURE|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
48681687|NCT02848456|PROCEDURE|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
47995550|NCT00511693|BEHAVIORAL|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
47995551|NCT00511693|BEHAVIORAL|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
48154915|NCT04733950|OTHER|Measurement of the pupil diameter for the evaluation of listening effort during speech perception|Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
48154916|NCT03352570|DEVICE|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
48512037|NCT02349867|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
48681688|NCT00988156|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
48681689|NCT00988156|DRUG|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
48681690|NCT05367193|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy for vitreoretinal disease in highly myopic eyes
47995552|NCT04849806|DIAGNOSTIC_TEST|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
48681691|NCT05367193|DEVICE|NGENUITY® 3D Visualization System (Alcon, TX, USA)|Injection of ICG to stain internal limiting membrane
48154917|NCT03591328|DIAGNOSTIC_TEST|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
48681692|NCT05959746|OTHER|AI-STROKE application|Complete neurological exam of stroke patients will be filmed by healthcare workers and themselves using the AI-STROKE application
47995553|NCT04849806|DIAGNOSTIC_TEST|OSA severity|OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture
47995554|NCT04849806|DIAGNOSTIC_TEST|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
47995555|NCT04849806|DIAGNOSTIC_TEST|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.
47995556|NCT04849806|DIAGNOSTIC_TEST|Assessment of systemic inflammation|Based on blood samples taken.
47995557|NCT04680689|DIAGNOSTIC_TEST|128 Multislice CT coronary angiography|128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
48154918|NCT04456296|DRUG|Aveed Injectable Product|Testosterone undecanoate administered by intramuscular injections.
48154919|NCT04456296|DRUG|Fortesta|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
48512038|NCT02349867|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48681693|NCT02284256|DRUG|Fibrocaps|
48681694|NCT02284256|DRUG|TachoSil|
48681695|NCT00590122|DRUG|Parcopa|at subjects current stable dose of comparator
47995558|NCT04680689|DIAGNOSTIC_TEST|2D Cardiac Transthoracic Echocardiography|2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
48681696|NCT00590122|DRUG|carbidopa-levodopa (Sinemet)|at subjects current stable dose
48681697|NCT04187248|DRUG|Asparaginase|
48681698|NCT01696799|DRUG|Econazole Nitrate|
48681699|NCT01696799|DRUG|placebo|
48681700|NCT01143961|DEVICE|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
48681701|NCT03159546|DEVICE|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
47995559|NCT04680689|DIAGNOSTIC_TEST|Laboratory Blood tests|Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
48365214|NCT03046069|OTHER|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
48365215|NCT03046069|OTHER|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
48365216|NCT03046069|OTHER|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
48681702|NCT04130893|BEHAVIORAL|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
48681703|NCT04130893|BEHAVIORAL|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
48681704|NCT02733822|DRUG|Naloxone|
47995560|NCT05106192|DEVICE|Med-Jet Injector|The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue
48681705|NCT00693446|DRUG|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
47995561|NCT05106192|DRUG|Triamcinolone Acetonide|The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).
47995562|NCT05106192|DRUG|Bexarotene 1% Top Gel|Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.
47995563|NCT05106192|DRUG|Nitrogen Mustard|Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.
47995564|NCT05106192|DEVICE|Conventional syringe|A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
48154920|NCT04456296|DRUG|Testim|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
48365217|NCT03046069|OTHER|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
48365218|NCT00000576|DRUG|beclomethasone|
48365219|NCT01921842|BEHAVIORAL|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
48365220|NCT03373006|DRUG|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
48365221|NCT04390711|OTHER|High density lipoprotein isolation, detection and in-vitro study.|All blood samples were taken on the day of cardiac catheterization after overnight fasting.High density lipoprotein from each participants was isolated and further collected for carbamylation level detection and in-vitro study.
48365222|NCT03579862|OTHER|Blood Draw|
48365223|NCT01742013|DRUG|GCJBP Laennec Inj.|Test drug
48365224|NCT01742013|DRUG|Placebo|Comparator
48365225|NCT05191927|OTHER|male|Nine preoperative predictors were identified for the nomogram: gender, age, platelet counts, TPOAb level and US signatures including maximum diameter, boundary, component, calcification and cervical lymph node enlargement.
48365226|NCT00261599|DRUG|AQUAVAN® (fospropofol disodium) Injection|
48365227|NCT00261599|DRUG|Midazolam HCI|
48154921|NCT04228068|OTHER|Rehabilitation Program|"PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program."
48154922|NCT04228068|OTHER|Pain self management|In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
48154923|NCT04228068|OTHER|Conventional care|The control group will receive the usual care provided by the healthcare system.
48154924|NCT01628822|BEHAVIORAL|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
48154925|NCT01628822|BEHAVIORAL|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
48154926|NCT00865033|DRUG|Metformin HCL Tablets, 1000 mg Sandoz|
48154927|NCT00865033|DRUG|Glucophage 1000 mg|
47995565|NCT03904238|BEHAVIORAL|Cognitive-Behavior Therapy for Hypersomnia (CBT-H)|"The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia."
48154928|NCT03502525|BEHAVIORAL|Break the Cycle Intervention|The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
48154929|NCT04993976|OTHER|Resistant training (Prehabilitation)|Resistance training (10-15 repetitions: major muscle groups of upper and lower limbs \[eg, shoulder overhead press, biceps curl, knee lift, and quadriceps extension in sitting and hamstrings curl exercises\], one to three sets each) for 20-60 minutes five days a week.
48365228|NCT04495166|BEHAVIORAL|Motherly 1.0|A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
48512039|NCT02349867|OTHER|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
48681706|NCT00693446|DRUG|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
47995566|NCT03200899|BEHAVIORAL|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
48154930|NCT04993976|OTHER|Active Comparator: Control group|Conventional physiotherapy group followed basic pre-operative respiratory physiotherapy including deep breathing exercises, instructions in coughing techniques, mobilization, and active exercises of the upper limbs and thorax. Walk 30 m in the hospital ward.
48154931|NCT00515879|DRUG|D-cycloserine|50 mg
48154932|NCT00515879|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
48154933|NCT00515879|DRUG|Placebo|Same dosage as active pill
48154934|NCT03185858|BEHAVIORAL|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
48365229|NCT04495166|BEHAVIORAL|Brief Psychotherapy|Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.
48154935|NCT00718744|OTHER|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
48154936|NCT00719056|DRUG|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
48365230|NCT04495166|BEHAVIORAL|Educational app|A simplified version of the Motherly 1.0 app consisting of psychoeducational content about various aspects of pregnancy, maternal physical and mental health, and child development. Active intervention functionalities, such as behavioral activation, activity scheduling, sleep hygiene, among others, are NOT present in this simplified version of the app.
47995567|NCT03200899|OTHER|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
47995568|NCT05334901|DEVICE|High intensity light cure|Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
47995569|NCT03902951|DRUG|Abiraterone Acetate|Given PO
47995570|NCT03902951|DRUG|Apalutamide|Given PO
47995571|NCT03902951|DRUG|Leuprolide Acetate|Given SC
47995572|NCT03902951|OTHER|Quality-of-Life Assessment|Ancillary studies
48154937|NCT00719056|DRUG|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
48154938|NCT03537534|DRUG|Lidocaine Jet Injector|Applying Lidocaine following endourologic procedure
48154939|NCT03537534|DRUG|Placebos|Applying surgilube following endourologic procedure
48154940|NCT02210949|DRUG|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
48154941|NCT05318716|DEVICE|Fat grafting - Revolve device|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
48154942|NCT05318716|DEVICE|Fat grafting - Decantation|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
47995573|NCT03902951|OTHER|Questionnaire Administration|Ancillary studies
47995574|NCT03902951|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
47995575|NCT05602415|DRUG|Anlotinib|Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles). The dose could be reduced to 8-10 mg once daily for patients who had grade 3 or 4 treatment-related toxicities, or for patients with intolerable grade 2 toxicity, despite maximum supportive care measures. If dose reduction was necessary, then the dose of anlotinib was reduced to 10 mg once daily. If further dose reduction was necessary, the dosage was reduced to 8 mg once daily. If the dosage of 8 mg once daily was not tolerable, then the patient stopped receiving anlotinib.
47995576|NCT05602415|RADIATION|Radiotherapy|Postoperative radiotherapy would be performed. Postoperative intensity-modu¬lated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). No boost dose would be added if the margin was negative, a boost dose of 10-16 Gy would be added if the margin was microscopically positive, and a boost dose of 16-18 would be added if the margin was gross positive.
47995577|NCT05602415|PROCEDURE|Surgery|Surgery
47995578|NCT01574612|DRUG|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
47995579|NCT00709774|DEVICE|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
48154943|NCT05778266|DIETARY_SUPPLEMENT|L-citrulline|oral supplementation of pure L-citrulline (6 g) for twelve weeks
48154944|NCT05778266|DIETARY_SUPPLEMENT|Carboxymethyl cellulose|oral supplementation of Carboxymethyl cellulose (6 g) as a placebo, for twelve weeks
48154945|NCT05778266|OTHER|High Intensity Intervals Training|participants will have sessions 3 days a week for twelve weeks
48154946|NCT04125342|DEVICE|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
48365231|NCT01464073|BEHAVIORAL|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
48365232|NCT01464073|BEHAVIORAL|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
48365233|NCT01464073|BEHAVIORAL|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
48512040|NCT02349867|OTHER|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
48365234|NCT01464073|DIETARY_SUPPLEMENT|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
47995580|NCT02245841|DRUG|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
47995581|NCT03171454|PROCEDURE|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
48681707|NCT04830839|BEHAVIORAL|Recovery after Stress Toolkit (ReSeT)|ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
48681708|NCT06172595|DIAGNOSTIC_TEST|FET PET|There is only one study visit during which study subjects will undergo a 18F-FET PET/CT in SGH. Following that, they will be followed up as per their routine clinical care. Data collection timepoints will be at 30 days, 4 months, 8 months and 1 year.
48681709|NCT05439278|RADIATION|Hypofractionated radiotherapy|40.05 Gy in 15 fractions (daily treatment, 5 per week)
48681710|NCT05439278|RADIATION|Conventional radiotherapy|60 Gy in 30 fractions (daily treatment, 5 per week)
47995582|NCT03171454|PROCEDURE|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
48681711|NCT05439278|DRUG|Temozolomide|concurrent (75 mg/m2/day qd) and adjuvant (6 cycles)
48681712|NCT00238082|DRUG|HFA-134A Beclomethasone DIpropionate (QVAR)|
48681713|NCT00480831|DRUG|bevacizumab|Intravenous repeating dose
48681714|NCT00480831|DRUG|carboplatin|Intravenous repeating dose
48681715|NCT00480831|DRUG|paclitaxel|Intravenous repeating dose
48681716|NCT00480831|DRUG|placebo|Intravenous repeating dose
48681717|NCT00480831|DRUG|PRO95780|Intravenous repeating dose
48681718|NCT06385457|BEHAVIORAL|Mindhelper- A national youth mental health promotion website|Mindhelper is an open-access, digital self-directed mental health service that provides information, self-help tools and guidance to young people in Denmark.
47995583|NCT03020823|DRUG|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
47995584|NCT03382119|DEVICE|Ultrasound with ARFI (acoustic radiation force impulse)|This technology uses sound waves to measure the stiffness of tissue.
48681719|NCT05948904|DIAGNOSTIC_TEST|Cryo Ex Vivo|"Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed."
48681720|NCT01927263|BIOLOGICAL|NI-071|100mg/vial
48681721|NCT01927263|BIOLOGICAL|Infliximab|100mg/vial
47995585|NCT03382119|DEVICE|Ultrasound with backscatter imaging|This ultrasound tool gathers data from the waves returning from imaged tissue.
48681722|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
47995586|NCT04854811|DRUG|Roflumilast Oral Tablet|Once daily for 12 weeks
48681723|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
48681724|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
48681725|NCT02095392|DIETARY_SUPPLEMENT|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
48681726|NCT04770688|DRUG|Osimertinib|Osimertinib, 80mg, QD, p.o.
47995587|NCT03797833|PROCEDURE|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
48681727|NCT04770688|DRUG|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
48681728|NCT05059093|DIAGNOSTIC_TEST|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
48681729|NCT05658250|DEVICE|CRE8 polymer-free Amphilimus-eluting stent, Cre8 evo stent|Percutaneous coronary intervention using a Cre8 stent, Cre8 evo stent for long lesions
48681730|NCT00273091|DEVICE|ICD with CRT therapy|permanently CRT pacing
48681731|NCT06226597|DEVICE|Fitbit device|Daily use of a fitbit wearable activity tracker device.
48681732|NCT05593354|DEVICE|Micropulse Transscleral laser therapy|Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
47995588|NCT03536403|RADIATION|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
47995589|NCT03536403|OTHER|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
48154947|NCT04125342|DEVICE|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
48154948|NCT03664271|BEHAVIORAL|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
48154949|NCT03664271|BEHAVIORAL|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
47995590|NCT02065960|RADIATION|Stereotactic body radiotherapy (SBRT)|
47995591|NCT02310685|OTHER|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
48154950|NCT00606723|BIOLOGICAL|Hematopoietic stem cells from bone marrow or peripheral blood|\> = 2 x 10\*8 nucleated cells (WBC)/kg body weight of the recipient or rather \> = 4 x 10\*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
48365235|NCT03595072|OTHER|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
48681733|NCT04171505|DRUG|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
48681734|NCT05255692|DIAGNOSTIC_TEST|invasive urodynamic evaluation|Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.
48681735|NCT05255692|DIAGNOSTIC_TEST|functional magnetic resonance imaging during bladder filling|Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
47995592|NCT04900688|DEVICE|LithoVue Elite|LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
47995593|NCT02347189|DEVICE|Melody Transcatheter Pulmonary Valve PB1016|
47995594|NCT03744533|OTHER|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
47995595|NCT03744533|OTHER|guideline-based treatment|guideline-based treatment
47995596|NCT02385266|DRUG|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
48365236|NCT01349881|DRUG|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
47995597|NCT02385266|DRUG|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
47995598|NCT01206179|BIOLOGICAL|cell injection|Injection of mesenchymal cells in fractured zone
47995599|NCT01802658|DRUG|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
47995600|NCT01802658|DRUG|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
48154951|NCT06192537|BEHAVIORAL|A role-playing exercise by utilizing an obesity suit in a simulation scenario|All participants will be asked to wear an obesity simulation suit (Unisex obesity Simulation suit, Erler-Zimmer, Germany) and to participate in a standardized scenario that simulates meetings between a person with obesity and a 'registered dietitian'. The 'registered dietitian' will be presented by a professional role-player and the scenario will encompass different levels of weight bias through dialogue and the use of inappropriate equipment.
48365237|NCT01349881|DRUG|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
48365238|NCT01349881|DRUG|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
48365239|NCT01349881|DRUG|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
48681736|NCT05257590|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
48154952|NCT05438511|BEHAVIORAL|Focus group|A semi-structured focus group discussion guide will be developed with question probes that cover 1) contextual factors, 2) barriers to implementation, and 3) facilitators to implementation, with secondary probing questions.
48365240|NCT06113276|RADIATION|Low dose computed tomography to evaluate biomechanical parameters in the lung|In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.
48512041|NCT05017597|OTHER|Rehabilitation|Exercises completed, and rate of perceived exertion (RPE) will be reviewed during \& after each exercise session. Exercises will be modified by either increasing or decreasing the intensity. Decisions will be made based RPE, physical symptoms \& any identified barriers or supports. Weeks 1, 3, 5, \& 7, Cancer-related fatigue (CRF) education will be assigned. During weeks 2, 4, 6, \& 8, CRF education will be reviewed and a plan for how to apply the information will be developed. Participant will be guided through 6 steps of problem solving to address one occupational performance problem identified by participant within Canadian Occupational Performance Measure. Goal \& action plan for the week will be shared with the participant electronically. At the beginning of each session, participant will describe progress on previous week action plan. Based on participant's response, either a new goal will be developed or the current one modified..
48512042|NCT05567510|DRUG|BMS-986369|Specified dose on specified days
48681737|NCT05257590|DRUG|CVM-1118|CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
48681738|NCT05415969|OTHER|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
48681739|NCT04098705|OTHER|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
47995601|NCT04327999|DRUG|Artificial Tears|Self-Administered - utilizing eye drop preservative free vials
48681740|NCT00389376|DRUG|Placebo|Placebo
48154953|NCT05438511|BEHAVIORAL|Organizational Readiness for Implementing Change|measures the extent to which organizational members are prepared to implement organizational change. The ORIC tool asks participants to rate their level of agreement with 12 statements pertaining to organizational readiness for change (change commitment and change efficacy) on a 5-point Likert Scale.
48154954|NCT02206607|DRUG|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
48154955|NCT02206607|DRUG|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
48154956|NCT02206607|DRUG|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
48154957|NCT02206607|DRUG|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
48681741|NCT00389376|DRUG|Silymarin|140 mg every 8 hours
48365241|NCT02015858|PROCEDURE|Chest drain withdrawal|
48154958|NCT05301842|DRUG|Tremelimumab|Tremelimumab IV (intravenous)
48154959|NCT05301842|DRUG|Durvalumab|Durvalumab IV (intravenous)
48154960|NCT05301842|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
48154961|NCT05301842|DRUG|Lenvatinib|Lenvatinib (oral)
48365242|NCT02015858|DEVICE|Pain Monitor|
48681742|NCT00389376|DRUG|Silymarin|280 mg single dose
48681743|NCT00389376|DRUG|Silymarin|280 mg single dose + every 8 hours
48681744|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
48681745|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
48681746|NCT00389376|DRUG|Silymarin|280 mg every 8 hours
48681747|NCT00389376|DRUG|Silymarin|700 mg single dose + every 8 hours
48365243|NCT04967729|DEVICE|Device: Butterfly iQ|The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
47995602|NCT01643993|OTHER|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
47995603|NCT01643993|OTHER|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
48154962|NCT05746845|BIOLOGICAL|Blood sample|"Blood sampling will be done on three groups:~Group 1: Healthy volunteers, so-called control donors whose blood samples will be ordered from the EFS (French Blood Establishment) Group 2: Stable MS patients without inflammatory activity of the disease treated with high efficacy treatment (Natalizumab or Ocrelizumab) Group 3: Stable MS patients without inflammatory disease activity treated with moderately effective treatment (Teriflunomide or Fumarate)"
48154963|NCT03994185|DEVICE|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
48154964|NCT01636700|DRUG|Tramadol 2mg/kg|2mg/kg
48154965|NCT01636700|DRUG|Saline solution|saline solution- 1 dose
48154966|NCT00416585|DRUG|isotretinoin (Roaccutane)|
48154967|NCT01693393|DRUG|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
48154968|NCT03586739|PROCEDURE|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
48154969|NCT03586739|PROCEDURE|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
48154970|NCT03586739|DEVICE|Duplex-scan|a Duplex-scan will be performed during patient follow up.
48154971|NCT03586739|DEVICE|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
48154972|NCT03586739|DEVICE|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
47995604|NCT01168635|BEHAVIORAL|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|"The Spirometry 360 program includes:~1. Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;~2. Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;~3. Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic."
48154973|NCT03586739|OTHER|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
47995605|NCT01188408|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
48154974|NCT05480280|DRUG|Dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
48154975|NCT05480280|DRUG|Oxaliplatin injection|85mg/m², ivdrip, D1
48154976|NCT05480280|DRUG|Calcium folinate|400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
48154977|NCT05480280|DRUG|5-fluorouracil|400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
48154978|NCT02823886|OTHER|MRI at D7|The infarct size measured on MRI at 7 days.
48154979|NCT02823886|BIOLOGICAL|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
48154980|NCT06315621|DEVICE|Scanning using intraoral scanner with markers|Scanning different types of nasal defects using intraoral scanner with skin markers.
48154981|NCT06315621|DEVICE|Scanning using intraoral scanner without markers|Scanning different types of nasal defects using intraoral scanner without skin markers.
48154982|NCT06315621|DEVICE|Physical Impression|Recording different types of nasal defects using physical impressions
48154983|NCT03809871|BIOLOGICAL|Cardiometabolic biomarkers|This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
48154984|NCT05845866|BEHAVIORAL|Modified Body Project|The Body Project, an evidence-based body image intervention developed for young women at risk for eating pathology, was adapted for use among adult women with high weight and shape concern and high body weight who want to lose weight.
48154985|NCT05845866|BEHAVIORAL|Facts about obesity, myths about weight loss|This intervention is designed to help individuals prepare for weight loss and is focused on facts about obesity, myths about weight loss, and the importance of a varied diet.
48512043|NCT06283732|DIETARY_SUPPLEMENT|Greens powder|Participants are to consume one scoop (8.5 g) of the greens powder mixed in 8-10 oz of water every morning before breakfast for two weeks.
47995606|NCT04173117|DIETARY_SUPPLEMENT|Low energy meal replacement plan (12 weeks)|Low energy meal replacement plan (12 weeks)
48154986|NCT05845866|BEHAVIORAL|Lifestyle intervention for weight loss|This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.
48154987|NCT02853188|OTHER|venous thromboembolism|
48154988|NCT03144076|OTHER|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
48154989|NCT05121649|OTHER|Video streaming|Video streaming as a supplement to telephone during emergency calls for dispatchers at EMCCs
48154990|NCT01289899|DRUG|BR-A-657|120, 360mg or placebo 7days
48154991|NCT03622242|DEVICE|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
48154992|NCT03622242|DEVICE|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
48154993|NCT03370861|BIOLOGICAL|Immunotherapy|Medications that increase the activity of the immune system.
48154994|NCT04086576|DEVICE|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
48154995|NCT04086576|DEVICE|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
48154996|NCT04086576|DEVICE|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
48154997|NCT04086576|DEVICE|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
48154998|NCT04086576|DEVICE|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
48154999|NCT04086576|DEVICE|Floome|Floome branded smartphone-paired breathalyzer
48155000|NCT04086576|DEVICE|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
48365244|NCT01465984|DRUG|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
48512044|NCT04379791|OTHER|Data collection from routine medical records|Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
48512045|NCT01689779|DRUG|100,000 IU cholecalciferol|active drug
47995607|NCT01912144|OTHER|Coffee|
47995608|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
47995609|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
47995610|NCT01588691|DEVICE|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
47995611|NCT06449963|BEHAVIORAL|Health Belief Model Education|"Participants in this group will receive a structured training program with the aim of increasing daily water consumption and reducing symptoms of dehydration. The program is based on the principles of the Health Belief Model and includes the following components:~Initial and mid-Program training: Will be conducted by a trained health educator, each lasting 60 minutes. Two weeks after the first training, the same training will be given again for reinforcement purposes.~Session Content: Covers the importance of hydration, strategies to increase water intake (using reminders, setting goals, integrating water-rich foods), and the health benefits of adequate hydration (e.g., improved cognitive function, better physical health).~Training Materials: Booklet prepared for training. Behavioral Strategies: Practical tips for overcoming barriers to drinking more water, such as setting daily water intake goals and using diaries to track progress."
47995612|NCT04694313|DEVICE|OPM|Simultaneous MEG SQUID + SEEG acquisition followed by a simultaneous MEG OPM + SEEG acquisition.
47995613|NCT03057938|DRUG|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
47995614|NCT04148950|OTHER|Kinesio Tape|
47995615|NCT04148950|OTHER|Compression Stockings|
47995616|NCT04148950|OTHER|Exercise Program|
47995617|NCT00736008|OTHER|Observational|Data summary only
47995618|NCT03137888|RADIATION|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
47995619|NCT03137888|PROCEDURE|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
47995620|NCT03137888|DRUG|Temozolomide|Given PO
48365245|NCT01297764|DRUG|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40"
47995621|NCT05231590|BIOLOGICAL|Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (12.5 µg) with Advax-SM adjuvant (7.5 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
47995622|NCT05231590|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
48155001|NCT02105688|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
48155002|NCT02105688|DRUG|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
48365246|NCT00000829|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
48512046|NCT01689779|DRUG|Placebo|comparator drug
47995623|NCT00451321|DRUG|Otelixizumab|Infusion
47995624|NCT04716127|BEHAVIORAL|Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening|"* Direct offer of a vaginal self-sampling kit with information to perform at home and send back to the laboratory for HR-HPV testing~* The psychosocial determinants involved in decision-making process and compliance to cervical cancer screening will be collected from open questionnaires and by semi-directive phone interviews~* Control ; Receive reminder to send the self-sample to the laboratory : After 3 and 6 months without return, women receive a remind letter to send the vaginal self-sample to the laboratory. We call return the receipt of the vaginal self-sample at the laboratory.~* Control ; Receive reminder to perform cervical smear in case of positive HR-HPV test : In case of a positive HR-HPV test, women are asked to perform a control cervical smear. After 3, 6 months and 12 months without return, women and their health-care professional will receive a remind letter or a call to perform a cervical smear for control. We call return the performance of a pap smear."
47995625|NCT01995799|DEVICE|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
47995626|NCT00336713|DRUG|Saredutant (SR48968C)|oral administration (capsules)
47995627|NCT00336713|DRUG|Placebo|oral administration (capsules)
47995628|NCT06151587|DRUG|QLM3004 Concentration 1|"Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
47995629|NCT06151587|DRUG|QLM3004 Concentration 2|"Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
48365247|NCT00000829|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
48365248|NCT00000829|BIOLOGICAL|Placebo|Administered at 0, 2, 4, and 15 months of age
48365249|NCT00701064|OTHER|Bright Light Exposure|Administered via bright light box
48365250|NCT00701064|OTHER|Negative Ion Generator|Administered via Negative Ion Generatore
48365251|NCT01652027|DRUG|FVIII concentrate|usual treatment as directed by treating physician
47995630|NCT06151587|DRUG|QLM3004 Concentration 3|"High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime"
48365252|NCT02478736|OTHER|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
48681748|NCT02440139|DEVICE|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
47995631|NCT06151587|OTHER|Placebo|Vehicle
47995632|NCT05614375|PROCEDURE|endoscopic surgery|transnasal endoscopic surgery
47995633|NCT03567837|OTHER|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
47995634|NCT03131336|DRUG|PeproStat|solution for local application
47995635|NCT03131336|DRUG|Saline|solution for local application
47995636|NCT04336891|DRUG|Testosterone gel|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day) for 6 months
47995637|NCT04336891|DRUG|Estradiol ovules|Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
47995638|NCT04336891|DRUG|Moisturizer|Local non-hormonal moisturizers applied regularly every 2-3 days and lubricants as needed
47995639|NCT04336891|DRUG|Testosterone gel + Estradiol ovules|Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
48681749|NCT05709704|DIAGNOSTIC_TEST|Self-palpation via telehealth|This will be used to determine if the participant has the diagnosis
48681750|NCT05709704|DIAGNOSTIC_TEST|Real-time Ultrasound|This will be used in a subgroup of participants to confirm/rule out a diagnosis
48681751|NCT06543459|DRUG|MY008211A tablets|Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
48681752|NCT06543459|DRUG|Placebo|Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
48681753|NCT05841719|OTHER|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
48681754|NCT03344783|OTHER|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
48681755|NCT01295151|DRUG|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
48681756|NCT01295151|DRUG|Abatacept|"Abatacept will be administered at a dose determined by body weight:~Body Weight (kg) Dose (mg) \< 60kg = 500 mg~\> or equal to 60kg and \< or equal to 100kg = 750 mg \> 100 kg = 1000mg~The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
48681757|NCT01295151|BIOLOGICAL|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).~In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.~Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
48681758|NCT01295151|DRUG|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
47995640|NCT01165138|DRUG|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
47995641|NCT01165138|DRUG|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
47995642|NCT01165138|DRUG|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
47995643|NCT04253288|OTHER|Morbidity Mortality Review (MMR)|"* Standardization of Morbidity Mortality Review (MMR) in radiotherapy centers~* National database from MMR board meetings which include clinical , radiation technique and biological parameters of intrinsic radiosensitivity of patients"
47995644|NCT05466747|BIOLOGICAL|RYMPHYSIA|RYMPHYSIA administered through an IV injection.
47995645|NCT05466747|BIOLOGICAL|Another Available A1PI|Another available A1PI administered through an IV injection.
47995646|NCT02313025|OTHER|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
47995647|NCT02313025|OTHER|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
48365253|NCT00983827|DEVICE|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
48365254|NCT03213106|DEVICE|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
48365255|NCT03213106|DEVICE|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
48681759|NCT01295151|DRUG|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
48681760|NCT01295151|DRUG|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.~The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.~Further treatment will be prescribed at the discretion of the treating clinician."
48365256|NCT05946837|DRUG|Indocyanine green (ICG) dye|ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
48512047|NCT04811937|DIAGNOSTIC_TEST|Computer-aided polypectomy decision support by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
47995650|NCT04026477|BEHAVIORAL|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
47995651|NCT04026477|BEHAVIORAL|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
47995652|NCT05325528|DRUG|Tislelizumab in Combination with Oxaliplatin and Tegafur|6 cycles of Tislelizumab plus SOX regimen every 21 days
47995653|NCT01442870|DRUG|Metformin|Metformin
47995654|NCT03632655|PROCEDURE|prostate biopsy|Men will be randomized to receiving either TPM or TRUS targeted biopsy
47995655|NCT00123864|PROCEDURE|Intensity-modulated radiation therapy|
48365257|NCT05946837|DEVICE|NIRF-LI imaging|Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
48365258|NCT05946837|DEVICE|Neuroglide pad|After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
47995656|NCT04754347|DEVICE|Computer Aided Detection device|The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.
48365259|NCT01094821|DRUG|ATI-7505|3 mg three times daily for 9 days
47995657|NCT02950077|BEHAVIORAL|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
48681761|NCT01295151|DRUG|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.~Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.~The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
47995658|NCT03525015|OTHER|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
47995659|NCT03525015|OTHER|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
47995660|NCT02865993|OTHER|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
47995661|NCT02865993|OTHER|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
47995662|NCT06434662|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (24 mg/m\^2) on day 1, every 4 weeks
47995663|NCT06434662|DRUG|Cytarabine|Cytarabine (1.0 g/m\^2, q12h ) on day 1,3,5, every 4 weeks
47995664|NCT06434662|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
47995665|NCT00117559|BEHAVIORAL|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
47995666|NCT05103527|DEVICE|Dorsal Root Ganglion Stimulation|Stimulation at L2, L3, L4 and S1 spinal levels
47995667|NCT05173649|OTHER|Calisthenic Training|"Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Abductor-Adductor leg raise~2. Alternate toe touch~3. Knee Bend~4. Prone leg extension~5. Forward Lunges~6. Toe Raise/ Calf raise Progressive training include following exercises.~1. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight."
47995668|NCT05173649|OTHER|Neuromuscular Training|"Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Up and down step exercise in posterior and lateral directions.~2. Walking in anterior and posterior~3. Directions with eyes opened and eyes closed.~4. Walking in lateral direction with eyes opened and eyes closed.~5. Standing on one extremity~6. Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline"
47995669|NCT01888146|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
47995670|NCT01196546|DRUG|vildagliptin/metformin|
47995671|NCT03679910|DIAGNOSTIC_TEST|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
47995672|NCT03679910|DIAGNOSTIC_TEST|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
47995673|NCT00575055|DRUG|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
47995674|NCT00575055|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
47995675|NCT00575055|DRUG|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
47995676|NCT06321133|OTHER|High flow nasal cannula immediate ending|High flow is immediately ended
47995677|NCT06321133|OTHER|High flow nasal cannula weaning|High flow is gradually weaned by reducing the flow rate
47995678|NCT04618133|BEHAVIORAL|Early time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from 6am to 2pm, with a 1-hour allowance according to their daily routine
47995679|NCT04618133|BEHAVIORAL|Late time-restricted eating|Participants will be advised to eat only during a selected window of 8 hours over the 24-hour cycle, i.e. from noon to 8pm, with a 1-hour allowance according to their daily routine
48512048|NCT00866944|DRUG|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
48512049|NCT00866944|DRUG|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
47995680|NCT04618133|BEHAVIORAL|Active control|Participants will be advised to eat a minimum of 3 meals over the 24-hour cycle, i.e. breakfast from 6am to 9am, lunch from 11am to 2pm, dinner from 6pm to 10pm. Snacks will be allowed between meals
47995681|NCT00102674|DRUG|cangrelor|
47995682|NCT01343563|PROCEDURE|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
48512050|NCT00866944|DRUG|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
48512051|NCT02348255|PROCEDURE|Electric Field Therapy|Undergo NovoTTF-100A
48512052|NCT02348255|BIOLOGICAL|Bevacizumab|Given IV
48512053|NCT02348255|DRUG|Carmustine|Given IV
48512054|NCT02348255|OTHER|Quality-of-Life Assessment|Ancillary studies
48512055|NCT01658501|DRUG|50 mg PB1023|
48512056|NCT01658501|DRUG|70 mg PB1023|
48512057|NCT01658501|DRUG|100 mg PB1023|
48512058|NCT01658501|DRUG|Placebo (0.9% Sodium Chloride)|
48512059|NCT01658501|DRUG|Victoza®|
48512060|NCT01658501|OTHER|Diet and Exercise|
48512061|NCT01658501|DRUG|Metformin|
48512062|NCT01658501|DRUG|Sulfonylurea|
48155003|NCT06266494|DEVICE|Long-Acting silver dressings|Mepilex Transfer Ag
47995683|NCT05289323|DRUG|Neostigmine Methylsulfate|0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
48155004|NCT06266494|OTHER|Aloe Vera|Dermaid Aloe Vera
48155005|NCT06266494|DRUG|Dalbavancin|1500mg IV dose
48155006|NCT02293278|BEHAVIORAL|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
48155007|NCT05413954|OTHER|Control|Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks
48155008|NCT05413954|OTHER|Test|Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
48155009|NCT00282009|BEHAVIORAL|Basic Internet|Basic Internet control intervention
48155010|NCT00282009|BEHAVIORAL|Enhanced Internet|enhanced Internet cessation intervention
47995684|NCT05289323|DRUG|Dextrose 5%/Nacl 0.9% Inj|one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
48155011|NCT00282009|BEHAVIORAL|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
48512063|NCT01658501|DRUG|Metformin and Sulfonylurea|
48512064|NCT00534404|DRUG|Nicotine patches|Participants will wear nicotine patches.
47995685|NCT03622346|PROCEDURE|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
47995686|NCT02342340|OTHER|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
47995687|NCT02342340|OTHER|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
47995688|NCT02342340|OTHER|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
48155012|NCT02816645|PROCEDURE|Magnetic Resonance Imaging (MRI)|
48681762|NCT00329823|DRUG|Etanercept sc 50mg per week for 12 weeks|
48365260|NCT01094821|DRUG|Placebo|Placebo capsule three times daily for 9 days
48681763|NCT00788060|DRUG|Everolimus (RAD001)|5mg per day, continuously
48681764|NCT00788060|DRUG|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
48681765|NCT05204095|DEVICE|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
47995689|NCT02342340|OTHER|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
47995690|NCT02342340|OTHER|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
47995691|NCT02342340|OTHER|White Rice|One time consumption of 3/4 cup of cooked white rice.
48155013|NCT05054361|DIAGNOSTIC_TEST|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
48365261|NCT01094821|DRUG|ATI-7505|10 mg ATI-7505 three times daily for 9 days
48365262|NCT01094821|DRUG|ATI-7505|20 mg ATI-7505 three times daily for 9 days
48365263|NCT06365840|DRUG|IMC-001|All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
48365264|NCT05049915|DEVICE|bioglass (S53P4)|surgical procedure: Masquelet defect augmentation with bioglass
48365265|NCT05049915|DEVICE|RIA and TCP|surgical procedure: Masquelet defect augmentation with RIA and TCP
48365266|NCT00623753|BIOLOGICAL|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
48681766|NCT06351982|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"1. Disclosure of biofilm with erythrosine,~2. Removal of supragingival and subgingival (up to 4 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS- Dental, Nyon Switzerland).~3. Supra- and sub- gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
48681767|NCT06351982|OTHER|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥4 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
48365267|NCT02062385|BIOLOGICAL|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
48365268|NCT02062385|BIOLOGICAL|Placebo to V260|Placebo control
48155014|NCT05054361|DIAGNOSTIC_TEST|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
48681768|NCT01673776|DEVICE|PulsioFlex® Monitoring|"* goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)"
48155015|NCT05054361|DIAGNOSTIC_TEST|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
48155016|NCT05054361|PROCEDURE|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
48155017|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
48155018|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
48155019|NCT06385418|DRUG|Colonic local administration of fluorouracil with enhanced adhesion|Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
48155020|NCT06014788|DEVICE|NPWTi|The wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg.
48155021|NCT06014788|DEVICE|Conventional NPWT|Conventional NPWT
48155022|NCT00080119|DRUG|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
48155023|NCT00080119|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
48155024|NCT00080119|DRUG|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
48155025|NCT01810328|OTHER|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
48155026|NCT01810328|OTHER|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
48155027|NCT04972318|PROCEDURE|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
48365269|NCT02062385|BIOLOGICAL|OPV|Oral poliovirus vaccine administered according to the standard of care
48681769|NCT03441529|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
48681770|NCT03441529|DRUG|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
47995692|NCT00298207|BEHAVIORAL|Walking (behavior)|
48155028|NCT04972318|PROCEDURE|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
48155029|NCT00203788|BEHAVIORAL|Individual Placement and Support|Supported education/employment
48155030|NCT00203788|BEHAVIORAL|Workplace Fundamentals Module|Group skills training on job/school topics
48155031|NCT00203788|BEHAVIORAL|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
48155032|NCT00203788|DRUG|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
48155033|NCT00203788|BEHAVIORAL|Skills training group|Group social skills training that did not focus primarily on work situations
48365270|NCT02062385|BIOLOGICAL|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
48365271|NCT05043493|PROCEDURE|Injection in the intraarticular space of glenohumeral joint|U/S guided injection of platelet rich plasma (PRP) or normal saline (NS)
48512065|NCT00534404|BEHAVIORAL|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
48512066|NCT00534404|BEHAVIORAL|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
48512067|NCT02535286|DRUG|Umbralisib|A once daily oral agent
48512068|NCT02535286|BIOLOGICAL|ublituximab|IV anti-CD20 monoclonal antibody
48512069|NCT02535286|BIOLOGICAL|TG-1501|IV immunotherapy for cancer
48512070|NCT06287138|DRUG|ciprofol|Ciprofol will be infused at 0.3，0.4，0.5，0.6，0.7，0.8 mg/kg/h in sequence for 30 minutes at each dose.
48681771|NCT03187405|DRUG|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
48681772|NCT02454530|BIOLOGICAL|Nivestim®|
48365272|NCT03782389|OTHER|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
48681773|NCT00603941|DRUG|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
48681774|NCT00603941|DRUG|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
47995693|NCT05442944|PROCEDURE|Physiotherapeutic procedures|As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
47995694|NCT01880112|DRUG|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
47995695|NCT02953379|DRUG|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
47995696|NCT02953379|DRUG|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
47995697|NCT06080386|DIAGNOSTIC_TEST|UDFF|quantification of liver fat: UDFF (lipid fraction derived from ultrasound) from one of the probes of an ultrasound system
47995698|NCT04821206|DRUG|DMARDs|New Initiation of a DMARDs
47995699|NCT04821206|DRUG|biologic DMARDs|New Initiation of a biologic DMARDs
47995700|NCT04821206|DRUG|JAK Inhibitor|New Initiation of a JAK Inhibitor
47995701|NCT00151320|DRUG|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
47995702|NCT05217407|OTHER|Genomic sequence|Genomic sequence
47995703|NCT00929682|DRUG|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
47995704|NCT02719132|DRUG|Dapagliflozin|Dapagliflozin, 10 mg
47995705|NCT02719132|DRUG|Metformin|Metformin, up to 2500 mg
47995706|NCT00002161|DRUG|Adefovir dipivoxil|
47995707|NCT05199454|OTHER|Exercise training|Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
47995708|NCT03870828|DIAGNOSTIC_TEST|Bronchoalveolar lavage and taking bronchial mucosa samples|"Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved."
47995709|NCT03870828|DIAGNOSTIC_TEST|6minute walk test|a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
47995710|NCT03870828|DIAGNOSTIC_TEST|Arterial blood gas|If SpO2 is measured to be \< 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
47995711|NCT03870828|PROCEDURE|Blood drawing|A vein will be punctured in order to take a blood sample for further tests
47995712|NCT05797493|DRUG|Atezolizumab|Upfront chemo-immunotherapy
47995713|NCT06244862|DRUG|Ruxolitinib|Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
48365273|NCT02369575|OTHER|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
48365274|NCT04998058|PROCEDURE|Maxillary sinus floor elevation grafting with synthetic bone substitute.|Bone augmentation at the floor of the maxillary sinus with bone substitutes.
48681775|NCT04466384|DEVICE|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
47995714|NCT05228392|OTHER|listening to music|listening to lullaby or other music types
47995715|NCT02162342|OTHER|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
47995716|NCT03829748|PROCEDURE|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
48365275|NCT00867061|DRUG|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
48365276|NCT03293706|OTHER|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
48681776|NCT01104480|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
48681777|NCT01899781|DRUG|Antibiotic-Cefamezin|
48681778|NCT05320484|OTHER|Clinical Pilates Exercises|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
48681779|NCT05320484|OTHER|Classic Posture exercise|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
48681780|NCT05561933|BEHAVIORAL|Healthy Minds Program Foundations Training|"The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose."
48681781|NCT02866162|GENETIC|High-throughput exome sequencing|
48681782|NCT00802620|PROCEDURE|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
48681783|NCT03235193|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
47995717|NCT05726396|DRUG|RMT|A single loading dose of RMT capsules containing \~5 x 10 11 bacteria on day 1 followed by 2 x 10 11 bacteria daily for 6 days. The RMT capsule preparation (\~2-5 capsules, size 00) is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
47995718|NCT05726396|DRUG|Placebo|Participants will receive an identical looking placebo capsules daily for 7 days (i.e 5 placebo capsules on day 1), followed by 2 placebo capsules daily from Day 2-7. The placebo capsule preparation is self-administered on an empty stomach with at least one glass of water. Clear liquids are allowed, and food can be resumed 2 hours after administration.
47995719|NCT05566210|DEVICE|acupuncture|acupuncture
47995720|NCT05566210|DEVICE|Sham acupuncture|Sham acupuncture
47995721|NCT02482987|DEVICE|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
47995722|NCT02482987|DEVICE|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
47995723|NCT02482987|PROCEDURE|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
47995724|NCT02482987|PROCEDURE|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
47995725|NCT01218555|DRUG|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
47995726|NCT01218555|DRUG|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
47995727|NCT01631058|DRUG|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
48681784|NCT03235193|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
48681785|NCT04645992|DEVICE|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
47995728|NCT06304090|BEHAVIORAL|routine rehabilitation treatment|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~Direct feeding training: with powdered milk, once a day, 5 days a week."
47995729|NCT06304090|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48155034|NCT04879823|DRUG|Dexamethasone|IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup
48365277|NCT03293706|OTHER|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
48512071|NCT02304666|PROCEDURE|Colonoscopy for biopsies samples|
48681786|NCT04645992|DEVICE|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
47995730|NCT06304090|DRUG|Lidocaine Hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
47995731|NCT00885755|DRUG|Standard taxane therapy|As prescribed
47995732|NCT00885755|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
47995733|NCT00885755|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
47995734|NCT03554356|DEVICE|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
47995735|NCT00527930|DRUG|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
47995736|NCT03558399|OTHER|FET according to ERA|Single euploid FET will be performed at the time indicated by the ERA test results.
47995737|NCT03558399|OTHER|FET according to standard protocol|Single euploid FET will be performed according to our standard FET protocol.
47995738|NCT03895983|PROCEDURE|Percutaneous primary coronary intervention|Percutaneous primary coronary intervention
47995739|NCT00535548|BIOLOGICAL|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
47995740|NCT00937417|DRUG|docetaxel|
47995741|NCT00937417|DRUG|vandetanib|
47995742|NCT00937417|GENETIC|proteomic profiling|
47995743|NCT00937417|OTHER|laboratory biomarker analysis|
47995744|NCT00937417|OTHER|pharmacological study|
47995745|NCT04094467|DRUG|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
47995746|NCT04094467|DRUG|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
47995747|NCT01267396|DRUG|Sertraline|Sertraline Hydrochloride Tablets 100 mg
47995748|NCT01318096|DRUG|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
47995749|NCT01318096|DRUG|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
47995750|NCT06045234|OTHER|Urine sampling|"Among the 300 people recruited:~* 300 will each provide 3 urine samples collected on 3 different days during a week (e.g. Monday, Wednesday and Friday)~* 50 will each provide 3 urine samples collected at sunrise, in the middle and then at the end of the day over a period of 24 hours, on 3 different days during a week (e.g. Monday, Wednesday and Friday)."
47995751|NCT05918679|BEHAVIORAL|Effects of speech variability on speech motor learning|This intervention will examine whether reducing normal variability of speech could improve error detection and speech motor learning. We will design training tasks to change subjects' speech variability. We will train subjects to decrease/decrease their speech variability. Upon completing the training tasks, subjects will complete a motor learning task.
47995752|NCT05918679|BEHAVIORAL|Effects of error-detection training on speech motor learning|This intervention will examine whether improving subjects' ability to detect and estimate auditory perturbation could improve speech motor learning. For this purpose, we will design training tasks to change subjects' estimation of the perturbation magnitude. After completing the training tasks, subjects will complete the motor learning task.
47995753|NCT05918679|BEHAVIORAL|Contributions of error awareness to speech motor learning|This intervention will examine the contributions of error awareness to speech motor learning. Subjects will produce a target word while receiving perturbed auditory feedback with different magnitudes. Subjects will be trained to indicate the magnitude of the error they perceived with or without visual feedback.
48365278|NCT03293706|OTHER|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
47995754|NCT05918679|BEHAVIORAL|Enhancing auditory-to-motor mapping with augmented visual feedback|This intervention will determine the contributions of enhanced auditory-to-motor mappings to speech motor learning. We will design training tasks in which we will use visual feedback to provide feedback regarding subjects' accuracy of auditory-to-motor mapping.
47995755|NCT05918679|BEHAVIORAL|Effects of enhanced auditory-motor awareness on speech motor learning|In this intervention, subjects will be trained to control their articulators more accurately and be more aware of their articulators' position and their auditory consequences. After the training tasks, subjects will complete a motor learning task.
48365279|NCT03293706|OTHER|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
48365280|NCT03293706|OTHER|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
48365281|NCT05359575|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps of c-collar application (totaling 1 minute, 19 seconds) and instructional flashcard with seven pictures corresponding to each of the 6 steps of c-collar application
48365282|NCT05359575|BEHAVIORAL|Instructional flashcard (version 1)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application.
48365283|NCT05359575|BEHAVIORAL|In-person training|10 minute of an LFR spinal immobilization course (extracted from the current LFR Level 1 trauma course).
48365284|NCT05359575|BEHAVIORAL|Instructional flashcard (version 2)|Single page with 7 pictures corresponding to each of the 6 steps of cervical collar (c-collar) application edited for clarity based on initial pilot feedback.
48365285|NCT01209299|GENETIC|DNA methylation analysis|
48365286|NCT01209299|GENETIC|gene expression analysis|
48365287|NCT01209299|OTHER|laboratory biomarker analysis|
48365288|NCT05237843|DRUG|Hydroxychloroquine|Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
48365289|NCT04500626|DRUG|Oxygen|Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
48155035|NCT04879823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
48155036|NCT04879823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
48155037|NCT04879823|DRUG|Placebo|An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
48155038|NCT01539902|BIOLOGICAL|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
48155039|NCT01539902|DRUG|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
48155040|NCT02634528|DRUG|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
48155041|NCT02634528|DRUG|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
48365290|NCT00493909|PROCEDURE|intrathecal opioids and thoracic paravertebral analgesia|
48365291|NCT00493909|PROCEDURE|thoracic epidural analgesia|
48365292|NCT01757821|DEVICE|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
48365293|NCT01757821|DEVICE|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
48681787|NCT02690766|BEHAVIORAL|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
48155042|NCT04203368|DRUG|adenosine|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
48365294|NCT01757821|DEVICE|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
48365295|NCT00499733|DRUG|cyclophosphamide|500 mg/m\^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
48365296|NCT00499733|DEVICE|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
48365297|NCT01592773|DRUG|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
48365298|NCT02102776|PROCEDURE|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
48365299|NCT02102776|PROCEDURE|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
48365300|NCT02102776|PROCEDURE|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
48681788|NCT04861779|DRUG|HSK29116|Oral HSK29116
48155043|NCT04203368|DRUG|verapamil|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
48155044|NCT04058847|OTHER|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
48155045|NCT04422210|DRUG|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
48155046|NCT04422210|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
48365301|NCT02102776|PROCEDURE|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
48681789|NCT04888416|BEHAVIORAL|I-STROM|I-STROM is a combination of the following implementation strategies: (a) initial and ongoing training, (b) learning collaboratives/knowledge sharing meetings, and (c) outcome measure champions
48155047|NCT04422210|DRUG|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
48365302|NCT00155428|PROCEDURE|rapid prototyping|
48365303|NCT00155428|PROCEDURE|computed tomography|
48365304|NCT02398643|OTHER|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
48365305|NCT02398643|OTHER|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
47995756|NCT06003556|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan|Additional staging PET scan prior to focal therapy to focal therapy.
48155048|NCT04422210|DRUG|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
48155049|NCT04051645|DEVICE|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
48155050|NCT04374175|BIOLOGICAL|Blood sample|Blood sample will be performed
48155051|NCT01767376|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
48155052|NCT01767376|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
48155053|NCT06177938|DIETARY_SUPPLEMENT|Lactose solution/Glucose solution|Single ingestion of a lactose/glucose solution.
48155054|NCT00004578|DRUG|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
48155055|NCT00004578|DRUG|Lamivudine|150 mg, every 12 hours
48155056|NCT00004578|DRUG|Stavudine|40 mg every 12 hours
48155057|NCT02121808|PROCEDURE|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
48365306|NCT04209140|DRUG|lithium treatment|"Decisions relating to treatment are also considered the clinician's responsibility to be made according to bipolar treatment guidelines and international standards of care (e.g. discontinuation, co-prescriptions, and according to SmPC in force). After the clinician has confirmed the indication of Lithium treatment as well as the absence of contra-indicated concomintant medication (NSAIDs and Diuretics) and after pre-~Lithium evaluations confirm the absence of contra-indication, Lithium is initiated following standard of care:~progressive titration to reach therapeutic plasma levels. Clinicians will use the therapeutic range provided by the laboratory they use in their usual clinical practice and according to the type of Lithium they prescribe."
48365307|NCT03125421|PROCEDURE|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
48365308|NCT03125421|PROCEDURE|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
48365309|NCT01091116|DRUG|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
47995757|NCT01536314|DRUG|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
47995758|NCT01536314|DRUG|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
47995759|NCT00942396|DEVICE|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
47995760|NCT01526265|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
47995761|NCT01526265|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
47995762|NCT01526265|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
48155058|NCT02121808|PROCEDURE|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
48155059|NCT00009763|BIOLOGICAL|filgrastim|
48155060|NCT00009763|BIOLOGICAL|monoclonal antibody m170|
48155061|NCT00009763|DRUG|cyclosporine|
48155062|NCT00009763|DRUG|paclitaxel|
48155063|NCT00009763|PROCEDURE|peripheral blood stem cell transplantation|
48155064|NCT00009763|RADIATION|yttrium Y 90 monoclonal antibody m170|
48155065|NCT04974021|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
48155066|NCT03873922|OTHER|Ketogenic diet intervention|Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
48155067|NCT05819177|OTHER|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
48155068|NCT01190488|BEHAVIORAL|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
48155069|NCT01190488|BEHAVIORAL|Active Comparator|TAU
48681790|NCT02489149|OTHER|Multi-sector interventions|"* Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights."
48681791|NCT02489149|OTHER|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
48681792|NCT02420184|DEVICE|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
48681793|NCT02420184|OTHER|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
48681794|NCT05582148|DEVICE|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
48681795|NCT05250921|PROCEDURE|Corticision|Corticision will be performed to enhance teeth alignment.
48155070|NCT01874470|DEVICE|renal denervation|
48155071|NCT01874470|OTHER|standard medication|
48512072|NCT02786225|BEHAVIORAL|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
48365310|NCT01091116|DRUG|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
48365311|NCT01091116|DRUG|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
48365312|NCT01091116|DRUG|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
48365313|NCT01091116|DRUG|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
48681796|NCT05250921|DEVICE|Conventional fixed appliance|No surgical intervention is going to be applied to the patients in this group.
48512073|NCT02786225|BEHAVIORAL|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
48512074|NCT00321178|DRUG|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
48681797|NCT00041470|DRUG|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
48681798|NCT00041470|DRUG|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
48681799|NCT00041470|DRUG|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
48155072|NCT03906240|BEHAVIORAL|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
48155073|NCT01123044|BIOLOGICAL|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
48155074|NCT01123044|PROCEDURE|Medical Therapy|Under usual care treatment
48155075|NCT05360134|DRUG|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
48365314|NCT04424589|OTHER|Myofascial release|Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.
48365315|NCT04424589|OTHER|Sham therapy|The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
48365316|NCT02665039|DRUG|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min"
48365317|NCT02665039|DRUG|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
47995763|NCT01526265|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
48155076|NCT05360134|OTHER|Placebo|Placebo will be given in a similar manner
48155077|NCT02031445|DRUG|MRX-6|
48155078|NCT02031445|OTHER|Placebo|
48155079|NCT02889172|BEHAVIORAL|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
48155080|NCT02755909|BEHAVIORAL|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
48155081|NCT01014013|DRUG|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
48155082|NCT01014013|DRUG|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
48155083|NCT03974308|OTHER|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
48155084|NCT03974308|OTHER|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
48155085|NCT03974308|OTHER|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
48155086|NCT03658018|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
48365318|NCT02665039|DRUG|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
48365319|NCT05810324|DRUG|18F-FAPI|Each patient receive a single intravenous injection of 18F-FAPI, and undergo PET/CT scan within specified time.
48365320|NCT00364351|DRUG|Vandetanib|once daily oral tablet
48365321|NCT00364351|DRUG|Erlotinib|oral dose
48365322|NCT01475981|DRUG|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
48365323|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
48365324|NCT00668876|DIETARY_SUPPLEMENT|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
48155087|NCT03522688|DRUG|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
48155088|NCT03522688|DRUG|Normal saline|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
48155089|NCT00585910|DRUG|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
48155090|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide (NAM)|500 mg a day
48155091|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|1000 mg a day
48155092|NCT05517122|DIETARY_SUPPLEMENT|Nicotinamide Mono Nucleotide (NMN)|1000 mg a day
48155093|NCT05517122|DIETARY_SUPPLEMENT|Microcrystalline cellulose|500 mg a day
48365325|NCT00668876|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition
48365326|NCT02715115|DRUG|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
48365327|NCT02715115|DRUG|Placebo|Strawberry flavored solution and Water for Injection
48365328|NCT02743494|DRUG|Nivolumab|Specified dose on specified days
48365329|NCT02743494|OTHER|Placebo|Specified dose on specified days
48365330|NCT00377273|DRUG|fluorouracil cream 0.5%|
48365331|NCT04104399|DRUG|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
48155094|NCT05703477|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
48681800|NCT00041470|DRUG|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
47995764|NCT01526265|BEHAVIORAL|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
47995765|NCT05768152|DEVICE|RLRL|RLRL will be performed twice per day with an interval of at least 4 hours, each treatment last 3 minutes, in addition to single vision spectacles with power for correcting distance refraction.
47995766|NCT02560337|DRUG|Cabazitaxel|
48681801|NCT04133350|BEHAVIORAL|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
47995767|NCT05750927|PROCEDURE|Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)|TAVI and PCI to be administered as per physician's indication and choice, in one or more stages
48365332|NCT04104399|DRUG|Placebo|Placebo supplied as matching capsules
48365333|NCT00012870|BEHAVIORAL|Behavioral Management|
48681802|NCT00851331|GENETIC|genome analyzes (genetic defects and pathophysiological mechanisms )|
47995768|NCT03783871|DEVICE|Microwave ablation|Subjects will be treated with microwave ablation.
48365334|NCT03943602|DRUG|Cabozantinib|Cabozantinib 60 mg/day orally
48681803|NCT03343678|DRUG|Venetoclax|Venetoclax given alone and then in combination with BI 836826
48681804|NCT03343678|DRUG|BI 836826|Venetoclax given in combination with BI 836826
48681805|NCT03247582|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
48681806|NCT03204604|DIETARY_SUPPLEMENT|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
48681807|NCT03204604|DIETARY_SUPPLEMENT|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
48681808|NCT03204604|PROCEDURE|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
47995769|NCT00746993|OTHER|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
48155095|NCT03369119|DRUG|Montelukast 4 Mg Oral Granule|
48155096|NCT03369119|DRUG|Placebos|
48155097|NCT01567176|BIOLOGICAL|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
48365335|NCT00104429|DRUG|GW873140|
48365336|NCT00104429|DRUG|Combivir|
48365337|NCT03138707|OTHER|patients who die|
48365338|NCT04937608|DIAGNOSTIC_TEST|Sperm analysis|Routine sperm analysis including analysis of sperm concentration, motility, vitality and morphology. Sperm DNA integrity will also be assessed.
48365339|NCT02074059|DRUG|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
48365340|NCT02074059|DEVICE|nCPAP alone|nCPAP therapy
48365341|NCT04794530|DRUG|cocoa flavanols|The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
47995770|NCT02037542|BEHAVIORAL|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
47995771|NCT05673096|BEHAVIORAL|PACT|Paediatric Autism Communication Therapy
47995772|NCT05673096|BEHAVIORAL|MAU|Management as usual
47995773|NCT03078621|BIOLOGICAL|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
48681809|NCT03204604|BEHAVIORAL|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
48681810|NCT03204604|BEHAVIORAL|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
47995774|NCT01530295|DRUG|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
47995775|NCT03445819|PROCEDURE|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
47995776|NCT03445819|OTHER|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
47995777|NCT02052232|OTHER|Experimental protein powder sachet|mixed with 8 oz. water
47995778|NCT02052232|OTHER|Control protein powder sachet|mixed with 8 oz. water
47995779|NCT04109664|PROCEDURE|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
47995780|NCT03314727|OTHER|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
47995781|NCT05270954|BIOLOGICAL|Betuvax-CoV-2|Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)
48681811|NCT03204604|BEHAVIORAL|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
47995782|NCT05270954|DRUG|Placebo|Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
47995783|NCT00003120|DRUG|paclitaxel|135 mg/m2 IV every 28 days
48681812|NCT03204604|BEHAVIORAL|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
48681813|NCT03263325|OTHER|Discarded urine sample|Collection of discarded urine during surgery and following surgery
48681814|NCT03667313|COMBINATION_PRODUCT|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
48681815|NCT03667313|COMBINATION_PRODUCT|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
47995784|NCT00860912|PROCEDURE|Collagen Matrix|surgical/reinforcing material
47995785|NCT04488965|OTHER|Autologous transplant|Autologous transplant obtained from cortical biopsy
47995786|NCT02564614|DRUG|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
47995787|NCT01747109|DEVICE|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
47995788|NCT01747109|PROCEDURE|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
48365342|NCT04794530|DRUG|placebo|The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
48365343|NCT03495999|DIAGNOSTIC_TEST|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
48365344|NCT00841854|DRUG|pantoprazole|pantoprazole 40mg bid
48365345|NCT00841854|DRUG|bismuth|bismuth 300mg qid
48365346|NCT00841854|DRUG|metronidazole|metronidazole 500mg tid
48365347|NCT00841854|DRUG|tetracycline|tetracycline 500mg qid
47995789|NCT00187460|BEHAVIORAL|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
47995790|NCT00370474|DEVICE|Bi-ventricular lead placement|
47995791|NCT05409872|DIETARY_SUPPLEMENT|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
47995792|NCT05409872|OTHER|Placebo|The subject takes the placebo twice a day for three months.
47995793|NCT03282292|PROCEDURE|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
47995794|NCT01059370|PROCEDURE|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
48681816|NCT04067791|DIETARY_SUPPLEMENT|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
48681817|NCT04067791|DIETARY_SUPPLEMENT|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
47995795|NCT00827255|DRUG|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
47995796|NCT01885546|DEVICE|AgaMatrix Blood Glucose Monitor|
47995797|NCT02504567|DEVICE|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
48365348|NCT02515604|DRUG|Misoprostol|
48365349|NCT04552340|OTHER|Patient with SAR-CoV-2 infection|Study population The study cohort will be enrolled among patients referred to our the Humanitas Research Hospital, the Hospital Cliniche Gavazzeni (Bergamo) hospitals for SARS-CoV-2 screening who will/will not be hospitalized in wards dedicated to COVID-19 patients or admitted to intensive care unit.
48681818|NCT04138511|DEVICE|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
48681819|NCT03336086|COMBINATION_PRODUCT|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
48681820|NCT01540786|PROCEDURE|High resolution urodynamic assessment|
48681821|NCT01540786|PROCEDURE|Conventional urodynamic assessment|
47995798|NCT02504567|DEVICE|RF ablation|Pulmonary vein isolation using the RF ablation catheter
47995799|NCT01957748|BEHAVIORAL|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
47995800|NCT04735120|DEVICE|iLASE DIODE LASERS|940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
47995801|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
47995802|NCT01094548|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
47995803|NCT01094548|DRUG|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
48155098|NCT02962609|OTHER|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
48365350|NCT00386152|DRUG|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
48365351|NCT00386152|DRUG|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
48365352|NCT01030731|DRUG|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
48365353|NCT06371560|OTHER|Questionnaire|online based questionnaire
48512075|NCT04172597|DRUG|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
48681822|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
48681823|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
47995804|NCT01094548|DRUG|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m\^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m\^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
47995805|NCT02646176|BEHAVIORAL|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
47995806|NCT05540964|OTHER|Antiretroviral Therapy Interruption(ATI)|Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.
47995807|NCT03221803|OTHER|OT Vertical attachment|new extra coronal castable attachment
47995808|NCT03221803|OTHER|OT cap attachment|standard extra coronal attachment
47995809|NCT04950569|DRUG|levosimendan|On the basis of standard conventional anti-heart failure treatment, levosimendan was used for 24 hours. The first load was 12 μg/kg, intravenous injection for 10 minutes, followed by intravenous infusion of 0.1 μg/Kg/min for 24 hours.
47995810|NCT00283933|DRUG|migalastat HCl|
47995811|NCT00963261|BEHAVIORAL|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
47995812|NCT02098109|DRUG|XM02 Filgrastim|
47995813|NCT02098109|DRUG|Filgrastim|
47995814|NCT02098109|PROCEDURE|Apheresis|
47995815|NCT02098109|DRUG|Plerixafor|
47995816|NCT02098109|PROCEDURE|Stem Cell Transplant|
47995817|NCT01758653|OTHER|No study intervention|There is no study-related intervention.
47995818|NCT06361823|DRUG|Semaglutide|Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
47995819|NCT06361823|DIETARY_SUPPLEMENT|Low calorie diet|Low calorie diet (max 1200 kcal/day)
47995820|NCT00842660|DRUG|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
47995821|NCT06030882|OTHER|Biologic Care Pathway|Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
47995822|NCT00005926|DRUG|Gemcitabine|
47995823|NCT00005926|DRUG|Herceptin|
47995824|NCT00005926|PROCEDURE|Radiation therapy|
47995825|NCT04344314|DEVICE|Peripheral Intravenous Catheter|Randomised controlled
47995826|NCT06488482|DRUG|nivolumab or pembrolizumab|See above
47995827|NCT02710890|DRUG|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
47995828|NCT02846207|DRUG|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
47995829|NCT02846207|DRUG|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
47995830|NCT02846207|DRUG|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
47995831|NCT02846207|DRUG|placebo|Dextrin,oral administration, twice one day, for 12weeks.
47995832|NCT01283126|PROCEDURE|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
47995833|NCT02493738|DRUG|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
47995834|NCT02493738|DRUG|Sporanox 100mg|Sporanox 100mg single dose under fed condition
47995835|NCT02070835|DEVICE|autologous skin cell|autologous skin cell and skin graft
47995836|NCT02070835|PROCEDURE|skin graft|split-thickness skin graft
47995837|NCT01241903|DRUG|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
47995838|NCT01241903|DRUG|placebo|frequency and duration
48365354|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
48512076|NCT04172597|DRUG|Loperamide|Loperamide as prescribed by the physician.
48681824|NCT04462029|DRUG|BR4002|"* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
47995839|NCT06052007|BEHAVIORAL|LC-Based Debriefing|LC-based debriefing encourages reflection by allowing learners to identify and explore topics of particular interest. The model is defined as a structured post-event LC, which is useful for improving competence, professional development, and clinical judgment among intensive care unit and trauma nurses. The model is useful not only for one recipient by allowing reflection on positive and negative experiences but also for the whole group by allowing them to make connections to their own practice that day or to previous experiences, supporting teamwork. It also helps them understand what good practice is by doing their own self-assessment with peers' benchmarking.
47995840|NCT06052007|BEHAVIORAL|3D Model-Based Debriefing|The model has three parts: defusing, discovering, and deepening. The experiential learning theory on which this model is based facilitates learning goals. This model allows its participants to create new mental models for future practice, develop critical thinking skills, and identify knowledge gaps. In the model, a debriefing session starts with preliminary information and ends with a summary of what has been learned. Participants' gaps in understanding and learning are identified, and how they can apply their learnings to practice is discussed.
47995841|NCT03548402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
47995842|NCT03276689|DRUG|Duloxetine|The patients will take duloxetine for 8 weeks.
47995843|NCT03276689|DRUG|Pregabaline|The patients will take pregabaline for 8 weeks.
47995844|NCT03276689|OTHER|Placebo|The patients will take placebo for 8 weeks.
48681825|NCT04462029|DRUG|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
48681826|NCT06038292|RADIATION|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
47995845|NCT03357484|PROCEDURE|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH \& Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
47995846|NCT03357484|PROCEDURE|Blood clot|Natural blood clot formed within extraction socket
47995847|NCT01650662|DRUG|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
47995848|NCT03676322|DRUG|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
47995849|NCT03676322|DRUG|Placebo|Participants will receive placebo matched to M5049.
47995850|NCT02681120|PROCEDURE|Biopsy|
47995851|NCT02681120|PROCEDURE|Blood draw|
47995852|NCT02681120|PROCEDURE|Mammogram|
47995853|NCT02681120|PROCEDURE|MRI|
47995854|NCT04983056|PROCEDURE|Necrotesectomy associated with cleanleness stoma|Excision of all necrotised tissues after stool diversion and wound dressing using
47995855|NCT01995084|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
47995856|NCT01980043|PROCEDURE|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
47995857|NCT00746941|DRUG|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
48155099|NCT02962609|OTHER|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
48155100|NCT02558816|DRUG|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
48155101|NCT02388399|PROCEDURE|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex\> cap thickness, spotty calcification)
47995858|NCT00030563|DRUG|irinotecan hydrochloride|
47995859|NCT00030563|PROCEDURE|adjuvant therapy|
47995860|NCT00030563|PROCEDURE|conventional surgery|
47995861|NCT00030563|PROCEDURE|radiofrequency ablation|
47995862|NCT05942261|OTHER|Survey to collect data|The study is a survey aimed to collect data about rehabilitation methods
47995863|NCT03617081|DRUG|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
48155102|NCT02388399|PROCEDURE|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
48681827|NCT02432937|DRUG|Corever|Corever
48681828|NCT03715725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
48681829|NCT03715725|DRUG|Apixaban (Eliquis)|Administration according to clinical practice
47995864|NCT03617081|DRUG|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
48681830|NCT03715725|DRUG|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
48681831|NCT03715725|DRUG|Warfarin (Marevan)|Administration according to clinical practice
47995865|NCT05346263|DEVICE|Intermittent Abdominal Pressure Ventilation|Patients of experimental group will use IAPV in daytime ventilation. Intermittent abdominal pressure ventilation (IAPV) is a portable ventilator with an internal battery and PneumoBelt corset as an interface.
47995866|NCT05346263|DEVICE|Usual ventilation|NIV
47995867|NCT01408121|OTHER|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
47995868|NCT01583335|BEHAVIORAL|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
47995869|NCT05720156|OTHER|99mTc-tilmanocept SPECT/CT scanning|99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
47995870|NCT01838642|DRUG|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
47995871|NCT02140437|DRUG|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
47995872|NCT02140437|DRUG|Anastrozole|standard endocrine therapy
47995873|NCT04391790|PROCEDURE|Cystectomy and modified urinary conduit|The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
47995874|NCT04391790|PROCEDURE|Cystectomy and standard urinary conduit ad modum Bricker|The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
47995875|NCT03024307|OTHER|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
47995876|NCT00002052|DRUG|Ceftriaxone sodium|
47995877|NCT00002052|DRUG|Ampicillin sodium|
47995878|NCT00002052|DRUG|Amoxicillin trihydrate|
47995879|NCT05541549|BIOLOGICAL|CE-VST01-JC|CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
47995880|NCT05563064|DRUG|Karika Syrup|To evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.
47995881|NCT05627882|DIAGNOSTIC_TEST|Forward viewing endoscope|Additional examination with standard forward viewing endoscope
47995882|NCT00625677|BIOLOGICAL|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
47995883|NCT00625677|BIOLOGICAL|Menjugate (Meningococcal C conjugate vaccine)|Dosage
47995884|NCT04939415|DRUG|mQFPD|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
47995885|NCT04939415|DRUG|organic brown rice|The dosage of mQFPD is 8 capsules three times a day for 14 consecutive days. It does not need to be consumed with food. It is best taken at least 30 minutes before OR at least 60 minutes after meals, in the morning, noon and evening. Accidentally missed doses will not need to be taken at a later time but will be recorded in a daily diary.
47995886|NCT00384800|DRUG|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
47995887|NCT06497114|OTHER|ABILHAND-Kids questioner|questioner
47995888|NCT03635710|DEVICE|The patient will undergo no intervention|Night coughs will be monitored using smartphone a app and interpreted using machine learning algorithm.
47995889|NCT06267079|OTHER|core stability exercise|Each participant in the group (A) underwent eighteen sessions of core stability exercises very other day for one and half months, 3 sessions /week, each session for 1hour (30 minutes for core exercises then 30 minutes Selected physical therapy program).
47995890|NCT00262509|DEVICE|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
47995891|NCT03234660|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
47995892|NCT03234660|OTHER|control|0.9% normal saline continuous infusion
47995893|NCT06275282|DEVICE|Intramuscular electrodes|Participants will have regenerative peripheral nerve interfaces (RPNIs) created on nerves in their residual thighs. During either the same surgery or a separate surgery, small electrodes will be implanted into these RPNIs.
47995894|NCT04546165|PROCEDURE|manipulation plus exercise|HLVA manipulation was performed for 8 sessions (twice a week for four weeks) using a segment-specific technique for segmental dysfunctions of the upper cervical spine. . By bringing the cervical spine to light flexion and about 15-20º lateral flexion without any rotational motion, the middle finger of the manipulating hand provided deep contact, and an HVLA thrust was applied out of the rotational slack by applying a deep force from the dorsal to the ventral direction
47995895|NCT04546165|PROCEDURE|suboccipital inhibition plus exercise|Suboccipital inhibition was performed for 8 sessions (twice a week for four weeks) as a combined muscle and soft tissue inhibition technique. While the patient was in the supine position, the physician sitting at the top end of the table placed the fingers of both hands on the patient's suboccipital region
47995896|NCT04546165|PROCEDURE|exercise|Patients were asked to exercise at least three days a week during treatment. The exercise program, which lasted 20 to 30 minutes, included cervical range of motion (ROM) exercises to warm-up and cool-down, and then stretching exercises of cervical and upper thoracic spine muscles (trapezius, levator scapula, sternocleidomastoid) and strengthening exercises (cervical isometric contraction and concentric contraction of the deep cervical flexor muscles).
47995897|NCT04911283|OTHER|Brucella serology test|MCs type 1 and type 2 patients were examined in terms of Brucella serology by using agglutination with Coombs test.
48155103|NCT05945823|DRUG|Futibatinib|TAS-120 20 mg tablets, oral; once daily
47995898|NCT04911283|OTHER|Medical history for brucellosis|Both of the MCs groups and healthy controls were investigated for their medical history regarding brucellosis.
48681832|NCT03954548|DEVICE|CB-17-08 CADe|CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
48681833|NCT03096639|DEVICE|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
48681834|NCT04170998|DRUG|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
48681835|NCT04170998|DRUG|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
48681836|NCT04170998|DRUG|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
48681837|NCT04170998|DRUG|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
48681838|NCT05224427|BEHAVIORAL|Near-Peer Coaching|Targeted coaching by near-peer medical students
48681839|NCT05445258|DEVICE|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
48681840|NCT06138808|OTHER|Stereoelectroencephalography (SEEG)|Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
48681841|NCT03773666|DRUG|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
48681842|NCT03773666|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
48681843|NCT04963283|DRUG|Cabozantinib|Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
48681844|NCT04963283|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
48681845|NCT04938284|DEVICE|PAS|Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)
48681846|NCT04938284|DEVICE|VNS|Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.
48681847|NCT00924001|DRUG|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
48681848|NCT00924001|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
48681849|NCT00924001|DRUG|Fludarabine|25 mg/m\^2/day intravenously x 5 days
48681850|NCT00924001|DRUG|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
48681851|NCT01890265|DRUG|Pamrevlumab|Solution for infusion
48681852|NCT01890265|DRUG|Placebo|Solution for infusion
48681853|NCT01890265|DRUG|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
47995899|NCT00735878|DRUG|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
47995900|NCT00703885|DRUG|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
47995901|NCT00703885|DRUG|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
48155104|NCT05945823|DRUG|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
48681854|NCT01890265|DRUG|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
48681855|NCT00809926|DRUG|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
48681856|NCT00809926|DRUG|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
48681857|NCT05475977|DIAGNOSTIC_TEST|MSCT chest|Multi slice Computed Tomography of the chest
48681858|NCT00974155|DRUG|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
48155105|NCT05945823|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy
48155106|NCT05945823|DRUG|5-FU|"4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy."
48155107|NCT05945823|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.
48155108|NCT05945823|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.
48155109|NCT05945823|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
48155110|NCT05945823|DRUG|Irinotecan|150 mg/m\^2 Q2W as part of mFOLFIRINOX chemotherapy.
48155111|NCT01196741|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
48155112|NCT01196741|DRUG|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
48155113|NCT01196741|DRUG|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
48155114|NCT00101387|OTHER|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
48155115|NCT00101387|OTHER|Lumbar PENS|As above
48155116|NCT00101387|OTHER|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
48155117|NCT00101387|OTHER|Control PENS + exercise|as above
48681859|NCT00974155|DRUG|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
48681860|NCT02168062|BEHAVIORAL|Behavioral Dietary Intervention|Receive individualized nutrition counseling
48681861|NCT02168062|OTHER|Counseling|Receive individualized symptom management service counseling
48681862|NCT02168062|OTHER|Educational Intervention|Review educational modules
48681863|NCT02168062|BEHAVIORAL|Exercise Intervention|Receive individualized exercise counseling
48681864|NCT02168062|DRUG|Goserelin Acetate|Given SC
48155118|NCT00006428|DRUG|Amitriptyline|
48155119|NCT01972373|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
48155120|NCT01972373|DEVICE|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
48155121|NCT04782570|DEVICE|Verum TMS|Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.
48681865|NCT02168062|OTHER|Laboratory Biomarker Analysis|Correlative studies
47995902|NCT00703885|DRUG|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
47995903|NCT01454570|DEVICE|powered exoskeleton|
47995904|NCT00323492|DRUG|Truvada|Truvada + NNRTI or PI.
48155122|NCT04782570|DEVICE|Sham TMS|Sham stimulation with same protocol, but without magnetic stimulation
48155123|NCT01184755|BEHAVIORAL|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
48155124|NCT01184755|DEVICE|RESPeRate|
48155125|NCT01560962|DRUG|povidone iodine|over the counter (OTC) 5% povidone iodine (PI)
48155126|NCT01560962|OTHER|No Intervention|
48155127|NCT01560962|DRUG|Azithromycin|
48155128|NCT01560962|DRUG|tobramycin-dexmethasone|
48155129|NCT01560962|OTHER|warm soaked eyelid wash|
48155130|NCT03991325|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
48155131|NCT06465433|DRUG|Tafasitamab|Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
48681866|NCT02168062|DRUG|Leuprolide Acetate|Given SC or IM
48155132|NCT03073122|DIAGNOSTIC_TEST|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
48512077|NCT04627428|BIOLOGICAL|RPESC-RPE-4W|RPESC-RPE-4W
48681867|NCT02168062|OTHER|Quality-of-Life Assessment|Ancillary studies
48681868|NCT02168062|DRUG|Triptorelin Pamoate|Given IM
48681869|NCT03087604|PROCEDURE|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
48365355|NCT03328325|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
48365356|NCT03036891|DRUG|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
48681870|NCT03087604|PROCEDURE|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
48681871|NCT03087604|DRUG|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
48681872|NCT06370312|PROCEDURE|Trapeziectomy|Patients scheduled for trapeziectomy due to thumb basal joint osteoarthritis are invited to participate. Synovial fluid is aspirated before the joint is opened. Bone and cartilage are collected. Blood samples are obtained preop. Patients are measured with grip strength, pinch strength, range of thumb motion, body mass index, central obesity and blood pressure.
48681873|NCT02859831|OTHER|water samples|
48681874|NCT05163327|PROCEDURE|Oxygen-enhanced Cardiac MRI|The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
48681875|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol
48681876|NCT04536051|BIOLOGICAL|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
48681877|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol
48681878|NCT04536051|BIOLOGICAL|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
47995905|NCT00323492|DRUG|Current HAART regimen|Maintain baseline regimen
47995906|NCT00089570|DRUG|terlipressin|
47995907|NCT00089570|DRUG|Placebo|
48681879|NCT03513913|PROCEDURE|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
48681880|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
48681881|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
48681882|NCT00251693|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
47995908|NCT00003814|DRUG|eflornithine|
47995909|NCT04782531|OTHER|peripheral ECG|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
47995910|NCT04782531|OTHER|Standard MRI|Standard MRI examination using a torso coil consists of morphological and phase-contrast flow sequences(standard and EPI acquisitions).
47995911|NCT04641611|OTHER|Bicaval cannulation|Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied
47995912|NCT04641611|OTHER|Cavoatrial cannulation|Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
47995913|NCT06094647|DEVICE|Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self-care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
47995914|NCT00316199|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
48681883|NCT00003262|BIOLOGICAL|bleomycin sulfate|
48681884|NCT00003262|BIOLOGICAL|filgrastim|
48681885|NCT00003262|DRUG|Stanford V regimen|
48681886|NCT00003262|DRUG|doxorubicin hydrochloride|
48681887|NCT00003262|DRUG|epirubicin hydrochloride|
48681888|NCT00003262|DRUG|etoposide|
48681889|NCT00003262|DRUG|mechlorethamine hydrochloride|
47995915|NCT00316199|DRUG|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
47995916|NCT01824186|PROCEDURE|SILC|Underwent single-incision laparoscopic cholecystectomy
47995917|NCT01824186|PROCEDURE|LC|Underwent conventional 4-port laparoscopic cholecystectomy
47995918|NCT00174915|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
47995919|NCT00174915|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
47995920|NCT00174915|DRUG|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
47995921|NCT00174915|DRUG|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
47995922|NCT00174915|DRUG|Placebo|Placebo, orally, once daily for up to 28 weeks.
48365357|NCT03036891|DRUG|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
48681890|NCT00003262|DRUG|prednisone|
48681891|NCT00003262|DRUG|vinblastine sulfate|
48681892|NCT00003262|DRUG|vincristine sulfate|
48681893|NCT03706027|DEVICE|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
48681894|NCT03706027|DEVICE|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
47995923|NCT06299774|OTHER|Emergency care at home|A mobile integrated health paramedic under the direction of a remote emergency care physician will arrive at the patient's home and deliver emergency care.
47995924|NCT06299774|OTHER|Emergency care at a brick-and-mortar emergency department|Standard emergency care delivered in a brick-and-mortar emergency department.
47995925|NCT04477343|DRUG|SX-682|Allosteric inhibitor to human CXCR1 and CXCR2 receptor
47995926|NCT04477343|DRUG|Nivolumab Injectable Product|humanized monoclonal antibody to program cell death receptor 1 (PD1)
47995927|NCT02820012|OTHER|Scoliosis|Questionnaires, radiography
47995928|NCT06294418|DEVICE|Field Cycling Imaging (FCI)|FCI scan
47995929|NCT02976974|OTHER|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
48681895|NCT04645511|PROCEDURE|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
48681896|NCT04645511|PROCEDURE|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
47995930|NCT02976974|OTHER|Therapeutic exercise|"* Shoulder extension: Elastic bands.~* Shoulder flexion: Elastic bands~* Shoulder external rotation: Elastic bands.~* Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~* Thoracic column movements: Flexion-extension"
48681897|NCT02628405|DRUG|Carboplatin|Given IV
47995931|NCT03163888|PROCEDURE|Navigation TKR|Traditional over Conventional TKR
47995932|NCT03030079|DEVICE|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
47995933|NCT00001086|DRUG|Indinavir sulfate|
47995934|NCT00001086|DRUG|Abacavir sulfate|
48365358|NCT03718624|DRUG|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
48681898|NCT02628405|DRUG|Etoposide|Given IV
48681899|NCT02628405|DRUG|Ifosfamide|Given IV
48681900|NCT02628405|OTHER|Laboratory Biomarker Analysis|Correlative studies
47995935|NCT00001086|DRUG|Efavirenz|
47995936|NCT03732885|DEVICE|densah burs osseo densification drills|maxillary sinus floor elevation during implant placement using Densah burs
47995937|NCT03732885|DEVICE|Summer's Osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
48681901|NCT02628405|DRUG|Lenalidomide|Given PO
47995938|NCT02234375|DRUG|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
48681902|NCT02628405|BIOLOGICAL|Rituximab|Given IV
48681903|NCT02544750|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
47995939|NCT05505513|DEVICE|percutaneous Utah Slanted Electrode Arrays (pUSEAs)|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
47995940|NCT03873870|DIAGNOSTIC_TEST|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
47995941|NCT04227821|OTHER|Vasopressor and/inotrope therapy|In pediatric patients admitted to the pediatric intensive care, with the persistent hemodynamic instability after fluid resuscitation, the vasopressor and/or inotrope therapy will be initiated
47995942|NCT06088433|DRUG|Ticagrelor|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
47995943|NCT06088433|DRUG|Clopidogrel|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
47995944|NCT06088433|DRUG|Aspirin|Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
47995945|NCT04338295|DEVICE|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
47995946|NCT04307446|DEVICE|Immersive Virtual Reality|Immersive Virtual Reality
48365359|NCT03718624|DRUG|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
48365360|NCT03718624|DRUG|S-1|S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
48365361|NCT02579889|DEVICE|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
48681904|NCT00001040|DRUG|Saquinavir|
48681905|NCT00001040|DRUG|Zidovudine|
48681906|NCT00001040|DRUG|Zalcitabine|
48681907|NCT04119752|DIETARY_SUPPLEMENT|Curcumin powder|10g of curcumin powder
48681908|NCT04119752|DIETARY_SUPPLEMENT|Placebo|1g of sucralose
48681909|NCT02386462|DRUG|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
48681910|NCT02386462|DRUG|Propofol|
48681911|NCT03535311|PROCEDURE|Measurement of sternal-notch to umbilicus distance|"* The sternal notch to upper border of umbilicus length measurement in centimetres.~* The length of the umbilical stump in centimetres.~* The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~* The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
48365362|NCT02579889|DEVICE|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
47995947|NCT00944151|PROCEDURE|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
47995948|NCT04401696|DEVICE|Bubble CPAP|"The bCPAP will be delivered using an oxygen flow meter as the oxygen source. This inspiratory limb containing oxygen from the flow meter will be connected to humidifier and tubing from humidifier will be connected to short binasal prongs, which would be applied to neonate with the help of adhesive bandage on both cheeks. It will be ensured that binasal prongs make appropriate seal. An orogastric tube will be placed for gastric decompression. A 1000 ml/500ml bottle filled with sterile water be used and marks will be made on it at 1cm distance, with '10' marked at base and '0' mark at the water interface.~The expiratory limb from the nasal prongs was connected to tubing that will be dipped in water up to the desired level to provide positive end expiratory pressure. Pressure is varied by varying the depth of the dipped end of tubing."
48365363|NCT04826315|BEHAVIORAL|COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
48155133|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with lidocaine hydrochloride injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
48155134|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with normal saline injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
48365364|NCT04342858|DRUG|Fluoride Varnish|Duraphat varnish®, Colgate-Palmolive (UK) Ltd., Guildford, Surrey, UK
48365365|NCT04342858|DRUG|Fluoride Varnish with tricalcium phosphate|Clinpro white varnishTM, 3M ESPE, St Paul, MN, USA
48365366|NCT04342858|OTHER|Oral health education|Standard oral hygiene instructions every 3 months
47995949|NCT04401696|OTHER|Nasal Oxygen|The oxygen will be delivered from a wall oxygen source, delivered between 1 to 6 L/min and the rate varied via a flow regulator.
48155135|NCT03054194|DRUG|E2730|capsules
48365367|NCT03436576|DRUG|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
48365368|NCT03436576|DRUG|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
48155136|NCT03054194|DRUG|Placebo|capsules
48155137|NCT05807542|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
48155138|NCT05807542|DRUG|Paclitaxel-albumin|Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
48365369|NCT00290329|BIOLOGICAL|Mencevax ACWY|1 subcutaneous injection.
48365370|NCT05917002|DEVICE|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
48365371|NCT05917002|DEVICE|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
48365372|NCT00830479|PROCEDURE|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
48365373|NCT00830479|PROCEDURE|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
48365374|NCT02127970|DRUG|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
48365375|NCT02127970|DRUG|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
48512078|NCT05536999|OTHER|Blood sample taking , like to measure hormonal level like LH, FSH, Perlakan ,in a follicular fluid after the oocyte retrival|Blood test measure basal FSH, follicular fluid testing
48512079|NCT05044702|OTHER|Retro walking|Retro walking will be performed on treadmill for 15 min per day for 3 days per week for 4 weeks at self-paced speed.
48681912|NCT00383331|DRUG|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
48681913|NCT00383331|DRUG|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
47995950|NCT06484998|BEHAVIORAL|Dental anxiety level and child's compomer colors selection|Patients without any syndromes or systemic disorders, without mental retardation, who needed restorative treatment for primary molars were included in the study. The examination forms of 275 patients requiring restorative treatment of primary teeth were analysed at the session they came for restorative treatment. To determine the child's anxiety, the Modified Child Dental Anxiety Scale-faces version was administered to the children before restorative treatment. The children were asked to choose from a scale consisting of 9 colours (pink, blue, gold, silver, orange, yellow, green, purple, white) for the compomer restoration color selections. The patients were asked what their favourite color was after the compomer restoration color selection so that the previous question would not have any effect on the child's restoration color selection.
47995951|NCT05224505|OTHER|GNT0006|Single intravenous infusion
47995952|NCT05224505|OTHER|Day 0: Placebo|Single intravenous infusion
47995953|NCT05224505|OTHER|Day 0: GNT0006|Single intravenous infusion
47995954|NCT05224505|OTHER|Day 365 (year 1): Placebo|Single intravenous infusion
47995955|NCT05224505|OTHER|Day 365 (year 1): GNT0006|Single intravenous infusion
47995956|NCT06142721|OTHER|3D Gait Analysis|3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated
47995957|NCT06352450|DIAGNOSTIC_TEST|Active isolated stretching (AIS)|Active isolated stretching (AIS) is a technique that involves stretching specific muscles or muscle groups while actively engaging the opposing muscles. It typically involves holding a stretch for 1-2 seconds and then releasing. This method aims to improve flexibility, increase range of motion, and enhance muscle function.
47995958|NCT06352450|DIAGNOSTIC_TEST|Myofascial release (MFR)|Myofascial release (MFR) is a technique used to release tension and tightness in the fascia, which is the connective tissue that surrounds and supports muscles and organs. It involves applying gentle, sustained pressure to specific areas of the body to help relax the fascia and alleviate restrictions. MFR aims to improve mobility, reduce pain, and enhance overall movement and function.
47995959|NCT02129985|DRUG|Exenatide|Exenatide (10 ug/bid for 3 months)
47995960|NCT02129985|DRUG|Metformin|Metformin 850 mg/bid for 3 months
47995961|NCT02253810|DRUG|Tranexamic Acid|Medication administered intra-operatively to promote blood clotting.
47995962|NCT02253810|DRUG|Placebo|Saline solution
47995963|NCT06074913|OTHER|infrared thermography (IRT)|Temperatures and infrared thermograms were recorded in the region of the extremities of three groups of subjects by using an infrared thermographic camera.
47995964|NCT06074913|PROCEDURE|Basal therapy+EA|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen. 2. Acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject.
47995965|NCT06074913|OTHER|Basal therapy|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen.
47995966|NCT06475482|OTHER|Lip hydrant|lip hydrant containing peppermint oil, perilla frutescens, and Emblica fruit extract or petroleum gel.
47995967|NCT06475482|OTHER|Petroleum gel|Vaseline
47995968|NCT05834517|DRUG|Hyaluronic acid|Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
47995969|NCT05834517|PROCEDURE|non surgical periodontal therapy|NSPT, with or without adjunctive therapies, is an effective treatment for periodontitis. It reduces PD and results in formation of some new attachment; however, it also has several limitations, and surgical therapy might be required to control inflammation and optimize outcomes. When used for non-surgical scaling and root planing, periodontal curettes can reach a mean PD of up to approximately 5.5 mm. The mean PD in which a plaque-free and calculus-free surface can be established is \<4 mm
47995970|NCT00684476|DRUG|venom immunotherapy|
47995971|NCT03603444|OTHER|No intervention are provided|
47995972|NCT00679185|BEHAVIORAL|expressive writing|four non-emotional writing assignments
47995973|NCT03380585|PROCEDURE|Reciprocating single-file system|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
47995974|NCT03380585|PROCEDURE|Rotational multi-file system.|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
47995975|NCT02191228|DRUG|Linagliptin - single dose|
47995976|NCT02191228|DRUG|Linagliptin - Multiple dose|
47995977|NCT05264194|OTHER|Suturing technique|The technique (subcuticular or transcutaneous) that will be used to close skin post-surgery.
48155139|NCT05807542|DRUG|Carboplatin|carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
48155140|NCT00002840|DRUG|lomustine|
47995978|NCT04222582|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a weak current (2mA direct current) to temporarily excite or inhibit underlying brain regions with small electrodes placed on the scalp.
47995979|NCT00729183|DRUG|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
47995980|NCT00729183|DRUG|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
47995981|NCT00729183|DRUG|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
47995982|NCT00729183|DRUG|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to \~1200 mg total) for 24 months.
47995983|NCT03758196|DEVICE|Radiofrequency ablation instruments|Renal Sympathetic Denervation from the adventitia of renal artery
47995984|NCT02642432|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
47995985|NCT05413252|OTHER|Practice Facilitation|Practices will be assigned a practice facilitator who will support practices in implementing all practice redesign components associated with TBC for HTN management.
47995986|NCT04863755|BEHAVIORAL|DASH|Patients receive DASH diet orientation and recommended to maintain their usual physical activity
47995987|NCT04863755|BEHAVIORAL|DASHPED|Patients receive DASH diet orientation and recommended to increase their usual activity with the use of a pedometer
47995988|NCT03917420|DRUG|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
47995989|NCT03917420|DRUG|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
47995990|NCT06029699|DEVICE|high flow nasal cannula|device are used for weaning patients after mechanical ventilation extubation
47995991|NCT06029699|DEVICE|non invasive positive pressure ventilation|device are used for weaning patients after mechanical ventilation extubation
47995992|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
47995993|NCT00048542|BIOLOGICAL|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
47995994|NCT00048542|DRUG|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
47995995|NCT00048542|DRUG|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
47995996|NCT03461900|OTHER|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
47995997|NCT03461900|OTHER|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
47995998|NCT05694728|BIOLOGICAL|Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)|"For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6."
47995999|NCT05694728|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)|A 3-dose regimen administered at months 0, 2 and 6.
47996000|NCT02028988|DRUG|Enzalutamide|
47996001|NCT02028988|RADIATION|External Beam Radiation|
47996002|NCT02893072|BEHAVIORAL|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
47996003|NCT01416727|OTHER|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
47996004|NCT01416727|OTHER|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
47996005|NCT05727228|OTHER|cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,|p16/Ki67 dual stain cytology, extended genotyping and DNA methylation will be performed from the residual cell-pellet from the HPV-positive screening samples. If no cytology-triage testing is performed as a part of the screening algorithm, a cytology will be performed at inclusion. If any residual material is left after DS, extended genotyping and DNA methylation, it will be stores at -80 degrees for future purposes.
47996006|NCT02850458|DEVICE|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
47996007|NCT03676881|DEVICE|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
48155141|NCT00002840|DRUG|procarbazine hydrochloride|
48155142|NCT00002840|DRUG|vincristine sulfate|
47996008|NCT03676881|DEVICE|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
48681914|NCT04755998|OTHER|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~* Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~* Cartoons and virtual reality glasses that the student wanted to watch were prepared.~* While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
47996009|NCT02064881|DRUG|Metformin glycinate|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
48155143|NCT00002840|RADIATION|radiation therapy|
48365377|NCT04561960|DRUG|Fluoride toothpaste|Fluoridated paste containing 1450ppm NaF
48365378|NCT04561960|DRUG|Toothpaste Product|Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
48365379|NCT04561960|DEVICE|Toothbrush|Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
48365380|NCT04561960|DEVICE|Miswak Stick|A miswak stick of 15 cm length
48365381|NCT00361504|DRUG|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
48365382|NCT00361504|DRUG|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
48365383|NCT01761682|OTHER|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
48365384|NCT04467216|DEVICE|Computerised cognitive training using virtual reality|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong.The VR systems available in the market for older people are only for non-interactive activities (e.g., watching movies) to provide unusual experiences for disabled older people who cannot travel too far from home.
48681915|NCT01396356|PROCEDURE|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
48681916|NCT02970136|DEVICE|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
48365385|NCT06111729|DEVICE|HabitAware group|A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
48681917|NCT02970136|DEVICE|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
48155144|NCT05321576|PROCEDURE|Erector spinae plane block (ESPB) technique without opioid use|Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.
48155145|NCT00887471|PROCEDURE|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
48365386|NCT05331547|DEVICE|BioFreedom BA9 (SS) Ultra DCS|BioFreedom Ultra stent for treatment of STEMI patients. Besides, in patients who are clinically indicated for a stage procedure, we aim to assess the angiographic and endovascular healing of BioFreedom Ultra stent at one month
48365387|NCT04427306|DRUG|T-Vec|(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
48365388|NCT02288663|OTHER|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
48365389|NCT02288663|BIOLOGICAL|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
48365390|NCT02288663|BIOLOGICAL|albumin or blood in urine|dipstick analysis for albumin or blood in urine
48365391|NCT02288663|DEVICE|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
48365392|NCT02288663|DEVICE|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
48365393|NCT02288663|BIOLOGICAL|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
48365394|NCT05212792|BIOLOGICAL|COVID-19 vaccines|Any licensing COVID-19 vaccine platform
48681918|NCT02970136|DEVICE|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
48681919|NCT02970136|OTHER|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
48681920|NCT02970136|DEVICE|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
48681921|NCT02970136|OTHER|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
47996010|NCT02064881|DRUG|Metformin Hydrochloride|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
48681922|NCT00049257|DRUG|carboplatin|Administered Day 1 of each cycle. AUC=6.
48681923|NCT00049257|DRUG|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
48365395|NCT04794491|DRUG|JZP-258|Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
48365396|NCT03187314|DRUG|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
48365397|NCT03187314|DRUG|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
48681924|NCT04060004|OTHER|Dry needling|Dry needling is a technique used by physiotherapists.
48681925|NCT04060004|OTHER|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
48681926|NCT04060004|OTHER|Electrotherapy + therapeutic exercise|Standard care of neck pain.
48681927|NCT00402324|DRUG|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
48681928|NCT00402324|DRUG|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
48681929|NCT00402324|DRUG|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
48365398|NCT01156857|DRUG|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
48365399|NCT01156857|DRUG|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
47996011|NCT05345639|DRUG|LRA Loco-regional anesthesia|"Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of the sternum.~The intervention (TTP or PSB) is performed by the anesthetist-resuscitator investigator."
47996012|NCT05345639|PROCEDURE|Standardized post-operative analgesia protocol|"The pain management protocol in intensive care is as follows:~* paracetamol 1g x 4 per day systematically (apart from the usual contraindications), IV then PO;~* PCA (Patient Controlled Analgesia) with oxycodone or morphine: 1mg bolus, 7min refractory period, maximum 4h dose 20mg.~The PCA is usually maintained until 24-48h after the intervention then relayed by oxycodone 5mg every 4h if EVA \> 3 sublingual and addition of oxycodone LP 10mg x 2 per day if daily intake on PCA \> 20mg.~Remedy molecules in case of ineffective analgesia:~ketoprofen 100mg q12h IV, or 50mg q8h PO; nefopam 20mg every 6h IV or PO; ketamine 1 to 1.5 mg/kg/24H IVSE."
48365400|NCT04403074|PROCEDURE|Celiac Plexus Neurolysis|When CPBs are not effective (less than one month of relief) then a Celiac Plexus Neurolysis may be completed to manage pain associated with Chronic Pancreatitis.
47996013|NCT01152463|PROCEDURE|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
47996014|NCT00271947|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
47996015|NCT03141281|BEHAVIORAL|BrainHQ|BrainHQ
48365401|NCT01047215|DRUG|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
47996016|NCT03141281|BEHAVIORAL|Rise of Nations|Rise of Nations
48155146|NCT01078571|BIOLOGICAL|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
48365402|NCT05034029|DRUG|Metformin hydrochloride sustained release tablets|Oral
48365403|NCT05034029|DRUG|Placebo|Placebo
48365404|NCT05723211|BEHAVIORAL|Vinyasa yoga group|Participants will be instructed to perform a pre-recorded 60-minute vinyasa yoga session 3 times a week for 4 weeks.
48681930|NCT00104338|DRUG|FK778|
47996017|NCT03141281|BEHAVIORAL|IADL Training|IADL Training
47996018|NCT03141281|BEHAVIORAL|Active Control|Puzzle solving
47996019|NCT04914845|DRUG|KPT-9274|KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule, dual modulator of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase /PBEF/visfatin (NAMPT). NAMPT is the rate-limiting enzyme in the metabolic scavenging pathway that utilizes nicotinamide to replenish nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor and second messenger. Recent investigations have shown that in in vitro and in vivo models, NAMPT is uniquely essential for relapsed or refractory AML stem cells. Targeting relapsed AML stem cells, through targeting of NAMPT, may allow for a promising therapeutic opportunity for patients with relapsed or refractory AML.
48681931|NCT00200707|PROCEDURE|Intracoronary injection of autologous bone marrow mononuclear cells|
48681932|NCT03067402|OTHER|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
47996020|NCT04706130|DRUG|Primaquine|After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
47996021|NCT04706130|DRUG|Artesunate|All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
47996022|NCT03406858|BIOLOGICAL|HER2Bi-Armed Activated T Cells|Given IV
47996023|NCT03406858|OTHER|Laboratory Biomarker Analysis|Correlative studies
47996024|NCT03406858|BIOLOGICAL|Pembrolizumab|Given IV
48365405|NCT05723211|OTHER|Non-active control group|Participants will be instructed to sit quietly for 60 minutes and watch a nature documentary during this time. The participants will be asked to maintain their current lifestyle habits and refrain from starting a new exercise and/or yoga program.
48365406|NCT00006082|DRUG|rubitecan|
48365407|NCT01180829|BEHAVIORAL|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
48681933|NCT03067402|DIAGNOSTIC_TEST|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
47996025|NCT01384396|DRUG|KW-3357|Intravenous infusion once a day
47996026|NCT01791842|DRUG|Tocilizumab|8 mg/kg/month
47996027|NCT01791842|DRUG|Placebo|
47996028|NCT06414174|DEVICE|Split septum needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
48155149|NCT05753358|OTHER|Total Worker Health for Wildland Firefighters|The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
48365408|NCT01180829|BEHAVIORAL|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
48512080|NCT05044702|OTHER|conventional physical therapy|"hot pack for 10 mints and conventional exercise program Conventional physiotherapeutic exercise program which consist of exercises such as~* prone leg extension~* prone lying chest elevation~* prone extension with alternate arm and leg lift~* supine bridging, bridging with one leg lift Each exercise will be performed as 2 sets of 12 repetitions of each exercise, each exercise position maintained for 10 s, and a rest of 1 min between the sets will be perform. No external load/resistance will be provided for the exercises, and the participants will be perform the exercise within their available range of motion"
48365409|NCT04021342|DIETARY_SUPPLEMENT|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
48365410|NCT04021342|DIETARY_SUPPLEMENT|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
48365411|NCT01869686|BIOLOGICAL|Denosumab|60 mg
48365412|NCT05147194|DRUG|Trimetazidine|Oral，35mg bid
48365413|NCT01612494|DRUG|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
48365414|NCT01612494|OTHER|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
48365415|NCT01443039|DRUG|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
48512081|NCT02541968|BEHAVIORAL|Cognitive-behavioral therapy (face-to-face)|
47996029|NCT06414174|DEVICE|Mechanical valve needleless connector|Participants in this study are limited to very preterm neonates or neonates with birth weight under 1500 grams. Split septum mechanism is still widely use in Indonesia, therefore the use of mechanical valve mechanism as needleless connector for central line access in very preterm neonates have never been tested.
47996030|NCT01667978|DRUG|Norethindrone acetate|
47996031|NCT02290106|DRUG|pitavastatin|
47996032|NCT02290106|OTHER|PLACEBO|
47996033|NCT01160068|DRUG|Metformin|Metformin Tablets 1000 mg
47996034|NCT01160068|DRUG|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
47996035|NCT04582110|DIAGNOSTIC_TEST|Optical coherence tomography angiography|Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
47996036|NCT00925418|PROCEDURE|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
47996037|NCT00481546|GENETIC|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
47996038|NCT04105998|DRUG|Oxytocin|Oxytocin 10 IU
48155150|NCT06309641|DIAGNOSTIC_TEST|Blood sample after treatment|Blood samples for measurement of methemoglobin are obtained directly before and 30-120 minutes after drug administration.
48155151|NCT06309641|OTHER|Case reports|Description of clinical course and methemoglobin levels in patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
48365416|NCT04927858|DRUG|Empagliflozin|Empagliflozin
48365417|NCT00495274|DRUG|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
48365418|NCT00495274|DRUG|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
48365419|NCT00495274|DRUG|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
48365420|NCT00495274|DRUG|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
48512082|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy|With therapist support
48512083|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy without therapist support|
48512084|NCT06321679|PROCEDURE|Imaging evaluation|each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
48512085|NCT03331835|BIOLOGICAL|Brodalumab|"Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis."
47996039|NCT04105998|DRUG|Placebo|Placebo
47996040|NCT04829773|DRUG|Palovarotene|oral capsules
47996041|NCT04829773|DRUG|midazolam|oral syrup
47996042|NCT00969787|DRUG|DWP05195|tablets, oral administration, single and multiple administrations
47996043|NCT01175733|DRUG|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
47996044|NCT01678417|DRUG|131I-rituximab|
47996045|NCT05669820|DIETARY_SUPPLEMENT|Salovum|Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.
47996046|NCT05669820|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Egg yolk powder derived from hen fed with normal feed.
47996047|NCT02669368|DRUG|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
47996048|NCT02669368|DRUG|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
47996049|NCT02669368|DRUG|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
47996050|NCT02669368|DRUG|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
47996051|NCT05749198|DIAGNOSTIC_TEST|MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.
47996052|NCT05141721|DRUG|GRT-C901|A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
47996053|NCT05141721|DRUG|GRT-R902|A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.
48681934|NCT02348580|BEHAVIORAL|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
48681935|NCT01881009|DEVICE|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
48155152|NCT04394585|BEHAVIORAL|smart phone app based human coaching program|"1. experimental arm~   * 1:1 coaching using smart phone app~  * Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~  * Patients are encouraged to report their diet diaries and exercise everyday by the coach.~  * Patients can ask to the coach using the app and the coach answer when they check them.~2. Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively."
48365421|NCT00495274|DRUG|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
48681936|NCT01881009|DEVICE|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
47996054|NCT05141721|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.
47996055|NCT05141721|DRUG|Ipilimumab|Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.
47996056|NCT05141721|DRUG|Fluoropyrimidine plus leucovorin|Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.
47996057|NCT05141721|DRUG|Bevacizumab|Bevacizumab administered as maintenance therapy per standard of care.
47996058|NCT04757636|BIOLOGICAL|2.0 mg OPT-302|intravitreal injection
47996059|NCT04757636|BIOLOGICAL|2.0 aflibercept|intravitreal injection
47996060|NCT04757636|PROCEDURE|Sham|intravitreal injection
47996061|NCT05718232|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients ≥ 60kg)
47996062|NCT05718232|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.
47996063|NCT05718232|RADIATION|SBRT|SBRT will be given within 3 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-5000 cGy in 5-8 fractions.
47996064|NCT03302585|DRUG|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
47996065|NCT03302585|DRUG|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
47996066|NCT02711423|DRUG|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
47996067|NCT02711423|DRUG|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
47996068|NCT04765150|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
47996069|NCT04765150|OTHER|Electronic Health Record Review|Medical charts are reviewed
47996070|NCT05528237|DEVICE|Flocked swab paired with Roche Cobas 4800|Consenting individuals will insert the sterile flocked swab into the vagina, rotate at least once, and store in the provided dry tube. The sample will be stored at ambient temperature and routed to the lab for HPV testing with Roche Cobas 4800.
47996071|NCT01948739|DEVICE|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
48155153|NCT01973296|BEHAVIORAL|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
48155154|NCT01973296|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
48155155|NCT03530345|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
48155156|NCT03530345|DRUG|Placebo|Glass vials with matching placebo.
48155157|NCT00296504|DRUG|fosamprenavir (GW433908)|
48155158|NCT00296504|DRUG|ritonavir|
48155159|NCT01295619|DEVICE|I-020805|A thin layer of I-020805 applied up to two times on the sutured dura mater
48155160|NCT02217891|BEHAVIORAL|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, \& qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits \& harms of tumor genomic profiling; 2) interest in \& perceived benefits \& harms of incidental findings arising from tumor genomic profiling; 3) anticipated process \& needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, \& those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; \& 6) implications of \& concerns about incidental findings for family.
48155161|NCT05791552|DIAGNOSTIC_TEST|Collection of nasal secretion|Standardized collection of nasal secretion in the vicinity of the olfactory cleft
48155162|NCT01615523|OTHER|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
48155163|NCT03671499|BEHAVIORAL|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
48155164|NCT02395406|DEVICE|Orotracheal intubation with Totaltrack|
48155165|NCT02395406|DEVICE|Orotracheal intubation with Airtraq|
48155166|NCT05557253|DRUG|Remimazolam|Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h
48155167|NCT05557253|DRUG|Balanced Anesthesia|Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
48155168|NCT02014298|RADIATION|non-ablative fractional laser|3 treatments with 4-6 weeks interval
48155169|NCT02014298|OTHER|control|observation, comparison to laser-treated area
48155170|NCT04854096|DRUG|NS-018|Experimental
48155171|NCT04854096|DRUG|Best Available Therapy|Active Comparator
48155172|NCT00614354|DRUG|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
48155173|NCT02391389|PROCEDURE|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
48365422|NCT00495274|DRUG|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
48512086|NCT03331835|DRUG|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
48512087|NCT00167284|BEHAVIORAL|physician and patient education; physician practice redesign|
47996072|NCT06038201|PROCEDURE|LAMS placement for cholecystostomy|The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
47996073|NCT06038201|PROCEDURE|Laparoscopic cholecystectomy|A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
47996074|NCT05350033|DEVICE|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
47996075|NCT05350033|DEVICE|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
47996076|NCT05350033|DEVICE|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
47996077|NCT05350033|DEVICE|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
47996078|NCT02523846|DRUG|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
48365423|NCT00495274|DRUG|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
48365424|NCT04094662|DRUG|Mirogabalin|Mirogabalin tablets for oral administration
48365425|NCT04094662|DRUG|Placebo|Matching placebo tablets for oral administration
48365426|NCT02061020|DRUG|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
47996079|NCT02523846|BEHAVIORAL|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
47996080|NCT04699682|OTHER|Control|During follow-up visits, as part of this research, additional stool samples are taken every month (M1 to M12).
47996081|NCT04699682|OTHER|BHR Case|"During follow-up visits, compared to the usual management of patients with BHRe (monthly sampling for 6 consecutive months), additional samples are taken as described below:~- stool samples taken at different times:~* every 7 days during the first month (M1)~* every 14 days for the following months until the end of the patient's participation (M2 to M12)."
47996082|NCT00588822|BIOLOGICAL|Rituximab|Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
47996083|NCT06159140|DEVICE|MRI|In vivo MRI
47996084|NCT02902510|OTHER|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
48365427|NCT00314028|BEHAVIORAL|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
48365428|NCT00314028|OTHER|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
48512088|NCT00109226|DRUG|Avastin (Bevacizumab)|
48512089|NCT04492592|BEHAVIORAL|Workshop|Workshop
47996085|NCT03221920|OTHER|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
47996086|NCT04991181|DRUG|400 mg BIA 5-1058|Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
47996087|NCT06160063|BEHAVIORAL|Education intervention|Board game was created in line with current literature. In each interview, it is expected that the child's negative behaviors will be transformed into positive behaviors.
47996088|NCT01712256|BIOLOGICAL|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
48512090|NCT04492592|BEHAVIORAL|SMS/Texting|SMS/Texting
47996089|NCT01065519|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
47996090|NCT01065519|DEVICE|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
47996091|NCT03823053|OTHER|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
48155174|NCT03316248|OTHER|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
47996092|NCT03823053|OTHER|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
47996093|NCT05929183|DEVICE|Repetitive Transcranial magnetic stimulation|"Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000."
47996094|NCT05929183|DEVICE|Sham Repetitive Transcranial magnetic stimulation|The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
47996095|NCT02250443|DRUG|BYM338 (Bimagrumab)|
48365429|NCT02956408|DIETARY_SUPPLEMENT|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
48365430|NCT04853069|DRUG|Transdermal estradiol gel|Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.
48365431|NCT06241495|OTHER|Placebo|Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
48155175|NCT03316248|OTHER|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
48155176|NCT03458494|OTHER|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
48365432|NCT06241495|OTHER|Aromatherapy|Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
48365433|NCT05671029|DRUG|Pritelivir and moxifloxacin placebo|oral administration
48512091|NCT06498882|OTHER|Press Needle Acupoint Stimulation Combined with Breast Massage|Press needle acupoint stimulation and breast massage were administered. Key press needle acupoints were identified for selection: Dan zhong (RN17), bilateral Ru gen (ST18), bilateral Shao ze (SI1), bilateral Zu san li (ST36) and bilateral San yin jiao (SP6). The areas were sterilized with 75% alcohol before installing 0.22\*1.55mm press needles. Within 4-6 hours post-surgery, mothers received acupoint stimulation through needle pressing. This procedure was administered by nurses who had undergone six-month standardized training in traditional Chinese medicine techniques. Instructions were then given to mothers and their family members to stimulate the acupoints pulsatively every 3-4 hours for 20-30 minutes per session, removing the press needles after 24 hours. Additionally, a specialized nurse massaged the back, both breast areas, and armpits for 10-15 minutes, three times daily over three days, using a circular and oscillating breast massage device.
48512092|NCT06498882|OTHER|routine care|Very early skin-to-skin contact was initiated by researchers within 30 to 40 minutes after birth, with newborns, optionally wearing caps, being placed on the mothers' chests. Mothers were encouraged to breastfeed 8 to 10 times per day to ensure steady milk production. It was ensured by researchers that mothers completely emptied one breast before switching to the other to maintain cleanliness. Additionally, mothers were guided by researchers on maintaining a well-balanced diet, achieving emotional stability, and securing adequate sleep to facilitate effective breastfeeding.
48512093|NCT03785327|DEVICE|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
48512094|NCT03785327|BEHAVIORAL|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism \& Developmental Disorders Lab at Simon Fraser University
48155177|NCT03458494|OTHER|Low-fat diet|Participants will receive meals with a low content of total fat.
48365434|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin and moxifloxacin placebo|oral administration
48512095|NCT05972369|OTHER|12-Week Tailored Exercise Intervention|12-week individually tailored exercise therapy program based on patient presentation. Supervised physiotherapy plus home exercise
48512096|NCT05507736|OTHER|Acupuncture|13 Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX® from 0.9 mm in length and 0.22 mm in diameter) on day 1 and 5 of the second cycle of irinotecan leaving them inserted for 4 days.
48365435|NCT05671029|DRUG|Pritelivir placebo, moxifloxacin placebo and moxifloxacin|oral administration
48365436|NCT01359865|PROCEDURE|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at \<0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
48681937|NCT05401539|DEVICE|Cardboard VR|Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
48155178|NCT01732419|BEHAVIORAL|Home-based training|Home-based exercise training for cardiac patients.
48155179|NCT01732419|BEHAVIORAL|Centre-based training|Usual exercise training in an outpatient setting.
48365437|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
48365438|NCT00851721|BIOLOGICAL|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
48681938|NCT01340222|BIOLOGICAL|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
47996096|NCT01275274|DRUG|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of \< 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to \< 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
48512097|NCT01609023|DRUG|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
48681939|NCT03939338|OTHER|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
48681940|NCT01393210|DIETARY_SUPPLEMENT|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
48681941|NCT01393210|OTHER|low-calorie diet|low-calorie diet only for 12 weeks.
47996097|NCT01275274|DRUG|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
48512098|NCT06630169|COMBINATION_PRODUCT|Cryopreserved AURN001|Corneal Endothelial Cells and Y27632
48155180|NCT03059056|DRUG|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
48155181|NCT04904731|OTHER|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
48155182|NCT04909593|DEVICE|Spinal Cord Stimulation|Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
48155183|NCT05569265|PROCEDURE|Intraoperative hemodynamic management|Goal directed Hemodynamic therapy
48155184|NCT06367244|BEHAVIORAL|Transplant Wellness Program - Kidney and Liver|The exercise prescription for the intervention will be multimodal, , will follow current chronic disease exercise guidelines, and will be tailored to meet the unique needs of each participant. . All participants will receive two 30-45-minute individual session with a CEP during their first week and two additional sessions during the second week if needed. The individual sessions will be followed by group sessions. Each participant will get a total of 24 individual and group sessions combined. These sessions can be conducted either in-person or online, based on participant preference and TWP logistics. For aerobic-based activities, a moderate rate of perceived exertion of 4-6 on a scale of 0-10 will be used. Resistance exercise will begin with functional movements and bodyweight exercises targeting major muscle groups with modifications for beginners and exercise progressions when deemed. Balance and flexibility training activities will also be included.
48365439|NCT02808299|OTHER|HBV infection history|HBV infection history or HBV carriers
48365440|NCT00420823|DRUG|Taurine 4g|
48681942|NCT04012827|DRUG|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
48681943|NCT05953298|DEVICE|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
48681944|NCT02882191|DRUG|LevoCept|placement of LevoCept IUD
48365441|NCT04726943|PROCEDURE|Radiofrequency Energy Applications|RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
48512099|NCT02204085|DRUG|GO-203-2c|
48512100|NCT02204085|DRUG|GO-203-2c + Decitabine|
48512101|NCT02004015|DRUG|injection of placebo|0.5 mg/kg milligram(s)/kilogram
48512102|NCT02004015|DRUG|injection of NMBA|
48512103|NCT02644473|DRUG|Tranexamic Acid|
48512104|NCT02644473|DRUG|Normal saline|Control
48681945|NCT06105515|PROCEDURE|Laparoscopic and Endoscopic Collaborative Surgery (LECS)|Minimal invasive surgery in collaboration between endoscopy and laparoscopic surgery, to locally remove the tumor
47996098|NCT01044082|PROCEDURE|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
48681946|NCT01212965|DRUG|Selenium|400 μg once a day for 6 months by mouth
48681947|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
48681948|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
48681949|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
48681950|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
48681951|NCT04263844|DRUG|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
48681952|NCT04263844|DRUG|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
48681953|NCT05929430|BEHAVIORAL|Mindfulness program|Six weeks mindfulness program. The program is explained in arm descriptions.
48681954|NCT05929430|BEHAVIORAL|Mindfulness program with Virtual Reality|Six weeks mindfulness program. The program is explained in arm descriptions.
48681955|NCT05940389|DEVICE|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique \[8\] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
47996099|NCT01044082|PROCEDURE|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
48681956|NCT05940389|DEVICE|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
47996100|NCT00291668|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
47996101|NCT00291668|OTHER|Placebo|"* Active Substance: isotonic sodium chloride solution~* Pharmaceutical Form: Solution for injection~* Concentration: 1 mL~* Route of Administration: Subcutaneous use"
47996102|NCT03360370|OTHER|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
47996103|NCT03451318|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
47996104|NCT03451318|PROCEDURE|tonsillar adenoidectomy|tonsillar adenoidectomy
47996105|NCT03451318|PROCEDURE|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
48681957|NCT04277546|DRUG|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
48681958|NCT04277546|DRUG|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
48155185|NCT02766764|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
48681959|NCT01143909|OTHER|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
48681960|NCT05361382|DRUG|18F-Flortaucipir radiopharmaceutical|Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
47996106|NCT04839094|DIAGNOSTIC_TEST|rapid antigen testing versus RT-PCR|Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients.
48155186|NCT02766764|DRUG|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
48155187|NCT02766764|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
48681961|NCT05361382|DRUG|18F-MK-6240 radiopharmaceutical|MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
48681962|NCT05361382|DRUG|Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)|"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."
48681963|NCT03440567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
48681964|NCT03440567|DRUG|Avelumab|Given IV
48681965|NCT03440567|DRUG|Carboplatin|Given IV
48681966|NCT03440567|DRUG|Etoposide Phosphate|Given IV
48681967|NCT03440567|DRUG|Ibrutinib|Given PO
48155188|NCT02766764|DRUG|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
48155189|NCT05711745|PROCEDURE|Calf myofascial technique|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
48155190|NCT01776749|DEVICE|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
48512105|NCT00747032|DRUG|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
48681968|NCT03440567|DRUG|Ifosfamide|Given IV
48681969|NCT03440567|OTHER|Laboratory Biomarker Analysis|Correlative studies
48681970|NCT03440567|BIOLOGICAL|Rituximab|Given IV
48681971|NCT03440567|BIOLOGICAL|Utomilumab|Given IV
48681972|NCT01027962|OTHER|ICBT Program|Intensive Computerized Brain Training.
48681973|NCT02229708|BEHAVIORAL|Healthy Lifestyle Group|
48681974|NCT04751227|DRUG|Modafinil|100-200 mg oral daily for for Wakefulness in the Critical Care Units
48681975|NCT04156334|PROCEDURE|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
48681976|NCT03177018|DIAGNOSTIC_TEST|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
48681977|NCT03679676|DRUG|Omalizumab|Omalizumab is injected every 2 to 4 weeks
48681978|NCT03679676|DRUG|Dupilumab|"Dupilumab is injected every 2 weeks~combination, or placebo."
48681979|NCT03679676|OTHER|Placebo|Placebo is injected every 2 to 4 weeks
47996107|NCT00353405|BEHAVIORAL|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
48155191|NCT00313963|DRUG|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
48681980|NCT02678962|DEVICE|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
48681981|NCT02678962|DEVICE|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
48681982|NCT02678962|DEVICE|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
48681983|NCT02678962|DEVICE|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
48681984|NCT02678962|DEVICE|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
48681985|NCT02678962|DEVICE|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
48681986|NCT06105411|DIAGNOSTIC_TEST|68Ga-labelled TAFC PET/CT scan|68Ga-labelled TAFC PET/CT scan (whole body)
48681987|NCT04548427|DRUG|CKD-352|Eye Drop
48681988|NCT04548427|DRUG|Diquafosol Sodium 3%|Eye Drop
48681989|NCT04951219|DRUG|Resmetirom|Tablet
48155192|NCT00313963|DRUG|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
48155193|NCT03977337|PROCEDURE|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
48155194|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate high dose|
48155195|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate low dose|
48155196|NCT03063346|DIETARY_SUPPLEMENT|Placebo|
48155197|NCT04750447|DEVICE|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
48681990|NCT01350050|DRUG|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
48155198|NCT05923554|OTHER|Changes in Probing Depth to non-surgical periodontal therapy|Changes in Probing Depth following non surgical periodontal treatment performed with hand and ultrasonic tips
48512106|NCT00747032|DRUG|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
48681991|NCT01350050|OTHER|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
48681992|NCT00845247|OTHER|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
48155199|NCT00002371|DRUG|Indinavir sulfate|
48681993|NCT01308645|DRUG|SB injection|Infusion SB injection of 21.87 ml/m\^2, IV route, 24 times for 4 months
48155200|NCT00002371|DRUG|Lamivudine|
48155201|NCT00002371|DRUG|Stavudine|
48155202|NCT00002371|DRUG|Zidovudine|
48155203|NCT03283449|DRUG|18F-AV-1451|
48155204|NCT03283449|DEVICE|PET|PET scanner for brain imaging
48155205|NCT06476483|BEHAVIORAL|DIALOG+|A person-centred and solution-focused intervention linked to the DIALOG outcome measure (a measure of patient experience and quality of life).
48512107|NCT02796638|DEVICE|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
48512108|NCT06550713|DRUG|TQB3455 tablet+Azacitidine for Injection|TQB3455 is a selective IDH2 mutant enzyme inhibitor. Azacitidine for injection is a cytosine nucleoside drug that is used for demethylation therapy.
48681994|NCT01465438|DRUG|Adalimumab|Adalimumab 40 mg every other week
48681995|NCT05080439|OTHER|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
48155206|NCT06476483|BEHAVIORAL|DIALOG|An outcome measure consisting of 11 questions, with 8 related to quality of life and 3 items on treatment satisfaction. Patients can rate their satisfaction on a 7-point scale for each of the 8 life domains and 3 treatment aspects, resulting in scores for both quality of life and treatment satisfaction. The DIALOG scale does not provide any guidance for patient and clinician interactions.
48155207|NCT00360971|BIOLOGICAL|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
48155208|NCT00360971|DRUG|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
48155209|NCT00360971|OTHER|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
48681996|NCT05080439|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
47996108|NCT00353405|BEHAVIORAL|Mass media|Mass media provides messages that support sexual health skills.
48155210|NCT00360971|PROCEDURE|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
48155211|NCT00360971|RADIATION|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
48155212|NCT05195034|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
48155213|NCT05195034|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
48155214|NCT05893017|OTHER|Virtual Reality Exercises|Virtual Reality Exercises will be apply for muscle strengthening
48155215|NCT05893017|OTHER|Virtual Reality Exercises and Kinesiotaping|Virtual Reality Exercises will be apply for muscle strengthening, Kinesiotaping will be applied at Quadriceps muscle and Hamstring muscle
47996109|NCT00353405|BEHAVIORAL|Control|Control group received no social skills training and no media mass media messages.
47996110|NCT01571206|BIOLOGICAL|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
47996111|NCT05850169|OTHER|Creative Dance Therapy|"After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015)."
47996112|NCT04779255|DRUG|Procedure (Tumesent anesthesia)|Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.
47996113|NCT04779255|DRUG|Control Arm (Paracetamol)|Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
48365442|NCT05460728|OTHER|Dry needling|A three-weekly session of DNT was administered with an acupuncture needle (0.30 × 50 mm; Huan Qiu, Suzhou, China). For each session, DNT was applied in the deltoid, biceps brachialis, wrist extensors and flexors, thenar muscles, vastus medialis, gastrocnemius medialis, and tibialis anterior (Hong, 1994). Following focal twitch responses (maximum three), the dry needle was left inserted for 15 minutes in each muscle.
48365443|NCT06221722|DIAGNOSTIC_TEST|BOLD-fMRI|Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging
48365444|NCT06221722|DRUG|Regular treatment of functional constipation|at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
47996114|NCT02283515|DRUG|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
47996115|NCT03573986|BIOLOGICAL|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
47996116|NCT03573986|DRUG|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
47996117|NCT03573986|RADIATION|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
48155216|NCT05893017|OTHER|Virtual Reality Exercises and Valgus Orthoses|Virtual Reality Exercises will be apply for muscle strengthening, Orthoses is for correction at knee alignment
48155217|NCT04103333|PROCEDURE|Lumbar Puncture|Administered as specified in the treatment arm.
48155218|NCT04103333|PROCEDURE|Blood Collection|Administered as specified in the treatment arm.
48155219|NCT02374476|DEVICE|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
48155220|NCT03030599|DRUG|JZP-258|JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
48155221|NCT03030599|OTHER|Placebo|Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial \[United States Pharmacopeia/ National Formulary\])
48155222|NCT04417907|DRUG|Perampanel 1 week titration|Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.
48155223|NCT04417907|DRUG|Perampanel 2 week titration|Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.
48155224|NCT04417907|DRUG|Perampanel 4mg|Healthy adults will take 4mg perampanel PO QD for six weeks
48155225|NCT04417907|DRUG|Placebo|Healthy adults will take 2mg placebo PO QD for six weeks
48365445|NCT06221722|DRUG|fluoxetine|Fluoxetine oral treatment for 4 weeks.
48365446|NCT04307264|PROCEDURE|Esophagogasrtoduodendoscopy, liver stiffness measurement|Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
48681997|NCT03269357|OTHER|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
47996118|NCT06072651|BEHAVIORAL|Relative Reinforcing Value of Food|Researcher gives child opportunity to press a button to earn three types of rewards: a high-reward food, a low-reward food, and a non-food reward.
47996119|NCT04252755|BEHAVIORAL|EEG Neurofeedback|Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
47996120|NCT04272528|OTHER|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
47996121|NCT04272528|OTHER|conventional care|Nurses carry out the routine care procedures.
47996122|NCT03341195|BEHAVIORAL|SMS messages and automated calls|The intervention consists of SMS and automated calls based messages
48681998|NCT03159910|BEHAVIORAL|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
47996123|NCT04667039|BIOLOGICAL|GNR-067|GNR-067 will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
48681999|NCT03159910|BEHAVIORAL|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
48365447|NCT06173726|BIOLOGICAL|BST02 Injection|"The TIL used for tumor tissue surgical sampling of qualified subjects was used to prepare BST02 injection, and the subjects who successfully received the surgical sampling were considered to be enrolled.~In the study process, cell transfusions were recorded as day 0 of the study. On the 3rd day (D-3) before infusion of BST02 injection, it is necessary to receive eluvial pretreatment. Considering that this product is unmodified autologous T lymphocytes, previous studies have shown that low-intensity cyclophosphamide can stimulate their proliferation in vivo. Therefore, the cyclophosphamide (Cy) single-drug regimen is recommended: Cy 250mg\~1.5g/m2, a single intravenous infusion"
48155226|NCT01551121|OTHER|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
48155227|NCT01018992|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
48155228|NCT01018992|DRUG|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
48155229|NCT05057819|DRUG|Empagliflozin 25 MG|Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
48155230|NCT05057819|DRUG|Placebo|Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
48155231|NCT01498354|PROCEDURE|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
48682000|NCT05490277|DEVICE|Active Vibrotactile coordinated reset|Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
48682001|NCT05490277|DEVICE|Sham vibrotactile coordinated reset|Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.
47996124|NCT04667039|BIOLOGICAL|Lucentis®|Lucentis® will be used intravitreally once every 4 weeks in 0.5 mg doses (the injection volume is 0.05 mL)
48155232|NCT01498354|PROCEDURE|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
48155233|NCT01762345|DEVICE|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter \& Gamble
48155234|NCT00329771|OTHER|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
48365448|NCT02744963|OTHER|Free and convenient medicine access|
48682002|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
48682003|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
47996125|NCT05102110|DIAGNOSTIC_TEST|Oricol Test|Assessment of rectal mucus for material from aero-digestive cancers.
47996126|NCT01559012|DRUG|Clonidine|transdermal clonidine patch 5 mg q. 5 days
47996127|NCT00962507|DRUG|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
47996128|NCT00962507|DRUG|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
47996129|NCT00962507|OTHER|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
47996130|NCT00962507|OTHER|pharmacological study|Pre-study, day 1 and day 26
48512109|NCT05759013|DEVICE|Breath synchronized abdominal NMES|Active abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.
48682004|NCT02777411|BIOLOGICAL|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
48682005|NCT02777411|BIOLOGICAL|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
48682006|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
48682007|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
48682008|NCT02777411|BIOLOGICAL|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
48682009|NCT05424835|DRUG|SHR-A1811|SHR-A1811
48682010|NCT05424835|DRUG|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
48682011|NCT02141672|DRUG|Voclosporin High Dose|
48682012|NCT02141672|DRUG|Voclosporin Low Dose|
48155235|NCT03985228|DIETARY_SUPPLEMENT|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
48155236|NCT03985228|DIETARY_SUPPLEMENT|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
48155237|NCT02965352|DEVICE|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
48155238|NCT02965352|DEVICE|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
48155239|NCT02965352|DEVICE|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
48155240|NCT03253783|BEHAVIORAL|Pulse|
48155241|NCT04698499|OTHER|Swallowing exercise from home|Treatment Arm A will consist of using pen and paper to complete the exercises. This is considered standard care. Treatment Arm B will consist of using Mobili-T to complete the exercises.
48155242|NCT04260100|BEHAVIORAL|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
48155243|NCT01870687|DRUG|20mg VAC BNO 1095 FCT|
48155244|NCT01870687|DRUG|Placebo|
48155245|NCT06647173|BEHAVIORAL|Blued+ Service Platform|During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.
48155246|NCT05714280|BEHAVIORAL|PA4Health Open Pilot|"The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app.~They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app."
48155247|NCT05586308|BEHAVIORAL|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
48155248|NCT05586308|BEHAVIORAL|Financial incentive|"1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
47996131|NCT02018458|BIOLOGICAL|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
47996132|NCT02018458|BIOLOGICAL|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
47996133|NCT00188019|PROCEDURE|diagnosis methods|
47996134|NCT01064492|DRUG|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
47996135|NCT00272571|PROCEDURE|External counter pulsation therapy|
48512110|NCT05759013|DEVICE|Sham breath synchronized abdominal NMES|Sham abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), five days per week, for 28 days or ICU discharge, whichever comes first.
48682013|NCT02141672|DRUG|Placebo|
48682014|NCT00447967|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
48682015|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
48682016|NCT00447967|DRUG|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
48682017|NCT00447967|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
47996136|NCT05815316|DRUG|18F-PSMA-1007|(3S, 10S, 14S)-1-\[4-\[\[(2S)-4-carboxy-3-\[(2S)-4-carboxy-2-(6-\[18F\]fluoropyridin-3- amido)butanamido\]butanamido\]methyl\]phenyl\]-3- \[(naphtalen-2-yl)methyl\]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
47996137|NCT00589316|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given via central line
47996138|NCT00589316|DRUG|Cyclophosphamide|Given IV
47996139|NCT00589316|DRUG|Fludarabine Phosphate|Given IV
47996140|NCT00589316|RADIATION|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
48512111|NCT02202707|DRUG|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
48682018|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
48682019|NCT02645032|BIOLOGICAL|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
47996141|NCT00589316|OTHER|Laboratory Biomarker Analysis|Correlative studies
47996142|NCT00589316|DRUG|Mycophenolate Mofetil|Given IV or PO
48682020|NCT02645032|BIOLOGICAL|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
47996143|NCT00589316|DRUG|Tacrolimus|Given IV or PO
47996144|NCT00589316|RADIATION|Total-Body Irradiation|Undergo TBI
48512112|NCT02976987|DRUG|Cidofovir|
48512113|NCT04420494|OTHER|Umbilical Cord Blood|The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome , Hgb \<100g / L and / or platelet count \<30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils \<0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.
48512114|NCT02083627|DRUG|rosuvastatin|Oral
48512115|NCT02083627|DRUG|fidaxomicin|Oral
48512116|NCT03619265|DIETARY_SUPPLEMENT|Prickly pear juice|3 ounces daily for 8 weeks.
48512117|NCT03619265|DIETARY_SUPPLEMENT|Pear-flavored juice|3 ounces daily for 8 weeks.
48512118|NCT00102947|DRUG|daptomycin (up to 14 days)|
48512119|NCT05332873|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
48682021|NCT02645032|BIOLOGICAL|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
48682022|NCT05703724|DEVICE|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
47996145|NCT05836207|BEHAVIORAL|Abstinence-focused Contingency Management (CM) - stand alone|Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
48155249|NCT05586308|BEHAVIORAL|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
48155250|NCT04400214|BEHAVIORAL|Food Allergy Superheroes Training (FAST) Program|The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session.
48365449|NCT03763942|BEHAVIORAL|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
48365450|NCT03763942|BEHAVIORAL|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
48682023|NCT01330095|DIETARY_SUPPLEMENT|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
48682024|NCT06101004|DEVICE|CVA-Flow|CVA-FLOW Software Device is indicated for the detection of Stroke and LVO in patients with suspected stroke.
48155251|NCT04400214|OTHER|Food Allergy Knowledge Intervention|"The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session."
48155252|NCT00095251|DRUG|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
48155253|NCT00095251|DRUG|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
48365451|NCT04808141|DEVICE|Digital program|Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
48365452|NCT04808141|OTHER|Conventional PT|Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.
47996146|NCT05836207|BEHAVIORAL|Standard Outpatient Cognitive Behavioural Therapy (CBT)|"CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence."
47996147|NCT06011239|BEHAVIORAL|Team-building processes|"All staff in one of the four role groups (medical assistants (MAs); clerical/administrative staff; nursing staff; and physicians/nurse practitioners/physician assistants) will be sent an anonymous survey. The survey will ask staff to consider what help participants wish to ask for and what help participants can offer to staff in the other three roles at times when people are busy or overwhelmed. These ideas will be combined into a typed idea list for each role and then staff in clinics will discuss. Once these are finalized the clinics will implement these.~At several points during the year, the study team will send out brief surveys. These surveys will collect the clinic and job role and ask participant to rate how much effort has been made in different ways, and if there are open-ended comments about what is or is not working. This information will be used to improve the intervention at each clinic."
47996148|NCT03379649|COMBINATION_PRODUCT|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
47996149|NCT03379649|COMBINATION_PRODUCT|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
47996150|NCT03022292|DRUG|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
48682025|NCT01018654|BEHAVIORAL|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
48682026|NCT01018654|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
48682027|NCT01899131|DEVICE|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
48682028|NCT01791491|DRUG|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
48682029|NCT02725476|BIOLOGICAL|XmAb5871|
48682030|NCT00060710|DRUG|CP-461|
48682031|NCT02063984|BEHAVIORAL|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
48682032|NCT02063984|BEHAVIORAL|Working Memory Training|25 computer-delivered sessions of neurocognitive training
48682033|NCT04929353|OTHER|Systematic symptom assessment|"* Systematic symptom assessment~* Conventional symptom assessment"
48682034|NCT02784158|DRUG|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
48682035|NCT06004206|DEVICE|nPSV and PSV|Ventilation with neurally adjusted modes or pressure support modes
47996151|NCT03022292|DEVICE|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
47996152|NCT04905212|DRUG|Telitacicept 160mg|Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
47996153|NCT04905212|DRUG|Telitacicept 240mg|Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
48682036|NCT02056444|DRUG|Tranexamic Acid|
48682037|NCT06015360|PROCEDURE|Fat Graft|Fat grafting
48682038|NCT05743712|OTHER|SMART-Wrap|This intervention, SMS (short message system)-based augmentation, seeks to improve the impact and approach of the Wraparound service model by utilizing SMS, which has been shown to increase treatment adherence and sustained engagement. This intervention will facilitate regular, repeated evaluation of intermediate outcomes through self-report assessments.
48682039|NCT03246581|DRUG|Tiotropium|inhalation
48682040|NCT01999686|DRUG|DLBS3233|
48682041|NCT01999686|DRUG|Metformin XR|
48682042|NCT01999686|DRUG|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
48682043|NCT01999686|DRUG|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
48682044|NCT04917367|PROCEDURE|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
48682045|NCT01598714|DEVICE|Darco shoe|Darco shoe
48682046|NCT01598714|DEVICE|Podalux shoe|Podalux shoe
48682047|NCT01598714|DEVICE|Standard dressing shoe|Standard dressing shoe
47996154|NCT04905212|DRUG|Placebo|Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
47996155|NCT02418195|DRUG|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
47996156|NCT03526458|DEVICE|Holmium:YAG laser|Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
47996157|NCT02615730|DRUG|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
47996158|NCT02615730|DRUG|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
47996159|NCT01894152|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
47996160|NCT00312091|DRUG|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
47996161|NCT00312091|DRUG|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
47996162|NCT00312091|DRUG|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
47996163|NCT00312091|DRUG|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
48365453|NCT05931614|OTHER|Unlimited fluid restrictions|Patients are recommended unlimited fluid intake
48682048|NCT04381299|OTHER|autologous platelet rich plasma|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
48682049|NCT04381299|OTHER|saline solution|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
48682050|NCT03384459|DEVICE|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
48682051|NCT02208375|DRUG|Capivasertib|Given PO
48682052|NCT02208375|OTHER|Laboratory Biomarker Analysis|Correlative studies
48365454|NCT03380806|DRUG|LHRH agonist|Standard LHRH agonist for 3 years
48682053|NCT02208375|DRUG|Olaparib|Given PO
48682054|NCT02208375|OTHER|Pharmacological Study|Correlative studies
48682055|NCT02208375|DRUG|Vistusertib|Given PO
48682056|NCT06368843|DRUG|Gargle with ketamine|The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
48682057|NCT06090630|PROCEDURE|Diffusion Weighted Imaging|Undergo DWI-MRI
48682058|NCT06090630|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
48682059|NCT04380051|BEHAVIORAL|sensory-tonic stimulation|sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time
48682060|NCT04380051|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact left free for parents
48682061|NCT03399942|PROCEDURE|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
48365455|NCT03380806|RADIATION|Pelvic Radiation|Pelvic Radiation
48682062|NCT00938262|DRUG|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
48682063|NCT00634140|DRUG|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
48682064|NCT00634140|DRUG|Placebo|placebo for 4-6 weeks
48682065|NCT05152251|OTHER|Evaluation|Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
48682066|NCT02185261|DRUG|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
48682067|NCT02975804|DEVICE|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
48682068|NCT06453343|PROCEDURE|Surgical approach: cochleostomy or extended round window|Surgical placement of a cochlear implant electrode array
48682069|NCT06510179|OTHER|Toothbrushing|Patients brush their teeth using the technique instructed to them using the toothbrush provided.
48682070|NCT01119066|RADIATION|total body irradiation|dose of 1375-1500 cGy
48682071|NCT01119066|DRUG|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
48682072|NCT01119066|DRUG|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
48365456|NCT03380806|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
48365457|NCT03380806|RADIATION|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
48365458|NCT03494140|DEVICE|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
48365459|NCT03230240|DRUG|HIPEC|heated intraIP chemotherapy
48365460|NCT04151654|OTHER|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
48365461|NCT03846466|DRUG|KHK4323 IV/S|IV / Single administration
48365462|NCT03846466|DRUG|KHK4323 SC/S|SC / Single administration
48365463|NCT03846466|DRUG|KHK4323 IV/M|IV / Multiple administration
48365464|NCT03846466|DRUG|Placebo IV/S|IV / Single administration
48365465|NCT03846466|DRUG|Placebo IV/M|IV / Multiple administration
48682073|NCT01119066|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
48682074|NCT01119066|DRUG|Melphalan|70mg/m2/day x 2
48682075|NCT01119066|DRUG|Fludarabine|25mg/m2/ day x 5
48682076|NCT01119066|DRUG|Clofarabine|20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
48682077|NCT01119066|PROCEDURE|(CliniMACS) T-cell depleted PBSC Transplant|
48682078|NCT03551613|DIETARY_SUPPLEMENT|honey supplementation|honey supplementation
48682079|NCT01118780|DRUG|Duloxetine|Administered by mouth, daily for 10 weeks
48682080|NCT01118780|DRUG|Placebo|Administered by mouth, daily for 10 weeks
48682081|NCT03117647|PROCEDURE|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
48682082|NCT00506467|PROCEDURE|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
47996164|NCT02295995|BEHAVIORAL|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
48365466|NCT03846466|DRUG|Placebo SC/S|SC / Single administration
48365467|NCT00182494|BEHAVIORAL|Modified diabetes prevention protocol & Metformin|
48682083|NCT03384186|DRUG|Danicopan Modified Release Prototype 1|Danicopan (400 milligrams \[mg\]) oral tablet.
48682084|NCT03384186|DRUG|Danicopan Modified Release Prototype 2|Danicopan (400 mg) oral tablet.
48682085|NCT03384186|DRUG|Danicopan Modified Release Prototype 3|Danicopan (800 mg) oral tablet.
48682086|NCT06485726|DRUG|Valproic Acid 500 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
48682087|NCT06485726|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
47996165|NCT04122859|DEVICE|Zip Skin Closure Device|The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
47996166|NCT04461782|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Oral food supplement
47996167|NCT03462550|DEVICE|Laryngeal mask|LMA insertion
47996168|NCT00264355|DRUG|cyclosporine A|
48682088|NCT00514722|OTHER|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
48155254|NCT05455281|DEVICE|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
48365468|NCT03110172|DRUG|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
47996169|NCT00980395|DRUG|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
48155255|NCT00029276|PROCEDURE|Prefrontal transcranial magnetic brain stimulation|
48155256|NCT05959382|DEVICE|Dental Loupe|Magnification aid
48155257|NCT05959382|DEVICE|Dental Operation Microscope|Magnification aid
48155258|NCT00329186|DRUG|desvenlafaxine SR|
48155259|NCT00329186|DRUG|venlafaxine ER|
48155260|NCT00788671|OTHER|Laboratory Biomarker Analysis|Correlative studies
48365469|NCT01768624|PROCEDURE|dialysis, kidney transplant|
48365470|NCT01452685|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
48365471|NCT01452685|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
48682089|NCT01838460|DRUG|sublingual nicotine tablets|6 mg = 3 tablets
48682090|NCT01838460|OTHER|Smokeless tobacco|Swedish type moist snuff
48682091|NCT03288454|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
48682092|NCT03288454|DRUG|Placebo|Saline for injection
48682093|NCT03288454|DRUG|Apixaban|Apixaban 10mg given twice daily (q12h)
48682094|NCT02318836|DRUG|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
48682095|NCT04790747|DRUG|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
47996170|NCT00980395|DRUG|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
47996171|NCT00980395|DRUG|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
47996172|NCT03207932|PROCEDURE|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
48155261|NCT00788671|DEVICE|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
48155262|NCT00788671|OTHER|Quality-of-Life Assessment|Ancillary studies
48155263|NCT03078699|RADIATION|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
48155264|NCT00003778|DRUG|dolastatin 10|
47996173|NCT04538703|BEHAVIORAL|acne vulgaris|Social media use of acne vulgaris patients, a questionnaire will be asked the patients and try to learn how they use social media for getting information about their disease.
47996174|NCT04722796|DEVICE|TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)|Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
47996175|NCT04722796|DEVICE|TAVR with Venus A plus using annular sizing and THV implantation technique|Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
47996176|NCT00729729|DRUG|PCA|Placebo tablet, once
47996177|NCT00729729|DRUG|PCA|PO, 700mg, once
47996178|NCT00729729|DRUG|PCA|PO, 1000mg, once
47996179|NCT04710706|OTHER|Colonoscopy insertion technique used during procedure|Each arm is using a different colonoscopy insertion technique: either water-alone colonoscopy or water-CO2 colonoscopy.
47996180|NCT01359254|DRUG|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
47996181|NCT01359254|DRUG|Fludarabine|Fludarabine is given through the vein daily for 5 days.
48155265|NCT03980171|DRUG|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
48155266|NCT03980171|DRUG|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
48155267|NCT03980171|DRUG|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
48155268|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
47996182|NCT01359254|DRUG|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
48682096|NCT01747915|DRUG|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
48682097|NCT01747915|DRUG|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
47996183|NCT01359254|DRUG|Busulfan|Busulfan is given daily for 4 days.
47996184|NCT01359254|DRUG|Total Body Irradiation (TBI)|TBI is given twice on the last day.
48155269|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
48155270|NCT03910491|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
48155271|NCT02819271|DRUG|CXL-1427 Ascending Dose|
48155272|NCT02819271|OTHER|Placebo|
48155273|NCT02819271|DRUG|CXL-1427 Descending Dose|
48682098|NCT01747915|DRUG|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
48682099|NCT02553928|DRUG|Memantine (once daily)|
48682100|NCT02553928|DRUG|Memantine (twice daily)|
48682101|NCT02168101|DRUG|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
48682102|NCT04352543|BEHAVIORAL|Active Video Game Exercise|Play during 30 minutes in the easy level
48682103|NCT04352543|BEHAVIORAL|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
48682104|NCT04352543|BEHAVIORAL|Sedentary Behavior|Quiet Rest: 30 minutes
48365472|NCT01452685|DRUG|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
48682105|NCT00542126|DRUG|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
48682106|NCT04899726|DEVICE|Rectoscope (P201630551)|Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
48682107|NCT03019757|RADIATION|DaTscan|A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
48682108|NCT03019757|RADIATION|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
48682109|NCT03019757|RADIATION|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
48682110|NCT03019757|GENETIC|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
48682111|NCT03019757|PROCEDURE|Polysomnogram|Overnight sleep study
48682112|NCT03019757|BEHAVIORAL|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
48682113|NCT03228784|PROCEDURE|LASIK|
48682114|NCT05014373|COMBINATION_PRODUCT|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
48682115|NCT05014373|PROCEDURE|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
48682116|NCT01448538|DRUG|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
48682117|NCT02118454|BEHAVIORAL|Daily IVR Calls Intervention|
48682118|NCT02118454|BEHAVIORAL|Weekly IVR Survey Only|
48682119|NCT01843166|DRUG|Premarin vaginal cream|2g at bedtime twice weekly
48682120|NCT01843166|DRUG|Placebo cream|2g at bedtime twice weekly
48682121|NCT02074943|BIOLOGICAL|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
48682122|NCT00529438|DRUG|Bardoxolone methyl|
48682123|NCT05794737|BIOLOGICAL|Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
48682124|NCT00941525|DRUG|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
48365473|NCT01452685|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
48682125|NCT04065698|DRUG|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
48682126|NCT03199794|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
48682127|NCT01798095|BIOLOGICAL|Aplisol@ PPD material|Determine equivalency of materials
48682128|NCT01798095|BIOLOGICAL|Reference Standard|Reference standard material for comparison to newly produced materials.
48682129|NCT00792090|OTHER|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
48682130|NCT00792090|OTHER|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
48682131|NCT04444739|OTHER|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
48682132|NCT04729933|DEVICE|V-Wave Shunt Placement|After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
48682133|NCT03976050|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
48682134|NCT03323216|DIAGNOSTIC_TEST|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention."
48682135|NCT03323216|DIAGNOSTIC_TEST|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention."
48682136|NCT03323216|PROCEDURE|Blood collection|"Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~- peripheral venous"
48682137|NCT03926910|DIAGNOSTIC_TEST|Detection of hypovolemia using a ventricular stimulation without atrial pacing|"Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is \>10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed."
48365474|NCT01452685|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
48682138|NCT05113316|BEHAVIORAL|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
48682139|NCT05025410|DRUG|Remimazolam|Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
48682140|NCT06388239|DRUG|Apixaban 5MG|Apixaban 5 mg Film-coated tablets
48682141|NCT06343272|DIETARY_SUPPLEMENT|EAA supplementation|"The experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5.~1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g"
48682142|NCT06343272|OTHER|Isocaloric placebo|The control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days
48682143|NCT06049147|DRUG|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
48682144|NCT06049147|DRUG|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
48682145|NCT06049147|DRUG|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
48682146|NCT00848887|BIOLOGICAL|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
48682147|NCT01922882|BEHAVIORAL|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
48682148|NCT04064190|DRUG|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
48682149|NCT01196013|DRUG|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
48682150|NCT05075733|OTHER|Survey|Survey was sent to all the Americas Hepato-Pancreato-Biliary Association's members
48682151|NCT01194219|DRUG|Apremilast|
48682152|NCT01194219|DRUG|Placebo|Identical matching placebo
48682153|NCT01194219|DRUG|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
48682154|NCT00886327|PROCEDURE|Colonic capsule endoscopy|
48682155|NCT03942198|DRUG|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
48682156|NCT03942198|DRUG|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
48682157|NCT05952297|DEVICE|Sleep Wellness Device (BeCurie)|This device emits micro electromagnetic stimulation
48682158|NCT05648877|DEVICE|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
48682159|NCT03412110|OTHER|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
48365475|NCT06381336|DEVICE|TRAK-SILVER platform|"The Experimental Group used TRAK-SILVER, a cross-platform web application that empowers healthcare professionals and patients. It facilitates the management of a patient's condition by providing therapeutic exercises, monitoring activity, and administering clinical assessment scales and questionnaires. The platform's advanced artificial vision algorithm, known for its precision, enhances patient engagement with real-time measurements and corrections during exercise.~Physiotherapists monitored the sessions through the TRAK-SILVER platform's monitoring system and weekly phone calls. The TRAK-SILVER platform had an alert notification system.~The program's second part involved weekly uploads of health-promoting information pills to the platform."
48365476|NCT02948452|OTHER|fMRI|fMRI: reward task, anxiety provocation
48365477|NCT00669240|DRUG|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
48365478|NCT03812614|BEHAVIORAL|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
48365479|NCT03812614|BEHAVIORAL|I-DSMES|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
48365480|NCT00754273|OTHER|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
48365481|NCT04149210|DRUG|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
48365482|NCT04149210|DRUG|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
48365483|NCT00740116|DRUG|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
48365484|NCT00740116|DRUG|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
48365485|NCT02132312|DRUG|OMS302|
48365486|NCT02132312|DRUG|Phenylephrine HCl|
47996185|NCT01412203|BEHAVIORAL|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
48365487|NCT05343403|OTHER|Family Integrated Care|The intervention will consist of FICare, including parental participation in medical rounds (FCR). Parents and healthcare professionals will be educated and supported by the four pillars of FICare: parent education, education of healthcare professionals, psychosocial support and a supportive environment of the neonatal ward.
48365488|NCT05892094|OTHER|Resistance and Aerobic Training|For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
48365489|NCT04971577|DRUG|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
48365490|NCT00508001|DRUG|Vandetanib|ZD6474 300mg
48365491|NCT00508001|DRUG|Vandetanib|ZD6474 100 mg
48365492|NCT00508001|DRUG|Best Supportive Care|Placebo + Best Supportive Care
48365493|NCT03646955|RADIATION|No partial breast irradiation|Omission of radiation therapy
48365494|NCT01966367|BIOLOGICAL|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
48365495|NCT02622217|BEHAVIORAL|Sleep deprivation|
48365496|NCT03114709|OTHER|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
48155274|NCT02430935|BEHAVIORAL|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
48155275|NCT02430935|BEHAVIORAL|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
48155276|NCT00109161|DRUG|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
48155277|NCT04586049|DEVICE|MRI|Participants will undergo an MRI scan while participating in a breathing test to measure brain blood flow.
48155278|NCT04586049|DEVICE|Transcranial Doppler Ultrasound|Participants will undergo a TCD scan while participating in a breathing test to measure brain blood flow.
48155279|NCT04586049|OTHER|Sympathetic Nerve Activity|Participants will undergo sympathetic nerve activity testing while participating in a breathing test.
48155280|NCT04609579|DRUG|SNX281|SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
48155281|NCT04609579|DRUG|pembrolizumab|pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.
48155282|NCT03588676|OTHER|Melatonin|5mg Melatonin
48365497|NCT03114709|OTHER|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
48682160|NCT02845986|PROCEDURE|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
48682161|NCT02845986|DRUG|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
48682162|NCT01960283|DRUG|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
48682163|NCT01960283|DRUG|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
48682164|NCT01834599|DEVICE|cerebral oximetry|tissue saturation measurement in pregnant women
48682165|NCT02614339|DRUG|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
48682166|NCT02614339|DRUG|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
47996186|NCT00275951|DRUG|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
47996187|NCT01115595|BIOLOGICAL|Intervention|Dermatophagoides pteronyssinus from ALK company
47996188|NCT01115595|OTHER|Control|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid)
48682167|NCT01970644|RADIATION|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
48682168|NCT05674227|PROCEDURE|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
48682169|NCT05674227|PROCEDURE|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
48682170|NCT05674227|PROCEDURE|Open surgery|Surgical treatment of operable lung cancers using open surgery
48682171|NCT00437268|DRUG|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
48682172|NCT00437268|DRUG|irinotecan|300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
48682173|NCT00437268|DRUG|cetuximab|400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
48155283|NCT03588676|OTHER|Placebo|5mg Placebo capsule
48155284|NCT01441258|BEHAVIORAL|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
48155285|NCT01441258|BEHAVIORAL|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
47996189|NCT05772936|BEHAVIORAL|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
47996190|NCT04903405|OTHER|No intervention|No intervention is involved in this study
47996191|NCT05616156|DEVICE|Cre8™ BTK|Implant of Cre8™ BTK stent the treatment of infrapopliteal peripheral artery disease
47996192|NCT01328860|BIOLOGICAL|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
47996193|NCT01218074|DEVICE|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
47996194|NCT01218074|DEVICE|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
48682174|NCT04192266|DRUG|Estradiol|2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
47996195|NCT03632187|DRUG|Abatacept|Subcutaneous abatacept every weeks during 3 months
48682175|NCT04192266|DRUG|Placebo oral tablet|2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
48682176|NCT06396702|OTHER|EASE-SOT|EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys) using electronic patient reported outcome measures (ePROMs). The intervention duration is 8 weeks. Based on individual preference, EASE-psy may be administered in person or virtually via Microsoft Teams. Based on individual preference, participants may receive ePROMs either on tablets or to their personal electronic devices via email, while at the hospital ward and in clinics, ensuring easy access and administration of these tools.
48682177|NCT06290492|DEVICE|transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
48682178|NCT06290492|DEVICE|sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
48682179|NCT02492308|PROCEDURE|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
47996196|NCT03632187|DRUG|Placebos|Subcutaneous placebo every week during 3 months
47996197|NCT01592344|DEVICE|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 100-250 µsec~* Pulse Rate: 50-100 Hz~* Intensity: 0-30mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
47996198|NCT01592344|DEVICE|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~* Waveform: Symmetric or Asymmetric~* Phase Duration: 200 µsec~* Pulse Rate: 1 Hz~* Intensity: 0 mA Time Settings~* Constant Stim: On~* Total Time: 6 hour"
47996199|NCT06233487|DIAGNOSTIC_TEST|Repeat hip ultrasound measurements|See earlier
47996200|NCT03639337|DIETARY_SUPPLEMENT|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
47996201|NCT06078033|BIOLOGICAL|Mobilization with movement|Sustained neutral apophyseal glide (SNAG) mobilization with movement applied to targeted vertebra while patients performed their painful movement.
47996202|NCT06078033|BIOLOGICAL|Sham mobilization with movement|Manual contact (without any pressure) applied to targeted vertebra while patients performed their painful movement.
47996203|NCT05715372|BEHAVIORAL|Mediterranean diet|12-week structured program for Mediterranean diet.
47996204|NCT05715372|BEHAVIORAL|AHA walking program|12-week structured AHA walking program.
47996205|NCT05715372|BEHAVIORAL|Mindfulness-based stress reduction|8-week structured mindfulness-based stress reduction (Cabot).
47996206|NCT05715372|BEHAVIORAL|Unstructured Mediterranean diet|Unstructured 12-week program with basic outline for Mediterranean diet.
47996207|NCT05715372|BEHAVIORAL|Unstructured walking program|Unstructured 12-week walking program.
47996208|NCT05715372|BEHAVIORAL|Unstructured stress reduction|Unstructured program using mobile application for stress reduction.
48682180|NCT02492308|DRUG|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
48682181|NCT05912595|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
48682182|NCT00399607|PROCEDURE|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
48682183|NCT00399607|PROCEDURE|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
48512120|NCT05885984|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) plus health education|Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.
48682184|NCT00399607|PROCEDURE|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
48682185|NCT00399607|PROCEDURE|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
48682186|NCT00399607|PROCEDURE|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
48682187|NCT03320967|DIAGNOSTIC_TEST|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
48682188|NCT05216718|PROCEDURE|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
48682189|NCT05216718|PROCEDURE|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
47996209|NCT04754776|BIOLOGICAL|ChAdOx1 RVF|Single dose of ChAdOx1 RVF
47996210|NCT05048810|RADIATION|68Ga-DOTA-NT-20.3|In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.
47996211|NCT06091280|DEVICE|Respiratory Muscle Strength Trainers|Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
48155286|NCT01441258|BEHAVIORAL|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
48155287|NCT02988232|DRUG|Sogyeonghwalhyeol-tang|herbal extract
47996212|NCT05078853|DEVICE|Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node|"FNA Clinic: When a bloody material is seen in the needle, 100 µL of 0.9% saline is drawn via the needle into the syringe. The aspirate is then transferred into an Eppendorf tube. 40 µL is aspirated from the Eppendorf tube and dripped into the middle of the sample well of the POC-Tg kit. Two drops of the buffer are then dispensed into the middle of the sample well. The result of the POC-Tg is obtained and documented after 10 minutes. To compare the accuracy of the POC-Tg kit to the formal immunoassay for Tg, 0.9% saline is added to the aspirate that was left in the Eppendorf tube to a final volume of 0.6 mL. This volume is transferred into a gel containing tube and sent to the clinical laboratory that performs Tg measurement.~Operating room: When an indeterminate or suspicious LN is found, the LN is dissected and evaluated by both the formal evaluation and the POC-Tg. Following dissection of the LN, the ex-vivo POC-Tg is conducted as described above."
48155288|NCT02988232|DRUG|Placebo|extract powder with same appearance, odor and color as SGHH
48155289|NCT00930644|DRUG|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
48155290|NCT01159756|DRUG|Travacom|Travacom ophthalmic solution (1 drop per day)
48155291|NCT03035149|OTHER|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
48155292|NCT06106256|DEVICE|Galvanic Vestibular Stimulation (GVS)|Four electrodes, forehead, behind both ears, and back of your neck, provide bidirectional electrical stimulation and receive information about the amplitude delivered accounting for skin impedance
48155293|NCT06106256|OTHER|Flight simulations in virtual reality (VR)|Highly immersive, 3D virtual flight simulation environment
48155294|NCT06106256|OTHER|3-DOF Bertec Portable Essential's dual-balance force plate system|Firm surface/plate to stand on while being presented disorienting visual patters of moving vertical and/or horizontal bars of alternating black and white.
48682190|NCT06556082|OTHER|Training|"Proprioceptive Neuromuscular Facilitation(PNF) based upper extremity strengthening exercises to increase upper extremity muscle strength will be applied to the participants in the training group 3 days a week for 8 weeks. PNF-based upper extremity strengthening exercises will be performed with an elastic resistive band using bilateral symmetrical PNF patterns of Flexion-Adduction-External Rotation-Extension-Abduction-Internal Rotation, Flexion-Abduction-External Rotation-Extension-Adduction-Internal Rotation on two different diagonals while individuals are in a sitting position in a supported chair. Core Stabilization Training will be continued for 8 weeks by increasing the difficulty and intensity of the exercises with limb movements and floor modifications after the amputee football players are taught how to find their neutral spine and how to maintain the position."
48682191|NCT06556082|OTHER|Control Group|The control group will be trained with isotonic strengthening exercises of upper extremity muscles with free weights and core stabilization training 3 days a week for 8 weeks. Isotonic exercises involve muscle contraction with movement, where the muscle length changes while maintaining constant tension. Free weights such as dumbells will be used in the implementation of the exercises. 1 Repetition Maximum (1RM) method will be used to determine the progression of the exercises.
48682192|NCT05350215|DRUG|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
48682193|NCT05350215|DRUG|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
48155295|NCT04169906|DRUG|Placebo|Participants will receive placebo once daily for 7 consective days
48682194|NCT03270059|DRUG|Ferumoxytol|Given IV
48682195|NCT03270059|DRUG|Gadolinium|Given IV
48682196|NCT03270059|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48682197|NCT04096950|BIOLOGICAL|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
48682198|NCT03449849|OTHER|Base Diet|Base Diet
47996213|NCT02722447|DRUG|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
47996214|NCT02722447|DRUG|Placebo|Placebo for 6 weeks
48155296|NCT04169906|DRUG|TS-142, 10 mg|Participants will receive 10 mg of TS-142 once daily for 7 consective days
48155297|NCT04169906|DRUG|TS-142, 20 mg|Participants will receive 20 mg of TS-142 once daily for 7 consective days
48155298|NCT04169906|DRUG|TS-142, 30 mg|Participants will receive 30 mg of TS-142 once daily for 7 consective days
48155299|NCT06584929|DRUG|Nicoderm CQ nicotine patch|Two week supply provided to participants on study.
48155300|NCT06584929|DRUG|Nicorette Nicotine Lozenges|Two week supply provided to participants on study.
48155301|NCT06299696|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration
48155302|NCT04927299|DRUG|Losartan/Chlorthalidone in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
48155303|NCT04927299|DRUG|Losartan + hydrochlorothiazide in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
48155304|NCT00014508|BIOLOGICAL|sargramostim|
48155305|NCT00014508|DRUG|cyclophosphamide|
48155306|NCT00014508|DRUG|cyclosporine|
48155307|NCT00014508|DRUG|fludarabine phosphate|
48155308|NCT00014508|DRUG|melphalan|
48155309|NCT00014508|PROCEDURE|peripheral blood stem cell transplantation|
48682199|NCT03449849|OTHER|Kale Treatment|Base Diet plus Kale
47996215|NCT04159233|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
47996216|NCT03155074|BEHAVIORAL|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
47996217|NCT04045496|DRUG|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
48155310|NCT05692232|OTHER|Pressure biofeedback guided DCFM strength training|A pressure biofeedback guided DCFM strength training was carried out according to the Jull protocol. Keeping the participant's cervical spine in a neutral position and ensuring a stabilizer pressure biofeedback unit placed beneath the cervical lordosis. The pressure sensor was inflated at 20mm Hg. The participants were asked to nod their heads slowly. As the DCFM is activated, the cervical lordosis gently flattens, and the pressure sensor measures an increase in pressure. The activation score is the maximum pressure that can maintain for 10 seconds.
48155311|NCT05692232|OTHER|Manual therapy|A manual therapy, including a slow, sustained elongation of muscles with a holding period of 7-10 seconds and a superficial oscillatory mobilization (grade-I) with 1-2 oscillations per second for 30 seconds per session was performed on the DCFM and at the cervical spine (C0-C5), respectively. The participants were asked to lie supine and prone while delivering stretching and mobilization, respectively.
48155312|NCT05692232|OTHER|Conventional intervention|A hot pads was applied for 20minutes underneath the cervical spine covering either side of shoulder in a relaxed supine position.
48155313|NCT00442026|DRUG|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
48155314|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
48155315|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
48155316|NCT03902327|DIETARY_SUPPLEMENT|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
48155317|NCT03902327|DIETARY_SUPPLEMENT|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
48155318|NCT02720783|DRUG|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
48155319|NCT02720783|DRUG|Placebo plus Econazole nitrate 150 mg vaginal pessary|
48155320|NCT02720783|DRUG|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
48155321|NCT02720783|DRUG|Placebo vaginal pessary|
48155322|NCT06276946|RADIATION|standard radiotherapy|radiotherapy planning goal is to restrict the mean parotid dose is equal to or less than 14Gy.
48682200|NCT04498286|DIAGNOSTIC_TEST|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
48682201|NCT01928290|DRUG|Irinotecan|
48682202|NCT01928290|DRUG|Trastuzumab|
48155323|NCT06276946|RADIATION|experimental radiotherapy|radiotherapy planning goal is to restrict the parotid duct dose is equal to or less than 14Gy
48155324|NCT00399659|DRUG|Tegaserod|
47996218|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga
47996219|NCT00492310|BEHAVIORAL|cognitive therapy|cognitive behavioral therapy once weekly
47996220|NCT00492310|BEHAVIORAL|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
47996221|NCT00492310|BEHAVIORAL|wellness|wellness program with smoking cessation
47996222|NCT00073359|BEHAVIORAL|Cognitive Behavioral Therapy|
48155325|NCT00896389|PROCEDURE|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
48155326|NCT00896389|DRUG|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
48682203|NCT01928290|DRUG|Oxaliplatin|
48682204|NCT01928290|DRUG|Leucovorin|
48682205|NCT01928290|DRUG|Fluorouracil|
48682206|NCT02439307|DRUG|Rifaximin|1200 mg of rifaximin for 2 weeks.
48682207|NCT02439307|DRUG|Placebo|Placebo for 2 weeks
48682208|NCT04535973|DIAGNOSTIC_TEST|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
48682209|NCT04535973|OTHER|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
48682210|NCT00400855|DRUG|Fluticasone propionate|Study drug
48682211|NCT05302895|DEVICE|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
48155327|NCT05567302|OTHER|Manual therapy|"In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present."
48155328|NCT05567302|OTHER|myofascial release|The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
48155329|NCT00732316|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
48155330|NCT00732316|PROCEDURE|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
48365498|NCT01347515|OTHER|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
48365499|NCT03377985|PROCEDURE|brachial plexus block|
48365500|NCT06492421|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
48365501|NCT02978404|DRUG|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
48365502|NCT02978404|RADIATION|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
48365503|NCT04680273|DRUG|[14C]-GDC-9545|Participants will receive a single oral dose of \[14C\]-GDC-9545 capsule, 30 milligrams (mg) (not more than \[NMT\] 4.6 megabecquerel \[MBq\]; 124 microcurie \[μCi\]) with approximately 240 millilitres (mL) water in the fasted state.
48365504|NCT04680273|DRUG|GDC-9545 Solution for Infusion|Treatment B: 30 mg GDC-9545 as a solution for infusion, 3 mg/mL administered intravenously (IV) in 10 mL as an infusion over 30 minutes.
48365505|NCT04680273|DRUG|GDC-9545/F12 Capsule|Treatment C: GDC-9545/F12 capsule, 30 mg, administered orally with approximately 240 mL water.
48365506|NCT04680273|DRUG|GDC-9545/F18 Capsule|Treatment D: GDC-9545/F18 capsule, 30 mg, administered orally with approximately 240 mL water.
48365507|NCT05627999|PROCEDURE|doppler endoanal ultrasound|The primary aim was to assess the reduction in the blood supply by comparing the hemorrhoidal arterial systolic peak (overall and sectorial) before and after Emborrhoid.
48365508|NCT02746276|DRUG|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
48365509|NCT02746276|DRUG|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
48365510|NCT02825589|DEVICE|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
48365511|NCT02063958|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
48365512|NCT05723172|DEVICE|active tACS|40 mins tACS for 10 consecutive daily sessions
48365513|NCT05723172|DEVICE|sham tACS|40 mins sham tACS for 10 consecutive daily sessions
48682212|NCT04657185|OTHER|OR PathTrac Feedback Optimization|OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
48682213|NCT05770297|DIETARY_SUPPLEMENT|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
48365514|NCT05779410|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks
48365515|NCT05779410|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily for 4 weeks
47996223|NCT02211131|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10\^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10\^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
47996224|NCT02211131|PROCEDURE|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
47996225|NCT05339451|DIAGNOSTIC_TEST|Blood biomarkers|Blood biomarkers in plasma and serum.
47996226|NCT03724812|DEVICE|Portico Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
47996227|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
47996228|NCT02292290|DRUG|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
48155331|NCT06228209|BEHAVIORAL|Tier - Palliative Care|TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines.
48155332|NCT05911191|OTHER|Exercise based prehabilitation|A peripheral muscle strengthening program
48512121|NCT05885984|OTHER|Health education|Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
48155333|NCT05283200|BEHAVIORAL|Yoga|Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction
48155334|NCT05283200|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills
48155335|NCT05283200|BEHAVIORAL|Music|Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
48682214|NCT05770297|OTHER|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
47996229|NCT02292290|DRUG|Sulfonylurea or Pioglitazone|Addition to Metformin
47996230|NCT02292290|DRUG|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
47996231|NCT05312229|BEHAVIORAL|Critical Time Intervention|An evidence-based, structured, and time-limited case management practice
47996232|NCT05312229|OTHER|External Facilitation|Site-specific support to help sites develop tailored plans to implement CTI.
47996233|NCT05312229|OTHER|Replicating Effective Programs|A stakeholder-informed training and technical assistance implementation strategy
47996234|NCT03805932|DRUG|Moxetumomab Pasudotox-tdfk|Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
47996235|NCT03805932|BIOLOGICAL|Rituximab|Rituximab will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
47996236|NCT03805932|BIOLOGICAL|Ruxience|Ruxience will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)
48155336|NCT02457078|DIETARY_SUPPLEMENT|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
48155337|NCT02457078|DIETARY_SUPPLEMENT|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
48155338|NCT03444155|DIETARY_SUPPLEMENT|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
48682215|NCT01853891|OTHER|dim light at night|
48155339|NCT03444155|DIETARY_SUPPLEMENT|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
48365516|NCT06201884|DEVICE|Early rehabilitation through Adapted Physical Activity|From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
47996237|NCT03805932|DRUG|Dexamethasone|12 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Administer 0.5-2 hours before rituximab/Ruxience. If participant has previous reaction to rituximab/Ruxience, give 12mg. If participants tolerate rituximab/Ruxience without problems, may hold at discretion of provider. Pre-medications are given prior to rituximab/Ruxience on day 1.
47996238|NCT03805932|DRUG|Acetaminophen|650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
47996239|NCT03805932|DRUG|Diphenhydramine|25-50 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Pre-medications are given prior to rituximab/Ruxience on day 1. May be given prior to moxetumomab pasudotox-tdfk at discretion of principal investigator.
47996240|NCT03805932|DRUG|Famotidine|20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
48365517|NCT05959876|OTHER|Training group|Face-to-face perineal care training
48365518|NCT05959876|OTHER|Control group|No intervention
48365519|NCT02990325|DRUG|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
48365520|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
48365521|NCT02990325|DRUG|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
48365522|NCT04322799|PROCEDURE|Device: Randomization between prosthetic components|Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
48365523|NCT00745004|DRUG|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
48365524|NCT00745004|DRUG|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
48365525|NCT05707104|OTHER|Pilates Exercises|"NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds"
48365526|NCT05707104|OTHER|plyometrics exercises|"1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6"
48365527|NCT05601271|DRUG|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
48365528|NCT03092076|DRUG|Ticagrelor|180 mg loading dose
48365529|NCT04536181|DRUG|Prednisolone|12 weeks prednisolone treatment
48365530|NCT04536181|DRUG|Placebo|12 weeks simulated tablets
48365531|NCT02936206|DRUG|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
48365532|NCT02936206|DRUG|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
48365533|NCT02327949|DEVICE|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
48365534|NCT02327949|DEVICE|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
48365535|NCT05409742|DIAGNOSTIC_TEST|Modified Hall technique|The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps
48365536|NCT04866147|PROCEDURE|Cardiothoracic surgery|Cardiac \& large intrathoracic vessels, respiratory, thoracic, mediastinal \& diaphragmatic procedures
48365537|NCT04866147|PROCEDURE|Breast surgery|Breast resections \& mastectomies
48365538|NCT04866147|PROCEDURE|Gastrointestinal surgery|Digestive \& spleen
48365539|NCT04866147|PROCEDURE|Genitourinary surgery|Urinary tract, genital \& retroperitoneal tissue
48365540|NCT04866147|PROCEDURE|Orthopaedic surgery|Back \& neck, shoulder \& upper arm, hip \& thigh, knees \& lower leg
48365541|NCT01397409|DRUG|AGN-150998|AGN-150998 Intravitreal injection.
48365542|NCT01397409|DRUG|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
48365543|NCT01397409|OTHER|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
47996241|NCT03805932|DRUG|Aspirin|81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
47996242|NCT01742741|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
47996243|NCT05650476|DRUG|Talazoparib|capsules
47996244|NCT02098590|BIOLOGICAL|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
47996245|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
47996246|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
47996247|NCT02098590|BIOLOGICAL|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
47996248|NCT02098590|DRUG|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
47996249|NCT04918212|DEVICE|Fabulous Stent Graft System|All patients received endovascular surgery using fabulous stent graft system
48365544|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as lozenges for local delivery in the oral cavity to provide oral health benefits. In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48365545|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing Streptococcus salivarius K12 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48365546|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)|In this study, a powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48365547|NCT05374070|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included|In this study, a powder formulation containing S. salivarius M18 and a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48365548|NCT06173973|DIETARY_SUPPLEMENT|Kenetik; Ketone Concentrate|Ketone Supplement
48365549|NCT06173973|DIETARY_SUPPLEMENT|Isocaloric dextrose placebo|Drink that is taste and visually matched to Ketone supplement
48365550|NCT01597076|DIETARY_SUPPLEMENT|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
48365551|NCT04873609|BEHAVIORAL|Patient portal message|Direct-to-patient message via the electronic patient portal (MyHealth) with HCV antibody lab order directed to their preferred laboratory
48365552|NCT00139373|DRUG|donepezil|
48365553|NCT02777294|BEHAVIORAL|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
47996250|NCT03318315|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
47996251|NCT03318315|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
47996252|NCT03318315|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
47996253|NCT03318315|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
47996254|NCT04538144|OTHER|Simulated heat wave|Individuals will be exposed to thermoneutral climate conditions and two simulated heat wave conditions.
47996255|NCT00020696|DRUG|cisplatin|
47996256|NCT00020696|DRUG|tirapazamine|
48365554|NCT02777294|BEHAVIORAL|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
47996257|NCT03747874|DIAGNOSTIC_TEST|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
47996258|NCT03632278|BEHAVIORAL|Mindfulness psychoeducation Programme|"A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties."
47996259|NCT01976234|OTHER|Fresh RBC|Patients will receive fresh blood only
48365555|NCT02119559|OTHER|Blood analysis by EPISPOT and CellSearch®|
48682216|NCT02148068|PROCEDURE|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
47996260|NCT01976234|OTHER|Old RBC|
47996261|NCT04792632|DEVICE|Veye Lung nodules|Veye Lung Nodules
47996262|NCT03084887|BEHAVIORAL|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
47996263|NCT05180214|DRUG|Bupivacain|analgesic
48365556|NCT03283813|DIETARY_SUPPLEMENT|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
47996264|NCT05180214|DRUG|Ketorolac|analgesia
47996265|NCT00778700|OTHER|Placebo Cream|Cream with no active drug
47996266|NCT00778700|DRUG|Ruxolitinib Phosphate|Ruxolitinib phosphate cream
47996267|NCT03930446|DRUG|Ethanol|The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
47996268|NCT03930446|OTHER|Placebo|The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
48682217|NCT06331039|OTHER|PFMT|PFM exercises were done. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
48682218|NCT06331039|OTHER|PFMT+Otago|It were done by combining Otago exercises and PFM exercises. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
47996269|NCT04634864|DEVICE|Anodal tDCS|40 minutes of 2mA intensity direct current stimulation was delivered over both the right and left motor cortex simultaneously
48682219|NCT02613663|PROCEDURE|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
48682220|NCT02613663|PROCEDURE|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
48682221|NCT05272722|DIAGNOSTIC_TEST|ECG,|Holter monitoring
47996270|NCT04634864|DEVICE|sham tDCS|The stimulator was switched off after 2 minutes of stimulation.
47996271|NCT04497077|DIETARY_SUPPLEMENT|tart cherry|Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
48682222|NCT02748876|OTHER|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
48682223|NCT00962728|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
48682224|NCT00962728|DEVICE|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
48682225|NCT05290662|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
48682226|NCT05290662|DRUG|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
48682227|NCT01740258|RADIATION|Radiation Therapy|
48682228|NCT01740258|DRUG|Temozolomide|
47996272|NCT04497077|DIETARY_SUPPLEMENT|placebo|either cornstarch capsule or kool-aid
47996273|NCT01087086|BEHAVIORAL|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
48365557|NCT03283813|DRUG|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
48682229|NCT01740258|DRUG|Bevacizumab|
48682230|NCT02610972|DEVICE|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
48682231|NCT06004388|DEVICE|Click Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
48682232|NCT04701060|DRUG|Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w|preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
48682233|NCT01138696|OTHER|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
48682234|NCT01138696|OTHER|RX|X-rays and clinical investigation of the knee 20 years after surgery
48682235|NCT05324592|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously."
48682236|NCT05324592|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously."
48155340|NCT04673071|OTHER|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
48155341|NCT04673071|OTHER|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
48155342|NCT01243086|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
48155343|NCT01243086|DRUG|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
48155344|NCT00100945|DRUG|gefitinib|
48155345|NCT01780584|DRUG|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
48155346|NCT01780584|DRUG|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
48155347|NCT01780584|DRUG|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
48155348|NCT01655498|DEVICE|vaginal bowel control system (LivSure)|
48155349|NCT04028128|DIETARY_SUPPLEMENT|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
48155350|NCT04028128|DIETARY_SUPPLEMENT|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
48155351|NCT01995565|OTHER|PLR|
48682237|NCT00845481|DRUG|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
48682238|NCT00845481|DRUG|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
48682239|NCT00845481|DRUG|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
48682240|NCT00845481|DRUG|Dermovat ointment|Once daily application 6 days a week for 3 weeks
48682241|NCT00845481|DRUG|Elocon ointment|Once daily application 6 days a week for 3 weeks
48682242|NCT00845481|DRUG|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
48682243|NCT04078204|DRUG|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
48682244|NCT04078204|DRUG|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
48682245|NCT01679938|BEHAVIORAL|primary obesity prevention|"1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
48682246|NCT04140786|DRUG|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
48682247|NCT00196794|DRUG|Tolevamer potassium-sodium (GT267-004)|
48682248|NCT06411613|OTHER|CC Program|The CC Program will be delivered through the existing HBPC infrastructure at VA Puget Sound Health Care System. Each HBPC team is comprised on a lead physician or nurse practitioner, nurse, pharmacist, nutritionist, social worker, psychologist, therapist, and chaplain. At a minimum, subsequent clinical encounters and assessments for each Veteran will be scheduled no less than on a quarterly basis and more often as needed based on the HBPC team's clinical judgment. On a monthly basis, the entire HBPC team will conduct MDC meetings to review each Veteran's medical plan. The Program aims to provide patient-centered, whole-person and team-based care, shared decision-making, active symptom management, advance care planning and end-of-life care.
48682249|NCT00187304|DEVICE|Aortic valve replacement|
48682250|NCT05232279|DRUG|Testofen 300mg|Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
48682251|NCT05232279|DRUG|Testofen 600mg|Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
48155352|NCT04872166|DRUG|BTX-A51|One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of 5 days on/2 days off.
48155353|NCT01746199|DRUG|cotrimoxazole daily prophylaxis|
48155354|NCT01746199|DRUG|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
48155355|NCT00098514|DRUG|talotrexin ammonium|
48155356|NCT00825643|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
48155357|NCT02227888|DRUG|N91115|S nitrosoglutathione reductase inhibitor
48155358|NCT02187120|DRUG|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
48155359|NCT02187120|DRUG|Placebo|
48155360|NCT05651334|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
48682252|NCT05232279|DRUG|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
48682253|NCT02790840|DRUG|Omeprazole|20 mg oral capsules administered once daily for 10 days
48682254|NCT02790840|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 10 days
48682255|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
48682256|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
47996274|NCT01087086|BEHAVIORAL|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
47996275|NCT04991545|DEVICE|Application of Infrared (Active IRD/ IRRIS) device|"The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~1. Group A: control group~2. Group B: Intervention group using Infrared"
47996276|NCT05636930|OTHER|Test the accuracy of the wearable device|No intervention was done for the subjects
47996277|NCT03027895|DEVICE|Lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage of WON with LAMS
47996278|NCT03027895|DEVICE|Double pigtail plastic stent (DPPS)|Endoscopic Ultrasound-guided Drainage of WON with DPPS
48682257|NCT04683406|DRUG|ZSP1273 600 mg|3 X 200-mg tablet taken orally
47996279|NCT06544811|OTHER|Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking.
48682258|NCT04683406|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
47996280|NCT06544811|OTHER|Cultural Smoking Cessation Program|A free text message smoking cessation program that provides 24/7 encouragement, advice, and tips to those trying to quit smoking and has been developed for American Indian and Alaska Native persons.
47996281|NCT03877627|PROCEDURE|Pelvic and Peritoneal Lymphadenectomy|Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
47996282|NCT06274541|GENETIC|Somatic and Germline BRCA1/2 Testing|Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
47996283|NCT05866861|DRUG|CUG252|CUG252 will be administered by subcutaneous injection.
48155361|NCT05651334|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
48365558|NCT03283813|DRUG|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
48682259|NCT04683406|DRUG|Oseltamivir(oral)|2 X 75-mg tablet taken orally
48682260|NCT04683406|DRUG|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
48682261|NCT06174155|OTHER|physical therapy treatment|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist. The primary focus of the program was to improve scar malleability, lengthen muscles and tendons, enhance joint mobility, and to restore functionality. Each session lasted almost for 45 minutes and consisted of therapeutic paraffin application; deep tissue massaging (5 minutes); stretching exercises; active ROM exercises.
48682262|NCT06174155|OTHER|Botulinum toxin-A injection in addition to physical therapy program|Two injection procedures will be used. The first is an EMG-guided BTX-A administration (Botox®, Allergan PLC, Dublin, Ireland) that will be localized to the motor endplate zone of the wrist flexors, radial and ulnar deviators. The second is a meso-injection procedure, where the BTX-A will be injected subdermal, intradermal, and into the scar (around the periphery and into the center).
48682263|NCT06174155|OTHER|shock wave therapy in addition to physical therapy program|After wound and skin graft healing (\~ 90 days post-surgery), the unfocused shockwave will be applied to the site of burn injury on the volar aspect of the hand of the subjects and will allocate to the shock wave therapy intervention arm. The treatment will be delivered using a portable shockwave device (Zimmer enPuls, EMS physio Ltd, Germany).
48682264|NCT02530476|DRUG|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
48155362|NCT06202547|BIOLOGICAL|Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles|he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
48682265|NCT02530476|DRUG|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
48682266|NCT03346187|DRUG|Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
48682267|NCT03346187|DRUG|Test drug(CKD-337)|CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
48682268|NCT01481350|DRUG|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
48682269|NCT03759639|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
48682270|NCT01034501|DEVICE|sham procedure|non activated laser tip
48682271|NCT01034501|DEVICE|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
48682272|NCT01460810|OTHER|1000CsK Silicon Oil Tamponade|Details covered in arm description
48682273|NCT06397859|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
48682274|NCT02656394|DRUG|GL101|Topical Gel
48682275|NCT02656394|DRUG|Placebo|Placebo topical gel
47996284|NCT05866861|DRUG|Placebo|Placebo will be administered by subcutaneous injection.
48155363|NCT03452735|OTHER|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
48682276|NCT03069040|PROCEDURE|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
48682277|NCT03069040|PROCEDURE|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
48682278|NCT04058015|OTHER|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
48682279|NCT04058015|OTHER|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
48682280|NCT04058015|OTHER|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose \< 200 mg/dL in the patients with Diabetes mellitus.
48682281|NCT04058015|OTHER|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose \< 200 mg/dL in patients who were absent of Diabetes mellitus.
48682282|NCT03132961|OTHER|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
48682283|NCT01768910|OTHER|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
48682284|NCT01768910|OTHER|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
48682285|NCT01768910|OTHER|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
48682286|NCT01768910|OTHER|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
47996285|NCT00004078|DRUG|irinotecan hydrochloride|Given IV
47996286|NCT04444609|OTHER|Blood tests sputum, nasal lavage and brushing|Venesection, sputum nasal lavage and brushing if appropriate
47996287|NCT00000514|DRUG|chlorthalidone|
47996288|NCT00000514|DRUG|atenolol|
47996289|NCT00000514|DRUG|reserpine|
48682287|NCT06289946|DRUG|NitroBid|We will apply nirobid to the wrist prior to left heart catheterization.
48682288|NCT06289946|DRUG|Placebo|We will apply placebo moisturizing cream to the wrist
48682289|NCT02257242|DRUG|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
48682290|NCT02257242|DRUG|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
48682291|NCT02257242|DRUG|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
48682292|NCT03833557|PROCEDURE|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
48682293|NCT03833557|PROCEDURE|MTA pulpotomy|Angleus grey MTA
48682294|NCT03833557|PROCEDURE|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
48682295|NCT04005391|OTHER|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
48682296|NCT00276068|DRUG|topical lidocaine + oral desipramine, and/or placebo|
48682297|NCT05831904|DEVICE|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
48682298|NCT03775824|DRUG|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
48682299|NCT03775824|DRUG|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
48682300|NCT02100423|DRUG|curcumin|Given PO
48682301|NCT02100423|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
48682302|NCT02100423|OTHER|laboratory biomarker analysis|Correlative studies
48682303|NCT02100423|OTHER|pharmacological study|Correlative studies
48682304|NCT01098253|BEHAVIORAL|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
48682305|NCT01583114|DRUG|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
48682306|NCT01583114|DRUG|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
48682307|NCT03748589|DEVICE|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
48682308|NCT06199804|BEHAVIORAL|Toy Hygiene Training|The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
48682309|NCT01589146|DRUG|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
48682310|NCT04801485|DIETARY_SUPPLEMENT|D-chiro inositol|Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
48682311|NCT04801485|DIETARY_SUPPLEMENT|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
48682312|NCT02855879|OTHER|Collection of biological data|
48682313|NCT02855879|OTHER|Collection of clinical data|
48682314|NCT02030769|DRUG|Pronase|use pronase to improve visibility during endoscopical iodine staining
48682315|NCT02030769|DRUG|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
48155364|NCT05567224|OTHER|Access to primary care services|Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
48682316|NCT03225248|DRUG|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
48682317|NCT03225248|DRUG|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
48682318|NCT03051295|OTHER|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
47996290|NCT03427736|DRUG|Ketorolac Tromethamine|IV ketorolac will be given per standard of care, not prescribed for this study
47996291|NCT03427736|DRUG|Hydromorphone|IV Hydromorphone will be given per standard of care, not prescribed for this study
47996292|NCT03427736|DRUG|Ketamine|IV Ketamine will be given per standard of care, not prescribed for this study
47996293|NCT03427736|DRUG|Oxycodone|PO Oxycodone(solution or tablet) will be given per standard of care, not prescribed for this study
47996294|NCT03427736|DRUG|Morphine|IV Morphine will be given per standard of care, not prescribed for this study
47996295|NCT04666064|DIAGNOSTIC_TEST|Covid19 RT-PCR|patients admitted to ER for suspicion of COVID-19 infection will have a SARS-CoV-2 RT-PCR test
47996296|NCT04666064|OTHER|lung ultrasound|patients admitted to ER for suspicion of COVID-19 infection who has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound
47996297|NCT01769040|DRUG|Rifaximin|550 mg two times daily for 28 days
47996298|NCT01769040|DRUG|placebo|
47996299|NCT03407742|BEHAVIORAL|CAPAS Youth|9-week parenting intervention
48682319|NCT05756920|DRUG|ABL301|SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
48682320|NCT05756920|DRUG|Placebo|SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
48682321|NCT02855658|DRUG|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
48365559|NCT05411705|DRUG|rhTPO|rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
47996300|NCT00669812|DRUG|carmustine|
47996301|NCT00669812|DRUG|cyclophosphamide|
47996302|NCT00669812|DRUG|cytarabine|
47996303|NCT00669812|DRUG|doxorubicin hydrochloride|
47996304|NCT00669812|DRUG|epirubicin hydrochloride|
47996305|NCT00669812|DRUG|etoposide|
47996306|NCT00669812|DRUG|ifosfamide|
47996307|NCT00669812|DRUG|melphalan|
47996308|NCT00669812|DRUG|methotrexate|
47996309|NCT00669812|DRUG|prednisolone|
47996310|NCT00669812|DRUG|vincristine sulfate|
47996311|NCT00669812|PROCEDURE|autologous hematopoietic stem cell transplantation|
47996312|NCT00669812|PROCEDURE|biopsy|
48365560|NCT05411705|DRUG|Control|Non-rhTPO treatment
48682322|NCT02855658|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
47996313|NCT00669812|PROCEDURE|peripheral blood stem cell transplantation|
48682323|NCT01943786|DRUG|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
48682324|NCT04103281|OTHER|Sepsis|Sepsis patients in the ICU with a breathing tube
48682325|NCT01274234|DEVICE|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
48682326|NCT00407602|DEVICE|Implant of Argus II Retinal Prosthesis|epiretinal implantation of device
48682327|NCT01605422|OTHER|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
48682328|NCT02100254|BEHAVIORAL|behavioral intervention|View personal narrative informational video
48682329|NCT02100254|BEHAVIORAL|behavioral intervention|View fact-based informational video
48682330|NCT02572297|OTHER|video-EEG|Registration of seizures during video-EEG
48682331|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 1 mg|Singel-dose; Subcutaneous
48682332|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 4 mg|Singel-dose; Subcutaneous
48682333|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 8 mg|Singel-dose; Subcutaneous
48682334|NCT06554119|PROCEDURE|Huanlei Huang|tricuspid valve replacement or plasty
48682335|NCT01004536|DEVICE|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
48682336|NCT01004536|OTHER|no treatment|left untreated during the study period
48682337|NCT01732705|BEHAVIORAL|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
48682338|NCT04236050|DRUG|Rocuronium|Rocuronium administered in continuous infusion or multiple bolus doses
48682339|NCT04858841|DRUG|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
48682340|NCT04858841|DRUG|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
48682341|NCT04858841|DRUG|Placebo|Administer placebo powder once a day in eligible patients
48682342|NCT03620032|DRUG|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
48682343|NCT03620032|DRUG|Vinorelbine|Chemotherapy
48682344|NCT03620032|OTHER|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
48682345|NCT00293228|DRUG|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
48682346|NCT00293228|DRUG|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
48682347|NCT01295944|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
47996314|NCT04509843|BEHAVIORAL|socioeconomic status|it is a cross-sectional study for assessment the impact of socioeconomic status on periodontal health through using a definite scale mentioned in the protocol related to the middle east people.
48682348|NCT01295944|DRUG|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
48682349|NCT03326635|OTHER|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
48682350|NCT05096975|OTHER|Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED|"The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children."
47996315|NCT03767920|DRUG|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
47996316|NCT03767920|DRUG|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
47996317|NCT03767920|DRUG|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
47996318|NCT02418858|PROCEDURE|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
47996319|NCT00116441|BIOLOGICAL|Therapeutic Cellular Vaccine, GM-CSF Producing|
48155365|NCT01156922|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
48155366|NCT03252899|OTHER|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
48682351|NCT05672940|BEHAVIORAL|Aerobic plus resistance training|Aerobic plus resistance training
48682352|NCT05672940|BEHAVIORAL|Stretching plus breathing training|Stretching plus breathing training
48682353|NCT01518725|DIETARY_SUPPLEMENT|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
48682354|NCT01518725|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
48682355|NCT00005844|DRUG|oxaliplatin|
47996320|NCT01341600|DRUG|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
47996321|NCT01341600|DRUG|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
47996322|NCT06045091|DRUG|Human BCMA targeted CAR-NK cells injection|Allogenic genetically modified anti-BCMA CAR transduced NK cells
48682356|NCT05592990|DRUG|NGI226|NGI226 MP
48682357|NCT05592990|DRUG|Placebo|Placebo MP
48682358|NCT03931499|DIAGNOSTIC_TEST|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
47996323|NCT01549964|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
47996324|NCT01549964|DRUG|Sitagliptin|Sitagliptin tablets
47996325|NCT01549964|DRUG|Placebo|Placebo-matching tablets
47996326|NCT02990169|DEVICE|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
48682359|NCT01127633|DRUG|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
48682360|NCT01127633|DRUG|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
48682361|NCT05052944|DEVICE|Cochlear implantation|Patients who receive cochlear implant for single-sided deafness
48682362|NCT00984776|OTHER|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
47996327|NCT02990169|DEVICE|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
48682363|NCT01799343|OTHER|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
47996328|NCT05315518|DIAGNOSTIC_TEST|single-shade universal resin composite (omnichroma) with blocker( omnichroma blocker)|(OMNICHROMA BLOCKER) is indicated for preventing shade-matching interference in Class IV restorations, Masking dark dentition and dentin. In cases where there is a lack of tooth structure to bond to, (BLOCKER) works as a supplementary product to provide a lingual wall to the restoration, prevent shade-match obstruction and mask staining.
47996329|NCT03384121|DRUG|Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension|Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
47996330|NCT05110911|BIOLOGICAL|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
48155367|NCT03252899|OTHER|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
48155368|NCT05757063|OTHER|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
48155369|NCT05757063|OTHER|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
48155370|NCT03939793|BEHAVIORAL|IMPaCT Community Health Worker|"Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~1. Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~2. Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining."
47996331|NCT05110911|BIOLOGICAL|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
47996332|NCT02453958|DEVICE|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
47996333|NCT00109395|DRUG|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
47996334|NCT00109395|DRUG|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
47996335|NCT00109395|DRUG|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
47996336|NCT04695860|DRUG|Burosumab|Q4w, 1mg/kg Body weight, s.c.
48682364|NCT03127696|PROCEDURE|Fecal Microbiota Transplantation|FMT
48682365|NCT03127696|BEHAVIORAL|Lifestyle Modification Program|Lifestyle
48682366|NCT03127696|PROCEDURE|Sham|Sham
48682367|NCT04264923|OTHER|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
48682368|NCT01069393|OTHER|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
48682369|NCT06069180|DRUG|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
48682370|NCT06069180|DRUG|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
48682371|NCT01565408|DRUG|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
48682372|NCT01565408|DRUG|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
48682373|NCT01872975|RADIATION|regional nodal XRT|
48682374|NCT01872975|RADIATION|chestwall XRT|
48682375|NCT01872975|RADIATION|WBI|
48682376|NCT00442377|PROCEDURE|exposure to malaria sporozoites|
48682377|NCT00088270|DRUG|OSI-7904L|
48682378|NCT00088270|DRUG|5-Fluorouracil/Leucovorin|
48682379|NCT03896477|BIOLOGICAL|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
48155371|NCT03939793|BEHAVIORAL|Digital health monitoring with financial incentives|Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
48155372|NCT03939793|OTHER|Usual Care|Usual Care
48682380|NCT03896477|BIOLOGICAL|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
48155373|NCT04888208|BEHAVIORAL|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
48682381|NCT03896477|BIOLOGICAL|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
48682382|NCT03973112|DRUG|HLX10 3mg/kg|anti-PD-1
48682383|NCT03973112|DRUG|HLX04 5mg/kg|anti-VEGF, a biosimilar to Avastin
48682384|NCT03973112|DRUG|HLX04 10mg/kg|anti-VEGF, a biosimilar to Avastin
48682385|NCT01125410|DRUG|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
48682386|NCT01125410|DRUG|Clindamycin|vaginal cream, 2%, once daily for 7 days
48682387|NCT01222988|DIETARY_SUPPLEMENT|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
48682388|NCT03396627|DIAGNOSTIC_TEST|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
48155374|NCT04546178|BEHAVIORAL|Prolonged exposure (PE)+ therapy|The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.
48682389|NCT01632852|BIOLOGICAL|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
47996337|NCT02761707|OTHER|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
48682390|NCT00044369|PROCEDURE|Varicocele repair|
48155375|NCT04546178|OTHER|Treatment as usual (TAU)|The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
48155376|NCT01133600|DRUG|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is \<30ml/min.
48155377|NCT01133600|DRUG|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
48682391|NCT00995098|DIETARY_SUPPLEMENT|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
48682392|NCT00995098|DIETARY_SUPPLEMENT|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
48682393|NCT02705482|BIOLOGICAL|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
48682394|NCT02705482|BIOLOGICAL|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
48155378|NCT03279172|PROCEDURE|direct laryngoscope|procedure entubatıon
48155379|NCT03279172|PROCEDURE|videolaryngoscope|
48682395|NCT02705482|BIOLOGICAL|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
48682396|NCT06288633|PROCEDURE|Ganglionated plexi ablation|"Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.~Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.~During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size."
48682397|NCT06288633|DIAGNOSTIC_TEST|Electrophysiological study|Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
48682398|NCT03400410|BEHAVIORAL|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
48682399|NCT05989438|OTHER|Orientations for families|"Guidance for parents will follow the guide/manual prepared by the researchers, in addition to verbal and video guidance. Once a week a reminder will be sent, and once a month researchers will contact you by phone for guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
48155380|NCT00814359|DRUG|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
48155381|NCT00814359|DRUG|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
48155382|NCT02440919|OTHER|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
48365561|NCT01663246|PROCEDURE|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
48155383|NCT02440919|OTHER|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
48155384|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
48365562|NCT01832272|PROCEDURE|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
48365563|NCT05884606|DEVICE|Allurion Digital Behaviour Change Intervention|The Allurion DBCI adheres to current National Institute for Health and Care Excellence (NICE) guidance for obesity.
48682400|NCT05989438|OTHER|Professional stimulation more orientations for families.|"Each session will last approximately 50 minutes, where the stimuli will be performed in: supine position; Ventral Decubitus; Seated; Four supports, kneeling/semi-kneeling and standing.~If the child no longer uses the posture or it is not an acquisition for the age group in which the baby is, the time will be distributed in order to contemplate the expected acquisitions for the age group in which the baby is. The stimuli will be performed based on the neuropsychomotor development, in order of progression and according to the corrected age of the baby.~The frequency of consultations may vary due to the different degrees of prematurity, and the stipulated initial frequency will vary between 1-8 times a month.~The orientations will also be provided to family members during consultations, and families will also perform stimuli at home according to written, verbal and video guidance.~There will be 3 evaluations with an interval of 4 months. (4 months; 8 months; 12 months)."
48682401|NCT03805061|OTHER|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
47996338|NCT02761707|OTHER|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
47996339|NCT02761707|OTHER|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
47996340|NCT02761707|OTHER|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
47996341|NCT00844272|BEHAVIORAL|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
48155385|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
48682402|NCT03805061|DEVICE|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
48682403|NCT02843438|OTHER|Fluorescein angiography|
48682404|NCT02843438|OTHER|Dilated fundus examination|
48682405|NCT02843438|BIOLOGICAL|Toxoplasmosis serology|
48682406|NCT02843438|DRUG|Anti-toxoplasmosis treatment|
48682407|NCT02843438|DRUG|Anti-inflammatory treatments|
48682408|NCT02843438|OTHER|Puncture in anterior chamber|
48682409|NCT00781443|DRUG|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
48682410|NCT00781443|DRUG|placebo|Repeating subcutaneous injection
47996342|NCT05748340|PROCEDURE|Unilateral cleft lip repair|Surgical repair unilateral cleft lip
48365564|NCT00824759|OTHER|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
48365565|NCT05288439|DIAGNOSTIC_TEST|Resting-state functional connectivity MRI|participants will undergo functional MRI
48365566|NCT05288439|OTHER|Neurocognitive battery with quality-of-life assessment|Cognitive and quality of life assessments performed by a trained neuropsychologist
48365567|NCT00006358|DRUG|temozolomide|
48365568|NCT00006358|DRUG|thalidomide|
48365569|NCT01402999|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
48682411|NCT00348959|BEHAVIORAL|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
48682412|NCT03276728|DRUG|AMG 986 IV|AMG 986 solution for infusion
47996343|NCT03812692|DEVICE|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
48682413|NCT03276728|DRUG|AMG 986 PO|AMG 986 tablets for oral (PO) administration
47996344|NCT01500707|DRUG|SCH 900800|SCH 900800, one 20 mg tablet, orally
47996345|NCT01380743|DRUG|duvoglustat|Single oral dose
47996346|NCT01380743|DRUG|rhGAA|Single intravenous infusion
48365570|NCT00690209|PROCEDURE|Autologous bone marrow derived stem cells myocardial transplantation|
48365571|NCT04659356|OTHER|Patients admitted in Intensive Care Units|Data will be collected computerized patient records by the clinicians in charge of the patient.
48365572|NCT01767844|DIETARY_SUPPLEMENT|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
48365573|NCT01767844|DIETARY_SUPPLEMENT|Placebo|
48682414|NCT03276728|DRUG|Placebo PO|Matching placebo tablets for oral administration
48682415|NCT03276728|DRUG|Placebo IV|Matching placebo solution for infusion
47996347|NCT00510354|DRUG|Imatinib mesylate|
47996348|NCT03981081|DRUG|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
47996349|NCT03500328|OTHER|Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy|Early Aggressive Therapy
47996350|NCT03500328|OTHER|Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod|Traditional Therapy
48155386|NCT02794441|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
48682416|NCT02508545|OTHER|perceived egocentric distance (PED) measurements|
48682417|NCT02508545|OTHER|Parabolic flight|
48682418|NCT01106157|DRUG|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
48682419|NCT01106157|DRUG|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
48365574|NCT04184674|OTHER|Pneumotachograph|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
48682420|NCT01106157|DRUG|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
48682421|NCT04615624|DRUG|Furosemide|Furosemide, a loop diuretic
48682422|NCT04615624|OTHER|Placebo|Normal saline
48682423|NCT01308255|DRUG|Infliximab|"Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
48682424|NCT01308255|DRUG|Methylprednisolone|Steroid
48682425|NCT01308255|DRUG|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
47996351|NCT05392361|DRUG|gabapentin (neurontin® capsule 300mg) treatment|Taking gabapentin (neurontin® capsule 300mg, Pfizer) medication at night as a conservative treatment
48682426|NCT01308255|DIETARY_SUPPLEMENT|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
48682427|NCT02671006|OTHER|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
48682428|NCT02410642|PROCEDURE|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
48682429|NCT02688192|BEHAVIORAL|Exercise Intervention|Participate in fitness program
48682430|NCT02688192|BEHAVIORAL|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
48682431|NCT02688192|DEVICE|Monitoring Device|Wear an electronic accelerometer
48682432|NCT02688192|OTHER|Quality-of-Life Assessment|Ancillary studies
48682433|NCT04308018|PROCEDURE|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
48682434|NCT04308018|PROCEDURE|S1 screws|Caudal end of the instrumentation at S1
48682435|NCT04738175|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
48682436|NCT04738175|DRUG|Placebo|Diluent solution
48682437|NCT03775499|DIETARY_SUPPLEMENT|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
48682438|NCT03775499|OTHER|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
48682439|NCT03775499|DIETARY_SUPPLEMENT|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
48682440|NCT03775499|OTHER|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
48682441|NCT03202433|DEVICE|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
48682442|NCT04106544|PROCEDURE|Investigational Procedures|The investigational assessments will be performed
48365575|NCT04184674|OTHER|Esophageal catheter|"Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
47996352|NCT05392361|DRUG|baclofen (baclofen Tab. 10mg) treatment|Taking baclofen (baclofen Tab. 10mg, Handok co, Seoul, Korea) medication at night.
48365576|NCT04184674|OTHER|Transthoracic and / or transesophageal cardiac ultrasound|"The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures)."
48365577|NCT04184674|OTHER|Electrical impedance tomography (EIT) for pediatric patients|For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
47996353|NCT03004066|DRUG|Daptomycin|standard care
48365578|NCT05568966|DIAGNOSTIC_TEST|Venous blood draw|Venepuncture to draw up to 24mL of venous blood.
48365579|NCT05568966|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
48365580|NCT04335227|OTHER|Structured yoga therapy program|Structured yoga therapy prepared according to traditional yoga scriptures of Patanjali yoga sutras will be administered to 32 females with PCOS. The structured yoga therapy which includes, Surya Namaskara (Sun Salutation) and asanas performed in four positions, standing, sitting, supine and prone for total duration of 60 minutes. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
48365581|NCT04335227|OTHER|Aerobic exercise training program|Thirty two females with PCOS in aerobic exercise (AE) group will be subjected to aerobic training of moderate intensity for 30-60 minutes six days per week for 12 weeks, in the light of guidelines framed by American College of Sports Medicine (ACSM). Aerobic exercise volume for each female recruited will be set at greater than 500 and up to 1000 MET-min/week, which will be approximately equal to 1000 kcal/week. They will be made sure that they exercise for minimum duration of 150 min/week and thereby covering 5400 to 7900 steps/day in pedometer readings. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
48365582|NCT04335227|OTHER|Combined yoga and aerobic training program|Thirty two females with PCOS in combined yoga therapy and aerobic exercise (cYTAE) group will be subjected to three days of structured yoga therapy and three days of aerobic training of vigorous intensity. In addition to this, they will be asked to undergo nutritional management uniquely prepared by dietitian
47996354|NCT01923415|PROCEDURE|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
47996355|NCT01923415|PROCEDURE|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
47996356|NCT01923415|PROCEDURE|No intervention, urine collection|Urine will be collected from all participants.
47996357|NCT02393885|DEVICE|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
47996358|NCT04254978|DRUG|Bomedemstat|Oral administration
47996359|NCT01770561|DEVICE|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
47996360|NCT03898596|DIAGNOSTIC_TEST|ECG|An ECG collects superficial readings of heart activity
48365583|NCT04335227|OTHER|Nutritional management|Thirty two females with PCOS will be asked to undergo only nutritional management uniquely prepared by dietitian
48365584|NCT02471625|DEVICE|ClearView Scanning|
48365585|NCT03217565|DRUG|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
47996361|NCT00000560|DRUG|adrenergic beta antagonists|
47996362|NCT02771990|DEVICE|Sham transcranial direct current stimulation|sham stimulation
47996363|NCT02771990|DEVICE|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
47996364|NCT04713826|DRUG|BAY2586116|160 µg, nasal spray administration.
47996365|NCT04713826|DRUG|Placebo|Placebo matching BAY2586116, nasal spray administration.
48365586|NCT03217565|DRUG|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
47996366|NCT03121326|DIAGNOSTIC_TEST|blood and urine sampling|Ten mL blood and 15mL urine are collected.
47996367|NCT02391103|DEVICE|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
48365587|NCT02118493|DEVICE|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
48365588|NCT04686591|DRUG|AZD9977 capsule 50 mg|100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
48365589|NCT04686591|DRUG|[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)|One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
48365590|NCT04686591|DRUG|[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)|One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
48365591|NCT02557269|DRUG|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
48365592|NCT02557269|DRUG|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
48365593|NCT02557269|DRUG|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
48365594|NCT02557269|DRUG|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
48365595|NCT02557269|OTHER|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
48365596|NCT02557269|DRUG|Bilastine 20 mg|1 tablet per os - as needed
47996368|NCT02391103|DEVICE|sham-stimulation|no electricity applied
47996369|NCT02636465|OTHER|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
47996370|NCT01436812|PROCEDURE|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
48365597|NCT02557269|DRUG|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
48365598|NCT03349957|DRUG|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
48365599|NCT03996993|DRUG|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
48365600|NCT03996993|RADIATION|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
48365601|NCT06431139|OTHER|INSPIRE intervention protocol|2-week training program with daily sit-to-stand exercises. Each working day the participant's goals will be adjusted, until exercising a minimum of 100 repetitions using an exercise progression table. When participants complete one level, they will progress to the next level the following day. Participants who do not reach the goals at level one will continue to strive to reach the 100 repetitions. The number of repetitions can be split and performed throughout the day. As the participants' capacity for doing the exercises increases, so will the number of repetitions within each bout of sit-to-stand. Participants are allowed to do the number of repetitions from a higher exercise level if they can and will continue by progressing from that level on the next day. The repetitions will be done from a height that makes it possible to accomplish the sit-to-stand movement. Therefore, the height of the sitting surface will be adjusted according to the participant's abilities.
48365602|NCT03100929|DIAGNOSTIC_TEST|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
48365603|NCT01230021|DRUG|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
48365604|NCT05910606|BEHAVIORAL|Digital Exercise|Fall Prevention Program: Our fall- risk reduction program overs digitally delivered exercise with real time feedback from expert instructors.
48365605|NCT04778111|OTHER|Measurement of the actual and perceived maximum reachable distance|A device (a table) will present luminous targets (green circles) to the subjects. Subjects will be asked to determine whether or not they are able to reach this target with their upper limb.
48682443|NCT03782623|DIAGNOSTIC_TEST|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
47996371|NCT01436812|PROCEDURE|positive end expiratory pressure|PEEP 0 cmH2O
47996372|NCT02945176|DEVICE|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
48365606|NCT04582695|BEHAVIORAL|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
48365607|NCT04582695|BEHAVIORAL|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
48365608|NCT01142960|DIETARY_SUPPLEMENT|Starch|1350mg/day
48365609|NCT01142960|DIETARY_SUPPLEMENT|Lycium Barbarum|1350mg/day
48682444|NCT00807183|OTHER|woodstove|installation of new EPA-certified woodstove
48682445|NCT00807183|OTHER|inactive air filter|air filter units without filter in place
48682446|NCT00807183|OTHER|Active air filter|air filter units correctly operating
48682447|NCT06455878|BEHAVIORAL|Full usage of diet management app group and with the full usage of an intelligent weight scale|Subjects will use the fully functional diet management application and an intelligent weight scale with full function designed for obese heart failure patients to help them losed weight and invitigate some important composite cardiovascular endpoint.
48512122|NCT02798588|RADIATION|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)-\>8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
48682448|NCT06455878|BEHAVIORAL|Limited usage of diet management app group and with the limited usage of an intelligent weight scale|Subjects will use the limited function diet management application and an intelligent weight scale with limited function designed for obese heart failure patients as a comparator.
47996373|NCT02090127|DRUG|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
47996374|NCT06370273|DRUG|Rivaroxaban|10mg once daily via oral ingestion
47996375|NCT06370273|DRUG|Apixaban|2.5mg twice daily via oral ingestion
48512123|NCT02290223|BEHAVIORAL|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
48682449|NCT00533130|PROCEDURE|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
48682450|NCT00533130|PROCEDURE|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
48682451|NCT06377384|OTHER|FLIGHT Intervention|Personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care.
48682452|NCT00095472|DRUG|L-NMMA|
48682453|NCT00095472|DRUG|Sodium Nitrite|
48682454|NCT06184685|DRUG|Sahasthara Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
47996376|NCT06370273|DRUG|Enoxaparin Injectable Solution|40mg once daily via subcutaneous injection
47996377|NCT06370273|DRUG|Tinzaparin Injectable Solution|4500 IU once daily via subcutaneous injection
47996378|NCT06370273|DRUG|Dalteparin Injectable Solution|5000 IU once daily via subcutaneous injection
47996379|NCT06370273|DRUG|Fondaparinux Injectable Product|2.5 mg once daily via subcutaneous injection
47996380|NCT05877092|DEVICE|implants with overdentures|two implants with bar attachment placed in interforaminal of the mandible mandible of the participants, the patients were delivered conventional upper complete denture constructed from heat cured acrylic rein, but in implanted mandibular arch they were received complete overdenture constructed from heat cured acrylic resin for Group I, and complete thermoplastic denture was constructed for Group II.
48512124|NCT03016975|DEVICE|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
48512125|NCT03016975|DRUG|Guideline Directed Medical Therapy|GDMT Only
48512126|NCT00898287|DRUG|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
48512127|NCT00898287|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
48682455|NCT06184685|DRUG|Diclofenac Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
47996381|NCT05344898|PROCEDURE|Subscap Tenotomy|Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.
47996382|NCT05344898|PROCEDURE|Subscap Repair|Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
48155387|NCT02794441|OTHER|Placebo|Matched oral solution
48155388|NCT01358175|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
48682456|NCT03920501|BEHAVIORAL|Tele-Critical Care|Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
47996383|NCT03864315|DEVICE|HGM|To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
48512128|NCT01890434|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
48682457|NCT06073080|OTHER|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
48682458|NCT04439864|DEVICE|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
48682459|NCT05399927|OTHER|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
48682460|NCT02685826|DRUG|Durvalumab|single use vials administered via intravenous infusion
48682461|NCT02685826|DRUG|Lenalidomide|capsules for oral administration
47996384|NCT05486221|OTHER|Extensive cardiologic work-up|Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
47996385|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
48682462|NCT02685826|DRUG|Dexamethasone|tablets for oral administration
48682463|NCT04483258|PROCEDURE|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
48682464|NCT04483258|PROCEDURE|intravenous sedation|midazolam +ketamine + atropine
48682465|NCT02027727|OTHER|No Intervention|no intervention- tihs is an observational study
47996386|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
47996387|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
47996388|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
47996389|NCT03805022|DRUG|At the discretion of the investigator|Drug at the discretion of the investigator.
47996390|NCT05316012|DEVICE|Smart diapers|"Residents receive standard continence care while using the smart diaper (without the alerting system) - fase 1~Diapers are changed as usual, e.g., after morning care, visual soiling, unpleasant odor, saturation, leakage.~Residents receive continence care while using the smart diaper with the alerting system - fase 2"
47996391|NCT04738916|DEVICE|Whole-body vibration training|Whole body vibration (WBV) is a form of treatment that has been shown to have an important role in increasing neuromuscular performance, improving muscular strength, balance. The technique involves standing and holding positions, or performing prescribed exercises, on a platform that is vibrating at a programmed frequency, amplitude, and magnitude of oscillationWhole-body vibration (WBV) is a therapeutic method that exposes the entire body to mechanical oscillations while the patient stands or sits on a vibrating platform.
48155389|NCT01358175|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
48155390|NCT01358175|DRUG|Placebo|Placebo
48682466|NCT02980107|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
48682467|NCT02980107|OTHER|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
48682468|NCT03503396|BEHAVIORAL|BAC Driving Feedback/Warning|Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
48682469|NCT03503396|BEHAVIORAL|No Feedback|Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
48682470|NCT02688270|DRUG|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
48682471|NCT02688270|DRUG|Vehicle Cream (placebo)|Vehicle administered topically
48682472|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
48682473|NCT00673231|DRUG|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
47996392|NCT05930730|BIOLOGICAL|Comvigen (Bivalent, ChulaCov19 BNA159.2)|single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
48365610|NCT05963581|BEHAVIORAL|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
48365611|NCT04691518|OTHER|Acute Intermittent Hypoxia|30 minute session of Acute Intermittent Hypoxia
47996393|NCT05930730|BIOLOGICAL|BIVALENT Pfizer/BNT vaccine|single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine
48365612|NCT04691518|OTHER|Sham Acute Intermittent Hypoxia|30 minute session of Sham Acute Intermittent Hypoxia
48365613|NCT03808194|OTHER|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
47996394|NCT06284785|PROCEDURE|Bariatric surgery|Patients included in our obese patient group are all scheduled to undergo bariatric surgery
47996395|NCT00102700|DRUG|ARQ 501 in combination with gemcitabine|
47996396|NCT04355000|PROCEDURE|Hall technique|SS Crown will be cemented on primary carious molar which satisfy the inclusion criterion without any carious removal, without any tooth preperation, without any local anaesthesia.
48365614|NCT03808194|OTHER|Optimized ART linkage package|Optimized ART linkage package
47996397|NCT04355000|PROCEDURE|RMGIC restoration|Complete removal of caries and filling will be done with RMGIC material
48365615|NCT04153799|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6 / kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
48365616|NCT00508118|DRUG|Nicardipine|on bypass
48365617|NCT00508118|DRUG|0.9% saline|on bypass
48365618|NCT01310426|OTHER|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
48365619|NCT02118272|DEVICE|Physica KR|
48365620|NCT04797572|DEVICE|Free Margin Cusp Sizer|The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
48365621|NCT03486067|DRUG|CC-93269|Specified dose on specified days
48512129|NCT04493567|DRUG|BMS-986036|Specified dose on specified days
48512130|NCT01721317|DRUG|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
48512131|NCT01721317|DRUG|Placebo|Matching placebo will be available
48682474|NCT00673231|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
48682475|NCT00673231|DRUG|Placebo|Placebo
48682476|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
47996398|NCT05398679|DRUG|Cefaclor|cefaclor intravenous 2 gr/day
47996399|NCT05398679|DRUG|Ciprofloxacin Tablets|500-750 mg/12 hrs (maximum 3g x day)
48365622|NCT05891457|COMBINATION_PRODUCT|Nutritional Intervention|"* Severe acute malnourished children were provided with appropriate nutritional therapy/treatment that include supplementation of a high-calorie diet; i.e., F-100 milk and khichuri-halwa for nutritional rehabilitation.~* Egg milk and micronutrient supplementation for recovery from severe stunting following standard guidelines for facility based management and recently conducted community based nutrition intervention studies.~* Wasted children were treated with suitable local nutritional management (NM), such as infant and young child feeding practices (IYCF), providing MNP and nutrition education."
48365623|NCT03884868|OTHER|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
48512132|NCT03254498|DEVICE|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
48682477|NCT00673231|DRUG|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
48682478|NCT00432068|DRUG|Octreotide pamoate|
48682479|NCT04951375|PROCEDURE|arthroscopic repair|arthroscopic repair
48682480|NCT05253742|OTHER|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
48682481|NCT05657535|DEVICE|Low-intensity continuous ultrasound stimulator|Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
48365624|NCT04218942|DEVICE|Exime is the name of the single use temporary prostatic stent used instead of the Foley catheter|"Insertion after instillation of a local lubricant anesthetic gel in the urethra like for Foley insertion. Calibration of the urethral meatus with a 22F Bougie. Insertion of the Bougie until abutment against the posterior wall of the bulbous urethra just below the striated sphincter. Note depth of abutment on the scale of the Bougie. Retrieve the Bougie and glide the device to the same depth until abutment against the posterior wall of the bulbous urethra. At this stage the stent is correctly positioned. Stent release: unlock the Luer connection between pusher tube and stylet . Retrieve pusher tube, stylet and flattener tube.~Control of correct positioning: ask patient to stand up to verify the absence of any urine leak. Ask patient to void immediately to control clear urine output."
48512133|NCT03254498|DEVICE|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
48512134|NCT00706862|DRUG|Talactoferrin|Oral, 1.5 grams twice per day
48682482|NCT05340673|DRUG|Agent Affecting Integumentary System|Apply Miaderm
48682483|NCT05340673|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Apply to skin
48155391|NCT00829517|OTHER|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
48365625|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
48365626|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
48512135|NCT00706862|DRUG|Placebo|Oral, twice per day
48682484|NCT05340673|OTHER|Quality-of-Life Assessment|Ancillary studies
48682485|NCT05340673|OTHER|Questionnaire Administration|Ancillary studies
48682486|NCT00257946|PROCEDURE|Repair of CDH w/SIS Gold|
48682487|NCT00257946|PROCEDURE|Repair of CDH w/Alloderm|
48682488|NCT06395116|OTHER|Denture base material|Denture base material constructed with different techniques for completely edentulous populations
48682489|NCT05130970|DRUG|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
48682490|NCT05130970|DRUG|Placebo|Same as the CSL312 formulation buffer
48682491|NCT01594840|DEVICE|Changing chat|Diapers with tips
47996400|NCT05398679|DRUG|Ciprofloxacin Injection|1200 mg/day maximum dose IV
47996401|NCT05398679|DRUG|Clindamycin Oral Capsule|600 mg/8 hours (maximum 1.800 mg x day)
47996402|NCT05398679|DRUG|Clindamycin Injection|600 mg/8 hours (maximum 1.800 mg x day) IV
48365627|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
48682492|NCT05072054|DRUG|Atorvastatin Oral Tablet|Atorvastatin 40 mg
48682493|NCT05072054|DRUG|Rosuvastatin Oral Tablet|Rosuvastatin 20 mg
48682494|NCT02565693|DRUG|Apixaban|
48682495|NCT02565693|DRUG|Aspirin|
48682496|NCT02565693|DRUG|Carbasalate calcium|
48682497|NCT02565693|DRUG|Clopidogrel|
48682498|NCT02565693|DRUG|Dipyridamole|
48682499|NCT02565693|OTHER|No antithrombotic treatment|
48682500|NCT01352208|DRUG|ASP9521|oral
48682501|NCT03890900|OTHER|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
48155392|NCT00829517|OTHER|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
48365628|NCT02055976|DRUG|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
48365629|NCT02055976|DRUG|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
48365630|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
48365631|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
48365632|NCT02055976|DRUG|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
48682502|NCT00403013|PROCEDURE|Positioning and anesthesia|Positioning during axillary plexus block
47996403|NCT05398679|DRUG|Dicloxacillin Oral Capsule|1g/8 hours (maximum 4 gr day)
47996404|NCT05398679|DRUG|Dicloxacillin|1g/8 hours (maximum 4 g x day) IV
47996405|NCT05398679|DRUG|Fusidic Acid Only Product in Oral Dose Form|0,750g/12 hours (maximum 1,5 g x day)
48365633|NCT02055976|DRUG|Placebo|Placebo Q14D SC for 16 week
48365634|NCT00792922|DRUG|Azithromycin|Comparison of community coverage rate
48365635|NCT00792922|DRUG|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
48365636|NCT01028599|OTHER|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
48365637|NCT03708042|COMBINATION_PRODUCT|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
48682503|NCT03902392|DIETARY_SUPPLEMENT|NaturOx Group (A)|Comparison between dietary supplement and placebo
48682504|NCT03902392|OTHER|Placebo Group (B)|Comparison between dietary supplement and placebo
48682505|NCT06553105|DIAGNOSTIC_TEST|ct scan|use ct scan for diagnosis fistula
48682506|NCT06286449|OTHER|Spinal tap|A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
48682507|NCT00440492|DRUG|PLA-695|
48682508|NCT00483678|OTHER|counseling intervention|
48682509|NCT00483678|OTHER|questionnaire administration|
48682510|NCT00483678|PROCEDURE|psychosocial assessment and care|
48682511|NCT06120686|OTHER|Biofeedback method|Study group - implementing a conventional therapy program supplemented additionally with visual and auditory biofeedback training on a dynamic balance platform
48682512|NCT06120686|OTHER|Conventional therapy program|Control group - rehabilitation management aimed at improving cognitive and motor functions in children with mild intellectual disabilities.
48682513|NCT03552107|DRUG|Lorcaserin|Treatment initiation with Lorcaserin
48682514|NCT04454346|DEVICE|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
48682515|NCT03765580|DIETARY_SUPPLEMENT|Fish|Lunch containing fish
48682516|NCT03765580|OTHER|Control|Lunch containing no fish
47996406|NCT05398679|DRUG|Fusidic Acid Only Product in Parenteral Dose Form|0,75 g/12 hours (maximum 1,5 g x day)
48365638|NCT03708042|COMBINATION_PRODUCT|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
48365639|NCT03919032|OTHER|This is an observational study without intervention|This is an observational study without intervention
48365640|NCT02489994|DEVICE|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
47996407|NCT05398679|DRUG|Levofloxacin Oral Tablet|0.5g/12-24hours (maximum 1 g x day)
47996408|NCT05398679|DRUG|Levofloxacin Injection|0.5g/12-24hours (maximum 1 g x day)
48365641|NCT06077409|OTHER|Skin To Skin|"Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure."
48365642|NCT06077409|BEHAVIORAL|Gentle Human Touch|Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
48365643|NCT00051246|BEHAVIORAL|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
48365644|NCT00051246|BEHAVIORAL|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
48365645|NCT02911324|DRUG|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
48365646|NCT02911324|BEHAVIORAL|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
48365647|NCT02361372|OTHER|Placebo|Placebo daily for 6 months
48682517|NCT04380909|BEHAVIORAL|Internet-based self-help|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
47996409|NCT05398679|DRUG|Linezolid Oral Tablet|0,6 g/12 hours (maximum 1200 mg x day)
47996410|NCT05398679|DRUG|Linezolid Injectable Product|0,6 g/12 hours (maximum 1200 mg x day)
47996411|NCT05398679|DRUG|Moxifloxacin tablet|0,4 g/day (maximum 400 mg x day)
47996412|NCT05398679|DRUG|Moxifloxacin Injectable Product|0,4 g/day (maximum 400 mg x day)
48512136|NCT02376673|OTHER|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
48512137|NCT02376673|OTHER|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
48682518|NCT04380909|BEHAVIORAL|Internet-based self-help after 3 weeks|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
48682519|NCT01559545|DRUG|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
47996413|NCT05398679|DRUG|Rifampicin Only Product in Oral Dose Form|0,3-0,5 g/12 hours (maximum 1200 mg x day)
48365648|NCT02361372|OTHER|CaCO3|CaCO3 daily for 6 months
48365649|NCT02361372|OTHER|Kefir|Kefir daily for 6 months
48512138|NCT03893643|OTHER|no intervention|no intervention in an observational study
48682520|NCT01559545|DRUG|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
47996414|NCT05398679|DRUG|Rifampicin Only Product in Parenteral Dose Form|0,3-0,6 g/12 hours (maximum 1200 mg x day)
47996415|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
47996416|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Injectable Product|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
47996417|NCT05398679|DRUG|Tedizolid Oral Tablet|200 mg tedizolid (maximum x day)
47996418|NCT05398679|DRUG|Tedizolid Injection|200 mg (maximum x day)
47996419|NCT05398679|DRUG|Amoxicillin Capsules|1 gr/6 hours (4 g x day)
47996420|NCT05398679|DRUG|Amoxicillin|1 gr/6 hours (4 g x day) Intravenous
47996421|NCT05398679|DRUG|Cefaclor Capsules|2 gr/day
47996422|NCT04226066|BIOLOGICAL|T601|"Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
47996423|NCT04226066|COMBINATION_PRODUCT|T601+5-FC|"Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1."
47996424|NCT03569332|OTHER|Alarm|"1. Alarm is provided from 9am to 9pm.~2. Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied."
48365650|NCT03859115|PROCEDURE|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
48365651|NCT03859115|PROCEDURE|sham intervention|sham stimulation without electrical pulse generation
48365652|NCT00232531|DRUG|Niaspan|
47996425|NCT03569332|OTHER|Nurse's dashboard|"1. Wireless data transmission system~2. The practicing rate of participants on study group is sent to Nurse's Dashboard.~3. It is only to display."
47996426|NCT03821493|DRUG|PF-06651600 10 mg tablets|"On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole."
47996427|NCT03821493|DRUG|Itraconazole Solution 200 mg|"Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets."
47996428|NCT05836064|DEVICE|GastroBot|An artificial intelligence-developed and WhatsApp-based software bot. It will send the instructions to the patient through the WhatsApp application, guided by the software bot with multiple and personalized alternative instructions according to results.
47996429|NCT05836064|OTHER|Conventional explanation|Patients will receive in writing detailed explanation about bowel preparation with polyethylene glycol
48682521|NCT01559545|DRUG|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
48155393|NCT01211717|DIETARY_SUPPLEMENT|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
48155394|NCT01211717|OTHER|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
47996430|NCT03329690|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
47996431|NCT03329690|DRUG|Physician's Choice|"Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)"
47996432|NCT02220244|DRUG|MD1003 100mg capsule|
47996433|NCT01428180|DRUG|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
47996434|NCT01428180|PROCEDURE|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
47996435|NCT01428180|DRUG|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
47996436|NCT00921180|DRUG|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
47996437|NCT00921180|DRUG|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
47996438|NCT06190431|OTHER|Learning the use of an in-exsufflation device with the guidance of a physiotherapist|Learning to use an in-exsufflation device with the guidance of a physiotherapist
47996439|NCT06190431|OTHER|Using the coaching mode|Learning the use of an in-exsufflation device using a coaching mode (playful visual stimulation) in addition to guidance of a physiotherapist
48365653|NCT05135637|OTHER|Mobile health services|Mobile health services (MHS) will be deployed with one team per UC. MHS will focus on underserved areas to provide basic health services, immunization, \& health and nutrition counseling for under-five children \& WRAs.
48365654|NCT05135637|OTHER|Private practitioner engagement for immunization|Private healthcare providers (HCPs) will be taken on board to increase coverage of immunization. HCPs will offer routine vaccination to all under-five children visiting their clinics. Project team will liaison with EPI to arrange vaccines for them.
48365655|NCT05135637|OTHER|Community engagement and mobilization|Community engagement \& mobilization will focus on immunization, breastfeeding practices, \& optimal care-seeking for both pregnant women and young children. Opinion leaders will be engaged to gain support for activities.
47996440|NCT06537349|DRUG|3% Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye
47996441|NCT06302192|DIAGNOSTIC_TEST|ARDS+AKI|according to the clinical practice Reanl doppler and VeXUS score will be performed
48365656|NCT05135637|OTHER|Sehat Nishani - a health, nutrition and immunization app|Sehat Nishani App will be launched to assess feasibility of a health, \& immunization app to capture information on birth, nutrition, immunization \& growth records. Lady health workers (LHWs), lady health visitors (LHVs) in government health facilities, EPI vaccinators \& HCPs will be engaged to use app.
48365657|NCT05867849|DRUG|Cannabidiol|Cannabinoid
48365658|NCT05867849|OTHER|Placebo|Inactive substance
48512139|NCT02064517|DEVICE|MTA|Creation of a barrier apicale in the MTA
48512140|NCT02064517|DEVICE|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
47996444|NCT02912234|DRUG|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
47996445|NCT02912234|DRUG|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
47996446|NCT00729027|DRUG|25 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
47996447|NCT00729027|DRUG|50 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
47996448|NCT00729027|DRUG|placebo|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
47996449|NCT03404479|DRUG|Diacerein|For 12 weeks, administered twice a day by oral.
47996450|NCT03404479|DRUG|Celecoxib|For 12 weeks, administered twice a day by oral.
47996451|NCT04546347|RADIATION|[14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)|Dose of \[14C\]AZD9833 Solution for Infusion
47996452|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 1|Dose 1 AZD9833 film-coated tablet A Dose 1
47996453|NCT04546347|DRUG|AZD9833 Oral Solution|AZD9833 Oral Solution
47996454|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 1|AZD9833 film-coated tablet B Dose 1
47996455|NCT04546347|DRUG|AZD9833 film-coated tablet A Dose 2|Dose 1 of AZD9833 film-coated tablet A Dose 2
47996456|NCT04546347|DRUG|AZD9833 film-coated tablet B Dose 2|Dose 1 of film-coated tablet B Dose 2
47996457|NCT03465332|OTHER|Doctor's questionnaire|The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
47996458|NCT03465332|OTHER|Subject file|All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
47996459|NCT04653779|DRUG|Evogliptin 5mg/Metformin 1000mg|Size reduction of a tablet formulation
47996460|NCT03830060|DIAGNOSTIC_TEST|Measurement of cortisol|Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
47996461|NCT00912314|PROCEDURE|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
47996462|NCT05983770|DRUG|AT-1501|IV infusions of AT-1501 20 mg/kg over 1 hour.
48365659|NCT04415931|PROCEDURE|Local infiltration analgesia|"Local infiltration injection intraoperatively prior to closing during the procedure. A standardized dose of 100 mL of infiltration will be utilized according to the following formula. The mixture will be injected into the deltoid and pectoralis major muscles and fasciae, and subcutaneous tissues using an 18-guage needle.~Total dose 100mL~Ropivacaine 0.5% 40mL Epinephrine 1mg/mL 0.1mL Ketorolac 30mg/mL 1mL Morphine 10mg/mL 0.5mL Normal saline 0.9% 58.4mL"
48365660|NCT04415931|PROCEDURE|Interscalene block|Standard interscalene brachial plexus regional block
48365661|NCT03145207|DRUG|Lidocaine patch|lidocaine patch
48365662|NCT02911285|DRUG|N-acetylcysteine|1200mg bid (2400mg/day)
48365663|NCT02911285|DRUG|Placebo|Placebo pills bid
48365664|NCT02911285|BEHAVIORAL|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
48365665|NCT00516217|BIOLOGICAL|galiximab|
47996463|NCT05983770|DRUG|Tacrolimus|Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.
47996464|NCT03574740|OTHER|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
47996465|NCT05567055|DRUG|Capmatinib|Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR
47996466|NCT02246673|DRUG|RDEA3170 15 mg|
47996467|NCT02246673|DRUG|RDEA3170 10 mg|
47996468|NCT02246673|DRUG|RDEA3170 2.5|
47996469|NCT02246673|DRUG|RDEA3170 5 mg|
47996470|NCT02246673|DRUG|Febuxostat 40 mg|
47996471|NCT02246673|DRUG|Febuxostat 80 mg|
47996472|NCT00188513|PROCEDURE|conformal intensity modulated radiotherapy (IMRT)|
47996473|NCT04094922|BEHAVIORAL|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
47996474|NCT05546931|BEHAVIORAL|Coaching application|A digital application for providing education and support for home-based blood pressure monitoring.
47996475|NCT05546931|OTHER|WebMD|Smartphone-based application for health education and/or monitoring.
47996476|NCT05546931|BEHAVIORAL|Home-based blood pressure monitoring|Device for measuring blood pressure at home with blue tooth connectivity for automated collection.
47996477|NCT00204854|BEHAVIORAL|telephone counseling|
47996478|NCT04540289|DRUG|Optimal Medical Therapy (OMT)|"Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure"
47996479|NCT04540289|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
47996480|NCT00994955|DEVICE|selective retina therapy (SRT)|laser treatment
47996481|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 1|Containing macro and micronutrients
47996482|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 2|Containing macro and micronutrients
47996483|NCT02051777|DIETARY_SUPPLEMENT|Dietary Advice|
48512141|NCT04143243|BEHAVIORAL|ACT on Life|1 day group workshop of ACT plus ERS
48512142|NCT04143243|BEHAVIORAL|Education, Resources, and Support|1 day group workshop of Education, Resources, and Support
48682522|NCT03773900|DIETARY_SUPPLEMENT|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
48682523|NCT03773900|DIETARY_SUPPLEMENT|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
48682524|NCT05582512|OTHER|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
47996484|NCT01077947|PROCEDURE|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
47996485|NCT01077947|PROCEDURE|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
47996486|NCT02486380|DEVICE|Toffee full face mask/toffee nasal mask|Toffee full face mask/toffee nasal mask
47996487|NCT02599155|DRUG|Crystalloid|normal saline administration for volume expansion in hypovolemic status
47996488|NCT02599155|DRUG|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
47996489|NCT01707953|DRUG|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
47996490|NCT01707953|DRUG|Placebo|Placebo capsule to mimic midodrine
47996491|NCT04458753|OTHER|Lumbar focused exercises|Transersus abdominis activation Multifidus activation Back extension exercise Curl up abdominal exercise
47996492|NCT04458753|OTHER|Knee focused exercises|Strengthening of quadriceps Stretching of calf and Hamstring muscles
48682525|NCT04399200|DEVICE|Treatment according to standard care recommandation|SDB treatment according to standard care recommandation: Continuous Positive Airway Pressure (CPAP), Mandibular Advancement Device, Positionnal Therapy, Adaptive Servo-Ventilation (ASV), Non-Invasive Ventilation (NIV)
48682526|NCT03369665|DRUG|Mavenclad®|Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
47996493|NCT03527199|DIAGNOSTIC_TEST|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
47996494|NCT00644293|DRUG|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
47996495|NCT00644293|DRUG|placebo|placebo
47996496|NCT00644293|DRUG|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
47996497|NCT00644293|DRUG|placebo|placebo
47996498|NCT01642017|DRUG|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
47996499|NCT00895258|BEHAVIORAL|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
47996500|NCT00895258|BEHAVIORAL|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
47996501|NCT00704028|DRUG|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
47996502|NCT00704028|DRUG|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
47996503|NCT05409781|OTHER|No Intervention|No Intervention
47996504|NCT04894396|DEVICE|Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
48682527|NCT01303952|DRUG|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
48682528|NCT03894696|DRUG|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
48682529|NCT01871545|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
47996505|NCT04894396|DEVICE|Aetrex L2300 Premium Memory Foam Orthotics|An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
48155395|NCT06274632|BEHAVIORAL|ADELANTE|A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
48155396|NCT04121949|DEVICE|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
47996506|NCT04709328|DRUG|SCTA01|Diluted by 0.9% normal saline，IV
47996507|NCT04709328|OTHER|Placebo|IV
47996508|NCT03493984|OTHER|Ginger exosomes|Naturally occurring plant exosomes from ginger
48365666|NCT04135599|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
48365667|NCT04818034|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
48682530|NCT04755764|DRUG|Labetalol|Beta blocker
48155397|NCT01350102|DRUG|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
48682531|NCT04755764|DRUG|Atenolol|Beta blocker
48682532|NCT04755764|DRUG|Nifedipine|Calcium channel blocker
48682533|NCT02137642|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
48682534|NCT02137642|DRUG|Placebo|Double blind placebo will be delivered once by injection during study procedure.
47996509|NCT03493984|OTHER|Aloe exosomes|Naturally occurring plant exosomes from aloe
47996510|NCT03493984|OTHER|Placebo|Exosome placebo tablet
48682535|NCT01569737|DRUG|ella|ella, single intake, tablet 30mg
48682536|NCT06011317|DRUG|EDG-7500|EDG-7500 is administered orally once daily
48682537|NCT06011317|DRUG|Placebo|Placebo is administered orally once daily
48682538|NCT01313910|DIETARY_SUPPLEMENT|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
48682539|NCT02508363|BEHAVIORAL|questionnaires|
48682540|NCT04470882|BEHAVIORAL|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
48682541|NCT04470882|BEHAVIORAL|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
48682542|NCT04470882|BEHAVIORAL|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
47996511|NCT02009631|DRUG|Veliparib (ABT-888)|
47996512|NCT02009631|DRUG|Placebo|
47996513|NCT04000048|GENETIC|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
47996514|NCT01830439|DRUG|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
47996515|NCT01830439|DRUG|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
48155398|NCT01350102|DRUG|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
48155399|NCT01350102|DIETARY_SUPPLEMENT|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
48155400|NCT02338310|DRUG|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
48155401|NCT01614899|DRUG|SM-13496 40mg|once daily orally
48682543|NCT00311025|PROCEDURE|intensive endurance, strength and balance exercises|
48155402|NCT01614899|DRUG|SM-13496 80mg|once daily orally
48155403|NCT01614899|DRUG|Placebo|once daily orally
48155404|NCT03628612|BIOLOGICAL|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
48512143|NCT05566184|DEVICE|Modified pacifier|In the experimental group, a modified pacifier will be given to the child during the procedure, and the data will be collected. In the application of vascular access to children, a) before the procedure (20 minutes before), b) just before the procedure (20. minutes), c) during the procedure (between 20.-40. minutes), and d) 20 minutes after the procedure (40. minutes). Physiological variables that will be evaluated four times, once for each application, will be observed on the monitor, the FLACC Pain Assessment Scale will be recorded by the researcher and salivary cortisol level will be measured.
48682544|NCT04181229|PROCEDURE|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
48682545|NCT06104007|DEVICE|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
48682546|NCT05605730|OTHER|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
48682547|NCT05605730|OTHER|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
48682548|NCT05605730|OTHER|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
48682549|NCT03633955|DRUG|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
48682550|NCT04522050|DRUG|Gemcitabine combined with cisplatin induction chemotherapy|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
48155405|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
48155406|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
48155407|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
48155408|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
48155409|NCT00729508|BIOLOGICAL|Cat-PAD|Placebo
48155410|NCT01265914|BIOLOGICAL|FP-01.1|Ascending doses of FP-01.1 will be administered
48155411|NCT01265914|BIOLOGICAL|placebo|
48155412|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
48155413|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly placebo plus 800 calcium alone
48155414|NCT05270889|DRUG|Tislelizumab+Zanidatamab|"Zanidatamab will be administered at a flat dose as follows:~* Subjects with body weight \<70 kg: 1800 mg IV on Day 1 of each 21-day cycle~* Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle."
48155415|NCT04890158|OTHER|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
48155416|NCT01810406|PROCEDURE|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
48155417|NCT01810406|PROCEDURE|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
48512144|NCT02104115|OTHER|MRI scanners|
48512145|NCT02104115|OTHER|VAS Symptom scores|
47996516|NCT06053294|OTHER|CS- Beverage|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
47996517|NCT06053294|OTHER|CS+Fast|(CS+): Flavored beverage solution with 110 calories of sucrose. Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
47996518|NCT06053294|OTHER|CS+Slow|(CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
47996519|NCT00296933|DRUG|Escitalopram|
47996520|NCT00296933|DRUG|Bupropion XL|
48365668|NCT01976494|DEVICE|The domestic PCA equipment 'Accufuser Omnibus®'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
47996521|NCT02784990|BIOLOGICAL|Lipase, amylase and CRP (C-reactive protein) dosages|
47996522|NCT05552872|DIAGNOSTIC_TEST|mNGS, IDSeq UltraTM|pathogen detection
47996523|NCT05847530|DEVICE|Potenza|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
47996524|NCT05847530|DEVICE|Icon|Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
47996525|NCT01533454|OTHER|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
47996526|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
47996527|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
48512146|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
48682551|NCT04522050|DRUG|concurrent chemoradiotherapy with gemcitabine|followed by concurrent gemcitabine chemoradiotherapy
48682552|NCT04616170|OTHER|Hip extension|Hips extended at the time of vaginal delivery
48682553|NCT04616170|OTHER|Usual Care|"Hips positioned in the usual care position per provider preference at the time of vaginal delivery"
48682554|NCT05703425|DRUG|Sulfasalazine|Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
48682555|NCT01266226|DEVICE|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
48682556|NCT01266226|DEVICE|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
48682557|NCT05836558|PROCEDURE|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
48682558|NCT01553292|DEVICE|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
48682559|NCT01553292|DEVICE|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
48682560|NCT04464811|DIAGNOSTIC_TEST|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
48682561|NCT06497751|BEHAVIORAL|Couple-based Dyadic Coping Group|"Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization."
47996528|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
47996529|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
47996530|NCT00798369|DRUG|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
48365669|NCT01976494|DEVICE|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"* Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
48682562|NCT03495141|BEHAVIORAL|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
48682563|NCT01882712|DRUG|CD07805/47 Gel 0.5%|
48682564|NCT01882712|DRUG|CD07805/47 Gel Placebo|
48682565|NCT05879731|OTHER|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained \<50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
48682566|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
48682567|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
48682568|NCT05508178|DRUG|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
47996531|NCT00798369|DRUG|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
47996532|NCT00843921|DRUG|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
47996533|NCT00142870|DRUG|Bupropion|150 mg, twice a day
48682569|NCT05934110|DRUG|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
47996534|NCT05577676|DRUG|Ultrasound-guided Hydrodissection of the Median Nerve|Hydrodissection for CTS includes injecting fluid around the median nerve (MN) with 5 ml volume, 3 ml of which is given in between the transverse carpal ligament \& MN, and 2 ml below the MN under Ultrasound guidance in-plane ulnar approach.
48365670|NCT00887601|DRUG|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
48365671|NCT00887601|DRUG|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
47996535|NCT00352521|DRUG|bevacizumab|
47996536|NCT00352521|DRUG|irinotecan|
47996537|NCT00352521|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
48682570|NCT05934110|DRUG|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
48682571|NCT05934110|DRUG|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
48155418|NCT04466293|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach. This will be adapted to the country context and may include a pre-printed prescription pad (Mozambique), adaptations in clinical stationary (Zimbabwe), or adaptations to an electronic prescribing system (Malawi).~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
48365672|NCT00887601|DRUG|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
47996538|NCT03878914|DRUG|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
48365673|NCT00887601|DRUG|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
48365674|NCT01005355|BIOLOGICAL|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
48365675|NCT02546739|BIOLOGICAL|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
48365676|NCT03467035|OTHER|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
48365677|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
48682572|NCT05934110|DRUG|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
48682573|NCT05934110|DRUG|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
47996539|NCT02093598|DRUG|Temsirolimus|
47996540|NCT01073852|DRUG|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
47996541|NCT01073852|DRUG|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
47996542|NCT03762382|DRUG|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
47996543|NCT03762382|DRUG|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
47996544|NCT03762382|DRUG|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
48155419|NCT03962270|DEVICE|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
47996545|NCT06386835|PROCEDURE|Collagen Paste|Collagen paste injection
47996546|NCT06386835|PROCEDURE|Mucosal advancement|Mucosal advancement flap
47996547|NCT03390881|OTHER|Fasting condition|Subjects will fast over the whole experimental period (480 min)
47996548|NCT03390881|OTHER|Sugar condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
47996549|NCT03390881|OTHER|Fat condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
48682574|NCT02158767|BIOLOGICAL|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
48365678|NCT05608122|OTHER|Obervation|This study is an observational study without any intervention
48682575|NCT02709577|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
48682576|NCT02709577|OTHER|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
48682577|NCT04774068|DRUG|Parsaclisib|Given PO
48682578|NCT04774068|DRUG|Romidepsin|Given IV
48682579|NCT06470620|DIAGNOSTIC_TEST|pelvic floor muscle assessment|no intervention will be performed - several diagnostic assessments tools
48682580|NCT03691298|DEVICE|Suturefix Ultra and Suturefix Curved Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone to stabilize hip
47996550|NCT04888546|DRUG|Anlotinib hydrochloride capsules＋ TQB2450 injection|"Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
47996551|NCT04922203|OTHER|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
47996552|NCT02602587|BIOLOGICAL|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
47996553|NCT02602587|BIOLOGICAL|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
47996554|NCT02023450|DRUG|saquinavir and ritonavir|micro and low dose
47996555|NCT02023450|DRUG|saquinavir and ritonavir|standard dose
47996556|NCT06252220|DRUG|DA-1726|Active
47996557|NCT06252220|DRUG|Placebo to DA-1726|Placebo
47996558|NCT05640570|DRUG|The individualized Jade Wind-Barrier Herbal Tea Bag|The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
47996559|NCT00000644|DRUG|Clarithromycin|
47996560|NCT03343483|BEHAVIORAL|Volunteering|"Volunteers provide non-medical caregiving for frail seniors-care receivers-to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided. Participants not interested in serving as peer companions are allowed other volunteer options as long as the activities are deemed 'social' by the volunteer coordinator and are options routinely provided as part of the AmeriCorps Senior RSVP Program. COVID update: due to physical distancing requirements, volunteer placements have transitioned to remote friendly calling/letter writing or activities that can be conducted with physical distancing, such as delivery for Meals on Wheels."
47996561|NCT03343483|BEHAVIORAL|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
47996562|NCT04390594|DRUG|Nafamostat Mesilate|"Nafamostat mesilate continuous intravenous injection. Daily dose ranging between 0.1 mg/kg/h and 0.2 mg/kg/h, based on the severity and underlying disease of the clinical trial participant.~Administration for 10-14 days based on the severity and underlying disease of the clinical trial participant"
47996563|NCT03790527|PROCEDURE|CBM training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
48155420|NCT00582192|OTHER|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
48365679|NCT01681004|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
48365680|NCT01681004|OTHER|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
48682581|NCT04023383|DRUG|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
48682582|NCT04023383|DRUG|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
48155421|NCT03052478|DRUG|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
48155422|NCT00370188|DRUG|Topiramate|
48365681|NCT02164890|OTHER|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
48512147|NCT00760734|DRUG|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
48512148|NCT00596076|BEHAVIORAL|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
48512149|NCT06038162|PROCEDURE|Parallel connection|The RRT machine is connected on a separate vascular access (dialysis catheter).
48512150|NCT06038162|PROCEDURE|Integrated connection|A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
48682583|NCT01492426|DRUG|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
48682584|NCT01492426|DRUG|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
48682585|NCT01492426|DRUG|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
48155423|NCT05685251|OTHER|Health Coaching|Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.
48155424|NCT05685251|OTHER|Home Blood Pressure Monitoring|Participants will be provided an A\&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
48682586|NCT01492426|DRUG|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
48682587|NCT01136525|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
48682588|NCT04901806|DRUG|PBI-200|PBI-200 will be administered orally over continuous 28-day cycles
48682589|NCT03409952|DEVICE|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
48682590|NCT03409952|DEVICE|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
48512151|NCT04613492|BIOLOGICAL|MEDI9253|Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab
48155425|NCT06037057|OTHER|no intervention name|no intervention description
48155426|NCT04503889|DEVICE|Transauricular electrical vagal nerve stimulation|transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
48155427|NCT04503889|DEVICE|taVNS sham|ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
48512152|NCT04613492|BIOLOGICAL|Durvalumab|Durvalumab treatment will be started sequentially or concurrently with MEDI9253
48512153|NCT01165528|PROCEDURE|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
48155428|NCT05407844|OTHER|Community Health Worker (CHW) based palliative care|Those in the intervention group will receive support from a dedicated CHW trained in motivational interviewing, components of palliative care communication, and social determinants of health.
48512154|NCT02423629|DEVICE|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
48512155|NCT04322058|OTHER|The Dads' Club|The core intervention is Core 24/7 workshop attendance
48512156|NCT03146429|DIAGNOSTIC_TEST|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
48512157|NCT02175901|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
48512158|NCT02175901|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
48682591|NCT03233139|DRUG|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
47996564|NCT03790527|PROCEDURE|Sham training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
47996565|NCT04087187|DRUG|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
47996566|NCT04087187|DRUG|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
47996567|NCT04087187|DRUG|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
48682592|NCT03233139|DRUG|Ipilimumab|To be administered per protocol
48682593|NCT03233139|DRUG|Platinum-doublet chemotherapy|To be administered per protocol
47996568|NCT02939560|DEVICE|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
47996569|NCT00984243|PROCEDURE|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm\^2 Excimer-dye laser: 100-200 Joules/cm\^2"
48155429|NCT03044951|PROCEDURE|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
48155430|NCT03044951|PROCEDURE|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
48682594|NCT03233139|DRUG|Gemcitabine|To be administered per protocol
48155431|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox]|
48155432|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel|
48512159|NCT02175901|DRUG|Amoxicillin|antibiotic of each quadruple therapy
48512160|NCT02175901|DRUG|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
48512161|NCT02175901|DRUG|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
48682595|NCT03233139|DRUG|Pemetrexed|To be administered per protocol
48682596|NCT03233139|DRUG|Paclitaxel|To be administered per protocol
48682597|NCT03233139|DRUG|Fianlimab|To be administered per protocol
48682598|NCT00335309|PROCEDURE|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
48682599|NCT00335309|DRUG|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
48682600|NCT01331746|DRUG|APD515|20 mg oromucosal-oral administration qds for 7 days
48682601|NCT01331746|DRUG|Placebo|qds for 7 days
48155433|NCT05527054|OTHER|Diuretics|Inpatients using diuretics
48155434|NCT05144854|DRUG|ONO-4538|Specified dose on specified days
48155435|NCT05144854|DRUG|Ipilimumab|Specified dose on specified days
48155436|NCT05144854|DRUG|Oxaliplatin|Specified dose on specified days
48155437|NCT05144854|DRUG|Capecitabine|Specified dose on specified days
48155438|NCT05144854|DRUG|S-1|Specified dose on specified days
48155439|NCT01799993|DRUG|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
48155440|NCT01799993|DRUG|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
48155441|NCT05634083|DIETARY_SUPPLEMENT|Uremic pateints with itching|Activated charcoal
48155442|NCT04061772|DRUG|Bortezomib|Bortezomib injection
48155443|NCT04061772|DRUG|Etoposide|Etoposide injection
48155444|NCT04061772|DRUG|Cyclophosphamide|Cyclophosphamide injection
48155445|NCT04061772|DRUG|Pharmorubicin|Pharmorubicin injection
48155446|NCT04061772|DRUG|Prednisone|Prednisone tablet
48155447|NCT06264661|BEHAVIORAL|Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia|Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried out with validated instruments for Mexican population and gene expression was evaluated by real-time PCR.
48155448|NCT02270125|PROCEDURE|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
48155449|NCT00609245|DRUG|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
48155450|NCT00609245|DRUG|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
48155451|NCT02551926|BEHAVIORAL|mobile text messages|
47996570|NCT06141447|DRUG|Oxytocin + normal saline|40 units IV oxytocin once in a 1000 mL bag of normal saline
48155452|NCT02551926|BEHAVIORAL|virtual community|
48155453|NCT02551926|BEHAVIORAL|brochures|
48155454|NCT02551926|OTHER|Usual care|
48155455|NCT02551926|DEVICE|mobile phone|
47996571|NCT06141447|DRUG|Normal saline|1000 mL bag of normal saline alone
47996572|NCT00930995|DRUG|Candesartan|16mg po daily
47996573|NCT00930995|DRUG|Placebo|once daily
47996574|NCT01524627|DRUG|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
47996575|NCT01524627|DRUG|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
48155456|NCT03748680|DRUG|Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy|"Six months of adjuvant combination chemotherapy with Capox (or FOLFOX) Patients will receive adjuvant chemotherapy with eight cycles of CAPOX (oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.~(Patients with an ileostomy are only eligible for FOLFOX and will be treated with 12 cycles of FOLFOX (oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every second weeks)"
48155457|NCT03748680|OTHER|Intensified Follow-up Schedule|Close monitoring with Imaging during follow-up Patients included in this trial will undergo intensified follow-up with CT-chest and abdomen every four months after surgery for the first 2 years, then every 6 months for 1 years and finally once yearly for the last 2 years up to 5 years follow-up is completed.
48155458|NCT04285151|PROCEDURE|Nd:YAG laser Hyaloidotomy|Using the YAG laser for opening the posterior hyaloid in eyes with premacular hemorrhage, and evacuating the entrapped hemorrhage
48155459|NCT01535625|DEVICE|Momo stent|Patients with PCI
48155460|NCT03096496|OTHER|QoL questionnaires|Quality of life questionnaires
48155461|NCT03111849|OTHER|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
48155462|NCT04620733|DRUG|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
48155463|NCT04620733|DRUG|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
48155464|NCT04620733|DRUG|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
48155465|NCT03735368|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
48155466|NCT03735368|DRUG|Placebo oral capsule|placebo oral capsules
47996576|NCT01603446|DRUG|L-Arginine|NOW® L-Arginine powder
47996577|NCT03229265|DRUG|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
47996578|NCT03532620|DRUG|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
48155467|NCT03735368|DRUG|Pregabalin Oral Capsule|150 mg pregabalin Oral Capsule
48155468|NCT03735368|DRUG|topical anesthesia|topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
48155469|NCT02333747|DEVICE|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
48155470|NCT03330197|BIOLOGICAL|Ad-RTS-hIL-12|2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
48155471|NCT03330197|DRUG|Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|1 dose level (10mg/day) 15 oral daily doses of veledimex
48155472|NCT03330197|DRUG|Oral Veledimex - Arm 2 (DIPG)|2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
48155473|NCT05481996|OTHER|App-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a smartphone application created especially for the study that will contain a program of progressive physical exercises with images and descriptions, educational messages and an online booklet for the study subjects, totaling 8 weeks of training and pain education.
48155474|NCT05481996|OTHER|Online booklet|An online booklet containing information about chronic low back pain and weekly messages about low back pain causes, suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
48155475|NCT04239976|DEVICE|FitBit|Wear FitBit for gait assessment test
48512162|NCT02035358|BIOLOGICAL|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
48512163|NCT02286258|DRUG|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
48512164|NCT02286258|DRUG|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
48512165|NCT04631536|DRUG|Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.
48512166|NCT04631536|DRUG|Placebo|Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
48682602|NCT03338400|DRUG|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
48682603|NCT03338400|DRUG|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
47996579|NCT03532620|DRUG|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
47996580|NCT01442415|BEHAVIORAL|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
47996581|NCT00314574|DRUG|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
47996582|NCT00314574|DRUG|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
47996583|NCT00314574|DRUG|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
47996584|NCT00314574|DRUG|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
47996585|NCT04156568|DRUG|INH、RFT|6INH 10mg/kg 3INH+RFT 15mg/kg
47996586|NCT04380987|BIOLOGICAL|Biological sampling|For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.
47996587|NCT02304263|DRUG|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
47996588|NCT01419548|DRUG|ABT-888|
47996589|NCT01419548|DRUG|Carboplatin|
47996590|NCT01419548|DRUG|Paclitaxel|
47996591|NCT06315699|DRUG|Clemastine Fumarate Tablets|The dose was administered 2mg once daily in a double-blind random crossover method
47996592|NCT06315699|DIETARY_SUPPLEMENT|fructose|The dose was administered 2mg once daily in a double-blind random crossover method
48155476|NCT04239976|OTHER|Gait Assessment Test|Undergo gait assessment test
48155477|NCT04239976|OTHER|MC5-A Scrambler Therapy|Undergo scrambler therapy
48155478|NCT04239976|OTHER|Quality-of-Life Assessment|Ancillary studies
48155479|NCT04239976|PROCEDURE|Quantitative Sensory Testing|Undergo quantitative sensory test
48155480|NCT04239976|OTHER|Questionnaire Administration|Ancillary studies
48155481|NCT05517577|BEHAVIORAL|Behaviour Change Communication and Male involvement intervention|For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
48155482|NCT03768986|BEHAVIORAL|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
47996593|NCT00451867|DRUG|Mycophenolate Mofetil|
47996594|NCT00451867|DRUG|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
47996595|NCT00451867|DRUG|Placebo|Placebo
47996596|NCT04353011|OTHER|questionnaire assesment|questionnaire assesment
47996597|NCT01271868|BIOLOGICAL|IB1001|
48365682|NCT03473821|BEHAVIORAL|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
48365683|NCT02280265|DRUG|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
48365684|NCT02892357|DRUG|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
47996598|NCT04500184|OTHER|cardiac rehabilitation|rehabilitation performed by professional trainers
47996599|NCT01860456|DRUG|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
47996600|NCT06125288|OTHER|lab investigation and radiation|"1. . Full history taking including~   * Environmental factors such as long term exposure to environmental hazards as bacteria, fungi, chemicals, tobacco smoke and air pollution.~  * Host factors Family history (you have a higher risk of ILD if a close relative has ILD). History of recurrent chest infection. History of exposure to medication such as radiation and chemotherapy. History of Multisystem autoimmune diseases~2. Full examination general and systemic especially chest examination~3. investigation~   * pulse oximetry.~  * lab investigation include complete blood count parameters .~  * radiological investigation including ( echocardiography - MSCT chest - chest -x ray"
47996601|NCT05109663|DRUG|SKLB1028|SKLB1028, capsule, oral
47996602|NCT05840354|DEVICE|repetitive transcranial magnetic stimulation|"1-4 weeks after administration of the SJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst pain. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 85% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
47996603|NCT05840354|DEVICE|sham repetitive transcranial magnetic stimulation|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
48155483|NCT03768986|BEHAVIORAL|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
48365685|NCT02892357|DRUG|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
48365686|NCT05330195|OTHER|Bicycle Ergometer Training|Bicycle ergometer training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 40 minutes total duration consisting of 5 min warm up and 5 min cool down period to children in treatment group.
47996604|NCT05840354|DRUG|Steroid Joint Injection|The steroid joint injection will be given 1-4 weeks ahead of active rTMS and sham rTMS commencement. A dose of 0.5mL of 40mg/mL triamcinolone and 0.5mL of 2% lidocaine will be given per joint via spinal needle. The treatment team will determine how many joints will be injected based on their standard clinical assessment. Usually, about 2-4 joints are injected depending on a person's pain presentation. Standard practice is to place the needle in the region of the facet joint opening, resulting in a peri- +/- intra-articular infusion of the injectate. This project will utilize standard clinical practice without modification.
47996605|NCT03198741|DRUG|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
47996606|NCT03198741|DRUG|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
47996607|NCT03198741|DRUG|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
47996608|NCT01787175|OTHER|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
47996609|NCT00004159|DRUG|gemcitabine hydrochloride|
47996610|NCT00004159|DRUG|paclitaxel|
47996611|NCT01527682|DRUG|Latanoprost, Dorzolamide|"* Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~* Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
47996612|NCT00673179|DRUG|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
47996613|NCT00673179|DRUG|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m\^2/day for 2 days continuous infusion.
48682604|NCT05870462|DRUG|Semaglutide Pen Injector|"* 0.25 mg/week (non-therapeutic dose) during Weeks 1-4~* 0.50 mg/week during Weeks 5-8~* 1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
48682605|NCT03381664|DRUG|AVP-923|capsule
47996614|NCT00673179|DRUG|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m\^2, max 20 gm over 4 hours.
47996615|NCT00673179|DRUG|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
47996616|NCT00673179|DRUG|Dexrazoxane|Dose 900 mg/m\^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
47996617|NCT00673179|DRUG|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2. Dose 2.8 grams m\^2/day.
47996618|NCT00673179|BEHAVIORAL|Questionnaire|Questionnaires to be completed on 5 different days during the study.
47996619|NCT00673179|DRUG|Gemcitabine|IV over 1 hour, every other week.
47996620|NCT00673179|DRUG|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
47996621|NCT00673179|PROCEDURE|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
47996622|NCT00673179|DRUG|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2/day.
47996623|NCT05612685|BEHAVIORAL|Healthcare provider referral to a tax filing app|Healthcare providers offer a referral to a tax filing app and briefly describe the potential benefits of tax credit receipt
47996624|NCT02797847|DRUG|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
48365687|NCT05330195|OTHER|Home-based exercise group|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
48365688|NCT06098001|DIETARY_SUPPLEMENT|Low dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose esacalation design
48365689|NCT06098001|DIETARY_SUPPLEMENT|High dose dietary fiber|Subjects will receive a low dose or high dose of the dietary fiber product in a dose escalation design
48365690|NCT03374228|DRUG|BMS-986205|Specified Dose on Specified Days
48365691|NCT03988465|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
48682606|NCT05211193|DEVICE|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
48682607|NCT01669694|OTHER|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
48682608|NCT02216916|DRUG|HM781-36B|
48682609|NCT01222819|DRUG|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
47996625|NCT02797847|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
48682610|NCT00628498|DRUG|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
47996626|NCT05892003|OTHER|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
48365692|NCT05014945|PROCEDURE|(atelocollagen group)|Epidural nerve block and atelocollagen injection into the multifidus muscle were performed sequentially. The target level is determined by the clinician by combining the pre-MRI and the patient's symptoms. All procedures are performed under the guidance of fluroscopy. For epidural nerve block, use 10cc of 0.9% normal saline mixed with 3000IU of hyaluronidase to be injected. After the epidural nerve block, a solution of 1 mL of atelocollagen mixed with 1 mL of 1% lidocaine is injected into the multifidus muscle to complete the entire procedure.
48365693|NCT04868760|DRUG|Ipilimumab|Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
48365694|NCT04868760|DRUG|IBI310|Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.
48365695|NCT04371068|BIOLOGICAL|Culture of removed prosthesis using DTT|No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
48365696|NCT01407068|BIOLOGICAL|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
48682611|NCT00628498|DRUG|Defibrotide|
48682612|NCT01725802|DRUG|Levodopa/carbidopa solution for SC administration|
47996627|NCT05892003|OTHER|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
47996628|NCT05892003|OTHER|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
47996629|NCT05492175|OTHER|robotic practice|According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
47996630|NCT05492175|OTHER|kinetic exergaming|All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
48155484|NCT03768986|BEHAVIORAL|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
48155485|NCT05384522|OTHER|blood samples collection|Blood samples will be drawn at baseline and at 6 and 12 months from baseline
48365697|NCT04013906|DIAGNOSTIC_TEST|Rotational atherectomy|Rotational atherectomy
48365698|NCT03458351|DEVICE|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
48155486|NCT03278808|DRUG|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
48365699|NCT03458351|DEVICE|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
48365700|NCT00224952|OTHER|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
48365701|NCT03640962|OTHER|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
48512167|NCT00357253|DRUG|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
48512168|NCT00357253|RADIATION|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
48512169|NCT06421298|DRUG|Tafolecimab|450mg Q4W ≤6cycle
48682613|NCT01725802|DRUG|Placebo|
48682614|NCT02460068|DRUG|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
48155487|NCT03278808|DRUG|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
48512170|NCT06421298|DRUG|Sintilimab|200mg Q3W ≤2years
48512171|NCT06421298|DRUG|Nab paclitaxel|130mg/m² Q3W 4-6cycles
48155488|NCT03278808|DRUG|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
48155489|NCT03649659|DRUG|Silver Diamine Fluoride|SDF will be applied twice during the study
48155490|NCT03649659|DRUG|Placebo|This is being compared to the SDF and will also be applied twice
48155491|NCT03563131|DEVICE|Persona® total knee arthroplasty|Insertion of the cemented or uncemented Persona® total knee arthroplasty
48512172|NCT06421298|DRUG|Docetaxel|75mg/m² Q3W 4-6cycles
48512173|NCT06421298|DRUG|Gemcitabine|1250mg/m² Q3W 4-6cycles
48512174|NCT04641052|OTHER|Music listening|The music type will be chosen by the patients and researchers will not have any influence on their choices.
48512175|NCT01855828|DRUG|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
48512176|NCT01855828|DRUG|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
47996631|NCT05492175|OTHER|conventional therapy|Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
48682615|NCT02460068|DRUG|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
48682616|NCT02460068|DRUG|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
47996632|NCT05584553|DEVICE|ToggleLoc 2.9 mm soft tissue device|The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
48155492|NCT03751280|DEVICE|PEAR-004|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
48155493|NCT03751280|DEVICE|Sham|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
48155494|NCT03320941|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
48155495|NCT03320941|DRUG|Placebo|Placebo will be supplied as tablets to be taken daily orally.
48512177|NCT01855828|DRUG|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
47996633|NCT05584553|DEVICE|JuggerLoc soft tissue device|The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
47996634|NCT01360658|DRUG|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
48155496|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
48512178|NCT01855828|DRUG|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
48512179|NCT01855828|DRUG|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
48512180|NCT01855828|DRUG|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
48155497|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
48155498|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
48155499|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
48155500|NCT01524887|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
48155501|NCT01524887|BIOLOGICAL|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
48155502|NCT03581344|DIAGNOSTIC_TEST|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
48365702|NCT03053466|DRUG|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
48365703|NCT06309524|DEVICE|Tricuspid transcatheter edge-to-edge repair|Transcatheter tricuspid leaflets approximation
48365704|NCT00143039|PROCEDURE|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
48365705|NCT05423847|DIAGNOSTIC_TEST|POCUS|POCUS of lungs, pericardium and abdomen
47996635|NCT05863039|OTHER|Blood flow restriction|Strength training of the lower leg muscles using blood flow restriction
48365706|NCT01317264|OTHER|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
47996636|NCT05863039|OTHER|Regular training type 1|Strength training of the lower leg muscles using high loads
47996637|NCT05863039|OTHER|Regular training type 2|Strength training of the lower leg muscles using low loads
47996638|NCT00324467|DRUG|Cyclophosphamide|"Dose: 750 mg/m\^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
48365707|NCT01317264|OTHER|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
48512181|NCT02128321|DRUG|Isavuconazole|oral
48512182|NCT02128321|DRUG|Repaglinide|oral
48512183|NCT02128321|DRUG|Caffeine|oral
48155503|NCT05280522|OTHER|Volitional Contractions (VOL)|Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.
48155504|NCT05280522|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.
48155505|NCT05280522|DEVICE|Noxious Electrical Stimulation (NXES)|The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
48155506|NCT03490942|DRUG|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
48155507|NCT03490942|DRUG|Placebo|The placebo solution is a non-active formulation containing excipients only.
48365708|NCT01317264|OTHER|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
48682617|NCT02905838|DEVICE|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
48365709|NCT01317264|OTHER|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
48365710|NCT06370494|BEHAVIORAL|Living Healthier with Diabetes|Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
48682618|NCT02905838|DEVICE|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
48682619|NCT00996658|DRUG|Placebo|Placebo matching linagliptin tablets once daily
48682620|NCT00996658|DRUG|Linagliptin|Linagliptin tablets once daily
48682621|NCT04980625|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
48682622|NCT04980625|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
48682623|NCT01926444|DRUG|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
48682624|NCT02198859|DRUG|Lithium Carbonate|
48682625|NCT00149539|DRUG|Buprenorphine/naloxone|
48682626|NCT05011175|OTHER|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
48365711|NCT06235281|DRUG|Mogamulizumab-Kpkc|Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.
48512184|NCT03793127|OTHER|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
47996639|NCT00324467|DRUG|Doxorubicin|"Dose: 50 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
48512185|NCT03793127|OTHER|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
48512186|NCT03793127|OTHER|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
48682627|NCT02986633|OTHER|Echocardiography|
48682628|NCT02175485|DRUG|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
48682629|NCT04767061|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
47996640|NCT00324467|DRUG|Vincristine|"Dose: 1.4 mg/m\^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
47996641|NCT00324467|DRUG|Prednisone|"Dose: 45 mg/m\^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5\*, 6\* (Week 1, 4, 7, 10, 14, 17)~\* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
47996642|NCT00324467|DRUG|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
47996643|NCT00324467|DRUG|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
47996644|NCT00324467|DRUG|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
47996645|NCT00324467|DRUG|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
47996646|NCT00324467|DRUG|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
47996647|NCT00324467|DRUG|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m\^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
47996648|NCT00324467|DRUG|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
47996649|NCT00324467|DRUG|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl\*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~\*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
47996650|NCT00324467|DRUG|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m\^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
47996651|NCT00324467|DRUG|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m\^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
47996652|NCT00324467|DRUG|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
47996653|NCT00324467|DRUG|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
48682630|NCT04770558|OTHER|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
47996654|NCT00324467|DRUG|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
47996655|NCT00324467|DRUG|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
47996656|NCT00324467|OTHER|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
47996657|NCT04849156|OTHER|Sperm selection by thermotaxis|Selection of healthy sperm by thermotaxis procedure
47996658|NCT02374879|DEVICE|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
47996659|NCT06238076|DEVICE|Universal surgical device FIBUMAND|This device is made of biocompatible resin for type IIa medical devices with a 3D printer.
48155508|NCT00570804|BEHAVIORAL|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
48682631|NCT02626156|DEVICE|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
48682632|NCT02626156|DEVICE|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
47996660|NCT05442164|BEHAVIORAL|DANAKIR support network|"The DANAKIR intervention will consist of:~* Structured written discharge information~* Invitation to the DANAKIR monthly information meeting DANAKIR meetings The monthly meetings are a core component of the support network. One time each month, a meeting will be held at Herlev Hospital with the participation of an emergency surgeon, an emergency surgery dedicated nurse, a dietician, and a physiotherapist. Each professional (surgeon, nurse, dietician, physiotherapist) will host an informative 15 minute session regarding the postoperative course after major emergency surgery. Following the presentations time for questions in plenum and private with the different experts will be held. Furthermore, there will be an opportunity for networking at the DANAKIR meeting. Each meeting is planned to last 2 hours. At the end of each meeting the patients will be asked to evaluate the meeting and content."
47996661|NCT01011842|PROCEDURE|Radiotherapy|Standard of care
47996662|NCT01011842|PROCEDURE|Align RT|Standard of care
47996663|NCT04164979|DRUG|Cabozantinib|Given PO
47996664|NCT04164979|DRUG|Pembrolizumab|Given IV
47996665|NCT03265197|DRUG|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
48155509|NCT00570804|BEHAVIORAL|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
48155510|NCT04745819|BEHAVIORAL|1. The Child Behavior Checklist (CBCL), parent form|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
48155511|NCT03785418|BEHAVIORAL|Multicomponent Risk Factor Modification|Healthy eating, regular exercise and behavioural therapy.
48155512|NCT04601090|OTHER|ICU treatment|This is an observational study, so all patients will undergo a variation of ICU treatment, and we will record that information (e.g., time on ventilator, time in ICU, SAPS score at admission)
48155513|NCT05024396|DIAGNOSTIC_TEST|maximum jump height|Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
48155514|NCT05229549|OTHER|GOLIKE PLUS 3-16|PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
48155515|NCT05229549|OTHER|Free AAs|It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
48365712|NCT06235281|DEVICE|Phototherapy|Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.
48365713|NCT02229513|PROCEDURE|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
48155516|NCT05327725|OTHER|Fatigue Reduction Diet|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
48155517|NCT00158561|DRUG|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
48155518|NCT03180788|PROCEDURE|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
48155519|NCT03180788|PROCEDURE|Traditional ESD|Endoscopic submucosa dissection
48155520|NCT04453306|DRUG|Topiramate|topiramate 25mg is coated in tablets in an independent laboratory
48155521|NCT04453306|DRUG|Placebo|innocuous substance is coated in tablets in an independent laboratory
47996666|NCT03265197|OTHER|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
47996667|NCT02930421|OTHER|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
47996668|NCT03266991|DRUG|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
48155522|NCT05097183|PROCEDURE|Accurate Commissural Alignment (ACA)|Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
48365714|NCT03402308|DIETARY_SUPPLEMENT|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
48682633|NCT06114940|DRUG|Toripalimab|240mg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
48682634|NCT06114940|DRUG|Lenvatinib|18 mg by mouth once each day for 12 weeks prior to nephrectomy
48682635|NCT01253369|DRUG|Pazopanib|
48365715|NCT03402308|DIETARY_SUPPLEMENT|Placebo|Starch placebo 1,000 mg/day for 12 weeks
48365716|NCT04324983|OTHER|Blood sample|"Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination."
48365717|NCT03863964|DIAGNOSTIC_TEST|blood test|13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
47996669|NCT03266991|DRUG|Isoniazid|Treatment with daily isoniazid in 6 months
47996670|NCT04422028|DRUG|Desogestrel 0.075 MG|Test Drug
48365718|NCT00627991|DRUG|Valsartan|
47996671|NCT04422028|DRUG|Desogestrel 0.075 MG|Reference Product
48365719|NCT03061864|BEHAVIORAL|Periviable Birth Plan|
48365720|NCT01674868|DRUG|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
48365721|NCT01674868|DRUG|placebo|subjects will take one pill po daily for 90 days.
48365722|NCT03016520|DRUG|DWJ1392|
48365723|NCT03016520|DRUG|DWC20164|
48365724|NCT00481533|DRUG|Methyl-Ergonovine-Oxytocin|
48682636|NCT06469190|DRUG|KN5501|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
48682637|NCT01724229|DRUG|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
48682638|NCT03614598|PROCEDURE|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
48682639|NCT03614598|PROCEDURE|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
48682640|NCT03614598|PROCEDURE|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
48365725|NCT00481533|DRUG|Oxytocin|
48365726|NCT00000610|DRUG|magnesium|
48365727|NCT00003230|DRUG|paclitaxel|
48682641|NCT05651763|OTHER|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
48512187|NCT05149326|DRUG|KN046|KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
48512188|NCT05149326|DRUG|placebo|placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
48155523|NCT02243488|DEVICE|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
48682642|NCT05651763|OTHER|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
48682643|NCT06361004|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (GPi, amGPi, pvGPi, Cm-Spv-Voi, Cm-Voi, NA-ALIC, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
48155524|NCT00666991|DRUG|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
48155525|NCT06646029|DEVICE|RMO flexion orthosis (splint)|RMO flexion is an orthosis fabricated by hand therapists made of thermoplastic material design to position the involved finger in relative flexion at the metacarpal joint compared to adjacent fingers to facilitate PIP extension during daily activity use.
48155526|NCT06646029|OTHER|Standard of care|Treatment includes finger stretches, active range of motion (AROM), passive range of motion (PROM), thermal modalities, LMB finger extension orthosis.
48155527|NCT02628613|DRUG|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
48365728|NCT04915742|BEHAVIORAL|exercises|The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.
48365729|NCT04915742|BEHAVIORAL|thetahealing and exercises|"The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform."
48155528|NCT02628613|DRUG|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
48155529|NCT01849185|OTHER|Food supplement|
48155530|NCT01738087|DRUG|NEXThaler 100/6 mcg DPI|
48365730|NCT01087151|DRUG|ABT-263|Oral repeating dose
48365731|NCT01087151|DRUG|rituximab|Intravenous repeating dose
48365732|NCT03114475|RADIATION|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
48365733|NCT03114475|OTHER|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
48155531|NCT01738087|DRUG|Flixotide Accuhaler 500 mcg|Active comparator
48155532|NCT01738087|DRUG|NEXThaler 200/6 mcg DPI|
48155533|NCT01738087|DRUG|NEXThaler placebo|Placebo comparator
48155534|NCT04803994|DRUG|Atezolizumab|1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
48155535|NCT04803994|DRUG|Bevacizumab|15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
48155536|NCT04803994|PROCEDURE|TACE|Locoregional therapy will be performed as a standard-of-care procedure
48512189|NCT04991207|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
48512190|NCT04991207|DRUG|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
48512191|NCT05575232|BEHAVIORAL|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
47996672|NCT03134755|DRUG|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
48512192|NCT02390128|OTHER|observational only|
48512193|NCT06328465|DIAGNOSTIC_TEST|Diffusion whole body MRI|Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
48512194|NCT06550765|DEVICE|Biodegradable Magnesium Metal Clips|The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
48512195|NCT00437359|DRUG|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
48512196|NCT00437359|DRUG|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
48512197|NCT06013748|BEHAVIORAL|VR-VOICES|7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
48512198|NCT06013748|OTHER|Treatment as usual|Treatment as usual as provided by the mental health centers
48512199|NCT04207307|BEHAVIORAL|Multimodal exercise program|Multimodal exercise intervention (machine-based resistance, coordination and endurance training).
48512200|NCT04207307|BEHAVIORAL|Usual Care|General recommendations for healthy ageing, no machine-based strength training intervention.
48512201|NCT03555383|DIAGNOSTIC_TEST|Coagulation factor levels|The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).
48512202|NCT00481117|DRUG|LY2405319|
48512203|NCT00481117|DRUG|Placebo|
48512204|NCT03518645|DEVICE|OPN strategy|Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
48512205|NCT03518645|DEVICE|standard strategy|Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
48512206|NCT04874831|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
48512207|NCT06543173|PROCEDURE|Prophylactic Catheter-based VT Ablation|Prophylactic Catheter-based VT Ablation refers to a treatment strategy where participants undergo a procedure known as catheter-based ventricular tachycardia (VT) ablation shortly after receiving their primary implantable cardioverter defibrillator (ICD).
48512208|NCT02274506|DRUG|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
48512209|NCT02274506|DRUG|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
48512210|NCT02274506|PROCEDURE|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
48512211|NCT02089607|DEVICE|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
48512212|NCT02089607|DEVICE|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
48682644|NCT01460069|DRUG|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
48682645|NCT01460069|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
48682646|NCT03890523|PROCEDURE|Airway stent implantation|The segmented airway stent modified with 3D printing were implanted to treat gastro-respiratory fistula involving carina and distal bronchi. The stents were removed because of stent-related complications or tracheobronchial healing.
48682647|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day
48682648|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
48682649|NCT00114127|DRUG|Placebo|60mg placebo 1x per day
48682650|NCT02769429|DEVICE|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
48682651|NCT02769429|DEVICE|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
48682652|NCT02419378|DRUG|Alemtuzumab|
48682653|NCT03450239|OTHER|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
48682654|NCT05040698|DRUG|Fostamatinib|Open label Fostamatinib
48682655|NCT01356862|DRUG|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
48682656|NCT01356862|DRUG|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
48512213|NCT03437031|DEVICE|Virtual Reality device|For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
48682657|NCT04731896|PROCEDURE|Amniotomy|artificial rupture of the amniotic sac
48682658|NCT06062381|PROCEDURE|Abdominal Massage|"The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles."
48682659|NCT03943290|DRUG|ACE-083|Recombinant fusion protein
48682660|NCT03448016|RADIATION|[C-11]|Radiolabel
47996673|NCT05083988|DEVICE|virtual reality glasses|a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
47996674|NCT05083988|DEVICE|music|Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
47996675|NCT01184547|BEHAVIORAL|Combex|12 weeks of exercise with a trainer post discharge.
47996676|NCT01184547|BEHAVIORAL|Standard of Care|No exercise training received.
47996677|NCT01038024|DIETARY_SUPPLEMENT|1 tablet composed of antioxidants and minerals|1 tablet daily
48682661|NCT03448016|DRUG|NOP-1A|Tracer
48365734|NCT00157157|BIOLOGICAL|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
47996678|NCT02970279|BEHAVIORAL|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
47996679|NCT03161028|DRUG|Lipoic acid|1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
48365735|NCT00387621|DRUG|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
48365736|NCT00387621|DRUG|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
48682662|NCT06090812|OTHER|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
48682663|NCT03619434|PROCEDURE|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
47996680|NCT03161028|DRUG|Placebo|The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
47996681|NCT00035854|DRUG|Zyvox® / Linezolid|
48682664|NCT03619434|PROCEDURE|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
48682665|NCT05691192|BEHAVIORAL|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
48682666|NCT05985525|DEVICE|Skeletal muscle and cerebral NIRS (research device)|NIRS applied on skeletal muscle and brain on days 1, 3, and 8 of ICU admission. Monitoring applied for up to 24hrs on each day.
48682667|NCT01007188|OTHER|1.5PD almonds|average American diet plus 1.5 oz per day almonds
48682668|NCT01007188|OTHER|3.0PD almonds|average American diet plus 3.0 oz per day almonds
48682669|NCT01007188|OTHER|Base (without almonds)|average American diet without almonds
48682670|NCT00858351|BEHAVIORAL|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
47996682|NCT02338869|BEHAVIORAL|Dialogue-based psychosocial rehabilitation|
47996683|NCT05071885|OTHER|games based exercise|Range of motion and strengthening exercises
48365737|NCT00387621|DRUG|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
48365738|NCT00529594|DRUG|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
48365739|NCT00529594|DRUG|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
48365740|NCT03584399|OTHER|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
48365741|NCT04777422|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
48682671|NCT00858351|BEHAVIORAL|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
48682672|NCT01487538|BEHAVIORAL|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
48682673|NCT01487538|BEHAVIORAL|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
48682674|NCT01487538|BEHAVIORAL|Discussion Boards|forum to exchange information and experiences
48682675|NCT01487538|BEHAVIORAL|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
48682676|NCT00583674|DRUG|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682677|NCT00583674|DRUG|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682678|NCT00583674|DRUG|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682679|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682680|NCT00583674|DRUG|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682681|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682682|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682683|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48365742|NCT06016166|DEVICE|Eye mask|The 3D eye mask with the ability to adjust for different faces and eliminate light
48512214|NCT01509014|BEHAVIORAL|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
48512215|NCT06552091|OTHER|self-hypnosis sessions|3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
48512216|NCT06034782|DIAGNOSTIC_TEST|Fine Needle Aspiration|Fine Needle Aspiration of a salivary gland tumor
48512217|NCT06034782|PROCEDURE|Histologic Examination|Histologic examination of resected salivary tumor
48512218|NCT00796055|DRUG|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
48682684|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
48682685|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered orally
48682686|NCT06102512|DRUG|LOXO-783|Administered orally
48682687|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered IV
48682688|NCT02366676|DRUG|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)
48682689|NCT00043745|DIETARY_SUPPLEMENT|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
48682690|NCT00043745|DIETARY_SUPPLEMENT|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
48365743|NCT02114736|PROCEDURE|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
48365744|NCT02114736|DRUG|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
48365745|NCT00740766|BEHAVIORAL|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
48365746|NCT03458468|DRUG|Tranexamic Acid|1g Tranexamic acid prior to skin incision
48365747|NCT03458468|DRUG|Saline|Equivalent volume of saline prior to skin incision
48365748|NCT06210828|BEHAVIORAL|Telerehabilitation|Two weekly exercise sessions over a 12-week period at home via LINE Video call with physical therapist. Focusing on lower extremity strengthening and balance exercises. In addition to the guided sessions, participants are encouraged to perform self-directed exercises one day per week.
48365749|NCT06210828|BEHAVIORAL|Control|Receive fall prevention exercise brochure
48365750|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
48365751|NCT00289510|BIOLOGICAL|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
48365752|NCT05186220|PROCEDURE|Cardioneuroablation|After 3D mapping of the surface of the left and right atrium and the superior vena cava (Ensite Navx, Carto), localization of ganglion plexus (GP) will be performed either anatomically and/or by means of high frequency stimulation (HFS). The anterior and superior right sided GP will always be ablated per protocol. Other GP will be ablated according to interventional electrophysiologist judgement. The endpoint of the ablation procedure will be 1) absence of a vagal response after HFS from the right jugular vein and 2) an increase in at least 10 bpm as compared to baseline.
48365753|NCT05186220|DEVICE|Permanent dual chamber pacemaker implantation|Under local anesthesia and using a subclavian or cephalic vein approach a dual chamber pacemaker implantation with a lead in the right atrium and a lead in the right ventricle will be performed. The device will be programmed in a AAI-DDDR mode to avoid unnecessary ventricular pacing.
48365754|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
48365755|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
48365756|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
48365757|NCT00987909|BIOLOGICAL|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
48365758|NCT01073384|DRUG|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
48365759|NCT00672464|DRUG|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
47996684|NCT04643262|PROCEDURE|Sleeve Gastrectomy|Once the left crus is reached, an optimal exposure of the hiatus is mandatory to find incidental hiatal hernias and a complete dissection of the left crus performed to prevent retained fundus. The greater omentum was opened close to the stomach wall in some part in between the fundus and the antrum to have greater curvature completely detached from the stomach; this dissection starts at 2 cm or _____proximal to the pylorus and continued along the greater curvature to the left crus. Posterior adhesions if present, were carefully divided. The left gastrophrenic ligament was divided to expose the angle of His to identify the complete hiatus and fundus. A bougie was positioned before starting resection of the stomach. We use a 36French bougie or --------- we have chosen cartridges Black at the antrum level and finished with a purple cartridge. We always checked the posterior wall before firing.
47996685|NCT00581568|OTHER|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
47996686|NCT02226003|DRUG|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
47996687|NCT02226003|DRUG|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
47996688|NCT02226003|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
47996689|NCT02226003|DRUG|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
47996690|NCT02226003|DRUG|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
47996691|NCT02098577|OTHER|Crossover|Crossover cycle
47996692|NCT02098577|OTHER|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
47996693|NCT00006294|DRUG|Chlorthalidone|participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
47996694|NCT00006294|DRUG|Lisinopril|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
47996695|NCT00006294|DRUG|Amlodipine|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
47996696|NCT00006294|DRUG|Doxazosin|participant's drug dose will be titrated from 2mg to 8mg over the course of the study
47996697|NCT00846755|DRUG|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
47996698|NCT05875233|OTHER|Elix Daily Harmony|"Elix Daily Harmony is a clinical-strength, organic blend of hormone-balancing Traditional Chinese Medicine (TCM) herbs and adaptogens. Contains Angelica Sinensis, licorice, ginger, Bupleurum, Cyperus Rotundus, White Peony, Mint, Poria, Atractylodes, White Ginseng, Reishi, Rehmannia Root, and Astragalus.~Participants should add 3 droppers full (half a teaspoon or 2.5 ml) of Elix Daily Harmony to their tea or other warm or room temperature beverage each morning, 1-2 hours after their first meal. The product should not be taken with iced drinks or with food."
47996699|NCT05875233|OTHER|Elix Cycle Balance|A tailored blend of medicinal herbs to holistically support menstrual symptoms by treating underlying imbalances. Participants should take 3 droppers full (half a teaspoon or 2.5 ml) of Elix Cycle Balance daily before bed with tea or other warm or room temperature beverage. The product should not be taken with iced drinks or with food.
47996700|NCT02487212|DRUG|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
48365760|NCT00672464|DRUG|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
47996701|NCT02487212|DRUG|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
47996702|NCT02487212|DEVICE|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
47996703|NCT00149916|DRUG|Mycophenolate sodium (enteric coated)|
47996704|NCT02723968|OTHER|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
47996705|NCT02723968|PROCEDURE|HGPIV diagnosis test|
47996706|NCT02723968|PROCEDURE|HOMAR-IR diagnosis test|
47996707|NCT03365700|PROCEDURE|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
47996708|NCT03365700|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
48365761|NCT00672464|DRUG|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
48365762|NCT00031824|DRUG|cyclosporine|
48365763|NCT00031824|DRUG|hydroxychloroquine|
47996709|NCT01770483|DRUG|nitazoxanide|nitazoxanide 500mg twice daily
47996710|NCT01770483|DRUG|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
47996711|NCT01770483|DRUG|Ribavirin|ribazole
48365764|NCT00031824|DRUG|prednisone|
48365765|NCT00031824|DRUG|tacrolimus|
48365766|NCT01376115|DRUG|Nelarabine|
48365767|NCT02003287|OTHER|VFSS|Videofluoroscopic Swallow Study
48365768|NCT02003287|OTHER|FEES|Fiberoptic Endoscopic Swallow Study
48365769|NCT05754242|DRUG|Ascorbic acid|1.5 gr of ascorbic acid
48365770|NCT05754242|DRUG|0.9% Saline solution|100 ml of 0.9% saline solution
48365771|NCT04418908|DRUG|Cetrorelix acetate, 0.25 mg/day|All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
48365772|NCT04418908|DRUG|Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release|Active estradiol transdermal patch.
47996712|NCT00075426|DRUG|arsenic trioxide|
47996713|NCT06546904|DEVICE|Artificial intelligence empowers anesthesia with ultrasound assistance|Artificial intelligence empowers anesthesia with ultrasound assistance
48512219|NCT06178341|DEVICE|Kata Inhalations-App|"The Kata Inhalations-App is a digital product that bears a CE mark. The application provides algorithms to run an inhalation trainer. The inhalation trainer shows patients how to improve their inhalation maneuver in a simple and understandable way. For this purpose, the signals from the camera and microphone of the patient's smartphone are used to evaluate the individual steps of the inhalation maneuver in real-time to provide automatic, personalized feedback. Additional functions of the Kata Inhalations-App include the possibility to document health parameters and to receive inhalation reminders.~After set-up, subjects will use the application on their own as an add-on to their usual therapy for asthma. The total duration of application use will be 13 weeks, 1 week use of the Messinstrument (Measurement)-App for all subjects (Baseline period), followed by 12 weeks use of the Kata Inhalations-App (intervention) or the Messinstrument-App (control)."
48512220|NCT06409819|DRUG|phage therapy|phage therapy will consist of an individualized combination of lytic phages that are active against the participant's E. coli/K. pneumoniae isolates and will be administered intravenously twice daily for 7 days.
48512221|NCT06409819|DRUG|control|Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.
48512222|NCT00808314|DRUG|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
48512223|NCT00808314|DRUG|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
48512224|NCT00230178|DRUG|Rasburicase (SR29142)|30-min IV infusion
48512225|NCT00230178|DRUG|Allopurinol|Oral administration
47996714|NCT03199027|OTHER|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
47996715|NCT00772499|DRUG|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
48365773|NCT04418908|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
48365774|NCT04246359|DRUG|Rituximab Biosimilar|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
48365775|NCT04246359|DRUG|Pegylated Interferon α-2b|To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
48365776|NCT03650387|DEVICE|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
48365777|NCT04420390|RADIATION|Radiotherapy|Low-dose radiotherapy
48365778|NCT02557828|PROCEDURE|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
48365779|NCT00743626|OTHER|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
48365780|NCT05647889|DRUG|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
48365781|NCT05647889|COMBINATION_PRODUCT|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
48365782|NCT05647889|OTHER|Standard PVC procedure|Standard PVC procedure will be applied
48512226|NCT00967460|BEHAVIORAL|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
48512227|NCT06032000|BIOLOGICAL|LEM-mR203|mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL
48512228|NCT06032000|BIOLOGICAL|Placebo|0.9% Sodium Chloride Solution
48512229|NCT00789243|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
48512230|NCT05753878|DRUG|HH-120 nasal spray, PartA cohort 1|A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
48365783|NCT04245813|BEHAVIORAL|Interdisciplinary educational program|Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
47996716|NCT00772499|DRUG|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
47996717|NCT00138944|DRUG|placebo|od
48365784|NCT05033106|DRUG|Bevacizumab, Ranibizumab|• A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
48365785|NCT01417949|OTHER|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
47996718|NCT00138944|DRUG|eplerenone|50mg od
47996719|NCT06185959|BEHAVIORAL|Psychoeducation and Process Group for Asian and Asian American Psychiatric Outpatients|Participants will be individuals enrolling in a 1.5 hour weekly therapy group lasting 12 weeks and will be invited to participate in research on group processes and outcomes. The psychoeducation and process group will be a 12-session weekly closed group with 10-15 participants per group (2-3 groups total) conducted via Zoom to enhance accessibility and reduce barriers to care. Groups will be co-led by licensed clinical psychologists with experience providing both group psychotherapy and culturally responsive services. Group sessions will include brief check-ins, collaborative agenda-setting, a mini-didactic, individual reflection, and group discussion. The didactics curriculum will include topics such as intergenerational trauma, cultural differences in emotional expression, the model minority myth, family dynamics, racism, and positive connections to culture.
47996720|NCT01485562|DRUG|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
47996721|NCT01485562|OTHER|placebo|4 tablets, administered sublingually if the woman experiences a PPH
47996722|NCT03664752|DRUG|IDP-120 Gel|IDP-120 Gel, once-daily application
47996723|NCT03664752|DRUG|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, once-daily application
47996724|NCT04220372|DRUG|Tongxinluo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
47996725|NCT04220372|DRUG|Placebo|Provided by Shijiazhuang Yiling Pharmaceutical CO., LTD
48365786|NCT00967811|DRUG|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
48365787|NCT00967811|DRUG|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
48365788|NCT05472168|OTHER|Olfactory Stimulation|Participants are exposed to different odours and energy expenditure is assessed via indirect calorimetry.
48512231|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 2-7|A single dose of HH-120 nasal spray.
47996726|NCT00752882|DRUG|ceftazidime|
47996727|NCT01422863|BEHAVIORAL|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
47996728|NCT00624494|DEVICE|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
47996729|NCT00624494|DEVICE|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
47996730|NCT06333288|BEHAVIORAL|PST-APPLE Watch group|PST combined APPLE Watch is a tailored behavioral intervention that enables college students with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake and teach problem-solving skills.
48512232|NCT05753878|DRUG|HH-120 nasal spray, Part A cohort 8-9|Two doses of HH-120 nasal spray.
47996731|NCT06333288|BEHAVIORAL|Education-only control group|Education-only control group receives Quit Drinking Motivation 20-min video created by the MotivationHub, followed by a 30-minute group discussion.
47996732|NCT02088983|DIETARY_SUPPLEMENT|CDP-Choline|Capsule
47996733|NCT02088983|DIETARY_SUPPLEMENT|Cellulose|Capsule
47996734|NCT01257958|DRUG|19 nor vitamin d|
47996735|NCT05796674|DEVICE|Clareon UVA IOL|Clareon UVA IOL placed in the capsular bag in the posterior chamber of the eye during cataract surgery to replace the natural crystalline lens. Models CC60WF and CCA0T0 are indicated for the visual correction of aphakia. Models CCW0T3, CCW0T4, CCW0T5, and CCW0T6 are indicated for the visual correction of aphakia and preexisting corneal astigmatism.
48365789|NCT03144596|DRUG|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
48365790|NCT03144596|DRUG|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
48365791|NCT03733704|DIAGNOSTIC_TEST|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
48512233|NCT05753878|DRUG|HH-120 nasal spray, Part B|HH-120 nasal spray, 10 times daily for 7 consecutive days.
47996736|NCT05796674|DEVICE|WaveTec Optiwave Refractive Analysis (ORA) System|Intra-operative system used during refractive cataract surgery to capture wavefront images of the patient's eye for the purpose of optimizing IOL implantation
47996737|NCT05796674|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation with a Clareon UVA IOL
48365792|NCT02307331|DEVICE|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
48682691|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
48682692|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium gluconate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
48682693|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of potassium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
47996738|NCT03090854|DIAGNOSTIC_TEST|ADASCog|Neuropsychological test
47996739|NCT03244865|DEVICE|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
47996740|NCT04318782|DEVICE|Pharmacodynamic thrombectomy|Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter
47996741|NCT03030690|OTHER|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
47996742|NCT03030690|OTHER|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
47996743|NCT03030690|OTHER|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
47996744|NCT00284479|BEHAVIORAL|Walking 45 mins 2x p.w.|
47996745|NCT01137942|DRUG|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
47996746|NCT03422393|DRUG|Venetoclax|On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.
47996747|NCT03422393|DRUG|Ibrutinib|"During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily."
48365793|NCT02307331|DEVICE|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
48365794|NCT02307331|DEVICE|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
48365795|NCT02307331|DEVICE|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
48682694|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium chloride|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
48682695|NCT06237712|DIETARY_SUPPLEMENT|Dietary supplement consisting of 40 mmol/daily of sodium bicarbonate|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
47996748|NCT04799899|BEHAVIORAL|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
47996749|NCT04799899|BEHAVIORAL|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
47996750|NCT02467465|OTHER|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
47996751|NCT02467465|DEVICE|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
47996752|NCT01632202|DEVICE|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
47996753|NCT01632202|DEVICE|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
47996754|NCT05048446|OTHER|observational|Non intervention
47996755|NCT04773444|BEHAVIORAL|Eccentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
48365796|NCT02307331|DEVICE|Sirius stem|A polished tapered stem
48365797|NCT02600715|DRUG|Onabotulinumtoxin A (BoNT)|
48365798|NCT02600715|DRUG|belladonna|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
48365799|NCT02600715|DRUG|Morphine|Part of dosage of the compounded active B\&O suppository of belladonna 16.2mg and morphine 7.5mg.
48365800|NCT02600715|DRUG|Placebo|matching placebo to B\&O suppository
48365801|NCT02600715|DRUG|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
47996756|NCT04773444|BEHAVIORAL|Concentric cycling training|"1. Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~2. Each training session: 3 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~3. Intensity: Firstly, set at 45% Wmax, and progressively increased 5% per week"
47996757|NCT02479256|DRUG|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
47996758|NCT02479256|DRUG|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
47996759|NCT02479256|DRUG|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
47996760|NCT02479256|DRUG|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
47996761|NCT06145360|DRUG|Empagliflozin 10 MG|the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
47996762|NCT06145360|DRUG|Insulin+Metformin+DPP4 inhibitor (DPP4I)|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
47996763|NCT03397082|DRUG|Lidocaine gel|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
47996764|NCT03397082|DRUG|Placebo|5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
47996765|NCT06520709|OTHER|No intervention|No intervention
47996766|NCT01514760|OTHER|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
47996767|NCT01263301|DEVICE|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
47996768|NCT03905460|DIAGNOSTIC_TEST|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
47996769|NCT04985812|DRUG|JNJ-67484703|Participants will receive JNJ-67484703.
47996770|NCT04985812|DRUG|Placebo|Participants will receive placebo to JNJ-67484703.
47996771|NCT06198556|DRUG|HRS-1167 tablets; rifampicin|HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
48682696|NCT06237712|DIETARY_SUPPLEMENT|Placebo caps|The supplements are delivered in plain vegetable 00 caps, stabelizing additives are potatostarch, sunflower lecithine and sunflower oil. The capsuels are free of titanium oxide and suited for human consumption.
47996772|NCT01262482|DRUG|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
47996773|NCT01262482|DRUG|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
47996774|NCT03779711|BIOLOGICAL|Autologous (self) mononuclear cells derived from umbilical cord blood|The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
47996775|NCT03779711|PROCEDURE|Stage II Surgical repair|This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
47996776|NCT05311696|OTHER|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
47996777|NCT01042730|DRUG|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
47996778|NCT04130243|OTHER|Blood test|Withdrawal of (extra) blood to measure serum biomarkers with a blood test
47996779|NCT01932827|BEHAVIORAL|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
47996780|NCT05973851|DRUG|Esketamine Nasal Product|See arm description
47996781|NCT05973851|DRUG|Ketamine Hydrochloride|See arm description
48682697|NCT00675831|DEVICE|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
48682698|NCT05365789|DEVICE|Blocked Nose Baby nasal spray|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
48682699|NCT05365789|OTHER|Standard of care|Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
48365802|NCT03586063|OTHER|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
48682700|NCT04833946|OTHER|Andrographis paniculata [150 mg]|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
48682701|NCT04833946|OTHER|Microcrystalline Cellulose (MCC)|One capsule to be taken orally, 30 minutes after breakfast \& 30 minutes before bedtime
48682702|NCT04118075|DRUG|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
48682703|NCT01430143|BEHAVIORAL|Exercise|Daily exercise for 12 weeks.
48682704|NCT02317601|DRUG|methylprednisolone sodium succinate|Single dose Intravenous
48682705|NCT02317601|DRUG|placebo saline|
48682706|NCT03559517|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
48682707|NCT03559517|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
48682708|NCT01412125|OTHER|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
48682709|NCT01412125|OTHER|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
48682710|NCT01177085|BEHAVIORAL|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
48682711|NCT03925103|PROCEDURE|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
48682712|NCT03925103|PROCEDURE|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
48682713|NCT05370976|DRUG|Cytotect®CP|"Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained"
48682714|NCT04805476|DEVICE|Non invasive mechanical ventilation|Prophylactic non invasive mechanical ventilation
48682715|NCT04805476|DEVICE|GP|GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
48365803|NCT05725837|DRUG|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
48682716|NCT06525688|OTHER|Bone, Serum and Plasma sample|Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
48682717|NCT03560583|DRUG|Metoclopramide|Metoclopramide 10 mg BID
48682718|NCT03560583|DRUG|Placebo Oral Tablet|Placebo 10 mg BID
48365804|NCT02400268|OTHER|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
48365805|NCT02400268|OTHER|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
48365806|NCT01531049|DRUG|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
48682719|NCT05070793|BEHAVIORAL|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
48682720|NCT03072472|DEVICE|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
48682721|NCT00650052|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fasting
48682722|NCT00650052|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fasting
47996782|NCT05973851|DRUG|Esketamine hydrochloride|See arm description
47996783|NCT05973851|DRUG|Second-line Antidepressants|See arm description
47996784|NCT04404075|OTHER|SkinTracker Mobile App|a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
48682723|NCT00335738|DRUG|liposomal vincristine sulfate|Given IV
48682724|NCT00335738|DRUG|carboplatin|Given IV
48682725|NCT00335738|DRUG|etoposide|Given IV
47996785|NCT05951530|OTHER|traditional physical therapy|this group received conventional upper extremity active ROMs and stretches for 30 minutes three to five times a week for 6 weeks without using the app-based cognitive training.
47996786|NCT05951530|OTHER|mobile app-based cognitive training|This group received mobile app-based cognitive training of 30minutes session three to five times a week for 6 weeks which includes a few activities such as the memory, coordination and alertness along with conventional UE exercises for 15 minutes three to five times a week for 6 weeks.
48682726|NCT05271747|DIETARY_SUPPLEMENT|AB-Kolicare|Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk
48682727|NCT05271747|DIETARY_SUPPLEMENT|Reuteri gotas|Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
48682728|NCT00534768|PROCEDURE|active debridement|debridement on 1st, 3-5th and 7th postoperative days
48682729|NCT00534768|PROCEDURE|control group|Postoperative debridement on 7th postoperative day
47996787|NCT04706195|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
47996788|NCT03936361|DRUG|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
47996789|NCT00822458|DRUG|vismodegib|Given orally
47996790|NCT00822458|OTHER|laboratory biomarker analysis|
48365807|NCT01531049|DRUG|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
48365808|NCT01531049|DRUG|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
48365809|NCT01531049|OTHER|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
47996791|NCT00822458|OTHER|pharmacological study|
47996792|NCT00022828|DEVICE|3-D Laser Imaging Device|
47996793|NCT01476696|DRUG|Prasugrel|Administered orally
47996794|NCT03095456|DRUG|Revefenacin|Revefenacin administered via nebulization.
47996795|NCT03095456|COMBINATION_PRODUCT|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
47996796|NCT03095456|DRUG|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
47996797|NCT03095456|DRUG|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
48365810|NCT01051414|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
48682730|NCT00283101|DRUG|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
48682731|NCT04636567|DRUG|Nerindocianine for injection|Procedure: routine minimally invasive abdominopelvic surgery.
48682732|NCT03947268|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
48682733|NCT01427218|OTHER|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
48682734|NCT01427218|BEHAVIORAL|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
47996798|NCT04589676|BEHAVIORAL|Naloxone training|The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
47996799|NCT04462809|DRUG|Talazoparib|"Talazoparib 1 mg a day (PO) (or 0.75 mg a day) for 2 years, started between 6 to 8 weeks after the end of chemotherapy discontinuation.~Talazoparib will be given for up to 2 years, or less length of time in the case of disease progression,.~unacceptable toxicity despite adequate management,patient decides to withdraw from the study, or general or specific changes in the patient's condition render the patient unacceptable for further treatment."
47996800|NCT01623596|DRUG|Fingolimod|
47996801|NCT01623596|DRUG|Disease Modifying therapy|
47996802|NCT02786485|BIOLOGICAL|rivogenlecleucel|T cells transduced with iCasp safety switch
47996803|NCT02786485|DRUG|Rimiducid|administered to treat GVHD
47996804|NCT04151290|DIAGNOSTIC_TEST|Cognoa ASD diagnostic device|Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
47996805|NCT04391387|PROCEDURE|prone position|a position with the patient lying face down with arms bent comfortably at the elbow and padded with the armboards positioned forward
48365811|NCT01051414|DRUG|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
48365812|NCT00915421|PROCEDURE|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
47996806|NCT01908257|DRUG|lesinurad 400 mg|
47996807|NCT01908257|DRUG|ranitidine 150 mg|
47996808|NCT01908257|DRUG|lesinurad 400 mg + ranitidine 150 mg|
48365813|NCT04168359|DEVICE|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
48365814|NCT06098976|DEVICE|Water Jet|The water jet works by directing a stream of water towards the gap between your teeth. The stream of water helps to loosen and remove plaque and food particles stuck in this area.
48365815|NCT06098976|DEVICE|Manual toothbrush|Manual toothbrush: The patients were taught to use the modified vertical method, and the patient brushed the teeth of the upper and lower jaws using traditional toothbrushes (Diamond, JolleyDent, Damascus, Syria), and anti-plaque toothpaste (Elgydium, UniPharma Co., Ltd, Ashrafiyat Sahnaya, Syria).
48682735|NCT01427218|BEHAVIORAL|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
48682736|NCT01427218|OTHER|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
48682737|NCT03577834|DIETARY_SUPPLEMENT|liquid vinegar|6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
48682738|NCT03577834|DIETARY_SUPPLEMENT|vinegar pill|Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
48682739|NCT02377024|DIETARY_SUPPLEMENT|TF 600mg|
48682740|NCT02377024|DIETARY_SUPPLEMENT|TF 1200mg|
47996809|NCT03045965|PROCEDURE|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
47996810|NCT02858219|DRUG|Botulinum Toxin Type A|
47996811|NCT02858219|OTHER|Saline solution|
47996812|NCT02858219|OTHER|Indexes|Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
47996813|NCT06011018|OTHER|Mirror Therapy|"Sitting, mirror place at the midline between the legs. Unaffected leg is placed in front of the mirror and perform ankle dorsiflexion exercises.~Duration: 5 seconds, Rest: 5 seconds"
47996814|NCT06011018|OTHER|Mirror Therapy + Electrical Stimulation|Same as the mirror therapy protocol. Affected leg: electrical stimulation on tibialis anterior muscle. Frequency: 35 Hz, Pulse width: 250µs, Duration: 5 seconds, Rest: 5 seconds.
47996815|NCT06011018|OTHER|Mirror Therapy + Binaural Beat|Same as the mirror therapy protocol. Listen to music (mozart's clarinex concerto in A major K622), with Alpha (8Hz) binaural beat stimulation
47996816|NCT01056809|PROCEDURE|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
47996817|NCT05749042|DRUG|Sintilimab|Concurrent Chemoradiotherapy Based of Cisplatin Plus Sintilimab.
47996818|NCT05749042|RADIATION|Radiotherapy|Concurrent Chemoradiotherapy Based of Cisplatin
47996819|NCT06169280|BIOLOGICAL|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
47996820|NCT06169280|DIETARY_SUPPLEMENT|N-acetylcysteine amide (NACA)|N-acetylcysteine amide (NACA) 600 mg oral, is taken daily from registration to just prior to dose 2 of NSC-CRAd-S-pk7.
48365816|NCT01384513|DRUG|Fludarabine|Given IV
48365817|NCT01384513|DRUG|Busulfan|Given IV
48682741|NCT02377024|DIETARY_SUPPLEMENT|placebo|
48682742|NCT01887964|OTHER|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
48682743|NCT01887964|OTHER|Control flour|Wheat flour without resistant starch (type-4)
48682744|NCT04020471|OTHER|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
48682745|NCT02261064|DRUG|Telmisartan/Amlodipine low dose|
48682746|NCT02261064|DRUG|Telmisartan/Amlodipine high dose|
48682747|NCT02261064|OTHER|Japanese meal|
47996823|NCT04010721|DEVICE|Experiment 1|Stimulation of one electrode at a time
47996824|NCT04010721|DEVICE|Experiment 2:|Stimulation in groups of 4, 8 and 12 electrodes
47996825|NCT04010721|DEVICE|Experiment 3|Stimulation total duration from 10 to 600 ms
47996826|NCT06061627|PROCEDURE|LOT-CRT group|"In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads~LBBAP includes LBBP and LVSP.~LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:~   1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;~  2. When reducing the output voltage, the LVAT undergoes a sudden change of\>10ms;~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
47996827|NCT06061627|PROCEDURE|BiVP group|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
48682748|NCT06371157|DRUG|AK104|intravenous
48682749|NCT06371157|DRUG|Lenvatinib|oral
48682750|NCT06371157|PROCEDURE|TACE|TACE (chemo and embolic agent injection into the hepatic artery)
48682751|NCT06371157|OTHER|Placebo for AK104|intravenous
48682752|NCT06371157|OTHER|Placebo for Lenvatinib|oral
48682753|NCT01791660|DEVICE|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
48682754|NCT06062264|BEHAVIORAL|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
48155537|NCT02161393|BEHAVIORAL|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
48155538|NCT02161393|BEHAVIORAL|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
48682755|NCT06062264|BEHAVIORAL|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
48682756|NCT00730353|DRUG|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
48155539|NCT05800990|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
48155540|NCT04871932|BIOLOGICAL|Recently Vaccination|
48155541|NCT04271956|BIOLOGICAL|Tislelizumab|Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
48155542|NCT04271956|DRUG|Zanubrutinib|Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
48155543|NCT04271956|DRUG|Sonrotoclax|"Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po"
48155544|NCT05029271|DEVICE|InPen with Guardian 4 System|Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
48512234|NCT05753878|OTHER|Placebo nasal spray, Part B|Placebo nasal spray, 10 times daily for 7 consecutive days.
48365818|NCT01384513|RADIATION|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
48365819|NCT01384513|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
48365820|NCT01384513|DRUG|Cyclophosphamide (CY)|Given IV
48512235|NCT05801224|DEVICE|Nitric Oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
48512236|NCT05000528|OTHER|therapeutic education|In groups of 5-6, patients will have a one-day therapeutic training session comprising 4 workshops: how to create a sleep agenda; normal sleep; sleep hygiene; medical treatments.
48512237|NCT05000528|OTHER|Actimetry|once from inclusion for 2 weeks, second for 2 weeks starting 2 weeks after intervention
48682757|NCT00730353|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
48365821|NCT01384513|DRUG|Tacrolimus|Given IV or PO
48365822|NCT01384513|DRUG|Mycophenolate mofetil|Given IV
48365823|NCT01384513|DEVICE|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
48365824|NCT01384513|PROCEDURE|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
48365825|NCT03673150|OTHER|non intervention|Observational study / non intervention
48512238|NCT03825718|BIOLOGICAL|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
48512239|NCT03960463|DEVICE|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
48682758|NCT01435694|BEHAVIORAL|Lokomat (Hocoma, Switzerland)|
48682759|NCT01435694|BEHAVIORAL|Conventional Therapy|
48682760|NCT00532129|DRUG|Rituximab|375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
48682761|NCT00532129|DRUG|Chlorambucil|10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
48682762|NCT02409641|DRUG|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
48682763|NCT04809493|PROCEDURE|Conventional dialysis treatment|Conventional dialysis treatment
48682764|NCT04809493|PROCEDURE|Isonatremic dialysis treatment|Isonatremic dialysis treatment
48682765|NCT04335630|DIAGNOSTIC_TEST|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
48682766|NCT05961683|DEVICE|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
48682767|NCT00682279|DRUG|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
48682768|NCT05020301|DEVICE|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
48682769|NCT05020301|DEVICE|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
48682770|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
48512240|NCT04325932|DRUG|Urinary Kallikrein|
47996828|NCT04295421|PROCEDURE|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
47996829|NCT04295421|PROCEDURE|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
47996830|NCT03602469|DRUG|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
47996831|NCT03602469|DRUG|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
47996832|NCT03602469|DRUG|Propofol|Using propofol 1.5-2.5 mg/kg
47996833|NCT03602469|DEVICE|Ultrasound|Ultrasound-guided suprascapular nerve block
47996834|NCT03602469|DRUG|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
47996835|NCT03602469|DRUG|Rocuronium|Rocuronium 0.6 mg/kg
47996836|NCT05990400|DRUG|Finasteride|finasteride topical 0,1%
48682771|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
47996837|NCT05990400|DRUG|Minoxidil|minoxidil topical 5%
47996838|NCT03678467|COMBINATION_PRODUCT|EB-CMF|Autologous, anatomically shaped bone graft
47996839|NCT06457841|BEHAVIORAL|Direct Discrimination|Simulated racial discrimination that is received directly from a perpetrator, commonly experienced in everyday lives by African American individuals
47996840|NCT06457841|BEHAVIORAL|Vicarious Discrimination|Hearing or observing racial discrimination experienced by another person of the same racial background
47996841|NCT06457841|BEHAVIORAL|Daily Hassles|Day-to-day stressors associated with school, work, finances
47996842|NCT00360828|DRUG|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
47996843|NCT00360828|DRUG|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
47996844|NCT03455660|OTHER|no intervention|no intervention
47996845|NCT02221375|DRUG|BHT low|
47996846|NCT02221375|DRUG|BHT medium|
47996847|NCT02221375|DRUG|BHT high|
47996848|NCT02221375|DRUG|BI 54903 XX low|
47996849|NCT02221375|DRUG|BI 54903 XX medium 1|
47996850|NCT02221375|DRUG|BI 54903 XX medium 2|
47996851|NCT02221375|DRUG|BI 54903 XX high|
47996852|NCT02221375|DRUG|Ciclesonide|
48512241|NCT02040441|DRUG|Spironolactone|
48512242|NCT02040441|DRUG|Placebo|
48512243|NCT02040441|DRUG|Standard care|Standard diabetes care
48682772|NCT00837161|DEVICE|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
48682773|NCT04388215|DRUG|CKD-828|orally, 1 tablet once a day for 8 weeks
48682774|NCT04388215|DRUG|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
48682775|NCT04388215|DRUG|D326|orally, 1 tablet once a day for 8 weeks
48682776|NCT04388215|DRUG|D326(placebo)|orally, 1 tablet once a day for 8 weeks
47996853|NCT03889821|BEHAVIORAL|Parent-implemented Early Start Denver Model|The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.
47996854|NCT03889821|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) protocol is derived from the work by Dykens et al. (2014), which is based on the stress reduction and relaxation program (Kabat-Zinn, 1982, 1990). In this study, it is offered as 6 weekly sessions that run concurrent with the P-ESDM intervention. Participants work one-on-one with a therapist for instruction and practice in mindfulness skills as well as discussions of stress, coping, and homework assignments.
47996855|NCT01127308|DRUG|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin
47996856|NCT04245384|OTHER|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
47996857|NCT04245384|OTHER|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
47996858|NCT04022096|DRUG|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
47996859|NCT04022096|DRUG|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
48365826|NCT02365246|DEVICE|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
47996860|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
47996861|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
47996862|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
47996863|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
48365827|NCT00529646|DRUG|APD791|
48682777|NCT04388215|DRUG|D337|orally, 1 tablet once a day for 8 weeks
48682778|NCT04388215|DRUG|D337(placebo)|orally, 1 tablet once a day for 8 weeks
47996864|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
47996865|NCT04087460|BIOLOGICAL|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
47996866|NCT06363565|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Folic acid, vitamin B6, vitamin B12, and betaine per day orally for 12 weeks.
47996867|NCT06363565|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste, and weight are same with the tablet of supplement.
47996868|NCT03340337|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
47996869|NCT03340337|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
47996870|NCT03340337|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
47996871|NCT00004888|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
47996872|NCT00004888|DRUG|docetaxel|Given IV
47996873|NCT00004888|BIOLOGICAL|trastuzumab|Given IV
47996874|NCT00004888|OTHER|laboratory biomarker analysis|Correlative studies
47996875|NCT02486042|DRUG|Omegaven|Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).
47996876|NCT02486042|DIETARY_SUPPLEMENT|Standard lipids (primarily omega-6 fatty acids)|Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.
48365828|NCT03428490|BEHAVIORAL|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
48365829|NCT03428490|BEHAVIORAL|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
48365830|NCT05136326|RADIATION|External-beam radiation|External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)
48365831|NCT05136326|DRUG|Capecitabine|825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
48365832|NCT05136326|DRUG|Temozolomide|75 mg/sqm p.o. 5 days/week for 5 weeks
48682779|NCT04388215|DRUG|D013|orally, 1 tablet once a day for 8 weeks
48682780|NCT04388215|DRUG|D013(placebo)|orally, 1 tablet once a day for 8 weeks
48682781|NCT00290719|DRUG|cisplatin|
48682782|NCT00290719|DRUG|gefitinib|
48682783|NCT00290719|DRUG|irinotecan hydrochloride|
48682784|NCT00290719|PROCEDURE|conventional surgery|
48682785|NCT00290719|PROCEDURE|neoadjuvant therapy|
48682786|NCT00290719|RADIATION|radiation therapy|
48682787|NCT01195818|DRUG|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
48365833|NCT04554888|DRUG|Doxepin Topical|Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
48365834|NCT04554888|DRUG|Papain|Papain will be applied by 1 SPT prick thought the skin
48365835|NCT04554888|DRUG|Histamine|Histamine will be applied by 1 SPT prick thought the skin
48365836|NCT04554888|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 µm at their tip. 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
48365837|NCT06439251|COMBINATION_PRODUCT|Group 1|The treatment included TENS therapy, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques. Participants in Group A also received Phonophoresis as an experimental technique.
48365838|NCT06439251|COMBINATION_PRODUCT|Group 2|The treatment included routine physiotherapy with TENS, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques.
48365839|NCT06382428|OTHER|Pelvic floor muscle training|The PFMT program was carried out for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. The program consisted of education, diaphragm breathing exercises, pelvic mobility exercises, exercises to strengthen and stretch the pelvic floor muscles and other muscles related to the pelvis. In addition, the participants were expected to do the same exercises at home 2 days a week.
48365840|NCT02636049|DRUG|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
48365841|NCT00307658|DRUG|Intravenous immunoglobulins (human immunoglobulins G)|
47996877|NCT03011255|BIOLOGICAL|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
47996878|NCT06038279|DRUG|INI-2004|INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
47996879|NCT06038279|DRUG|Placebo|The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
47996880|NCT00003463|DRUG|carmustine|
47996881|NCT00003463|DRUG|irinotecan hydrochloride|
47996882|NCT00003463|DRUG|polifeprosan 20 with carmustine implant|
47996883|NCT00003463|PROCEDURE|surgical procedure|
47996884|NCT02280590|DRUG|Rosuvastatin(Cresnon®)|10mg
47996885|NCT02280590|DRUG|Rosuvastatin(Crestor®)|10mg
48365842|NCT03081494|DRUG|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
48365843|NCT03081494|DRUG|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
48365844|NCT03742258|DRUG|Cyclophosphamide|Given IV
48682788|NCT02478814|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
48365845|NCT03742258|DRUG|Doxorubicin Hydrochloride|Given IV
48365846|NCT03742258|DRUG|Prednisone|Given PO
47996886|NCT06325956|DRUG|Metformin|Take metformin for six months.
47996887|NCT03546751|DEVICE|Continuous Positive Airway Pressure|This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
47996888|NCT03546751|OTHER|Diet And Exercise|This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
47996889|NCT00676299|DRUG|JNJ-26483327|
47996890|NCT02445495|DEVICE|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
47996891|NCT00799578|DRUG|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
47996892|NCT03975907|BIOLOGICAL|CAR-BCMA T Cells|The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
47996893|NCT01946997|OTHER|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
47996894|NCT05798390|DRUG|Bempedoic acid and/or its fixed dose combination with ezetimibe|This is a non-interventional study. No study medication will be provided as part of this protocol to the patients. Medications will be as prescribed by the treating physician in line with clinical practice.
47996895|NCT03067805|BEHAVIORAL|Sexual Infidelity Condition|
47996896|NCT03067805|BEHAVIORAL|Emotional Infidelity Condition|
47996897|NCT03067805|BEHAVIORAL|Neutral Condition|
47996898|NCT03067805|BEHAVIORAL|Player in Jealousy Condition|
47996899|NCT03067805|BEHAVIORAL|Player in Non-Jealousy Condition|
48365847|NCT03742258|BIOLOGICAL|Rituximab|Given IV
48365848|NCT03742258|DRUG|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
48365849|NCT03742258|DRUG|Vincristine Sulfate|Given IV
48365850|NCT00107536|DRUG|lapatinib ditosylate|
48365851|NCT00107536|OTHER|laboratory biomarker analysis|Correlative studies
48365852|NCT05837429|BEHAVIORAL|Low Volume High Intensity Exercise Training|Patients in the intervention group will be given a warm-up phase for 3 minutes at 50% VO2max, 1 minute at 80-100% VO2max and 1 minute at 50% VO2max in 10 cycles, and finally a cool-down phase for 3 minutes at 50% VO2max.
48682789|NCT00414076|DRUG|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
48682790|NCT04407156|OTHER|acute kidney injury|AKI in COVID positive cases
48682791|NCT00148031|DRUG|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
48682792|NCT00148031|BEHAVIORAL|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
48155545|NCT01233193|BEHAVIORAL|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
48155546|NCT05319444|DEVICE|Off-brand Waterpik®|"Study staff will use the Waterpik® device and brush for approximately two to five minutes on the participant's scalp until all scale and other debris appears to be resolved. Their scalp will then be rinsed and gently dried with a towel.~The off-label design utilizes the Waterpik® device, but with adjustments optimized for scalp health. The device settings are adjustable during the treatment, ranging from settings of 2-10. Study staff plan to utilize the setting of 10 unless the participant indicates discomfort. Investigators attached a small Losophy brush in replacement of the Waterpik® toothbrush. The small Losophy brush was connected to the device via PVC heat shrink and a hole was drilled on the brush in order to deliver water while simultaneously utilizing the brush on the scalp."
48155547|NCT01029418|DRUG|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
47996900|NCT05542927|DIAGNOSTIC_TEST|urine chloride|Serum chloride, urinary chloride \& serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride \& urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI \& mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
48155548|NCT05774418|BIOLOGICAL|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
48682793|NCT00148031|BEHAVIORAL|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
48155549|NCT02919865|DEVICE|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
48512244|NCT03936595|OTHER|Core exercises protocol|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
48682794|NCT00148031|BEHAVIORAL|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
48682795|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
48682796|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
48682797|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
47996901|NCT05450471|DRUG|Corticosteroid Topical|The L-lactide and trimethynele carbonate (TCM) Terpolymers polymer implant will be placed in the ethmoidal region, at the same time that the nasal endoscopic examination will be performed.
47996902|NCT05450471|OTHER|Placebo|Placebo
47996903|NCT03966755|BEHAVIORAL|UFA dietary recommendations|The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
48155550|NCT00647452|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
48512245|NCT03936595|OTHER|Structural exercises protocol|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
48682798|NCT00843440|DRUG|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
48682799|NCT04694118|OTHER|rebound therapy|3 days a week in 12 weeks
48682800|NCT01162473|DIETARY_SUPPLEMENT|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
48682801|NCT01162473|DRUG|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
48155551|NCT05135845|DRUG|Capmatinib|Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
48155552|NCT05135845|DRUG|Spartalizumab|Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
48155553|NCT01461343|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
48155554|NCT05680415|BIOLOGICAL|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
48155555|NCT03262753|PROCEDURE|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
48155556|NCT03262753|PROCEDURE|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
48155557|NCT03262753|PROCEDURE|Stent|Primary stent dilation treatment of coarctation of the aorta
48155558|NCT00843245|OTHER|No intervention|No intervention
48155559|NCT03833206|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
48365853|NCT05837429|BEHAVIORAL|Aerobic Exercise Training|Patients in the control group will be given exercise training on a bicycle ergometer for 5 minutes warm-up phase at 40% of maximal oxygen consumption (VO2max), 20 minutes exercise phase at 60% of VO2max and 5 minutes cool down phase at 40% of VO2max for a total of 30 minutes.
48365854|NCT00795717|DRUG|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
48365855|NCT00795717|DRUG|Placebo|2 capsules given twice daily
48682802|NCT01162473|OTHER|Food Challenge|
48682803|NCT02342769|DRUG|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
48682804|NCT04758481|RADIATION|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
48682805|NCT04758481|RADIATION|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
48682806|NCT04758481|RADIATION|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
47996904|NCT05263700|DRUG|68Ga-FAPi-46|FAPI-46 is a small molecular radiopharmaceutical that binds to the fibroblast activated protein on cancer associated fibroblasts. Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes.
47996905|NCT05263700|PROCEDURE|PET/CT imaging|PET with the investigational tracer 68Ga-FAPI-46 with accompanying low-dose CT for anatomical localisation
48682807|NCT00170326|PROCEDURE|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
47996906|NCT05533918|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
47996907|NCT05533918|BEHAVIORAL|Patient Navigation (PN)|"Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types."
47996908|NCT03700697|BEHAVIORAL|Family Stress Module Intervention|as above
47996909|NCT04707261|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10 mg once daily
47996910|NCT04707261|DRUG|Placebo|Participants will receive placebo 10 mg once daily
47996911|NCT03974815|DEVICE|ACTIVE|"We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
47996912|NCT03974815|DEVICE|SHAM|"We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
47996913|NCT04535895|RADIATION|Simultaneous integrated boost|Adjuvant breast cancer irradiation including simultaneous integrated boost
47996914|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
48155560|NCT01586494|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
48155561|NCT01586494|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
48155562|NCT02800512|PROCEDURE|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
48155563|NCT02800512|PROCEDURE|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
48155564|NCT01425697|OTHER|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
48155565|NCT01425697|OTHER|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
48682808|NCT00170326|PROCEDURE|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
47996915|NCT04006665|DIAGNOSTIC_TEST|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
48155566|NCT02276937|DRUG|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
48155567|NCT03607578|BEHAVIORAL|Other: Control Group - Minimal Intervention|Basic Campaign Folder
48365857|NCT00144417|DRUG|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
48512246|NCT03936595|OTHER|Accentuated eccentric load exercises protocol|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Hip thrusts, 4 sets of 5 repetitions at 30% BM"
48512247|NCT03936595|OTHER|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
47996916|NCT00001487|DRUG|Dehydroepiandrosterone|
48682809|NCT04769817|OTHER|177Lu-PSMA|Lu-PSMA will be administered as a standard-of-care procedure following assessment of suitability by a nuclear medicine physician and managed in close collaboration with the patient's medical oncologist.
47996917|NCT01820416|RADIATION|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
48682810|NCT02383186|PROCEDURE|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
48682811|NCT02383186|PROCEDURE|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
48682812|NCT00243867|DRUG|Taxoprexin|6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
48682813|NCT03740399|PROCEDURE|spinal anesthesia|Investigators will perform spinal anesthesia for section
48682814|NCT00153673|DRUG|celecoxib|Celecoxib 200mg bd
47996918|NCT01820416|OTHER|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
47996919|NCT01454921|BEHAVIORAL|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
48365858|NCT00144417|DRUG|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
48512248|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
48682815|NCT00153673|DRUG|Dologesics|Dologesics 2 tablets bd
47996920|NCT01367574|DRUG|SC MNTX|Dose 1
48365859|NCT00002715|BIOLOGICAL|Bleomycin sulfate|A component of the Stanford V regimen.
48365860|NCT00002715|DRUG|Stanford V regimen|
47996921|NCT01367574|DRUG|SC MNTX|Dose 2
47996922|NCT01367574|DRUG|SC MNTX|Dose 3
47996923|NCT01860755|OTHER|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
47996924|NCT01860755|OTHER|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
48365861|NCT00002715|DRUG|Doxorubicin hydrochloride|A component of the Stanford V regimen.
48365862|NCT00002715|DRUG|Etoposide|A component of the Stanford V regimen.
47996925|NCT06524310|DEVICE|Stimulation with low frequency rTMS at 1 Hz|Stimulation with low-frequency rTMS at 1 Hz with 90% MT will be applied with a total of 180 pulses each time, which contained 18 trains with ten pulses and an interval of 20 s between any two adjacent trains. The TMS treatment course will be administered twice per week for 9 weeks; the first six treatments will be over the left DLPFC, the second six sessions will be over the right DLPFC, and the remaining six times will be placed on the bilateral DLPFC stimulation (64).
48365863|NCT00002715|DRUG|Mechlorethamine hydrochloride|A component of the Stanford V regimen.
48365864|NCT00002715|DRUG|Prednisone|A component of the Stanford V regimen.
48365865|NCT00002715|DRUG|Vinblastine|A component of the Stanford V regimen.
48365866|NCT00002715|DRUG|Vincristine sulfate|A component of the Stanford V regimen.
48512249|NCT05229536|BIOLOGICAL|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.
48512250|NCT00199524|DEVICE|Navigator Ureteral Access Sheath|ureteral access sheath
48512251|NCT00693095|BIOLOGICAL|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
48512252|NCT00693095|BIOLOGICAL|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
48512253|NCT05919615|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
47996926|NCT03023865|PROCEDURE|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
47996927|NCT02293655|DRUG|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
47996928|NCT02430337|BEHAVIORAL|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
47996929|NCT02430337|BEHAVIORAL|SafeCare|SafeCare, an evidence-based home visiting program
47996930|NCT02311439|DRUG|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
47996931|NCT03031093|RADIATION|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
47996932|NCT03031093|DEVICE|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
48365867|NCT03151928|DIAGNOSTIC_TEST|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
48682816|NCT03374735|DEVICE|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
47996933|NCT05333900|BEHAVIORAL|Plant-Based Diet then animal-based diet|Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.
47996934|NCT05333900|BEHAVIORAL|Animal-based diet then plant-based diet|Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days
47996935|NCT02984566|DEVICE|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
47996936|NCT00210821|DRUG|topiramate|
47996937|NCT01852266|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
48365868|NCT03499496|DIAGNOSTIC_TEST|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
48682817|NCT00047905|BEHAVIORAL|examine the process of prenatal genetic counseling|
48365869|NCT03804138|OTHER|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
48682818|NCT04970173|OTHER|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
48682819|NCT03011112|PROCEDURE|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
48512254|NCT05919615|DRUG|Normal saline|0.9% sodium chloride normal saline
48512255|NCT02304497|OTHER|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
48512256|NCT01261923|DRUG|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
48512257|NCT00004212|BIOLOGICAL|filgrastim|
48512258|NCT00004212|DRUG|exatecan mesylate|
48682820|NCT02049346|DRUG|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
47996938|NCT01852266|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
47996939|NCT05978154|OTHER|Thigh muscle mass and muscle wasting (exposure)|Thigh muscle mass and muscle wasting (exposure variable)
48365870|NCT01075022|DRUG|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
48365871|NCT01075022|DRUG|Placebo|Placebo Capsule, Single Dose
48365872|NCT02303535|PROCEDURE|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
48512259|NCT03364842|DRUG|Furosemide|Administering furosemide
48512260|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
47996940|NCT01697865|PROCEDURE|Transfer group|
48155568|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
48155569|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
48155570|NCT03869411|BEHAVIORAL|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
48155571|NCT05793827|BEHAVIORAL|Adapted Hatha Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
48365873|NCT02303535|PROCEDURE|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
48682821|NCT02049346|DRUG|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
48682822|NCT02049346|DRUG|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
48682823|NCT05242341|BEHAVIORAL|application(APP) teaching|Teaching the use of the APP
48682824|NCT04836611|PROCEDURE|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
48682825|NCT06511544|DEVICE|Transcranial magnetic stimulation|rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
48682826|NCT02325024|DRUG|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
48682827|NCT00587808|PROCEDURE|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
48682828|NCT01292122|DEVICE|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
48682829|NCT03742570|BEHAVIORAL|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
47996941|NCT01697865|PROCEDURE|Control group|
47996942|NCT03435965|DIAGNOSTIC_TEST|AmnioQuickDuo+|AmnioQuickDuo+ kit for detection of PROM
47996943|NCT01184274|DRUG|SB939|"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. - 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. - 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
47996944|NCT04184531|OTHER|Medical Data Collect|It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
47996945|NCT04347382|DRUG|Honey|1gm/Kg/Day
47996946|NCT04347382|DRUG|Nigella Sativa / Black Cumin|80mg/Kg/day
47996947|NCT04347382|DRUG|Placebos|Empty capsule with 250ml of distilled water
47996948|NCT06167109|RADIATION|CTV optimized IMRT|The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as a potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
48155572|NCT05793827|BEHAVIORAL|Low-Impact Exercise|This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
48155573|NCT05417555|DEVICE|Low-Intensity Focused Ultrasound Pulsation (LIFUP)|Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
48155574|NCT02211859|DRUG|BI 2536|
48155575|NCT04282200|DRUG|Ketorolac|intravenous ketorolac 30 mg every 6 hours
48155576|NCT00881972|BEHAVIORAL|Exercise|walking/running/cycling
48155577|NCT01743807|DRUG|GNKG168|GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.
48155578|NCT03109600|BIOLOGICAL|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
48155579|NCT03109600|BIOLOGICAL|Vi polysaccharide vaccine|Vi polysaccharide vaccine
48155580|NCT03109600|BIOLOGICAL|Influenzae vaccine|1 dose of Influenzae vaccine
48155581|NCT03109600|BIOLOGICAL|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
48155582|NCT00371696|DRUG|diclofenac|
48155583|NCT00371696|DRUG|paracetamol|
48155584|NCT00371696|DEVICE|heat retaining knee support|
48155585|NCT00371696|DEVICE|standard knee support|
48155586|NCT01182285|DRUG|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
48155587|NCT01182285|DRUG|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
48155588|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 68Ga-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
48682830|NCT02594007|DEVICE|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
48682831|NCT02594007|DEVICE|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
48682832|NCT02594007|DEVICE|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
47996949|NCT00593671|PROCEDURE|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
47996950|NCT05004376|BEHAVIORAL|Text Messaging|Text messages based on behavioral theory to encourage scheduling colorectal cancer screening.
47996951|NCT04850014|OTHER|Anthropomorphism|Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender
47996952|NCT04850014|OTHER|Relevant clinical datas|"Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging."
48155589|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 18F-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
48155590|NCT03036722|OTHER|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
48155591|NCT03036722|OTHER|Placebo control porridge|control porridge matched for energy and fat content.
48155592|NCT04869046|DRUG|Instillation of levobupivacaine in surgical wound|Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
48155593|NCT02137603|OTHER|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
48155594|NCT03785041|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
48155595|NCT04532333|DRUG|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
48155596|NCT04532333|DRUG|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
48682833|NCT03585725|DRUG|Ribavirin|"Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food."
48682834|NCT03278795|PROCEDURE|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
47996953|NCT05195281|PROCEDURE|Fine Needle Biopsy or Aspiration|A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy
47996954|NCT01470742|DRUG|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
48155597|NCT05804552|DEVICE|Dorsal genital nerve stimulation|Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
48155598|NCT05444777|DRUG|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
48682835|NCT03278795|PROCEDURE|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
48682836|NCT01202890|DRUG|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
48155599|NCT00399945|DRUG|Tobramycin|
48155600|NCT01270347|DRUG|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
48155601|NCT01270347|DRUG|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
48155602|NCT05387785|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule.
48155603|NCT05387785|DRUG|Placebo|Orally administered placebo capsule
48155604|NCT04851444|DRUG|SI-F019|Single dose is administered IV.
47996955|NCT01470742|DRUG|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
47996956|NCT01718756|DRUG|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
48155605|NCT01556087|BEHAVIORAL|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
48155606|NCT01556087|BEHAVIORAL|Health Education|7 individual sessions with didactic health education information
48155607|NCT00006747|DRUG|carmustine|IV
48155608|NCT00006747|DRUG|melphalan|IV
48155609|NCT00006747|DRUG|etoposide|IV
48155610|NCT00006747|DRUG|cytarabine|IV
47996957|NCT01718756|DRUG|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
47996958|NCT01718756|DRUG|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
48155611|NCT00006747|DRUG|tacrolimus|IV
48155612|NCT00006747|DRUG|methotrexate|IV
48155613|NCT00006747|DRUG|sargramostim|IV
48155614|NCT00006747|PROCEDURE|transplant|
48155615|NCT05259592|BEHAVIORAL|Psychotherapy|Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen \& Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.
48155616|NCT01764204|DRUG|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
48155617|NCT04296409|OTHER|Turkish Deglutition Handicap Index|Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
48155618|NCT01628939|OTHER|MRI of the lumbar spine|standard protocol, approximately 30 minutes
48155619|NCT01628939|OTHER|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
48155620|NCT01970072|DRUG|Remimazolam Tosylate|
48155621|NCT01970072|DRUG|Midazolam|
48155622|NCT01170871|DRUG|Ixabepilone|
48155623|NCT01170871|DRUG|Pemetrexed|
48155624|NCT02469493|DEVICE|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
48155625|NCT02815709|DRUG|Oliceridine|
48155626|NCT02815709|DRUG|Placebo|
48155627|NCT02815709|DRUG|Morphine|
48155628|NCT03966027|OTHER|Postoperative protocol (Immediate weight bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace
48155629|NCT03966027|OTHER|Postoperative Protocol (Delayed Weight Bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
48512261|NCT00559806|OTHER|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
47996959|NCT01814501|BIOLOGICAL|panitumumab|Given IV
48512262|NCT04610333|BEHAVIORAL|Modified MBSR programme|1 hour group session once a week in 10 weeks
48682837|NCT01202890|DRUG|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
47996960|NCT01814501|DRUG|irinotecan hydrochloride|Given IV
47996961|NCT01814501|DRUG|fluorouracil|Given IV
47996962|NCT01814501|DRUG|leucovorin calcium|Given IV
47996963|NCT00399009|DEVICE|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
47996964|NCT05629832|PROCEDURE|mechanical ventilation strategy guided by transpulmonary pressure|Mechanical ventilation parameters adjust guided by transpulmonary pressure monitoring. For pressure assist control or volumn assit control mode; inspiratory pressure or volumn setting needs to maintain Ppeak less than 25 cm H2O; PEEP was set at such a level that expiratory Ptp stayed between 0 and 5 cm H2O.
47996965|NCT04278521|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
47996966|NCT01028508|DRUG|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
47996967|NCT01028508|PROCEDURE|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
47996968|NCT01925404|BEHAVIORAL|Free physical activity classes|100 hours of free activity classes will be provided
47996969|NCT01925404|BEHAVIORAL|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
47996970|NCT04252989|OTHER|data collection|"* Demographic data: age, sex~* Ophthalmological history: refraction of parents, previous refractions~* Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~* Potential undesirable events (halos, photophobia...)"
47996971|NCT04083807|BIOLOGICAL|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
47996972|NCT04083807|PROCEDURE|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
47996973|NCT00748267|OTHER|questionnaire administration|
47996974|NCT00748267|PROCEDURE|hypnotherapy|
48512263|NCT05018546|PROCEDURE|Irrigation force|RIRS with different irrigation force
48682838|NCT04916561|DIAGNOSTIC_TEST|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
48682839|NCT05641012|OTHER|data collection|helioderma evaluation
47996975|NCT00748267|PROCEDURE|therapeutic conventional surgery|
47996976|NCT00884299|DIETARY_SUPPLEMENT|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
47996977|NCT03096652|PROCEDURE|Approach for cancer resection|
47996978|NCT01097018|DRUG|Capecitabine|1000 mg/m2 BID/ Days 1-14
47996979|NCT01097018|DRUG|Perifosine|50 mg daily x 21 days
48512264|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
48512265|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
48682840|NCT00265486|DRUG|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
47996980|NCT01097018|DRUG|Placebo|1 pill daily x 21 days
47996981|NCT01528072|DEVICE|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
47996982|NCT04663581|OTHER|Left Sided Colonoscopy|Starting colonoscopy with the patient in left decubitus
47996983|NCT04663581|OTHER|Right Sided Colonoscopy|Starting colonoscopy with the patient in right decubitus
47996984|NCT03424265|DIETARY_SUPPLEMENT|EAA mixture|Dietary supplement intervention for 12-weeks
47996985|NCT03424265|DIETARY_SUPPLEMENT|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
48512266|NCT01356212|DRUG|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
48512267|NCT03761940|OTHER|EQ5D questionnaire and a demographic questionnaire|questionnaires
48512268|NCT03608527|BEHAVIORAL|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
48512269|NCT03608527|BEHAVIORAL|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
48155630|NCT02884622|OTHER|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
48155631|NCT02884622|OTHER|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
48155632|NCT05309356|OTHER|ACCEPT Decision Intervention|The intervention consists of the CPM (ACCEPT) that is integrated with a decision aid, together called the ACCEPT Decision Intervention (ADI). The ADI will provide physicians with a quantification of the exacerbation risk for each patient and the corresponding treatment recommendation, as well as information about the benefits and risks of different inhaled therapies to discuss with the patients. The intervention also includes a 1-page take-home pamphlet on evidence-based risk behaviour factor modification for COPD, tailored to the treatment recommendation.
48155633|NCT05309356|OTHER|Comparator|The patient will receive the physician-recommended treatment for COPD (usual care). All physicians will be provided refresher training on the Canadian Thoracic Society COPD guidelines during the phase in period (month 1).
48155634|NCT02072889|OTHER|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
48155635|NCT06057701|OTHER|corrective exercises|"corrective exercises:~1. Strengthening exercises :~   1. Thoracic extension exercises:~      * Mckanzie's thoracic extension exercise:~     * Thoracic spine stretching position~  2. Back extension exercise~  3. Abdominal curl up exercise~  4. Scapular retraction exercises~  5. Trunk rotation exercise~2. Stretching exercises:~   1. Pectoral muscles stretch from sitting~  2. self-stretch for pectoral muscle infront of door"
48155636|NCT06057701|OTHER|resisted diaphragmatic breathing exercises|"1. Diaphragmatic breathing exercise: From the supine position, overlapping hands on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly.~2. Resisted diaphragmatic breathing exercise: From the supine position, with a weight of 1 kg on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly"
48155637|NCT02619045|OTHER|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
48155638|NCT04196517|OTHER|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
48682841|NCT04414553|BEHAVIORAL|Community Active and Healthy Families|"Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes."
48512270|NCT00732485|DRUG|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
48512271|NCT00732485|DRUG|placebo|Placebo, sugar pill, from admission to 6 months post burn
48682842|NCT05243979|RADIATION|DEXA scan|bone study
48682843|NCT01813201|DRUG|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
47914448|NCT05858424|OTHER|Multidisciplinary day hospitalization|"This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.~The psychological interview will assess the needs for further care, and will refer the former patient if necessary.~The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.~If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment."
47996986|NCT05459103|OTHER|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
47996987|NCT05459103|OTHER|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
47996988|NCT02742012|OTHER|the study is observational|the study is observational
47996989|NCT05096845|BIOLOGICAL|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2\~8°C protected from light Expiry date: 24 months after production date"
47996990|NCT05096845|OTHER|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
48155639|NCT04196517|OTHER|WebMD|WebMD is a widely used educational platform for health information.
48512272|NCT00000691|DRUG|Foscarnet sodium|
48512273|NCT05412238|DIETARY_SUPPLEMENT|micro-and macro-nutrients fortified sachets|Every subject receives daily fortified sachets containing micro-and macronutrients for 6-9 months
48155640|NCT05085015|OTHER|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
48155641|NCT05085015|OTHER|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
48155642|NCT02418819|DRUG|PF-06412562 3mg BID|PF-06412562
48155643|NCT02418819|DRUG|PF-06412562 9mg BID|PF-06412562
48155644|NCT02418819|DRUG|PF-06412562 45mg BID|PF-06412562
48155645|NCT02418819|OTHER|Placebo|Placebo
48155646|NCT02363933|DRUG|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
48155647|NCT00799188|DRUG|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
47996991|NCT04891900|DRUG|TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine|"Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle"
47996992|NCT01413360|DRUG|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
47996993|NCT04914910|DEVICE|Minimed 780G insulin pump|This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
47996994|NCT05420207|OTHER|No intervention|No intervention included
47996995|NCT04706143|BIOLOGICAL|COVID-19 Vaccines|different available vaccines: live inactivated, mRNA and viral vector vaccines
47996996|NCT03035955|DRUG|Azelaic acid|15% gel twice daily for four weeks to one side of face
48365874|NCT01799291|BEHAVIORAL|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
48365875|NCT00265109|DRUG|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
48365876|NCT02330731|PROCEDURE|injection sclerotherapy for gastric varices|The intravariceal technique of injection
48365877|NCT04806191|OTHER|Evidence based treatment strategy|Evidence-based clinical examination and treatment plan
48155648|NCT04749771|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home.
48155649|NCT04749771|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction.
48365878|NCT04806191|OTHER|Targeted patient information package|GPs will in cooperation with the patients tailor a information package targeted to the patients needs regarding their clinical shoulder diagnosis and individual implications and needs (Pain, sleep, exercises etc.).
47996997|NCT00180895|DRUG|Rituximab|
48155650|NCT01975701|DRUG|BGJ398|Capsule for oral use.
48155651|NCT00331799|DRUG|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
48365879|NCT04806191|OTHER|Treatment as usual (TAU)|Usual care as provided by the GP
48365880|NCT01829542|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
47996998|NCT02580357|PROCEDURE|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
47996999|NCT02580357|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
47997000|NCT00563953|DRUG|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
48155652|NCT05384808|BEHAVIORAL|Standard Psychotherapy|Participants receive a standard psychotherapy session with no dog being present.
48365881|NCT01829542|DIETARY_SUPPLEMENT|Control|Macro- and micro-nutrient matched control in water
48365882|NCT01466972|DRUG|Pazopanib|Oral, 800mg tablet daily per cycle
48365883|NCT04602468|DRUG|Kaftrio|The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
47997001|NCT01970839|DEVICE|tourniquet, sensory nerve conduction abnormality|
47997002|NCT00239707|DRUG|GIP|One-time 20 ng/kg/min infusion over 3 hours
48155653|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog actively integrated.|A dog is present and actively integrated into the therapeutic narrative.
48155654|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog passively integrated.|A dog is present but not actively integrated into the therapeutic narrative.
48155655|NCT02074865|BIOLOGICAL|biological samples|
48155656|NCT05872958|DRUG|AZD3152|AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
48155657|NCT05872958|OTHER|Placebo|Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
48155658|NCT02823171|DRUG|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
48155659|NCT02823171|DRUG|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
48155660|NCT00591188|DRUG|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
48155661|NCT01398345|BEHAVIORAL|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
47997003|NCT00239707|DRUG|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
47997004|NCT00239707|DRUG|Normal Saline|one-time infusion over 3 hours
47997005|NCT04196946|DRUG|25 mcg fentanyl|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
47997006|NCT04196946|DRUG|250 mcg alfentanil|Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
47997007|NCT03496948|BEHAVIORAL|TeGeCoach|"12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription."
48155662|NCT04301609|DIETARY_SUPPLEMENT|Active|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
48155663|NCT04301609|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
48155664|NCT00682344|DRUG|Levobupivacaïne|1,75mg/kg
48155665|NCT01339156|DRUG|P3914|"Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
48155666|NCT01339156|DRUG|Placebo|"Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
48155667|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHPy|Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer
48155668|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHP|Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
48365884|NCT02101216|DRUG|Prurisol|Experimental Drug
48365885|NCT02101216|DRUG|Ziagen|Active comparator
48365886|NCT01654224|BIOLOGICAL|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
48682844|NCT01813201|DRUG|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
48365887|NCT01654224|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
48682845|NCT06187220|DEVICE|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
48682846|NCT05448729|DIAGNOSTIC_TEST|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
48682847|NCT04202185|OTHER|Data collection|Retrospective collection data from diagnostic Data collected following to medical exam as part of care
48682848|NCT04202185|GENETIC|Genetic analysis|Research of mutation and identification of genetic panel as part of care
48155669|NCT03440580|DEVICE|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
48155670|NCT05667688|DRUG|Tinlarebant (LBS-008)|A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
48155671|NCT00987155|DEVICE|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
48155672|NCT01651650|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
48155673|NCT06585189|DRUG|Pembrolizumab|
48155674|NCT06585189|DRUG|Pemetrexed|
48155675|NCT06585189|DRUG|Cisplatin|
48365888|NCT03463980|BEHAVIORAL|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
48365889|NCT03463980|BEHAVIORAL|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
47997008|NCT06348992|BEHAVIORAL|Acceptance commitment therapy and yoga|The intervention used a combination of online and offline methods, based on ACT, supplemented by hatha yoga exercise intervention, the intervention group used the combination of offline ACT psychological intervention and online hatha yoga training, and the control group used mental health education, so as to explore and validate the effect of ACT combined with yoga on the improvement of parental parental burnout in children with ASD. The offline ACT psychological intervention was implemented by the researchers and psychologists, and the ACT psychological intervention was carried out once a week in community health centers or hospitals for 8 weeks. Online, a WeChat group was set up for parents with ASD, and Hatha Yoga training content and videos were sent to the group chat, and the researchers and volunteers supervised the training and clocking in and out of the group, three times a week.
47997009|NCT06348992|BEHAVIORAL|Active Comparator: Mental Health Education Group|The control group was provided with 8 weeks of mental health education, including emotional management skills, positive coping styles, and scientific parenting methods.
47997010|NCT00935870|DEVICE|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
48365890|NCT01343940|BEHAVIORAL|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
47997011|NCT05148481|DRUG|BIIB104|Administered as specified in the treatment arm
48365891|NCT01343940|BEHAVIORAL|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
48365892|NCT02815982|BEHAVIORAL|NOURISH-T|Overweight/obesity family intervention
48365893|NCT02815982|BEHAVIORAL|Enhanced Usual Care|Publicly available overweight/obesity materials
48365894|NCT03814642|DRUG|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
48365895|NCT03814642|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
48365896|NCT03814642|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
48365897|NCT04568265|DRUG|APG-1387|Weekly intravenous infusion for 30 minutes
48365898|NCT04568265|DRUG|Entecavir 0.5 mg|Taken daily by mouth
48365899|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
47997012|NCT05148481|DRUG|Placebo|Administered as specified in the treatment arm
48155676|NCT06585189|DRUG|Carboplatin|
48155677|NCT02672345|DRUG|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
48155678|NCT03694249|DRUG|Ifetroban Sodium|Given by mouth
48155679|NCT03694249|OTHER|Placebo|Given by mouth
48155680|NCT02084589|OTHER|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
48155681|NCT02084589|OTHER|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
48155682|NCT03976102|BIOLOGICAL|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
48155683|NCT03976102|OTHER|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
48365900|NCT02632097|PROCEDURE|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
48365901|NCT00784680|DRUG|Anastrozole|1mg, orally, once daily
48365902|NCT00784680|DRUG|Tamoxifen|20mg, orally, once daily
48365903|NCT06247462|DRUG|Ibuprofen 600 mg|600 mg of ibuprofen was ingested 12- and 1-hours prior to exercise.
48365904|NCT06247462|DRUG|Placebo Corn Starch|600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
47997013|NCT02117999|DEVICE|Cross-linking with iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
48365905|NCT05747170|OTHER|Olfactory sstimulation|"The odors being tested (natural odor, neutral odor, chemical odor) are part of the 40 fragrances made by International Flavors and Fragrances (IFF) and each is contained in an approximately 15-mL glass bottle. The selected odors will be administered using a small paper strip (15 cm length and 0.7 cm width) that will be soaked in the selected odor and placed under the subject's nose at a minimum distance to prevent direct contact of the strip with the skin; the strip will be moved alternately from one nostril to the other.~Stimulation will have, for each odor the duration of 5 minutes. It will always be carried out within the same time slot (between 8:00 am and 4:00 pm) for 5 consecutive days for 2 weeks. Before and after the administration of each odor, a neutral odor (water) will be administered as a control in the same manner as described above.~The sequence of odor administration will be randomized according to a computer-generated sequence."
48682849|NCT06354530|DRUG|anlotinib|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles"
47997014|NCT02117999|DEVICE|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
48155684|NCT03514667|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
48155685|NCT03514667|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
48365906|NCT05878340|BEHAVIORAL|Miffy|A method to stimulate children to try different fruits and vegetables using reward and role modelling
48365907|NCT05878340|BEHAVIORAL|Reward|Reference method to stimulate children to try fruits and vegetables using reward alone
48365908|NCT01066624|DRUG|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
48682850|NCT06354530|RADIATION|Thoracic radiotherapy|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)"
48155686|NCT06646068|OTHER|Philips 66 with CBL|Each team is given six minutes to brainstorm ideas or solutions to specific clinical cases. This technique is applied during case-based learning sessions to enhance clinical judgment and critical thinking skills among nursing students.
48682851|NCT00003776|BIOLOGICAL|filgrastim|
48682852|NCT00003776|DRUG|cisplatin|
47914449|NCT02081326|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
47997015|NCT00908726|DRUG|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
47997016|NCT01148602|OTHER|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
48682853|NCT00003776|DRUG|doxorubicin hydrochloride|
48682854|NCT00003776|DRUG|ifosfamide|
48682855|NCT00003776|DRUG|leucovorin calcium|
47997017|NCT01859494|DEVICE|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
47997018|NCT02606188|DEVICE|Modified High-flow nasal cannula|Modified High-flow nasal cannula
47997019|NCT02606188|DEVICE|nasal cannula|Conventional oxygen therap
47997020|NCT06504199|DRUG|Obinutuzumab|No dose adjustment of Obinutuzumab is allowed.
47914450|NCT02081326|BIOLOGICAL|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
47914451|NCT01209325|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
47914452|NCT01209325|OTHER|laboratory biomarker analysis|
47997021|NCT06504199|DRUG|Zanubrutinib|Zanubrutinib was allowed to be titrated to 80 mg bid or 80 mg qd
47997022|NCT06504199|DRUG|Lenalidomide|Lenalidomide was allowed to be titrated to 15 mg/day (induction phase) or 5 mg/day (maintenance phase).
47997023|NCT06504199|DRUG|Cytarabine|The specific dose is determined by the investigator according to the actual situation of the patient.
47997024|NCT06504199|BIOLOGICAL|CAR-T|zanubrutinib in combination with lenalidomide was allowed for maintenance treatment in high-risk patients for 1 year and zanubrutinib for 2 years after recovery of hemogram 2 months after CAR-T. High-risk Patients with any of the following conditions: Mantle cell lymphoma International Prognostic Index (MIPI-c) high-risk, blastic/pleomorphic type, TP53 mutation/deletion, CDKN2A deletion, MYC amplification/translocation, or incomplete response at induction stage; Non-high-risk group: no high-risk features.
47997025|NCT00110409|BEHAVIORAL|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
48512274|NCT06453369|PROCEDURE|Y shaped Tunnel with Connective tissue graft|Sulcular incision followed by Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG insurted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.
47997026|NCT00110409|BEHAVIORAL|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
47997027|NCT05635851|DRUG|Glyceryl Trinitrate Only Product in Oromucosal Dose Form|Glyceryl trinitrate will be administered via sublingual spray.
47997028|NCT05635851|OTHER|Placebo sublingual spray|A placebo sublingual spray will be administered.
47997029|NCT05787314|BEHAVIORAL|Low Glycemic Index Diet|"1. Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.~2. The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI \> 55) were excluded from the diet and only low GI (GI \< 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided."
47997030|NCT05537571|DRUG|SLN360|SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)
47997031|NCT05537571|DRUG|Placebo|Sodium chloride, solution for injection
47997032|NCT04152720|DEVICE|Foley catheter|"If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured."
47997033|NCT01318031|DRUG|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
47997034|NCT01318031|DRUG|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
47997035|NCT02690610|PROCEDURE|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
47997036|NCT04637542|OTHER|Mobile Learning|"The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods."
47997037|NCT03102931|OTHER|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
48155687|NCT01396122|PROCEDURE|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA\* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
48682856|NCT00003776|DRUG|methotrexate|
47997038|NCT03102931|OTHER|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
47997039|NCT05717010|DEVICE|Near infrared spectroscopy|The Near Infrared Spectroscopy (NIRS) is the method used for monitorize the risk of the development of cerebral ischaemia while providing information about brain tissue oxygenation.
47997040|NCT00590109|OTHER|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
47997041|NCT00590109|OTHER|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
48155688|NCT06149533|DRUG|Edoxaban|Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
48155689|NCT00004311|DRUG|leuprolide acetate|
48155690|NCT00004311|DRUG|spironolactone|
47997042|NCT03608774|DRUG|Azithromycin|Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
47914453|NCT02052076|BEHAVIORAL|Meal pattern|
47997043|NCT03608774|DRUG|Doxycycline|Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
48365909|NCT01066624|OTHER|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
47914454|NCT00773318|PROCEDURE|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
48155691|NCT05115721|OTHER|no intervention|It's only observational study. No interventions.
48365910|NCT01066624|DEVICE|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
47997044|NCT03608774|OTHER|Placebo|Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
47997045|NCT06082882|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
47997046|NCT06082882|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
47997047|NCT04954963|DIAGNOSTIC_TEST|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
47997048|NCT02877784|PROCEDURE|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
47997049|NCT02877784|OTHER|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
47997050|NCT02877784|OTHER|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
47997051|NCT05839457|BEHAVIORAL|Empowerment Pilot|The Empowerment Pilot is a school-based program aimed to raise awareness and change attitudes around SRGBV among students and teachers and promote gender equality. This intervention includes training provided by Teacher Mentors to other teachers in school, learning sessions delivered via safe spaces for student learners, and guidance for engaging parent-teacher committees.
48155692|NCT00635752|OTHER|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
48155693|NCT00635752|OTHER|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
48155694|NCT03647709|OTHER|opioids|dosage frequency and duration
48512275|NCT03822104|DIETARY_SUPPLEMENT|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
48682857|NCT00003776|DRUG|trimetrexate glucuronate|
48682858|NCT00003776|PROCEDURE|surgical procedure|
48682859|NCT01687881|OTHER|Chiropractic|Chiropractic Spinal Manipulative Therapy
47914455|NCT05854498|DRUG|Liposomal irinotecan|50mg/m2 IV on days 1 and 15
47914456|NCT05854498|DRUG|TAS102|35mg/m2 PO BID on days 1-5 and 15-19
47914457|NCT05854498|DRUG|Bevacizumab|5mg/kg IV on days 1 and 15
48365911|NCT05190406|PROCEDURE|Pulpotomy|After achieving hemostasis, in pulpotomy group bioceramic material will be placed and then permanent restoration will be done.
48365912|NCT05190406|PROCEDURE|root canal treatment|Single visit root canal treatment will be done according to standard protocol.
48365913|NCT06106399|PROCEDURE|WALLANT|Comparison between (WALLANT) and (CPB) as a sole anesthesia in clavicle surgery
48365914|NCT02737514|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
48365915|NCT02737514|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
48365916|NCT02737514|PROCEDURE|water exchange|Water will infused and removed during insertion phase of colonoscopy
48365917|NCT01298661|OTHER|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
48682860|NCT01687881|OTHER|Sham Chiropractic|Sham manipulation
48682861|NCT00004215|BIOLOGICAL|filgrastim|
48682862|NCT00004215|BIOLOGICAL|leridistim|
48155695|NCT02521428|OTHER|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
47997052|NCT00441311|BEHAVIORAL|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
48155696|NCT01943370|OTHER|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
47997053|NCT00470574|BIOLOGICAL|QS21|
47997054|NCT00470574|BIOLOGICAL|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
48512276|NCT03822104|DIETARY_SUPPLEMENT|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
48512277|NCT05676515|OTHER|culture media|spliting of biological material and use of three culture media
48512278|NCT03043404|DEVICE|Transcatheter aortic valve replacement|TAVR with Lotus Valve Flex System
47997055|NCT00470574|OTHER|immunoenzyme technique|
47997056|NCT00470574|OTHER|immunologic technique|
47997057|NCT00470574|OTHER|laboratory biomarker analysis|
48512279|NCT00562783|DRUG|Vitaliver|
48512280|NCT00562783|DRUG|Placebo|
47997058|NCT02871388|BEHAVIORAL|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
47997059|NCT02157142|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
48155697|NCT01943370|OTHER|Routine Irrigation|Routine initiation of saline irrigation
48155698|NCT03985020|OTHER|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
48155699|NCT03985020|OTHER|Water Intervention|Bottled Water
48155700|NCT05254288|OTHER|Chlorhexidine|In-office and domiciliary use of chlorhexidine for 14 days.
48512281|NCT01396915|DIETARY_SUPPLEMENT|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
48512282|NCT02884570|OTHER|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
48512283|NCT00295061|DRUG|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
48682863|NCT00004215|DRUG|cytarabine|
48682864|NCT00004215|DRUG|daunorubicin hydrochloride|
48512284|NCT00295061|DRUG|alpha-1 proteinase inhibitor (human)|Prolastin
48682865|NCT02827760|DIETARY_SUPPLEMENT|Synergy1|Inulin type fructans
48682866|NCT02827760|DIETARY_SUPPLEMENT|Maltodextrin|
48682867|NCT05524636|DEVICE|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
48682868|NCT05524636|OTHER|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
48682869|NCT01861561|DRUG|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
47997060|NCT04606576|OTHER|Placebo|Fish Oil
47997061|NCT04606576|DRUG|ORMD-0801 QD|Oral Insulin once per day
47997062|NCT04606576|DRUG|ORMD-0801 BD|Oral Insulin, twice per day
47997063|NCT00821470|PROCEDURE|core decompression|core decompression procedure only
47997064|NCT00821470|PROCEDURE|Bone marrow implantation into the necrotic lesion|
47997065|NCT00369551|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
47997066|NCT00369551|DRUG|paclitaxel|Given IV
47997067|NCT00369551|BIOLOGICAL|bevacizumab|Given IV
47997068|NCT00369551|DRUG|carboplatin|Given IV
47997069|NCT00369551|OTHER|laboratory biomarker analysis|Correlative studies
47997070|NCT01586819|DRUG|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
48682870|NCT01861561|DRUG|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
48682871|NCT03723798|DRUG|SA001 Low dose|3 tablets b.i.d for 12 weeks
48682872|NCT03723798|DRUG|SA001 Mid dose|3 tablets b.i.d for 12 weeks
48682873|NCT03723798|DRUG|SA001 High dose|3 tablets b.i.d for 12 weeks
48682874|NCT03723798|DRUG|Placebo|3 tablets b.i.d for 12 weeks
47997071|NCT01586819|PROCEDURE|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution \[a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)\] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel \[35% Trichloroacetic acid\] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
47997072|NCT06224933|DEVICE|Augmented Reality System|Subjects will undergo image guided needle aspiration, injection, or biopsy facilitated by the Augmented Reality system. The Augmented Reality guidance system will be operated by the interventional radiologist in the MRI suite.
47997073|NCT03362281|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
47997074|NCT03362281|DRUG|Omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
47997075|NCT03362281|DRUG|Ilaprazole tablet|Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
47997076|NCT03362281|DRUG|amoxicillin and clarithromycin|The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
47997077|NCT00897988|GENETIC|gene expression analysis|
47997078|NCT00897988|GENETIC|mutation analysis|
48365918|NCT04018391|BEHAVIORAL|Stepped care for nonadherence and depression|"* Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
48365919|NCT04018391|OTHER|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
47997079|NCT00897988|GENETIC|polyacrylamide gel electrophoresis|
47997080|NCT00897988|GENETIC|polymerase chain reaction|
47997081|NCT00897988|GENETIC|protein expression analysis|
47997082|NCT00897988|GENETIC|reverse transcriptase-polymerase chain reaction|
47997083|NCT00897988|OTHER|flow cytometry|
47997084|NCT00897988|OTHER|immunoenzyme technique|
47997085|NCT00897988|OTHER|immunologic technique|
47997086|NCT00897988|OTHER|laboratory biomarker analysis|
47997087|NCT00897988|OTHER|pharmacological study|
47997088|NCT02520011|DRUG|Alvocidib|
47997089|NCT02520011|DRUG|Cytarabine|
47997090|NCT02520011|DRUG|Mitoxantrone|
47997091|NCT03817242|PROCEDURE|Tympanoplasty using tragal cartilage graft|tympanoplasty type I is performed using tragal cartilage in arm 1
47997092|NCT03817242|PROCEDURE|Tympanoplasty using temporalis fascia graft|tympanoplasty type I is performed using temporalis fascia in arm 2
47997093|NCT05952622|DEVICE|Continuous passive motion therapy|Patients will be supplied with a continuous passive motion device which will allow additional individual treatment of the affected shoulder for 6 weeks.
47997094|NCT03727412|DRUG|Drugs, Generic (Naprosyn)|naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
47997095|NCT03727412|DRUG|Placebo Oral Tablet|placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
47997096|NCT00870896|DRUG|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
47997097|NCT03079323|RADIATION|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
47997098|NCT00005955|DRUG|temozolomide|
47997099|NCT02120794|DEVICE|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
47997100|NCT05805787|OTHER|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
47997101|NCT03774589|PROCEDURE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
47997102|NCT03774589|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
47997103|NCT00002007|DRUG|Zidovudine|
47997104|NCT00002007|DRUG|Sargramostim|
47997105|NCT03501095|DIAGNOSTIC_TEST|Vocal analysis and Laryngostroboscopy|"Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement."
47997106|NCT01273402|DRUG|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
47997107|NCT04318496|OTHER|Press Tack Acupuncture|PYONEX Φ0.20×0.6 mm made by Seirin Corporation
48365920|NCT06221085|DIAGNOSTIC_TEST|Pain Pressure Threshold (PPT)|"Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure."
48365921|NCT04629235|OTHER|wonder around|wonder around after 8 hours of bedrest
47997108|NCT04318496|OTHER|Press Tack Placebo|PYONEX placebo sticker made by Seirin Corporation
47997109|NCT02213393|DIETARY_SUPPLEMENT|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
48365922|NCT04629235|BEHAVIORAL|bedrest|24 hours of bedrest
48365923|NCT00495794|BEHAVIORAL|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
48365924|NCT05157009|PROCEDURE|implant placement|autogenous bone reconstruction of damaged socket \& simultaneous implant placement
47997110|NCT02213393|DIETARY_SUPPLEMENT|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
47997111|NCT02522208|DRUG|BiDil XR|fixed combination capsule
47997112|NCT02522208|DRUG|BiDil Immediate Release (IR)|fixed combination tablet
47997113|NCT02954510|DRUG|ferumoxytol|ferumoxytol will assess patency of coronary arteries
47997114|NCT03133156|OTHER|Exercise Intervention|10-Week Aerobic Exercise Training
47997115|NCT05451979|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
47997116|NCT00429507|DRUG|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
48365925|NCT03024944|DRUG|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
48365926|NCT00724594|DRUG|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
48365927|NCT00724594|DRUG|Control|Saline was given in the same volume, at the same timing as NAC infusions
48365928|NCT04225182|DEVICE|traditional rehabilitation protocol|muscular strengthening protocol with traditional rehabilitation protocol without orthosis
48365929|NCT04225182|DEVICE|with instrumented Orthosis|8 weeks of muscular strengthening with the orthosis connected to the phone app associated
48365930|NCT03826641|DRUG|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
48365931|NCT03826641|DRUG|HCP1801|Dapagliflozin/Metformin 10/1000mg
47997117|NCT00429507|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
47997118|NCT00429507|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
47997119|NCT04339699|DEVICE|NobleStitch™EL Suture Mediated Closure System|Percutaneous closure of Patent Foramen Ovale (PFO) using NobleStitch™EL suture Medicate Closure System
47997120|NCT04339699|DEVICE|Amplatzer PFO Occluder|Percutaneous closure of Patent Foramen Ovale (PFO) using Amplatzer PFO Occluder
47997121|NCT00006101|DRUG|eflornithine|Take 500mg of DFMO per day for 12 months
47997122|NCT00006101|DRUG|Placebo|Take placebo per day for 12 months
47997123|NCT05542875|PROCEDURE|Thrust Manipulation|Prone thoracic extension manipulation technique will be applied from T2 - T6 to participants of Group A (Experimental group). Intervention will be applied on alternate days with a total of 4 treatment sessions
48365932|NCT05707403|DRUG|BI 1015550|Treatment T
48365933|NCT05707403|DRUG|BI 1015550 mixed with [C-14]-BI 1015550|Treatment R
48512285|NCT04284059|DRUG|Placebos|Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
47997124|NCT05542875|PROCEDURE|Non-Thrust manipulation|Maitland grade III or IV thoracic 0manipulation will be given to participants of Control group from T1 to T6. Posterior to anterior glide over spinous process will be maintained for 30 seconds. Intervention will be applied on alternate days with a total of 4 treatment sessions
48155701|NCT05254288|OTHER|Ozoral gels|In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
48155702|NCT05442593|OTHER|Plyometric training|Participants will perform: 8 sets of 10 maximal countermovement jumps
48155703|NCT05807555|OTHER|Ambulatory ECG|24h ECG monitoring
47997125|NCT05542875|PROCEDURE|Standard Treatment|"Standard treatment protocol includes moist heat, TENS and Post isometric relaxation technique. Standard treatment will be given to both groups on every session. Standard treatment consists of:~Superficial Moist Heat (Device): Superficial moist heat will me applied for 10 minutes on Upper Trapezius TENS (Device): TENS will be applied for 10 minutes at 80-100Hz, the electrodes will be placed at upper trapezius.~Post-isometric Relaxation (procedure/surgery): 5-10 repetions of Post Isometric relaxation technique will be applied on various muscle groups which include Upper trapezius, levator scapulae, sternocleidomastoid and scalenes."
47997126|NCT06083350|DIETARY_SUPPLEMENT|Yeast beta-glucan|Produced by Angel Yeast Co., LTD
47997127|NCT06083350|DIETARY_SUPPLEMENT|Starch|Produced by Angel Yeast Co., LTD
47997128|NCT02196272|BEHAVIORAL|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
47997129|NCT01883687|PROCEDURE|Septoplasty|
48365934|NCT05621109|BEHAVIORAL|Weight loss intervention|"Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of approximately 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of approximately 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022."
47997130|NCT03524807|DEVICE|Electrophysiologic therapy|Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
47997131|NCT01226381|DRUG|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
47997132|NCT03552575|DRUG|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
47997133|NCT03552575|DRUG|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
47997134|NCT00586183|PROCEDURE|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
48365935|NCT01747733|DEVICE|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
48365936|NCT01048827|DRUG|Busulfan|"1. 1250 uMol\*min (AUC to time 6 hrs)\^~2. 1400 uMol\*min (AUC to time 6 hrs~3. 1550 uMol\*min (AUC to time 6 hrs)\^"
48365937|NCT03720158|DIETARY_SUPPLEMENT|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
47997135|NCT05826899|OTHER|54Fe SO4|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe
47997136|NCT05826899|OTHER|57Fe Oat-1|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe
47997137|NCT05826899|OTHER|58Fe Oat-2|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.
47997138|NCT05826899|OTHER|54 FeSO4 + Acai puree with honey|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
47997139|NCT05826899|OTHER|57Fe Oat-1 + Acai puree with honey|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.
48365938|NCT03720158|DIETARY_SUPPLEMENT|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
48365939|NCT02409251|BEHAVIORAL|Education and feedback|
48365940|NCT03077399|DEVICE|SCALA|All items of SCALA are applied
48365941|NCT04059328|PROCEDURE|Surgical training|This was a gyn laparoscopy training and simulation course
48365942|NCT02117362|BIOLOGICAL|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
48155704|NCT05807555|BIOLOGICAL|Blood sample|The usual biological tests necessary for the management of the child and the addition of 1 tube of 2 ml
48155705|NCT01038128|DRUG|Memantine|Drug: Memantine, 10-40 mg daily
48365943|NCT02117362|BIOLOGICAL|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
48365944|NCT02117362|BIOLOGICAL|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
48365945|NCT02117362|BIOLOGICAL|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
48365946|NCT02117362|BIOLOGICAL|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
48365947|NCT02365961|DRUG|ropivicaine|
48365948|NCT02365961|DRUG|clonidine|
48365949|NCT02365961|DRUG|Epinephrine|
48365950|NCT02365961|DRUG|Noropin|
48365951|NCT04880148|DIETARY_SUPPLEMENT|Thyme and Honey-based oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
48365952|NCT04880148|DIETARY_SUPPLEMENT|Placebo oral spray|4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
48512286|NCT04284059|DIETARY_SUPPLEMENT|vitamin AD|A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
48682875|NCT05113199|BEHAVIORAL|Virtual Dignity Therapy|Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
47997140|NCT05826899|OTHER|58Fe Oat-2 + Acai puree with honey|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey
47997141|NCT02620514|BEHAVIORAL|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
48155706|NCT02785822|DRUG|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
48155707|NCT02785822|DRUG|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
48155708|NCT04515745|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
48155709|NCT04515745|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
48155710|NCT05145088|BEHAVIORAL|submaximal exercise testing according to ACSM guidelines|For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
48365953|NCT04946331|DEVICE|Electrical impedance tomography system|Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
48682876|NCT03215381|DRUG|[11C]AZD1390|\[11C\]AZD1390
48155711|NCT02032134|BIOLOGICAL|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
48155712|NCT04161872|DRUG|Uricemin|Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
48682877|NCT03980782|OTHER|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
47997142|NCT02620514|BEHAVIORAL|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
47997143|NCT02620514|BEHAVIORAL|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
47997144|NCT02620514|BEHAVIORAL|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
47997145|NCT03791216|OTHER|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
47997146|NCT05673642|OTHER|Myofascial Release Techniques|Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
48155713|NCT04161872|DRUG|Placebo|Placebo
48155714|NCT03120949|DRUG|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
48155715|NCT03120949|DRUG|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
48155716|NCT03120949|DRUG|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
48155717|NCT04332991|DRUG|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
48682878|NCT00712387|BEHAVIORAL|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
48682879|NCT04531280|OTHER|Home hospital care|Patients receive hospital-level care in their home.
48682880|NCT05949580|DEVICE|MS Care Platform (icobrain ms and icompanion ms)|"The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant."
48155718|NCT04332991|DRUG|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
47997147|NCT06390969|OTHER|Survey|Cross-sectional online survey
48155719|NCT03317288|DEVICE|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
48155720|NCT06104059|DEVICE|Nociception level index (NOL™)|If a NOL value \>25 persists for \>1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
47997148|NCT02912026|DRUG|IV F901318|Metabolic profile AUC 0 to infinity
48155721|NCT06104059|OTHER|Fentanyl|Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
48365954|NCT05608824|DEVICE|Shear wave elastography and microvascular flow imaging.|Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
47997149|NCT02912026|DRUG|Oral F901318|Metabolic profile AUC 0 to infinity
48365955|NCT02792387|OTHER|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
48365956|NCT04064463|BEHAVIORAL|Standard care|standard treatment for substance use disorders, along with sample monitoring
47997150|NCT00897065|GENETIC|microarray analysis|
47997151|NCT00897065|GENETIC|polymerase chain reaction|
47997152|NCT00897065|GENETIC|protein expression analysis|
47997153|NCT00897065|OTHER|diagnostic laboratory biomarker analysis|
48155722|NCT01879488|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
48155723|NCT01879488|DEVICE|Vibrating-mesh nebulizer|
48155724|NCT01879488|OTHER|Gamma scintigraphy|
48155725|NCT01879488|OTHER|Preoperative spirometry|
48155726|NCT02080117|PROCEDURE|kidney transplantation, living or deceased donor|
48365957|NCT04064463|BEHAVIORAL|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
47997154|NCT00897065|OTHER|fluorescent antibody technique|
47997155|NCT00897065|OTHER|immunohistochemistry staining method|
48365958|NCT05980494|DRUG|normal Saline|normal saline cyrstalloids infusion with rate of 4ml/kg /h for 3 hours
48365959|NCT05980494|DEVICE|lung ultrasound|Lung ultrasound by Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID:1385 will scan For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines for a total of 28 sectors will be identified
48365960|NCT05980494|DEVICE|inferior vena cava measurements|The inferior vena cava was explored in the subxiphoid window in its sagittal view-just below the junction between the inferior vena cava and suprahepatic veins which lie approximately 0.5 to 3 cm from the right atrium, following the American Society of Echocardiography guidelines.; The (IVC distensibility index (dIVC) was calculated as (maximum diameter - minimum diameter)/minimum diameter.
48365961|NCT05980494|DIAGNOSTIC_TEST|passive leg raising test (PLRT)|"Regardless of CVP (i.e., during blind PLR), noninvasiveΔPLR systolic arterial pressure (SAP) more than 17% reliably identify fluid responders. During CVP-guided PLR, in case of sufficient change in CVP (at least of 2 mmHg), noninvasiveΔPLR SAP perform better (cutoff of 9%). These findings, in sedated patients who had already undergone volume expansion and/or catecholamines, have to be verified during the early phase of circulatory failure (before an arterial line)."
48512287|NCT04284059|DIETARY_SUPPLEMENT|vitamin D|A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
48512288|NCT01808573|DRUG|neratinib|
48512289|NCT01808573|DRUG|capecitabine|
47997156|NCT00897065|OTHER|immunologic technique|
47997157|NCT02345967|DEVICE|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
47997158|NCT06115811|BEHAVIORAL|Radiation Treatment Plan Evaluation Learning Tool|Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
47997159|NCT03278990|BEHAVIORAL|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
47997160|NCT03278990|BEHAVIORAL|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
47997161|NCT02508025|OTHER|Functional Capacity Evaluation|Assessment of work related physical capacity
47997162|NCT00263068|DRUG|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
47997163|NCT02256761|DRUG|BIRT 2584 XX - multiple escalating dose|
48155727|NCT00229190|PROCEDURE|Nasal lavage|
48155728|NCT00229190|PROCEDURE|Allergy skin testing|
48155729|NCT00229190|PROCEDURE|Peak nasal inspiratory flow|
48155730|NCT00229190|PROCEDURE|Acoustic rhinometry|
48155731|NCT00229190|PROCEDURE|Nasal examination|
48155732|NCT00229190|PROCEDURE|Quality of Life Questionnaire|
48155733|NCT00229190|PROCEDURE|Physical examination|
47997164|NCT02256761|DRUG|Placebo|
47997165|NCT02256761|DRUG|BIRT 2584 XX - single dose|
47997166|NCT02256761|OTHER|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
48155734|NCT06196710|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto the vessels.
48155735|NCT06196710|DEVICE|Hemo-clipping|Contact thermocoagulation using a 3.3mm probe, hemo-clips, or both. The use of the bipolar device involves firm mechanical compression and coagulation for about 8 seconds.
48155736|NCT04370392|PROCEDURE|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
48155737|NCT02074878|DRUG|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
48155738|NCT02074878|DRUG|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
48155739|NCT02074878|DRUG|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
48365962|NCT05980494|DEVICE|pulse pressure variation|patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor ensuring that the respiratory changes in arterial pressure reflected only the effects of positive pressure ventilation. Modes of ventilation is selected to volume or pressure controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be at 14 breath/min. Positive end expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitores at base line.
48512290|NCT01808573|DRUG|lapatinib|
47997167|NCT01339728|PROCEDURE|far-infrared ray|The duration of far-infrared ray is 20 minutes.
47997168|NCT02413541|PROCEDURE|Polymyxin-B Hemoperfusion|Endotoxin removal
47997169|NCT02413541|PROCEDURE|Standard treatment|
47997170|NCT05777915|OTHER|Usability testing|Usability testing
47997171|NCT02338765|BEHAVIORAL|mHealth Physical Activity|
47997172|NCT02338765|BEHAVIORAL|Buddy-partnered exercise|
47997173|NCT00433563|RADIATION|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
47997174|NCT00433563|RADIATION|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
47997175|NCT01813669|BEHAVIORAL|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
48512291|NCT03003650|DEVICE|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
47997176|NCT05995158|PROCEDURE|Metagenomic testing of the subgingival plaque samples|sampling, extraction and sequencing of the oral microbiome in the samples
47997177|NCT03170973|OTHER|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
47997178|NCT05928052|DEVICE|Transcutaneous Biopac Electrical Stimulator|A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
47997179|NCT00225381|DEVICE|connection of measuring device to anesthesia circuit|same as name
47997180|NCT00225381|PROCEDURE|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
47997181|NCT00225381|PROCEDURE|changing operating room bed position (head down and up position)|same
47997182|NCT00225381|PROCEDURE|adding PEEP during anesthesia|same
47997183|NCT00225381|PROCEDURE|placement of esophageal Doppler for cardiac output measurements|same
47997184|NCT00225381|DEVICE|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
47997185|NCT00225381|DEVICE|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
47997186|NCT00225381|DEVICE|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
47997187|NCT00225381|DEVICE|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
48155740|NCT01345253|DRUG|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
48155741|NCT01345253|DRUG|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
48155742|NCT01884376|DEVICE|Neuromaix|
47997188|NCT01892631|OTHER|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
48682881|NCT05408273|DIAGNOSTIC_TEST|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
48682882|NCT01367379|PROCEDURE|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
47997189|NCT01892631|OTHER|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
48682883|NCT01367379|OTHER|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
48682884|NCT04863053|OTHER|Blood samples will be taken to assess platelet function. There is no change in treatment.|
47997190|NCT01848587|OTHER|acupuncture|
48682885|NCT02512289|DEVICE|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
48682886|NCT04901663|DRUG|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
48682887|NCT04901663|DRUG|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
48682888|NCT05971992|DIETARY_SUPPLEMENT|Chicory-derived inulin-type β-fructans|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of prebiotic. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-weeks intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of prebiotic per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
47997191|NCT01848587|OTHER|usual care|
47997192|NCT02050282|OTHER|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
48365963|NCT04035369|PROCEDURE|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
48682889|NCT05971992|DIETARY_SUPPLEMENT|Maltodextrin|This supplement will be portioned into moisture-impermeable sachets containing 7.5 grams of maltodextrin. During the first two weeks, to avoid eventual side effects, PS participants will be advised to consume the contents of one sachet at breakfast only. Starting in week 3 until the end of the 8-week intervention the participants will consume the content of two sachets daily (at breakfast and at dinner) resulting in a total dose of 15 grams of placebo per day. Participants will be provided with a package of sachets in the amount required for the whole 8-weeks nutritional intervention. They will be instructed to dissolve the sachet content with water or juice and to drink it 15-20 minutes prior to their regular meal. The medium for suspending the supplement (water or juice) could be chosen by the participants and could be changed during the study.
48682890|NCT00939887|DRUG|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
48682891|NCT03440801|DEVICE|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
48682892|NCT03440801|DEVICE|Xience|Durable-polymer everolimus-eluting stent Xience
48682893|NCT00004846|DRUG|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
48682894|NCT01445613|DEVICE|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
48682895|NCT05849350|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
48682896|NCT05849350|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
48682897|NCT02359032|DRUG|ASP6858|Oral tablets
48682898|NCT02359032|DRUG|Placebo|Oral tablets
47997193|NCT05928585|DRUG|HIB210|Experimental monoclonal antibody
47997194|NCT05928585|DRUG|Placebo|Placebo
47997195|NCT04073758|DRUG|Dexmedetomidine|Comparing effects of remifentanil versus dexmedetomidine
47997196|NCT03163745|PROCEDURE|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
47997197|NCT01840774|DRUG|Low-dose pain medication (Ketalar) and saline placebo|
47997198|NCT05582668|PROCEDURE|Bariatric surgery|Bariatric surgery
47997199|NCT02057471|DRUG|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
47997200|NCT03854422|DEVICE|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
47997201|NCT03854422|DEVICE|left supine position|Colonoscopy in the Left supine position
47997202|NCT03854422|DEVICE|dynamic position|Colonoscopy in the Dynamic position
47997203|NCT06131008|DIAGNOSTIC_TEST|Diastology|We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.
47997204|NCT06131008|BEHAVIORAL|Diastology-Guided Diuresis|If the daily urine output or weight loss are less than study-specified targets, then the research team will recommend changes to the diuretic regimen based on the degree of diastolic dysfunction.
48155743|NCT05065099|DEVICE|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
48155744|NCT04543942|DRUG|Alcohol|Alcohol will be administered by IV infusion (60mg%).
48155745|NCT04543942|DRUG|Saline|Saline is administered as the placebo
48155746|NCT05313945|PROCEDURE|Passive indwelling urinary catheter removal|"After washing the patient's perineal area with water and mild soap, the nurse deflates the indwelling urinary catheter balloon and instructs the patient to take a shower (standing).~During this time, the catheter will fall under gravity."
48155747|NCT05313945|PROCEDURE|Active indwelling catheter removal by a nurse|After washing the patient's perineal area with water and mild soap, the nurse deflates the balloon and removes the catheter from the urethra by manual traction.
48155748|NCT04269811|DRUG|Flu-Bu-Mel|5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
48155749|NCT00730392|DRUG|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
48155750|NCT00730392|DRUG|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
48155751|NCT03598023|DEVICE|Cytal® Burn Matrix|Cytal® Burn Matrix
47997205|NCT06131008|BEHAVIORAL|Usual Care|Clinicians will rely on usual care metrics and parameters to guide diuresis.
47997206|NCT03720912|BEHAVIORAL|Online Learning Modules|The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
48155752|NCT03598023|DEVICE|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
48155753|NCT06102538|BEHAVIORAL|# The importance of service in the IDF # Physical activity # Healthy nutrition # Psychological support|# Education for the importance of service in the IDF # Education and training for physical activity adapted to abilities # Training for a healthy diet # Psychological support
48155754|NCT01326624|DEVICE|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
48155755|NCT05646602|DRUG|Collagenase Clostridium Histolyticum|Intralesional injection
48155756|NCT05646602|DEVICE|Duolith SD1 T-TOP|Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
48155757|NCT03847220|DIAGNOSTIC_TEST|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
48155758|NCT00402298|DRUG|MDMA|Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long therapy session.
48155759|NCT00402298|DRUG|MDMA|Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long therapy sessions.
48155760|NCT04367506|BEHAVIORAL|BecomeAnEX|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
48155761|NCT04367506|BEHAVIORAL|Usual Care|Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
48155762|NCT00452322|DRUG|Testosterone Substitution by Testosterone Undecanoate i.m.|
47997207|NCT02685631|OTHER|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
47997208|NCT05169788|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
47997209|NCT04797949|DRUG|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
48682899|NCT05534477|DEVICE|Verily Clinical Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
48682900|NCT05534477|DEVICE|Vivalink ECG Patch|The Vivalink ECG Patch is a continuously recording ECG monitor and will be used as a reference device for measuring participants' pulse rate, pulse rate variability, and pulse rate coverage. The Vivalink ECG Patch is a medical device manufactured by VivaLNK Inc. and has been cleared by the FDA.
48682901|NCT05534477|DEVICE|Modus StepWatch 4|Modus StepWatch 4 is an ankle-worn wearable medical device, and will be used as a reference device for measuring participants' ambulatory time and daily step count. The Modus StepWatch 4 is FDA listed.
48682902|NCT04571060|DRUG|Zavegepant|One dose of zavegepant
48682903|NCT04571060|DRUG|Placebo|One dose of matching placebo
48682904|NCT00529776|PROCEDURE|Continuous lateral rotation therapy|
48682905|NCT03269539|OTHER|MRI Imaging|
48682906|NCT03320837|DIETARY_SUPPLEMENT|Infant formula|Breast milk substitute containing synbiotics
47997210|NCT03365817|DRUG|Opioids taper off|Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
47997211|NCT03365817|DRUG|Opioid stable treatment|No changes on prescribed opioids and adjuvant medication for the next six months
47997212|NCT03997656|BEHAVIORAL|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
47997213|NCT03997656|OTHER|usual care|standard health education from primary care providers in the clinic
47997214|NCT01124643|BIOLOGICAL|Replagal|0.2 mg/kg administered intravenously \[IV\] every other week
47997215|NCT05171283|OTHER|Oats or Oat Fibre|Interventions that contain whole grain oats or oat beta-glucan.
47997216|NCT00805974|BIOLOGICAL|Biological examinations (blood and urinary).|
47997217|NCT00382954|DRUG|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
48682907|NCT03320837|OTHER|Breast milk|Breast milk
47997218|NCT00382954|DRUG|Idarubicin|I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
47997219|NCT00751348|BIOLOGICAL|PriorixTM|Subcutaneous administration in left upper arm
47997220|NCT00751348|BIOLOGICAL|VarilrixTM|Subcutaneous administration in right upper arm
48682908|NCT02748252|OTHER|stroke center referral|
47997221|NCT00751348|BIOLOGICAL|Priorix-Tetra®|Subcutaneous injection in left upper arm
47997222|NCT01148511|DRUG|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
47997223|NCT01453283|DRUG|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
47997224|NCT04568590|BEHAVIORAL|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average \> 3), they will be given the informational handout along with a brief script.
48155763|NCT02650661|BEHAVIORAL|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
48155764|NCT02650661|BEHAVIORAL|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
48155765|NCT02650661|BEHAVIORAL|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
48155766|NCT02650661|BEHAVIORAL|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
48682909|NCT02316353|BIOLOGICAL|C1-esterase inhibitor|
48682910|NCT06003218|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
48682911|NCT06003218|DRUG|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
47997225|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
47997226|NCT00698581|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
47997227|NCT01832025|PROCEDURE|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
48682912|NCT06003218|DRUG|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
48682913|NCT03191942|DEVICE|Modified ortho-k lenses|KETT MC lens
47997228|NCT01832025|PROCEDURE|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
47997229|NCT01689129|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
47997230|NCT01689129|DRUG|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
47997231|NCT03337282|PROCEDURE|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
47997232|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
47997233|NCT01516944|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
47997234|NCT01516944|DRUG|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
47997235|NCT02696642|DRUG|Anetumab ravtansine (BAY94-9343)|All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
47997236|NCT03391596|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
47997237|NCT03391596|BEHAVIORAL|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
47997238|NCT03391596|BEHAVIORAL|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
48155767|NCT01252199|DRUG|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
48155768|NCT01252199|DRUG|Placebo|Placebo administered over 1 hour + standard of care
48155769|NCT05971186|DRUG|Ibuprofen 400 mg|Dosage Form: Tablet Dosage: 1 tablet of Ibuprofen (400 mg) Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption
48682914|NCT03191942|DEVICE|Ortho-k lenses|KATT BeFree lens
48155770|NCT05971186|OTHER|Young Coconut Water|Dosage Form: Liquid (coconut water) Dosage: 330 ml (milliliters) of young coconut water Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
48682915|NCT02668705|OTHER|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
48155771|NCT05971186|OTHER|Dark Chocolate Bar|Dosage Form: Solid (dark chocolate bar) Dosage: 35 grams of 70% dark chocolate Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
48155772|NCT01320514|DRUG|Fibrin Sealant (Artiss)|
48155773|NCT02739841|OTHER|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
48155774|NCT02739841|OTHER|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
48155775|NCT01816165|DRUG|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
48155776|NCT01816165|DRUG|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
48155777|NCT06379321|DEVICE|Triathlon Hinge Knee (THK) System|Participants receive Triathlon Hinge Knee (THK) System during primary or revision knee arthroplasty in accordance with the indications for use
48365964|NCT04035369|PROCEDURE|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
48682916|NCT02212366|DEVICE|Active TDCS|Active Stimulation
48682917|NCT02212366|DEVICE|Sham TDCS|Sham Stimulation
48155778|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the general population
48155779|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_cirrhosis|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population with liver cirrhosis
48155780|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_no_cirrhosis|neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population without liver cirrhosis
48155781|NCT03759262|DRUG|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
48155782|NCT03195699|DRUG|TTI-101|Oral capsule
48155783|NCT03195699|DRUG|TTI-101|Oral tablet
48682918|NCT02956746|BIOLOGICAL|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
48682919|NCT02956746|BIOLOGICAL|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
48682920|NCT02956746|BIOLOGICAL|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
48155784|NCT02261922|DRUG|ticagrelor|
48155785|NCT02261922|DRUG|prasugrel|
48155786|NCT00355771|DRUG|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
48155787|NCT00355771|DRUG|Placebo|1 tablet OD in the morning for 8 weeks
48155788|NCT05955222|DEVICE|PEEK|Participants receiving splints produced with CAD/CAM from PEEK blocks,
48155789|NCT05955222|DEVICE|PMMA|Participants receiving splints produced with CAD/CAM from PMMA blocks,
48155790|NCT05955222|DEVICE|Traditional|Participants receiving splints from vacuum forming system
48155791|NCT03094143|PROCEDURE|Aortic valve intervention|The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
48155792|NCT00036309|DRUG|Duloxetine Hydrochloride|
48682921|NCT02956746|BIOLOGICAL|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
48682922|NCT05334316|DRUG|Dexamethasone|Administered intravenously or orally based on daily CRP values and CRP corticosteriod dosing algorithm
48682923|NCT04635371|DEVICE|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
47997239|NCT05732623|BEHAVIORAL|Semi Quantitative Food Frequency Questionnaire (SQFFQ)|"The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:~* date of birth~* sex~* ethnicity~* weight (kg)~* height (m)~* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old~* country where they live permanently~* tobacco smoking at the time of eoCRC diagnosis and at 18 years old~* sitting time~* TV-viewing time~* moderate-to-vigorous physical activity (MVPA)~* waist circumference (cm)~* home blood pressure levels (mmHg)~* fasting blood glucose (mg/dl)~* regular consumption of aspirin/NSAID and years of consumptions~* calcium and folate supplements and years of consumptions~* oral contraceptive agents and years of consumptions~* post-menopausal hormones and years of consumptions"
48682924|NCT02088099|OTHER|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
48682925|NCT02088099|OTHER|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
48682926|NCT03766464|DIAGNOSTIC_TEST|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
47997240|NCT05744349|PROCEDURE|K-wires Fixation of Pediatric Shaft Both Bone Forearm Fractures|After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.
48155793|NCT05719155|DRUG|CKD-379|1 tablet administration under fed condition
48365965|NCT00616005|DRUG|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
47997241|NCT00858442|PROCEDURE|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width \& length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width \& length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
48365967|NCT03145584|DRUG|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
47997242|NCT04382131|OTHER|NaCl Solution|NaCl Solution prepared by participants at home using water and salt
47997243|NCT06024044|BEHAVIORAL|Mobilization Training|"The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
48682927|NCT03766464|DIAGNOSTIC_TEST|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
48155794|NCT05719155|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
48155795|NCT02623101|DEVICE|Reflectance confocal microscopy|Non-invasive imaging of the lesion
48155796|NCT02623101|PROCEDURE|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
48155797|NCT02623101|PROCEDURE|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
48155798|NCT00946010|BIOLOGICAL|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
48155799|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer A|Commercially available receiver-in-canal hearing instrument from manufacturer A
48365968|NCT03145584|OTHER|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
48365969|NCT00417911|DRUG|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
48365970|NCT04557189|DRUG|TAK-951|TAK-951 SC injection
48365971|NCT04557189|DRUG|Ondansetron|Ondansetron IV injection
48155800|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer B|Commercially available receiver-in-canal hearing instrument from manufacturer B
48155801|NCT03313544|DRUG|Nivolumab|NIVOLUMAB
48155802|NCT03313544|DEVICE|MRI|Cardiac MRI 6 MONTHS
47997244|NCT04434690|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeons bilateral TKA group
48155803|NCT03313544|BIOLOGICAL|BLOOD SAMPLES|biological (BNP and troponin)
48155804|NCT03313544|DEVICE|trans-thoracic echocardiography|1, 3 and 6 months
48155805|NCT04641156|OTHER|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
48155806|NCT02371278|DIETARY_SUPPLEMENT|Leucine|5 g leucine with sucrose and maltodextrin
48155807|NCT02371278|DIETARY_SUPPLEMENT|Placebo|5 g glycine with sucrose and maltodextrin
48155808|NCT05615753|BEHAVIORAL|Acupuncture|All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
47997245|NCT04434690|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
47997246|NCT01852812|DRUG|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
48155809|NCT03221634|BIOLOGICAL|Pembrolizumab|IV infusion
48155810|NCT03221634|BIOLOGICAL|Daratumumab|IV infusion
48155811|NCT04891536|PROCEDURE|Salvage cryoablation of the prostate (SCAP)|Cryotherapy of the prostate through transperineal freeezing needles
47997247|NCT01852812|DRUG|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
47997248|NCT01204476|BIOLOGICAL|Cixutumumab|Given IV
47997249|NCT01204476|DRUG|Everolimus|Given PO
47997250|NCT01204476|OTHER|Laboratory Biomarker Analysis|Correlative studies
47997251|NCT01204476|DRUG|Octreotide Acetate|Given IM
47997252|NCT01204476|OTHER|Pharmacological Study|Correlative studies
47997253|NCT02836899|DRUG|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
48155812|NCT01844362|PROCEDURE|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
48155813|NCT01021683|DRUG|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
48155814|NCT06585228|DIAGNOSTIC_TEST|Cardiac Computed Tomography|Cardiac CT acquired during the acute stroke imaging protocol
48155815|NCT06585228|DIAGNOSTIC_TEST|Transesophageal echocardiography|Ultrasound through the oesophagus to assess cardiac structures.
48155816|NCT06585228|DIAGNOSTIC_TEST|Repeated Cardiac Computed Tomography|A second cardiac CT performed after the TEE.
48365972|NCT04557189|DRUG|Ondansetron Placebo|Ondansetron placebo-matching IV injection
48365973|NCT04557189|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
48365974|NCT03798366|DRUG|GLPG1690|Film-coated tablets of GLPG1690 for oral use.
47997254|NCT02836899|OTHER|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
47997255|NCT04684147|BIOLOGICAL|single dose of CNCT19|Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
47997256|NCT05457374|PROCEDURE|PVE|Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected
47997257|NCT05457374|PROCEDURE|LVD|Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
47997258|NCT02138903|OTHER|trans thoracic echocardiography|
47997259|NCT04259957|DEVICE|Immersive Virtual Reality|Immersive virtual reality games and mindfulness in Oculus Quest Virtual Reality headset
47997260|NCT02360384|DRUG|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
48155817|NCT01518127|OTHER|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
48155818|NCT05439720|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
48155819|NCT05439720|DIETARY_SUPPLEMENT|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
48155820|NCT05439720|BEHAVIORAL|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
48155821|NCT02523417|PROCEDURE|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
48155822|NCT05736458|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
48155823|NCT05736458|PROCEDURE|High controllability TMS target|Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
48155824|NCT03323814|DEVICE|Slow-wave optimization|employing sensory stimulation to enhance slow waves
48155825|NCT02812706|DRUG|Isatuximab SAR650984|Pharmaceutical form: solution Route of administration: intravenous
48365975|NCT03798366|DRUG|Placebo|Film-coated tablets of GLPG1690 matching placebo for oral use.
48365976|NCT00408408|BIOLOGICAL|bevacizumab|15 mg/kg IV
48365977|NCT00408408|DRUG|capecitabine|825 mg/m2 orally
48365978|NCT00408408|DRUG|cyclophosphamide|600 mg/m2 IV
48365979|NCT00408408|DRUG|docetaxel|100 mg/m2 IV
48365980|NCT00408408|DRUG|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
47997261|NCT02360384|DIETARY_SUPPLEMENT|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
48155826|NCT04026022|DRUG|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
47997262|NCT04328324|PROCEDURE|Endoscopy|Diagnostic upper Git endoscopy
48155827|NCT04026022|DRUG|Placebo|Placebo plaster in the ER or PACU
48155828|NCT02447380|DRUG|AZD6094|AZD6094 600MG qd
48155829|NCT02447380|DRUG|Docetaxel|Docetaxel 60 mg/m2
48155830|NCT05332522|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
47997263|NCT01284283|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
48365981|NCT00408408|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV
47997264|NCT05580341|BIOLOGICAL|Zerun HPV-9|Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months
48682928|NCT03766464|DIAGNOSTIC_TEST|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
47997265|NCT05580341|BIOLOGICAL|GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
47997266|NCT03326011|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
47997267|NCT01662908|DRUG|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
47997268|NCT01662908|DRUG|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
47997269|NCT01662908|DRUG|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
47997270|NCT00177892|PROCEDURE|sleep disruption|experimentally-induced Sleep Fragmentation
47997271|NCT00177892|PROCEDURE|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
47997272|NCT00798109|BEHAVIORAL|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
48155831|NCT01863368|OTHER|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
48155832|NCT01863368|OTHER|Systane® ULTRA lubricant eyedrops|
48155833|NCT01863368|OTHER|OPTIVE® lubricating eyedrops|
48365982|NCT04547452|RADIATION|Stereotactic body radiation therapy|Sintilimab Combined with SBRT
48365983|NCT04547452|DRUG|Anti-PD-1 antibody drug named Sintilimab|Sintilimab
48155834|NCT06022406|BIOLOGICAL|FMT capsules|Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).
48682929|NCT04165551|BIOLOGICAL|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
48682930|NCT04165551|BIOLOGICAL|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
47997273|NCT00798109|BEHAVIORAL|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
47997274|NCT03756298|DRUG|Atezolizumab|Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
48365984|NCT01427855|OTHER|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
48365985|NCT01427855|OTHER|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
48365986|NCT01427855|OTHER|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
47997275|NCT03756298|DRUG|Capecitabine|capecitabine monotherapy (2,500mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
47997276|NCT02918149|OTHER|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
47997277|NCT02918149|DEVICE|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
48512292|NCT05555485|DEVICE|transcutaneous Auricular neurostimulation - Active|Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
48682931|NCT00096642|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
48682932|NCT02345616|DRUG|Nitric oxide|
48682933|NCT00981162|DRUG|sorafenib tosylate|Given PO
48682934|NCT00981162|DRUG|everolimus|Given PO
48682935|NCT00981162|OTHER|laboratory biomarker analysis|Correlative study
48682936|NCT00981162|OTHER|pharmacogenomic studies|Correlative study
48682937|NCT00981162|OTHER|pharmacological study|Correlative study
48682938|NCT04742777|DRUG|rapamycin|Taken orally 1mg daily for 8 weeks
48682939|NCT04831476|OTHER|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
48682940|NCT05313607|OTHER|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
48682941|NCT05313607|OTHER|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
48682942|NCT05313607|OTHER|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
48682943|NCT05313607|OTHER|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
48682944|NCT02020798|OTHER|Dietary Intervention|
48682945|NCT02752490|DRUG|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
48682946|NCT02752490|DRUG|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
48682947|NCT01751672|BEHAVIORAL|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
48682948|NCT01751672|BEHAVIORAL|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
48682949|NCT02372695|DRUG|Paricalcitol|
48365987|NCT01427855|OTHER|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
48682950|NCT01525862|DEVICE|Balloon sinus dilation|
48682951|NCT00125814|DRUG|Interferon alfa-2b|
48682952|NCT00125814|PROCEDURE|Structured treatment interruptions|
48682953|NCT04650997|BEHAVIORAL|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
48682954|NCT02507596|BIOLOGICAL|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
48682955|NCT02507596|PROCEDURE|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
48682956|NCT00235222|DRUG|stavudine|
48682957|NCT00249652|BEHAVIORAL|TAP|12-session motivational interviewing-based telephone intervention.
48682958|NCT00249652|OTHER|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
48682959|NCT05600361|DRUG|hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
48682960|NCT04512820|DEVICE|TRUCLEAR tissue removal system|evacuation of POC using the TRUCLEAR tissue removal system
48682961|NCT05491096|OTHER|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
48682962|NCT05491096|OTHER|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
48682963|NCT03240861|OTHER|18F-FHBG|Given IV
48682964|NCT03240861|BIOLOGICAL|Aldesleukin|Given SC
48682965|NCT03240861|DRUG|Busulfan|Given IV
48682966|NCT03240861|BIOLOGICAL|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
48365988|NCT01427855|OTHER|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
48365989|NCT01427855|OTHER|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
48365990|NCT03083613|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
48682967|NCT03240861|PROCEDURE|Computed Tomography|Undergo PET/CT
48365991|NCT03083613|DRUG|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
48682968|NCT03240861|BIOLOGICAL|Filgrastim|Given SC
48682969|NCT03240861|DRUG|Fludarabine|Given IV
48682970|NCT03240861|PROCEDURE|Leukapheresis|Undergo leukapheresis
48682971|NCT03240861|DRUG|Plerixafor|Given SC
47997278|NCT05421689|BIOLOGICAL|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|The study will treat 62 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.
47997279|NCT05421689|OTHER|Placebo|two doses of placebo will be administered and spaced 4-6 weeks apart.
48682972|NCT03240861|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48155835|NCT06022406|BIOLOGICAL|Placebo capsules|Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
48365992|NCT05794334|OTHER|Low Dye Taping|This second group also contains 20 participents.French functional method is similar to the Ponseti method. In this technique, the patient undergoes 30-minute daily session for 2 weeks and then twice a week until achieving foot correction. It consists of stretching of triceps surae to improve tibio-talar joint function. daily manipulations of the newborn's foot, stimulation and strenghtening of the muscles around the foot (particularly the peroneal muscles) and temporary immobilization of the foot with elastic and nonelastic adhesive taping so that the reduction achieved by.The average time of this method ranges between 6 to 8 weeks, with all the deformities being corrected apart from equinus. This method reports a 93% success rate
48365993|NCT05357105|OTHER|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
48682973|NCT02084498|DEVICE|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
48682974|NCT02084498|BEHAVIORAL|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
48682975|NCT00322413|DRUG|Epoetin|
48682976|NCT01833858|DRUG|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
48682977|NCT01833858|DRUG|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
48682978|NCT06502522|OTHER|Whole-body electrical stimulation|"Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes."
48682979|NCT03580538|OTHER|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
48682980|NCT03635632|GENETIC|C7R-GD2.CART cells|"Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI."
47997280|NCT04581642|DEVICE|PMD200|The NOL technology is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
47997281|NCT02629692|DRUG|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
47997282|NCT03422120|OTHER|Natural Killer Cell Activity Assay|Subjects had a blood test to measure NK cell activity (NKA) at different time points
47997283|NCT01816828|BEHAVIORAL|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
48365994|NCT00765726|BIOLOGICAL|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
48682981|NCT05153226|DRUG|Cyclophosphamide|50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
48682982|NCT05153226|BIOLOGICAL|ATG|10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
48682983|NCT06149676|DRUG|Saccharomyces Boulardii 250 MG [Florastor]|All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin
48682984|NCT04189302|PROCEDURE|connective tissue graft harvest using KPM blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
47997284|NCT01816828|OTHER|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
47997285|NCT02600637|BEHAVIORAL|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
48365995|NCT00765726|PROCEDURE|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
48512293|NCT05555485|DEVICE|transcutaneous auricular neurostimulation - Sham|Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
48512294|NCT05093829|BIOLOGICAL|NmCV-5|NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).
47997286|NCT02600637|BEHAVIORAL|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
47997287|NCT00210054|DRUG|denufosol tetrasodium (INS37217)|
47997288|NCT01771432|DRUG|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
47997289|NCT01771432|OTHER|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
47997290|NCT01684371|OTHER|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
47997291|NCT01315704|DRUG|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
48512295|NCT05093829|BIOLOGICAL|MenACWY-TT|MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
47997292|NCT06112028|DRUG|Tongxinluo capsule|On the basis of conventional treatment, the study participants in the experimental group were given Tongxinluo capsule for 12 months.
48682985|NCT04189302|PROCEDURE|connective tissue graft harvest using 15 C blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
48682986|NCT06094608|DEVICE|Morning light treatment|Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
48682987|NCT06094608|BEHAVIORAL|Treatment-as-usual|Participants will not make modifications to their activities or sleep schedule.
48682988|NCT03167788|DEVICE|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
47997293|NCT06112028|OTHER|Primary therapy|Routine oral aspirin enteric-coated tablets, clopidogrel bisulfate tablets and rosuvastatin calcium tablets (or atorvastatin calcium tablets)
47997294|NCT00244712|DRUG|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
48155836|NCT06584747|DIAGNOSTIC_TEST|PET scan|18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
48512296|NCT01408043|DRUG|plerixafor|Given SC
47997295|NCT00244712|DRUG|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
47997296|NCT02916615|OTHER|High nitrate vegetables|vegetables naturally high in nitrate
47997297|NCT02916615|DIETARY_SUPPLEMENT|Low nitrate vegetables + nitrate|pill containing KNO3
47997298|NCT02916615|OTHER|Low nitrate vegetables|vegetables naturally low in nitrate
48155837|NCT00233207|DRUG|IC14|
48155838|NCT04107844|DIAGNOSTIC_TEST|Novel facilitating agility dual-task test combined with already known tests|We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
47997299|NCT00521196|DEVICE|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
48155839|NCT05010499|DRUG|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
48155840|NCT05010499|DRUG|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
48365996|NCT01273207|DRUG|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
48365997|NCT03936868|PROCEDURE|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
48512297|NCT01408043|BIOLOGICAL|filgrastim|Given SC
47997300|NCT02437019|DRUG|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
48365998|NCT04865016|DEVICE|Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)|This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
48365999|NCT02119728|DRUG|HPPH|Undergo photodynamic therapy with HPPH
47997301|NCT06113133|DIAGNOSTIC_TEST|measurement of oxygen uptake|oxygen uptake is obtained during a maximal exercise test
47997302|NCT05648370|GENETIC|ctDNA testing and whole exome sequencing|Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
48366000|NCT02119728|DEVICE|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
48366001|NCT02119728|PROCEDURE|therapeutic conventional surgery|Undergo standard of care surgery
48366002|NCT04932915|DRUG|Niclosamide|Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
47997303|NCT03491618|OTHER|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
48366003|NCT04932915|DRUG|Placebo|The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.
48366004|NCT00877929|DRUG|Telmisartan 80|Telmisartan 80 mg
48366005|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
48366006|NCT00877929|DRUG|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
48366007|NCT02772042|OTHER|Intervention Group|
48366008|NCT02772042|OTHER|Control Group|
48366009|NCT01482598|DEVICE|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
48366010|NCT00134199|DRUG|CP-945,598|
48366011|NCT00134199|DRUG|sibutramine|
48366012|NCT01099670|DRUG|NRL001|Rectal suppository Placebo
47997304|NCT01154309|BEHAVIORAL|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
47997305|NCT04414709|OTHER|Double short implant|Patients receives 2 short implants to restore missing posterior teeth, loaded with splinted screw retained crowns.
47997306|NCT04414709|OTHER|Single short implant|Patients receives single short implants, loaded with single screw retained crowns.
47997307|NCT04174911|DRUG|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
47997308|NCT04174911|DRUG|Placebo|sublingual drops
47997309|NCT04523233|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
47997310|NCT02290821|DRUG|placebo|
48366013|NCT01099670|DRUG|Placebo|Placebo
48366014|NCT03674645|DEVICE|MRI acquisitions|Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
48366015|NCT03351660|DIAGNOSTIC_TEST|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
47997311|NCT02290821|DRUG|Placebos|
48366016|NCT04390620|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
48366017|NCT02715635|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
48366018|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice|140 ml containing \~8 mmol of inorganic nitrate
47997312|NCT01018199|OTHER|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
47997313|NCT01018199|OTHER|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
47997314|NCT05026684|OTHER|Personalized cost handout|Patients will be given a personalized cost handout to make transparent the full costs to Veterans of different types of ambulatory visits in order to optimize the value of their health care investments.
47997315|NCT02431754|DRUG|Tadalafil|Administered orally
47997316|NCT02431754|DRUG|Placebo|Administered orally
47997317|NCT02431754|DRUG|Alpha1 Blocker|Administered orally
48366019|NCT02715635|DIETARY_SUPPLEMENT|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
48366020|NCT00165256|OTHER|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
48366021|NCT02297867|DRUG|ADSCs|autologous ADSCs
48366022|NCT04273620|BEHAVIORAL|Optokinetic stimulation and cueing-based reading therapy (OKS-READ)|"Each intervention session starts with an optokinetic stimulation (OKS) of at least 15 minutes duration. A pattern of squares, dots, triangles and stars will coherently and continuously move to the left on a computer screen in front of the patients. Patients are instructed to choose one stimulus and follow it with the eyes until it has reached the left side of the screen, then jump to the right edge of the screen and start again.~The second part of each intervention session is the cueing-based reading therapy (READ), which will also last at least 15 minutes. The task of the patient is to read out loud words or a text presented on a paper in front of them. We will use exogenous (e.g., the therapist highlights words when they were omitted) and endogenous cues (verbal instructions which require intrinsic action by the patient) to facilitate attentional shifts to the left. The intensity of cueing will be matched to the actual severity of neglect (adaptive therapy)."
48366023|NCT04273620|BEHAVIORAL|General neuropsychological treatment|As a control treatment the patients will receive neuropsychological treatment without targeting visuospatial attention. Examples for components implemented are supporting conversations, diagnostic assessments (e.g. memory diagnostics) and training of memory and executive functions.
48366024|NCT03977376|OTHER|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
47997318|NCT02666183|BEHAVIORAL|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
47997319|NCT02666183|BEHAVIORAL|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
47997320|NCT02666183|BEHAVIORAL|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
47997321|NCT05796011|DEVICE|hearing aids|Hearing aid(s) fitted for one or two sides of ear.
47997322|NCT05796011|OTHER|without hearing intervention|neither earing aids nor other heaing treatment were applied.
47997323|NCT05796011|OTHER|healthy control|healthy control
47997324|NCT04794790|DRUG|Buprenorphine/naloxone|Buprenorphine/Naloxone induction via a standard dose protocol
47997325|NCT04917055|DRUG|ropivacaine 0.25% with epinephrine and 6mg dexamethasone|Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
47997326|NCT04917055|DRUG|Saline|Injection of Saline behind knee using ultrasound guidance
47997327|NCT02894177|PROCEDURE|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
47997328|NCT01869296|PROCEDURE|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
47997329|NCT01869296|PROCEDURE|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
47997330|NCT05778396|PROCEDURE|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
47997331|NCT05778396|PROCEDURE|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
47997332|NCT00328913|DRUG|5-hydroxytryptophan (food supplement)|
47997333|NCT05140031|OTHER|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
47997334|NCT04255355|OTHER|Pelvic alignment and forceful expiration|"The participant will be in supine with feet flat on a wall and the knees and hips flexed to 90 degrees. A standard 5 ball will be placed between the knees. The participant will hold a standard 9-inch balloon in the mouth with one hand. The subject will be instructed to isometrically contract the hamstrings to lift the ischium off the table while maintaining a posterior pelvic tilt. In this position, subject will be instructed to perform isometric hip adduction by squeezing the ball placed between the knees. The subject will then be instructed to breathe in through the nose and blow the air out into the balloon with full exhalation to activate the transverse and oblique abdominals. The participant will hold the breath for 3 seconds while maintaining hamstring contraction, adductor contraction, and transverse and oblique abdominal contraction. This process will be repeated four times. This exercise will be performed once daily under the supervision of the therapist for 5 days."
47997335|NCT04255355|OTHER|Pelvic repositioning exercise|The participant will be positioned supine with their feet flat on a wall and the knees and hips flexed to 90 degrees. The subject will be instructed to isometrically contract the hamstrings to allow the ischial tuberosities to lift off the table while also maintaining a posterior pelvic tilt. The tailbone should be slightly lifted off the table, the abdominal muscles should be relaxed, and the low back should be flat on the table. While maintaining the posterior pelvic tilt, the subject will be instructed to perform isometric hip adduction by squeezing the ball that is placed between the knees. The subject will hold for 3 seconds and then relax. This process will be repeated four times. This exercise will be performed daily under the supervision of the therapist for 5 days.
47997336|NCT04255355|OTHER|Diaphragmatic breathing exercise|For diaphragmatic breathing exercise, the subject will be in supine position. The investigator places both hands around the participant's lower ribs and abdominal area. The investigator applies slight manual resistance to the chest and abdominal wall during inhalation phase of breathing.The participant is instructed to apply outward pressure against the investigator resistance and to raise the chest and abdominal wall simultaneously with inhalation. Then participants performs a full exhalation and hold his/her breath for 3 seconds before breathing in again. This process is repeated for 4 breathing cycles. Participants will perform this exercise once a day under investigator supervision.
47997337|NCT04982055|DRUG|Nadroparin (intravenous Infusion)|Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
47997338|NCT04982055|DRUG|Nadroparin (subcutaneous group)|Subcutaneous route of administration of nadroparin 3800 IU
47997339|NCT05751330|PROCEDURE|Transcatheter ablation of cardiac ganglionated plexi|"The ablative procedure involves applying radiofrequency deliveries in the two~Right atrium anatomical sites close to the two main ganglionic plexuses of the right atrium:~* Inferior-posterior area (site of first ablation) corresponding to the right inferior atrial ganglion located between the inferior vena cava, coronary sinus ostium and near the atrioventricular node~* Upper-posterior area (site of second ablation) corresponding to the right superior atrial ganglion located between the superior vena cava and the posterior surface of the right atrium"
47997340|NCT04127916|DRUG|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
48366025|NCT01420523|DRUG|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
47997341|NCT02576028|OTHER|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
47997342|NCT02576028|OTHER|standard active exercises|two sessions of 45 minutes of active exercises
47997343|NCT02436278|OTHER|4MGS|Usual walking speed measured over 4 metres
48366026|NCT01511211|DRUG|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
47997344|NCT04444596|DIAGNOSTIC_TEST|Conjunctival swab and nasopharyngeal swab|Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
48366027|NCT01511211|DRUG|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
48366028|NCT00560872|DEVICE|remote magnetic catheter navigation|use of the Stereotaxis system
47997345|NCT03012113|DRUG|Mirabegron|
48366029|NCT00560872|PROCEDURE|cavotricuspid isthmus ablation|conventional (manual) approach
48512298|NCT01408043|DRUG|etoposide|Given IV
48512299|NCT01408043|PROCEDURE|leukapheresis|Undergo apheresis
48512300|NCT02369302|DRUG|DWC20141|Tablet
48512301|NCT02369302|DRUG|DWC20142|Tablet
48512302|NCT02369302|DRUG|DWC20141, DWC20142|Tablet
48512303|NCT01704274|OTHER|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
48512304|NCT01704274|OTHER|High Dose GTN 0.057 mg/hr|High Dose GTN
48512305|NCT01704274|OTHER|Placebo|Placebo
48512306|NCT02813941|OTHER|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
48512307|NCT02813941|OTHER|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
48366030|NCT03900182|DEVICE|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
48366031|NCT05609682|DRUG|Gabapentin|Scheduled gabapentin given for two weeks after surgery
48366032|NCT05609682|DRUG|Placebo|Placebo given for two weeks after surgery
48366033|NCT06322511|BEHAVIORAL|Dialogical Family Guidance (DFG)|DFG is family intervention including six meetings with family members. The individual needs and questions of each family are discussed and issues parents bring up are seemed as important.
48366034|NCT05015959|OTHER|observation|quality
48366035|NCT01019733|PROCEDURE|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
48366036|NCT02146352|DEVICE|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
48366037|NCT00735839|BIOLOGICAL|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
48366038|NCT00735839|BIOLOGICAL|Placebo|Saline placebo (0.5 ml) single injection on Day 1
48366039|NCT05870865|DRUG|ASN008|ASN008 topical gel applied twice daily.
48366040|NCT05870865|OTHER|ASN008 Matching Vehicle|The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
48366041|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
47997346|NCT03012113|OTHER|Short term mild cooling|
48366042|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
48366043|NCT01192581|DRUG|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
48366044|NCT03520842|DRUG|Methotrexate|Given PO
48366045|NCT03520842|OTHER|Pharmacokinetic Study|Correlative studies
48366046|NCT03520842|DRUG|Regorafenib|Given PO
48366047|NCT06085690|BEHAVIORAL|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
48366048|NCT01567046|OTHER|laboratory biomarker analysis|Correlative studies
47997347|NCT03012113|DRUG|Placebo Oral Capsule|
48366049|NCT04966442|BEHAVIORAL|GrandAides|Enhanced post acute care for patients recently admitted for congestive heart failure
47997348|NCT01835743|DEVICE|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
47997349|NCT01835743|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
48366050|NCT04454632|OTHER|Mirror therapy|affected arm stay behind the mirror while exercising
48366051|NCT04454632|OTHER|Visual feedback|visual feedback from mirror
48366052|NCT02599727|OTHER|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
48366053|NCT02599727|OTHER|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
48366054|NCT02785588|DEVICE|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
48366055|NCT05240872|BIOLOGICAL|PRP injection|Plantar fascia injection therapy with PRP
47997350|NCT04693390|PROCEDURE|Acupuncture|Application of acupuncture
47997351|NCT02943733|DRUG|TAS-102|Anti-metabolite agent, taken orally.
47997352|NCT02943733|DRUG|Temozolomide|Oral chemotherapy drug.
47997353|NCT02943733|DRUG|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
48366056|NCT05240872|BIOLOGICAL|ABI injection|ABI injection
48366057|NCT01143662|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
48366058|NCT01143662|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
48366059|NCT02145429|BEHAVIORAL|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
48512308|NCT02813941|OTHER|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
48366060|NCT05869513|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
48366061|NCT05869513|DIETARY_SUPPLEMENT|Krill oil|Superba Krill Oil
48366062|NCT05869513|OTHER|Home-based resistance exercise|Home based resistance band and body weight exercise
48366063|NCT06410833|DRUG|Rituximab|Rituximab weekly until B%\<0.5% or B#\<20×10\^6/L
48366064|NCT06410833|DRUG|Belimumab|Belimumab every four weeks
48512309|NCT03348618|BIOLOGICAL|IVIG|Intravenous immunoglobulin
47997354|NCT02943733|DRUG|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
47997355|NCT06372288|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS using Intermittent theta burst stimulation (iTBS)
47997356|NCT06372288|DEVICE|Sham Transcranial Magnetic Stimulation|Participants will not receive intermittent theta burst stimulation during the sham-TMS sessions
47997357|NCT06404151|DEVICE|monitoring|rc02, ORI , spO2
47997358|NCT02852096|OTHER|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
48366065|NCT05079100|OTHER|postpartum contraception method counselling|It will be face-to-face counseling with females about the use of postpartum contraception methods within 6 weeks postpartum.
47997359|NCT02852096|OTHER|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
47997360|NCT05023928|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
47997361|NCT01249612|OTHER|Thermotherapy|Knee joint icing
47997362|NCT01249612|OTHER|Thermotherapy|Elbow joint icing
48366066|NCT02173015|OTHER|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
48366067|NCT02846337|PROCEDURE|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
48366068|NCT02846337|PROCEDURE|ENHANCED MEDICAL TREATMENT|"* Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~* Medical care adjustment in order to apply European and American guidance for chronic heart failure care~* Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~* Physical rehabilitation suggestions by a physiologist~* Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
47997363|NCT03656419|PROCEDURE|photodynamic therapy|aPDT with methylene blue and red led irradiation.
47997364|NCT03656419|PROCEDURE|Tongue scraper|Tongue scraper 10 times from de back to the top.
48366069|NCT05834673|DRUG|Inclisiran Prefilled Syringe|Inclisiran, 284 mg, 1.5 ml Liquid in a single-use prefilled syringe (PFS) for s.c. administration and any standard medications to be used within registered indication and at the treating physician's discretion.
48366070|NCT05834673|OTHER|SMS messages|Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)
47997365|NCT05468437|BEHAVIORAL|Telenutrition|Nutrition education and individualized nutrition counseling will be done with a Registered Dietitian via video-conferencing with iPad FaceTime, which is aimed to decrease the risk of complications like obesity, high cholesterol, or diabetes, and explore associations between bowel and bladder function and nutrition. The telenutrition counseling consists of 6 sessions that are scheduled approximately 2 weeks apart. The first session will last approximately 1 hour, while sessions 2-6 will last approximately 30mins. During these sessions, the Registered Dietitian will share nutrition education tailored towards people with SCI. You will be involved in developing personal nutrition goals and the dietitian will help you address barriers to meeting your goals and provide individualized feedback to improve and maintain your nutrition. Telenutrition appointments will maintain privacy and will not be recorded.
47997366|NCT04173026|OTHER|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
47997367|NCT04173026|OTHER|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
47997368|NCT03444974|OTHER|adapted treatment according to the MATRIX-A therapy|cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
47997369|NCT00133874|DRUG|SB-275833 ointment, 1%|
47997370|NCT01214707|OTHER|Exercise|Exercise during EMU stay
47997371|NCT00319826|OTHER|No intervention|This is an observational study with no intervention
47997372|NCT05837936|OTHER|Total intravenous anesthesia (TIVA)|TIVA anesthetic -no inhalational gases for surgery
47997373|NCT05837936|OTHER|Sevoflurane initiated intravenous anesthesia (SIIVA)|SIIVA - sevoflurane anesthetic gases for surgery
47997374|NCT03721419|DEVICE|High Flow High Humidity device|High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
47997375|NCT03721419|DEVICE|Low Flow High Humidity device|Standard high humidity trach collar utilizing venturi device bleed in
47997376|NCT01722253|PROCEDURE|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
47997377|NCT01116258|DRUG|AZD5847|oral suspension, 15 days
47997378|NCT01116258|DRUG|Placebo|oral suspension, 15 days
47997379|NCT06036576|DRUG|Levothyroxine Pill|all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
47997380|NCT00422266|DRUG|Omega 3 fatty acids and plant sterol enriched drink|
48366071|NCT05834673|OTHER|Telephone-based support calls|Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.
48366072|NCT04046289|DIETARY_SUPPLEMENT|Low Calcium Milk|50 mg calcium/day
48366073|NCT04046289|DIETARY_SUPPLEMENT|Regular Calcium Milk|400 mg/day
48366074|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 1|regular calcium milk + probiotic
48366075|NCT04046289|DIETARY_SUPPLEMENT|Probiotic 2|regular calcium milk + probiotic
48366076|NCT00169273|BEHAVIORAL|Structured behavioral weight loss group|Structured group weight loss program
48366077|NCT00169273|BEHAVIORAL|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
48366078|NCT02838186|PROCEDURE|retroflexion|examination of the right colon with scope retroflexion
48366079|NCT02838186|PROCEDURE|forward view|examination of the right colon in forward view
48366080|NCT02668510|BIOLOGICAL|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
48366081|NCT02668510|DRUG|Normal saline|placebo injection of normal saline immediately following shockwave therapy
48366082|NCT00329836|OTHER|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
48366083|NCT00777439|DRUG|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
48366084|NCT03021733|PROCEDURE|Operative management|Rotator cuff surgery
48366085|NCT04541394|DEVICE|MolecuLight|MolecuLight is a device that utilizes a special light which, when used on wounds, helps identify the regions which pathogenic bacterial counts are the highest. The device applies 405nm violet light which is harmless to the human tissue. When specific components in bacteria catches up the light, a photoluminescent reaction is triggered and the fluorescence light is caught by the camera on this device in real time.
48366086|NCT00085189|BIOLOGICAL|gp100 antigen|Given SC
48366087|NCT00085189|BIOLOGICAL|tyrosinase peptide|Given SC
48366088|NCT00085189|BIOLOGICAL|recombinant MAGE-3.1 antigen|Given SC
48366089|NCT00085189|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given SC
48366090|NCT00085189|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
47997381|NCT00422266|DIETARY_SUPPLEMENT|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
47997382|NCT02653651|DRUG|Ketamine|Ketamine infused at 0.1 mg/kg/hour
47997383|NCT02653651|DRUG|Lidocaine|Lidocaine infused at 1 mg/kg/hour
47997384|NCT02653651|DRUG|Placebo|An equal volume of saline
47997385|NCT00006478|BIOLOGICAL|autologous tumor cell vaccine|
47997386|NCT00006478|BIOLOGICAL|keyhole limpet hemocyanin|
47997387|NCT00006478|BIOLOGICAL|sargramostim|
47997388|NCT00006478|PROCEDURE|adjuvant therapy|
47997389|NCT02515409|DEVICE|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
47997390|NCT02515409|DEVICE|CPAP|CPAP, as a first line treatment in OSAS.
47997391|NCT02046148|BIOLOGICAL|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
47997392|NCT02046148|BIOLOGICAL|Placebo|Intramuscular injection - Normal saline
47997393|NCT06281041|DRUG|Antiplatelet Agents|Aspirin or clopidogrel
47997394|NCT05096416|DEVICE|The three-dimensional (3D) printed hemodialysis vascular model|The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
47997395|NCT03143699|OTHER|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
47997396|NCT03202264|OTHER|TAPER|"The intervention is medication reduction. This arm is comprised of:~* Medication reconciliation~* Identification of patient priorities for care~* Identification of medications that are potentially appropriate for discontinuation/dose reduction~* Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~* Identification of medications for trial of discontinuation/dose reduction (shared decision making)~* Pause of medication and clinical monitoring"
47997397|NCT02691299|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
47997398|NCT02691299|DRUG|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
47997399|NCT06186778|PROCEDURE|secondary colonoscopy|After the routine colonoscopy, a repeat colonoscopy of the sigmoid colon is performed
47997400|NCT06186778|PROCEDURE|conventional colonoscopy|It starts from the rectum and progresses forward to the cecum, with observations made during withdrawal: from the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon to the rectum.
47997401|NCT03379207|OTHER|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
47997402|NCT03379207|OTHER|Tracheal Aspirates|Only for mechanically ventilated participants.
47997403|NCT03379207|OTHER|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
47997404|NCT06219460|OTHER|Ventilation using two types of face masks|ventilation using two types of face mask
47997405|NCT00877695|BEHAVIORAL|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
47997406|NCT04659746|DEVICE|MejoraCare|mHealth solution to support remote monitoring of symptoms and patient empowerment through education.
47997407|NCT02076828|DRUG|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
47997408|NCT02076828|DRUG|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
47997409|NCT02076828|DRUG|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
47997410|NCT00754754|PROCEDURE|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
47997411|NCT00851799|DRUG|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC"
48366091|NCT00085189|DRUG|Montanide ISA 51 VG|Given SC
48682989|NCT03167788|OTHER|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
47997412|NCT00851799|DRUG|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
47997413|NCT00851799|DRUG|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV"
48366092|NCT00085189|DRUG|agatolimod sodium|Given SC
47997414|NCT00851799|DRUG|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL"
48682990|NCT03810547|DRUG|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
47997415|NCT00851799|DRUG|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
47997416|NCT01495585|DRUG|Lonafarnib|Commercially approved products used to test the research hypothesis
47997417|NCT01495585|OTHER|Placebo|Placebo control
47997418|NCT03005821|OTHER|Chinese pediatric massage therapy + usual care|
48366093|NCT00085189|OTHER|laboratory biomarker analysis|Correlative studies
48366094|NCT05539040|PROCEDURE|Right Atrial ganglionated plexus ablation|"A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed).~All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs).~Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional."
47997419|NCT03005821|OTHER|Sham massage therapy + usual care|
47997420|NCT01673035|BEHAVIORAL|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
47997421|NCT01673035|BEHAVIORAL|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
47997422|NCT00896558|DRUG|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
47997423|NCT00896558|DRUG|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
47997424|NCT05216874|DEVICE|Oclusal Splint|"Cl III Laterognati volunteer group using occlusal stabilization splint before orthognathic surgery~-Splint will be used for at least two months"
47997425|NCT02869490|OTHER|Data collection|
47997426|NCT04650477|PROCEDURE|Fixation while forearm in extension-pronation position|Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
47997427|NCT05751837|BIOLOGICAL|Lipopolysaccharide|One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
47997428|NCT01464658|PROCEDURE|panniculectomy|surgery
47997429|NCT00731887|PROCEDURE|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
47997430|NCT02149173|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
47997431|NCT02149173|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
47997432|NCT02149173|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
47997433|NCT02149173|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
48682991|NCT00869635|DRUG|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
48682992|NCT00869635|PROCEDURE|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
47914458|NCT04927624|PROCEDURE|transversus abdominis plane block|The transversus abdominis plane (TAP) block was first introduced by Rafi et al. in 2001 as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle. Since the thoracolumbar nerves originating from the T6 to L1 spinal roots run into this plane and supply sensory nerves to the anterolateral abdominal wall , the local anesthetic spread in this plane can block the neural afferents and provide analgesia to the anterolateral abdominal wall.
47997434|NCT02149173|OTHER|Laboratory Biomarker Analysis|Correlative studies
47997435|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
47997436|NCT02149173|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
47997437|NCT01069133|DRUG|Rifaximin|550mg BID open-label
48366095|NCT05539040|DIAGNOSTIC_TEST|Holter Monitor|"48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF.~These will be performed at 3, 6, 9, 12 months"
47997438|NCT01069133|DRUG|rifaximin|550mg PO BID
47914459|NCT04927624|PROCEDURE|quoadratus lumborum block|quoadratus lumborum block
47997439|NCT00748475|BEHAVIORAL|Neurofeedback|
47997440|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
47997441|NCT01889784|DEVICE|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
48155841|NCT06289855|OTHER|MDS-UPDRS|"Movement disorder society- unified Parkinson disease rating scale (MDS-UPDRS) for Parkinson's disease.~Movement disorder society- non motor rating scale (MDS-NMS) Cognitive assessment using Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog)~Using Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale:~Timed up and go: originally aimed to clinically evaluate dynamic balance in elderly people during the performance of a task MR imaging of the brain will be performed with a 1.5T MR imaging scanner Assessment of Cortical excitability and unhibition by NIHON KOHDEN- neuropack2"
48682993|NCT00869635|PROCEDURE|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
48682994|NCT02011568|OTHER|Therapeutic Hypothermia|
48682995|NCT03038971|BIOLOGICAL|Dose Level 1|Short and Tall Ragweed Mix
48682996|NCT03038971|BIOLOGICAL|Dose Level 2|Short and Tall Ragweed Mix
48682997|NCT03038971|BIOLOGICAL|Placebo|Saline with 0.4% Phenol
48682998|NCT03844087|DEVICE|Multiplanar neuromuscular training|See arm description
48682999|NCT02018484|PROCEDURE|Unicompartmental Knee Replacement|
48683000|NCT03017339|OTHER|Functional Exercise|
48683001|NCT03017339|RADIATION|Low Level Laser Therapy|
47997442|NCT01889784|DEVICE|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
48683002|NCT03017339|RADIATION|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
48683003|NCT06373900|PROCEDURE|wound closure|Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
48683004|NCT03483792|BIOLOGICAL|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
48155842|NCT03639792|PROCEDURE|gastric cancer surgery|Gastric cancer surgery
47914460|NCT03706248|OTHER|Blood Draw|20 ml of blood will be drawn from subjects via venipuncture
48366096|NCT05539040|PROCEDURE|Pulmonary vein isolation|"Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy.~ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved."
48366097|NCT05539040|PROCEDURE|Right cavo-tricuspid and left roof linear ablation|CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.
48155843|NCT01204775|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
47914461|NCT00301613|DRUG|Mycophenolate mofetil|MMF,1.0g/d
47914462|NCT04551534|DRUG|DNL201|Oral dose(s)
48366098|NCT05539040|DIAGNOSTIC_TEST|Personal ECG recordings|All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.
48366099|NCT05539040|OTHER|Quality of life questionnaire|A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.
47914463|NCT04551534|DRUG|Placebo|Oral dose(s)
48155844|NCT01204775|DRUG|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
48155845|NCT01204775|DRUG|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
48155846|NCT01204775|DRUG|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
48155847|NCT01204775|DRUG|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
48683005|NCT03483792|GENETIC|placental biopsy|Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
48683006|NCT02931409|PROCEDURE|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
48683007|NCT02931409|PROCEDURE|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
48683008|NCT03869567|DEVICE|cone beam CT|Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
48683009|NCT03522415|DRUG|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
48683010|NCT03522415|DRUG|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
48683011|NCT01328028|OTHER|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
48683012|NCT01328028|OTHER|Data collection|Log sheet
48683013|NCT06075134|PROCEDURE|Botox injection|Botox injection
48683014|NCT06075134|DEVICE|EMG|Quantitative Electromyography
48155848|NCT06585358|OTHER|MIPD|This is a non-inverventional study
48155849|NCT04279054|DRUG|Morphine Sulfate 150 mcg|Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
48155850|NCT04279054|DRUG|Morphine Sulfate 50mcg|Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
48683015|NCT06075134|DRUG|Zinc Supplement|To increase efficacy of Botox
48683016|NCT02497222|DRUG|RNS60|
48683017|NCT02497222|DRUG|Normal Saline|
47997443|NCT01889784|DEVICE|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
48683018|NCT02777359|PROCEDURE|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
47997444|NCT06287983|DEVICE|Inspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic)|Inspiratory muscle training will be started at an intensity of 50% of the patient's measured PIMAX value and will be increased by 2 cm/H20 per day according to patient tolerance, and will be applied for a total of 6 weeks / 5 days per week / 3 sessions per day / 10 breaths per session.
47997445|NCT06287983|OTHER|The Sample Spondylitis Exercise Program|The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3\*10 sets. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.
48366100|NCT00000758|DRUG|Fluorouracil|
48683019|NCT01833494|DRUG|PA21|
48683020|NCT05372978|BEHAVIORAL|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
48683021|NCT05567445|DIAGNOSTIC_TEST|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
48683022|NCT05356988|BEHAVIORAL|Physical activity experiment|The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
48683023|NCT05356988|BEHAVIORAL|Balance and flexibility control|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
48683024|NCT05168046|BEHAVIORAL|Mindfulness based stress reduction|program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
48683025|NCT03083665|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use"
48683026|NCT03083665|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use"
48683027|NCT03353038|DEVICE|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
48683028|NCT04575545|DIAGNOSTIC_TEST|Serology test for COVID-19|ELISA test
48683029|NCT03375086|DRUG|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
48683030|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
48683031|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
48683032|NCT00888706|BEHAVIORAL|Control Condition|The group participated in the usual nursing home activities and routines.
48683033|NCT00888706|BEHAVIORAL|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
48683034|NCT00888706|BEHAVIORAL|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
47997446|NCT04898751|DRUG|Immune checkpoint inhibitor (ICI)|Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
47997447|NCT00063869|DRUG|Etanercept|
48683035|NCT00888706|BEHAVIORAL|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
48683036|NCT00003322|DRUG|cisplatin|
48683037|NCT00003322|DRUG|paclitaxel|
48683038|NCT00003322|PROCEDURE|quality-of-life assessment|
47997448|NCT01463371|DRUG|Azithromycin|250 mg three times a week during three months
47997449|NCT01907477|OTHER|Samples taken at the clinical hematology unit|
47997450|NCT05452395|OTHER|Post-acute care|"A personalized care program, focusing on managing geriatric syndromes and improving functional performances.~Strength training, activities of daily living (ADL) and instrumental activities of daily living (IADL) practice, basic mobility training, reconditioning exercise, and home environment assessment and modification."
48512310|NCT01000961|DRUG|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
48683039|NCT00540930|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
48683040|NCT03952767|OTHER|Digital Physical Measures and Survey Assessments|Data from at home and in clinic visits will assess physical function and survey data will be collected
48683041|NCT06513884|DRUG|HB-202/HB-201 alternating 2-vector therapy|Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
48683042|NCT06513884|DRUG|Placebo|Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
48683043|NCT06513884|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
47997451|NCT02541071|BEHAVIORAL|Stress Film|
47997452|NCT02541071|DRUG|Yohimbine|
47997453|NCT02541071|DRUG|Clonidine|
47997454|NCT02541071|DRUG|placebo|
47997455|NCT03226262|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
47997456|NCT06316752|OTHER|Observational study|It is an observational study involving non-invasive routine examinations without treatment, thus posing no additional risk to patients. This project does not involve the use of medications, medical techniques, or the market status of medical equipment.
48512311|NCT01000961|DRUG|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
48512312|NCT05896644|OTHER|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
48512313|NCT03655314|OTHER|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
48512314|NCT03655314|OTHER|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
48512315|NCT02285374|DRUG|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
48512316|NCT04641598|PROCEDURE|Endometrial Scratch|"An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch."
48512317|NCT04641598|PROCEDURE|Sham procedure|Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
48512318|NCT01869855|PROCEDURE|Subdural Drainage|
48512319|NCT01869855|PROCEDURE|Subperiosteal Drainage|
48512320|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
47997457|NCT01340157|DRUG|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
47997458|NCT05066971|COMBINATION_PRODUCT|Self-adjustment of medication|Each week, based on the information provided by HM (heart rate and hours of activity each day), the rate control medication is adjusted to increase the total of activity time.
47997459|NCT03806920|DIETARY_SUPPLEMENT|Intervention A|
47997460|NCT03806920|DIETARY_SUPPLEMENT|Intervention B|
47997461|NCT03806920|DIETARY_SUPPLEMENT|Intervention C|
47997462|NCT03806920|DIETARY_SUPPLEMENT|Intervention D|
48683044|NCT03953677|DRUG|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
48683045|NCT03953677|DRUG|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
48683046|NCT00819156|DRUG|degarelix|Degarelix was given as subcutaneous injections.
48683047|NCT05811754|OTHER|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
48683048|NCT00386620|BEHAVIORAL|Questionnaire|45 minute survey about health, pain and relationships
48683049|NCT00386620|BEHAVIORAL|Interview|Feedback on use of handheld computer electronic diaries (ED).
48683050|NCT04217707|BEHAVIORAL|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
48683051|NCT05069727|PROCEDURE|Regular Protocol with advanced carbohydrate counting|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD~* Finetune ICR~* Target 100 or 110 mg/dl~* AIT: 2-3 hour~* Insulin Bolus for meal (advanced carb counting)~* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
47997463|NCT01496092|DRUG|Keto Acid|12 tablets per day
47997464|NCT01110746|DRUG|Viaject 7|100IU/mL administered subcutaneously
47997465|NCT01110746|DRUG|LISPRO|100IU/mL administered subcutaneously
47997466|NCT05638685|OTHER|Questionnaire|The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.
47997467|NCT04020133|PROCEDURE|saphenous nerve block|"The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary."
47997468|NCT04020133|PROCEDURE|popliteal plexus block|After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
47997469|NCT04020133|DRUG|Plain bupivacaine|15ml of plain bupivacaine 0.5% will be given in both blocks
47997470|NCT04020133|DRUG|0.05 mg epinephrine|0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
47997471|NCT06097208|BEHAVIORAL|community-based health promotion and obesity prevention intervention|The intervention involving measurements of children aged three- to four-years old in kindergartens, parents of the children had the opportunity of individual contact with a community health nurse, and education to kindergartens manager and employees e.g. pedagogues and kitchen staff. as well to parents of children in kindergartens.
47997472|NCT04724954|DEVICE|Rehabilitation Therapy on Experimental Robotic Table and standard of care|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
47997473|NCT04724954|GENETIC|Rehabilitation Therapy as part of Standard of Care (Control)|Control group will receive Standard of Care training only
47997474|NCT02187588|DRUG|Eschscholtzia Californica - low dose|
47997475|NCT02187588|DRUG|Eschscholtzia Californica - high dose|
47997476|NCT02187588|DRUG|Ibuprofen|
47997477|NCT02187588|DRUG|Eschscholtzia Californica - low dose Placebo|
47997478|NCT02187588|DRUG|Eschscholtzia Californica - high dose Placebo|
47997479|NCT02187588|DRUG|Ibuprofen Placebo|
47997480|NCT00278109|DRUG|cyclophosphamide|chemotherapy
47997481|NCT00278109|DRUG|Doxorubicin|doxorubicin
47997482|NCT00278109|RADIATION|radiation|radiation
47997483|NCT06007599|PROCEDURE|Skin closure using skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures with skin adhesive
47997484|NCT06007599|PROCEDURE|Skin closure without skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures without skin adhesive
47997485|NCT03466476|DEVICE|Consensus TracPatch|Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
47997486|NCT06463951|OTHER|Psychotherapy - Gestalt psychotherapy|Gestalt psychotherapy is an aesthetic-phenomenological approach that aims to improve self-awareness and integration by promoting emotional and relational well-being through what is happening in the present moment in the relationship with the therapist. The patient's current experiences are explored to better understand problems and behaviors and by promoting relational self-regulation
47997487|NCT00312494|DRUG|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
47997488|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
47997489|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
47997490|NCT00730782|BIOLOGICAL|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
47997491|NCT00076011|DRUG|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
48155851|NCT03903185|DRUG|Ledipasvir / Sofosbuvir Oral Product|45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
48155852|NCT05065008|OTHER|Cranberry juice|The responders and non-responders will drink 20-30 oz of (590-885 mL) 27% cranberry juice daily for 3 weeks.
48155853|NCT05065008|OTHER|Apple juice|The participants will drink apple juice with matching sugar content and calories for 3 weeks
48512321|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
47914464|NCT05546203|OTHER|Ischemic compression|"IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain"
47914465|NCT05546203|DEVICE|Low-level laser therapy|LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.
47914466|NCT05546203|BEHAVIORAL|Standardized exercise program|The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
47914467|NCT02563067|DRUG|QAW039|QAW039 150 mg once daily
47914468|NCT02563067|DRUG|QAW039|QAW039 450 mg once daily
47914469|NCT02563067|DRUG|Placebo|Placebo once daily
47914470|NCT00461071|BEHAVIORAL|Guided Self-help for Bulimia nervosa|bibliotherapy
47914471|NCT05532306|DRUG|Ribavirin 400 mg film coated tablet (1*400mg)|an immediate release film-coated tablet containing 400 mg Ribavirin
47914472|NCT05532306|DRUG|Copegus® 200 mg film coated tablet (2*200mg)|an immediate release film-coated tablet containing 200 mg Ribavirin
47914473|NCT04692636|DIAGNOSTIC_TEST|Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension|BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
47914474|NCT01598129|GENETIC|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
47914475|NCT04202172|PROCEDURE|Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction|"The 6-month scheduled coronary angiography will perform 3 interventions:~1. Endothelial function assessment with intracoronary acetyl-choline infusion.~2. Microcirculatory function assessment with a pressure wire during endovenous adenosine infusion.~3. Stent healing assessment using optical coherence tomography"
47914476|NCT01429740|DRUG|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
47914477|NCT01429740|DRUG|Placebo|Placebo oral solution or capsules
47914478|NCT02905851|OTHER|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
47914479|NCT02905851|OTHER|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
48683052|NCT05069727|PROCEDURE|Simplified Protocol with fixed carbohydrate content|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)~* Target 100 mg/dl~* AIT: 2 hours~* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
48683053|NCT04910152|DRUG|BRD4 Inhibitor PLX51107|Given PO
48155854|NCT03449979|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
48155855|NCT03449979|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
48366101|NCT06199791|DRUG|Lamotrigine 100 MG|tablets
48366102|NCT05465850|DIAGNOSTIC_TEST|Modified USPHS criteria|It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
48366103|NCT05877495|BEHAVIORAL|Nutritional Education Intervention|A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
48512322|NCT01307345|BEHAVIORAL|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
48683054|NCT04513769|BEHAVIORAL|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
47914480|NCT00243269|BEHAVIORAL|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
47914481|NCT04681352|DEVICE|Octave-Ultherapy treatment|Micro-focused ultrasound delivered below the surface of the skin.
47914482|NCT01359085|DRUG|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
48366104|NCT05463315|DEVICE|Moziak Device|Applying Moziak Device Compared to Standard Manual Compression
48366105|NCT02405676|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
48366106|NCT02405676|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
48512323|NCT05054504|DEVICE|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
48512324|NCT04376931|DRUG|Intravenous Solution|Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
48683055|NCT05253755|BIOLOGICAL|DBI-001|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
48683056|NCT05253755|BIOLOGICAL|Aqueous gel|Topical application of aqueous gel on skin affected with atopic dermatitis.
48683057|NCT04312139|DIAGNOSTIC_TEST|Echocardiography|Baseline and prospective follow-up echocardiography
48683058|NCT04312139|DIAGNOSTIC_TEST|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
48683059|NCT04312139|OTHER|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
48683060|NCT04312139|OTHER|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
48683061|NCT04312139|DIAGNOSTIC_TEST|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
48683062|NCT05821452|DRUG|Camrelizumab|200mgQ3w
47914483|NCT01359085|PROCEDURE|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
47914484|NCT03257319|DRUG|inhaled titration of morphine chlorhydrate|Patient in arm A will receive 1 to 3 titration
47997492|NCT02933177|BEHAVIORAL|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
47997493|NCT02933177|BEHAVIORAL|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~* Boards of known photographs to recall autobiographical memories~* Newspapers to read, talk, associate memories around an article~* Massage Oil, refreshing wipes, cream to reconnect with the body~* Clay, cookie pieces, washable felt and paper to create shapes, draw.~* Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~* Listening to music~* Relaxation-Breathing~* Cushion, foam balls to vent his energy on secure hardware.~* Plush doll or to invest a vector object of affection and empathy~* Sensory flash balls that the patient can squeeze, throw, roll.~* Games with which the patient can play according to its possibilities."
47997494|NCT00531232|DRUG|Clofarabine|"Pharmaceutical form: Tablet,~Route of administration: Oral"
48366107|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
48366108|NCT02405676|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
48512325|NCT03062384|DIETARY_SUPPLEMENT|AT-001|
48512326|NCT03062384|DIETARY_SUPPLEMENT|Placebo|
48683063|NCT05821452|DRUG|Paclitaxel|175mg/m2，D1，Q3w
48683064|NCT05821452|DRUG|Cisplatin|75mg/m2，D1，Q3w
47914485|NCT03257319|DRUG|IV placebo|Patient in arm A will receive 1 to 6 injection
48683065|NCT05821452|RADIATION|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
48683066|NCT05646225|OTHER|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
48683067|NCT05646225|OTHER|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
47914486|NCT03257319|DEVICE|Inhaled placebo|Patient in arm B will receive 1 to 3 titration
47914487|NCT03257319|DRUG|IV titration of morphine chlorhydrate|Patient in arm BA will receive 1 to 6 injection
47914488|NCT04183543|DEVICE|Pulsed Electromagnetic Fields|The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak.
47914489|NCT04183543|DEVICE|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy
47914490|NCT01206088|DRUG|nilotinib|administration of nilotinib as 2nd line
47914491|NCT05426603|PROCEDURE|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode
48683068|NCT01166217|DRUG|PF-04620110|"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
48683069|NCT06196151|BEHAVIORAL|Antenatal training|"Training hours: Training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be given online via Zoom application. The training will consist of a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Pregnant women in both the control and intervention groups will be asked to fill out the Women's Introductory Information Form. The data of the intervention group will be filled out before the first Antenatal education lesson and after all six-hour Antenatal education lessons are completed. The data of the control group will be filled in parallel with the intervention group.~Group to receive the training: Healthy pregnant women who are at the 20th gestational week at the earliest will be included in the training. Trainings will be carried out in closed groups."
48683070|NCT03204877|DRUG|Melatonin|Oral capsules
48683071|NCT03204877|OTHER|Placebo|Oral capsules
48683072|NCT02661204|DEVICE|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
47997495|NCT04760158|OTHER|Exercise|Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
48683073|NCT05524077|PROCEDURE|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
47997496|NCT04697693|DRUG|Escitalopram|The participant will be begun on either escitalopram 10mg or duloxetine 30mg. Subjects will begin escitalopram 10mg, continue this dosage for 4 weeks, then if the HRSD \>7 at Week 4, he/she will have their dosage increased to 20mg for the remainder of the 8 week study.
48683074|NCT05524077|DRUG|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial)."
48683075|NCT05267535|DRUG|Piromelatine 20 mg|Tablets
48683076|NCT05267535|DRUG|Placebo|Tablets
48683077|NCT01453972|BEHAVIORAL|Long distanse moderate training|Moderate exercise
48683078|NCT01453972|BEHAVIORAL|Long interval training|High-intensity exercise, long duration
48683079|NCT01453972|BEHAVIORAL|Short interval training|High intensity exercise, short duration
48683080|NCT00132990|DEVICE|Deep brain stimulation|
48683081|NCT04543877|DIETARY_SUPPLEMENT|Inulin|Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
48683082|NCT04543877|DIETARY_SUPPLEMENT|Maltodextrin|Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
47997497|NCT04697693|DRUG|Duloxetine|Participants who have not responded to or not tolerated escitalopram in the current depressive episode will be started on duloxetine. They will take 30mg for the first 2 weeks, then, contingent on clinical assessment that the 30mg dose is sufficiently well tolerated, be increased to 60mg for the remaining 6 weeks of the study.
48155856|NCT04867499|OTHER|No intervention|Descriptive study. No intervention.
48155857|NCT06020495|DRUG|DDAVP|Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
48155858|NCT06020495|DRUG|Standard hyponatremia treatment|"Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic"
48155859|NCT06407973|DEVICE|OMNI Surgical System|The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma
48155860|NCT06407973|DRUG|Latanoprost plus adjunctive glaucoma medication|"* Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* An adjunctive topical glaucoma medication of a different class as selected by the Investigator"
48366109|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
48155861|NCT04174170|DRUG|Brexpiprazole|Up to 3 mg pill
48155862|NCT04174170|DRUG|Sertraline|Up to 150 mg pill
48366110|NCT02405676|DRUG|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
47997498|NCT04311879|DEVICE|Soft tissue Diode laser application|post-operative soft tissue diode laser application
48155863|NCT04174170|OTHER|Placebo|Pill
48155864|NCT04205045|DIAGNOSTIC_TEST|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
48155865|NCT04205045|OTHER|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
48155866|NCT04205045|OTHER|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
47997499|NCT04311879|OTHER|Placebo|mock diode laser application
47997500|NCT03173716|PROCEDURE|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
48155867|NCT00363389|DRUG|misoprostol and cervical ripening|
48155868|NCT03258983|OTHER|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
48155869|NCT00000940|DRUG|Ritonavir|
48155870|NCT00000940|DRUG|Abacavir sulfate|
48155871|NCT00000940|DRUG|Amprenavir|
48155872|NCT00000940|DRUG|Lamivudine|
48155873|NCT00000940|DRUG|Stavudine|
48155874|NCT06358040|DEVICE|Opioid-Dispensing Device|Addinex Opioid-Dispensing Device
48155875|NCT06358040|OTHER|App|Addinex App
48155876|NCT06358040|OTHER|Standard Opioid Pill Bottle|Standard Opioid Pill Bottle
48155877|NCT00275678|PROCEDURE|Blood stem cell versus bone marrow transplant|"1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.~2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.~3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.~4. Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
48366111|NCT02075580|BEHAVIORAL|psychological support (interactive/cognitive strategies)|"* cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~* metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~* psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~* questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
48366112|NCT05290935|DRUG|Anti-PD-1 antibody camrelizumab|Camrelizumab: 200 mg every time, every 3 weeks, which would be sustained until the appearance of disease progression on intolerable adverse events, and no more than 24 months
48683083|NCT04543877|BIOLOGICAL|Ty21a Typhoid Fever Vaccine|All participants will receive the vaccine. One capsule is swallowed on alternate days, e.g. days 30, 32, 34, and 36 for a total of 4 capsules.
47997501|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 4 mg|They will take astaxanthin 4 mg 1 capsule once daily for 2 months.
47997502|NCT05009810|DIETARY_SUPPLEMENT|astaxanthin 6 mg|They will take astaxanthin 6 mg 1 capsule once daily for 2 months.
47997503|NCT05009810|DIETARY_SUPPLEMENT|Placebo|They will take placebo 1 capsule once daily for 2 months.
47997504|NCT05584696|OTHER|Green light exposure|The experimental group wears green color glasses ten minutes before surgery until it ends.
47997505|NCT05584696|OTHER|Normal light exposure|The control group wears green color glasses ten minutes before surgery until it ends.
47997506|NCT02639104|RADIATION|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~1. The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~2. If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~3. The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
47997507|NCT02639104|OTHER|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
48155878|NCT03756896|DRUG|Carfilzomib|Given IV
48155879|NCT03756896|DRUG|Dexamethasone|Given PO
48155880|NCT03756896|DRUG|Pomalidomide|Given PO
48155881|NCT06328322|PROCEDURE|Percutaneous Coronary Intervention in Left Main Artery Disease|To investigate and assess the effectiveness and safety of percutaneous coronary intervention in left main coronary artery disease in sitting of acute coronary syndromes.
48155882|NCT04276142|BEHAVIORAL|ceprica (additional to treatment as usual)|ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
48155883|NCT04276142|BEHAVIORAL|active control intervention (additional to treatment as usual)|the active control intervention contains psychoeducational content regarding migraine
48155884|NCT05658445|OTHER|evacuation|after complete evacuation of uterus follow abortion
48683084|NCT03388762|DIETARY_SUPPLEMENT|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
47997508|NCT02381912|OTHER|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
47997509|NCT06368232|OTHER|püPatients undergoing bariatric surgery|Patients will not be intervened. Only nutritional status after bariatric surgery will be evaluated.The data of 76 patients aged 19-64 years who had undergone bariatric surgery and were followed by a dietitian dietitian for at least 6 months were included.
48683085|NCT03388762|OTHER|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
48683086|NCT06308744|BEHAVIORAL|Body-scan meditation|Participants listen to a 15-minute Body-Scan mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
48683087|NCT06308744|BEHAVIORAL|Mindful Breathing meditation|Participants listen to a 15-minute Mindful Breathing mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
48155885|NCT02334202|BEHAVIORAL|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
48155886|NCT02334202|OTHER|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
48155887|NCT01304953|DRUG|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
47997510|NCT02141997|BIOLOGICAL|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
47997511|NCT02141997|BIOLOGICAL|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
47997512|NCT03725189|DEVICE|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
48366113|NCT05290935|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel: 200-300 mg every time, every 3 weeks, no more than 6 courses
47997513|NCT04512248|BEHAVIORAL|Quit and Stay Quit Monday Model|Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT.
47997514|NCT02417012|BEHAVIORAL|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
47997515|NCT02417012|BEHAVIORAL|Standard care|Standard individual diabetes support
48366114|NCT04096781|BEHAVIORAL|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
48366115|NCT04096781|BEHAVIORAL|Usual Care|The participants will receive usual care.
48366116|NCT04746729|OTHER|No intervention|No intervention
48366117|NCT01968473|DEVICE|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
48366118|NCT00489216|BIOLOGICAL|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
48366119|NCT02798159|DRUG|TD0025|
48366120|NCT02798159|DRUG|Sildenafil Citrate 50mg|
48366121|NCT00466986|DRUG|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
48683088|NCT06308744|BEHAVIORAL|Loving Kindness meditation|Participants listen to a 15-minute Loving Kindness mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
47997516|NCT05164237|OTHER|nerve flossing technique|subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
47997517|NCT05164237|OTHER|multimodal electrotherapy|subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
48366122|NCT02172820|BEHAVIORAL|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
47997518|NCT05164237|OTHER|exercises|subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
48155888|NCT01304953|DRUG|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
48366123|NCT01884935|BIOLOGICAL|Natalizumab|As specified in the treatment arm
48683089|NCT06308744|BEHAVIORAL|Mindful Walking|Participants listen to a 15-minute Mindful Walking mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
48683090|NCT06308744|BEHAVIORAL|Listening of a story|Participants listen to a 15-minute story. The audio track is embedded in the Qualtrics survey.
48683091|NCT05480735|BEHAVIORAL|Prehabilitation|Multimodal prehabilitation program
48683092|NCT03235921|DRUG|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
48683093|NCT03235921|OTHER|placebo|no drug given to the control group
48683094|NCT03525002|DRUG|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
48155889|NCT01304953|DRUG|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
48155890|NCT01304953|DRUG|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
48155891|NCT03015415|PROCEDURE|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
47997519|NCT04073381|COMBINATION_PRODUCT|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
47997520|NCT00102232|PROCEDURE|supplementation with phosphatidylcholine|
48683095|NCT03525002|OTHER|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
48683096|NCT01738685|BEHAVIORAL|Behavioral Intervention.|
47997521|NCT03728894|DRUG|Midazolam-hydroxyzine with 100% O2|Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
48683097|NCT01738685|OTHER|Nutritional Education.|
48683098|NCT05733637|OTHER|No intervention|There will be no intervention apply to study participants.
48683099|NCT04941469|DEVICE|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
48683100|NCT04941469|DEVICE|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
47997522|NCT03728894|DRUG|Midazolam-hydroxyzine with 50% N2O/O2|Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
48155892|NCT03015415|PROCEDURE|Non-surgical intervention|Rehabilitation with splinting protocols
48366124|NCT06234995|DRUG|Levodopa|Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
48366125|NCT06234995|DEVICE|Clinical DBS Setting|Deep brain stimulation performed with the patients' optimized clinical setting.
48366126|NCT06234995|DEVICE|Sham DBS|Deep brain stimulation performed with sham stimulation.
48366127|NCT06234995|DEVICE|DBS Setting Maximizing Prefrontal Activation|Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.
48366128|NCT06234995|DEVICE|DBS Setting Minimizing Prefrontal Activation|Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.
48683101|NCT04873440|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg/d twice a week
48683102|NCT04873440|RADIATION|Radiotherapy|Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
48683103|NCT04873440|DRUG|Chemo-immunotherapy|The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
48683104|NCT00529243|DRUG|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
48683105|NCT01503346|DRUG|DaHuang GanTsao Tang|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
48683106|NCT04326010|DEVICE|Surgery|THA surgery
48683107|NCT04068077|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
47997523|NCT05445765|BIOLOGICAL|anti-CD33 CAR T cells|Anti-CD33 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
47997524|NCT03121092|DRUG|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
47997525|NCT05104515|BIOLOGICAL|OVM-200|"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."
47997526|NCT01909349|BEHAVIORAL|self-regulation|Web-based support for behavior change regarding physical activity and fruit \& vegetable consumption
47997527|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~* Lactobacillus gasseri KS-13 1.2~* Bifidobacterium bifidum G9-1 0.15~* Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
47997528|NCT01176227|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
47997529|NCT02396836|OTHER|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
47997530|NCT02396836|OTHER|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
47997531|NCT04720196|DEVICE|Active repetitive transcranial magnetic stimulation|High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
47997532|NCT04720196|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham stimulation to mimic the high frequency rTMS over the primary motor area.
47997533|NCT05172661|BEHAVIORAL|Integrated physical-cognitive training|Perform a postural task and a cognitive task at the same time (dual-task model) 70 minutes/session\*2 sessions/week\*6 weeks
47997534|NCT05172661|BEHAVIORAL|Consecutive physical-cognitive training|Perform a postural task and a cognitive task separately for identical durations 70 minutes/session\*2 sessions/week\*6 weeks
47997535|NCT03669835|DIETARY_SUPPLEMENT|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
47997536|NCT03669835|DRUG|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
48155893|NCT00441571|DRUG|177Lu-CYT-500|
47997537|NCT05851183|DRUG|Vitis Vinifera seed extract medication plus therapeutic lifestyle change|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
48155894|NCT01631825|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
48366129|NCT04718038|DRUG|Cetuximab combind mFOLFOX6/FOLFIRI|Cetuximab 500mg/m2 ivgtt 2h d1 ,q14d;mFOLFOX6: Oxaliplatin 85mg/m2 ivgtt 2h d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1, 5-Fu 2.4/m2 CIV 46h, q14d; FOLFIRI: CPT-11 180mg/m2 ivgtt 60-90mins d1, 5-Fu 400mg/m2 iv d1,Lefucovorin 400mg/m2 ivgtt 2h d1,5-Fu 2.4/m2 CIV 46-48h, q14d
48366130|NCT05345431|DEVICE|endovascular denervation|Treating with EDN at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
48683108|NCT03072043|DRUG|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
48683109|NCT03072043|DRUG|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
48683110|NCT03870464|DIAGNOSTIC_TEST|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
48683111|NCT03870464|DIAGNOSTIC_TEST|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
48683112|NCT03870464|OTHER|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
48155895|NCT00221156|DRUG|Acarbose|
48366131|NCT05345431|DEVICE|PTA|Treating with balloon dilation or stent implantation
48155896|NCT00730925|DRUG|BIBW2992|tablet BIBW high dose
47997538|NCT05851183|BEHAVIORAL|Therapeutic lifestyle change only|Implementing TLCs is a critical component of a comprehensive treatment plan for varicose veins. A key aspect of TLCs is the optimization of postural habits. Patients are advised to avoid extended sitting or standing periods, which exert additional pressure on the venous system in the lower extremities and exacerbate venous insufficiency. During rest periods, elevating the legs closer to the heart is recommended because this simple yet effective adjustment promotes venous return and reduces the gravitational burden on the venous valves of the legs. The use of graduated compression stockings during waking hours is another therapeutic lifestyle intervention that is often prescribed for patients with varicose veins. Additional TLCs include maintaining optimal body weight and engaging in regular physical exercise Walking or cycling are often recommended because of their effectiveness in promoting lower limb venous return.
47997539|NCT03263416|OTHER|Dedicated and coordinated follow-up|"* Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~* Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~* Completion of QLQ-C30 and GIRERD questionnaires"
48155897|NCT00730925|DRUG|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
47997540|NCT03263416|OTHER|Standard follow-up|- Completion of QLQ-C30 and GIRERD questionnaires
47997541|NCT06310850|DRUG|Ketamine|Patients will be administered 0.15 mg kg-1 intravenous ketamine (The sample provided contains equal proportions of two enantiomers, S and R ketamine hydrochloride.) 3 minutes before thoracic epidural catheter placement.
48155898|NCT03096262|BEHAVIORAL|Output-Focus Condition|Users are asked to tag more, and force feedback is exerted the more points the user has
48155899|NCT03096262|BEHAVIORAL|Input-Focus Condition|Users are asked to tag more and force feedback is exerted based on the number of images the user has analyzed.
48366132|NCT04984629|DEVICE|HYDRAFIL|The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
48366133|NCT01453439|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
48683113|NCT03870464|BEHAVIORAL|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
48683114|NCT05881681|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
48683115|NCT02016495|DIETARY_SUPPLEMENT|Magnesium plus alpha-lipoic acid|
48683116|NCT02016495|DRUG|Placebo|
48683117|NCT04162470|DRUG|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
48683118|NCT01670669|DRUG|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
48683119|NCT04279119|DRUG|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
48683120|NCT04746664|BEHAVIORAL|Nutritional counselling|Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
48683121|NCT01013324|DRUG|XL147 (SAR245408)|dosed as capsules taken orally daily
48683122|NCT00194077|DRUG|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
48683123|NCT00194077|DRUG|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
48683124|NCT02567799|DRUG|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
47997542|NCT06310850|OTHER|Placebo|Intravenous saline will be administered to patients 3 minutes before the thoracic epidural catheter is placed.
47997543|NCT02477501|DRUG|Norepinephrine|continuous infusion
47997544|NCT02477501|DRUG|Ephedrine|continuous infusion
47997545|NCT00112658|DRUG|fluorouracil|
48155900|NCT05534269|BIOLOGICAL|autologous muscle precursor cells|Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter
48155901|NCT02440698|BEHAVIORAL|Genetic test for personalized nutrition|
48155902|NCT06047795|OTHER|Experimental|"Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions \* 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks"
48155903|NCT06047795|OTHER|Control|"Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy."
48366134|NCT01453439|BEHAVIORAL|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
48366135|NCT02364362|DRUG|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m\^2
47997546|NCT00112658|DRUG|gemcitabine hydrochloride|
47997547|NCT00112658|DRUG|irinotecan hydrochloride|
48366136|NCT02364362|DRUG|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m\^2
47997548|NCT00112658|DRUG|leucovorin calcium|
48366137|NCT02364362|DRUG|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m\^2
48366138|NCT03149731|DEVICE|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
48683125|NCT02567799|DRUG|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
47997549|NCT00112658|DRUG|oxaliplatin|
47997550|NCT05300295|BEHAVIORAL|Mentoring Program|The Autism Mentorship Program is a psychosocial intervention that pairs adults and adolescents with autism spectrum disorder (ASD) in one-to-one mentoring relationships. AMP involves weekly meetings in an afterschool setting and targets the socio-emotional health and social connectedness of adolescents and adults with ASD.
48683126|NCT02567799|DRUG|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart."
48683127|NCT02567799|RADIATION|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
48683128|NCT04922853|DRUG|Capox chemotherapy|oxaliplatin: 130 mg/m2 iv d 1, capecitabine: 1000 mg/m2 bid d 1-14, repeated at 3 week intervals
48683129|NCT04304053|DRUG|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
47997551|NCT02614911|OTHER|Biological sampling|Biological sampling including blood, feces, biopsies...
47997552|NCT03000699|BEHAVIORAL|Cognitive Bias Modification|Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
47997553|NCT06160466|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
47997554|NCT06160466|DEVICE|White light|White light endoscopy
47997555|NCT02293070|OTHER|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
47997556|NCT02293070|PROCEDURE|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
47997557|NCT05721274|BEHAVIORAL|Community mobilization and Conditional community incentives|Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
48366139|NCT05767437|BEHAVIORAL|Abdominal drawing-in maneuver exercise|From the supine position to the hook-lying position (hip joint at 40 degrees and the knee joint at 80 degrees) and pull the navel deeply to the lumbar region through the Stabilizer™ Pressure Biofeedback that stabilize transversus abdominis muscle. At this time, subjects are controlled to maintain contraction while keep breathing lightly, to contract slowly, also to not move the pelvis and chest while exercising
48366140|NCT05767437|BEHAVIORAL|sham|Release pain or upper limb mobilization
48366141|NCT05597592|PROCEDURE|Feasability of a personalised physical rehabilitation program at home|Monitoring of the realization of a personalised physical rehabilitation program at home by patients with neuromuscular and neurodegenrative disease
48366142|NCT00211536|DRUG|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
48366143|NCT00211536|DEVICE|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
48366144|NCT00211536|DRUG|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
48366145|NCT00292513|DEVICE|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
48366146|NCT00512928|DRUG|acenocoumarol|max 5 mg per day during 10 weeks
48366147|NCT00512928|DIETARY_SUPPLEMENT|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
48683130|NCT04304053|OTHER|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
47997558|NCT05223855|OTHER|Physiotherapeutic hydrotherapy treatment|"Physiotherapeutic hydrotherapy treatment The intervention consists of physiotherapeutic one-on-one treatment in a 34-36 degrees centigrade hot water, where the participants are placed supine in the water supported by the physiotherapist as well as buoyant aqua noodles. The physiotherapist supports and moves the participants in the water and adapts to the participant's reaction.~The combination of heat, water, movement and touch affects the musculoskeletal and neuromuscular systems and thus has a depth-relaxing effect (Schoedinger, 2010)."
47997559|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Discontinued IST
47997560|NCT03483675|BIOLOGICAL|Immunosuppressive Therapy|Continued IST
47997561|NCT03483675|OTHER|Survey Administration|Ancillary studies
47997562|NCT06216431|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
48683131|NCT00787839|OTHER|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
48155905|NCT01375777|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
48683132|NCT00787839|OTHER|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
48683133|NCT06239883|OTHER|Voiding diary|The patients with diagnosed OSA will be asked to fill in the voiding diary.
48683134|NCT03534505|OTHER|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
48512327|NCT02784041|DRUG|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
47997563|NCT03897452|DRUG|Fentanyl (5 microgram/ml) prediluted ampoules|"Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation)."
47997564|NCT05939492|BEHAVIORAL|Mindfulness-Based Intervention|"Participants in the mindfulness-based intervention (MBI) group will be asked to use the Headspace app to sequentially complete the Basics, Basics 2, and Basics 3 courses. Each of these courses lasts 10 days, and participants have the ability to choose how long daily sessions last. Participants can choose between 3, 5, or 10-minute sessions for the Basics course; 10 or 15-minute sessions for the Basics 2 course; and 10, 15, or 20-minute sessions for the Basics 3 course. These daily sessions are audio recordings that prompt users to engage in a variety of mindfulness techniques, including focusing on their body and breathing, as well as acknowledging thoughts and emotions in a non-judgmental manner."
47997565|NCT04779866|BEHAVIORAL|Self-Administered Hypnosis|Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.
48155906|NCT01375777|DRUG|Ezetimibe|Administered orally once a day
48155907|NCT01375777|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
48155909|NCT05686343|DIAGNOSTIC_TEST|Echocardiography, Doppler ultrasonography, Near-infrared spectroscopy|Ecocardiography at 1st, 3rd and 7th day of life Doppler US (cranial and renal) at 1st, 3rd and 7th day of life Near-infrared spectroscopy monitoring after birth during first 3-days of life
48155910|NCT02244775|DEVICE|SR™MCP|
48155911|NCT03225092|BIOLOGICAL|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
48155912|NCT00248794|BEHAVIORAL|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
48155913|NCT00248794|BEHAVIORAL|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
48683135|NCT03534505|OTHER|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
47997566|NCT04779866|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
47997567|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
48683136|NCT02079909|DRUG|T-817MA-H|224 mg or 448 mg T-817 MA once daily
48683137|NCT02079909|DRUG|T-817MA-L|224 mg T-817 MA once daily
48683138|NCT02079909|DRUG|Placebo|Placebo
47997568|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via non-rebreather
48683139|NCT00703963|DEVICE|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
47997569|NCT04171037|OTHER|Questionnaire Administration|Ancillary studies
47997570|NCT04171037|DEVICE|Optiflow THRIVE|Oxygen Administration
48155914|NCT00248794|BEHAVIORAL|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
48155915|NCT03590067|OTHER|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
48683140|NCT00703963|OTHER|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
47997571|NCT01261182|OTHER|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
47997572|NCT01261182|OTHER|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
47997573|NCT06438042|DEVICE|Use of a powered low air pressure motorised therapeutic mattress that combines the motorised and static technologies|Patients with a high risk of pressure injury, without pressure injury, lying more than 20 hours a day, will ly a on a XTECH®25 mattress
47997574|NCT00978068|DRUG|Lopinavir/Ritonavir (LPV/r)|
48683141|NCT03266744|DIAGNOSTIC_TEST|Computerised Tomography|
48155916|NCT00892970|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
48155917|NCT00892970|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
48155918|NCT02435498|OTHER|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
48155919|NCT02435498|OTHER|Video|The online video will contain the same information within the website.
48155920|NCT02435498|OTHER|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
48683142|NCT03266744|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|
47997575|NCT00978068|DRUG|Nevirapine (NVP)|NVP will be used for children \< 3 years of age
48155921|NCT05020886|BEHAVIORAL|turning task|Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.
48155922|NCT00597779|DEVICE|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
48366148|NCT05080686|DEVICE|Posthorax Thoraxbelt|The patients will be assisted to put on the ThoraxBelt after surgery or at the emergency room by our research members and will be asked to keep it on except for showering through the whole study period.
48683143|NCT03266744|DIAGNOSTIC_TEST|Bone scan|
48683144|NCT04512677|DEVICE|Timed Inspiratory Effort (TIE index)|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
48683145|NCT05455125|DIAGNOSTIC_TEST|CMR CGI|High resolution ECGI plus advanced CMR
48683146|NCT06367660|DRUG|Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine|In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
48683147|NCT06386926|OTHER|Electro Therapy|radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks
47997576|NCT00978068|DRUG|Efavirenz (EFV)|EFV for children ≥3 years of age
47997577|NCT00978068|DRUG|2 nucleoside reverse transcriptase inhibitor (NRTI)|The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
47997578|NCT02140658|BEHAVIORAL|multiple health education interventions|
47997579|NCT02140658|BEHAVIORAL|conventional health education|
48155923|NCT01039116|BEHAVIORAL|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
48155924|NCT01039116|BEHAVIORAL|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
48683148|NCT04684576|DEVICE|Permobil Explorer Mini|The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
48683149|NCT04684576|DEVICE|Modified Ride-On Car|Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
48683150|NCT06339086|DRUG|Semaglutide Injection|"The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
48683151|NCT06339086|DRUG|Semaglutide Injection(Ozempic®)|"The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
48683152|NCT06339086|DRUG|Metformin|"Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks."
48683153|NCT05055609|DRUG|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
48683154|NCT00821158|DRUG|Antioxidant|Antioxidant iv bolus
48683155|NCT00821158|OTHER|Placebo|Placebo tablet and iv
48683156|NCT00821158|DRUG|Anti-inflammatory drug|Anti-inflammatory tablet
48683157|NCT05237362|BEHAVIORAL|Saga Stories|Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
48683158|NCT04014699|PROCEDURE|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
48683159|NCT04014699|PROCEDURE|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
48683160|NCT02229786|DRUG|Buscopan® plus|
48683161|NCT02229786|DRUG|Buscopan®|
48155925|NCT04175392|DRUG|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
48155926|NCT04175392|DRUG|Placebos|Placebos capsule 1 capsule Once daily
48683162|NCT02229786|DRUG|Paracetamol|
47997580|NCT05261711|DRUG|AB1|This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
48155927|NCT05119231|PROCEDURE|Pulmonary Vein Isolation|Catheter ablation (radiofrequency ablation or cryoablation) of atrial fibrillation according to local standard
48683163|NCT02229786|DRUG|Placebo|
48683164|NCT01530646|BEHAVIORAL|Weight loss|-750kcal/d
47997581|NCT00146874|DEVICE|cardiac resynchronization therapy|
48155928|NCT05119231|OTHER|Sham-Pulmonary Vein Isolation|Sham-Pulmonary Vein Isolation in deep sedation for at least one hour including femoral vein/artery puncture with introduction of sheaths and electrical cardioversion in presence of current atrial fibrillation
48155929|NCT06072352|OTHER|Perineal cleansing using chlorhexidine acetate solution|Perineal cleansing using chlorhexidine acetate solution
48155930|NCT06072352|OTHER|Normal saline|Perineal cleansing using normal saline
48683165|NCT01530646|DIETARY_SUPPLEMENT|Soy|2 x 25g/d SPC
48683166|NCT01530646|DIETARY_SUPPLEMENT|Whey|2 x 25g/d WPI
48683167|NCT05429320|PROCEDURE|Local ablative therapy|In part I, 33 patients with metastatic NSCLC with: a) NR-VAF but b) without radiographic progression of disease, will be treated with LAT. In Part II of the study, patients will be randomized to standard of care (continuation of systemic therapy) vs. LAT to all sites of disease
48683168|NCT05429320|OTHER|Blood collection to assess for ctDNA|Participants will undergo ctDNA collection in conjunction with their standard of care therapy.
48683169|NCT05795673|OTHER|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
48683170|NCT05100355|PROCEDURE|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
48683171|NCT05100355|PROCEDURE|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
48683172|NCT02809443|BIOLOGICAL|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
48683173|NCT04931797|BEHAVIORAL|video decision aid|advance care planning video decision aid
48683174|NCT04931797|BEHAVIORAL|control arm ACP information sheet|control arm ACP information sheet
48683175|NCT06005012|DRUG|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
48683176|NCT06005012|DRUG|Placebo|Placebo
48683177|NCT01780844|DRUG|ASKP1240|intravenous infusion
48683178|NCT01780844|DRUG|Tacrolimus|intravenous or oral
48683179|NCT01780844|DRUG|Mycophenolate Mofetil (MMF)|intravenous or oral
48155931|NCT04595110|OTHER|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
48683180|NCT01780844|DRUG|Basiliximab|intravenous
48683181|NCT01780844|DRUG|Methylprednisone|Intravenous
48683182|NCT01780844|DRUG|Prednisone|Oral
48683183|NCT01627626|DRUG|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
47997582|NCT04882527|DEVICE|Non-invasive brain stimulation|Stimulation will be applied once per subject with one mA for 20 minutes over either the left inferior frontal lobe, the right inferior frontal lobe or the right superior parietal lobe.
47997583|NCT04882527|DEVICE|Sham stimulation|The electrode positions and the attachment procedures correspond to those of real tDCS but the electrical current will only be ramped up to 1 mA and switched off completely after 30 s of stimulation.
47997584|NCT02155023|DRUG|Insulin dosing|
47997585|NCT02155023|DEVICE|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
47997586|NCT04750837|PROCEDURE|debridement of the wound|The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
47997587|NCT04750837|BIOLOGICAL|platelet rich plasma|Part of activated PRP was injected around the wound and under the base of the wound, while another portion of PRP was left over the floor of the wound and let to coagulate and form a gel.
47997588|NCT04750837|PROCEDURE|conventional dressing|The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
47997589|NCT05305872|DRUG|Gandouling|The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
47997590|NCT03938194|PROCEDURE|Aquablation|a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
48683184|NCT01627626|DRUG|saline|0.9% saline solution
48683185|NCT03926949|OTHER|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
47997591|NCT00132418|DRUG|Enbrel|Enbrel
47997592|NCT00132418|DRUG|Placebo|Placebo
47997593|NCT05383079|DRUG|Lutetium-177 PSMA-I&T|Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
47997594|NCT05383079|DRUG|Radium-223|During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
48683186|NCT03926949|OTHER|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
48683187|NCT02882438|DRUG|infected group|Ginkgo Biloba in different dosage forms
48683188|NCT02882438|DRUG|control group|placebo without Ginkgo Biloba
48683189|NCT00925665|DEVICE|Glidescope|Patients are to be intubated using the Glidescope technique
48683190|NCT00925665|DEVICE|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
48683191|NCT06431191|PROCEDURE|lateral raw|lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw
48683192|NCT06431191|PROCEDURE|double raw|double raw repair for full tear rotator cuff combined microfracture procedure
48683193|NCT02974829|OTHER|follow-up|
48683194|NCT01088295|DRUG|Telmisartan|
48683195|NCT06197074|OTHER|Ultrasound assessment|The morphological characteristics of the quadriceps muscle of the participants will be assessed using ultrasound.
48683196|NCT01360814|PROCEDURE|quality-of-life assessment|Ancillary studies
48683197|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive multidisciplinary structured intervention
48683198|NCT01360814|OTHER|questionnaire administration|Ancillary studies
48683199|NCT01360814|OTHER|counseling intervention|Receive multidisciplinary structured intervention
48683200|NCT01360814|BEHAVIORAL|exercise intervention|Receive multidisciplinary structured intervention
48683201|NCT01360814|OTHER|educational intervention|Receive multidisciplinary structured intervention
48683202|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive standard care
48683203|NCT01360814|PROCEDURE|standard follow-up care|Receive standard care
48683204|NCT04051749|PROCEDURE|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
48683205|NCT03330678|DIETARY_SUPPLEMENT|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
47997595|NCT03533387|DRUG|MN-166|an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
47997596|NCT00624533|BEHAVIORAL|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
47997597|NCT00624533|BEHAVIORAL|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
47997598|NCT00458523|BIOLOGICAL|alemtuzumab|
48155932|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
47997599|NCT00458523|GENETIC|fluorescence in situ hybridization|
47997600|NCT00458523|GENETIC|mutation analysis|
47997601|NCT00458523|OTHER|flow cytometry|
47997602|NCT02860715|DRUG|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
48683206|NCT05176340|OTHER|Specific Thematic Nursing Care Action Modules (STNC-AM)|"The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module."
48683207|NCT02742233|DRUG|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
47997603|NCT02860715|DRUG|Placebo|This is the placebo of GX-I7 described above.
47997604|NCT03562039|PROCEDURE|M-MIST|minimal invasive surgical technique without thorough removal of granulation tissue
47997605|NCT05067582|DRUG|L1-79|tyrosine hydroxylase inhibitor
47997606|NCT00017433|DRUG|arsenic trioxide|
47997607|NCT03226340|DRUG|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
47997608|NCT03226340|DRUG|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
47997609|NCT02676505|BEHAVIORAL|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
47997610|NCT02676505|BEHAVIORAL|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
47997611|NCT05697887|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet (KD) has been shown as an effective alternative for patients with drug-resistant epilepsy
47997612|NCT03738943|DRUG|Adenosine Triphosphate|See arm/group descriptions
48683208|NCT02742233|DRUG|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
48683209|NCT02220803|DRUG|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
48683210|NCT02220803|DEVICE|nasal Continuous Positive Airway Pressure (nCPAP)|
47997613|NCT03738943|DRUG|Acetylcholine|See arm/group descriptions
47997614|NCT03738943|DRUG|Sodium Nitroprusside|See arm/group descriptions
47997615|NCT03738943|DRUG|Adenosine Diphosphate|See arm/group descriptions
48155933|NCT00555620|DRUG|oxaliplatin|Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
48155934|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
48683211|NCT03584048|OTHER|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
48683212|NCT02204046|DRUG|BIWA 4|
48683213|NCT06003192|OTHER|Universal Opt-out HIV Screening|Using a tablet device, offering universal opt-out HIV screening to adolescents seeking care in a pediatric emergency department.
48683214|NCT01063062|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
48683215|NCT01063062|DRUG|Methotrexate|methotrexate as per standard of care in clinical practice.
48683216|NCT01312025|PROCEDURE|conventional laparoscopic cholecystectomy|
48683217|NCT01312025|PROCEDURE|modified laparoscopic cholecystectomy|
48683218|NCT03443856|DRUG|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
48683219|NCT03443856|OTHER|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
48683220|NCT01970241|DRUG|NPH|NPH given per study table based on steroid dose and patient weight in kg.
48683221|NCT01970241|DRUG|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
48683222|NCT06421480|OTHER|Detecting Risky Behaviors and Providing a Safe Environment in Patients Receiving Inpatient Treatment in a Psychiatric Clinic Using Machine Learning Model|Using machine learning, the computer will be trained to detect suicide and violent behavior. Cameras will be placed in patient rooms. These cameras will transfer the image to the computer. The computer will process these images and detect suicidal and violent behavior early. A warning will appear on the computer screen
48683223|NCT06018207|DRUG|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 4mg; (3) If not succeed, the second subject takes 8mg; (4) Until seven sequence reversal inflection points."
47997616|NCT03738943|DRUG|Adenosine Monophosphate|See arm/group descriptions
47997617|NCT03738943|DRUG|Uridine Triphosphate|See arm/group descriptions
47997618|NCT03738943|DRUG|Adenosine|See arm/group descriptions
48683224|NCT01457404|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
48683225|NCT01457404|BEHAVIORAL|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
48683226|NCT03075852|DEVICE|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
48683227|NCT00678171|DEVICE|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
48683228|NCT00550186|OTHER|placebo|
47997619|NCT03738943|DRUG|Vitamin B 6|See arm/group descriptions
47997620|NCT03738943|DRUG|Pyridoxal 5'-Phosphate|See arm/group descriptions
47997621|NCT02189564|BEHAVIORAL|Feedback about good performance|
47997622|NCT02189564|BEHAVIORAL|Feedback about good performance + money|
47997623|NCT02189564|BEHAVIORAL|Feedback about average performance|
47997624|NCT06400433|PROCEDURE|Ultrasound-guided median nerve hydrodissection|Injected wrist will be supinated and slightly dorsiflexed. The transducer of the ultrasound will be placed transversely at the proximal carpal inlet. After sterile preparation, a 22 gauge needle will be inserted using the short-axis technique, in-plane ulnar approach. During hydrodissection, separation of either between the median nerve and flexor retinaculum or between the median nerve and the underlying flexor tendons will be visually confirmed.
48683229|NCT00550186|DRUG|Ringers Lactate|
48683230|NCT00550186|DRUG|HaemoHES 6%|
48683231|NCT01541735|DRUG|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
48683232|NCT01541735|DRUG|placebo|Placebo 40 mg dose.
48683233|NCT03925571|OTHER|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music...).
48683234|NCT03649438|DRUG|131 I-Metaiodobenzylguanidine|"* Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~* Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~* Dose of \> 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
48683235|NCT03649438|DRUG|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
48683236|NCT03649438|DRUG|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
47997625|NCT06460649|OTHER|Progressive relaxation techniques|Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall
47997626|NCT06460649|OTHER|Benson relaxation techniques|Participants received Benson relaxation techniques 3 times a week for 12 weeks. 36 sessions overall.
47997627|NCT03810274|DEVICE|3DV+TPS；VARIAN TPS；FonicsPlan|
47997628|NCT02444572|DRUG|Enoxaparin 4000 IU|
48155935|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
48155936|NCT00555620|DRUG|cisplatin|Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
48155937|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
48155938|NCT04731428|BEHAVIORAL|Progressive Relaxation Exercise|Progressive Relaxation Exercise involves stretching sixteen muscle groups while breathing in sequentially, relaxing while exhaling. Exercise can be from head to toe or from foot to head. In order for the technique to be effective, it is important to have affective (music, etc.) and visual aids. During the exercise, the patient should complete the processes of perceiving the tension in his body, maintaining control and getting into a state of relaxation. After the patient is informed about the exercise, the person starts with breathing exercises. A deep but relaxing breath is taken from the nose, and lips are given by contracting simultaneously with relaxation. During this application, the patient keeps contracting the muscle group that he exercises for 10 seconds; the nurse provides the patient to notice the temperature / warming felt in the muscle group.
48155939|NCT01844908|PROCEDURE|Electroacupuncture|
47997629|NCT03999892|BEHAVIORAL|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (\~20-30 minutes) and group exercise (\~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
48155940|NCT02164578|DRUG|Rivaroxaban|
48155941|NCT02164578|DRUG|Aspirin|
48155942|NCT03722732|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy either laparoscopically or open will be done
47997630|NCT03034954|DEVICE|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
47997631|NCT03034954|DEVICE|Sham HD-tDCS|Participants will receive sham HD-tDCS
47997632|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
47997633|NCT01484574|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
47997634|NCT05410470|DRUG|Ruxolitinib|
47997635|NCT03827278|DRUG|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
47997636|NCT04702477|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level \[19\], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
47997637|NCT00001877|DRUG|Pentoxifylline|
47997638|NCT03046199|OTHER|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
47997639|NCT03046199|OTHER|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
48155943|NCT01898026|DIETARY_SUPPLEMENT|Bread|Samples of white bread, with or without the addition of PGX fibre blend
48155944|NCT01898026|DIETARY_SUPPLEMENT|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
48155945|NCT01898026|DIETARY_SUPPLEMENT|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
48155946|NCT01898026|DIETARY_SUPPLEMENT|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
48155947|NCT03856294|DRUG|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
48155948|NCT03856294|DRUG|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
48155949|NCT01958047|DRUG|ASP3652|Oral
48683237|NCT05712577|OTHER|Questionnaire|Rosenberg Self- Esteem scale
47997640|NCT03224702|DRUG|M6495|Subjects will receive M6495 on Day 1
47997641|NCT03224702|DRUG|Placebo|Subjects will receive placebo matched to M6495 on Day 1
47997642|NCT04761068|DEVICE|VEST|Venous External Support for vein grafts in CABG
47997643|NCT06302816|OTHER|TUPLER exercises|"will be conducting tupler exercises, exercises that are designed to target core muscles in order to improve posture, regain core strength and reducing discomfort.~Each exercise will be repeated 10reps for 3 times on 3 days a week for 8 weeks."
48683238|NCT05712577|OTHER|Questionnaire|Short Form 36 scale
48683239|NCT05712577|OTHER|Questionnaire|Coping orientation to the problems experienced - New Version in Italian
48683240|NCT05712577|OTHER|Questionnaire|Outcome Questionnaire - version 42.5
48683241|NCT05147753|DRUG|Moxonidine|0.6 mg moxonidine daily
48683242|NCT01495533|DEVICE|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
48683243|NCT01495533|COMBINATION_PRODUCT|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
47997644|NCT06302816|OTHER|SCOOP EXERCISES|will be required to complete scoop exercises basically deals with Pilates which is deep core and hip strengthening and stability through breathing patterns with the utilization of transversus abdominis muscle majorly. In each exercise participant will be asked to hold pelvic floor muscles for 8sec, then relax the muscles and count to 10, repeat I for 10 times each day for 3 days a week for 8weeks. Basic commands about the positing, activation and engagement of core along with breathing control were given to the subjects.
47997645|NCT00891137|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
48155950|NCT00365599|DRUG|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
47997646|NCT00253578|DRUG|sorafenib tosylate|Given PO
47997647|NCT00253578|OTHER|laboratory biomarker analysis|Correlative studies
47997648|NCT02143908|DIETARY_SUPPLEMENT|lysine supplementation|
48155951|NCT00365599|DRUG|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
48366149|NCT03899558|DEVICE|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
48366150|NCT03536689|DIAGNOSTIC_TEST|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
47997649|NCT02143908|DIETARY_SUPPLEMENT|Placebo|
47997650|NCT04998591|BEHAVIORAL|Fasting|fasting for 7 days (caloric intake \<500 kcal in liquid form)
47997651|NCT06429501|DRUG|Bupivacaine/Epinephrine|injection
47997652|NCT06429501|DRUG|Saline|injection
47997653|NCT04952870|OTHER|Inhaled NO|Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
47997654|NCT04952870|OTHER|routine care|Patients treated for respiratory failure
47997655|NCT03823248|DRUG|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
48366151|NCT05124145|OTHER|No intervention (surveillance system)|The surveillance network will collect data on all consecutive COVID-19 cases
48366152|NCT01042561|DIETARY_SUPPLEMENT|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
48683244|NCT05631314|PROCEDURE|operative treatment|Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.
48683245|NCT05631314|PROCEDURE|non-operative treatment|Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
48683246|NCT05721781|BEHAVIORAL|Oral Hygiene instruction|Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).
48683247|NCT05721781|PROCEDURE|Dental Cleaning|Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
47997656|NCT03823248|DRUG|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
47997657|NCT03823248|DRUG|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
47997658|NCT03823248|DRUG|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
47997659|NCT03823248|DRUG|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
47997660|NCT03823248|DRUG|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
47997661|NCT00037921|PROCEDURE|Bacterial colonization|
48155952|NCT04485793|DIETARY_SUPPLEMENT|Dietary supplement|"Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal"
48155953|NCT04485793|OTHER|Placebo|Oral administration: 1 tablet/day at evening meal
48155954|NCT02215447|DRUG|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
48155955|NCT02215447|DRUG|Carboplatin|
48683248|NCT04633369|DIETARY_SUPPLEMENT|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
47997662|NCT02327858|OTHER|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
47997663|NCT06259240|OTHER|Prone plank exercises|Patients in this group will recieve prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity. During the first four weeks, the exercises session began with light walking for five minutes followed by corrected exercises. Firstly, women will perform stable prone plank exercises. Secondly, women will be asked to apply the unilateral position of prone plank. Thirdly, using a 65 cm diameter Swiss ball, women will be asked to assume the prone bridge position. During the last four weeks, women will be asked to repeat the same program noting that the progressive prone plank exercises should be applied in a dosage of 20 repetitions, three sets, holding the contraction for one minute, and taking a break for two minutes.
47997664|NCT06259240|DEVICE|Electrical Stimulation|Electrical Stimulation
47997665|NCT01089088|DRUG|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
47997666|NCT01089088|DRUG|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
47997667|NCT01089088|DRUG|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
47997668|NCT03849742|OTHER|Quality-of-Life Assessment|Ancillary studies
47997669|NCT03849742|OTHER|Questionnaire Administration|Ancillary studies
47997670|NCT03849742|PROCEDURE|Supportive Care|Receive Uber rides
47997671|NCT06528392|BIOLOGICAL|Efgartigimod|Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG
48683249|NCT01946659|BEHAVIORAL|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
47997672|NCT06146530|DEVICE|Treatment|The intervention consists of 7 sessions of CBT for the treatment of GAD. Each session contains a range of information and tasks/exercises to help the user understand the condition of GAD, the treatment approach, and how it will be applicable to them. The intervention is based on an evidence-based treatment protocol; hence the sessions will flow from one to the other and the user will complete the sessions in a progressive direction. However, they can repeat a session before going on to the next session. Once all sessions have been completed, the user can go back over any of the sessions. There are anxiety management exercises, which the user can go to whenever they wish. There are also a therapy reflection journal and self-care resources including further anxiety management techniques, resources, and podcasts that the user will have access to whenever they want.
47997673|NCT06482008|DRUG|Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib|HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.
47997674|NCT02109146|DRUG|Prophylactic Transcatheter Arterial Chemoembolization|Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.
47997675|NCT02109146|OTHER|Observation|Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.
47997676|NCT02159521|DEVICE|EkoSonic® Endovascular System|
47997677|NCT02159521|BIOLOGICAL|Alteplase|Recombinant tissue plasminogen activator
47997678|NCT02086929|DRUG|Trazodone|
47997679|NCT02086929|DRUG|Venlafaxine|
47997680|NCT05091008|DRUG|Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet|proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
47997681|NCT05316831|BIOLOGICAL|PCV13|Pneumococcal polysaccharides conjugated to CRM197 carrier protein
47997682|NCT05316831|BIOLOGICAL|PPSV23|Pneumococcal polysaccharides
48155956|NCT04143802|DRUG|LY3437943|Administered SC
48155957|NCT04143802|DRUG|Dulaglutide|Administered SC
48366153|NCT01042561|DIETARY_SUPPLEMENT|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
48366154|NCT00872586|DRUG|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
48155958|NCT04143802|DRUG|Placebo|Administered SC
47997683|NCT01224639|BIOLOGICAL|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10\^3 PFU, TDV-2: 5 x 10\^3 PFU, TDV-3: 1 x 10\^4 PFU, and TDV-4: 2 x 10\^5 PFU, total virus per dose 2.2 x 10\^5 PFU
47997684|NCT01224639|BIOLOGICAL|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10\^4 PFU, TDV-2: 5 x 10\^4 PFU, TDV-3: 1 x 10\^5 PFU, and TDV-4: 3 x 10\^5 PFU, total virus per dose : 4.7 x 10\^5 PFU. TDV administered intradermally.
47997685|NCT01224639|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
47997686|NCT04480255|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
47997687|NCT04480255|OTHER|Group 2: NICU2HOME+ app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
47997688|NCT01050985|DRUG|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
47997689|NCT05132764|PROCEDURE|Microosteoperforations|2 inter radicular bone microosteoperforations using temporary anchorage device tip.
47997690|NCT02474095|OTHER|Quality-of-Life Assessment|Ancillary studies
47997691|NCT02474095|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
47997692|NCT02053181|DRUG|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
47997693|NCT04172441|DRUG|dasiglucagon|Glucagon analogue
47997694|NCT04172441|DRUG|Placebo|Placebo for dasiglucagon
47997695|NCT00699556|DRUG|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
47997696|NCT00699556|DRUG|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
47997697|NCT00699556|DRUG|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
47997698|NCT03488212|BEHAVIORAL|Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program|Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
48683250|NCT01946659|OTHER|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
47997699|NCT03488212|BEHAVIORAL|Training to Motivate and Support Patients' Weight Loss|Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.
47997700|NCT03488212|BEHAVIORAL|Online Behavioral Weight Loss Intervention|For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
47997701|NCT03488212|BEHAVIORAL|Control Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
47997702|NCT03488212|BEHAVIORAL|Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
47997703|NCT03488212|BEHAVIORAL|Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
47997704|NCT04398069|PROCEDURE|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
47997705|NCT04069156|DEVICE|LVAD Implant|Subjects will undergo Heartmate 3 LVAD implant prior to randomization
47997706|NCT04069156|DRUG|Aspirin 100mg|Subjects will be randomized to either Placebo or Aspirin post implant.
47997707|NCT04069156|DRUG|Placebo oral tablet|Subjects will be randomized to either Placebo or Aspirin post implant
47997708|NCT06255951|DRUG|Itraconazole|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
47997709|NCT06255951|DRUG|Rifampicin|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
48366155|NCT00872586|DRUG|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
48366156|NCT02545504|DRUG|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
48683251|NCT03462641|DRUG|Flumazenil|1mg in 10cc normal saline
48155959|NCT06361914|BEHAVIORAL|Digital CBT-I|"Sleep restriction includes behavioral instructions to limit the time spent in bed to increase sleep drive and further reduce time awake in bed.~Stimulus control therapy entails behavioral instructions to strengthen the association between bed and sleep and to eliminate conditioning of non-sleep behavior and bed.~Deactivation/relaxation training involves methods to reduce somatic tension and limit intrusive thought processes that interfere with sleep.~Cognitive therapy helps to identify, challenge, and modify dysfunctional beliefs about sleep.~Sleep hygiene education entails specific information relating to lifestyle and environmental factors that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake."
48155960|NCT06361914|BEHAVIORAL|Digital Sleep hygiene education|Sleep hygiene education entails specific information relating to lifestyle (diet, exercise, substance use) and environmental factors (light, noise, temperature) that may interfere with or promote sound sleep. Sleep hygiene education also includes specific sleep facilitating recommendations, such as avoiding visual access to a clock in the bedroom, regular sleep scheduling, avoiding long daytime naps, and limiting alcohol, caffeine, and nicotine intake.
48155961|NCT02655900|OTHER|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
48155962|NCT02829099|DRUG|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
48155963|NCT02714998|DRUG|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
48155964|NCT02714998|PROCEDURE|salpingectomy|Laparoscopic unilateral salpingectomy
48155965|NCT00322764|DRUG|Uridine|
48155966|NCT00658177|DRUG|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
48155967|NCT00658177|DRUG|Placebo|Matching placebo
48155968|NCT06240806|OTHER|Manuka Honey|Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.
48155969|NCT06240806|OTHER|Saline mouthwash|Saline mouthwash will be used 3 times per day for one month
48155970|NCT04376255|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
48155971|NCT01505699|GENETIC|RNA analysis|
48155972|NCT01505699|GENETIC|cytogenetic analysis|
48155973|NCT01505699|GENETIC|microarray analysis|
48155974|NCT01505699|OTHER|laboratory biomarker analysis|
48155975|NCT00003116|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
48155976|NCT00003116|DRUG|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
48155977|NCT00003116|DRUG|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
48155978|NCT00003116|DRUG|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
48155979|NCT00003116|PROCEDURE|bone marrow ablation with stem cell support|
48155980|NCT00003116|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
48155981|NCT02630147|OTHER|Vanilla scent|A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
48683252|NCT03462641|DRUG|Placebo|10 cc normal saline
48683253|NCT04200092|COMBINATION_PRODUCT|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
48155982|NCT04909099|OTHER|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
48155983|NCT00487253|DRUG|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
48155984|NCT00487253|DRUG|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
48155985|NCT01592422|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
48155986|NCT01592422|OTHER|Best Supportive Care|Best Supportive Care in the absence of disease progression
48155987|NCT06267326|PROCEDURE|debridment|resection of dead bone
48155988|NCT00362258|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
48155989|NCT05942833|PROCEDURE|Sigmoid resection|Timing of sigmoid resection
48683254|NCT04200092|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1.0 mg) of AZ-010 or matching Staccato Placebo
48683255|NCT04200092|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3.0 mg) of AZ-010 or matching Staccato Placebo
48155990|NCT06291597|OTHER|Vaping|Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
48366157|NCT02545504|DRUG|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
48366158|NCT02545504|DRUG|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
48683256|NCT04200092|COMBINATION_PRODUCT|AZ-010 1mg|2-period, 2-treatment open-label crossover design
48683257|NCT04200092|DRUG|IV Granisetron 1mg|2-period, 2-treatment open-label crossover design
48683258|NCT05706207|DRUG|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
48683259|NCT05706207|DRUG|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
48683260|NCT05706207|DRUG|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
47997710|NCT05129488|DEVICE|All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03)|Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution.EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
48683261|NCT05706207|DRUG|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
48683262|NCT05706207|DRUG|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
48683263|NCT05706207|DRUG|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
48683264|NCT05706207|DRUG|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
48683265|NCT05706207|DRUG|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
48683266|NCT05354492|OTHER|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
48683267|NCT02521038|DRUG|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
48683268|NCT02916511|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
48683269|NCT02916511|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
47997711|NCT01674231|OTHER|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
48683270|NCT02916511|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
47997712|NCT01674231|OTHER|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
47997713|NCT00175890|DRUG|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
47997714|NCT00175890|OTHER|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
48683271|NCT03000556|DRUG|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
48683272|NCT01552512|DIETARY_SUPPLEMENT|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
48683273|NCT01552512|OTHER|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
48683274|NCT00585637|DRUG|Vitamin D|Taken orally every day for three months
47997715|NCT04904185|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 is administered i.v. on day -4, -3 and -2
47997716|NCT04904185|DRUG|Fludarabine Phosphate|Fludarabine Phosphate 30 mg/m2 is administered on day -4 and -3
48683275|NCT00585637|DIETARY_SUPPLEMENT|Placebo|Placebo pill taken once daily for 3 month
48683276|NCT03497468|OTHER|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
48683277|NCT03497468|OTHER|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
48683278|NCT04910529|OTHER|Yoga|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
48683279|NCT01007175|BIOLOGICAL|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
47997717|NCT04904185|BIOLOGICAL|Multiple Antigen Specific Endogenously derived T cells|Antigen specific, ex vivo expanded T cells derived from peripheral blood T cells
47997718|NCT04904185|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered on day -1 and on day 21. The medicine is administered over 30 minutes
48683280|NCT01007175|BIOLOGICAL|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
48155991|NCT01324011|BEHAVIORAL|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
47997719|NCT02103283|DRUG|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
47997720|NCT02180334|DRUG|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
47997721|NCT02180334|DRUG|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
47997722|NCT02180334|DRUG|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
47997723|NCT01575184|OTHER|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
47997724|NCT01575184|OTHER|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
47997725|NCT02224911|DEVICE|Laser Interstitial Thermal Therapy|
47997726|NCT01133184|BIOLOGICAL|Sci B vac|Sci B vac
47997727|NCT03356249|DIAGNOSTIC_TEST|Next-Generation Sequencing|In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
47997728|NCT03640585|OTHER|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
47997729|NCT03841734|DRUG|treatment|8 patients will be treat with bosentan at 145 mg per day during 14 days
47997730|NCT02360163|PROCEDURE|Traditional Landmark Technique (TLT)|
47997731|NCT02360163|DEVICE|ultrasound guided peripheral intravenous access (USGPIVA)|
47997732|NCT00204620|DRUG|Bendamustin|
47997733|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
47997734|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~* For children \>/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~* For children \< 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~* Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols\*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
48155992|NCT03310372|RADIATION|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
48155993|NCT03310372|DRUG|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
48155994|NCT04971889|BEHAVIORAL|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
48155995|NCT04971889|BEHAVIORAL|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
47997735|NCT00619879|OTHER|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
48155996|NCT03866109|DRUG|Temferon|Genetically modified HSPCs
48155997|NCT01746628|PROCEDURE|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
48155998|NCT01379989|DRUG|Carboplatin|Carboplatin AUC 5
48155999|NCT01379989|DRUG|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
47997736|NCT00619879|RADIATION|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) \< 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~* Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~* Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
47997737|NCT03006913|BEHAVIORAL|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
48512328|NCT02784041|DRUG|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
48512329|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - in addition to standard of care|Up to 3 Tesla (T) MRI
47997738|NCT03006913|BEHAVIORAL|By phone|Patients in the phone arm will receive a scheduled call at their home.
47997739|NCT03006913|BEHAVIORAL|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
47997740|NCT00816075|DRUG|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
47997741|NCT04430439|BEHAVIORAL|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
48512330|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - not in addition to standard of care|Up to 3 Tesla (T) MRI
48512331|NCT00994578|BEHAVIORAL|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
48512332|NCT00994578|BEHAVIORAL|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
47997742|NCT04430439|BEHAVIORAL|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
48156000|NCT01379989|DRUG|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
48156001|NCT03109899|BEHAVIORAL|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
48156002|NCT02068079|DRUG|Vemurafenib and Trientine|
48366159|NCT02545504|DRUG|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
47997743|NCT05021367|DRUG|TQB3823 tablets|TQB3823 is a small molecule Poly ADP-ribose Polymerase (PARP) inhibitor that can inhibit the enzyme activity of PARP1/2, making it difficult to repair the DNA in cancer cells, leading to cell death and delaying or blocking tumor development.
48683281|NCT01007175|BIOLOGICAL|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
48683282|NCT01007175|BIOLOGICAL|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
48683283|NCT01007175|BIOLOGICAL|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
47997744|NCT01900028|PROCEDURE|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
47997745|NCT01900028|DRUG|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
47997746|NCT01900028|DRUG|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
47997747|NCT04533672|DIAGNOSTIC_TEST|MRI Sequences|New multiparametric MRI techniques
47997748|NCT03657355|DRUG|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
47997749|NCT03657355|DRUG|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
47997750|NCT03657355|DRUG|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
47997751|NCT03657355|DRUG|Placebo|Matching-placebo will be used.
47997752|NCT01959542|DEVICE|MRI|
47997753|NCT01959542|OTHER|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
47997754|NCT00624676|DRUG|Lipo Hydroxy Acid|Twice a day
47997755|NCT00624676|DRUG|5% benzoyl peroxide gel|Once a day
47997756|NCT01104636|DRUG|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
47997757|NCT02859233|OTHER|Lack of hyperhydration|
47997758|NCT01611181|DRUG|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
47997759|NCT01611181|DRUG|Kräuterblut|40 mg iron, 20 ml twice daily.
47997760|NCT01611181|DRUG|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
47997761|NCT06546254|DRUG|Lidocaine 1% Injectable Solution|10 cc 1% lidocaine paracervical injection
47997762|NCT06546254|DRUG|Saline|10 cc normal saline paracervical injection
47997763|NCT06546254|OTHER|Capped needle|Tapping the cervicovaginal junction with a capped needle
47997764|NCT02440386|BEHAVIORAL|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~1. Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~2. send a text message to the study team to let us know they have started ART;~3. Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
47997765|NCT03511612|DIAGNOSTIC_TEST|Measure ankle brachial index (ABI)|This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
47997766|NCT00983151|DRUG|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
47997767|NCT04567875|OTHER|No Intervention on patients|No Intervention on patients
48366160|NCT02545504|DRUG|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
48366161|NCT01840566|DRUG|Carmustine|
47997768|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on stool samples|"The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)"
47997769|NCT04203628|DIAGNOSTIC_TEST|Xpert MTB/Rif Ultra on respiratory sample|The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
47997770|NCT01483105|BEHAVIORAL|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
47997771|NCT03187457|OTHER|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
48366162|NCT01840566|DRUG|Etoposide|
48366163|NCT01840566|DRUG|Cytarabine|
48366164|NCT01840566|DRUG|Melphalan|
47997772|NCT03187457|OTHER|Control: no treatment|Healthy women without Bacterial Vaginosis
47997773|NCT01289847|BIOLOGICAL|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
47997774|NCT05277246|OTHER|Irrigant concentration|The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.
47997775|NCT05277246|DRUG|NaOCI|NaOCI
48366165|NCT01840566|BIOLOGICAL|Pegfilgrastim|
48366166|NCT01840566|BIOLOGICAL|19-28z T CELLS|
47997776|NCT06378099|OTHER|Patient guided and followed by the pharmacist|"The Study Coordinating Group will train the pharmacy Staff regarding these protocols.~The training will include both pharmacological and non-pharmacological aspects of managing MA. In the pharmacological component, emphasis will be placed on the appropriate selection of OTC medications to address different MA, with special attention to identifying potential drug interactions, contraindications, and potential ADRs. Tools will also be provided to advise patients on the correct and safe use of these medications, and the criteria for referral to a physician.~The staff will be divided into three groups, and every group will have a minimum of two sessions, each one of 4 hours. Additionally, there will be a practical component where simulations of real situations will be conducted.~Throughout the 12-month follow-up and intervention period, one of the researchers will be available to receive phone calls to address doubts and concerns about the Pharmaceutical Indication Protocol."
47997777|NCT01526889|DRUG|LFG316|LFG316 administered intravitreally (IVT)
48366167|NCT01840566|PROCEDURE|Autologous Stem Cell Transplantation|
48366168|NCT05848128|DRUG|5% Tavilermide ophthalmic solution|Twice a day topicial dosing
48366169|NCT05848128|OTHER|Vehicle ophthalmic solution|Twice a day topical dosing
48366170|NCT04787146|OTHER|No intervention|Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
48366171|NCT03334682|DRUG|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
47997778|NCT01526889|DRUG|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
47997779|NCT02510378|RADIATION|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
47997780|NCT03659305|BIOLOGICAL|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
47997781|NCT03659305|BIOLOGICAL|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
48156003|NCT04004520|BEHAVIORAL|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
48366172|NCT03334682|DRUG|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
48366173|NCT02602028|DRUG|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
48366174|NCT04576962|OTHER|Immunization Information System Review|Extraction of county- and state-level data on HPV vaccine completion from Indiana's Immunization Information System
48366175|NCT01842282|DRUG|Amlexanox|
48366176|NCT05882487|GENETIC|KL002 injection solution|Neurosurgical delivery of KL002 to the brain
48366177|NCT02509195|DRUG|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
48366178|NCT01004159|DRUG|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
48366179|NCT01475812|OTHER|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
47997782|NCT03967834|OTHER|Patient with Soft Tissue Sarcoma|"* Tumor specimens will be collected for the study at diagnosis.~* A blood sample will be collected in all included patients at baseline, after the completion of the treatment (for patients included with a localized disease) or at the time of the first tumoral evaluation (for patients included with a metastatic disease), and at the time of progression.~* Patient's data (clinical, biological and disease data) will also be collected at baseline visit and then at each time point planned in the center for clinical benefit assessment (i.e. every 2 or 3 months) until progression or for a maximum duration of 5 years."
47997783|NCT05777681|PROCEDURE|Aortic Surgery|open surgical repair with resection of infected aortic segment, debridement of surrounding tissue and in situ graft replacement.
47997784|NCT04930679|DRUG|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
48512333|NCT00994578|BEHAVIORAL|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
48683284|NCT04172350|OTHER|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
48683285|NCT04172350|OTHER|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
47997785|NCT04298996|DIAGNOSTIC_TEST|taking saliva samples to determine oxidative stress markers TAS and TOS|
47997786|NCT02261636|DRUG|mesalazine|
47997787|NCT00208936|DRUG|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
47997788|NCT01136096|BEHAVIORAL|Physical activity promoting intervention|"1. An interview with a physiotherapist~2. An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~3. An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~4. The daily record to check their body weight, exercise mode and duration~5. Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~6. Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
48156004|NCT04004520|BEHAVIORAL|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
48156005|NCT04004520|BEHAVIORAL|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
48156006|NCT05798754|PROCEDURE|Loss of resistance (LOR) technique|The thoracic epidural space will be identified by the loss of resistance (LOR) technique
48156007|NCT05798754|DEVICE|CompuFlo® technology|The thoracic epidural space will be identified by the CompuFlo® technology
48156008|NCT06247761|DEVICE|Skin closure at end of hand surgery|skin closure with vicryl rapide suture
48512334|NCT05088785|DRUG|FES|\[18F\]FES PET imaging.
48683286|NCT04556357|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
48683287|NCT04556357|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
48683288|NCT00745290|DRUG|Bupivacaine HCl|200 mg bupivacaine HCl
48683289|NCT00745290|DRUG|SKY0402|600 mg SKY0402 (study drug).
48683290|NCT06513000|DIAGNOSTIC_TEST|Dry eye diagnostic system|"following tests:~1. Non-invasive tear film break up time (TBUT), a parameter of tear film stability.~2. Non-invasive tear meniscus height.~3. Evaluation of Meibomian glands function.~4. Lipid layer thickness.~5. Eyelid margin.~6. Analysis of conjunctival hyperemia.~7. Cornea sodium fluorescein staining.~8. Schirmer I test"
48683291|NCT01976871|DRUG|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
48683292|NCT06072625|DIETARY_SUPPLEMENT|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
48683293|NCT04812535|DRUG|IFX-1|IFX-1 Monotherapy
48683294|NCT04812535|DRUG|IFX-1 + pembrolizumab combination therapy|IFX-1 + pembrolizumab combination therapy
48156009|NCT06232655|DRUG|Cladribine|A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
48156010|NCT06232655|DRUG|Venetoclax|A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
48156011|NCT06232655|DRUG|Azacitidine|Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
48683295|NCT02529111|DEVICE|"Echonavigator software"|
48683296|NCT01078792|OTHER|CT pulmonary angio, blood tests|
48683297|NCT01696773|OTHER|Tangerine tomato juice|Post-prandial feeding study
47997789|NCT01136096|BEHAVIORAL|General instruction and education|"1. Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~2. Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~3. Without individualized exercise program and interview with a physiotherapist"
48156012|NCT00110279|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
48156013|NCT03978299|DIAGNOSTIC_TEST|Positive Prostate-Specific Antigen test result|Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
48156014|NCT06600581|BIOLOGICAL|IMM01-STEM|IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling. This intervention is given 2mL twice a week.
48156015|NCT06600581|OTHER|Placebo|Saline. This intervention is given 2mL twice a week.
48156016|NCT06600581|BIOLOGICAL|IMM01-STEM alternating with placebo (saline)|This intervention consists of IMM01-STEM given once a week and placebo given one a week. IMM01-STEM is an allogeneic cell-free secretome product derived from partially differentiated human stem cells derived from a pluripotent embryonic stem cell line that was established from a single donor IVF discarded blastocyst. The cells are cultivated in bioreactors and the product of their secretion is collected, purified and concentrated to a standardized formulation. The secretome contains a mixture of molecules related to immunomodulation, growth, and extracellular matrix remodeling.
47997790|NCT00719004|PROCEDURE|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
47997791|NCT00745992|OTHER|Blood drawn (lab data)|"1. Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~2. Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
47997792|NCT01329640|DEVICE|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"1. Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~2. Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
48156017|NCT04636463|PROCEDURE|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
48366180|NCT03266159|DRUG|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
48366181|NCT03266159|DRUG|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
48366182|NCT03024151|DRUG|Comthyroid|T4/T3 combination replacement
48366183|NCT03024151|DRUG|Synthroid|T4 mono replacement
48366184|NCT01614951|PROCEDURE|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
48512335|NCT04187547|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
48512336|NCT04187547|DRUG|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
48512337|NCT02896790|OTHER|Interviews with 2 oncologists and 10 patients|
48512338|NCT02896790|OTHER|Interviews with 15 patients|
48512339|NCT03000478|BEHAVIORAL|Prolonged Exposure|
48512340|NCT03000478|BEHAVIORAL|Virtual Reality Exposure Therapy|
48683298|NCT01696773|OTHER|Red tomato juice|Post-prandial feeding study
48683299|NCT05299177|DEVICE|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
48366185|NCT01614951|DRUG|HTK Custodiol|Pulmoplegia before ECC.
48366186|NCT01614951|OTHER|Standard ECC|ECC after standard procedure
48366187|NCT02452034|DRUG|Posaconazole IV solution|Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
48366188|NCT02452034|DRUG|Posaconazole powder for oral suspension|Posaconazole once daily by PFS for a minimum of 10 days
48366189|NCT05133102|OTHER|Sample collection|Collection of saliva sample
48366190|NCT04273360|OTHER|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
48366191|NCT04273360|OTHER|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
48366192|NCT01226758|BIOLOGICAL|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
48683300|NCT00075764|DRUG|anastrozole|Given orally
48683301|NCT00075764|DRUG|fulvestrant|Given intramuscularly
48683302|NCT00194467|DRUG|valganciclovir|900 mg once a day for 8 weeks
48683303|NCT00194467|DRUG|placebo|matching placebo, once a day for 8 weeks
48683304|NCT04716686|DRUG|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
48683305|NCT00181818|DRUG|bupropion SR (sustained-release)|
48683306|NCT04907253|DRUG|Quercetin|500 mg twice daily
48683307|NCT04907253|DRUG|Placebo|twice daily
48683308|NCT02267291|OTHER|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
48156018|NCT04389944|OTHER|convalescent plasma application to SARS-CoV-2 infected patients|In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
48156019|NCT05939050|DEVICE|Powered toothbrush|Oral-B Powered toothbrush
48156020|NCT06283693|OTHER|mindfulness-based stress reduction|Müdahale grubundaki kadınlara depresyon, anksiyete ve stres düzeylerini azaltmak için farkındalık temelli bir stres azaltma programı uygulanacaktır. Program, haftada bir seans olmak üzere haftada iki kez toplam 4 hafta boyunca 8 seanstan oluşacaktır. Müdahale grubu haftada 2 seans alacaktır. Her seans 80 dakika sürecektir. Çalışmadaki seanslar, katılımcıların iş yoğunluğu, hayattaki sorumlulukları ve 4 hafta boyunca düzenli olarak katılamama ihtimalleri göz önünde bulundurularak zoom programı üzerinden gerçekleştirilecektir. 4 hafta/8 oturumluk MBSR programı tamamlandıktan sonra müdahale grubundaki kadınlara veri toplama formları tekrar uygulanacak ve son test ölçümleri yapılacaktır. Son test ölçümlerinden sonra müdahale grubundaki kadınların takip ölçümleri ölçümlerden 8 hafta sonra yapılacaktır.
48156021|NCT05315076|OTHER|thoracic Manipulation Posterior anterior and conventional therapy|A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.
48683309|NCT06291311|OTHER|Cold physical Plasma|The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
48683310|NCT06291311|OTHER|Control group|A potential natural healing of the HPV infection will be anticipated
48683311|NCT02589028|DIETARY_SUPPLEMENT|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
48683312|NCT02589028|OTHER|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
48512341|NCT03830372|DEVICE|VR Tier One|"10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms."
48512342|NCT03830372|OTHER|Control|10 sessions of 20 minutes of Schultz Autogenic Training
48683313|NCT03375931|BEHAVIORAL|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
48683314|NCT03375931|BEHAVIORAL|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
48683315|NCT00124969|DRUG|Amlodipine|10mg
48683316|NCT00124969|DRUG|Placebo|10mg
48683317|NCT06309602|OTHER|Free Water Protocol|Intake of plain, un-thickened water is allowed even when a patient has orders for thickened liquids. Risks of pulmonary complications are decreased with use of a strict oral care regimen and timed intake of water related to meals. Patient satisfaction and comfort is increased with ingestion of plain water.
48683318|NCT06309602|OTHER|Control / Standard Care|Standard care will be given to patients with orders for thickened liquids. This will include oral care twice a day and implementation of swallowing strategies and precautions as prescribed by the treating speech-language pathologist. Only fluids thickened to the recommended viscosity will be available to the patient.
48683319|NCT03752203|DRUG|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
48156022|NCT05315076|OTHER|Muscle Energy Technique (PIR) and conventional treatment|sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
48366193|NCT01226758|BIOLOGICAL|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
48366194|NCT02712892|GENETIC|Non Interventional Study|
48683320|NCT03752203|DEVICE|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
48683321|NCT06513741|BEHAVIORAL|Mentoring Workshop|"Faculty mentoring workshop with the title Faculty Mentoring; building stronger by digging deeper was designed as a two-day workshop of three hours each for the faculty members of the two institutions at separate times"
48683322|NCT03350451|DRUG|Lumasiran|Multiple doses of lumasiran by SC injection
48683323|NCT03981744|DRUG|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
48683324|NCT03981744|DRUG|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
48683325|NCT03981744|DRUG|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
48683326|NCT03981744|DRUG|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
48683327|NCT02477488|DRUG|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
48156023|NCT02332096|DEVICE|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
48156024|NCT01623180|DEVICE|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
48156025|NCT01623180|DEVICE|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
48366195|NCT04099940|BEHAVIORAL|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
48366196|NCT04099940|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
48366197|NCT01031368|DRUG|cytarabine|Given IV
48366198|NCT01031368|DRUG|clofarabine|Given IV
48366199|NCT01031368|DRUG|filgrastim|Given SC
48366200|NCT01031368|BIOLOGICAL|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
48366201|NCT01031368|OTHER|laboratory biomarker analysis|Correlative studies
47997793|NCT01216475|PROCEDURE|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
48156026|NCT00720629|DRUG|Visilizumab|3 mg/m\^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
48156027|NCT00720629|DRUG|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
48156028|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
48156029|NCT00720629|DRUG|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
48156030|NCT00720629|DRUG|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
48156031|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
48366202|NCT00757380|PROCEDURE|Trypan Blue|Membranepeeling with TB
48366203|NCT00757380|PROCEDURE|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
48366204|NCT01322711|DRUG|Atorvastatin|Atorvastatin 40 mg day
48366205|NCT01322711|DRUG|Placebo|Diet
48366206|NCT01947166|DIETARY_SUPPLEMENT|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
48366207|NCT06118853|BEHAVIORAL|yoga or gentle massage plus standard treatment for HSCT|The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
48366208|NCT01205646|DRUG|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
48683328|NCT00566046|DRUG|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
48683329|NCT00566046|DRUG|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
48683330|NCT00325507|BIOLOGICAL|TroVax|TroVax 1 x 10E9 TCID 50mL
48683331|NCT00325507|DRUG|IL-2|IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
48683332|NCT04892472|DEVICE|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
47997794|NCT01216475|PROCEDURE|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
48683333|NCT04892472|DRUG|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
48683334|NCT01791621|OTHER|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
47997795|NCT04153500|OTHER|Anatomy class with Pelvic+ methodology|Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
48156032|NCT02169245|OTHER|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
48156033|NCT01812707|DRUG|Alirocumab|Two SC injections in the abdomen only
47997796|NCT00199784|DRUG|Phenylephrine|
48156034|NCT01812707|DRUG|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
48156035|NCT01812707|DRUG|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
48156036|NCT05032651|DEVICE|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
48156037|NCT03683212|PROCEDURE|Early intensive care bundle|"The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~1. Treatment of the congestion: (international guidelines and recommendations)~2. Treatment of precipitating factors~3. NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH \< 7.35 in absence of contra indication.~4. Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy."
47997797|NCT04608500|DRUG|FMX103 minocycline foam 1.5%|Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
47997798|NCT04608500|DRUG|Vehicle foam|Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
48156038|NCT06309771|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a random order (6 predetermined order). Each module will be composed on 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
48156039|NCT04653571|OTHER|CASPR2 encephalitis|Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
48683335|NCT01333722|DRUG|Hydrocodone/Acetaminophen Extended Release|
48683336|NCT01333722|DRUG|Placebo|Placebo tablet
48156040|NCT05189288|DRUG|D418 Tab.|1T
48156041|NCT05189288|DRUG|CKD-388 Tab.|1T
48156042|NCT01702688|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
48683337|NCT05722834|BEHAVIORAL|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
47997799|NCT02680028|DEVICE|targon pft nail|220 mm vs 175mm nail
47997800|NCT01755923|DRUG|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
47997801|NCT01755923|DRUG|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
47997802|NCT03733821|DEVICE|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation tool
47997803|NCT02897674|DIETARY_SUPPLEMENT|Palm olein|two thirds of the 30% fat calories will come from palm olein
47997804|NCT02897674|DIETARY_SUPPLEMENT|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
47997805|NCT02897674|DIETARY_SUPPLEMENT|soybean oil|two thirds of the 30% fat calories will come from soybean oil
48683338|NCT02076529|DRUG|Ramosetron 0.3mg|
48683339|NCT02076529|DRUG|Ramosetron 0.45mg|
48683340|NCT02076529|DRUG|Ramosetron 0.6mg|
48683341|NCT00556439|DRUG|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
48366209|NCT01205646|DEVICE|PET Scan|2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
47997806|NCT04219982|DRUG|DPI-386 Nasal Gel|Nasal gel
47997807|NCT04219982|DRUG|DPI-386 Placebo Nasal Gel|DPI-386 Placebo Nasal Gel
47997808|NCT04219982|DRUG|Transderm Scop®|Transderm Scop®
48366210|NCT06399172|DEVICE|OncoSil|Intra-tumoural implantation
48366211|NCT00003159|DRUG|carboplatin|
48683342|NCT00556439|DRUG|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
48683343|NCT05697653|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
48683344|NCT02075424|OTHER|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
48366212|NCT00003159|DRUG|cisplatin|
48366213|NCT00003159|DRUG|docetaxel|
48366214|NCT00003159|DRUG|gemcitabine hydrochloride|
48366215|NCT00003159|DRUG|ifosfamide|
48366216|NCT00003159|DRUG|mitomycin C|
48683345|NCT03200483|OTHER|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
48366217|NCT00003159|DRUG|paclitaxel|
48366218|NCT00003159|DRUG|vinblastine sulfate|
48366219|NCT00003159|DRUG|vinorelbine tartrate|
48683346|NCT03200483|OTHER|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
48683347|NCT03200483|OTHER|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
48683348|NCT03480893|PROCEDURE|small size interarcuair decompression|A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.
47997809|NCT01938911|DRUG|Syntocinon-Spray|Intranasal oxytocin (24 IU)
47997810|NCT01938911|DRUG|Placebo of syntocinon|Intranasal administration
47997811|NCT01938911|BEHAVIORAL|Social support|Social support from the best friend
47997812|NCT02942355|DRUG|anastrozole|Anastrozole by mouth daily
47997813|NCT02942355|DRUG|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
47997814|NCT05896553|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
47997815|NCT05896553|DRUG|intranasal Placebo|Administration of intranasal Placebo
47997816|NCT05659628|COMBINATION_PRODUCT|CD19-7×19 CAR-T combined with Tislelizumab|Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.
47997817|NCT00145873|DRUG|nesiritide, continuous infusion|
48366220|NCT00003159|PROCEDURE|conventional surgery|
48366221|NCT00003159|PROCEDURE|neoadjuvant therapy|
48366222|NCT05352451|BEHAVIORAL|Interventional Survey|Complete the surveys before and after attending coaching sessions. The two interviews each lasting for about one hour and will be done in-person or through video-conferencing meeting (depending on which is more convenient for you) with a study team member. The first interview, will ask about some basic information. In the second and last interview, will ask about experience of the coaching sessions and about how you feel about your decisions regarding your treatment and care. At each of the two time points, you and your caregiver will be interviewed separately. The video-conferencing, will be conducted through Zoom, which is a secure, widely used software which allows people to communicate remotely with computers, tablets, or smart phones. The software is available free of charge to you if you have a computer or other suitable device and internet.
48366223|NCT01623492|OTHER|Subjects with diagnosis of Eisenmenger Syndrome|"1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine~2. Contraception counseling, and recommendations regarding avoidance of pregnancy~3. Documentation and prescription of the specific medications:~   1. Oxygen~  2. Diuretic~  3. ASA, Anticoagulant~  4. CCB, BB, ACEI, ARB~  5. Iron Supplementation~  6. Allopurinol~  7. PAH specific therapy"
48366224|NCT05943340|OTHER|Proprioceptive exercises|Specific proprioceptive exercises for the shoulder that the patient has to do during the immobilization period.
48366225|NCT02377401|DRUG|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
48366226|NCT00491062|PROCEDURE|Biopsies|
48683349|NCT03480893|PROCEDURE|Laminectomy|A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
48156043|NCT01702688|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
48156044|NCT06471842|OTHER|MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire|The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.
48156045|NCT04004663|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
48156046|NCT00124644|DRUG|cytarabine|
48156047|NCT00124644|DRUG|daunorubicin hydrochloride|
48156048|NCT00124644|DRUG|etoposide|
48156049|NCT00124644|DRUG|tipifarnib|
48156050|NCT00124644|PROCEDURE|chemotherapy|
48156051|NCT00124644|PROCEDURE|enzyme inhibitor therapy|
48156052|NCT00124644|PROCEDURE|high-dose chemotherapy|
48156053|NCT03133455|OTHER|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
48156054|NCT02995278|OTHER|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
48156055|NCT05863871|DRUG|Linperlisib|80 mg, qd
48156056|NCT00665392|DRUG|cisplatin|75 mg/m², day 1. 3 cycles
48156057|NCT00665392|DRUG|docetaxel|75 mg/m² Day 1. 3 cycles
48156058|NCT00665392|DRUG|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
48156059|NCT00665392|DRUG|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
48156060|NCT06111183|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
48156061|NCT06111183|OTHER|Placebo|Placebo is topically applied on chronic wounds and covered by wound dressing.
48156062|NCT00841165|DEVICE|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
48156063|NCT00841165|DEVICE|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
48156064|NCT01112163|DEVICE|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
48156065|NCT04928235|DIAGNOSTIC_TEST|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
48156066|NCT04544514|DIAGNOSTIC_TEST|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
48156067|NCT02648737|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch \& Craske, 2009; Craske, 2010).
48683350|NCT05079802|DRUG|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
48156068|NCT02648737|OTHER|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
48156069|NCT05833737|DRUG|Belantamab mafodotin|Injection for refractory/relapsed multiple myeloma
48366227|NCT02255162|DRUG|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
47997818|NCT01381133|BEHAVIORAL|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
48156070|NCT04248881|BEHAVIORAL|Healthy Lifestyle Education|"Healthy lifestyle information (education) is distributed to participants during the World Cancer Day Walk via brochure, lectures, and professional counseling."
48156071|NCT05736237|GENETIC|Whole exome sequencing|With Next Generation Sequenzing
48683351|NCT05079802|DRUG|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
48156072|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
48156073|NCT00857311|BIOLOGICAL|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
48683352|NCT03103646|DRUG|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
48366228|NCT02255162|GENETIC|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
48366229|NCT02255162|DRUG|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
48366230|NCT02362295|OTHER|qualitative interview|some patient are interviewed.
48366231|NCT03070054|DRUG|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
48366232|NCT00103207|BIOLOGICAL|cetuximab|
48366233|NCT03872739|PROCEDURE|enhanced computed tomography|undergoing enhanced computed tomography
48366234|NCT04058860|DEVICE|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
48366235|NCT04058860|DEVICE|Cox monitoring|Cerebral autoregulation monitoring
48683353|NCT03103646|DRUG|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
48683354|NCT03103646|DRUG|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
48683355|NCT01094834|DRUG|DWP05195|tablets, oral administration, multiple administration
48683356|NCT00410969|DEVICE|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
48156074|NCT00857311|BIOLOGICAL|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
48156075|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
47997819|NCT01381133|BEHAVIORAL|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
48156076|NCT06055400|DEVICE|AR-US|The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
48156077|NCT04301843|DRUG|Eflornithine|DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
48156078|NCT00475436|DRUG|GSK573719|
48156079|NCT06310278|DIAGNOSTIC_TEST|Ossicular mobility measurement|Measurements of ossicular mobility i.e. the dynamic velocity of middle ear structures (umbo of malleus and incus at the incudostapedial joint) normalized to sound pressure incident on the tympanic membrane.
48156080|NCT01268488|DEVICE|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
48156081|NCT05150704|DRUG|Methylprednisolone|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
48156082|NCT05150704|DRUG|saline solution|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
48156083|NCT05099068|BIOLOGICAL|Blood and tumor samples|Longitudinal molecular profiling of tumor and liquid biopsies.
48156084|NCT06381219|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms to assess maintained remission of EoE
48156085|NCT06381219|OTHER|Implementation of hen's egg in decreasingly heated forms|Implementation of hen's egg in decreasingly heated forms to assess maintained remission of EoE
48156086|NCT04267393|DRUG|BMS-986263|Specified dose on specified days
48156087|NCT04267393|OTHER|Placebo|Specified dose on specified days
48156088|NCT02305667|DEVICE|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
48156089|NCT02305667|DEVICE|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
48683357|NCT03032419|BIOLOGICAL|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
48683358|NCT03032419|BIOLOGICAL|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
48683359|NCT05568563|DRUG|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
48683360|NCT05568563|OTHER|Honey|Honey is a natural dietary product
47997820|NCT01381133|BEHAVIORAL|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
47997821|NCT04230837|DEVICE|Inmediate abutment height|The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
47997822|NCT06423911|DRUG|olverembatinib|olverembatinib QOD
48683361|NCT01527045|DRUG|Atorvastatin Calcium|Given PO
48683362|NCT01527045|DRUG|Cyclosporine|Given PO
48683363|NCT01527045|DRUG|Fludarabine Phosphate|Given IV
47997823|NCT06423911|DRUG|Bosutinib|Bosutnib QD
47997824|NCT05912699|OTHER|Slimbiotics Postbiotic|"SlimBiotics postbiotic formula contains the following ingredients:~* Heat-inactivated L. fermentum K8 Postbiotic.~* Microcrystalline cellulose."
47997825|NCT05912699|OTHER|Placebo|The placebo capsules contain microcrystalline cellulose only.
47997826|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
47997827|NCT01045109|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
47997828|NCT02876900|DRUG|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
47997829|NCT02876900|DRUG|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
47997830|NCT02876900|DRUG|Placebo|The study will evaluate placebo transdermal patch.
47997831|NCT03883932|BEHAVIORAL|Fatherhood Focused FVEP (F3)|F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
47997832|NCT03883932|BEHAVIORAL|Family Violence Education Program (FVEP)|FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
48683364|NCT01527045|OTHER|Laboratory Biomarker Analysis|Correlative studies
47997833|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
47997834|NCT00357188|DRUG|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
47997835|NCT05578287|DRUG|Anti-HER2 ADC|Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
47997836|NCT06281236|DRUG|Prednisolone|Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.
47997837|NCT06281236|DRUG|SPI-62|SPI-62 administered once daily.
48683365|NCT01527045|DRUG|Mycophenolate Mofetil|Given PO or IV
48683366|NCT01527045|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
48683367|NCT01527045|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
48683368|NCT01527045|RADIATION|Total-Body Irradiation|Undergo TBI
48683369|NCT01597648|DRUG|Maraviroc|300 mg
48683370|NCT01597648|DRUG|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
48683371|NCT01597648|DRUG|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
48683372|NCT05054491|BEHAVIORAL|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
48683373|NCT05483023|DRUG|18F-fluorofuranylnorprogesterone PET / MRI|Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
48683374|NCT00758693|DRUG|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
48683375|NCT00758693|DRUG|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
48683376|NCT05480982|BEHAVIORAL|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
48683377|NCT05480982|OTHER|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
48683378|NCT02151786|DRUG|Lansoprazole|Lansoprazole intravenous 30 mg
47997838|NCT04100707|PROCEDURE|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
47997839|NCT05413135|DRUG|ARO-APOC3|ARO-APOC3 Injection
47997840|NCT01908361|BEHAVIORAL|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
48683379|NCT01139541|BEHAVIORAL|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
48683380|NCT00302354|DRUG|OROS methylphenidate HCl|
48683381|NCT00302354|DRUG|SODAS methylphenidate HCl|
48683382|NCT00961740|BEHAVIORAL|Cognitive Behavioural Therapy|See summary
48683383|NCT00961740|OTHER|Waitlist condition|See Summary
48683384|NCT02109289|DRUG|etanercept|Etanercept is a tumor necrosis factor antagonist
48683385|NCT04967872|OTHER|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
48683386|NCT01545297|DRUG|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
48683387|NCT01545297|DRUG|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
48683388|NCT01545297|DRUG|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
48156090|NCT02305667|DEVICE|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
48366236|NCT04058860|DEVICE|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
48366237|NCT01503567|OTHER|No treatment given|Subject will only fill out a questionaire
48683389|NCT02924259|DEVICE|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
48683390|NCT02819297|DRUG|BLI400 Laxative|21 gm BLI400 powder
48683391|NCT02819297|DRUG|BLI400 Placebo|Equivalent amount of placebo powder
48683392|NCT00135330|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
48683393|NCT00135330|DRUG|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
48683394|NCT06249334|OTHER|Whole-body electrical stimulation|The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.
48683395|NCT06249334|OTHER|Routine physical therapy|The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
48683396|NCT02656966|DEVICE|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
48683397|NCT03102450|DRUG|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)"
48683398|NCT00331032|DRUG|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
48683399|NCT00331032|DRUG|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
48683400|NCT06361966|DEVICE|3d printed prosthetic socket|3d printed prosthetic socket produced through multi-jet fusion (MJF)
48156091|NCT02305667|DEVICE|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
48156092|NCT01763645|DRUG|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
48156093|NCT01763645|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
48683401|NCT03009162|DRUG|Lasmiditan|200 mg, single oral tablet
48683402|NCT03292003|DEVICE|Journey II BCS Total Knee System|
48683403|NCT00033046|DRUG|Modafinil|
48683404|NCT02655757|DRUG|Sitagliptin|5 mg, 1 tablet per day for 12 months
48683405|NCT02655757|DRUG|Placebo|Placebo,1 tablet per day for 12 months
48683406|NCT03399279|PROCEDURE|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
48683407|NCT03399279|OTHER|Perforated collagen membrane|Membrane perforations using dental needle
48683408|NCT03399279|OTHER|Occlusive membrane|Biotech collagen membrane
48683409|NCT03399279|OTHER|Nanohydroxyapetite|Nanbone Particles
48683410|NCT04792034|DRUG|Cocaine Hydrochloride Topical Solution|Topical Anesthetic
48683411|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
48683412|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
48683413|NCT02122497|PROCEDURE|abdominal aortic surgery|
48683414|NCT05909033|PROCEDURE|Kasai procedure|All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.
48683415|NCT03134391|DRUG|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
48156094|NCT01763645|DRUG|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
48156095|NCT05279417|DRUG|ATI-450 50 mg oral tablet BID|Oral, small molecule MK2 inhibitor
48156096|NCT05279417|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
48156097|NCT05279417|DRUG|Methotrexate|15 mg to 25 mg weekly
48156098|NCT05279417|DRUG|ATI-450 20 mg oral tablet BID|Oral, small molecule MK2 inhibitor
48683416|NCT05594771|PROCEDURE|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
48683417|NCT05594771|PROCEDURE|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
48683418|NCT00385385|DRUG|Rifalazil|
48683419|NCT00325130|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
48156099|NCT00612521|DRUG|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
48366238|NCT02514889|BEHAVIORAL|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
48683420|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
48683421|NCT00325130|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
48683422|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
48683423|NCT00325130|BIOLOGICAL|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
48156100|NCT00386802|DRUG|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
48683424|NCT04721158|DEVICE|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
48156101|NCT00004276|DRUG|thalidomide|
48156102|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Micro-coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
48156103|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Enteric coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
48156104|NCT00376259|DRUG|telbivudine|600mg/day oral tablet for 96 weeks
48156105|NCT00376259|DRUG|adefovir dipivoxil|10 mg of adefovir by mouth once daily
48156106|NCT02526199|DRUG|Bupivacaine|Sciatic nerve block
48683425|NCT03411018|OTHER|Mechanical ventilation exposure|
48156107|NCT02526199|DRUG|Epinephrine|Adjuvant to perinerual block
48156108|NCT02526199|DRUG|Dexamethasone|Adjuvant to perinerual block
48156109|NCT03881267|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
48156110|NCT03881267|OTHER|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
47997841|NCT01908361|BEHAVIORAL|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
48156111|NCT03881267|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
48156112|NCT00002099|DRUG|Lentinan|
48156113|NCT00002099|DRUG|Didanosine|
48156114|NCT00346359|BIOLOGICAL|anti-thymocyte globulin|
48156115|NCT00346359|DRUG|busulfan|
48156116|NCT00346359|DRUG|fludarabine phosphate|
48156117|NCT00346359|DRUG|methotrexate|
48618124|NCT03443648|PROCEDURE|External fixator assisted plaing|The plate length is marked on the skin. Limb reconstruction system (LRS) with one swivel clamp or Taylor Spatial frame (TSF) is used in all cases. The fixator is put in a plane parallel to that of the deformity. Two tapered pins are placed on either side of the planned osteotomy site and passed at a distance from the osteotomy so that they will not impede the subsequent internal fixation. Swivel clamps or the struts of the TSF are aligned in such a way that full correction is achieved. After osteotomy, swivel clamp is loosened and angular correction is achieved. Translation is carried out according to preoperative planning. If readjustment is required the swivel clamps or TSF struts are loosened and further correction is carried out. Once desired correction is achieved, the clamps or struts are tightened. Definitive internal fixation is carried out while external fixation holds the fragments. For internal fixation, locked T plate will be used.
48156118|NCT00346359|DRUG|tacrolimus|
48156119|NCT00346359|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48156120|NCT00346359|PROCEDURE|peripheral blood stem cell transplantation|
48156121|NCT01442207|PROCEDURE|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
48683426|NCT03012191|DRUG|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
48156122|NCT01442207|PROCEDURE|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids \> 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM \> 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
48156123|NCT02301078|PROCEDURE|Percutaneous Needle Aponeurotomy|single procedure (day 0)
48156124|NCT02301078|DRUG|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
48156125|NCT05943509|BEHAVIORAL|Alternative rehabilitation strategies|Counseling intervention.
48156126|NCT05943509|BEHAVIORAL|Usual Care|Usual care audiology pathway.
48156127|NCT04893993|DRUG|Thiamine|Tablets. 300mg/tablet. Dosage depends on gender and weight
48156128|NCT04893993|DRUG|Placebo|Tablets. Same number of tablets as Thiamine
48683427|NCT04911647|DEVICE|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
48156129|NCT00005843|DRUG|tipifarnib|
48683428|NCT04911647|DEVICE|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
48683429|NCT02408679|PROCEDURE|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
48683430|NCT02408679|OTHER|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
48683431|NCT01606904|BEHAVIORAL|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
48683432|NCT06335069|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
48683433|NCT01840813|DRUG|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
48683434|NCT01840813|DRUG|Normal saline|It is a placebo group
48683435|NCT04976790|BEHAVIORAL|Chinese Tuina therapy|Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
48683436|NCT04976790|DRUG|Flurbiprofen Cataplasms group (FCG).|One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
48683437|NCT00650663|DRUG|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
48683438|NCT00650663|DRUG|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
48683439|NCT06526312|BEHAVIORAL|SMS/Text (CAMPI)|Configurable Assessment Messaging Platform for Interventions (CAMPI) is a SMS text messaging platform to promote motivation and home practice.
48683440|NCT06526312|BEHAVIORAL|Fidelity Monitoring System (Lyssn)|Lyssn's HIPAA-compliant, cloud-based platform uses embedded speech-to-text transcription from audio recorded sessions for rapid assessment and easy session review for supervisors and interventionists,
47997842|NCT01908361|BEHAVIORAL|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
48156130|NCT05817864|DIAGNOSTIC_TEST|Capnography|"Index test: Capnography, which monitors ETCO2, the percentage concentration, or partial pressure of CO2 at the end of exhalation, will serve as the index test. It will be performed by connecting the end of the nasogastric tube with the sensor of the bedside sidestream capnography device. Placement within the airway is defined as detecting a capnogram waveform or an ETCO2 level \> 10 mmHg.~Reference standard: This study will use radiography (chest/abdominal X-ray) as the reference standard for determining the correct placement of nasogastric tubes. Radiology will be performed as soon as possible and interpreted by a physician. A repeat radiography will be performed if necessary. We will also use pH-Fix-4.5-10 to determine the pH value, and its accuracy is +/- 0.2 pH with minimum increments of 0.5. A pH of 5.5 or below indicates gastric placement."
48156131|NCT04201847|DIAGNOSTIC_TEST|Serum test|Serum Fetuin A and fetuin B
48683441|NCT06526312|BEHAVIORAL|Family Check-Up 4 Health (FCU4Health)|An evidence-based, data-driven, individually tailored parenting intervention with evidence of effectiveness on child and family health behaviors and psychosocial well-being. The program includes three components: 1) a comprehensive family assessment, 2) feedback and motivation session, and 3) individually tailored follow-up support (including parent training modules from the Everyday Parenting curriculum and connection with community resources). Dosage and content of these follow-up sessions are driven by the results of the assessment and family interest. The assessment, feedback and motivation session, and follow-up support are repeated annually.
48156132|NCT00639639|BIOLOGICAL|tetanus toxoid|Given by injection
48683442|NCT03472495|DRUG|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
48683443|NCT03472495|DRUG|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
48683444|NCT04354948|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
48683445|NCT04354948|BEHAVIORAL|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
48683446|NCT04313075|DRUG|Leronlimab|Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
48683447|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
48683448|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
48683449|NCT00749788|DRUG|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
48683450|NCT04667676|DEVICE|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
48683451|NCT05129163|BEHAVIORAL|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
48683452|NCT05129163|BEHAVIORAL|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
48512343|NCT05277662|DIAGNOSTIC_TEST|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
48683453|NCT05190978|DEVICE|Acellular Dermal Matrix|Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
48683454|NCT05190978|PROCEDURE|Reconstruction without ADM|Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
48156133|NCT00639639|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
47997843|NCT05754151|BEHAVIORAL|MAYA Mobile Application|The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
48683455|NCT03644498|OTHER|Non-Interventional|Non-Interventional
48683456|NCT06147076|BEHAVIORAL|Social Support Network Counseling Intervention|Social support counseling intervention for kidney transplant candidates along with their social support networks.
48683457|NCT04910386|DRUG|Envafolimab plus Gemcitabine&Cisplatin|Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
48683458|NCT04910386|DRUG|Gemcitabine&Cisplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
47997844|NCT02251795|DRUG|Tipranavir|
47997845|NCT02251795|DRUG|Ritonavir|
47997846|NCT02251795|DRUG|Darunavir|
48156134|NCT00639639|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
48156135|NCT02327702|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
47997847|NCT02251795|DRUG|Aspirin|single dose on day 2
47997848|NCT03733288|BEHAVIORAL|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
47997849|NCT03733288|BEHAVIORAL|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
48156136|NCT03391778|BIOLOGICAL|ADP adoptive cell therapy|No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
48156137|NCT02077556|DRUG|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
48156138|NCT02077556|DRUG|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell \< 4000/mcL)
48156139|NCT02077556|DRUG|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
48156140|NCT02077556|DRUG|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
48156141|NCT02077556|DRUG|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
48366239|NCT02514889|BEHAVIORAL|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits \& vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
48683459|NCT02569463|DRUG|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
48683460|NCT00330304|DRUG|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
48683461|NCT00330304|DRUG|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
48366240|NCT05486715|DRUG|Vit D|Vit D
48156142|NCT00183599|BEHAVIORAL|5 Minutes of Simple Advice|
48156143|NCT00183599|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
48156144|NCT00183599|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
48156145|NCT05219409|DRUG|Sitagliptin|The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)
48366241|NCT03956459|OTHER|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
48366242|NCT04456114|DEVICE|Acid etched brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
48366243|NCT04456114|DEVICE|Sandblasted brackets|The brackets will be bonded to the teeth with composite on the same patient in a split mouth design and observed for bracket debonding for 18 months
48366244|NCT02536209|DRUG|MT-8554 low dose|
48366245|NCT02536209|DRUG|MT-8554 high dose|
48512344|NCT04113785|DEVICE|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
48512345|NCT02685683|DRUG|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of \>50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI \<7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
48683462|NCT00330304|DRUG|isoniazid|Isoniazid, 10mg/kg daily for study period
48683463|NCT00330304|OTHER|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
48683464|NCT01784367|DEVICE|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
48683465|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
48683466|NCT00693069|DRUG|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
48683467|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
48683468|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
47997850|NCT03733288|BEHAVIORAL|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
47997851|NCT03733288|DEVICE|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
47997852|NCT00265512|BEHAVIORAL|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
47997853|NCT00265512|BEHAVIORAL|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
47997854|NCT02067910|DRUG|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
47997855|NCT03741556|OTHER|questionaire|a questionaire is sent to each participans
48366246|NCT02536209|DRUG|Oxycodone hydrochloride|
48366247|NCT02536209|DRUG|Placebo|
48683469|NCT03192293|DRUG|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
48366248|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
48366249|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
48366250|NCT00283062|DRUG|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
47997856|NCT03437109|DIAGNOSTIC_TEST|Laboratory tests|Testosterone HSBG Hb1Ac LH
48512346|NCT00663026|DRUG|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
48512347|NCT00663026|DRUG|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
48512348|NCT00663026|DRUG|placebo|Placebo subcutaneous injection once per week for 6 months
48512349|NCT02567877|PROCEDURE|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
48683470|NCT05933967|DRUG|Orelabrutinib+R-CHOP|Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
48683471|NCT00804895|DRUG|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
48683472|NCT00804895|DRUG|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
48683473|NCT00804895|DRUG|Verapamil|standard prophylactic treatment
47997857|NCT01089439|DRUG|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
47997858|NCT01089439|DRUG|Placebo|placebo
47997859|NCT05844852|DEVICE|P200TE|The P200TE provides OCT imaging including retinatopography and ONH (optic nerve head) scans.
47997860|NCT05507983|DRUG|Tranexamic acid|Tranexamic acid 1500 mg
48156146|NCT05219409|DEVICE|Professional CGM|The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
48512350|NCT02567877|DRUG|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
48683474|NCT02674113|DRUG|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
48683475|NCT02674113|DRUG|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
47997861|NCT05507983|DRUG|Placebo|Placebo, sodium chloride 0.9%
47997862|NCT01093911|BIOLOGICAL|CDP7657|Ascending single doses of CDP7657
48683476|NCT04839250|PROCEDURE|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
48156147|NCT03974997|DIAGNOSTIC_TEST|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
48156148|NCT01876823|DRUG|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
48683477|NCT02374060|DRUG|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
48683478|NCT02374060|DRUG|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
48683479|NCT02374060|DRUG|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
48683480|NCT05483959|OTHER|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
48683481|NCT04525144|DRUG|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
48683482|NCT02825446|PROCEDURE|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
48156149|NCT01876823|DRUG|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
48683483|NCT02825446|PROCEDURE|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
48683484|NCT01766037|DEVICE|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
48683485|NCT01766037|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
48683486|NCT02019953|OTHER|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
48683487|NCT02019953|OTHER|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
48683488|NCT02019953|OTHER|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
47997863|NCT01093911|OTHER|Placebo|Placebo: 0.9% sodium chloride aqueous solution
48156150|NCT01545271|DRUG|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
48512351|NCT04306536|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
48683489|NCT01994746|DRUG|Nasal Glucagon|
47997864|NCT05403242|DRUG|RC48-ADC|2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
47997865|NCT05403242|DRUG|S-1|40-60 mg, bid po, d1-10, every 2 weeks
48683490|NCT01994746|DRUG|Intramuscular Glucagon|
48683491|NCT03965104|BEHAVIORAL|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
47997866|NCT01672476|DRUG|Placebo|Placebo
47997867|NCT01672476|DRUG|Valsartan|Valsartan 80mg
47997868|NCT01672476|DRUG|Fimasartan|Fimasartan 30mg
47997869|NCT01936116|DEVICE|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
47997870|NCT01936116|DEVICE|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
47997871|NCT02731872|DEVICE|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
47997872|NCT05702593|PROCEDURE|Static stretching|The participant was positioned supine for static stretching to be applied to the hamstring muscles. The physiotherapist flexed the participant's hip to the point where resistance to the movement was first observed, with the knee extended.At this point, after waiting for 40 seconds, it was returned to the previous position. This application was made on both sides \[Bretischwerdt\]. The technique was repeated three times, with a 15-second rest interval between each repetition.
47997873|NCT05702593|PROCEDURE|Myofascial Release|For hamstring muscles, the participants were asked to assume a long sitting position on a firm, flat surface with their arms behind their backs and their body weight on their palms. A foam roller was placed under the hamstring muscles and slowly moved the tuberositas ischii popliteus back and forth with pressure for 4 minutes.
47997874|NCT01083095|BIOLOGICAL|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
47997875|NCT02922270|OTHER|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
47997876|NCT05965856|DRUG|BL-B01D1|Administration by intravenous infusion
47997877|NCT05965856|DRUG|SI-B003|Administration by intravenous infusion
47997878|NCT01652664|DRUG|Travoprost 0.004% PQ ophthalmic solution|
47997879|NCT01652664|DRUG|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to \< 3 years of age received 0.25%
48512352|NCT00742963|DRUG|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
47997880|NCT01652664|DRUG|Travoprost Vehicle|Inactive ingredients used to maintain masking
47997881|NCT00449644|DRUG|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
47997882|NCT00449644|DRUG|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
47997883|NCT00449644|DRUG|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
47997884|NCT02768675|DEVICE|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
48512353|NCT03338725|OTHER|Clinical pharmacy model|Patients who are being monitored by a clinical pharmacy model
47997885|NCT02780804|DRUG|Entinostat|Given PO
47997886|NCT02780804|OTHER|Laboratory Biomarker Analysis|Correlative studies
47997887|NCT02780804|OTHER|Pharmacological Study|Correlative studies
47997888|NCT01978028|DRUG|ferric carboxymaltose|
47997889|NCT01978028|DRUG|placebo|
47997890|NCT01616485|DRUG|TA-1790|2 TA-1790 100 mg capsules
48512354|NCT03223701|COMBINATION_PRODUCT|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
48683492|NCT05280665|OTHER|Specialization|"* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21"
48683493|NCT05597358|RADIATION|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
48683494|NCT05597358|RADIATION|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
48683495|NCT04916977|OTHER|FD patients|Patients with Fabry disease diagnosis
47997891|NCT01616485|DRUG|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
47997892|NCT01616485|DRUG|Placebo|2 placebo capsules for TA-1790 100 mg capsules
47997893|NCT01616485|DRUG|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
47997894|NCT03606954|COMBINATION_PRODUCT|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
47997895|NCT01814735|OTHER|Brown rice|
47997896|NCT01814735|OTHER|White rice|
47997897|NCT04941508|BEHAVIORAL|the mother's recorded voice|Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
47997898|NCT04941508|DRUG|Dexmedetomidine|Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
48512355|NCT01213277|OTHER|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
48156151|NCT01545271|DEVICE|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
48156152|NCT03894033|DEVICE|Ascyrus Medical Dissection Stent (AMDS)|The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
48156153|NCT03234842|RADIATION|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
48156154|NCT03234842|RADIATION|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
48156155|NCT03234842|DRUG|Chemotherapy|Concurrent weekly chemotherapy at standard doses
48366251|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
48366252|NCT00283062|DRUG|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
48512356|NCT01213277|OTHER|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
48512357|NCT03378752|PROCEDURE|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
48512358|NCT02290444|DRUG|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
48683496|NCT06503822|DEVICE|Long peripheral venous catheter|In this study, patients eligible for admission were subjected to peripheral vein long catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data were collected.
48156156|NCT01754545|DRUG|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
48156157|NCT01754545|DRUG|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
48366253|NCT03529552|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
48366254|NCT04176809|OTHER|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
48366255|NCT03485976|DRUG|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
48366256|NCT00303004|DRUG|Bosentan and Sildenafil|
48366257|NCT03327740|DRUG|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
48683497|NCT06503822|OTHER|Control group (Short peripheral venous catheter)|In this study, the patients eligible for admission will undergo peripheral venous short catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data will be collected.
48683498|NCT01014806|BIOLOGICAL|Influenza VLP Vaccine|Single dose; 0.5mL
48156158|NCT05614843|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
48156159|NCT05614843|DEVICE|Sham placebo|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
48156160|NCT02570971|DRUG|Mannitol|
48366258|NCT03327740|DRUG|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
48366259|NCT03327740|DRUG|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
48366260|NCT03327740|DRUG|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
48366261|NCT03327740|DRUG|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
48683499|NCT01014806|BIOLOGICAL|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
47997899|NCT04941508|OTHER|saline 0.9% placebo|Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
48683500|NCT02351492|PROCEDURE|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
48683501|NCT02351492|PROCEDURE|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
47997900|NCT05543486|DEVICE|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Spring Loaded Technology Levitation 2 Tri-Compartment Offloader (TCO) brace containing proprietary spring technology providing a knee extension assist.
47997901|NCT05543486|DEVICE|Knee sleeve|Neenca soft knee sleeve comprised of elastic air knit fabric with a silicone padded patella inset and flexible stays on the medial and lateral sides.
48156161|NCT03788941|PROCEDURE|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
48156162|NCT02978846|OTHER|Clinical Observation|Undergo side effects evaluation using cards
48156163|NCT02119572|BEHAVIORAL|peer support|
48156164|NCT02119572|OTHER|usual education lectures|
48156165|NCT05550584|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).|In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
48156166|NCT05550584|DEVICE|LMA|Mechanical ventilation performed by a laringeal mask
48683502|NCT02351492|DEVICE|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
48683503|NCT02351492|DEVICE|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
48683504|NCT01665911|DRUG|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
48683505|NCT01665911|DRUG|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
48683506|NCT01665911|DRUG|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
48366262|NCT03736122|DRUG|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
48683507|NCT01665911|DRUG|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
48683508|NCT01665911|OTHER|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
48156167|NCT02674555|DRUG|radio-labeled naquotinib|Oral administration
48156168|NCT02674555|DRUG|naquotinib|Oral administration
48156169|NCT02910336|OTHER|Quantitative Sensory Testing|sensory testing profile
48366263|NCT01226602|DRUG|AZD6140|P2Y12 receptor antagonist
48683509|NCT02433496|OTHER|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
48683510|NCT04633135|DEVICE|Philips stove|Philips Smokeless stove HD4012LS
48683511|NCT04633135|DEVICE|Gyapa stove|Wood stove made in Ghana
48683512|NCT04396795|DRUG|Autologous Platelet Rich Plasma|Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
47997902|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
47997903|NCT02497027|OTHER|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
47997904|NCT05616858|BEHAVIORAL|Complex exercise program|Stretching exercise, aerobic exercise, strengthening and balancing exercise
48366264|NCT01226602|DRUG|Placebo|
48366265|NCT03961984|PROCEDURE|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
48366266|NCT04594473|BEHAVIORAL|Comprehensive Oncology Rehabilitation and Exercise (CORE) Program|\[see arm/group descriptions\]
48512359|NCT01523002|DRUG|Metoprolol and pyronaridine-artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period."
48156170|NCT04306445|DEVICE|GF-IGB: Obalon Balloon|The balloon, which is attached to a thin catheter, is swallowed by the patient in a standing position. Once the two-step verification of balloon passage into the stomach by both fluoroscopy and pressure reading, the balloon is inflated to a volume of 250 ml with a nitrogen-mix gas, additional imaging of the inflated balloon is obtained, the catheter is ejected from the balloon, and the catheter is pulled out through the patient's mouth. The process is repeated at week 2 for the second balloon and between weeks 4-8 for the third balloon. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. The balloons are removed endoscopically 6 months after placement of the first balloon. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
48156171|NCT04306445|DIETARY_SUPPLEMENT|Medically Supervised Meal Replacement Program: My New Weigh|Patients are given an individualized calorie prescription by a registered dietitian for a goal of 2 pounds weight loss per week. Patients are seen in a group-based program once a week focused on long-term behavior change and use meal replacements for a nutritionally balanced very low-calorie diet for 20 weeks. 4-5 meal replacements are consumed per day. If only 4 meal replacements are consumed, individuals eat 3 servings of vegetables and 2 servings of fruit per day as well.
48156172|NCT04306445|PROCEDURE|Endoscopic sleeve gastroplasty: (ESG)|Endoscopic sleeve gastroplasty is a weight loss procedure that uses an FDA 510K cleared endoscopic suturing device known as Overstitch to reduce the size of the gastric body. The procedure is completed with an endoscope. It is inserted through the mouth, down the esophagus, and into the stomach. Sutures with 8-10 bites 1.5-2 cm apart in a U-shape pattern are placed starting distally 6 cm proximal to the pylorus. Additional sutures are placed moving proximally up to 2 cm distal to the gastroesophageal junction. An additional row of sutures is then placed again in the distal to proximal stomach to complete the gastroplasty. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
48156173|NCT03696147|DEVICE|Magnetic resonance imaging|Diffusion weighted sequence of MRI
48156174|NCT06164119|OTHER|manual treatment with osteopathic techniques and nutritional treatment|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
48156175|NCT06164119|OTHER|manual treatment with osteopathic techniques|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
48156176|NCT06164119|OTHER|nutritional treatment|nutritional treatment (personalized Mediterranean Diet)
48156177|NCT05153161|DEVICE|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
48156178|NCT00122707|DEVICE|catheters|
48156179|NCT01686256|DRUG|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
48156180|NCT00841321|DRUG|Ginkgo biloba|120 mg orally twice a day for 12 weeks
48156181|NCT00841321|DRUG|Placebo|One capsule orally twice a day for 12 weeks
48156182|NCT02618200|DEVICE|3D prostate ultrasound|
48156183|NCT04001582|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
48156184|NCT01891006|DEVICE|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
48156185|NCT01891006|OTHER|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
48156186|NCT06450275|DRUG|Dolutegravir 50 MG Film Coated Tablet|1 tablet of Dolutegravir 50mg film-coated tablets
48156187|NCT06450275|DRUG|Tivicay 50mg, film-coated tablets|1 tablet of Dolutegravir 50mg film-coated tablets
48156188|NCT00607789|DRUG|Duloxetine|30 mg/day - 120 mg/day
48156189|NCT00607789|DRUG|Placebo|identical to study drug
48156190|NCT03071341|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
48366267|NCT04169620|OTHER|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
47997905|NCT04762134|DRUG|Doxycycline Hyclate|STI PrEP arm: doxycycline capsules 100mg orally daily for 12 months STI PEP arm: doxycycline 200mg orally once within 24-72 hours following each sexual encounter deemed at risk (i.e. condomless anal or oral sex), to a maximum of six pills (i.e. 600 mg total) per week
47997906|NCT06126757|DEVICE|PelviSense-assisted pelvic floor muscle training|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays the electrical activity of the PFMs on the user's mobile device. The re-usable sensor can be attached to the user's perineal region, and when positioned correctly, the width of the sensor is oriented along the medial-lateral axis, and the length is oriented along the anterior-posterior axis of the perineal region. The sensor detects PFM activity as the voltage between the two surface electrodes and transmits this activity to the data acquisition unit, which processes the signal and conveys it to a smartphone via a Wi-Fi connection. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts.
47997907|NCT06126757|OTHER|Active Comparator|Pelvic Floor Muscle Training Exercise will be performed without the assistance of the PelviSense Device.
47997908|NCT01892696|DEVICE|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
47997909|NCT04519931|OTHER|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
47997910|NCT02532296|BEHAVIORAL|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
47997911|NCT02532296|BEHAVIORAL|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
47997912|NCT03624660|RADIATION|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
47997913|NCT03624660|RADIATION|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
47997914|NCT02233322|DIETARY_SUPPLEMENT|Iron|All subjects will receive iron supplementation based on iron levels in the blood
47997915|NCT04482504|DIAGNOSTIC_TEST|3 tests: Posturography, Questionnaire, vitamin D|Posturography platform Kistler 9281B Questionnaire focused on exercise activities and self-evaluation of postural stability The investigators also determine level of vitamin D in the blood.
47997916|NCT05707117|OTHER|Tendon neuroplastic training (TNT)|Subjects will attend physical therapy for three non-consecutive days per week for a total 4 consecutive weeks. Exercise would involve isolated flexion, extension with a dumbbell. This exercise would be paced with external audio/visual cue on smart phone using proMetronome app. Patients will listen to the sound and track the movement of metronome with the eyes. Pace of metronome will be set at 20 beats per minute such that each beat will be 3 sec apart. This will allow a 3sec concentric and 3 sec eccentric phases.4 sets of 8 repetitions would be completed with a 2-minute rest between each set. Exercise will begin with 3 pounds weight, but it would be made sure that this wouldn't cause pain during exercise (more than 5/10), gradual progression in weight to 5 pounds after 2nd weeks.
47997917|NCT05707117|OTHER|group B Conventional treatment|Subjects assigned to this group will undergo static stretching of Extensor carpi radialis brevis and myofascial release for 4 weeks, 3 sessions a week. Myofascial release technique will be applied for 5 minutes and 2 reptations per session
47997918|NCT02291055|DRUG|ADXS11-001|
47997919|NCT02291055|DRUG|MEDI4736|
47997920|NCT03320772|DRUG|TMVP1-ICG|Detection of SLN
47997921|NCT03320772|DRUG|ICG|Detection of SLN
47997922|NCT04818190|PROCEDURE|Sensory neurotization|The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
47997923|NCT04898933|PROCEDURE|eyelid lesion excision|eyelid lesion excision was done under local anesthesia
47997924|NCT00500292|DRUG|Vandetanib|once daily oral tablet two dose strengths
47997925|NCT00500292|DRUG|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
48512360|NCT01523002|DRUG|pyronaridine-artesunate|"On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period."
48156191|NCT04221308|DEVICE|Single port laparoscopic systems|The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
48156192|NCT06138522|BEHAVIORAL|Semi-structured interviews|Semi-structured interviews
47997926|NCT00044954|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48156193|NCT06138522|BEHAVIORAL|Child Post-Traumatic Stress Response Index (CPTS-RI) scale|Child Post-Traumatic Stress Response Index (CPTS-RI) scale
47997927|NCT00044954|DRUG|cyclosporine|
47997928|NCT00044954|DRUG|fludarabine phosphate|
47997929|NCT00044954|DRUG|mycophenolate mofetil|
47997930|NCT00044954|PROCEDURE|allogeneic bone marrow transplantation|
47997931|NCT00044954|PROCEDURE|peripheral blood stem cell transplantation|
47997932|NCT00044954|RADIATION|radiation therapy|
47997933|NCT00628602|DEVICE|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
47997934|NCT01660854|BIOLOGICAL|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
48156194|NCT06138522|BEHAVIORAL|- Therapeutic Alliance Questionnaire (HAQ-CP)|- Therapeutic Alliance Questionnaire (HAQ-CP)
47997935|NCT01660854|DRUG|Malarone treatment|Three days: 4 tablets 250/100mg per day
48156195|NCT03348800|PROCEDURE|Dental anesthesia|A tooth extraction will be performed
47997936|NCT05518968|BEHAVIORAL|Acceptance and commitment therapy|8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
48156196|NCT03463291|DEVICE|MRI|"* T1 weighted image.~* Fast spin-echoT2 weighted image.~* Short inversion recovery (STIR).~* T1-fat suppressed images.~* Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values."
48156197|NCT04768491|DRUG|Dacomitinib|effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
48156198|NCT02542293|BIOLOGICAL|Durvalumab +Tremelimumab|
48156199|NCT02542293|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
47997937|NCT03535428|DIAGNOSTIC_TEST|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
47997938|NCT01544751|DRUG|Low dose metformin|500 mg twice a day
47997939|NCT01544751|DRUG|Metformin|1000 mg twice a day
47997940|NCT01544751|DRUG|Atorvastatin|20 mg/day
47997941|NCT04672733|BIOLOGICAL|Hizentra|Solution for injection for subcutaneous use
47997942|NCT04851795|OTHER|supervised physical exercise sessions|Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).
47997943|NCT04851795|OTHER|unsupervised physical exercise|For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
47997944|NCT06244355|OTHER|Extra blood tubes|Extra blood tubes
47997945|NCT04098276|BEHAVIORAL|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
47997946|NCT02449174|BIOLOGICAL|Frozen Microbiota|Frozen Microbiota will be delivered via enema route.
47997947|NCT02449174|BIOLOGICAL|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
47997948|NCT04459117|DRUG|Acetaminophen|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
47997949|NCT04459117|DRUG|NACL 0.9%|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
47997950|NCT04014075|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
47997951|NCT02451410|OTHER|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
47997952|NCT04248933|BEHAVIORAL|Peer-Delivered Behavioral Activation (Peer Activate)|The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
48683513|NCT04396795|OTHER|Saline solution|Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
48683514|NCT03186092|OTHER|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
48683515|NCT03186092|OTHER|sham muscle training|sham comparator
47997953|NCT03469479|DRUG|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
47997954|NCT03469479|PROCEDURE|Hepatic resection|R0 resection
47997955|NCT03025061|OTHER|Assessment of E-nose measurements|Breath sampling through E-nose pneumopipe
47997956|NCT01024907|RADIATION|proton beam radiation therapy|Undergo radiation
47997957|NCT01024907|PROCEDURE|quality-of-life assessment|Ancillary study
47997958|NCT01024907|OTHER|questionnaire administration|Ancillary study
47997959|NCT05533853|OTHER|Posture corrective exercises|The exercises are of two types strengthening exercises and starching exercise ,). The strengthening exercises are to be done for 15 repetitions in 2 sets, Progression will be by increasing to 3 sets and adding 1 Kilogram of resistance in dumbbells exercises, the targeted muscles are teres minor, infraspinatus, medial and lower trapezius, rhomboids, and cervical flexor muscles. On the other hand, stretching exercises are to be hold for 30 seconds for 2 sets then progressed to 3 sets, the targeted muscles are pectoralis minor, sternocleidomastoid and levator scapulae.
48683516|NCT03331991|BIOLOGICAL|influenza vaccine|exposure to influenza vaccine
48683517|NCT00815048|DRUG|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
47997960|NCT05533853|OTHER|Denneroll extension traction|The participants will be instructed to lie supine and keep their legs extended. Based on the apex of each participant's cervical curvature on the initial radiograph, the therapist will position the apex of the denneroll in one of two regions (mid cervical placement or lower cervical placement). The duration of the traction session will start at 2-3 min and increased 1 min per session until reaching the goal of 20 min, the traction will repeated three times per week for 6 weeks
47997961|NCT01726738|DRUG|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
48683518|NCT00815048|DRUG|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
48156200|NCT02542293|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
48156201|NCT02542293|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
48156202|NCT02542293|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
48156203|NCT02542293|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
48156204|NCT05472233|PROCEDURE|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
48683519|NCT05748301|OTHER|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
48683520|NCT03180580|BEHAVIORAL|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
48683521|NCT04253210|OTHER|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
47997962|NCT02283710|DRUG|Pentoxifylline|Pentoxifylline 600 mg BD
47997963|NCT02283710|BEHAVIORAL|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
47997964|NCT05471050|DRUG|TAC|Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
47997965|NCT05471050|DRUG|Danazol|Danazol is given at 200mg bid for 12 weeks.
47997966|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- low dose|
48683522|NCT02785783|DEVICE|Standard colonoscopy|
47997967|NCT01150123|BIOLOGICAL|Group B streptococcus (GBS) vaccine- High dose|
47997968|NCT01150123|BIOLOGICAL|Placebo- Saline|
47997969|NCT01121692|BEHAVIORAL|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
47997970|NCT01121692|BEHAVIORAL|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
47997971|NCT01121692|BEHAVIORAL|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
47997972|NCT00896337|DEVICE|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
47997973|NCT00896337|DRUG|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
47997974|NCT00896337|DRUG|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
47997975|NCT00814086|DRUG|Paclitaxel|Given IV or intraperitoneally
47997976|NCT00814086|DRUG|Cisplatin|Given intraperitoneally
47997977|NCT05735223|PROCEDURE|Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias. Multiparametric MRI (MP-MRI) of the prostate were reviewed when available for surgical planning. All subjects underwent RALP with MULP using the technique previously published by Hamada et al. Continence defined as requiring no pads was assessed at 3 and 6 months postoperatively.
47997978|NCT04990960|OTHER|Physiotherapy|During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
48683523|NCT02785783|DEVICE|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
48683524|NCT03805854|DEVICE|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
47997979|NCT03001258|OTHER|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
47997980|NCT04592965|BEHAVIORAL|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
47997981|NCT04592965|BEHAVIORAL|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
47997982|NCT04592965|OTHER|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
47997983|NCT04592965|OTHER|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
47997984|NCT00914810|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
47997985|NCT00914810|DIETARY_SUPPLEMENT|Placebo|Placebo (sugar pill) daily for 6 weeks
47997986|NCT02149927|DRUG|Sevoflurane|
48156205|NCT06184321|BIOLOGICAL|Alteplase|Instilled into IPC
48156206|NCT06184321|DRUG|Placebo Administration|Instilled into IPC
48156207|NCT00319670|DRUG|MiraLax|
48683525|NCT03805854|DEVICE|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
48683526|NCT03805854|DEVICE|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
48156208|NCT05362253|PROCEDURE|Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation|"1. Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~2. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~3. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~4. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm \~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~5. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing."
48683527|NCT03805854|DEVICE|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
47997987|NCT05686213|BEHAVIORAL|combined aerobic exercise + resistance exercise intervention (AE + RE)|The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.
47997988|NCT05686213|BEHAVIORAL|Aerobic exercise prior to daily radiotherapy sessions (ExPR)|Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
47997989|NCT01883427|DRUG|Placebo|placebo containing saline+glucose
47997990|NCT01883427|DRUG|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
47997991|NCT01921179|BEHAVIORAL|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
47997992|NCT01921179|BEHAVIORAL|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
47997993|NCT05976035|OTHER|Exercise|Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks
47997994|NCT05976035|OTHER|Supplement|Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
47997995|NCT00914615|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
47997996|NCT01251380|BIOLOGICAL|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
47997997|NCT06385587|DEVICE|Oleena|Oleena™ is a software medical device for patients and their healthcare team which digitalizes some aspects of their supportive care, allows remote monitoring by healthcare professionals (HCP) and supports the management of targeted symptoms in adult cancer patients while they are being actively treated for their cancer.
47997998|NCT05163028|DRUG|HBI-2376|SHP2 Inhibitor
47997999|NCT01460433|PROCEDURE|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
48512361|NCT06206798|BEHAVIORAL|Resourcefulness Group|The content of the Resourcefulness intervention group includes 6 sessions such as session 1 to introduce resourcefulness skills; sessions 2-4 to discuss personal resourcefulness skills including planning daily activities, and positive self-talk; sessions 4-5 to discuss social resourcefulness skills including relying on family or friends, and seeking professional assistance.
48512362|NCT05810688|OTHER|eating rehabilitation training|The experimental group will receive eating rehabilitation training, including oral care, saliva gland massage, oral exercise, feeding strategy, and swallowing skill education.
48512363|NCT03046641|OTHER|Continuous training|Study group I (42 participants) received the continuous training.
48512364|NCT03046641|OTHER|The interval training|Study group II (40 participants) received the interval training.
48512365|NCT01425658|DRUG|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
48512366|NCT01425658|DRUG|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
48683528|NCT03805854|DEVICE|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
48156209|NCT05362253|PROCEDURE|Conventional Autologous Conjunctival Transplantation|"1. Routine disinfection and anaesthesia.~2. To bluntly separate and excise pterygium.~3. Remove pterygium tissue on the corneal surface with a round blade.~4. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~5. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~6. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~7. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation."
48156210|NCT02788305|DRUG|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
48683529|NCT03805854|DEVICE|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
48512367|NCT01425658|DRUG|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
47998000|NCT06034613|BEHAVIORAL|internet-based mindfulness intervention for emotional distress(iMIED）|The iMIED program integrates the rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from MBIs. In addition, the iMIED program selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks. In total, it took about 30 min per day to finish all the tasks. The program lasted for 49 days.
47998001|NCT00414804|DEVICE|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
47998002|NCT00414804|PROCEDURE|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
47998003|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing IVF|Patients undergoing hormonal stimulation for IVF will be sampled for cervical mucus.
47998004|NCT04619524|DIAGNOSTIC_TEST|Cervical mucus will be collected from patients undergoing transfer of cryopreserved embryos|Patients undergoing hormonal substitution for transfer of cryopreserved embryos will be sampled for cervical mucus.
48683530|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
48683531|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
47998005|NCT02190227|DEVICE|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
47998006|NCT01837992|DRUG|Primaquine|
47998007|NCT01837992|DRUG|delayed primaquine|
48512368|NCT05698433|OTHER|No intervention|No intervention
48683532|NCT03023306|OTHER|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
48156211|NCT04176549|OTHER|Management of Ectopic Pregnancy|Expectant, Medical or Surgical management of Ectopic Pregnancy
48156212|NCT04176549|OTHER|Management of termination of pregnancy|Surgical termination of pregnancy
48683533|NCT03456258|DIAGNOSTIC_TEST|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
48156213|NCT04176549|OTHER|Elective management of gynaecology patients|Elective hysterectomy and salpingo-oophorectomy
48512369|NCT00583388|DIETARY_SUPPLEMENT|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
48683534|NCT04903574|BEHAVIORAL|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
48156214|NCT06585579|DEVICE|Mucogyne Ovule|In Mucogyne group, patient will receive 2 boxes of Mucogyne® ovule. 24 hours after intervention, the patient will apply Mucogyne® ovule, 1 ovule per day for 10 days, to be repeated as needed (for practices' homogenisation, after the 10th day, it is recommended to apply one ovule every second day, until EOS visit)
48156215|NCT03918733|PROCEDURE|surgical treatment|surgical treatment will be done of failed root canal treated teeth
48156216|NCT03918733|PROCEDURE|Non surgical retreatment|Non surgical retreatment will be done.
48683535|NCT04903574|OTHER|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
48683536|NCT05598853|DRUG|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
48683537|NCT03232827|BEHAVIORAL|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
48156217|NCT06095817|BEHAVIORAL|Internet Delivered Brief Intervention (IDBI)|The intervention is an online module that can be accessed through smartphone, tablet, computer or other device. Participants will receive information about alcohol expectancies, alcohol use and norms, identity (service member, veteran, civilian), sleep, stress, and strategies for coping on the job.
48156218|NCT05879822|DRUG|INCB099280|Administered as specified in the treatment arm description
48156219|NCT02854436|DRUG|Niraparib|Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
48156220|NCT03539497|DIAGNOSTIC_TEST|Biomarker|Plasma mitochondrial DNA, plasma Cytochrome C
47998008|NCT04246606|DIAGNOSTIC_TEST|IHC4 score|"The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~* \<10%: low risk~* \[10-20%\]: intermediate risk~* \>20%: high risk"
47998009|NCT05014022|DIAGNOSTIC_TEST|Multiparametric renal MRI|10 patients in the cohort will undergo MRI scanning at day 30 and 90
47998010|NCT04504383|DRUG|PN-943|Administered by the oral route BID for the duration of the study.
47998011|NCT04504383|DRUG|Placebo|Administered by the oral route BID for 12 weeks.
48156221|NCT04240418|OTHER|Survey|The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
48156222|NCT04517604|DEVICE|Magventure MagProx100 with MagOption|iTBS will be delivered utilizing the MagVentrure MagPro X100 with MagOption stimulator that includes active and placebo coils (C-B60 Butterfly coils). Only the active setting will be used.A MagVenture C-B60 coil will be used to deliver single pulse TMS to the non-dominant MC to identify the ab-ductor pollicis brevis (APB) muscle coordinates. The integrated Localite neuronavigation system will be used.
48156223|NCT00216788|DRUG|Esomeprazole (Nexium) 40 mg/day|
48156224|NCT00203502|DRUG|Bevacizumab|IV 15mg/kg 21 days
48156225|NCT00203502|DRUG|Cyclophosphamide|500mg per meter squared, IV every 21 days
48618125|NCT03777501|BEHAVIORAL|non-random whole body vibration|Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
48618126|NCT03777501|BEHAVIORAL|occupational therapy|Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
48683538|NCT03232827|BEHAVIORAL|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
48683539|NCT03232827|BEHAVIORAL|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
47998012|NCT05540834|DRUG|Alteplase|The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
47998013|NCT00129363|DRUG|Carvedilol|
47998014|NCT03355586|COMBINATION_PRODUCT|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
47998015|NCT03610932|DIETARY_SUPPLEMENT|Vitamin C|Taken as 3 500mg capsules.
47998016|NCT03610932|OTHER|Placebo|Taken as 3 500mg capsules.
47998017|NCT05505032|DRUG|Oxygen|Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.
47998018|NCT05505032|DEVICE|Masimo Root Radical 7|We use it to measure the oxygen reserve index (ORi).
47998019|NCT00952107|DEVICE|FLARE imaging system|Testing of operation of imaging system
47998020|NCT02356692|DEVICE|enfilcon A|Test lens
47998021|NCT02356692|DEVICE|senofilcon A|Control lens
47998022|NCT00965822|OTHER|North American ginseng|3 day, once daily, dosing
47998023|NCT00965822|OTHER|Placebo|3 day, once daily dosing
47998024|NCT03293732|BIOLOGICAL|DCB07010|A protein based adjuvant originated from prokaryotic organism.
47998025|NCT03293732|BIOLOGICAL|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
47998026|NCT03220217|DRUG|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
47998027|NCT03220217|DRUG|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
47998028|NCT02159755|DRUG|Ibrutinib|Given PO
47998029|NCT02159755|OTHER|Laboratory Biomarker Analysis|Correlative studies
47998030|NCT02159755|DRUG|Palbociclib|Given PO
47998031|NCT02159755|OTHER|Pharmacological Study|Correlative studies
47998032|NCT00209677|DRUG|Gemcitabine|
47998033|NCT00209677|DRUG|S-1|
48156226|NCT00203502|DRUG|Docetaxel|60 mg per meter squared, IV every 21 days
48156227|NCT01385683|DRUG|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
48156228|NCT01385683|DRUG|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
48156229|NCT05566626|DEVICE|Hyperspectral retinal image|Hyperspectral image of both eyes
48156230|NCT05566626|DRUG|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
48156231|NCT06431126|OTHER|Nature and animal-assisted activities|Supervised activities on a farm, 2 half day/week for 12 weeks
48618127|NCT02049632|PROCEDURE|Omission of axillary clearance|
48156232|NCT04038723|BEHAVIORAL|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
48156233|NCT02920645|OTHER|AVM-related ICH|
48156234|NCT01341418|PROCEDURE|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
48156235|NCT01341418|PROCEDURE|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
47998034|NCT00273572|OTHER|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
47998035|NCT00273572|OTHER|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
48156236|NCT06647108|DIETARY_SUPPLEMENT|Food Supplement|The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium
48156237|NCT06647108|OTHER|Placebo|Placebo
48156238|NCT04676672|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
48156239|NCT02659488|DRUG|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
48156240|NCT03154827|DRUG|BL-8040|Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
47998036|NCT00000533|BEHAVIORAL|social support|
48156241|NCT03154827|DRUG|Atezolizumab|Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
47998037|NCT05619276|DEVICE|Standard serving utensil toolkit|Serving a meal using standard kitchen utensils (100% of subjects experiment with these tools first)
47998038|NCT05619276|DEVICE|Optimsed portion-control toolkit|Serving a meal using optimised, portion-control utensils (100% of subjects experiment with these tools second)
47998039|NCT04579042|PROCEDURE|cartilaginous batten graft septoplasty|septoplasty using cartilaginous batten graft in cases with caudal septal deviation
47998040|NCT01120756|BEHAVIORAL|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
48156242|NCT06359821|DRUG|ZA-001|Study drug ZA-001 administered via intravenous injection.
48156243|NCT06059963|DEVICE|Signal-C™|Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
48156244|NCT00319878|DRUG|Sirolimus|"Oral loading dose followed by a once daily dose:~* Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~* Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~* Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~* Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
48156245|NCT00319878|DRUG|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
48156246|NCT00685659|OTHER|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
48156247|NCT00685659|OTHER|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
48156248|NCT00685659|OTHER|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
48156249|NCT05174988|PROCEDURE|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
47998041|NCT01120756|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
47998042|NCT05093296|DRUG|Oxytocin nasal spray|24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
47998043|NCT05093296|DRUG|Naltrexone Pill|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
47998044|NCT05093296|DRUG|Placebo|Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
48156250|NCT02713217|OTHER|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
48156251|NCT02713217|OTHER|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
48156252|NCT06509477|DEVICE|Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
48156253|NCT06509477|DEVICE|Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)|Two treatments will be allowed over a 2-week period (initial treatment plus one touch-up) to achieve optimal correction of the NLFs based on investigator's opinion
48156254|NCT02585752|DEVICE|Noninvasive ventilation|Expiratory pressure modulation
48156255|NCT01257386|DRUG|Asacol®|400mg tablets
48156256|NCT01257386|DRUG|Mesalazine|400mg tablets
48366268|NCT04169620|OTHER|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
48366269|NCT05131139|DEVICE|Continuous Glucose Monitoring System|Eversense 524 CGM System and ROME CGM System.
48366270|NCT00733122|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
48366271|NCT04443855|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
48366272|NCT04443855|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
48366273|NCT04443855|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
48683540|NCT03232827|BEHAVIORAL|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
48156257|NCT04287361|OTHER|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
48156258|NCT05729152|OTHER|Sample blood|Partecipants will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram
48156259|NCT01264484|DEVICE|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
48156260|NCT03160859|OTHER|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
47998045|NCT01388075|DRUG|Rifampicin|oral, 450 mg/day , 7 days
47998046|NCT04664933|DRUG|Intra-arterial administration of neuroprotective agents|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min
48156261|NCT03160859|DEVICE|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
48156262|NCT03115619|DRUG|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
48156263|NCT02286427|DEVICE|Amniotic Membrane|
48156264|NCT05624229|DRUG|Proton Pump Inhibitors|PPI infusion continued to use for 5 days in experimental group
48156265|NCT05624229|DRUG|No Proton Pump Inhibitors|PPI infusion stopped in standard group after endoscopy.
48156266|NCT02426424|DEVICE|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
48156267|NCT02426424|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
48156268|NCT00464932|DRUG|Vasoactive Intestinal Peptide (VIP)|
48366274|NCT04443855|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of drinking water for children \< 36 months.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times as food preparation, defecation, and contact with feces."
48366275|NCT04443855|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
48366276|NCT04443855|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
48366277|NCT02408016|BIOLOGICAL|Aldesleukin|Given SC
48683541|NCT00785187|DEVICE|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
48683542|NCT04532346|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
48683543|NCT03466398|BEHAVIORAL|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
47998047|NCT05988398|BEHAVIORAL|READY To Stand Curriculum|Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
48366278|NCT02408016|BIOLOGICAL|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
48366279|NCT02408016|DRUG|Cyclophosphamide|Given IV
48366280|NCT02408016|OTHER|Laboratory Biomarker Analysis|Correlative studies
48366281|NCT02408016|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48683544|NCT04779307|DRUG|Vedolizumab|Vedolizumab IV infusion.
48683545|NCT01591408|DEVICE|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
48683546|NCT05002933|DRUG|Insulin glargine 300 U/ml|Solution for injection Subcutaneous injection
48683547|NCT04501939|DRUG|Cirmtuzumab|Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
48683548|NCT04501939|DRUG|Venetoclax|Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
47998048|NCT00811577|DRUG|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
47998049|NCT00811577|DRUG|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
47998050|NCT00680433|DRUG|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
47998051|NCT00680433|DRUG|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
47998052|NCT03733171|DRUG|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
47998053|NCT03733171|DRUG|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
47998054|NCT03733171|DEVICE|hemoclips|diluted epinephrine was injected followed by application of hemoclips
48683549|NCT06013722|DIAGNOSTIC_TEST|18F-Na PET Scan|For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
48683550|NCT01142076|DRUG|Xinju Xiaogao Prescription|treatment group
48683551|NCT01142076|DRUG|placebo|Therapeutic dose of 10%
48683552|NCT03549286|OTHER|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
48683553|NCT03696550|DRUG|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)"
48683554|NCT01664247|DRUG|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
48683555|NCT01664247|DRUG|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
48683556|NCT01664247|DRUG|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
48683557|NCT02805959|DEVICE|MTS2|
48683558|NCT04587206|DRUG|CKD-348|QD, PO
47998055|NCT02251951|DRUG|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
47998056|NCT01701115|PROCEDURE|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
47998057|NCT01701115|PROCEDURE|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
48366282|NCT00211198|DRUG|ONTAK (denileukin difitox, DAB389IL-2)|
48366283|NCT05706831|OTHER|Combinatory effect of music stimulation and neurostimulation|music
48512370|NCT00583388|DEVICE|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
48512371|NCT01467440|DEVICE|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
48683559|NCT04587206|DRUG|CKD-828, D097, D337|QD, PO
47998058|NCT01701115|DRUG|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
47998059|NCT01701115|DRUG|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
48366284|NCT04466592|BEHAVIORAL|Promotion of competences of participant involved in the management of the post operative period|The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
48366285|NCT03757702|OTHER|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
48683560|NCT05519111|DRUG|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
48683561|NCT05519111|DRUG|Placebo|placebo equivalent
48683562|NCT00690794|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
48683563|NCT00690794|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
48683564|NCT04981301|DRUG|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
47998060|NCT00804518|OTHER|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at \~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
47998061|NCT05913895|OTHER|hydrogen water|To investigate whether the intervention of hydrogen water adjuvant therapy can improve oral mucositis, oral frailty, pain and Quality of Life with head and neck cancer who have received radiation therapy or combined chemotherapy.
48683565|NCT02673983|PROCEDURE|Endoscopic full-thickness biopsy|
48366286|NCT04667585|RADIATION|De-escalated radiation dose|Reduced dose of radiation applied to remaining radiation therapy when favorable interim PET-CT signature is produced
48156269|NCT03079284|OTHER|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
48683566|NCT05088434|DIETARY_SUPPLEMENT|Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
48683567|NCT05088434|DIETARY_SUPPLEMENT|Donor fecal microbiota transplantation|Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
48156270|NCT03614923|BIOLOGICAL|Etokimab|Administered by subcutaneous injection
48156271|NCT03614923|BIOLOGICAL|Placebo|Administered by subcutaneous injection
48156272|NCT03614923|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
48366287|NCT04667585|RADIATION|Standard radiation dose|Standard dose of radiation applied to remaining radiation therapy when favorable PET-CT signature is not produced
48512372|NCT05908175|OTHER|FES-assisted gait training|The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
48618128|NCT05024942|PROCEDURE|Transfemoral TAVR (Transcatheter aortic valve replacement)|Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.
48683568|NCT05088434|DIETARY_SUPPLEMENT|Placebo|Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
47998062|NCT02599753|DRUG|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
47998063|NCT02550847|DEVICE|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
47998064|NCT02704078|DEVICE|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
47998065|NCT02704078|DEVICE|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
47998066|NCT05794178|BEHAVIORAL|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
47998067|NCT05794178|BEHAVIORAL|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
47998068|NCT05794178|BEHAVIORAL|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more \[40%\], sit less \[40%\], inspirational quotes \[20%\])
47998069|NCT05794178|BEHAVIORAL|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
47998070|NCT03500133|RADIATION|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
47998071|NCT03500133|DRUG|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
47998072|NCT03500133|DRUG|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
47998073|NCT03500133|RADIATION|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
47998074|NCT03500133|DRUG|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
47998075|NCT03500133|DRUG|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
47998076|NCT03500133|DRUG|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
48683569|NCT04904029|OTHER|Digital Assessment Routing Tool [DART]|"DART is a first contact web-based and mobile health system that uses clinical algorithms to triage patients and recommend management pathways. Participants complete an online web-based questionnaire that follows a clinical reasoning process commonly observed in face-to-face physiotherapy consultations. Based on the participant's answers, the clinical algorithm generates sets of questions, leading up to a triage disposition with recommended management pathway. The triage outcomes with management pathways are classified;~1. Medical care~   * A\&E referral~  * Urgent GP~  * Routine GP~  * Consultant review~2. Physiotherapy care~   * Post-fracture or surgery physiotherapy~  * Physiotherapy referral~  * Physiotherapy referral plus psychosocial support~3. Self-management~   * Self-management with SOS~  * Continue self-management advice"
48683570|NCT04904029|OTHER|Physiotherapy-led remote triage (usual care)|Participants will receive usual physiotherapy-led remote triage services by a registered health care professional. This service is either a telephone or video consult and includes any diagnostic procedure (e.g. patient history, remote assessments) and treatment, such as management advise or home-based exercise therapy. Participants may seek help elsewhere or opt-out the study at any point, which will not affect their usual physiotherapy-led remote care
48683571|NCT01741298|BEHAVIORAL|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
48683572|NCT00844142|DRUG|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
47998077|NCT03500133|DRUG|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
47998078|NCT03500133|DRUG|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
48683573|NCT00844142|DRUG|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
47998079|NCT02128191|DRUG|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
47998080|NCT02128191|DRUG|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
48683574|NCT04816981|DEVICE|EBUS-Elastography|Patients undergoing LN staging for lung cancer with EBUS-TBNA will have digital images and biopsy of every LN obtained in accordance with standards of care. Prior to the lymph node biopsy by EBUS-TBNA, elastography will be performed. The relative strain of tissues in the scanned area of the LNs will be displayed as a colour map, with stiffer areas in blue and softer tissue in red. Elastography and B-mode images will be displayed side by side and images recorded and saved onto an external drive for analysis. Elastography images will be fed to the NeuralSeg algorithm which has a network architecture similar to the standard U-Net for image segmentation. The automatically identified regions of interest will be overlaid onto the EBUS Elastography images to extract the LN stiffness measurements. After overlaying, NeuralSeg will determine the proportion of the LN area within 9 previously defined stiffness thresholds.
48683575|NCT04981964|PROCEDURE|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
47998081|NCT02407769|DIETARY_SUPPLEMENT|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
47998082|NCT06208436|OTHER|Adjuvant chemotherapy|Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone
47998083|NCT02506504|DEVICE|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
47998084|NCT02506504|DEVICE|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
47998085|NCT00915369|DRUG|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
47998086|NCT01026051|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
48156273|NCT06538727|OTHER|Osteopathic Manipulation Treatment - Scapular Release|First, the patient will be positioned in the supine position. The physician or trained fellow will then place his/her hands on the medial border of the scapula on the affected side. From the paraspinal fascia to the medial border of the scapula a lateral traction is added along with a superior to inferior traction and additionally an inferior to superior traction. The shoulder will be used as an additional fulcrum by having the shoulder in the forward flexion position at 90 degrees and then adduction of the humerus to aid in addition movement of the scapula by moving the upper arm into adduction and abduction in a rhythmic motion. The treatment with a rhythmic and/or static traction in the motions described above and manual movement of the scapula will be done for a maximum of 15 minutes.
48366288|NCT04667585|OTHER|18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)|The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
48366289|NCT05234762|DRUG|ES-481|Dose escalation during two Treatment Periods
48366290|NCT05234762|OTHER|Placebo|Placebo dosed at same dosing as ES-481
47998087|NCT01946399|DRUG|Ozurdex implant|Intravitreal injection of Dexamethasone implant
48366291|NCT00052013|DRUG|PTK787/ZK 222584|
48366292|NCT05107700|PROCEDURE|Stay at altitude 2500 m above sea level (high altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.
48366293|NCT05107700|PROCEDURE|Stay at altitude 470 m above sea level (low altitude)|Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
48683576|NCT05077839|DRUG|Trifluridine/Tipiracil|Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
48683577|NCT03439046|DRUG|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
47998088|NCT06112938|DRUG|Antibiotic|We aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
47998089|NCT05563753|DRUG|ABT|any antibiotic therapy in the first week of life
47998090|NCT02253212|DEVICE|SonoCloud|SonoCloud : dose escalation
48683578|NCT03439046|DRUG|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
48683579|NCT03439046|DRUG|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
48683580|NCT03439046|DRUG|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
47998091|NCT02253212|DRUG|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
47998092|NCT05322174|BEHAVIORAL|Baby Sleep|See arm description
47998093|NCT05322174|BEHAVIORAL|Baby Care|See arm description
47998094|NCT05462028|DEVICE|Vibration training|The vibration sessions were performed and supervised by a stroke care experienced registered nurses/researchers who had both nurse and physiotherapist license. The wearable leg vibration training with vibration frequency = 30 Hz, vibration amplitude = 1 mm in the WG was applied by the wearable leg vibration device (Myovolt, New Zealand) which fits comfortably around the knee and hamstring or calf and delivers focal vibration treatment. While the lower-extremity weight bearing vibration training with vibration frequency = 20 Hz, vibration amplitude = 3 mm in the LG was applied the Cozy Fit (HY-806, China) vibration device with vertical direction, which participants stand with both feet upright on the vibrator in a seated position.
48156274|NCT05490368|DEVICE|Bed mattress sensor system|The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
48156275|NCT04059185|OTHER|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
48683581|NCT03623698|DRUG|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
48683582|NCT00078806|DRUG|Etanercept|Administered by subcutaneous injection twice a week
48683583|NCT00078806|DRUG|Placebo|Administered by subcutaneous injection twice a week
47998095|NCT05462028|BEHAVIORAL|ergometer exercise|ergometer exercise training
47998096|NCT06485063|OTHER|Myofascial Reorganization|It is a manual technique in which the therapist applies a manual sustained oblique load of 45° with subsequent shear load. In general, the technique is divided into two stages, the first when the oblique load is accompanied by a passive shear load (applied by the therapist) during 1minute, and the second stage, when the shear oblique manual load is maintained but the shear load provoked by the participants' active movement (active shear load) during 1minute.
47998097|NCT06485063|OTHER|PLACEBO Myofascial Reorganization|it is light touch to the skin applied by the therapist, without provoking compression, or any constant or shear load during the fist minute. In the second minute, the participant adds active movements to the light touch. This two stage (each one during 1minute) is constructed to mimic the passive and the active stages of the real myofascial reorganization technique.
47998098|NCT03795675|DEVICE|Cochlear Implant|Cochlear implant device to be implanted at time of surgical intervention.
48683584|NCT04481607|DRUG|TQB3454|TQB3454 tablets is a small molecule oral drug.
48683585|NCT04073862|OTHER|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
48683586|NCT05247684|DRUG|AK112|IV infusion
48683587|NCT05247684|DRUG|Carboplatin|IV infusion
48683588|NCT05247684|DRUG|Cisplatin|IV infusion
48683589|NCT05247684|DRUG|Paclitaxel|IV infusion
48683590|NCT00002108|DRUG|Lamivudine|
48683591|NCT00002108|DRUG|Zidovudine|
48683592|NCT02136004|DEVICE|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
48683593|NCT02357199|OTHER|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
47998099|NCT00548704|DRUG|Dexrazoxane|
48683594|NCT00055926|DRUG|CP-724,714|
48512373|NCT05705037|OTHER|CPP-ACPF|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a sham therapy was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. Although the device was switched on, the hand piece did not work and the sound was emitted by a mobile phone. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown.
48683595|NCT04424459|DRUG|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
48683596|NCT02298309|OTHER|Test-and-Treat TB|
48683597|NCT02413476|PROCEDURE|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
48683598|NCT02413476|PROCEDURE|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
48683599|NCT04930146|OTHER|acupuncture and bloodletting|bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
48683600|NCT04192045|OTHER|Survey|A survey will be used at 24 hours and 30 days to assess the quality of recovery
48683601|NCT02463396|BEHAVIORAL|MBCT for ADHD|
48366294|NCT00705627|DRUG|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
48366295|NCT04269629|DRUG|Insect Venom|Patients receive insect venom immunotherapy. The frequency of systemic side-effects is recorded and compared between patients under antihypertensive treatment and patients not taking antihypertensive drugs.
48683602|NCT01274598|BIOLOGICAL|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10\^10 CFU by mouth twice daily for 28 days
48683603|NCT01123031|DRUG|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
48683604|NCT01123031|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
48683605|NCT00005097|DRUG|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
48683606|NCT01100333|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
48683607|NCT01097096|BIOLOGICAL|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
48683608|NCT01097096|BIOLOGICAL|Placebo|Identical placebo to CAD106 administered via intramuscular injection
48683609|NCT01097096|BIOLOGICAL|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
48683610|NCT01097096|BIOLOGICAL|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
48683611|NCT00422877|DRUG|Taxoprexin|DHA-paclitaxel
48683612|NCT01680354|PROCEDURE|ReLEx|
48683613|NCT01680354|PROCEDURE|LASIK|
48683614|NCT04209023|DEVICE|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
48683615|NCT03122145|DRUG|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
48683616|NCT03122145|DEVICE|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
48683617|NCT03789656|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
48683618|NCT04981106|OTHER|Elastic Band Exercise|"The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared."
48683619|NCT01973231|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
48683620|NCT01973231|DRUG|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
48683621|NCT00002124|DRUG|Delavirdine mesylate|
47998100|NCT05252039|BEHAVIORAL|Goals in Focus|"Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training."
47998101|NCT02307851|BIOLOGICAL|Quadrivalent VLP Vaccine|
48156276|NCT04059185|OTHER|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
48156277|NCT04059185|OTHER|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
48156278|NCT06381297|DIAGNOSTIC_TEST|Hearing test|Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
48156279|NCT06381297|DIAGNOSTIC_TEST|Speech in noise discrimination test|Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
48156280|NCT06381297|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale|Translated into Turkish as the Montreal Cognitive Assessment Scale and abbreviated as MOBID, MOCA assesses attention, executive/managerial functions, memory, visual-spatial skills, language, abstract thinking and arithmetic. It is easy and practical to apply. The score that can be obtained varies between 0-30. The cut-off point for cognitive impairment is 21. Patients who perform below 21 points are considered to have cognitive impairment. Although it is not a battery used in the MS patient group, a study conducted on 39 MS patients and 20 healthy people showed that it can be used safely for screening purposes in patients with MS (Aksoy et al., 2013; Nasreddine et al., 2005; Selekler \& Cangoz, 2009).
48156281|NCT06381297|DIAGNOSTIC_TEST|Symbol Number Modalities Test (SDMT)|Attention, visuospatial information processing speed and working memory are assessed. It is one of the subtests of the Short Repeatable Neuropsychological Battery developed to assess cognitive functions in MS (Smith, 1973).
48683622|NCT00002124|DRUG|Lamivudine|
48683623|NCT00002124|DRUG|Zidovudine|
48156282|NCT05556772|PROCEDURE|Biospecimen Collection|Collection of blood; urine; cervical, anal, vaginal samples
48156283|NCT05556772|OTHER|Interview|Attend interview
48683624|NCT04998500|BIOLOGICAL|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
48156284|NCT01601925|OTHER|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
48683625|NCT03125330|BEHAVIORAL|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
48683626|NCT04633395|OTHER|Music|The participant can choose between 5 different soothing playlists
48683627|NCT04633395|BEHAVIORAL|Sleep hygiene|These are behavioural guidelines to help establish a better sleep pattern
48683628|NCT02641756|OTHER|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
48683629|NCT05175131|DRUG|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
48683630|NCT05175131|DRUG|Mebeverine|Duspatalin®, coated tablets 135 mg
48683631|NCT05175131|DRUG|Simethicone|Espumisan® capsules 40 mg
48683632|NCT04175340|DEVICE|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
48683633|NCT04175340|DEVICE|OPTI-FREE|Replenish Rewetting Drops
48683634|NCT01875081|BIOLOGICAL|Livercellgram|"Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery"
48683635|NCT02322580|DRUG|etanercept|
48683636|NCT03731052|DRUG|188-0551 Spray|Topical Spray containing active drug
48683637|NCT03731052|DRUG|Vehicle Spray|Topical Spray containing no active drug
48683638|NCT05111431|DRUG|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
48683639|NCT05111431|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
48683640|NCT03154255|BEHAVIORAL|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
48683641|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
48683642|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
48683643|NCT03910725|OTHER|Electrocardiographic imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
48683644|NCT01632592|DRUG|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
48683645|NCT01632592|DRUG|Placebo|placebo given by injection 2mg subcutaneously daily
48683646|NCT06184230|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine
48683647|NCT02008942|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
48683648|NCT02008942|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
48156285|NCT06010368|DRUG|Tranexamic acid injection|In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
48683649|NCT00506402|DRUG|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
48683650|NCT06144294|OTHER|Whole-Body Hyperthermia|The Clearlight dome sauna is portable infrared sauna consisting of two lightweight domes and an infrared heating pad. The sauna will be used to deliver the intervention to the participant and the sauna session will end as soon as (1) an internal body temperature of 38.5 C (101.3 F) is reached for two consecutive minutes or, (2) 140 minutes have passed.
48683651|NCT06144294|DIAGNOSTIC_TEST|fMRI|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain.
48683652|NCT00714662|DEVICE|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
48683653|NCT02303210|DEVICE|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
48683654|NCT02303210|DEVICE|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
48683655|NCT03027518|OTHER|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
48683656|NCT03463863|PROCEDURE|rectus sheath midurethral sling|
48683657|NCT03484039|BEHAVIORAL|Medication Adherence|Some subjects will be enrolled in a medication adherence course.
48683658|NCT03484039|BEHAVIORAL|Seizure Documentation|Some subjects will be enrolled in a seizure documentation course.
48683659|NCT03484039|BEHAVIORAL|Memory Improvement|Some subjects will be enrolled in a memory improvement course.
48683660|NCT03484039|BEHAVIORAL|Stress Management|Some subjects will be enrolled in a stress management course.
48683661|NCT03271216|DEVICE|No intervention|no intervention
48683662|NCT03268408|BEHAVIORAL|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
48683663|NCT00626886|DRUG|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
48683664|NCT00626886|DRUG|placebo collagen sponge|collagen
48683665|NCT05737823|BEHAVIORAL|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
48683666|NCT05737823|BEHAVIORAL|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
48683667|NCT00205153|BEHAVIORAL|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
47998102|NCT02307851|BIOLOGICAL|Comparator TIV|
47998103|NCT00178841|DRUG|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
47998104|NCT00885599|DRUG|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
47998105|NCT00885599|DRUG|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
48156286|NCT06010368|DRUG|Oxytocin|the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
48156287|NCT05728619|DRUG|HTMC0435|Oral administration.
48156288|NCT05728619|DRUG|Temozolomide|Oral administration.
48156289|NCT01843699|DRUG|Topiramate flexible dosage|
48156290|NCT01843699|DRUG|Placebo matching tablets|
48156291|NCT01843699|BEHAVIORAL|4-session gambling cognitive restructuring|
48156292|NCT02366455|PROCEDURE|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
48156293|NCT02366455|PROCEDURE|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
48156294|NCT03534778|DIAGNOSTIC_TEST|Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)|LNY and LNR will be examined after neck dissection
48683668|NCT06014151|OTHER|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
47998106|NCT00885599|DRUG|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
47998107|NCT00885599|DRUG|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
47998108|NCT01531387|DRUG|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
47998109|NCT01785576|BEHAVIORAL|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
48156295|NCT04457583|DEVICE|Inspiratory muscle training with powerbreathe|Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
48156296|NCT02351609|BEHAVIORAL|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
48156297|NCT02351609|OTHER|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
48156298|NCT05415644|DRUG|hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets|"High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals."
48156299|NCT05415644|DRUG|hrx0701 tablets|"High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach)."
48156300|NCT04743453|DRUG|Dapagliflozin|Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
48156301|NCT04743453|DRUG|Placebo|Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
48156302|NCT05223452|DEVICE|UltraSound|we use prob that admit some of radiation to patient to see the organs inside the abdomen
48156303|NCT02671071|BEHAVIORAL|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
48156304|NCT02854709|BEHAVIORAL|Sleep extension|Sleep extension by 1 hour for 2 weeks
48156305|NCT05340283|PROCEDURE|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
48156306|NCT01090076|DIETARY_SUPPLEMENT|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
48366296|NCT04282343|BEHAVIORAL|The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
48366297|NCT04282343|BEHAVIORAL|Usual Care|Patients randomized to this arm will receive usual care.
48366298|NCT06143449|OTHER|Observational study - registry|Observational study - registry
48683669|NCT00222755|BEHAVIORAL|Disease Management|Self-management, care management, guidelines
48156307|NCT04404699|DIAGNOSTIC_TEST|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
48156308|NCT02181751|OTHER|Trauma Focused Cognitive Behavioural Therapy Group|Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
48156309|NCT00425906|DRUG|nicotine|
48156310|NCT00425906|OTHER|Placebo|
48156311|NCT00425906|PROCEDURE|Quality of life|
48683670|NCT06554106|OTHER|Neuromuscular Electrical Stimulation Group|All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
48156312|NCT04966351|BEHAVIORAL|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
48156313|NCT04966351|BEHAVIORAL|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
48156314|NCT03575572|DRUG|Colchicine|Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
48156315|NCT01874522|DRUG|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
48156316|NCT01874522|DRUG|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
48156317|NCT00170950|DRUG|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
48156318|NCT00170950|DRUG|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
48156319|NCT00170950|DRUG|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
48156320|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
48683671|NCT06554106|OTHER|Control Group|Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
47998110|NCT01602250|DRUG|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
47998111|NCT01602250|DRUG|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
48683672|NCT06080074|DEVICE|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
48683673|NCT03162133|OTHER|Baduanjin exercise|
48683674|NCT01896778|PROCEDURE|Hyperthermia Treatment|Undergo B-WARM
47998112|NCT02259309|DRUG|Misoprostol - buccal|buccal administration
47998113|NCT02259309|DRUG|Misoprostol - vaginal|vaginal administration
47998114|NCT04211701|PROCEDURE|Connective Tissue Massage|Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
47998115|NCT04211701|PROCEDURE|Classical Massage|Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
48156321|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
48156322|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
48683675|NCT01896778|OTHER|Laboratory Biomarker Analysis|Correlative studies
48683676|NCT05568160|DRUG|Vasopressin|The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1
48156323|NCT05510102|DEVICE|WHOOP strap 4.0 (full data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
48156324|NCT05510102|DEVICE|WHOOP strap 4.0 (partial data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
48156325|NCT01107717|DRUG|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
48156326|NCT01107717|DRUG|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
48156327|NCT05248269|PROCEDURE|Radiofrequency thermocoagulation|The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.
48156328|NCT02014402|BIOLOGICAL|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
48156329|NCT02014402|BIOLOGICAL|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
48156330|NCT03960437|DRUG|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
48156331|NCT01358643|OTHER|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
48156332|NCT04445246|DRUG|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
48156333|NCT01979822|OTHER|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
48156334|NCT05096741|DEVICE|OCS Liver|Transplanted with a OCS preserved liver
48156335|NCT03771573|OTHER|Physical exercise|Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
48156336|NCT03771573|OTHER|monitoring|the patients will be under monitoring to investigate the evolution of the disease
48156337|NCT00139971|DRUG|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
48156338|NCT00139971|DRUG|UFT 250mg/m2, daily for 1 year|
48156339|NCT04736602|DRUG|Triptorelin pamoate 15mg|Intramuscular injection (IM)
48156340|NCT00518596|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
48156341|NCT02338778|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
48366299|NCT05770882|DRUG|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
48366300|NCT05770882|DRUG|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
48683677|NCT05568160|DRUG|Norepinephrine|The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
48683678|NCT05568160|OTHER|Collection of clinical data|At D1, D2, D7, D30 or D60 and D90
48683679|NCT05568160|OTHER|Quality of Life Questionnaire EQ-5D|At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
48683680|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 3 months|Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
48683681|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 6 months|Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
48683682|NCT05870969|BEHAVIORAL|Liver cancer surveillance annually|Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
48683683|NCT01564823|DRUG|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
48683684|NCT01564823|DRUG|Metronidazole|Metronidazole 250 mg/8h 3 months
48683685|NCT01564823|DRUG|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
48683686|NCT01564823|DRUG|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
48683687|NCT00996957|BIOLOGICAL|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
48683688|NCT05604144|DEVICE|Cryoanalgesia (iovera°®)|iovera°® treatment will be administered via ultrasound guidance to 1-2 branches of the dorsal/digital/proper nerve/s that innervate the Morton's neuroma. The treatment will be completed one time per subject.
48683689|NCT03053557|BEHAVIORAL|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
48683690|NCT06059456|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
48683691|NCT06059456|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
48156342|NCT02338778|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
48156343|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Antecubital Approach|Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
48156344|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Femoral Approach|Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
48683692|NCT03183752|DRUG|Metformin|500 mg metformin three times daily
48156345|NCT01217723|BIOLOGICAL|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
48683693|NCT03183752|DRUG|Placebo|500 mg placebo three times daily
48156346|NCT01217723|OTHER|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
48156347|NCT02539602|BEHAVIORAL|The Need to Know students received the N2K curriculum as described previously|
48156348|NCT03331276|OTHER|BBN|BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
48156349|NCT03331276|OTHER|Brand|Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
48156350|NCT00358722|DRUG|Fermagate|Film coated tablet 500mg
48683694|NCT01227226|DRUG|Artificial tears|Instill one drop of artificial tears
48156351|NCT05707689|BEHAVIORAL|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
48156352|NCT02173561|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
48366301|NCT05139550|DEVICE|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises~ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises~bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities~Lift can, Lift pencil, Lift paper clip, Stack checkers,Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
48366302|NCT00483431|DIETARY_SUPPLEMENT|Placebo|
48366303|NCT00483431|DIETARY_SUPPLEMENT|MK7|
48512374|NCT05705037|OTHER|PBMT|A placebo mousse (Elmex Junior®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2
48683695|NCT03021603|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
48683696|NCT03990532|RADIATION|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
48683697|NCT03990532|RADIATION|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
48683698|NCT03091387|DIAGNOSTIC_TEST|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
48683699|NCT05547087|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
48683700|NCT02386787|DEVICE|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
48683701|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
48683702|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
48683703|NCT03274947|DEVICE|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
47998116|NCT01886183|OTHER|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
47998117|NCT01886183|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises.
47998118|NCT05301088|OTHER|Chocolate Scent|"Chocolate Scent:Children in this group will be given chocolate scent sniffing as a non-pharmacological distraction method.~Stress Ball:Stress ball squeezing will be used as a non-pharmacological distraction method for children in this group."
48156353|NCT02173561|BEHAVIORAL|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
48156354|NCT00841945|DRUG|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
48156355|NCT00841945|DRUG|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
48156356|NCT00841945|DRUG|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
48156357|NCT00841945|DRUG|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
48156358|NCT00841945|PROCEDURE|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
48156359|NCT02152995|PROCEDURE|Computed Tomography|Undergo iodine I-124 PET/CT
48156360|NCT02152995|OTHER|Iodine I 124|Undergo iodine I-124 PET/CT
47998119|NCT02723149|BEHAVIORAL|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
48156361|NCT02152995|RADIATION|Iodine I-131|Given PO
47998120|NCT03507712|PROCEDURE|Symmetrical IO weakening|Bilateral IO Myectomy / Bilateral equal graded IO Recession
48156362|NCT02152995|OTHER|Laboratory Biomarker Analysis|Correlative studies
48156363|NCT02152995|OTHER|Pharmacodynamic Study|Correlative studies
48156364|NCT02152995|PROCEDURE|Positron Emission Tomography|Undergo iodine I-124 PET/CT
48683704|NCT03274947|DEVICE|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
48156365|NCT02152995|DRUG|Trametinib|Given PO
48156366|NCT00003541|BIOLOGICAL|filgrastim|
48156367|NCT00003541|DRUG|CHOP regimen|
48156368|NCT00003541|DRUG|carboplatin|
48683705|NCT03299478|OTHER|Will look for immune infiltration|
47998121|NCT03507712|PROCEDURE|Asymmetrical IO weakening|IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
47998122|NCT03929848|PROCEDURE|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
48156369|NCT00003541|DRUG|cyclophosphamide|
48683706|NCT05746091|PROCEDURE|wrist arthroscopy|Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
48156370|NCT00003541|DRUG|doxorubicin hydrochloride|
48156371|NCT00003541|DRUG|etoposide|
48156372|NCT00003541|DRUG|ifosfamide|
48156373|NCT00003541|DRUG|prednisone|
48156374|NCT00003541|DRUG|vincristine sulfate|
48156375|NCT00003541|PROCEDURE|peripheral blood stem cell transplantation|
48156376|NCT00003541|RADIATION|radiation therapy|
48156377|NCT00194961|DRUG|Recombinant Human Growth Hormone|
48156378|NCT04454671|OTHER|Ultrasound-guided percutaneous neuromodulation (NMPE)|It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
48156379|NCT04454671|OTHER|Ultrasound-guided dry needling|Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
48156380|NCT02978235|DRUG|TAS4464|Intravenous (IV) Infusion
48156381|NCT01157442|BEHAVIORAL|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
48683707|NCT02998879|DRUG|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
48683708|NCT03036852|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
48156382|NCT04885478|OTHER|Immune response monitoring , blood samples|"In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring"
47998123|NCT04227106|BIOLOGICAL|EB-101|autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
47998124|NCT04384510|PROCEDURE|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
48366304|NCT00808665|DRUG|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
48366305|NCT00808665|DRUG|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
48366306|NCT02643316|DRUG|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
48366307|NCT02643316|DRUG|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
48366308|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with low-carbohydrate-high-protein content
48512375|NCT05705037|OTHER|CPP-ACPF+PBMT|CPP-ACPF mousse (MI Paste®) was applied with a microbrush on the cervical buccal surface of each tooth for 5 minutes and it was subsequently distributed for 20 seconds with a rubber cup coupled to a low speed handpiece. Right after, a PBMT was performed, using RAFFAELLO 980 BIO - Dental Medical Technologies - DMT S.r.l. The tip of the laser device was positioned on two areas for each dental element, located one in the center of the cervical region and the other in the middle third of the crown. The parameters used were: wavelength 980 nm, power 4 W, irradiation area1 cm2, application time 15 sec per 1 cm2, energy density 60 J/cm2.
48683709|NCT03482986|BEHAVIORAL|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
47998125|NCT04384510|PROCEDURE|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
47998126|NCT03322488|PROCEDURE|Fistulodesis|"Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
48156383|NCT01543009|OTHER|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
48512376|NCT05012189|DRUG|Oseltamivir|Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.
48512377|NCT05012189|DRUG|Baloxavir|Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.
47998127|NCT02801942|PROCEDURE|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
47998128|NCT02801942|PROCEDURE|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
48512378|NCT01691235|DEVICE|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
48512379|NCT06516003|DEVICE|Immersive Virtual Reality Goggles|Immersive Virtual Reality goggles are a head mounted device placed over a patient's head and eyes that allows them to play in a virtual reality game.
48683710|NCT00225862|DRUG|ropinirole|
47998129|NCT02801942|PROCEDURE|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
48156384|NCT01176747|DRUG|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
48156385|NCT01678755|DRUG|ABT-126|ABT-126 Low Dose
48156386|NCT01678755|DRUG|ABT-126|ABT-126 High Dose
48156387|NCT01678755|DRUG|Placebo|Placebo
48156388|NCT00475969|DRUG|duloxetine|
48156389|NCT00475969|DRUG|placebo|
48366309|NCT04472962|OTHER|Pre-exercise meal|Mixed meal with high-carbohydrate-low-protein content
48156390|NCT06092879|OTHER|Asciminib|There is no treatment allocation. Patients administered Asciminib by prescription will be enrolled
48156391|NCT04824456|PROCEDURE|bilateral sagittal split osteotomy using separators.|The final split is completed with a thin osteotomes, splitting the entire ascending ramus from the anterior to the posterior border of the ramus.
48512380|NCT06516003|BEHAVIORAL|Standard of Care|Distraction techniques like tablet, phone, television, parent, child life specialist
48512381|NCT01255137|DRUG|Axitinib|5 mg tab orally twice a day with food every 28 days
48683711|NCT06118424|BEHAVIORAL|deepfake video|The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
48683712|NCT00422188|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
47998130|NCT02801942|OTHER|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
47998131|NCT04914390|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
47998132|NCT04914390|DRUG|Tislelizumab|200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
47998133|NCT04914390|DRUG|Anlotinib|8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
47998134|NCT04912934|PROCEDURE|A survey form was applied to individuals included in the study face-to-face.|This study was completed with a descriptive, cross-sectional and relational screening model
47998135|NCT05465265|BEHAVIORAL|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
47998136|NCT03054662|OTHER|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
48156392|NCT04521933|OTHER|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
48156393|NCT02267746|DRUG|Tazarotene (Fabior™)|
48156394|NCT02267746|DRUG|Tazarotene (Actavis)|
48512382|NCT00316758|DRUG|GK Activator (2)|Escalating doses bid
48512383|NCT00316758|DRUG|Metformin|As prescribed, in patients who were in study BM18249
48512384|NCT03925259|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
48512385|NCT05430217|DRUG|Buspirone|1 tablet (15 mg) once per day for 28 days
48512386|NCT05430217|DRUG|Placebo|1 placebo tablet once per day for 28 days
47914327|NCT05882708|DRUG|Ivabradine|After randomization, the starting dose of ivabradine, 5mg, is given via the gastrointestinal tract every 12 hours. Heart rate control ranged from 70 to 94 bpm. Ivabradine was maintained until 96 hours after initiation of therapy. Beyond this period, the decision to continue ivabradine is left to the discretion of the treating intensivist. During the drug intervention period, heart rate is assessed before each dose. Ivabradine is tapered or discontinued if the heart rate is lower than the target rate; If the heart rate remains ≥95 bpm after 48 hours, the dose is increased to 7.5mg. If a heart rate of 95 or more bpm recurs after discontinuation during the intervention period, treatment with ivabradine can be resumed. Furthermore, Ivabradine is also discontinued at any time in the presence of severe liver impairment, malignant arrhythmia, cardiac conduction block, allergy, the need to take drugs with potentially harmful effects of ivabradine.
48156395|NCT02267746|DRUG|Vehicle foam|
48156396|NCT02494076|DRUG|EzPAP|
48156397|NCT02494076|OTHER|Standard Care|
48512387|NCT06281197|PROCEDURE|Conventional|Le Fort I osteotomy performed with conventional Le Fort
48512388|NCT06281197|PROCEDURE|Subspinal|Osteotomy was performed in the subspinal Le Fort I group that is described by Mommaerts
48512389|NCT00749892|DRUG|Erlotinib Hydrochloride|Given PO
48156398|NCT06448845|PROCEDURE|Arm intravenous regional anesthesia|After placement of the upper arm and forearm tourniquets and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the arm tourniquet cuff is inflated to a pressure of 250 mmHg. The double arm cuff pneumatic pressure tourniquet is placed immediately above the elbow crease and on the top of a circumferentially placed cotton cast padding before inflation. Subsequently, tourniquet failure is ruled out by observing the absence of distal circulation and 40 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand. The tourniquet remained inflated for 60 minutes from injection of lidocaine to reduce the risk of local anesthetic systemic toxicity (LAST)
48156399|NCT06448845|PROCEDURE|Forearm IVRA block|After placement of the forearm double tourniquet and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the forearm tourniquet cuff is inflated to a pressure of 250 mmHg. The forearm tourniquet will be placed 5 cm distal to the medial epicondyle of the humerus and on the top of a circumferentially placed cotton cast. Subsequently, tourniquet failure is ruled out by observing the distal circulation and 25 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand.
48156400|NCT00111163|DRUG|sulfadoxine-pyrimethamine with artesunate|
48156401|NCT00111163|DRUG|amodiaquine with artesunate|
48156402|NCT00111163|DRUG|chlorproguanil-dapsone|
48156403|NCT04096261|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
48156404|NCT03663699|BEHAVIORAL|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
48156405|NCT05304884|COMBINATION_PRODUCT|combined oxygen-ozone and corticosteroid|Subacromial injection using Ultrasound
48156406|NCT02430597|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
47914328|NCT03401814|OTHER|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
48156407|NCT02430597|DEVICE|NanoKnife|
48512390|NCT01105871|DRUG|naloxone|4 mg naloxone in 10 ml saline given iv bolus
48683713|NCT00422188|DRUG|Placebo|Administered via intralipomal injection.
48683714|NCT01053507|DRUG|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
47914329|NCT01238484|OTHER|Standard of care|shoe modification home stretching exercises
48512391|NCT01105871|DRUG|Placebo|10 ml of normal saline iv bolus
48512392|NCT02246114|DEVICE|piCO+ Smokerlyzer® monitor|
48512393|NCT02246114|OTHER|Text messages|
48512394|NCT04514484|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48683715|NCT01053507|DRUG|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
48683716|NCT01495039|DRUG|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
48683717|NCT04014894|DRUG|ET019003-T Cells|Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
48683718|NCT01862406|OTHER|Label|Participants were presented with either a generic label or a brand-name label
48683719|NCT05605548|DRUG|MitoQ|MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
48683720|NCT05605548|OTHER|Placebo|"A look-alike inactive substance, a sugar pill"
48683721|NCT05318300|DIETARY_SUPPLEMENT|tested formula with fiber|formula containing fibers
48683722|NCT05318300|DIETARY_SUPPLEMENT|Control|formula without fiber
48683723|NCT01295307|DRUG|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
47914330|NCT01238484|DEVICE|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
47914331|NCT04675008|DRUG|Dacomitinib|Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
47998137|NCT03054662|DIAGNOSTIC_TEST|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
47998138|NCT03054662|DRUG|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
47998139|NCT03054662|OTHER|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
47998140|NCT02865031|DRUG|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
47998141|NCT00316979|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
47998142|NCT04426565|BEHAVIORAL|motivational enhancement interview|Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
48156408|NCT02362100|OTHER|Non operative|non operative treatment
48156409|NCT02362100|PROCEDURE|locking plate surgical fixation|
48156410|NCT02552706|DIETARY_SUPPLEMENT|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
48156411|NCT02552706|DIETARY_SUPPLEMENT|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
48156412|NCT00281983|BIOLOGICAL|alemtuzumab|
48156413|NCT00281983|BIOLOGICAL|anti-thymocyte globulin|
48512395|NCT04514484|DRUG|Cabozantinib S-malate|Given PO
48512396|NCT04514484|PROCEDURE|Computed Tomography|Undergo CT
48512397|NCT04514484|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48512398|NCT04514484|BIOLOGICAL|Nivolumab|Given IV
48512399|NCT00536692|DRUG|mecamylamine|topical ocular drops
48683724|NCT05370027|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
48683725|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
48683726|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
48683727|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
48683728|NCT03301779|DEVICE|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
47998143|NCT04426565|BEHAVIORAL|the individual psychotherapy|It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
47998144|NCT04426565|BEHAVIORAL|the group psychotherapy|Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
47998145|NCT04426565|BEHAVIORAL|the family therapy|"According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence."
48156414|NCT00281983|BIOLOGICAL|filgrastim|
48156415|NCT00281983|BIOLOGICAL|rituximab|
48156416|NCT00281983|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48366310|NCT05883566|BEHAVIORAL|experimental|During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
48156417|NCT00281983|DRUG|busulfan|
48156418|NCT00281983|DRUG|cyclophosphamide|
47998146|NCT05276492|DRUG|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
47998147|NCT05276492|DRUG|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
47914332|NCT04802668|DEVICE|Patients were ventilated with assist-control ventilation（A/C） mode at different tidal volume|Ventilation mode was set to assist-control volume ventilation with different tidal volume, respiratory frequency 15 times/min, PEEP 5 centimeter water column.
47914333|NCT04802668|BEHAVIORAL|spontaneous breathing and no spontaneous breathing|Data were recorded when patients had and did not have spontaneous breathing
48156419|NCT00281983|DRUG|cyclosporine|
48156420|NCT00281983|DRUG|fludarabine phosphate|
48156421|NCT00281983|DRUG|methotrexate|
48156422|NCT00281983|DRUG|mycophenolate mofetil|
48156423|NCT00281983|PROCEDURE|peripheral blood stem cell transplantation|
48156424|NCT00281983|RADIATION|radiation therapy|
48366311|NCT05568251|DEVICE|transcranial Direct Current Stimulation|Participants will receive a single session of active/sham tDCS. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (right anodal/left cathodal).
48366312|NCT05568251|PROCEDURE|Cognitive training|Participants will be administered Game of Dice Task concurrent with the tDCS session
48512400|NCT02075515|BIOLOGICAL|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
48683729|NCT00768261|DRUG|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
48683730|NCT00768261|DRUG|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
48683731|NCT06221410|OTHER|Alternative teaching method: Funny Scenario-Based Education|"A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together."
48683732|NCT06221410|OTHER|Alternative teaching method: Mind-mapping Education|As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
48683733|NCT00002493|DRUG|cisplatin|
48683734|NCT00002493|DRUG|doxorubicin hydrochloride|
48683735|NCT00002493|RADIATION|low-LET photon therapy|
48683736|NCT05976152|DRUG|dl-3-butylphthalide|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
48156425|NCT03470701|OTHER|Mailed Urinalysis Smartphone Kit|Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
48156426|NCT03990376|OTHER|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
48156427|NCT01877720|DEVICE|noninvasive respiratory support with NAVA mode and PSV|
48156428|NCT02750371|OTHER|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
48156429|NCT04060641|GENETIC|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
48156430|NCT00139659|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
48156431|NCT00139659|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
48156432|NCT02718053|OTHER|L-stiff|spasticity measurement with Lokomat
48156433|NCT02718053|OTHER|Ashworth|spasticity measurement with Ashworth scale
48366313|NCT00527722|DEVICE|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
48156434|NCT00926978|RADIATION|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
48156435|NCT00557154|DEVICE|ultrasound|ultrasound used to identify target vein
48156436|NCT00557154|DEVICE|standard technique for venipuncture|routine equipment
48156437|NCT05120284|DRUG|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
48156438|NCT05120284|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
48156439|NCT03687918|OTHER|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~* To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
48366314|NCT00527722|OTHER|No lung plug|Standard lung biopsy without placement of the plug.
48366315|NCT01491828|DEVICE|Kai Strap|Medical device component that vibrates on a subject's neck.
48512401|NCT01941498|DEVICE|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
48512402|NCT01941498|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
48683737|NCT05976152|DRUG|dl-3-butylphthalide placebo|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
47998148|NCT05276492|OTHER|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
48512403|NCT03398603|PROCEDURE|blood sample and ultrasound|When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
47998149|NCT05276492|DRUG|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
47998150|NCT06332716|OTHER|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.|Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
47998151|NCT00322192|BEHAVIORAL|Conventional UK Physical therapy|
47998152|NCT00322192|BEHAVIORAL|Increased intensity of UK conventional physical therapy|
47998153|NCT00322192|BEHAVIORAL|UK conventional physical therapy plus functional strength training|
47998154|NCT06375733|DRUG|GFH009|administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
47998155|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
47998156|NCT06375733|DRUG|GFH009|the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
47998157|NCT06375733|DRUG|Zanubrutinib|administered at 160mg BID oral; 28-day a cycle until disease progresses.
47998158|NCT01150929|DEVICE|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
48156440|NCT04761614|BIOLOGICAL|Bevacizumab|Given IVPB
48156441|NCT04761614|DRUG|Fluorouracil|Given IV
48156442|NCT04761614|DRUG|Leucovorin Calcium|Given IVPB
48156443|NCT04761614|DRUG|Oxaliplatin|Given IVPB
48156444|NCT04761614|DRUG|Riluzole|Given PO
48156445|NCT00427245|DRUG|cyclophosphamide|
48156446|NCT00427245|DRUG|goserelin acetate|
48156447|NCT00427245|PROCEDURE|adjuvant therapy|
48156448|NCT00427245|PROCEDURE|fertility assessment and management|
48156449|NCT00427245|PROCEDURE|neoadjuvant therapy|
48156450|NCT04547504|DRUG|Pembrolizumab|Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
48366316|NCT00816543|DRUG|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
48366317|NCT00816543|DRUG|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
48366318|NCT00816543|DRUG|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
48512404|NCT03352466|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
48512405|NCT03352466|BIOLOGICAL|BioThrax|Commercially available anthrax vaccine
48156451|NCT04547504|DRUG|Pembrolizumab and Chemotherapy drugs|"An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop."
47998159|NCT05735301|PROCEDURE|Endovascular|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA"
48156452|NCT00689520|DRUG|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
48156453|NCT00689520|DRUG|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
48156454|NCT02247141|BIOLOGICAL|Subgam® (Human Normal Immunoglobulin Solution)|
48156455|NCT04549948|PROCEDURE|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
48156456|NCT04549948|PROCEDURE|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
47998160|NCT05735301|DRUG|Drug|best drug conservative therapy could be uesd in patients who with no indication of surgery
47998161|NCT05769959|DRUG|RO7515629|RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
47998162|NCT05769959|DRUG|tocilizumab|Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
48156457|NCT04549948|PROCEDURE|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
48366319|NCT02274987|OTHER|Specialized tumor board recommendation|A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
48366320|NCT02274987|RADIATION|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
47998163|NCT01527188|BIOLOGICAL|100IR|100IR sublingual tablet of
47998164|NCT01527188|BIOLOGICAL|300IR|300IR sublingual tablets of
48366321|NCT00723489|BIOLOGICAL|Live Yellow Fever Vaccine (YFV-17D)|
48366322|NCT00723489|DRUG|YFV-17D Placebo|
48366323|NCT05069623|BIOLOGICAL|VB10.2129|0.3 mg, 1 mg or 3 mg on Day 0 and Day 21 or 3 mg on Day 0
47998165|NCT01527188|BIOLOGICAL|500IR|500IR sublingual tablet of
48366324|NCT05069623|BIOLOGICAL|VB10.2210|3 doses (dose to be determined) on Day 0 and Day 21 or highest dose (TBD) on Day 0
48366325|NCT04600115|DRUG|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
48366326|NCT04600115|DRUG|Regadenoson|0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
48366327|NCT04600115|DRUG|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
48366328|NCT04600115|DEVICE|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
48366329|NCT04600115|DEVICE|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day
48366330|NCT04715867|DRUG|Rabix-VC|Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
48512406|NCT03352466|OTHER|Placebo|Normal saline
48512407|NCT05574608|BIOLOGICAL|CD123-CAR-NK cells|CD123-CAR-NK is an allogenic CD123-Targeted chimeric antigen receptor NK-cell (CAR-NK) therapy.
47914334|NCT06390306|DRUG|Ponatinib|CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.
47998166|NCT01527188|OTHER|Placebo|Placebo sublingual tablet of
47998167|NCT04152889|DRUG|Camrelizumab|Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
47998168|NCT04152889|DRUG|S-1|Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
48156458|NCT00004662|DRUG|dehydroepiandrosterone|
48156459|NCT00977340|BEHAVIORAL|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
48156460|NCT00977340|BEHAVIORAL|confrontation|Confrontation
48156461|NCT00977340|BEHAVIORAL|imagination|Imagination
48366331|NCT01028131|BEHAVIORAL|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
48512408|NCT05575609|OTHER|children with Diabetes Mellitus, Type 1|assessment of Relation between anthropometric measurements and balance in children with type 1 diabetes
48512409|NCT00061932|DRUG|bortezomib|Given IV
48512410|NCT00061932|DRUG|irinotecan|Given IV
48156462|NCT06502678|BIOLOGICAL|Fcr blocker of autoantibodies|in vitro assays, combined with multi-omics approach and in vitro experimental models, will gain insights into the pathogenesis of Systemic Sclerosis (SSc)dissecting the consequences of treatment with Fcblocker on functional and phenotypic cell behavior. Healthy microvascular endothelial cells, fibroblasts and monocytes will be challenged with serum and autoantibodies prior to or upon treatment with Efgartigimod in order to assess both the prevention and the recovery capacity of the FcR blocker. The putative modulatory effect of Efgartigimod on vascular remodeling, endothelial-to-mesenchymal transition, fibroblast-to-myofibroblasts transition and monocyte behavior will be evaluated in in-vitro consolidated assays. Integrated Omics analyses will support and complement the in vitro findings by unveiling potential prognostic signatures and by identifying specific treatment-related profiles that might guide the modulation of the drug usage in order to maximize its beneficial effect
48156463|NCT03761849|DRUG|RO7234292|Intrathecal injection
48156464|NCT03761849|DRUG|Placebo|Intrathecal injection
48156465|NCT06475092|OTHER|Tanita device|bioelectric impedance analysis
48156466|NCT00062270|DRUG|cisplatin|
48156467|NCT00062270|DRUG|docetaxel|
48156468|NCT00062270|DRUG|gefitinib|
48156469|NCT00062270|DRUG|gemcitabine hydrochloride|
48156470|NCT00062270|PROCEDURE|conventional surgery|
48156471|NCT00062270|PROCEDURE|neoadjuvant therapy|
48156472|NCT00062270|RADIATION|radiation therapy|
48156473|NCT06168994|DRUG|Eplerenone|Amiodarone vs eplerenone in AF
48156474|NCT00525200|DRUG|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
48156475|NCT00525200|DRUG|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
48156476|NCT06468618|BEHAVIORAL|DREAMS Program Video and Care Kit|A pediatric, circadian health program comprised of an introductory video to sleep experiences for stem cell transplant recipients, strategies to improve sleep, and a Sleep and Circadian Care Kit which includes ear plugs, a white noise machine, an eye mask, a lightbox, and kit instructions. Actigraph, Fitbit, and tablet will be provided to participant and family.
48156477|NCT02843698|DRUG|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
48156478|NCT02843698|DRUG|Normal saline|Normal saline
48156479|NCT02626689|OTHER|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
48366332|NCT01028131|BEHAVIORAL|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
48512411|NCT00394563|DRUG|RN624 (PF-04383119)|10 mcg/kg
48512412|NCT00394563|DRUG|RN624 (PF-04383119)|25 mcg/kg
48512413|NCT00394563|DRUG|RN624 (PF-04383119)|50 mcg/kg
48512414|NCT00394563|DRUG|RN624 (PF-04383119)|100 mcg/kg
48512415|NCT00394563|DRUG|RN624 (PF-04383119)|200 mcg/kg
48512416|NCT00394563|DRUG|placebo|
48512417|NCT02171780|DRUG|BI 1744 CL|
47998169|NCT04152889|DRUG|Docetaxel|Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
47998170|NCT00592566|DRUG|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
48512418|NCT02171780|DRUG|Placebo|
48512419|NCT01670617|OTHER|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
47998171|NCT05463185|OTHER|Stretching exercises|Stretching exercises along with manual lymphatic drainage
47998172|NCT05463185|OTHER|Soft tissue mobilization|Soft tissue mobilization along with manual lymphatic drainage
47998173|NCT03357692|PROCEDURE|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
47998174|NCT05606042|DEVICE|IM Implant|Patients that have had surgical interventions with one or more IM Implant as part of standard of care for a pelvic and/or acetabular fracture
47998175|NCT03759561|PROCEDURE|intubation with videolaryngoscope vs fiberoptic bronchoscope|Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
47998176|NCT06133231|DIETARY_SUPPLEMENT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Participants will take 2-3 capsules of EMP+ two to three times per day for eight weeks.
48156480|NCT02626689|OTHER|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
48156481|NCT00553800|DRUG|bevacizumab|
48156482|NCT00553800|DRUG|Erlotinib|
48156483|NCT01272388|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
48512420|NCT05102747|RADIATION|Hypofractionated SRT (stereotactic radiotherapy)|3\*10Gy over 1 week
48512421|NCT05102747|RADIATION|Historical single-dose SRS (stereotactic radiosurgery)|20 to 25Gy/1 fraction
48512422|NCT02551484|DEVICE|Measurements using NIRS|
48512423|NCT02551484|DEVICE|TCPO2 measurements|
48512424|NCT02551484|OTHER|2-minute walk test|
48512425|NCT03191591|BEHAVIORAL|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
48156484|NCT01272388|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
48156485|NCT01982266|DEVICE|GRADION™ Hip Total Cartilage Replacement (TCR)™|
48156486|NCT03887715|DEVICE|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
48156487|NCT00197262|DRUG|GW685698X Aqueous Nasal Spray|
48156488|NCT03841227|DEVICE|Active-tDCS|Active home-based tDCS applied at home. 5 days a week for 4 weeks.
48156489|NCT03841227|DEVICE|Sham-tDCS|Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
48366333|NCT04162145|DEVICE|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
48512426|NCT05770895|BIOLOGICAL|GS-2829|Administered intramuscularly
48512427|NCT05770895|BIOLOGICAL|GS-6779|Administered intramuscularly
48512428|NCT05770895|BIOLOGICAL|Placebo for GS-2829|Administered intramuscularly
48512429|NCT05770895|BIOLOGICAL|Placebo for GS-6779|Administered intramuscularly
48512430|NCT00233402|DRUG|Hexvix|Single Instillation, Transurethral Resection of the Bladder
47998177|NCT03464006|OTHER|Online Support Module|The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease
47998178|NCT03464006|OTHER|Standard of Care|The normal care that patients receive at the institution.
47998179|NCT05138679|PROCEDURE|Revascularization|Endovascular or surgical restoration of arterial blood flow.
47998180|NCT05138679|PROCEDURE|Primary major amputation|Primary below- or above knee major amputation without prior revascularization.
47998181|NCT05138679|OTHER|Best medical treatment|Conservative treatment of acute lower limb ischemia - without prior revascularization.
47998182|NCT03905785|BEHAVIORAL|Samarthan|Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
47998183|NCT02758392|DRUG|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
47998184|NCT02758392|DRUG|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
47998185|NCT02758392|DRUG|Placebo|Participants will receive placebo on Day 1.
47998186|NCT01120613|DRUG|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~1. ACE or ARB~2. Calcium Channel Blockers~3. Alpha Blocker~4. Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
47998187|NCT00177970|DRUG|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
47998188|NCT00177970|DRUG|Placebo|Placebo to be given IV to patients with C-Diff
47998189|NCT01169506|DEVICE|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
47998190|NCT05682131|DRUG|Realgar Indigo naturalis formula|Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk
47998191|NCT05682131|COMBINATION_PRODUCT|Conventional chemotherapy|conventional chemotherapy
48156490|NCT03556345|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
48156491|NCT01964118|OTHER|Intermittent Fasting group|Intermittent fasting for 12 months
48156492|NCT01964118|OTHER|control group|usual diet for 6 months and intermittent fasting for other 6 months
48156493|NCT06045221|DRUG|Orforglipron|Administered orally
48156494|NCT06045221|DRUG|Semaglutide|Administered orally
48156495|NCT04478799|DEVICE|Transcutanous Posterior Tibial Nerve Stimulation|children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months
48512431|NCT00233402|PROCEDURE|Standard white light cystoscopy|
48512432|NCT04215146|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
48512433|NCT04215146|BIOLOGICAL|Pelareorep|Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.
48512434|NCT04215146|DRUG|Avelumab|Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
48512435|NCT04887155|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
48512436|NCT01711515|DRUG|Cisplatin|Given IV
48512437|NCT01711515|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
48156496|NCT04478799|DEVICE|Sham Transcutanous Posterior Tibial Nerve Stimulation|Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.
48156497|NCT00070707|DRUG|Mometasone|Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
48156498|NCT00070707|DRUG|Placebo|Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
48156499|NCT00070707|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
48156500|NCT06048471|OTHER|HiTop|High tone transcutaneous electrical stimulation
48156501|NCT01562288|GENETIC|DNA analysis|
48156502|NCT01562288|GENETIC|gene expression analysis|
47998192|NCT04720729|BIOLOGICAL|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 \& L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (\> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
48683738|NCT03387709|BEHAVIORAL|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
48683739|NCT03387709|BEHAVIORAL|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
47998193|NCT05098145|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
47998194|NCT06361628|BEHAVIORAL|multicomponent intervention on vaccination awareness|Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.
47998195|NCT03858491|DRUG|Cobicistat|Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
47998196|NCT01525147|BIOLOGICAL|YHB1411-2: Level 2|IV infusion
47998197|NCT01525147|BIOLOGICAL|YHB1411-2: Level 3|IV infusion
48156503|NCT01562288|GENETIC|polymerase chain reaction|
48156504|NCT01562288|OTHER|enzyme-linked immunosorbent assay|
48156505|NCT01562288|OTHER|laboratory biomarker analysis|
48156506|NCT03188549|OTHER|AniosGel 85 NPC|Hand hygiene formula
48156507|NCT03188549|OTHER|Softa-Man (Braun)|Hand hygiene formula
48156508|NCT03188549|OTHER|Septol|alcohol-based hand rub
48156509|NCT01436045|DRUG|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
48156510|NCT01436045|DRUG|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
48156511|NCT03944499|DRUG|FS-1502|"Dose-Escalation Phase (Phase 1a)： FS-1502 dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle in the V1.2 and V2.0 regimens; IV, once per 21 days, 21 days as a cycle in the V3.0 regimens..~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg. If 1.3mg/kg is still tolerated safely and in line with linear kinetic characteristics, and combined with the results of PK, PD, safety and effectiveness, a comprehensive assessment is made to determine whether to continue the dose escalating. The subsequent dose increase ratio is 33% (the dose increase ratio can be adjusted according to the previous data results) until MTD or RP2D.~Dose-expansion Phase (Phase 1b) : RP2D determined in phase 1a, IV."
48512438|NCT01711515|RADIATION|Internal Radiation Therapy|Undergo intracavitary brachytherapy
48512439|NCT01711515|BIOLOGICAL|Ipilimumab|Given IV
48512440|NCT01711515|OTHER|Laboratory Biomarker Analysis|Correlative studies
48512441|NCT05516979|DRUG|100 mg AP1189|AP1189 tablets for oral use
48683740|NCT01060904|DRUG|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
47998198|NCT01525147|BIOLOGICAL|YHB1411-2: Level 4|IV infusion
47998199|NCT01525147|BIOLOGICAL|YHB1411-2: Level 5|IV infusion
47998200|NCT01525147|BIOLOGICAL|Placebo|IV infusion
47998201|NCT01525147|BIOLOGICAL|YHB1411-2: level 1|IV infusion
48512442|NCT05516979|DRUG|Placebo|Matching placebo for oral use
48512443|NCT00269984|DRUG|Epoetin alfa|
48683741|NCT01060904|DRUG|doxorubicin|25 mg/m2 IV every 2 weeks
48683742|NCT01060904|DRUG|vinblastine|6 mg/m2 IV every 2 weeks
48156512|NCT05621720|OTHER|Case management|On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance \& counseling, treatments \& procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
48156513|NCT05621720|OTHER|Social control call and usual are|Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
48156514|NCT06073665|DRUG|Levothyroxine Sodium|Levothyroxine dose will depend on dose at baseline and randomization group
48156515|NCT05989243|DEVICE|Conventional prosthetic socket|Participants will use their own conventional rigid socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
48156516|NCT05989243|DEVICE|Adjustable Quatro socket|Participants will use an adjustable Quatro socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
48156517|NCT04596358|OTHER|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
48156518|NCT05741866|DEVICE|Chlorhexidine gluconate impregnated bordered polyurethane dressing|"PIVCs will be dressed and secured at the participating sites~* RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~* QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
48156519|NCT05741866|DEVICE|Standard bordered polyurethane dressing|"PIVCs will be dressed and secured as per standard practice at the participating sites~* RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~* QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
48156520|NCT03015428|OTHER|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
48156521|NCT04731506|BEHAVIORAL|Family Connections|The program starts with 2 small group support sessions spaced one week apart that guides participants through developing an action plan; followed by 10 IVR calls (5-10 minutes) beginning with weekly (4), biweekly (4), and monthly (2) calls. During each IVR call parents provide information on current physical activities, and food consumption that is used to provide feedback on success in subsequent IVR calls.
48156522|NCT06644235|OTHER|Cold Application|Before DFU care, the patient was given an appropriate position and the materials (forceps, scalpel, sponge, pad, bandage, etc.) and the temperature of the 0.9% NaCl solution kept in the refrigerator for 24 hours were measured with an infrared thermometer (+4°C to +8°C) and taken to the treatment area. The solution was transferred to a 50 mL syringe in a sterile manner. The solution was instilled into the wound simultaneously with wound care (5-15 min).
48156523|NCT05981586|OTHER|Plyometric strengthening exercises|Comparative effects 1
48156524|NCT05981586|OTHER|Isotonic strengthening exercises|Comparative effects 2
48156525|NCT02018159|DRUG|menotropin|
48156526|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic extension exercises|"Thoracic Extension Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic spine extension and trunk muscle flexibility. A specialized program of thoracic extension in sitting, in prone lying, in quadruped position, on foam roller, wall angle stretch, corner stretch + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks.~Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week."
48366334|NCT04162145|DEVICE|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
48512444|NCT02445963|BIOLOGICAL|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
48512445|NCT05054257|DRUG|Autologous CAR19 T lymphocytes|First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
48366335|NCT01130831|DRUG|Lanthanum carbonate|
48512446|NCT02781038|BEHAVIORAL|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
48512447|NCT02781038|BEHAVIORAL|Control|Subjects in this group will not receive the pamphlet
48512448|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
48683743|NCT01060904|DRUG|dacarbazine|375 mg/m2 IV every 2 weeks
48156527|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic stabilization exercises|Thoracic Stabilization Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic musculature, static and dynamic thoracic posture. A specialized program of Draw- in and chin tucks in crook lying, prone, sitting and standing, prone chin- tuck elevation exercises with arm at sides, arms behind head or overhead (4) + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week.
48156528|NCT03110640|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
48366336|NCT04784559|DRUG|Plitidepsin|"Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes."
48683744|NCT01060904|DRUG|bleomycin|10 units/m2 IV every 2 weeks
48683745|NCT01060904|DRUG|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
48683746|NCT01423695|DRUG|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
48683747|NCT01759342|BEHAVIORAL|Aerobic exercise|
47998202|NCT02881645|BEHAVIORAL|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
48683748|NCT01759342|BEHAVIORAL|Resistance exercise|
47998203|NCT02857777|DRUG|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
47998204|NCT06182644|DIAGNOSTIC_TEST|FAPI PET/CT|The same group of patients underwent FAPI PET/CT and FDG PET/CT examinations respectively
47998205|NCT04721912|DRUG|Probiotic dietary supplement|GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
47998206|NCT03666923|DRUG|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
47998207|NCT03666923|DRUG|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
47998208|NCT03666923|DRUG|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
47998209|NCT03666078|PROCEDURE|cesarean delivery|women delivered by cesarean section
47998210|NCT02038595|RADIATION|PET imaging|
47998211|NCT03215329|PROCEDURE|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
47998212|NCT00046735|DRUG|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
47998213|NCT04944901|DRUG|SB-121|SB-121 is a formulation of L. reuteri
47998214|NCT04944901|DRUG|Placebo|Placebo oral formulation
47998215|NCT00277069|DRUG|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
47998216|NCT00277069|DEVICE|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
47998217|NCT00277069|DRUG|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
47998218|NCT05739851|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
47998219|NCT05739851|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
47998220|NCT01878539|DEVICE|coagulometer|
47998221|NCT01878539|BEHAVIORAL|training programme|
47998222|NCT05509699|DRUG|Surufatinib|The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.
47998223|NCT05509699|DRUG|Anti-PD-1/L1|Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.
47998224|NCT06539117|OTHER|Early feeding post caesarean section|In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
47998225|NCT06202781|DRUG|SOX plus PD-1 inhibitor|S-1, Oxaliplatin and nivolumab/sintilimab
47998226|NCT06202781|PROCEDURE|Gastroscopic biopsy|Gastroscopy and biopsy
47998227|NCT04384965|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single iTBS treatment, delivering 600 pulses of iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~3 minutes) at a target of 110% of the subject's resting MT.
47998228|NCT05400928|DEVICE|Pulsed Field Ablation|pulmonary vein isolation will be performed with ring-shaped pulsed field ablation catheter directed by integrated three-dimensional mapping system
47998229|NCT03897400|OTHER|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
47998230|NCT03873987|DRUG|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
48156529|NCT03110640|DRUG|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
48156530|NCT03110640|DRUG|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
48156531|NCT06540846|OTHER|No intervention|No intervention since this is an observational study
48156532|NCT06372756|DIAGNOSTIC_TEST|Deep learning image reconstruction|Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.
48156533|NCT00330135|DRUG|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
48156534|NCT00330135|DRUG|placebo injection|placebo injection - 1 injection
48156535|NCT06301529|DRUG|Invokana Pill|100 mg and 150 mg doses, taken every day and every-other day, respectively.
48156536|NCT02001207|OTHER|Salivary cortisol test|
48156537|NCT04810104|DRUG|AZD0328|Active study drug
48156538|NCT04810104|DRUG|Placebo|Non-active study drug
48156539|NCT04601883|DRUG|Colchicine 0.5 MG|"The intervention tablets are commercially available Colchicine Tiofarma"
48156540|NCT04601883|DRUG|Placebo|Encapsulated placebo tablets. Placebo is identical to the active intervention.
48156541|NCT06225050|DEVICE|CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
48156542|NCT01770509|DEVICE|NMBM|Daily application of NMBM in addition to compression therapy
48156543|NCT01770509|OTHER|Compression garments|Compression garments
48156544|NCT03460444|DIETARY_SUPPLEMENT|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
48156545|NCT03612999|DEVICE|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
48512449|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
48683749|NCT01759342|BEHAVIORAL|Flexibility and postural exercise|
48683750|NCT01759342|BEHAVIORAL|Balance exercise|
47998231|NCT03873987|DRUG|Kimyrsa|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
47998232|NCT01498952|DRUG|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
47998233|NCT01498952|DRUG|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
48156546|NCT03612999|DEVICE|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
48156547|NCT03612999|BEHAVIORAL|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
48156548|NCT03612999|BEHAVIORAL|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
48683751|NCT04194892|BIOLOGICAL|Pegilodecakin|Administered SQ
48683752|NCT00771927|DRUG|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
48683753|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
48683754|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
47998234|NCT00002137|DRUG|Tecogalan sodium|
47998235|NCT05464654|DRUG|3 g Polynucleotide vaginal suppositories|3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
47998236|NCT05464654|DRUG|Conjugated estrogens cream 1g Tube|Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
47998237|NCT04029714|PROCEDURE|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
48156549|NCT03441152|DEVICE|tDCS|Transcranial direct current stimulation
48156550|NCT01608919|OTHER|blood tests|thromboelastogram platelet mapping
48156551|NCT02987088|DRUG|Sodium Nitrite|
48156552|NCT00690950|DRUG|Dutasteride|0.5mg capsule, taken once daily for 12 months
48156553|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
48156554|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
48156555|NCT00464737|OTHER|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
48156556|NCT01765439|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
48156557|NCT02325752|OTHER|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~1. Post discharge surveillance of the patient to ensure adherence to care plans.~2. Coordination of follow-up visits with specialist care providers.~3. Patent education and care giver training.~4. Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
48156558|NCT03456206|OTHER|Intake of red and processed meat and fibres|The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of red and processed meat (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
48512450|NCT01733810|OTHER|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
48156559|NCT03456206|OTHER|Lifestyle factors independently or combined|Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
48156560|NCT06646900|BEHAVIORAL|Culturally adapted CBT (CaCBT) based guided self-help manual|The intervention consists of seven modules including cognitive restructuring, problem solving, behavioural activation and conflict management. Three additional modules focus on interpersonal relationships, mental health wellbeing and self-care. Each module is delivered over one week. The intervention uses culturally appropriate stories, drawings, examples from local folklore and religious context to describe the concepts of CBT.
48156561|NCT06646900|BEHAVIORAL|Standard CBT Manual|The standard CBT manual will follow conventional CBT techniques without specific cultural adaptations
48156562|NCT01189136|DEVICE|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
48366337|NCT04784559|DRUG|Dexamethasone|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
48366338|NCT04784559|DRUG|Remdesivir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
48683755|NCT02676895|BIOLOGICAL|Menveo|One injection of Menveo was administered in subjects in the Control Group.
48683756|NCT02676895|BIOLOGICAL|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
48683757|NCT05317650|OTHER|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
48683758|NCT04875468|OTHER|TheraCem self-adhesive resin cement|MDP, calcium and fluoride releasing cement for dental zirconia crowns
48683759|NCT04875468|OTHER|Multilink adhesive resin cement|(non MDP, non-calcium and fluoride releasing cement)
48683760|NCT05449041|DEVICE|Bulbicam|Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
48683761|NCT03822637|DRUG|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
48683762|NCT03822637|DRUG|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
48683763|NCT00408265|BEHAVIORAL|Contingency Management|
48683764|NCT02465476|PROCEDURE|telemedicine|treatment pathway organized by telemedicine
48683765|NCT03287193|BIOLOGICAL|Blood sample|for patient and its parents
48683766|NCT03287193|GENETIC|high-throughput sequencing|exome or whole genome sequencing
48683767|NCT01469481|DRUG|PF-04991532|a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
48683768|NCT04114071|BEHAVIORAL|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
48683769|NCT00298298|BIOLOGICAL|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
48683770|NCT01869634|DRUG|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
48683771|NCT00002811|DRUG|liposomal T4N5 lotion|
48366339|NCT04784559|DRUG|Favipiravir|Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
48366340|NCT01361724|BEHAVIORAL|Physical therapy|Physical therapy program for people with PD--one on one with a PT
48366341|NCT01361724|BEHAVIORAL|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
48683772|NCT03842774|DIETARY_SUPPLEMENT|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
48683773|NCT03842774|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be given to the test group.
48683774|NCT01282385|DRUG|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
48683775|NCT01282385|DRUG|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
48683776|NCT00318240|DEVICE|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
48683777|NCT05895305|COMBINATION_PRODUCT|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
48683778|NCT05897073|BEHAVIORAL|Time-restricted eating intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
48683779|NCT05897073|BEHAVIORAL|Exercise intervention|The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
47998238|NCT02612428|BIOLOGICAL|ELAD System|An extracorporeal human hepatic cell-based liver treatment
48156563|NCT01189136|OTHER|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
48156564|NCT00768911|DRUG|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
48683780|NCT05897073|BEHAVIORAL|Time-restricted eating plus exercise intervention|Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window. The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). This intervention has already been tested previously in our lab. Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program consisting of increasing 15% daily steps per week.
48683781|NCT06261008|BEHAVIORAL|TI group|CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
48683782|NCT02069977|DRUG|Aripiprazole|
48683783|NCT05792007|PROCEDURE|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
48683784|NCT05792007|PROCEDURE|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
48683785|NCT01063348|DRUG|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
48683786|NCT01063348|DRUG|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
48683787|NCT05892991|OTHER|interferential current|this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
47998239|NCT02612428|OTHER|Standard of Care (Control)|Standard medical treatment as defined by the protocol
47998240|NCT04274647|DEVICE|NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
48156565|NCT00768911|DRUG|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
48156566|NCT00768911|PROCEDURE|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
48156567|NCT02579941|PROCEDURE|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
48683788|NCT02542059|RADIATION|68Ga-exendin PET/CT|68Ga-exendin PET/CT
48683789|NCT01218217|DRUG|SQ109|SQ109 150 mg tablet
47998241|NCT00100243|DRUG|Plenaxis|
47998242|NCT03179150|DIAGNOSTIC_TEST|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
47998243|NCT02154555|PROCEDURE|debridement|post-operative debridement at 1 week follow-up visit
47998244|NCT02679859|OTHER|BNP guided medical therapy optimisation|
47914335|NCT06390306|DRUG|Azacitidine|CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.
47998245|NCT00258453|OTHER|metabolic assessment|
47998246|NCT00258453|OTHER|physiologic testing|
47998247|NCT00258453|PROCEDURE|biopsy|
47998248|NCT00258453|PROCEDURE|computed tomography|
47998249|NCT00258453|PROCEDURE|conventional surgery|
47998250|NCT00258453|PROCEDURE|magnetic resonance imaging|
47998251|NCT00258453|PROCEDURE|management of therapy complications|
48156568|NCT02579941|PROCEDURE|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
48156569|NCT04264416|DEVICE|WB-EMS|16 weeks of WB-EMS
48366342|NCT01361724|BEHAVIORAL|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
48366343|NCT02176122|DRUG|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
48366344|NCT02176122|DRUG|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
48512451|NCT03564938|DRUG|Regorafenib (Stivarga, BAY73-4506)|The recommended dose of regorafenib is 160 mg (consisting of 4 tablets, each containing 40 mg of regorafenib) for 3 weeks of every 4 week cycle, (ie. 3 weeks on therapy, 1 week off therapy).
47998252|NCT00258453|PROCEDURE|psychosocial assessment and care|
47998253|NCT00258453|PROCEDURE|quality-of-life assessment|
47998254|NCT00258453|RADIATION|radiation therapy|
47998255|NCT03934528|DEVICE|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
47998256|NCT05235334|DEVICE|MySOLIUS|MySOLIUS is a portable light therapy device that is designed to deliver a small amount of targeted ultraviolet B (UVB) light to trigger the body's natural production of vitamin D.
47998257|NCT02853240|PROCEDURE|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
47998258|NCT01347541|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
47998259|NCT01347541|BEHAVIORAL|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
48156570|NCT01463397|DRUG|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
48512452|NCT03104478|PROCEDURE|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
48683790|NCT01218217|DRUG|Rifampicin|Rifampicin 150 mg capsules
48683791|NCT02501681|OTHER|priming solution during cardiovascular surgery|
48683792|NCT05424965|OTHER|no intervention|no intervention
48683793|NCT04766320|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
48683794|NCT00486356|DRUG|capecitabine|
48683795|NCT00486356|DRUG|carboplatin|
48683796|NCT00486356|DRUG|epirubicin hydrochloride|
48683797|NCT00486356|GENETIC|microarray analysis|
48683798|NCT00486356|GENETIC|polymorphism analysis|
48683799|NCT00486356|OTHER|pharmacological study|
48683800|NCT05634824|DRUG|intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)|rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.
48683801|NCT05634824|DRUG|intravenous immunoglobulin|intravenous immunoglobulin
48683802|NCT01815424|DRUG|placebo|placebo BID for 16 weeks and then re-randomized into active groups
48683803|NCT01815424|DRUG|CP-690,550|CP-690,550 5mg BID for 52 weeks
48683804|NCT01815424|DRUG|CP-690,550|CP-690,550 10mg BID for 52 weeks
48683805|NCT02148263|DEVICE|senofilcon A|
48683806|NCT01464645|DEVICE|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
48683807|NCT00293930|DRUG|Tacrolimus|
48156571|NCT01463397|DRUG|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
48683808|NCT02442505|DEVICE|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
48683809|NCT01196897|DEVICE|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
48683810|NCT00778167|BIOLOGICAL|cixutumumab|Given IV
48683811|NCT00778167|DRUG|erlotinib hydrochloride|Given PO
48683812|NCT00778167|OTHER|laboratory biomarker analysis|Correlative studies
48156572|NCT04218708|OTHER|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
48366345|NCT01372020|OTHER|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
48366346|NCT02089165|DIETARY_SUPPLEMENT|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
48366347|NCT02089165|DIETARY_SUPPLEMENT|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
48366348|NCT02089165|DIETARY_SUPPLEMENT|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
48366349|NCT02576951|DRUG|Galcanezumab|Administered SC
48366350|NCT02576951|DRUG|Placebo|Administered SC
48366351|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
48366352|NCT03525613|DRUG|APL-2|Complement (C3) Inhibitor
48366353|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
48512453|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with complete internal limiting membrane peeling and SF6 tamponade|Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining and sulfur hexafluoride (SF6) tamponade
48512454|NCT04698226|PROCEDURE|25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade|"Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. Flower petal type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole."
48512455|NCT01644617|DRUG|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
48512456|NCT01644617|DRUG|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
48366354|NCT03525613|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
48512457|NCT01644617|DRUG|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
47998260|NCT01347541|DRUG|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
47998261|NCT01347541|BEHAVIORAL|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
48156573|NCT04218708|BEHAVIORAL|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
48366355|NCT05512273|PROCEDURE|Piezosurgery assisted osteotomy|Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
48366356|NCT05512273|PROCEDURE|Conventional drilling osteotomy|bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
48366357|NCT02412241|OTHER|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
48366358|NCT02412241|PROCEDURE|Technical measure|Undergo standard CT scan
48366359|NCT02412241|PROCEDURE|Technical measure|Undergo standard ultrasound
48366360|NCT01334008|BIOLOGICAL|Blood sampling|30ml of patient peripherical blood will be collected
48366361|NCT02198911|OTHER|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
48366362|NCT02198911|OTHER|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
48512458|NCT05446584|DEVICE|High Definition Transcranial Direct Current Stimulation|HD-tDCS for this study is not intended to be a treatment, and will be applied continuously for 30 minutes at sham (0 mA) or 2 mA for active conditions across 3 consecutive daily sessions to probe neural circuit integrity. This specific HD-tDCS device is completely computer driven, running on a laptop using specialized software. Circular electrodes (12-mm in diameter) filled with conductive gel will be placed in a 4x1 ring configuration with the central electrode being the anode surrounded by four cathodes.
48512459|NCT01998841|DRUG|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
48512460|NCT01998841|DRUG|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
48512461|NCT02922738|OTHER|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
48512462|NCT02897245|OTHER|No intervention|
48512463|NCT01447043|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
48512464|NCT00426101|DRUG|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
48512465|NCT00426101|DRUG|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
48512466|NCT00426101|DRUG|Cyclosporin|"WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR."
48683813|NCT01290042|DRUG|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
48366363|NCT02198911|OTHER|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
48366364|NCT01425242|DRUG|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
48512467|NCT00426101|PROCEDURE|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: \<1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, \>3 yrs 12 mg. Prednisolone: \<1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, \>3 yrs 10 mg."
48683814|NCT01290042|OTHER|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
47998262|NCT04566315|PROCEDURE|Arteriography knee arteriography|arteriography and an injection of inert microparticles of 75 μm in neovessels
48156574|NCT04218708|BEHAVIORAL|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
48512468|NCT00426101|PROCEDURE|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
47998263|NCT04384302|OTHER|Visual training|Pre-defined visual training protocol including the optometrical unit exercises
48156575|NCT04218708|BEHAVIORAL|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
48366365|NCT01425242|DRUG|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
48512469|NCT00031148|DRUG|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
47998264|NCT02270827|DRUG|Aminophylline|intravenous medication
47998265|NCT02270827|DRUG|Hydrocortisone|Intravenous medication
48512470|NCT06435442|DRUG|Epaminurad, Naproxen|Period 1: Epaminurad/ Period 2: Naproxen -\> Epaminurad+Naproxen
48512471|NCT06435442|DRUG|Epaminurad|Epaminurad
48512472|NCT06435442|DRUG|Epaminurad placebo|Epaminurad placebo
48512473|NCT00970593|DRUG|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
48512474|NCT00970593|DRUG|placebo comparator|Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
48683815|NCT02425787|BEHAVIORAL|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
47998266|NCT00846937|DIETARY_SUPPLEMENT|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
47998267|NCT01554618|DRUG|Exenatide Once Weekly|2 mg exenatide once weekly
47998268|NCT01554618|DRUG|Placebo|Placebo
47998269|NCT00718328|DRUG|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
48683816|NCT02425787|BEHAVIORAL|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~1. With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews \&/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~2. With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
48156576|NCT04218708|OTHER|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver \>300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
48156577|NCT03555708|OTHER|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
48156578|NCT02233504|DRUG|Exjade® (deferasirox, ICL670)|
48156579|NCT02518659|DIETARY_SUPPLEMENT|Inulin|This is the Intervention
47998270|NCT00718328|DRUG|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
47998271|NCT04553432|DEVICE|Amniotic membrane Omnigen[TM]|17mm circular disk of processed amniotic tissue donated by mother after birth with a 6mm laser cut aperture to allow unimpeded vision https://www.nu-vision.co.uk/omnigen
48156580|NCT00605384|DRUG|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
48156581|NCT00605384|DRUG|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
48156582|NCT05966623|OTHER|Video Remote Interpretation|To assess the effectiveness of the VRI system in improving communication outcomes between Deaf patients and doctors Produce a VRI model addressing the challenges faced by Deaf people that will be tested, implemented, and sustained in Bogota Colombia.
48156583|NCT06249594|PROCEDURE|targeted sensory reinervation|targeted sensory reinnervation (TSR) in hand amputation by using and reactivation of existing nerves to treat and prevent phantom pain
48156584|NCT05340426|DEVICE|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
48512475|NCT03791047|OTHER|Balance Analysis|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
48512476|NCT02658760|DRUG|Dexmedetomidine|dexmedetomidine plus placebo
48683817|NCT02425787|BEHAVIORAL|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
48683818|NCT02835703|PROCEDURE|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
48156585|NCT04100564|DEVICE|Supraglottic airway device|Initial advanced airway management with a supraglottic device
47998272|NCT04553432|DEVICE|Bandage soft Contact Lens OmniLenz[R]|18mm soft silicone-hydrogel contact lens https://www.nu-vision.co.uk/omnilenz
48156586|NCT04100564|OTHER|Standard airway management|Initial advanced airway management with standard care method
48156587|NCT00490243|DRUG|budesonide and montelukast|
48156588|NCT00490243|DRUG|budesonide and formoterol|
48156589|NCT00490243|DRUG|montelukast|
48366366|NCT00628680|DEVICE|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
48512477|NCT02658760|DRUG|Bupivacaine|dexmedetomidine and Bupivacaine
48512478|NCT01380600|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
47998273|NCT04646499|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) will be applied at 40 Hz (gamma band) during eight sessions over the course of a month.
47998274|NCT01758380|DRUG|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
47998275|NCT01758380|DRUG|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
48366367|NCT00628680|DRUG|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
47998276|NCT01758380|DRUG|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
48156590|NCT00490243|DRUG|budesonide|
48156591|NCT00490243|DRUG|placebo|
48512479|NCT05285904|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab, that have started before inclusion of the patient into the study will be enrolled.
48512480|NCT03861455|DRUG|Dupilumab|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
48512481|NCT03861455|DRUG|placebo|patient receive placebo
48156592|NCT02690025|DRUG|ZP1848|
48512482|NCT00600587|DRUG|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
48683819|NCT04900844|DEVICE|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
48683820|NCT01681667|DRUG|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
48683821|NCT00232323|BEHAVIORAL|simulation training|
48683822|NCT02343601|DEVICE|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
48156593|NCT05664061|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
48156594|NCT05664061|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
48366368|NCT02251782|DEVICE|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
48366369|NCT02251782|DEVICE|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
48366370|NCT00918905|DEVICE|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
48366371|NCT05644613|OTHER|aerobic exercise on land|aerobic exercise on land in form of walking on the treadmill
48366372|NCT05644613|OTHER|aerobic exercise in water|aerobic exercises in water in form of walking on the treadmill
48366373|NCT05782660|OTHER|Cash Benefit|Spending from the cards was not restricted to food but could be spent on anything and anywhere Visa was accepted. The debit cards were credited with the first payment on November 18th, 2020 and the second payment on December 18th, 2020. The program continued with monthly credits through August 2021.
48366374|NCT05782660|OTHER|No Cash Benefit|No monthly cash benefit.
48366375|NCT00100542|BEHAVIORAL|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
48512483|NCT00600587|DRUG|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
48512484|NCT00993421|DRUG|LY377604|Given daily, orally for 24 weeks
48156595|NCT05664061|DRUG|Placebo|twice daily inhalation throughout the treatment period
48156596|NCT05513222|PROCEDURE|flipped autograft|Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
48156597|NCT06633133|PROCEDURE|Virtual ileostomy|A pre-stage ileostomy, anchored under the abdominal wall by a vascular sling or rubber tape through the mesenteric window, is delivered to the outside of the abdomen, where the VI is pulled through the abdominal wall.
48156598|NCT04463888|OTHER|occupational therapy|occupational therapy targeted to goals that are relevant to the functional needs of the patient
48156599|NCT01596699|DRUG|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
48156600|NCT01596699|DRUG|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
48156601|NCT01596699|DRUG|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
48512485|NCT00993421|DRUG|Sibutramine|given daily, orally for 24 weeks
48512486|NCT00993421|DRUG|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
48156602|NCT01596699|DRUG|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
48156603|NCT05979987|BEHAVIORAL|Reminder of preventive care measures|"The investigators will send randomized participants an SMS reminder encouraging them to click the provided link and close their outstanding, overdue preventive care measures.~The provided link will take them to their MyChart login page; after logging in, they would see their personalized My Action Plan Letter detailing their personalized, overdue preventive care measures."
48156604|NCT05979987|BEHAVIORAL|Persuasion via anecdote|The message will contain an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message prompts patients to click on a link to read the story about the patient.
48512487|NCT00993421|DRUG|Placebo sibutramine|given daily, orally for 24 weeks
48512488|NCT00993421|DRUG|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
48512489|NCT00993421|DRUG|Placebo LY377604|given daily, orally for 24 weeks
48683823|NCT01816776|DEVICE|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
48156605|NCT05979987|BEHAVIORAL|Persuasion via anecdote without link|The message will contain a link to an anecdote of a patient whose cancer was caught early through similar, recommended preventive screenings. The message won't contain a link to the story, but it will briefly describe the story.
48156606|NCT05979987|BEHAVIORAL|Persuasion via research|This message will mention that research has shown promptly closing health gaps saves lives.The message will contain a link to an official website that supports the statement.
48156607|NCT06179719|DRUG|Propofol|Anesthesia will be induced intravenously using the hypnotic drug propofol. The drug is used regularly in everyday clinical practice to carry out general anesthesia, and the intended concentrations are within the usual clinical dosage range. Propofol will be applied via target-controlled infusion (TCI) with a perfusor using TCI set to effect mode as described by Schnider (Schnider et al., 2016). Starting at low concentrations, the effect site concentration will be increased stepwise to achieve the target level of sedation as measured by the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. We aim for three different levels of sedation: low (MOAA/S=5-4), mid (MOAA/S=3-2) and high (MOAA/S=1).
48156608|NCT06179719|BEHAVIORAL|visual flickering stimulation at the alpha frequency|Participants will receive visual stimulation as a flickering light during the different sedation levels, including wakefulness pre- and post-anesthesia. Stimulation will be done with eyes closed in all conditions.
48156609|NCT03934944|DEVICE|Phone application|Weekly foot alerts and educational video
48156610|NCT03934944|OTHER|Usual care|Usual routine of diabetic foot education
48156611|NCT03640754|BIOLOGICAL|G-CSF|G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
48156612|NCT03640754|OTHER|Placebo/Saline|Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
48156613|NCT00369239|DRUG|risperidone long acting injectable|
48156614|NCT04747717|PROCEDURE|chemotherapy/surgery|NEO chemotherapy/interval debulking surgery/AD chemotherapy
48156615|NCT04763863|OTHER|Body Assessment Tool|Assessment tool to evaluate stoma to find proper ostomy products
48156616|NCT04763863|OTHER|Clinical usability evaluation of the Body Assessment Tool|"The stoma care nurses evaluated the clinical usability of the Body Assessment Tool, which included answering the following questions:~Does the tool offer value in clinical practice? Does it provide a good starting point when choosing ostomy product(s)? Does it help raise the quality of care? Participants provided their responses on a 6 point-scale (1-6), where 1 indicated the lowest satisfaction and 6 the greatest satisfaction with the tool."
48156617|NCT04655014|OTHER|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
48156618|NCT04237987|DRUG|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
48156619|NCT04237987|DRUG|ciclosporin and corticosteroid|ciclosporin and corticosteroid
48156620|NCT06537063|OTHER|G4 DNAm test|Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.
48156621|NCT03380143|BEHAVIORAL|Wellness Landscape Intervention|Community and organization systems intervention targeting youth population physical activity
48366376|NCT03580707|DRUG|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
48366377|NCT03655951|BEHAVIORAL|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
48366378|NCT03655951|BEHAVIORAL|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
48683824|NCT01816776|DEVICE|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
48156622|NCT03380143|BEHAVIORAL|Standard Practice|Community development intervention
48366379|NCT01638546|OTHER|Laboratory Biomarker Analysis|Correlative studies
48156623|NCT03322449|OTHER|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
48156624|NCT03322449|OTHER|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
48156625|NCT02178878|GENETIC|Progress, Pain|Progress, Pain
48156626|NCT04528875|DEVICE|Ultrasound imaging|Imaging of low back with ultrasound
48156627|NCT01116830|DRUG|Placebo|Orally daily for 6 weeks
48156628|NCT01116830|DRUG|RO4917838|10 mg daily orally for 6 weeks
48156629|NCT01116830|DRUG|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
48156630|NCT03597997|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
48366380|NCT01638546|OTHER|Placebo|Given PO
48366381|NCT01638546|DRUG|Temozolomide|Given PO
48366382|NCT01638546|DRUG|Veliparib|Given PO
48366383|NCT01809028|PROCEDURE|EUS FNA with 2 passes|biopsy with 2 passes
48366384|NCT01809028|PROCEDURE|EUS FNA with 4 passes|biopsy with 4 passes
48683825|NCT00002395|DRUG|Topotecan|
48156631|NCT03597997|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
48683826|NCT05930847|DEVICE|Digital Game Application|The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
48156632|NCT00608387|BEHAVIORAL|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
48156633|NCT04436835|BEHAVIORAL|Psychotherapy|Undergo ART
48366385|NCT01988844|OTHER|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
48683827|NCT05930847|DRUG|Use of medication for asthma|The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
48683828|NCT04826263|OTHER|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
48683829|NCT04826263|OTHER|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
47998277|NCT01758380|DRUG|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
47998278|NCT01758380|DRUG|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
47998279|NCT02863133|DEVICE|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
47998280|NCT02073279|DRUG|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
47998281|NCT02073279|DRUG|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
47998282|NCT04848935|DEVICE|CURATE.AI|CURATE.AI will be utilised to provide personalised training intensity recommendations (low, medium or high) to the patients during the digital cognitive test battery DI session. The difficulty of each task will be modulated by CURATE.AI by adjusting the frequency of critical events that demand evaluation and/or response.
47998283|NCT05453942|DRUG|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
47998284|NCT05453942|DRUG|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
47998285|NCT01613781|OTHER|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
47998286|NCT01613781|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
47998287|NCT01213979|DRUG|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
47998288|NCT01213979|DRUG|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
47998289|NCT02459028|BEHAVIORAL|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
47998290|NCT02459028|BEHAVIORAL|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
48156634|NCT04436835|OTHER|Questionnaire Administration|Ancillary studies
48156635|NCT02351388|DEVICE|Transcranial Direct Current Stimulation|
48156636|NCT02351388|OTHER|Sham Stimulation|
48366386|NCT05336877|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
47998291|NCT05415696|PROCEDURE|Prostatic artery embolization|Patients will undergo PAE with 100-300 µm or 300-500 µm Embospheres following standard PAE technique performed by Interventional Radiology at Stanford University
48683830|NCT04826263|OTHER|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
48683831|NCT02779777|DRUG|Tipifarnib|Oral tablet
48683832|NCT01108328|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
48683833|NCT06231407|BEHAVIORAL|Recovery Oriented CBTp Medication Management|The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.
48683834|NCT06231407|BEHAVIORAL|Treatment as Usual|Residents will conduct medication management appointments as normally conducted
48683835|NCT02012855|BEHAVIORAL|Exercise|
48683836|NCT02012855|OTHER|Diet (meal type)|
48683837|NCT04713410|DRUG|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
48683838|NCT02678403|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
48683839|NCT02678403|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
48683840|NCT02981862|OTHER|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
48683841|NCT03220646|DRUG|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
48683842|NCT03220646|DRUG|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
48683843|NCT05323604|OTHER|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
48366387|NCT05336877|DEVICE|Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
48366388|NCT00374920|DRUG|MEM 1003|
48683844|NCT02540512|PROCEDURE|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
48683845|NCT02540512|DEVICE|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
48683846|NCT02540512|PROCEDURE|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
48683847|NCT02540512|DRUG|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
48683848|NCT02540512|DRUG|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
48683849|NCT01813695|PROCEDURE|Preemptive genotyping in medical record|
48366389|NCT02280382|DEVICE|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
48366390|NCT05396196|DEVICE|Kinesio® Tape|Manual Fascial Glide Application
48366391|NCT03438773|DRUG|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
48366392|NCT03438773|DRUG|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
47998292|NCT03803280|PROCEDURE|ERAS program|ERAS pathway according to the Spanish Via RICA
47998293|NCT04486846|OTHER|eVisit|electronic surveillance program in lieu of in-person clinic visit
48366393|NCT03547219|DRUG|Escitalopram|
48156637|NCT05988385|DEVICE|Positive airway pressure|Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.
48156638|NCT05988385|DEVICE|Oral appliance therapy|Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.
48156639|NCT05988385|DEVICE|Positional therapy|A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.
47998294|NCT02466555|BEHAVIORAL|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
48156640|NCT02295293|DRUG|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
48366394|NCT01820169|DEVICE|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
47998295|NCT02437955|OTHER|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
47998296|NCT02437955|OTHER|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
47998297|NCT02437955|OTHER|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
47998298|NCT02437955|OTHER|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
47998299|NCT02621814|DIETARY_SUPPLEMENT|Low glycation formula feeding|Formula feeding on demand for 3 months
47998300|NCT02621814|DIETARY_SUPPLEMENT|Commercially common formula feeding|Formula feeding on demand for 3 months
47998301|NCT05174910|DEVICE|Obsidian ASG|Application of an autologous platelet-rich fibrin matrix
48156641|NCT02295293|DRUG|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
48156642|NCT03998423|BIOLOGICAL|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
48156643|NCT03467594|BEHAVIORAL|High-intensity interval training|• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
48156644|NCT00669149|DRUG|clopidogrel + aspirin|
48156645|NCT00669149|DRUG|heparin + clopidogrel + aspirin|
48366395|NCT03811782|BEHAVIORAL|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
48366396|NCT03811782|BEHAVIORAL|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
48366397|NCT03811782|BEHAVIORAL|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
48156646|NCT00669149|DRUG|enoxaparin + clopidogrel + aspirin|
48156647|NCT00669149|DRUG|bivalirudin + clopidogrel + aspirin|
48156648|NCT01945593|BIOLOGICAL|BAX855|Antihemophilic Factor (Recombinant), PEGylated
48156649|NCT00676663|DRUG|entinostat|Entinostat 5 mg tablet orally once per week
48156650|NCT00676663|DRUG|exemestane|Exemestane 25 mg tablet orally once daily
48366398|NCT03351582|BEHAVIORAL|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
48156651|NCT00676663|DRUG|Placebo|Placebo-matching entinostat tablet orally once per week
48366399|NCT00204568|DRUG|Adriamycin|60 mg/m2, d1, W d22
48366400|NCT00204568|DRUG|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
48683850|NCT01813695|PROCEDURE|Genotyping not included in electronic medical record|
47998302|NCT04277754|OTHER|Observational|To Observe and describe motor and visual development
47998303|NCT00331175|DRUG|Peptide YY3-36|
47998304|NCT05698147|DRUG|Selinexor|"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
47998305|NCT05698147|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
47998306|NCT05698147|DRUG|Methotrexate|high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
47998307|NCT05215743|DRUG|Antioxidant therapy|Active therapy
47998308|NCT05215743|DRUG|NaCl 0.9%|Placebo
47998309|NCT01742338|DRUG|Low Dose Corticosteroids|
47998310|NCT01742338|DRUG|High Dose Corticosteroids|
47998311|NCT06308809|OTHER|PNF training|The subjects underwent rehabilitation training for 8 weeks, three times a week (Monday, Wednesday and Friday, 6:00 PM to 10:00 PM in the Physical Education College of Guangxi Normal University), and the rehabilitation training time was about 40-45 minutes per person. Before each rehabilitation training, the subjects warmed up the ankle and lower leg muscles for 5 minutes, followed by the corresponding rehabilitation training for 30-35 minutes, and relaxed the ankle and lower leg muscles for 5 minutes after the training.
47998312|NCT02670044|DRUG|Cobimetinib|Cobimetinib will be administered orally as per schedule in Arm description.
47998313|NCT02670044|DRUG|Idasanutlin|Idasanutlin will be administered orally as per schedule in Arm description.
47998314|NCT02670044|DRUG|Venetoclax|Venetoclax will be administered orally as per schedule in Arm description.
48683851|NCT00924677|PROCEDURE|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
47998315|NCT02474108|PROCEDURE|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
47998316|NCT02474108|DEVICE|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
47998317|NCT03087968|DRUG|GS-4997|Experimental drug
47998318|NCT03087968|DRUG|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
47998319|NCT03087968|DEVICE|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
47998320|NCT03087968|DRUG|Placebo|Placebo
47998321|NCT03167879|BEHAVIORAL|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
47998322|NCT02490722|OTHER|Patient education|Four times two hours group based patient education
47998323|NCT02071355|DRUG|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
47998324|NCT02071355|DRUG|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
47998325|NCT02361255|OTHER|no intervention|
47998326|NCT04027738|OTHER|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
47998327|NCT04980677|DEVICE|Tangiball|"To enable baseline scores comparison, children will be matched according to age and score on the four-strand Hands-On assessment tool which takes 30 minutes to complete. Children will then play with the Smart Toy during a 20 minute session. Sessions will be recorded using an SD card within the Smart Toy which captures information on user speed and accuracy of placement of the detachable segments of the toy when placed into the main hub of the toy, allowing comparison between neuro-typical children and children with Autism. The intervention will run either in clinic (preferred option) or in children's homes-and in this case will be sent to them via post with the Standard Operating Procedure which can then be employed when children are taking part in the intervention via online video link (not recorded)."
47998328|NCT04457609|DRUG|Oseltamivir|Current standardized treatment for Covid-19
47998329|NCT04457609|DRUG|Azithromycin|Current standardized treatment for Covid-19
47998330|NCT04457609|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
48156652|NCT02516371|OTHER|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
48683852|NCT00924677|PROCEDURE|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
47998331|NCT05512507|BEHAVIORAL|Physical Therapy Program|Physical Therapy Program
47998332|NCT00176553|DRUG|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
48683853|NCT02812238|DIETARY_SUPPLEMENT|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
48683854|NCT02812238|DRUG|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
47998333|NCT00885066|DRUG|capecitabine|
47998334|NCT00885066|DRUG|erlotinib hydrochloride|
47998335|NCT00885066|DRUG|gemcitabine hydrochloride|
47998336|NCT06055855|PROCEDURE|Traditional Two-Needle Arthrocentesis|Participants in this group will undergo arthrocentesis using the traditional two-needle technique. The procedure involves the placement of one or two needles into the temporomandibular joint (TMJ) to irrigate the joint space. Needle placement is guided by anatomical landmarks.
48366401|NCT02950428|DEVICE|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
48366402|NCT00573352|RADIATION|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
48683855|NCT00475553|OTHER|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
47998337|NCT06055855|PROCEDURE|Surgery-Guided Arthrocentesis|Participants in this group will receive arthrocentesis facilitated by a surgical guide. The guide is generated through pre-operative planning and is designed to aid in the accurate placement of the needle into the TMJ.
48683856|NCT00475553|OTHER|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
47914336|NCT06390306|DRUG|Venetoclax|CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.
47998338|NCT01478321|DRUG|Temozolomide|Given PO
48156653|NCT05450939|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
48156654|NCT05057767|DRUG|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
47998339|NCT01478321|RADIATION|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
48366403|NCT02109731|OTHER|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
47998340|NCT01478321|BIOLOGICAL|bevacizumab|Given IV
47998341|NCT01478321|OTHER|questionnaire administration|Ancillary studies
47998342|NCT03468907|DRUG|Telbivudine 600mg|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
47998343|NCT03468907|DRUG|Tenofovir disoproxil fumarate 300mg|Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
48366404|NCT02319798|OTHER|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
48683857|NCT03356353|DRUG|Sildenafil Citrate|20 mg tablets
48683858|NCT04178928|DRUG|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
48683859|NCT00510445|DRUG|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
48683860|NCT02456753|DEVICE|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
48683861|NCT04504344|DEVICE|Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)|We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
47998344|NCT00763165|DRUG|Triclosan|Brush twice daily
47998345|NCT00763165|DRUG|Fluoride|Brush twice daily
47998346|NCT00763165|DRUG|Fluoride|Brush twice daily
47998347|NCT02142127|DRUG|14C-labelled GFT505 120 mg|
47998348|NCT02799758|DRUG|NK-104-CR|NK-104-CR 8 mg for 52 weeks
47998349|NCT02799758|DRUG|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
48683862|NCT04711239|DIAGNOSTIC_TEST|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
48683863|NCT06377280|DEVICE|Navina Mini|CE-marked Navina Mini, released on the market May 2023
47998350|NCT02799758|DRUG|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
47998351|NCT02799758|DRUG|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
48156655|NCT05023304|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
48683864|NCT05396339|DRUG|IAE0972|IAE0972 is an investigational product
48683865|NCT01698203|DRUG|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
48683866|NCT01698203|DRUG|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
47998352|NCT05534763|BEHAVIORAL|IERGD|A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
47998353|NCT05534763|OTHER|IER SUPPORT|A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
47998354|NCT05112380|OTHER|Performing Xco endurance test|The subjects will perform the test two times, with 7-10 days between the two sessions
48156656|NCT05023304|DRUG|Topical Prednisolone|Standard of care topical drop treatment
48366405|NCT02319798|OTHER|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
47998355|NCT02270164|DIETARY_SUPPLEMENT|Artichoke Leaf Extract|Capsule
47998356|NCT02270164|OTHER|Placebo|Capsule
47998357|NCT05871359|DEVICE|Transcranial Direct Current Stimulation|The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.
48366406|NCT01383317|DEVICE|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
48683867|NCT01698203|DRUG|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
47998358|NCT05871359|PROCEDURE|Dual task|The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)
47998359|NCT02823275|OTHER|Functional mobilisation|functional mobilisation
47998360|NCT02823275|OTHER|Short term plaster cast fixation|2 weeks cast immobilisation
47998361|NCT04205760|COMBINATION_PRODUCT|Nutrition + exercise|Patients will receive preoperative optimization consisting of oral nutrition support (Fresubin 3.2 kcal) and bed-cycling (50 minutes per day) for 5-14 days before surgery.
47998362|NCT02151526|DRUG|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.
47998363|NCT01523548|DRUG|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
47998364|NCT05762146|DRUG|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
47998365|NCT05762146|DRUG|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
47998366|NCT05762146|DRUG|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
47998367|NCT06220708|OTHER|dance movement therapy|Our DMT program was adapted from an integrated somatic dance and visual arts program previously applied to the older population (Hsu, 2023). The intervention was scheduled in the afternoon and lasted for approximately 2 h. As previously recommended, rhythmic and contralateral movements on both sides of the body were emphasized in this study to enhance coordination and stimulation between the left and right cerebral hemispheres (Phillips-Silver and Trainor, 2007). The experimental groups were then subdivided into six groups. Balloons half-filled with water were used as the game in this study to guide individual and grouping rhythms and movements. Additionally, painting was incorporated to help participants understand their bodies and psychological states (Tjasink et al., 2023). Finally, group discussions and mutual support, along with verbal sharing after the DMT exercise, were encouraged.
47998368|NCT06220708|OTHER|yoga training|The yoga program included breathing exercises, Asanas, eye focus, body lock, and meditation. Participants were instructed to adjust their positioning based on their skill level to mitigate the risk of injury. The yoga intervention was scheduled at 2 pm and lasted for approximately 2 h.
47998369|NCT05337410|BEHAVIORAL|YES-ERACE|YES-ERACE is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES-ERACE curriculum empowers youth from diverse backgrounds to address racism and racial discrimination as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting inclusion, diversity, equity, appreciation, and solidarity in their community.
47998370|NCT01399242|DRUG|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
47998371|NCT04149951|DEVICE|Vestal Device|Vestibular nerve stimulator
47998372|NCT04149951|DEVICE|Placebo device|Sham nerve stimulator
47998373|NCT02750891|DRUG|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
47998374|NCT04774978|DEVICE|TTE|Transthoracic echocardiography
47998375|NCT03398720|DRUG|HTI-1066 dose level 1|Starting dose level
48366407|NCT01383317|DEVICE|Sham RIPC|Disposable sterile thigh tourniquet
47998376|NCT03398720|DRUG|HTI-1066 dose level 2|2nd dose level
48683868|NCT02186782|DRUG|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
47998377|NCT03398720|DRUG|HTI-1066 dose level 3|3rd dose level
47998378|NCT03398720|DRUG|HTI-1066 dose level 4|4th dose level
47998379|NCT03642717|DRUG|JARDIANCE DUO®|empagliflozin and metformin
47998380|NCT01492322|RADIATION|TRODAT|Smoker will receive a TRODAT injection
47998381|NCT02519920|DRUG|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
47998382|NCT02519920|DRUG|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
47998383|NCT02519920|DRUG|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
47998384|NCT02519920|DRUG|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
47998385|NCT00181012|DRUG|Lidocaine|
47998386|NCT01794052|OTHER|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~1. A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~2. Treating patients as per a standard clinical guidelines~3. Giving health education to patients on lifestyle changes for better self-care~4. Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~5. Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
48366408|NCT01265316|DEVICE|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
47998387|NCT06483854|DIAGNOSTIC_TEST|HIV counseling and testing from a traditional health practitioner|Healer provided HIV counseling and testing services offered to clients
48512490|NCT01555697|DRUG|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
48512491|NCT01555697|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
48512492|NCT02352688|PROCEDURE|Enhanced Colorectal Geriatric Care|
48512493|NCT06158620|DRUG|intra-nasal ketorolac|Experimental group receiving intra-nasal ketorolac for management of post-operative pain following ureteroscopy for kidney stone, and associated ureter stent discomfort.
48512494|NCT06158620|DRUG|oral diclofenac|Control group to receive oral diclofenac, which is a comparable medication to intra-nasal ketorolac.
48512495|NCT02317029|DEVICE|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
48683869|NCT02186782|DRUG|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
47998388|NCT02038582|OTHER|POC CD4 Testing|Point of Care CD4 testing
48156657|NCT01596777|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
48366409|NCT05485194|OTHER|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
48683870|NCT04614012|OTHER|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
47998389|NCT02038582|OTHER|CD4 Referral|Referral to CD4 testing
47998390|NCT02038582|BEHAVIORAL|Lay Counselor Follow-up|Follow-up from a lay counselor
48366410|NCT03506529|OTHER|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
48683871|NCT00334737|DRUG|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
48683872|NCT00334737|DRUG|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
48683873|NCT00334737|DRUG|sham injection|sham injection other names: not applicable
48683874|NCT02886910|OTHER|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
48683875|NCT02886910|OTHER|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
47998391|NCT02038582|BEHAVIORAL|Clinic Accompaniment|Accompaniment to the clinic by a counselor
47998392|NCT02038582|BEHAVIORAL|Clinic Referral|Referral to clinic
47998393|NCT02038582|BEHAVIORAL|SMS Reminder|SMS reminder for male circumcision
47998394|NCT02038582|BEHAVIORAL|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
47998395|NCT02038582|OTHER|POC VL|POC VL testing for HIV infected persons on ART
48156658|NCT01596777|DRUG|Loperamide placebo|200 ml apple juice
48366411|NCT01798433|DEVICE|One stent technique alone|One stent technique alone with drug-eluting stent
48366412|NCT01798433|DEVICE|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
48366413|NCT01798433|PROCEDURE|Provisional approach|Provisional approach with drung-eluting stents
48366414|NCT01798433|DEVICE|Elective 2-stent|Elective 2-stent with drug-eluting stents
48512496|NCT02317029|PROCEDURE|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
48512497|NCT02317029|DEVICE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
47998396|NCT02038582|OTHER|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
47998397|NCT00702403|DRUG|nilotinib|Given PO
47998398|NCT00702403|DRUG|imatinib mesylate|Given PO
47998399|NCT00702403|OTHER|pharmacological study|Correlative studies
48156659|NCT01596777|DRUG|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
48156660|NCT01596777|DRUG|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
48156661|NCT01596777|DRUG|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
48156662|NCT01596777|DRUG|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
48156663|NCT01596777|DEVICE|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
48366415|NCT02911311|DRUG|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
48366416|NCT02911311|DEVICE|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
48683876|NCT06216327|BEHAVIORAL|household safety intervention|This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.
48156664|NCT01596777|DRUG|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
48683877|NCT01794624|BEHAVIORAL|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
48683878|NCT01794624|BEHAVIORAL|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
48683879|NCT00156104|DRUG|Asenapine|5 mg BID
48683880|NCT00156104|DRUG|Asenapine|10 mg BID
48512498|NCT02317029|PROCEDURE|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
48683881|NCT00156104|DRUG|Haloperidol|4 mg BID
48512499|NCT00016081|DRUG|ribavirin|
48512500|NCT04077580|DRUG|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
48512501|NCT04727801|DEVICE|Verily Patch|The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
48683882|NCT00156104|OTHER|Placebo arm|
48512502|NCT02513212|DEVICE|Potassium Oxalate|Professionally applied liquid
48683883|NCT04894019|DEVICE|Continuous invasive blood pressure monitoring|Continuous invasive blood pressure monitoring using an arterial catheter
48156665|NCT06183944|OTHER|Hierarchical clustering methods|Hierarchical clustering methods will be used to form homogeneous groups of patients based on their data at diagnosis: presence or absence of symptoms, clinical and biological data, and presence or absence of favouring factors. Patient evolution at 6 months can fall into categories: stable, aggravation or progress, which are determined by events such as recurrence, hemorrhage, functional sequelae or death.
48156666|NCT01863888|DRUG|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
48156667|NCT01863888|DRUG|cholestyramine|Pharmaceutical form:powder Route of administration: oral
48156668|NCT01863888|DRUG|charcoal|Pharmaceutical form:granule Route of administration: oral
48512503|NCT02513212|DRUG|Stannous fluoride paste|SnF2 Paste
48512504|NCT02513212|DEVICE|Manual toothbrush|Marketed manual toothbrush
48512505|NCT02513212|DEVICE|Power toothbrush|Marketed power toothbrush
47998400|NCT03393156|BEHAVIORAL|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
47998401|NCT01981447|DRUG|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
48683884|NCT04894019|DEVICE|Intermittent non-invasive blood pressure monitoring|Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
48683885|NCT00470002|DRUG|Somatropin|
48683886|NCT05957458|DEVICE|Airdoc device of red light for Myopia|This light is Narrow-Band, Long-Wavelength Lighting with three different illumination (400lux, 800lux, 1200lux) or irridiance (1.2mW, 0.6mW, 0.37mW) respectively. And the wavelength is 650nm. It allows biocular therapy.
48683887|NCT05332392|DEVICE|INVSENSOR00040|Noninvasive wearable health monitoring device
48683888|NCT05712265|DRUG|Miricorilant|Miricorilant 6 x 100 mg coated tablets
48683889|NCT05712265|DRUG|Fluvoxamine|Fluvoxamine 50 mg tablet
48683890|NCT01487486|DRUG|IVF Antagonist Protocol|"1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle \>14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
48683891|NCT01463423|RADIATION|iSABR, 25 Gray in 1 fraction for small peripheral tumors|Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.
48683892|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium peripheral tumors|Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.
48683893|NCT01463423|RADIATION|iSABR, 54 Gray in 3 fractions for large peripheral tumors|Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.
48683894|NCT01463423|RADIATION|iSABR, 40 Gray in 4 fractions for small central tumors|Radiotherapy procedure for participants with small central tumors ≤ 10 cc.
48683895|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium central tumors|Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.
48683896|NCT01463423|RADIATION|iSABR, 60 Gray in 8 fractions for large central tumors|Radiotherapy procedure for participants with large central tumors \> 30 cc.
48683897|NCT00924794|PROCEDURE|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
48683898|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
48683899|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
48683900|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
47998402|NCT02200848|DRUG|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
47998403|NCT05279586|DRUG|lactulose|all interventions are used in secondary prophylaxis in cirrhotic patients
48512506|NCT00306995|BIOLOGICAL|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
48366417|NCT04435951|OTHER|Evaluation|No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
48366418|NCT00950755|BIOLOGICAL|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
48366419|NCT01144897|RADIATION|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
48366420|NCT01144897|DRUG|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
48366421|NCT04001426|DEVICE|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
48366422|NCT02572492|DRUG|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 \> 2.0 m CD34+ stem cells/kg body weight on day 0"
48366423|NCT02572492|DRUG|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
48512507|NCT00306995|BIOLOGICAL|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
48512508|NCT00306995|BIOLOGICAL|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
47998404|NCT05279586|DRUG|colistin|all interventions are used in secondary prophylaxis in cirrhotic patients
47998405|NCT01222975|DRUG|Risperidone|orally disintegrating tablets
47998406|NCT01393405|DRUG|Methotrexate|"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
47998407|NCT02993159|DRUG|Afimoxifene|Applied to the breast
47998408|NCT02993159|OTHER|Laboratory Biomarker Analysis|Correlative studies
47998409|NCT02993159|OTHER|Placebo|Given PO
48512509|NCT00306995|BIOLOGICAL|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
48512510|NCT00306995|BIOLOGICAL|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
48512511|NCT00306995|BIOLOGICAL|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
48512512|NCT00306995|BIOLOGICAL|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
48156669|NCT03151161|DRUG|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
48156670|NCT03151161|DRUG|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
48512513|NCT02018965|DRUG|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
47998410|NCT02993159|OTHER|Placebo|Applied to the breast
48512514|NCT02018965|DRUG|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
48366424|NCT02572492|DRUG|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
48512515|NCT04520009|BEHAVIORAL|Activity Restriction|Standard post-operative activity instructions (i.e., no bending, twisting, or lifting more than 10 lbs for 4 weeks, no return to work until cleared to do so).
48366425|NCT00749489|PROCEDURE|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
47998411|NCT02993159|DRUG|Tamoxifen Citrate|Given PO
47998412|NCT03257631|DRUG|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
47998413|NCT03257631|DRUG|Pomalidomide|Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
48156671|NCT05824078|PROCEDURE|Arthroscopic surgery|Arthroscopic approach involves smaller incision, offering less traumatic procedures and faster healing, but due to the limited space in this closed field with significant vasculature and nerve distribution, scoping has increased risk for iatrogenic injuries.
48156672|NCT05824078|PROCEDURE|Open Surgery|The open approach requires dissection of capsuloligamentous structures, which can lead to stiffness of the joint due to capsular scarring as it heals. However, it offers good visual field when treating the injury, allowing maneuverability to avoid iatrogenic soft tissue injuries.
48156673|NCT04842227|PROCEDURE|Nerve block|"Step 1: A small amount of local anesthetic (3-5cc of 0.5% ropivacaine) is administered under ultrasound guidance in the area of the supraclavicular nerve at the base of the neck under sterile conditions. This provides dense anesthesia of the skin and eliminates the need to introduce larger quantities of local anesthetic directly to the skin around the incision (usually 20mL).~The second step involves introducing 10-15cc of 0.5% ropivacaine under ultrasound guidance into the compartment between the pectoralis major and minor muscles to anesthetize the medial and lateral pectoral nerves. NOTE: Usual care involves blind administration of local anesthetic diffusely to the tissues in this region without targeting any particular nerves, and requires larger volumes of anesthetic (40mL for the blind approach vs 10-15mL for the nerve block)."
48156674|NCT03656926|DRUG|Liposomal Cyclosporine A|This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
48156675|NCT03656926|DRUG|Standard of Care|Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator
48366426|NCT05671302|BEHAVIORAL|Walk Together|Receive training in the use of a study-provided blood pressure cuff and hypertension education; engage in hypertension self-management goal-setting; identify barriers to self-management adherence and utilize shared problem-solving to address barriers; connect to existing clinic resources to address environmental barriers; promote relationship strengths; practice communication and behavioral skills to address relationship concerns; engage family in support of patient self-management goals.
48512516|NCT04520009|BEHAVIORAL|Activity as Tolerated|Instructions advising activity as tolerated and return to work based on patient discretion
48512517|NCT00311597|PROCEDURE|Radiosurgery|single fractionated radiation therapy
48512518|NCT01930201|PROCEDURE|Caudal epidural block|
48512519|NCT01930201|OTHER|General anesthesia|
48512520|NCT03306446|DRUG|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
48683901|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
48512521|NCT00668694|BEHAVIORAL|Stimulation|Stimulation given to the child by mother
48512522|NCT06550232|DRUG|Papaverine|Within 30-minutes prior to catheter insertion, women in the intervention group will receive IV-papaverine 80 mg in 100 ml 0.9% saline
48156676|NCT02305797|DRUG|Extended-release lorazepam|Extended-release lorazepam capsules
48512523|NCT06550232|OTHER|placebo|I.V Sallne
48156677|NCT02305797|DRUG|Placebo|Placebo capsules
48156678|NCT02359552|DRUG|Rasagiline|
48156679|NCT02359552|DRUG|Placebo|
48156680|NCT06027424|OTHER||observational study, no intervention
48156681|NCT04733989|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.
48156682|NCT06453304|DRUG|Calcium Hydroxide|Intracanal medication
48156683|NCT06453304|DRUG|Leddermix|Intracanal medication
48156684|NCT06453304|DRUG|Glycirrhizin|Intracanal medication
48156685|NCT00398749|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length
48156686|NCT00862225|DRUG|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
48156687|NCT00862225|DRUG|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
48156688|NCT00862225|DRUG|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
48156689|NCT05499117|DEVICE|Light terapy|Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
48156690|NCT05499117|DEVICE|pseudo-light therapy|The pseudo-light stimulation group was red light with intensity less than 100lux
48156691|NCT03984734|PROCEDURE|Pancreatoduodenectomy with antrectomy|
48156692|NCT03984734|PROCEDURE|Pylorus-preserving pancreatoduodenectomy|
48512524|NCT06490679|PROCEDURE|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥7 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
48512525|NCT06490679|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"(a) Disclosure of biofilm with erythrosine, (b) Removal of supragingival and subgingival (up to 10 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS-Dental, Nyon Switzerland).~(c) Supra- and sub-gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
48512526|NCT05734248|PROCEDURE|Facial filler injection|Hyaluronic acid will be injected on the cheek, based on the aesthetic evaluation of the face.
48512527|NCT02554162|OTHER|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
48512528|NCT00582010|DRUG|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
48512529|NCT00582010|DRUG|nitrogen gas|inhaled
48512530|NCT03862924|DEVICE|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
48156693|NCT00942799|DRUG|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
48512531|NCT00003183|BIOLOGICAL|filgrastim|
48512532|NCT00003183|DRUG|mitoxantrone hydrochloride|
48512533|NCT00948532|BIOLOGICAL|biologic, Osteocel Plus|Osteocel® Plus
48512534|NCT00901576|DRUG|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
48512535|NCT00901576|DRUG|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
48512536|NCT00901576|DRUG|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
47998414|NCT04972019|DEVICE|Telerehabilitation Experimental Group|"Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals and subjective pain level being measured and logged.~They will wear a computer system modified with biosensors, then do motor and cognitive baselines. Subsequently, participants will play an increasing number of games, targeted at cognitive domains of executive function (primary), memory and attention. At the end of every session vitals and subjective pain will be measured and logged.~Clinical Coordinator will call homes weekly to ascertain general health and issues with participation.~At the end of week 4 and 8 participants and their caregivers in the experimental group will fill a subjective evaluation questionnaire to gauge perceived benefits and technical difficulties when using the experimental system. Questions will be scored on a 5-point Likert scale."
47998415|NCT04972019|OTHER|Telerehabilitation Sham Control Group|"Sham control group will train playing web games while wearing a biosensor connected to a laptop provided, showing the web games. However biosensor data will not be used to control game difficulty.~Sham group controls will start every session with vitals and subjective pain levels being measured and logged. Then participants will play the same frequency and duration of sessions, however those will consist of web games training the same domains (memory, focusing, executive function). Interaction will be through a mouse, and data will be downloaded to a server maintained by the company doing the web games. Data will then be transferred to the research team.~At the end of every session vitals and subjective pain levels will again be measured and logged.~Once a week the Clinical Coordinator will call the home to ascertain general health and determine is there were issues with that week participation."
47998416|NCT04681482|DRUG|Apixaban|Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
48156694|NCT00942799|DRUG|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
48512537|NCT05545124|DRUG|Donafenib + Tislelizumab|Donafenib 100mg, BID+Tislelizumab 200mg, D1; q3w
48683902|NCT00288886|BEHAVIORAL|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
48683903|NCT00288886|BEHAVIORAL|Control arm|Routine residential treatment and orientation to continuing care.
48683904|NCT02453698|DRUG|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
48683905|NCT02453698|OTHER|Placebo|Lactose Placebo
48683906|NCT02031003|DIETARY_SUPPLEMENT|Infant formula|Infant formula
48683907|NCT04340388|DRUG|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
48683908|NCT04340388|DRUG|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
48683909|NCT02244307|DRUG|alpha-adrenergic blocker|
48683910|NCT03654118|OTHER|Phone follow-up|"Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score"
48683911|NCT06491225|BIOLOGICAL|GTE001 injection|GTE-001 injection to treat Advanced lung adenocarcinoma
48683912|NCT03749928|DEVICE|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
48683913|NCT03749928|DEVICE|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
48683914|NCT00395499|DRUG|Risperidone|
48683915|NCT06365658|DIAGNOSTIC_TEST|Psychological assessment|Psychological assessment of memory, learning and language
48683916|NCT00841412|BEHAVIORAL|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
47914337|NCT06390306|DRUG|Olverembatinib|CML-MBP receive ponatinib or olverembatinib daily combined with venetoclax ( 2 weeks) and azacitidine (D1-D7) in 28-day cycles. Subjects receive allogeneic HSCT after returning to chronic phase if applicable, whereas continuing the regimen until loss of response.
47914338|NCT01440192|BIOLOGICAL|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 \& 8
48683917|NCT00841412|BEHAVIORAL|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
48683918|NCT02229825|DRUG|Duloxetine|Capsule
48683919|NCT02229825|DRUG|Placebo|Capsule
48683920|NCT04961281|DRUG|Dexmedetomidine|injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
48683921|NCT04961281|DRUG|Triamcinolone|injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
48683922|NCT03170570|DEVICE|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
48683923|NCT03705559|DRUG|Vaporized Marijuana|Active Marijuana or Placebo, administered through vaporizer
48683924|NCT03705559|DRUG|Opioid Agonist|Active Opioid Agonist or Placebo, administered intranasally
48683925|NCT05077540|DRUG|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
48683926|NCT05077540|DRUG|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
47998417|NCT04381845|DIAGNOSTIC_TEST|COVID19 immunization testing|serological COVID19 test with confirmation at J15 during hospitalization
47998418|NCT01999595|DEVICE|Control TENS|Control TENS was the application of electrical stimulation via skin with no current
47998419|NCT01999595|DEVICE|Sham TENS|"Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it"
47998420|NCT01999595|DEVICE|High frequency TENS with large pads|High frequency TENS was delivered on large electrodes
47998421|NCT01999595|DEVICE|Low frequency TENS with large pads|Low frequency TENS was delivered on large electrodes
47998422|NCT01999595|DEVICE|High frequency TENS with small pads|High frequency TENS was delivered on small electrodes
47998423|NCT01999595|DEVICE|Low frequency TENS with small pads|Low frequency TENS was delivered on small electrodes
47998424|NCT01147861|DRUG|GSK256073|5mg in the AM and 5mg in the PM
47998425|NCT01147861|DRUG|GSK256073|10mg in the AM
47998426|NCT01147861|DRUG|GSK256073|50mg in the AM
47998427|NCT01147861|DRUG|GSK256073|25mg in the AM and 25mg in the PM
47998428|NCT01147861|OTHER|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
47998429|NCT00149942|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
47998430|NCT02357940|DRUG|Experimental Product|1% Colloidal Oatmeal Balm
47998431|NCT03843879|PROCEDURE|Transversus Abdominis Plane Block|Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
48683927|NCT03538886|PROCEDURE|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
47998432|NCT03843879|DRUG|Intravenous Lidocaine|Continuous intravenous lidocaine infusion
47998433|NCT01553006|DRUG|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
48512538|NCT02569918|DEVICE|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
48512539|NCT00685386|OTHER|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
48683928|NCT03538886|PROCEDURE|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
48683929|NCT03226327|DIETARY_SUPPLEMENT|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
48683930|NCT04449107|BEHAVIORAL|Android based mobile phone application|An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
47998434|NCT06371417|DRUG|RAY121|Injection
47998435|NCT01177540|DRUG|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
47998436|NCT01177540|DRUG|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
47998437|NCT06186037|DRUG|Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg|Oral administration once a day, taking it for 3 years
47998438|NCT06186037|DRUG|Mono drug group of Rosuvastatin 20 mg|Oral administration once a day, taking it for 3 years
47998439|NCT01913366|BEHAVIORAL|CM-PST|
47998440|NCT01913366|BEHAVIORAL|SG-PST|
47998441|NCT00433056|OTHER|STI|CD4 guided treatment interruption
47998442|NCT00433056|DRUG|stable HAART|continuous therapy
47998443|NCT02107599|DRUG|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
47998444|NCT05935007|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
47998445|NCT00235872|BIOLOGICAL|adalimumab|40 mg eow, sc
47998446|NCT04732975|DEVICE|CardioFlux|Non-invasive screening for ACS
47998447|NCT03237728|DRUG|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
47998448|NCT03237728|DRUG|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
47998449|NCT03237728|DRUG|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
47998450|NCT03237728|DRUG|Placebos|Placebos,Q8h,Day1-Day7
47998451|NCT03804112|DIAGNOSTIC_TEST|Ultrasound exam with Doppler|Ultrasound exam of the neck to search a perivascular inflammation at the level of the carotid bifurcation.
47998452|NCT03804112|BIOLOGICAL|Blood samples|blood count , CRP and viral serologies (herpes virus, chlamydia, mycoplasma),
48512540|NCT00685386|OTHER|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
48512541|NCT04280640|OTHER|Blood Draw|A blood sample will be collected once, prior to treatment.
48512542|NCT05577221|DEVICE|High Flow Nasal Air|Administration of air at high flow by using a high flow nasal oxygenation (FiO2 21%) device
48683931|NCT03686930|DRUG|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
48683932|NCT03686930|DRUG|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
48683933|NCT03686930|DRUG|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
48683934|NCT03686930|DRUG|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
48683935|NCT02522429|DEVICE|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
48683936|NCT05626179|DRUG|[14C] IBI351|The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
48683937|NCT00003730|DRUG|fluorouracil|
48683938|NCT00003730|DRUG|vinorelbine tartrate|
48683939|NCT04808791|DRUG|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
47998453|NCT06460896|OTHER|pharmacokinetic study|Multicenter pharmacokinetic study of the bioavailability of four compounds in GBP patients: candesartan, amlodipine, metformin and rosuvastatin.
48512543|NCT05538078|DRUG|Ozone gel|application of Ozone gel after scaling by ultrasonic scaler in the bottom of periodontal pocket
48512544|NCT05477108|DRUG|Treatment A (BGF MDI HFO with oral activated charcoal)|Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
48683940|NCT04808791|DRUG|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
48683941|NCT04808791|DRUG|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
48683942|NCT04308655|OTHER|Interview|Semi-structured interviews
48683943|NCT04308655|OTHER|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
48683944|NCT04124094|DRUG|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
48683945|NCT04124094|DRUG|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
48683946|NCT04124094|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
47998454|NCT01829776|BEHAVIORAL|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
47998455|NCT02562651|DRUG|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
48512545|NCT05477108|DRUG|Treatment B (BGF MDI HFA with oral activated charcoal)|Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
48683947|NCT01309204|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
48512546|NCT05727826|DEVICE|Thrive MD-01 .|The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG).
48512547|NCT00794339|DRUG|64Cu-ATSM|
48683948|NCT01309204|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
48683949|NCT01309204|DRUG|Brinzolamide 1% ophthalmic suspension|
48683950|NCT01309204|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
48683951|NCT01746381|DEVICE|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
48683952|NCT05400850|OTHER|YOGA|Five different YOGA Asana's will made randomly
48683953|NCT03114111|DRUG|aminolevulinic acid (ALA)|
48683954|NCT03114111|DRUG|Placebo|
48683955|NCT03940989|OTHER|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
48683956|NCT01582009|DRUG|panobinostat|Given orally
48683957|NCT01582009|DRUG|everolimus|Given orally
47998456|NCT02562651|OTHER|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
47998457|NCT03125434|OTHER|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
47998458|NCT04508270|BEHAVIORAL|Early mobilization|Mobilization as soon as patients can, which is not limited on walking
47998459|NCT06168487|DRUG|Telmisartan|Patients will be given telmisartan alone or with standard of care chemotherapy.
47998460|NCT06168487|OTHER|Standard of Care Regimen|Standard of Care Regimen
47998461|NCT00080743|DRUG|gefitinib|250 mg po once daily
47998462|NCT00080743|DRUG|tamoxifen citrate|20 mg po once daily
47998463|NCT00080743|DRUG|Placebo|One pill po once daily
47998464|NCT04031833|DRUG|MAT2203|Encochleated amphotericin B
47998465|NCT04031833|DRUG|Amphotericin B|Intravenous amphotericin B
48512548|NCT00794339|DRUG|FDG|
48683958|NCT01582009|OTHER|laboratory biomarker analysis|Correlative studies
48683959|NCT01582009|OTHER|pharmacological study|Correlative studies
48683960|NCT01582009|OTHER|liquid chromatography|Correlative studies
48683961|NCT01582009|OTHER|mass spectrometry|Correlative studies
48683962|NCT01582009|OTHER|enzyme-linked immunosorbent assay|Correlative studies
48683963|NCT01582009|OTHER|immunohistochemistry staining method|Correlative studies
48366427|NCT06010264|OTHER|Kinesiotape|"In the kinesiotaping group, kinesiotape was applied from the first postoperative day in addition to conservative treatment.~Kinesiobant application was performed regularly until the 6th week by a researcher with a certificate in kinesiobanting in accordance with the lymphatic correction and pain inhibition techniques described by Kenzo Kase.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
47998466|NCT02131402|DEVICE|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
47998467|NCT02131402|DEVICE|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
47998468|NCT02131402|DEVICE|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
47998469|NCT01810029|BEHAVIORAL|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
47998470|NCT01301495|DEVICE|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
47998471|NCT05820347|DEVICE|Artificial Intelligence Estimation of Muscle Pressure during Mechanical Ventilation|Estimation of inspiratory muscle pressure by an artificial intelligence algorithm integrated in the mechanical ventilator (FlexiMag, Magnamed, Brazil).
47998472|NCT03898349|OTHER|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
48366428|NCT06010264|OTHER|Shamtape|"In the sham taping group, sham tape was applied from the first postoperative day in addition to conservative treatment. Medical flasters were used as sham tape. Sham tapes were applied by cutting in the same fan shape as in kinesioband.~Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain"
48366429|NCT06010264|OTHER|Standard Physiotherapy Program|Conservative Treatment Program. 1-10 days: Patient education Pendulum exercises Active hand and wrist exercises Cold Application 1-6 Weeks: Pendulum exercises are continued Active hand and wrist exercises are continued Cold application is continued Passive arm elevation with opposite hand support in supine position Elbow flexion/extension exercise at the limit of pain
47998473|NCT03898349|OTHER|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
48156695|NCT00443755|DRUG|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
48156696|NCT00443755|DRUG|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
48366430|NCT03549546|BIOLOGICAL|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry."
48156697|NCT00443755|DRUG|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
47998474|NCT03898349|OTHER|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
47998475|NCT03987893|DRUG|PEG-3350 with Electolytes|experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
47998476|NCT03987893|DRUG|Lactulose|Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
47998477|NCT04927936|BIOLOGICAL|Vaccination once with Janssen vaccine (only priming)|Vaccination (priming) with janssen vaccine. There is no boosting.
47998478|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Janssen vaccine (homologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Janssen vaccine.
48366431|NCT04362527|DRUG|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
48366432|NCT04362527|DRUG|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
48683964|NCT06006936|BEHAVIORAL|Coping with Infertility Self-Help Program|"The CWI program consists of seven 10-minute videos, each with accompanying homework assignments.~The first module, cognitive restructuring, includes instructions on challenging extreme or unhelpful automatic thoughts. The second module, challenging negative core beliefs, includes looking for patterns in thinking that illustrate core beliefs. The third module features behavioural activation techniques and emphasizes the importance of regular pleasure and skill-based activities. The fourth module highlights coping with grief and factors that contribute to grief, such as individual differences in grieving style. The fifth module supports strengthening relationships through responding to requests for affection and outlines several common relationship mistakes. The sixth module demonstrates how to identify and use values to make decisions and guide behaviour. The seventh module summarizes how thoughts, actions, and interactions can contribute to well-being when experiencing infertility."
47998479|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Moderna vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Moderna vaccine.
47998480|NCT04927936|BIOLOGICAL|Vaccination with Janssen vaccine followed with Pfizer vaccine (heterologous boosting).|Vaccination (priming) with janssen vaccine. There is boosting with Pfizer vaccine.
47998481|NCT02816060|PROCEDURE|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
47998482|NCT01599507|DRUG|FG-4592|TIW dosing, capsule
48366433|NCT01421693|DRUG|Ceftriaxone|"* ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder."
48683965|NCT05339399|OTHER|oxytocin augmentation|Only observation of the outcome
47998483|NCT01599507|DRUG|Placebo|TIW dosing, capsule
48366434|NCT01421693|DRUG|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
48366435|NCT02442284|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
48366436|NCT02442284|DRUG|Ribavirin|Tablet
48366437|NCT01446835|DEVICE|nelfilcon A contact lens with print|Investigational spherical contact lens
48366438|NCT01446835|DEVICE|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
48683966|NCT01230190|DIETARY_SUPPLEMENT|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
47998484|NCT03448965|DIAGNOSTIC_TEST|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
47998485|NCT02741908|BEHAVIORAL|Calorie counting diet|
47998486|NCT02741908|BEHAVIORAL|Fixed diet plan|
47998487|NCT00841529|DEVICE|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
47998488|NCT03317171|DIETARY_SUPPLEMENT|Flavonoids, DHA, EPA|oral administration
47998489|NCT03317171|DIETARY_SUPPLEMENT|placebo compound|oral administration
47998490|NCT03330938|BEHAVIORAL|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
47998491|NCT03330938|BEHAVIORAL|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
47998492|NCT01334866|PROCEDURE|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
47998493|NCT03639766|DRUG|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
47998494|NCT03639766|OTHER|Saline solution|Non-bacteriostatic saline solution
47998495|NCT04585087|OTHER|Dietary Intakes|6 levels of threonine intake will be provided by the protein liquid drink
47998496|NCT01909908|DEVICE|ECM|ECM in saline applied to wound
47998497|NCT01909908|BIOLOGICAL|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
48366439|NCT06432582|DIAGNOSTIC_TEST|hepatomiR|hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
48366440|NCT04915365|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
47998498|NCT01909908|DEVICE|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
48156698|NCT03521076|DEVICE|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
48683967|NCT01230190|DIETARY_SUPPLEMENT|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
48683968|NCT02402530|DRUG|Placebo|Matching placebo administered as intravenous infusion.
47998499|NCT01865162|OTHER|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
47998500|NCT01613521|OTHER|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
48683969|NCT02402530|DRUG|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
48683970|NCT03497273|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
48683971|NCT03497273|DRUG|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
48683972|NCT00922402|PROCEDURE|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
48683973|NCT00472654|BEHAVIORAL|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
47998501|NCT03022760|BEHAVIORAL|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
47998502|NCT00828191|DRUG|Progesterone|25 mg, once a day, SC
48156699|NCT03727334|BEHAVIORAL|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
48156700|NCT01669720|DRUG|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
48366441|NCT04915365|DRUG|Placebo|"Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses~1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m."
48683974|NCT00472654|DIETARY_SUPPLEMENT|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
48683975|NCT00472654|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 weeks
48683976|NCT05466552|PROCEDURE|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
48683977|NCT03813875|DRUG|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
47998503|NCT00828191|DRUG|Progesterone|100 mg, twice a day, vaginally
47998504|NCT04475588|DRUG|Itolizumab IV infusion|"First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B"
47998505|NCT04475588|DRUG|Best supportive care (BSC)|Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
47998506|NCT06224842|DRUG|mitoxantrone liposome 16 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
48366442|NCT02843113|BEHAVIORAL|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
48366443|NCT06175845|PROCEDURE|Intraductal biliary radiofrequency ablation|Radiofrequency ablation via catheter and transpapillary access of malignant bile duct obstruction
47998507|NCT06224842|DRUG|mitoxantrone liposome 18 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
47998508|NCT06224842|DRUG|mitoxantrone liposome 20 and azacitidine|The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
47998509|NCT05142423|DRUG|AK109+AK104|It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.
47998510|NCT00067678|DRUG|soy protein|
47998511|NCT03342742|BEHAVIORAL|Weight Loss|Weight loss behavioral intervention via one of two strategies.
47998512|NCT06115265|BEHAVIORAL|Ketogenic diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
47998513|NCT06115265|BEHAVIORAL|Low Fat diet|KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.
47998514|NCT02891707|DEVICE|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
47998515|NCT03193411|DEVICE|Visumax femtosecond laser|
47998516|NCT03193411|DEVICE|Moria M2 microkeratome (MK)|
47998517|NCT04495127|DRUG|Selumetinib|Selumetinib 25 mg/m2 BID
47998518|NCT04149600|PROCEDURE|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
47998519|NCT01334203|DRUG|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
47998520|NCT04877938|BEHAVIORAL|Echolgical physical activity Intervention|'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
47998521|NCT02020005|OTHER|Non-flavored 2mg nicotine gum|
47998522|NCT02020005|OTHER|Non-flavored 4mg nicotine gum|
47998523|NCT02020005|OTHER|Mint-flavored 2mg nicotine gum|
47998524|NCT02020005|OTHER|Mint-flavored 4mg nicotine gum|
47998525|NCT02020005|OTHER|Non-flavored nicotine inhaler|
47998526|NCT02020005|OTHER|Mint-flavored nicotine ihaler|
47998527|NCT00983268|DRUG|capecitabine|1000 mg taken by mouth on the days of radiation only.
47998528|NCT00983268|DRUG|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~* Vorinostat,at 100 mg~* Vorinostat,at 200 mg~* Vorinostat, at 300 mg~* Vorinostat, at 400 mg"
47998529|NCT00983268|RADIATION|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
47998530|NCT00983268|PROCEDURE|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
47998531|NCT00559546|DRUG|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
48366444|NCT02774499|DRUG|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
47998532|NCT04822207|PROCEDURE|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
47998533|NCT04922918|BIOLOGICAL|Ligilactobacillus salivarius MP101|Administration of the strain through a fermented milk
47998534|NCT03304847|OTHER|ablation|radio-frequency applications on arrhythmogenic substrate
47998535|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
47998536|NCT00076687|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
47998537|NCT00076687|DRUG|saline|Saline injection at Day 1, Week 12, Week 18
47998538|NCT01296295|BEHAVIORAL|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
47998539|NCT01296295|BEHAVIORAL|Smoking cessation advice|Brief smoking cessation advice
47998540|NCT01215370|OTHER|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
47998541|NCT01215370|OTHER|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
47998542|NCT01215370|OTHER|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
47998543|NCT01215370|OTHER|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
48366445|NCT02774499|DRUG|Placebo|equivalent volume (5mL) of syrup given preoperatively
47998544|NCT01215370|OTHER|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
47998545|NCT03638310|PROCEDURE|intratympanic application of gentamicin|under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity
47998546|NCT03638310|PROCEDURE|microsurgical removal of vestibular schwannoma|surgery under general anesthesia
48512549|NCT05092984|DRUG|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
47998547|NCT02865915|DRUG|MLE4901|For 80% of subjects randomized to MLE4901 (n=24/30), the dose is 40 mg twice daily. Six subjects (20%) randomized to higher MLE4901 dose cohorts that were promptly discontinued.
47998548|NCT02865915|DRUG|Placebo|Placebo to match active drug
47998549|NCT01609920|DRUG|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
47998550|NCT02795728|OTHER|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
47998551|NCT02795728|OTHER|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
48512550|NCT05092984|DRUG|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
48683978|NCT03813875|OTHER|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
47998552|NCT03474887|OTHER|Physical Consultation|Regular physician consultation at the primary care clinic.
47998553|NCT03474887|OTHER|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
47998554|NCT02872779|PROCEDURE|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
47998555|NCT03231787|DIAGNOSTIC_TEST|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
47998556|NCT05162209|DIETARY_SUPPLEMENT|Synbiotic|Oral sachet, for 12 weeks
48512551|NCT05301595|PROCEDURE|TAP block|Please see description of TAP block group.
48512552|NCT05301595|PROCEDURE|QL Block|Please see description of QL block group.
48512553|NCT02890784|DRUG|dasatinib (SPRYCEL®)|Treatment optimization for patients with chronic myeloid leukemia (CML)
48512554|NCT02432053|DRUG|Advagraf|
48683979|NCT03813875|DRUG|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
48683980|NCT03813875|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0\~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
48683981|NCT03813875|DRUG|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0\~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
48683982|NCT03813875|DRUG|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0\~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
48683983|NCT01467466|DRUG|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
47998557|NCT04877275|DRUG|Selinexor (80mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm I：80mg/d QW ;"
47998558|NCT04877275|DRUG|Selinexor (100mg/d)|"Selinexor (ATG-010） is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Arm II：100mg/d QW ;"
47998559|NCT04877275|DRUG|Pegylated liposomal doxorubicin|25 mg/m\^2 intravenously on day 1 , QW
47998560|NCT04877275|DRUG|Dexamethasone|Dexamethasone 40mg/d QW
47998561|NCT04877275|DRUG|Cyclophosphamide|Cyclophosphamide：300mg/m2, d1 QW，
48156701|NCT05070637|PROCEDURE|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
48156702|NCT05070637|PROCEDURE|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
48156703|NCT05070637|PROCEDURE|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
48512555|NCT05372965|OTHER|experimental-periodontitis-mirna-223-gingival tissue-saliva samples|Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 6 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
48512556|NCT05372965|OTHER|control-clinical healthy mirna-223-gingival tissue-saliva samples|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
48683984|NCT01467466|DRUG|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
48683985|NCT01467466|DRUG|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
48683986|NCT01467466|DRUG|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
48156704|NCT05478200|BEHAVIORAL|physical exercise|Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
48683987|NCT00094926|DRUG|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
48683988|NCT00094926|DRUG|placebo|matching placebo IM injections every 2wks for 52wks
48683989|NCT03444545|DEVICE|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
47998562|NCT02533336|DRUG|abamectin and fenpyroximate|
48156705|NCT05478200|OTHER|Manual therapy|Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
48156706|NCT03787693|BEHAVIORAL|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
48366446|NCT03984643|DEVICE|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
48512557|NCT01799044|DEVICE|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
48683990|NCT03444545|DEVICE|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
48683991|NCT06023121|DIAGNOSTIC_TEST|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
48683992|NCT02941770|BEHAVIORAL|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
48683993|NCT02941770|OTHER|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
48683994|NCT03389698|DEVICE|GRASP Dynamic Contrast-Enhanced (DCE) MRI|Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
48683995|NCT03389698|DEVICE|3T Brain Scan|Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
48683996|NCT03389698|DRUG|Gadolinium-based Contrast Agent (GBCA) for MRI|Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
48683997|NCT03138551|BEHAVIORAL|Mealtime PREP (Promoting Routines of Exploration and Play)|
48683998|NCT03587896|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
48683999|NCT03085134|OTHER|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
48156707|NCT01774929|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
48156708|NCT02637362|PROCEDURE|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
48684000|NCT03085134|OTHER|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
48156709|NCT02637362|PROCEDURE|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
48156710|NCT02637362|PROCEDURE|Metatarsal block|A metatarsal block will be performed using a standardised technique
48156711|NCT02637362|PROCEDURE|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
48366447|NCT03102164|PROCEDURE|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
48366448|NCT01928758|DRUG|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
48366449|NCT01928758|DRUG|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
48512558|NCT00696787|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
48512559|NCT00696787|DRUG|Lyrica® (Pregabalin)|
48512560|NCT00696787|DRUG|Placebo|
48512561|NCT03675061|OTHER|Current care|Tocolysis and a complete corticosteroid treatment.
48512562|NCT03675061|DEVICE|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
48366450|NCT06308796|OTHER|Application of CaP dental mousse|Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.
48366451|NCT03396172|OTHER|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
48366452|NCT03396172|DEVICE|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
48366453|NCT00300989|DEVICE|Inion OTPS Biodegradable Fixation System|
48366454|NCT00736840|DEVICE|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
48366455|NCT03960476|BEHAVIORAL|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
48366456|NCT02487576|OTHER|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
48366457|NCT02487576|OTHER|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
48366458|NCT04879576|OTHER|Treatment|Telerehabilitation including pulmonary rehabilitation and posture exercises at 8 weeks in total with 2 sessions per week
48366459|NCT01732380|DRUG|Raltitrexed|
48366460|NCT01732380|DRUG|Oxaliplatin|
48366461|NCT01732380|RADIATION|Radiotherapy|
48366462|NCT04450420|OTHER|Simulation based curriculum|See arm/group description
48512563|NCT03675061|DEVICE|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
48366463|NCT04450420|OTHER|Standard training|See arm/group description
48366464|NCT00337935|DRUG|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
48366465|NCT00337935|OTHER|Standard of care|
48512564|NCT01108783|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
48512565|NCT01108783|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
48512566|NCT01108783|DRUG|Placebo|(encapsulated) Tablets QD/14 days
48366466|NCT06249074|OTHER|Gluten-free diet|Diet with gluten elimination followed by all participants for 8 weeks
48366467|NCT06249074|OTHER|Gluten capsules supplementation|2 g of gluten given in 3 capsules daily for 4 weeks (week 5 to week 8)
48366468|NCT06249074|OTHER|Placebo capsules supplementation|Rice starch in gastrosoluble capsules given in 3 capsules daily for 4 weeks (week 5 to week 8).
48366469|NCT03448458|PROCEDURE|CT (Computed Tomography)|Undergo PET/CT
48366470|NCT03448458|DRUG|Gallium Ga 68-DOTATATE|Given IV
48366471|NCT03448458|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48366472|NCT06041594|DEVICE|Laguna Thrombectomy System|Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
48366473|NCT03355001|DEVICE|Monosyn® Quick|"* Mucosal sutures in the facial and oral~* Dermal sutures, particularly in pediatrics~* Episiotomy~* Circumcision"
48366474|NCT01343121|OTHER|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
48366475|NCT01343121|OTHER|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
48366476|NCT01343121|OTHER|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
48512567|NCT03762694|DEVICE|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
48512568|NCT01715571|DEVICE|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
48512569|NCT01349777|DRUG|Pregrel®|Pregrel® 75mg daily for 12 months
48512570|NCT01349777|DRUG|Plavix®|Plavix® 75mg daily for 12 months
48512571|NCT02624180|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
48512572|NCT02624180|DRUG|Placebo|A substance containing no medication
48156712|NCT04343989|DRUG|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
48156713|NCT04343989|DRUG|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
48156714|NCT04343989|OTHER|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
48156715|NCT01879735|DRUG|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
48366477|NCT03764904|RADIATION|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
48366478|NCT00578006|BEHAVIORAL|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
48366479|NCT00578006|BEHAVIORAL|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
47998563|NCT02285907|OTHER|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
47998564|NCT02285907|OTHER|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
48366480|NCT05984914|BEHAVIORAL|PSAI|The 8 sessions included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention, introduction to the Pythagorean Self-Awareness Intervention, instructions for the implementation of the technique, analysis of the Golden Verses,and their connection with lifestyle medicine as well as active involvement of the participants with group conversation and sharing of experiences.
48512573|NCT04807400|DRUG|Inclisiran|Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection
48684001|NCT03644225|DEVICE|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
48684002|NCT03644225|DEVICE|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
47998565|NCT02285907|OTHER|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
47998566|NCT02285907|OTHER|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
47998567|NCT05296785|PROCEDURE|intramedullary nail with Limb Reconstruction System|bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia
47998568|NCT02017314|DRUG|Morphine|
48156716|NCT01879735|DRUG|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
48156717|NCT02085590|BIOLOGICAL|BCG vaccine|
48156718|NCT02085590|BIOLOGICAL|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
48156719|NCT02741297|DEVICE|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
48512574|NCT04807400|BEHAVIORAL|Behavioural Support|Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
48512575|NCT04807400|DRUG|Background lipid lowering therapy|lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
48512576|NCT01876446|OTHER|Laboratory Biomarker Analysis|Correlative studies
48512577|NCT01876446|DRUG|Pegylated Irinotecan|Given IV
48512578|NCT01876446|OTHER|Pharmacological Study|Correlative studies
48512579|NCT03310749|DRUG|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
48684003|NCT02078024|DRUG|IVM plus ALB|
48684004|NCT02078024|DRUG|IVM|
48684005|NCT00039039|DRUG|carboplatin|
48684006|NCT00039039|DRUG|chemotherapy|
48684007|NCT00039039|DRUG|cisplatin|
48684008|NCT00039039|DRUG|paclitaxel|
48684009|NCT00039039|RADIATION|radiation therapy|
48684010|NCT01941654|RADIATION|preemptive local ablative therapy|
48684011|NCT01941654|DRUG|Oral TKI|
47998569|NCT00741884|DRUG|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
47998570|NCT00741884|DRUG|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
47998571|NCT00741884|DRUG|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
48156720|NCT00966888|PROCEDURE|standard follow-up care|No intervention
48156721|NCT00966888|RADIATION|radiation therapy|Chest wall radiotherapy
48156722|NCT02633345|DIETARY_SUPPLEMENT|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
48156723|NCT02633345|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
47998572|NCT00741884|DRUG|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
47998573|NCT00741884|DRUG|Placebo|Placebo BID for 7 weeks
47998574|NCT04898673|DEVICE|CP1110|Sound Processor
47998575|NCT04898673|DEVICE|CP1000|Sound Processor
47998576|NCT00864877|DEVICE|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
47998577|NCT04099160|OTHER|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
47998578|NCT00206869|BEHAVIORAL|exercise|
47998579|NCT00206869|BEHAVIORAL|heat|
47998580|NCT00206869|PROCEDURE|red light illumination|
47998581|NCT05845879|OTHER|delivery|delivery
47998582|NCT02918851|BIOLOGICAL|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
47998583|NCT02918851|BIOLOGICAL|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
47998584|NCT02918851|BIOLOGICAL|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
47998585|NCT03147547|OTHER|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
47998586|NCT03147547|OTHER|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
48156724|NCT02159456|OTHER|Continuous enteral feeding via infusion pump|
48156725|NCT02159456|OTHER|Intermittent enteral feeding via gravity-based infusion|
48684012|NCT02364037|BEHAVIORAL|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
47998587|NCT03147547|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
47998588|NCT03147547|OTHER|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
47998589|NCT00564655|PROCEDURE|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
47998590|NCT00564655|PROCEDURE|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
48512580|NCT03310749|DRUG|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
47998591|NCT01611987|OTHER|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
47998592|NCT01611987|OTHER|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
47998593|NCT00860782|BEHAVIORAL|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
48156726|NCT01642771|DRUG|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
48684013|NCT02364037|BEHAVIORAL|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
48684014|NCT02364037|DEVICE|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
48684015|NCT02506855|DRUG|Ropivacaine|
47998594|NCT01973985|OTHER|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
48156727|NCT01642771|DRUG|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
48156728|NCT00538616|DRUG|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
48156729|NCT00538616|DRUG|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
48156730|NCT05432258|DEVICE|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
48156731|NCT05432258|DEVICE|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
48156732|NCT02638558|OTHER|written + oral explanation|
48156733|NCT02638558|OTHER|written explanation|
48156734|NCT01825785|DRUG|Romosozumab|Administered by subcutaneous injection
48156735|NCT01825785|DRUG|Placebo|Administered by subcutaneous injection
48156736|NCT04793555|OTHER|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
48156737|NCT00730496|PROCEDURE|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
48156738|NCT03174470|DEVICE|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
48156739|NCT01040299|DEVICE|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
48156740|NCT01040299|DEVICE|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
48156741|NCT01040299|OTHER|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
48156742|NCT02538055|BEHAVIORAL|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
48156743|NCT02538055|BEHAVIORAL|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
48156744|NCT05005572|OTHER|Payment adjustment for home dialysis and transplant|The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
48156745|NCT03214198|DRUG|Vonoprazan|Vonoprazan tablets
48366481|NCT05984914|BEHAVIORAL|One day seminar|The one day seminar included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention.
48366482|NCT00498069|DEVICE|Harvest Smartprep2 BMAC System|injection of 40cc bmac
48366483|NCT00498069|DEVICE|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
48684016|NCT02506855|OTHER|Placebo|
48156746|NCT04578691|DEVICE|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
48156747|NCT04578691|DEVICE|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
48366484|NCT00498069|BIOLOGICAL|placebo|injection of placebo into ischemic tissue of the lower extremity
48366485|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Endurance)|"* Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
48366486|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Attention and Motivation)|"* Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
48684017|NCT02506855|PROCEDURE|Transversus Abdominis Plane Block|
48684018|NCT01460706|DRUG|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
48512581|NCT03310749|DRUG|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
48156748|NCT02746783|DRUG|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
48684019|NCT02955108|PROCEDURE|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
48684020|NCT02955108|PROCEDURE|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
48684021|NCT02103062|DRUG|ABI-007|
48684022|NCT01679678|DEVICE|PolyHeal 2|PolyHeal is a sterile medical device
48684023|NCT01679678|DEVICE|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
48684024|NCT00475592|DEVICE|Esophageal Capsule Endoscopy|
48684025|NCT00475592|DEVICE|Upper Gastrointestinal Endoscopy|
48684026|NCT00191399|DRUG|Olanzapine|
48684027|NCT00191399|DRUG|Fluoxetine|
48684028|NCT03423303|DIAGNOSTIC_TEST|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
48684029|NCT00270751|PROCEDURE|1 apical pleurectomy|
48684030|NCT00270751|PROCEDURE|2 pleural abrasion + minocycline pleurodesis|
48684031|NCT01624961|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
48684032|NCT04807166|DRUG|Drug: Anlotinib|Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
48684033|NCT04807166|DRUG|Drug: Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
48684034|NCT01346943|DEVICE|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
48684035|NCT02110186|DEVICE|Dynamic Stabilization|
48684036|NCT02110186|PROCEDURE|Discectomy|
48684037|NCT02110186|DEVICE|Instrumentation and fusion|
48366487|NCT05419791|OTHER|Robot Asisted Gait Training with Lokomat (Activity Timing)|"* High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~* Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min."
48366488|NCT05419791|OTHER|Conventional Physiotherapy|-Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
48366489|NCT01490385|DEVICE|LED Phototherapy|
48512582|NCT00052598|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
48684038|NCT01453036|PROCEDURE|23S rRNA point mutation test of Helicobacter pylori|mutation test group\>\> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group \>\> no intervention
48684039|NCT01453036|PROCEDURE|UBT test & Gastroenterology with biopsy c silver stain|UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
48512583|NCT00052598|BIOLOGICAL|aldesleukin|Given SC
48512584|NCT00052598|OTHER|laboratory biomarker analysis|Correlative studies
48156749|NCT02746783|DRUG|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
48366490|NCT02592980|GENETIC|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
48366491|NCT02592980|DRUG|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
48512585|NCT00052598|OTHER|flow cytometry|Correlative studies
48366492|NCT03574727|PROCEDURE|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
48366493|NCT05620160|DRUG|RAY1216|RAY1216（tablet）
48512586|NCT04619212|DEVICE|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
48684040|NCT03194308|BEHAVIORAL|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
48684041|NCT00149240|BIOLOGICAL|Botulinum toxin type A|
48684042|NCT04961346|DEVICE|Ultrapro® mesh|large-pore, lightweight polypropylene mesh
48684043|NCT04961346|DEVICE|Premilene® mesh|small-pore, heavyweight polypropylene mesh
48684044|NCT00008411|DRUG|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
48684045|NCT00008411|DRUG|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
48684046|NCT03785353|BEHAVIORAL|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
48156750|NCT05611476|BEHAVIORAL|Cognitive Muscular Therapy for low back pain|Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
48156751|NCT01348763|DRUG|Maraviroc|Maraviroc 150 mg daily
48512587|NCT01474200|DEVICE|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
48512588|NCT01474200|DRUG|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
48512589|NCT04505254|DRUG|Acalabrutinib|Given PO
48512590|NCT04505254|BIOLOGICAL|Obinutuzumab|Given IV
48512591|NCT02418832|PROCEDURE|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
48366494|NCT05620160|DRUG|Placebo|placebo （tablet）
48684047|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
48684048|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
48684049|NCT04499027|DIAGNOSTIC_TEST|Lung ultrasound scan|"12 hours postoperatively using a convex ultrasound probe LUS will be performed by an experienced radiologist according to standardized protocols. For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines will be identified. Each one will be divided into upper and lower halves, making a sum of 6 different quadrants for each side: anterior superior, anterior inferior, lateral superior, lateral inferior, posterior superior, posterior inferior.~For each quadrant a score will be assigned based on B lines which are defined as comet like artifacts indicating subpleural interstitial edema as follows:~(0) normal aeration: A lines with lung sliding or fewer than two isolated B lines; (1) moderate loss of lung aeration: well-defined, multiple B lines ; (2) severe loss of lung aeration: multiple coalescent B lines; and (3) complete loss of lung aeration or lung consolidation."
48684050|NCT00348998|BIOLOGICAL|bevacizumab|
47998595|NCT01973985|OTHER|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.~Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.~Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.~Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
47998596|NCT01973985|PROCEDURE|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
47998597|NCT01973985|PROCEDURE|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
47998598|NCT05699083|OTHER|Body Image/Self-Esteem Questionnaires|Pre-operation and post-operation questionnaires to assess factors including but not limited to body image, quality of life, and self-esteem.
48366495|NCT05217017|DIAGNOSTIC_TEST|FACS|Diagnostic Test: Assessment of disability and behavior (by questionnaires)
48366496|NCT03554798|BIOLOGICAL|nOPV2 (monovalent oral polio vaccine)|"Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
48366497|NCT00980850|BIOLOGICAL|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
48366498|NCT00980850|BIOLOGICAL|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
48512592|NCT02613182|DRUG|NEOD001|NEOD001
48684051|NCT00348998|DRUG|bicalutamide|
48684052|NCT00348998|DRUG|goserelin acetate|
47998599|NCT04617691|DRUG|Guselkumab|Guselkumab will be administered as IV solution derived from FVP or PFS-U.
47998600|NCT03766854|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
47998601|NCT03766854|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
47998602|NCT01508975|OTHER|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
47998603|NCT00749320|OTHER|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
48156752|NCT01348763|DRUG|Truvada|daily until 10. day then stop
48156753|NCT01348763|DRUG|Darunavir|daily until 10. day then stop
48156754|NCT06647147|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
48366499|NCT02138929|DRUG|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
47998604|NCT01254435|PROCEDURE|Colonoscopy|Recording of colonoscopic extubation
47998605|NCT02578784|DEVICE|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
48512593|NCT02237391|OTHER|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
48512594|NCT02237391|OTHER|Treatment as Usual (TAU)|Control group
47998606|NCT02578784|DEVICE|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
47998607|NCT06362135|DEVICE|Virtual Home Visit|The virtual home visit will be made through the mobile application developed by the researchers. First, the patients who meet the sampling criteria will be included in the study after the caregivers of the patients apply to the Antalya Health Directorate Antalya Training and Research Hospital Home Health Unit. The virtual home visit is scheduled twice
47998608|NCT06362135|DEVICE|Control Group|"Face-to-face home visits will be carried out by the Antalya Education and Research Hospital home health team, as planned."
47998609|NCT05102786|OTHER|40007388|A non-combusted cigarette used with heated tobacco device 20020064
48512595|NCT02023294|PROCEDURE|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
48512596|NCT02023294|PROCEDURE|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
47998610|NCT05102786|OTHER|40007385|A non-combusted cigarette used with heated tobacco device 20020064
47998611|NCT05102786|OTHER|40007387|A non-combusted cigarette used with heated tobacco device 20020064
47998612|NCT05102786|OTHER|40007386|A non-combusted cigarette used with heated tobacco device 20020064
47998613|NCT03448315|DEVICE|tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
47998614|NCT01990274|PROCEDURE|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
48512597|NCT04030715|DRUG|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
48512598|NCT04683016|OTHER|Questionnaires|"Patients will be asked two sets of questions:~* questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy"
48512599|NCT01707017|OTHER|Strength training|
48512600|NCT01772797|DRUG|LDK378|LDK378 is a capsule to be taken daily by mouth.
47998615|NCT01990274|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
47998616|NCT04129788|DRUG|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
47998617|NCT04129788|DRUG|Placebo oral tablet|three doses taken, one per day on three consecutive days
47998618|NCT00656630|DRUG|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
47998619|NCT00656630|DRUG|Naltrexone|50mg capsule, Once daily, 1 week duration
47998620|NCT00656630|DRUG|Placebo|Matched placebo capsule, 1 week duration
47998621|NCT00624806|BEHAVIORAL|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
47998622|NCT00624806|BEHAVIORAL|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
47998623|NCT04535791|DRUG|Cholecalciferol|4,000 IU orally daily for 30 days
47998624|NCT04301765|DRUG|testosterone 1.62% gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
47998625|NCT04301765|OTHER|placebo gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
47998626|NCT02319031|DRUG|Daclatasvir|
47998627|NCT02319031|DRUG|Sofosbuvir|
47998628|NCT02319031|DRUG|Ribavirin|
47998629|NCT05544838|DEVICE|LMA insertion with standard technique|"Standard LMA insertion technique; LMA held like a pen and index finger placed at the junction of LMA tube and cuff. Index finger used to press LMA against hard palate and posterior pharyngeal wall until definite resistance felt at the base of hypopharynx. LMA then held with non- dominant hand and index finger removed.~Rotational LMA insertion; LMA inserted like guedel airway insertion: LMA proximally grasped close to anaesthesia circuit attachment. Insertion was conducted with LMA cuff facing towards nose, hard palate and then advanced into the base of hypopharynx until resistance was felt. At this point, LMA rotated at 180 degree anti-clockwise and LMA tube black line positioned and confirmed on the nasal side."
47998630|NCT05839210|BEHAVIORAL|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
47998631|NCT05839210|BEHAVIORAL|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
47998632|NCT05839210|BEHAVIORAL|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
47998633|NCT03581656|DEVICE|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
47998634|NCT04190134|BEHAVIORAL|Socially Assistive Robot for Low Vision Rehabilitation|A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
47998635|NCT04802265|PROCEDURE|Epiretinal membrane surgery|"The surgery consists of a 23 or 25-gauge pars plana vitrectomy (PPV). The surgery was performed peri-bulbar anesthesia and could be combined with phacoemulsification.~An intraocular dye is used to well visualized and facilitate ERM peeling. The ILM is not actively peeled. A search for iatrogenic breaks is performed towards the end of the procedure. Areas suspicious for breaks are treated with cryotherapy or peripheral endolaser."
47998636|NCT03904407|OTHER|Lactobacillus Probiotic Capsule|"One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~* Lactobacillus crispatus LbV 88~* Lactobacillus jensenii LbV 116~* Lactobacillus gasseri LbV 150N~* Lactobacillus rhamnosus LbV 96"
47998637|NCT03904407|OTHER|Matching Lactobacillus Probiotic Placebo Capsule|Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
48366500|NCT02138929|DRUG|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
48366501|NCT01391026|BEHAVIORAL|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
48366502|NCT00457951|DRUG|Open-Label|ODSH administered open-label
48684053|NCT00348998|RADIATION|radiation therapy|
48684054|NCT04531956|OTHER|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
48684055|NCT01223339|DRUG|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
48684056|NCT01223339|DRUG|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
48684057|NCT01223339|DRUG|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
48684058|NCT01223339|DRUG|Placebo|Placebo tablets administered once daily in the fed state for 7 days
48684059|NCT00109252|DRUG|Raptiva (efalizumab)|
48684060|NCT03604497|BEHAVIORAL|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
48684061|NCT03604497|BEHAVIORAL|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
48684062|NCT03782259|DRUG|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
48684063|NCT03782259|OTHER|Placebo|Placebo
48684064|NCT06513923|DRUG|Remimazolam|In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.
47998638|NCT01792947|PROCEDURE|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
47998639|NCT01792947|BEHAVIORAL|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
47998640|NCT05261984|PROCEDURE|Resistance exercise|Knee extensions in flywheel inertia machine in four sets of 10 repetitions.
47998641|NCT05261984|DIETARY_SUPPLEMENT|Oral protein supplementation|24 grams of hydrolyzed whey protein.
47998642|NCT03089203|BIOLOGICAL|CART-PSMA-TGFβRDN cells|autologous CAR T cells
47998643|NCT03089203|DRUG|Cyclophosphamide|300 mg/m2/day given over 3 days
47998644|NCT03089203|DRUG|Fludarabine|30 mg/m2/day given over 3 days
47998645|NCT00002130|DRUG|Vesnarinone|
47998646|NCT01740596|DEVICE|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
47998647|NCT02558790|DRUG|L-Threonic Acid Magnesium Salt (L-TAMS)|
47998648|NCT02935465|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
47998649|NCT02935465|BEHAVIORAL|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
47998650|NCT04075487|OTHER|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
48366503|NCT00457951|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
47998651|NCT03465878|DRUG|LY900014|Administered via SC injection
47998652|NCT03465878|DRUG|Insulin Lispro|Administered via SC injection
47998653|NCT05450887|DRUG|Obeticholic Acid Tablets（OCA）|Obeticholic Acid：Once a day (QD) by mouth (PO).
47998654|NCT05450887|DRUG|UDCA|UDCA：13\~15 mg/kg/day
47998655|NCT05450887|DRUG|Placebo|Placebo：Once a day (QD) by mouth (PO).
47998656|NCT02357147|DRUG|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
47998657|NCT02357147|DRUG|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
47998658|NCT02357147|DRUG|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
47998659|NCT02357147|DRUG|Cisplatin|Combination Phase - Cisplatin 75 mg/m\^2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
47998660|NCT00338910|DRUG|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
48156755|NCT06647147|OTHER|Diaphragmatic breathing exercises|From the hook-lying position, the women will receive instructions to position their hands on the rectus abdominis muscle located under the anterior chest wall. They will be advised to inhale slowly and deeply, expanding their abdomen without causing any movement in their upper chest, while simultaneously relaxing their shoulders. Slowly, the women will expel every breath. Air will be inhaled via the nose, swelling the abdomen. After the breath ceased, the women will purse her lips and exhale from his mouth with half-opened lips and a hollow belly. A single respiratory cycle consists of a three-second intake, followed by a three-second pause, and concluding with a six-second expiration phase.
48366504|NCT00457951|DRUG|ODSH|Randomized, Blinded, ODSH Arm
47998661|NCT00982813|OTHER|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.~Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
48366505|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
48366506|NCT01288742|DRUG|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
48366507|NCT01288742|DRUG|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
48366508|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
48366509|NCT01288742|DRUG|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
47998662|NCT03961542|OTHER|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
47998663|NCT06193746|DEVICE|non-invasive laser therapy|(diode laser, continuous output, in skin contact mode, 0.005W,0.2cm,beam spot area 0.03cm2, 288j/cm ,1800s) in the morning session, we measured lipid profile and kidney function before and after treatment to measure improvement
48366510|NCT00770731|DRUG|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
48366511|NCT00770731|DRUG|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
47998664|NCT05368740|DEVICE|integrated pulmonary index monitor|Integrated Pulmonary Index (IPI) is a new monitoring method calculated using respiratory rate (RR), end-tidal carbon dioxide (EtCO2), peripheral oxygen saturation (SpO2), and heart rate (HR). It is designed to obtain information about the patients' oxygenation and ventilation in the form of a single value or waveform from 1 to 10 with a mathematical algorithm using fuzzy logic. According to this scoring system; 10= normal, 8-9= within normal range, 7= close to normal range, requires attention, 5-6= requires attention and may require intervention, 3-4= requires intervention, 1-2= requires immediate intervention \[2\].
47998665|NCT00649896|DRUG|Mylan Estradiol Transdermal System 0.025 mg/day|
47998666|NCT00649896|DRUG|Climara® Transdermal System 0.025 mg/day|
47998667|NCT04612647|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Aquatic Opportunities, and 4) Physical activity and Sports (during intervention)
47998668|NCT04612647|BEHAVIORAL|Physical Activities & Activity Booklets|expected to engage in physical activity at least 3 hours per week
47998669|NCT03519568|BIOLOGICAL|EV71 (inoculation vaccine)|EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
47998670|NCT01960946|DIETARY_SUPPLEMENT|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
47998671|NCT01498458|DRUG|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
47998672|NCT06095791|DRUG|Immunomodulators with FDA approval on the 1st January 2023.|Disproportionnality analysis studying the association between immunomodulators with FDA approval on the 1st January 2023 and atrial fibrillation in the World Health Organization pharmacovigilance database.
47998673|NCT00882258|DRUG|12.5 mg Proellex|12.5 mg Proellex administered orally daily
47998674|NCT00882258|DRUG|25 mg Proellex|25 mg Proellex administered orally daily
47998675|NCT00882258|DRUG|Placebo|Administered orally daily
47998676|NCT00951028|BEHAVIORAL|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
48684065|NCT06513923|DRUG|Flumazenil|Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.
47998677|NCT00951028|BEHAVIORAL|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
47998678|NCT00951028|BEHAVIORAL|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
47998679|NCT00162565|DRUG|beta-blocker treatment|beta-blocker treatment
47998680|NCT03919461|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
47998681|NCT03919461|OTHER|Placebo|Placebo
47998682|NCT04358887|PROCEDURE|piezoelectric surgery|after flap reflection bone and root end cutting are done with piezoelectric surgical insert
47998683|NCT04358887|PROCEDURE|conventional bur|after flap reflection bone and root end cutting are done with surgical bur
47998684|NCT02367703|PROCEDURE|laparoscopic hysterectomy|
47998685|NCT01779193|DIETARY_SUPPLEMENT|lactic acid bacteria|oral lactobacillus capsule (dose of 2 \* 10\^9 cfu per capsule), one pill daily
47998686|NCT01779193|DIETARY_SUPPLEMENT|cranberry|oral cranberry capsule, one pill daily
47998687|NCT01779193|DIETARY_SUPPLEMENT|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
47998688|NCT02641379|DRUG|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
48156756|NCT02213458|BEHAVIORAL|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
48684066|NCT06513923|DRUG|Propofol|For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
47998689|NCT02641379|DRUG|Ribavirin|Ribavirin is available as 200 mg tablets
47998690|NCT03278964|PROCEDURE|Orbital decompression|
48156757|NCT04641234|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
47998691|NCT00212953|PROCEDURE|Advanced Life Support|
47998692|NCT02631863|DRUG|Aminolaevulinic acid|Aminolaevulinic acid with illumination
47998693|NCT02631863|DRUG|Placebo|Placebo with illumination
48156758|NCT04297423|DRUG|Plenvu|randomization 1:1
48156759|NCT03188978|DRUG|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
48156760|NCT03188978|OTHER|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
47998694|NCT04059146|OTHER|Pain Education and Exercise|Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
47998695|NCT04059146|OTHER|Standard Education and Exercise|The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
47998696|NCT02822989|DEVICE|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
47998697|NCT02822989|DEVICE|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
47998698|NCT02210936|OTHER|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
47998699|NCT03467087|DEVICE|Myopuls 2000D|Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
47998700|NCT00152581|DRUG|Pegylated interferon-alfa2a (Pegasys); ribavirin|
47998701|NCT06197594|OTHER|Proprioceptive neuromuscular facilitation techniques|Proprioceptive neuromuscular facilitation techniques
47998702|NCT06197594|OTHER|Rebound Therapy|Rebound Therapy
47998703|NCT01430013|DRUG|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
47998704|NCT02395796|PROCEDURE|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
47998705|NCT02307006|DRUG|Ceftaroline|Surgical prophylaxis
47998706|NCT02307006|DRUG|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
48156761|NCT04252794|PROCEDURE|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
48366512|NCT00770731|DRUG|Velcade (Bortezomib)|Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
48366513|NCT03999203|DRUG|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
48366514|NCT03999203|DEVICE|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
48366515|NCT03999203|OTHER|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
48366516|NCT03999203|OTHER|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
48366517|NCT03259607|DRUG|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
48366518|NCT03259607|DRUG|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
48366519|NCT03259607|DRUG|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
48366520|NCT03259607|DRUG|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
48366521|NCT03031613|PROCEDURE|PEEP group|Application of 5cmH20 positive end expiratory pressure
48366522|NCT03031613|PROCEDURE|ZEEP group|No application of positive end expiratory pressure
48366523|NCT04411316|COMBINATION_PRODUCT|Catheter directed thrombolysis plus anticoagulation|"Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation.~PCDT will be AngioJet along with alteplase."
48366524|NCT04411316|DRUG|Anticoagulation|Patients will receive anticoagulation alone. Anticoagulation will be heparin only.
48366525|NCT00231959|DRUG|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
48156762|NCT04252794|OTHER|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
48366526|NCT00231959|DRUG|Placebo|sugar pill
48366527|NCT05604781|DEVICE|Symfony & Synergy IOL combination|The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.
48366528|NCT00608426|BEHAVIORAL|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
48366529|NCT03193281|DRUG|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
48366530|NCT03193281|DRUG|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
48684067|NCT04185077|DRUG|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
48684068|NCT04185077|DRUG|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
48684069|NCT04194944|DRUG|Selpercatinib|Administered orally
48684070|NCT04194944|DRUG|Carboplatin|Administered IV
48684071|NCT04194944|DRUG|Cisplatin|Administered IV
48684072|NCT04194944|DRUG|Pemetrexed|Administered IV
48684073|NCT04194944|DRUG|Pembrolizumab|Administered IV
48684074|NCT00188617|DRUG|GEFITINIB|250 mg once a day for 28 days before surgery
48684075|NCT00187538|BEHAVIORAL|Dietary|dietary
48684076|NCT05226832|PROCEDURE|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
48684077|NCT03492502|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
48684078|NCT00074139|DRUG|cyclophosphamide|
48684079|NCT00074139|DRUG|docetaxel|
48684080|NCT00074139|DRUG|doxorubicin hydrochloride|
48684081|NCT01772550|DEVICE|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
48684082|NCT01772550|DEVICE|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
48684083|NCT00848835|DEVICE|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
48684084|NCT03069742|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
48366531|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
48366532|NCT00734916|DIETARY_SUPPLEMENT|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
48366533|NCT00734916|DIETARY_SUPPLEMENT|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
48366534|NCT05323370|OTHER|24h urine|Urine samples will be collected at home over 24 hours
48366535|NCT05323370|OTHER|urine sample|A urine sample of 20cc will be collected
48512601|NCT01772797|DRUG|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
47998707|NCT06244069|DIAGNOSTIC_TEST|Temporal arterial biopsy|Collection of 30 ml of peripheral blood in ethylenediaminetetraacetic acid (EDTA) tubes performed at baseline, 6 months, 12 months and in case of flare before month 12. In addition, the temporal artery specimen (at least 5 mm in length) exceeding that used for clinical activity (at least 10 mm in length in accordance with current clinical recommendations) will be digested to use for research purposes (about protocols for collecting, processing, storing and sending biopsy, refer to Standard Operating Procedures, SOP).
48156763|NCT04928196|OTHER|Microperimtery and optical coherence tomography angiography OCTA|observational: Investigations are done to assess the retinal microvasculature and function before and after silicone oil removal
48156764|NCT02268526|BIOLOGICAL|CSJ148|CSJ148 IV q 4weeks
48156765|NCT02268526|DRUG|Placebo|Placebo IV q 4weeks
48156766|NCT04659083|DEVICE|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
48156767|NCT02894216|PROCEDURE|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
48156768|NCT03703492|DRUG|(18F)FES|"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"
48512602|NCT05482711|OTHER|Time Restricted Eating Intervention|All participants will be asked to adhere to suggested fasting and feeding periods throughout the 8 week study period. These participants will self-monitor eating and sleeping habits as well to present to study staff at checkpoints. Self-reported information will be used during group-mediated intervention sessions throughout the duration of the study, as well.
48156769|NCT03703492|DRUG|Gadobenate dimeglumine|Gadolinium-based intravenous contrast agent used for the MRI portion of this study
48156770|NCT01445379|DRUG|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
48366536|NCT00902590|OTHER|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
48684085|NCT03069742|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
48684086|NCT06266026|DIAGNOSTIC_TEST|ThermoBreast - AI-based evaluation of dynamic breast thermography imaging|"Index test: AI-based evaluation of dynamic breast thermography imaging (ThermoBreast). The ThermoBreast evaluation will be performed independently of the routine breast cancer diagnostic evaluation. Some baseline risk variables (e.g. patient age, hormonal status) may be included in the ThermoBreast evaluation.~Reference test: Routine breast diagnostics will serve as a reference test against which the ThermoBreast outcome will be compared. Depending on national guidelines and clinical scenarios, routine breast cancer diagnostics can consist of several routine procedures, including clinical examination, ultrasound, mammography, tomosynthesis, MRI, follow-up imaging, biopsy, surgical excision, and histopathologic evaluation. All procedures will be performed as indicated and specified by the respective, current national guidelines."
48684087|NCT00938912|DRUG|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
48684088|NCT00938912|DRUG|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
48684089|NCT00405730|DRUG|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
48684090|NCT00405730|DRUG|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
48684091|NCT00405730|OTHER|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
48684092|NCT02307240|DRUG|CUDC-907|CUDC-907 oral with meals.
48156771|NCT04782596|PROCEDURE|Posterium nasal septum resection|Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
48156772|NCT05413811|DRUG|5 Fluorouracil (5 FU) Cream|Intravaginal topical chemotherapy, 5-fluorouracil cream
47998708|NCT06244069|DIAGNOSTIC_TEST|Whole exome sequencing|"Patients with CHIP will be identified and characterized by using whole exome sequencing from the peripheral blood samples. M-CHIP will be further characterized by:~i) clone dimension as defined by Variant Allele Fraction (VAF); ii) mutations in specific genes such as DNMT3A, Tet methylcytosine dioxygenase 2 (TET2), Additional Sex combs (ASXL1), or Janus kinase 2 (JAK2); iii) multiple mutations.~L-CHIP will be further characterized by:~i) clone dimension as defined by the VAF; ii) mutations in specific genes such as Dual Specificity Phosphatase 22 (DUSP22), FAT atypical cadherin 1 (FAT1), (Histone-lysine N-methyltransferase 2D (KMT2D); iii) multiple mutations; iv) co-occurrence of mutations heralding M- and L-CHIP."
47998709|NCT06244069|DIAGNOSTIC_TEST|Single cell transcriptomics|The investigators will identify actively inflamed arterial biopsies from three treatment-naïve patients without CHIP, and three treatment-naïve patients with CHIP driven by the most relevant gene mutation. Arterial wall Cluster of Differentiation (CD) 45+ leukocytes will be isolated after digestion of arterial tissue and characterized by single cell transcriptomics, with a specific focus on wall infiltrating T cells and macrophages and their subsets (eg: Vascular dendritic cells, Th1, Th2, Th17, Treg, M1- and M2-like,...). Frequencies of these subsets and their genetic expression will be compared between wall-infiltrating leukocytes from GCA patients with or without CH, focusing on histological events supposed to be pathogenic in GCA, or known to be dysfunctional in CHIP.
47998710|NCT00719836|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
47998711|NCT04428892|BEHAVIORAL|Pedagogyc Strategy|Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
48156773|NCT05413811|DRUG|Placebo|Intravaginal topical placebo cream
48512603|NCT01044108|DRUG|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
48512604|NCT01044108|DRUG|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
48512605|NCT01044108|DRUG|placebo|Placebo will be administered as a comparator at each dose level.
48512606|NCT04004585|BEHAVIORAL|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
48512607|NCT04735978|BIOLOGICAL|RP3|Genetically modified HSV-1
48512608|NCT04735978|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
48512609|NCT01114607|DRUG|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
48512610|NCT01114607|DRUG|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
48684093|NCT00820144|BIOLOGICAL|CTB by nasal way|
48684094|NCT00820144|BIOLOGICAL|absorption of CTB by oral way|absorption of CTB by oral way
48684095|NCT00820144|BIOLOGICAL|absorption of dukoral by oral way|absorption of dukoral by oral way
48684096|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
48684097|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
48684098|NCT04884763|DRUG|Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments|Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
48684099|NCT04884763|DRUG|Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments|Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
48684100|NCT04389905|BEHAVIORAL|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
48684101|NCT03573752|OTHER|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
48684102|NCT03573752|OTHER|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
48684103|NCT04083703|PROCEDURE|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
48366537|NCT00902590|OTHER|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
48512611|NCT01114607|DRUG|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
48512612|NCT01114607|DRUG|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
48512613|NCT01114607|DRUG|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
48684104|NCT04294381|BEHAVIORAL|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
48684105|NCT05140772|DRUG|Dipeptiven|IV administration daily for 7 days
48684106|NCT05140772|DRUG|normal Saline|IV administration daily for 7 days
48684107|NCT03820336|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
48684108|NCT03820336|DIETARY_SUPPLEMENT|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
48684109|NCT00434993|DRUG|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~* The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~* The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
48684110|NCT00434993|PROCEDURE|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
48684111|NCT00434993|DRUG|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
48684112|NCT01804049|DRUG|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
48684113|NCT01804049|DRUG|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
48684114|NCT01458301|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
48684115|NCT01458301|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
48684116|NCT01458301|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
48684117|NCT01458301|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
48684118|NCT01458301|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
48684119|NCT00579423|BIOLOGICAL|QS21|"* Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
48684120|NCT05701839|PROCEDURE|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
48684121|NCT05701839|PROCEDURE|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
48684122|NCT05701839|DEVICE|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
48684123|NCT05701839|DEVICE|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
48684124|NCT05576298|BIOLOGICAL|Insulin degludec injection, RD15003|single dose, s.c. injection
48684125|NCT05576298|BIOLOGICAL|Insulin degludec, Tresiba|single dose, s.c. injection
48684126|NCT05620810|BEHAVIORAL|neuropsychiatric symptoms|neuropsychiatric symptoms
48684127|NCT06453382|BEHAVIORAL|Behavioural change modification, Screening, NCD related knowledge practice and attitude|The investigators will provide periodic training regarding the control and prevention of NCDs to the stakeholders. The investigators will provide WHO-Package of Essential Non-Communicable Diseases (PEN) protocol training to the stakeholders involved in healthcare service delivery. The investigators will equip the government healthcare facilities with the equipment needed for the screening of NCDs. For the stakeholders who are not directly involved with healthcare service delivery, the investigators will train them about the 5 NCDs (diabetes, hypertension, chronic respiratory disease, cancer, and mental illness) and the 5 NCD risk factors (unhealthy diet, inadequate physical activity, tobacco cessation, alcohol cessation, and air pollution). The investigators will also share information, education, and communication (IEC) materials with the stakeholders, and then they will share the information with the community.
48512614|NCT02302989|DRUG|Ranibizumab 0.5mg|
48684128|NCT00657137|DRUG|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
47998712|NCT05282719|DRUG|venetoclax combined with azacitidine|On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
47998713|NCT05511142|OTHER|Classic Peyton's Four-Step Approach|Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
48156774|NCT02920216|DRUG|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
48156775|NCT02070289|DRUG|PF-06372865|Tablets, 2.5 mg BID, 14 days
48156776|NCT02070289|DRUG|Placebo|Tablets, BID, 14 days
48156777|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
48156778|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
48156779|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
48156780|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
48156781|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
48366538|NCT03159715|BEHAVIORAL|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
48512615|NCT03147625|BEHAVIORAL|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
48512616|NCT00511823|DRUG|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
48512617|NCT00511823|DRUG|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
48684129|NCT00657137|DRUG|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
48684130|NCT00211172|BEHAVIORAL|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
48684131|NCT02780934|OTHER|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
48156782|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
48156783|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
48684132|NCT02780934|OTHER|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
48684133|NCT04703192|DRUG|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
47914339|NCT00888043|DRUG|CNTO 95 and avastin|"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~  1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose"
47914340|NCT02977962|BEHAVIORAL|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
47914341|NCT02977962|OTHER|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
47914342|NCT01335737|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4 times/week
47914343|NCT01335737|BEHAVIORAL|Wait list|wait list control condition
47914344|NCT01968655|BIOLOGICAL|OBI-1|OBI-1 is a B domain deleted recombinant porcine factor VIII
48156784|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
48156785|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
48156786|NCT02246647|DIAGNOSTIC_TEST|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
48156787|NCT02246647|PROCEDURE|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
48156788|NCT02246647|PROCEDURE|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
48156789|NCT06261567|DRUG|Biologic treatment|Patients receiving treatment with any biologic treatment for severe asthma which is approved within the UK NHS. These include omalizumab, mepolizumab, reslizumab, benralizumab and/or dupilumab
48684134|NCT01656707|BEHAVIORAL|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
48684135|NCT01656707|BEHAVIORAL|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
48366539|NCT03159715|BEHAVIORAL|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
48684136|NCT05946161|BEHAVIORAL|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
48684137|NCT04213469|BIOLOGICAL|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
48684138|NCT02546726|BEHAVIORAL|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
48684139|NCT02546726|BEHAVIORAL|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
48684140|NCT02963883|OTHER|SVO2 group / control group|
48684141|NCT03900728|DEVICE|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
48366540|NCT03159715|BEHAVIORAL|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
48684142|NCT03900728|DEVICE|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
48366541|NCT00157638|BEHAVIORAL|integration of pharmacist into primary care|
48366542|NCT00157638|DRUG|optimizing therapeutic treatments|
48366543|NCT00157638|BEHAVIORAL|optimizing processes of care|
47998714|NCT05511142|OTHER|Modified Peyton's Four-Step Approach|Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
48684143|NCT03900728|DEVICE|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
48684144|NCT04834908|BIOLOGICAL|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
48684145|NCT04834908|DRUG|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
48684146|NCT02923531|DRUG|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
48684147|NCT02923531|DRUG|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
48684148|NCT03955328|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
47998715|NCT03031808|DRUG|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
47998716|NCT03031808|DRUG|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
47998717|NCT03031808|OTHER|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
47998718|NCT03062956|DRUG|MYK-491 or placebo|Oral suspension
47998719|NCT04656132|BEHAVIORAL|Physical activity assessment, promotion and monitoring in a preventive cardiology clinic|physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
47998720|NCT02245256|DRUG|Precedex|infusion of 0.1mcg/kg/hr of precedex
48684149|NCT05844202|DRUG|Alveavax-v1.2|BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
48684150|NCT05844202|DRUG|Janssen Ad26.COV2.S|COVID-19 vaccine by Janssen / Johnson \& Johnson
48684151|NCT04671563|DRUG|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
48366544|NCT03303144|DRUG|Triferic|ferric pyrophosphate citrate
48366545|NCT02443558|OTHER|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
48366546|NCT02443558|DEVICE|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
48366547|NCT00723060|DRUG|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
48684152|NCT04620616|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
48684153|NCT04620616|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
48684154|NCT04620616|OTHER|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
48684155|NCT03743714|OTHER|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
48684156|NCT05410496|DRUG|Tenofovir Alafenamide 25 MG|To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
47998721|NCT02245256|DRUG|placebo control|placebo
47998722|NCT00490516|DRUG|ACP-104|200 mg, tablet, BID, 6 weeks
48684157|NCT03652389|BEHAVIORAL|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
47998723|NCT00490516|DRUG|ACP-104|100 mg, tablet, BID, 6 weeks
47998724|NCT00490516|DRUG|Placebo|placebo, tablet BID, 6 weeks
48156790|NCT06136325|PROCEDURE|Obsidian RFP anal fistula surgery|Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF®
48156791|NCT01476137|DRUG|GSK1120212|MEK inhibitor
48156792|NCT01476137|DRUG|GSK2110183|AKT inhibitor
48156793|NCT00005088|DRUG|cisplatin|
48156794|NCT00005088|RADIATION|radiation therapy|
47998725|NCT00733044|BEHAVIORAL|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
47998726|NCT00733044|OTHER|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
47998727|NCT05514158|DRUG|RC48-ADC|RC48 for injection is a novel antibody-drug conjugate, with a her-2-targeting antibody and a microtube inhibitor
47998728|NCT05514158|DRUG|RC98|RC98 is a recombinant humanized IgG1 monoclonal antibody targeting programmed cell death-Ligand 1 (PD-L1)
47998729|NCT03752307|DRUG|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
47998730|NCT03752307|DRUG|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
47998731|NCT03752307|DRUG|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
47998732|NCT03832374|OTHER|Descriptive|
47998733|NCT00853554|DRUG|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
47998734|NCT00853554|DRUG|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
47998735|NCT04990752|DRUG|ulinastatin|In the ulinastatin group, early application of ulinastatin was performed for inflammation management and organ protection before ECMO initiation.The recommended clinical routine dosage of ulinastatin is 300,000 IU, q8h (continuous administration for more than 5 days).
47998736|NCT03050619|DRUG|Empagliflozin|
47998737|NCT03050619|DRUG|Other SGLT2 inhibitors|
47998738|NCT03050619|DRUG|Other non-insulin GLDs|metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
47998739|NCT04602637|OTHER|Training load|Monitoring training load during covid
47998740|NCT05078164|BEHAVIORAL|Bridging the Gap (BTG)|"Bridging the Gap: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program: The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
47998741|NCT02242851|DRUG|Telmisartan|
47998742|NCT06366880|OTHER|Parenteral nutrition cycling|"This study is a single-centre, non-blinded RCT in the NICU of Pediatric Hospital of Sinaloa, Northwest, Mexico.~A total of 66 infants born ≥34 weeks of gestation who have a high likelihood of intolerance to enteral nutrition (EN) for at least 10 days will be randomised to PNC o PNT after informed parental consent. In both groups, EN will be commenced as early as clinically feasible."
47998743|NCT02680639|DEVICE|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
48684158|NCT02626936|OTHER|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
48684159|NCT02626936|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
48684160|NCT02626936|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
48684161|NCT02626936|DEVICE|Dexcom G4 Platinum glucose sensor|
48684162|NCT02626936|DEVICE|Accu Chek Combo insulin pump|
47998744|NCT02759666|DRUG|SHR3162|SHR3162 capsule(s) is administered orally QD.
47998745|NCT05620576|DRUG|LY3857210|Administered orally
47998746|NCT05620576|DRUG|Placebo|Administered orally
47998747|NCT01734564|BIOLOGICAL|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
47998748|NCT01734564|RADIATION|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
47998749|NCT02689258|DRUG|HTX-011B|HTX- 011B (bupivacaine/meloxicam) via injection
47998750|NCT02689258|DRUG|Placebo|Saline placebo via injection
47998751|NCT02689258|DRUG|HTX-011A|HTX- 011A (bupivacaine/meloxicam) via injection
47998752|NCT02689258|DRUG|HTX-002|HTX-002 via combination
47998753|NCT02689258|DRUG|Bupivicaine HCl|Bupivacaine HCl via injection
47998754|NCT04783506|OTHER|Observational Study|There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
47998755|NCT00603746|DRUG|GW685698X|GW685698X
47998756|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
47998757|NCT04222712|DRUG|TRS01 eye drops|Dosed four times a day (QID)
48156795|NCT04172571|BIOLOGICAL|AK105|Anti-PD-1 antibody; IV infusion, 200 mg Q3W
47998758|NCT03302988|OTHER|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
47998759|NCT03302988|OTHER|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
48684163|NCT02289365|DRUG|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
47998760|NCT05263154|OTHER|Goal directed low oxygen|Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.
47998761|NCT05263154|OTHER|High oxygen|FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
47998762|NCT00943228|DRUG|mycophenolate mofetil|High dose 4gms daily
47998763|NCT02260284|OTHER|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
47998764|NCT02260284|OTHER|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
47998765|NCT02260284|OTHER|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
47998766|NCT01440738|BEHAVIORAL|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
47998767|NCT01462357|BIOLOGICAL|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
47998768|NCT01462357|BIOLOGICAL|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
48156796|NCT04172571|DRUG|Anlotinib Hydrochloride|multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
48156797|NCT00050167|DRUG|Paclitaxel|80 mg/m\^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
48366548|NCT05995548|OTHER|Interview|The interview will take place face-to-face. It will take place in a quiet room, with the door and windows closed. Only the participant and the investigator will be present. It will be recorded using a dedicated to this research. At the end of the interview, so as not to influence the participant's discourse, the participant will be asked to fill in the self-questionnaire 'EAI' (Exercise Addiction Inventory), which will confirm or refute the diagnosis, thus exploring a possible discrepancy between the participant's feelings and the diagnosis.
48684164|NCT02289365|DRUG|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
48684165|NCT02289365|DRUG|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
47998769|NCT01462357|DRUG|Placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
47998770|NCT04329312|RADIATION|Thoracic computed tomography|Patients undergo contrast-enhanced thoracic computed tomography as part of their routine clinical work up.
47998771|NCT05378620|BEHAVIORAL|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
48156798|NCT00050167|DRUG|Docetaxel|75 mg/m\^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
48156799|NCT00050167|DRUG|Capecitabine|1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
48156800|NCT04477954|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
48156801|NCT04712500|DRUG|AND017|AND017 oral capsule
48156802|NCT02547025|DRUG|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
48366549|NCT02227420|DRUG|Anakinra|Anakinra 100mg s.c. x 5
48366550|NCT01777022|OTHER|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
47998772|NCT05268159|OTHER|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
48156803|NCT02547025|DRUG|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
48366551|NCT05814744|DRUG|dexmedetomidine|adding dexmedetomidine as adjuvant with bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy surgery.
48366552|NCT05814744|DRUG|bupivacaine 0.25%|patients will receive bilateral Intermediate Cervical plexus block with 20 ml bupivacaine 0.25%.
48684166|NCT05945381|COMBINATION_PRODUCT|GIC on MIH|Subjects will be seated in a dental chair set-up using standard infection control guidelines. Then the study and its objectives will be explained to the patients and their caregivers. The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.
47998773|NCT01441674|BEHAVIORAL|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
48366553|NCT05814744|PROCEDURE|Thyroidectomy Surgery|surgical removal of all or part of thyroid gland.
48366554|NCT05814744|PROCEDURE|Ultrasound-guided intermediate Cervical Plexus Block Technique|the injection of local anesthetic in intermediate cervical plexus nerve block is made between the investing layer of the deep cervical fascia and the prevertebral fascia. Following negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site.
48366555|NCT02382419|DRUG|carrageenan-containing gel|Applied vaginally
48366556|NCT02382419|OTHER|Placebo|Applied vaginally
48684167|NCT00803738|DRUG|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
48684168|NCT00803738|DRUG|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
48366557|NCT02382419|OTHER|Laboratory Biomarker Analysis|Correlative studies
48684169|NCT01599598|BEHAVIORAL|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
48684170|NCT01599598|BEHAVIORAL|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
48684171|NCT00508105|PROCEDURE|subscapularis peel|"Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel."
47998774|NCT02231346|DRUG|Berodual® Respimat® - inhaler|
47998775|NCT06327399|DRUG|Dexmedetomidine infusion|patients will receive Dexmedetomidine infusion dose of 1 mcg/kg over 10 min before induction.
47998776|NCT06327399|DRUG|Dexmedetomidine bolus|patients will receive Dexmedetomidine bolus dose of 0.3 mcg/kg over 60 seconds.
48366558|NCT02382419|OTHER|Questionnaire Administration|Ancillary studies
48366559|NCT01932528|DRUG|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
47998777|NCT06327399|DRUG|Atropine Sulfate|If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given.
47998778|NCT06327399|DRUG|Ephedrine|If mean blood pressure decreases below 50 mmHg, boluses of 10 mg ephedrine will be given
47998779|NCT06327399|DRUG|Propofol|Propofol 20 mg boluses till loss of contact
47998780|NCT06034509|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
47998781|NCT04270838|BIOLOGICAL|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10
47998782|NCT04270838|BIOLOGICAL|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
47998783|NCT01478126|DRUG|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
48366560|NCT06049823|PROCEDURE|Alveolar ridge preservation|Different grafting strategy of alveolar ridge preservation with different sealing materials
47998784|NCT01478126|DRUG|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
47998785|NCT01438320|DIETARY_SUPPLEMENT|Quercetin|Bioflavonoid
47998786|NCT01044602|OTHER|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
47998787|NCT01044602|OTHER|Best Medical Management|Standard of care.
48156804|NCT02547025|DRUG|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
48156805|NCT03401788|DRUG|Belzutifan|120 mg once daily (three 40 mg oral tablets once daily).
48366561|NCT00166504|DRUG|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
48366562|NCT00166504|DRUG|atorvastatin|atorvastatin 10 mg
48366563|NCT01393444|DEVICE|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
48366564|NCT03876509|DIAGNOSTIC_TEST|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
47998788|NCT01044602|PROCEDURE|Roux-en-Y gastric bypass surgery|Surgical treatment.
48156806|NCT00781209|PROCEDURE|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:\<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
48156807|NCT05067556|BEHAVIORAL|Acceptance and Commitment Therapy for chronic pain (ACT-CP)|Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks.
48684172|NCT00508105|PROCEDURE|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
48156808|NCT01717755|OTHER|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
48684173|NCT02012036|DRUG|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
48684174|NCT05340946|PROCEDURE|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
48684175|NCT05340946|PROCEDURE|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
48684176|NCT03915444|DRUG|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
48684177|NCT01926951|DEVICE|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
48684178|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
48684179|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
48684180|NCT02217813|DRUG|Tafamidis|20 mg of current commercial formulation
47998789|NCT03626714|DRUG|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
48156809|NCT01007851|DRUG|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
48156810|NCT01007851|DRUG|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
48156811|NCT01993342|OTHER|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
48366565|NCT04040725|DRUG|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
48366566|NCT00978705|DRUG|Autologous cultured keratinocyte cell|3x10\^7 cell/ vial
48366567|NCT02449733|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
48512618|NCT00511823|DRUG|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
48512619|NCT00511823|DRUG|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
48684181|NCT02217813|DRUG|Tafamidis|20 mg of new formulation
47998790|NCT00017134|DRUG|fenretinide|
47998791|NCT00017134|PROCEDURE|conventional surgery|
47998792|NCT01280552|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
47998793|NCT01280552|BIOLOGICAL|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
47998794|NCT00584558|PROCEDURE|Catheter Ablation|Catheter Ablation of arrhythmias
47998795|NCT06108505|OTHER|Lacticaseibacillus with oats|Subjects will receive 7.5 gr of oats containing Lacticaseibacillus
47998796|NCT06108505|OTHER|Plain oats|Subjects will receive 7.5 gr of plain oats
48156812|NCT01993342|OTHER|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
48156813|NCT03296007|BEHAVIORAL|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
48156814|NCT01666171|DRUG|metformin hydrochloride|
48156815|NCT01666171|OTHER|clinical observation|
48512620|NCT03672227|BEHAVIORAL|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
48512621|NCT01822366|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy|
48512622|NCT01612065|DRUG|Misoprostol|200 ug
48512623|NCT01612065|DRUG|Misoprostol|Misoprostol vaginally, 400 ug
48684182|NCT05275088|DEVICE|Prizvalve® system|Transcatheter atrioventricular valve replacement
48684183|NCT01294137|DEVICE|ventilatory polygraphy|
48684184|NCT02001324|OTHER|Web-based data collection|
48684185|NCT02001324|OTHER|Paper-based data collection|
47998797|NCT04221685|OTHER|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
47998798|NCT04221685|OTHER|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
47998799|NCT00407563|DRUG|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
47998800|NCT00407563|DRUG|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
48156816|NCT01666171|OTHER|diagnostic laboratory biomarker analysis|
48156817|NCT01666171|OTHER|imaging biomarker analysis|
48156818|NCT01666171|OTHER|medical chart review|
48156819|NCT01666171|PROCEDURE|digital mammography|
48156820|NCT05698888|DRUG|VP301|VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
48156821|NCT01400217|DRUG|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
48156822|NCT01400217|DRUG|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
48156823|NCT05006859|OTHER|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
48156824|NCT05420701|PROCEDURE|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
48156825|NCT05347524|OTHER|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
48366568|NCT02449733|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
48366569|NCT02449733|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
47998801|NCT01514396|DEVICE|Surgiseal|surgical glue
48156826|NCT02020551|DRUG|Lidocaine Spray|
47998802|NCT02094001|RADIATION|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
48512624|NCT05968118|DRUG|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
48512625|NCT05968118|DRUG|Placebo|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections ) Other Name: Placebo
48512626|NCT00356655|BEHAVIORAL|Psychoeducation|
48512627|NCT03887312|BEHAVIORAL|t-CETA|Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
47998803|NCT04839159|OTHER|Blood sampling|Blood sampling at the age of 6 and 12 months, 2-3-4 years
47998804|NCT04839159|OTHER|Blood sampling|Blood sampling before any new sickle cell disease treatment as determined by a physician according to the standard of care to which the hospital adheres
47998805|NCT04112017|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid
48156827|NCT02020551|DRUG|Placebo|
48156828|NCT03371849|DRUG|montelukast and levocetirizine FDC|HCP1102
48156829|NCT03371849|DRUG|Singulair + xyzal|HGP0813 + HGP1408
48156830|NCT00308113|DRUG|Prednisone|Prednisone 0/75 mg/kg/day.
48156831|NCT00308113|DIETARY_SUPPLEMENT|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
48156832|NCT01290471|DRUG|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
48156833|NCT04792541|OTHER|HY containing gel; GUM® Afta Clear Gel, Sunstar|
48156834|NCT04792541|OTHER|saline solution|
48156835|NCT05082493|DRUG|Berubicin Hydrochloride|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
48156836|NCT03441789|DRUG|Enstilar|Enstilar foam applied to affected areas daily
48156837|NCT03441789|DRUG|Vehicle|vehicle foam applied to affected areas once daily
48156838|NCT03441789|DRUG|Otezla|Otezla 30mg
47998806|NCT06253065|DIAGNOSTIC_TEST|Artificial intelligence (AI)-based diagnostic model (developed)|Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
47998807|NCT03392116|BIOLOGICAL|NGM120|Subcutaneous Injection
47998808|NCT03392116|OTHER|Placebo|Subcutaneous Injection
47998809|NCT03243812|BIOLOGICAL|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
47998810|NCT03243812|OTHER|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
47998811|NCT03243812|OTHER|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
47998812|NCT03243812|OTHER|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
47998813|NCT02925546|DRUG|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
48512628|NCT03887312|BEHAVIORAL|Médecins du Monde treatment as usual|Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing \[EMDR\] for trauma, Interpersonal Therapy \[IPT\] for depression, Cognitive Behavioural Therapy \[CBT\], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
48512629|NCT06173856|OTHER|LED phototherapy|LED phototherapy (430-470nm) alone will be applied.
48684186|NCT04015570|BIOLOGICAL|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
48684187|NCT04015570|OTHER|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
47998814|NCT02925546|DRUG|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
47998815|NCT02925546|DRUG|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
47998816|NCT00868933|OTHER|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
47998817|NCT00868933|OTHER|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
48512630|NCT00000812|DRUG|Thalidomide|
48512631|NCT05937737|BEHAVIORAL|Type 2 Diabetes Diet Modification|A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
48512632|NCT06435910|BIOLOGICAL|DC vaccines|Antigen-presenting and immune modifying DCvacs to treat MM
48512633|NCT00789997|DRUG|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
48512634|NCT00789997|DRUG|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
48684188|NCT00221546|DRUG|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
48684189|NCT00236964|DRUG|Iron Sucrose + Erythropoietin|
47998818|NCT01957462|DEVICE|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
47998819|NCT01957462|DEVICE|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
47998820|NCT06481306|DRUG|BMS-986470|Specified dose on specified days
47998821|NCT06481306|DRUG|Placebo|Specified dose on specified days
48156839|NCT01356121|DRUG|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
48512635|NCT00789997|DRUG|levofloxacin|Levofloxacin 750 mg daily for 10 days.
48512636|NCT01378247|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
48512637|NCT06143852|BEHAVIORAL|Mindfulness|12 minute daily guided meditation
48512638|NCT06143852|BEHAVIORAL|Social Media Reduction + Exercise|Reduce social media use at least 30 minutes daily and exercise instead
48512639|NCT00194779|DRUG|doxorubicin hydrochloride|Given IV
48512640|NCT00194779|DRUG|cyclophosphamide|Given PO
48512641|NCT00194779|DRUG|paclitaxel|Given IV
48512642|NCT00194779|BIOLOGICAL|filgrastim|Given SC
48512643|NCT00194779|DRUG|capecitabine|Given PO
48512644|NCT00194779|DRUG|methotrexate|Given IV
48512645|NCT00194779|DRUG|vinorelbine tartrate|Given IV
48512646|NCT00194779|PROCEDURE|needle biopsy|Correlative studies
48684190|NCT00236964|DRUG|Ferrous Sulfate + Erythropoietin|
48684191|NCT00236288|DRUG|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
48684192|NCT02995512|DRUG|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
48366570|NCT02449733|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
47998822|NCT05937295|DRUG|Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination."
47998823|NCT05624346|OTHER|Deep-Breathing Exercises|In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
48366571|NCT02449733|OTHER|HIV Testing|Rapid HIV testing at multiple time points
48366572|NCT02449733|OTHER|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
48366573|NCT02449733|PROCEDURE|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
48366574|NCT02449733|BEHAVIORAL|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
48512647|NCT00194779|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
48512648|NCT00194779|OTHER|immunohistochemistry staining method|Correlative studies
48684193|NCT02487147|OTHER|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
48684194|NCT02487147|OTHER|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
48684195|NCT01454505|DRUG|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
48684196|NCT01454505|OTHER|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
48684197|NCT03075306|BEHAVIORAL|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
48684198|NCT01206140|OTHER|Laboratory Biomarker Analysis|Correlative studies
48684199|NCT01206140|DRUG|Selumetinib|Given PO
48684200|NCT01206140|DRUG|Temsirolimus|Given IV
48684201|NCT04373148|OTHER|There is no intervention|There is no intervention
48684202|NCT01544101|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
48684203|NCT01544101|DIETARY_SUPPLEMENT|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
48684204|NCT00581399|DEVICE|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
48684205|NCT00581399|DEVICE|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
48684206|NCT01248572|DEVICE|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
48684207|NCT03700840|DEVICE|Interdental brushes|interdental brush at 4 sites and PCR analysis
48684208|NCT00924014|DRUG|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
48684209|NCT00924014|DRUG|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
47998824|NCT06122142|DEVICE|Transfluthrin - delivery by paid study personnel|Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel
47998825|NCT06122142|DEVICE|Transfluthrin - delivery by voucher system|Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
47998826|NCT06122142|DEVICE|Transfluthrin - delivery by village health teams|Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
47998827|NCT05094219|OTHER|No intervention will be offered|No intervention will be offered
48512649|NCT00194779|BIOLOGICAL|trastuzumab|Given IV
48512650|NCT00194779|DRUG|tamoxifen citrate|Given PO
48512651|NCT00194779|DRUG|letrozole|Given PO
48512652|NCT00194779|OTHER|laboratory biomarker analysis|Correlative studies
48684210|NCT00924014|DRUG|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
48684211|NCT00562432|DEVICE|Plexisyl-AF|Plexisyl-AF implants
47998828|NCT04686864|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
47998829|NCT03526419|DRUG|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
47998830|NCT01926080|OTHER|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
47998831|NCT01839552|DRUG|Fentanyl Citrate Nasal Spray (FCNS)|
48366575|NCT02844751|BIOLOGICAL|[StroMed + platelet rich plasma (PRP)]|\[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
48366576|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
48366577|NCT02844751|BIOLOGICAL|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
48684212|NCT00562432|OTHER|No Treatment|CABG without the experimental treatment
48684213|NCT04311112|DRUG|Placebos|Placebo
47998832|NCT04721249|DIETARY_SUPPLEMENT|D-serine|Patients will receive four 500mg capsules of D-serine each day over a course of six weeks (two after breakfast and two after dinner).
47998833|NCT04721249|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive four placebo capsules each day (two after breakfast and two after dinner). The placebo capsules will contain Mannotol / Mannitol-Silica (99.5/0.5, respectively) and will be indistinguishable from D-serine by matching colour, shape, size and packaging.
47998834|NCT04128163|DRUG|QL1206|"subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
47998835|NCT04128163|DRUG|Placebos|"subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
48366578|NCT01995396|PROCEDURE|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
48366579|NCT01995396|PROCEDURE|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
48684214|NCT04311112|DRUG|ZA Low dose|ZA low dose
47998836|NCT00302458|DRUG|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
48366580|NCT04791111|OTHER|Questionnaire|validated questionnaire to assess side effects secondary to antimuscarinics treatment in neurogenic bladder
48366581|NCT06331884|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
48684215|NCT04311112|DRUG|ZA high dose|ZA high dose
47998837|NCT00302458|DRUG|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
48684216|NCT04820062|OTHER|Content Validity|For the validity of built, it is generally advisable to include a ratio of 100 participants for 30 questionnaire items. In order to have a suitable questionnaire, we will limit ourselves to 30 items which will be the size of our questionnaire. It was therefore planned to include 100 participants The selection of experts will be based on experience in this area, knowledge and availability. It will be a rescimant physician and an infectious disease doctor. Each expert will be invited in isolation to comment on the items in the questionnaire
47998838|NCT00302458|DRUG|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
47998839|NCT00802399|PROCEDURE|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
47998840|NCT06215963|DEVICE|App for Independence-O (A4i-O)|A4i-O is a digital health platform designed to support individuals with opioid use disorders. A4i-O will focus on providing education on treatment options, recovery navigation, social activation and connections to a range of resources. It aims to assist with fostering self-management and recovery through identifying risks for relapse, navigating urges/cravings, coping with shame/guilt, avoiding relapse, moving forward after relapse, and lived experiences. Daily wellness and goal attainment check-ins to highlight mental health trajectories will be prompted. With appropriate consent from both the client and provider, a provider dashboard is accessible to the client's provider prior to their appointment, generating a summary of day-to-day wellness ratings, responses to reminders, goal progressions, and other self-reported measures from the platform.
47998841|NCT04782856|DRUG|Levothyroxine|levothyroxine sodium tablet for oral use
48684217|NCT04565912|DRUG|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
48684218|NCT04565912|DRUG|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
47998842|NCT04782856|DRUG|Liothyronine|Liothyronine sodium tablets for oral use treatment of hypothyroidism
47998843|NCT04782856|DRUG|Placebo|inert sugar tablets for oral use blinding for treatment of hypothyroidism
47998844|NCT04291339|PROCEDURE|High-flow nasal oxygen technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
47998845|NCT04291339|PROCEDURE|Mask ventilation technique|Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
47998846|NCT03634787|DIAGNOSTIC_TEST|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
47998847|NCT03903354|OTHER|Incidence of infections within 7 days postoperatively|Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery
47998848|NCT03373383|DRUG|Padsevonil|Padsevonil in different dosages.
47998849|NCT03373383|OTHER|Placebo|Placebo will be provided matching Padsevonil.
47998850|NCT04390581|DEVICE|Juvéderm® VOLIFT with Lidocaine|Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.
48156840|NCT01356121|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
48366582|NCT06331884|DRUG|Placebo|Application of placebo
48156841|NCT00787345|OTHER|simulation based training|simulation based training in aseptic techniques that included specified AT categories
48156842|NCT02524951|DRUG|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
48366583|NCT00003524|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48366584|NCT01115205|BEHAVIORAL|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
48366585|NCT01115205|BEHAVIORAL|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
48366586|NCT04698200|OTHER|Cold exposure|Whole body resting cold (+10 degrees centigrade) and heat (+40 degrees centigrade) for 60 minutes.
48366587|NCT00623350|OTHER|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
48366588|NCT00623350|OTHER|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
48684219|NCT05731635|DIAGNOSTIC_TEST|plantar pressure values|Walking enables for extremely accurate and pointwise ground response force measurement because to plantar pressure measurement (pedobarography). It allows for the objective comparison and evaluation of the dynamic pressure put on the ground by the foot in contact with it. It is often used in clinics to assess foot mechanics and associated disorders that affect the foot sole. Additionally, plantar pressure analysis is useful for identifying, treating, and monitoring conditions that impact the lower extremity's axial alignment.
47998851|NCT01928862|DRUG|Prepopik® ½ Sachet x 2 (9-12 years)|
47998852|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (9-12 years)|
47998853|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
47998854|NCT01928862|DRUG|Prepopik® 1 Sachet x 2 (13-16 years)|
47998855|NCT01928862|DRUG|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
47998856|NCT01015586|DRUG|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
47998857|NCT01015586|DRUG|Placebo|Placebo once daily for 12 weeks
47998858|NCT03063476|DRUG|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
47998859|NCT03063476|DRUG|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
48156843|NCT01118429|DRUG|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
48156844|NCT01118429|DRUG|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
47998860|NCT05192746|OTHER|control group|Exercise Therapy and hot pack This tendon exercise program is very effective if done consistently. There are five steps to the program: warm up, stretching exercise, strengthening exercise, stretching exercise, and heat.
47998861|NCT05192746|DEVICE|extracorporeal shock wave therapy|Shock Master 500 device will be applied once a week for four weeks in total. Each treatment consists of 2000 shocks 3 bar pressure, 20 Hz. Each rESWT session will take about 10 minutes. rESWT application will be performed on the supraspinatus trigger point. In successive treatments, there will be using of an energy density equal to 0.28 mJ/mm2
48156845|NCT04156256|BIOLOGICAL|CD123-CD33 cCAR T cells|CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
48156846|NCT02181192|DEVICE|PET/CT|PET/CT
48156847|NCT02181192|RADIATION|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
47998862|NCT05192746|DEVICE|high power pain threshold ultrasound|"High-power, pain-threshold, ultrasound therapy application (in W/cm2) in continuousmodes, to elicit threshold pain, the ultrasound probe must be kept static on the tendon.~Intensity will be gradually increased to the level of maximum pain the patient could bear. It will be kept at that level for 4 to 5 seconds and then will be reduced to the half-intensitylevel for another 15 seconds. This procedure will be repeated 3 times.High-power,"
47998863|NCT02935790|DRUG|ACY-241|tablet
48156848|NCT02181192|RADIATION|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
48156849|NCT02246556|DEVICE|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
48156850|NCT02246556|OTHER|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
48156851|NCT02246556|DEVICE|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
48156852|NCT03684434|BEHAVIORAL|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
48512653|NCT03595007|BEHAVIORAL|Kids Kicking Cancer program|Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
48512654|NCT04220424|DIAGNOSTIC_TEST|MR and Histopathology images based prediction of molecular pathology and patient survival|MR and Histopathology images based prediction of molecular pathology and patient survival in gliomas by leverage artificial intelligence algorithms
48512655|NCT06632704|DEVICE|Colgate Toothbrush assist|toothbrush handle assignment to all subjects; subjects will have a choice between two brush heads
48512656|NCT02460406|OTHER|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching \& walking so on).
48512657|NCT02460406|OTHER|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball \& heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
47998864|NCT02935790|DRUG|nivolumab|infusion
47998865|NCT02935790|DRUG|ipilimumab|infusion
47998866|NCT02793518|BEHAVIORAL|psychological tests|
47998867|NCT03095066|DRUG|Placebo|Administered as capsules
48684220|NCT03441022|DEVICE|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
48366589|NCT04250246|DRUG|Ipilimumab plus nivolumab plus guadecitabine|"Cohort A Melanoma ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM A Guadecitabine: 30-45 mg/m2 s.c./day 1-5 q21 x 4 cycles and from W13 q28 x 6 cycles Ipilimumab: 1 mg/Kg i.v.q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 480mg i.v. q4wks for 2 years"
47998868|NCT03095066|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
48366590|NCT04250246|DRUG|Ipilimumab plus nivolumab|"Cohort A Melanoma ARM B Ipilimumab: 3 mg/Kg i.v. plus nivolumab 1 mg/Kg i.v. on W1, 4, 7 and 10 and from W14 nivolumab 480 mg i.v. q4 wks for 2 years~Cohort B NSCLC ARM B Ipilimumab: 1 mg/Kg i.v. q 6wks plus nivolumab 3 mg/Kg i.v. q2 wks until W13, then ipilimumab: 1 mg/Kg i.v. q6 wks plus nivolumab 480mg i.v. q4wks for 2 years."
48512658|NCT04495335|DEVICE|photobiomodulation|Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
47998869|NCT03095066|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
48512659|NCT01231204|PROCEDURE|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
48366591|NCT04087551|OTHER|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
48366592|NCT02895477|DEVICE|hearing aid|
48512660|NCT01231204|PROCEDURE|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
48512661|NCT02198963|DRUG|Hypochlorous acid solution 106 mg/L|test product
48512662|NCT02198963|DRUG|0.1% (w/v) Sodium Lauryl Sulfate|positive control
48512663|NCT02198963|DRUG|0.9% Physiological Saline, USP|negative control
48512664|NCT00002505|BIOLOGICAL|filgrastim|
48512665|NCT00002505|BIOLOGICAL|recombinant interferon gamma|
48512666|NCT00002505|BIOLOGICAL|tumor cell lysate vaccine therapy|
48366593|NCT03809702|DRUG|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
48366594|NCT03809702|DRUG|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
48366595|NCT04143815|DRUG|MBA-P01 (Botulinum toxin A)|Intramuscular injection, dose varies by groups
48512667|NCT05131828|DRUG|Metformin and clemastine in combination|"Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration."
48512668|NCT05131828|DRUG|Placebo|Placebo tablets to match both metformin and clemastine tablets.
47998870|NCT06109584|DEVICE|Insertion of central venous catheter|Central venous catheter verified by ultrasound and then verified by radiography.
47998871|NCT02848677|BEHAVIORAL|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
47998872|NCT02848677|BEHAVIORAL|usual care|usual care of hypertensive patients.
47998873|NCT00386412|DRUG|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
47998874|NCT05628077|OTHER|No intervention|No intervention
47998875|NCT03818165|BIOLOGICAL|CAR2 Anti-CEA CAR-T cells|doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)
47998876|NCT01279408|OTHER|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
47998877|NCT01998451|DRUG|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
47998878|NCT05457569|OTHER|Focus group (FC) - WP1|"3 group meetings for each group of parents:~1. Parents only~2. Parents and representatives of patient support groups~3. Parents and health professionals specialized in the care of these children at risk"
48512669|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
47998879|NCT05457569|OTHER|Child Neurodevelopment Questionnaires - WP2|during the 4th month of corrected infant age
48512670|NCT01662401|DRUG|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
48684221|NCT03441022|DEVICE|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
47998880|NCT05457569|OTHER|Evaluation of compliance for the acquired skills in terms of development support - WP2|during the 4th month of corrected infant age
47998881|NCT05457569|OTHER|Evaluation of physiotherapist satisfaction with the follow-up and the time spent at the consultation - WP2|at the end of the study
47998882|NCT05457569|OTHER|4 Focus Group (FC) - WP2|"* Parents who accepted the follow-up~* Parents who have partially completed the programme~* Maternal and Child Protection \& CAMSP professionals~* Physiotherapists in a private practice"
47998883|NCT01386736|DRUG|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
47998884|NCT01386736|DRUG|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
47998885|NCT01380184|DRUG|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
47998886|NCT04389125|DIETARY_SUPPLEMENT|Angelica Gigas Nakai and Allium Cepa L.Extract Mixtures|One packet once a day, after breakfast, for 12 week
47998887|NCT04389125|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 week
47998888|NCT04470999|OTHER|Leukapheresis|Blood collection and PBMC collection via apheresis machine will be conducted
47998889|NCT00144365|DRUG|Antiretroviral therapy|
47998890|NCT02134132|BIOLOGICAL|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
47998891|NCT02134132|OTHER|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
47998892|NCT06025630|DRUG|TUDCA|Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
47998893|NCT06025630|DRUG|Placebo|Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
47998894|NCT04924036|DRUG|glycopyrronium cloths|Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
47998895|NCT04924036|DRUG|Placebo|Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
47998896|NCT02945410|OTHER|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
47998897|NCT02945410|OTHER|Protein|Participants will consume 1.7 g protein/kg BW/day.
47998898|NCT02945410|OTHER|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
47998899|NCT02945410|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
47998900|NCT02945410|OTHER|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
47998901|NCT05609955|DRUG|MgSO4|The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
47998902|NCT00802412|DRUG|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
47998903|NCT00802412|DRUG|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
47998904|NCT02653742|DRUG|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
47998905|NCT02653742|DRUG|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
48366596|NCT04143815|DRUG|Placebo|Intramuscular injection
47998906|NCT00128921|DRUG|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
47998907|NCT02086669|PROCEDURE|Pneumatic dilatation|
47998908|NCT02086669|PROCEDURE|Laparoscopic myotomy|
48512671|NCT01786889|BIOLOGICAL|blood and urine|Blood collection and urine collection after consent of the patient
47998909|NCT01167231|DRUG|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
47998910|NCT01336075|PROCEDURE|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
48156853|NCT03684434|BEHAVIORAL|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
48512672|NCT01786889|BEHAVIORAL|Questionnaire|The patient complete the questionnaire alone at home
48366597|NCT05964933|PROCEDURE|Complete Pulpotomy|"Complete caries removal and excision of the entire coronal pulp to the level of the root canal orifices will be performed. After haemostasis, the pulp chamber will be filled with Biodentine® and a final direct restoration placed in 1 or 2 visits.~If there is no bleeding from the exposed pulp, pulpectomy and root canal treatment will be performed instead, and the patient will be excluded from the study."
48512673|NCT01786889|BEHAVIORAL|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
48512674|NCT03613727|DRUG|Intravenous (IV) and oral Vitamin C|"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"
48512675|NCT02959424|OTHER|Spanish Northwestern Esophageal Quality of Life questionnaire|
47998911|NCT01336075|PROCEDURE|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
47998912|NCT05868070|DEVICE|Conventional rehabilitation plus multimodal exercise|Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
47998913|NCT02014363|DRUG|ETS6103 (low dose)|
47998914|NCT02014363|DRUG|ETS6103 (high dose)|
47998915|NCT02014363|DRUG|Amitriptyline|
47998916|NCT00116831|DRUG|Glipizide|oral anti-diabetic medication
47998917|NCT00116831|DRUG|rosiglitazone maleate|oral antidiabetic medication
48366598|NCT05964933|PROCEDURE|Pulpectomy and Root Canal Treatment|After complete caries removal and pulp exposure, Pulpectomy will be performed to remove all pulp tissues. Conventional root canal treatment will be performed using rotary instrumentation followed by obturation with gutta percha and traditional sealers in 1 or 2 visits. A final restoration will be placed to ensure a good coronal seal, and this may include full coronal coverage restorations if clinically indicated.
48684222|NCT02840435|BEHAVIORAL|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
48684223|NCT02840435|BEHAVIORAL|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
48684224|NCT01101958|DEVICE|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
48684225|NCT01101958|DEVICE|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
48684226|NCT03754556|DEVICE|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
48684227|NCT04803864|DRUG|Roxadustat|Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
48684228|NCT04560686|DRUG|Bintrafusp Alfa|Given IV
48684229|NCT04560686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48684230|NCT02340169|DRUG|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
48684231|NCT02881411|OTHER|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
48684232|NCT02881411|OTHER|Fibromyalgia coping skills programme|Exercise, education programme
48684233|NCT01530503|DRUG|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
47998918|NCT04606979|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
47998919|NCT02724904|PROCEDURE|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
47998920|NCT02724904|DRUG|Fludarabine|Standard Treatment
47998921|NCT02724904|DRUG|Thiotepa|Standard Treatment
47998922|NCT02724904|DRUG|Methotrexate|IV Bolus
47998923|NCT05041933|DRUG|outsourcing of chemotherapy to Hospital at Home|outsourcing of chemotherapy to Hospital at Home
48366599|NCT00324519|DEVICE|Foley bulb|
48366600|NCT00324519|DRUG|misoprostol|
48512676|NCT01270191|DRUG|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
48512677|NCT01270191|DRUG|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
48512678|NCT00435760|DRUG|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
48512679|NCT00435760|DRUG|Placebo Tiotropium|1 puff once daily, 1 day treatment
48512680|NCT00435760|DRUG|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
48366601|NCT04083287|OTHER|Erector spinae plane block (Group E)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
48366602|NCT04083287|OTHER|Interscalen brachial plexus block (Group I)|"Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
48366603|NCT04465903|OTHER|Turkish Version of Sydney Swallow Questionnaire|The Turkish Version of Sydney Swallow Questionnaire consists of 17 questions related with dysphagia.
48684234|NCT01530503|DRUG|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
48684235|NCT04211285|DIAGNOSTIC_TEST|e-GAB|android application for comprehensive geriatric assessment
48684236|NCT04211285|DIAGNOSTIC_TEST|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
47998924|NCT04626869|OTHER|Evaluation of Diaphragm Movement|Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
47998925|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
47998926|NCT04916795|DRUG|Vupanorsen|80 mg subcutaneous injection
47998927|NCT03488979|OTHER|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
47998928|NCT05719012|BIOLOGICAL|UC-MSCs|Intravenous injection three times with one-month interval
47998929|NCT03741036|PROCEDURE|Autogenous bone graft as space filling in immidiate implant placment|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
47998930|NCT03741036|PROCEDURE|Deprotinized bovien as space filling in immidate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
48156854|NCT01818453|BEHAVIORAL|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
48366604|NCT02443727|DRUG|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
48366605|NCT02443727|OTHER|Placebo|Dosage and details described in arm.
48512681|NCT00435760|DRUG|Placebo LAS34273|1 puff, 1 dat treatment
48684237|NCT00910910|DRUG|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
48684238|NCT00910910|DRUG|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
48684239|NCT04165460|OTHER|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
48684240|NCT04165460|OTHER|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
48684241|NCT04165460|OTHER|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
48684242|NCT04165460|OTHER|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
48684243|NCT02942888|DIETARY_SUPPLEMENT|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
48684244|NCT02942888|DIETARY_SUPPLEMENT|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
48366606|NCT04135222|DIAGNOSTIC_TEST|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
48366607|NCT01439932|DEVICE|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]"
48366608|NCT00402376|DRUG|Pravastatin, Carvedilol, Perindopril|
48366609|NCT00402376|DEVICE|Biventricular assist device (Thoratec paracorporeal assist device)|
48366610|NCT01657994|OTHER|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
48366611|NCT00000649|DRUG|Nevirapine|
48366612|NCT00000649|DRUG|Zidovudine|
48366613|NCT06241144|DEVICE|Information and communication technology -based health behavior change support system|Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
48366614|NCT06313567|DRUG|Metronomic capecitabine group|500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
48156855|NCT03973437|DEVICE|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
48684245|NCT03398941|DRUG|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
48684246|NCT04212715|RADIATION|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
47998931|NCT03741036|PROCEDURE|Nano-hydroxiapatite alloplast in immidiate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
47998932|NCT02717988|DRUG|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
47998933|NCT02717988|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
48366615|NCT06313567|OTHER|Observation|observation
48366616|NCT00469391|DEVICE|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
47998934|NCT04961034|PROCEDURE|kasai portoenterostomy|surgical creation of stoma between porta hepatis and jejunal loop
47998935|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
47998936|NCT05767632|DRUG|Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)|1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water
47998937|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
47998938|NCT00003196|DRUG|chemotherapy|Undergo cytoreductive chemotherapy
47998939|NCT00003196|RADIATION|total-body irradiation|Undergo TBI
48366617|NCT00469391|PROCEDURE|Sham Procedure|Weight loss
48366618|NCT03418727|DRUG|Brimonidine|Two products delivered in sequence twice daily.
48366619|NCT03418727|DRUG|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
48366620|NCT03418727|DRUG|sodium carboxymethylcellulose|Placebo given twice daily.
47998940|NCT00003196|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
47998941|NCT00003196|DRUG|cyclosporine|Given IV or PO
47998942|NCT00003196|DRUG|mycophenolate mofetil|Given PO
47998943|NCT00003196|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
47998944|NCT00003196|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
47998945|NCT03387449|DEVICE|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
47998946|NCT03947151|DRUG|Degarelix injection(s)|1 or 2 degarelix injection(s)
48366621|NCT03418727|DRUG|Corticosteroid Eye Drop|Eye drop to be administered after Brimonidine in treatment arm 1
47998947|NCT02511470|OTHER|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
47998948|NCT02511470|OTHER|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
47998949|NCT01411306|OTHER|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
48366622|NCT06452680|PROCEDURE|Preserving IPL during surgery|IPL was preserved during surgery
48366623|NCT04917536|PROCEDURE|Humeral neailling in humeral fractures|Humeral neailling in humeral fractures
48366624|NCT01861587|DEVICE|tDCS|20 minutes of either real or sham stimulation
48366625|NCT03110497|RADIATION|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
48366626|NCT06337773|BEHAVIORAL|8-weeks's on-line precision nursing education program|The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
48366627|NCT00783055|OTHER|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
48366628|NCT01967927|DRUG|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
48366629|NCT01721213|DRUG|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
48366630|NCT05262946|BEHAVIORAL|sensorimotor training based on Feldenkrais method|8 weeks of balance and sensorimotor training twice a week
48366631|NCT05262946|BEHAVIORAL|foot care education|Recommendations for preventing foot ulcers
48366632|NCT05262946|COMBINATION_PRODUCT|usual care|drugs and diet usual care
48366633|NCT05868629|OTHER|Non-investigational|Participants obtaining commercial (non-investigational) dabrafenib plus trametinib (i.e. solid formulation or liquid formulation, if approved and commercially available locally) per local guidance or patient access program
48684247|NCT06517368|DEVICE|MRI, Ultrasound|The patients will undergo both B-mode and sonoelastographic examinations in the supine and lateral decubitus position and will perform during breath-holding after deep inspiration. The elastogram was displayed over the B-mode image in a color scale: red (greatest strain, softest tissue component), green (average strain, intermediate tissue component), and blue (no strain, hardest tissue component) Patients will be examined by MRI with diffusion images and ADC values.
48684248|NCT03005236|DRUG|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
48684249|NCT03005236|DRUG|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
48366634|NCT02503956|DEVICE|Perforated Punctal plugs|Perforated punctal plugs
47998950|NCT01411306|PROCEDURE|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
48366635|NCT02503956|PROCEDURE|Crawford tube insertion|
48366636|NCT02503956|DEVICE|Crawford lacrimal tube|
48366637|NCT03929237|OTHER|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
48366638|NCT05896800|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
48684250|NCT05748509|OTHER|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
48684251|NCT05135039|DRUG|Canagliflozin|Canagliflozin 100mg/day/patient
48684252|NCT05135039|DRUG|Placebo|Placebo 100mg/day/patient
48684253|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
48684254|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
47998951|NCT00496847|DRUG|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
48366639|NCT03375866|OTHER|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
48366640|NCT03375866|OTHER|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
48366641|NCT00771420|DRUG|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
48366642|NCT00771420|DRUG|CAM-3001|Dosed at 0.1mg/kg.
48366643|NCT00771420|DRUG|CAM-3001|Dosed at 0.3mg/kg
48366644|NCT00771420|DRUG|CAM-3001|Dosed at 1.0 mg/kg.
48366645|NCT00771420|DRUG|CAM-3001|Dosed at 3.0 mg/kg.
48366646|NCT00771420|DRUG|CAM-3001|Dosed at 10 mg/kg.
48366647|NCT00771420|OTHER|Placebo|Active: Placebo 5:1 for arms 2-6
48366648|NCT04642326|DEVICE|Test Group: experimental - UVC Therapy applied|in addition to traditional drug therapy, apply a surgical treatment procedures with using special UVC device.(Antiviral + Antimalarial + Antibiotic Treatment + UVC Therapy)
48684255|NCT04741841|DIETARY_SUPPLEMENT|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
48684256|NCT01635998|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
47998952|NCT00496847|DRUG|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
47998953|NCT02436759|DRUG|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
47998954|NCT02436759|DRUG|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
47998955|NCT02889094|OTHER|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
48366649|NCT04406324|OTHER|No intervention|No Intervention. The study consists in a prospective clinical longitudinal follow-up
48366650|NCT04843228|BEHAVIORAL|Cognitive Bias Modification|There will be four sessions of CBM. Each session will consist of two different part. The first part of the intervention will be the training based on the ambiguous scenario paradigm for perfectionism developed by Dodd (2019). Participants will need to complete word fragments in the last part of the scenario to resolve the ambiguity of the scenario. Then, a comprehension question will be presented to them to underscore the interpretation condition. Feedback will be given after each question. For the second part of the intervention aimed to intervene intolerance to uncertainty, word sentence association paradigm for intolerance to uncertainty developed by Oglesby (2017) will be used. In this intervention, participants will be asked to judge the relatedness of words and sentences which will be presented to them. Feedback will be given after each word-sentence.
48684257|NCT00873275|BIOLOGICAL|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
47998956|NCT00668486|DRUG|Lactic acid (Dermacid)|
47998957|NCT04328831|BIOLOGICAL|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody injection
47998958|NCT01803633|OTHER|Cheddar cheese|Tillamook medium cheddar cheese brand
48684258|NCT00873275|DRUG|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
48684259|NCT00873275|DRUG|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
48684260|NCT00873275|DRUG|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
48684261|NCT00873275|DRUG|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
48684262|NCT00873275|DRUG|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
47998959|NCT01803633|OTHER|Vegan cheese|Daiya brand vegan cheese
47998960|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate and Ipratropium Bromide|
47998961|NCT03480997|COMBINATION_PRODUCT|Albuterol Sulfate|
47998962|NCT05953662|PROCEDURE|Reduced-port laparoscopic surgery|compare different operational styles of colon and upper rectal cancer
47998963|NCT05953662|PROCEDURE|conventional laparoscopic surgery|conventional laparoscopic surgery
47998964|NCT04471753|BEHAVIORAL|Coma Recovery Scale-Revised|Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
48684263|NCT00873275|GENETIC|RNA analysis|Analysis on discard tissues
47998965|NCT02904057|DEVICE|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
48366651|NCT04843228|BEHAVIORAL|Cognitive Bias Modification for Control Group|For the first part of the intervention, the control group will be presented with the same procedures as the active group; however, feedbacks will be given to resolve the scenarios in a neutral way. When it comes to the second part of the intervention, different word-sentence pairings will be presented to the control group.
48366652|NCT00298506|DRUG|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
48366653|NCT05106101|DRUG|L-glutamine|L-glutamine oral powder in 5 gram packet
48684264|NCT00873275|GENETIC|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
48684265|NCT00873275|GENETIC|polymerase chain reaction|Analysis on discard tissues
48684266|NCT00873275|GENETIC|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
48684267|NCT00873275|OTHER|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
48684268|NCT00873275|OTHER|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
48684269|NCT00873275|OTHER|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
48684270|NCT00873275|PROCEDURE|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
48684271|NCT04723498|DIAGNOSTIC_TEST|screening questionnaire|Fill in screening questionnaire
48684272|NCT02951234|OTHER|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
48684273|NCT02951234|OTHER|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
48684274|NCT04220580|OTHER|Blood samples|3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
48684275|NCT00931125|DRUG|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
48684276|NCT00931125|PROCEDURE|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
47998966|NCT06300164|DIETARY_SUPPLEMENT|Unripre Carob|The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.
47998967|NCT03152539|RADIATION|MRI|
47998968|NCT03152539|DEVICE|EEG|
47998969|NCT03152539|DEVICE|NIRS|
47998970|NCT01475630|PROCEDURE|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
47998971|NCT01475630|PROCEDURE|control|relaxation
47998972|NCT05826782|BIOLOGICAL|Proxeed Plus 2*1 A arm|Proxeed plus 2 x daily sachets (2\*1) three mounths
48366654|NCT01243047|DRUG|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
48684277|NCT03109743|BEHAVIORAL|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
48684278|NCT03109743|BEHAVIORAL|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
48684279|NCT06099223|DEVICE|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
47998973|NCT05826782|BIOLOGICAL|Placebo|Placebo 2 x daily sachets (2\*1) three mounths
48684280|NCT06056206|RADIATION|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
48684281|NCT05809323|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
48366655|NCT04087733|DRUG|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
47998974|NCT04104009|OTHER|Education|"Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study."
47998975|NCT04104009|OTHER|No education|In the control group there will be no education, no breathing exercises and no listening to classical music.
47998976|NCT00045747|DRUG|7-hydroxystaurosporine|
47998977|NCT00045747|DRUG|fluorouracil|
47998978|NCT05993611|PROCEDURE|Biopsy|Undergo biopsy
48684282|NCT05809323|OTHER|Control Group|Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
48684283|NCT00828958|DRUG|Risperidone long-acting injectable|
48684284|NCT05626140|DRUG|Lacosamide 50 MG Oral Tablet [Vimpat]|Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
47998979|NCT05993611|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
47998980|NCT05993611|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD6-CAR Tregs IV
47998981|NCT05993611|PROCEDURE|Computed Tomography|Undergo CT
47998982|NCT05993611|PROCEDURE|Echocardiography|Undergo ECHO
47998983|NCT05993611|OTHER|Electronic Health Record Review|Ancillary studies
47998984|NCT05993611|PROCEDURE|Leukapheresis|Undergo leukapheresis
47998985|NCT05993611|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
47998986|NCT05993611|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
47998987|NCT05993611|OTHER|Quality-of-Life Assessment|Ancillary studies
48156856|NCT03973437|DEVICE|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
47998988|NCT05993611|BIOLOGICAL|Tafasitamab|Given IV
48156857|NCT03151109|DIAGNOSTIC_TEST|CT Scan|CT scan at minimum 1 year post op
48156858|NCT01588379|BEHAVIORAL|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
48156859|NCT01588379|BEHAVIORAL|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
48156860|NCT01588379|OTHER|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
48156861|NCT03288480|DRUG|PT-112|This is a single arm study
48156862|NCT04011995|BEHAVIORAL|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
48684285|NCT05626140|DRUG|Codeine Phosphate|Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
48684286|NCT05626140|DRUG|Diclofenac Sodium|Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
48684287|NCT03496064|OTHER|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
48684288|NCT03621072|DRUG|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
47998989|NCT05993611|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
47998990|NCT03239470|BIOLOGICAL|Cohort 1: 1.0 x 10^8 PolyTregs|Each participant will receive a target cell dose of 1.0 x 10\^8 polyclonal Tregs.
47998991|NCT03239470|BIOLOGICAL|Cohort 2: 2.5x10^8 PolyTregs|Each participant will receive a target cell dose of 2.5x10\^8 polyclonal Tregs.
47998992|NCT03681457|DRUG|LJN452|Dose A single dose
47998993|NCT01276093|PROCEDURE|PVI ablation|Pulmonary Vein Ablation using RF.
47998994|NCT01276093|DRUG|Amiodarone|Amiodarone tablets
47998995|NCT03025828|DRUG|ACTHar|for 6 months
47998996|NCT03254238|OTHER|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
47998997|NCT05250024|DEVICE|UHMWP Cranioplasty|patient specific cranial implant
47998998|NCT05250024|DEVICE|PEEK Cranioplasty|patient specific cranial implant
47998999|NCT04624321|BEHAVIORAL|Health and lifestyle tool|Health and lifestyle tool used online
47999000|NCT04624321|OTHER|Usual care|Usual care at ordinary healthcare provider
47999001|NCT03509038|OTHER|Exploratory pathophysiology Study|Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
47999002|NCT02972632|DRUG|Vortioxetine|Vortioxetine tablet
47999003|NCT05472558|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
47999004|NCT02357069|DRUG|Enbrel|Etanercept
47999005|NCT02357069|DRUG|LBEC0101|Etanercept
47999006|NCT06404827|OTHER|Horseback riding simulator|Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation.
48156863|NCT04011995|BEHAVIORAL|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
48512682|NCT03691727|DRUG|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
48684289|NCT03621072|DRUG|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
47999007|NCT06404827|OTHER|Routine Physiotherapy and Rehabilitation|Routine Physiotherapy and Rehabilitation within a spesific programme
47999008|NCT03387163|DRUG|Sacubitril/Valsartan|commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
47999009|NCT01302574|DIETARY_SUPPLEMENT|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
47999010|NCT02325336|DEVICE|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
47999011|NCT01126996|PROCEDURE|Venepuncture|"1. Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~2. A booster dose of a MenC conjugate vaccine (optional)."
47999012|NCT03072485|DRUG|Sirolimus|Topical sirolimus applied to the skin
47999013|NCT03072485|DRUG|Metformin|Topical metformin applied to the skin
47999014|NCT03072485|DRUG|Diclofenac|Topical diclofenac applied to the skin
48684290|NCT02562846|OTHER|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
47999015|NCT00806546|DRUG|NP101|NP101 study patch four hour application
47999016|NCT05605340|BEHAVIORAL|Meal Delivery|10 healthy, home-delivered meals per week + brief weekly remote behavioral support
47999017|NCT03462212|DRUG|Carboplatin|chemotherapy medication
48156864|NCT04011995|BEHAVIORAL|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
47999018|NCT03462212|DRUG|Paclitaxel|chemotherapy medication
47999019|NCT03462212|DRUG|Bevacizumab|Angiogenesis inhibitor
47999020|NCT03462212|DRUG|Rucaparib|PARP inhibitor
47999021|NCT01274624|BIOLOGICAL|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
48156865|NCT02835209|OTHER|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
48156866|NCT03130699|BEHAVIORAL|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
47999022|NCT01274624|DRUG|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
47999023|NCT01274624|DRUG|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
47999024|NCT01274624|DRUG|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
47999025|NCT01274624|DRUG|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
47999026|NCT00256919|DRUG|GW856553|
47999027|NCT04338438|DRUG|Apatinib Mesylate tablets combined with S-1 capsules|Apatinib Mesylate tablets combined with S-1 capsules, p.o.
47999028|NCT05898295|OTHER|no intervention|No intervention: only observation of the child behavior
47999029|NCT03587935|OTHER|3D-Colonoscopy Progression Score|The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000. A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
47999030|NCT03587935|OTHER|3D-Colonoscopy Retraction Score|The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000.
47999031|NCT05020340|PROCEDURE|External cephalic version|In the intervention group, ECV will be performed by two operators with one of them having experience of ≥ 5 successful ECV. The procedure will be performed by the first operator under real time continuous ultrasonographic guidance. The fetal head and buttock will be grasped by both hands and attempt to rotate the fetus to a longitudinal lie either in a clockwise or anti-clockwise fashion. The second operator will perform the ECV if the first operator fails the procedure.
48512683|NCT03691727|DIAGNOSTIC_TEST|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
48512684|NCT03691727|DIAGNOSTIC_TEST|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
48512685|NCT03691727|BEHAVIORAL|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
48684291|NCT04186533|BEHAVIORAL|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
48684292|NCT04186533|BEHAVIORAL|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
48684293|NCT04490525|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
48684294|NCT00057759|DRUG|sildenafil citrate|
48684295|NCT00057759|OTHER|Placebo|Placebo
48684296|NCT05028699|OTHER|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
47999032|NCT05838131|DRUG|Experimental: CAR-T cells Infusion|"Biological:~chimeric antigen receptor T cells"
47999033|NCT06296667|OTHER|core muscles training exercises|The sessions will be conducted three times per week for four weeks and each exercise will be performed two sets of 10 repetitions. For the static exercises, the final position will be held for 6 second. There will be a pause of 3 second between repetitions, and a 60 sec rest between each exercise. The exercise will be performed in three forms: abdominal bracing, dynamic stabilization, and advanced core strengthening.
48684297|NCT00530634|DRUG|cisplatin|
47999034|NCT06276959|DIAGNOSTIC_TEST|intraoral scanning|The patients underwent intraoral scanning using an iTero Element 5D imaging system (Align Technology, San Jose, CA, USA). This imaging system uses near-infrared light with a wavelength of 850 nm and provides multiple layers of data in a single scan, including a three-dimensional (3D) model, two-dimensional (2D) color images, and NIRI mapped to the 3D model
47999035|NCT06276959|DIAGNOSTIC_TEST|clinical oral examination|Under illumination in the dental unit, a UVE of the proximal surfaces of the patient's entire dentition was conducted by clinicians using a mouth mirror, dental probe, and an air-water syringe. Visual and tactile methods were performed according to the guidelines of the American Dental Association. Clinicians assessed the soundness of the proximal surfaces based on the presence of discoloration, surface alterations, or cavitation.
48684298|NCT00530634|DRUG|gemcitabine hydrochloride|
48684299|NCT00530634|GENETIC|gene expression analysis|
48684300|NCT00530634|GENETIC|reverse transcriptase-polymerase chain reaction|
48156867|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
48156868|NCT03130699|BEHAVIORAL|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
48156869|NCT00591084|DRUG|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
48684301|NCT00530634|OTHER|immunohistochemistry staining method|
48684302|NCT00530634|PROCEDURE|adjuvant therapy|
48512686|NCT03691727|DIAGNOSTIC_TEST|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
48512687|NCT03691727|OTHER|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
48512688|NCT06063057|BIOLOGICAL|low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml
48512689|NCT06063057|BIOLOGICAL|medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml
48512690|NCT06063057|BIOLOGICAL|high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated|Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml
48512691|NCT06063057|BIOLOGICAL|Enterovirus type EV71 vaccine (Vero cell), Inactivated|Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)
48512692|NCT06632652|BEHAVIORAL|Health Education|"Provide 'Health Education' for acquisition of self-management skills, acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients are able to manage their diet, exercise and medication.~Patients will start implementing diabetes management right after the group education. Each patient will develop monthly goal settings (behavior change plan) related to their diabetes management, daily practice them, and record the results every day on the self-monitoring notebook. The nurses call each patient on the scheduled day, ask/evaluate his/her behavior changes and monitored data, then make step-up goals for the next month. In addition, based on his/her knowledge and practice level, the nurses provide education using the education booklet. Patients and the nurses repeat these activities during 6 months."
48512693|NCT05771844|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
48512694|NCT00275119|DRUG|fluorouracil|
48512695|NCT00275119|DRUG|gemcitabine hydrochloride|
48512696|NCT00275119|DRUG|oxaliplatin|
48512697|NCT00275119|RADIATION|radiation therapy|
48684303|NCT00530634|PROCEDURE|conventional surgery|
48156870|NCT00591084|DRUG|placebo|infusion placebo (group B)once a day and continued for 14 days
48156871|NCT00591084|DRUG|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
47999036|NCT06276959|DIAGNOSTIC_TEST|cone-beam computed tomography|All enrolled patients underwent CBCT scans because clear aligner treatment required real root/bone visualization features. We would like to clarify that due to the retrospective cross-sectional nature of this study, the patients involved were not subjected to radiation beyond what was initially necessary for their orthodontic treatment.
47999037|NCT03439371|OTHER|HLA-mismatched micro-transplantation after induction chemotherapy|HLA-mismatched micro-transplantation after induction chemotherapy
47999038|NCT04975555|DRUG|Siltuximab|Siltuximab is administered at the dose of 11mg/kg via intravenous infusion over 1 hour. If no resolution of CRS is achieved then a repeat dose of siltuximab at the dose of 11mg/kg via intravenous infusion over 1 hour will be given.
48156872|NCT05283642|DIETARY_SUPPLEMENT|DCI|Oral supplementation with D-chiro-inositol once daily
48156873|NCT00965393|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
48156874|NCT00965393|DRUG|Placebo|Systemic infusion of placebo (saline)
48156875|NCT00965393|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
48156876|NCT05222178|DRUG|HMI-103|HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
48684304|NCT00530634|RADIATION|radiation therapy|
47999039|NCT00506090|PROCEDURE|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
48156877|NCT01332318|DRUG|XP13512|XP13512 once daily for 16 days
48156878|NCT01332318|DRUG|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
48684305|NCT00648921|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fasting
48156879|NCT01332318|DRUG|Placebo|XP13512 placebo once daily for 16 days
48156880|NCT05299099|DRUG|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
48156881|NCT05299099|DRUG|RCN301|RCN301 will be injected continuously for 3 days.
48156882|NCT00218075|DRUG|Levodopa|
48156883|NCT00218075|DRUG|Carbidopa|
48156884|NCT00218075|BEHAVIORAL|Clinical Management|
48156885|NCT00218075|BEHAVIORAL|Relapse Prevention Therapy|
48156886|NCT00218075|BEHAVIORAL|Contingency Management|
48156887|NCT03130127|DRUG|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
48156888|NCT00465699|DRUG|Topical B12 0.07%|
48156889|NCT04563026|DRUG|DUR-928 30 mg|IV infusion
48684306|NCT00648921|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fasting
48684307|NCT04413214|DRUG|Carrimycin|The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
48684308|NCT02509364|OTHER|No intervention|
48684309|NCT04646252|OTHER|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
48684310|NCT02291133|PROCEDURE|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
48684311|NCT02291133|DEVICE|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
48684312|NCT02291133|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
48684313|NCT00886860|DRUG|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
48684314|NCT00886860|DRUG|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
48684315|NCT01971671|OTHER|no intervention.|
47999040|NCT01734551|DRUG|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is \<0.1mg/kg/day, may discontinue."
47999041|NCT01734551|DRUG|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
48684316|NCT03873298|DRUG|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
48156890|NCT04563026|DRUG|DUR-928 90 mg|IV infusion
48156891|NCT04563026|DRUG|Placebo+ Standard of Care (SOC)|IV infusion
47999042|NCT03255343|DEVICE|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
47999043|NCT02599181|OTHER|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.
48684317|NCT02193009|BEHAVIORAL|SipSmarter|6-month behavioral trial
47999044|NCT04497779|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or nasopharyngeal swabs
47999045|NCT04497779|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
47999046|NCT04497779|OTHER|Electronic Health Record Review|Donors and recipients have their medical records reviewed.
47999047|NCT04497779|OTHER|Questionnaire Administration|Ancillary studies
48156892|NCT06539390|OTHER|Transforaminal Epidural Injections?|Pain, lumbar disc herniation,Transforaminal Epidural Injections?
48156893|NCT01256645|OTHER|blood transfusion|application of single units of red blood cell transfusions
48156894|NCT00266136|DRUG|Cytarabine|see protocol
48156895|NCT00266136|DRUG|Thioguanine|see protocol
48156896|NCT00266136|DRUG|Daunorubicin|see protocol
48156897|NCT00266136|DRUG|Cyclophosphamide|see protocol
48156898|NCT00266136|DRUG|G-CSF|see protocol
48684318|NCT02193009|BEHAVIORAL|MoveMore|6 month behavioral trial
48684319|NCT00322049|BIOLOGICAL|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
48684320|NCT00322049|BIOLOGICAL|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
48684321|NCT06354348|DIAGNOSTIC_TEST|USG, Grip strength, Chair stand test (CST)|Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
48684322|NCT01771991|DRUG|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
48684323|NCT01771991|DRUG|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
48684324|NCT03595150|DRUG|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
48684325|NCT03391830|DRUG|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
48684326|NCT03391830|DRUG|Placebo|Placebo
48684327|NCT06353048|PROCEDURE|fixation of tibial plateau fractures|fixation of tibial plateau fractures by screws only versus plate and screws
48684328|NCT05761288|BEHAVIORAL|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
48684329|NCT02508584|BIOLOGICAL|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
48684330|NCT04740086|PROCEDURE|Calcium alginate hydrogel|"1. The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~2. The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~3. Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~4. Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~5. The IFO was closed with a 3/0 braided resorbable suture.~6. The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
48684331|NCT00500565|DRUG|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
48684332|NCT00500565|DRUG|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
48684333|NCT06390046|PROCEDURE|Intubation|Comparing videao laryngospy with traditional laryngoscopy
48684334|NCT06390046|DRUG|TIVA versus Inhalation|comparing TIVA with genera anesthesia with inhalation agent
48684335|NCT01693198|PROCEDURE|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
47999048|NCT02181062|BEHAVIORAL|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
47999049|NCT04305795|BIOLOGICAL|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
47999050|NCT04305795|BIOLOGICAL|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
48156899|NCT00266136|PROCEDURE|Autologous stem cell transplantation|for details see protocol
48684336|NCT03026296|BEHAVIORAL|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
48684337|NCT05373758|OTHER|Standard of Care treatment strategy|Management of virologic failure on TLD using the Standard of Care strategy
48684338|NCT05373758|OTHER|Individualized Care treatment strategy|Management of virologic failure on TLD using the Individualized Care strategy
48684339|NCT05373758|OTHER|Immediate Switch|Management of virologic failure on TLD using the Immediate Switch strategy
48684340|NCT05117567|COMBINATION_PRODUCT|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
48684341|NCT06027619|DRUG|Topical aminolevulinate (10% ALA gel)|10% ALA gel to the entire face, without occlusion, followed by a prespecified incubation period
48684342|NCT06027619|DEVICE|Red light illumination|Illumination of red light of narrow spectrum of 635 nm with a light dose of approximately 37 J/cm2
48684343|NCT02846792|BIOLOGICAL|Nivolumab|Given IV
48684344|NCT02846792|DRUG|Plinabulin|Given IV
48684345|NCT04508933|DEVICE|Extravascular Lung Water Index|Measurement of the EVLWI
48684346|NCT04508933|DEVICE|Pulmonary Vascular Permeability Index|Measurement of the PVPI
48684347|NCT01819363|PROCEDURE|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
48684348|NCT02704975|DEVICE|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
48684349|NCT02704975|DEVICE|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
48684350|NCT02574767|BEHAVIORAL|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
48684351|NCT02574767|DIETARY_SUPPLEMENT|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
48684352|NCT02574767|BEHAVIORAL|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
48684353|NCT02574767|DIETARY_SUPPLEMENT|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
48684354|NCT02552095|DEVICE|Triathlon PKR|
48684355|NCT02327585|BEHAVIORAL|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
48684356|NCT06133556|DRUG|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
48684357|NCT06133556|DRUG|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
48684358|NCT05238272|DEVICE|Transcranial random noise stimulation (tRNS)|There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
48684359|NCT05238272|DEVICE|sham tRNS|the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
48684360|NCT05238272|BEHAVIORAL|the unilateral MT|For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
48684361|NCT05238272|BEHAVIORAL|the bilateral MT|For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
48156900|NCT00266136|PROCEDURE|Allogeneic stem cell transplantation|for details see protocol
48156901|NCT01026116|DRUG|Epirubicin|75 mg/m2 every-3-week for four cycles
48156902|NCT01026116|DRUG|Cyclophosphamide|600 mg/m2 every-3-week for four cycles
48156903|NCT01026116|DRUG|Paclitaxel|175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
48156904|NCT00113334|DRUG|ABT-510|100 mg subcutaneously twice daily
47999051|NCT04305795|COMBINATION_PRODUCT|ASP-1929|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
48684362|NCT05962216|DRUG|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
48684363|NCT04566952|DRUG|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
48366656|NCT03954054|BEHAVIORAL|"Choizitaconso - therapeutic patient education programme"|"Choizitaconso is a therapeutic patient education programme that teaches psychosocial skills to people with alcohol use disorder (PWAUD), to help them (re)establish controlled drinking and reduce harms.~It lasts for 10 weeks for each participant and consists of the following 5 modules, including one optional module focusing on the family environment:~1. Understand the mechanisms that trigger and/or maintain alcohol-related difficulties~2. Plan and evaluate personalized controlled drinking strategies~3. Understand and identify external and internal influences (e.g., thoughts and emotions), identify and manage risk situations~4. Identify alcohol effects and alcohol-related expectations (by developing self-observation skills)~5. Family environment: learning how to evaluate and take care of oneself (e.g., how to express feelings)~Each module consists of 2 to 4 collective workshops that each last 120 minutes and involve 5 to 10 persons."
48366657|NCT01026727|DRUG|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
48684364|NCT04566952|DRUG|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
48684365|NCT04742530|BEHAVIORAL|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
47999052|NCT00311896|DRUG|Bemiparin|
48156905|NCT04241380|DRUG|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
48366658|NCT01026727|DRUG|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
48684366|NCT04742530|BEHAVIORAL|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
48684367|NCT04742530|BEHAVIORAL|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
48684368|NCT05881486|DRUG|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
48684369|NCT05881486|DRUG|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
48684370|NCT00454740|DRUG|solifenacin succinate|Oral
48684371|NCT04482777|DRUG|Corticosteriod for treated patients|Drug given to some patients with autoimmune disease
48684372|NCT05874505|DRUG|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
48684373|NCT05874505|DRUG|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
48684374|NCT03088787|DEVICE|Nexfin measuremtents|There will be only observational recordings, no interevntion
47999053|NCT00311896|DRUG|Placebo|
48684375|NCT04042597|DRUG|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
47999054|NCT03302728|DRUG|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
47999055|NCT03302728|DRUG|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
47999056|NCT05096936|OTHER|Pilates|"The solo Pilates method will be applied twice a week for 12 weeks using the following exercises:~20 Breaths, Double leg stretch, Single leg stretch, Leg circles, Hip lift on ball, Abdominal tightening on ball, Alternating two supports, Side bend, Side kick - side kick, Side kicks, Shell and Swan and Neck pull stretches; in the tenth session, we evolved some exercises: The saw, Swan dive, Book close series, Hip lift on the ball and Front pulls; in the eighteenth session we changed again some exercises for: Leg pull back, Rolling like a Ball, Swimming, Roll over and Leg pull front."
48156906|NCT04241380|OTHER|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
48156907|NCT04241380|DRUG|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
48684376|NCT04495530|OTHER|Non-interventional study|semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
48684377|NCT03469622|DEVICE|EndoRings|EndoRings-assisted colonoscopy
48684378|NCT03469622|DEVICE|Standard colonoscopy|Standard colonoscopy without any additional devices
47999057|NCT05096936|OTHER|Photobiomodulation|Applications of FBM or placebo (MR4 ACTIVet PRO Laser Shower Portable, MRM, USA) will last for 115s and will deliver 60 J at each point. The mode of application, with the patient supine on a stretcher, with the grouping probe held stationary in contact with the skin, at a 90-degree angle, in the pubic mound and in the perineum region.
48684379|NCT05402215|BEHAVIORAL|The flipped classroom model was used to teach students' clinical practice skills.|Videos for clinical applications have been prepared by researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
48684380|NCT05402215|BEHAVIORAL|control group|To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher.
48684381|NCT00853710|OTHER|PSA assay|rapid prostate specific antigen assay.
48684382|NCT00644072|DRUG|SNX-5422|
48684383|NCT02140606|DRUG|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
48684384|NCT02483858|DRUG|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
48684385|NCT04791657|PROCEDURE|Appendectomy|Surgical treatment for appendicitis
48684386|NCT00286624|BIOLOGICAL|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
48684387|NCT00286624|DRUG|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
47999058|NCT02075944|BEHAVIORAL|High intensity aerobic exercise|
48156908|NCT05024578|DEVICE|DREEM2|Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
47999059|NCT02075944|BEHAVIORAL|Low intensity aerobic exercise|
47999060|NCT03202862|DRUG|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
47999061|NCT02678676|OTHER|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
47999062|NCT02678676|OTHER|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
47999063|NCT02442778|DRUG|AVP-786-18|18 mg of Deudextromethorphan hydrobromide (d6-DM) and 4.9 mg of Quinidine sulfate (Q)
47999064|NCT02442778|DRUG|Placebo|Administered as capsules.
47999065|NCT02442778|DRUG|AVP-786-28|28 mg of d6-DM and 4.9 mg of Q
47999066|NCT02442778|DRUG|AVP-786-42.63|42.63 mg of d6-DM and 4.9 mg of Q
48156909|NCT05024578|DEVICE|Placebo|EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
48156910|NCT06559072|DRUG|Atorvastatin|On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
48156911|NCT06427395|DRUG|Saroglitazar Magnesium 1 mg|Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
48156912|NCT00628706|DRUG|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
48156913|NCT04908488|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
48156914|NCT04908488|DEVICE|Etafilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
48156915|NCT00852345|DRUG|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
48156916|NCT06000371|DEVICE|Vacuum assisted Closure application|Vacuum assisted Closure Application in Diabetic Foot Ulcers
48156917|NCT03520088|PROCEDURE|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
48156918|NCT03520088|PROCEDURE|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
48366659|NCT04378855|OTHER|Questionnaire|Quality of life assessment
48684388|NCT00286624|DRUG|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
48684389|NCT00286624|DRUG|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
48684390|NCT04328545|DEVICE|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
48684391|NCT04328545|DEVICE|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
47999067|NCT04427969|BEHAVIORAL|prone position|to lay in prone position at least 12 hour in a day at ICU
47999068|NCT04419038|PROCEDURE|conjunctival autografting augmented with topical application of Mitomycin C|Group A included 32 eyes of 32 patients who underwent conjunctival autografting augmented with topical application of Mitomycin C (0.2 mg/mL).
47999069|NCT04419038|PROCEDURE|conjunctival autografting augmented with Ologen implantation|Group B included 31 eyes of 31 who underwent conjunctival autografting augmented with Ologen implantation.
47999070|NCT01747083|DRUG|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
48684392|NCT04328545|DEVICE|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
48684393|NCT03937388|OTHER|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
48684394|NCT02575872|BEHAVIORAL|Exercise Intervention|Participate in physical activity behavioral intervention
48684395|NCT01683136|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
48684396|NCT05159687|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
48684397|NCT05159687|DRUG|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
48684398|NCT04573790|PROCEDURE|eFONA|Surgical Tracheotomy
48684399|NCT02113423|RADIATION|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID\*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID\*2F
48684400|NCT03626012|DRUG|BIIB078|Administered as specified in the treatment arm.
48684401|NCT03626012|DRUG|Placebo|Administered as specified in the treatment arm.
48684402|NCT06351163|PROCEDURE|Laparoscopic reduction|A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.
48684403|NCT06351163|PROCEDURE|Transumbilical mini-open reduction|If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
48684404|NCT02595866|DRUG|Antiretroviral Therapy|Given PO
48684405|NCT02595866|PROCEDURE|Biopsy|Undergo biopsy
48684406|NCT02595866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48684407|NCT02595866|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48684408|NCT02595866|BIOLOGICAL|Pembrolizumab|Given IV
48684409|NCT02595866|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48684410|NCT01618240|OTHER|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
48684411|NCT01618240|OTHER|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
48684412|NCT06322550|BEHAVIORAL|cover story|After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.
48684413|NCT04709679|PROCEDURE|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
47999071|NCT02063516|DEVICE|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
47999072|NCT02063516|DEVICE|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
48684414|NCT05358626|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
48684415|NCT00245453|DRUG|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
48684416|NCT00245453|DRUG|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
48684417|NCT00245453|DRUG|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
48684418|NCT01055717|OTHER|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
48684419|NCT03697161|DRUG|OV101 (gaboxadol)|OV101 (gaboxadol)
48684420|NCT04773288|OTHER|Live feedback during handwashing|Live feedback provided during handwashing on display
48684421|NCT02821156|DRUG||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
48684422|NCT00314873|DRUG|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
48684423|NCT01255839|DEVICE|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
48684424|NCT01255839|DRUG|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
48684425|NCT00369850|OTHER|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
48684426|NCT00369850|PROCEDURE|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
48684427|NCT00369850|PROCEDURE|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
48684428|NCT01389726|BEHAVIORAL|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
47999073|NCT01306370|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
47999074|NCT01306370|DRUG|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
47999075|NCT01306370|BIOLOGICAL|Fibrin glue|Topical administration, before to close the surgical wound.
47999076|NCT01306370|OTHER|Habitual haemostasis|The surgical habitual haemostasis.
47999077|NCT01542385|PROCEDURE|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
47999078|NCT04909775|DRUG|Tislelizumab|200 mg per cycle, IV on day 1 of 3-week
48156919|NCT02326493|DEVICE|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
48156920|NCT06049199|OTHER|Speech Enhancer|Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
48156921|NCT02158793|PROCEDURE|Craniomaxillofacial allotransplantation|Transplantation of donor face
48684429|NCT01389726|BEHAVIORAL|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
48684430|NCT01389726|BEHAVIORAL|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
48684431|NCT03592771|BEHAVIORAL|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
48684432|NCT03592771|BEHAVIORAL|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
47999079|NCT04909775|DRUG|Cisplatin|70mg/m2 IV on Day 1 of 3-week, for 4 cycles. Dose fractionation is permissible.
47999080|NCT04909775|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
48684433|NCT02078050|OTHER|Phrenic nerves magnetic stimulations|
47999081|NCT05252611|OTHER|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
48684434|NCT02536716|PROCEDURE|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
48684435|NCT02536716|PROCEDURE|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
48684436|NCT00598923|DRUG|topiramate|100 mg twice per day for 3 months
48684437|NCT00598923|DRUG|topiramate|100 twice per day for 6 days after loading dose of phenytoin
48684438|NCT00598923|DRUG|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
48684439|NCT05623748|PROCEDURE|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
48684440|NCT03732716|DIAGNOSTIC_TEST|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
48684441|NCT03617718|DRUG|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
47999082|NCT00741481|PROCEDURE|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
47999083|NCT00544258|DRUG|PEP005|
48684442|NCT01689987|DRUG|Cyclophosphamide|Given IV
47999084|NCT02818777|DRUG|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
47999085|NCT06225726|PROCEDURE|urethral bladder resection|urethral bladder resection. Per-operative bladder ultrasound elastography and simultaneous cystometry
47999086|NCT00571506|DRUG|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
47999087|NCT00571506|DRUG|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
47999088|NCT03684915|DEVICE|Rotary files|using rotary files in cleaning root canals of infected primary molars
47999089|NCT05644704|OTHER|Lower extremity and core muscle training|Lower extremity training: single leg balance training Core muscle training: pelvic control training
47999090|NCT00816725|BEHAVIORAL|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
47999091|NCT02881996|DRUG|IV tylenol|IV tylenol given scheduled in addition to standard PCA
47999092|NCT02881996|DRUG|No IV tylenol|No additional IV Tylenol given
47999093|NCT02881996|DRUG|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
48684443|NCT01689987|DRUG|Dexamethasone|Given PO
48684444|NCT01689987|DRUG|Hydroxychloroquine|Given PO
47999094|NCT05243095|OTHER|Computer assited, game-based cognitive training|"After recording the demographic information of the participants, the Stroop Test was applied to evaluate attention. After the stages of the test were explained to the participants in detail, they were shown once in practice.~The training group received 20 minutes of cognitive training every day for 8 weeks. No training was applied to the control group. Groups were evaluated at baseline and after 8 weeks."
47999095|NCT00615277|DIETARY_SUPPLEMENT|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
47999096|NCT03615807|PROCEDURE|Surgical debridement (if needed)|Surgical debridement
47999097|NCT03615807|DIAGNOSTIC_TEST|Microbiological sampling|Microbiological sampling
47999098|NCT03615807|PROCEDURE|Revascularisation (if needed).|Revascularisation (if needed).
47999099|NCT03615807|DEVICE|Off-loading|Off-loading by Special shoes
47999100|NCT03615807|BEHAVIORAL|Patient's education and instructions|Patient's education and instructions by specialized nurses
47999101|NCT03615807|PROCEDURE|Wound debridement|Regular wound debridement by specialized nurses
47999102|NCT03615807|DRUG|Antibiotic duration|Systemic antibiotic duration according to the study arms
47999103|NCT03413553|DEVICE|immediate implant|Patient will receive immediate implant alone.
47999104|NCT03413553|BIOLOGICAL|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
47999105|NCT03413553|BIOLOGICAL|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
48366660|NCT05294510|OTHER|STAR Sick Child Job Aid|The STAR Sick Child Job Aid is a modified ICCM protocol that includes the addition of a point-of-care C-reactive protein (CRP) test to inform antibiotic treatment decisions for children presenting with febrile acute respiratory illness who do not have any danger signs. If CRP ≥ 40 mg/L, the village health worker (VHW) will dispense amoxicillin per local guidelines. If CRP \< 40 mg/L, the VHW will advise symptomatic care alone including acetaminophen for fever and additional fluids to maintain hydration.
48366661|NCT04399499|DEVICE|MitraClip implantation|The MitraClip® procedure is performed under general anesthesia and orotracheal intubation. The procedure is usually guided by 2 and 3-dimensional transesophageal echocardiography and fluoroscopy. This catheter-based technology is inserted through femoral venous access and advanced in the left atrium through the transseptal puncture. The MitraClip® is provided by 2 arms able to grasp the anterior and posterior mitral leaflets. The goal is to approximate both leaflets creating a double orifice mitral valve mimicking the edge-to-edge surgical repair procedure (Alfieri stitch).
48366662|NCT01122992|PROCEDURE|Limbal relaxing incision|
48684445|NCT01689987|OTHER|Laboratory Biomarker Analysis|Correlative studies
48684446|NCT01689987|OTHER|Pharmacological Study|Correlative studies
48684447|NCT01689987|DRUG|Sirolimus|Given PO
48684448|NCT01232127|DRUG|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
48684449|NCT01232127|DRUG|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
48684450|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
47999106|NCT05017194|DRUG|Emodepside|Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.
47999107|NCT03318991|PROCEDURE|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
47999108|NCT02203487|DRUG|BIIF 1149 BS - single rising dose|
47999109|NCT02203487|DRUG|Placebo|
47999110|NCT04936646|DEVICE|RepetitiveTranscranial Magnetic Stimulation (rTMS)|The rTMS protocol consist of one session per day for five days during the first week, then three sessions the second week and then one session the third week, followed by two monthly sessions.
47999111|NCT02550496|DEVICE|Dermoscopy|
47999112|NCT04425746|DRUG|Afamelanotide|
47999113|NCT04425746|DRUG|Placebo|
47999114|NCT03434041|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray.
47999115|NCT03434041|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray.
47999116|NCT03434041|DRUG|Placebo|Participants will self-administer matching placebo as intranasal spray.
48684451|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
48684452|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
47999117|NCT03434041|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
47999118|NCT03434041|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
47999119|NCT03434041|DRUG|Sertraline (Oral Antidepressant)|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
47999120|NCT03434041|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
47999121|NCT00360464|DRUG|Azithromycin SR|
47999122|NCT03127657|DRUG|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
47999123|NCT00046033|DRUG|Lopinavir/ritonavir|
47999124|NCT00046033|DRUG|Ritonavir|
47999125|NCT00046033|DRUG|Saquinavir|
47999126|NCT00046033|DRUG|Tenofovir disoproxil fumarate|
47999127|NCT00046033|DRUG|Amprenavir|
47999128|NCT02734810|DRUG|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
47999129|NCT00605046|DRUG|SPECT scan|AV151-01: Evaluation of \[123I\] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
47999130|NCT05235191|DRUG|methadone tablets|The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).
47999131|NCT05235191|DRUG|Placebo|In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
47999132|NCT05861739|BEHAVIORAL|Endometriosis Self-care Support Program|ESSP will be applied to the women in the intervention group in four sessions, one week apart. In the first and second sessions, a self-care training program will be applied. In the third and fourth sessions, motivational interview will be made by contacting the women by phone.
47999133|NCT00107211|BIOLOGICAL|therapeutic autologous dendritic cells|
47999134|NCT00107211|PROCEDURE|conventional surgery|
47999135|NCT00107211|PROCEDURE|neoadjuvant therapy|
47999136|NCT00145665|PROCEDURE|FLT-PET scan|PET scan using FLT
47999137|NCT00506155|DRUG|Avastin|10 mg/kg by vein over 90 minutes
47999138|NCT00506155|DRUG|Cisplatin|70 mg/m\^2 by vein over 4 hours
47999139|NCT00506155|DRUG|Doxorubicin|30 mg/m\^2 by vein over 15 minutes
47999140|NCT00506155|DRUG|Methotrexate|30 mg/m\^2 by vein over 30 minutes
47999141|NCT00506155|DRUG|Vinblastine Sulfate|3 mg/m\^2 by vein over 30 minutes
47999142|NCT00642668|DRUG|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
47999143|NCT03225911|DEVICE|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
48512698|NCT05006547|OTHER|Electromyograph Biofeedback training of the peroneal muscle|The exercise will be performed with the subject sitting in front of a computer monitor, on an elevated chair, and his feet will be in the air. The examiner will ask the subject to perform a maximum contraction of the paronal muscles, in an open kinematic chain. After reference, the subject will begin a five-minute practice. The practice will be divided into rounds of: eight seconds of muscle work and 15 seconds rest.
48512699|NCT01241747|BEHAVIORAL|Walking Exercise|3 times per week for 3 months
48512700|NCT01241747|BEHAVIORAL|Control|Resistance training 3 times per week for 3 months
48684453|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
48684454|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
48684455|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
48684456|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
47999144|NCT03225911|DEVICE|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
47999145|NCT03225911|DEVICE|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
47999146|NCT05408416|PROCEDURE|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
47999147|NCT02495311|PROCEDURE|myomectomy or adenomyomectomy|
47999148|NCT01846975|DRUG|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
47999149|NCT00271349|DRUG|Budesonide|
47999150|NCT00255593|DRUG|rituximab|
47999151|NCT00784511|DIETARY_SUPPLEMENT|cholecalciferol|4000 IU/d
47999152|NCT00784511|OTHER|microcrystalline cellulose|1/d
47999153|NCT00149981|DRUG|everolimus (RAD)|Everolimus
47999154|NCT04785274|DEVICE|non-invasive hemoglobin (SpHb)|hemoglobin measuring device
47999155|NCT06083506|DEVICE|NOVALOC TiN retained maxillary overdenture|4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture
47999156|NCT01919658|PROCEDURE|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
47999157|NCT03585452|DRUG|Dexmedetomidine Infusion|Patients with additional dexmedetomidine infusion
47999158|NCT03585452|DRUG|Propofol based general anesthesia|Patients with typical anaesthetic regimens
48684457|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
48684458|NCT02296710|PROCEDURE|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
48684459|NCT05542498|BEHAVIORAL|Mindfulness|Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.
48684460|NCT05542498|BEHAVIORAL|Relaxation|Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
48684461|NCT01107392|DRUG|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
48512701|NCT03555110|BEHAVIORAL|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
48684462|NCT01107392|DRUG|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
48684463|NCT02727816|DEVICE|filcon IV I (BC 8.6)|control lens
48684464|NCT02727816|DEVICE|filcon IV I (BC 8.7)|control lens
47999159|NCT04366167|OTHER|Cardiac surgery|Cardiac surgery during the COVID-19 pandemic
47999160|NCT04783805|DIAGNOSTIC_TEST|Conservative management with regular follow-up|Women will be followed-up every 4 months, with colposcopy and cytology at each visit.
47999161|NCT04783805|PROCEDURE|Conization|Women with progression of HSIL, HSIL persistence after 24 months of follow-up, or that no longer meet the criteria for surveillance will have conization
47999162|NCT00614913|RADIATION|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
47999163|NCT00632333|BIOLOGICAL|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
47999164|NCT03375541|OTHER|Risk Aversion Calculator|The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
47999165|NCT00218673|BEHAVIORAL|Peer mentor intervention|groups sessions, 8
47999166|NCT02455271|DRUG|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
47999167|NCT05568784|OTHER|Straight Leg Raise exercise|Patient lying supine will lift leg to the height of the contralateral knee flexed to 90 degrees with the ankle positioned and tested in all three positions (dorsiflexion, neutral, and plantarflexion)
47999168|NCT01049321|DIETARY_SUPPLEMENT|DASH diet|
47999169|NCT01049321|DIETARY_SUPPLEMENT|a usual diabetic diet|
48684465|NCT02727816|DEVICE|ocufilcon D|test lens
47999170|NCT03072966|DEVICE|Wearable device (Fitbit Charge HR® or Fitbit Alta ®)|Physical activities will be monitored by wearable device.
47999171|NCT01828372|OTHER|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
47999172|NCT03628911|DEVICE|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
47999173|NCT05657665|OTHER|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
48684466|NCT02727816|DEVICE|methafilcon A (BC 8.6)|control lens
48684467|NCT02727816|DEVICE|methafilcon A (BC 8.7)|control lens
48684468|NCT02727816|DEVICE|somofilcon A|test lens
48684469|NCT04784793|OTHER|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
48684470|NCT04784793|OTHER|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
48684471|NCT01248728|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
48684472|NCT01248728|DIETARY_SUPPLEMENT|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
48684473|NCT03498131|DRUG|3 mg Melatonin|3 mg melatonin once each day
48684474|NCT03498131|DRUG|5 mg Melatonin|5 mg Melatonin once each day
48684475|NCT02000024|BEHAVIORAL|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
47999174|NCT02403245|OTHER|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
48156922|NCT06510946|BEHAVIORAL|(Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease|"The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:~Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.~Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.~Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.~Personalized Dosing Systems (PDS): Helping manage medication intake.~Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet."
48156923|NCT03508882|DRUG|Botulinum Toxin Type A 100Unit/Vial (Product)|Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
48156924|NCT03508882|DRUG|Saline Solution for Injection|The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
48366663|NCT05772039|DRUG|Topical application of 38% Silver Diammine Fluoride Solution|"* Application of petroleum jelly on lips and around the mouth for prevention of temporary silver tattoo.~* Before SDF application, the affected area will be thoroughly dried and isolated using the cotton rolls or dri-angle.~* Isolation throughout the procedure and following three minutes is considered most desirable.~* The varnish should be allowed to be in place for 60 seconds. This is the most critical step in the process. Applied varnish will be dried with gentle flow of compressed air.~* SDF will be applied with a microbrush to all carious lesions and to all pits and fissures on posterior (molar) teeth for 60 seconds.~* To avoid gingival or mucosal irritation, contact of varnish with any oral tissue other than affected area will be avoided.~* If the application time is shorter due to unforeseen reasons reapplication will be considered."
48684476|NCT02000024|BEHAVIORAL|National Diabetes Education Program|
48684477|NCT06110949|DEVICE|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
47999175|NCT02382081|PROCEDURE|Patient-initiated shared care|
47999176|NCT00259506|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|
47999177|NCT04248595|DRUG|Homoharringtonine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
48684478|NCT05869253|BEHAVIORAL|The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation|: A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
48684479|NCT05141175|DEVICE|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
48684480|NCT05141175|DEVICE|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
48684481|NCT00550342|DRUG|rituximab|375 mg/m2 intravenously for 4 doses
48684482|NCT02535013|DEVICE|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
48684483|NCT02033681|PROCEDURE|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
48684484|NCT02033681|PROCEDURE|Saline Solution|Saline solution is injected into the tissue as a placebo control.
48684485|NCT00816010|BEHAVIORAL|telephone contact|for lifestyle and compliance counseling
48684486|NCT04075305|RADIATION|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
48684487|NCT01637584|DRUG|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
48684488|NCT01637584|DRUG|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
48156925|NCT05513261|DIAGNOSTIC_TEST|High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
48156926|NCT05513261|DIAGNOSTIC_TEST|PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
48156927|NCT03624023|DRUG|TWB-103|TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
48156928|NCT01498406|DIETARY_SUPPLEMENT|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (\>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
48156929|NCT01504919|BEHAVIORAL|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
48156930|NCT01504919|BEHAVIORAL|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
48156931|NCT01504919|BEHAVIORAL|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
48156932|NCT01504919|DRUG|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
48156933|NCT00848640|DRUG|Sorafenib|400 mg twice daily
48156934|NCT00002401|DRUG|Indinavir sulfate|
48156935|NCT00002401|DRUG|Delavirdine mesylate|
48156936|NCT00002401|DRUG|Lamivudine|
48156937|NCT00002401|DRUG|Zidovudine|
48156938|NCT04462653|DEVICE|Wearable Dynamic ECG Recorder|use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
48156939|NCT04462653|DEVICE|12-lead ECG recordings|use a 12-lead ECG recordings to record heart rate and atrial fibrillation
48156940|NCT00108355|DRUG|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
48156941|NCT00108355|DRUG|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
48684489|NCT06123273|BEHAVIORAL|Exercise-oriented training|IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
48684490|NCT01886235|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
47999178|NCT04248595|DRUG|Azacitidine|De novo AML or relapsed AML patients recieve chemotherapy regimen contained homoharringtonie and azacitidine.
47999179|NCT00370253|DRUG|Terlipressin|1mg/4 h per day
47999180|NCT00370253|DRUG|Noradrenalin|0,1 mcg/kg/min
48156942|NCT00108355|DRUG|Midodrine|Midodrine oral tablet at 10 mg three times a day.
48156943|NCT00108355|DRUG|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
48156944|NCT00108355|DRUG|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
48156945|NCT00108355|DRUG|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
48156946|NCT00108355|PROCEDURE|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
48156947|NCT05650580|DRUG|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
48684491|NCT01886235|DRUG|Fluorescein Sodium Injection|Given IV
48684492|NCT01886235|OTHER|Laboratory Biomarker Analysis|Correlative studies
48684493|NCT01886235|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48684494|NCT03394781|DRUG|DUR-928|oral suspension daily for 28 days
48684495|NCT03287323|OTHER|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
48156948|NCT04892004|BEHAVIORAL|Symptom recognition|The patient receives a leaflet, which includes information about HF, primary symptoms, awareness of its detection and the fluid management plan. It also receives a weight diary, which helps him/her recall weight fluctuation and contact the nurse or doctor to call for help in a previous stage and avoid hospitalisation. Patients have to explain what they understand by HF, on follow-ups contacts, which are the main symptoms, if they are experiencing any of them and which difficulties managing fluid restriction and weight control. The leading investigator validates the information and teaches back contents if required.
48156949|NCT02066389|DRUG|Placebo|Tablets for oral administration
48156950|NCT02066389|DRUG|Upadacitinib|Tablets for oral administration
48156951|NCT01808144|DRUG|lesinurad|Tablets, 400 mg once daily (QD)
48156952|NCT01808144|DRUG|lesinurad|Tablets, 200 mg QD
48156953|NCT01808144|DRUG|febuxostat|Tabletsm 80 mg QD
48156954|NCT04223661|DRUG|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
48156955|NCT04223661|DRUG|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
48156956|NCT04223661|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
48156957|NCT05262504|DEVICE|İntraocular lens implantation|Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
48512702|NCT03555110|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
47999181|NCT03327610|OTHER|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
47999182|NCT03327610|OTHER|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
47999183|NCT03327610|OTHER|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
47999184|NCT03327610|OTHER|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
48156958|NCT01469429|OTHER|placebo|Receive lozenge placebo PO
48156959|NCT01469429|OTHER|laboratory biomarker analysis|Correlative studies
48156960|NCT01469429|OTHER|questionnaire administration|Ancillary studies
48156961|NCT01469429|DRUG|chemoprevention|Receive LBR lozenge PO
48156962|NCT01469429|DRUG|chemoprevention|Receive LBR Saliva Substitute PO
48156963|NCT01469429|OTHER|placebo|Receive Saliva Substitute placebo PO
48156964|NCT04605471|DRUG|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
48512703|NCT05019950|DRUG|NIM-1324|Once daily oral tablet
48512704|NCT05019950|DRUG|Placebo|Once daily oral tablet
48684496|NCT02058004|PROCEDURE|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
48684497|NCT04133662|BEHAVIORAL|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
48684498|NCT02967419|OTHER|No Intervention|
48684499|NCT05340478|BEHAVIORAL|Intensive Transdiagnostic Cognitive Behavioral Therapy|cognitive behavioral treatment that addresses multiple anxiety problems simultaneously and delivered in a massed format over one weekend
48684500|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
48684501|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
48684502|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
48156965|NCT05692414|DIETARY_SUPPLEMENT|Preoperative carbohydrate drink|Allocation will be performed using an alternating weeks scheme. Patients undergoing surgery in the first week will be included in the control group and follow a conventional fasting protocol. However, patients undergoing surgery the following week will be included in the intervention group and take 800 ml of CHO drink on the day before surgery and 400 ml on the surgery day no later than 6 hours before the procedure.
48156966|NCT05018871|BIOLOGICAL|autologous adipose derived mesenchymal stem cells|cultured autologous adult adipose derived mesenchymal stem cells
48156967|NCT00417989|DEVICE|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
48156968|NCT04118088|BIOLOGICAL|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
48156969|NCT02316145|BEHAVIORAL|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
48156970|NCT01233089|DEVICE|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
48156971|NCT01233089|DEVICE|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
48156972|NCT01233089|DEVICE|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
48512705|NCT05016609|DEVICE|OraQuick HCV Antibody test (OraSure Technologies, Inc)|The OraQuick HCV test is a point of care antibody test for detecting HCV antibodies in fingerstick blood. The test takes 20 minutes to provide a result. Appropriate pre- and post-test counselling will be provided to participants.
48512706|NCT05016609|DEVICE|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|Xpert® HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Only participants who return a reactive OraQuick HCV Antibody test will be offered the Xpert® HCV VL Fingerstick test. Appropriate pre- and post-test counselling will be provided to participants.
47914492|NCT05426603|PROCEDURE|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
47999185|NCT03327610|OTHER|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
47999186|NCT03327610|OTHER|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
48512707|NCT05016609|DRUG|Sofosbuvir/Velpatasvir (Gilead)|Participants with a detectable HCV antibody will be offered treatment with sofosbuvir/velpatasvir.
48512708|NCT01546454|DRUG|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
48512709|NCT01546454|DRUG|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
48512710|NCT01546454|DRUG|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
48512711|NCT01546454|DRUG|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
47999187|NCT01027481|DRUG|Lucentis|intravitreally administration of 0.05 ml Lucentis
47999188|NCT00254007|DRUG|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
47999189|NCT02496455|PROCEDURE|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
47999190|NCT02496455|DRUG|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
47999191|NCT02869594|OTHER|Data collection|
47999192|NCT02986620|GENETIC|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
47999193|NCT02627599|DEVICE|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
48156973|NCT01233089|DEVICE|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
48156974|NCT01516710|PROCEDURE|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
48156975|NCT01516710|PROCEDURE|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
48156976|NCT04625023|OTHER|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
48156977|NCT06049888|BEHAVIORAL|Restricted Social Media|Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
48156978|NCT03856645|DRUG|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
48156979|NCT01836497|DEVICE|SD01 ICD lead|
48156980|NCT05707585|DIAGNOSTIC_TEST|Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)|Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs
48512712|NCT05435846|DRUG|Capmatinib|Given orally
48156981|NCT00648271|DRUG|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
48156982|NCT00648271|DRUG|Lopressor® Tablets 50 mg|1x50mg, single dose fed
48156983|NCT00579475|DRUG|Mifegyne|tablets, 50 mg every other day
48156984|NCT00579475|DRUG|placebo|
48156985|NCT05733013|OTHER|Surveillance Visit|Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.
48156986|NCT01224509|DRUG|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
48156987|NCT01224509|OTHER|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
48156988|NCT04173273|DRUG|Etrasimod|Dose A taken by mouth, once daily.
48156989|NCT04173273|DRUG|Etrasimod|Dose B taken by mouth, once daily.
47999194|NCT04578249|OTHER|Blue light-blocking goggles|Participants will be randomly assigned to one of the two intervention groups.
47999195|NCT04578249|OTHER|Clear goggles|Participants will be randomly assigned to one of the two intervention groups.
48156990|NCT04173273|DRUG|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
48156991|NCT03528161|OTHER|Measurement of hypersensitive troponin|"Telephone follow-up at one month, 3 months and 6 months by a clinical research technician. Collection of serious adverse events, reports of hospitalization.~The hypersensitive troponin assay will be recently proposed in a short-term risk stratification score after syncope (30 days), the canadian syncope risk score. If hypersensitive troponin benefits from interesting performances it needs to be evaluated prospectively, as measured only in 47.9% of syncope in this study. Hypersensitive troponin could be a prognostic marker of early serious adverse cardiovascular events in syncope."
48156992|NCT02122354|BEHAVIORAL|"Hide and Seek videogame"|
48156993|NCT03723057|DRUG|AG-221|Oral AG-221 administered as directed by treating physician.
48156994|NCT04741984|BIOLOGICAL|MT-201-GBM monocyte vaccine|monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
48156995|NCT05849220|DRUG|Dapagliflozin|Dapagliflozin
48156996|NCT05849220|OTHER|Standard of Care|Standard of Care
48156997|NCT04457011|DRUG|High dose Susu Xiao'er Zhike Granules 1 bag|High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
48156998|NCT04457011|DRUG|Middle dose Susu Xiao'er Zhike Granules 1 bag|Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.12 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
48512713|NCT05435846|DRUG|Trametinib|Given orally
48512714|NCT03689465|DRUG|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
48512715|NCT03689465|DRUG|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
48512716|NCT03689465|DRUG|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
48512717|NCT03689465|DRUG|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
48512718|NCT03689465|DRUG|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
48512719|NCT04063085|DEVICE|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
48512720|NCT04063085|DEVICE|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
48512721|NCT04063085|OTHER|No treatment|No anti-adhesion agent applied
47999196|NCT01250470|OTHER|Laboratory Biomarker Analysis|Correlative studies
48156999|NCT04457011|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
48157000|NCT01554371|DRUG|Eribulin|"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"
48157001|NCT01554371|DRUG|Cyclophosphamide|Given IV
48157002|NCT05311956|DEVICE|Active tDCS|The study intervention will be participants self-applying 40 tDCS active stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
48157003|NCT05311956|DEVICE|Sham tDCS|In this arm of the study participants will self-apply 40 sham tDCS stimulations with in-person supervision provided by trained study personnel. The self-applied intervention will continue 5 times per week over eight consecutive weeks. Treatment will occur in the home.
48157004|NCT02879669|BIOLOGICAL|ONCOS-102|
48157005|NCT02879669|DRUG|Pemetrexed/cisplatin (carboplatin)|
48157006|NCT02879669|DRUG|Cyclophosphamide|
48157007|NCT03360227|DEVICE|implantation of cardiac devices|implantation of cardiac devices
48512722|NCT04063085|DEVICE|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
48512723|NCT04063085|DEVICE|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
47999197|NCT01250470|DRUG|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
47999198|NCT01250470|BIOLOGICAL|Sargramostim|Given SC
47999199|NCT00001445|BIOLOGICAL|HIV-1 Immunogen|
48512724|NCT03545204|OTHER|Kangaroo Mother Care Package|"The KMC package will include creation of KMC Champions from within the community, social mobilization to create awareness and its acceptance with families using powerful IEC tools such as docudrama, flip charts, pictorials in local languages; engagement of community and community leaders, capacity building of health care providers on Kangaroo mother care, essential newborn care ENC, policy dialogues with stake holders in the public and private sectors and delivery of a KMC kit  to the pregnant female by the Implementation team"
48512725|NCT03545204|OTHER|Routine Standard Care|Routine Standard Care ( essential Newborn care )ENC
48157008|NCT05264649|DEVICE|acupuncture|"The acupuncture group were consisted of twelve 30 minutes sessions 2 times per week sessions for 6 weeks. The acupoints were included full body protocol (LI4, LR3, and PC7) and joint-specific protocol tailored as many as three of the patient's most painful joint areas. After 20 minutes De Qi reported by patients, needles were restimulated manually and removed after an additional 10 minutes."
48157009|NCT05264649|DRUG|Guizhi-Shaoyao-Zhimu decoction|The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.
48157010|NCT05182671|OTHER|Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion|"Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:"
48157011|NCT00487799|DRUG|Ularitide|
48157012|NCT03753256|DEVICE|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
48157013|NCT03753256|DEVICE|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
47999200|NCT05495581|DRUG|pudexacianinium chloride|Intravenous
47999201|NCT02477995|BIOLOGICAL|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
48157014|NCT03753256|DEVICE|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
48157015|NCT03753256|DEVICE|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
48157016|NCT01642888|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
48157017|NCT01642888|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
48157018|NCT05712850|PROCEDURE|SiJoin® Transfixing Sacroiliac Fusion Device|Sacroiliac Fusion
48157019|NCT06030999|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
48157020|NCT06030999|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
48157021|NCT06030999|DIETARY_SUPPLEMENT|Study product C (placebo)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
48157022|NCT03048058|DRUG|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
48512726|NCT05833087|BEHAVIORAL|Schema therapy|30 sessions of schema therapy. The therapy was developed by Jeffrey Young and others and encompasses elements from cognitive behavioral, psychodynamic, and gestalt therapies, as well as attachment theory.
48512727|NCT05833087|BEHAVIORAL|Other psychotherapy|In this arm, psychotherapy can be psychodynamic, cognitive behavioral, interpersonal or other evidence-based psychotherapies, aimed at changing cognitions, behavior, improve social relations and uncover unconstructive psychological patterns.
47999202|NCT02477995|BIOLOGICAL|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
47999203|NCT00002188|DRUG|Alitretinoin|
47999204|NCT00443586|BEHAVIORAL|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
48157023|NCT03048058|DRUG|brimonidine topical gel 0.33% & SOC|All subjects will receive standard-of-care brimonidine topical gel 0.33%
48157024|NCT04560322|DRUG|Venetoclax|Tablet, taken by mouth
48157025|NCT04560322|DRUG|Obinutuzumab|Intravenous infusion
48157026|NCT04560322|DRUG|Acalabrutinib|Capsule, taken by mouth
48157027|NCT00972036|DEVICE|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
48157028|NCT02877745|OTHER|Stratification, no intervention|
48157029|NCT05199701|DEVICE|Mammography|Hologic pre-market Mammography
48157030|NCT02916524|BEHAVIORAL|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
48157031|NCT04285671|BIOLOGICAL|Necitumumab|Given IV
48157032|NCT04285671|DRUG|Osimertinib|Given PO
48157033|NCT04285671|OTHER|Quality-of-Life Assessment|Ancillary studies
48157034|NCT04285671|OTHER|Questionnaire Administration|Ancillary studies
48157035|NCT04285671|BIOLOGICAL|Trastuzumab|Given IV
48157036|NCT03968744|DRUG|Safinamide|Safinamide taken per Os for 12 weeks
48157037|NCT03681171|OTHER|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
48157038|NCT04861571|DIETARY_SUPPLEMENT|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
48512728|NCT05833087|OTHER|Standard care package content|"The patient is offered prescription and monitoring of psychopharmacological treatment of up to 5 hours by a psychiatrist, when appropriate.~Additionally, patients have up to 3 hours of preparatory and diagnostic sessions and up to 4 hours of meetings with the participation of next-of-kin and/or collaboration partners in other public instances."
47999205|NCT00443586|BEHAVIORAL|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
47999206|NCT00443586|BEHAVIORAL|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
47999207|NCT00443586|BEHAVIORAL|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
47999208|NCT05700552|BEHAVIORAL|skin to skin contact|For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
47999209|NCT00922766|DRUG|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
47999210|NCT03674060|DRUG|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
48157039|NCT04861571|OTHER|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
48512729|NCT05465655|OTHER|ECG monitoring for Conduction Disturbances|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
48684503|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
48684504|NCT02968498|DIETARY_SUPPLEMENT|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
47999211|NCT03674060|DRUG|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
47999212|NCT02665208|OTHER|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
48157040|NCT05855499|DEVICE|CPtcube, CPTpatch|This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
48157041|NCT04716283|OTHER|Validated questionnaire : The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)|"The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score.~The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness .The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities."
48157042|NCT02720978|DRUG|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
47914493|NCT01632124|OTHER|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
48684505|NCT02968498|DIETARY_SUPPLEMENT|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
48684506|NCT04594629|DRUG|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
48684507|NCT04594629|DRUG|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
48684508|NCT01060748|BIOLOGICAL|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
48157043|NCT02720978|DRUG|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
47999213|NCT02665208|DRUG|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
47999214|NCT02665208|BEHAVIORAL|Text Message Intervention (TMI)|
47999215|NCT03794037|DRUG|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
47999216|NCT03794037|COMBINATION_PRODUCT|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&
47999217|NCT02363465|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
48157044|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
48157045|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
48157046|NCT04836234|OTHER|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum 65g 40 pieces
48512730|NCT06498440|DRUG|Ketorolac 0.5% Eye Drops|Participants in this arm will receive ketorolac 0.5% eye drops, administered twice daily for one week following Selective Laser Trabeculoplasty (SLT). Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the inflammatory process. This intervention aims to reduce postoperative inflammation and pain, promoting patient comfort and potentially improving outcomes following SLT.
48684509|NCT01060748|BIOLOGICAL|Placebo|Placebo
48684510|NCT00691457|DEVICE|Opti-Free contact lens solution|Solution
48684511|NCT00691457|DEVICE|ReNu Multiplus contact lens solution|Solution
47999218|NCT04829487|DRUG|Ergocalciferol Capsules|Given to subjects 50,000 IU per week for 8 weeks
47999219|NCT04829487|DRUG|Placebo|Placebo capsules
48157047|NCT00647387|DEVICE|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
47914494|NCT00935922|DIETARY_SUPPLEMENT|Flaxseed|Flaxseed omega-3 fatty acids and lignans
47999220|NCT01720433|PROCEDURE|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
48684512|NCT00691457|DEVICE|Clear Care contact lens solution|Solution
47999221|NCT00437684|DRUG|LPV/r|200/50 mg 2 cpr bid monotherapy
47999222|NCT00437684|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
47999223|NCT00437684|DRUG|Ribavirin|Ribavirin 1-1.2 g/day
47999224|NCT00437684|DRUG|NUCS|Nucleoside Reverse Transcriptase Inhibitors
47999225|NCT01074164|OTHER|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
48157048|NCT06232941|PROCEDURE|Full pulpotomy procedure|vital pulp therapy for molars with irreversible pulpitis instead of doing root canal treatment
48157049|NCT05734235|DIETARY_SUPPLEMENT|Vitamin C|Two Vitamin C tablets daily for 8 days.
48684513|NCT03184662|OTHER|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
48157050|NCT05734235|DIETARY_SUPPLEMENT|Vitamin E|One Vitamin E tablet daily for 8 days.
48157051|NCT04507503|DRUG|TAS-120|Futibatinib 20mg QD orally on a 28 days cycle
48157052|NCT01482871|DRUG|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
48684514|NCT03184662|OTHER|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
48684515|NCT03383250|DIETARY_SUPPLEMENT|Normal meal|
48684516|NCT05449912|OTHER|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
48684517|NCT00727545|OTHER|iron bisglycine chelate|
48684518|NCT00727545|OTHER|placebo|
48684519|NCT03203577|PROCEDURE|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
48684520|NCT03046446|DRUG|FX006 32 mg|Single intra-articular injection
48684521|NCT04047368|PROCEDURE|Rotablation|Percutaneous Coronary Intervention using Rotablation
47999226|NCT01074164|DEVICE|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
48157053|NCT01482871|DRUG|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
48157054|NCT01482871|DRUG|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
48157055|NCT01482871|DRUG|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
48157056|NCT03409276|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid.
48157057|NCT03409276|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid.
48157058|NCT03409276|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
47999227|NCT00855036|OTHER|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
48157059|NCT03409276|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
48157060|NCT02746237|DRUG|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
48157061|NCT02746237|DRUG|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
47914495|NCT00373893|DRUG|Lidoderm Patch|
47999228|NCT01752855|BIOLOGICAL|New formulation adalimumab|New formulation adalimumab 40 mg every other week
47999229|NCT03488316|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
47999230|NCT03488316|PROCEDURE|Absolute isolation|Absolute isolation with rubber dam
47999231|NCT03488316|DRUG|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
47999232|NCT03488316|DRUG|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
48512731|NCT06498440|DRUG|Ketorolac 0.5% and Fluorometholone 0.1% Eye Drops|Participants in this arm will receive a combination of ketorolac 0.5% eye drops and fluorometholone 0.1% eye drops. Ketorolac will be administered twice daily and fluorometholone four times daily for one week following SLT. Fluorometholone is a corticosteroid that reduces inflammation by stabilizing capillary permeability and inhibiting inflammatory cell activation. The combination aims to maximize anti-inflammatory effects and enhance patient comfort, potentially leading to better postoperative outcomes compared to ketorolac alone or no treatment.
48684522|NCT04047368|PROCEDURE|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
48684523|NCT06035952|DIAGNOSTIC_TEST|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
48684524|NCT01094977|DRUG|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
48684525|NCT01094977|DRUG|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
48684526|NCT01094977|DRUG|Saline Placebo|
48684527|NCT00720967|PROCEDURE|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
48157062|NCT05939349|OTHER|Produce Prescription Group|"Participants will receive vouchers equal to $40/household/month, with an additional $5/month per additional household member, for the purchase of fresh fruits and vegetables during the six-month intervention period. The vouchers will be administered in the form of a restricted Mastercard debit card.~A variety of nutrition education options will be offered throughout the intervention period and participation will be tracked. The Nutrition education options will include a periodic newsletter to participants that will include nutrition and diabetes prevention and management opportunities available through Griffin Hospital Population Health Team, the local health department, program and education opportunities available through the Registered Dietitians, local offerings by SNAP-Education and The Expanded Food and Nutrition Education Program."
48157063|NCT02325258|OTHER|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
48157064|NCT06585280|OTHER|No intervention|No intervention
48157065|NCT03436797|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
48157066|NCT06454799|BEHAVIORAL|Akupressur|The application will be carried out on 3 body points. These; Pericardium 6, Yintang and Shen men points. Acupressure will be applied to each of these acupressure points for 1 minute.
48684528|NCT00720967|PROCEDURE|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP \>75 mmHg, CVP \> 12 mmHg, Htc \> 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
48684529|NCT00720967|PROCEDURE|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if \> 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
48684530|NCT00143624|DRUG|Rosiglitazone maleate|See Detailed Description.
48157067|NCT05716971|PROCEDURE|Densiron-68 (heavy silicone oil) tamponade for retinal detachment|pars plana vitrectomy using Densiron-68 at thee end of surgery
47999233|NCT03488316|PROCEDURE|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
47999234|NCT03488316|PROCEDURE|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
48157068|NCT06476834|DRUG|Deucravacitinib|Specified dose on specified days
48157069|NCT02160548|DRUG|Standard care|Standard management for OP poisoning
48684531|NCT00143624|DRUG|Placebo|See detailed description.
48684532|NCT05009576|OTHER|silver alginate|silver alginate hydrofiber dressing
47999235|NCT03488316|PROCEDURE|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
48684533|NCT05009576|OTHER|VAC dressing without silver alginate|vaccum assisted dressing
48684534|NCT04975659|BEHAVIORAL|Placebo and Nocebo effect|Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
48684535|NCT04635709|DEVICE|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
47999236|NCT03488316|PROCEDURE|Definitve restoration|Definitve restoration confecction.
47999237|NCT03673163|DRUG|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
48157070|NCT02160548|DRUG|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
48157071|NCT02160548|DRUG|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
48157072|NCT03894280|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
48157073|NCT03894280|DRUG|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
47999238|NCT03673163|DRUG|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
47999239|NCT00208195|DRUG|Divalproex ER|
47999240|NCT03214809|DIAGNOSTIC_TEST|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
47999241|NCT05798416|DRUG|Exercise under inhalation CO2|Participants perform shuttle walk test at high altitude while using the novel portable device for inhalation of CO2
47999242|NCT05798416|OTHER|Exercise under inhalation ambient air|Participants perform shuttle walk test at high altitude while inhaling ambient air
48157074|NCT03894280|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
48157075|NCT03703999|DEVICE|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
48157076|NCT05599516|BIOLOGICAL|LIBP-Rec-Vaccine|Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
48157077|NCT05599516|BIOLOGICAL|BIBP-Rec-Vaccine|Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
48157078|NCT05599516|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
48684536|NCT05553769|OTHER|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
48157079|NCT00995618|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
48157080|NCT00995618|DRUG|Febuxostat|Febuxostat Tablets, 40 mg, QD
48157081|NCT00995618|DRUG|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
48157082|NCT02301104|DRUG|TAS-102|
48157083|NCT00735228|DEVICE|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
48157084|NCT06226896|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily plus RAS inhibitor
48157085|NCT06342635|DEVICE|Hydra Transcatheter Aortic Valve (THV) Series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
48157086|NCT02522299|DRUG|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
48157087|NCT02522299|DRUG|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
48157088|NCT02522299|DEVICE|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
48684537|NCT03271320|OTHER|appearance scales|appearance scales : AVS; ASWAP; DAS 59
47999243|NCT02889640|OTHER|SAGA Innovations|An intensive math tutoring program
48157089|NCT02522299|DEVICE|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
48684538|NCT04945473|PROCEDURE|Endoscopic placement of additional sutures|A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
48684539|NCT04013269|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
48684540|NCT03451487|DRUG|Panadol®|Acetaminophen 500mg Tablet
47999244|NCT02889640|OTHER|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
47999245|NCT02889640|OTHER|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
47999246|NCT01822132|DRUG|Extended release naltrexone|
47999247|NCT01822132|DRUG|Placebo|
47999248|NCT04016545|DEVICE|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
47999249|NCT03183414|OTHER|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
48157090|NCT05180526|DRUG|QLETLI|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
48157091|NCT01769352|DRUG|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
48157092|NCT00317317|PROCEDURE|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
48157093|NCT05285696|DRUG|CSB-111|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
48157094|NCT03090893|DRUG|ATryn continuous infusion|replenish serum thrombin levels
48157095|NCT02100189|OTHER|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
48157096|NCT02100189|PROCEDURE|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
48157097|NCT02100189|OTHER|Laboratory Biomarker Analysis|Correlative studies
48157098|NCT00795977|BIOLOGICAL|dendritic cells, OK-432|Single Group Assignment
48157099|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)|Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.
48157100|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)|Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
48157101|NCT04029727|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
48157102|NCT04029727|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
48157103|NCT01189994|PROCEDURE|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
48157104|NCT01189994|BEHAVIORAL|Orientation|Orientation sessions focusing in fibromyalgia
48157105|NCT02984787|PROCEDURE|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
48684541|NCT03451487|DRUG|SafeTynadol®|Acetaminophen 500mg Tablet
48157106|NCT02984787|PROCEDURE|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
48157107|NCT02980198|BIOLOGICAL|IFN-Kinoid|IM administration
48157108|NCT02980198|OTHER|Placebo|IM administration
48157109|NCT02980198|OTHER|ISA 51|adjuvant
48157110|NCT00768716|DRUG|Acetaminophen|2 x 500 mg by mouth once
48157111|NCT05844150|DRUG|PM8002|IV infusion
48157112|NCT05844150|DRUG|Platinum|IV infusion
48366664|NCT05772039|DRUG|Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish|"* According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~* The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~* Excessive contact with soft tissue should be avoided.~* Only enough varnish to form a thin coating on the desired treatment area should be used.~* After application, patient should be instructed to close their mouth to set the varnish.~* Rinsing or suctioning immediately after application is not recommended.~* The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue."
48684542|NCT01876680|OTHER|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
47999250|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme|Pre-Workout Dietary Supplement
47999251|NCT02952014|DIETARY_SUPPLEMENT|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
47999252|NCT02952014|DIETARY_SUPPLEMENT|Placebo|Pre-Workout Dietary Supplement
47999253|NCT00232310|DRUG|CELIVARONE (SSR149744C)|
47999254|NCT05289609|PROCEDURE|Liver Transplantation|Individuals with end-stage liver disease will be subjected to liver transplantation from deceased or living donors
48157113|NCT05844150|DRUG|Atezolizumab|IV infusion
48157114|NCT05844150|DRUG|Etoposide|IV infusion
48157115|NCT02615041|DRUG|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
48157116|NCT02615041|DRUG|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
48157117|NCT02615041|DRUG|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
48157118|NCT02632747|DRUG|Empagliflozin|Empagliflozin will be taken once daily
47999255|NCT00919399|DRUG|Exemestane|25mg a day during 4 months
47999256|NCT00919399|DRUG|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
48157119|NCT02632747|DRUG|Placebo (matching empagliflozin)|Placebo will be taken once daily
48157120|NCT02632747|DRUG|ramipril|Ramipril will be taken once or twice daily
48157121|NCT01860222|PROCEDURE|SR|
48157122|NCT01860222|PROCEDURE|PLAT|
48157123|NCT01595724|DRUG|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
48157124|NCT05888142|BEHAVIORAL|in clinic pain VR reduction exercises|"During the first two weeks of treatment, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality."
48157125|NCT05888142|BEHAVIORAL|In clinic VRpain reduction exercises + VR homeworks|"During the first two weeks of treatment, participants will use commercially available VR during in clinic physical therapy exercises, and during homeworks to help reduce their pain and improve functionality."
48157126|NCT00913562|DRUG|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
48157127|NCT00913562|DRUG|Placebo|one tablet a day for 12 weeks
48157128|NCT05105425|DIETARY_SUPPLEMENT|NUTRIOSE®|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
48157129|NCT05105425|DIETARY_SUPPLEMENT|GLUCIDEX® IT21 (Placebo)|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
48684543|NCT01876680|OTHER|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
48684544|NCT01861704|DEVICE|Lyric|Extended wear hearing instrument
48684545|NCT01861704|DEVICE|Lyric2|Extended wear hearing instrument
48684546|NCT01262560|DRUG|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
48157130|NCT02236299|PROCEDURE|Right Coronary Artery Percutaneous Coronary Intervention|
48157131|NCT02236299|OTHER|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
48157132|NCT02236299|OTHER|GLP-1 Infusion|30 minute infusion GLP-1
48157133|NCT03093233|OTHER|no intervention|only descriptive data analysis
48157134|NCT03572998|DRUG|Indocyanine Green (ICG)|Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
48157135|NCT01294358|DRUG|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
48684547|NCT01262560|DRUG|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
48684548|NCT01262560|DRUG|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
48684549|NCT05878873|BEHAVIORAL|Split-belt Treadmill|Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
48684550|NCT05878873|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and rectus femoris.
48684551|NCT04077489|PROCEDURE|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
48684552|NCT03601065|OTHER|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
48684553|NCT02805465|DEVICE|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
48684554|NCT02805465|DEVICE|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
48684555|NCT03096392|DRUG|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
48684556|NCT03096392|DRUG|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
47999257|NCT01749579|DRUG|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
48157136|NCT01138098|BIOLOGICAL|Engerix™-B|Intramuscular, single dose
48157137|NCT04969900|OTHER|Placebo oil|The placebo group will receive placebo oil.
48157138|NCT04969900|OTHER|Lavender oil.|Investigational Product. This group will receive Lavender oil.
48157139|NCT01823926|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
48157140|NCT01823926|DEVICE|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
48157141|NCT01823926|DEVICE|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
48157142|NCT00988429|DRUG|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
48157143|NCT00988429|DRUG|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
48157144|NCT00988429|DRUG|Placebo|Placebo tablet given QD
48157145|NCT03861078|OTHER|Own Brand Cigarette|Effects of own brand cigarette use.
48157146|NCT03861078|OTHER|ECIG 15 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, sweetened liquid
48157147|NCT03861078|OTHER|ECIG 15 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, unsweet liquid
48157148|NCT03861078|OTHER|ECIG 0 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
48157149|NCT03861078|OTHER|ECIG 0 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
48157150|NCT06090318|DRUG|Milademetan|260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
48157151|NCT06090318|DRUG|Atezolizumab|1680mg administered every 4 weeks
48157152|NCT06646952|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
48157153|NCT01598688|OTHER|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
48366665|NCT03502265|OTHER|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
47999258|NCT01749579|DRUG|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
48157154|NCT01598688|OTHER|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
48157155|NCT03651271|BIOLOGICAL|Nivolumab Monotherapy|Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
48157156|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab and Combination for Metastatic Cancer|For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
48157157|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.
48512732|NCT05108402|DIAGNOSTIC_TEST|Phenotyping|"After inclusion in the study, between V1 and V4, patients will be phenotyped among: NaCl sensitive patients and non-NaCl sensitive patients. they will have a low sodium diet for 2 weeks. The first week without salt supplementation and the second with salt supplementation. At the end of V4, if patient is NaCl sensitive he will continue into treatment period and go through randomization, and for patient non-NaCl sensitive they will drop out of study."
47999259|NCT01749579|DRUG|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
47999260|NCT02694146|DRUG|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
47999261|NCT02694146|DRUG|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
47999262|NCT00542581|DEVICE|The Acrysof toric SN60T3 IOL|Intraocular Lens
47999263|NCT02803918|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
47999264|NCT02803918|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
47999265|NCT02803918|DRUG|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
47999266|NCT02803918|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
47999267|NCT05090995|BEHAVIORAL|Behavioral Self-Management and Feedback|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
47999268|NCT05090995|BEHAVIORAL|Behavioral Self-Management|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
47999269|NCT03495882|DRUG|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
47999270|NCT05165212|DRUG|Amoxicillin|Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
47999271|NCT01215227|DRUG|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
47999272|NCT01215227|DRUG|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
48366666|NCT02534324|DRUG|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
48512733|NCT05108402|DIETARY_SUPPLEMENT|Drug intake|"After being phenotyped, NaCl sensitive patients will continue the study in one of the 2 treatments arms : royal water (bottle) or salt sachet."
48512734|NCT06149429|BEHAVIORAL|Personalized virtual reality experience|"The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
47999273|NCT01215227|DRUG|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
48157158|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
48366667|NCT02968277|DEVICE|LifeWalker Upright|LifeWalker (LW) upright walker
48684557|NCT02676648|BEHAVIORAL|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
48684558|NCT02676648|BEHAVIORAL|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
48684559|NCT02676648|BEHAVIORAL|Text messages|We will send participants text messages, to support intervention adherence.
47999274|NCT01215227|DRUG|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
47999275|NCT05379439|OTHER|Structured Family Deliberation|Intervention families will be guided through the six modules included in the web-based decisional aid using a Structured Family Deliberation Tool. Parents will view narrated videos corresponding to each module and will be asked a series of questions related to their own lives and values. The process will continue until all modules are reviewed and all questions are completed.
47999276|NCT04951934|DEVICE|EmoLED|This treatment consists of irradiation with the blue light emitted by the device for one minute on the injured area. If the wound has a greater extension than the irradiated area, multiple repeated applications will be performed on adjacent areas, until the entire wound is covered.
48684560|NCT02676648|BEHAVIORAL|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
47999277|NCT04951934|PROCEDURE|Standard treatment|"The standard treatment consists of: cleansing and possible debridement of the wound, application of the topical treatment indicated for that phase of the wound, intended as the standard of care of the structure, and subsequent bandaging."
47999278|NCT01776788|DRUG|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
47999279|NCT01776788|DRUG|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
47999280|NCT03679871|OTHER|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
47999281|NCT02927379|DRUG|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
47999282|NCT02927379|DRUG|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
48366668|NCT02968277|DEVICE|Predicate Device|Individual's personal walker
48366669|NCT02968277|DEVICE|Standard Rollator|A control rollator device
48366670|NCT03841500|DEVICE|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
48512735|NCT03196245|OTHER|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
48366671|NCT03841500|DEVICE|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
48512736|NCT03051477|DRUG|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
48366672|NCT01376765|DRUG|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
48684561|NCT01957293|DRUG|Salbutamol|single oral administration, 4 mg
48684562|NCT01957293|DRUG|Placebo|single oral administration
48684563|NCT02453750|DRUG|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
48684564|NCT02453750|DRUG|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
48684565|NCT05260138|OTHER|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
47999283|NCT02927379|DRUG|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
47999284|NCT03044132|OTHER|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
47999285|NCT02888548|PROCEDURE|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
47999286|NCT02888548|PROCEDURE|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
47999287|NCT06372444|RADIATION|Positron emission tomography (PET)|Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT
48157159|NCT01121497|DRUG|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
48157160|NCT03392688|OTHER|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
48157161|NCT03392688|DIAGNOSTIC_TEST|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
48157162|NCT03392688|OTHER|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
48157163|NCT01411176|DRUG|Menthol|20 mL NPO-11 in a prefilled plastic syringe
48157164|NCT01411176|DRUG|Placebo|The placebo is included same additives as active comparator.
48157165|NCT05266209|OTHER|Coconut oil skin care group|No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G\*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.
48512737|NCT00796757|DRUG|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
48512738|NCT00796757|DRUG|interferon alfa-2a|3 MIU sc t.i.w.
48157166|NCT00964756|GENETIC|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
48157167|NCT00964756|DRUG|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
48512739|NCT00840489|DRUG|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
48512740|NCT00840489|DRUG|Colchicine|Colchicine 0.5 mg bd for 24 weeks
48512741|NCT00080873|DRUG|Traumeel S|
48512742|NCT00080873|OTHER|Placebo|
48512743|NCT01308801|DEVICE|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
48512744|NCT01308801|DEVICE|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
47999288|NCT03348085|OTHER|No intervention|No intervention.
47999289|NCT03051048|PROCEDURE|Reperfusion|
47999290|NCT00142675|BEHAVIORAL|Physical Activity|
47999291|NCT04526483|DEVICE|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
47999292|NCT01388842|DRUG|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
47999293|NCT01388842|DRUG|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
47999294|NCT01583972|DIETARY_SUPPLEMENT|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
48512745|NCT03476538|DRUG|Gabapentin|Patients are tested for their normal prescription gabapentin medication
48512746|NCT06200051|DIAGNOSTIC_TEST|Prediction of high risk of cancer|This initiative is aimed at comprehending the incidence rates of these four types of cancers, including lung cancer (LCA), liver cancer (LC), upper gastrointestinal cancer (UGIC), and CRC, to provide a theoretical foundation for the implementation of more practical and effective cancer screening strategies.
48157168|NCT05558241|DEVICE|High-resolution micro-ultrasound|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
48157169|NCT01527500|DRUG|LFG316|LFG316 5 mg/50 μL solution for IVT injection,
48157170|NCT01527500|DRUG|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
48684566|NCT05260138|OTHER|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
48684567|NCT01643642|OTHER|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
47914496|NCT01145092|BEHAVIORAL|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
47999295|NCT01583972|DIETARY_SUPPLEMENT|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
47999296|NCT01845285|DEVICE|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
47999297|NCT01299922|DRUG|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
47999298|NCT01299922|DRUG|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
48512747|NCT04533997|DRUG|Hypertonic saline solution plus intravenous furosemide|"Intravenous 60-minutes of hypertonic saline therapy plus furosemide:~Furosemide:~125 mg if home oral furosemide ≤160 mg, 250 mg if home oral furosemide \> 160 mg~Hypertonic saline solution:~Na+ 125-134: 3.4%, Na+ 135-145: 2.6%"
48512748|NCT04533997|DRUG|Intravenous furosemide|"Intravenous 60-minutes infusion of furosemide:~125 mg if home oral furosemide ≤ 160 mg, 250 mg if home oral furosemide \> 160 mg"
48512749|NCT02989324|DRUG|MisoprostoL|Vaginal MisoprostoL
47999299|NCT03689166|DIETARY_SUPPLEMENT|Probiotic|Reduce preterm birth with this dietary supplement
47999300|NCT03689166|OTHER|Placebo|Placebo
47999301|NCT03054857|DRUG|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
47999302|NCT03054857|DRUG|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
47999303|NCT04327986|DRUG|M7824|Intravenous (IV) on Days 1 and 15 of every cycle
48157171|NCT01527500|DRUG|LFG316 Lower dose|LFG316 5 mg/50 μL solution for IVT Injection
48157172|NCT01181206|PROCEDURE|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
48157173|NCT03734614|DRUG|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
48157174|NCT01448447|DEVICE|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
47999304|NCT04327986|DRUG|M9241|Subcutaneous injection on Day 1 of every cycle
47999305|NCT04327986|RADIATION|SBRT|Radiation therapy will be starting on Day 17 (+5 days) of Cycle 1 and continue for 5 consecutive business days.
47999306|NCT06372847|DEVICE|Hypoglossal nerve stimulation implant|The hypoglossal nerve stimulation (HNS) implantation and therapy will be performed according to the standard clinical practice without additional procedures. Information about the surgical procedure will be collected. HNS implant information and settings will be collected throughout the study until the last study measurement (one year follow-up PSG and DISE) for that patient. No additional measures or interventions as part of the research project will be performed during implantation or treatment with HNS.
47999307|NCT06372847|DIAGNOSTIC_TEST|Polysomnography|A PSG at one-year follow-up is part of the standard follow-up pathway in patients receiving HNS therapy. In this study, PSG data will be collected from both baseline and one-year follow-up PSGs to assess treatment effect. Additionally, PSG data will be used for non-invasive prediction of the site and pattern of collapse using a novel, validated tool developed at our research group.
48157175|NCT01448447|DEVICE|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
48157176|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
48157177|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
48157178|NCT01248078|DRUG|saline solution|100cc administered before skin incision
48157179|NCT01399502|BEHAVIORAL|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
48157180|NCT04349124|DRUG|Nifedipine Extended-Release Tablets|Antihypertensive
48684568|NCT01643642|OTHER|Treatment As Usual|Other: Treatment As Usual
48157181|NCT00599599|BEHAVIORAL|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
48157182|NCT03721900|DRUG|SHX-001 Active low dose|ketamine transdermal patch
48684569|NCT01506635|DRUG|Timolol|
48366673|NCT01376765|OTHER|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
48366674|NCT01376765|BIOLOGICAL|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
48366675|NCT02271763|OTHER|ultrasound|subjects' neck will be scanned using ultrasound
48366676|NCT01294319|DRUG|Mifepristone|
48366677|NCT01294319|DRUG|Placebo|
48366678|NCT01294319|DRUG|Spironolactone|
48366679|NCT01294319|DRUG|Combined|
48684570|NCT01506635|DRUG|Placebo|artificial tear twice a day
48684571|NCT04981847|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for 3 months.
48684572|NCT04434430|DRUG|Gabapentin|Oral Gabapentin 600 mg
48366680|NCT01294319|DRUG|Dexamethasone|
48366681|NCT00953849|DRUG|Celecoxib|Celecoxib (400 mg twice daily)
48366682|NCT00953849|DRUG|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
48512750|NCT02989324|DEVICE|Foley Catheter|Misoprostol Plus Foley Catheter
47914497|NCT03543228|DIAGNOSTIC_TEST|MyoStrain|MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
48366683|NCT00953849|DRUG|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
48366684|NCT04226209|OTHER|PSSE|Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours. Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
48512751|NCT04151043|BEHAVIORAL|Suggestions|Verbal suggestions or no suggestions about treatment outcome
48512752|NCT04151043|DEVICE|Deep brain stimulation|Regulation of deep brain stimulation intensity
48684573|NCT04434430|OTHER|Placebo|Oral NaCl 500 mg
48684574|NCT02620800|DRUG|5FU|5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
48684575|NCT02620800|DRUG|nab-paclitaxel|nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
48684576|NCT02620800|DRUG|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
48684577|NCT02620800|DRUG|calcium leucovorin|calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
48684578|NCT02620800|DRUG|oxaliplatin|oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
48157183|NCT03721900|DRUG|Placebo|transdermal patch
48157184|NCT03721900|DRUG|SHX-001 Active High dose|ketamine transdermal patch
48157185|NCT01110551|DRUG|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
48157186|NCT01110551|DRUG|Placebo (ID)|Phosphate buffered saline administered intradermally.
48157187|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.
48157188|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.
48157189|NCT03614351|DIETARY_SUPPLEMENT|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
48157190|NCT03614351|OTHER|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
48157191|NCT01532024|OTHER|Microdose of NAP|Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
48157192|NCT01165944|DRUG|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
48157193|NCT03780699|PROCEDURE|Diagnostic hysteroscopic examination|The hysteroscopic criteria of the cesarean scar defect will be observed with comment on different niche features
48157194|NCT03613571|DRUG|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
48684579|NCT00753727|DRUG|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
48157195|NCT01985945|OTHER|Yoga|
48157196|NCT00312845|DRUG|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
48157197|NCT00312845|DRUG|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
48157198|NCT00160329|DRUG|Atazanavir|300 mg with ritonavir boosting or 400 mg without
48157199|NCT01007617|DEVICE|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.~Main evaluation criteria: mucositis maximal intensity (WHO scale).~Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
48157200|NCT04879875|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.
48157201|NCT04879875|DEVICE|IscAlert 72h|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
48684580|NCT00753727|RADIATION|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
48157202|NCT05401669|PROCEDURE|Trans-radial access|Cerebral angiography performed by trans-radial access
48157203|NCT05401669|PROCEDURE|Trans-femoral access|Cerebral angiography performed by trans-femoral access
48157204|NCT02332421|DEVICE|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
48157205|NCT02475499|DRUG|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
48157206|NCT02475499|DRUG|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
48157207|NCT02475499|DRUG|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
48157208|NCT02475499|DRUG|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
48157209|NCT02475499|DRUG|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
48157210|NCT02475499|DRUG|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
48157211|NCT02475499|DRUG|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
48157212|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic coils|Splenic artery embolization with vascular embolic coils
48157213|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic plugs|Splenic artery embolization with vascular embolic plugs
48157214|NCT00412802|DRUG|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
48684581|NCT04538300|DIAGNOSTIC_TEST|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
48157215|NCT00412802|DRUG|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
48157216|NCT03875794|OTHER|Osteopathic Manipulation|Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
48157217|NCT04855708|OTHER|Virtual visit|Patients randomized to this group will have a virtual 2-week post-operative visit
48366685|NCT01317368|DRUG|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
48366686|NCT01317368|DRUG|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
48157218|NCT04855708|OTHER|Office visit|Patients randomized to this group will have a in-person 2-week post-operative visit
48157219|NCT04229706|DRUG|High dose Xiang Ju Ru Pi Ning capsule|xingjurupining capsule,8 capsule,tid,3 months.
48684582|NCT04538300|DIAGNOSTIC_TEST|Degree of nausea|Degree of postoperative nausea was evaluated.
48157220|NCT04229706|DRUG|Low dose Xiang Ju Ru Pi Ning capsule|xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
48157221|NCT04229706|DRUG|Xiang Ju Ru Pi Ning capsule placebo|xiangjurupining capsule,8 capsule,tid,3 months.
48684583|NCT04538300|DIAGNOSTIC_TEST|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
48684584|NCT04538300|DIAGNOSTIC_TEST|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
48684585|NCT04538300|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
48684586|NCT04538300|OTHER|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
48157222|NCT02683213|DRUG|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
48157223|NCT02683213|DRUG|Placebo|Matching placebo.
48157224|NCT02592434|DRUG|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg."
48157225|NCT02592434|OTHER|placebo|matching placebo tablet or solution for tofacitinib
48157226|NCT03205345|DRUG|Emricasan (25 mg)|25 mg emricasan
48157227|NCT03205345|DRUG|Emricasan (5 mg)|5 mg emricasan
48157228|NCT03205345|DRUG|Placebo|Matching Placebo
48157229|NCT05658809|PROCEDURE|thyroidectomy|Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
48157230|NCT05697393|DEVICE|Shaker Pressure Band|
48157231|NCT03524092|DRUG|Mirikizumab SC|Administered SC
48157232|NCT03524092|DRUG|Mirikizumab IV|Administered IV
48157233|NCT03524092|DRUG|Placebo SC|Administered SC
48157234|NCT05618717|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation using irrigated ablation catheter
48157235|NCT02963922|DRUG|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
48157236|NCT02963922|DRUG|Placebo|Injected subcutaneously (s.c., under the skin) once daily
48157237|NCT04475497|OTHER|Blood management|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
48157238|NCT04475497|OTHER|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
48684587|NCT04570878|PROCEDURE|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
48157239|NCT05852054|BEHAVIORAL|OB Provider Clinical Decision Support (CDS)|When an eligible patients' chart is opened by a provider, the provider will be alerted to counsel patients about future risk for T2D and hypertension and the need to establish a primary care medical home. The alert will include a 'referral' to primary care and a brief guide with 'key points for counseling'. For patients with prior GDM, this will also include an option to order guideline-recommended oral glucose tolerance test (OGTT) with a single click.
48157240|NCT05852054|BEHAVIORAL|Patient Education (OB Visit)|A 1-page document will be printed or delivered electronically for eligible patients after every postpartum OB visit during the STEP-UP condition. The document will encourage patients to know the risk and will describe the importance of routine primary care and chronic disease evaluation and management. It will also provide tips for lowering risk through lifestyle changes. Patient materials will be delivered in English or Spanish based on the structured EHR variable for preferred language.
48157241|NCT05852054|BEHAVIORAL|Text messaging|At 3 months postpartum, all eligible patients who have not scheduled a primary care visit will receive a motivational text to prompt scheduling; a second text will be sent for those who still have not made an appointment. Among those who schedule a visit, a reminder text will be sent before the visit. Texts will be in English or Spanish based on patients' preferred language field in the EHR and written at a \<5th grade reading level.
48157242|NCT05852054|BEHAVIORAL|Patient Outreach|Patients who have not scheduled a primary care visit by 4 months postpartum will receive outreach from a trained coordinator who will assist with scheduling and help patients troubleshoot common barriers, such as concerns about transportation or cost.
48157243|NCT05852054|BEHAVIORAL|Primary Care Provider Clinical Decision Support (CDS)|The CDS will notify the provider that the patient had a recent high-risk pregnancy and signal the need to counsel the individual about their future risk for T2D and/or hypertension and the need for ongoing care. A brief guide with 'key points for counseling' described in plain language will be provided. For patients with prior GDM, the CDS will also include an easy to access 'smartset' to order appropriate testing (A1c, FG, or OGTT) based on time since delivery and provider discussions with the patient.
48157244|NCT05852054|BEHAVIORAL|Patient Education (Primary Care Visit)|A 1-page material will again be automatically printed or delivered electronically for eligible patients after their first primary care visit; it will replicate content from prior material provided after the OB visit.
48157245|NCT00278395|DRUG|Vorinostat|Given orally
48157246|NCT00845286|BEHAVIORAL|Munich Marathon|42,195 km marathon run
48157247|NCT02188784|DRUG|Polysaccharide Iron Complex 150 mg|Oral Iron
48684588|NCT04570878|PROCEDURE|Control|No regional block is provided at the end of surgery.
48157248|NCT02188784|DRUG|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
48157249|NCT06474234|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
48157250|NCT06474234|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
48157251|NCT04205500|OTHER|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
48157252|NCT02599077|DRUG|Dienogest|patients assigned to this treatment receive 2 milligrams per day
48157253|NCT02599077|DRUG|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
48157254|NCT06076746|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for İneffective Coping|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
48157255|NCT06076746|BEHAVIORAL|psychotherapeutic intervention|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
48157256|NCT04593771|DRUG|BCG-PPD|BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
48157257|NCT02871453|DEVICE|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
48157258|NCT02871453|OTHER|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
48157259|NCT03644186|DRUG|Paclitaxel|Chemotherapy plus HER2 Blockade
48157260|NCT03644186|DRUG|Trastuzumab|Chemotherapy plus HER2 Blockade
48157261|NCT03644186|DRUG|Pertuzumab|Chemotherapy plus HER2 Blockade
48157262|NCT03644186|DRUG|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
48684589|NCT04635150|BEHAVIORAL|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
48684590|NCT06307990|GENETIC|NGS sequencing|analysis of candidate genes for RTHs syndromes, transporters defects or gene involved in thyroid hormone metabolism. Whole exome sequencing (WES) in a minority of cases
48684591|NCT06307990|DIAGNOSTIC_TEST|serological tests|assessment of T4, T3 and other TH metabolites (LC-MS) in serum and dried blood spots
48684592|NCT03880370|BEHAVIORAL|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
48684593|NCT03880370|DIAGNOSTIC_TEST|Ultrasound imaging|Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side
48684594|NCT03880370|DIAGNOSTIC_TEST|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
48157263|NCT03644186|DRUG|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
48684595|NCT03880370|DIAGNOSTIC_TEST|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
48684596|NCT01453452|BEHAVIORAL|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
48157264|NCT03644186|DRUG|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
48157265|NCT03644186|DRUG|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
48366687|NCT01317368|OTHER|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
48684597|NCT01453452|BEHAVIORAL|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
48684598|NCT01453452|OTHER|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
48684599|NCT01453452|PROCEDURE|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
48684600|NCT02777450|PROCEDURE|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
48157266|NCT03003715|PROCEDURE|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
48157267|NCT03003715|PROCEDURE|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
48157268|NCT03003715|PROCEDURE|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
48157269|NCT03003715|OTHER|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
48157270|NCT00454545|DRUG|Atorvastatin|
48366688|NCT01265927|DRUG|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
48684601|NCT03544593|DEVICE|Revolve System|Fat grafting system
48684602|NCT05146219|DRUG|TY-9591 Tablets|TY-9591 Tablets 160mg/d
48684603|NCT06204588|PROCEDURE|control group: SFA only|Single flap approach
48684604|NCT06204588|PROCEDURE|Test group 1: VCMX + Low level LASER therapy + Single flap approach|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
48684605|NCT06204588|PROCEDURE|Test group 2: Low level LASER therapy + Single flap approach|Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
48157271|NCT01015794|DRUG|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
48157272|NCT01015794|DRUG|ephedrine hydrochloride|single dose of 1 mg/kg body weight
48157273|NCT00834483|DEVICE|Knotless suture for wound closure|Angiotech Quill SRS
48157274|NCT00834483|DEVICE|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
48157275|NCT01148017|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
48157276|NCT02465944|DRUG|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
48157277|NCT02465944|DRUG|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
48157278|NCT00161434|DRUG|valacyclovir|1 gram daily for 8 weeks
48157279|NCT00161434|DRUG|placebo|matching placebo for 8 weeks
48157280|NCT06209411|BEHAVIORAL|Home Based Testing|Community Health Workers (CHWs) will offer at home OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
48157281|NCT06209411|BEHAVIORAL|Clinic Based Screening|Community Health Workers (CHWs) will offer referral to clinic based OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
48157282|NCT04730570|BEHAVIORAL|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
48157283|NCT06286592|BEHAVIORAL|Ultra-brief mindfulness intervention video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
48157284|NCT06286592|BEHAVIORAL|Forgiveness video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
48157285|NCT06286592|BEHAVIORAL|ACT values video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
48157286|NCT04546360|PROCEDURE|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
48157287|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
48157288|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
48157289|NCT00714688|DRUG|Placebo|2xplacebo once daily for 13 weeks
48157290|NCT04120623|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
48512753|NCT04045483|OTHER|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
48157291|NCT04120623|DRUG|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
48157292|NCT05430607|BEHAVIORAL|Running therapy|A 9-week running program.
48157293|NCT02873442|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
48157294|NCT02873442|BIOLOGICAL|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
48157295|NCT00687128|BEHAVIORAL|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
48157296|NCT00687128|BEHAVIORAL|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
48157297|NCT00687128|BEHAVIORAL|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
48157298|NCT05480202|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
48157299|NCT05480202|OTHER|Designed chest physical therapy program|Percussion, vibration and postural drainage
48157300|NCT00198666|DRUG|Zinc|Elemental Zinc
48157301|NCT04502745|DEVICE|Minimally Invasive Cortical Access System (MICAS)|Temporary surgical tool that provides access to the sub-dural space through the cranium.
48157302|NCT01113541|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
48157303|NCT02791009|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
48157304|NCT02791009|OTHER|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
48157305|NCT02791009|OTHER|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
47999308|NCT06372847|PROCEDURE|Drug-induced sleep endoscopy (DISE)|"Drug-induced sleep endoscopy (DISE) is the clinical standard diagnostic test to assess site, pattern and degree of upper-airway collapse in OSA. Baseline DISE is part of the standard clinical pathway for HNS eligibility.~In this study, DISE data will be collected from routine baseline DISE without any additional procedures for the patient. They will undergo an additional DISE at one-year follow-up to assess the effect of HNS-therapy on site, pattern and degree of collapse. Both DISEs will be performed according to routine clinical practice in the operating theatre. Sleep will be induced using 1.5 mg bolus injection midazolam and target-controlled propofol infusion (2.0 - 3.0 μg). A flexible fiberoptic nasopharyngoscope will be transnasally inserted. Site, pattern and degree of collapse will be assessed using a standardized scoring system. Other maneuvers, including chin-lift, the use of a simulation bite or lateral position of the head will be performed according to clinical practice."
47999309|NCT01903304|OTHER|Olive Oil|3 months intervention
47999310|NCT05667623|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks/24 weeks.
48157306|NCT02791009|OTHER|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
48512754|NCT00381433|DRUG|AVI-4065 Injection|
48512755|NCT02488954|OTHER|Probiotics in the form of cheese portion|
48512756|NCT05776927|DRUG|QVM149|QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
48512757|NCT05776927|DRUG|Salmeterol Xinafoate / Fluticasone Propionate|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
47999311|NCT05667623|OTHER|0% OPA-15406 Vehicle|Twice-daily administration for 4 weeks/24 weeks.
47999312|NCT05211128|PROCEDURE|Robotic Surgery|Surgical procedure using robotic technologies.
47999313|NCT05211128|PROCEDURE|Open Surgery|Surgical procedure using a large, open cut in the skin.
48157307|NCT02791009|OTHER|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
48157308|NCT02791009|OTHER|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
48512758|NCT05776927|DRUG|Placebo to QVM149|Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
48512759|NCT05776927|DRUG|Placebo to Salmeterol Xinafoate / Fluticasone Propionate|Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
48512760|NCT05776927|DRUG|Run-In Medication|Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
48512761|NCT05776927|DRUG|Rescue Medication|Salbutamol 100μg / Albuterol 90μg
48512762|NCT05776927|DEVICE|Concept 1 Device|Concept1 (Breezhaler) used for QVM149 and placebo delivery
48512763|NCT05776927|DEVICE|Girohaler|Girohaler for Comparator and Placebo delivery.
48512764|NCT02521272|OTHER|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
48512765|NCT02521272|DEVICE|air pocket|Zero air pocket or one-liter air pocket in the snow.
48512766|NCT04019626|OTHER|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
48512767|NCT04019626|OTHER|myblu Tobacco 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
48512768|NCT04019626|OTHER|myblu Tobacco 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
48512769|NCT04019626|OTHER|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
48512770|NCT04019626|OTHER|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
48684606|NCT05082766|DRUG|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
48684607|NCT06339450|OTHER|walk tours|"* During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break."
48684608|NCT01125475|DEVICE|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
48684609|NCT05695794|OTHER|the group with a bed head height of 45 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving a 45 degree head height to 30 patients determined by Randomizer.org.
48684610|NCT05695794|OTHER|the group with a bed head height of 30 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving 30 degrees of bed head height to 30 patients determined by Randomizer.org.
48684611|NCT04058899|DRUG|Dexmedetomidine|sedative and might be analgesic drug
48684612|NCT04058899|DRUG|Nalbuphine|agonist antagonist narcotic
47914498|NCT05098262|DRUG|DA-5210 10/500mg|single dose administration (one tablet once a day)
47999314|NCT05211128|PROCEDURE|Laparoscopic Surgery|Surgical procedure using small incisions and trochars.
48512771|NCT04019626|OTHER|JUUL 5%|Ad-libitum use of JUUL 5% e-cigarette
48512772|NCT06413511|BIOLOGICAL|Belantamab|Belantamab will be administered.
48512773|NCT04221230|DRUG|BTRX-335140|Active Drug
48512774|NCT04221230|DRUG|Placebo|Placebo
48512775|NCT02713412|OTHER|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
48684613|NCT04058899|DEVICE|infusion pump|infusion pump for titration of fluid containing drug infusion
48684614|NCT01575236|DEVICE|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
48684615|NCT01575236|DEVICE|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
48684616|NCT00220155|DRUG|Gemcitabine|
48684617|NCT03917875|BEHAVIORAL|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
48684618|NCT02655952|DRUG|Foxy-5|
48684619|NCT01846299|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
48684620|NCT01846299|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
48157309|NCT00494286|BEHAVIORAL|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
48157310|NCT00494286|BEHAVIORAL|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
48157311|NCT01558245|DRUG|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
48157312|NCT00120952|DEVICE|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
48157313|NCT01840696|DRUG|Regadenoson|Vasodilator stress testing
48157314|NCT05500963|DEVICE|Transcutaneous electrical nerve stimulation|Electrical stimulation applied over selected leg muscle will activate sensory receptors that will transmit signals back into the central nervous system.
48157315|NCT05198323|DRUG|LT3001 Drug Product|Administered by intravenous infusion
48157316|NCT05198323|DRUG|Placebo|Administered by intravenous infusion
48157317|NCT00739024|DRUG|Ramelteon|8 mg tablet, oral, once daily
48157318|NCT00739024|DRUG|Placebo|Placebo tablet, oral, once daily
48157319|NCT04322864|OTHER|Therapeutic exercises|Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
48157320|NCT01126177|DRUG|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
48157321|NCT01126177|DRUG|Placebo|Placebo (excipients of the SNG001 solution only)
48157322|NCT06480864|DRUG|Adebrelimab Injection|Adebrelimab injection (1200mg) will be administered by intravenous infusion during the induction phase and maintenance phase on day 1 in a 3-week treatment cycle.
48157323|NCT06480864|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.
48157324|NCT06480864|DRUG|Carboplatin|Carboplatin (AUC 4-5mg/mL/min) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
48157325|NCT06480864|DRUG|Cisplatin|Cisplatin (75mg/m2) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
48157326|NCT06480864|DRUG|Etoposide|Etoposide(100mg/m2) intravenous infusion will be administered during the induction phase from day 1 to 3 in a 3-week treatment cycle.
48512776|NCT02713412|OTHER|Water|300ml water
48684621|NCT01389674|PROCEDURE|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
48684622|NCT03394742|BEHAVIORAL|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
48684623|NCT04909840|OTHER|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
48684624|NCT04909840|OTHER|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
48684625|NCT02014259|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
48684626|NCT02526953|DRUG|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
48684627|NCT02526953|DRUG|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
48684628|NCT02526953|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
48684629|NCT02526953|DRUG|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
48684630|NCT02526953|DRUG|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
48684631|NCT02526953|RADIATION|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
48684632|NCT00022295|DRUG|idronoxil|
48684633|NCT04732923|OTHER|Assigned intervention - procedure|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires"
48684634|NCT00244725|DRUG|Odiparcil|
48684635|NCT00244725|DRUG|Warfarin|
48684636|NCT00244725|DRUG|Coumadin|
48512777|NCT02521805|OTHER|Animal protein|
48684637|NCT00974506|OTHER|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
48684638|NCT00974506|OTHER|Routine care therapy|Routine care therapy by general practitioner
48684639|NCT03930771|DRUG|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
48684640|NCT03930771|DRUG|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
48684641|NCT03504891|DIAGNOSTIC_TEST|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
48684642|NCT03504891|DIAGNOSTIC_TEST|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
47999315|NCT05810090|PROCEDURE|Total knee arthroplasty|patient who received a TKA in our hospital
47999316|NCT05209022|DIETARY_SUPPLEMENT|Beetroot juice|140 mL of beetroot juice or beetroot juice placebo
47999317|NCT02478242|DRUG|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
47999318|NCT02478242|DRUG|Normal saline|
47999319|NCT04275596|DRUG|2QR complex|Application of topical gel containing 2QR complex on the anal wound until complete wound healing
47999320|NCT04275596|DRUG|Placebo|Application of topical placebo on the anal wound until complete wound healing
47999321|NCT01500642|BIOLOGICAL|Slit One|slit one sublingual immunotherapy 200 stu
47999322|NCT01500642|BIOLOGICAL|Slit One|slit one vestibular immunotherapy 200 stu
47999323|NCT01500642|BIOLOGICAL|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
47999324|NCT00573755|DRUG|anastrozole|given orally
47999325|NCT00573755|DRUG|exemestane|given orally
47999326|NCT00573755|DRUG|letrozole|given orally
47999327|NCT00573755|DRUG|sorafenib tosylate|given orally
47999328|NCT00573755|OTHER|placebo|given orally
47999329|NCT05151263|DRUG|Acetyl Salicylate|Aspirin is an effective antiplatelet agent, exhibiting its action by irreversibly inhibiting platelet cyclooxygenase-1 enzyme, thus preventing the production of thromboxane A2 (TXA2). It has been used in the primary and secondary prevention of thromboembolic vascular events
47999330|NCT05151263|DIAGNOSTIC_TEST|Optical Platelet Aggregation test|The evaluation of platelet aggregation was performed using an optical aggregometer (AggRAM, using fresh citrated blood. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 190 g for 5 min. The platelet count was adjusted to 200,000 to 300,000 platelets/mm3. Platelet-rich plasma (250 μl) was deposited in each equipment channel, and the activators adenosine diphosphate, epinephrine, collagen, and arachidonic acid were used according to the manufacturer's instructions. aspirin resistance was defined as platelet aggregation ≥ 20% with arachidonic acid and ≥70% with adenosine diphosphate.
47999331|NCT06032312|OTHER|description|no intervention, just description of the groups
48512778|NCT02521805|OTHER|Vegetable protein|
47914499|NCT05098262|DRUG|DA-5210-R 10/500mg|single dose administration (one tablet once a day)
47999332|NCT03448185|BEHAVIORAL|High intensity exercise|Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
47999333|NCT03448185|DIETARY_SUPPLEMENT|Omega-3 fish oil|Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
48512779|NCT02521805|OTHER|Dietary fiber (cereal food matrice)|
48512780|NCT02521805|OTHER|Dietary fiber (meat food matrice)|
48512781|NCT02521805|OTHER|Dietary fiber (vegetable food matrice)|
48512782|NCT03916705|OTHER|High Velocity Low amplitude spinal manipulation (HVLA-SM)|HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
48512783|NCT04414618|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
48512784|NCT04414618|DRUG|Placebo|Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive).
48512785|NCT02213510|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
48512786|NCT02213510|DEVICE|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
48512787|NCT00564330|DRUG|Esomeprazole|20mg bid
48512788|NCT00564330|DRUG|Placebo|Placebo bid
48512789|NCT03412799|DRUG|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
48512790|NCT03412799|DRUG|nab-paclitaxel|Administered as intravenous (IV) infusion
48512791|NCT03412799|DRUG|Gemcitabine Injection|Administered as intravenous (IV) infusion
48512792|NCT06064578|BEHAVIORAL|Project SOLVE|Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
48512793|NCT03923647|DEVICE|Laparoscopy|Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
48512794|NCT05354921|DEVICE|Indwelling Catheter|Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (\>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.
48157327|NCT03045289|BEHAVIORAL|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
48684643|NCT05227495|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
48157328|NCT04394078|OTHER|Online survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
48157329|NCT05288504|DRUG|AVTX-002|Dose of 600 mg administered subcutaneously three times during the study.
48684644|NCT05227495|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
48684645|NCT06554600|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
47999334|NCT03448185|BEHAVIORAL|Yoga|Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
48157330|NCT05288504|DRUG|Placebo|Placebo sourced as normal saline administered subcutaneously three times during the study.
48157331|NCT03514745|DEVICE|GlideScope|Endobronchial intubation is performed using the GlideScope.
48157332|NCT03514745|DEVICE|Lighted stylet|Endobronchial intubation is performed using a lighted stylet.
48157333|NCT02891018|DEVICE|paclitaxel controlled release balloon catheter Vasoguard TM|
48684646|NCT06554600|DRUG|Polatuzumab Vedotin|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
48684647|NCT06554600|DRUG|Bendamustine|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
47999335|NCT03448185|DIETARY_SUPPLEMENT|olive oil capsules|Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
47999336|NCT00161707|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
48157334|NCT02891018|DEVICE|paclitaxel release coronary balloon catheter SeQuent Please|
48157335|NCT01753323|DRUG|KAF156|KAF156 was supplied as tablets for oral use.
48157336|NCT02746497|PROCEDURE|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
48157337|NCT00084409|DRUG|iloprost|Given orally
48157338|NCT00084409|OTHER|placebo|Given orally
48157339|NCT00374673|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
48157340|NCT03743922|DRUG|Calciferol|calciferol capsule
48157341|NCT03743922|DRUG|Placebo|placebo capsule
48157342|NCT01330719|PROCEDURE|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
48684648|NCT06554600|DRUG|Rituximab|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
48684649|NCT05052463|OTHER|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
48684650|NCT03549494|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
47999337|NCT05669456|DEVICE|Halo Alert System|The Halo Alert System consists of an EEG sensor headband and is paired with a data transfer device.
47999338|NCT05830474|PROCEDURE|Continuous intra-airway monitoring and intervention during surgey|Continuous monitoring was performed by visual double lumen bronchial catheter. Once sputum or blood gushing into the tracheal carina was found in the distal bronchus on the surgical side, the above secretions were sucked out with a sputum suction tube under video monitoring until the removal was complete
48157343|NCT01330719|PROCEDURE|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
48684651|NCT06386978|PROCEDURE|Transverse Facia Plane Block (TAP Block)|Spinal Anesthesia + TAP block
48684652|NCT06386978|PROCEDURE|Transversalis Facia Plane Block (TFP Block)|Spinal Anesthesia + TFP block
48684653|NCT06386978|PROCEDURE|Control|Spinal anesthesia + No block
48684654|NCT00666653|DRUG|pramipexole|
48684655|NCT02310737|PROCEDURE|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
47999339|NCT05764187|OTHER|Orthodontic fixed appliance therapy|Follow up of white spot lesion development using quantitative light induced fluorescence in patients bonded with ceramic brackets versus patients bonded with conventional metal brackets
47999340|NCT00880529|DEVICE|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
47999341|NCT00880529|DRUG|IV opioid administration|Patient controlled analgesia with IV narcotics
47999342|NCT00417092|PROCEDURE|Postoperative Pacing|
47999343|NCT00218296|DRUG|Usual Care Group|Nicotine replacement therapy
47999344|NCT00218296|OTHER|Reduction Group|Subject selects preferred method for reduction.
47999345|NCT04620083|OTHER|Integrative Learning Program for Old People with Dementia|The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
47999346|NCT01806896|DRUG|PF-02545920|"* Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Treatment for 28 days."
47999347|NCT01806896|DRUG|Placebo|"- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
47999348|NCT01806896|DRUG|PF-02545920|"* 5mg dose~* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
48684656|NCT02310737|PROCEDURE|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
48684657|NCT03352999|PROCEDURE|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
48684658|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
48684659|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
48684660|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
48684661|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
48684662|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
47999349|NCT01806896|DRUG|Placebo|"* Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days."
47999350|NCT01301872|OTHER|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
47999351|NCT04557228|DIETARY_SUPPLEMENT|Placebo|4 weeks of placebo supplements
47999352|NCT04557228|DIETARY_SUPPLEMENT|Phosphatidylserine|4 weeks of phosphatidylserine supplements
47999353|NCT06402188|DEVICE|ColoSeal ICD Device|The subject will undergo scheduled resection per the surgeon's preferred technique. Following completion of the anastomosis, the Intraluminal Colonic Diversion (ICD) Device will be inserted, advanced and positioned with the ICD Delivery System transanally. The ICD Device will remain in place for 10± 2 days. Anastomotic leak testing will be performed prior to scheduled removal.
47999354|NCT05622279|PROCEDURE|Percutaneous tenotomy + PRP|The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
47999355|NCT05111691|PROCEDURE|Dry needling|Dry needling
47999356|NCT01869283|OTHER|Kinesiotherapy|
48684663|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
48684664|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
47999357|NCT01869283|OTHER|Ultrasound|
47999358|NCT01869283|OTHER|Diadynamic currents|
47999359|NCT04881357|OTHER|test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).|The experimental group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the test mouth rinse (Lacer Oros Acción Integral - new formula, Barcelona, Spain).
47999360|NCT04881357|OTHER|control group|The control group will use three times daily a provided manual toothbrush with a sodium fluoride dentifrice, followed by the use of the control mouth rinse (Lacer Oros Acción Integral - new formula, without active ingredients, Barcelona, Spain).
47999361|NCT03998553|PROCEDURE|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
47999362|NCT02389504|OTHER|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
48684665|NCT05272397|DRUG|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
48684666|NCT05272397|DRUG|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
48684667|NCT05272397|BEHAVIORAL|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
48684668|NCT05272397|BEHAVIORAL|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
48684669|NCT05272397|BEHAVIORAL|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
48684670|NCT05272397|BEHAVIORAL|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
48684671|NCT05272397|BEHAVIORAL|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
48684672|NCT05272397|BEHAVIORAL|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
48684673|NCT05272397|BEHAVIORAL|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
48684674|NCT06139614|BEHAVIORAL|PERSIST|PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
48684675|NCT06093269|BIOLOGICAL|Blood samples|"For all subjects (short kinetics):~* Pre-injection of cefazolin~* Start of next dialysis~* Two hours after start of subsequent dialysis~* End of next dialysis, before cefazolin administration~Only in hospitalized subjects (rich kinetics):~* 30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound~* 12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution"
48684676|NCT05487690|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.
48684677|NCT05487690|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
48684678|NCT03252041|DEVICE|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
48684679|NCT00109213|PROCEDURE|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
48684680|NCT00109213|PROCEDURE|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
48684681|NCT04105686|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
48684682|NCT04105686|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
48684683|NCT04377958|DIAGNOSTIC_TEST|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
48684684|NCT01488461|GENETIC|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
48684685|NCT00301145|BEHAVIORAL|smoking cessation intervention|
48684686|NCT00301145|DRUG|varenicline|
48684687|NCT00301145|OTHER|counseling intervention|
48684688|NCT00301145|OTHER|internet-based intervention|
47999363|NCT02389504|OTHER|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
47999364|NCT06271733|DEVICE|TMS|2 sessions of iTBS per day for 5 days
47999365|NCT06271733|DEVICE|Sham|2 sessions per day for 5 days of sham condition
47999366|NCT03317431|OTHER|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
47999367|NCT02727920|DIETARY_SUPPLEMENT|Energy drink|
47999368|NCT02727920|OTHER|Placebo|placebo drink
47999369|NCT01002755|DRUG|Lenalidomide|Given PO
47999370|NCT01002755|BIOLOGICAL|Ofatumumab|Given IV
47999371|NCT06468709|DRUG|Glucocorticoids|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
48684689|NCT05361538|DEVICE|True circular microwave needle|Use true circular microwave needle for thermal ablation
48684690|NCT05127408|PROCEDURE|Interventional Endoscopy|correct defects of the gastrointestinal tract.
48684691|NCT01500785|DRUG|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
48684692|NCT01500785|DRUG|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
47999372|NCT06468709|DRUG|Glucocorticoids+MMF|The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
47999373|NCT04145778|OTHER|6-minute walk test|The 6-minute walk test is performed as part of routine practice for patients with BMDS to assess patients' overall endurance. In order to compare patients' global endurance with controls, this walking test will also be offered to 50 of the healthy subjects already recruited in the study.
47999374|NCT03075670|DRUG|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
47999375|NCT03075670|DRUG|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
47999376|NCT06254053|OTHER|zirconia reinforced glass ionomer|Restorative material
48684693|NCT03136653|BIOLOGICAL|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
48684694|NCT02424500|DEVICE|d-Nav|Insulin dosage is adjusted as required
48684695|NCT02424500|DEVICE|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
48684696|NCT02205268|PROCEDURE|Near infrared spectroscopy neurofeedback training|
48684697|NCT05094063|OTHER|patient education by mobile application|Training will be given to the patients in the experimental group.
48684698|NCT02485509|DRUG|VM-1500/Placebo|VM-1500 or Placebo
48684699|NCT02869126|PROCEDURE|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"* During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later"
48684700|NCT02869126|DRUG|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
47999377|NCT06254053|OTHER|Glass ionomer cement|Restorative material
47999378|NCT06003530|BIOLOGICAL|hOMSC200|Human Oral Mucosal Stem Cells
47999379|NCT06003530|OTHER|Placebo|Animal component-free, defined cryopreservation medium with 5% DMSO
47999380|NCT04166838|BIOLOGICAL|CD19 UCARTcells|This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 \^ 6 cells/kg,3 × 10 \^ 6 cells/kg,5 × 10 \^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
47999381|NCT04330742|DRUG|lactated ringers|the intervention is one liter fluid bag of lactated ringers which is routinely used as a fluid coload for spinal anesthesia. All patients will receive the same amount of fluids however this will be paused at various time points in order to perform the echocardiogram.
48157344|NCT05383053|DEVICE|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
48157345|NCT05974371|OTHER|emotional context similarity|On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
48157346|NCT03171389|DRUG|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
47999382|NCT00006489|BEHAVIORAL|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
47999383|NCT00006489|DRUG|Naltrexone|Daily dosing 100 mg for 24 weeks
47999384|NCT00006489|DRUG|Placebo|Pill Placebo daily dosing 24 weeks
47999385|NCT02472938|DRUG|dimethyl fumarate|dimethyl fumarate 120 mg capsules
47999386|NCT02472938|OTHER|Placebo|Placebo for BG00012
48684701|NCT02869126|DRUG|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
48684702|NCT05985798|DRUG|Sin-Bev-TACE|Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
48157347|NCT00466856|DRUG|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* \>20% Do not give SIR-Spheres"
48157348|NCT00466856|RADIATION|yttrium Y 90 resin microspheres|radiation
48157349|NCT01282983|DIETARY_SUPPLEMENT|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
48157350|NCT01282983|DIETARY_SUPPLEMENT|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
48157351|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at Day 4|Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB
47999387|NCT05888129|PROCEDURE|surgery after neoadjuvant chemotherapy|surgery after neoadjuvant chemotherapy
47999388|NCT06312878|OTHER|Describe the anatomy of the IVC in the case of an anatomical variant|Evaluated technique by collecting data from the medical record.
47999389|NCT05662579|OTHER|Exercises|"There will be 2 reevaluations of the participants, similar to the initial: at the end of the exercise protocol and in a follow-up of 12 weeks after the end of the protocol.~The contraction phase of each exercise will be 2 concentric seconds, 1 isometric second and 2 eccentric seconds, followed by 1 second of rest; there will be approximately 90 seconds of rest between each set of 10 repetitions, time the other member will be exercising.~At the beginning and at the end of each session, the participants will be asked to point out the pain they feel in the hip at that time. In each of the 8 sessions, the physiotherapist will take note of the presence, lateral pain in the hip at the beginning and end of the therapy (by VAS), number of repetitions performed in each exercise (for the group that will do core exercises, it will be noted the time in seconds of each exercise) and any adverse events. Each series of exercises will be repeated 3 times, all performed bilaterally."
48157352|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at Day 4|Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.
48157353|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at week 26|Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.
47999390|NCT00864747|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
47999391|NCT00864747|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
48157354|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at week 26|Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
48684703|NCT05985798|DRUG|Len-TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
48684704|NCT03276832|DRUG|Imiquimod|Applied cutaneously
48684705|NCT03276832|PROCEDURE|Biopsy|Undergo biopsy
48157355|NCT00158886|DRUG|Topotecan|Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
48157356|NCT00158886|RADIATION|Radiation therapy|For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (\>=6 megavolt \[mv\]).
48157357|NCT06329661|DRUG|Cyclosporine ophthalmic solution, 0.1%|Colorless and clear opthalmic solution containing 0.1% Cyclosporine
48157358|NCT06329661|DRUG|Saline solution, 0.6%|Colorless and clear sodium chloride solution (0.6%)
48684706|NCT03276832|BIOLOGICAL|Pembrolizumab|Given IV
48684707|NCT03276832|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48684708|NCT03276832|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48684709|NCT03276832|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48684710|NCT02741986|OTHER|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
48684711|NCT04349358|OTHER|FDG and FCH PET/CT|"* during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~* just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
48684712|NCT00735553|DRUG|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
48684713|NCT00735553|DRUG|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
48684714|NCT00735553|DRUG|Placebo|Two placebo capsules orally daily for up to four months
48684715|NCT06080763|PROCEDURE|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
48684716|NCT01596855|DRUG|FG-4592|TIW dosing, capsule
47999392|NCT03237767|OTHER|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
48157359|NCT04950790|DRUG|Shuxinin injection|Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
48684717|NCT01596855|DRUG|Epoetin Alfa|TIW
48684718|NCT05562557|BEHAVIORAL|Motivational Enhancement|To encourage intrinsic motivation to engage in fatherhood activities
48684719|NCT05562557|BEHAVIORAL|HERO Dads Fatherhood Program|Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting
48684720|NCT05562557|BEHAVIORAL|Contingency Management|To reinforce healthy behaviors, including attendance at services
48684721|NCT05562557|BEHAVIORAL|Case Management|Referrals to treatment, social services, and employment services
48684722|NCT02445729|OTHER|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
48684723|NCT02445729|OTHER|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
48684724|NCT06046092|BIOLOGICAL|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
48684725|NCT02104791|DRUG|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
48684726|NCT02915627|DEVICE|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
48157360|NCT04950790|DRUG|Basic treatment|Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
48157361|NCT04950790|DRUG|Placebo|sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
48684727|NCT02334072|DEVICE|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
48684728|NCT02334072|DEVICE|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
48684729|NCT02334072|DEVICE|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
48684730|NCT02334072|DEVICE|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
48684731|NCT02334072|DEVICE|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
48157362|NCT04827602|OTHER|Drug allergy label status in electronic health records|Registered drug allergy labels in primary care and hospital electronic medical charts
48157363|NCT05417568|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
48157364|NCT05417568|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
48157365|NCT06451224|OTHER|Questionnaire|Online Questionnaire
48684732|NCT01496053|DIETARY_SUPPLEMENT|AndoSan|AndoSan 30 ml x 2 for 21 days
48684733|NCT01496053|DIETARY_SUPPLEMENT|Sugar Extract|Sham comparator
48684734|NCT05628870|DRUG|HRS-1358|HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
48684735|NCT00004744|DRUG|immune globulin|
48684736|NCT03974126|OTHER|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
48684737|NCT03974126|OTHER|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
48157366|NCT06340334|BIOLOGICAL|Tegoprazan-amoxicillin dual therapy|A total of 600 Hp-positive patients who had not received Hp eradication therapy before or had had Hp eradication in the early stage but had not undergone eradication therapy in the past six months were randomly divided into two groups: group A subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, tid; Group B subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days. The eradication rate, adverse reactions, and compliance of the two groups were compared.
48157367|NCT01061775|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
48157368|NCT05887479|DRUG|Botulinum toxin type A|Toxin of Clostridium Botulinum
48157369|NCT05887479|DRUG|%0,9 NaCl|%0,9 NaCl
48157370|NCT03321188|PROCEDURE|HIPEC|HIPEC with cisplatin
48157371|NCT03321188|DRUG|Carboplatin|Adjuvant IV chemotherapy
48157372|NCT03321188|DRUG|Paclitaxel|Adjuvant IV chemotherapy
48157373|NCT03829072|OTHER|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
48157374|NCT03829072|OTHER|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
48512795|NCT05354921|DEVICE|Intermittent Catheterization|"Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR\>400 mL, an intermittent catheter will be used. If PVR\> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR\>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR\>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR\>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time."
48157375|NCT05106023|DRUG|SHR-1701|SHR-1701 combined with temozolomide
48157376|NCT05106023|DRUG|Temozolomide|SHR-1701 combined with temozolomide
48157377|NCT05399667|OTHER|Early stimulation|Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
48157378|NCT05399667|OTHER|Conventional care|Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
48157379|NCT03953378|OTHER|Multi-parametric Flow Cytometry analysis on patients and healthy donors samples|"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."
48157380|NCT04010981|OTHER|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
48157381|NCT04010981|OTHER|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
48157382|NCT05873816|DEVICE|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
48157383|NCT05873816|DEVICE|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
48684738|NCT06207552|GENETIC|BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
48157384|NCT04826744|OTHER|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~* Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~* Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~* ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
48157385|NCT05385991|BIOLOGICAL|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
48157386|NCT06546566|OTHER|Video Game-Based Breathing Exercises|The video game-based breathing exercises program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
48157387|NCT06546566|OTHER|Conventional Breathing Exercises|The conventional breathing exercises program will consist of routine breathing exercises. Breathing exercises will be given 2 times a day, 5 repetitions, 2 sets. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
48157388|NCT05389254|DEVICE|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
48157389|NCT05389254|DEVICE|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
48157390|NCT00040729|GENETIC|mutation analysis|
48157391|NCT06477848|OTHER|Integrated Behavioral Health System with SUD Resources|This is a system-level intervention designed to improve collaboration among personnel from primary care clinics and SUD resources.
48157392|NCT00910871|DRUG|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
47999393|NCT03237767|OTHER|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
47999394|NCT05081856|OTHER|mobilization with moduler medical equipment carring vehicle|Mobilization of the patients was carried out with the vehicle in their modular vehicle.
47999395|NCT02586493|DRUG|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
48157393|NCT00910871|DRUG|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
48157394|NCT00830284|PROCEDURE|Recruitment maneuver|"Three types of maneuvers will be performed.~1. 6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~2. 6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~3. PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
48157395|NCT02843542|DEVICE|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
48366689|NCT04466852|OTHER|telemedicine-guided consultation|Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
48684739|NCT01147159|OTHER|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
48684740|NCT02366923|DEVICE|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
48684741|NCT02366923|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
48684742|NCT00083460|DRUG|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
48684743|NCT00083460|DRUG|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
48684744|NCT00083460|DRUG|Dexamethasone|A dose of 20mg for cylces 3-8.
48684745|NCT01739608|OTHER|Invitation to screening|Invitation to screening
47999396|NCT02586493|OTHER|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
48366690|NCT04797676|PROCEDURE|different methods of specimen acquisition|After informed consent, the investigators use two methods to obtain specimens for patients with pancreatic ductal adenocarcinoma, who needs eus-fnb for auxiliary diagnosis and had the opportunity of surgery. One method is EUS-FNB with wet suction technique, the other is surgery (including radical operation and cytoreductive surgery). Both methods are used on the same patient to remove deviations in results caused by tumor heterogeneity.
48684746|NCT05820841|DRUG|R-miniCHOP + Acalabrutinib|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
48684747|NCT05820841|DRUG|R-miniCHOP|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks"
48684748|NCT00725946|DRUG|Iodine-124|
48684749|NCT00725946|RADIATION|PET/CT with Iodine-124|
48684750|NCT04469088|OTHER|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
47999397|NCT02276612|DRUG|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
47999398|NCT02864849|DRUG|Oxaliplatin|
47999399|NCT02864849|DRUG|Capecitabine|
47999400|NCT02864849|RADIATION|Intensity modulated radiotherapy|
47999401|NCT02864849|PROCEDURE|Total mesorectal excision|
47999402|NCT01871610|DRUG|[18F]AV-45 PET amyloid binding imaging|
47999403|NCT04797260|GENETIC|Gene therapy|Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).
47999404|NCT05075226|DEVICE|Vivity Extended Depth of Focus|Cataract surgery
48684751|NCT04469088|OTHER|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
48684752|NCT05017389|DIAGNOSTIC_TEST|Griffiths development scales|Griffiths development scales Chinese Edition (gds-c) was used to evaluate the development levels of children up to 6 years and WISC for children more than 6 years.
48684753|NCT04638920|OTHER|No intervention|No intervention
48684754|NCT06027658|BEHAVIORAL|RECREATION therapy|Dance as therapy program with speech and movement co-therapy via body activity.
48684755|NCT00288015|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
48684756|NCT00353301|DRUG|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
48157396|NCT02843542|DEVICE|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
48366691|NCT03385395|DRUG|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
48684757|NCT00353301|DRUG|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
48366692|NCT03385395|DRUG|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
48366693|NCT02534181|DRUG|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
48684758|NCT06503627|PROCEDURE|bladder flap dissection|bladder flap dissection during caesarean section
48684759|NCT02713334|BEHAVIORAL|survey|
48684760|NCT02713334|BEHAVIORAL|semi-structured interview|
48157397|NCT04433247|BEHAVIORAL|Peer Led Group Intervention|Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
48157398|NCT01938209|OTHER|seated thoracic manipulation|seated general thoracic spine manipulation
48684761|NCT05246878|DRUG|EDP-235|Oral administration
48684762|NCT05246878|DRUG|Placebo|Placebo to match EDP-235, oral administration
48684763|NCT04612829|DEVICE|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
47999405|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
47999406|NCT05698264|DEVICE|concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment|Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.
48684764|NCT05978674|BEHAVIORAL|rocking bed group|Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
48157399|NCT01938209|OTHER|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
47999407|NCT04013620|DRUG|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
47999408|NCT04931056|DEVICE|Titanium Facial Plates|The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
47999409|NCT04931056|DEVICE|Titanium Mandibular Plates|"The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length."
47999410|NCT04931056|DEVICE|Add-on Condyle|The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
47999411|NCT04931056|DEVICE|HTR-PEKK|The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
47999412|NCT04424238|BEHAVIORAL|m-health management|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care.
47999413|NCT01437007|DRUG|TKM-080301|
47999414|NCT00639834|BIOLOGICAL|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
47999415|NCT03777293|DEVICE|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
47999416|NCT01136304|DRUG|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
47999417|NCT02013167|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
47999418|NCT02013167|DRUG|Standard of Care Chemotherapy|"* FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 \& 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients \> 60 years: Idarubicin 5 mg/m² day 1 \& 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~* HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~* High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~* Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
48157400|NCT02007421|PROCEDURE|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
48366694|NCT05973825|PROCEDURE|Leucapheresis|leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
48684765|NCT01591434|DEVICE|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
48684766|NCT01591434|DEVICE|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
47999419|NCT06340438|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
47999420|NCT06340438|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
47999421|NCT02009410|DRUG|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
47999422|NCT02009410|DRUG|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
47999423|NCT04860102|PROCEDURE|hands on|Hands-on was defined as involving one hand on the fetal head, applying pressure to control expulsion, with the other hand applying pressure on the maternal perineum
48157401|NCT02007421|PROCEDURE|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
48684767|NCT01350674|PROCEDURE|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
48366695|NCT06207708|OTHER|questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement|the patient is administered with questionnaires focused on diet, fatigue, nutrition screening and on body mass index at the beginning and at the end pf particle therapy radiation treatment
47999424|NCT01599273|DRUG|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
47999425|NCT04924829|DRUG|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
48684768|NCT02466425|DRUG|SHP465|12.5mg and 25mg capsules (one capsule daily)
48684769|NCT02466425|DRUG|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
47999426|NCT05336058|OTHER|No intervention|In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
47999427|NCT00484237|DRUG|etanercept|
47999428|NCT03924258|DIAGNOSTIC_TEST|Iron status testing|Blood sample for iron status testing
47999429|NCT03418909|PROCEDURE|Primary Trans Oral Robotic Surgery (TORS)|In the absence of severe mobidity patients with early stage disease (T1-2, N1, M0) were offered TORS, as an alternative to the standard of care (radiotherapy).
47999430|NCT03418909|RADIATION|Radio(chemo)therapy|As the standard of care radiotherapy was offered to all of the patients. Patients that qualified for both TORS and radiotherapy were free to choose between the two.
47999431|NCT01398956|DRUG|Levetiracetam|"formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily"
47999432|NCT06114758|DRUG|Cytotec 200Mcg Tablet|the admistiration of 400 Mcg rectal cytotec while starting the surgery, just before the patient is covered
47999433|NCT06114758|DRUG|Transamine|1 gram intravenous slow infusion intraoperatively as we start the laparatomy
47999434|NCT00210704|DRUG|Dapoxetine|
48157402|NCT02982070|BEHAVIORAL|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
48157403|NCT00357747|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
48366696|NCT06207708|DIAGNOSTIC_TEST|blood biomarkers|as per clinical routine, hemoglobin, lymphocytes, albumin and NLR will be collected
48366697|NCT02418000|DRUG|E6201|Single Group Assignment
48366698|NCT04693481|OTHER|nature exposure|Nature exposure has different ways, such as walk in the real nature environment; viewing nature photos. Two main reasons make this study will not use the real nature environment: (1) the limitation of time before or amid the soccer competition; (2) the pandemic situation does not allow people go outside as frequently as before. Therefore, the current study will select some nature photos, which are restorative environments and can restore directed attention to counteract mental fatigue.
48512796|NCT03452137|DRUG|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
48512797|NCT03452137|DRUG|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
48684770|NCT06402929|BEHAVIORAL|Honest Open Proud - College (HOP-C)|"The program consists of three weekly workshops that are two hours in duration. There is a fourth booster workshop (two hours in duration) one month following program completion. All workshops will be held over an online videoconferencing platform.~HOP-C is a group program led by trained peer facilitators who have lived mental illness experience. Major topics that the program covers are:~1. discussing different types of disclosure;~2. conducting a cost-benefit analysis of disclosing in different situations;~3. strategies to anticipate how certain people will respond to disclosure when deciding on who to disclose to;~4. disclosure via social media; and~5. a guided creation of participants' own disclosure narrative.~During the booster workshop, participants will be encouraged to reflect on their disclosure decisions, and periodically revisit their disclosure cost-benefit analysis in deciding if and when to disclose in the future."
48157404|NCT00357747|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
48684771|NCT03058198|DIAGNOSTIC_TEST|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
48684772|NCT03777046|BEHAVIORAL|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
48684773|NCT03777046|BEHAVIORAL|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
48157405|NCT03162523|RADIATION|High-Dose Rate Brachytherapy|
48157406|NCT01810640|PROCEDURE|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
48157407|NCT06270849|OTHER|Questionnaire|The questionnaire to assess severity of LUTS in women.
47999435|NCT03073590|COMBINATION_PRODUCT|Intervention factory with hot lunch|A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
48684774|NCT01916824|DRUG|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
48684775|NCT01995500|DEVICE|BioNIR|drug-eluting stent
48684776|NCT01995500|DEVICE|Resolute|drug-eluting stent
48157408|NCT03097302|PROCEDURE|Laser keratotomy|Penetrating femtosecond laser assisted keratotomy to treat preexisting corneal astigmatism during lens surgery.
48157409|NCT06434545|BEHAVIORAL|Palliative Reasoning methodology|Twenty nursing teams will be trained in the Palliative Reasoning methodology during a four hour training, split into two sessions. Additionally, teams receive a coaching session ones a month and practice with a real life case every week or two weeks during a one hour team meeting. This will be compared with 20 other nursing teams that will continue to provide care as usual.
48684777|NCT04224233|OTHER|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
48157410|NCT02713698|DRUG|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
48157411|NCT04291560|BEHAVIORAL|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
48157412|NCT05256914|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
48157413|NCT05256914|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
47999436|NCT03073590|COMBINATION_PRODUCT|Intervention factory without lunch program|In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
47999437|NCT03073590|COMBINATION_PRODUCT|Control factory with lunch program|One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
47999438|NCT03073590|BEHAVIORAL|Control factory without lunch program|One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
48684778|NCT04224233|OTHER|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
47999439|NCT00267722|DRUG|Visilizumab|
47999440|NCT00621881|DRUG|naproxcinod|750 mg bid
48684779|NCT04115124|BEHAVIORAL|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
48684780|NCT03747796|OTHER|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
48684781|NCT03747796|OTHER|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
48684782|NCT01798147|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
48684783|NCT01798147|PROCEDURE|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
48684784|NCT04875455|DEVICE|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
48684785|NCT05657938|DEVICE|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
48684786|NCT05657938|OTHER|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
48684787|NCT02720523|DRUG|Placebo|Tablet; Oral
48684788|NCT02720523|DRUG|Upadacitinib|Tablet; Oral
48157414|NCT03953209|DRUG|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
48157415|NCT03953209|DRUG|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
48157416|NCT03953209|DRUG|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
48157417|NCT01690286|DRUG|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
48157418|NCT01690286|DRUG|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
48684789|NCT03570242|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
48684790|NCT05744778|OTHER|Dry needling|In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
48684791|NCT05744778|OTHER|Physical therapy and rehabilitation|The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
48684792|NCT05535023|DRUG|SAR444245|Given by vein (IV)
48684793|NCT05535023|DRUG|Cemiplimab|Given by vein (IV)
48684794|NCT01563705|PROCEDURE|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
48684795|NCT01563705|PROCEDURE|Manual dexterity assessment|Purdue pegboard test
48684796|NCT03442556|DRUG|Carboplatin|Given IV
48684797|NCT03442556|DRUG|Docetaxel|Given IV
47999441|NCT00694369|DRUG|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
47999442|NCT00694369|DRUG|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
47999443|NCT00694369|DRUG|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
47999444|NCT00694369|DRUG|Comparator: placebo|matching placebo over three Days
47999445|NCT00694967|PROCEDURE|McDonald cerclage placement|Transcervical McDonald cerclage placement
48157419|NCT01690286|DRUG|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
48157420|NCT01690286|DRUG|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
48366699|NCT00709813|BEHAVIORAL|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
48512798|NCT01700231|PROCEDURE|Liver resection|Liver resection of patient with neoplastic hepatic tumors
47999446|NCT00694967|DRUG|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
47999447|NCT02763852|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
47999448|NCT02763852|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
47999449|NCT02763852|DRUG|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
48157421|NCT01765699|DEVICE|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
48157422|NCT05905445|DRUG|ozone gel|the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
48157423|NCT02499835|BIOLOGICAL|Pembrolizumab|Given IV
48157424|NCT02499835|BIOLOGICAL|pTVG-HP Plasmid DNA Vaccine|Given ID
48157425|NCT05635994|DIAGNOSTIC_TEST|AID strategy|AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
48157426|NCT01106586|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
48157427|NCT01106586|DRUG|ATV|Atazanavir 300 mg capsule administered orally once daily
47999450|NCT03072134|BIOLOGICAL|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
47999451|NCT00234988|DRUG|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
47999452|NCT01293240|DEVICE|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
47999453|NCT05517499|DRUG|Dexamethasone|Randomized clinical trial
47999454|NCT01771146|DRUG|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
48157428|NCT01106586|DRUG|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
47999455|NCT00624962|DIETARY_SUPPLEMENT|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
48157429|NCT01106586|DRUG|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
48157430|NCT01106586|DRUG|Stribild Placebo|Placebo to match Stribild administered orally once daily
48157431|NCT01106586|DRUG|ATV Placebo|Placebo to match ATV administered orally once daily
48157432|NCT01106586|DRUG|RTV Placebo|Placebo to match RTV administered orally once daily
48157433|NCT01106586|DRUG|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
48157434|NCT00711776|DRUG|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
47999456|NCT00624962|DIETARY_SUPPLEMENT|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
47999457|NCT03427359|DRUG|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
47999458|NCT00831532|DRUG|Dimebon|Dimebon 5mg in healthy controls
47999459|NCT00831532|DRUG|Dimebon|Dimebon 5mg in mild hepatic impairment patients
47999460|NCT00831532|DRUG|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
47999461|NCT00831532|DRUG|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
47999462|NCT02271191|DRUG|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
47999463|NCT01894165|DRUG|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
47999464|NCT01894165|DRUG|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
47999465|NCT01716013|DEVICE|BondEase|topical skin adhesive
47999466|NCT01716013|PROCEDURE|CWCD|traditional closure methods of sutures, staples or adhesive strips
47999467|NCT00448071|DRUG|MTR107|
47999468|NCT00165412|PROCEDURE|breast MRI|Repeated once a year for three years
47999469|NCT00165412|PROCEDURE|Mammogram|Repeated once a year for three years
47999470|NCT05326165|DEVICE|Juzo Compression Sleeve and Glove|Elasticized garment sized for arm and hand to create pressure to reduce swelling
48157435|NCT00711776|DRUG|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
48157436|NCT03258905|BEHAVIORAL|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
48157437|NCT03258905|BEHAVIORAL|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
48157438|NCT06057038|BIOLOGICAL|GEN1042|Intravenous
48157439|NCT06057038|DRUG|Pembrolizumab|Intravenous
48157440|NCT06057038|DRUG|Cisplatin|Intravenous
48157441|NCT06057038|DRUG|Carboplatin|Intravenous
48157442|NCT06057038|DRUG|5-Fluorouracil|Intravenous
48157443|NCT03735147|BIOLOGICAL|Live attenuated influenza vaccine (LAIV)|Single dose of LAIV
48157444|NCT05844280|PROCEDURE|BFR+NMES at therapeutic level|This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
48157445|NCT05844280|PROCEDURE|BFR+NMES at sub therapeutic level|This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
48157446|NCT00207935|BEHAVIORAL|Swallow instruction|
48157447|NCT00219635|DRUG|UK-390,957|
48157448|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
48157449|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
47999471|NCT05326165|DEVICE|Compression Sleeve Sensor|Small device embedded within compression sleeve garment collecting usage information
47999472|NCT03995212|DRUG|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
47999473|NCT03995212|DRUG|Placebo|Oral Placebo administered twice daily
47999474|NCT05808712|OTHER|validation|Translation and validation design
47999475|NCT06111365|DEVICE|CHLOE|"the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5"
47999476|NCT00892567|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
47999477|NCT00249470|BEHAVIORAL|Abstinence & Work|Participants in the Abstinence \& Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
47999478|NCT00249470|BEHAVIORAL|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
47999479|NCT05970315|BEHAVIORAL|PPC|Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.
47999480|NCT05970315|BEHAVIORAL|Usual care|Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
47999481|NCT04929652|DRUG|Surufatinib,Camrelizumab,Irinotecan,GM-CSF|"1. Dose climbing stage design (n=12) :~   Surufatinib: Oral, 3w.The initial dose of 250mg/ day (n=6) : If 2 out of 6 patients developed \> DLT in the first treatment cycle, the exploratory dose was 200 mg/ day; if ≤2 out of 6 patients developed DLT, the exploratory dose was 300mg/ day (n=6);At the next dose phase, if 2 out of 6 patients with \> developed DLT, the previous dose was recommended or the study was terminated;If no more than 2 out of 6 patients developed DLT, the dose was the recommended dose；PD-1,200mg, iv,D1, 3w；Irinotecan: 200mg/㎡, iv, D1, 3w；GM-CSF,D2, D3, D4, D5, D6 and D7 in the first week of each cycle ；~2. Dose expansion phase design(n=36):~   1. Surufatinib: Oral, 3w. the dose was set according to the recommended dose in the dose climbing stage;~  2. PD-1(Camrelizumab) : 200mg, iv,D1, 3w;~  3. Irinotecan: 200mg/㎡, iv, D1, 3w;~  4. GM-CSF: continuous administration of D2, D3, D4, D5, D6 and D7 in the first week of each cycle, 5ug/kg once per body weight, once a day, 3w."
47999482|NCT06497049|DRUG|GP40221|Solution for Subcutaneous Administration 1.34 mg/ml
47999483|NCT06497049|DRUG|ozempic|Solution for Subcutaneous Administration 1.34 mg/ml
47999484|NCT00001731|DRUG|Cyclosporin A|
47999485|NCT03893552|DEVICE|Negative expiratory pressure|Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
47999486|NCT02567006|BEHAVIORAL|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
47999487|NCT02567006|OTHER|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
47999488|NCT01164449|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
47999489|NCT03471533|DIETARY_SUPPLEMENT|nutraceutical: experimental product|84 days of consumption
47999490|NCT03471533|DIETARY_SUPPLEMENT|placebo|84 days of consumption
47999491|NCT03349216|PROCEDURE|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
47999492|NCT03349216|DRUG|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
47999493|NCT04052542|BEHAVIORAL|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
47999494|NCT04052542|BEHAVIORAL|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
47999495|NCT04052542|BEHAVIORAL|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
47999496|NCT03037528|BEHAVIORAL|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
47999497|NCT03037528|BEHAVIORAL|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
47999498|NCT03037528|BEHAVIORAL|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
47999499|NCT03037528|BEHAVIORAL|dietary tracking|Participants will be asked to track their diet consistently.
47999500|NCT02208609|OTHER|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
47999501|NCT02208609|OTHER|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
48512799|NCT05166616|PROCEDURE|Biopsy|Correlative studies
47999502|NCT02178384|PROCEDURE|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
47999503|NCT02178384|DEVICE|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
48512800|NCT05166616|DRUG|Osimertinib|Given PO
48512801|NCT05166616|DRUG|Triptolide Analog|Given PO
47999504|NCT02178384|PROCEDURE|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
47999505|NCT02310139|PROCEDURE|Colonoscopy|
47999506|NCT00343733|DRUG|OraVescent Fentanyl|
47999507|NCT04264910|BEHAVIORAL|Calm App|Calm is a subscription-based meditation app which provides guided meditations, sleep stories, soundscapes and calming music. Calm offers 7 Days of Calm for those new to meditation, the daily Calm, a meditation posted daily and a library of unique 10-12 minute meditations with topics related to acceptance, anxiety, self-compassion, and physical pain (to name a few).
48157450|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
47999508|NCT00747968|DRUG|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol\*kg-1\*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
47999509|NCT02803307|DRUG|TLC599|Single dose via intra-articular injection
47999510|NCT03583424|DRUG|Carmustine|Given IV
47999511|NCT03583424|DRUG|Cytarabine|Given IV
47999512|NCT03583424|DRUG|Etoposide|Given IV
47999513|NCT03583424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
47999514|NCT03583424|DRUG|Melphalan|Given IV
47999515|NCT03583424|DRUG|Venetoclax|Given PO
47999516|NCT02871739|BEHAVIORAL|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
47999517|NCT02871739|BEHAVIORAL|DA viewing|Participants will receive 3 decisions aids to review.
48157451|NCT00117650|OTHER|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
48512802|NCT03864887|PROCEDURE|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
48512803|NCT03864887|PROCEDURE|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
48512804|NCT03864887|DEVICE|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
48512805|NCT03638726|DRUG|Atropine sulfate and epinephrine|Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
48512806|NCT03638726|DRUG|Topical cyclopentolate and phenylephrine|Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
48512807|NCT02753920|OTHER|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
48512808|NCT02753920|DEVICE|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
48684798|NCT03442556|OTHER|Laboratory Biomarker Analysis|Correlative studies
47999518|NCT02871739|BEHAVIORAL|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
47999519|NCT05936866|OTHER|Pelvic floor stretching|Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises , seated pelvic tilts, cat stretches, seated hip openers (2 sets, 8 reps, sustained for 6 seconds) Week 5 to 8: Pelvic floor muscles awareness, Breathing exercises ,seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog (2 sets, 8 reps, sustained for 6 seconds) Week 9 to 13: Pelvic floor muscles awareness, Breathing exercises, seated pelvic tilts, cat stretches, Seated hip openers, Relaxed Frog side lying clamshells, mini squats with support (2 sets, 9 reps, sustained for 7 seconds)
47999520|NCT05936866|OTHER|Pelvic floor strengthening|"Week 1 to 4: Pelvic floor muscles awareness, Breathing exercises, 2 Sets of 10 Reps for pelvic floor squeeze and release Seated marching with elastic band with pelvic floor squeeze.~Week 5 to 8: 2 sets x 9 Reps for Pelvic floor squeeze and release, Seated marching with elastic band with pelvic. 2 Sets x 8 Reps for bridging with pelvic floor squeeze, side lying hip circles Week 9 to 13: 2 sets 10 reps for Pelvic floor squeeze-and-release, Seated marching with elastic band with pelvic floor squeeze, pelvic bridging with pelvic floor squeeze, side lying hip circles with pelvic floor squeeze. 2 sets, 8 reps for . side lying Clamshells with resistance band and pelvic floor squeeze and plie squats with pelvic floor squeeze"
47999521|NCT03221595|DEVICE|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
47999522|NCT05715203|DEVICE|Pulsotonometry|Evaluation of arterial stiffness
47999523|NCT03561415|OTHER|Universal Posaconazole Prophylaxis|All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
47999524|NCT03561415|OTHER|Pre-emptive Posaconazole Therapy|Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
47999525|NCT02856542|DRUG|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
47999526|NCT01274403|DRUG|Melphalan, Prednisone and Thalidomide|
48366700|NCT02286206|DRUG|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
48684799|NCT03442556|DRUG|Rucaparib Camsylate|Given PO
48684800|NCT03442556|DRUG|Rucaparib|Given PO
47999527|NCT05262634|OTHER|Data collection (laboratory and obstetric results)|"Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology"
47999528|NCT05773430|BEHAVIORAL|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
47999529|NCT02488603|BEHAVIORAL|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
47999530|NCT02488603|DRUG|tamoxifen|
47999531|NCT04629287|DRUG|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
47999532|NCT04629287|DRUG|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
47999533|NCT01250587|DRUG|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
48157452|NCT04624074|BEHAVIORAL|Teen Marijuana Check Up|Teen Marijuana Checkup will be adapted for youth and young adults with first episode psychosis. The Teen Marijuana Checkup includes two intervention sessions. In Session 1, the interventionist uses motivational interviewing skills to hear the adolescent's history and current concerns with marijuana. The personalized feedback report generated from the baseline assessment is reviewed. In Session 2, the interventionist elicits change talk and guides discussion on making changes to reduce or stop marijuana use.
48157453|NCT00340184|DRUG|paclitaxel, carboplatin|
48157454|NCT04533334|PROCEDURE|FOB measurement|A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
48157455|NCT04438369|PROCEDURE|Erector Spinae Plane Block|Cathether based Erector Spinae Plane Block for postoperative pain management.
48512809|NCT02017015|DRUG|nab-paclitaxel|nab-paclitaxel at 125 mg/m\^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
48157456|NCT05642663|DEVICE|Stapler|Stapling performed with ALTUS Powered Stapler
48157457|NCT02260583|DEVICE|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
48157458|NCT06361576|DRUG|Nivolumab|As per product label
48512810|NCT02017015|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m\^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
48512811|NCT03008174|OTHER|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
48512812|NCT05065255|DEVICE|SpeediCath® catheters|Patients using SC catheters will be followed up in order to understand the major criteria in the choice of the catheter by the patients.
48157459|NCT03059147|DRUG|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
48157460|NCT03059147|DRUG|Nivolumab|Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
48157461|NCT01682447|OTHER|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
48157462|NCT05704465|BEHAVIORAL|Reiki Therapy|Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.
48366701|NCT04667611|BEHAVIORAL|Psychosocial interventions|Cognitive behavioural therapy (CBT) based individual and group intervention
48366702|NCT02186548|PROCEDURE|Closed surgical technique|"* Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~* The bone covering the canine is being removed~* Attachment with a chain is bonded to the exposed tooth~* The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~* The canine is orthodontically moved beneath the palatal mucosa"
48512813|NCT01014377|DEVICE|VascuActive|
48512814|NCT00003131|DRUG|chemotherapy|
48512815|NCT00003131|DRUG|gemtuzumab ozogamicin|
48512816|NCT06023459|DRUG|Injectable extended-release buprenorphine|Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
47999534|NCT00648596|DRUG|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
47999535|NCT00648596|DRUG|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
48512817|NCT06023459|DRUG|Sublingual buprenorphine-naloxone|Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
47999536|NCT01746212|PROCEDURE|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
48157463|NCT05704465|BEHAVIORAL|Qi-gong Therapy|Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
48157464|NCT05681845|DRUG|NNC0365-3769 (Mim8)|Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
48157465|NCT00349661|DRUG|impact on VASP test|
48157466|NCT03750175|OTHER|Plasma circulating DNA analysis|Clinical utility of ctDNA analysis for treatment decision
48157467|NCT05740904|OTHER|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
48157468|NCT05740904|OTHER|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
47999537|NCT01746212|BIOLOGICAL|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
47999538|NCT01746212|DEVICE|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
47999539|NCT06495918|DRUG|OTX-TKI|Intravitreal Injection of OTX-TKI
47999540|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 2mg of aflibercept
47999541|NCT06495918|DRUG|Aflibercept|Intravitreal Injection of 8mg of aflibercept
48684801|NCT03196596|OTHER|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
47999542|NCT06370156|DRUG|Adalimumab|To suggests the role of TWEAK and the effectiveness of different treatments like adalimumab and methotrexate in managing plaque psoriasis and psoriatic arthritis.
47999543|NCT00001749|DRUG|Antithymocyte globulin|
47999544|NCT00001749|DRUG|Cyclosporine|
48157469|NCT05455554|DIAGNOSTIC_TEST|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
48512818|NCT01611857|DRUG|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
48157470|NCT05455554|DIAGNOSTIC_TEST|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
48157471|NCT01919255|DRUG|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
48512819|NCT01611857|DRUG|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
48512820|NCT01620294|PROCEDURE|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
48512821|NCT01620294|PROCEDURE|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
48512822|NCT00258960|DRUG|Liposomal Doxorubicin|
48512823|NCT00258960|DRUG|Cyclophosphamide|
48512824|NCT00258960|DRUG|Trastuzumab|
48684802|NCT01574820|DRUG|placebo tablet|placebo tablet for 6 months
48684803|NCT01574820|DRUG|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
48684804|NCT04764097|DRUG|Dapagliflozin|SGTL2 Inhibitor
48684805|NCT04764097|DRUG|Placebo|Placebo
48684806|NCT03415581|DRUG|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
47999545|NCT06310512|BEHAVIORAL|Structured drug therapy management|Interventions mainly included (1) information collection, clinical assessment, and evaluation of medication regimens; (2) identification of and intervention for medication-related problems; (3) pharmacy instruction and education, and development of personal medication lists; and (4) follow-up and reassessment
47999546|NCT02766244|DEVICE|ICG/SPY|indocyanine green fluorescence imaging
47999547|NCT02766244|DRUG|Antibiotic Ointment|Antibiotic ointment
47999548|NCT00729339|DRUG|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
47999549|NCT00729339|DRUG|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
48684807|NCT03415581|BEHAVIORAL|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
48684808|NCT00202215|BEHAVIORAL|Chrysalis Day Program|
47999550|NCT04437966|BEHAVIORAL|Enhanced Chronic Disease Self-management program|CDSMP workshops will last for approximately 2.5 hours and occur weekly for six weeks. Sessions will focus on appropriate diet for persons with hypertension and to facilitate weight loss; managing medications, adherence to medical clinic appointments; physical activity and stress management. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management program. Participants will also be given pill boxes and will be prompted by social media messages to make and keep clinic appointments as well as maintain a healthy lifestyle.
48157472|NCT01919255|DRUG|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
48157473|NCT00784277|DRUG|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
48512825|NCT04228497|DEVICE|gastric ultrasound|Children in both groups will be scanned in two positions: supine position and right lateral position (RLP) one and two hours following the clear fluid intake and before admission to the operation room in groups 1 and 2 respectively. Gastric antrum will be located in the sagittal plane with simultaneous identification of left lobe of the liver and the descending abdominal aorta or inferior vena cava.
48157474|NCT00784277|DRUG|oxycodone IR|10mg for 14 days
48157475|NCT00784277|DRUG|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
48157476|NCT00784277|DRUG|Tapentadol IR (CG5503)|50mg for 14 days
48157477|NCT00784277|DRUG|Tapentadol IR (CG5503)|75mg for 14 days
48157478|NCT00784277|DRUG|placebo|1 capsule for 14 days
48157479|NCT00784277|DRUG|placebo|Tablets and capsules 2 x a day for 28 days
48157480|NCT04818047|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
48157481|NCT03379909|DRUG|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
48157482|NCT01585597|DEVICE|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
48157483|NCT02618109|BIOLOGICAL|Collection of blood samples|Collection of blood samples
48157484|NCT01084408|DEVICE|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
48157485|NCT01084408|DEVICE|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
48157486|NCT04737499|BEHAVIORAL|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
48157487|NCT02115945|OTHER|DN4 test|The DN4 test was used to evaluate neuropathic pain.
48512826|NCT04228497|OTHER|the clear fluid intake|the clear fluid intake
48684809|NCT05711706|OTHER|Su Jok Application|Su Jok massage appplication
48684810|NCT00719498|DRUG|Epo-alpha|
47999551|NCT00816699|OTHER|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
48157488|NCT02115945|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
48157489|NCT02115945|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
48157490|NCT02115945|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
48157491|NCT02115945|PROCEDURE|femoral block|
48157492|NCT02115945|PROCEDURE|epidural block|
48157493|NCT03734588|GENETIC|SPK-8016|adeno-associated viral vector
48157494|NCT05986799|DIETARY_SUPPLEMENT|Amway Herbal Drink|1 sachet per time, 3 times daily, for 3 months period.
48157495|NCT05986799|DIETARY_SUPPLEMENT|Placebo Drink|1 sachet per time, 3 times daily, for 3 months period.
48157496|NCT00860899|DRUG|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine \[Catapres®, Boehringer Ingelheim, Germany\], 7 mL of 0.25% levobupivacaine \[Chirocaine®, Abbott S.p.A., Italy\] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
48512827|NCT06251089|DRUG|CPC mouthwash|0.07% CPC mouthwash
48512828|NCT06251089|DRUG|Placebo|placebo of the CPC mouthwash
48512829|NCT02465138|DRUG|Ketorolac|Intravenous ketorolac
48157497|NCT05823051|OTHER|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
48157498|NCT04826393|DRUG|ASP8374|every 3 weeks by intravenous infusion
48157499|NCT04826393|DRUG|cemiplimab|intravenous infusion
48366703|NCT02186548|PROCEDURE|Open surgical technique|"* Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~* Pack/filling material is applied on the tooth~* Spontaneous eruption of the palatally impacted canine is allowed expected~* The canine is orthodontically moved above the mucosa"
48366704|NCT00472628|PROCEDURE|Blood samples collected|
48512830|NCT02465138|DRUG|Placebo|Intravenous saline
48684811|NCT04738994|DIETARY_SUPPLEMENT|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
48684812|NCT04738994|OTHER|Control group|Standard hospital diet
48684813|NCT01370941|DIETARY_SUPPLEMENT|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
48157500|NCT01323309|BEHAVIORAL|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
48157501|NCT01323309|BEHAVIORAL|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
48684814|NCT01370941|DIETARY_SUPPLEMENT|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
48684815|NCT02704949|RADIATION|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
48684816|NCT02704949|RADIATION|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
48684817|NCT01939522|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|
48684818|NCT06554340|BEHAVIORAL|Home-based aerobic training|The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.
48157502|NCT01323309|BEHAVIORAL|enhanced usual care (EUC)|"We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals."
48157503|NCT04585815|DRUG|Sasanlimab Prefilled syringe|prefilled syringe
48157504|NCT04585815|DRUG|Encorafenib|capsules
48157505|NCT04585815|DRUG|Binimetinib|tablets
48157506|NCT04585815|DRUG|Sasanlimab|solution supplied in vials
48157507|NCT04585815|DRUG|Axitinib|tablets
48157508|NCT04585815|DRUG|SEA-TGT|solution in vials
48366705|NCT02567721|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
48366706|NCT03417102|DRUG|fitusiran|solution for injection; by subcutaneous (SC) injection
48366707|NCT03417102|DRUG|Bypassing agents|solution for injection; by intravenous (IV) injection
48366708|NCT00247962|DRUG|etanercept|50 mg
48366709|NCT00247962|DRUG|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
48366710|NCT01365897|DRUG|Modafinil|Modafinil 200mg
48366711|NCT04531891|OTHER|Fatigue protocol|During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
48366712|NCT03400228|DIETARY_SUPPLEMENT|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
48684819|NCT01480583|DRUG|GRN1005|550 mg/m2 IV every 3 weeks
48684820|NCT01480583|DRUG|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
48684821|NCT01480583|DRUG|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
48684822|NCT03838211|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
48684823|NCT03838211|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
47999552|NCT03145896|DIETARY_SUPPLEMENT|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
47999553|NCT02008448|PROCEDURE|Pulmonary vein isolation|
47999554|NCT02008448|PROCEDURE|Linear Lesion Ablation|
47999555|NCT02008448|DRUG|BT injection|
47999556|NCT02212587|DRUG|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
47999557|NCT00176592|DRUG|Betaseron|Betaseron 250 micrograms injected SQ every other day
47999558|NCT00176592|DRUG|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
48684824|NCT04727996|DRUG|Sitravatinib|120 mg will be administered orally once daily
48684825|NCT04727996|DRUG|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
47999559|NCT03530579|BEHAVIORAL|Educational group trainings|"Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~* Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease \& Diabetes Complication Session 5: Stress Management Session 6: Access to Service"
47999560|NCT03530579|BEHAVIORAL|Community Health Care Worker|A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
47999561|NCT02174848|DRUG|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
47999562|NCT02067377|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
47999563|NCT02067377|DIETARY_SUPPLEMENT|Placebo (for serum bovine immunoglobulin)|
47999564|NCT04779684|OTHER|Advance care planning by proxy for health care proxies of people without medical decision making capacity|Two discussions between a trained health professional and a health care proxy of an RACF resident who no longer has decision making capacity. First discussion focuses on life story, values, previous experiences with medical treatments, illness and death. Second discussion also includes treating physician and focuses on establishing general goals of care and medical orders in case of emergency.
47999565|NCT00368264|DRUG|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
47999566|NCT00368264|DRUG|placebo|azathioprine (2 mg/kg) plus four placebo infusions
47999567|NCT01527292|RADIATION|Stereotactic Radiation Therapy|SRT only
47999568|NCT01527292|RADIATION|SRT with Vertebral Augmentation Procedure|SRT with VAP
47999569|NCT02603432|BIOLOGICAL|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
47999570|NCT02603432|OTHER|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
47999571|NCT02603432|BIOLOGICAL|Following the planned interim analysis for this study: Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
47999572|NCT05687435|DRUG|Changyanning tablet|"Changyanning Tablet is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd，composed of Euphorbia humifusa, golden ear grass, camphor tree root, Elsholtzia splendens and maple leaves. It is mainly used for the treatment of acute and chronic intestinal diseases caused by various reasons.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
47999573|NCT05687435|OTHER|Changyanning tablet placebo|"Changyanning Tablet placebo is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd. Changyanning Tablet placebo has the same appearance, smell, taste, specifications and packaging with Changyanning Tablet, but does not contain active pharmaceutical ingredients.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation."
48366713|NCT03400228|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
48366714|NCT05389761|DIETARY_SUPPLEMENT|fibroDAO®|One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).
48684826|NCT03035864|DRUG|rhNGF|Eye Drop 20 μg/mL
48684827|NCT03035864|OTHER|Vehicle|Vehicle Eye Drop
48684828|NCT01550406|DEVICE|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
48684829|NCT01550406|DEVICE|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
48684830|NCT00315952|DRUG|Exubera|
48684831|NCT05200416|DEVICE|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
47999574|NCT05678556|BEHAVIORAL|all2GETHER|all2GETHER is an HIV prevention and relationship education program designed for young MSM and other individuals who have sex, date, and are in relationships with MSM. all2GEHTER consists of 3 online didactic skills modules that include videos, activities, and other self-paced education components and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV and STI prevention in couples, effective communication skills, coping skills for LGBTQ and relationship stress, problem-solving and acceptance. Individualized couple sessions led by facilitators focus on implementation of skills specific to the needs of each couple.
47999575|NCT02485028|DRUG|Dapoxetine 30mg tablet|
47999576|NCT02485028|DRUG|Mirodenafil 50mg tablet|
47999577|NCT03943563|DIAGNOSTIC_TEST|Dixon sequences acquisition|Dixon sequences acquisition
47999578|NCT03291210|OTHER|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
47999579|NCT03291210|OTHER|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
47999580|NCT03459664|BEHAVIORAL|RECOVER|"For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment."
47999581|NCT03459664|BEHAVIORAL|Treatment as usual|"For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help."
47999582|NCT00578175|BIOLOGICAL|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
47999583|NCT00578175|BIOLOGICAL|ProQuad®|One subcutaneous injection.
47999584|NCT00578175|BIOLOGICAL|Havrix®|Two intramuscular injections.
47999585|NCT00578175|BIOLOGICAL|Prevnar®|One intramuscular injection.
47999586|NCT03002051|DEVICE|EUS-guided drainage|"* Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~* EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~* After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~* After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~* After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
47999587|NCT04193475|OTHER|Analysis|No intervention planned. Novel analysis of echocardiographic data.
47999588|NCT02579265|DRUG|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein."
47999589|NCT02579265|DRUG|Intralipid® 20%|"Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein."
47999590|NCT06353880|OTHER|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.
47999591|NCT00902642|BEHAVIORAL|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
47999592|NCT00881192|PROCEDURE|IABP|preoperative IABP placement
47999593|NCT02250196|DRUG|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
47999594|NCT02250196|DRUG|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
47999595|NCT01034449|OTHER|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
47999596|NCT01482260|PROCEDURE|Biopsy|Biopsy
47999597|NCT03040635|DRUG|Risdiplam|Single oral doses of Risdiplam will be administered on Day 1.
47999598|NCT03040635|DRUG|Placebo|Single oral doses of Risdiplam matching placebo will be administered on Day 1.
47999599|NCT02852031|OTHER|Collaborative Learning Network|
48684832|NCT05200416|DEVICE|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
47999600|NCT04882007|DRUG|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
47999601|NCT04882007|DRUG|Placebo|Normal saline
48684833|NCT04934696|DRUG|BMS-986166|Specified dose on specified days
47999602|NCT05128175|DRUG|WD-1603 Carbidopa-Levodopa Extended-Release Tablets|For fasting conditions in the morning, a single oral dose will be administered to each subject under fasting conditions before 5 minutes of serving a standardized vegetarian breakfast as per the randomization schedule; for fasting conditions in the afternoon and evening, a single oral dose will be administered to each subject under fasting condition before 5 minutes of serving standardized vegetarian lunch and dinner as per randomization schedule. For fed condition, single oral dose will be administered to each subject after 30 minutes of serving standardized vegetarian breakfast, lunch and dinner as per randomization schedule. Dosing interval between two subsequent dosing should be 5 hours in each period. There will be one tablet for A, B, C, D and E.
47999603|NCT04699331|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
47999604|NCT01938274|OTHER|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
47999605|NCT06197789|BIOLOGICAL|TPX-105|Subjects will be administered with autologous fibroblasts through injection
47999606|NCT06197789|BIOLOGICAL|Placebo|Subjects will be administered with Placebo through injection
47999607|NCT03437785|DRUG|CKD-495 75mg|CKD-495 75mg Tab.
47999608|NCT03437785|DRUG|CKD-495 150mg|CKD-495 150mg Tab.
47999609|NCT03437785|DRUG|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
47999610|NCT03437785|DRUG|Rebamipide 100mg|Rebamipide 100mg Tab.
47999611|NCT03437785|DRUG|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
47999612|NCT03437785|DRUG|Placebo of the CKD-495 150mg|Placebo of the CKD-495 150mg Tab.
47999613|NCT03437785|DRUG|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
47999614|NCT03437785|DRUG|Placebo of the Rebamipide 100mg|Placebo of the Rebamipide 100mg Tab
47999615|NCT02857478|DRUG|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
47999616|NCT02857478|DRUG|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
47999617|NCT00311337|DRUG|bortezomib|
47999618|NCT05310110|DRUG|10% lidocaine spray|10% lidocaine spray 3 puff for the throat before induction
47999619|NCT05310110|DRUG|Placebo of lidocaine spray|Normal saline spray 3 puff for the throat before induction
47999620|NCT05310110|DRUG|Cisatracurium|Intravenous cisatracurium 0.12 mg/kg during induction
48157509|NCT04453709|BEHAVIORAL|Problem Management Plus for Immigrants at family settings|"PMP-I is a 5-week, peer-led, culturally tailored psychoeducation, behavioral activation (90 minutes), breathing and yoga intervention (90 minutes) in a family setting. PMP-I will use a structured approach, including once a week face-to-face sessions, breathing and yoga practices.~1. Managing Stress: Breathing and yoga practices, stress-management sessions, and behavioral activation exercises to strengthen positive coping strategies.~2. Managing Problems: Practice exercises to identify the problems, develop solutions, and plan a strategy to carry out those solutions.~3. Get Going, Keep Doing: Communication skill sessions and practice exercises to identify and carry out pleasant tasks.~4. Strengthening Social Support: Social skills session and practice exercise to identify social support.~5. Staying Well: Make a plan that helps to create supportive family environment."
48157510|NCT04453709|BEHAVIORAL|Talk program with Community Support Service Pamphlet (CSS)|Pamphlet including list of community support service institutions
48157511|NCT00473512|DRUG|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
47999621|NCT05310110|DRUG|Placebo of cisatracurium|Intravenous normal saline during induction
47999622|NCT05310110|DRUG|Propofol|The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.
47999623|NCT05402995|DRUG|Irrisept (Irrigation Solution)|Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
47999624|NCT05402995|DRUG|Saline|Saline irrigation
47999625|NCT02346084|DRUG|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
47999626|NCT03946397|OTHER|Mulstisensory massage|7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
47999627|NCT05360953|DRUG|Clonidine|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.
47999628|NCT05360953|DRUG|Doxazosin|"All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin.~Titration."
47999629|NCT05360953|DRUG|Placebo|All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
47999630|NCT05712408|BEHAVIORAL|800g Challenge|The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
48684834|NCT04934696|DRUG|Oral contraceptive|Specified dose on specified days
48684835|NCT04803175|DRUG|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
48157512|NCT00473512|DRUG|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
48157513|NCT00473512|DRUG|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
48157514|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
48157515|NCT06243666|OTHER|No intervention|No intervention was implemented.
48157516|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
48157517|NCT02137928|DRUG|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
47999631|NCT03646110|PROCEDURE|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
47999632|NCT00364780|DRUG|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 \& 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
47999633|NCT02306135|OTHER|n/a- this is an observational study|
48157518|NCT02137928|DRUG|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
48157519|NCT01325519|OTHER|video decision aid|video
48157520|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
48157521|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
48157522|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
48157523|NCT06086665|DRUG|Niraparib|Niraparib
48157524|NCT03332589|DRUG|E6201|E6201 formulated in cyclodextrin for IV administration.
48157525|NCT03332589|DRUG|E6201 plus dabrafenib|E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
48684836|NCT04803175|DRUG|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
48684837|NCT01185951|DRUG|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
48684838|NCT01185951|DEVICE|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
48684839|NCT01185951|DRUG|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
47999634|NCT01794091|DRUG|Eplerenone|Eplerenone 25 mg daily for 6 months
48684840|NCT01185951|BEHAVIORAL|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
48684841|NCT01185951|BEHAVIORAL|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
48684842|NCT01185951|BEHAVIORAL|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
47999635|NCT01794091|DRUG|Placebo|
47999636|NCT03088254|DRUG|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
47999637|NCT03088254|DRUG|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
47999638|NCT03088254|DRUG|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
47999639|NCT00222547|DRUG|Vitamin A|
47999640|NCT00222547|DRUG|Albendazole|
47999641|NCT05096507|PROCEDURE|Hip fracture Surgery (Primary)|Surgery for primary hip fracture requiring general or neuro-axial anaesthesia
47999642|NCT02596646|PROCEDURE|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
47999643|NCT02596646|PROCEDURE|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
47999644|NCT00181207|DEVICE|pneumatic vest|
47999645|NCT00181207|OTHER|placebo pneumatic vest|
47999646|NCT02177448|DRUG|BIBR277 low dose|
47999647|NCT02177448|DRUG|BIBR277 medium dose|
47999648|NCT02177448|DRUG|BIBR277 high dose|
47999649|NCT02177448|DRUG|Enalapril low dose|
47999650|NCT02177448|DRUG|Enalapril medium dose|
47999651|NCT02177448|DRUG|Enalapril high dose|
47999652|NCT02177448|DRUG|Placebo matching BIBR277|
48157526|NCT05673421|OTHER|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
48366715|NCT05389761|DIETARY_SUPPLEMENT|Placebo|One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
48684843|NCT05656222|DRUG|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
48684844|NCT03520296|OTHER|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
48684845|NCT03533959|DRUG|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
47999653|NCT02177448|DRUG|Placebo matching enalapril|
47999654|NCT05772533|PROCEDURE|Serratus anterior plane block|The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.
47999655|NCT05772533|PROCEDURE|PENG block|"Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
47999656|NCT01743287|DRUG|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
47999657|NCT01743287|DRUG|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
47999658|NCT05985538|BEHAVIORAL|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
47999659|NCT05985538|BEHAVIORAL|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
48366716|NCT00216112|DRUG|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
48366717|NCT00216112|DRUG|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
48366718|NCT02759939|OTHER|Video + Prompt Card|"1. A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~2. A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
48512831|NCT02393352|OTHER|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
48512832|NCT02393352|OTHER|Electrical Stimulation Therapy|
48684846|NCT01966354|PROCEDURE|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
48684847|NCT04954300|OTHER|no intervention|No intervention
47999660|NCT01001442|DRUG|BT062|intravenous administration
47999661|NCT00655967|DRUG|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
47999662|NCT00655967|DRUG|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
47999663|NCT05080452|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT)|Visualizing hot spots
47999664|NCT03342664|DEVICE|Artemis + Medical Management|Subject will receive best MM in addition to the MIS procedure with Artemis.
48157527|NCT05673421|OTHER|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
48157528|NCT05727553|RADIATION|Online adaptive radiotherapy|Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
48157529|NCT04337502|DIAGNOSTIC_TEST|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
48157530|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
48684848|NCT03531164|OTHER|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
48684849|NCT03531164|OTHER|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
48684850|NCT00348478|BEHAVIORAL|water and health education program to improve hygiene|
48684851|NCT03657784|DRUG|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
48684852|NCT02620033|BEHAVIORAL|Yoga therapy|
48684853|NCT02840942|BEHAVIORAL|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
48684854|NCT02840942|BEHAVIORAL|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
48684855|NCT02286804|DEVICE|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
48684856|NCT05507125|BEHAVIORAL|Mental health|Early life exposure to abuse and development of hidradenitis suppurativa
48157531|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
48157532|NCT00702520|DRUG|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
48157533|NCT00702520|BIOLOGICAL|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
48684857|NCT02021786|BEHAVIORAL|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
48684858|NCT00924612|DRUG|Oral testosterone undecanoate (containing 300 mg T)|
48684859|NCT04115774|DRUG|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
48684860|NCT02873455|OTHER|Short video clip including the circumstance of operation theater, and surgeon's interview|
48684861|NCT01065675|OTHER|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
48684862|NCT04259437|OTHER|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
47999665|NCT03342664|OTHER|Best Medical Management Alone (MM)|Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
47999666|NCT03811795|OTHER|ECG monitoring with a Kardia Mobile monitor|The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
47999667|NCT00764621|PROCEDURE|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
47999668|NCT00764621|PROCEDURE|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
47999669|NCT00764621|PROCEDURE|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
48157534|NCT00702520|BIOLOGICAL|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
48157535|NCT02375932|BEHAVIORAL|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
48157536|NCT02375932|BEHAVIORAL|Usual Care Control|Patients continue to receive usual care from their primary care provider
48157537|NCT00647374|OTHER|this is an observational study|
48684863|NCT06121076|OTHER|SDM-EBP training|A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
48684864|NCT02311036|OTHER|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
48684865|NCT01266278|OTHER|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
48684866|NCT01266278|OTHER|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
48684867|NCT01266278|OTHER|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
48684868|NCT04830306|BEHAVIORAL|Exercise|Completion of exercise in accordance with assigned protocol
48684869|NCT03519724|DRUG|Sugammadex|Reversal of deep NMB
48684870|NCT03519724|DRUG|Neostigmine|Reversal of moderate NMB
48684871|NCT03283488|DRUG|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
47999670|NCT04968899|DRUG|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
47999671|NCT04968899|DRUG|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
47999672|NCT00776646|DRUG|hydrochlorothiazide 50 mg tablet|
47999673|NCT02166983|OTHER|computer-assisted cognitive training|Complete Lumosity cognitive exercises
47999674|NCT02166983|OTHER|cognitive intervention|Complete Active Journaling cognitive exercises
48684872|NCT03283488|DRUG|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
48684873|NCT01062789|DEVICE|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
48684874|NCT00002552|BIOLOGICAL|filgrastim|
48157538|NCT00432445|RADIATION|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
47999675|NCT02166983|PROCEDURE|mind-body intervention procedure|Complete relaxation exercises
48157539|NCT00432445|PROCEDURE|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
48157540|NCT04383834|DEVICE|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
48157541|NCT02061189|OTHER|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
48157542|NCT00144937|DRUG|Stepwise therapy for dyslipidemia, hypertension and diabetes|
48157543|NCT00144937|BEHAVIORAL|Dietary recommendations|
48157544|NCT00144937|BEHAVIORAL|Increase in physical activity|
48684875|NCT00002552|BIOLOGICAL|sargramostim|
48684876|NCT00002552|DRUG|carmustine|
48684877|NCT00002552|DRUG|cyclophosphamide|
48684878|NCT00002552|DRUG|cytarabine|
47999676|NCT02166983|OTHER|memory intervention|Complete compensatory strategies
47999677|NCT02166983|OTHER|questionnaire administration|Ancillary studies
47999678|NCT04988217|DRUG|Interferon-Alpha2B|Nebulized interferon alpha 2B
48157545|NCT00144937|BEHAVIORAL|Smoking cessation|
48157546|NCT04088500|BIOLOGICAL|Nivolumab|Specific dose on specific days
48157547|NCT04088500|BIOLOGICAL|Ipilimumab|Specific dose on specific days
48157548|NCT01544153|BEHAVIORAL|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
48157549|NCT01544153|BEHAVIORAL|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
48157550|NCT01544153|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
48684879|NCT00002552|DRUG|etoposide|
48684880|NCT00002552|DRUG|leucovorin calcium|
48684881|NCT00002552|DRUG|methotrexate|
48684882|NCT00002552|DRUG|perfosfamide|
48684883|NCT00002552|DRUG|therapeutic hydrocortisone|
48684884|NCT00002552|PROCEDURE|allogeneic bone marrow transplantation|
48684885|NCT00002552|PROCEDURE|autologous bone marrow transplantation|
47999679|NCT04988217|DRUG|Placebo|Nebulized placebo
47999680|NCT02515942|DRUG|CLG561|
47999681|NCT02515942|DRUG|LFG316|
47999682|NCT02515942|DRUG|Sham injection|Empty syringe (without a needle) placed against the eye
47999683|NCT04263974|OTHER|Smartphone Application|Exercises and recommendations, based on current scientific evidence, and delivered through the app for Smartphone called CareHand. The intervention protocol is based on strengthening and stretching recommendations for rheumatoid arthritis and osteoarthritis in hands, transferred to an application format through explanatory videos together with tools to improve the autonomy, motivation and adherence of the patient
47999684|NCT04263974|OTHER|Conventional treatment|Conventional approach provided by the Andalusian Public Health System in Primary Care settings. This approach consists of routine visits to the general practitioner specialist, and the delivery of an exercise sheet and recommendations. This general mobility and stretching worksheet contains detailed images, as well as a description of how to perform the exercises and the dose to be taken. While most exercises are intended for the wrist and hands, this sheet also includes basic exercises for the elbow joint.
47999685|NCT04434131|DRUG|Convalescent Plasma|Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
48684886|NCT00002552|PROCEDURE|in vitro-treated bone marrow transplantation|
48684887|NCT00002552|PROCEDURE|peripheral blood stem cell transplantation|
48684888|NCT00002552|PROCEDURE|syngeneic bone marrow transplantation|
48684889|NCT00002552|RADIATION|radiation therapy|
48684890|NCT03172299|DRUG|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
48684891|NCT03172299|DRUG|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
48684892|NCT01786382|DRUG|PPI-668|
48684893|NCT01786382|DRUG|Midazolam|
48684894|NCT01786382|DRUG|Omeprazole|
48684895|NCT01786382|DRUG|Telaprevir|
48684896|NCT05156944|OTHER|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
48684897|NCT05842408|DRUG|DA-5212|Test drug: DA-5212
47999686|NCT02660320|DEVICE|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
47999687|NCT02660320|DEVICE|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
47999688|NCT05813158|DRUG|Group 1(low concentration-high volume bupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive low concentration-high volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room ) one syringe of 30ml bupivacaine 0.25% {15 ml bupivacaine 0.5% and 15ml normal saline} for each patient
47999689|NCT05813158|DRUG|Group 2(high concentration-low volumecbupivacaine US guided Erector Spinae Plane block)|Patients will preoperatively receive high concentration-low volume ultasound guided Erector Spinae Plane block, and then the patient will be transferred to the operating room (one syringe of 15 ml bupivacaine 0.5% {15 ml bupivacaine 0.5% } for each patien).
47999690|NCT04959968|DEVICE|eye patch and earplug|The use of eye patch and ear plugs in post-operative intensive care in craniotomy cases.
47999691|NCT04374890|DEVICE|CP308|3 weeks of baseline followed by 2x3 weeks use of the test device
47999692|NCT02993003|DEVICE|Nasopharyngeal probe|nasopharyngeal probe insertion
48157551|NCT02831439|BEHAVIORAL|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
48157552|NCT02831439|BEHAVIORAL|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
48157553|NCT02831439|BEHAVIORAL|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
48157554|NCT02800135|DRUG|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
48157555|NCT05690477|PROCEDURE|Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.
48157556|NCT02665806|DRUG|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
48157557|NCT02665806|DRUG|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
48157558|NCT03126188|DRUG|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
48157559|NCT03126188|DRUG|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
48684898|NCT05842408|DRUG|DA-5212-R|Control drug: DA-5212-R
48684899|NCT04062864|DEVICE|Pupil size|Measures the diameter of pupil before and after painful stimuli
48684900|NCT03684837|DIETARY_SUPPLEMENT|Vitamine D supplementation|a vitamine D dose for week
47999693|NCT01119989|DIETARY_SUPPLEMENT|Fructose+maltodextrin placebo|
47999694|NCT01119989|DIETARY_SUPPLEMENT|amino-acid + fructose|
47999695|NCT03601754|DIAGNOSTIC_TEST|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
47999696|NCT05543512|DEVICE|Algorithm to diagnose food allergens|An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
48684901|NCT03684837|OTHER|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
48684902|NCT05754398|BEHAVIORAL|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
47999697|NCT05543512|OTHER|Sham diet|Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
48157560|NCT03126188|DRUG|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
48684903|NCT04224103|DRUG|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
48684904|NCT03351868|GENETIC|Gene-modified autologous stem cells|Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
48684905|NCT02890745|DRUG|Empagliflozin|
47999698|NCT02526407|BEHAVIORAL|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
47999699|NCT02526407|BEHAVIORAL|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
47999700|NCT05725512|DRUG|Prednisolone|Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
47999701|NCT05725512|DRUG|Placebo|Placebo identical to prednisolone tablets
47999702|NCT06394869|DIAGNOSTIC_TEST|Cxbladder Detect+|Cxbladder Detect+ is a lab developed, test that is using RNA and DNA biomarkers in the urine to assess the likelihood of the presence of urothelial carcinoma in the bladder.
47999703|NCT02984358|OTHER|Animal protein based diet|
47999704|NCT02984358|OTHER|Low-nucleotide mycoprotein based diet|
47999705|NCT02984358|OTHER|High-nucleotide mycoprotein based diet|
47999706|NCT04874974|BEHAVIORAL|Metacognitive and Defusion Training|Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006).
47999707|NCT00451035|DRUG|LBH589|
47999708|NCT02404350|BIOLOGICAL|Secukinumab|Anti IL-17a monoclonal antibody
47999709|NCT04566419|DEVICE|HFNC - Airvo 2|high flow nasal cannulae delivering 60 l/min
47999710|NCT04566419|OTHER|Oxygen|oxygen delivered by Venturi mask
47999711|NCT01667666|DRUG|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
47999712|NCT04468932|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward translation.~Aim 2: We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS. The hypothesis to be tested is that premotor and motor cortical activity will decrease after cerebellar rTMS compared to sham TMS, reflecting improved cerebellar inhibition of the motor cortex after the intervention."
47999713|NCT03023033|BEHAVIORAL|mHealth messaging|SMS appointment reminders and health messaging via mobile phones
47999714|NCT03023033|BEHAVIORAL|Transport Payments|A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
47999715|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
47999716|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
47999717|NCT04037553|OTHER|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
47999718|NCT05423821|OTHER|Anesthesia efficacy in patients undergoing MRI|atropine will be administered when bradycardia develops, oxygen will be given if hypoxia develops
47999719|NCT00850031|DEVICE|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
48157561|NCT05673616|OTHER|Mckenzie Extension Exercises|"After two weeks of initial consultation, the patient will be taught to perform slouch-overcorrect on day 1 followed by flexion on day 2 in lying position and accompanied by flexion for 5 days in sitting position and finally flexion in standing will be performed.~The exercises will be repeated for 10 times and followed by extension in standing exercises."
48157562|NCT02383121|DRUG|Midodrine|Not appliciable
48684906|NCT02890745|DRUG|Placebo|
48684907|NCT05388604|DEVICE|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
47999720|NCT03653936|DEVICE|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
47999721|NCT03970863|DIAGNOSTIC_TEST|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
47999722|NCT02838212|DRUG|adverse drug reaction|drug-related death
47999723|NCT04420156|OTHER|No intervention administered.|Eye exams are standard of care and would be performed regardless of participation in this study.
48684908|NCT05388604|DEVICE|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
47999724|NCT05107258|DIAGNOSTIC_TEST|The Pine Trees Health Test System|Consists of the Pine Trees Health Reader and the Pine Trees Health COVID-19 Test Kit, which contains the Pine Trees Health Cartridge, Pine Trees Health Sample Vial containing Sample Lysis Buffer and the Pine Trees Health Nasal Swab (anterior nares) for collection. The Test System is a point-of-care test used for the qualitative detection of nucleic acid from SARS-CoV-2 viral RNA in nasal swabs taken from individuals who are suspected by a healthcare professional of having COVID-19. The COVID-19 test is a rapid molecular, in vitro diagnostic test using isothermal nucleic acid amplification technology and detection of the resulting amplicon using CRISPR-mediated collateral reporter unlocking.
47999725|NCT02822469|OTHER|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
47999726|NCT02822469|DEVICE|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
47999727|NCT01080898|OTHER|tests|color photographs, FLUORESCEIN angiography and OCT
47999728|NCT03127891|BEHAVIORAL|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
47999729|NCT03127891|OTHER|control group|no intervention should be given to patients allocated to this group
47999730|NCT01113879|BEHAVIORAL|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
47999731|NCT01113879|BEHAVIORAL|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
47999732|NCT00367952|DRUG|apricitabine|800mg apricitabine twice daily orally for 96 weeks
47999733|NCT01395329|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
47999734|NCT01395329|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
47999735|NCT01395329|DRUG|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
47999736|NCT01395329|OTHER|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
47999737|NCT01395329|OTHER|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
48366719|NCT02759939|OTHER|Decision Aids + Training|"1. Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~2. A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
48684909|NCT04346147|DRUG|Imatinib tablets|Imatinib 400 mg QD oral
48684910|NCT04346147|DRUG|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
47999738|NCT01395329|OTHER|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
47999739|NCT01395329|OTHER|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
47999740|NCT01395329|OTHER|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
47999741|NCT00685243|PROCEDURE|Laser treatment|Fraxel and pulsed dye laser
47999742|NCT02453763|DEVICE|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
47999743|NCT02453763|PROCEDURE|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
47999744|NCT00386087|DRUG|Enzastaurin Hydrochloride|
47999745|NCT01243359|DRUG|sunitinib malate|Given PO
47999746|NCT01243359|BIOLOGICAL|bevacizumab|Given IV
47999747|NCT01243359|OTHER|pharmacological study|Correlative studies
47999748|NCT01243359|OTHER|laboratory biomarker analysis|Correlative studies
47999749|NCT01243359|OTHER|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
48366720|NCT02718365|PROCEDURE|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
48366721|NCT02718365|PROCEDURE|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
48366722|NCT01867996|DRUG|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
47999750|NCT01243359|PROCEDURE|positron emission tomography|Undergo FLT PET/CT
47999751|NCT01243359|PROCEDURE|computed tomography|Undergo FLT PET/CT
47999752|NCT03492333|OTHER|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
47999753|NCT02164227|OTHER|Respiratory pattern|
47999754|NCT01023581|DRUG|Alogliptin|Alogliptin tablets.
47999755|NCT01023581|DRUG|Metformin|Metformin capsules
47999756|NCT01023581|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets.
47999757|NCT01023581|DRUG|Metformin Placebo|Metformin placebo-matching capsules.
47999758|NCT03718442|DEVICE|PhotonBlade vs Bovie for lumpectomy shaved surgical margins|For each enrolled patient, six shaved margins will be obtained (superior, inferior, medial, lateral, anterior, and posterior). For each patient, electrocautery will be used to obtain 3 of the shaved margins, and PhotonBlade to obtain the other 3 shaved margins. Once the lumpectomy site shaved margins have been obtained, the shaved surgical margins will be evaluated by a pathologist whom is blinded in regards to the dissection device that was used for each margin. The pathologist will be evaluating each shaved margin and reporting the outcomes (qualitative severity and depth of thermal artifact)
48366723|NCT01867996|DRUG|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
48366724|NCT05364203|DEVICE|DEEPSEN virtual reality mask|DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
48366725|NCT02107781|DEVICE|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
48366726|NCT02023476|RADIATION|MRI|MRI- imaging on the upper arm
48684911|NCT04346147|OTHER|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
47999759|NCT03462238|PROCEDURE|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
47999760|NCT03462238|RADIATION|CT Scan|A scanner will be performed
47999761|NCT02882555|BEHAVIORAL|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
47999762|NCT02882555|DRUG|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
47999763|NCT02882555|DRUG|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
47999764|NCT04448210|BEHAVIORAL|DigiKnowIt News: Teen|Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
47999765|NCT05347316|DRUG|Colchicine|0.5 mg per day colchicine for 12 months
47999766|NCT01988142|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
47999767|NCT03348696|DRUG|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
48366727|NCT02461173|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
48366728|NCT02461173|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
48684912|NCT04780802|PROCEDURE|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
48684913|NCT06513754|OTHER|Ozone|Ozone is a pollutant that forms as a result of nitrogen oxides or volatile organic compounds interacting with UV radiation. Ozone will be created via a generator in the lab
48684914|NCT06513754|BEHAVIORAL|Heavy Intensity|Heavy intensity exercise between the first and second ventilatory threshold for 45 minutes
48684915|NCT06513754|BEHAVIORAL|Moderate Intensity|Moderate intensity exercise below the first ventilatory threshold for approximately 75 minutes
48684916|NCT06513754|OTHER|Filtered Air|Exposure to filtered air (\<10 ppb ozone)
48684917|NCT02010593|DRUG|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
48684918|NCT02010593|DRUG|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
48684919|NCT03293355|BEHAVIORAL|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
48684920|NCT06285032|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Individuals will participate in a series of eight, 1hour weekly group sessions delivered by a study interventionalist who is a licensed social worker (see personnel list) using a HIPAA-compliant videoconferencing platform (Zoom). Each group will consist of 6-10 participants and participants randomized to this intervention will select between a series of date/time options. The investigators plan to run four groups with staggered start times. All participants will receive digital copies of the workbook for this intervention and each session, they will be given assignments to practice the strategies they learn during the intervention.
47999768|NCT03348696|DRUG|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
47999769|NCT03858946|PROCEDURE|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
47999770|NCT03858946|PROCEDURE|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
48366729|NCT02461173|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
47999771|NCT05113186|DRUG|Lenvatinib Pill|"The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)"
48684921|NCT06285032|BEHAVIORAL|Social Navigation Group|Those in the social navigation intervention, will meet with a navigator weekly through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 8 weeks. Each virtual visit will last approximately 30 minutes with a longer initial intake visit lasting 60 minutes. During the intake visit, the navigator will complete a patient narrative and an inventory of the patient's existing social network, former social network and interests. Using this, the navigator will work with the patient to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the 8 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection
48684922|NCT06285032|BEHAVIORAL|Controlled Group|Those randomized to the control group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.
47999772|NCT01025427|DRUG|Raltegravir, tenofovir/emtricitabine|16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
48157563|NCT06585631|BEHAVIORAL|CC PrTNER|Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
48684923|NCT02209792|DRUG|Placebo|
48684924|NCT02209792|DRUG|BIBR 796 BS, 5 mg|
48684925|NCT02209792|DRUG|BIBR 796 BS, 20 mg|
48684926|NCT05802472|OTHER|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
47999773|NCT03871127|PROCEDURE|Percutaneous coronary intervention|Using sirolimus eluting stent
47999774|NCT03871127|PROCEDURE|coronary artery bypass graft|coronary artery bypass graft
48684927|NCT05802472|OTHER|Placebo|During Visit 2. 250 ml of single potable water was administered orally.
47999775|NCT02482025|OTHER|SMMRT|Includes My HealtheVet registration and enrollment
47999776|NCT04562896|DEVICE|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
47999777|NCT02733536|DEVICE|Standard endotracheal tube|1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
47999778|NCT02733536|DEVICE|C-MAC|C-MAC introduced with a h size 3 blade.
47999779|NCT00106782|PROCEDURE|Transcranial Electrical Polarization (TEP)|
47999780|NCT01485523|OTHER|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
48684928|NCT04644276|DEVICE|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
48684929|NCT04644276|DEVICE|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
47999781|NCT01652391|DEVICE|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
47999782|NCT04908670|BEHAVIORAL|Understanding Pain in less than 5 minutes, and what to do about it! https://www.youtube.com/watch?v=C_3phB93rvI|Watching pain neuroscience education video
47999783|NCT04908670|PROCEDURE|PA manipulation|Low grade PA manipulation on the cervical, thoracic and lumbar spine
48157564|NCT02825849|BIOLOGICAL|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
48684930|NCT00977639|PROCEDURE|Pathwork TOO test|
48684931|NCT02252640|BIOLOGICAL|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
48684932|NCT02252640|BIOLOGICAL|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
48684933|NCT02252640|BIOLOGICAL|ChAd63 ME-TRAP (5 x 10^10 vp)|
48684934|NCT02252640|BIOLOGICAL|MVA ME-TRAP (2 x 10^8 pfu)|
48684935|NCT04744220|OTHER|Yoga Training Program (exercises)|Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
48684936|NCT04085146|PROCEDURE|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
48684937|NCT04085146|PROCEDURE|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
48684938|NCT05729555|DRUG|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
48684939|NCT05729555|DRUG|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
48684940|NCT04490213|OTHER|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
48684941|NCT04442633|DRUG|Glutamine Cap/Tab|Glutamine Capsules: One capsule three times daily on an empty stomach for one month
48684942|NCT04442633|DRUG|Miconazole Oral gel|Miconazole oral gel: applied three to four times daily for three weeks
48684943|NCT04442633|DRUG|Kenacort in orabase|Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
48684944|NCT05601583|DEVICE|Continuous Glucose Monitor (CGM)|FDA-cleared FreeStyle Libre Glucose Monitoring System manufactured by Abbott. Integrated continuous glucose monitoring system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts.
48157565|NCT05842278|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48684945|NCT05373095|BEHAVIORAL|PKC (adapted adherence counseling) and Conditional Cash Transfers|The intervention includes up to 3 cash transfers of 22,500 Tanzanian Shillings (\~$10) paired with attendance at each of the three adapted enhanced adherence counseling sessions (PKC sessions). The first cash transfer will occur at enrollment; the next two cash transfers are payable upon visit attendance and attendance of the two remaining PKC sessions. The cash transfers will include extra funds for transaction fees, typically \<$1.
48684946|NCT02346903|DRUG|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
48684947|NCT05813184|DRUG|Antibiotics|Any antibiotic therapy administered \> 7 days
48684948|NCT00091663|DRUG|Tarceva (erlotinib HCl)|
48157566|NCT05842278|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48157567|NCT05842278|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48157568|NCT05842278|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48157569|NCT05842278|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
48157570|NCT01154699|DEVICE|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
48157571|NCT01154699|OTHER|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
48157572|NCT01154699|OTHER|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
48366730|NCT02461173|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
48366731|NCT02461173|DEVICE|shepherd catheter|
48366732|NCT04102124|DRUG|SHR3680|Tablet. Specifications of 80mg
48366733|NCT04102124|DRUG|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
48366734|NCT04102124|DRUG|SHR3680(Placebo)|Tablet. Specifications of 80mg
48684949|NCT00633087|DRUG|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
48684950|NCT02399124|DEVICE|PROSENSE™|single arm, open label, PROSENSE™ treatment
48684951|NCT04621266|BEHAVIORAL|Online Home-based peer support|Online Home-based peer support will be provided to support participants' breastfeeding. There will be a minimum of 2 and maximum of 3 home visits between trained peer counsellors and participants. Each session will last approximately 30 minutes.
48684952|NCT02440204|PROCEDURE|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
48684953|NCT02440204|DRUG|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
48366735|NCT04102124|DRUG|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
48366736|NCT02477215|DRUG|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
48366737|NCT02477215|DRUG|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
47999784|NCT00697515|DRUG|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
48157573|NCT03623100|BEHAVIORAL|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
48366738|NCT02477215|DRUG|Bendamustine (multiple dose levels)|70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
48366739|NCT02477215|DRUG|Bendamustine (MTD)|80 mg/m\^2 on days 1 and 2
48684954|NCT02440204|DRUG|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
48684955|NCT03687775|OTHER|Stability assessment|Qualitative and quantitative stability assessment
48684956|NCT05892497|OTHER|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
48366740|NCT04647708|DRUG|M5049|Participants will receive low oral dose of M5049, twice daily in Part A.
48366741|NCT04647708|DRUG|M5049|Participants will receive ascending oral dose of M5049, twice daily in Part A.
47999785|NCT00697515|DRUG|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
47999786|NCT01187043|DRUG|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
47999787|NCT03419728|BEHAVIORAL|Healthy Families, Healthy Futures|Home visiting program for pregnant and parenting teens
47999788|NCT04154228|DIAGNOSTIC_TEST|PET/MR scan|"Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI)."
48366742|NCT04647708|DRUG|M5049|Participants will receive high oral dose of M5049, twice daily in Part B.
48366743|NCT04647708|DRUG|Placebo|Participants will receive placebo matched to M5049.
48684957|NCT02041390|OTHER|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
48684958|NCT02041390|OTHER|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
48684959|NCT05719779|DEVICE|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
48684960|NCT05010070|BEHAVIORAL|diet and lifestyle program|See description of main arm.
48684961|NCT04047615|OTHER|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
48684962|NCT05257421|DEVICE|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
48684963|NCT05257421|OTHER|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~* Bridge~* Plank~* Squat~* Push-ups~* Back extension Each exercise will be done for 3-5 sets."
48684964|NCT05257421|COMBINATION_PRODUCT|shockwave and exercises|both types of interventions will be applied for the patient
48684965|NCT04171908|OTHER|Conventional therapy|Conventional Physical therapy for the upper limb
48157574|NCT03623100|BEHAVIORAL|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
48157575|NCT00365183|DRUG|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
48157576|NCT01961804|DRUG|Reversion|Administration of prothrombin complex concentrates: KANOKAD before CT Scan
48157577|NCT06585176|OTHER|No intervention|This concerns a natural history study. No interventions will be used.
48157578|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of \[14C\]FTD administered as an oral solution on Day 1 (mass balance part)
48157579|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of \[14C\]TPI administered as an oral solution on Day 1 (mass balance part)
48157580|NCT02031055|DRUG|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
48157581|NCT06219902|DRUG|Elinzanetant (BAY3427080)|Oral administration of multiple doses of elinzanetant.
48157582|NCT06219902|DRUG|Placebo to elinzanetant|Oral administration
48684966|NCT04171908|OTHER|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
48684967|NCT05595265|DIAGNOSTIC_TEST|immunohistochemical|Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.
48684968|NCT05512481|DRUG|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
48157583|NCT06219902|DRUG|Zopiclone|Oral administration
48684969|NCT01405703|OTHER|xrays|xrays from 2 week postop to 5 year postop
48684970|NCT01236261|OTHER|Non intervention|Non interventional study
48684971|NCT01283438|DEVICE|Barricaid|Annular closure device
48684972|NCT01283438|DEVICE|Standard of Care|Standard Limited discectomy
48684973|NCT00969163|DRUG|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
48684974|NCT00969163|DRUG|Comparator: placebo|transdermal placebo gel for 6 weeks
48684975|NCT00100958|DRUG|indole-3-carbinol|
47999789|NCT03756610|DEVICE|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
47999790|NCT03756610|DEVICE|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
47999791|NCT03756610|DEVICE|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
47999792|NCT03756610|DEVICE|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
47999793|NCT02323854|DEVICE|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
48157584|NCT06219902|DRUG|Placebo to zopiclone|Oral administration
47999794|NCT02323854|PROCEDURE|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
47999795|NCT05811546|DIAGNOSTIC_TEST|Immunohistochemical staining for DNMT1 and EZH2|Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.
47999796|NCT03232385|DEVICE|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
47999797|NCT03232385|PROCEDURE|Renal Biopsy or Ablation|Standard of Care
47999798|NCT00462319|BEHAVIORAL|Education, weight reduction and physical exercise|
47999799|NCT05304260|OTHER|clinical and radiographic examination|Prevalence of dental anomalies in deciduous dentition and risk factors associated with non-syndromic oral clefts patients: A cross-sectional study.
47999800|NCT03463564|DEVICE|Insulin pump|Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
47999801|NCT03463564|DRUG|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
47999802|NCT02082210|DRUG|Emibetuzumab|Administered Intravenously (IV)
47999803|NCT02082210|DRUG|Ramucirumab|Administered Intravenously (IV)
47999804|NCT04307628|OTHER|Walnut|Study participants will eat 2 ounces of walnuts each day.
47999805|NCT04307628|OTHER|Nut-Free|Study participants will not eat nuts.
47999806|NCT05680922|BIOLOGICAL|LB2102|DLL3 directed autologous Chimeric Antigen Receptor T-cells
48366744|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
47999807|NCT00908960|DRUG|Enoxaparin|
47999808|NCT05044806|OTHER|Ultrasound-guided remote ischemic conditioning|Before conducting RIC, Doppler ultrasound was used to measure the total occlusion pressure (TOP) of brachial artery, which was then determined as the cuff inflation pressure during RIC. The RIC program encompasses four main components of (1) three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2) one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3) three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of RIC with 3 min intervals of reperfusion in between, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning.
48157585|NCT02008539|DRUG|MSC_apceth_101|
48157586|NCT02650453|PROCEDURE|Deep venous reconstruction|PTA \& stenting with/without endophlebectomy and/or arteriovenous fistula creation
48157587|NCT05464992|OTHER|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
48157588|NCT02177058|OTHER|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
48157589|NCT02177058|OTHER|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
48157590|NCT01550783|OTHER|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
48157591|NCT01550783|OTHER|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
48157592|NCT01550783|OTHER|Questionnaire Administration|Ancillary studies
48157593|NCT01550783|PROCEDURE|Screening Method|Undergo standard of care Pap test screening
48512833|NCT05650840|PROCEDURE|Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination"
48684976|NCT04920084|OTHER|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
48684977|NCT05218941|PROCEDURE|Implant surgery assisted by passive robotics|Implant surgery without flap assisted by passive robotics (X-Guide®)
48684978|NCT05218941|PROCEDURE|Conventional implant surgery|Flap implant surgery
48684979|NCT05265858|PROCEDURE|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
48684980|NCT05798546|BIOLOGICAL|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
48684981|NCT05798546|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
48684982|NCT05798546|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
48684983|NCT05798546|DRUG|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
48684984|NCT03396497|DRUG|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
48684985|NCT03396497|DRUG|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
48684986|NCT05128071|DRUG|Progesterone|Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
48684987|NCT05128071|DRUG|Placebo|Randomized to placebo twice daily
48684988|NCT05130684|DRUG|Nivolumab|adding nivolumab to conventional neoadjuvant CRT
48684989|NCT00460655|DRUG|GSK1358820|botulinum toxin type A
48684990|NCT00460655|DRUG|Placebo|Placebo
48684991|NCT00175565|DRUG|inhaled fluticasone 500 mcg b.i.d.|
48684992|NCT03578926|DEVICE|fanfilcon A toric lens|contact lens
48684993|NCT03578926|DEVICE|senofilcon A toric lens|contact lens
48684994|NCT03797066|DRUG|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
48684995|NCT00003587|DRUG|carboplatin|AUC=5.5 day 1 every 21 days X 3
48684996|NCT00003587|DRUG|cisplatin|IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3
48684997|NCT00003587|DRUG|docetaxel|IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
48684998|NCT00003587|DRUG|gemcitabine|IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3
48684999|NCT00003587|DRUG|paclitaxel|IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
48685000|NCT00003587|DRUG|vinorelbine|IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
48685001|NCT05689918|OTHER|No intervention|No intervention
48685002|NCT01343836|OTHER|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
48685003|NCT01343836|OTHER|Saline|Intratendinous saline injection with eccentric exercises
47999809|NCT05044806|OTHER|Traditional remote ischemic conditioning|The RIC program encompasses four main components of (1)three cycles of remote ischemic pre-conditioning which will be delivered right after the eligibility check and informed consent form signature before PCI; (2)one cycle of remote ischemic per-conditioning, which will be delivered during PCI; (3)three cycles of remote ischemic post-conditioning, which will be delivered within 10 min after PCI; and (4) two sessions per day of remote ischemic post-conditioning which will start on post-operative day 1 and last till hospital discharge. The remote ischemic pre- and post-conditioning share the RIC protocol, which comprises three 3 min cycles of upper limb ischemia on the arm that is opposite to the PCI side with 3 min intervals of reperfusion in between delivered by an automated cuff inflation/deflation device, while only one single 3 min cycle will be delivered for the remote ischemic per-conditioning. The pressure applied during cuff inflation is 20 mmHg above systolic blood pressure.
48366745|NCT02793115|BEHAVIORAL|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
47999810|NCT05044806|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) will be performed by a cardiologist or doctor who specializes in the heart to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI requires cardiac catheterization, which is the insertion of a catheter tube, and live x rays helping to guide the catheter into the heart to inject special contrast dye that will highlight the blockage. To open a blocked artery, another catheter will be inserted over a guidewire, a balloon will be inflated at the tip of that catheter, and a small mesh tube called a stent may be put in the artery to help keep the artery open. After PCI, the catheters will be removed, the opening on the wrist or groin will be closed and bandaged.
47999811|NCT01733914|PROCEDURE|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
47999812|NCT01733914|OTHER|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
47999813|NCT03667352|PROCEDURE|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
47999814|NCT03667352|PROCEDURE|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
47999815|NCT03667352|DRUG|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
47999816|NCT05217550|BEHAVIORAL|Veggie Brek|Offering vegetables to children at breakfast alongside their main breakfast food for three consecutive weeks (five days a week) between baseline and follow-up weeks where vegetables are also offered to children at breakfast alongside their main breakfast food for five days a week.
47999817|NCT04836299|DRUG|Ivermectin|Participants will be randomly assigned to receive a single 600 µg / kg dose of ivermectin or placebo.
47999818|NCT04836299|DRUG|Placebo|Participants will be randomly assigned to receive a single of placebo.
47999819|NCT04076800|PROCEDURE|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
47999820|NCT00355186|PROCEDURE|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
47999821|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
47999822|NCT00605774|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
47999823|NCT02535741|DEVICE|Triathlon CR Total Knee System|Primary total knee replacement
47999824|NCT00378066|DRUG|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
47999825|NCT06308068|DRUG|Diacerein 50 mg Capsule|Diacerein 50 mg Capsule
47999826|NCT05687279|BIOLOGICAL|RSVt Vaccine|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
47999827|NCT05687279|OTHER|Control Group|Pharmaceutical Form: Suspension of virus in a nasal spray Route of Administration: Intranasal
47999828|NCT03057028|DRUG|Anakinra|
48157594|NCT01550783|PROCEDURE|Screening Method|Undergo home-based HPV screening
48157595|NCT00893477|BIOLOGICAL|rituximab|
48366746|NCT02793115|BEHAVIORAL|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
48685004|NCT06187779|OTHER|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
48685005|NCT03415425|OTHER|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
47999829|NCT04656210|RADIATION|MRI|Non conventional MRI (35 minutes)
48685006|NCT03415425|OTHER|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
48685007|NCT04335838|OTHER|retrospective analysis|The investigators retrospectively analyzed the outcome and possible prognostic factors in polytrauma patients.
48685008|NCT05645796|OTHER|Adopted contrast media amount by using different approaches|Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
48685009|NCT03372720|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
47999830|NCT04656210|OTHER|neuropsychological tests|Standardized and quantified neuropsychological assessment
47999831|NCT06062966|DRUG|Anakinra|Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
48685010|NCT03372720|OTHER|Questionnaire Administration|Ancillary studies
48685011|NCT03372720|PROCEDURE|Sham Intervention|Undergo sham laser therapy
48685012|NCT00579553|DRUG|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
48685013|NCT00579553|DRUG|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
48685014|NCT02819986|BEHAVIORAL|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
47999832|NCT03616288|DIETARY_SUPPLEMENT|thiamine (as thiamine hydrochloride)|Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).
47999833|NCT02078583|DRUG|Fentanyl|
48685015|NCT03091790|DEVICE|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
48685016|NCT03091790|DEVICE|Biologic Mesh|Biologic mesh used during open ventral hernia repair
48685017|NCT01364129|PROCEDURE|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
47999834|NCT02078583|DRUG|Remifentanil|
47999835|NCT02078583|DRUG|Normal saline|
47999836|NCT02184221|DEVICE|High frequency stimulation|The parameter of DMS: alpha frequency
47999837|NCT02184221|DEVICE|Low frequency stimulation|The parameter of DMS: 0.5Hz
47999838|NCT00403000|DRUG|dutasteride|Oral
47999839|NCT03395769|BIOLOGICAL|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
48685018|NCT05174546|DIAGNOSTIC_TEST|T2 magnetic resonance|Samples for assessment by the T2MR will be collected once daily in occasion of any consecutive febrile episode during neutropenia when blood cultures are ordered as per standard of care. T2 magnetic resonance will be run according to manufacturer's instructions
47999840|NCT00002644|DRUG|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
47999841|NCT00002644|OTHER|Placebo|Placebo 20Mg Tab
47999842|NCT03782428|DIETARY_SUPPLEMENT|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
47999843|NCT03782428|OTHER|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
47999844|NCT01257373|DEVICE|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
47999845|NCT01024712|DRUG|carboplatin|
47999846|NCT01024712|DRUG|gefitinib|
47999847|NCT01024712|DRUG|paclitaxel|
47999848|NCT01024712|PROCEDURE|quality-of-life assessment|
47999849|NCT03979638|DRUG|BLU-5937|Four escalating doses of BLU-5937 administered BID over the course of the study
47999850|NCT03979638|DRUG|Placebo|Matching placebo for BLU-5937
47999851|NCT06003010|BEHAVIORAL|Yoga|6 yoga videos to be done 2-3x a week for 6 weeks before and after surgery.
47999852|NCT06163248|OTHER|Chrono nutrition|An integral nutritional strategy involving timing, order and distribution of macronutrients
47999853|NCT06163248|OTHER|Standard|Conventional nutritional strategy involving isocaloric distribution with no specific timing
47999854|NCT04925011|DRUG|Roxadustat|Starting doses of 20, 50, 70 or 100 mg/30,70,90,or 120mg based on weight and dialysis or not.
47999855|NCT03606525|PROCEDURE|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
48685019|NCT05475028|OTHER|RRBS|Reduced Representation Bisulfite Sequencing
48685020|NCT01050023|DEVICE|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
48685021|NCT01050023|DEVICE|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
48685022|NCT01789086|DRUG|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
48685023|NCT01789086|DRUG|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
48685024|NCT02283892|OTHER|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
48685025|NCT02283892|OTHER|Conventional evaluation|Physician evaluation without the use of checklists
48685026|NCT01048242|DRUG|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
48685027|NCT01048242|DRUG|Placebo|placebo
48685028|NCT02363777|PROCEDURE|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
48685029|NCT02363777|PROCEDURE|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
47999856|NCT03846258|DRUG|Low bicarbonate solution (22 mmol/L)|Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
47999857|NCT03846258|DRUG|High Bicarbonate solution (32 mmol/L)|Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
47999858|NCT05000983|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
47999859|NCT05000983|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
47999860|NCT05292560|OTHER|Training in positivity|The University of Twente developed an evidence-based positive psychology app that is aimed at increasing mental well-being and resilience (Training in positivity; TiP). TiP consists of a 3-week structured intervention, in which participants do two exercises every week for 6 days, aimed at increasing resilience and mental well-being. An exercise takes an average of 15 minutes per day.
47999861|NCT00752583|PROCEDURE|Peritoneal dialysis|Blood, urine and dialysate sampling
47999862|NCT00752583|PROCEDURE|Haemodialysis|Blood, urine and dialysate sampling
47999863|NCT04574804|OTHER|Online training program in weight management for osteoarthritis|"An evidence based online education training program for physiotherapists in weight management for osteoarthritis. Training modules cover the following topic areas:~1. Overweight and obesity and osteoarthritis~2. Overview of weight regulation, overweight and obesity~3. Examining weight stigma in physiotherapy and personal beliefs about weight~4. Communication approach for addressing weight management~5. Interventions for weight management~6. Health behaviour change support~These 6 e-learning modules comprise the online training program, access to which comprises the study intervention."
48157596|NCT00893477|BIOLOGICAL|sargramostim|
48157597|NCT00893477|GENETIC|gene expression analysis|
47999864|NCT01763775|DEVICE|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
47999865|NCT01763775|DEVICE|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
47999866|NCT04599296|DEVICE|Hip brace|Hip brace
47999867|NCT05067296|OTHER|By TVS|Uses of TVS to diagnosis of Cesarean section niche in patients with abnormal uterine bleeding
47999868|NCT04049539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
47999869|NCT03118128|DRUG|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
47999870|NCT04270916|DIAGNOSTIC_TEST|High frequency pure tone audiometry|Hearing test carried out routinely, non invasive
47999871|NCT03780842|DEVICE|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
47999872|NCT01561352|DRUG|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
48157598|NCT00893477|GENETIC|gene rearrangement analysis|
48157599|NCT00893477|GENETIC|polymerase chain reaction|
48685030|NCT03246516|OTHER|Questionnaire|"Auto and hetero questionnaires:~* STAI Y B, State-Trait Anxiety Inventoriage~* Brief COPE~* RHHI-24, Revised Health Hardiness Inventory~* IPQ-R, Illness Perception Questionnaire"
48685031|NCT05596539|OTHER|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
48685032|NCT03088644|DRUG|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
48157600|NCT00893477|GENETIC|polymorphism analysis|
48157601|NCT00893477|OTHER|laboratory biomarker analysis|
48685033|NCT03088644|DRUG|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
48685034|NCT02457650|DRUG|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
48685035|NCT02457650|DRUG|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
48685036|NCT02457650|BIOLOGICAL|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
48685037|NCT01949766|DRUG|Glycerol phenylbutyrate|
48685038|NCT05918016|DIAGNOSTIC_TEST|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
48685039|NCT04231682|DRUG|Denosumab Injection|Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
48157602|NCT02025023|DRUG|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
48157603|NCT02025023|DRUG|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
48157604|NCT02025023|PROCEDURE|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
48157605|NCT02025023|DRUG|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
48157606|NCT02820298|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
48157607|NCT00928876|DRUG|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
48157608|NCT00928876|DRUG|Placebo|placebo s/c daily for four weeks
48157609|NCT02468037|PROCEDURE|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
48157610|NCT06584994|OTHER|sample collection|Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).
48157611|NCT02416973|DEVICE|Provant|
48685040|NCT04231682|DRUG|Placebos|Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
48685041|NCT01422941|DEVICE|CAVU Attune Device|The CAVU Attune device is used with LAGB.
48685042|NCT05404191|DEVICE|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
48685043|NCT00851890|DRUG|ABT-333|50 mg capsules
48685044|NCT00851890|OTHER|Placebo for ABT-333|Capsule
48157612|NCT00437086|DRUG|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
48157613|NCT01016730|DRUG|Bortezomib|Given IV
48157614|NCT01016730|OTHER|Laboratory Biomarker Analysis|Correlative studies
48157615|NCT01016730|OTHER|Questionnaire Administration|Ancillary studies
48157616|NCT02339506|DRUG|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
48685045|NCT00851890|DRUG|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
48685046|NCT00851890|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
48685047|NCT00122616|BIOLOGICAL|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
48685048|NCT00122616|DRUG|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
48685049|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
47999873|NCT05902039|OTHER|MRI|All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
47999874|NCT06338592|BEHAVIORAL|MyLungHealth|MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.
48685050|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
48685051|NCT05271734|DEVICE|Lid retractor placement|Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
48685052|NCT00404378|DRUG|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
47999875|NCT06338592|BEHAVIORAL|DecisionPrecision+|DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
47999876|NCT01966965|DRUG|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
47999877|NCT01966965|DRUG|NEDAX|AS SPECIFIED AT THE LEAFLET
47999878|NCT02903186|BEHAVIORAL|SMS|This is an intervention using short mobile messages (SMS)
48157617|NCT02339506|DRUG|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
48157618|NCT05929222|RADIATION|Radiotherapy|Involved-Site Radiation Therapy 24Gy
48685053|NCT00404378|DRUG|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
48685054|NCT00404378|DRUG|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
48685055|NCT00843258|DEVICE|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
47999879|NCT00959842|DRUG|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
48157619|NCT05929222|OTHER|Radiotherapy plus Obinutuzumab|Involved-Site Radiation Therapy 24Gy followed by Obinutuzumab 1000mg flat dose 4 doses weekly plus addition 4 doses every 3 weeks
47999880|NCT06031974|BEHAVIORAL|DISCO Intervention|optimal medical management in accordance with European Society of Cardiology recommendations + dietary intervention based on Dietary Approaches to Stop Hypertension (DASH diet) + strict monitoring of eating and lifestyle behaviors
47999881|NCT01677091|OTHER|Cervical vibration|Vibration of neck muscles during 10 minutes
47999882|NCT01677091|OTHER|Prism adaptation|Prism adaptation during 10 minutes
47999883|NCT01677091|OTHER|Conventional rehabilitation|conventional rehabilitation
47999884|NCT05407246|DRUG|Hemay005|Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
47999885|NCT05033639|DRUG|Melatonin 6 MG|Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
47999886|NCT05033639|OTHER|Breast Milk|Naturally occurring milk from the mother of the infant.
47999887|NCT05010889|PROCEDURE|Peroral endoscopic myotomy (POEM)|POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
47999888|NCT02469116|DRUG|Docetaxel|
47999889|NCT02469116|DRUG|Carboplatin|
47999890|NCT02469116|DRUG|Pegylated G-CSF|
47999891|NCT02174835|DRUG|AVP-786|
47999892|NCT02174835|DRUG|AVP-923|
47999893|NCT06300333|DRUG|Methotrexate|use low dose of Methotrexate in treatment of un distectopic tubal pregnancy
47999894|NCT02753699|DRUG|Alisporivir|Intervention of interest; follow-up after ALV-active study
47999895|NCT05255770|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
47999896|NCT05255770|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
48685056|NCT05828719|PROCEDURE|Percutaneous coronary intervention|"Revascularization indication~1. Diameter stenosis \>90% by visual assessment~2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89)~3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory.~   * Left main artery~  * Proximal to mid left anterior descending artery~  * Proximal left circumflex artery in left dominant coronary arterial system~  * Proximal to distal right coronary artery in right dominant coronary arterial system"
47999897|NCT05255770|DEVICE|Control NRL condom|In each assessment period (intervention duration), subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period.
48685057|NCT05989672|BIOLOGICAL|HSVTI Formulation 1|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F1 Group.
47999898|NCT00880347|DEVICE|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
48685058|NCT05989672|BIOLOGICAL|HSVTI Formulation 2|This investigational intervention will be administered intramuscular as 2 doses to HSVTI_F2 Group.
48685059|NCT05989672|BIOLOGICAL|Placebo|This intervention will be administered intramuscular as 2 doses to Placebo group.
48685060|NCT04116177|DEVICE|Deep brain stimulation|Stimulation using VerciseTM system
48685061|NCT04792788|PROCEDURE|Weaning from mechanical ventilation|Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
48685062|NCT00216918|DRUG|Atomoxetine Hydrochloride|
47999899|NCT02130063|DRUG|iron isomaltoside 1000 (Monofer®)|
47999900|NCT02130063|DRUG|iron sucrose (Venofer®)|
47999901|NCT01139736|DIETARY_SUPPLEMENT|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
47999902|NCT05284838|OTHER|Error Management Training (Difficult)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter difficult questions.
47999903|NCT05284838|OTHER|Error Management Training (Easy)|Error Management Training is used to teach head computed tomography interpretation. Participants encounter easy questions.
47999904|NCT05284838|OTHER|Error Avoidance Training|Error Avoidance Training used to teach head computed tomography interpretation.
47999905|NCT01342510|DRUG|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
47999906|NCT01342510|DRUG|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
47999907|NCT01342510|DRUG|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
47999908|NCT01342510|DRUG|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
47999909|NCT04664504|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy Radiotherapy|50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.
48685063|NCT05434793|DEVICE|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
48685064|NCT02374788|BEHAVIORAL|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
48685065|NCT02374788|BEHAVIORAL|Group meetings|Participants receive 12 group meetings over two years' time.
48685066|NCT02374788|BEHAVIORAL|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
48685067|NCT06039215|OTHER|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
48685068|NCT06030973|BEHAVIORAL|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
48685069|NCT04538599|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
48685070|NCT03741907|PROCEDURE|FAUCS|extraperitoneal cesarean with a paramedian left section
48685071|NCT03741907|PROCEDURE|MLC|Gold standard
48685072|NCT00147992|PROCEDURE|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
48685073|NCT00819000|DRUG|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
48685074|NCT01461499|DRUG|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
48685075|NCT01461499|DRUG|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
48685076|NCT06473298|OTHER|Visual Light Tracking|visual light tracking program consists of 10 tasks every task lasts for 6 minutes and may be repeated for the child especially in the first sessions to give him trials to him/her to understand the exercise.
47999910|NCT04664504|RADIATION|Short-course Radiotherapy|25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
47999911|NCT04664504|RADIATION|Local dose increase of Short-course Radiotherapy|25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.
48685077|NCT03012828|DRUG|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
47999912|NCT04664504|DRUG|Consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses\*3 weeks per course.
48157620|NCT05559164|DRUG|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
48685078|NCT03012828|OTHER|Placebo|
48685079|NCT03374358|DRUG|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
48685080|NCT02615418|DEVICE|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
48685081|NCT01671553|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
48685082|NCT03067519|OTHER|Fast track surgery|early feeding and mobilization after surgery
48685083|NCT03067519|OTHER|Conventional management|Management per the primary surgeon
48685084|NCT05860907|DRUG|Huaier Granule|10g each time, three times a day
48685085|NCT06436222|DEVICE|HVNI|Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.
47999913|NCT04664504|DRUG|Adjuvant chemotherapy|2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses\*3 weeks per course
47999914|NCT04664504|PROCEDURE|TME|Total mesorectal excision
47999915|NCT03161483|DRUG|CC-220|CC-220
47999916|NCT03161483|OTHER|Placebo|Placebo QD PO
48157621|NCT03239171|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
48157622|NCT03239171|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
48685086|NCT02089932|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
48685087|NCT02089932|DRUG|Placebo|
48157623|NCT01732055|BEHAVIORAL|Partner-Assisted Interpersonal Psychotherapy|
48366747|NCT02793115|BEHAVIORAL|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
48685088|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
48685089|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
48685090|NCT05980065|DRUG|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
48685091|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
48685092|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
48685093|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
48685094|NCT00770627|DIETARY_SUPPLEMENT|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
48685095|NCT01229046|DRUG|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
48685096|NCT05124028|DRUG|Orelabrutinib|50mg po qd 6 weeks
48685097|NCT01735383|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
48685098|NCT01735383|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
48685099|NCT00610792|DRUG|bortezomib|1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
48685100|NCT00610792|DRUG|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
48685101|NCT02015949|DRUG|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
48685102|NCT02015949|DRUG|Placebo|Twice daily placebo tablet for two weeks
48685103|NCT04247893|DEVICE|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
48685104|NCT04247893|DEVICE|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
48685105|NCT04247893|DEVICE|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
48685106|NCT01735734|DEVICE|Air cooling to CM site|
48685107|NCT05960045|DIETARY_SUPPLEMENT|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
48685108|NCT05960045|DIETARY_SUPPLEMENT|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
47999917|NCT05591326|PROCEDURE|i-PRF application procedure|Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
47999918|NCT00367172|BEHAVIORAL|Directly Administered Antiretroviral Therapy|
47999919|NCT00589953|DRUG|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
48685109|NCT04414813|BIOLOGICAL|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
48685110|NCT00430989|OTHER|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
48685111|NCT00430989|OTHER|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
48685112|NCT01976702|BEHAVIORAL|Enhanced Behavioral Skills Training|
48685113|NCT03400358|OTHER|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
48685114|NCT03857932|PROCEDURE|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
47999920|NCT00589953|DRUG|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
48685115|NCT02236572|DRUG|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg"
48685116|NCT00080834|DRUG|DJ-927|
48685117|NCT03815448|DRUG|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
48685118|NCT03815448|OTHER|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
48685119|NCT01875393|DRUG|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
48685120|NCT05016024|DEVICE|Colilen IBS|Patients will take Colilen IBS in First or Second Period
48685121|NCT05016024|OTHER|Placebo|Patients will take PlaceboS in First or Second Period
48685122|NCT06068946|BIOLOGICAL|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist
48685123|NCT06068946|BIOLOGICAL|Placebo|Placebo comparator
48685124|NCT05859646|DIETARY_SUPPLEMENT|Probiotic use|Probiotics were used for 3 months and all participated patients were followed for 6 months.
48685125|NCT03121300|OTHER|CT Scan|Quantitative lung SPECT-CT
48685126|NCT03121300|OTHER|Lung CT|CT lung ventilation
48685127|NCT03121300|OTHER|MRI|DCE MRI
48685128|NCT03121300|OTHER|Walk Test|6 minute hall walk test
47999921|NCT00696137|DRUG|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
48685129|NCT03121300|OTHER|SGRQ|St. George Respiratory Questionnaire
48685130|NCT03121300|OTHER|Biological Sample Collection|Blood Draw
48157624|NCT01732055|OTHER|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
48685131|NCT03121300|OTHER|Toxicity|Toxicity Evaluation
48685132|NCT03121300|OTHER|Cardiac Assessment|Cardiac MRI Scan
48685133|NCT01504893|PROCEDURE|Protective one lung ventilation|Low tidal volume, PEEP and alveolar recruitment maneuver
48685134|NCT06045273|BEHAVIORAL|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
48685135|NCT01005641|DRUG|exemestane|25 mg daily
48685136|NCT01005641|DRUG|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
48685137|NCT01737983|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.
48685138|NCT01737983|DIETARY_SUPPLEMENT|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
48685139|NCT06274996|DRUG|Upadacitinib|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib\&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
48685140|NCT05013346|OTHER|No intervention needed|No intervention required. Not a clinical trial
48366748|NCT02793115|BEHAVIORAL|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
48685141|NCT00521209|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
48685142|NCT00521209|OTHER|Stand procedures, no intervention|
48685143|NCT02807220|DRUG|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
48685144|NCT01282255|DRUG|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
48685145|NCT01282255|DRUG|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
48685146|NCT00436046|BIOLOGICAL|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
48685147|NCT00436046|BIOLOGICAL|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
48685148|NCT05684692|DRUG|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
48685149|NCT05684692|DRUG|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
48685150|NCT05684692|DRUG|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
48685151|NCT05684692|DRUG|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
48685152|NCT00268944|BIOLOGICAL|Myozyme|20 mg/kg qow
48685153|NCT06374927|DEVICE|Rehabilitation Gaming System (VR-based mobile application)|The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
47999922|NCT00665600|DRUG|Levalbuterol HCl|Levalbuterol 0.63 TID
47999923|NCT00665600|DRUG|Levalbuterol HCl|Levabuterol 1.25 mg TID
47999924|NCT00665600|DRUG|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
47999925|NCT00665600|DRUG|Placebo|Placebo TID
47999926|NCT01183169|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
47999927|NCT01183169|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
47999928|NCT01183169|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
47999929|NCT01183169|DRUG|Placebo|ALV placebo soft gel capsules administered orally
47999930|NCT03547713|BEHAVIORAL|Social feedback|Social feedback regarding performance of a public speech is delivered to participants
47999931|NCT03547713|BEHAVIORAL|Self-referential paradigm|Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)
47999932|NCT03547713|BEHAVIORAL|Reward vs. punishment task|Reception of monetary gains vs. losses
47999933|NCT03547713|BEHAVIORAL|Emotional reactivity task|Exposure to emotional faces vs. shapes
47999934|NCT03500146|DRUG|Anticholinergic|Patients prescribed medication for OAB
47999935|NCT03500146|PROCEDURE|PTNS|Patients prescribed PTNS for OAB
48685154|NCT02317497|OTHER|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
47999936|NCT01452308|BIOLOGICAL|Simtuzumab|
47999937|NCT06291558|OTHER|Exercise|The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
47999938|NCT00733863|BIOLOGICAL|Placebo|
47999939|NCT00733863|BIOLOGICAL|CAD106|
47999940|NCT01459965|PROCEDURE|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
47999941|NCT01459965|PROCEDURE|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
47999942|NCT04398758|DRUG|SanaCutan Basiscreme|In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
47999943|NCT01153412|OTHER|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
47999944|NCT05768854|DRUG|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
47999945|NCT05768854|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
47999946|NCT04157595|OTHER|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
47999947|NCT04916730|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician but will not be required to adopt a 10-hr eating window.
47999948|NCT04916730|BEHAVIORAL|Time Restricted Eating|Participants in this arm will adhere to a daily, consistent self-selected 10-hr eating window for the course of the study intervention period as well as receive nutritional counseling from the study dietitian.
47999949|NCT02473315|OTHER|cryotherapy|"The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks)."
48157625|NCT06458309|PROCEDURE|spine surgery|"AO Classification6 It classifies thoracolumbar fractures into 3 major groups, based on the mechanism of injury.and each of them subdivided to 3 subgroups.~A. Compression B. Distraction C. multi-directional with translation Thoracolumbar AO spine injury score"
48157626|NCT01819428|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
47999950|NCT05321394|DRUG|Sotrovimab|Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
47999951|NCT05321394|DRUG|Tixagevimab Cilgavimab|"2 subsequent injections:~1. tixagevimab 300mg/3mL (100mg/mL)~2. cilgavimab 300mg/3mL (100mg/mL)"
47999952|NCT05321394|DRUG|Nirmatrelvir Ritonavir|300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
47999953|NCT04602858|DEVICE|Reactive Balance Training|Reactive balance training involves the use of the Trip and Slip walkway that is able to expose participants to unpredictable trips and slips. Trips and slips will occur at random location on the walkway and times within the gait cycle, with the participants receiving 3-monthly retraining sessions along with an educational booklet.
47999954|NCT04602858|OTHER|Control|The control intervention will be receiving an educational booklet as part of standard care. The education component will target a variety of fall risk factors and provide strategies to mitigate these risk factors.
47999955|NCT02236429|BIOLOGICAL|vaginal flora transplant|
47999956|NCT02284646|OTHER|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
47999957|NCT00973479|DRUG|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
48685155|NCT02317497|DRUG|Vasopressors to maintain normal blood pressure values, if needed|
48685156|NCT02317497|DRUG|Osmotherapeutics to lowr intracranial pressure, if needed|
48685157|NCT02317497|PROCEDURE|Endovascular stroke care to treat brain vessel occlusions, if needed|
48685158|NCT02317497|PROCEDURE|Decompressive neurosurgery, if needed|
47999958|NCT00973479|OTHER|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
48685159|NCT05453071|OTHER|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
48618129|NCT05456672|OTHER|Test meals and food baskets|"Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)"
48685160|NCT04808713|BEHAVIORAL|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
48685161|NCT05947916|DEVICE|Real-time Continuous Glucose Monitoring System|The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
48685162|NCT01142050|BIOLOGICAL|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
48685163|NCT05320354|DIAGNOSTIC_TEST|Microbial ID test|In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
48685164|NCT02349659|DEVICE|Implantation with the commercially available Axium neurostimulator|
48685165|NCT01279811|OTHER|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
48685166|NCT01559337|PROCEDURE|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
47999959|NCT00973479|DRUG|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
47999960|NCT05791474|DRUG|ATI-2231|Provided by Aclaris Therapeutics, Inc.
47999961|NCT03935633|DRUG|CN128 Tablets|Iron chelator， oral tablets
47999962|NCT02843035|DRUG|venglustat (GZ402671)|"Pharmaceutical form: capsule~Route of administration: oral"
48157627|NCT02804347|DEVICE|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
48157628|NCT02804347|DEVICE|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
48157629|NCT02804347|OTHER|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT
48157630|NCT00028509|PROCEDURE|management of therapy complications|
48157631|NCT05788406|OTHER|Short foot exercises, Dynamic balance exercises and insole|Short foot exercises is used to improve muscle strenght, Dynamic balance exercises is used to improve balance and insole is used to improve MLA
48157632|NCT05082441|DRUG|Liposomal bupivacaine|Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine
47999963|NCT02843035|DRUG|imiglucerase|"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"
47999964|NCT00504686|OTHER|manual therapy|manual therapy - thoracic spine thrust manipulation
47999965|NCT00504686|OTHER|exercise|therapeutic exercise
48685167|NCT05005273|DRUG|Nivolumab|Specified dose on specified days
48685168|NCT05005273|DRUG|Ipilimumab|Specified dose on specified days
48685169|NCT05005273|DRUG|BMS-986207|Specified dose on specified days
48685170|NCT05005273|OTHER|Placebo|Specified dose on specified days
48685171|NCT06004258|OTHER|Painless Vaccination|"Structural adaptation of the vaccination areas and cozy decoration (colorful room, mobiles to hang on the ceiling) Nursing uniforms decorated with children's pictures Introduction of toys, stuffed animals, stamps and reward stickers, drawings and crayons, soothing music in the background~Antalgic measures by age ranges:~0-6M (FLACC scale) Breastfeed for two minutes if infant is breastfeeding Glucose 33% or 50% or if rotavirus vaccination, on mother's pacifier or gloved finger (non-nutritive sucking) Comfort between vaccinations 6-15M (FLACC scale) Position infant sitting on guardian's lap facing forward Distraction techniques: stuffed animals, toys, audiovisual devices 3-6Y (Wong-Baker scale) Involve child, explain Child sits on tutor's lap facing forward Distraction techniques: audiovisual devices, drawings 6-14Y (VAS scale)Always seated. Distraction method: audio-visual devices, breathing"
48685172|NCT03674970|DRUG|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
48685173|NCT01350258|DRUG|Fludarabine|Part of the conditioning regimen
48685174|NCT01350258|DRUG|Thiotepa|Part of the conditioning regimen
48685175|NCT01350258|RADIATION|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
48685176|NCT01350258|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
48685177|NCT01350258|DRUG|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
48685178|NCT01350258|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
48685179|NCT05944588|OTHER|Pulmonary Ultrasound|2 pulmonary ultrasound exams, one before respiratory weaning test, and one other at the end of the respiratory weaning test, before extubation
48685180|NCT00568594|DRUG|APL180|
48157633|NCT05082441|DRUG|Bupivacaine Hydrochloride|plain bupivacaine subcutaneous injection as standard of care control
48685181|NCT00568594|DRUG|Placebo|
48685182|NCT02413944|PROCEDURE|ACTH stimulation test|ACTH stimulation test
48685183|NCT05799703|DEVICE|electrical stimulation device|the device has 2 channels ,4 electrodes with multiple ems programs
48685184|NCT05799703|OTHER|kinesio taping|kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
48685185|NCT00068315|DRUG|bortezomib|Given IV
48685186|NCT00068315|DRUG|fludarabine phosphate|Given IV
48685187|NCT00068315|BIOLOGICAL|rituximab|Given IV
48685188|NCT03130517|DRUG|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
48157634|NCT00060268|DRUG|HPPH|iv
48157635|NCT01129011|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
48157636|NCT01129011|DRUG|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
48685189|NCT05689450|OTHER|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
48685190|NCT02424058|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
48685191|NCT02424058|BEHAVIORAL|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
48685192|NCT01645774|PROCEDURE|10s injections duration|10s injections duration
48685193|NCT01645774|PROCEDURE|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
48685194|NCT01645774|PROCEDURE|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
48685195|NCT01645774|PROCEDURE|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
48685196|NCT03836846|BEHAVIORAL|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
48685197|NCT03836846|BEHAVIORAL|Treatment as usual|TAU as per standard of care
48157637|NCT00002540|OTHER|Laboratory Biomarker Analysis|Correlative studies
48157638|NCT00002540|PROCEDURE|Medical Examination|Undergo DRE
48157639|NCT00002540|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
48366749|NCT03883659|OTHER|Smartphone|patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
48685198|NCT06511479|BEHAVIORAL|MIND-BP|8-week program delivered to small groups by a trained facilitator using Zoom/Webex. Each session is one hour long and includes a check-in period, teaching on the week's topic, group discussion, a skill-building exercise and home practice assignment. Participants receive a workbook of all session content, audio guides for home practice, and practice logs. At the start of the program, the stress response and its importance for hypertension and cardiovascular disease is discussed, and the rationale for the mindfulness and cognitive skills to be taught are explained. Weekly sessions focus on learning and practicing skills.
48685199|NCT06511479|BEHAVIORAL|BOOST|The BOOST program is designed to control for attention, credibility, and expectation of benefit. To parallel MIND-BP, the BOOST program will be delivered in 8 weekly group sessions via Zoom/Webex and led by a trained facilitator. Each weekly BOOST session will be 1 hour long and comprised of a check-in period, introduction of the week's topic, and group discussion. Didactic information, skill-building instruction and home practice are not included. Weekly BOOST session topics include: (1) personal experience of hypertension; (2) personal experience of stress; (3) personal experience of mood-related challenges; (4) personal experience of social relationships; (5) concerns related to hypertension treatment; (6) concerns about other health problems; (7) personal experience related to healthcare; and (8) review of the BOOST experience.
48685200|NCT04710498|DRUG|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
48685201|NCT02225704|DRUG|Radium-223 and enzalutamide|
48685202|NCT02788032|OTHER|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
48685203|NCT05547919|RADIATION|18F-PSMA PET/CT|Patients with metastasized gastrointestinal tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
47999966|NCT05915767|DIETARY_SUPPLEMENT|Olive leaf tea|Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
47999967|NCT01124604|DRUG|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
48685204|NCT04358146|OTHER|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
48685205|NCT04358146|OTHER|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
48157640|NCT01531478|OTHER|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
48157641|NCT03138616|DRUG|vitamin D|take 1600 units of vitamin D daily for nine months
48685206|NCT04565340|OTHER|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
48685207|NCT00570778|DRUG|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
47999968|NCT01124604|DRUG|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
48157642|NCT00967915|PROCEDURE|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
48157643|NCT00967915|OTHER|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
48157644|NCT03743597|DEVICE|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
47999969|NCT04563091|DEVICE|Hemodialysis with online HFR|"1. Hemodialytic therapy using 240-minute online HFR on Flexya® hemodialysis machine (Medtronic, Mirandola, Italy). The blood flow from vascular access will be maintained at values \> 250 ml/minute, the flow of dialysis fluid will be 500 ml/minute. Weight loss during dialytic treatment will be prescribed according to the patient's clinical needs.~2. Assess potassium (intra and extra cellular), sodium, bicarbonatemia, calcemia, urea, blood sugar values and ECG every 30 minutes during dialysis and every 60 minutes after dialysis.~3. Body impedance analysis at time 0 at 240 minutes, after 60 minutes after the end of dialysis and after 7 hours after the end of dialysis.~4. Use of the Natrium sensor (Medtronic, Mirandola, Italy) during HFR dialytic treatment."
48512834|NCT05650840|PROCEDURE|Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).|"The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing"
48157645|NCT03743597|DEVICE|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
47999970|NCT06145009|BEHAVIORAL|Time restricted eating|Limit food intake to 10 hours per day as described in the experimental arm section.
48157646|NCT05335811|DRUG|4-[18F]Fluoro-1-Naphthol|By vein (IV)
48157647|NCT00317135|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
47999971|NCT04216875|PROCEDURE|Best Practice Diabetes Management in Primary Care|Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
48157648|NCT00317135|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
47999972|NCT03026257|DEVICE|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
47999973|NCT03026257|DEVICE|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
47999974|NCT03026257|DEVICE|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
47999975|NCT03026257|DEVICE|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
47999976|NCT03026257|DEVICE|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
47999977|NCT03026257|DEVICE|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
47999978|NCT03026257|DEVICE|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
47999979|NCT03026257|DEVICE|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
47999980|NCT05929092|PROCEDURE|Umbilical Cord Blood Transplantation|Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive. Since the first successful umbilical cord blood transplantation (UCBT) in a child with severe Fanconi anemia reported by Gluckman et al. in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. The first sibling UCBT for leukemia was performed successfully by Professor Yongping Song in China, who played a pioneering role in the development of UCBT for leukemia in China. On the basis of previous research, the TFBC regimen (TBI/Flu/Bu/Cy) combined with UCBT is safe and feasible for the treatment of patients with high-risk malignant hematological diseases, which has enormous potential to improve patient outcomes.
48157649|NCT06096142|DEVICE|Solaris DE|Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
48157650|NCT06096142|DEVICE|PTA|Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
48512835|NCT06581796|OTHER|pepsinogen-1|association between pepsinogen 1 serum level with hyperemesis gravidarum
48512836|NCT04597697|DRUG|Insulin icodec|Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
48512837|NCT04380597|DRUG|Calcipotriene and betamethasone dipropionate aerosol foam|Prescribed according to clinical practice and following Product Data Sheet instructions
48512838|NCT03893630|DRUG|Acetylsalicylic Acid 81 mg|Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
48512839|NCT03893630|DRUG|Acetylsalicylic Acid 162 mg|Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
48157651|NCT02732899|DRUG|Sirolimus|
48157652|NCT02732899|DRUG|EYLEA|
48366750|NCT03883659|OTHER|traditional paper hangouts|patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
48512840|NCT03893630|OTHER|Control|Standard of Care
48157653|NCT06248021|BEHAVIORAL|Ecological Footprint Awareness Program|The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature. The sessions were based on the principles of the Social Cognitive Learning Theory, developed by Bandura, which includes mutual determinism, symbolization, anticipatory capacity, vicarious learning, self-regulation capacity, and self-judgment capacity. During each session, various techniques such as animation, drawing, storytelling, memory cards, and games were employed. To ensure the program's content was appropriate for children's development, the opinions of two experts from the child development department of the university were obtained.
48157654|NCT05300217|OTHER|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
48157655|NCT05300217|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
48157656|NCT06285058|DIAGNOSTIC_TEST|No interventions|The high-throughput extraction of large amounts of quantitative image features from medical images
48157657|NCT04751019|DEVICE|Amber Glasses|It is hoped that the use of amber glasses to complement the natural sleep-wake by inducing a perceived 'physiological darkness' to aid the secretion of melatonin should help sleep and reduce the use of hypnotic medication
48157658|NCT02595593|DEVICE|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
48157659|NCT02558322|OTHER|Primary medical care|All study participants receive primary care as usual in the respective region
48157660|NCT00511147|BIOLOGICAL|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
48157661|NCT02232919|DEVICE|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
48157662|NCT03605745|DEVICE|Prostatic Vapor Ablation|"Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response."
48157663|NCT02639234|BIOLOGICAL|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10\^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
48512841|NCT00462150|BEHAVIORAL|home-based emotional disclosure|
48157664|NCT02639234|DRUG|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
48366751|NCT05220020|PROCEDURE|TACE(Transcatheter arterial chemoembolization)|Hepatic arterial chemoembolization treatment
48512842|NCT00462150|BEHAVIORAL|time management control condition|
48512843|NCT03842644|DEVICE|Tension reduction device|Continue using this device for 3 months post surgery.
48512844|NCT05300828|DRUG|Genexl PM|Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
48512845|NCT00939016|OTHER|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
48512846|NCT04688385|BIOLOGICAL|Multipeptide Vaccine+ XS15|Peptide vaccination will take place in CLL patients that achieved at least a partial remission with detectable MRD after at least 6 and less than 9 months of an ibrutinib-based treatment regime. MRD will be determined by flow cytometry. MRD positivity is defined as \> 10-4 CLL cells in peripheral blood or bone marrow. Patients will receive either ibrutinib monotherapy or combinational therapy before study treatment. Vaccination will be done under ibrutinib monotherapy (i.e. after the end of e.g. anti-CD20 treatment, if applicable).
48512847|NCT02455895|DEVICE|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
48512848|NCT00337337|BEHAVIORAL|Multiple grain|
48512849|NCT00337337|BEHAVIORAL|Ordinary Asian- rice|
48685208|NCT00570778|DRUG|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
48685209|NCT00570778|DRUG|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
48685210|NCT04643366|DRUG|Chemotherapy|Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
48685211|NCT04643366|RADIATION|Radiation Therapy|Pelvic Intensity-modulated radiation therapy (IMRT)
48512850|NCT05432661|DEVICE|HİGH-FLOW NASAL OXYGEN USE (HFNO)|It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
48512851|NCT01391897|BEHAVIORAL|psychotherapy|"multimodal complex psychotherapy"
48685212|NCT02596256|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
48685213|NCT02596256|DRUG|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
48685214|NCT04558541|OTHER|Sensitivity to phonological rules|Assess whether children with developmental language disorder (DLD) are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon; children with speech sound disorder (SSD) are not predicted to be sensitive to the same phonological patterns.
48685215|NCT04558541|OTHER|Sensitivity to semantic category cues.|Assess whether all children, including those with DLD, show improved learning of OR rules when a semantic category cue is used.
48685216|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
48685217|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
48685218|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
48157665|NCT05789407|DIAGNOSTIC_TEST|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
48157666|NCT02653001|OTHER|Stool sample collection|Collection of complete stool sample
48157667|NCT05361954|DRUG|STI-1386|Second generation oncolytic virus
48512852|NCT00843895|BIOLOGICAL|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
48685219|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
48685220|NCT03200197|OTHER|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
48685221|NCT03200197|OTHER|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
48685222|NCT00770562|DRUG|rituximab|
48685223|NCT00770562|DRUG|Dexamethasone|
48512853|NCT04290143|OTHER|Colored healing water|Patients will be treated with colored healing water for 20 minutes.
48512854|NCT04290143|OTHER|Placebo treatment (colored tap water)|Patients will be treated with colored tap water for 20 minutes.
48512855|NCT02653833|DRUG|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
48512856|NCT02653833|OTHER|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
48512857|NCT04402840|PROCEDURE|Stellate Ganglion Block|The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
48685224|NCT04944238|DEVICE|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
48685225|NCT03375645|DRUG|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
48685226|NCT04348812|BEHAVIORAL|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
48685227|NCT04348812|OTHER|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
48685228|NCT01650831|DEVICE|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
48685229|NCT03402191|DRUG|L-arginine|l-arginine for thalassemia with pulmonary hypertension
48685230|NCT03402191|DRUG|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
48685231|NCT04809519|OTHER|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
48685232|NCT04809519|OTHER|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
48685233|NCT00515528|BIOLOGICAL|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
48685234|NCT00515528|DRUG|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
48685235|NCT06177262|BEHAVIORAL|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
48685236|NCT03533699|DRUG|Propranolol|
48685237|NCT03533699|DRUG|Placebo Oral Tablet|oral tablets with no active drug
48685238|NCT01693250|BEHAVIORAL|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
48685239|NCT01693250|BEHAVIORAL|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
48685240|NCT05147532|PROCEDURE|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
48685241|NCT05059301|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
48157668|NCT04034056|DRUG|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
48157669|NCT00839306|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
48157670|NCT00839306|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
48157671|NCT00054730|DRUG|CX516 (Ampalex®)|
48685242|NCT00942370|DEVICE|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~* EMG and MMG Signals of rectus abdominis of the abdomen,~* Respiratory flow,~* An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
48685243|NCT03804892|DIAGNOSTIC_TEST|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
48157672|NCT06584773|DRUG|Everolimus|mTORi added as the fourth maintenance immunosuppressive drug in recipients
48157673|NCT06584773|DRUG|standard maintenance immunosuppression|standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
48157674|NCT01034683|DRUG|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
48157675|NCT00006104|BIOLOGICAL|trastuzumab|
48157676|NCT00006104|DRUG|docetaxel|
48157677|NCT05861323|BEHAVIORAL|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
48157678|NCT05664009|DIETARY_SUPPLEMENT|Redsenol-1 Plus|Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).
48157679|NCT05664009|OTHER|Placebo|Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).
48157680|NCT01942538|DEVICE|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
48157681|NCT01942538|DEVICE|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
48512858|NCT06006377|OTHER|conventional physiotherapy|hotpack electrotherapy ultrasound exercises
48685244|NCT03804892|DIAGNOSTIC_TEST|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
48685245|NCT03804892|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
48685246|NCT03804892|OTHER|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
48685247|NCT03804892|OTHER|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
48685248|NCT04800575|DEVICE|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
48685249|NCT04800575|DEVICE|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
48685250|NCT03563755|OTHER|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
48685251|NCT01084291|BIOLOGICAL|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
48685252|NCT01084291|OTHER|Placebo injection|Subcutaneous injection of placebo
48685253|NCT02204423|PROCEDURE|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
48685254|NCT01531582|DRUG|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
47999981|NCT05629013|BEHAVIORAL|After-Action Review|After-action reviews, or debriefs, are a relatively simple, inexpensive, and quick, tool to improve learning, performance, and the effectiveness of teams and individuals. After-action reviews are active self-learning processes wherein participants reflect on specific performance episode to actively engage in self-discovery and improve learning in a non-punitive/non-judgmental manner to result in enhanced performance. This proposal aims to apply the team effectiveness intervention of the after-action review (AAR) to the services intervention of the Child and Family Team (CFT) meetings currently used in the CWS.
48157682|NCT06352034|BEHAVIORAL|Empathy Training|"The intervention contains five themes: 1) An overview of empathy and emotions. 2) Cognitive empathy and clarification technique. 3) Emotional empathy and reflection of feelings technique. 4) Awaring and dealing with the inner feelings while empathizing. 5) Empathy timing and emotional pendulum technique."
48157683|NCT00796640|DRUG|ER Paliperidone|
48157684|NCT01090856|PROCEDURE|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
48366752|NCT05220020|DRUG|Lenvatinib|Experimental group(Synchronous treatment group): the first course of TACE treatment was started after 2-3 weeks Lenvatinib treatment.Control group:(Sequential treatment group)patients with uncontrolled TACE progression after TACE treatment were sequentially treated with Lenvatinib.
48618130|NCT06358833|PROCEDURE|endodontic needle (EN)|the irrigation of root canals will be done with 2.5 % sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The tip of the needle will be pre-measured and positioned within 1 millimeter of the working length. No activation of the irrigant will be performed.
48685255|NCT01471769|BEHAVIORAL|Pain management video|6-minute video
48685256|NCT01471769|BEHAVIORAL|Falls Prevention Video|6-minute video
47999982|NCT01365273|DEVICE|Mepitel One|Dressing
48512859|NCT06006377|OTHER|Backup therapy|The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
48512860|NCT06191835|BEHAVIORAL|myCare Start|The service consists of 2 times 10-minutes semi-structured pharmaceutical interventions between community pharmacist and patient, tailored to the patient's needs, positioned as partner, during the first 6 weeks after treatment initiation.
48512861|NCT06440993|DRUG|Gemcitabine|Gemcitabine, 1,000 mg/m2 IV
47999986|NCT00497172|DEVICE|CYPHER Sirolimus-eluting stent|drug-eluting stent
48685257|NCT05708573|DRUG|Rosuvastatin|In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
48685258|NCT05708573|DRUG|ALXN2040|In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
48685259|NCT00037440|GENETIC|Polymorphisms measured|
47999987|NCT00497172|DEVICE|Bx SONIC bare metal stent|bare-metal stent
47999988|NCT06353490|DEVICE|Infrared Forehead Thermometer (GE-TF03)|Infrared Forehead Thermometer (GE-TF03) is an investigational device intended to measure body temperature on the forehead. GE-TF03 took three measurements for each subject.
47999989|NCT06353490|DEVICE|Infrared Ear Thermometer (GE-TE06)|Infrared Ear Thermometer (GE-TE06) is an investigational device intended to measure body temperature in the ear canal. GE-TF06 took three measurements for each subject.
47999990|NCT06353490|DEVICE|Electronic Thermometer (MT-B321FB)|Electronic Thermometer (MT-B321FB) is an investigational device intended to measure body temperature on the temporal artery. MT-B321FB took three measurements for each subject.
47999991|NCT06353490|DEVICE|Electronic Thermometer (MT-B231)|Electronic Thermometer (MT-B231) is a reference device that measured axillary temperature one time for each subject.
47999992|NCT04113499|PROCEDURE|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
47999993|NCT04113499|PROCEDURE|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
47999994|NCT06301100|OTHER|Dual energy CT after routine simulation|Dual energy CT after routine simulation
48366753|NCT00800189|RADIATION|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
48685260|NCT02474576|PROCEDURE|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
48685261|NCT00776542|DRUG|Minocycline 100mg Tablets|
48685262|NCT06368414|DRUG|Asciminib|that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
48685263|NCT02342782|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
48685264|NCT02342782|DRUG|Carmustine|Given IV
48685265|NCT02342782|DRUG|Etoposide|Given IV
48685266|NCT02342782|DRUG|Cytarabine|Given IV
48685267|NCT02342782|DRUG|Melphalan|Given IV
48685268|NCT02342782|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
48366754|NCT03182673|DRUG|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
47999995|NCT01991002|BEHAVIORAL|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
47999996|NCT03522766|OTHER|urine sample|The subjects are asked to give a maximum of 15 urine samples during the study
48685269|NCT02342782|OTHER|Laboratory Biomarker Analysis|Correlative studies
48685270|NCT02342782|OTHER|Pharmacological Study|Correlative studies
48685271|NCT04019964|DRUG|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
48685272|NCT03815630|DRUG|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
48685273|NCT01585779|DEVICE|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
48685274|NCT01585779|DEVICE|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
47999997|NCT04330560|DEVICE|Exercise telemonitoring connects to healthcare platform|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) link to the healthcare practitioner
47999998|NCT04330560|DEVICE|Exercise self-monitoring|The participant is required to wear the fitness tracker every day during waking hours throughout the 12 weeks of intervention (except during sleeping, bathing, and swimming) for exercise self-monitoring.
47999999|NCT04330560|DEVICE|Exercise teleconsultation|Conducted through smartphone video call app.
48000000|NCT04330560|PROCEDURE|Other CR components|Including dietary, psychology, education conducted at the center.
48000001|NCT04330560|PROCEDURE|Standard care|Undergoing standard care by cardiac rehabilitation at the center
48000002|NCT05947136|BEHAVIORAL|Interpretation of the results from the detection visit|"- An interpretation of the results of the detection tests concerning~* the 7 complications of interest assessed at T1, T2, T3 and T4 ;~* the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"
48685275|NCT00626782|DRUG|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
48000003|NCT05947136|BEHAVIORAL|Explaining detection results and referrals to the patient|"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~* Clearly explain the results of the detection visit and the action to be taken for each referral;~* Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~* Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."
48366755|NCT03182673|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
48512862|NCT06440993|DRUG|Cisplatin|Cisplatin, 25 mg/m2 IV
48685276|NCT00626782|DRUG|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
48685277|NCT04111796|OTHER|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
48685278|NCT02094209|DEVICE|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
48685279|NCT02381314|BIOLOGICAL|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
48512863|NCT06440993|DRUG|Durvalumab|Durvalumab, 1,500 mg IV
48512864|NCT06440993|PROCEDURE|ID-RFA|endoscopic intraductal RFA
48512865|NCT03548727|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT Imaging of tumor hypoxia and proliferation
48685280|NCT01247454|BEHAVIORAL|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
48685281|NCT01247454|BEHAVIORAL|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
48685282|NCT01247454|BEHAVIORAL|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
48685283|NCT02554799|DRUG|MMV390048 formulation A|MMV390048 formulation A, tablet
48685284|NCT02554799|DRUG|MMV390048 formulation B|MMV390048 formulation B, tablet
48685285|NCT04754971|OTHER|psycho-education program|Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
48685286|NCT04251832|DRUG|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
48685287|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
48685288|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
48685289|NCT02991898|BIOLOGICAL|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
48685290|NCT06007508|DRUG|Insulin Glargine|Long-acting insulin
48685291|NCT01811069|PROCEDURE|Head up|30˚ reverse trendelenburg body position
48685292|NCT06093308|DRUG|Deuremidevir Hydrobromide Tablets|Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
48685293|NCT02346227|DRUG|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
48685294|NCT02346227|DRUG|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
48685295|NCT04736290|OTHER|NLR|Calculation of NLR
48685296|NCT04736290|OTHER|PLR|Calculation of PLR
48685297|NCT03799952|BEHAVIORAL|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
48685298|NCT03120663|DRUG|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
48685299|NCT05044650|DIETARY_SUPPLEMENT|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
48685300|NCT03075280|PROCEDURE|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
48685301|NCT03772795|OTHER|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
48000004|NCT05947136|BEHAVIORAL|Early medical care through the network|Early, proactive medical care through a network of dedicated healthcare professionals.
48000005|NCT05947136|BEHAVIORAL|Transmission of results from each detection visit to the referring onco-haematologists - Control Group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
48512866|NCT05738044|OTHER|No intervention|No intervention
48512867|NCT03451214|OTHER|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
48512868|NCT02445534|BIOLOGICAL|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
48512869|NCT00309686|DRUG|Paliperidone ER|
48512870|NCT04098510|DIETARY_SUPPLEMENT|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
48512871|NCT04496518|DEVICE|Intrinsic Antitachycardia Pacing (iATP) Therapy|iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).
48685302|NCT03772795|OTHER|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
48685303|NCT01633255|DRUG|18F-Fluciclatide|
48685304|NCT01056406|BEHAVIORAL|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
48685305|NCT05096143|DRUG|Sacubitril/valsartan|Participants who were prescribed with Sacubitril/valsartan
48685306|NCT05096143|DRUG|ACEi/ARB|Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
48685307|NCT00817323|PROCEDURE|Dietary amino-acid depletion|See detailed description
48000006|NCT00111969|DEVICE|Celacade™ system|
48685308|NCT06089733|DRUG|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
48685309|NCT06089733|DRUG|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
48685310|NCT06554561|DRUG|Pomalidomide|3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.
48685311|NCT06554561|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.
48685312|NCT06554561|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
48685313|NCT05296551|OTHER|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
48685314|NCT05296551|OTHER|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
48685315|NCT00110435|DRUG|MK0653A, ezetimibe (+) simvastatin|
48366756|NCT03182673|DRUG|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
48685316|NCT00110435|DRUG|Duration of Treatment: 4 wk placebo run in then 6 wk active|
48685317|NCT00110435|DRUG|Comparator: atorvastatin|
48685318|NCT05293600|DRUG|Placebo|Placebo capsule 30 min before bedtime
48685319|NCT05293600|DRUG|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
48000007|NCT00660348|DRUG|morphine sulfate|This is morphine given in the traditional methods.
48000008|NCT00660348|DEVICE|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
48000009|NCT05019924|DIETARY_SUPPLEMENT|Semaine|The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
48366757|NCT05689229|DRUG|Colistin|COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
48366758|NCT02711306|DIETARY_SUPPLEMENT|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
48366759|NCT02711306|DIETARY_SUPPLEMENT|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
48685320|NCT05293600|DRUG|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
48685321|NCT05293600|DRUG|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
48685322|NCT00481455|DRUG|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
48685323|NCT00481455|DRUG|Temozolomide|Fixed dose
48685324|NCT03993886|DEVICE|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
48685325|NCT03993886|OTHER|Activity Monitor|commercially available accelerometer to be worn on wrist
48685326|NCT03993886|OTHER|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
48685327|NCT03993886|OTHER|ECG|Commercially available electrocardiogram machine
48685328|NCT03993886|OTHER|respiratory rate sensor|Commercially available respiratory rate sensor.
48685329|NCT06398002|OTHER|Dialysate calcium 1.50 mmol/L|Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)
48685330|NCT01720589|DIETARY_SUPPLEMENT|Melt (test oil)|
48685331|NCT01720589|DIETARY_SUPPLEMENT|Corn oil (control)|
48685332|NCT01150786|DIETARY_SUPPLEMENT|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
48685333|NCT01150786|OTHER|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
48685334|NCT01510990|DRUG|Gefitinib|gefitinib 250mg/day daily
48685335|NCT02016716|DRUG|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
48685336|NCT02016716|DRUG|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
48000010|NCT02596854|DEVICE|Neurological MRI|Neurological MRI image collection
48000011|NCT01311193|OTHER|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
48000012|NCT01485211|DRUG|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
48000013|NCT04963582|PROCEDURE|Acupuncture|LI4 is located on the dorsum of the hand, midway between the 1st and 2nd metacarpal bones, approximately in the middle of the 2nd metacarpal bone on the radial side. Acupuncture is practiced by using 0,25x25mm sized needles. LI4 point is punctured perpendicularly 2cm in the direction of the palm center.
48157685|NCT04246099|OTHER|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
48157686|NCT00489151|DRUG|adefovir dipivoxil|
48157687|NCT00489151|DRUG|lamivudine|
48000014|NCT05828251|PROCEDURE|Vitrectomy (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
48157688|NCT02464306|DRUG|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
48157689|NCT05682040|DIAGNOSTIC_TEST|Bedside Compression Ultrasonography|Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
48157690|NCT04089332|OTHER|Oral Glucose Tolerance Test (OGTT)|Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.
48000015|NCT05828251|PROCEDURE|Combined phako-vitrectomy|Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
48000016|NCT05828251|PROCEDURE|Phako (Sequential phakoemulsification and vitrectomy)|Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
48000017|NCT05659173|DIAGNOSTIC_TEST|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
48000018|NCT01498640|BIOLOGICAL|Collagenase clostridium histolyticum|up to three 0.58 mg injections
48366760|NCT02833142|DRUG|BIIB033 (opicinumab)|
48512872|NCT05358509|DRUG|Ferric carboxymaltose|Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
48685337|NCT02016716|DRUG|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
48685338|NCT02016716|DRUG|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
48685339|NCT03028129|DRUG|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
48685340|NCT03028129|DRUG|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
48685341|NCT06293534|DIAGNOSTIC_TEST|TSH,T3,T4|Diagnosis of the psychiatric disorders among study group will be assessed and recorded and history of Electroconvulsive therapy (ECT) also will be recorded , physical examination for signs that suggests actual thyroid disease such as unexplained bradycardia or tachycardia, hypothermia , goiter or non palpable thyroid among study group will be assessed
48685342|NCT05511506|OTHER|aqueous humor collection|Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
48685343|NCT02144571|BEHAVIORAL|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
48685344|NCT04237181|DEVICE|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
48685345|NCT04858607|DIAGNOSTIC_TEST|Blood sample|Serology, immune status, T cell immunity, and T cell aging.
48685346|NCT04858607|DIAGNOSTIC_TEST|Saliva sample|Antibody tests
48685347|NCT04783311|BIOLOGICAL|EuCorVac-19|Two intramuscular doses (0.5mL per dose) at 3-week interval
48685348|NCT04783311|OTHER|Normal Saline|Two intramuscular doses (0.5mL per dose) at 3-week interval
48685349|NCT05031117|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
48685350|NCT05031117|PROCEDURE|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
48685351|NCT06057597|PROCEDURE|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
48685352|NCT06057597|PROCEDURE|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
48685353|NCT03256669|PROCEDURE|umbilical incision|exploration through umbilical incision
48685354|NCT03860831|DRUG|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
48685355|NCT03761589|BEHAVIORAL|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
48685356|NCT03761589|BEHAVIORAL|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
48157691|NCT04089332|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
48685357|NCT03569787|DIAGNOSTIC_TEST|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
48685358|NCT02427139|DEVICE|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
48685359|NCT02936518|PROCEDURE|Lingual frenotomy and/or maxillary labial frenectomy|
48685360|NCT01188902|DIETARY_SUPPLEMENT|walnut|walnut consumption 48 g/d
48685361|NCT00988052|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
48685362|NCT06298903|OTHER|Hip Activation|Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.
48157692|NCT04089332|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
48157693|NCT04089332|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
48366761|NCT04945239|BEHAVIORAL|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
48685363|NCT06298903|OTHER|Hip activation + Single leg balance|"Hip activation HEP: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.~Single leg balance: variety of single leg balance exercises with different upper extremity and lower extremity positions to provide different balance stimuli. Weeks are alternated performing these exercises with eyes open and eyes closed."
48685364|NCT03840044|OTHER|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during\*/post§ of heart rate (HR)§\* and blood pressure (BP)§\*, spirometry§\*, PNIF§, FeNO§, electrocardiogram (ECG)§\*, body \& exhaled air temperature§\*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
48685365|NCT06156878|COMBINATION_PRODUCT|Anti-EGFR and PD-1 inhibitor arm|Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.
48685366|NCT00056173|DRUG|GTI-2040|
48685367|NCT05848466|DRUG|BAT8010 for Injection|Intravenous
48685368|NCT04165408|DEVICE|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
48685369|NCT00641355|PROCEDURE|No intervention|No intervention
47914500|NCT00586781|DEVICE|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
48000019|NCT03891654|DIAGNOSTIC_TEST|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
48000020|NCT02732834|BEHAVIORAL|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
48157694|NCT02056873|DEVICE|Continuous DBS|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS."
48685370|NCT01506557|DIETARY_SUPPLEMENT|cholecalciferol|dose 800 IU/day for 6 month
48685371|NCT01506557|DIETARY_SUPPLEMENT|placebo|oil capsules
48685372|NCT04281420|DRUG|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
48685373|NCT04281420|COMBINATION_PRODUCT|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
48685374|NCT03260855|OTHER|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
48685375|NCT03260855|OTHER|Human blood sample|The intervention is based on blood test.
48685376|NCT03612063|DEVICE|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
48000021|NCT02732834|BEHAVIORAL|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
48000022|NCT02732834|BEHAVIORAL|Audio recordings of clinical consultations|
48000023|NCT02732834|BEHAVIORAL|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
48000024|NCT02732834|BEHAVIORAL|2-hour empathic communication skills training|2-hour empathic communication skills training
48000025|NCT02732834|BEHAVIORAL|Standardized Patient Assessments|pre-training SPA, post-training SPA
48685377|NCT03612063|DEVICE|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
48685378|NCT03612063|DEVICE|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
48000026|NCT02732834|BEHAVIORAL|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
48685379|NCT03612063|DEVICE|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
48685380|NCT03612063|DEVICE|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
48685381|NCT03612063|DEVICE|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
48685382|NCT02749201|DEVICE|Gastrisail|Light Intensity and gastric wall thickness assessment
48685383|NCT00995436|DEVICE|Extraoral anchorage|Extra oral anchorage
48685384|NCT00995436|DEVICE|Miniscrews|Intraoral skeletal anchorage using mini screws
48685385|NCT00995436|DEVICE|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
48685386|NCT05833009|DEVICE|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
48000027|NCT02732834|BEHAVIORAL|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
48685387|NCT06138353|DRUG|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
48000028|NCT01217060|DRUG|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
48000029|NCT01217060|DRUG|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
48000030|NCT01217060|RADIATION|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
48000031|NCT01217060|PROCEDURE|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
48000032|NCT01217060|DRUG|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
48000033|NCT01452464|BIOLOGICAL|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
48000034|NCT01076504|DRUG|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
48000035|NCT01076504|DRUG|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
48000036|NCT01076504|DRUG|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
48000037|NCT05180461|DRUG|emodepside|emodepside tablet
48000038|NCT05180461|DRUG|matching placebo of emodepside|emodepside matching placebo tablet
48685388|NCT01848067|DRUG|Alisertib|Given PO
48685389|NCT01848067|DRUG|Abiraterone acetate|Given PO
48685390|NCT01848067|DRUG|Prednisone|Given PO
48685391|NCT04404673|PROCEDURE|Evaluation of urinary and sexual dysfunction after rectal resection|Comparison among the 4 different surgical approaches for urinary and sexual function
48157695|NCT02056873|DEVICE|Responsive Brain Stimulation (RBS Setting)|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention."
48685392|NCT05744856|BEHAVIORAL|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
48685393|NCT01580709|PROCEDURE|Multiple brushings|Seven consecutive brush samples for cytology.
48685394|NCT01580709|PROCEDURE|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
48685395|NCT03582046|DEVICE|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
48685396|NCT03582046|DEVICE|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
48685397|NCT00839280|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
48685398|NCT00839280|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
48685399|NCT05221996|BEHAVIORAL|Resistance training|Resistance circuit training
48685400|NCT06269692|DEVICE|MRI screening|Cardiac Magnetic Resonance imaging for the quantification of the infarct intramural scar
48685401|NCT06269692|DEVICE|Implantable Loop Recorder|Inplantation of the Implantable Loop Recorder (ILR) for the patients assigned to the experimental group
48685402|NCT06269692|DEVICE|Implantable Cardioverter Defibrillator|Inplantation of the Implantable Cardioverter Defibrillator (ICD) for the patients assigned to the control group, according to the current guidelines
48685403|NCT04963816|PROCEDURE|ultrasound guided quadratus lumborum block|Ultrasound guided quadratus lumborum block will be done to all groups using curved array transducer 5_2 MHz with the patient in supine position and the block will be done by anterior approach
48685404|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
48685405|NCT04963816|DRUG|Bupivacaine Injection|Bupivacaine will be given to all groups locally with QLB
48685406|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution locally|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
48685407|NCT02628041|RADIATION|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
48685408|NCT02628041|RADIATION|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
48685409|NCT05595070|PROCEDURE|Haematopoietic stem cell transplantation|Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).
48685410|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
48685411|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
48685412|NCT04368013|PROCEDURE|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
48000039|NCT05180461|DRUG|ivermectin|ivermectin tablet (overencapsulated for blinding)
48000040|NCT05180461|DRUG|matching placebo of ivermectin|matching placebo of overencapsulated ivermectin tablet
48000041|NCT03741764|DEVICE|Vivosorb|Resorbable implant device
48000042|NCT01373749|DRUG|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
48000043|NCT01373749|DRUG|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
48685413|NCT01546233|BEHAVIORAL|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
48685414|NCT01546233|BEHAVIORAL|standard education|standard education before and after chemotherapy
48685415|NCT05964348|PROCEDURE|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
48685416|NCT05231850|DRUG|Tislelizumab|All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
48685417|NCT02368600|BEHAVIORAL|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
48685418|NCT00751959|DRUG|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
48685419|NCT00751959|DRUG|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
48366762|NCT04945239|BEHAVIORAL|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
48685420|NCT04054921|DRUG|PTG-300|PTG-300 is a hepcidin Mimetic
48000044|NCT06047353|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.
48685421|NCT00426868|OTHER|Direct injection of ADRCs into the Left Ventricle|Dose escalation
48685422|NCT00426868|OTHER|Direct injection of placebo into the Left Ventricle|
48000045|NCT06047353|DEVICE|Positive Airway Pressure (PAP) therapy|Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
48000046|NCT01272830|DRUG|Placebo|Two capsules taken twice daily with meals
48000047|NCT01272830|DRUG|Apatone®B|Two capsules taken twice daily with meals
48000048|NCT00954642|DRUG|bevacizumab|Intravenous repeating dose
48000049|NCT00954642|DRUG|MNRP1685A|Escalating intravenous dose
48366763|NCT03602911|DRUG|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
48366764|NCT00548366|OTHER|Sodium restriction|4 gram sodium diet
48366765|NCT00548366|OTHER|Sodium restriction|2 gram sodium diet
48366766|NCT03345927|OTHER|no intervention|no intervention
48000050|NCT00954642|DRUG|paclitaxel|Intravenous repeating dose
48685423|NCT05296746|DRUG|Ribociclib (neoadjuvant)|Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
48685424|NCT05296746|DRUG|Chemotherapy (adjuvant)|Adjuvant chemotherapy. 3 regimens are permitted.
48000051|NCT05525533|BEHAVIORAL|Harnessing prosocial and social image motivations for behavior change|The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
48000052|NCT05403879|PROCEDURE|fixation of greater tuberosity fractures|deltopectoral approach for shoulder, then open reduction and fixation of displaced greater tuberosity fractures using hooked Kirshner wires
48685425|NCT05296746|DRUG|Ribociclib (adjuvant)|Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
48685426|NCT01320345|DRUG|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
48366767|NCT00808197|PROCEDURE|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
48366768|NCT05798559|BEHAVIORAL|Sleep Training|These are the trainings given by the researchers in order to regulate the sleep routine and environment. Content will be presented to improve sleep processes by arranging living habits.
48685427|NCT01320345|DRUG|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
48685428|NCT05253937|DRUG|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
48685429|NCT06414343|OTHER|Observational - no intervention|Observational - no intervention
48685430|NCT02689414|PROCEDURE|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
48685431|NCT02689414|PROCEDURE|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
48157696|NCT02232009|DEVICE|3.0 T Neonatal MRI Scanner|Eligible subjects will undergo neonatal MRI scanning procedures.
48157697|NCT05659745|OTHER|VM-02|VM-02 is a personal care product for vaginal health.
48157698|NCT05659745|DIETARY_SUPPLEMENT|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
48000053|NCT03561493|OTHER|zumba exercise|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
48000054|NCT00256152|DEVICE|AF Suppression Pacing Algorithm|
48000055|NCT02340299|DEVICE|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
48000056|NCT02340299|DEVICE|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
48000057|NCT04078685|PROCEDURE|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
48000058|NCT04078685|PROCEDURE|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
48000059|NCT00790439|DRUG|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
48685432|NCT00758069|DRUG|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
48685433|NCT00758069|DRUG|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
48685434|NCT00758069|DRUG|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
48685435|NCT04506593|OTHER|no intervention|
48685436|NCT00124072|DRUG|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
48000060|NCT00790439|DRUG|Heparin|Anticoagulant
48000061|NCT00790439|DRUG|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
48000062|NCT00790439|DRUG|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
48000063|NCT00790439|DRUG|Tacrolimus|Calcineurin inhibitor
48000064|NCT00790439|DRUG|Cyclosporine|Calcineurin inhibitor, immunosuppressant
48000065|NCT00790439|DRUG|Daclizumab|Monoclonal IL-2 receptor blocker
48000066|NCT00790439|DRUG|Basiliximab|Monoclonal IL-2 receptor blocker
48000067|NCT00790439|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|
48000068|NCT01157507|DRUG|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
48000069|NCT01157507|PROCEDURE|Bladder overdistension|Bladder overdistension
48000070|NCT01157507|DRUG|Placebo|One single injection of placebo
48000071|NCT03365310|DRUG|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
48000072|NCT03365310|OTHER|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
48000073|NCT03595878|RADIATION|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
48000074|NCT03595878|RADIATION|Standard WBRT|Standard Whole Brain Radiation Therapy
48000075|NCT01188577|DRUG|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
48000076|NCT01188577|DRUG|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
48000077|NCT00217542|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
48000078|NCT00217542|DRUG|amifostine/azacitidine|Given SC
48000079|NCT02204748|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|
48000080|NCT02245542|DRUG|ALNA®OCAS®|
48000081|NCT04413084|OTHER|Gaze stability exercises|Business card will be placed at eye level. Begin with simpler exercises and progress toward harder one.
48000082|NCT04413084|OTHER|Brandt-Daroff Exercises|"Brandt-Daroff Exercises~1. Start sitting upright on the edge of the bed.~2. Turn your head 45 degrees to the left, or as far as is comfortable.~3. Lie down on your right side.~4. Remain in this position for 30 seconds or until any dizziness has subsided.~5. Sit up and turn head back to center.~6. Turn your head 45 degrees to the right, or as far as is comfortable.~7. Lie down on your left side.~8. Remain in this position for 30 seconds or until any dizziness has subsided.~9. Sit up and turn head back to center."
48000083|NCT01749722|DEVICE|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
48000084|NCT05251376|DRUG|Levomethadone HCl|One dose given orally on Day 8 of the study.
48000085|NCT05251376|DRUG|Methadone|Daily usual oral dose given on Day 1 and Day 2 of the study.
48685437|NCT00124072|DIETARY_SUPPLEMENT|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
48685438|NCT00124072|DRUG|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
48685439|NCT00124072|DRUG|Placebo|Placebo vitamin B12/folic acid tablet once daily
48685440|NCT04884880|DRUG|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
48685441|NCT04884880|DRUG|The placebo 10g|Placebo 10g，once daily，4 weeks
48685442|NCT03116906|DRUG|BI 685509|to be given for a total of up to 15 days
48685443|NCT03116906|DRUG|Placebo|to be given for a total of up to 15 days
48685444|NCT01817842|BEHAVIORAL|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
48000086|NCT05251376|DRUG|Morphine Sulfate|Administered daily and as needed from Day 3 of the study until subject back on usual daily methadone dose.
48685445|NCT01817842|BEHAVIORAL|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
48685446|NCT01817842|BEHAVIORAL|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
48685447|NCT01101893|DRUG|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
48685448|NCT01101893|DRUG|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
48685449|NCT01101893|DRUG|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
48685450|NCT04823728|GENETIC|Autoimmune encephalitis and paraneoplastic neurological syndromes|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
48685451|NCT05679960|DIAGNOSTIC_TEST|Urine PolypDx machine Versus Colonoscopy|"1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups"
48685452|NCT02509936|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
48685453|NCT02509936|DIETARY_SUPPLEMENT|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
48685454|NCT04148703|OTHER|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
48685455|NCT04148703|OTHER|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
48685456|NCT02180204|DRUG|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
48685457|NCT02180204|DRUG|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
48685458|NCT05072860|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
48685459|NCT05072860|OTHER|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
48685460|NCT01413711|DRUG|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
48685461|NCT06017960|OTHER|Dry needling + usual care|"Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated."
48000087|NCT05251376|DIAGNOSTIC_TEST|x-ray|Abdominal x-rays done at specific study timepoints to assess the location of the LYN-014.
48000088|NCT05251376|DIAGNOSTIC_TEST|blood tests|Done at specific timepoints throughout the study for PK (pharmacokinetics), genotyping and safety labs.
48000089|NCT03322228|OTHER|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
48512873|NCT05358509|DRUG|Iron isomaltoside|Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.
48000090|NCT03662542|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
48366769|NCT00981266|DEVICE|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
48000091|NCT03662542|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
48685462|NCT06017960|OTHER|Sham dry needling + usual care|"Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines."
48685463|NCT06005558|DRUG|Normal saline|100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
48000092|NCT03662542|DRUG|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
48000093|NCT03662542|DRUG|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
48000094|NCT03662542|DRUG|Placebo|Placebo will be administered.
48000095|NCT06545370|OTHER|Intervention 1 / Nurse-led patients' education|nurse-led education through oral sessions, educational materials, and regular phone calls
48000096|NCT06545370|OTHER|Intervention 2 / Nurse-led patients' & caregivers' education|nurse-led education while caregivers also undergo training through oral sessions, phone calls, and appropriately designed educational materials
48000097|NCT00975533|DEVICE|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
48000098|NCT00975533|DRUG|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
48000099|NCT06093464|OTHER|Natural Compound A (masked essential oil A)|"Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
48000100|NCT06093464|OTHER|Natural Compound B (masked essential oil B)|"Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
48000101|NCT02265822|DRUG|melatonin in children premedication|
48000102|NCT02265822|DRUG|midazolam in children premedication|
48000103|NCT01539187|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
48000104|NCT04846725|OTHER|Data collection|"Collect in medical records :~* Filter's retrieval rate~* Complications of vena cava filters~* Predictive factors of attempted inferior vena cava filters retrieval: age, the distance between the patient's home and the hospital, the indication or not given by the therapeutic medicine department, patients referred by external structures, patients whose filter was installed during the medical on-call period, the absence of a written request for filter placement, the presence of active neoplasia at the time of filter placement, a peri-surgical context."
48157699|NCT05659745|OTHER|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
48366770|NCT04084210|DEVICE|Juul Electronic cigarette|The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
48685464|NCT06005558|DRUG|Methylene Blue low dose|A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
48685465|NCT06005558|DRUG|Methylene Blue high dose|A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
48000105|NCT00870363|DRUG|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
48000106|NCT00870363|DRUG|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
48000107|NCT00870363|DRUG|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
48000108|NCT02220270|DEVICE|ASD and PDA closure|
48000109|NCT00550095|DRUG|valsartan|
48000110|NCT04264468|COMBINATION_PRODUCT|neoadjuvant chemotherapy|This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
48685466|NCT02594228|BEHAVIORAL|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
48685467|NCT02594228|BEHAVIORAL|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
48685468|NCT00091741|DRUG|Etanercept (Enbrel)|
48685469|NCT03599778|DRUG|Apatinib|XELOX + apatinib's MTD
48000111|NCT00736801|DRUG|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
48000112|NCT03447665|BEHAVIORAL|Bedtime routine|Tailored bedtime routine
48000113|NCT03447665|BEHAVIORAL|Sleep schedule|Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
48685470|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
48685471|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
48685472|NCT01795976|GENETIC|NY-ESO-1 T cells|
48685473|NCT01795976|DRUG|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
48685474|NCT01795976|DRUG|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
48685475|NCT01795976|BIOLOGICAL|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
48685476|NCT02413996|DEVICE|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
48685477|NCT02413996|BEHAVIORAL|Functional activities|Stairs, walking
48685478|NCT02413996|OTHER|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
48685479|NCT02413996|OTHER|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
48685480|NCT00620373|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
48685481|NCT00620373|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
48685482|NCT00620373|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
48685483|NCT05922228|OTHER|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
48000114|NCT03447665|BEHAVIORAL|Intervention (bedtime)|Parents implement behavioral sleep intervention at bedtime.
48000115|NCT03447665|BEHAVIORAL|Intervention (after night wakings)|Parents implement behavioral sleep intervention following each night waking.
48000116|NCT06021561|DIAGNOSTIC_TEST|Diagnosis of pain|Pain will be investigated - type, origin, level
48000117|NCT00006481|DRUG|Biafine cream|
48000118|NCT00006481|PROCEDURE|quality-of-life assessment|
48000119|NCT00006481|RADIATION|radiation therapy|
48000120|NCT04356963|BEHAVIORAL|Virtual Reality Session (VR Blu)|20-30 minute session of virtual reality immersive content.
48000121|NCT04356963|BEHAVIORAL|Tablet-based Session (Tablet Blu)|20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.
48685484|NCT05922228|OTHER|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
48685485|NCT04202068|DRUG|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
48685486|NCT01148901|DRUG|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
48685487|NCT02946177|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
48685488|NCT02946177|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
48685489|NCT03267784|BIOLOGICAL|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
48685490|NCT00042016|DRUG|decitabine (5-aza-2'deoxycytidine)|
48000122|NCT04356963|BEHAVIORAL|Use of Virtual Reality Head Mounted Display without Content (VR Blank)|20-30 minutes session using head mounted display to reduce light and sound.
48000123|NCT03371901|OTHER|Physical therapy with BFR-LLST|"The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication)."
48000124|NCT04832464|OTHER|RACE Protocol: Balance training along with resistance, aerobic and cognitive exercises.|therapy for the preservation, enhancement, or restoration of movement and physical function impaired or threatened by disease, injury, or disability that utilizes therapeutic exercise, physical modalities (such as massage and electrotherapy), assistive devices, and patient education and training.
48000125|NCT00902564|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
48366771|NCT04084210|OTHER|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
48685491|NCT04491903|PROCEDURE|REBOA|Endovascular balloon occlusion of the aorta
48685492|NCT03557957|OTHER|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
48685493|NCT03557957|OTHER|Standard care|Standard care of hyponatremia
48685494|NCT02623777|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
47914501|NCT01942733|DRUG|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
47914502|NCT03233984|BEHAVIORAL|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
48000126|NCT04605328|OTHER|Two dimension and three dimension ultrasound|Patient will undergo 2D and 3D ultrasound evaluation after CS for detection of CSD
48000127|NCT00113659|DIETARY_SUPPLEMENT|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
48000128|NCT00113659|DIETARY_SUPPLEMENT|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
48000129|NCT05696834|PROCEDURE|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst|Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
48000130|NCT03669120|OTHER|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
48000131|NCT03669120|BEHAVIORAL|Telephone-Based Intervention|Receive individualized text based messages
48000132|NCT02712944|DRUG|Testosterone|Testosterone
48000133|NCT02712944|DRUG|Saline|Placebo
48000134|NCT01675882|BIOLOGICAL|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
48157700|NCT00586807|OTHER|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
48685495|NCT02623777|DIETARY_SUPPLEMENT|Short chain fatty acids|Short chain fatty acids administered
48685496|NCT06311773|DEVICE|Boomerang Catheter|The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
48685497|NCT06375395|DEVICE|Active tACS Device|Transcranial Alternating Current Stimulation
48685498|NCT06375395|DEVICE|Sham tACS Device|Placebo Device that simulates active tACS treatment
48685499|NCT03047811|OTHER|TCR - T cell therapy|Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
48685500|NCT03896854|BIOLOGICAL|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).
48685501|NCT02487758|PROCEDURE|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
48685502|NCT02997865|BEHAVIORAL|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
48685503|NCT03183063|DEVICE|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
48685504|NCT03183063|DEVICE|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
48685505|NCT03183063|DEVICE|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
48685506|NCT02026947|DRUG|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
48685507|NCT02026947|DRUG|Placebo|
48685508|NCT00040742|DIETARY_SUPPLEMENT|ginger|Given orally
48685509|NCT00040742|OTHER|placebo|Given orally
48685510|NCT05302973|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
48685511|NCT05302973|OTHER|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
48685512|NCT05415423|BEHAVIORAL|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
48685513|NCT03545308|DRUG|Rocuronium|Dose: 1 mg/kg
47914503|NCT03214666|DRUG|GTB-3550 TriKE® Phase I|"The 1st two patients will be assigned Dose Level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~* Dose Level 1 - 5 μg/kg/day~* Dose Level 2 - 10 μg/kg/day~* Dose Level 3 - 25 μg/kg/day~* Dose Level 4 - 50 μg/kg/day~* Dose Level 5 - 100 μg/kg/day~* Dose Level 6 - 150 μg/kg/day~* Dose Level 7 - 200 μg/kg/day"
47914504|NCT03214666|DRUG|GTB-3550 TriKE® Phase II|Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
47914505|NCT04286906|OTHER|Questionnaire|MultiDimensional Profile (MDP), Anxiety-Depression Hospital Scale (HADs), Nijmegen
47914506|NCT04017845|DIAGNOSTIC_TEST|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
48000135|NCT01675882|BIOLOGICAL|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
48000136|NCT01675882|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
48000137|NCT01675882|BIOLOGICAL|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
48000138|NCT01350128|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
48512874|NCT05358509|DRUG|Ferric Sulfate|Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
48512875|NCT02353910|PROCEDURE|Ultrasound|
48512876|NCT04587999|OTHER|bladder stimulation|"The bladder stimulation technique requires the presence of 2 people:~* The child must be held by an adult (caregiver or parent) under the armpits, legs dangling.~* the first person (the investigator), performs the stimulation technique consisting of: rapid tapping (frequency of about 100 / min), over the pubic area, at the level of the bladder, alternated with external rotational movements of the pits lumbar, in the kidneys. Alternate these 2 maneuvers every 30 seconds.~* The second person starts the stopwatch at the start of the stimulation, and is about to collect the urine, 2nd jet in a sterile pot~* The maneuver ends as soon as urine is obtained, and will be stopped after 5 minutes in case of failure."
48512877|NCT04587999|OTHER|Quick wee|"The Quick wee technique requires the presence of only one person:~Stimulation of the suprapubic area by circular movements, with a cold and wet compress held by sterile forceps.~Collection of urine in a sterile container."
48512878|NCT06222320|OTHER|Kinesiotaping|Kinesiotaping will be applied to patients in this group in addition to painkillers. Kinesiotaping is a physical therapy technique used to treat muscle pain. It is performed with kinesiotaping tapes attached to the skin. These bands are removed after 4-5 days.
48512879|NCT06222320|DRUG|Painkillers|Patients in this group will be treated with painkillers consisting of paracetamol and dexketoprofen.
48512880|NCT02009592|DRUG|Rifaximin|Both arms receive Rifaximin
48512881|NCT06361719|OTHER|Experimental Group (EG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
48512882|NCT06361719|OTHER|Control Group (CG)|Starter infant formula will be administered to the participants orally, ad libtium to 6 months, after which they will transfer to a classical follow-up formula (non-trial formula) until the end of the trial (12 months of age).
48512883|NCT01654172|DIETARY_SUPPLEMENT|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is \~900mg
48512884|NCT01654172|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|
48685514|NCT02337101|OTHER|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
48000139|NCT01350128|DRUG|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
48157701|NCT02135419|DRUG|imiquimod|Applied topically
48512885|NCT02690987|DRUG|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of \~130-190 pg/mL."
48685515|NCT02337101|BEHAVIORAL|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
48685516|NCT03938987|BIOLOGICAL|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
48685517|NCT03419637|OTHER|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
48685518|NCT00175760|PROCEDURE|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
48685519|NCT05921591|DRUG|IRL201104|Lyophilised powder for reconstitution for IV dosing
48685520|NCT05921591|DRUG|Placebo|Matching placebo for IRL201104
48685521|NCT03102515|DRUG|USG-TAP block|
48512886|NCT02690987|BIOLOGICAL|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. Good Manufacturing Practice (GMP)-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of \~13-19 ng/mL."
48366772|NCT04084210|DRUG|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (\>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
48512887|NCT02690987|BIOLOGICAL|Saline|The placebo visit will involve an intravenous infusion of normal saline.
48685522|NCT03102515|DRUG|CIC|
48685523|NCT05232214|DEVICE|Biometry|Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
48685524|NCT04378101|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
48685525|NCT04206631|DRUG|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
48685526|NCT04206631|PROCEDURE|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
48685527|NCT02277574|BIOLOGICAL|AMP-110|2, 5, or 10 mg/kg
48366773|NCT04084210|OTHER|Placebo Patch|Placebo patch containing no nicotine.
48685528|NCT02277574|OTHER|Placebo|Placebo
48685529|NCT04544644|DRUG|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
48685530|NCT00092820|DRUG|MK0653, ezetimibe|
48685531|NCT00092820|DRUG|Comparator: placebo|
48685532|NCT00532311|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
48685533|NCT00532311|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
48685534|NCT04941430|DIAGNOSTIC_TEST|Magnetic Resonance Imaging using 7 Tesla MRI|Undergo 7T MRI
48366774|NCT05070182|DIAGNOSTIC_TEST|REE - Resting Energy Expenditure|"REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU."
48366775|NCT05070182|DIAGNOSTIC_TEST|Transcranial Doppler|"The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU."
48685535|NCT00521729|PROCEDURE|Exposure to Cold Temperature|
48685536|NCT00861692|DRUG|argatroban|
48685537|NCT06026605|DRUG|WTX212A|WTX212A infusion once every 21 days
48512888|NCT02982837|DRUG|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
48685538|NCT05625295|OTHER|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
48685539|NCT03835481|DRUG|BI 730357|Film-coated tablet
48685540|NCT03835481|DRUG|Placebo to match BI 730357|Film-coated tablet
48685541|NCT00783653|DRUG|Sunitinib|25 mg or 37,5 mg daily dose until DLT
48685542|NCT05677477|OTHER|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
48685543|NCT05179278|OTHER|Post-surgical nurse follow-up|Follow-up face-to-face consultation or follow-up telephone consultation a month after the intervention and telephone consultation at one year
48685544|NCT00243945|DRUG|Rotigotine|
48000140|NCT01350128|OTHER|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
48000141|NCT02410499|DRUG|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
48000142|NCT02410499|DRUG|MLN1202|MLN1202 solution for SC injection
48000143|NCT03517527|BEHAVIORAL|Exercise|
48000144|NCT06343064|DRUG|Vebreltinib|Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.
48000145|NCT06343064|DRUG|PLB1004|Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.
48000146|NCT02813603|PROCEDURE|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
48000147|NCT01253252|RADIATION|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
48000148|NCT01253252|RADIATION|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
48000149|NCT01253252|BIOLOGICAL|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
48000150|NCT00002524|BIOLOGICAL|Bleomycin Sulfate|
48000151|NCT00002524|BIOLOGICAL|Filgrastim|
48512889|NCT02982837|DRUG|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
48512890|NCT05579002|OTHER|Questionnaires and tests|"Application of three questionnaires:~1. Canadian Occupational Performance Measure (CORM),~2. a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~3. a questionnaire developed by CEREFAM~   * Two analytical and functional tests:~1) the Action Research Arm Test (ARAT) 2) modified 400-point assessment."
48685545|NCT01281384|OTHER|Advanced Imaging|
48366776|NCT05771974|DEVICE|Compression therapy using surgical gloves|Intervention group wear two-layer of normal-sized surgical gloves on both hands during chemotherapy infusion
48366777|NCT02663024|BIOLOGICAL|idursulfase beta|IV, weekly infusion for 24 weeks
48366778|NCT02663024|BIOLOGICAL|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
48685546|NCT01281384|OTHER|Standard Imaging|
48685547|NCT01906411|DIETARY_SUPPLEMENT|Dopamine depletion vs. Balanced aminoacid drink|
48685548|NCT05948527|DEVICE|high flow nasal canula|administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.
48685549|NCT02651324|DRUG|Ketamine|
48685550|NCT02651324|OTHER|Placebo|
48685551|NCT02967549|DEVICE|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
48685552|NCT02967549|DEVICE|PAV|PAV delivered by the Stephanie ventilator (Stephan)
48685553|NCT03964168|DRUG|Biologic Agent|Patients who discontinued a bioloic agent
48685554|NCT05092386|BIOLOGICAL|Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine|The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
48685555|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)|The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
48000152|NCT00002524|DRUG|Cisplatin|
48000153|NCT00002524|DRUG|Cyclophosphamide|
48366779|NCT05071742|GENETIC|2ml peripheral venous blood was collected to detect genetic genes|"Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection"
48685556|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)|The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
48685557|NCT04660695|DEVICE|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
48685558|NCT00465452|DRUG|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
48685559|NCT06291337|DRUG|Inhibition of Sweet Taste by Ibuprofen Oral Rinses|Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
48685560|NCT06291337|DRUG|Inhibition of Sweet Taste by Naproxen Oral Rinses|Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
48685561|NCT04087031|OTHER|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
48685562|NCT04087031|OTHER|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
48685563|NCT04087031|OTHER|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
48685564|NCT03419312|DEVICE|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
48685565|NCT03419312|DEVICE|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
48685566|NCT01805687|DRUG|Zileuton extended release|
48000154|NCT00002524|DRUG|Cytarabine|
48000155|NCT00002524|DRUG|Doxorubicin Hydrochloride (DOX)|
48000156|NCT00002524|DRUG|Etoposide|
48000157|NCT00002524|DRUG|Fluorouracil|
48000158|NCT00002524|DRUG|Ifosfamide|
48000159|NCT00002524|DRUG|Leucovorin calcium|
48000160|NCT00002524|DRUG|Methotrexate|
48000161|NCT00002524|DRUG|Methylprednisolone|
48366780|NCT05267327|OTHER|Verzenios|Study drug is Verzenios, it is an observational study.
48366781|NCT03301272|DRUG|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
48000162|NCT00002524|DRUG|Pentamidine|
48000163|NCT00002524|DRUG|Prednisone|
48000164|NCT00002524|DRUG|Trimethoprim-Sulfamethoxazole|
48000165|NCT00002524|DRUG|Vincristine Sulfate|
48366782|NCT03301272|OTHER|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
48685567|NCT02342860|OTHER|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package."
48685568|NCT04797689|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
48685569|NCT04797689|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
48685570|NCT04695470|DRUG|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
48685571|NCT03499860|DIAGNOSTIC_TEST|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
48685572|NCT02075294|DRUG|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
48685573|NCT02761473|OTHER|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
48685574|NCT02761473|OTHER|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
48685575|NCT00005987|DRUG|carmustine|
48685576|NCT00005987|DRUG|cyclophosphamide|
48685577|NCT00005987|DRUG|dexamethasone|
48685578|NCT00005987|DRUG|etoposide|
48685579|NCT00005987|DRUG|filgrastim|
48685580|NCT00005987|DRUG|mitoxantrone hydrochloride|
48685581|NCT00005987|DRUG|recombinant interferon alfa|
48685582|NCT00005987|DRUG|sargramostim|
48685583|NCT00005987|PROCEDURE|bone marrow ablation with stem cell support|
48685584|NCT00005987|PROCEDURE|peripheral blood stem cell transplantation|
48685585|NCT00005987|PROCEDURE|radiation therapy|
48685586|NCT00636103|DRUG|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
48685587|NCT00636103|OTHER|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
48685588|NCT03765216|DRUG|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
48685589|NCT03765216|DRUG|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
48685590|NCT04454320|OTHER|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
48685591|NCT01642056|DRUG|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
48000166|NCT00002524|DRUG|Zidovudine (AZT)|
48000167|NCT00002524|RADIATION|Radiation Therapy|
48685592|NCT01642056|DRUG|Placebo|
48685593|NCT04550780|DRUG|Mepolizumab|The first administration of mepolizumab.
48685594|NCT06333002|OTHER|machine learning analysis|We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.
48685595|NCT00625391|DRUG|Placebo|500 mg medicinal starch pills daily
48685596|NCT00625391|DRUG|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
48685597|NCT00625391|DRUG|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
48685598|NCT00625391|DRUG|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
48685599|NCT05828615|OTHER|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
48000168|NCT01010048|DRUG|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
48000169|NCT02612532|DEVICE|ReCIVA breath sampler|Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
48000170|NCT01895738|BEHAVIORAL|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
48512891|NCT03229200|DRUG|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
48157702|NCT02135419|DRUG|fluorouracil|Applied topically
48685600|NCT05828615|OTHER|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
48000171|NCT02416427|DRUG|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
48157703|NCT02135419|DEVICE|infrared photocoagulation therapy|Undergo infrared coagulation
48000172|NCT04991571|DRUG|Zibotentan (Treatment A)|Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
48000173|NCT04991571|DRUG|Dapagliflozin (Treatment A)|Dapagliflozin tablet will be administered orally as single dose in Part 2.
48000174|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
48000175|NCT04991571|DRUG|Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)|Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
48000176|NCT05531435|DRUG|local anaesthetic injection|Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
48157704|NCT02135419|DEVICE|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
48685601|NCT04918381|DEVICE|CellFX System|Nano-Pulse Stimulation (NPS)
48000177|NCT01212718|DRUG|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
48000178|NCT01212718|DRUG|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
48000179|NCT05300490|DRUG|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
48618131|NCT06358833|PROCEDURE|Endodontic activation (EA)|the irrigation of root canals will be done with 2.5% sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The irrigant will be activated with ultrasonic energy using the Endo-1 Ultrasonic Endo Activator (Guilin Woodpecker, Guilin, China). The tip of the Endo-1 Ultrasonic Endo Activator device will be pre-measured and kept within 1 mm from the working length. The manufacturer's instructions regarding irrigant activation will be followed.
48618132|NCT02818673|RADIATION|labelled human serumalbumin (125-I, Séralb®CisBio)|Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
48685602|NCT01458548|DRUG|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
48685603|NCT01458548|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
48685604|NCT01673854|DRUG|Ipilimumab|
48157705|NCT02135419|DEVICE|laser therapy|Undergo laser therapy
48157706|NCT02135419|OTHER|clinical observation|Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies
48157707|NCT02135419|OTHER|laboratory biomarker analysis|Correlative studies
48157708|NCT01545999|OTHER|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
48157709|NCT00083122|DRUG|cisplatin|Given IV
48157710|NCT00083122|DRUG|alvocidib|Given IV
48157711|NCT00083122|DRUG|cisplatin/flavopiridol|Given IV
48157712|NCT03759405|BIOLOGICAL|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
48000180|NCT03335982|PROCEDURE|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
48000181|NCT03828799|COMBINATION_PRODUCT|Folfirinox + regorrafenib|folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
48157713|NCT04335383|BIOLOGICAL|Isolation of anti-Pseudomonas antibodies from type B lymphocytes|Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
48157714|NCT04049578|DRUG|Balovaptan|Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
48157715|NCT03533803|DRUG|Indomethacin 100Mg Suppository|Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
48685605|NCT01673854|BIOLOGICAL|Vemurafenib|
48685606|NCT02423525|DRUG|Afatinib|
48685607|NCT02151903|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
48685608|NCT01682317|BEHAVIORAL|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, \< 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
48685609|NCT00739310|DEVICE|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
48685610|NCT00298441|DRUG|chondroitin sulfate-iron colloid|
48685611|NCT00633178|BEHAVIORAL|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
48685612|NCT00633178|BEHAVIORAL|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
48685613|NCT02149355|OTHER|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
48157716|NCT03533803|PROCEDURE|IVF/ICSI|patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
48157717|NCT06195150|OTHER|Blood collection|15ml of blood are harvested before surgery
48685614|NCT01489501|PROCEDURE|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
48685615|NCT05889780|OTHER|Food pantry referrals|Clients receive food for up to 21 meals per person in the household each month.
48685616|NCT05889780|OTHER|No-prep, ready-to-eat meals|12 nutritious no-prep, ready-to-eat meals are provided each month.
48685617|NCT05889780|OTHER|Vouchers|A $75 voucher is provided each month and participants are instructed to use the voucher to purchase food or transportation to food retailers.
48685618|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
48685619|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
48685620|NCT04405999|DRUG|Bromhexine Hydrochloride|Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
48000182|NCT04843709|DRUG|MRG004A|Administrated intravenously
48000183|NCT03468881|OTHER|Communication Skills Training Package (KEW)|A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
48000184|NCT01869192|DRUG|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
48000185|NCT01869192|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
48000186|NCT01869192|DRUG|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
48000187|NCT01869192|DRUG|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
48000188|NCT01869192|RADIATION|Radiation Therapy|Standard dosing, fields depending on clinical findings
48157718|NCT02596542|OTHER|Water immersion|Different temperatures of cold water immersion will be assessed
48157719|NCT03023878|DRUG|Blinatumomab|Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
48157720|NCT03023878|DRUG|Investigator's Choice Chemotherapy|"During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide)."
48157721|NCT03023878|DRUG|Dexamethasone|Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
48157722|NCT01854164|DIETARY_SUPPLEMENT|HGE (hydrolyzed ginseng extract)|
48157723|NCT01854164|DIETARY_SUPPLEMENT|Placebo|
48685621|NCT05360251|DEVICE|PDL(595nm)|One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.
48685622|NCT05360251|DEVICE|IPL(DPL)|One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.
48685623|NCT05360251|DEVICE|IPL(M22 590)|One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
48685624|NCT05360251|DEVICE|IPL(M22 vascular)|One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
48366783|NCT01467817|BEHAVIORAL|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
48000189|NCT05349149|DRUG|Tocilizumab/Actemra® (Roche)|The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
48157724|NCT06320509|BIOLOGICAL|Continuous measurement of uPO2 (both groups)|uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.
48366784|NCT01467817|BEHAVIORAL|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
48366785|NCT01522391|DRUG|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
48366786|NCT01522391|DRUG|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
48366787|NCT02939508|OTHER|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
48366788|NCT02939508|OTHER|Non-colon originated: Neostigmin, Colonoscopy decompression|
48157725|NCT00653419|DRUG|buspirone HCl|Tablets, 30 mg, single-dose
48685625|NCT06043180|PROCEDURE|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
48685626|NCT04833660|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
48685627|NCT06323850|BEHAVIORAL|Intervention Phase|After participants have been enrolled, they will be assigned to one of the trainer-pairs and will work with them to schedule the first two sessions. Most clients will be able to schedule one virtual session per week and one ride along session per week for the first five weeks, with the remaining three weeks allotted to practice ride-along sessions and module repetition (as needed). The additional time also provides a buffer if subjects are unavailable for a week during the intervention phase.
48685628|NCT06323850|BEHAVIORAL|Virtual Training Sessions|Virtual sessions will take place over Zoom each session lasting 20-30 minutes. Each of the five virtual sessions will be aligned with the five online modules. For each module, exercises are built in to test comprehension. If the participant does not complete an exercise accurately, the lead trainer will explain why the response was incorrect and prompt them to repeat the video modeling exercise. The support training partner will take notes to support the formative assessment process and complete fidelity checks.
48685629|NCT06323850|BEHAVIORAL|Ride-Along Training Sessions|The first ride-along session will be the baseline session for assessing level of independence (number of cues needed) and safety. The participant will have up to 8 ride-along sessions to reach full independence (no cues needed) and full marks on the safety assessment. The lead trainer will provide the cues as needed to complete each step of the Rideshare process.
48685630|NCT03551834|OTHER|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
48685631|NCT03551834|OTHER|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
48685632|NCT04661111|DEVICE|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
48685633|NCT02662426|DRUG|Lingdancao granules|4 packs per time (3g/pack), three times per day
48685634|NCT02662426|DRUG|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
48685635|NCT02662426|DRUG|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
48685636|NCT02662426|DRUG|analogous Lingdancao granules|4 packs per time, three times per day
48685637|NCT01754246|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
48685638|NCT00703846|DRUG|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
48685639|NCT06137885|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
48366789|NCT00689299|BIOLOGICAL|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
48685640|NCT06137885|OTHER|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
48157726|NCT00653419|DRUG|Buspar|Tablets, 30 mg, single-dose
48157727|NCT05118737|DRUG|Colchicine|colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
48157728|NCT02045745|BIOLOGICAL|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
48157729|NCT02453971|OTHER|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
48366790|NCT00689299|BIOLOGICAL|Placebo|Placebo Sublingual Drops
48366791|NCT02650518|OTHER|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
48366792|NCT02650518|DEVICE|Catheter Change|Urinary catheter change once randomization is complete.
48685641|NCT06137885|OTHER|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
48000190|NCT05349149|DRUG|Saline 9%|The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
48000191|NCT01538862|DRUG|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
48000192|NCT00423306|DRUG|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
48000193|NCT02815228|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-034)
48685642|NCT06137885|OTHER|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
48685643|NCT05965245|BEHAVIORAL|Suubi-Mhealth|Suubi-Mhealth is a theoretically-based digital therapeutics tool that aims to provide educational content on depression while considering the unique needs of SSA youth living with HIV. This educational content will be aligned with scientific recommendations for cognitive-behavioral therapy for adherence and depression as applied to HIV medication adherence. Core instruction will include psychoeducation on the interplay between HIV and depression; minimizing cognitive distortions related to ART adherence and stigma, as well as depression; challenging negative automatic thoughts; analysis and development of behavioral skills; reducing environmental stressors. Suubi-Mhealth will also have a social networking center in which patients can contact the research team, peers who are also taking part in this intervention, and other trusted individuals such as loved ones. Other features include tools for setting and monitoring goals, and a clinical management dashboard for the research team.
48685644|NCT02108756|DRUG|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
48000194|NCT04529889|OTHER||
48685645|NCT02108756|DRUG|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
48685646|NCT04338607|PROCEDURE|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
48685647|NCT04338607|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
48000195|NCT00046332|DRUG|GW810781|
48000196|NCT02886377|BIOLOGICAL|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
48000197|NCT02166489|BIOLOGICAL|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
48000198|NCT01659112|OTHER|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
48000199|NCT01659112|OTHER|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
48000200|NCT02264002|DRUG|Cilobradine low dose 1|
48157730|NCT05789927|PROCEDURE|Assessment of the microbial exposome|The assessment of the microbial exposome will be carried out by the deployment of 4 dust collectors (1 per season) at the patient's home. The evaluation of the endogenous myco-microbiome will be carried out by analyzing patient sputum obtained during follow-up visits or during routine care in the event of an exacerbation.
48157731|NCT05291962|OTHER|Retrospective observational study|Data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed.
48157732|NCT03715634|DRUG|INDV-6200|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
48000201|NCT02264002|DRUG|Cilobradine low dose 2|
48000202|NCT02264002|DRUG|Cilobradine medium dose|
48000203|NCT02264002|DRUG|Cilobradine high dose 1|
48000204|NCT02264002|DRUG|Cilobradine high dose 2|
48000205|NCT02264002|DRUG|Metoprolol succinate tablets|
48000206|NCT02264002|DRUG|Placebo|
48000207|NCT02242357|DRUG|Micardis®|
48000208|NCT02242357|DRUG|Micardis® Plus|
48000209|NCT05805761|PROCEDURE|Conventional Treatment|A bicarbonate jet will be used to remove the biofilm from the surface of the teeth.
48685648|NCT01930604|DRUG|Botox (onabotulinumtoxinA)|
48685649|NCT01930604|DRUG|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
48000210|NCT05805761|PROCEDURE|Antimicrobial Photodynamic Therapy|aPDT will be performed before each cleaning/prophylaxis session, only in one of the groups. Participants will swish with the photosensitizer erythrosine for 1 min of pre-irradiation time, so that the drug can stain all the bacterial biofilm. The D-2000 LED (DMC) will be applied, emitting at a wavelength of ʎ = 430-490 nm and 900-1100 mW/cm2. Irradiation will be performed until the biofilm of the cervical region is illuminated for 2 min per point. Each irradiation point will be approximately 0.4 cm2.
48685650|NCT01930604|DRUG|NaCl (placebo)|
48685651|NCT01485276|PROCEDURE|DBS Surgery|
48685652|NCT01104545|DRUG|MK-3614|
48685653|NCT01104545|DRUG|Comparator: Placebo|
48685654|NCT03689608|OTHER|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
48685655|NCT03689608|OTHER|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
48685656|NCT03689608|OTHER|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
48685657|NCT03915990|DIAGNOSTIC_TEST|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
48685658|NCT03060915|DEVICE|Polysomnography|Patient's undergo a polysomnography
48000211|NCT05603416|DIETARY_SUPPLEMENT|Perilla frutescens extract|oral dissolvable powder - dosage 300mg
48000212|NCT05603416|DIETARY_SUPPLEMENT|Placebo|oral dissolvable powder - dosage 300mg no active ingredient
48000213|NCT04663555|DRUG|Dexamethasone|Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.
48000214|NCT03509675|DRUG|Ibuprofen suspension 5mg/100ml|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
48000215|NCT03509675|DRUG|Placebos|Placebo
48685659|NCT03060915|DEVICE|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
48685660|NCT05545787|PROCEDURE|Cold snare endoscopic mucosal resection|During CS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The polyp and 1-2mm of surrounding mucosa will then be closely snared and transected mechanically.
48685661|NCT05545787|PROCEDURE|Hot snare endoscopic mucosal resection|During HS-EMR, methylene blue-tinted epinephrine saline will be injected into the submucosal space around the lesion to lift the lesion. The snare will be placed around the lesion, and then cautery will be applied using the electrosurgical generator.
48685662|NCT01720875|DRUG|Vorinostat Velcade Dexamethasone|
48685663|NCT04362800|OTHER|MRI|MRI at baseline and J90
48685664|NCT04362800|OTHER|Electro-Encephalography-High Density|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
48685665|NCT04362800|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
48685666|NCT04362800|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
48685667|NCT04221503|DRUG|Niraparib|Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
48685668|NCT04221503|DEVICE|Optune|"Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells."
48685669|NCT04221503|PROCEDURE|Planned surgical resection|Surgery of supratentorial glioblastoma (GBM).
48685670|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
48685671|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
48685672|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
48685673|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
48685674|NCT01608737|DRUG|BI 201335|BI 201335 once daily low dose for 24 weeks
48685675|NCT03576781|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
48000216|NCT00620438|DRUG|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
48000217|NCT00620438|DRUG|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
48000218|NCT00620438|DRUG|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
48000219|NCT02493699|OTHER|physical exercise- based intervention (Karate techniques training)|
48685676|NCT03576781|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
48685677|NCT03576781|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
48685678|NCT03576781|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
48000220|NCT05434806|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daly oral intake
48000221|NCT05225558|DRUG|Delpazolid|BID, PO
48000222|NCT05225558|DRUG|Vancomycin|IV infusion per 2020 IDSA guideline
48685679|NCT02944721|GENETIC|Genetical analyses|
48685680|NCT02944721|OTHER|Chronic pain identification questionnaires|
48685681|NCT02944721|OTHER|Neurophysiological and psychophysical evaluations|
48685682|NCT02944721|OTHER|Quality of life questionnaires|
48000223|NCT05225558|DRUG|Placebo of Delpazolid|BID, PO
48000224|NCT00854581|BIOLOGICAL|PEG-interferon alfa-2b|Administered subcutaneously.
48000225|NCT00854581|BIOLOGICAL|Interferon alfa-2b|Administered intravenously.
48000226|NCT00854581|DRUG|Valproic Acid|Administered orally.
48000227|NCT00854581|DRUG|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
48000228|NCT05851105|BIOLOGICAL|α-globin restored autologous hematopoietic stem cells|α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C
48000229|NCT04396093|BEHAVIORAL|psychological support|specific questionnaires administration: EORTC QLQ 30, EORTC- PAN 26, HADS, Millon Clinical Multiaxial Inventory
48000230|NCT05128851|PROCEDURE|HTO|Hight Tibial Osteotomy
48000231|NCT05128851|PROCEDURE|Arthroscopy treatment|Arthroscopy treatment
48000232|NCT05128851|PROCEDURE|Micro fractures|Micro fractures
48000233|NCT05179421|DRUG|Low dose oxytocin|10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
48000234|NCT05179421|DRUG|High dose oxytocin|10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
48000235|NCT02492529|OTHER|Neuropsychological tests|"Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood"
48000236|NCT02492529|DEVICE|A cranial MRI|
48000237|NCT02492529|OTHER|Experimental procedure|
48000238|NCT00000833|DRUG|Ribavirin|
48000239|NCT00000833|DRUG|Didanosine|
48000240|NCT03899948|BEHAVIORAL|Teacher Anxiety Program for Elementary Students|TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
48000241|NCT03899948|BEHAVIORAL|Teacher Anxiety Training|The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
48000242|NCT02526069|BEHAVIORAL|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
48000243|NCT05695716|DEVICE|CSI pVAD System|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
48000244|NCT02124863|DEVICE|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
48000245|NCT06377397|DRUG|Antibiotics|"In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment"
48000246|NCT03784573|BEHAVIORAL|Dog + handler|Dog + handler
48000247|NCT03784573|BEHAVIORAL|No dog|No dog
48000248|NCT05825898|PROCEDURE|Surgery or Transcatheter tricuspid valve intervention|Isolated tricuspid valve surgery or Transcatheter tricuspid valve intervention
48000249|NCT00834210|DRUG|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
48000250|NCT00834210|DRUG|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
48000251|NCT05904457|DRUG|bevacizumab|Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.
48000252|NCT05904457|DRUG|erlotinib|Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.
48000253|NCT02598180|DEVICE|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
48000254|NCT04884685|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
48000255|NCT04884685|BIOLOGICAL|Placebo|aluminium hydroxide solution only
48000256|NCT06050551|PROCEDURE|uniportal VATS|"1. elective uniportal VATS lung resection, pleural tumor removal or mediastinal lymph node biopsy, etc.~   (exclude the bil. operation, extended wound length over 5 cm, conversion to thoracotomy or multiportal VATS procedure, surgeon's decision for exclusion during operation.)~2. thoracoscopic internal costal nerve block with 10 mL of 1% Ropivacaine at the end of the operation,~3. routinely prescribed with oral Tramadol 37.5mg and Acetaminophen 325mg four times a day postoperatively and intravenous morphine as extra dose if need."
48157733|NCT03715634|DRUG|Placebo|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
48157734|NCT03715634|DRUG|SL Buprenorphine|All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
48157735|NCT03715634|DRUG|Nalorex|Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
48157736|NCT05538156|PROCEDURE|Control group|Vitrectomy and gas tamponade without internal limiting membrane peeling
48157737|NCT05538156|PROCEDURE|Intervention group|Vitrectomy, internal limiting membrane peeling and gas tamponade
48685683|NCT01527877|DRUG|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
48685684|NCT01453491|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
48685685|NCT02446769|DEVICE|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
48685686|NCT03501901|DIAGNOSTIC_TEST|Antibiotic susceptibility test|
48685687|NCT01407952|DEVICE|HydroCoil Embolic System|HydroCoil Embolic System
48685688|NCT01407952|DEVICE|Control (bare platinum coils)|bare platinum coils
48685689|NCT05266846|DRUG|Pembrolizumab injection|Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
48685690|NCT02872597|DRUG|Ipratropium|
48685691|NCT02872597|DRUG|0.9% Sodium Chloride|
48685692|NCT02872597|DRUG|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
48685693|NCT02872597|DRUG|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
48685694|NCT00326001|DEVICE|Gold tip catheter|Radiofrquency ablation using gold tip catheter
48685695|NCT00326001|DEVICE|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
48685696|NCT01174979|DRUG|Caroverin|treatment with eardrops 2 times for 48 hours
48685697|NCT00119028|PROCEDURE|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
48685698|NCT02406573|DEVICE|Crest® Sensi-Stop™ Strips|
48685699|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids Supplementation|
48685700|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
48685701|NCT05754411|DRUG|[14C]STI-1558|Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
48685702|NCT01489865|DRUG|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
48685703|NCT00130104|PROCEDURE|Transthecal Metacarpal Block|
48685704|NCT01894724|DEVICE|NeuroSave device|
48685705|NCT00582712|DRUG|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
48685706|NCT06400823|OTHER|VR+TENS|"During the invention, patients will be in VR scenarios and play task-oriented games, interacting with elements that appear in the virtual world, to improve mobility and functional independence of the upper limbs.~The task-oriented games will target different components depending on the disability of the patient."
48157738|NCT02039596|OTHER|Diet|
48685707|NCT06400823|OTHER|Conventional rehabilitation|Patients will perform conventional upper-limb stroke rehabilitation. The movement performed will be comparable with the movement performed in the VR+TENS group
48685708|NCT05551351|DIAGNOSTIC_TEST|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
48685709|NCT01344486|PROCEDURE|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
48685710|NCT01344486|PROCEDURE|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
48157739|NCT01309555|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
48157740|NCT05951777|BIOLOGICAL|Autologous HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
48685711|NCT03137680|BEHAVIORAL|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
48685712|NCT04868097|PROCEDURE|cervix biopsy|large loop electrosurgical cervix biopsy
48685713|NCT01229683|PROCEDURE|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
48000257|NCT06416696|DRUG|Toripalimab|"1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration."
48000258|NCT03549702|DRUG|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
48000259|NCT01660412|DRUG|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40.
48000260|NCT01660412|DRUG|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
48000261|NCT00682188|BEHAVIORAL|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
48000262|NCT00682188|BEHAVIORAL|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
48000263|NCT04216927|DRUG|Nitric Oxide|gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
48000264|NCT04216927|DRUG|Oxygen|Oxygen alone will be entrained for placebo arm
48000265|NCT02603835|DEVICE|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
48685714|NCT05689489|OTHER|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
48000266|NCT04146064|OTHER|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
48000267|NCT00847444|DRUG|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
48000268|NCT00847444|BEHAVIORAL|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
48000269|NCT04210752|DRUG|Treatment 1 (EG-HZ-001)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
48157741|NCT05951777|DRUG|Normal Saline|Sterile Saline Solution 0.9%
48685715|NCT05689489|OTHER|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
48157742|NCT04968314|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program (ChiPP) is a 12-session group-based parenting skills program
48000270|NCT04210752|DRUG|Treatment 2 (EG-HZ-002)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
48512892|NCT04314895|DRUG|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
48512893|NCT03962283|DRUG|Rifaximin|Rifaximin 200mcg four times daily
48512894|NCT03962283|DRUG|Placebo oral tablet|Placebo Rifaximin four times daily
48685716|NCT01555996|BEHAVIORAL|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
48685717|NCT01555996|BEHAVIORAL|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
48685718|NCT04152954|DEVICE|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
48685719|NCT01465880|OTHER|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
48000271|NCT04210752|DRUG|Treatment 3 (EG-HZ-003)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
48157743|NCT04291716|DEVICE|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
48157744|NCT06584591|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and the transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
48157745|NCT06584591|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training administered by the Physical therapist.
48157746|NCT04920045|OTHER|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
48157747|NCT04486742|BEHAVIORAL|Itch CBT|Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
48157748|NCT00043368|DRUG|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
48157749|NCT05401149|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
48157750|NCT01702155|DRUG|DFP-10917|
48157751|NCT03296176|BIOLOGICAL|blood sample|blood sample for metabolome analyse
48512895|NCT01966250|DEVICE|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
48157752|NCT03928171|OTHER|Intra-abdominal pressure during laparoscopy|Insufflation pressure of the abdomen during laparoscopy
48685720|NCT04599491|DEVICE|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
48618133|NCT02818673|RADIATION|labelled albumin (99m-Tc, Vasculocis®, Cisbio)|intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
48000272|NCT04210752|DRUG|Treatment 4 (EG-HZ-004)|"Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection"
48000273|NCT04210752|DRUG|Treatment 5|"Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection"
48000274|NCT00542919|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
48000275|NCT01986868|OTHER|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
48000276|NCT00446147|DRUG|Pyridoxine|100mg BID/daily, Per oral
48000277|NCT00446147|DRUG|Placebo|placebo 100mg BID/daily, Per oral
48000278|NCT02419118|DRUG|Daratumumab|Treatment of myeloma patients with Daratumumab
48000279|NCT02419118|DRUG|Lenalidomide|Treatment of myeloma patients
48000280|NCT02419118|DRUG|Dexamethasone|Treatment of myeloma patients
48000281|NCT06447844|DEVICE|OsteoGen Plug|OsteoGen® Plug is contoured to fill the three roots of the socket. Plug is delivered dry into a thoroughly debrided and actively bleeding socket. The OsteoGen® Plug is condensed firmly into the socket.
48000282|NCT06447844|DEVICE|BioGide|BioGide is a resorbable collagen membrane
48000283|NCT02353247|DRUG|Norethindrone acetate|
48000284|NCT03513484|DRUG|Azacitidine|Given IV or SC
48000285|NCT03513484|OTHER|Laboratory Biomarker Analysis|Correlative studies
48000286|NCT03513484|DRUG|Nintedanib|Given PO
48000287|NCT01859507|DRUG|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
48000288|NCT04489706|DRUG|Arsenic trioxide for injection|Arsenic trioxide for injection, 0.16 mg/kg (maximum single dose is 10 mg), daily IV drip, d1 to d14, once every 28 days, for six cycles of treatment or until one of the following events occurs: Initiation of new anti-tumor therapy, disease progression, withdrawal of Informed consent form (ICF) and/or death.
48000289|NCT03388138|COMBINATION_PRODUCT|etafilcon A with ketotifen|Etafilcon A with ketotifen
48000290|NCT03388138|DEVICE|1-Day ACUVUE|1-Day ACUVUE
48000291|NCT06407089|OTHER|Spinertial Group|"Endurance training program of deep cervical flexors and deep cervical extensors with Spinertial device for treatment.~Endurance training program of deep cervical flexors and deep cervical flexors with Spinertial device for treatment."
48000292|NCT06338345|DIAGNOSTIC_TEST|Therapeutic drug monitoring of beta-lactam|During the 24 first hours after inclusion, 5 blood samples will be collected to mesure plasmatic concentrations of the studied beta-lactam, of creatinin and of albumin
48000293|NCT03553732|OTHER|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
48000294|NCT01220479|BEHAVIORAL|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive."
48000295|NCT01234233|PROCEDURE|duration of preoperative active warming|"duration of prewarming by forced air warming"
48000296|NCT02064907|DRUG|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
48157753|NCT01690871|DRUG|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
48618134|NCT00010998|PROCEDURE|Yoga|
48000297|NCT02064907|DRUG|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
48000298|NCT01591473|DRUG|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
48000299|NCT01591473|DRUG|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
48000300|NCT01591473|DRUG|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
48000301|NCT01591473|DRUG|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
48000302|NCT01591473|DRUG|Placebo|Placebo; 3 doses; nasal administration every 28 days
48000303|NCT01591473|DRUG|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
48000304|NCT04895592|DRUG|Dexamethasone|Given PO or IV
48000305|NCT04895592|PROCEDURE|Resection|Undergo surgical resection
48157754|NCT06646250|DEVICE|NeoDoppler - CE certified|The NeoDoppler is small and light weighed constructed as a single element transducer, that can be gently fixed over the fontanelle. The system is fully compatible for cooccurring use with other intensive care equipment for neonates as well as caregiving from the parents. It is capable of measuring cerebral blood flow at different depths of the brain simultaneously. The Doppler velocity measurements arise from a cylindrical volume of tissue. It is therefore less sensitive to the exact position and angle of the probe over the fontanel to target the vessels of interest than standard hand-held Doppler. This means that the NeoDoppler system may be placed by healthcare professionals who do not have specialized training performing diagnostic ultrasound exams of the cerebral vasculature in neonates.
48157755|NCT03520790|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
48000306|NCT04895592|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48000307|NCT02808286|BEHAVIORAL|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
48157756|NCT03520790|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
48000308|NCT02808286|BEHAVIORAL|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
48000309|NCT03696433|DIETARY_SUPPLEMENT|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
48000310|NCT03696433|DIETARY_SUPPLEMENT|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
48000311|NCT01530321|OTHER|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
48000312|NCT01530321|OTHER|Light Massage|5 minutes of light pressure massage to the neck and upper back
48000313|NCT03811756|DIETARY_SUPPLEMENT|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
48000314|NCT03811756|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
48000315|NCT00365196|BEHAVIORAL|CBT Hostility Reduction Program|
48000316|NCT04675216|PROCEDURE|Posterior fossa intracranial pressure measurement|Measurement of posterior fossa pressure in an invasive way
48000317|NCT03184181|OTHER|EPTE® group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
48000318|NCT03184181|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
48000319|NCT05742451|OTHER|kids yoga|"The kids yoga was applied to the intervention group for 8 weeks, once a week (8 sessions), 40 minutes per session, by a yoga instructor occupational therapist.~Kids yoga training included: 5-minute warm-up consisting of jogging, jumping, stretching, relaxation exercises; 20 minutes of asanas (positions) consisting of standing, sitting, prone, supine postures and pranayamas (breathing exercises) consisting of vigorous inspiration and expiration, slow and rhythmic alternating nostril breathing; 10-minute yogic games about balance, reaction time and agility; meditation with focus for 5 minutes with resuscitation techniques."
48000320|NCT05735561|DIAGNOSTIC_TEST|X-Ray|Consenting participants will be asked to come into the clinic for a single visit, during this visit they will be asked to complete an x-ray to check for evidence of avascular necrosis.
48157757|NCT03520790|DRUG|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
48157758|NCT03520790|OTHER|Placebo|Placebo
48157759|NCT04380688|DRUG|Acalabrutinib|Acalabrutinib administered orally
48685721|NCT04599491|DEVICE|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
48000321|NCT02488681|DEVICE|Micra Pacemaker Implant|
48000322|NCT03886558|OTHER|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
48000323|NCT00549562|DRUG|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
48000324|NCT06287346|DEVICE|dental implant|ceramic dental implant
48000325|NCT03592147|OTHER|Guided Imagery Relaxation Tape|The meditation is approximately 7 minutes in duration.
48157760|NCT00884793|DRUG|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
48157761|NCT00884793|DRUG|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
48157762|NCT00884793|DRUG|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
48157763|NCT06275906|OTHER|Mediterranean diet and moderate intensity physical exercise (outdoor walking).|Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
48157764|NCT05852171|DRUG|Baricitinib|Baricitinib administered orally
48157765|NCT05872906|DEVICE|Acupuncture|A 1.5-inch needle of 34 gauge (CASOON stainless steel acupuncture needles) is inserted. The physician will then locate the de qi location of the test subjects and elicit a de qi response accompanied by muscle twitch.
48000326|NCT03592147|OTHER|Music Listening|Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.
48000327|NCT03592147|OTHER|Relaxation Lighting|The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.
48000328|NCT03592147|OTHER|Meditation and Relaxation Light|The guided imagery meditation and relaxation lighting were combined.
48157766|NCT00524693|DRUG|Montelukast|4mg sachets
48157767|NCT00524693|DRUG|Placebo granules|
48685722|NCT02176200|DRUG|Berodual® Respimat®, low inspiratory flow rate|
48000329|NCT03592147|OTHER|Music and Relaxation Light|The music and relaxation lighting were combined.
48157768|NCT05306223|DRUG|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
48512896|NCT01966250|DEVICE|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
48618135|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period."
48685723|NCT02176200|DRUG|Berodual® Respimat®, medium inspiratory flow rate|
48000330|NCT03592147|OTHER|Control/Silence|The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
48000331|NCT02658136|OTHER|Cardiac Computed tomography|
48000332|NCT06386614|OTHER|Routine treatment|Both groups were given routine treatment
48157769|NCT05306223|DRUG|Levofloxacin|Levofloxacin filmcoated will be administered orally
48157770|NCT05306223|DRUG|Linezolid|Linezolid tablets will be administered orally
48157771|NCT05306223|DRUG|Cycloserine|Cycloserine capsules will be administered orally.
48685724|NCT02176200|DRUG|Berodual® Respimat®, high inspiratory flow rate|
48685725|NCT02176200|DRUG|Berodual® HFA-MDI, low inspiratory flow rate|
48685726|NCT02176200|DRUG|Berodual® HFA-MDI, medium inspiratory flow rate|
48685727|NCT02176200|DRUG|Berodual® HFA-MDI, high inspiratory flow rate|
48685728|NCT00255723|DRUG|carboplatin|Given IV
48685729|NCT00255723|DRUG|etoposide|Given IV
48685730|NCT00255723|DRUG|ifosfamide|Given IV
48685731|NCT02110433|DEVICE|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
48000333|NCT06386614|OTHER|Transcranial Direct Current Stimulation|The common group routine training used sham TDCS stimulation, and the experimental group used real TDCS stimulation
48000334|NCT03960151|DRUG|Rolapitant|Rolapitant 180mg PO, Days 1 and 5
48685732|NCT02110433|DEVICE|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
48685733|NCT02110433|DEVICE|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
48685734|NCT00847899|DRUG|AR9281|AR9281 taken in BID dosing regimen for 28 days
48685735|NCT00847899|DRUG|AR9281|AR9281 taken in TID dosing regimen for 28 days
48157772|NCT05306223|DRUG|Clofazimine|Clofazimine capsules will be administered orally.
48157773|NCT05306223|DRUG|Pyrazinamide|Pyrazinamide tablets will be administered orally.
48157774|NCT05306223|DRUG|Protionamide|Protionamide enteric-coated tablets will be administered orally.
48618136|NCT02096913|DRUG|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment."
48618137|NCT04740853|BEHAVIORAL|Sensory Integration Therapy+Special Education|Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
48000335|NCT03960151|DRUG|Palonosetron|Palonosetron 0.25 mg IV, Days 1,3, and 5.
48000336|NCT03960151|DRUG|Olanzapine|Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
48000337|NCT03960151|DRUG|Dexamethasone|Dexamethasone 20 mg AM, Days 1,2 and 3
48000338|NCT03228004|BEHAVIORAL|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
48000339|NCT05401955|OTHER|Physical exercise|An adapted physical exercise protocol
48000340|NCT05446883|DRUG|QL1706|Intravenous Infusion
48000341|NCT05446883|DRUG|Placebo|Intravenous Infusion
48000342|NCT05446883|DRUG|Paclitaxel injection|Intravenous Infusion
48000343|NCT05446883|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
48000344|NCT02174458|PROCEDURE|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
48000345|NCT04649164|BEHAVIORAL|Peer mentor support and caregiver intervention|Sixteen-week modular curriculum with printed/online workbook, additional resources, and weekly phone discussion with Lewy Body Dementia peer mentor.
48000346|NCT04649164|OTHER|Focus group to provide feedback on educational materials and mentoring program|Participation in a 2-3 hour focus group to review pilot and revised materials and provide feedback
48000347|NCT02996864|OTHER|Healthy Detours App|"The app features:~* Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~* User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~* Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
48000348|NCT02996864|OTHER|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
48000349|NCT03283020|DRUG|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
48000350|NCT03283020|DRUG|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
48157775|NCT00070161|DIETARY_SUPPLEMENT|EGb761|
48157776|NCT00070161|DRUG|donepezil hydrochloride|
48157777|NCT00070161|PROCEDURE|cognitive assessment|
48157778|NCT02332434|OTHER|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
48157779|NCT06107205|DRUG|TTYP01|1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
48157780|NCT06107205|DRUG|Radicava|1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
48157781|NCT06107205|DRUG|Radicava ORS|1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
48618138|NCT02749734|PROCEDURE|Subretinal transplantation|Transplant hESC-RPE into subretinal space of patients with macular degeneration
48618139|NCT06092151|DEVICE|Silver diamine fluoride|silver diamine fluoride - maximum 1 drop to be applied per visit (manufacturer advises this would treat up to 5 teeth)
48618140|NCT06092151|PROCEDURE|Usual dental care|Usual restorative or preventative care determined by the child's dentist - for examples fillings or crowns
48618141|NCT03821597|PROCEDURE|Sequential compression devices (SCDs)|Application of sequential compression devices in surgery.
48685736|NCT00847899|DRUG|Placebo|Placebo taken in BID dosing regimen for 28 days
48685737|NCT00847899|DRUG|Placebo|Placebo taken in TID dosing regimen for 28 days
48685738|NCT05392673|OTHER|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
48685739|NCT05365958|BEHAVIORAL|HIV Podcast for Heterosexual African American Adults|"The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
48685740|NCT03685318|DEVICE|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
48157782|NCT06009770|DEVICE|"medical device Homing (TecnoBody); medical device Icone (Heaxel)"|Rehabilitation activities for PD and MS will be aimed at improving motor performance and balance using a task-oriented approach with Homing system technology; post-stroke patients will perform a home-based upper limb rehabilitation with the iCONE robotic device for robot-assisted neurorehabilitation of the upper limb.
48000351|NCT02572466|OTHER|Hemodialysis|ESRD group received long-term hemodialysis
48512897|NCT03490578|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
48000352|NCT02888847|DEVICE|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
48000353|NCT02888847|DEVICE|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
48000354|NCT02202733|OTHER|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
48000355|NCT02439320|DRUG|Lasmiditan 100 mg|
48000356|NCT02439320|DRUG|Lasmiditan 200 mg|
48000357|NCT02439320|DRUG|Placebo (matches lasmiditan doses)|
48157783|NCT06009770|BEHAVIORAL|Usual Care|Standard motor exercise training aimed at muscle mobilization and strengthening (MS and PD groups) or to mobilize and enhance motor control of upper limb functions (post-stroke group)
48685741|NCT03685318|DEVICE|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
48000358|NCT03238911|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was a single IV infusion of 1000 mg (10 mL containing 1000 mg iron isomaltoside/ferric derisomaltose diluted in 100 mL 0.9 % sodium chloride), given over approximately 20 minutes (50 mg iron/min) at baseline (cumulative dose: 1000 mg)."
48000359|NCT03238911|DRUG|Ferric carboxymaltose|"Ferric carboxymaltose (Injectafer®; 50 mg/mL) was the comparator in this trial.~Ferric carboxymaltose was administered as 750 mg, infused over at least 15 minutes at baseline and on day 7 (cumulative dose: 1500 mg)."
48157784|NCT00972114|PROCEDURE|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
48000360|NCT04976842|DEVICE|OFA|Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
48000361|NCT04976842|DRUG|OBA|Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
48157785|NCT00972114|PROCEDURE|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
48157786|NCT00972114|PROCEDURE|CABG alone|Coronary artery bypass graft surgery alone
48000362|NCT02079688|DRUG|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
48157787|NCT05361304|DEVICE|senofilcon A contact lenses made with a novel manufacturing technology|TEST Lens
48157788|NCT05361304|DEVICE|senofilcon A contact lenses made with the current manufacturing technology|CONTROL Lens
48157789|NCT04204707|OTHER|PROMS|Patient Reported Outcomes after different types of surgery for rectal endometriosis
48157790|NCT04431739|DEVICE|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
48157791|NCT04872465|DEVICE|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
48157792|NCT04872465|DEVICE|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
48157793|NCT00574106|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
48157794|NCT04631341|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg every night, for one year
48157795|NCT02065895|DEVICE|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
48157796|NCT02065895|DEVICE|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
48157797|NCT02065895|DEVICE|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
48157798|NCT00853203|BEHAVIORAL|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
48157799|NCT00853203|BEHAVIORAL|Questionnaires|Written survey taking about 1 hour.
48157800|NCT00853203|OTHER|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
48157801|NCT00853203|BEHAVIORAL|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
48157802|NCT00853203|BEHAVIORAL|Written Materials|Written educational materials plus community resource information.
48157803|NCT03635047|BIOLOGICAL|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
48157804|NCT03635047|OTHER|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
48157805|NCT04891809|DRUG|Isatuximab-Irfc 20 MG/ML [Sarclisa]|Induction: 10mg/kg on day 1,8,15,22 in cycle 1, subsequently on day 1, 15; every 28 days (q28 days) Maintenance: 10mg/kg, day1, q28 days until progression or intolerance but for a maximum of 24 cycles from start of maintenance
48157806|NCT04891809|DRUG|Lenalidomide|"Induction: 25mg\*, day 1-21, every 28 days (q28 days); Maintenance: 5-10mg, day 1-21, q28 days (according to individual tolerance) until progression or intolerance but for a maximum of 24 cycles from start of maintenance~\*) for patients with moderate renal impairment (30≤ GFR (MDRD formula) \< 50 mL/min) starting dose is 10 mg"
48618142|NCT03821597|PROCEDURE|No sequential compression.|No sequential compression devices are applied.
48618143|NCT04445168|BEHAVIORAL|Telephone-based motivational interviews|2-year telephone-based motivational interviews to increase physical activity.
48618144|NCT03661918|BEHAVIORAL|In-Person First Session|Conduct first session in person vs. over the phone
48618145|NCT03661918|BEHAVIORAL|Second Caregiver|Have second caregiver participate in three coaching calls
48618146|NCT03661918|BEHAVIORAL|WiFi-enabled Scale|Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
48618147|NCT03661918|BEHAVIORAL|10 Core Coaching Calls Only|Participant will receive 10 core phone coaching sessions
48618148|NCT01446705|OTHER|Active Health Information Exchange|Patients selected to share data between the VA \& external healthcare agencies.
48000363|NCT02079688|DRUG|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
48000364|NCT00951093|PROCEDURE|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
48000365|NCT05893420|DEVICE|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
48000366|NCT05893420|OTHER|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
48000367|NCT01446965|DEVICE|wearable defibrillator|LifeVest wearable defibrillator
48000368|NCT06028945|DEVICE|HMD: Virtual Reality Exposure Therapy|The virtual reality exposure therapy uses 360-degree videos delivered through a head mounted display (HMD). Participants will be matched with one of three available exposure hierarchies: Social Party Scenario, Subway Scenario, or Shopping Mall Scenario. Each hierarchy comprises seven 5-min scenes ordered in increasing intensity (from low to high anxiety). Participants are gradually exposed to scenes, viewed twice per day for up to 10 days, while rating their anxiety immediately before and after the exposures. Anxiety ratings will inform when participants may advance to the next level intensity in the exposure hierarchy.
48000369|NCT06028945|DEVICE|HMD: Neutral Game|The neutral game is a virtual-reality based game that is not designed to provoke anxiety. Participants assigned to the neutral game will play for 5 minutes twice per day for up to 10 days.
48000370|NCT03356496|DEVICE|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
48000371|NCT01649258|DRUG|granisetron transdermal system|Given granisetron transdermal system patch
48000372|NCT01649258|DRUG|fosaprepitant dimeglumine|Given IV
48000373|NCT01649258|OTHER|laboratory biomarker analysis|Correlative studies
48157807|NCT04891809|DRUG|Dexamethasone Oral|"Induction:~Patients aged \<75 years: 40mg, once weekly; Patients aged ≥75 years: 20mg, once weekly"
48157808|NCT05376735|BEHAVIORAL|Purrble intervention|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~The Purrble is introduced to the student as an anxious creature that may need kind attention from humans. When picked up, the Purrble emits a frantic heartbeat that slows down if the child uses calm stroking movements. If it's soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to students in emotional moments when they would attempt to practice emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in students' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
48512898|NCT03490578|DEVICE|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
48512899|NCT02614274|DIETARY_SUPPLEMENT|Nutraceutical joint health formulation|A Proprietary Blend
48685742|NCT01901614|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
48685743|NCT01901614|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
48685744|NCT01901614|DRUG|Retrobulbar Block or General Anesthesia|
48685745|NCT01901614|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
48685746|NCT01901614|DRUG|Topical Anesthesia|
48685747|NCT01901614|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
48685748|NCT00050830|DRUG|CI 1033|
48685749|NCT03475446|DEVICE|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
48685750|NCT03475446|DEVICE|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
48685751|NCT03475446|DEVICE|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
48685752|NCT03475446|DEVICE|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
48000374|NCT04889742|DEVICE|loco-regional hyperthermia|loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.
48000375|NCT01418209|DRUG|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
48157809|NCT05376735|BEHAVIORAL|Single Session Intervention|"The SSI has been co-produced with university students and clinical experts, combining the theories of ER with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~* Initial guided reflection exercise (helping understand one's experience with Purrble in the 1st week).~* Short interactive psychoeducation, introducing the concept of window of tolerance, the Process Model of Emotions (Gross2015), and specific ways in which Purrble can help students down-regulate emotions within the context of the process model.~* Action plan to identify: moments when Purrble could be useful, what ER strategies they would like to use in those moments, what obstacles they may encounter, and how to overcome them.~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
48157810|NCT06069596|COMBINATION_PRODUCT|Natalis Obstetric Lubrican Gel|The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
48157811|NCT00919061|DRUG|Gemcitabine|Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
48157812|NCT00919061|DRUG|Cisplatin|20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
48685753|NCT03475446|DEVICE|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
48157813|NCT00919061|DRUG|Sorafenib|400 mg PO once a day continuously.
48157814|NCT06470347|DRUG|A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy|During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
48685754|NCT03475446|DEVICE|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
48685755|NCT03475446|DEVICE|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
48685756|NCT03475446|DEVICE|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
48685757|NCT03475446|DEVICE|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
48685758|NCT00755963|DRUG|estradiol valerate|Progynova® 21; 2mg/d
48685759|NCT00755963|DRUG|micronized progesterone|Utrogestan®; 200mg/d
48685760|NCT00755963|DRUG|placebo|maltodextrin
48685761|NCT03743545|OTHER|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
48685762|NCT03190135|BEHAVIORAL|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
48685763|NCT03190135|BEHAVIORAL|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
48685764|NCT02344121|RADIATION|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
48685765|NCT06451367|OTHER|neuromuscular programm|neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
48685766|NCT04306458|PROCEDURE|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
48685767|NCT04306458|DEVICE|daVinci Xi system|robot assisted minimally invasive esophagectomy
48685768|NCT04822818|DRUG|BEVA+SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
48685769|NCT04822818|DRUG|SOC|patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
48685770|NCT04408391|OTHER|Brain MRI scan|Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
48685771|NCT05710133|OTHER|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
48685772|NCT05710133|OTHER|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
48685773|NCT06495320|OTHER|Rational drug use education|Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
48685774|NCT00241176|DRUG|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
48685775|NCT05879393|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Active|Multistrain probiotic
48685776|NCT05879393|OTHER|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
48685777|NCT03349138|DEVICE|Conventional Therapy|
48157815|NCT05893225|DRUG|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
48512900|NCT04363957|OTHER|Brachytherapy video|Patients will watch a video that contains information about brachytherapy
48157816|NCT05893225|DRUG|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
48685778|NCT03349138|DEVICE|Robotic Glove|
48685779|NCT03349138|DEVICE|Electrical Stimulation|
48157817|NCT04652050|DRUG|Tolsura|Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
48157818|NCT02395588|OTHER|Guideline based care|Patient education using guideline based teaching guides
48157819|NCT05603299|OTHER|Educational Materials on the Dawn test|Receive educational materials and sample test results replicating what physicians would receive in the real-world market as they learn about the probability of IO therapy response from the Dawn™ test.
48157820|NCT02419664|DRUG|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
48157821|NCT04640376|DRUG|Paracetamol Uniflash 125mg|Oromucosal solution 1.25 mL for buccal use
48512901|NCT04363957|OTHER|Standard Brachytherapy Consent Process|Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
48512902|NCT03512873|DRUG|Tranilast|Subjects will be treated with tranilast
48618149|NCT01446705|OTHER|Non-Active Health Information exchange|Patients not selecting to share data
48618150|NCT03445429|OTHER|3D-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.
48618151|NCT03445429|OTHER|4K-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
48685780|NCT02584062|PROCEDURE|no-touch fluid-air exchange|
48685781|NCT02584062|PROCEDURE|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
48685782|NCT00758940|DEVICE|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
48685783|NCT05053074|DEVICE|Nasal High Flow (NHF)|Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
48685784|NCT03353987|BEHAVIORAL|Cognitive training|"Procedure~1. A therapist will go through the daily routine of the participants at home before starting the intervention~2. Selections of exercise items based on familiar items/ activities at home~3. Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~4. Taught on how to perform the exercises~5. Perform at least one hour per day~6. Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~7. Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~8. The difficulty of the exercise will be adjusted weekly~List of exercises:~1. Memorizing a set of lists, household items, names and numbers~2. Summarising the contents of newspaper cuttings within a set of time~3. Searching and listing sets of words from newspaper cuttings"
48685785|NCT01047917|BEHAVIORAL|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
48685786|NCT03440515|DRUG|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
48685787|NCT02961504|BIOLOGICAL|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
48157822|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X1|Tablet masked in capsule
48157823|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X2|Tablet masked in capsule
48157824|NCT04640376|DRUG|Placebo|Dummy treatment
48157825|NCT04182542|DEVICE|Radiofrequency|The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
48157826|NCT06129656|OTHER|Routine diagnostics|Data collection of routine diagnostics
48685788|NCT02961504|BIOLOGICAL|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
48685789|NCT01132846|OTHER|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
48685790|NCT01132846|DRUG|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
48685791|NCT01132846|DRUG|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
48685792|NCT03556670|BEHAVIORAL|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
48685793|NCT03556670|OTHER|Control|Usual practice control
48685794|NCT00229697|DRUG|Gefitinib|
48685795|NCT00229697|DRUG|Tamoxifen|
48000376|NCT01418209|DRUG|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
48000377|NCT01418209|DRUG|Placebo|The placebo is an inactive pill that looks like the active medication.
48000378|NCT00222456|BEHAVIORAL|Sensitizing parents|
48000379|NCT02101502|OTHER|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
48000380|NCT00344773|DRUG|Gefitinib|250mg tablet oral tablet once daily
48685796|NCT02807389|DRUG|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
48685797|NCT05561439|OTHER|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
48000381|NCT04595864|OTHER|Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|TAI
48000382|NCT02051036|PROCEDURE|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
48157827|NCT06129656|OTHER|Routine treatment|Data collection of routine treatment
48685798|NCT04307069|DRUG|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
48685799|NCT04120246|DRUG|Alpha-tocopheryloxyacetic Acid|Given PO
48685800|NCT04120246|BIOLOGICAL|Trastuzumab|Given IV
48685801|NCT01849393|OTHER|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
48685802|NCT00923351|DRUG|Tumor Purged/CD25 Depleted Lymphocytes|
48685803|NCT00923351|BIOLOGICAL|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
48685804|NCT00923351|DRUG|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
48685805|NCT00923351|BIOLOGICAL|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
48685806|NCT01574287|DRUG|FACBC|Drug is give intravenously over 2 minutes at time of scan
48000383|NCT02851537|OTHER|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
48157828|NCT04228276|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 8 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
48157829|NCT06608459|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
48685807|NCT02357537|BEHAVIORAL|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
48157830|NCT00337922|DRUG|Lamivudine / Abacavir Sulfate|
48685808|NCT03274011|DRUG|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
48000384|NCT02366832|PROCEDURE|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
48685809|NCT00003566|PROCEDURE|videothoracoscopy|
48000385|NCT02366832|DEVICE|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
48000386|NCT02586896|BEHAVIORAL|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
48000387|NCT02586896|BEHAVIORAL|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
48000388|NCT06061393|DRUG|Venofer 200 MG Per 10 ML Injection|treat anemia with venofer up to 5 doses
48157831|NCT02961816|DRUG|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
48157832|NCT02961816|DRUG|Panobinostat|20 mg by mouth daily from Day -9 to -2.
48157833|NCT02961816|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
48157834|NCT02961816|DRUG|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
48157835|NCT02961816|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
48157836|NCT02961816|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
48157837|NCT02961816|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
48157838|NCT02961816|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
48685810|NCT05407116|OTHER|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
48157839|NCT02961816|DRUG|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
48157840|NCT02961816|OTHER|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
48000389|NCT06061393|DRUG|Ferinject|ferinject 500 mg, once a week for 2 weeks
48157841|NCT02961816|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
48157842|NCT02961816|BIOLOGICAL|Stem Cell Infusion|Stem cells administered by vein on Day 0.
48157843|NCT02961816|DRUG|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
48157844|NCT01953406|DRUG|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
48157845|NCT01953406|DRUG|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
48157846|NCT03553056|OTHER|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
48157847|NCT03553056|OTHER|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
48157848|NCT04214808|DRUG|AD-208|Dutasteride 0.2mg
48157849|NCT04214808|DRUG|Avodart Soft Capsule 0.5mg|Dutasteride 0.5mg
48157850|NCT05888402|DRUG|Toripalimab|Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
48157851|NCT05888402|RADIATION|Concurrent chemoradiation therapy and consolidation immunotherapy|Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
48157852|NCT02606617|DRUG|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
48157853|NCT02606617|DRUG|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
48157854|NCT05966545|PROCEDURE|pars plana vitrectomy and intraocular foreign body removal|removal of vitreous body and attachment to foreign body then extraction of foreign body
48157855|NCT03599934|OTHER|Lifestyle integrated functional exercise program|Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
48157856|NCT03599934|OTHER|Home safety assessment|Home safety assessment and modification that targets to reduce environmental risk factors of falls.
48157857|NCT03899285|DRUG|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
48157858|NCT02917993|DRUG|Itacitinib|In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
48157859|NCT02917993|DRUG|Osimertinib|Osimertinib 80 mg once daily (QD)
48157860|NCT04435522|DRUG|Maraviroc|Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
48157861|NCT05483192|DIETARY_SUPPLEMENT|Oral Dyglomera|"Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin."
48157862|NCT02099656|DRUG|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
48157863|NCT02099656|DRUG|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
48157864|NCT02099656|DRUG|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
48618152|NCT04459338|BIOLOGICAL|Exendin-9,39|Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor
48618153|NCT04459338|OTHER|Saline|Placebo comparator
48618154|NCT05692440|DEVICE|Intracept Procedure|Intraosseous radiofrequency ablation of the basivertebral nerve
48000390|NCT04262037|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
48618155|NCT04686032|OTHER|Advanced early Rehabilitation Program|Patient education, Ambulation, In bed exercises, Deep breathing exercises: (5 rep x 3set), Connective tissue manipulation for intestinal motility (5 min) and TENS\* for incisional pain (30min)
48157865|NCT02099656|DRUG|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
48157866|NCT05832216|DRUG|Daratumumab|Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
48157867|NCT05157464|DRUG|Losartan|Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
48157868|NCT02041897|PROCEDURE|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
48157869|NCT04468607|DRUG|BLYG8824A|BLYG8824A will be administered at a flat dose independent of body weight.
48157870|NCT06050837|OTHER|No intervention|No intervention
48157871|NCT05200299|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
48000391|NCT06095375|DRUG|Regorafenib|Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.
48157872|NCT05200299|DRUG|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
48157873|NCT01817088|PROCEDURE|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
48157874|NCT01817088|PROCEDURE|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
48157875|NCT03455153|OTHER|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
48157876|NCT02195219|PROCEDURE|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
48685811|NCT03335904|OTHER|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
48685812|NCT03335904|OTHER|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
48000392|NCT06095375|DRUG|Temozolomide|"Following a 3+3 design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.~In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy)."
48000393|NCT02006277|DRUG|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
48000394|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
48000395|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
48618156|NCT04686032|OTHER|Early ambulation|Patient education \& Assisted ambulation out of bed including walking away from bedside for at least 15 min gradually moving to Unsupervised ambulation for 30 min
48000396|NCT02006277|DRUG|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
48157877|NCT02195219|OTHER|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
48157878|NCT04013347|PROCEDURE|Rectal Resection|Low Anterior Resection and Abdominoperineal Resection
48157879|NCT01622088|DRUG|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
48157880|NCT06585410|DRUG|Cemiplimab|Administered per protocol
48157881|NCT06585410|PROCEDURE|Standard of care|Primary surgery
48157882|NCT02709265|DRUG|amikacin/fosfomycin|single aerosolized dose
48157883|NCT02053402|DRUG|Vitamin D|Vitamin D daily for six months
48618157|NCT02912936|DIETARY_SUPPLEMENT|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
48000397|NCT02006277|DRUG|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
48000398|NCT02006277|DRUG|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
48000399|NCT02006277|DRUG|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
48157884|NCT06584617|DEVICE|Berovenal®|Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.
48157885|NCT06584617|DEVICE|NU-GEL Hydrogel with Alginate|Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.
48000400|NCT02006277|DRUG|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
48000401|NCT02006277|DRUG|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
48000402|NCT05771181|DRUG|Vitamin E|Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.
48000403|NCT05771181|DRUG|Fruquintinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
48000404|NCT05771181|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
48000405|NCT02290288|PROCEDURE|vaginal surgery|
48000406|NCT02290288|PROCEDURE|laparoscopic surgery|
48000407|NCT03189030|BIOLOGICAL|pLADD|via IV infusion
48000408|NCT05085977|BIOLOGICAL|TARA-002|Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
48000409|NCT04932785|OTHER|Regular diet|Regular diet
48000410|NCT04932785|OTHER|Clear Liquid Diet|Clear Liquid Diet
48000411|NCT04590495|DRUG|300 mg Cannabidiol (CBD) oil|Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
48000412|NCT04590495|DRUG|Placebo|Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
48157886|NCT02176018|DRUG|Dextromethorphan and quinidine|
48157887|NCT02176018|DRUG|Placebo|
48157888|NCT02710578|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
48512903|NCT06536959|DRUG|PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine|"For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors)."
48512904|NCT05154825|OTHER|Imaging-Observational|Preoperative standing and supine, intraoperative pre- and post-correction, and postoperative standing imaging as well as imaging collected during follow-up exams for a year following surgery
48512905|NCT02960490|DRUG|E6011|subcutaneous administration
48512906|NCT02960490|DRUG|Placebo|subcutaneous administration
48512907|NCT05695066|PROCEDURE|Preoperative fasting instruction|Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
48000413|NCT00004065|DRUG|tanespimycin|
48000414|NCT03023085|DRUG|BLI4700|BLI4700 bowel preparation
48000415|NCT03425812|DRUG|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
48000416|NCT03425812|DRUG|To continue NSAIDs therapy|NSAIDs therapy will be continued.
48157889|NCT02710578|DRUG|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
48157890|NCT02931994|OTHER|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
48157891|NCT00293332|BIOLOGICAL|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
48157892|NCT00293332|DRUG|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
48157893|NCT00293332|DRUG|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
48685813|NCT03335904|OTHER|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
48000417|NCT02134873|OTHER|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
48000418|NCT02885155|OTHER|Echocardiography|planned at regular intervals
48000419|NCT02885155|OTHER|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
48000420|NCT00006916|BIOLOGICAL|bleomycin|
48000421|NCT00006916|DEVICE|Ommaya reservoir|
48000422|NCT00006916|RADIATION|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
48000423|NCT00091299|DRUG|warfarin|
48000424|NCT02948491|OTHER|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
48000425|NCT03898661|DRUG|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
48000426|NCT05385419|DIAGNOSTIC_TEST|Bronchoscopic and thoracoscopic frozen section biopsies|Flexible bronchoscopy for patients with lung endobronchial lesion, the bronchoscopic biopsy will be sent for frozen section and permenant paraffin section Medical thoracoscopy for patients with undiagnosed pleural effusion, the thoracoscopic biopsy will be sent for both frozen section and permenant paraffin section
48000427|NCT00918515|DRUG|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
48000428|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous \[IV\] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
48000429|NCT00615056|DRUG|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous \[IV\] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
48000430|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
48000431|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion \[IV\] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
48000432|NCT00615056|DRUG|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily \[BID\] continuous dosing until disease progression, intolerance or withdrawal of consent.
48000433|NCT00615056|DRUG|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion \[IV\] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
48000434|NCT00615056|DRUG|Bevacizumab (avastin)|Bevacizumab intravenous infusion \[IV\] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
48512908|NCT03022097|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
48000435|NCT00615056|DRUG|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion \[IV\] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
48000436|NCT04280367|DIAGNOSTIC_TEST|Standardised semi-structured talk|Comprehensive assessment of at-risk mental states (CAARMS) will be used.
48000437|NCT04280367|DIAGNOSTIC_TEST|Autistic spectre disorder screening|Autism-spectrum quotient (AQ) auto-questionnaire will be used.
48000438|NCT04280367|DIAGNOSTIC_TEST|Anxiety measuring|An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
48000439|NCT04536727|BEHAVIORAL|Fit & Strong!|The 8-week intervention will consist of the Fit \& Strong! program adapted to address the impact of exercise on enhancing positive affect and reducing negative affect and depressive symptoms. Exercise classes will meet three times per week for 90 minutes per session for eight weeks. Each class is divided into 60 minutes of strength training, flexibility, and cardiovascular exercise and 30 minutes of group education/discussion, which has been adapted to include affect-oriented content
48000440|NCT04536727|BEHAVIORAL|Wait list|Participants randomized to the wait list group receive the 8-week Fit \& Strong! intervention after the intervention group has competed it and after the wait list group has provided their post-outcomes.
48512909|NCT03022097|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
48512910|NCT03022097|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
48512911|NCT03022097|DRUG|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
48685814|NCT03335904|OTHER|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
48685815|NCT03335904|DRUG|Losartan|Losartan, 50mg, BID
48685816|NCT03335904|DRUG|Placebo|Placebo, 50mg, BID
48685817|NCT04729153|DRUG|DAAD Compound|Sofosbuvir , Daclatasvir and ribavirin
48157894|NCT00293332|PROCEDURE|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
48157895|NCT00615355|RADIATION|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
48685818|NCT04839653|DRUG|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
48157896|NCT00615355|DEVICE|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
48000441|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
48000442|NCT00634088|DRUG|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
48157897|NCT00748358|DRUG|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
48157898|NCT00771238|DEVICE|P500 Mattress|Study mattress
48157899|NCT01239225|DEVICE|Abdominal ultra-sound|
48685819|NCT04839653|DRUG|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
48685820|NCT04839653|DRUG|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
48157900|NCT01239225|PROCEDURE|Abdominal ultrasound|
48157901|NCT01495754|OTHER|coffee|Comparison of different amounts of coffee
48157902|NCT02771184|DEVICE|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
48512912|NCT04753697|DRUG|CC-93538|Subcutaneous
48512913|NCT04753697|OTHER|Placebo|Subcutaneous
48512914|NCT00996892|DRUG|Cobimetinib|Repeated oral dosing.
48512915|NCT00996892|DRUG|Pictilisib|Repeated oral dosing.
48685821|NCT02008149|OTHER|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
48685822|NCT03110211|PROCEDURE|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
48685823|NCT03110211|PROCEDURE|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
48512916|NCT04479644|DRUG|BRII-198|BRII-198 given intravenously
48512917|NCT04479644|DRUG|Placebo|Placebo given intravenously
48512918|NCT03548337|BIOLOGICAL|13vPnC|13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
48512919|NCT04201197|DRUG|Inje cocktail|Acute drug exposure
48512920|NCT04201197|DRUG|THC Cannabis extract|Acute drug exposure
48512921|NCT04201197|DRUG|THC/CBD Cannabis Extract|Acute drug exposure
48512922|NCT04832009|DRUG|Dextrose 20 % in 500 ML Injection|Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
48512923|NCT04832009|DRUG|Intralipid|Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
48512924|NCT04832009|DRUG|Saline|Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
48685824|NCT02391311|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
48685825|NCT00137488|DEVICE|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
48685826|NCT05710731|OTHER|Use of simulation in urinary catheterization training|To train students on urinary catheterization by using one of 3 different simulation methods.
48685827|NCT00399568|DRUG|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
48685828|NCT00399568|DRUG|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
48685829|NCT04294459|DRUG|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
48512925|NCT04832009|DRUG|Ascorbic acid|"(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant."
48512926|NCT01425411|DRUG|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
48512927|NCT05026827|OTHER|Iyengar Yoga|Participation in Iyengar Yoga classes
48512928|NCT05026827|OTHER|Socialization Control|Participation in socialization control group sessions
48000443|NCT00634088|DRUG|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
48000444|NCT00634088|DRUG|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
48000445|NCT00233623|DRUG|Iressa (Gefitinib)|
48000446|NCT00233623|DRUG|Irinotecan|
48000447|NCT00233623|DRUG|5Fluorouracil|
48000448|NCT00233623|DRUG|Leucovorin|
48512929|NCT03047629|DRUG|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
48512930|NCT03047629|OTHER|Placebo|Daily dosing with a placebo
48512931|NCT00842205|DRUG|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
48512932|NCT00842205|DRUG|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
48512933|NCT06633874|DIAGNOSTIC_TEST|TD Playing the Serious Game APSOU|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then, the child may interact with the Serious Game. Typically developed (TD) children engage under the clinician's face-to-face supervision with the serious game APSOU, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for TD children to play the whole game is estimated to be 45 minutes.
48685830|NCT04294459|DRUG|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
48685831|NCT04294459|DRUG|Ranitidine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
48685832|NCT04294459|DRUG|Diphenhydramine or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
48685833|NCT04294459|DRUG|Methylprednisolone or equivalent|"Pharmaceutical form: Solution~Route of administration: Intravenous"
48685834|NCT04294459|DRUG|Montelukast or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
48685835|NCT02680340|PROCEDURE|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
48685836|NCT03786926|DRUG|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
48685837|NCT03634098|DEVICE|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
48685838|NCT03634098|DIAGNOSTIC_TEST|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
48685839|NCT03634098|DIAGNOSTIC_TEST|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
48685840|NCT01413295|DRUG|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
48685841|NCT01413295|OTHER|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
48685842|NCT06380725|DEVICE|Transcranial alternating current stimulation(real stimulation)|Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.
48685843|NCT06380725|DEVICE|Transcranial alternating current stimulation(sham stimulation)|Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
48685844|NCT03879928|DRUG|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
48685845|NCT03879928|DRUG|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
48685846|NCT03879928|DRUG|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
48157903|NCT04200547|OTHER|Immunomonitoring-based follow-up|"Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~* If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~* If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study."
48000449|NCT01802957|OTHER|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
48157904|NCT04200547|OTHER|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI \> 220 together with an increase of 70 points) and biological relapse (CRP \> 10mg/mL and fecal calprotectin \> 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
48157905|NCT04018534|BEHAVIORAL|Standard Verbal/Written Education|This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
48157906|NCT04018534|BEHAVIORAL|Video Assisted Education|The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
48157907|NCT04018534|BEHAVIORAL|Hands-on Training|The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
48157908|NCT03196180|DRUG|Imiquimod|Given intravaginally
48157909|NCT03196180|DRUG|Topical Fluorouracil|Given intravaginally
48157910|NCT04953793|BEHAVIORAL|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
48157911|NCT04953793|OTHER|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
48157912|NCT05448950|DEVICE|VIG Continued Access Study|Small skin incisions will be made for tunneling the graft under the skin in a standard manner. The VIG device is provided pre-loaded within a customized catheter-based delivery system for over-the-wire delivery. The VIG is inserted through an introducer sheath placed in the target vein so that the 'vessel end' of the VIG is deployed within the vein, and the 'graft end' extends out of the vein for connection to the graft. Delivery and deployment will be performed under fluoroscopic guidance. The VIG will be deployed first, connected to the AVG, then the graft and VIG will be flushed and clamped. The arterial anastomosis will then be created using a standard suturing method.
48157913|NCT06210178|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI scans including abdominal 4D Flow MRI.
48157914|NCT03816332|BIOLOGICAL|Ipilimumab|Given IV
48157915|NCT03816332|BIOLOGICAL|Nivolumab|Given IV
48157916|NCT03816332|DRUG|Prednisone|Given PO
48157917|NCT03816332|DRUG|Tacrolimus|Given PO
48000450|NCT01802957|OTHER|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
48000451|NCT01802957|OTHER|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
48000452|NCT01802957|OTHER|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
48157918|NCT06646107|DEVICE|MInimed 780G|Minimed 780G HCL system (Metronic, Northridge, Ca, USA) is ConformitèEuropëenne(CE)-marked and includes additional functionality aiming to provide further protections from high glucose levels. When the system is used in Auto Mode automatically calculate the insulin dose based on information received from CGM. Signals are converted by the transmitter to sensor glucose values. Sensor values are then transmitted to the insulin pump. Sensor glucose and insulin delivery data are stored by the pump and may be uploaded. The HCL system can be programmed to automatically calculate insulin doses (both basal insulin and correction boluses) based on information received from CGM780G and the adherence to MD.
48512934|NCT06633874|DIAGNOSTIC_TEST|Non-TD Playing Serious Game|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then the child may interact with the serious game. Non-typically developed (non-TD) children engage under the clinician's face-to-face supervision with the serious game Apsou, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for non-TD children to play the whole game is estimated to be over an hour.
48157919|NCT05709145|OTHER|Written recommendation|"Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself."
48157920|NCT00471562|BIOLOGICAL|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
48157921|NCT04682223|BEHAVIORAL|Semantically-focused therapy tasks|1) Semantic feature analysis (SFA; Boyle \& Coelho, 1995; Boyle, 2004). For each pictured stimulus the participant is prompted to name the picture. Then, s/he is encouraged to produce semantically related words that represent features similar to the target word. 2) Semantic barrier task. This approach includes features of the Promoting Aphasics' Communication Effectiveness (PACE; Davis \& Wilcox,1985). The goal of the task is for one participant (e.g., person with aphasia) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. 3) Verb network strengthening therapy (VNeST; Edmonds et al., 2009; 2014) targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the participant to generate verb-noun associates with the purpose of strengthening the connections between the verb and its thematic roles.
48157922|NCT04682223|BEHAVIORAL|Phonologically-focused therapy tasks|1) Phonological components analysis task (PCA; Leonard et al., 2008). The participant first attempts to name a given picture and then to identify the phonological features of the target words. 2) Phonological production task focuses on the identification of phonological features of targeted, imageable nouns and verbs. It requires the participant to sort picture stimuli based on the number of syllables and then to identify a hierarchy of phonological features. Once each targeted feature is identified for the pair of words, the participant is required to blend the syllables/sounds together. 3) Phonological judgment task relies on computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features (e.g. # of syllables, initial phonemes, final phonemes, rhyming).
48157923|NCT05456113|BIOLOGICAL|Cannabidiol|Urbal Activ Extra Strength CBD Body Strong Balm applied to region of forearm to be stimulated by iontophoresis machine
48512935|NCT04976413|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy|Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
48512936|NCT04976413|BEHAVIORAL|Counselling as usual|Control arm will receive counseling as usual for 12-14 weeks
48512937|NCT05860114|DRUG|Givinostat|Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension
48685847|NCT02544867|BEHAVIORAL|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
48685848|NCT06246422|DRUG|Tranexamic Acid 500 MG|Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed
48685849|NCT06246422|DRUG|Normal saline|Local instillation of 20 ml normal saline in the gall bladder bed
48685850|NCT03609502|BEHAVIORAL|behavioral training|the participants will be trained to perceive a non-native speech contrast
48685851|NCT04444271|DRUG|Mesenchymal stem cells|1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
48685852|NCT04444271|OTHER|Placebo|100 ml of normal saline will be given intravenously to control arm
48685853|NCT02623205|DRUG|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
48685854|NCT02623205|DRUG|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
48685855|NCT03757624|PROCEDURE|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
48685856|NCT04029428|DRUG|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
48685857|NCT04029428|DRUG|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
48157924|NCT03303547|DIAGNOSTIC_TEST|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
48157925|NCT03600506|DRUG|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
48157926|NCT03600506|DRUG|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
48157927|NCT00515112|DRUG|AndroGel|Androgel 1%, 10g daily
48157928|NCT00515112|DRUG|placebo|placebo
48157929|NCT02332122|PROCEDURE|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is \>= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
48157930|NCT02332122|PROCEDURE|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (\>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of \>= 3mm is a positive result.
48157931|NCT02332122|OTHER|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
48157932|NCT00165035|DEVICE|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
48512938|NCT06633861|DEVICE|spot-check measurement|Spot-check measurement: different Philips SpO2 sensors and Philips FAST pulse oximeter system, capnography
48157933|NCT00165035|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
48512939|NCT04905940|DRUG|Turmeric mouthwash|Turmeric mouthwash evaluation in controlling halitosis
48512940|NCT04298268|DEVICE|CUSA Clarity Ultrasonic Surgical Aspirator System use|Assessment of the CUSA® Clarity Ultrasonic Surgical Aspirator System use during urological or general surgery for soft tissue removal
48512941|NCT02487225|DRUG|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
48512942|NCT02487225|DRUG|Placebo|A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
48685858|NCT04029428|DRUG|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
48685859|NCT00343499|DRUG|valsartan|
48512943|NCT03928210|DRUG|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
48157934|NCT03873376|BEHAVIORAL|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
48157935|NCT03873376|BEHAVIORAL|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
48512944|NCT04842292|DRUG|Heparin|Nebulized heparin 25,000 units every 6 hours
48512945|NCT04842292|DRUG|Placebo|Sodium chloride 0.9% every 6 hours
48512946|NCT05785884|BEHAVIORAL|Low-carbohydrate diet|A 6 week randomized diet low in carbohydrates
48512947|NCT05785884|BEHAVIORAL|USDA Diet|A 6 week randomized diet aligned with USDA recommendations
48512948|NCT04766112|OTHER|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
48685860|NCT02689206|DRUG|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
48685861|NCT02689206|DRUG|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
48157936|NCT03873376|BEHAVIORAL|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
48000453|NCT01802957|OTHER|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
48000454|NCT01802957|OTHER|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
48000455|NCT01802957|OTHER|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
48000456|NCT01802957|OTHER|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
48000457|NCT03531216|OTHER|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
48000458|NCT03531216|OTHER|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
48000459|NCT04471636|DEVICE|Withings ScanWatch|The smart watch is capable of recording SpO2, ECG, and heart rate.
48512949|NCT04766112|OTHER|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
48685862|NCT03794427|OTHER|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
48000460|NCT02522390|OTHER|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
48000461|NCT02656108|PROCEDURE|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
48000462|NCT02656108|PROCEDURE|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
48000463|NCT01467999|DRUG|Guanfacine|Guanfacine, 4mg given once daily
48000464|NCT02090517|DEVICE|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
48000465|NCT02090517|DEVICE|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
48000466|NCT02090517|DEVICE|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
48157937|NCT03775187|BIOLOGICAL|Burosumab|
48157938|NCT03322579|DEVICE|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
48157939|NCT06091982|PROCEDURE|Renal Replacement Therapy (RRT)|Renal Support therapy which consist of procedure of intermittent hemodialysis (IHD) or continuous veno-venous hemofiltration/hemodialysis/hemodiafiltration (CVVH/CVVHD/CVVHDF)
48366793|NCT02054624|BEHAVIORAL|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
48512950|NCT01861912|DEVICE|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
48512951|NCT01861912|DRUG|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.
48685863|NCT03794427|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
48000467|NCT02090517|PROCEDURE|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
48000468|NCT00136084|DRUG|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
48000469|NCT00136084|DRUG|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
48000470|NCT04056195|DRUG|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
48000471|NCT04056195|DRUG|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
48000472|NCT05683288|OTHER|IASTM|IASTM will be applied to the upper trapezius and sternocleidomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute.
48000473|NCT05683288|OTHER|Myofascial Release|Basic movements will be performed for 3 minutes in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions.
48157940|NCT05759000|DRUG|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF (6). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. In particular, dapagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization and improve quality of life in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively, regardless of the presence or absence of diabetes in the DAPA-HF and DELIVER trials (
48157941|NCT00588042|DEVICE|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
48157942|NCT00588042|DEVICE|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
48157943|NCT00488761|DRUG|Tigecycline|
48157944|NCT05921929|DRUG|Fluoroethylnormemantine (FENM)|Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
48000474|NCT05683288|OTHER|250W infrared application|For 15 minutes, 250W infrared application will be applied on the cervical region from a distance of 50 cm
48000475|NCT05683288|DEVICE|TENS|TENS will be applied for 20 minutes at 80Hz frequency, with a current transit time of 150ms.
48000476|NCT05683288|OTHER|Home exercise|Cervical strengthening and stretching exercises five days a week will given
48000477|NCT02165319|DEVICE|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
48000478|NCT02165319|DEVICE|Tapered|Tapered-shaped tube will be used during general anesthesia.
48000479|NCT00006347|RADIATION|indium In 111 monoclonal antibody MN-14|
48157945|NCT03538834|DIETARY_SUPPLEMENT|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
48157946|NCT03538834|DIETARY_SUPPLEMENT|Control|Placebo
48157947|NCT01107912|DRUG|prasugrel|administered orally, daily for 12 days
48157948|NCT01107912|DRUG|clopidogrel|Administered orally, daily for 12 days
48157949|NCT03660254|BEHAVIORAL|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
48157950|NCT02543294|DEVICE|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
48157951|NCT02543294|DEVICE|Electrocardiogram|Electrocardiogram performed at baseline.
48157952|NCT02543294|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
48000480|NCT00006347|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
48000481|NCT05133999|BIOLOGICAL|Plasma determination of iron, transferrin and ferritin|Iron, transferrin and ferritin levels in plasma
48000482|NCT05133999|OTHER|Fundus Examination by wide field digital imaging camera (PanocamTM camera)|ROP screening using wide field digital retinal imaging according to current recommendations.
48000483|NCT04200807|DEVICE|Ultrasound Cardiac Output Monitor (USCOM 1A)|doplerometry with USCOM and echocardiograph is made for assessing central blood flow and spectroscopy with NONIN- for the blood flow in individual peripheral organs (brain and kidney)
48000484|NCT03476083|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.|All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
48000485|NCT04607993|BEHAVIORAL|Prone position ventilation technique|"1. Inform the children's family members of the purpose and method of prone position ventilation~2. Assess the fixation of various catheters~3. Suspend feeding before placing prone position~4. Confirm the time to start prone position ventilation under the joint assessment of medical staff~5. Place the child in a prone position with the participation of researchers, doctors and nursing staff, with the child's head tilted to one side to avoid damage to the eyes and nose due to compression, and the arms are bent upward to form a W . Bend both lower limbs downward to form an M shape, and use a soft pillow cushion to measure the knee joints to avoid compression~6. The whole process ensures the smooth fixation of tracheal intubation and various catheters~7. Proper sedation during prone position ventilation to achieve good human-machine synchronization~8. At least 6-8 hours in prone position every day"
48000486|NCT00663052|DRUG|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
48000487|NCT00663052|DRUG|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
48000488|NCT01540058|OTHER|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
48000489|NCT01540058|OTHER|No test Empiric strategy|Empiric strategy
48000490|NCT04685304|GENETIC|Pharmacogenetic Testing|Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.
48000491|NCT04685304|OTHER|Pharmacist Consultation Note|Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.
48685864|NCT03794427|OTHER|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
48685865|NCT03794427|OTHER|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
48685866|NCT00164658|BEHAVIORAL|Familial risk assessment and personalized prevention messages|
48157953|NCT02543294|BEHAVIORAL|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
48685867|NCT03360682|DRUG|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
48685868|NCT03360682|DRUG|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
48000492|NCT04685304|OTHER|Delayed pharmacogenetic testing|Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
48000493|NCT00962104|DRUG|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
48157954|NCT03503643|DEVICE|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
48157955|NCT06178471|DIAGNOSTIC_TEST|Transesophageal Echocardiography|The use of transesophageal echocardiography to diagnose cardiopulmonary failure in ICU patients with suboptimal or inadequate transthoracic echocardiography examinations.
48685869|NCT03360682|DRUG|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
48685870|NCT03360682|DRUG|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
48685871|NCT03360682|DRUG|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
48685872|NCT05699018|DIAGNOSTIC_TEST|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
48685873|NCT01672879|BIOLOGICAL|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
48685874|NCT01672879|BIOLOGICAL|SIM|Intravenous infusion over 30 minutes every 2 weeks
48685875|NCT04672980|DRUG|RTX-321|RTX-321 monotherapy
48685876|NCT03045614|OTHER|No intervention|No intervention
48685877|NCT01104402|DEVICE|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
48685878|NCT02936869|BEHAVIORAL|Performance-based monetary incentives|
48685879|NCT01211977|DRUG|XOMA 052|
48685880|NCT05086900|OTHER|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
48685881|NCT05111197|RADIATION|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
48685882|NCT05111197|DRUG|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
48685883|NCT00240812|DRUG|ibuprofen; pseudoephedrine HCl|
48157956|NCT03266003|OTHER|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
48157957|NCT03266003|OTHER|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
48157958|NCT04384692|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
48157959|NCT04384692|DRUG|Busulfan|Given IV
48157960|NCT04384692|DRUG|Cyclophosphamide|Given IV
48157961|NCT04384692|DRUG|Fludarabine|Given IV
48157962|NCT04384692|DRUG|Melphalan|Given IV
48157963|NCT04384692|DRUG|Methotrexate|Given IV
48157964|NCT04384692|DRUG|Mycophenolate Mofetil|Given IV or PO
48157965|NCT04384692|DRUG|Ruxolitinib|Given PO
48157966|NCT04384692|DRUG|Tacrolimus|Given IV and PO
48157967|NCT04384692|RADIATION|Total-Body Irradiation|Undergo TBI
48157968|NCT04384692|PROCEDURE|Computed Tomography|Undergo CT scan
48000494|NCT00962104|DRUG|Placebo|Taken by mouth, once daily for 10 weeks.
48157969|NCT04384692|PROCEDURE|Echocardiography|Undergo echocardiography
48000495|NCT02018289|PROCEDURE|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
48000496|NCT02018289|PROCEDURE|No triclosan|Suture of the abdominal wall with suture without triclosan coat
48000497|NCT03417388|DRUG|High dose potent statin|The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
48000498|NCT03417388|DRUG|ACE-I (lisinopril) or ARB (losartan)|Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
48000499|NCT03417388|DRUG|Aspirin|Will be recommended to IMT women without contraindications or bleeding risk.
48000500|NCT03417388|BEHAVIORAL|Lifestyle Counseling|The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.
48000501|NCT03417388|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Questionnaires will be obtained.
48157970|NCT04384692|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48157971|NCT04384692|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48157972|NCT04384692|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
48157973|NCT03050372|DEVICE|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
48157974|NCT03050372|DEVICE|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
48000502|NCT00314236|DEVICE|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
48000503|NCT00314236|PROCEDURE|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
48000504|NCT05115383|OTHER|VO2 Max test|The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
48157975|NCT06313944|DIAGNOSTIC_TEST|Registry|Clinical data collection of patients scheduled for on-label treatment
48157976|NCT06154798|BEHAVIORAL|World Digital Detox Women's Health Program|World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
48157977|NCT01693159|DEVICE|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
48157978|NCT01693159|OTHER|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
48157979|NCT03594786|DEVICE|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
48157980|NCT02282917|DRUG|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
48157981|NCT06647121|BEHAVIORAL|ACT Psychoeducational Workshop|The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.
48157982|NCT06647121|BEHAVIORAL|ACTaide Mobile App|The ACTaide mobile app is a novel app that is designed to support home practice of exercises from ACT via annotated image sequences and reminder notifications. A prototype version that features the dropping anchor mindfulness exercise will be investigated in this study.
48000505|NCT04092166|OTHER|Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
48000506|NCT05747144|DIAGNOSTIC_TEST|Biometry|Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
48000507|NCT05747144|DIAGNOSTIC_TEST|Retinography (Color) + Autofluorescence (AF)|Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)
48000508|NCT05747144|DIAGNOSTIC_TEST|OCT B-scan and OCT angiography (OCTA)|"OCT B-scan:~2 scans (6 mm)~1 cross line~OCTA:~3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve"
48000509|NCT05747144|DIAGNOSTIC_TEST|Microperimetry|1) fixation pattern 2) retinal sensitivity map
48685884|NCT03268889|DRUG|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
48685885|NCT04465604|OTHER|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
48000510|NCT05747144|DIAGNOSTIC_TEST|Electrophysiological exams|Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus \< 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.
48000511|NCT02347748|BEHAVIORAL|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
48000512|NCT02347748|BEHAVIORAL|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
48000513|NCT02347748|BEHAVIORAL|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
48000514|NCT01933867|PROCEDURE|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
48000515|NCT01933867|PROCEDURE|Air insufflation insertion|
48000516|NCT05751239|OTHER|Questionaire|All participants answered an online questionaire. Out of the 837 participants 641 were included
48000517|NCT00277212|DRUG|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
48000518|NCT00277212|DRUG|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
48000519|NCT00198016|DEVICE|Coil|
48000520|NCT01781442|DRUG|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
48685886|NCT02977364|DRUG|HS-10241|
48685887|NCT03619577|BEHAVIORAL|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
48685888|NCT01743612|PROCEDURE|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
48000521|NCT02113956|BEHAVIORAL|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
48000522|NCT01200628|BEHAVIORAL|DEPITAC|heteroevaluation scale by a nurse during hospitalization
48000523|NCT05348382|PROCEDURE|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
48000524|NCT05348382|PROCEDURE|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
48512952|NCT01861912|DRUG|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
48000525|NCT03594097|OTHER|Treatment cookies|Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener
48000526|NCT03594097|OTHER|Control cookies|Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
48512953|NCT01861912|DRUG|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
48000527|NCT02423863|BIOLOGICAL|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC \[Hiltonol®\]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
48000528|NCT03569228|DEVICE|Study 1 - ITE hearing aids|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
48000529|NCT03569228|DEVICE|Study 1 - BTE hearing aids|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
48000530|NCT03569228|DEVICE|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
48000531|NCT03569228|DEVICE|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
48000532|NCT03569228|DEVICE|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
48000533|NCT03569228|DEVICE|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
48000534|NCT01450410|DRUG|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
48000535|NCT01450410|DRUG|Placebo|Placebo treatment will last for 12 weeks.
48157983|NCT06647121|BEHAVIORAL|Reminders-only mobile app|This app will include only reminder notifications to encourage home practice of the dropping anchor mindfulness exercise in the comparator condition. It will not include the annotated image sequence for the exercise (i.e., the primary feature of the ACTaide app to be investigated in the intervention condition).
48000536|NCT02122536|DRUG|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
48000537|NCT02122536|DRUG|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
48000538|NCT03547388|DEVICE|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
48000539|NCT05980533|DIAGNOSTIC_TEST|Ultrasound|Ultrasound at hospital discharge and at follow up at 7-10 days
48000540|NCT05766332|OTHER|Clinical Evaluation|Undergo clinical evaluation
48000541|NCT05766332|OTHER|Electronic Health Record Review|Medical records reviewed
48000542|NCT05492669|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
48000543|NCT05492669|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
48157984|NCT02725359|DRUG|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
48157985|NCT02725359|DRUG|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
48685889|NCT01743612|PROCEDURE|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
48685890|NCT03024112|DEVICE|Heated humified high-flow nasal cannula Oxygen|
48685891|NCT03024112|OTHER|Standard oxygen therapy|
48685892|NCT02317198|DRUG|Clopidogrel|
48157986|NCT02725359|DRUG|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
48157987|NCT02725359|DRUG|Saline|USG guided SCPB with saline bilaterally 10 ml each side
48157988|NCT01721759|DRUG|Nivolumab|
48157989|NCT00023465|PROCEDURE|FDG-PET|
48000544|NCT01862887|DRUG|PH-797804|Tablet, 24 mg, single dose
48000545|NCT01862887|DRUG|Moxifloxacin|Tablet, 400 mg, single dose
48000546|NCT01862887|DRUG|Placebo|Tablet, PH-797804 matched placebo, single dose
48157990|NCT00023465|PROCEDURE|spirometry|
48157991|NCT00023465|PROCEDURE|bronchoscopy with BAL|
48157992|NCT06539468|OTHER|Best Practice|Receive SOC treatment
48157993|NCT06539468|OTHER|Educational Activity|Watch an educational video on AS for LR-BCC
48157994|NCT06539468|OTHER|Patient Observation|Undergo active surveillance
48157995|NCT06539468|OTHER|Survey Administration|Ancillary studies
48685893|NCT02317198|DRUG|Ticagrelor or Prasugrel|
48685894|NCT05679596|DIETARY_SUPPLEMENT|ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate|Provided twice a day between meals.
48685895|NCT05679596|DIETARY_SUPPLEMENT|carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)|Provided twice a day between meals.
48157996|NCT01536795|DRUG|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
48157997|NCT01536795|DRUG|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
48157998|NCT05159778|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
48157999|NCT05159778|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
48158000|NCT03652792|DRUG|Azilsartan (Zhaoke)|Azilsartan 20mg tablets from Zhaoke
48158001|NCT03652792|DRUG|Azilsartan (Takeda)|Azilva 20mg tablets from Takeda
48158002|NCT06539936|DEVICE|Glide|Glide is a myoelectric prosthesis control strategy which enables multifunctional control using a limited set of input EMG signals (as few as two). The Glide control strategy uses the relative contributions of multiple electrode inputs to create a virtual cursor, calculated from a vector summation of multiple EMG channels, to select the type and speed of a movement from a circular map.
48158003|NCT06539936|DEVICE|Direct Control|Direct Control (DC) is the most common method of control for powered prostheses, which directly links the activity recorded from a single electromyography (EMG) electrode to a prosthesis action. Typically, a pair of EMG electrodes are placed over a pair of agonist/antagonist muscle groups to operate a single DOF (e.g., for transradial amputees the flexor muscles in the forearm may be mapped to the prosthetic hand closing and the forearm extensor muscles mapped to hand opening).
48158004|NCT01349699|DRUG|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
48158005|NCT01349699|DRUG|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
48158006|NCT01349699|DRUG|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
48158007|NCT01349699|DRUG|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
48158008|NCT01092936|OTHER|Rating Scale administration|Movement Disorder Society_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
48000547|NCT02180282|DEVICE|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
48000548|NCT03414463|BEHAVIORAL|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
48000549|NCT02886390|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
48000550|NCT05473312|BEHAVIORAL|Community Sensitization|One event will be developed and delivered for households in each cluster area. Approach and content will be informed by the formative research and CAC input (may include drama and nutrition fairs).
48000551|NCT05473312|BEHAVIORAL|28-day PD/Hearth Sessions|Mothers will come together in a home-like setting to rehabilitate their malnourished child (8 dyads/Hearth), learn and practice new feeding and childcare behaviours (during Covid-19: 4 dyads/Hearth). Curriculum and activities will be informed by CAC, CORE Guide and formative research. Two female facilitators will demonstrate, encourage, convey key messages and guide practices.
48000552|NCT05473312|BEHAVIORAL|Supplemental Print Information|The content will be informed by the formative research and CAC, will reinforce Hearth messages, and be adapted for each gender group. Material will be locally produced, engaging, user friendly, and target an illiterate audience (i.e. culturally relevant images with minimal text).
48000553|NCT03946735|BEHAVIORAL|Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination|Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
48000554|NCT03647540|PROCEDURE|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
48000555|NCT03647540|PROCEDURE|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
48000556|NCT01452412|DRUG|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
48000557|NCT01452412|DRUG|Placebo|To be taken on the same schedule as the active arm
48158009|NCT03948815|OTHER|interventional birthing room|The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
48158010|NCT02475733|DRUG|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
48000558|NCT02245789|PROCEDURE|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
48000559|NCT02245789|DRUG|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
48000560|NCT02452151|DRUG|Infliximab-Biosimilar|
48000561|NCT02452151|DRUG|Infliximab-Innovator|
48000562|NCT04953533|OTHER|no intervention|
48000563|NCT00607282|DRUG|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
48000564|NCT02606591|PROCEDURE|Electroencephalograph|EEG performed at beginning and end of school year.
48000565|NCT02606591|BEHAVIORAL|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
48000566|NCT02606591|OTHER|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
48000567|NCT00004258|DRUG|cilengitide|dose escalation of cilengitide
48000568|NCT05339139|COMBINATION_PRODUCT|Dialysis|In this study critically ill adult patients requiring Continuous Renal Replacement Therapy (CRRT) will receive Regional Citrate Anticoagulation (CRA) which will be delivered by multiFiltratePRO system.
48000569|NCT03678155|OTHER|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
48000570|NCT02166190|PROCEDURE|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
48000571|NCT02166190|PROCEDURE|Stenting only|Stenting only
48366794|NCT02054624|BEHAVIORAL|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
48158011|NCT02475733|DRUG|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
48158012|NCT02475733|DRUG|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
48158013|NCT00960284|DRUG|capecitabine|Given orally
48158014|NCT00960284|DRUG|cisplatin|Given IV
48158015|NCT00960284|DRUG|epirubicin hydrochloride|Given IV
48158016|NCT00960284|DRUG|fluorouracil|Given IV
48366795|NCT02054624|BEHAVIORAL|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
48000572|NCT04357210|PROCEDURE|fistula tract excision and anal sphincter reconstruction|The primary fistulous tract was excised together with any secondary tracts or residual cavities. Then on of the reconstructive steps was performed
48000573|NCT06212219|BEHAVIORAL|Neurofeedback procedure|Personalized NF will consist of adding to these motor imagery tasks, personalized aspects depending on the patient's profile, for example in terms of level of support and emotional support (addition of a relaxation exercise using an audio recording at the start of training - and in the middle of training if necessary, adding the presence of a companion is to provide social presence and emotional support, depending on the user's performance and progress.), of the virtual environment.
48000574|NCT06212219|OTHER|Fugl-Meyer test|419 / 5 000 Résultats de traduction Résultat de traduction This questionnaire assesses the motor selectivity of the upper limb. Several questions are asked about the movements that the patient can perform and to each question, the patient can answer either 0 (minimum) and 2 (maximum)
48000575|NCT06212219|OTHER|Intrinsic Motivation Inventory questionnaire|This psychometric motivation questionnaire offers the patient words representative of their motivation to carry out the neurofeedback session and for each proposition they can respond between rather positive (maximum) or rather negative (minimum)
48000576|NCT06212219|OTHER|Hospital Anxiety and Depression Scale|This questionnaire assesses the patient's state of anxiety and depression. Concerning anxiety, to each proposition, the patient can answer a number between 0 at minimum (never/not at all) and 3 at maximum (very often) and about depression, the patient can answer a number between 0 at minimum (often, always) and 3 at maximum (never/not at all) The patient can calculate his score at the end
48158017|NCT00960284|DRUG|gemcitabine hydrochloride|Given IV
48158018|NCT04232475|OTHER|1 minute of stair climbing and descending|1 minute of stair climbing and descending
48158019|NCT04232475|OTHER|3 minute of stair climbing and descending|3 minute of stair climbing and descending
48158020|NCT04232475|OTHER|10 minute of stair climbing and descending|10 minute of stair climbing and descending
48158021|NCT00042302|PROCEDURE|Chemotherapy|
48158022|NCT00042302|DRUG|tariquidar + paclitaxel/carboplatin|
48158023|NCT00042302|DRUG|placebo + paclitaxel/carboplatin|
48000577|NCT06212219|OTHER|State Anxiety Inventory scores|"This questionnaire measures the patient's anxiety at a given time. It features a number of statements that people have previously used to describe themselves. For each statement, choose a grade from 1 (not at all) to 4 (Very much)"
48366796|NCT02054624|BEHAVIORAL|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
48000578|NCT06212219|OTHER|Acceptability questionnaire (BCI-ACCEPT)|This questionnaire asks the patient about their level of acceptability of NF training using words representative of their motivation to carry out the neurofeedback session and for each proposal they can respond on their feelings regarding the proposals.
48685896|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
48000579|NCT06212219|OTHER|System Usability Scale questionnaire|This questionnaire evaluates the usability of personalized NF procedures compared to standard procedures. To each statement, the patient can respond between a minimum of 1 (strongly disagree) and a maximum of 5 (totally agree).
48000580|NCT06212219|OTHER|NASA Task Load Index questionnaire|"This scale assesses psychological validity from the perspective of mental workload. 6 words are offered to the patient about his mental load and he can respond at least little and at maximum A lot"
48000581|NCT06212219|OTHER|Agency test|Questionnaire in which statements referring to the patient's general feeling and/or beliefs are presented. the patient has the choice between completely disagree (minimum) and totally agree (maximum)
48000582|NCT06212219|OTHER|Visual and Kinesthetic Imagery Questionnaire|"The aim of this questionnaire is to obtain an index of individuals' ability to mentally represent different movements. Different movements to imagine are indicated and the patient responds based on their ability to imagine the movement.~He has the choice between as clear as a film (maximum) and no image (minimum)"
48000583|NCT06212219|OTHER|Technology Locus of Control Assessment Questionnaire|"The questionnaire focuses on patients' opinions on problems related to the use of technical devices. It presents twelve statements that the patient can affirm or deny, depending on their personal point of view. The patient can respond at least disagree at all and at maximum agree completely"
48000584|NCT06212219|OTHER|POSITIVE AFFECTIVITY AND NEGATIVE AFFECTIVITY SCALE|"This scale is made up of a list of words that indicate certain emotions or feelings. The patient must carefully read each of these words and spontaneously indicate at what level he feels this way at the time he responds to this scale. To do this, he can answer at least Very little or not at all and at maximum A lot"
48000585|NCT06212219|OTHER|Self-questionnaire: OCEAN of the five major factors of per- sound (or Big Five model)|"The model for measuring personality factors is the Anglo-Saxon model known as the Big Five or OCEAN in French. It measures 5 major personality traits: openness to experiences, conscientiousness, extroversion, agreeableness and neuroticism. The OCEAN questionnaire is a self-administered questionnaire to be given to a person who wishes to evaluate themselves. It includes 45 items presented in the table below. For each item, patients have 5 response possibilities numbered from 1 to 5: 1 for strongly disapproves and 5 for strongly approves. The patient can calculate his score at the end"
48000586|NCT06212219|OTHER|Feeling VAS scores|"The EVA scale relates to the patient's personal feelings: perceived difficulty, perceived fatigue, perceived ease of learning, level of embodiment, Relevance, Demonstrability of results, Fun aspect, Benefit/risk ratio, Self-efficacy.~For each statement, the patient can respond on a scale ranging from strongly disagree (minimum) to totally agree (maximum)."
48000587|NCT06212219|OTHER|Reaching Performance Scale|This scale analyzes the evolution of speed, precision and range of movement using motion capture tools. For each statement, the patient has a rating between 0 (corresponds to not possible) and 3 (corresponds to entirely possible)
48000588|NCT01358604|GENETIC|polymerase chain reaction|
48000589|NCT01358604|GENETIC|protein expression analysis|
48000590|NCT01358604|GENETIC|western blotting|
48000591|NCT01358604|OTHER|flow cytometry|
48000592|NCT01358604|OTHER|immunohistochemistry staining method|
48000593|NCT01358604|OTHER|laboratory biomarker analysis|
48000594|NCT02519712|DRUG|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
48000595|NCT02519712|PROCEDURE|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
48000596|NCT00801125|DRUG|natalizumab|
48000597|NCT04695938|DIAGNOSTIC_TEST|MRI|MRI examination with Black Bone, and ultrashort/zero echo time MRI techniques
48000598|NCT01051128|DEVICE|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
48000599|NCT01209442|DRUG|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
48366797|NCT03336307|OTHER|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~* endurance, strength, flexibility and balance with functional practice for all H/Y stage~* endurance also for H/Y stage 1,~* motor learning principles and cue functional for H/Y stage 2-3~* external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
48685897|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
48685898|NCT06089031|DIAGNOSTIC_TEST|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
48158024|NCT03517371|OTHER|mHealth delivered exercise program|"Participants in the mobile health condition have up to 10 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week."
48158025|NCT03517371|OTHER|Exercise only|Participants in the control group have up to 10 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
48158026|NCT05067972|DRUG|PF-07260437|B7-H4 x CD3 bi-specific mAb
48158027|NCT05067972|DIAGNOSTIC_TEST|B7-H4 IHC|B7-H4 expression
48158028|NCT04299581|DRUG|Camrelizumab|a PD-1 immune check inhibitor
48158029|NCT04299581|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
48000600|NCT01209442|DRUG|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
48158030|NCT00627432|DRUG|gemcitabine hydrochloride|
48158031|NCT00627432|DRUG|oxaliplatin|
48158032|NCT06292832|PROCEDURE|Ultrasound-guided pain block|Ultrasound-guided pain block after cesarean section
48158033|NCT06292832|DEVICE|Ultrasound Machine|Ultrasound machine used to guide the nerve block.
48158034|NCT00695149|PROCEDURE|Transplantation of bone marrow stromal cell|
48158035|NCT05315817|DEVICE|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
48158036|NCT05862779|DIETARY_SUPPLEMENT|Placebo Group|The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
48158037|NCT05862779|DIETARY_SUPPLEMENT|Whey Protein + Placebo|The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
48685899|NCT02201329|DRUG|Azacitidine|Azacitidine (subcutaneous)
48000601|NCT01209442|RADIATION|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
48000602|NCT01063764|DRUG|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
48000603|NCT03770650|PROCEDURE|Stenting|DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
48158038|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Placebo|The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
48512954|NCT05439967|OTHER|Augmented and Virtual Reality Gait and balanceTraining|C-Mill VR+ device used for training. The training was carried out 3 days a week for 6 weeks, with each exercise session lasting approximately 1.5 hours, accompanied by a physiotherapist. Training started with conventional exercises, continued with C-Mill VR+ training, and ended with stretching and relaxation exercises. The patients in the intervention group were applied the exercises with the same principles with conventional training, except the exercises performed in standing and walking. Patients performed 10 exercises in AR and VR gait training for 4 minutes and resting the individuals by sitting for 1 minute between exercises.
48000604|NCT06392243|DEVICE|Intracardiac ultrasound imaging system|The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention
48000605|NCT03088176|DRUG|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
48158039|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Whey Protein|The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
48000606|NCT03088176|DRUG|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
48000607|NCT03088176|DRUG|Dabrafenib|150mg PO qday
48685900|NCT02201329|DRUG|Volasertib|Volasertib escalating doses (intravenous)
48000608|NCT03088176|DRUG|Trametinib|2mg PO qday
48000609|NCT04862156|DEVICE|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
48000610|NCT02311491|DEVICE|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
48158040|NCT04385849|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48158041|NCT04385849|OTHER|Saline|Sterile saline solution
48685901|NCT03536481|DRUG|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
48000611|NCT03007511|DEVICE|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
48158042|NCT03741309|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
48000612|NCT01995695|BIOLOGICAL|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
48000613|NCT01995695|BIOLOGICAL|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
48158043|NCT03741309|OTHER|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
48158044|NCT03741309|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
48000614|NCT01881659|OTHER|HPV screening|Women who signed informed consent will be screened with HPV testing.
48000615|NCT00165490|DRUG|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
48000616|NCT00165490|DRUG|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
48685902|NCT03536481|DRUG|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
48685903|NCT06215365|BEHAVIORAL|Adult cancer survivors who have completed their heavy treatments|"The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
48685904|NCT05371834|DEVICE|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
48685905|NCT05371834|DEVICE|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
48685906|NCT04928885|BEHAVIORAL|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
48685907|NCT04928885|OTHER|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
48000617|NCT00165490|DRUG|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
48000618|NCT00165490|DEVICE|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
48000619|NCT00165490|PROCEDURE|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
48000620|NCT00876304|DRUG|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
48000621|NCT00876304|DRUG|Placebo|Placebo capsules every 12 hours for 10 days
48000622|NCT00558103|DRUG|lapatinib|Oral administration
48000623|NCT00558103|DRUG|Pazopanib|Oral administration
48158045|NCT01179659|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
48158046|NCT03771378|DRUG|rhTPO|After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
48158047|NCT03771378|DRUG|eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
48158048|NCT03055819|DEVICE|Brow Lift|Minimally Invasive Brow Lift
48158049|NCT02331771|DRUG|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
48158050|NCT02331771|DRUG|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
48000624|NCT04407130|DRUG|Ivermectin + Doxycycline + Placebo|"Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5"
48000625|NCT04407130|DRUG|Ivermectin + Placebo|Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5
48000626|NCT04407130|DRUG|Placebo|Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
48000627|NCT02234921|DRUG|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
48000628|NCT02234921|BIOLOGICAL|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
48000629|NCT02234921|BIOLOGICAL|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
48000630|NCT02234921|DRUG|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
48000631|NCT02120976|DRUG|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
48000632|NCT02120976|DRUG|JTT-252|Subjects will receive JTT-252
48000633|NCT04352751|OTHER|convalescent plasma|"* Plasmapheresis, 900 - 1000 mL each time.~* Standard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.~* Isovolumic saline replacement should be done.~* Each donor can donate convalescent plasma again after an interval of every 2 weeks"
48000634|NCT02342483|DIETARY_SUPPLEMENT|MSM|
48000635|NCT04817826|DRUG|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
48000636|NCT04817826|DRUG|Tremelimumab|tremelimumab 300 mg single administration (day 1)
48000637|NCT05677542|DRUG|secukinumab|all patients who received secukinumab
48000638|NCT05776654|DEVICE|Biometric wearable devices|Passive data collection using biometric wearable devices.
48000639|NCT04043312|DEVICE|Magstim SuperRapid|Transcutaneous magnetic stimulation targeting the left stellate ganglion.
48000640|NCT04043312|DEVICE|Magstim SuperRapid|Sham transcutaneous magnetic stimulation.
48000641|NCT00453999|DRUG|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
48158051|NCT03711799|BEHAVIORAL|Access to services via peer coaching|This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
48685908|NCT06471959|DRUG|Psilocybin|Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
48685909|NCT04476446|DRUG|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
48685910|NCT02515968|DRUG|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
48000642|NCT00453999|DRUG|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
48000643|NCT00453999|DRUG|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
48685911|NCT02515968|DRUG|Propofol|
48685912|NCT05139745|DEVICE|BTL-899|BTL-899 treatment
48000644|NCT02692677|DRUG|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
48000645|NCT00445328|DRUG|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
48000646|NCT00445328|DRUG|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
48158052|NCT02146300|BIOLOGICAL|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
48000647|NCT02117375|DEVICE|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
48000648|NCT02117375|OTHER|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
48000649|NCT02117375|OTHER|brain MRI follow-up|
48158053|NCT01244399|DIETARY_SUPPLEMENT|Inositol|
48158054|NCT03965247|DRUG|Lithium|
48158055|NCT03965247|OTHER|Placebo - Rayotabs|
48158056|NCT05324384|DRUG|Sirolimus|Use of different doses of the same drug
48000650|NCT06060626|DRUG|Sedation using only Propofol.|Patients in whom only propofol will be administered during sedation.
48000651|NCT06060626|DRUG|Sedation using combination of Propofol and Fentanyl.|Patients in whom combination of propofol and fentanyl will be administered during sedation.
48158057|NCT00266162|DRUG|Bosentan administration|
48158058|NCT02326740|DRUG|gevokizumab|
48158059|NCT02326740|DRUG|Placebo|
48158060|NCT02326740|DRUG|gevokizumab open-label|
48158061|NCT02658032|BEHAVIORAL|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
48158062|NCT02658032|BEHAVIORAL|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
48158063|NCT02658032|OTHER|standard care|
48158064|NCT01323335|DRUG|IV Uric Acid|
48158065|NCT01323335|DRUG|IV Rasburicase|
48000652|NCT02561975|OTHER|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~* Alveolar volume (VA)~* Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~* Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
48000653|NCT06042036|OTHER|Spontaneous mode of mechanical ventilation|any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
48000654|NCT00913744|DRUG|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
48000655|NCT00913744|DRUG|Sham injection|Sham injection
48000656|NCT01172652|DRUG|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
48000657|NCT01172652|DRUG|Placebo|Inactive control
48000658|NCT06255535|DEVICE|active iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
48000659|NCT06255535|DEVICE|sham iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
48000660|NCT05111977|DEVICE|Vibrant capsule|A capsule delivering mechanical vibrations
48000661|NCT02171481|DRUG|Dabigatran etexilate polymorph II|
48000662|NCT02171481|DRUG|Dabigatran etexilate polymorph I|
48000663|NCT02895958|DRUG|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
48000664|NCT06122090|DRUG|Bimatoprost|Bimatoprost will be delivered with laser
48158066|NCT04283097|DRUG|KPG-818|The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
48685913|NCT01915537|DRUG|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX\>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
48685914|NCT01915537|DRUG|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
48685915|NCT03402594|DEVICE|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
48685916|NCT03402594|DEVICE|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
48685917|NCT01380678|DRUG|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
48685918|NCT01380678|DRUG|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
48685919|NCT05620056|DRUG|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
48000665|NCT06122090|DRUG|Saline|Saline control will be delivered with laser
48000666|NCT01461772|RADIATION|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
48000667|NCT01461772|DRUG|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
48000668|NCT01461772|DRUG|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
48000669|NCT04047264|PROCEDURE|Microdialysis|Undergo microdialysis
48000670|NCT00363974|DRUG|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
48000671|NCT01736696|DRUG|tofacitinib|5 mg BID For 13 days and once on Day 14
48000672|NCT01736696|DRUG|tofacitinib|10 mg BID for 13 days and once on Day 14\*
48000673|NCT01736696|DRUG|tofacitinib|20 mg BID for 13 days and once on Day 14
48000674|NCT01736696|DRUG|tofacitinib|30 mg BID for 13 days and once on Day 14
48000675|NCT01736696|DRUG|tofacitinib|60 mg tablet once a day (QD) for 14 days
48000676|NCT01736696|DRUG|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
48000677|NCT03408015|DRUG|Lifitegrast|Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
48000678|NCT04745897|OTHER|eTB Catalogue of Recommendations (eTB)|eTB Catalogue of Recommendations (eTB)
48000679|NCT04745897|OTHER|World Health Organization Tuberculosis Website (WHO TB)|World Health Organization Tuberculosis Website (WHO TB)
48685920|NCT06140251|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
48685921|NCT06365255|OTHER|questionnaires|filling in questionnaires
48685922|NCT00003421|BIOLOGICAL|bleomycin sulfate|
48685923|NCT00003421|DRUG|ABVD regimen|
48685924|NCT00003421|DRUG|chlorambucil|
48685925|NCT00003421|DRUG|dacarbazine|
48685926|NCT00003421|DRUG|doxorubicin hydrochloride|
48685927|NCT00003421|DRUG|etoposide|
48685928|NCT00003421|DRUG|prednisolone|
48685929|NCT00003421|DRUG|procarbazine hydrochloride|
48685930|NCT00003421|DRUG|vinblastine sulfate|
48000680|NCT06213402|OTHER|Data collection from EHR.|Collection of clinical and laboratory data. Reviwe of the electronic health record
48000681|NCT04796831|DRUG|Quizartinib dihydrochloride|Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)
48685931|NCT00003421|DRUG|vincristine sulfate|
48685932|NCT00003421|RADIATION|radiation therapy|
48000682|NCT04796831|DRUG|14C-Quizartinib solution for infusion|50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
48000683|NCT03299192|BEHAVIORAL|Tai Chi|Yang Style Tai Chi
48000684|NCT03299192|BEHAVIORAL|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
48000685|NCT03299192|OTHER|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
48000686|NCT01930292|DRUG|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
48000687|NCT01930292|DRUG|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
48000688|NCT01930292|DRUG|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
48000689|NCT01930292|DRUG|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
48685933|NCT04859348|OTHER|routine physical therapy|G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
48158067|NCT05993832|OTHER|input cue|The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
48000690|NCT01280292|DRUG|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
48000691|NCT02235376|OTHER|weaning trial of mechanical ventilation|
48000692|NCT04106310|DEVICE|High-flux dialyzer|a dialyzer meeting the definition of high-flux
48158068|NCT04620681|BIOLOGICAL|CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes|Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent
48158069|NCT04620681|DRUG|Standard of Care Chemotherapy|Standard of care cytarabine-based chemotherapy
48158070|NCT06317311|BIOLOGICAL|Dostarlimab|Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)
48158071|NCT06317311|DRUG|Carboplatin|Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)
48158072|NCT06317311|DRUG|Paclitaxel|Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
48158073|NCT00802334|DRUG|generic lopinavir/ritonavir|"1. Screening visit~   • Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~2. Baseline visit~   • (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~3. Week 4~   * Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
48158074|NCT05264311|OTHER|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study \[31\]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
48158075|NCT01747616|DEVICE|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
48158076|NCT01747616|OTHER|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
48158077|NCT03741283|OTHER|Optimisation of nutrition and medication|"1. Inter-professional optimisation of medication prescribing:~   Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~2. Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~* Dysphagia: occupational therapy intervention.~* Oral cavity problems: odontological intervention.~* Depression: geriatric intervention.~* Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
48000693|NCT04106310|DEVICE|Theranova dialyzer|a middle cut-off dialyzer
48000694|NCT03773731|BEHAVIORAL|High intensity interval training (HIIT)|Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
48000695|NCT03773731|BEHAVIORAL|Moderate intensity continuous training (MICT)|Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
48000696|NCT06049056|OTHER|Invitation|During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
48158078|NCT01642030|DRUG|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
48000697|NCT06250062|DRUG|Recombinant humanized IL-17A Monoclonal Antibody（JS005）|Injection
48000698|NCT06250062|DRUG|Placebo（JS005）|Injection
48000699|NCT05906862|DRUG|AMT-253|Administered intravenously
48000700|NCT04616807|DRUG|Mexiletine|Observational Study
48000701|NCT04925063|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
48000702|NCT05938361|OTHER|Psoriasis clinical assessments|Global evaluation of psoriasis and specific evaluation by areas
48000703|NCT05938361|OTHER|Quality of life evaluation|DLQI questionnaire at each visit
48000704|NCT05938361|OTHER|Satisfaction assessment|Visual analogic scale at W16, W28, W52
48000705|NCT05938361|OTHER|Pruritus evaluation|Visual analogic scale at each visit
48000706|NCT03928951|OTHER|General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments|Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
48000707|NCT03168464|DRUG|Ipilimumab|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
48158079|NCT01642030|DRUG|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
48158080|NCT01642030|DRUG|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
48158081|NCT06388876|OTHER|Exercise|Members of the exercise group received an exercise intervention twice a week for six weeks accompanied by a physiotherapist.
48158082|NCT06388876|OTHER|lifestyle advice|At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).
48158083|NCT01169571|DRUG|Dexmedetomidine|
48158084|NCT01212952|DRUG|pomalidomide|Given orally
48158085|NCT01212952|DRUG|bortezomib|Given IV
48158086|NCT01212952|DRUG|dexamethasone|Given orally
48000708|NCT03168464|DRUG|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
48158087|NCT01212952|OTHER|laboratory biomarker analysis|Optional correlative studies
48000709|NCT03168464|RADIATION|Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
48000710|NCT01112527|DRUG|PF-00299804|Taken orally once a day
48000711|NCT03658083|PROCEDURE|Thoracotomy|Open surgery
48000712|NCT03658083|PROCEDURE|Robotic-assisted thoracic surgery|Minimally invasive surgery
48000713|NCT06167018|BEHAVIORAL|Gut-directed hypnotherapy|Gut-directed hypnotherapy for patients with irritable bowel syndrome (IBS). Gut-directed hypnotherapy (8-12 sessions), were given either in an individual manner or in a group setting.The hypnosis treatment is administered by two nurses specially trained in Cognitive Behavioral Therapy (CBT) and hypnotherapy. The treatment was based on the North Carolina protocol. Patients assessed gastro-intestinal symptom severity before, during and after treatment, as well as at follow-up.
48000714|NCT04947332|PROCEDURE|Auto-inoculation|A wart will be excised from the body, minced and will be inoculated in a subcutaneous pocket on forearm.
48000715|NCT00081614|DRUG|Avastin (bevacizumab)|
48000716|NCT00081614|DRUG|Tarceva (erlotinib HCl)|
48000717|NCT03981133|BEHAVIORAL|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
48158088|NCT01212952|OTHER|gene expression analysis|Optional correlative studies
48158089|NCT01552642|BEHAVIORAL|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
48158090|NCT03867123|DRUG|LAM561|Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
48158091|NCT03867123|RADIATION|RT|In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
48158092|NCT03867123|DRUG|TMZ|Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
48158093|NCT00895297|DRUG|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
48158094|NCT04389983|DIETARY_SUPPLEMENT|Medium Chain Triglyceride oil|Bulletproof Braine Octane MCT oil
48158095|NCT04503551|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
48158096|NCT04503551|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
48158097|NCT02814279|PROCEDURE|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
48158098|NCT02814279|PROCEDURE|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
48158099|NCT02814279|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
48158100|NCT02814279|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
48000718|NCT03981133|BEHAVIORAL|no pacifier|not to offer a pacifier at 15 days of life
48000719|NCT04110483|PROCEDURE|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
48000720|NCT04110483|PROCEDURE|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
48000721|NCT00480779|BEHAVIORAL|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
48000722|NCT00480779|BEHAVIORAL|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
48000723|NCT06350175|COMBINATION_PRODUCT|Nicotine Replacement Therapy Agent|The NRT Agents-- 21mg nicotine patches (x14) and 2 mg nicotine lozenges (\~210).
48000724|NCT06350175|OTHER|West Virginia Quit Line|Instructional Pamphlets and contact information for the WV QL. A telehealth line set up to assist people of WV to quit smoking.
48000725|NCT03203902|OTHER|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
48000726|NCT04055597|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
48000727|NCT04055597|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
48000728|NCT02979743|BEHAVIORAL|Occupational therapy|
48000729|NCT02979743|OTHER|Occupational therapy puls acupuncture and massage methods|
48000730|NCT03861260|PROCEDURE|Rigid cystoscopy with urethral dilatation|Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
48000731|NCT03861260|PROCEDURE|Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)|Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
48000732|NCT03821012|OTHER|in-hospital process optimization|
48000733|NCT03821012|OTHER|PPCI hospital-based regional STEMI transfer network construction|
48000734|NCT03821012|OTHER|the whole-city STEMI care network construction|
48685934|NCT04859348|OTHER|routine physical therapy and antenatal exercises|G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
48685935|NCT00265837|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
48000735|NCT02413827|DRUG|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
48685936|NCT00265837|PROCEDURE|allogeneic bone marrow transplantation|
48685937|NCT00265837|PROCEDURE|in vitro-treated bone marrow transplantation|
48685938|NCT05954949|PROCEDURE|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
48685939|NCT05156437|DRUG|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
48685940|NCT05156437|DRUG|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
48158101|NCT01459523|PROCEDURE|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
48000736|NCT02413827|DRUG|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
48000737|NCT01499888|PROCEDURE|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
48158102|NCT01459523|PROCEDURE|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
48366798|NCT06157411|BEHAVIORAL|Mindful Eating Intervention (AC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life."
48618158|NCT02912936|DIETARY_SUPPLEMENT|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
48618159|NCT02522845|DEVICE|Class II Compression Stockings (no specific device used)|This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
48618160|NCT02367560|PROCEDURE|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
48000738|NCT01499888|DRUG|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
48000739|NCT01499888|DRUG|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
48000740|NCT02146482|OTHER|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
48000741|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - TBW training|The investigators will use a temporal order judgment (TOJ) with a visual (light) cue and a motion (yaw rotation, y-translation) cue. The relative timing of the motion onset and the light are varied and subjects indicate which occurred first by pressing a button after the motion ends. The TOJ task will generate a psychometric curve and the PSS (point of subjective simultaneity) and TBW (temporal binding window) are calculated. Then training focuses on SOAs (stimulus onset asynchronies) near the TBW borders (e.g., PSS +/- 0.5xTBW), starting from 50 ms outside the TBW and moving randomly towards the PSS. The goal of the training is to narrow the TBW -- training trials will be provided for 30 min and after each response the subject is told if their response was right or wrong. After training, the TOJ task is repeated to determine how the TBW has changed. Sham training will be the same as the actual training except that verbal feedback of response accuracy will not be provided.
48000742|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS training|After the PSS and TBW are calculated with the standard TOJ paradigm, 100 training trials are provided where the SOA is set to \[PSS - 200 ms\], with the goal of shifting the PSS more negative. Then the TOJ task will be repeated but every 10 testing trials will be followed by 10 training trials (SOA = PSS - 200), and this pattern will be repeated 10 times to 100 more training trials interspersed with the Post TOJ data. Subjects will respond after all trials and testing and training will not be distinguished. After this is completed, the new PSS and TBW are calculated. Sham PSS training will be identical to the above except that the 'training' period will consist of random SOAs rather than a series of fixed SOAs.
48000743|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS adaptation with VI stimulation|The adaptation will utilize the same approach used in non-implanted patients. The investigators will provide a repeated, fixed SOA with either the CI or VI leading the other stimulus by 220 ms. After the training period, which will match the number of stimuli pairs provided to our normal vestibular-auditory control subjects undergoing PSS adaptation, the TOJ study is repeated to recalculate the PSS and TBW.
48000744|NCT04196933|BEHAVIORAL|Chronic Motion-modulated Stimulation|To provide 8 hours of 'physiologic' CI and VI inputs during normal activities, the investigators will employ standard motion-modulated stimulation with the VI. This requires pre-adaptation to a 200 pps tonic stimulation rate (to emulate the push-pull design of the native vestibular system allowing modulating stimulation upward or downward with opposite directions of motion). The three electrodes are connected to the head-mounted prosthetic circuit, which consists of three angular velocity sensors (one aligned with the sensitive axis of each canal) such that head rotations in the plane of the given canal modulate the stimulation rate of the corresponding electrode, upward (for ipsi) or downward (for contralateral) head rotations, thereby simulating normal canal-mediated modulations.
48000745|NCT00199290|DRUG|Trafermin (genetical recombination)|
48000746|NCT05930665|DRUG|Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin|Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
48000747|NCT01385475|BEHAVIORAL|RT|8 week RT Intervention
48685941|NCT03238274|DEVICE|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
48000748|NCT01100242|DRUG|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
48000749|NCT04859868|DEVICE|Galvanic Vestibular Stimulation|Low electrical currents to the vestibular system, to induce the realistic sensation of motion (i.e., the g-forces that occur during flight) as well as null out motion perception.
48000750|NCT01009099|OTHER|breathing retraining|breathing retraining using a metronome
48685942|NCT05640050|OTHER|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
48000751|NCT01009099|OTHER|exercise training|treadmill exercise training
48000752|NCT03249285|DRUG|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
48000753|NCT03249285|DRUG|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
48158103|NCT01459523|PROCEDURE|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
48618161|NCT02367560|PROCEDURE|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
48618162|NCT02367560|DRUG|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
48618163|NCT02367560|DEVICE|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
48618164|NCT01821313|OTHER|Moderate exercise|
48618165|NCT01821313|OTHER|High Intensity Interval Exercise|
48618166|NCT03033888|BEHAVIORAL|Health-Literacy Focused Education Session|
48685943|NCT05445921|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
48685944|NCT04372550|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
48685945|NCT04372550|OTHER|Standard of Care|Standard of care rehabilitation
48685946|NCT00452075|DRUG|erlotinib|150mg daily
48000754|NCT04601545|BEHAVIORAL|Pulmonary rehabilitation|"Three weeks of pulmonary rehabilitation conducted in an outpatient care facility:~* 5- time a week for 30 minutes a specific respiratory exercises- relaxation exercises for breathing muscles, exercises to increase breathing, prolonged exhalation exercise, chest percussion~* 5- time a week for 20-30 min training on a cycle ergometer - until the Heart Rate reaches 60% of the HRmax~* 5- time a week for 30 minutes a fitness and respiratory exercises - coordination and balance exercises, stretching exercises~* relaxation by Schultz Autogenic Training. The technique involves the daily practice of sessions that last around 15 minutes. During each session, the practitioner repeats a set of visualisations that induce a state of relaxation."
48000755|NCT04601545|DEVICE|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.~By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
48000756|NCT05394675|DRUG|DS-9606a|Intravenous infusion
48685947|NCT05842434|DEVICE|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
48685948|NCT04342949|BEHAVIORAL|quality of life|To observe the difference of quality of life
48685949|NCT00000788|DRUG|Methadone hydrochloride|
48000757|NCT01389180|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
48000758|NCT01389180|BEHAVIORAL|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
48000759|NCT01389180|BEHAVIORAL|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
48000760|NCT03454074|BEHAVIORAL|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
48000761|NCT03454074|BEHAVIORAL|Education|Education about healthy brain aging behaviors provided.
48000762|NCT04248816|BEHAVIORAL|Usual care|Subjects will receive outreach through their providers as is standard of care.
48000763|NCT04248816|BEHAVIORAL|Opt-out|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
48000764|NCT04248816|BEHAVIORAL|Opt-out + Incentive|Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
48000765|NCT01297868|OTHER|exercise|
48685950|NCT00000788|DRUG|Fluconazole|
48685951|NCT01811589|DEVICE|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
48685952|NCT01811589|OTHER|Free-hand|Ventricular catheter placement without a guidance (free-hand)
48685953|NCT03438708|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
48685954|NCT02570724|DRUG|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
48685955|NCT02570724|BIOLOGICAL|blood patch|
48685956|NCT04107740|DRUG|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
48000766|NCT02985632|DRUG|BMS-986141|
48685957|NCT04107740|DRUG|Placebo|BID, 10mg per day, for 24 weeks
48685958|NCT05849675|DRUG|Pitolisant 17.8 MG [Wakix]|Single dose pitoliosant (36mg)
48685959|NCT05849675|DRUG|Placebo|Single dose placebo
48685960|NCT01895400|DRUG|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
48685961|NCT01895400|DRUG|Placebo|Take placebo drug 1T bid po medication for 8 weeks
48685962|NCT06301776|DRUG|Ticagrelor|To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
48685963|NCT04848467|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
48685964|NCT04848467|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
48366799|NCT06157411|BEHAVIORAL|Conventional Dietetic Intervention (DC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1"
48000767|NCT01256112|BEHAVIORAL|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
48000768|NCT01256112|BEHAVIORAL|Nutrition/Activity Education (NAE)|
48000769|NCT03087656|DRUG|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
48000770|NCT03087656|DRUG|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
48000771|NCT00127712|DRUG|Amiodarone|
48000772|NCT05117411|DIAGNOSTIC_TEST|OCTA and pseudophakin cystoid edema|Patients underwent OCT angiografia after cataract surgery
48000773|NCT03098342|PROCEDURE|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
48000774|NCT03098342|DRUG|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
48000775|NCT03266120|OTHER|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
48000776|NCT03266120|OTHER|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
48000777|NCT03364296|OTHER|Blood Samples|Blood sample retrieved for biological assessment and biobanking
48000778|NCT01933906|DRUG|P1101|
48000779|NCT01520363|DRUG|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
48000780|NCT01520363|DRUG|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
48618167|NCT04908501|OTHER|Intervention|The program intervention has three focuses : the prioritization of appropriateness indicators, the automation and visualization of the prioritized indicators, and support for practice analysis groups (PAG) based on e-feedback from automated indicators
48000781|NCT02597556|DRUG|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
48000782|NCT02597556|DRUG|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
48000783|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg)|"Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
48000784|NCT04411433|DRUG|Favipiravir (3600 mg + 1600 mg)|"Drug: Favipiravir (3600 mg + 1600 mg) Dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
48685965|NCT04848467|OTHER|Placebo|One intramuscular injection as normal saline \[0.9% NaCl\].
48685966|NCT03861416|DRUG|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
48000785|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|"Hydroxychloroquine Dosage and method of administration: in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
48158104|NCT01459523|PROCEDURE|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
48000786|NCT04411433|DRUG|Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|"Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator."
48000787|NCT04411433|DRUG|Hydroxychloroquine|"Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total)."
48000788|NCT04411433|DRUG|Hydroxychloroquine combined with Azithromycin|"Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total)."
48000789|NCT04200248|DRUG|RBM-007 Injectable Solution|RBM-007 Injectable Solution
48000790|NCT04200248|DRUG|Aflibercept|EYLEA® (aflibercept) Injection, for Intravitreal Use
48000791|NCT04200248|DRUG|Sham|Sham intravitreal injection
48000792|NCT03323658|DRUG|Bexarotene|Given topically
48000793|NCT03323658|OTHER|Questionnaire Administration|Ancillary studies
48000794|NCT03645668|DRUG|Meropenem Injection|Different administration types between two groups
48000795|NCT04147312|DRUG|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
48000796|NCT04147312|DRUG|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
48000797|NCT06244264|PROCEDURE|Autoblood transfusion|Through a negative pressure suction device, the patient's blood that flows out during surgery is collected into a blood storage filter. During the suction process, it is mixed with an appropriate anticoagulant and passed through multiple layers of filters. When the volume of recovered blood reaches a certain level, it is continuously (or intermittently) centrifuged. Using a high-speed centrifugal blood recovery tank, the red blood cells are separated, and the plasma, waste, cell fragments, anticoagulants, and harmful components are diverted into a waste bag. A large amount of saline is used to repeatedly wash, purify, and concentrate the red blood cells. Finally, the concentrated red blood cells are prepared into a 70% red blood cell suspension with saline and stored in a collection bag for transfusion back to the patients. Open surgery is considered as the standard procedure for metastatic spinal cord compression
48000798|NCT00563238|DRUG|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
48000799|NCT04233970|BEHAVIORAL|web-based intervention programme|"The intervention will be designed as an individualized, dialogue-based system that will provide PwMS coordinated, individually tailored information based on the software platform broca®. The intervention programme will consist of three sections:~1. EBPI/decision aid (five modules plus decision aid in case of an acute relapse) provided by the broca® programme. The key element of the EBPI/decision aid is the information on glucocorticosteroids for the treatment of acute relapses.~2. A webinar led via WebEx by a trained MS nurse with questioning/chat session (approx. 60-75min).~3. A supervised chat room provided via the DMSG (https://www.dmsg.de/ms-connect). In addition, email reminders will be used to enhance involvement of participants."
48000800|NCT04233970|BEHAVIORAL|web-based information material offered via the same platform (broca®) in addition to usual care|Participants in the control group will have access to web-based information material offered via the same platform (broca®) in addition to usual care. The control group intervention will be based on material of the German Multiple Sclerosis Society (DMSG) on relapse management. The programme will accompany the participants over a period of 4 weeks and a reminder system with neutral e-mail reminders will be used to promote the use of the programme.
48000801|NCT01716728|OTHER|enzyme analysis|
48000802|NCT00476021|DEVICE|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
48000803|NCT03903627|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
48158105|NCT03214055|DRUG|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
48158106|NCT02297529|DRUG|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
48158107|NCT04248049|OTHER|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
48158108|NCT06538675|OTHER|Psychotherapy|Patients are assigned to a therapist and will receive psychotherapy
48158109|NCT01607099|PROCEDURE|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
48158110|NCT00191984|DRUG|pemetrexed|400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
48158111|NCT00191984|DRUG|irinotecan|180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
48158112|NCT03151551|DRUG|Ixekizumab|Administered SC
48158113|NCT03151551|DRUG|Adalimumab|Administered SC
48618168|NCT00250484|DEVICE|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
48000804|NCT00891358|BEHAVIORAL|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
48000805|NCT04796246|OTHER|Leap Motion Controller|Training with the Leap Motion Controller instrument will be carried out first for 5 minutes, for a presentation and interaction of the virtual immersion with it, in the initial meeting. After the second meeting, the attendance protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games it was adopted about 2 minutes of rest.
48000806|NCT04796246|OTHER|Conventional Physiotherapy|The conventional physiotherapy intervention will be based on the same activities developed (MMSS movements) of the IG: - First, attach pins with magnets with moving disc and after 1 minute and 25 seconds remove flower petals from inside a tube. The movements performed will be fine motricity, related to the tweezers handling (thumb and forefinger), alternating hands after 2 minutes and 30 minutes of play; - Hitting your hands on suddenly raised rulers, performing bilateral flexion / extension movements of the wrist simultaneously and alternating hands after 2 minutes and 30 minutes of play.
48000807|NCT00647127|DRUG|Buprenorphine|Buprenorphine: 20microg/h
48000808|NCT00647127|DRUG|Fentanyl|Fentanyl: 25microg/h
48000809|NCT00647127|DRUG|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
48000810|NCT02051465|DEVICE|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
48000811|NCT02051465|DEVICE|Removal without overtube|Endoscopic removal of polyp without overtube
48000812|NCT04995016|DRUG|Pembrolizumab|PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
48685967|NCT03861416|DRUG|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
48685968|NCT03861416|DRUG|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
48685969|NCT02036580|BIOLOGICAL|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
48685970|NCT02036580|BIOLOGICAL|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
48000813|NCT04995016|DRUG|Axitinib|Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
48158114|NCT00079599|DRUG|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
48158115|NCT00079599|OTHER|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
48000814|NCT00353743|DRUG|placebo|placebo
48158116|NCT03022734|DRUG|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
48158117|NCT03022734|RADIATION|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
48158118|NCT06484660|PROCEDURE|Minimally Invasive Approach In The Mucosal Advancement Flap Technique|Surgical treatment of complex perianal fistula. Less tissue damage. Electrocoagulation source with 75% lower power. Better de-epithelialization of the intra-sphinteric tract. More precise closure of orifice. More consistent mucosal flap
48158119|NCT04143100|OTHER|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
48685971|NCT02036580|OTHER|Placebo|
48685972|NCT03244709|DRUG|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
48685973|NCT04994665|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
48685974|NCT04994665|PROCEDURE|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
48685975|NCT05824663|DRUG|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
48685976|NCT00196690|DRUG|Donepezil|
48685977|NCT03493061|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
48685978|NCT03493061|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
48685979|NCT03493061|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
48685980|NCT01474005|DEVICE|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
48685981|NCT01098331|PROCEDURE|Radical Prostatectomy|
48685982|NCT01098331|PROCEDURE|Brachytherapy|
48685983|NCT00932438|DEVICE|LC beads loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan
48685984|NCT00932438|DRUG|Oxaliplatin|Oxaliplatin 85 mg/sqm, IV infusion every two weeks
48685985|NCT00932438|DRUG|Leucovorin|Leucovorin 200 mg/sqm, IV infusion every two weeks
48685986|NCT00932438|DRUG|5-Fluorouracil|5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
48685987|NCT00932438|DRUG|Bevacizumab|Bevacizumab 5 mg/kg given at the discretion of the treating physician
48685988|NCT04706780|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
48685989|NCT05779228|BEHAVIORAL|Mode Switching Training|Wear of colored lenses for 1 hr, 5 times per day, for 5 days
48685990|NCT03051464|PROCEDURE|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
48685991|NCT03051464|RADIATION|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
48685992|NCT03051464|RADIATION|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
48685993|NCT04984343|RADIATION|Radiation Therapy|"Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.~After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.~Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \>72 hours between beginning of each fraction."
48685994|NCT05570721|BEHAVIORAL|Trier Social Stress Test|The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.
48685995|NCT00287001|DEVICE|Cold air cooling|
48685996|NCT05891015|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
48685997|NCT03522935|DRUG|Elafin|Elafin subcutaneous.
48685998|NCT03522935|DRUG|Placebo|Placebo subcutaneous.
48158120|NCT00443599|DRUG|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
48158121|NCT00443599|OTHER|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
48366800|NCT05011240|BEHAVIORAL|Paediatric Autism Communication Therapy (PACT)|PACT is a parent-mediated therapy that aims to improve children's social-communication development. During PACT, a therapist uses video-feedback of parent-child play interactions to coach the parent in how to improve their sensitivity and responsiveness to their child's social-communication and interaction behaviours and to implement evidence-based strategies that facilitate social-communication development.
48685999|NCT06214676|DEVICE|OCT angiography|Detection of microvascular changes in patients with primary open angle glaucoma by using Optical Coherence Tomography Angiography
48686000|NCT02110849|RADIATION|Proton|Proton Therapy for Prostate Cancer
48686001|NCT01009970|DRUG|Rituximab|375 mg/m2 day 1
48686002|NCT01009970|DRUG|Cyclophosphamide|750 mg/m2 day 2
48686003|NCT01009970|DRUG|Vincristine|1,4 mg/m2 (max 2 mg) day 2
48686004|NCT01009970|DRUG|Prednisone|40 mg/m2 day 2-6
48686005|NCT01009970|DRUG|Doxorubicin|50 mg/m2 day 2
48686006|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
48686007|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
48686008|NCT02974140|DEVICE|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
48158122|NCT04392154|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
48158123|NCT06154733|PROCEDURE|Photobiomodulation usinf low level laser therapy|Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions.
48686009|NCT02974140|PROCEDURE|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
48000815|NCT00353743|DRUG|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
48686010|NCT02511795|DRUG|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
48686011|NCT02511795|DRUG|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
48158124|NCT06154733|PROCEDURE|Resin-based sealant|Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
48158125|NCT06154733|PROCEDURE|Glass ionomer sealant|"Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.~For the duration of the study, children will be instructed to undergo regular tooth brushing and flossing. Any other needed treatment will be done for the child."
48158126|NCT00938288|DRUG|KW-3357|50IU/mL, IV single dose
48158127|NCT05348642|DIETARY_SUPPLEMENT|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
48158128|NCT05348642|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
48686012|NCT03975335|BEHAVIORAL|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
48158129|NCT04715711|OTHER|Forearm coolng|forearm immersion will be performed for active cooling assessment
48158130|NCT04715711|OTHER|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
48158131|NCT04715711|OTHER|mist-fan|a mist-fan will be placed in front of the participant for active cooling
48158132|NCT04715711|OTHER|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
48686013|NCT03975335|OTHER|Carrier Guidance|Carrier opportunities and counselling
48686014|NCT05294484|DRUG|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
48000816|NCT01339351|BEHAVIORAL|Therapeutic Group by Teleconference|10 sessions
48000817|NCT05086796|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor"
48000818|NCT04649775|DEVICE|AirFLO2|Mask device
48158133|NCT02239666|OTHER|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
48158134|NCT05476978|DIAGNOSTIC_TEST|EUS-AI model|The test subset (approximately 20% of total patients) is reserved for the final evaluation of the EUS-AI model. Clinical parameters and EUS pictures of each patient in the test subset will be inputed into the trained EUS-AI model, and the most possible diagnosis will be given by the model.
48686015|NCT04051294|DIETARY_SUPPLEMENT|Commercial kombucha tea|Commercially-available kombucha tea.
48686016|NCT04051294|DIETARY_SUPPLEMENT|Brewed kombucha tea|Kombucha tea brewed
48686017|NCT04051294|OTHER|Control: Tea|Tea brewed in our lab.
48686018|NCT04051294|OTHER|Control: Water|Tap water
48686019|NCT00293813|DRUG|Alendronate|Alendronate 70 mg PO QW
48686020|NCT00293813|DRUG|Denosumab|denosumab 60 mg SC q 6 mos
48000819|NCT01571895|DRUG|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
48000820|NCT02457403|DEVICE|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
48000821|NCT02457403|OTHER|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
48000822|NCT03462316|BIOLOGICAL|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
48000823|NCT01139333|GENETIC|gene expression analysis|
48000824|NCT01139333|GENETIC|western blotting|
48000825|NCT01139333|OTHER|flow cytometry|
48000826|NCT01139333|OTHER|laboratory biomarker analysis|
48000827|NCT05761379|DEVICE|Photobiomodualtion Therapy|low lever light therapy with laser semi-conductor at wavelength of 650nm
48000828|NCT05761379|DEVICE|Single vision spectacles for correction myopia|Provide the distance best corrected vision acuity of refractive error of myopia for all the groups
48000829|NCT02281136|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
48000830|NCT02281136|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
48000831|NCT05377528|DRUG|AGEN1571|A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
48158135|NCT00647699|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
48158136|NCT00647699|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
48158137|NCT04911322|DEVICE|ultrasonography|"A full obstetric ultrasound scan will be performed to assess signs of placental invasion, to document fetal biometry, estimated fetal weight, amniotic fluid index, assess fetal lung maturity parameters as pulmonary artery Doppler waveforms, amniotic fluid free floating particles, bowel echogenicity, fetal epiphyseal ossific centers, liver/lung echogenicity and kidney length.~Pulmonary artery Doppler: Fetal echocardiography will be done. Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time ratio will be measured in the main pulmonary artery."
48158138|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
48158139|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
48158140|NCT01562821|DRUG|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
48366801|NCT05011240|BEHAVIORAL|Psychoeducation|Control participants will receive monthly psychoeducation sessions led by a developmental specialist
48366802|NCT06354075|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (explanatory video, information form, etc.).
48366803|NCT04809142|DRUG|TQB2450 Injection|TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
48366804|NCT04809142|DRUG|Anlotinib hydrochloride|Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
48000832|NCT05377528|DRUG|Balstilimab|A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.
48000833|NCT05377528|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
48000834|NCT04130295|OTHER|Wearable intensive nerve stimulator|The wearable device consists of 2 leads that provide biphasic, with alternating lead phase, asymmetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
48000835|NCT00762398|DEVICE|Masimo hemoglobin-meter|Placing a probe on the finger
48000836|NCT00762398|BIOLOGICAL|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
48000837|NCT01035944|DEVICE|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
48000838|NCT01035944|DEVICE|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
48000839|NCT01188603|DRUG|flibanserin 100 mg dose every evening|all subjects receive flibanserin
48000840|NCT01577667|DEVICE|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
48000841|NCT00856908|DRUG|AZD1656|Tolerable dose given twice daily
48000842|NCT00856908|DRUG|Placebo|Tolerable dose given twice daily
48000843|NCT04517916|DEVICE|Zephyr Valve|Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.
48000844|NCT02030171|OTHER|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
48000845|NCT01944995|DEVICE|glasses broadband|
48000846|NCT01944995|DEVICE|nasal CPAP|
48000847|NCT04066426|DRUG|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
48000848|NCT00483964|DRUG|Bacopa monnieri|
48000849|NCT00483964|DRUG|Nardostachys jatamansi|
48000850|NCT00483964|DRUG|Olanzapine|
48000851|NCT05150535|RADIATION|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
48000852|NCT05150535|RADIATION|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
48000853|NCT01302912|PROCEDURE|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
48000854|NCT06297707|OTHER|aquatic high intensity resistive training|The experimental group participants will involve in aquatic high intensity resistive training sessions. The participants in the intervention group will receive 1 h of supervised lower limb aquatic resistance training three times a week for 12 weeks, for a total of 36 training sessions.
48000855|NCT06297707|OTHER|usual care|The control group will maintain usual care and will be asked to continue their usual leisure time activities. They will be offered the possibility of participating in two sessions consisting of 1 h of light stretching and relaxation during the 3-month intervention period.
48158141|NCT06578247|DRUG|Quizartinib|Participants will receive quizartinib at 60 mg/day orally once daily
48686021|NCT00293813|DRUG|Placebo|Placebo for alendronate and placebo for denosumab
48686022|NCT04239261|DIETARY_SUPPLEMENT|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
48686023|NCT04239261|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed gelatin 10.0 g once daily
48686024|NCT04404790|DRUG|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
48686025|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
48000856|NCT03583996|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
48000857|NCT00779103|DRUG|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
48000858|NCT02539381|PROCEDURE|Formal Perimetry (Goldman or Octopus visual Field)|
48000859|NCT02539381|PROCEDURE|Albert's visual inattention test|
48000860|NCT02539381|PROCEDURE|Star cancellation visual inattention test|
48000861|NCT02539381|PROCEDURE|Visual field assessment to confrontation|
48000862|NCT02539381|PROCEDURE|Visual inattention assessment to bilateral stimuli|
48000863|NCT02539381|DEVICE|Digital tumbling E visual accuity assessment|
48000864|NCT02539381|DEVICE|Digital visual field assessment|
48000865|NCT02539381|DEVICE|Digital line crossing assessment|
48000866|NCT02539381|DEVICE|Digital shape cancellation assessment|
48000867|NCT00233727|PROCEDURE|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
48000868|NCT00233727|PROCEDURE|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
48158142|NCT06578247|DRUG|Placebo|Participants will receive placebo at 60 mg/day orally once daily
48158143|NCT06578247|DRUG|Chemotherapy|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
48366805|NCT04809142|DRUG|Oxaliplatin injection|Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
48366806|NCT04809142|DRUG|Capecitabine tablets|Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
48366807|NCT04809142|DRUG|Gemcitabine hydrochloride injection|Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
48618169|NCT00250484|DEVICE|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
48618170|NCT00185159|DRUG|Olmesartan medoxomil|tablets
48000869|NCT03532997|OTHER|ELOS|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study."
48000870|NCT04884711|OTHER|No Interventions. Participants will be using their everyday digital health technologies.|The investigators will be involving older people to understand the barriers \& facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.
48686026|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
48686027|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
48686028|NCT04404790|DRUG|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
48686029|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
48686030|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
48686031|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
48000871|NCT04884711|OTHER|In depth Interviews|In-depth interviews will be conducted to gather lived experiences of homebound older people.
48000872|NCT04884711|OTHER|Focus Group Discussions|Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
48000873|NCT02676531|OTHER|Exercise|Walking meditation exercise program
48686032|NCT01999244|BEHAVIORAL|Self-monitoring skills|
48686033|NCT01999244|BEHAVIORAL|Technology|
48686034|NCT01999244|BEHAVIORAL|Interventionist Contact|
48686035|NCT04009018|OTHER|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
48686036|NCT03060993|DRUG|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
48686037|NCT03060993|DRUG|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
48686038|NCT05383781|OTHER|Hip and Knee focused exercises|Exercises which improves muscle strength, ROM
48000874|NCT05328830|OTHER|Instrument assisted soft tissue mobilization|Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.
48000875|NCT05328830|OTHER|Foam Roller|Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
48000876|NCT05677620|RADIATION|Pharyngeal Computed Tomography|To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
48686039|NCT05383781|OTHER|Short foot exercise|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
48686040|NCT02406924|PROCEDURE|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
48618171|NCT00185159|DRUG|Placebo Tablets|Tablets
48618172|NCT01126424|DRUG|Solifenacin|tablet
48618173|NCT01126424|DRUG|Oxybutynin|capsule
48618174|NCT01126424|DRUG|Placebo|tablet
48618175|NCT03279315|DIETARY_SUPPLEMENT|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
48618176|NCT01981083|DIETARY_SUPPLEMENT|Egg albumin-based protein supplement|
48686041|NCT02406924|RADIATION|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
48686042|NCT02406924|OTHER|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
48686043|NCT02406924|OTHER|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
48686044|NCT04732442|DIETARY_SUPPLEMENT|Immunonutrition|Impact Oral® Nestle, Switzerland
48686045|NCT04732442|DIETARY_SUPPLEMENT|Standard Oral Nutritional Support|Fortimel Compact Protein® Nutricia, United Kingdom
48686046|NCT05170477|PROCEDURE|apical patency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
48686047|NCT05170477|PROCEDURE|Non-apical surgery|in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
48686048|NCT05082519|BEHAVIORAL|IDEAL2 Intervention|Intervention of diet and exercise to improve outcomes for ALL patients
48686049|NCT06289894|DRUG|BRY805 injection|BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
48686050|NCT06040684|DIAGNOSTIC_TEST|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
48000877|NCT05677620|DRUG|Drug-Induced Sleep Endoscopy (Propofol)|The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
48000878|NCT05677620|DEVICE|Mandibular Advancement Device|A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
48686051|NCT02236273|BEHAVIORAL|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
48000879|NCT00097721|DRUG|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
48000880|NCT03336216|BIOLOGICAL|Cabiralizumab|specified dose on specified days
48000881|NCT03336216|DRUG|Nab-paclitaxel|specified does on specified days
48000882|NCT03336216|DRUG|Onivyde|specified dose on specified days
48000883|NCT03336216|BIOLOGICAL|Nivolumab|specified dose on specified days
48000884|NCT03336216|DRUG|Fluorouracil|specified dose on specified days
48000885|NCT03336216|DRUG|Gemcitabine|specified dose on specified days
48000886|NCT03336216|DRUG|Oxaliplatin|specified dose on specified day
48000887|NCT03336216|DRUG|Leucovorin|Specified dose on specified days
48000888|NCT03336216|DRUG|Irinotecan Hydrochloride|Specified dose on specified days
48000889|NCT00588445|DRUG|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (\> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
48000890|NCT05683119|OTHER|Exercise and blood draw|This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle \[MC\] and oral contraceptive pill \[OCP\] use, on aspects of exercise physiology and athletic performance in female athletes. This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes. The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
48158144|NCT01219153|DRUG|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
48686052|NCT02236273|BEHAVIORAL|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
48686053|NCT00601614|DRUG|temozolomide|
48686054|NCT00601614|DRUG|vandetanib|
48000891|NCT00099125|DRUG|irinotecan hydrochloride|
48000892|NCT00099125|DRUG|temozolomide|
48000893|NCT00099125|PROCEDURE|adjuvant therapy|
48000894|NCT00099125|RADIATION|radiation therapy|
48000895|NCT06151236|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
48000896|NCT04585516|PROCEDURE|endoscopy|Colonoscopy or gastroscopy
48366808|NCT02855996|OTHER|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
48366809|NCT03484780|DEVICE|VisONE ADS|VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
48686055|NCT00601614|OTHER|immunoenzyme technique|
48686056|NCT00601614|OTHER|laboratory biomarker analysis|
48686057|NCT05085041|BEHAVIORAL|Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)|The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
48158145|NCT01219153|DRUG|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
48158146|NCT02156089|OTHER|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
48158147|NCT00826527|DRUG|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
48000897|NCT01876485|BEHAVIORAL|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
48000898|NCT01876485|BEHAVIORAL|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
48000899|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
48158148|NCT05776745|BEHAVIORAL|Speech|Patients read specific words and sentences
48512955|NCT05439967|OTHER|Conventional Training|Conventional training was applied to the patients in the control group. Conventional training was planned taking into account the following goals: increasing mobility by improving the impaired kinesthetic sensation; improving axial rotation, coordination, flexibility of soft tissues, mobility in and out of bed; increasing body image perception by improving upright and proper posture; and improving balance and gait. The training was applied 3 days a week for 6 weeks, with each exercise session lasting 40-50 minutes, accompanied by a physiotherapist. Each of the exercises was done in 2 sets of 10 repetitions. In gait training, each exercise was performed for 4 minutes.
48512956|NCT00001605|BIOLOGICAL|Nontypeable Haemophilus influenzae|
48686058|NCT04263116|PROCEDURE|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
48686059|NCT01277705|BIOLOGICAL|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
48686060|NCT01277705|BIOLOGICAL|Boostrix™|Intramuscular, single dose
48686061|NCT01277705|BIOLOGICAL|GSK Biologicals' IPV vaccine|Intramuscular, single dose
48686062|NCT01277705|BIOLOGICAL|Revaxis®|Intramuscular, single dose
48000900|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
48000901|NCT00714064|BIOLOGICAL|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
48000902|NCT03413059|DRUG|Morphine Sulfate|Thoracic Epidural morphine
48000903|NCT03413059|DRUG|Triamcinolone Acetonide|thoracic epidural triamcinolone acetonide
48512957|NCT04174612|DRUG|Cytarabine|100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
48512958|NCT04174612|DRUG|Daunorubicin|60 mg/m2/die day 1-3
48686063|NCT05369377|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
48000904|NCT01512953|DRUG|Lansoprazole|Lansoprazole 30 mg once a day
48000905|NCT01289769|DRUG|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
48000906|NCT01289769|DRUG|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
48000907|NCT04930887|DRUG|Exparel (Bupivacaine Liposome)|Non-opioid postsurgical analgesic used in the management of postsurgical pain; 133 mg/10 mL (13.3 mg/mL) single-dose vial (per Pacira), study administers 3cc bilaterally
48000908|NCT04930887|DRUG|Saline|Prescription medicine used for fluid and electrolyte replenishment for intravenous administration; Exparel-matched Placebo treatment
48000909|NCT01971853|DRUG|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
48000910|NCT01971853|DRUG|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
48000911|NCT05756686|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
48000912|NCT05756686|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
48512959|NCT04174612|DRUG|Midostaurin|50 mg/bid day 8-21
48512960|NCT04174612|DRUG|Cytarabine HD|100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
48366810|NCT01031784|DEVICE|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
48000913|NCT05049993|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty using the Aequalis Pyrocarbon Humeral Head
48686064|NCT05369377|DRUG|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
48000914|NCT02146638|DRUG|Morphine|
48686065|NCT05223023|OTHER|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
48000915|NCT02146638|DRUG|Fentanyl|
48366811|NCT01031784|DEVICE|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
48686066|NCT00479102|DRUG|Ferripel-3 - iron polysaccharide complex for prevention|
48686067|NCT01821092|PROCEDURE|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
48686068|NCT01821092|DEVICE|osseointegrated implant|Osseointegrated Implant Insertion
48686069|NCT00002028|DRUG|Didanosine|
48686070|NCT01903122|DRUG|Cevimeline|
48686071|NCT01501890|DRUG|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
48000916|NCT02229942|DRUG|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
48686072|NCT01501890|DRUG|Placebo|0.9% NaCl
48000917|NCT02229942|DRUG|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
48366812|NCT00914472|BIOLOGICAL|heparin sodium - APP|Heparin 5000 IU / mL
48366813|NCT00914472|BIOLOGICAL|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
48366814|NCT05853926|DIAGNOSTIC_TEST|Spinal Manipulation With Laser Therapy|Spinal Manipulation With Laser Therapy in Chronic Lower Backache
48366815|NCT05853926|DIAGNOSTIC_TEST|Dry Needling|Dry Needling in Chronic Lower Backache
48366816|NCT05043896|PROCEDURE|Li-ESWT|Li-ESWT twice weekly for 4 weeks
48000918|NCT05420246|DRUG|Ainuovirine|The regimen including Ainuovirine will be given to HIV-1 infected/AIDS patients.
48512961|NCT02439970|DRUG|Brincidofovir|
48512962|NCT02439970|DRUG|Valganciclovir|
48512963|NCT04406077|DEVICE|Ligasure|Using ligasure to treat hydrocele
48618177|NCT01981083|DIETARY_SUPPLEMENT|Renal-specific oral supplement|
48618178|NCT00455624|DRUG|Androgen deprivation therapy|According to standard medical care
48000919|NCT02926859|DRUG|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
48366817|NCT05043896|DRUG|Tadalafil 2.5Mg Tab|tadalafil 2.5mg once daily
48618179|NCT06003764|OTHER|Pulsed electromagnetic field|low-frequency PEMFT (15 Hz, 50% intensity output for 5 s/min for 20 minutes)
48686073|NCT04322409|DEVICE|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
48686074|NCT04322409|DEVICE|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
48686075|NCT05808582|DRUG|chidamide，fulvestrant|chidamide combined with fulvestrant
48686076|NCT00292071|DRUG|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
48686077|NCT02755662|DEVICE|Mandibular Retention Device|
48686078|NCT01498692|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
48000920|NCT02926859|DRUG|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
48000921|NCT00426283|DRUG|Flovent|1760 mcg daily
48000922|NCT00426283|OTHER|Placebo|Placebo
48000923|NCT00161993|DRUG|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
48366818|NCT00250042|DRUG|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, \& were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) \& then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
48366819|NCT04763460|DEVICE|Programming of CRT device settings|Reprogramming of CRT device to maximize the benefit derived from the electrocardiographic assessment.
48366820|NCT06278831|OTHER|Questionnaire|Patients will be approached three times throughout the study at the beforementioned interview dates to fill out a questionnaire. They will be contacted via e-mail, telephone and/or mobile app.
48366821|NCT06088017|DRUG|CKD-391(2)|QD, PO
48366822|NCT06088017|DRUG|CKD-331, D337|QD, PO
48366823|NCT03039699|DRUG|Ergoferon|
48366824|NCT03039699|DRUG|Placebo|
48366825|NCT01289964|PROCEDURE|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
48686079|NCT01439659|BEHAVIORAL|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
48366826|NCT01449604|RADIATION|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
48686080|NCT01439659|DIETARY_SUPPLEMENT|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
48686081|NCT03836872|DEVICE|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
48686082|NCT05711160|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
48686083|NCT05711160|DIAGNOSTIC_TEST|CBCT images|All patients have been undergoing CBCT scans for both jaws
48686084|NCT05711160|DIAGNOSTIC_TEST|IOS images|The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
48686085|NCT05582356|DIETARY_SUPPLEMENT|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
48686086|NCT05582356|DIETARY_SUPPLEMENT|Placebo group (Group OP|Placebo group (Group OP
48686087|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
48686088|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
48000924|NCT00161993|DRUG|Gammagard S/D (Solvent/Detergent)|
48686089|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
48686090|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
48686091|NCT03073083|PROCEDURE|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
48158149|NCT05776745|DEVICE|Stereoelectroencephalography|Using stereoelectroencephalography to record the Intracranial EEG of the patient
48158150|NCT05416970|BEHAVIORAL|SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES|To assess the impact of the SARS-CoV-2 spread related lifestyle changes on body composition analysis and metabolic syndrome components worsening as well as hepatocellular carcinoma occurrence.
48158151|NCT00072826|DRUG|Oxypurinol|
48158152|NCT00072826|DRUG|L-NMMA|
48366827|NCT01449604|RADIATION|stereotactic radiosurgery|Radio surgery 12 Gy
48366828|NCT04535921|OTHER|FCR7 questionnaire|A 7 item questionnaire about fear of cancer recurrence
48366829|NCT00386035|DRUG|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
48366830|NCT00386035|DRUG|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
48366831|NCT03284931|DRUG|SAGE-217 high dose|high dose
48366832|NCT03284931|DRUG|Placebo|placebo
48366833|NCT03284931|DRUG|SAGE-217 low dose|low dose
48366834|NCT02641665|PROCEDURE|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
48686092|NCT03073083|PROCEDURE|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
48686093|NCT03073083|PROCEDURE|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
48686094|NCT02455804|DEVICE|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
48686095|NCT02018536|DRUG|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
48686096|NCT02018536|DRUG|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
48686097|NCT02018536|DRUG|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
48686098|NCT02018536|DRUG|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
48158153|NCT00072826|DRUG|Acetylcholine|
48000925|NCT01811095|OTHER|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
48000926|NCT00358085|PROCEDURE|Endovascular Repair of Abdominal Aortic Aneurysm|
48158154|NCT03360071|DRUG|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
48366835|NCT01831570|OTHER|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
48366836|NCT01026558|DRUG|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
48366837|NCT02785094|BEHAVIORAL|Observation|Observation of Participants' behaviour
48366838|NCT03419481|DRUG|pembrolizumab|200mg every 3 weeks infusion
48158155|NCT03360071|DRUG|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
48158156|NCT05943379|DRUG|RC48-ADC in Combination with gemcitabine|RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W
48158157|NCT03878147|BEHAVIORAL|Cognitive Games Training|Brain Powered Games (BPG) uses games for neurocognitive assessment and training, using images and sounds more familiar to African children. As a computerized cognitive rehabilitation training (CCRT) program designed for Sub-Saharan African school-age children, it can help children infected affected directly or indirectly by HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records game play data for research purposes. Village Builder (VB) is a pro-social reasoning/planning world building strategy type game intended to evaluate frontal lobe executive functions in a culture-friendly and enjoyable game manner. It consists of many of the village artistic components as used in BPG but orchestrated into a village setting where children must gather resources and protect them in order to expand the capacity of the village.
48366839|NCT04334876|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody Testing Kit|A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
48366840|NCT01641731|OTHER|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
48366841|NCT01684930|DRUG|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
48686099|NCT02018536|DRUG|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
48000927|NCT00358085|PROCEDURE|Conventional open repair of Abdominal Aortic Aneurysm|
48000928|NCT04685876|DRUG|Liposomal bupivacaine|4-quadrant TAP block with liposomal bupivacaine
48000929|NCT04685876|DRUG|Plain bupivacaine|4-quadrant TAP block with plain bupivacaine
48000930|NCT04685876|DRUG|Normal saline|placebo (normal saline).
48000931|NCT03880903|DRUG|normal saline and salbutamol|patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
48158158|NCT03159065|OTHER|Bilberry|Fruit beverage with bilberry and fermented oatmeal
48158159|NCT03159065|OTHER|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
48158160|NCT03159065|OTHER|Mango|Fruit beverage with mango and fermented oatmeal
48158161|NCT03159065|OTHER|Beetroot|Fruit beverage with beetroot and fermented oatmeal
48158162|NCT03159065|OTHER|Rose hip|Fruit beverage with rose hip and fermented oatmeal
48158163|NCT03159065|OTHER|Glucose drink|A reference glucose drink
48158164|NCT00002347|DRUG|Saquinavir|
48366842|NCT01684930|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
48686100|NCT02018536|DRUG|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
48000932|NCT03880903|DRUG|hypertonic saline and salbutamol|patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
48000933|NCT03880903|DRUG|Hypertonic saline|patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
48000934|NCT00456716|DRUG|sorafenib|400mg po bid
48158165|NCT00002347|DRUG|Nevirapine|
48158166|NCT00002347|DRUG|Zidovudine|
48158167|NCT00002347|DRUG|Zalcitabine|
48366843|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
48366844|NCT03931928|DRUG|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)
48366845|NCT04824599|PROCEDURE|PECS II|Pectoral nerves block (PECS II) is performed with the help of ultrasound. Two injection are performed in two fascial planes. One between pectoralis major muscle and serratus anterior muscle. Second one between pectoralis major and minor muscles.
48366846|NCT04824599|PROCEDURE|Local anesthetic infiltration|Ropivacaine is administered by surgeon prior to scrubbing and following the removal of the tumor.
48366847|NCT04824599|PROCEDURE|Subcutaneus local anesthetic infiltration|Ropivacaine is administered by the surgeon at the end of surgery
48686101|NCT02018536|DRUG|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
48686102|NCT02601430|OTHER|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
48686103|NCT03080571|BIOLOGICAL|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
48686104|NCT03080571|OTHER|standard care|
48686105|NCT04437550|OTHER|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
48686106|NCT06430242|DEVICE|Tele rehabilitation|In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months.
48686107|NCT06430242|OTHER|Exercise|Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
48686108|NCT00296049|DRUG|daptomycin|
48686109|NCT00296049|DRUG|vancomycin|
48686110|NCT02727595|DEVICE|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
48686111|NCT00004573|DRUG|ganciclovir|
48686112|NCT04841785|DIAGNOSTIC_TEST|mailer-based finger-prick|All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
48686113|NCT04500392|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
48686114|NCT04500392|DEVICE|Regular nasal cannula|Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
48686115|NCT02782234|BEHAVIORAL|Contract management|
48686116|NCT02378077|PROCEDURE|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
48686117|NCT02378077|PROCEDURE|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
48686118|NCT02378077|DIETARY_SUPPLEMENT|Fish Oil Supplement|Fish Oil supplementation for three months.
48686119|NCT02281227|PROCEDURE|skin compression|skin compression with an indicator for determination of needle entry point
48686120|NCT00595881|DEVICE|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
48512964|NCT02229474|BEHAVIORAL|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
48686121|NCT06523764|DRUG|tegoprazan|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
48686122|NCT06523764|DRUG|Minocycline|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
48686123|NCT06523764|DRUG|bismuth potassium citrate|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
48686124|NCT06523764|DRUG|Esomeprazole 40mg|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
48686125|NCT06523764|DRUG|Amoxicillin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
48686126|NCT06523764|DRUG|clarithromycin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
48686127|NCT01826539|PROCEDURE|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
48686128|NCT05432830|OTHER|E-liquid Flavor 1|E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.
48366848|NCT04824599|DRUG|Ropivacaine|Local anesthetic ropivacaine is administered in both study arms according to the study protocol
48366849|NCT04824599|DEVICE|bk medical Flex Focus 500 Ultrasound Machine|Ultrasound with linear probe is performed. Using in-plane technique a correct placement of the injection needle is secured.
48686129|NCT05432830|OTHER|E-liquid Flavor 2|E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.
48686130|NCT05432830|OTHER|E-liquid Flavor 3|E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
48686131|NCT05959655|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
48686132|NCT02622295|BEHAVIORAL|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
48686133|NCT02622295|BEHAVIORAL|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
48686134|NCT02644252|DRUG|Day 1: Cisplatin 75 mg/m2|
48686135|NCT02644252|DRUG|Day 1: Vinorelbine 25 mg/m2|
48686136|NCT02644252|DRUG|Day 8: Capsule vinorelbine 50 mg/m2|
48686137|NCT02644252|DRUG|Day 1: Carboplatin AUC=5|
48686138|NCT02644252|DRUG|Day 1: Vinorelbine 30 mg/m2|
48686139|NCT02644252|DRUG|Day 8: Capsule vinorelbine 60 mg/m2|
48686140|NCT02644252|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily until progression|
48686141|NCT02644252|DRUG|Placebo 1 capsule x 3 daily until progression|
48000935|NCT03932396|OTHER|Observational study|No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
48000936|NCT00449956|DRUG|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
48000937|NCT00449956|DRUG|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
48000938|NCT00449956|DRUG|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
48000939|NCT02280135|BIOLOGICAL|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
48000940|NCT02280135|OTHER|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
48000941|NCT02578927|DIETARY_SUPPLEMENT|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
48000942|NCT02578927|DIETARY_SUPPLEMENT|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
48000943|NCT02578927|DIETARY_SUPPLEMENT|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
48000944|NCT06140095|DRUG|Evolocumab|See arm description
48000945|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided quadratus lumborum block|prospective randomized comparative study between Group (1) : quadratus lumborum block
48000946|NCT04827043|COMBINATION_PRODUCT|Ultrasound guided thoracic paravertebral block|PVB group: will receive 0.25ml/Kg/side of 0.375% bupivacaine with epinephrine 5ug/ml, yielding the same dose of bupivacaine of 1.875mg/ml at the level of T10 as a single injection sonar guided.
48000947|NCT04049656|DEVICE|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
48000948|NCT04682821|OTHER|Artificial intelligence assistant system|The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
48000949|NCT00326664|DRUG|Cediranib Maleate|Given orally
48000950|NCT03920631|DRUG|Nivolumab|Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule
48000951|NCT03920631|BIOLOGICAL|Microtransplantation|HLA-mismatched peripheral blood stem cells
48000952|NCT04384757|PROCEDURE|Distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
48000953|NCT01936935|OTHER|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
48000954|NCT01936935|OTHER|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
48366850|NCT00937703|DEVICE|placebo|paper support for glycaemia face to face visit at T4mounths
48000955|NCT02928510|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
48000956|NCT02928510|PROCEDURE|Colonoscopy|Undergo colonoscopy
48000957|NCT02928510|PROCEDURE|Colposcopic Biopsy|Undergo colposcopic biopsy
48000958|NCT02928510|DRUG|Idelalisib|Given PO
48000959|NCT02928510|OTHER|Laboratory Biomarker Analysis|Correlative studies
48512965|NCT05798455|DRUG|Sodium Pentaborate|Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
48512966|NCT05868525|DRUG|Aspirin 325Mg Tab, Aspirin 81Mg Tab|Patients will be administrated daily oral Aspirin 81 mg or oral Aspirin 325 mg according to their assigned group after randomization.
48000960|NCT02928510|OTHER|Pharmacological Study|Correlative studies
48000961|NCT02928510|PROCEDURE|Physical Examination|Undergo physical examination
48000962|NCT02928510|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
48000963|NCT01203072|DRUG|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
48000964|NCT01203072|DRUG|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
48000965|NCT01203072|DRUG|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
48000966|NCT01203072|DRUG|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
48000967|NCT01203072|DRUG|Placebo|Matching placebo oral tablets, once daily for 2 weeks
48000968|NCT01505127|DRUG|TAK-438|
48000969|NCT01505127|DRUG|Lansoprazole|
48000970|NCT01505127|DRUG|Amoxicillin|
48000971|NCT01505127|DRUG|Clarithromycin|
48366851|NCT00937703|DEVICE|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
48366852|NCT00937703|DEVICE|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
48366853|NCT03480360|DRUG|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
48366854|NCT03480360|DRUG|Fludarabine|30 mg/m2 daily for 5 days
48366855|NCT03480360|RADIATION|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
48366856|NCT03480360|DRUG|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
48000972|NCT01998048|PROCEDURE|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
48000973|NCT01998048|PROCEDURE|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
48000974|NCT05461131|BIOLOGICAL|BPZE1|Live attenuated vaccine
48000975|NCT05461131|BIOLOGICAL|Placebo|Placebo
48000976|NCT05461131|DRUG|Azithromycin|Antibiotic
48000977|NCT05461131|OTHER|Bordetella Pertussis Challenge Strain|Challenge Strain
48000978|NCT00044343|DRUG|lapatinib|
48158168|NCT02831751|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
48158169|NCT02831751|BIOLOGICAL|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
48158170|NCT02831751|BIOLOGICAL|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
48000979|NCT03591237|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
48000980|NCT02261376|DRUG|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
48000981|NCT03504358|PROCEDURE|Liver resection|Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
48000982|NCT04743661|DRUG|Irinotecan|"Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course."
48000983|NCT04743661|DRUG|Temozolomide|"An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course."
48000984|NCT04743661|DRUG|Bevacizumab|"Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only."
48158171|NCT02831751|BIOLOGICAL|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
48158172|NCT02877680|BEHAVIORAL|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
48158173|NCT05760300|DRUG|Bulevirtide (BLV)|Administered via subcutaneous (SC) injections
48158174|NCT00702234|BIOLOGICAL|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
48158175|NCT00702234|BIOLOGICAL|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
48158176|NCT00702234|BIOLOGICAL|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
48158177|NCT00702234|BIOLOGICAL|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
48512967|NCT01935518|DRUG|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
48512968|NCT03810326|DEVICE|CTR device (tradename named Xtend)|Non invasive active splint
48158178|NCT00702234|DRUG|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
48158179|NCT01177228|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
48000985|NCT04743661|DRUG|Omburtamab I-131|"Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy."
48000986|NCT04743661|DRUG|Liothyronine|Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
48000987|NCT04743661|DRUG|SSKI|SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
48000988|NCT04743661|DRUG|Dexamethasone|Dexamethasone will be given as premedication for 131I-omburtamab to prevent possible meningeal inflammatory reaction. Starting within 24 hours prior to each 131I-omburtamab injection, dexamethasone will be administered orally at 0.5 mg (if weight \< 15 kg) or 1 mg (if weight ≥ 15 kg) twice-daily doses for a total of 6 doses to alleviate infusion-related AEs: Two doses starting 24 hours pre-131I-omburtamab injection, two doses on the day of the injection (can be given before or after), and two doses 24 hours post-131I-omburtamab injection.
48000989|NCT04743661|DRUG|Antipyretic|An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
48000990|NCT04743661|DRUG|Antihistamine|An antihistamine (e.g., IV diphenhydramine \[1 mg/kg, 50 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
48000991|NCT04743661|DRUG|anti-emetics|An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
48000992|NCT00347724|DRUG|Tramadol HCl ER|
48000993|NCT02479737|DEVICE|Blood drainage post cardiac surgery using PleuraFlow System|
48000994|NCT05420558|DIAGNOSTIC_TEST|Fibroblast activation protein inhibitor PET/CT imaging|All participants will receive a 68Ga-labelled fibroblast activation protein inhibitor PET/CT imaging
48366857|NCT03480360|DRUG|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
48366858|NCT03480360|DRUG|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.
48366859|NCT03480360|PROCEDURE|Peripheral Blood Transplant|cell dose goal: \< 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
48686142|NCT03337802|BEHAVIORAL|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
48686143|NCT02705846|OTHER|Observation of treatment outcomes via Questionnaire|Collection of treatment data from participants
48686144|NCT01130909|DRUG|AZD6765|75 mg
48686145|NCT01130909|DRUG|AZD6765|150 mg
48686146|NCT01130909|DRUG|Ketamine|0.5 mg/kg
48686147|NCT01130909|DRUG|Placebo|125 mL sterile NaCl 0.9%
48366860|NCT02943876|OTHER|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
48686148|NCT02997696|DRUG|ONO-4474|
48686149|NCT02997696|DRUG|Placebo matching ONO-4474|
48686150|NCT03312790|DEVICE|Tasks|Augmented reality device Real condition
48686151|NCT02200926|OTHER|Loaded breathing training|7 days/weeks, for 8 weeks
48686152|NCT02200926|OTHER|Unloaded breathing training|7 days/week, for 8 weeks
48686153|NCT02200926|OTHER|Placebo|7 days/week, for 8 weeks
48686154|NCT01140594|PROCEDURE|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
48686155|NCT01140594|PROCEDURE|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
48686156|NCT02039167|DEVICE|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
48686157|NCT06514274|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
48686158|NCT06514274|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
48686159|NCT06514274|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
48686160|NCT06514274|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
48686161|NCT06514274|DRUG|Clarithromycin|Clarithromy 500mg, twice daily for 14 days.
48686162|NCT06514274|DRUG|Esomeprazole|Esomeprazole 10mg, twice daily for 14 days.
48686163|NCT04092803|OTHER|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
48686164|NCT01160393|DEVICE|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
48000995|NCT05603923|BEHAVIORAL|Lumen Coached PST Intervention.|Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.
48000996|NCT05603923|BEHAVIORAL|Human Coached PST Intervention.|Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.
48000997|NCT05603923|BEHAVIORAL|Optional (delayed) Lumen Coached PST (Waitlist control).|Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
48000998|NCT05013983|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
48000999|NCT05013983|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium
48001000|NCT00165425|PROCEDURE|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
48158180|NCT01177228|DRUG|Placebo|Placebo intravenous infusion
48158181|NCT03925402|DRUG|Ertapenem|Ertapenem injection
48686165|NCT05792982|BEHAVIORAL|12 hour fasting for 29 days|This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
48686166|NCT03076489|OTHER|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
48686167|NCT03076489|OTHER|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
48686168|NCT03076489|DEVICE|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
48158182|NCT03925402|DRUG|Carbapenems|Other carbapenems injection
48158183|NCT05324527|OTHER|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
48158184|NCT03921164|PROCEDURE|Trans-oesophageal Doppler|"As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta."
48158185|NCT03921164|PROCEDURE|Trans-thoracic echocardiography|Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
48158186|NCT03921164|PROCEDURE|Applanation tonometry|"Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature."
48158187|NCT04891263|PROCEDURE|Suture-Septoplasty|Patients receive suture-septoplasty for repair of nasal septal deviation.
48158188|NCT04891263|DEVICE|Surgical suture|Suture used for closure during septoplasty surgery.
48158189|NCT00908245|PROCEDURE|Control|Surgery without preconditioning surgery
48158190|NCT00908245|PROCEDURE|Preconditioning ischemia|Surgery with a preconditioning ischemia
48158191|NCT06167915|BIOLOGICAL|30μg dose of LYB002V14|30μg dose of LYB002V14 vaccine IM, on day 0
48158192|NCT06167915|BIOLOGICAL|60μg dose of LYB002V14|60μg dose of LYB002V14 vaccine IM, on day 0
48158193|NCT06167915|BIOLOGICAL|placebo|placebo IM, on day 0
48686169|NCT04381052|DRUG|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
48686170|NCT04381052|OTHER|Placebo|Intravenously administered over 30 minutes.
48001001|NCT00748215|DRUG|calcium aluminosilicate anti-diarrheal|Given orally
48158194|NCT00996619|PROCEDURE|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
48158195|NCT02798861|DEVICE|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
48158196|NCT02086071|PROCEDURE|re biopsy|re biopsy depending on the location of the pathology
48686171|NCT01178476|DEVICE|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
48686172|NCT04148066|DIAGNOSTIC_TEST|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
48686173|NCT02816268|OTHER|Pulmonary vein isolation|
48158197|NCT03053908|PROCEDURE|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
48001002|NCT00748215|OTHER|placebo|Given orally
48001003|NCT02509065|DEVICE|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
48001004|NCT02509065|OTHER|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
48001005|NCT01102413|DRUG|Monofer|Infusion or injections
48001006|NCT01102413|DRUG|Iron Sulphate|Oral intake
48001007|NCT02213211|DRUG|Artemether lumefantrine|
48001008|NCT02321462|DRUG|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
48001009|NCT02321462|DRUG|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
48158198|NCT03053908|PROCEDURE|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
48158199|NCT05935098|DRUG|BGB-A3055|Administered intravenously
48158200|NCT05935098|DRUG|Tislelizumab|Administered intravenously
48158201|NCT01634620|DEVICE|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
48001010|NCT05143970|DRUG|IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB|"Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months.~Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD)."
48001011|NCT06158191|BEHAVIORAL|Lifestyle modification program|Participants will take part in a lifestyle modification program focused on physical activity and diet.
48001012|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
48158202|NCT02201368|DRUG|Triheptanoin (SpezialölÒ 107®)|"* Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
48158203|NCT02201368|DIETARY_SUPPLEMENT|MCT (Medium-Chain Triglycerides)|"* Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months"
48158204|NCT05756348|DEVICE|Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant|All participants will receive both device interventions listed above.
48158205|NCT01904253|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
48158206|NCT01904253|DRUG|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
48158207|NCT01904253|DRUG|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
48158208|NCT05390697|OTHER|Educational videos|Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
48158209|NCT02829411|BEHAVIORAL|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
48158210|NCT02829411|BEHAVIORAL|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
48158211|NCT04854616|BEHAVIORAL|CoSTED Intervention|Brief smoking cessation advice, the provision of an e-cigarette starter kit and training in its use, and referral to stop smoking services.
48158212|NCT04822025|BIOLOGICAL|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
48158213|NCT04822025|BIOLOGICAL|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
48512969|NCT02593292|BEHAVIORAL|PROSPERO|"The intervention is carried out in 3 steps:~1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
48001013|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
48001014|NCT02910167|DRUG|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
48001015|NCT02910167|DRUG|Paracetamol|Paracetamol 500 mg
48001016|NCT03439969|DEVICE|Mobile Text Messages|Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
48001017|NCT03439969|DEVICE|Intra Oral Camera|"SPT - Appointment with Intra-Oral Camera~* Examination and diagnosis (15 min) using Intra-oral camera.~* Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min)."
48158214|NCT04945356|OTHER|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
48158215|NCT05422040|OTHER|Dry needling|Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.
48686174|NCT02342288|PROCEDURE|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
48686175|NCT02342288|PROCEDURE|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
48686176|NCT01734798|RADIATION|Radiation|
48686177|NCT01734798|DRUG|gemcitabine and cisplatin|
48686178|NCT01734798|OTHER|Radiotherapy and Drug|
48686179|NCT02220192|PROCEDURE|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
48686180|NCT01995526|DRUG|Insulin Peglispro|
48686181|NCT00075855|DRUG|therapeutic testosterone|
48686182|NCT00075855|OTHER|placebo|
48686183|NCT03115411|DEVICE|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
48686184|NCT04438759|DEVICE|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
48686185|NCT03449563|COMBINATION_PRODUCT|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
48686186|NCT03449563|COMBINATION_PRODUCT|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
48686187|NCT03449563|OTHER|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
48686188|NCT03340285|DIETARY_SUPPLEMENT|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
48001018|NCT01661712|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
48001019|NCT01661712|DEVICE|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
48001020|NCT03200678|OTHER|isokinetic assessment|muscle torque assessement
48686189|NCT03340285|DIETARY_SUPPLEMENT|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
48686190|NCT06085716|BEHAVIORAL|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
48686191|NCT06085716|DRUG|Open Label Placebo|This group will only take placebo capsules every day.
48686192|NCT06085716|BEHAVIORAL|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
48001022|NCT02609334|DRUG|CRD007|One single dose given 3 hours prior to Mannitol challenge
48001023|NCT02609334|OTHER|Placebo|One single dose given 3 hours prior to Mannitol challenge
48001024|NCT04400396|DIETARY_SUPPLEMENT|standard HM fortification|Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
48001025|NCT04400396|DIETARY_SUPPLEMENT|target HM fortification|Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
48686193|NCT06343545|BEHAVIORAL|Standard of Care|Standard of Care provided by enrolling hospitals
48686194|NCT06343545|BEHAVIORAL|Rehabilitation|An implementation bundle of measures to improve outcomes in intensive care unit, hospital, and after hospital discharge, including rehabilitation at home performed through telemedicine.
48686195|NCT03423030|DRUG|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
48686196|NCT03423030|DRUG|Placebo|matching placebo supplied as powder for oral solution
48686197|NCT03423030|DRUG|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
48158216|NCT05422040|OTHER|Tecartherapy treatment|Treatment will be carried out with deep thermotherapy in the lumbar region.
48001026|NCT05121883|DRUG|Edaravone Dexborneol|Edaravone dexborneol (Jiangsu Simcere Pharmaceutical, Co, Ltd) will be initiated within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days (maximum: 14 days)
48001027|NCT03559712|OTHER|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
48001028|NCT02623803|DRUG|Lidocaine|
48001029|NCT02623803|DRUG|Placebo D5W|
48001030|NCT04702490|DRUG|MET409 Active|MET409 Active (50mg)
48001031|NCT04702490|DRUG|MET409 Placebo|MET409 Placebo (50mg)
48001032|NCT04702490|DRUG|Empagliflozin|Empagliflozin (10mg)
48001033|NCT04407910|COMBINATION_PRODUCT|AIRFLOW® Master device +Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
48001034|NCT04407910|COMBINATION_PRODUCT|rubber-cup+Opalescence Xtra Boost.|Prophylaxis techniques for pre-bleaching treatment
48001035|NCT04820790|OTHER|Mobile applications|Monitoring of patients with home oxygen through a mobile application
48001036|NCT00017264|DRUG|atrasentan hydrochloride|
48001037|NCT01188694|DRUG|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
48001038|NCT01188694|BEHAVIORAL|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
48158217|NCT04566744|OTHER|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
48158218|NCT00471549|DRUG|Statin (simvastatin)|
48158219|NCT06600815|PROCEDURE|preemptive stepwise infiltration anaesthesia(PSIA)|For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.
48512970|NCT02593292|OTHER|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
48001039|NCT01188694|BEHAVIORAL|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
48001040|NCT06110988|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
48001041|NCT04377360|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
48001042|NCT04145258|DRUG|Aspirin|Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
48001043|NCT04145258|DRUG|Placebo of aspirin|Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
48001044|NCT04145258|DRUG|WHO TBM treatment|2 months of (R-H-Z-E) + 7 months of (R-H)
48001045|NCT04145258|DRUG|Intensified TBM treatment|2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
48001046|NCT01434524|DRUG|LIVACT|LIVACT contains 13.0 g of free amino acids
48001047|NCT06266455|DIETARY_SUPPLEMENT|Standardized Fortification|Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz
48001048|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein supplementation to maintain serum BUN levels within goal range (9-14mmol/dL)
48001049|NCT06266455|DIETARY_SUPPLEMENT|Adjustable Fortification|Additional liquid protein and/or MCT oil supplementation to maintain protein, fat, and energy intake within goal range based upon mid-infrared human milk analysis
48001050|NCT02281552|DRUG|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
48001051|NCT02281552|DRUG|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
48001052|NCT02753062|DRUG|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
48512971|NCT04015310|DEVICE|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
48512972|NCT03510598|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting machine will be used to perform the treatments.
48512973|NCT03510598|DRUG|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
48001053|NCT00594061|DEVICE|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
48001054|NCT04220411|DRUG|AR100DP1|topical ointment
48001055|NCT04400279|BEHAVIORAL|Yoga group|At-home yoga exercise instruction provided by a mobile/tablet app or through a computer web browser
48001056|NCT04400279|BEHAVIORAL|High Intensity Interval Training group|At-home HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
48158220|NCT06600815|PROCEDURE|postoperative local infiltration analgesia(PLIA)|Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.
48158221|NCT03142893|DRUG|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
48158222|NCT03142893|DRUG|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
48158223|NCT03142893|DRUG|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
48158224|NCT03142893|DRUG|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
48158225|NCT03142893|DRUG|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
48158226|NCT03142893|DRUG|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
48158227|NCT03142893|DRUG|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
48158228|NCT03142893|DRUG|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
48158229|NCT03142893|DRUG|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
48001057|NCT04400279|BEHAVIORAL|Combination|At-home yoga \& HIIT exercise instruction provided by a mobile/tablet app or through a computer web browser
48001058|NCT04534764|DEVICE|etafilcon A with cosmetic pattern|TEST
48158230|NCT03142893|DRUG|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
48158231|NCT03142893|DRUG|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
48158232|NCT03142893|DRUG|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
48158233|NCT04206384|DEVICE|Ultrasound|Ultimate Contour Body Sculpting Device
48158234|NCT03868930|BEHAVIORAL|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
48158235|NCT03868930|BEHAVIORAL|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
48158236|NCT03959579|DIAGNOSTIC_TEST|systematic endomyocardial biopsy.|"We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy"
48158237|NCT03973645|OTHER|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
48158238|NCT02536729|DRUG|Oral Sodium Phosphate - Normal preparation|
48158239|NCT02536729|DRUG|Oral sodium phosphate - Modified Preparation|
48158240|NCT02536729|DRUG|polyethylene glycol + Electrolytes|
48001059|NCT04534764|DEVICE|1-Day Acuvue DEFINE Vivid Style|CONTROL
48001060|NCT05296603|DRUG|IBI-322 Plus Lenvatinib|"IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg"
48001061|NCT04738110|OTHER|MRI|Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC
48001062|NCT06221033|DEVICE|manual hyperinflation|Each participant will assume a relaxed comfortable in supine position. Bag valve resuscitation circuit locked at pressure 35 cm H20 will be used. Six sets of six MHI breaths will be applied. MHI breaths had a slow inspiration for three seconds duration, a three second end inspiratory pause (hold) then an uninterrupted expiration as a quick release
48001063|NCT06221033|OTHER|Diaphragmatic proprioceptive neuromuscular facilitation technique|"Rhythmic initiation technique that is derived from the PNF concept will be initiated by four 20-second manual diaphragm stimulations. After every stimulation the patient rested for one minute. Therapist's hands will be placed below the rib cage, just below the costal arches and will support patient's exhalation phase by slight lengthening his diaphragm simultaneously in posterior-superior direction using a verbal cue exhale. At the same time, the patient will verbally be encouraged to take a deep breath"
48001064|NCT06221033|OTHER|traditional physiotherapy|This group will receive the traditional medical treatment and chest physiotherapy only.
48001065|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine high dose|Subjects should consume 4 intakes of 5 g of beta alanine every 3 hours each day.
48001066|NCT06167395|DIETARY_SUPPLEMENT|Beta Alanine low dose|Subjects should consume 4 intakes of 2,5 g of beta alanine every 3 hours each day.
48001067|NCT06167395|DIETARY_SUPPLEMENT|Control product|Subjects should consume 4 intakes of 2,5 g of wheat semolina every 3 hours each day.
48001068|NCT02196324|DRUG|serlopitant|NK1 receptor antagonist
48001069|NCT02196324|DRUG|Placebo|Placebo
48001070|NCT01508780|DEVICE|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
48001071|NCT01508780|DEVICE|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
48158241|NCT05464199|OTHER|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
48158242|NCT02574949|RADIATION|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
48158243|NCT02574949|RADIATION|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
48158244|NCT02574949|RADIATION|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
48158245|NCT03877133|DEVICE|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
48366861|NCT01509651|DRUG|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
48366862|NCT00282373|DEVICE|mild hypothermia|
48366863|NCT00451776|DRUG|etomidate|patients who received etomidate
48366864|NCT00451776|DRUG|propofol|patients who received propofol
48366865|NCT01828346|DRUG|Birinapant|"Dose escalation part: (Drug escalation dose levels)~* Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~* Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~* Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~* Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
48366866|NCT01828346|DRUG|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
48366867|NCT00427687|DRUG|AGG-523|
48366868|NCT01102439|DRUG|Clopidogrel|300 mg loading dose, then 75 mg daily
48366869|NCT01102439|DRUG|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
48366870|NCT01102439|DRUG|Aspirin|81 mg daily
48001072|NCT02462967|DRUG|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
48158246|NCT04729361|GENETIC|CGH array analysis|CGH array analysis
48158247|NCT01418599|DRUG|Torrent's Alfuzosin Extended Release Tablet|
48158248|NCT05374408|BEHAVIORAL|BBN for Trauma Informed Care|"Brief explanation of BBN will be provided. Patient will be directed to areas of the app that are congruent with treatment focus identified during their standard of care appointment.~Patient will complete by going online or being contacted by a member of the research team member. The research assistant will contact all the patients in 2-3 days to help the patient navigate the BBN and complete the baseline survey if needed.~The patient will continue to meet with their BHP as determined by the standard of care interactions. BHP will highlight features contained in BBN for patient to use in between appointments.~Follow-up phone calls will be scheduled for 2 week and 6 weeks after the initial visit. During these phone- calls the participant will be contacted by a member of the research team to complete follow-up surveys."
48158249|NCT05672862|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
48158250|NCT00489697|DEVICE|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
48158251|NCT00391521|DRUG|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
48366871|NCT01102439|DRUG|Aspirin|325 mg daily
48366872|NCT00800085|DRUG|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
48366873|NCT05454696|OTHER|Exercise|Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.
48366874|NCT05454696|OTHER|online physical activity counselling|CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
48001073|NCT02462967|DRUG|Placebo|Placebo for GR-MD-02
48001074|NCT02800356|PROCEDURE|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
48158252|NCT00391521|DRUG|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
48001075|NCT00281203|PROCEDURE|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
48001076|NCT00281203|PROCEDURE|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
48158253|NCT00391521|DRUG|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
48158254|NCT02038114|BEHAVIORAL|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
48001077|NCT02638142|DRUG|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
48001078|NCT02638142|DRUG|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
48001079|NCT01275495|BEHAVIORAL|Telephone Assessment and Skill-Building Kit (TASK II)|
48001080|NCT01275495|BEHAVIORAL|Information, Support, and Referral (ISR)|
48001081|NCT01251588|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
48001082|NCT01251588|PROCEDURE|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
48001083|NCT05819164|DEVICE|Masimo oximeter|During this period, the Masimo oximeter Radical 7 was used for SpO2 reading
48001084|NCT05819164|DEVICE|Nellcor oximeter|During this period, the Nellcor oximeter N-600 was used for SpO2 reading
48158255|NCT04562571|OTHER|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
48158256|NCT00936195|DRUG|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
48158257|NCT00936195|DRUG|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
48158258|NCT05676996|OTHER|attachment-based support|attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
48158259|NCT03697837|BEHAVIORAL|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
48158260|NCT01798238|DRUG|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
48366875|NCT06139978|BEHAVIORAL|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
48366876|NCT01206894|PROCEDURE|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
48001085|NCT05819164|DEVICE|Nonin oximeter|During this period, the Nonin oximeter was used for SpO2 reading
48158261|NCT01798238|DRUG|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
48158262|NCT05697822|OTHER|Mobile Phone and Cloud-based Electronic Contact and Recording System|A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
48158263|NCT03167645|DRUG|Human albumin|Substitution according to pre-specified dosage
48158264|NCT00215709|DRUG|docetaxel|
48158265|NCT04623671|BIOLOGICAL|CAP-1002|100-mL (total volume) infusion of 150M CDCs in 5% Human Serum Albumin (HSA)
48158266|NCT04623671|BIOLOGICAL|Placebo|Matching placebo solution
48158267|NCT00092378|DRUG|MK0966, rofecoxib|
48158268|NCT00092378|DRUG|Comparator: diclofenac sodium, placebo|
48158269|NCT04759599|PROCEDURE|Shock Wave Lithotripsy (SWL)|Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
48366877|NCT05327868|OTHER|Low Fat Diet (LFD)|Subjects will be asked to adhere to a low fat diet (assigned in random order) and be counseled by a dietitian using 5 days of sample menus, monitored online using a shared nutrient analysis program, and supplied with low fat foods to increase compliance
48366878|NCT05327868|OTHER|High Fat Diet (HFD)|Subjects will be asked to adhere to a high fat diet that is rich in SFAs (assigned in random order) and be counseled by a dietitian using sample 5 days of menus, monitored online using a shared nutrient analysis program, and supplied with high fat foods to increase compliance
48366879|NCT01790451|PROCEDURE|Irreversible Electroporation|
48158270|NCT01996098|DRUG|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
48001086|NCT01589081|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
48158271|NCT01996098|DRUG|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
48158272|NCT02569944|PROCEDURE|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
48158273|NCT02569944|PROCEDURE|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
48158274|NCT05652036|BIOLOGICAL|Intradetrusor Botox Injections|100 units of OnabotuliumtoxinA is injected into the detrusor muscle in 1 mL aliquots using a cystoscope.
48158275|NCT02970721|DRUG|Antipsychotic|Antipsychotic monotherapy
48158276|NCT02970721|DRUG|Antidepressant|Antidepressant monotherapy
48158277|NCT02970721|DRUG|Antipsychotic and Antidepressant|Polytherapy
48158278|NCT00860522|DRUG|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
48158279|NCT00860522|DRUG|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
48158280|NCT05028283|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks
48158281|NCT00301015|DEVICE|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
48158282|NCT05984147|DRUG|AUR108|3 Days dosing, and 4 days no dose in a week
48158283|NCT00563433|DRUG|ofloxacin|400 mg twice a day for 14 days
48158284|NCT00563433|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
48158285|NCT03595826|DRUG|Neurostimulant pharmaceutical drugs|The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
48158286|NCT03937076|PROCEDURE|PECS II block|"Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~1. between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~2. between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves."
48158287|NCT05143437|BEHAVIORAL|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
48158288|NCT01726634|OTHER|Elastic Tapping|
48158289|NCT00472056|DRUG|Carmustine|300 mg/m\^2 IV for 1 Day
48158290|NCT00472056|DRUG|Etoposide|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
48158291|NCT00472056|DRUG|Cytarabine|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
48158292|NCT00472056|DRUG|Melphalan|140 mg/m\^2 IV x 1 Day
48158293|NCT00472056|DRUG|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.
48158294|NCT04273854|DEVICE|OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
48158295|NCT06003881|DRUG|Pozelimab|Subcutaneous (SC) administration
48158296|NCT06057532|DIETARY_SUPPLEMENT|UCAN SuperStarch|Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.
48158297|NCT06057532|DIETARY_SUPPLEMENT|Gatorade|Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
48158298|NCT02274350|RADIATION|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
48158299|NCT05899673|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
48158300|NCT06027008|DEVICE|Mechanical Insufflation-Exsufflation|"MI-E will be applied twice a day in invasively ventilated patients. Since the severity of illness can change in the ICU, each day the attending nurse will check for clinical reasons to not apply MI-E with regard to safety. The following clinical criteria are predefined as a reason to refrain from MI-E at that day:~* severe ventilator instability (requiring \> 12 cm H2O PEEP and dependency of \> 60% FiO2);~* severe hemodynamic instability (a need for large and sustained increase in continuous administration of intravenous vasopressive medication that are adjusted on a frequent basis in each nursing shift);~* extra corporal membrane oxygenation (ECMO); and~* deeply sedated patient (RASS score ≤ -4)."
48158301|NCT01697592|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
48158302|NCT01697592|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
48158303|NCT06114511|DRUG|BL-M07D1|Administration by intravenous infusion
48158304|NCT04501354|DRUG|Mesenchymal Stem Cell|Mesenchymal Stem Cell + NaCl 0,9% 2ml
48366880|NCT00518167|BEHAVIORAL|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~1. weight reduction~2. dietary fibre 15 g /1000 kcal or more~3. energy proportion of dietary fat less than 30%~4. energy proportion of saturated fat less than 10%~5. moderate physical activity \>30 minutes per day or 4 hours per week"
48366881|NCT05066906|DEVICE|Use of Identifor assessment tool and Companion app|"Identifor pinpoints what players excel at by using objective metrics and quantifiable data to collect information relevant to employment, including Multiple Intelligence, Executive Function, and personality themes.~Companion is a 24/7 personalized aide for teens and adults iwth special needs that uses and artificial intelligence avatar to have back-and-forth conversations with users in a meaningful way to support the user in different domains of their everyday lives including public transit, managing personal schedules, and money management."
48158305|NCT03802513|OTHER|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
48512974|NCT06395805|DIAGNOSTIC_TEST|BREF, ADL, AIS.|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
48158306|NCT05934370|OTHER|Home-Based Environmental Interventions (HEI)|"Housing Specialist will conduct an environmental home assessment to identify asthma triggers.~• The participant will receive the following Breath Easy at Home Kit Products:~* HEPA filtered upright vacuum cleaner~* HEPA-filtered air purifier~* Hypoallergenic latex free mattress and pillow covers~* Healthier household cleaners~* Non-toxic pest control devices for rodent control~* Safe products to locate and kill roaches."
48158307|NCT03932032|BEHAVIORAL|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
48158308|NCT03932032|BEHAVIORAL|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
48158309|NCT00333554|DIETARY_SUPPLEMENT|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
48158310|NCT00333554|DIETARY_SUPPLEMENT|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
48158311|NCT04299698|BEHAVIORAL|lifestyle|Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
48512975|NCT04792424|OTHER|Regional citrate anticoagulation|Starting RCA 4 mmol/L (adjust the rate by BFR)
48001087|NCT01589081|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
48158312|NCT05229848|PROCEDURE|3D electroanatomical mapping alone guided CTI ablation|3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.
48158313|NCT05229848|PROCEDURE|ICE plus 3D electroanatomical mapping guided CTI ablation|ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
48158314|NCT03012321|DRUG|Olaparib|
48158315|NCT03012321|DRUG|Abiraterone Acetate|
48001088|NCT04715399|OTHER|No intervention|No intervention
48001089|NCT02315235|BIOLOGICAL|Normal saline|Normal saline is injected in one leg of patient.
48158316|NCT03012321|DRUG|Prednisone|
48158317|NCT01039597|DRUG|ORE1001|Oral capsules containing 300 mg of the active, study drug
48158318|NCT01039597|DRUG|Placebo|placebo capsules
48158319|NCT00002471|DRUG|asparaginase|
48158320|NCT00002471|DRUG|cyclophosphamide|
48158321|NCT00002471|DRUG|cytarabine|
48158322|NCT00002471|DRUG|daunorubicin hydrochloride|
48512976|NCT04792424|DRUG|Vasopressor|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
48686198|NCT06205563|BEHAVIORAL|high-intensity interval training|High-intensity interval training (to significantly faster breathing, a significant increase in breathing depth, a significant increase in heart rate, sweating, and the need to stop exercising and adjust your breathing before you can speak; Energy expenditure (METy ≥6.00 in children) : Participants randomly assigned to HIIT will perform a 10-minute warm-up at 60-70% of their maximum heart rate (HRmax). After this, they will walk, run, or bike at 85-95% of their maximum heart rate for four sessions of four minutes each, with three minutes of active recovery (50-70% of their maximum heart rate) in between. The participants were given a five-minute cooling-off period at the end, for a total of 40 minutes of exercise. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
48001090|NCT02315235|BIOLOGICAL|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
48001091|NCT01039896|DRUG|Period I : SLM0807, Period II : HKB0701 and SLM0807|
48001092|NCT01039896|DRUG|Period I : HKB0710 and SLM0807, Period II : SLM0807|
48001093|NCT04501614|DRUG|Ponatinib|Ponatinib tablets.
48001094|NCT04501614|DRUG|Ponatinib AAF|Ponatinib age appropriate formulation i.e., capsules with ponatinib minitablets.
48001095|NCT04501614|DRUG|Chemotherapy Agents|Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
48001096|NCT05134207|DIETARY_SUPPLEMENT|oral carbohydrate solution|Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
48158323|NCT00002471|DRUG|dexamethasone|
48158324|NCT00002471|DRUG|etoposide|
48158325|NCT00002471|DRUG|leucovorin calcium|
48158326|NCT00002471|DRUG|methotrexate|
48158327|NCT00002471|DRUG|methylprednisolone|
48158328|NCT00002471|DRUG|therapeutic hydrocortisone|
48158329|NCT00002471|DRUG|thiotepa|
48158330|NCT00002471|DRUG|vincristine sulfate|
48158331|NCT01150500|DEVICE|MDT-4107 Zotarolimus-Eluting Coronary Stent|
48158332|NCT02103426|DRUG|ASP0113|intramuscular injection
48158333|NCT02103426|DRUG|Placebo|intramuscular injection
48158334|NCT02893371|DRUG|Lithium Carbonate|Exposure to all dosages and delivery forms.
48158335|NCT02893371|DRUG|Lamotrigine|Exposure to all dosages and delivery forms.
48158336|NCT02893371|DRUG|Valproic Acid|Exposure to all dosages and delivery forms.
48158337|NCT02893371|DRUG|Oxcarbazepine|Exposure to all dosages and delivery forms.
48158338|NCT02893371|DRUG|Carbamazepine|Exposure to all dosages and delivery forms.
48158339|NCT02893371|DRUG|Ziprasidone|Exposure to all dosages and delivery forms.
48158340|NCT02893371|DRUG|Risperidone|Exposure to all dosages and delivery forms.
48158341|NCT02893371|DRUG|Quetiapine|Exposure to all dosages and delivery forms.
48158342|NCT02893371|DRUG|Olanzapine|Exposure to all dosages and delivery forms.
48158343|NCT02893371|DRUG|Aripiprazole|Exposure to all dosages and delivery forms.
48158344|NCT02893371|DRUG|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
48158345|NCT02893371|DRUG|Haloperidol|Exposure to all dosages and delivery forms.
48512977|NCT04792424|DRUG|Antibiotic|Antibacterial agents deemed appropriate by physicians in the ICU
48001097|NCT05655611|OTHER|first rib mobilization|To perform the first rib mobilization, the patient remained lying supine with the head in the examiner's right hand. Examiner then palpated the left first rib and passively side-bended the patient's head to the left to relieve any muscular tension on the first rib. Patient was then asked to take a deep breath in and out. During exhalation, the examiner applied pressure to depress the first rib, holding it in place at the end of the exhalation. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation. This process was repeated three times in two sets, for a total of six first rib depression mobilizations.
48001098|NCT05655611|OTHER|muscle energy technique|Muscle energy technique for glenohumeral joint restricted abduction-The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the glenohumeral joint to palpate for motion and the subjects are directed to press the elbow towards their body. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for three weeks with each repetition maintained for the duration of 7-1 seconds.
48001099|NCT02051530|DIETARY_SUPPLEMENT|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
48001100|NCT03047109|DRUG|Phenylephrine|30 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
48001101|NCT03047109|DRUG|Ephedrine|30 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
48001102|NCT01443247|DRUG|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
48001103|NCT01940926|DRUG|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
48001104|NCT05638373|OTHER|One shade universal composite|A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite
48001105|NCT05638373|OTHER|Nanohybrid resin composite|A conventional resin composite with multiple shades
48001106|NCT00533533|DRUG|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
48001107|NCT01076712|OTHER|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
48001108|NCT01076712|OTHER|Education Classes|Education Classes
48001109|NCT03576248|DEVICE|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
48001110|NCT03576248|DEVICE|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
48366882|NCT05066906|OTHER|Referral to employment agencies|Standard referral to employment agencies based on an individual's background, skillset, and preferences
48512978|NCT04792424|DEVICE|Dialysis with continuous renal replacement therapy|Prismaflex
48001111|NCT03576248|DEVICE|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
48001112|NCT03576248|DEVICE|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
48001113|NCT00753116|DEVICE|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
48001114|NCT00022321|DRUG|gemtuzumab ozogamicin|
48366883|NCT01851031|PROCEDURE|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
48366884|NCT05422950|OTHER|Relationship between physical condition and functionality in post-covid patients|Correlation study between the physical condition and functionality of patients after intubation due to covid 19
48512979|NCT01162707|DEVICE|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
48512980|NCT02638025|DEVICE|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
48001115|NCT05424536|OTHER|Bone measurement by DXA and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites plus femoral neck, one measurement will be performed by DXA to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
48158346|NCT02893371|DRUG|Perphenazine|Exposure to all dosages and delivery forms.
48158347|NCT02893371|DRUG|Clozapine|Exposure to all dosages and delivery forms.
48158348|NCT02893371|DRUG|Asenapine|Exposure to all dosages and delivery forms.
48158349|NCT02893371|DRUG|Lurasidone|Exposure to all dosages and delivery forms.
48512981|NCT06124937|DRUG|Empagliflozin 10 MG|The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital.
48512982|NCT06124937|DRUG|Placebo|The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital.
48512983|NCT04342195|PROCEDURE|Blood draw|Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.
48512984|NCT03613233|PROCEDURE|Glaucoma surgery|phacoemulsification
48158350|NCT02893371|DRUG|Paliperidone|Exposure to all dosages and delivery forms.
48001116|NCT05693610|DEVICE|Portable OSP|The portable open-source speech processing platform (OSP) is accessed on a browser via a wireless fidelity (WiFi)-enabled portable communication device that carries out all the signal processing. The processed sounds are transmitted to the ears via earpieces known as behind-the-ear receivers in the canal (same as those available with commercial hearing aids). The amount of amplification with the portable OSP will be customized for each listener based on a validated prescription.
48001117|NCT05693610|DEVICE|Cloud-based OSP|The cloud-based open-source speech processing platform (OSP) is hosted on a web-server which includes the software for all the signal processing. The processed sounds are transmitted to the ears via calibrated headphones. The amount of amplification with the cloud-based OSP will be customized for each listener based on a validated prescription.
48158351|NCT02893371|DRUG|Mirtazapine|Exposure to all dosages and delivery forms.
48158352|NCT02893371|DRUG|Bupropion|Exposure to all dosages and delivery forms.
48158353|NCT02893371|DRUG|Desvenlafaxine|Exposure to all dosages and delivery forms.
48001118|NCT01617057|DRUG|tiludronic acid|400 mg / day for 3 months
48001119|NCT01617057|DRUG|Placebo|400 mg / day for 3 month
48001120|NCT05372796|OTHER|IASTM|instrument-assisted soft tissue mobilization
48001121|NCT05372796|OTHER|home exercise|home exercise
48001122|NCT05372796|DEVICE|Chattanooga direct Tens device (DJO UK Ltd, Guildford Surrey, United Kingdom)|OTES (Occipital Transcutenous Electric Stimulation)
48001123|NCT04959838|BEHAVIORAL|Impact of prolonged work|Evaluate the impact of prolonged work (up to 60 consecutive hours) on the surgical capacities evaluated on a simulator, as well as on stress markers (questionnaires, saliva assays, skin conductance, quality of sleep) compared to a standard day.
48001124|NCT04078828|PROCEDURE|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
48001125|NCT04118309|BEHAVIORAL|Exercise|
48001126|NCT04118309|OTHER|Placebo|
48001127|NCT05698966|OTHER|we will use reduced dose of acceptable corticosteroids treatment for preterm birth|the two different group will differ in the doses of corticosteroids
48001128|NCT04010942|DRUG|Vit D|Injection
48001129|NCT04010942|DRUG|Metformin|tablets
48001130|NCT04010942|DRUG|Clomiphene|Tablet
48158354|NCT02893371|DRUG|Duloxetine|Exposure to all dosages and delivery forms.
48158355|NCT02893371|DRUG|Venlafaxine|Exposure to all dosages and delivery forms.
48158356|NCT02893371|DRUG|Citalopram|Exposure to all dosages and delivery forms.
48158357|NCT02893371|DRUG|Escitalopram|Exposure to all dosages and delivery forms.
48158358|NCT02893371|DRUG|Fluoxetine|Exposure to all dosages and delivery forms.
48158359|NCT02893371|DRUG|Fluvoxamine|Exposure to all dosages and delivery forms.
48512985|NCT03636997|PROCEDURE|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
48001131|NCT02622828|BEHAVIORAL|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
48366885|NCT02925780|DEVICE|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
48512986|NCT03636997|PROCEDURE|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
48512987|NCT02729909|DRUG|Lubiprostone|Lubiprostone capsules
48001132|NCT01976832|BEHAVIORAL|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
48001133|NCT01976832|BEHAVIORAL|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
48001134|NCT06367465|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
48001135|NCT00560690|DRUG|Metformin|500 mg oral three times a day for 6 months
48001136|NCT00560690|DRUG|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
48001137|NCT00560690|DRUG|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
48001138|NCT04733651|DRUG|Hospital standard of care for COVID-19|Standard care for COVID-19 as per the hospital guidelines
48001139|NCT04733651|DRUG|Isoquercetin|Daily 1000 mg Isoquercetin as 4 capsules
48158360|NCT02893371|DRUG|Paroxetine|Exposure to all dosages and delivery forms.
48158361|NCT02893371|DRUG|Sertraline|Exposure to all dosages and delivery forms.
48158362|NCT02893371|DRUG|Vilazodone|Exposure to all dosages and delivery forms.
48158363|NCT02893371|DRUG|Doxepin|Exposure to all dosages and delivery forms.
48158364|NCT05711017|DRUG|Huashibaidu granule|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
48158365|NCT05711017|DRUG|Placebo|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
48512988|NCT02729909|DRUG|Placebo|Lubiprostone placebo-matching capsules
48686199|NCT06205563|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training (rapid breathing, rapid heart rate, slight sweating, but still able to talk easily; Energy expenditure (children METy) 3.00 to 5.99) : Participants randomly assigned to the MICT group will walk, run, or cycle continuously for 40 minutes at 60-70% HRmax. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
48686200|NCT03774771|DRUG|Cinacalcet|Capsule for oral administration
48158366|NCT04931199|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The standard of care procedures for children with clinically elevated anxiety, depression, and PTSD is traditional CBT from their mental health provider.
48686201|NCT03774771|DRUG|Placebo|Capsules for oral administration
48158367|NCT04931199|BEHAVIORAL|CBT+App|Participants receive CBT as usual enhanced with a simple, HIPAA compliant, web-based application to help mental health providers implement homework during CBT with children with elevated PTSD, anxiety, and/or depression, and their caregivers. The three major components of the app help providers to (1) Practice interactive, digitized CBT exercises with patients in-session; (2) Remind patients to practice CBT exercises for homework, and (3) Review homework during the next session.
48512989|NCT04681716|OTHER|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
48512990|NCT04681716|OTHER|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
48512991|NCT03035929|DRUG|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
48512992|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
48512993|NCT01890863|DRUG|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
48158368|NCT05208593|BEHAVIORAL|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
48512994|NCT03108378|PROCEDURE|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
48512995|NCT02379572|DEVICE|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
48512996|NCT02379572|DRUG|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
48512997|NCT02031718|BEHAVIORAL|Virtual Counseling|
48512998|NCT03763474|COMBINATION_PRODUCT|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
48686202|NCT00127491|PROCEDURE|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
48686203|NCT00127491|OTHER|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
48686204|NCT00127491|OTHER|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
48686205|NCT02210988|OTHER|acupuncture|Intervention with acupuncture
48686206|NCT04706312|OTHER|stem cells|hAMSCs injection via venous in the dorsum of hand
48686207|NCT06554782|DEVICE|manual u-shaped toothbrush|manual u-shaped toothbrush with bristles angled 45 degrees to brush upper and lower teeth at the same time
48686208|NCT00811291|DIETARY_SUPPLEMENT|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
48686209|NCT00811291|DIETARY_SUPPLEMENT|calcium|according to protocol
48686210|NCT05143905|DRUG|AZD7503|Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).
48686211|NCT05143905|DRUG|Placebo|Randomised participants will receive placebo by SC injection
48366886|NCT02925780|DEVICE|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
48366887|NCT02600195|BEHAVIORAL|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
48366888|NCT04150523|OTHER|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
48366889|NCT02540811|DEVICE|dCELL® ACL Scaffold|
48366890|NCT05314621|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%)|Pataday® Once Daily Relief Extra Strength (eyedrop)
48366891|NCT05314621|DRUG|Fluticasone Propionate|Flonase® Allergy Relief (nasal spray)
48686212|NCT03086408|DEVICE|THRIVE|active nasal oxygen delivery system
48001140|NCT05714111|OTHER|Radiology evaluations and interventions|Diagnostic and interventional radiology procedures
48001141|NCT01909037|DIETARY_SUPPLEMENT|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
48001142|NCT02286193|BEHAVIORAL|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
48512999|NCT00004263|DRUG|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
48001143|NCT00136149|PROCEDURE|Immediate implants|Immediate implants are used.
48001144|NCT02032147|DRUG|NGF group|This group will be treated with NGF 18u per day im for 60 days
48001145|NCT02581696|DRUG|Lafutidine|Lafutidine 10mg, 1 tablet, bid
48001146|NCT02581696|DRUG|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
48001147|NCT04693585|BEHAVIORAL|MESSSSAGE - live|mHealth education and social support intervention, synchronous via call
48001148|NCT04693585|BEHAVIORAL|MESSSSAGE - asynchronous|mHealth education and social support intervention, asynchronous via text
48001149|NCT06351579|OTHER|Control|This is an observational (registry) study for data collection only. No device or intervention will be used in this study.
48001150|NCT05248516|DIETARY_SUPPLEMENT|Simplified dose of ready-to-use therapeutic food (RUTF)|"In the simplified arm all children receive the same dose: 1 sachet of RUTF/day. This until discharge from treatment.~Recovery from treatment will be defined as WAZ\>= -3 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
48001151|NCT05248516|DIETARY_SUPPLEMENT|Standard dose of ready-to-use therapeutic food (RUTF)|"In the standard arm, children will receive different doses of RUTF depending on their WHZ category and weight.~1. children with a WHZ\<-3 will receive the equivalent of 200kcal/kg/d of RUTF until discharge.~2. children with a WHZ between -3 and -2 will receive 1 sachet (500kcal) of RUTF per day until discharge.~3. children with a WHZ\>=-2 will receive no nutritional treatment.~Recovery from treatment will be defined as WHZ\>= -2 on 2 consecutive visits. A maximum of 12 treatment weeks are allowed before declaring non-response. Defaulting will be declared after 2 consecutively missed visits."
48158369|NCT05208593|BEHAVIORAL|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
48366892|NCT05314621|DRUG|Tears Naturale|Tears Naturale® II (eye drop)
48513000|NCT00004263|DRUG|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
48513001|NCT01473407|BIOLOGICAL|Epoetin Hospira|Variable dose
48513002|NCT01473407|BIOLOGICAL|Epogen (Amgen)|Variable dose
48513003|NCT03062761|OTHER|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
48513004|NCT03062761|OTHER|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
48513005|NCT03904108|DRUG|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
48001152|NCT05248516|DIETARY_SUPPLEMENT|No nutritional treatment|no nutritional treatment will be provided to children in the control arm.
48001153|NCT01482767|DRUG|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
48001154|NCT01482767|DRUG|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
48001155|NCT01482767|DRUG|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
48001156|NCT01725191|OTHER|Laboratory Biomarker Analysis|Correlative studies
48001157|NCT01725191|OTHER|Pharmacological Study|Correlative studies
48001158|NCT01725191|DRUG|Tivantinib|Given PO
48001159|NCT00697346|DRUG|Alisertib|Alisertib (MLN8237) PIC or ECT
48366893|NCT05314621|DRUG|Saline nasal spray|Saline nasal spray (nasal spray)
48686213|NCT03086408|DEVICE|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
48158370|NCT05208593|BEHAVIORAL|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
48158371|NCT05208593|BEHAVIORAL|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
48158372|NCT06355037|DRUG|Quercetin|quercetin 1000mg d1-d3, qw
48001160|NCT05040581|BEHAVIORAL|1-Day CBT-Based Workshop for Preventing PPD|The intervention is a 6-hour long CBT-based workshop. The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning.
48001161|NCT05777031|DRUG|Collagenase Clostridium Histolyticum (CCH)|Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
48001162|NCT02670655|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
48001163|NCT02670655|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
48158373|NCT06355037|DRUG|Dasatinib|Dasatinib 50mg d1-d3, qw
48366894|NCT03294798|BIOLOGICAL|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
48686214|NCT00814580|DRUG|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
48686215|NCT00814580|DRUG|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
48686216|NCT00133159|BIOLOGICAL|Grass MATAMPL|
48686217|NCT05801146|DRUG|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
48001164|NCT02670655|DRUG|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
48001165|NCT02670655|DEVICE|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
48001166|NCT02670655|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
48158374|NCT06355037|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
48158375|NCT05619445|OTHER|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
48158376|NCT05619445|OTHER|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
48158377|NCT02662023|DRUG|Bolus|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.
48158378|NCT02662023|DRUG|Basal|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
48158379|NCT01257698|DRUG|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
48158380|NCT00731276|DRUG|irinotecan hydrochloride|
48158381|NCT00731276|OTHER|pharmacogenomic studies|
48158382|NCT00731276|OTHER|pharmacological study|
48158383|NCT02721420|DRUG|dihydroartemisinin-piperaquine|
48158384|NCT02721420|OTHER|message(SMS) reminder|
48366895|NCT03294798|BIOLOGICAL|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
48513006|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
48686218|NCT05801146|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
48001167|NCT06231303|GENETIC|DNA extraction and PCR amplification|"Microbial community genomic DNA extraction from fecal samples will be done using extraction kit in accordance with the manufacturer's instructions. The DNA extract will be checked on a 1% agarose gel, and the DNA concentration and purity will be determined using the NanoDrop 2000 UV-vis spectrophotometer.~The hyper-variable region V3-V4 of the bacterial 16S rRNA gene will be amplified with the primer pair 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTATCTAAT) on a PCR thermocycler. PCR amplification of the 16S rRNA gene will performed as follows:~Initial denaturation at 95 ℃ for 3 min. 27 cycles of denaturing at 95 ℃ for 30 s, annealing at 55 ℃ for 30 s, and extension at 72 ℃ for 45 s.~Final extension step at 72 ℃ for 10 min and incubation at 10 ℃. The PCR product will then be used to quantify different bacterial species in stool samples of patients and controls using real time PCR."
48001168|NCT00117858|PROCEDURE|Anodal DC polarization of left prefrontal cortex|
48001169|NCT01268111|DRUG|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
48001170|NCT01268111|DRUG|Placebo|matching placebo
48001171|NCT04892238|DIAGNOSTIC_TEST|13-C urea breath test|"Standard urea breath test (UBT) (HELICARB, LLC ISOCARB, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.~Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer IRIS.Doc (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was \<4.0‰; test results with δ ≥4.0‰ are considered positive."
48366896|NCT01876056|BEHAVIORAL|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
48686219|NCT06264466|DEVICE|POEM with Speedboat Ultraslim|POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
48686220|NCT00150215|DRUG|PF-00184562|
48001172|NCT02877628|OTHER|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
48001173|NCT00500422|DRUG|Doxil|Starting dose of 20 mg/m\^2 IV over 2 hours on Day 1, 21 day cycle
48001174|NCT00500422|DRUG|Gemcitabine|500 mg/m\^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
48001175|NCT00500422|DRUG|Velcade|Starting dose of 0.7 mg/m\^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
48001176|NCT02434835|DRUG|[14C]KWA-0711|
48001177|NCT06162494|BIOLOGICAL|Recombinant Zoster Vaccine|After giving consent, participants will be given first dose of vaccine. Participants will be brought back 30-60 days post-vaccine for follow up testing and second dose of vaccine
48001178|NCT03080259|BEHAVIORAL|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
48158385|NCT02721420|OTHER|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
48158386|NCT02721420|OTHER|short message(SMS) reminder|
48001179|NCT02506816|DRUG|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
48001180|NCT06045039|OTHER|Stent-balloon-stent (SBS) technique|Patients with coronary bifurcation lesions underwent stent-balloon-stent (SBS) technique. The procedure of this technique is to implant the stent into the side branch at the 1\~2mm, which is away from the opening of the branch, and then implant the stent into the main vessel. The guide wire enters the side branch from the mesh at the distal end of the main vascular stent, and the drug balloon is used to dilate the opening of the side branch, so that the opening area of the side branch is more than 5mm².
48001181|NCT06258148|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
48158387|NCT04983147|OTHER|Obesity Training Based on Health Belief Model|Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
48158388|NCT04983147|OTHER|Post-training follow-up|"After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days."
48158389|NCT03677102|OTHER|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
48686221|NCT00150215|DRUG|Olanzapine|
48686222|NCT00375505|DRUG|Zoledronic acid|
48686223|NCT00375505|DRUG|Placebo|Placebo
48001182|NCT06258148|DRUG|Placebo|Placebo, SC, once a week
48001183|NCT02583932|DRUG|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
48158390|NCT03677102|OTHER|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
48366897|NCT00125736|DRUG|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
48366898|NCT00125736|DRUG|rabeprazole sodium|One 10mg tablet is administered orally each day
48366899|NCT00125736|DRUG|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
48513007|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
48686224|NCT02003976|PROCEDURE|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
48686225|NCT02003976|OTHER|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
48686226|NCT03583359|DEVICE|Radiesse (+)|Radiesse (+) for jawlines.
48001184|NCT02583932|BEHAVIORAL|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
48001185|NCT04056559|DEVICE|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
48001186|NCT04422145|BEHAVIORAL|Structured nurse led intervention programme|A diabetes research nurse, over a period of 12 months, provided a structured education programme to participants focussing on the avoidance of hypoglycaemia and the treatment of this if/when it occurred.
48001187|NCT04422145|OTHER|Standard care|Participants continue on their current diabetes care plan and are looked after by their usual diabetes care provider
48158391|NCT01613573|DRUG|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
48158392|NCT01613573|DRUG|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
48001188|NCT01552239|RADIATION|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
48158393|NCT03207620|DIAGNOSTIC_TEST|using serum periostin and eotaxin-2 level|"collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity."
48158394|NCT03207620|DIAGNOSTIC_TEST|airway corticosteroid sensitivity|each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
48158395|NCT05769361|BEHAVIORAL|UNST|Strength and balance training using different destabilizing devices
48158396|NCT05769361|BEHAVIORAL|ST|Strength and balance training over firm surfaces
48158397|NCT01023022|OTHER|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
48158398|NCT02827851|PROCEDURE|Liposuction|
48158399|NCT02827851|OTHER|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
48158400|NCT02827851|OTHER|Intraarticular administration of autologous SVF|
48366900|NCT04646668|COMBINATION_PRODUCT|E-cigarette and Heat not burn|Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
48366901|NCT01381601|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
48366902|NCT01025739|DEVICE|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
48001189|NCT02717481|DEVICE|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
48001190|NCT00916474|DRUG|telaprevir|
48366903|NCT06496399|BEHAVIORAL|psychoeducation|"-The elderly's preferences for art therapy (art activities such as wood painting, creating shapes with mud) will be taken into account.~2-Expression of emotions through motivational interviewing 3-Conscious Awareness therapy, staying in the moment here and now 4- Hobbies (growing flowers, gardening, handicraft knitting, puzzle solving, card games, chess game, etc., organizing trips, cinema, movie events and so on)"
48366904|NCT04799509|PROCEDURE|VATS lobectomy|VATS lobectomy
48366905|NCT01883362|DRUG|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
48366906|NCT01883362|OTHER|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
48366907|NCT00097916|DRUG|memantine HCl|
48001191|NCT01514968|DRUG|cyclosporine|Single oral dose
48158401|NCT06077695|OTHER|therapeutic education|The themes covered concern head trauma in the chronic phase.
48158402|NCT06077695|OTHER|tDCS|The constant electric current will be delivered at an intensity of 2 mA for 20 minutes.The anode will be placed opposite the dorsolateral prefrontal area on the right. The cathode (or reference electrode) will be positioned opposite the supraorbital area on the left. This methodology is based on the general directions and results from scientific studies which aimed to improve the efficiency of neural networks engaged in attentional processes and working memory.
48366908|NCT04697199|DRUG|Lactobacillus Reuteri Oral Drops|Subgingival delivery of probiotic suspension
48366909|NCT04697199|PROCEDURE|Scaling and root planing|Scaling and root planing using hand and ultrasonic instruments
48366910|NCT00987558|DRUG|Eslicarbazepine acetate|
48366911|NCT00987558|DRUG|Simvastatin|
48366912|NCT02050945|BEHAVIORAL|Resistance training|
48366913|NCT02050945|BEHAVIORAL|Endurance training|
48366914|NCT04330586|DRUG|Ciclesonide Metered Dose Inhaler [Alvesco]|Ciclesonide 320ug oral inhalation q12h for 14 days
48513008|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
48001192|NCT01514968|DRUG|danoprevir|Single oral dose
48001193|NCT01514968|DRUG|ritonavir|Single oral dose
48001194|NCT00925483|PROCEDURE|dialysis|different dialysis schedules for each arm
48513009|NCT01012310|DRUG|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
48513010|NCT02871492|DRUG|Pritelivir 5% w/w ointment|
48513011|NCT02871492|DRUG|Pritelivir ointment matching placebo|
48158403|NCT06077695|OTHER|cognitive remediation|"Personalized sessions combining 2 approaches:•Retraining deficit components of working memory.exercise the strengthening of metacognition and the learning of reorganization-facilitation strategies. At the end of each exercise, the participant will be asked to analyze their performance and will benefit from feedback from the rehabilitator as well as a discussion on the use of the strategies. Finally, all of the proposed tasks will be made up of several levels of complexity; moving to a more complex stage will require more than 90% success in the exercise.•More ecological exercises will also be carried out in order to get as close as possible to the difficulties encountered by the patient on a daily basis. The examiner will guide the rehabilitation and propose tasks imitating his daily life."
48686227|NCT04257643|OTHER|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
48686228|NCT04257643|OTHER|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
48686229|NCT05753254|OTHER|Firefighting training exercises with no fire|The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).
48686230|NCT05753254|OTHER|Firefighting training exercises under wood fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.
48686231|NCT05753254|OTHER|Firefighting training exercises under gas fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
48686232|NCT03823105|DEVICE|OHR Tracker and PulseWatch|Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
48686233|NCT06174012|DRUG|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
48686234|NCT02594930|PROCEDURE|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
48686235|NCT05768958|OTHER|Exercise|45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.
48686236|NCT05768958|OTHER|Control|45 min rest during the same time period as the exercise bout on exercise study visits.
48686237|NCT03050450|DRUG|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
48686238|NCT03050450|DRUG|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
48686239|NCT03050450|DRUG|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
48686240|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
48686241|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
48686242|NCT00034671|DRUG|Posaconazole oral suspension|
48686243|NCT06227312|DEVICE|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
48686244|NCT06227312|OTHER|exercises|calf raises and modified drop jumps
48686245|NCT03901625|DEVICE|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
48686246|NCT03901625|DEVICE|Dental floss|A dental floss is used to clean inter-proximal areas.
48686247|NCT03901625|DEVICE|Waterjet|A waterjet is used to clean inter-proximal areas.
48158404|NCT03437902|DIETARY_SUPPLEMENT|Rutin in combination with Vitamin C|Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.\& CHEM. IND. Company
48158405|NCT03437902|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
48686248|NCT03901625|DEVICE|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
48686249|NCT06435988|BEHAVIORAL|Training in the pecha kucha technique|Providing labor training to pregnant women with the Pecha Kucha technique
48513012|NCT02871492|DRUG|Zovirax® cream|
48513013|NCT05686226|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
48686250|NCT01949571|DRUG|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
48686251|NCT02526212|BEHAVIORAL|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
48686252|NCT02526212|BEHAVIORAL|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
48686253|NCT02526212|DRUG|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
48513014|NCT05686226|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
48513015|NCT00143871|DRUG|Rituximab|
48686254|NCT01823107|DEVICE|Meso BioMatrix Device|
48686255|NCT03018535|DRUG|Rituximab|Rituximab,1 g IV, day 1 and day 15
48513016|NCT00071292|BEHAVIORAL|stress reduction program|
48686256|NCT03018535|DRUG|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
48686257|NCT03018535|DRUG|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
48686258|NCT04505644|DRUG|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
48686259|NCT04505644|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
48686260|NCT04505644|DRUG|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
48686261|NCT05013021|OTHER|Sprint Interval Training|"The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)"
48001195|NCT01108536|DEVICE|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
48001196|NCT01965288|DEVICE|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
48001197|NCT01965288|DEVICE|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
48001198|NCT00486265|DRUG|AZD4877|intravenous infusion administered on days 1, 2 and 3
48001199|NCT04346472|OTHER|Repeated Measurements of the relative regional cerebral blood volume|Repeated Measurements of the relative regional cerebral blood volume variation through an every 6 monts Magnetic Resonance Imaging use.
48001200|NCT05159245|DRUG|Alectinib|ALK
48001201|NCT05159245|DRUG|Cobimetinib|MEK1, MEK2
48001202|NCT05159245|DRUG|Vismodegib|Hedgehog
48001203|NCT05159245|DRUG|Trastuzumab+Pertuzumab|HER2
48001204|NCT05159245|DRUG|Entrectinib|NTRK/ ROS1, ALK
48001205|NCT05159245|DRUG|Atezolizumab|PD-L1
48001206|NCT05159245|DRUG|Vemurafenib|BRAF V600
48001207|NCT05159245|DRUG|Regorafenib|KIT/BRAF, RET
48001208|NCT05159245|DRUG|Apalutamide|AR
48001209|NCT05159245|DRUG|Abemaciclib|CDK4/6
48001210|NCT05159245|DRUG|Tepotinib|MET ex14
48001211|NCT05159245|DRUG|Dabrafenib|RAF
48001212|NCT05159245|DRUG|Trametinib|MEK1, MEK2
48158406|NCT06355271|PROCEDURE|Fentanyl 1|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and no fentanyl
48158407|NCT06355271|PROCEDURE|Fentanyl2|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 10 mcg of of fentanyl
48513017|NCT00071292|BEHAVIORAL|meditation|
48686262|NCT06436014|OTHER|Providing VR experience|Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
48686263|NCT04221893|RADIATION|Radiation Therapy (RT)|Undergo radiation therapy
48001213|NCT05159245|DRUG|Dabrafenib+Trametinib|RAF, MEK1, MEK2
48001214|NCT05159245|DRUG|Pemigatinib|FGFR2
48001215|NCT04439032|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
48001216|NCT04049942|OTHER|Multimodal prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
48001217|NCT04049942|BEHAVIORAL|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
48158408|NCT06355271|PROCEDURE|Fentanyl 3|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 20 mcg of fentanyl
48158409|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
48158410|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
48513018|NCT03357744|OTHER|distress barometer|not applicable, observational study
48513019|NCT02192398|DRUG|Guanfacine|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
48686264|NCT02365610|DRUG|GWP42006|
48686265|NCT02365610|DRUG|Placebo Control|
48686266|NCT06474468|DRUG|SHR-A2102；Adebrelimab；Cisplatin|"Drug: SHR-A2102 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Cisplatin Administration by intravenous infusion for a cycle of 3 weeks."
48686267|NCT05822947|OTHER|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
48686268|NCT05822947|OTHER|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
48686269|NCT02202915|BEHAVIORAL|Behavioral Checklist|
48686270|NCT00056576|DRUG|Zonisamide|
48001218|NCT04147065|DRUG|Duration of eradication regimen|14 day eradication regimen
48001219|NCT00258076|DRUG|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
48001220|NCT04552691|DRUG|Pegunigalsidase Alfa|Pegunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).
48001221|NCT04240145|DEVICE|MSCT Abdomen|Visceral fat volumetry using MSCT and it's relation to NASH
48001222|NCT01378793|BEHAVIORAL|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
48001223|NCT01378793|BEHAVIORAL|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
48001224|NCT00211458|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
48001225|NCT01172951|OTHER|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
48001226|NCT01172951|OTHER|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
48001227|NCT01417481|DIETARY_SUPPLEMENT|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
48001228|NCT01417481|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
48001229|NCT05332769|GENETIC|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
48158411|NCT04260776|BEHAVIORAL|Phase 2: re-engagement text messages|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
48158412|NCT04260776|BEHAVIORAL|Phase 2: re-engagement emails|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
48158413|NCT06471413|OTHER|The Prevention Toolbox : BOAT®|The Prevention Toolbox targets all forms of violence, but in particular sexual and gender-based violence, through 1 out of 5 themes (Relationships and sexuality) and 10 out of 34 sub-themes. The other 4 themes (Psychosocial skills, Respect and difference, From the virtual to the real, and Understanding and respect for the law) cover all the risk and protection factors for all types of violence.
48158414|NCT06063564|BEHAVIORAL|PREVENT|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
48001230|NCT02417051|BEHAVIORAL|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
48158415|NCT06063564|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
48001231|NCT00587379|DRUG|Atorvastatin|40 mg atorvastatin pill daily
48001232|NCT00587379|DRUG|placebo|40 mg pill per day
48158416|NCT04272099|OTHER|Administration of standardized questionnaires|Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
48158417|NCT04272099|DEVICE|Physical activity tracker|PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
48513020|NCT02192398|DRUG|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
48513021|NCT00002960|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
48513022|NCT00294580|DRUG|Maloprim|
48158418|NCT04272099|OTHER|Dietary log|PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
48158419|NCT05903118|BIOLOGICAL|RBMRNA-176|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection
48158420|NCT05903118|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
48513023|NCT01153295|PROCEDURE|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
48513024|NCT01153295|PROCEDURE|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
48513025|NCT03629197|BEHAVIORAL|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
48513026|NCT03629197|OTHER|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
48513027|NCT05122559|DRUG|N-acetyl cysteine|N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
48513028|NCT05122559|DRUG|Placebo|Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
48513029|NCT01148615|DRUG|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48513030|NCT01148615|DRUG|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48001233|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
48001234|NCT02450227|DIETARY_SUPPLEMENT|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
48001235|NCT04037319|DIAGNOSTIC_TEST|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
48001236|NCT00134212|DRUG|Dopexamine and norepinephrine|
48001237|NCT00134212|DRUG|Epinephrine|
48001238|NCT03010787|DRUG|V565|single ascending dose of V565
48001239|NCT03010787|DRUG|V565|Multiple dose
48001240|NCT03010787|DRUG|Placebo|Single and multiple dose
48001241|NCT03010787|DRUG|V565|Open-label single dose
48001242|NCT03010787|DRUG|V565|Open-label single ascending dose
48001243|NCT04865432|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
48001244|NCT00254995|BIOLOGICAL|None administered in this study|N/A in this study
48158421|NCT03216915|DRUG|Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
48158422|NCT01132222|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
48158423|NCT05043298|DRUG|IBI 360 Injection|IBI 360 dose level of escalation IV Q3W Day 1
48158424|NCT05043298|DRUG|IBI 360 Injection Sintilimab|IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
48158425|NCT01198899|OTHER|blood sampling|Blood sampling will be used.
48001245|NCT02933242|RADIATION|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
48001246|NCT00196950|BIOLOGICAL|Meningococcal (vaccine)|
48158426|NCT02010021|DRUG|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
48158427|NCT05039047|OTHER|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
48001247|NCT05674552|DRUG|Exogenous ketone ester|500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
48001248|NCT00164346|BEHAVIORAL|neurocognitive habilitation|
48001249|NCT02963649|DEVICE|DCB|Drug Coated Balloon
48158428|NCT01262794|BIOLOGICAL|CDP6038|100 mg/mL solution for injection, single dose
48158429|NCT01262794|BIOLOGICAL|Placebo|0.9% sodium chloride for injection Single-dose
48158430|NCT01914302|DEVICE|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48158431|NCT01914302|DEVICE|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48158432|NCT01914302|DEVICE|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48158433|NCT01914302|DEVICE|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48001250|NCT02963649|DEVICE|PTA|Percutaneous Transluminal Angioplasty
48686271|NCT03138317|BIOLOGICAL|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
48686272|NCT03138317|BIOLOGICAL|Plasma|This group will receive a knee injection with 6 ml of plasma.
48001251|NCT01005004|BIOLOGICAL|HuCNS-SC cells|intracerebral transplantation
48001252|NCT01352312|DRUG|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
48001253|NCT01352312|DRUG|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
48001254|NCT01352312|DRUG|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
48158434|NCT01914302|DEVICE|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48158435|NCT01914302|DEVICE|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48158436|NCT01914302|DEVICE|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48158437|NCT01914302|DEVICE|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
48158438|NCT02625636|DRUG|SAR438544|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48158439|NCT02625636|DRUG|placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48158440|NCT02625636|DRUG|r-glucagon|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48158441|NCT02789098|OTHER|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
48158442|NCT00003359|DRUG|batabulin sodium|
48158443|NCT06537570|BEHAVIORAL|Guided Imagery Practice|"Before the guided imagery application, the language translation of the guided imagery usage steps guide prepared by Owen (2010)27 was done by a translation center in a certified manner. Then, a relaxing, soothing, soft and slow-paced CD consisting of mixed nature sounds, photographs and music lasting 15 minutes and 50 seconds was prepared in the sound recording studio with the psychological counselor.~Data collection forms were filled in by the researcher using face-to-face interview technique for the women who agreed to participate in the study. The guided imagery video was shared with the women and they were made to watch it once a day for 12 weeks in a quiet, calm, uncrowded, dimly lit room in their homes. The women in the control group did not receive any interventions other than routine interventions during outpatient follow-up."
48158444|NCT00669292|BIOLOGICAL|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
48686273|NCT03138317|BIOLOGICAL|Placebo|This group will receive a knee injection with 6 ml saline solution.
48001255|NCT04409288|DRUG|Apalutamide|Androgen receptor inhibitor.
48001256|NCT04409288|DRUG|Enzalutamide|Androgern receptor inhibitor
48001257|NCT01885312|BEHAVIORAL|Adaptive Tailored Intervention|Adaptive
48001258|NCT01885312|BEHAVIORAL|Consequence-based Intervention|Loss Framed
48001259|NCT01885312|BEHAVIORAL|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
48001260|NCT01885312|OTHER|Assessment only|EMA only
48001261|NCT01365390|OTHER|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to \< 6 years) or since birth (for subjects aged \< 1 year) will be recorded in the electronic case report form.
48686274|NCT02408172|DRUG|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
48686275|NCT02408172|DRUG|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
48001262|NCT01365390|OTHER|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
48158445|NCT03356145|DRUG|12 mL paracervical block|Injection of 12 mL of lidocaine
48158446|NCT03356145|DRUG|20 mL paracervical block|Injection of 20 mL of lidocaine
48158447|NCT02592486|BIOLOGICAL|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
48686276|NCT02342847|OTHER|N/A (non-interventional study)|
48686277|NCT01934907|OTHER|Washing of packed RBC by normal saline|
48686278|NCT01270932|DRUG|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
48686279|NCT02044224|DRUG|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
48686280|NCT02284815|DIETARY_SUPPLEMENT|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
48686281|NCT02046837|BEHAVIORAL|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
48001263|NCT00621218|DRUG|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
48001264|NCT00621218|DRUG|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
48001265|NCT03458533|PROCEDURE|Bariatric surgery|
48001266|NCT03458533|BEHAVIORAL|Diet and lifestyle changes|
48001267|NCT00702117|DRUG|flecainide|2 mg/kg iv in 10 minutes
48001268|NCT00702117|DRUG|ajmaline|1 mg/kg iv in 10 minutes
48001269|NCT00702117|DRUG|procainamide|10 mg/kg iv in 10 minutes
48158448|NCT02592486|BIOLOGICAL|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
48158449|NCT03949699|OTHER|Resistance training|Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
48158450|NCT04837235|DRUG|Hemay005|oral
48001270|NCT04499586|COMBINATION_PRODUCT|Radiotherapy Combined With Raltitrexed and Irinotecan|Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
48001271|NCT01982253|DRUG|Fasiglifam|Fasiglifam tablets
48001272|NCT01982253|DRUG|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
48001273|NCT01147185|DEVICE|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
48001274|NCT01147185|DEVICE|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
48158451|NCT03172897|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
48158452|NCT03172897|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
48158453|NCT05320068|DRUG|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
48158454|NCT05320068|DRUG|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
48158455|NCT00144378|DRUG|Irinotecan|
48686282|NCT02046837|BEHAVIORAL|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
48686283|NCT02046837|BEHAVIORAL|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
48686284|NCT01570517|DEVICE|IASD System|Implantation of the DC Devices Inc. IASD System
48686285|NCT00302744|DRUG|Psilocybin (drug)|Capsule (.2 mg/kg).
48686286|NCT00302744|OTHER|Niacin|Active Placebo
48686287|NCT00302744|DIAGNOSTIC_TEST|MRI|MRI required for study inclusion for purpose of ruling out metasteses to brain
48686288|NCT06482827|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
48686289|NCT06482827|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2004 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
48001275|NCT04516083|DIAGNOSTIC_TEST|Mismatch repair instability somatic and germline testing|Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.
48001276|NCT03863613|DEVICE|Pessary|A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix.
48001277|NCT03863613|PROCEDURE|Cervical cerclage|Cervical cerclage using Mc Donald technique, under anaesthesia
48001278|NCT03863613|DRUG|Vaginal progesterone|Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
48001279|NCT06209736|DRUG|OMS906 study drug|OMS906 study drug dose 5mg/kg IV administration at 4-week internals
48001280|NCT05366439|DRUG|AT-752|Parallel Assignment
48001281|NCT05366439|DRUG|Placebo Comparator|Parallel Assignment
48513031|NCT01971047|DRUG|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
48158456|NCT02660047|DRUG|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
48158457|NCT02660047|DRUG|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
48158458|NCT03190317|OTHER|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
48158459|NCT03190317|OTHER|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
48158460|NCT03190317|OTHER|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
48686290|NCT05739396|OTHER|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
48686291|NCT06496308|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
48001282|NCT06082466|PROCEDURE|FRAMED Infrainguinal Venous Bypass|The harvested vein graft will be covered with a mesh.
48001283|NCT06082466|PROCEDURE|Conventional Autologous Bypass|The harvested vein graft will be used without a mesh coating.
48001284|NCT04116645|OTHER|genital and rectal swab|6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
48686292|NCT06496308|DRUG|Bendamustine|Bendamustine IV will be administered as per the schedule specified in the respective arm.
48686293|NCT06496308|DRUG|Rituximab|Rituximab IV will be administered as per the schedule specified in the respective arm.
48001285|NCT00213837|DEVICE|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
48158461|NCT05128227|BEHAVIORAL|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
48513032|NCT01971047|DRUG|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose \> 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
48513033|NCT00553735|DRUG|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
48001286|NCT03051542|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
48001287|NCT01411163|DRUG|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
48001288|NCT01334658|PROCEDURE|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
48001289|NCT01334658|DRUG|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
48158462|NCT05128227|BEHAVIORAL|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
48513034|NCT00553735|DRUG|Arificial Tear|Artificial Tear - three times a day for 18 months.
48513035|NCT05441501|DRUG|JNJ-80038114|JNJ-80038114 will be administered.
48513036|NCT00028977|DRUG|herba scutellaria barbata|
48513037|NCT00028977|OTHER|herba scutellaria Barbatae (HSB)|
48513038|NCT04462432|OTHER|no intervention|This is an observation study, with no intervention.
48513039|NCT01471730|DRUG|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
48513040|NCT01471730|DRUG|Saline solution|Normal saline will be administered to control patients.
48686294|NCT06496308|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
48686295|NCT03742310|DRUG|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
48001290|NCT01334658|DRUG|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
48001291|NCT02735161|OTHER|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
48001292|NCT02735161|OTHER|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
48001293|NCT03424031|PROCEDURE|Verticalization|To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
48001294|NCT00457938|OTHER|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
48001295|NCT00457938|OTHER|Diet|10 % versus 35 % fat in diet
48001296|NCT05427396|DRUG|JS004|Usage and dosage: Inject 200mg once every 3 weeks
48001297|NCT05427396|DRUG|Toripalimab Injection|Usage and dosage: Inject 240mg once every 3 weeks
48158463|NCT01995149|BEHAVIORAL|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
48158464|NCT04225247|DRUG|Single Bond Universal|Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
48158465|NCT04225247|DRUG|Bifluorid 12|it is a fluoride varnish by VOCO.
48158466|NCT04225247|DRUG|Xeno V+|Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
48158467|NCT03469258|DRUG|Pancrelipase|Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
48158468|NCT01286870|DEVICE|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
48158469|NCT01286870|DEVICE|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
48158470|NCT03480945|DIAGNOSTIC_TEST|serotonin|Endothelium-dependent dilatation
48158471|NCT02627534|PROCEDURE|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
48001298|NCT03083496|DRUG|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
48001299|NCT03083496|DRUG|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
48001300|NCT06357611|OTHER|Simulated technique|"The participant was in a supine position, with her upper limbs at her sides and her neck in a neutral position.~The researcher sat in a cephalic position, making contact with the participant's shoulders, without any movement, until 5 minutes had elapsed."
48513041|NCT01471730|DRUG|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
48513042|NCT00736632|DRUG|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
48513043|NCT00736632|DRUG|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
48513044|NCT01885195|DRUG|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
48686296|NCT00902850|DEVICE|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
48686297|NCT00902850|DEVICE|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
48686298|NCT00943098|DRUG|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
48686299|NCT00943098|DRUG|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
48686300|NCT04062981|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
48686301|NCT00400218|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
48686302|NCT01773967|DRUG|LGG|LGG 10\^10 cfu PO BID X 5 days
48686303|NCT01773967|DRUG|micro-crystalline cellulose|1 capsule PO bid x 5 days
48686304|NCT02860234|DRUG|Oxaliplatin|
48686305|NCT02860234|DRUG|Capecitabine|
48686306|NCT02860234|RADIATION|intensity modulated radiotherapy|
48686307|NCT02860234|PROCEDURE|DRE-Endoscopy-MRI-CEA|
48686308|NCT02860234|PROCEDURE|Nonoperative Management|
48686309|NCT02860234|PROCEDURE|Local Excision|
48001301|NCT06357611|OTHER|Muscle energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~The researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. He then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively until the motor barrier was reached, and instructed her to perform an isometric contraction of the hamstrings. She was asked to perform three 7-second contractions with a 2 to 3-second interval, using approximately 20% of her maximum strength, gaining a new motor barrier between each set, for a total of three sets."
48001302|NCT06357611|OTHER|4th ventricle technique and muscular energy technique|"The participant was in a supine position, with her upper limbs alongside her body and her neck in a neutral position.~For CV-4, the researcher contacted the squamous portion of the occiput laterally, bringing it close to the posterior convexity of the occiput, bringing the skull into extension, changing the compression movement with decompression, until 3 minutes had elapsed.~For the MET, the researcher adopted a position homolateral to the dominant limb, contacting the lower limb with the caudal hand in the region of the malleoli. She then helped the participant to perform the movement, which consisted of flexing the hip and extending the knee passively to the motor barrier, having been instructed to perform an isometric contraction of the hamstring. A total of 3 7-second contractions with a 2-3 second interval were requested, using approximately 20% of her maximum strength, and with a new motor barrier being gained between each series, for a total of 3 series."
48001303|NCT06115538|OTHER|Levodopa|Levodopa benserazide (100+25 mg) will be given to one group of study patients, and levodopa carbidopa entacapone (100+25+200 mg) will be given to the other group of study patients. Just before the drugs are given (0th minute), at 90 and 180 minutes after the drugs are given, a total of 3 doses will be given.
48686310|NCT02860234|PROCEDURE|Total Mesorectal Excision|
48686311|NCT02860234|BEHAVIORAL|Quality of Life Questionnaires|
48001304|NCT04217486|OTHER|Patient will be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will then be shown a photograph of their knee at 2 weeks postoperative.
48686312|NCT04458246|OTHER|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
48686313|NCT00699946|DRUG|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
48686314|NCT00699946|DRUG|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
48686315|NCT03715140|DRUG|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
48686316|NCT03715140|DRUG|Placebo|Placebo
48686317|NCT03461562|OTHER|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
48686318|NCT03079687|DRUG|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
48686319|NCT05723692|BIOLOGICAL|ALTB-268|monoclonal antibody
48686320|NCT05723692|OTHER|Placebo|formulation buffer
48686321|NCT06521827|RADIATION|short course radiotherapy|short course palliative radiotherapy
48686322|NCT06093542|DRUG|AZD7053|Randomised participants will receive AZD7503 subcutaneously.
48686323|NCT06093542|DRUG|Placebo|Randomised participants will receive placebo subcutaneously.
48686324|NCT05231759|DEVICE|L'DISQ|
48686325|NCT00750035|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
48686326|NCT00750035|PROCEDURE|Subtotal abdominal hysterectomy|
48686327|NCT00617097|DRUG|lidocaine|paracervical block with lidocaine
48686328|NCT00617097|DRUG|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
48686329|NCT04798222|DRUG|Treatment A|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
48686330|NCT04798222|DRUG|Treatment B|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
48686331|NCT04798222|DRUG|Treatment C|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
48686332|NCT04798222|DRUG|Treatment D|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
48686333|NCT04798222|DRUG|Treatment E|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
48001305|NCT04217486|OTHER|Patient will not be shown a photograph of their knee at 2 weeks postop|Patients who undergo primary TKA surgery will not be shown a photograph of their knee at 2 weeks postoperative.
48158472|NCT02627534|PROCEDURE|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
48158473|NCT05582421|DRUG|Diclofenac Sodium|intracanal medication
48158474|NCT01771081|DRUG|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
48001306|NCT01904604|BIOLOGICAL|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
48158475|NCT00938041|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
48158476|NCT05490680|DRUG|Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg|Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
48158477|NCT05490680|DRUG|Placebo|Placebo Oral Film
48158478|NCT05066230|DRUG|KSI-301|Intravitreal injection
48513045|NCT05961917|OTHER|5 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 5 cmH2O
48686334|NCT04798222|DRUG|Treatment F|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
48001307|NCT01904604|BIOLOGICAL|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
48001308|NCT01904604|BIOLOGICAL|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
48001309|NCT05102188|COMBINATION_PRODUCT|Assessment of sleep and related factors|Eligible participants will be invited to fill out several forms and wear a watch-like device on their wrist (an accelerometer) for 7 days to assess their sleep habits. They will also be asked to sleep at home with a watch-like device attached to a sleeve which covers their index finger (an oximeter) for one night to assess whether they may have a sleep problem like sleep apnea.
48001310|NCT04782908|DEVICE|Transcatheter tricuspid valve edge-to-edge repair|Transcatheter tricuspid valve edge-to-edge repair is an interventional approach to treat severe tricuspid regurgitation. Under general anesthesia a clip delivery system is forwarded through the vena femoralis and right atrium in the right ventricle. A clip is deployed to clamp the tricuspid valve and reduce tricuspid valve regurgitation.
48001311|NCT01166828|BEHAVIORAL|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
48513046|NCT05961917|OTHER|10 cmH2O Positive end-expiratory pressure (PEEP)|PEEP will be set at 10 cmH2O
48513047|NCT02845700|BEHAVIORAL|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
48686335|NCT04798222|DRUG|Treatment G|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
48001312|NCT03912727|DIETARY_SUPPLEMENT|Alpha-Lipoic acid plus renal replacement therapy|Alpha lipoic acid (ALA) is a vitamin-like antioxidant
48001313|NCT03912727|OTHER|renal replacement therapy|standard renal replacement therapy
48001314|NCT03594383|DEVICE|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
48001315|NCT05130203|BEHAVIORAL|MouvMat Exergaming|Sessions engaging with exergaming device.
48001316|NCT05130203|BEHAVIORAL|Standard Recreational Programming|Conducted by recreational therapists.
48001317|NCT06343844|DIAGNOSTIC_TEST|cardiac imaging to assess left ventricular volumes and function|non-invasive cardiac imaging (echocardiography and MRI)
48001318|NCT00422331|DRUG|Lithium Carbonate Capsule|
48158479|NCT05066230|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
48158480|NCT02473913|DRUG|Milk Thistle|
48158481|NCT02473913|DRUG|Placebo|
48158482|NCT05519579|DRUG|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
48158483|NCT05519579|DRUG|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
48158484|NCT04728659|DRUG|Desogestrel 0.075 MG|It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation
48158485|NCT04728659|DRUG|Orgalutran|It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
48513048|NCT02845700|BEHAVIORAL|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
48686336|NCT04798222|DRUG|Treatment H|Participants will receive oral dose of dapagliflozin capsule in fasted condition.
48686337|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
48686338|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
48686339|NCT03838614|BEHAVIORAL|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
48686340|NCT03838614|OTHER|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
48686341|NCT03332199|OTHER|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
48686342|NCT00593177|DRUG|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
48366915|NCT04340167|BIOLOGICAL|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
48366916|NCT01621659|BEHAVIORAL|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
48686343|NCT01294111|BEHAVIORAL|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
48686344|NCT03078439|OTHER|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
48686345|NCT04002050|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
48686346|NCT05908357|OTHER|Exergaming|Use of the exergame XboX 360 series with kinect sensor
48686347|NCT05908357|OTHER|Booklet|Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
48686348|NCT06341595|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1, 4-6 cycles
48686349|NCT06341595|RADIATION|Extraperitoneal radiation therapy|Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)
48686350|NCT06341595|DRUG|Oxaliplatin|oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
48686351|NCT06341595|DRUG|S-1|S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
48686352|NCT02353013|DIETARY_SUPPLEMENT|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
48686353|NCT02353013|DIETARY_SUPPLEMENT|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
48686354|NCT05107063|DRUG|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
48686355|NCT02933879|DRUG|NVXT topical|topical treatment
48686356|NCT02933879|DRUG|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
48158486|NCT01444547|DRUG|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
48158487|NCT06030258|DRUG|IN10018|orally taken once daily
48158488|NCT06030258|DRUG|Tislelizumab|200mg D1, Q3W, intravenously
48158489|NCT06030258|DRUG|Carboplatin|AUC 5 mg/ml/min, D1, Q3W, intravenously
48158490|NCT06030258|DRUG|Etoposide|Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
48686357|NCT02944708|DRUG|Conventional chemotherapy|
48686358|NCT02944708|DRUG|Maintenance chemotherapy 1|
48686359|NCT02944708|DRUG|Maintenance chemotherapy 2|
48686360|NCT01448889|DRUG|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
48686361|NCT01448889|DRUG|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
48686362|NCT03663569|DRUG|Spiolto® Respimat®|Drug
48686363|NCT02715830|PROCEDURE|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
48686364|NCT01540526|DRUG|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
48686365|NCT03529838|OTHER|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
48001319|NCT00590954|DRUG|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
48001320|NCT06072937|DEVICE|IntelliStent|Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
48001321|NCT00058825|BIOLOGICAL|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
48686366|NCT04776161|BEHAVIORAL|Cue-Reward Intervention|"Patients in the first intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Patients will also receive text messages reminding them of the habit they decided to link to their medication-taking.~Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf."
48001322|NCT00058825|DRUG|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
48001323|NCT00058825|PROCEDURE|Stem Cell Transplant|Day 0: Donor stem cells infused.
48001324|NCT00058825|RADIATION|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
48001325|NCT00058825|DRUG|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
48001326|NCT02795559|OTHER|Glucose|75g glucose dissolved in 300ml water
48366917|NCT01134458|BEHAVIORAL|Web-Based Intervention|"1. Health Dialog Cardiac Risk Calculator~2. Health Dialog's Living with Coronary Heart Disease~3. Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
48366918|NCT02432924|BEHAVIORAL|Instant + Multidimensional Physical Activity Feedback|
48366919|NCT01028859|DRUG|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks
48001327|NCT02795559|OTHER|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
48001328|NCT02795559|OTHER|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
48001329|NCT01269697|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules 2 times per day during 6 month
48001330|NCT01269697|DIETARY_SUPPLEMENT|Placebo Nutrof total|2 capsules 2 times per day during 6 month
48001331|NCT00907374|DRUG|benazepril|benazepril 10 mg orally once daily
48001332|NCT00907374|DRUG|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
48001333|NCT06383663|PROCEDURE|Supraclavicular lymph node dissection combined with radiotherapy|Breast cancer patients in the expreimental cohort with only ipsilateral supraclavicular lymph node metastasis were first treated with supraclavicular lymph node dissection and received standard radiotherapy after surgery.
48001334|NCT06383663|RADIATION|radiotherapy|Patients in the control group received only standard radiation therapy.
48366920|NCT05232903|BIOLOGICAL|SVF therapy group|The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
48001335|NCT03169946|PROCEDURE|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
48001336|NCT03169946|PROCEDURE|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
48001337|NCT02659020|DRUG|Olaratumab|Administered IV
48001338|NCT02659020|DRUG|Gemcitabine|Administered IV
48001339|NCT02659020|DRUG|Docetaxel|Administered IV
48001340|NCT02659020|DRUG|Placebo|Administered IV
48001341|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
48001342|NCT01536431|DRUG|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
48001343|NCT01536431|DRUG|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
48001344|NCT00445510|DRUG|GSK256066|
48366921|NCT02115620|OTHER|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
48366922|NCT04862351|BEHAVIORAL|exercise training for TechCR|3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
48686367|NCT04776161|BEHAVIORAL|Cue-Reward Intervention with possible intensification|"Patients in the second intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.~After 6 weeks, patients who demonstrate an adherence under 80% to study medications (as measured by the electronic pill bottle) will begin receiving text messages reminding them of their selected cue."
48686368|NCT05730868|PROCEDURE|myofascial release|Soft tissue release will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
48686369|NCT05730868|PROCEDURE|muscle energy technique|Muscle energy Technique will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
48001345|NCT02464202|OTHER|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
48001346|NCT03812965|DRUG|Botulinum toxin type A|2 units/point of botulinum toxin type A
48001347|NCT04555837|DRUG|Alisertib|Given PO
48001348|NCT04555837|BIOLOGICAL|Pembrolizumab|Given IV
48001349|NCT05112692|DRUG|Dydrogesterone Tablets|first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle
48001350|NCT05112692|DRUG|cetrorelix 0.25mg|In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.
48001351|NCT05112692|DRUG|human menopausal gonadotropin|(150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger
48686370|NCT05730868|PROCEDURE|MFR & MET|combination of myofascial release and muscle energy technique will be performed on the trapezius, suboccipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
48686371|NCT05730868|PROCEDURE|conventional therapy|traditional physical therapy devices are used to relieve pain and spam. this will include a hot pack, ultrasound, and TENS (Transcutaneous electrical nerve stimulation)
48001352|NCT05112692|DRUG|triptorelin 0.1 mg|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
48686372|NCT04447235|DRUG|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
48686373|NCT04447235|DRUG|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
48686374|NCT04447235|DRUG|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
48686375|NCT05954208|OTHER|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
48686376|NCT05954208|OTHER|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
48686377|NCT02229981|DRUG|ABC294640|
48686378|NCT03825640|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
48001353|NCT05112692|DRUG|human chorionic gonadotropin|When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
48001354|NCT05112692|PROCEDURE|cryopreservation|All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification
48158491|NCT01124916|PROCEDURE|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
48158492|NCT01124916|PROCEDURE|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
48158493|NCT05734976|DEVICE|electroacupuncture|This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
48158494|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 18%-protein diet|
48158495|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 35%-protein diet|
48366923|NCT04862351|BEHAVIORAL|audio/video conference|weekly audio/video conference
48001355|NCT05112692|DRUG|Estradiol Valerate and progesterone|Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
48158496|NCT03771209|DIAGNOSTIC_TEST|ultrasound examination|ultrasound assessment
48366924|NCT04862351|BEHAVIORAL|educational video|weekly for 6 weeks, duration of video about 10-15 minutes
48366925|NCT04862351|BEHAVIORAL|Daily log|daily dietary and exercise log
48366926|NCT04862351|BEHAVIORAL|exercise training for centre-based|6 times of supervised exercise training
48366927|NCT05776511|PROCEDURE|eVOG|video digital oculography
48686379|NCT04648917|DRUG|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
48686380|NCT03116035|OTHER|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
48686381|NCT03116035|OTHER|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
48001356|NCT04287504|DIAGNOSTIC_TEST|SavvyCheck Vaginal Yeast Test|Point-of-care test for the detection of vaginal candidosis
48001357|NCT04287504|DIAGNOSTIC_TEST|OSOM BVBLUE Test|Point-of-care test for the detection of bacterial vaginosis
48158497|NCT03418701|BEHAVIORAL|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
48158498|NCT06561256|DRUG|Janus Kinase Inhibitor|Janus Kinase Inhibitor in combination with corticosteroids
48158499|NCT03523858|DRUG|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
48158500|NCT02952235|OTHER|SPF50+|Sun protection
48158501|NCT02952235|OTHER|SPF100+|Sun protection
48158502|NCT00518310|DRUG|Placebo|
48158503|NCT00518310|DRUG|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
48686382|NCT06018077|BEHAVIORAL|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
48686383|NCT04383028|PROCEDURE|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
48001358|NCT03342976|OTHER|My-AHA platform|ICT strategy for early detection of frailties
48001359|NCT03246113|DRUG|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
48158504|NCT05662878|OTHER|Assessment of Hand Strength and Spasticity|Assessment of Hand Strength and Spasticity
48001360|NCT03246113|DRUG|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
48001361|NCT03246113|RADIATION|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
48001362|NCT04196478|DEVICE|doppler ultrasound|a 7.5 MHz ultrasound (US) linear probe is needed, grey-scale ultrasound and Color Doppler and a minimum display facility of the Doppler velocity spectrum for blood flow calculation are mandatory tools.
48001363|NCT00732810|DRUG|SCH 727965|SCH 727965 50 mg/m\^2 IV on Day 1 of each 21 day cycle until disease progression.
48001364|NCT00732810|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
48001365|NCT00732810|DRUG|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
48001366|NCT03808168|DRUG|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
48001367|NCT02481895|BEHAVIORAL|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
48001368|NCT04753164|DRUG|ACT-539313|ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
48001369|NCT04753164|DRUG|Placebo|Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
48001370|NCT01719185|DRUG|Phentermine and B12|
48001371|NCT01719185|DRUG|Phentermine|
48001372|NCT02380651|PROCEDURE|Limb salvage|Local or free flaps
48001373|NCT02148172|PROCEDURE|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
48158505|NCT04514289|DRUG|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
48158506|NCT06646146|PROCEDURE|Fat grafting combine with hair transplantation|Patients enrolled in this experiment will be divided into two groups.The experimental group will have autologous fat tissue harvested during surgery for fat grafting in the patient's alopecia area, and a subsequent hair transplantation will be performed after three months when the transplanted fat has stabilized and survived.
48001374|NCT02148172|PROCEDURE|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
48001375|NCT05297539|OTHER|Point light display|Visualization of point-light human actions
48001376|NCT04226482|DEVICE|New Device|Laparoscopic appendectomy using new ultrasonic shears.
48686384|NCT05395039|OTHER|VCHIPS|Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
48686385|NCT04922372|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
48686386|NCT00290992|DRUG|rasburicase (SR29142)|
48686387|NCT03528655|OTHER|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
48001377|NCT04226482|DEVICE|Used Device|Laparoscopic appendectomy using reprocessed ultrasonic shears.
48001378|NCT05063110|DRUG|Itacitinib|Administration of 300 mg of ITACITINIB per os every day for 30 days.
48001379|NCT03476304|DEVICE|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
48001380|NCT03476304|DEVICE|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
48001381|NCT03476304|DEVICE|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
48001382|NCT02302651|DEVICE|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
48001383|NCT04965194|PROCEDURE|erector spinae plane block|Superficial probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic (LA), and 20 ml of 0.25% bupivacaine will be administered to perform ESP block. LA spread to both cranial and caudal directions will be seen.
48001384|NCT04965194|PROCEDURE|Quadratus lumborum plane block|"A curved array transducer for the transmuscular QL (TQL) nerve block is placed in the axial plane on the patient's flank just cranial to the iliac crest. The shamrock sign is visualized: The transverse process of vertebra L4 is the stem, whereas the erector spinae posteriorly, QL laterally, and psoas major anteriorly represents the three leaves of the trefoil. The target for injection is the fascial plane between the QL and psoas major muscles. The needle is inserted using an in-plane technique from the posterior end of the transducer through the QL muscle. The injectate (20ml of bupivacaine 0.25%) should ideally spread from the injection site inside the fascial plane between the QL and psoas major muscles to the thoracic paravertebral space with a goal to accomplish segmental somatic and visceral analgesia from T4 to L1."
48001385|NCT04965194|OTHER|placebo|patients received no regional block
48158507|NCT06646146|PROCEDURE|Hair transplantation|Patients enrolled in this experiment will be divided into two groups. The control group will undergo a simple hair transplantation surgery.
48686388|NCT03936907|DRUG|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
48686389|NCT03936907|DRUG|Sativex|Sativex® Oromucosal Spray
48686390|NCT06553586|OTHER|Data collection|"Data of the proposed study will be collected from two main sites, namely they:~1. All emergency departments of health service outlets received the concerned victims of RTAs in Riyadh Region throughout the last five years (2019-2023). The records and documents of these hospitals will be reviewed and the researcher will determine and pick up the victims of RTAs only and record them in a relevant form designed to fit with the proposed study.~2. The General Administration of Traffic in Riyadh Region."
48001386|NCT00981032|BEHAVIORAL|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
48001387|NCT00981032|BEHAVIORAL|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
48001388|NCT05422781|DRUG|ITI-3000|ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
48001389|NCT00066066|PROCEDURE|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
48001390|NCT00066066|DRUG|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
48001391|NCT00066066|DRUG|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
48001392|NCT00066066|DRUG|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
48001393|NCT00772356|DEVICE|Accu-Chek Spirit Insulin Pump|
48686391|NCT04786821|BEHAVIORAL|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
48001394|NCT00772356|DEVICE|Comparator insulin pump|
48001395|NCT01100099|DIETARY_SUPPLEMENT|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
48001396|NCT02048553|DEVICE|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
48001397|NCT02048553|PROCEDURE|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
48001398|NCT05181111|DEVICE|Wearable Sensor|The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
48001399|NCT05181111|OTHER|Usual Care|Usual Care Monitoring
48686392|NCT04786821|DEVICE|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
48686393|NCT00708136|BEHAVIORAL|water based training program to improve balance|
48686394|NCT01864148|DRUG|BIIB033|
48686395|NCT01864148|OTHER|Placebo|
48686396|NCT01864148|DRUG|Avonex|
48686397|NCT03061877|OTHER|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
48158508|NCT01604499|BEHAVIORAL|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
48158509|NCT01604499|BEHAVIORAL|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
48686398|NCT00594607|DEVICE|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
48686399|NCT00594607|DEVICE|Fx8 (Fresenius)|Polysulphone dialysis membrane
48686400|NCT06285565|COMBINATION_PRODUCT|Nurse-led telephone coaching intervention with home telemonitoring of vital signs|In addition to standard care, the intervention group will receive a nurse-led supportive programme that involves a pre-discharge educational meeting and 6-month telephone coaching sessions. Patient's caregivers will also be invited to participate. After discharge, patients will be asked to measure their vital signs, daily. In case of alteration, the nurse will ascertain the presence of congestion symptoms and decide to reinforce the recommendations for self-management, request a specialist medical consultant, or refer to the emergency services
48686401|NCT02259725|DRUG|regorafenib|Given PO
48686402|NCT02259725|OTHER|laboratory biomarker analysis|Correlative studies
48686403|NCT04283955|DRUG|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
48001400|NCT01347138|OTHER|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
48001401|NCT03551210|DRUG|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
48001402|NCT03551210|DRUG|Nemonoxacin|Capsules, 250 mg
48001403|NCT03551210|DRUG|Tavanic|Solution for infusion, 500 mg (100 ml)
48686404|NCT01844297|DRUG|TDF+3TC+EFV|
48001404|NCT03551210|DRUG|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
48001405|NCT03551210|DRUG|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
48001406|NCT03551210|DRUG|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
48158510|NCT03094520|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
48158511|NCT03094520|DEVICE|sham-tDCS|sham stimulation
48158512|NCT00762853|DRUG|Fluoride|Brush half mouth once with assigned study treatment
48158513|NCT00762853|DRUG|Fluoride and triclosan|Brush half mouth once with assigned study treatment
48158514|NCT05898802|DIETARY_SUPPLEMENT|Kimchi|Two different kimchi, one traditional kimchi and one fermented with a lactic acid bacteria having anti-obesity effect, hereafter starter kimchi, are flash freeze dried, powdered and encapsulated.
48686405|NCT01322724|PROCEDURE|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
48686406|NCT01403779|RADIATION|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
48686407|NCT03019523|DIETARY_SUPPLEMENT|Caffeine Blend|Taken orally in capsule form
48001407|NCT03454984|DRUG|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
48001408|NCT04361162|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
48001409|NCT04361162|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
48001410|NCT04361162|RADIATION|Radiation|3D Conformal Radiotherapy to shrink or kill tumors
48001411|NCT05742880|DIAGNOSTIC_TEST|6 Minute Walking Test|6 Minute walking test
48001412|NCT05742880|DIAGNOSTIC_TEST|Blood gas analysis|Blood gas analyisis
48001413|NCT05742880|PROCEDURE|Wearing a Surgical Facemask|Wearing a Surgical Facemask
48001414|NCT05742880|PROCEDURE|Wearing a FFP2- Facemask|Wearing a FFP2- Facemask
48158515|NCT05898802|DIETARY_SUPPLEMENT|Placebo|Lactose with kimchi flavor
48158516|NCT04539938|DRUG|tucatinib|300 mg orally twice daily
48686408|NCT03019523|OTHER|Sugar Pill|Taken orally in capsule form
48686409|NCT00002081|DRUG|Zidovudine|
48686410|NCT00002081|DRUG|Zalcitabine|
48686411|NCT02134561|BEHAVIORAL|psychological interview|
48158517|NCT04539938|DRUG|trastuzumab deruxtecan|5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle
48158518|NCT05815771|PROCEDURE|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
48001415|NCT05742880|PROCEDURE|Wearing no Mask|Wearing no Mask
48001416|NCT05886959|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
48001417|NCT05886959|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
48001418|NCT05886959|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
48001419|NCT05886959|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
48001420|NCT05886959|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
48001421|NCT05886959|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
48001422|NCT05886959|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
48001423|NCT05886959|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
48001424|NCT03010878|OTHER|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
48158519|NCT05815771|PROCEDURE|Bone Marrow stem cells aspirate|stem cells
48158520|NCT04388514|PROCEDURE|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
48158521|NCT01795183|DRUG|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
48158522|NCT05653921|OTHER|In vivo confocal microscopy (IVCM)|In vivo confocal microscopy (IVCM) allows for visualization of the corneal structures at the cellular level, allowing for assessment of corneal nerves. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
48158523|NCT05183997|DIAGNOSTIC_TEST|complete blood count|laboratory test
48686412|NCT02134561|RADIATION|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
48686413|NCT02134561|OTHER|cognitive tests|
48158524|NCT05183997|DIAGNOSTIC_TEST|prothrombin time|laboratory test
48158525|NCT05183997|DIAGNOSTIC_TEST|prothrombin concentration|laboratory test
48158526|NCT05183997|DRUG|Verapamil|drug will be add to prolong the effect of regional block
48158527|NCT02382913|BIOLOGICAL|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
48686414|NCT02134561|OTHER|neurological tests|
48686415|NCT02669394|BEHAVIORAL|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
48686416|NCT02669394|BEHAVIORAL|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
48686417|NCT03040739|OTHER|use of O'ARM imaging system|use of O'ARM imaging system
48686418|NCT06351423|BEHAVIORAL|Forest Bathing (FB)|"The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session."
48686419|NCT06351423|BEHAVIORAL|MIND diet|The participants will undertake four three-month nutrition programmes consisting of four nutrition counselling sessions in an activity room at each participating community centre. All intervention sessions will be conducted by a registered nutritionist. In the nutrition sessions, the participants will learn to modify their diet to meet the MIND diet guidelines. The MIND diet promotes 10 healthy food groups and limits five unhealthy food groups (Morris et al., 2015a; Arjmand et al., 2022). As a reference, a 7-day sample menu will be provided which meets the required number of servings per day.
48686420|NCT05363722|DRUG|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
48686421|NCT05363722|DRUG|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
48686422|NCT05363722|DRUG|sintilimab|sintilimab 200 mg IV d1 Q3W
48686423|NCT05363722|DRUG|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
48686424|NCT03235453|OTHER|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
48686425|NCT03235453|OTHER|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
48686426|NCT00393991|DRUG|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
48686427|NCT00393991|DRUG|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
48686428|NCT00393991|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
48686429|NCT00393991|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
48686430|NCT02339844|DRUG|Aripiprazole|6 weeks of individual doses of aripiprazole
48686431|NCT06032559|BEHAVIORAL|MORE|MORE plus TAU
48686432|NCT06032559|BEHAVIORAL|SMP|SMP plus TAU
48686433|NCT06032559|OTHER|TAU|TAU only
48686434|NCT04583124|OTHER|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
48686435|NCT04583124|OTHER|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
48686436|NCT02165943|DEVICE|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
48686437|NCT01151384|DRUG|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
48686438|NCT00154817|PROCEDURE|radiotherapy|
48001425|NCT03010878|OTHER|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
48686439|NCT02676674|DRUG|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
48686440|NCT02676674|DRUG|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
48001426|NCT01248299|DRUG|FU-CDDP|"every 21 days:~* Fluoro-uracil \[800 mg/m2, day 1 to day 5\]~* CisPlatin \[75 mg/m2, day 1 or day 2\]"
48001427|NCT01248299|DRUG|LV5FU2-CDDP|"every 14 days:~* Elvorin \[200 mg/m2, 2h IV, day 1 and day 2\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, 22h continous infusion, day 1 and day 2\]~* CisPlatin \[50 mg/m2, day 2\]"
48686441|NCT02072252|BEHAVIORAL|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
48686442|NCT00940290|OTHER|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
48686443|NCT02250131|PROCEDURE|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery \> 280 mL/min/m2
48686444|NCT00897780|BEHAVIORAL|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
48686445|NCT03125499|OTHER|Previous treated with TPX-100|No intervention, only observational
48686446|NCT03198481|BEHAVIORAL|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
48686447|NCT03198481|BEHAVIORAL|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
48686448|NCT05521347|BEHAVIORAL|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
48686449|NCT02226588|DRUG|Misoprostol|
48686450|NCT00652314|DEVICE|Thrombi-Gel|Applicaton of Hemostatic product during surgery
48686451|NCT04393038|DRUG|ABX464|ABX464 50mg QD for 28 days + Standard of Care
48686452|NCT04393038|DRUG|Placebo|Placebo 50mg QD for 28 days + Standard of Care
48686453|NCT02254044|DRUG|bivatuzumab mertansine|
48686454|NCT00536718|GENETIC|gene expression analysis|
48686455|NCT00536718|GENETIC|molecular diagnostic method|
48686456|NCT00536718|GENETIC|polymorphism analysis|
48686457|NCT00536718|GENETIC|protein expression analysis|
48686458|NCT00536718|OTHER|medical chart review|
48686459|NCT00536718|OTHER|questionnaire administration|
48686460|NCT03545087|DRUG|Lanabecestat|Administered orally
48686461|NCT03545087|DRUG|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
48686462|NCT01009905|DRUG|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
48686463|NCT05978349|DRUG|adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
48686464|NCT04626284|PROCEDURE|Heart Transplantation|Heart Transplantation
48686465|NCT04471376|DRUG|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
48158528|NCT02382913|BIOLOGICAL|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
48686466|NCT06228482|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
48686467|NCT02070328|OTHER|Registry|
48686468|NCT05797051|DIAGNOSTIC_TEST|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
48686469|NCT05800353|PROCEDURE|YAG vitreolysis|"A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye."
48686470|NCT02141230|DRUG|Alli® 60 mg|Participants purchasing Alli®
48686471|NCT01760499|DRUG|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
48686472|NCT01760499|PROCEDURE|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
48686473|NCT00272831|DRUG|Cilostazol|Cilostazol 100 mg twice daily
48686474|NCT00272831|DRUG|Placebo|1 tablet twice daily
48686475|NCT01279044|BEHAVIORAL|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
48158529|NCT02382913|BIOLOGICAL|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
48513049|NCT02682927|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
48686476|NCT01279044|BEHAVIORAL|Standard HIV testing with information only|Standard HIV testing with information only
48686477|NCT03699397|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
48686478|NCT01034982|DRUG|AZD9668|20 mg
48686479|NCT01034982|DRUG|AZD9668|60 mg
48686480|NCT03516175|DEVICE|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
48686481|NCT03516175|DEVICE|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
48686482|NCT02695017|DEVICE|Iso inertial|
48001428|NCT01248299|DRUG|FOLFOX|"every 14 days:~* Oxaliplatin \[85 mg/m2 by 2h infusion, day 1\]~* Fluoro-uracil \[400 mg/m2 as a bolus, day 1 and day 2\]~* Fluoro-uracil \[600 mg/m2, by 22h continous infusion, day 1 and day 2\]~* Elvorin \[500 mg/m2, day 1 and day 2\]"
48686483|NCT02695017|DEVICE|Conventional machine|
48686484|NCT05924581|OTHER|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
48686485|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
48686486|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
48686487|NCT05121298|DRUG|upadacitinib 15mg/day|Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
48686488|NCT00628459|DIETARY_SUPPLEMENT|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
48686489|NCT01245686|BEHAVIORAL|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
48686490|NCT02038946|DRUG|Nivolumab|
48686491|NCT04983693|BEHAVIORAL|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
48686492|NCT00651014|DRUG|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
48686493|NCT00651014|DRUG|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
48686494|NCT05070312|BIOLOGICAL|MEDI3506|MEDI3506
48686495|NCT05070312|DRUG|Placebo|Placebo
48686496|NCT02973139|OTHER|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
48686497|NCT02973139|OTHER|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
48686498|NCT05671406|BEHAVIORAL|Sensor-controlled digital game|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid hospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal Hypertension health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
48001429|NCT01248299|DRUG|TPF|"every 21 days:~* Docetaxel \[30 mg/m2, day 1 and day 8\]~* CisPlatin \[60 mg/m2, day 1\]~* Fluoro-uracil \[200 mg/m2/day by continous infusion\]~Or every 21 days:~* Docetaxel \[50 mg/m2, day 1\]~* CisPlatine \[70 mg/m2, day 1\]~* Fluoro-uracile \[700 mg/m2 /day, day 1 to day 5\]"
48001430|NCT01248299|OTHER|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
48686499|NCT05671406|BEHAVIORAL|Sensor only|Real-time behaviors of physical activity will be tracked by an off-the-shelf sensor and app (Withings). This group will also be provided with standardized evidence-based Hypertension educational material. However, the data from the Withings sensor will not be routed to the SCDG.
48686500|NCT02808325|DRUG|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
48686501|NCT02808325|DRUG|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
48686502|NCT04512001|DRUG|MSB11456|Participants will receive MSB11456 subcutaneously, once a week.
48001431|NCT02701972|DEVICE|BACE Device|Implanted BACE device
48001432|NCT01901003|DRUG|Lorazepam|
48001433|NCT01901003|OTHER|no premedication|
48001434|NCT01901003|DRUG|Placebo (microcrystalline celluloses)|
48001435|NCT02444091|DRUG|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
48001436|NCT03293251|PROCEDURE|Trabeculectomy with MMC|glaucoma surgeries
48686503|NCT04512001|DRUG|EU-approved RoActemra|Participants will receive EU-approved RoActemra® subcutaneously, once a week.
48686504|NCT04177004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
48686505|NCT04177004|DRUG|Cyclophosphamide|Given IV
48686506|NCT04177004|DRUG|Etoposide|Given IV
48001437|NCT03179176|OTHER|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
48001438|NCT04116164|DRUG|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
48001439|NCT03247166|DEVICE|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
48158530|NCT04512560|BEHAVIORAL|Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training|General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .
48686507|NCT04177004|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
48001440|NCT00623064|DRUG|cisplatin|
48686508|NCT04177004|DRUG|Goat Milk|Given human lysozyme goat milk PO
48686509|NCT04177004|BIOLOGICAL|Palifermin|Given IV
48686510|NCT04177004|DRUG|Sirolimus|Given PO
48001441|NCT00623064|DRUG|gemcitabine hydrochloride|
48001442|NCT00623064|DRUG|lapatinib ditosylate|
48001443|NCT00623064|OTHER|pharmacological study|
48686511|NCT04177004|DRUG|Tacrolimus|Given IV and PO
48686512|NCT02805634|OTHER|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
48686513|NCT02805634|DEVICE|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
48686514|NCT05366127|OTHER|IGA score|IGA score will be assessed by 2 blinded investigators
48001444|NCT00454090|DRUG|AZD8330|oral tablet
48686515|NCT05366127|OTHER|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
48001445|NCT04445558|DIETARY_SUPPLEMENT|oral nutritional supplementation|Adjunction of oral nutritional supplementation
48001446|NCT04445558|DIETARY_SUPPLEMENT|intradialytic parenteral nutrition|Adjunction of intradialytic parenteral nutrition
48001447|NCT03663283|DRUG|Liposomal Bupivacaine|Interscalene Nerve Blocks
48001448|NCT03663283|DRUG|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
48001449|NCT04014257|DRUG|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
48001450|NCT00313612|DRUG|oxaliplatin|Given IV
48001451|NCT00313612|DRUG|topotecan|Given IV
48001452|NCT03601221|OTHER|Sample collection|Collection of one sampling pouch from each blood donor
48001453|NCT05159895|DRUG|[14C]-DZD9008|Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
48001454|NCT03801564|DEVICE|Platelet Rich Plasma Treatment Group (PRP)|EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
48158531|NCT04512560|BEHAVIORAL|Surgical Training using Conventional Training Program|General surgery residents (PGY 1-5) will continue their usual residency training.
48158532|NCT00349713|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
48158533|NCT00349713|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
48158534|NCT03239353|DRUG|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
48686516|NCT01942824|BEHAVIORAL|Text Messages|
48686517|NCT04777006|BEHAVIORAL|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
48001455|NCT03801564|DEVICE|Hyaluronic Acid Treatment Group (HA)|REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
48001456|NCT04992221|PROCEDURE|arterial line|arterial line inserted for invasice mointroing and sampling
48001457|NCT02386696|OTHER|Ultrasound|Lung ultrasound examination on healthy volunteers
48001458|NCT04308317|DRUG|Tetrandrine|Tetrandrine 60mg QD for 1week
48001459|NCT01453842|DIETARY_SUPPLEMENT|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
48366928|NCT06115343|BEHAVIORAL|Mindfulness|Conscious awareness practice was carried out in 6 sessions. Various inventories are used depending on the nature of the session. For example, in the leaf theme, participants are asked to close their eyes and put their thoughts from the past on a leaf and drop them into running water.
48366929|NCT00580827|DRUG|Placebo|Matched placebo.
48001460|NCT01453842|DIETARY_SUPPLEMENT|Olive oil|Carrot and olive oil and 1½ g of paracetamol
48366930|NCT00580827|DRUG|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
48366931|NCT00580827|DRUG|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
48366932|NCT00580827|DRUG|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
48513050|NCT02682927|DRUG|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
48513051|NCT01654016|DRUG|Detralex|Detralex 500 mg twice daily for three month prior to surgery
48001461|NCT01453842|DIETARY_SUPPLEMENT|Carrot|Carrot and 1½ g of paracetamol
48158535|NCT04832724|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
48158536|NCT02790047|DEVICE|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
48001462|NCT06014073|BIOLOGICAL|TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|"Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (1 × 10\^7 cells/kg); Phase 2 : dose of RP2D.~No more than 2 × 10\^5 per kilogram of allogenic residual CD3+T cells harbouring in grafts can only be released for recipient infusion."
48158537|NCT02790047|OTHER|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
48366933|NCT06050811|DIETARY_SUPPLEMENT|2'-Fucosyllactose|2'-Fucosyllactose given orally with water or food for four weeks, followed by a three week washout period.
48513052|NCT04236934|OTHER|Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis|Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
48001463|NCT06014073|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
48001464|NCT06014073|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
48001465|NCT03146234|GENETIC|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
48001466|NCT05160688|BEHAVIORAL|Contingency management|Participants will be paid to abstain from cannabis use.
48001467|NCT02182362|DRUG|BI 201335 NA|
48001468|NCT02182362|DRUG|Placebo|
48001469|NCT02394938|OTHER|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
48001470|NCT00366990|BEHAVIORAL|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics with a focus on lowering sodium intake.
48366934|NCT06050811|DIETARY_SUPPLEMENT|Placebo|Maltodextrin given orally with water or food for four weeks, followed by a three week washout period.
48366935|NCT06196372|OTHER|MenoMind intervention group|To implement the MenoMind program, the women in the initiative group were divided into groups of 4-5 according to their convenient days and hours, and it was done via the Zoom© program. MenoMind program was carried out via video on WhatsApp© program for women who could not or did not want to use the Zoom© program. The researcher provided support to the women for eight weeks, in different groups, 2-3 days a week and at different times, depending on their availability. Each session is approximately 50 minutes. lasted. In addition, make-up sessions were organized for women who could not attend the sessions for various reasons or had difficulty complying with the program (day/date).
48513053|NCT05366140|OTHER|Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM)|To assess the clinical outcomes of patients receiving standard of care Implanet Jazz System(TM) at the time of their instrumented lumbar arthrodesis.
48513054|NCT05326282|DIAGNOSTIC_TEST|Multi-parametric ultrasound|Diagnostic ultrasound parameters used to evaluate the prostate. Transrectal scans will be performed
48513055|NCT04272424|PROCEDURE|laparoscopic mesh fixation|laparoscopic mesh fixation by non fixation,tacker and histoacryl
48513056|NCT02597127|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
48001471|NCT00366990|BEHAVIORAL|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral \& weight loss topics.
48001472|NCT05369858|DRUG|[14C] SKLB1028|A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028
48001473|NCT04991961|DIAGNOSTIC_TEST|withdraw antihypertensive drugs|patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior
48001474|NCT03818516|OTHER|Oral Glucose Tolerance Test (OGTT)|Participants will undergo a fasting blood draw for inflammatory and metabolic markers before a 75gm oral glucose tolerance test (OGTT) and at 1, 2 and 3 hours post-OGTT. Behavioral assessments will also be administered pre- and post-OGTT administration.
48366936|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
48001475|NCT00189228|DRUG|Xolair|Patients are administered Xolair
48001476|NCT03532464|DRUG|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
48001477|NCT03532464|DRUG|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
48686518|NCT04777006|DRUG|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
48686519|NCT01802580|BEHAVIORAL|Internet Survey|
48686520|NCT01802580|DRUG|fluocinonide 0.05% ointment|
48686521|NCT05561816|DRUG|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
48001478|NCT06146036|BEHAVIORAL|HIIT snacks|Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax
48001479|NCT06146036|BEHAVIORAL|Sprint snacks|Cycling Exercise. 3 times per day one ''all out'' sprint
48366937|NCT05355454|DEVICE|STYLAGE® XXL|"Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.~Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek before study exit, on each side of the face."
48001480|NCT06146036|OTHER|Control|No exercise, sedentary.
48686522|NCT05561816|DRUG|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
48001481|NCT03367377|DRUG|LY3209590|Administered SC
48001482|NCT03367377|DRUG|Insulin Glargine|Administered SC
48366938|NCT03807258|OTHER|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
48366939|NCT04275024|DRUG|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
48366940|NCT04275024|DRUG|PSORI-CM01 Granule|PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
48513057|NCT02597127|DRUG|Normal Saline|Saline (sterile, normal, 0.9%) solution given as SC injections
48686523|NCT00048945|DRUG|PEGASYS|
48686524|NCT06044233|DRUG|STI-1558|STI-1558 test preparation and reference preparation
48001483|NCT06162754|OTHER|A questionnaire and TREALD scales were applied to parents.|The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.
48001484|NCT01904708|OTHER|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
48001485|NCT03581240|DRUG|eflornithine HCl|"In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID~Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS."
48001486|NCT05685290|OTHER|Pushing with saline technique|Peripheral venous catheter placement by pushing with saline technique
48001487|NCT05685290|OTHER|Traditional method|Peripheral venous catheter placement with the traditional method by nurses in the clinic routinely.
48158538|NCT02790047|OTHER|Health education|"Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD"
48158539|NCT02790047|OTHER|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing"
48366941|NCT04275024|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg
48513058|NCT06191588|PROCEDURE|INFANT CIMT/BIT|Constraint induced movement therapy (CIMT) and Bimanual Intensive therapy (BIT)
48686525|NCT03298698|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
48686526|NCT03298698|DRUG|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
48686527|NCT04248712|DRUG|Famotidine|40 mg tab twice daily by mouth for 12 week duration
48686528|NCT04248712|DRUG|Loratadine|10 mg tab once daily by mouth for 12 week duration
48686529|NCT04248712|DRUG|Placebo|Contains no active ingredient
48686530|NCT01234038|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
48686531|NCT01234038|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
48366942|NCT02490111|DRUG|DWJ1319|
48686532|NCT01234038|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
48686533|NCT01234038|DRUG|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
48001488|NCT01161329|OTHER|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
48001489|NCT04728269|OTHER|Lactibiane Topic AD|Application of Lactibiane topic AD twice a day (morning and evening) on one lesional area
48001490|NCT04728269|OTHER|Placebo|Application of placebo twice a day (morning and evening) on the symmetrical lesional area
48158540|NCT02790047|DRUG|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
48158541|NCT00441493|DRUG|fluvastatin|
48158542|NCT01388088|DRUG|Spironolactone|25 mg twice a day
48158543|NCT01388088|DRUG|Amiloride|5 mg twice a day
48158544|NCT01388088|DRUG|Placebo|twice a day
48686534|NCT01234038|DRUG|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
48686535|NCT04294940|OTHER|Wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients"
48686536|NCT04294940|OTHER|Use the mobile application CardiCare™ and wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients~* wear their smartphone everyday and use the mobile application CardiCare™"
48158545|NCT00587899|PROCEDURE|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
48158546|NCT05104957|OTHER|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
48158547|NCT05104957|OTHER|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
48366943|NCT02490111|DRUG|Placebo|
48366944|NCT00336960|DRUG|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
48366945|NCT00336960|DRUG|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
48366946|NCT00336960|PROCEDURE|conventional surgery|4-10 weeks after completion of chemoradiotherapy
48686537|NCT05401344|DIAGNOSTIC_TEST|test strips,sponges and cold dry air test|Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
48686538|NCT00565396|DRUG|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
48686539|NCT01841021|DRUG|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
48686540|NCT03388801|OTHER|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
48686541|NCT01288170|DRUG|Nebcinal Tobi|
48686542|NCT01288170|DRUG|Tobi Nebcinal|
48001491|NCT04055688|DEVICE|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
48158548|NCT01190449|BIOLOGICAL|ofatumumab|Given IV
48686543|NCT04244695|DRUG|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
48001492|NCT04055688|DRUG|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
48001493|NCT02063737|BEHAVIORAL|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
48001494|NCT02063737|BEHAVIORAL|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
48001495|NCT04079153|DEVICE|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
48001496|NCT00649675|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fed
48001497|NCT00649675|DRUG|Mobic® Tablets 15 mg|15mg, single dose fed
48001498|NCT04339400|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
48001499|NCT00243178|DRUG|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
48686544|NCT03730714|DRUG|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
48001500|NCT04296552|OTHER|Dietary lowFODMAP intervention|Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
48001501|NCT04813770|BEHAVIORAL|Theory-based messages|COVID-19 vaccination information structured to address vaccination necessity and concerns.
48001502|NCT04813770|BEHAVIORAL|General messages|General messages about the COVID-19 virus and the vaccination programme.
48001503|NCT00793338|DRUG|Sildenafil|Sildenafil 20mg three times a day for 3 months.
48158549|NCT06153836|PROCEDURE|Neurotization Procedure|Undergo placement of nerve graft
48158550|NCT06153836|OTHER|Questionnaire Administration|Ancillary studies
48158551|NCT06153836|PROCEDURE|Subcutaneous Mastectomy|Undergo standard of care NSM
48001504|NCT01889316|DEVICE|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
48001505|NCT01889316|DEVICE|AN24|
48001506|NCT01885091|OTHER|Kinerase|
48158552|NCT03606759|PROCEDURE|Weekly assessment|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)"
48158553|NCT03606759|PROCEDURE|Weekly assessment ajusted|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)"
48158554|NCT06074055|OTHER|FET Protocol|Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
48158555|NCT04150250|DRUG|iOWH032|Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.
48686545|NCT03730714|DRUG|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
48686546|NCT03730714|DRUG|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
48686547|NCT06472323|PROCEDURE|PRF+PRP, PRF|Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion of the patient. After puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times. After removing the RF electrode in the combined treatment group, 2ml of LP-PRP mixture was injected slowly into the Gasserian ganglion and mandibular nerve and PRF group only receive PRF treatment.
48158556|NCT04150250|DRUG|Placebo|Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
48158557|NCT04150250|OTHER|V. cholerae Challenge|Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
48001507|NCT03561857|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in 2 parts.~1. Ex vivo study~   * Prostate specimens will be stained using Fluorescein~  * Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~2. In vivo study~   * Intravenous injection of contrast agent~  * pCLE imaging every 5mm of the NVB dissection zone."
48686548|NCT04452747|PROCEDURE|Vaginal Dinoprostone system (Propess®)|Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
48686549|NCT04452747|PROCEDURE|Dilatation balloon|Labour will be induced using a cervix dilatation balloon as a first strategy
48686550|NCT03458325|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
48686551|NCT04496908|PROCEDURE|amniotomy|Artificially rupturing membranes
48686552|NCT04496908|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.
48001508|NCT00386867|DRUG|800 mcg misoprostol via oral or buccal administration|
48001509|NCT02241499|RADIATION|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
48001510|NCT02241499|DRUG|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
48001511|NCT05775978|BEHAVIORAL|Más Presente, the UGRComp program|Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life.
48001512|NCT05775978|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice. The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
48158558|NCT04150250|DRUG|Antibiotics|"Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)"
48158559|NCT03013725|OTHER|No intervention|No intervention
48158560|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery|The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
48158561|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following placenta delivery|Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
48158562|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post placenta delivery (within 15 seconds).
48158563|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
48158564|NCT00672100|DRUG|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
48158565|NCT00672100|DRUG|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
48158566|NCT00672100|DRUG|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
48158567|NCT01772381|DRUG|Dexamethasone|Long acting corticosteroid
48686553|NCT04496908|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
48686554|NCT04719481|DRUG|Pravastatin Sodium 80 MG|daily oral administration of 80mg
48686555|NCT04719481|DRUG|Placebo|daily oral administration
48686556|NCT04346186|DIAGNOSTIC_TEST|IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
48158568|NCT01636778|DRUG|SB-497115-GR|TPO receptor agonist to increase platelet count
48158569|NCT06646549|OTHER|No intervention|No intervention
48686557|NCT04346186|DIAGNOSTIC_TEST|Elisa-test for IgM and IgG to SARS-CoV-2|Elisa-test for IgM and IgG to SARS-CoV-2
48686558|NCT03367403|DRUG|Donanemab|Administered IV
48686559|NCT03367403|DRUG|Placebo|Administered IV
48686560|NCT03367403|DRUG|LY3202626|Administered orally
48686561|NCT02776605|DRUG|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
48686562|NCT02776605|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
48686563|NCT02776605|DRUG|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
48686564|NCT02776605|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
48158570|NCT00972686|DRUG|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
48158571|NCT00629161|DRUG|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
48158572|NCT00629161|DRUG|placebo|12 months period of placebo plus 1 month period without placebo
48686565|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
48686566|NCT02776605|DRUG|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
48686567|NCT02776605|DRUG|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
48686568|NCT02776605|DRUG|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
48686569|NCT02776605|DRUG|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
48686570|NCT02776605|DRUG|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
48686571|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
48686572|NCT02776605|PROCEDURE|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
48686573|NCT02776605|PROCEDURE|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
48686574|NCT01037335|DRUG|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
48686575|NCT03146663|DRUG|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
48686576|NCT03146663|DRUG|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
48686577|NCT05561101|OTHER|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
48686578|NCT01014767|DRUG|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
48686579|NCT01014767|DRUG|Cisplatin|Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
48686580|NCT01014767|DRUG|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3"
48686581|NCT01014767|DRUG|Dactinomycin|Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
48686582|NCT01014767|DRUG|Doxorubicin|Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
48686583|NCT01014767|DRUG|Etoposide|"Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
48686584|NCT01014767|DRUG|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
48158573|NCT04371471|DIAGNOSTIC_TEST|STC-19 score|Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
48686585|NCT01014767|DRUG|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
48686586|NCT01014767|DRUG|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
48686587|NCT01014767|DRUG|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
48686588|NCT01014767|DRUG|Vincristine|"Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
48686589|NCT02516397|DIETARY_SUPPLEMENT|Omnia|12weeks of treatment
48686590|NCT02516397|DIETARY_SUPPLEMENT|Placebo|12weeks of treatment
48686591|NCT02954887|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
48158574|NCT06585007|RADIATION|Radiotherapy|Progression-directed therapy (stereotactic body radiation therapy)
48158575|NCT06585007|PROCEDURE|metastasectomy|Progression-directed therapy (metastasectomy)
48158576|NCT00269126|DRUG|fluticasone propionate/salmeterol combination DISKUS|
48158577|NCT00269126|DRUG|salmeterol xinafoate|
48158578|NCT02884219|DRUG|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
48158579|NCT02884219|OTHER|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
48158580|NCT02884219|DRUG|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
48158581|NCT00850993|DRUG|Stannsoporfin|Stannsoporfin administered as a single IM injection
48158582|NCT00850993|OTHER|Placebo|Placebo (sterile saline solution) administered as a single IM injection
48158583|NCT00850993|OTHER|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
48158584|NCT01090232|OTHER|blood samples|
48158585|NCT01090232|OTHER|blood samples|
48158586|NCT03369314|DRUG|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
48158587|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
48366947|NCT00336960|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
48686592|NCT02053922|DRUG|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
48686593|NCT02053922|DRUG|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
48158588|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
48001513|NCT05775978|BEHAVIORAL|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
48158589|NCT02899676|OTHER|neuropsychological testing|
48158590|NCT02899676|OTHER|functional magnetic resonance imaging|
48158591|NCT02899676|OTHER|simple arithmetic operations|
48686594|NCT02053922|DRUG|Misoprostol|Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
48686595|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6
48158592|NCT04984980|DRUG|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
48686596|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6
48686597|NCT02243371|DRUG|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
48686598|NCT02243371|BIOLOGICAL|GVAX|5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
48686599|NCT02243371|DRUG|CY|200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
48686600|NCT02483429|DEVICE|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
48158593|NCT00316589|BIOLOGICAL|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
48158594|NCT06584864|DIAGNOSTIC_TEST|bedside ultrasound examination of the lumbar spinal canal|The ultrasound examination will be performed using a Lumify linear probe (frequency range 4-12 MHz). In the longitudinal projection, the doctor will assess the spinal cord endings by marking them with a sterile marker - a horizontal line on the patient's back. In the same projection, the doctor will designate a safe and optimal place (the greatest width of the dural sac) for performing a lumbar puncture by marking it with a sterile marker. Additionally, in the longitudinal projection, the researcher will measure the depth from the skin surface to the dura mater. Then, in the transverse projection, the doctor will confirm the absence of the spinal cord at the planned puncture site and the optimal amount of cerebrospinal fluid in the selected space. This information will be passed on to the operator, who will ultimately decide on the lumbar puncture site.
48158595|NCT03886688|DRUG|HEC53856|oral administration
48158596|NCT03886688|DRUG|placebo|oral administration
48158597|NCT02465775|DEVICE|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
48158598|NCT01412398|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
48158599|NCT05109117|DRUG|CAP Unscented|Sunscreen lip balm.
48686601|NCT06550206|BEHAVIORAL|Children's stranger wariness response to strangers|Children will see two strangers, one from a familiar racial background and one from an unfamiliar racial background. Familiar race stranger will be from the same racial background as the child's caregiver and unfamiliar race stranger will not.
48686602|NCT00479570|DRUG|PF-00446687|Single 200mg dose
48686603|NCT00479570|DRUG|Placebo|
48158600|NCT03854071|OTHER|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
48158601|NCT05095233|BEHAVIORAL|Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)|"YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior."
48158602|NCT05095233|DEVICE|Min Plan Tool|Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
48158603|NCT01088347|DRUG|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
48158604|NCT01088347|DRUG|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
48158605|NCT01088347|RADIATION|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
48158606|NCT00645320|DRUG|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
48366948|NCT00336960|PROCEDURE|tumor biopsy|at baseline and then at the time of surgical resection
48686604|NCT04265248|DEVICE|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
48686605|NCT04265248|BEHAVIORAL|Exercise|The subjects will perform evidence-based exercises for the neck.
48686606|NCT04797455|BEHAVIORAL|DBT-Based Parenting Intervention|The intervention will consist of 4 individual telehealth parent sessions, to be completed within one month after the teen discharges from the inpatient hospital or within one month of linkage to care whatever comes first . Sessions will be 60-90 minute in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 4.
48686607|NCT04797455|BEHAVIORAL|Treatment as usual|No parenting intervention provided beyond standard practices on the adolescent psychiatric inpatient unit.
48686608|NCT02318368|DRUG|Ficlatuzumab|
48686609|NCT02318368|DRUG|Erlotinib|
48158607|NCT03206489|DEVICE|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
48158608|NCT03206489|DEVICE|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
48158609|NCT05466968|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
48158610|NCT05466968|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
48158611|NCT01239056|PROCEDURE|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
48001514|NCT05276245|BEHAVIORAL|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
48158612|NCT00598156|DRUG|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
48158613|NCT00598156|DRUG|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
48158614|NCT02857309|DEVICE|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
48158615|NCT02857309|DRUG|Optimal medical therapy|OMT using standard heart failure (HF) drugs
48158616|NCT03158519|BEHAVIORAL|iMETX intervention|"Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained."
48686610|NCT02318368|DRUG|placebo|
48686611|NCT00349349|DRUG|ofatumumab|Intravenous infusion
48686612|NCT05842941|DRUG|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
48686613|NCT05842941|DRUG|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
48001515|NCT01627938|DRUG|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
48686614|NCT06254092|PROCEDURE|tourniquet binding of cervical|The procedure will be performed by surgeons with rich experience in clinical work
48158617|NCT05620888|BEHAVIORAL|Walk behavior change: Tailored messages (TM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood! The intervention is provided for 30 days."
48158618|NCT05620888|BEHAVIORAL|Walk behavior change: Non tailored messages (NTM)|"Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: walking regularly in the fresh air improves your mood. The intervention is provided for 30 days."
48686615|NCT00682929|DRUG|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
48686616|NCT00682929|DRUG|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
48686617|NCT00682929|DRUG|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
48686618|NCT00682929|DRUG|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
48686619|NCT01490216|DRUG|lisdexamfetamine|20mg q.d. to 70mg b.i.d
48001516|NCT01627938|DRUG|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
48686620|NCT02435459|PROCEDURE|No lining|No lining material placed under amalgam dental restorations
48686621|NCT02435459|PROCEDURE|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
48001517|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
48001518|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
48001519|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
48001520|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
48001521|NCT01520116|DRUG|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
48001522|NCT01520116|DRUG|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
48001523|NCT01520116|DRUG|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
48001524|NCT01520116|DRUG|Timoptic|0.5%
48001525|NCT01742793|DRUG|lenalidomide (Revlimid) and romidepsin (Istodax)|
48158619|NCT04260282|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab|PCR for viruses and bacteria in nasal swab
48158620|NCT04260282|DIAGNOSTIC_TEST|Induced sputum microbiome|Microbiome in induced sputum
48158621|NCT03532568|OTHER|skin biopsy|4mm punch skin biopsy
48158622|NCT03532568|RADIATION|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
48686622|NCT02435459|PROCEDURE|RMGI cement|placement of lining material under amalgam dental restorations
48686623|NCT02435459|PROCEDURE|Resin Bonding Agent|placement of lining material under amalgam dental restorations
48686624|NCT02082444|OTHER|Skipping lunch|
48686625|NCT05639309|DEVICE|near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)|regional oxygen saturation measurement
48686626|NCT03792555|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
48686627|NCT03792555|DRUG|Placebo|Placebo, capsules, once daily by mouth
48686628|NCT02786212|DRUG|Dexmedetomidine|
48686629|NCT02786212|DRUG|Normal Saline|
48686630|NCT03902015|DEVICE|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
48686631|NCT00418600|DRUG|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
48686632|NCT00418600|DRUG|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
48686633|NCT00418600|DRUG|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
48686634|NCT04656808|BEHAVIORAL|Guilt Focused Intervention|Psychotherapy, group intervention
48686635|NCT04656808|BEHAVIORAL|Cognitive behavioral therapy|Psychotherapy, group intervention
48686636|NCT02929199|OTHER|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
48001526|NCT04584710|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
48001527|NCT04584710|DRUG|Placebo|Oral matching placebo once daily for 2 weeks
48686637|NCT02929199|OTHER|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
48686638|NCT02740244|DEVICE|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
48686639|NCT02740244|DEVICE|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
48686640|NCT02569424|BEHAVIORAL|Patient's position|Supine or Trendelenburg strict -20°)
48686641|NCT05331053|DRUG|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
48686642|NCT03130907|DEVICE|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
48686643|NCT01440114|DRUG|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
48686644|NCT01440114|DRUG|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
48001528|NCT00889954|BIOLOGICAL|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
48001529|NCT00253383|OTHER|counseling intervention|
48001530|NCT00253383|OTHER|educational intervention|
48001531|NCT00253383|PROCEDURE|psychosocial assessment and care|
48001532|NCT00253383|PROCEDURE|quality-of-life assessment|
48001533|NCT01988116|DRUG|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
48001534|NCT01988116|DRUG|Placebo|
48686645|NCT04492748|COMBINATION_PRODUCT|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
48686646|NCT04492748|COMBINATION_PRODUCT|Collagen|Ultrasound guided injections
48686647|NCT04492748|COMBINATION_PRODUCT|Platelet rich plasma (PRP)|Ultrasound guided injections
48686648|NCT03147378|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
48001535|NCT03096665|DIAGNOSTIC_TEST|blood test|Point of care blood analysis obtained from skin puncture
48001536|NCT04869072|DRUG|Convalescent plasma|"Convalescent plasma will be delivered as FFP. Three units of 200ml CP/FFP harvested from one donor will be transfused to one recipient, i.e. there will be a match between donor and recipient and each recipient will receive CP/FFP only from one donor.~CP/FFP will be administered intravenously at the infusion rate of 100ml/hour, starting from day 0, with a new transfusion every 24 hours, for a total of 3 transfusions (see scheme)."
48001537|NCT02635464|BIOLOGICAL|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
48001538|NCT02635464|BIOLOGICAL|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10\^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
48001539|NCT02635464|PROCEDURE|CABG|Patients underwent CABG alone.
48001540|NCT05053529|OTHER|Mirror therapy|Session consist of total 1hour,20 min of passive mobilization, 30 minutes for Movement mirror therapy,10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
48001541|NCT05053529|OTHER|CIMT group|Session consist of total 1hour ,20 min of passive mobilization, 30 min session to CIMT and 10 minutes standard ADL activities 5 times a week and for consecutive 3 weeks in a month.
48001542|NCT01297907|OTHER|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
48686649|NCT03978611|DRUG|Relatlimab|Specified dose on specified days
48686650|NCT03978611|DRUG|Ipilimumab|Specified dose on specified days
48686651|NCT05729113|BEHAVIORAL|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
48686652|NCT03306472|DRUG|Megestrol Acetate 40 MG|Progesterone Agonist
48686653|NCT03306472|DRUG|Megestrol Acetate 160 MG|Progesterone Agonist
48686654|NCT03306472|DRUG|Letrozole|Aromatase Inhibitor
48686655|NCT06421714|DRUG|Venglustat|Pharmaceutical form:Capsule-Route of administration:Oral
48686656|NCT06421714|DRUG|Itraconazole|Pharmaceutical form:Capsule-Route of administration:Oral
48686657|NCT03481842|BIOLOGICAL|Linifanib|in a minimally sufficient therapeutic dose
48686658|NCT03481842|DRUG|BIBW2992|in a minimally sufficient therapeutic dose
48686659|NCT03481842|DRUG|Axitinib|in a minimally sufficient therapeutic dose
48686660|NCT00543270|DEVICE|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
48686661|NCT00543270|PROCEDURE|Open Surgery|Open surgical abdominal aortic aneurysm repair
48686662|NCT05349968|DRUG|Lipovirtide for injection|Multiple dosing of Lipovirtide
48686663|NCT03263988|DEVICE|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
48158623|NCT01899183|PROCEDURE|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
48686664|NCT05657899|PROCEDURE|Cerclage fixation|The intervention is by surgical open reduction and internal fixation of the fracture using two 1.0mm cerclage.
48001543|NCT01297907|OTHER|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
48158624|NCT00469352|DRUG|Ranibizumab|Ranibizumab as needed
48158625|NCT06244745|DRUG|Administration of letrozole|Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.
48158626|NCT05308199|OTHER|thoracic manipulation|thoracic manipulation for unlocking of facet joints
48158627|NCT05308199|OTHER|muscle enegy technique|to release muscle spasm of cervical musces
48158628|NCT02879448|DEVICE|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
48686665|NCT05657899|PROCEDURE|Tension band wiring|The intervention is by surgical open reduction and internal fixation of the fracture using a 1.0mm cerclage and two 1.6 mm k-wires as described in AO-guidelines.
48686666|NCT05802420|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
48686667|NCT04293276|DRUG|Pyrotinib|Pyrotinib Tablets
48686668|NCT04293276|DRUG|SHR6390|SHR6390 Tablets
48686669|NCT03818763|BIOLOGICAL|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
48686670|NCT02092636|OTHER|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
48686671|NCT02092636|OTHER|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
47914507|NCT04017845|PROCEDURE|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
48001544|NCT01297907|OTHER|Blood Test|Blood Tests (Eosinophil Count)
48001545|NCT01297907|OTHER|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
48001546|NCT00928928|PROCEDURE|Open colectomy|Open colectomy. Epidural anaesthesia used
48158629|NCT02879448|DEVICE|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
48158630|NCT03011671|DRUG|Acetazolamide|ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.
48158631|NCT03011671|DRUG|Temozolomide|For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
48686672|NCT02092636|OTHER|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
48158632|NCT01100372|DRUG|gemcitabine hydrochloride|
48158633|NCT01100372|DRUG|liposome-encapsulated doxorubicin citrate|
48158634|NCT01100372|PROCEDURE|quality-of-life assessment|
48158635|NCT05459688|DRUG|CIN-107|2 mg of CIN-107, once a day for 52 weeks
48158636|NCT06233045|DRUG|Dapagliflozin-Test product|Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
48158637|NCT06233045|DRUG|Dapagliflozin-Reference product|Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
48158638|NCT03149887|DRUG|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
48158639|NCT03149887|DRUG|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
48158640|NCT04226183|OTHER|pregnancy workout|"Procedure of pregnancy workout has been legalized by the Ministry of Health of Indonesia act 2014 No.97.~100 ml fresh guava juice without sugar"
48686673|NCT05521191|DRUG|RGLS8429|Solution for subcutaneous injection
48686674|NCT05521191|DRUG|Placebo|Solution for subcutaneous injection
48686675|NCT03694769|OTHER|Semi-structured interview|One-hour interview with researcher
48686676|NCT03694769|OTHER|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
48686677|NCT05790044|DRUG|Bupivacaine|intra-oral infra-orbital nerve block with bupivacaine alone
48158641|NCT03366233|OTHER|Mental fatigue|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
48158642|NCT03366233|OTHER|Control|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
48366949|NCT00336960|OTHER|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
48686678|NCT05790044|DRUG|Clonidine|intra-oral infra-orbital nerve block with bupivacaine and clonidine
48686679|NCT03870373|DEVICE|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
48686680|NCT05002985|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
48686681|NCT04359862|DRUG|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
48686682|NCT04359862|DRUG|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
48366950|NCT03804476|DRUG|AER-271|AER-271, the test article for this study.
48366951|NCT03804476|DRUG|Placebo|Placebo control for this study.
48366952|NCT04579458|PROCEDURE|Collection of tears and saliva.|Saliva and ocular tears will be collected.
48366953|NCT02883894|OTHER|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
48366954|NCT05863065|OTHER|Exposure to a Virtual Reality scenarios|Exposure to a personalized, relaxing Virtual Reality scenario deployed by a Head-mounted tool (Oculus Quest 2). The administration was deployed in one session.
48686683|NCT02533544|DRUG|tenofovir disoproxil fumarate|
48686684|NCT06374680|PROCEDURE|laminectomy at C3 level|laminectomy at C3 level
48686685|NCT03148275|OTHER|Questionnaire Administration|Ancillary studies
48686686|NCT03148275|DRUG|Trametinib|Given PO
48686687|NCT00817765|DRUG|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
48686688|NCT00817765|DRUG|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
48686689|NCT00817765|DRUG|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
48686690|NCT06417827|DIAGNOSTIC_TEST|SP patients-actors|SP Actors employed by MesserMSR, the Israeli Center for Medical Simulation, trained to simulate symptoms of psychiatric illnesses.
48686691|NCT06417827|DIAGNOSTIC_TEST|Patients|Patients (n=150) examined in the psychiatric division and emergency room (ER) of Sheba Medical center. Or people who applied following an advertisement on social networks.
48686692|NCT06417827|DIAGNOSTIC_TEST|Control group- patients|Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history.
48686693|NCT00161616|DRUG|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
48686694|NCT06291493|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingerstick blood draws.
48686695|NCT02412189|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
48686696|NCT02412189|DRUG|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
48158643|NCT05835037|DRUG|Zinc Gluconate 30 MG|Participants will take one tablet per day (30 mg Zinc gluconate) for 1 year
48158644|NCT05835037|DRUG|Placebo|Participants will take one placebo tablet per day for 1 year
48158645|NCT05008315|OTHER|Myofascial abdominal diaphragm release|Myofascial abdominal diaphragm release
48158646|NCT05008315|OTHER|Direct focused scar release technique|Direct focused scar release technique
48158647|NCT05008315|OTHER|Direct manipulations to visceral structures|Direct manipulations to visceral structures
48158648|NCT05008315|OTHER|pelvic anatomy education|pelvic anatomy education
48158649|NCT05008315|OTHER|sham|sham
48158650|NCT03786003|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
48158651|NCT03786003|PROCEDURE|Thoracotomy|Standard thoracotomy
48158652|NCT03147742|DRUG|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
48158653|NCT04723784|OTHER|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
48686697|NCT05844735|DRUG|SAR441566|Tablet
48686698|NCT05844735|DRUG|Placebo|Tablet
48686699|NCT05844735|DRUG|Ciprofloxacin|Tablet
48686700|NCT04830215|DRUG|Brexpiprazole|Oral brexpiprazole tablets as adjunctive therapy to ADT
48686701|NCT03376711|BEHAVIORAL|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
48001547|NCT00928928|PROCEDURE|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
48001548|NCT04257812|DRUG|Ceftolozane/tazobactam|"The dose will be 1g ceftolozane + 0,5 g tazobactam every 8 hours or 2 g ceftolozane + 1 g tazobactam, it´s recommended to use this last dose regimen in patients with pneumonia or septic shock of any focus.~The patients will be followed as it´s done habitually. There will be done infection focus cultures and others according to usual clinical practice. It´ll be determined the clinical response and mortality in the days 14 and 30 after the beginning of the medicine, respectively.~The Ceftolozane-Tazobactam levels determination will always be made in state of equilibrium (after the third dose). Four samples will be collected:~1. Just before the antibiotic infusion.~2. One hour after the antibiotic infusion.~3. Three hours after the antibiotic infusion.~4. Six hours after the antibiotic infusion."
48158654|NCT04723784|OTHER|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
48686702|NCT03313999|DEVICE|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
48686703|NCT06534047|DEVICE|Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member."
48686704|NCT06534047|DRUG|Nicotine replacement|"Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)"
48686705|NCT02705105|BIOLOGICAL|Mogamulizumab + Nivolumab|i.v. administration
48686706|NCT00637624|DRUG|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
48686707|NCT00637624|DRUG|Placebo|Placebo once every 3 weeks intravenous saline fluid
48686708|NCT02510469|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
48158655|NCT04723784|OTHER|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
48001549|NCT06481722|OTHER|cerebral palsy|no intervention
48001550|NCT01894269|DRUG|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
48001551|NCT01723163|BEHAVIORAL|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
48158656|NCT00734851|DRUG|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
48686709|NCT03249324|BEHAVIORAL|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
48686710|NCT03249324|OTHER|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
48686711|NCT02831127|OTHER|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
48686712|NCT02831127|OTHER|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
48686713|NCT03731104|DEVICE|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=\[SpO2-rScO2\]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
48686714|NCT03731104|DEVICE|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
48686715|NCT03731104|DEVICE|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = \[π x d2 x VTI x HR\] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
48686716|NCT00282087|DRUG|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
48686717|NCT01628523|OTHER|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
48686718|NCT01738815|DRUG|Valproic Acid|500 mg orally, once daily for up to 30 days
48686719|NCT01888783|OTHER|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
48686720|NCT00740454|OTHER|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
48686721|NCT04600726|OTHER|no intervention|no interventioni
48686722|NCT03885154|DRUG|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
48001552|NCT01723163|BEHAVIORAL|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
48158657|NCT00734851|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
48513059|NCT02254434|DRUG|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
48686723|NCT03885154|DRUG|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
48686724|NCT03618771|DEVICE|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
48686725|NCT04898348|DRUG|KBL697|3 capsules twice a day dosing of KBL697
48686726|NCT04898348|DRUG|Placebo|3 capsules twice a day dosing of Placebo
48158658|NCT00734851|RADIATION|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
48686727|NCT02597452|DEVICE|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
48686728|NCT04497363|DEVICE|Brainsonix Pulsar 1002|Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
48686729|NCT02518165|DIETARY_SUPPLEMENT|Proprietary spearmint extract|Water extracted spearmint extract
48686730|NCT02518165|OTHER|Placebo|Microcrystalline Cellulose
48686731|NCT04616313|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
48686732|NCT04616313|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
48686733|NCT04616313|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
48686734|NCT04616313|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
48158659|NCT03747159|DRUG|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
48366955|NCT03236701|OTHER|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
48366956|NCT00026819|DRUG|Rofecoxib|
48366957|NCT02493712|DRUG|High dose|6 capsules of IBD98-M, twice a day
48366958|NCT02493712|DRUG|Low dose|4 capsules of IBD98-M
48366959|NCT02493712|DRUG|Placebo|Placebo
48366960|NCT03000920|OTHER|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
48686735|NCT04616313|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
48686736|NCT04616313|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
48686737|NCT04616313|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
48686738|NCT01607762|DRUG|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
48686739|NCT01607762|DRUG|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
48686740|NCT01607762|DRUG|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
48686741|NCT01607762|DRUG|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
48686742|NCT01607762|DRUG|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
48686743|NCT05829005|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
48686744|NCT03702062|DIAGNOSTIC_TEST|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
48686745|NCT04359524|DIETARY_SUPPLEMENT|Vitamin D3 (1200 IU/30µg)|
48686746|NCT04359524|DIETARY_SUPPLEMENT|Placebo|Placebo oil capsule
48366961|NCT03000920|OTHER|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
48686747|NCT05714514|DRUG|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
48158660|NCT00688051|OTHER|My Life with CF game|Play the game My Life with CF
48158661|NCT00645099|DRUG|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
48366962|NCT01066546|DRUG|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
48686748|NCT05714514|OTHER|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
48686749|NCT03528876|DRUG|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
48686750|NCT05178836|DRUG|F520+F007|"Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)."
48686751|NCT03612128|OTHER|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
48686752|NCT03612128|OTHER|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
48686753|NCT00001901|DRUG|Etanercept|
48686754|NCT01947283|BEHAVIORAL|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
48686755|NCT01947283|BEHAVIORAL|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
48686756|NCT05937256|PROCEDURE|Quadratus lumborum block type III|Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.
48686757|NCT05937256|PROCEDURE|Erector spinae plane block|Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
48686758|NCT00331656|DEVICE|Non-invasive positive pressure mask ventilators|
48686759|NCT00331656|DEVICE|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
48686760|NCT02544035|OTHER|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
48686761|NCT02544035|OTHER|Play Partner|Each child will first play alone then play with parent.
48686762|NCT00996879|DRUG|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
48686763|NCT00996879|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
48686764|NCT04789473|GENETIC|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
48001553|NCT05124665|BEHAVIORAL|Social Support|"The intervention to be evaluated in this study is a multidimensional, socio-behavioral Norming intervention. The various components of this intervention are designed to harness household dynamics and prosocial inclinations to encourage individuals to accept the HIV testing invitation. Each component is briefly described in the arm description."
48158662|NCT00645099|DRUG|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
48158663|NCT02623686|OTHER|Aroma Therapy Massage and Inhalation Patch|
48686765|NCT06502639|OTHER|theraplay program|"A play therapy method called thermaplay aids in children's development of stronger bonds and relationships with others. It emphasizes the parts of communication that are nonverbal. When it comes to giving cerebral palsy children with hand therapy that is both effective and motivating, fun approaches have been shown to be both successful and appealing."
48001554|NCT00005669|DRUG|Metformin HCL|Medication studied for ability to alter body weight and body composition.
48158664|NCT04369547|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
48158665|NCT04369547|DRUG|Roflumilast|Roflumilast 250mcg
48158666|NCT04369547|DRUG|Placebo oral tablet|Placebo capsule matched to roflumilast capsule
48158667|NCT00001079|DRUG|Testosterone enanthate|
48158668|NCT00001079|DRUG|Megestrol acetate|
48158669|NCT05112172|OTHER|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
48158670|NCT00003755|DRUG|MKC-1|
48158671|NCT02792296|OTHER|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
48686766|NCT06502639|OTHER|conventional physical therapy|conventional physical therapy program for like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises
48686767|NCT01413243|DRUG|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
48686768|NCT03213132|BEHAVIORAL|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
48686769|NCT03213132|BEHAVIORAL|Patient Education|Educational website containing information on insomnia
48686770|NCT00786968|DRUG|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
48001555|NCT00005669|DRUG|Placebo|Control capsules for metformin
48001556|NCT02656641|BEHAVIORAL|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
48001557|NCT02656641|BEHAVIORAL|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
48001558|NCT05423067|PROCEDURE|bilateral permanent occlusion of uterine arteries|bilateral permanent Occlusion of uterine arteries through abdominal route
48158672|NCT00214162|BEHAVIORAL|Comprehensive Health Enhancement Support System|Full CHESS
48158673|NCT00214162|BEHAVIORAL|computer with internet|computer with internet use x 1 year
48158674|NCT04958629|OTHER|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
48366963|NCT04589221|BEHAVIORAL|Ad libitum energy intake|Investigate ad libitum energy intake according to degree of food processing and eating behaviour
48001559|NCT01275066|DRUG|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
48001560|NCT01275066|DRUG|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
48001561|NCT01275066|DRUG|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
48158675|NCT02637947|DEVICE|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
48158676|NCT02637947|DEVICE|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
48158677|NCT00789399|DRUG|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
48158678|NCT00789399|OTHER|Placebo|subcutaneous equivolume isotonic saline
48158679|NCT03341312|BIOLOGICAL|LY900014|Administered SC
48158680|NCT03341312|BIOLOGICAL|Insulin Lispro|Administered SC
48158681|NCT00847847|PROCEDURE|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
48158682|NCT05417971|OTHER|Fludarabine|Reduced-intensity fludarabine with intermediate-dose TBI
48158683|NCT05494099|PROCEDURE|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
48158684|NCT05494099|PROCEDURE|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
48158685|NCT05494099|PROCEDURE|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
48158686|NCT06057870|OTHER|Application on Apple watch|To determine the feasibility and engagement with remote management of acutely decompensated cirrhosis patients using CirrhoCare® App, CyberLiver ART App, and remote monitors by assessing patient adherence to the monitoring device and the Apps over a 3-month period.
48158687|NCT00558220|PROCEDURE|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
48158688|NCT00558220|PROCEDURE|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
48158689|NCT00558220|PROCEDURE|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are \>20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
48158690|NCT00558220|PROCEDURE|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
48158691|NCT00558220|PROCEDURE|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
48158692|NCT00558220|RADIATION|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (\>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
48686771|NCT02272036|PROCEDURE|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
48686772|NCT02272036|DEVICE|mobile phone|SMS received by mobile phone
48686773|NCT03358355|DRUG|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
48686774|NCT06554054|DRUG|GZR18|Oral administered the GZR18 tablet
48001562|NCT02978742|BEHAVIORAL|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
48686775|NCT01118403|DRUG|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
48686776|NCT04191304|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
48686777|NCT04191304|BIOLOGICAL|Placebo|Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
48686778|NCT06287242|OTHER|spinal manipulation|High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
48686779|NCT05738798|DIETARY_SUPPLEMENT|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
48001563|NCT02978742|BEHAVIORAL|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
48001564|NCT03792672|DRUG|TAK-653|TAK-653 tablets.
48001565|NCT03792672|DRUG|Placebo|TAK-653 placebo-matching tablets.
48001566|NCT03792672|DRUG|Ketamine|Ketamine intravenous infusion.
48001567|NCT02844296|BEHAVIORAL|Video about exercise|Video about short-bout exercise will be played for the participants.
48001568|NCT02844296|BEHAVIORAL|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
48001569|NCT02844296|BEHAVIORAL|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
48001570|NCT02844296|BEHAVIORAL|Video about diet|Video about healthy diet will be played for the participants.
48001571|NCT02844296|BEHAVIORAL|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
48001572|NCT02844296|BEHAVIORAL|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
48001573|NCT01784783|BEHAVIORAL|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
48001574|NCT01784783|BEHAVIORAL|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
48001575|NCT06330922|OTHER|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be performed two times a week for one hour in small groups (4-5 people). The training will be conducted outdoors at track and field facilities with at least two coaches.
48001576|NCT05369351|DRUG|Standard treatment+mirabegron|In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
48001577|NCT05369351|OTHER|Standard treatment|Standard treatment
48001578|NCT00692770|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
48001579|NCT00692770|DRUG|Placebo|Placebo 2 tablets twice daily (BID)
48686780|NCT00256464|BEHAVIORAL|Multi-component Yoga Intervention|
48686781|NCT01415297|DRUG|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
48686782|NCT02880228|DRUG|Dexamethasone|Given PO
48686783|NCT02880228|OTHER|Laboratory Biomarker Analysis|Correlative studies
48686784|NCT02880228|DRUG|Lenalidomide|Given PO
48686785|NCT02880228|BIOLOGICAL|Pembrolizumab|Given IV
48686786|NCT04317443|PROCEDURE|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
48686787|NCT04317443|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
48686788|NCT03873727|BIOLOGICAL|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
48686789|NCT03873727|BIOLOGICAL|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
48686790|NCT03873727|BIOLOGICAL|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
48686791|NCT06164964|DIAGNOSTIC_TEST|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
48686792|NCT06422221|DRUG|Clindamycin|Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
48686793|NCT06422221|DRUG|Doxycycline|Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
48001580|NCT05404061|OTHER|Gut hormones|"Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~1. 0.9% saline,~2. GLP-1"
48001581|NCT04692961|DEVICE|Elastography|Use elastography to evaluate the stiffness of lower leg muscle after peroneal artery-based free flap harvested
48001582|NCT01581632|DEVICE|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
48158693|NCT03999697|DRUG|Autologous chimeric antigen receptor T cell transfusing agent targeting CD22|The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
48158694|NCT05599230|DRUG|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
48158695|NCT00303017|DIETARY_SUPPLEMENT|flavocoxid|flavonoid mixture
48158696|NCT00303017|DRUG|Naproxen|non-steroidal anti-inflammatory drug
48158697|NCT02942628|OTHER|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
48686794|NCT00306839|PROCEDURE|standardized Lichtenstein technique|
48686795|NCT05130385|DEVICE|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
48686796|NCT05130385|DEVICE|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
48001583|NCT05588102|DRUG|Selective Serotonin Reuptake Inhibitor（SSRIs，Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram）|Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)
48158698|NCT00347802|DRUG|Bimatoprost 0.03%, Travoprost 0.004%|
48158699|NCT02553616|BEHAVIORAL|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
48686797|NCT03066960|PROCEDURE|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
48686798|NCT03066960|PROCEDURE|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
48686799|NCT01812213|DRUG|[18F]NAV4694|
48686800|NCT04528550|BIOLOGICAL|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
48686801|NCT04528550|DRUG|Placebo|Included patients will receive the same amount of saline through lumbar injection.
48686802|NCT01803880|DEVICE|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
48686803|NCT01803880|DEVICE|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
48686804|NCT06300749|OTHER|Chiropractic Cervical Manipulation|"In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae."
48686805|NCT06300749|OTHER|Sham Technique Practice|The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
48686806|NCT02691910|DRUG|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
48686807|NCT02691910|DRUG|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
48686808|NCT00899821|BIOLOGICAL|aldesleukin|
48686809|NCT00899821|BIOLOGICAL|recombinant interleukin-12|
48686810|NCT00899821|BIOLOGICAL|sargramostim|
48686811|NCT00899821|OTHER|immunologic technique|
48686812|NCT00899821|PROCEDURE|biopsy|
48686813|NCT03957668|DRUG|PEG 3350|PEG 3350 17 g once daily for 14 days
48158700|NCT04293055|BEHAVIORAL|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
48686814|NCT03957668|DRUG|Lactulose|Lactulose 10 g once daily for 14 days
48686815|NCT03587428|DRUG|Zinc-A toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
48686816|NCT03587428|DRUG|Zinc-B toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
48686817|NCT03587428|OTHER|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
48686818|NCT03352232|COMBINATION_PRODUCT|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
48686819|NCT03506412|DRUG|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
48686820|NCT03987711|DRUG|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
48686821|NCT03987711|DRUG|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
48686822|NCT03987711|OTHER|No oral anticoagulation|No oral anticoagulation
48686823|NCT03376139|DRUG|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
48686824|NCT03376139|DRUG|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
48001584|NCT02998801|OTHER|IPAD|Patients undergoing surgery will watch the video using an PAD
48001585|NCT02998801|OTHER|VR Goggles|Patients undergoing surgery will watch the video using goggles
48001586|NCT01874496|DIETARY_SUPPLEMENT|GDS, no meal|GDS, no meal
48001587|NCT01874496|DIETARY_SUPPLEMENT|GDS, meal|GDS, meal
48001588|NCT01874496|DIETARY_SUPPLEMENT|control, no meal|control, no meal
48686825|NCT01865318|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin)
48001589|NCT01874496|DIETARY_SUPPLEMENT|control, meal|control, meal
48001590|NCT00850395|DRUG|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
48001591|NCT03961100|DRUG|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
48001592|NCT03961100|DRUG|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
48001593|NCT03961100|DRUG|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
48686826|NCT03144336|BEHAVIORAL|Information provision|All study participants will receive weekly messages with HIV prevention information.
48686827|NCT03144336|BEHAVIORAL|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
48686828|NCT03144336|BEHAVIORAL|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
48001594|NCT03961100|DRUG|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
48001595|NCT05092893|OTHER|Online parental questionnaires|"The SRS-2 is a parental 65-item questionnaire to detect difficulties in social responsiveness in children with autism spectrum disorder. Four different forms are available: preschoolers (2.5-4.5 years), school-aged children (4-18 years), adults (≥ 19 years) and adults self-report. In this study, only the form for school-aged children will be used.~The DCDQ'07 is a parental 15-item questionnaire to detect the risk of DCD in children between 5 and 15 years of age. Parents are asked to compare their child's motor performance to his/her peers using a 5-point Likert scale. The total sum score is compared to age-specific cut-off scores to determine the risk of DCD. Belgian norms are available since 2007."
48001596|NCT03829046|DRUG|Placebo|12 weeks of treatment
48001597|NCT03829046|DRUG|Evolocumab|12 weeks of treatment
48001598|NCT04328974|PROCEDURE|lumbar CSF drainage|We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
48001599|NCT01363596|OTHER|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
48001600|NCT04033159|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
48001601|NCT01727141|DRUG|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
48001602|NCT01727141|DRUG|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
48158701|NCT04293055|BEHAVIORAL|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
48001603|NCT01727141|DRUG|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
48001604|NCT01727141|DRUG|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
48001605|NCT03101904|DIETARY_SUPPLEMENT|Beetroot Juice|
48001606|NCT03101904|DIETARY_SUPPLEMENT|Placebo|
48686829|NCT06158464|OTHER|Functional Capacity Evaluation|In a FCE, an occupational therapist will evaluate a patient's ability to perform work-related tasks, using a battery of tests. Depending on the circumstances, he/she will for instance test fatigue, ask the patient to kneel, lift objects, or assess concentration. This assessment lasts ± 4 hours and includes physical tests and tests related to the (previous or reference) profession of the client. This means that an explicit match is made between the functional capacities of the patient (what is he/she capable of) and the demands of a certain job (what is he/she expected to do). Following this assessment, the occupational therapist will explain the results of this assessment to the patient. The evaluation will therefore take place during one or two visits.
48686830|NCT06314854|OTHER|Running water sound|Running water sound for experimental group Standard care for control group
48686831|NCT06282445|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
48001607|NCT06298175|BEHAVIORAL|Self management training|The self-management training programme for the study group consisted of eight sessions. Each session lasted between 40 and 50 minutes and followed a structured format: a 5-minute introduction, a 5-minute summary of the previous session, and a 30-40 minute presentation on the session's topic. Training plan on cognition, emotion regulation and self-management was implemented
48001608|NCT00009919|DRUG|semaxanib|Given IV
48001609|NCT01106456|BEHAVIORAL|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
48158702|NCT02035488|DRUG|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
48158703|NCT01142154|DRUG|Prodarsan|Prodarsan TID, oral solution, 6-8 days
48686832|NCT06282445|DRUG|Oxaliplatin|130 mg/m2, ivgtt, d1, Q3W
48001610|NCT01106456|BEHAVIORAL|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
48001611|NCT01106456|DRUG|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
48158704|NCT01854372|DRUG|R-HCVAD and R-MC|
48686833|NCT06282445|DRUG|Capecitabine|1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
48001612|NCT03507556|PROCEDURE|Triple paste and induced bleeding|
48001613|NCT03507556|DRUG|Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol|triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
48001614|NCT05478070|DEVICE|Dexcom G6|Continuous glucose monitor
48686834|NCT06282445|DRUG|Bevacizumab|7.5mg/kg，ivgtt, d1, Q3W
48686835|NCT03272386|OTHER|Observational study|Completing a questionnaire
48686836|NCT04389710|DRUG|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
48686837|NCT00955643|OTHER|oxygen|
48686838|NCT00955643|OTHER|other|
48686839|NCT01260688|DRUG|cediranib maleate|Given orally
48686840|NCT01260688|DRUG|dasatinib|Given orally
48686841|NCT03169868|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
48001615|NCT03250546|PROCEDURE|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
48001616|NCT03250546|PROCEDURE|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
48001617|NCT04537858|DEVICE|Virtual reality therapy first|First day of the protocol with Virtual Reality intervention in the morning and conventional intervention in the afternoon
48001618|NCT04537858|DEVICE|Conventional therapy first|First day of the protocol with conventional intervention in the morning and Virtual Reality intervention in the afternoon
48001619|NCT03227887|OTHER|Two samples of saliva|"1. Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~2. With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
48001620|NCT03227887|OTHER|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
48001621|NCT03227887|OTHER|Study of the food bolus|"2 tests:~1. Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~2. The bolus will be analysed visually"
48001622|NCT03227887|OTHER|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
48001623|NCT05771259|OTHER|Assessment of knowledge and behaviour|Assessment of knowledge and behaviour
48158705|NCT01388621|DRUG|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
48158706|NCT01388621|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
47914508|NCT04017845|PROCEDURE|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions \<25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
48001624|NCT02149342|DRUG|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
48001625|NCT02149342|DRUG|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
48158707|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
48158708|NCT01388621|DRUG|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
48158709|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
48158710|NCT01388621|DRUG|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
48001626|NCT01011517|DIETARY_SUPPLEMENT|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
48001627|NCT05188859|DRUG|Sintilimab+Anlotinib+Pemetrexed+Cisplatin|Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
48001628|NCT04406064|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.
48001629|NCT05873465|DRUG|Sedation with Midazolam, Fentanyl, and Propofol|Patients will have teeth extracted under sedation with Midazolam, Fentanyl, and Propofol
48001630|NCT05873465|PROCEDURE|Extraction of teeth|The necessary teeth will be extracted
48001631|NCT04654533|OTHER|COSC|"COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, \& Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study."
48366964|NCT01474993|DRUG|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing \~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to \~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~1. Subjects with body weight less than 101 lbs will receive \~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~2. Subjects with body weight 101 lbs to 199 lbs will receive \~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~3. Subjects with bidy weight \> 199 lbs will receive \~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
48366965|NCT01474993|DRUG|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
48366966|NCT03464929|DEVICE|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
48366967|NCT03464929|DEVICE|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
48366968|NCT03578341|BIOLOGICAL|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
48001632|NCT04446065|DRUG|Previfenon®|Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.
48001633|NCT04446065|DRUG|Placebo|Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.
48001634|NCT04454372|OTHER|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
48001635|NCT04332289|OTHER|Heavy water experiment|3 times daily heavy water (deuterated-water) and mixed meal administration for one week
48366969|NCT04274972|DIAGNOSTIC_TEST|Microbiome evaluation|The oral and rectal microbiome samples will be collected preoperatively. The PDAC tissue from the surgical specimen, the intestinal mucosal tissue from the enteric side of the pancreatic anastomosis, and the bile sample will be collected intraoperatively. On the 30th postoperative day, the oral and rectal samples will be repeated
48366970|NCT02784665|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
48001636|NCT02518477|OTHER|exercise|progressive resistance training
48366971|NCT02784665|DEVICE|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power"
48366972|NCT05299112|DIETARY_SUPPLEMENT|Arginine|The intervention parenteral nutrition contains additional arginine (18% arginine content) as compared to standard parenteral nutrition (6.3% arginine content).
48001637|NCT02972216|DRUG|Nolbaxol|
48001638|NCT02972216|DRUG|Taxotere|
48001639|NCT02972216|DRUG|cisplatin|
48001640|NCT04022135|DIETARY_SUPPLEMENT|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
48001641|NCT04022135|DIETARY_SUPPLEMENT|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
48001642|NCT00294164|DRUG|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
48001643|NCT00294164|DRUG|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
48158711|NCT04627259|OTHER|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
48158712|NCT01538901|OTHER|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
48366973|NCT03366649|PROCEDURE|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
48158713|NCT01538901|DRUG|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
48158714|NCT05544539|DRUG|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
48686842|NCT01628484|OTHER|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
48001644|NCT04237428|BIOLOGICAL|CD19 CAR-T cells infusion|"Biological: CD19 CAR-T cells infusion Biological: CD19 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD19 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD19 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD19 CAR-T cells are infused into patients for one time, the number of infused CD19 CAR-T cells are 0.5-4×10\^6/kg."
48001645|NCT05798572|DRUG|Sildosin group|Patients in this group had flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.
48001646|NCT05798572|PROCEDURE|Placebo/control group|included 70 patients for whom flexible ureteroscopy (F-URS) was done with daily preoperative intake of placebo tablets.
48001647|NCT02347566|BEHAVIORAL|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
48001648|NCT02347566|OTHER|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
48001649|NCT02871128|DIETARY_SUPPLEMENT|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
48001650|NCT02871128|DIETARY_SUPPLEMENT|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
48001651|NCT02871128|DRUG|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
48001652|NCT02861950|DRUG|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
48001653|NCT02861950|DRUG|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
48001654|NCT02327923|DRUG|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
48001655|NCT02327923|DRUG|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
48001656|NCT02327923|DRUG|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
48001657|NCT02327923|DRUG|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
48001658|NCT02327923|DRUG|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
48001659|NCT02327923|DRUG|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
48001660|NCT02327923|DRUG|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
48686843|NCT01628484|OTHER|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
48001661|NCT02327923|DRUG|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR \< 50/min)
48001662|NCT02327923|DRUG|Ephedrine|
48001663|NCT02327923|DRUG|Morphine|
48001664|NCT02327923|DRUG|Ketorolac|
48001665|NCT02327923|DRUG|Ondansetron|
48001666|NCT02327923|DRUG|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
48001667|NCT02327923|DRUG|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
48001668|NCT02327923|DRUG|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
48001669|NCT02327923|DRUG|Glycopyrrolate|10 mcg/kg with neostigmine
48001670|NCT00016952|DRUG|fluorouracil|
48001671|NCT00016952|DRUG|irinotecan hydrochloride|
48001672|NCT00016952|DRUG|leucovorin calcium|
48001673|NCT03523546|OTHER|Cancer Episode Payment Model (CEM)|Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
48001674|NCT05411822|DEVICE|Lighting Intervention Blue light|Custom made lighting fixture that will deliver the blue lighting intervention
48001675|NCT05411822|DEVICE|Lighting Intervention Green light|Custom made lighting fixture that will deliver the green lighting intervention
48001676|NCT00287664|DRUG|terlipressin|
48001677|NCT03729336|DEVICE|Midstream urine collection device|Non-invasive midstream urine collection device
48001678|NCT03729336|DEVICE|Catheter for urine collection|In-and-out catheter obtains urine through the urethra.
48686844|NCT01628484|OTHER|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
48686845|NCT01360424|DRUG|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
48686846|NCT01111383|DRUG|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
48686847|NCT04850924|OTHER|evaluation psychological trauma|9 classes of symptoms to be evaluated
48686848|NCT02968446|DIETARY_SUPPLEMENT|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
48686849|NCT02968446|DIETARY_SUPPLEMENT|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
48686850|NCT02968446|DRUG|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
48686851|NCT06202352|BEHAVIORAL|Meditation and Yoga|The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
48686852|NCT04267887|DRUG|Abiraterone Acetate|Given PO
48686853|NCT04267887|DRUG|Antiandrogen Therapy|Given ADT per standard of care
48686854|NCT04267887|DRUG|Apalutamide|Given PO
48686855|NCT04267887|DRUG|Prednisone|Given PO
48686856|NCT04267887|PROCEDURE|Computed Tomography|Undergo CT scan
48686857|NCT04267887|PROCEDURE|Bone Scan|Undergo bone scan
48686858|NCT04267887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48686859|NCT04267887|OTHER|Questionnaire Administration|Ancillary studies
48686860|NCT01643408|DRUG|asparaginase Erwinia chrysanthemi|
48686861|NCT03520686|DRUG|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~* Pembrolizumab (200 mg intravenous infusion \[IV\])~* N-803 (15 μg/kg subcutaneously \[SC\])"
48686862|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab|"The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV)~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)~Day 8:~* Nab-paclitaxel (100mg/m² IV)~Day 15:~* Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
48001679|NCT00963573|DRUG|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
48001680|NCT00963573|DRUG|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
48158715|NCT05544539|DRUG|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
48158716|NCT06645522|DRUG|Edaravone dexborneol|Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
48158717|NCT06645522|DRUG|Placebo|Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
48158718|NCT04475016|DRUG|Albumin-Bound Paclitaxel|260 mg/m² IV over 30 minutes on Day 1
48158719|NCT04475016|DRUG|Ifosfamide|1200 mg/m² IV over 2 hours on Days 1-3
48686863|NCT03520686|DRUG|N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~* N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)"
48686864|NCT03520686|DRUG|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
48686865|NCT03520686|DRUG|Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab|"The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~* Pembrolizumab (200mg IV)~Day 8:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
48686866|NCT03520686|DRUG|Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed|"The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)"
48686867|NCT03520686|DRUG|N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab|The treatment plan for the experimental arm of Cohort D will consist of repeated 6-week cycles for a maximum of 18 cycles (approximately 2 years). Nab-paclitaxel and Carboplatin will only be administered in cycle 1.
48686868|NCT04445207|BIOLOGICAL|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
48686869|NCT05710796|BEHAVIORAL|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
48686870|NCT01388179|DEVICE|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
48686871|NCT00237666|DRUG|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
48158720|NCT04475016|DRUG|Cisplatin|25 mg/m² IV over 2 hours on Days 1-3
48158721|NCT04475016|DRUG|Nimotuzumab|400 mg IV on Day 1
48158722|NCT04475016|DRUG|Triprilimab|240 mg IV on Day 1
48686872|NCT01169701|DRUG|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
48686873|NCT01169701|DRUG|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
48686874|NCT01169701|DRUG|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
48686875|NCT06179810|OTHER|Baduanjin exercise|Baduanjin exercise
48158723|NCT03115879|OTHER|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
48158724|NCT03115879|OTHER|Hip manipulation simulation|Hip manipulation simulation
48158725|NCT06440980|DRUG|Orforglipron|Administered orally
48686876|NCT01032070|DRUG|erlotinib|oral
48686877|NCT01032070|DRUG|etoposide|oral
48686878|NCT02998684|DEVICE|Active Transcranial Direct Current Stimulation|
48686879|NCT02998684|DEVICE|Sham Transcranial Direct Current Stimulation|
48686880|NCT02998684|BEHAVIORAL|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
48686881|NCT03544905|DRUG|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
48686882|NCT04311970|DEVICE|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
48686883|NCT01976546|DEVICE|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
48686884|NCT04879108|OTHER|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
48158726|NCT01745380|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
48158727|NCT01745380|DRUG|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
48158728|NCT03600090|BIOLOGICAL|EOC202|EOC202 will be SC injection.
48158729|NCT03600090|DRUG|Paclitaxel|Paclitaxol will be IV injection
48158730|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums with Fluoride|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.
48158731|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums Fluoride-Free|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
48158732|NCT04675086|DRUG|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
48158733|NCT04675086|DRUG|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
48158734|NCT00788632|BEHAVIORAL|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
48158735|NCT00788632|BEHAVIORAL|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
48158736|NCT00788632|BEHAVIORAL|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
48158737|NCT01846988|DEVICE|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
48158738|NCT00101062|DRUG|celecoxib|
48158739|NCT00101062|DRUG|letrozole|
48158740|NCT06416189|DEVICE|Fixed appliances|MBT Brackets 0.022 inch
48158741|NCT03856814|DEVICE|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
48001681|NCT02049242|PROCEDURE|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
48158742|NCT05202327|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
48158743|NCT05202327|DRUG|Placebo|The placebo contained corn starch.
48158744|NCT04074304|OTHER|I-HoME|A multi-component technology-based care intervention.
48158745|NCT04593641|BIOLOGICAL|CT-P59|administered
48158746|NCT05400525|DIETARY_SUPPLEMENT|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
48686885|NCT04879108|OTHER|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
48001682|NCT02049242|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
48001683|NCT01955057|BEHAVIORAL|Research interviews|
48001684|NCT01955057|BEHAVIORAL|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
48158747|NCT05400525|OTHER|Placebo control|3g Maltodextrin (i.e. DE 10) daily
48158748|NCT02543697|RADIATION|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
48158749|NCT01725087|DRUG|Matching Placebo|
48158750|NCT01725087|DRUG|Low Dose GRT6005|
48158751|NCT01725087|DRUG|Medium Dose GRT6005|
48158752|NCT01725087|DRUG|High Dose GRT6005|
48158753|NCT01725087|DRUG|Tapentadol|
48158754|NCT06422559|DEVICE|Transmagnetic stimulation|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
48158755|NCT06422559|DEVICE|TMS|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
48158756|NCT02095938|DRUG|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
48158757|NCT01446042|DRUG|Testosterone|Intranasal testosterone
48366974|NCT03366649|PROCEDURE|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
48366975|NCT02984631|PROCEDURE|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
48001685|NCT01955057|BEHAVIORAL|Projective methods (Thematic apperception Test, Rorschach)|
48001686|NCT01955057|BEHAVIORAL|Carbon monoxide test|
48001687|NCT03734471|DEVICE|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
48001688|NCT03734471|PROCEDURE|Tube thoracostomy|Traditional chest tube placement
48001689|NCT01358318|OTHER|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
48001690|NCT03751215|PROCEDURE|Cataract surgery|During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
48001691|NCT01139528|PROCEDURE|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
48158758|NCT01446042|DRUG|Testosterone|Intranasal testosterone
48158759|NCT02735278|OTHER|different test paradigms|
48158760|NCT03916159|PROCEDURE|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta \~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
48158761|NCT03916159|PROCEDURE|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
48158762|NCT03341858|OTHER|no intervention-strictly observational|
48158763|NCT03110432|DRUG|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
48158764|NCT03110432|DRUG|Standard lipid lowering therapy|drug use according to the respective product labelling
48158765|NCT04148716|PROCEDURE|additional biopsies|additional biopsies during a fibroscopy planned in the care
48158766|NCT04554316|DEVICE|Steri-strip|Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
48158767|NCT06266065|DEVICE|Coronary Sinus Reducer|Implantation of Coronary Sinus Reducer
48366976|NCT04656262|DRUG|Cyclophosphamide|Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
48366977|NCT04656262|DRUG|Doxorubicin|Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)
48686886|NCT03628105|BEHAVIORAL|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
48001692|NCT00363454|DRUG|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
48366978|NCT03852901|DRUG|empagliflozin (Jardiance) 25 mg|Oral empagliflozin 25 mg/day x 14 days
48686887|NCT03628105|BEHAVIORAL|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
48686888|NCT04608292|DIAGNOSTIC_TEST|Single-voxel MRS|Diagnostic test is a single voxel MRS scan
48686889|NCT04608292|DIAGNOSTIC_TEST|Multi-voxel MRSI|Diagnostic test is a multi-voxel MRS imaging scan
48686890|NCT04608292|DIAGNOSTIC_TEST|Magnetization Transfer Imaging|Diagnostic test is a set of magnetic transfer weighted images
48686891|NCT04608292|OTHER|Alcohol ingestion|Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
48686892|NCT04608292|DEVICE|ClearMate|Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
48686893|NCT04608292|DIAGNOSTIC_TEST|Blood sampling|Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
48686894|NCT04555863|DEVICE|haMSter smartphone app|the app tracks patient reported outcomes
48686895|NCT05073484|DRUG|BAT6021|Ⅳ infusions
48686896|NCT05073484|DRUG|BAT1308|Ⅳ infusions
48686897|NCT05062694|OTHER|Survey|It will be created a questionnaire to investigate, among Italian physiotherapists, their clinical approach to the patient with Central Sensitisation
48686898|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
48686899|NCT01059864|DRUG|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
48686900|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
48686901|NCT01059864|DRUG|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
48686902|NCT00632775|DRUG|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
48686903|NCT00632775|DRUG|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
48001693|NCT01782651|DRUG|Lapatinib plus capecitabine|Lapatinib plus capecitabine
48001694|NCT02218333|DIETARY_SUPPLEMENT|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
48001695|NCT02218333|DIETARY_SUPPLEMENT|Placebo|
48001696|NCT04657133|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
48366979|NCT01853319|DRUG|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
48686904|NCT03941964|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
48158768|NCT03959930|DEVICE|Transdermal Fluid Removal|"The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment."
48158769|NCT03825614|BEHAVIORAL|training|plates and therapeutic exercises applied on young adults
48686905|NCT03941964|DRUG|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
48686906|NCT03941964|DRUG|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
48686907|NCT05088330|DRUG|Daratumumab|treatment with D-VRD in NDMM
48686908|NCT00182078|DRUG|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
48686909|NCT00182078|DRUG|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
48686910|NCT01109615|DRUG|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
48686911|NCT01109615|DRUG|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
48686912|NCT01732510|DRUG|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
48686913|NCT01732510|DRUG|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
48686914|NCT05788666|PROCEDURE|GeriKit Mobile Application|Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
48686915|NCT01204905|DRUG|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart"
48686916|NCT06245005|DEVICE|Brain exercise gameplay on a portable electronic device|Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
48686917|NCT04725045|DEVICE|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
48158770|NCT05770193|OTHER|Pursed lip breathing|The position for every patient will be long sitting, and then he will be instructed to breathe in through the nose for 2 seconds. Purse the lips as if about to blow out the candles on a cake. Breathe out very slowly through pursed lips for 4 to 6 seconds, and then repeat for 5 to 10 minutes. The intervention will be done two days a week, through six weeks for all participants by a physiotherapist.
48001697|NCT04657133|DEVICE|Sham remote ischemic conditioning|Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.
48001698|NCT04657133|DRUG|Standard medication therapy|Standard medication therapy will be performed according to the national and international guidelines.
48686918|NCT02561481|DRUG|Sulforaphane|See under active arm description
48158771|NCT05770193|OTHER|Cognitive Behavior Therapy|A structured, 6-session psycho-therapeutic intervention, occurring once weekly, will be performed According to the CBT session structure provided by Cully and Teten, with some modifications, Each session will be approximately 1 hour.
48513060|NCT06501716|PROCEDURE|Indocyanine Green|"Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG."
48001699|NCT02746562|PROCEDURE|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
48001700|NCT03303833|OTHER|No intervention, observational study.|
48001701|NCT05206474|DEVICE|IRADYN|"One course of IRADYN® at baseline, consisting of a mono-dose intra-articular administration (2 ml).~From week 1 to week 6, injection will be performed, if necessary, during the visit, following the dosage reported in the instruction for use / summary of product characteristic."
48686919|NCT02561481|DRUG|Placebo|See under placebo arm description
48686920|NCT03992716|DRUG|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
48686921|NCT03992716|DRUG|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
48686922|NCT05171374|DRUG|Dabrafenib|Observational stusy. No intervention is planned
48001703|NCT01851720|DRUG|Low dose fentanyl PCA|
48001704|NCT01851720|DRUG|Standard IV fentanyl bolus|
48001705|NCT00424151|DRUG|Rituximab|
48001706|NCT06436846|OTHER|Biospecimen sample collection during standard-of-care surgery|Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
48686923|NCT05171374|DRUG|Trametinib|Observational stusy. No intervention is planned
48686924|NCT00192920|BEHAVIORAL|Transfusion practice|
48001707|NCT03942978|OTHER|Longitudinal Equity Action Plan|Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
48001708|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: control|The control/ sham comparator arm of the Mental Health Toolkit for Veterans (MeT4VeT) smart phone app contains only signposting information around support services available to military veterans
48001709|NCT05993676|BEHAVIORAL|MeT4VeT mobile phone app: intervention|"The Mental Health Toolkit for Veterans (MeT4VeT) smart phone app has been developed through careful and close collaboration with military veterans and key providers of veterans' mental healthcare services. The aim of this app is to provide both a degree of education to support military veterans' understanding of mental health and foster self-recognition and management of mental health symptoms whilst also encouraging those who need it to seek more formal support.~The elements of the app have been chosen for inclusion as they represent the intersection between:~1. Core components of cognitive behavioural therapy, the theoretical framework underwriting the app~2. Behaviour change constructs"
48001710|NCT04431791|DRUG|Regorafenib|oral regorafenib
48001711|NCT04431791|DRUG|Fruquintinib|oral fruquintinib
48001712|NCT01203592|DRUG|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
48001713|NCT01770288|OTHER|Anaerobic wingate test|
48001714|NCT05667922|DRUG|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
48158772|NCT05770193|OTHER|Diaphragmatic breathing exercise|"The patient will lie in supine position, and then he will be asked to rest for 5 min and lay on their back on a flat surface with pillows under their head and knees for support. One hand will be placed on the abdomen and the other on the upper part of the chest wall. When inhaling, the hand on the abdomen will move upward, while the other hand will remain as still as possible. When exhaling, the hand on the abdomen will move downwards, while the other hand will remain as still as possible again. Breathing will be performed quickly, deeply and without causing tiredness. The breaths should be inhaled through the nose and exhaled through the mouth.~The diaphragmatic breathing exercise will consist of three sets of 10 repetitions, with 30 seconds of rest between each set"
48158773|NCT05770193|OTHER|Kinesio tape|"The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 _75% tension and the tails will be applied toward the ribs."
48158774|NCT02852486|DRUG|Pioglitazone 30 Mg Oral Tablet|30 mg/day, orally, for 3 months, before imatinib discontinuation
48158775|NCT02852486|OTHER|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
48158776|NCT04783597|DIAGNOSTIC_TEST|Arterial Stiffness and Wave Reflection|Arterial stiffness and wave refection, a non-invasive test, will be collected and combined with standard clinical markers (blood biomarkers, ultrasound imaging) as well as medical and psychosocial questionnaires in order to test a comprehensive, multi-marker approach for pre-eclampsia prediction in high risk pregnant women.
48158777|NCT06326281|PROCEDURE|unilateral external oblique intercostal plane block group|USG guided external oblique intercostal plane block will perform unilateral with Bupivacaine 25 patient included and patients were observed for pain for 24 hours
48158778|NCT06326281|PROCEDURE|unilateral oblique subcostal transversus abdomınıs plane block group|USG guided oblique subcostal transversus abdomınıs plane block block will perform unilateral with Bupivacaine. 25 patient included and patients were observed for pain for 24 hours
48158779|NCT06326281|PROCEDURE|Local anesthetic infiltration group|Bupivacaine infiltration will be performed to trocar insertion sites. 25 patient included and patients were observed for pain for 24 hours
48513061|NCT03624920|DRUG|THN102 Dosage A|THN102 Dosages A: placebo
48513062|NCT03624920|DRUG|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
48001715|NCT05269693|OTHER|Brief Hope Intervention|The BHI consisted of 4 one-on-one sessions: 2 (1 hr) face- to-face sessions, and 2 (30 min) telephone follow-up sessions
48001716|NCT00706641|DRUG|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
48001717|NCT00706641|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
48001718|NCT00805935|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
48001719|NCT00805935|DRUG|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
48001720|NCT00805935|DRUG|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
48513063|NCT03624920|DRUG|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
48001721|NCT00805935|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
48158780|NCT06326281|DRUG|Control group|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) patient controlled analgesias were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
48158781|NCT03512288|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
48001722|NCT00805935|DRUG|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
48001723|NCT04977258|OTHER|Treadmill aerobic exercise without water intake|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
48001724|NCT04977258|OTHER|Treadmill aerobic exercise with water intake of a predetermined amount.|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
48158782|NCT03512288|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
48158783|NCT05610254|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
48158784|NCT02467049|DEVICE|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
48001725|NCT04977258|OTHER|Treadmill aerobic exercise with water intake according to the desire to drink|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
48366980|NCT06343259|PROCEDURE|General Anesthesia|After preoxygenation, intravenous fentanyl (1 μg/kg), propofol (2 mg/kg), and rocuronium (0.6 mg/kg) will be used for anesthesia induction. Intubation will be performed with a 7.0-8.0 sized tube, followed by the initiation of mechanical ventilation (tidal volume: 6-8 ml/kg, respiratory rate: 12 breaths/min). Sevoflurane will be used to maintain anesthesia (0.7-1 MAC), and remifentanil infusion will be administered for analgesia. Postoperatively, tramadol (1 mg/kg) and paracetamol (10 mg/kg) will be administered intravenously. Neuromuscular blockade will be reversed using sugammadex. Patients with an Aldrete Recovery Score ≥9 will be transferred to the post-anesthesia care unit after extubation.
48686925|NCT02988947|OTHER|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
48001726|NCT01892930|RADIATION|stereotactic body radiation therapy|Undergo SBRT
48686926|NCT04224831|COMBINATION_PRODUCT|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
48001727|NCT01892930|PROCEDURE|therapeutic conventional surgery|Undergo partial or radical nephrectomy
48001728|NCT01892930|OTHER|laboratory biomarker analysis|Correlative studies
48001729|NCT02265055|PROCEDURE|transfer early cleavage embryos|transfer early cleavage embryos
48001730|NCT02265055|PROCEDURE|transfer non early cleavage embryo|
48001731|NCT05087654|OTHER|Combination of 3D VR and Hands-on Horticultural Activities|The intervention program consisted of 8 two-hour sessions that were conducted once a week for 8 consecutive weeks.
48001732|NCT02427321|DEVICE|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
48158785|NCT02467049|DEVICE|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
48158786|NCT00527371|DEVICE|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
48158787|NCT00527371|PROCEDURE|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
48001733|NCT02086110|DIETARY_SUPPLEMENT|Synbiotic|
48513064|NCT03278626|DRUG|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
48513065|NCT04351555|DRUG|Osimertinib|Oral
48686927|NCT04808726|BEHAVIORAL|Teach Back Method|Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
48686928|NCT01266252|DRUG|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
48686929|NCT00867958|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
48686930|NCT05301621|OTHER|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
48686931|NCT03107052|DRUG|Fremanezumab|Fremanezumab
48686932|NCT02277691|DRUG|TAK-536TCH tablet|TAK-536TCH tablets
48686933|NCT02277691|DRUG|TAK-536CCB tablet|TAK-536CCB tablets
48686934|NCT02277691|DRUG|HCTZ 12.5 mg tablet|HCTZ tablets
48686935|NCT00606411|DRUG|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
48686936|NCT03653234|DEVICE|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
48686937|NCT02064049|DRUG|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
48513066|NCT04351555|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
48513067|NCT04351555|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
48513068|NCT04351555|DRUG|Placebo|Oral
48513069|NCT04351555|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles
48513070|NCT03008317|DEVICE|PEEK|a metallic denture base
48513071|NCT05676814|DRUG|Pecto-intercostal Fascial Block (PIFB)|PIFB done with bupivacaine and epinephrine
48686938|NCT05538377|OTHER|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
48001734|NCT02086110|DIETARY_SUPPLEMENT|Prebiotic|
48158788|NCT01038206|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
48158789|NCT00556296|DRUG|NRP104|NRP104 30mg capsule once daily in a.m.
48686939|NCT05538377|OTHER|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
48686940|NCT00531440|DRUG|Everolimus (RAD001)|
48686941|NCT01095991|DRUG|AZD1656|Oral tablet bd,
48686942|NCT01095991|DRUG|Sitagliptin|Oral tablet od
48686943|NCT06379503|OTHER|HEART YOGA|Heart yoga; It includes regular, balanced, safe light physical exercises, breathing exercises that provide breathing control, and meditation practices that include relaxation techniques.
48686944|NCT06379503|OTHER|routine nursing care|Basic nursing care after heart surgery
48686945|NCT06370624|DIAGNOSTIC_TEST|MRI-scan|IRM-scan at rest under neonatologist monitoring.
48686946|NCT03954886|DEVICE|Plus powered optical lens|A plus powered optical lens will be placed in front of one eye.
48686947|NCT01304615|BEHAVIORAL|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
48686948|NCT01304615|BEHAVIORAL|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
48686949|NCT01304615|BEHAVIORAL|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
48001735|NCT01845792|DRUG|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
48001736|NCT01845792|DRUG|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
48001737|NCT05943912|OTHER|Single Vision Spectacle Lens|36 months of therapy
48513072|NCT05676814|DRUG|PIFB with adjuvants|PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone
48001738|NCT05943912|OTHER|Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens|36 months of therapy
48001739|NCT01422499|DRUG|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
48513073|NCT03394157|OTHER|metabolic surgery|operation to cure type2 diabetes
48513074|NCT04987476|BIOLOGICAL|analyzes in singles cells|genome expression analyzes in single cells
48001740|NCT02978287|DRUG|BAVU Solution|Tissue preservation solution for transplantation
48001741|NCT00813358|DEVICE|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
48001742|NCT04366622|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
48158790|NCT00556296|DRUG|NRP104|NRP104 50mg capsule once daily in a.m.
48686950|NCT06549504|DRUG|AG2202T|AG2202T Single-dose
48686951|NCT06549504|DRUG|AG2202R|AG2202R Single-dose
48686952|NCT06180499|DRUG|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
48001743|NCT04036942|PROCEDURE|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
48158791|NCT00556296|DRUG|NRp104|NRP104 70mg capsule once daily in a.m.
48158792|NCT00556296|DRUG|Placebo|Placebo
48158793|NCT03600922|PROCEDURE|the patella was resurfaced.|Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
48686953|NCT06389344|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
48686954|NCT06389344|DRUG|normal saline|Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
48686955|NCT02334020|OTHER|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
48686956|NCT01715688|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
48686957|NCT01715688|DRUG|Saline|Administration of saline in the endotracheal tube cuff
48686958|NCT06200168|DEVICE|Electroacupuncture|"The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz."
48686959|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
48158794|NCT01580462|OTHER|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
48158795|NCT00346242|DRUG|Zoledronic Acid|
48158796|NCT02842125|DRUG|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
48158797|NCT02842125|DRUG|Xeloda|Oral metronomic chemotherapeutic agent
48686960|NCT06200168|DEVICE|Sham electroacupuncture|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation."
48686961|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
48686962|NCT02591537|DEVICE|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
48001744|NCT04036942|PROCEDURE|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
48001745|NCT02319538|PROCEDURE|Total thyroidectomy performed|Surgery combined with standard thyroxine treatment
48001746|NCT00978328|DRUG|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
48001747|NCT04564612|DRUG|BIIB091|Administered as specified in the treatment arm
48001748|NCT04564612|DRUG|Rabeprazole|Administered as specified in the treatment arm
48001749|NCT04564612|DRUG|Itraconazole|Administered as specified in the treatment arm
48001750|NCT06333327|DEVICE|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter|Pulmonary vein isolation with the multielectrode radiofrequency balloon catheter
48001751|NCT01542216|BEHAVIORAL|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
48001752|NCT01542216|BEHAVIORAL|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
48001753|NCT03510156|BEHAVIORAL|Behavior analytic treatment|Function-based treatment
48001754|NCT00886210|PROCEDURE|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
48158798|NCT02842125|DRUG|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
48158799|NCT02842125|DRUG|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
48158800|NCT06585319|DRUG|Collagen-polyvinylpyrrolidone|2 ml intramuscular q24 h
48158801|NCT06585319|DRUG|Pirfenidone 1200 mg|1,200 mg of oral q12 h
48158802|NCT01370161|PROCEDURE|TIPS treatment|"1. A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~2. Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~3. After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
48158803|NCT01370161|DRUG|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
48686963|NCT02859285|OTHER|Placebo vulvar cream|
48686964|NCT02859285|OTHER|Estradiol vulvar cream|
48686965|NCT01258556|DIETARY_SUPPLEMENT|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.
48686966|NCT01258556|DIETARY_SUPPLEMENT|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
48158804|NCT02085408|DRUG|Daunorubicin|Given IV
48686967|NCT04222894|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
48158805|NCT02085408|DRUG|Cytarabine|Given IV
48158806|NCT02085408|DRUG|Clofarabine|Given IV
48158807|NCT02085408|DRUG|Decitabine|Given IV
48158808|NCT02085408|OTHER|Observation|Undergo clinical observation
48158809|NCT02085408|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.
48686968|NCT04222894|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
48686969|NCT00565162|DRUG|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
48686970|NCT05263180|BIOLOGICAL|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
48686971|NCT03863561|BEHAVIORAL|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
48686972|NCT06117033|OTHER|video assisted mobilization training|Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
48686973|NCT02443337|DRUG|LY3023414|Administered orally
48686974|NCT02443337|DRUG|Necitumumab|Administered IV
48686975|NCT05679661|DIETARY_SUPPLEMENT|immunonutrition|Patients in the intervention group will receive additional immunonutrition supplementation, which is oral intake of ORAL IMPACT™ 2 servings per day from the day of allocation at the preoperative anesthesia clinic until the day before surgery.
48001755|NCT00886210|PROCEDURE|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
48158810|NCT02093078|BEHAVIORAL|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
48158811|NCT05834647|DRUG|Prilocaine 2%|50 mg prilocaine 2% (2.5 mL volume) before undergoing cystoscopy procedure
48158812|NCT05834647|DRUG|Hyperbaric Lidocaine 5%|50 mg Hyperbaric Lidocaine 5% (1.0 mL volume) before undergoing cystoscopy procedure
48686976|NCT05679661|BEHAVIORAL|oral chlorhexidine decontamination|Patients in the intervention group will receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
48686977|NCT00330980|DRUG|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
48686978|NCT00330980|DRUG|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
48686979|NCT00330980|DRUG|Placebo|Participants will receive placebo for 6 months.
48001756|NCT04483024|DIETARY_SUPPLEMENT|Collagen hydrolysate and chicken extract|One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
48158813|NCT04816539|DEVICE|TetraGraph|Use of two monitoring devices of neuromuscular function during surgery
48686980|NCT06216041|DRUG|IMM-H014|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
48158814|NCT00082784|DRUG|Bortezomib|Given IV
48158815|NCT00082784|DRUG|Alvocidib Hydrochloride|Given IV
48158816|NCT00082784|OTHER|Pharmacological Study|Correlative studies
48686981|NCT06216041|DRUG|Placebo|"SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort)."
48686982|NCT06216041|DRUG|IMM-H014 ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
48001757|NCT02188576|DRUG|high dose TXA|
48001758|NCT02188576|DRUG|Low dose TXA|
48001759|NCT01619033|DRUG|BF2.649|single dose 20 mg
48001760|NCT02809430|DEVICE|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
48001761|NCT03690388|DRUG|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
48158817|NCT04107688|OTHER|Control|Subjects will use plain water as an oral rinse twice a day for 3 days.
48158818|NCT04107688|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
48158819|NCT01001637|DIETARY_SUPPLEMENT|Curcumin Formulation|2000mg or 3000mg daily BID
48158820|NCT01001637|DIETARY_SUPPLEMENT|Placebo|Placebo
48158821|NCT00308009|PROCEDURE|Vaginal Repair for prolapse, TVT procedure|"1. TVT at the time of Vaginal Repair~2. TVT 3 months after Vaginal Repair"
48158822|NCT00308009|PROCEDURE|TVT and Prolapse surgery|"1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery"
48158823|NCT00485914|BEHAVIORAL|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
48158824|NCT00485914|BEHAVIORAL|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
48158825|NCT02023099|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
48158826|NCT02023099|DRUG|Placebo|Tablet
48158827|NCT02841176|OTHER|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
48158828|NCT02841176|BIOLOGICAL|Golimumab|Participants will start monthly Golimumab after their baseline visit
48513075|NCT05517083|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
48001762|NCT03690388|DRUG|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
48158829|NCT01751451|DRUG|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
48158830|NCT01751451|DRUG|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
48158831|NCT01751451|DRUG|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
48158832|NCT00291863|DRUG|Simvastatin|
48158833|NCT04312971|DRUG|Placebo|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
48158834|NCT04312971|DRUG|Norepinephrine|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
48158835|NCT04312971|OTHER|Increase infusion rate|Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
48158836|NCT04312971|OTHER|Decrease infusion rate|Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
48158837|NCT02797795|DRUG|NEV801|Dose Escalation
48513076|NCT05548387|DRUG|HCP2202|Take it once per period.
48513077|NCT05548387|DRUG|RLD2202|Take it once per period.
48158838|NCT05680298|DRUG|Dupilumab|solution for injection, Subcutaneous injection
48158839|NCT00059735|DRUG|E7070|
48158840|NCT00847223|DRUG|ZARNESTRA (Tipifarnib)|
48158841|NCT01827176|OTHER|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
48158842|NCT03806283|PROCEDURE|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
48513078|NCT05548387|DRUG|RLD2203|Take it once per period.
48513079|NCT00655343|DRUG|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
48158843|NCT03972137|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
48158844|NCT03972137|BEHAVIORAL|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
48513080|NCT01043887|DRUG|ridaforolimus|single oral dose administration 10 mg ridaforolimus
48686983|NCT06216041|DRUG|Placebo ( FE)|"FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts sentinel method .The treatment in food effect consists of 2 periods."
48158845|NCT03972137|DRUG|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
48158846|NCT02490059|OTHER|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
48686984|NCT05441423|RADIATION|CBCT|CBCT Scans. conventional \& ultra low dose
48686985|NCT01557101|PROCEDURE|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
48686986|NCT01557101|PROCEDURE|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
48158847|NCT04288778|DRUG|Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
48366981|NCT06343259|PROCEDURE|Spinal Anesthesia|Patients will be positioned laterally with the hip to be operated on the lower side, and skin asepsis will be ensured, followed by sterile draping. A dural puncture will be performed at the L3-4 spinal level using a 22-25 gauge Quincke-tip spinal needle. After the detection of cerebrospinal fluid, 7.5 mg of 0.5% hyperbaric bupivacaine will be slowly injected. Following a 10-minute interval, the sensory block level will be assessed using the pinprick test and modified Bromage scale, aiming for a T10 sensory block. Surgery will commence upon achieving adequate sensory block. Postoperatively, patients will be transferred to the recovery room. Patients failing to attain sufficient sensory block and experiencing pain will undergo transition to general anesthesia, terminating their cases.
48366982|NCT00148980|DEVICE|DBM for creation of bone marrow microenvironment|
48686987|NCT02782351|BIOLOGICAL|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
48686988|NCT00001335|DRUG|ADR-529|
48686989|NCT00001335|DRUG|Topotecan|
48686990|NCT00001335|DRUG|G-CSF|
48686991|NCT01720004|OTHER|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
48686992|NCT04345900|DRUG|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
48686993|NCT04345900|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
48686994|NCT01229007|BIOLOGICAL|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
48686995|NCT00428935|BIOLOGICAL|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
48686996|NCT00824252|BEHAVIORAL|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
48686997|NCT03687294|DEVICE|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
48158848|NCT03137654|OTHER|Affective Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
48158849|NCT03137654|OTHER|Neutral Training|Intervention includes up to 12 training sessions (\~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
48158850|NCT04006652|DRUG|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
48158851|NCT05912543|PROCEDURE|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
48686998|NCT06070389|DEVICE|Sansa device|The Sansa device will be used during a single overnight polysomnography study.
48686999|NCT01239277|OTHER|protein|20g protein
48687000|NCT01239277|OTHER|protein and carbohydrate|20g protein and 20g carbohydrate
48687001|NCT01239277|OTHER|protein and leucine|20g protein, 2.5g leucine
48687002|NCT00175916|DRUG|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
48687003|NCT04314700|DEVICE|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
48687004|NCT00000673|DRUG|Ganciclovir|
48687005|NCT04177589|OTHER|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
48158852|NCT02949622|BEHAVIORAL|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
48687006|NCT01788397|BEHAVIORAL|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
48687007|NCT05580263|BEHAVIORAL|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
48158853|NCT02949622|OTHER|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
48687008|NCT05580263|BEHAVIORAL|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
48687009|NCT05650463|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
48687010|NCT05382884|OTHER|Postpartumcare.ca (Web-Enabled Intervention)|Postpartumcare.ca is a web-enabled intervention accessible via computer, tablet or smartphone devices. The content and design of postpartumcare.ca were created based on the needs, opinions, and desires of birthing parents in British Columbia affected by postpartum depression and/or anxiety, which were solicited previously in phases 1 \& 2 of the SUPPORT study.
48158854|NCT03472859|DEVICE|PHOTOLASE|This is the investigational yellow laser (PHOTOLASE)
48158855|NCT03472859|DEVICE|KTP|This is the traditional green laser (KTP)
48158856|NCT04564027|DRUG|Ceralasertib|Tablets will be administered orally
48158857|NCT02316821|DRUG|RTA 402|
48687011|NCT04504539|BIOLOGICAL|mOPV|mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
48158858|NCT02316821|DRUG|Placebo|
48366983|NCT05505487|OTHER|integrated care model|The interventions in this study were to implement basic patient care only and did not involve any invasive procedures. On the basis of routine nursing, the content of nursing intervention was integrated, and a standardized nursing model was formed for clinical application to control the severity of pulmonary infection in patients with simple tracheotomy in the non-acute phase of stroke.
48687012|NCT04504539|BIOLOGICAL|bOPV|bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
48687013|NCT04504539|BIOLOGICAL|Full dose IPV|FIPV (full dose injectable polio vaccine)
48158859|NCT01608958|DRUG|Oxytocin|10 IU oxytocin in 500 ml infusion
48158860|NCT01608958|DRUG|Oxytocin|10 IU oxytocin IM injection
48687014|NCT04504539|BIOLOGICAL|fractional IPV|fIPV (fractional dose injectable polio vaccine)
48687015|NCT04351607|DIETARY_SUPPLEMENT|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
48687016|NCT01113177|DEVICE|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
48687017|NCT04021485|OTHER|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire"
48687018|NCT05206214|PROCEDURE|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
48687019|NCT05206214|PROCEDURE|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
48158861|NCT03715413|OTHER|pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.|Patients were lying prone. Firstly, T2, 3, 4 disc level was detected then the target 2nd, 3rd and 4th thoracic nerve roots were identified. After marking the entry points, adequate sterilization of the skin was achieved using bovidone iodine then the skin was anasthesied by 2 ml lidocaine 2% at each entry point. The Baileys radio frequency (RF) 22G, 10 cm, sharp needles with 10 mm active tip was introduced to face the 2nd, 3rd and 4th thoracic nerve roots.The PRF course was carried out at 42°C for 120 s twice at each level followed by injection of 1 ml lidocaine 2% and 1 ml dexamethasone 4 mg at each level.
48366984|NCT03563807|OTHER|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
48158862|NCT03715413|DRUG|Tamoxifen|received Tamoxifen 10 mg daily
48158863|NCT03323983|OTHER|data collection|data collection
48158864|NCT00244751|DRUG|GI262570 0.5 mg|GI262570 0.5 mg
48158865|NCT00244751|DRUG|GI262570 1.0 mg|GI262570 1.0 mg
48158866|NCT00244751|DRUG|Placebo|Placebo
48158867|NCT05006703|BEHAVIORAL|Breathe for Teens (Breathe4T)|A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma, how it affects the lungs, and how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan and log their practice and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include frequently asked questions (FAQs) and a progress chart.
48158868|NCT00537758|BEHAVIORAL|Cognitive Behavior Therapy|
48158869|NCT00537758|BEHAVIORAL|CBT and BWL|
48158870|NCT00537758|BEHAVIORAL|Behavioral Weight Loss Treatment|
48158871|NCT06279780|DIETARY_SUPPLEMENT|very low-calorie diet|Subjects undergo two cycles of a very-low-calorie diet (VLCD) for 6 weeks each, alternating with a hypocaloric diet (12 weeks). The dietetic intervention consists of a VLCD using a liquid formula (Optisource Plus, Nestlé S.A., Vevey, Switzerland), providing 52.8 g protein, 75.0 g carbohydrates, 13.5 g fat, 11.4 g fiber, and essential vitamins and minerals based on Recommended Dietary Allowances (RDA). This formula supplies 2738 kJ/day (654 kcal/day), replacing the participants' three daily meals. Following this and before the second VLCD cycle, a dietician performs an individualized nutritional assessment to calculate the resting energy expenditure, and personalized hypocaloric diets were prepared, reducing 500 kcal for each individual on their daily caloric expenditure, maintaining the recommended intake of each of the macronutrients (55% carbohydrates, 30% fats and 15% proteins) for 12-weeks.
48366985|NCT03563807|OTHER|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
48687020|NCT05833230|OTHER|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.
48366986|NCT02298790|BEHAVIORAL|Meal schedule|
48366987|NCT00625027|OTHER|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
48366988|NCT00034606|DRUG|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
48513081|NCT03428711|DRUG|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
48513082|NCT03428711|DRUG|Placebo Oral Tablet|Indistinguible placebo tablet
48618180|NCT06003764|OTHER|traditional skin care|traditional skin care( the patients received the institutional standard skin care, which encompassed 3×/day application of topical, hydroactive colloid gel, from the first day of RT. In case of a painful skin reaction and/or moist desquamation, a foam, absorbent, self-adhesive silicone dressing was used. Additionally, the patient was advised to follow the general skin care guidelines (e.g., no tie, no electric shaving, no aftershave, gentle washing with or without mild soap, patting dry with a soft towel instead of rubbing
48618181|NCT04004182|DIETARY_SUPPLEMENT|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
48687021|NCT00408707|PROCEDURE|local infiltration analgesia|
48687022|NCT03427593|GENETIC|FACS analyses|FACS analyses
48001763|NCT05016232|BEHAVIORAL|PrEP N' Shine: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
48687023|NCT03427593|GENETIC|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
48687024|NCT03427593|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing
48001764|NCT05016232|BEHAVIORAL|PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)|"1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist."
48001765|NCT00543764|OTHER|pathway|Comparison of pre and post pathway
48001766|NCT04145895|OTHER|Postoperative activity restrictions|Recommendations for return to full activity including return to school, sports, exercise, etc.
48513083|NCT05801588|OTHER|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
48687025|NCT06318247|PROCEDURE|site preservation|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
48158872|NCT03491774|BEHAVIORAL|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
48158873|NCT04542109|BEHAVIORAL|READyR A|Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.
48158874|NCT04542109|BEHAVIORAL|READyR B|Active comparator. Two sessions to deliver general information about dementia-related care needs.
48158875|NCT04639076|BEHAVIORAL|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
48158876|NCT04639076|BEHAVIORAL|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
48158877|NCT03845517|DRUG|Placebo|Placebo
48158878|NCT03845517|DRUG|PF-06700841 15 mg|PF-06700841 15 mg
48366989|NCT06150404|BEHAVIORAL|White Noises and Maternal and/or Paternal voices|"The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs."
48513084|NCT05801588|OTHER|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
48687026|NCT05330390|DRUG|Levetiracetam|Epilepsy, treatment with levetiracetam
48513085|NCT06551181|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.
48513086|NCT06551181|DRUG|Placebo|One dose of placebo is administered intramuscularly at Day 1.
48513087|NCT01645787|DRUG|4-aminopyridine|10 mg/twice daily
48513088|NCT01645787|DRUG|Placebo|Crossover study involving one trial with sugar pill (placebo)
48618182|NCT02355223|OTHER|FAST|See information in arm description
48618183|NCT04840719|DEVICE|RECO|
48618184|NCT00092001|DRUG|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
48618185|NCT04561492|DRUG|[68Ga]Ga-PentixaFor|Tomography by emission of positons (PET) with theradiopharmaceutic \[68Ga\]Ga-PentixaFor
48618186|NCT06168214|DRUG|Rabeprazloe+bismuth+amoxicillin+clarithromycin|PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
48618187|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 14 days|VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
48687027|NCT04314245|OTHER|Active Comparator: Pathology|Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
48687028|NCT04314245|OTHER|Active Comparator: Clinical Diagnosis|Routine clinical diagnosis and treatment of benign disease of the urinary system
48687029|NCT04314245|OTHER|Active Comparator: Clinical diagnosis|Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
48687030|NCT04314245|OTHER|Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay|A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
48158879|NCT03845517|DRUG|PF-06700841 30 mg|PF-06700841 30 mg
48158880|NCT03845517|DRUG|PF-06700841 45 mg|PF-06700841 45 mg
48687031|NCT00575107|OTHER|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
48366990|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with WVT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. WVT was used to fill the tooth when the months were January, March, May, July, September, and November.
48687032|NCT00575107|OTHER|Exercise|Standard training of leg extension
48687033|NCT03200431|OTHER|New adhesive strip|This is a newly developed strip.
48687034|NCT01816191|DRUG|Diltiazem Hydrochloride Cream and Oral Diltiazem|
48687035|NCT01779336|DRUG|PL225B|"* Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
48513089|NCT03685812|DIAGNOSTIC_TEST|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
48618188|NCT06168214|DRUG|Vonoprazan+amoxicillin+clarithromycin 7 days|VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
48687036|NCT00292045|BIOLOGICAL|NY-ESO-1 protein/CpG 7909|Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
48687037|NCT05970536|OTHER|Apple vinegar or EDTA 17%|Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.
48687038|NCT06173024|BIOLOGICAL|TAK-577|TAK-577 as IV injection at dose calculated based on the participant's body weight.
48687039|NCT03002324|BEHAVIORAL|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
48687040|NCT03002324|BEHAVIORAL|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
48687041|NCT03002324|BEHAVIORAL|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
48001767|NCT02501096|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
48001768|NCT02501096|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
48001769|NCT02850003|DRUG|IDP-120 Gel|Gel
48001770|NCT03711162|DRUG|GLPG1690|GLPG1690, film-coated tablets for oral use.
48001771|NCT03711162|DRUG|Placebo|Matching placebo, film-coated tablets for oral use.
48158881|NCT04934878|BIOLOGICAL|Referral information|first visit to our hospital/transfer from another hospital
48158882|NCT01523678|DRUG|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
48158883|NCT01523678|DRUG|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
48158884|NCT01523678|DRUG|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
48158885|NCT06647368|OTHER|PET with 18-FDG|The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.
48158886|NCT01563445|DRUG|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
48158887|NCT01563445|DRUG|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
48158888|NCT04422509|BIOLOGICAL|lanadelumab|single dose, or two doses administered iv
48687042|NCT03002324|BEHAVIORAL|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
48687043|NCT03002324|BEHAVIORAL|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
48687044|NCT01723046|DEVICE|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
48687045|NCT04290247|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
48687046|NCT03173989|DEVICE|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
48687047|NCT03173989|BEHAVIORAL|Orientation|Orientation for home.
48687048|NCT06340724|DRUG|Vonoprazan|20 mg tablet twice daily
48687049|NCT06340724|DRUG|Amoxicillin|1 g tablet three times daily
48687050|NCT06340724|DRUG|Banxiaxiexin decotion|100 ml liquid-medicine twice daily
48687051|NCT02147210|OTHER|biological analysis|
48687052|NCT02051751|DRUG|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
48687053|NCT02051751|DRUG|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
48687054|NCT01479751|DRUG|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
48687055|NCT01479751|DRUG|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
48687056|NCT01479751|DRUG|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
48687057|NCT00439595|DEVICE|Hemocue 210 meter|Diagnostic device
48158889|NCT04422509|OTHER|regular care|no lanadelumab administration, treated according to regular care
48158890|NCT00005908|DRUG|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1
48158891|NCT00005908|DRUG|Anastrozole|1 mg orally daily for five years
48687058|NCT00439595|DEVICE|Copack HBCS|
48687059|NCT00517010|DRUG|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
48687060|NCT02630069|DRUG|CDP-choline|CDP-choline 500mg once a day for 12 weeks
48687061|NCT02630069|DRUG|Placebo|Placebo 500mg once a day for 12 weeks
48158892|NCT00005908|DRUG|cyclophosphamide|600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
48158893|NCT00005908|DRUG|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1
48687062|NCT02630069|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
48687063|NCT03034005|DRUG|Budesonide|1600 ug inhaled daily for 6 weeks
48687064|NCT02972346|DRUG|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
48687065|NCT04883749|BIOLOGICAL|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
48687066|NCT04539054|DIETARY_SUPPLEMENT|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
48687067|NCT04539054|DIETARY_SUPPLEMENT|Nutricost caffeine powder|Caffeine powder.
48687068|NCT04539054|DIETARY_SUPPLEMENT|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
48687069|NCT03414203|OTHER|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
48001772|NCT02421133|OTHER|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
48001773|NCT02421133|OTHER|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician...) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
48001774|NCT01878201|DRUG|Fimasartan|Fimasartan 30 mg
48001775|NCT01878201|DRUG|Valsartan|Valsartan 80 mg
48158894|NCT00005908|DRUG|Doxorubicin hydrochloride|60 mg/m\^2 will be administered as a slow intravenous push on day 1
48687070|NCT02332993|DIETARY_SUPPLEMENT|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
48687071|NCT02151916|OTHER|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
48687072|NCT02151916|OTHER|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
48513090|NCT04107792|BEHAVIORAL|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
48687073|NCT05252494|OTHER|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
48687074|NCT05257395|DRUG|XZP-3287+ Letrozole/Anastrozole|XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
48158895|NCT00005908|DRUG|Tamoxifen Citrate|20 mg/day orally for five years
48158896|NCT00005908|DRUG|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
48158897|NCT00005908|DRUG|Capecitabine - Dose A|capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
48158898|NCT05965518|BEHAVIORAL|High-Intensity Interval Training|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
48513091|NCT05019599|OTHER|low protein diet|Low protein diet (\<0.8g/kg/BW/day)
48513092|NCT06486857|DIAGNOSTIC_TEST|a novel gas detection method for dyslipidemia screening|Multidimensional Mass Spectrometry Technologies Based on Exhaled Metabolic Fingerprint Spectra for Dyslipidemia Detection
48513093|NCT04603157|BEHAVIORAL|Hybrid Exercise Training|Personalized exercise program completing at least 3 aerobic exercise sessions a week and receive eight supervised training sessions over the 3-months
48001776|NCT05320991|DRUG|Ketamine|Ketamine is applied with a Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA). Target plasma levels are 100 ng/ml with an initial bolus administered as a 2 mg/ml solution.
48001777|NCT05320991|DRUG|Nacl 0.9%|Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
48001778|NCT02259153|BEHAVIORAL|Changes in cholesterol metabolism|
48001779|NCT02259153|OTHER|Lean red meat diet|
48687075|NCT05257395|DRUG|Placebo + Letrozole/Anastrozole|Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle
48001780|NCT02259153|OTHER|Fat red meat diet|
48001781|NCT00579111|DRUG|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
48001782|NCT00579111|DRUG|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
48001783|NCT00579111|DRUG|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
48001784|NCT00579111|PROCEDURE|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
48687076|NCT06064006|DRUG|NNC0487-0111|NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
48687077|NCT06064006|DRUG|Placebo (NNC0487-0111)|Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
48513094|NCT02699073|DRUG|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
48513095|NCT00534456|DRUG|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
48687078|NCT01455922|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
48687079|NCT01455922|DRUG|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
48687080|NCT03226249|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
48687081|NCT03226249|DRUG|Dacarbazine|Given IV
48687082|NCT03226249|DRUG|Doxorubicin Hydrochloride|Given IV
48687083|NCT03226249|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
48687084|NCT03226249|OTHER|Laboratory Biomarker Analysis|Correlative studies
48001785|NCT00579111|DRUG|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
48001786|NCT05455983|BIOLOGICAL|covid19 vaccines|different types of (COVID-19) vaccination
48001787|NCT01230931|DEVICE|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
48001788|NCT01230931|PROCEDURE|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
48687085|NCT03226249|BIOLOGICAL|Pembrolizumab|Given IV
48687086|NCT03226249|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
48687087|NCT03226249|DRUG|Vinblastine Sulfate|Given IV
48687088|NCT00189579|DRUG|Herceptin|
48687089|NCT01670279|DRUG|Brexpiprazole|up to 3mg oral dose once daily
48687090|NCT01670279|DRUG|Placebo|
48158899|NCT05965518|BEHAVIORAL|Continuous Moderate Exercise|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
48158900|NCT01825018|BEHAVIORAL|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
48158901|NCT01825018|BEHAVIORAL|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
48158902|NCT01234675|DRUG|Milnacipran|50 mg twice daily
48687091|NCT01420913|DRUG|Pregabalin|Pregabalin 300mg a day
48687092|NCT01740921|DRUG|Liraglutide|Administered once daily
48687093|NCT01740921|OTHER|diet|reduction of caloric intake to promote weight loss
48687094|NCT01740921|DRUG|Aspirin|300mg of Aspirin per day
48687095|NCT00742222|RADIATION|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
48687096|NCT00742222|RADIATION|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
48001789|NCT03266328|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
48001790|NCT00654277|DRUG|Ondansetron|ODT, 8 mg, single-dose
48001791|NCT00654277|DRUG|Zofran|ODT, 8 mg, fasting conditions
48001792|NCT04007172|PROCEDURE|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
48001793|NCT04007172|DEVICE|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
48158903|NCT01234675|DRUG|Placebo|50 mg twice daily
48158904|NCT03110692|BEHAVIORAL|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
48158905|NCT01283971|DRUG|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
48158906|NCT01283971|DRUG|adalimumab|Adalimumab 40 mg SC every 2 weeks.
48158907|NCT01283971|DRUG|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
48158908|NCT01283971|DRUG|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
48158909|NCT01283971|DRUG|methotrexate|Methotrexate 10-25 mg weekly.
48158910|NCT01283971|DRUG|folate|Folate at least 5 mg weekly.
48513096|NCT00534456|DRUG|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
48513097|NCT02319278|DRUG|Ferumoxytol|Infusion following between paired MRI scans
48687097|NCT04113356|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
48687098|NCT02183493|DRUG|BI 1356|
48687099|NCT03884387|OTHER|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
48687100|NCT02949050|BIOLOGICAL|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
48687101|NCT02949050|BIOLOGICAL|SCIT|Treatment group consists of patients who completed \> 1 year of SCIT while control group patients did not undergo SCIT
48687102|NCT02791035|DRUG|Oral administration of Ipragliflozin|
48687103|NCT00769223|OTHER|medical chart review|
48001794|NCT02574871|OTHER|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
48158911|NCT01568021|OTHER|No Intervention|No intervention was administered in this study.
48158912|NCT00523926|DRUG|TMC207|
48158913|NCT01100593|PROCEDURE|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
48513098|NCT03863548|OTHER|complication|collection of post-operative bleeding complications
48513099|NCT04482387|DEVICE|DigiVis visual acuity app|Self-testing of visual acuity app on two occasions
48513100|NCT02847988|DEVICE|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
48687104|NCT00769223|OTHER|questionnaire administration|
48687105|NCT00769223|PROCEDURE|quality-of-life assessment|
48158914|NCT03490747|BEHAVIORAL|Physical activity referral scheme|An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan \& Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.
48158915|NCT03490747|BEHAVIORAL|Usual care exercise referral scheme|A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
48158916|NCT06029920|OTHER|Overground Walking|Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
48158917|NCT03082196|DRUG|Test varnish|Topical application of test varnish to the teeth 4 times per year.
48687106|NCT00769223|RADIATION|brachytherapy|
48687107|NCT00769223|RADIATION|radiation therapy|
48687108|NCT02789436|DRUG|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
48687109|NCT02789436|OTHER|Placebo lozenges|Twice daily, for 28 days
48687110|NCT05760027|OTHER|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
48687111|NCT05760027|OTHER|Regular exercise|The group of athletes will perform their usual exercise for 30 days.
48687112|NCT04130438|DRUG|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
48158918|NCT03082196|DRUG|Standard varnish|Topical application of test varnish to the teeth 4 times per year
48158919|NCT04825210|BEHAVIORAL|Integrated Behavioral Health - Prevention|IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.
48158920|NCT04825210|BEHAVIORAL|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
48158921|NCT05257434|BEHAVIORAL|inbody|Body fluid composition
48158922|NCT00006436|BIOLOGICAL|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
48687113|NCT04130438|DRUG|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
48687114|NCT04130438|OTHER|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
48001795|NCT04659785|DRUG|Fluzoparib|Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity
48158923|NCT00006436|BIOLOGICAL|Filgrastim|Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
48158924|NCT00006436|DRUG|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
48158925|NCT01838499|BIOLOGICAL|MEDI8968|SC injection at baseline, Week 4 and Week 8
48158926|NCT01838499|BIOLOGICAL|Saline|SC injection at baseline, Week 4 and Week 8
48158927|NCT01975259|DRUG|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
48158928|NCT01975259|DRUG|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
48001796|NCT04659785|DRUG|Apatinib|Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
48001797|NCT01615471|BEHAVIORAL|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
48001798|NCT00180024|DRUG|irbesartan (drug)|
48158929|NCT01975259|DRUG|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
48158930|NCT01975259|DRUG|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
48158931|NCT01975259|DRUG|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
48158932|NCT01975259|DRUG|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
48158933|NCT01975259|OTHER|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
48687115|NCT06442904|OTHER|Digital education program|The approximately six hours long digital education program will be available for three months and implies further education in intraoral radiographic examinations.
48687116|NCT04227626|DEVICE|GlucoSTAT|Closed-loop blood glucose control using intravenous insulin and dextrose
48687117|NCT01769950|OTHER|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
48001799|NCT05820971|OTHER|C-short plus usual practice|"Peer reviewer will be reminded of the following 10 CONSORT items (including a short description):~* Outcomes (6a)~* Sample size (7a)~* Sequence generation (8a)~* Allocation concealment (9)~* Blinding (11a)~* Outcomes and estimation (17a/b)~* Harms (19)~* Registration (23)~* Protocol (24)~* Funding (25)"
48001800|NCT02381418|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
48001801|NCT01246947|PROCEDURE|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
48001802|NCT01246947|OTHER|Mitral surgery alone|Randomized to Mitral surgery alone
48001803|NCT05439408|DRUG|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
48158934|NCT01975259|OTHER|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
48158935|NCT01975259|OTHER|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
48513101|NCT02847988|DEVICE|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
48687118|NCT03326063|DRUG|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
48687119|NCT03326063|DRUG|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
48687120|NCT00451958|DRUG|Degarelix 80 mg / Degarelix 80 mg|
48687121|NCT00451958|DRUG|Degarelix 160 mg / Degarelix 160 mg|
48687122|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 80 mg|
48687123|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 160 mg|
48687124|NCT01618058|DRUG|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
48158936|NCT01975259|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid \& every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
48158937|NCT01532830|DEVICE|n-VNS|
48158938|NCT05080803|DRUG|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
48366991|NCT04462731|PROCEDURE|Non-surgical root canal treatment filled with SBT|All eligible teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% Sodium hypochlorite was used as the main irrigant with a 31-gauge needle. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% sodium hypochlorite and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth. SBT was used to fill the tooth when the months were February, April, June, August, October, and December.
48687125|NCT06162273|DEVICE|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
48687126|NCT05031299|BEHAVIORAL|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
48687127|NCT05031299|BEHAVIORAL|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
48001804|NCT05439408|DRUG|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
48001805|NCT01889680|DRUG|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
48001806|NCT01889680|DRUG|LV|400 mg/m2 IV day 1 every 14 days until disease progression
48001807|NCT01889680|DRUG|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
48001808|NCT01889680|DRUG|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
48001809|NCT05064956|BIOLOGICAL|Ad26.ZEBOV|"Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle."
48001810|NCT00606892|DRUG|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
48001811|NCT00606892|DRUG|Placebo|Sugar Pill
48001812|NCT00606892|DRUG|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
48158939|NCT05204771|OTHER|Ultrasound exam|Ultrasound exam
48158940|NCT05204771|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
48158941|NCT05204771|OTHER|Pediatric Follow up|Pediatric Follow up
48158942|NCT01578278|DRUG|Bepotastine besilate formulation|Nasal Spray
48158943|NCT01578278|DRUG|Fluticasone propionate|Nasal Spray
48158944|NCT01578278|DRUG|Bepotastine besilate-fluticasone propionate|Nasal Spray
48158945|NCT01578278|DRUG|Placebo Comparator|Nasal Spray
48158946|NCT04655222|DRUG|Interferon Beta Therapy|Administered as specified in the treatment arm.
48158947|NCT03436433|DRUG|Lacosamide|LCM 100mg twice a day.
48158948|NCT03436433|DRUG|Levetiracetam|LEV 1000mg twice a day.
48158949|NCT02409888|BEHAVIORAL|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
48158950|NCT02409888|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
48158951|NCT02409888|OTHER|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
48158952|NCT02409888|OTHER|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
48158953|NCT01509040|OTHER|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
48001813|NCT06432530|OTHER|C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Complete Blood Count (CBC) values, and indexes derived from the CBC.|Patients' hematological parameters were recorded, and hematological inflammatory indexes (NLR: neutrophil/lymphocyte; MLR: monocyte/lymphocyte; PLR: platelet/lymphocyte; NLPR: neutrophil/(lymphocyte\*platelet); SII (neutrophil\*platelet/lymphocyte): systemic inflammatory index; SIRI (neutrophil\*monocyte/lymphocyte): systemic inflammatory response index; AISI (neutrophil\*platelet\*monocyte/lymphocyte): aggregate index of systemic inflammation. ) were derived from baseline CBC tests.
48001814|NCT00005833|DRUG|R115777|300mg P.O. BID.
48158954|NCT01509040|DEVICE|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
48001815|NCT05312671|DRUG|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
48001816|NCT05312671|DRUG|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
48001817|NCT05312671|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
48001818|NCT05312671|DRUG|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
48001819|NCT05312671|PROCEDURE|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
48001820|NCT00014365|DRUG|MKC-1|
48158955|NCT01509040|DEVICE|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
48158956|NCT05165303|DRUG|lidocaine with propofol|different concentrations of lidocaine added to propofol varying from
48158957|NCT00550927|BIOLOGICAL|bevacizumab|
48158958|NCT00550927|DRUG|enzastaurin hydrochloride|
48366992|NCT02551900|OTHER|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
48513102|NCT03486665|OTHER|Blood Sampling|Blood samples will be taken from all patients and healthy volunteers.
48513103|NCT03486665|OTHER|CSF Sampling|CSF sample will be taken from hospitalized newly diagnosed patients only.
48001821|NCT04296981|OTHER|video-based patient information|explanatory video (8 minutes) concerning communication, stroke issues and stages of the continuum of care
48001822|NCT02094716|DRUG|Permethrin Foam 4%|Topical application, whole-body treatment
48001823|NCT02094716|DRUG|Permethrin Foam 5%|Topical application, whole-body treatment
48001824|NCT02094716|DRUG|Vehicle Foam|Topical application, whole-body treatment
48001825|NCT03323489|RADIATION|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
48001826|NCT03530475|DIAGNOSTIC_TEST|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
48001827|NCT03984786|BEHAVIORAL|Assessment Interview|An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
48158959|NCT00550927|OTHER|diagnostic laboratory biomarker analysis|
48158960|NCT00550927|OTHER|pharmacological study|
48513104|NCT05190692|DEVICE|Use simulators in Obstetrics vaginal examination|"Two simulators will be used in the study:~(1st ) : PROMPT Flex Birthing Simulator Advanced - Light (PRODUCT NO. 80106).UK, 2020 .~2nd): PROMPT Flex Cervical Dilatation \& Effacement Module -Light (PRODUCT NO. 80102),Uk,2020.~Both will be used to perform obstetric vaginal examination before examination of patients"
48687128|NCT05031299|DEVICE|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
48687129|NCT03822143|DIAGNOSTIC_TEST|Ultrasound|Use of ultrasound device to diagnosis anemia in a fetus
48687130|NCT04169204|DIAGNOSTIC_TEST|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
48687131|NCT00578851|DEVICE|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
48687132|NCT04059081|DRUG|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
48687133|NCT00711594|DRUG|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
48687134|NCT00711594|DRUG|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
48687135|NCT00711594|DRUG|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
48687136|NCT00711594|DRUG|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
48687137|NCT03621904|DRUG|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
48687138|NCT00862368|BEHAVIORAL|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
48687139|NCT00862368|BEHAVIORAL|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
48687140|NCT00862368|BEHAVIORAL|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
48687141|NCT03212508|DEVICE|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
48158961|NCT06338254|OTHER|percussion massage therapy|Pregnant women included in this group received a total of 12 sessions of percussion massage therapy, applied to their bilateral lower extremities for four weeks. Percussion massage was applied to both extremities at separate times for 5 minutes each with the Hypervolt device. (Fig. 2) Four muscles in total were focused on; These muscles are medial gastrocnemius, lateral gastrocnemius, peronus longus, and tibialis anterior. Percussion massage was applied in the longitudinal direction of the muscle, from distal to proximal and back to distal, going from posterior to anterior muscle groups. Percussion massage started on the medial side and ended on the lateral side for each muscle. Equal pressure and duration were applied to each muscle.
48158962|NCT00741689|DRUG|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
48158963|NCT00265096|BIOLOGICAL|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
48158964|NCT00265096|BIOLOGICAL|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
48158965|NCT00265096|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
48513105|NCT04799197|BEHAVIORAL|Kicking it with the Gurlz|The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
48687142|NCT02120768|PROCEDURE|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
48687143|NCT03776318|DRUG|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
48158966|NCT06121401|DRUG|Olaparib|Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks
48001828|NCT03984786|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
48001829|NCT03984786|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
48001830|NCT04246385|BEHAVIORAL|CO-OP Group|"Participants in the intervention group will attend one 1:1 session where one goal will be selected from their COPM results to focus on during the group, group expectations will be reviewed, caregivers will be invited, and questions answered. The group will run six sessions as supported by the literature (Chan, 2007; Lee, Fischer, Zera, Robertson, \& Hammel 2017).~Day Rehab CO-OP Group Curriculum Session Content~Introduction One on one session. COPM, introduction to group, education for caregiver. Session 1 Introduction to group and CO-OP approach, homework. Session 2 Review CO-OP approach, practice, homework. Session 3 Review CO-OP approach, plan outing, homework. Session 4 Review CO-OP approach, experiential learning according to participants' alternate COPM goals, homework. Session 5 Review CO-OP approach, outing, homework. Session 6 Review CO-OP approach, focus group, lessons learned, final COPM, homework"
48001831|NCT03204513|DEVICE|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
48001832|NCT03204513|DEVICE|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
48158967|NCT06121401|DRUG|Bevacizumab|Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
48687144|NCT00117780|DRUG|insulin detemir|
48687145|NCT00117780|DRUG|insulin aspart|
48687146|NCT06288308|DIAGNOSTIC_TEST|fibronigin to albumin ratio|"To investigate the association of fibrinogen to albumin ratio (FAR) with LN in different classes.~b. Secondary (subsidiary):~To prove the possible role of FAR as a novel diagnostic biomarker to predict LN progression"
48687147|NCT00444483|BEHAVIORAL|Structured diabetes teaching and treatment program|
48687148|NCT00535535|DIETARY_SUPPLEMENT|Fructose|Fructose, 0.5 g/kg
48687149|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
48001833|NCT01248858|DRUG|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
48158968|NCT00513461|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
48158969|NCT00513461|OTHER|placebo|Given PO
48158970|NCT00513461|OTHER|laboratory biomarker analysis|Correlative studies
48158971|NCT00513461|OTHER|immunoenzyme technique|Correlative studies
48158972|NCT00513461|OTHER|high performance liquid chromatography|Correlative studies
48158973|NCT04643496|PROCEDURE|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
48513106|NCT05963724|DEVICE|Real-Time Computer Aided Detection|This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
48158974|NCT01678898|DRUG|PRX-102|
48158975|NCT01124656|DRUG|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
48513107|NCT05963724|PROCEDURE|Stanford Colonoscopy|This involves white-light colonoscopy
48687150|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
48687151|NCT04381624|OTHER|Exercise program|exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
48687152|NCT04685980|PROCEDURE|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
48687153|NCT01457664|DRUG|Placebo|Placebo to RO4995819 once daily for 14 days
48687154|NCT01457664|DRUG|RO4995819|RO4995819 doses once daily for 14 days
48001834|NCT04098458|BEHAVIORAL|NDURE|NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
48001835|NCT02246803|PROCEDURE|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
48001836|NCT02246803|PROCEDURE|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
48001837|NCT01166685|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
48001838|NCT01166685|DEVICE|Bare-metal stent|Bare metal stent
48366993|NCT02551900|OTHER|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
48001839|NCT01166685|DEVICE|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
48158976|NCT03453489|OTHER|Carbon C 11 Alpha-methyltryptophan|Undergo AMT-PET
48158977|NCT03453489|OTHER|Laboratory Biomarker Analysis|Correlative studies
48366994|NCT02551900|OTHER|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
48513108|NCT04317079|DIETARY_SUPPLEMENT|Hydroxytyrosol|Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months
48513109|NCT04317079|OTHER|Diet|Consultation by a dietitian was offered to all participants
48687155|NCT04548700|DRUG|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
48513110|NCT03413579|BIOLOGICAL|Nimotuzumab ( h-R3)|Humanized monoclonal antibody
48001840|NCT01266213|DRUG|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
48001841|NCT01266213|DRUG|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
48001842|NCT01266213|DRUG|Goserelin|Goserelin s.c.
48001843|NCT01652716|DRUG|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
48513111|NCT03413579|OTHER|Placebo|
48513112|NCT05957744|PROCEDURE|Colorectal surgery|Right hemicolectomy, left colectomy, total colectomy, anterior resection
48513113|NCT05738278|BEHAVIORAL|HR-informed change in routine|"The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
48618189|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 14 days|VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
48001844|NCT01652716|DRUG|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
48001845|NCT02420028|DEVICE|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
48001846|NCT02420028|DEVICE|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
48158978|NCT03453489|PROCEDURE|Positron Emission Tomography|Undergo AMT-PET
48158979|NCT03453489|DRUG|Telotristat Etiprate|Given PO
48158980|NCT06128434|OTHER|zinc carbonate nano-hydroxyapatite toothpaste|Participants will brush their teeth with zinc carbonate nano-hydroxyapatite toothpaste twice daily.
48158981|NCT06128434|OTHER|8% arginine toothpaste|Participants will brush their teeth with 8% arginine toothpaste twice daily.
48158982|NCT06128434|OTHER|Fluoride toothpaste|Participants will brush their teeth with Fluoride toothpaste twice daily.
48158983|NCT04393779|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
48687156|NCT04548700|DRUG|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
48687157|NCT05451589|BEHAVIORAL|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
48158984|NCT06224335|DIAGNOSTIC_TEST|intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running|Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
48158985|NCT00527514|DRUG|Amlodipine|Tablets
48687158|NCT05451589|BEHAVIORAL|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
48158986|NCT00527514|DRUG|Olmesartan medoxomil plus amlodipine|Tablets
48158987|NCT04301063|OTHER|RV3278A|RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
48158988|NCT06456788|BIOLOGICAL|MMR vaccination|MMR vaccination status
48158989|NCT02762500|DRUG|LYC-30937-EC|
48158990|NCT02762500|DRUG|Placebo|
48158991|NCT01199445|DIETARY_SUPPLEMENT|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
48618190|NCT06168214|DRUG|Vonoprazan+tetracycline+furazolidone 7 days|VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
48687159|NCT02227030|DRUG|BIIB 722 CL solution|
48687160|NCT02227030|DRUG|BIIB 722 CL tablet|
48687161|NCT02227030|DRUG|Placebo solution|
48687162|NCT02227030|DRUG|Placebo tablet|
48687163|NCT02649920|DEVICE|Cervical ripening balloon|
48687164|NCT02649920|DRUG|Dinoprostone|
48687165|NCT02817776|DEVICE|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
48687166|NCT03786224|BEHAVIORAL|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
48687167|NCT01027559|DRUG|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
48687168|NCT01027559|BEHAVIORAL|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
48158992|NCT02832453|BEHAVIORAL|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
48158993|NCT02832453|BEHAVIORAL|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
48158994|NCT02832453|BEHAVIORAL|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
48158995|NCT03552471|OTHER|Laboratory Biomarker Analysis|Correlative studies
48158996|NCT03552471|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
48158997|NCT03552471|OTHER|Pharmacokinetic Study|Correlative studies
48158998|NCT03552471|DRUG|Rucaparib Camsylate|Given PO
48366995|NCT01156636|DRUG|Sildenafil|50 mg 3 times/day for 1 year
48618191|NCT06168214|DRUG|Vonoprazan+amoxicillin+furazolidone 7 days|hVAF: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; F: furazolidone 100mg bid.
48618192|NCT06168214|DRUG|Vonoprazan+amoxicillin+tetracycline 14 days|hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
48366996|NCT01156636|DRUG|Placebo|
48618193|NCT06168214|DRUG|Vonoprazan+amoxicillin 7 days|hVA7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
48001847|NCT06481540|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period).
48687169|NCT03995095|OTHER|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
48001848|NCT06481540|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period).
48158999|NCT05051683|PROCEDURE|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
48159000|NCT04203199|DEVICE|Real rTMS to the mPFC using H7 Coil|This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
48159001|NCT04203199|DEVICE|Real rTMS to the dlPFC using H1 Coil|This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
48001849|NCT01992731|OTHER|Drug: Follitropine Bèta|
48001850|NCT04134247|DRUG|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
48159002|NCT05476783|DRUG|TB006|Clear to slightly opalescent, sterile solution for injection
48159003|NCT03443752|OTHER|Shotokan-Karate|The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
48159004|NCT03443752|OTHER|Tai-Chi|The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
48159005|NCT02330861|DEVICE|combowire and IVUS|
48159006|NCT05577663|OTHER|Routine treatment of the extraction socket|Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
48687170|NCT01183429|DRUG|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
48159007|NCT05577663|PROCEDURE|Socket seal technique by a free gingival graft|Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
48159008|NCT05577663|PROCEDURE|Socket seal technique using a synthetic resorbable membrane|Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
48159009|NCT04342910|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
48159010|NCT04342910|DRUG|Apatinib Mesylate|250 mg qd
48159011|NCT04342910|DRUG|Paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
48159012|NCT04342910|DRUG|Irinotecan|180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
48159013|NCT01248143|DIETARY_SUPPLEMENT|Green tea|9 gram per day
48159014|NCT01248143|DIETARY_SUPPLEMENT|FPP|2 sachets twice daily
48159015|NCT05240482|PROCEDURE|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
48159016|NCT06011928|OTHER|MOPEX Exercise|"Exercises to be done in order:~1. Pelvic tilt in supine position~2. Bridge building~3. Pelvic stretching~4. Ball spin~5. Cat-camel exercise~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds"
48159017|NCT06011928|OTHER|Relaxation Exercise|Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened.
48618194|NCT06168214|DRUG|Vonoprazan+amoxicillin 14 days|hVA14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid.
48001851|NCT04134247|DRUG|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
48001852|NCT03578081|DRUG|Palonosetron Hydrochloride|Given IV
48001853|NCT03578081|DRUG|Ondansetron Hydrochloride|Given IV or PO
48366997|NCT06111755|OTHER|SmokefreeTXT|National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.
48366998|NCT06111755|DEVICE|Smartband|A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.
48687171|NCT05421169|DIAGNOSTIC_TEST|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
48687172|NCT03086616|DRUG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
48001854|NCT03578081|DRUG|Dexamethasone|Given PO
48001855|NCT03578081|DRUG|Fosaprepitant Dimeglumine|Given IV
48001856|NCT03578081|DRUG|Olanzapine|Given PO
48001857|NCT03578081|OTHER|Placebo|Given IV
48001858|NCT06517147|DEVICE|Cryogenx cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
48001859|NCT06517147|DEVICE|Regular cooling|During the cooling phase of both trials established field based cooling approaches e.g., temperate temperature water spraying (30°C, 5 mL.min-1), and air circulation (electric fan 2 m distance, 1.7 m.s-1 will be implemented. During the CRYOGENX cooling trial, the product will be affixed to the participant's torso in accordance with manufacturer's instructions and they will receive cooling via this intervention in addition to water spraying and air circulation. During the control visit, no intervention will be applied however water spraying and air circulation will be received.
48001860|NCT06040021|OTHER|standardized treatment|Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
48001861|NCT02061969|DRUG|linagliptin|5mg linagliptin tablets
48001862|NCT02061969|DRUG|insulin glargine|
48001863|NCT02331225|OTHER|No intervention given|There is no intervention for this study
48001864|NCT03048396|PROCEDURE|Uterus transplantation|
48001865|NCT00640705|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
48001866|NCT00640705|DRUG|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
48366999|NCT05336045|PROCEDURE|trigger finger release|The A1 pulley and tendon sheath is divided in local anaestethic through a small incision in the palm
48367000|NCT04951557|PROCEDURE|Transsphenoidal resection|Transsphenoidal resection of pituitary adenoma
48367001|NCT03658213|DRUG|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
48367002|NCT03658213|DRUG|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
48367003|NCT03982069|BIOLOGICAL|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
48367004|NCT03982069|BIOLOGICAL|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
48687173|NCT01084577|DEVICE|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
48687174|NCT01084577|DEVICE|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
48001867|NCT06342843|PROCEDURE|Total Hip Arthroplasty|a surgical procedure in which an orthopaedic surgeon removes the damaged bone and cartilage and replaces this with prosthetic components.
48001868|NCT00895466|BIOLOGICAL|PEP-223/CoVaccine HT|
48001869|NCT00206453|DRUG|Taxotere|Chemotherapy IV
48001870|NCT03489395|DRUG|Edoxaban|Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
48001871|NCT02528162|BEHAVIORAL|education|Evaluation of education for GDM
48001872|NCT00310908|DRUG|Tramadol Hcl|Active Comparator
48001873|NCT04914728|PROCEDURE|mini-invasive lumbar arthrodesis|"* The mini-invasive posterior approach is performed using a trans-muscular Wiltse approach. Pedicle screws, neurological decompression and intersomatic cage placement are performed.~* The mini-invasive anterior approach is performed via a left retroperitoneal pararectal approach. After complete discectomy, an intersomatic cage stabilised by a screwed plate will be placed."
48367005|NCT03240003|BEHAVIORAL|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
48367006|NCT03240003|BEHAVIORAL|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
48367007|NCT03240003|BEHAVIORAL|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
48367008|NCT01241643|DRUG|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
48159018|NCT06011928|OTHER|Combine Exercise|"Exercises to be done in order:~Pelvic tilt in supine position Bridge building Pelvic stretching Ball spin Cat-camel exercise Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds.~Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened."
48159019|NCT04285476|DIAGNOSTIC_TEST|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
48159020|NCT00481156|BEHAVIORAL|Cognitive Remediation|
48159021|NCT00481156|BEHAVIORAL|Cognitive Behavioral Social Skills Training|
48618195|NCT05494528|DRUG|Ropeginterferon alfa-2b|Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
48001874|NCT05190120|PROCEDURE|Femoral Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
48001875|NCT05190120|PROCEDURE|Adductor Canal Nerve Block|Patients having ACL reconstruction, meniscus surgery and knee arthroscopy
48001876|NCT05190120|DRUG|preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine|
48001877|NCT05190120|DRUG|Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.|
48618196|NCT05494528|DRUG|Entecavir|Entecavir 0.5 mg once per day
48618197|NCT06064240|OTHER|We do not have any intervention type|We do not have any intervention type
48618198|NCT02111044|DRUG|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
48159022|NCT00481156|OTHER|Retest in Health Controls|Pre/Post test performance and neuroimaging only
48159023|NCT02423447|DEVICE|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
48159024|NCT02423447|DEVICE|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
48159025|NCT02368977|DEVICE|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
48159026|NCT01730261|BEHAVIORAL|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
48159027|NCT05812547|DEVICE|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
48159028|NCT05812547|OTHER|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
48159029|NCT02135588|DRUG|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
48159030|NCT05938959|DRUG|Sham block|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline
48159031|NCT05938959|DRUG|ESPB|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
48159032|NCT03229525|BEHAVIORAL|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
48159033|NCT03229525|BEHAVIORAL|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
48159034|NCT00755924|DIETARY_SUPPLEMENT|Vinegar|Apple cider vinegar 2 TBlsp/day
48001878|NCT05970432|DRUG|TQH2722 injection 300mg-150mg|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
48001879|NCT05970432|DRUG|TQH2722 injection 600mg-300mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
48159035|NCT00755924|OTHER|Placebo|Water placebo colored with balsamic vinegar
48266830|NCT00523588|PROCEDURE|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
48001880|NCT05970432|DRUG|TQH2722 injection 900mg-450mg|TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
48001881|NCT05970432|DRUG|TQH2722 injection matching Placebo|Placebo without active substance.
48001882|NCT06065761|OTHER|Comprehensive ED heart failure management tool|The investigators plan a regional implementation of an electronic health record-based heart failure decision support tool across 21 EDs of Kaiser Permanente Northern California (KPNC).
48687175|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
48687176|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
48687177|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
48687178|NCT00391053|BIOLOGICAL|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
48687179|NCT02018523|DRUG|Lenalidomide|lenalidomide 10mg/day orally until disease progression
48687180|NCT05285761|BEHAVIORAL|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
48001883|NCT05058313|DEVICE|Photobiomodulation|Six weekly photobiomodulation sessions (PBMT) using the MILTA ™ GYNECO vaginal probe.
48001884|NCT04189458|OTHER|Multimodal exercise program|Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (30 min), cool-down (5 min), and finishing ritual (5 min). At the initial stage, the activation of different muscle groups will be performed. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities and will privilege IPS. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation - physical fitness (strength, balance and agility) - alternating with exercises mainly focused on cognitive stimulation - CF (planning ability, solving-problems, IPS, attention and DT performance). At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants sign an attendance sheet regarding the session, including perceived exertion (Borg Scale) and satisfaction (Caregiver Treatment Satisfaction questionnaire).
48001885|NCT05585970|DIAGNOSTIC_TEST|procalcitonin|The PCT level in healthy individual without infection is below the limit of detection (0.01 ng/mL), and it is significantly elevated under the stimulation of pathogens
48001886|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 1 for 84 days
48001887|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 2 for 84 days
48367009|NCT03924960|BEHAVIORAL|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
48367010|NCT03924960|BEHAVIORAL|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
48367011|NCT03924960|BEHAVIORAL|Control|Usual care control group
48367012|NCT02369406|DRUG|Nevirapine|
48367013|NCT02369406|DRUG|Kaletra|
48367014|NCT02369406|DRUG|Lamivudine|
48367015|NCT02369406|DRUG|Zidovudine|
48367016|NCT05686668|OTHER|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
48367017|NCT05984225|OTHER|Online learning|"The students performed a 10-week Online Learning (OL) program based on Professional Ethics. The program included:~1. Synchronous learning (1 session/week, 1 hour each).~2. Asynchronous learning: i) OL classes were recorded; ii) Moodle platform: for read breaking news, upload tasks or solve any doubt they may have through discussion forums; iii) An OL specific syllabus that consisted of five themes from the ethics knowledge; iv) An OL glossary, including the concept, explanation of the concept, and source; v) Bullet-point videos highlighting the most important issues of each theme; vi) Podcasts about Professional Ethics, Ethics in physiotherapy; vii) Links to websites; viii) Gamification using mobile Apps regarding ethical decision-making, healthcare, and Ethics or Professional Ethics, as well as an OL crossword; ix) OL activities were created and personalized comments about the activities were reported by the teachers to give feedback to the students."
48687181|NCT05285761|BEHAVIORAL|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
48687182|NCT00993863|DRUG|Placebo|single dose
48687183|NCT00993863|DRUG|ADL5859 30 mg|single dose
48687184|NCT00993863|DRUG|ADL5859 100 mg|single dose
48687185|NCT00993863|DRUG|ADL5859 200 mg|single dose
48687186|NCT00993863|DRUG|ibuprofen 400 mg|single dose
48687187|NCT05365516|OTHER|Implementing medical safety huddles|These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
48687188|NCT05421923|DRUG|SR1375 capsules|Ascending single and multiple doses of SR1375 orally
48687189|NCT05421923|OTHER|Placebo|Ascending single and multiple doses of Placebo orally
48687190|NCT01911650|OTHER|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
48687191|NCT01911650|OTHER|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
48687192|NCT01911650|OTHER|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
48687193|NCT01295138|DRUG|Lactulose|Lactulose liquid. 15mls twice daily
48687194|NCT04931914|OTHER|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
48687195|NCT00140179|DRUG|valnoctamide|
48687196|NCT03081663|PROCEDURE|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
48687197|NCT03081663|PROCEDURE|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
48687198|NCT02501148|DEVICE|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
48687199|NCT03712176|BEHAVIORAL|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
48367018|NCT01712763|DRUG|degarelix|180 women will be treated with degarlix 120 mg, in only one administration covering three months
48687200|NCT05388227|OTHER|Pole Walking|Group training sessions will be offered at the participating independent living/retirement communities. Training sessions will be held either indoors or outdoors, 2-3 times a week, for 20-60 min/session, over 12 weeks.
48001888|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 3 for 84 days
48367019|NCT01712763|DRUG|Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)|180 women will be treated with leuprolide acetate11.25 only once covering three months
48367020|NCT00865176|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
48367021|NCT00865176|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
48367022|NCT01078389|DRUG|Febuxostat|Febuxostat capsules
48367023|NCT01078389|DRUG|Placebo for Febuxostat|Febuxostat placebo-matching capsules
48687201|NCT02947802|OTHER|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
48687202|NCT02947802|OTHER|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
48687203|NCT03512808|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
48687204|NCT03512808|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
48687205|NCT02675933|BEHAVIORAL|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
48266831|NCT03715426|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
48001889|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
48001890|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 5 for 84 days
48001891|NCT01403038|DRUG|Elagolix|Elagolix Dose Regimen 6 for 84 days
48001892|NCT01403038|DRUG|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
48266832|NCT03242330|DEVICE|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
48266833|NCT00786877|OTHER|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
48266834|NCT00786877|OTHER|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
48367024|NCT03747497|DRUG|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
48367025|NCT03747497|DRUG|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
48367026|NCT01812564|BIOLOGICAL|Platelet Poor Plasma (PPP)|
48367027|NCT01812564|BIOLOGICAL|Platelet Rich Plasma (PRP)|
48618199|NCT02111044|DRUG|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
48618200|NCT02111044|DRUG|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
48618201|NCT02111044|DRUG|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
48618202|NCT04523376|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
48618203|NCT05303714|COMBINATION_PRODUCT|FOLFOX and PIPAC|"A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system."
48159036|NCT03897049|BEHAVIORAL|Trans Women Connected|The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
48159037|NCT03897049|BEHAVIORAL|General Health App|The control group will download a mobile app that addresses COVID and provides COVID resources.
48159038|NCT01763489|BEHAVIORAL|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
48159039|NCT06228417|OTHER|Adaptive digital intervention|Participants received reminder for medication intake on daily basis. Also, short message regarding hypertension, medication and lifestyle changes
48159040|NCT04061317|OTHER|Frailty Assessment|"We will use validated measures to determine existence of frailty prior to interventional cardiac procedures (PRISMA-7, Edmonton and FRIED Frailty Index). We will repeat the measures at 6 weeks and 6 months post procedure. We will also collect clinical data to assess any links between frailty and clinical outcomes.~We are also keen to understand the effects of health-related quality of life on frailty and will be collecting generic data via the SF-36 and EQ5-D."
48159041|NCT05428839|DIAGNOSTIC_TEST|Pharyngeal width measurement|A simple, non-invasive measurement of the pharyngeal width inside each subjects mouth
48159042|NCT06279637|BEHAVIORAL|Joint Home-DM-BAT Intervention|8 weekly sessions of telephone-delivered, manualized education on diabetes management, problem solving of social needs, and behavioral activation.
48159043|NCT06279637|BEHAVIORAL|Usual Care|Diabetes education materials will be mailed weekly and monthly according to the booster schedule
48159044|NCT00948103|DRUG|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
48159045|NCT00948103|DRUG|Oxygen|oxygen
48159046|NCT06645834|DEVICE|Smart MDI System|"The Smart MDI system consists of the InPen™ system and Simplera™ system.~The InPen™ system includes a reusable smart bolus insulin pen injector with Bluetooth combined with the InPen™ app to help users take insulin doses.~And InPen™ app which communicates with the InPen™ injector and compatible continuous glucose monitoring (CGM) devices to collect and display information on insulin delivered by the injector as well as current and past glucose values.~The Simplera™ system consists of a disposable integrated sensor-transmitter platform (Simplera™ Sensor) and the Simplera™ app which receives data from the Simplera™ sensor via Bluetooth Low Energy (BLE) radio signal"
48159047|NCT02701595|DRUG|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients \>70kg)
48159048|NCT02701595|PROCEDURE|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
48159049|NCT06585475|BEHAVIORAL|Structured training according to premenstrual syndrome symptom map|A symptom map consisting of evidence-based practices for coping with PMS symptoms was created. An educational content based on this map was prepared and applied to women with PMS to evaluate whether it was effective compared to the control group.
48159050|NCT02517476|DIETARY_SUPPLEMENT|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
48159051|NCT01631318|PROCEDURE|Dynamic contrast-enhanced ultrasound imaging|Ultrasound imaging procedure
48159052|NCT01631318|DEVICE|Optical Tracking Device|Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.
48159053|NCT01631318|DEVICE|Electromagnetic Tracking Device|Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.
48159054|NCT01631318|DRUG|Perflutren|Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
48159055|NCT00449917|DRUG|lutein|
48159056|NCT00449917|DRUG|DHA|
48159057|NCT00449917|DRUG|vitamins|
48159058|NCT02302625|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
48159059|NCT04061967|OTHER|Sending of screening summon.|"2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured.~2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent."
48159060|NCT02521025|OTHER|Intermittent feeding pattern|Intermittent feeding
48159061|NCT02521025|OTHER|Continuous feeding pattern|Continuous feeding
48159062|NCT01286376|DIETARY_SUPPLEMENT|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
48159063|NCT01286376|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
48266835|NCT02266108|BEHAVIORAL|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
48266836|NCT00356642|DRUG|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
48266837|NCT00356642|DRUG|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
48618204|NCT03229603|OTHER|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
48266838|NCT05850208|BIOLOGICAL|Transplantation of self BMSCs|Bone marrow was collected, cultured in vitro and injected back into the body
48266839|NCT04146142|PROCEDURE|Transperineal prostate biopsy with or without antibiotic prophylaxis|As described above.
48687206|NCT04307368|OTHER|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
48687207|NCT04307368|OTHER|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
48687208|NCT04307368|OTHER|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
48159064|NCT05668442|BEHAVIORAL|Online exercise and group meetings|"The intervention consists of 8 weeks of 30 minutes of online supervised high intensity physical exercise followed by 30 minutes of online group meeting once a week in Microsoft Teams. The program consist of a short warm-up, followed by interval.-based physical activity including bodyweight aerobic and strength training, followed by stretching.~Following the online exercise session, participants will be sent out in smaller break-out rooms in Microsoft Teams. The online group meeting sessions are intended to serve as a platform for group discussion evaluation of weekly physical acitvity.~Each online group will be facilitated by a participant. All participants will be encouraged to set physical activity goals to increase habitual physical activity As a part of the intervention, participants will wear a Garmin Vivofit 4 activity watch or a Garmin 245 watch."
48687209|NCT01746355|PROCEDURE|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
48159065|NCT00749671|DEVICE|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
48687210|NCT04077424|BIOLOGICAL|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
48687211|NCT04077424|BIOLOGICAL|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
48159066|NCT00749671|OTHER|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
48159067|NCT02101554|DRUG|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
48159068|NCT02101554|DRUG|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
48159069|NCT02946788|DRUG|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
48159070|NCT04715919|DIAGNOSTIC_TEST|Chest Computed Tomography|Evaluation of Lung Structure
48159071|NCT04715919|DIAGNOSTIC_TEST|Pulmonary Function Tests|Respiratory Capacity
48159072|NCT04715919|OTHER|Six Minutes Walk Test|Exercise Capacity
48159073|NCT04715919|OTHER|Quality of Life|Physical disability assessment tool
48159074|NCT00561275|BIOLOGICAL|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
48159075|NCT03101098|PROCEDURE|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
48159076|NCT03101098|PROCEDURE|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
48159077|NCT01841645|DIETARY_SUPPLEMENT|CLA depletion-repletion|
48159078|NCT01202383|BEHAVIORAL|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
48159079|NCT01202383|BEHAVIORAL|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
48159080|NCT01535196|DRUG|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
48159081|NCT03966014|DRUG|EM-amoxicillin 3 x 10 days|Patients will receive amoxicillin 500 milligram tid for 10 days
48159082|NCT03966014|DRUG|EM-amoxicillin 3 x 14 days|Patients will receive amoxicillin 500 milligram tid for 14 days
48159083|NCT03966014|DRUG|EM-amoxicillin 2 x 14 days|Patients will receive amoxicillin 500 milligram bid for 14 days
48159084|NCT03966014|OTHER|Controls|No intervention.
48159085|NCT05961488|OTHER|Coronary Calcium Score and Coronary CT angiogram|Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
48687212|NCT04077424|BIOLOGICAL|Flublock|Recombinant hemagglutinin vaccine
48159086|NCT06474442|GENETIC|BD111 Injection (investigational new drug)|BD111: intrastromally injection, single-dosing RP2D (TU/eye), specified injection volume is 0.15mL.
48159087|NCT06474442|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
48159088|NCT00002792|DRUG|busulfan|
48159089|NCT00002792|DRUG|cyclophosphamide|
48159090|NCT00002792|DRUG|cyclosporine|
48159091|NCT00002792|DRUG|methotrexate|
48159092|NCT00002792|DRUG|tacrolimus|
48367028|NCT05358158|PROCEDURE|Intraoperative air leak test|A standard 28 Fr chest drain is inserted through the anterior port hole with all port holes closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
48367029|NCT05358158|PROCEDURE|Intraoperative chest drain removal|Chest drain is removed intraoperatively.
48367030|NCT05358158|PROCEDURE|Standard chest drain placement|Chest drain is left in pleura.
48367031|NCT00307073|DEVICE|Implantable Pulse Generator|
48159093|NCT00002792|PROCEDURE|allogeneic bone marrow transplantation|
48159094|NCT00002792|PROCEDURE|peripheral blood stem cell transplantation|
48687213|NCT02827344|BIOLOGICAL|blood sample collection for CTC and MDSC analysis|"* Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
48159095|NCT03401411|BEHAVIORAL|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
48159096|NCT03401411|BEHAVIORAL|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
48159097|NCT02635711|BEHAVIORAL|Adapted Taekwondo training|Adapted Taekwondo training for beginners
48687214|NCT06163573|BIOLOGICAL|N-TEC|Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.
48367032|NCT03487120|PROCEDURE|facet joint denervation|Bipolar electrocautery
48367033|NCT05057000|OTHER|aerobic exercises + Diet|Frequency 5-6 days per week Intensity To perform moderate intensity for weight-bearing aerobic exercise Time Goal of 20-30 min per session of moderate-intensity aerobic activity per week
48367034|NCT05057000|OTHER|diet proram|diet program for anorexic adolescent girls
48367035|NCT00370994|PROCEDURE|Caudal epidural injection|Caudal epidural injection with catheterization
48367036|NCT00370994|PROCEDURE|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
48687215|NCT06163573|BIOLOGICAL|Platelet rich plasma|"Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks."
48159098|NCT02635711|BEHAVIORAL|Control|Daily jogging
48159099|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
48367037|NCT06263504|PROCEDURE|at correcting malocclusions or restoring the integrity of the dentition|Patients in this group will receive standard treatment aimed solely at correcting malocclusions or restoring the integrity of the dentition without interfering with the musculoskeletal system.
48687216|NCT00908323|BIOLOGICAL|JS7 DNA vaccine|
48367038|NCT06263504|PROCEDURE|comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.|): Patients will receive comprehensive treatment, including not only dental correction of bite or restoration of the integrity of the dentition, but also correction of disorders of the musculoskeletal system.
48367039|NCT05021159|OTHER|MTX, (but the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression)|the investigator is not using any intervention, the participants are already taking it in their treatment protocol and the investigator is just analyzing p-gp expression
48367040|NCT01219686|DRUG|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
48367041|NCT01219686|DRUG|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
48367042|NCT01219686|DRUG|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
48367043|NCT04073680|DRUG|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
48687217|NCT00908323|BIOLOGICAL|MVA/HIV62 vaccine|
48687218|NCT00733733|DRUG|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
48687219|NCT02831855|DRUG|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
48159100|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
48159101|NCT03083600|DIETARY_SUPPLEMENT|Placebo|Cellulose Placebo for 12-weeks
48159102|NCT04027673|BEHAVIORAL|TMW ECE Curriculum|The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
48159103|NCT06585345|BIOLOGICAL|CD7 CAR-T cell|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (1-100)x10\^6 CD7 CAR-T cells/kg\]
48001893|NCT06156592|PROCEDURE|Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia|Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
48001894|NCT03389464|BEHAVIORAL|computer-based confrontation with dysfunctional beliefs|"Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person)."
48159104|NCT05534451|BEHAVIORAL|video laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
48367044|NCT04073680|DRUG|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
48367045|NCT01941160|DIETARY_SUPPLEMENT|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
48367046|NCT01941160|DIETARY_SUPPLEMENT|Placebo|Placebo capsule twice daily
48687220|NCT02831855|DRUG|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
48687221|NCT02831855|DRUG|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
48687222|NCT05050968|OTHER|Physical activity|Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.
48687223|NCT00662831|DRUG|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
48687224|NCT00662831|DRUG|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
48367047|NCT02723539|DRUG|MBN-101|Topical application
48367048|NCT02723539|DRUG|Placebo|Topical application
48367049|NCT02067208|DEVICE|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
48367050|NCT02127580|PROCEDURE|BAV|
48687225|NCT05698615|BEHAVIORAL|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
48687226|NCT00969605|PROCEDURE|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
48687227|NCT01663766|DRUG|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
48687228|NCT04198766|DRUG|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
48001895|NCT03301194|OTHER|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
48001896|NCT05417932|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
48001897|NCT04804462|DEVICE|Virtual Reality Meditation|After donning the VR headset, participants will be able to use a handheld controller to choose from several virtual outdoor settings, three types of meditation, and three session lengths. After choosing their desired option, participants will experience virtual reality meditation in the desired virtual location, of the desired meditation type, and for the allotted duration chosen.
48001898|NCT00712465|DRUG|AZD1305|Extended Release tablet, repeated administration
48001899|NCT00712465|DRUG|Digoxin|Tablet, repeated administration
48001900|NCT00974714|DRUG|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
48001901|NCT00974714|OTHER|placebo|oral placebo 2 g twice a day for 14 weeks
48001902|NCT05077943|BEHAVIORAL|Breathing and chest mobilization exercises|Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.
48001903|NCT05077943|BEHAVIORAL|Second phase cardiac rehabilitation|Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.
48159105|NCT05534451|BEHAVIORAL|video rigid laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video rigid laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
48367051|NCT02127580|PROCEDURE|without BAV|
48367052|NCT03006549|BEHAVIORAL|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
48687229|NCT04198766|DRUG|pembrolizumab 200 mg|pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
48687230|NCT04198766|DRUG|pembrolizumab 400 mg|pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
48687231|NCT04198766|DRUG|Carboplatin AUC-5|carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
48001904|NCT06104501|DEVICE|RadiHeart|The participants' blood pressure will be measured multiple times by both the mercury sphygmomanometer and RadiHeart, by using the same arm sequential method.
48001905|NCT04395937|OTHER|exercises|One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
48001906|NCT04095507|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
48001907|NCT05375734|DRUG|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
48001908|NCT03411876|DEVICE|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
48001909|NCT03411876|DEVICE|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
48367053|NCT06413030|DIAGNOSTIC_TEST|10 Meter Walk Test|Gait Speed Test
48367054|NCT01829529|DRUG|Amoxicillin|Amoxicillin
48367055|NCT05000034|PROCEDURE|Weaning protocol|Application of a weaning protocol from the mechanical ventilation
48367056|NCT00617942|DRUG|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
48687232|NCT04198766|DRUG|Carboplatin AUC-6|carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
48687233|NCT04198766|DRUG|Pemetrexed 500 mg/m2|pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles
48367057|NCT00617942|DRUG|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
48001910|NCT04466865|OTHER|Best Case/Worst Case communication tool training|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of kidney disease. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning the intervention is designed to lead to a discussion of participants preferences and consideration of outcomes.~The nephrologist verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The nephrologist also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
48001911|NCT05859295|DEVICE|Red Low-Level Light Therapy|Visible red light (633nm) projected onto the face using an light emitting diode (LED) mask
48001912|NCT00178191|OTHER|Bladder diary|3-day bladder diary
48001913|NCT00178191|OTHER|Questionnaires|Incontinence Quality of Life questionnaires
48001914|NCT00178191|PROCEDURE|Urodynamics|Urodynamics
48001915|NCT00178191|OTHER|Pad weight|Pad weight
48001916|NCT05372692|DRUG|mesothelin-specific chimeric antigen receptor T cell injection|Autologous T cell injection
48367058|NCT00617942|DRUG|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
48367059|NCT00617942|DRUG|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
48367060|NCT05414422|DRUG|PCN-101|Concentrate for solution for infusion
48367061|NCT05414422|DRUG|Placebo|Concentrate for solution for infusion
48367062|NCT05356637|DEVICE|Werewolf Fastseal 6.0|bi-polar hemostatic wand
48367063|NCT03121625|BIOLOGICAL|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
48618205|NCT02346318|DRUG|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
48687234|NCT04198766|DRUG|Cisplatin 75mg/m2|cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
48687235|NCT04198766|DRUG|Paclitaxel 200mg/m2|paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
48687236|NCT04198766|DRUG|Nab paclitaxel 100mg/m2|Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
48687237|NCT04303013|BEHAVIORAL|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
48001917|NCT02385799|DRUG|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
48001918|NCT02385799|DRUG|Sertraline|Active medication
48001919|NCT01325779|DRUG|heparin|subcutaneous heparin 5000 units every 8 hours
48001920|NCT01325779|DRUG|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
48001921|NCT02680821|PROCEDURE|ALL reconstruction (Anterolateral ligament)|
48001922|NCT02680821|PROCEDURE|ACL revision (Anterior cruciate ligament )|
48001923|NCT05092555|DIAGNOSTIC_TEST|Nasopharyngeal swap for Reverse transcription polymerase chain reaction|Nasopharyngeal swap and Blood sample is taken for doing previous tests and CT chest is done for all patients
48001924|NCT04988256|DRUG|Cyclosporine|"Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description"
48001925|NCT04988256|DRUG|Methylprednisolone and Prednisone|All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
48001926|NCT00987116|DRUG|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
48001927|NCT06162286|DRUG|Omadacycline|Omadacycline IV/PO
48001928|NCT06162286|DRUG|Moxifloxacin|Moxifloxacin IV/PO
48001929|NCT04287738|BEHAVIORAL|Navigated Care|Telephone-based collaborative dementia care was delivered by a trained care team navigator, who provided education, support and care coordination with a team of dementia specialists (advanced practice nurse, social worker, and pharmacist). For more details, please see references below.
48618206|NCT04381715|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
48687238|NCT04303013|OTHER|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
48687239|NCT01270880|DRUG|Hsp90 inhibitor STA-9090|Given IV
48687240|NCT01270880|OTHER|laboratory biomarker analysis|Correlative studies
48687241|NCT01270880|GENETIC|polymerase chain reaction|Correlative studies
48687242|NCT01270880|OTHER|enzyme-linked immunosorbent assay|Correlative studies
48687243|NCT01270880|GENETIC|RNA analysis|Correlative studies
48687244|NCT01270880|OTHER|spectrophotometry|Correlative studies
48687245|NCT01270880|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
48687246|NCT01270880|GENETIC|gene expression analysis|Correlative studies
48687247|NCT04560816|DRUG|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
48687248|NCT04560816|DRUG|Placebo|Placebo will be administered orally.
48687249|NCT04560816|DRUG|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
48687250|NCT01798901|DRUG|HDAC inhibitor AR-42|Given PO
48687251|NCT01798901|DRUG|decitabine|Given IV
48687252|NCT01798901|OTHER|laboratory biomarker analysis|Correlative studies
48687253|NCT01798901|OTHER|pharmacological study|Correlative studies
48367064|NCT02528461|DRUG|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
48367065|NCT02528461|PROCEDURE|Gastroscopy|
48001930|NCT01063595|BIOLOGICAL|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
48687254|NCT01144416|BIOLOGICAL|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
48159106|NCT05534451|BEHAVIORAL|video fiberoptic scope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be randomly divided into video fiberoptic scope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
48001931|NCT01063595|BIOLOGICAL|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
48159107|NCT04174378|DRUG|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
48367066|NCT02528461|PROCEDURE|Liver biopsy|
48367067|NCT02528461|PROCEDURE|Fibroscan|
48001932|NCT03365596|OTHER|Conventional therapy|According to the status of a patient, optimized therapy will be applied.
48159108|NCT01007721|DRUG|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
48159109|NCT01007721|DRUG|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
48159110|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
48159111|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
48159112|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
48159113|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
48159114|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
48367068|NCT02528461|PROCEDURE|Liver vein catheterization|
48367069|NCT02528461|DRUG|Sofosbuvir|
48367070|NCT02533011|OTHER|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
48367071|NCT02238392|PROCEDURE|Adenosine test|Testing dormant conduction after PVI
48367072|NCT02238392|PROCEDURE|Termination of AF|Testing AF iducibility and ermination of
48367073|NCT01461018|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
48367074|NCT02450656|DRUG|Afatinib|Tablet
48367075|NCT02450656|DRUG|Selumetinib|Capsule
48367076|NCT02450656|DRUG|Docetaxel|
48367077|NCT04613076|BEHAVIORAL|"Me cuido y me siento mejor"|A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
48367078|NCT04613076|BEHAVIORAL|Enhanced Usual Treatment|Enhanced Usual Treatment
48367079|NCT04710628|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
48687255|NCT01144416|BIOLOGICAL|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
48687256|NCT01144416|DRUG|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
48687257|NCT01144416|DRUG|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
48687258|NCT04356846|DRUG|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
48687259|NCT04678362|DRUG|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
48367080|NCT04710628|DRUG|Lenvatinib 10 mg|Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
48687260|NCT03835182|DEVICE|Ultrasound group|Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
48687261|NCT03835182|DEVICE|Short wave diathermy group|SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
48687262|NCT03835182|OTHER|Control group|superficial heat, analgesic physical modality and exercise only
48001933|NCT01814306|DEVICE|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
48001934|NCT01814306|DEVICE|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
48001935|NCT05972538|DEVICE|Osstell ( Osstell AB, Goteborg, Sweden).|Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery
48001936|NCT05972538|DEVICE|periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein|Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery
48001937|NCT05972538|OTHER|questionnaire for patient satisfaction|A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
48001938|NCT03240133|DRUG|BCX7353|oral liquid formulation
48001939|NCT03240133|DRUG|Placebo|oral liquid formulation to match BCX7353
48001940|NCT05812014|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
48001941|NCT05812014|DRUG|0.9% sodium chloride solution|One dose was administered by intramuscular injection, 1.0ml/dose
48001942|NCT01200797|DRUG|SJG-136|Given IV
48001943|NCT01200797|OTHER|laboratory biomarker analysis|Correlative studies
48687263|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
48001944|NCT00666757|DRUG|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
48001945|NCT00666757|DRUG|fluoxetine|20-80 mgs orally daily for 12 weeks
48159115|NCT01007721|DRUG|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
48159116|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
48687264|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
48687265|NCT06091293|BEHAVIORAL|Narrative Intervention for Long COVID-19 (NICO)|The NICO intervention was delivered by a licensed psychotherapist asynchronously over a 3 month time period.
48687266|NCT03798639|BIOLOGICAL|Ipilimumab|Given IV
48687267|NCT03798639|BIOLOGICAL|Nivolumab|Given IV
48687268|NCT03798639|RADIATION|Radiation Therapy|Receive radiation therapy
48687269|NCT05447390|DIAGNOSTIC_TEST|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
48001946|NCT00666757|DRUG|citalopram|20-40 mgs orally daily for 12 weeks
48001947|NCT00666757|DRUG|paroxetine|20-50 mgs orally daily for 12 weeks
48159117|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
48367081|NCT06157970|PROCEDURE|Sphenopalatine Ganglion Block|For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
48687270|NCT01251718|DRUG|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
48687271|NCT05663177|DRUG|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
48687272|NCT04589572|PROCEDURE|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
48001948|NCT00666757|DRUG|sertraline|50-200 mgs orally daily for 12 weeks
48001949|NCT05203263|DEVICE|(810A-v1) device prototype|Sequence with Serial Number from (810-v1 101) to (810-v1 140). Application on brown spots located on the face (6 treatments during the study).
48001950|NCT05203263|DEVICE|(810B-v1) device prototype|Sequence with Serial Number (810-v1 141) to (810-v1 160). Application on brown spots located on the face (6 treatments during the study).
48001951|NCT05203263|DEVICE|(810C-v1) device prototype|Sequence with Serial Number (810-v1 161) to (810-v1 200). Application on brown spots located on the face (6 treatments during the study).
48001952|NCT05281614|DRUG|Etanercept|Etanercept is a fully humanized monoclonal antibody that targets TNFα.
48001953|NCT05281614|DRUG|Vedolizumab|Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
48001954|NCT01516957|DRUG|AMG 827 140|140 mg AMG 827 SC (subcutaneous)
48001955|NCT01516957|DRUG|Placebo|Placebo SC (subcutaneous)
48001956|NCT01516957|DRUG|AMG 827 280|280 mg AMG 827 SC (subcutaneous)
48001957|NCT01516957|DRUG|AMG 827 210|210 mg AMG 827 SC (subcutaneous)
48159118|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
48159119|NCT01007721|DRUG|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
48159120|NCT01007721|DRUG|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
48367082|NCT06421727|OTHER|Rehabilitation by optokinetic stimulation and virtual reality exercises .|Rehabilitation by optokinetic stimulation and virtual reality exercises(by deviceVirtual reality system(Meta Quest 2_Advanced All-In-One Virtual Reality Headset_ 128 GB)).
48367083|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg， KN046 5mg/Kg
48367084|NCT04984668|DRUG|GT90001+KN046|GT90001 7.0mg/Kg ， KN046 3mg/Kg
48367085|NCT04984668|DRUG|GT90001/KN046|GT90001 4.5mg/Kg / KN046 5mg/Kg
48001958|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
48001959|NCT02102633|DRUG|Bosutinib|Bosutinib 500 mg orally
48001960|NCT02102633|DRUG|Dabigatran|Dabigatran 150 mg orally
48001961|NCT04413578|DEVICE|Dexcom G6|Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
48367086|NCT04984668|DRUG|GT90001+KN046|GT90001 4.5mg/Kg， KN046 3mg/Kg
48367087|NCT04984668|DRUG|GT90001+KN046|GT90001 3mg/Kg ， KN046 3mg/Kg
48367088|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
48367089|NCT01475214|DIETARY_SUPPLEMENT|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
48367090|NCT01475214|OTHER|Inactive placebo capsule|microcrystalline cellulose
48367091|NCT05814965|PROCEDURE|endodontic treatment in the form of root canal treatment|Patients will receive endodontic treatment, and inflammatory markers will be assessed
48367092|NCT05814965|PROCEDURE|endodontic treatment|Patients will receive endodontic treatment in the form of root canal treatment, and inflammatory markers will be assessed along with metabolic markers assessment
48001962|NCT04413578|DEVICE|Contour NextOne|A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
48001963|NCT00733109|PROCEDURE|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
48001964|NCT00733109|OTHER|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
48367093|NCT05814965|DIAGNOSTIC_TEST|assessment of inflammatory marker|assessment of inflammatory markers
48367094|NCT05814965|DIAGNOSTIC_TEST|inflammatory markers will be assessed along with metabolic markers assessment|inflammatory markers will be assessed along with metabolic markers assessment
48367095|NCT04926129|OTHER|Other: Assessments|Administered as specified in the treatment arm.
48367096|NCT05943548|BEHAVIORAL|Omuyambi|HIV testing, referral, care linkage, and medication adherence support
48687273|NCT04589572|PROCEDURE|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
48001965|NCT03034785|DEVICE|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
48001966|NCT06190808|DIAGNOSTIC_TEST|Dexcom G7 Continuous Glucose Monitor|Continuous glucose monitor
48001967|NCT05804383|DRUG|BMS-984923|Capsules
48001968|NCT05804383|DRUG|Placebo|Capsules
48001969|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
48367097|NCT05943548|BEHAVIORAL|Control|HIV Testing and referral
48367098|NCT03822390|DEVICE|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
48367099|NCT04043676|DRUG|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
48001970|NCT01485315|BIOLOGICAL|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
48001971|NCT05504629|BEHAVIORAL|Concurrent training order 1|atag
48001972|NCT05504629|BEHAVIORAL|RT+ET|aetaer
48001973|NCT02221310|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning
48001974|NCT02619890|OTHER|Brain Glioma Registry|
48001975|NCT02975921|DRUG|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
48367100|NCT03564691|DRUG|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
48367101|NCT03564691|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV Q3W.
48367102|NCT03564691|DRUG|Carboplatin|Carboplatin will be administered IV Q3W.
48367103|NCT03564691|DRUG|Pemetrexed|Pemetrexed will be administered IV Q3W.
48687274|NCT05976568|DRUG|QL1706|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
48159121|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
48159122|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
48159123|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
48367104|NCT03564691|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily.
48687275|NCT05976568|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
48687276|NCT05976568|DRUG|Oxaliplatin injection|85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
48687277|NCT05976568|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
48687278|NCT05976568|DRUG|Sintilimab|200 mg administered as IV infusion on Day 1 of each 21-day cycle
48687279|NCT01282242|DRUG|IV rt-PA|open-label
48001976|NCT03214627|DEVICE|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
48001977|NCT03214627|DRUG|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
48001978|NCT03214627|DRUG|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
48001979|NCT03146988|DRUG|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
48001980|NCT06496841|DRUG|Transnasal Sphenopalatine ganglion block|The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.
48001981|NCT06496841|DRUG|Ultrasound-guided suprazygomatic sphenopalatine ganglion block|The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
48001982|NCT00265473|BIOLOGICAL|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
48687280|NCT00407615|DEVICE|Flex Pad/Static Magnet|
48687281|NCT03377595|DRUG|Exparel|TAP (Transversus Abdominis Plane) block
48001983|NCT02121587|BEHAVIORAL|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
48159124|NCT01007721|DRUG|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
48159125|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
48159126|NCT01007721|DRUG|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
48367105|NCT03564691|DRUG|Paclitaxel|Paclitaxel will be administered IV QW on Days 1, 8, and 15 of each 21-day cycle until disease progression or prohibitive toxicity (Arm J) and on Days 1, 8, and 15 Q4W until disease progression or prohibitive toxicity (Arm K).
48159127|NCT01007721|DRUG|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
48367106|NCT03564691|DRUG|Cisplatin|Cisplatin will be administered IV Q3W.
48367107|NCT03564691|BIOLOGICAL|MK-4830A|MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.
48367108|NCT03547674|OTHER|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
48367109|NCT03547674|OTHER|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
48367110|NCT03547674|OTHER|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
48367111|NCT03547674|OTHER|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
48367112|NCT00689611|DRUG|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
48367113|NCT00689611|DRUG|Placebo|Placebo
48367114|NCT04196010|DRUG|Cladribine|Given IV
48367115|NCT04196010|DRUG|Cytarabine|Given IV
48367116|NCT04196010|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given subcutaneously
48367117|NCT04196010|DRUG|Mitoxantrone|Given IV
48367118|NCT05994105|BEHAVIORAL|Art based Augmented Reality|The participants will be provided 14 sessions management plan
48367119|NCT02332616|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
48367120|NCT02332616|DRUG|Isotonic Sodium Chloride|Placebo
48159128|NCT02612116|DRUG|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
48159129|NCT02612116|DRUG|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
48159130|NCT02612116|DRUG|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
48687282|NCT03377595|DRUG|Exparel|Wound infiltration
48159131|NCT00276016|DRUG|phenylephrine|immediate-release 12 mg capsules for oral administration
48159132|NCT00276016|DRUG|pseudoephedrine|60 mg immediate-release tablets for oral administration
48159133|NCT00276016|DRUG|placebo|placebo capsules
48159134|NCT06093971|DRUG|remimazolam|Remimazolam is administered for anesthesia induction.
48687283|NCT03282344|DRUG|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
48687284|NCT03282344|DRUG|Nivolumab|360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
48687285|NCT06368284|PROCEDURE|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident between January 2017 and December 2023, managed and followed up in France
48001984|NCT03978364|DRUG|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
48001985|NCT03978364|DRUG|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
48001986|NCT01867593|DEVICE|C-11 methionine PET|
48159135|NCT06093971|DRUG|Propofol|Propofol is administered for anesthesia induction.
48159136|NCT03967093|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
48159137|NCT00521807|PROCEDURE|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
48159138|NCT06190145|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.
48159139|NCT00574301|PROCEDURE|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
48159140|NCT01190228|BIOLOGICAL|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
48687286|NCT01491061|DRUG|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
48687287|NCT01491061|DRUG|Placebo|os, two doses 12 hours apart prior to PCI
48687288|NCT01925768|DRUG|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
48001987|NCT02956733|PROCEDURE|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
48001988|NCT02956733|PROCEDURE|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
48687289|NCT01925768|DRUG|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
48687290|NCT01131806|DRUG|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
48687291|NCT01131806|DRUG|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
48687292|NCT00920361|DRUG|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
48001989|NCT03190070|DIETARY_SUPPLEMENT|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
48001990|NCT00260754|BEHAVIORAL|Community-Popular Opinion Leader Model|
48001991|NCT00260754|BEHAVIORAL|Diffusion of Innovations|
48001992|NCT03768115|DRUG|Autologous Plasma Eye Drop|Autologous plasma crimped segments
48159141|NCT01190228|BIOLOGICAL|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
48159142|NCT00113009|DRUG|VLTS-934|
48159143|NCT05168826|DEVICE|SAPIEN 3 Transcatheter Heart Valve|Implantation of the SAPIEN 3 valve
48159144|NCT00001623|PROCEDURE|Allogeneic Bone Marrow Transplant|
48159145|NCT05578976|DRUG|Epcoritamab|Subcutaneous Injection (SC)
48159146|NCT05578976|DRUG|Cyclophosphamide|Intravenous (IV) Injection
48159147|NCT05578976|DRUG|Rituximab|IV Infusion
48159148|NCT05578976|DRUG|Vincristine|IV Infusion
48159149|NCT05578976|DRUG|Doxorubicin|IV Infusion
48687293|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
48687294|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
48687295|NCT03388216|BIOLOGICAL|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
48001993|NCT02279186|DRUG|Tranexamic Acid|Intravenous Injection
48001994|NCT03149250|DIAGNOSTIC_TEST|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
48159150|NCT05578976|DRUG|Prednisone|Oral; Tablet
48159151|NCT02646644|OTHER|Metastasized intestinal NET|This is an observational study
48159152|NCT02413502|BIOLOGICAL|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10\^8 CFUs.
48159153|NCT00464217|DRUG|ARA-C|
48159154|NCT00464217|DRUG|Idarubicin|
48159155|NCT00464217|DRUG|Leucomax|
48159156|NCT01003379|DRUG|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
48687296|NCT03388216|OTHER|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
48001995|NCT01520129|OTHER|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
48001996|NCT00464828|PROCEDURE|Internal jugular vein cannulation|
48159157|NCT01003379|DRUG|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
48159158|NCT01874717|OTHER|Conscious sedation for dental care|
48159159|NCT01874717|DRUG|midazolam|
48159160|NCT05414071|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
48159161|NCT02133066|PROCEDURE|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
48159162|NCT02133066|DEVICE|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
48159163|NCT02133066|PROCEDURE|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
48159164|NCT06021834|OTHER|rehabilitation|The subjects will be invited to attend the program three times per week.
48687297|NCT02308592|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
48159165|NCT03282071|BEHAVIORAL|Joyful Parenting Intervention|"* Two-session interactive talks for parents to promote praise \& appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
48159166|NCT02001649|GENETIC|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
48159167|NCT02001649|GENETIC|SNP genotyping|
48159168|NCT01579461|DRUG|mirabegron|oral
48159169|NCT06288750|DEVICE|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
48159170|NCT06288750|DEVICE|No indocyanine green|Conventional means of identification and assessment of PGs are mainly based on surgeon-dependent identification of their anatomical location and appearance (color, shape, etc.) by the naked eye.
48159171|NCT02916745|DRUG|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
48159172|NCT02916745|DEVICE|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
48159173|NCT01818245|DRUG|LY2605541|
48001997|NCT00464828|DEVICE|ultrasound|
48001998|NCT06407466|OTHER|taping|"Kinesiology taping; In order to facilitate the muscle, while the subject is standing and his body is flexed to ensure hip flexion, both I bands will be applied from the origin to the insertion, with 30% stretching from the medial and lateral, starting from the Ischial Tuberositas to the border of the Popliteal Fossa."
48001999|NCT06407466|OTHER|Control|The routine training program will continue without intervention.
48159174|NCT04458376|BEHAVIORAL|Internet-based self-help program|The program is divided into six short weekly lessons providing information about chronic dizziness and vestibular rehabilitation, and demonstrating the exercises by video. The program is freely available in the Norwegian electronic handbook for physicians (NEL). The participants in the study will receive the internet address after inclusion in the study.
48002000|NCT06407466|OTHER|mobilization|Instrument-assisted soft tissue mobilization; The subject is in a prone position on a bed, with the lower extremity in a neutral position, and a hazelnut-sized amount of lubricant will be applied to the working surface, and will be applied to the skin on the back of the upper leg for 5 minutes, targeting the tissue structures. (Hamstring and deep fascia covering this muscle) Pressure and speed will be adjusted according to the subject's tolerance so as not to cause pain.
48002001|NCT05754606|DIAGNOSTIC_TEST|Audio recordings|Automatica analysis of audio recordings
48002002|NCT00394212|DEVICE|Transoral Suturing|suturing of anastomosis
48002003|NCT00394212|OTHER|Sham Endoscopy|suturing not performed
48159175|NCT04397822|BIOLOGICAL|Blood samples|Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers
48159176|NCT03749616|DRUG|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
48159177|NCT03749616|DRUG|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
48002004|NCT03189628|BIOLOGICAL|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
48002005|NCT03189628|DRUG|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
48002006|NCT00150046|DRUG|Everolimus|
48002007|NCT02995785|OTHER|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
48002008|NCT02995785|OTHER|traditional training|traditional training:Give TMS online lecture(15-min).
48002009|NCT06443762|DRUG|[68Ga] MDM2/MDMX Peptide|"Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic efficacy of \[68Ga\] MDM2/MDMX Peptide in patients with malignant tumors exhibiting high MDM2/MDMX expression. This approach not only provides a basis for the early diagnosis of malignant tumors but also facilitates the formulation of effective precision therapy strategies tailored to the tumor's MDM2/MDMX expression profile, particularly for patients with recurrent and metastatic disease.~\[68Ga\] MDM2/MDMX Peptide, a novel MDM2/MDMX-targeted molecular probe labeled with 68Ga, utilizes DOTA as a bifunctional chelator for complexing with 68Ga3+. The labeling process is straightforward, allowing for direct use without purification, and demonstrates high in vivo stability."
48002010|NCT00322010|PROCEDURE|early PT OT|"1. Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~2. Sessions began with active assisted and active range of motion exercises in the supine position.~3. If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~4. Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. The session progresses to transfer training, and finally pre-gait exercises and ambulation.~6. Progression of activities is dependent on patient tolerance and stability.~7. Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
48002011|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
48159178|NCT00888394|PROCEDURE|chiropody|basic procedure of chiropody in podiatry
48159179|NCT00888394|PROCEDURE|basic orthesis|individual basic orthesis of foot
48159180|NCT00888394|PROCEDURE|advantage orthesis|advantage orthesis of foot with special material and design
48159181|NCT00888394|PROCEDURE|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
48159182|NCT01973179|RADIATION|Radiation therapy|Radiation therapy with protons
48159183|NCT06423976|OTHER|Sequencing study|Sequencing of tumour samples for microbiome analysis and molecular charcterisation.
48159184|NCT02266589|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
48159185|NCT04242342|RADIATION|Adaptative MR-Guided Stereotactic Body Radiotherapy|"If lesion near organs at risk:~* Prescription of 50 Gy in 5 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~* Prescription of 60 Gy in 6 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment"
48002012|NCT01748253|DRUG|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
48002013|NCT02150564|DEVICE|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
48002014|NCT02150564|PROCEDURE|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
48002015|NCT01649375|DRUG|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
48159186|NCT02446912|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
48367121|NCT04717505|OTHER|Gait Assessments|"10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device."
48002016|NCT01649375|DRUG|Placebo|Placebo
48002017|NCT01649375|DRUG|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
48002018|NCT02400723|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
48002019|NCT02400723|BEHAVIORAL|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
48159187|NCT02446912|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
48159188|NCT00016978|DRUG|FOLFOX regimen|
48159189|NCT00016978|DRUG|fluorouracil|
48159190|NCT00016978|DRUG|leucovorin calcium|
48159191|NCT00016978|DRUG|oxaliplatin|
48002020|NCT02400723|OTHER|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
48002021|NCT05645822|OTHER|Screen&treat|Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
48002022|NCT04537728|BEHAVIORAL|My Healthy Brain Version 2|multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors
48159192|NCT05805033|OTHER|Mucointegration|Placement of abutment on a dental implant to study mucointegration
48367122|NCT04717505|OTHER|Arthritis Impact Measurement Scales 2|It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
48159193|NCT05763121|DRUG|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
48159194|NCT05763121|DRUG|Placebo|oral administration of placebo tablet
48159195|NCT02939859|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
48159196|NCT02939859|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
48159197|NCT02939859|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
48159198|NCT00961597|PROCEDURE|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
48159199|NCT00961597|PROCEDURE|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
48159200|NCT02211508|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
48159201|NCT05166785|OTHER|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
48159202|NCT05166785|OTHER|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
48159203|NCT03936309|OTHER|Scar Deactivation Surface Release Technique protocol|▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
48367123|NCT04717505|OTHER|Visual Analogue Scale|The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
48367124|NCT04717505|OTHER|Standardized Mini Mental Test|Although the test has limited specificity in terms of differentiating clinical syndromes, it is a short, useful and standardized method that can be used to determine the cognitive level globally.
48367125|NCT05136612|OTHER|conventional physiothrapy|Conventional physiotherapy program will be applied to the control group for 6 weeks, 3 days a week, 45 minutes a day. Strengthening, dynamic stretching, coordination and balance exercises and functional exercises for upper and lower extremities will be applied in this treatment program.
48002023|NCT04081948|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
48687298|NCT02308592|BEHAVIORAL|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
48159204|NCT03936309|OTHER|Scar Infiltration with 0.25-1% Lidocaine|▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
48159205|NCT03936309|OTHER|Physical therapy|▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
48687299|NCT03073811|DIETARY_SUPPLEMENT|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
48687300|NCT03073811|OTHER|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
48687301|NCT05310123|DIETARY_SUPPLEMENT|AC-11|6-months of treatment with AC-11
48159206|NCT05271799|DRUG|Gepotidacin|Gepotidacin will be administered
48159207|NCT02826759|OTHER|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
48159208|NCT04488809|OTHER|Exercise|Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
48159209|NCT02511847|DRUG|Afatinib|"1. Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~2. Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
48159210|NCT03713437|DIAGNOSTIC_TEST|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
48266840|NCT03337256|DIAGNOSTIC_TEST|GI bleeding score|"Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~* 75 2.5 Haemoglobin(g/L)~* 10.0 0 \<9.9 2 Systolic blood pressure (mmHg)~* 110 0 90-109 1.5 \<90 2.5 Pulse (beats per min) \<100 0~* 100 1.5 Creatinine (mmol/L) \<200 0~* 200 3.5 Number of blood transfusion 0 0~  1 1.5~* 2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5"
48687302|NCT05006989|OTHER|Blueberry Powder|Administered 10 grams/day
48687303|NCT05006989|OTHER|Placebo Powder|Administered 10 grams/day
48687304|NCT05075018|OTHER|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
48687305|NCT00352469|DRUG|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
48687306|NCT05965076|PROCEDURE|Glycine Perio Flow|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.
48367126|NCT05136612|OTHER|robotic rehabilitation|The study group will be included in the rehabilitation program with the Hocoma brand Armeo Spring pediatric upper extremity robot for 30 minutes a day, 3 days a week, for 6 weeks at hospital. Armeo spring robot enables the individual to perform active movement by carrying the weight of the upper extremity of children who have active movement in their upper extremities but do not have enough strength to overcome gravity with their upper extremities. The individual is actively involved in the study during the study. With the adjustments made, it becomes suitable for use for right and left extremities. In the process of working; The games named High Flyer, Frisbee, Balloons, Goalkepper, Save the Monster, Fishing, Helicopter Rescue, which are included in the Armeo Spring robot and created to increase shoulder, elbow and wrist movements, will be used.
48687307|NCT05965076|BEHAVIORAL|Angled Toothbrush|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.
48002024|NCT04081948|OTHER|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
48002025|NCT00489853|DRUG|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
48002026|NCT00489853|DRUG|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
48002027|NCT00489853|OTHER|Placebo|Placebo, 1 inhalation twice daily
48002028|NCT00803881|OTHER|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
48002029|NCT03657888|BEHAVIORAL|Family Club Denmark (FCD)|Participation in Family Club Denmark
48687308|NCT05965076|PROCEDURE|Standard Professional Oral Hygiene|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.
48159211|NCT02883140|OTHER|Three-dimensional sialography CBCT and MRI sialography|"1. MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~2. 3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
48159212|NCT01580735|DRUG|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
48159213|NCT03965481|RADIATION|Dynamic Enhanced CT|Undergo standard CECT
48159214|NCT03965481|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI scan
48687309|NCT05965076|BEHAVIORAL|Standard Domiciliary Oral Hygiene|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
48687310|NCT02236325|BEHAVIORAL|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
48687311|NCT02236325|BEHAVIORAL|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
48687312|NCT05441215|DRUG|nirmatrelvir|nirmatrelvir/ritonavir
48002030|NCT03657888|OTHER|Wait-list control|Participants on the waiting list
48159215|NCT03965481|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI scan
48159216|NCT00449033|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
48687313|NCT05441215|DRUG|ritonavir|nirmatrelvir/ritonavir
48687314|NCT04802031|BIOLOGICAL|Rapid Infusion Isatuximab|Given IV
48687315|NCT01047137|BEHAVIORAL|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
48687316|NCT01047137|BEHAVIORAL|General Supportive Therapy|There is no focus on stress intervention.
48687317|NCT00589706|DRUG|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
48002031|NCT01997268|DRUG|Placebo|Corn Oil
48002032|NCT01997268|DRUG|SC401B 2 capsules|
48002033|NCT01997268|DRUG|SC401B 4 capsules|
48002034|NCT01997268|DRUG|SC401B 6 capsules|
48002035|NCT00909948|OTHER|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
48002036|NCT00909948|RADIATION|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
48002037|NCT01165866|DRUG|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
48002038|NCT01165866|DRUG|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
48002039|NCT01663415|DRUG|Enzalutamide|oral
48002040|NCT02549508|DEVICE|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
48002041|NCT02549508|DEVICE|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
48367127|NCT03164291|DRUG|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
48002042|NCT04306809|BEHAVIORAL|Internet-delivered ACT for PTSD and chronic pain|The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
48002043|NCT04342104|OTHER|Monitoring for aggravation|"Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely:~* lymphopenia~* thrombocytopenia~* CRP~* ferritin~* LDH~* troponin I~* NT-ProBNP~* Liver enzymes~* D-dimers~* radiologic aggravation  1 day and 1 week after starting NIV or CPAP"
48002044|NCT04342104|OTHER|Evaluate HACOR score effectivity in this patients|Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure
48002045|NCT06456281|DIAGNOSTIC_TEST|A noninvasive cfDNA multi-omics assay|Peripheral venous blood samples will be collected from pancreatic cancer patients, individuals with precancerous lesions, and healthy controls. Subsequently, cfDNA will be extracted and subjected to low-pass whole genome sequencing (LP-WGS) and hybrid capture-based targeted methylation sequencing (TMS).
48002046|NCT00017706|BEHAVIORAL|physician-delivered weight control|
48002047|NCT05926167|DIAGNOSTIC_TEST|blood tests drawn days 1, 8, 22 and 90 of the study|Blood tests related to Factor VIII activity that are not a part of standard of care
48002048|NCT05539365|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given IT
48159217|NCT00449033|DRUG|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
48159218|NCT00449033|DRUG|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV
48159219|NCT00449033|DRUG|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m\^2 IV
48159220|NCT03999710|RADIATION|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
48159221|NCT03999710|DRUG|Durvalumab|A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
48367128|NCT05937373|DEVICE|Continuous Glucose monitor|Perioperative glucose management beginning preoperative through postoperative monitoring
48367129|NCT05937373|OTHER|Standard of Care|no study intervention. participant follows current medical providers recommendations for glucose management
48367130|NCT00431132|DRUG|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
48367131|NCT06326138|DRUG|Edoxaban Pharmacokinetics and Pharmacodynamics|Participants will be received single oral doses of edoxaban 60 mg.
48687318|NCT06243328|DEVICE|negative wound pressure therapy|nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
48002049|NCT05539365|PROCEDURE|Biopsy|Undergo biopsy
48367132|NCT05785559|PROCEDURE|uterine biopsies|uterine biopsies performed on the areas of cesarean section scars
48367133|NCT02605720|DRUG|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
48367134|NCT04146259|DRUG|calcium carbonate and alphacalcidol|treatment for hypocalcemia
48367135|NCT02506673|DEVICE|Zeiss, Cinema ProMED (audiovisual equipment)|
48002050|NCT05539365|PROCEDURE|Computed Tomography|Undergo CT scan
48002051|NCT05539365|PROCEDURE|Leukapheresis|Undergo leukapheresis
48002052|NCT05539365|BIOLOGICAL|Pembrolizumab|Given IV
48159222|NCT04399798|DRUG|Baricitinib|4 mg/day for 7 days
48159223|NCT03987672|DIETARY_SUPPLEMENT|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
48159224|NCT03997409|OTHER|Dietary Intervention|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
48159225|NCT00575900|BEHAVIORAL|dietary intervention|12 weeks of dietary intervention
48159226|NCT03314116|OTHER|Guidance on auditory protection|by video or medic
48159227|NCT05377827|BIOLOGICAL|WU-CART-007|Provided by Miltenyi Biotec
48367136|NCT02506673|DRUG|Midazolam|
48367137|NCT02506673|DEVICE|Skin Conductance Monitor|
48367138|NCT00902122|DRUG|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
48367139|NCT00902122|PROCEDURE|surgery|removal of thyroid tumor
48367140|NCT00902122|DRUG|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
48367141|NCT00902122|RADIATION|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
48367142|NCT03060109|OTHER|Blood draw within 12 hours of injury|
48367143|NCT03604016|DRUG|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
48367144|NCT03604016|DRUG|L-carnitine|Besifovir dipivoxil 150 mg
48367145|NCT03604016|DRUG|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
48687319|NCT02871349|DRUG|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
48002053|NCT05539365|OTHER|Quality-of-Life Assessment|Ancillary studies
48002054|NCT03442738|PROCEDURE|Endocuff group|Endocuff Vision cap on Standard colonoscope
48159228|NCT01502605|DRUG|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
48159229|NCT04727242|DRUG|Gemcitabine|Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.
48367146|NCT04774029|PROCEDURE|Basivertebral nerve block|Temporary intraosseous basivertebral nerve block using lidocaine
48367147|NCT04774029|DRUG|Lidocaine induced basivertebral nerve block|Intraosseous lidocaine basivertebral nerve block
48367148|NCT02492321|DRUG|EBI-005|
48687320|NCT02871349|DRUG|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
48687321|NCT02871349|DEVICE|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
48687322|NCT04401150|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
48687323|NCT04401150|DRUG|Control|Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
48687324|NCT03666520|OTHER|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
48687325|NCT04475419|PROCEDURE|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)|covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
48687326|NCT04501601|DIETARY_SUPPLEMENT|Fruit and vegetable solid drink|weight loss program supplement
48687327|NCT00269750|DRUG|OROS® oxybutynin or Ditropan®|
48687328|NCT02096250|OTHER|NaFeEDTA|
48687329|NCT02096250|OTHER|Ferrous fumarate|
48002055|NCT03496688|PROCEDURE|Sinus floor augmentation|
48002056|NCT02027844|BEHAVIORAL|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
48002057|NCT02027844|BEHAVIORAL|parental presence|parental presence during inhalational induction of sevoflurane
48002058|NCT05888168|PROCEDURE|CABG|All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
48002059|NCT05325567|PROCEDURE|Mini open incision CTR|two techniques commonly used for carpal tunnel release are being compared to determine if one vs. the other provides superior patient outcomes.
48002060|NCT02283112|OTHER|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
48002061|NCT02789176|OTHER|Surveys|Regarding development, epilepsy, and family impact
48002062|NCT02789176|OTHER|EEG|
48002063|NCT05082077|DEVICE|LIVERguard|The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
48002064|NCT05546684|OTHER|footbath|footbath for patients before sleeping
48002065|NCT01750580|DRUG|Lirilumab|
48002066|NCT01750580|DRUG|Ipilimumab|
48002067|NCT05278429|DEVICE|Myosuit robotic device|The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
48002068|NCT05225103|BEHAVIORAL|SAFETY-Acute intervention|The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
48159230|NCT04727242|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV
48159231|NCT04727242|PROCEDURE|Cytoreductive Surgery|Surgery for cancer removal
48159232|NCT04727242|BEHAVIORAL|Functional Assessment of Cancer Therapy (FACT) G questionnaire|Preoperative and Postoperative FACT G questionnaire to assess QoL
48159233|NCT04727242|PROCEDURE|Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan|Radiologic imaging after Cycle 3 and 6 and at each follow up visit
48159234|NCT04727242|DRUG|Gadolinium|Contrast Agent
48159235|NCT00213226|DRUG|dexamethasone|
48367149|NCT02492321|DRUG|Placebo Comparator|
48367150|NCT05162534|OTHER|effect of COVID-19 exposure|effect of COVID-19 exposure
48687330|NCT02096250|OTHER|NaFeEDTA + ferrous fumarate|
48687331|NCT05027347|DIAGNOSTIC_TEST|plasma circulating tumor DNA|A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
48687332|NCT02400970|OTHER|malignant cells|
48687333|NCT05442723|PROCEDURE|On-Pump CABG|coronary artery grafting by using cardiopulmonary bypass machine
48687334|NCT05442723|PROCEDURE|Off-Pump CABG|coronary artery grafting by beating heart technique
48687335|NCT00513084|BEHAVIORAL|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
48687336|NCT01014936|DRUG|MSC2156119J|
48687337|NCT06353633|DIETARY_SUPPLEMENT|formula|The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet
48002069|NCT05273268|OTHER|Personalized nutrition|Personalized nutrition based on individual traits delivered through mobile device app.
48002070|NCT05273268|OTHER|Generalized nutrition|General nutrition guidelines currently used by USDA.
48002071|NCT04800003|DIAGNOSTIC_TEST|Gonial angle and submandibular fossa depth measurements from CBCT images|CBCT images were obtained from dry human mandibles
48002072|NCT01874262|DEVICE|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
48687338|NCT06353633|BEHAVIORAL|exclusion diet|In this group, only the elimination diet is considered as an intervention
48002073|NCT01874262|DEVICE|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
48002074|NCT03094754|PROCEDURE|nevi excision|After general anesthesia, nevi excision in children is performed.
48159236|NCT01314014|DRUG|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
48159237|NCT02612363|DRUG|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose"
48002075|NCT02806050|DRUG|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
48002076|NCT02806050|DEVICE|FES PET|all patients will have a FES PET at baseline
48002077|NCT02806050|DRUG|Letrozole|all patients will be treated with Letrozole daily until progression
48002078|NCT00903617|DRUG|GSK256073|5 mg for 8 weeks
48002079|NCT00903617|DRUG|GSK256073|50 mg for 8 weeks
48159238|NCT01304251|OTHER|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
48002080|NCT00903617|DRUG|GSK256073|150 mg for 8 weeks
48002081|NCT00903617|DRUG|Placebo|placebo for 8 weeks
48159239|NCT01304251|OTHER|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
48159240|NCT06192693|DRUG|Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution|"1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
48002082|NCT00903617|DRUG|Niaspan|1500 mg for 8 weeks
48002083|NCT00903617|DRUG|GSK256073|x mg for 8 weeks based from data from Part A
48002084|NCT00903617|DRUG|GSK256073|optional dose based on data from Part A
48159241|NCT06192693|DRUG|Capsulized placebo transfer containing dilution solution|"1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%."
48687339|NCT04299828|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the role of immune cells in coagulopathy.
48159242|NCT00255515|DRUG|Quetiapine fumarate|oral
48687340|NCT04920071|DEVICE|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
48002085|NCT00118807|DRUG|Amodiaquine plus artesunate (AQ/AS)|
48002086|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
48002087|NCT00118807|DRUG|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
48002088|NCT06269081|BEHAVIORAL|Supportive-Expressive Peer Social Support Group Intervention|The social support group intervention involves weekly virtual support group meetings for 8 consecutive weeks. The groups, facilitated by trained research staff, will last approximately 90 minutes each week and include 5-12 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Facilitators will encourage mutual support among group members, promote greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy.
48002089|NCT06269081|BEHAVIORAL|Individual Strengths-Based Case Management Intervention|The strengths-based case management (SBCM) intervention helps participants address the multiple structural barriers faced by rural older people living with HIV. This intervention, delivered by trained research staff, includes two 60-minute telephone- or video-based SBCM counseling sessions, with shorter follow-up sessions to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
48159243|NCT00255515|DRUG|conventional treatment for schizophrenia|various standard therapies
48687341|NCT05276336|PROCEDURE|Radiofrequency turbinate reduction|Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
48687342|NCT05276336|DRUG|Pharmacology treatment|Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
48687343|NCT05225077|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
48002090|NCT04738773|DRUG|Naltrexone|On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
48002091|NCT04738773|DRUG|Placebo|Placebo
48002092|NCT05393557|OTHER|Upfront preparation of microcirculation to minimize risks of no-reflow and reperfusion injury|Tirofiban (intra-coronary bolus of 25µg/Kg) + Nitroglycerin (intracoronary 100-200 µg) + Verapamil (intracoronary 100-200 µg, yet excluding patients with 2nd or 3rd degree AV block, HR \< 60, or SBP \<100 mmHg) + 2 cycles of intermittent balloon inflation
48159244|NCT01114217|DRUG|Ferumoxytol|IV Ferumoxytol
48159245|NCT02676739|DRUG|Adderall XR|
48159246|NCT03992599|PROCEDURE|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
48159247|NCT05409066|DRUG|Epcoritamab|Subcutaneous Injection
48159248|NCT05409066|DRUG|Rituximab|Intravenous Infusion
48367151|NCT04406155|PROCEDURE|3D-RWC-TVS with bowel preparation|"Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure."
48367152|NCT04406155|PROCEDURE|3D-RWC-TVS without bowel preparation|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
48002093|NCT01185795|DIETARY_SUPPLEMENT|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
48159249|NCT05409066|DRUG|Lenalidomide|Oral Capsules
48266841|NCT02298933|DRUG|Eculizumab|300 mg single-use vials
48266842|NCT02690623|OTHER|Pediatric hospitalist program|In-house hospitalists available at all hours
48367153|NCT02715089|GENETIC|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
48687344|NCT05311514|BIOLOGICAL|Allogeneic platelet lysate eye drops|Eye drops
48002094|NCT01185795|DIETARY_SUPPLEMENT|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
48687345|NCT05351840|DRUG|LivaloV|Treatment A, Tablet, Oral, QD for 7 Days
48687346|NCT05351840|DRUG|A|Treatment B, Tablet, Oral, QD for 10 Days
48687347|NCT05351840|DRUG|LivaloVA|Treatment C, Tablet, Oral, QD for 7 Days
48687348|NCT01320852|OTHER|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
48159250|NCT02578628|OTHER|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
48159251|NCT04719273|DRUG|Extended-release Onapristone|Given PO
48159252|NCT04719273|DRUG|Anastrozole|Given PO
48159253|NCT04719273|OTHER|Quality-of-Life Assessment|Ancillary studies
48159254|NCT04719273|OTHER|Questionnaire Administration|Ancillary studies
48159255|NCT04719273|DIAGNOSTIC_TEST|Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)|Immunohistochemistry (IHC):Integral : Tissue
48159256|NCT04719273|DIAGNOSTIC_TEST|Progesterone Receptor Positive ( PGR Positive; PR Positive)|Immunohistochemistry (IHC)
48159257|NCT02429037|DRUG|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
48159258|NCT02429037|RADIATION|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
48159259|NCT02429037|DRUG|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
48367154|NCT04896476|DEVICE|EchoMark|The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.
48367155|NCT05907031|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
48159260|NCT00003057|DRUG|loperamide hydrochloride|
48159261|NCT00003057|DRUG|octreotide acetate|
48159262|NCT03999398|PROCEDURE|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
48159263|NCT02481349|OTHER|Best Practice|Undergo standard of care
48159264|NCT02481349|OTHER|Informational Intervention|Receive DVD for home practice
48159265|NCT02481349|OTHER|Quality-of-Life Assessment|Ancillary studies
48367156|NCT05907031|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
48687349|NCT02231528|DEVICE|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
48687350|NCT02231528|DEVICE|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
48687351|NCT01819207|OTHER|blood test by thromboelastography|
48687352|NCT00613548|PROCEDURE|CABG alone|CABG alone
48687353|NCT00613548|PROCEDURE|CABG + Mitral repair|CABG + Mitral repair
48687354|NCT00661726|DRUG|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
48687355|NCT03409081|DRUG|gilteritinib|oral
48687356|NCT03265145|DRUG|Stiolto Respimat|Duration - 12 months
48687357|NCT03265145|DRUG|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
48159266|NCT02481349|OTHER|Questionnaire Administration|Ancillary studies
48159267|NCT02481349|OTHER|Yoga|Complete couple-based Hatha yoga program
48687358|NCT03265145|DRUG|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
48687359|NCT03265145|DRUG|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
48687360|NCT03763812|PROCEDURE|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
48159268|NCT05046301|PROCEDURE|Biospecimen Collection|Correlative studies
48159269|NCT05046301|OTHER|Contrast Agent|Given IV
48159270|NCT05046301|PROCEDURE|Contrast-Enhanced Mammography|Undergo contrast-enhanced mammography
48159271|NCT05046301|OTHER|Questionnaire Administration|Ancillary studies
48159272|NCT04183803|PROCEDURE|anatomic anterior cruciate ligament (ACL) reconstruction|The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
48159273|NCT02109718|DRUG|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
48266843|NCT02690623|OTHER|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
48266844|NCT03341676|DRUG|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
48367157|NCT04401982|DRUG|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks|Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
48367158|NCT00995202|PROCEDURE|Standard Monitoring CEA|No specific follow-up of CEA
48367159|NCT00995202|PROCEDURE|Intensive Monitoring CEA|CEA levels are measured every 3 months for 3 years, then every 6 months for 2 years.
48687361|NCT03763812|PROCEDURE|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
48367160|NCT00995202|PROCEDURE|Standard Monitoring Imagery|Abdominal ultrasound examination every 3 months during 3 years then every 6 months during 2 years then annually. Chest X-ray examination eveyr 6 months during 3 years then annually during 2 years
48367161|NCT00995202|PROCEDURE|Intensive Monitoring Imagery|Alternation every 3 months of TDM thoraco-abdomino-pelvis and abdominal ultrasound examination during 3 years and twice a year after during 2 years. Coloscopy at 3 years and then evry 5 years if normal
48266845|NCT03341676|DRUG|Placebo|Sodium Chloride 0.9% w/v solution for injection
48367162|NCT00974727|OTHER|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
48367163|NCT06021028|PROCEDURE|complex proximal carious cavities in posterior teeth.|Selective enamel etching with 37% phosphoric acid for 30 second will be done then the bonding agent will be applied following the manufacturer's instructions.
48367164|NCT02053415|DIETARY_SUPPLEMENT|Krill oil low dose|3 capsules krill oil per day
48687362|NCT02783547|DRUG|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
48367165|NCT02053415|DIETARY_SUPPLEMENT|Krill oil high dose|9 capsules krill oil per day
48367166|NCT01693991|BEHAVIORAL|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
48367167|NCT01693991|BEHAVIORAL|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
48367168|NCT00003089|DRUG|amifostine trihydrate|
48367169|NCT00003089|DRUG|carboplatin|
48367170|NCT00003089|DRUG|paclitaxel|
48367171|NCT00003089|RADIATION|radiation therapy|
48367172|NCT06393205|DEVICE|Naso-Esophageal Tube Feeding|During nasogastric tube feeding, a thin, flexible tube is carefully inserted through one nostril and passed down the throat into the stomach. Once in place, liquid nutrition, medication, or fluids can be administered through the tube, providing essential nutrients and hydration directly to the patient's digestive system. Nasogastric tube feeding may be used temporarily to support patients during acute illness or surgery, or it may be a long-term solution for individuals with chronic conditions that affect their ability to eat normally.
48513114|NCT05738278|BEHAVIORAL|Delayed HR-informed specific change in routine|"The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure."
48513115|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (350 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
48687363|NCT01032187|DRUG|Meglumine antimoniate|20mg/kg/day IV for 20 days
48687364|NCT01032187|DRUG|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
48687365|NCT04105192|DIETARY_SUPPLEMENT|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
48687366|NCT04136548|DRUG|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
48687367|NCT04136548|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
48266846|NCT00503204|DRUG|Cediranib|oral tablet
48266847|NCT00503204|DRUG|Lomustine|oral capsule
48367173|NCT06393205|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48367174|NCT06393205|BEHAVIORAL|Routine treatment|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48687368|NCT00800696|PROCEDURE|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
48367175|NCT06167031|OTHER|chatbot facilitate teaching|"The experimental group will use chatbot to facilitate teaching."
48367176|NCT06167031|OTHER|lecture-based teaching|The control group only receives lecture-based teaching.
48687369|NCT01539070|BEHAVIORAL|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
48687370|NCT03215628|DIAGNOSTIC_TEST|TCEUS|Intravenous sulphur hexafluoride microbubbles
48687371|NCT05551793|DRUG|Dupilumab|Dupilumab: 300mg SC injections
48687372|NCT05551793|DRUG|Placebo|Placebo: SC injections of equivalent volume
48687373|NCT01736423|DRUG|YM060|oral
48687374|NCT03380637|OTHER|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
48687375|NCT04737434|DEVICE|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
48367177|NCT02120573|OTHER|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
48367178|NCT02120573|OTHER|Workshop using Educational Film|workshops using film review about CPR
48513116|NCT06551818|OTHER|SesZen-Bio Low Dose 1 (150 mg liposomal)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
48687376|NCT04737434|DEVICE|electromagnetic field with no wave|electromagnetic field with no wave
48266848|NCT06530784|PROCEDURE|Cryoablation|After the completion of screening, the subjects received cryoablation treatment
48367179|NCT02120573|OTHER|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
48513117|NCT06551818|OTHER|SesZen-Bio High Dose 1 (500 mg extract)|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
48513118|NCT06551818|OTHER|Placebo|"Mode of Usage: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Dosage form: Capsule Frequency: One time daily after meal Rout of administration: Oral"
48687377|NCT05508542|BEHAVIORAL|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
48687378|NCT05850819|DRUG|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
48687379|NCT05850819|DRUG|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
48687380|NCT02869581|OTHER|Data collection|
48687381|NCT05382741|DRUG|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
48687382|NCT05382741|DRUG|Regorafenib 30 mg capsules|BAY73-4506
48687383|NCT02452216|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
48687384|NCT02452216|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
48367180|NCT02120573|OTHER|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
48367181|NCT02359942|DRUG|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
48367182|NCT00156962|DRUG|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
48367183|NCT00156962|DRUG|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
48367184|NCT04663386|DRUG|Budesonide-Formoterol|Dry powder inhaler
48687385|NCT02452216|PROCEDURE|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
48687386|NCT04930913|DIAGNOSTIC_TEST|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
48687387|NCT06188598|BEHAVIORAL|Time-restricted eating|Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
48002095|NCT01199211|OTHER|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
48159274|NCT02109718|DRUG|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
48159275|NCT03534141|DEVICE|Esophageal cooling/warming device|The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
48513119|NCT02996773|DRUG|Bendamustine|After transplant, given intravenously on day +4 as part of Phase Ib.
48513120|NCT02996773|DRUG|Cyclophosphamide|After transplant, given intravenously on day +3 as part of Phase 1b.
48002096|NCT01238614|OTHER|CHICA PSF plus JIT|
48002097|NCT01238614|OTHER|CHICA maternal depression PSF|
48159276|NCT03534141|OTHER|Mild hypothermia|Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
48159277|NCT03534141|OTHER|Normothermia|After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
48367185|NCT04983849|DRUG|metronidazole hydrogel|scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket
48367186|NCT04983849|PROCEDURE|scaling and root planning|scaling and root planning
48367187|NCT00002624|PROCEDURE|adjuvant therapy|
48367188|NCT00002624|PROCEDURE|diagnostic thoracoscopy|
48367189|NCT00002624|PROCEDURE|therapeutic thoracoscopy|
48002098|NCT01238614|OTHER|Control|
48002099|NCT04365699|DRUG|AT-001|Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team
48002100|NCT01076829|OTHER|Spice polyphenols|spice
48002101|NCT04906785|DRUG|CKD-385|Test Drug
48002102|NCT04906785|DRUG|D744|Reference Drug
48002103|NCT05834296|BIOLOGICAL|ALZN002 (autologous DCs pulsed with E22W mutant peptide).|The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.
48002104|NCT05834296|DRUG|Placebo|Saline
48367190|NCT00002624|PROCEDURE|video-assisted surgery|
48513121|NCT00590512|DIETARY_SUPPLEMENT|High sodium|
48002105|NCT00075335|DRUG|AMD3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
48002106|NCT03099551|DEVICE|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
48002107|NCT03099551|DEVICE|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
48002108|NCT01236755|DEVICE|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
48002109|NCT01236755|DEVICE|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
48002110|NCT05352828|DRUG|Nivolumab|Dose: 480 mg or 6 mg/kg Q4W
48002111|NCT05352828|DRUG|Autologous CD30.CAR-T|Dose: 2 x 10e8 cells/m2
48002112|NCT05352828|DRUG|Fludarabine|Dose: 30 mg/m2/day x 3 days
48367191|NCT00002624|RADIATION|radiation therapy|
48367192|NCT05342727|DEVICE|transcranial direct current stimulation (tDCS)|In tDCS, direct electrical currents at the intensity of interest (2 mA for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
48367193|NCT05342727|DEVICE|transcranial alternating current stimulation (tACS)|In tACS, alternating electrical currents at the frequency of interest (8 Hz for example) are generated by an electrical stimulator and are noninvasively delivered to the scalp through a pair of saline-soaked sponge electrodes (7×5 cm).
48367194|NCT00055939|DRUG|exatecan mesylate|
48513122|NCT00590512|DIETARY_SUPPLEMENT|Low sodium|
48513123|NCT02090166|OTHER|Blood test|a blood test will be taken from each patient
48513124|NCT01870440|DRUG|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
48687388|NCT00880269|DRUG|Panobinostat/LBH589|
48159278|NCT06407193|OTHER|MRI and scintigraphy|Gastric emptying measured with MRI and scintigraphy
48367195|NCT05150392|BIOLOGICAL|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
48367196|NCT06103773|DRUG|TollB-001 tablets|TollB-001 treatment
48367197|NCT06103773|DRUG|TollB-001 placebo|TollB-001 Placebo
48513125|NCT00661895|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
48513126|NCT00661895|DRUG|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
48513127|NCT00661895|DRUG|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
48513128|NCT00661895|DRUG|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
48513129|NCT00661895|DRUG|Metoprolol tartrate|50 mg tablets \& 100 mg tablets
48513130|NCT00661895|DRUG|Atenolol|50 mg tablet
48513131|NCT00661895|DRUG|Valsartan|80 mg tablets \& 160 mg tablet
48513132|NCT00661895|DRUG|Doxazosin|4 mg tablets
48513133|NCT00661895|DRUG|Clonidine|0.2 mg tablets
48513134|NCT00661895|DRUG|Hydralazine|50 mg tablets
48513135|NCT00661895|DRUG|Metoprolol succinate|50 mg tablet \& 100 mg tablet
48513136|NCT00661895|DRUG|Amlodipine|5 mg tablets \& 10 mg tablets
48513137|NCT02655783|OTHER|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
48513138|NCT02655783|OTHER|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
48513139|NCT04498117|BIOLOGICAL|Oregovomab|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
48159279|NCT01343147|OTHER|Microwave diathermy|Deep tissue heating via microwave diathermy
48513140|NCT04498117|DRUG|Paclitaxel|175 mg/m\^2, every 3 weeks
48159280|NCT01343147|OTHER|Superficial hyperthermia|Superficial heating via hot pack application
48266849|NCT06530784|DRUG|PD-1 antibody and bevacizumab|Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.
48367198|NCT05460468|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
48367199|NCT01920087|DRUG|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
48367200|NCT01920087|DRUG|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
48367201|NCT05277805|OTHER|EMPOWER-UP questionnaire|Participants are asked to respond to the EMPOWER-UP questionnaire to test the psychometric properties of the questionnaire.
48367202|NCT05208749|DEVICE|Rotablation of shockwave|Patients will be randomized to treatment with rotablation or shockwave
48367203|NCT05617417|OTHER|Local applied injectable platelet-rich fibrin in women with stress urinary incontinence|Injectable platelet-rich fibrin was prepared by centrifuging venous blood taken from women with stress urinary incontinence and applied locally to the anterior vaginal wall of the patients.
48367204|NCT05737927|DRUG|Glucose 8 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 8 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
48367205|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 12 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
48367206|NCT05737927|DRUG|Glucose 16 g coated beads (47% w/w)|After an overnight fasting of about 10 hours, the subjects were administered 16 g glucose of the coated Glucose beads formulation starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
48367207|NCT05737927|DRUG|Glucose 12 g uncoated beads|After an overnight fasting of about 10 hours, the subjects were administered the uncoated Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
48367208|NCT05737927|DRUG|Glucose 12 g coated beads (60% w/w)|After an overnight fasting of about 10 hours, the subjects were administered the coated Glucose beads formulation (60 % w/w glucose/bead; 12 g glucose) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position.
48513141|NCT04498117|DRUG|Carboplatin|AUC 6 IV Day 1 x 6 cycles (every 21 days)
48513142|NCT04498117|BIOLOGICAL|Placebo|2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes
48513143|NCT04498117|DRUG|Carboplatin|AUC 5-6 IV Day 1 x 6 cycles (every 21 days)
48513144|NCT03568097|DRUG|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
48513145|NCT05282563|PROCEDURE|double and a half layered esophagojejunal anastomosis|After the end of esophagojejunostomy, 3/0 barbed suture or absorbable suture was used. First, the anastomotic site was sutured continuously for one circle, with the suture spacing of 3-4 mm and the width of 4-5 mm. Then, the continuous horizontal mattress type seromuscular layer varus suture was used to embed the anastomotic stoma for one circle, and the suture width was 5\~8 mm above and below the anastomotic stoma. After the completion of esophagojejunostomy, the full-thickness reinforcement of the anastomosis and the embedding of the seromuscular layer can ensure the complete anastomosis of the mucosal layer of the anastomosis. The embedding of the seromuscular layer can also improve the anti-pressure and anti-tension of the anastomosis, and provide a guarantee for the primary healing of the anastomosis.
48002113|NCT05352828|DRUG|Bendamustine|Dose: 70 mg/m2/day x 3 days
48002114|NCT02244580|DEVICE|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
48159281|NCT05723029|OTHER|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
48159282|NCT05723029|OTHER|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
48159283|NCT02884336|OTHER|No intervention|
48159284|NCT04088136|BEHAVIORAL|Everyday Metacognitive Memory Intervention|Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
48159285|NCT04088136|BEHAVIORAL|Memory Strategy Control Intervention|Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
48159286|NCT06402851|DRUG|Anticoagulant Oral|Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
48159287|NCT03392779|DRUG|ZSP1601 25 mg|ZSP1601 tablet administered orally once daily under fasted condition
48159288|NCT03392779|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
48002115|NCT06483035|DEVICE|Intensive Visual Stimulation (IVS)|The IVS system initially makes a video-recording of the intact body part (arm or leg) executing a set of specific movements. These video recordings will be digitally reversed and projected onto a large screen in front of the patient. On the screen, the patient will monitor an intact, life-like extremity in place of the amputated extremity. This digital extremity will then execute the recorded movements in a pre-planned manner. Simultaneously, the patient will follow the digital virtual limb moving on the screen with his/hers amputated arm/leg, which is hidden below the screen. Hence, IVS therapy comprises elements of both movement perception, motor planning, motor execution and visual feedback of two intact limbs moving which are distinctive from classical Mirror-Therapy.
48159289|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablet administered orally once daily under fasted condition
48159290|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
48159291|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily in the fasting state
48159292|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
48159293|NCT03392779|DRUG|ZSP1601 175 mg|ZSP1601 tablets administerekd orally once daily under fasted condition
48159294|NCT03392779|DRUG|Placebo 175 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
48513146|NCT03336528|DRUG|Degludec|Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.
48513147|NCT03336528|DRUG|Glargine|Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
48159295|NCT03392779|DRUG|ZSP1601 275 mg|ZSP1601 tablets administered orally once daily in the fasting state
48159296|NCT03392779|DRUG|Placebo 275 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
48159297|NCT03392779|DRUG|ZSP1601 350 mg|ZSP1601 tablets administered orally once daily under fasted condition
48159298|NCT03392779|DRUG|Placebo 350mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
48687389|NCT05733741|DRUG|Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)|"For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
48687390|NCT05733741|DRUG|Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).|"The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
48687391|NCT04177615|PROCEDURE|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
48159299|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition
48159300|NCT03392779|DRUG|Placebo 100mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
48687392|NCT01384565|DRUG|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
48002116|NCT06483035|OTHER|Usual Care (UC)|"After allocation to UC, the participants continue with their normal treatment as prescribed by their medical doctor. All control participants are offered to complete IVS treatment after the end of the study period. The participants in the control group will therefore be placed on a fictitious waiting list during the study period."
48002117|NCT04001842|OTHER|Surgical reconstruction of the mandible using an axially vascularized bone construct|Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
48159301|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
48159302|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
48159303|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
48159304|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
48159305|NCT01601821|DRUG|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
48159306|NCT01601821|DRUG|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
48002118|NCT05940974|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the surgery and after the surgery (on 4 dates over a 1-year period); the DASH and ASES questionnaires to measure their functional outcomes before the surgery and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the surgery and after the surgery (on 4 dates over a 1-year period).
48002119|NCT03146442|BEHAVIORAL|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
48002120|NCT03510117|BEHAVIORAL|Mindfulness|Mindfulness
48159307|NCT00582985|DRUG|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
48687393|NCT01384565|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
48159308|NCT02513979|DRUG|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
48159309|NCT03899259|DRUG|Baricitinib|Administered orally
48687394|NCT05681572|DRUG|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
48687395|NCT05681572|DRUG|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
48002121|NCT05180136|DIETARY_SUPPLEMENT|Rice bran extract group|Rice bran extract 1,000 mg/day for 8 weeks
48002122|NCT05180136|DIETARY_SUPPLEMENT|Control group|Placebo 1,000 mg/day for 8 weeks
48002123|NCT04644614|DEVICE|Magnetic Stimulation - Armchair type|MS and Sham MS will be applied two days a week, 20 minutes a day, for 8 weeks, a total of 16 sessions.
48159310|NCT03899259|DRUG|Placebo|Administered orally
48687396|NCT05681572|DRUG|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
48687397|NCT02808897|DEVICE|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
48687398|NCT02808897|DEVICE|Active Tube Clearance drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
48687399|NCT05559905|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
48687400|NCT05559905|DRUG|Placebo|Placebo capsule matched to molnupiravir taken twice daily by mouth.
48687401|NCT05559905|BIOLOGICAL|RSV A Memphis 37b|RSV A Memphis 37b viral challenge given once by intranasal administration at a dosage of \~4 Log10 plaque forming units (PFUs).
48687402|NCT04579406|PROCEDURE|non-cardiac surgery|All the patients are undergoing non-cardiac surgery.
48367209|NCT05737927|DRUG|Glucose 12 g coated beads (47% w/w)|After an overnight fasting of at least 10 hours, the subjects were administered the new developed Glucose beads formulation containing 12 g glucose starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. Treatment duration: Day 1 - Day 4
48513148|NCT03336528|DRUG|Aspart|Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
48513149|NCT04342455|OTHER|double-low scanning|a CT angiography protocol with low radiation and contrast agent exposure
48513150|NCT04805515|BEHAVIORAL|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
48687403|NCT04320212|PROCEDURE|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
48687404|NCT04320212|PROCEDURE|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
48687405|NCT02994485|DRUG|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
48159311|NCT05294328|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
48002124|NCT03758742|BEHAVIORAL|High-Fruit Diet|Participants will consume a diet rich in whole fruit. During Phase I (Weeks 1-4; supervised controlled feeding), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In Phase II (Week 5-12; supervised controlled feeding), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable during Phases I and II. In the Follow-Up Phase (Months 4-12; free-living), participants will be instructed to continue consuming at least one-third of their diet as whole fruit and to make healthy food choices.
48002125|NCT01068938|DEVICE|three different perimeters: HFA, Octopus, MATRIX|visual fields
48002126|NCT00323973|DRUG|Bisoprolol|10 mg qd
48513151|NCT05228431|DRUG|XELOX|Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
48513152|NCT05228431|DRUG|Capecitabine monotherapy|During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
48687406|NCT03903549|DRUG|[18F]P17-059|Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
48159312|NCT05294328|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
48687407|NCT01941381|PROCEDURE|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
48367210|NCT05464108|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
48513153|NCT05228431|RADIATION|Radiation|The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
48687408|NCT03179852|BEHAVIORAL|nutrition education|nutrition education
48159313|NCT05294328|DRUG|Vehicle Proprietary Ophthalmic Solution|Proprietary Vehicle Ophthalmic Solution
48687409|NCT00511628|DRUG|Risperidone|As prescribed
48687410|NCT01637532|DRUG|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
48687411|NCT01637532|DRUG|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
48687412|NCT00070109|DRUG|trabectedin|Given IV
48687413|NCT00070109|OTHER|pharmacological study|Correlative studies
48002127|NCT00116558|DEVICE|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
48002128|NCT00116558|DEVICE|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
48002129|NCT02867540|OTHER|MRI enterography|
48002130|NCT02626143|OTHER|Investigational nutrient-rich whey protein formula|
48687414|NCT06479512|DEVICE|ultrasonography to measure the index of the caval aorta and non-invasive pulse oximetry for perfusion index|Inferior vena cava and aortic diameter measurements will be made by ultrasonography and perfusion index determination using non-invasive pulse oximetry
48687415|NCT03576014|BIOLOGICAL|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2\~4 weeks after the transplant.
48687416|NCT01378650|DRUG|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
48687417|NCT01378650|DRUG|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
48687418|NCT01602601|DRUG|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
48687419|NCT01602601|DRUG|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
48159314|NCT00927316|BIOLOGICAL|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
48159315|NCT04178096|OTHER|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
48159316|NCT01396733|DRUG|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
48159317|NCT03865862|OTHER|Experimental|The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
48687420|NCT05223569|DEVICE|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
48159318|NCT03865862|OTHER|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
48159319|NCT04568304|BIOLOGICAL|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
48159320|NCT04568304|DRUG|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
48513154|NCT05196308|DRUG|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
48159321|NCT04568304|DRUG|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
48159322|NCT04568304|DRUG|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
48159323|NCT00525915|DRUG|5-Fluorouracil|"Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15."
48159324|NCT00525915|DRUG|Oxaliplatin|"Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15"
48159325|NCT00525915|RADIATION|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
48002131|NCT02626143|OTHER|Cow's milk based formula|
48513155|NCT05196308|DRUG|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
48513156|NCT03101176|DRUG|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
48687421|NCT05223569|DEVICE|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
48687422|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
48002132|NCT02205593|BEHAVIORAL|Control|Regular follow-up and treatment WITHOUT behavioural intervention
48367211|NCT02482727|DEVICE|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
48159326|NCT00525915|PROCEDURE|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
48159327|NCT01514630|DRUG|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
48159328|NCT00422786|DRUG|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
48159329|NCT06375018|OTHER|Placebo Technique|In the control group, manual contact will be carried out without any therapeutic intention. This contact will be maintained for the same period of time as the experimental group.
48159330|NCT06375018|OTHER|Diaphragm Stretching|The participant will be in supine position and the researcher will be at the headrest of the examination table, placing his hands on the lower costal margin. Superior direction traction is performed during inspiration, remaining during expiration. The procedure is repeated for a maximum period of 4 minutes.
48513157|NCT06112847|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48002133|NCT03712410|BEHAVIORAL|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
48002134|NCT02287311|BIOLOGICAL|MABEL CTLs|"Dose escalation:~DL1:2x10\^7 cells/m2+2x10\^7 cells/m2~DL2:2x10\^7cells/m2+5x10\^7 cells/m2~DL3:5x10\^7 cells/m2+1x10\^8 cells/m2~\*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
48159331|NCT05717647|OTHER|Observational study: neuromonitoring|collection of multimodality neuromonitoring data including ICP, brain tissue oxygen tension, cerebral microdialysis data
48159332|NCT02943109|OTHER|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
48159333|NCT02943109|OTHER|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
48159334|NCT02943109|OTHER|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
48159335|NCT02943109|OTHER|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
48159336|NCT02411422|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube
48159337|NCT02411422|DEVICE|Reinforced endotracheal tube|Reinforced endotracheal tube
48159338|NCT02867371|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
48159339|NCT06472960|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
48159340|NCT06472960|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
48159341|NCT06472960|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
48687423|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
48159342|NCT06646848|DEVICE|Vibration|The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the infants's extremity and routine heel blood collection procedure was performed.
48513158|NCT06112847|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48513159|NCT06112847|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48513160|NCT06112847|OTHER|Electronic Health Record Review|Ancillary studies
48513161|NCT06112847|BIOLOGICAL|Epcoritamab|Given SC
48513162|NCT06112847|DRUG|Lenalidomide|Given PO
48513163|NCT06112847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48513164|NCT06112847|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48513165|NCT03892018|DRUG|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
48513166|NCT01161485|BEHAVIORAL|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
48687424|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
48367212|NCT04116905|BEHAVIORAL|Intensive Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.
48687425|NCT03279159|OTHER|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
48687426|NCT03279159|OTHER|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
48687427|NCT02068677|OTHER|Sympathetic response|Sympathetic response will be defined as change in heart rate by \>10 bpm and change in BP \<10mmHg.
48002135|NCT02287311|DRUG|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
48002136|NCT02287311|DRUG|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
48266850|NCT06176937|DRUG|Hyaluronic acid|Alveolar ridge preservation by atraumatic tooth extraction and socket curettage then application hyaluronic acid gel after extraction and covering the socket by collagen membrane.
48002137|NCT00458653|BIOLOGICAL|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
48002138|NCT02245243|DRUG|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
48159343|NCT06646848|DEVICE|Heel Warming|The heel warning group will warm the heel of the infants using a hot thermal bag 3-5 minutes before the application. Then, the thermal bag will be removed and the nurse will take the heel blood.
48002139|NCT06329102|PROCEDURE|Surgical access|Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival
48002140|NCT06322056|DRUG|Intensive control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 70 mg/dL.
48002141|NCT06322056|DRUG|Intensive control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 120 mmHg and a LDL-C target of less than 100 mg/dL.
48002142|NCT06322056|DRUG|Standard control of SBP and intensive control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
48002143|NCT06322056|DRUG|Standard control of SBP and standard control of LDL-C|Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
48159344|NCT06646848|DEVICE|Shotblocker|The protruding surface of the Shotblocker was placed on the heel lance procedure site. While applying pressure on the skin through the Shotblocker, the nurse performed heel lancing with the needle through the opening in the center of the Shotblocker. During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure. Then Shotblocker was removed from the skin and routine capillary heel collection procedure was performed.
48159345|NCT00984347|DRUG|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
48159346|NCT00984347|PROCEDURE|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
48159347|NCT05766124|DRUG|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
48513167|NCT01161485|BEHAVIORAL|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
48687428|NCT02068677|OTHER|no sympathetic response|no Sympathetic response will be defined as change in heart rate by \<10 bpm and change in BP \<10mmHg.
48687429|NCT00212875|DRUG|epoetin alfa|
48687430|NCT05456997|PROCEDURE|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
48687431|NCT00740441|DRUG|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
48687432|NCT00935506|DRUG|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
48687433|NCT00935506|DRUG|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
48687434|NCT06091124|DRUG|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
48002144|NCT05609188|OTHER|Guaranteed Income|Monthly cash transfer of $500 per month for 12 months.
48002145|NCT05609188|BEHAVIORAL|Peer learning circles|Participants can opt-in to attend peer learning circles (also called My Money Hour), which are discussion groups of 10-12 participants about financial topics co-led by a peer (Black youth) with experience in financial programming and an adult financial coach. My Money Hour sessions will be offered on-line multiple times throughout every month of the project, with rotating themes, to ensure that the 50-minute sessions are available different days of the week and times of the day.
48002146|NCT05609188|BEHAVIORAL|Financial coaching|Participants can opt-in to receive financial coaching sessions with a trained financial mentor. Meetings will occur monthly and typically include six one hour sessions. The mentor will be responsive to individual needs, but will touch on the following priority areas: building credit (credit repair, improving credit scores, credit products); savings (emergency savings plans, savings habits and strategies, understanding savings accounts); money management (creating budgets, understanding income vs expense, assessing spending, making better financial decisions); financial products (credit building products, auto loans, credit cards); and long-term goals (home ownership, investments).
48002147|NCT03168672|DEVICE|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
48002148|NCT02492139|DEVICE|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
48687435|NCT06091124|DRUG|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
48687436|NCT06091124|DRUG|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
48687437|NCT06091124|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
48159348|NCT04357587|DRUG|Pembrolizumab|200 mg intravenously (IV) on days 1, 22, and 43
48159349|NCT04357587|RADIATION|External beam radiation|Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
48687438|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3A)|"The primary goal is to relate preoperative 64Cu-DOTA-ECL1i AAA uptake with CCR2+ cell activity in AAA tissue collected at the time of open repair. We will image AAA patients pre-operatively and collect tissue at the time of open repair in an attempt to demonstrate ex-vivo tissue corroboration of our imaging findings (n=20, 10 women and 10 men).~Participants with AAA will undergo routine clinical evaluation including ultrasound, CT scan and scheduling of open surgical repair. We will record age and tobacco use. If a renal function blood test has not been performed within the past 90 days, we will draw \~2 teaspoons of blood for a creatinine test. A contrast dye will be used for the CT portion of the PET-CT scan. Those having open surgery, their PET/CT imaging will be within 7-14 of the surgery and if available, collection of discarded aortic tissue at the time of surgery."
48687439|NCT04586452|DIAGNOSTIC_TEST|Non-AAA Group|We will determine the retention of 64Cu-DOTA-ECL1i in abdominal aorta of non-AAA volunteers (n=10, 5 women and 5 men). This group of participants will have a documented absence of AAA by screening ultrasound that was previously obtained as part of standard care. Both men and women, above the age of 40, with or without active tobacco use will be considered for participation.
48002149|NCT02492139|DEVICE|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
48002150|NCT05354128|DRUG|Thrombolytic|Standard intravenous thrombolysis.
48367213|NCT04116905|BEHAVIORAL|Conventional Treatment|Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
48367214|NCT04832243|OTHER|Survey questionnaire|Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
48002151|NCT05354128|PROCEDURE|percutaneous coronary stenting|Percutaneous coronary stenting
48002152|NCT03366064|BIOLOGICAL|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
48002153|NCT04073225|DEVICE|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
48159350|NCT04357587|DRUG|Capecitabine|825 mg/m2 orally twice a day on days where radiation therapy is given
48159351|NCT00145496|DRUG|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
48159352|NCT00145496|DRUG|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
48159353|NCT01955720|DRUG|BI 655075|
48159354|NCT01955720|DRUG|BI 655075|
48159355|NCT01955720|DRUG|Placebo|
48159356|NCT01955720|DRUG|BI 655075|
48159357|NCT01955720|DRUG|Placebo|
48002154|NCT04073225|DEVICE|Hand Bike|The control intervention in this study is a hand bike, a single-component upper-arm aerobic exercise device. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
48002155|NCT05817136|DIAGNOSTIC_TEST|Eko DUO|Acquisition of a single-lead ECG via patients self-examine themselves twice a week for 12 months.
48002156|NCT05242081|DRUG|S-ketamine|S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance
48002157|NCT05242081|DRUG|Sufentanil|Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance
48002158|NCT06106971|DRUG|Sodium tetradecyl sulfate|Subjects receive sodium tetradecyl sulfate via balloon-occluded retrograde transvenous obliteration at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding.
48002159|NCT06106971|DRUG|Cyanoacrylate|Subjects receive endoscopic cyanoacrylate injection at 3 to 5 days after initial hemostasis of acute gastric variceal bleeding then receive repeated endoscopic cyanoacrylate injection at 1-month intervals until obliteration of gastric varices.
48002160|NCT00360074|DRUG|Thyroxin, Triiodothyronine|
48002161|NCT00398853|DIETARY_SUPPLEMENT|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
48002162|NCT00398853|OTHER|Placebo|Placebo
48002163|NCT06063486|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48002164|NCT06063486|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48159358|NCT01955720|DRUG|Placebo|
48159359|NCT01955720|DRUG|Placebo|
48159360|NCT01955720|DRUG|BI 655075|
48513168|NCT01161485|BEHAVIORAL|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
48002165|NCT06063486|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48159361|NCT05465278|DRUG|Alirocumab|18 months treatment with alirocumab
48002166|NCT06063486|DIETARY_SUPPLEMENT|Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement|Given PO
48159362|NCT06098443|OTHER|Acupressure|Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety \& depression in patients with ESRD.
48513169|NCT03120325|DEVICE|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
48002167|NCT06063486|DIETARY_SUPPLEMENT|Piperine Extract (Standardized)|Given PO
48002168|NCT06063486|DRUG|Placebo Administration|Given PO
48002169|NCT06063486|OTHER|Questionnaire Administration|Ancillary studies
48002170|NCT01856790|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
48002171|NCT01856790|DRUG|liraglutide|Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
48159363|NCT06098443|DEVICE|Transcutaneous electrical nerve stimulation|TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).
48159364|NCT04910061|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Daily supplementation with NMN-C at 400 mg for 29 days in total
48159365|NCT01901302|DRUG|CB-5945|
48367215|NCT03280446|DEVICE|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
48367216|NCT01823991|DRUG|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
48367217|NCT01823991|OTHER|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
48002172|NCT05583396|DIAGNOSTIC_TEST|Acute exercise|The measurement will be repeated within one to seven days.
48002173|NCT04964453|DRUG|Placebo|Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
48002174|NCT04964453|DRUG|BI 474121|Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
48002175|NCT02076412|DRUG|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
48513170|NCT05991869|BEHAVIORAL|Point-of-care decision support intervention|"PCPs notified by EHR messages if they had an upcoming in-person or video visit with an eligible patient who had a predicted risk of incident HIV diagnosis of 0.2% or higher. Study team members manually sent messages marked as high priority one business day prior to scheduled visits, alerting PCPs that a patient may be at increased risk for acquiring HIV and may benefit from a conversation about PrEP. Additional information was provided about the study, the prediction model, clinical indications for PrEP, strategies for initiating discussions about HIV prevention and PrEP, and how to refer patients to KPSF's PrEP program. Messages did not include the numeric predicted HIV risk from the model. PCPs received a maximum of two messages per day; with the two patients with the highest predicted risk were selected. Patient with multiple visits were flagged no more than once monthly."
48513171|NCT03203681|DRUG|Natesto|4.5% nasal testosterone. 11.0 mg testosterone administered per dose (2 pump actuations, 1 pump per nostril) applied intranasally three times a day.
48687440|NCT04586452|OTHER|Ex Vivo Human AAA Specimens (Aim 2A)|The primary objective of this sub-aim is to assess the sensitivity and specificity of 64Cu-DOTA-ECL1i binding to ex vivo to human AAA specimens from the Washington University Vascular Surgery Biobank (VS-BB). We will first perform a histopathological evaluation of human AAA specimens (n=75, including samples from this study) and categorize them based on clinical status (e.g, diameter) and degree of inflammation. We will consider healthy, nonatherosclerotic aorta (n=25) as negative controls, and non-aneurysmal aortas (n=25) from patients that have undergone surgery for aortoiliac occlusive disease as positive controls.
48687441|NCT04586452|OTHER|Relationship between radiotracer and CCR2 (Aim 2B)|The objective of this sub-aim is to better understand the relationship between the levels of CCR2+ inflammatory cells and the inflammatory and clinical status of AAA, to gain insight into the importance of proinflammatory monocytes/macrophages in the development of AAA disease at the time of elective AAA repair. We will correlate the level of MMP expression and activity, as well as cytokine profiles, of each specimen, with the associated histopathological features. The relationship between 64Cu-DOTA-ECL1i binding and CCR2 expression in tissues with different degrees of disease severity will be evaluated using Pearson or Spearman correlation coefficients. This will allow us to speculate as to how tracer uptake will perform in vivo and what that uptake represents in regard to disease severity.
48687442|NCT04586452|DIAGNOSTIC_TEST|AAA Group (Aim 3B-Reproducibility)|We will demonstrate consistent 64Cu-DOTAECL1i uptake by performing repeated imaging studies in a separate group of non-surgical AAA patients (n=20, 10 women and 10 men). Completion of this sub-aim will provide support for the use of 64Cu-DOTA-ECL1i PET for evaluating AAA disease in a reliable fashion. These participants will have another PET/CT imaging study performed 10-14 days after the first PET/CT in order to determine the ability to reproduce the uptake results of Cu-64-DOTA-ECL1i. The physician will assess the participant's willingness and eligibility to have a second PET/CT scan.
48687443|NCT04894539|DEVICE|DS5 electrical stimulator|TENS
48687444|NCT00133263|BEHAVIORAL|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
48687445|NCT00133263|BEHAVIORAL|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
48367218|NCT01823991|DRUG|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
48367219|NCT04665492|DIAGNOSTIC_TEST|EEG recording 1|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). EEG device usbamp (company Guger Technologies, Austria) will be used."
48159366|NCT01901302|DRUG|Placebo|
48159367|NCT05056701|OTHER|annual follow-up during 10 years|an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD
48159368|NCT04419961|BEHAVIORAL|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
48159369|NCT04958434|DRUG|TST005|TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
48159370|NCT01074099|BIOLOGICAL|BMAC|Injection of BMAC into ischemic myocardium during CABG
48159371|NCT01074099|PROCEDURE|CABG only|Control subjects will undergo CABG surgery without BMAC injection
48159372|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
48159373|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
48687446|NCT01628354|DRUG|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of \>5 letters or increase in retinal thickness of \>100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
48687447|NCT01489709|DRUG|Vesicare|oral
48687448|NCT04842851|DEVICE|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
48687449|NCT05263570|DRUG|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
48687450|NCT03303053|DRUG|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
48687451|NCT03303053|DRUG|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
48687452|NCT03303053|DRUG|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
48687453|NCT03755219|PROCEDURE|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
48687454|NCT03755219|PROCEDURE|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
48687455|NCT00000407|BEHAVIORAL|Vocational counseling intervention|
48687456|NCT00000407|BEHAVIORAL|Reading materials for control participants|
48687457|NCT00000407|BEHAVIORAL|Standard of care|No education or behavioral intervention
48687458|NCT01420224|OTHER|Commercial airline flight|Normal scheduled passenger flight
48687459|NCT06378333|PROCEDURE|patients who underwent coronary angiography|All patients included in the ICAR project (Montpellier - Nîmes) benefit from a consultation at one year (12+or - 2 months), as they are systematically reviewed in our department: data will therefore be collected in the patient's medical record. Clinical biological parameters and events during the hospital phase are also collected in the patient's computerized record. Normal patient management remains unchanged.
48687460|NCT00631813|DRUG|Prucalopride|0.5 mg bid
48687461|NCT00631813|DRUG|Prucalopride|1 mg bid
48687462|NCT00631813|DRUG|Prucalopride|2 mg bid
48687463|NCT00631813|DRUG|Placebo|bid
48687464|NCT06526182|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously.
48687465|NCT01374321|DRUG|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
48687466|NCT01374321|DRUG|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
48002176|NCT02076412|DRUG|Placebo|Placebo tablet PO bid (morning and evening)
48159374|NCT01374971|DRUG|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
48159375|NCT01374971|PROCEDURE|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
48159376|NCT01827202|OTHER|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
48159377|NCT01827202|DRUG|Aliskiren|
48687467|NCT02192892|DIETARY_SUPPLEMENT|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
48687468|NCT02192892|DIETARY_SUPPLEMENT|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
48159378|NCT01827202|DRUG|Candesartan|
48159379|NCT03852875|OTHER|Education|Same
48159380|NCT03852875|OTHER|Control|Same
48159381|NCT03915951|DRUG|encorafenib|self-administered orally
48159382|NCT03915951|DRUG|binimetinib|self-administered orally
48159383|NCT00626158|DRUG|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
48159384|NCT00626158|DRUG|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
48159385|NCT06365177|OTHER|Physical consultation|"The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation."
48159386|NCT06365177|OTHER|Teleconsultation|"Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it."
48159387|NCT00147745|DRUG|Colesevelam|Colesevelam 3.8g for 12 weeks
48159388|NCT00147745|DRUG|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
48159389|NCT00147745|DRUG|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
48159390|NCT02395224|OTHER|cancer treatment and follow-up according to current regional and national guidelines|
48159391|NCT05649904|DEVICE|IRRAflow with Active Fluid Exchange System|"IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses)."
48159392|NCT05649904|DEVICE|External Ventricular Drain|The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
48159393|NCT03300661|BEHAVIORAL|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
48159394|NCT05324605|PROCEDURE|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
48159395|NCT00125619|BEHAVIORAL|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
48159396|NCT01407302|OTHER|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
48266851|NCT06176937|OTHER|empty socket|Alveolar ridge preservation by atraumatic tooth socket without application any drug but just covering the socket by collagen membrane.
48266852|NCT06454084|DRUG|Acetylcholine Chloride|Vasodilator solution
48513172|NCT00030225|BIOLOGICAL|ELAD|
48513173|NCT00030225|OTHER|Standard of care (Control)|
48513174|NCT04348695|DRUG|Ruxolitinib plus simvastatin|"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days"
48159397|NCT02604147|DEVICE|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
48159398|NCT02604147|DEVICE|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
48159399|NCT00119314|DRUG|capecitabine|
48159400|NCT00119314|DRUG|docetaxel|
48367220|NCT04665492|DIAGNOSTIC_TEST|EEG recording 2|"Multichannel EEG recording in eyes opened and eyes closed relaxed state and during imagined movement (all one experimental session). This intervention will take place six month after EEG recording 1. EEG device usbamp (company Guger Technologies, Austria) will be used."
48367221|NCT04665492|DIAGNOSTIC_TEST|Sensory Test|Test for mechanical sensations of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. Semmes-Weinstein Monofilaments will be used
48367222|NCT04665492|DIAGNOSTIC_TEST|Brief Pain Inventory 1|This questionnaire that ask about any acute or chronic pain
48367223|NCT04665492|DIAGNOSTIC_TEST|Multidimensional health locus of control|Questionnaire that test personal belief about control of one's own health
48367224|NCT04665492|DIAGNOSTIC_TEST|Sensory test thermal|"Test of thermal sensations (thermal roller) of the feet and shins of both legs as well as on the trapezoidal muscle on both sides. A Somedic SenseLab Rolltemp device will be used"
48367225|NCT04665492|DIAGNOSTIC_TEST|Neuropathic pain symptoms|Questionnaire that test for neuropathic pain symptoms
48513175|NCT04348695|OTHER|Standard of Care|Patients will receive treatment according to usual clinical practice in the participant site.
48002177|NCT04721990|DEVICE|Automatic Sound Management 3.0|The investigational front-end features include those within Automatic Sound Management 3.0 (i.e., Ambient Noise and Transient-Noise Reduction, and Adaptive Intelligence). Automatic Sound Management 3.0 will be accessed in the MAESTRO system software. The investigational front-end features within Automatic Sound Management 3.0 will be programmed in the SONNET2EAS processor.
48002178|NCT03402438|DRUG|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
48002179|NCT02258204|DRUG|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
48002180|NCT02258204|DRUG|Placebo|
48002181|NCT00469482|OTHER|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
48002182|NCT00469482|OTHER|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
48002183|NCT03996200|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
48002184|NCT05706688|PROCEDURE|Anesthetic technique (regional versus general)|Anesthetic technique (regional versus general)
48002185|NCT02459977|DRUG|Basiliximab|Basiliximab induction therapy
48002186|NCT02459977|DRUG|No basiliximab|No basiliximab induction therapy
48002187|NCT02459977|PROCEDURE|Kidney transplantation|kidney transplantation
48159401|NCT00119314|DRUG|gemcitabine hydrochloride|
48159402|NCT00119314|PROCEDURE|positron emission tomography|
48159403|NCT05758922|DRUG|AZ-3102 (Dose 1)|"Pharmaceutical form: capsule~Route of administration: oral"
48159404|NCT05758922|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
48159405|NCT05758922|DRUG|AZ-3102 (Dose 2)|"Pharmaceutical form: capsule~Route of administration: oral"
48159406|NCT04915157|DEVICE|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
48159407|NCT03427879|DRUG|Low flavonoid beverage|A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
48159408|NCT03427879|DRUG|High flavonoid beverage|A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
48159409|NCT05733793|OTHER|NGS tests|"This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required."
48159410|NCT01436604|OTHER|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
48159411|NCT04372186|DRUG|Placebo|Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
48159412|NCT04372186|DRUG|Tocilizumab|Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
48159413|NCT03247985|DEVICE|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
48159414|NCT03247985|DEVICE|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open \& laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
48159415|NCT02347839|PROCEDURE|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
48159416|NCT03362684|DRUG|Cetuximab|Cetuximab every 2 weeks
48159417|NCT03362684|DRUG|FOLFOX|FOLFOX-4 every 2 weeks
48159418|NCT01446822|DEVICE|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
48266853|NCT03900390|PROCEDURE|cross-preconditioning|After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.
48367226|NCT04665492|DIAGNOSTIC_TEST|McGill pain questionnaire|Questionnaire assess three separate components of experiencing pain; the sensory intensity, the emotional impact and the cognitive evaluation of pain.
48002188|NCT05783635|BEHAVIORAL|Enhanced Usual Care (pre-operative)|The enhanced usual care will receive standard surgical care, and a resource brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources. The resource brochure will be e-mailed to patients or sent via postal mail.
48002189|NCT05783635|BEHAVIORAL|Preoperative Virtual Health Coaching|"Preoperative Virtual Coaching is based on principles of health coaching, collaborative care, and motivational interviewing. Health and educational content is framed using the Health Belief Model. During two sessions, that take place approximately 3 and 5 weeks prior to surgery, the health coach presents alcohol use reduction/abstinence as important for surgical health (rather than addiction or chronic health reasons) and engages participants in discussion and patient-centered goal-setting.~Participants will also receive a brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources."
48002190|NCT05783635|BEHAVIORAL|Usual surgical care (post-operative)|This group will receive standard post-operative care.
48002191|NCT05783635|BEHAVIORAL|Postoperative Virtual Health Coaching|Postoperative Virtual Coaching uses the same framework and structure as Preoperative Virtual Coaching. These sessions will be delivered by a health coach using a collaborative, and motivational interviewing-based approach. The goal of these sessions is to promote well-being and help participants maintain alcohol abstinence or reduction long-term (or initiate change in alcohol use if they have not already). These sessions promote low-risk alcohol use, provide education on chronic health effects of heavy alcohol use, and teach skills for coping with or avoiding triggers for alcohol use including coping with stress and mood challenges. These sessions introduce skills to help participants manage alcohol, stress, and mood as they recover from surgery.
48002192|NCT05783635|BEHAVIORAL|On-Track (Post-operative)|"On-Track is a mobile and web-accessible health tool that uses self-monitoring and provision of feedback on progress towards goals to engage participants in self-management of alcohol use and motivate behavior change through increased self-awareness and accountability for health.~The On-Track application includes a) daily tracking of alcohol and other substance use; b) daily tracking of stress, mood, and pain; c) personalized health goals; and d) visual displays of alcohol use, stress, mood, pain, and goal achievement including graphs of trends over time.~On-Track also uses novel monetary and non-monetary incentives to encourage utilization including an escalating monetary incentive schedule for self-monitoring."
48002193|NCT02791620|DEVICE|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
48367227|NCT04665492|DIAGNOSTIC_TEST|Pain Catastrophising Scale|Questionnaire use to identify individual pain experience.
48687469|NCT02192892|DIETARY_SUPPLEMENT|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
48687470|NCT02192892|DIETARY_SUPPLEMENT|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
48159419|NCT01446822|DEVICE|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
48159420|NCT03873714|DEVICE|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
48159421|NCT03296423|BIOLOGICAL|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
48159422|NCT03296423|BIOLOGICAL|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
48159423|NCT02278822|OTHER|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
48159424|NCT02278822|OTHER|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
48159425|NCT02165696|OTHER|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
48159426|NCT02165696|OTHER|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
48159427|NCT00246129|DRUG|Campath|Monoclonal antibody induction therapy
48159428|NCT00246129|DRUG|Daclizumab|Monoclonal antibody induction therapy
48159429|NCT00966056|DRUG|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
48159430|NCT00966056|DEVICE|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
48159431|NCT03959735|OTHER|High Intensity Interval Training (HIIT)|HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
48367228|NCT05899946|OTHER|A community-based network training program|A 3-phase program including establishing a community-based network, video competition, and Video promotions will be conducted.
48367229|NCT03691831|DRUG|Active|A-101 45% (hydrogen peroxide 45% topical solution)
48367230|NCT03691831|OTHER|Vehicle|Vehicle solution containing isopropyl alcohol and water
48367231|NCT00612573|DRUG|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
48367232|NCT00612573|DRUG|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
48367233|NCT00612573|DRUG|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
48367234|NCT00612573|DRUG|Placebo|Placebo, 12 weeks
48687471|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
48687472|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
48687473|NCT02192892|DIETARY_SUPPLEMENT|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
48687474|NCT02192892|DIETARY_SUPPLEMENT|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
48687475|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge flour|Porridge from commercial porridge flour
48687476|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge bar|Porridge from commercial porridge bar
48687477|NCT02192892|DIETARY_SUPPLEMENT|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
48687478|NCT05078931|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks for up to 35 cycles
48687479|NCT05078931|DRUG|Lenvatinib|Lenvatinib 20mg will be administered orally daily.
48687480|NCT05503706|OTHER|1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo|dandruff shampoo
48687481|NCT06353152|DRUG|Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection|single-/multiple-dose infusion
48687482|NCT01461746|DRUG|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
48687483|NCT01461746|DRUG|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
48687484|NCT01461746|RADIATION|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
48687485|NCT06279117|BEHAVIORAL|therapeutic touch|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
48159432|NCT02433392|PROCEDURE|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
48159433|NCT02599376|DEVICE|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
48159434|NCT06646783|DRUG|[68Ga]Ga-NODAGA-SNA014|Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.
48159435|NCT06094842|DRUG|Bendamustine|Given IV
48687486|NCT00978419|DRUG|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
48159436|NCT06094842|PROCEDURE|Biopsy|Undergo tissue biopsy
48159437|NCT06094842|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48159438|NCT06094842|PROCEDURE|Bone Scan|Undergo bone scan
48159439|NCT06094842|PROCEDURE|Bridge Therapy|Undergo bridging therapy
48159440|NCT06094842|PROCEDURE|Computed Tomography|Undergo CT
48159441|NCT06094842|DRUG|Cyclophosphamide|Given IV
48159442|NCT06094842|PROCEDURE|Echocardiography|Undergo ECHO
48159443|NCT06094842|DRUG|Fludarabine|Given IV
48159444|NCT06094842|PROCEDURE|Leukapheresis|Undergo leukapheresis
48159445|NCT06094842|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48159446|NCT06094842|BIOLOGICAL|T-cell Receptor-engineered T-cells|Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
48159447|NCT06094842|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
48159448|NCT05597306|DRUG|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
48159449|NCT05597306|DRUG|Venetoclax|Venetoclax will be administered orally once daily via tablet.
48159450|NCT04117711|DRUG|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
48159451|NCT04117711|DRUG|Placebo|Matching placebo will be administered once in the morning before breakfast
48159452|NCT05644236|OTHER|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
48002194|NCT06207539|DRUG|hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
48159453|NCT05760885|BEHAVIORAL|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
48159454|NCT05760885|BEHAVIORAL|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
48159455|NCT00213915|DRUG|12 g of L-arginine glutamate during 6 weeks twice a day|
48159456|NCT06336707|DRUG|HS-20089|Intravenous infusion
48367235|NCT01234558|DRUG|GLYX-13|single IV dose
48367236|NCT03355872|DRUG|HLX01|Biosimilar of Rituximab
48159457|NCT06336707|DRUG|Adebrelimab|Intravenous infusion
48159458|NCT06336707|DRUG|Bevacizumab|Intravenous infusion
48159459|NCT06336707|DRUG|Cisplatin / carboplatin|Intravenous infusion
48159460|NCT06386575|OTHER|control group; Patients who received physiological saline|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the control group will be given 40 milliliters of physiological saline during the suprainguinal fascia iliaca block.
48159461|NCT06386575|OTHER|suprainguinal fascia block; Patients receiving local anesthetic|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the sfıb group will be given 40 milliliters of 0.25 % bupivacaine during the suprainguinal fascia iliaca block.
48367237|NCT05539664|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|The experimental group used the experimental medical device Hydrogen-Oxygen Generator with Nebulizer(Shanghai Asclepius Meditec Co., Ltd. ) The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
48687487|NCT00978419|DRUG|Placebo|Placebo administered every day for up to 28 days
48687488|NCT02858440|BIOLOGICAL|Infanrix-IPV/Hib|Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
48687489|NCT01184703|OTHER|Low GI food|Comparison of carbohydrates in diabetic patients
48687490|NCT05470985|DRUG|Ozanimod|Specific dose on specific days
48159462|NCT02040532|DRUG|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
48159463|NCT05872984|DIAGNOSTIC_TEST|adjustment of dry weight based on absolute blood volume measurement|adjustment of dry weight based on absolute blood volume measurement
48159464|NCT03640793|DEVICE|Implantation|Implantation of 6 PPIS implants
48159465|NCT04734171|BEHAVIORAL|Digital social activity video intervention|A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.
48159466|NCT04734171|BEHAVIORAL|Informational sheet|An informational sheet to learn about the COVID-19 outbreak (standard).
48159467|NCT04734171|BEHAVIORAL|Stigma awareness video intervention|A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
48159468|NCT05789199|DRUG|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
48002195|NCT06207539|DRUG|misoprostol under the generic name of misotac tablets|compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
48002196|NCT02114879|BEHAVIORAL|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
48159469|NCT05234008|OTHER|High intensity training at home|"A HIT exercise intervention is performed. Four sessions are performed at REVAL Research Center to educate participants on the exercise protocol. Eight exercise sessions are performed at home with support of Physitrack (a mobile application for participants and a software platform for researchers).~In-center program (2 weeks, 4 sessions): Participants perform a concurrent exercise protocol of 1h-1.5h, as published by our research team previously, consisting of cardiorespiratory, general resistance, and core muscle training, all at high intensity.~Home sessions (4 weeks, 8 sessions): Researchers provide participants with a fitness bike, smartwatch, and training mat. Using Physitrack, researchers formulate a personalized HIT program to be performed at home for each participant by selecting from \>3500 exercises or insert a new exercise to add to the library. This HIT program resembles the program performed in the rehabilitation center as much as possible."
48159470|NCT06115642|DRUG|HLX43|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
48159471|NCT03637621|OTHER|ORIF|open reduction internal fixation of the distal humerus
48159472|NCT00924209|DRUG|Gemcitabine|1250 mg/m\^2 dose for two doses on days 1 and 8
48159473|NCT00924209|DRUG|Cisplatin|80 mg/m\^2 on day 1
48159474|NCT00924209|DRUG|Bevacizumab|7.5 mg/m\^2 on day 1 every 21 days for first two cycles only
48159475|NCT00924209|PROCEDURE|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
48159476|NCT00924209|DRUG|Etoposide|100 mg/m\^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
48687491|NCT04285554|DEVICE|iRF System Hepatic Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
48687492|NCT03925272|PROCEDURE|Collection of samples (blood, stool, etc.)|
48687493|NCT03925272|GENETIC|Genetic determinants analysis|
48687494|NCT03925272|PROCEDURE|Sample obtained after surgery performed in the context of care|
48687495|NCT05100771|OTHER|Pediatric brain MRI|Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
48687496|NCT05600985|PROCEDURE|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
48002197|NCT02114879|BEHAVIORAL|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
48002198|NCT05324163|DRUG|X0002 Spray|X0002 spray 17.5mg, twice a day; Celecoxib placebo 200mg, once a day
48159477|NCT05639946|DRUG|brivaracetam|Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
48159478|NCT05639946|DRUG|Placebo|Participants will receive placebo drug
48159479|NCT01827800|BEHAVIORAL|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
48159480|NCT03435809|PROCEDURE|Intrauterine insemination|Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
48159481|NCT01951105|DRUG|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
48513176|NCT04410614|PROCEDURE|Free epithelial (gingival) graft|1mm thickness epithelial layer harvested from the palate (1st molar area) is grafted and stabilised at the dental or implant area deficient of keratinized mucosa
48002199|NCT05324163|DRUG|Celecoxib capsules|X0002 spray placebo 17.5 mg, twice a day; Celecoxib capsule 200mg, once a day
48002200|NCT05324163|DRUG|placebo|X0002 spray placebo 17.5 mg, twice a day; Celecoxibplacebo 200mg, once a day
48687497|NCT01536561|BIOLOGICAL|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
48159482|NCT01951105|DRUG|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
48159483|NCT01951105|DRUG|Placebo|Take two placebo capsules three times a day for 12 weeks.
48159484|NCT02507297|DEVICE|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
48266854|NCT06381830|OTHER|Apheresis|Participants will undergo two separate apheresis procedures, including: G-CSF primed hematopoietic stem cell collection and peripheral blood mononuclear cell apheresis for CAR-T cell manufacturing.
48513177|NCT00451945|PROCEDURE|biopsy|
48513178|NCT00451945|DEVICE|3d-ultrasound and fusion of UL and PET/CT|
48513179|NCT03892499|DRUG|Olinciguat|Oral Tablet
48513180|NCT03892499|DRUG|Itraconazole|Oral Capsule
48687498|NCT00093262|DRUG|clevidipine|
48002201|NCT01262885|DRUG|GSK2251052|500 mg tablet, dose levels detailed in Arm description
48002202|NCT01262885|DRUG|Placebo|matching placebo tablet
48002203|NCT00554671|OTHER|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
48002204|NCT00554671|BEHAVIORAL|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
48513181|NCT01516918|DRUG|VX-222|tablet, 400-mg twice daily
48513182|NCT01516918|DRUG|telaprevir|tablet, 1125-mg twice daily
48513183|NCT01516918|DRUG|ribavirin|tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
48513184|NCT01516918|BIOLOGICAL|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
48513185|NCT03311750|DRUG|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
48513186|NCT00442455|DRUG|Erlotinib chlorhydrate|150 mg/day for 7 weeks
48513187|NCT00442455|DRUG|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
48513188|NCT00442455|PROCEDURE|Radiation therapy|63 Gy, five days a week, for 7 weeks
48687499|NCT00093262|DRUG|placebo|
48687500|NCT01326091|OTHER|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
48687501|NCT05202899|DRUG|sugammadex|The use of sugammadex
48687502|NCT04317339|DRUG|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
48687503|NCT04317339|DRUG|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
48687504|NCT01564212|OTHER|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
48687505|NCT01564212|OTHER|laminar airflow with surgical drapes|
48687506|NCT01564212|OTHER|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
48687507|NCT01564212|OTHER|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
48687508|NCT05033184|BEHAVIORAL|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
48687509|NCT05033184|BEHAVIORAL|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
48687510|NCT00548626|PROCEDURE|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
48687511|NCT00548626|PROCEDURE|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
48159485|NCT03823261|BEHAVIORAL|Cognitive Behavioral Therapy|HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
48002205|NCT00554671|BEHAVIORAL|Group support|Peer support are provided in the group setting
48002206|NCT00554671|BEHAVIORAL|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
48002207|NCT01730183|OTHER|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
48687512|NCT01078194|DEVICE|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
48687513|NCT02531139|OTHER|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
48687514|NCT02531139|OTHER|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
48687515|NCT04717024|DEVICE|Observational Study - no intervention|Observational Study - no intervention
48687516|NCT05993988|OTHER|Exercise|Muscle relaxing Technique
48687517|NCT00822159|DEVICE|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
48687518|NCT02006108|DRUG|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
48687519|NCT02006108|OTHER|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
48687520|NCT02448992|RADIATION|hippocampal-sparing WBRT|
48687521|NCT05965050|DIAGNOSTIC_TEST|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
48002208|NCT02699203|BEHAVIORAL|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
48159486|NCT03535493|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
48159487|NCT03535493|BEHAVIORAL|Float REST|A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
48159488|NCT03535493|BEHAVIORAL|ACT + Float REST|The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
48159489|NCT00068718|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
48687522|NCT05965050|OTHER|Ultrasound Therapy|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
48687523|NCT00918606|DRUG|LIPO-102|LIPO-102
48687524|NCT06429709|DEVICE|Advanced Ultrasound Otoscope|The Advanced Ultrasound Otoscope is a tool for visualization of the human tympanic membrane and detection of middle ear effusion type
48002209|NCT02699203|BEHAVIORAL|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
48002210|NCT01192971|DRUG|Apatinib|apatinib p.o. once daily for 4 weeks
48002211|NCT01090726|DEVICE|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
48002212|NCT01090726|DEVICE|Airtraq|Airtraq being used for the actual intubation
48159490|NCT02497547|DRUG|Oxytocin|
48159491|NCT02497547|DRUG|Placebo|
48159492|NCT03191526|DRUG|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
48159493|NCT03191526|DRUG|Placebo (saline)|Intravenous injection every 12 weeks.
48687525|NCT00604318|DRUG|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
48687526|NCT03391557|DIAGNOSTIC_TEST|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
48687527|NCT00854724|DRUG|Puerarin, Placebo|400 mg, three times a day for 7 days
48687528|NCT05069597|DRUG|CREON|Capsule; Oral
48687529|NCT06262191|DEVICE|Differential and adjustable stiffness AFO (DAS-AFO)|Walking with a differential and adjustable stiffness AFO (DAS-AFO)
48159494|NCT02166788|PROCEDURE|Inguinal Lymphadenectomy|
48159495|NCT02166788|PROCEDURE|Ilio-inguinal Lymphadenectomy|
48513189|NCT03148665|DEVICE|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
48687530|NCT04960748|BEHAVIORAL|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
48687531|NCT00584818|DRUG|PB127 for Injectable Suspension|"Stages 1 \& 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 \& 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
48687532|NCT02345408|DRUG|CCX872-B|Tablets (oral administration)
48687533|NCT00438360|DRUG|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
48687534|NCT00438360|DRUG|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
48687535|NCT03470740|BEHAVIORAL|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
48002213|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 25G Whitacre needle|- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 25-gauge pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
48002214|NCT06184425|PROCEDURE|Dural Puncture Epidural technique using pencil-point 27G Whitacre needle|- DPE technique was performed in the sitting position at the L3/4 or L4/5 interspace via the midline approach using a 17-gauge Touhy needle and a loss of resistance to saline technique, then the dura was punctured with a 27-gauage pencil point Whitacre spinal needles using a needle-through-needle technique, and spontaneous flow of cerebrospinal fluid was confirmed, then the spinal needle was removed and a flexible 19-gauge, spring closed-tip catheter was inserted 5 cm into the epidural space toward the cranial side.
48002215|NCT06376240|DIETARY_SUPPLEMENT|Pyridoxamine 300mg per day|oral supplement
48002216|NCT06376240|OTHER|Placebo 300mg placebo per day|oral supplement
48159496|NCT02959255|DRUG|Esomeprazole|dosage difference
48159497|NCT05110651|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
48159498|NCT00665106|DRUG|"NOVA63035 Corticosteroid"|Single injection in the study eye
48159499|NCT05959109|DRUG|Peresolimab|Administered SC
48159500|NCT05897125|OTHER|Virtual at Home Medication Reconciliation Visit(s)|Patients will have their medications reviewed by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
48159501|NCT05897125|BEHAVIORAL|Virtual At Home Medication Education Visit(s)|Patients will be provided with inhaler education by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
48513190|NCT00644930|DEVICE|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
48002217|NCT00677807|DRUG|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
48002218|NCT00677807|DRUG|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
48159502|NCT05897125|OTHER|COPD advanced practice nurse Inpatient Consult|Patients will receive a COPD consult by an advanced practice nurse as part of standard of care
48159503|NCT05897125|OTHER|Inpatient Medication Reconciliation|Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care
48513191|NCT00644930|DEVICE|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist-control or synchronized intermittent mandatory ventilation (SIMV) mode.
48513192|NCT03973307|DIAGNOSTIC_TEST|UroX bladder cancer biomarker test|Urine test using novel UroX biomarker test for bladder malignancy
48513193|NCT01611779|DEVICE|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
48513194|NCT00219817|DRUG|RC-1291 HCl|
48687536|NCT05101733|DIAGNOSTIC_TEST|Nasal provocation|Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
48367238|NCT05539664|DEVICE|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen)|the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen). The flow rate was 3L/min, and the cumulative treatment time was not less than 6 hours per day.
48367239|NCT03682926|OTHER|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
48367240|NCT04855474|DIETARY_SUPPLEMENT|Amino Acid Intake|Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
48367241|NCT00203294|DRUG|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
48367242|NCT00203294|DRUG|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
48367243|NCT06067373|OTHER|questionnaire|"After agreeing to participate, the patients receive a questionnaire in paper form.~This consists of a total of 12 higher-level self-compiled questions as well validated survey instruments. The free questions relate, among other things, to to the surgery postponement, the associated burden, complications occurred, Effects on the employment situation, as well as the current state. The following validated survey instruments are used in the questionnaire: the NCCN Distress Thermometer to record the mental stress, a Severity Symptom Scale to record the symptom burden and the PROMIS-10 for recording the health-related life quality."
48367244|NCT00160147|DRUG|bifeprunox|One week titration with dose adjustments
48367245|NCT00160147|DRUG|Placebo|Placebo
48367246|NCT04678804|PROCEDURE|Mucogingival surgery for single recession coverage|"The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm."
48367247|NCT00113321|DRUG|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
48687537|NCT05101733|DIAGNOSTIC_TEST|Skin-Prick Test|Skin-Prick-Test is administered to determine an allergy against Alternaria
48002219|NCT00062569|BEHAVIORAL|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
48367248|NCT02414100|OTHER|Laboratory Biomarker Analysis|Correlative studies
48367249|NCT02414100|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48367250|NCT02082743|BEHAVIORAL|Outdoor activity in recess time|Outdoor activity in recess time
48367251|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg twice daily (BID)
48687538|NCT05101733|DIAGNOSTIC_TEST|Blood draw|For further analysis
48687539|NCT05101733|DIAGNOSTIC_TEST|Collection of nasal secretion|Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
48687540|NCT04014751|OTHER|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
48687541|NCT01324050|BEHAVIORAL|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
48002220|NCT00062569|BEHAVIORAL|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
48002221|NCT02507635|DRUG|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
48159504|NCT05897125|OTHER|Post-discharge nurse 48 hour phone follow-up call|Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care
48159505|NCT05897125|OTHER|Post-discharge follow-up advanced practice nurse outpatient visit|Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care
48002222|NCT02507635|DRUG|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
48002223|NCT01041872|DRUG|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
48687542|NCT01324050|BEHAVIORAL|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
48687543|NCT06531187|OTHER|Evidence-Based Practice (EBP) Teaching|"The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP)."
48159506|NCT03029611|DRUG|Carboplatin|Given IV
48159507|NCT03029611|PROCEDURE|Gynecological Surgical Procedure|Undergo cytoreductive surgery
48159508|NCT03029611|OTHER|Laboratory Biomarker Analysis|Correlative studies
48513195|NCT03495921|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
48002224|NCT01041872|DRUG|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
48002225|NCT01041872|DRUG|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
48159509|NCT03029611|DRUG|Paclitaxel|Given IV
48159510|NCT03029611|BIOLOGICAL|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
48159511|NCT03340766|DRUG|Blinatumomab|Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
48159512|NCT03340766|DRUG|Pembrolizumab|One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
48513196|NCT03495921|DRUG|Irinotecan|Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.
48002226|NCT01041872|DRUG|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
48159513|NCT02176317|BIOLOGICAL|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10\^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
48159514|NCT04828486|DRUG|Futibatinib|Given PO
48159515|NCT04828486|BIOLOGICAL|Pembrolizumab|Given IV
48159516|NCT04828486|OTHER|Quality-of-Life Assessment|Ancillary studies
48159517|NCT04929483|DRUG|BIO89-100|Subcutaneous injection
48159518|NCT04929483|DRUG|Placebo|Subcutaneous injection
48159519|NCT05840016|DRUG|AK112, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
48159520|NCT05840016|DRUG|Tislelizumab, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
48159521|NCT05306613|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
48687544|NCT04514627|DEVICE|Auricular percutaneous neurostimulation|The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
48002227|NCT01041872|DRUG|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
48002228|NCT01041872|DRUG|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
48002229|NCT05381584|PROCEDURE|laparoscopy|laparoscopy will be done under anesthesia for management for cases with blind vagina
48159522|NCT05306613|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
48159523|NCT03223935|OTHER|Corn nuts|Roasted corn nut snack
48159524|NCT03223935|OTHER|Chickpeas|Roasted chickpea snack
48159525|NCT03223935|OTHER|Yellow peas|Roasted yellow pea snack
48159526|NCT03223935|OTHER|Pinto beans|Roasted pinto bean snack
48159527|NCT03223935|OTHER|Soybeans|Roasted soybean snack
48159528|NCT03223935|OTHER|Almonds|Roasted almond snack
48159529|NCT03165344|OTHER|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
48159530|NCT03165344|OTHER|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
48159531|NCT03165344|OTHER|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
48159532|NCT03967119|DEVICE|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/\[(PWmax+PWmin)/2\].
48002230|NCT03718611|DRUG|BR9001|BR9001 is a test drug as generic
48002231|NCT03718611|DRUG|BR900A|BR900A is a reference drug
48002232|NCT06237153|DRUG|Triamcinolone Acetonide extended release suspension|Active steroid
48159533|NCT05813132|DRUG|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
48159534|NCT05813132|DRUG|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
48159535|NCT01095237|DEVICE|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
48159536|NCT04673305|OTHER|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
48159537|NCT05834972|DEVICE|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
48159538|NCT04128514|DEVICE|Panoptix Toric|Cataract surgery and IOL implantation
48687545|NCT03241277|PROCEDURE|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
48687546|NCT02644096|OTHER|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
48002233|NCT02273219|DRUG|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
48002234|NCT02273219|DRUG|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
48002235|NCT05594394|BEHAVIORAL|Orai: Master Public Speaking|"Participants will access the Orai: Master Public Speaking (Sani, Dhamani, \& Gupta, 2020) platform with mobile and web-based applications. Communication skill-building moduleswill be assigned using exercises, case scenarios, and AI-assisted feedback debriefing through the Orai application.~Participants will also complete case scenarios created with specific nursing conflict issues a charge nurse may encounter in an acute care facility. Upon completion of the competency development program, participants will complete the CMCSS to determine the effect on confidence levels and a brief survey (Appendix C) to assess the amicability of the program."
48002236|NCT03212625|DRUG|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
48002237|NCT03212625|DRUG|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
48159539|NCT05969119|DRUG|Pyridostigmine|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
48159540|NCT05969119|DRUG|Placebo|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
48159541|NCT03352661|OTHER|Collect retrospectively data|Collect retrospectively data
48159542|NCT04949789|OTHER|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
48159543|NCT04949789|OTHER|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
48367252|NCT01287260|DRUG|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg once daily (OD)
48513197|NCT03495921|DRUG|Temozolomide|Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
48513198|NCT03900052|DEVICE|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
48513199|NCT03900052|DEVICE|typical cane|Typical training cane loading training
48687547|NCT04415294|DIAGNOSTIC_TEST|Critical flicker frequency|Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device
48687548|NCT06549166|OTHER|Experimental: VR and exercise|Participants will perform a 20-minute exercise program consisting of neck joint mobility exercises, neck and scapulothoracic muscle strengthening exercises, and stretching exercises. Then, for the next 20 minutes, they will engage in active neck movements using the Oculus Quest2 headset with the Ocean Rift game.
48687549|NCT06549166|OTHER|Sham Comparator: exercise|The control group will perform a 40-minute same neck exercises.
48687550|NCT05864430|OTHER|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
48513200|NCT03876626|OTHER|PositiveLinks RX Mobile App|A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
48513201|NCT03876626|OTHER|PositiveLinks RX Portal|An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
48687551|NCT05864430|OTHER|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
48687552|NCT05864430|OTHER|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
48159544|NCT04949789|OTHER|IP I|2 Capsules to be taken 30 minutes before breakfast.
48159545|NCT04949789|OTHER|IP II|2 Capsules to be taken 30 minutes before breakfast.
48159546|NCT04949789|OTHER|IP III|2 Capsules to be taken 30 minutes before breakfast.
48159547|NCT00243217|DRUG|SPM 936|
48687553|NCT04351399|OTHER|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
48159548|NCT06379763|OTHER|diaphragmatic breathing exercise|15-minute diaphragmatic breathing exercise from a semi-Fowler's position. Patients will be instructed to position one hand on the chest and the other on the belly, gradually inhaling deeply through the nose, moving from functional residual capacity to total lung capacity, and holding the breath for three seconds. Patients will be advised to relax their shoulders, maintain quiet upper chest movement, and allow the abdomen to slightly rise. Subsequently, patients will exhale slowly through the mouth for up to five seconds. Diaphragmatic breathing exercises will be organized into three sets lasting 15 minutes, with 3 minutes of active exercise and a 2-minute rest period between sets. During rest intervals, patients will be instructed to breathe normally. If individuals experience dizziness or discomfort, the session will stop.
48159549|NCT06379763|OTHER|conventional physiotherapy exercise|conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
48513202|NCT05795647|DRUG|Pentoxifylline+Tocopherol|Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
48159550|NCT04923230|BEHAVIORAL|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
48367253|NCT04944121|DRUG|RSLV-132|10 mg/kg RSLV-132 administered by intravenous infusion
48367254|NCT04944121|DRUG|Sodium Chloride 0.9%|0.9% sodium chloride administered by intravenous infusion
48513203|NCT02413567|DEVICE|DMR Procedure (Fractyl)|Endoscopic procedure
48687554|NCT02836717|DEVICE|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
48687555|NCT00834600|DRUG|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg
48159551|NCT06350084|BEHAVIORAL|Mother's Touch|Heel blood will be taken while the infant was Mother's Touch. Mother's touch will be applied to the infants before, during and after the procedure.
48367255|NCT02391649|BEHAVIORAL|Self-learning program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5:Dealing with \[physical and mental health\] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
48687556|NCT00834600|DRUG|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
48687557|NCT03371576|DEVICE|intraocular lenses|
48687558|NCT05777668|RADIATION|Volumetric modulated radiotherapy|
48687559|NCT02931643|OTHER|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
48687560|NCT02931643|OTHER|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
48687561|NCT03292874|DIAGNOSTIC_TEST|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
48687562|NCT02516995|DEVICE|Functional magnetic resonance imaging|
48159552|NCT06350084|BEHAVIORAL|Nurse's Therapeutic Touch|Heel blood will be taken while the infant was Nurse's Therapeutic Touch.Therapeutic Touch will be applied to the infants before, during and after the procedure.
48159553|NCT00588991|DRUG|Carboplatin|Given IV
48159554|NCT00588991|OTHER|Laboratory Biomarker Analysis|Correlative study
48159555|NCT00588991|DRUG|Topotecan Hydrochloride|Given IV
48159556|NCT00588991|DRUG|Veliparib|Given orally
48159557|NCT02061215|OTHER|CMV viral load|
48159558|NCT06270407|DRUG|Tranexamic Acid 100 MG/ML|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
48159559|NCT06270407|DRUG|0.9%sodium chloride|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
48159560|NCT00040521|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|
48159561|NCT02286297|DEVICE|McGRATH® MAC|video-laryngoscopy-1
48159562|NCT02286297|DEVICE|AirTraq|video-laryngoscopy-2
48159563|NCT02286297|DEVICE|GlideScope|video-laryngoscopy-3
48367256|NCT02391649|BEHAVIORAL|Psycho-education program (in Phase 2)|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
48687563|NCT02516995|DEVICE|Ultrasound|
48687564|NCT02830854|OTHER|Molecular Hydrogen|
48687565|NCT03694340|OTHER|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
48687566|NCT03978741|DEVICE|Yōni.Fit Test Device|The Yōni.Fit Test Device is a silicone pessary.
48687567|NCT03978741|DEVICE|Yōni.Fit Comparator Device|The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
48687568|NCT01000298|DRUG|Placebo|liquid placebo medication given twice per day for 7 days
48687569|NCT01000298|DRUG|Amoxicillin|liquid amoxicillin given twice per day for 7 days
48687570|NCT01000298|DRUG|Cefdinir|liquid cefdinir given twice per day for 7 days
48687571|NCT03726658|DRUG|AGN-241751|AGN-241751 is supplied in tablet form
48687572|NCT03726658|DRUG|Placebo|Placebo is supplied in tablet form
48687573|NCT01018017|DRUG|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
48687574|NCT01018017|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
48687575|NCT00082368|DRUG|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
48687576|NCT00082368|DRUG|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
48687577|NCT02277249|DRUG|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
48687578|NCT02277249|DRUG|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
48687579|NCT05746013|DIETARY_SUPPLEMENT|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
48687580|NCT02524236|DRUG|Botox injection in the prostate|transrectal access of prostatic injection
48159564|NCT02286297|DEVICE|Miller|Direct laryngoscopy
48266855|NCT06381830|OTHER|Autologous Stem Cell Transplantation|Participants are designed to receive myeloablative conditioning regimen prior to infusion of a minimum 2 x 10\^6 CD34+ stem cells/kilogram.
48159565|NCT04127383|DEVICE|Assessment of Burden of Chronic Conditions (ABCC)-tool|The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient completes the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, diabetes type 2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a score on that domain. If a patient and healthcare provider select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
48159566|NCT00138645|BEHAVIORAL|MicroDiet|MicroDiet
48159567|NCT00138645|BEHAVIORAL|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
48687581|NCT00647244|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
48687582|NCT00647244|DRUG|Abacavir|Abacavir 300 mg oral tablet twice daily
48687583|NCT03855046|DRUG|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
48687584|NCT03855046|PROCEDURE|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
48687585|NCT02674464|BEHAVIORAL|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
48002238|NCT04079985|OTHER|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
48002239|NCT01618357|RADIATION|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
48002240|NCT01618357|PROCEDURE|Lumpectomy/Mastectomy|Resection of breast cancer.
48159568|NCT05001815|DEVICE|Continuous subcutaneous insulin infusion (CSII)|The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
48159569|NCT05001815|DEVICE|Multiple daily insulin injection (MDI)|Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
48159570|NCT00658801|RADIATION|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~1. Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~2. Group 2: 5cm \<Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
48266856|NCT06381830|DRUG|CAR-T Cell Therapy|CAR-T cells will be infused within 7 days after autologous hematopoietic stem cell infusion (2-10×10\^6 CAR-T/kg，ivgtt).
48367257|NCT06471686|DRUG|Acamprosate|2 pills three times a day
48367258|NCT05950399|PROCEDURE|Echocardiography|Undergo resting echocardiography
48367259|NCT05950399|OTHER|Electronic Health Record Review|Ancillary studies
48367260|NCT05950399|OTHER|Questionnaire Administration|Ancillary studies
48367261|NCT05950399|PROCEDURE|Stress Echocardiography|Undergo stress echocardiography
48367262|NCT05645939|OTHER|Diasgnosis of hypertrophic cardiomyopathy|Patients diagnosed with hypertrophic cardiomyopathy during study period
48367263|NCT05652361|OTHER|Additional visualisation of surgical assistance during surgery|Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
48687586|NCT02674464|BEHAVIORAL|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
48687587|NCT02674464|BEHAVIORAL|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
48687588|NCT02674464|BEHAVIORAL|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
48159571|NCT05889221|OTHER|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
48159572|NCT02375607|DEVICE|Algometer|Algometer performed patients
48159573|NCT04468633|DEVICE|Baerveldt 350 implant|The Baerveldt implant is an FDA-approved silicone, non-valved implant.
48159574|NCT04468633|DEVICE|Ahmed ClearPath 350 implant|The Ahmed ClearPath is a non-valved glaucoma drainage device.
48159575|NCT05750121|BEHAVIORAL|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
48159576|NCT04903912|DIAGNOSTIC_TEST|Vascular ultrasound or other imaging methods according to current guidelines|Peripheral vascular ultrasound / ankle/brachial index / CT angiography / MR angiography / angiography
48159577|NCT04903912|DIAGNOSTIC_TEST|Laboratory tests|Metabolic profile and platelet reactivity
48159578|NCT04903912|DRUG|Medical treatment according to current guidelines|Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
48159579|NCT04903912|PROCEDURE|Endovascular od surgical peripheral revascularizations|Endovascular od surgical peripheral revascularizations according to current guidelines
48159580|NCT03378895|BEHAVIORAL|online questionnaire|Risk assessment identified by online questionnaire
48159581|NCT02459132|BEHAVIORAL|High-intensity aerobic interval exercise|See arm/group description
48159582|NCT05126199|OTHER|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
48159583|NCT05126199|OTHER|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
48159584|NCT01024829|RADIATION|Radiotherapy|Radiotherapy
48159585|NCT02683317|DIETARY_SUPPLEMENT|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
48159586|NCT02683317|DIETARY_SUPPLEMENT|sunflower oil|Sunflower similar to the excipient used in experimental group
48159587|NCT03002233|DRUG|TRK-820|
48159588|NCT03336684|BEHAVIORAL|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
48159589|NCT05852496|DRUG|Vitamin D|vitamin D supplement in cancer patients which receive taxane drugs with vit D deficiency and complaining from Peripheral neuropathy.
48159590|NCT03427645|BEHAVIORAL|Decision tool|A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
48159591|NCT04783987|OTHER|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
48367264|NCT04663646|OTHER|Optokinetic stimulation|"Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected.~The study will be carried out for 10 weeks with a frequency of two weekly sessions. During them, the participants will receive stimulation with OKS.~Stimulation will be performed at 1 cm/second, the vertical black bars will move to the left. The bars change color and the participants will be asked to detect the changes that will occur in the stimulus."
48002241|NCT01618357|DRUG|Veliparib|Pills to be taken twice a day during radiation and for one week after completion of radiation for a total of 29 days.
48002242|NCT03194451|OTHER|non-interventional study|teeth collection
48159592|NCT00220116|DRUG|Capecitabine, Oxaliplatin|
48159593|NCT05639166|BIOLOGICAL|IBIO123|IBIO123 10 mg
48159594|NCT05639166|OTHER|Placebo|Matching Placebo
48159595|NCT04193397|BEHAVIORAL|Exercise training|Resistance training program performed during 6 months, 3 sessions per week
48159596|NCT04795076|DIETARY_SUPPLEMENT|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
48002243|NCT03778151|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
48002244|NCT04780386|DRUG|NVP-1805|orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4)
48687589|NCT02674464|BEHAVIORAL|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
48367265|NCT04663646|OTHER|Placebo|Participants are placed in a standing position, with support products, if necessary, and virtual reality glasses will be placed where the visual stimuli will be projected. In this group, stimulation consists of a video with static vertical bars that change their colour at a randon intervals, in the same way that in the intervention group. The difference between groups is that in control group, bars are not in movement, preventing from generating optokinetic stimulation.
48159597|NCT05213559|OTHER|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
48159598|NCT05213559|OTHER|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
48159599|NCT03441737|BEHAVIORAL|Exercise|20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
48159600|NCT03441737|BEHAVIORAL|Non-Exercise|20 minutes of sitting in the laboratory with access to magazines and the internet.
48159601|NCT06285383|OTHER|Music listening|Participants will listen to the music pieces Pachabel Canon in D major (30 minutes), free from external sounds (max 70 dB through headphones).
48159602|NCT06285383|OTHER|classic physical therapy|classic physical therapy
48159603|NCT02088723|BEHAVIORAL|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
48159604|NCT02211599|OTHER|15% protein|Meal to provide 15%en from protein.
48159605|NCT02211599|OTHER|30% protein|Meal to provide 30%en from protein.
48159606|NCT02211599|OTHER|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
48513204|NCT04004416|OTHER|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
48513205|NCT04004416|DRUG|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
48687590|NCT02674464|BEHAVIORAL|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
48687591|NCT02282072|DEVICE|Deep brain stimulation：PINS Stimulation System|
48687592|NCT01047007|DRUG|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
48687593|NCT01047007|DRUG|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
48687594|NCT01047007|DRUG|CDDP|CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
48687595|NCT01047007|DRUG|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
48687596|NCT01814865|DRUG|Abiraterone Acetate|1000 mg PO OD x 2 weeks
48002245|NCT04780386|DRUG|NVP-1805-R1and NVP-1805-R2|orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4)
48687597|NCT01814865|DRUG|Prednisone|5 mg PO OD x 2 weeks
48687598|NCT01814865|DRUG|Aromatase Inhibitor|1 mg PO OD x 2 weeks
48687599|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
48687600|NCT00255918|DRUG|Placebo|Placebo dosed to match active medication
48002246|NCT02608112|DRUG|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
48002247|NCT02608112|DRUG|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
48002248|NCT00945022|DEVICE|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
48159607|NCT03274206|BIOLOGICAL|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
48159608|NCT03274206|DRUG|Placebo|BLS-ILB-E710c-placebo
48159609|NCT02745184|BIOLOGICAL|Lung stem cells|Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
48159610|NCT05414435|BEHAVIORAL|Reading of informed consent form|Patients that adequately read informed consent forms
48159611|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
48159612|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
48159613|NCT00323895|DEVICE|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
48159614|NCT01039558|DRUG|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
48159615|NCT01039558|DRUG|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
48513206|NCT05537636|OTHER|Rehabiltiation using exercise and manual therapy|"A licensed Physical Therapist will provide manual therapy to help restore spinal and scapular mobility. In association with this patients will be prescribed home exercises using a phased approach.~Phase 1 to gain mobility of the spine and scapular motor control Phase 2 to gain shoulder mobility to strengthen scapular and spine musculature Phase 3 shoulder strengthening with long lever arms."
48002249|NCT02237846|BIOLOGICAL|Human umbilical cord tissue-derived mesenchymal stem cells|
48002250|NCT00576277|DRUG|AV411|
48159616|NCT01039558|DRUG|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
48159617|NCT01369706|DEVICE|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
48159618|NCT01083537|DRUG|Cisplatin|"1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
48159619|NCT01083537|DRUG|Paclitaxel|"2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
48159620|NCT00204100|DEVICE|Surface Functional Electrical Stimulation|
48159621|NCT01842399|DIETARY_SUPPLEMENT|Resveratrol|Nutriceutical
48159622|NCT01842399|DRUG|Placebo|2x/day orally
48002251|NCT02311465|OTHER|Palliative Care|"Components of the palliative care service intervention are expected to include:~* Establishment of a palliative care plan~* Care coordination by palliative care team~* Informational, patient friendly materials supporting Palliative Care~* Communication by palliative care team to all providers and teams involved in patient's care~* Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~* Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
48159623|NCT03759132|PROCEDURE|Transcranial direct current stimulation|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
48159624|NCT06589453|DEVICE|Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants|This is a unique nasal elevator aiming to improve nasolabial esthetics in conjunction with digital nasoalveolar molding appliance when used in bilateral cleft lip and palate infants.
48159625|NCT06589453|DEVICE|Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants|Nasal stent that is used in conjunction with digital nasoalveolar molding in bilateral cleft lip and palate infants
48159626|NCT02312609|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
48266857|NCT03118596|DEVICE|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
48367266|NCT04310852|DEVICE|BioCue Concentration Kit|The treatment will be carried out in the operating room under ordinary hospitalization and involves the application of 9 ml of autologous bone marrow concentrate in the knee affected by arthrosis. Specifically, 3 ml will be applied at the level of the bone-cartilage interface of the femur, 3 ml at the level of the bone-cartilage interface of the tibia, and 3 ml will be injected into the joint for a simultaneous action also at the level of the cartilage. To obtain the necessary amount of bone marrow concentrate, an aspirate of bone marrow will be taken from the iliac crest (60 ml) and homolateral tibia (30 ml) of the patient and concentrated by BioCue Concentration Kit, company Zimmer biomet, and centrifuge. This autologous bone marrow concentrate will be injected by means of the Perfuse at the level of the tibial and femoral bone-cartilage interface of the percutaneous arthrosis affected compartment under radiographic control.
48367267|NCT02203305|DEVICE|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
48367268|NCT02203305|OTHER|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
48367269|NCT04229342|PROCEDURE|Per-oral endoscopic myotomy|"Per-oral endoscopic myotomy (POEM) is an endoscopic modality for the management of achalasia cardia. In this study, we will evaluate the impact of two different techniques of posterior POEM on the incidence of gastroesophageal reflux disease (GERD).~Posterior POEM will be performed using the standard technique. The myotomy beyond the GEJ will be different in the two groups. In one group, the sling fibers will not be spared from dissection and in the second group, the sling fibers will be selectively spared from myotomy."
48367270|NCT02173158|DRUG|lomitapide|
48367271|NCT01616173|DRUG|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
48002252|NCT00000540|DEVICE|defibrillators, implantable|
48266858|NCT03118596|DEVICE|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
48002253|NCT02731729|DRUG|ipilimumab|
48002254|NCT02731729|DRUG|nivolumab|
48002255|NCT03800719|BEHAVIORAL|AWARD advice|"At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~* Ask about smoking history and habit~* Warn about the risks of smoking using a leaflet~* Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~* Refer subjects to free smoking cessation services in Hong Kong if they agree~* Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking"
48159627|NCT02973945|DEVICE|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
48687601|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
48687602|NCT03673280|PROCEDURE|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
48687603|NCT03863379|DIAGNOSTIC_TEST|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
48687604|NCT05664503|OTHER|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
48687605|NCT02964273|DRUG|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
48687606|NCT02964273|DRUG|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
48687607|NCT00389545|PROCEDURE|Intracoronary infusion of autologous bone-marrow derived stem cells|
48687608|NCT04094324|BEHAVIORAL|Questionnaires|4 questionnaires will be answered via iPads
48159628|NCT02973945|DEVICE|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
48159629|NCT02849509|DRUG|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
48367272|NCT01616173|DRUG|Dexamethasone|8mg/2mL
48687609|NCT02673099|PROCEDURE|HDF online|Hemodialysis by the HDF online method
48687610|NCT04789954|BIOLOGICAL|Eptacog alfa, activated|A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
48687611|NCT00879723|DIETARY_SUPPLEMENT|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
48002256|NCT03800719|BEHAVIORAL|Health warning leaflet|At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.
48159630|NCT02849509|DRUG|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
48159631|NCT04076956|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
48159632|NCT04213625|OTHER|Surgeon Personal Background|"Experimental group will receive an information sheet with their surgeon's educational and personal background.~Personal Background~* Favorite outdoor activity/form of exercise~* Favorite hobby~* Family information (children, pets)~* Single sentence about how the clinician conceptualizes excellent patient care"
48159633|NCT02520414|DEVICE|Symphion® Bipolar Hysteroscopic Tissue Resection System|
48159634|NCT05742256|DRUG|Oxycodone 1mg/kg|Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
48159635|NCT05742256|DRUG|Oxycodone 1.5mg/kg|Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
48159636|NCT05742256|DRUG|Sufentanil|Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
48159637|NCT04786431|OTHER|Blood collection for lipid profiling by LC-MS|Blood withdrawal
48367273|NCT01616173|DRUG|Saline|2mL
48687612|NCT06264908|BEHAVIORAL|Integrated self-management programme|"8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~1. Disease pathology and Pain management~2. Joint protection and stretching exercise~3. Psychosocial education~4. Aids prescription Each session will consist of education session, exercise session and group sharing sessions."
48687613|NCT03685474|BEHAVIORAL|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
48687614|NCT03685474|BEHAVIORAL|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
48687615|NCT04753346|OTHER|Physical Activity Level|International Physical Activity Questionnaire
48687616|NCT04753346|OTHER|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
48687617|NCT04753346|DIAGNOSTIC_TEST|Exercise Capacity|6 Minute Walk Test
48159638|NCT03043950|DRUG|Panitumumab|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
48159639|NCT03433378|DRUG|Tretinoin cream, 0.05%|Tretinoin cream, 0.05%
48159640|NCT03433378|DRUG|RETIN-A® (tretinoin) cream, 0.05%|RETIN-A® (tretinoin) cream, 0.05%
48159641|NCT03433378|DRUG|Vehicle of the test product|Vehicle of the test product
48687618|NCT04753346|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry
48687619|NCT04753346|DIAGNOSTIC_TEST|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
48687620|NCT04753346|OTHER|Cognitive Assessment|Montreal Cognitive Assessment
48687621|NCT00876096|OTHER|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
48687622|NCT03162796|DRUG|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
48687623|NCT03162796|DRUG|Placebo|Participants will receive matching placebo as SC injection.
48687624|NCT03752996|DEVICE|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
48687625|NCT04893317|DEVICE|Ablation in the ventricles with the Adagio Medical VT Cryoablation System|The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
48687626|NCT05328869|OTHER|Relaxation training|Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
48687627|NCT05328869|OTHER|No intervention|No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
48687628|NCT06271681|DRUG|15-valent pneumococcal conjugate vaccine|FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment
48687629|NCT06271681|DRUG|23-valent pneumococcal polysaccharide vaccine|23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
48687630|NCT02125838|DEVICE|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
48687631|NCT02125838|DEVICE|Endotracheal Tube|ETT
48687632|NCT02473094|DRUG|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
48159642|NCT04915456|DRUG|Systemic Steroid (Prednisolone)|Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
48159643|NCT04915456|OTHER|Placebo|Placebo additive to topical steroids in a postoperative setting after FESS
48367274|NCT01363232|DRUG|BKM120 + MEK162|
48687633|NCT02473094|DRUG|Metformin|Metformin up to 2500mg/d
48687634|NCT02473094|RADIATION|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
48687635|NCT02473094|DRUG|Placebo|Placebo up to 2500mg/d
48687636|NCT04909034|DRUG|MS-20|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
48687637|NCT04909034|DRUG|Placebo|Oral solution without active ingredients
48687638|NCT00797264|DRUG|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
48687639|NCT00797264|DRUG|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
48687640|NCT00797264|DRUG|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
48687641|NCT02370368|DEVICE|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
48687642|NCT02370368|OTHER|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
48687643|NCT02943070|DEVICE|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
48159644|NCT00003611|DRUG|acitretin|
48159645|NCT00003611|OTHER|placebo|
48159646|NCT02502851|DEVICE|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
48159647|NCT02502851|DEVICE|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
48159648|NCT04990128|COMBINATION_PRODUCT|Aspire Needle + Emcyte PureBMC|The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.
48159649|NCT04990128|DRUG|Triamcinolone|40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
48159650|NCT05954780|DRUG|Selinexor|Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
48159651|NCT00149071|DEVICE|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
48159652|NCT00149071|DEVICE|TMS|Transcraniel Magnetic Stimulation active and sham
48159653|NCT00149071|DEVICE|rTMS|active Transcranial Magnetic Stimulation
48159654|NCT00149071|DEVICE|rTMS|daily for three weeks
48159655|NCT03847389|DRUG|Clobetasol propionate 0.05% Topical Oil|thin film application of the oil twice daily
48159656|NCT06013982|BEHAVIORAL|Anxiety Reduction Bundle|"The Anxiety Reduction Bundle intervention comprises the following resources:~* Stroke Support Group~* Anxiety Reduction Sheet~* Understanding Anxiety Disorder sheet~* Your body's response to anxiety sheet~* Relaxation Tip sheet~* Breathing Tip sheet and video~* A sigh of Relief video"
48159657|NCT03745651|DRUG|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
48159658|NCT03745651|DRUG|Vehicle cream|Ruxolitinib matching vehicle cream.
48159659|NCT01630161|BEHAVIORAL|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (\<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
48159660|NCT01630161|BEHAVIORAL|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
48687644|NCT06133855|RADIATION|Pulsed electromagnetic field|The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.
47914509|NCT04017845|DIAGNOSTIC_TEST|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: \>10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
48159661|NCT04520685|DRUG|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
48159662|NCT04520685|DRUG|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
48159663|NCT03617016|DRUG|Domperidone|Participants will receive domperidone tablets orally.
48159664|NCT03617016|DRUG|Placebo|Participants will receive matching placebo to domperidone tablets orally.
48159665|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
48159666|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
48159667|NCT00946088|DRUG|Progesterone|Progesterone 400 mg per vagina qhs.
48159668|NCT00946088|DRUG|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate \& hydrogenated vegetable oil per vagina qhs.
48367275|NCT05245240|PROCEDURE|Dietary and physical intervention|"Low-caloric diet (energy deficit 600 kcal/day based on indirect calorimetry measurements), individually tailored by a nutritional specialist according to patients' individual food preferences.~Mild to moderate intensity exercise of aerobic/endurance type, performed 3 times a week for 30-90 minutes."
48367276|NCT05421559|PROCEDURE|thyroidectomy|removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
48687645|NCT06133855|OTHER|traditional physical therapy program|"A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles."
48687646|NCT06436612|RADIATION|Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy|stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
48687647|NCT05962684|OTHER|ERAS|Implementation of ERAS protocol in elective craniotomy patients
48687648|NCT03586024|DRUG|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
48687649|NCT05529082|OTHER|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
48159669|NCT06552910|PROCEDURE|Nerve Block|Since this study was conducted retrospectively, the choice of anesthesia method was made based on our own experience. For every patient undergoing LEA under PNB, a popliteal sciatic nerve block was carried out. A saphenous nerve block was also carried out if the procedure was on a level that was close to the metatarsal bone. In some circumstances (distal surgery, such as the metatarsal bone), a sensory block on the surgical site was tried following the popliteal sciatic nerve block to demonstrate that the saphenous nerve's anatomic abnormalities required an additional saphenous nerve block. The related block was later carried out, if needed. Under ultrasound guidance, every PNB was finished.
48159670|NCT02567786|PROCEDURE|Surgery with CPB|
48159671|NCT02567786|OTHER|Fresh Frozen Plasma|
48159672|NCT02567786|OTHER|Plasmalyte|
48159673|NCT06446024|DEVICE|Mechanical aspiration thrombectomy|Mechanical thrombectomy is an endovascular technique for removing blood clots from vessels. Penumbra's Indigo system actively extracts thrombus using a continuous vacuum pump, enabling aspiration of thrombus of various sizes and lengths.
48159674|NCT01767636|DRUG|Pazopanib Hydrochloride|Given PO
48159675|NCT02444884|DRUG|MLN8237|
48159676|NCT05803525|OTHER|Intra-canal medication protocol|"Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points."
48159677|NCT05079958|BEHAVIORAL|cognitive-behavioral education|four-week cognitive-behavioral education course
48159678|NCT05079958|BEHAVIORAL|12-week brisk walking|12-week brisk walking
48159679|NCT02551471|OTHER|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
48159680|NCT02551471|OTHER|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
48159681|NCT02551471|OTHER|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
48687650|NCT05529082|OTHER|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
48687651|NCT05444907|OTHER|No Intervention / Exposure|No intervention / exposure since this is an observational study
48687652|NCT03435120|OTHER|No intervention|No intervention
48687653|NCT05971368|PROCEDURE|thoracic paravertebal block|"o Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~A high-frequency linear ultrasound probe will be placed between transverse processes from the T4 level (the level of port introduction) in the paramedian plane while patients is in the lateral decubitus position. The transverse processes, superior costotransverse ligaments, and pleura will be well visualized. The block needle (22 gauge) will be advanced until it crosses the superior costotransverse ligament. The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) in the thoracic paravertebral space. Depression of the pleura will be observed as a result of the spread of local anesthetic."
48687654|NCT05971368|PROCEDURE|serratus anterior muscle block|"Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~While the patient is in the supine position, a high-frequency linear ultrasound probe will be placed horizontally on the mid-axillary line at the level of 4th or 5th ribs on the side of the block. The serratus anterior, latissimus dorsi, and intercostal muscles will be identified. The block needle (22-gauge) will be advanced below the serratus anterior muscle (SAM) towards the fifth rib (using in-plane technique). The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) between the SAM and the rib. It will be observed that the solution of local anesthesia will spread between the SAM and the rib."
47914510|NCT04017845|DRUG|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
47914511|NCT04017845|DRUG|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
48159682|NCT02357355|DEVICE|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
48159683|NCT04117256|DEVICE|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
48159684|NCT04117256|DEVICE|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
47914512|NCT02472067|BEHAVIORAL|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
48159685|NCT04105764|DRUG|Rocuronium|DEEP block to PTC 1-3
48159686|NCT04105764|DRUG|Rocuronium bromide|MODERATE block to TOF1-2
48159687|NCT03322475|DEVICE|PiQo4 laser system|The PiQo4 laser system
48159688|NCT05094947|PROCEDURE|intermittent catheterization|clean intermittent catheterization with catheter Nelaton
48159689|NCT05094947|PROCEDURE|trial without catheter|catheter Foley
48002257|NCT03800719|BEHAVIORAL|Active referral to smoking cessation (SC) services|At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
48687655|NCT05342324|DIAGNOSTIC_TEST|Optical coherence tomography angiography|To evaluate the vessel density in choriocapillary vascular networks, using optical coherence tomography angiography
48002258|NCT03800719|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.
48002259|NCT03800719|BEHAVIORAL|Psychosocial support and referral to SC services through IM|Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.
48002260|NCT03800719|BEHAVIORAL|Message on general health delivered by short message service (SMS)|After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
48002261|NCT06195397|OTHER|Evidence-Based Education intervention|A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
48002262|NCT01598792|BIOLOGICAL|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
48002263|NCT01800617|DRUG|Liothyronine, Sodium|
48002264|NCT01879566|OTHER|No intervention will be done. The study is observational|
48002265|NCT00994448|DRUG|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
48002266|NCT00994448|DRUG|Placebo tablets|One placebo tablet twice daily
48002267|NCT06200675|OTHER|Compassion-based intervention|Participants assigned to this intervention will be asked to engage in one brief compassion-focused exercise, where they will be asked to be asked to connect to their inner compassionate self. They will be asked to stay connected to that feeling while rereading what they wrote about their feelings of shame and imagining it was someone else who wrote it. Participants will then be asked to write a compassionate response to themselves. Participants will then be asked to reread this response while remaining connected to their compassionate self.
48367277|NCT05578664|DRUG|Pembrolizumab injection plus metastasis directed treatment (surgery or RT)|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1
48687656|NCT03953248|DRUG|L-Carnitine|
48687657|NCT03150290|OTHER|Indirect Calorimetry.|REE measurement
48002268|NCT06200675|OTHER|Logic-based intervention|Participants assigned to this intervention will be asked to engage in one brief (10-15 minute) online logic-based exercise that was adapted from a CBT thought record. Participants will be asked to reread what they wrote about their feelings of shame and chose a thought central to their shame to use for this exercise. Participants will be asked to generate evidence for and against their chosen thought, and then generate a more balanced thought. After the exercise, participants will be asked to reread their newly generated more balanced thought.
48159690|NCT05094947|DRUG|alpha-blockers|tamsulosin, alfuzosin, doxazosin, silodosin
48159691|NCT05669339|DRUG|Irinotecan|All subjects will be given either 25 mg/m2 (dose level -1), 50 mg/m2 (dose level 0), or 75 mg/m2 (dose level +1) irinotecan intravenously every 7 days.
48367278|NCT05578664|OTHER|Tumor resection or RT|Tumor resection or RT will be applied within 42 days from randomization.
48367279|NCT03600311|OTHER|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
48367280|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
48367281|NCT03600311|OTHER|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
48367282|NCT03600311|DIETARY_SUPPLEMENT|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
48687658|NCT03150290|DEVICE|18-FDG-PET|18-FDG-PET
48687659|NCT00213941|DEVICE|Echocardiography|
48687660|NCT02526810|DRUG|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
48687661|NCT02526810|DRUG|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
48687662|NCT01264692|DRUG|ACT-280778|10 mg once daily for 28 ± 2 days
48687663|NCT01264692|DRUG|Placebo|Placebo oral capsules matching ACT-280778
48687664|NCT01264692|DRUG|Amlodipine|10 mg once daily for 28 ± 2 days
48002269|NCT06200675|OTHER|Placebo control condition|"Participants assigned to this intervention will be asked to listen to an audio recording of The Hobbit and then re-read what they wrote about their feelings of shame. They will then be asked to write a reflection about the thoughts and feelings arising from doing so. They will then be asked to re-read what they wrote in this reflection."
48002270|NCT06113952|DEVICE|Sharps bin to collect used needles/injections|Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.
48002271|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
48002272|NCT00709371|DRUG|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
48159692|NCT05669339|DRUG|Sonidegib|All subjects will take 200 mg sonidegib orally either every 96 hours (dose level -1), every 48 hours (dose level 0), or every 24 hours (dose level +1).
48687665|NCT00159679|DRUG|Pregabalin|
48687666|NCT02045888|DEVICE|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
48687667|NCT02045888|BIOLOGICAL|Placebo|Placebo is visually matched solution
48687668|NCT00285155|DRUG|Bupropion|
48687669|NCT06403553|DIAGNOSTIC_TEST|Fecal Calprotectin|Fecal Calprotectin measurement on days 1and 3
48687670|NCT05077982|DIAGNOSTIC_TEST|Spirometry|Spirometry to assess lung function
48002273|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
48002274|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
48002275|NCT00709371|DRUG|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
48002276|NCT00709371|DRUG|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
48002277|NCT03251573|OTHER|cognitive impairment|one are of patients were exposed to cognitive impairment
48159693|NCT05669339|DRUG|Sorafenib|All subjects will take 200 mg sorafenib orally either every 48 hours (dose level -1), every 24 hours (dose level 0), or every 12 hours (dose level +1).
48159694|NCT00721019|OTHER|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
48367283|NCT03600311|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
48159695|NCT00721019|OTHER|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
48513207|NCT00997867|PROCEDURE|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
47914513|NCT02279706|OTHER|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
47914514|NCT03396952|DRUG|Aspirin|Given PO
47914515|NCT03396952|BIOLOGICAL|Ipilimumab|Given IV
47914516|NCT03396952|OTHER|Laboratory Biomarker Analysis|Correlative studies
47914517|NCT03396952|BIOLOGICAL|Pembrolizumab|Given IV
48159696|NCT01209936|DEVICE|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
48159697|NCT01306409|DRUG|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
48159698|NCT01306409|DRUG|ESA|Sequential application of three different ESA
48159699|NCT02115542|DRUG|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.
48159700|NCT03924193|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
48159701|NCT03924193|BEHAVIORAL|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
48159702|NCT03924193|OTHER|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
48687671|NCT05077982|DIAGNOSTIC_TEST|6-minute walk|Exercise tolerance
48687672|NCT03221465|BEHAVIORAL|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
48687673|NCT03221465|BEHAVIORAL|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
48687674|NCT00428181|BEHAVIORAL|Brief alcohol intervention|Brief alcohol intervention
48687675|NCT00428181|BEHAVIORAL|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
48687676|NCT04300504|OTHER|observational study|observational study
48687677|NCT04044196|PROCEDURE|Rotator cuff repair|Rotator cuff repair performed arthroscopically
48687678|NCT02531360|DRUG|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
48687679|NCT00048022|DRUG|Dual Integrin Antagonist|
48367284|NCT04061668|OTHER|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
48513208|NCT00131495|DRUG|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
47914518|NCT05525806|OTHER|Education Materials for MyProstateScore|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
47914519|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Remote (DPP-R)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Zoom.
47914520|NCT05387434|BEHAVIORAL|Diabetes Prevention Program-Facebook (DPP-FB)|The DPP is an evidenced based lifestyle intervention that includes topics on nutrition and physical activity delivered over Facebook.
48002278|NCT03616353|PROCEDURE|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
48513209|NCT00131495|DRUG|Placebo patch|placebo patch changed twice a week for one year
48513210|NCT01315327|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
48513211|NCT01315327|DRUG|Olive oil|Placebo
48513212|NCT02833337|RADIATION|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
48513213|NCT05022212|DRUG|LACTIN-V|administered vaginally
48513214|NCT05022212|DRUG|Placebo|administered vaginally
47914521|NCT05773378|DEVICE|Pessary Intervention|Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 12-week period.
48513215|NCT01098487|DRUG|Eltrombopag olamine|Thrombopoietin receptor agonist
48687680|NCT02579148|BIOLOGICAL|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
48687681|NCT02579148|BIOLOGICAL|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
48687682|NCT00861172|PROCEDURE|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
48687683|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (200 µg/kg) oro-dispersible minitablets
48002279|NCT03616353|PROCEDURE|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
48687684|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (400 µg/kg) oro-dispersible minitablets
47914522|NCT05773378|DEVICE|Tampon Intervention|Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 12-week period.
48002280|NCT00524446|DIETARY_SUPPLEMENT|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
48002281|NCT00524446|DIETARY_SUPPLEMENT|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
48687685|NCT05579847|OTHER|mHealth Smart Phone Application|The mHealth interactive application consists of educational intervention geared towards eligible patients who are receiving Nivolumab/ Pembro with Axitinib/Cabozantinib/Lenvatinib. These patients commonly experience immune-related side effects, higher rate of fatigue, high blood pressure, and palmar-plantar erythrodysesthesia. The educational intervention will consist of multiple modules covering relevant information on treatment and adverse events and provided over a six-week period through an mHealth platform. This educational intervention includes a patient-friendly algorithm for early detection and management of the most common adverse events in patients with advanced renal cell carcinoma receiving combination immunotherapy.
48002282|NCT00524446|DIETARY_SUPPLEMENT|Maize-soy flour|Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
48002283|NCT03424837|BEHAVIORAL|ASCENT|"ASCENT includes the following components:~* Survivorship care plan created through the ASCENT tool~* Online tool which assesses health care needs and facilitates receipt of care~* A national-level navigator who helps the participant to access support services~* Periodic reminders for the participant to pursue recommended survivorship care"
48159703|NCT02150109|DEVICE|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
48513216|NCT02713919|BEHAVIORAL|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
48687686|NCT05579847|BEHAVIORAL|eHEALS digital literacy test|"The eHEALS digital literacy test is an 8-item measure of eHealth literacy developed to measure the participants combined knowledge, comfort and perceived skills at finding, evaluating and applying electronic health information to health problems. The test is measured with a 5-point Likert scale with response options ranging from strongly disagree to strongly agree. Total scores of the eHEALS are summed to range from 8 to 40, with higher scores representing higher self-perceived eHealth literacy."
48687687|NCT05579847|BEHAVIORAL|Weekly Quiz|Participants will take a weekly true/false quiz to assess knowledge of their diagnosis, expected outcome and treatment associated adverse effects at baseline and longitudinally. Each quiz will be administered at the beginning of the week before the weekly educational content is available, then the same quiz will be administered after the educational content is reviewed by the patient. Each quiz will be scored based on the number of correct answers.
48002284|NCT01561066|PROCEDURE|Autologous platelet-rich fibrin glue (PRFG)|"1. Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~2. PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
48159704|NCT02150109|DEVICE|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
48159705|NCT06445023|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
48159706|NCT06445023|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
48159707|NCT04024371|BEHAVIORAL|Self-rating Questionnaires|"* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)"
48159708|NCT04024371|BEHAVIORAL|Measures of Reward processing/reinforcement learning|"* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
48159709|NCT04024371|BEHAVIORAL|Additional Schizophrenia-specific Questionnaires and Interviews|"* Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
48159710|NCT02650388|BEHAVIORAL|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
48159711|NCT05516836|OTHER|Multicomponent exercise program|"Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
48159712|NCT05516836|OTHER|Tele-health primary care rehabilitation program|A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence.
48159713|NCT03143634|BEHAVIORAL|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
48159714|NCT03143634|BEHAVIORAL|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
48002285|NCT01561066|DRUG|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
48002286|NCT05581316|DIAGNOSTIC_TEST|Patients' procalcitonin, thrombocyte, and leukocyte levels were assessed every other day for 4 weeks, beginning on the first day they were admitted to the burn center.|This patients who were included in this study were assessed for four weeks from the first day of hospitalization and taken to the treatment program. All patients who use peripheral venous catheters in this group.
48159715|NCT03701581|DRUG|4-Aminopyridine|FDA-approved tablets.
48159716|NCT03701581|OTHER|Placebo|Placebo will be tooled to look similar to the study drug.
48159717|NCT00672347|DRUG|Clonidine|1 mcg/kg
48159718|NCT00672347|DRUG|Morphine|20 mcg/kg
48159719|NCT00672347|DRUG|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
48159720|NCT00672347|DRUG|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
48159721|NCT00294879|PROCEDURE|pressure support ventilation at 0, 5, and 10% IRT|
48159722|NCT03261934|OTHER|No intervention|No intervention
48159723|NCT03015961|DRUG|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
48159724|NCT03015961|DRUG|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
48002287|NCT02485106|DRUG|Rifaximin|400mg three times per day for 28 days
48002288|NCT02485106|DRUG|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
48159725|NCT04323111|PROCEDURE|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
48159726|NCT04091945|DRUG|LT3001 Drug Product|Active comparator
48159727|NCT04091945|DRUG|Placebo|Placebo comparator
48513217|NCT02397876|OTHER|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
48513218|NCT05035277|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
48687688|NCT05579847|BEHAVIORAL|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|"The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) comprises 30 single questions, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact) scales assess symptoms. No item occurs in more than one scale.~Scoring of the QLQ-C30 is performed according to QLQ-C30 Scoring manual. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient)."
48266859|NCT01539980|DEVICE|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith\&Nephew, London, UK) are applied on the other half of the skin graft donor site
48002289|NCT03166280|DRUG|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
48266860|NCT01044966|DRUG|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
48687689|NCT05579847|BEHAVIORAL|Patient Post Intervention Survey|The Patient Post Intervention Survey is a 7 question survey to help determine the effectiveness of the mHealth app. 3 questions are open fields for patient feedback, and 4 questions ask how often the app was used, how often the educational module was used and if the patient found it useful.
48687690|NCT06479291|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
48687691|NCT06479291|DRUG|Eltrombopag|Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
48687692|NCT05136222|OTHER|Intervention polysomnography|Please refer to 'Arms: Intervention' section.
48687693|NCT05136222|OTHER|Sham polysomnography|Please refer to 'Arms: Control' section.
48002290|NCT03166280|DRUG|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
48002291|NCT00436943|DRUG|nicotine replacement therapy and bupropion|3-6 months
48002292|NCT00436943|BEHAVIORAL|smoking cessation counseling and referrals|Organizational counseling and referrals
48513219|NCT05035277|DRUG|Apixaban|Standard dose apixaban will be one of the options for the patients in the experimental arm.
47914523|NCT02948517|OTHER|Time restricted feeding|Time restricted feeding
48002293|NCT02611622|BEHAVIORAL|LUMA ENT™|
48002294|NCT02611622|OTHER|Survey|Demographic and Patient Satisfaction Survey
48002295|NCT03878472|DRUG|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
48002296|NCT03878472|DRUG|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
48002297|NCT03878472|DRUG|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
48002298|NCT03878472|DRUG|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
48002299|NCT00819988|DRUG|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
48002300|NCT00819988|OTHER|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
48266861|NCT04428606|DIETARY_SUPPLEMENT|Metabolic Rheostat|Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder
48513220|NCT05035277|DRUG|Rivaroxaban|Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
48513221|NCT05035277|DRUG|Edoxaban|Standard dose edoxaban will be one of the options for the patients in the experimental arm.
48266862|NCT04428606|DIETARY_SUPPLEMENT|Butyrate Ultra|An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.
48266863|NCT04428606|DIETARY_SUPPLEMENT|Placebo|Placebo
48159728|NCT05756361|BEHAVIORAL|Family-Based Treatment for T1D|"Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on Food Literacy including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment"
48159729|NCT03071900|DIAGNOSTIC_TEST|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
48367285|NCT04061668|OTHER|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
48002301|NCT06100666|BEHAVIORAL|Observational Tests|The Sustainable and Healthy Eating Behaviors Scale will be used to assess sustainable eating behaviors, one-day food consumption records will be collected with the 24-hour Dietary Recall method, the International Diet Quality Index and EAT-Lancet Diet Score will be used to assess diet quality, and body weight, height, waist circumference and neck circumference will be measured to determine nutritional status.
48002302|NCT03250468|BEHAVIORAL|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
48367286|NCT02010099|DRUG|PP110 Gel|
48367287|NCT02010099|DRUG|PP110 Medicated wipes|
48367288|NCT02010099|DRUG|Preparation-H Cream|
48159730|NCT04613219|DRUG|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
48367289|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
48367290|NCT01377194|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
48367291|NCT01377194|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
48367292|NCT03196401|DRUG|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
48367293|NCT03196401|RADIATION|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
48367294|NCT05020470|DEVICE|Virtual Auricular Point Acupressure (APA)|Participants will learn how to self-administer APA by themselves.
48367295|NCT05020470|OTHER|In-Person Training|Participants will receive in-person training to self-administer APA.
48367296|NCT05020470|OTHER|Usual Care|Participants will continue to do whatever they are instructed by theirs physicians.
48367297|NCT01273012|DRUG|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
48002303|NCT05928910|DEVICE|SmileyScope VR|The SmileyScope Virtual Reality Headset is a VR headset to reduce pain and anxiety undergoing medical procedures. The device comes pre-loaded with a static virtual reality scenario. Participants will use the device in person when coming to clinic during an in-person, one time PNE procedure.
48367298|NCT01381237|BEHAVIORAL|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
48367299|NCT02432027|DRUG|C-82 Topical Gel, Placebo|placebo
48002304|NCT05928910|OTHER|Standard of Care Treatment|Participants in this group will receive standard of care treatment during an in-person, one time PNE procedure.
48159731|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram on visit 5 single dose
48159732|NCT01257048|DRUG|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
48367300|NCT02432027|DRUG|C-82 Topical Gel, 1%|active
48367301|NCT02432027|DRUG|Daivonex cream|comparator
48367302|NCT02432027|DRUG|Diprosis gel|comparator
48367303|NCT01738906|OTHER|Orange juice|
48159733|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
48266864|NCT00226551|DRUG|Isoproterenol|
48367304|NCT01738906|OTHER|maltodextrin|
48367305|NCT01738906|OTHER|Vodka|
48367306|NCT01738906|OTHER|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
48367307|NCT01738906|OTHER|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
48367308|NCT01639807|DRUG|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
48367309|NCT01639807|PROCEDURE|SLT|Selective Laser Trabeculoplasty
48513222|NCT03905616|DEVICE|functional Magnetic Resonance Imaging|In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
48513223|NCT04770675|DIAGNOSTIC_TEST|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
48513224|NCT00079430|PROCEDURE|adjuvant therapy|
48513225|NCT00079430|DRUG|paclitaxel|Given IV
48513226|NCT00079430|DRUG|carboplatin|Given intraperitoneally
48513227|NCT00079430|BIOLOGICAL|bevacizumab|Given IV
48513228|NCT06240195|OTHER|data collection|Collection of data relating to the effectiveness of sacituzumab govitecan and evaluation in a real-world context and planned research of predictive biomarkers of efficacy/tolerability
48513229|NCT05015283|PROCEDURE|The laparoscopic One-anastomosis gastric bypass will consist of:|gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect
48002305|NCT03409471|DEVICE|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
48002306|NCT03409471|DEVICE|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
48002307|NCT03409471|DIAGNOSTIC_TEST|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
48002308|NCT05527431|DEVICE|high flow nasal cannula|high flow nasal cannula
48159734|NCT05289778|OTHER|Survey|Students will complete structured questionnaires in classroom settings, and parents will complete telephone interviews in the absence of their children.
48513230|NCT05015283|PROCEDURE|The laparoscopic Roux-en-Y gastric bypass will consist of:|the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect
48159735|NCT00010322|DRUG|atamestane|
48513231|NCT00339144|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
48513232|NCT00339144|DRUG|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
48513233|NCT00339144|DRUG|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
48513234|NCT05147012|OTHER|Data collected|"The variable of the characteristic of the patients (i.e.: age, sex, hypertension, diabetes, atrial fibrillation, coronary arteries diseases, body mass index (BMI), surgery, medications) were retrieved from the anesthesia consultation file (Easily, Hospices Civiles de Lyon, France).~We retrieved the mean arterial pressure from our local anesthesia software for each patient ( Diane®, Bow medical, Amiens France). We also performed an automatic extraction of data from our anesthesia software (Diane, Bow Medical, France) with a rate of 1 value / minute for some continuous arterial pressure.~All data was extracted from our institutional database and collected by a physician who was not involved in the care of the study patients."
48513235|NCT05998876|DEVICE|Remote Medication Monitor (RMM) - Prototype|Inserted Microneedle Electrode Array for assaying dermal interstitial fluid.
48513236|NCT05998876|DRUG|Daily Methadone Dose|patient takes their prescribed daily dose of methadone
48513237|NCT04198857|BEHAVIORAL|Develop a mobile app that supports self- management and treatment for Nepalese GDM patients|We will use a user-centered design approach to develop a mobile app for GDM (GDM-DH) that matches the needs and technological sophistication of the target users. The goal of the app would be to assist patients in self management of GDM by improving their adherence to the recommended diet and physical activity regimens. The app will be used to collect information such as the carbohydrate consumption, the daily activity status and blood glucose and blood pressure measurements taken at home by the patients. The app will be set up in the phone of the participants and their data will be collected. The participants will be able to assess the usability and feasibility of the app. The app will also help clinicians by generating easily digestible visual displays of patient data and behaviors, which can aid in their clinical decision-making and counseling.
48513238|NCT01078870|DRUG|Lexapro|10mg/cap 1\~2# QD
48513239|NCT01078870|DRUG|Cymbalta|30mg/cap 30\~60mg/QD
48513240|NCT01078870|DRUG|Placebo|1\~2#/cap QD
48513241|NCT05860855|PROCEDURE|Augmentative craniotomy|Expansion of the skull
48513242|NCT05860855|PROCEDURE|Decompressive craniotomy|Standard hemicraniectomy
48513243|NCT05712798|OTHER|No intervention|No intervention
48513244|NCT04274257|DRUG|Double-Blind Placebo|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
48513245|NCT04274257|DRUG|Double-Blind Rituximab|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
48513246|NCT06443723|DIAGNOSTIC_TEST|USG, blood tests, waist, hip, height and blood pressure measurements|"MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction.~Metabolic dysfunction (two or more of the following)~1. waist circumference ≥ 90 cm in men and 88 cm in women,~2. blood pressure ≥ 130/85 mmHg or on specific drug treatment,~3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment,~4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment,~5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%),~6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5."
48513247|NCT02203331|DRUG|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
48513248|NCT02203331|DRUG|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
48002309|NCT05527431|DEVICE|noninvasive ventilation|noninvasive ventilation
48002310|NCT02062762|BEHAVIORAL|Online-MBSR|8 week mindfulness based stress reduction online
48002311|NCT02062762|BEHAVIORAL|Expressive Writing Online|Online distributed expressive writing intervention as active control
48002312|NCT03588221|PROCEDURE|four sets of hand hygiene measurements per participant|"1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds"
48159736|NCT00010322|DRUG|toremifene|
48159737|NCT01592565|OTHER|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
48513249|NCT02203331|DRUG|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
48687694|NCT04522882|DEVICE|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
48687695|NCT04522882|OTHER|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
48687696|NCT04522882|OTHER|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
48002313|NCT00717769|DRUG|SUN13834|Low dose, orally 3 times a day (tid) for 28 days of SUN13834
48002314|NCT00717769|DRUG|Placebo|Placebo, orally (tid) for 28 days of SUN13834
48159738|NCT02039297|OTHER|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
47914524|NCT05018208|OTHER|Computer-Assisted Intervention|Use smartphone app
47914525|NCT05018208|PROCEDURE|Patient Monitoring|Wear Biofourmis wearable device(s)
48002315|NCT05601310|DEVICE|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
47914526|NCT05018208|OTHER|Questionnaire Administration|Complete questionnaires
47914527|NCT02586779|OTHER|whatsApp|whatsApp application will be used for consultations.
47914528|NCT02586779|OTHER|without whatsApp|whatsApp application will be not used for consultations.
48266865|NCT03221218|OTHER|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
48513250|NCT02203331|DRUG|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
48687697|NCT04087941|BIOLOGICAL|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
48687698|NCT01977729|DRUG|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S\<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
48687699|NCT01977729|BEHAVIORAL|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
48159739|NCT02419040|PROCEDURE|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
48687700|NCT03851627|DRUG|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
48687701|NCT03851627|DRUG|Placebo|Placebo Arm
48687702|NCT05969639|BEHAVIORAL|HEYA|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
48687703|NCT05999578|OTHER|Hypnosis|Hypnosis support before, during and at the end of cardiac MRI exam
48687704|NCT01717196|OTHER|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
48513251|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
48513252|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
48513253|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
48687705|NCT02798224|BEHAVIORAL|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
48687706|NCT02798224|BEHAVIORAL|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
48687707|NCT02552173|RADIATION|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
48687708|NCT04094493|DRUG|vit D|preoperative intra muscular vit D injection
48687709|NCT00368745|DRUG|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
47914529|NCT01221935|OTHER|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
48002316|NCT01129141|PROCEDURE|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
48002317|NCT01129141|PROCEDURE|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
48002318|NCT01556529|PROCEDURE|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
48002319|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
48002320|NCT01556529|PROCEDURE|standard DMP care|standard disease management of T2DM care
48002321|NCT01488097|DRUG|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase.
48002322|NCT00314366|BIOLOGICAL|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
48002323|NCT00314366|OTHER|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
48002324|NCT02268409|DRUG|luspatercept|subcutaneous injection
48002325|NCT02244203|DRUG|BI 60732|
48002326|NCT02244203|DRUG|Placebo|
48002327|NCT01367769|OTHER|No intervention|There will be no intervention in this study.
48002328|NCT05079464|OTHER|tDCS|All participants randomized to tDCS will receive active tDCS
48002329|NCT05079464|OTHER|Exercise|Participants will exercise at Toronto Rehab.
48002330|NCT05079464|OTHER|Sham stimulation|The same procedure for tDCS will be used for the sham condition, except without active current.
48687710|NCT00368745|DRUG|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
48687711|NCT05023785|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
48687712|NCT06246838|DIAGNOSTIC_TEST|Ga-68 V/Q PET/CT|Head-to-head comparison of Ga-68 V/Q PET/CT vs Tc-99m V/Q SPECT/CT
48687713|NCT03154515|DRUG|Ingavirin|
48687714|NCT03154515|DRUG|Placebo|
48687715|NCT02147197|DRUG|Ulipristal acetate (UPA)|UPA tablet
48687716|NCT02147197|DRUG|Placebo|Matching placebo tablet.
48687717|NCT05281627|OTHER|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
48687718|NCT05315934|OTHER|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
48687719|NCT05315934|OTHER|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
48687720|NCT02534025|PROCEDURE|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
48002331|NCT05079464|OTHER|Treatment as usual|Exercise education/ treatment as usual will include routine advice about physical activity.
48002332|NCT00180375|DEVICE|Prizm, Vitality, Renewal|Follow-up during 2 years
48002333|NCT03331692|OTHER|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
48002334|NCT03175094|BEHAVIORAL|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
48002335|NCT00004238|DRUG|pralatrexate|
48002336|NCT02643654|DRUG|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
48002337|NCT02643654|DRUG|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
48513254|NCT03436056|DRUG|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
48513255|NCT02199886|DRUG|BIBH 1|labeled with eight to ten millicurie of 131I
48687721|NCT04216849|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
48002338|NCT03073096|PROCEDURE|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
48002339|NCT03566628|OTHER|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
48002340|NCT03566628|OTHER|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
48687722|NCT04216849|OTHER|saline|Saline solution containing human serum albumin will be infused to the control group
48687723|NCT05919784|BEHAVIORAL|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
48687724|NCT01117298|DRUG|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
48687725|NCT01117298|DRUG|Placebo|Tab Placebo every alternate day for 8 weeks
48687726|NCT01919073|BEHAVIORAL|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
48002341|NCT05040633|DEVICE|BTL 4110 Smart Laser Therapy Equipment (BTL Industries Ltd, United Kingdom (UK))|Participants will receive 12 LLLT sessions during the course of the trial, thrice weekly for 4 consecutive weeks. Doses will be as per the recommendations of the Wold Association of Laser Therapy.
48002342|NCT05040633|OTHER|Standard Exercise Therapy|Exercise therapy will consist of strengthening and stretching exercises. At each visit, participants will perform each of the exercises under the supervision of a licensed physiotherapist.
48687727|NCT01919073|BEHAVIORAL|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
48687728|NCT05088759|BEHAVIORAL|Alert|The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
48002343|NCT02167256|DRUG|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
48513256|NCT03612349|BEHAVIORAL|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
48513257|NCT01243112|DRUG|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
48687729|NCT00935493|DRUG|Guanfacine|Guanfacine 0.1 mg po qhs
48687730|NCT00935493|DRUG|Guanfacine|Guanfacine 0.5 mg po qhs
48687731|NCT00935493|DRUG|Placebo|Placebo po qhs
48002344|NCT02167256|DRUG|AZD0530 125mg daily|Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
48513258|NCT01243112|DRUG|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
48002345|NCT02167256|DRUG|Placebo|50% of patients will receive placebo treatment for the duration of the study.
48159740|NCT02419040|PROCEDURE|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
48687732|NCT04432649|BIOLOGICAL|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
48687733|NCT00003065|BIOLOGICAL|filgrastim|
48687734|NCT00003065|DRUG|paclitaxel|
48159741|NCT02419040|PROCEDURE|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
48687735|NCT00003065|DRUG|topotecan hydrochloride|
48002346|NCT02857452|OTHER|SLA Questionnaire|
48002347|NCT02857452|OTHER|Lupus Qol Questionnaire|
48159742|NCT06565221|DEVICE|Heat and negative pressure|Heat and negative pressure applied to the feet
48159743|NCT02350127|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
48513259|NCT01243112|DRUG|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
48687736|NCT01849692|DRUG|ESBA1008 solution|Intravitreal injection or infusion
48687737|NCT01849692|DRUG|Ranibizumab|Intravitreal injection
48687738|NCT04900246|PROCEDURE|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
48002348|NCT02112825|BEHAVIORAL|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
48002349|NCT05244629|DEVICE|BMS vs. CS|Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
48002350|NCT02132585|PROCEDURE|Speckle tracking echocardiography|
48002351|NCT02280980|OTHER|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
48002352|NCT00215046|DRUG|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
48002353|NCT00215046|DRUG|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
48367310|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency and transcutaneous tibial nerve stimulation|The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies. 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side. Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a transdiscal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds. Two 50x50 mm electrode pads were placed on the posterior-superior aspect of the medial malleolus for posterior tibial nerve stimulation. Stimulation was delivered in continuous mode at a frequency of 20 Hz and a pulsed width of 200 ms. It was applied once a week for 30 min for 4 weeks.
48687739|NCT04900246|RADIATION|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
48687740|NCT04900246|DEVICE|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
48687741|NCT01147250|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
48687742|NCT01147250|DRUG|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
48687743|NCT01908491|DEVICE|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
48002354|NCT05390268|BEHAVIORAL|Mobile app-assisted behavioral treatment|"The app-assisted training group have access to a newly developed app in which they are taught how to handle tics. A new app session is released at each new treatment session and the content of the app videos is comparable to the information and training at face-to-face individual treatment, as defined by the manual Niks to Tics\["
48159744|NCT02350127|BEHAVIORAL|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
47914530|NCT01221935|OTHER|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
47914531|NCT01221935|OTHER|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
48159745|NCT00472069|PROCEDURE|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
48159746|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 2 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
48687744|NCT01908491|DEVICE|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
48367311|NCT06256679|PROCEDURE|superior hypogastric plexus pulsed radiofrequency|"The L5-S1 intervertebral space was visualized using fluoroscopy. A 22G, 15 cm injection needle was advanced along the bilateral disc, and under lateral imaging, the needle position was confirmed anterior to the vertebral bodies.~After negative aspiration of blood, 2 ml of contrast solution was injected to confirm the correct needle placement, and then 8 mg of dexamethasone and 40 mg of bupivacaine (0.25%) were injected separately on each side.~Two weeks later, patients who showed more than 50% improvement from the diagnostic block, as assessed by NRS, underwent a superior hypogastric pulsed radiofrequency procedure using a trans discal technique with a 22G, 15 cm, 10 mm active-tipped radiofrequency needle at 42°C for 120 seconds."
48367312|NCT02324426|DRUG|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
48367313|NCT05507346|DEVICE|Cross over Device (PCD or Dayspring - alternate to first group)|Cross over after three month of use and a month of washout period
48367314|NCT00232128|PROCEDURE|Radiofrequency Ablation of pulmonary neoplasms|
48367315|NCT00683852|DRUG|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
48367316|NCT00683852|DRUG|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
48367317|NCT00683852|DRUG|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
48367318|NCT01247376|DEVICE|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
48367319|NCT01569568|OTHER|MRI scanning|1H MRS, DTI, FMRI
48367320|NCT01569568|BEHAVIORAL|Cognitive testing|Behavioral testing
48367321|NCT02628574|DRUG|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
48687745|NCT06238336|DRUG|CAR-T cell therapy|The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
48687746|NCT00136695|DRUG|anastrozole|1 mg QD
48687747|NCT03280199|OTHER|simulation types|Different types of simulation interfaces and image acquisitions
48002355|NCT06062043|BEHAVIORAL|Brief ACT with CPP Education Treatment|The Brief ACT with CPP Education treatment provides women veterans with new ways of responding to difficult thoughts and emotions related to pain while also encouraging them to engage in meaningful life activities. The CPP educational component includes information about pathology, risk factors, health outcomes, and treatment that are specific to women's biological and reproductive functioning. Treatment content has been further tailored to reflect the cultural experiences of women veterans (including discussions on the interplay between military culture, perceived social norms, and gender role expectations).
48002356|NCT01220271|DRUG|LY2157299|Administered orally
48687748|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
48687749|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
48687750|NCT05523557|BEHAVIORAL|Urban Training|1) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
48687751|NCT01671709|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
48687752|NCT05068323|DIAGNOSTIC_TEST|Digital electroencephalography (EEG) for an hour (16 channels)|Digital electroencephalography (EEG) for an hour (16 channels)
48002357|NCT01220271|DRUG|Radiation|Administered as approved
48002358|NCT01220271|DRUG|Temozolomide|Administered orally
48002359|NCT00688480|DRUG|Placebo|1 capsule, orally for 9 months
48002360|NCT00688480|DRUG|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
48002361|NCT03339609|DIAGNOSTIC_TEST|Uroflow|Isolated uroflow measurement
48002362|NCT03339609|DIAGNOSTIC_TEST|Uroflow/EMG|Uroflow measurement with superficial EMG testing of the pelvic floor
48002363|NCT03339609|DIAGNOSTIC_TEST|US|Ultrasound of post void residual urine
48002364|NCT04180696|DEVICE|aCRT ON|CRT device with AdaptivCRT enabled
48002365|NCT04180696|DEVICE|aCRT OFF|CRT device with AdaptivCRT disabled
48002366|NCT05145166|BIOLOGICAL|Safety group|All of the participants(N=10000) received one dose of live attenuated mumps vaccine.Vaccine will given by single intramuscular injection(0.5 ml) on day 0.
48002367|NCT04123496|DEVICE|rTMS|Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
48002368|NCT01596764|DRUG|Loperamide placebo|200 ml apple juice
48002369|NCT01596764|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
48002370|NCT01596764|DEVICE|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
48002371|NCT01596764|DRUG|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
48002372|NCT01596764|DRUG|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
48002373|NCT01596764|DRUG|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
48002374|NCT01596764|DRUG|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
48002375|NCT00184262|BEHAVIORAL|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
48002376|NCT00184262|BEHAVIORAL|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
48002377|NCT06424054|OTHER|eChemoCoach|the eChemoCoach is an electronic questionnaire which is accessible for patients via the secured electronic health portal (EHP) of the EHR, which is CE-certified. By utilizing the eChemoCoach, patients (for this project we focus on breast cancer patients) have the ability to complete a questionnaire on a daily basis, when experiencing side effects. The eChemoCoach has the potential to evaluate the severity of adverse effects based on the CTCAE criteria and triage them, mimicking the decision-making process of a HCP through computer adaptive testing (CAT). Upon completing the questionnaire, the eChemoCoach translates the responses for each specific side effect into corresponding CTCAE grades. The tool then promptly offers patients personalized advice, tailored to their individual condition.
48159747|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 4 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
48002378|NCT00499096|BEHAVIORAL|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
48002379|NCT05935579|DRUG|Durvalumab|Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
48002380|NCT05935579|DRUG|Lenvatinib Oral Product|The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.
48002381|NCT05935579|DRUG|Chemotherapy|GEMOX regimen: Gemcitabine 1000mg/m2 will be administered intravenously over 30 minutes on Day 1 and Day 8; Oxaliplatin 100mg/m2 will be administered intravenously over 2 hours on Day 1, and the cycle will be repeated every 3 weeks.
48159748|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section.
48367322|NCT02628574|DRUG|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
48367323|NCT02628574|DRUG|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
48367324|NCT02628574|DRUG|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
48367325|NCT01298011|DRUG|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
48002382|NCT02445027|DEVICE|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
48513260|NCT01243112|DRUG|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
48159749|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
48159750|NCT00762554|DRUG|Fentanyl|Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
48159751|NCT05164133|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
48159752|NCT05473221|BIOLOGICAL|CD33 CAR-T|CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
48159753|NCT05074004|OTHER|Psychoeducation|Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
48513261|NCT02939053|DEVICE|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
48513262|NCT05972330|DIETARY_SUPPLEMENT|VRx MyBiotics Oral Lozenges|VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
48513263|NCT04134338|OTHER|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
48002383|NCT04242888|OTHER|pragmatic manual therapies|three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
48002384|NCT02795390|DRUG|Chinese herbal medicine|
48002385|NCT02795390|DRUG|Placebo|
48159754|NCT05055141|OTHER|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
48159755|NCT04966247|OTHER|Microdialysis|Monitoring real-time cerebral biomarkers using microdialysis method
48513264|NCT03127514|DRUG|AMX0035|AMX0035
48159756|NCT03612453|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
48159757|NCT03612453|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
48159758|NCT03087851|DRUG|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
48159759|NCT05099978|GENETIC|NGS analysis of ctDNA|Diagnostic Test: plasma circulating tumor DNA
48159760|NCT04746690|OTHER|Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius|neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.
48159761|NCT06296888|PROCEDURE|Radiofrequency balloon catheter ablation|Radiofrequency balloon ablation using the HELIOSTAR™ ablation catheter.
48002386|NCT03438890|DEVICE|Warm saline|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
48159762|NCT05593016|BEHAVIORAL|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|"Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity."
48159763|NCT05593016|BEHAVIORAL|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer."
48159764|NCT06253689|DEVICE|Defecation Posture Modification Device|Patients assigned to the experimental arm will be asked to use the defecation posture modification device to aid with bowel movements during the postoperative period.
48159765|NCT03548272|PROCEDURE|Percutaneous Coronary Intervention with stent implantation|PCI with BiOSS LIM C or rDES depending on the randomization
48159766|NCT00421122|DRUG|budesonide/formoterol (Symbicort)|inhalation therapy
48159767|NCT00421122|DRUG|budesonide (Pulmicort)|inhalation
48159768|NCT00421122|DRUG|terbutaline sulfate (Bricasol)|inhalation therapy
48159769|NCT02811302|DEVICE|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
48159770|NCT03924596|DRUG|AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)|AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
48159771|NCT03924596|DRUG|Potassium Sodium Hydrogen Citrate|Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
48367326|NCT03584412|BEHAVIORAL|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
48513265|NCT03127514|OTHER|Placebo|Matching Placebo Comparator
48513266|NCT05741177|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound score
48159772|NCT01347099|BEHAVIORAL|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
48159773|NCT01347099|BEHAVIORAL|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
48159774|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, 10 Hz condition|10 Hz (2,000 pulses) at left DLPFC
48159775|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, Sham condition|sham
48159776|NCT03480737|DEVICE|Magstim Super Rapid2 stimulator, iTBS condition|50 Hz, iTBS (600 pulses) at left DLPFC
48159777|NCT02245971|PROCEDURE|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
48159778|NCT02245971|PROCEDURE|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
48367327|NCT03584412|OTHER|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
48002387|NCT03438890|DEVICE|anti-fog agent|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
48002388|NCT03438890|DEVICE|chlorhexidine|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
48159779|NCT02896218|OTHER|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
48159780|NCT01714414|DRUG|FZD|
48159781|NCT01714414|DRUG|3TC|
48159782|NCT01714414|DRUG|EFV|
48367328|NCT04346017|DIAGNOSTIC_TEST|Cytokines dosage|Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).
48159783|NCT01714414|DRUG|AZT|
48367329|NCT04346017|DIAGNOSTIC_TEST|Complement dosage|Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
48367330|NCT06419023|BEHAVIORAL|supervised physical activity intervention using the Pilates Method (exercises on the mat)|"Each Pilates session was consisted of: a) introduction to the goal of training, familiarizing new skills (2-3 min); b) Pre-Pilates warm-up and respiratory exercises (5-10 min); c) mat Pilates exercises with the traditional Pilates repertoire: basic, beginner (40 min); d) cool down and endings exercises (5 min); e) session summary (2-3min). When required, exercises were adapted for breast cancer body needs and restrictions. Depending on the purpose of the exercise, different equipment was used (Pilates small ball 22 cm, Swiss ball, small massage balls, resistance band, towels, rollers, boxes, Magic Circle)."
48367331|NCT03475173|DEVICE|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
48367332|NCT04271904|OTHER|Placebo Diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
48367333|NCT04501991|OTHER|antidiabetic treatment|Every kind of antidiabetic treatment, oral or injective, were considered including patients treated only with diet
48367334|NCT02079077|DRUG|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
48687753|NCT04238091|DRUG|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
48159784|NCT05773209|DEVICE|RLRL device|Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
48159785|NCT03343509|DRUG|Metronidazole Oral|Oral Metronidazole
48159786|NCT03343509|DRUG|Metronidazole Ointment|Metronidazole Ointment
48159787|NCT03343509|DRUG|Placebo Oral Tablet|Placebo Tablet
48159788|NCT03343509|DRUG|Placebo Ointment|Placebo Ointment
48159789|NCT06244706|COMBINATION_PRODUCT|Opioid drug + CNS-acting add-on drug|Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).
48159790|NCT02636751|BEHAVIORAL|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
48159791|NCT02636751|DEVICE|Walking aid adjustment|Walking aid adjustment
48367335|NCT02079077|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
48367336|NCT03328741|BEHAVIORAL|Online Osteoarthritis treatment|6 week online-program
48367337|NCT03328741|BEHAVIORAL|Face-to-face osteoarthritis treatment|3 months face-to-face program
48367338|NCT00247052|DRUG|diclofenac|diclofenac 50 mg bid versus placebo bid
48367339|NCT00247052|DRUG|diclofenac|diclofenac 100 mg per day for 14 days
48367340|NCT00247052|DRUG|matching placebo|
48367341|NCT04730024|OTHER|Not applicable(observational study)|Not applicable(observational study)
48687754|NCT04238091|PROCEDURE|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
48159792|NCT02636751|BEHAVIORAL|Information about pain control|General information about pain control, such as ice application and medication usage
48159793|NCT04946097|OTHER|gross Myofascial Release|Gross Myofascial Release : is amanual technique in form of Stretch of the Posterior Cervical Musculature and Gross stretch of gross Myofascial Release upper quarter: Arm Pull for duration of 10-15 min per session each stretch position was healed for 90sec
48159794|NCT04946097|OTHER|conventional selected exercise program|stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes
48159795|NCT04946097|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes
48159796|NCT01598389|OTHER|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
48159797|NCT01033097|DRUG|DNK333 5 mg|5 mg oral
48159798|NCT01033097|DRUG|Placebo to 5 mg|5 mg placebo oral
48159799|NCT01033097|DRUG|DNK333 25 mg|25 mg oral
48159800|NCT01033097|DRUG|Placebo to 25 mg|25 mg placebo oral
48159801|NCT01033097|DRUG|DNK333 100 mg|100 mg oral
48159802|NCT01033097|DRUG|Placebo to 100 mg|100 mg placebo oral
48159803|NCT01033097|DRUG|Betamethasone 4 mg|4 mg oral
48159804|NCT01033097|DRUG|DNK333 1mg|1 mg oral
48159805|NCT01033097|DRUG|Placebo to 1mg|1 mg placebo oral
48159806|NCT01107249|DEVICE|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
48159807|NCT04695249|BEHAVIORAL|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
48159808|NCT02214836|DEVICE|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
48159809|NCT02154893|DEVICE|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
48159810|NCT02154893|DEVICE|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
48159811|NCT02154893|DEVICE|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
48159812|NCT06501885|BEHAVIORAL|Ethnodrama Intervention|The intervention is six drama performances that are designed to transform community member beliefs about and foster support of young women's PrEP use, reduce PrEP-related enacted stigma toward young women, and reduce PrEP-related anticipated and internalized stigma among young women.
48159813|NCT02503839|DRUG|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
48159814|NCT02503839|BIOLOGICAL|H56:IC31|Therapeutic and prophylactic TB vaccine
48687755|NCT04238091|DIAGNOSTIC_TEST|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
48687756|NCT04238091|PROCEDURE|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
48159815|NCT04994314|DRUG|nCaF2 primer|Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
48159816|NCT04994314|DRUG|Control primer|Conventional orthodontic primer
48159817|NCT00184496|DRUG|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
48367342|NCT00565721|DRUG|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
48159818|NCT04559516|BEHAVIORAL|Exercise Intervention|"The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session."
48159819|NCT04559516|BEHAVIORAL|Standard Care|Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
48687757|NCT04238091|PROCEDURE|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
48687758|NCT04238091|DRUG|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
48687759|NCT04238091|DRUG|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
48687760|NCT05445219|DIAGNOSTIC_TEST|RespirAct|The RespirAct device is an automated breathing circuit that uses a gas bladder to control and deliver CO2 to measure cerebrovascular reactivity
48687761|NCT01463163|DRUG|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
48687762|NCT01463163|DRUG|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
48159820|NCT00161954|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
48159821|NCT05954156|OTHER|injectable composite|The introduction of injectable composites, according to available literature, offers a simple and efficient solution for the cementation of veneers. This versatile, injectable restorative composite unites easy handling, high physical properties and excellent aesthetics. Generally used as a restorative material, it can also be used for the cementation of veneers and some inlays/onlays, thus considered as good alternative to preheated composite. (Alajrash MM et al., 2020)
48687763|NCT01731340|DIETARY_SUPPLEMENT|Calcium Citrate|750mg
48687764|NCT01731340|OTHER|Low Dietary Calcium|450 mg
48687765|NCT01731340|OTHER|High Dietary Calcium|1200 mg
48687766|NCT05974384|DEVICE|No Music|No listening to music while intervention is carried out
48687767|NCT05974384|DEVICE|Music|Listening to music while intervention is carried out
48159822|NCT02214017|DEVICE|A videotelephone, TandBerg E20,|
48159823|NCT02214017|BEHAVIORAL|Behavioral motivation|Optimization of medical care in diabetes
48159824|NCT00500539|DRUG|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
48159825|NCT05434533|DRUG|Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)|IV 1gm
48687768|NCT02188940|BEHAVIORAL|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
48002389|NCT05437978|OTHER|"Cap Sport Santé 83 program"|"In Var department (France), the  Maison Sport-Santé 83  has set up a program called Cap Sport Santé 83 to support patients who received a prescription to practice APA regularly. This program helps long-term illnesses patients to restart physical activity by considering their pathology. The Cap Sport Santé 83 program is composed of 5 stages which aim to encourage adherence to APA practice by relying on the medical prescription system. Throughout the process, the patient is supervised and supported by the program's coordinator."
48687769|NCT02188940|BEHAVIORAL|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
48687770|NCT02188940|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
48687771|NCT02188940|OTHER|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
48687772|NCT02188940|OTHER|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~\*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
48002390|NCT05651464|DRUG|Vancomycine|Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
48002391|NCT05516082|DEVICE|Lens A|DDH contact lens for 15 minutes
48002392|NCT05516082|DEVICE|Lens B|DDSH contact lens for 15 minutes
48159826|NCT04533971|OTHER|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
48367343|NCT03410641|BEHAVIORAL|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
48687773|NCT00684710|DRUG|PAZ-417|
48687774|NCT00684710|DRUG|Placebo|
48687775|NCT04098653|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
48687776|NCT04098653|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
48002393|NCT04763499|OTHER|freeze dried strawberry powder|approximately 24 strawberries that have been freeze dried into a powder
48002394|NCT05199480|DRUG|Tobacco flavored liquid type 1|A commercially available cartridge-based device with tobacco flavored liquid.
48002395|NCT05199480|DRUG|Tobacco flavored liquid type 2|A commercially available cartridge-based device with tobacco flavored liquid.
48002396|NCT03921060|DRUG|Denosumab|treatment with denosumab every 6 months for up to 5 years
48002397|NCT04211337|DRUG|Selpercatinib|Administered orally
48002398|NCT04211337|DRUG|Cabozantinib|Administered orally
48002399|NCT04211337|DRUG|Vandetanib|Administered orally
48002400|NCT02353767|PROCEDURE|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
48159829|NCT01493947|DRUG|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
48367344|NCT03641690|OTHER|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
48367345|NCT03219372|DRUG|Pravastatin Pill|statin
48367346|NCT03219372|DRUG|Placebo Oral Tablet|placebo
48687777|NCT04098653|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
48002401|NCT01494610|DRUG|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
48687778|NCT02417610|DEVICE|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
48367347|NCT04609436|DEVICE|"Cardiac monitoring with the wireless device SmartCardia"|Monitoring of arrhythmia with a wireless device (SmartCardia)
48002402|NCT01494610|DRUG|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
48002403|NCT04259112|PROCEDURE|high pressure|High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.
48002404|NCT04259112|DRUG|deep neuromuscular block|Deep neuromuscular block is defined as PTC 1-2.
48002405|NCT04259112|PROCEDURE|low pressure|Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.
48002406|NCT04259112|DRUG|moderate neuromuscular block|Moderate neuromuscular block is defined as TOF twitch 1-2.
48002407|NCT02825069|OTHER|Early introduction of solid foods|Early introduction of solid foods
48002408|NCT02946060|OTHER|Audiobooks|iPods with audiobooks
48687779|NCT02417610|DEVICE|Hyaluronic acid - HA - Ialart|Hyaluronic acid
48687780|NCT04646746|DIETARY_SUPPLEMENT|100% wheat|100 g of bread backed with 100% wheat
48687781|NCT04646746|DIETARY_SUPPLEMENT|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
48687782|NCT04646746|DIETARY_SUPPLEMENT|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
48002409|NCT02946060|OTHER|Tempo-pace synchronized playlists|Playlists with or without RAS
48002410|NCT02946060|OTHER|Usual Care|iPods containing either a silent track or white noise
48687783|NCT04646746|DIETARY_SUPPLEMENT|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
48687784|NCT02329977|OTHER|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
48687785|NCT03898271|OTHER|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
48687786|NCT03660865|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary eye will receive Light adjustable lens with Light delivery Device treatments
48687787|NCT03660865|DEVICE|Control IOL|Fellow eye will receive control IOL
48687788|NCT03995745|BEHAVIORAL|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
48002411|NCT00006211|DRUG|Capravirine|
48002412|NCT00006211|DRUG|Nelfinavir mesylate|
48002413|NCT01364090|DRUG|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
48002414|NCT01364090|DRUG|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
48159830|NCT01493947|DRUG|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
48367348|NCT03606265|DEVICE|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
48367349|NCT03606265|DEVICE|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
48367350|NCT00943566|DRUG|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
48367351|NCT00943566|DRUG|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
48367352|NCT02879968|OTHER|Non-interventional study|
48687789|NCT02894957|DRUG|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
48687790|NCT02628600|DRUG|LAI 590 mg|LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
48687791|NCT02628600|DRUG|Multi-drug regimen|Multidrug antimycobacterial regimen from study INS-212
48687792|NCT00346658|DRUG|magnesium|
48002415|NCT02378766|BEHAVIORAL|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
48159831|NCT05312190|DRUG|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
48159832|NCT05312190|DRUG|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
48159833|NCT01114334|BEHAVIORAL|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
48159834|NCT01114334|BEHAVIORAL|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
48367353|NCT01053143|BIOLOGICAL|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
48367354|NCT05214131|DEVICE|gogoband|use of biometric alarm to wake patient prior to wetting
48159835|NCT05261100|OTHER|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
48367355|NCT05214131|DEVICE|SNEA group|standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
48367356|NCT02908594|DEVICE|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
48513267|NCT05873790|DRUG|Serplulimab plus chemotherapy|"Serplulimab: 4.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. Chemotherapy drugs: etoposide + carboplatin/cisplatin Etoposide: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Carboplatin: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles."
48513268|NCT05742035|PROCEDURE|Venipuncture|Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
48159836|NCT05261100|OTHER|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
48159837|NCT03878290|BEHAVIORAL|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
48513269|NCT02498041|PROCEDURE|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
48513270|NCT02498041|DEVICE|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
48513271|NCT02498041|DEVICE|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
48513272|NCT02498041|PROCEDURE|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
48159838|NCT01425541|DRUG|estrace|0.5-1 mg once a day PO for 7 days
48159839|NCT01425541|DRUG|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
48159840|NCT00223132|DEVICE|Absorbable sutures|
48367357|NCT00517166|DEVICE|CAT (Combat Arms Tourniquet)|device
48367358|NCT01041742|PROCEDURE|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
48513273|NCT02473926|BEHAVIORAL|Physical Activity|Physical Activity Program Intervention
48513274|NCT02473926|BEHAVIORAL|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
48513275|NCT04868500|DEVICE|AMAZE™ Application|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
48513276|NCT04868500|DEVICE|AMAZE™ Dashboard|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
48513277|NCT01687972|COMBINATION_PRODUCT|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
48513278|NCT01687972|COMBINATION_PRODUCT|Absorbable sutures|placement of absorbable sutures at cesarean section
48687793|NCT01058681|DIETARY_SUPPLEMENT|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
48687794|NCT04189796|DIETARY_SUPPLEMENT|Cheese|Daily oral intake of cheese
48687795|NCT05606211|OTHER|No intervention|Observational, no intervention
48687796|NCT04098887|RADIATION|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
48687797|NCT02297815|DRUG|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
48687798|NCT02297815|DRUG|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
48687799|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
48687800|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
48367359|NCT05445999|DEVICE|High-Definition transcranial electrical stimulation|According to the results of structural phase magnetic resonance and electroencephalogram, four optimal stimulation parameters will be determined.Transcranial electrical stimulation devices (Sorterix)will be used for intervention.In each cycle, the stimulation will be performed every night during weekdays,a total of 10 times.A maximum of four cycles of intervention will be performed for each patient, depending on the efficacy and the their wishes.
48367360|NCT02383966|DRUG|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m\^2) on Day 1 and a subsequent dose of 250 mg/m\^2 on Day 8 and Day 15 of each 21-day treatment cycle.
48513279|NCT02405130|OTHER|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
48513280|NCT02405130|OTHER|no intracoronary epinephrine|patients will receive standard therapy only
48513281|NCT03742791|DRUG|TS-134|5 mg to 80 mg oral solution
48367361|NCT02383966|DRUG|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m\^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
48513282|NCT03742791|DRUG|Placebo|Matched Placebo oral solution
48159841|NCT05740371|DRUG|Argatroban|"Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible."
48159842|NCT05302271|BIOLOGICAL|AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN|AAVrh.10hFXN will be administered intravenously.
48159843|NCT05302271|DRUG|Prednisone|All participants will remain immunosuppression therapy with prednisone for a total of 14 weeks.
48159844|NCT06041334|BIOLOGICAL|Collection of a urine sample|Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)
48159845|NCT06041334|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the bladder|Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
48159846|NCT01757171|DRUG|Cabazitaxel|20mg IV over 1 hour every 3 weeks
48159847|NCT06646731|DEVICE|cryoneurolysis|Peripheral nerve cryoneurolysis of the foot
48159848|NCT06646731|DEVICE|sham cryoneurolysis|a sham probe will be placed percutaneously proximal to target nerves. No cryoneurolysis will be given.
48159849|NCT03570996|PROCEDURE|Esophagectomy|"Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal"
48159850|NCT03570996|PROCEDURE|Transversus abdominis plane catheter|TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
48159851|NCT03570996|PROCEDURE|Epidural|Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
48159852|NCT01502787|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
48159853|NCT01502787|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
48159854|NCT01502787|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
48367362|NCT02383966|DRUG|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m\^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
48367363|NCT00016068|DRUG|ganciclovir|
48367364|NCT00016068|DRUG|valganciclovir|
48159855|NCT01502787|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
48367365|NCT02983968|OTHER|Description of the cirrhosis management|
48367366|NCT05677841|OTHER|Stabilization exercise+lifestyle recommendation|Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
48367367|NCT05677841|OTHER|lifestyle recommendations|The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
48367368|NCT02361606|BEHAVIORAL|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
48367369|NCT02594150|OTHER|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
48159856|NCT01502787|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
48159857|NCT01502787|PROCEDURE|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
48159858|NCT01502787|DRUG|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
48159859|NCT01976156|DIETARY_SUPPLEMENT|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
48002416|NCT02378766|OTHER|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
48159860|NCT01976156|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
48159861|NCT04390971|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
48159862|NCT06646887|OTHER|Electroporation|Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.
48159863|NCT05122078|DEVICE|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
48159864|NCT05122078|OTHER|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
48159865|NCT03865940|DRUG|Lidocaine|6 mL of 1% lidocaine
48159866|NCT03865940|DRUG|Guanfacine|250 mcg
48159867|NCT03148301|OTHER|Survey|Survey
48159868|NCT05292170|OTHER|Heat acclimation|10 consecutive days of heat acclimation
48367370|NCT05944731|DEVICE|Continuous glucose monitor|Continuous Glucose Monitoring (CGM) device is a small electronic tool that you put on your skin, and it tells you the amount of glucose in your body. It is different from a finger prick glucose machine in that you do not need to prick your finger to get some blood to put on the reader paper like you have to do for a finger prick glucose machine.
48002417|NCT00096512|DRUG|sorafenib tosylate|Given orally
48002418|NCT00096512|OTHER|laboratory biomarker analysis|Correlative studies
48002419|NCT02306512|PROCEDURE|H&E|Sample will be stained with H\&E according to standard procedures
48159869|NCT02218671|DRUG|WE 941 OD tablets|
48159870|NCT06108752|OTHER|Scapular stabilization exercises|The scapular stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
48159871|NCT06108752|OTHER|Thoracic extension exercises|Thoracic extension exercises will be comprised of three exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
48159872|NCT03237598|OTHER||
48159873|NCT02971683|DRUG|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
48159874|NCT02971683|DRUG|Placebo|Placebo of Abatacept subcutaneous
48367371|NCT04370808|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
48367372|NCT00174460|DRUG|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
48002420|NCT02306512|PROCEDURE|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
48159875|NCT04661189|BEHAVIORAL|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
48159876|NCT04661189|BEHAVIORAL|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
48159877|NCT03518047|DRUG|risankizumab|rizankizumab subcutaneous (SC) infusion
48687801|NCT01208324|DRUG|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
48687802|NCT01208324|DRUG|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
48687803|NCT01208324|DRUG|Placebo Patch|placebo
48687804|NCT01208324|DRUG|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
48687805|NCT02263326|DRUG|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
48687806|NCT02263326|DRUG|lamivudine|300 mg tablet by mouth once daily for 48 weeks
48687807|NCT02263326|DRUG|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
48687808|NCT03459469|DRUG|Tegavivint|This is an Investigational drug
48687809|NCT01268046|DRUG|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
48687810|NCT01268046|DRUG|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
48687811|NCT01268046|DRUG|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
48687812|NCT01268046|DRUG|placebo oral capsule|placebo oral capsule administered daily for one month.
48687813|NCT00241072|DRUG|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
48687814|NCT03456349|DRUG|HTL0018318|HTL0018318
48687815|NCT03456349|DRUG|Placebo|Placebo
48687816|NCT03001193|DRUG|DF 01|
48687817|NCT03001193|DRUG|Oxytocin|
48687818|NCT03001193|DRUG|Placebo|
48687819|NCT03742479|DEVICE|Restylane® Silk|Injectable Hyaluronic Acid (HA)
48687820|NCT01864681|DRUG|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
48687821|NCT01864681|DRUG|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
48002421|NCT02306512|PROCEDURE|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
48159878|NCT03518047|DRUG|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
48687822|NCT02400606|OTHER|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
48687823|NCT02400606|OTHER|Solving VP cases|See above
48687824|NCT01389453|PROCEDURE|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
48687825|NCT04520152|DEVICE|FreeFlowMedical Lung Tensioning Device|Bronchoscopic lung tensioning device implantation
48687826|NCT02137447|DEVICE|Negative Pressure treatment|
48002422|NCT02306512|PROCEDURE|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
48159879|NCT05278442|OTHER|LaserArc|LaserArcs.com is an online arcuate incision nomogram calculator initially developed on the basis of 12 months of data tabulation of patients undergoing femtosecond surgery with arcuate incisions
48159880|NCT05382299|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
48159881|NCT05382299|DRUG|Paclitaxel|Administered intravenously
48002423|NCT04813055|PROCEDURE|Therapeutic EUS|"1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~6. EUS-guided pancreatic duct drainage"
48159882|NCT05382299|DRUG|nab-Paclitaxel|Administered intravenously
48159883|NCT05382299|DRUG|Gemcitabine|Administered intravenously
48159884|NCT05382299|DRUG|Carboplatin|Administered intravenously
48159885|NCT00021021|BIOLOGICAL|anti-FLT-1 ribozyme|
48159886|NCT03027999|OTHER|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~1. a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~2. A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP \> 2.7"
48159887|NCT06416111|DEVICE|NIRS|Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).
48159888|NCT06416111|OTHER|Pinprick Test|"With the pinprick test, the practitioner gently touches the skin with the pin and asks the patient whether it feels sharp or blunt .Test begins distally and then move proximally (aiming to test each dermatome and each main nerve).~Assessment of sensorial blockade uses 3 grade system. Grade 0.Sharp pain Grade 1.Analgesia ,numbness Grade 2.Anesthesia ,no feeling"
48159889|NCT06416111|OTHER|Modified Bromage Scale|"Assessment of motor blockade uses 4 point Modified Bromage Score. 0.Normal motor function with full extension and flexion of elbow, wrist and fingers~1. Decreased motor strengths with ability to full flexion elbow and move fingers but inability to raise arm~2. More decreased motor strengths with inability to move elbow but ability to move fingers 3.Complete motor block with inability to move elbow, wrist, and fingers."
48159890|NCT06416111|DRUG|Bupivacaine|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
48159891|NCT06416111|DRUG|Prilocaine|Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
48159892|NCT02259296|PROCEDURE|Lower eGFR for AVF construction|Lower eGFR patients (eGFR\<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR\<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
48159893|NCT02259296|PROCEDURE|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
48159894|NCT03553459|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
48367373|NCT00174460|OTHER|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
48367374|NCT02370173|DEVICE|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
48002424|NCT04813055|PROCEDURE|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
48002425|NCT04813055|PROCEDURE|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
48002426|NCT04813055|PROCEDURE|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
48002427|NCT05548192|DEVICE|SmartPICC-1 System|The SmartPICC system is indicated for use as an alternative method to chest x-ray or fluoroscopy confirmation of PICC tip placement in adult patients when proper ECG detection is available. The SmartPICC system provides a supplemental intravascular ionic dilution feature that provides qualitative blood flow information to the user to aid catheter navigation during PICC placement.
48687827|NCT06058663|PROCEDURE|Angiography|Undergo mapping angiography
48002428|NCT05506202|OTHER|Individual basic body awareness therapy|"Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state."
48159895|NCT02064361|OTHER|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
48367375|NCT02370173|DEVICE|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
48002429|NCT05506202|OTHER|Respiratory physiotherapy interventions|Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
48002430|NCT02897128|OTHER|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
48002431|NCT01468766|OTHER|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
48002432|NCT01468766|OTHER|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
48002433|NCT03307733|BEHAVIORAL|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
48002434|NCT00573027|PROCEDURE|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
48687828|NCT06058663|PROCEDURE|Biopsy|Undergo biopsy
48687829|NCT06058663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48002435|NCT01398111|DRUG|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
48159896|NCT02936193|PROCEDURE|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
48159897|NCT02936193|PROCEDURE|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
48367376|NCT04854356|OTHER|Exercise with blood flow restriction (BFR)|All participants completed high-intensity interval exercise plus (1) BFR applied during exercise phase, or (2) BFR applied during interval phase, or (3) no BFR applied.
48687830|NCT06058663|PROCEDURE|Computed Tomography|Undergo CT
48687831|NCT06058663|BIOLOGICAL|Durvalumab|Given IV
48687832|NCT06058663|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48687833|NCT06058663|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48687834|NCT06058663|BIOLOGICAL|Tremelimumab|Given IV
48687835|NCT06058663|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Receive transarterial Y90 radioembolization
48687836|NCT05076773|PROCEDURE|Ultrasound guided block|Giving one regional block
48687837|NCT05076773|DRUG|IV morphine|given when VAS\>3
48687838|NCT04469023|DRUG|TS-142|Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
48687839|NCT04539613|DRUG|HPFSH & HMG|. Various gonadotropin preparations
48687840|NCT00783835|DRUG|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
48002436|NCT01398111|DRUG|Glycopyrrolate|glycopyrrolate pMDI
48002437|NCT01398111|DRUG|Formoterol|formoterol pMDI
48002438|NCT01398111|DRUG|Placebo|placebo pMDI
48002439|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SAPB
48002440|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
48002441|NCT05090761|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
48159898|NCT01270217|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
48159899|NCT04092699|DEVICE|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
48159900|NCT01464671|DRUG|Bivalirudin|Anticoagulation during percutaneous coronary intervention
48159901|NCT01464671|DRUG|Heparin|Anticoagulation during percutaneous coronary intervention
48159902|NCT06401005|DRUG|Cadonilimab (AK104)|8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of albumin paclitaxel (260mg/m2, d1, Q3W) and carboplatin (AUC=6, d1, Q3W) were administered, followed by four cycles of sequential Doxorubicin 50mg/m2/d1 (Q3W) + Cyclophosphamide 600mg/m2/d1, Q3W for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.
48367377|NCT04545645|BEHAVIORAL|median nerve mobilization|The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.
48367378|NCT04545645|BEHAVIORAL|Neural stress provocation with cognitive auditory distraction|Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.
48367379|NCT04545645|BEHAVIORAL|Providing neural stress with a motor distraction|The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.
48687841|NCT01500252|DEVICE|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
48002442|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 1
48002443|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 2
48002444|NCT01529424|DRUG|ISIS apoC-III Rx|Dose 3
48002445|NCT01529424|DRUG|Placebo|Dose 1
48002446|NCT01529424|DRUG|Placebo|Dose 2
48002447|NCT01529424|DRUG|Placebo|Dose 3
48002448|NCT00262067|DRUG|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
48002449|NCT00262067|DRUG|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
48002450|NCT00262067|DRUG|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~1. Docetaxel 75-100 mg/m\^2 IV~2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV~3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV~Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle"
48159903|NCT04004169|DEVICE|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
48159904|NCT04004169|DEVICE|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
48159905|NCT04004169|DEVICE|Stimulation-ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
48159906|NCT06647160|DEVICE|Blue star MAX-5 spectacle lens|The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.
48159907|NCT06647160|DEVICE|Single-vision spectacle lens|The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.
48159908|NCT06006754|OTHER|Observational study|No intervention: observational study
48002452|NCT01556204|PROCEDURE|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
48002453|NCT01556204|PROCEDURE|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
48002454|NCT06274710|BEHAVIORAL|ODYSSEE-KH|Automated digital counselling program
48159909|NCT05068687|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"Included patients are given a single weight-dependent activity of 18F-FDG at the department of Nuclear Medicine. After administration, patients are brought to the operating room where standard of care surgical removal of the malignancy is performed.~The resected specimen(s) are brought to the imaging lab and scanned using a preclinical and/or a dedicated specimen PET/CT device. Following PET/CT imaging, the specimen is brought to the department of pathology, where it is sliced. Some of these slices are then rescanned using the preclinical PET/CT device. Moreover, frozen sections are made from one of these slices with macroscopically visible malignant tissue and placed on an autoradiograph overnight. Finally, the imaging results are then correlated to the results found during histopathological analysis of the specimens."
48159910|NCT01540877|PROCEDURE|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
48159911|NCT01540877|PROCEDURE|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
48159912|NCT01540877|PROCEDURE|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
48159913|NCT01540877|PROCEDURE|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
48002455|NCT06241027|OTHER|Nerve flossing technique|The nerve flossing technique will be perform actively with the participant sitting on the chair. The participant flexed the knee of the target lower extremity backward beside the chair as far back as possible and flexed the neck at the same time, holding both the flexed knee and neck in thisposition for 5 seconds. The participant in turn extended the neck and knee of the target lower extremity, abducted and flexed the hip until pain will feel and did not push beyond that point. This extended position will be hold for 5 seconds.
48159915|NCT01920399|DRUG|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
48159916|NCT01920399|DRUG|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
48367380|NCT04545645|BEHAVIORAL|Neural stress provocation with auditory and motor cognitive distraction.|The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
48367381|NCT05543980|DEVICE|Sham device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 33ºC.
48367382|NCT05543980|DEVICE|Leg heat therapy device|The leg heat therapy device consists of a water tank coupled with a circulator, a sous-vide water heater and water-circulating trousers. The water heater in the sham device is adjusted to heat up the water to 42ºC.
48687842|NCT01500252|DEVICE|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
48159917|NCT02625922|DRUG|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
48159918|NCT02625922|DRUG|Placebo|Matching placebo i.v infusion
48159919|NCT03559452|PROCEDURE|Eccentric exercise|300 eccentric contractions of the knee extensors
48367383|NCT05699382|OTHER|practiced mindfulness through the application for 6 weeks|Physicians working at a tertiary hospital were recruited and randomly divided into two groups, a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
48367384|NCT03716128|DIAGNOSTIC_TEST|18F-PET|Bone biopsy and 18F-PET
48159920|NCT02515500|BEHAVIORAL|Gradual Cessation|
48159921|NCT02515500|BEHAVIORAL|Gradual Cessation w/ Quitbit|
48367385|NCT01967992|BEHAVIORAL|Behavioral: Low Carbohydrate, Ketogenic Diet|
48367386|NCT01967992|BEHAVIORAL|American Diabetes Association Diet|
48367387|NCT01967992|BEHAVIORAL|Mindfulness and Positive Affect Skills|
48687843|NCT02434549|DRUG|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
48687844|NCT02434549|DRUG|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
48687845|NCT06421506|PROCEDURE|Less invasive surfactant administration during high flow nasal cannula treatment|Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.
48688206|NCT05691790|BEHAVIORAL|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview \~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
48688207|NCT05691790|BEHAVIORAL|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
48688208|NCT00348738|DRUG|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of \>14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
48688209|NCT02195700|DRUG|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
48688210|NCT02195700|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks.
48002679|NCT01054638|DRUG|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
48688211|NCT01479244|BIOLOGICAL|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
48002680|NCT01582997|DRUG|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
48688212|NCT01479244|BIOLOGICAL|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
48688213|NCT04079231|DRUG|Brolucizumab|Intravitreal Injection
48688214|NCT04079231|DRUG|Aflibercept|Intravitreal injection
48688215|NCT04947345|DRUG|Remimazolam Besylate|Remimazolam Besylate are used as sedatives for subjects in this arm.
48688216|NCT04947345|DRUG|Propofol|Propofol are used as sedatives for subjects in this arm.
48688217|NCT04384705|OTHER|research specific blood sample|"* one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase"
48688218|NCT01322854|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
48002681|NCT02630784|PROCEDURE|Non-Invasive Ventilation with Homecare ventilator|
48002682|NCT02630784|PROCEDURE|Non-Invasive Ventilation with ICU ventilator|
48002683|NCT05551143|OTHER|LiftKit|"The LiftKit contains 7 tools that could assist EMS providers when lifting/moving patients. These tools are:~1. Simple Strap - A sling to lift a seated patient~2. Strap and slide stick - A strap system for raising a supine patient to a sitting posture.~3. Slip Preventer- An envelope that goes over the patients feet with high friction straps for the EMS providers to stand on that prevent the patient from sliding forward when lifted.~4. Drag Straps - straps with handles that can be clipped on tarps used to drag patients~5. The Binder Lift - a vest with handles that allow EMS providers to easily get hold of patient they need to lift.~6. Patient Turning Straps - a way to log-roll a patient that in on the floor while in a standing posture.~7. The ELK - an inflatable seat cushion that can raise a patient who in the floor to chair level"
48688219|NCT05631340|OTHER|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
48688220|NCT05653245|DRUG|RGD Peptide|adhesion molecules
48002684|NCT02832310|PROCEDURE|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
48002685|NCT01064557|DRUG|all-trans retinoic acid (ATRA)|
48002686|NCT05967962|BEHAVIORAL|The Trauma Film Paradigm|"Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes)."
48688221|NCT05906680|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
48688222|NCT00456755|DRUG|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
48688223|NCT00456755|OTHER|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
48688224|NCT02523092|DRUG|Acthar gel|Acthar gel given IM or SQ as per package insert
48688225|NCT06279949|BEHAVIORAL|Provider training|Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
48688226|NCT06279949|BEHAVIORAL|Clinic protocols|Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
48688227|NCT01262638|DRUG|ETC-1002|ETC-1002 daily for 12 weeks
48688228|NCT01262638|DRUG|Placebo|Placebo daily for 12 weeks
48688229|NCT05145751|OTHER|Simple inflammatory biomarkers measurement|In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
48002687|NCT05967962|BEHAVIORAL|non-traumatic (neutral) film|non-traumatic (neutral) film
48688230|NCT02148536|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
48688231|NCT01308814|DRUG|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
48387986|NCT05573646|OTHER|Dual-task training|Participants will receive a one-hour online group-based dual-task training session twice a week for 12 weeks, giving a total intervention time of 24 hours. A co-design approach will be adopted to develop the training components in the dual-tasks. For the cognitive training component, arithmetic operation, verbal fluency, and upper limb/ finger movements are included. For the physical training component, we select chair-based exercises are included. A group-based training mode led by a facilitator will be adopted. During the session, participants will be asked to turn on their camera so that they can see and interact with each other. They will also have their audio on as they will have to participate in the cognitive tasks by voicing out their answers.
48688232|NCT01308814|DRUG|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
48688233|NCT03770741|OTHER|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
48688234|NCT03770741|OTHER|Treatment as usual|Monitoring and treatment according to local guidelines and practice
48688235|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
48688236|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
48688237|NCT00395070|BIOLOGICAL|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
48688238|NCT00395070|DRUG|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
48002688|NCT01760083|DEVICE|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
48002689|NCT05548023|DEVICE|The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent|The Angiolite stent is a thin-strut cobalt-chromium sirolimus-eluting stent with an open-cell design and a high overexpansion capacity that might overcomes some of these challenges in LMCA PCI. The ANGIOLITE randomized trial confirmed the non-inferiority of the Angiolite stent against the conventional DES
48688239|NCT00395070|DRUG|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
48688240|NCT03820986|BIOLOGICAL|Pembrolizumab|IV infusion
48688241|NCT03820986|DRUG|Lenvatinib|Oral capsule
48688242|NCT03820986|DRUG|Placebo for lenvatinib|Oral capsule
48688243|NCT03797963|DEVICE|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
48688244|NCT03797963|DEVICE|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
48688245|NCT06467071|BEHAVIORAL|SH+ combined with a session for PMLD|The intervention integrates WHO's Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. SH+ is a guided self-help program with five weekly sessions led by facilitators, aimed at managing stress and psychological distress without requiring a diagnosis. This scalable intervention is based on solid research, proven effective in reducing stress and preventing mental health disorders (Tol et al., 2020; Turrini et al., 2019). The PMLD session, based on WHO's Problem Management Plus (PM+), involves focus groups to identify post-migration challenges. Participants share experiences, learn coping strategies, discover local resources, and strengthen social support networks. This integrated approach aims to enhance mental health, address post-migration difficulties, and improve stress reduction skills, supporting adaptation to a new country.
48688246|NCT02688829|DEVICE|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
48002690|NCT00951431|DRUG|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
48688247|NCT01221623|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
48002691|NCT00951431|DRUG|Placebo|Placebo in the form of study drug
48002692|NCT02563028|DEVICE|SightSaver Visual Stimulator|Evoked response photic stimulator
48002693|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
48688248|NCT01221623|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
48387987|NCT05573646|OTHER|Attention Control|Participants will receive eight one-hour online group-based interactive education on health topics other than exercise and cognitive health.
48688249|NCT01373255|PROCEDURE|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
48688250|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
48688251|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
48688252|NCT06182098|OTHER|1/2 maintenance fluids|Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.
48688253|NCT06182098|DRUG|Ketorolac|0.5mg/kg, with a maximum of 30mg
48688254|NCT06182098|DRUG|Diphenhydramine|0.5mg/kg, with a maximum of 25mg
48688255|NCT06182098|DRUG|Prochlorperazine|0.15mg/kg, with a maximum of 10mg
48688256|NCT06182098|OTHER|bolus|20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
48688257|NCT00809835|DRUG|Galantamine|Daily 8 mg galantamine capsule
48688258|NCT00809835|BEHAVIORAL|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
48688259|NCT04089670|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
48688260|NCT00915759|DEVICE|ProKera|ProKera placed in non-dominant eye after PRK
48688261|NCT00915759|DEVICE|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after PRK
48002694|NCT00983216|DRUG|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
48688262|NCT03704844|OTHER|non applicable|non applicable
48688263|NCT04423679|DEVICE|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
48688264|NCT01142869|DRUG|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
48002695|NCT00983216|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
48002696|NCT01787084|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
48002697|NCT02531321|DRUG|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
48002698|NCT01566448|DRUG|Ketamine|20mg/5ml swish and spit four times daily
48387988|NCT01481961|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
48387989|NCT04461080|BEHAVIORAL|Community Health Worker|Trained Community Health Worker
48387990|NCT06539689|DEVICE|Sperstent® peripheral spot stent system|Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
48387991|NCT06539689|DEVICE|Everflex® self-expanding peripheral stent system|Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）
48387992|NCT01817764|DRUG|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
48002699|NCT06165796|DEVICE|routine cataract surgery and intraocular lens implantation|routine cataract surgery and intraocular lens implantation
48002700|NCT00243308|DRUG|Serine proteinase-1 (Serp-1)|
48688265|NCT03560102|DEVICE|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
48688266|NCT05570656|DEVICE|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
48688267|NCT02048644|DRUG|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
48688268|NCT02048644|DRUG|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
48688269|NCT00254150|PROCEDURE|Increase oxygen extraction rate|
48688270|NCT03275246|DEVICE|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
48688271|NCT02792309|BEHAVIORAL|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
48688272|NCT03776812|DRUG|Relacorilant, 100mg QD|Relacorilant is supplied as capsules for oral dosing
48688273|NCT03776812|DRUG|Nab-paclitaxel, 80mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
48688274|NCT03776812|DRUG|Nab-paclitaxel, 100mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
48002701|NCT03569371|DRUG|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
48002702|NCT02353091|DEVICE|Remote Microphone Hearing Aids|The ear receivers connect wirelessly with the microphone being worn by the teacher within a range of 25m.
48002703|NCT05720325|DRUG|Dupilumab|Dupixent is an interleukin-4 receptor alpha antagonist
48002704|NCT05720325|OTHER|House Dust Mites (HDM)|House Dust Mites used to challenge subjects using an aeroallergen challenge chamber
48002705|NCT05720325|OTHER|Placebo|Inert placebo administered to placebo arms of study.
48002706|NCT03887039|OTHER|clinical examination|clinical examination for all the oral findings
48387993|NCT01817764|DRUG|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
48688275|NCT03776812|DRUG|Relacorilant, 150mg QD|Relacorilant is supplied as capsules for oral dosing
48002707|NCT04968132|OTHER|Multicomponent opioid reduction and pain management pathway|Pre-operative pain education and expectation setting, identification and modification of risk factors in high risk patients, postoperative individualized analgesic prescriptions, and continued support for pan control and recovery facilitated by an interventions coordinator.
48002708|NCT04968132|OTHER|Standard care|Standard perioperative care, surgical treatment, and pain medications.
48002709|NCT06307275|OTHER|Fasting|Fasting for 16 hours from participant last meal of the previous evening's meal to the first meal of the next day. Then for 8 hours, participant is able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.
48387994|NCT01817764|DRUG|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
48688276|NCT06552975|OTHER|Infection|Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
48688277|NCT02739386|BIOLOGICAL|Ipilimumab|Intravenous monoclonal antibody injection
48688278|NCT03279887|DIAGNOSTIC_TEST|Lung Ultrasound|
48688279|NCT05371158|BEHAVIORAL|Online intervention|The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
48688280|NCT05657080|DEVICE|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
48688281|NCT00830375|DRUG|Memantine|10-30mg, by mouth, daily
48688282|NCT01156025|DRUG|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
48688283|NCT01156025|DRUG|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
48002710|NCT06307275|OTHER|non fasting|Participants will not be fasting during these four weeks. They will eat their normal food intake and keep their normal physical activity levels.
48002711|NCT04147442|DEVICE|Hearing aid with fine-tuned and standard programs|A digital, wireless hearing aid is programmed specifically to each subject's hearing loss and fitted with both a program that is fine-tuned for their specific music playing as well as the standard music program that uses pre-determined settings.
48002712|NCT01385124|DRUG|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
48002713|NCT04766242|OTHER|Spiritual healing|"The spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient's body, known as power points, outside the patients clothing. The consultation might also include possible life-style advice. The treatments will last for 45-60 minutes each time."
48688284|NCT03685903|DEVICE|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
48688285|NCT03770208|DRUG|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
48688286|NCT03770208|DRUG|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
48688287|NCT01532921|PROCEDURE|Tricuspid valve repair|
48522594|NCT03119870|OTHER|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
48002714|NCT04766242|OTHER|Usual care|The care the general practitioner (GP) prescribe when the patients are diagnosed with moderate depression.
48002715|NCT02086942|DRUG|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
48028565|NCT02563912|OTHER|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
48367573|NCT04151420|OTHER|Remote monitoring tool (infections questionnaire) validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
48367574|NCT04027504|DIETARY_SUPPLEMENT|Fitabisc|Biscuits containing antioxidants
48367575|NCT03909035|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* Detailed feedback to the general practitioner.~* An appointment with the patient to explain the modifications made by the general practitioner (GP)"
48367576|NCT05115812|PROCEDURE|Pre-Operative Information|Demographics (e.g., age, gender), patient characteristics (e.g., BMI, American Society of Anesthesiologists class), and pre-operative medical history (e.g., tobacco use; comorbidities: hypertension, cardiopulmonary disease, diabetes; indication for RAT; lesions; previous renal revascularization; serum creatinine level).
48367577|NCT05115812|PROCEDURE|Intra-Operative Data|Operative time, total OR time, concomitant procedures, transfusions, conversions, intraoperative adverse events, autotransplantation technique
48367578|NCT05115812|OTHER|Post-Operative Data (up to discharge)|Postoperative adverse events, discharge status, hospital length of stay, information on enhanced recovery program
48688288|NCT01532921|PROCEDURE|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
48688289|NCT01532921|DEVICE|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
48688290|NCT04966312|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
48688291|NCT04966312|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
48688292|NCT00956722|DRUG|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
48688293|NCT01188551|DRUG|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
48688294|NCT01188551|DRUG|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
48688295|NCT01188551|DRUG|Midazolam|Sedative given pre-op.
48688296|NCT00269113|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
48688297|NCT00269113|DRUG|Standard chemotherapy|As prescribed
48002716|NCT02086942|DRUG|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
48688298|NCT01653587|DEVICE|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
48688299|NCT04535817|DRUG|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
48367579|NCT05115812|OTHER|Short-Term Follow-Up Data|Adverse events, re- admissions, re-operations related to the index procedure
48688300|NCT00135538|DEVICE|Noninvasive positive pressure ventilation|
48002717|NCT02086942|DRUG|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
48002718|NCT03592433|BEHAVIORAL|I Can PIC|Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
48002719|NCT02679911|DRUG|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
48002720|NCT02679911|DRUG|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
48002721|NCT02484703|DRUG|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
48002722|NCT02484703|DRUG|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
48002723|NCT00922883|DRUG|Eltrombopag|
48002724|NCT05401838|BEHAVIORAL|Group Brief Cognitive-Behavioral Therapy (G-BCBT)|G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.
48185159|NCT02172911|BIOLOGICAL|INO-3112|1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
48185160|NCT02172911|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
48387995|NCT00288106|OTHER|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
48387996|NCT01881178|DIETARY_SUPPLEMENT|NOPALEA|
48688301|NCT03541889|DRUG|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
48688302|NCT02472587|OTHER|Questionnaire|
48688303|NCT05089552|OTHER|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
48688304|NCT05089552|OTHER|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
48688305|NCT05089552|OTHER|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
48688306|NCT02173483|PROCEDURE|Quadriceps graft|
48688307|NCT02752919|DRUG|Galunisertib|Administered orally
48002725|NCT05401838|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Group|DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
48688308|NCT03790813|DIAGNOSTIC_TEST|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
48002726|NCT03549247|BEHAVIORAL|quality of life in healthy,gingivitis,periodontitis groups|a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
48002727|NCT00283439|BIOLOGICAL|AMG 531|"Planned Cohorts:~1. 100 mcg,~2. 300 mcg,~3. 700 mcg,~4. 1000 mcg;~   Optional Cohorts:~5. cohort expansion,~6. schedule change,~7. new dose"
48002728|NCT04547062|DRUG|Tocilizumab|Administration of tocilizumab at day 8 of induction following a classical induction
48002729|NCT02752932|OTHER|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
48002730|NCT06304142|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
48002731|NCT06304142|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48002732|NCT06304142|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
48688309|NCT03790813|DIAGNOSTIC_TEST|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
48002733|NCT06115928|DEVICE|Virtual reality|Participants will perform cardiac rehabilitation with hardware-type technology consisting of a PICO 4® head mounted display (HMD) headset and the software TREADMILL XR®.
48002734|NCT00843713|DRUG|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
48002735|NCT00843713|DRUG|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
48002736|NCT00400647|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
48002737|NCT00400647|DRUG|Mycophenolate mofetil|
48688310|NCT05711875|OTHER|Virtual Reality (VR) glasses|During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
48002738|NCT04270825|BEHAVIORAL|Group CBT with IPT|Group treatment designed to target relationships with both possessions and people.
48002739|NCT04413929|DRUG|Ergoferon|Oral administration
48688311|NCT01924039|BEHAVIORAL|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
48688312|NCT01924039|OTHER|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
48688313|NCT04397367|DRUG|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
48688314|NCT04397367|DRUG|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
48688315|NCT04397367|DRUG|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
48002740|NCT00620594|DRUG|BEZ235|
48185161|NCT01150461|DRUG|losartan|Losartan 50 mg b.i.d
48185162|NCT01150461|DRUG|placebo|Placebo b.i.d.
48729771|NCT01920737|DRUG|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
48159923|NCT04560192|OTHER|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"1. Waiting period with TAU.~2. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
48002741|NCT03093675|DEVICE|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
48159924|NCT02794428|DRUG|Eflornithine|Eflornithine\*, 2 tablets, Oral, Daily for 18 months
48159925|NCT02794428|OTHER|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
48159926|NCT04694300|DRUG|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
48159927|NCT04694300|DRUG|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
48159928|NCT04694300|DRUG|Tramadol|50 mg by mouth every 6 hours as needed for pain
48159929|NCT04748445|DIAGNOSTIC_TEST|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
48159930|NCT01102985|BEHAVIORAL|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
48513432|NCT05931653|OTHER|Proprioceptive training along with and Multimodal Physical therapy|"* Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-\<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~* Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~  2. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s."
48513433|NCT00645632|DRUG|cisplatin|
48729772|NCT01920737|DRUG|Vincristine|
48729773|NCT01920737|DRUG|Prednisone|
48729774|NCT01920737|DRUG|PEG-Asparaginase|
48729775|NCT01920737|DRUG|Methotrexate|
48002742|NCT02803112|PROCEDURE|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
48159931|NCT01102985|BEHAVIORAL|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
48159932|NCT01249599|PROCEDURE|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
48159933|NCT04382183|BEHAVIORAL|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
48159934|NCT04382183|BEHAVIORAL|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the recommendations from the Norwegian Health Directorate for 1 year.
48159935|NCT05291585|DEVICE|the dedicated venous sinus thrombectomy stent|the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
48159936|NCT05291585|DEVICE|balloon catheter thrombectomy|Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
48159937|NCT05532319|COMBINATION_PRODUCT|HAIC sequential TAE combined with lenvatinib and tislelizumab|Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
48159938|NCT06313099|OTHER|Survey|Participants' musculoskeletal system disorders were assessed using the Cornell Musculoskeletal Disorders Questionnaire (CMDQ), fatigue levels were measured using the Fatigue Severity Scale (FSS), sleep quality was evaluated using the Visual Analog Scale (VAS), depression levels were assessed using the Beck Depression Inventory (BDI), and quality of life was measured with the Nottingham Health Profile (NHP). Google Forms was used to create the data collection tools, which were then sent to the participants' email addresses and collected online.
48159939|NCT00295100|DRUG|Tamoxifen|
48159940|NCT03483597|OTHER|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
48159941|NCT06080178|DRUG|Plasma-lyte|Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg
48159942|NCT06080178|DRUG|Norepinephrine|When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).
48729776|NCT01920737|DRUG|6-MP (6-Mercaptopurine)|
48387997|NCT06565637|BEHAVIORAL|Promoting Resilience to Improve Disordered Eating|"See description under Arms"
48002743|NCT04091503|DRUG|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
48002744|NCT02581774|OTHER|normal delivery tracking|normal delivery tracking
48002745|NCT02346136|BEHAVIORAL|Tai Chi training|
48002746|NCT02346136|BEHAVIORAL|Educational Control|
48002747|NCT03571919|DRUG|Lidocaine infusion|Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
48159943|NCT06080178|DRUG|Plasma-lyte|"Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg."
48513434|NCT00645632|DRUG|doxorubicin hydrochloride|
48513435|NCT00645632|DRUG|ifosfamide|
48688316|NCT04397367|DRUG|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
48002748|NCT03571919|DRUG|Saline infusion|Intravenous bolus of saline and then infusion
48688317|NCT03608241|DRUG|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
48002749|NCT04982666|OTHER|Whole-Food, Plant-Based Diet|This diet is focused on nutritional needs with natural, minimally-processed plant foods.
48688318|NCT03608241|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
48002750|NCT04982666|OTHER|FODMAP Diet|An elimination diet of fermentable, oligosaccharides, disaccharides, monosaccharides and polyols
48002751|NCT01959152|DEVICE|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
48002752|NCT00062465|DRUG|TwHF|
48002753|NCT00641095|BIOLOGICAL|rituximab|concentrate for solution for infusion
48688319|NCT00970723|BEHAVIORAL|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
48002754|NCT00641095|DRUG|Cyclophosphamide|Tablets
48688320|NCT00970723|BEHAVIORAL|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
48002755|NCT00641095|DRUG|Fludarabine|Film coated tablet
48002756|NCT01071928|DRUG|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
48002757|NCT01071928|DRUG|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
48002758|NCT05069922|OTHER|Fresh Frozen Plasma|Fresh Frozen Plasma
48513436|NCT00645632|DRUG|methotrexate|
48513437|NCT00645632|PROCEDURE|adjuvant therapy|
48513438|NCT00645632|PROCEDURE|neoadjuvant therapy|
48513439|NCT00645632|PROCEDURE|therapeutic conventional surgery|
48688321|NCT00970723|BEHAVIORAL|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
48688322|NCT02855021|OTHER|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
48688323|NCT05368389|DEVICE|Healthdot attachment|"The wearable health monitoring device Healthdot 5 will be attached to the patient's skin at left lower rib and data like heart rate, respiratory rate, posture and activity will be collected for 10 days.~A questionnaire will be sent to patients to fill out at the 10th day after the device attachment."
48688324|NCT05947838|PROCEDURE|Circulating tumoral DNA directed neoadjuvant therapy arm|Given by IV (vein)
48688325|NCT01266109|BEHAVIORAL|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
48688326|NCT01266109|OTHER|Usual Services (US)|Typical community-based substance abuse treatment services
48688327|NCT04856605|PROCEDURE|surgery|regular surgery
48688328|NCT06155006|DIAGNOSTIC_TEST|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
48688329|NCT03635164|DRUG|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
48688330|NCT03635164|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 8 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
48688331|NCT03635164|PROCEDURE|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
48729777|NCT01920737|DRUG|Cyclophosphamide|
48729778|NCT01920737|DRUG|Cytarabine|
48513440|NCT03867097|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
48688332|NCT01800331|BEHAVIORAL|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
48688333|NCT01225133|OTHER|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
48688334|NCT01225133|OTHER|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
48002759|NCT05433454|OTHER|Outreach From Navigators|Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.
48002760|NCT03352921|OTHER|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
48002761|NCT03352921|OTHER|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
48002762|NCT03870152|PROCEDURE|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
48002763|NCT04441333|DEVICE|AspivixTM cervical vacuum tenaculum|Traction of the cervix for IUD insertion using the AspivixTM cervical vacuum tenaculum
48002764|NCT00129129|BIOLOGICAL|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
48002765|NCT00129129|BIOLOGICAL|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
48002766|NCT00129129|BIOLOGICAL|Pediarix|Primary phase: 3 IM doses
48002767|NCT00129129|BIOLOGICAL|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
48002768|NCT00129129|BIOLOGICAL|Menomune|Primary phase: 1 SC dose
48002769|NCT02330796|DRUG|Bucillamine|Bucillamine Tablets
48002770|NCT02330796|DRUG|Colchicine|
48002771|NCT04143451|BIOLOGICAL|Vaxigrip tetra|quadrivalent influenza vaccine
48002772|NCT04143451|BIOLOGICAL|Fluzone high-dose|high-dose trivalent influenza vaccine
48002773|NCT04143451|DRUG|Aldara 5% Topical Cream|imiquimod cream
48002774|NCT04143451|DRUG|Aqueous cream BP|inactive aqueous cream
48002775|NCT02308735|OTHER|N/A - No intervention|
48002776|NCT05409027|DRUG|SPI-62|SPI-62 is supplied as 1 mg tablets for oral dosing.
48002777|NCT05409027|DRUG|Cortisone-d8|Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion
48002778|NCT03060772|DRUG|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
48002779|NCT03455465|OTHER|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
48002780|NCT01352494|DRUG|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
48002781|NCT01352494|DRUG|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
48002782|NCT02478138|PROCEDURE|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
48002783|NCT02478138|DRUG|Indocyanine Green (ICG)|
48002784|NCT02478138|DEVICE|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
48729779|NCT01920737|DRUG|Leucovorin|
48729780|NCT01920737|DRUG|Dexamethasone|
48729781|NCT01920737|OTHER|Blood draw|
48002785|NCT04362917|OTHER|There is no intervention|There is no intervention
48002786|NCT02583581|DEVICE|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
48002787|NCT02583581|DEVICE|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
48002788|NCT00207142|DRUG|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
48002789|NCT00207142|DRUG|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
48002790|NCT02084771|DRUG|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
48002791|NCT02084771|BIOLOGICAL|Oral Salt and Water|Oral salt capsules and water, based on patient weight
48002792|NCT01581463|DRUG|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
48159944|NCT06080178|DRUG|Norepinephrine|"When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg."
48002793|NCT04642729|PROCEDURE|Fresh Corneal Lenticule Implantation using Relex-Smile Surgery|Knowing that the most important element is damage of stroma we used all preoperative procedures atlas, optic tomography and especially electron microscope. Approximately we planned how much microns we remove and insert, for example we remove 80 µm and we insert fresh corneal lenticule 90 µm with the purpose to remove more dead keratocytes which increase biomechanical instability of corneal metabolism (abnormal increase collagenase activity, decrease proteinase inhibitors, excessive premature keratocyte apoptosis, increase cytokine binding). Fresh Corneal Lenticule and autologous serum contains live stem cells that produce keratocytes, collagen fibers, extracellular matrix which contribute to the regeneration of the cornea, and all this results at increasing of corneal transparency and visual acuity in patients with corneal macular dystrophy.
48688335|NCT04262882|BEHAVIORAL|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
48002794|NCT02605668|BEHAVIORAL|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
48002795|NCT02605668|BEHAVIORAL|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
48688336|NCT04262882|BEHAVIORAL|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
48688337|NCT00816491|DEVICE|conventional white light colonoscopy|conventional white light colonoscopy
48002796|NCT05705622|OTHER|Oral mukositis nurse's education for patients|Education given to patients by nurses on the prevention, treatment and care of oral mucositis
48513441|NCT03867097|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
48688338|NCT00816491|DEVICE|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
48688339|NCT00335283|DRUG|Lansoprazole Tablet|40 mg bid x 16 weeks
48688340|NCT00335283|PROCEDURE|PH and impedence testing|24 hour ph monitoring
48688341|NCT00335283|PROCEDURE|manometry|done prior to pH probe to measure length of esophagus
48688342|NCT00335283|DRUG|lansoprazole|40mg bid
48002797|NCT04984655|DEVICE|30-minute Virtual Reality (VR) Experience delivered through Oculus Quest 2 VR headset|All participants will go through the same intervention described above
48002798|NCT05161130|PROCEDURE|Lumbar Spinal Fusion|Lumbar Spinal Fusion with or without posterior stabilization
48002799|NCT04090554|DEVICE|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
48002800|NCT01407913|PROCEDURE|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
48002801|NCT03164798|PROCEDURE|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
48002802|NCT06216392|BIOLOGICAL|GR1802 injection|150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
48002803|NCT06216392|BIOLOGICAL|placebo|0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
48002804|NCT00228592|DRUG|HepeX-B|
48002805|NCT00228592|DRUG|Hepatitis B Immune Globulin (HBIg)|
48688343|NCT00335283|DRUG|placebo|one tablet bid
48688344|NCT02667041|DEVICE|NeuroQore rTMS Device|
48688345|NCT01144169|DRUG|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
48688346|NCT00600275|DRUG|BGT226|
48688347|NCT02479958|PROCEDURE|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
48688348|NCT02479958|PROCEDURE|Tooth drying|The tooth was dried with air jet.
48002806|NCT05372120|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression
48367580|NCT05304078|BEHAVIORAL|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
48688349|NCT02479958|PROCEDURE|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
48002807|NCT03437200|DRUG|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
48002808|NCT03437200|DRUG|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
48002809|NCT03437200|OTHER|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
48002810|NCT05318144|OTHER||
48002811|NCT04697979|OTHER|Questionnaire|"Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary."
48159945|NCT02867332|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
48159946|NCT02867332|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
48159947|NCT02867332|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
48688350|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
48729782|NCT01920737|DEVICE|CT/PET scans|PET or CT scan every 6 months for 3 years
48002812|NCT01194947|DEVICE|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
48002813|NCT00000537|BEHAVIORAL|meditation|
48159948|NCT01624012|DEVICE|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
48159949|NCT01624012|DEVICE|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
48002814|NCT00000537|BEHAVIORAL|relaxation|
48002815|NCT00397982|BIOLOGICAL|Bevacizumab|Given IV
48002816|NCT00397982|OTHER|Laboratory Biomarker Analysis|Correlative studies
48367581|NCT05304078|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
48002817|NCT00397982|DRUG|Temsirolimus|Given IV
48002818|NCT00397982|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
48002819|NCT02581384|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
48002820|NCT02131480|DRUG|Doxorubicin|60 mg/m²
48002821|NCT02131480|DRUG|Trabectedin|1,1 mg/m²
48367582|NCT01230073|DEVICE|Home-Monitoring|Home-Monitoring
48367583|NCT01230073|DEVICE|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
48367584|NCT06338527|OTHER|Aromatherapy|Lavender oil was used for aromatherapy intervention.
48159950|NCT04348383|DRUG|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
48688351|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
48688352|NCT03472820|OTHER|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
48002822|NCT03325686|DIETARY_SUPPLEMENT|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
48688353|NCT03472820|OTHER|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
48688354|NCT03472820|OTHER|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
48688355|NCT03472820|OTHER|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
48002823|NCT03325686|OTHER|Placebo|placebo
48159951|NCT04348383|DRUG|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
48159952|NCT06492057|DEVICE|Electromyostimulation (EMS)|EasymotionSkin body suit for digitally controlled electric impulses via Easymotion-2 software on crew iPad (frequency, impulse rate, duration) are transferred from integrated dry electrodes of the EMS- stimulation suit to activate surface muscle groups of the body (trunk), arms and legs
48159953|NCT06492057|DEVICE|Myoton|The non-invasive Myoton technology collects data from passive muscle properties (tone and stiffness) obtained from selected anatomical surface muscle groups
48002824|NCT05451771|DRUG|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
48002825|NCT05451771|DEVICE|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
48002826|NCT05451771|DRUG|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
48159954|NCT06492057|DIAGNOSTIC_TEST|Electromyography (EMG)|As a standard method, surface EMG collects data from nerve impulse-triggered active muscle contractions, pre/postflight only
48159955|NCT06492057|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI is a clinically standard (non-radiation) imaging method to study structural changes of the human body (organs, muscle, bones, tendons) at the macroscopic level, pre/postflight only
48159956|NCT06492057|DIAGNOSTIC_TEST|Dynamometry|Dynamometry is a standard functional and diagnostic method to test muscle strength in sports and rehabilitation. pre/postflight only
48159957|NCT00210288|BIOLOGICAL|SC599|
48159958|NCT02478762|PROCEDURE|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
48002827|NCT05451771|DRUG|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
48002828|NCT05451771|DRUG|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
48159959|NCT02478762|PROCEDURE|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
48159960|NCT00212290|DRUG|pioglitazone|
48159961|NCT00212290|DRUG|nateglinide|
48688356|NCT03472820|OTHER|PhytoGanix (tropical fruit flavor)|Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
48688357|NCT03472820|OTHER|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
48729783|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
48729784|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
48002829|NCT05451771|DRUG|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
48002830|NCT05451771|DRUG|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.
48159962|NCT00212290|DRUG|placebo|
48159963|NCT03911141|BEHAVIORAL|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
48159964|NCT03911141|BEHAVIORAL|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
48159965|NCT00307671|DRUG|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
48159966|NCT00307671|DRUG|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
48159967|NCT00307671|DRUG|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
48159968|NCT05743114|DEVICE|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
48159969|NCT01889771|DRUG|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
48159970|NCT05474378|DRUG|B7-H3CART|"B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12."
48159971|NCT02284802|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
48159972|NCT02269033|BEHAVIORAL|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
48159973|NCT02269033|BEHAVIORAL|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged \> 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
48159974|NCT05041842|DRUG|Tucatinib|300 mg orally twice daily
48159975|NCT05041842|DRUG|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
48159976|NCT05041842|DRUG|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
48159977|NCT05041842|DRUG|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
48002831|NCT05451771|DRUG|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
48159978|NCT05041842|DRUG|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
48159979|NCT00274846|BIOLOGICAL|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
48159980|NCT00274846|BIOLOGICAL|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10\^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10\^9
48367585|NCT06338527|OTHER|No intervention|No aromatherapy intervention was performed during the period of the study.
48367586|NCT01922869|DIETARY_SUPPLEMENT|Flavonoids|
48367587|NCT02185638|OTHER|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
48729785|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
48729786|NCT05407857|BEHAVIORAL|multi-modal non-pharmacological intervention|multi-modal non-pharmacological intervention including the management with nutrition, exercise and cognitive programs
48367588|NCT04766411|OTHER|Unresisted sprint training|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
48688358|NCT03949452|OTHER|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
48729787|NCT00525096|DRUG|placebo|2 tablets twice a day per os
48729788|NCT00525096|DRUG|Celecoxib|2\*200 mg tablets twice a day per os
48729789|NCT00525096|DRUG|Exemestane|Exemestane 25 mg per day per os
48002832|NCT05451771|DRUG|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
48002833|NCT05451771|DRUG|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
48002834|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class A
48002835|NCT00651027|DRUG|PF-868554|200 mg, Child-Pugh Class B
48002836|NCT00651027|DRUG|PF-868554|200 mg, healthy volunteers
48002837|NCT02196285|BIOLOGICAL|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
48002838|NCT00966238|BIOLOGICAL|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
48002839|NCT02767427|DEVICE|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
48002840|NCT02767427|OTHER|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
48002841|NCT05098353|DRUG|Quetiapine|25-75 mg per day for 6 weeks
48002842|NCT00768729|DRUG|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
48002843|NCT00768729|DRUG|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
48002844|NCT00265824|DRUG|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
48002845|NCT00265824|DRUG|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
48002846|NCT03951922|BEHAVIORAL|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
48002847|NCT01972672|DRUG|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
48002848|NCT02533271|RADIATION|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
48002849|NCT02533271|RADIATION|Long-term chemoradiotherapy|Standard chemoradiotherapy
48002850|NCT04087122|DEVICE|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
48002851|NCT02099214|DEVICE|3Tesla cardiac MRI|
48002852|NCT02099214|DEVICE|Electrocardiogram (EKG)|
48002853|NCT02099214|BIOLOGICAL|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
48002854|NCT02099214|BIOLOGICAL|Pregnancy test|Beta-hCG
48002855|NCT02099214|DEVICE|Echocardiography at rest|Transthoracic echocardiograph
48002856|NCT02099214|BIOLOGICAL|Urinary pregnancy test|
48002857|NCT02099214|DEVICE|3Tesla abdominal MRI|
48002858|NCT05225896|GENETIC|Description of clinical characteristic and genetic tumors|"This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
48002859|NCT00218348|DRUG|Dextro-Amphetamine Sulfate|
48002860|NCT00934739|DRUG|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
48002861|NCT00934739|DRUG|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
48002862|NCT02694419|DEVICE|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
48002863|NCT03998007|DEVICE|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
48002864|NCT01831232|DRUG|pravastatin sodium|Given PO
48002865|NCT01831232|DRUG|idarubicin|Given IV
48002866|NCT01831232|DRUG|cytarabine|Given IV
48002867|NCT01831232|OTHER|laboratory biomarker analysis|Correlative studies
48159981|NCT00274846|DRUG|cyclophosphamide|Days -5 and -4: 60 mg/kg
48159982|NCT00274846|DRUG|fludarabine phosphate|Days -5 through -2: 25 mg/m\^2
48159983|NCT00274846|PROCEDURE|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
48002868|NCT04628312|OTHER|Static footprint|The static footprint will measure the plantar pressures and surface area of the back of the foot, midfoot and forefoot. Subjects were instructed to stand barefoot on the force platform, participants were instructed to remain in a relaxed standing posture with feet shoulder-width apart and positioned 30 degrees from the midline.
48688359|NCT03949452|OTHER|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
48688360|NCT04594135|DRUG|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
48367589|NCT04766411|OTHER|Resisted sprint training with load equal to 10% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
48688361|NCT04894838|PROCEDURE|Distal gastric bypass|Distal gastric bypass, revisonal surgery after failed RYGB
48688362|NCT02085044|DIETARY_SUPPLEMENT|Ready-to-Used Supplement Food administration|
48688363|NCT00861757|DRUG|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
48688364|NCT00861757|DRUG|Placebo|PO, QD (30 min after meal) for 12 weeks
48688365|NCT00861757|DRUG|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
48002869|NCT02310919|DRUG|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
48002870|NCT02310919|DRUG|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
48002871|NCT01020058|PROCEDURE|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
48002872|NCT01125111|PROCEDURE|surgery(robot versus laparoscopy)|
48002873|NCT02665416|DRUG|Selicrelumab|Selicrelumab will be provided as concentrate for solution to be administered via SC injection
48002874|NCT02665416|DRUG|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
48002875|NCT02665416|DRUG|Bevacizumab|Bevacizumab will be administered via IV infusion.
48002876|NCT02663635|DEVICE|Safe'N'Sound|
48002877|NCT03365206|OTHER|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
48002878|NCT04672005|DRUG|Folfirinox alternating with Gemcitabine-nab-Paclitaxel|modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
48002879|NCT00969553|DRUG|BI 6727|Dose level 1
48002880|NCT00138983|DRUG|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
48002881|NCT03802448|COMBINATION_PRODUCT|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
48002882|NCT03802448|DEVICE|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
48002883|NCT05992506|DIAGNOSTIC_TEST|POD risk estimation using PEUMA|A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
48002884|NCT00774631|PROCEDURE|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 \[6, 48\]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
48002885|NCT00774631|PROCEDURE|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
48002886|NCT01433432|DRUG|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
48002887|NCT05126927|BIOLOGICAL|68Ga-NODAGA-SNA006|A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors
48002888|NCT00344383|DRUG|Norgestimate/Ethinyl Estradiol tablet|
48688366|NCT00399217|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) system|
48688367|NCT00399217|DEVICE|ICD|
48688368|NCT00720356|DRUG|bevacizumab|10mg/kg administered intravenously every 2 weeks
48688369|NCT00720356|DRUG|erlotinib hydrochloride|150 mg/daily orally
48688370|NCT03813758|DIAGNOSTIC_TEST|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
48688371|NCT06268184|DIETARY_SUPPLEMENT|D3 LAB SYRUP|omega 3 suplementation
48688372|NCT06268184|DIETARY_SUPPLEMENT|placebo syrup|placebo syrup contains purified water, glycerin, xanthan gum, tween 80, methyl paraben, propyl paraben, sorbitol solution70% and apple flavor.
48729790|NCT01710098|DRUG|Degarelix|subcutaneous injection
48729791|NCT04855656|DRUG|RP-6306|Oral PKMYT1 Inhibitor
48729792|NCT04855656|DRUG|RP-3500|Oral ATR Inhibitor
48729793|NCT04855656|DRUG|Debio0123|Oral WEE1 Inhibitor
48688373|NCT03641781|OTHER|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
48688374|NCT03072394|DRUG|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
48688375|NCT03072394|DRUG|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
48002889|NCT02703636|DRUG|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
48367590|NCT04766411|OTHER|Resisted sprint training with load equal to 20% of body weight|"Particiapants will perform:~2 sets of 3 x 20m sprint~1 set of 3 x 30m sprint"
48367591|NCT04766411|OTHER|Control trial|Participants will not perform any sprint training protocol
48367592|NCT06329245|OTHER|Do not take any interventions|Do not take any interventions
48002890|NCT04487327|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into 2-4 muscles of the participant either at the MTrP or 2 cm away from the MTrP, but within the same muscle. To assist in the reduction of infection risk and protection of the participants, the site will be cleaned with alcohol prior to treatment and investigators performing the needling treatment will wear gloves and handle needles using aseptic technique throughout the procedure. Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
48513442|NCT06363903|DIAGNOSTIC_TEST|mesh allergy test|a 5 mm\^2 part of polypropylene mesh will be dissolved in 1 mL Methyl ethyl ketone (MEK), 25 microliters of this solution will be topically applied in a Finn chamber, and a reaction to the topical applicant will be assessed within 48 hours after application.
48513443|NCT06363903|DIAGNOSTIC_TEST|blood tests|Blood tests for diagnosis of autoimmune diseases will be performed
48688376|NCT03447405|DEVICE|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
48688377|NCT00090961|OTHER|educational intervention|
48688378|NCT00090961|OTHER|supervised exercise program|
48002891|NCT03119415|BEHAVIORAL|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
48002892|NCT04845607|DRUG|Amiodarone Injection|Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
48002893|NCT04150224|DRUG|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
48002894|NCT04150224|DRUG|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
48002895|NCT04150224|DRUG|PBTZ169 960 mg SD|Once a day fasted
48688379|NCT06464731|PROCEDURE|EVT|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
48688380|NCT04169984|OTHER|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
48002896|NCT04150224|DRUG|PBTZ169 1280 mg SD|Once a day fasted
48002897|NCT04150224|DRUG|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
48002898|NCT05550051|PROCEDURE|Awake nasal fiberoptic intubation|Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
48002899|NCT00581074|BEHAVIORAL|diet (grapefruit or grapefruit juice)|weight loss diet
48002900|NCT04842539|OTHER|Fecal Microbiota Transplantation|In the Fecal Microbiota Transplantation procedure 100 ml volume of strained and filtered stool will be delivered through a nasojejunal tube.The recipient patient will be kept nil per oral for at least 4 hours prior to the stool instillation. 100 mL of freshly prepared stool suspension will be given.
48513444|NCT06363903|PROCEDURE|Mesh removal|If wish for mesh removal persists, this procedure can be performed after separate informed consent (within the study), as standard practice of care.
48002901|NCT04842539|OTHER|Standard of care|Nutritional supplementation and other supportive measures as per standard guidelines
48002902|NCT01847391|DRUG|GS-6615|GS-6615 tablet(s) administered orally once daily
48688381|NCT04169984|OTHER|Placebo|Exercises that do not alter the function or morphology of the upper airway.
48688382|NCT01018173|DRUG|placebo|sc weekly
48688383|NCT01018173|DRUG|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
48688384|NCT03451513|BEHAVIORAL|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
48688385|NCT03451513|BEHAVIORAL|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
48688386|NCT01897727|DRUG|Spironolactone|
48159984|NCT00411463|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
48159985|NCT00411463|DRUG|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
48688387|NCT01897727|DRUG|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
48688388|NCT04979026|DEVICE|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
48159986|NCT05965726|DRUG|Paxlovid 25 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 30 days
48159987|NCT05965726|DRUG|Paxlovid 15 day dosing|nirmatrelvir 300mg and ritonavir 100mg taken bid for 15 days then ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 15 days
48688389|NCT04979026|DEVICE|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
48688390|NCT00485563|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
48688391|NCT00485563|BIOLOGICAL|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
48688392|NCT00485563|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
48688393|NCT00485563|DRUG|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
48159988|NCT05965726|DRUG|Control|ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid for 30 days
48159989|NCT04388917|PROCEDURE|Patial nephrectomy|Partial nephrectomy assisted with robot to remove kidney cancer
48513445|NCT01285297|BIOLOGICAL|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
48522595|NCT03119870|OTHER|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
48002903|NCT01847391|DRUG|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
48002904|NCT04741165|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
48688394|NCT00485563|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
48002905|NCT04741165|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
48002906|NCT04741165|DRUG|Lenvatinib|Administered orally once a day during each 21-day cycle
48159990|NCT01136733|DRUG|Lenvatinib|taken orally, once a day
48159991|NCT01136733|DRUG|Everolimus|taken orally, once a day
48159992|NCT06559098|DEVICE|Vibrotactile coordinated reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
48159993|NCT03347773|DIETARY_SUPPLEMENT|ReGen 18%|ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
48159994|NCT00205205|BEHAVIORAL|peer mentoring|
48159995|NCT02523443|OTHER|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
48159996|NCT02523443|OTHER|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
48159997|NCT04523571|BIOLOGICAL|BNT162b1|Intramuscular injection
48159998|NCT04523571|OTHER|Placebo|Intramuscular injection
48159999|NCT06646978|DRUG|Imatinib (STI571)|Imatinib-based regimen
48160000|NCT03071874|DRUG|AZD2014|AZD2014 is a dual mTORC1/mTORC2 inhibitor
48160001|NCT05055999|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
48160002|NCT00728832|DRUG|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
48160003|NCT00002388|DRUG|Abacavir sulfate|
48160004|NCT05746676|DRUG|Insulin|in treatment of periodontal defects
48160005|NCT05746676|DRUG|Hyaluronic acid|in treatment of periodontal defects
48002907|NCT03729531|PROCEDURE|Conventional vein harvesting technique|Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
48002908|NCT03729531|PROCEDURE|no-touch vein harvesting technique|The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
48002909|NCT01567969|BEHAVIORAL|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
48002910|NCT01567969|BEHAVIORAL|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
48002911|NCT02350309|DRUG|Lemborexant 5 mg|Lemborexant 5 mg tablet.
48002912|NCT02350309|DRUG|Lemborexant 10 mg|Lemborexant 10 mg tablet.
48002913|NCT02350309|DRUG|Lemborexant-matched placebo.|Lemborexant-matched placebo tablet.
48002914|NCT02350309|DRUG|Flurazepam 30 mg|Flurazepam 30 mg capsule.
48002915|NCT01955070|OTHER|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
48160006|NCT06247878|DEVICE|Skiin underwear chest band|Participants will be asked to wear a skiin underwear chest band during a polysomnography test.
48160007|NCT03291899|COMBINATION_PRODUCT|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
48160008|NCT00141336|DRUG|Pregabalin|
48688395|NCT00810771|BEHAVIORAL|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
48688396|NCT00810771|BEHAVIORAL|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
48688397|NCT02886507|DIETARY_SUPPLEMENT|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
48688398|NCT02886507|DIETARY_SUPPLEMENT|Placebo|The placebo capsules contain microcrystalline cellulose.
48002916|NCT06159972|DEVICE|EndoFLIP|EndoFLIP is a small balloon catheter that is inserted through the endoscope at the time of endoscopy.
48160009|NCT05618054|BEHAVIORAL|Looming task|Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
48160010|NCT05845099|DEVICE|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patients will receive Complete Removable Dentures processed by Heat cured acrylic resin.
48160011|NCT05845099|DEVICE|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patients will receive a 3D-printed removable denture digitally manufactured using a 3d printer device with light polymerized resin.
48160012|NCT02375243|DRUG|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
48160013|NCT03494907|DRUG|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
48160014|NCT03494907|OTHER|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
48160015|NCT03494907|OTHER|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
48160016|NCT03494907|DRUG|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
48160017|NCT02535598|BEHAVIORAL|Normal presentation|All the material will be presented as plain text.
48367593|NCT03582254|RADIATION|[18F]-FDG PET/MR|"\[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~* prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~* after two chemotherapy cycles (PET#2),~* at the end of the first-line chemotherapy regimens (PET#3)."
48688399|NCT04810364|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
48688400|NCT01116466|DEVICE|ActiGait|ActiGait - implantable drop foot stimulator
48688401|NCT03748706|DRUG|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
48002917|NCT01550419|DRUG|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
48688402|NCT03698578|OTHER|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
48688403|NCT03993444|BEHAVIORAL|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
48688404|NCT03993444|BEHAVIORAL|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
48688405|NCT01063608|BIOLOGICAL|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
48688406|NCT04325295|PROCEDURE|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached \> 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
48688407|NCT04325295|DRUG|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
48688408|NCT00003923|DRUG|porfimer sodium|
48688409|NCT02701244|RADIATION|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
48688410|NCT05114707|DRUG|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
48002918|NCT01550419|DRUG|Placebo|The smell and shape of placebo are the same as atorvastatin
48160018|NCT02535598|BEHAVIORAL|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
48367594|NCT00660829|DRUG|Placebo|Placebo
48688411|NCT05806554|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
48002919|NCT04209179|DRUG|PCO371|PCO371 capsule
48002920|NCT04209179|DRUG|Placebo|Placebo capsule
48367595|NCT00660829|DRUG|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
48522596|NCT03119870|OTHER|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
48522597|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
48688412|NCT04099355|DRUG|Dronabinol 5mg Cap|1 QAM and 2 QHS PO 14 days
48688413|NCT04099355|DRUG|Non-active comparator|1 QAM and 2 QHS PO 14 days
48002921|NCT05861791|DRUG|Fentanyl|opioid group receives only fentanyl citrate 1200mcg for continuous infusion drug
48688414|NCT00148993|BIOLOGICAL|Tumor Cell Vaccine|
48002922|NCT05861791|DRUG|ketorolac tromethamine with nefopam hydrochloride|non-opioid group receives ketorolac tromethamine 150mg with nefopam hydrochloride 100mg for continuous infusion drug
48002923|NCT00012558|DRUG|lithium|
48002924|NCT00012558|DRUG|valproate|
48002925|NCT00012558|DRUG|bupropion|
48002926|NCT00012558|DRUG|paroxetine|
48002927|NCT00012558|DRUG|lamotrigine|
48002928|NCT00012558|DRUG|risperidone|
48002929|NCT00012558|DRUG|inositol|
48688415|NCT01667133|DRUG|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
48688416|NCT01667133|DRUG|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
48688417|NCT04479059|OTHER|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
48688418|NCT02492191|DEVICE|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
48002930|NCT00012558|DRUG|tranylcypromine|
48002931|NCT00012558|BEHAVIORAL|Cognitive Behavioral Therapy|
48002932|NCT00012558|BEHAVIORAL|Family-focused Therapy|
48002933|NCT00012558|BEHAVIORAL|Interpersonal and Social Rhythms Therapy|
48160019|NCT02535598|BEHAVIORAL|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
48160020|NCT02535598|BEHAVIORAL|Enhanced support|Participants are offered daily support through the internet from trained therapists.
48160021|NCT02042625|PROCEDURE|Nasopharyngeal|
48522598|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
48688419|NCT02963363|OTHER|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
48688420|NCT05363501|DRUG|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
48688421|NCT05363501|DRUG|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
48160022|NCT05400226|DRUG|VGT-309|VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
48160023|NCT02586961|DRUG|0.9% saline solution|"Placebo:~Nebulized 0.9% saline solution"
48160024|NCT02586961|DRUG|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
48160025|NCT02586961|DRUG|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
48688422|NCT05363501|DRUG|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
48688423|NCT05363501|DRUG|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
48688424|NCT05363501|DRUG|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
48688425|NCT05363501|DRUG|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
48002934|NCT01041625|DRUG|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
48002935|NCT01112384|DRUG|SB939|Given orally 3 times per week
48002936|NCT06175143|BIOLOGICAL|GR2002 injection|TSLP monoclonal antibody
48002937|NCT04372602|DRUG|Duvelisib|-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.
48160026|NCT02586961|DRUG|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
48160027|NCT06611657|DRUG|Antirotinib hydrochloride|Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
48002938|NCT04372602|PROCEDURE|Peripheral blood draw|"* First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"
48002939|NCT04372602|DRUG|Placebo|-Provided by Verastem
48002940|NCT00367068|DRUG|baclofen, intrathecal|
48002941|NCT00367068|DEVICE|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
48002942|NCT01371097|OTHER|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
48160028|NCT06275087|DRUG|Propofol|The experimental group will not receive volatile anesthetic, instead, they will receive propofol infusion
48160029|NCT06275087|DRUG|Sevoflurane|The control group will not receive TIVA, instead, they will receive sevoflurane via inhalation
48160030|NCT00254722|DRUG|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury
48160031|NCT04812925|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
48522599|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
48522600|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
48688426|NCT05944068|BEHAVIORAL|midfulness training|For this study we chose for a mindfulness based intervention. Mindfulness is defined as the ability to notice and observe details about one's present internal and external environment with the goal of non-judgemental and non-elaborative awareness of cognitions, emotions and physical sensations. The goal of the mindfulness intervention will be to teach patients a way of coping with negative emotions without acting on them, letting patients take control of their disease related behaviour and come to better disease acceptance. Where medical treatments fail to take away all disabling symptoms, psychological interventions like mindfulness could offer patients a coping method through which symptoms are experienced as less disabling and patients regain their quality of life. This research may further strengthen the need for a multidisciplinary approach in patients with Crohn's disease.
48688427|NCT05425498|OTHER|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
48688428|NCT00796731|DRUG|SAR3419|administered by intravenous infusion
48522601|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
48688429|NCT01808638|DRUG|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
48688430|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
48688431|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
48002943|NCT05180903|OTHER|X-tra base & GrandioSO reinforced by Ribbond|The missing peripheral tooth structure will be built up via 2-mm wedge-shaped a universal hybrid resin composite, GrandioSO . Then the polyethylene fibers will be wetted with an unfilled resin first . After removing the excess resin, fibers will be covered with a very thin layer of flowable composite X-tra base . After that, fibers will be bonded immediately against the peripheral missing walls and cured for 20 seconds. Then a bulk-fill flowable resin composite lining X-tra base will be applied in approximately 4 mm thick in bulk increments as needed to fill the cavity 2 mm short of the occlusal cavosurface and each increment will be light cured for 20 s. The remaining occlusal part of the cavity will be restored with a universal hybrid resin composite, GrandioSO . The shade of the composite will be selected according to the teeth to be restored. All cavities will be restored with open-sandwich technique (Deliperi, et al. 2017).
48002944|NCT00423969|DRUG|Galantamine|
48002945|NCT00423969|DRUG|Escitalopram|
48002946|NCT03762655|DEVICE|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
48002947|NCT03634553|OTHER|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
48002948|NCT03634553|OTHER|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
48002949|NCT02829593|OTHER|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
48002950|NCT01664013|DRUG|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
48002951|NCT02142166|PROCEDURE|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
48002952|NCT02142166|PROCEDURE|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
48002953|NCT01666756|DIETARY_SUPPLEMENT|Chinese herbal formulation PHY906|Given PO
48002954|NCT01666756|DRUG|sorafenib tosylate|Given PO
48002955|NCT01666756|OTHER|laboratory biomarker analysis|Correlative studies
48002956|NCT01666756|OTHER|pharmacological study|Correlative studies
48002957|NCT00402675|PROCEDURE|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
48002958|NCT05920434|OTHER|randomized controlled study|randomized controlled study,no drugs or devices were administered to the participants.
48002959|NCT05595408|DRUG|Adjuvant chemotherapy|cisplatin/carboplatin-gemcitabine 4-6 cycles
48002960|NCT05595408|DRUG|adjuvant immunotherapy|immunotherapy for one year
48002961|NCT01268384|DRUG|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
48002962|NCT04977323|OTHER|TICK-B group|These interventions will use as distraction techniques.
48002963|NCT00924872|OTHER|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
48002964|NCT04750031|PROCEDURE|Liver Biopsy|Liver biopsy is a procedure to obtain small amount of liver by a needle.
48688432|NCT06095934|OTHER|neo-antigen vaccine|anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
48688433|NCT04211792|DEVICE|Icare Tonometer|Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
48688434|NCT00463138|BEHAVIORAL|Crisis intervention|
48688435|NCT02672189|BEHAVIORAL|EVA-Online|Internet-based cognitive behavioral therapy
48002965|NCT02800330|DRUG|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
48002966|NCT02800330|DRUG|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
48002967|NCT02800330|DRUG|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
48002968|NCT03999411|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
48002969|NCT03999411|BEHAVIORAL|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
48002970|NCT03999411|BEHAVIORAL|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
48002971|NCT03999411|BEHAVIORAL|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
48160032|NCT03684278|DRUG|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
48367596|NCT04369443|PROCEDURE|Large volume Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
48367597|NCT02984228|BIOLOGICAL|PRP|
48002972|NCT03999411|BEHAVIORAL|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
48002973|NCT04175093|DIAGNOSTIC_TEST|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
48002974|NCT01858012|BEHAVIORAL|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
48002975|NCT01879228|DRUG|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
48002976|NCT01879228|DRUG|Placebo|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
48002977|NCT06496802|OTHER|no intervention|no intervention
48002978|NCT03767218|COMBINATION_PRODUCT|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.
48002979|NCT03767218|COMBINATION_PRODUCT|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
48002980|NCT04568252|DEVICE|Wristband with millimeter wave emission.|Wristband treatment with millimeter wave emission twice a day for 3 months.
48002981|NCT04568252|DEVICE|Placebo of wristband with millimeter wave emission.|Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
48002982|NCT05832671|PROCEDURE|Erector Spinae muscle block|In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction
48002983|NCT05832671|PROCEDURE|caudal block|In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
48002984|NCT00461695|BIOLOGICAL|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
48002985|NCT01654965|OTHER|Laboratory Biomarker Analysis|Correlative studies
48002986|NCT01654965|BIOLOGICAL|Pegfilgrastim|Given SC
48002987|NCT01654965|OTHER|Pharmacological Study|Correlative studies
48002988|NCT01654965|DRUG|Tivantinib|Given PO
48002989|NCT01654965|DRUG|Topotecan Hydrochloride|Given IV
48002990|NCT03633981|OTHER|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~* right and left pupillometry (3 times)~* BIS values~* right and left NIRS values~* right and left transcranial Doppler~* neurological clinical examination"
48002991|NCT03633981|OTHER|neurological assessment when a neurological event occurs|"next neurological event:~* seizures~* pupillary asymmetry~* myoclonias~* brain stem reflex abnormalities~* osteotendinous reflex abnormalities"
48002992|NCT03633981|OTHER|mortality assessment|to 28 days
48002993|NCT01120431|OTHER|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
48160033|NCT03684278|DRUG|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
48160034|NCT03684278|OTHER|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
48160035|NCT04303598|DRUG|FNC|3mg, 1 tablet，QD
48367598|NCT02984228|DRUG|Hyaluronic Acid|
48367599|NCT02984228|DEVICE|Ultrasound|
48367600|NCT01866891|OTHER|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
48688436|NCT00588237|DRUG|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
48688437|NCT04075747|DRUG|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
48002994|NCT01120431|DRUG|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
48002995|NCT03034993|BEHAVIORAL|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
48002996|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
48002997|NCT01364428|DRUG|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
48002998|NCT05525845|OTHER|Functional Magnetic Resonance Imaging (pCASL-MRI)|MRI's will be performed at multiple points on each visit day.
48002999|NCT05525845|OTHER|Intragastric Balloon|Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.
48003000|NCT05525845|OTHER|Elemental Meal|Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.
48003001|NCT05525845|OTHER|Hedonic Meal|Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI
48003002|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
48003003|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
48003004|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
48003005|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
48003006|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
48003007|NCT00984854|DRUG|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
48003008|NCT00984854|DRUG|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
48003009|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
48003010|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
48003011|NCT05180435|BEHAVIORAL|Family Meals|A family-based multicomponent lifestyle modification intervention with the goal to increase the frequency of family meals and meet physical activity recommendations.
48003012|NCT05180435|BEHAVIORAL|Standard|A family-based multicomponent lifestyle modification intervention with the goal to increase the consumption of fruits and vegetables and and meet physical activity recommendations.
48160036|NCT04303598|DRUG|3TC|300mg, 1 tablet，QD
48160037|NCT04303598|DRUG|TDF|300mg, 1 tablet，QD
48688438|NCT04075747|DRUG|Venetoclax|Will be administered over specified duration during induction and consolidation courses
48688439|NCT04075747|DRUG|Midostaurin|Will be administered over specified duration during induction and consolidation courses
48160038|NCT04303598|DRUG|EFV|200mg, 1 tablet，QD
48688440|NCT04075747|DRUG|Enasidenib|Will be administered over specified duration during induction and consolidation courses
48688441|NCT00191568|DRUG|Gemcitabine|
48688442|NCT00191568|DRUG|Oxaliplatin|
48688443|NCT00191568|PROCEDURE|Radiotherapy|
48160039|NCT04303598|DRUG|FNC placebo|1 tablet，QD
48160040|NCT04303598|DRUG|3TC placebo|1 tablet，QD
48160041|NCT05493605|PROCEDURE|Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope|The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
48160042|NCT02498418|DRUG|Rifaximin|Tablets, generic formulation of the brand product.
48160043|NCT02498418|DRUG|Xifaxan®|Tablets, brand product.
48367601|NCT04527458|OTHER|Patient Characteristics|Characteristics of the patients
48367602|NCT04527458|OTHER|COVID-19 treatments|Specific treatments used on COVID-19 patients
48367603|NCT04527458|OTHER|Differences in triage|Triage criteria for treating COVID-19 patients
48367604|NCT04527458|OTHER|Surge capacity|Capacity of hospitals
48688444|NCT01769664|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
48688445|NCT01769664|DRUG|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
48688446|NCT01769664|DRUG|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
48688447|NCT05607173|DRUG|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
48003013|NCT06305533|DEVICE|LASER disinfection|In test group 1, the diode Laser will be used to disinfect the inner layer of the pockets and thus reducing the microbial load. Diode laser (Biolase, EpicX, BIOLASE, Inc, USA) settings will be as follows: wavelength: 940nm; power: 1W; 300μm uninitiated fibers; continuous radiation mode; and energy level: 80 J/s. The laser fibers then will be inserted into the pockets in such a way that they will be in contact with the soft tissue wall of the pockets and parallel to the root surface and then will be moved to the apical surface through a horizontal sweeping motion (1mm/s) while remaining in contact with the soft tissue wall of the pockets.
48003014|NCT06305533|DEVICE|Photodynamic therapy|the second test group will receive additional adjunctive aPDT using a ICG photosensitizer activated with diode laser. In details, pockets will be irrigated by a syringe loaded with an ICG photosensitizer solution (Verdye, Diagnostic green, Germany) at a concentration of 5mg/ml. The ICG solution will be allowed to stay in the pockets for 2min, and washing out excess solution from the pockets before laser irradiation. Afterwards, a 300μm bulb optical fibre of the 810nm diode laser unit (QuickLase, United Kingdom) set at 300mw in pulsed mode (100ms ON/100ms OFF) will be inserted along the pocket and activated for 30s with continuous vertical movements from the bottom of the pocket to the gingival margin
48003015|NCT06305533|PROCEDURE|Root surface debridement|For all groups, sites with initial PPD 4-6 mm will be treated with RSD using area specific (Graecy) curettes.
48003016|NCT06127082|DEVICE|Echocardiography|Do echocardiography to obese patient
48003017|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
48003018|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
48003019|NCT02838264|DRUG|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
48003020|NCT02838264|DRUG|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
48003021|NCT02838264|DRUG|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
48003022|NCT00389116|DRUG|gastrograffin|ingestion
48003023|NCT00389116|DRUG|water|oral water ingestion
48003024|NCT03377777|OTHER|No intervention|
48003025|NCT05894642|BEHAVIORAL|0|It is a case-control study, cross-sectional, so there is no intervention possible.
48003026|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:200,000|
48003027|NCT02696369|DRUG|2% lidocaine HCl with epinephrine 1:80,000|
48003028|NCT05626946|OTHER|Observation|Observation
48003029|NCT02212821|DRUG|Erythromycin|
48003030|NCT02212821|DRUG|Placebo|physiological saline
48003031|NCT02635191|DRUG|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
48003032|NCT02635191|DRUG|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
48003033|NCT04249258|DRUG|Dobutamine|Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.
48003034|NCT01449526|DEVICE|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
48003035|NCT01449526|DEVICE|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
48003036|NCT01876069|DEVICE|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
48003037|NCT01876069|DEVICE|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
48003038|NCT03002168|DIETARY_SUPPLEMENT|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
48003039|NCT03002168|DIETARY_SUPPLEMENT|Placebo|Placebo tablets identical in appearance to the active comparator
48003040|NCT03002168|RADIATION|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
48688448|NCT03403530|DRUG|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
48688449|NCT00574392|DEVICE|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
48003041|NCT03002168|RADIATION|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
48003042|NCT05799092|DIAGNOSTIC_TEST|Invasive coronary angiography|As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
48367605|NCT03420846|OTHER|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
48367606|NCT04511533|DRUG|Dacomitinib|Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
48160044|NCT02498418|DRUG|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
48160045|NCT03334799|DEVICE|sacroiliac belt|standing and walking with the belt on and with the belt off
48160046|NCT04905511|BIOLOGICAL|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
48160047|NCT04934124|DRUG|ITI-333|ITI-333 oral solution
48160048|NCT04934124|OTHER|Placebo|Matching placebo
48160049|NCT03126721|DRUG|midazolam|a single oral dose of 2 mg midazolam
48160050|NCT03126721|DRUG|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
48160051|NCT00747149|DRUG|Rosuvastatin|Oral
48160052|NCT02684942|DRUG|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
48160053|NCT02684942|DRUG|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
48160054|NCT00495612|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
48160055|NCT00495612|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
48367607|NCT01012765|DRUG|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
48003043|NCT05799092|DIAGNOSTIC_TEST|Non-invasive functional test|Standard non-invasive functional testing will be performed.
48003044|NCT01515800|BEHAVIORAL|Text message reminder|Receive text message
48003045|NCT04093778|OTHER|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
48003046|NCT02338752|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
48003047|NCT02338752|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
48003048|NCT02084628|DRUG|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
48160056|NCT01073774|BEHAVIORAL|Side by side|
48160057|NCT01073774|BEHAVIORAL|couples control condition|
48160058|NCT03927742|BEHAVIORAL|Shade + app with messaging|Shade wearable device and application with UV messaging activated
48160059|NCT03927742|BEHAVIORAL|Shape + app without messaging|Shade wearable device and application without UV messaging activated
48160060|NCT06003478|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
48160061|NCT06113822|DEVICE|ultrasonography|We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
48160062|NCT04925245|OTHER|Clinical Reminder|Clinical reminder in the electronic medical record
48160063|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
48367608|NCT01012765|DRUG|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
48367609|NCT01012765|DRUG|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
48367610|NCT01379911|OTHER|Yogurt|
48367611|NCT02357108|OTHER|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
48367612|NCT02357108|BEHAVIORAL|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
48160064|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
48160065|NCT02572999|PROCEDURE|Not applicable (observational design)|
48160066|NCT03302559|OTHER|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
48160067|NCT03302559|OTHER|Facial cleanser|Facial cleanser in the morning and in the evening.
48160068|NCT03302559|OTHER|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
48160069|NCT03302559|OTHER|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
48160070|NCT03302559|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
48160071|NCT03395873|DRUG|Avelumab|"* Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days"
48160072|NCT01350388|DRUG|Febuxostat|80 mg/day of febuxostat for 24 weeks
48160073|NCT01350388|DRUG|Placebo|1 placebo tablet per day for 24 weeks
48160074|NCT04427397|OTHER|Sulcular Bristle Tip Technique (SBTT)|Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
48367613|NCT04271189|DRUG|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
48367614|NCT04271189|DRUG|Standard of care|Usual medical care to treat diabetes.
48688450|NCT04033614|DEVICE|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
48688451|NCT04311268|DEVICE|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
48688452|NCT06547333|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
48003049|NCT01277354|BEHAVIORAL|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
48003050|NCT01277354|BEHAVIORAL|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
48003051|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to modifined points group|Point 1 place 10mm higher than the boundary between Femur's medial epicondyle and shaft. The 2nd point is targeted 20mm above the patella. Point 3 is targeted 10mm above the femur lateral epicondyle and shaft boundary. At point 4, find the boundary position between the tibia epicondyle and the shaft in the AP view and move it superolateral by 10 mm to target the central part of the medial shaft of the tibia and perform the main touch. Point 5 targets the center of the fibular head.
48003052|NCT05202847|PROCEDURE|pulsed radiofrequency ablation to conventional points group|Under AP view X-ray fluoroscopy, enter the cannula into the tunnel view until reaching the bone, reaching the border of the shaft and epicondyle, then stop the cannula tip at the anterior 2/3 junction in the lateral view. A total of three target points are the boundary position between the femur medial epicondyle and the shaft, the boundary position between the femur lateral epicondyle and the shaft, and the boundary position between the tibia meidal epiconcyle and the shaft. Subsequent procedure will be proceed same as Arm 1
48003053|NCT02340533|PROCEDURE|hysteroscopic endo-myometrial biopsy|
48003054|NCT02340533|DEVICE|ultrasound|two dimensional trans-vaginal ultrasonography
48003055|NCT01959620|BEHAVIORAL|1-Session Exposure Therapy|One exposure therapy session lasting one hour
48003056|NCT01959620|BEHAVIORAL|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
48160075|NCT00185783|DRUG|Hydrocortisone Administration (Standard of Care Therapy)|
48160076|NCT02686983|DRUG|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
48160077|NCT05549479|BEHAVIORAL|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
48367615|NCT05587621|DRUG|statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran|dietary advice for low cholesterol food
48367616|NCT03971773|OTHER|hypnosis|patient with cancer will undergo sessions of hypnosis
48367617|NCT01090167|DRUG|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
48367618|NCT02285699|DRUG|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
48367619|NCT01979692|PROCEDURE|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
48688453|NCT06547333|DRUG|Placebo|Placebo
48729794|NCT05374629|BEHAVIORAL|Use different methods of teaching|Both groups will receive a smoking cessation education guideline and post-test three months after the intervention.
48160078|NCT05549479|BEHAVIORAL|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
48160079|NCT01870999|DRUG|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
48160080|NCT01870999|DRUG|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
48160081|NCT01792206|DRUG|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
48160082|NCT01792206|DRUG|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
48160083|NCT05631379|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
48160084|NCT05631379|DIAGNOSTIC_TEST|GLIM malnutrition criteria|GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition
48160085|NCT05631379|DIAGNOSTIC_TEST|EWGSOP2 sarcopenia criteria|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia
48367620|NCT01979692|DEVICE|CT guided trans thoracic needle biopsy|
48003057|NCT03341988|DRUG|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
48003058|NCT05923203|OTHER|Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)|This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
48003059|NCT06259331|DRUG|SPN-812 (600mg, QD)|Viloxazine ER
48003060|NCT04350151|BEHAVIORAL|no intervention|no intervention
48003061|NCT02029651|DEVICE|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
48003062|NCT02029651|PROCEDURE|Conventional occupational therapy|conventional occupational therapy
48003063|NCT02592746|DRUG|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
48003064|NCT02592746|DRUG|Exemestane|Exemestane 25mg, orally once daily
48003065|NCT02592746|DRUG|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
48003066|NCT02592746|DRUG|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
48003067|NCT03062475|BEHAVIORAL|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
48003068|NCT02456610|BIOLOGICAL|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
48003069|NCT00291122|DRUG|celecoxib 400 mg BID|
48003070|NCT04371380|DRUG|Cabotegravir Tablets|Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.
48003071|NCT04371380|DRUG|Rilpivirine Tablets|Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
48003072|NCT04371380|DRUG|Cabotegravir extended release suspension for injection (long-acting)|Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.
48003073|NCT04371380|DRUG|Rilpivirine extended release suspension for injection (long-acting)|Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
48003074|NCT06058195|PROCEDURE|Quadratus lumborum plane block|QLB (quadratus lumborum plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
48160086|NCT05631379|DIAGNOSTIC_TEST|ESPEN-EASO criteria for sarcopenic obesity|The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity
48160087|NCT05631379|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
48160088|NCT05631379|DIAGNOSTIC_TEST|The high-sensitivity modified Glasgow prognostic score|The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
48160089|NCT00354809|DRUG|GW679769|
48367621|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
48367622|NCT01111331|DRUG|Warfarin 25 mg|25 mg Warfarin single dose
48367623|NCT01111331|DRUG|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
48367624|NCT01111331|DRUG|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
48688454|NCT05366088|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
48729795|NCT06583551|DRUG|Botulinum toxin|Botulinum toxin, produced by Clostridium botulinum, is a neurotoxin. Presently, there are 7 serotypes (A, B, C1, D, E, F, G). Botulinum neurotoxin A (BoNT-A) is the most frequently used variant in clinical applications.
48003075|NCT06058195|PROCEDURE|Transverse abdominis plane block|TAPB (transverse abdominis plane block): 20 ml of 0.25% bupivacaine will be used each time for plane block on both sides. Patients will be sedated with 1 mg midazolam and 50 mcg fentanyl intravenously in the preoperative preparation room in the operating room and 20 ml of 0.25% bupivacaine was administered bilaterally on each side under ultrasound guidance. After the block application, the patient was taken to the operating room and standard general anaesthesia was applied.
48003076|NCT06058195|PROCEDURE|Intravenous analgesia|IVA (Intravenous analgesia): These patients will be administered 1000 mg paracetamol intravenously in the preoperative waiting room in the operating room approximately 20-30 minutes before induction of anaesthesia. No block procedure will be performed. Patients will not be given any analgesic medication before awakening from anaesthesia.
48003077|NCT03125512|DEVICE|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
48003078|NCT03125512|DEVICE|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
48003079|NCT00454168|BIOLOGICAL|PR1 leukemia peptide vaccine|Given subcutaneously
48003080|NCT00454168|BIOLOGICAL|sargramostim|Given subcutaneously
48003081|NCT00454168|OTHER|placebo|Given subcutaneously
48003082|NCT02883296|OTHER|Pelvis Magnetic resonance imaging|
48003083|NCT01162382|DEVICE|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
48003084|NCT01127750|DRUG|FTY720|
48003085|NCT00385528|BEHAVIORAL|Multi-faceted psychiatric intervention|
48003086|NCT03080961|DEVICE|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
48003087|NCT04705285|DEVICE|Erbium Yag Laser|Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month
48003088|NCT04705285|BEHAVIORAL|Pelvic Floor Training|Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
48003089|NCT01391975|PROCEDURE|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
48003090|NCT02582099|DRUG|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
48003091|NCT02582099|DRUG|Normal saline nasal irrigation|Nasal wash with normal saline solution
48003092|NCT05311371|OTHER|Breathing exercise group|"The exercise was applied in accordance with the Guideline on Breathing Exercise for Reducing Nausea and Vomiting prepared by the researcher in accordance with the literature. In addition, the researcher has a breath coaching certificate. The guideline include the application steps of breathing exercise. First, the researcher will demonstrate to the patients the practice of breathing exercise in accordance with the guideline. In the next step, patients they will be asked to do this application on themselves. The training is planned to take about 15-20 minutes for each patient. This guide will be given to patients after the training. They will be asked to do this breathing exercise correctly and effectively in accordance with the guideline for at least 5 min in case of sensation of nausea and vomiting for 14 days. The researcher will follow up the patients for 14 days by visiting room them every day."
48003093|NCT05311371|OTHER|Control group|No intervention
48003094|NCT05719363|DEVICE|Inogen Rove 6 Portable Oxygen Concentrator|"The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
48003095|NCT02540954|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
48003096|NCT03196011|OTHER|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
48003097|NCT03196011|OTHER|TKR with alternative alignment method|TKR implanted using alternative alignment methods
48003098|NCT00006095|DRUG|irinotecan hydrochloride|
48688455|NCT05366088|BEHAVIORAL|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
48688456|NCT06260449|PROCEDURE|Surgical removal|Removal of the granuloma
48688457|NCT05606848|OTHER|Nutrition Emulsion (TPF-T)|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy."
48688458|NCT05606848|OTHER|Foods for special medical purposes [FSMP] for patients with tumors|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy."
48688459|NCT02441907|DRUG|aflibercept|
48688460|NCT05533307|DIAGNOSTIC_TEST|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
48003099|NCT00006095|DRUG|vincristine sulfate|
48003100|NCT01312584|DIETARY_SUPPLEMENT|Processed High-flavanol|
48003101|NCT02280174|DRUG|linagliptin|linagliptin 5 mg/d for12 weeks
48003102|NCT05351346|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
48003103|NCT05351346|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
48003104|NCT05351346|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
48003105|NCT05351346|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
48003106|NCT05351346|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
48003107|NCT05351346|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
48003108|NCT05351346|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
48003109|NCT05351346|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
48003110|NCT06071455|OTHER|Platelet-rich fibrin|injected distal to the canine on the experimental side.
48003111|NCT06071455|OTHER|Vitamin D3|injected distal to the canine on the experimental side.
48003112|NCT01650363|OTHER|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
48003113|NCT01650363|DRUG|Homeopathic placebo medication|2-3 mm small spheric suger pils
48003114|NCT01978314|DEVICE|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
48003115|NCT05595317|DEVICE|Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. In the non-immersive virtual reality application, Microsoft Kinect Xbox 360 Adventures games will be applied at the light level exercise level under the supervision of a physiotherapist. The participant will play a game in which he stands in a standing boat in a boat going on a flowing river and has to overcome obstacles by jumping, crouching and stepping left and right (River rush game).
48003116|NCT05595317|DEVICE|Sham Non-immersive Virtual Reality|The traditional physiotherapy program will consist of hot pack (15 minutes), TENS (20 minutes), and 1 set of /10 repetitions of knee flexion/extension exercise for the right and left in a sitting position with hands clasped on opposite shoulders. As a sham application, the participants will sit in a chair in front of the screen and try to prevent the balls sent from the opposite direction by using their upper extremities while their bodies are fixed with the help of a belt, under the supervision of a physiotherapist (Rally ball game).
48003117|NCT06092515|DIETARY_SUPPLEMENT|Fermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from fermented high zinc wheat flour.~* The flatbreads will be prepared using traditional fermentation methods.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
48003118|NCT06092515|DIETARY_SUPPLEMENT|Unfermented High Zinc Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from unfermented high zinc wheat flour,~* The flatbreads will not undergo a fermentation process.~* These flatbreads will be provided to participants to consume daily, along with vegetables or pulses (daal), for six days a week over the course of six months."
48003119|NCT06092515|DIETARY_SUPPLEMENT|Post-Harvest Fortified Whole Wheat Flour Flatbread|"* Participants in this group will receive flatbreads made from whole wheat flour fortified post-harvest~* These fortified flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months."
48688461|NCT04251234|OTHER|Light intensity, ~30 lux|\~30 lux compared to very dim light baseline condition \<1 lux
48688462|NCT04251234|OTHER|Baseline light intensity, <1 lux|Very dim light condition
48729796|NCT06583551|PROCEDURE|Dry needling|Dry needling (DN) is a type of acupuncture therapy, that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points (MTrPs) and muscular, and connective tissues.
48729797|NCT06583551|DRUG|Myorel|Metacarbamol (380mg), paracetamol (300mg)
48003120|NCT06092515|DIETARY_SUPPLEMENT|Low Zinc Whole Wheat Flour Flatbread (Control Group)|"* Participants in this group will serve as the control group.~* They will receive flatbreads made from whole wheat flour with a low zinc content~* These low zinc flatbreads will be provided to participants for daily consumption, along with vegetables or pulses (daal), for six days a week over the course of six months. six days a week over the course of six months."
48003121|NCT00275210|DRUG|Oxaliplatin (SR96669)|
48160090|NCT04225234|OTHER|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
48160091|NCT04472442|PROCEDURE|Intermittent hypoxia|"Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
48160092|NCT04472442|PROCEDURE|Sham hypoxia|"Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
48688463|NCT05345405|BEHAVIORAL|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
48160093|NCT00367445|DRUG|Inhaled Human Insulin (Exubera)|
48160094|NCT00367445|DRUG|Insulin Glargine (Lantus)|
48160095|NCT00692523|OTHER|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
48003122|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
48160096|NCT00692523|OTHER|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
48688464|NCT05345405|BEHAVIORAL|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
48160097|NCT00185848|RADIATION|[18F]FHBG|\< 7mCi and 2 ug, iv
48160098|NCT00148616|DRUG|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
48160099|NCT00148616|DRUG|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
48160100|NCT01670032|DRUG|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
48160101|NCT01670032|DRUG|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
48160102|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
48160103|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
48160104|NCT03868618|DEVICE|Genio™ system|The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
48185163|NCT03620097|DIETARY_SUPPLEMENT|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
48367625|NCT00918489|DRUG|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
48367626|NCT00450814|DRUG|Cyclophosphamide|Given IV
48367627|NCT00450814|OTHER|Laboratory Biomarker Analysis|Correlative studies
48003123|NCT01489072|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
48160105|NCT06291584|OTHER|Exercise|In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
48367628|NCT00450814|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
48688465|NCT02685566|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
48367629|NCT00450814|OTHER|Pharmacological Study|Correlative studies
48003124|NCT00261742|DRUG|Penicillin versus cefuroxim per os|
48003125|NCT03495232|DEVICE|Zimmer Biomet Persona total knee system|Product manufactured by Zimmer Biomet used to replace the knee joint.
48003126|NCT01087047|DEVICE|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
48003127|NCT01168024|DEVICE|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
48003128|NCT01168024|OTHER|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
48003129|NCT04632251|DEVICE|SENSEI®|SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
48160107|NCT03169530|OTHER|Alcohol|\~15 gm daily of beer, wine, or spirits for \~6 years
48003130|NCT03966716|DEVICE|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
48003131|NCT03966716|DEVICE|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
48003132|NCT06418386|PROCEDURE|manual saline IA|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution, All carious tissue will be removed by hight speed handpiece, distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min ,The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium),using manual k file starting with #15 and irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
48367630|NCT05929872|OTHER|Non-invasive brain stimulation|ACTIVE transcranial direct current stimulation( tDCS)
48688466|NCT02685566|DEVICE|FFDM|FujiFilm Aspire Cristalle System
48688467|NCT00000333|DRUG|Benztropine|
48688468|NCT02340858|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
48688469|NCT00656058|DRUG|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
48688470|NCT03717753|OTHER|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
48688471|NCT03719092|DIETARY_SUPPLEMENT|Vitamin A Compound|Given PO or enterally
48688472|NCT05700058|OTHER|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
48160108|NCT05306730|DEVICE|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
48160109|NCT06032702|PROCEDURE|tooth alignment|Alignment will be assessed by Little's Irregularity Index
48160110|NCT03770299|BIOLOGICAL|Nivolumab|Specified dose on specified days
48160111|NCT03770299|DRUG|Vinorelbine|Specified dose on specified days
48160112|NCT03770299|DRUG|Gemcitabine|Specified dose on specified days
48160113|NCT03770299|DRUG|Docetaxel|Specified dose on specified days
48160114|NCT03770299|DRUG|Pemetrexed|Specified dose on specified days
48367631|NCT05929872|OTHER|Sham non-invasive brain stimulation|SHAM tDCS
48522602|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
48688473|NCT00395824|PROCEDURE|anticoagulation procedure|
48688474|NCT04796272|OTHER|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
48688475|NCT04796272|OTHER|traditional training program|Same training program for all patients in this group
48160115|NCT03770299|DRUG|Cisplatin|Specified dose on specified days
48688476|NCT04381416|DEVICE|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
48513446|NCT04391296|PROCEDURE|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
48688477|NCT03042650|BEHAVIORAL|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
48688478|NCT03042650|BEHAVIORAL|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
48003133|NCT06418386|PROCEDURE|manual neem IB|"* The procedural tooth is anesthetized and isolated with rubber dam. The tooth and adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by high speed hand piece~  , distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with neem leaf extract 100%~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
48003134|NCT06418386|PROCEDURE|manual sodium hypochlorite IC|"* adjacent rubber dam will be disinfected with tincture of iodine solution~* . All carious tissue will be removed by hight speed hand piece~* distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min 19 The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using manual file and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
48003135|NCT06418386|PROCEDURE|rotary saline IIA|"* shaping and cleaning done with using AF baby fanta files open file:#17 taper 08,then #20 taper 04 ,yellow then #25 taper 04 red , then #30 taper 04 blue . the files activated with torque 2 and speed 350 . Irrigation with normal saline~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then restored with glass inomar and stainless steel crown"
48003136|NCT06418386|PROCEDURE|rotary neem IIB|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by high speed hand piece ,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS METION BEFORE ,and irrigation with 100%neem extract~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
48003137|NCT06418386|PROCEDURE|rotary sodoium hypochlorite IIC|"* The procedural tooth is anesthetized and isolated with rubber dam as mentioned~* All carious tissue will be removed by hight speed hand piece,distal cannel of mandibular primary molars and palatal cannel of maxillary primary molars will be chosen for sampling procedure.~* A sterile broach will be inserted to obtain root cannel content then sterile paper point inserted to root canal and will be left for 1 min The paper point will be removed with sterilized tweezer which will immediately transferred to tube containing transport medium (eppendrof of containing 200 μl nutrient broth medium).~* using AF baby fanta files SAME AS MENTION BEFORE , and irrigation with 1% sodium hypochlorite~* Post irrigation sample and pre-preparation sample will be transferred to microbiological laboratory Canals will be filed with obturation material(Metapex)then crown will be restored with glass inomar and stainless steel crown"
48003138|NCT03422341|DEVICE|Comparison between GenePOC CR and Reference Method|The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
48003139|NCT01412866|BEHAVIORAL|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
48003140|NCT01412866|BEHAVIORAL|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
48160116|NCT03770299|DRUG|Carboplatin|Specified dose on specified days
48160117|NCT03770299|DRUG|Paclitaxel|Specified dose on specified days
48160118|NCT03770299|OTHER|Observation|Observation by the investigator
48160119|NCT06040138|DIAGNOSTIC_TEST|End expiratory occlusion maneuver|An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
48160120|NCT02232958|OTHER|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
48367632|NCT03740724|GENETIC|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
48367633|NCT03740724|DRUG|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
48367634|NCT01836900|DEVICE|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
48367635|NCT02538705|DRUG|Neovasculgen|
48367636|NCT05722418|BIOLOGICAL|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
48367637|NCT02978300|DEVICE|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
48367638|NCT02978300|DEVICE|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
48367639|NCT00280540|DRUG|Valsartan/Hydrochlorothiazide|
48367640|NCT05199285|BIOLOGICAL|Ipilimumab|Given IV
48367641|NCT05199285|BIOLOGICAL|Nivolumab|Given IV
48367642|NCT00355251|DRUG|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
48003141|NCT06095466|DEVICE|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
48003142|NCT06095466|DIAGNOSTIC_TEST|Histopathology and Immunohistochemistry|"In patients who do not survive, we will take a trucut core biopsy from the ventricular myocardium, using ultrasound guidance. Cardiac tissue slices preserve the heterogeneous structure and multicellularity of the myocardium and allow its functional characterization. However, in this protocol, only those patients who consent to autopsy or those who consent to most mortem biopsy will be sampled for cardiac histology in CCM. Thus samples for histology and immunohistopathology will be available in only a few patients.~For the immunohistochemistry study, the sections will be collected on the poly-L-lysine covered slides and dried in a thermostat, at 37°C, for 24 hours, for increasing the adherence of the biological material to the histological slide."
48003143|NCT02239536|PROCEDURE|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
48003144|NCT02239536|PROCEDURE|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
48003145|NCT00136487|DRUG|Celecoxib|
48003146|NCT04060329|BEHAVIORAL|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
48003147|NCT02595853|OTHER|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
48003148|NCT01091792|DRUG|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
48003149|NCT02945527|DRUG|Acetazolamide|As described above
48003150|NCT02945527|DRUG|Dexamethasone|As described above
48003151|NCT01024543|DRUG|Angiotensin II|Angiotensin II
48003152|NCT01024543|DRUG|Phenylephrine|Phenylephrine
48003153|NCT01024543|DRUG|Placebo|
48003154|NCT03523117|DRUG|Ferric carboxymaltose|Intravenous iron
48003155|NCT03523117|DRUG|Ferrous Sulfate|oral iron therapy
48003156|NCT02876965|PROCEDURE|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
48003157|NCT02876965|PROCEDURE|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
48367643|NCT01655368|BEHAVIORAL|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
48367644|NCT01655368|BEHAVIORAL|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
48003158|NCT01024296|DEVICE|Port Close|Device for applying loop suture to close surgical site
48003159|NCT04019743|DRUG|CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|single oral administration under fasting condition
48367645|NCT01411059|BEHAVIORAL|yoga|yoga classes 2 times per week for 32 weeks
48367646|NCT01177943|DRUG|Atomoxetine|Administered orally, once.
48367647|NCT01219959|DRUG|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
48367648|NCT01219959|DRUG|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
48160121|NCT01435499|BIOLOGICAL|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
48160122|NCT01435499|DRUG|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
48688479|NCT04660552|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
48688480|NCT02580032|OTHER|No treatment given|No treatment given.
48160123|NCT04788472|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
48160124|NCT00126555|DRUG|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
48160125|NCT00126555|RADIATION|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
48160126|NCT00126555|PROCEDURE|Conventional surgery|Undergo surgery
48160127|NCT00126555|OTHER|laboratory biomarker analysis|Correlative studies
48160130|NCT04919330|BEHAVIORAL|Family Acceptance and Commitment Therapy-based Eczema Management Programme|"The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation."
48160131|NCT04919330|BEHAVIORAL|Wait-list Control Group|The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
48160132|NCT04130373|PROCEDURE|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
48160133|NCT04130373|PROCEDURE|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
48160134|NCT04339543|OTHER|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
48160135|NCT06376344|OTHER|myofascial release with tennis ball|Movement of the Tennis Ball on the Sole of the Foot: The tennis ball is moved under the foot by back and forth movements and by applying pressure. The aim is to briefly keep the pressure of the ball on the body and the stress indicated by the massage on.
48688481|NCT03528122|PROCEDURE|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
48003160|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 1 Tab. 1T|single oral administration under fasting condition
48003161|NCT04019743|DRUG|CKD-333 16/10/40mg formulation 2 Tab. 1T|single oral administration under fasting condition
48160136|NCT05655715|RADIATION|Stereotactic body radiotherapy|8 Gray x 3
48160137|NCT05655715|DRUG|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
48160138|NCT05655715|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
48160139|NCT05655715|PROCEDURE|Biopsies|From soft tissue metastases.
48160140|NCT03386799|DEVICE|E-motion device|Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
48367649|NCT05643794|DRUG|rozanolixizumab|Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
48688482|NCT02835612|OTHER|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
48688483|NCT02835612|OTHER|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
48729798|NCT06583551|PROCEDURE|Manual therapy|Manual therapy (MT) entails the use of the hands to apply a force with a therapeutic intent, including techniques such as massage, joint mobilization/manipulation, myofascial release, nerve manipulation, strain/counterstrain, and acupressure.
48003162|NCT00193882|DRUG|Cisplatin|80mg/m2 IV day 1
48003163|NCT00193882|RADIATION|Radiotherapy|35 Gy in 15 fractions
48003164|NCT00193882|DRUG|5-Fluorouracil|800mg/m2/day IV days 1 - 4
48003165|NCT02825303|OTHER|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
48160141|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 1)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
48160142|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 2)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™(D168)"
48160143|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 3)|"* 10 mcg R21 in 50 mcg Matrix-M™ (D0)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
48160144|NCT06320535|PROCEDURE|Fine needle aspiration (FNA)|Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
48160145|NCT04320602|BIOLOGICAL|Eculizumab|Participants must have been prescribed and be receiving a stable dose of eculizumab 1200 milligrams (mg) every 2 weeks (q2w) for at least 3 months prior to the Screening Period. During the Screening Period, participants will continue to receive eculizumab 1200 mg q2w.
48160146|NCT04320602|BIOLOGICAL|Ravulizumab|During the Treatment Period, participants will receive a loading dose of ravulizumab on Day 1, followed by maintenance doses on Day 15 and every 8 weeks, administered by intravenous infusion. Ravulizumab loading and maintenance doses will be based on participants' body weight per approved dose regimen.
48160147|NCT00372099|DRUG|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
48367650|NCT05643794|OTHER|Placebo|Study participants will receive Placebo during the dosing periods as pre-defined.
48513447|NCT04726176|BIOLOGICAL|Exposure to COVID-19|To study the exposure of COVID-19 on the brain and executive functioning
48513448|NCT03639818|OTHER|individual sessions of cognitive remediation|The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
48513449|NCT02863926|BIOLOGICAL|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
48729799|NCT05900492|PROCEDURE|cesarean section|caesarean delivery, is the surgical procedure by which one or more babies are delivered through an incision in the mother's abdomen
48003166|NCT00873548|DEVICE|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~1. Positioning of the patient~2. Definition of the CCD-angle~3. Fracture reduction~4. Determination of the nail diameter~5. Incision~6. Insertion of the device"
48003167|NCT03675490|BEHAVIORAL|ABLE - exercise with interactive technology|Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
48003168|NCT06323252|DIETARY_SUPPLEMENT|MastihaOil|1 soft gel capsule of Mastiha oil every day for 3 months
48003169|NCT06323252|BEHAVIORAL|nutritional counsel|nutritional counsel
48160148|NCT05268185|BEHAVIORAL|Moderna Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
48160149|NCT05268185|BEHAVIORAL|Pfizer Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
48160150|NCT03219476|DRUG|Anastrozole|1 mg once daily.
48160151|NCT03219476|DRUG|Letrozole|2.5mg once daily.
48160152|NCT03219476|DRUG|Exemestane|25 mg once daily.
48367651|NCT01868126|DRUG|DE-117 ophthalmic solution|
48367652|NCT01868126|DRUG|latanoprost ophthalmic solution|
48367653|NCT01868126|OTHER|Placebo|
48003170|NCT06249282|PROCEDURE|Biopsy|Undergo biopsy
48003171|NCT06249282|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48003172|NCT06249282|DRUG|Carfilzomib|Given IV
48003173|NCT06249282|PROCEDURE|Computed Tomography|Undergo CT
48003174|NCT06249282|PROCEDURE|Echocardiography|Undergo ECHO
48003175|NCT06249282|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48003176|NCT06249282|DRUG|Sotorasib|Given PO
48003177|NCT04625751|OTHER|CO2-enriched air|To assess cardiovascular reactivity
48003178|NCT04625751|OTHER|Meal response test|Meal response test to assess changes in splanchnic blood flow.
48367654|NCT04537312|PROCEDURE|Robot-assisted Nipple Sparing Mastectomy|Under RNSM
48367655|NCT04537312|OTHER|Survey Administration|ancillary correlative
48367656|NCT04537312|DEVICE|RNSM|Robot-assisted Nipple Sparing Mastectomy
48367657|NCT03844620|OTHER|Best Practice|Receive SOC
48367658|NCT03844620|OTHER|Laboratory Procedure|Undergo ctDNA testing
48367659|NCT03844620|OTHER|Quality-of-Life Assessment|Ancillary studies
48522603|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
48160153|NCT03219476|DRUG|Tamoxifen|20 mg once daily.
48160154|NCT06645990|DEVICE|Impella|LV unloading with Impella (ECMELLA) before or within 24 h of ECMO initiation
48160155|NCT06645990|DEVICE|IABP|LV unloading with IABP before or within 24 h of ECMO initiation
48160156|NCT06193486|BIOLOGICAL|MSGV1-PSCA-8T28Z|Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.
48160157|NCT06193486|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
48160158|NCT06193486|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
48160159|NCT02977780|DRUG|Temozolomide|Temzolomide capsules
48160160|NCT02977780|DRUG|Neratinib|Neratinib tablets
48160161|NCT02977780|DRUG|QBS10072S|QBS10072S administered intravenously
48160162|NCT06324188|OTHER|Early atrial fibrillation ablation|Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.
48160163|NCT06324188|OTHER|Usual Care|Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
48160164|NCT01685307|DIETARY_SUPPLEMENT|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
48160165|NCT01481701|DRUG|Oxaliplatin|85 mg/m² / 14days
48160166|NCT01481701|DRUG|oxaliplatin|oxaliplatin
48160167|NCT06584682|OTHER|Sub-occipital muscle inhibition technique|Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion and cervical muscle METs
48160168|NCT06584682|OTHER|conventional therapy|stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamics.
48729800|NCT02661074|OTHER|Questionnaire|"A questionnaire will be completed in order to collect data on:~* Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~* Occupational and/or domestic exposure to fish."
48729801|NCT04218591|OTHER|PRP|Platelet rich plasma
48729802|NCT04218591|OTHER|Placebo|Saline
48160169|NCT04260984|PROCEDURE|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
48160170|NCT04260984|PROCEDURE|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
48160171|NCT00701597|DRUG|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
48160172|NCT04809545|OTHER|Acusticare|Acusticare is an internet connected speaker which delivers an environmental intervention by playing sounds to adjust the soundscape in the room.
48160173|NCT04809545|OTHER|Treatment as usual|Usual care provided on the Specialized Dementia Unit
48160174|NCT02078778|DEVICE|CPAP|3 months of CPAP treatment
48729803|NCT02986854|BIOLOGICAL|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
48160175|NCT06645509|DRUG|TTB gel (dose 1)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
48160176|NCT06645509|DRUG|TTB gel (dose 2)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
48160177|NCT06645509|DRUG|Placebo|A topical administration of a vehicle (Placebo) gel to both hands, once daily for 28 days
48160178|NCT02366702|DEVICE|Lower Limb Powered Knee-Ankle Prosthesis|
48160179|NCT01594697|DRUG|Metformin|
48160180|NCT01367613|DRUG|SC Methylnaltrexone|
48160181|NCT01366144|DRUG|Carboplatin|Given IV
48160182|NCT01366144|OTHER|Laboratory Biomarker Analysis|Correlative studies
48160183|NCT01366144|DRUG|Paclitaxel|Given IV
48160184|NCT01366144|OTHER|Pharmacological Study|Correlative studies
48160185|NCT01366144|DRUG|Veliparib|Given PO
48367660|NCT03844620|OTHER|Questionnaire Administration|Ancillary studies
48367661|NCT03844620|DRUG|Regorafenib|Given by mouth
48367662|NCT03844620|DRUG|Trifluridine and Tipiracil Hydrochloride|Given by mouth
48367663|NCT05519891|OTHER|Custom 3D printed device|A 3D printed adaptation for a mobile device.
48003179|NCT03709537|BEHAVIORAL|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
48003180|NCT01449578|DRUG|Dexpramipexole|Oral Tablet at varying doses
48003181|NCT01449578|DRUG|Dexpramipexole Placebo|Oral tablet at varying doses
48003182|NCT04625608|DRUG|Paracetamol|Standard care of 3 ml/kg water, plus 15 mg/kg oral paracetamol suspension, a minimum of 1 hour prior to the induction of general anaesthesia.
48160186|NCT06646835|BEHAVIORAL|Stress Ball Intervention|The stress ball is a simple and effective tool for reducing anxiety and relaxation as a non-pharmacological method (Yanes et al., 2018). Due to the limited pharmacological options available for pregnant women to reduce anxiety during cesarean section, alternative, complementary or supportive non-pharmacological methods and low-risk approaches are needed (Baltacı \& Başer, 2020). It is thought that squeezing the stress ball may be advantageous in reducing anxiety.
48160187|NCT00907699|GENETIC|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
48003183|NCT04625608|OTHER|Standard care|Standard care of 3.6 ml/kg water, a minimum of 1 hour prior to the induction of general anaesthesia.
48003184|NCT01436279|DRUG|Mifepristone|200 mg po 20-24 hours prior to the procedure
48003185|NCT01436279|DEVICE|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
48160188|NCT00907699|GENETIC|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
48160189|NCT00907699|GENETIC|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
48160190|NCT00907699|GENETIC|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
48160191|NCT00907699|GENETIC|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
48160192|NCT00907699|GENETIC|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
48367664|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 1)|Comparator
48688484|NCT06180629|BEHAVIORAL|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
48367665|NCT04874129|DRUG|YYC506 (phase 1)|Test
48367666|NCT04874129|DRUG|YYC506-T and YYC506-A (phase 2)|Comparator
48367667|NCT04874129|DRUG|YYC506 (phase 2)|Test
48367668|NCT02387827|BEHAVIORAL|Diet+ short term versus long -term physical activity|
48688485|NCT06180629|OTHER|normal treatment routine|normal treatment routine
48688486|NCT06123715|DRUG|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
48688487|NCT06123715|DRUG|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
48688488|NCT03877614|OTHER|ASCVD risk score|ASCVD score\< 10% will be in the control or low-risk group
48688489|NCT04053972|DRUG|Lenvatinib|oral lenvatinib after hepatectomy
48003186|NCT00899691|GENETIC|protein expression analysis|
48160193|NCT00907699|GENETIC|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
48160194|NCT00907699|OTHER|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
48160195|NCT02270606|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48003187|NCT01140425|DRUG|PF-00232798|600 mg oral solution once daily x 7 days
48003188|NCT01140425|DRUG|PF-00232798|300 mg oral solution once daily x 7 days
48003189|NCT01140425|DRUG|Placebo|Oral solution once daily x 7 days
48003190|NCT01140425|DRUG|Moxifloxacin|400 mg tablet single dose
48688490|NCT00019968|DRUG|melphalan|
48688491|NCT00019968|DRUG|tumor necrosis factor|
48003191|NCT00691496|BEHAVIORAL|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
48003192|NCT05728346|DRUG|Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers|stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
48003193|NCT05297396|OTHER|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
48003194|NCT00829881|DRUG|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
48003195|NCT00829881|DRUG|Placebo Capsule|A single placebo capsule
48688492|NCT06351774|BEHAVIORAL|Physical therapy|Physical therapy for the treatment of chronic low back pain, as directed by a licensed Physical Therapist. The Healthy Minds Innovations (HMI) program is an app-based learning platform developed through the University of Wisconsin-Madison Center for Healthy Minds. The HMI app includes foundational meditation practices and short podcast-style lessons based on the science of wellbeing to cultivate mindfulness, positive relationships, and insight into the nature of the self.
48003196|NCT02265978|DEVICE|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
48003197|NCT02776228|DRUG|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
48688493|NCT01872585|BEHAVIORAL|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
48160196|NCT02270606|DRUG|fluorouracil|Given IV
48160197|NCT02270606|DRUG|oxaliplatin|Given IV
48160198|NCT02270606|DRUG|leucovorin calcium|Given IV
48160199|NCT02270606|PROCEDURE|therapeutic conventional surgery|Undergo total mesorectal excision
48160200|NCT05765409|OTHER|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
48160201|NCT05765409|OTHER|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
48160202|NCT00685347|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
48160203|NCT00685347|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
48160204|NCT00752999|DRUG|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
48160205|NCT00752999|DRUG|Placebo|Placebo tablet, oral, twice-a-day
48160206|NCT05647109|OTHER|No intervention|No intervention
48367669|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
48367670|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
48688494|NCT03444103|DRUG|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
48688495|NCT03444103|DRUG|Placebo / Clazakizumab|0.9% Saline
48160207|NCT02876003|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
48160208|NCT00212888|BIOLOGICAL|Remune and ALVAC|"* Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~* Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~* Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
48367671|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
48688496|NCT00062855|PROCEDURE|Skin Biopsy|
48688497|NCT00062855|GENETIC|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
48160209|NCT03942861|DRUG|Solu-Medrol|Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
48160210|NCT05102760|PROCEDURE|Nerve Block using FIC Proceedure|Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
48160211|NCT05102760|PROCEDURE|Nerve Block using PENG Proceedure|Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
48160212|NCT01386411|GENETIC|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
48160213|NCT05465499|PROCEDURE|ERAS|This study is a cross-sectional observational study by distributing questionnaires regarding the readiness to implement ERAS at Dr Soetomo General Hospital to the subjects, so there is no treatment whatsoever on the subjects.
48367672|NCT01234142|DRUG|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
48160214|NCT00942513|OTHER|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
48367673|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
48688498|NCT06474000|BEHAVIORAL|Oxytocin induction group|"Participants in the oxytocin induction group filled out the Information Form at the time of application to the delivery room. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
48160215|NCT00942513|OTHER|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
48367674|NCT01234142|DRUG|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
48160216|NCT00942513|OTHER|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
48688499|NCT06474000|BEHAVIORAL|Control group|"Participants in the control group filled in the Information Form when they applied to the birth centre. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
48688500|NCT05858476|OTHER|21-Day Detox and Green Drink supplement|"Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement."
48688501|NCT04625101|DRUG|NBI-827104|Triple T-type calcium channel blocker.
48688502|NCT04625101|DRUG|Placebo|Non-active dosage form.
48688503|NCT01761006|DEVICE|NIOX MINO®|
48688504|NCT00164008|DRUG|zoledronic acid vs pamidronate|
48688505|NCT04532294|DRUG|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
48688506|NCT04532294|DRUG|Placebo|Placebo to match BGB-DXP593
48688507|NCT00434980|BEHAVIORAL|Family-Directed Cognitive Adaptation Program|
48003198|NCT02776228|DRUG|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
48003199|NCT03584269|DEVICE|NIV Device + LTOT|Respiratory assistance by a facial mask without intubation or tracheotomy
48003200|NCT03584269|DEVICE|LTOT|Long term oxygenatory tyherapy without NIV
48003201|NCT05091268|BEHAVIORAL|Exercise|"All participants will attend a four-hour pain education session including gynecologist, psychologist, sexologist, and physiotherapist at Akershus University Hospital.~The education will be held twice, with half of the participants at the time. The training group will then attend a 60 minutes weekly group training session led by a physiotherapist with specialist training in women's health over a period of four months. In addition, participants will perform a progressive home exercise program performed daily over the same period. The focus will be general strength training using own body weight and cardiovascular fitness (walking, low-impact aerobic exercise), stretching, and relaxation"
48003202|NCT03037788|DRUG|WO3979|Application of cream to each axilla
48003203|NCT03037788|DRUG|WO3970|Application of cream to each axilla
48003204|NCT03037788|DRUG|WO3992|Application of cream to each axilla
48003205|NCT03037788|DRUG|Placebo (WO3988)|Application of cream to each axilla
48003206|NCT01728025|DRUG|Ranolazine|
48003207|NCT02502266|DRUG|Cediranib|Given PO
48003208|NCT02502266|DRUG|Cediranib Maleate|Given PO
48003209|NCT02502266|PROCEDURE|Computed Tomography|Undergo CT
48003210|NCT02502266|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48003211|NCT02502266|DRUG|Olaparib|Given PO
48003212|NCT02502266|DRUG|Paclitaxel|Given IV
48688508|NCT05891535|PROCEDURE|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
48003213|NCT02502266|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48003214|NCT02502266|OTHER|Questionnaire Administration|Ancillary studies
48688509|NCT05891535|PROCEDURE|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
48003215|NCT02502266|DRUG|Topotecan|Given IV
48003216|NCT02502266|DRUG|Topotecan Hydrochloride|Given IV
48003217|NCT03661814|DEVICE|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
48003218|NCT06311890|DRUG|N-chlorin e6 triglumine|a photodynamic therapy with chlorin-e6
48160217|NCT00942513|OTHER|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
48160218|NCT00942513|OTHER|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
48160219|NCT00942513|OTHER|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
48003219|NCT06311890|PROCEDURE|acne removal surgery|acne removal surgery will be given before red light exposure
48003220|NCT06224530|DRUG|Levetiracetam|Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
48003221|NCT06224530|DRUG|Placebo|Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
48003222|NCT01902446|DRUG|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
48003223|NCT01358227|DRUG|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
48003224|NCT06437210|DIETARY_SUPPLEMENT|Viusid Oral Solution|Patients in the experimental intervention group will be administered Viusid Oral Solution (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
48003225|NCT06437210|DIETARY_SUPPLEMENT|Placebo|Patients in the experimental intervention group will be administered Placebo (CATALYSIS S.L., Madrid, Spain) 30 mL orally 3 times a day with the main meals (breakfast, lunch and dinner) for 30 days.
48003226|NCT03913091|DRUG|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
48160220|NCT00942513|OTHER|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
48160221|NCT01514864|DRUG|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
48160222|NCT02157688|OTHER|no intervention : case control study|
48160223|NCT03866434|DRUG|SPD422|Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
48160224|NCT03866434|DRUG|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
48160225|NCT03049306|DRUG|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
48688510|NCT04550520|DIAGNOSTIC_TEST|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
48160226|NCT03049306|DRUG|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
48367675|NCT01234142|DRUG|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
48367676|NCT00847951|PROCEDURE|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
48688511|NCT04550520|DIAGNOSTIC_TEST|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
48729804|NCT04371692|OTHER|self-administered questionnaire|Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
48003227|NCT03913091|DRUG|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
48003228|NCT03592615|PROCEDURE|cataract surgery|Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
48003229|NCT03592615|PROCEDURE|Corneal refractive surgery|Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
48003230|NCT04640519|OTHER|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
48003231|NCT04640519|OTHER|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
48003232|NCT03292081|DEVICE|OFDI|PCI under OFDI guidance
48003233|NCT03292081|DEVICE|IVUS|PCI under IVUS guidance
48003234|NCT01590407|DRUG|ALS-002200|ALS-002200
48003235|NCT01590407|DRUG|Placebo|Placebo
48003236|NCT03671902|DEVICE|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
48003237|NCT04134000|DRUG|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
48003238|NCT04134000|DRUG|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle-invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
48003239|NCT02165046|DRUG|Budesonide|
48003240|NCT02165046|DRUG|Procaterol|
48003241|NCT00079924|DRUG|teriparatide|
48003242|NCT00079924|DRUG|aldrenodate|
48003243|NCT00079924|DRUG|raloxifene|
48160227|NCT04038034|DIETARY_SUPPLEMENT|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
48160228|NCT04038034|DIETARY_SUPPLEMENT|Placebo|Placebo
48160229|NCT02721628|PROCEDURE|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
48160230|NCT02721628|PROCEDURE|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
48160231|NCT02721628|DEVICE|Femtosecond laser|Use in the epic-keratoplasty surgery
48160232|NCT00819676|OTHER|analysis of exhaled breath by biosensors|
48160233|NCT00819676|OTHER|measurement of exhaled nitric oxide|
48160234|NCT03256760|BIOLOGICAL|Endotoxin|Endotoxin
48160235|NCT03256760|BIOLOGICAL|Placebo|Placebo
48160236|NCT06477887|BIOLOGICAL|Allogeneic Dentin Matrix|"Steps of Allogenic Dentin Processing:~Wash with distilled water for 30-120 minutes. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours. Demineralization with 0.5N HCL for 10-60 min. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin"
48160237|NCT06477887|BIOLOGICAL|Autogenous Partially Demineralized Dentine Matrix|"The extracted tooth will be cleaned with a diamond bur under abundant irrigation with physiological water. All filling materials (gutta-percha, composite, luting cements, etc.) will be removed with the outmost care and under magnification.~Subsequently, the tooth will be cut into fragments (5 × 5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). According to the manufacturer, a disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.~After 25 minutes, particle graft biomaterials will be obtained. The particle size will range from 815 µm with peaks up to 1110 µm.~The socket will be filled with the graft."
48160238|NCT05044065|OTHER|Physical exercise|The intervention group will receive an exercise program consisting of a combination of supervised and home-based exercise with a focus to induce metabolic stress (blood flow restriction exercise) during both a pre- and postoperative period consisting of a total of 6-10 weeks. Protein supplementation will be given to exclude insufficient intake.
48160239|NCT00745069|DRUG|tapentadol HCl|
48160240|NCT05118009|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
48160241|NCT05547503|DRUG|AFA-281|Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
48160242|NCT01638533|OTHER|Pharmacological Study|Correlative studies
48160243|NCT01638533|DRUG|Romidepsin|Given IV
48003244|NCT02940171|PROCEDURE|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
48003245|NCT02940171|PROCEDURE|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
48003246|NCT03856437|BEHAVIORAL|HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV, the costs of not being vaccinated against HPV, or neither benefits or costs but simply a call for action.
48003247|NCT03338062|DIAGNOSTIC_TEST|Hepatobiliary Iminodiacetic Acid (HIDA) scan|HIDA scan was used as the planning scan for SBRT.
48003248|NCT04911738|OTHER|Virtual Reality , immersion in a virtual titlted room|The immersion in virtual reality will be based on the HTC VIVE® device and the software developed by the Virtualis Society.
48003249|NCT00218374|DRUG|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
48003250|NCT04527861|PROCEDURE|Single-incision Laparoscopic Surgery|In this group，the surgery is performed through a single incision. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
48003251|NCT04527861|PROCEDURE|Conventional Laparoscopic Surgery|In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
48003252|NCT04334499|OTHER|Sample collection from tissue discard|Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
48003253|NCT00002510|BIOLOGICAL|filgrastim|
48003254|NCT00002510|DRUG|cyclophosphamide|
48003255|NCT00002510|DRUG|etoposide|
48003256|NCT00002510|DRUG|mesna|
48003257|NCT00002510|PROCEDURE|peripheral blood stem cell transplantation|
48367677|NCT03044730|DRUG|Capecitabine|Given PO
48367678|NCT03044730|OTHER|Laboratory Biomarker Analysis|Correlative studies
48367679|NCT03044730|BIOLOGICAL|Pembrolizumab|Given IV
48003258|NCT00002510|RADIATION|radiation therapy|
48003259|NCT01116232|BIOLOGICAL|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
48003260|NCT01116232|BIOLOGICAL|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
48003261|NCT01116232|DRUG|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
48003262|NCT01116232|DRUG|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
48003263|NCT01116232|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
48003264|NCT01116232|PROCEDURE|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
48003265|NCT01116232|PROCEDURE|management of therapy complications|management of therapy complications
48003266|NCT01116232|PROCEDURE|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
48160244|NCT01132378|PROCEDURE|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
48003267|NCT04126395|DIAGNOSTIC_TEST|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
48367680|NCT02545465|DRUG|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
48513450|NCT03768362|PROCEDURE|Plication strabismus surgery|The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
48003268|NCT04126395|DIAGNOSTIC_TEST|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
48003269|NCT04126395|DIAGNOSTIC_TEST|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
48003270|NCT04126395|OTHER|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
48003271|NCT00915512|DRUG|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
48003272|NCT00218517|DRUG|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
48003273|NCT00218517|DRUG|Placebo|Matching placebo capsules using blue 00 capsules
48003274|NCT04210635|OTHER|ZEN cart|essential oils + relaxing music + dim light
48003275|NCT05539807|BEHAVIORAL|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
48003276|NCT00779012|BIOLOGICAL|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
48003277|NCT02531412|DRUG|Spironolactone|After a major surgery event a time 0, 24h and 48h
48003278|NCT02531412|DRUG|Placebo|After a major surgery event a time 0, 24h and 48h
48003279|NCT05132621|DIAGNOSTIC_TEST|Smear|A smear of the posterior vaginal fornix collected with a gynecological speculum.
48003280|NCT04814290|OTHER|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 [SF-36]).|health-related quality of life (HRQoL) (36-item short-form health survey, version 1 \[SF-36\]).
48003281|NCT00903812|OTHER|No intervention|No intervention as observational study
48003282|NCT02155738|DRUG|IV Acetaminophen|
48003283|NCT02155738|DRUG|IV normal saline|IV normal saline
48003284|NCT01564303|DRUG|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
48003285|NCT05410626|DRUG|prolong-release methylphenidate|This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
48003286|NCT04023877|DRUG|E2027|E2027 oral capsule.
48003287|NCT05256238|OTHER|comprehensive supervised exercise program (CSEP)|"The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:~* week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,...~* week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home~* maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation"
48003288|NCT03129516|BEHAVIORAL|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
48003289|NCT01224249|DIETARY_SUPPLEMENT|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
48003290|NCT03719313|DRUG|Lonafarnib|Lonafarnib (LNF) 50 mg BID
48003291|NCT03719313|DRUG|Ritonavir|Ritonavir (RTV) 100 mg BID
48003292|NCT03719313|DRUG|PEG IFN-alfa-2a|PEG IFN alfa-2a 180 mcg QW
48003293|NCT03719313|DRUG|Placebo Lonafarnib|Placebo
48003294|NCT03719313|DRUG|Placebo Ritonavir|Placebo
48003295|NCT04004728|PROCEDURE|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
48003296|NCT03221933|BIOLOGICAL|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
48003297|NCT03221933|BIOLOGICAL|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
48003298|NCT01963390|DRUG|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
48513451|NCT03768362|PROCEDURE|Resection strabismus surgery|resection strabismus surgery
48513452|NCT05622240|DRUG|99mTc-MIRC213|99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
48513453|NCT02680951|DRUG|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
48003299|NCT04115943|OTHER|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
48003300|NCT04115943|OTHER|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
48003301|NCT05695222|OTHER|This is not an interventional study|This is not an interventional study
48160245|NCT01347281|PROCEDURE|Injection of [18F]HX4|"Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~\[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position"
48160246|NCT04870814|DEVICE|Tactical tourniquet set up|The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
48003302|NCT06122207|DIETARY_SUPPLEMENT|Probiotic|"* Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months."
48003303|NCT06122207|DIETARY_SUPPLEMENT|Placebo|"* Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months."
48003304|NCT00806884|OTHER|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
48003305|NCT00806884|OTHER|Control group measurements|None other than control group measurements
48003306|NCT00371943|PROCEDURE|band ligation|
48003307|NCT02501980|BIOLOGICAL|Biomarker testing and Ultrasonography|
48160247|NCT04870814|DIAGNOSTIC_TEST|Medical ultrasound|The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
48160248|NCT04870814|OTHER|Questionnaire|"The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter)."
48160249|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
48160250|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
48513454|NCT02680951|DRUG|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
48513455|NCT02680951|DRUG|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
48729805|NCT04371692|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
48003308|NCT05669079|DRUG|decitabine|15 mg/m2 daily intravenously for consecutive 3 days
48003309|NCT05669079|BIOLOGICAL|umbilical cord blood|MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6
48003310|NCT05669079|DRUG|Granulocyte-colony stimulating factor|Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
48003311|NCT05669079|DRUG|Recombinant human thrombopoietin / thrombopoietin receptor agonist|Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
48003312|NCT05669079|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L
48003313|NCT04999046|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2 (the focused ultrasound intensity in brain area considering transcranial attenuation), burst length: 3 ms, duration: three consecutive 5-minute FUS exposures with two 5-minute intermission intervals.
48160251|NCT00522678|DRUG|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
48160252|NCT00522678|DRUG|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
48160253|NCT00662415|DEVICE|mirror-box treatment|15 minutes daily for 4 weeks
48160254|NCT00662415|BEHAVIORAL|observation|observation
48160255|NCT03235401|OTHER|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
48160256|NCT00850798|DRUG|Intensive glycemic control|Intensive glycemic control
48160257|NCT00850798|DRUG|Conservative glycemic control|OADs and insulin
48160258|NCT01394263|DRUG|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
48160259|NCT01394263|DRUG|Zoladex goserelin implant|goserelin implant injection.
48160260|NCT00403299|PROCEDURE|MDCT of the coronary arteries.|
48160261|NCT03238326|DRUG|Brexpiprazole|Once daily, oral tablets
48160262|NCT02652299|BIOLOGICAL|Synovial biopsy|Synovial tissue for analysis and biobank.
48160263|NCT05582135|DRUG|2 mg morphine sulfate|The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
48160264|NCT05582135|DRUG|0.25mg/kg esketamine|The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
48160265|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 2 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
48160266|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 1 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
48367681|NCT05654740|DEVICE|Virtual Reality Experiences|Virtual Reality experiences including stress reduction, distraction and entertainment
48367682|NCT00433979|DRUG|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
48160267|NCT03367845|BEHAVIORAL|Control|Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.
48367683|NCT04174430|BIOLOGICAL|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
48367684|NCT00815373|DRUG|Dorzolamide+Timolol Maleate0.5%|Cosopt\* b. i. d.
48367685|NCT00815373|DRUG|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom\* QHS
48513456|NCT02680951|DRUG|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
48729806|NCT01955538|OTHER|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
48003314|NCT00297037|DRUG|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
48003315|NCT03331796|DEVICE|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
48003316|NCT03331796|DEVICE|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
48003317|NCT03331796|DEVICE|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
48003318|NCT02476968|DRUG|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
48160268|NCT03367845|BEHAVIORAL|Sensitivity Intervention|4 home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
48160269|NCT03367845|BEHAVIORAL|Couples' Intervention|The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
48160270|NCT03367845|BEHAVIORAL|Sensitivity and Couples' Intervention|This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention). Because of COVID-19, we now conduct remote visits using Zoom.
48367686|NCT04186754|PROCEDURE|Comprehensive functional care plan|The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.
48367687|NCT04186754|PROCEDURE|Traditional intervention without rehabilitation|Clinical control by nursing professionals and exclusively pharmacological treatment
48522604|NCT00102622|BIOLOGICAL|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m\^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
48729807|NCT01955538|OTHER|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
48729808|NCT01955538|OTHER|Mixed physical activity|20 weeks, 1 hour/week.
48729809|NCT04544579|DEVICE|Stent grafts anchored in different areas|Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
48367688|NCT05489146|DEVICE|transcranial random noise stimulation and functional electrical stimulation facilitated task practice|Participants were randomized to one of the two intervention groups \[transcranial current stimulation (tRNS) and functional electrical stimulation (FES) or FES with sham tRNS\] before pre-intervention testing. After randomization, participants underwent pre-intervention testing, followed by intervention 3 times per week for 6 weeks. Each intervention session lasted for 1 hour, where tRNS or sham-tRNS were delivered concurrently with the FES-facilitated task practice. tRNS or sham-tRNS was delivered for the first 30 minutes. Both tRNS and sham tRNS were delivered by the Starstim system. FES was delivered using the Neuromove system. All participants were treated by a licensed occupational therapist, who was trained on a manualized protocol.
48367689|NCT06342440|DIAGNOSTIC_TEST|DENEB|A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
48003319|NCT03258827|PROCEDURE|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
48003320|NCT03258827|PROCEDURE|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
48003321|NCT02544529|DRUG|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
48003322|NCT02544529|DRUG|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
48003323|NCT02693509|OTHER|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
48003324|NCT04300569|OTHER|Non-interventional|No intervention will be administered.
48003325|NCT04160793|DEVICE|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
48003326|NCT04837092|DRUG|FR104|FR104 treatment administration at day 0, day 14 then every 28 days until month 12
48003327|NCT03376178|COMBINATION_PRODUCT|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
48003328|NCT04703452|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
48003329|NCT03179085|BEHAVIORAL|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
48003330|NCT01977586|OTHER|Magnetic Resonance Imaging (MRI)|
48003331|NCT05094934|DRUG|NNC0385-0434 A 100 mg|All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.
48003332|NCT01945489|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
48003333|NCT01945489|DRUG|Normal saline|Normal saline (placebo) injected into the detrusor.
48003334|NCT04249804|DRUG|Magnesium Sulfate 1000 MG|intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
48003335|NCT04601688|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
48003336|NCT04601688|DRUG|Bevacizumab Ophthalmic|Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
48003337|NCT01510119|DRUG|Hydroxychloroquine|
48003338|NCT01510119|DRUG|RAD001|
48003339|NCT05374265|OTHER|Cardiovascular Magnetic Resonance Scan|Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
48003340|NCT05233566|DRUG|Ketamine|NMDA antagonist
48003341|NCT05233566|DRUG|Normal saline|IV fluid acting as a placebo
48003342|NCT01132495|OTHER|Stenting plus OMT|FFR guided PCI, plus OMT
48003343|NCT01132495|OTHER|OMT|OMT alone
48003344|NCT01132495|OTHER|Standard of care|FFR \> 0.80; treatment according to local practice
48003345|NCT01157533|DRUG|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
48003346|NCT02674620|OTHER|Aerobic Exercise|Patients are treated with progressive exercise
48003347|NCT05263492|DRUG|Lenvatinib|Lenvatinib once a day by mouth every day
48003348|NCT05263492|DRUG|Pembrolizumab|Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
48003349|NCT04209309|DEVICE|repetitive transcranial magnetic stimulation|
48003350|NCT04985630|DIETARY_SUPPLEMENT|Mitopure|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
48003351|NCT04985630|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice
48003352|NCT04360564|OTHER|Recurrent pregnancy loss|As described before.
48003353|NCT04781634|BIOLOGICAL|CD19 and CD22 targeted prime CAR-T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
48003354|NCT01837628|DRUG|Lidocaine Gel|
48003355|NCT01837628|DRUG|Paraffin Oil|
48003356|NCT00397800|BIOLOGICAL|rituximab|
48003357|NCT00397800|DRUG|cyclophosphamide|
48003358|NCT00397800|DRUG|fludarabine phosphate|
48003359|NCT00397800|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48003360|NCT03160833|DRUG|HMPL-453|oral administrative
48003361|NCT04935021|DRUG|ATTR-CM|Current treatment
48003362|NCT04473651|DRUG|Lu AG06479|capsules, orally (Part A and B)
48003363|NCT04473651|DRUG|Placebos|Placebo - capsules, orally (Part A only)
48160271|NCT06001814|BEHAVIORAL|One-Mind One-Heart|One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
48003364|NCT03011359|OTHER|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
48160272|NCT06001814|OTHER|Education|Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
48160273|NCT00543634|DRUG|Premarin/MPA|0.625 mg/2.5 mg X4
48688512|NCT05068505|BEHAVIORAL|Community health worker delivered multicomponent intervention|"The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters"
48688513|NCT04303104|OTHER|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
48688514|NCT04303104|OTHER|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
48688515|NCT02341768|DEVICE|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
48688516|NCT01890590|DEVICE|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
48688517|NCT00248911|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
48688518|NCT04683146|DRUG|Hand antisepsis with Propanolol- 1 60%.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later"
48003365|NCT03011359|OTHER|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
48003366|NCT04138615|DRUG|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
48003367|NCT04138615|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
48160274|NCT00543634|DRUG|Premarin/MPA|0.625 mg/5 mg X 2
48160275|NCT00543634|DRUG|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
48160276|NCT00774306|DRUG|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
48160277|NCT00774306|DRUG|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
48003368|NCT02787473|DRUG|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
48003369|NCT02787473|DRUG|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
48160278|NCT00774306|DRUG|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
48522605|NCT00102622|DRUG|Paclitaxel|80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
48522606|NCT01565889|DRUG|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
48522607|NCT01565889|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
48522608|NCT01565889|DRUG|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
48522609|NCT01565889|DRUG|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
48522610|NCT01565889|DRUG|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
48522611|NCT01565889|DRUG|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
48522612|NCT01565889|DRUG|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
48522613|NCT01565889|DRUG|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
48522614|NCT01565889|DRUG|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
48522615|NCT01565889|DRUG|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
48522616|NCT01565889|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
48522617|NCT02811965|OTHER|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
48160279|NCT06255899|BEHAVIORAL|Education Program on Injury Prevention|The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
48003370|NCT02787473|RADIATION|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
48185164|NCT03620097|OTHER|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
48185165|NCT02465918|DEVICE|motor cortex stimulation (Change of Stimulation Timing)|
48688519|NCT04683146|DRUG|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later."
48688520|NCT06089863|OTHER|PAMPERO program|"This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation"
48688521|NCT01667497|DRUG|Fampridine SR|
48688522|NCT01667497|DRUG|Placebo|
48688523|NCT03985462|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
48688524|NCT04930835|PROCEDURE|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
48688525|NCT02583633|DRUG|Transdermal nitroglycerin|
48688526|NCT02583633|DRUG|nifedipine|
48688527|NCT04818307|OTHER|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
48688528|NCT04818307|OTHER|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
48688529|NCT03958864|DRUG|CC-90001|CC-90001
48688530|NCT01794507|DRUG|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
48688531|NCT01794507|DRUG|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
48688532|NCT01794507|DRUG|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
48688533|NCT00009880|BIOLOGICAL|filgrastim|
48688534|NCT00009880|DRUG|cisplatin|
48688535|NCT00009880|DRUG|fluorouracil|
48003371|NCT02787473|DRUG|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
48003372|NCT03068975|DRUG|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
48688536|NCT00009880|DRUG|paclitaxel|
48688537|NCT00009880|RADIATION|radiation therapy|
48003373|NCT03068975|DRUG|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
48003374|NCT00861107|BIOLOGICAL|AlloStim-7|intradermal injection once a week for 3 weeks
48003375|NCT00861107|PROCEDURE|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
48003376|NCT00861107|BIOLOGICAL|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
48003377|NCT00861107|BIOLOGICAL|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10\^8 cell dose and if no toxicity dose escalates to 10\^9 cell dose.
48003378|NCT05430828|DRUG|Repatha (evolocumab); Praluent (alirocumab)|Dosage form: Injection
48003379|NCT02153866|BIOLOGICAL|rotavirus vaccine|3ml/dose, oral
48003380|NCT02153866|BIOLOGICAL|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
48688538|NCT04073511|DRUG|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
48003381|NCT02153866|BIOLOGICAL|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
48003382|NCT02106728|BEHAVIORAL|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
48003383|NCT02106728|BEHAVIORAL|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
48003384|NCT06137443|DEVICE|Balance Training|Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
48003385|NCT02270866|DEVICE|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
48160280|NCT06255899|BEHAVIORAL|Individualized Feedback + Education Program on Injury Prevention|In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
48160281|NCT00201214|DRUG|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
48688539|NCT04073511|DRUG|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
48688540|NCT04073511|DRUG|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
48688541|NCT01562392|DIETARY_SUPPLEMENT|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
48003386|NCT04133493|DEVICE|Kerecis Omega3 Wound|"The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week."
48003387|NCT04133493|DEVICE|Fibracol|The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
48160282|NCT06584578|OTHER|Whole-Body Electromyostimulation|Participants were included in tree exercise programs (Yoga, Pilates, WB-EMS) by an expert trainer 2 days a week for 12 weeks. At the same time, an active control group conducted a weekly diet counseling for 12 weeks by an expert dietician.
48160283|NCT06584578|OTHER|Pilates|Pilates exercise twice weekly for 12 weeks
48688542|NCT01562392|DIETARY_SUPPLEMENT|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
48688543|NCT04963855|DRUG|GT300|SIngle oral dose
48688544|NCT04963855|DRUG|Microcrystalline cellulose|placebo
48688545|NCT03981094|DRUG|BMS-986278|suspension
48688546|NCT03981094|DRUG|Pirfenidone|capsule
48688547|NCT05003973|BEHAVIORAL|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
48688548|NCT05003973|BEHAVIORAL|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
48688549|NCT03271242|OTHER|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
48688550|NCT03271242|OTHER|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
48688551|NCT02290496|BEHAVIORAL|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
48688552|NCT02290496|BEHAVIORAL|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
48003388|NCT00594464|DRUG|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
48003389|NCT06483971|DIAGNOSTIC_TEST|Oral Isotretinoin|20 mg/kg/day that affects sebaceous glands and is used to treat severe acne Frequency: Once daily
48688553|NCT00001033|DRUG|Ethambutol hydrochloride|
48688554|NCT00001033|DRUG|Isoniazid|
48688555|NCT00001033|DRUG|Pyrazinamide|
48688556|NCT00001033|DRUG|Pyridoxine hydrochloride|
48688557|NCT00001033|DRUG|Levofloxacin|
48688558|NCT00001033|DRUG|Rifampin|
48003390|NCT06483971|COMBINATION_PRODUCT|Antibiotics|250 mg on laternate day/3 months Frequency: Once or twice daily
48003391|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
48003392|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
48003393|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
48160284|NCT06584578|OTHER|Tai Chi|Pilates exercise twice weekly for 12 weeks
48160285|NCT06584578|OTHER|Nutritional counseling|Nutritional counseling for 12 weeks
48003394|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
48160286|NCT04257786|PROCEDURE|1ry cyto-reductive surgery|1ry surgery then chemotherapy
48688559|NCT03153891|OTHER|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
48688560|NCT03153891|OTHER|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
48688561|NCT06287541|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
48688562|NCT06467786|DRUG|Irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection combined with platinum
48160287|NCT04257786|COMBINATION_PRODUCT|Neoadjuvant chemotherapy followed by surgery|chemotherapy then surgery
48688563|NCT04925219|BEHAVIORAL|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
48688564|NCT04925219|BEHAVIORAL|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
48688565|NCT02959294|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
48688566|NCT02959294|DEVICE|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
48688567|NCT02959294|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
48688568|NCT04074070|OTHER|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
48003395|NCT00743652|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
48003396|NCT05718635|DIAGNOSTIC_TEST|coloured duplex|colored duplex to locate numbers sites and size of perforators.
48688569|NCT03201575|DEVICE|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
48688570|NCT03201575|DEVICE|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
48688571|NCT03969745|BEHAVIORAL|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
48688572|NCT03969745|BEHAVIORAL|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
48003397|NCT05718635|PROCEDURE|supra facial dissection|flap raising in supra facial plane
48003398|NCT02189057|OTHER|AssureRx GeneSight genotyping results|
48688573|NCT02029456|DRUG|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
48003399|NCT02189057|OTHER|Treatment as usual|
48003400|NCT03298750|PROCEDURE|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~1. One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~2. A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
48003401|NCT00862784|BIOLOGICAL|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
48003402|NCT00862784|DRUG|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
48003403|NCT00862784|DRUG|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
48003404|NCT00862784|DRUG|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
48003405|NCT00862784|DRUG|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
48003406|NCT05987865|BEHAVIORAL|Neurofeedback training|Features related to PD symptoms will be extracted from the brain recordings in real-time and used to drive a visual cursor on a computer screen placed in front of the participant, while the participant will be asked to try to control the cursor by regulating their brain signals.
48003407|NCT04853225|OTHER|Prospective observational cohort study|Prospective observational cohort study
48003408|NCT00021268|DRUG|tocladesine|
48003409|NCT00749983|DIETARY_SUPPLEMENT|Creatine supplementation|
48003410|NCT00749983|DIETARY_SUPPLEMENT|Dextrose supplementation|
48003411|NCT00684606|DRUG|Oxytocin IV|5 miu/1000ml Glu/Saline
48003412|NCT00420524|DRUG|Patupilone/EPO906|
48003413|NCT05230212|OTHER|Pecan Breakfast Shake|The pecan breakfast shake contains 68 grams of blended raw pecans. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
48003414|NCT05230212|OTHER|Cream Breakfast Shake|The cream breakfast shake contains 138 grams of heavy whipping cream. Participants will consume this shake at either visit 1 or visit 2 depending on randomization procedures.
48688574|NCT01335256|DRUG|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
48160288|NCT00555334|PROCEDURE|RFA|radiofrequency ablation
48160289|NCT00555334|DRUG|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
48160290|NCT01596634|OTHER|questionnaire administration|Ancillary studies
48160291|NCT01596634|PROCEDURE|quality-of-life assessment|Ancillary studies
48003415|NCT05129072|DEVICE|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D|kalifilcon A Daily Disposable Toric LD213001 lens
48160292|NCT01596634|OTHER|laboratory biomarker analysis|Correlative studies
48003416|NCT05245422|OTHER|Infant Formula - Partially hydrolyzed protein|Partially hydrolyzed cow's milk protein
48003417|NCT05245422|OTHER|Infant Formula - Intact protein|Intact cow's milk protein
48160293|NCT01596634|DIETARY_SUPPLEMENT|bovine lactoferrin|Given PO
48160294|NCT05016674|DEVICE|LipoLife system|Abdominal Laser-Assisted Liposuction
48160295|NCT05813249|DRUG|Rybelsus Oral Product|Oral Semaglutide
48160296|NCT05813249|DRUG|Ozempic Injectable Product|Subcutaneous Semaglutide
48160297|NCT05813249|DRUG|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
48160298|NCT00991133|DRUG|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
48160299|NCT06406387|DIAGNOSTIC_TEST|ATRX/DAXX immunohistochemistry|Immunohistochemistry will be performed using an Autostainer Leica (Leica Biosystems) according to the manufacturer's instructions. Four μm formalin-fixed paraffin-embedded sections will be immunostained with antibodies for Cytokeratin AE1/AE3 (AE1-AE3, 1:100 dilution, Novocastra/United Kingdom) Chromogranin A (DAK-A3, 1:2500, Dako/Denmark), and Synaptophysin (27G12, 1:100, Novocastra), Ki67 (MIB1, 1:100, Dako/Denmark), ATRX (1:400, Sigma-Aldrich), DAXX (1:200, Sigma-Aldrich). After antigen retrieval, immunostaining will be performed in an automated Bond instrument (Vision-Biosystem, Leica, Milan, Italy) using a sensitive peroxidase-based 'Bond polymer Refine' detection system.
48160300|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
48160301|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
48688575|NCT00332579|DRUG|Naltrexone|daily
48688576|NCT00332579|DRUG|Placebo|daily
48688577|NCT03758131|BEHAVIORAL|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
48003418|NCT04943731|DEVICE|Provox Life|Phase 1: Like for like transition, Phase 2: Provox Life day/night regimen
48160302|NCT03138356|DRUG|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
48160303|NCT03138356|DRUG|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
48160304|NCT03138356|DRUG|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
48160305|NCT03138356|DRUG|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
48160306|NCT03138356|DRUG|500 mg Glucophage XR®|Used in treatments C, F and I.
48160307|NCT05560945|DRUG|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
48160308|NCT05560945|DRUG|1.5% Arginine Dentifrice|Toothpaste
48160309|NCT05560945|DRUG|8.0% Arginine Dentifrice|Toothpaste
48160310|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
48160311|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
48160312|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
48160313|NCT02828592|DRUG|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
48160314|NCT02828592|DRUG|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
48160315|NCT02828592|RADIATION|Total Body Irradiation|300 cGy x1 dose (Day -1)
48160316|NCT02828592|DRUG|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
48160317|NCT02828592|DRUG|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
48160318|NCT03895892|BEHAVIORAL|20 km time trial|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
48160319|NCT03895892|BEHAVIORAL|Wingate test|30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
48160320|NCT03895892|DIETARY_SUPPLEMENT|Ketone/Caffeine|Dietary supplement containing ketone salts and caffeine
48160321|NCT03895892|DIETARY_SUPPLEMENT|Ketone|Dietary supplement containing only ketone salts
48160322|NCT03895892|DIETARY_SUPPLEMENT|Water Placebo|Dietary supplement containing only water
48160323|NCT02367742|BEHAVIORAL|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
48160324|NCT02367742|BEHAVIORAL|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~* Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~* Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
48160325|NCT06647212|OTHER|introducing breathing exercises with the harmonica|In addition to regular breathing exercises, participants will perform harmonica exercises
48160326|NCT06153901|PROCEDURE|endoloop mediated cardioplication (ECLC) procedure|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
48160327|NCT06480396|DIAGNOSTIC_TEST|High-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
48160328|NCT06480396|DIAGNOSTIC_TEST|Lower-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
48160329|NCT01060163|DRUG|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
48160330|NCT01060163|DRUG|Saline|Saline served as placebo
48160331|NCT03937596|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
48160332|NCT03937596|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
48160333|NCT03937596|DRUG|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
48160334|NCT06222034|DRUG|Filgotinib|Film-coated mini-tablets administered orally once daily
48160335|NCT06222034|DRUG|Filgotinib|Commercially developed film-coated tablet administered orally once daily
48160336|NCT06141694|DEVICE|The LIBERTY® Robotic System|"The LIBERTY® Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, to facilitate navigation to anatomical targets in the peripheral vasculature.~The LIBERTY® Robotic System is not intended for coronary or neurointerventional procedures."
48160337|NCT03195127|OTHER|multimodal physical therapy|Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
48160338|NCT01333137|DRUG|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
48688578|NCT03758131|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
48688579|NCT03758131|OTHER|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
48688580|NCT01030952|DRUG|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
48003419|NCT04516265|PROCEDURE|neurodevelopmental treatment|A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.
48003420|NCT04516265|PROCEDURE|video-based trunk training|Games developed for the use of children with cerebral palsy will be used for trunk training.
48160339|NCT01333137|DRUG|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
48160340|NCT02065726|DIETARY_SUPPLEMENT|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
48160341|NCT02065726|OTHER|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
48160342|NCT01948882|DEVICE|ESS505 (BAY1454033)|
48688581|NCT01030952|DRUG|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
48003421|NCT04516265|PROCEDURE|Video-based trunk training will apply with Theratogs|Video-based trunk training will apply with Theratogs
48003422|NCT04067362|OTHER|food containing dietary fiber|commercially available chicory root flour and chicory root fiber
48160343|NCT03003832|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
48160344|NCT03769129|DRUG|Pembrolizumab|Pembrolizumab
48003423|NCT00343057|OTHER|Patients' questionnaire|
48003424|NCT02151448|BIOLOGICAL|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
48160345|NCT03769129|PROCEDURE|microwave ablation|microwave ablation
48160346|NCT03877952|DRUG|14C-CORT125281|14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
48160347|NCT02504034|PROCEDURE|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
48160348|NCT02504034|DEVICE|6-French sheath|
48160349|NCT02504034|DEVICE|22-gauge chiba needle|
48160350|NCT02504034|DEVICE|260-cm-long stiff shaft wire|
48160351|NCT02504034|DEVICE|Balloon catheter|
48003425|NCT02151448|DRUG|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
48003426|NCT02151448|DRUG|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
48003427|NCT02151448|BIOLOGICAL|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
48160352|NCT02504034|DEVICE|Bare metal stent|
48160353|NCT02504034|DEVICE|Covered stent|
48160354|NCT06646523|OTHER|High-speed bodyweight resistance training|"The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits."
48160355|NCT06646523|OTHER|Control group (Bodyweight intervention, usual speed)|"The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group."
48160356|NCT02409732|DRUG|aminolevulinic acid hydrochloride|
48160357|NCT02409732|PROCEDURE|Photodynamic therapy with blue light|
48160358|NCT06181968|DIAGNOSTIC_TEST|Cardiothoracic ultrasound protocol|Combined echocardiography and lung ultrasound for guiding therapy
48160359|NCT02552693|OTHER|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
48160360|NCT05320861|DRUG|[14C]SJP-0008|Single oral dose of \[14C\]SJP-0008
48160361|NCT03729544|BEHAVIORAL|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
48160362|NCT04091919|DIAGNOSTIC_TEST|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
48160363|NCT00023621|DRUG|celecoxib|
48160364|NCT01905293|OTHER|Feeding Study|
48688582|NCT01930422|DEVICE|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
48003428|NCT06164132|OTHER|Evaluation|Evaluation through PCOS Phenotypes, measurements of Body weight, height, waist and hip circumferences, Dual-energy X-ray absorptiometry, and Sonographic examination.
48003429|NCT06262841|DEVICE|Piezosurgery|Piezosurgery used as an osteotomy device
48160365|NCT02113540|DRUG|Atorvastatin|
48688583|NCT01930422|DEVICE|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
48003430|NCT06262841|DEVICE|Conventional burs|Conventional burs used as an osteotomy device
48160366|NCT05581589|PROCEDURE|Lymphadenectomy|Undergo pelvic lymph node dissection
48160367|NCT05581589|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
48160368|NCT05581589|BIOLOGICAL|Sacituzumab Govitecan|Given IV
48160369|NCT01785797|DEVICE|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
48160370|NCT04194541|DEVICE|Cutimed Sorbact Hydroactive B wound dressing|Wound dressing applied and changed as needed.
48160371|NCT04194541|DEVICE|Cutimed Siltect wound dressing|Wound dressing applied and changed as needed.
48160372|NCT04194541|DEVICE|Sorbion Sana multi-star wound dressing|Wound dressing applied and changed as needed.
48160373|NCT00126061|DRUG|Tedisamil sesquifumarate|
48160374|NCT02802579|RADIATION|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
48160375|NCT02802579|RADIATION|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
48160376|NCT02802579|RADIATION|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
48160377|NCT05990309|DIAGNOSTIC_TEST|skin biopsy|skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
48160378|NCT00009789|RADIATION|accelerated conformational radiotherapy|
48160379|NCT01391533|DRUG|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
48160380|NCT02744898|DRUG|Carboplatin AUC|
48160381|NCT02744898|DRUG|Abraxane|100mg/m2
48160382|NCT03390270|OTHER|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
48688584|NCT04168164|OTHER|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
48688585|NCT04168164|OTHER|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
48003431|NCT03249779|DEVICE|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
48003432|NCT00911261|DRUG|Oxymorphone Extended Release|"* Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
48003433|NCT03995381|OTHER|Decision aids|Shared decision making with decision aids
48003434|NCT02858245|OTHER|No intervention - registry|
48003435|NCT00817167|DEVICE|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
48003436|NCT00817167|DEVICE|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
48160383|NCT05865782|BEHAVIORAL|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
48160384|NCT03178318|PROCEDURE|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
48160385|NCT01048983|DRUG|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
48160386|NCT01048983|DRUG|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
48160387|NCT01048983|DRUG|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
48160388|NCT01048983|DRUG|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
48688586|NCT04168164|OTHER|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
48688587|NCT06091436|DRUG|GenSci094|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg or 100μg (0.5 mL) GenSci094 was administered in the abdominal wall.
48688588|NCT06091436|DRUG|Placebo RecFSH / follitropin alfa|powder-injection, but without the active ingedient, SC injection . Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
48688589|NCT06091436|BIOLOGICAL|Biological: RecFSH / Follitropin alfa (Days 1 to 7)|Daily SC injections with 150IU or 225IU recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
48688590|NCT06091436|DRUG|Placebo GenSci094|Pre-filled syringe containing an identical solution when compared to GenSci094. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
48160389|NCT01048983|BEHAVIORAL|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
48160390|NCT02033499|BEHAVIORAL|SMBG|Blood glucose levels are tested once daily.
48160391|NCT00475787|PROCEDURE|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
48160392|NCT00475787|PROCEDURE|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
48160393|NCT03711825|DRUG|LYN-057|Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
48160394|NCT03711825|PROCEDURE|Imaging Assessment (MRI)|Imaging assessments \[MRI\] will be performed on specified days according to protocol
48688591|NCT06091436|BIOLOGICAL|RecFSH / Follitropin alfa (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose 75IU～300 IU recFSH was administered up to and including the Day of hCG.
48688592|NCT06091436|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
48688593|NCT06091436|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
48688594|NCT06091436|DRUG|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 400 mg/day vaginally, and 40mg/d oral, which continued for at least 6 weeks, or up to menses.
48688595|NCT01843673|PROCEDURE|computed tomography|Undergo FBCT
48688596|NCT01843673|PROCEDURE|cone-beam computed tomography|Undergo dual CBCT
48688597|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian kV OBI
48688598|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
48688599|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian MV OBI
48688600|NCT01843673|PROCEDURE|electronic portal imaging|Undergo EPID imaging
48688601|NCT01843673|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
48688602|NCT01823198|BIOLOGICAL|Aldesleukin|Given SC
48367690|NCT01233284|DRUG|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
48367691|NCT01233284|DRUG|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
48160395|NCT03711825|PROCEDURE|Imaging Assessment (U/S)|Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
48160396|NCT02181400|DEVICE|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
48160397|NCT06065202|DIETARY_SUPPLEMENT|Nutrition Supplement|Total parenteral nutrition (TPN) will be administered within 72 hours of abdominal surgery. Nutritional shakes will be started with a liquid diet and given 3 times a day. This will continue for 4 weeks after discharge.
48160398|NCT06178055|DRUG|KUS121 high dose|Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
48160399|NCT06178055|DRUG|KUS121 low dose|Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
48160400|NCT06178055|DRUG|Sham procedure|Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
48160401|NCT06053047|DEVICE|Bluedrop Monitoring Service (BMS)|Remote use of ThermoVisual monitoring
48367692|NCT01233284|DRUG|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
48688603|NCT01823198|BIOLOGICAL|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
48688604|NCT01823198|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
48688605|NCT01823198|DRUG|Busulfan|Given IV
48688606|NCT01823198|DRUG|Fludarabine Phosphate|Given IV
48688607|NCT01823198|OTHER|Laboratory Biomarker Analysis|Correlative studies
48160402|NCT05065164|DRUG|Denosumab Only Product|denosumab subcutaneous injection /6 months, twice a year
48160403|NCT00523133|DRUG|naltrexone|50 mg naltrexone daily for 3 months
48367693|NCT01233284|DRUG|tiotropium bromide 1.25µg once daily|IMP
48367694|NCT00969462|DRUG|Doxorubicin|measurements of serum Doxorubicin levels
48367695|NCT00422942|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
48688608|NCT01823198|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
48688609|NCT01823198|OTHER|Pharmacological Study|Correlative studies
48688610|NCT02471534|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
48160404|NCT00523133|DRUG|naltrexone|50 mg of naltrexone daily for 6 months
48367696|NCT00422942|DRUG|Methotrexate|10-25mg po weekly
48367697|NCT04761835|BIOLOGICAL|Peanut powder or peanut butter|Commercially available peanut powder or peanut butter.
48367698|NCT02705001|OTHER|all admissions except accident and emergency|No additional intervention, retrospective study
48688611|NCT06110364|DEVICE|Low-Level Tragus Stimulation|Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
48688612|NCT06110364|BEHAVIORAL|Heart Rate Variability- Biofeedback|Heart Rate Variability- Biofeedback will be monitored with a Holter.
48688613|NCT06110364|OTHER|Conventional Medical Therapy|Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
48160405|NCT00523133|BEHAVIORAL|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
48160406|NCT00523133|BEHAVIORAL|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
48160407|NCT00276783|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
48160408|NCT02556918|DRUG|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
48160409|NCT02556918|DRUG|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
48160410|NCT02556918|DRUG|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
48160411|NCT02556918|DRUG|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal"
48003437|NCT06441734|DIAGNOSTIC_TEST|cbc serum ferritin serum iron|by using sample of blood to do cbc and serum ferritin and serum iron during 1year
48003438|NCT02499393|DRUG|Magnesium Sulfate|intravenous infusion of magnesium sulphate
48160412|NCT02556918|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro"
48160413|NCT02556918|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart"
48160414|NCT05762978|DEVICE|In-Check Dial|Patient will have their NIF measured with In-Check Dial
48160415|NCT05762978|DEVICE|Inhaler Device|Children will use inhaler per standard of care.
48160416|NCT04501107|DRUG|Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Administration of IMP1 during a 12-hour euglycaemic clamp.
48160417|NCT04501107|DRUG|Administration of Ready-to-use BioChaperone insulin lispro (IMP2)|Administration of IMP2 during a 12-hour euglycaemic clamp.
48367699|NCT04480359|DRUG|Bawei Shenqi Pill|5.1g, once a day, 3month, oral
48367700|NCT04480359|DRUG|Bawei Shenqi Pill placebo|5.1g, once a day, 3month, oral
48367701|NCT04480359|DRUG|Meloxicam|7.5mg, once a day, 3 month, oral
48688614|NCT04036201|DRUG|Bupivacaine|peribulbar block
48688615|NCT01977196|BIOLOGICAL|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
48688616|NCT02160249|BEHAVIORAL|Community-based rehabilitation|
48688617|NCT02160249|OTHER|Facility based care|
48688618|NCT03311581|DRUG|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
48688619|NCT03311581|DEVICE|Sevoflurane|sevoflurane inhalation 2\~4%
48688620|NCT01508377|BEHAVIORAL|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
48729810|NCT02145351|DEVICE|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
48729811|NCT02145351|DEVICE|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
48688621|NCT01508377|BEHAVIORAL|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
48688622|NCT00392587|DRUG|GW856553|
48160418|NCT04501107|DRUG|Administration of US-approved Humalog® (IMP3)|Administration of IMP3 during a 12-hour euglycaemic clamp.
48160419|NCT04501107|DRUG|Administration of EU-approved Humalog® (IMP4)|Administration of IMP4 during a 12-hour euglycaemic clamp.
48160420|NCT02897063|DRUG|Droxidopa|Single oral dose 300 mg
48160421|NCT02897063|DRUG|Midodrine|Single oral dose 10 mg
48160422|NCT02897063|DRUG|Placebo|sugar pill
48160423|NCT02264717|PROCEDURE|SPECT|Patients are randomized to either SPECT or Cardiac MRI
48160424|NCT02264717|PROCEDURE|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
48160425|NCT01295775|DRUG|sulodexide|"A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A."
48160426|NCT01601639|DEVICE|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
48688623|NCT03302689|DRUG|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
48688624|NCT03302689|DRUG|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
48160427|NCT01601639|DEVICE|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
48160428|NCT00393198|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
48688625|NCT06554977|OTHER|Laboratory|CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
48160429|NCT00393198|DRUG|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
48160430|NCT00393198|DRUG|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
48160431|NCT01032200|DRUG|Armodafinil|Given orally
48160432|NCT01032200|OTHER|placebo|Given orally
48160433|NCT00306735|DRUG|Palonosetron|
48160434|NCT05987839|PROCEDURE|robotic system|Total knee arthroplasty assisted by knee navigation and positioning system
48367702|NCT00650689|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
48367703|NCT00650689|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
48367704|NCT03792230|BEHAVIORAL|Video|Video group receive body mechanic education via CD material,
48367705|NCT03792230|BEHAVIORAL|Brochure|Brochure group receive body mechanic education via written material (brochure)
48160435|NCT00144716|DEVICE|Insect Repellent plus Insecticide Treated Net|
48160436|NCT06402916|DIETARY_SUPPLEMENT|Blueberry drink|Blueberry drink equivalent to 240g fresh blueberries.
48160437|NCT06402916|DIETARY_SUPPLEMENT|Placebo drink|Drink containing no active ingredient.
48160438|NCT06453161|OTHER|Post-operative acute kidney injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
48160439|NCT00156975|DRUG|Capecitabine|
48160440|NCT00156975|DRUG|Oxaliplatin|
48160441|NCT05276011|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
48160442|NCT05276011|BIOLOGICAL|Placebo Control|2 mL normal saline injection
48160443|NCT05358184|DEVICE|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
48185166|NCT04833309|PROCEDURE|pharmacopuncture therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
48367706|NCT00208702|DRUG|Triiodothyronine|
48160444|NCT02423252|BEHAVIORAL|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
48160445|NCT02423252|OTHER|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
48160446|NCT02420938|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
48160447|NCT02420938|DRUG|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
48160448|NCT01116453|PROCEDURE|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
48160449|NCT01116453|PROCEDURE|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
48160450|NCT04881396|BIOLOGICAL|Evaluation of the immunogenicity of the vaccine in haemodialysis patients|The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
48160451|NCT04054193|DRUG|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
48160452|NCT04054193|DRUG|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; \[5-HT\]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
48160453|NCT04054193|DRUG|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
48160454|NCT04458012|DIAGNOSTIC_TEST|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
48160455|NCT01631799|DEVICE|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
48160456|NCT01631799|DEVICE|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
48160457|NCT05360290|DEVICE|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
48160458|NCT05325658|OTHER|FEES, treatment with modified diet, electrical swallowing muscle stimulation.|Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
48160459|NCT00260702|DRUG|Omalizumab (Xolair)|
48160460|NCT04402632|PROCEDURE|Surgical Management|SDH Evacuation (Control)
48688626|NCT05474703|OTHER|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
48160461|NCT04402632|DEVICE|Surgical Management + Treatment|SDH Evacuation + Onyx™ LES Embolization
48160462|NCT04402632|OTHER|No Treatment|Observation Only (Control)
48160463|NCT04402632|DEVICE|Treatment|Onyx™ LES Embolization
48160464|NCT02125656|OTHER|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
48367707|NCT00208702|OTHER|Placebo|
48688627|NCT03529617|OTHER|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
48688628|NCT00230776|DRUG|pregabalin|
48688629|NCT00230776|DRUG|placebo|
48688630|NCT05090163|OTHER|PREP Plus|Group based exercise in addition to PREP exercises
48160465|NCT06646354|DRUG|Ezetimibe/Rosuvastatin/Candesartan/Amlodipine|PO, QD, 8 weeks
48160466|NCT06646354|DRUG|Candesartan/Amlodipine|PO, QD, 8 weeks
48367708|NCT00208702|DRUG|Sertraline|
48522618|NCT02811965|OTHER|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
48367709|NCT01139645|DRUG|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
48003439|NCT00914030|OTHER|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
48003440|NCT00084669|DRUG|venlafaxine|
48003441|NCT00084669|DRUG|zolpidem tartrate|
48688631|NCT05090163|OTHER|PREP|Group based exercise
48688632|NCT05187897|BEHAVIORAL|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
48003442|NCT00084669|PROCEDURE|management of therapy complications|
48160467|NCT06646354|DRUG|Candesartan/Rosuvastatin/Ezetimibe|PO, QD, 8 weeks
48160468|NCT00359385|DRUG|Alendronate 70mg weekly|70mg weekly
48513457|NCT02680951|DRUG|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
48513458|NCT00467324|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
48688633|NCT04299152|COMBINATION_PRODUCT|Stem Cell Educator-Treated Mononuclear Cells Apheresis|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
48688634|NCT04631198|OTHER|Thoracoabdominal rebalancing|the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
48688635|NCT01555970|DRUG|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
48003443|NCT05785364|DEVICE|Mpact 3D metal MONOCER cup|adult patients requiring a total hip arthroplasty under 75 years old, will receive the Mpact 3D metal cup, as acetabular sheel device implanted
48003444|NCT02755376|BIOLOGICAL|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
48003445|NCT02755376|BIOLOGICAL|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
48160469|NCT06045364|DRUG|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
48160470|NCT06045364|DRUG|Anisodamine|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
48160471|NCT02502487|PROCEDURE|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
48160472|NCT02502487|DRUG|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
48160473|NCT02502487|DRUG|Tetracaine|1% Tetracaine gel instilled into urethra
48513459|NCT02802904|OTHER|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
48522619|NCT02811965|DEVICE|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
48688636|NCT01555970|DRUG|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
48688637|NCT06345261|DRUG|DiphenhydrAMINE 50 Mg/mL Injectable Solution|injection of Diphenhydramine 50 Mg/mL
48688638|NCT06345261|DRUG|Saline|injection of saline
48003446|NCT02755376|PROCEDURE|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
48003447|NCT01221961|DEVICE|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
48003448|NCT04518007|DEVICE|hyperbaric oxygen therapy|"The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes.~Investigational product:~Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sago l Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel."
48028566|NCT05263388|DRUG|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE is 15 μg fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose can be increased or decreased by 5 μg based on the subject's response. The minimum REKOVELLE dose is 5 μg and the maximum REKOVELLE is 20 μg. Subjects can be treated for a maximum of 20 days.
48160474|NCT02449993|DEVICE|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
48513460|NCT02802904|OTHER|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
48003449|NCT03389711|COMBINATION_PRODUCT|DMARD´s and multidisciplinary treatment|"At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.~Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.~Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II)."
48003450|NCT00228345|PROCEDURE|Optical coherence tomography,Fluorescein angiography|
48003451|NCT05009394|PROCEDURE|Targeted Muscle Reinnervation (TMR)|Surgical procedure used to rewire injured proximal nerves to motor nerves directly innervating an otherwise redundant target muscle.
48003452|NCT05009394|PROCEDURE|Regenerative Peripheral Nerve Interface (RPNI)|Surgical procedure where the the nerve is split into fascicles and wrapped in free muscle grafts.
48003453|NCT05009394|PROCEDURE|Standard neuroma treatment, neuroma excision, and muscle burying|Surgical procedure where the neuroma is excised and the nerve stump is buried in an adjacent deep muscle.
48688639|NCT02680938|DRUG|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
48003454|NCT02155335|DRUG|Prefilled Syringe delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
48003455|NCT02155335|DRUG|Smartject Device delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
48003456|NCT03464864|DRUG|Treprostinil Inhalation Powder|Single ascending dose
48003457|NCT02362165|DRUG|Cyclophosphamide|500mg/d,once-weekly,per oral.
48003458|NCT02362165|DRUG|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
48003459|NCT02362165|DRUG|Dexamethasone|40mg/d,once-weekly,per oral
48513461|NCT02802904|OTHER|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (\~50g of test fats, brownies (\~15g test fat each) for breakfast and 4 pieces cookies (\~5g test fat each) with low fat palm olein based background diet daily.
48513462|NCT02964572|DRUG|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
48688640|NCT02680938|DRUG|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
48688641|NCT03316716|PROCEDURE|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
48688642|NCT05290506|DRUG|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
48688643|NCT00301262|DRUG|Viagra (Sildenafil citrate)|
48688644|NCT05245682|DRUG|Tolinapant|Given PO
48688645|NCT05245682|RADIATION|Radiation Therapy|Undergo radiation therapy
48688646|NCT02853552|DRUG|Misoprostol|800mcg misoprostol taken sublingually
48688647|NCT03823586|DIAGNOSTIC_TEST|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
48688648|NCT01713582|DRUG|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
48688649|NCT00100568|DRUG|Efavirenz|600 mg tablet taken orally daily
48003460|NCT02362165|DRUG|Doxorubicin|9mg/㎡,d1-4
48160475|NCT00730210|DRUG|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
48160476|NCT00730210|DRUG|b:placebo|100 microgram placebo subcutaneous a day for 6 months
48160477|NCT05204316|OTHER|Digital Analysis of Speech|Recordings will be transcribed manually to written digital text formats, on which NLP tools such as tokenisation and lexical analysis will be performed.
48160478|NCT01022671|DRUG|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
48160479|NCT05113212|DEVICE|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
48160480|NCT05113212|DEVICE|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
48160481|NCT00761618|PROCEDURE|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
48160482|NCT00761618|PROCEDURE|IPC Placement|IPC placed in chest cavity to drain excess fluid
48160483|NCT00761618|RADIATION|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
48160484|NCT02894385|DRUG|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
48160485|NCT04457245|PROCEDURE|Computed Tomography|Undergo whole body PET/CT
48160486|NCT04457245|OTHER|Fluorine F 18 DCFPyL|Given IV
48160487|NCT04457245|PROCEDURE|Positron Emission Tomography|Undergo whole body PET/CT
48160488|NCT04457245|RADIATION|Radiation Therapy|Undergo standard of care definitive radiation therapy
48688650|NCT00100568|DRUG|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
48003461|NCT03416400|OTHER|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
48160489|NCT06115239|OTHER|Questionnaires|The patients will fulfill the EORTC-LC29 and HADS questionnaires in 5 different moments.
48160490|NCT06646445|DRUG|Pembrolizumab 200mg IV q3w day 1 of 21-day cycle|Pembrolizumab 200 mg via a 30-minute IV infusion q3w on Day 1 of each 21-day cycle; 8 cycles ± 9 additional cycles (17 cycles in total).
48160491|NCT06646445|PROCEDURE|Watch-and-wait approach|"Watch-and-wait strategy:~* TAP-CT scan every 3 months (± 7 days) for 2 years from inclusion.~* Colonoscopy with biopsies at months 3, 6, 12, 24."
48160492|NCT06646445|PROCEDURE|Surgery|Standard of care surgery performed with a maximal delay of 21 days (3 weeks) from inclusion.
48160493|NCT06646445|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) will be prescribed according to the current guidelines, at the investigator's discretion.
48160494|NCT03786783|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
48160495|NCT03786783|DRUG|Carboplatin|Given IV
48160496|NCT03786783|DRUG|Cisplatin|Given IV
48160497|NCT03786783|DRUG|Cyclophosphamide|Given IV
48160498|NCT03786783|DRUG|Dexrazoxane|Given IV
48160499|NCT03786783|BIOLOGICAL|Dinutuximab|Given IV
48513463|NCT02964572|DRUG|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
48688651|NCT04949516|DRUG|Aspirin|Aspirin is discontinued the day after drug-eluting stent implantation
48688652|NCT04949516|DRUG|Colchicine|Colchicine is started the day after drug-eluting stent implantation
48160500|NCT03786783|DRUG|Doxorubicin|Given IV
48160501|NCT03786783|DRUG|Etoposide|Given IV
48160502|NCT03786783|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48160503|NCT03786783|DRUG|Isotretinoin|Given PO
48160504|NCT03786783|DRUG|Melphalan|Given IV
48160505|NCT03786783|BIOLOGICAL|Sargramostim|Given SC
48160506|NCT03786783|DRUG|Thiotepa|Given IV
48160507|NCT03786783|DRUG|Topotecan|Given IV
48160508|NCT03786783|DRUG|Vincristine|Given IV
48367710|NCT03152643|PROCEDURE|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
48160509|NCT01811823|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
48160510|NCT06212765|DRUG|L-citrulline|to take 1 pod a day for 45 days
48160513|NCT05952583|DIAGNOSTIC_TEST|Ultrasound|Additional ultrasound measurements during pregnancy
48160514|NCT00562484|BIOLOGICAL|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
48160515|NCT00562484|BIOLOGICAL|Placebo|Placebo
48185167|NCT04833309|PROCEDURE|physical therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
48522620|NCT02811965|DEVICE|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
48688653|NCT06386055|BEHAVIORAL|Active exercise|The intervention group will be provided with training courses for 3 months.
48688654|NCT00002032|DRUG|Rifabutin|
48688655|NCT00106119|DRUG|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
48688656|NCT02661737|DEVICE|YVOIRE volume s|
48688657|NCT00348101|DRUG|Combined therapy with enoximone and esmolol|
48688658|NCT05256888|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
48003462|NCT04488328|OTHER|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks|patients received the routine medical treatment in addition to pulsed magnetic therapy and moderate-intensity aerobic exercise for 12 weeks(3 sessions/ week)
48003463|NCT01787578|DRUG|Sobetirome|50 mcg or 100 mcg once-daily oral
48003464|NCT06105385|OTHER|Suboccipital Myofascial Release Technique|With the patient in a supine position, the therapist sits behind the patient with his or her forearms on the treatment table. The therapist places his fingers between the occiput and axis, with his fingers in semi-flexion (2nd, 3rd and 4th fingers), and continues to hold his hands on the occiput until relaxation is achieved in the suboccipital muscles. A light traction is applied at the end of the technique. Average application time is 4-5 minutes.
48003465|NCT06000865|BEHAVIORAL|Action video game training|20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)
48003466|NCT06000865|BEHAVIORAL|Conventional physical training|20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
48003467|NCT03198377|DEVICE|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
48003468|NCT03198377|DEVICE|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
48003469|NCT03198377|DEVICE|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
48003470|NCT03198377|DEVICE|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
48003471|NCT05111132|DIAGNOSTIC_TEST|Fluid challenge (cristalloïd, NaCl 0,9%)|A fluid challenge according to group will be administrated by infusion pump
48003472|NCT01072201|DRUG|Triclosan and Fluoride|Brush twice daily
48003473|NCT01072201|DRUG|Fluoride|Brush twice daily
48003474|NCT03219697|BEHAVIORAL|Parenting education program|8-week parent/caregiver education program, followed by two booster sessions. You and/or your partner will attend weekly parenting sessions which will take place either at the office of your child's primary care provider or virtually. Our Toronto Public Health Nurse, will arrange 2 home visits/virtual visits with you and your family along with 4 coaching calls during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions for your family, and making connections in your community that you find helpful such as recreational or nutrition programs or other supports for your family.
48003475|NCT03323528|DRUG|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
48003476|NCT03323528|DRUG|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
48003477|NCT00613509|BIOLOGICAL|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
48003478|NCT00613509|BIOLOGICAL|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
48688659|NCT05256888|BEHAVIORAL|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
48003479|NCT03950518|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
48003480|NCT03950518|DRUG|Arginine hydrochloride|AHC,12mg/d AH,40g/d
48003481|NCT03950518|DRUG|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
48003482|NCT04173143|DEVICE|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
48185168|NCT04371120|DIAGNOSTIC_TEST|BICS Q|assess perceived self-efficacy (PSE) regarding a person's brain injury and proved responsive to treatment effects in the original BICS study.15-16 Specifically, it measures a person's perceptions about his or her ability to both understand the effects of brain injury, as well as, perceived capability of managing BI-related challenges. As the literature suggests, it is important to utilize a measure that would assess PSE specific to the person's challenge, rather than a general PSE scale.
48513464|NCT06176651|DRUG|Miebo|Subjects will be instructed to use the Miebo eye drop four times per day in both eyes during their participation in clinical trial. The subjects will be required to remove their contact lenses prior to instillation of the Miebo eye drop and must wait 30 minutes before reinserting their contact lenses.
48513465|NCT01722201|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
48688660|NCT02905539|DRUG|Iron Isomaltoside 1000|
48688661|NCT02905539|DRUG|Ferric Carboxymaltose|
48160516|NCT06196229|OTHER|Action Observation Therapy|"During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted .~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks"
48160517|NCT06196229|OTHER|Action Observation Therapy combined with Virtual Reality|"In the VRT group, participants will execute VR-based activities conducted by the same therapist.~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions"
48003483|NCT04173143|OTHER|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
48160518|NCT03340818|OTHER|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
48160519|NCT03340818|OTHER|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
48160520|NCT04132388|OTHER|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
48160521|NCT04132388|DRUG|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
48160522|NCT02657018|DEVICE|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
48160523|NCT02657018|OTHER|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
48688662|NCT03680833|PROCEDURE|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
48003484|NCT00348556|DRUG|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
48003485|NCT05155384|OTHER|Pain Neuroscience Education|main topics of pain neuroscience education; neurophysiology of the nervous system, protective mechanism of pain, acute pain formation and chronic pain, factors that increase/reduce pain, central sensitization mechanism, neuroplasticity and treatment strategies in chronic pain.
48003486|NCT05155384|OTHER|Relaxation exercises|Relaxation exercises are a training based on deep relaxation techniques and visual imagery. Relaxation exercises will be applied at the end of the training sessions.
48003487|NCT05155384|OTHER|Cognition target exercise|Cognition target exercises are a time-based approach that is not symptom-conditioned (not based on fatigue or pain). It includes functional and dynamic exercises.
48688663|NCT02725450|BEHAVIORAL|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
48688664|NCT02725450|BEHAVIORAL|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
48688665|NCT05894356|OTHER|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
48003488|NCT05155384|OTHER|Pelvic floor stretching exercises|Pelvic floor stretching exercises; consists of stretching exercises involving the pelvic floor muscles and surrounding group muscles (such as piriformis, hamstring, adductor group muscles and lumbar extensors).
48003489|NCT05155384|DEVICE|Transcutaneous electrical nerve stimulation|It will be used with superficial electrodes attached to the suprapubic region of the patients for 20 minutes in each session.
48160524|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
48003490|NCT05222113|DRUG|Remdesivir|The patients, based on their clinical condition, got remdesivir OR favipiravir at least five days of treatment. The WHO ordinal scale was used to assess patients' clinical progress in the first and second weeks.
48003491|NCT00422032|DRUG|Clofarabine|"Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days"
48003492|NCT00414388|DRUG|Sorafenib|400mg twice daily
48003493|NCT03602937|DIETARY_SUPPLEMENT|Renastep|Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
48003494|NCT04464681|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
48003495|NCT04464681|DRUG|Placebo|Placebo: M201-A Placebo Route of administration: continuous intravenous injection
48003496|NCT02617550|DRUG|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
48688666|NCT04661423|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
48688667|NCT05586906|DEVICE|Multiple Breath Washout (MBW) tests|LCI measurements (EXHALYZER® D with Nitrogen Washout System, ECO Medics AG) will be performed every month during follow-up beginning 3 months after lung transplantation.
48688668|NCT05286476|COMBINATION_PRODUCT|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
48003497|NCT02617550|DRUG|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].
48003498|NCT02617550|DRUG|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41
48160525|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
48003499|NCT03160053|DEVICE|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
48688669|NCT05286476|OTHER|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
48688670|NCT03177512|BEHAVIORAL|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
48688671|NCT04129983|COMBINATION_PRODUCT|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
48688672|NCT01032603|PROCEDURE|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
48688673|NCT01032603|PROCEDURE|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
48688674|NCT00652743|BIOLOGICAL|Pandemic influenza vaccine GSK1562902A|IM administration
48003500|NCT01399593|DRUG|Eculizumab|
48160526|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
48160527|NCT01502371|DRUG|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
48688675|NCT03800537|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
48688676|NCT03423238|OTHER|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
48688677|NCT03423238|BEHAVIORAL|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
48688678|NCT03423238|OTHER|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
48003501|NCT04594850|BIOLOGICAL|Cellgram-ED|Patients will receive single injection of Cellgram-ED(mesenchymal stem cell) intracavernously.
48160528|NCT01502371|DRUG|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
48160529|NCT01502371|DRUG|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
48160530|NCT04581356|DRUG|Voxelotor|daily voxelotor 1500mg oral medication
48160531|NCT00762502|DEVICE|senofilcon A toric contact lens|soft contact lens
48160532|NCT00762502|DEVICE|balafilcon A toric contact lens|soft contact lens
48160533|NCT03489837|DRUG|Levotuss|oral taken
48160534|NCT03353155|BEHAVIORAL|Usual Care|
48160535|NCT03353155|BEHAVIORAL|CareHub|
48160536|NCT00460577|DRUG|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
48160537|NCT00460577|DRUG|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
48160538|NCT00517270|DRUG|Rabeprazole 20mg twice daily|
48160539|NCT06089083|OTHER|Physical function assessment|Physical assessments of frailty will be conducted in person.
48160540|NCT06089083|OTHER|Self-reported Assessments and Questionnaires|Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
48160541|NCT06089083|PROCEDURE|Surgery (Standard of Care, Non-Interventional)|Surgical data will be reviewed via medical record
48160542|NCT05153499|BIOLOGICAL|CP101|CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).
48160543|NCT05153499|OTHER|Placebo|Placebo
48160544|NCT06143488|PROCEDURE|Endovascular therapy|"Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
48160545|NCT06143488|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
48160546|NCT00765921|DRUG|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
48160547|NCT06302010|BEHAVIORAL|Stress Ball Intervention|The stress ball has a soft plastic or silicone structure that can be held comfortably. Each ball is approximately 6 cm in diameter, in different colors, and is a soft toy that can be squeezed and manipulated with fingers to relieve stress and muscle tension and exercise the muscles (Apaydin Cirik et al., 2023). Squeezing a stress ball is a distraction and relaxation method. It is thought that squeezing a stress ball may be advantageous for reducing anxiety, considering its reliability, easy accessibility, effectiveness, low cost, sustainability, non-pharmacological and non-invasive properties.
48160548|NCT01828476|DRUG|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
48160549|NCT01828476|DRUG|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
48003502|NCT01170728|DEVICE|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
48003503|NCT01939587|DRUG|PBF-680 5 mg|
48003504|NCT01939587|DRUG|PBF-680 20 mg|
48003505|NCT01939587|DRUG|Placebo|
48003506|NCT00747435|DEVICE|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
48003507|NCT04238728|DEVICE|Silverlon|silver nylon dressing will be applied daily
48003508|NCT05358275|DEVICE|surgical cutting guide with piezo|3D planned lid surgery
48003509|NCT05358275|OTHER|control|ordinary cyst enucleation
48003510|NCT01755416|DRUG|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
48160550|NCT01828476|DRUG|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
48160551|NCT05655624|OTHER|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
48160552|NCT05655624|OTHER|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
48160553|NCT04063267|OTHER|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
48160554|NCT04063267|OTHER|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
48160555|NCT01359514|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
48160556|NCT01359514|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
48160557|NCT03813602|DRUG|Cannabis Sativa|750 mg cannabis cigarette with 12.5% THC
48160558|NCT00355602|DRUG|Cefuroxime|
48160559|NCT00355602|DRUG|Ciprofloxacin|
48160560|NCT00355602|DRUG|Clarithromycin|
48160561|NCT00355602|DRUG|Cotrimoxazole|
48160562|NCT00355602|DRUG|Coamoxiclav|
48160563|NCT00355602|DRUG|metronidazole|
48160564|NCT00355602|DRUG|neomycin|
48160565|NCT00355602|DRUG|rifaximin|
48160566|NCT00355602|DRUG|Vancomycin|
48160567|NCT00355602|DRUG|Doxycycline|
48160568|NCT06138132|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
48160569|NCT06138132|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
48160570|NCT01072396|DRUG|Tiotropium|double blind randomized crossover
48160571|NCT01072396|DRUG|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
48160572|NCT05406206|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
48513466|NCT01722201|DRUG|Risperidone|1 mg tablet once a day
48688679|NCT03423238|DIETARY_SUPPLEMENT|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, \<30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
48688680|NCT03423238|BEHAVIORAL|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
48688681|NCT03423238|OTHER|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
48688682|NCT03423238|OTHER|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
48688683|NCT04892524|OTHER|Virtual multidisciplinary review|The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
48688684|NCT01581229|PROCEDURE|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
48688685|NCT01581229|PROCEDURE|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
48688686|NCT05083611|OTHER|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
48688687|NCT06221761|DRUG|not using antibiotic|no antibiotic application
48688688|NCT06221761|DRUG|using antibiotic|antibiotic application
48688689|NCT00140153|DRUG|testosterone gel (Androgel)|
48688690|NCT04230265|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion over 3 days
48688691|NCT04230265|DRUG|Fludarabine (Non-IMP)|Intravenous infusion over 3 days
48688692|NCT04230265|DRUG|TM123 (IMP)|Intravenous Infusion for 20 days
48688693|NCT04230265|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
48688694|NCT00373646|DRUG|Thalidomide, Pharmion|200 mg p.o. daily
48688695|NCT04923633|DEVICE|Quantifiable Soft Tissue Manipulation (QSTM)|Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
48688696|NCT04492241|DRUG|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
48688697|NCT04492241|DRUG|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
48688698|NCT03915158|PROCEDURE|bariatric surgery|sleeve gastrectomy
48688699|NCT03281031|PROCEDURE|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
48688700|NCT00828802|DRUG|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
48160573|NCT05406206|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W
48513467|NCT00002031|DRUG|Dinitrochlorobenzene|
48688701|NCT01706731|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
48688702|NCT01706731|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
48688703|NCT01762774|DRUG|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
48688704|NCT01762774|DRUG|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
48688705|NCT03809078|DRUG|68Ga RM2|PET radiopharmaceutical
48688706|NCT03809078|DRUG|68Ga-PSMA-11|PET radiopharmaceutical
48688707|NCT03809078|DEVICE|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
48688708|NCT03678337|OTHER|observational cohort with plasma samples|plasma samples
48513468|NCT02679638|OTHER|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
48513469|NCT02679638|OTHER|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
48513470|NCT04899544|BEHAVIORAL|Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)|Pivotal Response Treatment in autism center.
48688709|NCT00422448|GENETIC|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
48688710|NCT02107625|BEHAVIORAL|Diet A i.e. Low FODMAP diet|
48003511|NCT01755416|DRUG|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
48513471|NCT04899544|BEHAVIORAL|Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H)|Pivotal Response Treatment in home environment.
48688711|NCT02107625|BEHAVIORAL|Diet B, i.e. Traditional IBS diet|
48688712|NCT03617601|DIAGNOSTIC_TEST|MET|Testing of the metabolic equivalent of task before aortic procedure
48688713|NCT01127984|DRUG|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
48688714|NCT01127984|PROCEDURE|drainage system|application of vacuum drainage system
48688715|NCT00129090|DRUG|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
48688716|NCT04884750|BEHAVIORAL|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
48688717|NCT05662540|DEVICE|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
48688718|NCT01135888|DEVICE|Skin cooling devices|Cooling vest and cooling bandana
48688719|NCT01146184|DEVICE|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
48688720|NCT04166773|DRUG|Tirzepatide|Administered SC
48688721|NCT04166773|DRUG|Placebo|Administered SC
48688722|NCT00791050|DEVICE|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
48003512|NCT03383328|DRUG|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
48003513|NCT03383328|DRUG|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
48003514|NCT03383328|DRUG|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
48003515|NCT03383328|DRUG|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
48688723|NCT04734483|DIAGNOSTIC_TEST|spirometry|spirometry
48688724|NCT04734483|RADIATION|MRI and CT|MRI and CT
48003516|NCT03383328|DRUG|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
48688725|NCT04734483|OTHER|Laryngoscopy|laryngoscopy
48688726|NCT04734483|OTHER|electromyography|electromyography
48688727|NCT04154644|DEVICE|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
48688728|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
48688729|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
48688730|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
48688731|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
48688732|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
48688733|NCT00396786|DRUG|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
48160574|NCT05828602|OTHER|Conventional treatment|Conventional treatment
48513472|NCT02214537|OTHER|MACS|
48688734|NCT02266147|DRUG|SD-101|
48688735|NCT02266147|RADIATION|Radiation therapy|
48688736|NCT03144128|DIETARY_SUPPLEMENT|Vitamin D|5,000IU vitamin D given daily for 12 weeks
48688737|NCT03144128|DIETARY_SUPPLEMENT|Placebo|Placebo capsules given daily for 12 weeks
48688738|NCT04779450|OTHER|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
48688739|NCT04779450|OTHER|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
48688740|NCT00778076|DEVICE|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
48688741|NCT00778076|DEVICE|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
48688742|NCT00002509|BIOLOGICAL|filgrastim|
48688743|NCT00002509|DRUG|carboplatin|
48688744|NCT00002509|DRUG|cyclophosphamide|
48688745|NCT00002509|DRUG|etoposide|
48688746|NCT00002509|DRUG|mesna|
48688747|NCT00002509|PROCEDURE|autologous bone marrow transplantation|
48688748|NCT00002509|PROCEDURE|peripheral blood stem cell transplantation|
48688749|NCT01661751|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
48688750|NCT01661751|BIOLOGICAL|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
48160575|NCT05828602|OTHER|TeleRehabilitation|TeleRehabilitation
48160576|NCT03314233|PROCEDURE|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
48688751|NCT05877937|OTHER|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
48688752|NCT01956747|PROCEDURE|venapunction|
48688753|NCT01956747|PROCEDURE|bone marrow punction|
48688754|NCT05084079|DRUG|CSII with formula-based initial insulin regimen|Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
48688755|NCT05084079|DRUG|CSII with weight-based initial insulin regimen|TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
48688756|NCT03760198|DRUG|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
48688757|NCT03760198|OTHER|Placebo|normal saline is injected intradermally to each axilla
48688758|NCT02434653|OTHER|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
48688759|NCT02434653|OTHER|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
48003517|NCT04484324|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
48003518|NCT03534856|BEHAVIORAL|Mindfulness meditation|Short guided mindfulness meditations were provided on an MP3 player.
48003519|NCT00922571|PROCEDURE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
48003520|NCT00922571|DEVICE|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
48160577|NCT04012099|DRUG|BMT101|Intradermal injection to each of 3 dose-groups.
48160578|NCT04351100|DRUG|Diacerein|Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
48185169|NCT04849377|RADIATION|RT 50 Gy|Radiation Therapy (RT) 50 GY
48160579|NCT02669888|DRUG|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
48160580|NCT02669888|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
48160581|NCT04573257|OTHER|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
48688760|NCT04031248|DEVICE|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
48688761|NCT04031248|OTHER|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
48688762|NCT05556083|DRUG|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
48688763|NCT05556083|DRUG|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
48688764|NCT02517255|DEVICE|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
48688765|NCT02467192|DEVICE|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
48688766|NCT00002848|PROCEDURE|psychosocial assessment and care|
48688767|NCT00002848|PROCEDURE|quality-of-life assessment|
48688768|NCT03440463|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
48688769|NCT03440463|BEHAVIORAL|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
48688770|NCT03440463|BEHAVIORAL|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
48003521|NCT03751085|DEVICE|AW frame|AW stereotactic frame for intracranial lesion biopsy
48003522|NCT05909371|OTHER|exercise|Application of two different exercises to liver transplant individuals.
48160582|NCT06646705|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
48160583|NCT01847599|OTHER|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
48160584|NCT00729885|DEVICE|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
48160585|NCT00729885|DEVICE|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
48160586|NCT03941990|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
48160587|NCT03941990|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
48160588|NCT05343988|DEVICE|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|PENFS device will be used to treat children with paroxysmal sympathetic hyperactivity (PSH) due to acute severe brain injury.
48160589|NCT00169962|DRUG|rhDNAse (pulmozyme)|
48185170|NCT04849377|RADIATION|RT 54 GY|Radiation Therapy (RT) 54 GY
48003523|NCT01492634|OTHER|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO \< -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO \> 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
48003524|NCT02769702|DRUG|Acthar|Acthar 80 IU SC twice a week
48003525|NCT03433664|DEVICE|CO2 laser|Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
48003526|NCT00382811|DRUG|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
48160590|NCT03861429|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
48160591|NCT01618227|DEVICE|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
48160592|NCT01618227|PROCEDURE|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
48160593|NCT01718613|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
48160594|NCT01718613|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
48160595|NCT05771558|DEVICE|Tailored Lighting Intervention (TLI)|The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
48003527|NCT00382811|DRUG|carboplatin|AUC=2 weekly in 28 day cycles
48003528|NCT00382811|DRUG|placebo|every 8 hours daily in 28 day cycles
48003529|NCT03149237|BEHAVIORAL|Couples-based services|Couples-based services, including treatment, counseling and peer mentoring in the community.
48003530|NCT04618120|OTHER|Virtual reality-based exercise|"Virtual reality-based exercises with Microsoft Xbox 360 Kinect and breathing exercises.~Patient education"
48003531|NCT04618120|OTHER|Exercise|Shoulder range of motion, stretching, posture and breathing exercises. Patient education
48003532|NCT05932186|PROCEDURE|Interscalene brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position. Interscalene block will be done as follows. US probe will be placed slightly lower to the level of the cricoid cartilage, followed by scanning of the neck to search for C5 and C6 nerve roots enclosed between the anterior and middle scalene muscles. The needle will be introduced in-plane from lateral to medial through the middle scalene muscle until the tip enters the brachial plexus sheath between the C5 and C6 roots, where LA will be injected.~Patients will be transported to the operation room where general anaesthesia will be induced with tracheal intubation Fentanyl (0.5 μg/kg) will be given to maintain the heart rate and mean blood pressure 20% lower than preinduction values. Intravenous 1 gram paracetamol and 8 mg dexamethasone will be given to all patients as part of multimodal analgesia"
48160596|NCT05771558|DEVICE|Actigraph|An actigraph is a wrist worn devices that measures rest and activity.
48003533|NCT05932186|PROCEDURE|Upper trunk brachial plexus block combined with general anesthesia|"Baseline diaphragmatic assessment will be performed before the nerve block in the sitting position like the the ISB group~Upper trunk will be visualized distal to the convergence of the C5 and C6 nerve roots but proximal to the departure of the suprascapular nerve (This nerve is a small hypoechoic circle that depart the lateral aspect of the upper trunk and courses posterolateral under the omohyoid muscle). The needle will be introduced in-plane from lateral to medial under the deep cervical fascia and through a very small portion of the middle scalene muscle, until the needle tip lies adjacent to the upper trunk, LA will be distributed below and above the upper trunk. Scanning for the upper trunk can be started from the supraclavicular fossa and moving proximal or opposite to cricoid cartilage and moving distal.~The following steps will be done as in the ISB group"
48160597|NCT04133259|DRUG|Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody|Treatment of CHB patient with HLX10
48160598|NCT04133259|DRUG|Nucleoside/nucleotide analogues|Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
48160599|NCT00767286|DRUG|flutamide|
48160600|NCT00767286|DRUG|goserelin acetate|
48003534|NCT05625035|DRUG|Lianhua Qingwen capsules|Lianhua Qingwen capsules: 4 capsules once, three times daily
48003535|NCT01760148|DRUG|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
48160601|NCT00767286|RADIATION|low-LET cobalt-60 gamma ray therapy|
48160602|NCT00767286|RADIATION|low-LET photon therapy|
48160603|NCT06540248|DEVICE|Ialuadapter|minimally invasive syringe device for bladder catherization
48160604|NCT00579657|OTHER|control diet, supported by dietary supplement twice daily|control diet, see above
48160605|NCT00579657|OTHER|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
48160606|NCT00579657|OTHER|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
48160607|NCT00579657|OTHER|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
48160608|NCT02813447|DRUG|Sertraline|
48160609|NCT02813447|DRUG|Placebo|
48003536|NCT06065826|OTHER|Assessment|All subjects will be assessed for FHP by taking a lateral view picture to calculate the CVA using the Kinovea software. Each subject with FHP will be examined for myofascial trigger points done by the therapist finger to palpate bilaterally on tender nodules in masticatory and neck muscles. Then using a pressure algometer, the PPT value will be scored for each trigger in each muscle bilaterally. Masticatory muscle endurance will be measured by asking the subject to bite on load sensor for as long as the subject can until exhaustion. Using a stopwatch, the time will be recorded in seconds. Using the craniocervical extension endurance test, the subject will lie prone with their head unsupported and with a bubble inclinometer attached to their head. Using a stopwatch, time in seconds will be recorded to test how long the subject can sustain the neck in neutral position. Finally, a smartphone addiction scale will be answered by the subject to identify how much they are addicted to its use.
48003537|NCT04213456|DIETARY_SUPPLEMENT|Nutritional Sport Formula|Powder added to water,high protein and multi vitamins and minerals
48160610|NCT02173249|DRUG|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
48185171|NCT04849377|RADIATION|RT 60 GY|Radiation Therapy (RT) 60 GY
48185172|NCT04849377|OTHER|Induction Therapy|Induction Therapy: Cisplatin, Docetaxel, Fluorouracil
48185173|NCT04849377|DRUG|Carboplatin|Carboplatin AUC 9.0
48185174|NCT04849377|DRUG|Cisplatin 200|200 mg/m2
48513473|NCT04472676|DRUG|LY3473329|Administered orally.
48513474|NCT04472676|DRUG|Placebo|Administered orally.
48688771|NCT02509468|DRUG|Sirolimus|"* each patient will be followed during a 12-month-period~* each patient will start by an observational period and end being treated by sirolimus~* at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
48003538|NCT04213456|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals.
48003539|NCT00532285|DRUG|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
48003540|NCT05062265|DEVICE|Tight rope fixation|a traditional tight rope fixation is performed on one randomized set of subjects
48003541|NCT05062265|DEVICE|Tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace|A tight rope fixation with an anterior inferior tibiofibular ligament (AITFL) repair augmentation with an internal brace set of subjects to compare syndesmotic volume
48003542|NCT01886248|DRUG|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
48003543|NCT00819416|DRUG|5% albumin|5% albumin for the first 7 days of care in the ICU
48003544|NCT00819416|DRUG|Normal Saline|Normal Saline for the first 7 days of care in the ICU
48003545|NCT00191828|DRUG|olanzapine|
48003546|NCT02932904|DRUG|Vortioxetine|Vortioxetine Overencapsulated Tablet
48003547|NCT02932904|DRUG|Paroxetine|Paroxetine Overencapsulated Tablets.
48003548|NCT02932904|DRUG|Placebo|Vortioxetine Placebo-matching Capsules.
48003549|NCT00112242|BIOLOGICAL|Melan-A ELA + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
48003550|NCT00112242|BIOLOGICAL|Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
48003551|NCT00112242|BIOLOGICAL|Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
48003552|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
48003553|NCT00112242|BIOLOGICAL|Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2|"A maximum of 3 vaccination cycles (cycles 1-3) has been given, each cycle consisting of 4 vaccines in 4 week intervals. The intervals between cycles were 8 weeks. After 3 cycles, patients without major tumor progression requiring other treatment who showed an immunological response received booster vaccinations every 3 months."
48003554|NCT02584504|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
48003555|NCT02584504|DRUG|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
48003556|NCT02584504|DRUG|Atorvastatin|Atorvastatin 5 mg tablet orally.
48003557|NCT02584504|DRUG|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
48003558|NCT02584504|OTHER|Diet Alone|Stable cholesterol-lowering diet as background therapy.
48185175|NCT04849377|DRUG|Cisplatin 240|240mg/m2
48513475|NCT00002638|BIOLOGICAL|filgrastim|
48513476|NCT00002638|BIOLOGICAL|sargramostim|
48513477|NCT00002638|DRUG|carmustine|
48513478|NCT00002638|DRUG|cyclophosphamide|
48513479|NCT00002638|DRUG|cytarabine|
48513480|NCT00002638|DRUG|etoposide|
48513481|NCT00002638|PROCEDURE|peripheral blood stem cell transplantation|
48688772|NCT02818764|PROCEDURE|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
48688773|NCT02818764|PROCEDURE|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
48688774|NCT02818764|DEVICE|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
48688775|NCT02818764|DEVICE|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
48160611|NCT06182800|DRUG|Adebrelimab Combined with Bevacizumab and Docetaxel|"Adebrelimab: 1200 mg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Docetaxel: 60-75 mg/m2 Docetaxel is given on days 1 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
48688776|NCT05268692|DRUG|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
48688777|NCT05268692|DRUG|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
48688778|NCT00976287|PROCEDURE|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
48688779|NCT00976287|PROCEDURE|Conserved Therapy|Conserved Therapy
48003559|NCT03695731|PROCEDURE|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
48003560|NCT05676957|DEVICE|Thermogard XP3|Patients received endovascular hypothermia for 12 hours following endovascular treatment and recanalization.
48003561|NCT05520008|OTHER|Game-based exercise|Patients in the active group will put on a sensor connected to a tablet to play a game-based foot/ankle exercise twice a day for 5 minutes for four weeks.
48003562|NCT04905056|OTHER|Ablation therapy|Ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
48160612|NCT02212197|DRUG|leuprolide acetate FluidCrystal® injection depot|
48513482|NCT00002638|RADIATION|radiation therapy|
48513483|NCT02645331|BEHAVIORAL|Remind-to-move|
48160613|NCT02212197|DRUG|leuprolide acetate|
48688780|NCT00068263|RADIATION|radiation therapy|
48160614|NCT04787900|DEVICE|iPhone measurement application|The iPhone measurement application will be used to ensure validity and reliability.
48688781|NCT03626064|BEHAVIORAL|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
48688782|NCT03626064|DRUG|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
48688783|NCT05506072|OTHER|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
48688784|NCT05506072|OTHER|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
48688785|NCT01846962|DRUG|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
48688786|NCT01846962|DRUG|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
48160615|NCT04787900|DEVICE|Bubble inclinometer|Bubble inclinometer with proven validity and reliability will be used for this study.
48513484|NCT02645331|BEHAVIORAL|Modified constraint induced movement therapy|
48160616|NCT05144802|PROCEDURE|acute hypoxia|Participants will be exposed to a 3-hour acute hypoxia
48160617|NCT02243436|DRUG|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
48688787|NCT01846962|BEHAVIORAL|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
48688788|NCT01846962|DRUG|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
48688789|NCT02704624|DIETARY_SUPPLEMENT|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
48003563|NCT02016625|DRUG|Faldaprevir|
48160618|NCT02243436|DRUG|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
48160619|NCT02243436|DRUG|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
48160620|NCT02243436|DRUG|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
48160621|NCT02243436|DRUG|Ara C|Intravenous use, 2g/m2, day 5
48160622|NCT06646627|DRUG|B7-H3CART|"Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg"
48160623|NCT04764864|PROCEDURE|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
48513485|NCT02645331|BEHAVIORAL|Conventional rehabilitation|
48513486|NCT00002780|BIOLOGICAL|aldesleukin|
48513487|NCT00002780|BIOLOGICAL|cytokine therapy|
48513488|NCT00002780|BIOLOGICAL|sargramostim|
48513489|NCT00002780|DRUG|carboplatin|
48513490|NCT00002780|DRUG|cyclophosphamide|
48513491|NCT00002780|DRUG|thiotepa|
48688790|NCT02704624|OTHER|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
48688791|NCT06425913|OTHER|Kinesio Taping (KT)|KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.
48160624|NCT04764864|PROCEDURE|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
48160625|NCT01779427|BEHAVIORAL|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
48003564|NCT02016625|DRUG|Faldaprevir|
48003565|NCT02016625|DRUG|Cyclosporine|
48160626|NCT01325818|DRUG|pravastatin, rosuvastatin|"1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
48688792|NCT06425913|OTHER|Cold Therapy (CT)|The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, ...). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.
48688793|NCT06425913|OTHER|standardized home exercise program|All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
48160627|NCT03227432|DRUG|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
48160628|NCT03227432|DRUG|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
48513492|NCT00002780|PROCEDURE|peripheral blood stem cell transplantation|
48688794|NCT05046873|DRUG|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
48688795|NCT05046873|DRUG|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
48688796|NCT05046873|DRUG|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
48003566|NCT02016625|DRUG|Tacrolimus|
48003567|NCT00401765|DRUG|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
48003568|NCT00401765|DRUG|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
48003569|NCT02855749|PROCEDURE|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
48003570|NCT02263066|BIOLOGICAL|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
48160629|NCT03227432|DRUG|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
48003571|NCT04382248|OTHER|Smartphone App|An app for monitoring medications, blood pressure, exercise, healthy eating
48160630|NCT03227432|DRUG|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
48160631|NCT04297436|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
48160632|NCT05066178|BEHAVIORAL|CAS Treatment for Minimally Verbal Children with Autism|Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
48160633|NCT02988245|DRUG|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
48160634|NCT02988245|DRUG|JNC-8|Using JNC-8 guidelines to guide therapy
48160635|NCT01151878|DIETARY_SUPPLEMENT|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
48513493|NCT03479801|PROCEDURE|Thyroid Surgical Methods|Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
48688797|NCT05046873|DRUG|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
48688798|NCT00496678|BEHAVIORAL|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
48688799|NCT00496678|BEHAVIORAL|Standard of Care|Cancer patients receive standard of care for their cancer treatment
48003572|NCT04382248|BEHAVIORAL|Tailored education|in-person coaching
48003573|NCT01810666|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
48003574|NCT01933048|DRUG|FluMist|FluMist Intranasal Vaccine
48003575|NCT05664724|BEHAVIORAL|Receives interdisciplinary sessions|"Along with usual care, participants receive six interdisciplinary sessions at 2 months and 1 month pre-operatively and 2 weeks, 6 weeks, 3 months, and 6 months post-operatively attended by an orthopedic surgeon, a physiotherapist, a patient navigator, and the patient. The pre-operative interdisciplinary sessions will outline expectations, explore patients' questions and concerns, set expectations for the next interdisciplinary session, and ensure goal congruence between all members of the team.~Along with usual care during the post-operative period, participants will receive interdisciplinary sessions that address safety and medical issues, revisit patient expectations, reinforce care team expectations, focus on a personalized rehabilitation plan, and ensure goal congruence between the various team members."
48003576|NCT03925324|BIOLOGICAL|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
48003577|NCT03925324|OTHER|Placebo|1.5 mL/kg Lactated Ringer's Solution
48003578|NCT04895384|DEVICE|Edwards ClearSight and Masimo SET|Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
48003579|NCT04297930|DEVICE|Paul Glaucoma Implant Surgery|This group of patients had glaucoma surgery with the Paul Glaucoma Implant
48003580|NCT02182375|DRUG|BI 201335 NA|
48003581|NCT02182375|DRUG|Raltegravir|
48003582|NCT05925491|DRUG|Pembrolizumab|Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care
48003583|NCT05925491|DRUG|Cisplatin|Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.
48003584|NCT05925491|DRUG|Docetaxel|Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.
48003585|NCT05925491|DRUG|Carboplatin|Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.
48003586|NCT05017610|DRUG|Liothyronine|Given PO
48160636|NCT01151878|DIETARY_SUPPLEMENT|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
48160637|NCT03661749|OTHER|clean catch|clean catch technique applied to collect urine for PR/CR ratio
48160638|NCT06003868|OTHER|traditional physiotherapy|Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
48160639|NCT06003868|OTHER|hippotherapy-assisted physiotherapy|"The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level."
48367711|NCT03152643|PROCEDURE|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
48367712|NCT05471401|DEVICE|Balloon-tipped catheter|Gastric balloon
48367713|NCT05001672|DRUG|Tenofovir alafenamide|Tenofovir alafenamide (TAF, brand name: Vemlidy) is a hepatitis B virus nucleotide reverse transcriptase inhibitor oral medication for the treatment of chronic hepatitis B virus infection. It is a prodrug of tenofovir. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. Vemlidy was approved by the U.S. Food and Drug Administration (FDA) in November 2016 and the TAIWAN Food and Drug Administration (TFDA) in April 2017.
48367714|NCT04366869|DEVICE|overdenture|removal of overdenture at night
48367715|NCT04366869|DEVICE|occlusal splint|occlusal splint on overdenture
48367716|NCT04366869|DRUG|Botox|Botox injection i masseter in temporalis
48367717|NCT06080308|OTHER|No intervention|No intervention
48003587|NCT05017610|DRUG|Lomustine|Given PO
48003588|NCT05017610|DRUG|Methimazole|Given PO
48003589|NCT02170584|DRUG|BIBR 953 ZW IV|
48003590|NCT02170584|DRUG|BIBR 1048 MS tablet|
48003591|NCT02170584|DRUG|BIBR 1048 MS oral solution|
48003592|NCT02170584|DRUG|BIBR 953 ZW IV Placebo|
48003593|NCT01225445|DRUG|Ramipril|2.5 mg daily
48160640|NCT00176761|DRUG|Interleukin-2 (IL-2)|
48160641|NCT04398355|COMBINATION_PRODUCT|acupuncture|acupuncture
48160642|NCT04398355|COMBINATION_PRODUCT|Liu-Zi-Jue Gongfa|Liu-Zi-Jue Gongfa
48160643|NCT06244693|OTHER|No intervention|No intervention
48160644|NCT01878253|DEVICE|Sidus Stem-Free Total Shoulder Arthroplasty System|
48160645|NCT06645756|OTHER|Test meal|Test meal consisting of fries, chicken nuggets and eggs
48160646|NCT03912298|OTHER|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
48160647|NCT06159933|PROCEDURE|Supine positioning|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
48160648|NCT06159933|PROCEDURE|Early pronation|According to our local protocol, starting from January 2022, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
48160649|NCT06159933|PROCEDURE|Late pronation|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
48160650|NCT01797822|DRUG|Dexamethasone|
48160651|NCT01797822|DRUG|Artificial tear|
48160652|NCT03788421|DEVICE|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
48160653|NCT03788421|PROCEDURE|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
48003594|NCT06368453|DEVICE|INSTI® HIV Self-Test|"Each participant will be provided with the INSTI® HIV Self-Test and asked to conduct self testing. The operator will observe the participant and record the subject's interpretation of the results. Subjects will perform the test without intervention from the operator.~The operator will then perform the comparator test and collect a fingerstick blood sample. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing."
48003595|NCT03181542|DEVICE|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
48003596|NCT00324831|DRUG|autologous immunoglobulin idiotype-KLH conjugate vaccine|
48003597|NCT00324831|DRUG|cyclophosphamide|
48003598|NCT00324831|DRUG|doxorubicin hydrochloride|
48003599|NCT00324831|DRUG|prednisone|
48003600|NCT00324831|DRUG|rituximab|
48160654|NCT03794128|PROCEDURE|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
48367718|NCT06499129|BEHAVIORAL|Sensory ball, progressive relaxation exercise, training|The effect of sensory ball use on fatigue, peripheral neuropathy and anxiety will be examined
48003601|NCT00324831|DRUG|sargramostim|
48003602|NCT00324831|DRUG|vincristine|
48003603|NCT00324831|PROCEDURE|Intervention/procedure|
48003604|NCT00324831|PROCEDURE|antibody therapy|
48003605|NCT00324831|PROCEDURE|biological therapy|
48003606|NCT00324831|PROCEDURE|chemotherapy|
48003607|NCT00324831|PROCEDURE|colony-stimulating factor therapy|
48003608|NCT00324831|PROCEDURE|cytokine therapy|
48003609|NCT00324831|PROCEDURE|monoclonal antibody therapy|
48003610|NCT00324831|PROCEDURE|non-specific immune-modulator therapy|
48003611|NCT00324831|PROCEDURE|therapeutic procedure|
48003612|NCT00324831|PROCEDURE|tumor cell derivative vaccine|
48003613|NCT00324831|PROCEDURE|vaccine therapy|
48003614|NCT05098535|OTHER|Visual Aid|"The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual description stating the anticipated risk.~For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS."
48003615|NCT05098535|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
48003616|NCT01786265|DRUG|Abiraterone Acetate|Given PO
48160655|NCT03794128|PROCEDURE|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
48160656|NCT06231550|DRUG|FC084CSA tablets|"FC084CSA accelerated doses at 100mg QD, and then started the conventional 3+3 design from 200mg QD."
48160657|NCT05043688|DRUG|Camrelizumab|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
48160658|NCT05043688|RADIATION|radiotherapy|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
48160659|NCT02711553|DRUG|Ramucirumab|Administered IV
48160660|NCT02711553|DRUG|Merestinib|Administered orally
48160661|NCT02711553|DRUG|Cisplatin|Administered IV
48160662|NCT02711553|DRUG|Gemcitabine|Administered IV
48160663|NCT02711553|DRUG|Placebo Oral|Administered orally
48160664|NCT02711553|DRUG|Placebo IV|Administered IV
48003617|NCT01786265|DRUG|Bicalutamide|Given PO
48003618|NCT01786265|DRUG|Degarelix|Given via injection
48003619|NCT01786265|DRUG|Flutamide|Given PO
48003620|NCT01786265|DRUG|Goserelin Acetate|Given via injection
48003621|NCT01786265|DRUG|Leuprolide Acetate|Given via injection
48003622|NCT01786265|DRUG|Nilutamide|Given PO
48003623|NCT01786265|DRUG|Prednisone|
48003624|NCT02882321|DRUG|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
48003625|NCT02882321|OTHER|Pharmacological Study|Correlative studies
48003626|NCT03013543|DRUG|Setmelanotide|RM-493 QD SC injection
48160665|NCT01485991|DRUG|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
48160666|NCT01485991|DRUG|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
48160667|NCT03145519|DEVICE|Vasofix Certo Catheter|Placement of IV-catheter
48160668|NCT03145519|DEVICE|OptiVein Catheter|Placement of IV-catheter
48160669|NCT06321900|DIAGNOSTIC_TEST|Personalized risk model|WE will test the hypothesis that interpretable artificial intelligence models including clinical, bio-humoral, genetic, electrocardiography, echocardiography, cardiac magnetic resonance, and nuclear imaging data will predict the risk of SCD in patients with left ventricular dysfunction more accurately than NYHA class and LVEF, and this will translate in a more cost-effective use of ICDs compared to current clinical practice.
48160670|NCT05289375|DRUG|Vacucis autovaccine|A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
48003627|NCT03303404|DEVICE|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
48003628|NCT01317238|DRUG|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
48003629|NCT01321775|DRUG|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
48003630|NCT04268420|DRUG|FMP013|Falciparum Malaria Protein-13
48160671|NCT05289375|DRUG|Placebo|A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
48367719|NCT05502406|PROCEDURE|Instrument Assisted Soft tissue Mobilization|Using a C shaped IASTM tool gentle horizontal stroking at an angle of 45 degree will be given over the cervicodorsal fascia
48513494|NCT01632657|DRUG|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
48003631|NCT04268420|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
48513495|NCT01632657|OTHER|Placebo|Single injection saline 0.5ml subcutaneously in recovery
48003632|NCT05905484|DRUG|Bemnifosbuvir (BEM)|A single dose of BEM will be administered.
48003633|NCT05905484|DRUG|Placebo|A single dose of matching placebo will be administered.
48003634|NCT05905484|DRUG|Moxifloxacin|A single dose of Moxifloxacin will be administered.
48003635|NCT03305510|DIAGNOSTIC_TEST|vitamin D is below 20ng/ml|
48003636|NCT04566237|PROCEDURE|Objective Scatter Index (OSI)|On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
48003637|NCT04566237|PROCEDURE|Average Lens Density (ALD)|on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
48003638|NCT01861496|DRUG|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
48003639|NCT02507414|OTHER|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
48003640|NCT02507414|OTHER|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
48003641|NCT02507414|OTHER|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
48003642|NCT05464004|OTHER|Nintendo Wii balance board|"Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar"
48513496|NCT02850185|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
48688800|NCT04852549|OTHER|Oculomotor exercise|"1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
48688801|NCT03567967|BEHAVIORAL|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
48688802|NCT00371215|BIOLOGICAL|rThrombin|1000 U/mL applied topically
48688803|NCT04368299|OTHER|Telemedicine|Videoconferencing for follow-up
48688804|NCT04368299|OTHER|Standard care|Standard in-person outpatient follow-up
48003643|NCT00547703|DRUG|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
48688805|NCT05695040|BEHAVIORAL|"dietary workshop proteins"|"The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
48688806|NCT02498054|BEHAVIORAL|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
48003644|NCT00547703|DRUG|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
48003645|NCT00323154|DRUG|Nalbuphine|
48003646|NCT02508636|DRUG|Enzalutamide|Given orally
48003647|NCT02508636|DRUG|Leuprolide|Given via intramuscular injection
48003648|NCT02508636|RADIATION|Intensity-Modulated Radiation Therapy|A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
48003649|NCT03580603|OTHER|Visualization tool|Visual representation of past microbiological culture data
48003650|NCT00302133|DRUG|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
48003651|NCT00302133|OTHER|Placebo|Placebo arm
48003652|NCT02347527|BEHAVIORAL|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
48003653|NCT02347527|BEHAVIORAL|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
48003654|NCT02559869|DRUG|[18F] GE-180|PET Tracer Ligand
48003655|NCT04155008|DRUG|Dexamethasone|If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
48003656|NCT04155008|DRUG|Dronabinol|If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
48003657|NCT04155008|DRUG|Mirtazapine|If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
48003658|NCT04155008|BEHAVIORAL|Nutrition Intervention|"Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status"
48003659|NCT00788827|BIOLOGICAL|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
48003660|NCT02984410|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
48003661|NCT02984410|PROCEDURE|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
48003662|NCT01314209|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
48003663|NCT03272451|PROCEDURE|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
48688807|NCT04763252|OTHER|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
48160672|NCT02391116|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
48160673|NCT03275441|DIAGNOSTIC_TEST|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
48160674|NCT02640807|DRUG|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000
48688808|NCT01057693|DRUG|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
48160675|NCT02640807|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
48160676|NCT06645886|DRUG|KQB198|Oral KQB198
48160677|NCT06645886|DRUG|Dasatinib|Oral dasatinib
48160678|NCT00574171|DRUG|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
48160679|NCT00574171|DRUG|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
48160680|NCT06096376|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm ultrasound to assess respiratory muscle function and respiratory efficiency
48160681|NCT06646562|DRUG|Cabotegravir LA + Rilpivirine LA|Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.
48160682|NCT02878720|DEVICE|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
48160683|NCT03282799|DRUG|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
48160684|NCT03103178|OTHER|Quality of life questionnaire|Measurement of quality of life
48688809|NCT01057693|DRUG|Placebo|Placebo is supplied as capsules and given 3 times daily.
48688810|NCT04061824|DRUG|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
48688811|NCT04061824|DRUG|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
48688812|NCT01017224|OTHER|18F-FAZA|PET scan
48688813|NCT02467127|DIETARY_SUPPLEMENT|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
48688814|NCT05688202|PROCEDURE|Simultaneous combination of fractional CO2 laser and subcision|"Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
48160685|NCT06645873|DEVICE|Continuous glucose monitoring (CGM) device|All included study participants recieve a CGM sensor (Dexcom G7) to monitor blood glucose. The treatment team is blind for the CGM values; the gold standard for glucose control (POC interval measures) will be followed.
48160686|NCT02756299|OTHER|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
48688815|NCT05688202|PROCEDURE|Sequential combination of fractional CO2 laser and subcision|"Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
48003664|NCT03272451|PROCEDURE|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
48160687|NCT02756299|OTHER|Standard Support|General information about OSA and PAP treatment at baseline
48003665|NCT00011089|DRUG|Tenofovir disoproxil fumarate|
48160688|NCT04577586|OTHER|oral contrast|negative oral contrast utilization in PET/CT studies
48003666|NCT00094965|DRUG|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
48003667|NCT05145829|DIAGNOSTIC_TEST|Diagnostic Test: Sentinel node mapping using MRI|Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
48003668|NCT04565054|DRUG|Abemaciclib 50 MG; 150mg 1-0-1 per os|Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
48185176|NCT04038242|OTHER|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
48185177|NCT01635023|DRUG|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
48003669|NCT05691231|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
48003670|NCT01735656|DEVICE|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
48003671|NCT04281381|DIAGNOSTIC_TEST|Cross-sectional imaging|MRI with gadolinium contrast will be the imaging modality of choice. In patients with contraindications to MRI who instead undergo baseline evaluation by CT scan, tumor evaluation will be by serial CT scans with IV contrast throughout the study period.
48003672|NCT04671810|BIOLOGICAL|Elizaria®|Elizaria® will be prescribed by the Physician according to the actual SMPC.
48003673|NCT04488120|DEVICE|transcatheter closure of secundum atrial septal defects in patients|transcatheter closure of secundum atrial septal defects in patients
48003674|NCT03941210|OTHER|Detection of molecular Biomarkers|MicroRNA expression profile analysis by flow cytometry
48003675|NCT00099463|PROCEDURE|Blood Test|
48003676|NCT00099463|PROCEDURE|Urine Test|
48003677|NCT00099463|PROCEDURE|Physical Exam|
48003678|NCT00099463|DRUG|Vaccine|
48003679|NCT00099463|DRUG|VRC-SRSDNA015-00-VP|
48160689|NCT00588341|DRUG|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
48185178|NCT01635023|DRUG|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
48185179|NCT01635023|DRUG|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
48688816|NCT05688202|DEVICE|Fractional CO2 laser|Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
48003680|NCT02658890|DRUG|BMS-986205|
48003681|NCT02658890|DRUG|Nivolumab|
48003682|NCT02658890|DRUG|Ipilimumab|
48003683|NCT01045564|BIOLOGICAL|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
48003684|NCT02269462|DRUG|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
48003685|NCT02269462|DRUG|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
48003686|NCT01890772|DRUG|Telaprevir|
48003687|NCT01890772|DRUG|Peginterferon alfa-2a|
48003688|NCT01890772|DRUG|Ribavirin|
48003689|NCT01890772|DIETARY_SUPPLEMENT|Vitamin D|
48003690|NCT03467633|BEHAVIORAL|High-intensity interval training|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
48003691|NCT01972269|DRUG|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
48003692|NCT01972269|DRUG|Lidocaine|2% lidocaine
48003693|NCT03127969|OTHER|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
48003694|NCT03127969|OTHER|Joint protection and exercise|joint protection and exercise
48003695|NCT03837548|OTHER|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
48003696|NCT03837548|OTHER|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
48003697|NCT02127632|DEVICE|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
48003698|NCT02127632|DEVICE|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson \& Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
48003699|NCT05361681|OTHER|Electromagnetic Field Exposure|All participants were exposed to the electromagnetic field of 4-5 different high power charging systems, charging 4-5 different, commercially available full electric cars
48003700|NCT03780153|OTHER|No intervention|Observation study. No intervention
48003701|NCT02901951|BIOLOGICAL|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
48003702|NCT03135041|DIETARY_SUPPLEMENT|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
48003703|NCT03135041|DIETARY_SUPPLEMENT|Placebo|Effects of placebo supplement on weight loss during energy restriction
48003704|NCT02812758|DEVICE|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
48160690|NCT04895202|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
48160691|NCT03344913|BEHAVIORAL|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
48160692|NCT02134899|DRUG|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
48160693|NCT02134899|DRUG|Calcineurin inhibitors maintenance|Usual treatment
48160694|NCT00953199|DRUG|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
48160695|NCT00953199|DRUG|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
48160696|NCT01095809|DRUG|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
48160697|NCT01095809|DRUG|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
48688817|NCT05688202|PROCEDURE|Subcision|Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
48160698|NCT01119534|DRUG|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
48160699|NCT01119534|DRUG|guaiacol suppository|2 times per day
48160700|NCT01119534|DRUG|Guaifenesin syrup|4.19 mL - 4 in 4 hours
48160701|NCT05878990|BEHAVIORAL|Culturally-tailored Tobacco Treatment|Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
48160702|NCT05878990|BEHAVIORAL|Culturally-tailored Content Newsletters|Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.
48688818|NCT05688202|DRUG|Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream|Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
48688819|NCT05688202|DRUG|Paracetamol|A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
48688820|NCT05688202|DRUG|Lidocaine 2% Injectable Solution|The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
48688821|NCT03593122|DEVICE|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
48688822|NCT03976024|OTHER|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
48688823|NCT03976024|OTHER|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
48688824|NCT02403063|DRUG|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
48160703|NCT05878990|BEHAVIORAL|Control Preference Scale|Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
48160704|NCT05878990|BEHAVIORAL|Active Content Newsletter or Passive Content Newsletter|Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.
48160705|NCT04057937|DRUG|Apremilast|Apremilast
48160706|NCT04057937|DRUG|Placebo|Placebo
48160707|NCT00600223|BEHAVIORAL|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
48160708|NCT03398434|DRUG|MAA868|3 MAA868 doses, single administration, subcutaneous,
48160709|NCT03398434|DRUG|Apixaban|Apixaban 5 mg b.i.d
48160710|NCT06210737|BIOLOGICAL|PCV13|3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10
48160711|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13, and a booster dose
48160712|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13
48160713|NCT06210737|BIOLOGICAL|PCV13|single dose of PCV13
48688825|NCT02403063|DRUG|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
48003705|NCT03302481|OTHER|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
48688826|NCT02403063|DRUG|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
48003706|NCT02361710|PROCEDURE|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
48003707|NCT02984384|DRUG|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
48003708|NCT02984384|DRUG|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
48003709|NCT03876327|PROCEDURE|fecal microbial transplantation|Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
48003710|NCT02048020|DRUG|paclitaxel|Given IV
48003711|NCT02048020|DRUG|carboplatin|Given IV
48003712|NCT02048020|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48003713|NCT02048020|PROCEDURE|quality-of-life assessment|Ancillary studies
48003714|NCT00637195|BIOLOGICAL|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
48003715|NCT00637195|BIOLOGICAL|Engerix™|Intramuscular administration, 4 doses.
48003716|NCT01263548|DRUG|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
48003717|NCT05994716|OTHER|Telemonitoring|"A) Monthly completion data on the web platform: 1) SCCAI for Ulcerative colitis and Harvey-Bradshaw index for Crohn disease. 2) IBD disk questionnaire to evaluate disease dynamics. 3) General blood test.~B) Possibility of online consultation with a gastroenterologist upon request via chat or phone call.~C) Access to educational information about IBD, necessary lifestyle changes, dietary recommendations;~D) monthly phone call will be made to each patient from the intervention group to answer any questions or concerns they may have and to interview them according to the checklist."
48688827|NCT02263196|OTHER|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
48688828|NCT02263196|OTHER|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
48688829|NCT00021567|DRUG|Interferon Gamma for Aerosol|
48003718|NCT01492452|OTHER|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
48003719|NCT06227507|BEHAVIORAL|Front-of-package label|Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.
48003720|NCT00735371|DRUG|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
48185180|NCT01635023|DRUG|AZD6244 Dosing Period 4|Treatment B
48185181|NCT00000770|DRUG|Nevirapine|
48513497|NCT02850185|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
48688830|NCT06510803|DRUG|The case intervention is the sevoflurane concentrations with the Drager Apollo workstation|The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
48688831|NCT02733549|OTHER|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
48688832|NCT01384552|OTHER|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
48513498|NCT02850185|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
48688833|NCT01384552|OTHER|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
48688834|NCT04741321|OTHER|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
48688835|NCT06352697|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
48688836|NCT06352697|DIETARY_SUPPLEMENT|Placebo|Placebo
48688837|NCT00612378|DEVICE|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
48688838|NCT02794896|DRUG|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
48688839|NCT02794896|DRUG|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
48688840|NCT04637776|OTHER|Hospitalization|Hospitalization for any reason
48688841|NCT02429804|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
48688842|NCT02429804|DRUG|Fludeoxyglucose F-18|Given IV
48688843|NCT02429804|DRUG|Fluorine F 18 Sodium Fluoride|Given IV
48688844|NCT02429804|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
48688845|NCT02429804|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
48688846|NCT03550443|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
48688847|NCT03550443|DRUG|Placebo|Capsules containing an inert placebo
48688848|NCT01296893|BEHAVIORAL|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
48688849|NCT02297711|PROCEDURE|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
48688850|NCT02297711|PROCEDURE|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
48688851|NCT04790669|PROCEDURE|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
48160714|NCT03739333|OTHER|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
48160715|NCT03306693|BEHAVIORAL|Emotional skills|2-hour 3 group sessions
48160716|NCT03306693|BEHAVIORAL|Relaxation and talking group|2-hour 3 group sessions
48513499|NCT05106608|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
48688852|NCT04790669|PROCEDURE|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline \& post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
48688853|NCT04069949|DRUG|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
48688854|NCT04254653|BEHAVIORAL|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 \~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
48688855|NCT04182477|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Neuro-cognitive test evaluating general mental status and performance
48688856|NCT03574766|BEHAVIORAL|Meditation|Daily meditation
48688857|NCT06093958|DIAGNOSTIC_TEST|Manual loading of the chest wall|The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
48688858|NCT02455336|DRUG|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
48185182|NCT00000770|DRUG|Zidovudine|
48185183|NCT00000770|DRUG|Didanosine|
48185184|NCT02798497|OTHER|Serum and Blood samples|
48185185|NCT03614676|PROCEDURE|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
48688859|NCT02455336|OTHER|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
48688860|NCT02371785|DEVICE|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
48367720|NCT05502406|PROCEDURE|Manual Myofascial Release|"Participants will receive myofascial release through velvet glove technique on upper trapezius and sternocleidomastoid muscle using four strokes in the following fashion:~* Begin superior to the clavicle with a loose fist and move the back of the hand over the upper trapezius, fastening the tissue and bringing it over the table.~* The next stroke addresses the curve of the neck, again hooking the tissue while moving the bak of your fist towards the table.~The last stroke goes over the entire cervical spine hooking over the sternocleidomastoid muscle bringing it into myofascial release. Stay away from the carotid pulse, and incase a pulse is felt, do not apply pressure and reposition your hand"
48367721|NCT05204576|BEHAVIORAL|CBT4CBT COPES|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily IVR assessment calls
48688861|NCT00193011|DRUG|Docetaxel|Docetaxel
48367722|NCT03573921|DRUG|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
48688862|NCT00193011|DRUG|Cyclophosphamide|Cyclophosphamide
48688863|NCT00193011|DRUG|Methotrexate|Methotrexate
48688864|NCT00193011|DRUG|5-Fluorouracil|5-Fluorouracil
48688865|NCT01963793|DRUG|Aprepitant|Aprepitant gel (10 mg/g)
48367723|NCT03573921|OTHER|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
48688866|NCT01963793|DRUG|Placebo|gel without active component
48688867|NCT00631280|BEHAVIORAL|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
48688868|NCT00631280|BEHAVIORAL|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
48367724|NCT04234841|DIAGNOSTIC_TEST|Blood test|Blood test
48367725|NCT00145080|BEHAVIORAL|Disease Management Assessment|
48367726|NCT01398176|DIETARY_SUPPLEMENT|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
48367727|NCT01398176|DIETARY_SUPPLEMENT|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
48688869|NCT05815433|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
48185186|NCT03614676|PROCEDURE|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
48367728|NCT04160884|PROCEDURE|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
48367729|NCT04692324|PROCEDURE|Biospecimen Collection|Undergo collection of CSF samples
48367730|NCT04692324|OTHER|Electronic Health Record Review|Review of medical records
48367731|NCT04692324|OTHER|Survey Administration|Ancillary studies
48367732|NCT05302999|DRUG|Gabapentin|Generic gabapentin
48367733|NCT05302999|DRUG|Placebo|Inert cellulose
48367734|NCT03077074|OTHER|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
48688870|NCT03483779|DRUG|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
48688871|NCT03483779|DRUG|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
48185187|NCT03614676|OTHER|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
48513500|NCT05106608|DEVICE|Energy density photobiomodulation (3)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
48688872|NCT06190470|DRUG|Cannabis|Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
48688873|NCT06190470|DRUG|Placebo|Placebo is similar to Cannabis product but do not contain THC.
48688874|NCT04393597|DRUG|DWJ1458 (fasted)|Subjects take single dose of DWJ1458 on a fated condition
48688875|NCT04393597|DRUG|DWJ1458 (fed)|Subjects take single dose of DWJ1458 after high-fat diet
48688876|NCT03071315|OTHER|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
48688877|NCT03071315|OTHER|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
48688878|NCT04699032|DRUG|Apraglutide|Single dose of apraglutide 5 mg.
48513501|NCT05106608|DEVICE|Sham placebo|In addition, a mobile health application (LAXER) will be provided.
48688879|NCT05420961|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
48688880|NCT05420961|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
48688881|NCT05420961|BIOLOGICAL|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
48688882|NCT04321473|PROCEDURE|PCI on left main|PCI on left main coronary stenosis
48688883|NCT04413916|DIAGNOSTIC_TEST|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
48513502|NCT01198132|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
48688884|NCT03745872|BEHAVIORAL|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
48688885|NCT01404143|PROCEDURE|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
48185188|NCT03614676|PROCEDURE|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
48688886|NCT01404143|PROCEDURE|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
48688887|NCT04517344|OTHER|Initial Flow Rate|Patients placed on High Flow Nasal Cannula by treating physician will be randomized to initial flow rates of 1 L/kg/min, 1.5 L/kg/min, or 2 L/kg/min
48688888|NCT02793973|DEVICE|shoe lifts|
48688889|NCT02350075|PROCEDURE|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
48688890|NCT02350075|DEVICE|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
48688891|NCT02289196|DRUG|Vx-006: 0,5mg|
48688892|NCT02289196|DRUG|Vx-006: 1mg|
48688893|NCT02289196|DRUG|Vx-006: 5mg|
48003721|NCT00735371|DRUG|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
48367735|NCT04627389|PROCEDURE|orbicularis oris muscle Z- plasty modification of modified millard technique|After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
48367736|NCT04627389|PROCEDURE|modified millard technique|no z-plasty modification
48688894|NCT02289196|DRUG|Vx-006: 10mg|
48367737|NCT03682471|DRUG|Deoxycholic acid Injection|Solution for subcutaneous injection.
48367738|NCT03682471|DRUG|Placebo|Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
48513503|NCT01198132|DIETARY_SUPPLEMENT|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
48688895|NCT03333928|DRUG|HTD1801|HTD1801 tablets, 250 mg
48003722|NCT00735371|DRUG|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
48003723|NCT00735371|DRUG|Placebo|Placebo will be identical to test product.
48513504|NCT01198132|DRUG|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
48688896|NCT03333928|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
48688897|NCT01765036|DRUG|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
48688898|NCT03665766|DRUG|Cycloserine,Tacrolimus|
48688899|NCT01119196|OTHER|Icodextrin dialysate|use of alternate SOC dialysate
48688900|NCT04452305|PROCEDURE|Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting|Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
48688901|NCT04031898|OTHER|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
48003724|NCT02617316|OTHER|Barefoot|barefoot running test was 20 minutes.
48003725|NCT02617316|OTHER|In shoes|In shoes test was 20 minutes.
48003726|NCT01914224|BEHAVIORAL|dietary education of low sodium and high potassium consumption|
48003727|NCT01914224|BEHAVIORAL|dietary education of low sodium consumption only|
48003728|NCT00500370|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
48003729|NCT00500370|DRUG|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
48688902|NCT00757952|OTHER|Fourier transform ion cyclotron resonance mass spectrometry|
48688903|NCT00757952|OTHER|chromatography|
48688904|NCT00757952|OTHER|diagnostic laboratory biomarker analysis|
48688905|NCT00757952|OTHER|questionnaire administration|
48688906|NCT06385379|DEVICE|WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system|The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
48003730|NCT03884621|OTHER|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
48003731|NCT02382016|DRUG|Macitentan|Macitentan film-coated tablet 10 mg once daily.
48367739|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
48688907|NCT05656183|DIAGNOSTIC_TEST|TruGenome Cardiovascular Disease test|The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
48688908|NCT04420832|PROCEDURE|Surgical treatment|Se above
48688909|NCT04420832|OTHER|Non-surgical treatment|See above
48688910|NCT01375816|DRUG|FOLFIRI 1-Bevacizumab|
48688911|NCT01375816|DRUG|fluorouracil|
48688912|NCT01375816|DRUG|irinotecan hydrochloride|
48688913|NCT01375816|DRUG|leucovorin calcium|
48688914|NCT01375816|DRUG|liposome-encapsulated irinotecan hydrochloride PEP02|
48688915|NCT01375816|DRUG|Bevacizumab|
48688916|NCT04387006|OTHER|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
48513505|NCT03172195|PROCEDURE|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
48513506|NCT03172195|BIOLOGICAL|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
48688917|NCT04387006|OTHER|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
48688918|NCT01014572|BEHAVIORAL|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
48688919|NCT01014572|DRUG|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
48688920|NCT01014572|BEHAVIORAL|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
48688921|NCT00367562|DRUG|ENALAPRIL VALSARTAN METHYLPREDNISONE|
48003732|NCT02382016|OTHER|Placebo|Matching placebo tablet once daily.
48003733|NCT00003268|DRUG|amifostine trihydrate|
48003734|NCT00003268|DRUG|cytarabine|
48688922|NCT06138600|DRUG|Cabotegravir Injection [Apretude]|White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.
48688923|NCT06138600|DRUG|Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)|TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.
48688924|NCT04154423|OTHER|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
48003735|NCT00003268|DRUG|idarubicin|
48003736|NCT05400616|PROCEDURE|Microbiome Transplant|A raw microbiome, is collected from a donor without any sinonasal health problems, as a nasal lavage.
48003737|NCT05400616|PROCEDURE|Placebo|Normal saline.
48185189|NCT03614676|OTHER|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
48513507|NCT03172195|BIOLOGICAL|blood sample|Blood sample will be collected in more.
48688925|NCT04154423|OTHER|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
48003738|NCT04472936|PROCEDURE|Single catheter approach|Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is \>80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
48367740|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
48367741|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
48367742|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
48367743|NCT01359319|DRUG|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
48367744|NCT03268603|DRUG|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
48367745|NCT00667381|DEVICE|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
48367746|NCT01165268|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
48367747|NCT04629105|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Longeveron Mesenchymal Stem Cells (LMSCs)
48367748|NCT04629105|OTHER|Placebo|Placebo
48367749|NCT05659342|OTHER|ELDOA Technique|"the patients treated with ELDOA technique, followed for 3 alternative days for 4 weeks.~the ELDOA techniques for level L4/L5 and L5/S1 were applied. the ELDOA positions hold for one minute, 3 alternative days for 4 weeks under supervision.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
48367750|NCT05659342|OTHER|Mechanical Lumbar Traction|"Mechanical Traction Technique: traction unit, 50% of body weight was applied with the patients lying in supine position, with the hip and knee at 90 degree flexion, and legs were supported. Traction were applied for 3 alternative days for 4 weeks.~Hot pack (10-15 minutes) McKenzie Extension Exercises"
48367751|NCT03243318|DIAGNOSTIC_TEST|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
48367752|NCT05752591|DIAGNOSTIC_TEST|Diagnostic testing|Blood diagnostic testing for hypothalamic-pituitary-gonadal axis and hypothalamic-pituitary-thyroid axis. In case of gonadal or thyroid dysfunction, genetic testing for known implicated genes
48367753|NCT02139891|DEVICE|Cardiac Resynchronization Therapy with MultiPoint Pacing|
48367754|NCT02406131|OTHER|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
48513508|NCT02292095|PROCEDURE|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
48028567|NCT05263388|OTHER|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F is 225 IU fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose may be adjusted by 75 IU based on the subject's response. The minimum GONAL-F dose is 75 IU and the maximum GONAL-F dose is 300 IU. Subjects can be treated for a maximum of 20 days.
48513509|NCT02292095|PROCEDURE|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
48688926|NCT05412927|DEVICE|PMA P150009 AngelMed Guardian® System|"The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.~A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention."
48688927|NCT04583436|DEVICE|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
48688928|NCT04583436|OTHER|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
48688929|NCT05131334|DEVICE|auriStim, for auricular vagal stimulation|For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
48688930|NCT01692496|DRUG|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
48688931|NCT02860208|PROCEDURE|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
48688932|NCT04102709|DEVICE|Health Tag|Health Monitoring Device
48688933|NCT05560243|BEHAVIORAL|Tobacco cessation|Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
48028568|NCT01926106|DEVICE|nIPPV|one of the twins was randomly allocated to nIPPV
48028569|NCT01926106|DEVICE|nCPAP|another of the twins was allocated to nCPAP
48688934|NCT05525130|DIETARY_SUPPLEMENT|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
48367755|NCT05618769|COMBINATION_PRODUCT|LONG LOVE Framework|In order to identify modifiable influencing factors, clinical data of the infants included in our multidisciplinary framework will be continuously collected by eHealth (Luscii Healthtech BV, Netherlands). Study visits take place at 1-1,5 3, 6, 12 and 18 months of age. Outdoor air quality measurements will be conducted using RIVM Luchtmeetnet. Indoor air quality measurements will be collected during a period of 6 weeks using a commercial available device. Lung function analysis using impedance pneumatography (Ventica Recorder, Revenio Research LTD, Finland) will take place during 2 nights at 3, 6 and 12 months of age. In the event of modifiable influencing factors medical or lifestyle interventions will be undertaken.
48688935|NCT05525130|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
48688936|NCT04173286|PROCEDURE|antibiotherapy|\< 7 days
48688937|NCT04320056|OTHER|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
48367756|NCT01060410|GENETIC|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
48367757|NCT01060410|DRUG|Cyclophosphamide|intravenous injection, 0.2g, once every two days
48367758|NCT01060410|OTHER|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
48367759|NCT04227561|PROCEDURE|Pudendal nerve block|"Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally."
48522621|NCT02811965|DEVICE|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
48522622|NCT02811965|DEVICE|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
48522623|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
48522624|NCT00919126|DRUG|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
48522625|NCT00919126|DRUG|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
48522626|NCT01666665|DRUG|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
48522627|NCT01666665|DRUG|Sugar pill|Sugar pill up to 3 times per day for 12 months
48522628|NCT05085379|DEVICE|Ossiview|Imaging of the ear using Optical Coherence Tomography
48522629|NCT00154154|BEHAVIORAL|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
48522630|NCT00154154|BEHAVIORAL|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
48522631|NCT05869864|BEHAVIORAL|Schools Championing Safe South Africa|The intervention consists of 2 parts - a poster campaign with social norms messages on violence and HIV risk, and 2 lessons in life orientation (a health curriculum delivered during school).
48522632|NCT04214977|PROCEDURE|Spinal Anesthesia for Anorectal Surgeries in Prone Position|Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
48522633|NCT04214977|PROCEDURE|General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position|General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
48688938|NCT04320056|DEVICE|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
48688939|NCT02081508|BEHAVIORAL|Interference onset|Temporal duration of interference onset.
48688940|NCT02485639|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
48688941|NCT03950544|DRUG|Fosfomycin|Fosfomycin and meropenem
48688942|NCT03950544|DRUG|Tigecycline|Tigecycline and meropenem
48688943|NCT03950544|DRUG|Polymyxin B|Polymyxin B and meropenem
48367760|NCT04227561|PROCEDURE|Penile nerve block|"The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally."
48688944|NCT00442533|DRUG|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
48688945|NCT04970823|DEVICE|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
48688946|NCT04970823|DEVICE|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
48688947|NCT02181946|DRUG|Fluconazole|
48160717|NCT05613504|OTHER|Acupuncture treatment|"Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
48160718|NCT05613504|OTHER|Sham acupuncture treatment|"Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
48160719|NCT06379451|DRUG|NKG2D Chimeric Antigen Receptor NK Cell Injection|Administer KN1102 cell injection three times on day 0, day 7, and day 14, respectively.
48367761|NCT04130360|BEHAVIORAL|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
48513510|NCT03451357|DIAGNOSTIC_TEST|Dependence degree already certificated by Dependence Law.|The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
48688948|NCT02181946|DRUG|Nevirapine|
48688949|NCT04778891|OTHER|Comprehensive Medication Management services|Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
48688950|NCT05210088|DRUG|Hypoxia, intermittent|"The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored."
48688951|NCT05210088|OTHER|Normoxia|The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
48688952|NCT04601532|DEVICE|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
48688953|NCT04601532|DRUG|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
48688954|NCT00712686|DRUG|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
48688955|NCT00712686|DRUG|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
48688956|NCT01822899|DRUG|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
48688957|NCT01822899|DRUG|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
48688958|NCT01822899|DRUG|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
48688959|NCT01822899|DRUG|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
48688960|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
48688961|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
48688962|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
48688963|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
48688964|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
48688965|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
48688966|NCT02237001|DEVICE|Suture-based meniscal repair|Suture-based meniscal repair
48160720|NCT05307120|DEVICE|Diameter integrated in secondary diabetes care|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on smartphones that enables continuous monitoring of physical activity (via activity tracker Fitbit and self-reported activities) and nutrition (via food diary) and blood glucose values (via Freestyle Libre sensor). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
48160721|NCT00743223|OTHER|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
48688967|NCT01644669|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
48688968|NCT01645735|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
48367762|NCT05358301|DIETARY_SUPPLEMENT|Probiotic|Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).
48688969|NCT01645735|DRUG|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
48688970|NCT00325260|BIOLOGICAL|Influvac; subunit influenza vaccine|
48688971|NCT04142138|OTHER|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
48688972|NCT00610857|DRUG|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
48688973|NCT04737356|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
48688974|NCT06130475|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
48688975|NCT06130475|OTHER|Water|Participants will be administered water during one of the study visits
48367763|NCT05358301|DIETARY_SUPPLEMENT|Placebo|N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
48367764|NCT00189059|DRUG|amitriptyline|
48688976|NCT04662775|BEHAVIORAL|HERizon Project|"1. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
48688977|NCT02789358|OTHER|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
48688978|NCT02789358|OTHER|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
48688979|NCT02789358|DEVICE|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
48688980|NCT02789358|DRUG|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
48688981|NCT02789358|DEVICE|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
48688982|NCT02659033|DRUG|ceftriaxone|ceftriaxone (1 gram per day)
48688983|NCT02659033|DRUG|Cefotaxime|cefotaxime (1 gram every 8 hours)
48688984|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, iron and B12 in Whey Protein|Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
48688985|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Rice Protein|Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
48688986|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Maltrodextrin|Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
48003739|NCT04472936|PROCEDURE|Traditional approach|Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
48028570|NCT02001727|OTHER|13C-Urea breath test for Helicobacter Pylori|
48028571|NCT02001727|OTHER|Questionaire|
48367765|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
48367766|NCT01434927|PROCEDURE|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
48367767|NCT02661789|DRUG|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
48367768|NCT02661789|DRUG|Placebo|Injection of saline
48367769|NCT04460651|DRUG|Icosapent ethyl (IPE)|"Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)"
48367770|NCT04460651|DRUG|Placebo|Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
48688987|NCT01557543|OTHER|Cell Therapy|Intramyocardial Injection of BMSCs
48688988|NCT02314156|DRUG|Telapristone Acetate|Given transdermally
48688989|NCT02314156|OTHER|Placebo|Given PO
48688990|NCT02314156|DRUG|Telapristone Acetate|Given PO
48688991|NCT02314156|OTHER|Placebo|Given transdermally
48688992|NCT02314156|OTHER|Laboratory Biomarker Analysis|Correlative studies
48688993|NCT02314156|OTHER|Questionnaire Administration|Ancillary studies
48688994|NCT01688245|BEHAVIORAL|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
48688995|NCT01688245|BEHAVIORAL|SMS Assessments|Weekly post-weekend drinking outcome assessments
48688996|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
48688997|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
48688998|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
48688999|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
48689000|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
48689001|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
48689002|NCT03365687|DIETARY_SUPPLEMENT|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
48689003|NCT03365687|DIETARY_SUPPLEMENT|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
48689004|NCT02684617|BIOLOGICAL|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
48689005|NCT02684617|DRUG|dinaciclib|dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
48689006|NCT04593186|PROCEDURE|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
48689007|NCT02943317|DRUG|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
48689008|NCT02943317|DRUG|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
48689009|NCT04166370|OTHER|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
48689010|NCT04166370|OTHER|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
48367771|NCT05712174|DRUG|[18]F-PSMA-1007|\[18\]F-PSMA-1007 is a diagnostic radiopharmaceutical for use with PET/CT or PET/MRI scanning to diagnose prostate cancer.
48367772|NCT00352404|DEVICE|Endomicroscope|
48367773|NCT00000740|DRUG|Sitamaquine|
48367774|NCT03946072|PROCEDURE|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or radio frequency (RF) device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
48367775|NCT03946072|PROCEDURE|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
48367776|NCT03382639|DRUG|Luvadaxistat|TAK-831 tablets.
48003740|NCT02843945|DEVICE|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
48003741|NCT05736679|DEVICE|In2Care EaveTube|In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
48003742|NCT05388942|PROCEDURE|Virtual reality hypnosis|VRH offers predefined hypnosis sessions with no need of trained physician or nurse or caregiver mobilization. Consisting of a headset including headphones and a virtual reality screen, VRH allow patients to select a visual and sound environment (e.g.: tropical beach, space, underwater...) into which the hypnotic speech is delivered. That way, the patient's attention is distracted and muscular relaxation is obtained, a major relaxation factor. HRV is simple, quick, and presumably safe.
48003743|NCT05388942|DRUG|Nitrous oxide|inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
48003744|NCT04847674|DRUG|TEV-53275 Dose A|subcutaneous (sc) injection
48003745|NCT04847674|DRUG|TEV-53275 Dose B|subcutaneous (sc) injection
48003746|NCT04847674|DRUG|Placebo|Matching subcutaneous (sc) placebo injection
48367777|NCT03382639|DRUG|Placebo|Luvadaxistat placebo-matching tablets.
48367778|NCT04409262|DRUG|Remdesivir|Participants will receive intravenous (IV) RDV
48367779|NCT04409262|DRUG|Tocilizumab|Participants will receive IV TCZ
48367780|NCT04409262|DRUG|Placebo|Participants will receive IV placebo matched to TCZ
48028572|NCT01140035|OTHER|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
48028573|NCT05377177|DEVICE|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
48367781|NCT06437223|DRUG|Tonabersat|Tonabersat 40mg. Two tablets per day
48367782|NCT06437223|DRUG|Placebo|Placebo 40mg, Two tablets per day
48367783|NCT03067701|DRUG|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
48367784|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the FC formulation
48513511|NCT03129555|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
48513512|NCT03129555|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
48028574|NCT05410574|BEHAVIORAL|Family-based Behavioral Weight Loss Treatment|The treatment includes: 1) the Traffic Light Eating Plan; 2) the Traffic Light Activity Program, 3) a variety of behavioral change strategies e.g., stimulus control, self-monitoring, planning, goal setting and 4) facilitation of support in the family and peer environments to optimize the durability and generalizability of health habits across multiple social and environmental contexts
48028575|NCT02222220|DRUG|Metoclopramide|30 mg/day during 4 weeks
48028576|NCT02222220|DRUG|placebo|
48367785|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
48160722|NCT02990299|BEHAVIORAL|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
48160723|NCT02519270|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein.
48160724|NCT04985071|PROCEDURE|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
48367786|NCT04856293|DRUG|Crizotinib|A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
48160725|NCT06595706|DRUG|Lucid-21-302|Capsule containing a small molecule inhibitor of hypercitrullination
48160726|NCT06595706|DRUG|Placebo|Capsule containing only Silicified Microcrystalline Cellulose
48367787|NCT00074789|BEHAVIORAL|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
48367788|NCT00074789|BEHAVIORAL|Attention control/usual care|Participants will receive the usual care for depression.
48367789|NCT01636076|DRUG|QMF149|delivered via Concept1 device
48367790|NCT01636076|DRUG|Salmeterol|delivered via Accuhaler®
48367791|NCT01586013|DRUG|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
48367792|NCT00769821|OTHER|questionnaire administration|
48367793|NCT00769821|PROCEDURE|assessment of therapy complications|
48367794|NCT00769821|PROCEDURE|bioimpedance spectroscopy|
48367795|NCT00769821|PROCEDURE|quality-of-life assessment|
48367796|NCT03955731|DEVICE|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
48367797|NCT06145269|DRUG|New oral anticoagulant (rivaroxaban) and Marevan (warfarin)|comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)
48689011|NCT04166370|OTHER|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
48689012|NCT00936637|OTHER|Extensively hydrolyzed infant formula|
48689013|NCT01061723|DRUG|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48689014|NCT01061723|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
48689015|NCT02922816|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
48689016|NCT02922816|PROCEDURE|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
48367798|NCT01142011|DRUG|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
48367799|NCT02206776|DRUG|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
48689017|NCT02922816|PROCEDURE|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
48689018|NCT02922816|OTHER|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
48689019|NCT03470194|OTHER|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
48689020|NCT03470194|OTHER|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
48689021|NCT05934591|BEHAVIORAL|Community Wise|The intervention received by each group will be Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
48689022|NCT01539122|DEVICE|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
48689023|NCT01539122|DEVICE|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
48689024|NCT02764359|DRUG|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
48689025|NCT06552845|DIAGNOSTIC_TEST|LGE-MRI Scan|Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
48689026|NCT05037695|DRUG|empagliflozin 25 MG|empagliflozin 25mg - daily
48689027|NCT00659386|DRUG|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
48689028|NCT03828097|DIETARY_SUPPLEMENT|Experimental supplement|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
48689029|NCT03828097|DIETARY_SUPPLEMENT|Placebo|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
48689030|NCT00148486|DRUG|NS 2330|
48689031|NCT05233488|DEVICE|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
48689032|NCT03375489|OTHER|Telehealth|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
48003747|NCT00577512|DRUG|DTPACE|"* Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4"
48003748|NCT06173206|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
48028577|NCT01308580|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
48367800|NCT02206776|DRUG|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
48689033|NCT03375489|OTHER|In-person PC|"In person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
48689034|NCT04574180|OTHER|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
48003749|NCT06173206|DRUG|SPAQ (Guilin Pharmaceuticals)|Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.
48003750|NCT06173206|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
48003751|NCT02313753|BEHAVIORAL|CLASP|
48003752|NCT02313753|BEHAVIORAL|SAFE|
48367801|NCT01508221|DRUG|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
48367802|NCT01508221|DIETARY_SUPPLEMENT|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
48689035|NCT04416334|DRUG|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
48003753|NCT02504697|OTHER|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
48003754|NCT04952194|DRUG|Stalevo|The dose of Stalevo initially ranges from (Levodopa/Carbidopa/Entacapone) 50/12.5/200 mg 3 times a day to a target dose of 100/25/200 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
48003755|NCT04952194|DRUG|Carbidopa and Levodopa Controlled Release Tablets|The dose of Carbidopa and Levodopa Controlled Release Tablets initially ranges from (Levodopa/Carbidopa) 50/12.5mg 3 times a day to a target dose of 100/25 mg 5 times a day, with an interval of 3 hours. No other anti-Parkinson's disease drugs are added.
48003756|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for three months|period of treatment
48367803|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard XP|
48689036|NCT04416334|DRUG|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
48689037|NCT05538949|DRUG|EB-203|"* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8."
48689038|NCT05538949|DRUG|Placebo|Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
48367804|NCT02921594|DEVICE|Total knee arthroplasty with Vanguard CR|
48367805|NCT03802500|DIAGNOSTIC_TEST|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is \< 2,5 mV."
48367806|NCT02030067|DRUG|RX-3117|
48367807|NCT05640141|PROCEDURE|MRI evaluation|"Multimodal MRI evaluation :~* T1 structural,~* Resting echo planar imaging~* Diffusion-weighted imaging~* Arterial sping labeling~* Fluid-attenuated inversion recovery"
48367808|NCT05640141|BEHAVIORAL|Actimetry & IMU|"Evaluation of daily activities and life rythms (physical activity, inactivity, sleep) using actimeters (Motion 8), inertial sensors (GaitUP) and questionaires during 14 days :~* Actimetry : evaluation of daily activity and inactivity, sleep rythms~* Inertial sensors : gait evaluation during daily activities~* Questionaires : sleep (Spiegel \& St Mary's Hospitral) and fatigue (MFI-20)"
48367809|NCT05640141|BEHAVIORAL|Gait evaluation|"Evaluation of gait characteristics (spatio-temporal parameters \& non-linear characteristics) in virtual environment :~* Locomotor simple task : gait only in congruent environment~* Locomotor dual task : gait in similar environment combined with a visually displayed Stroop task~* Sensorimotor gait adaptaition : evaluation of the adaptation capability throughout a split-belt treadmill sequence (realized in simple or dual -combined with the visual Stroop task-)"
48367810|NCT05640141|BEHAVIORAL|Neuropsychological evaluation|"Complete neuropsychological examination including attentional and executive functions, learning and retrieval abilities in episodic memory and general cognitive skills :~* Divided attention (TAP; test of attentional performance)~* California Verbal Learning Test~* The Rey-Osterrieth Complex Figure~* Symbol search and coding (WAIS-IV)~* Go/No-go (TAP)~* Flexibility (TAP)~* Original task of multimodal integration~* Verbal fluencies (GREFEX)"
48367811|NCT00787280|BEHAVIORAL|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
48367812|NCT00787280|BEHAVIORAL|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
48367813|NCT06287554|OTHER|PRONE POSITION|early placed in prone positions within 24 hours of intubation
48367814|NCT02112396|BEHAVIORAL|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
48367815|NCT03606018|DRUG|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
48367816|NCT03606018|DRUG|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
48367817|NCT00004795|DRUG|dehydroepiandrosterone|
48689039|NCT01496287|DEVICE|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
48689040|NCT03203941|BIOLOGICAL|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
48003757|NCT00632554|DRUG|prednisolone 0.5 mg/kg/day for six months|period of therapy
48003758|NCT02022228|DRUG|triptorelin|0.2 mg triptorelin, ih
48160727|NCT01503515|DRUG|Caspofungin Acetate|Given IV
48367818|NCT04722731|BEHAVIORAL|Confident Parents - Brave Children (CPBT)|"Session 1: Psychoeducation.~Session 2: How to decrease criticism and rejection. Skills that provide a warm parenting style and acceptance of the child: validation and child directed play/activities.~Session 3: Strategies to increase the autonomy of the child. The parents will learn how to use a stepladder approach to decrease overprotective behaviours.~Session 4: How to decrease modelling of anxious behaviours and how to be a brave role model.~Session 5: How to recognise and respond when your child is anxious. How to help your child approach new or scary things by using a stepladder approach.~Session 6: Review of the principles and skills learned during the program. The group members will make a plan for how to continue the work on their own."
48513513|NCT03129555|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
48689041|NCT00648427|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
48003759|NCT02022228|DRUG|hCG|1000 IU hCG, im
48160728|NCT01503515|DRUG|Fluconazole|Given IV or PO
48160729|NCT01503515|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48160730|NCT01503515|DRUG|Voriconazole|Given IV or PO
48160731|NCT06445361|DIAGNOSTIC_TEST|FibroScan|Performance of a FibroScan measurement to determine steatosis and fibrosis.
48185190|NCT04766190|BEHAVIORAL|Group 2: The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
48185191|NCT04766190|BEHAVIORAL|Group 1: Usual Care|Patients randomized to this arm will receive usual care.
48689042|NCT00648427|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
48003760|NCT02022228|DRUG|hCG|500IU hCG, im
48003761|NCT05054738|BEHAVIORAL|Combined Recovery Program|A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
48003762|NCT05054738|BEHAVIORAL|Stable & Able (S&A)|A 90-day Home Telehealth program designed to help maintain skills to stay sober.
48003763|NCT05433779|DEVICE|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
48003764|NCT03222843|DRUG|Hetrombopag Olamine|once daily
48003765|NCT03222843|DRUG|matching placebo|once daily
48003766|NCT03610243|BEHAVIORAL|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
48003767|NCT01231581|DRUG|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
48003768|NCT01231581|DRUG|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
48003769|NCT01231581|DRUG|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
48367819|NCT04722731|BEHAVIORAL|"Self-help book What all parents ought to know"|Participants in the control group will receive a self-help parenting book containing general research-based parenting strategies. They will be instructed to read the book within the 10 weeks from baseline to post.
48689043|NCT03886194|PROCEDURE|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
48689044|NCT04670263|DEVICE|Tear Film Imager|Tear Film Imager recording
48003770|NCT05675553|DEVICE|robot-assisted rehabilitation intelligent treatment|Participants assigned to this condition were offered 10 individual sessions of robot-assisted rehabilitation treatment, delivered by the Robot-assisted rehabilitation intelligent system. The system contains 10 core cognitive-behavioral therapy (CBT) skill topics (such as functional analysis, coping skills training, reviewing practice exercises, and explaining CBT concepts). A robot therapist demonstrates the target CBT skills and assigns homework to participants. The treatment framework is semi-structured through human-computer interaction. The forms of interaction include inquiries, statements, recommendations summaries, and knowledge assessments.
48513514|NCT03129555|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
48513515|NCT01840306|OTHER|Biomarker Analysis|
48003771|NCT05675553|OTHER|treatment as usual|Both groups will receive treatment as usual, including medication, exercise, and psychological education.
48513516|NCT02940431|OTHER|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
48689045|NCT01447342|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
48689046|NCT01643265|DIETARY_SUPPLEMENT|Whey Milk Protein|20 grams of Whey Milk Protein
48367820|NCT01480401|OTHER|low-sodium diet (1500 mg daily)|
48689047|NCT01643265|DIETARY_SUPPLEMENT|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
48689048|NCT02590276|BEHAVIORAL|characterization|
48003772|NCT00405548|DRUG|BNP (nesiritide)|
48003773|NCT00405548|DRUG|Placebo|
48003774|NCT02438748|DEVICE|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
48003775|NCT06148922|OTHER|Brief Mental Health First Aid Workshop|a 2-hour workshop delivered by a registered nurse with a MHFA training certificate
48003776|NCT06148922|OTHER|Semi-structured interviews|One-to-one, face-to-face semi-structured interviews will be conducted by a research assistant. The duration would be around 30 minutes.
48003777|NCT00409383|DRUG|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
48003778|NCT00409383|DRUG|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
48367821|NCT05331326|DRUG|RC48-ADC|RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
48689049|NCT02466035|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
48689050|NCT05745337|DRUG|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
48689051|NCT00771706|DRUG|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
48689052|NCT00771706|DRUG|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
48689053|NCT03180333|DRUG|PNA|
48689054|NCT03180333|DRUG|PNA placebo|
48689055|NCT02295228|OTHER|No intervention|There are no interventions. This is an observational trial.
48689056|NCT00062491|DRUG|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
48689057|NCT02525484|DRUG|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
48689058|NCT05209620|DRUG|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
48689059|NCT05209620|DRUG|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
48689060|NCT04242628|OTHER|Facebook course|The intervention consists of the attendance to a course on Facebook and Social Networking Sites use
48513517|NCT02940431|OTHER|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
48689061|NCT04242628|OTHER|Lifestyle Course|The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
48689062|NCT05151159|OTHER|immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3|
48689063|NCT01520649|DRUG|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
48689064|NCT01520649|DRUG|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
48689065|NCT06521385|DEVICE|Makani Science Respiratory Monitoring System|Subjects monitored by the Makani Science Respiratory Monitoring System
48689066|NCT00855777|DRUG|etoricoxib|etoricoxib 120 mg/day for 3 days
48689067|NCT00855777|DRUG|ibuprofen|ibuprofen 1,800 mg/day for 3 days
48689068|NCT01963182|DRUG|Irinotecan|
48689069|NCT00497419|PROCEDURE|fast track|
48689070|NCT04952662|GENETIC|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
48689071|NCT01541007|DRUG|Cabazitaxel|25 mg/m2 every three weeks
48689072|NCT01541007|DRUG|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
48689073|NCT05609305|OTHER|Discharge|observational study, not intervention
48689074|NCT05436522|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
48689075|NCT05436522|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
48689076|NCT01901289|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
48689077|NCT03899233|DEVICE|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
48689078|NCT03899233|DRUG|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
48689079|NCT00540241|DRUG|Pemetrexed|in-label use
48689080|NCT04192669|DEVICE|Heart rate monitoring|The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
48689081|NCT05064501|DIAGNOSTIC_TEST|spirometry|Lung function test: pre and post bronchodilator spirometry
48689082|NCT05064501|OTHER|Asthma control test|Asthma control test
48689083|NCT02572505|DRUG|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
48689084|NCT01268540|DEVICE|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
48689085|NCT01268540|DEVICE|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
48689086|NCT04022525|DRUG|Leflunomide 20Mg Tab|blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
48003779|NCT00409383|DRUG|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
48003780|NCT00259090|DRUG|Fulvestrant|500 mg intramuscular injection
48689087|NCT05820139|PROCEDURE|Control Group|Patients will be randomized to a 200mL (control group)
48689088|NCT05820139|PROCEDURE|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
48367822|NCT04993183|BEHAVIORAL|3-day PLUS Convention|Participants will participate in a 3-day PLUS Convention, comprising an inclusivity education workshop, a service-learning seminar, a disability simulation workshop, and two community contact sessions which will consist of a 60-minute interview with an older adult with a physical disability and an outdoor experience. Discussion sessions will be facilitated throughout to consolidate learning.
48367823|NCT02736487|DEVICE|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
48689089|NCT04788485|DRUG|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
48689090|NCT01364480|DEVICE|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
48689091|NCT03203824|DIETARY_SUPPLEMENT|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
48689092|NCT03203824|OTHER|non dark chocolate|No dark chocolate will be given to this group during the procedures.
48689093|NCT01212887|BIOLOGICAL|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
48689094|NCT01212887|BIOLOGICAL|aldesleukin|
48689095|NCT01212887|DRUG|cyclophosphamide|
48513518|NCT00001946|PROCEDURE|Magnetic resonance angiography|
48513519|NCT03988686|PROCEDURE|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
48513520|NCT03988686|DRUG|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
48367824|NCT02736487|DEVICE|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
48367825|NCT02488265|OTHER|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
48367826|NCT02488265|OTHER|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
48689096|NCT01212887|DRUG|fludarabine phosphate|
48689097|NCT01212887|OTHER|laboratory biomarker analysis|
48689098|NCT01212887|OTHER|pharmacological study|
48003781|NCT00259090|DRUG|Anastrazole|oral tablet
48003782|NCT04377282|OTHER|Food-1|Cooked buckwheat
48003783|NCT04377282|OTHER|Food-2|Cooked couscous
48003784|NCT04377282|OTHER|Food-3|Water
48003785|NCT01418937|BIOLOGICAL|CervarixTM (GSK580299)|Three intramuscular injections
48028578|NCT01308580|DRUG|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
48028579|NCT02352064|PROCEDURE|PET (18-FDG)|Every patient will have a PET
48028580|NCT05528081|OTHER|Phone interview|Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans.
48522634|NCT03674736|DIETARY_SUPPLEMENT|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
48689099|NCT04666142|OTHER|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
48689100|NCT04666142|OTHER|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
48689101|NCT06176781|DRUG|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
48689102|NCT06176781|DRUG|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
48689103|NCT00294671|DRUG|diflunisal|given twice daily for 24 months
48689104|NCT00294671|OTHER|placebo|an inactive substance given twice daily for 24 months
48689105|NCT00851552|BIOLOGICAL|rituximab|Given IV
48689106|NCT00851552|DRUG|bortezomib|Given IV
48689107|NCT00851552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
48689108|NCT00851552|GENETIC|gene expression analysis|Correlative Study
48689109|NCT00851552|GENETIC|polymerase chain reaction|Correlative Study
48689110|NCT00851552|GENETIC|polymorphism analysis|Correlative Study
48028581|NCT04853004|DIAGNOSTIC_TEST|SARS-CoV2 antibody measurement|Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
48689111|NCT00851552|GENETIC|proteomic profiling|Correlative Study
48689112|NCT00851552|OTHER|flow cytometry|Correlative Study
48689113|NCT00851552|OTHER|laboratory biomarker analysis|Correlative Study
48689114|NCT01434628|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
48689115|NCT03233828|BIOLOGICAL|Aldesleukin|500,000 IU in 0.1mL
48689116|NCT03233828|OTHER|Saline|0.1 mL of sterile saline solution (0.9% m/v)
48689117|NCT00025792|DRUG|Pramipexole|
48689118|NCT00849355|DRUG|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
48689119|NCT04642118|PROCEDURE|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
48689120|NCT01899508|PROCEDURE|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
48689121|NCT01899508|DEVICE|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
48160732|NCT05527509|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
48522635|NCT06582654|DEVICE|Sampling|"Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study)."
48689122|NCT04300205|DEVICE|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
48160733|NCT05527509|BEHAVIORAL|Active Monitoring|Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
48160734|NCT06645782|BEHAVIORAL|Virtual, Group CF-CBT|Virtual, group CF-CBT is an online, tailored CBT program for adults diagnosed with CF. Participants will attend eight weekly sessions (90 minutes each) delivered online. The sessions include: Introduction to CBT; Relaxation Skills; Depression in CF: What Helps?; Adaptive Thinking Skills, Part 1; Adaptive Thinking Skills, Part 2; Taking Charge of My Health; Anxiety in CF: What Helps?; and Maintaining Positive Changes.
48689123|NCT04300205|DEVICE|Sham LED light device|Participants have the light treatment moved off their wound after masking
48689124|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
48028582|NCT03219112|OTHER|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
48689125|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
48689126|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
48689127|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
48689128|NCT04266392|DRUG|[18F]-DCFPyl Ligand|To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
48689129|NCT04588220|OTHER|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
48689130|NCT05195645|DRUG|Abatacept 250 MG|Abatacept will be administered by intravenous injection over 1h15 to 2h30 on D1, D5+/-2 and D14+/-2 at 10mg/kg (arm A), or 20mg/kg (arm B) or 25mg/kg (arm C) depending on the randomization (max 3 000 mg per administration). Starting Day 21 (after evaluation of the primary outcome), other injection of abatacept may be given (D22 at D90) with dosage (10 or 20mg/kg max) decided by the treating physician (max 2 500 mg per administration) as a function of the relapse or not of the ICI myocarditis after immunosuppressant therapeutics tapering. After day 21, the administrations will be carried out in open but the blind administration 1 to 3 (D1 to D21) will be kept.
48160735|NCT04881045|BIOLOGICAL|PF-07257876|CD47-PDL-1 bispecific antibody
48003786|NCT04126291|BEHAVIORAL|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
48003787|NCT03521986|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
48003788|NCT03521986|PROCEDURE|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
48003789|NCT01354496|DRUG|LY2409021 Reference Form|Administered orally
48689131|NCT00983333|DEVICE|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
48003790|NCT01354496|DRUG|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
48003791|NCT01354496|DRUG|LY2409021 Test-High Formulation (high particle size)|Administered orally
48003792|NCT01354496|DRUG|LY2409021 Test-Low Formulation (low particle size)|Administered orally
48689132|NCT00027144|BIOLOGICAL|Heat Shock Protein 70 HSP70|
48689133|NCT00023933|DRUG|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
48689134|NCT01732029|OTHER|Normobaric hypoxia chamber|
48689135|NCT06035406|DRUG|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
48689136|NCT01207609|PROCEDURE|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
48689137|NCT03092999|DRUG|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
48689138|NCT01964495|DRUG|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
48689139|NCT01964495|DRUG|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
48689140|NCT01964495|DRUG|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
48689141|NCT00219193|DRUG|aliskiren|
48003793|NCT02958839|PROCEDURE|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
48003794|NCT01895673|OTHER|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
48003795|NCT01772641|OTHER|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
48160736|NCT00935129|DEVICE|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
48160737|NCT00935129|DEVICE|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
48689142|NCT05270941|PROCEDURE|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
48689143|NCT03657134|DIAGNOSTIC_TEST|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
48689144|NCT05544201|DEVICE|High-definition transcranial current stimulation|High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
48689145|NCT00419211|BEHAVIORAL|Exercise|Tailored exercise program
48689146|NCT00086983|DRUG|becatecarin|Given IV
48689147|NCT00086983|DRUG|oxaliplatin|Given IV
48689148|NCT00086983|OTHER|pharmacological study|Correlative studies
48367827|NCT00804596|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
48367828|NCT05453318|PROCEDURE|Treatment of cervical neoplasia by thermal ablation|Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
48367829|NCT05151952|RADIATION|Other: Registry|Registry of cancer patients who receive proton radiation therapy.
48367830|NCT01089075|DRUG|Hydrocortisone|20 mg po for 7 days (2 tablets)
48367831|NCT01089075|DRUG|Placebo|2 tablets po
48513521|NCT03435510|BEHAVIORAL|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
48689149|NCT00718575|PROCEDURE|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
48689150|NCT00989846|OTHER|biomarker|measuring serum-biomarkers
48689151|NCT06005532|DRUG|Adalimumab|Adalimumab injection 40 mg / 0.8 ml
48689152|NCT06005532|DRUG|Humira|Adalimumab injection 40 mg / 0.4 ml
48689153|NCT00799227|DRUG|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
48689154|NCT01631487|DRUG|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
48689155|NCT01631487|DRUG|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
48689156|NCT01631487|DRUG|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
48185192|NCT04766190|BEHAVIORAL|Group 3: The DISCO App + Booster|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.
48367832|NCT02283801|DRUG|Eslicarbazepine acetate|
48367833|NCT02283801|DRUG|Lamotrigine|
48367834|NCT05403775|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in TFESI combined with dorsal root ganglion PRF to help to reduce intra-operative radiation.
48367835|NCT05403775|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy.
48513522|NCT06551376|OTHER|Ovarian Stimulation Start|To compare ovarian response accordin to ovarian stimualtion start
48513523|NCT04969731|DRUG|Immuncell-LC|IV
48689157|NCT01631487|DRUG|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
48689158|NCT05856929|OTHER|no Intervention|no intervention
48689159|NCT06519240|RADIATION|18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)|Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.
48689160|NCT04607434|DRUG|Ocotillol Type Ginsenoside Derivatives|Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
48689161|NCT06125067|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
48689162|NCT06125067|PROCEDURE|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
48367836|NCT01352923|OTHER|blood test|preparation of blood platelets
48367837|NCT01854918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
48160738|NCT05048407|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
48160739|NCT03630458|OTHER|Pearl millet couscous - made in Senegal|Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
48367838|NCT01854918|DRUG|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
48367839|NCT03235245|DRUG|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
48367840|NCT03235245|DRUG|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
48689163|NCT06125067|PROCEDURE|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
48367841|NCT05303051|DEVICE|Application Validation|After creating accounts, participants in both groups will download the Azumio Instant Diabetes Test and provide a Photoplethysmography (PPG) waveforms by placing their index finger over their smartphone camera for 20 seconds to provide PPG waveform data for the study .
48689164|NCT05221567|BEHAVIORAL|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
48689165|NCT05464238|OTHER|Exercise rehabilitation|The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
48689166|NCT05464238|OTHER|Standard treatment|Standard treatment during study duration
48689167|NCT04835220|OTHER|Telehealth Calls|The telehealth nurse will record data in a case report form within the VA REDCap electronic data capture system that is stored within the VA firewall.
48689168|NCT02797301|OTHER|synthetic test|The children performed the synthetic test with no time restriction.
48160740|NCT03630458|OTHER|Pearl millet couscous - made in USA|Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
48367842|NCT04041648|DRUG|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
48689169|NCT02797301|OTHER|computerised test|The children performed the computerised test with no time restriction.
48689170|NCT03198767|DRUG|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
48689171|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 50%|50% carbohydrate in breakfast meal
48689172|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 25%|25% carbohydrate in breakfast meal
48689173|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 8%|8% carbohydrate in breakfast meal
48160741|NCT03630458|OTHER|Pearl millet thick porridge|Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
48160742|NCT03630458|OTHER|Wheat couscous|Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
48689174|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 0%|0% carbohydrate in breakfast meal
48689175|NCT03198767|DIETARY_SUPPLEMENT|Psyllium|Powder 6 grams
48689176|NCT03198767|DIETARY_SUPPLEMENT|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
48689177|NCT05116397|OTHER|Inspired gas|Inspired gas content
48160743|NCT03630458|OTHER|White rice|White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
48160744|NCT03097458|BEHAVIORAL|Short-term Counselling for Families|Counselling for Families which can take up to 6 weeks, with regular meetings under the guidance of a trained psychotherapist.
48160745|NCT04421118|OTHER|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
48367843|NCT04041648|DEVICE|L606 Inhalation System|Single ascending dose
48367844|NCT04041648|OTHER|Placebo Solution|Single ascending dose
48367845|NCT03985358|OTHER|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
48367846|NCT05521542|DEVICE|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable angina, unstable angina, or NSTEMI
48367847|NCT03198585|DRUG|Empagliflozin 10 MG|Capsule, once a day for 90 days
48689178|NCT03287882|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
48689179|NCT03287882|BEHAVIORAL|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
48689180|NCT02180685|OTHER|Anchor fixation|
48689181|NCT05046717|DEVICE|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~1. HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~2. ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~3. FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
48689182|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
48689183|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
48689184|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
48689185|NCT06221943|BEHAVIORAL|Group-based Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
48689186|NCT06221943|BEHAVIORAL|One-on-one Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
48689187|NCT06221943|BEHAVIORAL|ASD Diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
48003796|NCT01772641|OTHER|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
48689188|NCT04726930|PROCEDURE|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
48689189|NCT04726930|PROCEDURE|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
48689190|NCT00422643|DRUG|Sodium hyaluronate (hyaluronic acid)|
48689191|NCT05713981|PROCEDURE|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
48689192|NCT05469425|BEHAVIORAL|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
48003797|NCT01772641|OTHER|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
48003798|NCT01772641|OTHER|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
48160746|NCT01486277|DRUG|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
48160747|NCT00130728|DRUG|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
48513524|NCT04969731|DRUG|Gemcitabine|IV
48003799|NCT03759756|OTHER|AI presentation|AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.
48367848|NCT03198585|OTHER|Placebo|Capsule, once a day for 90 days
48367849|NCT04033718|DIAGNOSTIC_TEST|Inpatient lab bundling|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.
48367850|NCT04033718|BEHAVIORAL|Inpatient navigation|Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
48367851|NCT02502591|DRUG|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
48367852|NCT01356615|DRUG|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
48367853|NCT01356615|DRUG|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
48367854|NCT06272773|DEVICE|Forced Oscillation Test|Participant will breathe normally through the device which sends different frequency sounds into the airways, monitoring the response coming back from central and peripheral airways to calculate airway impedence, reactance and resistance.
48003800|NCT03759756|OTHER|no AI presentation|AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
48003801|NCT04208906|DEVICE|Masimo O3|"After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~* T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~* T2: before CPB, FiO2 0.5~* T3: before CPB, FiO2 0.8~* T4: after CPB, FiO2 0.8~* T5: after CPB, FiO2 0.5~* T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2."
48003802|NCT06485271|DRUG|Camrelizumab|200mg,iv,d1,Q2W/Q3W
48003803|NCT06485271|DRUG|apatinib|250mg,qd
48003804|NCT06485271|DRUG|chemotherapy|Standard treatment
48003805|NCT04732637|DIAGNOSTIC_TEST|"Test At Home's Proprietary Lollipop Buccal Cavity Swab"|"Self-collected Test At Home's proprietary Lollipop Buccal Cavity Swab with VTM."
48003806|NCT01660828|OTHER|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
48003807|NCT01218516|BIOLOGICAL|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
48003808|NCT01218516|OTHER|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
48160748|NCT00130728|DRUG|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
48160749|NCT00130728|DRUG|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
48367855|NCT05823155|PROCEDURE|Detailed penicillin allergy evaluation|The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
48689193|NCT00711230|BIOLOGICAL|DermaVir|
48689194|NCT00711230|BIOLOGICAL|Placebo|glucose/dextrose
48003809|NCT01218516|DRUG|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
48003810|NCT01218516|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 will be administered intravenously.
48003811|NCT01218516|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously.
48003812|NCT01218516|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered intravenously.
48003813|NCT03914742|DRUG|PARP Inhibitor BGB-290|Given PO
48003814|NCT03914742|DRUG|Temozolomide|Given PO
48003815|NCT03914742|PROCEDURE|Therapeutic Conventional Surgery|resection surgery
48003816|NCT02372669|DEVICE|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
48003817|NCT02372669|PROCEDURE|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
48003818|NCT02282956|DRUG|Ropivacaine 0,75%|Ropivacaine injection
48003819|NCT02282956|PROCEDURE|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
48003820|NCT02282956|DRUG|morphine and droperidol|i.v PCA
48689195|NCT02672059|OTHER|Observation|No intervention
48689196|NCT00295009|DEVICE|ProDisc|Total disc replacement with ProDisc
48160750|NCT03319719|DEVICE|Belotero® Balance with integral lidocaine|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
48003821|NCT00698269|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48160751|NCT03319719|DEVICE|Belotero® Balance|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
48160752|NCT01189617|DEVICE|Formula PD-F-7619|Off-White to Beige Lotion
48160753|NCT00992654|DRUG|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
48160754|NCT03698305|DRUG|ASP5354|Intravenous
48160755|NCT03698305|DRUG|Placebo|Intravenous
48367856|NCT04041401|OTHER|PICU storybook|Narrative and developmentally appropriate intervention
48367857|NCT06519903|BEHAVIORAL|BREATH technique|The BREATH techniques include deep breathing, rapid breathing, and alternate nostril breathing exercises. Participants were first instructed on the breathing exercises (at the lowest point of breathing, close the left nostril with the right index finger and exhale through the right nostril): Breathe in through the right nostril, then close it with your thumb and breathe out through the left nostril. This cycle was repeated at least three more times.
48367858|NCT04139161|PROCEDURE|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion \>12, indicating a transition to moderate physical activity, or 3) self-reported pain \>5.
48367859|NCT01375491|DRUG|Doxycycline|generic doxycycline 100mg twice daily
48689197|NCT00295009|PROCEDURE|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
48367860|NCT01375491|OTHER|Placebo|Placebo comparator to doxycycline
48367861|NCT01512758|DRUG|Alisertib|Alisertib enteric-coated tablets
48367862|NCT06046937|DRUG|Monolaurin|applied thinly twice a day
48367863|NCT06046937|DRUG|Mupirocin ointment|applied thinly twice a day
48367864|NCT05702840|BEHAVIORAL|Resistance exercise training + weight loss group|Doing resistance exercises as well as following the weight watchers weight loss programme for a 12-week period
48367865|NCT05702840|BEHAVIORAL|Weight loss only group (WL)|Only following the weight watchers weight loss programme for a 12-week period
48367866|NCT06510192|BEHAVIORAL|Yuva Sath|The Yuva Sath Intervention comprises 6 one-on-one sessions with peer counselors who will use an intervention manual. The intervention also includes weekly phone text check-ins by peer counselors
48689198|NCT00025571|DRUG|HPPH|
48689199|NCT05018195|PROCEDURE|Excise adipose tissue|Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
48689200|NCT02821065|DEVICE|Remote Patient Monitoring|
48689201|NCT05182658|DRUG|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
48003822|NCT00698269|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48003823|NCT00698269|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48003824|NCT00082433|DRUG|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
48003825|NCT00082433|DRUG|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
48160756|NCT06311448|DRUG|Single target immunomodulation|Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.
48689202|NCT05182658|DRUG|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
48689203|NCT00482040|DEVICE|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
48160757|NCT06311448|DRUG|Standard of care|Standard of care during COVID-19 pandemic including steroids.
48160758|NCT05363098|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
48160759|NCT05223283|OTHER||
48185193|NCT03936842|BEHAVIORAL|Breast Pain video|An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.
48367867|NCT01997827|DEVICE|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
48367868|NCT01997827|DEVICE|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
48367869|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (0.5 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)
48689204|NCT05627232|DRUG|Tazemetostat|Given PO
48003826|NCT04950777|BEHAVIORAL|patient education document|The patient education will be designed to address and investigate the four domains of physical literacy including, knowledge and understanding, motivation and confidence, daily behavior, and physical competence, (i.e., referral based training/PT (passive), self-motivated/directed exercise choice (speaks to child ownership/motivation), simple play outside 60 minutes/day (middle)).
48003827|NCT04122378|OTHER|acupuncture|The acupuncture will be provided by the licensed acupuncturist using standard methods.
48003828|NCT03321669|PROCEDURE|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
48003829|NCT01163409|PROCEDURE|exercise training|exercise training comprises aerobic and strength training
48003830|NCT01163409|PROCEDURE|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
48003831|NCT01163409|PROCEDURE|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
48003832|NCT00886431|OTHER|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
48003833|NCT01076985|DRUG|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
48003834|NCT02194868|BIOLOGICAL|Recipients|"1. Adult recipient:~   * collected 20 ml pre-transplant~  * collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~  * collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~2. Children recipients~   * collected residual blood pre-transplant~  * collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~  * collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
48367870|NCT04185766|DIETARY_SUPPLEMENT|Administration of a placebo solution (1 ml / kg)|43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)
48367871|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel (0.5 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)
48003835|NCT02194868|BIOLOGICAL|Donors|"1. Adult donors :~   * collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~  * collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~2. Children donors samples~   * collected residual blood~  * 2ml of bone marrow (bottom of tube)"
48003836|NCT01853033|BIOLOGICAL|ABT-122|Injection
48003837|NCT01853033|BIOLOGICAL|Placebo|Placebo Injection
48003838|NCT01193491|DRUG|IPI-493|Capsules, ascending dose, multiple schedules
48003839|NCT06188442|DRUG|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
48003840|NCT06188442|DRUG|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
48367872|NCT04185766|DIETARY_SUPPLEMENT|Administration of 40% glucose in gel 1 ml / Kg)|43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
48367873|NCT04415749|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
48003841|NCT05210790|DRUG|Placebo|Placebo
48003842|NCT05210790|DRUG|Rusfertide|Experimental drug
48003843|NCT04907032|DRUG|Mirabegron 50 MG|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
48003844|NCT04907032|DEVICE|Posterior Tibial Nerve Stimulation (PTNS)|Posterior Tibial Nerve Stimulation with Mirabegron vs. Posterior Tibial Nerve Stimulation Plus Placebo
48003845|NCT02734888|OTHER|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
48003846|NCT02119546|OTHER|Aerobic exercise|Aerobic exercise and dual-task training
48367874|NCT04415749|OTHER|Placebo|Normal saline
48367875|NCT03934333|DRUG|BDA MDI 160/180 mcg|Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
48367876|NCT03934333|DRUG|Pulmicort Flexhaler 180 mcg|Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
48367877|NCT03627442|PROCEDURE|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
48367878|NCT03627442|PROCEDURE|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
48513525|NCT05373199|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
48689205|NCT05627232|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48689206|NCT05627232|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48367879|NCT03524560|OTHER|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up \& Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL \& IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG \&TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
48689207|NCT05627232|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48689208|NCT05627232|DRUG|Palbociclib|Given PO
48689209|NCT02422693|OTHER|Aquatic Exercises|Exercises performed in the water.
48689210|NCT02422693|OTHER|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
48003847|NCT02119546|OTHER|Stretch exercise|Stretch exercise \& sitting balance
48003848|NCT05103228|DRUG|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
48367880|NCT02104232|BEHAVIORAL|THPP-I|
48367881|NCT02104232|BEHAVIORAL|EUC|
48367882|NCT00302731|DRUG|Estradiol , estriol , progesterone|
48689211|NCT01504516|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
48689212|NCT01504516|DRUG|Aricept|Aricept 10 mg Tablets
48689213|NCT00879034|DRUG|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
48689214|NCT00879034|DRUG|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
48689215|NCT00879034|DRUG|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
48689216|NCT06245486|DIETARY_SUPPLEMENT|Crispact®|Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247
48689217|NCT06245486|DIETARY_SUPPLEMENT|Placebo|Placebo
48689218|NCT00584532|DRUG|Placebo|10 Placebo Capsules taken orally every day.
48689219|NCT00584532|DRUG|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
48689220|NCT05498935|OTHER|CPB time|Cardiopulmonary bypass time
48367883|NCT00302731|DRUG|estradiol, progesterone|
48367884|NCT00302731|DRUG|estriol, progesterone|
48367885|NCT00302731|DRUG|equine estrogens m-progesteroneacetate|
48513526|NCT05373199|DRUG|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
48003849|NCT05103228|DRUG|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
48367886|NCT02135848|DRUG|GSK1278863|GSK1278863
48689221|NCT03680196|DRUG|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
48367887|NCT02135848|DRUG|Placebo|Placebo
48367888|NCT03266211|OTHER|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
48367889|NCT03266211|OTHER|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
48367890|NCT01363973|DEVICE|VITALSTIM transcutaneous electrical stimulation|
48367891|NCT06448520|OTHER|Muscle Power Sprint Test|The Muscle Power Sprint Test (MPST) is an easy-to-perform field test of anaerobic capacity for children and adolescents. The only necessities for the administration of this test are an open space, a stopwatch and two cones or lines. Test subjects are encouraged to perform six 15-meter sprints at a maximal pace between the two cones/lines, with a 10-second rest in between each effort. The distance covered during these short runs corresponds well to the distances children cover during daily play activities. The power that is generated with each sprint can be calculated using the formula: power = (total mass x 15 m²)/time³.
48367892|NCT01593800|DIETARY_SUPPLEMENT|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
48367893|NCT00003309|BIOLOGICAL|filgrastim|
48003850|NCT05103228|DRUG|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
48003851|NCT04188262|COMBINATION_PRODUCT|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
48367894|NCT00003309|DRUG|cisplatin|
48367895|NCT00003309|DRUG|cyclophosphamide|
48367896|NCT00003309|DRUG|etoposide|
48367897|NCT00003309|DRUG|vincristine sulfate|
48367898|NCT00003309|PROCEDURE|adjuvant therapy|
48367899|NCT00003309|RADIATION|radiation therapy|
48367900|NCT02569268|OTHER|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
48367901|NCT05199389|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
48367902|NCT01289730|DRUG|Etanercept|Etanercept 25 mg subcutaneously twice a week
48367903|NCT03193918|DRUG|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
48367904|NCT03193918|DRUG|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
48367905|NCT03193918|DRUG|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
48513527|NCT05373199|DRUG|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
48513528|NCT00717288|DRUG|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
48513529|NCT00717288|DRUG|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
48513530|NCT00717288|DRUG|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
48513531|NCT04902937|RADIATION|Adjuvant radiotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
48513532|NCT04902937|DRUG|neoadjuvant and adjuvant chemotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
48513533|NCT01679509|PROCEDURE|Single-port laparoscopic adnexal surgery|
48513534|NCT01679509|PROCEDURE|Three-port laparoscopic adnexal surgery|
48689222|NCT01650649|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
48367906|NCT01953419|DRUG|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
48367907|NCT01645215|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
48367908|NCT05094258|PROCEDURE|unicondylar knee prosthesis with mobile insert|Patients with unicondylar knee replacement using the mobile insert option
48689223|NCT01650649|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
48689224|NCT01877850|PROCEDURE|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
48689225|NCT05097560|DEVICE|high flow nasal cannula|HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.
48689226|NCT05097560|DEVICE|Venturi mask|VM is commonly used by COPD patients during exercise training.
48689227|NCT01927523|BEHAVIORAL|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
48689228|NCT01927523|OTHER|Match|An intensive math tutoring program.
48689229|NCT04733118|DRUG|Trastuzumab and Pertuzumab (FDC SC) and T-DM1|"Patients will receive Trastuzumab and Pertuzumab as a subcutaneous fixed-dose combination (PH FDC SC) (± ET depending on HR status) for 8 3-week cycles, on day 1 only. ET will consist of letrozole for post-menopausal women or tamoxifen ± ovarian function suppression (OFS) for pre-menopausal women administered continuously. Men will receive tamoxifen.~After completing neoadjuvant therapy, a final breast MRI will be performed 2 weeks prior to surgery. Surgery will be performed within 4 weeks after completion of the last cycle of PH FDC SC.~Adjuvant systemic therapy will start within 4 weeks from surgery. There will be three different cohorts depending on pathological report:~* Cohort A: PH FDC SC ± ET for 10 additional 3-week cycles~* Cohort B: T-DM1 ± ET for 10 cycles~* Cohort C: T-DM1 ± ET for 10 cycles, with possibility of physician's choice chemotherapy before adjuvant T-DM1."
48689230|NCT01634880|DRUG|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
48689231|NCT04747236|DRUG|Azacytidine|Azacytidine, 300 mg po daily on Days 1-14
48689232|NCT04747236|DRUG|Romidepsin|Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
48003852|NCT00153400|BEHAVIORAL|Enhanced Lifestyle Intervention|Three face-to-face counseling sessions for nutrition and physical activity. Used a Spanish culturally tailored materials. These interventions were delivered by community health workers (CHWs) who are trained.
48160760|NCT02394509|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
48689233|NCT04747236|DRUG|Belinostat|Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
48689234|NCT04747236|DRUG|Pralatrexate|Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
48689235|NCT04747236|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
48160761|NCT04859218|PROCEDURE|RBC transfusion|two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
48367909|NCT05094258|PROCEDURE|unicondylar knee prosthesis with fixed insert|Patients with unicondylar knee replacement using the fixed insert option
48367910|NCT05099458|BIOLOGICAL|Additional blood sampling (100 ml)|only an additional blood volume will be collected at the same time of the standard blood collection for these patients
48367911|NCT00367380|OTHER|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
48003853|NCT04619706|DRUG|FSD201|Tablets for oral administration.
48003854|NCT04619706|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
48003855|NCT04619706|OTHER|Standard of Care for Covid-19|Standard of care for Covid-19 as determined by site PI
48003856|NCT02696551|OTHER|Medical education|
48160762|NCT01953471|OTHER|Allergic rhinitis|Questionnaire
48003857|NCT00802022|DEVICE|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
48003858|NCT04401891|BEHAVIORAL|Formal pre-operative education|One group of patients will receive formal pre-operative education prior to surgery from an occupational or physical therapists while the other group of patients will only receive routine education in the MD office.
48003859|NCT02294877|DRUG|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
48003860|NCT05210127|PROCEDURE|Scarf osteotomy for Hallux Valgus deformity|An experiment of foot muscle strength and activation, during gate phases after hallux valgus correction with the use of core foot system protocol
48003861|NCT03948373|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
48160763|NCT03451994|OTHER|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
48160764|NCT00006137|DRUG|enalapril|
48160765|NCT00273650|DRUG|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
48160766|NCT00273650|OTHER|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
48160767|NCT02469051|DEVICE|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
48160768|NCT02469051|DEVICE|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
48160769|NCT02469051|DEVICE|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
48160770|NCT01643018|PROCEDURE|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
48160771|NCT01643018|PROCEDURE|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
48160772|NCT00212979|OTHER|non intervention study|
48160773|NCT03698721|PROCEDURE|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
48367912|NCT00367380|OTHER|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
48160774|NCT05155553|DEVICE|QIAstat-Dx® Meningitis/Encephalitis (ME) Panel|The performance of QIAstat-Dx® Meningitis/Encephalitis Panel will be evaluated in comparison with another validated comparator method, followed by bidirectional sequencing using residual specimens of cerebrospinal fluid (CSF) obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis.
48160775|NCT04369664|DRUG|Statin|Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
48160776|NCT04369664|DRUG|PCSK9 inhibitor|Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
48513535|NCT03936803|BEHAVIORAL|aerobic interval training exercise .|Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down
48513536|NCT03936803|DEVICE|electro acupuncture|"electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
48367913|NCT00367380|OTHER|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
48367914|NCT03612635|DEVICE|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
48367915|NCT04065711|DEVICE|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
48367916|NCT01663155|DEVICE|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
48513537|NCT04357548|DEVICE|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
48513538|NCT01944111|DEVICE|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
48513539|NCT06250946|DRUG|HRS-7535;Placebo|HRS-7535;Placebo
48513540|NCT06250946|DRUG|Placebo|Placebo
48003862|NCT06420154|BIOLOGICAL|anti-CD19-CAR-T cells|"The subjects received infusions of anti-CD19 CAR-T cells following completion of lymphodepleting preconditioning chemotherapy.~Dosage：1×10\^5 cells/Kg; 3×10\^5 cells/Kg; 1×10\^6 cells/Kg~frequency：single infusion"
48367917|NCT05021731|DRUG|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
48367918|NCT05021731|DRUG|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
48367919|NCT05021731|DRUG|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
48367920|NCT00479973|DIETARY_SUPPLEMENT|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
48367921|NCT00479973|DIETARY_SUPPLEMENT|Placebo|Placebo. 2 capsules after the two largest meals of the day
48367922|NCT06186154|DIETARY_SUPPLEMENT|Folinic acid (oral); Cyanocobalamin sublingual|"* Vitamin B12 (also known as Cyanocobalamin) daily sublingual supplementation of 1000 mcg/day and folinic acid orally 1mg/day~* Laboratory: Complete blood count, electrolytes, reticulocytes, creatinine, urea, alkaline phosphatase (ALP), alanine transaminase, ferritin, total homocysteine, lactate and hemoglobin A1c. Routine blood will be collected as regular standard of care with each visit. MMA will also be assessed. Peripheral serum values (CBC, B12) will serve as a representation of central micronutrient availability~* Clinical Evaluation: the Newcastle mitochondrial disease adult scale (NMDAS)"
48367923|NCT00816244|DRUG|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
48367924|NCT04737226|DIAGNOSTIC_TEST|myotonometric assessment|The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.
48367925|NCT04737226|DIAGNOSTIC_TEST|Ankle mobility assessment|The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
48367926|NCT02108561|OTHER|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
48367927|NCT00490828|DRUG|Hydrocortisone|Hydrocortisone
48367928|NCT03429894|DEVICE|Percutaneous Coronary Intervention|Drug eluting stent implant
48367929|NCT04419220|OTHER|Doppler Ultrasound|Flow measurements using Doppler ultrasound
48367930|NCT06082011|DEVICE|da Vinci SP Surgical System|Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
48367931|NCT02554721|DRUG|Cilostazol|
48689236|NCT05450224|BEHAVIORAL|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
48367932|NCT02554721|DRUG|Acetylsalicylic acid|
48003863|NCT04448899|DRUG|Ivabradine Oral Tablet|Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.
48367933|NCT02554721|DRUG|Clopidogrel|
48367934|NCT05177666|DRUG|Targeted therapy|Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
48367935|NCT00945945|DRUG|Duloxetine (DLX)|dose daily by mouth
48367936|NCT00945945|DRUG|Placebo (PLA)|Placebo Comparator daily by mouth
48513541|NCT04514432|OTHER|Music|If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
48513542|NCT04252339|DRUG|RLY-1971|RLY-1971 is an oral inhibitor of SHP2.
48513543|NCT01970774|OTHER|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
48513544|NCT03369197|DEVICE|Nasal Mask|Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
48003864|NCT04448899|DRUG|Blacebo plus standard treatment|Blacebo plus standard treatment
48367937|NCT01768182|DIETARY_SUPPLEMENT|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
48367938|NCT01768182|OTHER|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
48367939|NCT00768040|DRUG|Aliskiren|300 mg once daily
48367940|NCT00768040|DRUG|Placebo|Matching placebo once daily
48367941|NCT00984958|DEVICE|Bulkamid|injection of Bulkamid in the urethra
48367942|NCT00984958|DEVICE|Bulkamid expectation|expectance
48367943|NCT06401902|PROCEDURE|carotid clamping|Occurrence of consciousness perturbations, language difficulties and/or contralateral motor deficit during the carotid-clamping test and requiring shunt placement.
48513545|NCT03369197|DEVICE|Control: Nasal Cannula|Nasal cannula as per usual care
48689237|NCT02027311|DRUG|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
48003865|NCT00327704|DRUG|albumin|albumin 20% 100 ml/8 hours for 3 days
48367944|NCT01652651|BEHAVIORAL|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
48367945|NCT04424758|OTHER|Video information about mammography screening|A video informing about mammography screening
48367946|NCT04424758|OTHER|Video information about smart energy systems|A video informing about smart energy systems
48367947|NCT06321796|COMBINATION_PRODUCT|MTP-101P|"MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.~Duration: 12.5 Weeks"
48367948|NCT06321796|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 10 Days"
48003866|NCT00327704|DRUG|saline|saline 100 ml/8hours for 3 days
48160777|NCT04369664|DRUG|Ezetimibe 10mg|Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
48160778|NCT06366724|DRUG|Pyridostigmine|"Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)"
48160779|NCT06366724|DRUG|Low-Dose Naltrexone|"LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)"
48367949|NCT06321796|COMBINATION_PRODUCT|Magnesium Citrate|"Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day"
48367950|NCT06321796|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks"
48367951|NCT06321796|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks"
48367952|NCT06321796|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days"
48513546|NCT02905747|BEHAVIORAL|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
48513547|NCT05549505|DRUG|ARV-471|tablets
48513548|NCT05549505|DRUG|Anastrozole|1mg tablet
48689238|NCT02027311|DRUG|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
48003867|NCT03090100|DRUG|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
48003868|NCT03090100|DRUG|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
48003869|NCT03090100|DRUG|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
48003870|NCT01587495|DRUG|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
48003871|NCT03715608|OTHER|Psychological Intervention|The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
48160780|NCT06366724|OTHER|Placebo|"Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)"
48513549|NCT05549505|PROCEDURE|Surgical resection of breast tumor|Participants will have surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
48513550|NCT06582940|RADIATION|MRI-guided adaptive SRT|MRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. MRI will be acquired.
48513551|NCT06582940|RADIATION|Conventional SRT|Conventional SRT (with PTV expansion margin). The total dose will be 30Gy/5 fractions, administered once daily. CBCT will be acquired.
48513552|NCT01117649|DRUG|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
48689239|NCT02027311|DRUG|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.
48689240|NCT00613327|DRUG|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
48689241|NCT05319808|OTHER|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
48003872|NCT05652296|DEVICE|External Ventricular Drainage (EVD)|EVD of Cerebral Spinal Fluid from the lateral ventricles of the brain
48003873|NCT02376946|DEVICE|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
48367953|NCT02357394|DEVICE|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
48003874|NCT02376946|DEVICE|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
48003875|NCT02552316|DEVICE|NB-UVB Phototherapy|
48160781|NCT04345783|DRUG|Camrelizumab for injection, apatinib mesylate and tegio|Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
48160782|NCT05797116|OTHER|Survey|29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
48160783|NCT01657071|DRUG|YH14659|YH14659 capsule by oral
48367954|NCT00389922|DRUG|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
48367955|NCT00389922|DRUG|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
48367956|NCT00389922|GENETIC|comparative genomic hybridization|Molecular correlative study
48513553|NCT01117649|DRUG|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
48513554|NCT01117649|DRUG|balanced electrolyte solution|plasma adapted Ringer's solution
48513555|NCT01965054|DIETARY_SUPPLEMENT|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
48513556|NCT05948176|OTHER|The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition|It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years
48689242|NCT05319808|DEVICE|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
48689243|NCT05319808|OTHER|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
48689244|NCT00150111|DRUG|Methimazole|
48003876|NCT05583903|OTHER|Virtual Reality Software|The ReCognition virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
48513557|NCT00687024|PROCEDURE|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
48513558|NCT00687024|PROCEDURE|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
48513559|NCT00687024|PROCEDURE|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
48689245|NCT00150111|DRUG|Rituximab|
48003877|NCT03496142|PROCEDURE|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
48160784|NCT01657071|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
48160785|NCT00571558|DRUG|aminolevulinic acid hydrochloride|Given PO
48160786|NCT00571558|DRUG|photodynamic therapy|Undergo photodynamic therapy
48160787|NCT00571558|OTHER|laboratory biomarker analysis|Correlative studies
48367957|NCT00389922|GENETIC|cytogenetic analysis|Molecular correlative study
48367958|NCT00389922|GENETIC|gene expression analysis|Molecular correlative study
48367959|NCT00389922|GENETIC|mutation analysis|Molecular correlative study
48367960|NCT00389922|GENETIC|polymerase chain reaction|Molecular correlative study
48367961|NCT00389922|GENETIC|polymorphism analysis|Molecular correlative study
48367962|NCT00389922|GENETIC|proteomic profiling|Molecular correlative study
48367963|NCT00389922|GENETIC|reverse transcriptase-polymerase chain reaction|Molecular correlative study
48367964|NCT00389922|OTHER|immunohistochemistry staining method|Molecular correlative study
48367965|NCT00389922|OTHER|laboratory biomarker analysis|Molecular correlative study
48689246|NCT00150111|BIOLOGICAL|Immunization with various vaccines|
48689247|NCT03379948|DIAGNOSTIC_TEST|blood culture|blood culture to diagnose blood stream infection
48689248|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
48689249|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
48689250|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
48689251|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
48689252|NCT02274935|OTHER|Exercise|Balance and gait exercise twice a week for an hour
48160788|NCT01368055|RADIATION|70 Gy/CGE|Low Risk
48689253|NCT02323126|DRUG|EGF816|EGF816 150 mg once daily (QD) administered orally as a capsule
48160789|NCT01368055|RADIATION|72.5 Gy/CGE|Intermediate Risk
48689254|NCT02323126|DRUG|INC280|INC280 400 mg twice daily (BID) administered orally as a tablet
48689255|NCT02323126|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
48689256|NCT06311955|RADIATION|Carbon ion radiotherapy|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
48689257|NCT06311955|OTHER|combined with platinum-based regimen|combined with platinum-based regimen
48689258|NCT03162744|BEHAVIORAL|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
48689259|NCT02901249|DRUG|sertraline|
48689260|NCT02901249|DRUG|Nortriptyline|
48689261|NCT02901249|DRUG|Lithium|
48689262|NCT01183520|DIETARY_SUPPLEMENT|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
48689263|NCT00003420|PROCEDURE|computed tomography|
48689264|NCT06391008|RADIATION|Stereotactic radiotherapy|Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f
48689265|NCT06391008|DRUG|Evoximab|Evoximab (20mg/kg, Q3W)
48689266|NCT06391008|DRUG|Pemetrexed|Pemetrexed (500mg/m2, Q3W)
48689267|NCT06391008|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 260 mg/m2, Q3W
48689268|NCT06391008|DRUG|Carboplatin|Carboplatin (AUC5, Q3W)
48689269|NCT02973295|DRUG|Silymarin|Capsules contains 100 mg of silymarin
48689270|NCT02973295|OTHER|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
48689271|NCT01709110|DRUG|Teriparatide|Administered SC
48689272|NCT01709110|DRUG|Risedronate|Administered orally
48689273|NCT01709110|DRUG|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
48160790|NCT04263909|DRUG|Sublingual Tablet|sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
48160791|NCT04675671|OTHER|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
48160792|NCT00612716|DRUG|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
48689274|NCT01709110|DRUG|Calcium|Administered orally
48689275|NCT01709110|DRUG|Vitamin D|Administered orally
48689276|NCT03548896|PROCEDURE|Post extraction socket|\*\*Dental implant will be placed 3 months after tooth extraction
48689277|NCT02120781|BIOLOGICAL|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
48689278|NCT02120781|DRUG|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
48689279|NCT04470050|DRUG|Dexmedetomidine|Sublingual Film of Dexmedetomidine
48160793|NCT00612716|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
48160794|NCT00612716|BIOLOGICAL|Stem cell infusion|Infused on Day 0
48160795|NCT00612716|RADIATION|Total body irradiation|165 cGy morning and evening on days -4 through -1.
48367966|NCT00389922|DRUG|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
48513560|NCT03151304|DRUG|Pracinostat|45 mg capsule
48689280|NCT04470050|DRUG|Placebo|Sublingual Placebo film
48689281|NCT02182778|DRUG|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
48689282|NCT02182778|DRUG|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
48689283|NCT06421519|OTHER|BiPAP setting|"Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O"
48689284|NCT02398136|DRUG|Ketamine|
48689285|NCT02398136|DRUG|Midazolam|
48689286|NCT05891080|DRUG|Toripalimab|Specified dose on specified days.
48689287|NCT05891080|DRUG|JS004|Specified dose on specified days.
48689288|NCT05891080|DRUG|Pemetrexed|Specified dose on specified days.
48689289|NCT05891080|DRUG|Nab-paclitaxel|Specified dose on specified days.
48689290|NCT05891080|DRUG|Carboplatin|Specified dose on specified days.
48689291|NCT05891080|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
48689292|NCT04091932|DRUG|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
48689293|NCT02547246|DEVICE|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
48160796|NCT00515281|DRUG|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
48367967|NCT00389922|DRUG|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
48367968|NCT02136719|PROCEDURE|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
48367969|NCT04166721|DRUG|Atezolizumab|Immunotherapy
48367970|NCT04480905|DEVICE|Dynamic tape|The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
48367971|NCT04480905|DEVICE|Sham tape|The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
48367972|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
48367973|NCT03137212|COMBINATION_PRODUCT|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
48689294|NCT02547246|DEVICE|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
48689295|NCT01321255|DRUG|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
48689296|NCT01321255|DRUG|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
48367974|NCT05325502|DIETARY_SUPPLEMENT|caffeine|two doses per day: 200 mg caffeine in the morning; 100 mg caffeine in the afternoon
48689297|NCT02551380|DRUG|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
48689298|NCT02551380|OTHER|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
48689299|NCT00868972|PROCEDURE|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
48689300|NCT00868972|DEVICE|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
48689301|NCT04017780|DEVICE|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
48689302|NCT04017780|DEVICE|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
48689303|NCT04017780|DEVICE|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
48160797|NCT00515281|DRUG|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
48689304|NCT02021890|BEHAVIORAL|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
48689305|NCT02021890|BEHAVIORAL|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
48367975|NCT05325502|DIETARY_SUPPLEMENT|mannitol|two doses per day: 200 mg in the morning \& 100 mg in the afternoon
48367976|NCT00553319|DRUG|Placebo|Placebo group
48367977|NCT00553319|DRUG|Adderall-XR|Adderall-XR 60mg/day
48367978|NCT00553319|DRUG|Adderall-XR|Adderall-XR 80mg/day
48367979|NCT04981080|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment, including noninstrumented uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and urethral pressure profilometry, was performed with the patient in a sitting position according to the recommendations by the International Continence Society.
48367980|NCT00142714|PROCEDURE|Sympathetic manipulation on sexual arousal in women|
48367981|NCT02204722|DRUG|600mg/day of Imatinib|
48367982|NCT02204722|DRUG|400mg/day of Imatinib|
48689306|NCT04457791|BEHAVIORAL|Personalized dietary advice|Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
48367983|NCT01874288|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
48367984|NCT03964311|OTHER|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
48367985|NCT03104270|DRUG|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
48367986|NCT03104270|DRUG|Pomalidomide|Pomalidomide PO at 3mg
48367987|NCT03104270|DRUG|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
48367988|NCT03104270|DRUG|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
48367989|NCT05744466|DRUG|Deucravacitinib|As prescribed by treating clinician
48367990|NCT05744466|DRUG|Apremilast|As prescribed by treating clinician
48367991|NCT03017131|BIOLOGICAL|Aldesleukin|Given SC
48367992|NCT03017131|DRUG|Cyclophosphamide|Given IV
48689307|NCT02505022|DRUG|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
48689308|NCT02505022|BEHAVIORAL|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
48689309|NCT04396548|DRUG|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
48160798|NCT06647355|OTHER|Effectiveness of physical exercise in preventing pain and improving plantar pressure distribution|At the beginning of the study, the participants underwent a baropodometric and photometric analysis. At the same time, anthropometric data and self-assessed body pain data were collected. For 12 continuous weeks, the participants completed a training programme that included specific exercises designed for each group. At the end, the baropodometry images were analysed again, which led to the final conclusion of the study.
48003878|NCT03496142|PROCEDURE|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
48003879|NCT03414346|OTHER|Exclusively ice pack|Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
48160799|NCT03296488|DRUG|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
48160800|NCT03296488|DRUG|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
48160801|NCT06585501|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
48160802|NCT05534802|DRUG|Ulinastatin|On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
48160803|NCT05534802|OTHER|saline|On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
48513561|NCT03151304|DRUG|Azacitidine|SC or IV injection
48003880|NCT03414346|OTHER|Ice pack added 10% of water|Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
48160804|NCT01564134|BIOLOGICAL|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
48160805|NCT01856647|PROCEDURE|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.
48160806|NCT05584709|BIOLOGICAL|STI-6129|Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
48160807|NCT03308383|OTHER|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
48160808|NCT01665014|RADIATION|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
48160809|NCT00981578|DEVICE|ExAblate 2100|Conformal Bone System
48160810|NCT03570606|DEVICE|bone graft substitute|orthopaedic or spine bony defects
48513562|NCT04114487|OTHER|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
48160811|NCT01192672|BEHAVIORAL|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
48513563|NCT02422524|DRUG|PA-824|Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
48513564|NCT03630380|OTHER|Clinical History|We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).
48689310|NCT04396548|DRUG|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
48367993|NCT03017131|DRUG|Decitabine|Given IV
48367994|NCT03017131|BIOLOGICAL|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
48367995|NCT03017131|OTHER|Laboratory Biomarker Analysis|Correlative studies
48367996|NCT05649020|DRUG|Dose of prilocaine|With the patient in the sitting position, spinal anesthesia was performed using the midline approach at the L3-L4; L4-L5 interspace with a spinal needle. The dose of HP that a patient received was determined by the previous patient's response. If successful anesthesia was obtained, the next patient's dose was decreased. The first patient will receive a dose of 20 mg. The dose decrement/increment for each subsequent patient will be set at 2 mg. A nurse blinded to the dose, will assess the sensitive level achieved with each block. Furthermore, all patients will be unaware of the injected dose of HP. For purposes of the study, anesthesia was considered successful when there was complete loss of pinprick and cold sensation at the L1 dermatome. Values of ED 50 will be determined by calculating the midpoint concentration after at least 8 crossover points sufficient/insufficient anesthesia will be obtained. A single measurement will be obtained from each patient.
48367997|NCT02254616|BEHAVIORAL|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
48367998|NCT02254616|BEHAVIORAL|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
48367999|NCT02254616|BEHAVIORAL|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
48368000|NCT02254616|BEHAVIORAL|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
48003881|NCT03414346|OTHER|Ice pack added 100% of water|Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
48368001|NCT03445494|PROCEDURE|Brace|A brace to be weared according to protocol
48368002|NCT03445494|PROCEDURE|Normal sling|A normal sling to be weared according to protocol
48368003|NCT05714176|DRUG|Ferric Pyrophosphate Liposomal|30 pediatric patients who will receive oral liposomal iron (Novoferr) 30 mg/day for 12 weeks.
48689311|NCT05894304|DEVICE|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
48689312|NCT05894304|OTHER|Scapular training exercises|Scapular muscle strength by resistance
48689313|NCT06149221|DEVICE|NTAP|Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline
48368004|NCT05714176|DRUG|Lactoferrin|30 pediatric patients who will receive oral iron supported Lactoferrin (Provan) 100 mg/day for 12 weeks.
48368005|NCT05714176|DRUG|Iron Dextran Injection|30 pediatric patients who will receive IV iron dextran 50 mg /3 times weekly for 12 weeks.
48368006|NCT02078674|BIOLOGICAL|Monovalent Avian Influenza VLP (H7N9)|
48368007|NCT02078674|BIOLOGICAL|Matrix-M1™ adjuvant|
48368008|NCT02078674|BIOLOGICAL|Placebo|
48513565|NCT03630380|OTHER|Physical Exam Findings|We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.
48513566|NCT03630380|OTHER|Laboratory Findings|We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.
48689314|NCT04742439|DEVICE|Sham transcranial direct current stimulation|Participants will receive 30 seconds of ramp up and down stimulation at the start and end of the 20 minute stimulation period.
48689315|NCT04742439|DEVICE|Individualized transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at the individualized dose (maximum of 4mA).
48689316|NCT04742439|DEVICE|2mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 2mA dose.
48689317|NCT04742439|DEVICE|4mA transcranial direct current stimulation|Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at a 4mA dose.
48689318|NCT05827328|OTHER|Observation|Observe the 30-day mortality and 30-day morbidity.
48368009|NCT06428331|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
48368010|NCT04513249|DIAGNOSTIC_TEST|dynamics of coagulation parameters|the effects of fresh frozen plasma administered during a plasma exchange therapy on viscoelastic tests
48368011|NCT03425240|DEVICE|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
48368012|NCT00630760|DRUG|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
48368013|NCT00976521|DRUG|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
48368014|NCT00976521|OTHER|No local infusion|Intervention without local infusion
48368015|NCT00976521|PROCEDURE|Thrombus aspiration|Thrombus aspiration
48368016|NCT05221658|DRUG|HLX07+HLX10+ Cisplatin+5-FU|HLX07 1000mg + HLX10 200mg + Cisplatin 50 mg/m2 + 5-FU 2400mg/m2
48689319|NCT02173639|DRUG|BI 1356/metformin|fixed dose combination tablet
48689320|NCT02173639|DRUG|BI 1356|
48689321|NCT02173639|DRUG|Metformin|
48689322|NCT06244407|DRUG|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets|Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
48689323|NCT05025397|DRUG|Danavorexton|Danavorexton intravenous infusion.
48689324|NCT05025397|DRUG|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
48160812|NCT01192672|BEHAVIORAL|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
48160813|NCT03314389|DEVICE|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
48160814|NCT04093583|PROCEDURE|Exodontia|Atraumatic exodontia followed by simple suture
48160815|NCT04093583|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
48160816|NCT04093583|DEVICE|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
48160817|NCT05313815|RADIATION|Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
48689325|NCT05025397|DRUG|Propofol|Propofol intravenous bolus.
48689326|NCT05025397|DRUG|Sevoflurane|Sevoflurane inhalation.
48689327|NCT05025397|DRUG|Propofol|Propofol intravenous infusion.
48160818|NCT04891159|OTHER|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
48160819|NCT00549042|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
48160820|NCT00549042|DRUG|Placebo|Placebo
48160821|NCT05194813|OTHER|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
48160822|NCT05194813|OTHER|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
48160823|NCT00195416|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
48160824|NCT01862614|DRUG|Articaine Hydrochloride + Epinephrine|
48003882|NCT04383821|DEVICE|Double-Trunk Mask|The DTM (oxygen delivery system) is worn by the patient for 30 minutes.
48689328|NCT06180616|DRUG|Tirzepatide|"Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study."
48003883|NCT04383821|DEVICE|Non-Rebreather mask|The NRM (standard oxygen delivery system) is worn by the patient for 30 minutes.
48003884|NCT04269967|OTHER|Receiving routine rehabilitation care via tele-rehabilitation system|Drain care education, self-massage techniques and exercise (PT and OT)
48003885|NCT02759068|BEHAVIORAL|sounds and odors|presentation of sounds and odors
48003886|NCT02227485|DRUG|Punica granatum Pleniflora (Golnaar) mouth rinse|"All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks."
48160825|NCT01862614|DRUG|Buffered Articaine Hydrochloride + Epinephrine|
48689329|NCT03957915|DRUG|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
48689330|NCT02585986|DIETARY_SUPPLEMENT|Probiotic|daily intake of 1 capsule probiotic
48689331|NCT02585986|DIETARY_SUPPLEMENT|Placebo|daily intake of 1 capsule containing placebo
48689332|NCT02700620|BEHAVIORAL|Internet-delivered CBT|Guided internet treatment
48689333|NCT04313777|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
48689334|NCT04313777|DEVICE|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
48689335|NCT04313777|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
48689336|NCT03461549|DEVICE|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
48003887|NCT02227485|DRUG|Chlorhexidine (0.2%)|All the patient in control group use 10 ml of chlorhexidine (0.2%) for 2 minutes every night for 2 weeks.
48003888|NCT02227485|PROCEDURE|Tooth bleaching|Tooth bleaching for both groups one time after using mouth rinses.
48003889|NCT00096044|BIOLOGICAL|rituximab|IV
48160826|NCT01585688|DRUG|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
48003890|NCT00096044|DRUG|lenalidomide|Oral
48160827|NCT01789229|OTHER|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
48513567|NCT03630380|OTHER|Lung Ultrasound|We will perform lung ultrasound on all patients.
48513568|NCT04604340|PROCEDURE|transradial access for neuroangiography|The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.
48003891|NCT06358456|DRUG|Artificial tear|Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
48003892|NCT06358456|OTHER|No artificial tears|Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
48003893|NCT00144586|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks
48003894|NCT01331694|DRUG|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
48003895|NCT01331694|DRUG|tiotropium|patients initiating treatment with tiotropium
48003896|NCT01331694|DRUG|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
48003897|NCT03588637|OTHER|No intervention|No intervention
48003898|NCT05672121|DRUG|KH631|KH631: AAV vector containing a coding sequence for an anti-VEGF protein
48003899|NCT02972528|BIOLOGICAL|Platelet Lysate|Direct injection of allogenic Platelet Lysate
48003900|NCT02972528|BIOLOGICAL|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
48003901|NCT03825289|DRUG|Hydroxychloroquine|Given PO
48003902|NCT03825289|DRUG|Trametinib|Given PO
48003903|NCT06344819|PROCEDURE|Acupuncture|Acupuncture involves insertion of thin filiform needles (gauze 30-40) at certain points on the body.
48003904|NCT06344819|OTHER|Sham Acupuncture|During sham acupuncture, the point on the participant's thigh 6 inches proximal to the ST36 acupuncture point is gently tapped with an acupuncture needle guide tube and an acupuncture needle is taped flat to the skin. This point is not on any acupuncture meridian or point.
48003905|NCT04283643|OTHER|Transcranial Focused Ultrasound|Non-invasive brain stimulation technique
48003906|NCT04283643|OTHER|Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
48689337|NCT04370587|BIOLOGICAL|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
48689338|NCT04370587|COMBINATION_PRODUCT|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
48368017|NCT05221658|DRUG|HLX07|HLX07 1000mg iv Q2w
48689339|NCT04315727|GENETIC|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
48689340|NCT04315727|GENETIC|Hair collection|Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
48689341|NCT05199636|OTHER|Dragon fruit product|Frozen dragon fruit based beverage
48689342|NCT02642393|DRUG|Inosine|capsules containing 500 mg of inosine
48689343|NCT02642393|DRUG|Placebo|capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
48689344|NCT03125031|DEVICE|Rainbow adhesive adult/pediatric sensor|
48689345|NCT03125031|DEVICE|Rainbow adhesive adult/neonatal sensor|
48689346|NCT03909906|DRUG|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
48003907|NCT03653793|OTHER|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
48160828|NCT01789229|OTHER|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
48003908|NCT06391879|GENETIC|Single cell sequencing, whole genome and metabolomic sequencing|The blood specimen of subjects in this cohort would be collected to conduct single cell sequencing, whole genome and metabolomic sequencing.
48160829|NCT01789229|OTHER|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
48689347|NCT03909906|DRUG|Placebo Oral Tablet|Placebo comparator
48160830|NCT01789229|OTHER|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
48689348|NCT04603313|OTHER|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
48689349|NCT00763191|OTHER|examination of ocular movements|
48368018|NCT00401726|DRUG|Venlafaxine ER|
48689350|NCT00763191|OTHER|MATTIS test|
48003909|NCT01195805|DRUG|Spironolactone|1 tablet twice a day for 28 days
48003910|NCT01195805|OTHER|Placebo|1 tablet twice a day for 28 days
48003911|NCT01195805|DRUG|Amiloride|1 tablet twice a day for 28 days
48003912|NCT03425929|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin.
48003913|NCT03425929|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
48160831|NCT01789229|OTHER|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
48160832|NCT01789229|OTHER|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
48368019|NCT00401726|BEHAVIORAL|Dialogues Time to Talk Program|
48368020|NCT00412425|DRUG|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
48368021|NCT00809549|DRUG|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
48368022|NCT05497570|DRUG|Tenoxicam Injectable Product|After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
48368023|NCT01797042|BEHAVIORAL|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
48513569|NCT04604340|PROCEDURE|transfemoral access for neuroangiography|By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
48689351|NCT00763191|OTHER|UPDRS test|
48689352|NCT00763191|OTHER|CRST test|
48689353|NCT06293716|DRUG|CVL237 tablets|CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
48689354|NCT06293716|DRUG|CVL237 placebo tablets|CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
48689355|NCT04120844|BEHAVIORAL|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
48689356|NCT04120844|BEHAVIORAL|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
48003914|NCT00000796|DRUG|Cycloserine|
48368024|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency|Mechanical vibrations are applied at brief bursts of 80Hz that occur at the individual tremor frequency. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
48368025|NCT05152836|DEVICE|Vibrotactile stimulation at tremor frequency*1.5|Mechanical vibrations are applied at 80Hz bursts at individual tremor frequency\*1.5. Vibrations are delivered via a small device, which is worn on the wrist of the most-affected arm.
48689357|NCT00154700|DRUG|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
48003915|NCT00000796|DRUG|Ethionamide|
48160833|NCT01789229|OTHER|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
48160834|NCT00711555|DRUG|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
48160835|NCT06646575|OTHER|Qualitative data, no intervention|This is a qualitative study
48003916|NCT00000796|DRUG|Capreomycin sulfate|
48689358|NCT02450435|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
48689359|NCT02450435|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
48003917|NCT00000796|DRUG|Aminosalicylic acid|
48368026|NCT05152836|DEVICE|Vibrotactile stimulation at continuous stimulation|Continuous 80Hz stimulation is applied via a small device worn on the wrist of the most-affected arm.
48003918|NCT00000796|DRUG|Streptomycin sulfate|
48689360|NCT02144688|DRUG|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
48368027|NCT05152836|DEVICE|Vibrotactile stimulation 10% below and above step frequency|This intervention is applied during assessment of gait. Two devices are worn on both ankles which allows alternating stimulation of both ankles with brief bursts of 80 HZ at the individual step frequency plus or minus 10%.
48368028|NCT00282607|DRUG|DA-8159|
48003919|NCT00000796|DRUG|Ethambutol hydrochloride|
48003920|NCT00000796|DRUG|Amikacin sulfate|
48003921|NCT00000796|DRUG|Isoniazid|
48003922|NCT00000796|DRUG|Pyrazinamide|
48368029|NCT04191928|DRUG|Apixaban|Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
48513570|NCT00258128|DRUG|Salsalate|Active
48003923|NCT00000796|DRUG|Pyridoxine hydrochloride|
48003924|NCT00000796|DRUG|Levofloxacin|
48003925|NCT00000796|DRUG|Rifampin|
48003926|NCT00000796|DRUG|Clofazimine|
48003927|NCT02745964|DEVICE|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
48003928|NCT02745964|DEVICE|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
48003929|NCT00072150|DRUG|bortezomib|Given IV
48003930|NCT01261858|DEVICE|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
48003931|NCT01163994|DRUG|ceftriaxone|intravenously, 2 g, qd, 15 days
48003932|NCT01163994|DRUG|doxycycline|orally, 100 mg, bid, 15 days
48003933|NCT01163994|OTHER|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
48003934|NCT04010266|DEVICE|RelieVRx headset|RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain
48003935|NCT04010266|DRUG|multi-modality pain management|combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
48003936|NCT03984422|OTHER|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
48003937|NCT04046185|DRUG|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
48003938|NCT04046185|DRUG|progesterone|progesterone
48689361|NCT00553436|DEVICE|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
48689362|NCT05435131|DIAGNOSTIC_TEST|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
48689363|NCT05435131|DIAGNOSTIC_TEST|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
48689364|NCT05435131|DIAGNOSTIC_TEST|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
48689365|NCT03357029|DEVICE|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
48160836|NCT05453292|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
48689366|NCT03357029|DEVICE|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
48368030|NCT00528294|RADIATION|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
48689367|NCT02658552|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
48689368|NCT00958360|OTHER|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
48003939|NCT01600586|DEVICE|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
48160837|NCT05115136|DRUG|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
48160838|NCT05115136|DRUG|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
48160839|NCT04374253|DRUG|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
48689369|NCT00958360|OTHER|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
48003940|NCT00015275|BEHAVIORAL|Cocaine-Related Disorders|
48689370|NCT01636336|OTHER|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
48003941|NCT00964392|PROCEDURE|Atrial fibrillation ablation|Radiofrequency ablation
48003942|NCT00146718|DRUG|Amodiaquine and Sulphadoxine/Pyrimethamine|
48003943|NCT05826964|DRUG|AI+CDK4/6i|"Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
48160840|NCT04374253|DRUG|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
48185194|NCT03936842|BEHAVIORAL|Semi-structure interviews|A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
48513571|NCT00258128|DRUG|Placebo|Placebo for salslate, used only in the third trial
48513572|NCT00118534|BEHAVIORAL|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
48513573|NCT00118534|BEHAVIORAL|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
48513574|NCT04148573|DRUG|NFX88 - 1|3 times a day
48513575|NCT04148573|DRUG|NFX88 - 2|3 times a day
48513576|NCT04148573|DRUG|NFX88 - 3|3 times a day
48003944|NCT05826964|DRUG|SERD+CDK4/6i|"Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib"
48160841|NCT04318587|DIAGNOSTIC_TEST|Allosure|Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
48160842|NCT03403556|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
48160843|NCT03403556|DRUG|Monorova|Rosuvastatin 20mg qd for 24 weeks
48160844|NCT04498871|DRUG|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
48160845|NCT04868734|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy give to patient with Acute Coronary Syndrome
48160846|NCT02589678|BIOLOGICAL|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
48160847|NCT02589678|BIOLOGICAL|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
48368031|NCT06368596|DIAGNOSTIC_TEST|Fusobacterium detection|"One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium."
48368032|NCT06212973|DRUG|Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln|Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
48368033|NCT06212973|DRUG|Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln|Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
48368034|NCT00517673|DRUG|GSK945237|
48368035|NCT00517673|DRUG|Sugar Pill|Placebo
48368036|NCT00409565|DRUG|Cetuximab|"* Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
48368037|NCT00409565|DRUG|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
48003945|NCT05826964|DRUG|mTOR inhibitor + AI|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
48003946|NCT05826964|DRUG|mTOR inhibitor + SERD|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with SERD therapy (Fulvestrant), in Step 2 Arm 2 and Step 3. mTOR inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
48368038|NCT01720901|DRUG|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
48003947|NCT05826964|DRUG|mTOR inhibitor + Selective estrogen receptor modulator|Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with selective estrogen receptor modulator therapy (Tamoxifen) in Step 2 Arm 2 and Step 3. mTOR inhibitor + Selective estrogen receptor modulator therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
48003948|NCT05826964|DRUG|PI3K inhibitor + SERD|Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
48160848|NCT00459433|PROCEDURE|Biopsychosocial intervention|Psychosocial versus usual care
48368039|NCT05288764|DEVICE|Bispectral Index|Comparing Bispectral index values (usually adopted during general anaesthesia monitoring) to Ketamine concenetration at the effector site calculated with Domino model pump (usually adopted for Ketamine infusion during general anaesthesia)
48689371|NCT01636336|OTHER|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
48160849|NCT05285878|DRUG|Fingolimod|0.5 mg daily
48160850|NCT05285878|DRUG|Placebo|0.5 mg daily
48160851|NCT00025545|DRUG|cyclophosphamide|
48160852|NCT00025545|DRUG|methotrexate|
48160853|NCT00025545|PROCEDURE|peripheral blood stem cell transplantation|
48160854|NCT00025545|RADIATION|radiation therapy|
48689372|NCT02097719|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
48689373|NCT02097719|DRUG|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
48368040|NCT02972658|DRUG|Lanabecestat|Administered orally
48368041|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at t=0 via IM route
48368042|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
48689374|NCT02097719|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
48689375|NCT02097719|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
48689376|NCT02701959|DIETARY_SUPPLEMENT|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).
48689377|NCT02701959|DIETARY_SUPPLEMENT|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
48689378|NCT06235593|BEHAVIORAL|Self-care Intervention|"The intervention will focus on self-care behavior of people with chronic diseases according to two distinct periods (through a longitudinal study - follow-up nursing interventions):~(i) baseline; and (ii) 4 months;"
48689379|NCT00318279|DEVICE|Surgical simulator to practice vascular anastomosis|
48689380|NCT01032408|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
48160855|NCT05558761|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics. PTX exerts anti-inflammatory effects by inhibiting phosphodiesterase and activating the adenosine 2 receptor
48160856|NCT01855997|DRUG|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
48160857|NCT00586430|DRUG|lorazepam|single 2 mg dose of lorazepam
48368043|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
48689381|NCT01032408|BIOLOGICAL|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
48513577|NCT04148573|DRUG|PLACEBO - 4|3 times a day
48513578|NCT04936711|DEVICE|Resteck Shiatsu Neck and Back Massager|back massager device sold on the market that can readily be purchased online or in store
48689382|NCT01505036|OTHER|SMARTCARE service|U-Healthcare service
48513579|NCT04936711|DRUG|Marcaine|Marcaine spray at incision site after closure
48513580|NCT02123446|DRUG|Cephalexin|Administered orally.
48513581|NCT06164366|DEVICE|0 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 0 degrees
48160858|NCT00586430|DRUG|placebo|single dose of placebo
48160859|NCT03199170|DRUG|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
48160860|NCT03199170|DRUG|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
48513582|NCT06164366|DEVICE|45 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 45 degrees
48513583|NCT03366441|OTHER|Telephone call|From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
48513584|NCT03366441|OTHER|SMS|Text messages were sent to an equal number of donors in the SMS group
48160861|NCT03199170|DRUG|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
48160862|NCT03688022|DRUG|MT-7117|MT-7117
48160863|NCT03688022|DRUG|PPI|Proton pump inhibitor
48160864|NCT03688022|DIETARY_SUPPLEMENT|Acidic beverage|Acidic beverage
48368044|NCT00440362|BIOLOGICAL|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
48368045|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
48368046|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
48368047|NCT00440362|BIOLOGICAL|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
48368048|NCT00440362|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
48368049|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the IM route
48368050|NCT00440362|BIOLOGICAL|Placebo|1 dose of placebo given at T=0 via the SC route
48368051|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
48513585|NCT00802932|DEVICE|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
48513586|NCT00802932|DEVICE|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
48513587|NCT06508320|BIOLOGICAL|mRNA-1083|IM injection in a deltoid muscle.
48513588|NCT03464630|BEHAVIORAL|Mom & Baby Net|CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral
48689383|NCT01884324|OTHER|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
48689384|NCT05007418|BIOLOGICAL|STI-1492|Anti-CD38 A2 KOKI DAR T cells
48689385|NCT00842283|OTHER|skin tissue sample|skin tissue sample
48689386|NCT01191645|DRUG|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
48689387|NCT01191645|DRUG|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
48689388|NCT01191645|DRUG|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
48689389|NCT01191645|DRUG|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
48689390|NCT01334216|OTHER|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
48689391|NCT01334216|OTHER|CHICA Placebo|This was CHICA without the study module.
48689392|NCT00761384|DRUG|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
48689393|NCT00460460|DRUG|AZD4877|
48689394|NCT00678938|BEHAVIORAL|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
48689395|NCT00678938|BEHAVIORAL|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
48689396|NCT01967797|BEHAVIORAL|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
48689397|NCT03989349|DRUG|Placebo|Placebo
48689398|NCT03989349|DRUG|Nemolizumab|Nemolizumab
48689399|NCT02745678|DRUG|Thermosensitive gel rectal formulation|
48689400|NCT01597765|DRUG|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
48689401|NCT01597765|DRUG|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
48689402|NCT04379687|OTHER|Virtual reality|Use of virtual reality glasses for balance work
48689403|NCT04379687|OTHER|Control group|Balance treatment with according to Bayouk physiotherapy
48689404|NCT04974827|DRUG|Camrelizumab|200mg/3weeks
48689405|NCT04974827|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
48689406|NCT05937386|DRUG|AGMB-129|Oral capsule
48689407|NCT05937386|DRUG|MDZ|Pre-filled oral syringes
48689408|NCT01547351|OTHER|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
48689409|NCT02298868|DRUG|Baclofen|
48689410|NCT03533816|DRUG|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
48689411|NCT03533816|DRUG|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
48689412|NCT01652053|DEVICE|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
48689413|NCT05096117|DRUG|ASP8062|ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
48689414|NCT05096117|DRUG|Placebo|1 x per day for 6 weeks
48689415|NCT02934841|DRUG|Conbercept|
48689416|NCT02934841|DRUG|sham|
48689417|NCT01648244|OTHER|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
48689418|NCT00140296|BEHAVIORAL|Contraceptive counseling|
48689419|NCT02013778|DRUG|HCQ|
48689420|NCT04959227|OTHER|Sema activity|sema activity 3 days a week for at least a year
48368052|NCT00440362|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
48689421|NCT00284414|PROCEDURE|Ultrasonography or MRI|
48689422|NCT01825512|DRUG|Deferiprone|Deferiprone 80 mg/mL oral solution
48689423|NCT01825512|DRUG|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
48689424|NCT00780767|DEVICE|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
48689425|NCT05592327|PROCEDURE|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
48368053|NCT03377218|DIETARY_SUPPLEMENT|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
48689426|NCT05211674|OTHER|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
48003949|NCT05826964|DRUG|PI3K inhibitor + AI|Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
48368054|NCT03377218|DIETARY_SUPPLEMENT|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
48368055|NCT03216499|DRUG|HIF-2alpha Inhibitor PT2385|Given PO
48368056|NCT03216499|OTHER|Pharmacological Study|Correlative studies
48368057|NCT03216499|OTHER|Laboratory Biomarker Analysis|Correlative studies
48368058|NCT03216499|OTHER|Pharmacogenomic Study|Correlative studies
48368059|NCT03397472|DEVICE|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
48368060|NCT03397472|DEVICE|placebo device|use the sleep pillow without magnetic field modulation treatment
48689427|NCT05561283|DIAGNOSTIC_TEST|Self-questionnaires|Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
48689428|NCT00799630|DIETARY_SUPPLEMENT|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
48689429|NCT01373008|DRUG|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
48689430|NCT02565875|BEHAVIORAL|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
48689431|NCT02565875|BEHAVIORAL|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
48689432|NCT02565875|OTHER|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
48689433|NCT00061035|BIOLOGICAL|Transgenic Lymphocyte Immunization Vaccine (TLI)|
48689434|NCT00276939|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|
48003950|NCT05826964|DRUG|Chemotherapy|Chemotherapy administered standard of care as an alternative therapy in Step 2 Arm 2 and Step 3.
48003951|NCT05826964|DRUG|Oral SERD|Participants will receive standard of care oral SERD therapy (Elacestrant) in Step 2 Arm 2 and Step 3. Oral SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
48003952|NCT04043195|DRUG|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
48003953|NCT04043195|DRUG|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
48003954|NCT04043195|DRUG|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
48368061|NCT04631835|DRUG|HS-10352|Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
48368062|NCT01410331|BIOLOGICAL|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
48368063|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
48368064|NCT01410331|BIOLOGICAL|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
48368065|NCT01410331|BIOLOGICAL|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
48368066|NCT05519189|DRUG|Ropivacaine|Peri-anal infiltration of Ropivacaine
48368067|NCT05519189|OTHER|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
48368068|NCT02247167|PROCEDURE|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
48368069|NCT04692285|DRUG|Zolpidem|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single 5 mg dose of Zolpidem.
48368070|NCT04692285|DRUG|Placebo|Patients will undergo transcranial magnetic stimulation, 18F-FDG-PET brain imaging, and clinical testing after a single dose of placebo.
48368071|NCT02452138|OTHER|Severe sepsis management|
48689435|NCT03309254|OTHER|High Glycemic Index|High Glycemic Index Food
48689436|NCT03309254|OTHER|Low Glycemic Index|Low Glycemic Index Food
48160865|NCT06447298|OTHER|Satisfaction questionnaires|Use of a post-laparoscopy satisfaction questionnaire designed to be adapted to the context of laparoscopic surgery. This post-laparoscopy questionnaire was inspired by the PedsQL generic care satisfaction questionnaire, a standardised and validated questionnaire.
48368072|NCT02978339|DRUG|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
48368073|NCT02577107|DRUG|ranibizumab|
48160866|NCT02511808|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
48160867|NCT02511808|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
48160868|NCT02511808|BEHAVIORAL|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
48160869|NCT00866502|DRUG|sNN0031|Continuous ICV infusion for two weeks
48160870|NCT00866502|DRUG|Placebo|Continous ICV infusion
48160871|NCT01243658|DRUG|Oxytocin|Oxytocin
48160872|NCT01243658|OTHER|placebo|placebo
48368074|NCT02577107|DRUG|Conbercept|
48368075|NCT06444399|DRUG|Deucravacitinib|6 mg administered orally twice daily for 24 weeks.
48368076|NCT02917369|OTHER|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
48689437|NCT00742131|DRUG|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
48689438|NCT02469701|DRUG|nivolumab and ablation|
48689439|NCT02044952|DRUG|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
48003955|NCT04333810|DEVICE|Whoop strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks sleep duration, resting heart rate, heart rate variability, activity (calories).
48003956|NCT00159588|DRUG|Betablockers or other preventive drugs based on primary headache type|Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
48003957|NCT05516576|DEVICE|endomina®|Endoscopic gastroplasty
48003958|NCT03960502|DRUG|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.
48003959|NCT03960502|DRUG|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
48003960|NCT06481202|BIOLOGICAL|Complarate®|The test drug Complarate® was administered as an intravenous infusion at a single dose of 8 mg/kg.
48160873|NCT01565239|DEVICE|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
48160874|NCT04127578|BIOLOGICAL|LY3884961|Participants will receive a single dose of LY3884961, administered intra-cisterna magna
48160875|NCT04127578|DRUG|Methylprednisolone|6 IV pulses administered as concomitant medication over 3 months
48160876|NCT04127578|DRUG|Sirolimus|Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
48185195|NCT03608059|DRUG|ATG/PTCy|low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
48185196|NCT03608059|DRUG|standard ATG|in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
48368077|NCT04301557|DRUG|PD-1 Antibody|PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
48003961|NCT06481202|BIOLOGICAL|Actemra®|The reference drug Actemra® was administered as an intravenous infusion at a single dose of 8 mg/kg.
48368078|NCT04301557|DRUG|Oxaliplatin|Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
48368079|NCT04301557|DRUG|Capecitabine|Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
48368080|NCT04301557|RADIATION|External beam radiotherapy|Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
48368081|NCT04301557|PROCEDURE|Total mesorectal excision|Total mesorectal excision
48368082|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) peptide vaccine|Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
48689440|NCT06294262|BIOLOGICAL|TETRALITE|Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
48689441|NCT06277856|BEHAVIORAL|Peer interaction/control|This study was planned as a randomised controlled study with a two-group pretest and posttest design.
48689442|NCT00939289|DEVICE|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
48689443|NCT03299244|DRUG|Etelcalcetide|Administered intravenously three times per week.
48160877|NCT05240664|BEHAVIORAL|Have A Say Programme|Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
48160878|NCT05240664|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
48160879|NCT06644391|DIAGNOSTIC_TEST|Carebot AI Bones|The use of a deep learning-based artificial intelligence software, Carebot AI Bones version 1.2.2, designed to aid in the detection of fractures on musculoskeletal radiographs. The AI model analyzes digital X-ray images to identify fractures, highlighting areas of interest with bounding boxes.
48160880|NCT03456830|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
48160881|NCT03456830|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
48160882|NCT03233204|DRUG|Olaparib|Given PO
48160883|NCT06396923|DIAGNOSTIC_TEST|Wingate test|Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
48368083|NCT00972309|BIOLOGICAL|T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine|Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
48368084|NCT04440176|BIOLOGICAL|MenABCWY|Neisseria meningitidis group A, B, C, W, and Y vaccine
48368085|NCT04440176|BIOLOGICAL|Saline|Placebo
48368086|NCT06417658|PROCEDURE|Endoscopic Supraorbital Eyebrow Craniotomy|The Endoscopic Supraorbital Eyebrow Craniotomy is a minimally invasive neurosurgical procedure used to access and remove brain tumors located in the anterior skull base region. In this approach, surgeons make a small incision within the eyebrow area to gain access to the underlying pathology, avoiding larger incisions and more extensive tissue disruption associated with traditional open craniotomies.
48368087|NCT06417658|PROCEDURE|Conventional Frontal Craniotomy|The Conventional Frontal Craniotomy is a traditional surgical approach used to access and treat lesions located in the frontal region of the skull base. In this procedure, surgeons make a single or multiple large incisions in the scalp overlying the frontal bone to gain access to the underlying pathology.
48513589|NCT03464630|BEHAVIORAL|Depression & Developmental Awareness System|Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
48003962|NCT03000582|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
48003963|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
48513590|NCT01888510|PROCEDURE|computed tomography|Undergo conventional free breathing CT
48689444|NCT03299244|DRUG|Cinacalcet|Cinacalcet administered orally once a day.
48689445|NCT02702609|DEVICE|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
48003964|NCT03000582|DIETARY_SUPPLEMENT|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
48003965|NCT03000582|DIETARY_SUPPLEMENT|Placebo|Placebo (6.5 g dextrose)
48003966|NCT02235779|OTHER|Transbronchial lung cryobiopsy|
48003967|NCT01353378|DRUG|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
48003968|NCT05254795|OTHER|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
48003969|NCT03816631|DRUG|Pimodivir|Participants will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablets) under fasted condition on Day 1.
48003970|NCT04552366|BIOLOGICAL|Ad5-nCoV|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
48003971|NCT04872855|DEVICE|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
48003972|NCT00508742|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
48003973|NCT00508742|BIOLOGICAL|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
48689446|NCT02702609|DEVICE|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
48689447|NCT00100074|DRUG|Lobeline|
48689448|NCT03292549|PROCEDURE|Robotic partial surgery|Robotic partial surgery
48689449|NCT02370823|PROCEDURE|Regenexx SD|stem cell treatment
48689450|NCT00635349|DRUG|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
48689451|NCT00635349|DRUG|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
48160884|NCT04093466|DRUG|CX1003|Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
48689452|NCT00635349|DRUG|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
48689453|NCT04277481|OTHER|10 minute cold pack|10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
48689454|NCT04277481|OTHER|12 minute cold pack|12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
48689455|NCT04277481|OTHER|15 minute cold pack|15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
48689456|NCT04277481|OTHER|20 minute cold pack|20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
48689457|NCT06520696|BEHAVIORAL|MILC application|Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
48689458|NCT06520696|BEHAVIORAL|Usual care|"Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect."
48689459|NCT05215470|DRUG|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
48003974|NCT01391728|BEHAVIORAL|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
48003975|NCT04277091|OTHER|High-intensity interval training|Arm-cranking exercise
48003976|NCT04277091|OTHER|Moderate-intensity continuos training|Arm-cranking exercise
48003977|NCT04382911|DRUG|18F-fluoroestradiol|Patients will receive the FES tracer during a PET/MRI scan
48003978|NCT03202004|DRUG|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
48160885|NCT04581772|DRUG|DNL343|Multiple oral doses
48160886|NCT04581772|DRUG|Placebo|Single oral dose
48160887|NCT04581772|DRUG|DNL343|Single oral dose
48160888|NCT03856424|PROCEDURE|Modality 1|Pressure support ventilation (PSV) modality
48160889|NCT03856424|PROCEDURE|Modality 2|T-Piece modality
48160890|NCT03856424|PROCEDURE|Modality 3|High-flow oxygen
48160891|NCT02176512|DRUG|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
48689460|NCT05215470|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
48160892|NCT02176512|DRUG|BIBR 277 SE|Treatment B - Monocomponent
48160893|NCT02176512|DRUG|HCTZ|Treatment B -Monocomponent
48689461|NCT01996696|DRUG|Metformin|Metformin 500 mg PO TID x 30-36 months
48689462|NCT01996696|DRUG|Placebo|Identical placebo TID x 30-36 months
48689463|NCT06460493|DRUG|Ensifentrine 3mg|All subjects will receive ensifentrine.
48689464|NCT03166462|OTHER|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
48689465|NCT02216968|BEHAVIORAL|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
48689466|NCT01213459|PROCEDURE|Cervical samples|Human papillomavirus detection and typing in cervical samples.
48689467|NCT01213459|OTHER|Data collection|Questionnaire completion
48689468|NCT01538355|OTHER|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
48689469|NCT01538355|OTHER|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
48689470|NCT01538355|OTHER|Control diet|Patients stay on their regular diet.
48689471|NCT04166578|DRUG|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
48689472|NCT04166578|PROCEDURE|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
48689473|NCT04166578|PROCEDURE|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
48689474|NCT04166578|BEHAVIORAL|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
48160894|NCT02775123|DEVICE|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
48160895|NCT00220571|DEVICE|Coronary Angioplasty (PTCA)|
48160896|NCT04822337|DRUG|Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin|Phase I - Chemotherapy multiple agents systemic Phase II - Maximum Tolerated Dose from Phase I
48160897|NCT05999513|DRUG|casdatifan|Administered as specified in the treatment arm
48160898|NCT04214548|OTHER|No Intervention|There is no intervention for this study
48689475|NCT04166578|BEHAVIORAL|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
48689476|NCT04166578|DIAGNOSTIC_TEST|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
48689477|NCT04166578|DIAGNOSTIC_TEST|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
48160899|NCT02333071|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
48160900|NCT02333071|OTHER|Placebo|Placebo
48160901|NCT05854160|PROCEDURE|Electrical Pulse Train Stimulation|sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
48160902|NCT00148499|DRUG|Ambroxol hydrochloride (Mucoangin?)|
48160903|NCT00148499|DRUG|benzocaine|
48160904|NCT06363877|DRUG|Povidone-Iodine|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of dilute aqueous povidone-iodine solution allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the povidone-iodine solution then wash-out with 2L of normal saline followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL povidone-iodine solution, suctioned, then washed-out with 500 mL normal saline."
48160905|NCT06363877|DRUG|Normal Saline|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline."
48689478|NCT06026072|OTHER|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
48689479|NCT04098185|DEVICE|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
48689480|NCT04827342|OTHER|data collection in the Ada DDSS prototype|Entry of patients' data (medical history, symptoms and findings) in the Ada DDSS prototype. The tool then automatically creates a list of possible diagnostic suggestions based on the information, which are compared with the diagnoses of the attending physician.
48185197|NCT03608059|DRUG|standard PTCy|post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
48160906|NCT01278511|OTHER|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
48160907|NCT00006006|BIOLOGICAL|recombinant interferon alfa|
48160908|NCT00006006|DRUG|thalidomide|
48160909|NCT06057259|DEVICE|Joint position sense measurement|The participants' wrist joint position sense was evaluated.
48689481|NCT03853382|BEHAVIORAL|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
48160910|NCT04286893|DIAGNOSTIC_TEST|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
48160911|NCT04286893|DIAGNOSTIC_TEST|High resolution ECG|Measurement HRV using high resolution ECG
48513591|NCT01888510|PROCEDURE|4-dimensional computed tomography|Undergo 4D CT
48160912|NCT04286893|DIAGNOSTIC_TEST|Blood withdrawal|Measurement of endothelial inflammation markers
48160913|NCT03942783|OTHER|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
48160914|NCT03942783|OTHER|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
48689482|NCT02264379|RADIATION|normal fractionated irradiation|25\*2 Gy (once a day, 5 days a week)
48689483|NCT02264379|RADIATION|hypo fractionated irradiation|3\*10 Gy (once a day, 2-3 days a week)
48689484|NCT00442494|DRUG|intravenous hydrocortisone|
48689485|NCT00224120|DRUG|Silodosin|8 mg daily for 12 weeks
48689486|NCT00224120|OTHER|Placebo|One capsule daily for 12 weeks
48160915|NCT02794558|DEVICE|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
48160916|NCT03263104|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
48513592|NCT01888510|PROCEDURE|computed tomography|Undergo ABC CT
48160917|NCT03263104|DIETARY_SUPPLEMENT|Maltodextrin|
48513593|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo ABC CBCT
48513594|NCT01888510|PROCEDURE|cone-beam computed tomography|Undergo free breathing CBCT
48513595|NCT05758233|PROCEDURE|Patients undergoing transversalis fascia plane block|The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
48513596|NCT05758233|PROCEDURE|Patients undergoing transversus abdominis plane block|The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
48513597|NCT00649779|DRUG|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
48513598|NCT00649779|DRUG|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
48689487|NCT01388049|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
48160918|NCT04481334|OTHER|Collaborative occupational therapy interactive vaulting group|Children will participate in a weekly 60 minute group that focuses on the devilment of social skills by incorporating activities that require team work. Part of the intervention will incorporate the equine to better understand non-verbal body language. It should be noted that each child will have two agreed upon goals developed that are agreed upon by the child and the parent and will be of emphasis during each group.
48160919|NCT01498523|OTHER|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
48160920|NCT01498523|OTHER|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
48513599|NCT01403220|PROCEDURE|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
48513600|NCT01403220|PROCEDURE|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
48689488|NCT00768846|DEVICE|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
48689489|NCT00768846|DEVICE|Xience V Stent|Everolimus-eluting Xience V Stent
48689490|NCT00232999|DRUG|Nebulized IVX-0142|
48689491|NCT01198704|OTHER|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
48160921|NCT01498523|OTHER|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
48160922|NCT01498523|OTHER|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
48513601|NCT00380744|DRUG|LY2189102|
48513602|NCT00380744|DRUG|placebo|
48513603|NCT05766137|PROCEDURE|Alveolar ridge preservation|Socket preservation
48689492|NCT03066323|OTHER|Rice with tea extract|Rice with tea extract
48689493|NCT03066323|OTHER|Rice without tea extract|Rice without tea extract
48689494|NCT05961111|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
48689495|NCT00005947|BIOLOGICAL|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
48003979|NCT03202004|DRUG|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
48003980|NCT06277804|DRUG|LTC004 in Combination With Cyclophosphamide and Fludarabine|LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
48513604|NCT00051935|DRUG|Alglucosidase alfa|20 mg/kg (qow); intravenous
48513605|NCT02827734|DEVICE|multiple breath washout tests|
48513606|NCT02827734|DEVICE|impulse oscillometry|
48513607|NCT02827734|DEVICE|body plethysmography|
48513608|NCT01437930|DIETARY_SUPPLEMENT|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~1. linseed oil (20g/d)(PPM, Magdeburg)~2. echium oil (20g/d) (HARKE Nutrition)~3. microalgae powder(12g/d)(HARKE Nutrition)"
48513609|NCT04615351|DRUG|Metformin|Medication
48522636|NCT05031312|PROCEDURE|inferior oblique weakening|inferior oblique myectomy versus inferior oblique anterior nasal transposition in superior oblique palsy treatment
48689496|NCT00005947|BIOLOGICAL|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
48160923|NCT00000647|DRUG|CD4-IgG|
48160924|NCT00000647|DRUG|Zidovudine|
48160925|NCT00000647|DRUG|Interferon alfa-n1|
48689497|NCT04130776|DIAGNOSTIC_TEST|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from \<1% to \>95% of a man having aggressive cancer in a prospective biopsy.
48160926|NCT00000647|PROCEDURE|Peripheral lymphocyte infusion|
48160927|NCT00000647|PROCEDURE|Bone marrow transplant|
48160928|NCT02767596|DRUG|Lixisenatide|
48003981|NCT03680274|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
48003982|NCT03680274|OTHER|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
48003983|NCT01200875|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
48160929|NCT02767596|DRUG|Basal insulins|patients are on basal insulin treatment
48160930|NCT02544841|BEHAVIORAL|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
48513610|NCT05594901|OTHER|Application of a prognostic score|The CRECOOLT score, for the prospective cohort, will be systematically calculated once week, or at the occurrence of complications, until 60 days after OLT. The therapeutic management of all patients, during both retrospective and prospective periods, will be established by the attending physicians according with routine practice and not dictated by study protocol.
48513611|NCT00004126|DRUG|oxaliplatin|
48513612|NCT00004126|DRUG|paclitaxel|
48513613|NCT01960023|DRUG|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
48513614|NCT01960023|DRUG|Neratinib|"Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
48003984|NCT01200875|PROCEDURE|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
48003985|NCT04270500|BEHAVIORAL|Prehabilitation program|The preoperative period (prehabilitation) represents a more appropriate time than the postoperative period to implement an intervention. Prehabilitation is a process of enhancing an individual's functional capacity before the scheduled surgery, aimed at improving the patient's tolerance to upcoming physiologic stress, by three principal elements: exercise training, nutritional intervention, and psychological support.
48160931|NCT02544841|BEHAVIORAL|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
48160932|NCT06504446|DRUG|NOC-110|Inhalation powder
48160933|NCT06504446|OTHER|Placebo|Inhalation powder
48160934|NCT06280716|DRUG|Placebo|Subcutaneous injection
48160935|NCT06280716|DRUG|Lebrikizumab|Subcutaneous injection
48160936|NCT06280716|DRUG|Topical Corticosteroid|Topical Corticosteroid
48160937|NCT04796948|DRUG|Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)|irinotecan liposome in combination with oxaliplatin and 5-FU/LV
48160938|NCT02062671|PROCEDURE|renal denervation|
48160939|NCT01225705|DRUG|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
48160940|NCT01225705|DRUG|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
48160941|NCT04185142|COMBINATION_PRODUCT|cryoballoon ablation combining with left atrial appendage closure|cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.
48160942|NCT04696926|OTHER|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
48160943|NCT04627064|DRUG|Abemaciclib|Tablet taken orally
48160944|NCT04627064|DRUG|MK-6482|Tablet taken orally
48160945|NCT02924532|BIOLOGICAL|immediate post operative bioassay of Parathyroid Hormone|
48160946|NCT03792035|DRUG|Tongxinluo|tid, po.
48160947|NCT03792035|DRUG|Placebos|tid, po.
48513615|NCT05497791|DEVICE|transcranial laser stimulation associated with NMES|"The cluster was applied on the skin covering the head. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.~The NMES was started, after 5 minutes the transcranial laser stimulation (active or placebo-treatment) was started. Then, the therapies were combined. After finishing the transcranial laser stimulation (active or placebo-treatment), the NMES was continued until completing 30 minutes."
48160948|NCT01447251|BEHAVIORAL|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
48160949|NCT04332367|DRUG|Carboplatin|Carboplatin IV
48160950|NCT04332367|DRUG|Paclitaxel|Paclitaxel IV
48160951|NCT04332367|DRUG|Ramucirumab|Ramucirumab IV
48160952|NCT03990909|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
48160953|NCT03990909|DIETARY_SUPPLEMENT|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
48160954|NCT03990909|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
48160955|NCT05644041|DRUG|Gemcitabine|Gemcitabine will be administered intravesically at a dose of 2000 mg.
48160956|NCT05167734|DRUG|Iron Dextran|1000 mg IV
48160957|NCT05167734|DRUG|Erythropoietin (EPO)|40,000 units subcutaneous
48160958|NCT03460496|BEHAVIORAL|neonatologists|will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.
48160959|NCT03460496|BEHAVIORAL|psychological support|Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.
48160960|NCT03460496|BEHAVIORAL|lactation consultant|during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.
48160961|NCT03460496|BEHAVIORAL|physiotherapeutic interventions|physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.
48160962|NCT03460496|BEHAVIORAL|social workers|social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
48160963|NCT03460496|BEHAVIORAL|music therapy|music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.
48160964|NCT03460496|BEHAVIORAL|other health care professionals|the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
48160965|NCT03460496|BEHAVIORAL|interprofessional roundtable meetings|interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
48185198|NCT02034097|DRUG|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
48185199|NCT02034097|DRUG|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
48522637|NCT01305161|OTHER|Blood simple|Single Blood simple at Day 1
48003986|NCT04561401|DEVICE|Repeated Transcranial Magnetic Stimulation (rTMS)|rTMS will be applied at 10 Hz. Each train will consist of 40 supra threshold (120% resting motor threshold) pulses over 4 seconds with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3,000 pulses), and occur at the same time of day on every weekday for a period of three weeks (15 days total). During TMS, only passive activities will be allowed (i.e., watching movies or TV, listening to music). Three weeks of treatment was selected based on existing rTMS evidence in youth with treatment resistant major depressive disorder.
48689498|NCT04102800|DRUG|Benralizumab|subcutaneous injection
48689499|NCT02810288|BEHAVIORAL|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
48689500|NCT01419496|GENETIC|protein expression analysis|
48513616|NCT05497791|OTHER|Placebo|The transcranial laser was applied identically for all groups, but the null dose was used in the placebo group. NMES of the paretic limbs was programmed to generate, alternately, ankle dorsiflexion and wrist extension.
48513617|NCT02419781|PROCEDURE|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
48003987|NCT04561401|OTHER|Intensive Pain Rehabilitation Program (IPRP)|The paediatric Intensive Pain Rehabilitation Program (IPRP) in Canada was established to target youth with severe chronic pain and consequent functional disability who do not respond to standard outpatient pain therapies. The IPRP at the Alberta Children's Hospital (ACH) involves three- to six-weeks of day-treatment rehabilitation, provided by an interdisciplinary team (e.g. Psychology, Physiotherapy, Family Therapy). This rehabilitative program teaches self-management strategies with the goal of helping youth and their families resume normal daily functioning.
48513618|NCT02419781|PROCEDURE|No endovascular therapy|
48689501|NCT01419496|OTHER|flow cytometry|
48513619|NCT03011593|OTHER|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
48513620|NCT00430066|DRUG|Imatinib Mesylate|400 mg/die for 6 months
48003988|NCT04561076|DRUG|HLX70|Single-dose, intravenous infusion
48160966|NCT03460496|BEHAVIORAL|Advanced practice nurses' interventions|The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
48160967|NCT03581253|OTHER|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
48689502|NCT01419496|OTHER|laboratory biomarker analysis|
48689503|NCT01006655|DRUG|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
48689504|NCT01006655|DRUG|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
48689505|NCT03049358|OTHER|Physiologic Testing|Undergo UPSIT smell test
48689506|NCT03049358|OTHER|Quality-of-Life Assessment|Ancillary studies
48689507|NCT03049358|PROCEDURE|Sham Intervention|Undergo sham training
48003989|NCT04561076|OTHER|Placebo|Single-dose, intravenous infusion
48003990|NCT05968846|DRUG|Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)|124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
48003991|NCT00824863|DRUG|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
48160968|NCT03581253|OTHER|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
48160969|NCT00572299|DRUG|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
48513621|NCT02859753|OTHER|Percutaneous Radiofrequency Ablation|
48513622|NCT02859753|OTHER|Percutaneous Microwave Ablation|
48513623|NCT00773474|DRUG|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
48689508|NCT03049358|PROCEDURE|Therapeutic Procedure|Undergo olfactory training
48689509|NCT03049358|OTHER|rose essential oil|patient smells rose oil in vial
48689510|NCT03049358|OTHER|lemon essential oil|patient smells lemon oil in vial
48689511|NCT03049358|OTHER|clove essential oil|patient smells clove oil in vial
48689512|NCT03049358|OTHER|eucalyptus essential oil|patient smells eucalyptus oil in vial
48689513|NCT03049358|OTHER|canola oil placebo|patient smells canola oil in vial
48689514|NCT01764269|OTHER|text message surveillance for fever|
48003992|NCT02144740|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
48160970|NCT04440579|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
48160971|NCT04440579|PROCEDURE|Sham Percutaneous Tibial Nerve Stimulation (PTNS)|Patients will be connected to the PTNS device but the device will remain off for the entirety of the procedure
48160972|NCT04440579|PROCEDURE|Standard Cystoscopy|Patient will undergo standard cystoscopy
48003993|NCT02144740|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
48003994|NCT03508856|DRUG|Ingenol Mebutate (Picato®) 0.015% gel|
48003995|NCT01265446|DRUG|Lidocaine 8mg + CPC 2mg|one single dose
48160973|NCT05944133|OTHER|No intervention, observational retrospective study|No intervention
48160974|NCT00703599|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
48160975|NCT06159114|DRUG|Ningmitai capsule|Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
48513624|NCT01109147|OTHER|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
48513625|NCT01109147|GENETIC|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
48689515|NCT05712369|OTHER|Blood sampling|"Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction."
48689516|NCT01781793|OTHER|Room air|Humidified room air (21% oxygen) will be inspired
48689517|NCT01781793|OTHER|Hyperoxia|60% oxygen will be inspired
48689518|NCT05129657|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
48689519|NCT05129657|OTHER|Product B|P1012914, A nicotine pouch product with 4 mg of nicotine
48689520|NCT05129657|OTHER|Product C|P1012915, A nicotine pouch product with 8 mg of nicotine
48689521|NCT05129657|OTHER|Product D|P1012919, A nicotine pouch product with 12 mg of nicotine
48513626|NCT01149408|DRUG|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
48003996|NCT01265446|DRUG|Lidocaine 1mg + CPC 2mg|one single dose
48003997|NCT02097355|OTHER|TriVox for clinical care|Use TriVox disease modules to manage patients
48003998|NCT02202928|BIOLOGICAL|DC-CIK|8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
48003999|NCT02202928|RADIATION|Radiotherapy|45\~50 Gy in 25-28 fractions.
48004000|NCT02202928|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
48004001|NCT05513378|DEVICE|Needle guide|Please see the arm/group description
48160976|NCT06159114|DRUG|Celecoxib capsule|Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
48160977|NCT06159114|DRUG|Ningmitai placebo|Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
48160978|NCT06159114|DRUG|Celecoxib placebo|Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
48513627|NCT04515381|OTHER|Therapeutic Touch|Therapeutic Touch
48513628|NCT04515381|OTHER|Control group|Making measurements at the beginning of the research and 4 weeks
48513629|NCT04515381|OTHER|Sham Therapeutic Touch|Sham Therapeutic Touch
48689522|NCT05129657|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
48689523|NCT04002583|DIAGNOSTIC_TEST|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
48160979|NCT04635241|DRUG|Unfractionated heparin|Inhaled nebulised 6 hourly
48689524|NCT06365437|BIOLOGICAL|TCD601|Investigational Product
48689525|NCT06365437|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
48689526|NCT06365437|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
48689527|NCT06365437|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
48689528|NCT06365437|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
48689529|NCT05661864|BEHAVIORAL|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
48689530|NCT01887561|DRUG|dasatinib|
48689531|NCT03671421|PROCEDURE|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
48689532|NCT02052115|BEHAVIORAL|12 month exercise and weight loss intervention|
48689533|NCT00564733|DRUG|carboplatin|Given IV
48689534|NCT00564733|DRUG|docetaxel|Given IV
48689535|NCT00564733|DRUG|gemcitabine hydrochloride|Given IV
48689536|NCT00564733|DRUG|paclitaxel|Given IV
48689537|NCT00564733|PROCEDURE|computed tomography|Undergo FDG PET/CT
48689538|NCT00564733|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
48689539|NCT00564733|RADIATION|fludeoxyglucose F 18|Given IV
48689540|NCT00564733|OTHER|imaging biomarker analysis|Correlative studies
48689541|NCT05684445|OTHER|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
48689542|NCT00583752|BIOLOGICAL|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
48689543|NCT01049204|DRUG|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
48689544|NCT01049204|DRUG|placebo|Placebo twice daily for 24 weeks
48689545|NCT01756573|DRUG|Dexamthsone|
48689546|NCT01756573|DRUG|Bupivacaine|
48689547|NCT00985608|DRUG|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
48689548|NCT00985608|DRUG|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
48689549|NCT01534351|DRUG|Finasteride|Finasteride 5 mg oral tablet taken once daily.
48689550|NCT01534351|DRUG|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
48689551|NCT01534351|DRUG|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
48689552|NCT01534351|DRUG|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
48689553|NCT02224443|DRUG|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
48689554|NCT02224443|DRUG|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
48689555|NCT02224443|DRUG|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
48689556|NCT02224443|DRUG|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
48689557|NCT02224443|DRUG|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
48160980|NCT00562926|PROCEDURE|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
48160981|NCT05983328|DRUG|HUYPS-1 one tablet|After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
48689558|NCT00960791|DEVICE|AZD1656|Oral single dose
48689559|NCT01058915|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
48689560|NCT01058915|DRUG|Rosuvastatin 40mg|Rosuvastatin 40mg/day
48689561|NCT02956252|PROCEDURE|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
48689562|NCT02956252|PROCEDURE|General anesthesia|General anesthesia was used in patients who underwent LC
48689563|NCT05914077|DRUG|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
48689564|NCT05914077|PROCEDURE|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
48689565|NCT05914077|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
48689566|NCT03581149|DRUG|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
48689567|NCT03581149|DRUG|2L polyethylene glycol/ascorbic acid|"* First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
48160982|NCT05983328|DRUG|HUYPS-1 nine tablets|After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
48689568|NCT05633836|PROCEDURE|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
48689569|NCT00982046|DEVICE|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
48160983|NCT06127966|PROCEDURE|Erector Spinae Plane Block|The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
48160984|NCT06127966|PROCEDURE|0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).|The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
48160985|NCT05558098|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
48160986|NCT05558098|OTHER|Standard of Care|Current standard of care for management of critically ill patients
48160987|NCT01125735|DEVICE|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
48160988|NCT01125735|OTHER|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
48185200|NCT04855045|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
48368088|NCT04956133|BEHAVIORAL|Physical Activity|Participants will receive the IMPACT program, which includes a combination of aerobic, resistance, balance, and flexibility exercises conducted 1:1 and delivered online by a physical activity specialist via Zoom. The IMPACT program follows basic physical activity progression principles (i.e., principles of frequency, intensity, time, type, overload and progression). Tailoring will be used to promote fitness and wellness benefits, while ensuring safety. In addition, prominent behaviour change techniques will be provided by physical activity specialists within each 1:1 session. Discussions and worksheets will be provided, depending on participants needs.
48513630|NCT04944524|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12months;~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
48689570|NCT00982046|DEVICE|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
48689571|NCT00982046|DEVICE|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
48004002|NCT06286462|OTHER|Cancer Tracking System (CATSystem)|The CATSystem provider dashboard highlights patients with overdue services or those in need of outreach and sends automated, customized texts to support screening and treatment follow-up per national guidelines. Points of intervention and alerts include: cervical cancer screening and treatment counseling, initial and follow up cervical cancer screening per national guidelines, treatment for precancer and cancer, referral tracking and follow up. In addition, the CATSystem can securely store images of the cervix taken with colposcopes to allow for remote expert consultation if needed to correctly diagnose a patient or can be reviewed at clinical team meetings for input. Primary goals of the CATSystem are to increase rates of guideline-adherent cervical cancer screening/ rescreening and improve guideline-adherent treatment, referral, and follow-up rates of women with positive screens.
48004003|NCT03522181|OTHER|saline|saline
48160989|NCT01951261|PROCEDURE|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
48160990|NCT02415335|DRUG|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
48160991|NCT02415335|DRUG|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
48160992|NCT05076955|DRUG|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
48160993|NCT02929706|GENETIC|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
48185201|NCT04845399|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
48513631|NCT04944524|DRUG|Methotrexate|"1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization."
48689572|NCT00982046|DEVICE|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
48689573|NCT00982046|DEVICE|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
48689574|NCT00982046|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
48004004|NCT03522181|OTHER|Insulin|
48004005|NCT04817228|DRUG|EscharEx (EX-02 formulation)|EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
48004006|NCT05605665|DRUG|low-dose interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.
48004007|NCT05605665|DRUG|rapamycin|Rapamycin 0.5ml was taken orally once per day
48004008|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
48689575|NCT04475562|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
48689576|NCT03150745|PROCEDURE|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
48689577|NCT03150745|PROCEDURE|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
48689578|NCT03150745|PROCEDURE|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
48689579|NCT02077829|BEHAVIORAL|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
48689580|NCT05734911|DRUG|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
48689581|NCT03066700|DEVICE|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
48160994|NCT06584721|OTHER|Anti-pronation taping (Low dye taping) + Conventional therapy|"They would be receiving treatment as follow:~Anti-pronation taping (Low dye taping) Applied on alternate days. 3 days / week for 4 weeks.~Conventional Therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsxset1, 10sec hold) 3sessions/ week."
48160995|NCT06584721|OTHER|Short Foot Exercises + Conventional PT|"They would be receiving treatment as follow:~Short foot exercises are used to reduce the foot pronation: Frequency: 30 reps x 1 set, 30 sec hold and 10 sec relaxation for 4 weeks. 3 session/ week).~Short foot Exercises includes a four-week plan, 1- Shortening of foot in Anterior-posterior direction, 2- Increase medial longitudinal arch, 3- Balanced loading in standing, 4- Approximating Head of first, second meta-tarsal and calcaneus with patient in standing (single leg).~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsx1set, 10sec hold) 3sessions/ week."
48160996|NCT06645587|DEVICE|Active HD-tDCS over pre-SMA|Active cathodal HD-tDCS over pre-SMA cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over Fz. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
48160997|NCT06645587|DEVICE|Active HD-tDCS over left DLPFC|Active cathodal HD-tDCS over left DLPFC cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over F3. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
48160998|NCT06645587|DEVICE|Sham HD-tDCS|Sham HD-tDCS will be delivered over pre-SMA or left-dlPFC cortex for 10 days (3 sessions per week). The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. Each Sham session will last 20 minutes.
48160999|NCT06584825|DEVICE|Enhanced Vitals Monitoring|"For participants in the intervention group, they will receive the enhanced continuous vital sign monitoring, on top of the standard of care monitoring as prescribed per the care team. The enhanced monitoring will be provided during the entire time period of hospitalization (up to 30 days after surgery), using the Philips monitor (i.e. heart rate and oxygen saturation continuously and blood pressure once an hour while awake). Participants and caregivers will be educated how to put on and off the devices by the study coordinator.~When participants return home, they will perform thrice-daily monitoring using the Cloud DX Inc. Home kit and daily questionnaires at home 7 days after discharge (or 30 days after surgery, whichever occurs first)."
48161000|NCT05971758|DRUG|Fimepinostat|The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.
48689582|NCT03335072|DRUG|Azithromycin|Mass Drug Administration
48689583|NCT03378544|BEHAVIORAL|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
48689584|NCT03066206|DRUG|Poziotinib|Given PO
48004009|NCT03561181|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
48161001|NCT04090216|DEVICE|Primary Percutaneous Coronary Intervention|Primary PCI will be done for patients with STEMI in both groups of patients
48161002|NCT02921438|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
48161003|NCT00428441|DRUG|Warfarin|tablets, based on INR levels, according to D-dimer levels
48161004|NCT05935683|OTHER|Severe Uncontrolled Chronic Rhinosinusitis patients (CRS)|Obsertvation
48161005|NCT06050226|DRUG|MY008211A tablets|The first 10 participants will be received low-dose MY008211A tablets, and the next 30 participants will be randomized to low-dose or high-dose treatment arms in a 1:2 ratio.
48161006|NCT00183222|DRUG|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
48161007|NCT06636149|OTHER|Circuit of maternal position changes during labor|"The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5"
48161008|NCT04113902|BEHAVIORAL|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
48368089|NCT04796649|DEVICE|B-Cure laser pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
48689585|NCT02289911|OTHER|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
48689586|NCT00596674|BEHAVIORAL|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
48689587|NCT00596674|OTHER|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
48689588|NCT00952328|DIETARY_SUPPLEMENT|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
48689589|NCT02488135|DEVICE|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
48689590|NCT02488135|PROCEDURE|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
48689591|NCT02457689|BIOLOGICAL|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
48689592|NCT02457689|OTHER|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
48689593|NCT02994082|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
48368090|NCT04796649|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
48368091|NCT04156464|DRUG|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
48368092|NCT04156464|DRUG|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
48368093|NCT03555227|PROCEDURE|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
48368094|NCT03555227|PROCEDURE|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
48368095|NCT03555227|PROCEDURE|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
48689594|NCT02994082|BEHAVIORAL|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
48689595|NCT02994082|BEHAVIORAL|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
48161009|NCT01523028|OTHER|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter"
48368096|NCT03555227|PROCEDURE|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
48689596|NCT02994082|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
48368097|NCT06319365|BEHAVIORAL|yoga|the yoga practice of the group should completed at the end of 12 weeks
48368098|NCT04305158|DRUG|Nitrous Oxide|Patient receiving nitrous oxide are evaluated for success of the procedure
48368099|NCT01347359|BEHAVIORAL|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
48689597|NCT02994082|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
48689598|NCT02994082|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
48689599|NCT02994082|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
48689600|NCT02994082|DRUG|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
48689601|NCT02994082|DRUG|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
48689602|NCT02994082|DRUG|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
48689603|NCT02994082|DRUG|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
48689604|NCT02994082|BEHAVIORAL|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
48689605|NCT02994082|BEHAVIORAL|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
48689606|NCT00077714|DRUG|Paliperidone ER|
48689607|NCT00780143|DRUG|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
48689608|NCT01978054|OTHER|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
48689609|NCT00171457|DRUG|Tegaserod|
48689610|NCT05234918|DEVICE|Pediatric Rotary File Systems|"* Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6"
48185202|NCT02544165|DIETARY_SUPPLEMENT|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
48689611|NCT05088915|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
48689612|NCT05088915|BEHAVIORAL|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
48689613|NCT06349265|DRUG|Carpal Tunnel Hydrodissection with %5 dextrose in water injection|Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.
48689614|NCT05032677|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
48689615|NCT05032677|PROCEDURE|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
48689616|NCT04193449|DIAGNOSTIC_TEST|colonoscopy|colonoscopy procedure
48689617|NCT06321445|OTHER|providing ASA score|ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.
48004010|NCT04117126|BEHAVIORAL|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
48004011|NCT04538066|DRUG|Bryostatin 1|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
48689618|NCT04041544|DRUG|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
48689619|NCT04041544|DRUG|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
48689620|NCT06554704|BEHAVIORAL|Isometric hand grip test|The five-minute heart rate variability and respiration rate will be measured for each condition including resting in supine, sitting and standing position, as well as the isometric hand grip test in supine, sitting and standing position.
48689621|NCT03690401|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
48689622|NCT03690401|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
48689623|NCT04426175|DEVICE|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
48689624|NCT05036655|PROCEDURE|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
48689625|NCT04624867|DRUG|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
48689626|NCT03640507|DRUG|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
48689627|NCT03640507|DRUG|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
48689628|NCT03640507|DRUG|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
48689629|NCT01039545|DRUG|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
48689630|NCT01039545|DRUG|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
48689631|NCT05709561|PROCEDURE|Acupresur|acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
48689632|NCT05709561|PROCEDURE|Mindfulness|Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
48689633|NCT05709561|PROCEDURE|Plasebo|No intervention was applied to the control group.
48689634|NCT05447520|DRUG|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
48689635|NCT05447520|DRUG|Placebo|Oral tablet once daily
48004012|NCT04538066|OTHER|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
48004013|NCT00448422|DRUG|prulifloxacin|Tablet
48004014|NCT03041012|DRUG|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
48004015|NCT03041012|DRUG|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
48004016|NCT03041012|DRUG|Antiretrovirals|Combination antiretroviral therapy
48004017|NCT05160428|BIOLOGICAL|COVID-19 vaccination|different types of covid-19 vaccinations.
48004018|NCT01321788|DRUG|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
48004019|NCT01321788|DRUG|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
48004020|NCT00782262|DIETARY_SUPPLEMENT|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
48004021|NCT03880721|PROCEDURE|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
48161010|NCT05063292|PROCEDURE|Patients in Group II will receive active prewarming with an air forced blanket (full body blanket) 30 minutes prior to the operation|Core temperature and 4-points skin temperatures measurements will be recorded all over the operation. Patients will be delivered 2 Litre/minute oxygen with a nasal cannula.Iv hydration will be continued by room temperatured balanced electrolyte solution with an infusion rate of 2mL/kg/hr. Spinal anesthesia will be applied at the level of L3-L4 by a 25 Gauge Quincke needle with a dose of 12.5-15 mg hyperbaric bupivacaine in the sitting position.
48513632|NCT02879903|PROCEDURE|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
48513633|NCT02879903|PROCEDURE|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
48689636|NCT05447520|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
48689637|NCT00006459|DRUG|gemcitabine hydrochloride|
48689638|NCT00006459|DRUG|paclitaxel|
48004022|NCT05414643|OTHER|Standard care|No interventions were used, as this is an observational study.
48513634|NCT02879903|PROCEDURE|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
48689639|NCT00127452|DIETARY_SUPPLEMENT|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
48689640|NCT05151510|PROCEDURE|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
48689641|NCT05151510|DRUG|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
48689642|NCT04795115|OTHER|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
48689643|NCT01111734|DIETARY_SUPPLEMENT|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
48689644|NCT01111734|DRUG|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
48689645|NCT05667610|OTHER|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
48689646|NCT00489320|DEVICE|Cypher Stent|
48689647|NCT04145544|DEVICE|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
48689648|NCT04145544|DEVICE|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
48689649|NCT05612893|OTHER|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
48689650|NCT00574041|DRUG|Interferon beta-1a|injected, once a week
48689651|NCT01059045|PROCEDURE|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
48689652|NCT01059045|OTHER|Control|No intervention
48689653|NCT03926923|OTHER|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
48689654|NCT00615693|DRUG|AEB071|
48689655|NCT02236234|BIOLOGICAL|HPV vaccine|HPV vaccine
48689656|NCT03824873|PROCEDURE|Internal iliac artery ligation|Internal iliac artery ligation and cesarean hysterectomy
48689657|NCT03824873|PROCEDURE|cesarean hysterectomy|cesarean hysterectomy
48689658|NCT04775355|PROCEDURE|Biospecimen Collection|Undergo collection of stool and urine
48689659|NCT04775355|OTHER|Electronic Health Record Review|Medical records are reviewed
48004023|NCT05962411|OTHER|Dress in Professional Attire|"Adolescents pretend to be adult e-cigarette buyers by dressing in professional attire."
48368100|NCT01347359|BEHAVIORAL|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
48161011|NCT04104724|OTHER|Self-help|self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
48368101|NCT01938443|DRUG|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
48368102|NCT01938443|DRUG|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
48368103|NCT00511602|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
48368104|NCT00511602|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
48368105|NCT03181139|OTHER|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
48161012|NCT04304898|OTHER|Home spirometry|"* Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~* Hospital-based spirometry will be performed according to international guidelines.~* Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
48161013|NCT02821689|DRUG|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
48689660|NCT04775355|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
48689661|NCT04775355|OTHER|Questionnaire Administration|Complete questionnaires
48004024|NCT02273843|DRUG|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
48161014|NCT06438120|BEHAVIORAL|Chatbot-based positive psychology intervention|Eight positive psychology exercises will be delivered, including positive introduction, personal strengths, using strengths, three good things, gratitude, hope and optimism, active/constructive responding, and savoring.
48161015|NCT00702338|DRUG|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
48161016|NCT00702338|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
48368106|NCT00211133|DRUG|epoetin alfa|
48368107|NCT00715780|DRUG|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48368108|NCT00715780|DRUG|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48368109|NCT00715780|DRUG|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48368110|NCT00715780|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48368111|NCT00715780|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48368112|NCT00715780|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
48368113|NCT03834857|DEVICE|Stentrode|Implantation of Stentrode device
48368114|NCT01245296|PROCEDURE|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
48368115|NCT00666640|DEVICE|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
48368116|NCT00666640|DEVICE|CT scan of hip|Computed Tomography scan
48368117|NCT03965416|OTHER|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
48689662|NCT03248167|DRUG|Cannabidiol|600 mg daily
48161017|NCT00702338|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
48368118|NCT03965416|OTHER|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
48689663|NCT03248167|DRUG|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
48004025|NCT02273843|DRUG|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
48004026|NCT00053794|DRUG|perifosine|
48689664|NCT05724862|DEVICE|Needle-less jet anaesthesia|Infiltration anesthesia without needle depending on injection pressure
48689665|NCT05724862|DEVICE|Conventional Injection Anesthesia|Regular Infiltration local anesthesia
48689666|NCT04888026|DEVICE|Quantitative sensory testing|"The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation"
48004027|NCT00579826|DRUG|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
48689667|NCT01003756|OTHER|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
48689668|NCT02480413|OTHER|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
48689669|NCT02057640|DRUG|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
48689670|NCT02057640|DRUG|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
48689671|NCT02057640|DRUG|MLN9708|4mg on day 1, 8, 15, 28
48004028|NCT00579826|DRUG|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
48161018|NCT00702338|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
48368119|NCT01538680|DRUG|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
48368120|NCT05535803|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Autologous olfactory mucosa-derived mesenchymal stem cells
48368121|NCT05535803|OTHER|Patients treated according to current clinical protocols|Patients treated according to current clinical protocols
48689672|NCT01596712|DRUG|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
48689673|NCT01596712|DRUG|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
48689674|NCT05464771|PROCEDURE|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
48689675|NCT03572231|DRUG|mirabegron|oral
48689676|NCT03572231|DEVICE|solifenacin|oral
48689677|NCT03572231|DRUG|darifenacin|oral
48689678|NCT03572231|DRUG|imidafenacin|oral
48689679|NCT03572231|DRUG|tolterodine|oral
48689680|NCT03572231|DRUG|oxybutynin|oral
48689681|NCT03572231|DRUG|trospium|oral
48004029|NCT02567071|OTHER|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
48004030|NCT02567071|OTHER|clean swab|After planned C-section birth, newborns will suck on clean swab.
48004031|NCT00217360|BEHAVIORAL|a customised multifactorial falls prevention program|
48004032|NCT04630093|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
48004033|NCT03892811|OTHER|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
48368122|NCT05426694|OTHER|Scapular clock exercises|In scapular clock exercises, the hand is placed on the wall in front of your body. Move the hand in direction of 12 and 6 o'clock to elevate and depress the scapula. Then move hands towards 9 o' clock and 3 o'clock direction to protract and retract the scapula. Hold each position for 10 seconds. From 3rd week and onward the patient will use thera-band and then perform clock exercises.
48161019|NCT04658537|RADIATION|Radiation Therapy|Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
48368123|NCT05426694|OTHER|Stretching and strengthening exercises|Stretching and strengthening exercises of shoulder and scapular muscles was performed including wall washes, corner stretch, pectoral muscles stretch and wall push ups.
48368124|NCT01476982|DEVICE|ClearView Scan|Assessment with ClearView device
48368125|NCT03795233|BIOLOGICAL|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
48689682|NCT03572231|DRUG|fesoterodine|oral
48689683|NCT03572231|DEVICE|propiverine|oral
48689684|NCT05939245|PROCEDURE|Furosemide Injection|Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
48689685|NCT05939245|PROCEDURE|Placebo Injection|Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
48004034|NCT03080103|PROCEDURE|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
48161020|NCT03265262|DIAGNOSTIC_TEST|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
48161021|NCT02894359|DEVICE|cone beam imagery of cervical spine|
48161022|NCT05563428|PROCEDURE|Free gingival graft|A free gingival graft will be carried out for recession treatment.
48161023|NCT05563428|PROCEDURE|Connective tissue graft|The pouch technique with a connective tissue graft will be carried out for recession treatment.
48161024|NCT00984399|DRUG|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
48161025|NCT06297876|BEHAVIORAL|Storytelling|Narrative stories will be videos that are 2-3 minutes long and will show community members speaking based on community identified themes.
48161026|NCT06297876|BEHAVIORAL|Learn More (Active Comparator)|Informational videos that are of similar length and on the same topic as the storytelling videos.
48368126|NCT03795233|OTHER|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
48368127|NCT02493829|BIOLOGICAL|AML Cell Vaccine|
48689686|NCT00066599|DRUG|voriconazole|
48689687|NCT05653843|DEVICE|Endoscopic clip placement in the gastrointestinal tract.|The placement of a mechanical endoscopic clip in the gastrointestinal tract.
48004035|NCT03080103|DRUG|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
48161027|NCT04212559|OTHER|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
48161028|NCT03869541|OTHER|Mobilization|Physical rehabilitation
48161029|NCT05242913|DIETARY_SUPPLEMENT|Resistant Potato Starch|Unmodified potato starch containing \>60% resistant starch Type 2
48161030|NCT05242913|DIETARY_SUPPLEMENT|Placebo|Fully digestible corn starch
48161031|NCT05201170|DRUG|Vehicle Ophthalmic Solution|Ophthalmic Solution
48161032|NCT05201170|DRUG|PL9643 Ophthalmic Solution|Ophthalmic Solution
48161033|NCT04406142|DEVICE|VISUAL|thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
48368128|NCT03844282|DIAGNOSTIC_TEST|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
48368129|NCT03844282|DIAGNOSTIC_TEST|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online or using desktop software in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
48689688|NCT01268592|PROCEDURE|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
48689689|NCT05303506|DIAGNOSTIC_TEST|serum ferritin and AST|observiational study
48689690|NCT01700959|DRUG|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
48689691|NCT01700959|DRUG|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
48689692|NCT01170052|DRUG|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
48689693|NCT01170052|DRUG|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
48689694|NCT01170052|DRUG|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
48161034|NCT04546971|BEHAVIORAL|Brief Intervention|Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking
48161035|NCT04546971|BEHAVIORAL|Telehealth Counseling|5 sessions of counseling on alcohol use based on Motivational Interviewing.
48161036|NCT04546971|BEHAVIORAL|Text messaging|A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.
48368130|NCT03844282|BEHAVIORAL|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) platform includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
48368131|NCT03844282|DIAGNOSTIC_TEST|I-PAS/Dx100|I-PAS™ (now re-named Dx 100) is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
48368132|NCT03844282|BIOLOGICAL|Saliva sample|Micro RNA's (miRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include miRNA and other markers of injury.
48161037|NCT04290156|OTHER|joint visits|The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
48161038|NCT03623399|PROCEDURE|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
48161039|NCT01643902|DRUG|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
48161041|NCT06647030|DEVICE|CURATE.DTx sessions|"Participants will interact with CURATE.DTx twelve minutes per day for two weeks.~CURATE.DTx is a cognitive training DTx developed by our research team in The N.1 Institute for Health (N.1) and The Institute for Digital Medicine (WisDM). CURATE.DTx is comprised of CURATE.AI and a modified version of the Multi-Attribute Task Battery (MATB), Online MATB.~CURATE.AI is a small data AI-derived platform that can dynamically personalize treatment by modulating drug dose or therapy intensity. We previously implemented CURATE.AI into Online MATB - the modernized, online version of MATB, a flight deck simulator program developed by NASA and the United States Air Force."
48161042|NCT06647030|BEHAVIORAL|Interview|After the last DTx session (regardless of study completion by the participant), a 60-minute interview session will be conducted by a team member, either at the Institute for Digital Medicine (WisDM) in person or via Zoom. All responses will be audio-recorded and transcribed verbatim. We will use categorical analysis of anonymized transcripts to identify emerging or recurring themes. Data will be analyzed using NVivo. The analysis will begin with open/primary coding, where we will descriptively label data. Subsequently, we will group the labels into categories based on literature (i.e., secondary coding). These categories will then help create broader themes/assertions.
48161043|NCT02502721|DRUG|DWC20151|
48161044|NCT02502721|DRUG|DWC20152|
48689695|NCT01894048|DRUG|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
48689696|NCT05291546|DRUG|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
48689697|NCT05291546|DRUG|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
48689698|NCT05291546|OTHER|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
48689699|NCT00700882|DRUG|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
48689700|NCT05092828|DRUG|Intrathecal Morphine Injection|In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
48689701|NCT05092828|DRUG|Pain Relieving|Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
48689702|NCT03689049|PROCEDURE|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
48689703|NCT03689049|PROCEDURE|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
48689704|NCT01099748|DRUG|Methadone|Methadone 50 - 150 mg QD (Day 1)
48689705|NCT01099748|DRUG|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
48689706|NCT00729911|PROCEDURE|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
48689707|NCT00729911|DRUG|Amiodarone|Taken orally on a daily basis.
48689708|NCT01877525|PROCEDURE|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
48161045|NCT01161706|OTHER|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
48161046|NCT05207449|OTHER|Questionnaire|"The questionnaire will include:~1. The demographic data of the patients~2. Chronic disease related questions~3. Assessment of adherence to treatment by using Arabic validated version of Medication Adherence Report Scale (MARS)~4. Patients' beliefs about medication will be assessed using Arabic validated version of Beliefs about Medicines Questionnaire (BMQ)~5. Disease acceptance will be evaluated using: Arabic validated version of Acceptance to Illness Scale (AIS)~6. Assessment of health-related quality of life (HRQoL) using the Arabic version of the Pediatric Qualify of Life Inventory Generic Core Scale (PedsQL) 4.0 GCS~7. Assessment of readiness for transition to adult health care settings using The Transition Readiness Assessment Questionnaire (TRAQ)"
48161048|NCT01309633|DRUG|12.5mg sunitinib with Cisplatin and Gemcitabine|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
48161049|NCT01309633|DRUG|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
48161050|NCT01309633|DRUG|7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
48161051|NCT01309633|DRUG|2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
48161052|NCT05394727|DEVICE|Needle-free injection device, Then traditional insulin pen|Patients first received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks.
48004036|NCT00710320|PROCEDURE|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:~1. the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~2. both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
48004037|NCT00380393|BIOLOGICAL|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
48161053|NCT05394727|DEVICE|Traditional insulin pen , Then Needle-free injection device|Patients first received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks.
48161054|NCT04284774|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48161055|NCT04284774|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration or biopsy
48161056|NCT04284774|PROCEDURE|Computed Tomography|Undergo a CT scan
48161057|NCT04284774|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48161058|NCT04284774|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
48161059|NCT04284774|PROCEDURE|Radionuclide Imaging|Undergo a MIBG scintigraphy scan
48161060|NCT04284774|DRUG|Tipifarnib|Given PO or via nasogastric or gastric tube
48368133|NCT03844282|OTHER|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI), proton spectroscopy and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), completed at 7T (Tesla), or 3T if this is not possible.
48522638|NCT01881477|PROCEDURE|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk."
48004038|NCT00380393|BIOLOGICAL|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
48185203|NCT02544165|OTHER|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
48368134|NCT05359094|DIETARY_SUPPLEMENT|Placebo|Placebo (Microcrystalline α-cellulose) supplement with a Plant-Dominant Low-Protein Diet
48368135|NCT05359094|DIETARY_SUPPLEMENT|Probiotics|Probiotics(Pediococcus acidilactici GKA4) supplement with a Plant-Dominant Low-Protein Diet
48689709|NCT03897465|DEVICE|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
48004039|NCT01339390|BEHAVIORAL|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
48161061|NCT00974402|BEHAVIORAL|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
48161062|NCT01461161|DRUG|bardoxolone methyl|oral, single dose
48161063|NCT04134455|PROCEDURE|Mesh reinforcement|Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
48161064|NCT04134455|PROCEDURE|RTL reinforcement|Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
48161065|NCT05952908|OTHER|Proficiency-Based Progression simulation training|The simulation-based training curriculum is delivered - with proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
48161066|NCT05952908|OTHER|Traditional simulation training|The simulation-based training curriculum is delivered - without proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
48161067|NCT06584942|DRUG|Suvorexant (20mg/day)|Participants will take 20mg suvorexant daily for 14 days.
48161068|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
48161069|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
48161070|NCT01679457|BEHAVIORAL|ACT-Focused ERP|
48161071|NCT01679457|BEHAVIORAL|TAU-ERP|
48161072|NCT02581371|DRUG|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
48368136|NCT03815006|DEVICE|Free Style Libre 2|FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
48004040|NCT01339390|BEHAVIORAL|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
48004041|NCT02135575|BEHAVIORAL|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
48161073|NCT02581371|OTHER|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
48161074|NCT05768321|DRUG|GEC255 tablets|"Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee.~Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1"
48368137|NCT00712608|OTHER|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
48368138|NCT00712608|OTHER|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
48368139|NCT00712608|OTHER|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
48368140|NCT03016260|BIOLOGICAL|Infliximab|Anti-TNF alpha originator
48368141|NCT03016260|BIOLOGICAL|Adalimumab|Anti-TNF alpha originator
48368142|NCT03016260|BIOLOGICAL|Etanercept|Anti-TNF alpha originator
48368143|NCT03016260|BIOLOGICAL|Golimumab|Anti-TNF alpha originator
48689710|NCT03897465|DEVICE|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
48368144|NCT03016260|BIOLOGICAL|Certolizumab Pegol|Anti-TNF alpha originator
48368145|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
48689711|NCT02011230|OTHER|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
48161075|NCT03904888|PROCEDURE|r-TAPP|Robot-assisted repair
48161076|NCT03904888|PROCEDURE|l-TAPP|Laporoscopic repair
48161077|NCT03904888|PROCEDURE|local anesthetics|local anesthetics will be administred
48161078|NCT01372735|RADIATION|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
48368146|NCT03016260|BIOLOGICAL|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
48368147|NCT03016260|BIOLOGICAL|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
48368148|NCT01866280|BEHAVIORAL|Normal sleep|Normal sleep= sleep 2300-0700
48368149|NCT01866280|BEHAVIORAL|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
48368150|NCT01866280|BEHAVIORAL|Late sleep|Late sleep=sleep at 0230-1030 hours
48522639|NCT01934439|DEVICE|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
48689712|NCT02023580|BEHAVIORAL|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility."
48689713|NCT00284505|DRUG|thalidomide|
48689714|NCT00118638|DRUG|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
48689715|NCT00118638|DRUG|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
48689716|NCT01297608|DRUG|caoted suppository|coated suppository with active drug
48004042|NCT06072547|OTHER|Access to all varieties of on! 4mg nicotine pouches (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original)|Access to all varieties of on! 4mg nicotine pouch products (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original), throughout the trial.
48004043|NCT06072547|OTHER|Access to Original on! 4mg nicotine pouches|Access to non-flavored (i.e., Original) 4mg on! nicotine pouch products throughout the trial.
48161079|NCT01372735|RADIATION|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
48161080|NCT02542085|PROCEDURE|Laparoscopic repair|operative method
48161081|NCT02542085|PROCEDURE|Hybrid repair|operative method
48161082|NCT03985826|OTHER|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
48161083|NCT01846637|PROCEDURE|laparoscopic sleeve gastrectomy|
48368151|NCT01866280|BEHAVIORAL|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
48368152|NCT01897779|DRUG|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
48368153|NCT01897779|DRUG|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
48368154|NCT01897779|DRUG|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
48368155|NCT01897779|DRUG|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
48368156|NCT06386276|PROCEDURE|Colorectal bowel resection|The TrEnd is a single-institutional retrospective/prospective study, conducted in a high-volume referral centre for the endometriosis diagnosis and management, with the aim of systematically collecting data from consecutive patients undergoing segmental sigmoid colon/rectal resection for deep endometriosis.
48161084|NCT00382408|BIOLOGICAL|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
48161085|NCT00382408|OTHER|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
48368157|NCT05764694|OTHER|bullied children|A questionnaire will be answered by parent to measure the primary outcome of the study, which is Presence, duration, and frequency of Oral habits (Bruxism, Nail biting) in addition to a questionnaire answered by child to measure the secondary outcome which is Prevalence of Bullying and victimization.
48689717|NCT01297608|DRUG|coated suppository|coated suppository with placebo
48689718|NCT03984890|DRUG|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
48689719|NCT03984890|DRUG|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
48689720|NCT04482972|PROCEDURE|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
48689721|NCT04482972|PROCEDURE|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
48161086|NCT00701506|DEVICE|Patterned Electrical Neuromuscular Stimulation|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings"
48161087|NCT00701506|DEVICE|Placebo PENS|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings."
48161088|NCT03714997|PROCEDURE|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
48161089|NCT03512587|PROCEDURE|Personalized quantum sonotherapy|Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
48522640|NCT03317418|OTHER|ATR-FTIR Spectrophotometry|Spectrometry imaging
48368158|NCT02974673|PROCEDURE|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
48689722|NCT00100256|DRUG|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
48689723|NCT02822183|OTHER|Online Survey|
48004044|NCT06072547|OTHER|Non-Flavored then complete flavor on! nicotine pouches|Access to non-flavored (i.e., Original) on! 4mg nicotine pouch products during the first 3 weeks and then access to all varieties (Berry, Citrus, Cinnamon, Wintergreen, Mint, Coffee, and Original) of on! 4mg nicotine pouch products during the rest of the trial
48004045|NCT04138875|DRUG|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a \>10% change in weight dosing will be readjusted.
48004046|NCT04138875|DRUG|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
48004047|NCT04138875|DRUG|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
48004048|NCT03904771|BEHAVIORAL|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
48004049|NCT03904771|BEHAVIORAL|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
48004050|NCT04855643|DEVICE|home-based active tDCS|Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.
48004051|NCT04855643|DEVICE|home-based sham tDCS|For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
48004052|NCT04505891|BEHAVIORAL|Education|Kidney health education will be delivered prior to discharge by trained nurse educators.
48161090|NCT03512587|PROCEDURE|Placebo|Headphones will be place in patients without playing quantum sonotherapy
48161091|NCT01498445|DRUG|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
48368159|NCT04212221|DRUG|MGD013 monotherapy|MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
48522641|NCT04241588|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.
48522642|NCT04241588|OTHER|Control|A 3D printed hand with be fitted to simulate a prosthesis.
48689724|NCT00873821|DRUG|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
48689725|NCT00873821|DRUG|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
48689726|NCT00039780|DRUG|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
48689727|NCT00039780|DRUG|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
48161092|NCT01498445|DRUG|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
48161093|NCT01498445|DRUG|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
48161094|NCT00237900|DRUG|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
48004053|NCT04505891|BEHAVIORAL|Education and follow-up|In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
48004054|NCT01323075|PROCEDURE|Truncal block|Patients will have a truncal block during hand or wrist surgery.
48004055|NCT01991171|OTHER|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
48004056|NCT00853177|PROCEDURE|MEOPA inhalation|N2O of 50% and 50% O2
48004057|NCT00853177|PROCEDURE|xylocaine|Ampoule-bottle of 20 ml
48161095|NCT02956876|DRUG|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
48004058|NCT02506335|DRUG|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
48368160|NCT04212221|DRUG|MGD013 in combination with Brivanib Alaninate|After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
48161096|NCT02956876|OTHER|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
48004059|NCT02995291|DRUG|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
48004060|NCT02995291|DRUG|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
48004061|NCT02203812|DRUG|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
48004062|NCT02203812|DRUG|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
48004063|NCT01112293|DRUG|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
48004064|NCT04369248|OTHER|hepassocin|hepassocin levels in polycystic ovary syndrome
48004065|NCT00007033|DRUG|magnesium gluconate|
48004066|NCT00007033|DRUG|magnesium sulfate|
48004067|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led education module using virtual reality
48004068|NCT04278534|OTHER|Educational Intervention|Receive the usual verbal and written education materials
48004069|NCT04278534|OTHER|Educational Intervention|Complete radiation therapist-led face-to-face education module
48004070|NCT04278534|OTHER|Survey Administration|Ancillary studies
48004071|NCT00353678|DRUG|YM150|
48161097|NCT02956876|OTHER|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
48161098|NCT04531852|OTHER|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
48004072|NCT06382233|DIAGNOSTIC_TEST|Identification of Diagnostic Biomarkers|Urinary single-cell and EVs screening to stage the intrarenal injury and repair processes in UPJO babies and identification of the whole blood gene expression profiling of babies with unilateral UPJO. Data deriving from patients with unilateral UPJO will be compared with data deriving from controls.
48161099|NCT04531852|BEHAVIORAL|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
48161100|NCT00263783|DRUG|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
48161101|NCT03244202|OTHER|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
48161102|NCT03244202|OTHER|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
48161103|NCT01794650|DIETARY_SUPPLEMENT|Meal composition|
48161104|NCT04067206|OTHER|RECORDED MOTHER'S VOICE|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
48689728|NCT04257968|DIAGNOSTIC_TEST|Ultrasonography|carotid ultrasonography (IMT and elastography)
48161105|NCT04067206|OTHER|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
48689729|NCT04257968|DIAGNOSTIC_TEST|MRI|MRI of carotid artery and brain
48161106|NCT04067206|OTHER|MiniMuff|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
48161107|NCT05312021|DRUG|IMR-687|150 mg and 200 mg tablets
48161108|NCT05312021|OTHER|IMR-687 Placebo|Matching placebo to IMR-687
48161109|NCT02409121|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
48161110|NCT06395961|PROCEDURE|high ankle block|"The block position is in the middle and lower third of the calf, about 15cm above the inner or outer ankles. 0.375% ropivacaine is used for the block and the total dose is 35ml. The ultrasound probe is placed vertical to the longitudinal axis of the body. On the lateral of tibia and fibula, 5ml of local anesthetic was injected to block the superficial peroneal nerve and 10ml for the deep peroneal nerve. On the posterior of the calf, 10ml of local anesthetic was injected to block the tibial nerve and 5ml for the sural nerve. On the inner side of the calf, 5ml of local anesthetic was injected to block the saphenous nerve. The water separation technique is used and 2ml of physiological saline is injected before blocking to clarify the position of the needle tip and avoid nerve damage. 20 minutes after, the effect was measured using acupuncture by visual analogue scale (VAS) score. If the VAS score is less than 3, the block is considered successful and surgery is immediately performed."
48368161|NCT01199952|BEHAVIORAL|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
48689730|NCT04257968|DIAGNOSTIC_TEST|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
48689731|NCT04257968|DIAGNOSTIC_TEST|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
48689732|NCT01421238|BEHAVIORAL|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
48689733|NCT01498744|DRUG|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
48161111|NCT06395961|PROCEDURE|general anesthesia|intravenous injection of midazolam 0.03-0.05 mg/kg, etomidate 0.15-0.20 mg/kg, cisatracurium 0.15-0.20 mg/kg, and sufentanil 0.3-0.5 μg/kg. Intraoperative anesthesia maintenance using intravenous infusion of remifentanil 0.1-0.3 μg/kg·min, propofol 4-6 mg/kg·h, maintain bispectral index (BIS) value of 40-60, maintain intraoperative blood pressure and heart rate fluctuations within ± 20% of the baseline value, intermittently inject cisatracurium intravenously as needed. After the surgery, the patient was transferred to post-anaesthesia care unit (PACU). After regaining consciousness and regaining autonomous breathing, the tracheal catheter was removed and transferred to the ward when the indications for transfer were met.
48689734|NCT04476901|BIOLOGICAL|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
48161112|NCT02409823|DRUG|Atypical Antipsychotics|any atypical antipsychotic
48161113|NCT04785742|DRUG|Almonertinib|Almonertinib
48004073|NCT03921710|DRUG|CAPA-IVM|Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
48161114|NCT00470041|DRUG|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
48368162|NCT05608811|BEHAVIORAL|Social Skills Training|"Intervention:~The training is planned as 8 sessions. During this 4-week period, 2 sessions were held each week. The training, which will be held via Zoom, was carried out as a group or individual application. The first session was planned as four basic skills, the second session communication skills, the third session assertiveness skills, the fourth session conflict management skills, the fifth session social life skills, the sixth session friendship flirting skills, the seventh session health maintenance skills, and the eighth session professional/work skills."
48368163|NCT03570476|DRUG|Olaparib|Given orally
48368164|NCT03570476|PROCEDURE|Radical Prostatectomy|Undergo surgery
48004074|NCT03921710|DRUG|Standard-IVM|Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
48004075|NCT03890679|DIAGNOSTIC_TEST|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
48368165|NCT02549040|DRUG|Treatment A: Doravirine 100 mg film coated tablet|Single doravirine 100 mg film coated tablet administered orally at the start of Period 2
48368166|NCT02549040|DRUG|Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)|Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1
48368167|NCT02549040|DRUG|Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)|Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3
48522643|NCT01483703|DEVICE|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
48004076|NCT04804709|DRUG|Panobinostat 15 MG|After each instance of opening the BBB using specific parameters of focused ultrasound in the specific number of tumor sites (one, two, or three), the subjects will receive oral Panobinostat (15 mg/m\^2).
48004077|NCT04804709|DEVICE|Focused Ultrasound with neuro-navigator-controlled sonication|"The purpose of this study is to evaluate the feasibility of opening the BBB safely using specific parameters of focused ultrasound in progressive/recurrent diffuse midline gliomas in one, two, or three tumor sites. The trial will follow a 3+3 Number of Tumor Sites (NOTS) escalation scheme. The number of tumor sites in reference to here is the number of openings in the blood-brain barrier using Focused Ultrasound (FUS). Subjects will start the first cycle of the treatment arm with 1 tumor site and move on to incrementing NOTS levels if no dose-limiting toxicities (DLTs) are observed."
48004078|NCT06408116|RADIATION|photon|radiation with 4-5 cm safte margin
48004079|NCT06408116|PROCEDURE|surgical therapy|surgery based on PET-CT/MRI staging
48689735|NCT04476901|OTHER|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
48004080|NCT06408116|DRUG|Chemotherapy|neoadjuvant chemotherapy
48004081|NCT01071512|DRUG|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
48368168|NCT02549040|DRUG|Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)|Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4
48689736|NCT04486638|BIOLOGICAL|Dengue Tetravalent Vaccine, Live|Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
48004082|NCT06022185|DIAGNOSTIC_TEST|Web Based Training on E-health Literacy, Digital Literacy and Healthy Lifestyle Behaviors.|"In the trainings planned for elderly individuals, digital literacy and e-health literacy levels will be improved, knowledge and awareness levels of elderly individuals will be increased and they will be provided with information in this direction. healthy lifestyle behaviors.~Personal information form, E-Health Literacy Scale, Acquisition and Confirmation of Health Information in Digital Environment Scale, Healthy Lifestyle Behaviors Scale-II will be used in the research."
48368169|NCT02549040|DRUG|Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)|Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5
48004083|NCT02649881|PROCEDURE|The heart subject will undergo OCT|
48004084|NCT04152122|DIAGNOSTIC_TEST|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
48004085|NCT05970120|DEVICE|NUVISION NAV Ultrasound Catheter|Participants will be scheduled to have a clinically-indicated ablation procedure using NUVISION NAV ultrasound catheter for management of atrial procedure.
48161115|NCT04701073|DEVICE|LombaStab belt|"Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it.~The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study."
48161116|NCT04287816|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
48522644|NCT00711087|DRUG|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
48522645|NCT00711087|OTHER|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
48004086|NCT01863472|DEVICE|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
48689737|NCT00050557|BEHAVIORAL|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
48689738|NCT00050557|BEHAVIORAL|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
48689739|NCT05580770|DRUG|Mirdametinib|Mirdametinib administered orally
48689740|NCT05580770|DRUG|BGB-3245|BGB-3245 administered orally
48689741|NCT00752739|DIETARY_SUPPLEMENT|selenium|Given orally
48689742|NCT00752739|OTHER|placebo|Given orally
48689743|NCT02929160|PROCEDURE|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
48689744|NCT02929160|PROCEDURE|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
48004087|NCT01863472|DEVICE|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
48004088|NCT03876730|OTHER|ICF CP Core Set|Core set
48004089|NCT02143115|PROCEDURE|Optical colonoscopy|Examination of the colon with a colonoscope
48004090|NCT02143115|RADIATION|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
48161117|NCT04287816|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
48161118|NCT04287816|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
48161119|NCT04287816|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
48689745|NCT05292495|DRUG|HR17031 injection|HR17031 injection; administered subcutaneously.
48004091|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
48004092|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
48004093|NCT00941083|DRUG|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
48689746|NCT01186887|DRUG|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
48004094|NCT03755141|DRUG|Herzuma|Herzuma + Treatment of Physician's Choice
48004095|NCT00787774|DRUG|resume raltegravir|resume raltegravir after 16 weeks of stopping
48004096|NCT03001921|OTHER|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
48004097|NCT00187746|DRUG|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
48004098|NCT02072967|OTHER|Ribomustin|Routine practice
48004099|NCT02072967|OTHER|rituximab|Routine practice
48004100|NCT03880851|RADIATION|Plan adaptation of Radiation Treatment in case of anatomical changes|Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
48004101|NCT04586179|OTHER|Aerobic (treadmill) Exercise|"Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5."
48004102|NCT04586179|OTHER|Dynamic (Agility) Exercise|"Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5."
48004103|NCT04364529|OTHER|The pit crew model|The pit crew model
48004104|NCT00983580|DRUG|Aspirin|Given PO
48161120|NCT04287816|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
48004105|NCT00983580|DRUG|Eflornithine|Given PO
48004106|NCT00983580|OTHER|Laboratory Biomarker Analysis|Correlative study
48004107|NCT00983580|OTHER|Placebo|Given PO
48004108|NCT00983580|OTHER|Telephone-Based Intervention|Ancillary studies
48004109|NCT00555984|DRUG|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
48004110|NCT00555984|DRUG|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
48004111|NCT04139928|DIETARY_SUPPLEMENT|Picometer-ionic form of magnesium chloride|Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
48161121|NCT04287816|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
48161122|NCT01437384|DRUG|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
48161123|NCT00000922|DRUG|Indinavir sulfate|
48689747|NCT01186887|DRUG|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
48161124|NCT00000922|DRUG|Abacavir sulfate|
48161125|NCT00000922|DRUG|Nelfinavir mesylate|
48004112|NCT04139928|DIETARY_SUPPLEMENT|Magnesium citrate or magnesium oxide|Single-dose (300 mg) of magnesium citrate or magnesium oxide
48004113|NCT04139928|DIETARY_SUPPLEMENT|Placebo|Placebo
48689748|NCT00812396|DRUG|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
48161126|NCT00000922|DRUG|Efavirenz|
48161127|NCT00000922|DRUG|Nevirapine|
48689749|NCT00812396|DRUG|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
48004114|NCT00324064|PROCEDURE|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
48004115|NCT06423235|DRUG|regular dose of JiRui® Prunella oral liquid|Take 10ml twice a day
48004116|NCT06423235|DRUG|2x regular dose of JiRui® Prunella oral liquid|Take 20ml twice a day
48004117|NCT06423235|DRUG|regular dose of placebo|Take 10ml twice a day
48004118|NCT06423235|DRUG|2x regular dose of placebo|Take 20ml twice a day
48161128|NCT00000922|DRUG|Lamivudine|
48161129|NCT00000922|DRUG|Stavudine|
48161130|NCT00000922|DRUG|Didanosine|
48161131|NCT00958633|DRUG|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~* In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points."
48689750|NCT00812396|DRUG|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
48689751|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
48004119|NCT04027166|DRUG|Methadone|Methadone will be administered before study procedures
48004120|NCT04027166|DRUG|Methadone|Methadone will be delayed (4 hours) until the end of the procedures
48004121|NCT04076969|BEHAVIORAL|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
48004122|NCT06405139|DRUG|Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine|Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
48004123|NCT05851729|OTHER|Kegal exercises with postural correction|Kegal exercises with postural correction
48004124|NCT05851729|OTHER|Kegal exercises without postural correction|Kegal exercises without postural correction
48004125|NCT01393769|DRUG|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
48161132|NCT00958633|DRUG|Wellbutrin XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~* In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~* The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points."
48161133|NCT04330261|OTHER|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
48161134|NCT01236963|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
48161135|NCT01236963|DEVICE|Dental Floss|
48161136|NCT02596178|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
48689752|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
48368170|NCT05997511|BEHAVIORAL|Card-Sorting Activity (Pre-intervention design)|Study team members within each country will free list misinformation or misconceptions that they commonly encounter in clinical practice or daily life. Each item will be used to create paired cards - one containing the misinformation and a second containing the corresponding correct information. During qualitative interviews, we will ask CHWs to participate in a series of card sorting activities, which is a participatory research method that can inform the design of health interventions.
48513635|NCT01561261|OTHER|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
48513636|NCT04134195|DEVICE|Transcranial direct current stimulation|2mA stimulation for 20 minutes
48689753|NCT05618210|OTHER|regional anesthesia|"in the ESPB group, the linear ultrasound probe was placed in the erector spina muscles were visualized on the side where VATS was planned. block needle can be seen on ultrasound, the skin and erector spina muscles are passed in the cranio-caudal direction. ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.~In the rhomboid intercostal block group, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection."
48689754|NCT01869036|DRUG|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
48689755|NCT01869036|DRUG|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
48689756|NCT00907322|DRUG|Dimebon|Oral tablet; 20 mg Dimebon, single dose
48689757|NCT00907322|DRUG|Dimebon|Oral tablet; 40 mg Dimebon, single dose
48004126|NCT04522037|OTHER|No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups|Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
48004127|NCT01497210|DEVICE|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
48689758|NCT00907322|DRUG|Dimebon|Oral tablet; 60 mg Dimebon, single dose
48689759|NCT00907322|DRUG|Dimebon|Oral tablet; placebo, single dose
48689760|NCT00305903|DRUG|Rivastigmine, memantine|
48689761|NCT01576939|RADIATION|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to \< 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
48689762|NCT04563403|BEHAVIORAL|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
48689763|NCT05421130|DEVICE|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
48004128|NCT01504321|DRUG|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
48004129|NCT01504321|DRUG|Placebo|Encapsulated lactose powder
48004130|NCT05489315|DEVICE|Positioning with peanut ball|If participants are randomly selected to receive a peanut ball, the intent is for the patient to remain on the peanut ball during their labor progression.
48004131|NCT05489315|OTHER|Traditional positioning|If participants are randomly selected to NOT receive a peanut ball, the intent is for the patient to undergo traditional positioning/use wedge pillows during their labor progression.
48004132|NCT04062916|OTHER|BSGE pelvic pain questionnaire and VAS scores|Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
48004133|NCT03377712|DEVICE|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
48004134|NCT03377712|DEVICE|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
48689764|NCT04662190|DEVICE|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
48689765|NCT04662190|PROCEDURE|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
48689766|NCT00864175|DRUG|INCB007839|100 mg BID
48513637|NCT03580473|DRUG|SATURNO II association|opthalmic solution, 4 times a day
48513638|NCT03580473|DRUG|Vigadexa®|opthalmic solution, 4 times a day
48689767|NCT00864175|DRUG|INCB007839|200 mg BID
48689768|NCT00864175|DRUG|INCB007839|300 mg BID
48689769|NCT00864175|DRUG|INCB007839|300 mg BID
48161137|NCT03045549|DEVICE|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
48689770|NCT00864175|DRUG|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
48161138|NCT03045549|OTHER|Conventional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
48004135|NCT03377712|DEVICE|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
48004136|NCT03377712|DEVICE|Pain evaluation|by means of questionnaires
48161139|NCT03024593|BEHAVIORAL|Health- and illness-related internet use|
48161140|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4"
48161141|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1"
48004137|NCT03377712|DEVICE|Evaluation of the function|through questionnaires
48161142|NCT00292305|PROCEDURE|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
48161143|NCT01802476|DRUG|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
48689771|NCT00864175|DRUG|Docetaxel|
48004138|NCT03377712|DEVICE|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
48004139|NCT03377712|DEVICE|Quality of life assessment|through questionnaire
48689772|NCT03962907|DRUG|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
48689773|NCT03962907|DRUG|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
48004140|NCT05865288|DRUG|Oxytocin nasal spray|Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with the nursing staff supervising for proper administration of substance, after training and guiding the patient, and for supervision of side effects.
48004141|NCT04183556|DRUG|Naproxen|use of naproxen twice a day orally in mens time
48004142|NCT04183556|DIETARY_SUPPLEMENT|Turmeric|Use of turmeric orally (1 gram powder formula) in mens time
48004143|NCT02272413|DRUG|BI 695502|
48004144|NCT02272413|DRUG|Avastin|
48004145|NCT01076907|OTHER|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
48004146|NCT01076907|OTHER|Control|Air will be used instead of warm water for unsedated colonoscopy.
48004147|NCT04361526|DEVICE|Cytokine Adsorption|Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
48004148|NCT05846620|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
48161144|NCT01802476|DRUG|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
48161145|NCT02648282|DRUG|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
48004149|NCT04260958|OTHER|Exercise-based cardiac rehabilitation|The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
48004150|NCT03325907|DEVICE|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
48689774|NCT02425956|DEVICE|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
48689775|NCT05087368|BIOLOGICAL|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
48689776|NCT05087368|BIOLOGICAL|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
48689777|NCT05087368|BIOLOGICAL|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
48689778|NCT05889793|DRUG|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
48689779|NCT05889793|DRUG|Placebo|Participant takes a placebo for 10 consecutive days.
48689780|NCT01918605|DEVICE|Diluted spacer|
48689781|NCT01918605|DEVICE|Non-diluted spacer|
48689782|NCT06128889|BEHAVIORAL|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
48004151|NCT04248569|DRUG|DNAJB1-PRKACA peptide vaccine|"1. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and Day 1 of cycle 2, 3, 4 and 5 (priming phase). Boost vaccinations: every 3 cycles beginning C6D1. For Cohort A-(Initial) only: Patients with FLC cancer with no prior checkpoint inhibitor therapy treatment.~2. DNAJB1-PRKACA peptide vaccine: Day 1, 8, 15 of cycle 1 and on Day 1 of cycle 2, 3 and 4 (priming phase). Boost vaccinations: every 3 cycles beginning C5D1.~   * Cohort A-(Expansion): Patients with FLC cancer with no prior checkpoint inhibitor treatment.~  * Cohort B: Patients with FLC cancer with prior checkpoint inhibitor treatment.~  * Cohort C: Patients with non-FLC cancer (solid tumors) with prior checkpoint inhibitor treatment eligible.~3. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5mg Poly-ICLC"
48004152|NCT04248569|DRUG|Nivolumab|"1. Cohort A (Initial): Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 2-5 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 6.~2. Cohort A (Expansion), B and C: Nivolumab 3mg/kg will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 during the priming phase. Boost/maintenance vaccinations will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5.~3. Drug: 3mg/kg and 480mg IV"
48004153|NCT04248569|DRUG|Ipilimumab|"1. Cohort A (Initial): Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 2, 3, 4 and 5 of the study, every 3 weeks of the priming phase.~2. Cohort A (Expansion), B and C: Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycles 1, 2, 3 and 4 of the study, every 3 weeks of the priming phase.~3. Drug: 1mg/kg IV"
48513639|NCT01842997|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
48004154|NCT03053895|PROCEDURE|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
48004155|NCT03053895|PROCEDURE|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
48689783|NCT02562300|DRUG|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
48689784|NCT02562300|DRUG|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
48004156|NCT04114253|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
48161146|NCT02648282|DRUG|GVAX Pancreatic Cancer Vaccine|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
48522646|NCT04540991|PROCEDURE|implant placement|The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
48689785|NCT04153981|DRUG|Insulin Glargine|Administered SC
48689786|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
48689787|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
48689788|NCT03789123|DRUG|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
48689789|NCT05657249|DIAGNOSTIC_TEST|Non-contrast focused MRI|non-contrast liver MRI focusing on HCC surveillance in a short scan time.
48689790|NCT00107900|DRUG|DU-176b|
48689791|NCT00124163|PROCEDURE|Imaging procedure of CT colonography|
48161147|NCT02648282|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
48689792|NCT02159898|DEVICE|EndoMAXX Endoluminal Valve Technology (EVT)|
48004157|NCT05729334|DEVICE|Clinicgram Euclides|"Clinicgram Euclides is a software that allows automated calculation of the area of skin lesions using a mobile device. Three different photographs will be taken of the subject's skin lesion. The area of the skin lesion will be calculated using the photograph of the skin lesion, and:~* for EUCLIDES 2D, an external marker. The investigator will outline the skin lesion and the external marker in the photograph prior to the calculation of the skin lesion area.~* for EUCLIDES 3D, a two reference points selected by the investigator."
48689793|NCT02159898|DEVICE|EndoMAXX|
48689794|NCT00190229|DRUG|Cyclophosphamide|Cyclophosphamide
48689795|NCT02653443|BIOLOGICAL|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
48689796|NCT02653443|BIOLOGICAL|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
48004158|NCT02356783|DEVICE|Pedometer|Wireless pedometer
48004159|NCT00962130|DEVICE|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
48004160|NCT00581958|OTHER|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
48004161|NCT01907828|DEVICE|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
48161148|NCT02648282|RADIATION|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
48161149|NCT05243498|OTHER|Assessment of the Allogenomic Mismatch Score (AMS)|Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
48161150|NCT05243498|OTHER|Assessment of the optimised Allogenomic Mismatch Score (AMS)|Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).
48161151|NCT03327051|DRUG|Omeprazole|Proton pump inhibitor (PPI) that suppresses gastric acid secretion
48161152|NCT03327051|DIETARY_SUPPLEMENT|VSL #3|Probiotics
48004162|NCT01907828|DEVICE|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
48004163|NCT03023566|DRUG|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
48161153|NCT03327051|DRUG|Placebo|Placebo to match omeprazole
48161154|NCT02156999|DEVICE|Ibandronic acid, vitamin D|
48161155|NCT00221481|DRUG|divalproex or olanzapine|
48161156|NCT03199495|OTHER|electroacupuncture|acupuncture needle with TENS device
48161157|NCT03579680|BEHAVIORAL|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
48689797|NCT03030352|BEHAVIORAL|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
48689798|NCT05487677|DEVICE|BioBrace Augmentation|During shoulder replacement surgery, the subscapularis (rotator cuff muscle) is sometimes repaired back again. This will be stitched and augmented with a BioBrace. The Biobrace is a biocomposite scaffold meaning both synthetic and biologic, compared to other traditional implants that are either synthetic or biologic. The stitch in the BioBrace group will be anchored to and reinforced by this material.
48689799|NCT05487677|PROCEDURE|Standard Repair with Sutures|During shoulder replacement surgery, the Subscapularis (rotator cuff muscle) is sometimes repaired back again. This is usually repaired with stitches per standard of care treatment.
48689800|NCT01095081|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
48689801|NCT02723552|BEHAVIORAL|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
48689802|NCT02363972|DEVICE|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
48689803|NCT05369962|DEVICE|Ultrasound|Ultrasound measurements of the Qcsa
48004164|NCT02254707|DRUG|BILB 1941 ZW|
48689804|NCT00505973|DRUG|SCA-136|
48004165|NCT02254707|DRUG|Placebo|
48004166|NCT02152410|DEVICE|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
48004167|NCT02152410|DRUG|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS\> 30).
48689805|NCT00690690|BEHAVIORAL|Video (group-delivered video-based intervention)|group-delivered video-based intervention
48689806|NCT00690690|BEHAVIORAL|HCT|Offer of HIV counseling and testing
48689807|NCT05524857|DRUG|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
48689808|NCT05524857|DRUG|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
48689809|NCT05524857|DRUG|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
48689810|NCT05441605|OTHER|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
48689811|NCT03611816|BIOLOGICAL|Blood taken|Collection of clinical data
48689812|NCT03611816|GENETIC|Blood taken|Collection of DNA
48689813|NCT03611816|GENETIC|Blood taken|Collection of plasma
48689814|NCT02405247|OTHER|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
48689815|NCT02406469|DIETARY_SUPPLEMENT|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
48689816|NCT06489184|DRUG|Zanubrutinib|patients with treatment naive or R/R CLL who treatment with Zanubrutinib
48689817|NCT05541627|GENETIC|AB-1001 Gene Therapy|One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
48689818|NCT03115827|DRUG|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
48689819|NCT03115827|DRUG|Carbidopa|Carbidopa 200mg twice a day
48689820|NCT04519216|BEHAVIORAL|Telesimulation|Telesimulation educational intervention
48689821|NCT00407368|PROCEDURE|Blood Sample|
48689822|NCT03163134|DEVICE|Lumbar Drain|
48689823|NCT04245449|BEHAVIORAL|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
48004168|NCT02811939|DRUG|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
48161158|NCT03579680|BEHAVIORAL|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
48161159|NCT04838145|DRUG|Ribavirin + Pleconaril|Randomized to treatment with study drugs (ribavirin and pleconaril)
48004169|NCT02811939|DRUG|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
48004170|NCT02811939|DRUG|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
48004171|NCT02811939|DRUG|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
48004172|NCT00855491|PROCEDURE|Phaco|AcrySof Single-Piece IOL
48161160|NCT04838145|DRUG|Placebos|Randomized to treatment with placebo
48689824|NCT06169787|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy
48689825|NCT06169787|PROCEDURE|comprehensive pelvic lymphadenectomy|comprehensive pelvic lymphadenectomy
48689826|NCT01309997|DRUG|imatinib mesylate|Given PO
48689827|NCT01309997|BIOLOGICAL|rituximab|Given IV
48689828|NCT06454136|DEVICE|OTX-207|Experimental Pscyhoeducation and Intervention App
48689829|NCT06454136|DEVICE|Comparator App + Treatment as Usual (TAU)|Digitized content and information included in standard of care (i.e., TAU)
48689830|NCT03896061|DEVICE|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
48689831|NCT03935867|BEHAVIORAL|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
48689832|NCT04812782|DIETARY_SUPPLEMENT|EVOO supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
48689833|NCT04812782|DIETARY_SUPPLEMENT|Butter supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
48689834|NCT04176874|PROCEDURE|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
48689835|NCT03727022|DRUG|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
48689836|NCT03727022|DRUG|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
48004173|NCT03748199|DRUG|POL6014|"DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
48004174|NCT03748199|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
48161161|NCT06543407|BEHAVIORAL|SWITCH IT|"Behavioral support for switching, 7-10 sessions with SWITCH IT coach delivered during the first 8 weeks of the study. SWITCH IT participants will also have the opportunity to receive supported field trips to explore e-cigarette options based on availability, cost, and preferences during week 4 and week 6."
48368171|NCT05997511|BEHAVIORAL|SMS Crafting (Pre-intervention design)|A two-person team consisting of one local communication expert and one clinician will draft clinically correct, easy-to-understand SMS messages designed to counter identified misinformation. We will draft messages that use various styles and use cognitive interviewing with CHWs to assess their understanding of and responses to each style. The final messages used in our intervention will be determined by CHW preference.
48004175|NCT03216850|DEVICE|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
48004176|NCT00231101|DRUG|Quetiapine|
48004177|NCT00419562|DRUG|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
48522647|NCT04540991|PROCEDURE|gingiva former placement|Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
48689837|NCT05740631|DRUG|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
48004178|NCT00419562|DRUG|Placebo|Placebo capsule designed to match active drug
48004179|NCT04466475|BIOLOGICAL|Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|Given IV
48004180|NCT04466475|DRUG|Melphalan|Given via infusion
48004181|NCT04466475|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
48004182|NCT06221228|BEHAVIORAL|Audio-visual assisted Flipped Classroom (FC) CAPD Training Programme|"FC CAPD programme is a one-week individual intervention, which consists of five sessions (8-hours each).~Pre-class audio-visual tutorials will be provided for self-study prior to face-to-face (F2F) sessions. Six instructional videos, each dedicated to a specific procedure, are accessible for preview and repeated viewing as needed. Such flexibility allows the patients to revise at their own preferred time and pace.~Participants will be asked to take note of any issues or difficulties they encounter while watching the video.~A CAPD education booklet will be prepared and distributed to the patients at the beginning of the F2F training session.~Take-home exercises will allow participants to revise the materials covered in the videos and consolidate their learning."
48004183|NCT03909009|DEVICE|rTMS + Neuronavigation|Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
48004184|NCT01839448|BIOLOGICAL|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
48004185|NCT04601051|BIOLOGICAL|NTLA-2001|A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
48004186|NCT01709695|DRUG|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
48004187|NCT01709695|DRUG|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
48004188|NCT01687491|DRUG|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
48004189|NCT01687491|DRUG|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
48004190|NCT00210314|DRUG|high dose methotrexate|
48004191|NCT00210314|DRUG|high dose cytarabine|
48004192|NCT00210314|RADIATION|radiotherapy|
48161162|NCT06543407|OTHER|E-cig Provision Only|Provision of e-cigarettes (NJOY) based on combusible use for the first 8 weeks of the study.
48004193|NCT04892576|OTHER|Physical Therapy|"The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks"
48004194|NCT02839616|PROCEDURE|orthotopic liver transplantation|
48004195|NCT00382538|DRUG|Addition of mifepristone 200 mg 24 hours before induction|
48004196|NCT01414335|DIETARY_SUPPLEMENT|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
48004197|NCT01414335|OTHER|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
48004198|NCT03055000|BIOLOGICAL|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
48004199|NCT03055000|BIOLOGICAL|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
48004200|NCT03055000|OTHER|Placebo|WFI (0.5mL) on Day 0 and Day 21
48161163|NCT06487897|DEVICE|Optimal laser keratoplasty|Laser
48368172|NCT05997511|BEHAVIORAL|SMS Messaging|Final messages will be sent via SMS to all CHWs working in our study area. CHWs will also be provided with contact information for a helpline staffed by a local team member who can answer follow-up questions in the local language.
48368173|NCT01467531|DRUG|Dolutegravir|50mg q 24h
48368174|NCT01467531|DRUG|Rlipivirine|25mg q24h
48689838|NCT05740631|DRUG|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
48689839|NCT00795444|DRUG|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
48004201|NCT04734496|OTHER|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)|National Healthcare System Standard of care for each disease type (National Institute for Health and Care Excellence guidelines)
48161164|NCT03740932|DIAGNOSTIC_TEST|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
48161165|NCT00139308|DEVICE|high frequency stimulation|
48161166|NCT00447239|PROCEDURE|glucontrol (insulin therapy)|
48161167|NCT03216252|BIOLOGICAL|samples|Blood samples, oral smear and urine
48161168|NCT01338051|BIOLOGICAL|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
48161169|NCT03875599|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
48161170|NCT00642499|DRUG|Dronabinol|2.5 mg to 40 mg
48368175|NCT01467531|DRUG|GSK1265744|30mg q24h
48004202|NCT00600756|DRUG|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
48004203|NCT00600756|DRUG|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
48161171|NCT00642499|DRUG|Placebo|placebo
48161172|NCT02270463|DRUG|Tagraxofusp-erzs|Tagraxofusp-Erzs administered by IV infusion at doses of 7, 9, and 12 µg/kg/day
48161173|NCT03287375|DRUG|PIPAC|
48368176|NCT01011959|BIOLOGICAL|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
48513640|NCT05501535|DEVICE|ND:YAG LASER|The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
48513641|NCT03600987|BEHAVIORAL|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
48513642|NCT03600987|BEHAVIORAL|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
48004204|NCT05326139|DRUG|Tranexamic acid|TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
48004205|NCT05326139|OTHER|Isotonic saline|Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
48004206|NCT03670810|DRUG|Lasmiditan|Administered orally.
48004207|NCT03670810|DRUG|Placebo|Administered orally.
48004208|NCT04019041|DRUG|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
48004209|NCT04019041|DRUG|placebo|placebo 2 mL pre-filled syringe
48004210|NCT06007014|DRUG|Chiglitazar sodium|tablets 48mg/ day administered for 18 weeks
48004211|NCT06007014|DRUG|Chiglitazar placebo|tablets 48mg/ day administered for 18 weeks
48161174|NCT05041439|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 6 months.
48161175|NCT04163835|DRUG|Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g."
48161176|NCT04163835|DRUG|1/2 Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g."
48161177|NCT04163835|DRUG|Twice Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g."
48161178|NCT04163835|DRUG|Placebo|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g."
48161179|NCT05744557|OTHER|num Vapocoolant|Spray will be administered for 4 to 6 seconds from a distance of 3 to 6 inches to desired sites of skin
48368177|NCT02505945|DRUG|Omeprazole|
48368178|NCT02505945|DEVICE|LINX Reflux Management System|
48368179|NCT05741528|DRUG|SEP-363856|SEP-363856 tablet
48368180|NCT05615948|DRUG|VTS-K|Proprietary oral formulation of 486mg aspirin and 80mg ketamine
48368181|NCT01639599|DRUG|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
48368182|NCT01639599|DRUG|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
48513643|NCT03600987|BEHAVIORAL|Control|control condition using reading materials without music.
48513644|NCT00762112|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
48689840|NCT01591837|BIOLOGICAL|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
48689841|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
48161180|NCT02241642|DEVICE|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
48689842|NCT02507661|DRUG|no-preservation of alveolar ridge - 2 months|
48689843|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
48004212|NCT04453917|BIOLOGICAL|Collection of blood and urine|Collection of blood (47 mL) and urine (5 mL) at PML diagnosis and 1, 3 and 6 months after, for analysis of immune checkpoint molecules expression, detection of antiviral immune responses and virological analyses.
48004213|NCT04453917|BIOLOGICAL|Spinal tap|Spinal tap for monitoring of JC viral load at PML diagnosis and 1, 3 and 6 months after, and collection of CSF (2 mL) for virological analyses.
48161181|NCT00999271|OTHER|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:~* 0.8 pmol/kg/min~* 1.5 pmol/kg/min for 300 minutes"
48689844|NCT02507661|DRUG|no-preservation of alveolar ridge - 4 months|
48689845|NCT02507661|PROCEDURE|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
48689846|NCT02507661|DRUG|no-preservation of alveolar ridge - 9 months|
48161182|NCT05731414|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis (CBTp)|Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness. This approach has demonstrated moderate to large improvements on symptoms and small to moderate effects on functioning. The first four sessions are devoted to building therapeutic rapport and developing collaborative treatment goals. The following phase focuses on developing formulations of why difficulties persist and using cognitive and behavioural change strategies. A longitudinal formulation is then offered to better understand how their difficulties developed. The final 2-4 sessions focus on consolidating the learning that occurred during treatment so that participants can maintain their improvement. Therapy homework is collaboratively assigned at the end of sessions to promote new learning in between sessions.
48368183|NCT01639599|DRUG|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
48368184|NCT00396864|DRUG|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
48689847|NCT01195376|DRUG|BEZ235|
48689848|NCT00107432|DRUG|sorafenib tosylate|Given orally
48004214|NCT04453917|DIAGNOSTIC_TEST|Brain MRI|Brain MRI at at PML diagnosis and 3 and 6 months after
48004215|NCT04453917|BIOLOGICAL|Neurological evaluation|Neurological evaluation at PML diagnosis and 1, 3 and 6 months after
48368185|NCT01951833|DEVICE|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
48368186|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
48368187|NCT01016912|DRUG|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
48368188|NCT01016912|DRUG|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
48689849|NCT00107432|OTHER|laboratory biomarker analysis|Correlative studies
48689850|NCT04624919|OTHER|Hot/Dry|Work is completed in a hot/dry environment.
48689851|NCT04624919|OTHER|Warm/Humid|Work is completed in a warm/humid environment
48689852|NCT03337867|DEVICE|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
48689853|NCT03337867|DEVICE|Magstim Super Rapid2 System|Sham stimulation
48689854|NCT03029039|OTHER|Blood samples|Blood samples will be collected at inclusion.
48689855|NCT03711370|OTHER|Clear Bottle|These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
48689856|NCT03711370|OTHER|Opaque Bottle|These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
48689857|NCT02295696|BEHAVIORAL|EMMA|Consultations using dialogue tools
48689858|NCT04234347|PROCEDURE|Intravenous access method|Comparing long and short axis approach to USGPIV access.
48689859|NCT02501967|OTHER|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
48689860|NCT02729116|DRUG|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
48689861|NCT02729116|DRUG|Ertapenem|Patients are given IV ertapenem for 14 days
48689862|NCT03297684|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
48689863|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
48689864|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
48689865|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
48368189|NCT01016912|DRUG|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
48368190|NCT01016912|DRUG|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
48368191|NCT00026559|DEVICE|Shock Device|Shock Device
48689866|NCT03818607|DRUG|ABP 959|intravenous infusion
48689867|NCT03818607|DRUG|Eculizumab|intravenous infusion
48689868|NCT02020434|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
48689869|NCT05237063|BIOLOGICAL|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
48689870|NCT06554535|DRUG|Serplulimab，Platinum-based Chemotherapy，Aspirin|Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
48689871|NCT06456008|OTHER|Standard of care|Standard of care
48689872|NCT02356523|DIAGNOSTIC_TEST|Confusion Assessment Method|Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
48689873|NCT06442566|DRUG|Buprenorphine Patch|Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
48689874|NCT06442566|DRUG|Placebo|double-blinded randomization to placebo or transdermal buprenorphine
48689875|NCT06442566|DEVICE|Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS
48689876|NCT06442566|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
48689877|NCT03922594|DIAGNOSTIC_TEST|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
48689878|NCT02305589|DRUG|Sugammadex|Muscle relax reversing agent
48689879|NCT06233162|DRUG|Febuxostat-Test product|Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
48689880|NCT06233162|DRUG|Febuxostat-Reference product|Febuxostat 80 mg tablets Manufactured by: Patheon France, France
48689881|NCT02110355|DRUG|AMG 232|Given as an oral tablet in escalating doses
48689882|NCT02110355|DRUG|Trametinib|Trametinib is an anti-cancer agent
48689883|NCT02110355|DRUG|Dabrafenib|Dabrafenib is an anti-cancer agent
48689884|NCT00145210|DRUG|Nebivolol and Atenolol|
48689885|NCT02303756|DEVICE|Pillcam® COLON Capsule|colonoscopy
48689886|NCT06454279|OTHER|Dual Task Training|"Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree"
48185204|NCT02544165|OTHER|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
48368192|NCT00026559|DEVICE|Auditory Startle Device|Auditory Startle Device
48689887|NCT06454279|OTHER|Task Specific Training|"Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible"
48689888|NCT00356772|DRUG|Azithromycin|
48689889|NCT03605927|DRUG|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
48185205|NCT03195361|DEVICE|SRS - Self Retaining Support system|
48368193|NCT03715127|DRUG|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
48368194|NCT03715127|DRUG|Placebo oral capsule|single dose of placebo (100% mannitol)
48368195|NCT02514109|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
48368196|NCT06182839|DRUG|Canagliflozin 300Mg Tab|Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
48368197|NCT06182839|DRUG|Placebo|Patients will get 1 pill of placebo daily for one year.
48368198|NCT05499208|OTHER|Giving side position with patient turning and movement system|To provide effective breastfeeding by placing the mother in position.
48368199|NCT02708524|DEVICE|Senofilcon C Contact Lens|
48368200|NCT02708524|DEVICE|Comfilcon A Contact Lens|
48368201|NCT02708524|DEVICE|Lotrafilcon B Contact Lens|
48368202|NCT02708524|DEVICE|Samfilcon A Contact Lens|
48368203|NCT01920165|OTHER|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
48689890|NCT03605927|DRUG|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
48161183|NCT05731414|BEHAVIORAL|Cognitive Remediation Therapy (CR)|Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials. ABCR involves practicing computerized training exercises with difficulty level dynamically titrated to improve neurocognitive abilities. Then participants engage in strategy discussions with other group members to develop new cognitive strategies. Finally, participants complete role-play simulations of real-world activities to practice their cognitive strategies in simulations of everyday life. ABCR is more effective for improving functioning than traditional approaches to CR. Homework consists of additional cognitive training and practicing cognitive strategies in everyday life.
48689891|NCT03605927|DRUG|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
48689892|NCT01175876|DEVICE|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
48689893|NCT01175876|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
48689894|NCT03611881|BEHAVIORAL|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
48689895|NCT03611881|DRUG|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
48689896|NCT03611881|BEHAVIORAL|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
48161184|NCT05731414|BEHAVIORAL|Befriending|Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth. Befriending consists of 1-hour individual sessions once per week and involves a series of conversations similar to those one might have with a social acquaintance. These conversations involve discussion of neutral topics without problem-solving, coping strategies, or exploration of emotion. If emotional or mental health-related topics are brought up therapists redirect back to a neutral topic.
48689897|NCT03980743|BEHAVIORAL|iOTA text messaging intervention|Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
48368206|NCT05658133|OTHER|Survey of sports nutrition knowledge|Questionnaire
48689898|NCT03980743|BEHAVIORAL|Health Education text messaging intervention|Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
48368207|NCT03762187|BEHAVIORAL|Self-affirmation|Individuals select important values and then write about why that value is important to them.
48689899|NCT00368680|DEVICE|Early Bubble CPAP|
48689900|NCT03087877|DEVICE|Acetaminophen Challenge (G6 CGM)|Evaluation of acetaminophen effect on CGM glucose sensing
48161185|NCT05731414|BEHAVIORAL|Sham Cognitive Remediation|Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion. Participants practice similar computerized exercises to ABCR, however, the exercises do not increase in difficulty. Participants then discuss enjoyment of the exercises but any discussion of cognitive strategies is redirected back to a neutral topic. We have previously found this condition to be an effective control for CR, with similar engagement to the active training group.
48161186|NCT05041478|PROCEDURE|Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
48689901|NCT01193634|DEVICE|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
48689902|NCT02693080|DEVICE|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
48161187|NCT05041478|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
48161188|NCT00890214|DRUG|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
48161189|NCT00890214|DRUG|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
48161190|NCT02134249|DRUG|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
48689903|NCT02693080|DRUG|Isovue-200|Contrast agent
48161191|NCT02134249|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
48161192|NCT02321371|DRUG|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
48161193|NCT02321371|DRUG|Lactulose|Continuation of Lactulose therapy for further 48 hours.
48689904|NCT02693080|RADIATION|Computed Tomography Perfusion Imaging|
48689905|NCT06024616|BEHAVIORAL|TARANG|"TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria."
48689906|NCT03703232|DEVICE|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
48689907|NCT04004338|DRUG|Kyprolis|Patients receiving kyprolis (carfilzomib)
48689908|NCT05400603|COMBINATION_PRODUCT|Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate|"The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels."
48689909|NCT00432328|DRUG|Avotermin|
48161194|NCT03038152|PROCEDURE|Axillary Lymph Node Dissection|Undergo targeted axillary lymph node dissection
48161195|NCT03038152|PROCEDURE|Localization|Undergo axillary lymph node localization
48161196|NCT03038152|DEVICE|Medical Device|Receive Magseed via ultrasound guided injection
48161197|NCT05179096|BEHAVIORAL|Mindfulness-based intervention|The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
48161198|NCT02625571|BEHAVIORAL|Phase-based treatment of sexual behavior problems of children|
48161199|NCT03939416|OTHER|Experimental|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~1. Rhythmic transversal muscle mobilization in posterior chain musculature.~2. General vertebral decompression from the sacrum and pelvis~3. Metameric subcutaneous mobilization~4. Rhythmic vertebral mobilization from the spinous processes."
48513645|NCT05449860|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Twin Cooled-Wet electrodes|Radiofrequency ablation will be performed by using twin cooled-wet electrodes. Two electrodes will be places on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will be delivered by using the 200 watts single generator.
48161200|NCT03939416|OTHER|Control|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
48161201|NCT01018576|OTHER|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
48161202|NCT04712786|OTHER|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
48513646|NCT04679493|DRUG|XC7 100 mg single|The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
48513647|NCT04679493|DRUG|XC7 200 mg single|The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
48513648|NCT04679493|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 capsules once)
48513649|NCT04679493|DRUG|XC7 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
48513650|NCT04679493|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily)
48513651|NCT01193179|DRUG|OPC-262|Oral administration of tablets for 52 weeks
48513652|NCT02125864|PROCEDURE|intravitreal injection|collecting blood samples
48513653|NCT00121537|DEVICE|Wound Care -Wound Vacuum Assisted Closure (VAC)|
48513654|NCT00121537|PROCEDURE|Wound Care - Wet to Dry Dressing Changes|
48513655|NCT02040077|BEHAVIORAL|Computer + Fluency|
48513656|NCT02040077|BEHAVIORAL|Computer Only|
48513657|NCT02040077|BEHAVIORAL|Treatment as Usual|
48513658|NCT03740373|DRUG|BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
48513659|NCT03740373|DRUG|BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
48513660|NCT00489255|DRUG|Tigan®|Oral capsule, 300mg three times daily
48513661|NCT00489255|DRUG|Placebo|Oral capsule, three times daily
48513662|NCT06548945|DRUG|GZR18|5 mg-maximum tolerated dose (MTD), single dose
48513663|NCT06548945|OTHER|Placebo|administered the same volume as GZR18
48513664|NCT03304301|BEHAVIORAL|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
48513665|NCT05549180|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo|The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
48513666|NCT05549180|DRUG|Dovato 50Mg-300Mg Tablet + Biktarvy placebo|The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
48513667|NCT06548425|OTHER|Smart Phone Based Cardiac Telerehabilitation|"Smart Phone Based Cardiac Telerehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60 % THR and modified borg scale 9 (very light- 13 (somewhat hard) Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
48513668|NCT06548425|OTHER|Center based cardiac Rehabilitation|"Center based cardiac Rehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60% THR and modified borg scale 9 (very light- 13 (somewhat hard)~Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
48513669|NCT05528601|BEHAVIORAL|use of Endo App®|use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
48513670|NCT05123430|PROCEDURE|Monitoring of the pressure of the middle left atrium|During the MitraClip surgery, additional catheter is installed in order to monitoring the ppressure of the middle left atrium
48513671|NCT03591042|DIAGNOSTIC_TEST|cervical length screening|transvaginal ultrasound cervical length
48513672|NCT03054584|OTHER|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
48513673|NCT00497913|DRUG|NaCl 0.9%|
48513674|NCT00497913|DRUG|Botulinum Toxin A|
48513675|NCT05643872|DRUG|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
48513676|NCT04853095|PROCEDURE|Peritoneal fixation (PerFix)|PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
48513677|NCT04853095|PROCEDURE|Standard of care|ePLND without peritoneal flap fixation
48513678|NCT03062046|DEVICE|RF ablation|RF ablation
48513679|NCT03437070|DRUG|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
48513680|NCT03437070|DRUG|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
48513681|NCT03437070|DRUG|Olaratumab|Administered intravenously per protocol
48004216|NCT06363487|DRUG|Semaglutide, 0.5 mg/mL|Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
48004217|NCT06363487|OTHER|Placebo, 0.9% NaCl 1.5mL|Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
48004218|NCT04709666|PROCEDURE|Endsocopic Retrograde ColangioPancreatography (ERCP)|
48004219|NCT00098111|DRUG|azathioprine|
48004220|NCT00855088|DRUG|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
48004221|NCT00855088|DRUG|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
48004222|NCT00855088|DRUG|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
48004223|NCT03033472|DRUG|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
48004224|NCT03033472|DRUG|Oral Placebo|Oral Placebo 30 minutes before treatment
48004225|NCT04809909|PROCEDURE|Peripheral stimulation of acupuncture points (PSAP)|Electrode leads will be implanted at Bladder 25-bilateral (BL25), the acupoint commonly used for relief of chronic Low Back Pain in standardized acupuncture.
48004226|NCT04809909|PROCEDURE|Peripheral nerve field stimulation (PNFS)|Electrode leads will be implanted at the region of pain.
48004227|NCT03369938|OTHER|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
48689910|NCT01687543|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
48689911|NCT01687543|OTHER|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
48004228|NCT03533062|DRUG|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
48004229|NCT03200782|DRUG|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
48004230|NCT03200782|DRUG|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
48004231|NCT03200782|OTHER|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
48004232|NCT03200782|OTHER|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
48513682|NCT02046603|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
48004233|NCT03111420|DRUG|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
48004234|NCT03111420|DEVICE|Platelet function test|Blood is drawn for testing of platelet aggregation activity
48689912|NCT03683420|BEHAVIORAL|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
48689913|NCT00149799|DRUG|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
48004235|NCT01374308|BIOLOGICAL|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
48689914|NCT00149799|DRUG|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
48689915|NCT05183516|BIOLOGICAL|tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
48689916|NCT00256360|DRUG|dose dense with neulasta|
48689917|NCT02738541|DRUG|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
48689918|NCT02738541|DRUG|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
48689919|NCT01472354|BEHAVIORAL|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
48689920|NCT02850224|BEHAVIORAL|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
48689921|NCT01449396|OTHER|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
48689922|NCT01449396|PROCEDURE|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
48689923|NCT01449396|PROCEDURE|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
48689924|NCT01948219|DEVICE|ENTegral Artificial Larynx implant|
48689925|NCT06485713|DRUG|trifluridine/tipiracil combined with fufuquitinib|trifluridine/tipiracil combined with fufuquitinib
48689926|NCT06485713|DRUG|fufuquitinib|fufuquitinib
48689927|NCT06485713|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil
48689928|NCT02752633|DRUG|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
48689929|NCT02752633|DRUG|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
48689930|NCT01017042|DRUG|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
48689931|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
48689932|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
48689933|NCT05109429|BEHAVIORAL|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
48689934|NCT05109429|BEHAVIORAL|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
48689935|NCT05109429|BEHAVIORAL|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
48689936|NCT01483235|BEHAVIORAL|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
48513683|NCT02046603|DRUG|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
48513684|NCT02046603|DRUG|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
48513685|NCT02046603|DRUG|Methotrexate|Methotrexate per investigator's discretion.
48513686|NCT00911300|DRUG|fondaparinux|Comparison of different drugs
48004236|NCT01374308|DRUG|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
48004237|NCT04146480|DIAGNOSTIC_TEST|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions."
48004238|NCT04528446|RADIATION|Dual-energy X-ray absorptiometry|DXA whole body, hip, spine, and radius at baseline, and 12-month visit.
48004239|NCT04528446|RADIATION|High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)|HR-pQCT of the radius and tibia at baseline, and 12-month visit.
48004240|NCT04528446|OTHER|Blood draw and Urine collection|The blood draw can be completed +/- 3 weeks from baseline or 12-month visit.
48004241|NCT04528446|OTHER|Questionnaires|Questionnaires regarding fracture history, physical activity and dietary intake at baseline, and 12-month visit.
48004242|NCT05873569|BEHAVIORAL|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
48004243|NCT03298828|BIOLOGICAL|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
48004244|NCT03298828|BIOLOGICAL|CD19 CAR T-cells|A single dose of 1 x 10\^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
48004245|NCT03822728|DIAGNOSTIC_TEST|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
48004246|NCT05471362|DEVICE|Postpartum IUD|Postpartum IUD prevents pregnancy and short inter-pregnancy interval and allow spacing and family regulation
48004247|NCT05411796|DEVICE|Tampax menstrual cup|regular flow size
48004248|NCT05411796|DEVICE|Other menstrual cup|size 1
48161203|NCT01112371|DRUG|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
48513687|NCT00911300|DRUG|unfractionated heparin|Comparison of different drugs
48513688|NCT00911300|DRUG|Vitamin-K-Antagonist|Comparison of different drugs
48161204|NCT05533645|OTHER|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
48161205|NCT04501978|BIOLOGICAL|LY3819253|Participants are no longer being randomized to this intervention.
48161206|NCT04501978|DRUG|Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion
48161207|NCT04501978|BIOLOGICAL|Remdesivir|Provided to all study participants as SOC unless contraindicated for an individual patient.
48161208|NCT04501978|BIOLOGICAL|VIR-7831|Participants are no longer being randomized to this intervention.
48161209|NCT04501978|BIOLOGICAL|BRII-196/BRII-198|Participants are no longer being randomized to this intervention.
48161210|NCT04501978|BIOLOGICAL|AZD7442|Participants are no longer being randomized to this intervention.
48161211|NCT04501978|DRUG|MP0420|Participants are no longer being randomized to this intervention.
48161212|NCT04501978|DRUG|PF-07304814|250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
48161213|NCT00840918|DRUG|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
48161214|NCT00840918|OTHER|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
48161215|NCT00793299|BEHAVIORAL|Video Illness Narrative|video
48161216|NCT03003884|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
48161217|NCT03003884|DRUG|Propofol|Initial dose plus supplemental doses as necessary.
48161218|NCT05361083|DRUG|F18CETO|Injection of F18CETO or O15water followed by PET/CT
48161219|NCT05804526|DRUG|RC88|1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
48161220|NCT05804526|DRUG|Sintilimab Injection|Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
48161221|NCT05750017|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
48161222|NCT05750017|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
48161223|NCT05750017|DRUG|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
48161224|NCT00076063|BIOLOGICAL|ALVAC-HIV (vCP1452)|experimental vaccine
48161225|NCT00076063|BIOLOGICAL|LIPO-5|experimental vaccine
48161226|NCT05375383|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48513689|NCT05585021|DIETARY_SUPPLEMENT|Wonderlab Kids instant probiotics|"During study intervention, subjects are required to take the randomly assigned product based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, take it half an hour after meal.1 bottle a day. Lasting for 24 weeks intervention period."
48161227|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48161228|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48161229|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
48161230|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
48161231|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
48161232|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
48161233|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
48513690|NCT05585021|DIETARY_SUPPLEMENT|Instant probiotic placebo|"Subjects are required to take the randomly assigned Instant probiotic placebo based on the randomization list.~Taking assigned product directly or mix it with milk/water/other liquids below 37 ℃, half an hour after meal.~1 bottle a day. Lasting for 24 weeks intervention period."
48161234|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48161235|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48161236|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48161237|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48513691|NCT02389231|DRUG|Interleukine-2|"Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
48161238|NCT05199597|DRUG|0.01% atropine|0.01%, room temp, Lab A
48161239|NCT05199597|DRUG|0.05% atropine|0.05%, room temp, Lab A
48004249|NCT01256593|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
48004250|NCT03548584|DRUG|Brexpiprazole|Oral tablets
48513692|NCT02220517|DEVICE|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
48689937|NCT01483235|BEHAVIORAL|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
48368208|NCT03762187|BEHAVIORAL|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
48368209|NCT02793024|BEHAVIORAL|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
48689938|NCT04347512|DRUG|Hydroxychloroquine and azithromycin treatment arm.|"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
48689939|NCT04347512|DRUG|Hydroxychloroquine|"Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
48004251|NCT03548584|OTHER|Placebo|Oral tablets
48161240|NCT05199597|DRUG|0.05% atropine|0.05%, refrigerated, Lab A
48161241|NCT05199597|DRUG|0.05% atropine|0.05%, room temperature, Lab B
48161242|NCT06646588|DRUG|Fruquintinib|Fruquintinib: Oral, once daily, 2 weeks on and 1 week off. The product can be taken with food or orally on an empty stomach, and needs to be swallowed whole. It is recommended that the dose be taken at the same time each day; if the patient vomits after taking the dose, no refill is needed; a missed dose should not be added the next day, but the next prescribed dose should be taken as usual.
48161243|NCT06646588|DRUG|Tislelizumab|Tislelizumab: intravenous drip 200mg，day1，once every three weeks.
48161244|NCT06646588|RADIATION|Radiotherapy|Radiotherapy synchronised with drugs.
48513693|NCT02220517|DEVICE|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
48004252|NCT04185233|OTHER|Games on an iPad|Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.
48004253|NCT04185233|DRUG|Nitrous Oxide|Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
48004254|NCT05974904|OTHER|high-sensitivity C-reactive protein to albumin ratio|High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
48004255|NCT02180516|DRUG|Meloxicam|
48161245|NCT02956915|PROCEDURE|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
48161246|NCT04611724|DRUG|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
48161247|NCT06646796|OTHER|Yoga|Yoga with certified teacher, 3 times a week during 3 months.
48161248|NCT05653609|DEVICE|Cureety TechCare|Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
48161249|NCT03240458|DEVICE|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
48513694|NCT04419012|OTHER|observation|observation
48161250|NCT02672137|BEHAVIORAL|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
48368210|NCT05465200|PROCEDURE|Structured treatment of cardiogenic shock patients|"Creation of hub\&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
48689940|NCT04347512|DRUG|Control arm|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
48004256|NCT02180516|DRUG|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
48161251|NCT02592928|OTHER|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
48161252|NCT06642337|OTHER|Educational program +Oral Iron therapy|The Nutritional Education Program is a structured intervention designed to enhance caregivers' understanding of nutrition and improve dietary practices for children suffering from iron deficiency anemia. The program comprises six weekly workshops lasting 1.5 hours each, focusing on essential topics such as the importance of iron in child development, identifying and preparing iron-rich foods, and practical meal planning strategies. Participants will engage in hands-on cooking demonstrations and receive educational materials, including recipe cards and meal planning tools, to support their learning. Knowledge assessments will be conducted at the beginning and end of the program to measure improvements in caregivers' nutritional knowledge.
48161253|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
48161254|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
48161255|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
48161256|NCT05286775|OTHER|Clinical treatment and Knee educational program|"Three weekly medical interventions, according to the patient's need as observed at baseline.~1. 3ml paraspinal infusion of 1% Lidocaine (segmental spinal level);~2. 5,000 impulses of Radial Shockwave Therapy (pneumatic generator, 0.16mJ/mm² of energy and 20Hz of frequency) at the most painful spot of the knees;~3. \*6,000 pulses of Focused Shockwave Therapy (electromagnetic generator) at four sites of the painful knee.~   For those with knee pain of 7 or above in Visual Analogue Scale after the treatments above, the interventions below will be delivered in the order they appear:~4. Ultrasound guided genicular nerve block: infusion of up to 10ml 0.50% Levobupivacaine without vasoconstrictor;~5. Hydrodissection of superficial and deep plane nerves: infusion of 10ml 5% dextrose diluted in water (D5W);~6. Intra-articular Infusion of Hyaluronic Acid: ultrasound guided infusion of 2.5ml of sodium hyaluronate at the knee joint.~   * Four weekly applications."
48161257|NCT05286775|OTHER|Knee educational program|"Three weekly 60-minute educational program sessions with the following services:~Stretching and strengthening exercises for specific muscle groups (hip flexors, extensors, and abductors; knee flexors and extensors; plantar flexors; and abdominal muscles), using one's own body and gravity resistance. Patients will be encouraged to practice them at home at least twice a week after the end of the sessions.~Nutritional guidance: Instructions on the importance of adequate weight management, healthy food consumption, and the adequate intake of nutrients.~Physical activities: Counseling on home-based physical activities, according to their physical capacities, to protect knee joints.~General health: psychology counseling, encouraging participants to apply strategies and self help conduct to improve their general health; Occupational Therapy: Activities of Daily Living strategies to protect knee joints; Nursing: Counseling on strategies for improving healthy sleeping habits."
48368211|NCT03331393|OTHER|Non-interventional|Non-interventional
48368212|NCT03055208|RADIATION|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
48368213|NCT03223025|DRUG|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
48368214|NCT03223025|DRUG|Nordilet®|0.03 mg/kg daily subcutaneous injections
48368215|NCT01785342|OTHER|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
48368216|NCT03166774|OTHER|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
48368217|NCT02177227|DEVICE|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
48368218|NCT06248515|DRUG|Sacituzumab govitecan-hziy|10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
48368219|NCT05894187|OTHER|animated video|Participants randomized to the intervention group will receive a link to a short survey gauging parent anxiety levels three days prior to their childs surgery date. If randomly assigned to watch the informative animated video, the survey will be followed by a link to a video which families are free to watch prior to your child's surgery date. Once participants and there family watch the video, they will be asked to rate the quality of the video on a scale of 0 (very bad) to 10 (excellent). Responses to this question will be used to confirm that participants watched the video to the end.
48368220|NCT06313242|DRUG|Polyethylene Glycol Electrolytes Powder (II)|Polyethylene Glycol Electrolytes Powder (II) was used for bowel preparation.
48368221|NCT06313242|OTHER|Low residue diet|Low residue diet 1 day before the test, fasting from 20:00 pm.
48368222|NCT06313242|OTHER|Normal diet|Normal diet 1 day before the test, fasting from 20:00 pm.
48689941|NCT03774043|OTHER|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
48161260|NCT02934815|OTHER|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
48161261|NCT06525753|OTHER|Weaning off Parenteral Nutrition|pediatric intestinal failure patients who have been weaned off parenteral nutrition
48161262|NCT00027963|DRUG|gabapentin|
48161263|NCT00027963|OTHER|placebo|
48161264|NCT05879991|DRUG|BI 1810631 (C-14) formulation 1|BI 1810631 (C-14) formulation 1
48161265|NCT05879991|DRUG|BI 1810631|BI 1810631
48161266|NCT05879991|DRUG|BI 1810631 (C-14) formulation 2|BI 1810631 (C-14) formulation 2
48689942|NCT03774043|OTHER|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
48689943|NCT00392834|BIOLOGICAL|filgrastim|given subcutaneously
48689944|NCT00392834|BIOLOGICAL|pegfilgrastim|given subcutaneously
48689945|NCT00392834|BIOLOGICAL|rituximab|given IV
48689946|NCT00392834|DRUG|cyclophosphamide|given IV
48689947|NCT00392834|DRUG|cytarabine|given intrathecally
48368223|NCT03289442|PROCEDURE|supine position|patients were positioned on their supine position to receive colonoscopy insertion
48689948|NCT00392834|DRUG|doxorubicin hydrochloride|given IV
48689949|NCT00392834|DRUG|etoposide|given IV
48689950|NCT00392834|DRUG|ifosfamide|given IV
48689951|NCT00392834|DRUG|leucovorin calcium|given IV
48161267|NCT06344494|DEVICE|Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system|Novel ICE catheter and combined ultrasound system
48161268|NCT06344494|DEVICE|SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system|Commercially available devices
48161269|NCT01372202|DRUG|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
48161270|NCT01372202|DRUG|Cisplatin|"Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29."
48161271|NCT01372202|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
48161272|NCT01372202|DRUG|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29."
48161273|NCT01372202|RADIATION|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
48689952|NCT00392834|DRUG|liposomal cytarabine|given intrathecally
48689953|NCT00392834|DRUG|methotrexate|given intrathecally
48689954|NCT00392834|DRUG|therapeutic hydrocortisone|given intrathecally
48689955|NCT00392834|DRUG|vincristine sulfate|given IV
48689956|NCT03026231|BIOLOGICAL|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
48368224|NCT03414372|BEHAVIORAL|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
48689957|NCT03026231|DRUG|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
48513695|NCT03299946|DRUG|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
48689958|NCT02131090|DEVICE|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
48161274|NCT01372202|PROCEDURE|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
48689959|NCT02131090|DEVICE|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
48689960|NCT02131090|DEVICE|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
48689961|NCT04891718|BIOLOGICAL|MVC-101|Intratumoural microdose injection by the CIVO device.
48689962|NCT04891718|BIOLOGICAL|Nivolumab|Intratumoural microdose injection by the CIVO device.
48689963|NCT04891718|COMBINATION_PRODUCT|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
48689964|NCT02795624|PROCEDURE|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
48689965|NCT02795624|PROCEDURE|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
48689966|NCT02795624|PROCEDURE|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
48689967|NCT06129461|BEHAVIORAL|Single-session acceptance-based online workshop targeting food cravings as predictors of loss of control and binge eating in pregnancy|Participants in the intervention will learn acceptance-based strategies for reducing the adverse impact of food cravings on eating behaviors. Unlike control-based strategies, acceptance-based strategies do not attempt to change the content or frequency of thoughts; rather, they foster willingness to acknowledge and experience uncontrollable thoughts, urges, and emotions as what they are - nothing more, nothing less. Acceptance-based approaches have demonstrated efficacy in reducing the adverse impact of food cravings on eating behaviors in non-pregnant samples.
48004257|NCT01823874|PROCEDURE|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
48004258|NCT04638465|PROCEDURE|Transoral robotic surgery|Transoral resection with neck dissection
48689968|NCT05810909|DIETARY_SUPPLEMENT|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
48689969|NCT02242136|BEHAVIORAL|FORNET|
48689970|NCT05869058|DIAGNOSTIC_TEST|a deep convolutional neural network|a deep convolutional neural network developed for detection and assessing the perfusion of parathyroid gland during endoscopic thyroidectomy
48689971|NCT00706108|BEHAVIORAL|Observational study|Observational (descriptive) study of technical and non-technical performance
48689972|NCT06166459|PROCEDURE|Drug-coated balloon combined with provisional drug-eluting stent implantation|(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
48689973|NCT04701853|OTHER|Specific abdominal muscle training|Specific abdominal muscle training
48004259|NCT04638465|DRUG|Cisplatin - Dose Level 1|6 Cycles of 40 mg/m2
48004260|NCT04638465|DRUG|Cisplatin - Dose Level 2|7 Cycles of 40 mg/m2
48004261|NCT04638465|RADIATION|Dose Level 1|60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
48004262|NCT04638465|RADIATION|Dose Level 2|70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
48004263|NCT04157946|DIAGNOSTIC_TEST|CT|"Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch)."
48004264|NCT05272982|DIAGNOSTIC_TEST|Thoracic fluid content by electrical cardiometry group|Thoracic fluid content will be measured using electrical cardiometry device (ICON ® Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). The ICON device will be connected to four electrocardiogram electrodes which will be placed over patients' skin after cleaning with alcohol at the neck below the left ear, just above the left clavicular midpoint, and two electrodes at left mid-axillary line one at the level of the xiphoid process, and the other electrode 5 cm below this point. The thoracic fluid content will be observed for 30 s and the average of the highest and lowest values will be recorded.
48368225|NCT03414372|BEHAVIORAL|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks. The in-person sessions were adapted to be delivered via Zoom or a similar HIPAA compliant platform due to the COVID-19 pandemic.
48368226|NCT03414372|BEHAVIORAL|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
48368227|NCT00122395|BEHAVIORAL|Screening via pen and paper|
48368228|NCT00122395|BEHAVIORAL|Screening via audiotape|
48689974|NCT04701853|OTHER|Usual care|Care according to each center.
48689975|NCT01532076|PROCEDURE|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
48689976|NCT01532076|PROCEDURE|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
48689977|NCT04183504|BEHAVIORAL|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
48368229|NCT03339440|BEHAVIORAL|Hearts & Parks|The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
48368230|NCT02287831|BIOLOGICAL|umbilical cord mesenchymal stem cells|
48368231|NCT01074086|DRUG|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
48368232|NCT05946564|DRUG|Pioglitazone (ACTOS®)|Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
48368233|NCT05946564|DRUG|Placebo of Pioglitazone|Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
48368234|NCT00466284|DRUG|Tarceva (erlotinib)|
48689978|NCT05962619|PROCEDURE|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
48368235|NCT01237665|DRUG|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
48004265|NCT05272982|DIAGNOSTIC_TEST|Ultrasound examination group|The 12-region technique for lung assessment will be performed using Philips ® (CX50 - Extreme edition) equipped with phased array transducer. B-line will be defined as laser like vertical hyperechoic artefact which extends between the pleural line and the bottom of the screen and moves with respiratory movements. Two types of B-lines will be evaluated.
48004266|NCT04792112|BEHAVIORAL|Decision support tool|Decision support tool for late preterm antenatal corticosteroids
48004267|NCT04415541|BEHAVIORAL|Psychodynamic Psychotherapy|Intensive psychotherapy that is psychodynamically oriented.
48368236|NCT05771246|DIAGNOSTIC_TEST|Radiographic evaluation|Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
48004268|NCT04415541|BEHAVIORAL|Usual Care|Conventional treatment offered in the community.
48161275|NCT01442623|OTHER|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
48161276|NCT02609035|BEHAVIORAL|Telephonic prompt|
48161277|NCT03373500|OTHER|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
48161278|NCT01898442|DRUG|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
48368237|NCT06205875|PROCEDURE|High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
48513696|NCT03299946|DRUG|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
48513697|NCT04455321|PROCEDURE|Suture materials effect on istmocel|Effect of suture materials with different absorption times on istmocel
48513698|NCT02687217|DRUG|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
48689979|NCT05962619|PROCEDURE|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
48004269|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
48004270|NCT03493828|PROCEDURE|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
48004271|NCT03493828|PROCEDURE|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
48513699|NCT04316793|OTHER|Dry needling|Intramuscular insertion of an OPTIMED 40mm x 0.3mm acupuncture needle in a trigger point of the infraspinatus muscle
48513700|NCT04316793|OTHER|Sham needling (SN)|Intradermal insertion of an OPTIMED 40mm x 0.3mm acupuncture needle over the infraspinatus region
48513701|NCT02497911|PROCEDURE|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
48689980|NCT04114708|DIAGNOSTIC_TEST|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
48689981|NCT04114708|DIAGNOSTIC_TEST|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
48689982|NCT05905224|DEVICE|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
48689983|NCT05905224|DEVICE|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
48689984|NCT02262026|DRUG|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
48689985|NCT02262026|DRUG|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
48689986|NCT02262026|DRUG|Placebo|Placebo
48689987|NCT05655533|DIAGNOSTIC_TEST|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
48689988|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
48689989|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
48689990|NCT00705445|OTHER|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
48368238|NCT06205875|PROCEDURE|Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
48368239|NCT06205875|DRUG|PCIA with morphine|A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
48161279|NCT01898442|DRUG|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
48161280|NCT01898442|DRUG|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
48368240|NCT00656136|DRUG|placebo|Patients receive placebo once daily
48689991|NCT02690688|DEVICE|determination of dynamic preload variables|
48689992|NCT03544424|OTHER|No intervention|No intervention
48689993|NCT03983720|OTHER|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
48161281|NCT05662215|DRUG|CK-3828136|CK-3828136
48161282|NCT05662215|DRUG|Placebo for CK-3828136|Placebo for CK-3828136
48161283|NCT00457171|DRUG|GI-270384|
48161284|NCT02599987|DEVICE|POWERbreathe® Classic Light|Inspiratory Muscle Training
48689994|NCT03983720|OTHER|Questionnaires|"* Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)"
48689995|NCT03983720|BIOLOGICAL|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
48161290|NCT03054792|DRUG|18F-FAZA (F18-Fluoroazomycin Arabinoside)|Intravenous administration of a hypoxia marker, 18F- Fluoroazomycin arabinoside (FAZA), before a PET-MR imaging in order to identify areas of lower oxygen content on samples of a tumour.
48161291|NCT03054792|DIAGNOSTIC_TEST|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
48161292|NCT03054792|DIAGNOSTIC_TEST|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
48513702|NCT02497911|PROCEDURE|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
48513703|NCT02497911|DRUG|Ropivicaine|
48004272|NCT02788734|OTHER|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
48004273|NCT01301222|DRUG|Inj. Octreotide|100 mcg subcutaneously for 5 days
48004274|NCT05315999|DRUG|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
48004275|NCT05315999|DRUG|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
48004276|NCT03674866|DRUG|Insulin degludec|Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
48004277|NCT02385175|OTHER|Different objective clinical tests of Eustachian tube function|
48161293|NCT03054792|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
48161294|NCT06512181|OTHER|Conservative/Expectant Management|At time of caesarean section, participants will not have a hysterectomy, but will be treated clinically to preserve their uterus.
48161295|NCT02149576|PROCEDURE|Low Dose Computed Tomography Imaging|
48161296|NCT02149576|PROCEDURE|Chest Radiograph Imaging|
48161297|NCT05191121|BEHAVIORAL|FTP Alone|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
48161298|NCT05191121|BEHAVIORAL|FTP+Con-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
48161299|NCT05191121|BEHAVIORAL|FTP+WPHF-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
48161300|NCT01424176|DRUG|Dexpramipexole (dose 1)|
48161301|NCT01424176|DRUG|Dexpramipexole (dose 2)|
48161302|NCT01345188|DRUG|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
48161303|NCT01345188|DRUG|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
48513704|NCT02497911|DRUG|Bupivicaine|
48513705|NCT03636178|PROCEDURE|Classic alar base suture technique|An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure
48513706|NCT03636178|PROCEDURE|Modified alar base suture technique|The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
48689996|NCT03983720|OTHER|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
48004278|NCT02385175|OTHER|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
48004279|NCT02398552|DRUG|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
48004280|NCT01442363|DRUG|BLI-1300 low dose|topical ointment
48004281|NCT01442363|DRUG|BLI-1300 high dose|topical ointment
48004282|NCT01442363|DRUG|placebo|topical ointment
48004283|NCT06149416|DEVICE|Experimental Masimo RD SET SpO2 Adhesive Sensors|Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)
48161304|NCT04380038|DRUG|Dupilumab Injectable Product|Nasal inoculation, single dose 300 TCID50 in 1ml.
48161305|NCT02815618|DEVICE|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
48161306|NCT00033462|DRUG|erlotinib hydrochloride|Given orally
48161307|NCT00033462|OTHER|laboratory biomarker analysis|Correlative studies
48161308|NCT02046057|PROCEDURE|PNB of SLN|Percutaneous biopsy of sentinel node
48161309|NCT04589689|BEHAVIORAL|Insul-In This Together|Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
48161310|NCT04238299|DIAGNOSTIC_TEST|Multiparametric renal MRI|Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping
48161311|NCT04073849|DRUG|EPOGEN® (epoetin alfa)|Active drug
48161312|NCT04073849|OTHER|Normal Saline|Placebo
48161313|NCT04927559|OTHER|Survey Administration|Complete survey
48689997|NCT03983720|DEVICE|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
48689998|NCT03983720|DEVICE|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
48004284|NCT04695132|BEHAVIORAL|Illness Management and Recovery treatment programme|The Illness Management and Recovery treatment programme is a psychosocial treatment aimed at attaining illness management skills and promoting a sense of personal recovery amongst patients with serious mental illness. The original treatment protocol has been translated to Swedish and adapted to a forensic mental health setting. The treatment consists of ten chapters containing information and practical exercises relating to topics relevant for mental health and mental health recovery. These topics include medication use, stress reduction, problem solving, recovery goals and navigating the forensic mental health system. Participants are assigned practical homework and tasks to be completed outside of treatment sessions. Group sessions are conducted to present and discuss treatment material. Individual sessions are used to rehearse treatment content, personalize the treatment and review progress in achieving tasks agreed upon in the group setting.
48689999|NCT03983720|DEVICE|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
48690000|NCT03983720|OTHER|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation"
48690001|NCT05532722|DRUG|ABC008|Given subcutaneous injection
48690002|NCT06567340|DEVICE|StratCare|The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
48690003|NCT05466136|BEHAVIORAL|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
48690004|NCT05466136|BEHAVIORAL|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
48690005|NCT00245388|DRUG|Muraglitazar|
48690006|NCT01352962|DRUG|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
48004285|NCT02693574|DRUG|Clarithromycin|
48004286|NCT02693574|DRUG|Levofloxacin|
48004287|NCT03897790|OTHER|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
48161314|NCT00249847|DRUG|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
48161315|NCT00249847|DRUG|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
48161316|NCT00911183|BIOLOGICAL|filgrastim|Given subcutaneously
48161317|NCT00911183|BIOLOGICAL|pegfilgrastim|Given subcutaneously
48161318|NCT00911183|BIOLOGICAL|rituximab|Given IV
48161319|NCT00911183|DRUG|cyclophosphamide|Given IV
48161320|NCT00911183|DRUG|liposome-encapsulated doxorubicin citrate|Given IV
48161321|NCT00911183|DRUG|prednisone|Given orally
48513707|NCT03965897|BEHAVIORAL|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
48690007|NCT01352962|DRUG|Carboplatin|AUC 5\*\* IVPB over 30 min x 1
48690008|NCT01352962|DRUG|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
48690009|NCT02248649|BEHAVIORAL|Structured physical activity|Walking instruction and encouragement
48690010|NCT02248649|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
48161322|NCT00911183|DRUG|vincristine sulfate|Given IV
48161323|NCT02488070|PROCEDURE|Computed Tomography|Part of PET/CT scan
48161324|NCT02488070|DRUG|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
48161325|NCT02488070|PROCEDURE|Magnetic Resonance Imaging|Part of PET/MRI scan
48161326|NCT02488070|PROCEDURE|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
48161327|NCT06362265|DRUG|LY3209590|Administered SC.
48161328|NCT00310024|DRUG|bortezomib|Given IV
48690011|NCT04497103|OTHER|control|The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
48690012|NCT04497103|OTHER|Xbox kinect|The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
48690013|NCT04497103|OTHER|task oriented training|The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
48690014|NCT03168165|OTHER|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
48004288|NCT06269172|BEHAVIORAL|intereviews|"An individual's experience of their breathlessness is influenced by multiple factors including their medical condition, psychology, sociological and situational circumstances which will include ethnicity. There is currently a lack of evidence exploring the impact of ethnicity in the experience and presentation of breathlessness.~The non-medical management of breathlessness in respiratory diseases includes pulmonary rehabilitation (PR). PR is a highly evidenced exercise-based intervention to help manage breathlessness, improving health-related quality of life and improving survival. Recent audits in England and Wales showed 89% of patients attending PR were recorded as having a White British ethnicity which is in contrast to national ethnicity demographics. This may be because the cultural acceptability of PR components are not fully considered."
48004289|NCT03026465|DEVICE|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
48004290|NCT03026465|DEVICE|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
48161329|NCT00310024|DRUG|vorinostat|Given orally
48161330|NCT00310024|OTHER|laboratory biomarker analysis|Correlative studies
48161331|NCT00310024|OTHER|pharmacological study|Correlative studies
48161332|NCT04083690|DEVICE|Reprogramming of CRT Device Settings to Optimal Electrical Synchrony|Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
48161333|NCT03334747|DRUG|KAE609|Exploration of different doses of KAE609 to establish safety profile.
48161334|NCT03334747|DRUG|Coartem|Control Arm
48161335|NCT03964545|BEHAVIORAL|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
48368241|NCT00656136|DRUG|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
48513708|NCT03965897|OTHER|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
48513709|NCT01832571|DRUG|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
48161336|NCT04160000|DEVICE|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
48161337|NCT04160000|DRUG|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
48161338|NCT04160000|DEVICE|Insertion of CardioMems Hemodynamic monitor|Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.
48513710|NCT00959218|DRUG|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
48513711|NCT00959218|DRUG|Placebo|oral solution
48161339|NCT04160000|DRUG|Empiric heart failure drug therapy|Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
48368242|NCT01745159|DRUG|tacrolimus|
48368243|NCT01728870|OTHER|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
48368244|NCT01728870|OTHER|Exclusive Enteral Nutrition (Modulen)|
48368245|NCT02735876|DRUG|acalabrutinib|
48368246|NCT02735876|DRUG|ibrutinib|
48368247|NCT02735876|DRUG|rituximab|
48368248|NCT01122719|DEVICE|Drug Eluting Stent|
48513712|NCT04087915|DRUG|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
48513713|NCT06257381|OTHER|VO2max|"Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h)."
48513714|NCT01371539|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
48513715|NCT01371539|DEVICE|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
48513716|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days
48513717|NCT04775615|DRUG|DDO-3055 tablets；Placebo|Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days
48513718|NCT04775615|DRUG|DDO-3055 tablets；Placebo|High dose：DDO-3055 tablets for 7 days or Placebo for 7 days
48513719|NCT01770717|OTHER|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
48690015|NCT00118248|DRUG|tanespimycin|Given IV
48690016|NCT04904419|DIAGNOSTIC_TEST|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
48690017|NCT00141648|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
48690018|NCT00141648|RADIATION|Radiotherapy|Total 45 Gy in 25 fractions
48161340|NCT05150002|DEVICE|Spinal cord stimulation|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
48161341|NCT05065918|BEHAVIORAL|sexual violence and alcohol use harm reduction text message content|The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.
48161342|NCT05065918|BEHAVIORAL|alcohol use reduction content|"The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback)."
48522648|NCT04540991|DIAGNOSTIC_TEST|Collecting gingival epithelial cellsusing the swab technique|Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
48690019|NCT05953597|BEHAVIORAL|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
48690020|NCT03951766|BEHAVIORAL|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
48004291|NCT03577431|BIOLOGICAL|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 125 x 10\^6 total cells. If a minimum arTreg-CSB dose of 1 to \< 2.5 x 10\^6 cells, the product will be infused. If the dose obtained after product manufacture is \< 1 x 10\^6 cells, the product will not be infused. When the dose obtained after product manufacture is \> 125 x 10\^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 125 x 10\^6 cells, and ≥ 2.5 to 125 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
48161343|NCT01605435|DRUG|Ghrelin Group 1|The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
48161344|NCT01605435|DRUG|Ghrelin Group 2|The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
48522649|NCT00927589|DRUG|carboplatin|Intravenous repeating dose
48522650|NCT00927589|DRUG|docetaxel|Intravenous repeating dose
48522651|NCT00927589|DRUG|trastuzumab|Intravenous repeating dose
48522652|NCT03067025|DEVICE|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
48522653|NCT01366924|DIETARY_SUPPLEMENT|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
48522654|NCT01366924|OTHER|Endurance exercise|60 minute endurance exercise session
48690021|NCT02142335|DRUG|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
48690022|NCT06411327|DEVICE|Augmented reality|Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
48690023|NCT06411327|DEVICE|LCD Screen|LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
48690024|NCT04511143|OTHER|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
48690025|NCT01586598|BEHAVIORAL|sensory retraining protocol|"1. within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~2. one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~3. three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
48004292|NCT03577431|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure 72 to 120 hours prior to Treg product (arTreg-CSB) IV infusion."
48161345|NCT01511744|BIOLOGICAL|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
48161346|NCT01613183|DRUG|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
48368249|NCT02219750|DRUG|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
48368250|NCT04654819|DEVICE|Dental anesthesia simulator usage|Training on dental anesthesia simulator
48368251|NCT05805332|OTHER|pulmonary rehabilitation|The participants would undergo pulmonary rehabilitation.
48368252|NCT03471143|DRUG|adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
48368253|NCT02240901|DEVICE|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
48368254|NCT02240901|DEVICE|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
48368255|NCT04576585|BEHAVIORAL|Lexicon training|Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
48161347|NCT01613183|OTHER|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
48690026|NCT01244230|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
48690027|NCT06009991|DRUG|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
48690028|NCT06009991|DRUG|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
48004293|NCT03577431|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 to 72 hours prior to Treg product (arTreg-CSB) infusion.
48004294|NCT03577431|DRUG|mesna|Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide. Administration of mesna is per institutional practice with cyclophosphamide.
48161348|NCT04208815|OTHER|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
48161349|NCT04208815|OTHER|Milk Fat|Effects of the addition of 20 g milk fat.
48004295|NCT03577431|DRUG|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 48 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
48161350|NCT04877132|DRUG|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
48368256|NCT05411731|OTHER|Conventional physical therapy treatment|"The control group (group A) will receive the exercise program which focused on improving the arm function as well as shoulder abduction and external rotation for 10 week.~stretching Aeroplan positioning"
48368257|NCT05411731|OTHER|Constraint induced movement therapy|The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
48690029|NCT05474287|PROCEDURE|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
48690030|NCT05474287|PROCEDURE|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
48690031|NCT02371460|DIETARY_SUPPLEMENT|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
48690032|NCT02371460|COMBINATION_PRODUCT|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
48690033|NCT03931850|PROCEDURE|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
48690034|NCT04296188|PROCEDURE|serratus anterior plane block|ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
48161351|NCT03571347|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
48161352|NCT03571347|OTHER|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
48161353|NCT03468387|PROCEDURE|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
48161354|NCT03468387|PROCEDURE|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
48368258|NCT00241371|DRUG|Clofarabine|
48368259|NCT05450380|DEVICE|LIFT001|"The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face.~The dermal filler of hyaluronic acid LIFT001 is applied to the facial area to provide firmness and counteract sagging for the correction of deep wrinkles and imperfections of face."
48690035|NCT04296188|PROCEDURE|erector spina plane block|ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
48004296|NCT00446433|DRUG|CC-5013|
48161355|NCT01379521|DRUG|everolimus|
48161356|NCT01379521|DRUG|everolimus placebo|
48161357|NCT00951574|DRUG|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
48161358|NCT00951574|DRUG|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
48161359|NCT00551187|BIOLOGICAL|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
48161360|NCT00551187|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
48161361|NCT00551187|BIOLOGICAL|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
48161362|NCT04728217|DRUG|Efmoroctocog Alfa Injection [Eloctate]|Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
48161363|NCT01189370|DRUG|sorafenib|"Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week."
48161364|NCT01984853|OTHER|OBSERVATIONAL REGISTRY|
48161365|NCT03604289|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
48368260|NCT05457712|DIETARY_SUPPLEMENT|protocol|The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.
48368261|NCT05457712|OTHER|Control|Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
48368262|NCT03462628|PROCEDURE|CPVI plus low-voltage substrate modification|CPVI plus low-voltage substrate modification in the left atrium during SR
48368263|NCT03462628|PROCEDURE|CPVI alone|circumferential pulmonary vein isolation
48368264|NCT01334138|OTHER|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
48368265|NCT02380599|OTHER|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
48690036|NCT05288361|DIAGNOSTIC_TEST|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
48690037|NCT00332085|DRUG|Chromium Picolinate|
48690038|NCT04701606|DRUG|Artecom® (pyronaridine-artesunate)|"\* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
48690039|NCT04701606|DRUG|Placebo|"\* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)"
48690040|NCT01668446|DRUG|Sildenafil|sildenafil tablets(50 mg) daily
48004297|NCT04657497|DRUG|FOY-305|Specified Dosage and Duration of Treatment
48004298|NCT04657497|DRUG|Placebo|Specified Dosage and Duration of Treatment
48004299|NCT04985851|DRUG|durvalumab + anlotinib|Approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease.
48004300|NCT04985851|DRUG|Durvalumab|durvalumab
48690041|NCT01668446|DRUG|estradiol valerat|
48004301|NCT06237166|BEHAVIORAL|mylovia|Participants will receive access to the digital health intervention mylovia in addition to TAU.
48690042|NCT03363191|DRUG|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
48368266|NCT02380599|OTHER|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
48368267|NCT02380599|OTHER|Sham Ultrasound|Sham ultrasound to T3-5 region
48368268|NCT04862273|DIAGNOSTIC_TEST|Native T1 CMR|Observed method
48690043|NCT03363191|DRUG|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
48004303|NCT04974658|PROCEDURE|Inter-semispinal plane block|Ultrasound Inter-semispinal plane block in block group
48004304|NCT06178172|OTHER|Remote home monitoring|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. At home, patients receive guidance for the management of pain, nutrition and pancreatitis-related complaints by a daily phone call from a nurse from the Virtual Monitoring Centre (VMC). The pancreatitis-related complaints, intake of fluids and food, pain and the use of analgesics are assessed using short questionnaires in a smartphone app. Core temperature is monitored using an ear thermometer and a wearable sensor measures heart rate, respiratory rate, posture and movement every 5 minutes. Remote home monitoring will continue for at least 4 days.
48368269|NCT04862273|DIAGNOSTIC_TEST|Web-based ATTR probability estimator (Pfizer, New York)|Observed method
48368270|NCT04862273|DIAGNOSTIC_TEST|99mTc-DPD scintigraphy|Reference method
48368271|NCT04862273|DIAGNOSTIC_TEST|Laboratory screening for multiple myeloma / AL amyloidosis|Reference method
48368272|NCT04862273|PROCEDURE|Cardiac biopsy|If non-invasive tests for CA (99mTc-DPD scintigraphy, biochemistry) are inconclusive
48690044|NCT03363191|DRUG|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
48004305|NCT02944318|BEHAVIORAL|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
48368273|NCT05633394|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
48690045|NCT02330354|BEHAVIORAL|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
48690046|NCT02504398|OTHER|Fast injection speed by immunizer|
48690047|NCT02504398|OTHER|Slow injection speed by immunizer|
48690048|NCT05947851|DRUG|Nemtabrutinib|5 and 20 mg tablets
48690049|NCT05947851|DRUG|Venetoclax|10, 50, and 100 mg tablets
48690050|NCT05947851|BIOLOGICAL|Rituximab|100 mg/10 mL, 500 mg/50 mL (10 mg/mL) IV Infusion
48690051|NCT02833584|DRUG|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
48690052|NCT02833584|DRUG|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
48690053|NCT03637257|DEVICE|modified Guedel airway|Monitoring of breathing
48690054|NCT00289289|DEVICE|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
48690055|NCT00252031|BEHAVIORAL|Dialectical Behavioral Therapy|
48690056|NCT02463708|BEHAVIORAL|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
48690057|NCT05563311|OTHER|Exercise on High-intensity interval training|3 times a week, for 8 weeks
48690058|NCT00310336|DRUG|S-adenosyl-L-methionine|
48690059|NCT00310336|DRUG|betaine|
48690060|NCT00310336|DRUG|pegylated interferon alpha2b|
48690061|NCT00310336|DRUG|ribavirin|
48690062|NCT00164840|DRUG|Esomeprazole|
48690063|NCT05494463|DEVICE|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
48690064|NCT00526656|DRUG|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
48690065|NCT05331300|DRUG|LASN01|Escalating single and multiple doses of LASN01
48690066|NCT05331300|DRUG|LASN01|LASN01 will be administered intravenously
48690067|NCT05331300|DRUG|Placebo|Escalating doses of matching placebo
48690068|NCT05331300|DRUG|Placebo|Placebo will be administered intravenously
48690069|NCT06129422|DRUG|NMK89|Route of administration: intravenous infusion
48690070|NCT00069875|DRUG|Gemcitabine|
48690071|NCT00069875|DRUG|LY293111|
48690072|NCT00069875|DRUG|cisplatin|
48690073|NCT05468697|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg.
48690074|NCT05468697|DRUG|Palbociclib|75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
48690075|NCT01166789|DRUG|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
48690076|NCT01166789|DRUG|Placebo|2 capsules daily, taken in morning and evening
48690077|NCT03216343|DRUG|Chiauranib|CS2164
48690078|NCT03714984|OTHER|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
48690079|NCT03714984|OTHER|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
48690080|NCT02482298|DRUG|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
48004306|NCT02579746|BEHAVIORAL|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
48004307|NCT02579746|BEHAVIORAL|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
48004308|NCT02588924|OTHER|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
48690081|NCT02482298|DRUG|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
48690082|NCT01140867|DRUG|zonisamide|zonisamide 100 mg tablet
48690083|NCT00906178|BEHAVIORAL|CyberSenga|Internet-based HIV prevention program
48690084|NCT04691245|DEVICE|3D US|3D US guided access to femoral artery
48690085|NCT04691245|DEVICE|2D US|2D US guided access to femoral artery
48690086|NCT06196658|DRUG|anti-EX02 CAR T cells|"Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg"
48690087|NCT01390298|OTHER|Observational|Observational study only
48690088|NCT04535102|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
48690089|NCT06658912|OTHER|TOPS Classes|Attend Dietician-Led Sessions
48690090|NCT05922943|BEHAVIORAL|Harmony & Health program|Harmony \& Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
48690091|NCT00282633|DEVICE|Dermabond|
48690092|NCT04193111|DIAGNOSTIC_TEST|TMD pain screener|The danish TMD pain screener is given to all participants
48690093|NCT01026090|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
48690094|NCT01026090|DRUG|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
48004309|NCT02588924|OTHER|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
48004310|NCT01032135|BEHAVIORAL|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
48690095|NCT03136224|DEVICE|Thermocautery|
48690096|NCT03136224|DEVICE|Plastic Clamping|
48690097|NCT03136224|DEVICE|Surgical Circumcision|
48690098|NCT01672281|OTHER|vibrox- vs. resistance training|Comparison between two exercise interventions
48690099|NCT05056558|DRUG|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
48690100|NCT05056558|DRUG|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
48690101|NCT02111915|BEHAVIORAL|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
48004311|NCT01032135|BEHAVIORAL|Telephone counseling|one telephone counseling session per week for 10 weeks.
48690102|NCT02111915|OTHER|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
48690103|NCT03148379|DEVICE|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
48690104|NCT03148379|DEVICE|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
48004312|NCT01032135|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
48004313|NCT01032135|DRUG|medication management|Prescription for naltrexone
48004314|NCT01032135|BEHAVIORAL|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
48161366|NCT03604289|DRUG|Saline|Saline will be used as the placebo comparator
48161367|NCT02186587|DEVICE|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
48161368|NCT06051097|DIAGNOSTIC_TEST|sleep study|over-night polysomnography
48161369|NCT01062854|OTHER|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
48161370|NCT00386997|DRUG|liposomal amphotericin B (AmBisome®)|
48161371|NCT00207298|PROCEDURE|Positron Emission Tomography|Each patient will receive an 18F-FDG PET/CT scan
48690105|NCT05026840|PROCEDURE|GDM screening criteria|difference in risk factors and clinical outcomes between groups
48161372|NCT02200029|DRUG|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
48690106|NCT01220401|BEHAVIORAL|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
48690107|NCT04545424|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
48690108|NCT04545424|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
48690109|NCT04545424|DEVICE|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
48690110|NCT03577340|OTHER|implant of cardiac device as per guidelines|Observation of performance to validate matrix
48690111|NCT02565758|DRUG|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
48690112|NCT00116038|DEVICE|Femoral implant (Versys Fiber Metal Taper®)|
48690113|NCT03098433|DRUG|Liothyronine|Single dose
48690114|NCT03098433|DRUG|Levothyroxine|Active comparator
48690115|NCT03098433|DRUG|Placebos|Placebo
48690116|NCT06421064|PROCEDURE|Perforation repair|All patients were operated with slight difference but all had perforation repaired.
48690117|NCT06147128|PROCEDURE|Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model|Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
48690118|NCT05034042|DRUG|Fezolinetant|oral
48690119|NCT05034042|DRUG|Placebo|oral
48690120|NCT01761799|BEHAVIORAL|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
48690121|NCT03254706|OTHER|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
48690122|NCT03254706|OTHER|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
48690123|NCT03254706|OTHER|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
48690124|NCT03254706|OTHER|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
48690125|NCT00351793|DEVICE|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
48690126|NCT04010656|PROCEDURE|PVR-based self-catheterization|Home self-catheterization based on standard of care
48690127|NCT06552832|OTHER|CAVEAT|Brief manualized parent-child psychotherapy
48690128|NCT05815095|OTHER|PREAUT grid|Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
48690129|NCT02122666|PROCEDURE|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
48690130|NCT06429046|OTHER|LIDOCAINE GEL|To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.
48690131|NCT06429046|OTHER|COLD LIDOCAINE GEL|In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
48690132|NCT04119804|DIAGNOSTIC_TEST|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
48690133|NCT01804933|DRUG|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
48690134|NCT02543073|BIOLOGICAL|MSCs|MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.
48690135|NCT02543073|DRUG|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
48690136|NCT02543073|DRUG|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
48004315|NCT01392950|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
48004316|NCT01392950|DEVICE|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
48004317|NCT01410734|DRUG|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
48690137|NCT04848519|DRUG|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
48690138|NCT04848519|DRUG|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
48690139|NCT04848519|DRUG|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
48690140|NCT04848519|DRUG|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
48690141|NCT02810769|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
48690142|NCT02810769|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
48690143|NCT02810769|DIETARY_SUPPLEMENT|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
48690144|NCT04992013|DRUG|Niraparib|Capsule taken by mouth
48004318|NCT03296306|DRUG|Treatment duration of cisplatin based chemotherapy|"* GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~* GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~* MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~* HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
48004319|NCT01665274|DRUG|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
48004320|NCT01665274|DRUG|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
48004321|NCT01665274|PROCEDURE|D2 resection|D2 resection
48690145|NCT05245110|BEHAVIORAL|tele-exercise training|a 12-week tele-exercise training program
48690146|NCT03970876|BIOLOGICAL|ATGC-100|Clostridium Botulinum Type A
48513720|NCT01708018|PROCEDURE|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
48513721|NCT03513991|OTHER|Infant formula|
48004324|NCT02983006|BIOLOGICAL|DS-8273a|"* Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~* Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
48161373|NCT02200029|DRUG|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
48161374|NCT00168805|DRUG|enoxaparin|40 mg once daily
48161375|NCT00168805|DRUG|dabigatran etexilate|150 mg once daily
48161376|NCT00168805|DRUG|dabigatran etexilate|220 mg once daily
48161377|NCT02784535|DRUG|Atomoxetine|norepinephrine transporter inhibitor
48161378|NCT02784535|DRUG|Placebo|placebo
48513722|NCT05258903|PROCEDURE|Ulnar artery cannulation|Ulnar artery will be cannulated under USG guidance
48513723|NCT05258903|PROCEDURE|Radial artery cannulation|Radial artery will be cannulated under USG guidance
48513724|NCT05864989|PROCEDURE|Non-incised papila surgical approach only|Reconstructive periodontal surgery
48513725|NCT05864989|PROCEDURE|Non-incised papila surgical approach with connective tissue grafting|Reconstructive periodontal surgery
48513726|NCT06128486|DEVICE|Soft Contact Lens|Vision Correction
48513727|NCT03390803|OTHER|effect of hemifacial spasm on intraocular pressure|To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
48513728|NCT03536611|DRUG|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
48690147|NCT03970876|BIOLOGICAL|Botox®|Clostridium Botulinum Type A
48690148|NCT02152475|DRUG|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
48690149|NCT02152475|DEVICE|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
48690150|NCT04409561|DEVICE|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
48690151|NCT02638467|DRUG|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
48690152|NCT02638467|PROCEDURE|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant \> 3 x 106 CD34+ cells/kg BW recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow"
48690153|NCT02638467|DRUG|Bone Marrow cells|
48690154|NCT02221635|PROCEDURE|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
48004325|NCT02983006|BIOLOGICAL|Nivolumab|5 mg/kg IV Q 3 weeks
48513729|NCT03536611|DRUG|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
48004326|NCT01944059|DRUG|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
48690155|NCT02221635|DRUG|Risperidone|Risperidone (2-4 mg) was took orally.
48004327|NCT01944059|OTHER|Placebo (l-alanine)|Theramine like placebo comparator
48004328|NCT04405609|DEVICE|ArmAssist|"The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~1. First phase: 5 weeks.~2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support."
48690156|NCT05918133|DRUG|PM8002|IV infusion
48004329|NCT05314686|OTHER|Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.|"1. Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~2. Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system."
48004330|NCT05314686|OTHER|Telerehabilitation|"An eight-week program including:~* Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~* Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~* Daily walking with automated coaching.~* Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~* A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms."
48004331|NCT04347304|DIETARY_SUPPLEMENT|Dark chocolate (20 grams) per day providing 508 mg of polyphenols|subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
48004332|NCT04347304|DIETARY_SUPPLEMENT|white chocolate (20 grams) with no polyphenols|subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks
48690157|NCT05918133|DRUG|nab-paclitaxel|IV infusion
48690158|NCT05667883|DRUG|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
48690159|NCT03865433|OTHER|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
48161379|NCT05545319|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours
48161380|NCT05545319|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
48161381|NCT05545319|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
48161382|NCT01233492|DRUG|boron phenylalanine|
48161383|NCT01233492|DRUG|mannitol|
48513730|NCT06277765|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
48161384|NCT01233492|OTHER|biologic sample preservation procedure|
48161385|NCT01233492|RADIATION|radiation therapy treatment planning/simulation|
48690160|NCT03865433|OTHER|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
48161386|NCT00356213|PROCEDURE|sleeve gastrectomy|laparoscopic sleeve gastrectomy
48161387|NCT00356213|PROCEDURE|Roux-Y-gastric bypass|laparoscopic gastric bypass
48513731|NCT06277765|OTHER|placebo|Placebo
48513732|NCT04243031|DEVICE|QFT Access|Measure of Interferon Gamma
48513733|NCT03888963|PROCEDURE|PRF|patients will receive pulsed radiofrequency, 4 cycles (each cycle, 2 minutes) on the thoracic paravertebral nerves number 2,3, and 4 under fluroscopic guidance
48690161|NCT01712581|OTHER|Magnetic Resonance Imaging|
48161388|NCT04044352|BIOLOGICAL|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
48161389|NCT06035237|OTHER|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
48004333|NCT02047799|DIETARY_SUPPLEMENT|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
48004334|NCT02047799|DIETARY_SUPPLEMENT|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
48161390|NCT05936905|OTHER|Acupuncture|Acupuncture 1 time per month
48161391|NCT05936905|OTHER|Chiropractic|Chiropractic 1 time per month
48161392|NCT06551116|DIAGNOSTIC_TEST|CE-10-IVD|Leftover tumor tissue from a routine biopsy will be sent for analysis.
48004335|NCT01232296|DRUG|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
48004336|NCT01232296|DRUG|sorafenib|400 mg p.o. b.i.d.
48004337|NCT04156815|RADIATION|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
48161393|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
48161394|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
48161395|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
48161396|NCT03168009|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
48161397|NCT04290416|DIAGNOSTIC_TEST|Microwire electrodes|
48161398|NCT02243605|DRUG|Cabozantinib S-malate|Given PO
48161399|NCT02243605|OTHER|Laboratory Biomarker Analysis|Correlative studies
48161400|NCT02186015|DRUG|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
48004338|NCT04156815|DRUG|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
48004339|NCT04156815|OTHER|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
48004340|NCT01159964|BIOLOGICAL|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
48004341|NCT01281748|DRUG|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
48004342|NCT01281748|OTHER|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
48004343|NCT00715793|DRUG|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
48004344|NCT00715793|DRUG|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
48004345|NCT00715793|PROCEDURE|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
48161401|NCT05858047|DRUG|Placebo|Administered orally, once daily (QD)
48161402|NCT05858047|DRUG|SYHX1901|Administered orally, once daily (QD)
48161403|NCT05732922|DEVICE|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
48004346|NCT03950128|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
48004347|NCT03950128|BEHAVIORAL|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
48004348|NCT03571087|DRUG|HL140 5/10|"1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
48004349|NCT03571087|DRUG|HL140 10/10|"1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
48004350|NCT03571087|DRUG|HL140 20/10|"1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
48004351|NCT03571087|DRUG|Rosuvastatin 5mg → HL140 5/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
48004352|NCT03571087|DRUG|Rosuvastatin 10mg → HL140 10/10|"1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
48004353|NCT03571087|DRUG|Rosuvastatin 20mg → HL140 20/10|"1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
48004354|NCT03411473|BIOLOGICAL|AGEN1884 in combination with pembrolizumab|AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
48004355|NCT05932446|DRUG|LY3819469|Administered SC.
48004356|NCT01278459|DRUG|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
48004357|NCT00898703|OTHER|flow cytometry|
48004358|NCT00898703|OTHER|immunoenzyme technique|
48004359|NCT00898703|OTHER|laboratory biomarker analysis|
48004360|NCT03395314|DRUG|Ketamine|1 single dose of IV ketamine
48004361|NCT03395314|DRUG|Midazolam|1 single dose of IV midazolam
48161404|NCT03738397|BIOLOGICAL|Upadacitinib|Extended release tablet
48161405|NCT03738397|BIOLOGICAL|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
48161406|NCT03738397|DRUG|Placebo to dupilumab|Placebo administered as a subcutaneous injection
48161407|NCT03738397|DRUG|Placebo to upadacitinib|Tablet
48004362|NCT01462669|DRUG|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
48004363|NCT01462669|DRUG|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
48004364|NCT01462669|DRUG|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
48004365|NCT01462669|DRUG|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
48161408|NCT02727647|DRUG|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
48161409|NCT02727647|DRUG|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
48161410|NCT02338206|DRUG|Growth hormone|
48161411|NCT00404547|DRUG|Ciclesonide|Asthma Care with Alvesco
48161412|NCT00404547|DRUG|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
48161413|NCT06575153|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
48161414|NCT04476849|DRUG|fezolinetant|Oral
48161415|NCT02801916|OTHER|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
48161416|NCT02801916|OTHER|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
48161417|NCT02801916|OTHER|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
48161418|NCT02801916|OTHER|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
48161419|NCT04494425|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
48161420|NCT04494425|DRUG|Capecitabine|Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
48690162|NCT00632827|DRUG|Gemcitabine|Chemotherapy medication used to treat a number of types of cancer
48690163|NCT00632827|DRUG|Navelbine|Navelbine is an chemotherapy medication used to treat a number of types of cancer
48690164|NCT00632827|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
48004366|NCT04576533|BEHAVIORAL|walk out from operating room|After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
48690165|NCT00632827|DRUG|Granulocyte-colony stimulating factor (G-CSF)|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
48690166|NCT00632827|DRUG|Pegfilgrastim|Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF
48690167|NCT00632827|DRUG|Cyclophosphamide|Cancer medication that interferes with the growth and spread of cancer cells in the body
48690168|NCT00632827|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer
48690169|NCT00632827|DRUG|Leucovorin|Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
48690170|NCT00632827|DRUG|Methotrexate|Methotrexate is a chemotherapy medication used to treat cancer
48690171|NCT00632827|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
48690172|NCT00632827|DRUG|Cytarabine|Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma
48690173|NCT00632827|DRUG|Etoposide|Etoposide is a is a chemotherapy medication used to treat cancer
48690174|NCT00632827|DRUG|Carmustine|Carmustine is a chemotherapy medication used to treat cancer
48004367|NCT03726177|DRUG|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
48004368|NCT03726177|DRUG|aspirin 81 mg|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
48004369|NCT03726177|DRUG|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
48161421|NCT04494425|DRUG|Paclitaxel|Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
48690175|NCT00632827|DRUG|Denileukin diftitox|Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
48690176|NCT02435667|OTHER|Resistance Exercise Training|"1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
48690177|NCT02435667|RADIATION|DEXA bone scan|A DEXA scan that provides bone density measures.
48690178|NCT02435667|OTHER|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
48690179|NCT02435667|OTHER|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
48690180|NCT02435667|OTHER|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
48690181|NCT02435667|OTHER|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
48690182|NCT04626687|DEVICE|test DCB|use paclitaxel coated coronary balloon catheters to treat SVD
48690183|NCT04626687|DEVICE|RESTORE DCB|use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
48004370|NCT04449367|PROCEDURE|ultrasound guided erector spinae plane block|bilatral block given to patients under general anaesthesia for thoracic spine sugery to contorl post operative pain
48004371|NCT00308711|DRUG|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
48004372|NCT00308711|DRUG|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
48161422|NCT04494425|DRUG|Nab-Paclitaxel|Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
48161423|NCT05389319|BIOLOGICAL|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
48161424|NCT06464614|DRUG|Adebrelimab|Adebrelimab 1200mg，d1，q3w, until disease progression or unacceptable toxicity
48161425|NCT06464614|DRUG|Apatinib|Apatinib 250mg，d1-21，q3w, until disease progression or unacceptable toxicity
48690184|NCT04886102|OTHER|An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital|Research protocol involving the human person (Category 3 - Non-interventional research_ not related to a health product) Serology, molecular biology, phylogenetic and phylodynamic analyzes of hepatitis B and D
48004373|NCT00308711|DRUG|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
48004374|NCT01254799|DRUG|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
48004375|NCT01254799|DRUG|Placebo|Placebo capsules twice daily for 5 days
48690185|NCT02069821|DRUG|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
48690186|NCT00723151|BEHAVIORAL|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
48690187|NCT00342628|BIOLOGICAL|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
48690188|NCT00342628|BIOLOGICAL|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
48004376|NCT02296814|DRUG|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
48004377|NCT02296814|DRUG|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
48004378|NCT01686646|DRUG|paracetamol + caffeine|paracetamol with caffeine
48004379|NCT01686646|DRUG|paracetamol|paracetamol
48004380|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
48004381|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
48368274|NCT04369560|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
48690189|NCT00342628|BIOLOGICAL|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
48690190|NCT02534012|DRUG|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
48004382|NCT01027169|DRUG|safinamide|single dose of 50mg safinamide on Day 1
48004383|NCT04777539|OTHER|At-home natalizumab treated MS patient|"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"
48004384|NCT00960518|DRUG|adefovir|adefovir at 10 mg daily for 48 weeks
48004385|NCT00960518|PROCEDURE|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
48004386|NCT04385602|DRUG|Intratracheal dexmedetomidine|Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
48004387|NCT04385602|DRUG|Saline Solution|Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
48004388|NCT01388829|DRUG|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
48690191|NCT02534012|DRUG|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
48004389|NCT01388829|DRUG|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
48004390|NCT01103934|DRUG|Vitamin D3|4000 IU once daily
48004391|NCT01103934|DRUG|Placebo|Placebo taken once daily
48004392|NCT01103934|DRUG|Fluticasone Propionate|200 mcg daily, intranasal
48004393|NCT01505192|DEVICE|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
48004394|NCT00661700|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
48004395|NCT00661700|DRUG|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
48004396|NCT01346267|PROCEDURE|Real Acupressure Band|Acupressure wristband
48004397|NCT01346267|PROCEDURE|Placebo Acupressure Band|Sham wristband
48004398|NCT04759625|OTHER|Novel biscuit enriched with mushroom powder containing 3g of β-glucans|Daily consumption of a novel biscuit enriched with mushroom powder containing 3g of β-glucans
48004399|NCT04759625|OTHER|Placebo biscuit|Daily consumption of placebo biscuit
48004400|NCT06442735|OTHER|intrapartum ultrasound|In IPUS group, the patient's labor was observed by intrapartum ultrasound.
48004401|NCT06442735|OTHER|vaginal examination|In VE group, the patient's labor was observed by vaginal examination.
48004402|NCT00499135|OTHER|Computed Tomography|Correlative studies
48004403|NCT00499135|OTHER|Fluorothymidine F-18|Correlative studies
48004404|NCT00499135|OTHER|Laboratory Biomarker Analysis|Correlative studies
48004405|NCT00499135|OTHER|Pharmacological Study|Correlative studies
48004406|NCT00499135|OTHER|Positron Emission Tomography|Correlative studies
48004407|NCT00499135|DRUG|Sunitinib Malate|Given PO
48004408|NCT03814954|DRUG|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
48004409|NCT03814954|DRUG|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
48004410|NCT03217227|OTHER|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
48161426|NCT06464614|DRUG|Investigator chosen chemotherapy (ICC)|"Nab-paclitaxel: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles;Intravenous infusion of 100 mg, D1, qw is used at the same time as radiotherapy.~Ilinotecan: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles; Capecitabine, 625 mg/m2 orally, d1-14, q3w; continued until disease progression, intolerable toxicity, or withdrawal due to other reasons; when synchronized with radiotherapy, 625mg/m2, bid, oral, d1-5, qw."
48690192|NCT02534012|PROCEDURE|Major abdominal surgery|
48004411|NCT03217227|PROCEDURE|Cardiac Catheterization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina"
48004412|NCT03217227|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
48004413|NCT03217227|DIAGNOSTIC_TEST|I123 MIBG Scintigraphy (Optional)|"The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test."
48004414|NCT03608488|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
48004415|NCT03608488|OTHER|Exercise|Core stability, balance exercises
48004416|NCT03759067|DRUG|clopidogrel 75mg|clopidogrel once daily 75mg
48004417|NCT03759067|DRUG|Clopidogrel 300 mg|clopidogrel 300mg reloading
48004418|NCT03759067|DRUG|clopidogrel 600mg|clopidogrel 600mg loading
48004419|NCT01479803|PROCEDURE|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
48161427|NCT06464614|RADIATION|Radiotherapy|Radiotherapy mode: IMRT for the primary lesion and SBRT for the metastasis; If the patient has symptoms of dysphagia, the radiation dose is 1.8 Gy×28 F or 2 Gy×25 F, d1-5 5 times a week; If oligometastatic lesions occur in the body: the radiation dose is 8 Gy×5F, d1-5; If oligometastatic lesions occur in the brain, the radiation dose is 7 Gy×5F, d1-5.
48513734|NCT03888963|PROCEDURE|SHAM|patients will be subjected to the same procedure like PRF group without giving PRF
48690193|NCT02547038|DRUG|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
48690194|NCT02547038|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
48690195|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture|Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.
48690196|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride|Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
48690197|NCT06537765|DRUG|Medical treatment|All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
48004420|NCT03974230|OTHER|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
48004421|NCT03974230|BIOLOGICAL|blood sample|Blood sample will be performed (genetic analyses).
48004422|NCT03974230|OTHER|slit lamp examination|Slit lamp examination will be performed.
48004423|NCT01398566|BEHAVIORAL|SuperBetter play|average 10 min of game play per day for 6 week period
48004424|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with polyphenol supplement (PPS)|Test meal with polyphenol supplement
48004425|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with placebo|Test meal with placebo (maltodextrin) supplement
48004426|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with PPS|Test drink with polyphenol supplement
48004427|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with placebo|Test drink with placebo (maltodextrin) supplement
48004428|NCT06329869|DRUG|Sacituzumab govitecan|Sacituzumab govitecan, 10 mg/kg intravenous infusion (the first infusion is to be administered over 3 hours; subsequent infusions may be administered over 1 to 2 hours if previous infusions were well tolerated) on day 1 and 8 of 21-day cycle.
48004429|NCT04055857|OTHER||There is no Intervention.
48004430|NCT05210686|OTHER|subgingival re-instrumentation|subgingival re-instrumentation (control)
48004431|NCT04380311|DEVICE|Tacrolimus Dosing Support Tool|The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
48004432|NCT04138407|OTHER|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
48004433|NCT04138407|OTHER|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
48004434|NCT03001570|DRUG|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
48004435|NCT05660694|DRUG|Triamcinolone|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
48690198|NCT06537765|DEVICE|Therapeutic ultrasound (US)|Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel.
48690199|NCT06537765|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
48690200|NCT02368093|DRUG|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
48690201|NCT00203918|BEHAVIORAL|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
48004436|NCT05660694|DRUG|Pentoxifylline with Vitamin E|Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
48004437|NCT06522308|DIAGNOSTIC_TEST|Hepatobiliary ultrasound|The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound
48004438|NCT06522308|DIAGNOSTIC_TEST|Umbilical region superficial tissue ultrasound|The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
48004439|NCT04074317|DRUG|PRAM9|SC injection
48004440|NCT04074317|DRUG|Regular Insulin + Pramlintide|Separate SC injections
48004441|NCT04074317|DRUG|Regular Insulin|SC injection
48004442|NCT03862391|DRUG|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
48004443|NCT03862391|DRUG|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
48004444|NCT02659215|DEVICE|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
48004445|NCT02659215|PROCEDURE|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
48004446|NCT05385939|OTHER|Observational|This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
48004447|NCT02909556|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
48690202|NCT00203918|BEHAVIORAL|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
48690203|NCT04547634|OTHER|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
48690204|NCT02924441|OTHER|Lidocaine|Applied to breast skin
48690205|NCT02924441|OTHER|Calming Music|Played during mammography
48004448|NCT05164900|PROCEDURE|pterygium excision with sutures fixed conjunctival auto-graft|Pterygium excision with vicryl 8/0 fixed conjunctival auto-graft under local anesthesia. During the follow up period, indicators of ocular irritation were assessed.
48690206|NCT02924441|OTHER|No Music|No music played during mammography
48004449|NCT03100708|PROCEDURE|PIPAC|"* Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~* Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
48004450|NCT05300165|DIETARY_SUPPLEMENT|Beer|A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
48161428|NCT05584761|DRUG|unrelated umbilical cord blood|"A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection."
48161429|NCT05267249|PROCEDURE|Autotransplantation and Apicoectomy|Autotransplantation of a mature teeth with simultaneous extra-oral root-end resectoin
48161430|NCT00092456|BIOLOGICAL|rotavirus vaccine, live, oral, pentavalent|Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
48161431|NCT00092456|BIOLOGICAL|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
48690207|NCT02250508|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
48690208|NCT02250508|BIOLOGICAL|Haemate P® (Human Coagulation Factor VIII)|
48690209|NCT04012502|OTHER|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
48690210|NCT04012502|OTHER|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
48690211|NCT03800524|DRUG|Tauroursodeoxycholic Acid|"* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
48690212|NCT03800524|DRUG|Placebo|"* Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
48690213|NCT01922362|DEVICE|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
48690214|NCT01922362|DEVICE|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
48690215|NCT00869492|DRUG|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
48004451|NCT00323414|DRUG|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
48004452|NCT00323414|DRUG|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
48004453|NCT00751816|DRUG|systemic chemotherapy|
48161432|NCT01990378|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
48161433|NCT01482819|DEVICE|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
48161434|NCT01482819|DEVICE|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
48161435|NCT01482819|DEVICE|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
48161436|NCT01482819|DEVICE|polymacon|contact lenses worn bilaterally for 8-12 hours
48161437|NCT01482819|OTHER|spectacles|habitual spectacles owned by subject, non-specific manufacturer
48161438|NCT00719277|DEVICE|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
48161439|NCT02840812|DRUG|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
48690216|NCT00869492|DRUG|nadifloxacine|Nadifloxacine 1% cream twice dailly
48690217|NCT05376059|BEHAVIORAL|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
48690218|NCT05376059|BEHAVIORAL|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
48690219|NCT05376059|BEHAVIORAL|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
48690220|NCT01003236|DRUG|placebo|140 mg placebo tablets, 3 times per day for 3 months
48690221|NCT01003236|DRUG|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
48004454|NCT00751816|OTHER|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
48004455|NCT00751816|PROCEDURE|adjuvant therapy|
48690222|NCT02476032|DEVICE|Prof applied oxalate|Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
48690223|NCT02476032|DEVICE|Self applied oxalate|Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
48690224|NCT02476032|DEVICE|Prof applied placebo|Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
48004456|NCT00751816|PROCEDURE|management of therapy complications|
48004457|NCT00751816|PROCEDURE|musculoskeletal complications management/prevention|
48004458|NCT00751816|PROCEDURE|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
48004459|NCT00751816|RADIATION|radiation therapy|
48004460|NCT06223646|BIOLOGICAL|KQ-2003 CAR T-cells|KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy.
48004461|NCT01067404|BIOLOGICAL|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
48690225|NCT03158740|BEHAVIORAL|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
48690226|NCT03158740|BEHAVIORAL|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
48690227|NCT05962645|DRUG|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
48690228|NCT05511376|DEVICE|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
48004462|NCT03848845|DRUG|belantamab mafodotin|belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
48513735|NCT06070558|DEVICE|MRI with Real Time MRI Rapid Flash sequence|MRI examination of temporomandibular joint with Real Time MRI Rapid Flash sequence
48690229|NCT05511376|BEHAVIORAL|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
48690230|NCT05511376|BEHAVIORAL|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
48690231|NCT02142400|DRUG|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
48690232|NCT02142400|DRUG|placebo|matching placebo capsules to DS-1093 capsules
48004463|NCT03848845|DRUG|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
48161440|NCT04230993|OTHER|Sea water solution|Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
48368275|NCT04369560|DRUG|Gadobutrol intravesical administration (4mM)|A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
48690233|NCT04704687|OTHER|Transcranial Direct Current Stimulation|Children will perform two successive interventions composed each by a set of 15 sessions of effective-tDCS combine with cognitive-training exercises.
48690234|NCT05308407|OTHER|Focus Groups|No intervention involved in this phase of the study
48690235|NCT05308407|OTHER|Pilot randomized controlled trial|The intervention is a virtually delivered, 12 weekly group-based active video game-centered lifestyle physical activity intervention (POWER UP) targeting affect to improve function and quality of life in insufficiently active AYAs with central nervous system tumors.
48690236|NCT06661252|DEVICE|ABEL microsampler device|The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
48690237|NCT04599803|DEVICE|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
48004464|NCT03267862|OTHER|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
48004465|NCT02646579|PROCEDURE|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
48513736|NCT00445146|DRUG|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
48513737|NCT00445146|DRUG|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
48690238|NCT03764319|OTHER|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume \> 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
48690239|NCT03764319|OTHER|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
48004466|NCT02646579|PROCEDURE|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
48004467|NCT02825836|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
48004468|NCT02825836|DRUG|Navtemadlin|Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
48690240|NCT05755932|DRUG|HFO MDI|"* Dose formulation: MDI~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
48690241|NCT05755932|DRUG|HFA MDI|"* Dose formulation: MDI~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
48185206|NCT01432626|DRUG|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
48004469|NCT01023165|PROCEDURE|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
48004470|NCT03554291|DRUG|Famotidine 20 MG|Famotidine 20 mg capsule taken daily for 24 weeks.
48004471|NCT03554291|OTHER|Placebo|Placebo capsule taken daily for 24 weeks.
48004472|NCT03309280|OTHER|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
48690242|NCT03569878|BEHAVIORAL|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
48690243|NCT03569878|BEHAVIORAL|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
48161441|NCT06645639|OTHER|Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)|"The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment)."
48161442|NCT04047680|DRUG|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
48161443|NCT04047680|DRUG|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
48004473|NCT03309280|DIAGNOSTIC_TEST|Evolution of the renal function|Evolution of the renal function in the next two days
48004474|NCT00040885|BIOLOGICAL|infliximab|
48161444|NCT04047680|DRUG|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
48161445|NCT04047680|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
48161446|NCT04047680|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
48161447|NCT04047680|DRUG|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
48161448|NCT03781583|DEVICE|No HMD used|Participants will use their existing mobility skills and strategies to navigate toward a goal. If the participant cannot perform this task, the participant will not be forced to.
48161449|NCT03781583|DEVICE|HMD worn but not active|Participants will wear the HMD, but the HMD will not be active. This will test whether or not the HMD physical components obscure the participants remaining vision and reduce the participants ability to navigate toward a goal.
48161450|NCT03781583|DEVICE|HMD worn and active|Participants will wear the HMD and the HMD will be active. This will test the HMD function for navigation toward a goal.
48161451|NCT04357522|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
48161452|NCT04357522|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
48690244|NCT03133819|DEVICE|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
48690245|NCT03569449|BEHAVIORAL|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
48690246|NCT03569449|BEHAVIORAL|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
48690247|NCT03569449|BEHAVIORAL|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
48004475|NCT00040885|DRUG|docetaxel|
48004476|NCT00040885|OTHER|placebo|
48004477|NCT02299050|DRUG|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
48004478|NCT00684853|DRUG|bevacizumab|1.25 mg of bevacizumab intravitreal
48004479|NCT00684853|DRUG|vetaporfin|full fluence of vetaporfin
48004480|NCT05175066|DRUG|Bisoprolol|For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.
48690248|NCT03569449|BEHAVIORAL|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
48690249|NCT03569449|BEHAVIORAL|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
48690250|NCT03569449|BEHAVIORAL|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
48690251|NCT03569449|BEHAVIORAL|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
48690252|NCT03569449|BEHAVIORAL|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
48690253|NCT05020834|OTHER|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
48690254|NCT05020834|OTHER|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
48690255|NCT03811535|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
48690256|NCT03811535|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
48690257|NCT02348034|DEVICE|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
48690258|NCT01509976|OTHER|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
48690259|NCT04644588|DIAGNOSTIC_TEST|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
48690260|NCT05483231|BEHAVIORAL|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
48690261|NCT05483231|BEHAVIORAL|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
48690262|NCT02209558|BEHAVIORAL|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
48690263|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
48690264|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
48004481|NCT05175066|DRUG|Placebo|Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
48185207|NCT05163223|BIOLOGICAL|AST-301(pNGVL3-hICD)|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
48690265|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 3|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
48690266|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 4|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
48690267|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 5|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
48690268|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
48690269|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
48690270|NCT02220153|BIOLOGICAL|Intravenous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion"
48004482|NCT01503827|RADIATION|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
48004483|NCT01391065|RADIATION|MR PET Guided Brachytherapy|
48690271|NCT02220153|BIOLOGICAL|Subcutaneous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion"
48004484|NCT05850650|OTHER|Application of a collagen sponge after surgical extraction of impacted 3rd molar|Application of a collagen sponge after surgical extraction of impacted 3rd molar
48004485|NCT05850650|OTHER|No collagen sponge application after surgical extraction of impacted 3rd molar|No collagen sponge application after surgical extraction of impacted 3rd molar
48161453|NCT03336749|BEHAVIORAL|Sensory group|The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.
48004486|NCT03015051|DRUG|Oxygen|
48161454|NCT03336749|OTHER|Control group|Traditional task-specific training
48161455|NCT00019136|BIOLOGICAL|MOv-gamma chimeric receptor gene|
48161456|NCT00019136|BIOLOGICAL|aldesleukin|
48161457|NCT00019136|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48161458|NCT05833776|PROCEDURE|spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
48161459|NCT06036797|DRUG|Hydromorphone|For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
48161460|NCT06036797|DRUG|Sufentanil|For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
48161461|NCT06036797|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
48161462|NCT01202305|PROCEDURE|Lymph node biopsy|Inguinal lymph node biopsy
48161463|NCT03994900|DIAGNOSTIC_TEST|Blood sampling for HbNO assessment|Blood sampling
48161464|NCT05134948|DRUG|BMS-986213|Specified dose on specified days
48161465|NCT01890499|DIETARY_SUPPLEMENT|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
48690272|NCT06440954|DRUG|Intrathecal pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
48161466|NCT03558750|BIOLOGICAL|Nivolumab|Given by IV
48161467|NCT03558750|BIOLOGICAL|Rituximab|Given by IV
48161468|NCT03558750|DRUG|Lenalidomide|Given by mouth
48161469|NCT05182827|OTHER|Tactile stimulation|"The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness."
48161470|NCT01568112|DRUG|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
48161471|NCT01568112|DRUG|BG00012 placebo|Placebo matching BG00012
48161472|NCT01568112|DRUG|ASA|325 mg microcoated aspirin (ASA)
48161473|NCT01568112|DRUG|ASA placebo|Placebo matching aspirin
48161474|NCT02581137|OTHER|Laboratory Biomarker Analysis|Correlative studies
48161475|NCT02581137|DRUG|Metformin Hydrochloride|Given PO
48368276|NCT04369560|DRUG|Ferumoxytol intravesical administration (5 mM)|An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
48161476|NCT04171258|DRUG|Botulinum toxin type A injection|Experimental
48161477|NCT04171258|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
48161478|NCT03043170|DEVICE|Ultrasound Cardiac Output Monitor|a device for assessing haemodynamics continuously and non-invasively using Doppler wave ultrasound
48161479|NCT02625168|DRUG|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
48690273|NCT03423446|DRUG|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
48690274|NCT03574376|DRUG|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
48690275|NCT03574376|DRUG|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
48690276|NCT03248531|DRUG|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
48690277|NCT03248531|DRUG|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
48690278|NCT03248531|OTHER|Placebo|Placebo will be provided matching Bimekizumab.
48690279|NCT01247025|OTHER|No intervention|This study will not contain a specific intervention
48690280|NCT01518686|DEVICE|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
48690281|NCT01071499|DRUG|Morphine|One dose of morphine (0.1 mg/kg)
48161480|NCT02625168|DRUG|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
48161481|NCT06330857|PROCEDURE|Laparoscopic vaginorectopexy|Modified laparoscopic anterior rectopexy for multiple pelvic prolapses
48161482|NCT02785900|DRUG|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
48161483|NCT02785900|DRUG|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
48690282|NCT01071499|DRUG|Morphine|One dose of morphine (0.2 mg/kg)
48690283|NCT01071499|DRUG|Morphine|One dose of morphine (0.3 mg/kg)
48690284|NCT00789152|DRUG|desloratadine|desloratadine 5 mg daily x 8 days
48690285|NCT00789152|DRUG|levocetirizine|levocetirizine 5 mg daily x 8 days
48690286|NCT04979793|DRUG|L-citrulline|3 gram sachet, L-citrulline
48690287|NCT04979793|DRUG|Placebo|Milk powder placebo
48690288|NCT04654221|DIAGNOSTIC_TEST|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
48690289|NCT02469987|DRUG|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
48690290|NCT02469987|DRUG|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
48690291|NCT02469987|DRUG|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
48690292|NCT01001767|DRUG|Lovaza|Lovaza one gram twice a day for 24 weeks
48690293|NCT01001767|DRUG|Placebo|Placebo
48690294|NCT03107858|DRUG|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
48690295|NCT03107858|DRUG|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
48690296|NCT05142696|DRUG|[177Lu]Lu-DOTA-TATE|"Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed"
48690297|NCT05142696|DRUG|Atezolizumab|Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
48690298|NCT05142696|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
48690299|NCT05142696|OTHER|Carboplatin|Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
48690300|NCT05142696|OTHER|Etoposide|Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
48690301|NCT00207623|BEHAVIORAL|Arthritis Basics for Change Education program|
48690302|NCT05132179|DRUG|Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution|Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
48690303|NCT00533728|DRUG|Soluble beta-glucan (SBG)|
48690304|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
48690305|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
48690306|NCT01153711|DRUG|Ketoconazole|400 mg tablet
48690307|NCT01153711|DRUG|Ketoconazole|400 mg tablet
48690308|NCT05778864|DRUG|LY3473329|Administered orally.
48690309|NCT05117684|PROCEDURE|Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
48690310|NCT05117684|PROCEDURE|Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
48690311|NCT05047302|DEVICE|BlueLeaf Procedure|The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
48690312|NCT02258568|BEHAVIORAL|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
48690313|NCT04224714|COMBINATION_PRODUCT|FFR|FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
48690314|NCT05454462|DRUG|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
48004487|NCT02453295|BEHAVIORAL|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
48004488|NCT01703793|DRUG|Test Product 49778|
48004489|NCT01703793|DRUG|Test Product 10156|
48161484|NCT02785900|DRUG|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
48004490|NCT01703793|DRUG|Vehicle (placebo)|
48161485|NCT02785900|DRUG|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
48185208|NCT05163223|DRUG|rhuGM-CSF|Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
48185209|NCT05163223|DRUG|Placebo|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
48185210|NCT05163223|DRUG|Pembrolizumab|Q3W; IV infusion
48690315|NCT05454462|DIAGNOSTIC_TEST|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
48690316|NCT05454462|DIAGNOSTIC_TEST|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
48690317|NCT05454462|DIAGNOSTIC_TEST|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
48690318|NCT05454462|DIAGNOSTIC_TEST|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
48690319|NCT05454462|DIAGNOSTIC_TEST|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
48690320|NCT05454462|DIAGNOSTIC_TEST|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
48690321|NCT05454462|DIAGNOSTIC_TEST|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
48690322|NCT05454462|PROCEDURE|Physical Examination|patients will undergo a physical examination on all the clinical visits
48185211|NCT05163223|DRUG|Capecitabine|On days 1-14 (Q3W), BID ; Oral administration,
48185212|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
48690323|NCT05454462|PROCEDURE|Vital signa|patient's vital signs will be measured on all the clinical visits
48690324|NCT05454462|DIAGNOSTIC_TEST|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
48690325|NCT05454462|DIAGNOSTIC_TEST|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
48690326|NCT05454462|OTHER|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
48690327|NCT01114087|DRUG|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
48690328|NCT01312805|OTHER|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
48690329|NCT01312805|OTHER|CHICA Control|This is CHICA without the asthma module, and was used as a control
48690330|NCT05536414|DRUG|Centanafadine|capsule
48690331|NCT05536414|DRUG|Escitalopram|capsule
48161486|NCT04263883|DEVICE|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
48161487|NCT04627662|BEHAVIORAL|Tele-STELLA|Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
48004491|NCT03445624|DRUG|Infliximab|follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
48004492|NCT04082988|DIAGNOSTIC_TEST|18F-FDG PET-CT|18F-FDG PET-CT scan
48004493|NCT05360563|OTHER|Home-based physical training|Patients allocated to this group will participate in a 16-week home-based physical training program, structured in three weekly sessions of aerobic and muscle strengthening exercises (which also have components that stimulate flexibility and balance). A third of the weekly physical training sessions will be supervised via telemedicine (with video call) by a clinical exercise specialist, but all patients will have illustrated exercise booklets and a full-time remote support service available for the remaining sessions (via text or voice messages).
48004494|NCT00190801|DRUG|pemetrexed|
48004495|NCT00190801|DRUG|cisplatin|
48004496|NCT05827627|OTHER|simulation|Midwifery student directing the birth of a fetus with frank breech presentation.
48004497|NCT02903667|DEVICE|Bone grafting|
48004498|NCT01474642|DRUG|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
48161488|NCT06315647|PROCEDURE|DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation|comparison between different technique in difficult CBD cannulation
48161489|NCT03586752|OTHER|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
48690332|NCT05536414|DRUG|Placebo|capsule
48690333|NCT04839458|DEVICE|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
48690334|NCT03040518|BEHAVIORAL|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
48690335|NCT03040518|BEHAVIORAL|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
48690336|NCT00437957|DRUG|Temozolomide|75 Mg/m2/day for all Cohorts
48690337|NCT00437957|DRUG|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
48004499|NCT01474642|DRUG|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
48004500|NCT01416168|OTHER|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
48690338|NCT00437957|PROCEDURE|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
48161490|NCT03586752|OTHER|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
48161491|NCT06025877|OTHER|PrecivityAD2(TM) blood test|The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
48161492|NCT05514054|DRUG|Imlunestrant|Administered orally.
48690339|NCT01201824|PROCEDURE|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
48161493|NCT05514054|DRUG|Tamoxifen|Administered per local approved label.
48161494|NCT05514054|DRUG|Anastrozole|Administered per local approved label.
48690340|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
48161495|NCT05514054|DRUG|Letrozole|Administered per local approved label.
48161496|NCT05514054|DRUG|Exemestane|Administered per local approved label.
48161497|NCT06268600|RADIATION|Modified neck target volume delineation|Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
48161498|NCT01381614|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
48161499|NCT02617667|DRUG|Cyclosporine A|topical ocular, eye drops
48161500|NCT02617667|DRUG|Placebo|topical ocular, eye drops
48161501|NCT06191133|DRUG|Fenofibrate|Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
48161502|NCT06191133|PROCEDURE|Cervical Conization|Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix
48690341|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
48161503|NCT06191133|PROCEDURE|Hysterectomy|In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.
48161504|NCT06191133|RADIATION|Chemoradiation|Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
48161505|NCT02509754|PROCEDURE|Atrial fibrillation catheter ablation|
48161506|NCT02509754|PROCEDURE|Rate control|Composite of optimal medical therapy and device implantation
48161507|NCT00328276|DRUG|Sarcosine|
48004501|NCT01421784|OTHER|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
48004502|NCT00002417|DRUG|Amprenavir|
48004503|NCT03289507|DIETARY_SUPPLEMENT|Treatment1|Longvida Capsule formulation A
48161508|NCT01516502|OTHER|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
48161509|NCT04896502|BEHAVIORAL|Standard of Care Education|Education regarding recognition and removal of in-home asthma triggers
48004504|NCT03289507|DIETARY_SUPPLEMENT|Treatment2|Longvida Capsule formulation B
48161510|NCT04896502|OTHER|Interactive Video (IAV) Telemedicine|Interactive video assessment of asthma triggers in the home.
48161511|NCT03261713|DEVICE|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
48161512|NCT03261713|DEVICE|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
48368277|NCT00125138|DRUG|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
48368278|NCT00125138|DRUG|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
48690342|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
48004505|NCT03289507|DIETARY_SUPPLEMENT|Treatment3|Curcuma longa extract of Rhizomes
48161513|NCT05827809|BEHAVIORAL|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression|A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
48004506|NCT01791738|PROCEDURE|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
48004507|NCT06019156|BEHAVIORAL|Exercise video distribution of Metaverse|Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
48004508|NCT06019156|BEHAVIORAL|Exercise video distribution of YouTube|Participants view exercise videos with the same content as the metaverse group.
48004509|NCT02190799|BIOLOGICAL|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
48004510|NCT02534831|PROCEDURE|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
48004511|NCT04587193|DEVICE|Robotic-assist gait training device|PD participants will walk while wearing a robotic-assist gait training device
48004512|NCT05530122|BIOLOGICAL|infliximab, adalimumab, golimumab, vedolizumab, ustekinumab|
48004513|NCT05638646|OTHER|Intervention group|Practice standard for clinical diagnosis and treatment of chronic obstructive pulmonary disease
48004514|NCT05638646|OTHER|control group|Maintain current treatment
48004515|NCT02690675|DIETARY_SUPPLEMENT|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
48004516|NCT01105507|DRUG|canakinumab (company code: ACZ885D)|
48004517|NCT01209910|OTHER|Water|Subjects in this arm will be able to drink water with some conditions.
48004518|NCT02597010|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
48004519|NCT02597010|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
48690343|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
48004520|NCT02558998|OTHER|Survey|
48004521|NCT01489969|DRUG|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
48004522|NCT03012386|DRUG|Sildenafil Citrate in G allele carrier|chronic use of phosphodiesterase 5 inhibitor in G allele carrier
48004523|NCT03012386|DRUG|Sildenafil Citrate in non G allele carrier|chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier
48004524|NCT04334460|DRUG|BLD-2660|BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
48004525|NCT03324763|OTHER|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
48004526|NCT00898976|OTHER|immunohistochemistry staining method|
48004527|NCT00898976|OTHER|laboratory biomarker analysis|
48004528|NCT03033017|OTHER|Blood Testing|
48004529|NCT01307566|DEVICE|Continuous Positive Airway Pressure CPAP|CPAP treatment
48004530|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
48004531|NCT00184015|DRUG|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
48004532|NCT05874180|DRUG|DW6013|"Drug: DW6013 Single oral administration of DW6013 in fed condition~Drug: Linagliptin and Metformin Single oral administration of Linagliptin and Metformin in fed condition"
48004533|NCT04784286|OTHER|Telemedicine 30-day post-op visit|Consented subjects randomized to the telemedicine visit arm will do their 30-day post-op visit via secure telemedicine video application through the Center of Connected Care. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
48004534|NCT04784286|OTHER|In-Person 30-day post-op visit|Consented subjects randomized to the in-person visit arm will physically come to a clinical visit with the bariatric surgery midlevel providers. A survey will be asked via telephone about their post-op care visit, costs incurred, and feedback.
48004535|NCT06226727|DRUG|BR1019|One tablet administered alone
48004536|NCT06226727|DRUG|BR1019-1|One tablet administered alone
48004537|NCT06226727|DRUG|BR1019-2|One tablet administered alone
48368279|NCT00125138|DRUG|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
48690344|NCT00699387|DRUG|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
48690345|NCT06290466|DRUG|Low dose group|300 mg,single dose.
48690346|NCT06290466|DRUG|High dose group|400 mg, single dose.
48004538|NCT02479152|DEVICE|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
48004539|NCT06273228|BEHAVIORAL|Family Check-Up Online|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
48004540|NCT02029534|DRUG|Atorvastatin 20 mg|
48004541|NCT02029534|DRUG|Atorvastatin 80 mg|
48004542|NCT01924169|DRUG|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
48004543|NCT01924169|BIOLOGICAL|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
48004544|NCT01924169|BIOLOGICAL|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
48004545|NCT05209685|OTHER|Resistance exercise on the lower extremities|Resistance exercise mainly on the lower extremities will be executed by carrying weight according to each participant's tolerance while performing certain movements, such as side step-up, sit-to-stand, and tip-toe-standing.
48004546|NCT05209685|OTHER|Resistance exercise on the lower extremities with blood flow restriction|Blood flow restriction on the thigh of the dominant leg will be used in combination with resistance exercise.
48004547|NCT04844554|OTHER|Active HD-tDCS 3mA|This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min.
48004548|NCT04844554|OTHER|Sham HD-tDCS|This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off.
48004549|NCT03993938|DEVICE|PVI measurement|Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
48004550|NCT05618106|OTHER|variations of the low FODMAP diet|"Cross-over of 3 interventions in IBS patients:~1. Low Polyol diet~2. Low FOS+GOS diet~3. Low FODMAP diet"
48004551|NCT03867513|OTHER|Multimodal imaging|All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
48004552|NCT03287388|PROCEDURE|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
48368280|NCT00125138|DRUG|Placebo|Syrup formulation
48368281|NCT01072227|PROCEDURE|Sample Collection|Tissue
48004553|NCT03287388|DRUG|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
48004554|NCT03287388|DRUG|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
48004555|NCT00430092|DRUG|Difluprednate|
48004556|NCT00430092|DRUG|Difluprednate|
48004557|NCT00430092|DRUG|Placebo|
48004558|NCT01358617|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
48004559|NCT04155515|DRUG|TG-2349|TG-2349 400mg
48004560|NCT04155515|DRUG|DAG181|DAG181 200mg
48004561|NCT04155515|DRUG|Ribavirin|Ribavirin 1000mg/1200mg
48004562|NCT01801787|DEVICE|tDCS|active vs. sham tDCS left hemisphere
48004563|NCT00203528|DRUG|divalproex sodium ER|
48004564|NCT00203528|DRUG|risperidone|
48161514|NCT05530928|OTHER|Reproductive life plan counseling|The intervention group will receive in addition to the standard contraceptive counseling, a reproductive life plan counseling: midwives will discuss the different options with the woman depending if she wants or not more children, and she will give her general information about preconception health.
48161515|NCT04117477|DRUG|Xylitol|Xylitol dental wipes
48368282|NCT04679064|DRUG|Niraparib|PARP-inihibitor
48368283|NCT04679064|DRUG|Dostarlimab|PD-1 inihibitor
48368284|NCT04679064|DRUG|Pegylated liposomal doxorubicin|Chemotherapy drug
48368285|NCT04679064|DRUG|Paclitaxel|Chemotherapy drug
48368286|NCT04679064|DRUG|Gemcitabine|Chemotherapy drug
48368287|NCT04679064|DRUG|Topotecan|Chemotherapy drug
48368288|NCT04679064|DRUG|Bevacizumab|Chemotherapy drug
48690347|NCT01127672|BIOLOGICAL|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
48004565|NCT04570293|DRUG|5% lidocaine medicated plaster|The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
48690348|NCT01127672|DRUG|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
48690349|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose1|A topical drop of BRM424 ophthalmic solution.
48690350|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose2|A topical drop of BRM424 ophthalmic solution.
48690351|NCT00231686|BEHAVIORAL|Supervised aerobic training|
48690352|NCT00231686|BEHAVIORAL|Supervised strength training|
48690353|NCT00231686|BEHAVIORAL|Unsupervised training|
48690354|NCT00543933|DRUG|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
48690355|NCT03102827|DRUG|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
48690356|NCT03102827|OTHER|Placebo|Ambient air without high-flow therapy administered during first night
48690357|NCT06280768|DRUG|SHR-2004 injection|dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
48690358|NCT00014443|DRUG|thalidomide|
48004566|NCT04570293|DRUG|vehicle plaster|Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
48004567|NCT04582851|OTHER|some risk factors correlated with TMD|exposure factors causing TMD
48004568|NCT02774681|PROCEDURE|Cognitive Assessment|Ancillary studies
48690359|NCT00014443|DRUG|topotecan hydrochloride|
48004569|NCT02774681|DRUG|Palbociclib|Given PO
48161516|NCT04117477|OTHER|Placebo|Placebo dental wipes
48004570|NCT02774681|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
48004571|NCT02774681|BIOLOGICAL|Trastuzumab|Given IV
48004572|NCT03395366|OTHER|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts \& worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
48161517|NCT00015171|DRUG|Buprenorphine/naloxone|
48690360|NCT03539744|DRUG|Pomalidomide|capsule, oral
48004573|NCT01185873|DRUG|danoprevir|Repeated oral doses
48004574|NCT01185873|DRUG|ritonavir|Repeated oral doses
48004575|NCT00820742|DRUG|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
48004576|NCT04725435|BEHAVIORAL|Kangaroo care|Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
48161519|NCT02431832|DRUG|Augmentin tab|
48161520|NCT01799785|BEHAVIORAL|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
48161521|NCT01799785|OTHER|Usual Care|
48161522|NCT00331851|DRUG|liraglutide|
48690361|NCT03539744|DRUG|Dexamethasone|oral, locally available form
48690362|NCT03539744|DRUG|Venetoclax|tablet; oral
48690363|NCT03073317|DIAGNOSTIC_TEST|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
48690364|NCT04452058|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
48690365|NCT04301934|DEVICE|Mona Lisa Touch|Fractional CO2 LASER
48004577|NCT04725435|BEHAVIORAL|Facilitated Tucking Position|"Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.~Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure."
48004578|NCT01122667|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
48004579|NCT02781636|DEVICE|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
48004580|NCT04242108|DIAGNOSTIC_TEST|Deep learning algorithm based on AS-OCT scans|The OCT scans of study subjects would be imported into the algorithm. Automated classfication of angle width and detection of synechia would be performed by the algorithm. The diagnostic performance of the algorithm would be compared with gonioscopy records.
48004581|NCT04059848|COMBINATION_PRODUCT|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
48004582|NCT04059848|COMBINATION_PRODUCT|NMES(Enraf Nonius, Endomed-182, Netherlands)|
48004583|NCT04966676|DIAGNOSTIC_TEST|cfDNA blood test|Blood sample will be taken for cfDNA testing
48004584|NCT04966676|DRUG|Nivolumab|Antineoplastic agent
48004585|NCT04966676|DRUG|Ipilimumab|Antineoplastic agent
48004586|NCT04966676|COMBINATION_PRODUCT|Platinum-based Chemotherapy|May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
48161523|NCT00331851|DRUG|insulin glargine|
48004587|NCT02990793|DEVICE|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/ECG resonance therapy (MeRT) treatment that is tailored specifically to each participant's EEG intrinsic alpha frequency (IAF). rTMS is applied at the participant's IAF.
48004588|NCT02990793|DEVICE|Sham MeRT Treatment|rTMS coil does not emit magnetic stimulation.
48161524|NCT00331851|DRUG|metformin|
48161525|NCT00331851|DRUG|glimepiride|
48161526|NCT00166361|DEVICE|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
48161527|NCT00166361|DEVICE|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
48161528|NCT06551064|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
48161529|NCT06551064|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
48185213|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
48185214|NCT00172939|PROCEDURE|foreskin from healthy adults|
48690366|NCT04301934|DRUG|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
48004589|NCT01384435|DRUG|KPS-0373|
48004590|NCT01384435|DRUG|KPS-0373|
48004591|NCT01384435|DRUG|KPS-0373|
48004592|NCT01384435|DRUG|KPS-0373|
48004593|NCT01384435|DRUG|Placebo|
48004594|NCT04760210|OTHER|Control Group|Treatment for this group is conventional physical therapy along with the bed rest.
48004595|NCT04760210|OTHER|Decompression Group|Treatment for this is conventional physical therapy along with the spinal decompression.
48004596|NCT04760210|OTHER|ELDOA|Treatment for this is conventional physical therapy along with the ELDOA.
48004597|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules with 1 pack of Omethyl cutielet
48004598|NCT05365438|DRUG|Omega 3-Atorvastatin|Atmeg 2 capsules
48004599|NCT05365438|DRUG|Atorvastatin-Ezetimibe|ezetimibe/atorvastatin 10/20 mg
48004600|NCT05179733|DRUG|six courses of zanubrutinib, rituximab and lenalidomide|Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.
48161530|NCT05128539|DRUG|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
48161531|NCT03504371|DEVICE|bilateral erector spinae block|The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
48004601|NCT05179733|DRUG|six courses of rituximab combined with low-dose CHOP|Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m² on days 2-6, every 21 days.
48690367|NCT04301934|DRUG|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
48004602|NCT04419116|PROCEDURE|tibial preservation bone cut|tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
48004603|NCT03666169|OTHER|Survey|Survey
48004604|NCT03143270|DRUG|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
48004605|NCT03143270|DRUG|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
48004606|NCT02619695|DRUG|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
48004607|NCT05440292|DEVICE|Transcranial magnetic stimulation|For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
48161532|NCT03504371|DEVICE|Thoracic epidural anesthesia|patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
48161533|NCT03325608|OTHER|POISED Care|Program of dementia care management.
48368289|NCT03085160|BEHAVIORAL|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
48368290|NCT03085160|BEHAVIORAL|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
48690368|NCT03139994|OTHER|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
48690369|NCT01019122|RADIATION|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
48690370|NCT01202188|DRUG|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
48004608|NCT03270917|PROCEDURE|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
48004609|NCT05138939|OTHER|Red wine A|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
48004610|NCT05138939|OTHER|Red wine B|8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
48004611|NCT05138939|OTHER|Control|8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
48004612|NCT04679077|OTHER|Cytocam-IDF imaging device|Observation of the microcirculation
48690371|NCT01202188|DRUG|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
48690372|NCT01202188|DRUG|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
48690373|NCT01202188|DRUG|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
48690374|NCT01202188|DRUG|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
48690375|NCT03021655|BEHAVIORAL|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
48690376|NCT03021655|BEHAVIORAL|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
48690377|NCT03021655|BEHAVIORAL|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
48004613|NCT05973916|OTHER|Comprehensive intervention|"cleaning of patients' rooms will be subjected to a comprehensive intervention, consisting of: 1) a patient's unit commando team for daily and for terminal cleaning, 2) all lights in patients' room are VYV led lights, and 3) in each room, a QleanAir Scandinavia® filtering machine will be placed."
48690378|NCT03914430|OTHER|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
48004614|NCT01039181|DRUG|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
48004615|NCT01971658|DRUG|Thalidomide®|
48004616|NCT01971658|DRUG|Cyclophosphamide|
48004617|NCT01971658|DRUG|Velcade®|
48004618|NCT01971658|DRUG|Dexaméthasone|
48004619|NCT06290310|DEVICE|EIT|continuous electric impedance tomography measurement
48004620|NCT06290310|DEVICE|patient-ventilator asynchrony assessment|patient-ventilator asynchrony assessment by flow/time curve and machine learning
48004621|NCT00844792|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
48161534|NCT02683356|OTHER|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
48161535|NCT02683356|OTHER|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
48161536|NCT02825719|DRUG|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
48690379|NCT00292201|DRUG|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
48004622|NCT00844792|DRUG|Placebo|Twice a day with meals.
48004623|NCT02066012|OTHER|dysmetabolic iron overload syndrome|
48004624|NCT03139890|OTHER|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
48004625|NCT03139890|OTHER|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
48004626|NCT03139890|OTHER|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
48161537|NCT02825719|OTHER|Placebo pills|Placebo pills will be prescribed
48161538|NCT02825719|DRUG|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
48161539|NCT02825719|DRUG|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
48368291|NCT03007472|DEVICE|CI532|Cochlear implant
48690380|NCT05648617|DIETARY_SUPPLEMENT|SUSTINEX Hydrolyzed Whey Protein|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.
48690381|NCT01469936|DIETARY_SUPPLEMENT|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
48690382|NCT01469936|DIETARY_SUPPLEMENT|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
48690383|NCT04834193|PROCEDURE|Endoscopic ultrasound-guided fine-needle biopsy|Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
48690384|NCT01485731|DRUG|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
48690385|NCT01485731|DRUG|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
48004627|NCT04460222|PROCEDURE|Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure|"Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~* EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~* FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg"
48004628|NCT04460222|PROCEDURE|Conventional transfusion methods to guide blood product transfusion pre invasive procedure|Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
48004629|NCT00838201|DRUG|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
48161540|NCT01357564|OTHER|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
48368292|NCT03007472|DEVICE|Nucleus 7|Sound processor
48513738|NCT00445146|DRUG|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
48513739|NCT02770898|BEHAVIORAL|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
48690386|NCT01485731|RADIATION|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
48690387|NCT01485731|RADIATION|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
48004630|NCT00003681|BIOLOGICAL|epoetin alfa|
48004631|NCT00003681|DRUG|amifostine trihydrate|
48004632|NCT01302392|DRUG|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \[Days 1, 2, 8, 9, 15, 16\] for individual subjects).
48513740|NCT01128543|DRUG|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
48004633|NCT01302392|DRUG|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
48004634|NCT01544530|OTHER|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
48004635|NCT05857124|DEVICE|Vielight Neuro RX Gamma active device|The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.
48004636|NCT05857124|DEVICE|Vielight Neuro RX Gamma sham device|The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
48004637|NCT01190254|DRUG|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
48004638|NCT01190254|DRUG|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
48004639|NCT01190254|DRUG|placebo|asenapine-matched placebo tablets for sublingual administration
48690388|NCT01485731|PROCEDURE|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
48004640|NCT03621878|OTHER|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
48004641|NCT03621878|OTHER|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
48004642|NCT03621878|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
48161541|NCT01357564|OTHER|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
48161542|NCT00226746|DRUG|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
48690389|NCT01485731|PROCEDURE|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
48690390|NCT01485731|PROCEDURE|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
48690391|NCT01485731|PROCEDURE|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
48690392|NCT01485731|PROCEDURE|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
48690393|NCT01485731|PROCEDURE|Proctoscopy|Optional. Pre-Treatment
48690394|NCT01485731|PROCEDURE|Cytoscopy|Optional. Pre-Treatment
48690395|NCT01485731|PROCEDURE|Renal Ultrasound|Optional. Pre-Treatment
48690396|NCT01485731|PROCEDURE|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
48690397|NCT01485731|PROCEDURE|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
48690398|NCT02520544|DEVICE|Accolade stem|Total hip replacement
48690399|NCT02520544|DEVICE|Accolade II stem|Total hip replacement
48690400|NCT02520544|DEVICE|Trident/Tritanium cup|Total hip replacement
48161543|NCT04614285|PROCEDURE|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
48368293|NCT03161184|BEHAVIORAL|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
48690401|NCT04094259|BEHAVIORAL|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
48690402|NCT02333825|PROCEDURE|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
48690403|NCT02333825|OTHER|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
48690404|NCT02031991|BIOLOGICAL|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
48690405|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
48690406|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
48690407|NCT02952313|DEVICE|Nasal Implant|
48690408|NCT03934580|OTHER|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
48690409|NCT03934580|OTHER|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
48690410|NCT04930861|DRUG|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
48690411|NCT04930861|DIAGNOSTIC_TEST|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
48690412|NCT04930861|DIAGNOSTIC_TEST|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
48690413|NCT04930861|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
48690414|NCT04930861|DIAGNOSTIC_TEST|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
48690415|NCT04930861|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram with report.
48690416|NCT04930861|DIAGNOSTIC_TEST|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
48690417|NCT04930861|DIAGNOSTIC_TEST|NEWS-2 score|assessment of the participant by the NEWS-2 score.
48690418|NCT04930861|DIAGNOSTIC_TEST|WHO score|assessment of the participant by the score of the World Health Organization.
48690419|NCT03176862|DIAGNOSTIC_TEST|cardiac magnetic resonance scan|An MRI scan of the heart
48690420|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
48690421|NCT03176862|DIAGNOSTIC_TEST|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
48690422|NCT03176862|DIAGNOSTIC_TEST|12-lead ECG|Can be done immediately by the bedside.
48690423|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
48513741|NCT00000139|BEHAVIORAL|Stress|
48513742|NCT00000139|DRUG|Acyclovir|
48690424|NCT03176862|BIOLOGICAL|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
48690425|NCT05312749|OTHER|progressive relaxation exercises|progressive relaxation exercises
48690426|NCT02977429|OTHER|standardized fluid therapy|The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.
48690427|NCT02977429|OTHER|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
48690428|NCT00540657|DRUG|CCX282-B|250mg capsule, twice daily, 13 weeks
48690429|NCT00540657|DRUG|Placebo|Placebo capsule, twice daily, 13 weeks
48690430|NCT01132950|BEHAVIORAL|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
48690431|NCT01132950|OTHER|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
48690432|NCT00956137|PROCEDURE|Ultrasound guidance|ultrasound imaging
48690433|NCT00956137|PROCEDURE|Manual palpation|Manual Palpation of vertebra
48690434|NCT00191945|DRUG|Atomoxetine Hydrochloride|
48690435|NCT00191945|DRUG|placebo|
48161544|NCT05347602|DIETARY_SUPPLEMENT|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
48161545|NCT05347602|DIETARY_SUPPLEMENT|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
48161546|NCT02449837|OTHER|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up visit to UNC (roughly \~1 month interval), up until 24 months after completion of radiation.
48161547|NCT01370564|DRUG|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
48161548|NCT01242033|DIETARY_SUPPLEMENT|red raspberries|single serving of one, two or four cups red raspberries
48368294|NCT03161184|BEHAVIORAL|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
48690436|NCT00758368|DRUG|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
48690437|NCT00163241|DRUG|celecoxib|
48690438|NCT05587179|OTHER|recovery position|A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
48690439|NCT03146559|DEVICE|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
48690440|NCT03146559|DEVICE|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
48690441|NCT05757518|OTHER|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
48690442|NCT02321917|DEVICE|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
48690443|NCT03562975|DRUG|Ocrelizumab|Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds
48690444|NCT02019615|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
48690445|NCT04209634|DRUG|Pozelimab|Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
48690446|NCT03394651|DRUG|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
48690447|NCT03394651|PROCEDURE|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
48513743|NCT02881697|OTHER|Adipose tissue sampling|
48690448|NCT03614741|DRUG|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
48690449|NCT03614741|DRUG|Tinzaparin bolus|4500 IU bolus of Tinzaparin
48690450|NCT06091943|DRUG|Tislelizumab IV|Planned doses will be administered intravenously.
48690451|NCT06091943|DRUG|Tislelizumab SC|Planned doses will be administered via subcutaneous injection.
48690452|NCT06091943|DRUG|Histology-Based Chemotherapy Doublet|"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
48690453|NCT06404021|OTHER|interventional cardiology procedures with proctoring system|Interventional procedures are performed by utilizing a monitoring platform that provides real-time support without engineer in the electrophysiology laboratory
48690454|NCT06404021|OTHER|interventional cardiology procedures with engineer in the electrophysiology laboratory|Biomedical engineers supervise the performance of interventional cardiology procedures in the electrophysiology laboratory.
48690455|NCT04453358|DEVICE|InCourage-Connect|This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
48690456|NCT04453358|DEVICE|InCourage|This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
48690457|NCT01545869|PROCEDURE|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
48690458|NCT03026114|OTHER|No intervention is planned in our study.|No intervention is planned in our study.
48161549|NCT01242033|DIETARY_SUPPLEMENT|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
48161550|NCT04245878|OTHER|gastric ultrasound|gastric ultrasound for measurement of the antral area
48161551|NCT02103816|DEVICE|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
48161552|NCT01284634|DRUG|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
48690459|NCT01447498|OTHER|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; \>=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___"
48690460|NCT04589234|DRUG|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
48690461|NCT04589234|DRUG|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
48690462|NCT04589234|DRUG|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
48690463|NCT04998916|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
48690464|NCT04998916|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
48161553|NCT01284634|DRUG|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
48161554|NCT01284634|DRUG|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
48161555|NCT01284634|DRUG|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
48161556|NCT02791126|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
48161557|NCT02791126|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
48690465|NCT03910790|DEVICE|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
48690466|NCT00333411|DRUG|BIRT 2584 XX|
48690467|NCT00333411|DRUG|Placebo|
48690468|NCT02350335|DRUG|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
48161558|NCT00456183|BIOLOGICAL|MVA 85A|
48161559|NCT04713878|OTHER|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
48161560|NCT01661244|DRUG|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
48368295|NCT03339622|COMBINATION_PRODUCT|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
48368296|NCT03339622|COMBINATION_PRODUCT|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
48161561|NCT01661244|DRUG|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
48161562|NCT01661244|DRUG|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
48161563|NCT01661244|DRUG|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
48513744|NCT02026687|DRUG|Epidural|
48513745|NCT02026687|DRUG|Intrathecal|
48690469|NCT01159678|BEHAVIORAL|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~1. Important of sexuality to quality of life. \& Definitions of sexual desire and arousal.~2. Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~3. Sexual beliefs.~4. Mindfulness.~5. Genital anatomy and physiology.~6. Body Image.~7. Relationship satisfaction and communication.~8. Body-oriented mindfulness exercises (focusing and self-observation).~9. Using Thought records.~10. Mindfulness and the thought stream.~11. Sexual aids to boost arousal.~12. Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
48690470|NCT02919891|OTHER|Questionnaire|Questionnaires
48690471|NCT06407128|BIOLOGICAL|Collection of biological samples|Collection of biological samples (blood sample + valve tissue sample + saliva, periodontal and feces sample)
48690472|NCT06005428|DRUG|CRD-4730|Oral CRD-4730 in capsule form
48690473|NCT06005428|DRUG|Placebo|Placebo to match CRD-4730 in capsule form
48690474|NCT03636672|PROCEDURE|perturbation training|perturbation training during stationary bicycle riding
48690475|NCT04651764|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
48690476|NCT03654924|DEVICE|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
48690477|NCT03879616|BEHAVIORAL|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
48690478|NCT01709617|DIETARY_SUPPLEMENT|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
48690479|NCT05772689|OTHER|Usual Care|Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
48690480|NCT05772689|OTHER|Caring While Black|Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
48690481|NCT03504293|PROCEDURE|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
48690482|NCT06631469|BEHAVIORAL|Personalised behavioural sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support (based on previous personalised nutrition trials and usual care in dietetic practice), plus the addition of receiving personalised behavioural support and strategies.
48161564|NCT05106816|OTHER|skin surface vibration|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
48161565|NCT05106816|OTHER|light skin surface vibration- SHAM|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
48368297|NCT04678089|DRUG|Bortezomib|Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
48690483|NCT06631469|BEHAVIORAL|Personalised sustainable and healthy dietary recommendations|Personalised dietary plan and standardised behavioural support and strategies (based on previous personalised nutrition trials and usual care in dietetic practice).
48690484|NCT00601692|DRUG|cisplatin|Given IV
48690485|NCT00601692|DRUG|docetaxel|Given IV
48161566|NCT01971424|DIETARY_SUPPLEMENT|Mg oxide|
48161567|NCT01971424|OTHER|healthy diet|
48161568|NCT04950049|DRUG|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
48513746|NCT02984371|PROCEDURE|Coronary artery bypass grafting|
48690486|NCT00601692|DRUG|irinotecan hydrochloride|Given IV
48690487|NCT00601692|RADIATION|radiation therapy|Given 5 days a week for 3 weeks
48690488|NCT00269087|DRUG|fluticasone propionate/salmeterol combination DISKUS|
48690489|NCT03962894|DRUG|Prednisolone|During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
48161569|NCT04950049|OTHER|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
48161570|NCT04950049|OTHER|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
48161571|NCT04950049|OTHER|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
48690490|NCT05135559|DRUG|Concizumab|"Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.~Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose."
48690491|NCT05503095|GENETIC|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
48161572|NCT06646432|PROCEDURE|Tunnel with connective tissue graft and injectable platelet rich fibrin|Tunnel with connective tissue graft and injectable platelet rich fibrin
48690492|NCT03267979|OTHER|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
48690493|NCT03267979|OTHER|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
48690494|NCT03540706|DIAGNOSTIC_TEST|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
48690495|NCT04923737|DRUG|Dexmedetomidine|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
48690496|NCT04923737|DRUG|0.9% sodium chloride|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
48690497|NCT05273372|OTHER|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
48690498|NCT05273372|OTHER|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
48690499|NCT06403982|OTHER|Continuation of oxytocin after ELA|"The use of oxytocin will be continued after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor.~Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery."
48690500|NCT06403982|OTHER|Discontinuation of oxytocin after ELA|The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor. If no progress is detected due to the secondary weakening of uterus contractile function, the oxytocin will be reintroduced. Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery.
48690501|NCT04941183|DRUG|NTR-441|NTR-441
48690502|NCT04941183|DRUG|Placebo|Placebo
48690503|NCT05714449|DEVICE|eye patch|standard amblyopia treatment
48690504|NCT05714449|DEVICE|After-image and MIT trainer|Common clinical training for foveation
48690505|NCT05466084|PROCEDURE|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
48004643|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
48161573|NCT06646432|PROCEDURE|Tunnel with connective tissue graft only|Tunnel technique with connective tossue graft only without injectable platelet rich fibrin
48161574|NCT01443546|DRUG|HCG|hCG Trigger
48161575|NCT01443546|DRUG|Lupron Trigger|leuprolide acetate 2 mg SQ
48161576|NCT01443546|DRUG|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
48161577|NCT02490878|DRUG|bevacizumab|IV
48161578|NCT02490878|DRUG|corticosteroids|IV
48690506|NCT05466084|PROCEDURE|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
48161579|NCT02490878|OTHER|placebo|IV
48161580|NCT03194789|DEVICE|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
48513747|NCT02984371|PROCEDURE|Epicardial ganglionated plexi ablation|
48690507|NCT06291012|DRUG|Quick response: Amoxicillin for 3 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
48161581|NCT03194789|OTHER|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
48161582|NCT06453174|OTHER|Adherence to the first prescribed antipsychotic medication|We shall compare adherence to the first prescribed antipsychotic medication and pragmatic clinical and functional outcomes between two cohorts of patients with first-episode psychosis. One cohort will be comprised of patients treated before the implementation of an early intervention in psychosis model of Personalised Precision Psychiatry including pharmacogenetics, and the other of patients treated under this new model. Also, we shall compare the pharmacogenetic profiles and possible phenocopies (variations of phenotypes produced environmentally, e.g., due to polypharmacy, rather than genetically) between these first episode psychosis patients and a national cohort of patients with longer-term psychotic disorders or with other mental health conditions, to evaluate potential implications for clinical management at different stages of a psychotic illness, and across mental disorders.
48161583|NCT05829278|PROCEDURE|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
48690508|NCT06291012|DRUG|Delayed response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days"
48161584|NCT04542200|BIOLOGICAL|Antibody testing|The antibody results include understanding modifications from environments at work and the community.
48161585|NCT04263558|BEHAVIORAL|Emotion child|The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
48161586|NCT06358339|OTHER|TEEM|The TEEM app will provide four types of gamified intervention elements as Routine Tracker, Mind Care, Social Connectivity, and Achievement \& Rewards which providing services including brief contact intervention, mCBT, health education, venting space, mood sharing, etc. Only enrolled participants have access to log in and use the app.
48161587|NCT04685759|OTHER|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
48004644|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
48690509|NCT06291012|DRUG|Quick response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
48690510|NCT06291012|DRUG|Delayed response: Amoxicillin for 7 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days"
48004645|NCT00582933|DRUG|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
48004646|NCT04548674|OTHER|Whiteness HP 35%|Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
48004647|NCT04548674|DEVICE|Whiteness HP 35% + LASER|A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.
48690511|NCT05965869|OTHER|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
48161588|NCT04685759|OTHER|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
48004648|NCT04548674|OTHER|Whiteness HP 35% + CPP|Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.
48161589|NCT00019019|DRUG|carboxyamidotriazole|
48161590|NCT00019019|DRUG|paclitaxel|
48161591|NCT01093222|DRUG|Erlotinib Hydrochloride|Given PO
48690512|NCT03601039|DEVICE|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
48690513|NCT04431843|DIETARY_SUPPLEMENT|Spirulina maxima extract|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
48690514|NCT04431843|DIETARY_SUPPLEMENT|Placebo|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
48690515|NCT01301053|OTHER|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
48690516|NCT01301053|OTHER|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl)."
48690517|NCT01023685|BIOLOGICAL|CAD106|
48690518|NCT01707680|OTHER|SOC|Patient are given standard of care
48690519|NCT04166591|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
48690520|NCT04166591|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
48690521|NCT00998452|BEHAVIORAL|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
48690522|NCT04154293|DRUG|Isotretinoin|Topical Isotretinoin ointment
48690523|NCT04154293|OTHER|Vehicle|Topical Vehicle Ointment
48690524|NCT03969290|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
48690525|NCT03969290|DEVICE|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
48690526|NCT01604525|BEHAVIORAL|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
48690527|NCT01604525|BEHAVIORAL|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
48690528|NCT01604525|OTHER|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
48161592|NCT01093222|DRUG|Sorafenib Tosylate|Given PO
48161593|NCT04686370|OTHER|laser treated implant surface|Better marginal bone stability is expected for this type
48161594|NCT03121599|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
48161595|NCT06170983|DRUG|Azithromycin|500 mg once daily for 3 days
48161596|NCT06170983|DIAGNOSTIC_TEST|Biopsy|Skin punch biopsy
48161597|NCT06170983|OTHER|Skin inflammation model|LPS- or imiquimod induced skin inflammation
48690529|NCT02819843|DRUG|TALIMOGENE LAHERPAREPVEC (TVEC)|
48690530|NCT02819843|RADIATION|Hypofractionated Radiotherapy|
48690531|NCT01918891|BEHAVIORAL|Nurse Practitioner Only|
48690532|NCT01918891|BEHAVIORAL|Nurse Practitioner + Health Coach|
48690533|NCT05415254|DRUG|Calcitriol|Calcitriol supplementation orally
48004649|NCT04548674|OTHER|Whiteness HP 35% + NANO|A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
48161598|NCT01269190|PROCEDURE|High-Resolution Microendoscopy|Undergo evaluation of oral lesions using a high-resolution microendoscope
48161599|NCT01269190|PROCEDURE|Multispectral Imaging|Undergo evaluation of oral cavity using a widefield multispectral imaging
48161600|NCT01269190|DRUG|Proflavine|Proflavine) used to stain the mouth tissue after initial imaging.
48161601|NCT02278133|DRUG|WNT974|
48161602|NCT02278133|DRUG|LGX818|
48161603|NCT02278133|BIOLOGICAL|Cetuximab|
48161604|NCT04283396|COMBINATION_PRODUCT|systemic treatment|Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin
48161605|NCT02194777|DRUG|BIBN 4096 BS - in single rising doses|
48161606|NCT02194777|DRUG|Placebo|
48690534|NCT02471118|DRUG|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
48690535|NCT02471118|DRUG|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
48690536|NCT01681186|DRUG|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
48690537|NCT01681186|DRUG|LY2940680 Tablet (Test)|Administered orally as a tablet
48690538|NCT01681186|DRUG|Lansoprazole|Administered orally as a capsule
48690539|NCT01681186|DRUG|Placebo Capsule(s)|Administered orally as a capsule(s)
48161607|NCT05036499|BEHAVIORAL|Personalized Feedback Intervention|Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
48161608|NCT03170947|DEVICE|Custom Insoles|"Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.~Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned."
48690540|NCT04811755|BEHAVIORAL|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
48690541|NCT05421663|BIOLOGICAL|JNJ-90014496|JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
48690542|NCT04973202|OTHER|Stay for alcohol detoxification|Stay for alcohol detoxification : routine care.
48004650|NCT01572038|DRUG|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
48004651|NCT01572038|DRUG|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
48004652|NCT01572038|DRUG|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
48004653|NCT01572038|DRUG|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
48004654|NCT01572038|DRUG|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
48004655|NCT06391866|OTHER|extracorporeal circulation|extracorporeal circulation during cardiosurgical operation
48004656|NCT03063996|PROCEDURE|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
48004657|NCT03063996|PROCEDURE|Peripheral IJ access procedure|standard of care guided IV access into IJ
48004658|NCT03854916|OTHER|Caminemos Juntas App|A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
48004659|NCT03854916|OTHER|World Walking App|A mobile app that encourages users to walk.
48004660|NCT01660893|DRUG|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
48004661|NCT01660893|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
48004662|NCT01660893|DRUG|Placebo|3 unilateral intranasal sprays per dose
48004663|NCT00763074|BEHAVIORAL|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30\~35kcal/day"
48004664|NCT00763074|BEHAVIORAL|Diet restriction|"Education for diet and exercise every 2 weeks~----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
48004665|NCT00763074|BEHAVIORAL|Exercise|"Education for diet and exercise every 2 weeks~----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
48004666|NCT00763074|BEHAVIORAL|Diet and exercise|"Education for diet and exercise every 2 weeks~----------- Exercise education like as exercise group and diet education like as diet group"
48004667|NCT05492396|DEVICE|Standard gluteus medius repair with Tapestry Biointegrative implant|Patients will undergo standard gluteus medius repair utilizing augmentation.
48004668|NCT02346240|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use"
48004669|NCT02346240|BIOLOGICAL|Etanercept|"* Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use"
48690543|NCT03085459|BEHAVIORAL|work Time|nurse got qualification certificate and the working time
48690544|NCT00420082|DRUG|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
48690545|NCT00420082|DRUG|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
48690546|NCT00420082|DRUG|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
48690547|NCT00420082|DRUG|Placebo|Encapsulated Placebo tablets Q.D.
48161609|NCT03170947|DEVICE|Standardized insoles|Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
48690548|NCT06433154|PROCEDURE|Arthroscopic surgery|Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
48690549|NCT00162591|DRUG|remifentanyl|
48690550|NCT01162954|DRUG|DA-6034|
48690551|NCT01162954|DRUG|Placebo|
48161610|NCT01694199|DEVICE|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
48161611|NCT01694199|DEVICE|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
48690552|NCT02364245|DEVICE|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
48690553|NCT02364245|OTHER|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
48690554|NCT02364245|OTHER|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
48161612|NCT00789932|BEHAVIORAL|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
48004670|NCT02346240|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
48004671|NCT00094653|DRUG|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
48004672|NCT00094653|BIOLOGICAL|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
48161613|NCT00789932|BEHAVIORAL|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
48161614|NCT03787719|OTHER|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment
48161615|NCT06632769|DEVICE|No intervention|No intervention
48161616|NCT03887871|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration after meal
48161617|NCT03887871|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
48161618|NCT06472011|OTHER|lean steak and potatoes|Participants will be fed \~400 kcal lean steak and potatoes on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
48690555|NCT05033587|DRUG|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
48690556|NCT05033587|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
48690557|NCT05033587|RADIATION|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
48004673|NCT00829322|DRUG|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
48004674|NCT00829322|DRUG|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
48004675|NCT03821558|OTHER|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
48161619|NCT06472011|OTHER|lentil and sweet potato chili|Participants will be fed \~400 kcal lentil and sweet potato chili on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
48161620|NCT06472011|OTHER|macaroni and cheese|Participants will be fed \~400 kcal macaroni and cheese on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
48161621|NCT06472011|OTHER|fish tacos|Participants will be fed \~400 kcal fish tacos on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
48513748|NCT02984371|PROCEDURE|implantable loop recorder|
48690558|NCT01473199|DEVICE|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
48690559|NCT05966090|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
48690560|NCT05966090|BIOLOGICAL|HZ/su vaccine|Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
48690561|NCT06316856|DRUG|Autologous CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.
48690562|NCT06316856|DRUG|Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.
48690563|NCT06316856|DRUG|Newly matched donor-derived CD5 CAR T-cells|Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.
48690564|NCT06084182|OTHER|Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment|6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
48690565|NCT02649959|DRUG|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
48690566|NCT01876303|OTHER|laboratory biomarker analysis|Correlative studies
48690567|NCT01876303|OTHER|questionnaire administration|Ancillary studies
48690568|NCT05264987|OTHER|intensive care follow-up|The need for the mechanical ventilator, the length of stay in the intensive care unit, and outcomes of mothers were recorded. Deceased patients were evaluated in detail.
48690569|NCT03982784|PROCEDURE|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
48161622|NCT06472011|OTHER|chicken and pea fried rice|Participants will be fed \~400 kcal chicken and pea fried rice on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
48690570|NCT03982784|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
48690571|NCT03370419|BEHAVIORAL|Treatment|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
48690572|NCT03370419|BEHAVIORAL|Usual care|Usual care
48513749|NCT01952314|DRUG|Naftopidil 75mg|naftopidil 75mg 1T qd hs
48690573|NCT05965583|DRUG|BI 1815368|BI 1815368
48690574|NCT05965583|DRUG|Itraconazole|Itraconazole
48690575|NCT06555016|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
48690576|NCT06555016|BEHAVIORAL|Walking|Overground walking.
48690577|NCT05533294|DRUG|ARO-RAGE Injection|ARO-RAGE injection for sc administration
48690578|NCT05533294|DRUG|Placebo|normal saline (0.9% NaCl) by sc injection
48690579|NCT02403934|DEVICE|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
48690580|NCT05626322|DRUG|Maplirpacept|Intravenous infusion
48690581|NCT05626322|DRUG|Tafasitamab|Intravenous infusion
48690582|NCT05626322|DRUG|Lenalidomide|Oral (by mouth)
48690583|NCT03932318|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
48161623|NCT06472011|OTHER|pita and hummus|Participants will be fed \~400 kcal pita and hummus on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
48513750|NCT01952314|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
48690584|NCT03932318|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
48513751|NCT01952314|DRUG|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
48513752|NCT00426439|DRUG|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
48690585|NCT03932318|DRUG|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
48690586|NCT01032434|DRUG|sertraline|sertraline: 50-200mg/day
48368298|NCT04621825|DEVICE|ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
48690587|NCT05719857|PROCEDURE|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
48368299|NCT02986321|DRUG|CHF6001|Dose response: Test one of 4 different doses of CHF6001
48368300|NCT02986321|DRUG|Budesonide|active control
48368301|NCT02986321|DRUG|Placebo|placebo control
48368302|NCT05393986|DRUG|CT048 Autologous Injection (CT048)|up to 3 times CT048 Autologous Injection infusion
48368303|NCT01826305|PROCEDURE|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
48161624|NCT06472011|OTHER|creamy pork pasta|Participants will be fed \~400 kcal creamy pork pasta on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
48690588|NCT05719857|PROCEDURE|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
48690589|NCT05719857|DIAGNOSTIC_TEST|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
48161625|NCT00448786|DRUG|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
48161626|NCT00448786|DRUG|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
48368304|NCT01826305|PROCEDURE|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
48368305|NCT04542863|OTHER|18F-DX600 PET/CT|DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
48690590|NCT02279368|BEHAVIORAL|Family Counselling and safeguarding|
48004676|NCT02718638|OTHER|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
48004677|NCT03789552|DRUG|T89 capsule|T89 capsules (75mg)
48004678|NCT03789552|DRUG|Placebo capsule|Placebo capsules (0mg)
48004679|NCT02821962|BEHAVIORAL|Sedentary prompts from a VTAP device|
48004680|NCT01514695|DRUG|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
48004681|NCT01514695|DRUG|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
48004682|NCT01514695|OTHER|Placebo|One dose of saline (2ml)
48004683|NCT04891848|OTHER|inflammation|inflammatory values in complete blood count (CBC)
48004684|NCT01428193|DRUG|Flutamide|Subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day.
48004685|NCT01428193|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
48004686|NCT01428193|DRUG|estrace|0.5-1 mg once a day for seven days
48161627|NCT00448786|DRUG|AMG 706|AMG 706 125 mg daily continuously (Arm A)
48161628|NCT04513535|OTHER|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
48185215|NCT04589299|BIOLOGICAL|Immunoglobulin|Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
48368306|NCT05249504|OTHER|VIVIFRAIL|"VIVIFRAIL is a set of physical activity programs (designed according to several elderly functional level profiles) aimed to prevent motor disability and improve quality of life. It works endurance, flexibility, balance and strength.~https://web.archive.org/web/20210907041944/https://vivifrail.com/"
48690591|NCT04749888|BEHAVIORAL|Targeted nurse-led home visiting|The KECHI encompasses 25-29 home visits, group activities, and community service linkage by social workers from the prenatal period until the child reaches the age of 2 years; as such, it is a complex intervention involving various domains to address a wide range of outcomes. Pregnant women with two or more risk factors who are deemed to have difficulties in raising children are eligible for the targeted multiple nurse home visits. Each home visit is implemented based on families' needs, and individualized interventions are provided to improve parenting and the home environment in order to promote the child's health and development and maternal health. The program includes educational materials for parents, such as a booklet covering issues on prenatal care, child development, postnatal child care, parent-child attachment, play, communication, safety, and goal-setting.
48690592|NCT02679937|BEHAVIORAL|Fit4Duty|Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
48690593|NCT02679937|OTHER|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
48690594|NCT05777785|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
48690595|NCT03511014|DEVICE|Microcurrent|Micrucurrent will be apply
48690596|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|200 mg dose daily for 12 weeks.
48690597|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|400 mg dose daily for 12 weeks.
48004687|NCT01790334|OTHER|Ultrasonography|
48004688|NCT02456324|DEVICE|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
48004689|NCT02456324|DEVICE|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
48004690|NCT03925727|DRUG|Tavilermide ophthalmic solution|BID topical dosing
48004691|NCT03925727|OTHER|Placebo|BID topical dosing
48004692|NCT00855309|DRUG|acyclovir sodium|Given IV
48185216|NCT05688163|OTHER|programme based on everyday cognition|Will carry out a programme based on everyday cognition, As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above. Each day one of these tasks will be worked on.
48185217|NCT05688163|OTHER|traditional cognitive stimulation|Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
48004693|NCT05934292|DRUG|Enlicitide Decanoate|Single oral dose
48004694|NCT04492891|DRUG|Cyclosporine|2.5 mg/kg PO BID 7 days
48690598|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|600 mg dose daily for 12 weeks.
48690599|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|800 mg dose daily for 12 weeks.
48004695|NCT04492891|OTHER|Standard of Care Treatment|Standard of Care Treatment, N= 25 Patients, 7 days
48161629|NCT04513535|OTHER|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
48161630|NCT04513535|OTHER|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
48161631|NCT04513535|OTHER|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
48161632|NCT00837096|DEVICE|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
48161633|NCT00837096|DEVICE|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
48161634|NCT04310800|PROCEDURE|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
48161635|NCT00965302|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
48161636|NCT00965302|BEHAVIORAL|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
48161637|NCT01066897|DRUG|Pramipexole|Patients will received increasing dose of pramipexole
48690600|NCT03377816|BEHAVIORAL|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
48004696|NCT04623580|DEVICE|Surgical inguinal or femoral hernia repair|Surgical inguinal or femoral hernia repair (primary or mesh)
48004697|NCT06375005|DRUG|Telitacicept|Telitacicept is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. Telitacicept will be subcutaneously injected at a dose of 160mg per week, lasting for 48 weeks.
48161638|NCT06258447|DEVICE|Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system|the ABM MNC is obtained from the study patient via bone marrow aspiration in the hip and processed and delivered using the CardiAMP cell therapy system during the cardiac catheterization.
48185218|NCT00508209|DRUG|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
48690601|NCT03377816|BEHAVIORAL|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
48690602|NCT04829526|OTHER|data collection|Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records
48690603|NCT02514811|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
48690604|NCT01821066|DRUG|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
48690605|NCT01821066|DRUG|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
48690606|NCT01821066|DRUG|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
48690607|NCT01821066|DRUG|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
48004698|NCT06375005|DRUG|Mycophenolate Mofetil|All patients will receive background therapy with Mycophenolate Mofetil (MMF), administered orally at a dose of 0.5g twice daily for 48 weeks.
48004699|NCT02189421|DEVICE|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
48004700|NCT00012051|BIOLOGICAL|filgrastim|
48004701|NCT00012051|BIOLOGICAL|rituximab|
48161639|NCT03047278|PROCEDURE|Serial Blood Samples|Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
48161640|NCT03047278|PROCEDURE|Serial Urine Samples|Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
48161641|NCT03047278|DRUG|Gabapentin 300 mg|All patients were treated with oral single dose of gabapentin 300 mg.
48690608|NCT02102685|PROCEDURE|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
48004702|NCT00012051|DRUG|carmustine|
48690609|NCT02102685|PROCEDURE|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
48690610|NCT00952861|DRUG|Doxycycline|200 mg QD in 5 days
48690611|NCT00952861|DRUG|Placebo (matching)|Placebo QD i 5 days
48004703|NCT00012051|DRUG|cisplatin|
48161642|NCT03047278|DRUG|Cetirizine Hydrochloride 10 mg|Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
48368307|NCT05249504|OTHER|Nutrition|Sessions to learn about personal nutrition habits, offer nutritional advice, and acquire skills to incorporate simple healthy nutrition guidelines into everyday life. A visit to a supermarket to make it easier to read and understand the basic information on nutrition labels.
48690612|NCT05426967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active rTMS
48004704|NCT00012051|DRUG|cytarabine|
48004705|NCT00012051|DRUG|dexamethasone|
48004706|NCT00012051|DRUG|etoposide|
48004707|NCT00012051|DRUG|ifosfamide|
48690613|NCT05426967|DEVICE|Sham rTMS|Sham comparator to active rTMS
48690614|NCT04571424|DRUG|BIIB133 (Dapirolizumab pegol)|Administered as specified in the treatment arm
48004708|NCT00012051|DRUG|melphalan|
48004709|NCT00012051|DRUG|methotrexate|
48004710|NCT00012051|PROCEDURE|bone marrow ablation with stem cell support|
48004711|NCT00012051|PROCEDURE|peripheral blood stem cell transplantation|
48004712|NCT00012051|RADIATION|radiation therapy|
48004713|NCT03774940|DIAGNOSTIC_TEST|peripheric blood count|preoperative peripheric blood count
48004714|NCT04206293|DEVICE|Juvederm® VOLITE|1 mL of Juvéderm® VOLITE contains hyaluronic acid gel 12.0 milligram (mg), lidocaine hydrochloride 3.0 mg in a phosphate buffer pH 7.2 q.s. 1 mL (or gram).
48004715|NCT04499079|OTHER|Learning Health System|This is a system-level intervention designed to improve collaboration among personnel from the juvenile and behavioral healthcare systems.
48004716|NCT03155009|DRUG|Alectinib|600 mg orally BID with food
48185219|NCT02127125|DRUG|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
48185220|NCT02127125|DRUG|Synbiotic|Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
48690615|NCT04571424|DRUG|Placebo|Administered as specified in the treatment arm
48690616|NCT04025762|DEVICE|Hybrid closed-loop system (CamAPS FX)|Hybrid closed-loop system
48690617|NCT04025762|DEVICE|Sensor augmented pump therapy|Sensor augmented pump therapy
48004717|NCT02613533|OTHER|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
48004718|NCT02188238|OTHER|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
48004719|NCT03145441|DEVICE|CytoSorb®|CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
48004720|NCT02547662|DRUG|Dexamethasone|Given PO
48004721|NCT02547662|DRUG|Ixazomib Citrate|Given PO
48690618|NCT05887713|DEVICE|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
48004722|NCT02547662|OTHER|Laboratory Biomarker Analysis|Correlative studies
48161643|NCT05937971|OTHER|plantar sensitivity training|"Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)"
48690619|NCT05887713|DEVICE|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
48690620|NCT03565250|OTHER|self understanding interview|semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
48690621|NCT01625416|BEHAVIORAL|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
48185221|NCT02127125|DRUG|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
48185222|NCT02812095|PROCEDURE|Refeeding|when amount of feeding reach to 120mL/kg a day,
48690622|NCT02061072|OTHER|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
48513753|NCT00426439|DRUG|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
48185223|NCT02480699|BIOLOGICAL|Recurring blood sample|
48368308|NCT05249504|BEHAVIORAL|Psychology|Relaxation techniques to manage mood, a photo-elicitation dynamic to address loneliness, and a dynamic to collectively develop a map of health assets in the neighborhood or territory to obtain information on community resources. Finally, a group visit is planned to a community facility previously agreed upon by the participants.
48368309|NCT05249504|BEHAVIORAL|Personal autonomy|Review practical cases on personal autonomy, the proper use of medications, and discover basic cognitive stimulation strategies.
48513754|NCT00524966|PROCEDURE|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
48690623|NCT00002134|DRUG|Ganciclovir|
48690624|NCT01168830|DEVICE|AMS-3.0|
48690625|NCT02763813|DEVICE|Herbst (propulsion type oral appliance)|Oral appliance
48368310|NCT05249504|OTHER|Community resources|Learn about community resources
48368311|NCT05249504|OTHER|Standard recommendations|Usual advice provided at primary care office accompanied to booklets about healthy lifestyles
48004723|NCT02547662|DRUG|Pomalidomide|Given PO
48004724|NCT01197469|DRUG|Tadalafil|Tadalafil 10mg once daily for 3 months
48368312|NCT05132751|DEVICE|Machine Learning Ventilator Decision System|Artificial intelligence ventilator system for personalized mechanical ventilation
48368313|NCT01110603|DRUG|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
48368314|NCT01110603|DRUG|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
48161644|NCT05937971|OTHER|aerobic exercise training|Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
48161645|NCT00073788|PROCEDURE|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
48161646|NCT01313299|BIOLOGICAL|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
48161647|NCT01313299|BIOLOGICAL|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
48161648|NCT01313299|DRUG|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
48004725|NCT01197469|DRUG|Placebo|
48004726|NCT01606046|DEVICE|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
48004727|NCT01606046|DRUG|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
48004728|NCT00992810|PROCEDURE|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
48004729|NCT00992810|PROCEDURE|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
48004730|NCT06060392|DRUG|Semaglutide Pill|Patient will receive oral semaglutide
48004731|NCT02582853|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
48004732|NCT02582853|PROCEDURE|Blood Sample|Blood sample
48161649|NCT06478056|PROCEDURE|pancreatectomy|patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
48161650|NCT00228813|DRUG|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
48161651|NCT05888558|DEVICE|Body fluid diagnosis|miRNAs derived from exosomes in the serum
48161652|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
48161653|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
48690626|NCT02763813|DEVICE|Retention type appliance (ORM)|
48690627|NCT05358262|DEVICE|Airvo|Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM
48368315|NCT01110603|DRUG|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
48513755|NCT03152734|PROCEDURE|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
48004733|NCT00578942|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
48004734|NCT06182358|DRUG|Lotilaner ophthalmic solution, 0.25%|XDEMVY (lotilaner ophthalmic solution) 0.25%, administered topically twice a day for approximately 43 days
48004735|NCT06182358|DRUG|Vehicle control|Vehicle of XDEMVY administered topically twice a day for approximately 43 days
48004736|NCT00869739|BEHAVIORAL|telephone-based intervention|
48004737|NCT00869739|OTHER|educational intervention|
48513756|NCT03404739|DRUG|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
48004738|NCT00869739|OTHER|partner-assisted coping skills training|
48004739|NCT00869739|OTHER|questionnaire administration|
48004740|NCT00869739|PROCEDURE|psychosocial assessment and care|
48004741|NCT00869739|PROCEDURE|quality-of-life assessment|
48004742|NCT02377089|DEVICE|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
48004743|NCT02377089|DEVICE|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
48004744|NCT05961566|DEVICE|Use of collagen matrix after subepithelial connective tissue graft harvest|A collagen matrix is placed under the overlying flap after the subepithelial connective tissue graft harvesting.
48161654|NCT02367664|BIOLOGICAL|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
48161655|NCT00447629|DRUG|PPM-204|
48161656|NCT05463445|OTHER|Only observation|No intervention is needed.
48161657|NCT05657275|DIAGNOSTIC_TEST|CRP dosage|multimodal algorithm
48161658|NCT05657275|DIAGNOSTIC_TEST|multiplex PCR|multimodal algorithm
48161659|NCT05657275|DIAGNOSTIC_TEST|chest scan without injection|multimodal algorithm
48161660|NCT06554288|DRUG|Trihexyphenidyl|6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
48004745|NCT00189735|DRUG|FK778|
48161661|NCT04143737|BEHAVIORAL|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
48161662|NCT03777553|BEHAVIORAL|Narrative Exposure Therapy for Justice-Involved Veterans|Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
48161663|NCT06207084|BEHAVIORAL|asynchronous content only|Receives asynchronous exercise content and no live training
48161664|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and no live training|Receives asynchronous content, health coaching and no live training.
48161665|NCT06207084|BEHAVIORAL|asynchronous content only and 1 on 1 live training|receives asynchronous content and live 1 on 1 training
48161666|NCT06207084|BEHAVIORAL|asynchronous content and health coaching and 1 on 1 training|receives asynchronous content, health coaching, and live training
48161667|NCT06207084|BEHAVIORAL|asynchronous content and group training|receives asynchronous content and live group training
48161668|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and group training|receives asynchronous content, health coaching, and live group training
48161669|NCT03127618|DRUG|Lorlatinib|
48161670|NCT01949649|BEHAVIORAL|Peer-Led Group Intervention|
48161671|NCT01949649|BEHAVIORAL|Internet-Based Intervention|
48161672|NCT01949649|BEHAVIORAL|Clinician-Led Group Intervention|
48161673|NCT01949649|BEHAVIORAL|Education Video|
48161674|NCT00957671|DRUG|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
48161675|NCT00016237|BIOLOGICAL|tucotuzumab celmoleukin|
48161676|NCT04283058|DRUG|Ketamine|d. Ketamine 0.5mg/kg\* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg\* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
48161677|NCT05928689|DRUG|Propranolol Hydrochloride tablet|Single dose of 40 mg propranolol tablet
48161678|NCT05928689|BEHAVIORAL|Reminder|Reactivation of misophonia trigger memory
48161679|NCT05928689|BEHAVIORAL|Counterconditioning|Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.
48161680|NCT05928689|DRUG|Placebo|Matching placebo tablet
48161681|NCT02841085|GENETIC|Genetic sample|Blood sample or saliva collection
48161682|NCT02884921|DRUG|Paracetamol|Paracetamol
48004746|NCT04425330|OTHER|physiotherapy exercises|The evidence on the effectiveness of physical therapy in children with myelomeningocele is limited. The International Classification of Functionality, Disability and Health for Children and Youth is a useful tool to assist therapists in analyzing problems about the focus of the intervention. The evidence in physical therapy practice for individuals of all ages with neurological disorders, focuses on 5 Ps: prevention, prediction, participation, personalized and plasticity. Thus, neurological physiotherapists must perform the care with a focus on preventing the patient's disabilities, predicting the ideal response of an intervention, through measures of results of the movement system. In addition, it is of paramount importance that the goal of rehabilitation is that people with neurological disabilities are fully included and participate in life activities that are important to them and that their care is personalized. All of these measures facilitate the process of positive plasticity.
48161683|NCT02884921|DRUG|Paracetamol|Paracetamol
48161684|NCT02884921|DRUG|Placebo|Placebo
48161685|NCT00871455|DRUG|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
48690628|NCT02342691|DRUG|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
48690629|NCT02342691|DRUG|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
48690630|NCT03818906|PROCEDURE|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
48690631|NCT03818906|PROCEDURE|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
48690632|NCT03818906|PROCEDURE|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
48690633|NCT03818906|PROCEDURE|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
48690634|NCT01892150|OTHER|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
48690635|NCT04743219|PROCEDURE|Selective removal to soft dentin, Biodentine|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
48161686|NCT00102271|DRUG|Oxypurinol|
48161687|NCT00102271|DRUG|Sodium Nitrite|
48161688|NCT04260256|DRUG|[18F]F-AraG|\[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion
48161689|NCT01395706|PROCEDURE|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
48161690|NCT02503488|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
48161691|NCT02503488|BEHAVIORAL|Treatment as Usual|See arm description
48161692|NCT04407533|OTHER|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
48161693|NCT03029234|DRUG|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
48161694|NCT03029234|DRUG|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
48161695|NCT05012397|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
48161696|NCT05399082|DEVICE|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
48161697|NCT05399082|PROCEDURE|Forceps biopsy|Biopsy forceps used to collect tissue
48161698|NCT01766414|DRUG|C1-esterase inhibitor|intravenously
48161699|NCT01766414|DRUG|Endotoxin|intravenously
48161700|NCT05295992|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
48161701|NCT02127645|PROCEDURE|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
48161702|NCT02127645|PROCEDURE|LRT-TEM|TEM following 46 Gy RT
48161703|NCT02127645|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
48004747|NCT04425330|OTHER|PBM|Photobiomodulation occurs from the application of low intensity light such as low intensity laser and light emitting diode (LED). The therapeutic effectiveness of phototherapy is based on the absorption of photons by photoreceptors or chromophores. Studies on the experimental model of spinal cord injury have shown that both wavelengths have the potential to be an effective and non-invasive means of therapy, promoting axonal appearance, increased concentration of glial cells and nerve connections, in addition to functional and sensitive. The findings of a clinical trial involving individuals diagnosed with spinal cord injury demonstrate that PBM exerted positive effects on motor function, especially during isotonic contraction of stimulated muscles assessed by electromyography, and there was a recovery in sensory perception and muscle strength.
48004748|NCT04425330|OTHER|SHAM PBM|SHAM PBM
48004749|NCT01968018|DRUG|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
48161704|NCT02127645|PROCEDURE|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
48004750|NCT02160366|OTHER|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
48004751|NCT04854915|BEHAVIORAL|LOOP + mHealth technology assisted exercise counselling|Participants will complete a 3 month exercise and physical activity intervention supported by mHealth technology
48004752|NCT04854915|BEHAVIORAL|LOOP Only|Participants will complete the LOOP @ Alder Hey programme
48004753|NCT02977234|DRUG|Isoamyl 2-Cyanoacrylate|
48004754|NCT05705063|OTHER|LCHF Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 6 weeks
48004755|NCT01715818|DRUG|Placebo|matching aleglitazar placebo tablet orally daily
48513757|NCT03404739|DRUG|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
48690636|NCT04743219|PROCEDURE|Selective removal to soft dentin, No Base|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
48690637|NCT05960643|OTHER|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
48004756|NCT01715818|DRUG|aleglitazar|150 mcg orally daily
48004757|NCT04637958|DEVICE|THA|Total hip arthroplasty
48004758|NCT02561130|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
48690638|NCT05960643|OTHER|Control|No intervention will be made against people in this group.
48690639|NCT06094244|DRUG|Atorvastatin|Doses of atorvastatin of up to 20 mg/d.
48690640|NCT06094244|DRUG|Rosuvastatin|Doses of rosuvastatin of up to 10 mg/d.
48690641|NCT06094244|OTHER|No drugs|No drugs
48690642|NCT03956992|OTHER|Mouth gel|Stop using the mouth gel
48690643|NCT01503684|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
48690644|NCT02024425|DIETARY_SUPPLEMENT|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
48690645|NCT02024425|DIETARY_SUPPLEMENT|Control supplement|
48690646|NCT00585988|DEVICE|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
48690647|NCT00585988|DEVICE|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
48690648|NCT02033629|DRUG|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
48690649|NCT02033629|DRUG|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
48004759|NCT02561130|DRUG|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
48004760|NCT02561130|DRUG|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
48004761|NCT02561130|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
48368316|NCT01110603|DRUG|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
48004762|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
48004763|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
48004764|NCT01489046|DRUG|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
48004765|NCT01489046|DRUG|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
48368317|NCT03164304|DRUG|Magnesium Sulfate|intravenous
48368318|NCT02861521|DEVICE|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
48513758|NCT05326035|DRUG|WJ05129|WJ05129:Twice daily (except for single dose), 12 hours apart, fixed time is recommended
48513759|NCT02842073|DRUG|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
48690650|NCT02033629|DRUG|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
48690651|NCT00688467|DRUG|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
48690652|NCT00688467|DRUG|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
48690653|NCT04768205|DEVICE|Kinesio tape|The Kinesio tex tape is a medical tape that had been certified and patented.
48161705|NCT04783519|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
48161706|NCT04783519|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
48004766|NCT01489046|DRUG|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
48161707|NCT00871143|BEHAVIORAL|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
48368319|NCT02861521|DEVICE|Sham|Sham shoe modification
48368320|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
48368321|NCT00960323|DRUG|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
48513760|NCT02842073|DRUG|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
48004767|NCT01489046|DRUG|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
48004768|NCT01489046|DRUG|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
48368322|NCT00960323|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
48368323|NCT00014560|BIOLOGICAL|bispecific antibody 4G7xH22|
48368324|NCT00014560|BIOLOGICAL|sargramostim|
48513761|NCT03488082|BEHAVIORAL|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
48513762|NCT05257681|PROCEDURE|Interlobar fissure completion and pleural adhesiolysis|A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
48690654|NCT05160012|BEHAVIORAL|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
48690655|NCT06517069|OTHER|TEAS|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction
48690656|NCT06517069|DRUG|Oxycodone|Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
48690657|NCT05070455|BIOLOGICAL|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
48004769|NCT05157932|BEHAVIORAL|Talk test prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on the Talk test method.
48004770|NCT05157932|BEHAVIORAL|CPET prescription|Participants will be enrolled in the virtual cardiac rehab program and receive an exercise prescription based on their CPET results completed at baseline
48004771|NCT05558293|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
48368325|NCT02434666|DRUG|CPC-201|
48368326|NCT00006382|PROCEDURE|bronchoscopic and lung imaging studies|
48368327|NCT00006382|PROCEDURE|comparison of screening methods|
48368328|NCT00006382|PROCEDURE|computed tomography|
48368329|NCT00006382|PROCEDURE|radiography|
48368330|NCT00006382|PROCEDURE|study of high risk factors|
48513763|NCT05187390|PROCEDURE|VATS application|The chronic pain findings of the patients who underwent VATS will be questioned at the postoperative 1st and 3rd months.
48690658|NCT04333979|OTHER|Drainage|Using drain after operation
48690659|NCT05235165|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood
48690660|NCT05235165|PROCEDURE|Computed Tomography|Undergo CT
48690661|NCT05235165|OTHER|Questionnaire Administration|Ancillary studies
48161708|NCT00871143|BEHAVIORAL|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
48161709|NCT02876302|DRUG|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
48690662|NCT05235165|PROCEDURE|Thoracoscopy|Undergo video-assisted thoracoscopic surgery or VATS
48161710|NCT02876302|DRUG|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
48161711|NCT02876302|DRUG|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
48161712|NCT02876302|DRUG|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
48161713|NCT05173259|BEHAVIORAL|F|The participant will be asked to chew the two-coloured chewing gum naturally.
48161714|NCT05173259|BEHAVIORAL|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
48690663|NCT05235165|PROCEDURE|Thoracotomy|Undergo open thoracic surgery
48690664|NCT03338478|DIAGNOSTIC_TEST|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
48690665|NCT06282237|OTHER|survey|Quality of life survey and motor performace survey
48690666|NCT03489772|DRUG|ITI-214|Oral
48690667|NCT03489772|DRUG|Placebo|Oral
48690668|NCT06515574|BEHAVIORAL|developmental care|Individualized Developmental Care that includes the light, noise, sleep, etc.
48690669|NCT06496425|BEHAVIORAL|Music|Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
48161715|NCT05173259|BEHAVIORAL|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
48161716|NCT05173259|BEHAVIORAL|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
48161717|NCT05173259|BEHAVIORAL|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
48161718|NCT05173259|BEHAVIORAL|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
48161719|NCT03474042|DRUG|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
48161720|NCT03474042|DRUG|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
48004772|NCT03467269|DIAGNOSTIC_TEST|Brush sign|presence of a brush sign in MRI image in acute cerebral ischaemia
48004773|NCT00003217|BIOLOGICAL|filgrastim|
48004774|NCT00003217|DRUG|cyclophosphamide|
48004775|NCT00003217|DRUG|cytarabine|
48004776|NCT00003217|DRUG|dexamethasone|
48004777|NCT00003217|DRUG|doxorubicin hydrochloride|
48161721|NCT05946447|DEVICE|Ultrasound|The gastric antrum will be scanned using ultrasound.
48161722|NCT00764855|PROCEDURE|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
48161723|NCT06350071|BEHAVIORAL|Kangaroo Care|Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.
48161724|NCT06350071|BEHAVIORAL|Swaddling|Heel blood will be taken while the infant was swaddled in the maternal holding.
48161725|NCT06227442|DIAGNOSTIC_TEST|KDIGO criteria of 2010|They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
48161726|NCT00067925|BEHAVIORAL|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
48161727|NCT01424189|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
48161728|NCT01424189|DEVICE|AcrySof® ReSTOR® Multifocal IOL Model SA60D3|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
48161729|NCT03149432|PROCEDURE|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
48161730|NCT03149432|DRUG|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
48161731|NCT03149432|PROCEDURE|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
48690670|NCT05647837|DIAGNOSTIC_TEST|lumper puncture|lumper puncture
48690671|NCT01997593|DRUG|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
48690672|NCT02677207|DRUG|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
48690673|NCT02677207|DRUG|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
48690674|NCT04667598|DRUG|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
48004778|NCT00003217|DRUG|methotrexate|
48004779|NCT00003217|DRUG|vincristine sulfate|
48004780|NCT00009048|DRUG|EMD 128130|
48004781|NCT00009048|DRUG|IV Levodopa|
48004782|NCT06096415|DRUG|ABX-101 1mg|ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
48004783|NCT06096415|DRUG|ABX-101 2mg|ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
48368331|NCT00787527|DRUG|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
48513764|NCT01884038|DRUG|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
48004784|NCT04683991|PROCEDURE|Subepithelial connective tissue graft|A de-epithelialized connective tissue graft is harvested from the homolateral palate and transplanted around the implant.
48004785|NCT03029624|DEVICE|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
48004786|NCT01968642|BEHAVIORAL|Educational Intervention|
48004787|NCT06221696|DIETARY_SUPPLEMENT|Active Fiber Supplement Group|Three daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
48004788|NCT06221696|OTHER|Placebo Group|Three daily packets of placebo powder, taken 30 minutes before each main meal.
48004789|NCT06362148|DIAGNOSTIC_TEST|Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay|Blood sampling for circulating tumor DNA analysis at baseline, cycle 2 day 1, cycle 3 day 1, mid-treatment, end of induction/end of treatment, 100 day follow-up, 6 month, 12 month, 18 month and 24 month follow-up. Blood sampling will also be done in case of relapsing/refractory disease at any point prior to the abovementioned time points.
48004790|NCT06362148|DIAGNOSTIC_TEST|18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)|FDG-PET/CT performed at baseline, mid-treatment, end of induction/end of treatment and 6 month, 12 month, 18 month and 24 month follow-up.
48004791|NCT02449239|BIOLOGICAL|Vicinium|Intravesical administration
48004792|NCT03437122|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
48004793|NCT01217970|DRUG|Ibudilast 20mg|Ibudilast 20mg BID
48004794|NCT01217970|DRUG|Ibudilast 50mg|Ibudilast 50mg BID
48004795|NCT01217970|DRUG|Placebo oral tablet|
48004796|NCT02150655|BIOLOGICAL|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
48004797|NCT02150655|BIOLOGICAL|Placebo|
48004798|NCT00733720|DRUG|Suboxone|4/1mg, 8/2mg 16/4mg
48004799|NCT02199405|OTHER|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
48004800|NCT02199405|OTHER|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
48004801|NCT02199405|OTHER|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
48004802|NCT02199405|OTHER|Cervical traction|
48004803|NCT05788458|DRUG|Bupivacain|"The blocks will be performed in supine position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) will be initially placed in a transverse plane over the anterior superior iliac spine (ASIS) and then alignes to identify the following landmarks: Anterior inferior iliac spine, ilio-pubic eminence, iliopsoas muscle and tendon, the femoral artery, and Pectineus muscle. Point of injection will be musculo-fascial plane between the psoas tendon and ilio-pubic eminence."
48004804|NCT05019222|DRUG|Sevoflurane based inhalation anesthesia|Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.
48004805|NCT05019222|DRUG|Remimazolam based total intravenous anesthesia|Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
48004806|NCT04388943|OTHER|Observation|Physiological Measurements Patient reported questionnaire Blood sampling
48004807|NCT05414903|BEHAVIORAL|Dynamic Visual Acuity|"First, participants will report the direction of the open portion of a Landolt C (right, left, up, or down) with the head still. Ten targets at 5 acuity levels (LogMAR -0.3, 0, 0.3, 0.7, 1.0, corresponding to Snellen visual acuity of 20/10, 20/20, 20/40, 20/100, 20/200) will be identified. Next, a rate sensor will be placed on the subject's head in the plane of the horizontal canals and htDVA will be measured. The Landolt C will be presented automatically when the examiner has moved the subject's head \> 150˚/sec. htDVA scores will be the LogMAR at which the subject fails to correctly identify 50% of the visual targets or reaches a LogMAR of -0.3. The overall htDVA score is calculated by subtracting the head still LogMAR from the htDVA LogMAR. htDVA scores will be calculated for right and left head movements separately."
48161732|NCT03149432|OTHER|Local care|local care for directed healing of the stump.
48161733|NCT01509599|PROCEDURE|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
48161734|NCT01509599|PROCEDURE|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
48368332|NCT00787527|DRUG|Cyclophosphamide|750 mg/m\^2 by vein over 1 hour on Day 1 of 21 day cycle
48368333|NCT00787527|DRUG|Doxorubicin|50 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
48513765|NCT01884038|DRUG|Placebo|
48513766|NCT01749423|BIOLOGICAL|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
48690675|NCT04772352|DRUG|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
48004808|NCT05414903|BEHAVIORAL|Reading Outcomes|"The TOSWRF will be used to assess reading fluency. Children get 3 minutes to identify as many words as possible by drawing boundaries between successive unrelated words.~The TOSCRF will be used to assess reading fluency. Children are allowed 3 minutes to identify as many contextually related words as possible by drawing boundaries between successive words.~The TILLS will be used to assess reading comprehension. Each subject will read a short passage and answer 3 yes/no questions assessing reading comprehension.~A computer based MNREAD Test will be used to assess reading acuity, critical print size and Reading Accessibility Index.~During the TILLS and MNRead test, eye tracking (Eye Link 1000+ eye tracker) will be used to record fixation duration, saccade length, regression frequency, and total time spent."
48690676|NCT04772352|BEHAVIORAL|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
48690677|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
48690678|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
48161735|NCT02406040|OTHER|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
48368334|NCT00787527|DRUG|Vincristine|1.4 mg/m\^2 by vein over 15 minutes on Day 1 of 21 day cycle
48513767|NCT01362543|OTHER|Cognitive behavioural therapy (stress management)|Following a manual
48513768|NCT01362543|OTHER|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
48513769|NCT01932866|OTHER|diabetic risk score|
48513770|NCT04003493|OTHER|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
48513771|NCT00573261|DRUG|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
48513772|NCT00573261|DRUG|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
48513773|NCT06434974|OTHER|Interview|Interviewer administered questionnaire
48513774|NCT01804972|OTHER|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
48513775|NCT01804972|OTHER|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
48513776|NCT05005897|BIOLOGICAL|Cyanocobalamin|Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment
48690679|NCT05619094|OTHER|Corrective exercise program|"Strengthening exercises for deep cervical flexor muscles and shoulder retractors.~Stretching exercises for cervical extensors and pectoral muscles."
48690680|NCT04505319|DEVICE|DEFINISSE CORE FILLER|"DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face"
48690681|NCT05242068|DEVICE|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
48690682|NCT05242068|OTHER|Standard care|Patients received standard intravenous catheterization.
48690683|NCT05386862|BEHAVIORAL|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
48690684|NCT02765815|DRUG|Liposomal bupivacaine, 266mg|
48690685|NCT02765815|DRUG|Bupivacaine 0.5 % with Epinephrine|
48690686|NCT02765815|DRUG|Ketorolac 30mg|
48690687|NCT02765815|DRUG|Morphine 10mg|
48690688|NCT02765815|DRUG|Bupivacaine 0.25% with Epinephrine|
48690689|NCT01832493|DEVICE|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
48513777|NCT01229137|DEVICE|SRD-1 conversion|
48513778|NCT04538183|OTHER|WO 5000|WO 5000
48513779|NCT04538183|OTHER|WO 5001|WO 5001
48513780|NCT00234962|DRUG|Lopinavir/Ritonavir|
48513781|NCT02458859|DEVICE|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
48513782|NCT05041920|DRUG|famitinib、omeprazole|famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
48513783|NCT06488339|DIETARY_SUPPLEMENT|Protein and oil supplement|Take 1 sachet/day replaced dinner
48513784|NCT02989909|DEVICE|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
48690690|NCT00562822|PROCEDURE|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
48690691|NCT00562822|OTHER|Physical and medical therapy|Treatment with physical and medical therapy alone
48004809|NCT05414903|BEHAVIORAL|Static Visual Acuity|"The subject's head will be in a headrest. Static visual acuity will be assessed in 9 domains (3 levels of visual target complexity x 3 levels of presentation complexity). The 3 levels of visual target complexity are identifying: 1) colors, 2) the direction of the open prongs of the Landolt C (right, left, up, or down), which does not require alphabet knowledge, and 3) single letters (C, D, H, K, O, N, S, R, V, and Z; NIH Toolbox, Li 2014)). The 3 levels of presentation complexity are identifying: 1) 1-visual optotype, 2) a successive row of 5 visual optotypes flashed for 3 seconds (Hillman 1999), and 3) successive rows of optotypes in paragraph form as quickly as possible (i.e., rapid automatized naming). Outcome parameters will be %-correct at each acuity level and reaction time. Fixation duration, saccade length, saccade frequency, regression frequency, and total time spent will be collected via an eye tracker (Eye Link 1000+ eye tracker \[SR Research, EyeLink, Ontario, Canada\])."
48004810|NCT05633706|DEVICE|fluid biopsy capsule|Collection of a fluid biopsy from the small intestine via ingestible capsule
48004811|NCT04002414|BEHAVIORAL|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
48004812|NCT04002414|BEHAVIORAL|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
48004813|NCT03929965|DRUG|Anlotinib|Anlotinib
48004814|NCT00738972|DRUG|valsartan|80 mg valsartan. Duration: 12 months. Tablets
48004815|NCT00738972|DRUG|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
48004816|NCT00738972|DRUG|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
48004817|NCT00738972|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
48004818|NCT04831775|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|The intervention is composed of 4 small-group webinar classes and home-based individual online cognitive skills practice and will be held over 8 weeks. The classes will be taught by a GRA. Classes 1 \& 2 will focus on common cognitive problems in T2DM and strategies to improve cognitive skills. Classes 3 \& 4 focus on lifestyle changes to support cognitive functioning and DM-SM skills. Each online class will follow the same format: (1) introduction/revisiting content from the previous class; (2) review of progress on computer exercises; (3) practicing cognitive strategies in class; and (4) a weekly topic. The GRA will also prescribe exercises for the following weeks.
48161736|NCT05197153|BIOLOGICAL|Half dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
48513785|NCT02989909|DEVICE|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
48161737|NCT05197153|BIOLOGICAL|Full dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
48513786|NCT02523300|PROCEDURE|TEVAR|The patients will be undertaken TEVAR
48513787|NCT02523300|DRUG|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
48513788|NCT02523300|DRUG|saline|The other 120 patients will be given saline as control group
48513789|NCT01375179|DRUG|KRP203|
48513790|NCT01375179|DRUG|Placebo matching KRP203|
48690692|NCT06320106|OTHER|Virtual Reality baseline assessment|"They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric).~After the session, the participants fill questionnaires related to cyber-sickness and usability of the application."
48161738|NCT05197153|BIOLOGICAL|AZD1222|Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
48161739|NCT05197153|BIOLOGICAL|Half dose of mRNA-1273|Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
48161740|NCT00187135|DRUG|Fentanyl|"1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
48161741|NCT00187135|DRUG|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
48161742|NCT00187135|DRUG|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
48161743|NCT00187135|DRUG|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
48161744|NCT06269796|DIAGNOSTIC_TEST|Little Developmental Coordination Disorder Questionnaire (LDCDQ)|"The Little Developmental Coordination Disorder Questionnaire (LDCDQ) is a parent questionnaire consisting of 15 items designed to screen for motor coordination difficulties in 3- and 4-year-old children. It comprises 15 items grouped into two distinct factors: gross motor skills and fine motor skills. A Likert scale is used, ranging from one to five, where one (1) indicates Not at all like your child and five (5) indicates Very much like your child. The total of the 15 items is added up to obtain a total score of 75."
48161745|NCT06269796|DIAGNOSTIC_TEST|Bruininks- Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2)|The BOT-2 is standardized for children and adolescents aged 4 to 21 years and 11 months, and the full test takes 45 to 60 minutes to perform. The BOT-2 test was used to detect deviation from the norm and the likelihood of a diagnosis for DCD. The BOT-2 measures fine and gross motor proficiency, with subtests focusing on stability, mobility, strength, coordination, and object manipulation.
48161746|NCT00580047|DRUG|Zoledronic Acid|4mg IV Annually
48161747|NCT00580047|COMBINATION_PRODUCT|Calcium with vitamin D|1200 mg Calcium with 800 International Units of vitamin D
48161748|NCT00580047|DRUG|Alendronate|70mg weekly
48161749|NCT03188809|PROCEDURE|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
48161750|NCT03188809|PROCEDURE|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
48161751|NCT01573741|DRUG|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
48161752|NCT00737997|DRUG|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
48161753|NCT00737997|OTHER|Saline|10 ml saline alone
48161754|NCT05188729|DRUG|LTX-315 Part 1|LTX-315 once-daily dosing; starting total daily dose of 2 mg for the first subject. Ascending once-daily 1 mg dosing increments (eg, 2 mg on Day 1, 3 mg on Day 2). Subjects may be treated for a maximum of 2 weeks and a maximum total daily dose of 8 mg in Part 1. The starting dose will be escalated between subject cohorts in 1-mg increments after the previous cohort has completed Week 1 dosing (the DLT observation period).
48161755|NCT05188729|DRUG|VP-315 Part 2|VP-315 once-daily dosing; Part 2 will be initiated upon completion of Part 1 to determine the optimal dosing regimen of VP-315. There were no DLTs observed in Part 1 of the study and the maximum dose of 8 mg was achieved. Therefore, the dose to be evaluated in Part 2 will be a total daily dose of 8 mg in 4 Cohorts.
48161756|NCT03204045|DRUG|fentanyl|2 mL mixture of fentanyl with isotonic saline
48161757|NCT03204045|DRUG|Oxycodone|2 mL mixture of oxycodone with isotonic saline
48161758|NCT03204045|DRUG|control|isotonic saline 2 mL
48161759|NCT06388785|OTHER|No Intervention|This is a non-interventional study.
48161760|NCT00759681|DEVICE|ArterX Surgical Sealant|Apply at the suture site.
48161761|NCT00759681|DEVICE|Gelfoam and Thrombin|Apply at the suture site.
48161762|NCT05698511|DRUG|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
48690693|NCT04568486|OTHER|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
48690694|NCT05616546|BIOLOGICAL|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
48690695|NCT05725226|DEVICE|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
48690696|NCT05725226|DEVICE|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
48690697|NCT05003180|PROCEDURE|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
48690698|NCT00046293|DRUG|Reopro|
48690699|NCT00046293|DRUG|Retrovase|
48690700|NCT03206970|DRUG|Zanubrutinib|Administered as specified in the treatment arm.
48004819|NCT04831775|BEHAVIORAL|Brain Games|The computer-training component uses a model for cognitive training that adapts to the user through an integrated hierarchical structure. The BrainHQ website houses the interactive program that runs on standard web browsers. Participants will only need a computer, smart phone, or tablet with Internet access to securely log onto the website. Each participant will be registered by the project staff using anonymous ID numbers that will allow unlimited access during the study. The website stores each session completed, and participants can start subsequent sessions wherever they stopped the last time logged on.
48161763|NCT05154539|DIAGNOSTIC_TEST|Remote digital assessment|Remote digital assessment of test group participants
48161764|NCT05154539|DIAGNOSTIC_TEST|Conventional physical assessment|Conventional physical assessment of control group participants
48161765|NCT03135821|DIAGNOSTIC_TEST|TCM|
48161766|NCT03973047|DRUG|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
48368335|NCT00787527|DRUG|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
48690701|NCT00763295|OTHER|T-Spot.TB test|diagnostic test
48690702|NCT02101996|OTHER|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
48690703|NCT00851292|DEVICE|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
48690704|NCT06643858|OTHER|No intervention|This study does not involve any interventions.
48690705|NCT05723536|PROCEDURE|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
48690706|NCT05723536|PROCEDURE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
48004820|NCT01041716|OTHER|None - Observational study|None - Observational study
48004821|NCT03758911|OTHER|Semi-structured Interview|
48161767|NCT03973047|DRUG|Zofran|8 mg tablet (over-encapsulation in a capsule)
48161768|NCT03973047|DRUG|Placebo|capsule
48161769|NCT05970783|DRUG|Jincaopian Tablets|Jincaopian Tablets 0.2g tid p.o.
48161770|NCT05970783|OTHER|Placebo|Placebo 0.2g tid p.o.
48161771|NCT06645574|OTHER|The multidisciplinary preventive approach among young people involved in intensive sports activities. Athlete will see doctor and physiotherapist.|"Athletes will have 2 times per years prevention examination:~* A standard medical examination~* A physiotherapy assessment with strength assessment~* They will complete psychometric evaluation self-questionnaires"
48161773|NCT02806817|DRUG|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
48161774|NCT02806817|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
48161775|NCT02806817|OTHER|Normal saline|Use saline as placebo
48368336|NCT04253652|OTHER|Fasted breath samples|Will be completed pre and post iron therapy
48690707|NCT02519478|BEHAVIORAL|Helmetless Tackling Training (HuTT)|see previous sections
48690708|NCT03504488|BIOLOGICAL|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
48368337|NCT04253652|OTHER|IBS-SSS|Will be completed pre and post iron therapy
48368338|NCT04253652|OTHER|Daily diary|Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
48368339|NCT04253652|OTHER|Exploratory research: stool samples|Completed pre and post iron therapy for a subset of patients enrolled in the study
48368340|NCT02098291|DRUG|G17DT|
48368341|NCT03104361|BIOLOGICAL|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
48690709|NCT03504488|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
48690710|NCT02982772|OTHER|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
48690711|NCT02982772|OTHER|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
48690712|NCT04473274|DRUG|Pioglitazone|Receive pioglitazone 15mg - 30mg daily
48690713|NCT05894135|DRUG|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
48690714|NCT05894135|DRUG|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
48690715|NCT05894135|DRUG|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
48690716|NCT05894135|DRUG|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
48690717|NCT05894135|DRUG|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
48690718|NCT05894135|DRUG|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
48161776|NCT04906707|DEVICE|EaseVRx|EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
48161777|NCT04906707|BEHAVIORAL|Audio-only version of EaseVRx|Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
48690719|NCT06253455|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
48690720|NCT06417385|DEVICE|taVNS soterix device|Soterix is a custom modified, FDA-cleared electrical stimulator that meets the criteria of the FDA for investigational use. Neoleads will be placed in order to deliver electrical stimulation using microcurrent (\<2.5mA) with breastfeeding, on with sucking and swallowing and off with rest for 5 feeds per week for 2 weeks.
48690721|NCT00113633|BEHAVIORAL|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
48690722|NCT05271253|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
48690723|NCT05271253|DRUG|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
48161778|NCT02709798|DRUG|Shenfu Injection|
48368342|NCT02005458|DRUG|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
48690724|NCT05271253|DRUG|normal Saline|injection of normal Saline
48690725|NCT00856596|DRUG|Sertaconazole nitrate cream 2%|Once a day topical cream
48690726|NCT01701362|DRUG|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
48690727|NCT01701362|DRUG|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
48004822|NCT04551846|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
48004823|NCT04551846|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
48004824|NCT06031571|PROCEDURE|dry cupping massage|Dry cupping is a form of massage therapy that involves using Hijamat cups without skin injury while applying suction and then performing circular and transverse movements
48004825|NCT06031571|PROCEDURE|Myofacial release|Myofascial release is a form of manual therapy using hands-on techniques to regain tissue extensibility and elasticity
48004826|NCT00169143|DRUG|Rituximab + ACVBP regimen plus Pegfilgrastim|
48004827|NCT00169143|PROCEDURE|Autologous stem cell transplant|
48690728|NCT00971581|DRUG|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
48690729|NCT00140049|DRUG|Xalacom|
48690730|NCT00140049|DRUG|Cosopt|
48690731|NCT06659146|DEVICE|Superficial hyperthermia|Superficial hypothermia will be delivered using a CE-marked water-filtered infrared A (wIRA) machine (hydrosun® TWH1500)
48690732|NCT03693677|DRUG|Irinotecan Liposomal Injection|Nal-IRI at 80 mg/m2 IV over 90 minutes
48690733|NCT03693677|DRUG|5-FU/LV|5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
48690734|NCT03693677|DRUG|Nab-Paclitaxel|Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
48690735|NCT03693677|DRUG|Gemcitabine|1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
48690736|NCT06192472|PROCEDURE|Chemical sclerotherapy|Sclerosant will be retained within the vein
48690737|NCT06192472|DRUG|1% Sodium Tetradecyl Sulphate|1% Sodium Tetradecyl Sulphate
48690738|NCT06192472|DRUG|3% Sodium Tetradecyl Sulphate|3% Sodium Tetradecyl Sulphate
48690739|NCT06192472|DRUG|0.5% Polidocanol|0.5% Polidocanol
48690740|NCT06192472|DRUG|3% Polidcanol|3% Polidcanol
48690741|NCT04022629|PROCEDURE|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
48690742|NCT04022629|PROCEDURE|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
48161779|NCT02709798|DRUG|5% Glucose Injection|
48368343|NCT02005458|DRUG|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
48368344|NCT02005458|DRUG|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
48368345|NCT02005458|DRUG|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
48690743|NCT03846427|DRUG|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
48690744|NCT00006144|DRUG|Lopinavir/Ritonavir|
48690745|NCT00006144|DRUG|Emtricitabine|
48690746|NCT00006144|DRUG|Stavudine|
48161780|NCT02231814|DIETARY_SUPPLEMENT|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
48161781|NCT02231814|OTHER|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
48161782|NCT00912275|DRUG|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
48161783|NCT01109602|OTHER|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
48368346|NCT01369394|OTHER|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
48368347|NCT05416086|DEVICE|cryoablation procedure using the iCLAS Cryoablation System|all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
48690747|NCT04896619|OTHER|Kori tofu bread|34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
48004828|NCT02203864|BIOLOGICAL|BIBW2 component A|BIBW2 without IL-2 secreting cell line
48004829|NCT02203864|BIOLOGICAL|BIBW2 component B|BIBW2 with IL-2 secreting cell line
48004830|NCT03007394|DRUG|Lorcaserin|Lorcaserin Capsule
48368348|NCT04264611|OTHER|Experimental: Short Foot Exercise Group|Short foot exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
48368349|NCT04264611|OTHER|Experimental: Towel Curl Exercise Group|Towel curl exercise which was performed under the supervision of physiotherapist for four weeks in 30 repetitions five days a week.
48368350|NCT02853097|OTHER|Cytology Specimen Collection Procedure|Undergo blood collection
48368351|NCT02853097|OTHER|Laboratory Biomarker Analysis|Correlative studies
48690748|NCT04896619|OTHER|Whey protein bread|Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
48004831|NCT03007394|DRUG|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
48004832|NCT01921829|DRUG|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
48004833|NCT06481059|RADIATION|Head and Neck cancer post-radiotherapy|Head and Neck Cancer patients who received radiotherapy after 6 months
48004834|NCT06021067|BIOLOGICAL|Death mesenchymal stem cell|A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks.
48004835|NCT04222738|DIETARY_SUPPLEMENT|GINOFF1|The intervention lasted for six weeks and consisted of the administration of powdered ginger extracts in the form of capsules at a dose of 2g/day.
48004836|NCT01153581|DRUG|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
48004837|NCT01153581|DRUG|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
48004838|NCT01153581|DRUG|Progesterone|progesterone, 200 mg day-1 oral
48004839|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
48004840|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
48004841|NCT02165930|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
48004842|NCT02165930|DRUG|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
48004843|NCT02646696|OTHER|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
48004844|NCT02123199|DRUG|Indacaterol (Onbrez®) /QAB149|
48161784|NCT00598637|DEVICE|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
48161785|NCT00598637|DEVICE|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
48161786|NCT05335343|OTHER|no intervention|no intervention
48161787|NCT00796497|DRUG|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
48161788|NCT05045638|DRUG|Rosuvastatin|Oral dose
48161789|NCT05045638|DRUG|Sotorasib|Oral dose
48161790|NCT01389609|DRUG|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
48368352|NCT01414686|OTHER|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
48368353|NCT00702637|DRUG|Modafinil|
48368354|NCT05515887|DRUG|Shenqu Xiaoshi Oral liquid|The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
48161791|NCT01389609|DRUG|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
48161792|NCT01389609|DRUG|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
48161793|NCT06329531|OTHER|Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)|Given by Questionnaire
48161794|NCT05388864|BEHAVIORAL|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
48161795|NCT06646185|OTHER|Menstrual Pads|Participants adopt menstrual pads to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
48161796|NCT06646185|OTHER|Menstrual Cups|Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
48161797|NCT06646185|OTHER|Tampons|Participants adopt tampons to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
48161798|NCT03971799|BIOLOGICAL|CD33CART autologous|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
48368355|NCT06305793|DRUG|IVIG (intravenous immunoglobulin)|Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
48004845|NCT01457495|BIOLOGICAL|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
48004846|NCT01457495|BIOLOGICAL|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
48004847|NCT01457495|BIOLOGICAL|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
48004848|NCT01296516|BEHAVIORAL|Non-intervention group|A pedometer and written material on a healthy lifestyle.
48004849|NCT01296516|BEHAVIORAL|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
48004850|NCT01296516|BEHAVIORAL|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
48690749|NCT04093193|PROCEDURE|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
48690750|NCT03580278|BIOLOGICAL|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
48690751|NCT05081167|DRUG|REL-1017|REL-1017 tablet
48690752|NCT05081167|DRUG|Placebo|Placebo tablet
48690753|NCT01703052|DRUG|CHF 6001 SD or placebo|Dry Powder Inhaler
48690754|NCT01703052|DRUG|CHF 6001 MD or placebo|Dry Powder Inhaler
48690755|NCT03944564|BEHAVIORAL|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
48690756|NCT03944564|BEHAVIORAL|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
48690757|NCT03944564|BEHAVIORAL|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
48690758|NCT05092997|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
48690759|NCT05092997|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
48690760|NCT03292640|DRUG|DFD-03 (0.1% tazarotene) Lotion|DFD-03 Lotion (0.1% tazarotene) - twice daily application
48690761|NCT03292640|DRUG|DFD-03 (0% tazarotene) Lotion (Placebo)|DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
48690762|NCT01482806|BEHAVIORAL|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
48690763|NCT01482806|BEHAVIORAL|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
48690764|NCT02458131|BEHAVIORAL|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
48690765|NCT05672641|OTHER|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
48690766|NCT05672641|OTHER|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
48690767|NCT02739763|BIOLOGICAL|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
48690768|NCT04185337|PROCEDURE|Fine-Needle Aspiration|Undergo ultrasound-guided FNA
48690769|NCT04185337|PROCEDURE|Lymph Node Biopsy|Undergo ultrasound-guided lymph node biopsy
48690770|NCT04185337|PROCEDURE|Photoacoustic Imaging|Undergo ultrasound-guided PAI
48690771|NCT04185337|PROCEDURE|Ultrasound|Undergo ultrasound
48690772|NCT04185337|DEVICE|Multispectral optoacoustic tomography (MSOT) acuity instrument|Use multispectral optoacoustic tomography (MSOT) acuity instrument
48690773|NCT04554693|DRUG|Metronidazole Oral|250 mg oral three times a day for 14 days
48161799|NCT03971799|BIOLOGICAL|CD33CART allogeneic|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
48004851|NCT04035304|OTHER|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
48004852|NCT03316833|DEVICE|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score \<33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
48004853|NCT03266068|GENETIC|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
48004854|NCT03266068|PROCEDURE|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
48004855|NCT03266068|PROCEDURE|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
48004856|NCT03266068|DIAGNOSTIC_TEST|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
48004857|NCT01783951|BIOLOGICAL|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
48004858|NCT01783951|DRUG|S-1|The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
48690774|NCT04554693|DRUG|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
48690775|NCT00624468|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
48161800|NCT04124016|DIETARY_SUPPLEMENT|Inulin|Powder of inulin fractions dissolved into 250 ml of water
48161801|NCT04124016|DIETARY_SUPPLEMENT|green tea extract|Powder of green tea extract dissolved into 200 ml of water
48161802|NCT04124016|DIETARY_SUPPLEMENT|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
48161803|NCT04124016|DIETARY_SUPPLEMENT|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
48161804|NCT04245839|DRUG|Fludarabine|Fludarabine
48161805|NCT04245839|DRUG|Cyclophosphamide|Cyclophosphamide
48161806|NCT04245839|DRUG|JCAR017|JCAR017
48161807|NCT00516178|DRUG|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
48161808|NCT00516178|DRUG|Saline|3 infusions, perioperative or post-PTCA
48690776|NCT00624468|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
48513791|NCT01988129|OTHER|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
48004859|NCT01783951|DRUG|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
48004860|NCT05824806|BIOLOGICAL|PRP Protocol A|Platelet rich plasma protocol A
48004861|NCT05824806|BIOLOGICAL|PRP Protocol B|Platelet rich plasma protocol B
48161809|NCT04872842|OTHER|Obervation|This study is an observational study without any intervention
48161810|NCT03074097|DRUG|Bupivacaine 0.25%|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
48690777|NCT05175430|DRUG|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
48690778|NCT05175430|DRUG|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
48690779|NCT05175430|DRUG|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
48004862|NCT05824806|DEVICE|Hyaluronic acid|Hyaluronic acid
48004863|NCT03430804|OTHER|Bishop score calculation of modified Bishop score in numbers by digital vaginal examination|Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
48004864|NCT06022016|GENETIC|For each person (index case or related) included in this study:|"* an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~* a saliva sample will be taken (if applicable) so that a genetic analysis can be performed."
48004865|NCT04566796|DRUG|Sugammadex|give 2 mg/ kg as muscle reversal drug in premature infants
48161811|NCT00975130|BIOLOGICAL|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
48161812|NCT00975130|BIOLOGICAL|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
48161813|NCT04970654|DRUG|somapacitan|Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
48004866|NCT04566796|DRUG|Neostigmine|give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
48004867|NCT05140577|OTHER|Maximal voluntary isometric strengthening|The subject is asked to perform a maximum voluntary isometric force work against a wall during 5 seconds
48004868|NCT04729166|BEHAVIORAL|Structured education and follow-up|This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
48004869|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. \[three video banks of RDE + Support\]).
48004870|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders.|Self-monitoring of pain, stress, and opioid use + alerts/reminders.
48004871|NCT03479866|OTHER|Dietary intervention|To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.
48004872|NCT04593030|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
48004873|NCT04593030|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure
48004874|NCT00712296|DRUG|ASHMI 4|4 capsules orally twice a day
48004875|NCT00712296|DRUG|ASHMI 12|12 capsules orally twice a day
48004876|NCT00712296|DRUG|Placebo|Placebo 6 capsules twice a day
48004877|NCT06492811|DRUG|GAT@F nanoenzyme hydrogel complex|The wound condition was recorded by taking photos each time the dressing was changed. The diabetic wound was routinely treated with a dressing change, after which GAT@F nanoenzyme hydrogel complex was applied externally and a secondary dressing - medical surgical gauze was added. According to existing clinical data, it is recommended to use no more than 10ml per dressing change.
48004878|NCT02312232|DRUG|levodopa, carbidopa, ODM-104|
48004879|NCT04415606|DEVICE|QuikClot Control+|Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
48368356|NCT06305793|DRUG|IVIG Placebo|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months)."
48368357|NCT06305793|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
48513792|NCT03450473|DEVICE|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
48004880|NCT01578928|DRUG|SOM230|
48004881|NCT03098511|DIAGNOSTIC_TEST|Neurological Diagnostic Evaluation|"Clinical Data:~* Demographic data~* Daily data (clinical exams, laboratory data)~* Drug administration~* Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~* CT-Perfusion~* CT-Angiography reconstructions~Reference Standard:~- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory \& Nanovesicles Parameters):~* At the time of patient enrolment~* 6 hours after patient enrolment~* At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~* extended Glasgow Outcome Scale (GOSe)~* modified Rankin Scale (mRS)"
48004882|NCT05763888|OTHER|No drug will given|No intervention will be given to the subject
48004883|NCT03261583|OTHER|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
48004884|NCT03435549|BEHAVIORAL|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
48161814|NCT04970654|DRUG|Norditropin®|Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
48368358|NCT06305793|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.
48513793|NCT06362863|DIETARY_SUPPLEMENT|enteral nutrition biscuits|Addition of enteral nutritional biscuits to existing pharmacological treatment.
48690780|NCT02241733|BEHAVIORAL|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
48690781|NCT02241733|BEHAVIORAL|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
48690782|NCT05330936|COMBINATION_PRODUCT|Potent topical steroid|Cyanocobalamin in Avocado Oil Cream
48004885|NCT03435549|BEHAVIORAL|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
48161815|NCT05083871|OTHER|European Trauma Course|"Structured learning program specifically focused on Trauma management. The course provides frontal lessons, workshops for the technical skills and simulated scenarios.~Please see https://www.erc.edu/courses/european-trauma-course for additional details"
48161816|NCT04745455|OTHER|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
48161817|NCT02919397|DEVICE|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
48161818|NCT02919397|BEHAVIORAL|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
48161819|NCT02919397|BEHAVIORAL|Motivational messaging|Messages sent via smartphone application
48161820|NCT04066400|OTHER|Nutritional Intervention|Dietary Counselling
48004886|NCT00696956|DEVICE|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
48004887|NCT00696956|DEVICE|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
48690783|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
48004888|NCT04431037|DIETARY_SUPPLEMENT|Early oral feeding/Enhanced recovery after surgery protocols|Early oral feeding refers to NG tube and foley's catheter removed within 12 hours and patients allowed oral sips on day 1 with gradual shift to liquid diet after 12 hrs and semisolid food started after 24 hours later.Patients were given i/v antibiotics,painkillers and i/v PPIs and shifted to oral pain killers on 2nd POD.
48004889|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
48004890|NCT01331070|OTHER|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
48004891|NCT02409836|DRUG|Marketed Dentifrice|Marketed Dentifrice
48004892|NCT02409836|DRUG|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
48004893|NCT02409836|DRUG|Marketed Flavored Dentifrice|Bubble Gum Flavored
48004894|NCT00832403|OTHER|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
48004895|NCT03528746|OTHER|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
48161821|NCT00262769|DRUG|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
48368359|NCT00584428|PROCEDURE|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
48368360|NCT03881072|OTHER|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
48161822|NCT00262769|DRUG|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
48368361|NCT03417999|DRUG|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
48690784|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
48161823|NCT05466942|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate|Measurement of physiological parameters
48161824|NCT06329544|DIETARY_SUPPLEMENT|Fructose|12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
48161825|NCT06329544|DIETARY_SUPPLEMENT|glucose|12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
48161826|NCT01047306|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
48161827|NCT00889733|DRUG|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
48161828|NCT05800483|BEHAVIORAL|Healium|web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
48368362|NCT00087685|DRUG|RAD001|10 mg by mouth Daily
48161829|NCT04225078|DRUG|Loperamide|Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
48161830|NCT04225078|OTHER|Placebo|Matching loperamide placebo capsules will be administered orally.
48161831|NCT04225078|DRUG|Moxifloxacin|Moxifloxacin tablets will be administered orally.
48161832|NCT00940914|DRUG|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
48368363|NCT05102773|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
48368364|NCT05102773|PROCEDURE|Computed Tomography|Undergo CT
48004896|NCT03528746|OTHER|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
48004897|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
48368365|NCT05102773|OTHER|Laboratory Biomarker Analysis|Correlative studies
48690785|NCT02177734|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
48004898|NCT00404352|DRUG|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
48004899|NCT00404352|DRUG|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
48004900|NCT03072173|DRUG|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
48004901|NCT03072173|DRUG|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
48004902|NCT03493490|DRUG|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
48004903|NCT03493490|DRUG|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
48004904|NCT03493490|DRUG|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
48004905|NCT06425471|DEVICE|KARL STORZ fetoscope arm|The type of fetoscope used in utero(either straight or curved or both ) will depend on the location of the placenta. The fetoscope will be used to cauterize abnormal blood vessels that cause twin-to-twin transfusion syndrome (TTTS)
48004906|NCT00002882|BIOLOGICAL|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
48004907|NCT00002882|BIOLOGICAL|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
48004908|NCT00002882|DRUG|Cisplatin|IV Days 1-4
48368366|NCT05102773|OTHER|Questionnaire Administration|Complete questionnaire
48368367|NCT04429269|DIAGNOSTIC_TEST|mammography and ultrasound screening|Patients screened by both mammography and ultrasound.
48690786|NCT01912443|DRUG|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
48690787|NCT05483712|DEVICE|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
48690788|NCT00079261|DRUG|CHOP regimen|
48690789|NCT00079261|DRUG|cyclophosphamide|
48690790|NCT00079261|DRUG|doxorubicin hydrochloride|
48690791|NCT00079261|DRUG|gemcitabine hydrochloride|
48690792|NCT00079261|DRUG|prednisone|
48690793|NCT00079261|DRUG|vincristine sulfate|
48690794|NCT03780621|DIETARY_SUPPLEMENT|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
48690795|NCT03780621|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule
48690796|NCT04169529|DEVICE|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
48690797|NCT06132724|OTHER|Signal acquisition|"Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days."
48004909|NCT00002882|DRUG|Dacarbazine|IVPB on day 1
48004910|NCT00002882|DRUG|Vinblastine|IVPB on days 1-4
48004911|NCT00002882|PROCEDURE|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
48004912|NCT05937048|BIOLOGICAL|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
48161833|NCT04685018|DEVICE|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
48161834|NCT04757961|BEHAVIORAL|LifeStories|The content of LifeStories is divided thematically into core ACT concepts across the four episodes as follows: 1) cultivating awareness of the transient nature of mood experiences and the benefit of trying out various strategies to cope with depression when it arises; 2) clarifying one's own values and setting personal goals related to these values; 3) developing a more accepting and nonjudgmental stance towards difficult thoughts and feelings and practicing self-compassion;and 4) living more mindfully in the present moment.
48161835|NCT01475370|DRUG|OCV-501|"1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
48161836|NCT06645730|DIAGNOSTIC_TEST|hypertension|diagnosed with hypertension
48161837|NCT06645730|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
48690798|NCT06493786|OTHER|Collection of body odor samples|"Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion."
48690799|NCT03987139|OTHER|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
48004913|NCT05937048|OTHER|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
48004914|NCT05508412|BEHAVIORAL|CancerPEP|CancerPEP
48368368|NCT05267964|PROCEDURE|Epping resection arthroplasty|Follwing the described epping resection arthroplasty, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
48004915|NCT06375057|PROCEDURE|laparoscopic cholecystectomy|A blood sample is taken the day after surgery
48161838|NCT06645730|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver on CT
48161839|NCT05310344|COMBINATION_PRODUCT|Albumin-bound paclitaxel and bevacizumab|Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
48161840|NCT02951416|OTHER|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
48690800|NCT03987139|OTHER|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
48690801|NCT03987139|OTHER|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
48368369|NCT05267964|PROCEDURE|CMC I prosthesis|Follwing the described CMC I prosthesis procedure, The first ray was immobilized using an orthosis for four weeks postoperatively in both study groups followed by eight weeks of physical therapy.
48368370|NCT04076280|BEHAVIORAL|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education \[4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes\] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
48004916|NCT01522066|PROCEDURE|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
48004917|NCT01522066|PROCEDURE|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
48004918|NCT06450548|OTHER|Parametric acquisition|Parametric acquisition for 18F-FDG PET/CT and 68GA-PSMA PET/CT with 24 h at 15 days of interval
48004919|NCT02110316|OTHER|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
48004920|NCT05716828|OTHER|Balint group activities|A Balint group is a working form that focuses on the professional doctor-patient relationship. Participants in the Balint group completed Balint training for a period of at least three months, which included two lectures and 10 small group discussion sessions held once a month for one hour at a time (on Thursdays from 12 to 1 PM). Balint group is a closed group including one to two group leaders and six to twelve participants, with sessions lasting 60 to 90 minutes.
48161841|NCT05122052|OTHER|Psychological session|Just before the oncology visit, each patient is invited to undergo a psychological session of 20-30 minutes. During the session with a psycho-oncologist the following tasks are addressed: 1) favor emotional expression identifying the most difficult issues to promote mechanisms of elaboration of living experiences; 2) offer a containment of intense emotions; 3) assess awareness of diagnosis and prognosis; 4) favor expression of fears of treatment expectancy; 5) favor expression of difficulties on the inability to cope with prior commitments after the disease; 6) assess family and friend network; 7) improve the patient medic communication and relationship. At the end of the session, the distress thermometer and ESAS-r scale are compiled together with the demographic characteristics. All outstanding issues that are relevant to the therapeutic plan are then discussed between the psychotherapist and the medic before the oncology visit together with delivery of the DT and ESASr scale result.
48690802|NCT04760860|DRUG|Terazosin Hydrochloride|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
48690803|NCT04760860|OTHER|Placebo|In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
48690804|NCT04823286|OTHER|Virtual reality health platform during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
48690805|NCT03254628|OTHER|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
48690806|NCT03254628|OTHER|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.
48690807|NCT03254628|BEHAVIORAL|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
48690808|NCT03254628|BEHAVIORAL|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
48161842|NCT06209905|PROCEDURE|Alveolar ridge augmentation|Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
48690809|NCT03254628|DRUG|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
48690810|NCT03254628|DEVICE|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
48690811|NCT03926741|DRUG|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
48690812|NCT04493424|DRUG|Spesolimab|Spesolimab
48690813|NCT01921556|BEHAVIORAL|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
48690814|NCT06604858|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
48690815|NCT06604858|DRUG|Carboplatin|Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
48690816|NCT06604858|DRUG|Paclitaxel|Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
48690817|NCT06263608|DEVICE|(Cardio)Respiratory polygraphy (NOX T3s)|This home-based device enables the detection of obstructive sleep apnea by calculating the apnea hypopnea index (AHI).
48690818|NCT06263608|DIAGNOSTIC_TEST|Polysomnography|Polysomnography allows both sleep and respiration monitoring during an overnight stay in a dedicated sleep clinic.
48690819|NCT06263608|DEVICE|Devices to deliver Continuous Positive Airway Pressure (CPAP), Bilevel Positive Airway Pressure (BiPAP) or Adaptive support ventilation (ASV)|Devices can be used to deliver CPAP, BiPAP, or ASV treatment to open up the airways, making breathing during sleep possible.
48690820|NCT06263608|DEVICE|Fitbit smartwatch|The smartwatch enables the semi-continuous monitoring of the heart rhythm via the installed FibriCheck algorithm.
48690821|NCT01766804|DIETARY_SUPPLEMENT|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
48690822|NCT01766804|DIETARY_SUPPLEMENT|placebo|
48690823|NCT05357339|OTHER|20% Albumin|100ml boluses 20% Albumin
48690824|NCT05357339|OTHER|Crystalloid|100ml bolus of crystalloid
48004921|NCT05811611|BEHAVIORAL|WeChat Mini Program plus tailored online health promotion videos|Participants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
48004922|NCT05811611|BEHAVIORAL|WeChat Mini Program Only|Participants only have access to a WeChat Mini Program.
48004923|NCT06325150|DEVICE|Light emitting glasses|Assess the capacity of 20 min use of AYO light emitting glasses on different outcomes
48004924|NCT01813318|DRUG|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
48004925|NCT01813318|DRUG|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
48004926|NCT00060996|DRUG|Remodulin® (treprostinil sodium) Injection|
48004927|NCT02832869|OTHER|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
48004928|NCT02832869|OTHER|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
48004929|NCT06344741|BEHAVIORAL|Accepted in latent phase|Participants admitted to the delivery room in the latent phase will be included. Routine procedures will be performed.
48161843|NCT06645470|OTHER|Standard Medical Care (SMC)|Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
48004930|NCT06344741|BEHAVIORAL|Accepted in active phase|Participants admitted to the delivery room in the active phase will be included. Routine procedures will be performed.
48004931|NCT01344369|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
48004932|NCT01344369|DRUG|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
48004933|NCT01133691|DIETARY_SUPPLEMENT|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
48004934|NCT01427088|DEVICE|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
48004935|NCT02702401|BIOLOGICAL|Pembrolizumab|IV infusion
48004936|NCT02702401|DRUG|Placebo|0.90% w/v sodium chloride IV infusion
48161844|NCT06645470|BEHAVIORAL|Monitoring Contacts|Participants will receive contacts with the research staff at weeks 6, 12, and 18.
48161845|NCT06645470|BEHAVIORAL|Aerobic Training|Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.
48368371|NCT04076280|BEHAVIORAL|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
48368372|NCT04084275|BEHAVIORAL|breastfeeding education|
48161846|NCT06645470|BEHAVIORAL|Resistance Training|Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.
48368373|NCT04084275|BEHAVIORAL|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
48368374|NCT04084275|BEHAVIORAL|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
48368375|NCT04084275|BEHAVIORAL|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
48368376|NCT04084275|BEHAVIORAL|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
48004937|NCT02702401|OTHER|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
48004938|NCT04974970|DRUG|Peanut Immunotherapy|Treatment will be injected peanut extract every 2 weeks for a period of 3 months.
48004939|NCT00245765|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: solution for injection in pre-filled syringe~* Route of Administration: subcutaneous use"
48004940|NCT00245765|OTHER|Placebo|Matching Placebo to Certolizumab Pegol
48004941|NCT04360577|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
48004942|NCT02610699|OTHER|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
48004943|NCT02610699|OTHER|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
48004944|NCT03999307|RADIATION|Low-Level Laser Therapy (LLLT)|LLLT will be applied in this group
48004945|NCT03999307|PROCEDURE|Flapless Corticopunture|Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
48004946|NCT03999307|OTHER|Control|Typical orthodontic treatment with no LLLT or flapless corticopuncture
48004947|NCT01050738|PROCEDURE|Position of catheter|Position of catheter for administration of local anestesia.
48004948|NCT04111094|DIAGNOSTIC_TEST|No intervention|No intervention
48004949|NCT00721695|DRUG|OMS302|OMS302 Irrigation Solution
48004950|NCT00721695|DRUG|OMS302-PE|OMS302-PE HCI Irrigation Solution
48004951|NCT00721695|DRUG|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
48004952|NCT00390975|DRUG|Tegaserod|
48004953|NCT03132051|DRUG|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
48004954|NCT06288516|DRUG|Benralizumab 30 mg/ml|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
48161847|NCT06645470|OTHER|Nutrition Education|A single counseling session to discuss the dietary recommendations when taking an obesity medication.
48161848|NCT02511171|OTHER|Cranial osteopathic manipulative therapy|
48161849|NCT03604653|DEVICE|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
48690825|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
48690826|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine|0.5 mL, IM
48690827|NCT00000401|DRUG|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
48690828|NCT01221753|DRUG|docetaxel|
48690829|NCT01221753|DRUG|cisplatin|Given intravenously on day 1 of each cycle
48161850|NCT03604653|DRUG|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
48690830|NCT01221753|DRUG|5-FU|
48004955|NCT01393743|DRUG|Perampanel|
48004956|NCT01393743|DRUG|Placebo comparator|
48161851|NCT03604653|DRUG|CDDP 50|50mg/m2@T0
48161852|NCT03604653|DRUG|CDDP 75|75mg/m2@T0
48161853|NCT03604653|DRUG|Doxorubicin|15mg/m2@T0
48161854|NCT01138137|DRUG|Paclitaxel|"Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles"
48690831|NCT01221753|RADIATION|IMRT|
48004957|NCT05686265|DRUG|Oxygen|Physiological intervention consisting of 1 hour of mild hypoxia (PaO2 9-10 kPa), 1 hour of mild hyperoxia (PaO2 13-14 kPa), and in healthy subjects also 1 hour of an inspired oxygen fraction of 100%.
48004958|NCT02271633|DIETARY_SUPPLEMENT|Sodium nitrate|
48004959|NCT02271633|DIETARY_SUPPLEMENT|Beetroot juice|
48004960|NCT02271633|DIETARY_SUPPLEMENT|Spinach|
48161855|NCT01138137|DRUG|N-acetylcysteine|"A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg"
48161856|NCT01138137|DRUG|Cisplatin|"Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles"
48161857|NCT05382390|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
48161858|NCT05382390|DRUG|Decitabine|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
48161860|NCT06016179|DRUG|Tocilizumab|Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
48161861|NCT01536535|DRUG|Mesalazine|Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
48161862|NCT01536535|DRUG|IV Corticosteroid|Treatment with IV Corticosteroid
48161863|NCT01536535|DRUG|Oral Corticosteroids|Treatment with oral corticosteroids
48161864|NCT01536535|OTHER|Additional Therapies|Anti-TNFα, Calcineurin inhibitor, Immunomodulator
48161865|NCT01536535|PROCEDURE|Colectomy|Colectomy
48161866|NCT00355732|PROCEDURE|Weaning from mechanical ventilation|
48161867|NCT02394171|BEHAVIORAL|Group Cohesion|See description in arm/group above
48161868|NCT01816100|OTHER|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
48690832|NCT01221753|DRUG|cetuximab|
48690833|NCT01221753|DRUG|carboplatin|
48004961|NCT02271633|DIETARY_SUPPLEMENT|Rocket salad|
48004962|NCT04552938|OTHER|pre-LVA|Venous serum samples were collected from patients before LVA.
48004963|NCT04552938|OTHER|post-LVA|Venous serum samples were collected from patients one-month after LVA.
48004964|NCT01537783|DRUG|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
48161869|NCT01816100|BEHAVIORAL|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
48690834|NCT05537064|BEHAVIORAL|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
48161870|NCT04450771|BEHAVIORAL|Family-based Treatment for ARFID|This treatment includes 14 1-hour sessions that will be conducted approximately weekly over a 4 month period. It is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior.
48690835|NCT05537064|BEHAVIORAL|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
48690836|NCT01905943|DRUG|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
48690837|NCT01905943|DRUG|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
48690838|NCT01905943|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
48690839|NCT01905943|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
48690840|NCT01905943|DRUG|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
48690841|NCT05962151|DRUG|Nalbuphine ER|Oral tablets
48690842|NCT05962151|DRUG|Placebo|Oral tablets
48690843|NCT01435473|PROCEDURE|Cardiac Surgery|
48690844|NCT05327075|OTHER|questionnaire|it is in the form of questionnaire and scoring tool
48690845|NCT02371577|DRUG|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
48690846|NCT05178316|DRUG|JZP150|Oral administration of JZP150 once daily in the morning
48690847|NCT05178316|DRUG|Placebo|Oral administration of placebo once daily in the morning
48690848|NCT04643587|BIOLOGICAL|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
48004965|NCT01537783|DRUG|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
48004966|NCT01574703|DRUG|placebo|All dosing to have taken place per study A3051123
48161871|NCT04450771|BEHAVIORAL|Manualized Non-Specific Usual Care for ARFID|This treatment is a manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model. It consists of sessions with the child alone and 5 parent-only meetings, all of which are 1-hour over a 4 month period.
48368377|NCT04084275|BEHAVIORAL|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
48004967|NCT01574703|DRUG|varenicline tartrate|All dosing to have taken place per study A3051123
48368378|NCT00034476|DRUG|sPLA2 Inhibitor|
48368379|NCT00952146|PROCEDURE|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
48368380|NCT04051320|DRUG|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
48690849|NCT04643587|DRUG|Placebo|Normal saline (0.9% NaCl)
48004968|NCT01574703|DRUG|bupropion hydrochloride|All dosing to have taken place per study A3051123
48690850|NCT01139203|DRUG|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
48690851|NCT00579618|OTHER|Saliva or Blood samples|Extracting sample of saliva or blood only once.
48690852|NCT06352151|OTHER|Routine Physiotherapy Group|Children with Down syndrome who receive routine physical therapy treatment in special education centers will undergo evaluation after eight weeks of treatment, followed by a control evaluation after 12 weeks.
48004969|NCT01574703|DRUG|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
48004970|NCT00123188|PROCEDURE|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
48368381|NCT04051320|DRUG|Estradiol 2 Mg tablet|2 mg estradiol tablet
48368382|NCT04051320|DRUG|Micronized progesterone|200 mg micronized progesterone tablets
48368383|NCT05381740|DEVICE|Novel rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
48161872|NCT05721378|PROCEDURE|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
48004971|NCT05886569|DEVICE|DIGIPREDICT Physiopatech|Application of the DIGIPREDICT Physiopatch investigational device
48004972|NCT00518804|BEHAVIORAL|Functional Behavioural Skills Group and Parent Training|
48161873|NCT05721378|PROCEDURE|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
48161874|NCT02994264|RADIATION|adjuvant concurrent chemoradiation|
48185224|NCT02480699|OTHER|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
48368384|NCT05381740|DEVICE|Sham rTMS Approach|Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
48368385|NCT06177145|OTHER|HASCV-R program|"Healthy nutrition, Active life, Ways to cope with Stress, Cancer and cancer screening, Vaccination - Reproductive health Training programme"
48368386|NCT05941494|DRUG|Propofol|Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min.
48368387|NCT05941494|DRUG|Sevoflurane|Patient's anesthesia will be maintained with 1 MAC of sevoflurane during surgery.
48368388|NCT05941494|DRUG|Ephedrine|The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
48368389|NCT05941494|DRUG|Phenylephrine|Patient will receive phenylephrine infusion as the primary vasopressor of choice. The typical dose of phenylephrine infusion is 10-40 mcg/min (dilution 100 mcg/ml).
48690853|NCT06352151|OTHER|Orofacial Treatment Group|"The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. Each week, one or two target exercises will be taught to the child with Down syndrome, and the exercises will gradually increase throughout the process. Parental involvement will be encouraged during the treatment to ensure active participation in therapy.~The goals of the therapy are as follows:~First Goal: Nasal hygiene and Sleep hygiene education~Second Goal: Nasal Breathing Exercise Training~Third Goal: Creating Awareness of Tongue Resting Position~Fourth Goal: Creating Lip Position Awareness - Lip Exercises~Goal Five: Chewing Muscle Exercises~Sixth Goal: Strengthening the Soft Palate~Seventh Goal: Reshaping Correct Swallowing"
48690854|NCT06352151|OTHER|Therapeutic Yoga Group|The therapeutic yoga group receives therapeutic yoga treatment and routine physiotherapy treatment. Children with Down syndrome will be given yoga exercises suitable for their age.
48004973|NCT02439112|OTHER|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly \>65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
48004974|NCT02644707|DIETARY_SUPPLEMENT|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
48004975|NCT02644707|OTHER|Placebo|The group will be randomized to receive placebo (control group) for 6 months
48690855|NCT06051318|OTHER|Standardized breakfast A|Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
48690856|NCT06051318|OTHER|Standardized breakfast B|Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
48690857|NCT01697475|BEHAVIORAL|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
48690858|NCT00119769|DRUG|Placebo|Placebo, 0.7 mg/day injected subcutaneously
48690859|NCT00119769|DRUG|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
48690860|NCT06661018|DRUG|Coenzyme Q 10|participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
48690861|NCT06661018|DRUG|Placebo|participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
48690862|NCT06445647|OTHER|core Stability exercise|core stability exercise training
48690863|NCT06445647|OTHER|Breathing exercises|Deep breathing and diaphragmatic breathing exercises
48690864|NCT00000487|DRUG|antihypertensive agents|
48690865|NCT00000487|BEHAVIORAL|smoking cessation|
48690866|NCT00000487|BEHAVIORAL|diet, fat-restricted|
48690867|NCT00000487|DRUG|diuretics|
48690868|NCT04818216|DRUG|Placebo|Placebo capsule containing inert ingredient
48690869|NCT04818216|DRUG|Nicotinamide riboside|250 mg Nicotinamide riboside capsules
48161875|NCT06116942|DEVICE|Active rTMS|"The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas."
48161876|NCT06116942|DEVICE|Sham rTMS|To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
48161877|NCT00390936|DRUG|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
48161878|NCT00215631|DRUG|tadalafil|
48161879|NCT05272787|OTHER|TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
48690870|NCT02582814|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
48690871|NCT02582814|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
48690872|NCT02920528|DRUG|Ketamine|sub-dissociative ketamine
48161880|NCT05272787|OTHER|TH Lip Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
48690873|NCT02920528|DRUG|Placebo|Normal Saline
48690874|NCT03760887|OTHER|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
48690875|NCT03760887|OTHER|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
48690876|NCT06137430|DRUG|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
48690877|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
48690878|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
48690879|NCT04200794|BEHAVIORAL|musical instrumental training|Learning to play a string instrument in a group setting (school class)
48690880|NCT04200794|BEHAVIORAL|sensitization to music|sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
48690881|NCT03325348|DRUG|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
48690882|NCT03325348|DRUG|Labetalol|IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
48690883|NCT04975412|DIAGNOSTIC_TEST|Whole blood zinc level|whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
48690884|NCT03450694|DEVICE|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
48690885|NCT01230996|DRUG|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
48690886|NCT01230996|RADIATION|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
48690887|NCT01230996|PROCEDURE|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
48690888|NCT05241860|OTHER|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
48690889|NCT05241860|OTHER|Follow-Up|Undergo follow-up
48690890|NCT05241860|OTHER|Questionnaire Administration|Ancillary studies
48690891|NCT05241860|OTHER|Quality-of-Life Assessment|Ancillary studies
48690892|NCT06400290|PROCEDURE|Percutaneous coronary intervention (PCI)|Coronary artery stenting for stable angina
48690893|NCT06400290|DIAGNOSTIC_TEST|Symptom assessment during experimentally induced ischaemia|Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.
48004976|NCT06441383|OTHER|Pittsburgh Sleep Quality Index|"The the Pittsburg Sleep Quality Index (PSQI) questionnaire is a standardized tool for the subjective assessment of sleep. Sleep is described according to 7 components: subjective sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disorders, medication use and daytime dysfunction. The sum of the scores for these 7 components gives an overall score of 21 points maximum.~The presence of sleep disorders will be defined according to the results of the PSQI, with a value above 5 defining the presence of sleep disorders."
48004977|NCT02888899|BEHAVIORAL|Biofeedback|
18249528|NCT06566963|DRUG|MK-1708|MK-1708 oral suspension
18249529|NCT06566963|DRUG|Placebo|Placebo oral suspension
48161881|NCT05272787|OTHER|Facial Moisturizer B (Control)|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
48161882|NCT05272787|OTHER|Sunscreen|Auxiliary product
48161883|NCT05272787|OTHER|Facial wash|Auxiliary product.
48690894|NCT05511727|DEVICE|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method
48004978|NCT02888899|DRUG|Loperamide|
48004979|NCT02888899|DRUG|Stool bulking agent (sterculia or ispaghula husk)|
48004980|NCT02888899|OTHER|PTNS|
48004981|NCT06408467|OTHER|aMMP-8 diagnostic test|40 patients
48690895|NCT05388383|DEVICE|Ti-robot|Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
48004982|NCT05572619|DEVICE|1st Reading|The medical team visually checks the non-contrast CT without cELVO and diagnose the large vessel occlusion.
48004983|NCT05572619|DEVICE|2nd Reading|The medical team visually checks the non-contrast CT with assistance from the cELVO and diagnose the large vessel occlusion.
48004984|NCT00872846|DEVICE|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
48004985|NCT02206516|DEVICE|Transcranial Direct Current Stimulation|
48161884|NCT01103271|OTHER|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
48004986|NCT01767922|DIETARY_SUPPLEMENT|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~* visit V1, so-called inclusion visit (D0),~* visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~* visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
48161885|NCT02133183|OTHER|Laboratory Biomarker Analysis|Correlative studies
48161886|NCT02133183|OTHER|Pharmacological Study|Correlative studies
48161887|NCT02133183|DRUG|Sapanisertib|Given PO
48161888|NCT02133183|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48161889|NCT02905877|OTHER|Behavioural study|reaching studies and other behavioural studies.
48185225|NCT02430753|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
48690896|NCT04015817|OTHER|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
48690897|NCT01360749|DRUG|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
48690898|NCT01360749|DRUG|Placebo|Placebo dose: 2 g for 10 cm2.
48690899|NCT05207644|DRUG|30 mg letrozole followed by 800 mcg misoprostol|30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
48690900|NCT03245554|DRUG|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
48185226|NCT02430753|DEVICE|NanoKnife|
48185227|NCT00515788|DRUG|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
48690901|NCT05311176|BIOLOGICAL|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
48161890|NCT04187963|OTHER|Physical therapy|"The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances."
48161891|NCT06285227|BIOLOGICAL|CM313 injection|CM313
48161892|NCT04833842|OTHER|Web-based childbirth preparation program developed based on health belief model and supported by motivational interview|In the three-month study, primigravida women in the initiative group will be given a web-based childbirth preparation program, which is prepared based on the Health Belief Model and supported by motivational interviews. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
48161893|NCT04833842|OTHER|Web-based childbirth preparation program based on health belief model|In the three-month study, a web-based childbirth preparation program based on the Health Belief Model will be applied to primigravida women in the control group. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
48161894|NCT01316809|DRUG|AZD8055|Patients will start at 120 mg once daily
48161895|NCT02380885|BEHAVIORAL|SCIT|psychosocial group intervention
48004987|NCT01767922|DIETARY_SUPPLEMENT|Placebo - Excipient only|
48161896|NCT02380885|BEHAVIORAL|TAFT|psychosocial group intervention
48004988|NCT04871295|BEHAVIORAL|Noom Healthy Weight|Behavioral: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach. Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
48161897|NCT06584669|DIETARY_SUPPLEMENT|Krill oil|The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).
48690902|NCT05311176|DRUG|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
48690903|NCT05311176|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
48690904|NCT00858728|BEHAVIORAL|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
48161898|NCT06584669|OTHER|Placebo|The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.
48690905|NCT00858728|BEHAVIORAL|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
48690906|NCT01147887|DRUG|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
48690907|NCT02808052|DRUG|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
48690908|NCT04622501|PROCEDURE|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
48690909|NCT03999099|DRUG|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
48690910|NCT03999099|DRUG|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
48690911|NCT03999099|DRUG|Placebo oral tablet|Placebo
48004989|NCT04489030|OTHER|Magnifying narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
48004990|NCT00807534|DRUG|ipratropium bromide|ipratropium bromide nebulization
48004991|NCT00807534|DRUG|placebo|placebo nebulization
48004992|NCT00807534|BEHAVIORAL|constant rate step test|nebulization of 500ug
48004993|NCT00807534|BEHAVIORAL|constant rate shuttle walk test|nebulization of 500ug
48004994|NCT05982535|DEVICE|Easy Dew MD Regen Cream|The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.
48004995|NCT00829296|DRUG|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
48004996|NCT00829296|DRUG|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
48690912|NCT00014989|DRUG|magnesium sulfate|
48690913|NCT05757440|OTHER|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
48690914|NCT06553118|PROCEDURE|Total knee arthroplasty|Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
48690915|NCT00386750|DRUG|Artemether-lumefantrine|
48004997|NCT03978975|BEHAVIORAL|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~* session 27°C :aquatic cycling at 27°C without water jet during 40 min~* session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~* session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
48004998|NCT02376192|DEVICE|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
48004999|NCT02376192|DRUG|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
48161899|NCT04392297|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
48161900|NCT04392297|DIAGNOSTIC_TEST|CMV specific T-cells|CMV specific T-cells detected by flow cytometry
48161901|NCT04392297|DIAGNOSTIC_TEST|serum CMV IgM / IgG antibodies|serum CMV IgM / IgG antibodies detected by ELISA
48690916|NCT02244840|DEVICE|Electronic bidet|commercial electronic bidet
48161902|NCT02376322|RADIATION|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
48690917|NCT02244840|DEVICE|Sitz bath|Conventional sitz bath
48161903|NCT03982082|PROCEDURE|Physical Therapy|Undergo physical therapy
48161904|NCT03982082|OTHER|Questionnaire Administration|Ancillary studies
48161905|NCT03982082|PROCEDURE|Ultrasound|Undergo ultrasound via MuscleSound technology
48161906|NCT05356195|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
48690918|NCT02574884|PROCEDURE|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
48161907|NCT00675519|BEHAVIORAL|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
48161908|NCT01372826|DRUG|NKTR118 Group1|Oral dose, 25 mg
48161909|NCT01372826|DRUG|NKTR118 Group 2|Oral dose, 25 mg
48005000|NCT02376192|DEVICE|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
48005001|NCT02376192|DRUG|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
48005002|NCT02376192|DRUG|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
48161910|NCT01372826|DRUG|NKTR118 Group3|Oral dose, 25 mg
48161911|NCT01372826|DRUG|NKTR118|Oral dose, 25 mg
48161912|NCT02577848|DRUG|GLP-1|GLP-1 were taken daily for 7 days
48161913|NCT02577848|DRUG|Placebo|Placebo were taken daily for 7 days
48161914|NCT02028234|DRUG|Pantoprazole,|os, 20 mg, once per day, for 30 days
48161915|NCT02028234|DRUG|Omeprazole|os, 20 mg, once per day, for 30 days
48185228|NCT00515788|DRUG|Temozolomide|100 mg/m\^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
48185229|NCT00538772|OTHER|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
48185230|NCT05144945|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine (RIV4)|Solution for intramuscular injection
48690919|NCT00053677|DRUG|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
48690920|NCT00053677|DRUG|Placebo|For subjects who were randomly assigned to placebo.
48690921|NCT05927519|DEVICE|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
48690922|NCT04163861|DIAGNOSTIC_TEST|2d speckle tracking echocardiography|2d speckle tracking echocardiography
48690923|NCT04163861|DIAGNOSTIC_TEST|serum BNP level|serum BNP level of HFpEF study subjects
48690924|NCT02408718|BEHAVIORAL|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
48185231|NCT05144945|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV4)|Suspension for intramuscular injection
48690925|NCT05222412|DRUG|Iptacopan|Patients receive Iptacopan
48690926|NCT03465137|BEHAVIORAL|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
48690927|NCT00070928|DRUG|valerian|
48161916|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM)."
48161917|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"All samples will be tested pre- and post-vaccination by comparing Access anti-HAV assay results to final anti-HAV status, according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT)."
48161918|NCT01378533|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
48161919|NCT02209688|DRUG|ESR 1150 CL|
48161920|NCT02209688|DRUG|Placebo|
48161921|NCT05456308|PROCEDURE|Hydrodistention during cystoscope|Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
48161922|NCT04222335|OTHER|Blood samples|"Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes."
48161923|NCT06399640|DRUG|Eltanexor|Eltanexor will be taken by mouth
48161924|NCT06399640|DRUG|Venetoclax|Venetoclax will be taken by mouth
48161925|NCT06399640|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48161926|NCT06399640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48161927|NCT00509925|DRUG|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
48161928|NCT00509925|DRUG|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
48161929|NCT00509925|DRUG|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
48161930|NCT02042170|DRUG|human growth hormone self-injection|
48161931|NCT03630783|BEHAVIORAL|Combined Cognitive Bias Modification|
48161932|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via prefilled syringe (PFS)
48161933|NCT05274100|DRUG|Risankizumab|Intravenous Infusion
48161934|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via on-body delivery system (OBDS)
48690928|NCT05146154|DRUG|Imipenem/Cilastatin/Relebactam 1.25g|Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
48005003|NCT05992792|BEHAVIORAL|App message|Participantes push App message cancer prevention from the recomendations ECAC. 2 SMS notifications (push) per week or frequency of app notifications per week.
48005004|NCT05992792|BEHAVIORAL|SMS message|Participants push SMS message cancer prevention from the ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
48161935|NCT03722485|DEVICE|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
48161936|NCT03722485|BIOLOGICAL|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
48161937|NCT00001436|DRUG|OncoLAR® (Registered Trademark)|
48161938|NCT00001436|DRUG|tamoxifen|
48161939|NCT04608006|DRUG|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
48161940|NCT00396721|DRUG|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
48161941|NCT00396721|DRUG|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
48161942|NCT03731572|OTHER|Power Training|Hip abductor-adductor resistance exercises at maximum execution speed
48161943|NCT03731572|OTHER|Strength Training|Hip abductor-adductor resistance exercises at reduced execution speed
48161944|NCT05580302|OTHER|Transcranial Magnetic Stimulation (TMS)|An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
48690929|NCT05397041|DRUG|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
48005005|NCT05992792|BEHAVIORAL|Internet|Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
48005006|NCT05992792|BEHAVIORAL|Whithout internet|Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
48005007|NCT03595410|OTHER|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
48005008|NCT03765736|OTHER|Genetic Testing|Undergo genetic testing
48005009|NCT05071703|DRUG|Trilaciclib|"* Carboplatin combined with Etoposide (ES-SCLC patients)~* plus Topotecan (second/third line ES-SCLC patients)"
48005010|NCT01219725|BEHAVIORAL|Exercise training|6 months of moderate intensity exercise training 3 times per week
48005011|NCT04569045|DEVICE|HA+Lidocaine|20 mg
48005012|NCT04569045|DEVICE|HA|20 mg
48005013|NCT02284503|DRUG|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
48005014|NCT01404091|DRUG|LY2940094|Administered orally
48005015|NCT04292730|DRUG|Remdesivir|Administered as an intravenous infusion
48005016|NCT04292730|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
48005017|NCT00003491|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48005018|NCT05005390|DEVICE|TTIP ventilation|In TTIP ventilation, an endotracheal tube is inserted via the nostril or oral cavity and subsequently advanced until the tip of the tube reaches approximately the level of the glottis.
48005019|NCT05005390|DEVICE|Mask Ventilation|In mask ventilation, a mask is placed over the nose and mouth.
48005020|NCT06183359|OTHER|SIP|compare the SIP group versus the ACT group
48005021|NCT02983071|DRUG|G1T38|
48005022|NCT02983071|DRUG|Fulvestrant|
48005023|NCT03881137|OTHER|Geriatric assessment with management|"A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT."
48005024|NCT01530971|DRUG|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
48005025|NCT00337103|DRUG|Eribulin Mesylate|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
48368390|NCT04686396|DEVICE|Demineralized bone matrix|Demineralized bone matrix
48368391|NCT02906644|DRUG|lorcaserin|
48690930|NCT05397041|DRUG|Placebo|Matched Placebo
48005026|NCT00337103|DRUG|Capecitabine|Capecitabine 2.5 g/m\^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
48005027|NCT00143702|DRUG|d4T|See Detailed Description.
48005028|NCT00143702|DRUG|Abacavir|See Detailed Description.
48005029|NCT00143702|DRUG|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
48005030|NCT01182493|DEVICE|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
48368392|NCT02906644|DRUG|nicotine patch|
48368393|NCT02906644|DRUG|placebo lorcaserin|
48690931|NCT03753360|BEHAVIORAL|Internet-Based Mindfulness Program - Stress Free Now for Healers|Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
48161945|NCT06646198|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA
48690932|NCT03753360|BEHAVIORAL|Active Control Group - Relaxing Music|The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
48690933|NCT01712997|DRUG|Iloprost|
48005031|NCT05503719|PROCEDURE|Surgical wound closed with an absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with an absorbable suture according to their respective study group.
48161946|NCT06646198|DRUG|Donafenib|Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
48161947|NCT04266366|OTHER|Face-to-Face Rehabilitation program|In each hospital, two trained therapists will carry out a face-to-face rehabilitation program consisting of electroanalgesia and an exercise program that follows the Mckenzie method. The physiotherapists place the electrodes in the patients, for this they use 5x9 cm electrodes, which they place at the bilateral paravertebral level, in the patients who present with radicular pain, the electrodes will be placed in the path of the affected nerve. The duration will be sufficient to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal periarticular components of the spine.
48161948|NCT04266366|OTHER|Telemedicine program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
48161949|NCT04798508|OTHER|Evoked related potential - P3 paradigm|Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
48161950|NCT05004688|BIOLOGICAL|Biological/Vaccine: Bacillus Calmette-Guerin (BCG)|Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
48161951|NCT03965468|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
48161952|NCT03965468|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
48161953|NCT03965468|DRUG|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
48161954|NCT03965468|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
48161955|NCT03965468|PROCEDURE|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
48161956|NCT03965468|RADIATION|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
48690934|NCT01712997|DRUG|Bosentan|
48005032|NCT05503719|PROCEDURE|Surgical wound closed with a non-absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with a non-absorbable suture according to their respective study group.
48005033|NCT03736850|DRUG|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
48005034|NCT02202447|DRUG|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
48005035|NCT02202447|OTHER|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
48161957|NCT03965468|DRUG|Tremelimumab|Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
48161958|NCT06401447|RADIATION|Radiotherapy|Simultaneously optimizing the target, dosage, and synchronized drugs for radiotherapy.
48161959|NCT01766323|DRUG|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
48161960|NCT01766323|DRUG|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
48005036|NCT03499392|OTHER|psychological tests|psychological tests psychological interviews
48005037|NCT00481442|DRUG|Phenylephrine|
48161961|NCT05127122|DRUG|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Injectable
48161962|NCT05127122|OTHER|Saline|Placebo Saline
48161963|NCT00647985|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fed
48690935|NCT05816343|DRUG|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
48690936|NCT05816343|DRUG|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
48690937|NCT03046927|DRUG|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
48161964|NCT00647985|DRUG|Allegra® Tablets 180 mg|180mg, single dose fed
48161965|NCT01507753|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
48005038|NCT05515848|OTHER|No intervention|There is no intervention in this retrospective study.
48161966|NCT01507753|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
48161967|NCT01507753|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
48005039|NCT01619670|DEVICE|Apligraf|non adhesive layer
48161968|NCT02136797|BIOLOGICAL|CMVpp65 Specific T-cells|
48690938|NCT03046927|OTHER|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
48005040|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
48005041|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
48005042|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
48005043|NCT00235989|DRUG|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
48161969|NCT00762723|DEVICE|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
48161970|NCT00652496|DRUG|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
48161971|NCT00652496|DRUG|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
48161972|NCT00652496|DRUG|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
48161973|NCT00652496|DRUG|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
48161974|NCT00652496|DRUG|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
48005044|NCT01595360|DRUG|Placebo|It is applied directly to the bleeding site after tooth extraction
48005045|NCT01595360|DRUG|TT-173|It is applied directly to the bleeding site after tooth extraction
48690939|NCT06531213|OTHER|experimental|"Experimental Group: Baseline rehabilitation, Visual Perception Interventions. Home base activities, Baseline Rehabilitation (Strengthing exercise, achieving missing milestones).~Visual Perception Interventions~• Puzzle:Give step-by-step • printable activities • Sudoku. SET, Search Word, Spot it, what is missing, Tic Tac Toe, I Spy"
48005046|NCT00378703|BIOLOGICAL|Bevacizumab|Given IV
48005047|NCT00378703|OTHER|Laboratory Biomarker Analysis|Correlative studies
48005048|NCT00378703|OTHER|Pharmacological Study|Correlative studies
48005049|NCT00378703|DRUG|Sorafenib Tosylate|Given PO
48005050|NCT00378703|DRUG|Temsirolimus|Given IV
48005051|NCT06158022|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
48005052|NCT06158022|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
48005053|NCT00797082|DEVICE|MRI|MRI = Myocardial Perfusion Stress
48005054|NCT00797082|DEVICE|MPS|MPS = Myocardial Perfusion Scintigraphy
48005055|NCT00545857|DRUG|pioglitazone|Pioglitazone daily; dose varies with size
48005056|NCT00545857|DRUG|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
48005057|NCT04090593|OTHER|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
48005058|NCT01344447|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
48005059|NCT02366078|BEHAVIORAL|SMART|Paced breathing meditation with cognitive training
48005060|NCT02233010|OTHER|The level of NGAL after pre op,post op 4hr, post op 12hr|
48005061|NCT06225089|DRUG|pericapsuler nerve block|-Ultrasound Guided pericapsuler nerve block: will be externally rotated and abducted to 45 degrees. The shoulder area will be sterilized with povidone-iodine. High-frequency linear ultrasound perpendicularly between the coracoid and the humeral head probe. The deltoid muscle, subscapular muscle and tendon, and humeral head will be identified on the ultrasound screen. With the in-plane technique, a 22 gauge, 50 millimeter (mm) simplex A peripheral nerve block needle will be used. After passing the deltoid muscle, the needle will contact the tendon of the subscapularis muscle. The needle will be slightly withdrawn and directed between the deltoid muscle and the tendon of the subscapularis muscle and a local injection consisting of will be applied.
48005062|NCT05164458|DRUG|IBI 308 injection|IBI308 IV 200mg Q3W Day1
48005063|NCT05164458|DRUG|IBI 389 Injection|IBI 389 IV Q2\~Q3W Day 1
48005064|NCT01737567|OTHER|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
48005065|NCT01737567|OTHER|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
48005066|NCT02150668|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|
48005067|NCT02150668|BEHAVIORAL|Homework Support Intervention (HSI)|
48005068|NCT05028504|DRUG|Penpulimab|Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48005069|NCT05028504|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
48005070|NCT06123546|OTHER|Patient oriented discharge summary|"The intervention consists of three components: the patient-oriented discharge summary (PODS), the teach-back technique and the involvement of caregivers.~The PODS will be completed with participants over the course of the hospitalisation as teaching content related to the six sections of information is delivered. Participants will take the PODS home at discharge to use it as a reference for relevant and individualized discharge information in the post-discharge period.~Healthcare providers will receive a training refresher on the teach-back technique and will be reminded to use it when they deliver discharge teaching during participants' hospital stay.~Involvement of caregivers will include early identification by the healthcare provider responsible for patient admission of a caregiver who will provide care at home, at least one teaching session during hospitalization and the review of the PODS the day of discharge."
48005071|NCT06264388|DRUG|DB107-RRV|Patients will undergo surgery to remove as much of the high-grade glioma (HHG) tumor as possible and will receive combination intravenous (IV) and adaptive repeat intratumoral delivery of DB107-RRV in the vein (IV) and in the walls of the cavity that remains where tumor is removed.
48005072|NCT06264388|DRUG|DB107-FC|Patients will start taking DB107-FC three times by mouth every day for a period of seven days, which is one cycle of treatment. A cycle of treatment is medication taken on a set schedule with periods of rest in between. Patients will wait five weeks before taking the next seven day course of DB107-FC. The first dose of DB107-FC will be taken at the hospital or clinic; afterward, patients will take the doses of DB107-FC at home. Patients will take DB107-FC for up to 12 months after surgery.
48005073|NCT04408846|DEVICE|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
48005074|NCT03216447|DRUG|Advagraf|Tacrolimus prolonged-release hard capsules (QD)
48005075|NCT03216447|DRUG|Prograf|Tacolimus capsules (q12h)
48005076|NCT03382483|DEVICE|Low intensity pulsed ultrasound|bone growth stimulator
48185232|NCT05102058|DRUG|Magnesium-Dexmedetomidine|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively
48005077|NCT05371600|DRUG|Midazolam|midazolam IV at 0.04 mg/kg
48005078|NCT05371600|OTHER|Saline|an equal volume of saline IV
48005079|NCT05410327|OTHER|Chokeberry (Aronia melanocarpa) juice|A water-infused chokeberry (Aronia melanocarpa) juice will be used as the intervention. The brand being used is called 'Superberries'.
48005080|NCT00892164|DEVICE|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
48005081|NCT00892164|DEVICE|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
48005082|NCT05256121|OTHER|AD Risk factors balance|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
48005083|NCT05933681|DEVICE|Neural recordings and stimulation|Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
48185233|NCT05688553|DEVICE|Flexi-bar|two groups, experimental group intervention Flexi-bar with balance and strength training
48690940|NCT06531213|OTHER|controlled|Controlled: Baseline rehabilitation. Home-based activities, Baseline Rehabilitation (strengthening exercise, achieving missing milestones).3. Activities Play Dough ( Manipulation) Draw on sketch Cup stacking.
48005084|NCT00554437|BEHAVIORAL|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
48161975|NCT06646315|BEHAVIORAL|Early Intervention|The Early Intervention consists of the proper attention given to those patients who participate in a Phase I Clinical Trial. The attention will be based on a monthly assessment of their physical, psychological/emotional symptoms and, also their sociofamiliar needs. After having discussed patients's needs in a multidisciplinary committee, each professional (paliiative physician, clinical psychologist and/or wocial orker) will proportionate them the required attention in order to increase their quality of life.
48161976|NCT03092323|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
48161977|NCT01403805|BIOLOGICAL|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
48161978|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
48161979|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
48161980|NCT01403805|OTHER|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
48161981|NCT03779126|DEVICE|Electrical stimulation|1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
48161982|NCT04946656|PROCEDURE|sphenopalatine ganglion block|The sphenopalatine ganglion will be blocked with bupivacaine for this study
48161983|NCT01963858|PROCEDURE|Functional relaxation|Functional relaxation during colonoscopy
48161984|NCT01963858|PROCEDURE|No relaxation|No relaxation during colonoscopy
48161985|NCT00998114|BEHAVIORAL|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
48161987|NCT00376207|BEHAVIORAL|Physical exercise|
48161988|NCT02029027|DEVICE|GYNEFFIK(R)|Vaginal electro-stimulation medical device
48161989|NCT02029027|OTHER|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
48161990|NCT00375778|DRUG|memantine (drug)|
48161991|NCT05043428|BEHAVIORAL|The roles of peers and functional tasks in enhancing exercise training for adults with COPD: a pilot randomized controlled trial|An 8 week two-arm pilot randomized control trial aimed to evaluate the effects of an online exercise and peer support intervention for people living with COPD.
48161992|NCT01393314|DEVICE|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
48161993|NCT04299971|DRUG|Methotrexate Tablets|"The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead."
48161994|NCT04299971|DRUG|Tofacitinib tablet|"The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead."
48161995|NCT03742232|DRUG|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
48690941|NCT03500016|OTHER|High intensity interval training|See under arm description.
48690942|NCT00577707|DRUG|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
48690943|NCT00577707|DRUG|Pemetrexed|pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
48690944|NCT00577707|DRUG|Cisplatin|cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
48161996|NCT03742232|DRUG|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
48005085|NCT00280254|PROCEDURE|Hemodynamically Oriented Echocardiography-based Strategy|
48690945|NCT00577707|PROCEDURE|Resection|
48161997|NCT04361916|OTHER|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
48690946|NCT04615234|DEVICE|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
48161998|NCT06646211|DRUG|Zanubrutinib , Thiotepa|"First 1-4 cycle~Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 1 for up to 4 cycle Drug: Zanubrutinib~* Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
48690947|NCT04597216|DEVICE|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
48690948|NCT05118165|DIETARY_SUPPLEMENT|Dietary supplement with protein|Will be included protein supplements in the preoperative diet.
48690949|NCT06106581|BIOLOGICAL|VLA1553 full dose|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate
48690950|NCT06106581|BIOLOGICAL|VLA1553 half dose|Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate
48005086|NCT05196919|BIOLOGICAL|XT-150|XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
48161999|NCT06646211|DRUG|Methotrexate , Thiotepa and Zanubrutinib|"Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
48162000|NCT06646211|DRUG|ASCT±Zanubrutinib|"Consolidation / maintenance treatment Patients who achieve a Complete Response (CR) or Partial Response (PR) after the ZT/ZMT treatment will enter consolidation/maintenance therapy.~Patients age ≤65 years old will undergo Autologous Stem Cell Transplantation (ASCT, with a recommended conditioning regimen that includes Thiotepa), followed by 6 months of maintenance treatment with zanubrutinib.~Patients age \> 65 will receive 6 months of maintenance treatment with zanubrutinib.~\*The study permits the prophylactic use of Granulocyte Colony-Stimulating Factor (G-CSF). For detailed usage, please refer to the guidelines from the National Comprehensive Cancer Network (NCCN) or the Chinese Society of Clinical Oncology (CSCO)"
48162001|NCT02256488|BIOLOGICAL|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
48162002|NCT02256488|BIOLOGICAL|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
48162003|NCT02256488|BIOLOGICAL|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
48162004|NCT02256488|BIOLOGICAL|TIVf|Single IM administration dose of 0.5 mL of TIVf
48162005|NCT05788081|DRUG|golcadomide|BMS-986369 is an orally administered Cereblon-modulating compound
48162006|NCT05788081|DRUG|Nivolumab 10 MG/ML|Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
48162007|NCT05788081|DRUG|Rituximab|Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
48690951|NCT06106581|BIOLOGICAL|Control|Nimenrix
48005087|NCT05196919|BIOLOGICAL|Placebo|Phosphate-buffered saline for injection
48005088|NCT03070353|DRUG|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
48005089|NCT02848976|OTHER|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
48162008|NCT01063127|OTHER|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
48162009|NCT01063127|OTHER|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
48162010|NCT00132925|DRUG|Triamcinolone|
48162011|NCT04231266|DRUG|ManNAc|Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
48162012|NCT04231266|OTHER|Placebo|Placebo
48162013|NCT02273180|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
48162014|NCT02273180|DRUG|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
48185234|NCT05688553|OTHER|balance and strength training|the control group intervention only balance and strength training
48690952|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
48690953|NCT03281369|DRUG|Leucovorin|Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
48690954|NCT03281369|DRUG|Oxaliplatin|Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
48690955|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
48690956|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle
48690957|NCT03281369|BIOLOGICAL|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
48690958|NCT03281369|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
48690959|NCT03281369|BIOLOGICAL|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
48690960|NCT03281369|DRUG|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
48690961|NCT03281369|DRUG|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
48162015|NCT02273180|DRUG|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
48162016|NCT06584565|OTHER|microbiome; metabolomics; proteomics|post-stroke change of microbiome; metabolomics; proteomics
48162017|NCT05381077|OTHER|MRI|Whole body MRI (ZTE sequence)
48162018|NCT05923359|OTHER|Apple Watch|Apple Watch
48162019|NCT06646471|GENETIC|Bio-bank repository|Blood samples taken during the screening phase prior to the first administration of systemic treatment and stored in a repository for a maximum duration of 10 years
48162020|NCT06646471|OTHER|Quality of Life (QoL)|"Collection of EORTC QoL questionnaires QLQ-F17, QLQ-LC13 and QLQ-ELD14:~* stage 3 non-operable/non-radiable, stage 4: at inclusion, 12 weeks, 6 months of treatment, first-line progression.~* operable stage 1 to 3b: at inclusion, end of neoadjuvant period before surgery post-operative baseline, at 6 months, at 12 months.~* radiable stages 3a to 3c: at inclusion, at the end of thoracic radiotherapy, at 6 months, at 12 months."
48162021|NCT06646471|PROCEDURE|G-Code|G-CODE: Katz Autonomy Scale (ADL), Instrumental Activities of Daily Living questionnaire (IADL), Charlson score, mini GDS, mini COG, falls history, Timed Get Up and Go test, social environment.
48690962|NCT03281369|DRUG|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
48690963|NCT03281369|DRUG|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.
48690964|NCT03281369|DRUG|Cisplatin|Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.
48690965|NCT03281369|DRUG|Tiragolumab|Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.
48162022|NCT05401201|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
48162023|NCT05401201|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self care.
48162024|NCT03603223|BIOLOGICAL|Pembrolizumab|Given IV
48162025|NCT04466059|DIAGNOSTIC_TEST|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
48162026|NCT00111839|DRUG|Pemetrexed|Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
48162027|NCT00111839|DRUG|Matuzumab|Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
48162028|NCT04542642|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
48162029|NCT04542642|DEVICE|PEAR-008|PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
48162030|NCT02081196|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
48185235|NCT03671577|BEHAVIORAL|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
48690966|NCT03281369|DRUG|5-Fluorouracil (5-FU)|5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.
48690967|NCT03834610|DRUG|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
48690968|NCT03834610|DRUG|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
48690969|NCT03834610|DIAGNOSTIC_TEST|serum testosterone level|measurement of serum testosterone level
48690970|NCT03834610|DIAGNOSTIC_TEST|HbA1C|measurement of HbA1C levels
48690971|NCT03834610|DEVICE|penile doppler|penile doppler to measure the degree of erection and penile vasculature
48690972|NCT05809544|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
48690973|NCT05809544|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
48690974|NCT02378233|DIETARY_SUPPLEMENT|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
48690975|NCT02378233|DIETARY_SUPPLEMENT|Placebo|Patients are given a non-iodine containing multivitamin tablet
48690976|NCT05749991|DEVICE|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
48690977|NCT05749991|DEVICE|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
48690978|NCT01152593|DRUG|Mupirocin|Intranasal cream given to patient after confirmation of colonization
48162031|NCT06164041|BEHAVIORAL|The use of mobile applications promoted from the physical education classroom to improve adolescent health.|"Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken."
48162032|NCT02642471|PROCEDURE|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
48162033|NCT03037814|DEVICE|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
48162034|NCT03037814|DEVICE|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
48690979|NCT04870463|PROCEDURE|Maxillary and mandibular Cone Beam Computed Tomography record|A Cone Beam Computed Tomography image of each patient of each group at three different moments of the study (baseline/T0, 8-9 months of treatment/T1 and end of treatment/T2)
48690980|NCT04975984|DIAGNOSTIC_TEST|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
48690981|NCT04707118|DRUG|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
48690982|NCT04707118|DRUG|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
48690983|NCT06200597|DRUG|LAD603|LAD603 SC injection.
48162035|NCT03037814|DEVICE|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
48162036|NCT03037814|DEVICE|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
48162037|NCT02445781|DEVICE|Glucose clamp|Different levels of hypoglycemia
48690984|NCT06200597|OTHER|Placebo|Matching placebo SC injection.
48690985|NCT06012747|OTHER|Questionnaire|The patients receive a questionnaire every 6 hours during the first 24 hours after their cesarean section, and again after 2, 7, and 30 days.
48162038|NCT05181891|BEHAVIORAL|Contingency Management|Incentives for submitting negative-alcohol urine samples
48162039|NCT05181891|BEHAVIORAL|Non-contingent control|Incentives for submitting urine samples
48162040|NCT06477562|OTHER|Endoscopy|surveillance endoscopy was routinely performed to the patients with proximal gastrectomy with double tract reconstruction group.
48162041|NCT06438705|DIAGNOSTIC_TEST|SPECT-CT imaging|The subjects were intravenously injected with 99mTc labeled FAPI imaging agent, and drank 300-500ml of water after administration. SPECT-CT imaging was performed 60 minutes later
48690986|NCT06433479|DRUG|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation|Dapagliflozin 10 mg per day for 3 months after initial catheter ablation
48690987|NCT00602225|DRUG|clofarabine|Given IV
48162042|NCT00946998|DRUG|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
48690988|NCT00602225|DRUG|cytarabine|Given IV
48690989|NCT00602225|BIOLOGICAL|filgrastim|Given subcutaneously
48690990|NCT05610163|DRUG|Capecitabine|Given PO
48690991|NCT05610163|DRUG|5-fluorouracil|Given IV
48690992|NCT05610163|DRUG|Leucovorin calcium|Given IV
48162043|NCT00946998|DRUG|placebo|Placebo tablet will be identical and matched to sertraline tablet.
48162044|NCT02062281|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
48162045|NCT02062281|BIOLOGICAL|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
48162046|NCT02062281|BIOLOGICAL|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
48690993|NCT05610163|DRUG|Irinotecan|Given IV
48690994|NCT05610163|DRUG|Oxaliplatin|Given IV
48690995|NCT05610163|RADIATION|Long Course Chemoradiotherapy|Receive LCRT
48690996|NCT05610163|PROCEDURE|Computed Tomography|undergo CT
48690997|NCT05610163|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
48690998|NCT05610163|PROCEDURE|Sigmoidoscopy|undergo sigmoidoscopy
48690999|NCT05610163|PROCEDURE|biopsy|undergo biopsy
48691000|NCT04674111|DEVICE|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
48691001|NCT03638050|OTHER|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
48005090|NCT02787252|DEVICE|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
48691002|NCT05878678|DEVICE|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
48691003|NCT05849272|DRUG|toludesvenlafaxine hydrochloride sustained-release tablets|orally once a day
48691004|NCT06107374|DRUG|[18F]F-AraG|Two PET scans
48691005|NCT05289648|DRUG|Niraparib oral capsule|Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
48691006|NCT00496977|PROCEDURE|annual CT screening|
48691007|NCT03935789|BEHAVIORAL|BLAST|12-week self-guided intervention using a web-based platform
48691008|NCT00412958|DRUG|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
48691009|NCT00412958|DRUG|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
48691010|NCT00412958|DRUG|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
48005091|NCT03156010|DEVICE|Neuro Kinetics IPAS|Testing with PAS device
48005092|NCT03156010|DEVICE|Oculogica EyeBox|Testing with Oculogica EyeBox device
48691011|NCT00412958|DRUG|Placebo|Intravitreal injection of placebo
48691012|NCT06335537|DRUG|Potassium citrate|Urocit-K 30 mEQ orally taken in the morning and evening.
48691013|NCT06335537|DRUG|Sodium bicarbonate|Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.
48691014|NCT02047422|DRUG|Furosemide|furosemide (doubling previous furosemide dose)
48691015|NCT02047422|DRUG|metolazone|metolazone (add 2.5mg qod)
48691016|NCT02047422|DRUG|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
48691017|NCT02047422|DRUG|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
48005093|NCT03156010|DEVICE|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
48005094|NCT00955266|DRUG|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
48691018|NCT05549258|DRUG|Inebilizumab|Inebilizumab administered intravenously (IV) over a total of 28 weeks.
48005095|NCT00955266|DRUG|Placebo|Normal saline, 50cc delivered over 5 minutes
48005096|NCT01856816|OTHER|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
48005097|NCT01856816|OTHER|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
48005098|NCT01856816|OTHER|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
48005099|NCT00757835|DRUG|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
48005100|NCT00757835|DRUG|latanoprost/timolol fixed combination drops|once in the evening
48005101|NCT05522465|DRUG|Prednisone|Prednisone 4mg/kg.d, d1-4
48005102|NCT05522465|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg.d, d1-4
48691019|NCT05558358|DEVICE|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- \> 6 months of sham stimulation
48691020|NCT05558358|DEVICE|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- \> 6 months of active stimulation
48691021|NCT02364804|DRUG|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
48691022|NCT06051019|OTHER|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
48691023|NCT06051019|OTHER|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
48005103|NCT04152512|BEHAVIORAL|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
48005104|NCT03799484|DRUG|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
48005105|NCT03799484|DRUG|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
48162047|NCT05005338|DRUG|BIIB122 (DNL151)|Oral doses
48691024|NCT06334159|PROCEDURE|Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).
48691025|NCT06334159|PROCEDURE|Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
48162048|NCT05005338|DRUG|[14C] BIIB122 ([14C] DNL151)|Intravenous doses
48162049|NCT05422859|OTHER|MobiDig|"The application will contain the following modules:~1. information and knowledge about heart failure;~2. vital sign diary, which can be sent to the certified HFU~3. pedometer (individualized step-goal), cardiac home training videos~4. frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
48691026|NCT05600894|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
48162050|NCT04258215|DEVICE|Experimental: Routine positive pressure airway management.|The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
48691027|NCT05600894|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48691028|NCT05600894|DRUG|Decitabine and Cedazuridine|Given PO
48162051|NCT00119795|BEHAVIORAL|Exercise|Increase Physical Activity to 150 min/wk
48162052|NCT00119795|BEHAVIORAL|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
48691029|NCT05600894|DRUG|Venetoclax|Given PO
48162053|NCT00119795|BEHAVIORAL|Health Education Control|Lectures on information relevant to successful aging
48691030|NCT00033423|BIOLOGICAL|rituximab|
48691031|NCT00033423|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48691032|NCT05577000|BIOLOGICAL|Manufactured Anti-BCMA CAR-T cells|Given IV
48691033|NCT05577000|DRUG|Fludarabine|Given IV
48691034|NCT05577000|DRUG|Cyclophosphamide|Given IV
48691035|NCT00648388|DRUG|Cilostazol Tablets 100 mg|100mg, single dose fasting
48691036|NCT00648388|DRUG|Pletal® Tablets 100 mg|100 single dose fasting
48691037|NCT05407012|OTHER|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
48691038|NCT02156206|BEHAVIORAL|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
48162054|NCT05117879|PROCEDURE|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
48162055|NCT04634812|DRUG|KBP-5074|a single oral dose of \[14C\]-KBP-5074
48162056|NCT05422742|PROCEDURE|SRP + MM|Subjects will be randomized into either SRP only or SRP +MM. Periodontal therapy will consist of one visit full-month SRP alone or in-combination with MM placed at all sites regardless of probing pocket depth. Each site will recieve 1mg of MM for a total of 6mg of MM per tooth.
48162057|NCT05422742|PROCEDURE|Scaling and Root Planing (SRP)|Procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation.
48162058|NCT05818995|DRUG|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
48162059|NCT00945178|DRUG|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
48691039|NCT02853396|OTHER|Cognitive Behaviour Therapy|
48691040|NCT02853396|OTHER|Psychoeducation|
48691041|NCT06369753|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period
48691042|NCT06369753|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
48691043|NCT06203457|BIOLOGICAL|Efgartigimod|Patients receiving efgartigimod infusions
48162060|NCT00945178|DRUG|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
48691044|NCT05040971|DRUG|Semaglutide 2.4 mg|Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
48691045|NCT05040971|DRUG|Placebo|Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week
48162061|NCT00945178|DRUG|Naproxen|Tablet, single oral dose, 500mg
48162062|NCT00945178|DRUG|Placebo for Naproxen|Tablet, single oral dose
48162063|NCT04013932|BEHAVIORAL|KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)|"KUPAA is composed of 3 key components:~1-2 Joining sessions \[\~30 to 45 minutes each\] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions \[\~1.5 hours each session\] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided."
48162064|NCT04454489|DRUG|Pembrolizumab (immunotherapy)|Pembrolizumab 200 mg will be given every 3 weeks to tumor progression or treatment tolerance.
48162065|NCT04454489|RADIATION|Quad-shot palliative radiotherapy|"* Each cycle of quad-shot radiotherapy will be comprised of 14.8 Gy in 4 fractions (3.7 Gy per fraction) delivered twice daily (at least 6 hours apart) over two consecutive days.~* All patients will receive 1 cycle of quad-shot radiotherapy between ICI cycles 2-3.~* Subsequent cycles may occur between immunotherapy cycles 6-7 and 11-12, if more than 1 cycle can be safely delivered and the patient has experienced less than a partial response at protocol-specified tumor assessments (after C5 and C10). The eligibility for subsequent cycles will be at the discretion of the treating radiation oncologist.~Therefore, the total prescription dose will be:~* 14.8 Gy in 4 fractions for those that complete 1 cycle (all patients will receive 1 cycle)~* 19.6 Gy in 8 fractions for those that complete 2 cycles~* 44.4 Gy in 12 fractions for those that complete 3 cycles"
48162066|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
48162067|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
48162068|NCT04364022|DRUG|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
48162069|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
48691046|NCT02515799|DRUG|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
48691047|NCT02515799|OTHER|Placebo|Inhaled Placebo
48691048|NCT05952973|BEHAVIORAL|SkillTalk|Online Educator Mircoskill Training and Parent Microskill Training
48691049|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
48691050|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
48162070|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
48691051|NCT06315673|BEHAVIORAL|Digital Speech and Handwriting Assessment|"Subjects may complete all or some of these tests, depending on functional ability.~* Handwriting battery~* Pattern tracing battery~* Speech Assessment Battery"
48691052|NCT00320554|BEHAVIORAL|Durometer analysis|
48691053|NCT00617058|DRUG|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
48691054|NCT00617058|BEHAVIORAL|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
48691055|NCT01055938|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
48162071|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
48162072|NCT06646055|DRUG|AK112, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
48162073|NCT06646055|DRUG|nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
48691056|NCT00453037|BEHAVIORAL|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
48691057|NCT00453037|BEHAVIORAL|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
48691058|NCT02115724|DIETARY_SUPPLEMENT|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
48162074|NCT01012999|DRUG|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
48691059|NCT02115724|OTHER|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
48691060|NCT02115724|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
48691061|NCT02115724|DRUG|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
48691062|NCT05734105|DRUG|Ripretinib|50 mg tablets
48691063|NCT05734105|DRUG|Sunitinib|12.5 mg tablets
48162075|NCT05607732|DIAGNOSTIC_TEST|MyCog|MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
48162076|NCT02112578|DRUG|Meclizine|25 mg, 3 times per day up to 30 days
48691064|NCT05783128|OTHER|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
48691065|NCT00425022|PROCEDURE|thoracoscopy|
48691066|NCT02293252|DEVICE|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
48691067|NCT05430503|DIAGNOSTIC_TEST|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
48691068|NCT01581021|DEVICE|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
48691069|NCT01581021|DEVICE|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
48162077|NCT02112578|DRUG|Dimenhydrinate|50 mg, 3 times per day up to 30 days
48691070|NCT02841579|DRUG|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
48691071|NCT02249091|DRUG|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
48691072|NCT02249091|DRUG|Idarubicin|Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
48691073|NCT02249091|DRUG|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
48691074|NCT06270082|DRUG|IK-595|Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
48691075|NCT01127464|DRUG|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
48691076|NCT01127464|DRUG|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
48691077|NCT01127464|DRUG|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
48691078|NCT03490292|COMBINATION_PRODUCT|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
48005106|NCT03799484|DEVICE|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
48005107|NCT02752009|PROCEDURE|Axillary Lymph Node Sampling Clip|
48691079|NCT03490292|DRUG|Carboplatin|Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
48691080|NCT03490292|DRUG|Paclitaxel|Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
48691081|NCT03490292|RADIATION|Radiation|Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
48691082|NCT04488354|COMBINATION_PRODUCT|CLBR001 and SWI019|No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
48691083|NCT06097078|DEVICE|Eso-SPONGE®|minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
48691084|NCT00800527|DRUG|Gabapentin|Gabapentin 800 mg one a day up to 30 day
48691085|NCT00800527|DRUG|Diclofenac|Diclofenac 75 mg one a day up to 30 day
48691086|NCT03184493|DRUG|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
48691087|NCT03184493|DRUG|Celebrex|This group patients will receive celebrex.
48691088|NCT03184493|DRUG|Metformin|This group patients will receive metformin.
48691089|NCT00002050|DRUG|Thymopentin|
48005108|NCT05022758|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|One of NOAC (Non-vitamin K antagonist oral anticoagulants)
48005109|NCT05022758|DRUG|Warfarin|One of OAC (Oral anticoagulation therapy)
48005110|NCT05946538|DIAGNOSTIC_TEST|SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel|The SARS-CoV-2, Influenza and RSV PCR test is multiplex-tandem polymerase chain reaction (MT-PCR) based on qualitive in vitro diagnostic testing for the detection and identification of pathogens in nucleic acid extracts.
48162078|NCT01863537|BEHAVIORAL|Multimedia Connect|
48162079|NCT01863537|BEHAVIORAL|Traditional Connect|
48162080|NCT06537141|PROCEDURE|selective embolization of thyroid arteries (SETA)|selective embolization of thyroid arteries
48162081|NCT03093597|OTHER|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
48162082|NCT03093597|OTHER|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
48162083|NCT03093597|OTHER|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
48691090|NCT02193737|PROCEDURE|Early oral fluid recovery.|
48691091|NCT02193737|PROCEDURE|Delayed oral fluid recovery.|
48691092|NCT01434901|DRUG|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
48691093|NCT01434901|DRUG|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
48691094|NCT01434901|DRUG|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
48691095|NCT01434901|DRUG|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
48691096|NCT04839068|DEVICE|covid 19 on pregnancy outcomes|covid 19 on pregnancy outcomes and sex ratio at birth
48691097|NCT03718884|DRUG|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
48691098|NCT03718884|DRUG|Mirikizumab|Administered SC
48691099|NCT04739319|OTHER|N/A Observational study|N/A Observational study
48691100|NCT02200757|DRUG|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
48691101|NCT02200757|DRUG|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
48691102|NCT06299865|OTHER|Ungrouped|Ungrouped
48691103|NCT03756051|OTHER|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
48162084|NCT03093597|OTHER|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
48691104|NCT03756051|OTHER|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
48162085|NCT04845087|OTHER|Ozonized water|Irrigation of dental implants with ozonized water
48162086|NCT04845087|OTHER|Placebo|Irrigation of dental implants with water
48691105|NCT00003352|DRUG|cyclophosphamide|600 mg/m2, IV, every 3 weeks
48691106|NCT00003352|DRUG|Taxotere|60 mg/m2, IV, every 3 weeks
48691107|NCT00003352|DRUG|Adriamycin|60 mg/m2, IV, every 3 weeks
48691108|NCT04749628|DRUG|cannabidiol|Epidiolex (cannabidiol) oral solution
48691109|NCT04749628|OTHER|Ora-sweet SF|Ora-sweet SF placebo
48691110|NCT05634785|BIOLOGICAL|ATLCAR.CD30 Cells|The cellular product consists of ATLCAR.CD30 cells will be administered via intravenous injection, over 5 - 10 minutes after lymphodepletion. The expected volume will be 1 - 50 mL, the prescribed dose will be 2 × 108 CAR-T cells per meter square and the maximum dose will be 5 × 108 CAR-T cells per meter square.
48691111|NCT05634785|DRUG|Cyclophosphamid|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.
48162087|NCT06379906|OTHER|Assessment|Baseline assessment
48162088|NCT01440699|BIOLOGICAL|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
48162089|NCT01427231|DIETARY_SUPPLEMENT|glucose|The effect of a glucose solution on cognitive performance will be measured.
48162090|NCT01427231|DIETARY_SUPPLEMENT|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
48162091|NCT01427231|DIETARY_SUPPLEMENT|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
48162092|NCT04188119|DRUG|Avelumab|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)
48691112|NCT05634785|DRUG|Fludarabine|Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
48691113|NCT03851328|OTHER|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
48691114|NCT05046067|PROCEDURE|Computed Tomography|Undergo CT
48691115|NCT05046067|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery per standard of care
48691116|NCT01521923|BIOLOGICAL|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
48691117|NCT01521923|BIOLOGICAL|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
48691118|NCT03141125|OTHER|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
48691119|NCT03141125|OTHER|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
48162093|NCT04188119|DRUG|Aspirin|300mg tablets
48162094|NCT04188119|DRUG|Lansoprazole|30mg
48162095|NCT05577689|OTHER|Tissue|Tissue will be derived from patients during a standard of care procedure
48162096|NCT04175834|DRUG|cetrizine|prophylaxis
48162097|NCT04175834|DRUG|diphenhydramine|prophylaxis
48162098|NCT03538223|OTHER|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
48162099|NCT03538223|RADIATION|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
48162100|NCT00206609|PROCEDURE|Oxygen and air administration|
48162101|NCT02868788|DIETARY_SUPPLEMENT|dietary fiber|Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal
48691120|NCT06446596|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software a digital physiotherapy and telerehabilitation. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
48691121|NCT06446596|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
48691122|NCT05542095|DRUG|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
48162102|NCT02868788|OTHER|HFHC meal|910 Calorie HFHC meal
48691123|NCT01958580|DRUG|Gemcitabine Hydrochloride|Given IV
48691124|NCT01958580|DRUG|Docetaxel|Given IV
48691125|NCT01958580|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
48162103|NCT05168696|OTHER|Virtual Reality Glasses|Virtual Reality Glasses
48162104|NCT03885622|DEVICE|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
48691126|NCT01958580|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48162105|NCT02584075|DRUG|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
48162106|NCT02584075|DRUG|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
48162107|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
48162108|NCT01679613|DRUG|Nintedanib|low dose oral administration
48162109|NCT01679613|DRUG|Ketoconazole|oral administration
48162110|NCT01679613|DRUG|Nintedanib|low dose oral administration
48691127|NCT01958580|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48691128|NCT01958580|OTHER|Laboratory Biomarker Analysis|Correlative studies
48162111|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
48162112|NCT01679613|DRUG|Ketoconazole|oral administration
48691129|NCT05066750|BEHAVIORAL|Mindful breathing|Participants watch a 10 minute mindful breathing video
48691130|NCT05066750|BEHAVIORAL|Control video|Participants watch a 10 minute control video
48691131|NCT03222362|OTHER|Surgery|
48691132|NCT01794208|DRUG|Follitropin Epsilon|
48691133|NCT01794208|DRUG|Follitropin Alfa|
48691134|NCT05262777|DEVICE|GP0112|Injectable gel
48691135|NCT05262777|DEVICE|Restylane Lyft Lidocaine|Injectable gel
48691136|NCT05880849|DRUG|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
48691137|NCT05727007|DIAGNOSTIC_TEST|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
48691138|NCT05727007|DIAGNOSTIC_TEST|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
48691139|NCT02502292|BEHAVIORAL|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
48691140|NCT05720949|DRUG|Genicular Nerve Block with bupivacaine and preservative free dexamethasone|"A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid"
48691141|NCT03465579|DIAGNOSTIC_TEST|pelvic MRI|multi-parametric pelvic MRI
48691142|NCT03465579|DIAGNOSTIC_TEST|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
48691143|NCT02748044|DEVICE|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
48691144|NCT05538910|OTHER|Placebo Nicotine Patch|Comparator
48691145|NCT05538910|DRUG|Nicotine Patch|Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
48691146|NCT04227795|DEVICE|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
48691147|NCT00392158|DEVICE|Closed-loop anesthesia system|
48691148|NCT04749043|DEVICE|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
48691149|NCT04749043|DRUG|Nitrous oxide|30 min exposure for labor analgesia
48162113|NCT04410003|BIOLOGICAL|Fecal microbial transplant|Fecal microbial transplant
48162114|NCT06349317|COMBINATION_PRODUCT|Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib|"1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week;~2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle)."
48162115|NCT06446531|DRUG|Placebo|Oral tablet administered once daily
48162116|NCT06446531|DRUG|Rybelsus Tablet|Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.
48162117|NCT06446531|DRUG|Jardiance 25Mg Tablet|Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily
48691150|NCT04929223|DRUG|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
48691151|NCT04929223|DRUG|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
48691152|NCT04929223|DRUG|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
48691153|NCT04929223|DRUG|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
48691154|NCT04929223|DRUG|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
48691155|NCT04929223|DRUG|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
48691156|NCT04929223|DRUG|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
48691157|NCT04929223|DRUG|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
48691158|NCT04929223|DRUG|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
48691159|NCT02016391|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
48162118|NCT06446531|DRUG|Metformin|Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)
48162119|NCT06446531|DRUG|Actos|Oral tablet dosed at 15mg once daily
48691160|NCT05365997|OTHER|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
48691161|NCT04491435|DIAGNOSTIC_TEST|Summated Xerostomia Inventory|structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
48691162|NCT04491435|DIAGNOSTIC_TEST|Sialometry|unstimulated whole saliva (UWS) flow measurement
48691163|NCT02688699|PROCEDURE|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
48691164|NCT03478254|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
48691165|NCT03478254|BIOLOGICAL|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
48691166|NCT03478254|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
48691167|NCT04939090|DRUG|Olanzapine|Given PO
48691168|NCT04939090|DRUG|Megestrol Acetate|Given PO
48691169|NCT04939090|OTHER|Questionnaire Administration|Ancillary studies
48691170|NCT05302869|OTHER|None intervention|None intervention
48691171|NCT01762384|PROCEDURE|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
48691172|NCT01762384|PROCEDURE|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
48691173|NCT01762384|DEVICE|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
48691174|NCT05410925|DRUG|Recombinant staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
48691175|NCT05410925|DRUG|Placebo|Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
48691176|NCT06481436|BEHAVIORAL|Use of ChatGPT|Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.
48691177|NCT05941208|PROCEDURE|continuous fascia iliaca compartment block|ultrasound Patients were in supine position and the puncture site was selected at 1 cm below the junction point at 1/3 of the connection of anterior superior spine and pubic tubercle. An ultrasound apparatus (Sonosite) high-frequency probe was placed in parallel to the inguinal fold to distinguish the femoral fascia and fascia iliaca, the needle was inserted with out-of-plane technique at an angle of 45° and the tip of the needle was pointed to the head. Once needle-tip placement under the fascia iliaca by hydrolocation was confirmed, the probe was rotated 90° into a longitudinal parasagittal orientation to visualize the needle tip in-plane and to track cephalad spread of the injectate under fascia iliaca, identification of the fascia iliaca plane through the linear probe and introducing epidural catheter 18 G , continuous infusion of bupivacaine 0.25% by a set rate of 7 ml per hour for 24 hours,
48691178|NCT02540187|OTHER|blood specimen|
48691179|NCT00868088|PROCEDURE|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
48691180|NCT05977816|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
48691181|NCT05977816|OTHER|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
48691182|NCT01891396|DEVICE|Hyaluronic Acid and TH (Cingal®)|Injection into knee
48691183|NCT01891396|DEVICE|Hyaluronic Acid (Monovisc®)|Injection into knee
48691184|NCT01891396|DEVICE|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
48691185|NCT04435600|DRUG|Risankizumab|Subcutaneous Injection
48691186|NCT04435600|DRUG|Ustekinumab|Subcutaneous Injection
48691187|NCT02283905|DRUG|amphotericin-B|continuously infused
48162120|NCT05028647|DEVICE|Virtual reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)
48162121|NCT05028647|DEVICE|Augmented reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
48162122|NCT05004805|DRUG|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
48162123|NCT05004805|DRUG|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
48162124|NCT00002216|DRUG|Lamivudine/Zidovudine|
48005111|NCT05946538|DIAGNOSTIC_TEST|BioFire Respiratory Panel 2.1|The BioFire Respiratory Panel 2.1 (RP2.1) is a PCR-based multiplexed nucleic acid test intended for use with the BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections.
48005112|NCT05155228|BEHAVIORAL|Attachment Regulation and Competency|Trauma informed psychotherapy intervention for children with a history of exposure to trauma and their caregivers.
48162125|NCT00002216|DRUG|Abacavir sulfate|
48162126|NCT00002216|DRUG|Amprenavir|
48162127|NCT00002216|DRUG|Nelfinavir mesylate|
48162128|NCT00900471|OTHER|biologic sample preservation procedure|
48162129|NCT00900471|OTHER|medical chart review|
48162130|NCT02965599|DRUG|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
48162131|NCT02965599|DRUG|Placebo|Placebo is a white, opaque, gelatin capsule.
48162132|NCT05225285|BIOLOGICAL|Inactivated Coronavac/Butantan vaccine|Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
48005113|NCT05155228|BEHAVIORAL|Treatment as usual|Supportive psychotherapy
48005114|NCT01638962|DRUG|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
48005115|NCT01638962|OTHER|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
48005116|NCT00838227|DRUG|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
48005117|NCT02859649|BEHAVIORAL|neuropsychological test|neuropsychological test
48005118|NCT06277115|DEVICE|Continuous positive airway pressure (CPAP)|Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA. It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
48162133|NCT05225285|BIOLOGICAL|BNT162b2 (Pfizer)|BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
48162134|NCT03450018|DRUG|SLC-0111|Oral SLC-0111
48162135|NCT03450018|DRUG|Gemcitabine Injection|1000 mg/m\^2 IV
48162136|NCT01075100|DRUG|Ixabepilone|20 mg/m2 on Days 1 and 8
48162137|NCT01075100|DRUG|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
48162138|NCT06645496|OTHER|Evaluation of ehealth literacy|All patients undergoing radiotherapy at the Clinic for Radiotherapy (Campus Virchow Klinikum, Campus Benjamin Franklin) will be informed about the possibility of participating in the study (RO_eHEALTH I). If written consent is given, patients will be asked to complete the established questionnaires (EORTC QLQ-C30 and eHEALS) and a questionnaire to collect epidemiological data at their next visit to the respective clinics.
48162139|NCT04250181|OTHER|RF ablation of atrial fibrillation|Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
48691188|NCT02283905|DRUG|voriconazole|intravenously or orally administered
48005119|NCT04124107|DEVICE|multiparametric MRI and 68Ga-PSMA PET/MRI|All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination
48005120|NCT04124107|PROCEDURE|Prostate biopsy|Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
48005121|NCT03087370|OTHER|No intervention|No intervention
48005122|NCT00356551|BEHAVIORAL|Family Spirit curriculum|
48162140|NCT04796389|OTHER|Music|Preferred music of the participant administered using headphones.
48162141|NCT06646744|BIOLOGICAL|mRNA COVID-19 vaccine|Children will be vaccinated according to standard local procedure
48162142|NCT00722488|DRUG|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
48162143|NCT00167323|BEHAVIORAL|Adherence therapy|
48162144|NCT05990075|BEHAVIORAL|self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
48162145|NCT02536547|DEVICE|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
48162146|NCT03740737|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed."
48691189|NCT01157572|DRUG|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
48691190|NCT01157572|DRUG|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
48691191|NCT00969306|DRUG|Chloroquine, A-CQ 100|"Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form."
48691192|NCT06516081|DIETARY_SUPPLEMENT|Micronutrient powder (Sprinkles®)|
48691193|NCT05306834|PROCEDURE|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
48691194|NCT05306834|GENETIC|Blood sample|Analyses of molecular biomarkers including
48691195|NCT05306834|PROCEDURE|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
48691196|NCT05306834|PROCEDURE|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
48691197|NCT05306834|OTHER|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
48691198|NCT05306834|OTHER|Geriatric Depression Scale (GDS)|15 items
48005123|NCT05927753|DEVICE|Deseyne Daily Disposable Contact Lens (Test Device)|Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
48691199|NCT05306834|OTHER|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
48691200|NCT05306834|DIAGNOSTIC_TEST|Unipodal standing test|Unipodal standing test
48691201|NCT05306834|OTHER|Walking speed measurement|over 5 meters
48005124|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
48162147|NCT03740737|OTHER|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
48162148|NCT05116865|BIOLOGICAL|HH-120 Dose 1|Dose level 1 of HH-120
48162149|NCT05116865|BIOLOGICAL|HH-120 Dose 2|Dose level 2 of HH-120
48162150|NCT05116865|BIOLOGICAL|HH-120 Dose 3|Dose level 3 of HH-120
48162151|NCT05116865|DRUG|Placebo|Placebo to match
48691202|NCT03089333|DRUG|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
48691203|NCT03089333|DRUG|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
48691204|NCT02177331|DRUG|Lacidipine|
48691205|NCT04340141|DRUG|Oxaliplatin|Given IV
48691206|NCT04340141|DRUG|Irinotecan Hydrochloride|Given IV
48691207|NCT04340141|DRUG|Leucovorin Calcium|Given IV
48691208|NCT04340141|DRUG|Fluorouracil|Given IV
48691209|NCT04340141|PROCEDURE|Resection|Undergo surgical resection
48691210|NCT04340141|OTHER|Questionnaire Administration|Ancillary studies
48691211|NCT03709069|DIETARY_SUPPLEMENT|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
48691212|NCT05096273|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
48691213|NCT02364427|DEVICE|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
48691214|NCT00741897|DRUG|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
48162152|NCT05880771|OTHER|Immediate Implant Placement|Tooth extraction followed by immediate implant placement. One group will have Allograft graft in the buccal gap, the other will have Xenograft graft.
48162153|NCT03371706|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
48162154|NCT03371706|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
48162155|NCT03379311|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
48162156|NCT01740999|PROCEDURE|silicone arthroplasty|silicone arthroplasty
48691215|NCT06110936|DEVICE|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
48691216|NCT05501210|DEVICE|WBV|Whole body vibration (WBV) therapy
48691217|NCT05501210|DEVICE|PEMF|Pulsed electromagnetic fields (PEMF)
48691218|NCT05733949|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48691219|NCT05733949|PROCEDURE|Computed Tomography|Undergo CT
48691220|NCT05733949|RADIATION|Stereotactic Body Radiation Therapy|Undergo ST-SBRT
48691221|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
48691222|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
48162157|NCT01740999|PROCEDURE|arthrodesis|arthrodesis
48162158|NCT02251405|BEHAVIORAL|One bag, stainless container|
48691223|NCT02957747|BEHAVIORAL|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
48691224|NCT03594747|DRUG|Tislelizumab|Administered intravenously as described
48691225|NCT03594747|DRUG|Paclitaxel|Administered intravenously as described
48691226|NCT03594747|DRUG|Nab-paclitaxel|Administered intravenously as described
48005125|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
48005126|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
48005127|NCT03857633|DIAGNOSTIC_TEST|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
48005128|NCT03857633|DIAGNOSTIC_TEST|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
48005129|NCT00799968|DRUG|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
48005130|NCT00799968|DRUG|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
48162159|NCT03549299|BIOLOGICAL|LSC2|Topical application of IMP on target eye
48691227|NCT03594747|DRUG|Carboplatin|Administered intravenously as described
48691228|NCT06316934|DRUG|Lavandula angustifolia, Aura Cacia|Lavender essential oil will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
48005131|NCT00969293|DRUG|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
48162160|NCT05016778|DRUG|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
48691229|NCT06316934|OTHER|Placebo|Distilled water will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
48162161|NCT03997708|OTHER|Med-LFD|All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
48162162|NCT03997708|OTHER|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
48691230|NCT02836470|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
48691231|NCT02836470|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
48691232|NCT03940846|DIAGNOSTIC_TEST|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
48691233|NCT05504187|DRUG|KP104|KP104 will be administered.
48691234|NCT05289492|DRUG|EOS884448|EOS884448 will be administered in arm A,B and C
48691235|NCT05289492|DRUG|Iberdomide|Iberdomide will be administered in arm B and C
48005132|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
48005133|NCT01541826|DIETARY_SUPPLEMENT|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
48162163|NCT06617832|DRUG|Active drug for acute migraine treatment|Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine
48162164|NCT06617832|DRUG|Placebo Oral Tablet|Inactive placebo pill (100 mg) looking like the active drug
48162165|NCT05580783|OTHER|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
48162166|NCT05580783|OTHER|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
48691236|NCT05289492|DRUG|Dexamethasone|Dexamethasone will be administered in arm C
48691237|NCT02749006|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
48691238|NCT02749006|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
48005134|NCT01541826|DIETARY_SUPPLEMENT|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
48005135|NCT03382106|DRUG|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
48162167|NCT05580783|OTHER|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
48005136|NCT03382106|DRUG|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
48162168|NCT06588283|DRUG|Ixekizumab|Administered SC
48162169|NCT06588283|DRUG|Tirzepatide|Administered SC.
48162170|NCT01651416|DRUG|Artemether-lumefantrine combination|
48162171|NCT01651416|DRUG|Dihydroartemisinin Piperaquine combination|
48691239|NCT05424978|OTHER|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
48162172|NCT01651416|DRUG|Amodiaquine plus sulphadoxine-pyrimethamine combination|
48162173|NCT00790777|DRUG|Paliperidone ER|
48162174|NCT00470171|DRUG|Ursodesoxycholic acid|
48162175|NCT01309399|DRUG|Teriparatide|six weeks of teriparatide
48162176|NCT01309399|OTHER|placebo|placebo
48162177|NCT05882344|PROCEDURE|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
48162178|NCT05882344|DEVICE|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
48691240|NCT03145064|DRUG|Zanubrutinib|Administered at a dose of 160 mg BID orally.
48691241|NCT01887613|DRUG|Regnite|oral
48005137|NCT03382106|DIAGNOSTIC_TEST|Pulse wave velocity|Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
48005138|NCT03382106|DIAGNOSTIC_TEST|Carotid artery compliance and stiffness|An echocardiogram is done by using a probe placed on the skin.
48005139|NCT03382106|DIAGNOSTIC_TEST|Pressure wave reflection|Carotid pulse measurement taken using a tonometer probe
48005140|NCT04813796|BIOLOGICAL|mRNA-1283|Sterile liquid for injection
48005141|NCT04813796|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
48005142|NCT04813796|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48162179|NCT04758156|DRUG|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
48162180|NCT04758156|DRUG|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
48162181|NCT00131690|DRUG|Nescafé Gold Blend (exposed)|
48005143|NCT00180856|PROCEDURE|Radiofrequency ablation|
48005144|NCT00038922|DRUG|rhIL-11|
48005145|NCT01828034|DRUG|Gemcitabine|
48005146|NCT01828034|DRUG|Cisplatin|
48005147|NCT01828034|DRUG|MEK162|
48162182|NCT00131690|DRUG|Nescafé Decaffeinated (controls)|
48162183|NCT03058237|DRUG|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
48162184|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
48162185|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
48162186|NCT03058237|DRUG|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
48162187|NCT05512910|DRUG|Minocycline|200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
48162188|NCT02580019|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
48162189|NCT02944526|DRUG|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
48162190|NCT02944526|DRUG|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
48162191|NCT05311774|DRUG|Duloxetine 30 mg|tablet
48162192|NCT05311774|DRUG|Tramadol|tablet
48162193|NCT05311774|DRUG|Placebo|tablet
48162194|NCT05028153|DRUG|Azithromycin Oral Liquid Product|10 mg/kg for 3 consecutive days
48162195|NCT05028153|OTHER|Placebo mixture|Placebo mixture containing no active substance
48162196|NCT01868516|DRUG|dexmecamylamine|
48162197|NCT01868516|DRUG|Placebo|
48162198|NCT06315751|DRUG|Gemlapodect|Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with TS. Administered in the form of oral capsules.
48162199|NCT06315751|DRUG|Placebo|Administered in the form of oral capsules with inert ingredients.
48691242|NCT05694871|DRUG|Palbociclib|Given PO
48691243|NCT05694871|BIOLOGICAL|Cemiplimab|Given IV
48691244|NCT05694871|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
48162200|NCT00705042|DRUG|Etanercept|
48162201|NCT02503306|DRUG|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
48162202|NCT02503306|DRUG|placebo|Pharmaceutical form:tablets Route of administration: oral
48162203|NCT06047379|DRUG|NEO212 Oral Capsule|NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
48691245|NCT05694871|PROCEDURE|Computed Tomography|Undergo a CT Scan
48691246|NCT05694871|PROCEDURE|Biospecimen collection|Undergo blood sample collection
48691247|NCT05694871|OTHER|Questionnaire Administration|Ancillary Studies
48691248|NCT02775591|DRUG|DA-9701|DA-9701 30mg Tablet
48691249|NCT02775591|DRUG|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
48691250|NCT01391169|OTHER|seromuscular flap enforcement|seromuscular flap enforcement
48691251|NCT03628066|DRUG|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
48691252|NCT03628066|DRUG|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
48691253|NCT03628066|DRUG|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
48691254|NCT03628066|DIAGNOSTIC_TEST|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
48162204|NCT06047379|DRUG|Ipilimumab|Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
48162205|NCT06047379|DRUG|Pembrolizumab|Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
48162206|NCT06047379|DRUG|Nivolumab|Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
48162207|NCT06047379|DRUG|Regorafenib|Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
48162208|NCT06047379|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
48162209|NCT06047379|DRUG|Paclitaxel|Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
48162210|NCT06047379|DRUG|FOLFIRI Protocol|"FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating."
48162211|NCT06047379|DRUG|Bevacizumab|Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
48162212|NCT04030988|DRUG|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
48162213|NCT04030988|DRUG|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
48162214|NCT01933659|DRUG|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
48691255|NCT04106258|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
48691256|NCT06547697|OTHER|Dialysate sodium concentration|
48691257|NCT02443246|DRUG|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
48691258|NCT02443246|DRUG|Placebo|
48691259|NCT01496326|DRUG|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
48691260|NCT01496326|DRUG|placebo|2 grams of placebo cream for 14 days
48691261|NCT00904670|DRUG|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
48691262|NCT00904670|DRUG|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
48691263|NCT00904670|DRUG|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
48691264|NCT00351767|DRUG|placebo|Topically applied
48691265|NCT00351767|DRUG|telbermin|Topically applied
48691266|NCT00429676|DRUG|Haloperidol|
48691267|NCT01143363|BEHAVIORAL|resting - control|
48691268|NCT01143363|BEHAVIORAL|Moderate intensity exercise|
48691269|NCT01143363|BEHAVIORAL|High intensity intermittent training|
48691270|NCT01143363|BEHAVIORAL|Short sprint|
48162215|NCT02113150|DRUG|remifentanil|renal function
48162216|NCT02113150|DRUG|Ketamine|renal function
48162217|NCT01896921|DRUG|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
48162218|NCT06181929|DIAGNOSTIC_TEST|Low dose CT|A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
48162219|NCT01266499|DRUG|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
48162220|NCT01266499|DRUG|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
48005148|NCT02239809|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
48162221|NCT01266499|DRUG|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
48162222|NCT01266499|DRUG|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
48162223|NCT00212862|OTHER|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
48162224|NCT06378918|PROCEDURE|puncture|Local anesthesia is previously carried out with 2-5 cc of 1% lidocaine. The puncture is then carried out using a 16 gauge needle. Antibiotic coverage will be offered. A work stoppage is recommended until the day after the puncture/aspiration but the duration is left to the discretion of the surgeon. A visit is systematically realised 15 days after the puncture/aspiration with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. In the event of fistulization following the puncture, associated with discharge and skin necrosis, local nursing care is recommended. The definitive resection procedure is then planned 4 to 6 weeks after the puncture/aspiration if the evolution is favorable.
48005149|NCT02239809|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
48005150|NCT01909661|OTHER|Damira/Celia peptide hydrolyzed casein|
48005151|NCT01909661|OTHER|Picot riz/Celia rice/Sanutri arroz|
48005152|NCT03672435|DRUG|Topical Solution|proparacaine 0.5% eye drop
48005153|NCT05817929|OTHER|blood sample|5 ml blood sample will be withdrawn at the surgery start and at the surgery end
48162225|NCT06378918|PROCEDURE|incision of the abscess|This is carried out according to the habits of the department: in the operating room under general or local anesthesia or in consultation (or emergencies) under local anesthesia. The procedure is carried out on an outpatient basis but, if necessary, short-term hospitalization is carried out. Daily drying is then carried out with nursing care at home until healing. A work stoppage is recommended for a period of approximately 10 days. A visit is systematically realised 15 days after the incision with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. The definitive resection procedure is then planned 4 to 6 weeks after the initial operation if the evolution is favorable.
48162226|NCT01516606|DRUG|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
48162227|NCT06434571|BEHAVIORAL|Telehealth cognitive behavioral therapy for insomnia (tCBT-I)|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
48691271|NCT04820114|OTHER|Proprioceptive wrist exercises|Exercises for recognition of writs position and thumb force sense.
48691272|NCT04820114|OTHER|Wrist exercises|Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
48691273|NCT04655807|DRUG|JNJ-64304500|JNJ-64304500 will be administered as SC injection.
48691274|NCT04655807|DRUG|Placebo|Matching placebo will be administered as SC injection.
48005154|NCT06137456|DEVICE|Exoskeletal robotic therapy for walking.|Exoskeletal robotic therapy for walking. Therapy sessions were scheduled for 40 minutes each. The study group performed exoskeleton walking and balance exercises 3 days a week.
48691275|NCT04655807|DRUG|Adalimumab|Adalimumab will be administered as SOC biological therapy.
48691276|NCT04655807|DRUG|Ustekinumab|Ustekinumab will be administered as SOC biological therapy.
48691277|NCT02557776|GENETIC|Germline genetic testing of BRCA1 and BRCA2|
48005155|NCT06137456|OTHER|Conventional exercise therapy|Conventional treatment consisted of walking and balance exercises, stretching, strengthening, and mobility exercises, for 40 minutes, 5 days a week.
48005156|NCT00615563|BEHAVIORAL|NO BI Drug administered|
48691278|NCT04774588|OTHER|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
48162228|NCT06434571|BEHAVIORAL|Web-based cognitive behavioral therapy for insomnia (wCBT-I)|Participants receive a daily e-mail reminder to access the program and to complete a sleep log for the prior night's sleep. After completing the sleep log, the daily lesson is made available. Each participant will be provided with a unique password to access the online program.
48005157|NCT02000375|DRUG|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
48162229|NCT06434571|BEHAVIORAL|Treatment as usual (TAU)|They will be encouraged to avoid starting any new treatment for their sleep unless recommended by their physician. They will be offered access to the web-based CBT-I program following the 6-month reassessment to complete if they wish.
48162230|NCT04021147|BEHAVIORAL|Exercise plus action observation|Orofacial exercise plus action observation (video) of the same exercise
48005158|NCT05363735|OTHER|Ultrasound Elastography|Patients will be examined by ultrasound elastography.
48005159|NCT04087291|OTHER|Chiropractic Care|"Chiropractic interventions:~1. Patient education.~2. Passive interventions, such as spinal manipulation and myofascial therapies which include thrust type (high velocity-low amplitude) spinal manipulation for the low back, non-thrust manipulation (joint mobilization), and use of manually held instruments, such as an Activator. Myofascial therapies are also commonly used, such as myofascial release and trigger point therapy.~3. Transitional interventions, such as therapeutic exercise.~4. Recommendations for active interventions, such as general exercise and mind-body therapies.~5. Self-management advice, which refers to advice given to build the capacity of a person to self-monitor, control, and/or reduce the impact of a condition over time."
48162231|NCT04021147|BEHAVIORAL|Exercise plus motor imagery|Orofacial exercise plus motor imagery of the same exercise
48162232|NCT04021147|BEHAVIORAL|Exercise plus visual mirror feedback|Exercise plus visual mirror feedback
48162233|NCT04021147|BEHAVIORAL|Exercise|Orofacial exercises
48162234|NCT03224689|DEVICE|PEEK-Optima Femoral Component|TKA Surgery
48162235|NCT03785210|DRUG|nivolumab|480 mg intravenous (IV) every 4 weeks
48162236|NCT03785210|DRUG|tadalafil|10 mg by mouth (PO) daily
48691279|NCT05945069|DEVICE|TriLift device|Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
48691280|NCT03702959|DRUG|Betamethasone|Corticosteroids
48691281|NCT00815568|DRUG|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
48691282|NCT03938766|DIAGNOSTIC_TEST|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
48691283|NCT03160248|DRUG|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
48005160|NCT01457599|PROCEDURE|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
48162237|NCT03785210|DRUG|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
48162238|NCT02029521|DIETARY_SUPPLEMENT|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
48162239|NCT02029521|DIETARY_SUPPLEMENT|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
48162240|NCT03662854|BIOLOGICAL|Hair Stimulating Complex (HSC)|Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
48162241|NCT03662854|OTHER|Phosphate Buffered Saline|Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
48691284|NCT03160248|DRUG|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
48691285|NCT06409936|DRUG|Asciminib|both arms will include asciminib treatment
48691286|NCT06409936|DRUG|Nilotinib|in the arm B the nilotinib will be added on in all patients
48691287|NCT04075513|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
48005161|NCT02989207|PROCEDURE|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
48005162|NCT02989207|DEVICE|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
48005163|NCT02989207|DRUG|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
48005164|NCT00463359|DRUG|Imiquimod cream|
48005165|NCT00463359|PROCEDURE|curettage and cautery|
48005166|NCT02697162|DEVICE|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
48005167|NCT02697162|DEVICE|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
48005168|NCT02697162|DRUG|Octenidine chloride|Antiseptic
48005169|NCT04377607|OTHER|File scanning|RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
48005170|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
48005171|NCT06190561|DRUG|PF-07940367|Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
48691288|NCT04075513|DRUG|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
48005172|NCT06439979|BEHAVIORAL|RAYS Intervention|Developmental baseball leagues will be randomly assigned to RAYS vs. control. Outcomes include directly-observed child sun safety behaviors after controlling for environmental ultra-violet radiation (UVR), with parent-reported child sun protection and other related endpoints at 1 year.
48005173|NCT06469255|OTHER|Diet Treatment|4 weeks low calorie diet treatment
48691289|NCT04075513|DRUG|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
48691290|NCT06662253|DRUG|Anti-Xa Guided Dosing of Low Molecular Weight Heparin|Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
48691291|NCT06662253|DRUG|Standard of Care Dosing|Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
48691292|NCT00321243|BEHAVIORAL|Visual clues|
48162242|NCT05310734|DRUG|Spinosad Topical|A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study
48691293|NCT05103579|DEVICE|MindMics|Patients rhythms was recorded using MindMics device
48691294|NCT06204900|DEVICE|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
48005174|NCT03172936|DRUG|MIW815|MIW 815 (ADU-S100) is a STING agonist
48005175|NCT03172936|BIOLOGICAL|PDR001|PDR001 is an anti-PD-1 antibody
48005176|NCT02262481|DRUG|dydrogesterone|
48005177|NCT02262481|DRUG|placebo|
48005178|NCT00000403|DRUG|Doxycycline|
48005179|NCT04185168|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 tablets)
48005180|NCT04185168|OTHER|control|2 tablets of placebo
48005181|NCT00205712|DRUG|Ketamine|Ketamine without dexmedetomidine
48005182|NCT00205712|DRUG|Dexmedetomidine|Ketamine plus dexmedetomidine
48005183|NCT00758628|DRUG|Bromefenac|Bromfenac BID 3 months
48005184|NCT00758628|DRUG|Blink|Blink BID for 3 months
48005185|NCT03152370|DRUG|E7046|oral administration
48005186|NCT03152370|RADIATION|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
48162243|NCT04159051|DEVICE|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
48162244|NCT02161185|DRUG|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
48005187|NCT03152370|RADIATION|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
48005188|NCT03152370|DRUG|capecitabine|chemotherapy
48005189|NCT03152370|DRUG|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
48005190|NCT01524770|BIOLOGICAL|Dulaglutide|Administered by subcutaneous (SC) injection
48005191|NCT01942629|OTHER|their will be no intervention in any of the groups, the study is retrospective|
48005192|NCT05418452|DRUG|Metformin|metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects
48005193|NCT02694315|OTHER|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
48005194|NCT02694315|OTHER|cervical length|measuring cervical length by trans-vaginal ultrasound
48005195|NCT02455310|BEHAVIORAL|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
48005196|NCT05827497|DRUG|Baricitinib 2 MG|baricitinib 2 mg once daily
48005197|NCT05827497|DRUG|Methotrexate 25mg|25mg daily
48005198|NCT00917891|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
48162245|NCT05562583|BEHAVIORAL|SAGE LEAF|"SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time."
48162246|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
48162247|NCT01704859|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
48162248|NCT01704859|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
48368394|NCT00499395|PROCEDURE|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
48368395|NCT00499395|PROCEDURE|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
48368396|NCT01974310|PROCEDURE|Vitrectomy & Intraocular gas fill|
48691295|NCT01553682|BEHAVIORAL|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
48691296|NCT01553682|BEHAVIORAL|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
48691297|NCT06090305|BEHAVIORAL|levidex|Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
48005199|NCT00917891|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
48005200|NCT03367143|DRUG|Lenalidomide|
48005201|NCT03367143|DRUG|Ifosfamide|
48005202|NCT03367143|DRUG|Carboplatin|
48005203|NCT03367143|DRUG|Etoposide|
48005204|NCT02549157|PROCEDURE|Pelvic Floor Muscle Training|
48005205|NCT06176950|OTHER|Oral History Interviews|I will ask interview subjects about their educational and career path, their research interests and clinical work in the field of neonatology. I will also ask them about their personal and professional motivations and thoughts about their work. And we will discuss how their interactions with colleagues and patients/caregivers shaped their work experience and decision making.
48005206|NCT01855295|DIETARY_SUPPLEMENT|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
48691298|NCT06090305|BEHAVIORAL|Control|Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
48005207|NCT05529212|PROCEDURE|ischemic reperfusion injury|ischemic reperfusion injury is a pathological process in which the ischemic myocardium is restored to normal perfusion, but the tissue damage is progressively aggravated when the coronary artery supply is completely blocked after cardiopulmonary bypass surgery and then recanalised at a certain time.
48005208|NCT02818595|DEVICE|electroencephalogram (HR-EEG)|
48005209|NCT02818595|DEVICE|Near Infra Red Spectroscopy (NIRS)|
48162249|NCT01704859|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
48005210|NCT01285648|PROCEDURE|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
48005211|NCT03696654|PROCEDURE|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
48162250|NCT03501524|DEVICE|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
48691299|NCT06090305|OTHER|treatment as usual (TAU)|treatment as usual (TAU)
48691300|NCT02422641|DRUG|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
48691301|NCT06036355|DRUG|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
48691302|NCT00020098|PROCEDURE|evaluation of cancer risk factors|
48691303|NCT04573439|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
48005212|NCT03254134|DRUG|Warfarin|patients treated with warfarin
48162251|NCT03501524|DEVICE|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
48691304|NCT06040385|DEVICE|Implant supported hybrid prosthesis|For each patient, implant supported mandibular hybrid prosthesis will be fabricated digitally. Frameworks will be tried in patient's mouth, scanned intraorally by intraoral scanner (IOS).
48691305|NCT04521946|DRUG|Etoposide|Given IV
48691306|NCT04521946|DRUG|Fludarabine Phosphate|Given IV
48691307|NCT04521946|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
48691308|NCT04521946|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
48691309|NCT04521946|DRUG|Melphalan|Given IV
48691310|NCT04521946|DRUG|Mycophenolate Mofetil|Given PO or IV
48691311|NCT04521946|DRUG|Tacrolimus|Given IV
48691312|NCT04521946|DRUG|Thiotepa|Given IV
48691313|NCT02470585|DRUG|Veliparib|Capsules for oral administration
48691314|NCT02470585|DRUG|Paclitaxel|Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
48691315|NCT02470585|DRUG|Carboplatin|Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
48691316|NCT02470585|OTHER|Placebo to Veliparib|Capsules for oral administration
48691317|NCT06029868|DIETARY_SUPPLEMENT|Black seed oil capsule|700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
48691318|NCT06029868|DIETARY_SUPPLEMENT|Placebo Black seed oil capsule|Placebo Black seed oil capsule
48691319|NCT00353808|DRUG|[S,S]-Reboxetine|
48691320|NCT05781945|DIETARY_SUPPLEMENT|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
48691321|NCT05781945|OTHER|standard therapy|standard therapy for sars-cov-2
48691322|NCT04930120|OTHER|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
48691323|NCT01835288|DRUG|arsenic trioxide|Given IV
48691324|NCT01835288|OTHER|laboratory biomarker analysis|Correlative studies
48691325|NCT00617084|DEVICE|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
48691326|NCT00617084|DEVICE|Abbott Xience V|Abbott Xience V
48691327|NCT04597645|OTHER|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
48005213|NCT03254134|DRUG|Dabigatran|patients treated with Dabigatran
48691328|NCT03063723|DRUG|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
48691329|NCT03063723|DRUG|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
48005214|NCT03941535|DRUG|Vitamin K|Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
48162252|NCT03425045|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
48162253|NCT03425045|PROCEDURE|Sham stimulation|Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
48162254|NCT03425045|DRUG|Ginkgo Biloba Extract|Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
48368397|NCT01974310|PROCEDURE|Postoperative face-down positioning|
48691330|NCT05523830|OTHER|No Intervention|No intervention
48691331|NCT00967694|DRUG|Nitrous oxide|Nitrous oxide sedation by inhalation
48691332|NCT03575663|DIAGNOSTIC_TEST|Indirect bronchial challenge|Mannitol dry powder inhalation
48691333|NCT03575663|OTHER|Sham bronchial challenge|Mock dry powder inhalation
48691334|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
48691335|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
48691336|NCT05883995|OTHER|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
48005215|NCT02721316|OTHER|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
48005216|NCT03425617|DRUG|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
48005217|NCT03425617|OTHER|PLACEBO|PLACEBO via Respimat® single dose
48005218|NCT00232908|DRUG|ARV regimen|As prescribed
48005219|NCT00232908|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
48005220|NCT03003975|DEVICE|PVI by single cryoballoon application guided by Achieve Mapping Catheter|Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff \< or = -40 degrees C)
48005221|NCT03003975|DEVICE|PVI by 2 routine cryoballoon applications|Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
48005222|NCT00189046|BEHAVIORAL|driving and laboratory tests|
48005223|NCT04830527|BEHAVIORAL|EMA prompting for patients|"EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day."
48005224|NCT04830527|BEHAVIORAL|PDF Reports for therapists|After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
48691337|NCT05027633|DRUG|Pembrolizumab|given by IV
48691338|NCT05027633|DRUG|Docetaxel|given by IV
48005225|NCT03461224|RADIATION|accelerated hypofractionated RT|
48005226|NCT03461224|RADIATION|conventional fractionated RT|
48005227|NCT04915391|DIAGNOSTIC_TEST|Skin biopsy and blood sample for inflammation markers, RNA and proteins|A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
48005228|NCT00000946|BIOLOGICAL|HIV p24/MF59 Vaccine|
48691339|NCT05027633|DRUG|Cisplatin|given by IV
48691340|NCT05027633|DRUG|Carboplatin|given by IV
48691341|NCT03920462|DEVICE|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
48005229|NCT00000946|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
48005230|NCT00000946|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
48005231|NCT00000946|BIOLOGICAL|rgp120/HIV-1 SF-2|
48005232|NCT02214121|DRUG|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
48005233|NCT02214121|DRUG|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
48005234|NCT03385239|DRUG|ISIS 678354|ISIS 678354 solution for SC injection.
48005235|NCT03385239|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl).
48691342|NCT05295121|DRUG|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
48691343|NCT01071252|DRUG|AIN457|
48691344|NCT01071252|DRUG|Placebo|
48691345|NCT01116999|PROCEDURE|light guided tracheal intubation|Tracheal intubation light guided technique.
48691346|NCT03032211|DEVICE|Alfapump|Implant Alfapump® System
48691347|NCT04366830|DRUG|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
48691348|NCT04493541|DRUG|BMS-986256|Specified Dose on Specified Days
48691349|NCT04493541|OTHER|BMS-986256 Placebo|Specified Dose on Specified Days
48691350|NCT01719458|DRUG|(S,S)-[11C]MRB|PET radioligand
48691351|NCT06653153|DRUG|Remternetug|Administered SC
48691352|NCT06653153|DRUG|Placebo|Administered SC
48691353|NCT04507048|OTHER|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
48691354|NCT04507048|OTHER|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
48691355|NCT05405114|DRUG|NDec - oral decitabine-tetrahydrouridine|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
48005236|NCT05983497|OTHER|Self-Care Skill Educational Intervention|An evidence-based interactive self-care skill educational intervention that supports the clinical nurses to reduce compassion fatigue and increase the compassion satisfaction. The intervention will be delivered as 1-day activity-based educational training. The educational activity consists of the following content: the concept of compassionate fatigue, burnout awareness and recognition, eight dimensions of well-being, and followed by a demonstration of 7 guided self-care skill activities \*on practicing sleep hygiene, self-talk, gratitude practice, Journaling, breathing exercise, heartfulness relaxation, and heartfulness meditation. After the activity participants will develop their own self-care plan for practicing the self-care skills. At the end of the session, they will receive the instructional leaflet to practice the 7 self care skills that they gained from the educational activity.
48162255|NCT03369652|BEHAVIORAL|Medication review|Conducted by the pharmacist and discussed with hospital physician
48162256|NCT05521555|PROCEDURE|Total knee arthroplasty|First intention total knee arthroplasty
48162257|NCT03264599|DEVICE|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
48005237|NCT02927028|OTHER|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
48005238|NCT01052545|BEHAVIORAL|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
48005239|NCT01690390|DRUG|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
48005240|NCT01690390|DRUG|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
48005241|NCT05764213|BEHAVIORAL|Listening to Women & Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.
48162258|NCT04466917|DRUG|ABP 215|ABP 215 will be administered at a dose of 15 mg/kg IV
48162259|NCT04466917|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg IV
48162260|NCT04466917|DRUG|Paclitaxel|Paclitaxel will be administered 175 mg/m2 IV
48162261|NCT04466917|DRUG|Carboplatin|Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
48162262|NCT00828542|DRUG|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
48162263|NCT00828542|DRUG|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
48691356|NCT05405114|DRUG|HU - Hydroxyurea|Participants will get capsules daily (oral administration) according to local labelling
48691357|NCT05405114|DRUG|Placebo|Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
48691358|NCT00319202|DRUG|Candesartan|32 mg/d for 6 months
48691359|NCT00319202|DRUG|Placebo|Placebo administration for 6 months
48691360|NCT02876458|OTHER|Immediate coronary angiogram|An immediate coronary angiogram will be performed
48691361|NCT02876458|OTHER|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
48691362|NCT04970901|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion
48691363|NCT04970901|DRUG|Polatuzumab Vedotin|IV infusion
48691364|NCT04970901|DRUG|Glofitamab|IV infusion
48691365|NCT04970901|DRUG|Mosunetuzumab|Subcutaneous (SC) injection
48691366|NCT04970901|DRUG|Obinutuzumab|IV infusion
48691367|NCT01468948|DRUG|Octanoic Acid|
48691368|NCT02548481|OTHER|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
48691369|NCT06158867|DEVICE|FMD WK|micro-needle patches containing active anti-wrinkle ingredients
48691370|NCT05769218|BEHAVIORAL|CHORUS+|The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.
48691371|NCT05769218|OTHER|Standard of care|Normal protocols for care of participants who inject opioids will be followed.
48691372|NCT03008668|OTHER|acupuncture|a stimulation of the body or auricular points
48691373|NCT04416152|PROCEDURE|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
48691374|NCT01555073|DRUG|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
48691375|NCT01555073|DRUG|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
48691376|NCT01555073|DRUG|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
48691377|NCT01555073|DRUG|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
48162264|NCT06575699|PROCEDURE|Rectus sheath block|bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side deposited between the rectus abdomens muscle and the posterior rectus sheath.
48691378|NCT03138460|OTHER|standard medications crossed over to cannabis|
48005242|NCT00665184|BEHAVIORAL|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
48005243|NCT00665184|BEHAVIORAL|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
48691379|NCT01858441|DRUG|Abiraterone Acetate|
48005244|NCT06406738|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform newborn first-care.
48162265|NCT06575699|PROCEDURE|Thoracic Epidural Analgesia|Low thoracic Epidural Analgesia.
48162266|NCT06575699|DRUG|Liposomal bupivacaine|133 mg liposomal bupivacaine per side for rectus sheath block
48162267|NCT06575699|DRUG|Bupivacaine Hydrochloride|20 mL bupivacaine 0.25% per side for rectus sheath block
48162268|NCT06575699|DRUG|Bupivacaine-Hydromorphone Cassette|Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
48162269|NCT00694135|DRUG|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
48162270|NCT00694135|DRUG|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
48691380|NCT01465867|DIETARY_SUPPLEMENT|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
48691381|NCT01465867|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
48691382|NCT01465867|OTHER|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
48691383|NCT01465867|OTHER|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
48691384|NCT02596568|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
48691385|NCT02596568|OTHER|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
48691386|NCT02653586|OTHER|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
48691387|NCT01904396|DRUG|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
48691388|NCT01903772|OTHER|Inspiratory Muscle Training|
48005245|NCT03688412|DEVICE|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
48162271|NCT00694135|DRUG|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
48162272|NCT00694135|DRUG|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
48005246|NCT04890392|DRUG|PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)|S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
48005247|NCT05010928|COMBINATION_PRODUCT|mouthwash with tea|Using tea as a base, supplemented with licorice to make mouthwash to relieve stomatitis.
48005248|NCT03231306|DRUG|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
48005249|NCT03592121|DRUG|AB-101|Apply approximately 1 hour prior to sexual activity
48691389|NCT05330494|OTHER|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
48005250|NCT03592121|DRUG|Placebo|Apply approximately 1 hour prior to sexual activity
48005251|NCT05625763|DIAGNOSTIC_TEST|sonoclot signature analysis|Investigate the value of global hemostasis studies (Sonoclot signature analysis) in cases of pre-eclampsia and if there a correlation between it and the specific traditional assays of hemostasis.
48005252|NCT00974571|DRUG|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
48005253|NCT00974571|DRUG|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
48005254|NCT00974571|DRUG|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
48162273|NCT03472976|OTHER|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
48162274|NCT03472976|DRUG|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
48691390|NCT03333096|DEVICE|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
48691391|NCT03333096|DIAGNOSTIC_TEST|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
48691392|NCT00681395|DRUG|ABT-143|once daily for 6 days
48691393|NCT00681395|DRUG|ABT-335|once daily for six days
48005255|NCT03688672|DEVICE|Apioc Contact Lens Design|Novel soft contact lens design.
48005256|NCT01908569|OTHER|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
48005257|NCT01908569|OTHER|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
48005258|NCT06132607|DEVICE|Preoperative 3D lung reconstruction created with open-source software|Preoperative 3D lung reconstruction created with open-source software 3D Slicer
48005259|NCT03490370|DEVICE|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
48005260|NCT02835274|DEVICE|BSC Deep Brain Stimulation System with Directional Lead|
48005261|NCT00957203|DRUG|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
48005262|NCT03689764|OTHER|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
48162275|NCT03472976|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
48162276|NCT05354726|OTHER|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
48162277|NCT05331716|PROCEDURE|Cardiac ablation therapy|In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned
48162278|NCT00287183|DRUG|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
48162279|NCT00287183|OTHER|Placebo|Placebo
48368398|NCT06138912|RADIATION|plain radiography (x-ray)|Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
48691394|NCT00681395|DRUG|Rosuvastatin|Once daily for 6 days
48691395|NCT03960567|DEVICE|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
48005263|NCT03689764|OTHER|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
48005264|NCT04482296|DRUG|SSRI with Zinc Sulfate|Zinc sulfate (30 mg) once daily for 8 weeks SSRI
48005265|NCT03761732|BEHAVIORAL|Islamic Trauma Healing|6 session behavioral intervention program designed to reduce PTSD and related symptomatology
48162280|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
48162281|NCT00577096|BEHAVIORAL|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
48162282|NCT00577096|BIOLOGICAL|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
48162283|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
48162284|NCT00577096|DRUG|Thalidomide|Fifty percent of the participants received 400 mg daily
48162285|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
48162286|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
48162287|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
48162288|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
48162289|NCT00577096|DRUG|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
48162290|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
48162291|NCT00577096|DRUG|Thalidomide|Fifty percent of participants received 400 mg daily
48162292|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
48162293|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
48162294|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
48162295|NCT01621321|DRUG|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
48162296|NCT01621321|DRUG|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
48162297|NCT00273351|DRUG|[123I]B-CIT|Subjects will receive up to 6 mCi of \[123I\] B-CIT injected intravenously
48368399|NCT00134563|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
48368400|NCT00134563|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
48691396|NCT04377321|DRUG|Colchicine Tablets|colchicine tabletes for 6 months
48691397|NCT01582516|BIOLOGICAL|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
48005266|NCT01171716|OTHER|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
48162298|NCT03924778|BEHAVIORAL|DASH diet|brief description
48162299|NCT03924778|BEHAVIORAL|standard American diet|describe
48162300|NCT06643884|DRUG|AU-011|AU-011 Via Suprachoroidal Administration with laser treatment
48005267|NCT01224886|BEHAVIORAL|Physical activity|Supervised exercise intervention
48162301|NCT06643884|DEVICE|SCS Microinjector|Suprachoroidal Injection Device
48368401|NCT02020681|DEVICE|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
48368402|NCT02020681|OTHER|Placebo|Formulation of Curodont Repair without the peptide P11-4
48368403|NCT02020681|DEVICE|Fluoride|Single application on day D90
48368404|NCT03734601|RADIATION|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
48005268|NCT05426837|BEHAVIORAL|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
48005269|NCT05426837|BEHAVIORAL|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
48162302|NCT06643884|DEVICE|Laser|Laser Administration
48162303|NCT01334905|DRUG|YM178|oral
48368405|NCT03734601|DRUG|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
48368406|NCT03734601|DRUG|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
48368407|NCT03734601|DRUG|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
48368408|NCT03734601|RADIATION|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
48691398|NCT06329466|OTHER|intervention (EFT) group|It is the group to which EFT is applied.
48691399|NCT03420495|BEHAVIORAL|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
48005270|NCT03516669|DRUG|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
48005271|NCT03516669|DRUG|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
48162304|NCT00662883|DRUG|PMI-150 (intranasal ketamine HCl); mometasone furoate|"* 1 dose PMI-150 (intranasal ketamine HCl); day 1~* mometasone furoate, daily; days 2-15~* 1 dose PMI-150 (intranasal ketamine HCl); day 15"
48368409|NCT00917917|BEHAVIORAL|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
48368410|NCT00917917|BEHAVIORAL|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
48368411|NCT06289543|DIETARY_SUPPLEMENT|Preoperative carbohydrate solution|water and solution will be given to patients to drink 2 hours before the operation
48368412|NCT04590976|OTHER|Semi-Structured Interview Healthcare Professional|Interview
48368413|NCT04590976|OTHER|Semi-Structured Interview Patients|Interview
48368414|NCT04590976|OTHER|Think Aloud Interview Patients|Interview
48691400|NCT01393483|OTHER|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
48005272|NCT02423616|OTHER|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
48005273|NCT05830630|DRUG|Bupivacaine methylene blue|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
48691401|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
48005274|NCT05830630|DRUG|bupivacaine saline|"Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively"
48005275|NCT05018715|DIAGNOSTIC_TEST|Machine learning model diagnosis|Machine learning model diagnosis
48005276|NCT05892848|DIAGNOSTIC_TEST|serum ostecalcin,serum sclerostin and parathroid profile|evaluation of bone turnover markers in blood
48368415|NCT04590976|OTHER|Discrete Choice Experiment (DCE) Patients|DCE Questionnaire
48368416|NCT06151821|BEHAVIORAL|Guided meditation|Meditation with guidance
48691402|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
48691403|NCT06346431|COMBINATION_PRODUCT|DSPT - Digital Support for Problem-solving Therapy|Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.
48691404|NCT00073736|DRUG|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
48691405|NCT00073736|DRUG|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
48691406|NCT00073736|DRUG|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
48691407|NCT00073736|DRUG|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
48005277|NCT05039346|OTHER|Phone interviews|Phone interviews will be used to determine the patient's quality of life, symptoms and performance status
48005278|NCT01607983|DRUG|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
48005279|NCT01435291|DRUG|Advagraf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
48162305|NCT04761341|DRUG|NUTROF TOTAL|1 per day over a course of 3 months
48368417|NCT02976909|DRUG|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
48368418|NCT00142207|DRUG|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
48368419|NCT00142207|DEVICE|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
48368420|NCT03643744|DRUG|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
48162306|NCT02246387|PROCEDURE|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
48162307|NCT02775214|DEVICE|Video Laryngoscopy|
48162308|NCT06268431|OTHER|Oxytocin rest|60-minute oxytocin rest
48162309|NCT00187122|DRUG|Vincristine|See Detailed Description section for description of treatment plan.
48162310|NCT00187122|PROCEDURE|Radiation Therapy|See Detailed Description section for description of treatment plan.
48368421|NCT03643744|DRUG|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
48368422|NCT01013805|RADIATION|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
48691408|NCT00073736|DRUG|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
48691409|NCT02965794|OTHER|Care pathways for colorectal cancer|development of a care pathway for this patient group
48691410|NCT04239066|PROCEDURE|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
48005280|NCT01435291|DRUG|Prograf Capsule|"Other Names:~* FK506E~* MR4~* tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
48005281|NCT03689361|COMBINATION_PRODUCT|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion).
48005282|NCT03689361|DIAGNOSTIC_TEST|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion)
48691411|NCT04239066|PROCEDURE|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
48005283|NCT03689361|OTHER|telephone consultation|telephone consultation
48005284|NCT00197327|DRUG|Epidural bupivacaine (0.25% versus 0.0625%)|
48005285|NCT04212585|DIAGNOSTIC_TEST|Serology test|"Serology for Helicobacter pylori (immunoglobulin G for all sites, immunoglobulin M optional, immunoglobulin A optional) will be collected from all participants. 90 samples (immunoglobulin G, immunoglobulin M and immunoglobulin A) at least needed from each site.~Stool antigen for Helicobacter pylori"
48005286|NCT04116710|BIOLOGICAL|HS-110 (viagenpumatucel-L)|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
48005287|NCT04116710|BIOLOGICAL|HS-130|Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
48005288|NCT00632697|DRUG|pentoxifylline|800 mg daily for six months
48691412|NCT03566771|BEHAVIORAL|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
48691413|NCT03566771|BEHAVIORAL|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
48005289|NCT00632697|DRUG|placebo|
48005290|NCT05882227|BEHAVIORAL|video|The patients will receive the discharge information through the visualization of a video with discharge information extracted from the optimized hip prosthesis recovery program document; information for patients, relatives or caregivers. The video will consist of two parts: a first part where it will be explained what will happen in the next hours in the unit, the documentation that will be delivered at discharge and the pharmacological treatment. The second part will consist of a video explaining wound care at discharge, discharge recommendations, symptoms that may appear after surgery and alarm symptoms.
48005291|NCT05882227|BEHAVIORAL|Traditional information|"Patients will receive the information at discharge by means of the document entitled Optimized Hip Replacement Recovery Program; information for patients, relatives or caregivers, which will act as a control group."
48005292|NCT03879889|DRUG|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
48005293|NCT04602572|BEHAVIORAL|Lifestyle course.|Pharmacotherapy
48005294|NCT04602572|PROCEDURE|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
48005295|NCT04889625|DEVICE|senofilcon A C3|Test Lens
48691414|NCT04199975|DEVICE|Orthoses|Power-Driven or Mechanical Orthoses
48691415|NCT00304616|DRUG|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
48691416|NCT00586716|DRUG|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
48691417|NCT00759876|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
48691418|NCT01016717|DRUG|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
48005296|NCT04889625|DEVICE|Dailies Total 1® Multifocal Contact Lenses|Control Lens
48162311|NCT00187122|DRUG|Daunomycin|See Detailed Description section for description of treatment plan.
48162312|NCT00187122|DRUG|L-Asparaginase|See Detailed Description section for description of treatment plan.
48162313|NCT00187122|DRUG|Cytarabine|See Detailed Description section for description of treatment plan.
48162314|NCT00187122|DRUG|Methotrexate|See Detailed Description section for description of treatment plan.
48162315|NCT00187122|DRUG|Mercaptopurine|See Detailed Description section for description of treatment plan.
48162316|NCT00187122|DRUG|Etoposide|See Detailed Description section for description of treatment plan.
48162317|NCT00187122|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
48691419|NCT01016717|DRUG|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
48691420|NCT03593486|DEVICE|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
48691421|NCT03593486|DEVICE|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
48162318|NCT00187122|DRUG|Prednisone|See Detailed Description section for description of treatment plan.
48162319|NCT00187122|DRUG|Dexamethasone|See Detailed Description section for description of treatment plan.
48691422|NCT04097275|OTHER|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
48691423|NCT04097275|OTHER|Withdraw of blood|"Blood will be collected in:~* 1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~* 1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~* 1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
48691424|NCT01939977|DRUG|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
48691425|NCT01939977|DRUG|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
48691426|NCT04801459|PROCEDURE|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
48162320|NCT03086070|DRUG|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
48162321|NCT03086070|DRUG|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
48162322|NCT04491136|DRUG|ACEI/ARB|Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study
48162323|NCT04491136|DRUG|ARNI|Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
48162324|NCT06538818|DEVICE|Ultra Phonophoresis|"Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of a hyaluronic acid-containing gel will be applied gel pad over the wrist and along the course of median nerve at the carpal tunnel.~The following parameters will be used: intensity of 1.0 W/em2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the hyaluronic acid-containing gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.~The following parameters will be used:~* intensity of 1.0 W/cm2~* 1MHz frequency~* pulsed (25%)~* 5 min/session, 5 d/wk, for 3 weeks."
48162325|NCT04026074|DRUG|Fentanyl|Weight adapted drug application
48162326|NCT04026074|DRUG|Remifentanil|Weight adapted drug application
48162327|NCT04026074|DRUG|Clonidine|Weight adapted drug application
48691427|NCT06053151|BEHAVIORAL|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
48162328|NCT04026074|DRUG|EMLA Cream|Salve application on the body part where the regional anaesthesia will be administered
48162329|NCT04026074|DRUG|Placebo iv|i.v. administration of 0,9% NaCl
48162330|NCT04026074|DRUG|Placebo salve|Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
48162331|NCT01737034|OTHER|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
48162332|NCT02367339|OTHER|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
48162333|NCT00776984|DRUG|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
48162334|NCT00776984|DRUG|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
48162335|NCT06135779|BEHAVIORAL|A Lust for Life|A Lust For Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
48162336|NCT06135779|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life School programme.
48162337|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
48162338|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
48162339|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
48691428|NCT01774669|DEVICE|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
48162340|NCT04414254|DRUG|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
48162341|NCT00527696|PROCEDURE|transvaginal obturator tape|
48162342|NCT05579587|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
48162343|NCT02177435|DRUG|Telmisartan|
48162344|NCT02177435|DRUG|Telmisartan/Hydrochlorothiazide|
48162345|NCT02177435|DRUG|Placebo|
48162346|NCT04868981|DRUG|GST-HG141 tablets|Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
48162347|NCT04868981|DRUG|Matching Placebos for GST-HG141 tablets|Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
48005297|NCT00649337|PROCEDURE|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
48005298|NCT00701129|BIOLOGICAL|Alglucosidase Alfa|Administered as IV infusion.
48005299|NCT00701129|DRUG|Methotrexate|Administered subcutaneously.
48162348|NCT05835466|DRUG|reparixin|reparixin at 1200mg TID three times per day.
48162349|NCT03525483|DIAGNOSTIC_TEST|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
48162350|NCT05562492|DEVICE|CamAPS FX|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data."
48162351|NCT05562492|OTHER|Standard insulin therapy with CGM|Usual insulin therapy and study CGM.
48162352|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
48162353|NCT05996458|OTHER|Risk factor investigation;|Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
48368423|NCT01013805|DRUG|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
48691429|NCT01774669|OTHER|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
48005300|NCT00701129|DRUG|Rituximab|Administered as IV infusion.
48005301|NCT04169867|BIOLOGICAL|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
48005302|NCT05979103|BEHAVIORAL|Listening to Reggae Music and told the stereotype|Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.
48005303|NCT05979103|BEHAVIORAL|Listening to Nature Sounds|Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to nature sounds over the 4 weeks. Each day, we will send them a playlist to listen to.
48005304|NCT01440348|PROCEDURE|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
48162354|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
48005305|NCT05561972|DEVICE|injectable multifractional intercalated hyaluronic acid [Armonia®, Regenyal, Italy]|Armonia® 2 ml was injected into the vaginal wall with a standardized injection technique called Cannulated Intravaginal Injection Technique®. In this technique, Armonia® was injected as drops at 40 different points on the entire vaginal wall using 8 different entry points
48005306|NCT00743912|DRUG|rifaximin|550 mg TID
48005307|NCT02716233|DRUG|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
48005308|NCT02716233|DRUG|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
48368424|NCT01013805|DRUG|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
48368425|NCT01013805|DRUG|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
48368426|NCT01013805|PROCEDURE|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
48005309|NCT05156580|OTHER|No intervention|This is an observational study without any intervention
48005310|NCT04667403|OTHER|Telemedicine|"In addition to his standard follow-up, the patient benefits from a home follow-up of his pain for 6 months from his inclusion in the study.~The patient has to log on via the application, every week. to fill in the questionnaire to evaluate the pain over the past week.~The questionnaire consists of 4 questions to which the patient answers using a numerical scale from 0 to 10.~If the patient's pain is not controlled, the patient can log on in emergency mode as many times as he or she deems necessary.~A nurse path coordinator will be informed of each connection. Depending on the type of alert received, she may initiate a telephone consultation with the oncologist or pain specialist:~* If necessary within 24 hours of the connection if it is a weekly connection,~* Systematic within 3 hours if it is an emergency connection or if the data entered at the time of the weekly connection requires medical intervention."
48005311|NCT00094874|PROCEDURE|Acupuncture|
48162355|NCT06537219|OTHER|Assessment|Assessment of pain severity,pain thresold of the fascia, pain sensitivity
48162356|NCT04864236|DEVICE|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
48691430|NCT03716778|OTHER|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
48368427|NCT00137982|PROCEDURE|Treatment of ectopic pregnancy|
48368428|NCT04824092|DRUG|Tafasitamab|Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
48368429|NCT04824092|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
48368430|NCT04824092|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
48368431|NCT04824092|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
48368432|NCT04824092|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
48368433|NCT04824092|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
48368434|NCT04824092|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
48691431|NCT02445105|BEHAVIORAL|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
48162357|NCT05426655|OTHER|Self management|"The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held."
48162358|NCT01108484|BEHAVIORAL|Exercise|Supervised exercise: Three 90-minutes sessions per week.
48691432|NCT02445105|BEHAVIORAL|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
48691433|NCT00551434|DIETARY_SUPPLEMENT|Creatine|Creatine 21 g daily
48691434|NCT00551434|DIETARY_SUPPLEMENT|L-arginine and creatine|L-arginine
48691435|NCT00551434|DIETARY_SUPPLEMENT|l-arginine|l-arginine 9 g daily
48691436|NCT00551434|DIETARY_SUPPLEMENT|placebo, double|placebo
48691437|NCT05625516|DEVICE|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
48691438|NCT03878381|COMBINATION_PRODUCT|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
48691439|NCT03878381|DRUG|Placebo|The placebo will be a formula with no active ingredients
48691440|NCT02660593|DIETARY_SUPPLEMENT|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
48691441|NCT04483193|DIAGNOSTIC_TEST|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
48691442|NCT00086528|DRUG|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
48162359|NCT01108484|BEHAVIORAL|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
48691443|NCT06544785|DRUG|Zanubrutinib Oral Product|"Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day."
48691444|NCT06544785|DRUG|Obinutuzumab|"Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg)."
48691445|NCT00705250|DRUG|bendamustine hcl|Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is \> 1000/ul and the platelet count is \> 75,000/ul.
48005312|NCT06408103|OTHER|Multi-component, transdisciplinary and multifocal intervention for the cognition|"Multi-component intervention (12 weeks, twice/week, with professional support at home)~Physical activity for the patient: dual training, strength, balance, with intensity increase monthly, plus moderate walking of 30 minutes/day, 5 days per week.~Nutritional advice for the patient: Month 1- reduction of added sugars and processed carbohydrates. Month 2- increase consumption of healthy fats and reduction of saturated fats; Month 3- increase in consumption of fruits and vegetables, and a monthly group practical workshop.~Cognitive training for the patient: activities focused on orientation, attention and concentration, working memory, mathematical reasoning, language, visual construction, executive functions, and reminiscence therapy.~Accompaniment for the family member: Activities aimed at care and self-care, understanding cognitive deterioration and its progression, support for patient adherence to the intervention, and activities in groups once a week."
48005313|NCT05358496|DIAGNOSTIC_TEST|Data collection|Clinical data collection
48162360|NCT01108484|BEHAVIORAL|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
48162361|NCT01521221|OTHER|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
48005314|NCT01940120|DEVICE|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
48162362|NCT00705614|BIOLOGICAL|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
48162363|NCT05340439|DRUG|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
48162364|NCT06106789|DRUG|Tobramycin inhalation solution|"Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital."
48691446|NCT05907096|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
48691447|NCT05907096|OTHER|Placebo|Intravenous administration of placebo
48162365|NCT00306878|DRUG|Abatacept|
48162366|NCT05872620|DRUG|Orforglipron|Administered orally
48368435|NCT04824092|DRUG|Tafasitamab placebo|0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
48368436|NCT04824092|DRUG|Lenalidomide placebo|Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
48368437|NCT01103661|DEVICE|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
48005315|NCT01401933|DRUG|Linifanib|QD on Days 1 and 13
48005316|NCT01401933|DRUG|Rifampin|QD on Days 5-16
48005317|NCT06132022|OTHER|Mandala|Mandala work is one of the non-pharmacological approaches and is used to support patients and caregivers in various diseases. Mandala is a method that anyone can apply based on coloring a circular shape.
48005318|NCT06132022|OTHER|Routine care|The clinic's routine information will be given to the caregivers of the control group.
48162367|NCT05872620|DRUG|Placebo|Administered orally
48691448|NCT01951989|DRUG|Imiglucérase (drug) pharmacokinetics|
48162368|NCT02515526|DRUG|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
48368438|NCT05007366|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
48691449|NCT02942836|DEVICE|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
48005319|NCT03839589|BEHAVIORAL|Mindfulness Based Stress Reduction Adapated (MBSR-A)|Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
48005320|NCT03926234|OTHER|Four-level Chinese Emergency triage scale|a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
48005321|NCT02188485|BEHAVIORAL|ENGAGE|Up to 10 sessions delivered in the home.
48005322|NCT06212102|DRUG|Progestin primed ovarian stimulation|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
48005323|NCT06212102|DRUG|GnRH antagonist|HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
48005324|NCT03588481|DEVICE|DESyne X2|Novolimus-eluting stent
48005325|NCT02794272|DEVICE|tDCS|
48005326|NCT02794272|DEVICE|sham-tDCS|
48005327|NCT03171350|DIAGNOSTIC_TEST|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
48005328|NCT04033003|BEHAVIORAL|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
48005329|NCT05590585|DRUG|dupilumab|Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
48368439|NCT05007366|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 9th and 10th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
48691450|NCT06497283|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
48691451|NCT03171584|DRUG|Terbinafine|oral antifungal drugs
48005330|NCT05590585|OTHER|Topical emollient (moisturizer)|Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
48005331|NCT06173466|DRUG|Liposomal bupivacaine|Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
48691452|NCT01935323|OTHER|High Intensity Interval Training|
48691453|NCT01935323|OTHER|Moderate Intensity Training|
48162369|NCT02515526|DRUG|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
48162370|NCT05360342|DRUG|Vitamin K supplement|Single dose of vitamin K supplement
48691454|NCT06215820|DRUG|MR-107A-02|tablet
48691455|NCT06215820|DRUG|Tramadol|over-encapsulated tablet
48691456|NCT06215820|DRUG|Placebo|over-encapsulated tablet and/or tablet
48691457|NCT05740527|DEVICE|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
48691458|NCT05290402|OTHER|JEEVA (new digital health navigator app)|An app can be used on a mobile phone or tablet.
48691459|NCT05665335|DEVICE|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
48691460|NCT02889497|BIOLOGICAL|the first batch vaccine|
48691461|NCT02889497|BIOLOGICAL|the second batch vaccine|
48691462|NCT02889497|BIOLOGICAL|the third batch vaccine|
48691463|NCT03866408|BEHAVIORAL|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
48162371|NCT05262920|BEHAVIORAL|The BSM Intervention|The BSM intervention entailed a daily electronic journal for monitoring BF and BNP with feedings, bi-weekly texting for 6 weeks from a research nurse for informational support and to promote personalized goal-setting and problem-solving, and hyperlinks to eight uniform BNP educational modules (knowledge and skills) and online resources. 1. Fundamentals of BF (FBF), 2. Deep breathing (DB), 3. BNP non-pharmacological strategies (BNPS), 4. Guided imagery (GI), 5. Pain neurophysiology specifically related to BF (PN-BF), 6. Catastrophizing, 7. Stress reactivity, and 8. Common pumping issues and interventions (CPI).
48368440|NCT03710395|PROCEDURE|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
48691464|NCT03866408|DRUG|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
48691465|NCT03866408|BEHAVIORAL|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
48691466|NCT03866408|DRUG|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
48691467|NCT05287958|DIAGNOSTIC_TEST|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
48691468|NCT02499913|BEHAVIORAL|breath alcohol monitoring|Daily breath alcohol monitoring
48005332|NCT06173466|DRUG|Bupivacaine Hydrochloride combined with dexamethasone|Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
48005333|NCT01381861|BIOLOGICAL|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
48005334|NCT04787939|BEHAVIORAL|Early Feeding|Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
48005335|NCT03907683|BEHAVIORAL|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
48005336|NCT02367599|DRUG|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
48005337|NCT03735862|BIOLOGICAL|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
48005338|NCT01139281|DRUG|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
48005339|NCT01139281|DRUG|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
48005340|NCT03740425|PROCEDURE|Blood Transfusion|Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
48005341|NCT06457594|OTHER|Questionnaire|EORTC QLQ-INFO25 EORTC QLQ - H\&N43 and EORTC QLQ-C30
48005342|NCT04615559|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
48005343|NCT03640065|DRUG|freeze-dried probiotic sachets|"* The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~* This procedure will be repeated once daily for the following 4 weeks.~* 4 weeks supply will be given to the participants."
48005344|NCT03640065|DIETARY_SUPPLEMENT|fermented dairy product ( yogurt)|"* The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~* 4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
48691469|NCT02499913|BEHAVIORAL|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
48005345|NCT03060746|OTHER|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
48005346|NCT00004918|BIOLOGICAL|PR1 leukemia peptide vaccine|Given SC
48005347|NCT00004918|DRUG|Montanide ISA 51 VG|Given SC
48368441|NCT03710395|DRUG|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
48368442|NCT02516605|DRUG|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
48368443|NCT02516605|DRUG|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
48368444|NCT02516605|DRUG|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
48368445|NCT02516605|DRUG|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
48368446|NCT02516605|DRUG|Part 2: LJN452 Dose level 2|LJN452
48368447|NCT03661658|PROCEDURE|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
48368448|NCT03661658|PROCEDURE|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
48368449|NCT01038609|DRUG|Hydrocodone/Acetaminophen Extended Release|
48368450|NCT01038609|DRUG|Acetaminophen|
48005348|NCT00004918|BIOLOGICAL|sargramostim|Given SC
48005349|NCT00004918|OTHER|laboratory biomarker analysis|Correlative studies
48162372|NCT05262920|BEHAVIORAL|Attention Control|The Attention Control and Intervention groups both receive fourth-trimester care videos. The educational modules are the following: Urgent maternal warning signs, caring for the maternal body after birth; infant care; COVID-19 and infant health prevention; maternal and infant immunization; infant safety in the home; maternal and infant dietary recommendations; and national and health resources to support BF in the workplace
48368451|NCT01038609|DRUG|Morphine Extended Release|
48368452|NCT01038609|DRUG|Placebo|
48691470|NCT00911976|DEVICE|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
48691471|NCT00586040|PROCEDURE|tissue bonding|application of rose bengal and treatment with green light
48691472|NCT00586040|PROCEDURE|sutures|interrupted superficial sutures
48691473|NCT03650413|DRUG|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
48691474|NCT06277947|PROCEDURE|China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)|The C-HIPEC would be performed at bedside in the general ward within 24 hours after surgery. The HIPEC treatment instruments are BR-TRG-II system, which can control the temperature stably to 43℃±0.1℃.
48691475|NCT05773807|OTHER|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
48691476|NCT05773807|OTHER|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
48005350|NCT03671291|BEHAVIORAL|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
48005351|NCT06415643|OTHER|Islet organoids transplantation|autologous transplantation of ex vivo expanded islet organoids.
48005352|NCT00125866|BEHAVIORAL|Flavonoid rich or flavonoid depleted chocolate drink|
48005353|NCT00786695|DRUG|esomeprazole|esomeprazole (40 mg o d) for 14 days
48005354|NCT00786695|DRUG|Placebo|Identical looking Placebo, same regimen, for 14 days
48005355|NCT04542070|DRUG|Cabotegravir Tablets|CAB tablets were available as film coated tablets for oral administration.
48005356|NCT04542070|DRUG|Cabotegravir Injectable Suspension (CAB LA)|CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.
48005357|NCT04542070|DRUG|Rilpivirine Tablets|RPV was administered as tablets for oral administration.
48005358|NCT04542070|DRUG|Rilpivirine Injectable Suspension (RPV LA)|RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.
48005359|NCT04542070|DRUG|BIKTARVY Tablets (BIK)|BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
48005360|NCT02089061|DRUG|BMS-919373|
48005361|NCT02089061|DRUG|Rosuvastatin|
48005362|NCT02089061|DRUG|Atorvastatin|
48005363|NCT06243133|DRUG|clopidogrel for 90 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
48005364|NCT06243133|DRUG|clopidogrel for 30 days combined with aspirin for 90 days|Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
48005365|NCT01438970|DEVICE|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
48005366|NCT05949138|DEVICE|ECG-Less Cardiac CT using SmartPhase|"Administration of medications and biologic products (such as contrast agent administration, and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational workflow on an existing CT device that has regulatory clearance. The investigational workflow includes preforming the CT acquisition according to the hospital's usual care with the exception that the ECG signal which triggers the scan will be coming from an ECG simulator based on an estimate of the patient's heart rate, rather than through ECG leads connected to the subject. Clinically-indicated Cardiac CTs take approximately 30-60 minutes. No additional imaging is needed as part of the study."
48005367|NCT04752501|OTHER|Psychologically Informed Education|This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain
48005368|NCT04752501|OTHER|Biomedical Education (Control)|This arm will provide education of basic knee anatomy, lower extremity mechanics, and simple exercises and will not address maladaptive psychological behaviors
48005369|NCT02908113|BEHAVIORAL|collection data|
48005370|NCT02908113|BEHAVIORAL|IRM|
48005371|NCT03850873|DRUG|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
48162373|NCT01588847|PROCEDURE|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
48162374|NCT01588847|PROCEDURE|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
48368453|NCT05500742|DIETARY_SUPPLEMENT|Coenzyme Q10|Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
48368454|NCT05500742|DIETARY_SUPPLEMENT|Selenium|100 mcg tablets provided by Pharma Nord
48368455|NCT05500742|DIETARY_SUPPLEMENT|Resveratrol|350 mg capsules provided by NOW Foods
48162375|NCT04883541|BEHAVIORAL|yoga and meditation|The pregnant women in the study group were given yoga and meditation classes, which included a total of twenty 10-week lessons, which were done by the researchers as 6-week birth preparation training, and with the onset of the birth action, birth processes were followed in the course of labour period yoga and meditation.
48162376|NCT04883541|BEHAVIORAL|Birth preparation training|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
48162377|NCT05488002|BEHAVIORAL|Pharmaceutical intervention|Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
48162378|NCT06255288|OTHER|SNAK intervention|The intervention consists of structured dialogue, patient information, and a protein supplement. The structured dialogue part of the intervention consists of an A3 poster with illustrations and keywords which will be hanging in the outpatient clinics. The poster will be utilized by nurses, patients, and their relatives to facilitate a dialogue regarding nutrition and wound healing. The patient information part of the intervention consists of a leaflet with easy-to-read information, which patients and their relatives can bring home after their visit to the outpatient clinic. The leaflet will consist of general information as well as food categories and recipes they can use to enhance their daily protein intake. For the protein supplement part of the intervention, the patients will have access to protein supplement beverages while they are in the outpatient clinic waiting room. Furthermore, they will receive prescriptions for protein drinks, that they can pick up at their local pharmacy.
48162379|NCT05973357|PROCEDURE|Sub-crestal implant|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
48162380|NCT05973357|PROCEDURE|Equi-crestal implant|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
48162381|NCT01549249|DEVICE|optical coherence tomography|spectral-domain optical coherence tomography
48162382|NCT05620654|DRUG|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
48162383|NCT02948205|PROCEDURE|3D group|infertility patient get TU-LESS by 3D Laparoscopy
48162384|NCT02948205|PROCEDURE|normal group|infertility patient get normal laparoscopic surgery
48162385|NCT05626478|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
48162386|NCT05626478|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
48368456|NCT05500742|DIETARY_SUPPLEMENT|TA-65 MD|100 unit capsules provided by TA Sciences
48368457|NCT05500742|OTHER|Placebo-1|Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
48691477|NCT05773807|PROCEDURE|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
48368458|NCT05500742|OTHER|Placebo-2|Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
48691478|NCT05773807|DRUG|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
48691479|NCT03844672|BEHAVIORAL|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
48691480|NCT03844672|BEHAVIORAL|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
48691481|NCT03844672|BEHAVIORAL|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
48691482|NCT03844672|BEHAVIORAL|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
48691483|NCT01734785|DRUG|Linagliptin|tablet
48368459|NCT03609775|DRUG|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
48368460|NCT03609775|OTHER|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
48368461|NCT03609775|OTHER|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
48368462|NCT03609775|OTHER|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
48691484|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
48691485|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
48691486|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
48691487|NCT01734785|DRUG|Empagliflozin placebo + Linagliptin placebo|Matching Empagliflozin + Linagliptin low dose
48368463|NCT02312934|DRUG|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
48368464|NCT02312934|OTHER|Placebo Transdermal Patch|Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
48368465|NCT02013999|OTHER|Virtual reality program for upper extremity rehabilitation|
48368466|NCT02013999|OTHER|standard occupational therapy|
48691488|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
48691489|NCT02546258|DEVICE|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
48691490|NCT04643457|DRUG|UCB9741|- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
48691491|NCT04643457|DRUG|Intravenous Placebo|- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.
48691492|NCT04643457|DRUG|Subcutaneous Placebo|Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.
48162387|NCT05626478|DRUG|Prolensa 0.07% Ophthalmic Solution|Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
48162388|NCT04725617|DRUG|Varenicline|Standard smoking cessation treatment.
48162389|NCT04725617|BEHAVIORAL|Smoking Cessation Counseling|Standard smoking cessation treatment
48162390|NCT04725617|BEHAVIORAL|Health Approach 1 to Reduce Smoking|Behavioral health intervention option 1
48162391|NCT04725617|OTHER|Health Approach 2 to Reduce Smoking|Behavioral health intervention option 2
48162392|NCT05834361|DRUG|early vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is 20 minutes before the surgery.
48162393|NCT05834361|DRUG|delayed vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
48368467|NCT01180452|PROCEDURE|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
48368468|NCT00003824|DRUG|cephalexin|500 mg oral bid for 3 days starting the night before resection
48368469|NCT00003824|PROCEDURE|surgical procedure|
48368470|NCT00003824|DRUG|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
48005372|NCT04560634|DRUG|Norepinephrine|Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
48005373|NCT04560634|DEVICE|ClearSight®, Edwards Lifescience, Irvine, CA|"All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis."
48005374|NCT01598116|PROCEDURE|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
48005375|NCT01598116|PROCEDURE|Urine collection|Bagged urine collection
48005376|NCT01966926|BEHAVIORAL|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
48005377|NCT00117143|DRUG|Romiplostim|Administered subcutaneously on day 1 and on day 15 or 22 if the platelet count was ≤ 50 x 10⁹/L and not rising, peak platelet count was ≤ 450 x 10⁹/L and no serious adverse events related to treatment were observed.
48005378|NCT03863028|OTHER|Simulation training|It is not a randomized trial - all three groups are exposed to simulation training.
48005379|NCT03707769|DEVICE|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
48005380|NCT02915653|OTHER|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
48005381|NCT06008613|DEVICE|3D Holographic Guidance, Navigation, and Control (3D GN&C)|"Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of:~1. experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS),~2. FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and~3. 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2."
48005382|NCT00113256|DRUG|Rubitecan|
48005383|NCT02739191|DEVICE|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
48005384|NCT05094297|BEHAVIORAL|Investigate the effects of an exercise intervention on U.S. Veterans.|Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
48162394|NCT00392314|OTHER|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
48162395|NCT02704026|OTHER|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
48162396|NCT01099150|DIETARY_SUPPLEMENT|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~900 mg of total flavan-3-ols and procyanidins.
48368471|NCT00270010|DRUG|epoetin alfa|
48368472|NCT05836688|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
48368473|NCT05836688|BEHAVIORAL|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
48368474|NCT02043704|DRUG|IV Acetaminophen|Details covered in arm description.
48691493|NCT00111449|DRUG|Etanercept|
48691494|NCT06656923|DIAGNOSTIC_TEST|Biopsies|Analyze previous biopsies to quantify changes induced by Poly-L-Lactic Acid in Adipose Tissue
48162397|NCT01099150|DIETARY_SUPPLEMENT|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~400 mg total flavan-3-ols and procyanidins.
48005385|NCT03314467|DIAGNOSTIC_TEST|polysomnography|"* classical polysomnography~* non invasive measurement of blood pressure~* blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
48162398|NCT01099150|DIETARY_SUPPLEMENT|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
48162399|NCT05926232|DRUG|Repotrectinib|Repotrectinib
48162400|NCT01885377|OTHER|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
48162401|NCT01885377|OTHER|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
48162402|NCT06643052|OTHER|No intervention|No intervention
48162403|NCT05942573|DRUG|Serplulimab+Paclitaxel+Apatinib|Immunotherapy+chemotherapy
48162404|NCT05942573|DRUG|Paclitaxel±Ramucirumab|chemotherapy±Targeted therapy
48162405|NCT03743987|PROCEDURE|control group|a procedure used to prevent or resolves apical periodontitis.
48162406|NCT03743987|PROCEDURE|MTA group|a procedure used to prevent or resolves apical periodontitis.
48162407|NCT03743987|PROCEDURE|PRF group|a procedure that is used for wound healing
48162408|NCT03743987|PROCEDURE|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
48162409|NCT06244030|OTHER|core stabilization group|The athletes in the training group will be applied 15-20 repetitions of core stabilization exercise program 3 days a week for 6 weeks by the researcher.
48162410|NCT01887418|DRUG|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
48162411|NCT01887418|DRUG|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
48162412|NCT01887418|DRUG|Delatestryl 200 mg IM Treatment C|Standard of care
48162413|NCT04346433|BEHAVIORAL|Restricted Sleep|During the restricted sleep condition adolescents will sleep 4 hours ±1 hour (0100-0500). This condition will last 1 night.
48162414|NCT04346433|BEHAVIORAL|Adequate Sleep|During the adequate sleep condition adolescents will sleep 9 hours ±1 hour (2100- 0800). This condition will last 1 night.
48368475|NCT04335929|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
48162415|NCT01513447|DRUG|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
48368476|NCT04585789|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.
48368477|NCT04585789|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
48368478|NCT04585789|DRUG|Entecavir (ETV)|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
48368479|NCT04585789|DRUG|Tenofovir disoproxil|Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.
48368480|NCT04585789|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
48368481|NCT04585789|DRUG|PegIFN-alpha-2a (Optional)|PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
48368482|NCT02651311|OTHER|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
48368483|NCT02651311|DRUG|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
48005386|NCT01470391|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
48368484|NCT02651311|DRUG|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
48005387|NCT01470391|PROCEDURE|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
48162416|NCT05450705|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
48162417|NCT04764877|OTHER|Osteopathic Manipulative Medicine|Provided 15-20 minute long OMT session for patients in the OMT arm
48162418|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
48162419|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
48162420|NCT06023134|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.
48162421|NCT06023134|DIAGNOSTIC_TEST|Right heart catheterization|"Right heart catheterization is the gold standard for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload."
48162422|NCT04131699|DEVICE|Cardiotronic ICON continuous non-invasive cardiac output monitor.|cardiac index, cardiac output \& stroke volume measured and recorded with every change in intrathoracic pressure.
48368485|NCT04586608|DIETARY_SUPPLEMENT|MCT/ω-3 fatty acids|The provision of ω-3 fatty acids to premature neonates in the Parenteral Nutrition.
48368486|NCT04586608|DIETARY_SUPPLEMENT|soybean oil-based IVFE|soybean oil-based IVFE
48162423|NCT03269149|OTHER|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
48162424|NCT03269149|BEHAVIORAL|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q\&A will be encouraged.
48162425|NCT02895854|RADIATION|Hypofractionated RT 5 x 7,25 Gy|
48162426|NCT02895854|RADIATION|LDR-brachytherapy with I125 seeds|
48162427|NCT04937205|BEHAVIORAL|MOVE|The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
48162428|NCT00678899|DEVICE|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
48162429|NCT00116584|DRUG|heliox|continuous heliox therapy
48162430|NCT00116584|DRUG|oxygen|continuous oxygen therapy
48162431|NCT01965041|DRUG|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
48162432|NCT00240097|DRUG|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
48162433|NCT00240097|DRUG|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
48162434|NCT05325476|OTHER|JomPrEP App|The JomPreP app will be ideally designed to optimize HIV prevention cascade by providing a virtual platform to access to HIV prevention (e.g., HIV testing and PrEP) and other support services (e.g., mental health). The JomPrEP app will be available on the Apple Store and the Google Play Store for the users to download. However, access to the app will be restricted to the research participant using a unique registration code.
48162435|NCT05325476|OTHER|Inactivated JomPrEP app|Participants will have access to the JomPrEP app with major intervention features inactivated. Information and resources for HIV testing, PrEP, and available mental health and addiction services will be available along with access to risk assessment tools. The RA will assist in downloading the app and provide a tutorial in using the assessment tool of the app.
48162436|NCT05253547|BEHAVIORAL|Healthy climate-friendly dietary guidelines|Personalised climate-friendly healthy dietary recommendations
48162437|NCT05253547|BEHAVIORAL|Healthy dietary guidelines|Personalised healthy dietary recommendations
48162438|NCT02824029|DRUG|Ibrutinib|Given PO
48162439|NCT02824029|OTHER|Laboratory Biomarker Analysis|Correlative studies
48162440|NCT02824029|OTHER|Pharmacological Study|Correlative studies
48162441|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Slow activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.
48162442|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Rapid activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
48162443|NCT00637325|DRUG|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
48162444|NCT03455569|BEHAVIORAL|Behavioral sleep education|This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
48162445|NCT03455569|BEHAVIORAL|Education only|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
48162446|NCT03175835|DRUG|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
48162447|NCT03175835|DRUG|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21
48162448|NCT03175835|DRUG|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
48162449|NCT04757519|BEHAVIORAL|DPP-GLB Standard|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
48162450|NCT04757519|BEHAVIORAL|DPP-GLB Enhanced|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
48368487|NCT05257876|OTHER|Breathing exercise|Participants will receive breathing exercise training, and a 4-week self exercise
48005388|NCT00086580|BIOLOGICAL|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
48005389|NCT00086580|BIOLOGICAL|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
48005390|NCT01456442|DEVICE|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
48005391|NCT01456442|DEVICE|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
48005392|NCT02957175|OTHER|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
48005393|NCT00924911|DRUG|GSK1322322|Four different formulations of 1000mg of GSK1322322
48005394|NCT00924911|DRUG|GSK1322322|GSK1322322 1000mg
48005395|NCT04700748|RADIATION|Brain metastases radiation|Brain metastases radiation according to clinical practice.
48005396|NCT05274256|PROCEDURE|implant placement with simultaneous soft tissue augmentation|implant placement with simultaneous soft tissue augmentation using De-epithelialized free gingival graft and immediate temporization in the maxillary aesthetic zone .
48005397|NCT00208377|DEVICE|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
48005398|NCT03080558|DRUG|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
48005399|NCT04125316|OTHER|Observation, no intervention|Observational study, no intervnetion
48005400|NCT02513524|PROCEDURE|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
48005401|NCT01617603|OTHER|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
48005402|NCT02188615|PROCEDURE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
48005403|NCT02188615|DRUG|Cisplatin|only Radical Chemoradiotherapy
48005404|NCT02188615|DEVICE|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
48005405|NCT04568122|DEVICE|Saliva test kit|Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
48005406|NCT02365636|DRUG|TV-45070|TV-45070 is an ointment applied topically twice daily to area of pain.
48005407|NCT02365636|DRUG|Placebo|The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
48005408|NCT05709171|DRUG|18F-FDG|PET/CT scan approximately 60 min after injection of 18F-FDG
48005409|NCT05709171|DRUG|64Cu-Dotatate|PET/CT scan approximately 60 min after injection of 64Cu-Dotatate
48005410|NCT03494036|DIETARY_SUPPLEMENT|Synbiotic|capsule
48005411|NCT03494036|DIETARY_SUPPLEMENT|Placebo|capsule
48162451|NCT06034964|DRUG|Tislelizumab|Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity
48162452|NCT00616486|DEVICE|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
48368488|NCT03618576|PROCEDURE|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
48368489|NCT00575003|DRUG|CYT003-QbG10|6 subcutaneous injections
48368490|NCT00072085|BIOLOGICAL|aldesleukin|
48005412|NCT02121691|BEHAVIORAL|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
48005413|NCT03732053|OTHER|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
48005414|NCT04126928|DIAGNOSTIC_TEST|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
48005415|NCT02296112|DRUG|trametinib|Given PO
48005416|NCT02296112|OTHER|laboratory biomarker analysis|Correlative studies
48368491|NCT00072085|BIOLOGICAL|gp100 antigen|
48162453|NCT00616486|DEVICE|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
48162454|NCT01939483|DRUG|irinotecan hydrochloride|Given IV
48162455|NCT01939483|OTHER|laboratory biomarker analysis|Correlative studies
48162456|NCT04964609|DEVICE|EmbracePlus|"A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter."
48162457|NCT06645652|BEHAVIORAL|Training in observational drawing|"* 6 weeks of online gallery browsing based on different topics~* Daily practice drawing from observation with training adding up to 1 hour a week~* Documenting progress and reflection writing"
48005417|NCT02296112|OTHER|pharmacological study|Correlative studies
48005418|NCT06447090|DRUG|Mitoxantrone hydrochloride liposome|Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7; Mitoxantrone Liposomal 30 mg/m2, d1; Cytosine arabinoside(Ara-C) 100 mg/m2/d, d1-7; Cyclophosphamide (CTX) 400 mg/m2/d, d2, 5); After 1 day of rest, cryopreserved donor stem cells MNC1-2X10\^8 /kg infusion, add low-dose (25 mg Bid) and short-course treatment (stop 2-3 weeks after DLI) oral cyclosporine (CSA) to prevent graft-versus-host disease (GVHD) 3 days before cryopreserved stem cell infusion.
48162458|NCT06645652|BEHAVIORAL|Arts engagement through digital galleries|"* 6 weeks of online gallery browsing based on different topics~* 2 hours of weekly activities consist of reading and navigating technology~* Reflection writing"
48162459|NCT05842915|BEHAVIORAL|Questionnaire|Baseline and 3 month questionnaire
48005419|NCT01147991|BIOLOGICAL|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
48005420|NCT01147991|OTHER|laboratory biomarker analysis|
48162460|NCT00156377|DRUG|Mupirocin|
48162461|NCT01401036|DEVICE|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
48162462|NCT01401036|PROCEDURE|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
48162463|NCT04773054|DIAGNOSTIC_TEST|Microbiological analysis of periprosthetic tissue|Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
48162464|NCT04773054|DIAGNOSTIC_TEST|Histological analysis of periprosthetic tissue|Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
48162465|NCT04773054|OTHER|Characterization of tissue microbiota|"Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone."
48162466|NCT04773054|OTHER|Characterization of gut microbiota|"Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples."
48162467|NCT04773054|OTHER|Characterization of oral microbiota|"Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate."
48162468|NCT05213117|BEHAVIORAL|Co-Localization with Nursing|Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
48162469|NCT06465615|DEVICE|Self-education with dichoptic reading on tablet|"Intervention 25 min/day, 5 days a week for 6 weeks at home (125-minute weekly load), under the supervision of a parent, on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and the patient's optical correction (if applicable).~During the first half of treatment (first 3 weeks), dichoptic separation takes place at the word level, and during the second half of treatment (last 3 weeks), it takes place at the individual letter level to promote precise eye alignment. This shift from dichoptic separation at word level to letter level increases the difficulty of the task. The text is freely chosen by the child and parent from a bank of age-appropriate books."
48162470|NCT06465615|PROCEDURE|Conventional orthoptic rehabilitation|Conventional orthoptic rehabilitation consisting of 12 x 25-minute sessions twice a week over 6 weeks, carried out with an orthoptist from Montpellier University Hospital, combined with reinforcement exercises to be carried out at home for 15 minutes a day under parental supervision, 5 days a week (125-minute weekly load). This is the standard orthoptic treatment offered in France to patients with symptomatic convergence insufficiency, according to orthoptic procedures (10-15 sessions of the order of 20-25 minutes and 10-15 minutes of daily reinforcement exercises at home).
48162471|NCT05733000|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48162472|NCT05733000|PROCEDURE|Computed Tomography|Undergo CT
48162473|NCT05733000|DRUG|Devimistat|Receive IV
48162474|NCT05733000|DRUG|Fluorouracil|Receive IV
48005421|NCT01147991|OTHER|pharmacological study|
48005422|NCT02722928|OTHER|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
48162475|NCT05733000|DRUG|Gemcitabine Hydrochloride|Receive IV
48162476|NCT05733000|DRUG|Hydroxychloroquine|Receive PO
48162477|NCT05733000|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48162478|NCT01158716|OTHER|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
48162479|NCT05985109|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
48162480|NCT05985109|DRUG|regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
48162481|NCT05876364|BIOLOGICAL|QTP104 1ug|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
48162482|NCT05876364|BIOLOGICAL|QTP104 5ug|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
48368492|NCT00072085|BIOLOGICAL|incomplete Freund's adjuvant|
48691495|NCT06116890|DRUG|KHK4951|KHK4951 eye drop for 44 weeks until end of the trial
48691496|NCT06116890|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
48162483|NCT05876364|BIOLOGICAL|QTP104 25ug|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
48162484|NCT02801500|DEVICE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
48162485|NCT02801500|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
48162486|NCT00885859|DEVICE|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
48162487|NCT02572778|PROCEDURE|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
48162488|NCT03302871|DRUG|Botulinum toxin type A|
48162489|NCT03302871|DEVICE|transcranial direct current stimulation|
48162490|NCT03302871|OTHER|hybrid training model of CIMT and BIT|
48162491|NCT03302871|OTHER|usual care|
48162492|NCT01198067|DRUG|Pomalidomide|Given PO
48162493|NCT02600988|DRUG|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
48162494|NCT02600988|DRUG|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
48162495|NCT01116440|DRUG|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
48162496|NCT01116440|DRUG|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
48691497|NCT02606123|DRUG|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
48691498|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
48691499|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
48691500|NCT00913887|DRUG|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
48691501|NCT02516982|OTHER|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
48691502|NCT02516982|OTHER|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
48691503|NCT02516982|OTHER|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
48691504|NCT02516982|OTHER|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
48162497|NCT06575998|OTHER|Training|A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.
48162498|NCT06575998|OTHER|Pro-active identification|Pro-active identification of patients with clinical insomnia symptoms. Patients receiving care from the participating practices will be asked to fill-out the Insomnia Severity Index (ISI).The ISI is used to identify patients with clinical insomnia symptoms in the general practice. Trained practices will receive feedback on the ISI for half of the patients with clinical symptoms according to the ISI.
48162499|NCT04665349|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
48162500|NCT02213224|DRUG|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
48162501|NCT02213224|DRUG|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
48162502|NCT02213224|DRUG|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
48162503|NCT01567670|DRUG|Naloxone|2 mg x 1-2
48162504|NCT01567670|DRUG|naloxone placebo|h2o placebo spray
48005423|NCT06458894|BEHAVIORAL|Prerehabilitation|Home prerehabilitation was performed on the basis of routine preoperative preparation
48691505|NCT06659497|BEHAVIORAL|web-based patient education|"The web-based training, which will provide the following information about the IUI treatment process, will last a total of 60 minutes.~MODULE 1: General Information About Fertility MODULE 2: Diagnostic and Therapeutic Methods in Infertility / Insemination Treatment MODULE 3: Drugs Used in Insemination Treatment and Their Application MODULE 4: Things to Consider After Insemination"
48162505|NCT01882088|DRUG|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
48162506|NCT02341599|DRUG|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
48162507|NCT04293341|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
48162508|NCT04293341|BEHAVIORAL|Cognitive Processing Therapy for PTSD|CPT is a well established evidence-based psychotherapy for PTSD. CPT focuses on teaching patients to evaluate and change the upsetting thoughts that they have had since their trauma.
48162509|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for MDD|CBT for MDD is a well established evidence-based psychotherapy for depression. CBT for MDD focuses teaching patients how to change their behaviors and challenge their negative thoughts to improve their mood.
48162510|NCT04293341|BEHAVIORAL|Cognitive Behavioral Therapy for Panic Disorder|CBT for Panic Disorder is a well established evidence-based psychotherapy. CBT for Panic Disorder focuses teaching patients how to change their behaviors through exposure practices and challenge their anxious thoughts to reduce their experience of panic attacks and avoidance.
48162511|NCT05430074|DEVICE|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
48691506|NCT05132400|BEHAVIORAL|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
48691507|NCT00000805|DRUG|Ganciclovir|
48691508|NCT04787549|DEVICE|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
48691509|NCT03018197|OTHER|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
48691510|NCT00120081|BIOLOGICAL|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
48691511|NCT00120081|BIOLOGICAL|Saline placebo|Inactive saline placebo control
48691512|NCT05483699|OTHER|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
48691513|NCT05483699|OTHER|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
48691514|NCT05483699|OTHER|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
48691515|NCT03316573|DRUG|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
48691516|NCT03520920|DRUG|Zanubrutinib|Administered zanubrutinib 160 mg orally (PO) BID continuously
48691517|NCT03520920|DRUG|Rituximab|Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
48691518|NCT04887168|BEHAVIORAL|Survive & Thrive|Psychoeducational Intervention: Survive \& Thrive (Ferguson, 2008; Mahoney et al, 2018). A total of 10 manualised sessions of approximately 1.5 hour duration are offered. Individual sessions run using an educational format and in an informal setting, with a strong emphasis on avoiding individual disclosures. Groups will be delivered utilising a multi-disciplinary work force consisting of mental health staff in a ratio of 2 per group. Groups will consist of a maximum of 8-10 participants
48691519|NCT06516874|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)|This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.
48691520|NCT06516874|OTHER|TAU|waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
48691521|NCT06152042|DRUG|BMF-219|BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
48691522|NCT01267864|DRUG|Metoclopramide|10mg IVSS
48691523|NCT01267864|DRUG|Ketorolac|30g IVSS
48691524|NCT01267864|DRUG|Valproate|1gm IVSS
48691525|NCT05636046|PROCEDURE|transseptal catheterization|puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
48691526|NCT04789629|DEVICE|low level laser therapy|3 session per week laser with exercises
48691527|NCT00042952|DRUG|imatinib mesylate|Given orally
48691528|NCT00042952|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
48691529|NCT00042952|OTHER|laboratory biomarker analysis|Correlative studies
48691530|NCT06115499|DRUG|Nab paclitaxel|Given IV
48005424|NCT00424905|DRUG|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
48162512|NCT05430074|DEVICE|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
48162513|NCT04416321|DEVICE|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
48162514|NCT01861795|OTHER|Preterm Neonates|Preterm Neonates
48162515|NCT00000121|DEVICE|Prisms in Eyeglasses|
48162516|NCT01497951|OTHER|Aminolaevulinic acid|Photodynamic therapy
48162517|NCT01497951|OTHER|Methylcellulose Placebo|Methylcellulose
48162518|NCT05576727|OTHER|Unruptured intracranial aneurysms|Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
48162519|NCT01924806|DEVICE|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
48162520|NCT01924806|DEVICE|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
48162521|NCT04186884|OTHER|Quality-of-Life Assessment|Ancillary studies
48691531|NCT06115499|DRUG|Gemcitabine|Given IV
48162522|NCT04186884|OTHER|Questionnaire Administration|Complete questionnaires
48162523|NCT01329419|DRUG|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
48162524|NCT05160402|DRUG|IGM-6268|Active comparator
48162525|NCT05160402|DRUG|Placebo|Placebo comparator
48162526|NCT02933996|DEVICE|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
48162527|NCT02933996|DEVICE|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
48162528|NCT03440788|DRUG|Brentuximab Vedotin|Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
48691532|NCT06115499|DRUG|Cisplatin|Given IV
48162529|NCT06205576|DEVICE|DCB catheter|Trade name of DCB catheter：Acoart Orchid＆Dhalia
48162530|NCT02368691|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
48162531|NCT05914155|DRUG|Rituximab (genetical recombination)|Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
48162532|NCT05914155|DRUG|Placebo|Administer placebo IV infusion every two weeks for two doses in double-blind phase.
48162533|NCT05914155|DRUG|Rituximab (genetical recombination)|Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
48162534|NCT05067543|DEVICE|Tornier Perform Humeral - Stem|The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
48005425|NCT01223144|BEHAVIORAL|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
48162535|NCT04136587|OTHER|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
48162536|NCT03068676|BEHAVIORAL|Space from Depression|internet-delivered CBT
48162537|NCT03068676|BEHAVIORAL|Space from Anxiety|internet-delivered CBT
48162538|NCT02115178|OTHER|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
48162539|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
48162540|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
48691533|NCT06115499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48691534|NCT06115499|PROCEDURE|Computed Tomography|Undergo CT
48691535|NCT06115499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48691536|NCT03944265|OTHER|Counseling|Participate in treatment decision counseling session
48691537|NCT03944265|OTHER|Questionnaire Administration|Ancillary studies
48691538|NCT03944265|OTHER|Medical Chart Review|Ancillary studies
48691539|NCT05398029|DRUG|VERVE-101|Intravenous (IV) infusion.
48691540|NCT03013387|RADIATION|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
48691541|NCT03013387|PROCEDURE|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
48368493|NCT06087133|BEHAVIORAL|StEP:Prenatal|StEP is a health care-based intervention based on elements of Social Cognitive Theory, in which registered dietitians with additional certified lactation counselor training (RD/CLC) provide individual and group-based support for healthy diet, physical activity, other lifestyle behaviors, stress reduction, and healthy gestational weight gain. StEP:Prenatal will be delivered remotely. There are up to 8 sessions scheduled around the routine prenatal care visits and designed to be offered from the first trimester of pregnancy through delivery.
48005426|NCT05333549|DRUG|Istradefylline medication|2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
48005427|NCT00981006|PROCEDURE|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
48691542|NCT03013387|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
48005428|NCT02980965|DRUG|letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
48005429|NCT02980965|DRUG|fluorouracil, epirubicin, cyclophosphamide, docetaxel|Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
48005430|NCT03621228|DEVICE|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
48005431|NCT01640366|DEVICE|PICO|Single-use Negative Pressure Wound Therapy System
48005432|NCT02658279|DRUG|Pembrolizumab|
48162541|NCT03653689|DIETARY_SUPPLEMENT|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
48005433|NCT05523206|OTHER|No intervention|No intervention
48005434|NCT00264641|DRUG|Human insulin|Hyperinsulinaemic induced hypoglycaemia
48005435|NCT01194024|OTHER|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
48005436|NCT00052728|DRUG|tamoxifen citrate|
48368494|NCT06087133|OTHER|Routine Care|Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).
48368495|NCT04220645|OTHER|Opportunstic treatment|opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
48691543|NCT04989556|OTHER|Interview|Participate in interview
48005437|NCT00052728|DRUG|tipifarnib|
48691544|NCT04989556|OTHER|Palliative Therapy|Receive standard symptom management by palliative care team
48005438|NCT04702087|DIETARY_SUPPLEMENT|OLEP|omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23
48691545|NCT04989556|OTHER|Palliative Therapy|Receive provider initiated remote contact
48162542|NCT03653689|DIETARY_SUPPLEMENT|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
48162543|NCT03653689|DIETARY_SUPPLEMENT|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
48162544|NCT03212183|BEHAVIORAL|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
48162545|NCT03212183|OTHER|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
48162546|NCT05164718|BEHAVIORAL|Supervised home-based exercise|150-300 minutes of moderate intensity activity (55-75% of maximum heart rate in sinus rhythm or RPE 12-13 on the Borg Scale) or 75-150 minutes of vigorous intensity activity (75-90% of maximum heart rate or 14-16 on the Borg Scale) per week, or an equivalent combination of both, according to current general recommendations, including also those with established CVD. To maximize the potential for improvements in cardiorespiratory fitness, we encourage that at least 40-60 minutes per week (i.e. 2 sessions á 20-30 minutes) should be of vigorous intensity.
48162547|NCT05164718|OTHER|Usual care|Standard management according to usual practice at the respective participating centers, including medical therapy as per guidelines. Prior to randomization all will be provided an ICM (Confirm RX™). The UC group will receive information about general PA recommendations as per guidelines at study enrollment. No further supervision is given.
48162548|NCT05885464|BIOLOGICAL|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
48162549|NCT05819983|DRUG|Ivermectin Tablets|Ivermectin 200µg/kg BW
48162550|NCT05819983|DRUG|Permethrin Cream|Permethrin cream 5%
48005439|NCT04702087|COMBINATION_PRODUCT|Placebo|Isocaloric formula
48005440|NCT02386111|DRUG|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
48162551|NCT05933083|BEHAVIORAL|In-person cardiac rehabilitation|In-person exercise training, health education, and counseling
48162552|NCT05933083|BEHAVIORAL|Telehealth cardiac rehabilitation|Telehealth exercise training, health education, and counseling
48162553|NCT01033279|OTHER|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
48162554|NCT05453396|BIOLOGICAL|Loncastuximab Tesirine|Given IV
48162555|NCT05330325|DRUG|Somapacitan|Somapacitan will be administered subcutaneously (s.c.) once weekly using PDS290 pen-injector.
48162556|NCT05330325|DRUG|Norditropin®|Norditropin® will be administered s.c. once daily using FlexPro® pen-injector.
48162557|NCT06344949|DRUG|Ciprofol|The sedation before tracheal intubation with Ciprofol
48691546|NCT04989556|OTHER|Quality-of-Life Assessment|Ancillary studies
48005441|NCT01466192|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
48691547|NCT04989556|OTHER|Questionnaire Administration|Complete questionnaire
48005442|NCT01466192|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
48005443|NCT01466192|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
48691548|NCT04216472|DRUG|Alpelisib|Given PO
48691549|NCT04216472|DRUG|Nab-paclitaxel|Given IV
48691550|NCT00503412|DRUG|AZD2171|oral 14C
48691551|NCT04874883|DIETARY_SUPPLEMENT|Simbyotic|6 grams of the symbiotic will be administered twice a day
48691552|NCT04874883|DEVICE|Control Group|6 grams of the maltodextrin will be administered twice a day
48005444|NCT05349162|DEVICE|Implantable cardioverter defibrillator use|Implantation of an implantable cardioverter defibrillator (epicardial or transvenous)
48691553|NCT03831178|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
48691554|NCT03831178|DRUG|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
48691555|NCT00332384|DRUG|brimonidine/timolol fixed combination|
48691556|NCT03383913|BEHAVIORAL|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
48691557|NCT01149005|DRUG|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
48005445|NCT04633096|BEHAVIORAL|tailored feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.
48162558|NCT06344949|DRUG|Propofol|The sedation before tracheal intubation with Propofol
48162559|NCT04648111|DIAGNOSTIC_TEST|Vital sign measurement|Vital signs measurement will be obtained by the research staff using hospital standard medical devices and the Anura Research App will also be used to measure vital signs. Measurement will take place before surgery and post surgery (1 ±2hrs and 2 ±4hrs after surgery).
48162560|NCT00372255|BIOLOGICAL|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
48691558|NCT01149005|DRUG|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
48691559|NCT05530863|BEHAVIORAL|Assisted Therapy|The participant will receive coaching calls and support
48691560|NCT05530863|BEHAVIORAL|Sleep Hygiene|Standard Sleep Hygiene instructions.
48005446|NCT04633096|BEHAVIORAL|standardized feedback of depression screening results|The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
48005447|NCT01991119|DRUG|Propafenone|
48005448|NCT01991119|DRUG|Dronedarone|
48691561|NCT01932372|DRUG|Tofacitinib (Xeljanz)|5 mg Tablet BID
48691562|NCT01932372|DRUG|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
48691563|NCT02243319|DRUG|HGP1201|
48005449|NCT06210087|OTHER|Spontaneous pushing technique|Pregnant women selected for the experimental group were trained on spontaneous pushing technique in the first stage of labor. During the second stage of labor, the women were encouraged and supported in this direction.
48005450|NCT04971564|OTHER|Blood sampling|Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
48005451|NCT03643562|DRUG|Adrabetadex|Administered via lumbar puncture (LP) and IT infusion
48005452|NCT05595915|DIETARY_SUPPLEMENT|COMP-4|COMP-4 is a novel compound that consists of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.
48162561|NCT01379261|PROCEDURE|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
48162562|NCT06318364|OTHER|NO Intervention|NO Intervention
48162563|NCT02722759|OTHER|hemoglobin measurement|
48162564|NCT04919044|OTHER|Motor Imagery Training|The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
48162565|NCT06247488|DRUG|Placebo|Participant will receive oral dose of placebo.
48162566|NCT06247488|DRUG|Oxycodone 20 mg|Participant will receive oral dose of oxycodone 20 mg.
48162567|NCT06247488|DRUG|GE-IR 200 mg|Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
48162568|NCT06247488|DRUG|GE-IR 450 mg|Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
48162569|NCT02246634|OTHER|Diffusion Weighted MRI scan|Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
48162570|NCT03273283|BEHAVIORAL|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
48162571|NCT06158412|DRUG|All-trans Retinoic Acid in combination with the KPD Regimen|"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day."
48162572|NCT01670747|RADIATION|Chest computed tomography|
48162573|NCT02892006|BEHAVIORAL|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
48162574|NCT04127019|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
48162575|NCT04127019|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
48162576|NCT04127019|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
48162577|NCT04127019|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
48162578|NCT04127019|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
48691564|NCT02243319|DRUG|HGP0904|
48691565|NCT02243319|DRUG|HGP0904 and HGP1201 co-administraion|
48162579|NCT04688086|DIAGNOSTIC_TEST|Thermalytix|Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
48368496|NCT04220645|OTHER|Standard of care|Referral at discharge
48368497|NCT05503043|DRUG|Lidocaine|Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
48368498|NCT05503043|DRUG|Normal saline|Patients are received equal volumes of saline intravenously until the end of the surgery
48005453|NCT04295603|OTHER|Toucher Massage (TM) on the feet|The intervention for the Experimental Group (EG) includes a massage time of about 15 minutes (according to current Geneva Hospital practice) on the foot area. At least four sessions will be delivered and spread over two weeks. The TM will be provided by the care team. The training time for the workers corresponds to 2 times 2 hours. In order to be as close as possible to a standardized session, practitioners will benefit from an intervention guide.
48005454|NCT04295603|OTHER|Homedics HM MP RELEX 90 device|"The Control Group (CG) will benefit from an intervention of identical duration. The treatment consists of a foot massage with a Homedics HM MP RELEX 90 device, a heat-free shiatsu program, which lasts about 15 minutes. The use of the Homedics device is no more a common treatment than the practice of Touch-Massage. TM involves a therapeutic relationship between caregiver and patient. It is for this reason that we need a comparator that should allow us to keep the aspect of the massage while decreasing the aspect of the therapeutic relationship and therefore offer us an adequate comparator."
48005455|NCT04900077|DEVICE|Carriere® Motion™ Appliance|class II malocclusion corrector
48005456|NCT06263335|OTHER|Mindfulness Based Stress Reduction Intervention|During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session. The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management. Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program. In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
48005457|NCT00952094|DRUG|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
48005458|NCT01347437|BEHAVIORAL|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
48005459|NCT03717038|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
48005460|NCT03717038|DRUG|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
48005461|NCT02148328|BIOLOGICAL|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
48005462|NCT02148328|BIOLOGICAL|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
48005463|NCT02148328|BIOLOGICAL|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
48005464|NCT02148328|BIOLOGICAL|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
48005465|NCT04514575|BIOLOGICAL|Plasma transfusion|Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
48005466|NCT00472134|DRUG|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
48005467|NCT00472134|DEVICE|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
48368499|NCT05223764|OTHER|Follow up survey|phone call follow-up to investigate women's decision not to return for embryo transfer after cancer treatment.
48368500|NCT04781127|DEVICE|Soterix Medical mini-CT tDCS stimulator|Stimulation will last 30 minutes per day, 5 days per week, for 5 weeks, then 3 days per week for 1 week and then 1 day per week for 4 weeks.
48368501|NCT06236425|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
48005468|NCT04689256|DEVICE|MR-010|MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
48005469|NCT03341052|OTHER|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
48005470|NCT03341052|OTHER|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
48005471|NCT03341052|OTHER|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
48005472|NCT00003075|DRUG|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
48005473|NCT00003075|OTHER|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
48005474|NCT01227512|DRUG|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
48005475|NCT01227512|OTHER|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
48005476|NCT02091791|PROCEDURE|Traction sessions|
48005477|NCT02773043|DEVICE|CZT SPECT camera|
48005478|NCT04736238|PROCEDURE|Arthroscopy surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
48005479|NCT04736238|PROCEDURE|BrostrÖm surgery|The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
48162580|NCT01838447|DIETARY_SUPPLEMENT|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
48162581|NCT06647290|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
48162582|NCT04134221|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
48162583|NCT00214318|DRUG|Terbutaline plus Metoprolol or carvedilol|
48162584|NCT06646393|OTHER|Skin to skin contact|Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
48162585|NCT00199992|PROCEDURE|application of autologous platelet gel|
48162586|NCT03293329|OTHER|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
48162587|NCT03293329|OTHER|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
48162588|NCT03293329|OTHER|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
48162589|NCT01137123|DRUG|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
48162590|NCT01137123|PROCEDURE|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
48162591|NCT01137123|PROCEDURE|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
48162592|NCT01137123|PROCEDURE|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
48162593|NCT03198416|DEVICE|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
48162594|NCT02024399|OTHER|Exercise|Strength training, aerobic exercise and core strengthening, running
48162595|NCT02336113|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
48162596|NCT01040403|DRUG|olodaterol (BI 1744) low|olodaterol (BI 1744) low
48162597|NCT01040403|DRUG|low tiotropium bromide|low tiotropium bromide
48162598|NCT01040403|DRUG|olodaterol (BI 1744) high|olodaterol (BI 1744) high
48368502|NCT06236425|DRUG|Pembrolizumab|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
48005480|NCT04466163|BEHAVIORAL|Schema Therapy and the Healthy Adult|The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
48368503|NCT06236425|DRUG|Platinum based chemotherapy|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
48368504|NCT06236425|DRUG|Cyclophosphamide|Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
48368505|NCT06236425|DRUG|Fludarabine|Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
48368506|NCT06236425|DRUG|Aldesleukin|After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
48368507|NCT05386368|DRUG|ReCell|"The perioral area of the face will be treated with CO2 laser. Randomization would occur before study initiation with subjects assigned either left perioral or right perioral RECELL treatment based on their subject enrollment number. The study team member who prepares and blinds the RECELL will create the list of subject ID numbers with subject ID number randomly assigned to either left perioral or right perioral treatment group. This will be completed prior to any patient enrollment in the study. Intraoperatively, RECELL and Placebo will be provided to surgeons and assistants in opaque application devices prepared by a trained, designated study team member.~Both the treatment and placebo sides, will be dressed with a standard autologous cell suspension post treatment dressing (Telfa Clear and Xeroform)."
48368508|NCT04853368|DRUG|ABBV-576|Oral capsules
48368509|NCT04853368|DRUG|Galicaftor|Oral capsules
48368510|NCT04853368|DRUG|Placebo|Oral capsules
48368511|NCT04853368|DRUG|Navocaftor|Oral capsules
48162599|NCT01040403|DRUG|medium tiotropium bromide|medium tiotropium bromide
48162600|NCT01040403|DRUG|high tiotropium bromide|high tiotropium bromide
48162601|NCT01040403|DRUG|Placebo|Placebo
48162602|NCT01040403|DEVICE|Respimat|Respimat inhaler
48162603|NCT01961453|DRUG|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
48162604|NCT01961453|DRUG|Placebo capsule|One capsule of placebo administered once daily at 8 am.
48162605|NCT01110161|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
48162606|NCT04781543|DRUG|HZN-825 BID|300 mg oral tablets BID
48368512|NCT04853368|DRUG|ABBV-119|Oral capsules
48368513|NCT05957315|DEVICE|Mobile Cardiac Outpatient Telemetry Device (MCOT)|Application of a Philips/Biotel MCOT device
48162607|NCT04781543|DRUG|Placebo|Placebo BID
48162608|NCT04781543|DRUG|HZN-825 QD|300 mg oral tablets QD
48162609|NCT05165563|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
48162610|NCT05234645|OTHER|Kefir consumption|Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
48162611|NCT01857362|DRUG|Nitisinone 20 mg|Nitisinone 20 mg capsules
48162612|NCT01857362|DRUG|Nitisinone 10 mg|Nitisinone 10 mg capsules
48162613|NCT00635011|BEHAVIORAL|psychotherapy|Cognitive Behavioral therapy
48162614|NCT03682237|DEVICE|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
48162615|NCT03682237|DEVICE|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
48162616|NCT03321656|DRUG|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
48368514|NCT02386605|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
48368515|NCT02386605|BEHAVIORAL|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
48368516|NCT05177861|DIAGNOSTIC_TEST|EMG|Electromyelography
48368517|NCT03607968|PROCEDURE|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
48368518|NCT00052403|DRUG|monoclonal antibody anti-anb3 integrin|
48368519|NCT00052403|PROCEDURE|anti-cytokine therapy|
48368520|NCT00052403|PROCEDURE|antiangiogenesis therapy|
48368521|NCT00052403|PROCEDURE|antibody therapy|
48368522|NCT00052403|PROCEDURE|biological response modifier therapy|
48368523|NCT00052403|PROCEDURE|growth factor antagonist therapy|
48368524|NCT00052403|PROCEDURE|monoclonal antibody therapy|
48368525|NCT02789566|DRUG|Primaquine|Primaquine 30 mg taken after meal in the morning.
48368526|NCT01072175|DRUG|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
48005481|NCT05121584|PROCEDURE|Placement of an anterior crown restoration as a final restoration|Placement of an anterior crown restoration as a final restoration
48162617|NCT03321656|DRUG|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
48162618|NCT01952106|OTHER|play computer game|
48162619|NCT06645613|DEVICE|Transcranial Magnetic Stimulation Device|Transcranial magnetic stimulation uses FDA-approved coils to generate varying magnetic fields in the brain of the participant and induce an electric field in the underlying brain tissue. The standard intermittent Theta Burst Stimulation (iTBS) TMS protocol will be applied in this study. The same coil can be applied to generate sham stimulations that only generate sound and stimulations to the scalp without stimulating the brain.
48162620|NCT05098197|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
48162621|NCT01509937|DEVICE|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
48691566|NCT00276055|DRUG|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
48691567|NCT00203736|DRUG|Sulfadoxine-pyrimethamine|
48691568|NCT00203736|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
48691569|NCT06655363|OTHER|Anatomical description|Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
48691570|NCT06655363|OTHER|Radiological (MRI) description|Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
48691571|NCT02172573|DRUG|Pramipexole|
48691572|NCT02172573|DRUG|Bromocriptine|
48691573|NCT02172573|DRUG|Placebo pramipexole|
48691574|NCT02172573|DRUG|Placebo bromocriptine|
48691575|NCT05267470|DRUG|Bemarituzumab|Intravenous (IV) infusion
48691576|NCT05267470|DRUG|Docetaxel|IV infusion
48691577|NCT05267470|DRUG|Pembrolizumab|IV infusion
48162622|NCT01509937|DEVICE|Device|participants in control arm will not receive BCM measurement.
48162623|NCT00400959|PROCEDURE|cd133+cell intracoronary administration|
48162624|NCT02025985|DRUG|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
48162625|NCT03920761|DEVICE|EarlySense Insight system|a small piezoelectric sensor pad that can be placed under the mattress and provide contact-free monitoring by measuring and recording a patient's vital signs and motion parameters
48162626|NCT03920761|DEVICE|Advanced Neonatal Epidermal System|a system of neonatal non-invasive adhesive sensors. Sensors are attached directly on the patient's body and are capable of continuously measuring and recording heart rate, respiratory rate, oxygen saturation, and skin temperature.
48162627|NCT01529541|DRUG|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
48162628|NCT01529541|DRUG|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
48162629|NCT06430671|DRUG|CLS12311 low|Peptide-coupled Red Blood Cells (RBCs)
48162630|NCT06430671|DRUG|CLS12311 medium|Peptide-coupled Red Blood Cells (RBCs)
48368527|NCT01072175|DRUG|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
48691578|NCT05267470|DRUG|Carboplatin|IV infusion
48691579|NCT05267470|DRUG|Paclitaxel|IV infusion
48691580|NCT05267470|DRUG|Nab-paclitaxel|IV infusion
48691581|NCT01027494|DRUG|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
48691582|NCT03117868|OTHER|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
48691583|NCT04069468|DEVICE|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
48005482|NCT03196752|PROCEDURE|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
48005483|NCT03196752|OTHER|simple palpation|conventional
48005484|NCT01485458|PROCEDURE|Early surgery|Surgery within 24 hours after admission
48005485|NCT01485458|PROCEDURE|Delayed surgery|Surgery more than 2 weeks after injury
48005486|NCT02577237|BEHAVIORAL|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
48162631|NCT06430671|DRUG|CLS12311 high|Peptide-coupled Red Blood Cells (RBCs)
48162632|NCT06430671|DRUG|uncoupled RBCs|autologous Red Blood Cells (RBCs)
48162633|NCT02473588|DEVICE|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
48691584|NCT03814382|DEVICE|Acupuncture needle|Acupuncture needle
48691585|NCT04491682|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
48691586|NCT04491682|DRUG|Rosuvastatin|At a dosage of 10 mg/day
48162634|NCT05818137|BIOLOGICAL|Sotatercept|SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
48162635|NCT00038961|DRUG|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
48162636|NCT00038961|OTHER|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
48162637|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
48162638|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom \& Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
48162639|NCT04611048|DIAGNOSTIC_TEST|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, \& Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
48162640|NCT06443541|BEHAVIORAL|High-intensity implementation strategies (HIS)-Students|Students in the HIS group will receive educational outreach in a pre-implementation in-person orientation to GlobalConsent, covering similar topics and three monthly one-hour learning sessions during implementation in which technical questions about program access or progression can be addressed; more intensive intervention to enhance adherence with more frequent email/Short Message Service (SMS), completion reminders; and demand generation encouraging program completion.
48162641|NCT06443541|BEHAVIORAL|Low-intensity implementation strategies (LIS) for Students|Students in the LIS group will receive basic implementation strategies of the GlobalConsent often used to deliver online programs at US universities with email/SMS completion reminders with a predetermined frequency for 12 weeks.
48005487|NCT02577237|BEHAVIORAL|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
48005488|NCT02577237|OTHER|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
48005489|NCT02577237|OTHER|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
48005490|NCT05914116|DRUG|DB-1311|Administered I.V.
48005491|NCT05960396|BEHAVIORAL|Diet intervention|investigators use different diet intervention to observe the changes of biochemical indicators, body composition, Gut microbiota, metabonomics, etc. for patients with MAFLD during different periods
48005492|NCT03162601|PROCEDURE|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
48368528|NCT02297672|RADIATION|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
48368529|NCT02297672|DEVICE|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
48368530|NCT02297672|DEVICE|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
48368531|NCT04953182|OTHER|Pain scale registry|The nurses ask the patient about the pain filling every two hours during the hospitalization.
48005493|NCT00637039|DRUG|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
48005494|NCT03898765|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening biliary atresia
48005495|NCT00024089|DRUG|gefitinib|
48005496|NCT02633956|DRUG|Obeticholic Acid|Once a day (QD) by mouth (PO)
48005497|NCT02633956|DRUG|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
48368532|NCT01396811|DRUG|33525|Daily for 14 days
48005498|NCT02633956|DRUG|Placebo|Once a day (QD) by mouth (PO)
48005499|NCT06247033|DEVICE|Tibial Nerve Stimulation with TENS device|Tibial nerve stimulation was applied with TENS device transcutaneously and electrodes were positioned in medial part of the ankle. Negative transcutaneous electrode was positioned 3 centimeter posteriorly to the medial malleol. And positive transcutaneous electrode was positioned 10 centimeter above the negative electrode.
48162642|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Faculty|"* Passive access to web-based educational materials~* Town halls (3) with general faculty to define sexual violence; rates in young people; acute/chronic effects over the life course; primary-prevention evidence-based interventions (EBIs)"
48162643|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Faculty|Passive access to web-based educational materials
48162644|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials~* Monthly emails from trained internal facilitators to university leaders with updates on implementation progress~* One post-implementation webinar to share anonymized findings (by IS group); discuss plan for sustainment (including guidance on how to handle reporting of sexual violence in existing university counseling centers)"
48162645|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) for Leaders|"* Site-specific invitation to participate~* Passive access to web-based educational materials~* One pre-implementation webinar to define sexual violence; rates among young people in Vietnam; acute/chronic effects over life course; primary-prevention EBIs; recap of project description and collaboration; share GlobalConsent website for passive access to educational materials"
48185236|NCT02214680|DRUG|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
48691587|NCT04098419|BEHAVIORAL|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
48691588|NCT02686632|BEHAVIORAL|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
48691589|NCT01252160|DRUG|QUTENZA|Cutaneous patch
48691590|NCT05243524|OTHER|Maveropepimut-S|SC injection on days 7, 28, then q8w
48691591|NCT05243524|DRUG|Cyclophosphamide 50mg|PO BID, one week on, one week off
48691592|NCT05257499|BEHAVIORAL|On line debriefing|Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
48691593|NCT00003321|PROCEDURE|psychosocial assessment and care|
48691594|NCT00003321|PROCEDURE|quality-of-life assessment|
48691595|NCT01013649|RADIATION|3-Dimensional Conformal Radiation Therapy|daily fractions
48691596|NCT01013649|DRUG|Capecitabine|tablet
48691597|NCT01013649|DRUG|Chemotherapy|single agent chemotherapy or combination chemotherapy using allowed agents
48185237|NCT02214680|DRUG|Timolol|0.5% eye drop
48691598|NCT01013649|DRUG|Erlotinib Hydrochloride|tablet
48691599|NCT01013649|DRUG|Fluorouracil|intravenously
48691600|NCT01013649|DRUG|Gemcitabine Hydrochloride|intravenously
48691601|NCT01013649|RADIATION|Intensity-Modulated Radiation Therapy|daily fractions
48691602|NCT04982315|PROCEDURE|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
48691603|NCT04982315|PROCEDURE|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
48691604|NCT03193970|BEHAVIORAL|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
48691605|NCT01332591|PROCEDURE|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
48691606|NCT01834950|OTHER|Blood test|
48691607|NCT06405165|OTHER|student success|The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
48691608|NCT03450343|DRUG|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
48691609|NCT03450343|DRUG|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
48691610|NCT06660303|BEHAVIORAL|Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery|The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.
48368533|NCT01396811|DRUG|Placebo|Daily for 14 days
48368534|NCT03288558|OTHER|A comprehensive perioperative mechanical ventilation strategy|"1) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
48368535|NCT02463097|DEVICE|Insulin Pump|Closed Loop Algorithm
48368536|NCT03253380|OTHER|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
48368537|NCT00213668|DIETARY_SUPPLEMENT|glutamine (dipeptiven)|
48691611|NCT06660303|OTHER|Routine hospital care|The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
48691612|NCT05844111|DRUG|[14C]-BGB-11417|A single oral dose of liquid formulation
48691613|NCT04222699|DRUG|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
48691614|NCT04222699|DRUG|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
48691615|NCT05999630|DRUG|Artificial Tears Methylcellulose|Participants will self-administer the artificial tears according to the schedule.
48691616|NCT05629585|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion
48691617|NCT05629585|DRUG|Durvalumab|Experimental drug. Provided in 50mg vials. IV infusion
48691618|NCT05629585|DRUG|Capecitabine|Active Comparator. Tablet. Oral route of administration
48691619|NCT05629585|DRUG|Pembrolizumab|Active Comparator. Provided in 100mg vials. IV infusion
48691620|NCT01849575|BEHAVIORAL|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
48691621|NCT05294497|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
48691622|NCT05294497|OTHER|Product B|Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
48691623|NCT05294497|OTHER|Product C|Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
48691624|NCT05294497|OTHER|Product D|Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
48691625|NCT05294497|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
48691626|NCT05294497|OTHER|Product E|Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
48691627|NCT06548087|DEVICE|Gigstride Ambulatory Device|"For patients who are scheduled to be seen by the investigator in clinic with one of the above diagnoses, and recommended to use some type of ambulatory aid, the investigator will offer the Gigstride ambulatory device as an alternative and inquire about the patient's interest in participating in the study. After choosing to be a part of the study, the participant will use Gigstride device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participant will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour."
48368538|NCT00332982|BEHAVIORAL|Focused knowledge translation strategies|
48368539|NCT04632316|DRUG|Cyclophosphamide-Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
48691628|NCT01255176|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
48691629|NCT05219149|BEHAVIORAL|Qualitative Interviews|Conduct qualitative interviews with patients and families who are considering treatment options for new or recurrent CNS tumors to identify specific barriers to full participation in treatment and clinical trial enrollment (e.g., transportation, childcare, ancillary expenses). Qualitative interviews will be structured to comprehensively address potential barriers but also open-ended to give patients and families freedom to discuss a wide range of challenges.
48691630|NCT01773005|DRUG|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
48691631|NCT01773005|DRUG|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
48691632|NCT04078958|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
48691633|NCT04078958|DIETARY_SUPPLEMENT|Whey|Whey with high protein content
48691634|NCT04458532|OTHER|Aerobic Training|300 min/wk for 16 weeks
48691635|NCT04458532|OTHER|Aerobic Training|150 min/wk for 32 weeks
48691636|NCT04458532|OTHER|Aerobic Training|300 min/wk for 32 weeks
48691637|NCT04458532|OTHER|Aerobic Training|150 min/wk for 16 weeks
48691638|NCT06024239|DRUG|ABBV-932|Capsule; oral
48691639|NCT06024239|DRUG|Placebo for ABBV-932|Capsule; oral
48691640|NCT02270528|BEHAVIORAL|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (\~5 minutes)
48691641|NCT02270528|BEHAVIORAL|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
48691642|NCT04712097|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12
48691643|NCT04712097|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 of Cycles 2-12 (M + Len) or Cycles 1-12 (R + Len)
48691644|NCT04712097|DRUG|Rituximab|Participants will receive IV rituximab on Days 1, 8, 15, and 22 of Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11
48691645|NCT04712097|DRUG|Tociluzumab|Tocilizumab will be administered as needed to manage cytokine release syndrome (CRS) events
48691646|NCT05787899|OTHER|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
48691647|NCT00889603|DRUG|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
48691648|NCT05143593|DIAGNOSTIC_TEST|results of SSBD are used to guide antibiotics adjustment|secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
48691649|NCT01781806|DRUG|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
48691650|NCT03620136|DRUG|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
48691651|NCT03620136|DRUG|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
48691652|NCT04433741|DRUG|Oxytocin|Oxytocin administered intravenously
48691653|NCT04433741|DRUG|Placebo|Placebo administered intravenously
48368540|NCT04632316|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
48368541|NCT00124865|BIOLOGICAL|rFla-MBP|
48185238|NCT03358368|DEVICE|Vitalscan|Vitalscan is a magnetocardiograph device
48368542|NCT04071028|PROCEDURE|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
48005500|NCT06247033|BEHAVIORAL|Pelvic muscle training exercise with bladder training|Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut off. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
48691654|NCT02079116|OTHER|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
48691655|NCT02079116|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
48691656|NCT03602157|BIOLOGICAL|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10\^7, 5x10\^7, 1x10\^8
48691657|NCT03602157|BIOLOGICAL|ALTCAR.CD30 cells|Fixed dose level of 1x10\^8
48005501|NCT00113737|DRUG|fluoxetine|
48691658|NCT03602157|DRUG|Bendamustine|70 mg/m\^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
48005502|NCT00113737|BEHAVIORAL|cognitive behavioral therapy|
48005503|NCT04270981|DRUG|[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C|960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
48005504|NCT00842348|DRUG|lanreotide (Autogel formulation)|Autogel 120 mg
48005505|NCT02313610|DRUG|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
48005506|NCT02313610|DRUG|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
48005507|NCT02961699|DEVICE|Transpose ® RT System|adipose-derived stem cell therapy
48005508|NCT02961699|OTHER|debridement/dressing of wound|standard of care debridement and wound dressing
48005509|NCT06116331|OTHER|Data collection|Participants will answer questionnaires and submit stool samples.
48005510|NCT00417794|DRUG|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
48005511|NCT00417794|DRUG|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
48005512|NCT01088646|DEVICE|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
48005513|NCT01693328|DRUG|PecFent® (fentanyl) nasal spray|
48368543|NCT04954560|DRUG|losartan and eprosartan|. Each study drug was given in a random order as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.
48368544|NCT05936190|DRUG|Lidocaine IV|Intravenous infusion rate of lidocaine is 2 mg/kg/min
48368545|NCT05936190|DRUG|Lidocaine|Intravenous infusion rate of lidocaine is 1 mg/kg/min
48368546|NCT04675034|BIOLOGICAL|MEDI7352|Dose A: MEDI7352 Q2W
48368547|NCT04675034|BIOLOGICAL|MEDI7352|Dose B: MEDI7352 Q2W
48368548|NCT04675034|BIOLOGICAL|MEDI7352|Dose C: MEDI7352 Q2W
48368549|NCT04675034|BIOLOGICAL|MEDI7352|Dose D: MEDI7352 Q2W
48691659|NCT03602157|DRUG|Fludarabine|30 mg/m\^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
48691660|NCT02250794|DRUG|metformin and sitagliptin|metformin 750 mg PO twice daily
48691661|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin glargine given once daily
48691662|NCT02250794|DRUG|metformin and sitagliptin|sitagliptin 100 mg PO once daily
48005514|NCT05713032|PROCEDURE|Pulsed radiofrequency on lumbar dorsal root ganglion|voltage of pulsed radiofrequency on DRG
48005515|NCT05111366|DRUG|TQB2450 injection|TQB2450 is an injection in the form of 1200mg, ivgtt, q3W.
48005516|NCT05111366|DRUG|Anlotinib hydrochloride capsules|Anlotinib Hydrochloride is a capsule in the form of 8 mg,10 mg, and 12 mg, orally, once daily, 2 weeks on/1 week off.
48005517|NCT02739269|OTHER|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
48005518|NCT02739269|OTHER|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
48005519|NCT04648865|DRUG|LY3537031|Administered SC.
48005520|NCT04648865|DRUG|Placebo|Administered SC.
48368550|NCT04675034|BIOLOGICAL|Placebo|Placebo to match MEDI7352 Q2W
48368551|NCT06231186|RADIATION|iHD-SRT|received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits
48368552|NCT03937739|OTHER|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
48691663|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
48691664|NCT06661928|PROCEDURE|Papilla preservation flap|"Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure."
48691665|NCT06661928|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
48691666|NCT05128786|BIOLOGICAL|CCT301-38|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
48691667|NCT06661369|OTHER|Sensory Perceptual Motor Training on Group|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
48005521|NCT00616850|PROCEDURE|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
48005522|NCT00616850|DRUG|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
48162646|NCT06443541|OTHER|High-intensity implementation strategies (HIS) for Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual~* In-person leadership training to champion GlobalConsent with internal stakeholders (leaders, implementation teams, faculty, students); leadership styles; managing teams; influence without authority; managing conflict; emotional intelligence; negotiation; leading change~* Biweekly (six) 1-hr recorded quality-improvement team webinars to provide refresher training; assess implementation progress; assess modifications; build peer-network; provide anonymized data on implementation progress for discussion"
48691668|NCT06661369|OTHER|Sensory Perceptual Motor Training on Individual|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
48691669|NCT03473730|PROCEDURE|Biopsy|Undergo biopsy
48691670|NCT03473730|BIOLOGICAL|Daratumumab|Given IV
48691671|NCT03473730|OTHER|Laboratory Biomarker Analysis|Correlative studies
48691672|NCT03473730|PROCEDURE|Metastasectomy|Undergo metastasectomy
48691673|NCT03473730|PROCEDURE|Nephrectomy|Undergo nephrectomy
48691674|NCT06659900|OTHER|CORE Plus (+)|CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
48691675|NCT06659900|OTHER|CORE|CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
48691676|NCT01951586|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
48162647|NCT06443541|OTHER|Low-intensity implementation strategies (LIS) Implementation Team Members|"* Passive access to web-based educational materials~* In-person technical training on campus-wide implementation of GlobalConsent; discussion and demonstration of GlobalConsent program; standardized implementation manual"
48162648|NCT05598203|BEHAVIORAL|Operative group of nutrition education|The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
48162649|NCT01145859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
48162650|NCT03601949|DEVICE|SInergy Cooled Radiofrequency|ablation of low back pain
48162651|NCT03601949|OTHER|Medical Management|physical therapy, medications, lifestyle changes
48691677|NCT01951586|DRUG|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
48691678|NCT01951586|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
48691679|NCT01951586|DRUG|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
48691680|NCT01951586|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
48691681|NCT06251375|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
48005523|NCT00616850|OTHER|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
48691682|NCT06251375|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
48691683|NCT06478316|PROCEDURE|Intracervical block|local injection of lidocain to the cervix
48691684|NCT06659133|OTHER|Music intervention|"The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play"
48691685|NCT06662123|DRUG|Anifrolumab|Participants will receive a single SC or IV dose of anifrolumab at day 1
48162652|NCT06512116|DRUG|SIBP-A17|"Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design."
48162653|NCT00607737|DRUG|insulin detemir|3 cutaneous injections
48162654|NCT00607737|DRUG|saline|3 cutaneous injections
48162655|NCT04719819|PROCEDURE|Spinal anaesthesia for caesarean section|Descriptive questionnaire with open and closed questions, to be completed during the procedure
48162656|NCT01615107|DEVICE|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
48162657|NCT01615107|DRUG|PITOCIN|: Oxytocin infusion alone (Standard Protocol
48162658|NCT01615107|OTHER|double balloonand oxytocin|balloonand oxytocin
48162659|NCT01615107|OTHER|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
48368553|NCT04241705|OTHER|Treatment of positive individuals per national treatment guidelines|"Treatment for everyone except children \<6 months of age, pregnant women, women breastfeeding children \<6 months of age, and women 12-49 years of age with an unknown pregnancy status:~* P. falciparum cases: artemether-lumefantrine (AL) plus single dose primaquine (PQ) (0.25mg/kg daily)~* P. vivax cases: chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily)~* Mixed infections: AL plus 14 days of PQ (0.25mg/kg daily)~Treatment for pregnant women and women breastfeeding children \<6 months of age:~* P. falciparum cases or mixed infections: Quinine (1st trimester); AL (2nd \& 3rd trimesters or breastfeeding)~* P. vivax cases: Chloroquine (CQ)"
48162660|NCT01615107|PROCEDURE|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
48691686|NCT04295681|DRUG|MMH-MAP|Oral administration
48691687|NCT04295681|DRUG|Placebo|Oral administration
48691688|NCT05851534|BEHAVIORAL|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
48691689|NCT01679600|DEVICE|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
48691690|NCT01679600|DEVICE|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
48691691|NCT00140907|DRUG|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
48691692|NCT00140907|DRUG|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
48691693|NCT03454997|OTHER|training including in-person and online|training, motivational interviewing practice
48162661|NCT05632016|PROCEDURE|erector spinae block (ESP)|the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
48162662|NCT00727259|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
48162663|NCT00727259|DRUG|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
48162664|NCT05741294|DRUG|Tirbanibulin 2.5 mg ointment|Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
48162665|NCT05664126|DRUG|VST infusion|single intravenous (IV) infusion.
48162666|NCT05664126|DEVICE|CliniMACS|Cells infusions are prepared using the ClinMACS
48691694|NCT03454997|OTHER|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
48691695|NCT03454997|OTHER|performance coaching|to enhance ability to deliver the weight management intervention
48162667|NCT01399684|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
48162668|NCT01399684|DRUG|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
48691696|NCT01703091|DRUG|Ramucirumab|Administered IV
48691697|NCT01703091|DRUG|Placebo|Administered IV
48691698|NCT01703091|DRUG|Docetaxel|Administered IV
48691699|NCT06660108|GENETIC|blood draw|Multiple blood draw for genomic and transcriptomic investigations
48691700|NCT03462927|DRUG|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
48691701|NCT03462927|DRUG|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
48691702|NCT01523743|DEVICE|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
48691703|NCT01523743|DEVICE|Standard care|The coated intermittent catheter normally used by subject
48691704|NCT02096952|DRUG|Methylphenidate extended-release liquid formulation|
48691705|NCT03996681|DRUG|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
48691706|NCT06129591|DRUG|Lazarus Naturals THC-Free CBD Tincture (flavorless) + Silicone patch|"The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessment will be done over a period of 6 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale. Statistical analysis will assess whether CBD oil improves short-term and long-term scar appearances."
48691707|NCT06129591|DRUG|Silicone patch|A non-treatment group is included in this study to comply with the standard of care, as to treat post-operative wounds with silicone patches to improve final scar outcomes.
48691708|NCT03213743|DRUG|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
48691709|NCT02066831|BEHAVIORAL|Telemedical coaching|
48005524|NCT05667233|OTHER|Resistance Training Program|Participants will undergo a high exertion machine-based resistance training protocol.
48005525|NCT06273176|PROCEDURE|Awake mapping under local anesthesia|During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.
48005526|NCT06273176|PROCEDURE|Asleep mapping under general anesthesia|During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.
48005527|NCT06273176|PROCEDURE|Resection under general anesthesia without mapping|During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
48005528|NCT03606681|DRUG|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
48005529|NCT03606681|DRUG|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
48005530|NCT03606681|DRUG|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
48005531|NCT06493630|BEHAVIORAL|Hypnobreastfeeding Education|Hypnobreastfeeding Education: Monitoring breastfeeding myths, breastfeeding expectations and breastfeeding self-efficacy with hypnobreastfeeding education
48005532|NCT05435378|DRUG|Vitamin B3 100 MG Oral Tablet|After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
48005533|NCT05435378|DRUG|vitamin B9|After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
48005534|NCT05435378|DRUG|Placebo|After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
48005535|NCT05435378|PROCEDURE|full mouth non surgical periodontal treatment|full mouth scaling and debridement will be done by the primary investigator using ultrasonic scaler and periodontal curettes. After the non surgical treatment patients will be given oral hygiene instructions where they will be instructed to brush twice daily and shown how to brush using the horizontal scraping technique they will also be instructed to use the dental floss and shown how to use it.
48005536|NCT06482333|OTHER|Time for resumption of DOAC|Time for resumption of DOAC
48005537|NCT03982329|DEVICE|navigated repetitive transcranial magnetic stimulation|
48005538|NCT03982329|PROCEDURE|physical therapy|
48005539|NCT05277311|DRUG|LongShengZhi capsule|LongShengZhi capsules, orally, 5 capsules each time, three times a day.
48005540|NCT05277311|DRUG|LongShengZhi capsule placebo|LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
48691710|NCT02066831|OTHER|Telemedicine|
48005541|NCT04710251|DEVICE|Speedometer|We will measure and monitor the withdrawal time of colonoscopy with a speedometer.
48005542|NCT00204256|DRUG|Iron sucrose|
48005543|NCT02965443|DRUG|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
48005544|NCT02965443|DRUG|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
48005545|NCT02239250|DEVICE|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
48005546|NCT03164499|BEHAVIORAL|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
48162669|NCT01399684|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
48162670|NCT01399684|DRUG|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
48162671|NCT01399684|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
48691711|NCT05767398|DRUG|Zanubrutinib|Administered as a tablet or capsule
48691712|NCT02021383|BEHAVIORAL|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
48005547|NCT03164499|BEHAVIORAL|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
48691713|NCT02021383|BEHAVIORAL|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
48691714|NCT01469143|DRUG|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
48691715|NCT01469143|DRUG|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
48691716|NCT02482428|DRUG|Investigational Treatment|Applied twice daily for up to 12 weeks
48691717|NCT02482428|DRUG|Aldara|Applied 3 times a week for 16 weeks
48691718|NCT05541406|BEHAVIORAL|Proud & Empowered|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
48691719|NCT04678986|OTHER|ER2|No intervention, data analysis only
48691720|NCT00698438|DEVICE|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
48691721|NCT00698438|PROCEDURE|Trabeculectomy|standard trabeculectomy
48691722|NCT06658717|DIETARY_SUPPLEMENT|Investigational product (IP): Natural orange extract|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
48691723|NCT06658717|DIETARY_SUPPLEMENT|Group II: Placebo: Microcrystalline cellulose (MCC)|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
48691724|NCT03393936|BIOLOGICAL|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
48691725|NCT03393936|BIOLOGICAL|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
48162672|NCT01399684|DRUG|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
48162673|NCT03036124|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
48691726|NCT06273735|DIAGNOSTIC_TEST|Pre- and postoperative determination of troponin as part of the study and 24-month FU survey|An intervention is carried out as part of the normal clinical procedure regardless of the study measurement parameters.
48691727|NCT02397915|DRUG|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
48691728|NCT02397915|DRUG|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
48691729|NCT04607174|OTHER|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
48691730|NCT04270682|DRUG|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
48691731|NCT04270682|DRUG|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
48691732|NCT04270682|DRUG|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
48005548|NCT03766178|DRUG|Nimotuzumab + SHR-1210|"SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle."
48005549|NCT01577758|DRUG|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
48005550|NCT03548766|BIOLOGICAL|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
48005551|NCT03548766|BIOLOGICAL|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
48162674|NCT03036124|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
48162675|NCT00644735|DRUG|Esomeprazole|
48162676|NCT00644735|DRUG|Lansoprazole|
48513794|NCT01776632|BEHAVIORAL|Physical activity|Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.
48691733|NCT04270682|DRUG|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
48691734|NCT04270682|DRUG|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
48691735|NCT05702645|PROCEDURE|Biospecimen Collection|Patients undergo saliva/buccal and blood sample collection
48691736|NCT05702645|OTHER|Clinical Evaluation|Undergo a clinical assessment
48005552|NCT03320681|DEVICE|Electrical Stimulation|Percutaneous electrical nerve stimulation
48005553|NCT03320681|OTHER|Dry Needling Stimulation|Percutaneous nerve stimulation
48005554|NCT03732911|BEHAVIORAL|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
48162687|NCT05737797|PROCEDURE|cervical cytology during surgery.|Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
48162688|NCT06038578|BIOLOGICAL|TRK-950|5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle
48162689|NCT06038578|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
48162690|NCT06038578|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
48162691|NCT04778683|PROCEDURE|Virtual Reality|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing. Before commencement of the study, the VR applications were administered to five children aged between five and ten years, and these children shared no negative feedback about the VR programs. Before the surgery, the children were allowed to watch the VR program of their choice, the average duration of which was 4.5 minutes, using the VR glasses. Parts of the device that come in contact with the children's faces were cleaned before each application
48162692|NCT05009147|OTHER|Home-based massage by caregivers for dementia|A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.
48691737|NCT05702645|OTHER|Questionnaire Administration|Ancillary studies
48691738|NCT05702645|OTHER|Survey Administration|Ancillary studies
48691739|NCT03070223|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
48691740|NCT03070223|DRUG|Placebos|One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
48691741|NCT00969644|DRUG|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
48691742|NCT00969644|DRUG|Pegvisomant|s.c. injections once daily (10-15 mg/day)
48691743|NCT00680979|BEHAVIORAL|Interpersonal Psychotherapy|
48691744|NCT00680979|BEHAVIORAL|Health Education|
48691745|NCT01404403|DEVICE|Rapid System|
48005555|NCT03078946|DRUG|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
48005556|NCT03078946|DRUG|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
48005557|NCT02299531|OTHER|Varying meal energy density and portion size|
48005558|NCT02187328|OTHER|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
48005559|NCT02187328|OTHER|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
48005560|NCT01226719|DRUG|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
48005561|NCT01226719|DRUG|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
48005562|NCT01226719|DRUG|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
48005563|NCT01226719|DRUG|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
48513795|NCT01776632|BEHAVIORAL|Cancer screening|Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
48513796|NCT01119573|GENETIC|RNA analysis|
48691746|NCT06658171|BEHAVIORAL|Relaxation training and stimulus control|"Relaxation training: Progressive muscle relaxation; Breathing relaxation; Imagery training; Mindfulness relaxation.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
48005564|NCT01226719|DRUG|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
48005565|NCT01565330|DRUG|florbetapir F 18|single dose IV injection
48005566|NCT03420482|DRUG|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
48005567|NCT03420482|DRUG|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
48005568|NCT02510794|DRUG|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
48005569|NCT01228630|DRUG|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
48005570|NCT01228630|DRUG|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
48162693|NCT04739462|BEHAVIORAL|mHealth Platform|All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
48185239|NCT06376877|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise.
48513797|NCT01119573|GENETIC|microarray analysis|
48513798|NCT01119573|GENETIC|reverse transcriptase-polymerase chain reaction|
48513799|NCT01119573|OTHER|laboratory biomarker analysis|
48162694|NCT03089502|OTHER|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
48162695|NCT05729347|BEHAVIORAL|Virtual Reality headset with calming scenery|Participants will be immersed in a virtual environment. Calming scenery will be shown via the headset for 20-30 minutes
48162696|NCT01103141|DEVICE|Micropuncture needle set|Groin access for vascular intervention
48162697|NCT01103141|DEVICE|Standard gauge-18 needle set|Groin access for vascular intervention
48162698|NCT04244708|DRUG|Radiotherapy plus temozolomide|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
48162699|NCT04244708|OTHER|Radiotherapy plus placebo|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
48162700|NCT02261545|DIETARY_SUPPLEMENT|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
48162701|NCT02261545|DIETARY_SUPPLEMENT|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
48162702|NCT04505488|BEHAVIORAL|ASD Screening Parent ENgagement Intervention Program (ASPEN)|The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
48368554|NCT04241705|OTHER|Presumptive treatment with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ)|"Everyone who is eligible for the study except pregnant women and women breastfeeding children \<6 months of age AND who are confirmed to have normal G6PD status will be treated presumptively with artemether-lumefantrine (AL) plus 14 days of primaquine (PQ). Treatment will be given without RDT for malaria.~* Women in the first trimester of pregnancy will be treated presumptively with quinine.~* Women in the second and third trimesters or women who are breastfeeding will receive artemether-lumefantrine (AL).~Again, treatment will be given without RDT for malaria."
48368555|NCT04241705|OTHER|Optimized malaria control interventions|Optimized malaria control interventions that includes strengthened surveillance systems and commodities management, scale-up of vector control and case management services including follow-up, and social and behavior change communication to seek prompt treatment and use long lasting insecticidal nets (LLINs). Case management includes passive detection of malaria cases and treatment with artemether-lumefantrine (AL) plus single low dose primaquine (PQ) (0.25mg/kg once) for Plasmodium falciparum (Pf) cases and chloroquine (CQ) plus 14 days of PQ (0.25mg/kg daily) for Plasmodium vivax (Pv) cases, and AL plus 14 days of PQ (0.25mg/kg daily) for mixed infections as well as follow-up at the health post or health center on days 3, 7, and 13 for those receiving 14 days of PQ to assess for adverse events and adherence as per the national treatment guidelines.
48691747|NCT06658171|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
48691748|NCT06417814|DRUG|Dato-DXd|Dato-DXd will be administered as IV infusion.
48691749|NCT06417814|DRUG|Osimertinib|Osimertinib will be administered orally.
48691750|NCT06417814|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion.
48162703|NCT05051696|DRUG|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
48691751|NCT06417814|DRUG|Carboplatin|Carboplatin will be administered as IV infusion.
48691752|NCT06417814|DRUG|Cisplatin|Cisplatin will be administered as IV infusion.
48691753|NCT06660186|DEVICE|Rigid Sternal Fixation|The surgeon will close the sternum (breastbone) using the SternalPlate system. The SternalPlate System consists of implants and instruments used to hold the two halves of the sternum together.
48691754|NCT06660186|DEVICE|Wire Cerclage|The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of your sternum together.
48162704|NCT05939739|BIOLOGICAL|Blood samples|Samples collected during blood sampling for array CGH (1 EDTA tube for index case and 2 biological relatives)
48162705|NCT05939739|OTHER|Consultation for results delivery|at 4 months
48162706|NCT05939739|OTHER|Study Humanities and Social Sciences|Interview offered to 20 families with positive results and 10 families with negative results
48691755|NCT01534585|DRUG|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
48162707|NCT03078751|DRUG|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
48162708|NCT03078751|DRUG|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
48162709|NCT03078751|DRUG|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
48162710|NCT06293014|DRUG|TAS-102+bevacizumab|TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.
48162711|NCT06293014|DRUG|Standard chemotherapy+bevacizumab|Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab
48162712|NCT00794911|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
48162713|NCT00794911|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
48162714|NCT05141071|DRUG|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
48162715|NCT05141071|DRUG|Placebo|50 ml of saline will be administrated enterally
48162716|NCT06585293|DEVICE|Mitra Microsampling Device|Microsampling tool for finger-prick blood collection
48162717|NCT02985255|DRUG|Docetaxel|Neoadjuvant Arm
48691756|NCT01534585|RADIATION|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
48691757|NCT01534585|DRUG|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
48691758|NCT01534585|OTHER|Quality of life|The EORTC QLQ-C30 and H\&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
48162718|NCT02985255|DRUG|Cisplatin|Neoadjuvant Arm
48162719|NCT02985255|DRUG|5FU|Neoadjuvant Arm
48162720|NCT02985255|RADIATION|Radiotherapy|Neoadjuvant Arm
48162721|NCT02985255|PROCEDURE|Glossectomy|Neoadjuvant Arm
48162722|NCT03237741|DRUG|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
48162723|NCT03237741|DRUG|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
48162724|NCT03237741|DRUG|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
48162725|NCT05317299|OTHER|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
48162726|NCT06015620|PROCEDURE|Mini gastric bypass surgery|Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
48162727|NCT06150222|OTHER|Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)|The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
48162728|NCT05026242|BEHAVIORAL|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
48162729|NCT05026242|BEHAVIORAL|Control|Participants will be provided with isocaloric snacks
48162730|NCT03524547|DEVICE|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
48162731|NCT03524547|DEVICE|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
48513800|NCT01921686|OTHER|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
48513801|NCT00453050|DRUG|imiquimod|
48162732|NCT05022927|DRUG|ERY974|ERY974 vial
48162733|NCT05022927|DRUG|Tocilicumab|Tocilizumab vial
48513802|NCT00453050|DRUG|indocyanine green solution|
48691759|NCT01534585|GENETIC|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
48691760|NCT06049095|DRUG|LTG-001|Oral doses
48691761|NCT06049095|DRUG|Placebo|Oral doses
48691762|NCT05336734|BEHAVIORAL|Psychotherapy|see group description
48162734|NCT05022927|DRUG|Atezolizumab|Atezolizumab vial
48162735|NCT05022927|DRUG|Bevacizumab|Bevacizumab vial
48162736|NCT00764010|DIETARY_SUPPLEMENT|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
48162737|NCT00764010|DIETARY_SUPPLEMENT|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
48162738|NCT00764010|DIETARY_SUPPLEMENT|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
48162739|NCT03226106|BEHAVIORAL|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
48005571|NCT05005858|PROCEDURE|Alveolar ridge splitting|Patients with Kennedy Class I. and II. mandibles with insufficient bone width were included in this study. Ridge splitting was carried out with the use of a piezoelectric surgery device by preparing osteotomies and after mobilization of the buccal cortical by placing an autologous bone block harvested from the retromolar region as a spacer between the buccal and lingual cortical plates. Block-grafts were stabilized by osteosynthesis screws. Implant placement was carried out after a 3-month healing period.
48005572|NCT05005858|DEVICE|Creating osteotomies with piezoelectric device|Osteotomies were carried out with piezoelectric surgery device (NSK Variosurg3 Ultrasonic Bone Surgery System, NSK Europe GmbH, Eschborn, Germany)
48005573|NCT02812667|DRUG|Nivolumab + Plinabulin|
48005574|NCT06008964|OTHER|Ylang Ylang oil with inhalation|Ylang Ylang OIL WILL BE INHALED
48005575|NCT06008964|OTHER|Lavender oil with inhalation|LAVENDER OIL WILL BE INHALED
48005576|NCT00726570|DEVICE|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
48691763|NCT06233942|DRUG|BG-C9074|administered by intravenous infusion
48691764|NCT06233942|DRUG|Tislelizumab|administered by intravenous infusion
48691765|NCT04620772|DRUG|Cyclophosphamide injection|Cyclophosphamide vs placebo
48691766|NCT06112288|OTHER|Compressive Myofascial Release|Compressive myofascial release is manual therapy technics.
48691767|NCT06112288|OTHER|Ankle mobilisation|ankle mobilization is manual therapy technics.
48691768|NCT04926636|BEHAVIORAL|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
48691769|NCT03756155|PROCEDURE|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
48691770|NCT03334981|PROCEDURE|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
48691771|NCT02584452|DRUG|Mepivacaine|20cc of 2% mepivacaine \<20 minutes prior to in room time.
48691772|NCT02584452|PROCEDURE|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
48691773|NCT02584452|DRUG|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
48691774|NCT02584452|PROCEDURE|adductor canal nerve block|ultrasound guided adductor canal nerve block
48691775|NCT02584452|DRUG|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
48005577|NCT00726570|DRUG|Dalteparin|"* 2500 UI qd if ≤ 50 kg body weight~* 5000 UI qd if \> 50 kg"
48005578|NCT00726570|PROCEDURE|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~* Patient admission (before SCD start)~* 40-60 min after admission~* Morning after surgery"
48162740|NCT03226106|OTHER|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
48162741|NCT04841811|DRUG|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
48513803|NCT00453050|OTHER|flow cytometry|
48513804|NCT00453050|OTHER|immunologic technique|
48513805|NCT00453050|OTHER|laboratory biomarker analysis|
48691776|NCT02584452|DRUG|Propofol|Anesthesia induction will include a propofol bolus.
48691777|NCT02584452|DRUG|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
48691778|NCT01091038|OTHER|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
48691779|NCT01091038|OTHER|Routine Care|Routine Care
48691780|NCT01626586|BEHAVIORAL|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
48005579|NCT02550327|DRUG|Nab-paclitaxel|125 mg/m2
48005580|NCT02550327|DRUG|Gemcitabine|1000 mg/m2
48005581|NCT02550327|DRUG|Cisplatin|25 mg/m2
48691781|NCT02032758|DRUG|Propranolol|Single oral dose of 10 mg propranolol
48691782|NCT02032758|DEVICE|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
48691783|NCT02032758|PROCEDURE|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
48691784|NCT02032758|DEVICE|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
48691785|NCT03079934|DEVICE|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
48691786|NCT03606967|PROCEDURE|Biopsy|Undergo tumor biopsy
48691787|NCT03606967|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
48691788|NCT03606967|DRUG|Carboplatin|Given IV
48691789|NCT03606967|PROCEDURE|Computed Tomography|Undergo CT scan
48691790|NCT03606967|BIOLOGICAL|Durvalumab|Given IV
48691791|NCT03606967|DRUG|Gemcitabine Hydrochloride|Given IV
48691792|NCT03606967|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48691793|NCT03606967|DRUG|Nab-paclitaxel|Given IV
48691794|NCT03606967|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Given SC
48691795|NCT03606967|DRUG|Poly ICLC|Given SC
48691796|NCT03606967|BIOLOGICAL|Sacituzumab Govitecan|Given IV
48691797|NCT03606967|BIOLOGICAL|Tremelimumab|Given IV
48691798|NCT04524715|DEVICE|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
48691799|NCT04524715|DEVICE|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
48691800|NCT06658691|OTHER|Multidisciplinary approach|"The study investigated a multidisciplinary approach consisting of an endocrinologist, a diabetes specialized nurse, and a clinical pharmacist to assess and improve diabetic foot care by systematic screening, patients' risk categorization, therapy optimization, and tailored education.~Risk of Diabetic Foot Ulcer (DFU) occurrence was assessed and evaluated by the endocrinologist, and the nurse based on the 2019 International Working Group on Diabetes Mellitus (IWGDF). At that point, only the clinical pharmacist knew about patients' allocations.~According to risk stratification, the clinical pharmacist provided intervention patients with educational sessions and tailored materials during scheduled three months follow-up interviews at Jordan University Hospital (JUH) DFU-related clinics.~Moreover, the study evaluated the impacts of the multidisciplinary approach on health-related Quality of Life (QoL) at baseline and at the end of the study. Economic impacts were also further analyzed."
48691801|NCT03353363|DRUG|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
48691802|NCT03353363|DRUG|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
48691803|NCT03353363|DRUG|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
48691804|NCT00954564|OTHER|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
48691805|NCT00954564|OTHER|medical chart review|Observational only
48691806|NCT00954564|OTHER|questionnaire administration|Observational only
48691807|NCT00954564|PROCEDURE|assessment of therapy complications|Observational only
48691808|NCT00708591|DRUG|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
48691809|NCT00708591|DRUG|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
48691810|NCT06419959|DEVICE|NightWare|Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.
48691811|NCT03994211|DRUG|pamiparib 60 mg|Single dose of 60 mg pamiparib orally on Days 1 and 10
48691812|NCT03994211|DRUG|pamiparib 20 mg|Single dose of 20 mg pamiparib orally on days 1 and 7
48691813|NCT03994211|DRUG|itraconazole|200 mg itraconazole once a day al Day 3 to day 8
48691814|NCT03994211|DRUG|rifampin|600 mg rifampin once a day from days 3 to 11
48691815|NCT03994211|DRUG|pamiparib|60 mg pamiparib orally twice a day in 28-day cycles
48691816|NCT04262466|DRUG|Brenetafusp|Brenetafusp IV infusions
48691817|NCT04262466|DRUG|Brenetafusp and pembrolizumab|Brenetafusp and pembrolizumab IV infusions
48691818|NCT04262466|DRUG|Brenetafusp and chemotherapy|Brenetafusp and chemotherapy IV infusions
48691819|NCT04262466|DRUG|Brenetafusp and monoclonal antibodies and chemotherapy|Brenetafusp and a monoclonal antibody therapy and chemotherapy
48162742|NCT02679079|DRUG|NBI-98854|
48368556|NCT00911508|DEVICE|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
48368557|NCT00911508|DRUG|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
48005582|NCT02550327|DRUG|Anakinra|100 mg
48005583|NCT06276257|PROCEDURE|Paravertebral block|An ultrasound-guided technique will be used to inject a volume of 40 mL of ropivacaine 0.2%, up to a maximum of 1.5 mg/kg, into the paravertebral space between the T3 and T4 vertebrae.
48691820|NCT04262466|DRUG|Brenetafusp and tebentafusp|Brenetafusp and tebentafusp IV infusions
48691821|NCT04262466|DRUG|Brenetafusp and bevacizumab|Brenetafusp and bevacizumab IV infusions
48005584|NCT06276257|PROCEDURE|Usual analgesia|The patient will receive analgesia as per the anesthesiologist's preferences.
48005585|NCT02965612|DEVICE|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
48005586|NCT02965612|PROCEDURE|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
48368558|NCT03436212|DEVICE|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
48691822|NCT04262466|DRUG|Brenetafusp and kinase inhibitors|Brenetafusp and oral kinase inhibitors
48691823|NCT02904850|BIOLOGICAL|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
48162743|NCT02679079|DRUG|Placebo|
48162744|NCT05343819|DRUG|AON-D21|AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
48691824|NCT04812769|DEVICE|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
48162745|NCT05343819|DRUG|Placebo|Isotonic glucose solution identical in appearance to AON-D21.
48162746|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
48185240|NCT06376877|PROCEDURE|Sham transcranial magnetic stimulation|The sham TMS coil mimics the scalp sensation of real TMS by delivering a small amount of electrical current with a pair of surface electrodes.
48185241|NCT04249570|OTHER|Povidone iodine|
48368559|NCT04130633|DRUG|Placebo|Placebo vapor (distilled water)
48368560|NCT04130633|DRUG|THC|Pure THC vapor
48368561|NCT04130633|DRUG|Alpha-Pinene|Pure alpha-pinene vapor
48005587|NCT02696356|BIOLOGICAL|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
48005588|NCT00136292|DRUG|daptomycin|
48005589|NCT03350503|DEVICE|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
48005590|NCT03350503|PROCEDURE|Cataract surgery|Removal of cataractous lens and implantation of IOL
48368562|NCT02103400|OTHER|Experimental group|Exercise Training Group
48368563|NCT02103400|OTHER|Control group|Exercise control group
48368564|NCT01978717|PROCEDURE|epidural anesthesia|
48368565|NCT01978717|PROCEDURE|general anesthesia|Patients received general anesthesia for surgery
48691825|NCT04812769|OTHER|Standard of Care|Standard of care will be delivered to the control home.
48691826|NCT05435807|BEHAVIORAL|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
48691827|NCT06621732|PROCEDURE|cutanous biopsy and blood sample|cutanous biopsy and blood sample
48162747|NCT00348283|BIOLOGICAL|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
48691828|NCT05772455|DRUG|XZB-0004|Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
48691829|NCT06557356|DRUG|LY3532226|Administered SC
48691830|NCT06557356|DRUG|Placebo|Administered SC
48691831|NCT03150550|BEHAVIORAL|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
48691832|NCT03150550|BEHAVIORAL|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
48691833|NCT06186908|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
48691834|NCT00769171|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
48691835|NCT00769171|DRUG|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
48691836|NCT05446038|BEHAVIORAL|Multi-Family Guided Self-Help FBT|Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
48691837|NCT05645393|DRUG|topical estrogen product|estrogen topical gel or cream
48691838|NCT04463563|OTHER|Physiological|Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.
48691839|NCT06662175|DRUG|Hyperbaric bupivacaine|Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
48691840|NCT06662175|DRUG|hyperbaric bupivacaine and dexmedetomidine|Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
48691841|NCT06659796|DEVICE|LifeVac|Removal of airway obstruction during choking emergency
48691842|NCT04250558|PROCEDURE|Lower Extremity Amputation|patients 18 years of age or older who will have a planned lower leg (either below knee, through knee, or above knee) amputation surgery are scheduled to undergo a lower extremity amputation (either below knee, through knee or above knee), performed by a participating surgeon or delegate. Provision of informed consent.
48691843|NCT05207033|OTHER|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
48691844|NCT05207033|OTHER|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
48691845|NCT01933698|DRUG|amoxicillin|Comparison of pharmacokinetics of both formulations
48691846|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy|CPT as described in the treatment manual
48691847|NCT06000475|BEHAVIORAL|Cognitive Processing Therapy (CPT) + Memory Support|CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
48691848|NCT04528017|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
48691849|NCT04528017|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
48691850|NCT03934372|DRUG|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
48691851|NCT00000428|DRUG|Amitriptyline|Amitriptyline 25 mg po
48691852|NCT00000428|DRUG|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
48691853|NCT05479097|DRUG|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
48691854|NCT05788419|DIAGNOSTIC_TEST|sonography|imaging method, functional test of hip joint
48691855|NCT05523609|DRUG|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
48691856|NCT05523609|DRUG|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
48691857|NCT05140304|DEVICE|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
48691858|NCT06658886|OTHER|No intervention|No intervention
48691859|NCT00204594|DRUG|rM28|
48005591|NCT03696524|DEVICE|tunneled pleural catheter|Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
48005592|NCT01327352|DRUG|Oshadi D|oral administration
48368566|NCT03331939|OTHER|no stimulation|Vagal nerve stimulator will be set to no stimulation
48005593|NCT02994537|OTHER|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
48005594|NCT02607514|BEHAVIORAL|hyperthermic yoga|heated yoga, 90-minutes
48005595|NCT02489175|DEVICE|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
48005596|NCT01252290|DRUG|Lovaza™|4 capsules daily for 6 months
48005597|NCT02553746|DEVICE|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
48005598|NCT02553746|PROCEDURE|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
48005599|NCT04107480|PROCEDURE|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
48162748|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
48162749|NCT00640042|DRUG|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
48368567|NCT03331939|OTHER|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
48368568|NCT03331939|OTHER|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
48368569|NCT01390376|DRUG|DAAOI-1|DAAOI-1 1g
48368570|NCT01390376|DRUG|DAAOI-1|DAAOI-1 2g
48368571|NCT01390376|DRUG|placebo|starch pill
48368572|NCT02473029|RADIATION|Vascular tomodensitometry|
48368573|NCT02473029|OTHER|Magnetic resonance angiography|
48691860|NCT00204594|DRUG|autologous PBMCs|
48691861|NCT06072144|OTHER|Validity and reliability study|Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.
48368574|NCT02473029|OTHER|Vascular ultrasonography|
48368575|NCT02473029|OTHER|Retinal angiography|
48691862|NCT03490591|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
48691863|NCT04149470|DRUG|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
48368576|NCT02473029|OTHER|Retinal optical coherence tomography|
48368577|NCT00468013|BEHAVIORAL|Resilience Building Exercises|Weekly exercises for 6 weeks
48368578|NCT00468013|BEHAVIORAL|Journaling|Weekly exercises for 6 weeks
48368579|NCT00137527|DEVICE|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
48368580|NCT03856242|DRUG|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
48368581|NCT03856242|PROCEDURE|TURP|Routine transurethral prostatic resection
48368582|NCT00005068|DRUG|fluorouracil|
48368583|NCT00005068|DRUG|irinotecan hydrochloride|
48513806|NCT00862732|BEHAVIORAL|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
48513807|NCT00862732|OTHER|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
48513808|NCT02411916|BIOLOGICAL|misoprostol|rectal insertion
48368584|NCT00005068|DRUG|leucovorin calcium|
48368585|NCT00005068|DRUG|oxaliplatin|
48368586|NCT02648152|DEVICE|Osteoarthritis|Total Hip Arthroplasty
48368587|NCT06195033|PROCEDURE|Surgical protocol guided by artificial intelligence software|At present, the indications for internal fixation of intertrochanteric fractures are not clear. We developed an artificial intelligence software to assist surgeons in determining whether to immobilize lateral and medial posterior wall fractures.
48368588|NCT03172026|DRUG|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
48691864|NCT00211796|DRUG|Divalproex Sodium ER|
48691865|NCT04329728|DRUG|AVM0703|Intravenous infusion over \~1 hours
48691866|NCT04638413|BEHAVIORAL|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
48691867|NCT04638413|BEHAVIORAL|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
48691868|NCT03783442|DRUG|Cisplatin|Administered IV
48691869|NCT03783442|DRUG|Oxaliplatin|Administered IV
48691870|NCT03783442|DRUG|Fluorouracil (5-FU)|Administered IV
48691871|NCT03783442|DRUG|Capecitabine|Administered orally
48691872|NCT03783442|DRUG|Paclitaxel|Administered IV
48691873|NCT03783442|DRUG|Tislelizumab|Administered IV
48691874|NCT03783442|DRUG|Placebo|Placebo to match Tislelizumab
48691875|NCT05335304|OTHER|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
48691876|NCT05335304|OTHER|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
48691877|NCT05335304|OTHER|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
48691878|NCT05335304|OTHER|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
48691879|NCT05335304|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
48691880|NCT06012084|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
48691881|NCT02902302|DRUG|Ibuprofen 400 mg/10 mL oral suspension|
48691882|NCT02902302|DRUG|MOMENT 400 mg coated tablet|
48691883|NCT04861818|BEHAVIORAL|Moderate-intensity aerobic exercise|Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
48691884|NCT04249297|DRUG|Duphaston® (Dydrogesteron)|No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
48691885|NCT05558137|DRUG|Mivacurium|0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
48691886|NCT01861691|PROCEDURE|Open surgery|Conventional technique
48691887|NCT01861691|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
48691888|NCT01292980|DEVICE|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
48691889|NCT05645237|RADIATION|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
48691890|NCT00520702|PROCEDURE|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
48691891|NCT00520702|PROCEDURE|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
48691892|NCT00203866|DRUG|G250 peptide|
48691893|NCT00203866|DRUG|IL-2|
48691894|NCT02096211|DEVICE|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
48691895|NCT03645096|DRUG|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
48691896|NCT03645096|DRUG|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
48691897|NCT03645096|DRUG|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
48691898|NCT04728360|DRUG|BAT2206|45 mg/0.5 mL
48691899|NCT04728360|DRUG|Stelara (EU-sourced)|45 mg/0.5 mL
48691900|NCT04042909|BEHAVIORAL|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
48691901|NCT04042909|BEHAVIORAL|Personalized Normative Feedback|same as Personalized Normative Feedback arm
48691902|NCT00249808|DRUG|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
48691903|NCT06660160|OTHER|Exercise program supported by audiovisual media|"The intervention group will perform the group exercise protocol during HD sessions. The videos with the exercises will be broadcast on all televisions simultaneously, so that the volunteers perform the exercises along with the person in the video.~* The first level of difficulty includes 5 exercises for the lower limbs and 3 exercises for the upper limbs. One set of 10 repetitions will be performed for each exercise per session.~* The second level includes 3 exercises for the lower limbs and 2 exercises for the upper limbs. These consist of proprioceptive neuromuscular facilitation diagonals for both the lower and upper limbs. One set of 10 repetitions will be performed for each exercise, once per week, for 3 weeks.~* The third level includes 8 combined lower and upper limb exercises performed simultaneously. One set of 20 repetitions will be performed for each exercise.~Exercises will be performed 3 times per week over a 4-week period, for a total of 12 planned exercise sessions."
48691904|NCT02697981|BEHAVIORAL|nutrition counseling|nutrition counseling and guidance.
48691905|NCT02966288|DRUG|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
48691906|NCT02966288|DRUG|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
48691907|NCT05045430|DEVICE|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
48691908|NCT03777254|BIOLOGICAL|RC28-E|RC28-E intravitreous injection 50ul
48691909|NCT00232284|DRUG|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
48691910|NCT00232284|BEHAVIORAL|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
48691911|NCT04206397|BEHAVIORAL|affective touch|Various types of touch such as brushing, pressure, and tapping, as well as heat pain
48691912|NCT05170724|DRUG|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
48691913|NCT02144402|OTHER|infant formula with DHASCO|
48691914|NCT02144402|OTHER|infant formula with DHASCO-B|
48691915|NCT03532698|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
48691916|NCT03532698|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
48691917|NCT04027595|PROCEDURE|Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy|A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.
48691918|NCT04963244|OTHER||
48691919|NCT00576628|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
48691920|NCT06328270|OTHER|Ozone - oxygen Therapy|Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
48691921|NCT06328270|OTHER|Corticosteroid|1 ml betamethasone
48691922|NCT05915195|OTHER|Postural and Kinesthetic Awarness|Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
48691923|NCT05915195|OTHER|Routine Physical Therapy|Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
48691924|NCT02431780|DEVICE|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
48691925|NCT00394043|PROCEDURE|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
48691926|NCT00394043|PROCEDURE|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
48691927|NCT05908994|OTHER|Examination|Exmainations including imaging, neurophysiological, kinetic and kinematic measurmetns. Behavioral assessments
48691928|NCT05339841|OTHER|Mobile health application|The mHealth app delivers a personalized support program of digital health. Specifically, using ad hoc designed algorithms which uses the data self-reported by the subject and/or collected by the recruiter at baseline, the App delivers periodic messages with advice, motivational reminders and support to improve lifestyle habits and risk factor control.
48691929|NCT00784888|OTHER|Aromatase inhibitors|non-interventional study
48691930|NCT06224140|PROCEDURE|Heparin Anticoagulation|Conventional dialysis with heparin as anticoagulant treatment
48005600|NCT04107480|DRUG|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
48691931|NCT06224140|PROCEDURE|Regional Anticoagulation Procedure (RAP)|Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
48691932|NCT00933608|DRUG|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
48691933|NCT00933608|DRUG|Placebo|participants will be asked to take 2 tablets per day to match active drug
48691934|NCT03082911|OTHER|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
48691935|NCT03082911|OTHER|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
48691936|NCT01062724|OTHER|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
48005601|NCT06440031|BEHAVIORAL|CaMaPi|CaMaPi is a manually assisted brief psychological intervention that is based on the principles of Cognitive Behaviour Therapy (CBT). The intervention includes psycho-education and a comprehensive cognitive behavioural assessment of the suicidal ideation and self-harm attempt using virtual stories of four young people to be delivered in 8-10 sessions for over three months
48691937|NCT01278238|DRUG|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
48005602|NCT06440031|OTHER|TAU|Treatment as Usual (TAU) is routine care, such as diagnosis, assessment, psychotherapy, monitoring and any form of intervention (e.g., medication prescription) available at the collaborating service.
48005603|NCT01481116|DRUG|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
48005604|NCT01481116|DRUG|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
48005605|NCT01481116|DRUG|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
48005606|NCT00292357|PROCEDURE|Application of autologous bone marrow|
48005607|NCT05639270|DEVICE|use of an auricular electrode|Use of the auricular electrode throughout the duration of the study (30minutes/day) combined with assessment of pain, tolerance, vagal tone.
48691938|NCT01278238|DEVICE|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
48691939|NCT01278238|OTHER|Placebo|Neither phenylephrine nor lower limb bandaging
48368589|NCT03172026|BEHAVIORAL|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
48368590|NCT03172026|DRUG|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
48368591|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
48691940|NCT04878510|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
48368592|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin, topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
48691941|NCT04878510|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
48691942|NCT02058316|DEVICE|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
48162750|NCT01610622|DEVICE|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
48368593|NCT01370499|DRUG|LY2216684|
48368594|NCT01370499|DRUG|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
48368595|NCT04473989|DRUG|recombinant teriparatide for injection|weekly subcutaneous administration of 40 ug
48368596|NCT04473989|DRUG|Placebo|weekly subcutaneous administration of 40 ug
48691943|NCT02993822|DRUG|Orvepitant Maleate|Tablet, once daily, oral
48368597|NCT01559142|DRUG|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
48691944|NCT02993822|DRUG|Placebo|Tablet, once daily, oral
48691945|NCT02245269|DRUG|Tipranavir|
48691946|NCT02245269|DRUG|Ritonavir|
48691947|NCT02245269|DRUG|Atorvastatin|
48368598|NCT01559142|DRUG|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
48368599|NCT00703729|DEVICE|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
48368600|NCT00703729|OTHER|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
48691948|NCT02245269|DRUG|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
48005608|NCT01637350|PROCEDURE|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
48005609|NCT05148312|DRUG|Budesonide Inhalant Product|Single-dose of budesonide solution administered by nebulization.
48005610|NCT04765358|OTHER|Virtual Clinic|CGM, Clinical Care Support and Behavioral Health Support
48005611|NCT05207020|DEVICE|Glycemia estimated by exhaled air analyzer|Measurement of volatile compounds in the air exhaled by the volunteer on 3 different MIBs (3 breaths in total) at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
48005612|NCT05207020|BEHAVIORAL|Questionnaire|The questionnaire focuses on the methods and feelings of the blood glucose self-monitoring that he is currently carrying out, a first feedback on user experience on the operation of the prototype and the collection of his expectations for a future commercial device
48162751|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
48162752|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
48368601|NCT03990168|DEVICE|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
48691949|NCT02468687|DRUG|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
48691950|NCT04793204|DRUG|fezolinetant|oral
48005613|NCT05207020|BIOLOGICAL|Veinous glycemia|Measurement of the veinous glycemia at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
48691951|NCT03861104|OTHER|medical educational video|information based on visual and auditory communication
48691952|NCT06660251|OTHER|Egg intervention|Oral administration of three hard-boiled eggs to be ingested within 15 minutes on one occasion.
48691953|NCT06660251|OTHER|Meatball intervention|Oral intervention with 170 g meatballs to be ingested within 15 minutes on one occasion.
48691954|NCT04769271|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
48162753|NCT03807271|DEVICE|Calculated and graphically produced depth of anesthesia (Smart Pilot® View)|Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
48162754|NCT03199261|DRUG|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
48691955|NCT04769271|DRUG|Scaling and Root Planing with tea tree oil|Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
48691956|NCT05119374|DEVICE|SenseGuard Investigational Device|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~* RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~* ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~* SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
48691957|NCT05024916|DIETARY_SUPPLEMENT|Intervention|26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.
48691958|NCT05024916|DIETARY_SUPPLEMENT|Control|26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
48691959|NCT03855787|PROCEDURE|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
48691960|NCT04985201|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.
48691961|NCT04985201|DRUG|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
48005614|NCT05207020|BIOLOGICAL|Capillary glycemia|7-step capillary glycemia measurement: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
48005615|NCT05207020|BIOLOGICAL|constitution biological collection|Sampling for storage of serum at 7 times: T0, 30min, 1H, 1H30, 2H, 2H30, 3H after test meal
48005616|NCT05207020|BIOLOGICAL|Blood sample|Single blood sample before mealtimes for HbA1C molecular analysis
48005617|NCT05207020|OTHER|Test meal|taking a test meal before the various blood sugar measurements
48005618|NCT00482495|BIOLOGICAL|bevacizumab|
48005619|NCT00482495|GENETIC|gene expression analysis|
48005620|NCT00482495|GENETIC|protein expression analysis|
48005621|NCT00482495|OTHER|laboratory biomarker analysis|
48005622|NCT06093724|DIAGNOSTIC_TEST|Static and dynamic perineo-pelvic MRI|Static and dynamic perineo-pelvic MRI before surgery, and at 6 and 24 months after surgery.
48005623|NCT01941446|DRUG|Eravacyline, Moxifloxacin, and placebo|
48005624|NCT06336369|DIAGNOSTIC_TEST|analyzing brown adipose tissue, body composition and metabolic health|cooling procedure, PET-CT imaging, MR imaging, blood sampling, indirect calorimetry, thermograpy, impedance analysis
48005625|NCT05370404|OTHER|Prescription by surgical team|The surgical team prescribes medications to the patient
48005626|NCT05370404|OTHER|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
48005627|NCT05213858|DIAGNOSTIC_TEST|CAPS questionnaire|PTSD diagnosis and severity will be done using the CAPS-5 questionnaire.
48005628|NCT05213858|DIAGNOSTIC_TEST|Beck Depression Inventory|depression symptoms will be measured by the BDI-II. The BDI-II consists of 21 items and uses a 0 to 3 severity scale. Total scores range from 0 to 63, with higher scores indicating more severe depression.
48162755|NCT03199261|DRUG|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
48185242|NCT01035268|PROCEDURE|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
48185243|NCT00092183|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
48691962|NCT01635270|RADIATION|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
48162756|NCT05657613|DRUG|CYP450 Cocktail and Transporter Substrates with Pacritinib|"Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg."
48368602|NCT03990168|BEHAVIORAL|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
48691963|NCT01635270|RADIATION|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
48691964|NCT03474913|DEVICE|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
48691965|NCT03474913|DEVICE|Standard MRI|standard of care closed 3T MRI
48691966|NCT04003051|OTHER|Internet-Based Intervention|Use Project Prepare website
48691967|NCT04003051|OTHER|Quality-of-Life Assessment|Ancillary studies
48691968|NCT04003051|OTHER|Questionnaire Administration|Ancillary studies
48005629|NCT05213858|DIAGNOSTIC_TEST|The Fibromyalgia Impact Questionnaire|The FIQ was developed from information gathered from patient reports, functional status instruments and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue and well-being over the past week.
48691969|NCT03097523|DEVICE|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
48691970|NCT04967287|DEVICE|MyopiaX|MyopiaX treatment twice a day
48691971|NCT04967287|DEVICE|Myopia control spectacles|To be used all as prescribed
48691972|NCT03171519|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
48691973|NCT03171519|BEHAVIORAL|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
48691974|NCT06488092|OTHER|Cesarean Risk Calculator|The cesarean risk calculator will be incorporated into routine care at the site
48691975|NCT03449940|PROCEDURE|Immediate repair|
48162757|NCT05657613|DRUG|Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID"
48162758|NCT05657613|DRUG|Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD."
48162761|NCT03341754|BIOLOGICAL|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
48162762|NCT03341754|BIOLOGICAL|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
48162763|NCT03341754|OTHER|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
48162764|NCT00915460|DRUG|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
48162765|NCT01247870|DRUG|Metformin|Metformin 1 g twice daily for 28-35 days
48162766|NCT01247870|DRUG|Placebo|Placebo
48162767|NCT03030053|DIETARY_SUPPLEMENT|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
48162768|NCT03030053|DIETARY_SUPPLEMENT|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
48368603|NCT03990168|DEVICE|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
48368604|NCT01061762|BEHAVIORAL|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
48691976|NCT03449940|PROCEDURE|Delayed repair|
48691977|NCT03449940|DRUG|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
48691978|NCT03449940|DRUG|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
48691979|NCT03449940|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
48368605|NCT01061762|BEHAVIORAL|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
48368606|NCT01061762|BEHAVIORAL|Health Counseling|3-session of health improvement counseling to serve as an attention control.
48368607|NCT04676581|OTHER|Leech Therapy|Patient who received leeches (for more than 2 days) at the Amiens University Hospital over a period of 9 years (2010-2018)
48513809|NCT01632280|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes-anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
48005630|NCT05213858|DIAGNOSTIC_TEST|The Pittsburgh Sleep Quality Index|"sleep patterns will be measured using the PSQI. This index assesses the quality and patterns of sleep in adults. It differentiates poor from good sleep quality by measuring seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, the use of sleeping medications and daytime dysfunction over the last month. Items are rated using a 0 to 3 scale. The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality."
48513810|NCT00537511|DRUG|Pomalidomide|
48513811|NCT00537511|DRUG|Cisplatin|
48005631|NCT05213858|DIAGNOSTIC_TEST|Depression, Anxiety and Stress Scale-21 items|The DASS-21 is a three-scale self-report questionnaire designed to measure the emotional state of depression, anxiety and stress. Each scale contains 7 items, divided into subscales with similar content. Scores range between 0 and 21 in each subcategory.
48005632|NCT05213858|DIAGNOSTIC_TEST|Traumatic Events Questionnaire|"The TEQ examines experiences of traumatic events (e.g. sexual abuse, accidents and crime) that are considered potential triggers of PTSD symptoms. To assess trauma intensity, respondents provide information for each event that was experienced, as well as their age at the time of the event. The items are measured on a 9-point Likert scale from not at all to severely/extremely. The TEQ has previously been used in Israel."
48005633|NCT05213858|DIAGNOSTIC_TEST|Clinician Administered Dissociative States Scale|The CADSS is a 28-item structured clinical interview to assess state dissociation.
48162769|NCT05971147|DIETARY_SUPPLEMENT|Fish oil|Participants in this group will receive 5g fish oil with high EPA and DHA content per day
48185244|NCT00092183|DRUG|Comparator: ondansetron / Duration of Treatment: 3 days|
48691980|NCT06660082|PROCEDURE|Experimental treatment: Head movements|"These are gaze stabilisation exercises under vHIT control, between post-operative days 1 to 6.~The patient sits facing a wall 2 metres away. The investigator places the vHIT device on the participant's head and ensures that it fits properly.~This is followed by an initial calibration phase (the patient must follow a laser dot with his eyes).~Then comes stimulation phase: the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The investigator then performs a series of low-amplitude, high-speed head movements in the plane of the lateral canals and on the side of the vestibular deficit.~The patient is encouraged to resume fixation of the visual target as quickly as possible.~For each treatment session, patients should perform a minimum of 10 impulses and a maximum of 30 impulses on the deafferented side. Each"
48691981|NCT06660082|PROCEDURE|Sham treatment: only eye movements|"These are visually guided saccade exercises under vHIT device control but without head movements (saccade module), between post-operative days 1 to 6.~For this sham treatment, the modalities are identical to the experimental treatment session, up to the calibration phase described above.~For the stimulation phase, the investigator, standing behind the patient, places his hands on the sides of the patient's lower jaw, which he is asked to clench. The investigator asks the subject to stare at a visual target on the wall in front of the patient. The target then jumps horizontally to trigger visually guided saccades or slides horizontally to trigger an eye-tracking movement. The investigator stabilises the patient's head to prevent any head movement. The patient is encouraged to resume or maintain fixation of the visual target as quickly as possible.~A minimum of 5 horizontal saccade sequences and 5 horizontal eye-tracking sequences will be performed. Each training session lasts approxi"
48691982|NCT02855866|PROCEDURE|thyroidectomy|
48691983|NCT02855866|OTHER|cryotherapy|
48691984|NCT02855866|DRUG|cortisone aerosol|
48691985|NCT02855866|DRUG|Dexamethasone acetate|
48691986|NCT02855866|DRUG|paracetamol|
48513812|NCT00537511|DRUG|Etoposide|
48513813|NCT01233895|DRUG|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
48513814|NCT01233895|DRUG|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
48513815|NCT05798910|OTHER|ALS VR (VR based serious gaming module for advanced life support training)|Using VR based serious gaming module for advanced life support training instead of taking part in a classical lecture about advanced life support.
48513816|NCT05798910|OTHER|Lecture based training for advanced life support|Taking part in a classical lecture about advanced life support.
48513817|NCT04642365|DRUG|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
48005634|NCT05213858|DIAGNOSTIC_TEST|A diary will be used for seven consecutive nights|"A diary will be used for seven consecutive nights for the evaluation of:~* Mean sleep latency~* The number and duration of awakenings.~* Subjective total sleep time~* Subjective wake after sleep onset~* Sleep efficiency"
48005635|NCT05213858|DIAGNOSTIC_TEST|MRI|Brain imaging will include DTI and resting state for structural and functional MRI scanning. Images will be acquired on MAGNETOM Vida 3T Scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany) at the Department of Radiology at Shamir Medical Center.
48005636|NCT05213858|DIAGNOSTIC_TEST|Functional brain imaging|Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain. This technology measures brain activity by detecting changes associated with blood oxygenation, using blood-oxygen-level-dependent imaging (BOLD) contrast.
48005637|NCT05213858|DIAGNOSTIC_TEST|EEG analysis|EEG will be obtained using a point-of care device that consists of an EEG-Sense Headset, EEG-Sense Single-Use brush sensors, a pneumatic sensor positioning mechanism, EEG sampling electronics and software. The EEG-Sense Headset is an EEG electrode positioning system that quickly places electrodes in a uniform and consistent manner, to transfer electrophysiological EEG signals from an individual to a suitable EEG data collection device. The device is nonsterile, non-invasive and non-radiation emitting, and was developed for use in healthcare facilities and hospitals. Typical set-up and procedure time is several minutes. The device does not contain biologics, drugs, coatings or any claim of sterility. The EEG-Sense Single-Use brush sensors are made from well-established medical-grade materials; the Headset is made from Nylon 101. Electronic components and harnesses are embedded between two layers of nylon and are attached to each electrode port.
48005638|NCT05213858|DIAGNOSTIC_TEST|Autonomic nervous system monitors|"Data will be collected using Empatica's E4 wristband. Each of the study participants will wear the wristband for 7 days.~Data collected from the band will include:~ACC - Data from 3-axis accelerometer sensor in the range \[-2g, 2g\]. (sampled at 32 Hz) BVP - Data from photoplethysmography (PPG). (sampled at 64 Hz) EDA - Data from the electrodermal activity sensor in μS. (sampled at 4 Hz) IBI - Inter-beat intervals. (intermittent output with 1/64 second resolution) TEMP - Data from temperature sensors, expressed in degrees on the Celsius (°C) scale. (sampled at 4 Hz)"
48005639|NCT04307485|DRUG|Ticagrelor|90mg ticargrelor based DAPT vs 60mg ticargrelor based DAPT
48185245|NCT00322569|DEVICE|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
48368608|NCT01390727|DEVICE|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
48368609|NCT01390727|OTHER|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
48368610|NCT02183220|DRUG|Metamizol|
48368611|NCT02183220|DRUG|Acetylsalicylic acid (ASA)|
48691987|NCT05237505|DEVICE|bi-level positive pressure non invasive ventilation|Participants randomized to the bi-level arm will be provided with an auto bi-level device that automatically delivers the required pressure. The settings in the auto bi-level will be minimum EPAP of 4 cmH2O, maximum IPAP of 24 cmH2O, and a range of pressure support between 6-10 cmH2O. For those participants who have been randomized to the bi-level group but have not successfully acclimated to the device with the automatic bi-level settings, we will conduct an in-lab titration of the bi-level therapy during the optional Overnight visit 2.
48691988|NCT05237505|DRUG|Oxygen gas|The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
48691989|NCT04762992|DRUG|subcutaneous Enoxaparin|Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
48691990|NCT04762992|OTHER|standard of care|Obsteric standard of care.
48691991|NCT03300024|DEVICE|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
48691992|NCT03300024|DEVICE|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
48691993|NCT06370923|BEHAVIORAL|Peer Distribution|In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
48691994|NCT06370923|BEHAVIORAL|Community Health Worker Distribution|Distribution of HIV self tests by community health workers
48005640|NCT05041790|DRUG|Choline Alfoscerate|Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
48005641|NCT05041790|DRUG|Placebo|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.
48005642|NCT01110421|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
48368612|NCT02183220|DRUG|Metamizol placebo|
48368613|NCT02183220|DRUG|ASA placebo|
48368614|NCT04156984|DRUG|Golimumab Prefilled Syringe|See arm description
48513818|NCT04642365|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
48691995|NCT06416878|DEVICE|Brief ES at the time of decompression for cauda equina syndrome|In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.
48691996|NCT06416878|DEVICE|Brief ES to facilitate mcturition/removal of catheter|In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
48691997|NCT05055011|OTHER|Electronic Health Record Review|Review of medical records
48691998|NCT05055011|OTHER|Survey Administration|Complete survey
48691999|NCT04619238|DIAGNOSTIC_TEST|King's Health Questionnaire|patients fulfilled questionnaire
48692000|NCT04619238|DIAGNOSTIC_TEST|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
48692001|NCT06306196|BIOLOGICAL|Hecolin® Recombinant Hepatitis E Vaccine|30㎍/dose, 0.5mL administered intramuscularly
48692002|NCT06306196|BIOLOGICAL|Isotonic Sodium Chloride injection|0.5mL administered intramuscularly
48005643|NCT01110421|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
48005644|NCT01110421|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
48005645|NCT01110421|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
48005646|NCT01110421|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
48005647|NCT05766306|DIETARY_SUPPLEMENT|Probiotic Blend|Participants will be taking 1 sachet a day, 3 billion CFU.
48005648|NCT05766306|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
48005649|NCT02394080|DEVICE|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
48005650|NCT03423732|DRUG|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
48162770|NCT03617458|DRUG|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
48162771|NCT03617458|DRUG|Placebo|A treatment with no active ingredients or therapeutic effect.
48185246|NCT00322569|DEVICE|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
48185247|NCT00322569|DEVICE|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
48368615|NCT03987165|OTHER|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
48368616|NCT05238246|BEHAVIORAL|Behavioral guidance with tell-show-do|The effect of tell-show-do technique during dental treatment on behavior in pediatric patients was evaluated and compared.
48692003|NCT05895877|DRUG|Goofice®|Once daily before breakfast.
48692004|NCT05895877|DRUG|Goofice® Placebo|Once daily before breakfast.
48692005|NCT02417662|RADIATION|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
48692006|NCT02417662|OTHER|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
48692007|NCT01887730|BEHAVIORAL|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
48692008|NCT01887730|BEHAVIORAL|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
48692009|NCT01887730|BEHAVIORAL|Control|
48692010|NCT06301516|BEHAVIORAL|Virtual Reality|VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
48692011|NCT06301516|OTHER|Comparative Control|Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.
48692012|NCT06002555|DRUG|Apraglutide|Peptide analogue of GLP-2
48692013|NCT02706418|PROCEDURE|Clinical Massage Therapy|
48692014|NCT02483091|BEHAVIORAL|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
48162772|NCT03617458|DEVICE|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPAA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
48162773|NCT03617458|DEVICE|Usual Care|Our HIPAA data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
48162774|NCT06646939|BEHAVIORAL|PT and OT with a simulated environment|Upon admission to the inpatient rehabilitation unit, participants will undergo a physical and occupational therapy evaluation. The evaluations will include the outcome measures chosen to track for this study (10-meter walk test and Quality Indicators). If a patient meets inclusion/exclusion criteria, informed written consent will be obtained. Throughout the patient's stay, therapists will have the opportunity to perform community integration treatments using the simulated environment. This could include activities such as negotiating a curb, crossing a street, or shopping at a marketplace. The therapist will document the amount of time (units billed) spent performing these interventions. The research investigators will not act as a patient's therapist throughout their admission.
48162775|NCT03816202|DEVICE|Sundt carotid shunt|The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
48162776|NCT02982096|DEVICE|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
48162777|NCT02982096|OTHER|Standard of Care|Acellular burn wound management
48162778|NCT04979234|DEVICE|Endomina- Endoscopic Sleeve Gastroplasty|Endoscopic gastric reduction
48162779|NCT04979234|BEHAVIORAL|Diet|Multidisciplinary follow up
48162780|NCT00128908|DRUG|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
48692015|NCT01271907|DRUG|fludarabine|Fludarabine 25 mg/m\^2 x 5 days
48162781|NCT00128908|DRUG|Rapidly Cycled HAART|
48162782|NCT05752955|OTHER|SMARThealth Pregnancy|"At each visit, the CHW will:~* Update history and contact details~* Check haemoglobin with a point of care device.~* Check BP~* Check iron folic acid (IFA) supply and compliance~* Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~* Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~* Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults."
48692016|NCT01271907|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
48692017|NCT01271907|DRUG|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
48162783|NCT02404012|DIETARY_SUPPLEMENT|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
48162784|NCT00433498|DRUG|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
48162785|NCT00433498|DRUG|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
48185248|NCT00064142|DRUG|halofuginone hydrobromide|Applied topically
48692018|NCT01271907|DRUG|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
48692019|NCT05785286|OTHER|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
48692020|NCT04037254|BIOLOGICAL|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
48692021|NCT04037254|RADIATION|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
48692022|NCT04037254|DRUG|Niraparib|Given PO
48513819|NCT01948531|DRUG|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
48692023|NCT03714217|BEHAVIORAL|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
48692024|NCT00475085|DRUG|aprepitant|Given orally or IV
48005651|NCT03423732|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
48005652|NCT00177437|BEHAVIORAL|home testing kit|
48005653|NCT02322554|BIOLOGICAL|Cellular and tissue based products|Procedure: Application of device or biological to wounds
48005654|NCT00375843|DRUG|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
48005655|NCT00375843|DRUG|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
48005656|NCT03412916|BEHAVIORAL|GetActive|GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
48005657|NCT03412916|BEHAVIORAL|Get Active with Fitbit|The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
48005658|NCT02660918|DRUG|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
48005659|NCT02660918|OTHER|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
48005660|NCT00409292|DRUG|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
48005661|NCT01077960|BIOLOGICAL|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
48005662|NCT03862664|PROCEDURE|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
48005663|NCT02609022|BIOLOGICAL|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
48162786|NCT00433498|DRUG|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
48162787|NCT00433498|DRUG|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
48185249|NCT00064142|OTHER|placebo|Applied topically
48513820|NCT06292221|OTHER|A mobile Health (mHealth) tool called 'DepWatch'|The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants
48692025|NCT00475085|DRUG|dexamethasone|Given orally or IV
48692026|NCT00475085|DRUG|granisetron hydrochloride|Given orally or IV
48692027|NCT00475085|DRUG|palonosetron hydrochloride|Given orally or IV
48692028|NCT00475085|DRUG|prochlorperazine|Given orally or IV
48692029|NCT00475085|DRUG|placebo|Given orally
48692030|NCT06049017|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
48692031|NCT06049017|DRUG|Placebo|Placebo tablet will be administered orally.
48692032|NCT04481204|DRUG|Cisplatin|Given IV
48692033|NCT04481204|DRUG|Fluorouracil|Given IV
48692034|NCT04481204|DRUG|Gemcitabine|Given IV
48692035|NCT04481204|DRUG|Irinotecan|Given IV
48692036|NCT04481204|DRUG|Leucovorin|Given IV
48692037|NCT04481204|DRUG|Nab-paclitaxel|Given IV
48692038|NCT04481204|DRUG|Oxaliplatin|Given IV
48692039|NCT04481204|RADIATION|Radiation Therapy|Undergo RT
48692040|NCT04715828|OTHER|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
48692041|NCT04715828|OTHER|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
48513821|NCT06484686|BIOLOGICAL|Live Attenuated Varicella Vaccine|lyophilized powder, subcutaneous injection
48513822|NCT05543798|DEVICE|Vision-MR Ablation Catheter 2.0|Catheter ablation of ventricular tachycardia
48005664|NCT02609022|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
48005665|NCT03618264|DRUG|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
48005666|NCT03618264|DRUG|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
48005667|NCT00122720|DRUG|Darbepoetin Alfa|
48005668|NCT00006484|DRUG|carboplatin|
48005669|NCT00006484|DRUG|paclitaxel|
48005670|NCT00006484|DRUG|tirapazamine|
48005671|NCT04583813|DRUG|Empagliflozin|Empagliflozin 10 mg oral tablet, once daily, for 24 months
48005672|NCT04583813|OTHER|Placebo|Empagliflozin matching placebo, once daily, for 24 months
48005673|NCT00219674|BEHAVIORAL|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
48005674|NCT00219674|BEHAVIORAL|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
48513823|NCT04561271|OTHER|foot reflexology|Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.
48692042|NCT04715828|OTHER|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
48005675|NCT00219674|BEHAVIORAL|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
48005676|NCT00219674|BEHAVIORAL|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
48005677|NCT04578847|DRUG|Imatinib|Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
48162788|NCT04814992|BEHAVIORAL|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
48162789|NCT02228083|DRUG|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
48162790|NCT02706834|DRUG|TAK-828|TAK-828 oral solution
48162791|NCT02706834|DRUG|Placebo|TAK-828 placebo-matching oral solution
48162792|NCT01245803|DRUG|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
48692043|NCT04715828|OTHER|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
48692044|NCT05718570|DRUG|Somapacitan|Sogroya therapy in participants with AGHD.
48692045|NCT05906472|OTHER|Feeds continued|Enteral feeds are continued up until time of surgery
48692046|NCT05906472|OTHER|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
48692047|NCT05784129|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
48005678|NCT04578847|DRUG|Nilotinib|Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
48005679|NCT04578847|DRUG|Dasatinib|Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
48005680|NCT04578847|DRUG|Bosutinib|Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.
48005681|NCT01138280|DEVICE|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
48005682|NCT04970758|OTHER||no intervention
48162793|NCT01245803|DRUG|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
48513824|NCT04561271|OTHER|toucher massage|one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.
48692048|NCT05784129|DRUG|Placebo|Placebo will be administered subcutaneously.
48162794|NCT05615558|OTHER|Dietary Intervention|Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
48162795|NCT06585748|DRUG|Lidocaine spray|4 puffs of lidocaine spray was applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder. After bladder catheterization, pain scores were evaluated by a neutral emergency medicine physician at 0 minutes (during the procedure), and at 15, 30, and 60 minutes post-procedure. The Face Legs Arms Cry Consolability Pain Scale (FLACC) and Wong-Baker pain scales were used for this evaluation.
48162796|NCT06585748|OTHER|Placebo|No medication/application will be administered as placebo.
48162799|NCT01540071|DRUG|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
48162800|NCT06500013|BEHAVIORAL|Self-designed messages|Messages designed by participants
48162801|NCT06500013|BEHAVIORAL|Standardized messages|Messages designed by researchers based on behavioral change theories
48368617|NCT05238246|BEHAVIORAL|Behavioral guidance with robot|The effect of the tell-show-do and distraction technique during dental treatment on behavior in pediatric patients was evaluated and compared.
48368618|NCT05727696|PROCEDURE|Henry approach; volar approach|Radial Shortening : Supine position, general anesthesia, volar approach, Henry approach, osteotomy 1 inch from radio-carpal joint surface, shortening 2.5 mm of distal shaft radius, fixation by small DCP or small T plate.
48368619|NCT05727696|PROCEDURE|dorsal approach|Capitate Shortening : Supine position, general anesthesia, dorsal approach, separation between 2nd and 3rd compartments of extensor tendons, osteotomy \& shortening 2.5 mm of capitate, compression by Herpert screw.
48513825|NCT04413110|DEVICE|Polysomnography|PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
48513826|NCT00791895|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme
48005683|NCT01588912|DRUG|Telbivudine|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
48005684|NCT01588912|DRUG|Tenofovir|If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
48005685|NCT01588912|DRUG|Entecavir|Maintain the entecavir through the study period
48162802|NCT02131155|DRUG|Placebo|Once daily
48162803|NCT02131155|DRUG|Afatinib|Once daily
48162804|NCT03432286|DRUG|Galcanezumab|Administered SQ
48162805|NCT03432286|DRUG|Placebo|Administered SQ
48162806|NCT04161547|DRUG|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
48162807|NCT04161547|DRUG|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
48162808|NCT04161547|DRUG|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
48162809|NCT04161547|DRUG|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
48162810|NCT02391571|DRUG|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
48162811|NCT02391571|DRUG|Oxycodone|Oxycodone to be taken with stable dose of Methadone
48513827|NCT03745079|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
48005686|NCT02211469|DRUG|BMS-986104|
48005687|NCT02211469|DRUG|Placebo|
48005688|NCT02771262|OTHER|Pulmonary Rehabilitation|
48005689|NCT03026621|DIETARY_SUPPLEMENT|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
48005690|NCT03026621|OTHER|Herbal tea|This is an herbal tea that will look like the control
48005691|NCT01556542|DEVICE|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
48005692|NCT01556542|DEVICE|nitinol stent implantation|nitinol stent implantation
48162812|NCT02391571|DRUG|Placebo|2 day placebo run in prior to test and active drug phase of study
48185250|NCT00064142|OTHER|laboratory biomarker analysis|Correlative studies
48185251|NCT00064142|OTHER|pharmacological study|Correlative studies
48005693|NCT05984355|OTHER|Individual interviews|Discussion between the searcher and the participant about representations and acceptability about a potential application and captors which suggest a Walking itinerary
48005694|NCT01762943|DRUG|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
48005695|NCT01762943|DRUG|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
48005696|NCT01762943|DRUG|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
48162814|NCT04659278|DIETARY_SUPPLEMENT|Endourage 1200 mg OMD ™ Oral Mucosal Drops|The CBD/THC ratio of OMD 1200 is 14:1 and the CBD/Terpene ratio is 1:1. Each ¼ dropper contains 10.2 mg of CBD and 0.7 mg of THC. The total % THC is 0.28%. These ratios indicate that the product will not cause euphoria.
48162815|NCT04659278|DIETARY_SUPPLEMENT|Isolate|The isolate formulation contains 0% cannabinoids (CBD 0.00%; CBDa 0.00%; detla 9 THC 0.00%; THCa 0.00%).
48162816|NCT04659278|OTHER|Placebo|Total CBD = CBD + (CBD-A \* 0.877). Total THC = THCA-A \* 0.877 + Delta 9 THC, ND = \<LOQ, T-Caryophyllene = Trans-Caryophyllene, \<LOQ = Less Than Limit of Quantitation, QNS = Quantity Not Sufficient. (%) = Percent, (ppm) = Parts per Million, (ppb) = Parts per Billion, (μg/Kg) = Microgram per Kilogram, (mg/g) = Milligram per Gram, ppm = (μg/g), ppb = (μg/kg),
48162817|NCT04659278|DIETARY_SUPPLEMENT|Peppermint Oil, masking flavor|Mentha piperita Leaf /Stem Oil; Physical state: Liquid. Color: Colorless to pale yellow; Characteristic peppermint odor; Not dangerous goods.
48368620|NCT02198040|OTHER|Manual Therapy|"* 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
48368621|NCT02198040|OTHER|Educational group|"* Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
48162818|NCT06550297|BEHAVIORAL|Medically Tailored Meals and Nutritional Counseling|God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.
48368622|NCT01402882|DRUG|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
48513828|NCT03745079|OTHER|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
48692049|NCT03981640|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
48005697|NCT03142880|COMBINATION_PRODUCT|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
48005698|NCT03910218|BEHAVIORAL|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
48005699|NCT03910218|BEHAVIORAL|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
48005700|NCT06087965|DRUG|Fingolimod|0.5mg/day oral fingolimod over a course of 3 consecutive days
48005701|NCT01642238|DRUG|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
48005702|NCT01642238|DRUG|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
48005703|NCT01414569|DRUG|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
48005704|NCT00755066|DRUG|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
48005705|NCT00755066|DRUG|Placebo|Placebo intranasal spray
48185252|NCT02761798|DEVICE|Automated Mobile Interactive Audiometer|iPad game
48162819|NCT06550297|BEHAVIORAL|Cardiovascular Health Promotion Educational Program|Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
48162820|NCT04436484|DIAGNOSTIC_TEST|Peripheral blood sampling|Non-interventional study
48162821|NCT04668534|DEVICE|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
48162822|NCT04668534|DEVICE|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
48162823|NCT04668534|DEVICE|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
48162824|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-F8scFv|89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.
48162825|NCT06645808|BIOLOGICAL|89Zr-DFO-N-Suc-C9scFv|89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.
48162826|NCT06645808|RADIATION|PET/CT scan|IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
48162827|NCT04402021|BEHAVIORAL|Outdoor Walking|Unsupervised outdoor walking will be the mode used for moderate-intensity aerobic exercise. The walking intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
48162828|NCT04402021|OTHER|Quiet Rest|The quiet rest condition will consist of watching a nature documentary in a quiet room. The quiet rest intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
48162829|NCT05530083|BEHAVIORAL|group education|Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
48162830|NCT05530083|BEHAVIORAL|conventional smoking cessation management|Including regular follow-up of smoking status and giving advice of smoking cessation
48162831|NCT06254079|PROCEDURE|video based education|The patients in the experimental group will be shown a video containing information about the operating room environment and care during surgery. The video content includes the following details: the operating room temperature being maintained at 18-24°C; the patient being placed on the operating table by the staff in the presence of an anesthesia technician; the establishment of intravenous access by the anesthesia technician; monitoring of blood pressure, pulse, respiration, and EKG indicators; the insertion of a urinary catheter by the surgical nurse after the patient is anesthetized; post-awakening transfer to the postoperative recovery unit with the anesthesia technician and personnel; reception and monitoring of vital signs, pain assessment, intervention, and observation for a period by a nurse in this unit; and finally, transfer to the General Surgery Service.
48162832|NCT01037829|OTHER|Non-intervention observational study|Non-intervention observational study
48162833|NCT00449488|DRUG|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
48513829|NCT03745079|OTHER|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
48513830|NCT05083897|OTHER|hip adduction isometric contraction|addition of isometric hip adduction contraction to the knee extension for measuring knee extension peak torque by the isokinetic dynamometer
48513831|NCT02620579|DRUG|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
48513832|NCT02620579|DRUG|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
48692050|NCT03981640|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
48162834|NCT03134976|DRUG|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
48162835|NCT04980755|OTHER|Body Reprogramming|An educational intervention originally designed for patients with fibromyalgia.
48162836|NCT03642288|DRUG|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
48162837|NCT03487302|OTHER|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
48162838|NCT03487302|OTHER|Neuropsychological test battery|"1. Mini Mental State Examination (MMSE), Measso et al. (1993);~2. Frontal Assessment Battery (FAB), Appollonio et al. (2005);~3. Symbol Digit Test, Amodio et al. (2002);~4. Digit Cancellation Test, Della Sala et al. (1992);~5. Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~6. Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~7. Digit Span, Orsini et al (1987);~8. Corsi block-tapping test, Orsini et al. (1987);~9. Babcock story recall test, Carlesimo et al. (2002);~10. Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~11. Semantic verbal fluency, Novelli (1986);~12. Imitating gestures, De Renzi et al. (1980);~13. Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
48162839|NCT02686359|BIOLOGICAL|sample|
48162840|NCT04007848|DRUG|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
48162841|NCT04007848|DRUG|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
48162842|NCT05552014|BEHAVIORAL|Natural Psychotherapy|"Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics."
48162843|NCT05552014|BEHAVIORAL|Mental Health Education|Mental Health Education Seminar
48162844|NCT04309006|PROCEDURE|CTG and customized healing abutment|screw- retained customized healing abutment
48162845|NCT04309006|PROCEDURE|CTG and conventional healing abutment|conventional healing abutment
48162846|NCT05153642|PROCEDURE|Microsurgical intervention|The EC-IC bypass distal to the occlusion will be prepared in patients with a failure to pass the lesion using microwire and subjects with a failure to reach the occlusion. Middle cerebral artery exploration and eventual embolectomy will be performed before the bypass. A transverse arteriotomy will be used in the M1 segment occlusion, while a longitudinal arteriotomy with optional subsequent lesion retrieval using a Fogarty catheter will be used in the upper or lower M2 trunk occlusions. Minimally invasive and rapid surgical embolectomy technique will be used in cases with atrial fibrillation as the suspected source of emboli. In cases with successful passage using a microwire or catheter, but with failure of thrombus retrieval, a calcified cerebral embolus can be an example of failure. In cases with suspected occlusion due to intracranial atherosclerosis, the superior temporal artery will be always dissected and EC-IC bypass was performed.
48162847|NCT04565392|DRUG|Famotidine 20 milligram tablet|1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
48162848|NCT04077775|DIAGNOSTIC_TEST|assesment|assesment
48162849|NCT05130502|OTHER|Foam roller|The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests
48162850|NCT05130502|OTHER|Kinesiotape|The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
48692051|NCT03981640|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
48162851|NCT01363297|DRUG|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2."
48162852|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo electroacupuncture therapy
48513833|NCT02620579|BEHAVIORAL|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
48162853|NCT02754752|PROCEDURE|Electroacupuncture Therapy|Undergo modified electroacupuncture therapy
48162854|NCT02754752|OTHER|Laboratory Biomarker Analysis|Correlative studies
48162855|NCT02754752|OTHER|Quality-of-Life Assessment|Ancillary studies
48162856|NCT02754752|OTHER|Questionnaire Administration|Ancillary studies
48162857|NCT03963583|BEHAVIORAL|HEROIC|"The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals."
48162858|NCT02864342|DEVICE|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
48162859|NCT02864342|DEVICE|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
48162860|NCT04365738|OTHER|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
48162861|NCT06472882|DEVICE|tDCS targeting DLPFC|The anodic electrode will be placed on the left DLPFC (area F3) and the cathode on the right orbitofrontal cortex (area Fp2). Participants will receive 20 minutes of tDCS at 2 mA while seated.
48162862|NCT06472882|DEVICE|tDCS targeting M1|The anodes will be placed over C3 and C4 (according to EEG 10-20 system), and the cathodes over the ipsilateral shoulders. Participants will receive 20 minutes of tDCS at 2 mA while seated.
48162863|NCT06472882|DEVICE|SHAM tDCS|The electrodes will be placed as in the other conditions, but the stimulation will be switched off after 30 seconds, providing an initial stinging sensation without continuous stimulation.
48162864|NCT01510314|BIOLOGICAL|C-reactive protein and procalcitonin dosages|
48162865|NCT00183235|DRUG|aripiprazole (up to 15 mg/day) for 8 days|
48162866|NCT05686681|BEHAVIORAL|Brief Behavioral Activation for Improving Social Connectedness|"Brief Behavioral Activation for Improving Social Connectedness (BBAISC): BBAISC was developed to address social connectedness. Grounded in Behavioral Activation (Lejuez et al., 2011), BBAISC is a structured, 6-session skill-building intervention that has 4 key elements (Pepin et al., 2020):~1. Psychoeducation: Psychoeducation focused on homebound status, social connectedness, and associated changes in behavior.~2. Behavioral Activation intervention rationale: Framing how changing behavior can positively impact social connectedness (i.e., improve social connectedness and reduce loneliness).~3. Exploration of life areas, values, and activities: Focused on identifying life areas and values most relevant to the participant. Then, these values are used to generate activities that are aligned with those values.~4. Activity monitoring and planning: Participants are encouraged to schedule and organize their day based on what is important rather than their current mood or feeling state."
48162867|NCT05359926|OTHER|Experimental|Early urethral foley removal after the surgery
48162868|NCT05359926|OTHER|Active comparator|Delayed urethral foley removal after the surgery
48513834|NCT02620579|BEHAVIORAL|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
48162869|NCT00692250|DRUG|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
48162870|NCT06538831|OTHER|Diet N-P-|Low in saturated fatty acids (SFAs), free sugar and sodium; Low in ultra-processed foods (UPFs)
48162871|NCT06538831|OTHER|Diet N+P-|Rich in SFAs, free sugar and sodium; Low in UPFs
48162872|NCT06538831|OTHER|Diet N-P+|Low in SFAs, free sugar and sodium; High in UPFs
48162873|NCT06538831|OTHER|Diet N+P+|Rich in SFAs, free sugar and sodium; High in UPFs
48162874|NCT03761407|DRUG|100 mg GRT0151Y|100 mg capsule (1 x 100 mg capsule)
48162875|NCT03761407|DRUG|125 mg GRT0151Y|125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
48162876|NCT03761407|DRUG|150 mg GRT0151Y|150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
48162877|NCT03761407|DRUG|225 mg GRT0151Y|Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
48162878|NCT03761407|DRUG|Matching placebo|Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
48162879|NCT06528314|DRUG|Efruxifermin|Administered by subcutaneous injection
48005706|NCT05551806|BEHAVIORAL|Internet-based self-help cognitive behavioural therapy|The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
48005707|NCT05510869|PROCEDURE|"Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally"|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
48005708|NCT05510869|PROCEDURE|Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.|microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
48005709|NCT05510869|PROCEDURE|Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.|small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
48513835|NCT01867983|BEHAVIORAL|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
48162880|NCT06528314|DRUG|Placebo|Administered by subcutaneous injection
48162881|NCT04981184|DEVICE|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
48692052|NCT04891575|BEHAVIORAL|Active Control Intervention educational sessions|The participant will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
48692053|NCT04891575|BEHAVIORAL|Family Dyad Intervention|The participant and a co-participating family member will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
48692054|NCT06284460|DRUG|ASTX029|Given by PO
48692055|NCT06284460|DRUG|ASTX727|Given by PO
48692056|NCT04461639|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
48692057|NCT02160665|DRUG|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
48692058|NCT02160665|DRUG|Vehicle|Vehicle of Test product (G \& W Laboratories, Inc.)
48692059|NCT02160665|DRUG|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
48513836|NCT01867983|BEHAVIORAL|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
48692060|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
48692061|NCT02500407|DRUG|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
48692062|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
48692063|NCT05139316|GENETIC|DTX401|nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)
48692064|NCT05139316|OTHER|Placebo|Normal Saline infusion
48692065|NCT05139316|DRUG|Oral corticosteroids|Participants who receive DTX401 solution will receive oral corticosteroids
48692066|NCT05139316|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo oral corticosteroids to maintain the study blind
48162882|NCT04390451|BEHAVIORAL|Whole Health STEPS|A peer-delivered package of Whole Health services.
48162883|NCT03389321|DRUG|Riociguat (Adempas)|Riociguat film-coated tablets for oral administration at a strength of 1 mg
48162884|NCT03389321|DRUG|Macitentan (Opsumit)|Macitentan film-coated tablets for oral administration at a strength of 10 mg
48513837|NCT01412086|DRUG|No Intervention|No Intervention.
48692067|NCT06658496|DEVICE|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.
48162885|NCT03117842|OTHER|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
48162886|NCT05065892|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
48162888|NCT04271514|DRUG|RPT193|Antagonist of the CCR4 chemokine receptor
48162889|NCT04271514|DRUG|Placebo|Matching placebo
48162890|NCT04717362|DRUG|Natesto Nasal Product|Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
48162891|NCT00468884|DRUG|Increasing doses of GLP-1|
48162892|NCT00468884|DRUG|PYY3-36|
48162893|NCT06425094|DIETARY_SUPPLEMENT|Microalgae Extract Capsules|Tetrasol extract
48162894|NCT06425094|DIETARY_SUPPLEMENT|Placebo|maltodextrin \& vegetable magnesium stearate
48162895|NCT02429232|DRUG|Pioglitazone|Pioglitazone 30mg/tablet once daily
48162896|NCT02429232|DRUG|Linagliptin|Linagliptin 5mg/tablet once daily
48162897|NCT05607485|PROCEDURE|Randomized video numbers|See arm/group description
48162898|NCT03331848|DRUG|Placebo oral capsule|BID
48005710|NCT01495845|OTHER|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
48162899|NCT03331848|DRUG|PXT002331 - 20mg|Oral
48162900|NCT03298347|DRUG|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
48162901|NCT03298347|DRUG|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
48162902|NCT00404508|DRUG|Hydralazine and magnesium valproate|
48162903|NCT03941769|BIOLOGICAL|Recombinant Interleukin-7|Given IM or SC
48162904|NCT02515097|DRUG|IDP-122 Lotion|Medicated topical lotion
48162905|NCT02515097|DRUG|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
48162906|NCT04284722|DRUG|Metformin Hydrochloride|Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
48162907|NCT05071378|BEHAVIORAL|Our Family, Our Voices|Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
48162908|NCT02222844|OTHER|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
48162909|NCT02259569|OTHER|Pressure-controlled ventilation|
48162910|NCT02259569|OTHER|Volume-controlled ventilation|
48162911|NCT04155333|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
48162912|NCT00329498|DRUG|L-Ascorbic Acid|
48162913|NCT00829647|DRUG|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
48162914|NCT05139576|DIAGNOSTIC_TEST|serum 25OHD testing|Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels \>150 ng/ml were contacted via telephone.
48162915|NCT00011778|DRUG|bortezomib|
48162916|NCT00011778|RADIATION|radiation therapy|
48162917|NCT05216952|DRUG|Ulipristal Acetate Tablets|90mg (three 30mg tablets) administered orally once
48162918|NCT05216952|DRUG|Misoprostol Pill|800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
48162919|NCT00424723|DRUG|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
48162920|NCT06549218|DIAGNOSTIC_TEST|newborn genetic screening and whole genome sequencing|newborn genetic screening (panel of treatable diseases); whole genome sequencing (if newborn develops symptoms suggestive of a genetic disease)
48162921|NCT03501888|BEHAVIORAL|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
48162922|NCT03501888|BEHAVIORAL|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
48692068|NCT02820246|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
48162923|NCT05017883|DRUG|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
48162924|NCT03393065|OTHER|Fluid management guided by BLS|We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
48162925|NCT05044078|OTHER|Autogenic Inhibition MET|If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.
48368623|NCT04384276|OTHER|The Weigh Easy System|By use of a small user-friendly luggage scale, the family can easily and safely obtain a weight within the comfort of their own home. Using the Weigh Easy eClipboard, a message will be sent to the family on a weekly basis via Cerner's Message Center that will include a link. The link will be used by parents to enter and submit the patient's current weight. Upon submission, the weight will be transmitted into the patient's EMR after it's reviewed and accepted by a member of the study team. When the weight is received in the system, an alert will be triggered that will notify the study team of its arrival. While the Weigh Easy eClipboard function does qualify as a device, as the investigators will be making clinical decisions based off of the data received through the form, the device is not being used investigationally on this study. The eClipboard function is a standard part of the Cerner framework and has been previously investigated and vetted by for safety and efficacy.
48368624|NCT04384276|OTHER|Retrospective Control|No interventions will be administered to the historical control group.
48692069|NCT05070819|DIAGNOSTIC_TEST|pro-ANP|pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
48692070|NCT04270149|BIOLOGICAL|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
48005711|NCT04288622|OTHER|Weekly standardised, personalised feedback|The ESM-F group will receive standardised ESM-derived feedback immediately followed the weekly ESM data collection procedure, totalling 6 times in the entire intervention period. The feedback will be provided by the researcher in the format of written report and verbal explanation. The feedback on participants' momentary affective state in specific daily life contexts and the association with depressive symptoms will be given. The changes in positive affect level and the number of depressive complaints over the course of the ESM intervention will be shown.
48005712|NCT02781103|OTHER|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
48005713|NCT02781103|OTHER|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
48005714|NCT04708717|BEHAVIORAL|Stimulation Rate|Psychophysical training listening to stimulation rate as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
48005715|NCT04708717|BEHAVIORAL|Electrode Location|Psychophysical training listening to electrode location as a cue for auditory pitch perception. The intervention is the listening rehabilitative exercises. Exercises are completed daily as 30-minute sessions for 2 weeks.
48005716|NCT01819805|DRUG|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
48005717|NCT00539838|DRUG|Prednisone|Oral repeating dose
48005718|NCT00539838|DRUG|Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
48005719|NCT00539838|DRUG|Methylprednisolone|Intravenous repeating dose
48005720|NCT00539838|DRUG|Ocrelizumab|Intravenous repeating dose
48005721|NCT00539838|DRUG|Placebo|Intravenous repeating dose
48162926|NCT05044078|OTHER|Reciprocal Inhibition MET|If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
48162927|NCT03635437|DRUG|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
48162928|NCT03635437|DRUG|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
48162929|NCT00884884|DRUG|Double Placebo|1 capsule daily
48162930|NCT00884884|DRUG|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
48162931|NCT00884884|DRUG|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
48162932|NCT00884884|DRUG|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
48162933|NCT00884884|DRUG|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
48162934|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
48162935|NCT00884884|DRUG|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
48162936|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
48162937|NCT00884884|DRUG|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
48162938|NCT00884884|DRUG|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
48368625|NCT05763030|BEHAVIORAL|Adapted Sleep Well, Bee Well (SWBW)|The SWBW is a 3-week multilevel behavioral sleep intervention that targets organizational (daycare worker-parent), interpersonal (parent-child, daycare worker-child), and individual (child) levels. It provides parent education supporting parent-child interaction at bedtime, helps to adopt a bedtime routine and early bedtime (Table 4). At the beginning of the 3-week intervention period, the parent and teacher co-develop tailored sleep health goals towards meeting the Bedtime, Environment, and Duration (BED) recommendations139-141 for the child. Parents receive an inexpensive bedtime kit, a storybook, and an informational brochure. The parent and child select four activities from the kit to perform at bedtime every night. The brochure has a section for the parents to write sleep goals. During the intervention, daycare teachers provide daily feedback support to parents at pick-up or drop-off. The program has a manualized structured curriculum suitable for use by paraprofessionals.
48368626|NCT02345902|DRUG|Haloperidol|haloperidol 1.25 mg P.O q.d
48368627|NCT02345902|OTHER|Placebo|placebo 1.25 mg P.O q.d
48368628|NCT02345902|OTHER|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
48368629|NCT03679117|BEHAVIORAL|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
48368630|NCT02833779|OTHER|Individual exercises|
48162939|NCT01906645|OTHER|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
48162940|NCT06646224|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.
48162941|NCT01346826|DRUG|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
48162942|NCT01346826|DRUG|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
48368631|NCT02833779|OTHER|Group exercises|
48162943|NCT01346826|DRUG|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
48162944|NCT02389725|DEVICE|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
48162945|NCT02389725|DEVICE|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
48162946|NCT00598858|DRUG|Docetaxel|Given IV
48162947|NCT00598858|DRUG|Prednisone|Given PO
48162948|NCT05107999|DRUG|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
48162949|NCT05107999|DRUG|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
48692071|NCT06426875|DIAGNOSTIC_TEST|Isometric Exercises|Isometric External Rotation (Perform isometric external rotation exercises with a resistance band to strengthen the rotator cuff.) Hold each contraction for 10-15 seconds. Isometric Internal Rotation (Hold each contraction for 10-15 seconds) Isometric Abduction (Supraspinatus). ( each contraction for 10 -15 sec) 10 repetition 3 sets Isometric Adduction (Subscapularis) Overhead Isometric Holds (Hold each contraction for 15-20 seconds) Isometric Shoulder External Rotation Against Resistance: (Hold each contraction for 15-20 seconds) Isometric Shoulder Press (Hold each contraction for 15-20 seconds) 15 to 20 repetitions 4 sets Total duration of 30 to 35 minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week
48005722|NCT00485446|PROCEDURE|blood analysis|
48005723|NCT03460587|DEVICE|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
48005724|NCT03615950|DIAGNOSTIC_TEST|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
48005725|NCT03615950|DIAGNOSTIC_TEST|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
48005726|NCT03615950|DIAGNOSTIC_TEST|Height measurement|Height will be measured at baseline and 12 months.
48005727|NCT03615950|OTHER|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
48005728|NCT05409235|DRUG|OTT166|Participants will receive OTT166 ophthalmic solution
48005729|NCT05409235|DRUG|Vehicle control|Participants will receive vehicle control
48162950|NCT04987034|DEVICE|EchoTip® Insight™|Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
48162951|NCT01014663|BEHAVIORAL|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
48368632|NCT01267682|BEHAVIORAL|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
48692072|NCT01329276|DRUG|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
48005730|NCT05479578|DRUG|Cyclophosphamide|Given PO
48005731|NCT05479578|DRUG|Dexamethasone|Given PO
48005732|NCT00131235|DRUG|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
48005733|NCT00131235|DRUG|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
48692073|NCT06486662|DRUG|OM-85-IN|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
48162952|NCT01014663|BEHAVIORAL|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
48162953|NCT03467789|DRUG|Dietary Vitamin D3 pre-treatment|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is \< 31 ng/mL, and 5 days if the D3 level is \> 31 ng/mL
48162954|NCT03467789|RADIATION|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
48162955|NCT03467789|DRUG|Serum Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
48162956|NCT00161902|DRUG|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
48162957|NCT01502202|DRUG|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
48162958|NCT01502202|DRUG|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
48005734|NCT00131235|DRUG|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
48162959|NCT01502202|DRUG|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
48162960|NCT06647342|DRUG|Bleomycin|In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
48162961|NCT04120064|DRUG|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
48162962|NCT00614536|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
48162963|NCT02504502|OTHER|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
48162964|NCT02189122|DRUG|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
48162965|NCT02189122|DRUG|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
48162966|NCT02189122|DRUG|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
48162967|NCT02189122|DRUG|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
48162968|NCT02189122|DRUG|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
48162969|NCT02189122|DRUG|Placebo|Subjects will take matching placebo for five days.
48692074|NCT06486662|DRUG|Placebo|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
48692075|NCT02921230|DEVICE|Peripheral stenting|stent implantation during the index procedure
48692076|NCT03966963|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
48692077|NCT04551898|DRUG|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
48692078|NCT04551898|DRUG|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
48162970|NCT04106336|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
48162971|NCT00489489|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
48162972|NCT00489489|DRUG|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
48162973|NCT00489489|DRUG|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
48162974|NCT05173506|OTHER|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
48162975|NCT00797186|OTHER|Intensive risk factor management|Aggressive medical and lifestyle therapy.
48162976|NCT04809298|DEVICE|Free-hand therapeutic CT-guided punction for lumbar pain|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
48162977|NCT04809298|DEVICE|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
48162978|NCT03106337|DEVICE|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
48692079|NCT04019288|DRUG|Batiraxcept|Given IV
48692080|NCT04019288|BIOLOGICAL|Durvalumab|Given IV
48162979|NCT04387916|DRUG|KC1036|Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
48162980|NCT02127983|BEHAVIORAL|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention"
48162981|NCT02127983|BEHAVIORAL|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
48162982|NCT06473480|DEVICE|Abott FreeStyle Libre System 2|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
48162983|NCT06473480|DEVICE|Abott Freestyle Libre Pro|The sensor is placed subcutaneously at the back of the participant's upper arm with one insertion and measures the subcutaneous glucose concentration.
48162984|NCT03410095|DIAGNOSTIC_TEST|Brain MRI, cognitive testing, bloodwork|"Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease."
48162985|NCT01145547|DEVICE|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
48692081|NCT04379635|DRUG|Tislelizumab|administered via Intravenous (IV) injection
48162986|NCT00420797|DRUG|10% Phenylephrine hydrochloride gel|
48162987|NCT02860559|BIOLOGICAL|TBX-1400|Hematopoietic stem cells transplantation
48368633|NCT05121818|PROCEDURE|PCI|Primary percutaneous coronary intervention
48368634|NCT04901702|DRUG|Onivyde|Given intravenous on Days 1 and 8
48368635|NCT04901702|DRUG|Talazoparib|Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
48368636|NCT04901702|DRUG|Temozolomide|Given once a day on Days 1-5.
48368637|NCT06423118|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a pair of non-invasive, flexible sensors originally designed for vital signs monitoring in the paediatric intensive care unit.
48368638|NCT05879016|OTHER|Functional Correction Technique|A single I strip will be used for this technique. Taping will be done by applying moderate (25-35%) degree of stretching to the middle 1/3 of the tape, with the stretched area centered on the trigger point. The ends of the tape will be adhered without stretching.
48368639|NCT05879016|OTHER|Fascia Correction Technique|Y tape will be applied to prevent fascia adhesions. In the Y tape application, first the tail strips of the Y will be adhered with maximum tension so that the muscle fiber is transverse. Then it will be glued so that its base is in front of the pain point. No tension will be applied to the ends of the tape. The application will be applied when the patient is in a resting position and his joints are in a tense position.
48692082|NCT04379635|DRUG|Cisplatin injection|administered via IV infusion
48005735|NCT02045771|BEHAVIORAL|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
48005736|NCT02045771|BEHAVIORAL|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
48005737|NCT04999111|BIOLOGICAL|Ad26.COV2.S|Participants will receive IM injection of Ad26.COV2.S.
48005738|NCT05658744|BEHAVIORAL|Video group|Insulin administration video was sent to the mobile phones of the patients assigned to the video group
48162988|NCT06570434|DRUG|budoprutug|monoclonal antibody
48162989|NCT01994135|OTHER|Reference food|Reference food will be used to which test food samples will be compared to.
48005739|NCT04488029|OTHER|PCT|PCT is designed to deliver similar therapy as is conventionally provided in-clinic by a Speech Language Pathologist (SLP), which the patient can access from any location using the application installed on a supported tablet. The device functions by allowing clinicians to create a personalized therapy program for each patient from 75 categories of clinical therapies, which patients may access from their tablet device remotely. The PCT software is comprised primarily of authentication and an algorithm that suggests advancement of the therapy program based on observed patient deficits and progress.
48162990|NCT01994135|OTHER|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
48162991|NCT01994135|OTHER|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
48162992|NCT03568708|DRUG|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
48162993|NCT05854056|PROCEDURE|Accelerated rehabilitation protocol|See Arms section
48005740|NCT04488029|OTHER|Workbooks|Subjects in this group will be provided with a standard regime of paper workbooks (e.g. Workbook for Aphasia: Exercises for Expressive and Receptive Language Functioning; Brubaker, 2006) that are typically used by clinicians to practice therapy tasks with individuals. Notably, the control procedure employed here is similar to that employed on a large-scale study examining technology as a treatment option and involved usual care control group by Palmer and colleagues (2015).
48162994|NCT05854056|PROCEDURE|Conservative rehabilitation protocol|See Arms section
48162995|NCT00003926|DRUG|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
48162996|NCT00003926|DRUG|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
48162997|NCT00003926|DRUG|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
48162998|NCT00003926|DRUG|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
48162999|NCT00003926|DRUG|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
48163000|NCT00003926|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
48163001|NCT03334773|BEHAVIORAL|Nutrition education|
48163002|NCT06326216|OTHER|Non-Interventional Study|Non-interventional study
48163003|NCT05418335|OTHER|Clinical examination, functional status evaluation|Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
48368640|NCT05879016|OTHER|Star Taping Technique|4 I tapes of the same length between 15 cm and 20 cm will be glued on top of each other. After the first I tape is adhered, the 2nd I tape will be adhered at 90 degrees, then the 3rd and 4th I tapes will be adhered at 45 degrees to obtain a star appearance. There will be no tension at the ends of the tapes
48368641|NCT05879016|OTHER|Sham Comparator|I shape tape will be adhered for sham purpose without applying any tension.
48368642|NCT05431816|DIETARY_SUPPLEMENT|Dietary intervention|dietary fiber （Inulin 4g，Resistant Starch 4g，β-glucan 2g）
48368643|NCT05158504|OTHER|Motivation|Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
48368644|NCT04594122|BEHAVIORAL|Improve hygiene practice of pork sellers|includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
48368645|NCT04606797|DRUG|Nicotine patch|Nicotine transdermal patches as per product monograph
48692083|NCT04379635|DRUG|Paclitaxel injection|administered via IV infusion
48163004|NCT06454071|OTHER|Blood test|Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.
48163005|NCT03198351|DRUG|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
48163006|NCT01811628|BEHAVIORAL|Questionnaire|Questionnaire completion taking about 10-15 minutes.
48163007|NCT01811628|BEHAVIORAL|Interview|Audio-recorded interview that will last about 1 hour.
48163008|NCT03016364|DEVICE|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
48163009|NCT04705883|DRUG|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
48163010|NCT06472414|BEHAVIORAL|Individualized Counselling Sessions|Four counselling sessions led by an experienced exercise physiologist will be provided. At the first session, benefits of cardiovascular rehabilitation (CR), functioning of the CR program, barriers to attendance, strategies to overcome them will be explained and discussed, leading to the choice of the best suitable CR modality/schedule. Physical activity (PA) recommendations will be discussed and an action plan to increase/maintain PA levels and decrease sedentary behaviour will be given. WFG will receive access to an online platform where 4 pre-recorded different exercise sessions will be placed, and a booklet to register weekly PA. The second session will be to discuss barriers and facilitators. For the third session PA goals will be re-established, a new action plan constructed and strategies to overcome barriers given. For the final session, overall feedback, results of the intervention, satisfaction, doubts, knowledge acquired and recommendations for the future will be discussed.
48185253|NCT02947100|DRUG|SCD-Omegatex™|"Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose."
48368646|NCT04323345|DIETARY_SUPPLEMENT|Natural Honey|Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.
48005741|NCT04321304|DEVICE|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
48368647|NCT04323345|OTHER|Standard Care|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
48368648|NCT05638594|DRUG|Pyrotinib|320mg, qd
48692084|NCT04379635|DRUG|Pemetrexed Disodium|administered via IV infusion
48005742|NCT04321304|DEVICE|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
48005743|NCT04321304|DEVICE|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
48005744|NCT04086264|DRUG|Azacitidine|Commercially available formulation given subcutaneously (SC) or intravenous (IV)
48005745|NCT04086264|DRUG|IMGN632|Study formulation given intravenously (IV)
48005746|NCT04086264|DRUG|Venetoclax|Commercially available formulation administered orally
48368649|NCT05638594|DRUG|Trastuzumab|8 mg/kg first dose, then 6 mg/kg，q3w
48368650|NCT05638594|DRUG|Dalpiciclib|125mg , qd，d1-21, q4w
48368651|NCT05638594|DRUG|Letrozole|2.5mg，qd
48692085|NCT04379635|DRUG|Placebos|Placebo to match tislelizumab IV infusion
48692086|NCT04379635|DRUG|Carboplatin|administered via IV infusion
48692087|NCT05181618|DRUG|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
48005747|NCT05957133|PROCEDURE|Multicomponent exercise without action observation.|Different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
48005748|NCT05957133|PROCEDURE|Multicomponent exercise associated with action observation|Different exercise modalities are integrated: aerobic, mobility, strength, balance and coordination exercises carried out at all times by the physiotherapist and observed by the participants.
48005749|NCT00972803|DRUG|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
48005750|NCT00972803|DRUG|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
48005751|NCT00972803|DRUG|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
48005752|NCT04640948|DEVICE|High flow nasal therapy|Controlled oxygen administration using at least 20 L/min of flow rate and titrated up as tolerated. Titration of supplemental oxygen to an arterial saturation between 88 - 92%.
48005753|NCT04640948|DEVICE|Low flow oxygen|Controlled oxygen administration using (venturi mask or nasal cannulae) titrated to an arterial saturation between 88 - 92% as the initial oxygen administration method with a flow rate of \<20 L/min.
48692088|NCT06660355|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase inhibitor.
48692089|NCT06660355|DRUG|Prednisone|Prednisone is a glucocorticoid.
48692090|NCT00596557|DRUG|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
48692091|NCT01777464|BIOLOGICAL|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
48692092|NCT01777464|BIOLOGICAL|sham|sham solution
48692093|NCT03299205|BEHAVIORAL|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
48005754|NCT04966338|BIOLOGICAL|Ocrelizumab (CinnaGen, Iran)|Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
48005755|NCT04966338|BIOLOGICAL|Ocrelizumab (Roche, Switzerland)|Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
48005756|NCT03445416|BEHAVIORAL|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
48005757|NCT03445416|BEHAVIORAL|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
48368652|NCT05638594|DRUG|Pertuzumab|840 mg first dose, then 420 mg, q3w
48368653|NCT05638594|DRUG|Docetaxel|75 mg/m2, q3w
48368654|NCT05638594|DRUG|Carboplatin|AUC 6, q3w
48368655|NCT05638594|DRUG|Gonadotropin-releasing hormone agonist|Every 4 weeks for 5 cycles, premenopausal patients only
48368656|NCT01809717|OTHER|Weight Lifting Exercises|
48368657|NCT05474482|OTHER|kinesio taping with exercises|Kinesio taping with full stretch of 75 to 100 % for 2 days session per week and exercises for 3 days session per week for total 8 weeks.
48368658|NCT05474482|OTHER|Kinesio taping without exercises|Kinesio taping with a full stretch of 75 to 100 % for 2 days session per week without exercises for 8 weeks.
48692094|NCT03346421|BEHAVIORAL|diet and physical activity|
48163011|NCT06472414|BEHAVIORAL|Educational Women-Focused Sessions|Five pre-recorded women-focused educational sessions will be placed in an online platform at the end of each month. There will be a first short session explaining the importance of cardiovascular rehabilitation, followed by four sessions regarding: women and cardiovascular disease, benefits of physical exercise in women, women and mental health and women and healthy eating. Each session will have a duration of 10/15 minutes and will be delivered by specialized professionals according to the theme (cardiologists, exercise physiologists, nutritionists, psychologists). After every session, a short Likert-type questionnaire will be applied to assess what they thought of the topic in terms of importance and what they have learned.
48163012|NCT06472414|BEHAVIORAL|Supervised Exercise Training Sessions|Participants will exercise 2-3 times/week (60 min/session), on non-consecutive days, for 6 months (weekly target of 10 kcal/kg). Blood pressure and heart rate (HR) will be measured before and after each session. During exercise, a HR chest strap (POLAR H10) will be used to monitor HR and control intensity. Aerobic prescription will be based on the baseline cardiopulmonary exercise test, each session will start with a 5'-10' minutes warm-up - low to moderate intensity \[\<40% of HR Reserve (HRR), 9-10 Rated Perceived Exertion Borg Scale (RPE)\], mobility and low impact exercises, followed by a 30'-45' minutes of combined training with an aerobic component - moderate intensity (40% to 59% of HRR; 12-14 RPE) using ergometers, aerobic exercises, walking/jogging; and a strength component - 8/10 exercises, 30-80% of 1-Repetition Maximum, 12-15 repetitions, 2 sets - ending with a 5'-10' minute cool down - static/dynamic stretching exercises for all major muscle groups.
48163013|NCT01193283|DRUG|Cyclophosphamide|30 my/kg for 4 days
48163014|NCT01193283|DRUG|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
48163015|NCT03902145|OTHER|Egg|One egg per day for 6 months
48163016|NCT04374019|DRUG|Ivermectin|"Ivermectin:~Days 1-2: Weight \< 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight \> 75kg: 5 tabs (15 mg total daily dose)"
48163017|NCT04374019|DRUG|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
48163018|NCT04374019|DIETARY_SUPPLEMENT|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
48163019|NCT04374019|DRUG|Artesunate|Days 1-14:
48163020|NCT00124137|DEVICE|Aquadex system|
48163021|NCT00124137|DRUG|IV diuretic|
48368659|NCT05474482|OTHER|Kinesio taping without stretch as control|kinesio taping without any stretch for 2 days session per week for total 8 weeks.
48692095|NCT04050787|PROCEDURE|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
48692096|NCT04050787|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
48692097|NCT06532929|DEVICE|Orthopaedic surgeries (ankle)|ankle lateral ligament reconstruction in ligamentoplasty procedures
48163022|NCT04265742|RADIATION|bone densitometry|Bone Mineral Density (BMD), body composition, vertebral fractures
48163023|NCT04265742|RADIATION|High resolution peripheral QCT|High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
48368660|NCT00895999|BEHAVIORAL|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
48692098|NCT06532929|DEVICE|Orthopaedic surgeries (shoulder)|rotator cuff repair
48692099|NCT06532929|DEVICE|Orthopaedic surgeries (knee)|knee cruciate ligaments reconstruction in ligamentoplasty procedures
48692100|NCT06532929|DEVICE|Orthopaedic surgeries|rotator cuff repair or closure of capsule after arthroplasty surgery
48163024|NCT04265742|DIAGNOSTIC_TEST|Collection of biological samples|Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
48163025|NCT04265742|OTHER|questionnaires|Epidemiologic and nutritional questionnaire and physical activity scale
48163026|NCT04265742|OTHER|clinical tests|physical performance tests and grip strenght measurement
48163027|NCT05190224|OTHER|Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.|In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
48163028|NCT04939324|BIOLOGICAL|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~* Blood samples at 2 sites: peripheral vein and tumor-draining vein~* Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
48692101|NCT06532929|DEVICE|Orthopaedic surgeries (foot)|stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
48005758|NCT05137795|DRUG|ZYESAMI™ (aviptadil acetate)|Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer
48005759|NCT05137795|DRUG|Placebo|Normal Saline Inhalation
48163029|NCT00786721|DEVICE|Diffuse Optical Spectroscopy|muscle properties scanning
48163030|NCT00678132|DRUG|AZD 2281|
48005760|NCT05137795|DEVICE|Nebulized administration of ZYESAMI™ or Placebo|Use of 510(k) cleared mesh nebulizer to deliver investigational product
48005761|NCT01918527|DRUG|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
48005762|NCT01918527|DRUG|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
48005763|NCT03676530|DEVICE|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
48163031|NCT00678132|DRUG|Cisplatin|
48163032|NCT00678132|DRUG|Gemcitabine|
48163033|NCT04506359|OTHER|Experimental Group|The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
48368661|NCT00895999|BEHAVIORAL|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
48005764|NCT02096458|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
48368662|NCT02956226|DRUG|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
48692102|NCT04252313|OTHER|Music|Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
48163034|NCT01842919|OTHER|Kinesthetics tests|
48163035|NCT01842919|OTHER|Psychological questionnaires|
48368663|NCT02956226|DRUG|Placebo|Olive oil and flavors solution.
48368664|NCT02956226|DRUG|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
48368665|NCT02930889|DEVICE|Prostate Artery Embolization|Prostate Artery Embolization
48005765|NCT05692661|RADIATION|proton plus carbon ion radiotherapy|CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels \[10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx \].
48005766|NCT03022617|DRUG|Apremilast|
48005767|NCT04886011|COMBINATION_PRODUCT|placebo gel|just methyl cellulose gel was applied to the ulcer
48005768|NCT04886011|COMBINATION_PRODUCT|camel whey protein gel|camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
48005769|NCT01559311|DEVICE|CRT-P OFF|CRT Pacemaker
48005770|NCT01559311|DEVICE|CRT-P ON|CRT Pacemaker
48005771|NCT01559311|DEVICE|DDDR|Dual-chamber, rate-modulated pacemaker
48163036|NCT01842919|OTHER|structural Magnetic ResonanceImaging (MRI)|
48163037|NCT01553578|OTHER|questionnaire administration|Ancillary studies
48163038|NCT01553578|PROCEDURE|therapeutic touch|Receive healing touch therapy
48005772|NCT03616912|DRUG|Baricitinib|Administered orally.
48005773|NCT03616912|DRUG|Placebo|Administered orally.
48005774|NCT03806582|DRUG|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
48005775|NCT06192225|BEHAVIORAL|pre-trained guided slow paced breathing (~6 breaths per minute)|Slow PACE breathing
48005776|NCT04174313|DIAGNOSTIC_TEST|CT scan|"Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning."
48163039|NCT01553578|BEHAVIORAL|management of therapy complications|Receive healing touch therapy
48163040|NCT01553578|BEHAVIORAL|management of therapy complications|Receive guided imagery audiotapes
48163041|NCT01553578|PROCEDURE|standard follow-up care|Receive standard care
48163042|NCT02653066|OTHER|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
48163043|NCT02653066|OTHER|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
48163044|NCT01730742|BEHAVIORAL|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
48163045|NCT01730742|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
48163046|NCT01730742|PROCEDURE|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
48005777|NCT00213148|DRUG|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
48163047|NCT06646484|DIAGNOSTIC_TEST|Impedancemetry evaluation|Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
48692103|NCT05464940|OTHER|Intravenous caffeine|"Group assigned to receive caffeine will receive intravenous(IV) caffeine and sodium benzoate infusion starting at 250-500 mg.~This method will use an automated algorithm that adjusts the flow of the infusion depending on the individual's sex and weight and then in a serial fashion in response to blood caffeine measurements. Serial blood caffeine measurements at pre-determined intervals according to the algorithm will be until a steady state is obtained."
48692104|NCT05464940|OTHER|Masked Placebo|"The patients assigned to the masked placebo will receive 5% dextrose in 0.45% saline using the same infusion protocol for a random length of time that was within 1 standard deviation(SD) of the mean time to achieve a steady state using the caffeine protocol (17+4 min).~To maintain blinding, caffeine blood concentration measurements that will be randomly generated within 2 SDs of the predicted values calculated by the algorithm will be used and verbally communicated for placebo infusions."
48692105|NCT06395896|OTHER|Breast Cancer Prevention Journey Program Group|"The researcher will invite individuals to the study at Necip Fazıl Family Center and conduct a pre-test application. The day and time for the Fight Against Breast Cancer training, which is structured based on the Health Belief Model prepared by the researchers, will be determined and announced to the participants. The training will be held in a single session of 45-60 minutes. Slide presentation and a breast model showing the symptoms of breast cancer will be used as training materials. At the end of the training, it will be announced that free shuttle service will be provided for mammography screening and individuals will be invited to screening. On the specified day and time, participants will be taken to the Cancer Early Diagnosis, Screening and Education Center (KETEM) in Mamak and mammography screening will be performed. After the screening, a post-test will be performed."
48692106|NCT06395896|OTHER|Routine Cancer Screening Program Group|Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Health Ministry of Türkiye offers free mammography screening for breast cancer to women over the age of 40. In this context, women are called to the centers by phone and mammography screening is performed free of charge.
48692107|NCT00178919|DRUG|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
48692108|NCT00178919|DRUG|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
48692109|NCT01604577|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
48692110|NCT00253773|DRUG|acetominophen, sulfer amino acids; cysteine and methionine|
48692111|NCT00453609|DRUG|long-lasting injectable naltrexone|
48692112|NCT02675751|DEVICE|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
48692113|NCT06658704|BEHAVIORAL|Supervised exercise in a group setting|Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16.
48692114|NCT06658704|BEHAVIORAL|Usual care (Physical activity on Prescription)|Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks.
48692115|NCT05346744|OTHER|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
48692116|NCT04142424|DRUG|AZD2693|Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
48692117|NCT04142424|DRUG|Placebo|Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
48692118|NCT05633654|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
48692119|NCT05633654|DRUG|Pembrolizumab|Administered intravenously
48692120|NCT05633654|DRUG|Capecitabine|Tablets administered orally
48692121|NCT04309877|DRUG|Theophylline ER|Capsules of theophylline ER
48692122|NCT04309877|OTHER|PO placebo|Capsules of methylcellulose
48692123|NCT04309877|BIOLOGICAL|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
48005778|NCT00213148|DRUG|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
48005779|NCT00213148|DRUG|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
48163048|NCT01812837|DEVICE|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
48163049|NCT01812837|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
48005780|NCT00213148|DRUG|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
48163050|NCT01812837|RADIATION|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
48005781|NCT00213148|DRUG|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
48163051|NCT06038383|DEVICE|Group A - Intervention with Virtual Reality (VR)|Group of people with kidney disease that performed VR intervention during hemodialysis.
48005782|NCT04287907|DEVICE|Monitor Group|Use of colorimetric end tidal CO2 to guide provider during provision of mask ventilation, where colour change indicates effective breaths
48163052|NCT06038383|DEVICE|Group B - Intervention with Stationary Bike (SB)|Group of people with kidney disease that performed SB intervention during hemodialysis.
48163053|NCT06038383|DEVICE|Group A - Intervention with Stationary Bike (SB) - Crossover|Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.
48163054|NCT06038383|DEVICE|Group B - Intervention with Virtual Reality (VR) - Crossover|Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
48163055|NCT00585208|DRUG|Ramelteon|Ramelteon 8mg daily
48692124|NCT04309877|OTHER|IV placebo|Normal (0.9%) saline
48163056|NCT00585208|DRUG|Placebo|matching placebo for ramelteon 8mg daily
48005783|NCT02501603|DRUG|afatinib|Afatinib 40mg daily oral administration
48163057|NCT05021757|DEVICE|Shockwave C2 Coronary IVL|PCI procedure using a Shockwave C2 coronary IVL catheter
48163058|NCT03386305|DRUG|EnvarsusXR|Patients randomized to study drug will be converted to EnvarsusXR once daily.
48163059|NCT03386305|DRUG|Tacrolimus|Patients continue to take Tacrolimus BID, as a part of routine care.
48163060|NCT02898350|DEVICE|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
48692125|NCT04400019|DRUG|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
48692126|NCT03122808|DIAGNOSTIC_TEST|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
48005784|NCT02501603|DRUG|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
48163061|NCT02898350|DEVICE|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
48163062|NCT02898350|DEVICE|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
48163063|NCT02898350|DEVICE|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
48163064|NCT01910740|OTHER|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
48163065|NCT01910740|OTHER|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
48163066|NCT01910740|OTHER|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
48163067|NCT04323332|DRUG|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
48163068|NCT05018949|PROCEDURE|Lower limb angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
48163069|NCT01695525|OTHER|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
48163070|NCT01829685|DRUG|Entecavir, Adefovir|
48163071|NCT03795935|OTHER|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
48692127|NCT03122808|DIAGNOSTIC_TEST|Partogram Analysis|Analysis of slope of partogram
48692128|NCT03322046|BEHAVIORAL|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
48692129|NCT05997914|BEHAVIORAL|Storytelling Intervention|Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
48005785|NCT01504724|DRUG|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
48005786|NCT04604457|OTHER|Palliative care contacts primary care|Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
48163072|NCT01599377|DRUG|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
48368666|NCT01633762|DRUG|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
48005787|NCT05357872|DEVICE|deep anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
48163073|NCT01599377|DRUG|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
48692130|NCT02644213|OTHER|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control."
48692131|NCT06657859|DRUG|GLM101|GLM101 IV infusion
48163074|NCT05189171|DEVICE|MicroOrganoSphere (MOS) drug screen|Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
48163075|NCT01100268|DRUG|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
48368667|NCT01248429|BIOLOGICAL|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
48368668|NCT01248429|OTHER|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
48368669|NCT03511222|DRUG|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
48368670|NCT03511222|DRUG|Nivolumab|Standard of care
48368671|NCT03511222|DRUG|Pembrolizumab|Standard of care
48513838|NCT04637802|BEHAVIORAL|CBT (SurgeryPal)|The SurgeryPal intervention is a cognitive-behavioral program for youth undergoing major surgery. SurgeryPal is delivered in two 4-week phases: the pre-operative phase, and the post-operative phase. Each phase consists of 3 separate treatment modules for youth and parents, which teach cognitive and behavioral coping skills to target known psychosocial and behavioral risk factors (i.e. anxiety/distress and sleep disturbance) for poorer postsurgical outcomes, and provide training in pain self-management skills. Pre-operative modules include: 1) Preparing for surgery, 2) Coping with stress before surgery, and 3) Getting ready for the hospital. Postoperative modules include: 1) Coping at home after surgery, 2) Return to activities and school, and 3) Long-term recovery. Modules are self-guided and interactive, and focus on phases of preparation and recovery from surgery. The goal of the program is to reduce pain and enhance quality of life following surgery in youth.
48692132|NCT05313269|OTHER|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
48692133|NCT05313269|OTHER|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
48005788|NCT05357872|DEVICE|light anesthesia depth|The anesthesiologist adjusted the intravenous speed of remifentanil and propofol to maintain the bispectral index (BIS, BIS monitor; Aspect Medical System, Newton, MA) between 40-50 and 50-60 during the operation.
48005789|NCT01064895|DEVICE|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
48005790|NCT02757079|DRUG|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
48368672|NCT01365182|BEHAVIORAL|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
48368673|NCT01365182|BEHAVIORAL|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
48368674|NCT05184868|DRUG|AT247|Ultra rapid acting prandial insulin aspart
48368675|NCT05184868|DRUG|NovoLog|Rapid acting prandial insulin aspart
48368676|NCT05184868|DRUG|Fiasp|Fast acting prandial insulin aspart
48368677|NCT01697631|DRUG|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
48368678|NCT01697631|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
48368679|NCT03029793|OTHER|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
48368680|NCT03029793|OTHER|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
48005791|NCT00950534|DRUG|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
48005792|NCT00950534|DRUG|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
48005793|NCT03086174|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
48005794|NCT03325166|DRUG|Ferumoxytol|Given IV
48005795|NCT03325166|OTHER|Laboratory Biomarker Analysis|Correlative studies
48005796|NCT03325166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48005797|NCT03325166|BIOLOGICAL|Pembrolizumab|Given IV
48005798|NCT04355884|DIAGNOSTIC_TEST|Standard 12-lead ECG, NT-proBNP, echocardiography|Cardiac assessment
48005799|NCT04648930|DRUG|Xolair|There was no treatment allocation. Patients administered Xolair by prescription that started before inclusion of the patient into the study were enrolled.
48005800|NCT04187196|DRUG|Propofol|Propofol will be given at an initial dose of 0.8 mg/kg followed by 20 mg every minute after 2 minutes, if adequate sedation is not achieved
48005801|NCT04187196|DRUG|Methohexital|Methohexital will be given at an initial dose of 0.5 mg/kg, followed by 10 mg every minute after 2 minutes, if adequate sedation is not achieved
48005802|NCT05855564|BEHAVIORAL|mindfulness matters|Classroom program will be provided to primary one students in eight primary schools and they will receive an 8 session mindfulness matters program, developed by Eline Snel, delivered by their teachers. Each session lasts for 30 minutes. The program includes mindfulness exercises, psychoeducation, discussion and sharing activities. For students with special needs, same programs will be delivered by teachers or social workers in small groups and each groups has 4 to 7 students. Program content is consistent with the classroom program.
48005803|NCT04675320|BIOLOGICAL|blood samples|Blood sampling during PARP inhibitor therapy
48005804|NCT04978792|BEHAVIORAL|Online self-compassion intervention|An online self-guided intervention that uses widely available exercises and information.
48692134|NCT06156176|OTHER|COVIDEx|The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
48692135|NCT06206291|DRUG|Placebo|Matching placebo twice daily for first 4 weeks
48692136|NCT06206291|DRUG|Cannabidiol (CBD) 200mg|First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
48005805|NCT04978792|BEHAVIORAL|Active Control|Participants will complete written exercises and breathing exercises that are not associated with self-compassion
48005806|NCT03148743|BIOLOGICAL|Fecal microbiota|fecal microbiota transplantation
48005807|NCT00654069|DRUG|Placebo|2 tablets every 6 hours for 48 hours
48005808|NCT00654069|DRUG|Acurox 5/30 mg|2 tablets every 6 hours for 48 hours
48005809|NCT00654069|DRUG|Acurox 7.5/30|2 tablets every 6 hours for 48 hours
48163076|NCT02217241|OTHER|Handoff Workshop|
48163077|NCT00312364|DRUG|MRE0094|
48692137|NCT06206291|DRUG|Cannabidiol (CBD) 400mg|Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
48692138|NCT04109807|OTHER|Ozone|ozone exposure
48692139|NCT04109807|OTHER|FA|Filtered air exposure
48692140|NCT01140100|DRUG|propofol|
48692141|NCT01140100|DRUG|thiopental,propofol|
48005810|NCT00333684|DEVICE|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
48005811|NCT04619056|DRUG|CEB-01 membrane loaded with SN-38|CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.
48005812|NCT06267235|OTHER|Dietary protein restriction|The consumption of different diets restricted in protein replaced by either carbohydrate or fat and an habitual diet.
48005813|NCT03800498|OTHER|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
48005814|NCT05828017|DEVICE|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
48005815|NCT05828017|DEVICE|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
48005816|NCT05466578|DRUG|abrocitinib|
48005817|NCT00186004|DEVICE|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
48163078|NCT00674258|BIOLOGICAL|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
48163079|NCT05484713|DIAGNOSTIC_TEST|Cardiac imaging|Baseline - 2D transthoracic echocardiography, 128-multislice CT coronary angiography, CCTA of peripheral lower limbs vessels 12-months follow-up - 128-multislice CT coronary angiography with transthoracic echocardiography
48163080|NCT05484713|DEVICE|3D printing of the aortic valve|3D printing of the aortic valve based on CCTA image acquisition
48163081|NCT05671744|OTHER|Cell-based non-invasive prenatal testing|Blood sampling
48368681|NCT00456586|DRUG|KW-6002 (istradefylline)|
48692142|NCT06659978|DEVICE|Device tolerance|"After being fed (breastmilk or formula), video will be turned on and the infant is placed on the Gentle Touch Stimulator (GTS) in deactivated mode. After a baseline period of 5- minutes the device will be activated. It will be deactivated after 10 minutes or earlier if there are any signs of distress from the infant. A 10-minute washout observation period will be followed.~Higher levels of comfort will be considered as fewer instances of stress behaviours. The sessions will be videoed, and coded at a later date using Observation of infant behaviours."
48163082|NCT01468025|DRUG|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
48692143|NCT06659978|OTHER|Acceptability questionnaire|Parental and clinical staff acceptability of the device assessed by interviewing person(s) of parental responsibility and clinicians involved in the trial. Interviews will be conducted by researcher following the intervention.
48692144|NCT06655181|DEVICE|Respiratory Muscle Training|Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.
48692145|NCT03907046|DRUG|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
48163083|NCT01468025|OTHER|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
48163084|NCT01468025|DRUG|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
48163085|NCT01940692|DRUG|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
48163086|NCT01940692|DRUG|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
48692146|NCT03907046|DRUG|Aspirin|Aspirin is an oral antiplatelet drug.
48692147|NCT05612061|BEHAVIORAL|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
48692148|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. suturing the nasal conformer in the cleft side
48692149|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. No nasal conformers used in this group
48692150|NCT05636969|BEHAVIORAL|Multimodal prehabilitation|The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.
48692151|NCT03385915|PROCEDURE|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
48692152|NCT04627025|DRUG|apraglutide|Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
48692153|NCT05614609|DRUG|Lidocaine topical|Comparing lidocaine spray and muscle relaxing medication
48692154|NCT06393270|DIAGNOSTIC_TEST|Modified US Public Health Service (USPHS) criteria|Dental caries classification system
48005818|NCT02850874|PROCEDURE|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
48163087|NCT06003738|PROCEDURE|fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of 0.25% bupivacaine will be injected."
48163088|NCT06003738|PROCEDURE|pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of 0.25% bupivacaine will be injected .
48185254|NCT03138642|RADIATION|RT|All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)
48185255|NCT04040218|PROCEDURE|Dry Needling|Dry needling is utilized by multiple practitioners to address impairments in neuromusculoskeletal function, often related to pain and loss of mobility. Dry needling, according the American Physical Therapy Association (APTA), is defined as a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
48368682|NCT06420921|BEHAVIORAL|Speech in noise comprehension test|Speech in noise comprehension tests consisting of listening to a speech source and one or more competing sources (noise, speech or sound cues) simultaneously. The volunteers will have to repeat the speech source in order to assess intelligibility for each situation, as a function of the intensity ratio of the two sources (SNR).
48692155|NCT03404063|DRUG|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
48692156|NCT03404063|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
48692157|NCT05247905|DRUG|Lutetium Lu 177 Dotatate|Given IV
48692158|NCT05247905|DRUG|Capecitabine|Given PO
48692159|NCT05247905|DRUG|Temozolomide|Given PO
48692160|NCT05247905|OTHER|Quality-of-Life Assessment|Ancillary studies
48005819|NCT02850874|PROCEDURE|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
48692161|NCT05247905|OTHER|Questionnaire Administration|Ancillary studies
48692162|NCT05828589|DRUG|BGB-21447|BGB-21447 will be administered orally
48692163|NCT06660810|DRUG|Talimogene Laherparepvec|"Talimogene laherparepvec (HSV-1 \[strain JS1\]/ICP34.5-/ICP47-/hGM-CSF) is an oncolytic immunotherapy, formerly known as OncoVEXGM-CSF, an immune-enhanced, oncolytic herpes simplex virus type 1 (HSV-1)~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
48692164|NCT06660810|RADIATION|Neoadjuvant Radiation|"Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given.~Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec"
48692165|NCT06660810|PROCEDURE|Surgery|Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care
48692166|NCT05303467|DEVICE|TheraSphere GBM|Single treatment of TheraSphere GBM device
48692167|NCT06312579|BEHAVIORAL|12-week home based exercise|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week (Monday, Wednesday and Friday), and strength/balance exercise performed 2 days a week (Tuesday and Thursday).
48692168|NCT06312579|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
48692169|NCT03332173|DRUG|Zanubrutinib|Oral administration using 80 mg capsules
48692170|NCT02083341|DEVICE|Lelo® Siri vibrator|external vibration device
48692171|NCT02083341|DEVICE|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
48692172|NCT06661447|PROCEDURE|Tridimensional Onlay autologous bone graft|A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
48692173|NCT06661447|PROCEDURE|Tridimensional Onlay xenogeneic bone graft|A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
48185256|NCT02574325|DRUG|Placebo|Control
48692174|NCT06661447|PROCEDURE|Tridimensional Onlay allogenic bone graft|A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
48692175|NCT06661525|DEVICE|Free Flap NIRS|Monitoring of tissue oxygenation after Free Tissue Transfer (FTT) surgeries.
48692176|NCT06661655|DEVICE|Liver ultrasound|Hepatoscope is a point of care ultraportable ultrasound device that is capable of conventional grayscale ultrasound imaging, of 2D transient elastography (imaging + liver stiffness measurement), and of quantitative ultrasound properties measurement (ultrasound attenuation, backscattering coefficient, sound speed) related to liver steatosis.
48692177|NCT06054113|DRUG|Blinatumomab|Administered via CIVI
48692178|NCT06653803|PROCEDURE|Rhomboid Intercostal Block (RIB)|Intraoperative Ipsilateral Ultrasound-guided RIB
48692179|NCT06653803|PROCEDURE|Retrolaminar Block (RLB)|Intraoperative Ipsilateral Ultrasound-guided RLB
48692180|NCT05051670|PROCEDURE|da vinc SP gastrectomy|radical subtotal gastrectomy performed by da vinci SP
48692181|NCT03029182|OTHER|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
48692182|NCT03029182|BEHAVIORAL|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
48005820|NCT02850874|DRUG|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
48005821|NCT03195959|OTHER|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
48163089|NCT06003738|PROCEDURE|palcebo fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of normal saline will be injected."
48163090|NCT06003738|PROCEDURE|palcebo pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of normal saline will be injected .
48163091|NCT00003478|PROCEDURE|conventional surgery|
48163092|NCT00003478|RADIATION|iodine I 131 monoclonal antibody 81C6|
48163093|NCT00003478|RADIATION|radiation therapy|
48005822|NCT02643251|DRUG|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
48163094|NCT01026103|DEVICE|Tri Staple Technology stapler|This is a single arm study.
48005823|NCT02643251|DRUG|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
48163095|NCT03220659|DEVICE|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
48005824|NCT01514552|OTHER|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
48692183|NCT04976881|BEHAVIORAL|Medication Reconciliation (MedRec) Tool|Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
48005825|NCT01514552|OTHER|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
48005826|NCT03108248|DRUG|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
48163096|NCT03220659|DEVICE|Standard settings|Normal bipolar LV pacing
48163097|NCT06127485|PROCEDURE|Neuropilates+occupational therapy and physiotherapy conventional|Participants assigned to the experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physical therapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method. Pilates routines will be performed on a mat through the practice of Pilates activation exercises. Each participant will be given the necessary adaptations of each exercise according to their difficulties/disabilities.
48163098|NCT06127485|PROCEDURE|Occupational Therapy and Physiotherapy conventional|Conventional physical therapy in both groups will include stretching techniques and muscle activation of the lower limb and gait reeducation. Conventional occupational therapy will include stretching techniques and muscle activation in the upper limb as well as training in activities of daily living and functional activities of the upper limb.
48163099|NCT02639078|DRUG|TD-0714|One time dosing in capsule formulation
48163100|NCT02639078|DRUG|Placebo Comparator|One time dosing in capsule formulation
48163101|NCT01289197|BEHAVIORAL|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
48163102|NCT05627583|OTHER|Rehabilitation|Hospitalized patients with AN under treatment for rehabilitation
48163103|NCT01024036|DRUG|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
48163104|NCT01024036|DRUG|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
48163105|NCT01024036|DRUG|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
48163106|NCT04682340|DIAGNOSTIC_TEST|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
48163107|NCT03609671|BEHAVIORAL|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
48163108|NCT03609671|OTHER|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
48368683|NCT06420921|BEHAVIORAL|Objective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. The volunteers will have to identify sound cues in order to assess the ability to perceive the sound environment for each situation, depending on the intensity ratio of the different sources.
48368684|NCT06420921|BEHAVIORAL|Subjective tests of perception of ambient sound cues in noise|Tests of perception of the sound environment consisting of listening to a source of noise, sound cues and a competing source of speech simultaneously. Using a simple interface, the volunteers will have to identify the intensity ratio of the sources that they consider to be the best compromise between understanding speech and perceiving the sound environment.
48692184|NCT04976881|BEHAVIORAL|Provider Alert and Decision Support|During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
48692185|NCT04976881|BEHAVIORAL|PREPSheet|When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
48692186|NCT04976881|BEHAVIORAL|Text Messaging|Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
48368685|NCT00867594|DRUG|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
48368686|NCT00412555|DRUG|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
48692187|NCT04776616|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
48368687|NCT03287960|DRUG|Setmelanotide|Once daily subcutaneous injection
48692188|NCT04776616|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
48692189|NCT06191874|OTHER|Standard-of-care (SOC) surgery plan|Use of SOC clinical planning tools to prepare for DBS (deep brain stimulation) surgery
48692190|NCT06191874|OTHER|HoloDBS hypothetical surgery plan|Use of next generation visualization tools and surgical targeting models to hypothetically prepare for DBS (deep brain stimulation) surgery
48692191|NCT05712785|DEVICE|Use of shuotong ureteroscopy|Treatment of patients with ureteral stones using the Shuotong-scopy
48692192|NCT03955783|DRUG|Venetoclax|Given by mouth
48692193|NCT03955783|DRUG|Selinexor|Given by mouth
48692194|NCT04904406|DRUG|Dolutegravir / Lamivudine Oral Tablet|Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
48692195|NCT00211354|DRUG|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
48005827|NCT03108248|DEVICE|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
48005828|NCT03458130|DRUG|AG10|TTR stabilizer
48005829|NCT03458130|DRUG|Placebo Oral Tablet|Nonactive control
48005830|NCT03904706|OTHER|Audits only|Formalized audit teams with monthly meetings at each facility.
48005831|NCT03904706|OTHER|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
48005832|NCT04332328|DIETARY_SUPPLEMENT|Diet|Group of diet types
48005833|NCT01864291|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
48005834|NCT02809703|OTHER|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
48005835|NCT00072865|DRUG|Pemetrexed|
48005836|NCT00072865|DRUG|Carboplatin|
48005837|NCT01150695|OTHER|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
48005838|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine \[approximately 1x10\^9 colony forming units (cfu)/mL\] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
48163109|NCT03439345|DRUG|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
48163110|NCT03439345|DRUG|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
48185257|NCT02574325|DRUG|ARI-3037MO|Treatment
48185258|NCT02960503|DRUG|Azithromycin|Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
48005839|NCT01150695|BIOLOGICAL|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10\^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
48005840|NCT03367312|DRUG|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
48692196|NCT06659484|DIAGNOSTIC_TEST|Assessment|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 (after the exercise program at around 3 months) including:~1. Clinical assessment by a geriatrician~   * Medical history; systematic search for symptomatic elements (asthenia, anorexia, weight loss); research into antecedents (chronic pathologies, etc.), treatments, lifestyle, eating habits, sedentary lifestyle,~  * Complete clinical examination: particularly of the musculoskeletal system, morphological data (weight and height, calf circumference), analysis of risk of falls,~  * Current medical treatments~  * Autonomy for basic activities (ADL), instrumental activities of daily living (IADL), visual disorders, hearing impairment, etc.~  * Assessment of comorbidities (Charlson score)~  * Screening for sarcopenia (using the SARC-F questionnaire),~  * An inventory of falls and their traumatic consequences,~  * Assessment of frailty status using FRIED criteria,~2. Nutritional assessment :~   * nutritional status will also be asses"
48692197|NCT06659484|OTHER|Multicomponent exercise program|"After inclusion in the protocol, participants with mobility disability risk factors are assigned to specialized and experienced kinesiologists at the end of the medical consultation.~Patients will be invited to take part in group-based exercise sessions, in small groups of no more than 10 patients, under the supervision of a kinesiologist. There will be 20 sessions over 10 weeks, at a rate of 2 sessions per week, each lasting one hour. The Multicomponent exercise program included progressive resistance and balance training."
48163111|NCT03942276|OTHER|High intensity interval training|Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate\> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.
48163112|NCT03942276|OTHER|Moderate intensity continuous training|Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
48163113|NCT03942276|OTHER|Control|Consist of performing no exercise training.
48368688|NCT03287960|DRUG|Placebo|Once daily subcutaneous injection
48005841|NCT00816868|DRUG|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
48368689|NCT00850213|DEVICE|Endeavor Resolute Stent|Single implantation
48368690|NCT05555134|BEHAVIORAL|educational intervention|will also have an extra educational intervention, a group intervention (4-6 people) through a one-hour training session via zoom, which will be given by the PI (extensive experience in the subject) a week after discharge from the ER. Information will be reinforced and doubts will be solved
48692198|NCT06659484|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3 + 6 months :~- After the T3 visit, patients will either be redirected to independent practice (booklet) or to relay structures. At T3 + 6 months (6 months after the 3-month visit), the kinesiologists will call each patient to assess their compliance with the program, any difficulties encountered, any falls (and their severity and consequences), fear of falling, their level of ADL/IADL autonomy, level of PA practice (RAPA), presence of frailty appreciation (FRIED), whether or not they have entered an institution.~Follow-up at T3 + 12 months :~At T3+12 months (12 months after the 3-month visit), patients will be seen again by the kinesiologists to make a final assessment of their physical and functional conditions, with measurements (Handgrip, SPPB, TUG, gait parameters, leg strength) and questionnaires (SarQol and FES-I).~Patients will only be seen again by the kinesilogists, as this is mainly a check-up and final advice visit, to continue the exercises performed since."
48692199|NCT06661382|BIOLOGICAL|Infiltrative treatment with CB-PRP|Injection of CB-PRP or placebo into the vulvar site. Three treatments are planned four weeks apart. Three and six months after the last treatment with CB-PRP/ placebo each participant will be re-evaluated by vulvoscopy and biopsy, and will be given validated questionnaires to assess satisfaction, symptoms, and quality of life, psychological state, and sexual function.
48692200|NCT05844943|DEVICE|ReHeal glove with Negative Pressure Wound Therapy (NPWT)|ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).
48692201|NCT06661538|BEHAVIORAL|Food Security Screening & Referral Program|The I-FRESH (Implementing Food Referrals for Equity and Sustained Health) program is the food security nutrition support program that involves some combination and form of: 1) screening and identification of families experiencing food insecurity; 2) discussions with families to determine readiness to engage with nutrition support programs and other community resources; 3) referrals and support to engage with a program; and 4) conducting follow-up assessments to determine fit of program, track utilization, and assess need for additional referrals. The exact implementation and workflow for this program will be optimized for each clinic.
48692202|NCT04507828|RADIATION|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
48692203|NCT06539338|GENETIC|INT2104|INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
48692204|NCT04400916|DRUG|Tranexamic acid|A single drop administered topically
48692205|NCT04400916|OTHER|Balanced Salt Solution|A single drop administered topically
48692206|NCT05041907|DRUG|Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
48692207|NCT05041907|DRUG|Nitazoxanide|Nitazoxanide 1.5g BD 7/7
48692208|NCT05041907|DRUG|Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
48692209|NCT05041907|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
48692210|NCT05041907|OTHER|No treatment|No treatment (except antipyretics- paracetamol)
48692211|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
48163114|NCT06084260|DIETARY_SUPPLEMENT|Diet group|Individual diet, with caloric restriction, associated with weekly meetings about eating habits modifications.
48368691|NCT01430520|DRUG|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
48692212|NCT05041907|DRUG|Fluoxetine|Fluoxetine 40mg OD for 7/7
48163115|NCT06084260|BEHAVIORAL|Self-compassion group|Weekly meetings using self-compassion techniques to improve body dissatisfaction and eating behavior.
48692213|NCT05041907|DRUG|Molnupiravir|Molnupiravir 800mg BD for 5/7
48692214|NCT05041907|DRUG|Sotrovimab|Sotrovimab 500mg given once on D0
48692215|NCT05041907|DRUG|Ensitrelvir|Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
48692216|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
48692217|NCT05041907|DRUG|Favipiravir|Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
48692218|NCT05041907|DRUG|Ivermectin|Ivermectin 600micrograms/kg/day for 7/7.
48692219|NCT05041907|DRUG|Remdesivir|Remdesivir 200mg D0 and 100mg for a further 4/7.
48692220|NCT05041907|DRUG|Atilotrelvir/ritonavir|Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
48692221|NCT05041907|DRUG|Metformin|Metformin 500mg TDS 5/7
48185259|NCT02960503|OTHER|Placebo|Study participants will be randomized to the control arm (placebo three times a week for 6 months).
48368692|NCT01430520|DRUG|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
48692222|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
48692223|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
48692224|NCT05041907|DRUG|Nirmatrelvir|Nirmatrelvir 300mg BD for 5/7
48692225|NCT01519687|DRUG|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
48692226|NCT05200611|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
48692227|NCT04556591|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
48692228|NCT04556591|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
48692229|NCT02258971|DRUG|BEA 2180 BR oral|Oral solution
48692230|NCT02258971|DRUG|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
48692231|NCT05563805|DEVICE|Virtual Reality-based physical activity intervention|The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
48692232|NCT00372619|DRUG|clofarabine|Given IV for 5 days
48692233|NCT00372619|DRUG|cytarabine|Given IV
48692234|NCT00372619|DRUG|methotrexate|Given intrathecally or IT age based dosage
48692235|NCT00372619|OTHER|laboratory biomarker analysis|
48692236|NCT02293967|DRUG|MT-1303|
48692237|NCT06252870|DRUG|Methotrexate|15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
48692238|NCT06252870|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
48692239|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
48692240|NCT06252870|DRUG|Cycophosphamide|Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
48692241|NCT06252870|DRUG|Anti-Thymoglobulin|Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
48692242|NCT06252870|RADIATION|total body irradiation|2 grays on Day-1 before graft (=Day0)
48692243|NCT06252870|OTHER|hematopoietic stem cells|High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
48692244|NCT06252870|OTHER|Graft nuclear cells|Graft nuclear cells CD3+ cells if needed after transplantation
48692245|NCT06252870|OTHER|Donor Lymphocytes Injection|DLI with CD3+ if relapse after transplantation or in prevention of relapse
48692246|NCT06252870|DRUG|Clofarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
48005842|NCT00881946|DRUG|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
48163116|NCT06645795|COMBINATION_PRODUCT|Robot assisted gait training plus conventional physical therapy|Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.
48692247|NCT06252870|DRUG|Thiotepa|Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
48692248|NCT06252870|DRUG|Busulfan|Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
48692249|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
48692250|NCT05103384|OTHER|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
48692251|NCT02388477|DRUG|Doxycycline|antibiotic used to treat infection
48692252|NCT02388477|DRUG|sugar pill|placebo with no pharmacologic effect
48692253|NCT03367962|DRUG|[18F]F-Ara-G|the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
48692254|NCT04234009|OTHER|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
48692255|NCT05126511|DEVICE|Application of CES via ear clips|Use of 100µA CES for one hour per day over PR program
48692256|NCT05126511|DEVICE|Sham: No application of CES via ear clips|Use of Sham CES for one hour per day over PR programm
48692257|NCT00328887|GENETIC|CD40 Gene Transfer|gene transfer, intratumoral administration
48692258|NCT06661356|BEHAVIORAL|COMPrEP|Participants will be paired with peer lay workers and will meet with peer lay workers at private community location. They will discuss options for oral PrEP with peer lay workers and be provided provide daily oral PrEP or event-driven (2-1-1) PrEP. Participants will take part in rapid HIV testing at each visit. They will also meet with peer lay workers at private community location for follow-up at 1,3,6,9, and 12 months
48692259|NCT05912894|PROCEDURE|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
48692260|NCT04806061|DRUG|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH \>7.5
48163117|NCT06645795|OTHER|Conventional pjysical therapy|Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.
48163118|NCT01641289|DRUG|Paracetamol|\>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
48163119|NCT01641289|DRUG|No Paracetamol|"No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
48163120|NCT02248753|DRUG|Pharmacological cardioversion - Flecainide|
48692261|NCT04806061|DRUG|standard care|standard care
48692262|NCT06131983|DRUG|ARO-DUX4 for Injection|single or multiple doses of ARO-DUX4 by intravenous (IV) infusion
48692263|NCT06131983|DRUG|Placebo|calculated volume to match active treatment by IV infusion
48692264|NCT02812264|BEHAVIORAL|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
48692265|NCT02812264|BEHAVIORAL|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
48692266|NCT02812264|BEHAVIORAL|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
48692267|NCT02812264|BEHAVIORAL|scale|Connected scale that will transfer weight information to app
48692268|NCT02181491|OTHER|[11C]-P943|
48692269|NCT03280849|OTHER|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
48692270|NCT05704257|DEVICE|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the gastroschisis.
48692271|NCT03889340|DEVICE|IQool|Subjects will undergo hypothermia therapy with the IQool system
48692272|NCT00964002|DRUG|efavirenz|
48163121|NCT02248753|PROCEDURE|Electrical cardioversion|
48163122|NCT02248753|DRUG|Metoprolol|
48163123|NCT02248753|DRUG|Verapamil|
48163124|NCT02248753|DRUG|Digoxin|
48163125|NCT02248753|DRUG|Pharmacological cardioversion - Amiodarone|
48163126|NCT00065234|PROCEDURE|Acupuncture|
48163127|NCT01296178|DRUG|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
48163128|NCT01296178|DRUG|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
48163129|NCT01107353|DRUG|Imipramine Pamoate|75 mg capsule
48163130|NCT00402584|DRUG|sibutramine|
48163131|NCT05273177|OTHER|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
48163132|NCT04768751|DIAGNOSTIC_TEST|kidney assessment|Urea, BUN, and Creatinine BLOOD LEVELS
48163133|NCT04177732|DIAGNOSTIC_TEST|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
48692273|NCT02353819|RADIATION|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
48692274|NCT03673085|DRUG|CN128|CN128
48692275|NCT03673085|OTHER|placebo|The tablets without CN128
48692276|NCT05006716|DRUG|BGB-16673|Orally administered
48692277|NCT04636840|DEVICE|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
48692278|NCT03832322|PROCEDURE|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
48692279|NCT03832322|PROCEDURE|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
48692280|NCT01804686|DRUG|Ibrutinib|Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
48692281|NCT04309851|DIAGNOSTIC_TEST|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
48005843|NCT03061539|DRUG|Nivolumab & Ipilimumab|"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
48005844|NCT05439603|DRUG|ANC-501|Five 10 mg capsules per day
48005845|NCT01040585|DRUG|Linezolid|Treatment for VAP as indication approved and as physician criterium.
48692282|NCT06433687|DEVICE|HekaHeart platform medication management and remote monitoring|Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.
48005846|NCT05289596|BEHAVIORAL|Sleep Healthy Using the Internet (SHUT-i)|SHUTi is a six session, 6-8 week cognitive behavioral therapy for insomnia program over the internet. The online, self-paced program offers illustrations, graphics, videos and built-in algorithms offering brief sleep diaries, personalized sleep window recommendations, education from sleep experts, peer stories about insomnia, and skills to help participants relearn proper sleep dynamics and increase sleep efficiency.
48692283|NCT06659302|BEHAVIORAL|I-inTERACT North Step 1|Initial questionnaires completed followed by initial meeting with therapist for baseline evaluation.
48692284|NCT06659302|BEHAVIORAL|I-inTERACT North step 2|Two online modules completed by family plus two online zoom coaching sessions with therapist.
48692285|NCT06659302|BEHAVIORAL|I-inTERACT North|Full program will consist of an additional 5 sessions with online modules and virtual coaching sessions with therapist.
48692286|NCT04746118|BEHAVIORAL|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
48692287|NCT04746118|BEHAVIORAL|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
48692288|NCT04746118|OTHER|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
48692289|NCT06499415|DRUG|5FU-Calcipotriol|topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
48692290|NCT06499415|DRUG|5-FU 50 MG/ML Topical Cream|topical 5FU, twice daily, 7 days a week, during 4 weeks
48692291|NCT03989375|DEVICE|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
48692292|NCT03370380|DRUG|Aflibercept|Patients are treated according to authorization of Aflibercept
48692293|NCT05322291|BEHAVIORAL|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
48692294|NCT03028415|DEVICE|AMPLEX|A bone graft substitute
48692295|NCT03028415|PROCEDURE|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
48692296|NCT02402205|BEHAVIORAL|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
48005847|NCT05585814|DRUG|Capecitabine|Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3weeks for 3 cycles
48005848|NCT05585814|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 3cycles
48005849|NCT05585814|DRUG|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 3 cycles
48005850|NCT05585814|DRUG|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
48005851|NCT02126540|DEVICE|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
48005852|NCT04902495|OTHER|MTA Pro Root|pulp therapy
48005853|NCT04902495|OTHER|MTA HP Repair|pulp therapy
48005854|NCT04902495|OTHER|Biodentine|pulp therapy
48005855|NCT03270046|PROCEDURE|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
48005856|NCT02845752|DRUG|Stiolto Respimat|Oral inhalation spray
48005857|NCT02845752|DRUG|Placebo Respimat|Oral inhalation spray
48005858|NCT02849548|DRUG|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
48005859|NCT02849548|OTHER|placebo|Pill with inactive ingredients
48005860|NCT05686512|BEHAVIORAL|Step-by-Step|"The Step-by-Step follows a stepped care approach, were all children (and caregivers) complete the first step (a brief group intervention followed by an individual session). Those with more needs are offered to continue to step 2 where individual CBT is given. See Figure 1 for a schematic representation of the stepped care approach, and Table 2 for an overview of session content.~Step 1 Session 1-4: Group sessions including psychoeducation, parenting skills and mapping stress and vulnerability factors, exposure and coping skills (90 minutes) Session 5: Individual session - If ending after step 1 a maintenance plan is completed. If continuing to step 2 continued exposure and selection of optional focus areas such as emotion regulation, social skills, stress- and vulnerability factors, child worry or parental worry. (45 minutes)~Step 2 Session 6-8: Individual sessions - Exposure and selected focus areas. (45 minutes)"
48005861|NCT05686512|BEHAVIORAL|Cool Kids|"The Cool Kids Program is an Australian manualized group CBT treatment of child anxiety, which has been broadly implemented in Sweden. Several studies have found evidence of its efficacy.~Session 1-10: Group sessions including psychoeducation, cognitive restructuring (gather evidence to reevaluate anxiety related thoughts), parent skills, exposure, social skills, coping skills (cognitive and behavioral strategies to handle anxiety reactions, learning problem-solving skills). (120 minutes)"
48005862|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
48005863|NCT01467232|BIOLOGICAL|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
48005864|NCT03151759|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
48005865|NCT00838565|DRUG|Placebo|intravenous infusion on three consecutive months
48005866|NCT00838565|DRUG|dose level 1|intravenous infusion on three consecutive months
48005867|NCT00838565|DRUG|dose level 2|intravenous infusion on three consecutive months
48005868|NCT00838565|DRUG|dose level 3|intravenous infusion on three consecutive months
48005869|NCT00838565|DRUG|dose level 4|intravenous infusion on 3 consecutive months
48163134|NCT04177732|DIAGNOSTIC_TEST|Probing depth|Williams SE manual probe will be used to measure the probing depth
48163135|NCT04177732|DIAGNOSTIC_TEST|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
48163136|NCT04177732|DIAGNOSTIC_TEST|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
48692297|NCT05750056|DRUG|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
48692298|NCT05750056|DRUG|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
48005870|NCT04917276|DIAGNOSTIC_TEST|Circulating tumor cell|Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)
48005871|NCT03810066|DRUG|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
48005872|NCT03703635|DEVICE|intracranial balloon angioplasty|A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter \[Sinomed Inc., Tianjin, China\]) is navigated by the microwire to the lesion of the target artery.
48005873|NCT03703635|DRUG|aggressive medical management|Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.
48005874|NCT03844126|OTHER|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
48005875|NCT05605262|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
48005876|NCT02805530|OTHER|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
48005877|NCT02805530|OTHER|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
48005878|NCT02805530|RADIATION|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
48163137|NCT04177732|DIAGNOSTIC_TEST|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
48163138|NCT05811455|OTHER|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
48163139|NCT05811455|OTHER|Progressive muscle relaxation|progressive muscle relaxation exercises.
48163140|NCT04999683|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory diet for 14 days
48005879|NCT02805530|OTHER|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
48005880|NCT03431116|RADIATION|ultrasound|to detect the placental site
48005881|NCT05252533|DRUG|Ustekinumab|This study does not provide dosing instructions for ustekinumab but will engage participants who have been treated with ustekinumab by their corresponding HCPs independent of this study.
48692299|NCT05750056|DRUG|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
48005882|NCT02334228|BEHAVIORAL|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
48005883|NCT02334228|BEHAVIORAL|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
48005884|NCT05037838|PROCEDURE|Longitudinal strain obtained thanks to transesophageal ultrasound data recorded during liver transplantation|Longitudinal strain of Left Ventricule and longitudinal strain of Right Ventricule free wall obtained thanks to TransEosophagal Ultrasound performed during the Liver Transplant
48005885|NCT03470337|DRUG|Phlogenzym|Bromelain / Trypsin / Rutoside
48005886|NCT03470337|OTHER|Placebo|
48005887|NCT00366392|DEVICE|Optical Aids|
48005888|NCT04385784|OTHER|Balance exercise program.|Multimodal exercise program that combines strength, mobility, elasticity and postural control exercises. It develops once a week for a total of 24 weeks. Each session lasts one hour and is carried out in small groups of 8 to 10 people maximum.
48005889|NCT04385784|OTHER|Home-based exercise program.|Exercises based on the OTAGO program that are carried out at home without supervision. Participants are explained to carry out the program three or four times a week in a safely way.
48005890|NCT06193902|BIOLOGICAL|LEU011|Immunotherapy
48005891|NCT00365326|BIOLOGICAL|Catheter-based intracoronary injection|This Phase I single arm clinical study, was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO.
48005892|NCT00004066|BIOLOGICAL|filgrastim|
48692300|NCT05750056|DRUG|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
48692301|NCT06159244|OTHER|stool withdrawal|stool withdrawal at day 0 and day 7
48692302|NCT06548165|DEVICE|Wearable|Participants will wear an electrode on the chest for the measurement of the heart rate variability, a sensor for temperature measurement, and a sensor for continuous blood glucose measurement. Food intake will be recorded via pictures. One mixed meal tolerance test will be performed as a reference for further analyses. Females have the option to use a device for intravaginal temperature measurement.
48692303|NCT06170463|DRUG|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
48163141|NCT01858064|DRUG|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
48163142|NCT05388149|DRUG|Neratinib|Neratinib administered as 40mg tablets
48692304|NCT06170463|DRUG|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
48692305|NCT06170463|DRUG|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
48692306|NCT05502718|OTHER|Stretching and Strengthening Exercises|The patients in the study group will be given exercise videos. These exercise videos will be selected in accordance with the patient's cervical dystonia type (Torticollis, laterocollis, retrocollis, anterocollis). During the exercises, stretching exercises will be applied to the muscle groups that cause dystonia, and isometric strengthening exercises will be applied to the contralateral muscle groups. Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week. Patients will be asked to mark after each exercise on the exercise chart prepared to determine continuity and compliance with exercise. Patients will be called and followed up on a weekly basis with the exercise chart given to the patients and by telephone.
48005893|NCT00004066|DRUG|docetaxel|
48005894|NCT00004066|DRUG|gemcitabine hydrochloride|
48005895|NCT03521258|DEVICE|Dehydrated Human Amnion/Chorion Membrane|
48005896|NCT03521258|PROCEDURE|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
48163143|NCT03716947|PROCEDURE|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
48368693|NCT02585089|OTHER|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
48692307|NCT05502718|OTHER|Breathing and Rhythmic Coordination Exercises|The patients in the study group will be given exercise videos prepared in the Department of Physical Medicine and Rehabilitation of Ankara University Faculty of Medicine. . Videos including breathing exercises and rhythmic coordination exercises will also be given to all patients in the study and control groups. Patients will be asked to do these exercises for 10 repetitions, three times a day, five days a week.
48692308|NCT06529003|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) unit|All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
48692309|NCT06529003|DEVICE|Placebo|Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
48692310|NCT03126916|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HSCT
48692311|NCT03126916|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48692312|NCT03126916|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48692313|NCT03126916|DRUG|Busulfan|Given IV
48692314|NCT03126916|DRUG|Carboplatin|Given IV
48692315|NCT03126916|DRUG|Cisplatin|Given IV
48692316|NCT03126916|PROCEDURE|Computed Tomography|Undergo CT scan
48692317|NCT03126916|DRUG|Cyclophosphamide|Given IV
48692318|NCT03126916|DRUG|Dexrazoxane Hydrochloride|Given IV
48692319|NCT03126916|BIOLOGICAL|Dinutuximab|Given IV
48692320|NCT03126916|DRUG|Doxorubicin Hydrochloride|Given IV
48692321|NCT03126916|PROCEDURE|Echocardiography|Undergo echocardiography
48692322|NCT03126916|DRUG|Etoposide Phosphate|Given IV
48692323|NCT03126916|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48692324|NCT03126916|RADIATION|Iobenguane I-123|Given 123 I-MIBG
48692325|NCT03126916|RADIATION|Iobenguane I-131|Given IV
48368694|NCT02585089|OTHER|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
48163144|NCT03716947|PROCEDURE|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
48368695|NCT06279169|BEHAVIORAL|Heart Sound|In the Heart sound group, this sound will be played to the newborn 5 minutes before Hep B vaccine administration, during the procedure (at 1 minute) and 5 minutes after Hep B vaccine administration
48368696|NCT06279169|BEHAVIORAL|White Noise|"Musician Osman Orhan's song Bebeğiniz Ağlamasın from his album Kolik will be used for white noise. The volume will be set to 45 db."
48692326|NCT03126916|DRUG|Isotretinoin|Given PO
48692327|NCT03126916|DRUG|Lorlatinib|Given PO
48692328|NCT03126916|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48692329|NCT03126916|DRUG|Melphalan Hydrochloride|Given IV
48692330|NCT03126916|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48692331|NCT03126916|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48692332|NCT03126916|BIOLOGICAL|Sargramostim|Given SC
48692333|NCT03126916|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
48692334|NCT03126916|DRUG|Thiotepa|Given IV
48692335|NCT03126916|DRUG|Topotecan Hydrochloride|Given IV
48692336|NCT03126916|DRUG|Vincristine Sulfate|Given IV
48692337|NCT04963036|OTHER|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
48692338|NCT04963036|OTHER|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate...), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
48692339|NCT04317521|DEVICE|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
48005897|NCT04054687|DRUG|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
48005898|NCT04054687|OTHER|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
48005899|NCT04294004|COMBINATION_PRODUCT|TGplPTH1-34 in fibrin|TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage
48005900|NCT04294004|OTHER|Autologous Bone Graft|Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.
48005901|NCT06306456|DRUG|GH21|Oral, 15mg BIW/6mg QD
48005902|NCT06306456|DRUG|Tagrisso|Oral, 80mg QD
48692340|NCT04058561|DEVICE|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
48692341|NCT00090779|DRUG|Emtricitabine/ tenofovir disoproxil fumarate|once daily
48005903|NCT03420703|OTHER|erector spinae plane block|ultrasound guided erector spinae plane block will be administered to this group.
48005904|NCT03420703|DEVICE|Intravenous morphine patient controlled analgesia device|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
48005905|NCT01899599|DRUG|PankoMab-GEX|start dose 500mg at C0D1, maintenance dose 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
48005906|NCT01899599|DRUG|Placebo|start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
48005907|NCT00354445|DRUG|pegaptanib sodium (Macugen)|
48163145|NCT03716947|PROCEDURE|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
48005908|NCT01192152|DRUG|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
48005909|NCT01192152|DRUG|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
48692342|NCT00090779|DRUG|Lopinavir/Ritonavir|twice daily
48005910|NCT01192152|DRUG|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
48005911|NCT00003256|DRUG|alvocidib|
48005912|NCT05596760|BEHAVIORAL|Jumpstart Guide|The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families in the outpatient setting. The intervention's goal is to prompt clinicians to provide, during a scheduled (non-urgent) clinic visit, standard of care which includes a discussion with patients (and/or their LNOKs) about their goals of care. It is designed to promote and guide these discussions for older adults with memory problems through suggestions and tips on the Jumpstart Guide.
48005913|NCT00107458|DRUG|valproic acid|
48163146|NCT02920021|DRUG|Etokimab|Humanized monoclonal antibody, administered by intravenous infusion
48163147|NCT02920021|DRUG|Placebo|Administered by intravenous infusion
48163148|NCT01314898|DRUG|3 mg PF-03882845|3 mg PF-03882845, single oral dose
48005914|NCT02705690|DEVICE|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:~The phone is kept stable against the lower back of the participant using the belt.~The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.~These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
48005915|NCT02790346|PROCEDURE|arthrodesis talonavicular|
48005916|NCT02790346|PROCEDURE|tendon gestures|
48163149|NCT01314898|DRUG|10 mg PF-03882845|10 mg PF-03882845, single oral dose
48163150|NCT01314898|DRUG|30 mg PF-03882845|30 mg PF-03882845, single oral dose
48163151|NCT01314898|DRUG|100 mg PF-03882845|100 mg PF-03882845, single oral dose
48692343|NCT00551343|DRUG|Exenatide|10ug Exenatide single s.c. injection
48692344|NCT03870451|DEVICE|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
48692345|NCT04287309|OTHER|CAR-T cells|CD19 targeted CAR-T treatment
48692346|NCT01415583|DRUG|Dexamethasone|0.5mg/kg (max dose 20mg)
48692347|NCT04645680|OTHER|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
48692348|NCT04645680|OTHER|Dietary Intervention|Whole foods diet
48692349|NCT04645680|OTHER|Quality-of-Life Assessment|Ancillary studies
48692350|NCT04645680|OTHER|Questionnaire Administration|Ancillary studies
48692351|NCT05898620|GENETIC|NGN-401|NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.
48692352|NCT01279291|BIOLOGICAL|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
48005917|NCT00518908|DRUG|Sevoflurane|3.2 Vol % for postconditioning
48163152|NCT01314898|DRUG|Spironolactone|100 mg spironolactone, single oral dose
48163153|NCT03936075|BEHAVIORAL|the Guided Imagery and Music method|the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills
48692353|NCT01279291|DRUG|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
48692354|NCT01279291|DRUG|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
48005918|NCT00273728|DRUG|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
48005919|NCT00302003|RADIATION|radiation therapy|Undergo radiation therapy
48005920|NCT00302003|DRUG|doxorubicin hydrochloride|Given IV
48005921|NCT00302003|DRUG|vincristine sulfate|Given IV
48005922|NCT00302003|DRUG|prednisone|Given orally
48005923|NCT00302003|DRUG|cyclophosphamide|Given IV
48163154|NCT03936075|BEHAVIORAL|standard care and verbal counselling|the participants receive their usual cancer treatment and two individual counselling sessions
48163155|NCT00841477|BIOLOGICAL|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
48692355|NCT01279291|DRUG|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
48692356|NCT06644833|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (rTMS) sessions, targeting the dorsolateral prefrontal cortex, at a frequency of 10 Hz. Each session will last approximately 30 minutes, with 5 sessions per week for 4 to 6 weeks.
48692357|NCT06644833|DRUG|Antidepressant|Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
48692358|NCT03101488|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
48005924|NCT00302003|DRUG|ifosfamide|Given IV
48005925|NCT00302003|DRUG|vinorelbine tartrate|Given IV
48692359|NCT06331156|COMBINATION_PRODUCT|HRV PCV-free|2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
48692360|NCT06331156|COMBINATION_PRODUCT|IPV|3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
48692361|NCT03688334|DRUG|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
48692362|NCT03688334|DRUG|Medical air (sham O2)|Medical air supplementation via Venturi mask
48692363|NCT06151964|DRUG|AZD9550|Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks
48692364|NCT06151964|DRUG|Placebo|Matching administration volumes for SC injection
48692365|NCT06355414|DRUG|Psilocybin|Drug administration under supportive conditions
48692366|NCT06355414|DRUG|Methylphenidate|Drug administration under supportive conditions
48005926|NCT00302003|DRUG|dexamethasone|Given IV
48005927|NCT00302003|DRUG|etoposide phosphate|Given IV
48005928|NCT00302003|DRUG|cisplatin|Given IV
48005929|NCT00302003|DRUG|cytarabine|Given IV
48692367|NCT06650748|DRUG|Dalpiciclib|Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
48692368|NCT06650748|DRUG|Letrozole|2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
48692369|NCT03178825|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
48692370|NCT00382421|DRUG|bisoprolol|
48163156|NCT00841477|BEHAVIORAL|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
48163157|NCT02772445|BEHAVIORAL|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
48005930|NCT00302003|BIOLOGICAL|filgrastim|Given IV or subcutaneously
48005931|NCT06440070|PROCEDURE|Loop Carpal Tunnel Release|Under the guidance of ultrasound, needles are inserted above and below the transverse carpal ligament, respectively, to form a loop around the ligament. Finally, the ligament is cut by pulling the looped thread.
48005932|NCT01387321|DRUG|BYL719|
48692371|NCT00382421|DRUG|amlodipine|
48005933|NCT04546958|DIETARY_SUPPLEMENT|Whey protein supplements|Nutritional counseling and whey protein supplements for 3 months
48163158|NCT06309849|OTHER|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique)|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique) strengthening exercises for neck muscles, ultrasound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2.
48163159|NCT00509821|DRUG|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
48163160|NCT00509821|DRUG|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
48163161|NCT06646809|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
48692372|NCT00382421|DRUG|molsidomine|
48692373|NCT00382421|DRUG|acetylsalicylic acid|
48163162|NCT06646809|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
48163163|NCT06646809|OTHER|Standard care|Standard care
48163164|NCT05996497|BEHAVIORAL|behavioral measures|behavioral measures
48163165|NCT05996497|OTHER|Electrophysiological measures|Electrophysiological measures
48163166|NCT05996497|OTHER|Training 1|Training 1
48692374|NCT01803100|OTHER|No intervention|There is no intervention in this trial
48692375|NCT05215665|DRUG|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
48163167|NCT05996497|OTHER|Training 2|Training 2
48692376|NCT05215665|DRUG|Lenvatinib|8/12mg PO QD continuously
48692377|NCT05215665|DRUG|Toripalimab|240mg IV d1 Q3W
48005934|NCT04546958|OTHER|Nutritional counseling|Nutritional counseling by dietitians for 3 months
48005935|NCT01120210|DRUG|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
48005936|NCT01120210|DRUG|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
48005937|NCT01120210|DRUG|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
48005938|NCT01120210|DRUG|Placebo|1-hour infusion of matching placebo on Day 1
48005939|NCT01120210|DRUG|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
48005940|NCT04244786|DEVICE|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
48005941|NCT04244786|OTHER|No intervention|No intervention for participants who discontinued prior to randomization
48005942|NCT04712604|BEHAVIORAL|My Sleep Our Sleep (MSOS) Program|MSOS Program is a weekly one-hour Zoom session that focuses on psychoeducation on sleep health for both patients and their sleep partners.
48005943|NCT05437289|DRUG|AZD7442 IM|In cohort 1, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) administered sequentially as direct gluteal IM injections.
48005944|NCT05437289|DRUG|Placebo IM|In cohort 1, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
48005945|NCT05437289|DRUG|AZD7442 IM|In cohort 2, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) administered sequentially as direct gluteal IM injections.
48005946|NCT05437289|DRUG|Placebo IM|In cohort 2, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort administered sequentially as direct gluteal IM injections.
48005947|NCT05437289|DRUG|AZD7442 IV|In cohort 3, participants will be randomized to receive 300 mg AZD7442 (150 mg AZD8895 and 150 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
48005948|NCT05437289|DRUG|Placebo IV|In cohort 3, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
48005949|NCT05437289|DRUG|AZD7442 IV|In cohort 4, participants will be randomized to receive 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) mixed in IV bag co-administered as a single IV infusion.
48005950|NCT05437289|DRUG|Placebo IV|In cohort 4, participants will be randomized to receive placebo with dose match to AZD7442 in the same cohort as a single IV infusion.
48163168|NCT06245499|BEHAVIORAL|Aging Brain Care Virtual Program|The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
48163169|NCT02410317|DRUG|Ropivacaine|
48163170|NCT02410317|DRUG|Morphine|
48163171|NCT01083407|DRUG|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
48005951|NCT04700696|BEHAVIORAL|Peer Recovery Support|Weekly visits with peer who has lived experience related to child welfare and addiction
48005952|NCT04700696|BEHAVIORAL|Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)|Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)
48005953|NCT04700696|BEHAVIORAL|Relational Skill Building based on the Nurturing Parenting Program (NPP)|Home-based parenting support
48163172|NCT01083407|OTHER|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
48163173|NCT00131547|BEHAVIORAL|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
48163174|NCT00717925|DRUG|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
48163175|NCT01547689|BIOLOGICAL|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10\^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
48163176|NCT06584838|PROCEDURE|ACL reconstruction|Patients that underwent ACL reconstruction using either allograft or autograft tendons, at least 2 years of follow-up, gender male and female, no comorbidities
48163177|NCT06072833|BEHAVIORAL|Patient Financial Education / Navigation|The investigator anticipates that this will include a baseline financial assessment and educational content, likely using a virtual platform. Participants will be connected with a PAF case manager. There will be monthly follow-ups to the participant for 6-months to address any financial concerns through additional counseling/navigation.
48163178|NCT01878188|DRUG|BC-819/PEI|Intravesical instillation
48005954|NCT02657811|DEVICE|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
48005955|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
48005956|NCT02657811|DEVICE|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
48005957|NCT03746821|DIETARY_SUPPLEMENT|Biotin|Biotin supplements (2) to be taken daily
48005958|NCT04334642|OTHER|A mindfulness based intervention|It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
48005959|NCT06208241|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
48163179|NCT01878188|DRUG|BCG Vaccine|intravesical instillations
48005960|NCT01885390|DEVICE|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
48692378|NCT03919084|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
48692379|NCT03919084|OTHER|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
48005961|NCT04167774|DRUG|Camrelizumab|Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
48005962|NCT04167774|DRUG|nb-Paclitaxel|nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
48005963|NCT04990934|BEHAVIORAL|Semistructured Interview|Patients with breast cancer (Stage I-III) will be interviewed about their experiences of telemedicine.
48005964|NCT01637688|DIETARY_SUPPLEMENT|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
48163180|NCT05904288|DEVICE|Smartwatch Garmin Vivosmart [wearable sensor]|Garmin Vivo Smart is a fitness tracker, which is aimed at collecting patient's motor activity and heart rate data from embedded Inertial Movement Unit (IMU) and Photoplethismograph (PPG) sensors.
48163181|NCT05904288|DEVICE|Soturi™ [digital mobile app]|Soturi software is a proprietary mobile application, for people with Parkinson's Disease (PD) designed to record symptoms, by means of self-report diary, set reminders for medication intake. Soturi™ Physical Exercise Program and Speech Exercise Program.
48163182|NCT05904288|OTHER|Clinical Assessment|Outpatient repeated-measures clinical evaluations, which include assessment of motor symptoms through MDS-UPDRS and ecological motor tasks, to observe changes with respect to medication intake, and changes over a 6 month period time.
48005965|NCT01239368|PROCEDURE|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
48163185|NCT01134718|DRUG|TMC435 (G006)|one morning dose of 150 mg
48163186|NCT01134718|DRUG|TMC435 (F021)|one morning dose of 150 mg
48163187|NCT01134718|DRUG|TMC435 (G007)|one morning dose of 150 mg
48163188|NCT00214071|BIOLOGICAL|Influenza vaccine|
48163189|NCT01703988|DRUG|Nusinersen|Single IT injection for each dose
48163190|NCT06084455|OTHER|Aerobic exercise|30 minutes of aerobic exercise on a stationary bike
48163191|NCT01914458|PROCEDURE|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
48163192|NCT03964038|DRUG|gilteritinib|oral
48163193|NCT03964038|DRUG|gilteritinib mini tablet|oral
48692380|NCT03919084|OTHER|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
48692381|NCT03919084|OTHER|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
48692382|NCT03919084|OTHER|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
48692383|NCT01108731|DRUG|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
48692384|NCT01108731|DRUG|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
48692385|NCT00752934|DRUG|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
48692386|NCT00752934|DRUG|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
48692387|NCT03286543|DEVICE|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
48005966|NCT01239368|BIOLOGICAL|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
48005967|NCT01239368|BIOLOGICAL|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
48163194|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
48163195|NCT00396214|DRUG|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
48163196|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
48163197|NCT01959607|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
48163198|NCT01959607|OTHER|CC|Single use of subject's own cigarette (CC)
48163199|NCT01959607|OTHER|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
48163200|NCT06146088|BIOLOGICAL|EV71 Vaccine|Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
48692388|NCT05027802|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
48692389|NCT01241188|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
48692390|NCT01241188|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
48692391|NCT02143856|DRUG|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
48692392|NCT06227676|DIETARY_SUPPLEMENT|Cramp Bites by Aunt Flo's Kitchen|Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
48692393|NCT04627090|OTHER|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
48692394|NCT06658223|OTHER|Exercise with virtual reality|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
48692395|NCT06327373|DRUG|Oxygen|Supplemental oxygen by oxygen concentrator
48692396|NCT06327373|DRUG|Room air|Room air without oxygen concentrator
48692397|NCT01454609|DRUG|0.9% Normal saline|Saline
48692398|NCT01454609|DRUG|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
48692399|NCT01454609|DEVICE|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg"
48692400|NCT04964505|DRUG|Azacitidine|Given IV or SC
48163201|NCT00002855|DRUG|Bicalutamide|
48163202|NCT00002855|DRUG|Doxorubicin hydrochloride|
48163203|NCT00002855|DRUG|Estramustine Phosphate Sodium|
48163204|NCT00002855|DRUG|Flutamide|
48163205|NCT00002855|DRUG|Ketoconazole|
48163206|NCT00002855|DRUG|Nilutamide|
48163207|NCT00002855|DRUG|Therapeutic Hydrocortisone|
48163208|NCT00002855|DRUG|Vinblastine|
48163209|NCT00002855|PROCEDURE|Conventional Surgery|Surgical castration
48163210|NCT04748497|OTHER|Standardization of evaluation and follow-up|"Standardization of evaluation and clinical and sportive follow-up of athletes.~Made-to-measure technical supports will be tested regarding the Paralympic regulations."
48163211|NCT06288256|OTHER|No Intervention|No Intervention
48163212|NCT02637258|OTHER|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
48163213|NCT05453877|OTHER|No intervention will be applied.|This is an observational study.
48163214|NCT04482270|DRUG|fezolinetant|Oral
48163215|NCT04337034|BEHAVIORAL|Mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
48163216|NCT04337034|PROCEDURE|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured.
48692401|NCT04964505|DRUG|Uproleselan|Given IV
48692402|NCT04964505|DRUG|Venetoclax|Given PO
48692403|NCT06112080|DEVICE|RESP™ Biosensor|The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
48692404|NCT05739006|DRUG|BCD-201|up to 8 treatment cycles
48692405|NCT05739006|DRUG|Keytruda|up to 8 treatment cycles
48692406|NCT02657694|DRUG|Sofosbuvir+Ledipasvir|DAA medication treatment
48692407|NCT02657694|DRUG|Sofosbuvir+Daclatasvir|DAA medication treatment
48692408|NCT02657694|DRUG|Sofosbuvir+Velpatasvir|DAA medication treatment
48692409|NCT04829786|DRUG|palovarotene low-dose|oral capsules
48692410|NCT04829786|DRUG|palovarotene high-dose|oral capsules
48692411|NCT03773237|DIETARY_SUPPLEMENT|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
48005968|NCT06267612|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of left ventricular assist device for hemodynamic support
48005969|NCT00152217|DRUG|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
48005970|NCT00152217|PROCEDURE|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
48163217|NCT05364541|DEVICE|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
48513839|NCT04637802|BEHAVIORAL|Education|The patient education website will serve as the active comparator. The purpose is to control for time, attention, and online usage. Youth and parents will be provided access to an education website containing information about pediatric surgery at the same time interval as the active intervention; however, there will be no exposure to cognitive and behavioral coping skills. Similar to the CBT condition, the presurgery period of Education will be administered for one month prior to surgery and the postsurgery period will be administered for one month after the post-discharge assessment.
48005971|NCT03265626|BEHAVIORAL|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
48005972|NCT03265626|BEHAVIORAL|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
48005973|NCT03265626|OTHER|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
48005974|NCT01458327|DRUG|Midomafetamine|125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
48005975|NCT01458327|BEHAVIORAL|Therapy|Non-directive therapy
48005976|NCT01308307|DEVICE|photorefraction|photorefraction is a name of device.
48163218|NCT05354557|DRUG|Iberdomide|Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
48005977|NCT04838314|PROCEDURE|regional analgesia|Peri operative regional analgesia by bilateral ESP catheter for 72h
48005978|NCT04426617|PROCEDURE|Ultrasound Guided Transversus Abdominis Plane Block|The patient will lie in the supine position. The transducer will be placed in the axial plane on the mid-axillary. transversus abdominis muscle will be visualized. A skin wheel using 3 ml of lidocaine 1 % is made 2 to 3 cm medial to the medial aspect of the transducer and the 22 gauge is inserted in-plane pointing laterally. Then Injection of local anaesthetic mixure in the right plane.
48005979|NCT04655716|DRUG|Sodium Bicarbonate 150Meq/L/D5W Inj|Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
48163219|NCT01405521|BIOLOGICAL|Vaccine placebo (excipients only)|single oral dose,
48163220|NCT01405521|BIOLOGICAL|Ty21a|3 oral doses, alternate days
48163221|NCT01405521|BIOLOGICAL|M10ZH09 vaccine|single oral dose
48163222|NCT00288379|DRUG|formoterol|
48163223|NCT00288379|DRUG|budesonide/formoterol|
48163224|NCT02958475|BEHAVIORAL|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
48163225|NCT02958475|BEHAVIORAL|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
48163226|NCT02958475|BEHAVIORAL|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
48692412|NCT03773237|DIETARY_SUPPLEMENT|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
48692413|NCT05139329|DIAGNOSTIC_TEST|Imaging|To better understand the prevalance of further imaging for evaluation of myocarditis, all patients with negative workup will be included and see what number of patients undergo further CMRI, FGD-PET, or speckle tracking echocardiography. Patients will then be categorized as those with myocarditis with positive diagnosis, negative diagnosis or unknown.
48692414|NCT06660563|DRUG|JNJ-80948543|JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.
48692415|NCT06660563|DRUG|JNJ-75348780|JNJ-75348780 will be administered as SC injection.
48692416|NCT02620423|BIOLOGICAL|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
48005980|NCT04182035|OTHER|patient-tailored therapy|The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.
48163227|NCT03081351|PROCEDURE|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
48692417|NCT02620423|DRUG|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
48692418|NCT02620423|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
48692419|NCT02620423|DRUG|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
48163228|NCT03081351|PROCEDURE|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
48163229|NCT02089984|BEHAVIORAL|Internet Based CBT Training|
48163230|NCT06012305|OTHER|Taping|Taping has the effect of accelerating the flow in the tissue by increasing the epidermal dermal distance. The muscle technique used in the study will be applied to the trapezius muscle and aims to reduce the working level of the muscle. The EDF technique, which will be used in another group, aims to create a stronger base taping effect.
48692420|NCT02620423|DRUG|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
48005981|NCT04182035|OTHER|Non-patient tailored therapy: generalized exercise program|The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).
48005982|NCT04182035|OTHER|Education|Education considering neck pain information
48005983|NCT01397175|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
48163231|NCT06468462|DRUG|WHO-recommended periodic presumptive treatment|400 mg po cefixime plus 1 gram azithromycin po under direct observation
48163232|NCT06468462|DRUG|Doxycycline post-exposure prophylaxis|200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
48163233|NCT00095017|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
48692421|NCT02620423|DRUG|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
48692422|NCT02620423|DRUG|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
48692423|NCT05617989|OTHER|lung ultrasound|non-invasive ventilation and diuretic
48692424|NCT02065843|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
48692425|NCT02065843|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
48692426|NCT02065843|DRUG|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
48692427|NCT02065843|DRUG|midazolam|15 mg/single dose/1 hour before dental surgery
48692428|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
48692429|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
48692430|NCT01999842|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
48692431|NCT03617536|DRUG|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
48692432|NCT03617536|DRUG|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
48692433|NCT03617536|DRUG|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
48692434|NCT03617536|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
48692435|NCT05812807|BIOLOGICAL|Pembrolizumab|Given IV
48692436|NCT05812807|OTHER|Patient Observation|Undergo observation
48692437|NCT05812807|PROCEDURE|Biopsy|Undergo biopsy
48692438|NCT05812807|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48692439|NCT05812807|OTHER|Questionnaire Administration|Ancillary studies
48692440|NCT05812807|OTHER|Quality-of-Life Assessment|Ancillary studies
48692441|NCT03962088|DIAGNOSTIC_TEST|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at -80 °C."
48692442|NCT00193791|OTHER|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
48692443|NCT05976646|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
48692444|NCT05976646|DRUG|Auvelity|Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
48692445|NCT02724579|DRUG|Cisplatin|Given IV
48005984|NCT01397175|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
48163234|NCT03585621|RADIATION|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
48692446|NCT02724579|DRUG|Cyclophosphamide|Given IV
48692447|NCT02724579|OTHER|Laboratory Biomarker Analysis|Correlative studies
48692448|NCT02724579|DRUG|Lomustine|Given PO
48163235|NCT05262439|DEVICE|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
48692449|NCT02724579|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48005985|NCT01397175|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
48005986|NCT00234195|DRUG|bupropion extended release (Wellbutrin XL)|
48163236|NCT06646458|OTHER|Healthy Elderly Volunteers|Take the elderly milk power 2 times every day up to 28 days
48163237|NCT01065493|OTHER|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
48163238|NCT01065493|BEHAVIORAL|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
48692450|NCT02724579|RADIATION|Radiation Therapy|Undergo craniospinal radiation therapy
48163239|NCT02236598|DRUG|K+ supplement|
48163240|NCT02236598|DRUG|Placebo|
48163241|NCT00092209|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium|
48163242|NCT00092209|DRUG|Comparator: placebo, losartan, hydrochlorothiazide|
48163243|NCT01585805|PROCEDURE|Biopsy|Undergo biopsy
48692451|NCT02724579|DRUG|Vincristine|Given IV or via minibag
48692452|NCT02724579|DRUG|Vincristine Sulfate|Given IV or via minibag
48692453|NCT04711109|DRUG|Denosumab|Given SC
48692454|NCT04711109|DRUG|Placebo|Given SC
48692455|NCT04711109|OTHER|Quality-of-Life Assessment|Ancillary studies
48692456|NCT03465644|DRUG|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
48692457|NCT03465644|DRUG|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
48692458|NCT05677490|DRUG|Fluorouracil|Given IV
48692459|NCT05677490|DRUG|Leucovorin Calcium|Given IV
48692460|NCT05677490|DRUG|Oxaliplatin|Given IV
48692461|NCT05677490|DRUG|Irinotecan|Given IV
48692462|NCT05677490|BIOLOGICAL|Nivolumab|Given IV
48692463|NCT05677490|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48692464|NCT05677490|PROCEDURE|Computed Tomography|Undergo a CT Scan
48692465|NCT05677490|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48692466|NCT05677490|OTHER|Questionnaire Administration|Ancillary studies
48368697|NCT01031667|DRUG|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
48368698|NCT03927209|DRUG|BI 1467335|tablet
48368699|NCT02561689|OTHER|Fissure sealing|"Procedure:~* The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~* Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~* The occlusal surface is sealed by the dentist or dental hygienist.~* Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
48368700|NCT01005966|DRUG|Sodium Fluoride Toothpaste|Test product
48368701|NCT01005966|DRUG|Amine Fluoride Toothpaste|Test product
48368702|NCT01005966|DRUG|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
48368703|NCT01005966|DRUG|Placebo|placebo and washout treatment
48692467|NCT06342375|OTHER|Outbound phone call|Participants will receive either a live or pre-recorded outbound phone call
48005988|NCT05523531|OTHER|Self-administered questionnaires|"* Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire"
48005989|NCT05523531|PROCEDURE|Bilateral ophthalmologic examination|"* Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy"
48368704|NCT01005966|DRUG|675 ppmf toothpaste|dose response
48005990|NCT02553421|DEVICE|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
48368705|NCT04192292|DRUG|Sulfonylurea|Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
48368706|NCT04192292|DRUG|DPP4 Inhibitor|Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
48368707|NCT01444638|DEVICE|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
48368708|NCT00195117|BEHAVIORAL|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
48368709|NCT00135694|DRUG|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
48368710|NCT00135694|PROCEDURE|liver transplant|Occurs at study entry
48368711|NCT00135694|DRUG|corticosteroids|3-month course of corticosteroids
48005991|NCT04122573|DIAGNOSTIC_TEST|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
48005992|NCT04122573|DIAGNOSTIC_TEST|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
48005993|NCT04122573|DIAGNOSTIC_TEST|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
48005994|NCT04122573|DIAGNOSTIC_TEST|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
48005995|NCT04122573|DIAGNOSTIC_TEST|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
48163244|NCT01585805|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
48368712|NCT00135694|OTHER|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
48368713|NCT04148976|DIETARY_SUPPLEMENT|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
48368714|NCT04148976|DIETARY_SUPPLEMENT|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
48368715|NCT04348825|DEVICE|Electroconvulsive therapy|
48513840|NCT03835273|OTHER|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
48692468|NCT04217811|OTHER|No intervention|No intervention
48692469|NCT04905524|DIETARY_SUPPLEMENT|VIOME Precision Nutrition Program|Diet and supplements recommendations
48692470|NCT06556875|BEHAVIORAL|HIIT|high intensity interval training
48692471|NCT06556875|BEHAVIORAL|HIIT combined IET|high intensity interval training combined with isometric exercise training
48163245|NCT01585805|DRUG|Cisplatin|Given IV
48692472|NCT06492616|DRUG|Elacestrant|Administered as oral tablets
48692473|NCT06492616|DRUG|Anastrozole|Administered as oral tablets
48692474|NCT06492616|DRUG|Letrozole|Administered as oral tablets
48692475|NCT06492616|DRUG|Exemestane|Administered as oral tablets
48692476|NCT06492616|DRUG|Tamoxifen|Administered as oral tablets
48692477|NCT03851887|COMBINATION_PRODUCT|TAI combine SBRT|TAI combine SBRT
48692478|NCT06134115|DIETARY_SUPPLEMENT|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
48692479|NCT06134115|DIETARY_SUPPLEMENT|Lipocet Placebo|Lipocet Placebo matching to Lipocet
48692480|NCT02791516|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
48005996|NCT06075680|PROCEDURE|Non-Surgical Periodontal Treatment|The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease
48163246|NCT01585805|PROCEDURE|Computed Tomography|Undergo CT
48163247|NCT01585805|DRUG|Gemcitabine|Given IV
48692481|NCT02791516|DRUG|Placebo|Administered by subcutaneous injections once a month
48005997|NCT03941522|OTHER|Early discharge from hospital|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
48163248|NCT01585805|DRUG|Gemcitabine Hydrochloride|Given IV
48163249|NCT01585805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48513841|NCT03835273|OTHER|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
48163250|NCT01585805|DRUG|Veliparib|Given PO
48163251|NCT01628783|DRUG|escitalopram 10 mg|orally once daily
48163252|NCT01628783|DRUG|Placebo|once daily
48163253|NCT03668041|DRUG|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
48163254|NCT03668041|DRUG|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
48163255|NCT03668041|OTHER|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
48692482|NCT01234454|DRUG|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
48692483|NCT01234454|DRUG|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
48692484|NCT05709223|DEVICE|Categorical loudness scaling based fitting using the Nexus Research System.|The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.
48692485|NCT05709223|DEVICE|Behavioural fitting using Custom Sound Suite (CSS 6.3) Software|The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
48692486|NCT06373354|DEVICE|Digital Breast Tomosynthesis (DBT)|Undergo tomosynthesis imaging
48692487|NCT02003794|DRUG|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
48692488|NCT04157153|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
48692489|NCT06658977|DRUG|Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)|One Triumeq tablet per day
48692490|NCT05254951|DIAGNOSTIC_TEST|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
48163256|NCT03388021|PROCEDURE|completion angiography followed by endovascular treatment of residual or underlying lesions|completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
48692491|NCT05613322|DIAGNOSTIC_TEST|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
48692492|NCT01807169|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
48692493|NCT04603495|DRUG|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
48692494|NCT04603495|DRUG|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
48163257|NCT01520285|DRUG|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
48163258|NCT01520285|DRUG|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
48163259|NCT06549699|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
48513842|NCT03835273|OTHER|Questionnaires|Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system \[7,8\]
48163260|NCT06549699|OTHER|Usual Care|Usual care plus healthy recipes provided
48163261|NCT02812628|PROCEDURE|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
48163262|NCT02812628|PROCEDURE|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
48163263|NCT00660764|DRUG|Rosuvastatin|Oral
48163264|NCT05382871|BIOLOGICAL|BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
48163265|NCT05382871|BIOLOGICAL|WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
48163266|NCT05382871|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
48163267|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
48163268|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
48163269|NCT05287698|OTHER|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
48368716|NCT00967473|DEVICE|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
48005998|NCT01550874|BEHAVIORAL|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
48005999|NCT04065789|DRUG|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
48006000|NCT04065789|DRUG|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
48006001|NCT04065789|DRUG|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
48163270|NCT03074383|BEHAVIORAL|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
48163271|NCT03074383|BEHAVIORAL|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
48163272|NCT05671133|DIAGNOSTIC_TEST|Clinician Decision Support Tool|Clinician Decision Support Tool that provides information about patient's statistical probability of suicide attempt in next 1 month
48163273|NCT06125639|BEHAVIORAL|Sauna Bathing|Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
48163274|NCT02686671|OTHER|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
48163275|NCT06588725|BEHAVIORAL|Play Nicely|Multimedia tool and handbook designed to educate parents about healthy discipline strategies.
48163276|NCT06588725|BEHAVIORAL|Cavity Prevention Handout|Two page handout with information about how to prevent cavities.
48163277|NCT02539238|OTHER|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
48185260|NCT05823753|DRUG|Cannabidiol|"The CBD product to be used in this study is Epidiolex (Jazz Pharmaceuticals/Greenwich), a plant-derived, highly purified CBD oral solution that is FDA approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.~Doses will be 300 mg/d or 900 mg/d according to participants' assigned condition. Participants will receive CBD or placebo oral solution twice daily (evenly split doses at morning and evening meals) for three days (to achieve steady state) following the baseline assessment (day 0), and in the morning of day 4 (before the post-test)."
48185261|NCT05823753|DRUG|Placebo|Placebo solution (excipients only, also by Jazz Pharmaceuticals/Greenwich).
48185262|NCT01817920|BEHAVIORAL|integrated multidisciplinary fall prevention program|
48163278|NCT06647186|PROCEDURE|Non Incised Papillae Surgical Approach|Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. A single horizontal or oblique incision was made in the mucosa located on the cortical bone tissue, apical to the intrabony defect. The mesiodistal extension of the incision was sufficient to allow access to the defect. Tissue coronal to the incision was raised to full thickness from the incision line to expose the bone peaks delimiting the intrabony defect. The granulation tissue was removed from the bone walls of the defect. Dental plaque and calculus deposits were removed from the root surface with ultrasonic scaler tips and micro-minicurettes. A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with horizontal internal mattress sutures then simple interrupted sutures.
48006002|NCT04065789|DRUG|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
48006003|NCT00849368|DRUG|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
48368717|NCT03703609|BEHAVIORAL|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
48692495|NCT04603495|DRUG|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
48692496|NCT02680041|DRUG|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
48692497|NCT04974905|PROCEDURE|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
48692498|NCT06661031|BEHAVIORAL|Motivational Enhancement Therapy plus Ecological Momentary Intervention|Two Motivational Enhancement Therapy (MET) sessions (1st, \~45 minutes; 2nd, \~30 minutes) between counselor and participant occur one week apart. MET sessions are personalized, interactive, face-to-face, and delivered according to a manual. MET session discussion topics include triggers for cannabis use, life goals/values, and development of a change plan. Participants then complete a 2-week Ecological Momentary Intervention (EMI) period. Survey prompts are sent 4x/day (3x/day at quasi-randomized times, 1x/day at fixed time; \~2 mins each) that ask about the participant's recent cannabis use. Depending on answers reported, the participant can receive tailored messages that support their self-efficacy and prompt use of coping strategies.
48185263|NCT02114762|PROCEDURE|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
48513843|NCT03678571|OTHER|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
48692499|NCT06661031|BEHAVIORAL|Enhanced Usual Care|Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
48006004|NCT01332617|DRUG|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
48368718|NCT04946721|DIAGNOSTIC_TEST|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
48163279|NCT06647186|PROCEDURE|Conventional flap design|"Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. Intrasulcular incision was made splitting the buccal papilla from the palatal papilla. All defects were approached by elevating a flap only on the buccal side and leaving the oral portion of the interdental supracrestal soft tissues undetached. The full-thickness elevation of the marginal portion of the flap was performed with a microsurgical periosteal elevator.~After removal of granulation tissue from the bone walls of the defect, root and defect debridement was performed with manual and mechanical (ultrasonic) instruments with tips for subgingival instrumentation.~A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with simple interrupted sutures."
48163280|NCT01027247|DEVICE|Ologen TM|
48163281|NCT00308841|DRUG|Lidocaine (drug)|
48163282|NCT02608697|DRUG|CAT-2054|
48163283|NCT02608697|DRUG|Placebo|
48163284|NCT02608697|DRUG|Atorvastatin|
48163285|NCT00530049|OTHER|questionnaire administration|
48368719|NCT00241891|BEHAVIORAL|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
48368720|NCT00241891|BEHAVIORAL|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
48368721|NCT00241891|BEHAVIORAL|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
48163286|NCT00530049|PROCEDURE|assessment of therapy complications|
48163287|NCT00530049|PROCEDURE|psychosocial assessment and care|
48163288|NCT00530049|PROCEDURE|quality-of-life assessment|
48163289|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
48513844|NCT05847348|DRUG|68Ga-PSMA-11|A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
48692500|NCT03601442|BIOLOGICAL|CTL019|CTL019
48692501|NCT06010303|DRUG|LBL-007|LBL-007 will be administered at a standard dose intravenously.
48692502|NCT06010303|DRUG|Tislelizumab|Tislelizumab will be administered at a standard dose intravenously.
48692503|NCT06010303|DRUG|Chemotherapy Doublet|"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
48692504|NCT04382586|DRUG|Zanubrutinib|320 mg (4 x 80 mg) capsules administered orally once daily
48692505|NCT04382586|DRUG|Supportive Care|Supportive care treatment was selected and administered as deemed appropriate by the study investigator
48692506|NCT04382586|DRUG|Placebo|Placebo to match zanubrutinib
48692507|NCT04452357|RADIATION|PLDR|"PLDR radiation will be delivered as 10 fractions of 20 cGy, initiated once every 3 minutes. Dose levels will be selected as follows:~Dose level 1: 56 Gy; Dose level 2: 66 Gy Drug: Gemcitabine"
48692508|NCT06269185|DRUG|Infliximab|Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
48692509|NCT06269185|DRUG|Adalimumab|Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
48692510|NCT06078371|OTHER|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
48692511|NCT00050206|DRUG|Olanzapine|
48692512|NCT00050206|DRUG|Placebo|
48692513|NCT05236725|DEVICE|Remote Blood Pressure Cuff|specialized, Bluetooth enabled BP monitoring cuff
48692514|NCT05236725|DEVICE|Blood Pressure (BP) monitoring smart phone app, BabyScripts™|app that works with the monitoring cuff
48692515|NCT05236725|BEHAVIORAL|Instructions|Verbal and written instructions to conduct BP checks at home
48692516|NCT00395486|DRUG|Rosuvastatin|10mg
48692517|NCT00395486|DRUG|Atorvastatin|10mg
48692518|NCT04994028|OTHER|Conventional treatment|Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.
48692519|NCT04994028|OTHER|conventional treatment with volume Spirometry and deep breathing|Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
48692520|NCT00361231|DRUG|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
48163290|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
48163291|NCT02453802|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
48163292|NCT02453802|DRUG|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
48006005|NCT04409821|BEHAVIORAL|Tele-delivered psychological intervention|The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
48163293|NCT02453802|DRUG|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
48006006|NCT05599178|OTHER|Ultrasound examination in early labor|Combined trans-abdominal and trans-perineal ultrasound examination
48163294|NCT04451031|BEHAVIORAL|LiFT Program|
48163295|NCT05595369|DRUG|Experimental: Paxlovid 25 day dosing|Drug: Paxlovid 25 day dosing Paxlovid (nirmatrelvir 300mg, ritonavir 100mg) bid x 25 days See NCT05965726 (Paxlovid Sub-study)
48163296|NCT05595369|DRUG|Experimental: Paxlovid 15 day dosing|Drug: Paxlovid 15 day Dosing Paxlovid (nirmatrelvir 300mg and ritonavir 100mg) bid x 15 days then ritonavir 100mg bid plus nirmatrelvir matching placebo bid x 10 days See NCT05965726 (Paxlovid Sub-study)
48163297|NCT05595369|DRUG|Placebo Comparator: Control|Drug: Control ritonavir 100mg taken bid plus nirmatrelvir matching placebo bid bid x 25 days See NCT05965726 (Paxlovid Sub-study)
48692521|NCT00361231|DRUG|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
48692522|NCT00361231|DRUG|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
48692523|NCT06651268|DRUG|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
48692524|NCT05685238|DRUG|Mim8|Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 will use the DV3407 pen injector.
48692525|NCT03110978|BIOLOGICAL|Nivolumab|Given IV
48692526|NCT03110978|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
48692527|NCT06566170|DRUG|Donanemab|Administered IV
48006007|NCT05130411|DIETARY_SUPPLEMENT|DLM - Test product|The group will receive 60 gummies each (to take two gummies per day) across a four-week period. Each participant shall take two gummies per day
48006008|NCT00876473|PROCEDURE|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
48006009|NCT05355844|DRUG|Benzoyl peroxide|Benzoyl peroxide application in the incision area before surgery
48692528|NCT06566170|DRUG|Usual Care|Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
48006010|NCT05017116|DRUG|RBD1016|subcutaneous injection
48006011|NCT05017116|DRUG|Placebo|subcutaneous injection
48006012|NCT05017116|DRUG|Entecavir|Take orally.
48006013|NCT02881294|DRUG|SUVN-G3031|
48163298|NCT06162637|DEVICE|femoral neck locking plate|femoral neck fractures fixation by femoral neck locking plate
48163299|NCT06162637|DEVICE|multiple cannulated cancellous screws|femoral neck fractures fixation by multiple cannulated cancellous screws
48163300|NCT06089486|DIAGNOSTIC_TEST|ICA|Patients will undergo annual CAV surveillance with ICA
48163301|NCT06089486|DIAGNOSTIC_TEST|PET|Patients will undergo annual CAV surveillance with PET
48163302|NCT03317678|DIETARY_SUPPLEMENT|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
48163303|NCT03317678|DIETARY_SUPPLEMENT|Non-fermented milk|A non-fermented milk drink.
48163304|NCT03448354|PROCEDURE|HIPEC|HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
48163305|NCT00247117|DRUG|Metformin|
48163306|NCT01341444|DEVICE|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
48163307|NCT01341444|OTHER|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
48163308|NCT04289714|DEVICE|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
48163309|NCT02747121|BEHAVIORAL|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
48163310|NCT01129115|BEHAVIORAL|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
48163311|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
48163312|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
48163313|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
48163314|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
48163315|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
48163316|NCT01187147|DIETARY_SUPPLEMENT|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
48163317|NCT01886391|BEHAVIORAL|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
48163318|NCT02931240|DEVICE|Revivent TC|Treatment of LV scar
48163319|NCT05814679|OTHER|Relaxation with virtual reality|In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.
48163320|NCT05814679|OTHER|Attention match|kidney function instruction
48163321|NCT05927714|OTHER|Amnion-chorion Membrane|Amnio-chorion membranes specifically for palatal wound healing following free soft tissue autografts (FTSA) procedures.
48163322|NCT05927714|OTHER|ActCel Cellulose Gauze|When these products come in contact with blood, they convert to a gel that expands to cause direct pressure on blood vessels and control bleeding. ActCel is water-soluble and dissolves over a short time period. It can be removed easily when water, saline or hydrogen peroxide is applied.
48163323|NCT01297452|DRUG|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
48163324|NCT01297452|DRUG|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
48163325|NCT01297452|DRUG|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
48006014|NCT03073278|RADIATION|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
48006015|NCT06319326|OTHER|Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.|This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
48006016|NCT04949269|DRUG|Deucravacitinib|Specified dose on specified days
48006017|NCT04949269|DRUG|Famotidine|Specified dose on specified days
48006018|NCT01211028|BIOLOGICAL|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
48163326|NCT01297452|DRUG|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
48163327|NCT06640998|DEVICE|Matrix Pro|Study subjects received up to three (3) study treatments with the Matrix Pro applicator
48163328|NCT05542225|PROCEDURE|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
48163329|NCT05542225|PROCEDURE|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
48163330|NCT05542225|PROCEDURE|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
48163331|NCT05614024|OTHER|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
48163332|NCT05614024|OTHER|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
48163333|NCT04034914|OTHER|Questionnaire administration|Ancillary studies
48163334|NCT02005029|DRUG|Erythromycin|
48163335|NCT02005029|DRUG|placebo|
48163336|NCT05844436|DRUG|Pritelivir|Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
48163337|NCT04017637|BEHAVIORAL|Resistance Training|Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
48163338|NCT06647433|OTHER|Observation|case study will be observed participants, methods will include observation, interview and video reflexive ethnography
48163339|NCT06647225|DEVICE|Artificial intelligence augmented ultrasound|"The hip ultrasound is performed using a handheld device (Exo Iris) that uses a pocket-sized ultrasound probe and is run through an application on an IoS (Apple mobile) operation system. . A real-time algorithm detects and records the anatomical landmarks. When there are enough images for analysis the operator is notified that the scan is complete. From here, the images are then classified as: the hips as healthy, follow-up recommended, or suboptimal (repeat scan)."
48163340|NCT05056129|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
48163341|NCT05056129|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
48163342|NCT03657537|DRUG|Ketone infusion|β-hydroxybutyrate is infused intravenously.
48163343|NCT03657537|DRUG|Saline infusion|saline is infused intravenously.
48163344|NCT03326193|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.
48163345|NCT03326193|BIOLOGICAL|Bevacizumab|Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
48163346|NCT02865759|BEHAVIORAL|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
48163347|NCT02452125|DIETARY_SUPPLEMENT|Nicotine gum|Nicotine chewing gum
48163348|NCT04700397|DIAGNOSTIC_TEST|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
48163349|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
48163350|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID DIET|2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
48368722|NCT04176237|OTHER|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
48368723|NCT03190304|DRUG|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
48368724|NCT03190304|DRUG|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
48368725|NCT06005792|BIOLOGICAL|XmAb27564|Subjects to receive four doses of XmAb27564 at one of six escalating dose-levels administered subcutaneously every 2 weeks (Q2W).
48163351|NCT05783154|BIOLOGICAL|Autologous Adipose Tissue-Derived Mesenchymal Stem Cell|"After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle"
48692529|NCT04110756|BEHAVIORAL|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
48163352|NCT02364609|DRUG|Afatinib Dimaleate|Given PO
48163353|NCT02364609|BIOLOGICAL|Pembrolizumab|Given IV
48163354|NCT02806596|DRUG|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
48692530|NCT02483793|DRUG|Tamsulosin|
48006019|NCT05483946|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
48006020|NCT01547416|DRUG|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
48006021|NCT01547416|DRUG|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
48692531|NCT02483793|DRUG|Oxybutynin|
48006022|NCT01336686|DRUG|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
48006023|NCT01336686|DRUG|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
48006024|NCT01336686|DRUG|Placebo comparator|Matching placebo once daily for 4 weeks
48006025|NCT01336686|DRUG|Colchicine|0.6 mg colchicine daily for flare prophylaxis
48163355|NCT06052683|RADIATION|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
48163356|NCT06052683|RADIATION|Stereotactic Body Radiation Therapy to the prostate|Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
48368726|NCT06005792|BIOLOGICAL|Placebo|Subjects to receive four doses of placebo administered subcutaneously every 2 weeks (Q2W).
48368727|NCT01679756|PROCEDURE|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
48368728|NCT02960802|PROCEDURE|kidney transplantation|
48368729|NCT06212960|BIOLOGICAL|DWP712|Clostridium botulinum Toxin
48368730|NCT06212960|BIOLOGICAL|BOTOX®|Clostridium botulinum Toxin
48368731|NCT00021125|PROCEDURE|adjuvant therapy|
48692532|NCT06170619|DEVICE|Obsidio™ Conformable Embolic|Embolization with Obsidio™ Conformable Embolic.
48368732|NCT00021125|RADIATION|radiation therapy|
48368733|NCT03264560|BEHAVIORAL|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
48513845|NCT05847348|OTHER|PET/CT or PET/MRI|PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11
48692533|NCT00192764|DRUG|high-dose cyclophosphamide|
48692534|NCT04296305|DRUG|Hydromorphone|Given IV after
48006026|NCT02423941|PROCEDURE|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
48006027|NCT02423941|PROCEDURE|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
48006028|NCT05232604|OTHER|Aerobic exercise|30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
48692535|NCT04296305|DRUG|Placebo Administration|Given IV after
48692536|NCT04296305|OTHER|Questionnaire Administration|Ancillary studies
48163357|NCT04112355|OTHER|Blood Collection|Blood draw
48163358|NCT00661466|DRUG|Bupivacaine Collagen Sponge|
48163359|NCT00661466|DRUG|Placebo|placebo
48163360|NCT01872156|OTHER|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
48163361|NCT01872156|OTHER|Control Group|The group control will act according to usual management.
48163362|NCT02540343|OTHER|questionnaires|fill out all questionnaires twice
48163363|NCT01537900|DRUG|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
48163364|NCT06646497|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow|"1. Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7), Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day -1).~2. Stem cell source Bone Marrow only. Target of 4 × 10\^8 nucleated cells/kg recipient body weight. Granulocyte colony stimulating factor is given subcutaneously starting on day +5 at 5 mg/ kg/day until the absolute neutrophil count is greater than 1.5 × 10\^9/L for 3 days.~3. GVHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4. Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE) and mycophenolate (MMF) will begin from D+5. In absence of GvHD, MMF will be stopped between D35 and D45 and Tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT (except patients and their donor with EBV serology and EBV PCR negative)."
48163365|NCT05501483|DRUG|Pioglitazone 45 mg|Starts with 45 mg
48163366|NCT05501483|DRUG|Empagliflozin 25 MG|Starts with 25 mg
48163367|NCT05501483|DRUG|Semaglutide 7 MG|Starts with 3 mg daily for the first 2 weeks
48163368|NCT02968121|DRUG|Brexpiprazole, OPDC-34712|
48163369|NCT02093117|PROCEDURE|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
48163370|NCT02093117|PROCEDURE|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
48163371|NCT01770314|BEHAVIORAL|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
48006029|NCT05232604|OTHER|Neck motor control exercise|An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
48006030|NCT03277261|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
48163372|NCT06328725|DRUG|EN001|"Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals."
48163373|NCT01803789|DEVICE|Single Kirschner Wire|
48006031|NCT03277261|DRUG|Teriflunomide|Film-coated tablets administered orally.
48163374|NCT01803789|DEVICE|Double Kirschner Wire|
48163375|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol Env A/B/C|1×10\^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
48163376|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol|5×10\^9 PU rAd5 Gag-Pol delivered via intramuscular injection
48163377|NCT01637337|PROCEDURE|laparoscopic pyelolithotomy|laparoscopy
48163378|NCT01637337|PROCEDURE|percutaneous nephrolithotomy|percutaneous nephrolithotomy
48163379|NCT00309621|DRUG|alitretinoin|
48163380|NCT05364047|BIOLOGICAL|Low-dose of LVRNA009|25μg/person
48163381|NCT05364047|BIOLOGICAL|Middle-dose of LVRNA009|50μg/person
48163382|NCT05364047|BIOLOGICAL|High-dose of LVRNA009|100μg/person
48692537|NCT05197933|PROCEDURE|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
48692538|NCT02681419|PROCEDURE|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
48692539|NCT02681419|PROCEDURE|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
48006032|NCT03277261|DRUG|Oral Placebo|Administered orally.
48006033|NCT03277261|DRUG|IV Placebo|Administered as an IV infusion.
48006034|NCT01935765|OTHER|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
48006035|NCT01935765|OTHER|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
48163383|NCT05364047|OTHER|Placebo|0.5ml/person
48692540|NCT03940638|OTHER|Data collection|Data collection
48692541|NCT01198210|DRUG|saline|local peritonsillar infiltration of 2 ml saline,
48163384|NCT04553029|OTHER|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
48163385|NCT06052345|DEVICE|Garmin smartwatch|"* Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~* Meal detection and meal characteristics (accelerometry and gyroscope data)~* Oxygen saturation (pulse oximetry)~* Number of steps (pedometer)~* Stress level indicators (based on heart-rate analytics)~* Sleep patterns (sleep and wake-up time, sleep quality)"
48006036|NCT01935765|OTHER|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
48006037|NCT01935765|OTHER|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
48006038|NCT01935765|OTHER|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
48006039|NCT01935765|OTHER|Electrocardiogram (ECG)|Electrocardiogram (ECG)
48006040|NCT01935765|OTHER|Carotid echography|Carotid echography
48006041|NCT01935765|OTHER|Blood pressure|Blood pressure
48006042|NCT03076424|OTHER|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
48006043|NCT01459172|OTHER|limonene containing massage oil|daily massage application to the breast for 4 weeks
48006044|NCT04707534|DRUG|Dexamethasone|Dexamethasone
48006045|NCT03524703|OTHER|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
48006046|NCT04174729|DEVICE|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
48006047|NCT04174729|DEVICE|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
48006048|NCT04174729|DEVICE|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
48006049|NCT04174729|DEVICE|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
48006050|NCT04174729|DEVICE|Linear Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
48513846|NCT05389644|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of repetitive TMS. TMS is a form of non-invasive brain stimulation. In this modality, a current is rapidly passed through a TMS coil. This coil is placed on a subject's scalp. The rapidly discharging current creates a magnetic field perpendicular to the plane of the coil. This magnetic field diffuses through the subject's scalp and skull until it reaches the brain parenchyma. There, it causes focal neuronal depolarization.
48006051|NCT04174729|DEVICE|Door Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
48006052|NCT00423891|DRUG|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
48006053|NCT05626036|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
48006054|NCT05626036|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
48513847|NCT02458209|BIOLOGICAL|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
48513848|NCT02458209|BIOLOGICAL|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
48513849|NCT02458209|BIOLOGICAL|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
48692542|NCT01198210|DRUG|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
48692543|NCT01198210|DRUG|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
48006055|NCT02140034|PROCEDURE|Extensive Peritoneal Lavage|
48006056|NCT03372512|DIAGNOSTIC_TEST|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
48006057|NCT00003585|BIOLOGICAL|aldesleukin|
48006058|NCT00003585|BIOLOGICAL|recombinant interferon alfa|
48006059|NCT00003585|DRUG|fluorouracil|
48006060|NCT00003585|DRUG|isotretinoin|
48006061|NCT00003585|PROCEDURE|surgical procedure|
48006062|NCT02383667|DEVICE|Electrocardiogram holter|
48006063|NCT05142683|OTHER|Treatment As Usual|Various typical interventions for adolescents with depression.
48006064|NCT05142683|OTHER|CARIBOU-2|Integrated Care Pathway intervention for adolescents with depression.
48006065|NCT00934544|DRUG|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
48006066|NCT00934544|DRUG|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
48006067|NCT04936958|OTHER|patients having had an osteomyelitis since 2017|description of osteomyelitis and their management
48006068|NCT02353559|BEHAVIORAL|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
48006069|NCT03640676|DEVICE|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
48006070|NCT01725568|DEVICE|BioMonitor|Implantable cardiac monitor
48006071|NCT02874365|PROCEDURE|Endoscopic biopsies|intestinal biopsies
48006072|NCT06037746|OTHER|Graston|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 10 minutes in the longitudinal, vertical and oblique directions.
48692544|NCT01198210|DRUG|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
48163386|NCT06052345|OTHER|REBECCA Mobile application|"* GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~* Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~* Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)"
48163387|NCT06052345|OTHER|REBECCA PC plug-in|"* the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~* These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites"
48163388|NCT02599870|GENETIC|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
48163389|NCT02580981|OTHER|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
48692545|NCT02308163|DRUG|Peficitinib|oral
48163390|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)
48163391|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale|"Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line"
48163392|NCT04804228|OTHER|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
48185264|NCT03656250|DIAGNOSTIC_TEST|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
48185265|NCT03995797|PROCEDURE|Laser therapy|Erbium YAG laser
48185266|NCT06234553|PROCEDURE|surgery of pituitary adenomas|evaluate pathological type and treatment effect after treatment
48368734|NCT04374331|OTHER|video-assisted training|The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
48368735|NCT02039687|DRUG|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
48006073|NCT06037746|OTHER|Percussive massage|For the application, the individual was asked to lie face down, flex the knee to 90 degrees and release the ankle. The therapist took a position next to the individual on the side to be treated. Application was applied to the entire plantar fascia for 5 minutes in all directions without being bound to a single direction.
48006074|NCT01914666|DRUG|Duloxetine|Administered orally
48006075|NCT00112203|DRUG|Itopride|
48692546|NCT02308163|DRUG|Placebo|oral
48692547|NCT02308163|BIOLOGICAL|Etanercept|subcutaneous injection
48006076|NCT04061200|DRUG|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
48006077|NCT04061200|OTHER|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
48006078|NCT04061200|DRUG|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
48006079|NCT02197390|BEHAVIORAL|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
48006080|NCT02197390|BEHAVIORAL|Obesity chronic care model|
48006081|NCT02197390|BEHAVIORAL|Physical activity, healthy eating, water drinking, healthy sleep promotion|
48006082|NCT02197390|BEHAVIORAL|Environment, policy, systems changes in clinic setting only|
48006083|NCT02197390|BEHAVIORAL|No intervention|No intervention.
48006084|NCT02197390|BEHAVIORAL|Environment, policy, and systems changes in schools, early child care education & recreation|
48006085|NCT05137873|OTHER|Dunn-2 infant Sensory Profile (PS2-N)|The Dunn-2 infant Sensory Profile evaluates the child's sensory integration process
48006086|NCT05668065|BIOLOGICAL|CoronaVac/CoronaVac|Two doses at 21-day +/- 3 days. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.
48163393|NCT04804228|OTHER|Ischemic compression, analytical stretching and postural habits educational dossier|The control group G2, formed by 40 subjects, will perform an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifidus and iliocostal muscles, 1 weekly session for 6 weeks, in addition to providing them with a training dossier on postural education in their activities of daily life.
48163394|NCT00400257|BEHAVIORAL|Early detection of heart failure|Early detection of heart failure
48163395|NCT02314169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48692548|NCT00603096|DEVICE|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
48692549|NCT01038479|DIETARY_SUPPLEMENT|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
48006087|NCT05668065|BIOLOGICAL|CoronaVac/BNT162b2|"First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.~Second dose of BNT162b2 at 21-day +/- 3 days. Each dose of the Pfizer-BioNTech COVID-19 Vaccine is 0.3 ml. Each prefilled syringe contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2"
48006088|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
48692550|NCT01038479|BEHAVIORAL|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
48692551|NCT06281652|OTHER|Go classes|Classes of board games (Go), performed in groups of 6-10 subjects, once a week
48692552|NCT06281652|OTHER|Chess classes|Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
48006089|NCT03970473|OTHER|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
48006090|NCT01202825|DRUG|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
48006091|NCT01202825|DRUG|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
48006092|NCT01202825|DRUG|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
48006093|NCT01202825|DRUG|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
48006094|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
48006095|NCT01202825|DRUG|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
48006096|NCT01202825|DRUG|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
48006097|NCT01202825|DRUG|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
48006098|NCT01202825|DRUG|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
48163396|NCT02314169|PROCEDURE|Computed Tomography|Undergo CT scan
48368736|NCT02039687|OTHER|Placebo|Formulation buffer
48513850|NCT03539263|DIETARY_SUPPLEMENT|Bifihappy|"During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~* Lactobacillus fermentum~* Lactobacillus rhamnosus~* Lactobacillus plantarum~* Bifidobacterium longum"
48692553|NCT06045858|DRUG|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
48163397|NCT02314169|BIOLOGICAL|Ipilimumab|Given IV
48163398|NCT02314169|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48163399|NCT02314169|BIOLOGICAL|Nivolumab|Given IV
48163401|NCT06641128|DRUG|MTX SC or IM|IM or SC Methotrexate
48163402|NCT06641128|DRUG|Empagliflozin 25mg tab|Empa tablets 25 mg once daily for 3 months.
48368737|NCT04865380|DRUG|Tranexamic Acid 100 MG/ML|1g IV x 1 dose of Tranexamic Acid administered preoperatively.
48368738|NCT05404321|OTHER|Establishment of ex vivo breast cancer organoid models|This study includes 2 steps: The constitution of a collection of tumor and blood samples and the analysis of the ex vivo response of the tumor samples to the treatments for the development of functional tests and the research of predictive biomarkers of this response
48513851|NCT03539263|OTHER|Placebo|During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
48513852|NCT02523261|PROCEDURE|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
48513853|NCT02523261|PROCEDURE|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
48692554|NCT00434447|DRUG|Zoledronic acid|
48692555|NCT05023291|DIAGNOSTIC_TEST|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
48006099|NCT01202825|DRUG|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
48006100|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
48006101|NCT00866632|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
48006102|NCT02410720|OTHER|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
48006103|NCT02410720|OTHER|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
48006104|NCT02410720|OTHER|Explanation of paper and application instructions|The research fellow will explain instructions to patients
48006105|NCT02410720|OTHER|Picoprep solution|
48006106|NCT00330551|DRUG|Oral Risperidone|Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
48006107|NCT00330551|DRUG|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
48006108|NCT03851016|BEHAVIORAL|Life Story Book|Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.
48006109|NCT03851016|BEHAVIORAL|Usual Care|Three weeks of Usual Care with no visits from research team
48006110|NCT05425420|DRUG|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
48006111|NCT03275558|DRUG|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
48006112|NCT03275558|DRUG|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
48006113|NCT03275558|DRUG|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
48006114|NCT04666090|DRUG|Carillizumab|administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.
48006115|NCT04666090|PROCEDURE|Esophagectomy|Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma
48006116|NCT04666090|OTHER|Samples|Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use
48163403|NCT04604951|DEVICE|Transcutaneous Spinal Cord Stimulation|This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
48006117|NCT00794196|BEHAVIORAL|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
48006118|NCT04249128|DIETARY_SUPPLEMENT|Vegetarian Collagen|Collagen is a protein made up of amino-acids, which are in turn built of carbon, oxygen and hydrogen.
48163404|NCT02809677|OTHER|Non-Interventional|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
48006119|NCT04249128|DIETARY_SUPPLEMENT|Keratin|Keratin (/ˈkɛrətɪn/) is one of a family of fibrous structural proteins known as scleroproteins. α-Keratin is a type of keratin found in vertebrates. It is the key structural material making up hair, nails, feathers, horns, claws, hooves, calluses, and the outer layer of skin among vertebrates.
48006120|NCT04249128|DIETARY_SUPPLEMENT|Ceramides|Ceramides are a family of waxy lipid molecules. A ceramide is composed of sphingosine and a fatty acid. Ceramides are found in high concentrations within the cell membrane of eukaryotic cells, since they are component lipids that make up sphingomyelin, one of the major lipids in the lipid bilayer.
48006121|NCT04249128|DIETARY_SUPPLEMENT|Astaxanthin|is a naturally-occurring carotenoid found in algae, shrimp, lobster, crab and salmon.
48006122|NCT01826162|OTHER|acetate or placebo infusion|
48006123|NCT06311383|DRUG|First-line Ribociclib + endocrine therapy|Ribociclib + letrozole, or Ribociclib + anastrazole, or Ribociclib + exemestane, or Ribociclib + fulvestrant
48006124|NCT06311383|DRUG|First-line endocrine therapy|As of physicians choice
48006125|NCT06311383|DRUG|First-line chemtherapy|As of physicians choice
48692556|NCT05028348|DRUG|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
48006126|NCT06202742|BEHAVIORAL|cognitive behavioral therapy for insomnia|Online meeting, weekly for 8 weeks, to deliver CBTI by psychologist/ psychiatrist
48163405|NCT02206087|DRUG|PER977|Reversal of heparin-induced anticoagulation
48163406|NCT02206087|DRUG|Placebo|Reversal of heparin-induced anticoagulation
48163407|NCT02206087|DRUG|Heparin Sodium|
48163408|NCT05583734|DEVICE|Portomar(TM) Device|Portomar(TM) access device for bone marrow biopsy
48692557|NCT05028348|DRUG|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
48692558|NCT05028348|DRUG|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
48006127|NCT06202742|BEHAVIORAL|Health education|Online meeting, weekly for 8 weeks, to deliver general health knowledge
48006128|NCT06484153|DRUG|Pirfenidone|Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
48006129|NCT06484153|DRUG|Fruquintinib|3mg, orally, qd
48006130|NCT06484153|DRUG|Pembrolizumab|200mg iv every 3 weeks
48006131|NCT06210529|DEVICE|a high-intensity focused ultrasound tumor treatment system (Super Knife)|All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.
48006132|NCT00220025|DEVICE|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
48006133|NCT05254262|PROCEDURE|Elderly surgical patients|Patients who needs elective or emergency surgery for any reason
48006134|NCT00502697|BEHAVIORAL|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
48006135|NCT00502697|OTHER|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
48163409|NCT06223958|DRUG|OTX-TKI (axitinib implant)|Intravitreal Injection of OTX-TKI (axitinib implant)
48163410|NCT06223958|DRUG|Aflibercept|Injection of 2mg (0.05mL) of aflibercept
48163411|NCT01764152|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
48163412|NCT05433311|OTHER|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
48163413|NCT06639698|DIETARY_SUPPLEMENT|Diosgenin|Patients will take a tablet containing diosgenin (120 mg), alpha-lactalbumin (100 mg) and vitamin D (50 mcg) - two times per day for six months
48163414|NCT03267069|OTHER|survey|surveys will be administered at inclusion and follow-ups
48163415|NCT02997397|PROCEDURE|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
48163416|NCT02997397|PROCEDURE|tourniquet(-)|
48692559|NCT05028348|DRUG|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
48692560|NCT03365258|DIETARY_SUPPLEMENT|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
48163417|NCT05915884|OTHER|SGLT-2 inhibitors|This study is an observational study. It is not planned to do an interventional activity.
48692561|NCT03365258|DIETARY_SUPPLEMENT|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
48006136|NCT00643370|OTHER|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
48163418|NCT00119756|DRUG|paliperidone palmitate|
48163419|NCT05255250|BEHAVIORAL|PLAYshop|The intervention includes: 1. Educational Training - the 60 min virtual workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be sent physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
48163420|NCT03709485|OTHER|rectal swab for microbial culture.|Rectal swab and culture.
48163421|NCT00412828|DRUG|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
48163422|NCT06339385|BEHAVIORAL|PADIS assessment|Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium.
48163423|NCT05971017|DIETARY_SUPPLEMENT|Control Group|Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days
48163424|NCT05971017|DIETARY_SUPPLEMENT|Biostimulated group|Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
48163425|NCT03659890|DIETARY_SUPPLEMENT|Low nucleotide|2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
48006137|NCT01113125|DRUG|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
48006138|NCT01113125|DRUG|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
48163426|NCT03659890|DIETARY_SUPPLEMENT|High nucleotide|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
48006139|NCT00572507|DEVICE|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
48006140|NCT01446731|BIOLOGICAL|mRNA transfected dendritic cell|"Autologous monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
48006141|NCT01446731|DRUG|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
48006142|NCT00889343|DRUG|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
48006143|NCT00889343|DRUG|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
48006144|NCT00889343|DRUG|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
48006145|NCT00889343|DRUG|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
48006146|NCT00889343|DRUG|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
48006147|NCT05255458|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
48006148|NCT05255458|DRUG|Placebo|Administered placebo by subcutaneous injection Drug: Statins and/or Ezetimibe lipid-lowering therapies
48006149|NCT02997033|OTHER|No intervention|No intervention
48006150|NCT04078776|OTHER|No intervention|There is no intervention in this study
48006151|NCT06442501|OTHER|routine care|routine care
48006152|NCT01247090|DRUG|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU \* 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
48006153|NCT01247090|DRUG|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU \* 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
48006154|NCT01247090|DRUG|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
48006155|NCT00989833|DRUG|budesonide|400 yg x 1
48006156|NCT00989833|DRUG|terbutaline|0.4 mg as-needed
48006157|NCT00989833|DRUG|budesonide/formoterol|160/4.5 yg as-needed
48006158|NCT06019793|DEVICE|DBS for Chronic Pain|Participants ill receive deep brain stimulation to relieve their chronic pain symptoms.
48006159|NCT03379116|OTHER|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
48006160|NCT00656006|DRUG|Albuferon|
48006161|NCT00656006|DRUG|Ribavirin|
48006162|NCT02277496|BEHAVIORAL|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
48006163|NCT02052739|DRUG|SAGE-547|Solution for injection for IV infusion
48006164|NCT03976427|BEHAVIORAL|Guided Imagery|The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
48163427|NCT03659890|DIETARY_SUPPLEMENT|High nucletide + Ribose|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
48692562|NCT06151639|PROCEDURE|general anesthesia|General anesthesia was performed by muscle relaxant(rocuronium 0,6 mg/kg), opioids(phentanyl 1-2 mcg/kg) and propofol 2mg/kg. Inhation anesthetics and remiphentanyl infusion were used for maintance general anesthesia.
48006165|NCT01290848|BEHAVIORAL|Take TIME Health Campaign|"1. Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~2. Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~3. Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
48006166|NCT04230148|DRUG|Egaten (Triclabendazole) 250 mg tablets|Egaten 250 mg scored tablets for oral use.
48163428|NCT01572493|BIOLOGICAL|rh IL-15 (10 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle
48163429|NCT01572493|BIOLOGICAL|rh IL-15 (5 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
48163430|NCT02261285|DRUG|ONO-4538|
48006167|NCT00836875|DRUG|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (\<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing \<50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
48006168|NCT04931901|DEVICE|EMG TOF device|Use of Stimpod NMX450X as an electromyographic neuromuscular monitor
48692563|NCT06151639|PROCEDURE|peripheral nerve blocks|With the help of ultrasonography, at the 2nd rib level, between the fasciae of the pectoralis major and minor muscles at the mid-clavicle level (PECS I block, interpectoral fascial plane block) and at the 4th rib level, at the mid-axillary level, between the fasciae of the pectoralis minor and serratus muscles (PECS II block, pectoroseratal fascial plane block) local anesthesia was applied. In patients who underwent PECS block, a high-frequency linear ultrasonography (Esaote, My LabFive-Genova, Italy) probe and a 50 mm tip insulated needle (echoplex+, Vygon Ecouen-France) were used. 0.200% bupivacaine 15 ml was applied for the PECS I block, and 0.200% bupivacaine 20 ml was applied for the PECS II block, and fascial separation was observed. Sensory control was performed in the breast and axilla area and the patients were taken into surgery.
48692564|NCT05940857|DEVICE|OCS Liver|The TransMedics® Organ Care System (OCS) Liver is an FDA approved portable extracorporeal liver perfusion and monitoring system.
48692565|NCT01009944|DRUG|Lisinopril, Atenolol|once a day for 14 weeks
48692566|NCT02841007|DEVICE|geko neuromuscular electrostimulation device|
48692567|NCT04103944|PROCEDURE|Core Decompression|10 patients will be randomized chosen in this group
48692568|NCT04103944|PROCEDURE|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
48692569|NCT00084708|DIETARY_SUPPLEMENT|calcitriol|
48692570|NCT00084708|DRUG|dexamethasone|
48692571|NCT00084708|DRUG|gefitinib|
48692572|NCT02771574|DRUG|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
48692573|NCT02771574|DRUG|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
48692574|NCT04081402|BIOLOGICAL|HU-014|Hutox Inj(Clostridium botulinum type A)
48692575|NCT04081402|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
48692576|NCT03668470|DRUG|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
48692577|NCT03668470|DRUG|Placebo|Placebo: one injection per week during 24 weeks
48692578|NCT01536028|DRUG|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
48692579|NCT01536028|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
48006169|NCT01469468|DRUG|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
48006170|NCT01469468|DRUG|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
48163431|NCT03453177|DRUG|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
48692580|NCT01536028|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
48692581|NCT01536028|DRUG|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
48692582|NCT04632238|BEHAVIORAL|Metrics-driven quality improvement (MDQI)|The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
48692583|NCT06427096|BEHAVIORAL|Multifaceted intervention|"The multifaceted interventions is comprised of the following components:~1. To establish a BP management team led by healthy family instructor. The team members also include family leaders and village doctors.~2. To conduct multifaceted intervention, which includes low-sodium diet, weight management, physical exercise, BP monitoring and antihypertensive treatment."
48692584|NCT00001766|DRUG|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
48006171|NCT04939285|PROCEDURE|PEEP|The patients who met the withdrawal screening criteria were randomly divided into low pressure support level PSV spontaneous respiration test.The duration of the spontaneous breathing test was 30 minutes, and the results of the spontaneous breathing test were evaluated at the end of the test.
48185267|NCT01348152|DRUG|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
48692585|NCT00570011|DRUG|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
48692586|NCT00570011|DRUG|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
48692587|NCT05913050|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
48692588|NCT05913050|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
48692589|NCT03734926|DRUG|ZSP1241|ZSP1241 tablets for oral administration.
48006172|NCT05749081|DRUG|Lacidophilin tablets in combination with vonorazan dual therapy|2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
48006173|NCT05749081|DRUG|Placebo in combination with vonorazan dual therapy|2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
48006174|NCT00526058|DEVICE|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
48006175|NCT00526058|DEVICE|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
48006176|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 500 mg/day for 4 weeks.
48006177|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1000 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 10000 mg/day for 4 weeks.
48006178|NCT06404203|DIETARY_SUPPLEMENT|Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement 1500 mg/day|Volunteers will receive Balparmak Apitera Royal Jelly Herbal Capsule Food Supplement in a dose of 1500 mg/day for 4 weeks.
48692590|NCT06419556|PROCEDURE|Cervical Plexus Block|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt."
48692591|NCT05754944|DIAGNOSTIC_TEST|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
48692592|NCT05754944|OTHER|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
48692593|NCT01543282|DEVICE|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
48692594|NCT00911196|OTHER|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
48692595|NCT06661187|PROCEDURE|Cryoanalgesia|Patients who received cryoanalgesia: patients subjects underwent arterial puncture. patients in the intervention group had a small plastic bag filled with 12 oz of crushed ice applied to the radial artery puncture site for 3 min (timed with a stopwatch) without external compression or massage.
48692596|NCT06661187|PROCEDURE|Psychological instructions|Psychological interventions using verbal signals of the impending procedure, music distraction, visual distraction, and breathing interventions be used during arterial puncture in adults
48692597|NCT06661187|PROCEDURE|Routine care|No intervention deliver routine care
48692598|NCT04579536|OTHER|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
48006179|NCT06404203|OTHER|Plasebo|Volunteers will receive a soft vegan gelatin capsule containing lactose in a dose of 1500 mg/day for 4 weeks.
48006180|NCT03291613|OTHER|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
48006181|NCT03650010|PROCEDURE|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
48006182|NCT03528434|DIETARY_SUPPLEMENT|Zinc|10mg dispersible zinc sulfate tablet
48368739|NCT04758624|DEVICE|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
48006183|NCT03528434|OTHER|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
48006184|NCT04061603|DEVICE|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
48006185|NCT05052424|DIAGNOSTIC_TEST|Analysis of cytokines and immun cell related markers|blood samples
48006186|NCT01579396|DEVICE|septeX|12 h septeX CVVH treatment after cardiac surgery
48006187|NCT01579396|OTHER|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
48006188|NCT00811564|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
48692599|NCT04579536|OTHER|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
48006189|NCT00811564|DRUG|latanoprost 0.005%|1 drop of study medication taken once daily
48006190|NCT00670228|DRUG|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
48185268|NCT01348152|DRUG|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
48368740|NCT01136759|DRUG|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
48368741|NCT01136759|OTHER|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
48368742|NCT01393925|DRUG|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
48513854|NCT03951220|OTHER|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
48006191|NCT00670228|DRUG|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
48006192|NCT00670228|DRUG|Standard Therapy|Standard insulin therapy titrated to blood sugar control
48006193|NCT02805335|DEVICE|KTFIX PLUS|
48006194|NCT04338711|DRUG|tofacitinib modified release (MR)|"Single oral 10 mg multi particulate dose of dose of tofacitinib MR with different levels of enteric coating (MR E1, MR E2, and MR E3) in the fasted state. Additionally, the lowest and highest enteric coating levels will also be evaluated in the fed state.~Treatment F: a 10 mg oral dose of tofacitinib IR solution"
48006195|NCT06179082|COMBINATION_PRODUCT|Botox then threads|patients in which Botox injection then threads insertion were used
48006196|NCT06179082|PROCEDURE|threads only|patients in which threads insertion only was used
48006197|NCT01533246|DRUG|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
48006198|NCT01533246|OTHER|laboratory biomarker analysis|Correlative studies
48006199|NCT05706363|PROCEDURE|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
48513855|NCT03951220|OTHER|DXA scan|Used to assess bone density
48006200|NCT04541875|OTHER|MAR-Scale|The MAR-Scale is a 20-item questionnaire based on commonly reported reasons for non-adherence to medications.
48006201|NCT01721590|DRUG|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
48006202|NCT01721590|DRUG|placebo|3 capsules/time，3times/day for 1 year
48006203|NCT01303575|BEHAVIORAL|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
48006204|NCT01303575|BEHAVIORAL|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
48513856|NCT03951220|OTHER|Bloods and urine|Samples will be taken to assess bone biomarkers
48513857|NCT02711878|BEHAVIORAL|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
48006205|NCT01841814|RADIATION|Bone densitometry.|
48006206|NCT02437565|OTHER|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
48006207|NCT02437565|OTHER|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
48006208|NCT01403090|DEVICE|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
48006209|NCT00963690|DEVICE|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
48006210|NCT00963690|PROCEDURE|Standard compression|Use standard compression to achieve hemostasis
48006211|NCT01786629|DRUG|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
48006212|NCT01786629|DRUG|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
48006213|NCT04204018|OTHER|Experimental Arm|"* First, these providers will receive educational materials (e.g. a slide deck) meant to mimic what physicians will receive in the real-world market as they learn about the Progenity technology.~* Second, within each of their four cases, intervention-arm physicians only will receive simulated test results from the Progenity PE test at the clinically-appropriate point in each case."
48163432|NCT03453177|PROCEDURE|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
48163433|NCT03453177|PROCEDURE|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
48185269|NCT00079755|DRUG|SGN-30 (anti-CD30 mAb)|
48185270|NCT01766713|DRUG|Ezetimibe|10mg daily oral dose of ezetimibe
48368743|NCT05931094|OTHER|Augmented Reality based games|Games of Wonder Tree Augmented Reality
48006214|NCT04915404|DRUG|Berubicin Hydrochloride|Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
48006215|NCT02493634|PROCEDURE|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
48006216|NCT02493634|DEVICE|MRWire|
48006217|NCT02248090|DRUG|AZD9496|AZD9496
48006218|NCT02248090|DRUG|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
48006219|NCT04436523|DEVICE|Blood flow restriction (Delfi Personalized Tourniquet System)|The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.
48513858|NCT02711878|BEHAVIORAL|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
48006220|NCT04436523|OTHER|Standard rehabilitation|Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.
48006221|NCT03069625|BEHAVIORAL|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
48006222|NCT03069625|BEHAVIORAL|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
48006223|NCT03031171|BEHAVIORAL|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
48006224|NCT03031171|BEHAVIORAL|Non-Navigated|Randomly matched sample of non-navigated clinic patients
48513859|NCT02711878|BEHAVIORAL|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
48692600|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
48692601|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
48692602|NCT04798352|OTHER|6-minute walk test|6-minute walk test
48692603|NCT04798352|OTHER|WIQ functional questionnaire|WIQ functional questionnaire
48692604|NCT04798352|OTHER|quality of life questionnaires (EQ5D5L and SF-36)|quality of life questionnaires (EQ5D5L and SF-36)
48692605|NCT03932773|DEVICE|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
48006225|NCT03357458|BEHAVIORAL|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
48006226|NCT05074433|DRUG|casirivimab+imdevimab|Co-administered sequentially subcutaneous (SC)
48006227|NCT05074433|DRUG|Placebo|Administered SC
48006228|NCT06084195|BIOLOGICAL|Blood sample and tissue sample|"During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data"
48006229|NCT05066620|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
48006230|NCT02342704|DRUG|natalizumab|Administered as specified in the treatment arm
48006231|NCT02342704|DRUG|fingolimod|Administered as specified in the treatment arm
48006232|NCT01087424|DRUG|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
48006235|NCT00378313|DRUG|gemcitabine, epirubicin, paclitaxel|
48006236|NCT01753453|DRUG|Plerixafor|240mcg/kg, solution, subcutaneous injection
48006237|NCT01753453|DRUG|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
48006238|NCT03581110|DIAGNOSTIC_TEST|computed tomography|noncontrast-enhanced chest computed tomography
48513860|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
48513861|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
48006239|NCT03548012|BEHAVIORAL|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
48006240|NCT02915614|PROCEDURE|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
48006241|NCT03591575|DRUG|Deferiprone oral solution|Liquid formulation of deferiprone, with a concentration of 80 mg/mL
48006242|NCT03591575|DRUG|Placebo|Liquid solution that matches deferiprone oral solution in appearance and taste
48006243|NCT05001243|DRUG|Compound Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac|PBOHB to improve uncorrected near vision in healthy presbyopic patients
48006244|NCT05001243|DRUG|Pilocarpine Hydrochloride|Apply in the fellow eye
48513862|NCT05065710|DRUG|ZL-1211|Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort
48513863|NCT01756079|DRUG|boceprevir|
48692606|NCT03932773|DEVICE|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
48692607|NCT03932773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
48692608|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
48006245|NCT05001243|DRUG|Brimonidine Tartrate|Apply in the fellow eye
48006246|NCT02457533|BEHAVIORAL|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
48692609|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
48692610|NCT05786937|OTHER|Commercial ringer´s lactate solution|Placebo
48006247|NCT05360836|OTHER|Conservative treatment via telerehabilitation|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks."
48692611|NCT04651686|OTHER|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
48006248|NCT05360836|OTHER|Conservative treatmen + motor imagery|"Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images."
48006249|NCT05279521|BEHAVIORAL|pulmonary rehabilitation exercise|The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
48006250|NCT02934230|BEHAVIORAL|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
48006251|NCT02515266|OTHER|nutrition: protein intake|additional protein fortification of human milk
48006252|NCT01469286|DEVICE|TEA|Electroacupuncture at ST36
48513864|NCT01756079|BIOLOGICAL|PegIFN-2b|
48513865|NCT01756079|DRUG|RBV|
48513866|NCT06291714|DEVICE|GDT-based hemodynamic management based on Clearsight device|Intraoperative use of a HPI-guided hemodynamic goal-directed protocol based on the non-invasive measurement of HPI (Clearsight system)
48513867|NCT06582043|OTHER|SCARCr tester 1|Twice daily
48513868|NCT06582043|OTHER|Placebo|Twice daily
48006253|NCT01469286|DEVICE|Sham-TEA|Electroacupuncture at sham-points
48006254|NCT01970683|DIETARY_SUPPLEMENT|VSL #3 BID|
48006255|NCT02733978|DEVICE|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
48006256|NCT00810953|DRUG|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
48006257|NCT01100411|DEVICE|Air Optix Aqua|Contact lens material: Lotrafilcon A
48006258|NCT01100411|DEVICE|Biofinity|Contact lens material: Comfilcon A
48006259|NCT01100411|DEVICE|Proclear|Contact lens material: Omafilcon A
48006260|NCT01100411|DEVICE|Acuvue Oasys|Contact lens material: Senofilcon A
48006261|NCT01100411|DEVICE|Acuvue 2|Contact lens material: Etafilcon A
48006262|NCT01100411|DEVICE|Purevision|Contact lens material: Balafilcon A
48006263|NCT02915029|OTHER|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
48006264|NCT03973346|OTHER|Risk screening tool exposure|Risk screening tool is available to providers
48006265|NCT03793907|DEVICE|FitBit|Wear Fitbit
48006266|NCT03793907|OTHER|Quality-of-Life Assessment|Ancillary studies
48006267|NCT03793907|OTHER|Questionnaire Administration|Ancillary studies
48006268|NCT03793907|OTHER|Resistance Training|Complete strength training
48006269|NCT03793907|BEHAVIORAL|STEPS to Enhance Physical Activity|Complete a walking program
48006270|NCT04767009|DRUG|PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)|Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
48006271|NCT04767009|RADIATION|SBRT|Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
48006272|NCT00983554|DRUG|Anastrazole|Arimidex 1mg daily
48006273|NCT00983554|DRUG|Testosterone|Testim 10g daily
48006274|NCT00983554|DRUG|Dutasteride|Avodart 2.5mg daily
48006275|NCT00983554|DRUG|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
48006276|NCT00617682|BIOLOGICAL|PNCRM9|0.5 mL IM at 30-35 wks gestation
48006277|NCT00617682|BIOLOGICAL|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
48006278|NCT00792610|BIOLOGICAL|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
48006279|NCT04352140|DEVICE|Tetragraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
48006280|NCT04352140|DEVICE|ToFscan|ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
48006281|NCT04935476|DRUG|Dapsone 85 mg PO BID|Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
48006282|NCT04935476|DRUG|Placebo 85 mg PO BID|Placebo oral tablet, twice daily for 21 days.
48513869|NCT06019884|DEVICE|Caries detection method: Intraoral camera|A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
48006283|NCT03391973|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
48006284|NCT01217918|DRUG|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
48006285|NCT01217918|DRUG|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
48006286|NCT01217918|DRUG|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
48006287|NCT01726010|DEVICE|22-G Procore Needle|
48006288|NCT03200925|OTHER|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
48006289|NCT01483196|PROCEDURE|ultrasound imaging|Undergo TCD
48006290|NCT01483196|OTHER|questionnaire administration|Complete neurocognitive questionnaires
48006291|NCT01483196|PROCEDURE|assessment of therapy complications|Undergo TCD
48006292|NCT01483196|PROCEDURE|quality-of-life assessment|Ancillary studies
48006293|NCT01483196|PROCEDURE|magnetic resonance imaging|Undergo MRI
48006294|NCT02969928|PROCEDURE|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
48006295|NCT02969928|DRUG|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
48006296|NCT02969928|DRUG|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
48006297|NCT02969928|DRUG|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
48006298|NCT03786757|DRUG|Rivaroxaban|Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
48006299|NCT00645333|DRUG|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
48006300|NCT02802280|OTHER|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
48006301|NCT03131063|OTHER|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
48006302|NCT04345952|BEHAVIORAL|Calm Meditation Mobile App|The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants. The Calm app is downloaded onto the participant's smartphone.
48006303|NCT06296303|OTHER|Pulsed electromagnetic therapy|Pulsed etromagnetic therapy (1000 gauss) on sciatic nerve in gluteal fold. ( 30 min )
48006304|NCT06296303|OTHER|Ultrasound phonophoresis|Phonophoresis using dexamethasone and topical diclofenac sodium gel on sciatic nerve in subgluteal fold and mid thigh
48006305|NCT06296303|OTHER|Conventional physical therapy|"Conventional physical therapy consisting of~1. IF current on lumbar spine. (15 min )~2. Hotpack on lumbar spine . (15 min )~3. Neurodynamic mobilization .~4. Mobilization and manipulation for lumbar spine.~5. Exercises"
48006306|NCT05318638|DEVICE|Soft robotic glove|The soft-robotic glove used in the study is the Carbonhand system (Bioservo Technologies, Sweden). It is a CE-marked medical device and it consists of a glove that supports finger flexion via sewn-in tendons and a control unit housing the actuators that pull on the tendons and the batteries. The grip support is activated by applying very light pressure on sensors in the fingertips of the glove, and de-activated by releasing the pressure on the sensors.
48163434|NCT02368366|BEHAVIORAL|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
48163435|NCT02368366|BEHAVIORAL|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
48006307|NCT03081585|BEHAVIORAL|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
48163436|NCT02368366|BEHAVIORAL|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
48163437|NCT02764788|OTHER|Specific auriculotherapy|Specific auriculotherapy with needles
48163438|NCT02764788|OTHER|non-specific auriculotherapy|non-specific auriculotherapy with needles
48163439|NCT02764788|OTHER|seed auriculotherapy|non-specific auriculotherapy with seeds
48006308|NCT01554566|DIETARY_SUPPLEMENT|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
48163440|NCT01093690|DRUG|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
48368744|NCT05931094|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
48692612|NCT02870517|OTHER|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
48692613|NCT02870517|OTHER|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
48692614|NCT06657950|BEHAVIORAL|Integrative hatha yoga and mindful self-compassion|12 weeks of integrative hatha yoga and mindful self-compassion training
48692615|NCT05199233|DEVICE|Muse S™ Headband system|Clinical grade, headband style, wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (smartphone or tablet).
48692616|NCT02859727|DRUG|CDZ173|140 mg/day
48692617|NCT03514511|DRUG|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
48692618|NCT03514511|DRUG|LEO 138559 placebo|LEO 138559 placebo
48692619|NCT04692649|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
48692620|NCT04692649|OTHER|cross body stretch|crossbody stretch performed by an individual
48692621|NCT03523416|DEVICE|Transcatheter Atrial Shunt System|Transcatheter treatment of symptomatic left heart failure patients
48692622|NCT06659107|PROCEDURE|Closed reduction and fixation by K- wires|Fixation by k-wires with mutual linking technique
48163441|NCT01093690|DRUG|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
48692623|NCT06365216|DRUG|NX210c|3 times a week, for 4 weeks
48006309|NCT06406127|DRUG|Alpha Lipoic Acid 600 MG Oral Capsule|Single 600 mg daily dose
48006310|NCT03730948|BIOLOGICAL|DC vaccine|DC vaccine for colorectal cancer
48163442|NCT01081730|BIOLOGICAL|anti-TNF biologics|as prescribed
48692624|NCT06365216|DRUG|Placebo|3 times a week, for 4 weeks
48692625|NCT06402955|RADIATION|11C-UCB-J|Radiotracer for imaging.
48692626|NCT05010200|BIOLOGICAL|PGV-001|personalized genomic peptide vaccine
48692627|NCT05010200|BIOLOGICAL|Poly-ICLC|immune modulator
48006311|NCT01552772|DRUG|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
48006312|NCT06207058|DRUG|Baloxavir Marboxil|Subjects testing positive for influenza will receive a dose of Baloxavir Marboxil orally, according to the dosing indicated in the package insert.
48006313|NCT02448875|DEVICE|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
48006314|NCT02448875|DEVICE|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
48692628|NCT05010200|BIOLOGICAL|CDX-301|soluble recombinant human protein to work on stem cell
48692629|NCT01321944|OTHER|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
48692630|NCT05906485|BEHAVIORAL|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
48692631|NCT05906485|BEHAVIORAL|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
48692632|NCT05871424|DRUG|buprenorphine patch group|5 mcg/h buprenorphine patch will be applied preoperatively
48692633|NCT05871424|DRUG|placebo group|simple dressing tape only will be applied
48692634|NCT05422534|DIETARY_SUPPLEMENT|CoQ10|Participants will receive 1800 mg/day for 12 weeks
48692635|NCT05422534|DRUG|Placebo|Participants will receive placebo or CoQ10/day for 12 weeks
48692636|NCT05422534|BEHAVIORAL|HB-HIIT|Participants will be performed on non dialysis days. It will be video supervised exercise sessions with self directed exercises using pre-recorded bodyweight and strength exercise videos.
48692637|NCT05422534|BEHAVIORAL|Observational|Participant regular activities
48692638|NCT02489318|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
48692639|NCT02489318|DRUG|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
48692640|NCT02489318|DRUG|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
48692641|NCT06090864|DRUG|Chemotherapy|Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.
48692642|NCT06090864|BIOLOGICAL|Cell infusion|ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
48692643|NCT06660199|BEHAVIORAL|Text-based intervention|Parents randomized to the texting intervention will receive up to 3 messages each day for 6 weeks: The intervention is comprised of adolescent-centered (A-C) texts focusing on parental adherence to recommended suicide prevention strategies to promote adolescents' safety and parent-centered (P-C) texts focused on improving parents' own well-being.
48692644|NCT01109121|DRUG|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
48692645|NCT01109121|DRUG|Allopurinol|Allopurinol 400 mg, QD
48692646|NCT01109121|DRUG|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
48692647|NCT00197418|DRUG|rabeprazole, amoxicillin, clarithromycin, metronidazole|
48692648|NCT02374281|DRUG|Glucose sucking|
48692649|NCT02374281|DRUG|Water sucking|
48692650|NCT02374281|OTHER|No sucking|
48692651|NCT06345001|DRUG|BAY3630942|IV, Single administration
48692652|NCT06345001|DRUG|BAY3547922|IV, Single infusion
48692653|NCT05858164|DRUG|BAY2862789|Oral administration, solution or tablets
48006315|NCT03769272|PROCEDURE|Measurement of electrical delay during LV lead placement|Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
48692654|NCT02781129|OTHER|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
48692655|NCT04075006|DRUG|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
48692656|NCT05988528|DRUG|Mesalamine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis.
48692657|NCT05988528|DRUG|Nifuroxazide|Nifuroxazide is an oral antibiotic that has been approved as an effective antidiarrheal agent with no side effects in several gastrointestinal infections
48692658|NCT04246775|DEVICE|Peristeen|rectal irrigation
48692659|NCT05809050|DIAGNOSTIC_TEST|BM aspirate|Bone Marrow aspiration \& Examination
48692660|NCT04919031|DEVICE|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
48692661|NCT04919031|OTHER|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
48692662|NCT06308341|OTHER|Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy|Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min
48163443|NCT01081730|OTHER|general population|non-treated cohort
48163444|NCT01081730|BIOLOGICAL|non-anti-TNF biologics|as prescribed
48163445|NCT01081730|BIOLOGICAL|ustekinumab|as prescribed
48692663|NCT06308341|OTHER|Virtual Reality + Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities."
48692664|NCT06308341|OTHER|Motor Imagery +Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min."
48692665|NCT06095115|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally.
48692666|NCT06095115|DRUG|Placebo|Placebo will be administered orally
48163446|NCT01081730|DRUG|systemic non-biological treatments|as prescribed
48163447|NCT06647277|COMBINATION_PRODUCT|Fecal Microbiota Transplant|Fecal Microbiota Transplant
48163448|NCT01655992|DRUG|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
48163449|NCT01655992|DRUG|S1 generic|40mg／m2 bid four weeks on two weeks off
48163450|NCT05955365|DRUG|P2Y12 inhibitor|The choice of P2Y12 inhibitor is left at investigator's discretion.
48163451|NCT05955365|DRUG|Aspirin|Aspirin is administered for up to 1 month after PCI at investigator's discretion
48692667|NCT06565780|DEVICE|Device under test evaluation against references|"Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate."
48692668|NCT05337982|OTHER|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
48692669|NCT06658938|DRUG|Blinatumomab|"Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14"
48692670|NCT06660823|DRUG|L-thyroxine|"Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI."
48692671|NCT06660823|DRUG|Placebo|patients will receive placebo in form of inert starch tablet
48513870|NCT06019884|DEVICE|Caries detection method: Smartphone camera|This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
48692672|NCT04517695|DEVICE|BVA-100|The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
48513871|NCT06019884|OTHER|Referral pathway: User fee removal|The child's parent/ legal guardian will receive financial incentives. These a are designed to cover the costs of treatment and transportation and are tied to attending the preventive dental visit. The child will receive complete dental care.
48163452|NCT05955365|DRUG|DOAC|The choice of DOAC is left at investigator's discretion.
48163453|NCT00692445|DRUG|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
48163454|NCT00692445|DRUG|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
48163455|NCT04685317|DEVICE|Sentinel® Cerebral Protection System|A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
48163456|NCT04685317|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
48163457|NCT01582412|DRUG|Isavuconazole|oral
48163458|NCT01582412|DRUG|digoxin|oral
48163459|NCT00449202|DRUG|oleoyl-estrone (MP 101)|
48006316|NCT01552538|DEVICE|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
48006317|NCT01586468|DRUG|WF10|0.5 mg/kg B.W.
48006318|NCT01586468|DRUG|NaCl Solution|NaCl Solution
48006319|NCT03038464|DIAGNOSTIC_TEST|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
48006320|NCT02002494|OTHER|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
48513872|NCT06019884|OTHER|Referral pathway: Conventional referral|Children will be referred without providing financial incentives following the current standard of care in dental clinics in the public sector in Egypt. Care is planned by the receiving/ treating dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family about the oral health condition/s and planned treatment costs for which the child needs care and of available public and private facilities that offer the required care.
48513873|NCT06552039|OTHER|Polyherbal Hair Oil|Apply oil with the help of fingertips on your scalp and massage it gently enabling it to penetrate into the roots (follicle) of your hair. Don't apply with your palms and never rub it vigorously as it may uproot weak hair. Let the oil gradually seep into follicle of your hair \& nourish them for the whole night. The oil may be removed in the morning by washing of hair with Ayurvedic Shampoo. Dosage form: liquid frequency: Three times a week Route of Administration: Topical
48513874|NCT06552039|OTHER|Minoxidil Herbal Hair Oil + Minoxidil 5 (%) Hair Serum|"First, apply the herbal hair oil generously to your scalp and hair, ensuring thorough coverage. Gently massage it in with your fingertips to promote circulation and absorption. After the oil application, follow the instructions provided for the application of the minoxidil hair serum. Apply the serum to the areas of your scalp where you desire hair growth, using the dropper provided or as directed. Massage it gently into your scalp to ensure even distribution and absorption. Leave the serum on without rinsing.~Dosage form: liquid Frequency : For Minoxidil - Daily Night Application For Herbal Hair Oil- Thrice a week.~Route of Administration: Topical"
48513875|NCT06552039|OTHER|Minoxidil Hair Serum|Apply the amount prescribed to the area of the scalp being treated, beginning in the center of the area. Dosage form: liquid Frequency : Daily night Application of Minoxidil Route of Administration: Topical
48513876|NCT01118975|DRUG|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
48006321|NCT05726578|OTHER|Lung recruitment|establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
48513877|NCT01118975|DRUG|Lapatinib|1,250 mg once daily
48513878|NCT02876757|DRUG|5ARI|Exposure to finasteride/dutasteride
48163460|NCT04135469|OTHER|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
48513879|NCT02524457|OTHER|This is an observational study. There are no interventions|
48513880|NCT02931981|PROCEDURE|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
48513881|NCT03232671|DIAGNOSTIC_TEST|MIF ELISA|Blood sample
48513882|NCT05076461|DRUG|Ondansetron|Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
48513883|NCT00168935|DRUG|Fresubin protein energy Drink (CAVE! nutritional intervention)|
48513884|NCT04993066|DEVICE|GentleMax Pro Plus|The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
48513885|NCT02057887|DRUG|HM10660A|
48513886|NCT02057887|DRUG|Pegasys|180 mcg Pegasys SC once weekly
48513887|NCT02015065|DRUG|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
48006322|NCT04054037|OTHER|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
48006323|NCT02677090|DRUG|Placebo (including Maltodextrin)|
48163461|NCT04135469|OTHER|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
48163462|NCT04456049|DRUG|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
48513888|NCT06341205|DRUG|RiTUXimab Injection|Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months
48692673|NCT04517695|DEVICE|Transpulmonary Thermodilution (TPTD)|TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
48163463|NCT02538718|DRUG|MgSO4|
48006324|NCT02677090|DRUG|Dose 1 - Promitor®|
48006325|NCT02677090|DRUG|Dose 2 - Promitor®|
48006326|NCT02677090|DRUG|Dose 3 - Promitor®|
48006327|NCT03865329|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
48163464|NCT02538718|DRUG|YTP(Ritodrine)|
48163465|NCT03238599|BEHAVIORAL|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
48513889|NCT02892929|BEHAVIORAL|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
48513890|NCT02892929|BEHAVIORAL|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
48692674|NCT04517695|DEVICE|Sublingual Microcirculation|With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
48163466|NCT04297839|DRUG|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
48163467|NCT04297839|DRUG|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
48163468|NCT05301361|DRUG|Methylphenidate Oral Solution|The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
48163469|NCT02155218|OTHER|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
48163470|NCT02155218|OTHER|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
48692675|NCT04164433|DEVICE|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
48692676|NCT04869059|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
48006328|NCT05325463|PROCEDURE|conventional lung recruitment|The recruitment maneuver will be performed by pressure controlled mode maintaining a steady airway pressure of 15 cmH2O, with 5 cmH2O increments in positive end-expiratory pressure (PEEP) until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 sec. The peak airway pressure will be maintained for 10 sec or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings.
48163471|NCT02155218|OTHER|gadolinium contrast|
48163472|NCT02598934|DRUG|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
48513891|NCT02941835|RADIATION|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
48513892|NCT04821193|DRUG|Skin antisepsis with 5% NaHCO3 water solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
48513893|NCT04821193|DRUG|Skin antisepsis with 2% Chlorhexidine Gluconate solution|In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
48006329|NCT05325463|PROCEDURE|ultrasound- guided lung recruitment|The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area was visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit was 40 cmH2O.
48006330|NCT00486122|DRUG|Atomoxetine Hydrochloride|
48006331|NCT00486122|DRUG|Placebo|
48006332|NCT04999631|DRUG|Squaric Acid Dibutyl Ester|Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.
48163473|NCT05054517|DIETARY_SUPPLEMENT|Glutamine|Oral Supplement
48163474|NCT06269393|DRUG|Placebo|Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
48163475|NCT06269393|DRUG|IBI311|IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
48006333|NCT04999631|DRUG|Ethanol Solution|Control
48006334|NCT03938142|OTHER|Filling in an online survey regarding goalsettings|Patients are asked to fill in an online survey regarding their individual goalsettings.
48006335|NCT02863835|OTHER|EIT|All participants will have continuous monitoring of EIT whilst self venting
48163476|NCT02328209|DRUG|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
48163477|NCT05658575|DRUG|Dapansutrile|An initial loading dose of 2000 mg dapansutrile on Day 1 followed by a maintenance regimen of 1000 mg dapansutrile twice daily starting 12 hours later through the second dose on Day 7, inclusive.
48163478|NCT05658575|OTHER|Placebo Tablet|An initial loading dose of matching placebo (to mimic dapansutrile dosing) on Day 1 followed by a maintenance regimen of matching placebo twice daily starting 12 hours later through the second dose on Day 7, inclusive.
48163479|NCT04750577|DRUG|Placebo matching BI 685509|film-coated tablet
48163480|NCT04750577|DRUG|BI 685509|film-coated tablet
48163481|NCT05609721|OTHER|no intervention, only observational study|no intervention, only observational study
48163482|NCT01052870|DRUG|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
48692677|NCT04869059|DEVICE|sham tDCS|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
48163483|NCT06645769|DRUG|Sodium Phenylbutyrate|will be compared to placebo
48163484|NCT06645769|OTHER|Placebo|will be compared to NaPB
48692678|NCT03730233|PROCEDURE|Hiatal hernia repair by tension-free mesh closure|
48163485|NCT01383616|DEVICE|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
48163486|NCT04186117|OTHER|Blood sample|Blood sample before any treatment
48163487|NCT02921152|PROCEDURE|bone marrow aspiration /trephine biopsy|
48163488|NCT05122793|BEHAVIORAL|Prevention offer|Improvement of outcomes through lifestyle changes and improved health literacy
48163489|NCT02411214|OTHER|survey|questionnaire survey sent by regular mail for 3 groups
48368745|NCT06118840|DEVICE|True-AI-integrated intracranial aneurysms diagnosis strategy|The True-AI deep-learning based model for intracranial aneurysms detection had a patient-wise sensitivity, lesion-wise sensitivity and specificity of 0.96, 0.87, and 0.80 in the internal validation dataset.
48692679|NCT03730233|PROCEDURE|Hiatal hernia repair by simple suturing|
48692680|NCT00002297|DRUG|Inosine pranobex|
48692681|NCT06414733|BIOLOGICAL|Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified in ISA 720 vehicle. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with a Montanide ISA 720, and will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
48692682|NCT01827436|BEHAVIORAL|Conventional physical therapy|
48692683|NCT01827436|BEHAVIORAL|Asymmetrical gait training|
48692684|NCT00177294|DRUG|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
48692685|NCT00177294|BEHAVIORAL|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
48692686|NCT00177294|BEHAVIORAL|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
48692687|NCT06341114|DRUG|BAT8008 injection|BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.
48692688|NCT06341114|DRUG|BAT1308 injection|One vial of 4 mL of concentrate contains 100 mg of BAT1308
48692689|NCT04715854|DEVICE|Mask|addition of the mask above the nasal cannulas
48692690|NCT06477003|DEVICE|Multispectral Optoacoustic Tomography|The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
48692691|NCT06477003|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
48368746|NCT06118840|DEVICE|Sham-AI-integrated intracranial aneurysms diagnosis strategy|The Sham-AI deep-learning based model for intracranial aneurysms detection is designed to have a sensitivity close to 0% and a similar specificity to the True-AI. In the internal validation dataset, the Sham-AI had a patient-wise sensitivity, lesion-wise sensitivity, specificity of 0.02, 0.01, and 0.80, respectively.
48368747|NCT04246996|DRUG|gentamicin sulfate|Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.
48163490|NCT04978688|DRUG|Relugolix|Administered as an oral tablet once daily.
48006336|NCT02863835|OTHER|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
48006337|NCT01335958|DRUG|DMUC5754A|Escalating intravenous dose
48006338|NCT05983718|DEVICE|Surgical Guide|For this case, after the patient is given anesthesia, the guide will be placed on the teeth. All the drillings will be performed through the guided path. There will be no need for raising flap according to flapless surgery. At the end of the operation, the operation site will be checked and hemostasis will be provided. The operator will record the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
48006339|NCT05983718|PROCEDURE|Guide-pin-assisted Freehand surgery|The regular protocol of the implant surgery will be followed. Before the surgery begins, the patient will be given anesthesia to ensure they are comfortable and pain-free during the procedure. Doctors will go through the digital planning to understand the desired angulation. Then the bony bed will be prepared raising flap from targeted area. Then a guide-pin will be inserted by drilling and through radiographic image the direction will be confirmed. Following the hole of the guide-pin, the implant will be inserted. At the end of the operation, the raised flap will be sewn and hemostasis will be provided. The operator records the operation in the source documentation. 2 ± 1 days later, a postoperative CT scan will be taken. A follow-up visit will be due 14 ± 2 weeks later, after the osseointegration period.
48006340|NCT04596540|DRUG|SEL-212 low-dose|"SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR"
48006341|NCT04596540|DRUG|SEL-212 high-dose|"SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR"
48006342|NCT04596540|OTHER|Placebo|Normal saline
48006343|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
48006344|NCT02957890|BIOLOGICAL|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
48163491|NCT04978688|DRUG|E2/NETA|Administered as an oral tablet once daily.
48163492|NCT02145195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
48163493|NCT01905371|DRUG|Dextroamphetamine|
48163494|NCT01905371|OTHER|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
48163495|NCT01905371|DRUG|Placebo|
48163496|NCT00192166|BIOLOGICAL|CAIV-T|
48163497|NCT00556764|DRUG|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
48163498|NCT00556764|DRUG|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
48163499|NCT00993018|DRUG|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
48163500|NCT00993018|DRUG|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
48513894|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group|The regimen includes resistance training (using bands, weights, and bodyweight for major muscle groups) and core strengthening (targeting abdominal, lower back, hip, and gluteal muscles) exercises.
48513895|NCT06377618|DIAGNOSTIC_TEST|Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation|Group 1 Intervention plus Vitamin D Supplementation: Daily vitamin D supplementation, with the dosage adjusted based on initial serum 25(OH)D levels to achieve and maintain optimal vitamin D
48513896|NCT04975295|DRUG|LY3361237|Administered SC
48513897|NCT04975295|DRUG|Placebo|Administered SC
48513898|NCT05407311|DRUG|64Cu-SAR-BBN|64Cu-SAR-BBN
48513899|NCT05783232|DIETARY_SUPPLEMENT|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
48006345|NCT02957890|BIOLOGICAL|Placebo|Round 2 (May): 0.5mL normal saline
48163501|NCT00993018|DRUG|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
48163502|NCT00993018|DRUG|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
48163503|NCT01709643|DIETARY_SUPPLEMENT|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
48163504|NCT01709643|DIETARY_SUPPLEMENT|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
48163505|NCT04022603|DEVICE|Cyclometer Ergometer|The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
48163506|NCT05021965|PROCEDURE|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
48006346|NCT05466227|OTHER|Implementation of Modified Valsalva maneuvre|"Modified Valsalva maneuvre:~* Patient is attached to 12-lead ECG monitoring~* The patient sits in an upright position and performs forced expiration for 15 seconds by blowing on a 10 mL syringe~* Patient's legs are elevated (45°) for 15 seconds~* Afterwards, the patient is placed back in an upright position~* If not efficient, this maneuver can be repeated up to two times"
48006347|NCT04605757|OTHER|Clinical, functional and radiological lung involvement evolution|Observational / Clinical, functional and radiological long term evolution of SARS-COV-2 lung involvement
48006348|NCT01541930|DRUG|GK567|Once or twice daily, for 14 days, up to 30 g per day
48163507|NCT04176926|DIAGNOSTIC_TEST|Electrocardiogram|Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
48163508|NCT05414656|DEVICE|Saddle contoured metal matrix, Pre-contoured self-adhesive matrix|Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.
48163509|NCT03184519|DIAGNOSTIC_TEST|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
48163510|NCT06108596|DRUG|Sintilimab with Interleukin-2+CAPOX|Sintilimab with Interleukin-2+CAPOX
48163511|NCT03707418|DRUG|Heparin Sodium|Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
48163512|NCT03707418|DRUG|Bivalirudin Injection [Angiomax]|Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
48163513|NCT06407583|BEHAVIORAL|ProMIO2.0 program|"ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals:~* moderate/intensive exercise (e.g. walking) for 150-300 minutes per week~* Muscle-strengthening exercises 2x a week~* Supplemented with balance and flexibility exercises~* 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support.~The intervention is divided into 2 phases, which indicate the degree of professional guidance:~1. intensive guidance (month 0 - 3)~2. average guidance (months 4 - 6)"
48163514|NCT03925519|OTHER|Supervised aerobic exercise|
48163515|NCT02567227|OTHER|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
48163516|NCT02567227|OTHER|Active Control|Computer, multimedia and group based health education programs.
48163517|NCT01263275|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
48513900|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
48513901|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
48006349|NCT02181556|DRUG|FOLFIRI Protocol|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
48006350|NCT02181556|DRUG|Aflibercept Injection|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
48006351|NCT03957434|OTHER|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
48006352|NCT01147653|BIOLOGICAL|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
48006353|NCT01147653|OTHER|Placebo|Placebo
48163518|NCT04034602|OTHER|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
48163519|NCT04034602|OTHER|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
48163520|NCT06035003|BEHAVIORAL|Internet-based Mindfulness Intervention for Emotional Distress (iMIED)|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
48185271|NCT04996368|DRUG|Tranexamic acid injection|Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
48513902|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
48513903|NCT04201184|BEHAVIORAL|Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules|Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
48163521|NCT06176378|OTHER|traditional pulpotomy|After complete deroofing, the coronal pulp was amputated to the level of the orifice using a high-speed size #2 round bur followed by rinsing the pulp chamber thoroughly with 5ml 0.9% saline solution.Hemostasis was then achieved by placing a sterile cotton pellet moistened with saline in the access cavity for 6 min.Retro MTA capping material was then applied,
48692692|NCT05860257|BEHAVIORAL|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
48692693|NCT04003207|DRUG|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
48006354|NCT00413725|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
48006355|NCT00413725|OTHER|Placebo|Placebo
48006356|NCT02320890|DEVICE|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48006357|NCT02320890|DEVICE|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48163522|NCT06176378|DEVICE|diode laser pulpotomy|after establishing hemostasis, low-level laser energy at (970nm, power .5W, duty cycle 50%, and frequency 5H) was applied to each pulp stump for 10 sec. through 320 microns optical fiber tip . The laser was used in pulsed non-contact mode at the level of the occlusal surface of the tooth.Retro MTA capping material was then applied,
48163523|NCT06095518|DIAGNOSTIC_TEST|DIC markers and Thrombin Generation Parameters|Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
48163524|NCT01378481|DRUG|Vorinostat|Given PO
48163525|NCT01378481|RADIATION|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
48163526|NCT01378481|OTHER|Laboratory Biomarker Analysis|Correlative studies
48163527|NCT01378481|OTHER|Pharmacological Study|Correlative studies
48163528|NCT01378481|PROCEDURE|Therapeutic Conventional Surgery|Undergo neurosurgery
48163529|NCT02991781|OTHER|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
48163530|NCT02991781|DRUG|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
48163531|NCT02991781|OTHER|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
48692694|NCT05932654|DRUG|BSI-045B|Patients will be treated with BSI-045B.
48692695|NCT06439654|OTHER|Supportive care|The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.
48692696|NCT06495645|DEVICE|AI-assisted upper gastrointestinal endoscopy|AI-assisted upper gastrointestinal endoscopy
48692697|NCT06312410|OTHER|VIA Family 2.0|Multidisciplinary team based preventive intervention. For details, please see arm/group description.
48692698|NCT05570760|DEVICE|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
48692699|NCT05570760|PROCEDURE|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
48163532|NCT02991781|OTHER|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
48006358|NCT03940365|DEVICE|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
48006359|NCT04765488|PROCEDURE|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
48163533|NCT06108687|OTHER|water spray application|cold water kept in the refrigerator at +4 degrees
48006360|NCT01825408|DRUG|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
48006361|NCT01825408|DRUG|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
48006362|NCT01825408|DRUG|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
48692700|NCT05570760|DEVICE|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
48692701|NCT02712983|DRUG|TIP|TIP dose regimen
48692702|NCT02712983|DRUG|TIP and placebo|TIP and inhaled placebo dose regimen
48692703|NCT02712983|DRUG|Placebo|Inhaled placebo dose regimen
48006363|NCT01308190|DRUG|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
48006364|NCT01308190|RADIATION|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
48006365|NCT01308190|PROCEDURE|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
48006366|NCT01308190|PROCEDURE|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
48692704|NCT01934712|DRUG|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
48692705|NCT01934712|DRUG|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
48692706|NCT05236179|OTHER|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
48692707|NCT04322318|PROCEDURE|Biopsy|Undergo a biopsy
48692708|NCT04322318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48692709|NCT04322318|PROCEDURE|Bone Scan|Undergo a bone scan
48692710|NCT04322318|DRUG|Carboplatin|Given IV
48006367|NCT02310178|PROCEDURE|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
48006368|NCT02480556|PROCEDURE|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction \& cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
48006369|NCT02480556|PROCEDURE|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu \& uterus is massaged awaiting spontaneous placental separation"
48006370|NCT01158222|DRUG|sunitinib malate|Given orally
48163534|NCT01626677|BIOLOGICAL|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
48163535|NCT01626677|PROCEDURE|Microfracture|Active control
48163536|NCT06160986|BEHAVIORAL|Horizons Group Intervention|The Horizons Group intervention in English or Spanish language (per participant preference) contains 8 weekly group sessions delivered via video conference by a bone marrow transplant clinician and behavioral health specialist, over approximately 8 weeks, approximately 1.5 hours per session every week. The intervention pairs state-of-the-science information about survivorship and chronic graft versus host disease with self-management strategies. Intervention sessions will be delivered via video conference (Zoom), which participants may access by computer, laptop, tablet, or smart phone. As part of the intervention, participants will have access to an intervention manual and audio-recorded relaxation exercises to support learning and skills practice.
48163537|NCT04673799|DRUG|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
48163538|NCT04673799|DRUG|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
48692711|NCT04322318|PROCEDURE|Computed Tomography|Undergo a CT scan
48692712|NCT04322318|DRUG|Cyclophosphamide|Given IV
48692713|NCT04322318|DRUG|Doxorubicin|Given IV
48692714|NCT04322318|DRUG|Etoposide|Given IV
48692715|NCT04322318|DRUG|Ifosfamide|Given IV
48692716|NCT04322318|DRUG|Irinotecan|Given IV
48692717|NCT04322318|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48692718|NCT04322318|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
48692719|NCT04322318|RADIATION|Radiation Therapy|Undergo RT
48692720|NCT04322318|PROCEDURE|Surgical Procedure|Undergo surgery
48692721|NCT04322318|DRUG|Topotecan|Given IV
48692722|NCT04322318|PROCEDURE|Transabdominal Ultrasound|Undergo abdominal ultrasound
48692723|NCT04322318|DRUG|Vincristine|Given IV
48692724|NCT04322318|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
48692725|NCT06364150|BIOLOGICAL|Autologous Peripheral Blood Stem Cell injection|For peripheral blood stem cell mobilization, G-CSF and EPO will be injected for a total of 4 days, followed by collection of mobPBSC via apheresis. In ex-vivo setting, mobPBSC will be primed with Ang1 for 1 hour. A total of 2 X109 Ang1 primed mobPBSC will be injected to the culprit artery.
48692726|NCT04982341|PROCEDURE|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
48692727|NCT05749666|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
48692728|NCT05749666|DRUG|Prednisolone|Prednisolone taken daily according to preset tapering protocol
48692729|NCT05749666|OTHER|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
48692730|NCT05749666|OTHER|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
48692731|NCT02029755|PROCEDURE|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
48163539|NCT03343288|DEVICE|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
48163540|NCT05530460|DEVICE|retinal imaging with low-cost OCT device|Retinal imaging with low-cost OCT device
48163541|NCT05530460|DEVICE|retinal imaging with commercial OCT device|retinal imaging with commercial OCT device
48163542|NCT01137552|DRUG|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
48163543|NCT05313529|DRUG|Liraglutide|Liraglutide will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study
48163544|NCT05313529|DRUG|Empagliflozin|Empagliflozin will be initiated and maintained at 10mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
48163545|NCT05313529|DRUG|Linagliptin|Iinagliptin will be initiated at 5mg/ day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
48163546|NCT05680285|DEVICE|diode lazer|diode laser was applied during the pulpotomy procedure
48163547|NCT05680285|DEVICE|low level diode laser|Low-dose diode laser was applied during the pulpotomy procedure
48163548|NCT02775175|BEHAVIORAL|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
48163549|NCT04291703|DRUG|Antithymocyte Globulin|Thymoglobulin
48163550|NCT04291703|DRUG|Placebo (for ATG)|Normal Saline administered by IV infusion to mimic ATG
48163551|NCT02186496|DRUG|CKD-330 8/5mg|
48163552|NCT02186496|DRUG|Candesartan 8mg and Amlodipine 5mg|
48163553|NCT05102656|OTHER|Best Practice|Physician conversations occur in-person
48163554|NCT05102656|PROCEDURE|Discussion|Physician conversations occur via video call
48163555|NCT05102656|OTHER|Questionnaire Administration|Ancillary studies
48163556|NCT02787135|BEHAVIORAL|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
48163557|NCT05930002|DRUG|Ivermectin Tablets|oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
48163558|NCT05930002|DRUG|Colchicine 0.5 MG|0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
48163559|NCT05930002|DRUG|Standared managment|(Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
48163560|NCT05156216|OTHER|Patient education|Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
48163561|NCT04753281|OTHER|Lifestyle counselling|brief psychological intervention, based on the behaviour change whee
48163562|NCT03075111|DIAGNOSTIC_TEST|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
48163563|NCT02659384|DRUG|Bevacizumab|
48163564|NCT02659384|DRUG|atezolizumab|
48163565|NCT02659384|DRUG|acetylsalicylic acid|
48006371|NCT00849966|DRUG|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
48163566|NCT02659384|DRUG|placebo|
48006372|NCT00849966|DRUG|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
48006373|NCT03790826|DEVICE|cystoscopy|Comparison of bladder mucosa via cystoscopy.
48006374|NCT02677792|BEHAVIORAL|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
48006375|NCT02256891|DEVICE|PRFM|
48006376|NCT02256891|PROCEDURE|Double Row|
48006377|NCT04242056|DRUG|18F-PM-PBB3|"18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets."
48006378|NCT01424553|OTHER|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
48006379|NCT02150174|BEHAVIORAL|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
48006380|NCT01180738|BEHAVIORAL|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
48006381|NCT01180738|BEHAVIORAL|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
48692732|NCT02029755|PROCEDURE|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
48006382|NCT00997503|DEVICE|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
48163567|NCT06435624|DEVICE|intelligent rehabilitation robot training system|"Using an intelligent rehabilitation robot training system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function.~The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd."
48006383|NCT00997503|DRUG|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
48006384|NCT00997503|DRUG|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
48163568|NCT06435624|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
48163569|NCT06435624|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
48163570|NCT05123144|BEHAVIORAL|BHS+ORCHID|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
48163571|NCT04494243|DRUG|AD-214 10/600mg|1 tablet administered before the breakfast during 7 days
48006385|NCT00997503|DRUG|aspirin|"Oral, as prescribed by physician through end of study.~."
48163572|NCT04494243|DRUG|Rabeprazole 10mg|1 tablet administered before the breakfast during 7 days
48163573|NCT00346177|BIOLOGICAL|Autologous Stem Cells|Intramyocardial injections
48163574|NCT03129971|PROCEDURE|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
48163575|NCT03129971|PROCEDURE|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
48692733|NCT02029755|PROCEDURE|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
48692734|NCT05407649|RADIATION|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
48692735|NCT05031338|DEVICE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
48692736|NCT05031338|PROCEDURE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
48692737|NCT03939962|DRUG|SHR1210 combined with FOLFOX|"1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
48692738|NCT06407349|OTHER|Communication Board|communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)
48692739|NCT06407349|OTHER|Traditional Therapy|Traditional Therapy
48163576|NCT02968654|PROCEDURE|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
48692740|NCT04833686|BEHAVIORAL|Mozart|Music composed by Mozart, a musical piece 24 minutes long.
48692741|NCT04833686|BEHAVIORAL|Instrumental music|Instrumental music , a musical piece 24 minutes long
48692742|NCT04833686|BEHAVIORAL|Silence|Silence, a piece 24 minutes long.
48692743|NCT06660862|DRUG|Darolutamide|How darolutamide and hormone therapy affects the step count of older men who have prostate cancer
48692744|NCT06660862|DRUG|Physician choice Androgen Deprivation (Hormone) Therapy|How step count/physical activity affects certain quality of life changes these men experience such as differences in pain, mood, function, memory and fatigue
48692745|NCT05484934|PROCEDURE|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
48692746|NCT03629223|DRUG|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
48006386|NCT03781076|BEHAVIORAL|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
48006387|NCT00003694|DRUG|omacetaxine mepesuccinate|Given IV
48006388|NCT00003694|DRUG|cytarabine|Given IV
48368748|NCT04246996|OTHER|Catheter clamping only|Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
48513904|NCT04201184|BEHAVIORAL|Active nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
48513905|NCT01404676|DRUG|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
48006389|NCT00003694|OTHER|laboratory biomarker analysis|Correlative studies
48006390|NCT01451346|DIETARY_SUPPLEMENT|B. Infantis 35624|One sachet daily for 12 weeks
48006391|NCT04498962|DRUG|Danzhu Fuyuan Granule|Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
48006392|NCT02682316|OTHER|dry gauze|
48006393|NCT02682316|DEVICE|The Prevena Incision Management System|
48006394|NCT05404269|DEVICE|AGC mode|Automated Gas Control mode at Maquet FLOW-i anesthesia machine
48006395|NCT01038271|OTHER|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
48513906|NCT01404676|DRUG|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
48513907|NCT03104855|DRUG|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
48513908|NCT06115083|OTHER|Pelvic floor re-education using bio-feedback and home training|Pelvic floor re-education using bio-feedback and home training
48513909|NCT04979351|OTHER|Abdominal Massage|Abdominal massage will be applied twice a day.
48006396|NCT01038271|OTHER|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
48006397|NCT03299842|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
48006398|NCT04683185|DRUG|E6742|E6742 tablets.
48006399|NCT04683185|DRUG|Placebo|E6742-matched placebo tablets.
48006400|NCT04163744|DEVICE|Double balloon catheter|Induction of labour with double balloon catheter
48006401|NCT03072212|OTHER|Observational study|No intervention
48006402|NCT00647621|DRUG|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
48006403|NCT00647621|DRUG|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
48006404|NCT01833403|OTHER|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~--------------------------------------------------------------------------------"
48006405|NCT03632291|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
48006406|NCT03365674|DEVICE|Vibration|Vibration applied with vibrator switch-on state (100Hz)
48006407|NCT03365674|DEVICE|Placebo vibration|Vibrator applied with switch-off state
48006408|NCT00658112|DRUG|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
48006409|NCT04218058|PROCEDURE|reduction of zygomatic arch in zygomaticomaxillary complex fracture|ultrasound guided reduction of zygomatic arch
48006410|NCT04675424|DEVICE|ANSwatch|"ANSwatch wrist sphygmomanometer and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients. Two measurements will be obtained:~1. Pulse diagnosis: Pulse diagnosis done on radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.~2. Heart rate variability: Heart Rate Variability represents significant information on autonomic nervous system (ANS)'s regulating function and balance status."
48006411|NCT04495114|OTHER|40g carbohydrate load (Apple juice)|A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
48006412|NCT01470846|PROCEDURE|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
48163577|NCT02968654|PROCEDURE|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
48692747|NCT03629223|DRUG|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
48692748|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g
48692749|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g
48692750|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g
48692751|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g
48692752|NCT03813407|DRUG|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
48692753|NCT03941873|DRUG|Sitravatinib|Administered orally as a capsule
48692754|NCT03941873|DRUG|Tislelizumab|Administered intravenously
48006413|NCT01470846|PROCEDURE|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
48006414|NCT06502288|DRUG|625 mg of amoxicillin with combined clavulanic acid tablet|The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
48692755|NCT04723355|DEVICE|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
48006415|NCT05817396|BEHAVIORAL|Promotion of Physical Activity-related Health Competence (PAHCO)|"Intervention for the curriculum content PAHCO at nursing schools in Bavaria"
48006416|NCT04198727|OTHER|DPD activity assessment|Phenotyping DPD with enzyme activity measure and uracil dosage
48006417|NCT04198727|DRUG|Capecitabine|Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
48163578|NCT03425461|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
48692756|NCT04723355|DEVICE|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
48006418|NCT00286416|DRUG|omalizumab (Xolair)|
48163579|NCT03425461|BIOLOGICAL|Ipilimumab|Given IV
48692757|NCT06071793|OTHER|Family involvement|Family delivery of mobility activities
48692758|NCT01731158|DRUG|Avastin in combination with Roferon-A|
48692759|NCT01731158|DRUG|Afinitor|
48692760|NCT01731158|DRUG|TKI: Sutent, Nexavar or Votrient|TKI
48692761|NCT01404559|DEVICE|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
48692762|NCT01404559|DEVICE|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
48006419|NCT03587610|BIOLOGICAL|Remedial vaccination|"* if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
48006420|NCT00610493|DRUG|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
48006421|NCT00610493|DRUG|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
48006422|NCT00610493|PROCEDURE|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
48006423|NCT00610493|PROCEDURE|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
48006424|NCT00610493|PROCEDURE|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
48163580|NCT03425461|OTHER|Laboratory Biomarker Analysis|Correlative studies
48368749|NCT05732324|PROCEDURE|IVUS guided PCI optimization|PCI to long lesion will be optimized according to the IVUS.
48368750|NCT05732324|PROCEDURE|FFR guided PCI optimization|PCI to long lesion will be optimized according to the FFR.
48368751|NCT05732324|DIAGNOSTIC_TEST|FFR measurement|Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
48368752|NCT00496574|BIOLOGICAL|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
48368753|NCT03088306|DRUG|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
48692763|NCT01404559|DEVICE|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
48692764|NCT06655792|OTHER|Educational Program on Mental Illness Stigma Reduction|The intervention consists of an 8-session educational program designed to reduce stigma towards mental illness among primary healthcare providers. The program includes lectures and multimedia presentations on mental health, stigma, and its effects. It engages participants in role-playing exercises to simulate the experience of stigma and improve communication skills. Group discussions allow participants to reflect on personal beliefs and attitudes, and case studies provide real-world examples of stigma and intervention strategies. The program spans four days, with two sessions per day, each lasting 50-60 minutes.
48692765|NCT06660927|DEVICE|liac Bifurcation Stent Graft System|to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
48006425|NCT00240370|DRUG|Muraglitazar|
48006426|NCT05093699|DEVICE|Butterfly iQ+ ultrasound probe|Diagnostic ultrasound probe on-market (FDA approved) capable of dual-plane viewing
48006427|NCT05093699|DEVICE|Ultrasound probe|Standard single-view ultrasound probe
48368754|NCT03088306|DRUG|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
48368755|NCT03088306|DRUG|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
48368756|NCT03088306|DRUG|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
48513910|NCT05361915|DRUG|Abivertinib|Abivertinib is a small molecule inhibitor
48513911|NCT05361915|DRUG|Abiraterone|Hormone-based chemotherapy
48513912|NCT05706857|BEHAVIORAL|Ultra Fast-track|Patients are extubated in the operating room
48692766|NCT05431595|DRUG|Haloperidol|Given by Vein (IV)
48692767|NCT05431595|DRUG|Chlorpromazine|Given by Vein (IV)
48692768|NCT05431595|DRUG|Valproate|Given by Vein (IV)
48692769|NCT05431595|DRUG|Placebo|Given by Vein (IV)
48692770|NCT04801849|DRUG|Vitamin E|Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
48692771|NCT04801849|DRUG|Placebo|Participants will take a placebo vitamin E capsule daily for 24 weeks
48163581|NCT03425461|BIOLOGICAL|Nivolumab|Given IV
48163582|NCT03425461|OTHER|Pharmacological Study|Correlative studies
48163583|NCT04664985|DEVICE|Mucogyne® ovule|hyaluronic acid, vaginal ovule
48163584|NCT02852811|OTHER|Group education|Intervention involving two education session with topics common in menopause transition.
48163585|NCT01369147|DRUG|Parenteral Nutrition|The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
48163586|NCT01369147|DRUG|Propofol|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
48163587|NCT01369147|DRUG|Clevidipine|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
48163588|NCT01369147|DRUG|Dextrose-containing IV Fluids|The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
48006428|NCT05819034|OTHER|Scoliosis-Specific Exercise Program|"Adolescents in the control group will receive a scoliosis-specific exercise program which will be prescribed to control the progression of the scoliotic curve. This exercise program will include frontal plane active or passive correction exercises for scoliotic posture. The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour.~The exercise program for every participant will be three sessions per week for 12 successive weeks. Every treatment session was applied for one hour."
48006429|NCT05819034|OTHER|Soft orthoses with external strapping.|Adolescents in the experimental group will receive a scoliosis-specific exercises program which will be prescribed to control the progression of the scoliotic curve in addition to wearing the soft orthoses with external strapping. The wearing schedule of the soft orthosis with the external strapping for every participant in this group will be 12 hours daily for 12 successive weeks.
48006430|NCT01521611|RADIATION|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
48006431|NCT03467425|DRUG|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
48006432|NCT03467425|DRUG|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
48006433|NCT03467425|DRUG|LAMA|LAMA as prescribed by the physician.
48006434|NCT03467425|DRUG|LABA|LABA as prescribed by the physician.
48006435|NCT03467425|DRUG|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
48006436|NCT05112198|DEVICE|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
48006437|NCT03688321|DIETARY_SUPPLEMENT|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
48006438|NCT03688321|DIETARY_SUPPLEMENT|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
48006439|NCT00271479|BIOLOGICAL|A, C, Y, W135 meningococcal polysaccharide vaccine|
48006440|NCT00002183|DRUG|Abacavir sulfate|
48692772|NCT05923827|DEVICE|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
48692773|NCT04436107|DRUG|Zanubrutinib|160 mg administered orally twice daily (BID)
48692774|NCT04436107|DRUG|Lenalidomide|Administered as specified in the treatment arm
48006441|NCT00002183|DRUG|Amprenavir|
48006442|NCT00002183|DRUG|Lamivudine|
48006443|NCT00002183|DRUG|Zidovudine|
48692775|NCT06504459|DRUG|Azacitidine|Given IV or SC
48692776|NCT06504459|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48692777|NCT06504459|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
48006444|NCT02927457|DRUG|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
48006445|NCT02927457|DRUG|Placebo|Subjects will receive matching Placebo topically.
48006446|NCT04067284|BEHAVIORAL|Nutrition education|"Nutrition Education on~* Continued breastfeeding until two years of age~* Food groups~* Balanced diet~* Introduction to locally available nutritious and low-cost foods~* Amount and frequency of complementary feeding~* Safe water, and~* Handwashing with soap before feeding"
48006447|NCT04067284|DIETARY_SUPPLEMENT|Homemade yogurt supplementation|The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.
48006448|NCT04067284|OTHER|Usual care|No intervention/ control group
48006449|NCT02036099|OTHER|Driving in Mild Dementia Decision Tool|
48006450|NCT01467076|DRUG|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
48692778|NCT06504459|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
48692779|NCT06504459|DRUG|Cladribine|Given IV
48692780|NCT06504459|DRUG|Cytarabine|Given SC
48692781|NCT06504459|PROCEDURE|Echocardiography|Undergo ECHO
48692782|NCT06504459|PROCEDURE|Lumbar Puncture|Undergo LP
48513913|NCT02522923|OTHER|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
48692783|NCT06504459|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48692784|NCT06504459|OTHER|Questionnaire Administration|Ancillary studies
48692785|NCT06504459|DRUG|Venetoclax|Given PO
48006451|NCT01467076|DRUG|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 \[150\], IPGE1 \[300\], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
48006452|NCT04973761|OTHER|Zirconium crowns|Prefabricated pirmary anteroir teeth zirconium crowns
48006453|NCT04973761|OTHER|Strip composite crowns|Strip composite crowns
48513914|NCT02522923|OTHER|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
48692786|NCT06173544|BEHAVIORAL|Standard of Care (SOC)|Participants randomized to this arm will received enhanced standard of care.
48692787|NCT06173544|BEHAVIORAL|Adapted Friendship Bench (AFB)|Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
48692788|NCT06173544|BEHAVIORAL|Enhanced Friendship Bench (EFB)|Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
48692789|NCT04502316|DEVICE|Barostim™ System|Implantation of the Barostim™ System
48692790|NCT00158249|DRUG|citicoline|2 gm/day, 8 weeks treatment
48692791|NCT00158249|DRUG|placebo|matched for physical appearance
48692792|NCT01454128|BEHAVIORAL|exercise|36 session supervised exercise intervention
48006454|NCT03108846|DRUG|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
48006455|NCT03108846|DRUG|Placebo|Masked placebo
48692793|NCT06637254|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
48692794|NCT06637254|DRUG|Placebo|the placebo comparator of study
48692795|NCT03172078|PROCEDURE|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
48692796|NCT06503848|DRUG|Sumatriptan|Register the response to treatment and headache characteristics.
48692797|NCT04876404|DIAGNOSTIC_TEST|PET/MR Imaging|The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.
48692798|NCT01562314|DRUG|GWP42003|1 to 5 50 mg capsules taken BID
48692799|NCT01562314|DRUG|Placebo|1 to 5 matching capsules taken BID
48692800|NCT05171400|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
48692801|NCT05171400|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
48163589|NCT01369147|DRUG|Enteral feeding|Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
48163590|NCT04158453|DRUG|AUT00201|Oral dose of AUT00201
48163591|NCT04158453|DRUG|Placebo|Oral dose of placebo
48368757|NCT03088306|DRUG|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
48368758|NCT03088306|DRUG|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
48692802|NCT05171400|DEVICE|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
48692803|NCT06412835|OTHER|cooperative learning|Students working in groups
48006456|NCT01423448|OTHER|bulletin board|An asynchronous online bulletin board for people with experience of depression
48006457|NCT05761275|PROCEDURE|Elective cystectomy|Adnexal cyst removal for presumed benign adnexal pathology.
48006458|NCT05761275|PROCEDURE|Elective oophorectomy|Ovarian removal for presumed benign adnexal pathology.
48006459|NCT05761275|PROCEDURE|Elective salpingectomy|Tubal removal for presumed benign adnexal pathology.
48006460|NCT05761275|PROCEDURE|Elective tubal sterilization|Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).
48006461|NCT01037946|BEHAVIORAL|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
48006462|NCT05940935|PROCEDURE|Arterial Blood Gas Base Deficit|The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.
48163592|NCT03857516|DEVICE|Multipolar left ventricular lead implantation|Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
48163593|NCT04433949|OTHER|Best Practice|Receive standard of care
48692804|NCT05961241|OTHER|runnin training program|gradual training program
48692805|NCT05033886|DRUG|fezolinetant|oral
48692806|NCT05033886|DRUG|placebo|oral
48692807|NCT06331546|DIETARY_SUPPLEMENT|Low-oxalate diet|4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
48692808|NCT06331546|DIETARY_SUPPLEMENT|High-oxalate diet|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
48163594|NCT04433949|RADIATION|Low Dose Radiation Therapy|Undergo LDRT
48163595|NCT03358303|DEVICE|Medly|Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
48692809|NCT06331546|OTHER|soluble oxalate gut absorption test|Oral ingestion of 13C2-oxalate and sucralose.
48692810|NCT00316706|BIOLOGICAL|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
48163596|NCT00647283|PROCEDURE|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
48163597|NCT00733551|DRUG|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
48163598|NCT00733551|DRUG|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
48692811|NCT00316706|BIOLOGICAL|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
48692812|NCT00146926|DRUG|kétamine 20mg|
48692813|NCT00146926|DRUG|ephedrine 3mg|
48692814|NCT00146926|DRUG|lidocaine 40mg|
48692815|NCT04932434|DRUG|Psilocybin therapy|"* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"
48692816|NCT03848130|OTHER|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
48692817|NCT03848130|OTHER|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
48692818|NCT03848130|OTHER|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
48692819|NCT00901238|PROCEDURE|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
48692820|NCT01741233|GENETIC|VitDgen|
48692821|NCT02780583|DRUG|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
48692822|NCT02780583|DRUG|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
48692823|NCT01766297|RADIATION|Proton Radiotherapy|
48163599|NCT04585737|DRUG|Dolutegravir / Lamivudine Pill|Experimental
48163600|NCT04585737|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill|Active comparator
48163601|NCT06329011|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48692824|NCT06477952|DRUG|Dronabinol|Open label Dronabinol treatment for two weeks.
48692825|NCT06401668|BEHAVIORAL|Community health worker (CHW) strategy|CHWs will offer participants personalized support to assist in overcoming barriers and leveraging facilitators to PRx uptake. CHWs are trained lay members of the communities they serve. The CHW strategy is an evidence-based.
48692826|NCT06401668|BEHAVIORAL|PRx Program|The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.
48692827|NCT05504291|PROCEDURE|Biospecimen Collection|Undergo aqueous humor and tissue sample collection
48692828|NCT05504291|DRUG|Carboplatin|Given IV
48692829|NCT05504291|DRUG|Etoposide|Given IV
48692830|NCT05504291|PROCEDURE|Examination Under Anesthesia|Undergo imaging of the eye during EUA
48692831|NCT05504291|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48692832|NCT05504291|DRUG|Melphalan|Given I-VITRE
48692833|NCT05504291|PROCEDURE|Ultrasound Biomicroscopy|Undergo UBM during EUA
48692834|NCT05504291|DRUG|Vincristine|Given IV
48163602|NCT06329011|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48163603|NCT06329011|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
48006463|NCT03588364|OTHER|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
48006464|NCT01849588|DRUG|Sorafenib|
48692835|NCT06581224|OTHER|Primary Hospital Provider Team|The PHP team aims to enhance continuity during hospital readmissions with a consistent cohort of seven hospital medicine physicians and two advanced practice providers (APPs). To improve care transitions, the team will have an integrated case manager who will continue following PHP patients during subsequent hospitalizations. Physicians will follow a standard seven-day service schedule, with the two APPs alternating five-to-seven-day periods. Daily huddles between physicians and APPs will further promote continuity. During the index admission, the PHP team will create a care plan in consultation with the patient to improve standardization of inpatient care and transition to outpatient settings. Communication will be a core tenet of the team, with scheduled monthly team meetings of physicians, APPs, case manager, dyad partner, and representatives from nursing and therapy services to revise individualized care plans for PHP patients and brainstorm solutions for complex challenges.
48692836|NCT05254990|DRUG|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
48006465|NCT05714488|DEVICE|blue halo coil catheter|device inserted with coil at the bladder and straight arm in the prostatic urethra proximal to the external sphincter
48006466|NCT00534235|PROCEDURE|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
48006467|NCT00534235|DEVICE|Posterolateral Fusion and Implantation of Pedicle Screws|
48006468|NCT00534235|DEVICE|Implantation of coflex Interlaminar Technology|
48006469|NCT05794256|OTHER|No interventions are planned|No interventions are planned
48006470|NCT04524312|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior-stabilized or retaining cruciate-retaining with dynamic congruence implant
48006471|NCT04524312|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
48006472|NCT04524312|DEVICE|NexGen Ps or Bioimplanti K-MOD implant|Participant are randomly allocated to receive one of the NexGen PS or Biomplanti K-MOD total knee implant for treatment of end-stage knee osteoarthritis.
48006473|NCT02023151|DRUG|Omalizumab|
48006474|NCT05934435|OTHER|Empowered Relief|psycho-educational pain skills training
48006475|NCT06174324|DEVICE|PreserFlo Microshunt|The PreserFlo MicroShunt was invented to create a minimally invasive glaucoma drainage device, that comes close to the eye pressure reduction and safety profile of the current gold standard, the trabeculectomy. Reference: Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK 2nd, Weber BA, Kwon Y, Parel JM. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017 Jan;105(1):211-221. doi: 10.1002/jbm.b.33525. Epub 2015 Sep 18. PMID: 26380916; PMCID: PMC5215625.
48006476|NCT01276314|DRUG|anti- TNF-a|25mg BIW, SC
48006477|NCT01276314|DRUG|Prednisolone|1-1.5 mg / kg / day
48006478|NCT03892980|DEVICE|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Surgical Systems.
48006479|NCT05374811|OTHER|Neuropathic Pain|Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
48006480|NCT00446719|DRUG|Rellidep|2000 mg P.O. daily for 8 weeks
48006481|NCT04433468|DEVICE|RIPC|The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
48006482|NCT03440671|BIOLOGICAL|Hutox Inj|Hutox Inj(Clostridium botulinum type A)
48006483|NCT03440671|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
48692837|NCT05254990|OTHER|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
48692838|NCT06659003|OTHER|Pilot Implementation of Network Canvas into HBH Partner Services|Our team deployed our network data capture software - Network Canvas - into Partner Services at HBH to examine feasibility and acceptability and to provide initial evidence of efficacy (examining impacts on data quality, number of partners notified, and timeliness). Further, our team worked closely with HBH on developing implementation strategies, a Network Canvas interview protocol, evaluation measures, and training materials for their staff. Finally, we provided the HBH team technical support, and regular coaching, supervision, and evaluation.
48006484|NCT04165668|OTHER|Exposure: First on scene|To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
48163604|NCT06329011|BEHAVIORAL|Placebo Transcranial direct current stimulation|The Transcranial direct current stimulation will be performed without being turned on.
48163605|NCT02966600|OTHER|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
48163606|NCT02966600|OTHER|Physical Activity|The control group followed its usual weekly physical activity routine
48163607|NCT05469867|DEVICE|CorNeat EverPatch|The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
48692839|NCT06017609|DRUG|JTT-861 Capsules|Active drug capsules containing JTT-861
48692840|NCT06017609|DRUG|Placebo Capsules|Placebo capsules matching in appearance to the active drug capsules
48163608|NCT01960114|DRUG|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
48163609|NCT01960114|DRUG|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
48163610|NCT04140422|OTHER|Hyperosmolar eye drops|Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators
48163611|NCT04140422|OTHER|Placebo|Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
48163612|NCT02885883|DEVICE|MRI 3T|
48163613|NCT05246618|DRUG|TUM012|Ex-vivo infusion
48006485|NCT05147896|DRUG|Semaglutide Oral Tablet|Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
48006486|NCT01679275|OTHER|measuring cerebral oxygenation|
48006487|NCT03900299|PROCEDURE|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
48006488|NCT03160963|OTHER|Power Testing|Chair stand, vertical jump, computerized squat
48163614|NCT05246618|DRUG|Placebo|Ex-vivo infusion
48368759|NCT03088306|DRUG|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
48692841|NCT05315674|DIAGNOSTIC_TEST|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
48163615|NCT02880306|OTHER|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
48163616|NCT02754310|OTHER|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
48163617|NCT02754310|OTHER|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
48163618|NCT03979235|DIAGNOSTIC_TEST|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
48163619|NCT00375583|DRUG|DEC/Albendazole|
48163620|NCT04700488|DIAGNOSTIC_TEST|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
48163621|NCT05160597|PROCEDURE|Biopsy of Prostate|Undergo image-guided prostate biopsy
48163622|NCT05160597|OTHER|Gallium Ga 68 Gozetotide|Given IV
48163623|NCT05160597|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo standard of care TRUS
48163624|NCT01954758|OTHER|personalized Embryo Transfer (pET)|
48368760|NCT03088306|DRUG|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
48692842|NCT01691105|OTHER|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
48006489|NCT02418468|DRUG|Indacaterol|Indacaterol 150µg capsules for inhalation daily
48006490|NCT02418468|DRUG|Placebo|Matching placebo indacaterol capsules for inhalation daily
48006491|NCT05190042|DEVICE|Cotinuous suture|Cotinuous suture using surgery thread
48006492|NCT05190042|DEVICE|Clips|Hemostatic clips
48163625|NCT01954758|OTHER|Frozen Embryo Transfer (FET)|
48163626|NCT01954758|OTHER|Fresh Embryo Transfer (ET)|
48163627|NCT05878249|PROCEDURE|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
48006493|NCT02530424|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
48006494|NCT02530424|DRUG|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
48006495|NCT02530424|DRUG|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
48692843|NCT00705497|PROCEDURE|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
48692844|NCT03990623|RADIATION|Computed Tomography Perfusion Imaging|Undergo perfusion CT
48692845|NCT03990623|PROCEDURE|Liver Biopsy|Undergo liver biopsy
48692846|NCT06659042|DRUG|Tislelizumab|administered via Intravenous (IV) injection
48692847|NCT06659042|DRUG|Cisplatin|administered via IV infusion
48692848|NCT06659042|DRUG|Carboplatin|administered via IV infusion
48692849|NCT06659042|DRUG|Pemetrexed Disodium|administered via IV infusion
48692850|NCT04654169|PROCEDURE|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
48692851|NCT04654169|PROCEDURE|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
48692852|NCT02182024|DRUG|Dabigatran etexilate high dose|
48006496|NCT02530424|DRUG|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
48006497|NCT06484777|DRUG|SHR-9539 for injection|SHR-9539 for dose escalation/dose extension
48006498|NCT01533610|PROCEDURE|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
48006499|NCT02703571|DRUG|ribociclib|Combination treatment with LEE and TMT
48006500|NCT02703571|DRUG|Trametinib|Combination treatment with LEE and TMT
48006501|NCT06466174|DIETARY_SUPPLEMENT|Placebo 1 to Probiotic A|42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)
48006502|NCT06466174|DIETARY_SUPPLEMENT|Probiotic A to Placebo 1|42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)
48006503|NCT06466174|DIETARY_SUPPLEMENT|Placebo 2 to Probiotic B|42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)
48006504|NCT06466174|DIETARY_SUPPLEMENT|Probiotic B to Placebo 2|42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)
48006505|NCT01289808|DRUG|Glucose 25%|1ml of glucose 25% once
48006506|NCT01289808|DRUG|Glucose 25%|1ml glucose once per os
48368761|NCT00579605|BEHAVIORAL|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
48368762|NCT04892095|OTHER|No intervention|This is an observational cross-sectional study. No intervention is considered.
48368763|NCT06155851|PROCEDURE|Upper Endoscopy|Endescopy
48368764|NCT04367324|DEVICE|Low-level laser therapy|The low-level laser was applied to each patient in low-level laser therapy group.
48368765|NCT01191359|BIOLOGICAL|oral immunotherapy|orally applied specific immunotherapy
48368766|NCT00755976|DRUG|epirubicin hydrochloride|
48368767|NCT00755976|DRUG|sulindac|
48368768|NCT00755976|OTHER|immunologic technique|
48513915|NCT05975528|DRUG|SGLT2 inhibitor|"For the SGLT2 inhibitor group, total drug adminstration days are 180 days, but non-SGLT2 inhibitor administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.~For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered."
48513916|NCT05975528|DRUG|Glimepiride|For non-SGLT2 inhibitor (glimepiride) administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.
48692853|NCT02182024|DRUG|Dabigatran etexilate low dose|
48692854|NCT05764005|BEHAVIORAL|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
48692855|NCT05764005|BEHAVIORAL|MUSIC website|Standard of care educational materials {add more detail}
48692856|NCT06102200|BEHAVIORAL|CBT4CBT|This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.
48692857|NCT06102200|BEHAVIORAL|RC|Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.
48692858|NCT06102200|BEHAVIORAL|Sandard of care|Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.
48692859|NCT06264986|DIETARY_SUPPLEMENT|Ashwagandha|The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
48692860|NCT06264986|OTHER|Placebo|600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
48692861|NCT02052882|BIOLOGICAL|romiplostim|
48692862|NCT01606176|DRUG|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
48692863|NCT01606176|DRUG|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
48692864|NCT06249152|DRUG|QLS-111, 0.015%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
48692865|NCT06249152|DRUG|QLS-111, 0.030%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
48692866|NCT06249152|DRUG|QLS-111, 0.075%|QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
48692867|NCT06249152|DRUG|QLS-111 vehicle ophthalmic solution|Vehicle drops applied QPM for 14 days the BID for 14 days.
48692868|NCT05431387|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
48692869|NCT05431387|DRUG|Placebo|film-coated oral tablets containing matched placebo
48692870|NCT05431387|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
48006507|NCT02620098|OTHER|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
48006508|NCT02164552|DIETARY_SUPPLEMENT|Vitamin D3 pills|Dietary supplement
48006509|NCT02164552|OTHER|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
48006510|NCT02410811|OTHER|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
48006511|NCT00906191|DRUG|SAM-531|
48006512|NCT04061694|PROCEDURE|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
48006513|NCT04061694|PROCEDURE|Immediate loading|Only subjected to immediate loading. Conventional procedure.
48006514|NCT02386943|DRUG|Sitagliptin|100mg po once.
48006515|NCT02386943|DRUG|Saxagliptin|5mg po once.
48006516|NCT02386943|DRUG|Blank control|No medication is taken.
48368769|NCT01856920|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
48368770|NCT01101321|DRUG|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
48368771|NCT01101321|DRUG|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
48368772|NCT02440191|RADIATION|3DCRT|conventional radiotherapy
48692871|NCT04610619|OTHER|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
48692872|NCT03842228|PROCEDURE|Biopsy|Undergo tumor biopsy
48692873|NCT03842228|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48692874|NCT03842228|PROCEDURE|Computed Tomography|Undergo CT
48692875|NCT03842228|DRUG|Copanlisib Hydrochloride|Given IV
48692876|NCT03842228|BIOLOGICAL|Durvalumab|Given IV
48692877|NCT03842228|PROCEDURE|Echocardiography|Undergo ECHO
48692878|NCT03842228|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48692879|NCT03842228|DRUG|Olaparib|Given PO
48692880|NCT03842228|PROCEDURE|X-Ray Imaging|Undergo x-ray
48692881|NCT06388746|OTHER|BRIX3000®|A gel that when applied to the tooth completely removes carious tissues in a chemo mechanical way without rotary instruments. It contains an enzyme that has bactericidal, bacteriostatic and anti-inflammatory properties and proteolytic properties that help soften and break down decayed tissue without destroying the underlying healthy collagen fibers.
48692882|NCT06388746|OTHER|Riva Star Aqua, SDI Limited, Australia|A solution that contains 44,800 ppm F and 253,870 ppm Ag. It acts as a fluoride storage for the acid challenges, while inhibites demineralization of hydroxyapatite crystals and preserves collagen from degradation in demineralized tissues.
48006517|NCT05161065|DEVICE|Cardiologs|Apple Watch recordings interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
48006518|NCT00191503|DRUG|Pemetrexed|
48006519|NCT00191503|DRUG|Gemcitabine|
48006520|NCT03385252|OTHER|Eggs|Eggs provided as complementary food for the infant
48692883|NCT04745637|DRUG|Ruxolitinib|Patients receive Ruxolitinib
48006521|NCT03385252|BEHAVIORAL|Visits|Twice weekly household visits by study staff
48006522|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) in water|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) in water containing 0,41 g of tested protein/kg of body weight.
48006523|NCT06381869|DIETARY_SUPPLEMENT|Pea protein (NUTRALYS ® S85 plus) within meal|After selection and randomization, the subjects will consume per os Pea protein (NUTRALYS® S85 plus) within a meal containing 0,41 g of tested protein/kg of body weight.
48006524|NCT06381869|DIETARY_SUPPLEMENT|Whey protein in water|After selection and randomization, the subjects will consume per os whey protein in water containing 0,41 g of tested protein/kg of body weight.
48006525|NCT06381869|DIETARY_SUPPLEMENT|Whey protein within meal|After selection and randomization, the subjects will consume per os whey protein within a meal containing 0,41 g of tested protein/kg of body weight.
48006526|NCT01127503|DRUG|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
48006527|NCT01127503|DRUG|Placebo|Placebo capsules were identically matched to Metyrosine.
48006528|NCT02117037|OTHER|blood sample|
48006529|NCT01816464|BIOLOGICAL|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
48006530|NCT01515969|DRUG|Erlotinib hydrochloride|Given PO
48692884|NCT02844244|BEHAVIORAL|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
48692885|NCT03718806|DRUG|Zoliflodacin|oral suspension; oral administration
48006531|NCT01515969|DRUG|Dovitinib lactate|Given PO
48006532|NCT04737538|OTHER|Experimental Dentrifrice|Toothpaste containing sodium bicarbonate, sodium hyaluronate and sodium fluoride
48006533|NCT04737538|OTHER|Positive control dentifrice|Dentifrice containing 67% w/w sodium bicarbonate and 0.221% w/w sodium fluoride
48006534|NCT04737538|OTHER|Negative control dentifrice|Dentifrice containing 1100ppm fluoride as sodium fluoride (Crest Cavity Protection)
48006535|NCT03702478|OTHER|Questionnaire|No intervention only observational
48006536|NCT01337297|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
48006537|NCT01876264|PROCEDURE|Extended resection|
48006538|NCT01876264|PROCEDURE|Conventional resection|
48006539|NCT00186667|PROCEDURE|high dose chemotherapy and autologous hematopoietic cell transplant|
48006540|NCT05431062|DRUG|Bupivacain|%0.25
48006541|NCT02008500|OTHER|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
48692886|NCT03718806|OTHER|high calorie, high fat breakfast|fasted/fed conditions
48692887|NCT06440122|DIAGNOSTIC_TEST|FDG-PET Scan|Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan
48692888|NCT04797273|BEHAVIORAL|Internet-based cognitive behavior therapy|12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
48006542|NCT02008500|OTHER|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
48006543|NCT02008500|OTHER|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
48006544|NCT00675857|DRUG|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
48006545|NCT00675857|OTHER|placebo|Dosage: 4 capsules BID for 26 weeks
48006546|NCT02075320|DEVICE|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
48006547|NCT00075166|PROCEDURE|Stereotactic surgery (SRS)|
48006548|NCT00075166|PROCEDURE|Craniotomy|
48006549|NCT04021264|DRUG|Ropivacaine-Sufentanil|Local anesthetic injection
48006550|NCT04021264|DRUG|Dextrose 5|Sham injection
48006551|NCT02686346|DRUG|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
48692889|NCT04797273|BEHAVIORAL|Internet-based structured treatment-as-usual|This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.
48692890|NCT03245242|OTHER|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
48692891|NCT03245242|OTHER|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
48692892|NCT00344318|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
48692893|NCT00344318|BIOLOGICAL|Prevenar|3 Intramuscular injections
48692894|NCT00344318|BIOLOGICAL|Tritanrix-HepB|3 Intramuscular injections
48692895|NCT00344318|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix before injection
48692896|NCT00344318|BIOLOGICAL|Polio Sabin.|3 oral doses.
48692897|NCT00344318|BIOLOGICAL|Poliorix.|3 intramuscular injections
48692898|NCT05562206|DEVICE|CGMIS (Continuous Glucose Monitoring Infusion Set)|An integrated combination CGM/insulin infusion system
48692899|NCT03357796|DRUG|LY03005|80 mg, oral tablets, single dose
48692900|NCT03357796|DRUG|Pristiq|50 mg, oral tablets, single dose
48006552|NCT02686346|DRUG|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
48163628|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
48692901|NCT00883168|DRUG|Placebo|Placebo
48692902|NCT00883168|DRUG|azelastineHcl|azelastine hydrochloride 548 mg
48163629|NCT05878249|PROCEDURE|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
48163630|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
48692903|NCT00883168|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
48692904|NCT00883168|DRUG|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
48692905|NCT06458062|DEVICE|Pocket Colposcope|Each patient will receive treatment in order to prevent cervical cancer
48692906|NCT03651765|DRUG|Setmelanotide|Once daily subcutaneous injection
48692907|NCT06250322|DEVICE|Intervention|No study treatments will be administered during this study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
48692908|NCT04646304|OTHER|Objective Feedback (Motion Capture)|Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
48692909|NCT03325296|DRUG|LEO 124249|Ointment containing LEO 124249
48692910|NCT03325296|OTHER|Ointment vehicle|Ointment without active ingredients
48692911|NCT04266730|BIOLOGICAL|PANDA-VAC|The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).
48006553|NCT02686346|DRUG|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
48006554|NCT02686346|DRUG|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
48163631|NCT05809726|OTHER|Manual lymph drainage|one session 20 minutes
48692912|NCT04266730|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
48692913|NCT06553300|PROCEDURE|Autotransplantation with PRF|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF
48692914|NCT06553300|PROCEDURE|Autotransplatation Only|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
48006555|NCT04974775|DIAGNOSTIC_TEST|Blood collection|Sampling on admission to ICU (all patients)
48006556|NCT04974775|DIAGNOSTIC_TEST|Blood collection, serial sampling|"Additional sampling to admission samples in~1. the Cardiac Arrest group after 12 and 48 hours~2. the Covid-19 group on day 2 and 7 while in the ICU~3. the Covid-19 group after 3 and 12 months."
48006557|NCT05652166|OTHER|telephone interview|telephone call to parents to know the information given following the ingestion of foreign body by their child
48163632|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris|Manufactured at Viatris
48692915|NCT04693702|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
48692916|NCT03427814|DRUG|Pamiparib|60 mg orally twice daily
48692917|NCT03427814|DRUG|Placebo|60 mg orally twice daily
48692918|NCT00582543|OTHER|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
48692919|NCT01150058|GENETIC|western blotting|
48692920|NCT01150058|OTHER|flow cytometry|
48163633|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.|Manufactured at Neolpharma.
48163634|NCT03793140|DRUG|CPI-613|CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
48163635|NCT03121729|PROCEDURE|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
48163636|NCT04608032|OTHER|[Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder|The first group will have \[Eco-Sz\] Ecological Cognitive training program for schizophrenia spectrum disorder
48692921|NCT01150058|OTHER|laboratory biomarker analysis|
48692922|NCT01173107|DRUG|colchicine|colchicine 1T tid
48692923|NCT04772625|DEVICE|Patellofemoral arthroplasty|Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
48006558|NCT04685564|DRUG|RBD1016|"Sentinel cohort design is used in each cohort: each cohort will be administered in two batches, the first 2 subjects will receive RBD1016 or placebo respectively, and safety assessment will be done on D8±1. After safety is confirmed through SRC assessment, the remaining 6 subjects will be randomly assigned to receive RBD1016 or placebo in a ratio of 5:1. SRC will assess the safety after all the subjects in each cohort complete the 28-day safety observation and the subjects may proceed to the next dose cohort with permission.~Only after all the subjects in the previous dose cohort have completed the safety assessment by SRC (observed for 28 days) may the next dose cohort be initiated with permission."
48006559|NCT04685564|DRUG|Placebo|the same as RBD1016
48006560|NCT05428475|DIAGNOSTIC_TEST|[18F]FDG-PET Scan|185 MBq of \[18F\]FDG will be administered IV 30 minutes prior to PET scan. Images will be acquired for 30 minutes. Resulting images will be evaluated for patterns of FDG-uptake to support the diagnosis of the participant symptoms of cognitive impairment.
48006561|NCT01790464|DRUG|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
48006562|NCT01790464|DRUG|placebo|
48006563|NCT03284216|PROCEDURE|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
48006564|NCT03284216|PROCEDURE|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
48006565|NCT03284216|BEHAVIORAL|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
48163637|NCT04608032|OTHER|Recovery-Oriented Therapy|The second group will have \[THoR\] Recovery-Oriented Therapy
48163638|NCT05432583|BIOLOGICAL|BNT163|Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection
48692924|NCT06630234|DRUG|DCC-3009|Administered orally
48006566|NCT04860310|PROCEDURE|Endometrial biopsy|Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
48006567|NCT04216082|DRUG|Anlotinib|Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
48006568|NCT02321696|DEVICE|Acupuncture|
48006569|NCT02321696|OTHER|Physiotherapy and eccentric exercise|
48006570|NCT02321696|OTHER|Watchful waiting and eccentric exercise|
48163639|NCT05432583|OTHER|Placebo|Placebo
48185272|NCT04857567|BEHAVIORAL|TSC program (Three Self-Commitment program)|"1. Self-Competence program~   - A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~2. Self-Care program~   - A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~3. Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent"
48185273|NCT02667106|DRUG|RX0041-2|Pharmacokinetic study
48006571|NCT02321696|OTHER|eccentric exercise|
48692925|NCT01339819|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
48692926|NCT01339819|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
48006572|NCT05321862|DRUG|[68Ga]Ga-PentixaFor|Tomography by Emission of Positons (PET) with the radiopharmaceutic \[68Ga\]Ga-PentixaFor
48692927|NCT05415267|BIOLOGICAL|diphtheria and tetanus toxoids (adsorbed) vaccine|The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.
48692928|NCT05415267|BIOLOGICAL|COVID-19 vaccine|All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
48006573|NCT00225836|DEVICE|OVA (TENS apparatus)|
48006574|NCT00079833|DRUG|Esomeprazole magnesium (Nexium)|
48006575|NCT04197570|DRUG|Opioid Anesthetics|see arm/group description
48163640|NCT06333496|DIETARY_SUPPLEMENT|GLP1 Booster (GB)|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, White kidney bean (Phaseolus vulgaris) extract, berberine (from Berberis aristata bark extract), and chromium (III) an essential trace mineral. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
48163641|NCT02238691|PROCEDURE|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
48692929|NCT05001152|DRUG|Ozanimod|Taste assessment
48692930|NCT05144893|BEHAVIORAL|Virtual Mindfullness-Based Intervention|Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
48692931|NCT06658925|DRUG|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
48692932|NCT03953508|OTHER|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
48692933|NCT05306665|BEHAVIORAL|ACT intervention|One day in person workshop + telephone booster
48692934|NCT05457556|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48692935|NCT05457556|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48692936|NCT05457556|DRUG|Busulfan|Given intravenously (IV)
48006576|NCT04197570|DRUG|Non Opioid Analgesics|see arm/group description
48006577|NCT04347395|PROCEDURE|Respiratory Bundle & Prevention|The respiratory care bundle intervention comprised of: bed tilt, swallow screen, mouth wash and vaccinations. The bed tilt was a 30-degree whole bed-up positioning both day and night throughout the hospital stay and is shown in Figure 1. Swallow screen was undertaken within 48 hours of admission. Chlorhexidine mouth wash was prescribed initially four times daily. The protocol was amended to twice daily chlorhexidine mouth wash in August 2017 due to poor compliance with four times daily administration. Mouthwash administration was monitored in the intervention group only and deemed non-compliant if missed more than 3 times during the admission. Pneumococcal and influenza vaccination was offered at discharge or within 2-4 weeks post discharge, at no charge to the patient. Post discharge advice was to use pillows in bed to minimize the time the patient laid flat and to avoid lying down for an hour after meals.
48692937|NCT05457556|DRUG|Cyclophosphamide|Given IV
48692938|NCT05457556|PROCEDURE|Echocardiography|Undergo ECHO
48692939|NCT05457556|DRUG|Fludarabine|Given IV
48163642|NCT01249976|OTHER|blood culture|blood culture
48185274|NCT00196469|DRUG|heparin|
48185275|NCT01385046|BEHAVIORAL|Project Fit|physical activity and nutrition education
48368773|NCT04372251|PROCEDURE|Sinus tarsi approach (STA)|Osteosynthesis
48692940|NCT05457556|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo haploHCT
48692941|NCT05457556|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
48692942|NCT05457556|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48692943|NCT05457556|PROCEDURE|Matched Unrelated Donor Hematopoietic Cell Transplantation|Undergo MUD-HCT
48692944|NCT05457556|DRUG|Melphalan|Given IV
48692945|NCT05457556|DRUG|Methotrexate|Given IV
48692946|NCT05457556|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48692947|NCT05457556|DRUG|Mycophenolate Mofetil|Given IV
48692948|NCT05457556|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning regimen
48692949|NCT05457556|OTHER|Quality-of-Life Assessment|Ancillary studies
48692950|NCT05457556|OTHER|Questionnaire Administration|Ancillary studies
48692951|NCT05457556|BIOLOGICAL|Rituximab|Given IV
48692952|NCT05457556|PROCEDURE|T-Cell Depletion Therapy|Undergo haploHCT with alpha beta T cell depletion
48006578|NCT06251856|BEHAVIORAL|lymphedema education program|On post-op day 2, patients will receive Symptom Management Model-Based Lower Extremity Lymphedema Training. Brochures will be introduced and delivered to the patient.
48006579|NCT04349722|DRUG|Hyoscine Butylbromide|Intervention is given once a participant is in established labor
48692953|NCT05457556|DRUG|Tacrolimus|Given IV
48692954|NCT05457556|DRUG|Thiotepa|Given IV
48692955|NCT05457556|RADIATION|Total-Body Irradiation|Undergo TBI
48692956|NCT04908384|BEHAVIORAL|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
48692957|NCT06176690|BIOLOGICAL|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
48692958|NCT03053440|DRUG|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
48692959|NCT03053440|DRUG|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
48163643|NCT01600235|DRUG|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
48006580|NCT04349722|OTHER|Placebo|Intervention is given once a participant is in established labor
48006581|NCT00122343|DRUG|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
48163644|NCT03974789|DIAGNOSTIC_TEST|Blood test|Plasma cortisol level test
48163645|NCT03974789|DIAGNOSTIC_TEST|24-hour Urine test|Urinary free cortisol test
48692960|NCT06120140|DRUG|Amivantamab|Amivantamab will be administered as intravenous (IV) infusion or SC injection.
48692961|NCT06120140|DRUG|Lazertinib|Lazertinib tablet will be administered orally.
48692962|NCT06120140|DRUG|Doxycycline|Doxycycline tablet will be administered orally.
48692963|NCT06120140|DRUG|Minocycline|Minocycline capsule will be administered orally.
48692964|NCT06120140|DRUG|Clindamycin|Clindamycin lotion will be used as topical application on the scalp.
48692965|NCT06120140|DRUG|Chlorhexidine|Chlorhexidine solution will be used as topical application on hands and feet.
48692966|NCT06120140|OTHER|Noncomedogenic skin moisturizer|Noncomedogenic skin moisturizer will be used as topical application.
48692967|NCT00999635|DEVICE|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
48692968|NCT05733091|BEHAVIORAL|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
48692969|NCT02701283|DEVICE|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
48692970|NCT02701283|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
48692971|NCT00253513|DRUG|fludarabine|30 mg/m2, IV for 5 days
48692972|NCT00253513|DRUG|treosulfan|12 or 14 g/m2, IV for 5 days
48692973|NCT00253513|PROCEDURE|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
48692974|NCT05505396|OTHER|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
48692975|NCT04000607|DEVICE|APTURE transcatheter shunt|Transcatheter treatment of symptomatic left heart failure patients
48692976|NCT01341535|RADIATION|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
48692977|NCT01341535|RADIATION|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
48006582|NCT05316662|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
48006583|NCT00694980|DRUG|placebo|Intravenous and subcutaneous escalating doses
48006584|NCT00694980|DRUG|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
48006585|NCT01690767|DRUG|2% lidocaine gel|Children \< 7 kg and \> 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
48006586|NCT01690767|DRUG|Health Care Lubricating Jelly|Non-medicinal lubrication gel
48006587|NCT02959281|OTHER|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
48006588|NCT00769847|PROCEDURE|Endoscopic strip craniectomy|Surgery
48163646|NCT03974789|DIAGNOSTIC_TEST|Saliva swab|salivette® for salivary cortisol quantification
48163647|NCT03974789|DIAGNOSTIC_TEST|Dexamethasone test|Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
48163648|NCT02860858|BIOLOGICAL|Intravitreous aflibercept injection|
48163649|NCT02573883|DEVICE|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
48368774|NCT04372251|PROCEDURE|Percutaneous Arthroscopically Assisted Osteosynthesis (PACO)|Osteosynthesis
48692978|NCT02438683|DRUG|BI 409306|high dose, single dose, oral administration
48692979|NCT02438683|DRUG|BI 409306|low dose, single dose, oral administration
48692980|NCT02438683|DRUG|Placebo|single dose, oral administration
48692981|NCT06266364|DEVICE|Active VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
48692982|NCT06266364|DEVICE|Sham VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
48692983|NCT04653922|DEVICE|LinkCor Bioengineered Corneal Implant|Intrastromal implantation of a bioengineered corneal equivalent device
48692984|NCT02143453|OTHER|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
48692985|NCT02143453|OTHER|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
48006589|NCT02355327|DEVICE|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
48006590|NCT02355327|BEHAVIORAL|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
48006591|NCT01034410|DRUG|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
48006592|NCT01034410|DRUG|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
48006593|NCT02304224|OTHER|eye masks|eye masks from 21:00 to 6:00 each night during admission
48006594|NCT02355132|OTHER|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
48163650|NCT02573883|DRUG|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
48163651|NCT02937051|OTHER|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
48163652|NCT00093743|DRUG|fludarabine phosphate|Given IV
48692986|NCT05425732|BIOLOGICAL|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
48163653|NCT00093743|DRUG|cyclosporine|Given IV or PO
48163654|NCT00093743|RADIATION|total-body irradiation|Undergo TBI
48692987|NCT05425732|BIOLOGICAL|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
48006595|NCT03331068|BEHAVIORAL|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
48006596|NCT00358462|DRUG|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
48006597|NCT00358462|DRUG|Doxycycline|one 100mg capsule administered twice daily for seven days
48006598|NCT03012100|DRUG|Cyclophosphamide|Given PO
48006599|NCT03012100|OTHER|Laboratory Biomarker Analysis|Correlative studies
48006600|NCT03012100|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
48006601|NCT03012100|OTHER|Placebo Administration|Given ID
48006602|NCT03012100|BIOLOGICAL|Sargramostim|Given ID
48006603|NCT00758511|PROCEDURE|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
48006604|NCT00758511|PROCEDURE|facilitated tucking|facilitated tucking before, during and after heel stick
48006605|NCT00758511|PROCEDURE|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
48006606|NCT00358202|DRUG|cefepime|cefepime hydrochloride 1gm IM q24h
48006607|NCT00358202|DRUG|ceftriaxone|ceftriaxone 1 gm IM q24h
48006608|NCT01234545|DRUG|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
48692988|NCT02696057|OTHER|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
48692989|NCT02696057|OTHER|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
48692990|NCT06166342|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
48006609|NCT06481956|DRUG|Ribociclib Oral Tablet|Patients with advanced breast cancer with at least one evaluable lesion and histologically proven invasive breast cancer were eligible for inclusion. Histopathologically positive for HER2 (IHC 3+, or IHC 2+ with fluorescence in situ hybridization (FISH) positive, either primary or metastatic. Patients with advanced breast cancer must have previously received first-line therapy or initial rescue therapy and have been treated with trastuzumab against HER2.
48006610|NCT05371964|DRUG|Imetelstat|Imetelstat sodium will be administered as intravenous (IV) every 28 days.
48692991|NCT06166342|DIETARY_SUPPLEMENT|TCI153 probiotic sachet|Consume 1 sachet daily
48692992|NCT00152711|DEVICE|nCPAP|
48006611|NCT05371964|DRUG|Ruxolitinib|Ruxolitinib will be administered, orally (PO), twice daily (BID) as the standard of care per local prescribing guidelines.
48006612|NCT00737516|BIOLOGICAL|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
48006613|NCT01746784|DRUG|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
48006614|NCT01746784|DRUG|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
48006615|NCT06416865|DRUG|AJU-C52L, AJU-C52|"AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.~AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks."
48006616|NCT06416865|DRUG|C52R1L, C52R1M|"C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.~C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks."
48006617|NCT02627612|BEHAVIORAL|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
48163655|NCT00093743|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
48368775|NCT02318082|DRUG|Interleukin-2|
48692993|NCT05274971|OTHER|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
48692994|NCT06656663|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and LW, based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have an excellent knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
48692995|NCT06656663|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
48006618|NCT02627612|BEHAVIORAL|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
48006619|NCT05149417|OTHER|SMS reminding|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
48006620|NCT05149417|OTHER|telemonitoring|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
48163656|NCT00093743|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
48163657|NCT00093743|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
48692996|NCT04234204|DRUG|Fezolinetant|Oral
48163658|NCT00093743|DRUG|mycophenolate mofetil|Given PO or IV
48006623|NCT05449028|DRUG|H. pylori eradication scheme A|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days
48006624|NCT05449028|DRUG|H. pylori eradication scheme B|Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h, for 14 days
48163659|NCT00162058|DRUG|Peflutren Lipid Microsphere Injectable Suspension|
48163660|NCT00655369|DRUG|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
48163661|NCT00655369|DRUG|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
48163662|NCT00655369|DRUG|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
48163663|NCT00655369|DRUG|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
48692997|NCT04234204|DRUG|Placebo|Oral
48006625|NCT05449028|DRUG|H. pylori eradication scheme C|Esomeprazole 40mg bid + bismuth subsalicylate 420mg 6/6h + metronidazole 375mg 6/6h + tetracycline 375mg 6/6h, for 10 days
48006626|NCT05449028|DRUG|H. pylori eradication scheme D|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
48163664|NCT00655369|DRUG|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
48692998|NCT00331994|DRUG|Bacillus clausii|3 bacillus clausii vials/day for one month
48692999|NCT00331994|DRUG|Metronidazole|3 Metronidazole tablets/day for one week
48006627|NCT05449028|DRUG|H. pylori eradication scheme E|Esomeprazole 40mg bid + amoxicillin 1g 12/12h for 7 days, followed by esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 12/12h for 7 days
48006628|NCT05981638|OTHER|group WM|Patients were given 5ml/kg dose of water and patients were mobilized.
48006629|NCT05981638|OTHER|group WR|Patients were given 5ml/kg dose of water and patients were rest.
48006630|NCT05981638|OTHER|Group AR|Patients were given 5ml/kg dose of apple juice and patients were rest.
48163665|NCT00655369|DRUG|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
48163666|NCT04759118|BEHAVIORAL|modified childbirth education program|The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
48163667|NCT01979757|OTHER|Puregraft|
48006631|NCT05981638|OTHER|Group AM|Patients were given 5ml/kg dose of apple juice and patients were mobilized.
48693000|NCT04668833|PROCEDURE|Autologous lymphocyte infusion (ALI)|On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
48006632|NCT01715506|BEHAVIORAL|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
48006633|NCT01408186|DRUG|Rabeprazole|Rabeprazole 20 mg daily
48006634|NCT01408186|DRUG|Famotidine|Famotidine 40mg daily
48006635|NCT04845737|OTHER|sympathetic skin response measurement|"Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis."
48006636|NCT00783042|DRUG|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
48163668|NCT01979757|OTHER|Centrifugation|
48693001|NCT03573206|DEVICE|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
48006637|NCT00783042|DRUG|Placebo|Tablet, oral, once daily for 1 month (double blind)
48006638|NCT02928328|DRUG|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
48006639|NCT02928328|DRUG|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
48163669|NCT02399982|OTHER|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
48693002|NCT06326008|DRUG|Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy|Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors and haematopoietic stem cells are collected from donors.
48006640|NCT02928328|DRUG|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
48006641|NCT04865796|OTHER|Lactoferrin products|Patiens will use a toothpaste and 2 tablets per day (between foods) for home oral care.
48006642|NCT04865796|OTHER|Probiotics products|Patiens will use a toothpaste and a chewing-gum (for 10 minutes a day) for home oral care.
48368776|NCT01718574|OTHER|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
48006643|NCT04865796|OTHER|Standard home oral care|Patiens will use a normal toothpaste for home oral care.
48006644|NCT01262014|DRUG|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
48006645|NCT04874506|DRUG|MBM-02|Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
48006646|NCT00164242|DRUG|Galantamine|
48006647|NCT05853133|OTHER|Erector Spinae Plane Block|Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
48163670|NCT02399982|OTHER|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
48163671|NCT02382406|DRUG|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
48163672|NCT02382406|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
48163673|NCT02382406|DRUG|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
48368777|NCT06373640|PROCEDURE|Insertion of drains|Insertion of lumbar drain and basal cistern drain
48368778|NCT06373640|DRUG|Vancomycin|Administration of vancomycin
48368779|NCT00277862|DRUG|Pegylated IFN- alpha 2b|
48368780|NCT00277862|DRUG|Ribavirin|
48368781|NCT00859495|DRUG|Doxorubicin|A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.
48368782|NCT00859495|DRUG|Cisplatin|Platinum-based antineoplastic
48368783|NCT00859495|DRUG|Pemetrexed|Folate Analog Metabolic Inhibitor
48163674|NCT02382406|DRUG|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
48163675|NCT03320642|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
48163676|NCT03320642|DRUG|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
48163677|NCT06646757|BEHAVIORAL|APP|1) My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs
48163678|NCT06646757|BEHAVIORAL|CBT|"2) Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)"
48163679|NCT06646757|BEHAVIORAL|HELP|3) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost
48163680|NCT06646757|BEHAVIORAL|PEER|4) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
48163681|NCT00847158|PROCEDURE|phacoemulsification alone|phacoemulsification alone
48163682|NCT00847158|DEVICE|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
48163683|NCT04769895|DRUG|MaaT013|MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
48163684|NCT05550077|DIAGNOSTIC_TEST|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
48163685|NCT05550077|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
48693003|NCT06225518|BEHAVIORAL|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
48163686|NCT04284592|PROCEDURE|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
48163687|NCT04440514|PROCEDURE|endoscopic preperitoneal repair of parastomal hernia|repair of parastomal hernia after the Sugarbaker principle with TAR and preperitoneal mesh reinforcement
48163688|NCT03228654|PROCEDURE|Unipolar Electrocautery sealing of vessels|"1. Vaginal walls are incised by monoplar current (40 W)~2. A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~3. uterine vessels are individually secured.~4. Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
48368784|NCT00859495|RADIATION|Radiotherapy|Standard procedure given 3 weeks after last dose of chemotherapy
48513917|NCT01320384|OTHER|O2 conventional|standard low flow therapy
48006648|NCT05853133|OTHER|Wound Infiltration|Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
48693004|NCT01664611|PROCEDURE|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
48693005|NCT01664611|PROCEDURE|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
48693006|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose L|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48693007|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose A|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48693008|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose B|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48693009|NCT06134648|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48693010|NCT01926899|DRUG|Bortezomib administration|
48693011|NCT06262048|DRUG|Tamsulosin Hydrochloride|2 days pre-op, day of surgery, 2 days post-op
48693012|NCT06262048|OTHER|Placebo|2 days pre-op, day of surgery, 2 days post-op
48693013|NCT01863069|DRUG|Interferon beta 1a|
48693014|NCT01863069|DRUG|(IM) AVONEX®|
48693015|NCT03186443|DRUG|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
48693016|NCT03186443|DRUG|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
48693017|NCT02250079|DEVICE|polyethylene plastic bag|Inborn neonates with both a gestational age \>29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
48693018|NCT02250079|DEVICE|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
48693019|NCT05712096|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
48693020|NCT06420349|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48693021|NCT06420349|PROCEDURE|Computed Tomography|Undergo CT
48693022|NCT06420349|BIOLOGICAL|Heat Shock Factor 1 Pathway Inhibitor NXP800|Given PO
48693023|NCT06420349|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48693024|NCT06420349|PROCEDURE|Positron Emission Tomography|Undergo PET
48693025|NCT06420349|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided liver biopsy
48693026|NCT01450696|DRUG|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
48693027|NCT01450696|DRUG|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
48693028|NCT01450696|DRUG|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
48693029|NCT06658964|DRUG|Cohort 1: JMKX003142 and itraconazole|"JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD"
48693030|NCT06658964|DRUG|Cohort 2: JMKX003142 and rifampicin|"JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD"
48693031|NCT04513054|GENETIC|Blood collection for genetic analysis|Blood collection for genetic analysis
48693032|NCT06657599|PROCEDURE|Major Abdominal Surgery|Patients with ASA I-IV, over 18 years of age, undergoing major abdominal surgery, have gynecological and GIS tumor, expected to stay in postoperative care unit for more than 24 hours.
48006649|NCT00368589|DRUG|atorvastatin|
48513918|NCT01320384|DEVICE|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
48693033|NCT04424823|PROCEDURE|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
48693034|NCT04588415|OTHER|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
48693035|NCT05223179|BIOLOGICAL|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
48693036|NCT05223179|BIOLOGICAL|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
48693037|NCT05223179|OTHER|Saline|Saline
48693038|NCT06040424|COMBINATION_PRODUCT|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
48693039|NCT06040424|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
48693040|NCT01157338|PROCEDURE|diagnostic cardiac catheterization|coronary intervention: angiography
48693041|NCT01157338|PROCEDURE|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
48693042|NCT06661213|DRUG|Tapinarof|A thin layer of tapinarof cream is applied to affected areas once daily.
48693043|NCT04802512|PROCEDURE|validity and reability study|validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
48006650|NCT01883401|DIETARY_SUPPLEMENT|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
48006651|NCT01883401|DIETARY_SUPPLEMENT|Dietary fiber|4g or 8g dietary fiber blended in water
48693044|NCT00072046|BIOLOGICAL|bevacizumab|10mg/kg IV infusion on Days 1 \& 15 of each cycle
48006652|NCT01971346|DRUG|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
48006653|NCT01465646|DRUG|levothyroxine|
48693045|NCT00072046|BIOLOGICAL|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
48006654|NCT01465646|DRUG|levothyroxine|
48006655|NCT04300972|DIAGNOSTIC_TEST|Body/weight adaption|contrast media dose is adapted to weight and body type
48163689|NCT03228654|PROCEDURE|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
48693046|NCT05994924|BEHAVIORAL|Educational Handout|Educational handout describing responsive feeding practices.
48693047|NCT05994924|BEHAVIORAL|Video Series|Videos geared toward responsive feeding practices.
48693048|NCT05994924|BEHAVIORAL|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
48693049|NCT01120470|DRUG|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
48693050|NCT01120470|DRUG|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
48693051|NCT05070845|BIOLOGICAL|PF-06835375|CXCR5 inhibitor
48693052|NCT03316118|DRUG|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
48693053|NCT03316118|DRUG|saline|Group 2 will receive genicular nerve block using normal saline
48693054|NCT02987361|DEVICE|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
48006656|NCT04300972|DIAGNOSTIC_TEST|Standard dose|a fixed amount of contrast media is used, independently of weight and body type
48006657|NCT02603809|DRUG|Aprocitentan 5 mg|One capsule of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
48006658|NCT02603809|DRUG|Aprocitentan 10 mg|Two capsules of 5 mg aprocitentan, orally, once daily in the morning for 8 weeks.
48006659|NCT02603809|DRUG|Aprocitentan 25 mg|One capsule of 25 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
48006660|NCT02603809|DRUG|Aprocitentan 50 mg|One capsule of 50 mg aprocitentan, orally, once daily in the morning for 8 weeks, along with placebo capsule matching lisinopril.
48006661|NCT02603809|DRUG|Lisinopril 20 mg|One capsule of 20 mg lisinopril, orally, once daily in the morning for 8 weeks, along with placebo capsule matching aprocitentan
48006662|NCT02603809|DRUG|Placebo|One capsule each of placebo matching aprocitentan and placebo matching lisinopril orally, once daily in the morning for 8 weeks.
48006663|NCT00569686|DRUG|lovaza|lovaza 4 gm po daily
48006664|NCT00569686|DRUG|placebo|placebo
48006665|NCT01574872|DEVICE|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
48006666|NCT01574872|DEVICE|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
48368785|NCT04675437|OTHER|Aerobic exercise|12-weeks aerobic exercise program
48693055|NCT05492227|DIAGNOSTIC_TEST|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
48693056|NCT00814021|DRUG|sunitinib malate|
48693057|NCT06352060|OTHER|No intervention or administration will be performed due to the observational nature of the study|Charts of patients enrolled in the study will be reviewed for an initial monitoring method and any changes in management.
48163690|NCT01890798|DRUG|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
48006667|NCT03650907|BEHAVIORAL|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
48006668|NCT03650907|BEHAVIORAL|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
48006669|NCT06308991|OTHER|Yakson touch|Yakson touch method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes).
48006670|NCT06308991|OTHER|Gentle Human Touch|Gentle Human Touch (GHT) method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The GHT method continued for 15 minutes.
48368786|NCT04095494|BEHAVIORAL|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
48368787|NCT02173470|OTHER|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
48006671|NCT06308991|OTHER|Routine care|Infants in the Routine care will be applied swaddling. It will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.
48006672|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
48006673|NCT00659867|DEVICE|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
48163691|NCT02574351|BIOLOGICAL|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
48163692|NCT04390893|DEVICE|ultrasound|Anesthesiologist would scan three planes of the neck to position the LMA
48163693|NCT04390893|DIAGNOSTIC_TEST|air leakage test|Anesthesiologist would use air leakage test to position the LMA
48163694|NCT05335005|DRUG|MK-2060|MK-2060 administered via IV infusion
48163695|NCT05610319|DRUG|Faricimab|Faricimab will be administered via intravitreal injection.
48693058|NCT01377909|DRUG|statin|daily statin orally for 48 weeks
48693059|NCT01755962|OTHER|Glycemic Load|
48693060|NCT01755962|OTHER|Resistance Training|
48163696|NCT05820087|DEVICE|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
48693061|NCT03043690|DIETARY_SUPPLEMENT|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
48368788|NCT04795570|PROCEDURE|Transurethral resection of the prostate or bladder|All patients undergoing TUR P/B will undergo a blood draw within 6 months after surgery to determine hormonal status and coagulation disorders.
48368789|NCT03551158|DIAGNOSTIC_TEST|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
48368790|NCT00285857|DRUG|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
48693062|NCT03043690|OTHER|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
48693063|NCT05366816|DRUG|Sunitinib|37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.
48693064|NCT05366816|DRUG|Regorafenib|120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
48006674|NCT00000707|DRUG|Pentamidine isethionate|
48006675|NCT01313429|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
48006676|NCT01313429|BIOLOGICAL|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
48006677|NCT01313429|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
48006678|NCT04070300|BEHAVIORAL|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
48006679|NCT03397290|DEVICE|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
48163697|NCT00001666|DEVICE|Cadwell High-Speed Magnetoelectric Stimulator|
48163698|NCT00001666|DEVICE|Magpro High-Speed Magnetoelectric Stimulator|
48368791|NCT01197846|DRUG|Quetiapine|quetiapine 300 mg or 600 mg
48368792|NCT01197846|DRUG|Placebo|Placebo
48693065|NCT01096368|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
48693066|NCT01096368|DRUG|Carboplatin|Given IV
48693067|NCT01096368|DRUG|Cisplatin|Given IV
48693068|NCT01096368|OTHER|Clinical Observation|Patients undergo observation
48693069|NCT01096368|DRUG|Cyclophosphamide|Given IV
48693070|NCT01096368|DRUG|Etoposide|Given IV
48693071|NCT01096368|BIOLOGICAL|Filgrastim|Given SC or IV
48693072|NCT01096368|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48693073|NCT01096368|DRUG|Mesna|Given IV
48693074|NCT01096368|DRUG|Vincristine|Given IV
48693075|NCT05936359|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
48693076|NCT05936359|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
48163699|NCT06397950|OTHER|Assessment of potential fatigue factors|"3 visits will be carried out: V0: Inclusion V1: Familiarization visit V2: Experimental visit~V1~* Completion of MFI-20 questionnaire for familiarisation.~* Information about accelerometry and activity journal use will be delivered to the patient.~* The participant will be equipped with an accelerometer and asked to complete the activity journal for seven days.~V2~* Completion of questionnaires: MFI-20, GATS tobacco consumption questionnaire, caffeine consumption questionnaire, Fatigue Catastrophizing Scale, PSQI.~* Assessment of cognitive function: Sustained Attention to Response Task (SART), AX-Continuous Performance Task (AX-CPT) and verbal fluency test (animals and P categories).~* Assessment of physical evaluation: isometric evaluation of maximal handgrip strength, one-minute sit-to-stand test, isometric evaluation of maximal quadriceps strength, QIF test.~Negative symptoms will be assessed. Calf circumference will be measured for sarcopenia risk."
48693077|NCT00568763|BIOLOGICAL|sargramostim|
48693078|NCT00568763|OTHER|immunoenzyme technique|
48163700|NCT01591668|DRUG|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
48163701|NCT01591668|DRUG|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
48693079|NCT00568763|OTHER|immunohistochemistry staining method|
48163702|NCT02865135|DRUG|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.
48368793|NCT00843128|DEVICE|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
48368794|NCT00843128|DEVICE|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
48693080|NCT00568763|OTHER|immunologic technique|
48693081|NCT00568763|OTHER|laboratory biomarker analysis|
48006680|NCT01865825|RADIATION|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
48006681|NCT02285231|DIETARY_SUPPLEMENT|Arginyl-fructose|
48006682|NCT02285231|DIETARY_SUPPLEMENT|Placebo|
48006683|NCT00984581|DRUG|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
48006684|NCT00984581|DRUG|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
48006685|NCT00984581|DRUG|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
48693082|NCT00568763|PROCEDURE|biopsy|
48693083|NCT00568763|PROCEDURE|cryosurgery|
48693084|NCT00568763|PROCEDURE|radiofrequency ablation|
48693085|NCT03420755|BEHAVIORAL|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
48693086|NCT03420755|BEHAVIORAL|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
48006686|NCT01574352|BEHAVIORAL|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
48006687|NCT01574352|BEHAVIORAL|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
48006688|NCT03341130|DEVICE|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
48163703|NCT02865135|DRUG|Cyclophosphamide|Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
48163704|NCT01309113|DRUG|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
48163705|NCT06373146|DRUG|Tirzepatide|Administered SC
48006689|NCT03341130|DEVICE|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
48163706|NCT06373146|DRUG|Mibavademab|Administered SC
48163707|NCT06373146|DRUG|Tirzepatide-Placebo|Administered SC
48163708|NCT06373146|DRUG|Mibavademab-Placebo|Administered SC
48163709|NCT04658771|DEVICE|MR-HIFU treatment|"MR-HIFU is an innovative technology that allows for non-invasive thermal ablation of tissues and tumors by integrating an external high intensity focused ultrasound (HIFU) transducer with a conventional MRI scanner.~The focused ultrasound transducer is placed outside of the body and generates and focuses acoustic energy to heat tumors or other pre-defined focal regions of tissues inside the body. Because the acoustic energy is precisely focused over tiny areas of tissue, potential thermal injury to surrounding tissues is minimal. Cell death inside the selected treatment area occurs via coagulative necrosis while avoiding injury to intervening and adjacent tissues."
48163710|NCT05283213|DIAGNOSTIC_TEST|Early biomarkers of acute kidney injury|"The biomarkers tested will be:~* creatinine levels \[pre-, post-CC, H6\],~* urinary TIMP2\*IGFBP7 \[H6\],~* Plasma NGAL \[Pre-, Post-CC, H6\].~* Urinary NGAL \[H6\]~* Plasma cystatin C \[Pre-CC, Post-CEC \& H6\],~* plasma HI \[pre-, post-CC, H6\],~* plasma IL-6 \[post-CC, H6\],~* uremia \[pre-, post-CC, H6\],~* urinary DKK3 \[pre-CC\], These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using \[pre-, post-CC, H6\] protein and \[pre-, post-CC, H6\] creatinine, respectively."
48163711|NCT05245084|DRUG|CKD-386(3)|QD, PO
48163712|NCT05245084|DRUG|D013, D326, D337|QD, PO
48163713|NCT04141722|BEHAVIORAL|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
48368795|NCT02647021|BEHAVIORAL|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
48163714|NCT04141722|BEHAVIORAL|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
48163715|NCT00295048|BEHAVIORAL|Computer Assisted Cognitive Remediation (CACR)|
48163716|NCT03775278|DRUG|PHP-303|Investigational drug
48006690|NCT00004028|DRUG|carmustine|
48006691|NCT00004028|PROCEDURE|conventional surgery|
48006692|NCT03949829|DIAGNOSTIC_TEST|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
48163717|NCT03775278|OTHER|Placebo|Matching placebo
48163718|NCT01946529|DRUG|vincristine|Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
48163719|NCT01946529|DRUG|doxorubicin|Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
48163720|NCT01946529|DRUG|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
48163721|NCT01946529|DRUG|ifosfamide|Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
48368796|NCT02647021|BEHAVIORAL|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
48368797|NCT05205642|DEVICE|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.
48513919|NCT01320384|DEVICE|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
48513920|NCT02995408|BEHAVIORAL|Relaxation Response Resiliency Program for Parents of Children with ASD|
48163722|NCT01946529|DRUG|etoposide|Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
48513921|NCT06423378|DEVICE|OSSIOfiber® Trimmable Fixation Nails|"Subjects will be treated with cannulated nails before or after arthroscopic management of their concomitant pathology at the discretion of the investigator. Technique described below. Following nail placement, tissue layers will be closed in standard fashion.~1. Preop MRI views used to estimate the proper depth \& location of nail placement on the femur and/or tibia~2. Exposure is gained to medial tibia~3. 1.4 mm K-Wire is placed through medial tibia parallel to the articular joint surface \~ 1 cm distal to the articular joint line~4. A depth gauge is placed over K-Wire to determine required length of cannulated nail~5. A 4.0 mm cannulated drill bit used over K-Wire to prepare the pilot hole~6. Tamp is used to insert pre-trimmed 4.0 mm cannulated nail into the pilot hole and K-Wire is subsequently removed~7. Intraop fluoroscopy can confirm adequate nail placement prior to removing K-wire~8. Repeat steps for additional nails"
48513922|NCT02671747|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
48513923|NCT05461326|PROCEDURE|Quad tendon|quadriceps tendon autograft
48513924|NCT05461326|PROCEDURE|BTB|patellar tendon autograft
48368798|NCT05205642|DEVICE|Peripheral Arterial Tonography (PAT) using the EndoPAT™ device|A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.
48693087|NCT06661239|BEHAVIORAL|benson relaxation|"The benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes"
48693088|NCT06661239|BEHAVIORAL|Routine care in unit|The routine care include in the unit will be delivered to control group
48693089|NCT06412978|PROCEDURE|absorbable subcuticular polyglycolic acid staples (INSORB)|Insorb absorbable staples are used for skin closure
48693090|NCT06412978|PROCEDURE|subcuticular, polyglecaprone suture (Monocryl)|Monocryl absorbable staples are used for skin closure
48693091|NCT06434337|DIAGNOSTIC_TEST|"Novel point-of-care diagnostic test for detecting HPV (Rice HPV test)"|Given by Diagnostic Test
48693092|NCT06660888|BEHAVIORAL|• Fatigue Severity Scale (FFS). • Hamilton Rating Scale for Depression (HRSD-17). • Hamilton Anxiety Rating Scale (HAM-A).|"1. Fatigue Severity Scale The FSS is one of the most commonly used fatigue questionnaires in chronic diseases. It measures how fatigue affects motivation, exercise, physical functioning, carrying out duties, work, family, or social life.~2. Hamilton Depression Rating Scale The 17-item Hamilton Depression Rating Scale (HRSD-17) is the most popular depression measure in antidepressant clinical trials.~3. Hamilton Anxiety Rating Scale The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms."
48693093|NCT02026674|DEVICE|FloRite|Disposable home use urine flow meter.
48693094|NCT01996488|DRUG|Olanzapine Orally Disintegrating Tablets 5mg|
48513925|NCT05823012|DRUG|levothyroxine sodium|Levothyroxine sodium 10 mg/mL
48006693|NCT01095588|DRUG|200 mg Avanafil|2 X 100mg tablets avanafil
48006694|NCT01095588|DRUG|Placebo|2 tablets
48368799|NCT05205642|DIAGNOSTIC_TEST|Endothelin|For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
48513926|NCT06429293|BEHAVIORAL|Cognitive processing therapy|The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician
48513927|NCT02760745|OTHER|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
48513928|NCT03591510|DRUG|Midostaurin|midostaurin 30mg/m2 bid
48513929|NCT03591510|DRUG|Fludarabine|30mg/m2/day on D1-D5 of Block 2 FLADx
48006695|NCT02397330|DRUG|bupivacaine|
48006696|NCT02397330|DEVICE|ultrasound|ultrasound guided nerve blocks
48006697|NCT02397330|DRUG|morphine|
48006698|NCT01818804|DIETARY_SUPPLEMENT|n-3PUFA|
48163723|NCT01946529|DRUG|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
48693095|NCT03407469|BEHAVIORAL|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
48693096|NCT05815810|OTHER|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
48693097|NCT05815810|OTHER|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
48693098|NCT06615661|DEVICE|C-Rex Instrument|The C-Rex Instrument is a manual ophthalmic surgical instrument used for ab interno goniotomy and inner wall trabeculotomy.
48693099|NCT03724058|DEVICE|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
48163724|NCT01946529|DRUG|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
48163725|NCT01946529|DRUG|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
48693100|NCT03724058|DEVICE|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
48693101|NCT05085093|BIOLOGICAL|HPV vaccine|Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes
48693102|NCT01814046|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
48693103|NCT01814046|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
48693104|NCT01814046|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
48163726|NCT01946529|DRUG|sorafenib|Dosage and route of administration: 90 mg/m\^2/dose PO BID
48163727|NCT01946529|PROCEDURE|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
48163728|NCT01946529|RADIATION|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
48368800|NCT02143427|BEHAVIORAL|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
48693105|NCT01814046|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
48693106|NCT00764543|DEVICE|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
48163729|NCT03470103|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
48368801|NCT02143427|BEHAVIORAL|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
48368802|NCT02335411|BIOLOGICAL|pembrolizumab|IV infusion
48368803|NCT02335411|DRUG|cisplatin|IV infusion
48368804|NCT02335411|DRUG|5-FU|IV infusion
48513930|NCT03591510|DRUG|Cytarabine|"Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC"
48368805|NCT02335411|DRUG|capecitabine|oral tablets
48513931|NCT03591510|DRUG|Daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx
48006699|NCT01818804|DIETARY_SUPPLEMENT|olive oil|
48163730|NCT04389996|OTHER|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
48163731|NCT06299956|OTHER|Supervised exercise therapy|Walking on a treadmill at increasing elevation and pace.
48163732|NCT03229096|DRUG|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
48163733|NCT00300963|DRUG|Talnetant|
48163734|NCT04373642|DRUG|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
48163735|NCT01644825|DRUG|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
48163736|NCT01644825|DRUG|pazopanib|orally, 800 mg orally daily
48163737|NCT04602039|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (Neovite)
48006700|NCT01277939|BEHAVIORAL|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
48006701|NCT01277939|BEHAVIORAL|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
48163738|NCT05910502|BEHAVIORAL|Autism Family Empowerment Coaching and Training Program|Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
48006702|NCT04476030|DRUG|SAGE-217|Oral capsules
48006703|NCT04476030|DRUG|Matching Placebo|Oral capsules
48368806|NCT02924922|PROCEDURE|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
48006704|NCT04476030|DRUG|Sertraline|Oral tablets
48006705|NCT04476030|DRUG|Escitalopram|Oral tablets
48006706|NCT04476030|DRUG|Citalopram|Oral tablets
48368807|NCT02924922|PROCEDURE|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
48006707|NCT04476030|DRUG|Duloxetine|Oral capsules
48006708|NCT04476030|DRUG|Desvenlafaxine|Oral tablets
48006709|NCT01857063|DRUG|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
48006710|NCT01857063|DRUG|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
48006711|NCT06109428|DRUG|HTX-011|400 mg
48006712|NCT06109428|DRUG|Bupivacaine Hydrochloride|125 mg
48163739|NCT04031547|DEVICE|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
48163740|NCT02676440|OTHER|Treatment|F13/T38
48368808|NCT02924922|DEVICE|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
48368809|NCT02924922|DEVICE|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
48368810|NCT02924922|DRUG|Mannitol|
48368811|NCT01882101|PROCEDURE|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
48513932|NCT03591510|DRUG|Mitoxantrone|10mg/m2/day D3 and D4
48513933|NCT03591510|DRUG|Etoposide|100mg/m2/day D1 to D5
48513934|NCT02285088|DRUG|GBT440|GBT440 will be administered as oral capsules
48006713|NCT06109428|DRUG|Ibuprofen|400 mg
48006714|NCT06109428|DRUG|Acetaminophen|1 g
48006715|NCT06109428|DEVICE|Luer lock applicator|Applicator for instillation
48006716|NCT00859170|DEVICE|Accordion device|an antiretropulsion device
48006717|NCT03450707|DRUG|Thiamine 500 mg IV|Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
48006718|NCT03450707|OTHER|Placebo|100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
48006719|NCT01465464|DRUG|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
48006720|NCT01465464|DRUG|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
48006721|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
48006722|NCT00376168|DRUG|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
48006723|NCT04720365|DEVICE|play-based rehabilitaion|usual re-education treatment by their physiotherapist
48006724|NCT00006012|BIOLOGICAL|filgrastim|
48006725|NCT00006012|DRUG|amifostine trihydrate|
48006726|NCT00006012|DRUG|cisplatin|
48006727|NCT00006012|DRUG|etoposide|
48006728|NCT00006012|DRUG|paclitaxel|
48006729|NCT00006012|DRUG|topotecan hydrochloride|
48006730|NCT00006012|RADIATION|radiation therapy|
48006731|NCT01893424|DRUG|Sativex buccal spray|buccal spray
48006732|NCT01893424|DRUG|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
48006733|NCT04618055|DEVICE|NiTiDent Tuah Porous NiTi Dental Implants|A newly developed NiTiDent Tuah porous NiTi cylindrical bone level dental implant measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations produced by Nitium Technology Sdn Bhd.
48006734|NCT04618055|DEVICE|Control Dental Implant Systems|A market approved bone level dental implant systems measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations
48163741|NCT02676440|OTHER|Comparator|M26
48163742|NCT05859009|PROCEDURE|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
48693107|NCT01833728|DRUG|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
48693108|NCT01833728|DRUG|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
48693109|NCT06552793|BIOLOGICAL|autogenous partially demineralized dentin graft|tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.
48693110|NCT06552793|BIOLOGICAL|Xenograft|Cortico-cancallous Bovine powder
48693111|NCT01059487|OTHER|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
48006735|NCT00578500|PROCEDURE|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
48163743|NCT05859009|DRUG|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
48368812|NCT01882101|PROCEDURE|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
48368813|NCT03290196|DRUG|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
48368814|NCT04486586|DEVICE|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2 mA (estimated current density 0.04 mA/cm\^2; estimated total charge 0.048 C/cm\^2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will target apraxia of speech (AOS).
48693112|NCT05011136|OTHER|No intervention. This is a qualitative study|US nephrologists who care for dialysis patients will be asked to complete an internet based survey evaluating the time and effort required for home dialysis patient care.
48693113|NCT04017819|DRUG|18F-C-SNAT4|Radiotracer- Dose 10 mCi
48368815|NCT04486586|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will target apraxia of speech (AOS).
48368816|NCT03783312|DRUG|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
48006736|NCT01573780|DRUG|Smac mimetic TL32711|Given IV
48368817|NCT03783312|DRUG|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
48006737|NCT01573780|DRUG|gemcitabine hydrochloride|Given IV
48006738|NCT01573780|OTHER|laboratory biomarker analysis|Correlative studies
48163744|NCT04889833|BEHAVIORAL|hypnosis therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
48368818|NCT03783312|DRUG|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
48006739|NCT01573780|OTHER|pharmacological study|Correlative studies
48006740|NCT01573780|PROCEDURE|biopsy|Optional correlative studies
48368819|NCT04843189|PROCEDURE|Da Vinci Robotic Surgery|Da Vinci Robotic Surgery
48368820|NCT02063802|DRUG|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
48513935|NCT02285088|DRUG|Placebo|Matching placebo will be administered as oral capsules
48693114|NCT04017819|DEVICE|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
48693115|NCT05243121|DIAGNOSTIC_TEST|MRI|undergoing enhanced MRI
48006741|NCT00218543|DRUG|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
48006742|NCT04203550|PROCEDURE|Intraoperative irrigation|Operation with irrigation
48163745|NCT04620122|OTHER|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
48368821|NCT02063802|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
48368822|NCT02063802|DRUG|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
48006743|NCT04203550|PROCEDURE|No irrigation|Operation without irrigation
48006744|NCT00358527|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
48006745|NCT00358527|OTHER|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
48368823|NCT02063802|BEHAVIORAL|Healthy habits program|
48368824|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test at 90° of hip flexion|anterior drawer test at 90° of hip flexion
48006746|NCT06331793|DEVICE|Active AlgoCare|Device that emits Pulsed Electromagnetic Fields
48006747|NCT06331793|DEVICE|Non-active AlgoCare|Device that doesn't emit Pulsed Electromagnetic Fields
48006748|NCT04727658|RADIATION|Radiosurgical thalamotomy on GammaKnife|fractional radiosurgical thalamotomy on an accelerator (3 sessions of 50 Gy at the isocenter )
48163746|NCT06103721|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize the patients for 5 minutes, 15 minutes prior to induction of General Anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
48368825|NCT04957706|DIAGNOSTIC_TEST|Lachman test|Lachman test
48368826|NCT04957706|DIAGNOSTIC_TEST|anterior drawer test|anterior drawer test
48006749|NCT04501731|OTHER|Transcranial Magnetic Stimulation (TMS)|With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.
48006750|NCT04501731|OTHER|Magnetic Resonance Imaging (MRI)|With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.
48006751|NCT04501731|OTHER|Motor assessment|"The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes."
48163747|NCT06103721|DRUG|Normal Saline|Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
48163748|NCT02359578|DRUG|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
48163749|NCT03891485|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)
48163750|NCT02068352|DRUG|OPA-15406|OPA-15406 topical ointment
48163751|NCT02068352|DRUG|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
48006752|NCT04501731|OTHER|Questionnaires|Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
48006753|NCT05797506|DRUG|Sulforaphane (Avmacol Extra Strength)|4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
48006754|NCT05797506|DIETARY_SUPPLEMENT|Placebo|These tablets will be matched placebos and will be provided by Avmacol.
48006755|NCT04319939|OTHER|Assist Control Mode and Pressure Support Mode Mechanical Ventilation|Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
48368827|NCT04957706|DIAGNOSTIC_TEST|pivot-shift test|pivot-shift test
48368828|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
48368829|NCT02255942|OTHER|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
48368830|NCT02255942|OTHER|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
48368831|NCT02255942|OTHER|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
48368832|NCT00296569|DRUG|MK0686|
48368833|NCT02213965|DEVICE|Peripheral IV catheter|Intravenous access according to Instructions For Use
48006756|NCT00482755|DRUG|sunitinib malate|
48368834|NCT00603369|BEHAVIORAL|group intervention|13-session intervention
48006757|NCT00482755|OTHER|immunohistochemistry staining method|
48006758|NCT00482755|OTHER|laboratory biomarker analysis|
48368835|NCT00603369|BEHAVIORAL|group intervention|2-session intervention
48368836|NCT00121485|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
48368837|NCT00106860|DRUG|a benzodiazepine drug|
48368838|NCT03380091|DRUG|Metformin|Oral medication daily
48006759|NCT00482755|OTHER|pharmacological study|
48006760|NCT00482755|PROCEDURE|needle biopsy|
48006761|NCT00482755|PROCEDURE|neoadjuvant therapy|
48368839|NCT03380091|DRUG|Vitamin D|Oral medication daily
48368840|NCT00807768|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
48368841|NCT00807768|DRUG|Carboplatin|Given IV
48368842|NCT00807768|RADIATION|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
48368843|NCT00807768|RADIATION|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
48368844|NCT00807768|OTHER|Laboratory Biomarker Analysis|Correlative studies
48368845|NCT00807768|DRUG|Paclitaxel|Given IV
48006762|NCT04698356|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
48006763|NCT02302196|PROCEDURE|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
48006764|NCT02302196|OTHER|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
48163752|NCT04707456|OTHER|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
48185276|NCT05226676|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive and painless brain stimulation technique that allows the brain excitability to change based on Faraday's Law of Electromagnetic induction . Since the presentation of the CNP is usually bilateral, the coil will be targeting the dominant hand abductor pollicis brevis (APB) muscle. If the pain is more intense in one of the arms, that arm will be targeted. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
48693116|NCT02088879|BEHAVIORAL|chest compression with kneeling position|
48693117|NCT02088879|BEHAVIORAL|chest compression with standing position|
48006765|NCT02375672|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
48185277|NCT04621461|DIETARY_SUPPLEMENT|Zinc Sulfate 220 MG|220mg once daily for 5 days
48185278|NCT04621461|DRUG|Placebo|Once daily for 5 days
48368846|NCT00807768|OTHER|Quality-of-Life Assessment|Ancillary studies
48368847|NCT00807768|OTHER|Questionnaire Administration|Ancillary studies
48368848|NCT03302260|BEHAVIORAL|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
48368849|NCT04064099|DEVICE|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
48368850|NCT04191590|PROCEDURE|nasal brushing and bacteriological sample|A nasal brushing as well as a bacteriological sample using a swab under general anesthesia at the beginning of the endonasal surgery procedure
48368851|NCT01044095|BIOLOGICAL|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
48693118|NCT04299503|DRUG|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
48006766|NCT02375672|DRUG|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion"
48006767|NCT06474494|PROCEDURE|Application of one layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive
48693119|NCT04299503|DRUG|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
48693120|NCT04435639|OTHER|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
48693121|NCT04435639|PROCEDURE|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
48693122|NCT04435639|DEVICE|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
48693123|NCT06210594|COMBINATION_PRODUCT|Mupirocin + Nozin + chlorhexidine gluconate|Education/household supplies + antibiotic + antiseptic regimen
48693124|NCT06210594|BEHAVIORAL|Education + Household supplies|Education/household supplies
48693125|NCT04155619|BEHAVIORAL|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
48693126|NCT04155619|BEHAVIORAL|No change in light exposure|Participants will not change their light exposure habits.
48693127|NCT04155619|BEHAVIORAL|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
48693128|NCT04155619|BEHAVIORAL|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
48693129|NCT04641728|DRUG|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
48368852|NCT01044095|BIOLOGICAL|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
48368853|NCT04542252|DRUG|SyB V-1901|SyB V-1901 10 mg via IV infusion for 2 hours
48368854|NCT04542252|DRUG|Cyclosporine|200 mg Capsule
48513936|NCT03567980|DRUG|Crisaborole|Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
48513937|NCT02011477|OTHER|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
48693130|NCT04641728|DRUG|Olaparib|olaparib 300 mg twice daily (BID)
48693131|NCT05968495|DEVICE|Renuvion APR Handpiece|The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures. The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min. APR Handpiece has a non-extendable electrode to generate helium plasma.
48693132|NCT06156657|OTHER|subcostal TAP block|Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
48693133|NCT02048137|DEVICE|Transcranial direct current stimulation|
48693134|NCT06348251|BEHAVIORAL|FoodSteps|Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
48693135|NCT03985943|DRUG|Placebo|Placebo
48693136|NCT03985943|DRUG|Nemolizumab|Nemolizumab
48693137|NCT04952597|DRUG|Ociperlimab|Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
48693138|NCT04952597|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
48693139|NCT04952597|DRUG|Concurrent Chemoradiotherapy|"Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
48693140|NCT04659408|DIETARY_SUPPLEMENT|Multistrain probiotic preparation|One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
48368855|NCT05577572|DIETARY_SUPPLEMENT|Probiotics packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Probiotics packets is taken from day 1\~56.
48368856|NCT05577572|DIETARY_SUPPLEMENT|Placebo packets|The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and Placebo packets is taken from day 1\~56.
48368857|NCT03775642|BEHAVIORAL|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
48368858|NCT03775642|BEHAVIORAL|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
48368859|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
48368860|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
48368861|NCT05949827|DEVICE|Dynamic Light Therapy Device, LSA-3|Dynamic Light Therapy
48693141|NCT04659408|DIETARY_SUPPLEMENT|Oat Bran|5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
48006768|NCT06474494|PROCEDURE|Application of double layer|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying double layer of Scotchbond Universal Plus adhesive
48163753|NCT06283563|OTHER|Physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in MS will be given. Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app. Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group. In this regard, it will be emphasized that he/she should exercise at least 3 days a week. In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine. The total intervention period will be 8 weeks. Reminders to exercise will be given by the researchers in the created messaging app group. Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.
48163754|NCT06283563|OTHER|No physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. Participants will be encouraged to continue their routine lives and no reminders will be given.
48693142|NCT01621256|DRUG|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
48693143|NCT01621256|DRUG|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
48693144|NCT00738569|DRUG|Raltegravir|Raltegravir 400 mg PO BID for 12 months
48693145|NCT05671718|OTHER|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
48693146|NCT02579421|DRUG|Progesterone|generic progesterone
48163755|NCT04893902|DEVICE|medit intra oral scanner|ear scanning with intra oral scanner
48163756|NCT05931289|BEHAVIORAL|Enhanced Crisis Response Planning (ECRP)|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
48163757|NCT05931289|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
48163758|NCT01732926|DRUG|Idelalisib|150 mg tablet administered orally twice daily
48368862|NCT06219304|OTHER|Multimodal functional training|40 minutes of multimodal functional training: 20 minutes of aerobic training on treadmill, 10 minutes of dynamic balance training; 10 minutes of functional strength training.
48368863|NCT06219304|OTHER|Usual care|Exercises aimed at improving balance and mobility
48368864|NCT00390741|BEHAVIORAL|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
48368865|NCT03251716|DRUG|berberine|berberine 300mg TID add-on for berberine adjunctive group
48693147|NCT02579421|DRUG|placebo|placebo
48693148|NCT04410848|OTHER|To determine the diagnostic of Choledocholithiasis with symbolic regression model|To determine the diagnostic of Choledocholithiasis with symbolic regression model
48693149|NCT06024109|DEVICE|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
48693150|NCT03652766|BEHAVIORAL|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
48693151|NCT05687773|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
48006769|NCT06474494|PROCEDURE|Etch-and-rinse application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as etch-and-rinse application mode
48006770|NCT06474494|PROCEDURE|Selective enamel etching application mode|35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying Scotchbond Universal Plus adhesive applied as selective enamel etching mode
48693152|NCT05687773|DEVICE|Leap Motion Controller in Head-Mounted Display|For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
48006771|NCT01627613|DRUG|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
48693153|NCT02806336|BEHAVIORAL|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
48693154|NCT02806336|BEHAVIORAL|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
48693155|NCT06400576|OTHER|Headphone and Smartphone Intervention|Asessment of participants' static balance and pressure distrubiton, posturographic balance and dynamic balance whilst using headphones and messaging.
48693156|NCT05148650|DIAGNOSTIC_TEST|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
48006772|NCT01627613|DRUG|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
48006773|NCT00739752|BEHAVIORAL|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
48006774|NCT00739752|BEHAVIORAL|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
48006775|NCT00739752|BEHAVIORAL|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
48163759|NCT01732926|DRUG|Rituximab|375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
48163760|NCT01732926|DRUG|Bendamustine|90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
48163761|NCT01732926|DRUG|Placebo|Tablet administered orally twice daily
48163762|NCT02093897|BIOLOGICAL|rVIII-SingleChain|
48163763|NCT03950596|OTHER|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
48163764|NCT03950596|BEHAVIORAL|Background Questionnaire|Background questionnaire will be filled out by participants
48163765|NCT03950596|OTHER|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
48163766|NCT03950596|GENETIC|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
48163767|NCT03950596|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
48368866|NCT04640792|PROCEDURE|Screening or Surveillance Conventionall colonoscopy|Patients in Group A (CC) will undergo Screening or Surveillance Conventual Colonoscopy, Patients in Group B (MEAC) will undergo Screening or Surveillance Colonoscopy with ME-ADPS Device
48006776|NCT00739752|BEHAVIORAL|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
48006777|NCT00739752|BEHAVIORAL|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
48006778|NCT00739752|BEHAVIORAL|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
48006779|NCT01639040|DRUG|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
48006780|NCT01639040|DRUG|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
48006781|NCT01639040|OTHER|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
48006782|NCT00189748|DRUG|Tacrolimus|
48006783|NCT02727348|PROCEDURE|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
48006784|NCT02727348|PROCEDURE|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
48006785|NCT04573036|DRUG|HRS4800 tablets|single oral administration
48006786|NCT04573036|DRUG|Placebo tablets|single oral administration
48163768|NCT03950596|DIAGNOSTIC_TEST|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
48163769|NCT03377959|OTHER|Pilates Mat Classes|The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
48163770|NCT03377959|OTHER|Ballet Classes|The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
48163771|NCT00383864|DRUG|Pegylated interferon and ribavirin|
48163772|NCT05204472|DEVICE|Burst DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -\> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
48368867|NCT01840332|DRUG|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
48368868|NCT05517031|OTHER|ASDAS score , VAS score, BASFI score , Katz ADL index|Scores that done on patient to fullfill criteria of diagnosis , and measure affection of disease on patients and their daily living activity
48368869|NCT01363999|DRUG|atorvastatin|single dose of atorvastatin on day 1
48368870|NCT01363999|DRUG|dalcetrapib|single dose of dalcetrapib on day 1
48693157|NCT03070639|BEHAVIORAL|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
48368871|NCT02786368|BEHAVIORAL|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
48693158|NCT03070639|BEHAVIORAL|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
48693159|NCT04115514|DRUG|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.|"Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway."
48693160|NCT04115514|OTHER|Non-intervention|Standard of Care (SOC)
48693161|NCT06073821|DRUG|Sonrotoclax|Administered orally
48693162|NCT06073821|DRUG|Zanubrutinib|Administered orally
48693163|NCT06073821|DRUG|Venetoclax|Administered orally
48693164|NCT06073821|DRUG|Obinutuzumab|Administered intravenously
48693165|NCT04837703|DRUG|Eltrombopag|Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (\< 50 mg) or preferably no calcium.
48693166|NCT06410352|DRUG|Semaglutide, Empagliflozin|subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
48163773|NCT05204472|DEVICE|Tonic DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -\> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
48368872|NCT02786368|BEHAVIORAL|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
48368873|NCT02384096|DEVICE|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
48368874|NCT02384096|DEVICE|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
48368875|NCT04391192|BEHAVIORAL|Virtual Overdose Response|All participants will be provided the phone number and encouraged to call when they use alone.
48368876|NCT03846323|OTHER|Visiting policies: 24 hours a day, 7 days a week|
48368877|NCT03846323|OTHER|Restriction of visiting policies < 6 hours|
48368878|NCT04533932|DIAGNOSTIC_TEST|Elastography|Endosonographic shear wave elastography
48368879|NCT03506165|COMBINATION_PRODUCT|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
48368880|NCT04662957|DIETARY_SUPPLEMENT|Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo|Oral supplementation with multi-strain probiotic preparation
48368881|NCT04662957|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin as placebo
48368882|NCT00039936|BEHAVIORAL|Cognitive Behavior Treatment|
48368883|NCT00039936|BEHAVIORAL|Self Help|
48368884|NCT00039936|BEHAVIORAL|Partial Self Help|
48368885|NCT03378531|DRUG|AEB1102|modified human arginase I
48368886|NCT03759340|DRUG|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
48368887|NCT01475942|DIETARY_SUPPLEMENT|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
48368888|NCT04657809|COMBINATION_PRODUCT|Insulin film|Insulin suspension vials
48368889|NCT04657809|DEVICE|Fast dissolving film|Fast dissolving film
48368890|NCT00883896|OTHER|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
48368891|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
48368892|NCT00883896|DRUG|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
48693167|NCT06410352|PROCEDURE|Minigastric bypass|Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.
48163774|NCT01533181|OTHER|Laboratory Biomarker Analysis|Correlative studies
48368893|NCT00883896|OTHER|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
48693168|NCT06410352|DIETARY_SUPPLEMENT|Analimentary detoxication|very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.
48693169|NCT06410352|BEHAVIORAL|Ramadan fast's weight loss|"The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset)."
48693170|NCT05103553|OTHER|Outpatient Clinic|Follow-up in outpatient clinic
48693171|NCT04887584|OTHER|Control diet|The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
48693172|NCT04887584|OTHER|Low Pulse diet|The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
48693173|NCT04887584|OTHER|High Pulse diet|The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
48693174|NCT01436656|DRUG|LGX818|
48693175|NCT01722526|DRUG|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
48368894|NCT00883896|DRUG|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
48163775|NCT01533181|DRUG|Linsitinib|150 mg given orally (PO) twice a day (BID)
48163776|NCT01533181|OTHER|Pharmacological Study|Correlative studies
48163777|NCT01533181|DRUG|Topotecan Hydrochloride|1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
48163778|NCT01676883|DEVICE|Bioelectric impedance|removal of calluses and corns by pedicure
48163779|NCT01676883|DEVICE|Air displacement plethysmography|
48163780|NCT03672383|DEVICE|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
48368895|NCT01277757|DRUG|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
48368896|NCT01277757|OTHER|Laboratory Biomarker Analysis|Correlative studies
48368897|NCT01277757|OTHER|Pharmacological Study|Correlative studies
48368898|NCT04592822|DRUG|WD-1602|dabigatran etexilate mesylate granules for oral suspension
48368899|NCT04592822|DRUG|Pradaxa®|dabigatran etexilate capsules
48368900|NCT00759551|DRUG|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
48368901|NCT00759551|DRUG|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
48368902|NCT00759551|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
48368903|NCT00759551|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
48368904|NCT00759551|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
48368905|NCT00759551|DRUG|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
48368906|NCT00759551|DRUG|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
48693176|NCT03888924|DRUG|Bacille Calmette-Guerin vaccine|"One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride."
48693177|NCT03888924|DRUG|Placebo|isotonic solution of sodium chloride (2mL vials).
48693178|NCT01697423|DRUG|platelet-rich plasma|
48693179|NCT01697423|DRUG|durolane|
48693180|NCT03143153|BIOLOGICAL|Nivolumab|Specified dose on specified days
48693181|NCT03143153|BIOLOGICAL|Ipilimumab|Specified dose on specified days
48693182|NCT03143153|DRUG|Cisplatin|Specified dose on specified days
48693183|NCT03143153|DRUG|Fluorouracil|Specified dose on specified days
48368907|NCT06099860|OTHER|Kinesio Taping|Kinesio tape with a 5 cm width was used. Participants were positioned on the side lying on the non-involved side with the hip joint of the involved side flexed to 45 degrees and the femur supported in neutral rotation. First, the tape was placed over the area between the ASIS and PSIS to protect the skin. Next, two strips of tape were applied over the first tape to correct anterior innominate rotation. The first piece was applied at the ASIS and pulled firmly to the PSIS in a straight anterior-to-posterior direction. The second piece was applied in an arching manner pulled firmly from the ASIS to the PSIS. the tape was changed once every 3 days
48368908|NCT06099860|OTHER|Balance Training (BT)|The balance training was performed on the Biodex balance system, participants wwere instructed to stand on a podium and stabilize themselves to keep the cursor in the middle of co-centered circle on the displayed screen/monitor. Stability level of platform was set on eight for first two sessions and then reduced to one level on every two sessions so that in the 9th and 10th session the stability level was four. From session four onwards, the participants performed the limit of stability exercises with Biodex Balance System. The participants performed this exercise protocol two times in each session. Total 12 sessions were given in time period of six weeks.
48368909|NCT06099860|OTHER|Hot Pack and Stretching Exercises|A hot pack was applied for 20 minutes, stretching exercises were performed.
48693184|NCT03853850|BEHAVIORAL|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
48693185|NCT02145052|OTHER|Continuous suture|A continuous suture is considered standard of care.
48693186|NCT02145052|OTHER|Interrupted suture|Interrupted sutures are considered standard of care.
48693187|NCT00425698|DRUG|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
48693188|NCT00425698|DRUG|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
48693189|NCT06096090|DRUG|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
48693190|NCT06096090|DRUG|Placebo|Placebo administration
48693191|NCT00313144|DRUG|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
48693192|NCT05007899|DRUG|Ferrous sulfate|Alternate day dosing of ferrous sulfate
48693193|NCT02231892|DEVICE|TMS|HAC coil (real rTMS or sham rTMS)
48693194|NCT06662084|DIAGNOSTIC_TEST|phenotype|"Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping."
48693195|NCT02340208|DRUG|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
48693196|NCT06482099|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
48368910|NCT02033642|BEHAVIORAL|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
48693197|NCT05359276|DRUG|Olipudase alfa|GZ402665
48693198|NCT05049564|PROCEDURE|keyhole microneurosurgery|microsurgical clipping via keyhole approach
48693199|NCT05049564|PROCEDURE|conventional microneurosurgery|microsurgical clipping via conventional craniotomy
48693200|NCT05049564|PROCEDURE|endovascular coiling|endovascular coiling via femoral approach
48693201|NCT03229772|DEVICE|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
48693202|NCT00073411|DRUG|duloxetine|
48693203|NCT00073411|DRUG|escitalopram|
48693204|NCT00073411|DRUG|placebo|
48693205|NCT06215859|DRUG|MR-107A-02|tablet
48693206|NCT06215859|DRUG|Tramadol|over-encapsulated tablet
48693207|NCT06215859|DRUG|Placebo|over-encapsulated tablet and/or tablet
48006787|NCT05263427|DEVICE|TOCONAUTE|"This study will be carried out during delivery. The will be placed on the mother's abdomen to capture fetal and maternal heart rate as well as the uterine contractions in parallel of the cardiotocograph.~For each of the participants, the TOCONAUTE will remain on the mother's abdomen till childbirth. This procedure will not affect the usual care of the patient."
48006788|NCT00431171|DRUG|Lithium carbonate|
48006789|NCT04943965|DIAGNOSTIC_TEST|Ultrasound imaging|"The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC"
48006790|NCT02643524|BEHAVIORAL|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
48163781|NCT05715502|RADIATION|brachytherapy|Radiation: focal low dose rate or high dose rate brachytherapy for the lesion with appropriate margin, defined in magnetic resonance or positron emission tomography All recruited participants will be treated with interstitial brachytherapy for local recurrence of prostate cancer. The low dose rate of brachytherapy is used with a total dose of 145 Gy in the clinical target volume for participants after hypofractionated radiotherapy, a high dose rate brachytherapy as monotherapy or boost with external beam radiotherapy The high dose rate brachytherapy with two fractions of 13 Gy in the clinical target volume with a 3 to 14 days break is used after primary low dose rate brachytherapy or external beam radiotherapy alone.
48163782|NCT04238559|OTHER|Self-report questionnaire|Fill in the SWAMECO questionnaire
48006791|NCT02643524|BEHAVIORAL|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
48006792|NCT05863741|DEVICE|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
48368911|NCT02033642|BEHAVIORAL|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
48368912|NCT01160029|DRUG|Nateglinide|Nateglinide Tablets 120 mg
48006793|NCT05863741|DEVICE|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
48006794|NCT02204891|DIETARY_SUPPLEMENT|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
48006795|NCT02204891|DIETARY_SUPPLEMENT|Probiotics|One capsule twice daily for 30 days
48006796|NCT03607916|DRUG|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
48006797|NCT03607916|DRUG|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
48006798|NCT03607916|DRUG|Morphine|100µg morphine
48006799|NCT03641352|DRUG|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
48368913|NCT00656331|DRUG|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
48368914|NCT05078476|OTHER|Manchester Short Splint|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
48368915|NCT05078476|OTHER|Relative Motion Flexion|3-5 days after tendon repair the patient will start with hand therapy and the described protocol.
48368916|NCT03699774|DRUG|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
48368917|NCT03699774|DRUG|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
48368918|NCT02249273|OTHER|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
48693208|NCT01674049|DIETARY_SUPPLEMENT|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
48693209|NCT01674049|DIETARY_SUPPLEMENT|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
48693210|NCT01674049|OTHER|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
48693211|NCT03624478|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48693212|NCT06656650|BEHAVIORAL|Commensality groups|Participants will attend at least 3 out of 6 commensality groups over the course of 6 months.
48693213|NCT02038972|GENETIC|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
48693214|NCT06430463|DIAGNOSTIC_TEST|pure tone audiometry levels|The patient will be examined by ENT physician on the morning of the operation, otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
48693215|NCT04868682|BEHAVIORAL|Behavioral Education Intervention I|Manual-based education program provided in individual sessions.
48693216|NCT04868682|BEHAVIORAL|Behavioral Education Intervention II|Manual-based education program provided in individual sessions.
48693217|NCT03780530|PROCEDURE|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
48513938|NCT02011477|OTHER|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
48513939|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg|single-dose:1mg/kg
48693218|NCT03780530|PROCEDURE|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
48693219|NCT03780530|PROCEDURE|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
48693220|NCT06660654|DRUG|Raludotatug deruxtecan|IV administration Q3W
48006800|NCT03641352|DRUG|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
48006801|NCT00947492|BIOLOGICAL|Venous blood sample|Venous blood sample twice a year during 3 years
48163783|NCT05326633|COMBINATION_PRODUCT|MRP and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|Mobility-based physical rehabilitation sessions performed 5 times/week by a study PT to provide strength and cardiopulmonary endurance training. High whey protein shakes prescribed to a total intake of 1.6-1.8 g/kg/d in 2 divided doses based on caloric needs. 2 x 30-minute lower extremity electric stimulation sessions/day, 5 times/wk performed by study PT.
48163784|NCT06027697|DEVICE|AccuFill® Porous Bone Substitute Material (BSM)|The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
48368919|NCT02985541|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
48368920|NCT04226053|OTHER|Parenting, Child Development|The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
48368921|NCT04730791|DIAGNOSTIC_TEST|Algo(s)rithm/ IASP clinical criteria|IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.
48368922|NCT04730791|DIAGNOSTIC_TEST|Pressure Pain Threshold|The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
48368923|NCT05174013|DRUG|GSK3858279|GSK3858279 will be administered
48368924|NCT05174013|DRUG|Placebo|Placebo will be administered
48368925|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
48368926|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
48368927|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
48368928|NCT01619176|DRUG|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
48368929|NCT01619176|DRUG|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
48163785|NCT06036784|DRUG|MBX 1416 (Part A)|Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
48163786|NCT06036784|DRUG|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
48163787|NCT06036784|DRUG|Placebo|Single dose or repeated subcutaneous (SC) dose of placebo.
48368930|NCT01619176|DRUG|leflunomide|leflunomide: 20mg/day for 3 months
48513940|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg|single-dose: 3mg/kg
48513941|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg|single-dose:10mg/kg
48513942|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg, q2w*6|multiple dosing: 1mg/kg, q2w\*6
48513943|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w*6|multiple dosing: 3mg/kg, q2w\*6
48513944|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg, , q2w*6|multiple dosing: 10mg/kg, , q2w\*6
48513945|NCT03374007|BIOLOGICAL|Geptanolimab Injection 280mg, q3w|multiple dosing: 280mg, q3w
48513946|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w|multiple dosing: 3mg/kg, q2w
48693221|NCT01463696|DRUG|MK-8242|10 mg, 100 mg and 150 mg capsules
48693222|NCT04401800|DRUG|Lenvatinib|Capsules administered orally once daily
48693223|NCT04401800|DRUG|Tislelizumab|200 mg intravenous (IV) infusion administered on Day 1 of each cycle
48693224|NCT05700786|BEHAVIORAL|Mindful compassion for perfectionism|The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
48693225|NCT00297960|DRUG|ziprasidone or olanzapine|
48693226|NCT00297960|PROCEDURE|hyperinsulinaemic euglycaemic clamp|
48693227|NCT00297960|PROCEDURE|microdialysis (skeletal muscle)|
48693228|NCT05509647|DRUG|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
48693229|NCT03294044|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
48513947|NCT01384903|DRUG|KW-3357|Intravenous infusion once a day
48693230|NCT03294044|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
48693231|NCT03702569|DIAGNOSTIC_TEST|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
48693232|NCT05107011|DRUG|LBL-015 for Injections|Initial dose - MTD ; Q2W ; intravenous infusion
48693233|NCT03637361|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
48693234|NCT03637361|DRUG|Placebo|
48693235|NCT00104416|DRUG|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
48693236|NCT00104416|DRUG|Placebo|Placebo control
48693237|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
48693238|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
48693239|NCT03691337|DRUG|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
48693240|NCT04557098|DRUG|Teclistamab|Teclistamab will be administered SC.
48693241|NCT05422495|BEHAVIORAL|training with Cycléo device (COTTOS ®),|8 weeks of training
48163788|NCT06036784|DRUG|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
48368931|NCT01619176|PROCEDURE|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
48513948|NCT01384903|DRUG|Plasma-derived antithrombin|Intravenous infusion once a day
48513949|NCT05697614|DRUG|Valproic acid|valproic acid is used for general epilepsy type, used in experimental group
48513950|NCT05697614|DRUG|Carbamazepin|carbamazepine is used for focal type epilepsy, used in experimental group
48163789|NCT01823640|OTHER|placebo|
48513951|NCT05697614|DRUG|Phenytoin|phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
48513952|NCT05697614|DRUG|Lamotrigine|lamotrigine is used for general epilepsy type, used in control group
48513953|NCT05697614|DRUG|Clobazam|clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
48513954|NCT05697614|DRUG|Oxcarbazepine|oxcarbazepine is used for focal type epilepsy, used in control group
48693242|NCT05422495|OTHER|non intervention|non intervention
48693243|NCT04475523|DRUG|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
48693244|NCT02150551|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :\> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : \>34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
48693245|NCT03668496|DRUG|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
48693246|NCT03668496|DRUG|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
48693247|NCT03208660|DRUG|Fycompa|Oral suspension
48693248|NCT04469387|PROCEDURE|Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
48693249|NCT04469387|PROCEDURE|Responsible segments fused|In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
48163790|NCT01823640|OTHER|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
48006802|NCT05687240|BEHAVIORAL|Qigong/Tai Chi|Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.
48006803|NCT05687240|BEHAVIORAL|Heart rate variability biofeedback|"Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance."
48163791|NCT05589584|DRUG|N acetyl cysteine with weight reduction|high dose 2400mg/day
48163792|NCT02542800|BEHAVIORAL|Episodic memory task|
48513955|NCT03438019|DEVICE|PrO2|The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
48513956|NCT03438019|DEVICE|Threshold Inspiratory Muscle Trainer|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
48163793|NCT02542800|DEVICE|fMRI|
48163794|NCT00550771|DRUG|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
48163795|NCT00550771|DRUG|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
48163796|NCT00613223|DRUG|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
48163797|NCT02298855|BEHAVIORAL|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
48163798|NCT00741351|DRUG|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
48163799|NCT00741351|DRUG|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
48163800|NCT00741351|DRUG|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
48163801|NCT05925114|DRUG|S-309309|Administered as oral capsules
48513957|NCT00450801|DRUG|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
48513958|NCT00450801|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
48513959|NCT00450801|DRUG|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
48513960|NCT00450801|DRUG|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
48513961|NCT00450801|DRUG|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
48513962|NCT00450801|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
48006804|NCT01891851|DRUG|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
48163802|NCT05925114|DRUG|Placebo|Administered as an oral capsule that looks identical to S-309309 capsule
48513963|NCT00450801|DRUG|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
48513964|NCT00450801|DRUG|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
48513965|NCT00450801|DRUG|Thalidomide|Maintenance therapy.
48513966|NCT00450801|DRUG|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
48163803|NCT00030303|BIOLOGICAL|recombinant 70-kD heat-shock protein|
48368932|NCT01539473|DRUG|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
48693250|NCT06661070|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
48163804|NCT03009877|DEVICE|Optiflow F&P 850™ System|"Optiflow™ (Fisher \& Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
48163805|NCT03009877|DEVICE|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
48693251|NCT06661070|OTHER|Dry Needling|A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
48693252|NCT00479128|DRUG|Bortezomib|Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds
48693253|NCT00479128|DRUG|Gemcitabine|Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
48693254|NCT00479128|DRUG|Doxorubicin|Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
48693255|NCT00958347|DEVICE|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
48693256|NCT02315248|RADIATION|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
48693257|NCT01039324|OTHER|Reports|Primary care event reports and patient letters
48693258|NCT01039324|OTHER|Reports and Notices|Primary care event reports, patient letters and care manager notices
48693259|NCT01039324|OTHER|Usual care|This is the study's control group
48693260|NCT06656052|OTHER|1. working memory task.|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants will be asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher.
48693261|NCT06656052|OTHER|2. Visual and Verbal Fluency Task|Stroop colour word test (modified Stroop test): participants will be asked to name the colour of ink that each word is printed in. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
48693262|NCT06656052|OTHER|3. Motor Task|Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
48693263|NCT04060108|DRUG|MDMA|80mg, 120mg, Placebo
48693264|NCT01790646|OTHER|intubation|intubation using Glidescope videolaryngoscope
48693265|NCT02222688|DRUG|cirmtuzumab|
48693266|NCT05665101|PROCEDURE|Coil embolization of aneurysm sac|Patients are treated with standard EVAR with additional coiling of the aneurysm sac. The distinct type of coils used is not predefined.
48693267|NCT00559104|DRUG|carmustine|Unique to the Carmustine in Conditioning arm
48693268|NCT00559104|DRUG|cyclophosphamide|Used in Both Arms
48693269|NCT00559104|DRUG|etoposide|Used in Both Arms
48693270|NCT00559104|PROCEDURE|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
48693271|NCT00559104|PROCEDURE|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
48693272|NCT00559104|RADIATION|total-body irradiation|Unique to the Radiation in Conditioning Arm
48693273|NCT00559104|DRUG|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
48693274|NCT04115878|DRUG|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
48163806|NCT03009877|DRUG|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
48163807|NCT03009877|DRUG|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
48163808|NCT03009877|DRUG|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
48163809|NCT03009877|DRUG|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
48693275|NCT06406582|DEVICE|Zirconia laminate veneer|Zirconia veneers are milled with computer-aided manufacturing technology from multilayered zirconia discs with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with a hydrofluoric acid-nitric acid mixture. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
48693276|NCT06406582|DEVICE|Lithium Disilicate laminate veneer|Lithium Disilicate veneers are milled with computer-aided manufacturing technology from lithium disilicate blocks with shade matched with adjacent teeth. After sintering, veneer surfaces are treated with hydrofluoric acid. Next, veneers are cut back if necessary to provide space for characterization. Veneers are bonded with a light-cured veneer adhesive system (Relyx Veneer LC, 3M, USA).
48368933|NCT01539473|DRUG|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
48513967|NCT00450801|DRUG|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
48693277|NCT04542499|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
48693278|NCT04542499|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
48693279|NCT06426693|DEVICE|Experimental feedback|Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
48163810|NCT03009877|DEVICE|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
48163811|NCT02777242|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|SC injections of QST 50 mg or 75 mg or 100 mg
48163812|NCT04320199|DIETARY_SUPPLEMENT|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
48693280|NCT06426693|DEVICE|Control feedback|Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
48163813|NCT04320199|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
48513968|NCT00450801|DRUG|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
48693281|NCT05484973|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
48006805|NCT01891851|DRUG|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
48163814|NCT03122405|DEVICE|RAM sensors|Noninvasive acoustic monitoring device
48513969|NCT00450801|DRUG|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
48513970|NCT00450801|DRUG|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
48006806|NCT04063033|DRUG|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
48513971|NCT06021691|BEHAVIORAL|Acquired nurturing environment|Superimposed effects of intrauterine high-sugar environment exposure and postnatal nurturing environment exposure
48513972|NCT02625597|DEVICE|Cotton Pellet|
48006807|NCT02088658|BEHAVIORAL|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
48006808|NCT05907304|DRUG|Naporafenib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
48006809|NCT05907304|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
48513973|NCT02625597|DEVICE|Polytetrafluoroethylene Tape|
48513974|NCT02625597|DEVICE|Synthetic Foam|
48513975|NCT02625597|DEVICE|Polyvinylsiloxane|
48513976|NCT00659958|DRUG|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
48513977|NCT00176618|DRUG|sulindac|Sulindac 150 mg po BID
48513978|NCT00176618|DRUG|curcumin|Curcumin 250 mg po BID
48513979|NCT00852202|DRUG|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
48513980|NCT00852202|DRUG|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
48693282|NCT06658834|DRUG|Dexamethasone Combined with romiplostim N01|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
48163815|NCT05823805|OTHER|Community Health Worker|"Physicians will work with a Community Health Worker (CHW) to review the data presented in their Quality Improvement reports, and triage patients for proactive outreach (e.g. No action necessary, Call patient to check-in, Arrange BP, weight and labs, Book for phone appointment, Book for in-person appointment)."
48163816|NCT00672763|DRUG|Colecalciferol D3 (Vigantol Oil)|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
48163817|NCT00672763|DRUG|Medium chain triglycerides|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)"
48163818|NCT05699369|OTHER|Digital health interventions|Described in arm descriptions.
48513981|NCT00852202|DRUG|placebo|placebo capsules, oral administration, once daily dosing
48693283|NCT06658834|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
48006810|NCT00745914|DRUG|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
48006811|NCT00745914|DRUG|Placebo comparator|Placebo comparator
48006812|NCT01859715|DRUG|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
48006813|NCT01859715|DRUG|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
48006814|NCT01859715|DRUG|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
48006815|NCT02333916|OTHER|overfeeding + exercise pre-training|
48006816|NCT02333916|BEHAVIORAL|fitness training|
48006817|NCT02333916|OTHER|overfeeding + exercise post-training|
48163819|NCT02753764|DRUG|AZD7624|
48163820|NCT02753764|DRUG|prednisone|oral prednisone 20 mg bid for one week
48163821|NCT02753764|DRUG|Placebo|
48693284|NCT03090659|BIOLOGICAL|LCAR-B38M CAR-T cell injection|
48006818|NCT00247728|DRUG|PI-88|Once-daily SC injection for four consecutive days per week, for 3 weeks out of every 4 weeks
48006819|NCT05371314|DIAGNOSTIC_TEST|P/FP ratio|PaO2/FiO2 X PEEP, SpO2/FiO2 X PEEP
48006820|NCT02142686|DEVICE|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
48163822|NCT03229356|OTHER|Best Practices Advisory (BPA)|"1. BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~2. Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
48163823|NCT03229356|OTHER|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
48368934|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 9-17)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
48513982|NCT05019287|BIOLOGICAL|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
48693285|NCT06559306|DRUG|Seltorexant|Seltorexant will be administered orally.
48693286|NCT06559306|DRUG|Placebo|Matching Placebo tablets will be administered orally.
48693287|NCT06559306|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|SSRI/SNRI will be administered orally.
48693288|NCT04168203|DRUG|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
48006821|NCT02142686|DEVICE|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
48006822|NCT02142686|DEVICE|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
48006823|NCT01416883|DRUG|ICI176,334-1|Subject will receive single dose of ICI176,334-1
48006824|NCT00127140|DRUG|vorinostat|
48006825|NCT00132015|DRUG|tanespimycin|
48006826|NCT01571661|DRUG|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
48006827|NCT01571661|OTHER|Placebo|Placebo
48513983|NCT05019287|OTHER|Intravenous saline injection|Intravenous saline injection in addition to standard care
48513984|NCT05550506|DRUG|Duloxetine|Patients who use duloxetine for chronic pain or fibromyalgia
48693289|NCT04168203|DRUG|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
48693290|NCT00990431|PROCEDURE|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
48693291|NCT00990431|PROCEDURE|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
48693292|NCT05171309|DRUG|Apatinib|250 mg once daily (QD) oral dosing.
48693293|NCT05171309|DRUG|Camrelizumab|200 mg intravenously every 2 weeks.
48006828|NCT05961774|DEVICE|Transcranial magnetic stimulation|The stimulation point is the lumbar multifidus hotspot. The parameters will be set at frequency 10 Hz, 50 number of pulses, 40 train of stimulation (5 seconds stimulation and 25 seconds inter-stimulation interval). The position of coil will be placed tangentially at 45 degrees on the LM hotspot. The stimulation will be 20 minutes.
48006829|NCT05961774|DEVICE|Neuromuscular electrical stimulation|The neuromuscular electrical stimulation will be set as interferential current 6000 Hz, amplitude 20-50 Hz with scanning mode, duration 20 minutes, intensity to elicit the LM contraction.
48006830|NCT01471548|DRUG|TKI258|
48006831|NCT00330291|DRUG|Xyrem|
48006832|NCT05222061|DEVICE|Drug coated balloon for the side brunch|Intervention is explained in group description
48006833|NCT05222061|DEVICE|Conventional balloon for the side brunch|Intervention is explained in group description
48163824|NCT03268850|OTHER|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
48163825|NCT03268850|BEHAVIORAL|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
48163826|NCT03268850|BEHAVIORAL|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
48513985|NCT01598194|DEVICE|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
48163827|NCT00983424|DRUG|Cyclosporins|dose escalation, administered orally twice a day
48163828|NCT00983424|DRUG|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
48163829|NCT04991623|DEVICE|Kinesiology taping|We used kinesiology taping in abdominal muscles
48163830|NCT04991623|OTHER|Conventional physiotherapy|We used conventional physiotherapy to comparate
48513986|NCT03555123|DRUG|Simdax|Levosimendan2.5mg/ml
48693294|NCT05171309|DRUG|NK cell|Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
48693295|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
48693296|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
48693297|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
48693298|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
48693299|NCT01541904|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
48693300|NCT06164652|DEVICE|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
48693301|NCT05936840|DEVICE|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
48693302|NCT01596140|DRUG|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
48693303|NCT01596140|DRUG|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
48693304|NCT01596140|DRUG|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
48006834|NCT01505686|PROCEDURE|MRI scan|MRI scan with a 1,5 T MRI scanner
48006835|NCT04498793|BIOLOGICAL|Tislelizumab|On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
48163831|NCT02864147|DRUG|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
48513987|NCT00166647|PROCEDURE|Blood Sampling|
48693305|NCT00559455|DRUG|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
48006836|NCT04498793|DRUG|Nab paclitaxel|On Days 1 and 8 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
48163832|NCT02864147|DRUG|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
48163833|NCT02055053|DRUG|0.5% Bupivicaine|Local anesthetic
48693306|NCT00559455|DRUG|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
48693307|NCT00559455|DRUG|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
48693308|NCT02907216|BIOLOGICAL|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
48693309|NCT02907216|BIOLOGICAL|Rotarix|Two doses administered orally
48693310|NCT03978598|DRUG|Etonogestrel|Immediate v. Standard insertion.
48693311|NCT03978598|DEVICE|Nexplanon|Implant.
48693312|NCT01748708|DEVICE|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
48693313|NCT01748708|DEVICE|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
48006837|NCT04498793|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
48163834|NCT03714711|PROCEDURE|total hip arthroplasty|Total hip replacement
48163835|NCT03714711|PROCEDURE|total knee arthroplasty|Total knee replacement
48513988|NCT01450683|DRUG|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-\[4-(4-{\[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl\]methoxy}phenyl)piperazin-1-yl\]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
48693314|NCT05046990|DIAGNOSTIC_TEST|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
48693315|NCT05398159|DEVICE|Trim II|"Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment)."
48163836|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of SOCS3 gene|Detection of expression of SOCS3, in each samples using Real-Time PCR
48163837|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-α gene|Detection of expression of IFN-α gene in each samples using Real-Time PCR
48163838|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-β gene|Detection of expression of IFN-β gene in each samples using Real-Time PCR
48163839|NCT00249119|DRUG|risperidone|
48163840|NCT00301730|BIOLOGICAL|aldesleukin|
48163841|NCT00301730|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
48163842|NCT00301730|BIOLOGICAL|trastuzumab|
48693316|NCT04653090|DIAGNOSTIC_TEST|Xray|Hip AP Xray
48163843|NCT00301730|DRUG|paclitaxel|
48163844|NCT00301730|PROCEDURE|conventional surgery|
48163845|NCT00994396|DIETARY_SUPPLEMENT|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
48163846|NCT00994396|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
48513989|NCT03375177|OTHER|Natural history of disease|registry plan
48513990|NCT02005835|OTHER|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
48693317|NCT03652363|DRUG|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
48163847|NCT01785771|DRUG|ITCA 650 (exenatide in DUROS)|
48513991|NCT02005835|OTHER|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
48693318|NCT04216563|DRUG|Asciminib|Given PO
48693319|NCT04741789|DRUG|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
48693320|NCT02905799|DRUG|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
48693321|NCT02905799|DRUG|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
48693322|NCT01133756|DRUG|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
48006838|NCT04498793|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
48006839|NCT04498793|DEVICE|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
48006840|NCT02431208|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
48163848|NCT03113214|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
48163849|NCT03113214|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
48006841|NCT02431208|DRUG|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
48006842|NCT02431208|DRUG|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
48006843|NCT02431208|DRUG|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
48006844|NCT02431208|DRUG|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
48163850|NCT03113214|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
48163851|NCT03113214|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
48163852|NCT03113214|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
48163853|NCT03113214|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
48163854|NCT04428983|DIETARY_SUPPLEMENT|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
48163855|NCT03134274|DEVICE|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
48163856|NCT05892822|OTHER|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
48513992|NCT02975778|DEVICE|Pain Monitor™|Pain measured by Pain Monitor™
48163857|NCT02650934|PROCEDURE|Percutanous coronary intervention|
48163858|NCT06646874|BEHAVIORAL|VR game|Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
48163859|NCT01723332|BEHAVIORAL|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
48163860|NCT01723332|BEHAVIORAL|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
48513993|NCT01121081|DRUG|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
48006845|NCT01466946|BEHAVIORAL|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin \& Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
48006846|NCT06143475|DEVICE|FPS group|"Vibration frequency ranged from 0 to 100 Hz. There were 3 modes of FPS application during rehabilitation course. 1) anti-spasticity mode (FV): the stimulators were placed in the middle of the muscles of the affected limb (i.e. unilaterally); 2) bilateral mode of proprioceptive facilitation; and 3) the unilateral mode of the proprioceptive facilitation.~The 2 first sessions were realized with bilateral FPS stimulations plus the anti-spasticity FV mode to reduce the level of hypertonia. Then for 6 consecutive sessions unilateral FPS stimulations of the affected sides imitating the drawing of a straight lines (horizontal, vertical, diagonal), preparing for writing (drawing a circle, triangle, square, spiral) were realized. At last, the 4 remaining FPS sessions were realized unilaterally imitating and promoting the realization of everyday life activities."
48006847|NCT06143475|OTHER|Conventional therapy group|Patients received sessions of traditional physical therapy: individual therapy sessions including exercises to strengthen muscles, stretching, reflex exercises for large, medium and small muscle groups of the upper limbs (ontogeny-oriented kinesiotherapy (OOKT), PNF - proprioceptive neuro-muscle facilitation, training and practice of functional rational self-service tasks). 12 sessions in total were realized 5 times a week and lasted 40 minutes each.
48006848|NCT05072353|DEVICE|SEFFICARE|"The SEFFI is a 5-step technique:~1. Preparation: the lower/lateral abdomen is chosen as the donor site.~2. Anesthesia: the donor site is injected with a local anesthetic.~3. Harvesting: a 0.8 mm or 0.5 mm cannula connected to a 10-ml VacLok® syringe is used to harvest the adipose tissue. The total amount of the harvested tissue could vary from 10 to 30 mL.~4. Washing: The syringe containing the lipoaspirate tissue is immediately filled with sterile physiological solution. After some minutes the syringes in the decanting stand will show a separation by the gravity of the tissue (top) from the physiological solution (bottom).~5. Fluidification: the syringe containing the adipose tissue should be connected to an empty 10 ml syringe. After pushing the tissue about 3 times from one syringe to the other, a good fluidification of the tissue is obtained.~The resulting tissue (2.5 mL per syringe) is ready for grafting the amputation wound."
48513994|NCT01121081|DRUG|Placebo|"Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month"
48513995|NCT05344131|OTHER|Bilişsel Egzersiz Terapi Yaklaşımı (BETY, Cognitive Exercise Therapy Approach)|Biopsychosocial approach
48163861|NCT03828877|OTHER|Group A ( Group Acupuncture)|Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
48163862|NCT01988883|DRUG|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
48163863|NCT01988883|DRUG|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
48163864|NCT01988883|DRUG|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
48163865|NCT02519829|PROCEDURE|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
48163866|NCT02519829|PROCEDURE|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
48513996|NCT03106389|DRUG|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
48513997|NCT03106389|DEVICE|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
48513998|NCT02407639|OTHER|CO2|gas
48513999|NCT02407639|OTHER|air|air
48514000|NCT04200027|PROCEDURE|total mesorectal excision|Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
48693323|NCT01133756|DRUG|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
48163867|NCT02519829|PROCEDURE|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
48163868|NCT02519829|PROCEDURE|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
48163869|NCT04727190|PROCEDURE|Transbronchial Cryobiopsy|The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.
48368935|NCT03724552|DEVICE|Transcranial LED Therapy (Participants ages 18-59)|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
48693324|NCT01133756|DRUG|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
48693325|NCT04714827|BIOLOGICAL|KQ-2003 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .
48693326|NCT06615817|DIETARY_SUPPLEMENT|Intermittent Fasting|In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
48693327|NCT05645107|DRUG|Xembify|SC infusion pump
48693328|NCT05645107|DRUG|Placebo|SC infusion pump
48693329|NCT06310642|OTHER|Immediate descent from altitude.|Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.
48693330|NCT06310642|DRUG|Diphenhydramine|Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
48693331|NCT06310642|DRUG|Prochlorperazine 10 mg|Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
48006849|NCT06484608|DRUG|Isotonic Saline with Dextrose|This clinical trial involves two interventions for maintaining fluid therapy in neonates post-surgery. The first intervention, isotonic saline with dextrose, involves administering 0.9% saline solution combined with 5% dextrose. This isotonic solution aims to maintain serum sodium levels within the normal range and minimize the risk of hyponatremia and hypernatremia in postoperative neonates. The second intervention, hypotonic saline with dextrose, involves administering 0.45% saline solution combined with 5% dextrose. This hypotonic solution is being compared to the isotonic solution to evaluate its effectiveness in maintaining electrolyte balance.
48163870|NCT04727190|PROCEDURE|Transbronchial Forceps Biopsy|The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.
48163871|NCT02214771|DRUG|Fidaxomicin|oral
48163872|NCT02214771|DRUG|Treatment for CDI other than fidaxomicin Type|Oral
48163873|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 1|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
48368936|NCT01955005|BEHAVIORAL|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
48368937|NCT01955005|OTHER|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
48368938|NCT03048981|DRUG|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
48368939|NCT01710709|DRUG|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
48368940|NCT00964470|DEVICE|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
48693332|NCT06463743|DRUG|metformin|metformin
48693333|NCT06463743|DRUG|Placebo|Placebo
48693334|NCT00443053|DRUG|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
48693335|NCT05845710|DEVICE|Neuroguard IEP Direct System|carotid artery stenting, direct access with blood flow redirection
48006850|NCT06476223|DRUG|Artificial saliva containing cumin and ginger extract|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
48163874|NCT06182124|BIOLOGICAL|Multivalent Pneumococcal Vaccine - Formulation 2|Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2).
48163875|NCT06182124|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
48163876|NCT04734847|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Non-invasive magnetic stimulation of the brain
48163877|NCT04734847|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)|Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
48163878|NCT02329223|BIOLOGICAL|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
48163879|NCT02329223|OTHER|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
48368941|NCT04681469|DRUG|Niraparib|"For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months."
48368942|NCT02160262|DRUG|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
48693336|NCT06658431|BEHAVIORAL|music group therapy|90 minutes music group therapy
48693337|NCT05195437|OTHER|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
48693338|NCT02265536|DRUG|LY3022855|Administered IV
48368943|NCT04718376|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
48163880|NCT05350514|DRUG|PI-2620 tracer|Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
48368944|NCT03802331|DRUG|BI 1323495,|single oral doses
48163881|NCT00733564|DRUG|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
48368945|NCT00987857|PROCEDURE|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
48368946|NCT00987857|PROCEDURE|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
48368947|NCT00987857|PROCEDURE|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
48368948|NCT00987857|PROCEDURE|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
48368949|NCT00987857|PROCEDURE|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
48006851|NCT06476223|DRUG|Placebo|The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
48368950|NCT00987857|PROCEDURE|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
48368951|NCT00987857|PROCEDURE|screening method|All Barretts patients to be screened
48368952|NCT02874222|OTHER|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
48368953|NCT03127072|DEVICE|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
48368954|NCT03127072|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
48368955|NCT05585099|OTHER|Exercise|Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
48368956|NCT06347146|BEHAVIORAL|Financial Literacy Training (FLT) workshops|Adolescents and youths and their caregivers will receive six 1-2 hour workshop sessions that cover components on saving, and financial management. The sessions will: introduce participants to saving, saving strategies, career planning, and the utilization of financial institutions, including saving in banks.
48368957|NCT06347146|BEHAVIORAL|Mentorship|Each adolescent and youth will have a mentor who will visit with them monthly for the duration of the intervention. The one-to-one mentorship program is intended to help AYaAIDS overcome a variety of challenges they face in daily life by fostering meaningful and lasting relationships with near peer or adult role models. Resilience theory posits that having a supportive adult outside the family reduces the impact of stress on AY's mental health. Mentors will be high school students who will be trained by the schools or NGO staff depending on study condition. All mentors will be reimbursed for their transport expenses to the field, plus an equivalent of a $5 gift card for airtime per visit.
48368958|NCT06347146|BEHAVIORAL|Income Generation Activity (IGA)|Participants will be trained on investing in income-generating activities (IGA) during the FLT workshops and will be allowed to use up to 30% of their matched savings to invest in an IGA intended to benefit the adolescent and youth (AY) and their caregiving families. The IGA portion is intended to promote economic stability.
48368959|NCT06347146|BEHAVIORAL|Youth Development Accounts (YDA)|Each adolescent and youth (AY) will receive a youth development account, which is a matched savings account held in the AY's name in a financial institution under the Central Bank (Bank of Uganda). Any of the AY's family members, relatives, or friends is encouraged to contribute towards the YDA. The account is then matched with money from the program. The match cap (maximum family contribution to be matched by the program) will be an equivalent of US$10 a month per family or US$200 for the 20-months intervention period. AY who save the maximum amount will have $600 ($200 plus $400 in match-a 2:1 match rate).
48514001|NCT02847871|BEHAVIORAL|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~* Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~* Perform a nutritional assessment by a dietician followed by appropriate care management.~* Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~* At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~* Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
48514002|NCT01573104|OTHER|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
48514003|NCT01573104|OTHER|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
48163882|NCT00733564|DRUG|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
48514004|NCT01573104|OTHER|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
48163883|NCT00733564|DRUG|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
48006852|NCT02307552|DEVICE|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
48163884|NCT06646913|DEVICE|Transcutaneous Electrical Nerve Stimulation|Patients will utilize the TENS device for 45 minutes, two times per day for the 4 week treatment period.
48163885|NCT01763034|PROCEDURE|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
48163886|NCT05512234|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
48163887|NCT05512234|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days
48163888|NCT04783883|DEVICE|Vestal DM|Battery powered non-invasive neurostimulation device (1.5mA)
48006853|NCT00557791|DRUG|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
48006854|NCT00557791|DRUG|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
48006855|NCT06270550|OTHER|Dynamic Movement Intervention|Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
48006856|NCT06242210|OTHER|pursed lip|pursed lip breathing technique for group A through videos on smart phones and a brochure given to patients. Each session takes 15-20 minutes until researchers ensure that patients understand how to perform exercises and re-demonstrate them. • Each group applied it twice per day for a period of 4 weeks. Telephone follow-up was used for patients in both groups
48006857|NCT06242210|OTHER|Stacked Breathing|The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed
48368960|NCT05596864|DIAGNOSTIC_TEST|gastric contrast ultrasound|"Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.~In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed."
48006858|NCT00013663|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
48368961|NCT00545584|DRUG|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
48368962|NCT00545584|BEHAVIORAL|Comparator: Diet|Diet
48368963|NCT00545584|BEHAVIORAL|Comparator: Physical Activity|Physical Activity
48006859|NCT00013663|DRUG|Aldesleukin|
48006860|NCT01148004|DRUG|Fenofibrate|
48368964|NCT03923062|DEVICE|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~* The patients must be sitting at an angle of 45.~* A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~* We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~* We then will wait for a few minutes and will observe the frost developing.~* The patient will be then allowed to wash her face."
48006861|NCT01148004|DRUG|Ritonavir|
48163889|NCT00926952|DRUG|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
48514005|NCT04957030|DIAGNOSTIC_TEST|ULDCT group|underwent ultralow-dose chest CT
48514006|NCT06286657|DIETARY_SUPPLEMENT|Xanthohumol|Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
48163890|NCT00926952|DEVICE|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
48514007|NCT06286657|DIETARY_SUPPLEMENT|Placebo|Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
48006862|NCT01148004|DRUG|Lopinavir/Ritonavir|
48006863|NCT05441059|DRUG|Mepolizumab 100 MG|Treatment with mepolizumab for severe asthma
48006864|NCT03294603|DRUG|CC-220|1mg \[14C\]-CC-220 will be administered as a single dose
48006865|NCT03294603|RADIATION|[14C]|Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
48006866|NCT02562313|DRUG|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
48006867|NCT02562313|DRUG|Humalog®|Humalog® bolus infusion followed by test meal intake
48006868|NCT03878134|DEVICE|PHOTON COUNTING CT Scanner|Enrolled patients will undergo the requested clinical diagnostic CT study on the investigational system using the standard detector, with or without IV and/or oral contrast as indicated and an limited scan of one body region using the PCCT detector. Both scans are able to be performed on the same scanner during the same examination.
48006869|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
48006870|NCT00863642|PROCEDURE|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
48006871|NCT02886052|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|
48006872|NCT02886052|OTHER|Active control|
48006873|NCT04347486|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium on reappearance of T2
48006874|NCT04347486|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium on reappearance of T2
48006875|NCT04347486|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium on reappearance of T2
48006876|NCT04347486|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
48006877|NCT05076266|OTHER|Questionnaire|Complete the survey questions
48163891|NCT04760327|COMBINATION_PRODUCT|Electrochemotherapy with bleomycin or cisplatin|Electrochemotherapy with cisplatin or bleomycin of gynecological cancers
48163892|NCT02345707|DRUG|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
48368965|NCT03923062|DEVICE|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
48514008|NCT06113835|PROCEDURE|CTO PCI|percutaneous coronary intervention
48514009|NCT05336032|OTHER|Food (rice)|Cooked rice with 75 gm carbohydrate
48514010|NCT02303821|DRUG|Carfilzomib|
48514011|NCT02303821|DRUG|Dexamethasone|
48514012|NCT02303821|DRUG|Mitoxantrone|
48514013|NCT02303821|DRUG|PEG-asparaginase|
48368966|NCT03923062|COMBINATION_PRODUCT|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~* After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~* The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
48006878|NCT04253717|OTHER|Motor control exercise program|Structure physical training aimed at strengthening muscles of the lumbo-pelvic-hip core complex in order to improve stabilization and alignment of the spine and pelvis.
48368967|NCT03189680|OTHER|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
48368968|NCT05574920|DIAGNOSTIC_TEST|Al18F-NOTA-FAPI-04 PET/CT scan|Patients enrolled underwent PET/CT after injection of Al18F-NOTA-FAPI-04 to image lesions of breast cancer.
48368969|NCT02033369|DRUG|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
48006879|NCT01397695|DRUG|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
48006880|NCT04025528|PROCEDURE|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
48368970|NCT01909492|PROCEDURE|Blood Draw|Patients will provide a serum sample for research.
48368971|NCT01909492|PROCEDURE|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
48693339|NCT06661291|DEVICE|Pip Care Digital Health Platform|Pip Care Digital Health Platform is a smartphone application granting access to a health coach who will assist the patient in completing a health intake, creating personalized perioperative care plans, and meets regularly with the patient to encourage goal accomplishments and supports healthy surgical recovery.
48006881|NCT00797953|DRUG|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
48006882|NCT05425290|BEHAVIORAL|Single-session emotion regulation training|The single-session emotion regulation skills training will blend psychotherapeutic approaches that emphasize effective ER. First, participants will be taught to adopt a detached (i.e., 'distanced') and nonjudgmental attitude towards an emotional situation. Detachment, or 'distancing' as it will be introduced to participants, will be taught by examining the situation with objectivity or putting spatial or temporal distance between the current moment and the situation. Second, research participants will be taught reframing. Specifically, they will be introduced to the relationship between thoughts and emotions and how to find interpretations that are less upsetting in order to be more effective when upset. Participants will identify elements of a situation that they did not pay attention to or information that was missing, and to reframe their thoughts based on the full picture. The emotion regulation training is expected to take approximately 30-45 minutes.
48006883|NCT04507932|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.
48163893|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
48368972|NCT02574429|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions \& 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
48693340|NCT06661291|OTHER|Standard of Care Protocol|Subjects in this intervention group will receive routine, standard of care throughout their surgery and hospital stay as determined by their acting clinical care team.
48693341|NCT04027283|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water
48163894|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
48163895|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
48368973|NCT03279731|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
48368974|NCT03279731|DRUG|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
48368975|NCT03726840|OTHER|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
48368976|NCT02491593|DEVICE|fecal occult blood test|
48368977|NCT05475119|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of an individual.
48514014|NCT02303821|DRUG|Vincristine|
48514015|NCT02303821|DRUG|Intrathecal (IT) Methotrexate|
48693342|NCT04027283|DIETARY_SUPPLEMENT|Erythritol + lactisole|50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
48693343|NCT04027283|DIETARY_SUPPLEMENT|D-allulose|25g D-allulose dissolved in 300mL tap water
48693344|NCT04027283|DIETARY_SUPPLEMENT|D-allulose + lactisole|25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
48693345|NCT04027283|DIETARY_SUPPLEMENT|Tap water|300mL tap water
48693346|NCT04027283|DIETARY_SUPPLEMENT|Tap water + lactisole|300mL tap water + lactisole (450ppm)
48693347|NCT06032104|DIETARY_SUPPLEMENT|Dry beans|0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)
48693348|NCT06032104|DIETARY_SUPPLEMENT|Usual diet|Usual diet without adding the bean smoothie
48693349|NCT03273647|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
48693350|NCT01258790|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
48693351|NCT01258790|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
48693352|NCT03084094|DEVICE|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
48693353|NCT04405778|BIOLOGICAL|TAK-102|TAK-102 intravenous infusion
48163896|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
48693354|NCT06542978|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
48163897|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
48693355|NCT06660134|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
48693356|NCT04367155|DRUG|Tranexamic acid injection|hemostatics use
48693357|NCT01885884|BEHAVIORAL|Embedded Supportive Care|
48693358|NCT06568731|DRUG|Danuglipron|Danuglipron oral tablets
48693359|NCT02774746|OTHER|35-week delivery|Induction at 35 weeks gestational age
48693360|NCT02774746|OTHER|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
48693361|NCT06387927|OTHER|home exercise program|Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.
48693362|NCT06387927|OTHER|the core stability exercise|supervised conventional core stability exercise
48693363|NCT06122961|OTHER|No treatment given|No treatment given
48693364|NCT06405438|OTHER|No intervention|No intervention.
48693365|NCT03884660|DEVICE|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
48693366|NCT06400589|DRUG|tanfanercept|TNF inhibitor
48693367|NCT06400589|DRUG|Vehicle|Same composition as tanfanercept but without the active ingredient
48693368|NCT05083884|OTHER|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
48163898|NCT02537236|BEHAVIORAL|TLC nutritional intervention|nutritional orientation.
48163899|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
48163900|NCT01049984|DRUG|Rasagiline|1mg tablet daily for 18 weeks
48163901|NCT01049984|DRUG|Placebo|one tablet daily for 18 weeks
48163902|NCT01406171|DRUG|Isavuconazole|oral
48693369|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 1|Creatine hcl
48163903|NCT01406171|DRUG|Midazolam|Oral
48693370|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 2|Creatine hcl
48693371|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 3|Creatine ethyl ester
48693372|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 4|Placebo
48693373|NCT05546697|OTHER|Online- Yoga-based Intervetion|See arms description
48693374|NCT05546697|BEHAVIORAL|Online- BA|See arms description
48163904|NCT06353919|OTHER|Yoga Nidra|"Recordings were created to allow participants access to a variety of Yoga Nidra practices. Participants will be instructed to complete a 30-minute Yoga Nidra 3-5 times per week, at any time of day or night (including before bed and/or during bouts of sleeplessness). This duration and frequency is informed by previous studies.~Related to intentionally decreasing BZRA use, the recording requests each practitioner to set a resolve/personal goal at the start of each practice, and they are asked to repeat it again at the end. In our study, participants will be asked to develop a short and simple resolve in their own words, related to reducing BZRA use, improving sleep and decreasing anxiety, and they will be asked to recite it at each practice."
48163905|NCT06353919|OTHER|Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education|Participants will be instructed to access excerpts from standardized and trusted materials through our online platform for 30 minutes, 3-5 times per week.
48163906|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
48163907|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
48163908|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
48693375|NCT03447210|BEHAVIORAL|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
48693376|NCT03249909|DEVICE|Exufiber Ag+|gelling fibre dressing with silver
48163909|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
48163910|NCT00434577|BIOLOGICAL|Placebo|Single intramuscular injection
48693377|NCT03249909|DEVICE|Exufiber|gelling fibre without silver
48163911|NCT05177770|DRUG|SRF617|SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
48163912|NCT05177770|DRUG|etrumadenant|Etrumadenant is an A2aR and A2bR antagonist.
48368978|NCT05475119|DEVICE|High Flow Nasal Cannula (HFNC)|High Flow Nasal Cannula (HFNC) is an oxygen supply system capable of delivering up to 100% humidified and heated oxygen at a flow rate of up to 60 liters per minute
48693378|NCT03249909|DEVICE|Aquacel Ag Extra|gelling fibre with silver
48163913|NCT05177770|DRUG|zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
48163914|NCT03039088|OTHER|Follow-up after 12 weeks after TNF alpha blockers initiation|
48368979|NCT00461552|DRUG|Leptin|weight based, sub-cutaneous injection, twice daily
48693379|NCT02950155|DRUG|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
48368980|NCT00461552|OTHER|Placebo|weight based, sub-cutaneous injection, twice daily
48368981|NCT02140996|DRUG|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
48368982|NCT02693405|OTHER|Executive functions|measures of executive functioning with tasks
48693380|NCT02950155|DRUG|Sodium Chloride solution|A single infusion of Placebo/Sham.
48163915|NCT03612492|DRUG|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
48163916|NCT03612492|DRUG|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
48163917|NCT01939821|BEHAVIORAL|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
48163918|NCT01939821|BEHAVIORAL|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
48163919|NCT02146729|PROCEDURE|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
48368983|NCT02693405|OTHER|social cognition|measures of socio-cognitive functioning with tasks
48368984|NCT02693405|OTHER|quality of life|measures of quality of life with questionnaires
48693381|NCT03684603|BEHAVIORAL|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
48693382|NCT03684603|BEHAVIORAL|melody only during motor training|sequence of tones which are presented to the patient using earphones
48693383|NCT03778749|DIAGNOSTIC_TEST|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
48163920|NCT02146729|PROCEDURE|Open Treatment|Midline posterior incision with instrumentation.
48163921|NCT03824353|BEHAVIORAL|Social Intelligence Training|The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
48163922|NCT03824353|BEHAVIORAL|The Healthy Living Program|A placebo condition delivered online which presents health-related information only.
48163923|NCT06263296|BEHAVIORAL|Self Management Education|Smartphone assisted self management education incorporated with the concept of motivational interviewing
48163924|NCT01292317|OTHER|application of intravenous volume|weight based intravenous application of volume
48163925|NCT01292317|OTHER|oral fluid application|oral fluid application
48163926|NCT01256372|DRUG|AP214|AP214
48006884|NCT05168007|DRUG|WID-RGC20(Cariprazine) 3mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
48163927|NCT01256372|DRUG|Placebo|Placebo; intravenous infusion
48163928|NCT05249309|DRUG|Ketamine|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
48006885|NCT05168007|DRUG|WID-RGC20(Cariprazine) 6mg/day|The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).
48368985|NCT01572129|DRUG|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
48368986|NCT01572129|DRUG|Placebo|Placebo in addition to the chronic daily dose of 75 mg
48368987|NCT03984682|PROCEDURE|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
48006886|NCT05168007|DRUG|Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day|The placebo comparator is administered during the double-blind treatment period(6 weeks).
48368988|NCT02653131|DRUG|Dipeptidyl peptidase-4 inhibitor|
48693384|NCT02047773|OTHER|Duration|If bacterial load checked on day 7 is less than 10\^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10\^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
48693385|NCT02047773|DRUG|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
48693386|NCT02047773|DRUG|Meropenem|
48693387|NCT06025695|COMBINATION_PRODUCT|GSK's liquid oral live attenuated HRV|2 doses of GSK's liquid oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China.
48693388|NCT06025695|COMBINATION_PRODUCT|PCV-free liquid formulation of GSK's oral live attenuated HRV|2 doses of PCV-free liquid formulation of GSK's oral live attenuated HRV study intervention administered orally at Day 1 and Month 1, according to the immunization schedule for HRV study intervention licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
48006887|NCT01557400|DRUG|Ataluren|Oral powder for suspension
48006888|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
48006889|NCT03288597|RADIATION|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
48163929|NCT03698071|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
48163930|NCT03698071|BIOLOGICAL|urine sample|6 ml
48163931|NCT00317603|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
48163932|NCT05501665|PROCEDURE|Biospecimen Collection|Correlative studies
48163933|NCT05501665|DRUG|Carboplatin|Given carboplatin
48163934|NCT05501665|PROCEDURE|Computed Tomography|Undergo PET/CT
48163935|NCT05501665|OTHER|Fludeoxyglucose F-18|Given IV
48163936|NCT05501665|DRUG|Nab-paclitaxel|Given nab-paclitaxel
48163937|NCT05501665|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
48163938|NCT05501665|DRUG|Pemetrexed|Given pemetrexed
48163939|NCT05501665|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48163940|NCT05501665|RADIATION|Radiation Therapy|Undergo radiation therapy
48163941|NCT05501665|OTHER|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
48163942|NCT05501665|BIOLOGICAL|Ipilimumab|Given Ipilimumab
48163943|NCT05501665|BIOLOGICAL|Nivolumab|Given Nivolumab
48163944|NCT05501665|BIOLOGICAL|Cemiplimab|Given Cemiplimab
48163945|NCT05501665|BIOLOGICAL|Atezolizumab|Given Atezolizumab
48163946|NCT02652715|OTHER|Laboratory Biomarker Analysis|Correlative studies
48163947|NCT02652715|OTHER|Quality-of-Life Assessment|Ancillary studies
48163948|NCT02652715|OTHER|Questionnaire Administration|Ancillary studies
48163949|NCT02652715|DIETARY_SUPPLEMENT|Salvia hispanica Seed|Given PO
48368989|NCT00231322|DRUG|praziquantel|
48368990|NCT00958399|DIETARY_SUPPLEMENT|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
48514016|NCT02303821|DRUG|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
48693389|NCT05556291|DRUG|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
48006890|NCT02485912|BIOLOGICAL|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
48006891|NCT02485912|BIOLOGICAL|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
48163950|NCT04848116|DRUG|Nivolumab|Nivolumab is an investigational drug in this study.
48693390|NCT04697537|DRUG|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
48693391|NCT04697537|DRUG|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
48693392|NCT01925040|DEVICE|Placement of restoration|Placement of restorations
48693393|NCT03267433|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
48163951|NCT04848116|DRUG|HuMax-IL8|HuMax-IL8 is an investigational drug in this study.
48693394|NCT03267433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48368991|NCT00958399|DIETARY_SUPPLEMENT|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
48163952|NCT03600519|DEVICE|NOTAL OCT V2.5|AMD Patients
48163953|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
48163954|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.25ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
48693395|NCT03267433|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
48693396|NCT03267433|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
48693397|NCT03267433|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48693398|NCT03267433|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
48693399|NCT03267433|BIOLOGICAL|Rituximab|Given IV
48693400|NCT03267433|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
48693401|NCT03784911|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
48693402|NCT03784911|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
48693403|NCT00151684|DRUG|Diazoxide|
48006892|NCT03569670|DEVICE|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
48006893|NCT03569670|DEVICE|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
48163955|NCT05645900|BIOLOGICAL|Quadrivalent split influenza virus vaccine|This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
48368992|NCT00958399|DIETARY_SUPPLEMENT|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
48006894|NCT03400033|DRUG|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
48368993|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
48514017|NCT02303821|DRUG|6-Mercaptopurine|
48514018|NCT02303821|DRUG|Cyclophosphamide|
48693404|NCT02358200|DRUG|BMN-673|
48693405|NCT02358200|DRUG|Carboplatin|
48693406|NCT02358200|DRUG|Paclitaxel|
48693407|NCT06053138|DIETARY_SUPPLEMENT|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
48693408|NCT06053138|DIETARY_SUPPLEMENT|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
48693409|NCT06660043|OTHER|physical activity|40 min circuit training session
48693410|NCT06660043|OTHER|analgesic physical therapy|physical therapy with massage and Transcutaneous Electrical Nerve Stimulation in a 40min session
48693411|NCT06660043|OTHER|analgesic physical therapy AND physical activity|25 min circuit training session and 15 min physical therapy
48693412|NCT03302884|OTHER|biological sampling|Tumor and blood samples
48693413|NCT01618435|BIOLOGICAL|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
48693414|NCT03067181|OTHER|Best Practice|Undergo observation
48693415|NCT03067181|PROCEDURE|Biopsy|Undergo a tumor biopsy
48693416|NCT03067181|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48693417|NCT03067181|BIOLOGICAL|Bleomycin Sulfate|Given IV
48163956|NCT03154684|OTHER|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~* Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~* Inspection of the environment at the patient's home~* Care and autonomy support~* Social life support~* Secondary prevention strategies:~* Home exercise program (3x/weeks)~* Protein enriched food preparation (20g whey protein/day)~* Support to take vitamin D supplementation (2000 IU/day)~* Recommendation and support to eat calcium rich foods~* Motivation to be physically active"
48163957|NCT03154684|OTHER|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
48006895|NCT03400033|DRUG|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
48006896|NCT03400033|DRUG|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
48006897|NCT03400033|DRUG|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
48006898|NCT01125215|DRUG|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
48006899|NCT01125215|DRUG|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
48006900|NCT04415099|OTHER|Muscle fatigue protocol|"Tibialis posterior was fatigued using 2 exercises:~1. Unilateral heel raise exercise~2. Close chain resisted foot adduction exercise"
48006901|NCT04394728|DRUG|Trabectedin|1.3 mg/m2 with a top-dose of 2.6 mg per cycle, via a central venous catheter as a 24-hour infusion every 21 days.All patients received premedication with dexamethasone 20 mg i.v. 30 min before administration of trabectedin.
48006902|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
48163958|NCT05383651|DEVICE|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
48163959|NCT05383651|DEVICE|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
48163960|NCT00930683|DRUG|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
48163961|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
48163962|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
48163963|NCT00930683|DRUG|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
48163964|NCT00930683|DRUG|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
48163965|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
48163966|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
48006903|NCT00347152|DRUG|Divalproex|Divalproex, 8-20% taper
48006904|NCT05580731|DIAGNOSTIC_TEST|Diagnostic test: 5 different Rapid diagnostic test and Reference tests|Diagnostic test: 5 different Rapid diagnostic test and Reference tests
48006905|NCT06486571|OTHER|Electromyography recording with HD-sEMG|Measurement of muscle electrical signal with HD-sEMG sensors, training of a pattern recognition classifier for hand gesture recognition, verification and comparison with state of the art.
48006906|NCT06486571|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application of TENS by means of non-invasive superifical electrodes on the stump skin of the participants to restore multimodal somatotopical sensations of mechanoception, nociception and thermoception.
48006907|NCT03791658|OTHER|The 12-question TAI|The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
48006908|NCT03791658|OTHER|Information from patients file|Depending on which arm or group specific information will be gathered from the patients file after informed consent.
48006909|NCT03791658|OTHER|The Asthma Control Test (ACT)|An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
48163967|NCT00930683|DRUG|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
48163968|NCT00930683|DRUG|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
48163969|NCT01930877|DRUG|Lidocaine|Lidocaine iv bolus followed by infusion
48163970|NCT01930877|OTHER|Placebo (normal saline)|Normal saline bolus followed by infusion
48163971|NCT02896439|DEVICE|Neurophysiological MONITORING|"The neurophysiology team perform:~* Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~* Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~* Establishment of a spacer or forceps in the greater or lesser sciatic notch~* Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~* At the end of the incision~* On the establishment of a spacer or forceps in the greater or lesser sciatic notch~* When towing layout~* At the end of the intervention"
48163972|NCT04473118|OTHER|Survey|An online-based questionnaire sent to participants via email
48163973|NCT06538649|DRUG|Rosuvastatin|Statin provided at 10mg start; 5mg for Asians. Dose will be increased to 20mg for those tolerating and without contraindication.
48163974|NCT06538649|OTHER|Placebo|Placebo pill
48163975|NCT01537120|DRUG|Vildagliptin|
48163976|NCT01537120|DRUG|Placebo|
48163977|NCT06316778|BEHAVIORAL|Pelvic floor muscle training|12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.
48514019|NCT02303821|DRUG|Cytarabine|
48514020|NCT02303821|DRUG|Daunorubicin|
48693418|NCT03067181|DRUG|Carboplatin|Given IV
48006910|NCT03791658|OTHER|The COPD Assessment Test (CAT)|An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
48163978|NCT05693480|DEVICE|Balance sensor|Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
48006911|NCT01060267|DRUG|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
48006912|NCT01060267|DRUG|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
48006913|NCT05441735|COMBINATION_PRODUCT|APP|APP as an instructional tool for visiting health education
48163979|NCT03275402|BIOLOGICAL|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
48163980|NCT03658694|PROCEDURE|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
48163981|NCT03658694|PROCEDURE|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
48693419|NCT03067181|DRUG|Cisplatin|Given IV
48693420|NCT03067181|PROCEDURE|Computed Tomography|Undergo a CT scan
48693421|NCT03067181|DRUG|Etoposide|Given IV
48693422|NCT03067181|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48693423|NCT03067181|OTHER|Pharmacogenomic Study|Correlative studies
48693424|NCT03067181|PROCEDURE|Pulmonary Function Test|Undergo a pulmonary function test
48693425|NCT03067181|OTHER|Quality-of-Life Assessment|Ancillary studies
48693426|NCT03067181|OTHER|Questionnaire Administration|Ancillary studies
48006914|NCT02192944|DRUG|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
48163982|NCT03658694|PROCEDURE|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
48163983|NCT03658694|PROCEDURE|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
48693427|NCT00485758|DRUG|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
48693428|NCT00485758|DRUG|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
48693429|NCT00405392|DRUG|Ibandronate (SB743830HD)|
48693430|NCT04915118|OTHER|Decompensation event|NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
48693431|NCT04332536|OTHER|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
48693432|NCT02713984|BIOLOGICAL|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
48693433|NCT05788796|BEHAVIORAL|Band-aid application|"Before starting the study, cotton and band-aids will be provided to the women in the application group by the researchers.~• Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid."
48693434|NCT02295631|DEVICE|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
48693435|NCT02295631|DEVICE|ETView VivaSight SL|ETI with ETView VivaSight SL
48693436|NCT01599312|DEVICE|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
48006915|NCT02192944|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
48006916|NCT03092180|DRUG|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
48006917|NCT03791866|OTHER|Nutrition|Enteral nutrition
48006918|NCT00284531|DRUG|Daclizumab|
48163984|NCT01259440|BEHAVIORAL|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
48163985|NCT01259440|BEHAVIORAL|Usual Care|Consists of one week telephone call and one month clinic visit
48006919|NCT02922452|DRUG|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
48006920|NCT02922452|DRUG|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
48163986|NCT01653093|PROCEDURE|3-Tesla magnetic resonance imaging (3T MRI)|Undergo 3T MRI
48163987|NCT01653093|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
48163988|NCT01653093|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
48163989|NCT01653093|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
48693437|NCT05723055|DRUG|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
48693438|NCT05723055|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
48693439|NCT01379248|DEVICE|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
48693440|NCT06471361|DRUG|Zilucoplan|Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
48693441|NCT02963168|DRUG|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
48693442|NCT06651775|DEVICE|High intensity laser therapy|lumbosciatalgia mode of the HILT device
48693443|NCT06651775|DEVICE|Sham Comparator|sham mode of the HILT device
48163990|NCT05360199|BEHAVIORAL|PROMs|evaluate the impact of recall bias on post proms scores
48163991|NCT00801450|DRUG|Triamcinolone acetonide|4 mg
48163992|NCT00801450|DRUG|Triamcinolone acetonide|40 mg
48163993|NCT02108483|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
48163994|NCT02108483|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
48163995|NCT06370143|BEHAVIORAL|Questionnaire|The questionnaire on clinical, environmental, lifestyle, and dietary risk factors will be administered
48163996|NCT05192226|BEHAVIORAL|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
48163997|NCT02621047|DRUG|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
48163998|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-10 mg/kg per dose
48163999|NCT05478720|DRUG|Placebo|Single intravenous dose of saline
48693444|NCT06027814|BEHAVIORAL|Patient Navigation and mHealth (PN+mHealth)|Intervention consists of patient navigation with the mHealth adherence application facilitating telehealth visits, two-way chats, video-DOT, and delivery of financial incentives via smartphone.
48164000|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
48164001|NCT01091844|PROCEDURE|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
48164002|NCT01420900|DEVICE|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
48164003|NCT01420900|DEVICE|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
48164004|NCT01996397|PROCEDURE|Cardiac resynchronization therapy device implantation|
48164005|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
48164006|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
48164007|NCT05283525|DIETARY_SUPPLEMENT|Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches|0 - 90 Days of Treatment
48164008|NCT05283525|DIETARY_SUPPLEMENT|Oxygen Saturation|0 - 90 Days of Treatment
48164009|NCT05283525|DIETARY_SUPPLEMENT|Total Blood Chemistry|0 and 90 Days of Treatment
48164010|NCT05283525|DIETARY_SUPPLEMENT|Adverse Event Monitoring|Adverse Event Monitoring Throughout the Study
48164011|NCT05283525|DIETARY_SUPPLEMENT|Body Weight Monitoring|0 - 90 Days of Treatment
48164012|NCT05283525|DIETARY_SUPPLEMENT|Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health|0 - 90 Days of Treatment
48164013|NCT01630395|PROCEDURE|protective ventilation|low tidal volume and PEEP
48164014|NCT01630395|PROCEDURE|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
48164015|NCT05924048|OTHER|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
48164016|NCT04270656|PROCEDURE|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
48164017|NCT04270656|PROCEDURE|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
48164018|NCT00006578|DRUG|Ritonavir|
48164019|NCT00006578|DRUG|Abacavir sulfate|
48164020|NCT00006578|DRUG|Amprenavir|
48164021|NCT00006578|DRUG|Lamivudine|
48164022|NCT00006578|DRUG|Filgrastim|
48164023|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
48164024|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
48164025|NCT04051190|DIETARY_SUPPLEMENT|VLED group|10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.
48368994|NCT00958399|DIETARY_SUPPLEMENT|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
48164026|NCT04051190|PROCEDURE|Sleeve Gastrectomy group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
48164027|NCT04051190|PROCEDURE|Gastric Bypass group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)
48164028|NCT01845558|DRUG|Wobenzym® plus|
48164029|NCT01845558|OTHER|Placebo|
48164030|NCT01881100|OTHER|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
48164031|NCT01881100|OTHER|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
48164032|NCT05411471|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
48164033|NCT06111443|DRUG|Dapagliflozin 10 mg [Farxiga]|Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
48164034|NCT02672514|DEVICE|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
48164035|NCT02672514|DEVICE|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
48164036|NCT04872634|BIOLOGICAL|SNK01 (Super Natural Killer Cells 01)|Investigational Product : SNK01 (Super Natural Killer Cells 01) Principal Component : Autologous Natural Killer Cell To induce anti-tumor immunity in Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior TKI therapy for EGFR, ALK, or ROS1 Gene Mutation and to strengthen the Antibody-Dependent Cellular Cytotoxicity (ADCC) of Cetuximab, 4x10\^9 or 6x10\^9 cells are infused through the veins of the subjects within 45 minutes (±15 minutes) per 100 mL total 8 times at intervals of one week.
48164037|NCT04872634|DRUG|GC|"Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour."
48164038|NCT04872634|BIOLOGICAL|Cetuximab|"First administration: 400mg/m2 Subsequent administration: 250mg/m2 (Premedication before administration\*) Weekly Administration continues until the disease progresses or unacceptable toxicity develops.~400mg/m2: Administered into a vein for 120 minutes 250mg/m2: Administered into a vein for 60 minutes"
48164039|NCT01501747|DRUG|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
48164040|NCT01501747|DRUG|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
48164041|NCT04199676|DIAGNOSTIC_TEST|Glucose tolerance test|Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
48164042|NCT04139239|DIAGNOSTIC_TEST|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
48164043|NCT00136175|DRUG|Paclitaxel|
48164044|NCT00136175|DRUG|Carboplatin|
48164045|NCT00136175|DRUG|Gemcitabine|
48164046|NCT05359705|DEVICE|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
48164047|NCT05359705|DEVICE|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
48164048|NCT05359705|DEVICE|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
48164049|NCT05359705|DEVICE|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
48164050|NCT02895750|DRUG|Metformin|Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
48164051|NCT03904875|OTHER|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
48368995|NCT02094131|OTHER|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
48006921|NCT02269891|DIETARY_SUPPLEMENT|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
48006922|NCT02269891|OTHER|Placebo|
48006923|NCT05897879|BIOLOGICAL|Nasopharyngeal swab|"For hospitalized patients :~Nasopharyngeal swab (1 aspiration or 2 swabs (1 in each nostril))~For ambulatory patients :~Deep nasal swab: 2 swabs (1 in each nostril), or 1 swab only for children for whom taking 2 swabs is complicated."
48164052|NCT00196378|DRUG|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
48164053|NCT00196378|OTHER|Placebo|1 tablet daily
48693445|NCT06222346|BEHAVIORAL|CommonGround|"Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support."
48164054|NCT02728375|OTHER|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
48164055|NCT02728375|OTHER|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
48164056|NCT01395914|DRUG|Anamorelin HCl|
48164057|NCT01395914|DRUG|Placebo|
48164058|NCT03067610|RADIATION|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
48693446|NCT06222346|BEHAVIORAL|NHS Mental Health|"Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements."
48693447|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
48164059|NCT03067610|DRUG|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
48164060|NCT06645860|PROCEDURE|SDF+KI+LED Light 20s|After the silver diamine fluoride (SDF) and potassiım iodide (KI) application, 20-second LED light will be applied to the cavity.
48164061|NCT06645860|PROCEDURE|SDF+KI|Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
48164062|NCT01716923|BIOLOGICAL|S-303 Red Blood Cells (RBCs) - Test|
48368996|NCT02094131|OTHER|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
48368997|NCT01224171|DRUG|vedolizumab|Vedolizumab for intravenous infusion
48006924|NCT05897879|BIOLOGICAL|Blood samples|For hospitalized patients : 3 to 7.5 ml For ambulatory patients: Fingertip blood sampling
48006925|NCT01565135|BEHAVIORAL|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
48164063|NCT01716923|BIOLOGICAL|Conventional, untreated red blood cells (RBCs) - Control|
48164064|NCT05582590|DRUG|Fludarabine|Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
48368998|NCT01224171|OTHER|Placebo|Placebo intravenous infusion
48368999|NCT04614142|DRUG|Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]|The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
48164065|NCT05582590|DRUG|Cyclophosphamide|Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
48006926|NCT02100007|DRUG|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
48006927|NCT02100007|DRUG|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
48164066|NCT05582590|BIOLOGICAL|NEXI-003 T cells|Adoptive Cell Therapy specified dose on specified day(s)
48164067|NCT04778449|OTHER|Medical Chart Review|Medical charts are reviewed
48164068|NCT04778449|OTHER|Questionnaire Administration|Complete questionnaires
48006928|NCT00613028|DRUG|Temo + Avastin|Patients have progressed/had gr3/\> toxicity related to etoposide, with no had progression/gr 3/\> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
48006929|NCT00613028|DRUG|VP-16 + Avastin|Patients have progressed/had gr3/\> toxicity related to temozolomide, but have not progressed/gr3/\> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
48164069|NCT06001827|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
48164070|NCT06001827|PROCEDURE|Untreated AVF Control|AVF creation surgery without any intervention
48164071|NCT06410625|DIAGNOSTIC_TEST|FLT PET imaging|Evaluation of response to chemotherapy with FLT PET imaging
48164072|NCT03212755|DIAGNOSTIC_TEST|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
48164073|NCT04461938|OTHER|Fasting|The study intervention consists of one fasting cycle of 72 hours prior to biopsy/resection. Depending on clinical condition, patients can be hospitalized during the course of the study (e.g. need for medical assistance due to immobilization). Patients in good clinical condition will be admitted on day 3.
48164074|NCT03445507|OTHER|Chat bot|Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
48164075|NCT03445507|OTHER|Usual care|Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
48164076|NCT05011617|DEVICE|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
48164077|NCT03696732|OTHER|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
48693448|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
48693449|NCT02091362|DRUG|LY2409021|Administered orally
48006930|NCT01064791|DRUG|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
48006931|NCT01064791|DRUG|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
48006932|NCT01064791|DRUG|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
48006933|NCT01064791|DRUG|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
48006934|NCT04702373|OTHER|passive range of motion exercise therapy|Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
48006935|NCT00846924|DEVICE|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
48006936|NCT00846924|DEVICE|24-hour Holter|Repeat standard 24-hour Holter Monitor
48006937|NCT02183441|DRUG|BI 1356|
48164078|NCT03696732|OTHER|VAS questionnaire|verbal numerical scale (VNS) anxiety score
48164079|NCT05180487|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
48164080|NCT02091297|DRUG|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
48164081|NCT02091297|DRUG|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
48369000|NCT03975881|OTHER|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
48369001|NCT00005803|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
48693450|NCT02091362|DRUG|Placebo|Administered orally
48693451|NCT02091362|DRUG|Metformin|Administered as background therapy.
48693452|NCT05420181|OTHER|Short 10hr fast|Participants will fast from 11pm the night before the study day
48693453|NCT05420181|OTHER|Long 16h fast|Participants will fast from 5pm the night before the study day
48006938|NCT02183441|DRUG|Ritonavir|
48006939|NCT02170610|DRUG|BIBR 1048 MS|
48006940|NCT02170610|DRUG|Pantoprazole|
48693454|NCT01947621|OTHER||
48693455|NCT06273722|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
48006941|NCT04256616|OTHER|This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.|"urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC."
48164082|NCT02091297|DRUG|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
48164083|NCT02091297|DRUG|Morphine|
48164084|NCT05571553|OTHER|Recommendations and reorientation towards healthcare resources|"Phase 1~* After completing the CARE© questionnaire, participants will be given recommendations.~* After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~* After completing the CARE© questionnaire, participants will be given recommendations.~* If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care."
48164085|NCT05060237|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):~Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing."
48164086|NCT06538220|BEHAVIORAL|Questionnaires and focus group|"To evaluate the Chronic Disease Unit care pathway, patients will respond to questionnaires : quality of life (SF-12), personal efficacy scale (GSES), Specific self Efficacy related to Weight Management (SEWM), Rosenberg self-esteem, body image satisfaction (QIC), state of anxiety and depression (HAD), Chronic Disease Unit satisfaction. Some patients will also participate to focus group."
48164087|NCT00912054|DRUG|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
48164088|NCT00912054|DRUG|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
48164089|NCT00507429|DRUG|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
48164090|NCT00507429|DRUG|paclitaxel|200mg/m squared on Day 1
48164091|NCT00507429|DRUG|carboplatin|6 AUC on Day 1 following paclitaxel
48164092|NCT06479447|OTHER|PORTAL-PTSD|Patients will be eligible if they are 18+ years, have had a primary care visit in the last 2 years, and have not been screened for PTSD in the last year. The validated PC-PTSD-5 (Primary Care Post Traumatic Stress Disorder-5) screener will be used. Clinics will implement visit-based and population health screening for patients enrolled in the patient portal who have not been screened for PTSD in the last year and have had a clinic appointment in the last 2 years. The PCBH care manager or patient navigator will follow-up with patients every 2 weeks to ensure they have been connected to care and re-measure their PTSD symptoms. The follow-up calls will continue until symptom remission, after which follow-ups will occur quarterly for 6 months. Primary care clinicians will receive training on trauma-informed care and PTSD management, and will be surveyed at baseline, immediately after training, and 6 months-post intervention to evaluate changes in their knowledge of trauma-informed care.
48164093|NCT06158971|DEVICE|Flexible Bronchoscopic Microwave Ablation|The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
48164094|NCT00742898|OTHER|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
48164095|NCT01911936|DRUG|LM716|
48164096|NCT06553768|DRUG|Maralixibat|Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
48369002|NCT00005803|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
48369003|NCT00005803|DRUG|Carmustine|Given IV
48369004|NCT00005803|DRUG|Cyclophosphamide|Given IV
48693456|NCT03852381|DEVICE|Spinal Cord Stimulation|Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
48693457|NCT04727632|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT
48006942|NCT02807181|DRUG|Cisplatin-gemcitabine|Systemic chemotherapy
48006943|NCT02807181|DEVICE|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
48006944|NCT05547321|DRUG|OMTX705|The investigational product is OMTX705 administered as monotherapy.
48006945|NCT05547321|DRUG|Pembrolizumab|The investigational product is OMTX705 administered in combination with pembrolizumab.
48006946|NCT00690963|PROCEDURE|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
48693458|NCT06169943|OTHER|mHealth social support program|This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
48006947|NCT00004881|BIOLOGICAL|MVA-MUC1-IL2 vaccine|
48693459|NCT06169943|OTHER|Control|The same mobile app as the intervention group but with limited function.
48693460|NCT06659354|BEHAVIORAL|Pregnant Body Project (PBP)|The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
48006948|NCT06147011|OTHER|3D printed educational model|Slide-based presention plus 3D printed thyroid fine needle aspiration model
48693461|NCT06659354|BEHAVIORAL|Pregnancy Health Education (PHE)|This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
48693462|NCT06611345|DEVICE|Tumor Treating Fields|Tumor treating fields will be used each day.
48693463|NCT06611345|DRUG|Durvalumab|Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
48693464|NCT06611345|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
48693465|NCT06611345|DRUG|Cisplatin|Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
48006949|NCT05776758|DRUG|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
48006950|NCT05776758|PROCEDURE|Radical cystectomy alone|RC alone
48006951|NCT00006890|DRUG|prednisone|Prednisone 50mg on alternate days
48006952|NCT00006890|DRUG|thalidomide|THALIDOMIDE 200 mg qhs
48164097|NCT06553768|OTHER|Placebo|Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
48164098|NCT03104309|DEVICE|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
48164099|NCT00694564|DRUG|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
48693466|NCT03781973|BEHAVIORAL|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
48693467|NCT06512675|OTHER|Resistance combined with cardiovascular training|Participants will undergo a 6-week exercise program designed under the supervision of a board certified sports medicine physician. The exercise program will consist of a 3 day per week schedule: Monday will be lower body resistance training, Wednesday will be aerobic exercise, and Friday will be upper body resistance training. Each session will be approximately up to 1 hour.
48693468|NCT04812028|DRUG|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
48006953|NCT03405142|DRUG|Panitumumab-IRDye800|Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.
48164100|NCT05990283|PROCEDURE|Socket shield technique|For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth. Healing caps were placed, and the periphery of the caps was covered with an absorbable gelatin sponge.
48693469|NCT06199375|BEHAVIORAL|Routine treatment|The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
48006954|NCT03405142|DRUG|Lymphoseek|Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution
48164101|NCT05990283|PROCEDURE|Guided bone regeneration|For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
48164102|NCT01414543|OTHER|Information Sheet|Providing the Participant with information regarding the aim of the experiment
48006955|NCT05902208|DRUG|Antiviral treatment with conventional non-surgical treatment|Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered during 28 days.
48006956|NCT05902208|DRUG|Placebo with conventional non-surgical treatment|Placebo of valaciclovir (same composition, without active substance) will be added to the conventional non-surgical treatment of generalized periodontitis. One gram a day will be administered during 28 days.
48006957|NCT04354259|DRUG|Peginterferon Lambda-1A|Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain. Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.
48164103|NCT01414543|OTHER|Consent|Providing a consent form for participants. The participant is aware of his or her rights
48164104|NCT01414543|OTHER|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
48164105|NCT01414543|OTHER|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
48164106|NCT03254992|DEVICE|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
48164107|NCT03254992|DEVICE|ASD - Tangible task|Experimental group using Keyboard with more real activity.
48164108|NCT03254992|DEVICE|TD - Abstract task|Control group using Kinect with more virtual activity.
48164109|NCT03254992|DEVICE|TD - Tangible task|Control group using Keyboard with more real activity.
48164110|NCT00067548|DRUG|EKB-569|
48164111|NCT06646601|OTHER|Intervention of prevention|A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.
48164112|NCT04823117|OTHER|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
48164113|NCT03638401|PROCEDURE|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
48164114|NCT04054596|BEHAVIORAL|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
48164115|NCT01707498|PROCEDURE|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
48164116|NCT01707498|PROCEDURE|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
48164117|NCT04809168|OTHER|Questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
48164118|NCT05615662|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
48164119|NCT05615662|BEHAVIORAL|Treatment as Usual|Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
48164120|NCT00666835|DRUG|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
48164121|NCT00666835|DRUG|ERYPO®, Janssen-Cilag|Solution for i.v. injection
48164122|NCT02324088|DRUG|Docetaxel|
48164123|NCT02324088|DRUG|Cyclophosphamide|
48164124|NCT02324088|DRUG|Epirubicin|
48164125|NCT06297590|DRUG|LY3954068|Administered IT
48164126|NCT06297590|DRUG|Placebo|Administered IT
48006958|NCT04354259|OTHER|placebo|injection of 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
48006959|NCT03071796|DIETARY_SUPPLEMENT|multivitamin supplement|supplement includes 97 natural extracts
48006960|NCT03071796|DIETARY_SUPPLEMENT|Placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
48006961|NCT05241886|OTHER|anthoropometric measurement, SARC- F questionnare|SARC-F, CC, MUAC
48006962|NCT04001569|DRUG|AZD8186 in combination with paclitaxel|"Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks"
48164127|NCT06297590|DRUG|Flortaucipir F18|Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
48164128|NCT04292925|OTHER|New treatment protocol|The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
48164129|NCT04292925|OTHER|Conventional therapy|conventional therapy
48164130|NCT02768077|DRUG|Melatonin(Circadin®)|
48164131|NCT02768077|DRUG|Placebo|
48369005|NCT00005803|DRUG|Cyclosporine|Given PO
48369006|NCT00005803|DRUG|Cytarabine|Given IV
48369007|NCT00005803|DRUG|Etoposide|Given IV
48369008|NCT00005803|DRUG|Fludarabine Phosphate|Given IV
48006963|NCT04909086|PROCEDURE|Standard physical Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
48006964|NCT04909086|PROCEDURE|Closed Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
48006965|NCT04909086|PROCEDURE|Open Kinetic Chain|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
48006966|NCT04019691|DEVICE|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
48006967|NCT04019691|DEVICE|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
48006968|NCT04019691|DEVICE|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
48006969|NCT04222179|DEVICE|ultrathın esophagogastroduodenoscope|Place the naso-enteric tube together with the ultrathin esophagogastroduodenoscope from the same nasal cavity
48006970|NCT06332521|OTHER|Acoustic signal analysis method|Evaluate at birth in 2 characterized populations of babies born at term or prematurely, the correlation between bioacoustic characteristic of a cry specific to each baby, with the neurodevelopmental data at 2 years.
48369009|NCT00005803|OTHER|Laboratory Biomarker Analysis|Correlative studies
48006971|NCT02674412|DRUG|Buspirone|
48006972|NCT02674412|DRUG|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
48006973|NCT01178892|DIETARY_SUPPLEMENT|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
48006974|NCT01178892|DIETARY_SUPPLEMENT|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
48006975|NCT01178892|BEHAVIORAL|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
48006976|NCT01178892|BEHAVIORAL|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
48164132|NCT06006897|OTHER|Physical Evaluations of post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.
48164133|NCT06006897|OTHER|Physical evaluations of non-post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
48164134|NCT06646861|OTHER|Exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included.
48164135|NCT03835403|OTHER|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
48164136|NCT03005483|DRUG|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
48369010|NCT00005803|DRUG|Melphalan|Given IV
48369011|NCT00005803|DRUG|Mycophenolate Mofetil|Given PO
48369012|NCT00005803|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
48369013|NCT00005803|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
48006977|NCT01178892|BEHAVIORAL|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
48164137|NCT03005483|OTHER|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
48164138|NCT06141772|OTHER|Measure of the circulating tumor DNA|Blood assessment to measure the kinetics au circulating tumor DNA
48164139|NCT02582034|RADIATION|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~* An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~* A dose at the treated healthy liver \< 120 Gy in case of lobar treatment~* Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve \> 30%~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
48164140|NCT02582034|RADIATION|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~* An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
48164141|NCT02728947|DRUG|ROTIGOTINE|1 week at each dose
48164142|NCT03487341|OTHER|Cord drainage|Cord drainage
48164143|NCT03487341|OTHER|Cord clamping|Cord clamping
48164144|NCT00003402|DRUG|carmustine|
48693470|NCT06199375|BEHAVIORAL|Rehabilitation training|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
48693471|NCT06199375|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
48006978|NCT03225612|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
48164145|NCT00003402|DRUG|cisplatin|
48164146|NCT00003402|DRUG|cyclophosphamide|
48164147|NCT00003402|DRUG|dexamethasone|
48164148|NCT00003402|DRUG|etoposide|
48164149|NCT00003402|DRUG|melphalan|
48164150|NCT00003402|DRUG|paclitaxel|
48164151|NCT00003402|PROCEDURE|bone marrow ablation with stem cell support|
48164152|NCT00003402|PROCEDURE|peripheral blood stem cell transplantation|
48164153|NCT06212934|OTHER|Acupuncture|"Chou's Tiaoshen acupoints includes Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1), Sanyinjiao (SP-6), Shenmen (HT-7) . Using stainless steel needles (0.32×40)mm, HuaTuo, China). Then some other points like, Danzhong(CV-17), Daling(PC-7), Taixi (KI-3), Qihai (CV-6), Taichong (LR3), and Qiuxu(GB-40) are chosen. Operation: Patients in supine position. Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1) are punctured at a depth of 20-25mm obliquely. Sanyinjiao (SP-6) and Shenmen (HT-7) are inserted 15mm perpendicularly. Until feeling tactile sensation then manually manipulated by rotation methods to produce a characteristic sensation known as De Qi; Technique: Mild reinforcing and attenuating, retaining the needle for 30minutes. The treatment will be givenonce a day and 5 times a week in weekdays, the course will last two weeks."
48164154|NCT06212934|DRUG|Estazolam|Participants will take estazolam 1mg 30min prior to bedtime everyday. The course of treatment is two weeks.
48164155|NCT05787171|DEVICE|WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
48164156|NCT05787171|DEVICE|WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
48164157|NCT05787171|DEVICE|WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
48006979|NCT00720941|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
48006980|NCT00720941|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
48006981|NCT04522024|PROCEDURE|Epicardial focal cryoablation|Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area
48164158|NCT06646302|OTHER|Low frequency burst sound stimulation|Patients will be given low frequency burst sound stimulation at 10 dB above the threshold of the minimum masking level of tinnitus for a duration of 1 minute.
48164159|NCT06646302|OTHER|Tinnitus frequency-centered narrowband noise stimulation|Patients will be given tinnitus frequency-centered narrowband noise stimulation at 10 dB above the threshold of the minimum masking level of tinnitus for a duration of 1 minute.
48164160|NCT06632834|DRUG|simvastatin therapy|Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
48164161|NCT06645847|OTHER|Ketone ester|"* 37.5 mL tropical flavored KE beverage containing 12.5 g/day of ketone ester will be consumed for the first 7 days, with the first meal of the day.~* 75 mL tropical flavored KE beverage containing 25 g/day of ketone ester will be consumed for week 2 (for 1 week) also with the first meal of the day.~* 112.5 mL tropical flavored KE beverage containing 37.5g/day of ketone ester will be consumed from week 3 (for 1 week). 25g (75mL) with the first meal of the day and 12.5g (37.5mL) with the last meal of the day.~* 150 mL tropical flavored KE beverage containing 50g/day of ketone ester will be consumed from week 4 (for 17 week). 25g (75mL) with the first meal of the day and 25g (75mL) with the last meal of the day."
48164162|NCT06645847|OTHER|Placebo Comparator: Non-ketone placebo|"* 37.5 mL tropical flavored, non-ketogenic canola oil, beverage containing 12.5 g/day of canola oil will be consumed for the first 7 days, with the first meal of the day.~* 75 mL (25 g/day) of canola oil will be consumed at week 2 (for 1 week) also with the first meal of the day.~* 112.5 mL (37.5g/day) of canola oil will be consumed from week 3 (for 1 week). 25g (75mL) with the first meal of the day and 12.5g (37.5mL) with the last meal of the day.~* 150 mL (50g/day) of canola oil will be consumed from week 4 (for 17 week). 25g (75mL) with the first meal of the day and 25g (75mL) with the last meal of the day."
48164163|NCT03809650|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
48164164|NCT06647459|DIAGNOSTIC_TEST|EP Study|To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
48164165|NCT04721132|BIOLOGICAL|Atezolizumab|Given IV
48164166|NCT04721132|BIOLOGICAL|Bevacizumab|Given IV
48006982|NCT04522024|PROCEDURE|Mei Mini Maze procedure|Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
48006983|NCT00779675|BIOLOGICAL|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
48006984|NCT00861211|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
48006985|NCT00861211|DRUG|Placebo|Placebo comparator
48006986|NCT02847793|BEHAVIORAL|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
48006987|NCT02847793|BEHAVIORAL|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
48006988|NCT05071092|BEHAVIORAL|Dietary counselling|Participants assigned to the intervention group will receive coaching from a dietitian to improve adherence to the Dutch dietary guidelines. Several behavioral change techniques will be used.
48006989|NCT04309435|BEHAVIORAL|Self-esteem intervention|See relevant study arm for description
48006990|NCT04309435|BEHAVIORAL|Self-stigma intervention|See relevant study arm for description
48006991|NCT04309435|BEHAVIORAL|Jumping to conclusions intervention|See relevant study arm for description
48164167|NCT04721132|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48164168|NCT04403178|DIAGNOSTIC_TEST|Radiographic examination with a Migration of > 40 %|Radiographic examination
48164169|NCT06640075|OTHER|Community co-produced action|"Participatory workshops will be conducted with community members by a multidisciplinary team with the aim to co-develop a strategy for cervical cancer screening adapted to the local setting (including primary HPV screening, triage of HPV-positive patients and treatment of patients triaged positive). This intervention is referred to as 'community co-produced action'. Possible strategies co-developed may include collaboration with community health workers or local associations, awareness campaigns, development of health education materials, integration of primary HPV screening at local integrated health centers, organization of group transportation to the district screening center, etc.~Using purposive sampling methods, approximately 15 participants will be invited to take part in the workshops in each health area of the intervention, including approximately 3 health care providers, 3 community health workers or members of women's associations, 3 men and 6 eligible women for screening."
48164170|NCT06640075|OTHER|Standard screening strategy|Recruitment of study participants will be coordinated centrally at district level (from the Bafoussam Regional Hospital) following procedures previously established in a cervical cancer screening program in the health district of Dschang. This standard procedure includes the training of 2 community health workers (CHW) by health area to raise awareness around cervical cancer. After an initial theoretical and practical training in cervical cancer prevention, CHWs recruit women by going door-to-door or through community meetings in their respective health areas. Through a system of nominal invitation vouchers distributed to eligible women, CHWs receive a financial incentive for each woman that shows up for cervical cancer screening. Twice a year, CHWs of all health areas are invited to a feedback session to discuss difficulties encountered on the field and propose solutions to face any identified challenges.
48369014|NCT00005803|BIOLOGICAL|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
48369015|NCT00005803|RADIATION|Total-Body Irradiation|Undergo radiotherapy
48006992|NCT04309435|BEHAVIORAL|Control procedure (assessment only)|See relevant study arms for description
48006993|NCT00973791|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
48006994|NCT00973791|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
48164171|NCT04355052|DRUG|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
48164172|NCT04355052|DRUG|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
48164173|NCT05135156|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
48006995|NCT01838005|BEHAVIORAL|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
48164174|NCT05135156|BEHAVIORAL|Publicly available transplant education resource (Attention Control)|Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
48369016|NCT01845129|DEVICE|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
48514021|NCT03573830|BEHAVIORAL|Transport Canada material|The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
48693472|NCT06303375|OTHER|Kinesio taping|"Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
48693473|NCT06303375|OTHER|Conventional physical therapy|"10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
48693474|NCT06658990|PROCEDURE|buccal acupuncture|ultrasound positioning assisted buccal acupuncture
48693475|NCT06658990|DRUG|control|Sufentanil is used after surgery
48693476|NCT02094378|DRUG|Esketamine|84 mg esketamine administered intranasally
48693477|NCT02094378|DRUG|Placebo|Placebo administered intranasally
48693478|NCT04208386|DRUG|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
48693479|NCT03530995|DRUG|Belumosudil|Development candidate
48006996|NCT00095758|DRUG|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
48006997|NCT00095758|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
48006998|NCT00085943|DRUG|LEXIVA (GW433908)|
48006999|NCT00085943|DRUG|Ritonavir|
48007000|NCT00085943|DRUG|KALETRA|
48007001|NCT00085943|DRUG|EPIVIR|
48007002|NCT00085943|DRUG|Ziagen|
48007003|NCT00085943|DRUG|Abacavir/Lamivudine|
48007004|NCT00085943|DRUG|Fosamprenavir|
48007005|NCT03304899|DRUG|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))"
48164175|NCT03451526|PROCEDURE|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
48164176|NCT00024102|DRUG|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 \& 8 and 5-FU 600 mg/sq m IV push d 1 \& 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
48164177|NCT00024102|DRUG|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
48164178|NCT00778141|DRUG|metformin HC1 750 mg extended-release tablets|
48164179|NCT00540384|DRUG|Placebo|Placebo
48164180|NCT00540384|DRUG|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
48164181|NCT00352391|OTHER|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
48164182|NCT06197113|DEVICE|Magstim Rapid2 Magnetic Stimulator|For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
48369017|NCT01845129|DEVICE|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
48369018|NCT00187655|DRUG|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
48693480|NCT03530995|DRUG|Itraconazole|Perpetrator drug
48693481|NCT03530995|DRUG|Rabeprazole|Perpetrator drug
48693482|NCT03530995|DRUG|Rifampicin|Perpetrator drug
48693483|NCT03530995|DRUG|Omeprazole|Perpetrator drug
48693484|NCT02185573|PROCEDURE|Bulk fill|This is one of the composite restoration application techniques
48164183|NCT05319002|BEHAVIORAL|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure \& future template: Strong closure with artwork. 8. Re-evaluation: if possible.
48164184|NCT03480919|DEVICE|Shen Men acupuncture|20-minute acupuncture session
48164185|NCT03480919|PROCEDURE|Epidural injection|Epidural injection for the relief of back pain
48164186|NCT03526471|DEVICE|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
48164187|NCT05648448|DRUG|Oseltamivir|Oral oseltamivir 75mg BD for 5/7
48164188|NCT05648448|DRUG|Favipiravir|Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
48164189|NCT05648448|DRUG|Zanamivir|Inhaled zanamivir 10mg BD for 5/7
48164190|NCT05648448|DRUG|Baloxavir|"Oral baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
48164191|NCT05648448|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5/7
48164192|NCT05648448|DRUG|Peramivir|Intravenous peramivir 600mg once only
48164193|NCT05648448|DRUG|Laninamivir|Inhaled laninamivir 40mg once only
48164194|NCT05648448|DRUG|Oseltamivir and Baloxavir|"Oseltamivir 75mg BD for 5/7 and~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
48164195|NCT05648448|DRUG|Oseltamivir and Favipiravir|"Oseltamivir 75mg BD for 5/7 and~favipiravir 1800mg BD D0 and 800mg BD for a further 4/7"
48164196|NCT05648448|DRUG|Favipiravir and Baloxavir|"favipiravir 1800mg BD D0 and 800mg BD for a further 4/7~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
48164197|NCT02513810|DEVICE|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
48164198|NCT02513810|DEVICE|BioMatrix or Ultimaster with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
48164199|NCT00094497|DRUG|Etoposide|
48164200|NCT00094497|DRUG|Doxorubicin|
48164201|NCT00094497|DRUG|Cisplatin|
48164202|NCT00094497|DRUG|Streptozotocin|
48369019|NCT02809651|DEVICE|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
48693485|NCT02185573|PROCEDURE|SonicFill|This is the recent intervention under evaluation
48693486|NCT06660615|BEHAVIORAL|MIDWIFE-LED CARE|The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
48164203|NCT00094497|DRUG|Mitotane|
48693487|NCT01018329|PROCEDURE|Magnetic Resonance Imaging|
48369020|NCT00167713|DRUG|Ibuprofen|
48369021|NCT04264949|OTHER|Education in the use of smartphone app (Mon coach dos)|In addition to conventional care and the therapeutic education program, GA will benefit from three education sessions (one per week) on the use of the smartphone app mon coach dos
48369022|NCT04264949|OTHER|conventional care|conventional care and the therapeutic education program
48514022|NCT03573830|BEHAVIORAL|Enhanced material|Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
48693488|NCT01018329|PROCEDURE|Diffusion Tensor Imaging|
48693489|NCT01018329|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|
48693490|NCT01018329|PROCEDURE|Dynamic Contract-Enhanced magnetic resonance imaging|
48693491|NCT01018329|PROCEDURE|Diffusion-weighted magnetic resonance imaging|
48693492|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.
48164204|NCT04985747|OTHER|Polished palatal surface|Polishing of the anterior palatal surface using a polisher
48164205|NCT04985747|OTHER|Roughened palatal surface|Roughening of the anterior palatal surface using a sandblaster
48164206|NCT04985747|OTHER|Opened palatal surface|Opening of the anterior palatal surface using acrylic bur
48164207|NCT01404377|PROCEDURE|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
48164208|NCT02737670|DRUG|Sulodexide|25 mg morning and evening for 40 days
48164209|NCT02737670|DRUG|Placebo|1 tablet morning and evening for 40 days
48369023|NCT00208858|DRUG|Topiramate|
48693493|NCT06660069|DRUG|CPC Mouthwash (Parodontax Active Gum Health Mouthwash)|Mouthwash containing 0.07% w/w CPC.
48693494|NCT06660069|DRUG|Regular Fluoride Toothpaste (Crest Cavity Protection)|Toothpaste containing 0.243% w/w sodium fluoride.
48007006|NCT04515303|OTHER|Diverse Intervention Participation in DASH|A qualitative examination of barriers and facilitators of the DASH dietary pattern, and quantitative investigation of the types of recruitment methods effective for black adults entering a digital DASH-promoting intervention.
48007007|NCT06382987|DRUG|Deucravacitinib|According to the product label
48164210|NCT04464434|PROCEDURE|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg."
48007008|NCT06382987|DRUG|Apremilast|According to the product label
48007009|NCT02538926|DRUG|Asparaginase|Given IM or IV
48164211|NCT04691336|BEHAVIORAL|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
48164212|NCT05442424|BEHAVIORAL|Produce Voucher|see arm/group description
48164213|NCT05442424|BEHAVIORAL|Wait-List Control|see arm/group description
48164214|NCT00988897|DRUG|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
48164215|NCT00988897|DRUG|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
48693495|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454% w/w SnF2.
48693496|NCT05733234|DEVICE|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
48693497|NCT05733234|DRUG|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
48693498|NCT04654624|DRUG|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
48164216|NCT00988897|DRUG|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
48164217|NCT00988897|DRUG|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
48164218|NCT03635775|DEVICE|Active tDCS|Low-level (1.5 milliampere) current delivered to the scalp using saline-soaked sponges.
48164219|NCT03635775|DEVICE|Sham tDCS|Sham-setting--no electrical current delivered.
48164220|NCT05353296|BEHAVIORAL|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
48007010|NCT02538926|DRUG|Cyclophosphamide|Given IV
48007011|NCT02538926|DRUG|Doxorubicin Hydrochloride|Given IV
48007012|NCT02538926|DRUG|Etoposide|Given IV
48007013|NCT02538926|DRUG|Imatinib Mesylate|Given PO
48007014|NCT02538926|OTHER|Laboratory Biomarker Analysis|Correlative studies
48007015|NCT02538926|DRUG|Prednisone|Given PO
48007016|NCT02538926|BIOLOGICAL|Rituximab|Given IV
48007017|NCT02538926|DRUG|Vincristine Sulfate|Given IV
48007018|NCT00431457|DEVICE|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
48007019|NCT00431457|PROCEDURE|amygddohyppocampertomy|Resective surgery
48007020|NCT04316624|DRUG|C-CAR066|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
48007021|NCT04168177|PROCEDURE|PCA|Patient controlled analgesia
48007022|NCT04168177|PROCEDURE|ESP|erector spinae plane block
48164221|NCT05353296|BEHAVIORAL|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
48369024|NCT03391427|DRUG|Lidocaine|This group will receive lidocaine infusion
48164222|NCT05353296|DEVICE|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
48164223|NCT00990821|DRUG|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
48164224|NCT00990821|DRUG|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
48164225|NCT00990821|DRUG|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
48164226|NCT00990821|DRUG|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
48164227|NCT00990821|DRUG|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
48164228|NCT00990821|DRUG|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
48164229|NCT00990821|DRUG|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
48164230|NCT00990821|DRUG|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
48369025|NCT03391427|DRUG|Ketamine|This group will receive Ketamine infusion
48369026|NCT03391427|DRUG|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
48369027|NCT03391427|DRUG|Saline|This group will receive saline infusion
48007023|NCT06135662|PROCEDURE|CAF + CTG|Surgical techniques for mandibular gingival recession: coronally advanced flap + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
48007024|NCT06135662|PROCEDURE|Tunnel Technique + CTG|Surgical techniques for mandibular gingival recession: tunnel technique + connective tissue graft. Participants undergo initial evaluations, including periodontal exams and digital imaging, followed by standardized pre-operative preparations. Post-surgery, uniform care includes pain management and oral hygiene instructions, with follow-ups to monitor healing and assess outcomes. Primary and secondary outcomes, like root coverage and patient-reported satisfaction, are consistently measured across groups. Standardized data collection and analysis procedures ensure reliable, comparable results, facilitating an effective comparison of the surgical methods' efficacy.
48164231|NCT00990821|DRUG|Placebo|Placebo matching MK-0517
48164232|NCT00990821|DRUG|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
48164233|NCT00990821|DRUG|125 mg Aprepitant|Aprepitant oral tablet, single dose
48164234|NCT00990821|DRUG|2 mg Midazolam|Midazolam oral tablet, single dose
48164235|NCT05672498|DRUG|Traditional Chinese Medicine Formulation|The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
48164236|NCT05672498|OTHER|Placebo Treatment|Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
48164237|NCT02941432|OTHER|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
48164238|NCT02392429|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48164239|NCT02392429|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
48164240|NCT02392429|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
48164241|NCT02392429|DRUG|Chemotherapy|Given anthracycline IV
48164242|NCT02392429|PROCEDURE|Computed Tomography|Undergo FLT PET/CT
48164243|NCT02392429|DRUG|Cytarabine|Given IV
48164244|NCT02392429|OTHER|Fluorothymidine F-18|Undergo FLT PET/CT
48164245|NCT02392429|OTHER|Laboratory Biomarker Analysis|Correlative studies
48164246|NCT02392429|PROCEDURE|Positron Emission Tomography|Undergo FLT PET/CT
48164247|NCT06352424|DRUG|BI 456906|BI 456906
48164248|NCT06352424|DRUG|BI 1820237|BI 1820237
48164249|NCT06352424|DRUG|Placebo for BI 1820237|Placebo for BI 1820237
48164250|NCT06352424|DRUG|Placebo for BI 456906|Placebo for BI 456906
48164251|NCT05517265|DRUG|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
48164252|NCT05517265|DRUG|Calquence|acalabrutinib according to Calquence® SmPC.
48164253|NCT03814278|BEHAVIORAL|complete bed rest|Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.
48164254|NCT03814278|BEHAVIORAL|activity restriction|Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
48164255|NCT05904171|BEHAVIORAL|Tangotherapy|"Learning and practicing a series of moves - both individual and with a partner - taken from Argentine Tango, according to the Riabilitango (R) approach. The training is aimed at improving both physical (e.g., balance, change of direction, coordination, endurance) and cognitive (i.e., learning, divided attention, inhibition, planning) domains, in a pleasant, enjoyable, and inclusive environment.~This group-based training will take place twice a week (1h each session), for 6 weeks."
48369028|NCT03103724|DRUG|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
48369029|NCT03723746|BIOLOGICAL|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
48369030|NCT03723746|BIOLOGICAL|Placebo|Participants will receive matching placebo in all cohorts.
48369031|NCT05406882|DRUG|Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules|Live Combined Bifidobacterium and Lactobacillus Tablets：probiotics. Compound Glutamine Entersoluble capsules：combined traditional Chinese medicine and glutamine
48164256|NCT05904171|BEHAVIORAL|Physical activity|Walking and stretching in group twice a week (1h each session), for 6 weeks.
48007025|NCT01140763|DEVICE|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin \& eosin (H\&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
48007026|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
48007027|NCT01604343|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
48164257|NCT03052283|DIAGNOSTIC_TEST|Questionnaire Patient Reported Outcome Measure (PROM)|non-interventional
48164258|NCT06632340|PROCEDURE|TUR-BT|Transurethral resection of bladder tumor
48164259|NCT02117856|PROCEDURE|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
48164260|NCT02117856|PROCEDURE|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
48164261|NCT02117856|PROCEDURE|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
48164262|NCT02117856|DEVICE|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
48693499|NCT04654624|DRUG|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
48693500|NCT00260767|DRUG|HEC placebo gel|
48693501|NCT06306911|DIETARY_SUPPLEMENT|Aronia Melanocarpa extract|Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols
48693502|NCT01054560|DEVICE|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
48693503|NCT01054560|DEVICE|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
48007028|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
48007029|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
48007030|NCT01604343|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
48007031|NCT00351234|DRUG|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
48007032|NCT02953899|BEHAVIORAL|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
48007033|NCT02953899|BEHAVIORAL|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
48007034|NCT05713123|OTHER|A SPECT-CT whole body is added in VERITON-CT camera|A SPECT-CT whole body in VERITON-CT camera is added after the conventional procedure recorded in Anger camera
48007035|NCT01567488|DRUG|Everolimus|Everolimus 10mg/day
48007036|NCT01567488|DRUG|octreotide LAR|30 mg each 28 days
48164263|NCT02117856|DEVICE|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
48164264|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
48164265|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
48164266|NCT02077153|BEHAVIORAL|Reminiscence therapy|
48164267|NCT02077153|BEHAVIORAL|Active participation in group setting|
48164268|NCT03799354|OTHER|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
48369032|NCT01609049|DRUG|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
48693504|NCT02337998|OTHER|load carriage|
48693505|NCT05764161|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
48693506|NCT05764161|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
48164269|NCT03799354|OTHER|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
48164270|NCT05436145|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
48164271|NCT05729477|DEVICE|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
48164272|NCT05729477|DEVICE|Phaco Subject Cohort|Phaco Subject Cohort
48164273|NCT02642159|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
48164274|NCT02642159|DRUG|Statins|Statins at stable dose without other LMT as clinically indicated.
48693507|NCT06660940|DRUG|Keluoxin Capsules|Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
48007037|NCT02752295|BEHAVIORAL|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
48164275|NCT02642159|DRUG|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
48164276|NCT02642159|DRUG|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
48164277|NCT02642159|DRUG|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
48164278|NCT02642159|DRUG|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
48007038|NCT02752295|BEHAVIORAL|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
48164279|NCT02642159|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
48164280|NCT04257942|PROCEDURE|carotid endarterectomy|carotid endarterctomy that is being used for carotid stenosis disease
48164281|NCT01020487|DRUG|Paricalcitol|Paricalcitol capsules taken with water.
48369033|NCT01609049|DRUG|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
48369034|NCT01618929|DRUG|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
48693508|NCT06660940|DRUG|Keluoxin Capsule Simulants|Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
48369035|NCT04135300|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
48007039|NCT00501202|DRUG|placebo|twice daily for 4 weeks
48007040|NCT00501202|DRUG|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
48007041|NCT05091307|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as an IM injection.
48007042|NCT05091307|OTHER|Placebo|Placebo will be administered as an IM injection.
48007043|NCT05091307|BIOLOGICAL|Influenza Vaccine|Influenza vaccine high and standard dose will be administered as IM injection.
48007044|NCT02580370|BIOLOGICAL|Botulinum toxin type A|Topical botulinum toxin type A
48007045|NCT02580370|BIOLOGICAL|Placebo comparator|Topical placebo comparator
48007046|NCT02474199|BIOLOGICAL|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
48164282|NCT01020487|DRUG|Placebo|Placebo capsules taken with water
48369036|NCT01986179|OTHER|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
48369037|NCT01986179|OTHER|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
48369038|NCT05384756|DRUG|Alemtuzumab|Given IV
48369039|NCT05384756|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
48369040|NCT05384756|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TMLI
48369041|NCT05384756|DRUG|Sirolimus|Medication to prevent the development of graft-versus-host disease (GVHD)
48693509|NCT06660940|DRUG|Irbesartan|"1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD"
48693510|NCT06388148|DRUG|Medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
48693511|NCT06388148|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
48693512|NCT00560651|PROCEDURE|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
48007047|NCT02474199|DRUG|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
48693513|NCT03842189|DRUG|M281|Participants will receive once weekly intravenous (IV) infusions of M281
48164283|NCT04999956|PROCEDURE|dynamic navigation surgery|immediate implant placement using dynamic navigation
48164284|NCT04999956|PROCEDURE|freehand surgery|immediate implant placement using freehand surgery
48164285|NCT00721825|DRUG|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
48164286|NCT00721825|DRUG|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
48164287|NCT01138189|PROCEDURE|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
48164288|NCT01138189|PROCEDURE|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
48164289|NCT04627441|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
48164290|NCT04627441|DEVICE|Epidural spinal cord stimulator system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
48164291|NCT02908412|DRUG|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
48164292|NCT01026883|OTHER|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
48164293|NCT04893785|DRUG|Cabozantinib and Temozolomide|"Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner."
48164294|NCT03986983|DEVICE|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
48007048|NCT02474199|DRUG|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
48164295|NCT03986983|OTHER|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
48514023|NCT06398301|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
48514024|NCT05721287|DRUG|SBS-1000|SBS-1000 administered as a single continuous IV infusion over 60 minutes
48164296|NCT01290783|DRUG|Irintoecan|"* Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment."
48693514|NCT06283394|BEHAVIORAL|Storefront Choice Architecture|An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)
48693515|NCT06283394|BEHAVIORAL|Fresh Funds|The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.
48693516|NCT06283394|BEHAVIORAL|Loss Framing|They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).
48693517|NCT00080080|DRUG|talabostat (PT-100) tablets|
48693518|NCT00080080|DRUG|Docetaxel|
48693519|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
48693520|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
48693521|NCT06302426|DRUG|INI-4001|INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
48693522|NCT06302426|COMBINATION_PRODUCT|Nivolumab|During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.
48693523|NCT06302426|COMBINATION_PRODUCT|Pembrolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
48693524|NCT06302426|COMBINATION_PRODUCT|Cemiplimab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
48693525|NCT06302426|COMBINATION_PRODUCT|Avelumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
48693526|NCT06302426|COMBINATION_PRODUCT|Atezolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
48514025|NCT05721287|DRUG|Placebo|Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes
48164297|NCT01290783|DRUG|HA-Irinotecan solution for Infusion|"* HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks~* 8 months of treatment."
48164298|NCT05669287|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
48007049|NCT02474199|DRUG|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
48007050|NCT02474199|PROCEDURE|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
48369042|NCT02874755|OTHER|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
48369043|NCT03950271|DRUG|SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine|"1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."
48007051|NCT00482079|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
48693527|NCT06302426|COMBINATION_PRODUCT|Durvalumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
48693528|NCT01681069|DIETARY_SUPPLEMENT|IQP-VV-102|
48007052|NCT00482079|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
48007053|NCT02567461|DRUG|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
48007054|NCT02567461|DRUG|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
48007055|NCT02567461|DRUG|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
48007056|NCT02567461|DRUG|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
48007057|NCT05540366|OTHER|Physical therapy combined with aerobic exercise|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
48007058|NCT05540366|OTHER|Physical Therapy|30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
48007059|NCT00994331|PROCEDURE|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
48007060|NCT00577083|DEVICE|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
48007061|NCT02880982|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
48007062|NCT02880982|OTHER|Placebo|Weekly oral placebo softgel capsule
48007063|NCT04237961|PROCEDURE|Botox and brow lift|Botox injection
48007064|NCT04237961|PROCEDURE|Injection|Fat injection and botox
48007065|NCT04237961|PROCEDURE|Suture|Suspension suture
48007066|NCT04029467|DRUG|Dexmedetomidine|addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
48007067|NCT05991102|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
48007068|NCT00684424|OTHER|Non-Interventional Study|Observational Only
48369044|NCT00697242|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
48369045|NCT00697242|BIOLOGICAL|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
48369046|NCT02789761|DIETARY_SUPPLEMENT|High-flavanol milk choocolate|
48369047|NCT02789761|DIETARY_SUPPLEMENT|Low-flavanol milk chocolate|
48693529|NCT01681069|OTHER|Placebo|
48693530|NCT06658366|DIAGNOSTIC_TEST|impression of the teeth|Only conventional and digital impressions (comparable with taking videography) are taken of the patients teeth.
48693531|NCT04521686|DRUG|LY3410738|Oral LY3410738
48693532|NCT04521686|DRUG|Gemcitabine|Intravenous gemcitabine
48007069|NCT05338190|DRUG|Combination of Rituximab with subcutaneous belimumab|Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
48007070|NCT05338190|DRUG|Combination of Rituximab with subcutaneous placebo|Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
48007071|NCT04338464|BEHAVIORAL|Psychosocial therapy for South Asian women experiencing mood disorders|"The 12 week intervention has four major components:~* Relational theory (Belgrave, 2002) \& South Asian identity development (Inman et al., 2001). These foundational components focus on strengthening cultural identity through the exploration of values, navigation and reconciliation of two cultures.~* Transdiagnostic treatment of mood disorders (Ehrenreich-May et al., 2017). This component will focus on skill building in the areas of emotion awareness, resilience, adaptability, self-compassion and healthy coping strategies (Farchione et al., 2012; Bilek \& Ehrenriech-May, 2012; Ritschel, Noriel \& Lindsay, 2015).~* Psychoeducation on mental health, sexual health, and substance use.~* Peer support is a critical component of the intervention and will be provided by the peer researcher on the team. Participants will have access to optional individual peer support for 30 minutes to one hour per week for the duration of the intervention, this can be in person or telephone support."
48007072|NCT03525197|DIETARY_SUPPLEMENT|Whey protein-based supplement|High quality protein supplement to be consumed twice daily
48007073|NCT03525197|DIETARY_SUPPLEMENT|Collagen protein-based supplement|Lower quality protein supplement to be consumed daily
48007074|NCT04464642|DRUG|Methotrexate|Methotrexate 25 mg subcutaneous is given in group A
48007075|NCT04464642|DRUG|Tofacitinib|tofacitinib 10 mg given in group B
48007076|NCT01140477|DEVICE|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
48007077|NCT01140477|DEVICE|Accommodating Lens|Accommodating lens implanted after cataract extraction
48007078|NCT01897675|PROCEDURE|Incision and Drainage with packing (wick) placement|
48007079|NCT01897675|PROCEDURE|Abscess drainage with loop placement|
48007080|NCT00006125|DRUG|doxorubicin hydrochloride|
48007081|NCT00006125|DRUG|topotecan hydrochloride|
48164299|NCT02899481|OTHER|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
48164300|NCT05463835|DIETARY_SUPPLEMENT|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
48164301|NCT05463835|DIETARY_SUPPLEMENT|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
48007082|NCT02295748|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
48007083|NCT05374499|DRUG|Liposomal bupivacaine|Dosage: 3 mL Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
48007084|NCT05374499|DRUG|0.5% bupivacaine with 1:100,000 epinephrine|Dosage: 3 mL of diluted 0.5% bupivacaine with 1:200,000 epinephrine (2:1 ratio of saline to standard bupivacaine) Frequency: Administer via buccal infiltration technique immediately following mandibular third molar extraction surgery and at least twenty minutes following most recent lidocaine injection.
48007085|NCT02995252|OTHER|Blood draws|
48164302|NCT05463835|DIETARY_SUPPLEMENT|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
48164303|NCT02660034|BIOLOGICAL|Tislelizumab|
48007086|NCT02995252|DRUG|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
48007087|NCT02995252|OTHER|Knowledge Index Questionnaire|
48007088|NCT02995252|OTHER|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
48007089|NCT02995252|PROCEDURE|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
48007090|NCT00449293|BEHAVIORAL|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
48164304|NCT02660034|DRUG|Pamiparib|
48164305|NCT04667442|DIAGNOSTIC_TEST|Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)|COVID-19 Rapid Antigen Diagnostic Test
48164306|NCT05469763|OTHER|Circuit training|"Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week."
48007091|NCT00449293|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
48164307|NCT01275872|OTHER|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
48164308|NCT04502888|DRUG|Drug: SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
48693533|NCT04521686|DRUG|Cisplatin|Intravenous cisplatin
48693534|NCT04521686|DRUG|Durvalumab|Intravenous durvalumab
48693535|NCT00005643|DRUG|pegylated liposomal doxorubicin hydrochloride|
48693536|NCT06425887|DIAGNOSTIC_TEST|Smart watch|not interventional
48693537|NCT00737217|BEHAVIORAL|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
48164309|NCT02950870|DRUG|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
48007092|NCT05905588|DIETARY_SUPPLEMENT|Hydrogen-rich water|Patients drink 600mL hydrogen-rich water per day by applying hydrogen-rich water cup (Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks. The dissolved hydrogen concentration is 5 ppm.
48164310|NCT02950870|DRUG|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
48164311|NCT02950870|DRUG|Ribavirin|Patients will be treated with ribavirin if necessary.
48164312|NCT02615834|PROCEDURE|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
48164313|NCT00088075|DRUG|Risperidone|
48693538|NCT04934839|DIAGNOSTIC_TEST|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
48693539|NCT06661603|BEHAVIORAL|GSY Yoga Intervention|In the GSY yoga intervention, where participants received 90 minutes/week yoga intervention for duration of 10 weeks.
48164314|NCT06457347|PROCEDURE|Ultra early (<24 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.
48164315|NCT06457347|PROCEDURE|Early (24-72 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
48164316|NCT03854214|DEVICE|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 RPM. Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
48164317|NCT03854214|DEVICE|Passive cycling|The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
48007093|NCT05905588|DIETARY_SUPPLEMENT|placebo|Patients drink 600mL tap water per day by applying analogue cup for 12 weeks. This cup has the same appearance as the hydrogen-rich water cup, and the hydrogen-rich water and placebo water were indistinguishable. The dissolved hydrogen concentration is 0 ppm in placebo water.
48007094|NCT03818022|PROCEDURE|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
48164318|NCT04990973|BEHAVIORAL|Average American Diet (AAD)|"Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet)."
48164319|NCT04990973|BEHAVIORAL|Mediterranean Diet|"Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet)."
48693540|NCT02748421|PROCEDURE|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
48693541|NCT02748421|PROCEDURE|Conventional Microscope|macular membrane dissection without OCT RESCAN
48693542|NCT05068791|DRUG|Psilocybin|0.36 mg/kg will be administered orally to participants
48693543|NCT05068791|DRUG|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
48693544|NCT06659250|DRUG|PF-06414300|Participants will receive oral ascending doses.
48693545|NCT06659250|DRUG|Placebo|Participants will receive matching placebo.
48007095|NCT03962335|BEHAVIORAL|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
48693546|NCT00115271|DRUG|Nutritional supplements|
48007096|NCT03962335|BEHAVIORAL|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
48007097|NCT03962335|BEHAVIORAL|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
48007098|NCT03643965|DRUG|Nefecon|Nefecon 16 mg for daily administration by mouth for 9 months.
48693547|NCT05111002|DRUG|Lefamulin|600mg tablet orally twice daily
48693548|NCT05111002|DRUG|Doxycycline|100mg tablet orally twice daily
48693549|NCT04164199|DRUG|Tislelizumab|Administered intravenously.
48693550|NCT04164199|DRUG|Pamiparib|Administered orally.
48693551|NCT04164199|DRUG|Temozolomide|Administered orally.
48693552|NCT04164199|DRUG|Sitravatinib|Administered orally.
48693553|NCT04164199|DRUG|Ociperlimab|Administered intravenously.
48693554|NCT04164199|DRUG|BAT1706|Administered intravenously.
48693555|NCT04164199|DRUG|Fruquintinib|Administered orally.
48693556|NCT04164199|DRUG|BGB-15025|Administered orally.
48693557|NCT04164199|DRUG|Zanidatamab|Administered intravenously.
48693558|NCT04164199|DRUG|BGB-A445|Administered intravenously.
48164320|NCT06619210|DRUG|HL231 Dose 1/2/3/4|HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
48164321|NCT03467997|BEHAVIORAL|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
48164322|NCT03467997|OTHER|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
48164323|NCT04145089|DEVICE|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
48164324|NCT02917083|GENETIC|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2."
48164325|NCT06363409|OTHER|Cereal Bar as a recovery food snack|Cereal bar as a recovery snack food
48164326|NCT06363409|OTHER|Almond|Almond as a recovery snack food
48693559|NCT04164199|DRUG|Surzebiclimab|Administered intravenously.
48164327|NCT06080919|DEVICE|Drug coated-balloon percutaneous coronary intervention.|Patients will undergo DCB-PCI under IVUS guidance (OpticrossTMHD 60 MHz). Target lesion will be predilated with semi-compliant balloons or non-compliant balloons.The lesion will be then treated with DCB with a reference vessel diameter/balloon diameter ratio of 1.
48164328|NCT06080919|DEVICE|Angiography-derived coronary physiology (IMRangio)|Angiography-derived coronary physiology will be assessed after the procedure using Angio Plus software (Pulse Medical Imaging Technology, Shanghai, China). The angiography images will be used to obtain the IMRangio values, prior and post to DCB-PCI
48164329|NCT06026826|DEVICE|transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
48164330|NCT06026826|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
48164331|NCT02510404|BIOLOGICAL|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
48164332|NCT02646189|DRUG|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
48164333|NCT02646189|DRUG|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
48164334|NCT02646189|DRUG|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
48164335|NCT02739490|PROCEDURE|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
48164336|NCT04679597|DRUG|Capecitabine|comparison of two treatments
48164337|NCT03697070|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
48164338|NCT03697070|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
48164339|NCT02262390|PROCEDURE|Partner Notification Reminders|"For all 3 arms, the following will be done:~* All participants will have an antenatal clinic visit every 4 weeks until delivery.~* All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~* Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
48164340|NCT03410953|BIOLOGICAL|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
48164341|NCT01203956|DEVICE|SmartFlex|Device used with smartflex engaged.
48693560|NCT04164199|DRUG|Lenvatinib|Administered orally.
48693561|NCT04164199|DRUG|LBL-007|Administered intravenously.
48693562|NCT05638412|BEHAVIORAL|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
48164342|NCT01203956|DEVICE|Standard|
48007099|NCT03643965|DRUG|Placebo oral capsule|Placebo capsules for daily administration by mouth for 9 months.
48164343|NCT04528537|OTHER|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
48164344|NCT06413017|DRUG|Nimotuzumab|Nimtuzumab：400mg,i.v.,once a week,until tumor progression、Death or untalerable toxicity
48164345|NCT06413017|DRUG|ICIs(Immune checkpoint inhibitors)|Use it as it is describe in the instructions from the specification
48164346|NCT03083093|DIAGNOSTIC_TEST|The initial CTPA will be reviewed|The initial CTPA will be reviewed
48693563|NCT05638412|BEHAVIORAL|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
48693564|NCT03709277|BEHAVIORAL|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
48007100|NCT02505633|DEVICE|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
48007101|NCT02505633|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
48007102|NCT01109082|PROCEDURE|posterior spine fusion|vertebrae are fused to straighten a spinal curve
48007103|NCT05796128|PROCEDURE|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|In this group, infants will receive NIPPV during LISA procedure.
48007104|NCT05796128|PROCEDURE|Nasal continuous positive airway pressure (NCPAP)|In this group, infants will receive NCPAP during LISA procedure.
48007105|NCT00223106|DEVICE|Vaginal Sling|
48007106|NCT01289925|DIETARY_SUPPLEMENT|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
48007107|NCT01289925|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
48007108|NCT03706807|OTHER|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
48007109|NCT03706807|OTHER|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
48007110|NCT01433263|DRUG|BYM338 active drug|
48007111|NCT01433263|DRUG|Placebo|
48007112|NCT03570866|DIAGNOSTIC_TEST|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
48007113|NCT03570866|PROCEDURE|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
48007114|NCT05379296|BEHAVIORAL|Diabetes Prevention Program Plus (DPP+)|The DPP+ includes the CDC-approved DPP lifestyle program expanded to include a CDC-approved module on hypertension prevention and treatment
48007115|NCT05379296|BEHAVIORAL|Diabetes Prevention Program (DPP)|CDC-approved DPP lifestyle program
48007116|NCT03030027|BEHAVIORAL|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
48007117|NCT03030027|OTHER|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
48007118|NCT01723228|DRUG|Rasagiline|
48007119|NCT01723228|DRUG|Placebo|
48007120|NCT02438228|OTHER|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
48007121|NCT01347190|BIOLOGICAL|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
48007122|NCT01347190|BIOLOGICAL|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
48007123|NCT04320940|DRUG|Phenobarbital Sodium Injection|The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
48007124|NCT00724516|DEVICE|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
48007125|NCT02547129|DEVICE|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
48007126|NCT02547129|DEVICE|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
48007127|NCT02403908|DEVICE|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery \<2 mm proximal from both ostia of right and left pulmonary arteries.
48007128|NCT03090256|DEVICE|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
48007129|NCT00167934|DRUG|Valproate|Depakote ER 500 mg to 3000 mg taken every night
48007130|NCT00167934|DRUG|Placebo|Placebo given at same frequency as Valproate
48164347|NCT05624697|PROCEDURE|sticky bone housed in PEEK Shell|Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
48007131|NCT01698229|OTHER|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
48007132|NCT02699294|OTHER|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
48007133|NCT02699294|OTHER|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
48164348|NCT06444347|DEVICE|Biosynthetic Mesh|The biosynthetic mesh group will undergo hiatal hernia repair with Phasix Mesh (Becton Dickinson, Franklin Lakes, NJ) reinforcement, secured with permanent suture.
48007134|NCT02699294|OTHER|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
48164349|NCT06444347|PROCEDURE|Hiatal Hernia Repair|The non-mesh group will undergo hiatal hernia repair with permanent suture only.
48164350|NCT02781077|PROCEDURE|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
48164351|NCT00236483|DRUG|tramadol hydrochloride + acetaminophen|
48693565|NCT04917952|DEVICE|Blood Flow Restriction (BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, 80% at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
48164352|NCT00414219|BEHAVIORAL|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
48164353|NCT03595137|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
48164354|NCT03595137|DEVICE|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
48164355|NCT00169585|DRUG|Levofloxacin oral tablets|
48164356|NCT04557865|DIAGNOSTIC_TEST|18F-PMPBB3 (APN-1607) PET imaging|"1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical"
48164357|NCT02262364|BIOLOGICAL|APS|See above
48164358|NCT04148521|BEHAVIORAL|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
48007135|NCT02282696|OTHER|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
48007136|NCT03801616|DEVICE|Virtual Reality|Virtual Reality in controlling pain
48007137|NCT05960591|DEVICE|ADEPTH|ADEPTH sensor will be used for bore depth measurements during plate osteosynthesis procedures.
48164359|NCT04072198|DRUG|Nivolumab|240 mg every 2 weeks for 8 cycles followed by maintenance
48164360|NCT04072198|DRUG|Bevacizumab|5 mg/kg every 2 weeks for 8 cycles followed by maintenance
48164361|NCT04072198|DRUG|Irinotecan|165 mg/m2 every 2 weeks for 8 cycles
48164362|NCT04072198|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks for 8 cycles
48164363|NCT04072198|DRUG|Leucovorin|200 mg/m2 every 2 weeks for 8 cycles
48164364|NCT04072198|DRUG|fluoruracil|3200mg/m2 every 2 weeks for 8 cycles
48164365|NCT04075097|BEHAVIORAL|Aerobic exercise|1 session
48164366|NCT04075097|BEHAVIORAL|Iyengar yoga|1 session
48164367|NCT01706393|DIETARY_SUPPLEMENT|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
48007138|NCT00523185|DRUG|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
48164368|NCT01706393|DIETARY_SUPPLEMENT|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
48164369|NCT03716583|DRUG|Melatonin|25 mg
48693566|NCT04917952|DEVICE|Sham Blood Flow Restriction (sham BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, Sham BFR, 10mm Hg at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
48693567|NCT06592014|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
48007139|NCT00523185|DRUG|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
48007140|NCT02462577|DRUG|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
48007141|NCT01256710|DEVICE|Trifecta™ aortic bioprosthesis|Surgical aortic valve replacement with the Trifecta™ valve.
48007142|NCT03348358|BEHAVIORAL|quiet music|playing quiet music during labor
48007143|NCT03348358|BEHAVIORAL|Rhythmic music|playing rhythmic music during labor
48007144|NCT03348358|BEHAVIORAL|control|No music during labor
48007145|NCT05599035|DEVICE|repititive transcranial magnetic stimulation|a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
48007146|NCT06390228|PROCEDURE|Major hepatectomy|the extent of liver resection
48007147|NCT05498558|OTHER|No intervention.|No intervention.
48007148|NCT01922024|DEVICE|LRT55 Testing|Testing on the Unyvero LRT55
48007149|NCT00238277|DRUG|temozolomide|
48007150|NCT00238277|PROCEDURE|adjuvant therapy|
48007151|NCT00238277|PROCEDURE|chemotherapy|
48164370|NCT03716583|DRUG|Dimethyl Sulfoxide|150 mg
48164371|NCT03716583|DRUG|Placebos|1 g
48164372|NCT00627523|DRUG|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
48164373|NCT00627523|DRUG|Control-no treatment|Control-no treatment
48164374|NCT04646135|DRUG|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
48007152|NCT00238277|PROCEDURE|radiation therapy|
48007153|NCT05217797|BEHAVIORAL|Wearing glasses (any type)|Participants are asked to wear glasses in public spaces.
48007154|NCT04429009|DEVICE|ZEPHYRx Respiratory Therapy (RT) System|A breath controlled video game system for respiratory therapy
48007155|NCT04429009|DEVICE|Standard Incentive Spirometer|A simple (not digital) plastic device that contains a piston that rises inside the device and measures the volume of your breath
48007156|NCT01143090|DRUG|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
48007157|NCT03091803|DEVICE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
48007158|NCT03091803|DRUG|Gadobenate Dimeglumine|Given IV
48007159|NCT03091803|DRUG|Gadoterate Meglumine|Given IV
48007160|NCT03091803|DEVICE|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
48007161|NCT04126512|OTHER|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
48007162|NCT00495716|DRUG|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
48007163|NCT00495716|DRUG|acyclovir|400 mg acyclovir orally twice daily for 1 year
48007164|NCT05262205|OTHER|measuring depth of anesthesia and its relation to the globe|measuring feasibility of BIS monitor in detecting depth of anesthesia in pediatric population and whether it will be beneficial as a tool for helping anesthesiologist in maintaining central globe alignment
48007165|NCT02555995|DEVICE|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
48007166|NCT03883204|DRUG|Aripiprazole|Initial dose: 10 mg.
48007167|NCT03883204|DRUG|Risperidone|Initial dose: 2 mg.
48164375|NCT04739293|DRUG|ON123300|ON 123300 hard gelatin capsules
48164376|NCT04615715|BEHAVIORAL|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
48164377|NCT04615715|BEHAVIORAL|Stress Reduction Messaging|Stress Reduction Messaging
48164378|NCT04237675|PROCEDURE|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
48164379|NCT04445519|DRUG|NCX 470 0.065% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
48164380|NCT04445519|DRUG|Latanoprost 0.005% (initial phase of trial)|Latanoprost Ophthalmic Solution, 0.005%
48164381|NCT04445519|DRUG|NCX 470 0.1% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.1%
48164382|NCT04445519|DRUG|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1%
48164383|NCT04445519|DRUG|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005%
48164384|NCT03390933|DRUG|Fluoxetine|Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
48164385|NCT05014906|DRUG|Minocycline 45 MG|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
48164386|NCT05014906|DRUG|Azelaic acid|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
48164387|NCT00001077|DIETARY_SUPPLEMENT|Multivitamin and mineral supplements|Oral tablets taken daily
48164388|NCT00001077|DIETARY_SUPPLEMENT|Peptamen|Solution received daily
48164389|NCT00001077|DIETARY_SUPPLEMENT|NuBasics|Solution or dietary bar received daily
48164390|NCT03011554|DEVICE|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
48164391|NCT03152500|DEVICE|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
48007168|NCT04948138|DIETARY_SUPPLEMENT|Glutamine oral supplementation|Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
48693568|NCT04220827|DRUG|Paclitaxel|Given IP
48007169|NCT00742313|BIOLOGICAL|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
48007170|NCT00864773|PROCEDURE|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
48007171|NCT00425399|PROCEDURE|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
48007172|NCT01248026|OTHER|Buttermilk|"Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)"
48164392|NCT03152500|DEVICE|Acrysof SN60WF IOL|IOL in the bag
48164393|NCT06262776|BIOLOGICAL|Recombinant zoster vaccine adjuvanted (SHINGRIX)|2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
48164394|NCT02429752|OTHER|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
48164395|NCT05211453|PROCEDURE|atrioventricular node ablation|atrioventricular node ablation
48164396|NCT03955952|PROCEDURE|Bariatric Surgery|"Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085"
48164397|NCT06353009|OTHER|NOVA4 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 4 - Ultra-processed foods. They are the ones that use many ingredients including food additives that improve palatability, processed raw materials (hydrogenated fats, modified starches, etc.) and ingredients that are rarely used in home cooking such as soy protein or mechanically separated meat. These foods are mainly of industrial origin and are characterized by a good pleasantness and the fact that they can be stored for a long time."
48164398|NCT06353009|OTHER|NOVA1-3 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 1 - Unprocessed or minimally processed foods (fruit, vegetables, eggs, meat, milk, etc.)~Group 2 - Foods processed in the kitchen with the aim of extending their shelf life. In practice, these are ingredients to be used in the kitchen such as fats, aromatic herbs, etc. to be kept in jars or in the refrigerator to be able to use them later.~Group 3 - Processed foods. These are the foods obtained by combining foods of groups 1 and 2 to obtain the many food products for domestic use (bread, jams, etc.) made up of a few ingredients"
48164399|NCT04557332|BEHAVIORAL|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
48164400|NCT05329649|BIOLOGICAL|CTX001|Administered by intravenous infusion following myeloablative conditioning with busulfan.
48164401|NCT00415025|PROCEDURE|adjuvant therapy|
48164402|NCT00415025|PROCEDURE|management of therapy complications|
48693569|NCT02998411|OTHER|Titration|
48693570|NCT06657963|DIETARY_SUPPLEMENT|Opuntia ficus-indica Supplementation|Participants are required to consume oral supplementation of OFi fine powder packaged in individual sachets (LifeGreenTM, LifeTree Asia, Selangor, Malaysia) at the dosage of 1500 mg once daily for 3 months.
48007173|NCT00748956|DRUG|Low dose NPY|50nmol, administered intranasally
48007174|NCT00748956|DRUG|High dose NPY|100nmol administered intranasally
48007175|NCT00748956|DRUG|Placebo|placebo comparator (0nmol)) administered intranasally
48007176|NCT00437034|BIOLOGICAL|aflibercept|Given IV
48007177|NCT03343769|OTHER|BERG scale|Complete the BERG balance scale
48007178|NCT03343769|OTHER|Functional tests|timed up and go, Mini motor test, retropulsion test
48007179|NCT03343769|OTHER|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
48007180|NCT03343769|OTHER|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
48164403|NCT00415025|PROCEDURE|quality-of-life assessment|
48164404|NCT00415025|RADIATION|intensity-modulated radiation therapy|
48164405|NCT03322514|DIETARY_SUPPLEMENT|Inulin-Propionate Esters|Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
48693571|NCT06275776|DEVICE|Ethicon Monocryl Smooth Suture|Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
48693572|NCT06275776|DEVICE|Ethicon Vicryl Rapide Braided Suture|Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
48007181|NCT03343769|OTHER|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
48007182|NCT00000252|DRUG|0% N2O|
48164406|NCT03322514|DIETARY_SUPPLEMENT|Inulin|Inulin
48007183|NCT00000252|DRUG|10% N2O|
48007184|NCT00000252|DRUG|20% N2O|
48007185|NCT00000252|DRUG|30% N2O|
48007186|NCT00000252|DRUG|40% N2O|
48007187|NCT01670162|DRUG|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
48007188|NCT03732066|BEHAVIORAL|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
48164407|NCT04520971|DEVICE|780G|780G closed-loop insulin delivery system (Medtronic)
48007189|NCT03732066|BEHAVIORAL|Personalized Reminders|"1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of \>180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
48007190|NCT03732066|BEHAVIORAL|Interactive Responses|"1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month."
48164408|NCT04520971|DEVICE|standard of care|continue with standard of care treatment (pump without closed-loop or MDI)
48164409|NCT04506086|DRUG|Blinatumomab|Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
48164410|NCT04506086|DEVICE|Current Wearable Heatlth Monitoring System (CWHMS)|The study will use the CWHMS device to monitor participants' vital signs while they are at home.
48164411|NCT02245464|DRUG|Telmisartan|
48164412|NCT04236622|OTHER|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
48164413|NCT00581009|OTHER|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
48164414|NCT00581009|DRUG|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
48164415|NCT00581009|RADIATION|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
48693573|NCT06275776|DEVICE|Flexifuze Indermil Topical Skin Adhesive|Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
48007191|NCT05390203|DIAGNOSTIC_TEST|Penile duplex study, Hormonal Assay (Total Testosterone, Prolactin and E2)|we will do penile duplex and hormonal profile preoperatively and 6 months postoperatively.
48007192|NCT03407326|DIETARY_SUPPLEMENT|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
48007193|NCT03407326|DIETARY_SUPPLEMENT|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
48007194|NCT05098639|BEHAVIORAL|BASICS|In the BASICS condition, individuals receive information about alcohol use on campus and discuss safe drinking practices. They also receive personalized normative feedback based on their alcohol use and their use of protective behavioral strategies.
48007195|NCT05098639|BEHAVIORAL|Deviance Regulation Theory (DRT)|The Deviance Regulation Intervention comprises tailored intervention messages based on perceived norms. Participants complete an initial session that focuses on perceived norms of protective behavioral strategy (PBS) use and heavy drinking among peers. The therapist engages participants in a tailored discussion based on their perceived norms. If individuals believe PBS use is uncommon, the therapist discusses the positive social image that PBS use portrays. If the participant believes PBS is common, the therapist engages the participant in discussion of the negative aspects of non-PBS use. A similar strategy is taken for common and uncommon heavy alcohol use. Finally, the participant carries a mobile device which provide real-time adaptive positive or negative messages (consistent with the initial session) based on the perceived drinking and PBS norms of their current drinking environment.
48007196|NCT05572983|DRUG|Chidamide combined with CHOP|A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
48164416|NCT05610943|PROCEDURE|ultrasound-guided quadratus lumborum nerve block|The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
48164417|NCT05610943|PROCEDURE|ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block|The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
48164418|NCT00224809|DRUG|Angiotensin-Converting Enzyme Inhibitors|
48164419|NCT00224809|PROCEDURE|Coronary Artery Bypass Graft|
48164420|NCT00224809|DRUG|Angiotensin Receptor Blockers|
48164421|NCT00224809|DRUG|Spironolactone|
48164422|NCT00224809|DRUG|Aspirin|
48164423|NCT00224809|DRUG|Clopidogrel|
48164424|NCT00224809|PROCEDURE|Surgical Ventricular Restoration|
48164425|NCT02541799|PROCEDURE|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
48007197|NCT05572983|DRUG|Chidamide|Chidamide: 20mg，qw（d1,d4）,po
48164426|NCT02541799|PROCEDURE|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
48007198|NCT02489747|DIETARY_SUPPLEMENT|WBE|wheat bran extract (3 g/day)
48164427|NCT00349245|DRUG|Remifentanil|
48164428|NCT00349245|DRUG|Dexmedetomidine|
48693574|NCT06275776|DEVICE|Dermabond Prineo Skin Closure System|Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
48164429|NCT00002519|DRUG|chemotherapy|
48164430|NCT00002519|DRUG|paclitaxel|
48164431|NCT00002519|RADIATION|radiation therapy|
48164432|NCT03209297|OTHER|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
48164433|NCT02003664|DRUG|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
48164434|NCT02003664|DRUG|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
48164435|NCT00465478|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
48164436|NCT05753241|OTHER|no intervention|It's only observational study. No interventions.
48164437|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
48164438|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
48164439|NCT01474421|DRUG|Placebo|Patients will receive placebo once daily orally for 28 days.
48164440|NCT04089345|DRUG|Ustekinumab|All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
48693575|NCT06275776|DEVICE|Stryker Zip Skin Closure System|Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
48693576|NCT03597581|DRUG|ompenaclid|RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.
48693577|NCT03597581|DRUG|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
48693578|NCT03597581|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor inhibitor.
48007199|NCT02489747|DIETARY_SUPPLEMENT|Placebo|Placebo
48007200|NCT00165971|PROCEDURE|BIS monitoring|
48007201|NCT05558228|DEVICE|FloPatch FP120|FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
48007202|NCT03019276|DRUG|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
48007203|NCT00945984|PROCEDURE|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
48007204|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.
48693579|NCT03597581|DRUG|FOLFOX regimen|The FOLFOX regimen used for this protocol consists of oxaliplatin given at 85 mg/m2 IV together with leucovorin at 400 mg/m2 IV (substitution with levo-leucovorin 200 mg/m2 IV is allowed) (duration per institutional policy), followed by a 5-FU bolus of 400 mg/m2 (over 2-5 minutes), and then continuous infusional 5-FU given at a dose of 2400 mg/m2 over 46-48 hours (1200 mg/m2/day), given on Days 1 and 15 of each 28-day cycle. A minimum of 8 FOLFOX cycles should be received if tolerated per standard of care guidelines
48693580|NCT04091581|DRUG|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
48693581|NCT03946774|DIETARY_SUPPLEMENT|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
48693582|NCT02613494|DRUG|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
48693583|NCT02613494|DRUG|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
48693584|NCT02613494|OTHER|Placebo|Placebo twice daily, increasing to placebo three times daily
48693585|NCT03966209|DRUG|JS001(PD-1 inhibitor)|240mg I.V. Q3W
48693586|NCT01882556|DRUG|onabotulinumtoxinA|
48693587|NCT01882556|DRUG|Placebo|
48693588|NCT00956007|BIOLOGICAL|cetuximab|intravenously
48693589|NCT00956007|RADIATION|intensity-modulated radiation therapy|daily fractions
48693590|NCT02217423|OTHER|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
48693591|NCT02217423|OTHER|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
48693592|NCT00081549|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
48693593|NCT04265157|PROCEDURE|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
48693594|NCT05931471|OTHER|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
48693595|NCT03275506|DRUG|Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
48693596|NCT03275506|DRUG|Chemotherapy - Bevacizumab|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
48007205|NCT02434770|BIOLOGICAL|BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
48007206|NCT02434770|BIOLOGICAL|BioFarma Bivalent Oral Poliomyelitis Vaccine|Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
48164441|NCT06446999|OTHER|Yoga-Based Breathing Exercise|"Breathing Exercise Protocol Purpose: This protocol is a guide prepared for patients who agree to participate in the study within the scope of scientific research to do breathing exercises.~Materials Required: A comfortable chair/a comfortable bed to lie on and comfortable clothing.~Exercise Duration: Approximately 20 minutes Exercise Time and Frequency: It should be done twice a day, at the same time, in the morning and in the evening.~You can do the exercise before going for a walk in the corridor in the morning and before going to sleep in the evening.~Normal Breathing and Focusing on Breathing (3 minutes) Alternate Nose Breathing-Nadi Shodhana (15-20 times/6 minutes) Normal Breathing and Focusing on Breathing (3 minutes) Bhramari Pranayama-Bee Buzzing Sound(8-10 times/5 minutes) Normal Breathing and Focusing on Breathing (3 minutes)"
48164442|NCT04117906|BEHAVIORAL|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
48164443|NCT06223100|DRUG|Eravacycline|There is no other intervention.
48693597|NCT03916536|PROCEDURE|Holmium Laser|Holmium laser enucleation of large sized prostate
48693598|NCT03916536|PROCEDURE|Thulium Laser|Thulium laser enucleation of large sized prostate
48693599|NCT03916536|PROCEDURE|Bipolar diathermy|Bipolar enucleation of large sized prostate
48007207|NCT01748786|BEHAVIORAL|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
48007208|NCT01748786|OTHER|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
48007209|NCT03128697|BEHAVIORAL|Satiating diet|
48007210|NCT03128697|BEHAVIORAL|Control diet|
48007211|NCT01126164|BEHAVIORAL|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
48007212|NCT04164147|PROCEDURE|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with either Posterior Cruciate Ligament sacrificing or retaining implant
48007213|NCT04164147|DIAGNOSTIC_TEST|CT scan|CT scans of the affected knee joint before and after the surgical procedure
48007214|NCT04164147|DIAGNOSTIC_TEST|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
48164444|NCT00560807|PROCEDURE|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
48693600|NCT06658327|OTHER|Dynamic stretching|Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
48007215|NCT04164147|DEVICE|one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and NexGen PS total knee implant|Participant are randomly allocated to receive one of the Persona MC Retained PCL, Persona MC Sacrificed PCL and the NexGen PS total knee implant for treatment of end-stage knee osteoarthritis.
48007216|NCT04400097|PROCEDURE|suture|suture methods of autograft conjunctival transplantation
48007217|NCT04594096|BEHAVIORAL|Telehealth visits|Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
48007218|NCT04594096|BEHAVIORAL|Standard of Care|Receiving care as usual from the UC Davis Comprehensive Cancer Center
48007219|NCT01583010|DEVICE|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
48007220|NCT06068569|BIOLOGICAL|GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)|Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II.
48007221|NCT05009758|PROCEDURE|Blood sampling|Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
48693601|NCT06658327|OTHER|Static stretching|Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
48693602|NCT06660277|DEVICE|Super High-Flux Dialyzer|Dialyzer currently approved and available for use across Canada.
48007222|NCT05009758|PROCEDURE|Nasosorption|Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
48007223|NCT05009758|PROCEDURE|Oral sampling|For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
48007224|NCT05009758|PROCEDURE|Bronchoscopy|The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
48164445|NCT03521206|BEHAVIORAL|ACP+ programme|Training program for nursing home staff.
48693603|NCT06660277|DEVICE|High-Flux Dialyzer|Dialyzer that is widely used across Canada for hemodialysis treatments.
48693604|NCT03150693|DRUG|Allopurinol|Given PO
48693605|NCT03150693|DRUG|Cytarabine|Given IT, IV, SC
48007225|NCT05009758|PROCEDURE|Nasal biopsy|Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
48164446|NCT03022383|DEVICE|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
48164447|NCT01589380|DRUG|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
48693606|NCT03150693|DRUG|Daunorubicin Hydrochloride|Given IV
48693607|NCT03150693|DRUG|Vincristine Sulfate|Given IV
48007226|NCT05009758|PROCEDURE|Nasal sampling|Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
48693608|NCT03150693|DRUG|Dexamethasone|Given PO or IV
48693609|NCT03150693|DRUG|Pegylated L-Asparaginase|Given IV
48007227|NCT05009758|PROCEDURE|Nasal mucosa mRNA sampling|Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
48693610|NCT03150693|DRUG|Methotrexate|Given IT, IV, PO
48007228|NCT05009758|DIAGNOSTIC_TEST|Pregnancy test|In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
48007229|NCT05009758|OTHER|Medical history of patients, demographic data, concomitant medication, questionnaire|Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
48693611|NCT03150693|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48007230|NCT05009758|DIAGNOSTIC_TEST|UPSIT smell test|University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
48693612|NCT03150693|DRUG|Cyclophosphamide|Given IV
48693613|NCT03150693|DRUG|Mercaptopurine|Given PO
48693614|NCT03150693|BIOLOGICAL|Rituximab|Given IV
48693615|NCT03150693|DRUG|Doxorubicin|Given IV
48693616|NCT03150693|DRUG|Thioguanine|Given PO
48693617|NCT03150693|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
48693618|NCT03150693|OTHER|Laboratory Biomarker Analysis|Correlative studies
48693619|NCT00801073|PROCEDURE|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
48693620|NCT06660758|DEVICE|Feeding tube (Entarik)|Feeding tube placement will be verified using multiple methods in the duodenum and stomach.
48693621|NCT06463431|BEHAVIORAL|Cognitive Processing Therapy|We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
48693622|NCT00002389|DRUG|Abacavir sulfate|
48693623|NCT00002389|DRUG|Lamivudine|
48693624|NCT00002389|DRUG|Zidovudine|
48693625|NCT05936619|DEVICE|Mind Extender (MindEx)|NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.
48693626|NCT01524224|DRUG|LY2495655|administered intravenously
48693627|NCT00623233|DRUG|Gemcitabine|Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
48693628|NCT00623233|DRUG|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
48693629|NCT06660797|OTHER|Group1: A matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by matching gutta percha master cone , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
48164448|NCT01589380|DRUG|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
48007231|NCT05009758|PROCEDURE|Spirometry|Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
48164449|NCT01074437|DRUG|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
48164450|NCT01074437|DRUG|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
48164451|NCT01074437|DRUG|Placebo|Liquid placebo will be given during the two month treatment trial.
48164452|NCT00462202|DRUG|sulodexide|
48164453|NCT03277586|DRUG|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
48164454|NCT03277586|DRUG|Placebo|Identically formulated and packaged inactive substance
48164455|NCT06016764|DEVICE|Continuous Theta Burst in Transcranial Magnetic Stimulation|This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia and social-emotional impairment in autism
48164456|NCT00312871|DRUG|Epoetin alfa|
48164457|NCT03021031|OTHER|Observational|Observational study
48164458|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy for Couples|"Interpersonal Psychotherapy for Couples (IPT-C) consists of 8 weekly conjoint sessions. The clinical goals are to promote resolution of the role dispute via renegotiation of role relations between the marriage partners and improve common mental disorders in the woman. Like Interpersonal Psychotherapy, IPT-C has an initiation phase (Session 1-2), middle phase (Sessions 3-6), and termination phase (Sessions 7-8)."
48164459|NCT06252909|BEHAVIORAL|Interpersonal Psychotherapy (Individual)|Interpersonal Psychotherapy (IPT) is an evidence-based treatment to reduce depression and other common mental disorders. It focuses on helping patients resolve interpersonal problems of disagreements, loneliness, life changes, and grief, and/or change their orientation to the problem.
48164460|NCT02722122|DRUG|AIR DNase™|
48164461|NCT00806741|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
48164462|NCT00806741|DRUG|Phenylephrine|1μg/kg/min, infusion period 20 minutes
48164463|NCT00806741|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
48164464|NCT00806741|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
48164465|NCT00806741|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
48164466|NCT00806741|OTHER|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
48693630|NCT06660797|OTHER|Group2: XP-endo Finisher activation: The XP-endo Finisher instrument will be used in continuous rotation for 1 mintute|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by XP-endo Finisher used in continuous rotation for 1 minute , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
48164467|NCT04851145|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~* Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~* Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
48164468|NCT06493669|DIAGNOSTIC_TEST|Cognitive assessment|MoCA
48164469|NCT04053517|OTHER|Medical Chart Review|Medical chart is reviewed
48164470|NCT04053517|OTHER|Quality-of-Life Assessment|Ancillary studies
48164471|NCT04053517|OTHER|Questionnaire Administration|Ancillary studies
48164472|NCT03289416|COMBINATION_PRODUCT|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
48164473|NCT03289416|COMBINATION_PRODUCT|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
48164474|NCT06088355|BEHAVIORAL|HV-PDAE: High Volume Partnered Dance Aerobic Exercise|HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
48164475|NCT06088355|BEHAVIORAL|MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise|MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.
48164476|NCT06088355|BEHAVIORAL|MV-WALK: Moderate Volume Walking|MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for
48007232|NCT05009758|PROCEDURE|FeNO|Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
48007233|NCT05009758|PROCEDURE|Lung X-Ray|After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
48007234|NCT05867147|DRUG|Vanzacaftor|Tablets for oral administration.
48007235|NCT05867147|DRUG|Vanzacaftor Placebo|Placebo for oral administration.
48007236|NCT05867147|DRUG|Moxifloxacin|Tablets for oral administration.
48007237|NCT05867147|DRUG|Moxifloxacin Placebo|Tablets for oral administration.
48007238|NCT01536639|DRUG|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
48007239|NCT03454555|BEHAVIORAL|Shared Decision Making|"The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. The intervention will have both clinician and patient educational components. The content of the clinician component will be based on the Agency for Healthcare Research and Quality's SHARE: Seek, Help, Assess, Reach, Evaluate Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient. Participants randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice."
48007240|NCT03454555|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. One individual MI session will focus on patient engagement and enhancing a patient's own intrinsic motivation for CBT-CP participation. MI will also be woven into the group CBT-CP sessions. We will deliver 8 sessions of CBT-CP, as is standard in a group setting, in-person or virtually.
48007241|NCT06452524|DEVICE|axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)|Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.
48007242|NCT06504030|DRUG|modified-DEP|"For non-EBV-HLH patients: Liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed.~For EBV-HLH patients: PD-1 monoclonal antibody, 2 mg/kg (maximum dose, 200 mg) d-3, liposomes doxorubicin, 25 mg/m2 d1, etoposide 100 mg/m2 d1, methylprednisolone 1 mg/kg d1-3, then tapering according to patients condition, fully stop with d7 to d10; ruxolitinib, 15 mg bid. Emapalumab, if needed."
48007243|NCT04262336|DRUG|DB-020|Injectable sterile viscous solution of DB-020 and sodium hyaluronate in sterile water
48693631|NCT06660797|OTHER|Group 3:EasyClean system activation : EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.|after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by EasyClean system activation , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
48164477|NCT03824145|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
48164478|NCT03824145|BEHAVIORAL|Attention Control|The attention control participants will receive a home/work organization intervention:
48164479|NCT01287416|BEHAVIORAL|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
48164480|NCT01287416|BEHAVIORAL|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
48164481|NCT02480244|BEHAVIORAL|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
48164482|NCT02480244|OTHER|Control|Control arm receives no health-related behavioral intervention
48164483|NCT00497198|DRUG|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
48164484|NCT00497198|DRUG|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
48164485|NCT03045302|DRUG|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
48164486|NCT04448821|DRUG|Metformin|Single administration of metformin
48164487|NCT04448821|DRUG|Metformin + Nilotinib|Coadministration of metformin and nilotinib
48164488|NCT04836338|DEVICE|orotracheal intubation|orotracheal intubation
48164489|NCT04449133|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
48164490|NCT04449133|DRUG|Placebo|Oral administration of two capsules before sleep for 7 days.
48164491|NCT00452985|DRUG|Docetaxel|60-75 mg/m²
48164492|NCT00452985|DRUG|Carboplatin|AUC 5
48164493|NCT02411253|DRUG|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
48164494|NCT02411253|DRUG|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
48164495|NCT02084355|DRUG|oral oxycodone|
48164496|NCT02084355|DRUG|oral hydromorphone|
48164497|NCT02084355|DRUG|fentanyl patch|
48164498|NCT02030847|BIOLOGICAL|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
48164499|NCT02030847|BIOLOGICAL|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.
48164500|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
48164501|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8).
48164502|NCT04405856|DEVICE|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
48164503|NCT01532102|DRUG|AP611074|
48164504|NCT01532102|DRUG|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
48164505|NCT03802487|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
48164506|NCT03802487|DRUG|14C-microtracer|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
48164507|NCT03802487|DRUG|Charcoal|"Pharmaceutical form: Granules for suspension~Route of administration: Oral"
48164508|NCT00953342|BEHAVIORAL|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
48164509|NCT00953342|BEHAVIORAL|Usual care|Standard medical care
48164510|NCT05532683|BEHAVIORAL|Health Behaviors Group|The proposed intervention will include eight modules across nine weekly group sessions targeting psychoeducation of CHR-P symptoms, goal setting, physical activity, sleep, substance use, nutrition, and evidence-based strategies for stress management. Intervention facilitators will utilize motivational interviewing (MI; Miller \& Rollnick, 2012) strategies to engage youth in goal setting to target change in health promotion behaviors. Caregivers will be invited to join at the end of each session for a 10-minute check-out where an outline of content covered and patient goals for the week will be shared.
48164511|NCT06584643|DIAGNOSTIC_TEST|gasdermin d|evaluation of serum gasdermin d in vitligo patients and healthy controls
48164512|NCT02384083|DRUG|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
48164513|NCT03246256|OTHER|Group 1|
48164514|NCT06625645|COMBINATION_PRODUCT|Modified triple antibiotic paste (TAP) mixed with chlorehexidine|M-TAP with CHX 2%
48164515|NCT06625645|COMBINATION_PRODUCT|Modified Triple Antibiotic Paste mixed with saline|M-TAP mixed with saline
48164516|NCT06625645|COMBINATION_PRODUCT|Calcium Hydroxide mixed with chlorohexidine Intracanal medication|calcium hydroxide powder mixed with CHX 2% solution as intracanal medication
48164517|NCT06625645|COMBINATION_PRODUCT|calcium hydroxide mixed with saline as intracanal medication|calcium hydroxide mixed with saline as intracanal medication for necrotic primary molars
48007244|NCT04262336|DRUG|Placebo|Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
48007245|NCT03310424|OTHER|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
48164518|NCT05046652|BIOLOGICAL|Convalescent Plasma Therapy|In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
48164519|NCT01196247|DRUG|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
48164520|NCT01364545|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
48164521|NCT01364545|DIETARY_SUPPLEMENT|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
48164522|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive dietary counseling
48164523|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive guidelines for low-fat diet
48164524|NCT02176902|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
48164525|NCT02176902|OTHER|laboratory biomarker analysis|Correlative studies
48164526|NCT06399003|BIOLOGICAL|SIBP MMR Vaccine|This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of Biological Products. A single dose of 0.5 mL, containing not less than 3.0 log CCID50 of both live measles virus and rubella virus and 4.3 log CCID50 of live mumps virus. 0.5ml per dose.
48164527|NCT06399003|BIOLOGICAL|GSK MMR Vaccine (PRIORIX)|PRIORIX (combined measles, mumps and rubella vaccine, live, attenuated) is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses, separately obtained by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). 0.5ml per dose.
48164528|NCT06399003|BIOLOGICAL|Yellow Fever Vaccine (Stamaril)|This is a live, attenuated, lyophilized yellow fever vaccine manufactured by Sanofi Pasteur Europe, Lyon, France. A single dose of 0.5 mL contains with not less than 1000 IU of yellow fever virus 17D-204 strain. 0.5ml per dose.
48164529|NCT06336941|DEVICE|Ultrasound|Ultrasonographic scan with a 70 MHz probe
48164530|NCT05979402|OTHER|Training group Face-to-face pressure ulcer training|Face-to-face presure ulcer training
48164531|NCT05979402|OTHER|Control group|No intervention
48164532|NCT05313178|DIETARY_SUPPLEMENT|Bacillus Coagulans GBI-30, 6086|In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
48164533|NCT01902381|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
48164534|NCT01730118|BIOLOGICAL|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
48164535|NCT04912102|DEVICE|high flow nasal oxygen device (HFNO)|it is a novel technique by which heated humidified oxygen is supplied via nasal prongs at flow rates ranging from 40 to 70 L/minute. The Fio2 ranges from 0.21 to 1.0.
48164536|NCT01068223|DRUG|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
48164537|NCT01068223|DRUG|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
48164538|NCT01068223|DRUG|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
48164539|NCT04063878|DEVICE|Conometric Abutment and Conometric Final Cap|Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
48164540|NCT01763346|DRUG|Metformin|metformin 1000 mg bid
48164541|NCT01763346|DEVICE|gastric banding|LAP-BAND
48164542|NCT05087797|DRUG|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
48164543|NCT05648136|BIOLOGICAL|blood sample|"Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation"
48164544|NCT01653171|DRUG|Water (Placebo)|Water 100 mL
48164545|NCT01653171|DRUG|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
48164546|NCT01653171|DRUG|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
48164547|NCT01653171|DRUG|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
48164548|NCT02832219|DIETARY_SUPPLEMENT|Molecular hydrogen|
48164549|NCT02832219|DIETARY_SUPPLEMENT|Placebo|
48164550|NCT06505239|DIETARY_SUPPLEMENT|FSD-F2R6-A-CP|FSD-F2R6-A-CP is a unique dietary supplement with natural ingredients, vitamins and minerals that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism and may accelerate alcohol metabolism in the body.
48164551|NCT06505239|DIETARY_SUPPLEMENT|Placebo|Placebo drink designed to match FSD-F2R6-A-CP in color and taste.
48369048|NCT05707364|BEHAVIORAL|Pre-visit Lab Workflow|"1. Based on buy-in from the providers/staff one or both of the practices below will be introduced into the clinic workflow to order pre-visit labs.~   1. All procedures are within the standard of care, only the order of operations is being changed. After sharing lab results with patient from the most recent routine physical, physician records labs for the next calendar year in EMR.~  2. Prior to appointment, Medical Assistant (MA) will review notes and orders to setup pre-visit labs.~2. Patient contacted to complete labs prior to the scheduled routine physical.~3. Resulted labs are triaged based on urgency.~4. After Visit Summary used to communicate about labs and surveys."
48369049|NCT04211506|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
48007246|NCT03346122|DRUG|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
48007247|NCT03346122|DRUG|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
48007248|NCT03346122|DRUG|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
48007249|NCT03346122|DRUG|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
48007250|NCT03346122|DRUG|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
48007251|NCT03346122|DRUG|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
48007252|NCT03346122|DRUG|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
48007253|NCT03346122|DRUG|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
48007254|NCT03346122|DRUG|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
48007255|NCT03346122|DRUG|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
48007256|NCT02300324|DIETARY_SUPPLEMENT|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
48007257|NCT02300324|DIETARY_SUPPLEMENT|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
48007258|NCT02300324|DIETARY_SUPPLEMENT|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
48007259|NCT01454726|OTHER|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
48007260|NCT01454726|OTHER|drug|the Western medical treatment alone.
48164552|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
48164553|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
48164554|NCT06028399|OTHER|Concurrent Training|The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise \& toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.
48369050|NCT02961231|BIOLOGICAL|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
48007261|NCT04219865|DRUG|Group 1: Compound Edaravone/Placebo Injection|Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min
48007262|NCT04219865|DRUG|Group 2: Compound Edaravone/Placebo Injection|Compound Edaravone 60mg-1200mg (containing edaravone 60 mg and 2-aminoethanesulfonic acid 1200 mg) / placebo single intravenous infusion for 30min
48164555|NCT06028399|OTHER|Aerobic Training|The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
48369051|NCT02961231|BIOLOGICAL|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
48369052|NCT02961231|BIOLOGICAL|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
48369053|NCT02961231|BIOLOGICAL|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
48369054|NCT04923009|PROCEDURE|ICE visualization and map construction|Radio-frequency ablation of atrial fibrillation
48369055|NCT02027324|DRUG|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
48369056|NCT02027324|DRUG|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
48007263|NCT04219865|DRUG|Group 3: Compound Edaravone/Placebo Injection|Compound Edaravone 90mg-1800mg (containing edaravone 90 mg and 2-aminoethanesulfonic acid 1800 mg) / placebo single intravenous infusion for 30min
48007264|NCT04219865|DRUG|Group 4: Compound Edaravone/Placebo Injection|Compound Edaravone 120mg-2400mg (containing edaravone 120 mg and 2-aminoethanesulfonic acid 2400 mg) / placebo single intravenous infusion for 30min
48007265|NCT04219865|DRUG|Group 5: Compound Edaravone/Placebo Injection|Maximum tolerated dose of drug / placebo for a single intravenous infusion for 30 minutes three times a day at an interval of 8 h until the last dose on the morning of Day 3, after which the sequential test drug 30 mg-600 mg / placebo will be administered daily from Day 3 night Intravenous infusion, 30 minutes at 12-hour intervals until morning on Day 7
48007266|NCT01069289|DRUG|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
48007267|NCT01069289|DRUG|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
48007268|NCT00646412|DEVICE|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
48007269|NCT06323642|DIETARY_SUPPLEMENT|probiotic containing Lactobacillus rhamnosus GG.|probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days
48007270|NCT06323642|OTHER|placebo|milk as placebo
48007271|NCT00005770|DEVICE|Acupuncture|
48164556|NCT05666063|DIAGNOSTIC_TEST|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
48164557|NCT02292641|PROCEDURE|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
48164558|NCT01906658|DRUG|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
48164559|NCT01547182|BEHAVIORAL|Caloric restriction|Caloric restriction
48164560|NCT01547182|BEHAVIORAL|Aerobic Training|Walking
48164561|NCT01547182|BEHAVIORAL|Resistance Training|Lifting weights
48164562|NCT06405516|DEVICE|Autologous blood cell salvage with in-house device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
48164563|NCT06405516|DEVICE|Autologous cell salvage with i-Sep SAME device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
48164564|NCT02212301|DEVICE|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
48693632|NCT05853705|BEHAVIORAL|Strong Hearts Exercise Program|The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
48164565|NCT02212301|DEVICE|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
48164566|NCT02160561|OTHER|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
48164567|NCT02801747|BEHAVIORAL|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
48007272|NCT04696705|BIOLOGICAL|Ex-vivo expanded allogeneic γδT cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
48007273|NCT00001249|DRUG|Yttrium-90 radiolabeled anti-Tac antibody|
48007274|NCT03984695|BEHAVIORAL|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
48164568|NCT03551197|DRUG|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
48164569|NCT00078858|DRUG|fludarabine phosphate|Given IV
48164570|NCT00078858|RADIATION|total-body irradiation|Undergo TBI
48164571|NCT00078858|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
48164572|NCT00078858|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
48164573|NCT00078858|DRUG|cyclosporine|Given PO
48007275|NCT04001153|OTHER|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
48007276|NCT02128295|DEVICE|Electric breast pump - A|
48007277|NCT02128295|DEVICE|Electric breast pump - B|
48007278|NCT02550457|OTHER|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
48164574|NCT00078858|DRUG|mycophenolate mofetil|Given PO or IV
48164575|NCT00078858|OTHER|laboratory biomarker analysis|Correlative studies
48164576|NCT00004740|DRUG|isoniazid|
48164577|NCT00640185|DRUG|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
48164578|NCT00640185|DRUG|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
48164579|NCT05335668|PROCEDURE|Clinical Testing|Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
48164580|NCT02977468|DRUG|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
48007279|NCT02550457|OTHER|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
48007280|NCT02550457|OTHER|Rigid Tape|Application of Micropore tape in the erector spine muscles.
48164581|NCT02977468|RADIATION|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
48164582|NCT05833399|DRUG|Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone|Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
48164583|NCT05656807|BEHAVIORAL|Go NAPSACC Enhanced|Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
48164584|NCT05656807|BEHAVIORAL|Go NAPSACC|Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
48007281|NCT00243516|DEVICE|PREtest Consult|
48164585|NCT06455202|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
48164586|NCT06455202|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
48164587|NCT03792789|DEVICE|mCIMT with real rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses)."
48164588|NCT03792789|DEVICE|mCIMT with sham rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil."
48164589|NCT05958147|BIOLOGICAL|C-PRF|thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
48164590|NCT05347121|DIAGNOSTIC_TEST|difficult airway|ultrasonography of airway
48007282|NCT02482350|BEHAVIORAL|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
48007283|NCT01778166|DRUG|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
48007284|NCT01778166|DRUG|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
48007285|NCT02940691|DRUG|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
48007286|NCT02371499|DIETARY_SUPPLEMENT|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
48007287|NCT02371499|DIETARY_SUPPLEMENT|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
48007288|NCT02108821|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
48007289|NCT04525612|DIAGNOSTIC_TEST|68Ga-BNU-PSMA|Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.
48164591|NCT06539520|OTHER|Aerobic training program|Aerobic training program; on interval moderate mode, 3 session per week, for 16 weeks, along 30-40 minutes, plus 5-10 minutes of warm up and 5 minutes cooling down, with 50-80% of maximal heart rate for each patient based on age. that progress every month by 10% directed by rating of perceived exertion.
48164592|NCT06539520|OTHER|Selected physical therapy program for post stroke patients|Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
48164593|NCT01545778|DRUG|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
48164594|NCT01545778|DRUG|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
48007290|NCT02543931|DRUG|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
48007291|NCT02543931|DRUG|placebo|Placebo capsules containing inert ingredients
48007292|NCT01536496|BIOLOGICAL|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
48007293|NCT01536496|BIOLOGICAL|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
48007294|NCT01080313|OTHER|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
48007295|NCT05218759|DRUG|Anlotinib|anlotinib administration at a dose of 10 mg daily
48007296|NCT06278597|DIAGNOSTIC_TEST|NACA Estimator|Grading of peripheral anterior chamber width with the Narrow Anterior Chamber Angle (NACA) Estimator
48007297|NCT02900820|OTHER|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
48007298|NCT02900820|OTHER|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
48007299|NCT04979585|DRUG|Camrelizumab|200mg ,IV,d1,Q3W.
48007300|NCT04979585|DRUG|Anlotinib|8mg,oral, d1-14,Q3W.
48007301|NCT04979585|DRUG|nab-Paclitaxel|260mg/m2,IV,d1,Q3W.
48007302|NCT00077168|DRUG|anastrozole|
48007303|NCT00077168|DRUG|tamoxifen citrate|
48007304|NCT00077168|PROCEDURE|adjuvant therapy|
48007305|NCT00077168|RADIATION|radiation therapy|
48164595|NCT06155487|DRUG|AJH-2947 100 mg (SAD)|Oral Tablet, Single dose of AJH-2947 100 mg
48693633|NCT02923830|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
48693634|NCT02923830|DRUG|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
48007306|NCT04099667|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
48007307|NCT04099667|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
48007308|NCT04099667|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
48693635|NCT04053855|BIOLOGICAL|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
48007309|NCT04099667|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
48007310|NCT04099667|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
48007311|NCT05328492|DEVICE|iVAPS-AE|Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
48007312|NCT05328492|DEVICE|ST-mode|Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
48007313|NCT06114264|BEHAVIORAL|Multimodal + Resistance Programs|"Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc."
48007314|NCT06114264|OTHER|Control group|No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
48007315|NCT04454450|DIAGNOSTIC_TEST|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
48007316|NCT04454450|DIAGNOSTIC_TEST|Contrast enhanced CT|Standard of care contrast enhanced CT
48007317|NCT00134381|DRUG|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
48007318|NCT00134381|DRUG|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
48007319|NCT03357406|PROCEDURE|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
48007320|NCT03357406|PROCEDURE|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
48007321|NCT03544775|PROCEDURE|Isolated General Anesthesia|No nerve block identified through physician billing codes
48007322|NCT03544775|PROCEDURE|Peripheral Nerve Block|Nerve block identified through physician billing codes
48164596|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 100 mg
48164597|NCT06155487|DRUG|AJH-2947 200 mg (SAD)|Oral Tablet, Single dose of AJH-2947 200 mg
48164598|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 200 mg
48007323|NCT01868633|DRUG|Dexamethasone|
48164599|NCT06155487|DRUG|AJH-2947 300 mg (SAD)|Oral Tablet, Single dose of AJH-2947 300 mg
48164600|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 300 mg
48164601|NCT06155487|DRUG|AJH-2947 400 mg (SAD)|Oral Tablet, Single dose of AJH-2947 400 mg
48164602|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 400 mg
48164603|NCT06155487|DRUG|AJH-2947 600 mg (SAD)|Oral Tablet, Single dose of AJH-2947 600 mg
48164604|NCT06155487|DRUG|Placebo|Oral Tablet,Single dose of Placebo 600 mg
48164605|NCT06155487|DRUG|AJH-2947 800 mg (SAD)|Oral Tablet, Single dose of AJH-2947 800 mg
48164606|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 800 mg
48164607|NCT06155487|DRUG|AJH-2947 200 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
48164608|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
48693636|NCT06661135|PROCEDURE|TLPD total laparoscopic pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the laparoscopy
48693637|NCT06661135|PROCEDURE|OPD open pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the open technique
48007324|NCT01868633|DRUG|Placebo|
48007325|NCT00275158|DRUG|L-Arginine Supplementation|
48007326|NCT05737472|DIETARY_SUPPLEMENT|High-protein RUTF|The high-protein RUTF is isocaloric to the standard RUTF. To have a higher protein quantity and quality, the recipe has greater proportions of milk powder plus whey protein and vegetable oil. A total of 15% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS )of the high protein, RUTF is 1.18 which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 1.19
48164609|NCT06155487|DRUG|AJH-2947 400 mg (MAD)|Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
48164610|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
48164611|NCT06155487|DRUG|AJH-2947 600 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
48164612|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
48164613|NCT03377179|DRUG|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
48164614|NCT03377179|DRUG|Hydroxychloroquine Sulfate 200 MG|HCQ tablets will be taken at a dose that will be determined
48164615|NCT03862105|OTHER|Mobile Health app tool - Twistle|The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
48164616|NCT04610645|DEVICE|OCT|3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck
48164617|NCT04610645|DEVICE|Dermatoscope|2x2 pictures taken with a dermatoscope
48164618|NCT04610645|GENETIC|3-Colour FISH|Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual
48164619|NCT05191186|DRUG|Grass pollen extract - Alutard Phleum pratense, ALK|injection in lymph node
48164620|NCT03282877|BEHAVIORAL|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
48164621|NCT00043407|DRUG|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
48164622|NCT03463538|PROCEDURE|arthroscopic capsular release|surgical release of shoulder joint capsule
48164623|NCT03463538|PROCEDURE|Hydro-dilatation|dilatation of shoulder joint capsule using water pressure under local anesthetic
48164624|NCT00003924|BIOLOGICAL|recombinant interferon alfa|
48164625|NCT00658983|OTHER|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
48164626|NCT00658983|OTHER|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
48693638|NCT06492707|BIOLOGICAL|Decoy-resistant interleukin-18|Given SC
48693639|NCT06492707|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48693640|NCT06492707|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48693641|NCT06540703|DIETARY_SUPPLEMENT|Therapeutic Ketogenic Diet (TKD)|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
48693642|NCT00883818|DRUG|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
48693643|NCT04809766|BIOLOGICAL|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
48693644|NCT04809766|DRUG|Cyclophosphamide|Given IV
48693645|NCT04809766|DRUG|Fludarabine|Given IV
48693646|NCT04809766|DRUG|Bendamustine|Given IV
48693647|NCT05052255|DRUG|RVU120|RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
48693648|NCT03548025|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
48164627|NCT03230110|DIAGNOSTIC_TEST|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
48164628|NCT00420563|DRUG|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
48164629|NCT00420563|DRUG|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
48164630|NCT05284006|DIAGNOSTIC_TEST|Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.|This study includes 15 major assessments: clinical assessment procedures; anthropometric measurements; activity of daily living and quality-of-life questionnaires; gait kinematics and kinetics analysis; pulmonary function tests (PFT); skeletal radiographs and dual-energy x-ray absorptiometry (DXA); MRI in cervical spine, temporal bones, and hip; computed tomography angiography (CTA) for tracheal obstruction; CT for temporal bones; anesthetic encounters; joint mobility; hearing function; biochemical analyses; and pathological analyses.
48693649|NCT03005561|BEHAVIORAL|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
48693650|NCT02951403|PROCEDURE|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
48693651|NCT02951403|OTHER|Conservative treatment|Physiotherapy protocol is introduced to patients.
48693652|NCT02497365|DRUG|Besifloxacin|
48693653|NCT02497365|DRUG|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
48693654|NCT06588322|OTHER|Blood samples will be taken on several times (36 mL of blood taken at each time):|"* Inclusion visit (T0): prior to initiation of Olaparib treatment~* Follow-up period (T1 to T8): every 3 months for a maximum of 24 months~* End of study (Tx): on definitive cessation of Olaparib treatment for any reason (progression, toxicity or definitive cessation of treatment after 2 years)."
48693655|NCT02569255|PROCEDURE|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
48693656|NCT04171219|BIOLOGICAL|Pembrolizumab|Given IV
48693657|NCT04171219|DRUG|Talabostat Mesylate|Given PO
48693658|NCT04150237|OTHER|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
48693659|NCT03625778|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
48693660|NCT03625778|DRUG|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
48007327|NCT05737472|DIETARY_SUPPLEMENT|Standard RUTF|The standard RUTF was manufactured according to WHO recommendations, with at least 50% of protein-sourced dairy, mainly skim milk. A total of 10% of energy is from protein. The protein quality score, digestible indispensable amino acid score (DIAAS) of the standard RUTF is 0.76, which is equivalent to a Protein Digestibility Corrected Amino Acid Score (PDCAAS) of 0.86.
48007328|NCT06448741|OTHER|Replantation of amputated penis|Replantation of the amputated penis done macroscopically, but testicular replantation was not done because of lack of microsurgical access
48007329|NCT02678039|DEVICE|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
48007330|NCT02678039|PROCEDURE|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
48693661|NCT02625480|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|
48693662|NCT02625480|DRUG|Fludarabine|Administered intravenously
48007331|NCT02252627|DRUG|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
48007332|NCT02252627|OTHER|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
48007333|NCT02252627|OTHER|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
48693663|NCT02625480|DRUG|Cyclophosphamide|Administered intravenously
48693664|NCT03006458|DEVICE|comfilcon A|toric contact lens
48693665|NCT03006458|DEVICE|omafilcon B|toric contact lens
48164631|NCT02271737|BEHAVIORAL|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
48164632|NCT03327688|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
48164633|NCT06219161|DIETARY_SUPPLEMENT|NAD3|NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)
48164634|NCT06274892|OTHER|Remote monitoring PROs|Attendance at RT review appointments triaged based on remotely monitored PROs
48164635|NCT04532008|BEHAVIORAL|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
48164636|NCT06350591|OTHER|Immobilization|single-leg immobilization
48164637|NCT06350591|OTHER|Resistance training|Leg extension and leg press; 3 sets of 8-12 reps
48007334|NCT02252627|DRUG|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
48007335|NCT06075485|OTHER|Ketocal|ketogene diet
48007336|NCT05103124|DEVICE|Hydral|The investigational product GUM Hydral will be administered for a 30-days treatment period
48007337|NCT05103124|OTHER|Placebo|The placebo product will be administered for a 30-days treatment period
48007338|NCT04765007|OTHER|mindfulness-based stress reduction|"Eight sessions of two hours and a half, one day per week during eight weeks. In addition, patients will perform a day of intensive silent practice of 6-8 hours of duration.~The content of each session balances three activities: the presentation of a topic, moments of dialogue and group exploration (using appreciative inquiry) and a Mindfulness practice.~The sessions will take place in online format, through the google meet application"
48007339|NCT04765007|OTHER|Minimal intervention|A guided meditation program of eight weeks of duration will be provided to the patients and they will be informed about the procedure and the beneficial effects of the therapy.
48007340|NCT01812928|DRUG|Diclofenac|
48007341|NCT00858871|DRUG|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
48007342|NCT00858871|DRUG|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
48007343|NCT00858871|DRUG|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
48007344|NCT00858871|DRUG|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
48164638|NCT03594578|BEHAVIORAL|Episodic future thinking|Prospective thinking intervention
48164639|NCT03594578|BEHAVIORAL|Episodic recent thinking|Sham episodic thinking
48164640|NCT04656860|DIETARY_SUPPLEMENT|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
48007345|NCT01530126|BIOLOGICAL|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
48007346|NCT01530126|BIOLOGICAL|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
48007347|NCT01530126|BIOLOGICAL|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
48007348|NCT03989297|RADIATION|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
48164641|NCT06146790|PROCEDURE|endovascular treatment|For the subjects randomized to endovascular treatment (EVT) treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 24 hours since the subject was last known well.Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
48164642|NCT06146790|OTHER|Standard medical management|Standard medical management
48164643|NCT03139383|OTHER|dextrose solution|The patients received 5%D/N/2 during surgery
48164644|NCT03139383|OTHER|saline solution|The patients received NSS during surgery
48369057|NCT03492242|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
48369058|NCT02756182|DEVICE|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP \& AC measurements
48369059|NCT02944604|DRUG|PEG-rhG-CSF|
48007349|NCT03388190|DRUG|Nivolumab|"FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks."
48164645|NCT03334071|BEHAVIORAL|Exercise|"High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last \<1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions."
48164646|NCT00035061|DRUG|pemetrexed|
48164647|NCT06644222|BEHAVIORAL|AIRROSTI exercises|Group A will receive AIRROSTI exercises for 45 minutes / one session daily for five days per week
48164648|NCT06644222|BEHAVIORAL|Thera band exercises|Group B will receive Thera band exercises for 45 minutes/one session per day for five days per week.
48164649|NCT00744796|PROCEDURE|DSAEK|Endothelial Keratoplasty
48164650|NCT00744796|DIAGNOSTIC_TEST|Anterior Segment Optical Coherence Topography (OCT)|Non-contact, high resolution, cross sectional imaging of the anterior segment of the eye.
48164651|NCT00744796|DIAGNOSTIC_TEST|Best Spectacle Corrected Visual Acuity (BSCVA)|Visual acuity determined using a combination of detecting hand motion, counting fingers displayed and reading Snellen charts at specific distances.
48164652|NCT05261347|PROCEDURE|mulligan mobilisation|an active mobilisation with movement on elbow according to mulligan's protocol
48164653|NCT05261347|PROCEDURE|sham|a lateral glide
48164654|NCT05221216|OTHER|Collect data of medical record|Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
48164655|NCT06194786|BEHAVIORAL|Group D|Usual care
48164656|NCT03806218|DEVICE|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
48164657|NCT03806218|DEVICE|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
48164658|NCT03806218|DEVICE|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
48164659|NCT03806218|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
48164660|NCT05640947|DEVICE|The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System|EUS-guided gastro-gastrostomy using the Hot Axios device: Using a therapeutic endoscopic ultrasound endoscope with a working channel of 3.7mm and under fluoroscopic control, the excluded stomach will be identified and punctured with a 19G needle. Contrast injection will confirm the good position of the needle in the excluded stomach. If needed, the excluded stomach will be filled with blue-stained aqua (5% indigocarmine) until a sufficient distension is obtained for placement of the lumen-apposing metal stent. A lumen-apposing metal stent with a diameter of 20mm will be used according to the manufacterers' instructions to create a gastrogastrostomy. Position will be checked with fluoroscopy.
48164661|NCT06295237|DEVICE|Intellisync+|mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
48164662|NCT00877188|OTHER|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
48164663|NCT00230971|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
48164664|NCT00230971|DRUG|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
48164665|NCT01126879|DIETARY_SUPPLEMENT|genistein|Given orally
48164666|NCT01126879|OTHER|placebo|Given orally
48164667|NCT01126879|PROCEDURE|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
48164668|NCT04029792|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
48164669|NCT04029792|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
48164670|NCT00377312|DRUG|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
48007350|NCT03388190|DRUG|FLOX|FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
48164671|NCT05372913|DEVICE|Woebot for Adolescents (W-GenZD) Mobile Application|"Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
48164672|NCT05372913|BEHAVIORAL|CBT-Lite Teletherapy Group|The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
48007351|NCT03027466|BEHAVIORAL|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
48693666|NCT00602004|DRUG|losartan|losartan 50 mg a day
48693667|NCT06659653|DRUG|PRG2302|Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
48693668|NCT06657989|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
48693669|NCT06657989|BEHAVIORAL|Walking|Overground walking
48693670|NCT06596616|OTHER|Radiology|Radiology - MRI Scans
48007352|NCT02332551|DEVICE|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
48164673|NCT05095714|OTHER|Liver ultrasound and fast-MRI|Half-yearly liver ultrasound and fast-MRI
48164674|NCT05095714|OTHER|Liver ultrasound|Half-yearly liver ultrasound
48369060|NCT04559048|DRUG|FK506|FK506 (tacrolimus), a calcineurin inhibitor, is widely used as an immunosuppressant to lower the risk of organ rejection after organ transplantation
48369061|NCT04089423|DEVICE|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
48693671|NCT06596616|OTHER|Gadopiclenol|Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
48693672|NCT05751993|BEHAVIORAL|ADAPT|The intervention is testing the feasibility of a reinforcement learning model to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (morning, midday, and evening on a daily basis), the system evaluates which behaviors a participant is eligible to receive a message about (eating, activity, self-weighing), which intervention options a participant is eligible to receive, and then chooses what type of behavioral message a participant should receive. Over time, the model uses participant data and response to interventions to better tailor message choice.
48693673|NCT05561595|BEHAVIORAL|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
48693674|NCT05561595|BEHAVIORAL|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
48693675|NCT06495970|DEVICE|Gradient Denervation System|The Gradient Denervation System delivers ultrasound ablation to planned locations in the pulmonary artery to down-regulate the sympathetic nervous drive. The system includes a sterile, single-use catheter that is designed to centrally position the transducer within the arterial target zone for consistency of ablation.
48693676|NCT06482567|BEHAVIORAL|iCOVER|"The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., I'm right here with you); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior."
48369062|NCT03955068|OTHER|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
48007353|NCT04733157|DRUG|Tranexamic acid injection|Tranexamic 1g administered intravenously at the onset of skin incision at caesarean section
48007354|NCT04733157|OTHER|Normal saline placebo|10ml of normal saline will be administered intravenously at onset of skin incision at caesarean section to the placebo group
48369063|NCT06001021|DRUG|Psychopharmacological Intervention|Escitalopram 5-10 mg in antenatal period; Sertraline 12.5-25 mg in postnatal period) and/or Benzodiazepine (Alprazolam, 0.25-0.50 mg).
48369064|NCT06001021|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT intervention from a trained psychologist in CBT.
48369065|NCT06001021|OTHER|Combination of Psychopharmacological Intervention and CBCT|Medication will be prescribed by a consultant gynecologist and CBCT (conditions: with or without Zikr) will be provided by a trained psychologist.
48693677|NCT06482567|BEHAVIORAL|Physical Presence with Reassurance|The RA who performed randomization, initially approached the individual, and obtained assent will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
48693678|NCT06372652|DRUG|TE-8214 - SAD|Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg
48007355|NCT03553316|DRUG|PK101-002|-(Single) PK101-002
48007356|NCT03553316|COMBINATION_PRODUCT|PK101|-(Combination) PK101-001, PK101-002
48007357|NCT05912504|OTHER|Phoen survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
48007358|NCT03023488|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
48369066|NCT06001021|OTHER|Placebo and No Intervention|Control waitlist group will be provided with either a placebo by a consultant gynaecologist or no intervention by a trained psychologist
48369067|NCT02625610|DRUG|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
48369068|NCT02625610|DRUG|Oxaliplatin|"Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
48693679|NCT06372652|DRUG|Placebo|Single subcutaneous dose of matching placebo across the cohorts
48693680|NCT00241410|BIOLOGICAL|OralvacB2MPL|Comparison of different dosages of drug
48369069|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
48693681|NCT06660953|PROCEDURE|Erector Spinae Plane Block|For ESP, high frequency linear ultrasound probe was planned transversely to the midline and spinous features were visualized. Cervical C7 and T7 vertebrae at the lower end of the scapula, which were accepted as landmarks, were determined and marked with a sterile surgical drawing pen. According to these landmarks, the USG probe was moved 2-3 cm laterally towards the points where kidney transplantation was planned at the T10 vertebral level, and the transverse parts, trapezius, latissimus dorsi, serratus and erector spina muscles were visualized. Using the block needle that can be visualized on USG with in-plane surgery, the skin, subcutaneous tissue and trapezius, latissimus dorsi, serratus and erector spina muscles were passed in a cranio caudal direction and the needle location was confirmed by hydrodissection with 2-5 ml of serum. The distribution of the block procedure and the spread of local anesthetic were linearly visualized with 10 ml bupivacaine and 10 ml 0.9% saline.
48007359|NCT03023488|DEVICE|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
48369070|NCT02625610|DRUG|Leucovorin|"Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
48007360|NCT03023488|DEVICE|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
48007361|NCT04952220|DEVICE|ultrasound|Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
48007362|NCT05448482|PROCEDURE|Transobturator tape|Mid urethral sling for treatment of female stress urinary incontinence
48007363|NCT04428866|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed during visit 1 in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
48007364|NCT04428866|DIAGNOSTIC_TEST|activity monitor|The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days to assess activity, concurrent with CGM sensor wear.
48164675|NCT02958813|BEHAVIORAL|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
48693682|NCT06660953|PROCEDURE|Quadratus Lumborum Block (QLB)|The QL block II was done under aseptic technique, in lateral position with the side intended to block side up. A high frequency ultrasound linear probe covered in sterile sheath was placed anterior and superior to the iliac crest. The three anterior abdominal muscles were visualized. The external oblique muscle was followed posterolaterally until its posterior border was identified. Subsequently, the probe was tilted towards the attachment site of both the internal and external oblique muscles over the quadratus (QL) muscle until the midline of the thoracolumbar fascia was seen as a bright hyperechogenic line located between the posterior border of the quadratus lumborum muscle and the middle thoraco-lumbar fascia (anterior to latissiumus dorsi and erector spinae muscles). A 22-gauge Facet-tip SonoPlex needle of appropriate length estimated from the depth and length of required needle trajectory during scout scanning was inserted via in-plane technique. The needle was directed from a
48693683|NCT05402163|DEVICE|Adaptive DBS|aDBS vs cDBS
48693684|NCT05402163|DEVICE|Continuous DBS|aDBS vs cDBS
48693685|NCT06187766|DIAGNOSTIC_TEST|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
48693686|NCT01145001|BEHAVIORAL|Cognitive Behavioural Therapy|Weekly CBT for all subjects
48693687|NCT01145001|BEHAVIORAL|Contingency Management|incentives given for abstinence based on urine analysis
48693688|NCT01145001|DRUG|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
48693689|NCT04322474|DEVICE|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
48007365|NCT04428866|DIAGNOSTIC_TEST|Mixed meal tolerance test|After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
48007366|NCT04428866|DIAGNOSTIC_TEST|Glucagon Sensitivity Testing|After baseline blood sampling, glucagon will be administered by injection, and blood samples will be collected for analysis of glucose and hormone responses. This will allow us to assess whether sensitivity to glucagon is altered in PBH.
48007367|NCT04428866|DIAGNOSTIC_TEST|Hypoglycemic Hyperinsulinemic Clamp|This test will assess hormonal responses to hypoglycemia. Participants will arrive after an overnight fast. After baseline blood sampling, an infusion of insulin and glucose will be started, and infusions will be adjusted to allow glucose levels to drop very gradually. Blood samples will be collected for measurement of hormonal responses to lowering of glucose. This test will allow us to determine whether secretion of hormones which counteract hypoglycemia (counterregulatory hormones) is reduced in patients with PBH as compared with other groups.
48007368|NCT04428866|DIAGNOSTIC_TEST|analysis of fecal microbiome|Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
48007369|NCT02262351|OTHER|30 Second Pulse Check|To detect atrial fibrillation
48007370|NCT02262351|DEVICE|Watch BP Home A|Blood pressure device that detects atrial fibrillation
48007371|NCT02262351|DEVICE|HeartCheck Hand-held ECG device|To detect atrial fibrillation
48007372|NCT01984138|DRUG|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
48007373|NCT01984138|DRUG|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
48007374|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
48007375|NCT00143611|DRUG|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
48007376|NCT00143611|DRUG|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
48007377|NCT01538693|DRUG|escitalopram oxalate|10 mg 4.5 hours prior to testing
48007378|NCT01538693|DRUG|Cyproheptadine|8mg 4.5 hours prior to testing
48007379|NCT01538693|DRUG|sugar pill|4.5 hour prior to testing
48007380|NCT01538693|OTHER|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
48007381|NCT06297356|DEVICE|Stress ball|Stress balls are soft sponges with a diameter of 2-4 cm. The lightest starting level was preferred for the patients. Patients were allowed to take the stress ball in any hand they wanted. They were asked to squeeze and loosen the ball in their palm at 2-3 second intervals.
48007382|NCT01069055|OTHER|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
48007383|NCT01069055|DRUG|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
48007384|NCT01069055|DRUG|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
48007385|NCT00749775|DRUG|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
48007386|NCT03537118|PROCEDURE|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
48693690|NCT04973683|DRUG|AL101|Given IV
48693691|NCT04973683|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
48693692|NCT06407453|OTHER|control|There will be no interference ergonomics training
48693693|NCT06407453|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
48164676|NCT02958813|BEHAVIORAL|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
48007387|NCT06048484|RADIATION|Stereotactic body radiotherapy (SBRT)|SBRT 40 gray (Gy) over 5 fractions
48164677|NCT02874248|DRUG|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
48164678|NCT02874248|DRUG|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
48164679|NCT02874248|DRUG|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
48164680|NCT02874248|DRUG|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
48164681|NCT02874248|DRUG|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
48164682|NCT04149587|DRUG|Brodalumab|Brodalumab will be administered per dose and schedule specified in the arm.
48164683|NCT05129371|OTHER|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
48164684|NCT05129371|OTHER|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
48164685|NCT04420897|PROCEDURE|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
48164686|NCT02396550|BEHAVIORAL|Positive Expectations|Give positive expectation of the treatment efficacy to patients
48164687|NCT02396550|PROCEDURE|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
48007388|NCT06048484|DRUG|Zimberelimab|240 mg intravenously (IV)
48164688|NCT01295788|DEVICE|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
48164689|NCT01295788|DEVICE|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
48164690|NCT04392479|DRUG|Aflibercept-FOLFIRI|Aflibercept-FOLFIRI
48164691|NCT04392479|DRUG|Aflibercept-mFOLFIRI3|Aflibercept-mFOLFIRI3
48164692|NCT06089967|OTHER|Medical chart review|Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.
48164693|NCT02544113|DRUG|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
48164694|NCT02544113|DRUG|Placebo|Normal transplant immunosuppression
48164695|NCT06194929|DRUG|Defactinib|Defactinib will be administered at 200 mg twice daily orally per arm description.
48164696|NCT06194929|DRUG|Avutometinib|Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
48693694|NCT02709460|PROCEDURE|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
48164697|NCT06194929|DRUG|Encorafenib|Encorafinib administered orally per arm description.
48164698|NCT00609323|DRUG|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
48164699|NCT00609323|DRUG|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
48164700|NCT05615896|DEVICE|Imaging Session|Various scans will be captured on both devices
48164701|NCT05416879|DEVICE|Actigraph GT3X+BT|7 day monitoring of physical activity, sedentary behaviour and sleep using the Actigraph GT3X+BT
48007389|NCT06048484|DRUG|Quemliclustat|100 mg IV
48007390|NCT06048484|DRUG|Etrumadenant|150 mg orally
48007391|NCT06048484|DRUG|Modified FOLFIRINOX|"* Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)"
48164702|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Application of photobiomodulation;~4. Relative isolation (lip bumper, cotton roll and aspirator);~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Cleaning with cotton and water;~7. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~8. Application of mild compressed air on adhesive for 3 seconds;~9. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~10. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~11. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
48693695|NCT02709460|PROCEDURE|Cervical occlusion|Cervical occlusion of the uterine artery
48693696|NCT05582395|DRUG|Mavacamten|Specified dose on specified days
48693697|NCT05582395|OTHER|Placebo|Specified dose on specified days
48693698|NCT03530254|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
48164703|NCT06538142|PROCEDURE|Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Relative isolation (lip bumper, cotton roll and aspirator);~4. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~5. Cleaning with cotton and water;~6. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~7. Application of mild compressed air on adhesive for 3 seconds;~8. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~9. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~10. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
48164704|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment;~3. Relative isolation;~4. Application of photobiomodulation;~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Selective etching of enamel adjacent to demarcated opacities with 35% phosphoric acid for 20s;~7. Active application of universal adhesive (Ambar) on dentin and enamel for 20 seconds (repeat procedure);~8. Application of mild compressed air on adhesive for 5 seconds;~9. Photoactivation for 10s;~10. Restoration with Tetric N Ceram bulk-fill composite resin; with increments up to 4 mm, extending to demarcated opacities;~11. Photoactivation for 10 seconds;~12. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~13. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
48164705|NCT02281214|OTHER|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
48164706|NCT04636879|OTHER|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
48164707|NCT04636879|OTHER|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
48164708|NCT04636879|OTHER|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
48164709|NCT05953818|DIAGNOSTIC_TEST|Chinese version of the Montreal Cognitive Assessment Scale (MoCA) and brain magnetic resonance high resolution structural imaging|Chinese version of Montreal cognitive assessment scale and brain magnetic resonance high resolution structural imaging
48164710|NCT06584981|PROCEDURE|pectoral nerve block (PECS II), parasternal and serratus plane blocks|These block applications are performed under sterile conditions under the guidance of ultrasonography
48164711|NCT06584981|OTHER|analgesic|Analgesia needs of patients who do not receive blockade are met with intravenous drugs.
48693699|NCT03530254|DIAGNOSTIC_TEST|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
48693700|NCT03186508|BEHAVIORAL|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
48693701|NCT03186508|BEHAVIORAL|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
48007392|NCT01531946|PROCEDURE|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~1. Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~2. Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
48007393|NCT00610532|DRUG|phenytoin|intravenous phenytoin (15 mg/kg) single dose
48007394|NCT00610532|DRUG|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
48007395|NCT03553628|OTHER|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
48007396|NCT03553628|OTHER|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
48007397|NCT00670800|DRUG|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
48007398|NCT04118010|DRUG|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
48007399|NCT04118010|DRUG|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
48007400|NCT04118010|DRUG|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
48007401|NCT04118010|DRUG|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
48007402|NCT00846118|DRUG|Pitavastatin|1-4mg/day
48007403|NCT00630968|DRUG|Levetiracetam (Keppra)|
48007404|NCT05268861|BEHAVIORAL|Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
48164712|NCT06047041|BEHAVIORAL|EIS Only|"The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~* Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~* Asks teachers and students to report on 7 areas of student social-emotional functioning~* Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~* Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~* Individualized technical assistance for schools to support EIS implementation."
48164713|NCT06047041|BEHAVIORAL|EIS + ECHO|"EIS + ECHO supports include supports from the EIS Only condition plus:~* Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~  * Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Collaboration with colleagues in schools that are also implementing the EIS.~ * Opportunities to consult with university faculty and content experts in school mental health.~* Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions."
48164714|NCT05869149|BEHAVIORAL|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
48164715|NCT04015128|DEVICE|Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
48164716|NCT03800264|DRUG|Bisoprolol|PREVENTIVE DOUBLE BLINDED
48164717|NCT01880944|OTHER|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
48164718|NCT04368533|DRUG|Livionex Dental Gel|The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.
48164719|NCT04368533|DRUG|A standard children's toothpaste containing 1500 ppm fluoride|The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
48369071|NCT02625610|DRUG|Capecitabine|"Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
48369072|NCT02625610|OTHER|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.
48514026|NCT02048332|BIOLOGICAL|Viral specific VST Infusion|"VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \>1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus."
48514027|NCT04552860|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
48514028|NCT03776149|DIETARY_SUPPLEMENT|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
48514029|NCT03776149|DIETARY_SUPPLEMENT|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
48007405|NCT05268861|BEHAVIORAL|No Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
48007406|NCT00958776|DRUG|Peramivir+SOC|"* Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~* Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
48007407|NCT00958776|DRUG|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
48007408|NCT03731533|BEHAVIORAL|WellStart|"1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
48007409|NCT05053984|PROCEDURE|Percutaneous Echoguided Neuromodulation|Once the nerve is located, a needle is introduced in the vicinity of the nerve and is stimulated using an electrical current with a frequency of 10 Hz, with a pulse width of 250 µs and a tolerable intensity causing a visible muscle contraction for 1.5 minutes.
48007410|NCT06292715|PROCEDURE|microwave ablation of the spleen|Ultrasound-guided percutaneous puncture for splenic ablation treatment
48164720|NCT04095598|DIAGNOSTIC_TEST|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
48164721|NCT00247702|DRUG|warfarin|
48164722|NCT03230071|DRUG|TMBCZG|0.1g per pill which contains 14mg TMBCZG
48164723|NCT03230071|OTHER|placebo|0.1g per pill which contains 0mg TMBCZG
48164724|NCT05138432|BEHAVIORAL|Fruit and Vegetable Prescription Voucher|Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
48164725|NCT05980975|OTHER|Coffee|4th hour, 8th hour and 12th hour of after the surgery, the patients in the coffee group received 10 gr. granulated coffee.
48164726|NCT05980975|OTHER|Hot water|hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of after the operation
48164727|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.
48514030|NCT02737904|OTHER|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
48007411|NCT06292715|OTHER|Splenic artery balloon implantation|Splenic artery balloon implantation
48007412|NCT02470728|OTHER|New Clinical Pathway|
48007413|NCT01242657|BEHAVIORAL|Physical Activity Module|"Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log."
48007414|NCT01242657|BEHAVIORAL|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
48164728|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.
48164729|NCT06058117|OTHER|No intervention|no intervention, this is an observational study
48164730|NCT02788617|DEVICE|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
48164731|NCT05196022|OTHER|Cochlear implant|G2 will receive a cochlear implant during the study
48164732|NCT04050319|DIAGNOSTIC_TEST|Screening and diagnosis if injured|physical therapy
48164733|NCT04092959|BEHAVIORAL|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
48514031|NCT02737904|OTHER|Usual care|Personalised in-patient rehabilitation programme
48164734|NCT04092959|BEHAVIORAL|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
48164735|NCT04092959|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
48164736|NCT03529084|DRUG|EFG816|It will be administered orally daily.
48164737|NCT03529084|DRUG|erlotinib or gefitinib|"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."
48164738|NCT00453934|DEVICE|h-Patch|
48164739|NCT00836914|DRUG|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
48164740|NCT00836914|DRUG|Placebo|Placebo capsules administered orally BID for 7 days
48164741|NCT04595526|PROCEDURE|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
48369073|NCT02625610|DRUG|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
48369074|NCT02625610|DRUG|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
48369075|NCT02625610|DRUG|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
48369076|NCT02625610|DRUG|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
48369078|NCT00308568|BEHAVIORAL|Mailed educational brochure|
48369079|NCT02249858|PROCEDURE|Cranial Vault Hold|
48369080|NCT02249858|PROCEDURE|Cervical HVLA|
48369081|NCT01274104|DIETARY_SUPPLEMENT|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
48369082|NCT01274104|OTHER|Placebo|Placebo
48007415|NCT02426281|DRUG|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
48007416|NCT02426281|DRUG|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
48007417|NCT00640510|DRUG|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
48007418|NCT00640510|DRUG|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
48007419|NCT00676442|DRUG|PN400|naproxen/esomeprazole
48007420|NCT05576116|PROCEDURE|Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)|"Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure."
48007421|NCT05576116|PROCEDURE|Combined Sleeve Gastrectomy and Pancreas transplantation|Simultaneous SG and pancreas transplantation
48007422|NCT06380478|DEVICE|aspicio Monofocal IOL|A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
48369083|NCT00332930|BIOLOGICAL|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
48369084|NCT00332930|BIOLOGICAL|HIV gag-pol antigens and interferon-gamma (IFN-y)|
48369085|NCT04025736|DRUG|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
48369086|NCT04025736|DRUG|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
48693702|NCT05285215|PROCEDURE|Integrated psychological program (IPP)|"Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted."
48007423|NCT03594162|DRUG|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10\^5 or 5 x 10\^5
48007424|NCT03594162|DRUG|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
48164742|NCT04595526|PROCEDURE|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
48164743|NCT06045871|PROCEDURE|Corticotomy followed by compression osteogenesis|Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
48164744|NCT01475019|DRUG|Orlistat|Tablet, 120 mg, three times daily, for six months
48164745|NCT01475019|DRUG|Sibutramine|Tablet, 10 mg, once daily, for six months
48007425|NCT03594162|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
48007426|NCT03594162|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
48007427|NCT01965808|DRUG|LY2157299|Administered orally
48007428|NCT02361528|DRUG|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
48007429|NCT02361528|DRUG|Placebo|placebo subcutaneously, for 5 days
48007430|NCT04282356|DRUG|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
48007431|NCT00157599|PROCEDURE|various diagnostic measures for DVT (e.g., CUS)|
48007432|NCT02409862|DRUG|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
48164746|NCT01475019|BEHAVIORAL|Diet and physical exercise|Hypocaloric diet and regular physical exercise
48164747|NCT04313036|DRUG|Defibrotide|25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for \>/= 21 days or per discretion of enrolling physician.
48164748|NCT00223561|DRUG|methylphenidate|
48164749|NCT02312622|DRUG|Pegylated Irinotecan|Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
48164750|NCT03692689|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
48164751|NCT00321529|DEVICE|motion analysis by durometer|
48164752|NCT02924558|OTHER|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
48164753|NCT02924558|OTHER|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
48164754|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
48164755|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
48164756|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
48164757|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
48164758|NCT05210374|DRUG|Disulfiram|"To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day"
48164759|NCT05210374|DRUG|Copper Gluconate|"To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles"
48164760|NCT05210374|DRUG|Liposomal Doxorubicin (Doxil)|"To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles"
48164761|NCT05880459|DRUG|propofol and magnesium sulphate ,propofol and nalbuphine|"The patients will be randomly divided into 2 groups by using a computer-generated randomization tableAll patients will fast from solids for 8 h and from liquids for 2 h. After arrival at preoperative area an intravenous cannula will be placed in the peripheral vein of right hand for fluid infusion and medicine administration.~All of the patients will be interviewed by the patient sedation satisfaction assessment tool (PSSI) regarding their experience 1 hour after the operation."
48164762|NCT00823004|DRUG|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
48164763|NCT00823004|DRUG|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
48164764|NCT00823004|DRUG|GnRH agonist (buserelin)|50 µg SC twice daily
48164765|NCT00823004|DRUG|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
48164766|NCT00823004|DRUG|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
48164767|NCT01716091|PROCEDURE|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
48164768|NCT05611489|PROCEDURE|Open appendectomy|performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.
48369087|NCT03521089|DEVICE|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
48693703|NCT01601756|DEVICE|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
48693704|NCT01601756|DEVICE|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
48164769|NCT05611489|PROCEDURE|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
48164770|NCT05804981|OTHER|PRO-CS|4 questions about cognitive function added to annual wellness visit protocol
48164771|NCT01620398|BEHAVIORAL|BALANCE|
48369088|NCT05503758|DEVICE|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
48369089|NCT02819882|OTHER|No intervention|
48369090|NCT04084860|DRUG|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
48369091|NCT04084860|DRUG|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
48369092|NCT04084860|BEHAVIORAL|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
48369093|NCT04084860|BEHAVIORAL|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
48164772|NCT01620398|BEHAVIORAL|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
48693705|NCT06659666|DEVICE|COPD Optimiser|Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.
48693706|NCT03957421|OTHER|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
48164773|NCT03681002|BEHAVIORAL|structured lifestyle program|Intensive Lifestyle counseling during one year
48164774|NCT04364503|DEVICE|Multiple interventions depending on diagnostic test being run.|Remnant samples and corresponding data from multiple diagnostic tests will be stored for future research and development.
48164775|NCT00437619|DRUG|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
48164776|NCT00415883|DRUG|Valsartan|
48164777|NCT03974100|BIOLOGICAL|GP2411|60 mg /mL subcutaneous injection every 6 months
48164778|NCT03974100|BIOLOGICAL|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
48164779|NCT03627130|DRUG|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
48164780|NCT03627130|DRUG|Potassium Chloride|Potassium Chloride capsules for 5 days
48164781|NCT02592044|PROCEDURE|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
48164782|NCT02592044|PROCEDURE|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
48164783|NCT02592044|PROCEDURE|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
48164784|NCT05023941|DRUG|Acetazolamide|Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
48007433|NCT02409862|DRUG|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
48164785|NCT05023941|DEVICE|Doctormate® (twice daily for 6 days)|Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.
48164786|NCT05023941|DEVICE|Doctormate® (forth daily for 3 days)|Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
48164787|NCT06338293|DRUG|Inclisiran sodium|The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.
48164788|NCT06338293|DRUG|Rosuvastatin|Rosuvastatin
48164789|NCT04800133|BIOLOGICAL|Tozinameran|mRNA vaccine developed by BioNTech against COVID-19
48164790|NCT04800133|BIOLOGICAL|CoronaVac|Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
48164791|NCT04800133|BIOLOGICAL|CoronaVac, intradermal|Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
48164792|NCT04306549|OTHER|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
48164793|NCT01675050|DRUG|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
48164794|NCT01675050|DRUG|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
48164795|NCT04163185|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 tablet taken once upon the earliest onset of migraine pain.
48164796|NCT04163185|DRUG|Placebo|Placebo tablet taken once upon the earliest onset of migraine pain.
48007434|NCT05371535|DEVICE|MatrixOssTM Bone Graft plus Bio-Gide membrane|To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
48007435|NCT00062582|DRUG|Roflumilast|
48007436|NCT01495481|DRUG|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
48007437|NCT01495481|DRUG|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
48007438|NCT03517709|OTHER|Primary Care Physician Management of blood pressure|"* You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~* Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. ."
48007439|NCT03517709|DEVICE|Withings Smart Blood Pressure Monitor|We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
48007440|NCT00712088|BEHAVIORAL|Project ICARE|Group-level intervention (Project ICARE)
48007441|NCT00712088|BEHAVIORAL|HCT|Offer of HIV counseling and testing
48007442|NCT03636750|DRUG|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
48007443|NCT03161561|OTHER|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
48007444|NCT04212468|OTHER|no intervention|no intervention
48007445|NCT05878548|PROCEDURE|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture|corrective osteotomy and intramedullary telescoping nail for deformed femur and Wagner technique to fix NOF fracture
48007446|NCT06354153|OTHER|Polarity Management Training Program|60 first-line nurse managers received a training program involving theoretical and practical sessions
48007447|NCT02665975|BEHAVIORAL|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
48007448|NCT02665975|BEHAVIORAL|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
48007449|NCT02107703|DRUG|Abemaciclib|Administered Orally
48164797|NCT03348969|DRUG|Mitomycin c|Neoadjuvant Mitomycin C
48164798|NCT04157959|DRUG|SHR4640 dose1|Tablet,dose1,QD
48164799|NCT04157959|DRUG|Febuxostat dose2|Tablet,dose2,QD
48164800|NCT05306340|DRUG|Giredestrant|Participants will receive treatment with giredestrant 30 milligrams (mg) orally once a day (QD) on Days 1-28 of each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
48164801|NCT05306340|DRUG|Exemestane|If exemestane is chosen as the physician's choice of endocrine therapy, the participant will receive exemestane at a dose of 25 mg orally once a day (QD) on Days 1-28 of each 28-day cycle or as per local label, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
48164802|NCT05306340|DRUG|Fulvestrant|If fulvestrant is chosen as the physician's choice of endocrine therapy, the participant will receive fulvestrant in the clinic at a dose of 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, then Day 1 of each cycle thereafter (1 cycle is 28 days) or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
48369094|NCT04000074|BEHAVIORAL|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
48693707|NCT06661486|BEHAVIORAL|Uniformed intervention group|The investigators provide lifestyle intervention through a health education programme which is in a group setting. The sessions consisted of short talks on a health-related topic targeting lifestyle factors associated with dementia risk, followed by group activities that required interactions, cognitive engagement, and the acquisition of certain skills (for example, how to read food labels, how to measure blood pressure, how to recognize signs of depression, et al).
48693708|NCT06661486|BEHAVIORAL|Individualised intervention group|On top of the uniformed intervention group, the individualised intervention group receives also 1:1 sessions every 3 months within 2 years. Participants will review the knowledge taught in the group sessions individually and the investigator will address the participant's concerns and provide advice to the participant for a better lifestyle accordingly.
48693709|NCT06464705|DEVICE|PEMF treatment|Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
48007450|NCT02107703|DRUG|Fulvestrant|Administered IM
48007451|NCT02107703|DRUG|Placebo|Administered Orally
48007452|NCT03611569|DRUG|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
48007453|NCT03611569|DRUG|Placebo|placebo - concentrate for solution for infusion, single dose
48007454|NCT03789201|DEVICE|TMS EEG|attempt to use TMS EEG to measure connectivity between cortical areas
48007455|NCT03789201|DEVICE|TMS fMRI|compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
48007456|NCT04028011|DIAGNOSTIC_TEST|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
48007457|NCT05716035|DRUG|Tocilizumab Injection|Participants will receive IV tocilizumab
48007458|NCT05340153|DRUG|Artemether-Lumefantrine Drug Combination|Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
48007459|NCT05340153|DRUG|Dihydroartemisinin-Piperaquine drug combination|Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
48007460|NCT02920983|DEVICE|somofilcon A|contact lens
48007461|NCT02920983|DEVICE|nelfilcon A II 2|contact lens
48007462|NCT02920983|DEVICE|omafilcon A ll 2|contact lens
48164803|NCT05306340|DRUG|Tamoxifen|If tamoxifen is chosen as the physician's choice of endocrine therapy, the participant will receive tamoxifen at a dose of 20 mg orally QD on Days 1-28 of each 28-day cycle or as per local prescribing information, until unacceptable toxicity or disease progression as determined by investigator according to RECIST v1.1.
48693710|NCT06464705|DEVICE|Placebo treatment|In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
48693711|NCT05881278|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
48164804|NCT05306340|DRUG|Everolimus|Participants will receive treatment with everolimus 10 mg orally QD during each 28-day cycle until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.
48164805|NCT05306340|DRUG|LHRH Agonist|Only premenopausal/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
48164806|NCT05306340|DRUG|Dexamethasone Mouth Rinse|A compounded alcohol-free mouthwash of dexamethasone (0.5 mg in 5 mL) will be supplied, where feasible. It is strongly recommended for prophylaxis or treatment of stomatitis/mucositis. Participants should use the alcohol-free mouthwash of dexamethasone four times QD for 8 weeks started concurrently with study treatment, and use it reactively thereafter with the first appearance of symptoms.
48514032|NCT05860673|PROCEDURE|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
48693712|NCT05658796|BEHAVIORAL|+RxWell|During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.
48693713|NCT05658796|BEHAVIORAL|-RxWell|Treatment as usual
48693714|NCT03076216|DEVICE|OncoSil™|The implantation of OncoSil™ under EUS
48693715|NCT04730635|DRUG|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
48693716|NCT04730635|DRUG|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
48693717|NCT06661694|DRUG|Treatment A|Single 875 mg dose of mevrometostat standard tablet formulation
48693718|NCT06661694|DRUG|Treatment B|Single 875 mg dose of mevrometostat alternative tablet formulation
48693719|NCT06661694|DRUG|Treatment C|Single 875 mg dose of mevrometostat alternative tablet formulation
48693720|NCT06661694|DRUG|Treatment D|Single 875 mg dose of mevrometostat alternative tablet formulation
48693721|NCT06660641|DEVICE|TaurolockTMHep100|1.35% taurolidine containing catheter losk solution
48693722|NCT06660641|DEVICE|0.9 % saline|placebo
48693723|NCT06525636|DRUG|KK8123|Subcutaneous administration
48693724|NCT04763200|DEVICE|Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®|Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.
48693725|NCT04763200|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
48693726|NCT04116411|DRUG|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
48693727|NCT04116411|DRUG|Temozolomide 120 mg|Chemotherapy
48164807|NCT04448925|OTHER|inertial-load exercise (ILE)|Length of time between exercise bouts
48164808|NCT06201715|DRUG|Tofacitinib 5 MG|5mg tofacitinib tablet twice daily
48693728|NCT04116411|RADIATION|Radiotherapy 60 Gy|Radiation therapy
48164809|NCT01280383|DEVICE|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
48164810|NCT06232317|OTHER|Virtual Reality Software|The ReCognitionVR virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.
48164811|NCT06232317|OTHER|Traditional Orientation Methods|Standard-of-care methods to orient patients after surgery
48164812|NCT00104013|DRUG|xaliproden (SR57746A)|
48369095|NCT04000074|BEHAVIORAL|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
48693729|NCT04116411|DRUG|Placebo oral tablet|Placebo treatment of glioblastoma
48693730|NCT03501992|BEHAVIORAL|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
48693731|NCT03501992|BEHAVIORAL|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
48007463|NCT05395819|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
48007464|NCT05395819|PROCEDURE|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
48007465|NCT06469008|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
48693732|NCT03501992|BEHAVIORAL|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
48007466|NCT01800292|DRUG|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
48007467|NCT06030414|BIOLOGICAL|LMN-301|Intranasally administered powder.
48007468|NCT00658281|PROCEDURE|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
48007469|NCT00658281|PROCEDURE|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
48007470|NCT00157378|DRUG|Risperidone, Haloperidol|
48007471|NCT03692546|DRUG|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
48007472|NCT05092659|BEHAVIORAL|Patient interview|Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
48693733|NCT03501992|BEHAVIORAL|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
48693734|NCT00879151|BEHAVIORAL|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
48693735|NCT00879151|BEHAVIORAL|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
48693736|NCT00879151|BEHAVIORAL|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
48007473|NCT04257682|DRUG|Bupivacaine|Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
48007474|NCT04257682|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
48007475|NCT04257682|DRUG|Mepivacaine|Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
48007476|NCT05187416|DIAGNOSTIC_TEST|two-dimensional shear wave elastography|Preoperative ultrasound elastography examination
48007477|NCT05339607|OTHER|Thermal ablation of resection margins by STSC and biliary orifice by cystotome.|Patients who are eligible will undergo thermal ablation of the resection margins.
48164813|NCT06339814|OTHER|Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol|An Eye Movement Desensitization and Reprocessing psychotherapist will hold the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol sessions, dedicated to psychoeducation, imagery exercises, stabilization techniques and the reprocessing of traumatic events. The Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol will be composed of 4 sessions of 120 minutes each.
48164814|NCT06339814|OTHER|Treatment As Usual|Treatment As Usual condition will receive only standard support.
48164815|NCT00733577|DRUG|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
48007478|NCT00322335|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
48007479|NCT00322335|BIOLOGICAL|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
48007480|NCT00322335|BIOLOGICAL|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
48007481|NCT00322335|BIOLOGICAL|Engerix-B|Intramuscular injection into the thigh as a birth dose
48007482|NCT00322335|BIOLOGICAL|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
48007483|NCT00322335|BIOLOGICAL|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
48007484|NCT00322335|BIOLOGICAL|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
48007485|NCT04037202|OTHER|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
48007486|NCT04634149|DRUG|BMS-986036|Specified dose on specified days
48007487|NCT05193474|BEHAVIORAL|integrated palliative care|shared decision making with patient, and timely integrated palliative care according to patient's preference
48007488|NCT00980551|DRUG|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
48007489|NCT00980551|DRUG|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
48164816|NCT01928407|DRUG|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
48007490|NCT00980551|DRUG|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
48007491|NCT00980551|DRUG|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
48007492|NCT02139566|BEHAVIORAL|Video consent (high-tech)|Consent provided by an animated video with captions
48007493|NCT02139566|BEHAVIORAL|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
48007494|NCT02139566|BEHAVIORAL|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
48007495|NCT02139566|BEHAVIORAL|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
48007496|NCT02139566|BEHAVIORAL|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
48007497|NCT06019416|BEHAVIORAL|culturally tailored mindfulness-positive psychological intervention|"This 3-week culturally tailored mindfulness-positive psychological intervention instructs techniques to enhance positive emotions and meditation exercise lasting approximately 30 minutes. The culturally tailored mindfulness-positive psychological intervention consists of four modules: 1) noticing positive events, 2) amplifying positive events, 3) gratitude, and 4) mindfulness and meditation. This 3-dimensional software includes gamification features, including a virtual living room, Japanese garden, art gallery, and meditation garden.~A private office and/or space was utilized to implement the culturally tailored mindfulness-positive psychological intervention for older Korean Americans/immigrants, provided by the recruitment sites such as non-profit organization and church. The private room at the sites had a desktop (or laptop) computer, a virtual reality device (Oculus Quest 2), a chair, and a desk."
48007498|NCT03995576|OTHER|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
48007499|NCT00544076|DRUG|sildenafil citrate|Given orally
48007500|NCT00544076|DRUG|alprostadil|Given intraurethrally
48007501|NCT00544076|PROCEDURE|robotic-assisted laparoscopic surgery|Undergo prostatectomy
48007502|NCT00544076|PROCEDURE|quality-of-life assessment|Ancillary studies
48007503|NCT00544076|OTHER|questionnaire administration|Ancillary studies
48007504|NCT04101266|OTHER|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,25 bupivacain 20 cc .The sham block consisted of after patients were placed in the lateral decubitus position skin preparation, ultrasound scanning of the suprascapular region, and a dry-needling, all performed to preserve patient blinding in the ISB group patients.
48164817|NCT01928407|DRUG|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
48164818|NCT06331533|DRUG|Botulinum toxin A|Intradermal botulinum toxin A was applied to the treatment side
48164819|NCT06331533|DRUG|Placebo|NaCl was injected into the placebo side
48164820|NCT06462612|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
48164821|NCT06462612|DRUG|Placebo|Matching capsules administered orally, once daily
48164822|NCT00000904|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
48164823|NCT00000904|BIOLOGICAL|gp160 MN/LAI-2|
48164824|NCT00000904|BIOLOGICAL|ALVAC(1)120(B,MN)GNP (vCP1433)|
48164825|NCT00000904|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
48164826|NCT00000904|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
48164827|NCT01774461|OTHER|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
48164828|NCT01561885|OTHER|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
48164829|NCT01215032|DRUG|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
48164830|NCT02166047|DRUG|Vesatolimod|Vesatolimod tablet administered orally
48007505|NCT04101266|OTHER|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,25 bupivacain 10 cc .and infraclavicular nerve block with %0,25 bupivacain 10 cc will be applied with ultrasound guidance
48164831|NCT02166047|DRUG|Placebo|Placebo to match vesatolimod tablet administered orally
48007506|NCT03483935|OTHER|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
48164832|NCT03313583|PROCEDURE|Transfusion of blood products|
48164833|NCT06385314|OTHER|Collecting data with oral health related quality of life, dental anxiety and state anxiety|Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.
48164834|NCT06079203|BEHAVIORAL|Emergency Care Redesign (ECR)|"Care Process Redesign: Care process redesign with a shared structured worksheet for data gathering, standardized assessment and referral. Education of all providers (Physician, Nurse, and Social Work Champion) on new processes at huddles and via on-line training, smart phone-compatible animated videos, faculty meetings, e-mail and from ED champions on shift~CDS System: Alerts and new workflow to refer the dyad to social work or care manager. Continued use throughout study period and beyond~Follow up: Within 72 hours of ED visit if discharged home Social Work Champion will have a single phone call. Triadic telephone encounter to ensure understanding of discharge plan, medication management and connection to community services"
48693737|NCT05208606|BEHAVIORAL|Wawokiya Health Advocate|"Study visits 1 and 2 will follow the same broad procedures. Subsequent visits will be structured around needs. WHAs will cover multiple domains of assessment utilizing a visit guide.~Visit 1: Specific topics covered in this visit will include; 1) an explanation of palliative care, study, and WHA role and 2) mapping of providers/family/caregivers The WHA will arrange dates and times for future visits.~Visit 2: Occurs 1 week after the first visit. WHAs will begin to assess patient needs utilizing a needs assessment tool. Specific topics covered will include: 1) Documentation of disease history 2) Needs assessment screen~Following Visits: After visit 2, activities will be based on needs assessed. Activities may entail: 1) Review of palliative care and WHA role, 2) Assessment of needs, 3) Addressing needs 3) Exploring goals of care.~We anticipate patients will receive an average of 2-3 WHA visits per month. Investigators will hold regular supervisory meetings with the WHA."
48007507|NCT06228430|DRUG|Acyclovir 800 mg Tablet|Acyclovir 800 mg Tablet (Test Drug)
48693738|NCT06629220|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
48007508|NCT06228430|DRUG|Zovirax™ 800 mg Tablet|Zovirax™ 800 mg Tablet (Reference Drug)
48007509|NCT04618718|DEVICE|cerebral embolic protection during TAVR|The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
48007510|NCT02009033|DRUG|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
48007511|NCT02009033|DRUG|Hydroxyethylstarch|
48007512|NCT04884152|PROCEDURE|Home Exercise Group|Educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
48007513|NCT04884152|PROCEDURE|Telerehabilitation Group|Telerehabilitation program combined with educational training program about bruxism and the other oral parafunctional activities in patients with myofascial temporomandibular disorders.
48369096|NCT01262040|OTHER|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
48007514|NCT03779412|BEHAVIORAL|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
48007515|NCT03779412|BEHAVIORAL|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
48007516|NCT00733343|DEVICE|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
48007517|NCT01179971|DIETARY_SUPPLEMENT|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
48007518|NCT00864162|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
48514033|NCT05860673|PROCEDURE|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
48007519|NCT00864162|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
48164835|NCT06079203|BEHAVIORAL|Nurse-led Telephonic Care (NLTC)|Telephonic support for dyad for safe ED to home care transition, and to enhance knowledge and management of AD/ADRD and co-morbid conditions. First call to dyad within 72 hours of index ED visit from Registered nurses. Each call \~30 minutes depending on needs and willingness of dyad. Calls also occur at 14 days, and at least monthly thereafter for 6 months. Dyad or nurse can initiate additional as-needed calls and coordinate care and care needs with other providers
48369097|NCT05222516|DRUG|Broncho-Vaxom|Daily administration of Broncho-Vaxom 3.5mg capsules
48369098|NCT05222516|DRUG|Placebo|Daily administration of Placebo capsules
48007520|NCT01282593|OTHER|Impact of CD9 expression level on motility assays|"1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL."
48164836|NCT06079203|BEHAVIORAL|Community Paramedic-led Transitions Intervention (CPTI)|Community paramedics to provide coaching with dyad to improve medication management, outpatient follow up, understanding of red flags necessitating medical care. Home visit within \~5 days of index ED visit. One home visit and three telephone encounters over 30 days
48164837|NCT00978497|DRUG|placebo|oral BID
48164838|NCT00978497|DRUG|ANA598|oral 200mg BID
48007521|NCT01282593|OTHER|Post-transcriptional regulation of CD9|"2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
48007522|NCT00145509|DRUG|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
48164839|NCT00978497|DRUG|ANA598|oral 400mg BID
48164840|NCT00978497|DRUG|Peginterferon|180 μg dose via subcutaneous injection weekly
48007523|NCT00145509|DRUG|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
48007524|NCT00772551|DRUG|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
48007525|NCT00772551|DRUG|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
48007526|NCT02042924|RADIATION|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
48693739|NCT06079190|DRUG|GSK4527226|GSK4527226 will be administered.
48007527|NCT02042924|DEVICE|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
48164841|NCT00978497|DRUG|Ribavirin|oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
48164842|NCT04645953|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3mg)
48164843|NCT04645953|COMBINATION_PRODUCT|1mg AZ010|Subject will receive a single inhaled dose (1mg)
48007528|NCT05243212|BIOLOGICAL|CAR-BCMA|CAR-BCMA T-cells are genetically modified autologous T-cells directed to the B-cell maturation antigen (BCMA). CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells. Upon binding to BCMA-expressing cells, the CAR transmits a signal to promote T cell expansion, activation, persistence and elimination of malignant plasma cells.
48007529|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
48007530|NCT03962803|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
48007531|NCT03962803|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
48007532|NCT01346384|DEVICE|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
48164844|NCT04645953|COMBINATION_PRODUCT|Staccato Placebo|Subject will receive a single inhaled dose (Staccato Placebo)
48693740|NCT06079190|OTHER|Placebo|Placebo will be administered.
48693741|NCT04333888|BEHAVIORAL|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
48693742|NCT06662110|DIAGNOSTIC_TEST|PSRscore|PSRscore calculated based on baseline serum immune proteomics
48164845|NCT01463514|PROCEDURE|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
48164846|NCT01463514|PROCEDURE|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
48164847|NCT02814097|DRUG|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
48164848|NCT02814097|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
48693743|NCT03332017|DRUG|Zanubrutinib|Oral administration as a capsule
48693744|NCT03332017|DRUG|Obinutuzumab|Intravenous administration
48693745|NCT00222235|DRUG|d-cycloserine|
48693746|NCT00222235|DRUG|glycine|
48693747|NCT00222235|DRUG|placebo|
48693748|NCT00386217|BEHAVIORAL|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
48693749|NCT05327660|COMBINATION_PRODUCT|Quitline Treatment as Usual (TAU)|Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).
48164849|NCT03408821|OTHER|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
48007533|NCT05630027|OTHER|Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water|observational, prospective study
48164850|NCT06095154|RADIATION|CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma|CTVp2 is generated by expanding GTVp by 10 mm and including the nasopharyngeal mucosa.
48164851|NCT02735798|DRUG|MM-302|
48693750|NCT05327660|COMBINATION_PRODUCT|Remote Carbon Monoxide (CO) Monitoring|Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor.
48164852|NCT02735798|DRUG|Trastuzumab|
48164853|NCT02811042|DEVICE|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
48164854|NCT02811042|DEVICE|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
48164855|NCT06646367|OTHER|Conventional therapy|All participants in the two groups will receive conventional therapy in the form of TENS and moist heat for 5 weeks.TENS will be applied 5 times a week for 5 weeks at a frequency of 80Hz with 10- to 30-mA intensity for 25 minutes. Four surface electrodes (5x5 cm each) were situated over the painful region in the neck (two electrodes will be placed in either side of the spine high on neck, just underneath the skull and the other two electrodes will be placed about 5cm underneath them) with intensity in the tactile sensation threshold. The hot packs will be applied for 30 minutes on the cervical area, 5 times per week for 5 weeks.
48693751|NCT05327660|COMBINATION_PRODUCT|Incentivized Remote CO Monitoring|Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor.
48693752|NCT05008848|BEHAVIORAL|Smoking Cessation Intervention|Participate in schedule gradual reduction program
48693753|NCT05008848|OTHER|Health Promotion and Education|Receive cessation support messages
48693754|NCT05008848|OTHER|Informational Intervention|Receive NCI's Clearing the Air booklet
48693755|NCT05008848|OTHER|Questionnaire Administration|Ancillary studies
48693756|NCT06659016|DRUG|Fosfomycin 3 g|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months.
48693757|NCT06659016|DIETARY_SUPPLEMENT|Uroxin 4G|Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
48164856|NCT06646367|OTHER|Alexander technique|Women in the experimental group will attend 10 Alexander Technique classes (60 minutes each, twice a week for 5 weeks). The Alexander Technique focuses on body awareness, reducing muscle tension, and improving coordination through three principles: enhanced awareness, purposeful inhibition, and mental imagery. Participants will learn to release habitual muscle tension and explore alternative movement patterns, covering biomechanics and ergonomics of the neck, spine, and limbs. The sessions involve hands-on guidance, verbal instruction, and group activities. Daily practice in a semi-supine position is encouraged to improve posture, coordination, and overall well-being.
48164857|NCT04741815|DEVICE|Forced Air Warming|It consists of the WarmAir® unit and FilteredFlo® blankets. FilteredFlo® blankets are a cover designed to cover the entire body and extremities with air channels that provide the appropriate distribution of patient warm. The WarmAir® warming device connected to the shroud via a pipe; it has three temperature settings, 32.2 C, 37.8 C, and 43.3 C.
48164858|NCT04741815|DEVICE|Peripheral Carbon Fiber Warming|It was developed by the researcher. Designed as gloves and socks, these warming materials have three layers. The first layer in contact with the patient and the third layer in contact with the external environment is a thermal material to maintain body temperature. The second floor consists of a USB-connected carbon fiber warmer and foil.
48164859|NCT00631098|PROCEDURE|venous cannulation|External jugular and cubital vein cannulation
48164860|NCT04090788|DIETARY_SUPPLEMENT|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
48164861|NCT04090788|DIETARY_SUPPLEMENT|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
48164862|NCT03303521|DRUG|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
48164863|NCT03303521|DRUG|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
48693758|NCT06659016|DRUG|Combination of dietary supplement and fosfomycin|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months, combined with an oral formulation of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
25728176|NCT05710081|BIOLOGICAL|Bacterial Lysate|Bacterial Lysate
25728177|NCT05710081|DRUG|Placebo|Placebo
48007534|NCT01166308|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
48007535|NCT01166308|RADIATION|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
48007536|NCT01563068|DRUG|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
48007537|NCT02743572|OTHER|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
48007538|NCT02743572|OTHER|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
48164864|NCT01089387|BIOLOGICAL|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
48164865|NCT01974661|BIOLOGICAL|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
48007539|NCT02743572|OTHER|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
48007540|NCT02743572|OTHER|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
48007541|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
48693759|NCT06635434|DEVICE|AR Pain assessment|Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
48007542|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
48007543|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
48007544|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
48007545|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
48007546|NCT01332942|DRUG|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
48007547|NCT02348528|DRUG|Lenalidomide|
48007548|NCT02348528|DRUG|Dexamethasone|
48164866|NCT00938132|DRUG|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
48164867|NCT00069628|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
48164868|NCT00069628|DEVICE|Continuous Glucose Monitoring System (CGMS)|
48164869|NCT04373356|DEVICE|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
48693760|NCT05394597|OTHER|Repellent lotion|lotion of the repellent active ingredient IR3535
48007549|NCT06391463|OTHER|Carriage of MRB ou BC|Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
48007550|NCT03775668|DRUG|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
48007551|NCT00370526|PROCEDURE|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
48007552|NCT00749931|DEVICE|MarginProbe|Device use to assess margin status of the excised specimen surface.
48007553|NCT00749931|PROCEDURE|Lumpectomy|Standard of care lumpectomy procedure
48007554|NCT04201561|DRUG|sodium selenite pentahydrate|High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.
48007555|NCT04201561|DRUG|Normal saline|Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
48164870|NCT04373356|DEVICE|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
48164871|NCT04092621|DRUG|Amiodarone in Parenteral Dosage Form|Amiodarone IV
48164872|NCT04092621|DRUG|Amiodarone Pill|Amiodarone tablet
48164873|NCT04092621|PROCEDURE|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
48164874|NCT04092621|DRUG|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
48164875|NCT06297031|OTHER|heat application|• Thermophore Application: Before the application, the thermophore was wrapped in a towel to prevent skin damage. Studies in the literature indicate that the surface temperature of the thermophore should be 38-45 °C. For this reason, water with a temperature of 70°C when measured with a thermometer was added into the thermophore. Similarly, studies in the literature indicate that thermophore application should be applied for 10-30 minutes. Therefore, the application takes 20 minutes. The researcher stayed with the woman for 20 minutes.
48693761|NCT05394597|OTHER|Repellent Wipe|wipe of the repellent active ingredient IR3535
48693762|NCT06661499|OTHER|establish an artificial neural network model|to establish an artificial neural network model for pathogen diagnosis in ICU pneumonia
48007556|NCT04201561|DRUG|Chemotherapy|Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
48007557|NCT05548608|OTHER|Reposition error (RE), pain at target positions of RE and flexibility of the TLF were assesed with iphone tiltmeter app, VAS and goniometric platform, respectively.|Target positions of reposition error were: 30º forward bending and 15º backward bending in sitting and standing.
48007558|NCT03945812|DRUG|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
48007559|NCT03945812|OTHER|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
48007560|NCT03945812|OTHER|Saline|Saline 9%
48007561|NCT00685932|DEVICE|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
48007562|NCT00515307|PROCEDURE|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
48007563|NCT05584007|DRUG|Flucloxacillin Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by blinded flucloxacillin 500mg for 2 days, reaching a total of 7 days of antibiotic treatment
48007564|NCT05584007|DRUG|Placebo Only Product in Oral Dose Form|Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
48007565|NCT00004031|BIOLOGICAL|rituximab|375 mg/m2 IV every 21 days
48007566|NCT00004031|DRUG|CHOP regimen|
48007567|NCT00004031|DRUG|carmustine|
48007568|NCT00004031|DRUG|cyclophosphamide|
48007569|NCT00004031|DRUG|doxorubicin hydrochloride|
48164876|NCT05188547|DEVICE|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
48164877|NCT01093183|DRUG|lenalidomide|Given PO
48164878|NCT01093183|DRUG|cyclophosphamide|Given PO
48164879|NCT01093183|OTHER|laboratory biomarker analysis|Correlative studies
48164880|NCT01093183|OTHER|questionnaire administration|Ancillary studies
48164881|NCT01093183|OTHER|quality-of-life assessment|Ancillary studies
48164882|NCT05393388|DRUG|[18F]AV-1451|\[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
48514034|NCT02975947|DEVICE|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher \& Paykel's HUMIGARD system (Fisher \& Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
48693763|NCT00097227|BIOLOGICAL|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
48693764|NCT00097227|DRUG|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
48693765|NCT00097227|DRUG|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
48693766|NCT03967977|DRUG|Tislelizumab|200 mg administered Intravenously (IV) as specified in the treatment arm
48693767|NCT03967977|DRUG|Placebo|Tislelizumab placebo to match
48693768|NCT03967977|DRUG|Cisplatin|70 mg/m2 administered IV as specified in the treatment arm
48693769|NCT03967977|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 administered IV as specified in the treatment arm
48007570|NCT00004031|DRUG|etoposide|
48007571|NCT00004031|DRUG|prednisone|
48007572|NCT00004031|DRUG|vincristine sulfate|
48007573|NCT00004031|PROCEDURE|bone marrow ablation with stem cell support|
48007574|NCT00004031|PROCEDURE|peripheral blood stem cell transplantation|
48007575|NCT00004031|RADIATION|radiation therapy|
48007576|NCT05118841|DRUG|ZX-4081|Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
48007577|NCT04310761|PROCEDURE|one single blastocyst transfer, both fresh and warmed|Ultrasound guided transvaginal embryo transfer.
48007578|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
48007579|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
48007580|NCT01193907|BIOLOGICAL|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
48007581|NCT01193907|BIOLOGICAL|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
48164883|NCT05307237|DEVICE|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
48164884|NCT05307237|DEVICE|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
48164885|NCT00761410|DEVICE|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
48007582|NCT04069403|OTHER|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
48007583|NCT05060393|BEHAVIORAL|Mindfulness-based cognitive therapy|Mobile application, mindfulness-based therapy
48164886|NCT00659971|DRUG|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
48693770|NCT03967977|DRUG|Carboplatin|Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
48693771|NCT00428571|PROCEDURE|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
48693772|NCT00428571|PROCEDURE|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
48693773|NCT00428571|PROCEDURE|Intensive Medical Management|lifestyle, diet, medication optimization
48007584|NCT02379585|DRUG|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
48007585|NCT02379585|DRUG|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
48007586|NCT02379585|DRUG|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
48007587|NCT02379585|DRUG|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
48007588|NCT02379585|DRUG|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
48007589|NCT02379585|DRUG|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
48007590|NCT00882531|DRUG|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
48007591|NCT00882531|DRUG|placebo|
48007592|NCT00006219|DRUG|clarithromycin|
48007593|NCT00006219|DRUG|prasterone|
48007594|NCT03561974|DEVICE|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
48007595|NCT02584309|DRUG|Dexrazoxane|
48007596|NCT02584309|DRUG|Doxorubicin|
48007597|NCT06131515|DEVICE|extra corporeal shock wave therapy device|"Patients were seated in a relaxed position with their forearm and finger placed on the table. The median nerve was identified at the pisiform level of the proximal carpal tunnel, with the palm facing upwards. rESWT was delivered with the Physio Shock Wave Therapy system .The rESWT probe was located and oriented perpendicularly on the median nerve, and treatment comprised graduated shots at a bar pressure of 4 and a pulse repetition frequency of 5Hz for each patient ( The treated area was parallel to the median nerve from the pisiform level to 2 cm proximal to the inlet of the carpal tunnel with equal diffusion of 800, 900, 1000, 1100 shots from first to fourth session respectively. The procedure was painless, and there was no need for additional anesthesia or analgesia.~In the control group, sham rESWT just made the same sound without energy emission"
48007598|NCT05429450|DRUG|Methotrexate|Three periocular injections of methotrexate at week 0, week 3 and week 6.
48007599|NCT05429450|DRUG|Triamcinolone Acetonide|Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
48693774|NCT00863044|PROCEDURE|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
48007600|NCT04731844|DRUG|Curcumin plus Piperine|Curcumin with piperine is a well-tolerated over-the-counter supplement.
48007601|NCT04820816|OTHER|pelvic tilt effect on balance, sensory integration and risk of fall|BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
48369099|NCT02011646|BEHAVIORAL|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
48007602|NCT04623164|DRUG|Cocktail from complex phytoadaptogens (CFA)|Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.
48693775|NCT00863044|PROCEDURE|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
48693776|NCT00289172|BIOLOGICAL|Live attenuated human rotavirus vaccine|
48693777|NCT03839849|PROCEDURE|: i-PRF|The description of this intervention has been already given before
48693778|NCT03839849|PROCEDURE|saline|The description of this intervention has been already given before
48164887|NCT02551692|DRUG|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
48164888|NCT02551692|DRUG|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
48164889|NCT02551692|DRUG|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
48164890|NCT02551692|DRUG|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
48164891|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
48164892|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
48164893|NCT04963998|DEVICE|Application of Wound Dressings with Copper Oxide|Application of Wound Dressings with Copper Oxide on chronic foot wounds in diabetic patients
48164894|NCT05371678|OTHER|Therapeutic motor control interventions|Treatment duration will be 8 weeks, two sessions a week. Each session will take approximately 60 minutes. This intervention includes education, dietary advices, core stabilization exercises and pelvic floor muscle training with surface Electromyographic-Biofeedback. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Core stabilization exercises will be performed 2 days a week with a physiotherapist and the session will be approximately 50 minutes. Diaphragmatic breathing will be taught to children in breathing exercises. The pelvic floor muscles exercises will be do by surface Electromyographic-Biofeedback. The Electromyographic-Biofeedback teaches the child how to relax the external anal sphincters with visual and auditory feedback techniques.The child will learn to relax the pelvic floor muscles during defecation by monitoring the recorded electromyographic activity.
48369100|NCT02011646|BEHAVIORAL|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
48369101|NCT03698032|DIETARY_SUPPLEMENT|Water|Participants will consume water only
48514035|NCT02975947|DEVICE|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
48693779|NCT05656469|OTHER|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
48693780|NCT05852938|DRUG|BION-1301|BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
48693781|NCT05852938|DRUG|Placebo|Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
48693782|NCT01814397|DRUG|Anastrozole|1 mg orally daily
48693783|NCT01814397|DRUG|exemestane|25 mg orally daily
48693784|NCT01814397|DRUG|letrozole|2.5 mg orally daily
48693785|NCT02767869|DRUG|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
48693786|NCT02767869|DRUG|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
48693787|NCT03935672|PROCEDURE|PET-CT scans|"Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV_P. bGTV_P will then be used as an adjunct to help us delineate the GTV_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
48007603|NCT04623164|PROCEDURE|Standard non-surgical periodontal treatment (NSPT)|Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
48007604|NCT03242681|PROCEDURE|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
48007605|NCT04655911|BIOLOGICAL|ABO-101|Gene therapy rAAV9.CMV.hNAGLU
48007606|NCT05758740|BEHAVIORAL|E-health enhanced behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, a conventional behavioural change intervention will begin following a standardized intervention implementation manual and the physical activity amount will be logged by the participants using a logbook. Physical activity counselling will be conducted by a trained research assistant face-to-face at the elderly community centre. Each counselling session lasts for one hour and is once per week for 12 weeks.
48007607|NCT05758740|BEHAVIORAL|Conventional behavioural change intervention|Participants will first receive a face-to-face brisk-walking training programme with lectures and demonstrations following a standardized brisk training content. The training will be provided face-to-face at the elderly community centres and parks. Each training session lasts for one hour and is two times per week for two weeks. After that, e-health enhanced behavioural change intervention will begin following a standardized intervention implementation manual and using participants' own smartphones installed with two Apps (i.e., Samsung Health and WhatsApp). The physical activity amount will be logged by the smartphone using Samsung Health. Physical activity counselling will be conducted by a trained research assistant remotely using a smartphone. The remote counselling sessions totally last for accumulatively 1 hour per week for 12 weeks.
48007608|NCT02135224|DRUG|Fentanyl|
48007609|NCT02135224|DRUG|Normal saline|
48007610|NCT02756793|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
48007611|NCT02756793|OTHER|Standard of Care Treatment|"May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
48007612|NCT05878613|DEVICE|treadmill training with KT group (TTKT group)|The area to be taped will be cleaned with an alcohol swab, and the I-shaped elastic KT was applied to the four trunk muscles from their insertion to their origin. Patients will then undergo treadmill walking with easy speed control for 20 minutes. The training will be immediately stopped if the subject complain of fatigue during treadmill training; training will be resumed after sufficient rest.
48007613|NCT05878613|DEVICE|treadmill training without KT group (TT group)|General treadmill training without taping will be carried out for the same time as the gait training of the experimental group, and the treadmill speed will also be a comfortable speed in the same manner as in the experimental group.
48007614|NCT03307668|DEVICE|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
48007615|NCT03307668|DEVICE|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
48164895|NCT05371678|OTHER|Conventional treatment|Treatment duration will be 8 weeks. This intervention includes education, dietary advices and laxative therapy. In the education will be taught to the child and their parents in the first session. Dietary advices will be given by specialist dietitian. Laxative therapy will be adjusted at different doses according to the child's age and weight. Laxative therapy will be administered to children by a specialist doctor.
48164896|NCT02631616|DRUG|Somatostatin|Monthly injections of Somatostatin
48007616|NCT02515539|DEVICE|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
48007617|NCT02806726|DEVICE|iDesign 1.3-PRESBY treatment|Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
48164897|NCT01724047|BEHAVIORAL|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
48164898|NCT01724047|BEHAVIORAL|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
48164899|NCT05269303|DEVICE|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
48007618|NCT02806726|DEVICE|iDesign 1.3 treatment|Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
48007619|NCT04400721|DRUG|Erector spinae plane block with ropivacaine 3.75mg/ml|Single shot erector spinae block
48007620|NCT04908254|DEVICE|Crossover Device (PCD or Dayspring - alternate to first group)|Cross over arms after a month of use and a month of washout period
48164900|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock 360 app.|"Visit 5, during week 4.~Randomization will be applied:~Active group will use all functionalities of Insulclock 360. They will have reminders, all their information and statistics at the disposition of the patient and healthcare providers, they have the assistance if desired of an ally or caregiver, a bolus calculator and the rest of functionalities described in the protocol."
48164901|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.|"Visit 5, during week 4.~Randomization will be applied:~Masked group will remain with the masked system, without functionalities."
48164902|NCT03377283|BIOLOGICAL|organ perfusion with rabbit anti-thymocyte globulin (rATG)|
48164903|NCT03377283|OTHER|organ perfusion with saline|
48164904|NCT01827449|DEVICE|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
48164905|NCT03359187|OTHER|Normal saline with salt/Soda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
48369102|NCT03698032|DIETARY_SUPPLEMENT|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
48693788|NCT03935672|PROCEDURE|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV_P and bGTV_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
48693789|NCT03935672|PROCEDURE|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
48693790|NCT03935672|PROCEDURE|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
48693791|NCT05128864|PROCEDURE|High Tibial Osteotomy|Surgery procedure - High Tibial Osteotomy
48164906|NCT03359187|OTHER|Clinacanthus nutans|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
48164907|NCT03359187|OTHER|Boesenbergia rotunda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
48164908|NCT05255276|DRUG|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
48369103|NCT03698032|DIETARY_SUPPLEMENT|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
48369104|NCT03608124|BEHAVIORAL|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
48369105|NCT02569996|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
48369106|NCT00222066|PROCEDURE|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
48514036|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
48693792|NCT04935190|DIAGNOSTIC_TEST|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
48007621|NCT05473975|PROCEDURE|Placement of the EGG|Placement of the EGG before the beginning of the thrombectomy
48007622|NCT00101101|DRUG|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
48007623|NCT00101101|DRUG|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
48164909|NCT05255276|DRUG|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
48164910|NCT05255276|DRUG|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
48164911|NCT05255276|DRUG|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
48164912|NCT02461719|DRUG|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
48164913|NCT02461719|DRUG|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
48164914|NCT06038929|DEVICE|Vagal nerve stimulant|Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
48693793|NCT05224076|OTHER|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
48164915|NCT02578667|DEVICE|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
48693794|NCT01232504|DRUG|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
48514037|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
48514038|NCT04160624|PROCEDURE|transcatheter aortic valve replacement|Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
48514039|NCT02598921|RADIATION|three dimensional ultrasound|
48007624|NCT00101101|DRUG|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
48007625|NCT00101101|DRUG|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
48007626|NCT00101101|DRUG|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
48164916|NCT05269147|PROCEDURE|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
48164917|NCT00724750|DEVICE|Gauze suction (G-SUC)|Negative pressure wound therapy
48007627|NCT00101101|BIOLOGICAL|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
48007628|NCT00101101|DRUG|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
48007629|NCT04296396|DRUG|0 to 20 tablets of oxycodone 5mg|Individualized opioid prescription protocol (IOPP) that includes shared decision making
48007630|NCT04296396|DRUG|Fixed opioid prescription|20 tablets of oxycodone 5mg
48007631|NCT03817619|DRUG|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
48007632|NCT03817619|DRUG|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
48164918|NCT00724750|DEVICE|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
48164919|NCT04385940|DIETARY_SUPPLEMENT|Ddrops® products, 50,000 IU, Oral|Vitamin D3
48007633|NCT01206985|OTHER|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
48007634|NCT04403321|DRUG|Tacrolimus|Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
48164920|NCT04385940|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 1000IU
48164921|NCT03305471|DRUG|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
48007635|NCT04403321|DRUG|Placebo (for Tacrolimus)|placebo will be given at 1mg bid.
48007636|NCT01079871|OTHER|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
48164922|NCT03305471|DRUG|Placebo|Placebo matching stock solution in bottle
48164923|NCT03305471|DRUG|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
48164924|NCT03305471|DRUG|DS-2330b Tablet|DS-2330b as tablet formulation
48164925|NCT04960436|PROCEDURE|Meniscus Allograft Transplantation|patients received surgery of Meniscus Allograft Transplantation
48164926|NCT04960436|PROCEDURE|Meniscectomy|patients received surgery of Meniscectomy
48164927|NCT01021202|PROCEDURE|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
48164928|NCT00220441|BEHAVIORAL|Aerobic exercise|
48514040|NCT02598921|DEVICE|Office hysteroscopy|
48164929|NCT04995406|DIAGNOSTIC_TEST|ISIT-TB prototype|Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
48007637|NCT01356433|DRUG|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
48007638|NCT01356433|DRUG|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
48007639|NCT02730416|DRUG|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
48007640|NCT01302821|BIOLOGICAL|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
48007641|NCT01302821|DRUG|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
48693795|NCT01232504|DRUG|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
48007642|NCT01302821|RADIATION|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
48007643|NCT06123884|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).
48007644|NCT06123884|DRUG|Cisplatin|the usage and dosage should be determined by the investigator
48007645|NCT06123884|DRUG|Bevacizumab Injection|Strength 100 mg/4 mL, recommended dose 15 mg/kg body weight, administered every 3 weeks (15 mg/kg, Q3W)
48007646|NCT06123884|DRUG|carboplatin|the usage and dosage should be determined by the investigator
48007647|NCT06123884|DRUG|Paclitaxel for Injection|the usage and dosage should be determined by the investigator
48007648|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
48007649|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
48007650|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
48007651|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
48007652|NCT00949624|DRUG|CP-868,596|Oral tablet 100 mg BID continuous
48007653|NCT00949624|DRUG|Docetaxel|Intravenous 100 mg/m2 every three weeks
48007654|NCT00949624|DRUG|CP-868,596|Oral tablet 60 mg BID continuous
48007655|NCT00949624|DRUG|AG-013736|Oral tablet 5 mg BID continuous
48007656|NCT00949624|DRUG|Docetaxel|Intravenous 75 mg/m2 every three weeks
48164930|NCT05235776|OTHER|observation|observation
48164931|NCT01095601|DRUG|Avanafil|"* Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~* Treatment B: 2x100 mg Formulation II avanafil tablet, fed~* Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~* Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
48007657|NCT06153290|PROCEDURE|Chiropractic adjustment|A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
48007658|NCT06153290|PROCEDURE|Sham adjustment|A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
48007659|NCT03663595|OTHER|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
48007660|NCT03663595|OTHER|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
48007661|NCT05715567|OTHER|Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)|Following the intervention of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (NCT03374800)
48164932|NCT05470218|OTHER|Meal|Liquid mixed meal with different amounts of protein and leucine
48693796|NCT01232504|DRUG|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
48514041|NCT03714919|DRUG|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
48007663|NCT06265402|PROCEDURE|Tab block versus retrolaminar block in abdominal plastic surgery|i inject 20ml bupivacine either 4mg dead in each side
48007664|NCT01144156|DRUG|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
48007665|NCT03066765|DEVICE|Linguaflex Tongue Retractor|Tongue implant
48007666|NCT02577965|PROCEDURE|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
48164933|NCT01931683|DRUG|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
48514042|NCT03714919|DRUG|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
48514043|NCT03714919|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
48514044|NCT03714919|DRUG|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
48693797|NCT00272155|BEHAVIORAL|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
48007667|NCT02577965|DEVICE|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
48007668|NCT02142530|DRUG|Carfilzomib|
48693798|NCT00272155|BEHAVIORAL|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
48693799|NCT00785590|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
48693800|NCT06659237|DIAGNOSTIC_TEST|16s rRNA or shotgun metagenomics|16s rRNA or shotgun metagenomics on oral and fecal samples
48693801|NCT05517980|DRUG|KP104|Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
48693802|NCT03815058|BIOLOGICAL|Autogene cevumeran|Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.
48693803|NCT03815058|DRUG|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
48693804|NCT05611645|RADIATION|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
48693805|NCT05611645|DRUG|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
48693806|NCT05502926|DIAGNOSTIC_TEST|lung ultrasound score|peroperative and postoperative 12 point trans-thoracic lung ultrasound
48693807|NCT03983382|DIAGNOSTIC_TEST|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
48693808|NCT04472650|DRUG|Sitravatinib|Administered orally as a free base capsule
48693809|NCT04472650|DRUG|Sitravatinib|Administered orally as a malate salt capsule
48693810|NCT00883545|OTHER|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
48693811|NCT00883545|OTHER|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
48007669|NCT02142530|DRUG|Belinostat|
48007670|NCT02419846|OTHER|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
48007671|NCT02419846|PROCEDURE|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
48007672|NCT02419846|OTHER|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
48007673|NCT02419846|OTHER|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
48007674|NCT02419846|OTHER|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
48007675|NCT02419846|OTHER|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
48164934|NCT01931683|DEVICE|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
48164935|NCT06042270|DIETARY_SUPPLEMENT|Betaine|3 grams per day for \~4 weeks
48164936|NCT06042270|DIETARY_SUPPLEMENT|Placebo|3 grams per day for \~4 weeks
48164937|NCT05499247|OTHER|SkinQ Glow Bright Wonder Mask|"Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical"
48693812|NCT04985500|PROCEDURE|ESP block|peripheral nerve block
48693813|NCT04985500|PROCEDURE|PIF block|peripheral nerve block
48693814|NCT04985500|PROCEDURE|Ultrasound|Ultrasound guidance
48693815|NCT04985500|DRUG|Bupivacain|10-20 mL of 0.25% bupivacaine
48693816|NCT00113399|BIOLOGICAL|filgrastim|
48693817|NCT00113399|DRUG|cisplatin|
48693818|NCT00113399|DRUG|docetaxel|
48693819|NCT00113399|DRUG|fluorouracil|
48693820|NCT00113399|DRUG|paclitaxel|
48693821|NCT00113399|RADIATION|radiation therapy|
48693822|NCT06658535|DRUG|dodecafluoropentane (0.025 mL/kg)|dodecafluoropentane (0.025 mL/kg)
48693823|NCT06658535|DRUG|dodecafluoropentane (0.032 mL/kg)|dodecafluoropentane (0.032 mL/kg)
48007676|NCT01336478|PROCEDURE|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
48007677|NCT01336478|PROCEDURE|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
48007678|NCT05856838|DEVICE|NovaSure ablation|Ablation of the endometrial tissue using the NovaSure device
48007679|NCT02059148|DRUG|LY2835219|Administered orally.
48693824|NCT06658535|DRUG|dodecafluoropentane (0.050 mL/kg)|dodecafluoropentane (0.050 mL/kg)
48693825|NCT03245268|PROCEDURE|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
48693826|NCT02483923|DRUG|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
48164938|NCT04714697|DRUG|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
48693827|NCT02483923|DRUG|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
48693828|NCT04877288|BIOLOGICAL|Belatacept|Specified dose on specified days
48164939|NCT05928858|DRUG|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
48693829|NCT04877288|DRUG|Tacrolimus|Specified dose on specified days
48164940|NCT05928858|DRUG|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
48693830|NCT04877288|DRUG|Cyclosporine A|Specified dose on specified days
48693831|NCT04877288|DRUG|Mycophenolate Mofetil|Specified dose on specified days
48693832|NCT04877288|DRUG|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
48693833|NCT04877288|DRUG|Corticosteroids|Specified dose on Specified days
48693834|NCT04207411|DRUG|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
48693835|NCT04207411|DRUG|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
48514045|NCT03296111|OTHER|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.~They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).~Patients will be asked to complete several questionnaires :~* Questionnaire about the characteristics of ocular neuropathic pain (7 items)~* DEQ-5 (Dry Eye Questionnaire)~* ODI (Ocular Surface Disease Index)~* BPI (Brief Pain Inventory)~* HADS (Hospital Anxiety and Depression Scale)"
48693836|NCT00626509|DRUG|sunitinib malate|
48693837|NCT00626509|PROCEDURE|adjuvant therapy|
48693838|NCT00626509|PROCEDURE|neoadjuvant therapy|
48693839|NCT00626509|PROCEDURE|therapeutic conventional surgery|
48693840|NCT06344104|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm"
48007680|NCT05958212|BEHAVIORAL|Gait training program|"Gait training program at PolyU is a supervised rehabilitation program performed on the dual-belt treadmill. It consists of forward walking at increased speed over the affected leg and retro walking (backward walking) at individual's own pace (5 minutes/set for three sets, with rest periods in each session). This program also consists of a standardized set of warm-up and cool-down exercises at each training session.~Participants will also receive conventional physiotherapy treatment in the outpatient physiotherapy clinic."
48164941|NCT04056117|BIOLOGICAL|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
48164942|NCT04056117|BIOLOGICAL|MenACWY|Control vaccine administrated to adults and infants
48164943|NCT04056117|BIOLOGICAL|Rabies|Control vaccine administrated to children
48693841|NCT06344104|DRUG|Placebo|Placebo tablet administered orally, once daily (QD).
48164944|NCT04056117|BIOLOGICAL|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
48164945|NCT04056117|BIOLOGICAL|Placebo|Control administrated to adults
48693842|NCT05675722|BIOLOGICAL|biologic vaginal-construct implantation|biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
48164946|NCT01654445|DRUG|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
48164947|NCT03315988|OTHER|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
48693843|NCT05432596|DRUG|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
48693844|NCT05432596|DRUG|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
48693845|NCT05432596|DRUG|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
48164948|NCT02053740|DRUG|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
48164949|NCT02053740|DRUG|Routine western medicine|
48693846|NCT05432596|DRUG|Vehicle|Vehicle topical solution
48693847|NCT06614101|OTHER|Exhaled air analysis|The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
48693848|NCT03407079|OTHER|Sucralose|Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.
48693849|NCT03407079|OTHER|Placebo|Placebo capsules will be taken orally for 28 days
48693850|NCT05327127|DRUG|K-877-ER|K-877-ER tablet
48693851|NCT05327127|DRUG|CSG452|CSG452 tablet
48693852|NCT05327127|DRUG|Placebo|Placebo tablet
48693853|NCT05549232|DEVICE|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
48693854|NCT04629391|DEVICE|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
48693855|NCT06517277|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
48693856|NCT00423982|DRUG|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
48693857|NCT00423982|DRUG|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
48693858|NCT04136093|OTHER|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
48693859|NCT04136093|OTHER|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
48693860|NCT04136093|OTHER|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
48007681|NCT05958212|BEHAVIORAL|Conventional training only|Conventional physiotherapy treatment in the outpatient physiotherapy clinic.
48007682|NCT06099262|BEHAVIORAL|GenPMTO|GenPMTO is a parenting programme which involves trained practitioners using active teaching approaches (such as group problem-solving, role-play, and video modelling) to support caregivers in using positive parenting strategies at home. The programme is designed to improve parenting practices, as well as a range of outcomes for young people, including improving academic performance, reducing school exclusions, and reducing offending and criminal behaviour. The version of the programme investigated in this project is delivered to groups of parents.
48164950|NCT04545983|OTHER|Motion Analysis|Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
48164951|NCT04509583|DIETARY_SUPPLEMENT|PROFortil|Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months
48164952|NCT04509583|OTHER|Vitamin E|Only Vitamin E (Enat 400, once per day) in 3 months
48693861|NCT02566187|DRUG|Fimasartan/Atorvastatin Combination Tablet|
48693862|NCT02566187|DRUG|Fimasartan|
48693863|NCT02566187|DRUG|Atorvastatin|
48693864|NCT06401694|OTHER|Home-delivered meals|Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
48693865|NCT06401694|OTHER|Wellness check and socialization visit|At-home delivery with opportunity for driver observation and interaction
48693866|NCT06401694|BEHAVIORAL|Community Health Worker calls|Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination
48007683|NCT05689840|PROCEDURE|Receiving inpatient surgical intervention|Receiving inpatient surgical intervention in Peking Union Medical College Hospital
48007684|NCT01404468|DEVICE|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
48007685|NCT01404468|OTHER|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
48164953|NCT03051529|OTHER|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
48693867|NCT06401694|OTHER|Supplemental grocery bag|Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
48007686|NCT01404468|DEVICE|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
48007687|NCT01086592|OTHER|No intervention|Daily life activities
48007688|NCT01086592|OTHER|Strong progressive strengthening exercises of lower limbs|Lower limb weight
48007689|NCT01086592|OTHER|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
48007690|NCT01086592|OTHER|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
48007691|NCT01800071|DRUG|MVA-EBNA1/LMP2 vaccine|
48693868|NCT04249492|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
48007692|NCT00688766|DRUG|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
48007693|NCT00688766|DRUG|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
48007694|NCT00688766|OTHER|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
48007695|NCT03189394|BEHAVIORAL|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
48007696|NCT03189394|BEHAVIORAL|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
48007697|NCT03189394|BEHAVIORAL|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
48007698|NCT05884697|OTHER|K-Talk Intervention (Storytelling and K-Bot)|The K-Talk intervention group receives a combination of a storytelling intervention and an artificial intelligence chatbot (K-Bot) education.
48514046|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction by Therapeutic VR|Therapeutic VR+MBT was provided using a head-mounted display which designed to enclose eyes and block external stimuli almost entirely. Patients can see immersive natural scenes through VR devices and hear stereo sounds through headphones. We uploaded a programme, which was designed to induce recordings of guided meditations (The same as the MBT), musics for meditation and consists of meditation-videos of 40 minutes. We will guide patients to choose their favorite meditation videos, such as forest, seaside, lake, snow mountain, field and so on.
48693869|NCT04249492|DEVICE|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
48007699|NCT05884697|OTHER|Storytelling Intervention|The storytelling intervention features 12 authentic stories from young Korean immigrants and Americans. Each video is about 3 minutes long and includes stories from 1st, 1.5, and 2nd generation young Korean individuals, highlighting their perceptions of HPV and HPV vaccines, and their experiences with HPV vaccination.
48007700|NCT05884697|OTHER|K-Bot Intervention|The K-Bot intervention is a conversational and button-based artificial intelligence Chatbot that is available in both English and Korean.
48007701|NCT05884697|OTHER|Written Information|The written information provided includes the Centers for Disease Control and Prevention's (CDC) details on HPV and HPV vaccines.
48007702|NCT04447092|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)
48007703|NCT04447092|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)
48007704|NCT04447092|DRUG|Pembrolizumab|Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)
48693870|NCT06247345|DRUG|ADEL-Y01 - healty participants|In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
48693871|NCT06247345|DRUG|Placebo - Healthy Participants|In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
48007705|NCT04447092|DRUG|Oxaliplatin|Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)
48164954|NCT01742949|DEVICE|Heated humidification (ThermoSmart)|Heated Humidification (ThermoSmart) Turned On
48693872|NCT06247345|DRUG|ADEL-Y01 - MCI/AD|"In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy."
48007706|NCT04447092|DRUG|Leucovorin|Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
48007707|NCT04447092|DRUG|Irinotecan|Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)
48007708|NCT04447092|DRUG|5FU|5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
48164955|NCT01742949|DEVICE|No Humidification|Heated Humidification (ThermoSmart) Turn Off
48007709|NCT00279708|DRUG|Atorvastatin|Placebo vs. Atorvastatin
48007710|NCT00279708|OTHER|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
48007711|NCT01956110|DRUG|Follitropin Delta (FE 999049)|
48007712|NCT01956110|DRUG|Follitropin Alfa (GONAL-F)|
48007713|NCT05228782|OTHER|HOW R U? Intervention|HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
48007714|NCT05439356|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
48164956|NCT05561296|PROCEDURE|Femtosecond laser assisted cataract surgery with astigmatism management|The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.
48164957|NCT01956071|DEVICE|WAPD|The objective was to assess workers' acceptability of the Pennington Pedal Desk.
48369107|NCT04556942|DIAGNOSTIC_TEST|Flow Mediated Dilation (FMD) measurement|FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or \> 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
48514047|NCT05637736|BEHAVIORAL|Mindfulness-based Stress Reduction|39 participates randomized and allocated to this group. MBT was conducted as an 8-week group intervention. Sessions typically began with formal mindfulness meditations that include breathing exercises, prolonged expiratory relaxation, body scan, and meditation. MBT was delivered by the first author, who has specialized training in mindfulness meditation.
48514048|NCT03188744|OTHER|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
48514049|NCT03188744|OTHER|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
48514050|NCT05493501|DRUG|Aumolertinib monotherapy|Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
48514051|NCT05493501|DRUG|Osimertinib monotherapy|80 mg tablet administered orally, once daily
48514052|NCT05493501|DRUG|Pemetrexed|Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
48693873|NCT06247345|DRUG|Placebo - MCI/AD|"In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions."
48693874|NCT05532735|BIOLOGICAL|ANXV|ANXV (Human recombinant Annexin A5 protein)
48693875|NCT04188067|DEVICE|ACTIVE rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
48693876|NCT04188067|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
48693877|NCT06402526|OTHER|Mobile Epilepsy Education Package|"MEEP education section contains a range of topics. After completing the relevant section at the end of each week, participants complete the end-of-section test and switch to the next week's topic. Completion of the first part will take approximately 90-120 minutes per week for a total of 4 weeks of use.~Parental Monitoring Section, parents can actively record information on the mobile application related to their child's diagnosis (anonymous); treatments; timing and frequency of the seizures; and appointments; and schedule treatment and examination reminders to optimize compliance. Completion of this second part will take approximately 1-2 minutes and depends on the parental choice to use and how much information they would like to share. The second part, together with the first part, will be evaluated for a total of 1 month."
48693878|NCT06402526|OTHER|Standard care consisting of epilepsy education|This standard care includes the information and education provided by nurses and physicians during visits and hospitalisations. Standard information and education include topics such as: counseling by the neurologist regarding seizure safety precautions, prognosis, and sudden unexpected death in epilepsy (SUDEP); provision of paper or electronic resources regarding epilepsy; and telephone support provided by neurology clinic nurse regarding any issues or concerns). Information and education is usually provided orally and through printed brochures.
48514053|NCT05493501|DRUG|Cisplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
48007715|NCT05439356|DRUG|Placebo colchicine|Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
48164958|NCT04653207|OTHER|Glucose Solution 1|50g glucose dissolve in 300ml of water
48164959|NCT04653207|OTHER|Glucose Solution 2|50g glucose dissolve in 300ml of water
48514054|NCT05493501|DRUG|Carboplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
48514055|NCT05493501|DRUG|Paclitaxel|Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
48514056|NCT05493501|DRUG|Nab paclitaxel|Administered by IV Infusion given over 4 fixed cycles per prescribing information.
48514057|NCT05493501|DRUG|Gemcitabine|Administered by IV Infusion over 4 fixed cycles per prescribing information.
48693879|NCT06661473|DEVICE|Avance Solo Negative Pressure Wound Therapy|Avance Solo NPWT 7-14 days after high-risk revision TKA or THA.
48164960|NCT04653207|OTHER|Glucose Solution 3|50g glucose dissolve in 300ml of water
48164961|NCT04653207|OTHER|Sucrose/Isomaltulose 100:0|50g sucrose dissolve in 300ml of water
48514058|NCT01831102|OTHER|none- observational study|
48514059|NCT00862615|OTHER|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
48514060|NCT05955183|DRUG|AZD5055|AZD5055 will be given orally to randomized participants as per the arm they are assigned.
48514061|NCT05955183|DRUG|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
48369108|NCT04556942|OTHER|Blood pressure, pulse and blood oxygen saturation measurement|"Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient."
48514062|NCT05186792|OTHER|Test:mycoplasma|Retrospective analysis of records of recruits to a previous mycoplasma study.
48369109|NCT04556942|OTHER|ST George Respiratory Questionnaire|The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
48007716|NCT04047082|DIAGNOSTIC_TEST|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
48007717|NCT00360334|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
48007718|NCT00360334|DRUG|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
48007719|NCT05268250|BEHAVIORAL|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
48007720|NCT01100008|PROCEDURE|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
48369110|NCT04556942|OTHER|Physical activity level (PAL) measurement|PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
48693880|NCT06116916|DRUG|KHK4951|KHK4951 eye drop for 36 weeks until end of the trial
48007721|NCT00093457|DRUG|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
48007722|NCT01434290|RADIATION|36.25 Gy IMRT|36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
48007723|NCT01434290|RADIATION|51.6 Gy IMRT|51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
48007724|NCT01657110|OTHER|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
48514063|NCT00074828|DRUG|LY517717|
48514064|NCT00074828|DRUG|enoxaparin|
48514065|NCT00005553|PROCEDURE|Catheter Ablation|
48693881|NCT06116916|DRUG|Aflibercept Injection|Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
48693882|NCT06658158|BEHAVIORAL|Cognitive correction and stimulus control|"Cognitive correction:~a) correcting unrealistic sleep expectations; b) maintaining a natural sleep onset; c) avoiding worry about losing control oversleep; d) not associating nocturnal dreaming with adverse daytime consequences; e) avoiding feelings of frustration due to one night of poor sleep; f) developing tolerance to the impact of insomnia and avoiding compensatory behaviors.~Stimulus control:~1. Minimize wakefulness during time in bed and establish a positive association between sleepiness and the bed.~2. Use the bed only for sleep and sexual activities.~3. Go to bed only when feeling sleepy at night or at the designated sleep time.~4. If unable to fall asleep within approximately 20 minutes of being in bed, leave the bedroom, engage in relaxing activities, and return to bed when feeling sleepy. Repeat this process if unable to fall asleep within approximately 20 minutes.~5. Wake up at the same time every morning, including weekends."
48007725|NCT04260815|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
48007726|NCT01445392|BIOLOGICAL|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles
48007727|NCT01445392|DRUG|Pemetrexed|500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
48007728|NCT01445392|DRUG|Cisplatin|75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
48007729|NCT01445392|BIOLOGICAL|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
48007730|NCT04508569|BEHAVIORAL|Big Decisions|Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
48164962|NCT04653207|OTHER|Sucrose/Isomaltulose 0:100|50g isomaltulose dissolve in 300ml of water
48514066|NCT03149796|OTHER|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
48164963|NCT04653207|OTHER|Sucrose/Isomaltulose 50:50|25g sucrose and 25g isomaltulose dissolve in 300ml of water
48369111|NCT04556942|BIOLOGICAL|Withdrawal of a blood sample|5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
48514067|NCT05411341|DEVICE|Argos (Alcon Laboratories, Inc.)|An ocular biometry examination will be performed on the affected eyes using the Argos device.
48514068|NCT05411341|DEVICE|IOLMaster 500 (Carl Zeiss Meditec AG)|An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
48514069|NCT01108718|OTHER|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
48514070|NCT01108718|OTHER|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
48514071|NCT05375253|BIOLOGICAL|Donor Enriched Activated Natural Killer Cell Infusion|αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
48007731|NCT00571129|PROCEDURE|DCR with no tubes or mitomycin|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
48514072|NCT00741338|BIOLOGICAL|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
48693883|NCT06658158|BEHAVIORAL|Sleep hygiene education|"1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight.~7. Avoid daytime napping."
48693884|NCT06657885|DRUG|his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi|"cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48"
48693885|NCT05304975|BEHAVIORAL|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
48693886|NCT05304975|BEHAVIORAL|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
48514073|NCT00741338|DRUG|Cyclosporine A (CsA)|Orally three times daily.
48514074|NCT00741338|DRUG|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
48514075|NCT02017470|OTHER|Gender-tailored women's heart health outpatient programme|
48514076|NCT02210624|BIOLOGICAL|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
48007732|NCT01620580|BEHAVIORAL|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
48369112|NCT04556942|PROCEDURE|Immediate Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
48514077|NCT05376644|DRUG|99mTc-ADAPT6|One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
48514078|NCT05376644|DRUG|99mTc-DARPinG3|One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
48514079|NCT05283564|OTHER|Percussive Ventilation Breathhold SABR (PVB-SABR)|Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
48514080|NCT03316274|DRUG|Nivolumab|Given via intralesional injection
48514081|NCT05309811|DEVICE|RLRL therapy|Each RLRL treatment lasts three minutes. RLRL treatments will be performed twice a day, with at least four hours between each RLRL treatment.
48007733|NCT01620580|BEHAVIORAL|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills \& adherence to renal diet and fluid restriction without discussing any intervention with the group.
48514082|NCT05309811|DRUG|Routine IOP-lowering medications|Medications prescribed for IOP control by glaucoma specialists in the outpatient.
48514083|NCT02633748|BEHAVIORAL|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
48693887|NCT05304975|BEHAVIORAL|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
48693888|NCT05304975|OTHER|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
48693889|NCT05522582|DRUG|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
48693890|NCT05522582|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
48693891|NCT05522582|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
48693892|NCT03890926|RADIATION|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
48693893|NCT02819258|OTHER|Endodontic treatment|
48693894|NCT05315115|OTHER|Sham intervention|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.
48693895|NCT05315115|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
48693896|NCT05315115|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
48693897|NCT04178525|DEVICE|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
48693898|NCT04178525|DEVICE|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
48693899|NCT01685242|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
48693900|NCT01685242|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
48007734|NCT04209361|OTHER|Questionnaire|Data will be obtained through a printed questionnaire for assessment of knowledge, attitude and practice of dentists at military hospitals regarding child abuse and neglect. The collected data will be saved and tabulated on a computer and finally will be statistically analyzed.
48007735|NCT06146387|DIETARY_SUPPLEMENT|Investigational Formula|Participants in this arm will receive stage 1 and stage 2 investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
48693901|NCT00488020|PROCEDURE|stem cells transplant|
48693902|NCT06659562|DRUG|HER-096|Administered as a single dose via s.c. injection
48693903|NCT06659562|DRUG|HER-096|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
48693904|NCT06659562|DRUG|Placebo|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
48693905|NCT06653764|OTHER|Chest physiotherapy and aerobic exercise training|Chest Physiotherapy including Percussion, vibration and shaking; along with it aerobic exercises such as walking up and down stairs, bedside ambulation, step walking
48693906|NCT01132651|OTHER|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
48693907|NCT01132651|OTHER|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
48007736|NCT06146387|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
48007737|NCT06146387|DIETARY_SUPPLEMENT|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
48007738|NCT03438526|DRUG|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
48693908|NCT05734443|BEHAVIORAL|non-treadmill trip training|Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.
48693909|NCT05734443|BEHAVIORAL|treadmill trip training|Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
48007739|NCT03438526|DRUG|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
48007740|NCT01988571|DRUG|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
48007741|NCT01988571|DRUG|Placebo|One placebo tablet taken each morning orally for 24 months.
48007742|NCT03693768|BEHAVIORAL|Health coaching|Health coaching
48007743|NCT03766100|BEHAVIORAL|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
48693910|NCT03305588|DEVICE|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
48007744|NCT01479907|DIETARY_SUPPLEMENT|Synbiotics|12 gr in 250 cc of water once daily X 15 days
48007745|NCT01479907|DIETARY_SUPPLEMENT|Placebo|12 gr in 250 cc of water once daily X 15 days
48007746|NCT00626262|DRUG|Esomeprazole|Oral and Intravenous
48693911|NCT03220477|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
48693912|NCT03220477|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
48007747|NCT00006184|DRUG|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
48007748|NCT00006184|DRUG|Bortezomib|Induction chemotherapy: 1.3 mg/m\^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
48514084|NCT02301195|OTHER|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
48693913|NCT03220477|DRUG|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
48007749|NCT00006184|DRUG|Cyclophosphamide|Induction chemotherapy: 600 mg/m\^2 day 4 Transplant: 1200 mg/m\^2 intravenous x 4 days (days -6, -5, -4, -3)
48007750|NCT00006184|DRUG|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
48007751|NCT00006184|DRUG|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
48007752|NCT00006184|DRUG|Etoposide|Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
48007753|NCT00006184|DRUG|Fludarabine phosphate|Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
48007754|NCT00006184|DRUG|Prednisone|60 mg/m\^2 day 1-4
48007755|NCT00006184|DRUG|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
48007756|NCT00006184|DRUG|Methotrexate|Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
48007757|NCT00006184|BIOLOGICAL|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m\^2 subcutaneously every day, days 1-4
48007758|NCT00006184|BIOLOGICAL|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) \> 1000/ul x 2 days
48007759|NCT05697042|BEHAVIORAL|MY-Skills for Long COVID|8 week online intervention with therapeutic yoga and self-management education
48007760|NCT02941679|DRUG|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
48007761|NCT02941679|DRUG|HGP1011|Boehringer Ingelheim
48007762|NCT02941679|DRUG|HCP0910|GlaxoSmithKline
48164964|NCT04653207|OTHER|Sucrose/Isomaltulose 60:40|30g sucrose and 20g isomaltulose dissolve in 300ml of water
48164965|NCT04653207|OTHER|Sucrose/Isomaltulose 70:30|35g sucrose and 15g isomaltulose dissolve in 300ml of water
48164966|NCT04653207|OTHER|Sucrose/Isomaltulose 80:20|40g sucrose and 10g isomaltulose dissolve in 300ml of water
48164967|NCT02032420|BEHAVIORAL|STAR|
48164968|NCT02032420|BEHAVIORAL|ART|
48164969|NCT02127814|DIETARY_SUPPLEMENT|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
48514085|NCT02301195|OTHER|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
48164970|NCT02358499|DRUG|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
48164971|NCT00141908|DRUG|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
48164972|NCT00141908|DRUG|Castor oil|weekly IM injections
48164973|NCT05570578|DEVICE|HD-tDCS|The anode electrode will be placed over Broca's area, 4 cathode electrodes will be placed at about 2 cm distance each from the anode in 4 directions.
48164974|NCT05017688|PROCEDURE|Blood and stool sample collection|Collection of blood samples (55 mL) Collection of fecal samples (10g)
48693914|NCT03293849|OTHER|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
48693915|NCT06658392|OTHER|cognitive tasks|no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
48693916|NCT03720626|DRUG|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
48693917|NCT03390504|DRUG|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
48693918|NCT03390504|DRUG|Vinflunine|Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.
48693919|NCT03390504|DRUG|Docetaxel|Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.
48693920|NCT03390504|DRUG|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
48693921|NCT03390504|DEVICE|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
48693922|NCT05546658|DRUG|Psilocybin|Psilocybin administration under supportive conditions
48007763|NCT00200954|DIETARY_SUPPLEMENT|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
48007764|NCT00200954|DIETARY_SUPPLEMENT|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
48164976|NCT04636099|DEVICE|CT angiography（CTA）|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
48164977|NCT00484172|PROCEDURE|blood draws|
48164978|NCT02773407|DRUG|Azithromycin|
48164979|NCT02773407|DRUG|Co-trimoxazole|
48164980|NCT00189683|PROCEDURE|Monitoring|
48164981|NCT00189683|PROCEDURE|Xeloda|
48369113|NCT04556942|PROCEDURE|Delayed Bronchoscopic Lung Volume Reduction|Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 6-8 weeks after T0 and 3-4 days after T1
48514086|NCT05173857|DEVICE|Advance PTX|PTA in Dysfunctional Haemodialysis Access
48514087|NCT05173857|DEVICE|Advance LP (Low Profile)|Plain Old Balloon Angioplasty (POBA)
48514088|NCT05173857|DRUG|Paclitaxel (PTX)|Paclitaxel (PTX)
48514089|NCT04657211|OTHER|prospective observational cohort study|prospective observational cohort study
48369114|NCT05263973|OTHER|Music|The infants in the music group (Acem Aşiran Maqam music prepared by TÜMATA group) will be applied music for a about total of 12 minutes, starting 3 minutes before the ROP examination and continuing during the ROP examination, 3 minutes after ROP examination
48693923|NCT06544616|DRUG|JNJ-64042056|JNJ-64042056 will be administered intramuscularly.
48693924|NCT06544616|DRUG|Placebo|Placebo will be administered intramuscularly.
48693925|NCT05072314|DRUG|lidocaine 2% and 10%|"Lidocaine infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).\*~2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
48514090|NCT05013125|DIAGNOSTIC_TEST|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
48007765|NCT02904811|OTHER|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
48007766|NCT02904811|OTHER|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
48007767|NCT03612037|DIETARY_SUPPLEMENT|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
48007768|NCT03612037|DIETARY_SUPPLEMENT|Cellulose|600mg/day oral dose of placebo cellulose
48007769|NCT06336772|DEVICE|Restylane Shaype|Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion
48514091|NCT02257775|GENETIC|n/a - observational|
48693926|NCT05072314|DRUG|Placebo|"Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only"
48693927|NCT00887367|DRUG|GSK598809|Two 175 mg doses of GSK598809 will be given.
48007770|NCT06336772|DEVICE|Juvéderm Volux|Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
48007771|NCT02963493|DRUG|Melphalan flufenamide (Melflufen)|
48514092|NCT02904941|BIOLOGICAL|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
48007772|NCT02963493|DRUG|Dexamethasone|IV dexamethasone may be substituted for oral dexamethasone in the US. Oral only in Europe.
48007773|NCT05597007|BEHAVIORAL|VPICS Clinic|Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
48007774|NCT03306342|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
48007775|NCT01569529|BEHAVIORAL|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
48007776|NCT00895180|BIOLOGICAL|olaratumab|Given IV
48007777|NCT00895180|BIOLOGICAL|ramucirumab|Given IV
48007778|NCT05487963|DRUG|Tofacitinib Citrate|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
48007779|NCT05487963|OTHER|placebo ointment|Topical application of a pea-sized amount of ointment (active or vehicle) over a maximum surface of 30 cm2 up to 2 times a day.
48007780|NCT00178945|DRUG|Botulinum Toxin Type A|
48007781|NCT00450710|PROCEDURE|ileal interposition with a sleeve gastrectomy|
48007782|NCT00753207|DRUG|epirubicin hydrochloride|
48007783|NCT00753207|DRUG|lapatinib ditosylate|
48007784|NCT00753207|OTHER|biomarker analysis|
48007785|NCT00753207|OTHER|immunohistochemistry staining method|
48007786|NCT00753207|OTHER|liquid chromatography|
48007787|NCT00753207|OTHER|mass spectrometry|
48007788|NCT00722917|DRUG|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
48007789|NCT00722917|DRUG|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
48007790|NCT00722917|DRUG|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
48007791|NCT00722917|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
48007792|NCT00722917|DRUG|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
48007793|NCT03913949|DRUG|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
48369115|NCT00381017|DRUG|Peg interferon alpha-2b|
48164982|NCT04281875|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
48164983|NCT05497037|DEVICE|PRF stimulation|One time 500 kHZ stimulation for 15 min
48164984|NCT05497037|DEVICE|Sham stimulation|Sham stimulation for 15 min
48693928|NCT00887367|OTHER|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
48007794|NCT03167762|DEVICE|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
48007795|NCT05291299|BEHAVIORAL|Anti-inflammatory diet|Patients randomized to the intervention group will work with a registered dietitian to create an individualized diet program to help reduce inflammation and Rheumatoid arthritis related symptoms.
48007796|NCT05291299|OTHER|Control/Standard of Care|Patients randomized to the control group will be following standard of care where their doctor will instruct them to follow a Mediterranean diet and provides them with an instructional sheet.
48007797|NCT00931307|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
48007798|NCT03989193|DEVICE|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
48007799|NCT00595582|DIETARY_SUPPLEMENT|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
48007800|NCT04237077|OTHER|telephone coaching program|telephone coaching program : 7 phone calls by nurse
48007801|NCT04237077|OTHER|no telephone coaching program|no telephone coaching program : 7 phone calls by nurse
48007802|NCT05598229|OTHER|Tik Tok|Encourage and do not restrict watching Tik Tok
48007803|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
48007804|NCT03109678|DEVICE|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
48007805|NCT03109678|DEVICE|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
48164985|NCT00981929|DRUG|Tramadol|50 mg single oral dose
48164986|NCT00981929|DRUG|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
48164987|NCT00981929|DRUG|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
48164988|NCT03329547|DRUG|Cefixime test capsule|"SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule."
48164989|NCT03329547|DRUG|Cefixime reference capsule|"Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule."
48164990|NCT06149052|OTHER|SMART TRAINING|Patients in Group A received SMART training intervention. For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given (26). For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up
48369116|NCT04606225|DRUG|Losartan|administration of losartan (50 mg) (oral) Cozaar Oral Tablet
48369117|NCT04606225|DRUG|Placebo Oral Tablet|administration of placebo (oral)
48693929|NCT02676947|DRUG|Tocilizumab|
48007806|NCT03109678|DEVICE|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
48369118|NCT03054311|BEHAVIORAL|Lifestyle Matters|
48369119|NCT02399345|DRUG|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
48693930|NCT02580123|BEHAVIORAL|Intervention taught by trained educators|
48693931|NCT04870944|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48164991|NCT06149052|OTHER|FIRE training|Patients in Group B was received foot intensive rehabilitation (FIRE).The FIRE intervention was include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were targeted the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension
48693932|NCT04870944|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
48693933|NCT04870944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48693934|NCT04870944|PROCEDURE|Echocardiography|Undergo ECHO
48693935|NCT04870944|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IV
48693936|NCT01016119|DRUG|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
48693937|NCT01016119|DRUG|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
48693938|NCT05213637|BIOLOGICAL|Expanded Activated Lymphocytes (EAL)|12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
48693939|NCT05213637|PROCEDURE|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
48514093|NCT02904941|DEVICE|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
48693940|NCT06662149|OTHER|Pleasant Smell|The participants will be in an environment with an assumed pleasant smell while consuming the meal.
48693941|NCT06662149|OTHER|Unpleasant Smell|Participants will be in an environment with an assumed unpleasant smell while consuming the meal.
48007807|NCT03262948|DRUG|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
48007808|NCT03262948|DRUG|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
48007809|NCT03262948|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
48007810|NCT00228891|PROCEDURE|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
48164992|NCT04313790|DRUG|Heparin Infusion|500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)
48164993|NCT04313790|OTHER|subcutaneous heparin|5000 unit subcutaneous heparin /8 hours control group n=(20)
48164994|NCT01557699|BIOLOGICAL|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
48164995|NCT01557699|BIOLOGICAL|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
48369120|NCT02399345|DRUG|sofosbuvir (SOF)|tablet
48514094|NCT02904941|PROCEDURE|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
48693942|NCT01887938|BIOLOGICAL|HGT-1110|Participants will receive IT injection of HGT-1110.
48693943|NCT01986231|DRUG|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
48693944|NCT00234663|DRUG|PTC124|
48693945|NCT02110680|DEVICE|Sports TENS 2|transcutaneous electric stimulation
48693946|NCT00515606|DRUG|helium:oxygen|
48693947|NCT06662318|DRUG|Fentanyl Citrate|Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.
48693948|NCT06662318|DRUG|Dexmedetomidine|Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.
48693949|NCT06662318|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
48007811|NCT00228891|PROCEDURE|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
48007812|NCT02267629|DRUG|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
48693950|NCT06568003|DEVICE|Transcatheter Tricuspid Valve Intervention|Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
48007813|NCT05857657|OTHER|: lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes for one session
48007814|NCT05857657|OTHER|propriocepticve neuromuscular facilitation|:Proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
48007815|NCT05857657|OTHER|propriocepticve neuromuscular facilitation with lower leg kinesiotaping|Kinesiotaping will be applied on tibialis anterior for 30 minutes with proprioceptive neuromuscular facilitation hold relax technique will be applied to ankle with 15-30 repititions on affected side for one session
48369121|NCT02399345|DRUG|ribavirin (RBV)|tablet
48693951|NCT05332639|BEHAVIORAL|Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's) tool|We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
48007816|NCT02759120|DRUG|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight \> 50 kilograms for up to 36 months
48007817|NCT02759120|OTHER|No Intervention: Standard of Care|Standard of care
48007818|NCT02529384|OTHER|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
48007819|NCT03085329|DEVICE|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
48007820|NCT03085329|DEVICE|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher \& Paykel bubbler device, which is the standard of care at Nationwide Children's.
48007821|NCT01158625|OTHER|Change of time of administration|Change of time of administration
48007822|NCT02534792|OTHER|Revalvulation|
48007823|NCT03289104|DEVICE|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
48007824|NCT03289104|DEVICE|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
48164996|NCT01557699|BIOLOGICAL|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
48164997|NCT02998918|DIETARY_SUPPLEMENT|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
48514095|NCT01905436|DRUG|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
48693952|NCT05332639|BEHAVIORAL|Standard Crohn's Disease Education|The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
48007825|NCT02151708|DRUG|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
48007826|NCT02151708|DRUG|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
48007827|NCT03819231|DRUG|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
48369122|NCT04951726|DRUG|Neostigmine|cholinesterase inhibitor
48514096|NCT02892552|RADIATION|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
48514097|NCT02892552|RADIATION|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
48007828|NCT03819231|BEHAVIORAL|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
48007829|NCT03819231|DRUG|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
48007830|NCT03819231|BEHAVIORAL|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
48007831|NCT00649064|DRUG|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
48007832|NCT01464515|DEVICE|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
48007833|NCT01464515|DEVICE|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
48007834|NCT05594342|DRUG|Ivabradine 7.5Mg Tab|Patients will receive ivabradine 7.5 mg twice daily via oral route after dobutamine infusion by 30 minutes.
48007835|NCT05594342|DRUG|DOBUTamine Injectable Solution|Dobutamine infusion by a dose that is titrated according to blood pressure Ranging from 5 to 20 ug/kg/minute
48007836|NCT04431362|BEHAVIORAL|Self-selected music|Participants will be given iPods and headphones to listen to their music
48007837|NCT04359368|OTHER|collection of patient data|Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
48007838|NCT04670991|RADIATION|EXATRAC imaging|Exatrac imaging performed before the standard CBCT imaging prior to each chemotherapy session
48007839|NCT02967250|DRUG|ursodeoxycholic acid|Subjects will be provided \~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over \~2 weeks to a stable dose for 4 weeks.
48007840|NCT06110676|BIOLOGICAL|LZM012|Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
48007841|NCT06110676|BIOLOGICAL|Secukinumab|Cosentyx
48007842|NCT01176292|DEVICE|Rotating Platform High-Flex Cruciate Substituting TKA|
48007843|NCT01176292|DEVICE|Rotating Platform Cruciate Substituting TKA|
48007844|NCT02976896|DRUG|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
48007845|NCT04261270|DRUG|ASC09F+Oseltamivir|ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
48007846|NCT04261270|DRUG|Ritonavir+Oseltamivir|Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
48007847|NCT04261270|DRUG|Oseltamivir|75mg ,once a day
48007848|NCT01502644|DRUG|Oxycodone|Daily dosage up to 120 mg
48007849|NCT01502644|DRUG|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
48164998|NCT02998918|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
48164999|NCT01797705|DEVICE|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
48693953|NCT05555641|DRUG|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
48693954|NCT05555641|DRUG|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
48007850|NCT01502644|DRUG|Placebo|Placebo-matching oxycodone, placebo-matching morphine
48007851|NCT01870622|PROCEDURE|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
48007852|NCT01870622|PROCEDURE|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
48007853|NCT05844696|DEVICE|Soterix MXN-5 HD-tES Model 5005A. Medtronic Percept DBS platform.|"〔Part 1〕Using Soterix MXN-5 HD-tES Model 5005A. Three treatment groups: sham control, continuous tDCS, slow-oscillatory tDCS.~〔Part 2〕Using Medtronic Percept DBS platform. Single group:Neuromodulation."
48007854|NCT00706966|DRUG|dutasteride|6 months of dutasteride 3.5 mg daily
48007855|NCT03950284|DEVICE|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
48007856|NCT01589432|DRUG|ABT-639|two 50 mg oral capsules
48007857|NCT01589432|DRUG|Placebo|2 placebo capsules
48007858|NCT01589432|DRUG|Lidocaine|3mg/kg infusion over 30 minutes
48165000|NCT05376787|DEVICE|Medline NE Grounding Pad|Split Universal Grounding Pads
48165001|NCT04499014|DEVICE|ultrasound|5 days a week, a total of 10 sessions
48165002|NCT04973332|DEVICE|Intracranial thrombectomy stent|Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
48693955|NCT00311740|DRUG|Valsartan|
48007859|NCT04772534|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
48007860|NCT00702130|DRUG|Pravastatin|pravastatin 40mg per os once daily
48007861|NCT06130722|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
48007862|NCT03018392|DEVICE|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
48007863|NCT01920815|OTHER|No interventions|
48007864|NCT00481728|DRUG|Tolterodine|Single dose per patient as determined by protocol.
48007865|NCT00481728|PROCEDURE|Filling cystometry|This is a procedure.
48007866|NCT00481728|PROCEDURE|Intravesical neurostimulation|This is a procedure.
48007867|NCT02215590|DEVICE|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle stretching, and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises for 40 minutes with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by an increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 10 min of cool-down exercises~22 training sessions of 60 minutes each, twice a week."
48693956|NCT00311740|DRUG|Hydrochlorothiazide|
48693957|NCT06325657|BIOLOGICAL|RSVpreF vaccine|RSVpreF vaccine
48693958|NCT06325657|BIOLOGICAL|Placebp|Placebo
48693959|NCT02617563|DEVICE|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
48693960|NCT05538065|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
48693961|NCT05538065|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
48693962|NCT05538065|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
48693963|NCT00431444|DRUG|Raloxifene|
48693964|NCT00431444|DRUG|Zoledronic acid|
48693965|NCT00431444|DRUG|Placebo oral pills|
48693966|NCT00431444|DRUG|Placebo intravenous (i.v.) infusion|
48007868|NCT05924035|DEVICE|HBOT|HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
48007869|NCT03973242|DEVICE|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
48007870|NCT03934866|RADIATION|Low Dose CT scan|Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
48007871|NCT04528810|OTHER|not applicable (Observational Study)|This is an observational study and does not include interventions.
48514098|NCT04994405|PROCEDURE|Tourniquet Pressure|"The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used."
48693967|NCT05618340|DEVICE|Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter|"Routinely placing a coronary sinus electrode catheter, puncturing the interatrial septum, placing one sheath into the left atrium, confirming that the catheter is well in place, and setting the treatment time of the pulse ablation system in advance.~Pulmonary vein-by-pulmonary vein ablation using a circular pulse catheter, waiting for the end of the pulse ablation phase and immediate effect confirmation."
48007872|NCT01807052|OTHER|laboratory biomarker analysis|Correlative studies
48007873|NCT00436748|DRUG|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
48007874|NCT00436748|DRUG|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
48007875|NCT05221853|DIAGNOSTIC_TEST|cardiovascular magnetic resonance|CMR scan at 3 Tesla
48007876|NCT03624621|BEHAVIORAL|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
48007877|NCT03624621|DEVICE|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
48007878|NCT03624621|BEHAVIORAL|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
48007879|NCT03624621|DEVICE|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
48514099|NCT02963233|PROCEDURE|Closed reduction and percutaneous pinning and immobilization|
48514100|NCT02963233|PROCEDURE|Non-operative reduction and immobilization|
48514101|NCT01690702|DRUG|Epirubicin|
48514102|NCT01690702|DRUG|nab-Paclitaxel|
48693968|NCT05568680|BIOLOGICAL|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
48007880|NCT00748644|DRUG|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
48007881|NCT00748644|DRUG|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
48007882|NCT00183716|BEHAVIORAL|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
48007883|NCT00183716|BEHAVIORAL|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
48007884|NCT05818371|DIAGNOSTIC_TEST|Sonographic determination of the optic nerve sheath diameter|Ultrasound-based determination of the optic nerve sheath diameter
48007885|NCT05473533|DRUG|Placebo|Placebo; formulated as solution for inhalation without active substance.
48007886|NCT05473533|DRUG|PRS-220|PRS-220; formulated as solution for inhalation.
48007887|NCT04911725|DEVICE|Elastic Compression Prototype|Elastic Compression device - No medical, surgical or laboratory procedure is implied in the use of the IMD.
48693969|NCT02360670|OTHER|control imaging|
48693970|NCT02360670|OTHER|additional multimodal imaging|
48007888|NCT05012605|OTHER|Observation|Observe physical function and sleep disorder symptoms following stroke
48007889|NCT05976919|DIAGNOSTIC_TEST|Pulmonary function testing|Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
48007890|NCT03826758|OTHER|E-DYNAMIC Clinical Decision Support|Clinical decision support system
48007891|NCT00856024|BIOLOGICAL|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
48007892|NCT00856024|DRUG|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
48007893|NCT00473720|DRUG|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
48007894|NCT00473720|DRUG|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
48007895|NCT06533189|DEVICE|Enhanced Diffusion Software|Application of specific sequences with the use of Enhanced Diffusion Software during Patient MRI
48007896|NCT01167062|DRUG|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
48007897|NCT01167062|OTHER|Placebo|One tablet OD for a maximum of 28 days
48165003|NCT01298219|DRUG|Lubiprostone|24 mcg administered orally twice daily (BID)
48165004|NCT01298219|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
48165005|NCT03410108|DRUG|Brigatinib|Brigatinib tablet
48165006|NCT05181878|DEVICE|The AcQMap 2.1 System with Electro-Magnetic Tracking Feasibility System|Demonstrate the ability of the AcQMap 2.1 System to support EMT in conjunction with the existing impedance localization capabilities. The new EMT technology is expected to continuously provide fully synchronized and similar localization information to the impedance-based localization information associated with the location of the catheter's magnetic sensor position.
48165007|NCT06008288|DRUG|JAB-21822|800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
48165008|NCT02223507|DRUG|BIIR 561 CL|
48165009|NCT02223507|DRUG|Placebo|
48165010|NCT06577649|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|cTBS (50 Hz, 600 pulses, 80% resting motor threshold) for 40s was applied continuously as active rTMS at the face representation area of primary somatosensory cortex (S1)
48165011|NCT06577649|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|A sham rTMS was applied using the same stimulation parameters as with cTBS, but using a placebo coil, which produced similar sound as the real coil.
48165012|NCT06415747|OTHER|Observational pain and motor function assessments, and also comorbidities assessments with x-ray.|There was no intervention in our study, only observational and quantitative clinical evaluations.
48165013|NCT06647316|OTHER|Physiotherapy|The subjects will receive the first physiotherapy session : early mobilization, postural and joint ergonomics, sensory stimulation, temporal-spatial orientation and health education for the patient and the main caregiver are carried out.The plan will progress with postural control in a seated position, head and trunk control, re-education of transfers, balance, standing and walking, depending on the subject's abilities.The second physical therapy session incorporates taste and preference-based elements into the therapy itself. The third physiotherapy session is planned to take place in the physiotherapy unit. Following the individualized session, group interaction is encouraged, whether with other patients, the rehabilitation team and/or the patient's primary caregiver.In the fourth physiotherapy session, it is promoted therapeutic compliance.
48165014|NCT03207698|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
48165015|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
48165016|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
48514103|NCT01690702|DRUG|Cyclophosphamide|
48693971|NCT03871010|DEVICE|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
48693972|NCT02793349|DEVICE|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
48693973|NCT04771299|DRUG|Cariprazine|Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
48165017|NCT06645561|PROCEDURE|X-ray|defined radiographic semiological criteria to determine an analytical methodology to facilitate the dating of long bone fractures of infants under one year of age
48165018|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
48007898|NCT05676892|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured"
48007899|NCT05833503|BEHAVIORAL|Integrative Couple Treatment for Addiction (ICT-A)|Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).
48007900|NCT05833503|BEHAVIORAL|Treatment individual as usually offered|Individual-based treatment as usually offer by the specialized centres in addiction.
48007901|NCT04940845|DRUG|HS-20090-2|Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day
48007902|NCT04940845|DRUG|Prolia|Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
48165019|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~* Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
48165020|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~* Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
48165021|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
48693974|NCT04771299|OTHER|Placebo|Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.
48693975|NCT04817839|BEHAVIORAL|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
48007903|NCT00350766|PROCEDURE|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
48693976|NCT04817839|BEHAVIORAL|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
48693977|NCT03062280|DRUG|Hydrocortisone|Modified release hydrocortisone
48693978|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
48007904|NCT02064452|OTHER|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
48007905|NCT02064452|BEHAVIORAL|Placebo Comparator|Enhanced Usual Community Care-Waitlist
48007906|NCT00874068|OTHER|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
48007907|NCT00874068|OTHER|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
48514104|NCT01690702|DRUG|Docetaxel|
48514105|NCT05880329|DIAGNOSTIC_TEST|Candidate POCTs for detecting UTI|POCT performance will be evaluated in participants who experience possible UTI.
48514106|NCT05176873|DRUG|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
48514107|NCT05176873|DRUG|Placebo|A single oral dose of placebo will be given.
48514108|NCT00003302|PROCEDURE|biopsy|
48514109|NCT00003302|DIAGNOSTIC_TEST|magnetic resonance imaging|
48514110|NCT00003302|DIAGNOSTIC_TEST|mammography|
48693979|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
48693980|NCT03658343|DIAGNOSTIC_TEST|T2* Imaging|T2\* imaging sequences for MRI
48693981|NCT06434064|PROCEDURE|Biopsy|Undergo tumor biopsy
48693982|NCT06434064|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48693983|NCT06434064|PROCEDURE|Computed Tomography|Undergo CT scan
48693984|NCT06434064|PROCEDURE|Echocardiography|Undergo echocardiography
48007908|NCT01461304|DRUG|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
48514111|NCT01609205|BIOLOGICAL|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
48007909|NCT01964911|DRUG|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN \<3/10 : non opioids, EN 3-5/10 : weak opioids, EN\>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
48007910|NCT04044417|PROCEDURE|currettage|open flap debridement
48514112|NCT04000282|DRUG|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
48514113|NCT05509075|DIETARY_SUPPLEMENT|nutraceuticals|antioxidants
48693985|NCT06434064|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48007911|NCT04044417|DRUG|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
48693986|NCT06434064|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48693987|NCT06434064|DRUG|Tamoxifen|Given PO
48693988|NCT05586503|DIAGNOSTIC_TEST|ECG-gated CTAs|ECG-gated CTAs will be performed instead of static CTAs comparing to standard of care
48693989|NCT05935657|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion
48007912|NCT04044417|DRUG|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
48514114|NCT00807716|OTHER|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
48007913|NCT04503564|DEVICE|coil-reinforced soft polymer indwelling cannula|This is a prospective, non-randomized, home-use feasibility study of device performance, usability, tolerability, and safety of the Capillary Biomedical, Inc. (CapBio) Achilles infusion set for continuous subcutaneous insulin infusion (CSII or insulin pump therapy) in up to 20 participants diagnosed with type 1 diabetes mellitus (T1DM).
48514115|NCT00807716|OTHER|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
48693990|NCT05935657|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
48693991|NCT02851797|DRUG|givinostat|"The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid"
48693992|NCT02851797|DRUG|placebo|The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
48693993|NCT05143528|DRUG|Nilotinib BE 84mg|84 mg capsule
48165022|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~* Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
48514116|NCT01105624|DRUG|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
48514117|NCT01105624|DRUG|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
48514118|NCT00242632|DRUG|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
48514119|NCT05994885|PROCEDURE|Root surface debridement|the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.
48514120|NCT02522715|DRUG|Cabazitaxel|Given IV
48514121|NCT02522715|DRUG|Enzalutamide|Given PO
48514122|NCT02522715|OTHER|Laboratory Biomarker Analysis|Correlative studies
48514123|NCT02522715|OTHER|Pharmacological Study|Correlative studies
48514124|NCT02522715|DRUG|Prednisone|Given PO
48514125|NCT03353012|DRUG|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
48514126|NCT03353012|DRUG|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
48514127|NCT03537131|DRUG|Dapagliflozin 10 MG Oral Tablet|taken once a day
48514128|NCT02875223|DRUG|CC-90011|Specified dose on specified days
48693994|NCT05143528|DRUG|Nilotinib BE 112 mg|112 mg capsule
48693995|NCT05143528|DRUG|Placebo|placebo capsule
48693996|NCT06654505|BEHAVIORAL|Paired Community Health Workers|Community Health Workers will promote maternal and child health services as paired female and male
48369123|NCT05689645|DRUG|F573 for injection|The first 16 patients with liver injury were given doses of 0.5, 1.0 and 2.0 mg/kg,2 mL,intramuscular injection (IM),once a day for 7 daysand. the subsequent 9 patients with CHB were given doses of 2 mL intramuscular injection (IM), once a day for 7 days, according to the results of the efficacy and safety trials of the first 16 patients. The dose of the second stage was determined according to the results of the efficacy and safety trials in the first stage. The dose volume was 2 mL, and was administered intramuscular injection (IM) once a day for 14 days. The dosage of the third stage was determined according to the results of the first and second stage efficacy and safety trials. The dosage volume was 2 mL and intramuscular injection (IM) was administered once a day for 28 consecutive days. The dosage of the above three stages of administration was calculated according to the weight of the most recent visit
48369124|NCT05689645|DRUG|Sterilizing water for injection|"The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days."
48693997|NCT05267054|DRUG|Ociperlimab|administered intravenously
48693998|NCT05267054|DRUG|Tislelizumab|administered intravenously
48693999|NCT05267054|DRUG|Rituximab|administered intravenously
48694000|NCT06208293|BEHAVIORAL|KPZ Program (KPZ)|The KPZ package includes a culturally adapted approach to a co-designed safety plan. The assigned Peers will provide safety planning and Brief Contact Follow-Up. Contact follow up sessions will occur at the household level.
48694001|NCT06208293|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants receive usual care enhanced by Lady Health Workers (LHWs) trained in WHO Mental Health Gap Action Programme (mhGAP) that will link at-risk women with the primary care facility based medical officer. The LHWs will follow the mhGAP protocol for imminent or low risk of suicide including ensuring the participant is safe, removing or reducing means, assigning a family member to ensure safety (if appropriate), providing psychoeducation, and referring and accompanying the individual to their primary care health center where a mhGAP trained doctor is staffed to resume care or make a referral to specialized care. Additionally, all women and healthcare workers are provided a 24 hour hotline number (hosted by a Pakistani based mental health organization called Taskeen) and are briefed on exactly what will happen if participant calls.
48694002|NCT06659952|OTHER|HIV-positive heart transplant|Receipt of heart from HIV-positive deceased donor only as part of this study
48694003|NCT06661746|DRUG|Multimodal IV analgesia|Multimodal IV analgesia of lidocaine, ketamine and MS
48694004|NCT06661746|DRUG|epidural analgesia|Opioid-based and epidural analgesia
48514129|NCT02875223|DRUG|Rifampicin|Specified dose on specified days
48694005|NCT01745744|OTHER|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
48694006|NCT06661785|PROCEDURE|large orbital floor fracture|Twenty two patients with large orbital floor fracture will be reconstructed with interlocking polyetheretherketone patient-specific implant
48694007|NCT03994796|DRUG|Abemaciclib|Given PO
48694008|NCT03994796|DRUG|PI3K Inhibitor paxalisib|Given PO
48694009|NCT03994796|DRUG|Entrectinib|Given PO
48694010|NCT03994796|DRUG|Adagrasib|Given PO
48694011|NCT03811392|PROCEDURE|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
48694012|NCT03811392|PROCEDURE|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
48694013|NCT06574126|DRUG|Group 1: Dara-VRD followed by apheresis and cilta-cel infusion|In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
48694014|NCT06574126|DRUG|Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion|In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
48694015|NCT05803161|DRUG|Congrong Runtong oral liquid|"Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola"
48694016|NCT05803161|DRUG|Placental Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid
48694017|NCT04826107|DRUG|DP303c treatment|DP303c injection, every 3 weeks.
48694018|NCT04826107|DRUG|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
48694019|NCT04826107|DRUG|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
48694020|NCT04826107|DRUG|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
48694021|NCT04826107|DRUG|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
48694022|NCT02454439|OTHER|CRT implantation|
48694023|NCT03763656|DRUG|Oral Hydroxyurea (100 mg/mL) Solution|Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
48369125|NCT04337463|DRUG|ATG-008|Tablet
48514130|NCT02875223|DRUG|Itraconazole|Specified dose on specified days
48165023|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~* Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
48694024|NCT04541043|DRUG|Nefecon 16mg daily|All study patients received Nefecon 16 mg daily for 9 months.
48694025|NCT04909008|OTHER|Exercise Training|10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
48694026|NCT02745704|DRUG|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
48694027|NCT04161092|PROCEDURE|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
48165024|NCT00103116|BIOLOGICAL|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
48165025|NCT06401096|PROCEDURE|Preoperative respiratory exercises|The Triflo Exerciser
48369126|NCT04337463|DRUG|Toripalimab|IV infusion
48369127|NCT05527418|DRUG|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
48694028|NCT04161092|OTHER|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
48694029|NCT01760538|BEHAVIORAL|Exercise training|exercise training
48694030|NCT01760538|BEHAVIORAL|usual care|received usual medical care after heart transplantation
48694031|NCT02553551|DRUG|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
48694032|NCT02553551|DRUG|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
48694033|NCT06658548|OTHER|Isometric handgrip exercise training with resistance exercise|The subjects will perform 24 consecutive days, an isometric handgrip exercise at 30% Maximum Voluntary Contraction (M.V.C)continue the exercise protocol for another 48 consecutive days.
48694034|NCT06658548|OTHER|Resistance Exercise|The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).
48694035|NCT02010242|DRUG|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
48694036|NCT02010242|DRUG|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
48694037|NCT03661307|DRUG|Decitabine|Given IV
48694038|NCT03661307|DRUG|Quizartinib|Given PO
48694039|NCT03661307|DRUG|Venetoclax|Given PO
48694040|NCT04552041|DRUG|Prospekta|Oral administration.
48694041|NCT04552041|DRUG|Placebo|Oral administration.
48165026|NCT04765540|BEHAVIORAL|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors \& hand-shaped sign posts pointing to the station"
48165027|NCT04765540|BEHAVIORAL|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board \& general encouragement"
48165028|NCT04765540|BEHAVIORAL|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
48165029|NCT06132906|PROCEDURE|Orthognathic surgery (lefort1)|"1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure"
48165030|NCT05720702|DIETARY_SUPPLEMENT|homocysteine (Hcy) lowering supplements|NAFLD participants will take homocysteine (Hcy) lowering supplements daily for 12 weeks.
48165031|NCT03732950|BIOLOGICAL|Pembrolizumab|Given IV
48369128|NCT05527418|DRUG|Placebo|Placebo during 16 weeks.
48369129|NCT01286766|DRUG|DCS (docetaxel with cisplatin with TS-1)|"1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
48369130|NCT01286766|DRUG|DCF (docetaxel with cisplatin with 5-FU)|"1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles"
48369131|NCT03854552|DRUG|BI 764198|capsule
48694042|NCT06656117|OTHER|Elliptical training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
48694043|NCT06656117|OTHER|Resistance training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
48694044|NCT02876237|OTHER|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
48694045|NCT02876237|RADIATION|Radiotherapy|standard radiotherapy
48694046|NCT06385795|DRUG|NOE-115|NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
48369132|NCT03854552|DRUG|Placebo|capsule
48369133|NCT05463146|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
48694047|NCT01437579|PROCEDURE|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
48165032|NCT05895110|BIOLOGICAL|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
48165033|NCT03597542|OTHER|Eggs and Carbohydrates|Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
48369134|NCT05463146|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
48694048|NCT01437579|PROCEDURE|cystoscopy|cystoscopy under general anesthesia
48694049|NCT06435416|OTHER|No intervention|No intervention
48694050|NCT06029127|DRUG|BGB-A445|Administered intravenously at protocol defined dose
48694051|NCT06029127|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) administered intravenously
48694052|NCT06029127|DRUG|Ramucirumab|10 mg/kg administered intravenously
48694053|NCT06029127|DRUG|BGB-15025|Administered orally at protocol defined dose
48165034|NCT04693650|DEVICE|NeuroBlock UHF stimulation|NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
48694054|NCT06659809|BEHAVIORAL|Tele-care video-feedback intervention (TVFI)|The TVFI 6 weekly sessions are organized in two subsequent phases: 4 sharing the focus sessions and 2 integration sessions. Sharing the focus sessions are dedicated to the discussion between the psychologist and the mother of specific themes related to parenting and parent-infant interaction: physical stimulation, responsiveness, teaching, and parenting experience. The goal of the sharing the focus sessions is to develop insights about the infants' behavioral signals, the best ways to provide stimulations and get in touch, strategies to promote emotion regulation, and to sustain cognitive and behavioral achievements. In the subsequent two integration sessions, the mother plays with the infant while the psychologist provides guidance based on topics previously discussed during the first four sessions. The goal is to promote a pragmatical translation of the insights developed during the sharing the focus sessions into the interactive exchanges between the mother and the infant.
48694055|NCT03239951|DEVICE|iTind|temporary implant
48694056|NCT03822455|DRUG|OligoG DPI|OligoG Dry Powder for Inhalation
48694057|NCT05849194|DIAGNOSTIC_TEST|POCUS examination|Point of care ultrasound examination
48694058|NCT01748188|PROCEDURE|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
48694059|NCT01748188|PROCEDURE|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
48694060|NCT01748188|PROCEDURE|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
48694061|NCT01748188|PROCEDURE|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
48694062|NCT01748188|PROCEDURE|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
48694063|NCT04842149|DIETARY_SUPPLEMENT|Bif195 capsules|1 capsule daily for 8 weeks
48694064|NCT04842149|DIETARY_SUPPLEMENT|Placebo capsules|1 capsule daily for 8 weeks
48694065|NCT04510987|DRUG|BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|Tablet, oral
48694066|NCT04510987|OTHER|BAY2433334 on dialysis treatment day|Tablet, oral
48369135|NCT05463146|OTHER|Deep breathing exercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
48369136|NCT02259452|PROCEDURE|SPECT Lung Perfusion Scan|
48369137|NCT02259452|PROCEDURE|SPECT Heart Perfusion Scan|
48369138|NCT02259452|PROCEDURE|Pulmonary Function Tests|
48369139|NCT00374452|OTHER|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
48369140|NCT00374452|OTHER|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
48369141|NCT03737305|DEVICE|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
48369142|NCT03737305|DEVICE|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
48369143|NCT01287403|OTHER|Refined wheat flour|A treated cereal flour mixed with milk.
48369144|NCT01287403|OTHER|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
48694067|NCT06659185|DIETARY_SUPPLEMENT|Exercise|The effects of placobo mouth rinsing on softball batting performance
48694068|NCT06268873|DRUG|Baxdrostat/dapagliflozin|"baxdrostat tablet~dapagliflozin tablet"
48694069|NCT06268873|DRUG|Dapagliflozin in combination with placebo|"dapagliflozin tablet~placebo tablet"
48165035|NCT04722848|DRUG|Ponatinib + Blinatumomab|"Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation"
48165036|NCT04722848|DRUG|Chemotherapy + Imatinib|patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
48369145|NCT01287403|OTHER|Wholegrain wheat flour|A treated cereal flour mixed with milk.
48694070|NCT06643234|PROCEDURE|Ventral hernia repair|Comparative between both techniques
48007914|NCT05614245|BIOLOGICAL|VBI-2901e|Intramuscular injection of VBI-2901e, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate and E6020 adjuvants
48369146|NCT01287403|OTHER|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
48369147|NCT01287403|OTHER|Wholegrain barley flour|A treated cereal flour mixed with milk.
48369148|NCT01287403|OTHER|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
48694071|NCT01811485|DRUG|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
48694072|NCT01811485|DRUG|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
48694073|NCT01811485|DRUG|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
48694074|NCT05039801|BIOLOGICAL|Bevacizumab|Given IV
48694075|NCT05039801|DRUG|Glutaminase-1 Inhibitor IACS-6274|Given by PO
48694076|NCT05039801|DRUG|Paclitaxel|Given by IV (vein)
48694077|NCT05039801|DRUG|Capivasertib|Given by PO
48694078|NCT04559022|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
48694079|NCT03440151|PROCEDURE|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
48694080|NCT03440151|PROCEDURE|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
48694081|NCT03924219|OTHER|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
48694082|NCT05591859|DEVICE|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
48694083|NCT01527305|DRUG|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
48694084|NCT06658639|DEVICE|Ultrasound lipolysis|Ultrasound lipolysis uses a Luvitra device to emit low-frequency ultrasound pulsed waves. The abdominal area is divided into two sections and the patient is placed in a comfortable supine lying position. The cavitation head is applied slowly to each segment in small circular movements. The treatment lasts 30 minutes on each side, with each session lasting 60 minutes. The same abdominal area is treated every two weeks for three months. The procedure involves cleaning the skin with alcohol cotton.
48694085|NCT06658639|DEVICE|Cryolipolysis|The study utilized Lipocool, a cryolipolysis apparatus from Korea, with a thermoelectric cooling element. Participants were treated with thermal coupling gel on their abdomen, and the tissue was drawn into the applicator with a moderate vacuum. The device was used for 40-50 minutes, with energy extraction controlled by sensors. The system stopped cold exposure and the clinician released the vacuum. Participants underwent cryolipolysis sessions every 2 weeks for 3 months.
48694086|NCT06658639|OTHER|Low Caloric Diet|A low-calorie diet is a structured plan that restricts daily caloric intake, often used for weight loss. It involves consuming 1,200 to 1,500 calories daily, creating a calorie deficit. However, it requires discipline and safety. The diet is low in fat (20-25%), high in complex carbohydrates (60%), and sufficient in protein (25-50%).
48694087|NCT02464995|DEVICE|Bronchial thermoplasty with the Alair System|
48694088|NCT01943058|DRUG|megestrol acetate|Given PO
48694089|NCT01943058|DEVICE|levonorgestrel-releasing intrauterine system|Given IUD
48694090|NCT01943058|OTHER|laboratory biomarker analysis|Correlative studies
48694091|NCT01943058|OTHER|questionnaire administration|Ancillary studies
48165037|NCT02534129|DRUG|Difinsa53|Difinsa53 cream is applied to one half of radiation field
48165038|NCT02534129|DRUG|Aquaphor|Aquaphor is applied to one half of radiation field
48694092|NCT03640325|BEHAVIORAL|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
48694093|NCT06658301|OTHER|plyometric push up exercises|The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.
48165039|NCT00511459|DRUG|AMG 386 Placebo|AMG 386 Placebo \[blinded\]
48165040|NCT00511459|DRUG|AMG 386|AMG 386 3mg/kg IV QW \[blinded\]
48165041|NCT00511459|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
48694094|NCT06658301|OTHER|swiss ball push up exercises|. The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
48694095|NCT05636124|DEVICE|Kaneka i-ED coil|The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
48694096|NCT05005403|DRUG|ABBV-514|Intravenous (IV) Infusion
48694097|NCT05005403|DRUG|Budigalimab|IV Infusion
48165042|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[Open-Label\]
48165043|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[blinded\]
48165044|NCT00511459|DRUG|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
48165045|NCT00271466|DRUG|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
48165046|NCT02179710|BEHAVIORAL|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
48165047|NCT00466622|DRUG|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
48165048|NCT00466622|DRUG|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
48165049|NCT04788277|PROCEDURE|Biospecimen Collection|Undergo collection of urine samples
48165050|NCT01705223|BIOLOGICAL|DNA vaccine|4mg/dose, three doses at week 0,4,8
48694098|NCT03540589|DEVICE|Buzzy specific vibration device|It is a device that produces vibration
48694099|NCT03540589|BEHAVIORAL|Distraction|The distraction will be obtained through tablet with videos
48007915|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
48007916|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
48007917|NCT01712984|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
48007918|NCT01368575|PROCEDURE|CABG|CABG
48007919|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
48007920|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
48694100|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
48694101|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
48694102|NCT06384313|DIETARY_SUPPLEMENT|butyrate/hexanoate-enriched triglycerides|The oils are consumed two times a day for 24 weeks (six months).
48694103|NCT06659692|DRUG|Gonadotropins Subcutaneous|Gonadotropins s.c. multiple dose
48694104|NCT04608383|OTHER|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"* Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~* Swab from the laparoscopy filter"
48694105|NCT04956640|DRUG|LY3537982|Oral
48694106|NCT04956640|DRUG|Pembrolizumab|Intravenous
48694107|NCT04956640|DRUG|Cetuximab|Intravenous
48694108|NCT04956640|DRUG|Pemetrexed|Intravenous
48694109|NCT04956640|DRUG|Cisplatin|Intravenous
48694110|NCT04956640|DRUG|Carboplatin|Intravenous
48694111|NCT04516070|OTHER|Questionnaire Administration|Ancillary studies
48694112|NCT04516070|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48694113|NCT06550895|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
48694114|NCT06550895|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
48694115|NCT06550895|DRUG|Daratumumab|Daratumumab will be administered subcutaneously as a part of DRd induction therapy.
48694116|NCT06550895|DRUG|Lenalidomide|Lenalidomide will be administered orally as a part of DRd induction therapy.
48007921|NCT01368575|PROCEDURE|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
48007922|NCT01368575|PROCEDURE|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
48007923|NCT02109328|DRUG|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
48007924|NCT02109328|DRUG|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
48694117|NCT06550895|DRUG|Dexamethasone|Dexamethasone will be administered orally or intravenously as a part of DRd induction therapy.
48694118|NCT04310436|BEHAVIORAL|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
48694119|NCT04310436|BEHAVIORAL|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
48694120|NCT06320678|OTHER|Nursing Students Education|Effect of Concept Mapped Blended Learning Self-Directed Learning
48694121|NCT06660511|DRUG|Disitamab Vedotin in Combination With Anlotinib Hydrochloride|"The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)"
48694122|NCT03560960|DRUG|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
48007925|NCT02109328|DRUG|Placebo|Placebo oral tablets
48007926|NCT01911507|DRUG|INC280|Given PO
48007927|NCT01911507|DRUG|erlotinib hydrochloride|Given PO
48007928|NCT01990677|DRUG|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
48007929|NCT01990677|DRUG|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
48694123|NCT04493970|OTHER|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
48165051|NCT01705223|BIOLOGICAL|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
48694124|NCT03892057|BEHAVIORAL|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
48694125|NCT00665054|DRUG|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
48694126|NCT00665054|DRUG|Placebo|Matching placebo tablets orally prior to sexual activity
48165052|NCT01705223|BIOLOGICAL|rTV boost|at week 16
48165053|NCT01705223|BIOLOGICAL|rTV boost|at week 24
48165054|NCT01705223|BIOLOGICAL|rTV boost|at week 32
48165055|NCT05465486|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|"The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics \& Digital Innovation Lab."
48165056|NCT05465486|DEVICE|Serious game with augmented reality|"The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket \& gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics \& Digital Innovation Lab"
48165057|NCT06140576|DRUG|Sindilimab|Sindilimab, 200mg, Intravenous，every three weeks
48165058|NCT06140576|DRUG|Nab-paclitaxel|Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
48165059|NCT06140576|DRUG|Lenvatinib|Lenvatinib 8mg, 12mg, 16mg everyday
48369149|NCT00166595|DRUG|Risperidone|
48165060|NCT04360642|OTHER|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
48165061|NCT04274699|DIAGNOSTIC_TEST|Hemosonics Quantra coagulation monitor|There is no categorisation or allocation of any subject to any intervention vs non-intervention group. Blood sampling and the addition of a Quantra coagulation test is the only 'intervention', and the sampling protocol is identical for all subjects. Post-testing treatment of all subjects is as per established routine and Quantra results will not be used by clinical team.
48165062|NCT00005797|DRUG|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
48369150|NCT05136989|BEHAVIORAL|Individual and collective semi-structured interviews|Individual and collective semi-structured interviews will be performed with professionals to identify levers (practices, knowledge, tools, regulations) which, at the level of services and establishments, enable the development of a policy of less recourse to coercion
48369151|NCT05136989|BEHAVIORAL|Individual semi-structured interviews with ex-patients|Individual semi-structured interviews will be performed with ex-patients in order to gather their experiences in the seven institutions concerned and to better understand the impact of their hospitalization in these institutions on their lives
48694127|NCT01677598|DRUG|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
48694128|NCT04904744|OTHER|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
48694129|NCT04904744|OTHER|No message|No reminders are sent
48165063|NCT00005797|DRUG|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
48165064|NCT00005797|DRUG|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.
48694130|NCT04904744|OTHER|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
48007930|NCT06249308|OTHER|Blood collection|Blood sample will be collected
48007931|NCT06021236|BEHAVIORAL|mindfulness-based intervention|Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
48165065|NCT00005797|RADIATION|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
48007932|NCT06021236|OTHER|CIED procedure routine care|CIED procedure home care guidance
48007933|NCT02129075|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
48007934|NCT02129075|DRUG|Poly ICLC|Given SC
48007935|NCT02129075|BIOLOGICAL|Recombinant Flt3 Ligand|Given SC
48007936|NCT03410979|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
48007937|NCT03410979|DRUG|Placebo single dose|Placebo, oral suspension.
48007938|NCT03410979|DRUG|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
48007939|NCT03410979|DRUG|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
48165066|NCT04052932|DRUG|SHR4640 dose1|tablets，dose1，QD
48165067|NCT04052932|DRUG|SHR4640 dose2|tablets，dose2，QD
48694131|NCT02615938|DRUG|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
48694132|NCT02615938|OTHER|Placebo|Apply Placebo not to modify lysosomal pH
48007940|NCT03979443|PROCEDURE|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
48007941|NCT03493334|OTHER|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
48007942|NCT03493334|OTHER|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
48007943|NCT03492697|DRUG|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
48007944|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
48165068|NCT04052932|DRUG|Placebo oral tablet|tablets，QD
48694133|NCT02274480|DEVICE|cardiac MRI with DWI|
48165069|NCT04052932|DRUG|Allopurinol 300 MG|tablets，300mg，QD
48165070|NCT00791102|DRUG|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
48007945|NCT03492697|DRUG|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
48165071|NCT00791102|DRUG|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
48165072|NCT00000137|PROCEDURE|Histocompatibility Matching|
48165073|NCT01801813|OTHER|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
48165074|NCT03185910|BEHAVIORAL|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
48165075|NCT03185910|BEHAVIORAL|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
48165076|NCT00902226|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
48369152|NCT05136989|BEHAVIORAL|Observations out in the services|Observations will be carried out in the services in order to measure the gap between rhetoric and practice, and to observe the effective implementation of lesser use practices
48694134|NCT06659848|OTHER|high intensity interval training|The subjects in the four groups performed 12 weeks of supervised HIIE program on a motorized treadmill (h/p/cosmos, Pulsar 4.0, Nussdorf-Traunstein, Germany) with a rate of three sessions weekly. The session commenced with a 5 min warming-up and concluded with a 5 min cooling down period. The exercise effort component consisted of 5 intervals of HIIT. Each interval continues for four min of HIIT with exercise intensity ranging from 75% to 90% of the peak heart rate. Each active recovery period between exercise intervals included moderate exercise at intensity of 50% to 60% of the peak heart rate. Every 3 weeks, the exercise intensity was increased by 5% starting with 75% of the HRmax in the first 3 weeks, 80% in the following 3 weeks and progressed to 90% the HRmax in the last 3 weeks. The subject's heart rate throughout the HIIT session was monitored using a polar heart rate monitor (Polar, Kempele, Finland).
48694135|NCT04590430|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
48007946|NCT03492697|DRUG|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
48007947|NCT05233410|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
48007948|NCT05233410|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
48007949|NCT02476838|PROCEDURE|Hand Transplantation|microvascular VCA transplant
48007950|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg|
48007951|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg|
48007952|NCT02667938|DRUG|HGP1201|
48007953|NCT02667938|DRUG|HCP1303 capsule 5/0.2mg placebo|
48007954|NCT02667938|DRUG|HCP1303 capsule 5/0.4mg placebo|
48007955|NCT02667938|DRUG|HGP1201 placebo|
48007956|NCT05795894|BEHAVIORAL|STAI-Y|Situational Anxiety and Trait Anxiety Inventory
48007957|NCT05795894|BEHAVIORAL|BDI scale|• Beck Depression Inventory scale
48007958|NCT05795894|BEHAVIORAL|M.I.N.I.Kid|"Suicidal risk module of the Mini-International Neuropsychiatric Interview child/adolescent version"
48007959|NCT05795894|BEHAVIORAL|PCL-5|Post-traumatic Check List Scale
48007960|NCT04140461|DRUG|Amphotericin B|The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
48165077|NCT05983068|DRUG|dupilumab|solution for injection; by subcutaneous (SC) injection
48165078|NCT00768209|DRUG|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
48369153|NCT03047408|PROCEDURE|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
48369154|NCT02330406|DRUG|Anagliptin|Suiny 100 mg
48165079|NCT03441750|DRUG|metformin|Metformin tablets will be administrated in the experimental arm.
48369155|NCT02330406|DRUG|Sitagliptin|Januvia 50 mg Glactiv 50 mg
48369156|NCT02982122|OTHER|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
48369157|NCT02506101|DEVICE|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
48007961|NCT04140461|DRUG|Flucytosine|The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
48007962|NCT01027793|DRUG|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
48165080|NCT03441750|OTHER|Standard lifestyle intervention|"Standard lifestyle advice will be united for all subjects by providing special booklet.~* All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~* The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~* Moderate intensity physical activity (150 minutes per week) is recommended.~* Smoking cessation is encouraged for the smoker.~* Excessive alcohol intake is encouraged to avoid."
48369158|NCT02546193|DEVICE|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
48369159|NCT02546193|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
48369160|NCT00953173|DEVICE|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
48369161|NCT02218424|DRUG|Magnesium|
48369162|NCT02218424|DRUG|Normal saline|
48369163|NCT01310491|BEHAVIORAL|Health coaching|Telephone based health coaching supported by tele-monitoring.
48369164|NCT01255449|DRUG|albuterol|400 mcg by inhalation
48694136|NCT04590430|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
48369165|NCT03028649|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate and a placebo supplementation|
48694137|NCT01191736|BEHAVIORAL|No training, assessed within 60 mins|Subjects receive no training in resuscitation
48007963|NCT01027793|DEVICE|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
48007964|NCT03042234|OTHER|Group Insulin-Resistant|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
48007965|NCT03042234|OTHER|Group Insulin-Sensitive|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
48007966|NCT02777125|DEVICE|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
48165081|NCT06337786|DEVICE|Digital app RB4.1|Standard routine care and the digital app RB4.1
48165082|NCT06337786|OTHER|Control arm|Standard routine care
48165083|NCT06141902|OTHER|Jing Si Herbal Drink|Jing Si Herbal Drink
48165084|NCT04070183|BEHAVIORAL|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
48694138|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
48694139|NCT01191736|BEHAVIORAL|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
48694140|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
48694141|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
48694142|NCT01191736|BEHAVIORAL|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
48007967|NCT02777125|DEVICE|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
48007968|NCT01221974|DEVICE|Essure Micro Insert|
48007969|NCT00006412|DRUG|Pravastatin sodium|
48007970|NCT00006412|DRUG|Fenofibrate|
48165085|NCT04070183|BEHAVIORAL|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
48165086|NCT03193216|DRUG|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
48369166|NCT00074399|DRUG|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
48165087|NCT05264298|OTHER|VIRTUAL|At the time of discharge, stroke survivors in the VIRTUAL arm will receive a package containing an iPad and a remote BP monitoring device that allows transmission of BP to the study team.The first telehealth visit will occur 7-14 days after discharge. Patient will be counseled on the importance of BP monitoring, salt reduction, and the importance of diet and exercise for stroke prevention. Medications, side effects and interactions will be reviewed. The social worker will refer the patient to specific resources according to social needs abd patient will be referred to a primary care provider if they do not have one. Subsequent video visits will be 1-month (30 days +/- 7) , 3 months (90 days +/- 14), and 5 months (150 days +/- 14) days after enrollment.
48165088|NCT05264298|OTHER|Standard care|Participants randomized to standard care will receive an educational packet and a blood pressure monitor prior to hospital discharge. They will be contacted by a social worker to determine if they received their medications and appointments. The stroke practitioner will evaluate the patients at 7-14 days and then follow up according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities. The pharmacist will contact patients at 1-month (30 +/- 7 days) days over the telephone to review BP logs and will make recommendations to their primary care provider to adjust BP medications. Subsequent pharmacist calls will occur monthly until 6 months and recommendations for medication adjustments will be communicated to their primary care provider.
48369167|NCT00074399|DRUG|Nevirapine placebo|Placebo tablet taken orally daily
48369168|NCT03276858|DRUG|CRN00808|Investigational drug
48369169|NCT03276858|DRUG|Placebo Oral Solution|Placebo
48369170|NCT03276858|DRUG|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
48369171|NCT03276858|DRUG|Placebo oral capsule|Placebo
48369172|NCT05778734|BEHAVIORAL|CM-PST|CM-PST is a tailored behavioral intervention that enables young adults with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake.
48694143|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
48165089|NCT03427606|PROCEDURE|Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
48165090|NCT03644706|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
48165091|NCT03644706|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
48165092|NCT01536613|DRUG|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
48165093|NCT06566209|DEVICE|Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)|Receive 18F-FDG PET/CT
48369173|NCT05778734|BEHAVIORAL|CM only|CM is a behavior therapy that rewards individuals for evidence of positive change (alcohol abstinence).
48369174|NCT05114031|OTHER|FB101|Microbial intervention using product FB101
48369175|NCT05114031|OTHER|Placebo|Saline water
48369176|NCT02816853|DRUG|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
48369177|NCT02816853|DRUG|Placebo|Matching placebo will be administered.
48369178|NCT02816853|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
48369179|NCT05413655|DRUG|EX039|The dosage form of EX039 is the capsule for oral use
48369180|NCT05413655|DRUG|Placebo|The dosage form of Placebo is the capsule for oral use
48369181|NCT01869920|BEHAVIORAL|Intervention group|Education on breastfeeding
48369182|NCT01869920|BEHAVIORAL|Usual care|Usual care
48165094|NCT01031186|DRUG|GSK356278|GSK356278
48369183|NCT06051461|DIETARY_SUPPLEMENT|Oral lipid emulsions|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFAs) or refined olive oil (MUFAs) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA (ω3-LCPUFAs).
48369184|NCT04099329|BEHAVIORAL|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
48369185|NCT05720923|DEVICE|Analysis with Ergometer|The analysis with the ergometer aims at assessing neuromuscular function
48369186|NCT04247802|OTHER|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
48369187|NCT04247802|OTHER|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
48369188|NCT00291109|DRUG|letrozole 2.5 mg|
48694144|NCT06343818|OTHER|The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff|Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
48694145|NCT05983198|DRUG|225Ac-PSMA-R2|PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide
48165095|NCT01031186|DRUG|PLACEBO|PLACEBO
48694146|NCT05983198|RADIATION|68Ga-PSMA-R2|Kit for radiopharmaceutical preparation
48694147|NCT05983198|RADIATION|68Ga-PSMA-11|Kit for radiopharmaceutical preparation
48165096|NCT04340726|PROCEDURE|One time abutment|
48165097|NCT06031870|DEVICE|Vaginal pessary|In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
48165098|NCT06031870|BEHAVIORAL|Standard care|Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
48165099|NCT06031870|PROCEDURE|Pelvic floor muscle training|Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
48165100|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 10 mg
48165101|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 5 mg
48165102|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg
48165103|NCT05674578|BEHAVIORAL|Patient Navigation|Assigned a patient navigator and receive coaching
48165104|NCT05674578|OTHER|Quality-of-Life Assessment|Ancillary studies
48694148|NCT06447779|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|"0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection"
48694149|NCT06447779|BIOLOGICAL|NaCl solution Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
48694150|NCT03379259|DRUG|BGB-A333|Anti-PD-L1 antibody
48694151|NCT03379259|DRUG|BGB-A317|Anti-PD-1 antibodies
48694152|NCT05155345|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
48694153|NCT05155345|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
48694154|NCT04873141|DRUG|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
48694155|NCT06660693|DRUG|Upadacitinib Oral Product|Upadacitinib oral 45mg once daily.
48694156|NCT01210963|DEVICE|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
48694157|NCT02619591|OTHER|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
48694158|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
48694159|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
48694160|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
48694161|NCT04679506|DRUG|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
48694162|NCT00426595|DRUG|Administration of omeprazole suspension|
48694163|NCT00426595|DRUG|omeprazole administered as a multi-unit-pellet system|
48694164|NCT00599534|DRUG|Montelukast|4 mg oral tablets
48694165|NCT00599534|DRUG|Placebo|5mg tablets
48694166|NCT05170958|DRUG|LBL-024 for Injection|LBL-024 was given every three weeks for treatment
48694167|NCT06101342|DRUG|Lenacapavir Injection|Administered subcutaneously
48694168|NCT06101342|DRUG|Lenacapavir Tablet|Administered orally
48165105|NCT05674578|OTHER|Questionnaire Administration|Ancillary studies
48165106|NCT01032746|OTHER|educational intervention|
48165107|NCT01032746|OTHER|internet-based intervention|
48165108|NCT01032746|PROCEDURE|evaluation of cancer risk factors|
48165109|NCT01032746|PROCEDURE|fecal occult blood test|
48165110|NCT01032746|PROCEDURE|screening colonoscopy|
48694169|NCT06101342|DRUG|Emtricitabine/tenofovir disoproxil fumarate (F/TDF)|Administered orally
48165111|NCT02605772|DRUG|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
48165112|NCT02605772|DRUG|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
48165113|NCT02605772|DRUG|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
48694170|NCT01289275|DRUG|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
48694171|NCT01289275|BEHAVIORAL|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
48694172|NCT01289275|BEHAVIORAL|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
48694173|NCT00479505|DRUG|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
48694174|NCT00479505|DRUG|Placebo|Placebo
48694175|NCT06482203|OTHER|Trunk Extensor Endurance training & Scapular mobilization|"Trunk Extensor Endurance Training Level 1:Prone shoulder extension or prone shoulder raises Level 2: Prone back extension Level 3: Prone Ys or Y raises Level 4:Super man pose Level 5:Super man or prone cobra~(The given position should be hold for 10 seconds and performs 25 repetitions with 3 sec rests in between the efforts)~Scapular Mobilization:~Intervention program includes, supero-inferior, medio-lateral along with circumduction movements).~3 sets of 10-15 repetitions of each of the supero-inferior ,medio-lateral, and circumduction movements Between each session, there was a10 or 30-second break. The length of rests was adjusted depending on the patient's endurance"
48694176|NCT02665663|DEVICE|medical device|
48165114|NCT01968083|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
48694177|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.
48694178|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.
48165115|NCT01968083|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
48165116|NCT00639964|OTHER|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
48165117|NCT00639964|OTHER|diet questionnaire|questions about nutrition before and during pregnancy
48165118|NCT00639964|OTHER|umbilical cord blood collect|collected at the delivery
48165119|NCT00639964|OTHER|placenta collect|collected at the delivery
48165120|NCT02730676|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
48165121|NCT02730676|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
48694179|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)|Performed booster immunization at 18 months of age.
48694180|NCT00309985|DRUG|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
48694181|NCT00309985|DRUG|docetaxel|Given IV
48694182|NCT06552936|OTHER|Diode Laser 980 nm.|A Diode laser is commonly used in simple surgical procedures on soft tissue, such as skin or mucosa. Its tip can work when non-activated, causing inductive effects, and when activated, it causes the ablation of soft tissue.
48694183|NCT03536780|DRUG|Avelumab and Gemcitabine|"* Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
48694184|NCT02191878|DRUG|TKM-080301|TKM-080301 intravenous infusion
48694185|NCT03260374|DEVICE|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
48694186|NCT03260374|DEVICE|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
48694187|NCT03260374|DEVICE|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
48694188|NCT04171635|RADIATION|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
48694189|NCT04171635|RADIATION|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
48694190|NCT00152828|DRUG|Celecoxib|
48694191|NCT00362271|DRUG|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
48694192|NCT03697005|OTHER|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
48694193|NCT03697005|OTHER|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
48694194|NCT05710406|DRUG|Encorafenib|Given PO
48165122|NCT05753319|OTHER|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
48165123|NCT03628456|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
48165124|NCT03628456|DEVICE|Hill-Rom Monarch|High-frequency chest wall oscillation vest
48694195|NCT05710406|BIOLOGICAL|Cetuximab|Given IV
48694196|NCT05710406|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48694197|NCT05710406|PROCEDURE|Computed Tomography|Undergo CT
48694198|NCT05710406|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48165125|NCT05532618|PROCEDURE|Adductor canal block|Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.
48165126|NCT05532618|DRUG|Levobupivacaine|Levobupivacaine
48694199|NCT05710406|OTHER|Patient Observation|Undergo observation per usual care
48694200|NCT02621541|DEVICE|PET/CT|
48694201|NCT03122899|DEVICE|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
48694202|NCT01231334|DRUG|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
48694203|NCT01231334|DRUG|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
48694204|NCT06014606|DRUG|placebo|oral formulation
48694205|NCT06014606|DRUG|haloperidol 2mg|oral formulation
48694206|NCT06014606|DRUG|propranolol 40mg|oral formulation
48694207|NCT01736072|PROCEDURE|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
48694208|NCT01736072|PROCEDURE|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
48694209|NCT04678037|BEHAVIORAL|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
48694210|NCT01880294|DRUG|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
48694211|NCT05641584|OTHER|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
48694212|NCT04406818|DRUG|Carbon Dioxide|Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
48694213|NCT06319820|COMBINATION_PRODUCT|TAR-210|TAR-210 will be administered intravesically.
48165127|NCT05532618|DRUG|Placebo|10 ml of sodium chloride 0.9%
48165128|NCT04315129|DIAGNOSTIC_TEST|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
48694214|NCT06319820|DRUG|Gemcitabine|Gemcitabine will be administered intravesically.
48694215|NCT06319820|DRUG|MMC|MMC will be administered intravesically.
48694216|NCT04990505|DIAGNOSTIC_TEST|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
48165129|NCT03115229|BEHAVIORAL|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
48694217|NCT02074670|OTHER|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
48694218|NCT04748328|PROCEDURE|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
48694219|NCT03802630|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
48694220|NCT03802630|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
48694221|NCT03802630|OTHER|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
48165130|NCT06431295|DEVICE|FaceScan|"Digital visual acuity device built for iOS (iPhone) that conducts an assessment of visual acuity using a combination of integrated light detection and ranging (LiDAR) and voice processing."
48165131|NCT01971034|DRUG|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
48165132|NCT01971034|DRUG|Metformin|850mg, PO, every 8 hours, daily.
48165133|NCT00854152|DRUG|GDC-0980|Escalating repeating dose
48165134|NCT02229396|DRUG|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
48369189|NCT03150706|DRUG|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
48369190|NCT01822886|DRUG|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
48369191|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
48165135|NCT02229396|DRUG|Exentide|2 mg
48165136|NCT02229396|DRUG|Dapagliflozin|10 mg once daily Dapagliflozin
48165137|NCT05424094|BEHAVIORAL|multi-professional group programme 'kinderleicht'|12-16 children/adolescents who participate in the multi-professional group programme 'kinderleicht' receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals on fridays during 11 months.
48369192|NCT01334281|PROCEDURE|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
48369193|NCT03116789|DIETARY_SUPPLEMENT|probiotics|Two capsules for daily
48369194|NCT01349816|DRUG|PT003|PT003 MDI administered as two puffs BID for 7 days
48369195|NCT01349816|DRUG|PT001|PT001 MDI administered as two puffs BID for 7 days
48694222|NCT03803358|OTHER|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
48694223|NCT03803358|OTHER|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
48694224|NCT06290531|DEVICE|Buzzy device (cold and vibration)|The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction
48694225|NCT06290531|DEVICE|Buzzy device (vibration only)|The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction
48694226|NCT06290531|OTHER|precooling|Ice cubes used for applying coolness at the injection area
48165138|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m\^2 on Day 1 plus gemcitabine 1250 mg/m\^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
48369196|NCT01349816|DRUG|PT005|PT005 MDI administered as two puffs BID for 7 days
48369197|NCT05961124|DRUG|Niraparib|Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
48369198|NCT04530227|DRUG|Biological: Camrelizumab|PD-1
48369199|NCT04530227|DRUG|Pemetrexed|chemotherapy
48369200|NCT04530227|DRUG|Nab-paclitaxel|chemotherapy
48369201|NCT02569398|DRUG|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
48369202|NCT02569398|DRUG|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
48369203|NCT02569398|DRUG|Placebo|One matching placebo tablet orally once daily up to 54 months.
48369204|NCT02926833|BIOLOGICAL|KTE-C19|A single infusion of KTE-C19 CAR-T cells administered intravenously
48694227|NCT06290531|OTHER|Flavored Benzocaine topical anesthetic gel 20%|Topical anesthetic gel
48694228|NCT02370316|BEHAVIORAL|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
48694229|NCT02370316|BEHAVIORAL|Clinical Structured Treatment|structured case management and symptom-targeted medication
48694230|NCT05947461|DRUG|100mg diclofenac|All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
48694231|NCT05947461|DRUG|100mg indomethacin|All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
48694232|NCT03947281|OTHER|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
48694233|NCT03947281|OTHER|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
48694234|NCT04097028|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
48694235|NCT04097028|DRUG|Oxaliplatin|Given IV
48694236|NCT04245306|OTHER|computerized test for pragmatic inferences|Computerized tests
48694237|NCT06658314|OTHER|Experimental interventional group 1(Kinesiotaping)|"Kinesiotape will be applied by using two I-bands application technique:~Short band: to apply this ask the patient to move your arm behind her back as much as possible, then apply kinesiotape at the anterior glenohumeral joint.~Longer band: to apply this ask the patient to horizontal adduct her arm as much as possible, than apply kinesiotape targeting the posterior side of glenohumeral joint.~Apply both these band with paper-off stretch for 3-5 days or as depending upon skin sensitivity and tape adherence.~Kinesiotape will be applied once a week for total time period of 3 weeks."
48694238|NCT06658314|OTHER|Experimental interventional group II (Graded exposure therapy)|"First week: gentle arm raises with 10 repetitions/day, slow and controlled stretch 25 to 50% force with 5 repetitions, passive internal and external rotations (with towel) with 5 repetitions each/day.~Second week: overhead arm raises (wall climbing) with 10 repetitions/day, pendulum exercises 10 repetitions/day, cross arm stretches 5 repetitions/day, active internal and external rotations with 5 repetitions each/day.~Third week: resistance exercises (initially with minimum weight or manual resistance), scapular squeezes 10 repetitions/day, gentle chest stretches 5 repetitions/day and gentle stretch with 75 to 100 % force 5 repetitions each/day."
48694239|NCT04022226|DRUG|Ketamine|Induction agent that suppresses infra-slow waves
48694240|NCT04022226|DRUG|Methohexital|Induction agent that does not suppress infra-slow waves
48694241|NCT06236815|DRUG|Delta-9-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
48694242|NCT06236815|DRUG|Delta-8-THC|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
48694243|NCT06236815|DRUG|Placebo|Healthy volunteers will attend three test sessions, at least 14 days apart, in which cognition and driving performance will be assessed following vaporization of (1) Δ9-THC, (2) Δ8-THC, or (3) a placebo. The order of these conditions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick.
48165139|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
48694244|NCT02945358|PROCEDURE|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
48694245|NCT05724953|BEHAVIORAL|Affective Awareness|Intervention involving psychoeducation and daily emotion awareness practices
48694246|NCT05572606|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
48369205|NCT02926833|BIOLOGICAL|Atezolizumab|Administered intravenously
48369206|NCT02926833|DRUG|Cyclophosphamide|Administered intravenously
48694247|NCT05314543|OTHER|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
48694248|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
48694249|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
48694250|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
48694251|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
48165140|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
48369207|NCT02926833|DRUG|Fludarabine|Administered intravenously
48369208|NCT01295073|DRUG|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
48369209|NCT01295073|OTHER|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
48369210|NCT01430559|DRUG|Meloxicam|7.5mg x2 once a day for 12 weeks
48369211|NCT01430559|DRUG|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
48694252|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
48694253|NCT05730556|DEVICE|Nerivio ®|Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
48694254|NCT05730556|DEVICE|Sham|Electrical stimulation to mimic study treatment intervention
48165141|NCT02083679|DRUG|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
48165142|NCT05540262|DRUG|Edaravone|Edaravone injection 30mg three times a day
48165143|NCT01894256|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
48165144|NCT03134937|DEVICE|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
48165145|NCT04747847|DRUG|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
48369212|NCT03778281|DRUG|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
48369213|NCT03778281|DRUG|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
48369214|NCT00658918|DRUG|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
48369215|NCT00658918|DRUG|Placebo|placebo
48369216|NCT00779506|DRUG|Quetiapine Fumarate XR|oral, once daily, flexible dose
48369217|NCT03159455|DRUG|BI 1467335|Duration - 28 days
48165146|NCT03279536|COMBINATION_PRODUCT|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
48165147|NCT03279536|COMBINATION_PRODUCT|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
48165148|NCT04528147|BEHAVIORAL|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
48165149|NCT04528147|BEHAVIORAL|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
48165150|NCT04483791|COMBINATION_PRODUCT|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
48165151|NCT01741636|OTHER|educational intervention|Undergo Survivorship Care Planning
48165152|NCT01741636|OTHER|questionnaire administration|Ancillary studies
48165153|NCT01741636|PROCEDURE|quality-of-life assessment|Ancillary studies
48369218|NCT03159455|DRUG|Placebo|Duration - 28 days
48369219|NCT03373656|BIOLOGICAL|Vaccination|"Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine"
48369220|NCT03373656|OTHER|No Vaccination|Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
48369221|NCT04387396|OTHER|Exercise|Exercise specific to knee osteoarthritis.
48369222|NCT00028496|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
48369223|NCT00028496|BIOLOGICAL|sargramostim|Given subcutaneously
48369224|NCT00028496|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
48369225|NCT04784806|OTHER|Ground beef|Subjects will consume a 106g patty of cooked ground beef.
48369226|NCT04784806|OTHER|Ground pork|Subjects will consume a 118g patty of cooked ground pork
48369227|NCT04784806|OTHER|Tofu|Subjects will consume a 113g patty of cooked tofu
48694255|NCT05145322|DEVICE|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
48694256|NCT05145322|DEVICE|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
48007971|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day."
48369228|NCT04784806|OTHER|Beyond Meat|Subjects will consume a 113g BeyondMeat patty.
48369229|NCT04682158|DRUG|Carboplatin|Given IV
48369230|NCT04682158|RADIATION|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
48369231|NCT04682158|DRUG|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
48369232|NCT04682158|RADIATION|Intensity Modulated Radiation Therapy|Undergo IMRT
48369233|NCT04682158|DRUG|Paclitaxel|Given IV
48369234|NCT00033683|DRUG|CMF regimen|
48369235|NCT00033683|DRUG|cyclophosphamide|
48369236|NCT00033683|DRUG|docetaxel|
48369237|NCT00033683|DRUG|epirubicin hydrochloride|
48369238|NCT00033683|DRUG|fluorouracil|
48369239|NCT00033683|DRUG|methotrexate|
48369240|NCT00033683|DRUG|tamoxifen citrate|
48369241|NCT00033683|PROCEDURE|adjuvant therapy|
48369242|NCT00033683|RADIATION|radiation therapy|
48369243|NCT02247102|DIETARY_SUPPLEMENT|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
48694257|NCT05016817|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48007972|NCT05811624|BEHAVIORAL|Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.|"14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful."
48007973|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
48007974|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
48007975|NCT00993096|DRUG|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
48007976|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
48007977|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
48007978|NCT00993096|DRUG|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
48007979|NCT02923518|OTHER|Questionnaire|Observational study without any intervention described under intervention type
48007980|NCT02852265|DRUG|Etonogestrel contraceptive implant|Place nexplanon
48007981|NCT05369910|BEHAVIORAL|Light exposure (Flash)|Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
48007982|NCT05369910|BEHAVIORAL|Light deprivation (Dark)|Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
48165154|NCT02373605|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
48369244|NCT02247102|DIETARY_SUPPLEMENT|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
48369245|NCT05600101|BEHAVIORAL|Care.Coach|"Care.coach is a human-in the-loop conversational agent (avatar) used to interact and converse with patients through natural dialogue and text-to-speech software that is powered by a team of trained human staff, called health advocates."
48369246|NCT05440227|DRUG|PG2 Lyo. Injection 500mg|PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.
48369247|NCT05440227|DRUG|Placebo 0.9% normal saline|0.9% normal saline 500ml will be administered weekly for 8 weeks.
48369248|NCT02426359|DRUG|Q301 Cream|
48369249|NCT02426359|DRUG|Placebo|
48694258|NCT00043355|DRUG|interferon gamma-1b|500 mcg, oral, three times weekly
48694259|NCT00061854|DRUG|soblidotin|
48694260|NCT04938310|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
48694261|NCT04938310|DEVICE|support garment|A custom made support garment
48694262|NCT05297786|DRUG|Lanadelumab Injection [Takhzyro]|Lanadelumab 300 mg subcutaneous injection
48694263|NCT05297786|DRUG|Placebo|Placebo injection
48694264|NCT05611255|PROCEDURE|Systematic Intermittent Catheterization|A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
48694265|NCT05611255|PROCEDURE|Bladder Scan Guided Catheterization|A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
48694266|NCT04787783|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application
48694267|NCT02919202|PROCEDURE|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
48694268|NCT02919202|PROCEDURE|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
48007983|NCT06571188|OTHER|THORACIC EPIDURAL BLOCK|In group TEB, The epidural catheter will be inserted preoperatively at the T5-T7 vertebral level; the exact level will be at the discretion of the attending anaesthesiologist. A loading dose of bupivacaine 0.25% (max 10 ml) will be administered, followed by an intraoperative infusion of bupivacaine 0.125 % with fentanyl 1 μg/ml.\].
48007984|NCT06571188|OTHER|ERECTOER SPINE BLOCK|The ESP block will be performed as described by Forero et al
48007985|NCT00164450|DRUG|Rifapentine + isoniazid once weekly for 3 months|
48165155|NCT02373605|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
48165156|NCT02188277|DRUG|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
48165157|NCT02188277|DRUG|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
48165158|NCT02611375|OTHER|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
48165159|NCT02611375|OTHER|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
48694269|NCT05302167|BEHAVIORAL|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
48694270|NCT05302167|DEVICE|Molehill Mountain app|As above.
48007986|NCT02615951|OTHER|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
48007987|NCT04089540|PROCEDURE|New intubation method|
48694271|NCT03960060|BIOLOGICAL|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
48694272|NCT01301066|DRUG|Pitavastatin|Pitavastatin 4 mg QD
48694273|NCT01301066|DRUG|Pravastatin|Pravastatin 40 mg QD
48007988|NCT04089540|PROCEDURE|Conventional intubation method|
48007989|NCT00043693|BEHAVIORAL|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
48007990|NCT00043693|BEHAVIORAL|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
48694274|NCT03794349|BIOLOGICAL|Dinutuximab|Given IV
48165160|NCT02611375|OTHER|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
48165161|NCT03461211|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
48165162|NCT01046071|PROCEDURE|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
48165163|NCT01046071|PROCEDURE|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
48165164|NCT04443881|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
48165165|NCT04872101|DRUG|Delgocitinib cream|Cream for topical application
48007991|NCT01889017|OTHER|patient questionnaire (tablet pc based)|
48165166|NCT04872101|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
48165167|NCT01086878|DRUG|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
48165168|NCT03968536|BEHAVIORAL|fall prevention|Training in physiotherapy sessions and ergonomic home development
48369250|NCT06242886|BEHAVIORAL|Oxytocin massage|Oxytocin massage group: The mother was positioned on a chair with her breasts bare and free, placing her arms on the table at her height and her head on her arms. The researcher who applied the massage applied the massage up and down to either side of the spine between the mother's scapula bones with her thumbs in front and pressing her fists tightly and making small circular movements with her thumbs for three minutes. The mothers received four oxytocin massages over the course of 24 hours.
48165169|NCT03643705|OTHER|Multi-component intervention|4 components as described
48369251|NCT06242886|BEHAVIORAL|and Breast massage|Breast massage group: The mother's upper clothes were removed by the researcher. With the palms of the hand the breast grasped from the bottom and top. The hands were advanced by pressing slowly from the base of the nipple towards the nipple. With the palms, the breast was grasped from the bottom and top and gently pressed. Using fingertips, the breast was scanned by massaging from the base of the nipple to the nipple in circular movements. The mothers received breast massage four times over the course of 24 hours.
48369252|NCT01977664|OTHER|no intervention|
48369253|NCT02968095|BEHAVIORAL|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
48369254|NCT02968095|BEHAVIORAL|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
48007992|NCT02259933|DRUG|KUC 7483 CL|
48007993|NCT02259933|DRUG|Placebo|
48007994|NCT05068973|DEVICE|NOVATECH® LUCIOLA™ EB - (Fiducial Marker)|Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker
48007995|NCT03575884|BEHAVIORAL|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
48007996|NCT05908279|OTHER|Walking test|Walk with and without a metronome
48007997|NCT05908279|OTHER|Disease assessement|Disease stage assessed by a doctor
48165170|NCT03643705|OTHER|General prevention education|General education as described
48369255|NCT03914131|DRUG|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
48369256|NCT03914131|OTHER|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
48369257|NCT03824574|DEVICE|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
48369258|NCT05222841|DIETARY_SUPPLEMENT|Spermotrend|Patients who are treated with Spermotrend (536,62g) are given 3 capsules every day for 3 months, taken orally every 8 hours.
48007998|NCT01565291|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
48007999|NCT00326612|DRUG|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
48165171|NCT05244226|DRUG|Fentanyl/Hydromorphone|Per routine care
48165172|NCT05244226|DRUG|Methadone|Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis
48165173|NCT02222532|DRUG|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
48165174|NCT02222532|DRUG|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
48165175|NCT05114902|DIAGNOSTIC_TEST|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
48165176|NCT05144438|DIAGNOSTIC_TEST|Toxseek test|Hair taking
48165177|NCT02536885|PROCEDURE|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
48369259|NCT04772118|OTHER|Carevive PROmpt™|Patient Reported Outcomes Mobile Patient (Carevive PROmpt™), a digital cancer symptom monitoring platform.
48369260|NCT00606463|DEVICE|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
48165178|NCT02536885|PROCEDURE|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
48369261|NCT04905160|OTHER|COMPASSION Digital Biomarker|Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.
48369262|NCT03241134|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
48694275|NCT03794349|DRUG|Eflornithine Hydrochloride|Given PO or via NG or G tube
48008000|NCT00326612|DRUG|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
48008001|NCT00004144|DRUG|bryostatin 1|
48008002|NCT00004144|DRUG|gemcitabine hydrochloride|
48008003|NCT00771433|BIOLOGICAL|filgrastim|Given subcutaneously
48369263|NCT03241134|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
48369264|NCT00773994|OTHER|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
48369265|NCT03086252|PROCEDURE|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
48369266|NCT03845426|OTHER|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
48369267|NCT01939015|DEVICE|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
48369268|NCT01939015|DEVICE|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
48369269|NCT04357834|OTHER|Equipment with smartwatch throughout hospital stay on the general ward|Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
48008004|NCT05291364|DRUG|Group 1|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
48008005|NCT05291364|DRUG|Group 2|Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
48008006|NCT03521453|OTHER|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
48165179|NCT03364283|PROCEDURE|Surgical position|
48165180|NCT00574626|PROCEDURE|PBSCT|Peripheral Blood Stem Cell Transplant
48165181|NCT00574626|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant
48165182|NCT03168425|OTHER|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
48369270|NCT04257656|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
48165183|NCT03168425|OTHER|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
48165184|NCT01903928|BIOLOGICAL|ASP0113|injection
48165185|NCT02815735|DEVICE|comfilcon A|contact lens
48165186|NCT02815735|DEVICE|lotrafilcon B|contact lens
48165187|NCT02961777|OTHER|implementation of care pathway|implementation of a care pathway
48369271|NCT04257656|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
48369272|NCT02930928|OTHER|Accuracy of weight estimation|Computer based comparison
48369273|NCT02045940|DRUG|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
48694276|NCT03794349|DRUG|Irinotecan Hydrochloride|Given IV
48694277|NCT03794349|BIOLOGICAL|Sargramostim|Given SC or IV
48694278|NCT03794349|DRUG|Temozolomide|Given PO or via NG or G tube
48694279|NCT06446375|OTHER|exercise|FIFA 11+ KIDS Training Protocol consists of seven different exercises: three for unilateral, dynamic stability of the lower limbs (hopping, jumping and landing); three for whole body and trunk strength/stability; and one exercise on falling technique.
48694280|NCT06446375|OTHER|Regular daily activity|Regular physical activity
48694281|NCT01067118|DRUG|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
48008007|NCT05886166|OTHER|robot assisted training|Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
48008008|NCT03627728|DRUG|Regorafenib|regorafenib/placebo
48008009|NCT03627728|OTHER|placebo|regorafenib/placebo
48165188|NCT03053635|DRUG|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
48165189|NCT06411210|DRUG|Semaglutide Pen Injector|Escalated to 2.4mg or max tolerated dose
48694282|NCT01067118|DRUG|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
48165190|NCT06411210|DRUG|Placebo|Matched placebo.
48165191|NCT01913288|OTHER|Biological Maternal Sounds|
48165192|NCT02391545|DRUG|Duvelisib|PI3K Inhibitor
48165193|NCT02391545|DRUG|Rituximab|monoclonal antibody
48694283|NCT00841776|DRUG|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
48694284|NCT00841776|DRUG|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
48694285|NCT06125184|DRUG|Vasopressor test|Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
48694286|NCT02468531|OTHER|oxygen|50% oxygen inhalation
48694287|NCT02468531|DRUG|Xenon|50% Xenon inhalation
48694288|NCT04060888|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
48694289|NCT04060888|DRUG|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
48694290|NCT04060888|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
48694291|NCT00810277|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
48694292|NCT01716039|DRUG|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
48694293|NCT01716039|DRUG|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
48694294|NCT01716039|DRUG|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
48694295|NCT01166893|DEVICE|Modulated Imaging and Laser Speckle Imaging|wound healing
48694296|NCT03563742|DRUG|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
48694297|NCT03563742|DRUG|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
48008010|NCT06156254|BEHAVIORAL|Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
48694298|NCT06659510|OTHER|education|ACCORDING TO THE RESULTS AFTER THE SURVEY APPLICATION, TRAINING WAS PROVIDED TO THE ADDICTIVE STUDENTS IN THE EXPERIMENT GROUP AND MESSAGES WERE SENT FROM WHATSAPP APPLICATION IN THE FOLLOWING 2 MONTHS AFTER THE TRAINING.
48694299|NCT05471843|DRUG|BGB-11417|Administered orally
48694300|NCT06659926|OTHER|68Ga-PSMA-PET/CT scan|68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
48694301|NCT06212063|BEHAVIORAL|Cadet Health|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
48694302|NCT06574880|DRUG|Lu-PSMA-617|"Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule:~* Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT.~* Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2.~* Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3."
48694303|NCT06574880|RADIATION|5-fraction Stereotactic Body Radiation Therapy (SBRT)|Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).
48694304|NCT04549571|OTHER|Decision Aid iCanDecide - ESE website|Utilize the iCanDecide - ESE website
48694305|NCT04549571|OTHER|Decision Aid iCanDecide - S website|Utilize the iCanDecide - S website
48694306|NCT04549571|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48694307|NCT04549571|OTHER|Interview|Participate in interview
48694308|NCT04549571|OTHER|Training|Receive training
48694309|NCT04549571|OTHER|Media Intervention|Utilize the CDB
48694310|NCT04549571|OTHER|Best Practice|Utilize usual care
48694311|NCT04549571|OTHER|Survey Administration|Ancillary studies
48694312|NCT04549571|OTHER|Quality-of-Life Assessment|Ancillary studies
48694313|NCT03839225|OTHER|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
48694314|NCT06658262|OTHER|Tai Chi Exercises With Cycling Exercises|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.
48694315|NCT06658262|OTHER|Tai Chi Exercises Alone|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
48694316|NCT01651819|PROCEDURE|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
48694317|NCT06568237|DRUG|TEV-56286|TEV-56286 capsules administered orally
48514131|NCT05076448|PROCEDURE|Gonadal veins resection|"Gonadal veins resection (GVR) was performed open, transperitoneal and retroperitoneal endoscopic methods under general anesthesia.~Open GVR was performed in the Trendelenburg position, on the back with the operating table rotating 30° The retroperitoneal approach was employed in the left and/or right iliac region. The GV was mobilized for 10-12 cm and the vein was resected..~Transperitoneal GVR was performed with 3 ports were placed: one 10-mm port in the umbilical region, one 5-mm port in the left or right iliac region, and one 5-mm port 5 cm below the umbilicus. The GV was mobilized over a length of 10-12 cm and the vessel was resected.~Retroperitoneal GVR was performed with the patient in a lateral position and in the reverse Trendelenburg position. A 10-mm camera port was installed in the lumbar region between the posterior superior iliac spine and the lower edge of the XII rib. The GV was mobilized over a length of 10-12 cm and the vessel was resected."
48694318|NCT06568237|DRUG|Placebo|Matching placebo administered orally
48694319|NCT02453152|OTHER|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
48694320|NCT02453152|OTHER|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
48008011|NCT00754182|DEVICE|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
48008012|NCT00754182|DEVICE|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
48165194|NCT02391545|DRUG|Obinutuzumab|monoclonal antibody
48165195|NCT03087461|BEHAVIORAL|Exercise and self-management|The intervention will include aerobic exercise and self-management education using technology.
48008013|NCT02388984|DRUG|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
48008014|NCT02388984|DRUG|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
48008015|NCT02930850|DEVICE|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
48165196|NCT03258099|GENETIC|detection of genotype|detection of genotype by next generation sequencing
48165197|NCT04043806|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
48165198|NCT04043806|DRUG|IVA|Tablet for oral administration.
48008016|NCT02353481|OTHER|Heart Failure Management|
48008017|NCT03215134|OTHER|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre \& Rimes, submitted) and is now being evaluated in a primary mental-health service.
48008018|NCT02872636|DEVICE|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
48008019|NCT03872180|DRUG|Bendamustine|Given IV
48165199|NCT02618785|PROCEDURE|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
48165200|NCT06117761|OTHER|Attention Placebo|Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
48165201|NCT06117761|OTHER|Home-based exercises combined with cognitive training|An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.
48165202|NCT06117761|OTHER|Home-based exercises|An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
48165203|NCT00058942|DEVICE|home drinking water treatment device|
48165204|NCT01645358|DEVICE|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
48165205|NCT01645358|DEVICE|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
48165206|NCT04613622|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
48165207|NCT06344364|DIAGNOSTIC_TEST|Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)|Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.
48165208|NCT05087667|DEVICE|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
48165209|NCT05087667|DEVICE|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
48165210|NCT01178281|DRUG|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
48165211|NCT01178281|DRUG|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
48165212|NCT01178281|DRUG|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
48165213|NCT04369300|BEHAVIORAL|Registery Data Collection|Observational Data Collection
48008020|NCT03872180|BIOLOGICAL|Obinutuzumab|Given IV
48165216|NCT00803335|DRUG|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
48008021|NCT03872180|DRUG|Venetoclax|Given PO
48008022|NCT03742141|DEVICE|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
48008023|NCT03742141|DRUG|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
48008024|NCT03710278|DEVICE|LPat Device|Performing Lumbar Puncture utilizing LPat device
48008025|NCT02214277|DEVICE|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
48008026|NCT02214277|DEVICE|TAVR|
48694321|NCT02453152|OTHER|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
48165217|NCT00803335|DRUG|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
48165218|NCT03669900|PROCEDURE|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
48165219|NCT00543166|DRUG|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
48165220|NCT04547166|DRUG|HLX10|a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
48165221|NCT04547166|DRUG|HLX04、|7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
48008027|NCT02484495|OTHER|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
48008028|NCT02911675|DEVICE|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
48165222|NCT00397202|DEVICE|Diva Cup TM|See Detailed Description.
48165223|NCT04702399|DEVICE|GEL GROUP|Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
48165224|NCT03375697|DRUG|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
48165225|NCT03375697|DRUG|Placebo|Subjects will receive matching placebo intravenously.
48694322|NCT02453152|OTHER|Peak cough flow|Subjects' strongest coughs will be measured.
48369274|NCT02045940|DRUG|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
48694323|NCT02453152|OTHER|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
48694324|NCT02453152|OTHER|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
48008029|NCT00542152|DRUG|CYCLOSPORINE VS INFLIXIMAB|"* Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~* Infliximab 5mg/kg at weeks 0, 2 and 6"
48008030|NCT00049062|DRUG|anastrozole|
48008031|NCT00049062|DRUG|gefitinib|
48008032|NCT06023784|PROCEDURE|left bundle branch area pacing|Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
48694325|NCT02453152|OTHER|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
48694326|NCT05051722|DIAGNOSTIC_TEST|Tampon Collection|A tampon will be self-inserted by each participant prior to any exams or procedures and removed after 40 minutes..
48694327|NCT05051722|DIAGNOSTIC_TEST|Blood Collection|A blood sample will be collected from each participant prior to undergoing any exams or procedures.
48694328|NCT05609370|DRUG|LBL-007|Low dose intravenously (IV) once every 3 weeks.
48694329|NCT05609370|DRUG|LBL-007|Medium dose IV once every 3 weeks
48694330|NCT05609370|DRUG|LBL-007|High dose IV once every 2 or 3 weeks
48694331|NCT05609370|DRUG|Tislelizumab|Low dose IV once every 3 weeks
48694332|NCT05609370|DRUG|Tislelizumab|High dose IV once every 4 weeks
48694333|NCT05609370|DRUG|Bevacizumab biosimilar|7.5 mg/kg IV every 3 weeks
48694334|NCT05609370|DRUG|Bevacizumab biosimilar|5 mg/kg IV once every 2 weeks
48694335|NCT05609370|DRUG|Capecitabine|850 milligrams per square meter (mg/m\^2) twice daily orally for 2 weeks, followed by a one-week treatment break every 3 weeks
48694336|NCT05609370|DRUG|5-Fluorouracil|1600 to 2400 mg/m\^2 IV every 2 weeks
48694337|NCT03851406|DEVICE|5% Hypertonic Saline|Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
48694338|NCT03851406|OTHER|No treatment|No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
48694339|NCT06094361|PROCEDURE|Iontophoresis Intervention|Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.
48694340|NCT06094361|PROCEDURE|Phonophoresis|Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.
48694341|NCT06094361|PROCEDURE|Conventional Therapy|All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
48694342|NCT01707654|DEVICE|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
48694343|NCT03424993|OTHER|Dietary Sodium Restriction|A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
48694344|NCT03424993|OTHER|Control|Participants will consume their routine habitual dietary sodium intake \> 3400mg per day with regular pre determined check in phone calls from a registered dietician.
48694345|NCT01764477|DRUG|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
48694346|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
48694347|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
48694348|NCT01407835|BIOLOGICAL|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
48694349|NCT04637724|DEVICE|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
48694350|NCT02933424|DIETARY_SUPPLEMENT|Protein Powder|
48694351|NCT06584916|DRUG|Orforglipron|Administered orally
48694352|NCT06584916|DRUG|Placebo|Administered orally
48694353|NCT06414135|BIOLOGICAL|Relma-cel|All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
48694354|NCT06653751|DEVICE|Reminder App|he purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
48694355|NCT06284590|DRUG|L19IL2|Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.
48369275|NCT03642249|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
48369276|NCT03642249|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
48008033|NCT06023784|PROCEDURE|right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
48008034|NCT04306510|PROCEDURE|Blood samples for immunoglobulins|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for immunoglubulins at a clinic visit every 4 months for up to 2 years.
48008035|NCT04306510|PROCEDURE|Blood samples for inflammatory markers|Following an injection of TEGSEDI as prescribed by their physician per the product label, patients will have additional blood tests at 1, 2, 4, 8 and 24 hours post injection for inflammatory markers at a clinic visit every 4 months for up to 2 years.
48008036|NCT04306510|PROCEDURE|Blood samples for anti-drug antibodies|Patients taking TEGSEDI as prescribed by their physician per the product label, patients will have additional blood samples for anti-drug antibodies at various time-points as indicated in the event of hypersensitivity reactions.
48008037|NCT01008111|DRUG|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
48008038|NCT01008111|DRUG|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
48008039|NCT00754247|DRUG|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
48008040|NCT00754247|DRUG|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
48008041|NCT00754247|DRUG|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
48008042|NCT05828277|DRUG|repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
48165226|NCT05063981|DRUG|Mepolizumab|Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
48165227|NCT04672655|BEHAVIORAL|ONBOARD|Session 1: Overview; Wearing diabetes devices; Session 2: Managing CGM data; Session 3: CGM \& social situations; Session 4: Building trust with your CGM
48165228|NCT01243398|PROCEDURE|quality-of-life assessment|
48369277|NCT03642249|BEHAVIORAL|E-learning|delirium care video
48369278|NCT04893382|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
48369279|NCT04893382|PROCEDURE|Ringer's Lactate for fluid resuscitation|Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
48369280|NCT01854502|BEHAVIORAL|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
48165229|NCT05526456|PROCEDURE|Esophagectomy|McKeown, Ivor-Lewis, and Sweet procedure
48165230|NCT02979613|DRUG|TAF|25 mg tablet administered orally once daily
48165231|NCT02979613|DRUG|TDF|300 mg tablet administered orally once daily
48165232|NCT02979613|DRUG|TAF Placebo|Tablet administered orally once daily
48165233|NCT02979613|DRUG|TDF Placebo|Tablet administered orally once daily
48165234|NCT03771534|DRUG|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
48165235|NCT02445183|OTHER|None, N/A|
48369281|NCT01854502|BEHAVIORAL|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
48369282|NCT00287261|DRUG|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
48369283|NCT01855919|DRUG|Duloxetine|Administered orally
48369284|NCT01855919|DRUG|Placebo|Administered orally
48369285|NCT04524663|DRUG|Camostat Mesilate|Camostat Mesilate administered as oral tablets
48369286|NCT04524663|DRUG|Placebo|Placebo to match camostat mesilate
48369287|NCT04524663|OTHER|Standard of Care Treatment|Standard of Care Treatment for COVID-19 Infection
48369288|NCT04422301|OTHER|Blood flow restriction|an alternative method to produce strength and muscle hypertrophy with lower intensities
48694356|NCT06284590|DRUG|L19TNF|Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.
48165236|NCT06312995|DEVICE|T3DDY01|Digital acquisition of the patient's forearm using Intel RealSense D415 cameras (CE devices certified according to EN/IEC 60825-1 2007 - Safety of Laser product as Class I Laser Devices, i.e., Non-Hazardous Laser Radiation). The patient's arm is placed on a support to allow the plaster nurse to position the wrist at the correct angle needed to treat the fracture.
48165237|NCT06312995|DEVICE|PLASTER|Standard treatment plaster for fractures.
48165238|NCT01276509|DRUG|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
48369289|NCT02713633|OTHER|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
48369290|NCT02713633|OTHER|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
48369291|NCT01213121|DRUG|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
48369292|NCT03911401|DRUG|0.3% OPA-15406|Twice daily
48369293|NCT03911401|DRUG|1% OPA-15406|Twice daily
48369294|NCT03911401|DRUG|Placebos|Twice daily
48369295|NCT06191562|DEVICE|Tympanostomy tube|Participants will receive an ear tube in the usual location (anterior-inferior) in one ear and a new location (posterior-inferior) in the other ear during surgery.
48369296|NCT05782504|BEHAVIORAL|Patient-centered teleprehabilitation|"Education about the consequences of stress and low physical activity levels with examples of how improving stress tolerance and physical activity can influence QoL and oncological treatment outcomes.~Exercise therapy based on shared-decision making and using a patient-centered approach. The goal will be to strive for 150-220 min. of moderate physical activity/week, including a home exercise program (at least 1 session/week) of 30-45 min. moderate aerobic exercise, 20 min. of strength training and 10 min. cool down. The latter is guided by Physitrack software.~Stress management, including questioning personal stress experiences and perceptions, relevant stressors, and stress coping strategies. Next, 3 different relaxation strategies will be explained. Also, cognitive-emotional approaches to stress management and identification of uplifts will be introduced.~Motivational interviewing will be used during the whole intervention."
48369297|NCT02873806|PROCEDURE|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
48694357|NCT06284590|DRUG|L19IL2/L19TNF|Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
48694358|NCT06284590|DRUG|KEYTRUDA®|KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
48694359|NCT06347068|BIOLOGICAL|iC9-CAR.B7-H3 T Cell Therapy|iC9-CAR.B7-H3 T cells will then be administered intravenously
48694360|NCT06347068|DRUG|cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
48694361|NCT06347068|DRUG|fludarabine|fludarabine 30 mg/m2 IV will be given.
48694362|NCT04659174|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
48694363|NCT05058196|RADIATION|Whole breast radiotherapy|Whole breast radiotherapy after surgery
48694364|NCT05058196|RADIATION|Intra Operative Radiotherapy|Intra Operative Radiotherapy
48694365|NCT05926349|DRUG|Andexanet alfa|Andexanet is a recombinant version of human FXa
48694366|NCT05926349|DRUG|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
48165239|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
48165240|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
48165241|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
48165242|NCT00114543|PROCEDURE|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
48165243|NCT00114543|PROCEDURE|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
48165244|NCT00114543|PROCEDURE|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
48694367|NCT05647772|BEHAVIORAL|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
48694368|NCT05647772|BEHAVIORAL|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
48694369|NCT05647772|BEHAVIORAL|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
48694370|NCT04294901|BEHAVIORAL|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
48694371|NCT06519513|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
48694372|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
48694373|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
48694374|NCT05492500|DRUG|Main cohort (Cohort A): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
48694375|NCT05492500|OTHER|Main cohort (Cohort A): Matched placebo|Matched placebo subcutaneous injection
48694376|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab low dose|ponsegromab low dose subcutaneous injection
48694377|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
48694378|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
48694379|NCT05492500|DRUG|Optional Cohort C: Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
48694380|NCT05492500|OTHER|Optional Cohort C: Matched placebo|Matched placebo subcutaneous injection
48694381|NCT05492500|DRUG|Optional Cohort D: Ponsegromab high dose|Ponsegromab high dose subcutaneous injection
48694382|NCT05492500|OTHER|Optional Cohort D: Matched placebo|Matched placebo subcutaneous injection
48694383|NCT05904496|DRUG|BGB-30813|Specified dose administered on specified days
48694384|NCT05904496|DRUG|Tislelizumab|Specified dose administered on specified days
48694385|NCT06657092|PROCEDURE|Erector Spinae Plane Block|Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.
48694386|NCT06657092|PROCEDURE|Standart therapy|Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
48165245|NCT00114543|PROCEDURE|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
48694387|NCT06658769|OTHER|Theta Burst Stimulation|Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.
48694388|NCT06658769|OTHER|Theta Burst Stimulation Sham|Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.
48694389|NCT06232603|OTHER|Education of medication management|Video and handout materials will be provided
48694390|NCT04785534|OTHER|Clinical Evaluation|Undergo clinical evaluation
48369298|NCT02873806|DRUG|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
48165246|NCT02895698|DEVICE|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
48165247|NCT02895698|OTHER|Stretching exercises|"* The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~* Standing self-stretching of the calf muscles.~* Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~* All stretches were done six times and the duration of each stretch is 30 seconds."
48369299|NCT02873806|DEVICE|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
48369300|NCT02873806|DRUG|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
48694391|NCT04785534|OTHER|Laboratory Biomarker Analysis|Correlative studies
48694392|NCT04785534|PROCEDURE|Liver Ultrasonographic Elastography|Undergo fibroscan
48694393|NCT04785534|OTHER|Survey Administration|Complete survey
48694394|NCT04829682|BEHAVIORAL|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
48694395|NCT04829682|BEHAVIORAL|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
48694396|NCT06469359|DEVICE|Nasal tissue-resident memory T and B cells|Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
48694397|NCT06469359|DEVICE|Nasal fluid sampling|Nasal fluid is collected using strip (Hunt Development) in both nostrils
48165248|NCT01480440|DEVICE|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
48165249|NCT00287157|DRUG|Sublingual Tizanidine HCl|
48369301|NCT02873806|DRUG|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye"
48369302|NCT05973565|OTHER|Musicokinetic Training|The intervention protocols are either a) synchronous learning format, b) asynchronous remote video- based, and c) control.
48369303|NCT04020042|OTHER|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
48369304|NCT04020042|OTHER|Landmark palpation|Epidural landmarks will be determined with palpation
48694398|NCT06469359|DEVICE|Saliva sampling|Saliva is collected using Oracol (Malvern Medical Developments)
48165250|NCT04027491|BEHAVIORAL|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
48165251|NCT05765838|DIAGNOSTIC_TEST|(NPS right - Nasal swab left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165252|NCT05765838|DIAGNOSTIC_TEST|(NPS left - Nasal swab right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48369305|NCT00781027|PROCEDURE|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
48694399|NCT06469359|OTHER|Blood sampling|Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood
48694400|NCT06469359|DIAGNOSTIC_TEST|ELISA|ELISA to measure antibody responses in mucosal fluids and blood
48694401|NCT06469359|DIAGNOSTIC_TEST|Neutralization test|Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
48694402|NCT06469359|DIAGNOSTIC_TEST|ELISPot|ELISPot to measure cellular responses in blood
48694403|NCT06469359|DIAGNOSTIC_TEST|Transcriptomics|Transcriptomics to quantify the gene expression of immunological markers in blood
48694404|NCT06658626|DRUG|[¹⁴C]Enlicitide chloride|IV Injection
48694405|NCT00113204|DRUG|IPI-504|
48165253|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - NPS left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165254|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - NPS right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165255|NCT05765838|DIAGNOSTIC_TEST|(NPS right - OPS - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165256|NCT05765838|DIAGNOSTIC_TEST|(NPS left - OPS - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48369306|NCT01594164|RADIATION|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
48369307|NCT01594164|RADIATION|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
48694406|NCT06662019|DRUG|N-IP-00001 inhalation solution|Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).
48694407|NCT06662019|DRUG|0.9% NaCl isotonic saline solution|Nebulized treatment consisting of 0.9% saline solution.
48694408|NCT06660836|DEVICE|Mouthguard|After the participants' records are taken with intraoral scanners, custom mouthguards will be prepared from soft EVA sheets in a dental laboratory setting.
48694409|NCT06660836|OTHER|Performance test|Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
48008043|NCT00203749|BEHAVIORAL|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
48694410|NCT01684696|BEHAVIORAL|Virtual experience|
48694411|NCT01684696|BEHAVIORAL|Videos|
48694412|NCT06586138|OTHER|STAI (State-Trait Anxiety Inventory) Scale : Psychological inventory of 20 self-report items on a 4-point scale|Patient completed STAI Scale in the 24 hours before Maintenance of Wakefulness Test during the hospitalization
48694413|NCT04023591|PROCEDURE|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
48369308|NCT02828852|OTHER|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
48369309|NCT01560806|OTHER|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
48369310|NCT05512585|OTHER|awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)|in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
48694414|NCT06660420|DRUG|Cyclophosphamide|Given by IV
48694415|NCT06660420|DRUG|Fludarabine|Given by IV
48694416|NCT06662266|DEVICE|Induce XT™ is a mixture of human cortical bone fibers and microparticulates that have been processed into Natural Matrix Protein® (NMP®) to which cancellous bone microparticulates have been added|"Bone graft material is required for successful foot and ankle fusion surgery. Current bone grafting materials include autogenous bone, Augment Bone Graft and demineralized bone matrix (DBM), each of which have limitations.~Induce XT is a novel bone graft material that can potentially be used in foot and ankle fusions that may overcome some of these limitations."
48694417|NCT06192758|DEVICE|TheraSphere PCa|Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
48694418|NCT01235845|BIOLOGICAL|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
48694419|NCT05995678|BEHAVIORAL|STEP-Home-SP|This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
48008044|NCT00203749|BEHAVIORAL|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
48008045|NCT01529359|DIETARY_SUPPLEMENT|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
48008046|NCT01529359|DIETARY_SUPPLEMENT|Placebo|Placebo 2 gelules per days for 6 weeks
48008047|NCT02696096|OTHER|FMRI|all participants will complete 2 FMRIs
48008048|NCT02696096|DRUG|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
48008049|NCT00347295|DRUG|Brotizolam|
48008050|NCT00347295|DRUG|Estazolam|
48165257|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - OPS - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165258|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - OPS - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48369311|NCT05801679|DRUG|Sugammadex|Fifteen minutes after ICU arrival, subjects will be administered sugammadex (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
48165259|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS right - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48369312|NCT05801679|OTHER|Placebo|Fifteen minutes after ICU arrival, subjects will be administered placebo (2 mg/kg assuming a twitch count of 2-4 of 4 or 4mg/kg assuming a twitch count less than 2 of 4) by the anesthesia provider. Five minutes after administration, a quantitative neuromuscular monitor (TetraGraph, Senzime, Uppsala, Sweden) will be applied and the TOF ratio will be recorded.
48369313|NCT03262246|OTHER|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
48369314|NCT03938857|DRUG|Fentanyl|Fentanyl standard of care
48369315|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
48369316|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
48369317|NCT03938857|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
48369318|NCT04279041|PROCEDURE|root canal preparation|root canal preparation
48369319|NCT01489449|DEVICE|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
48694420|NCT05995678|BEHAVIORAL|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
48694421|NCT05995678|BEHAVIORAL|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
48008051|NCT04131101|BEHAVIORAL|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
48369320|NCT01489449|COMBINATION_PRODUCT|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
48369321|NCT04884009|DRUG|SHR-1701； Famitinib|SHR-1701+ Famitinib
48369322|NCT04884009|DRUG|SHR-1701|SHR-1701
48369323|NCT02390167|DEVICE|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
48165260|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS left - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165261|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab left - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165262|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab right - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
48165263|NCT00012636|PROCEDURE|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
48165264|NCT03342170|GENETIC|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
48165265|NCT06645548|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
48369324|NCT00899327|GENETIC|DNA methylation analysis|
48369325|NCT00899327|GENETIC|RNA analysis|
48369326|NCT00899327|GENETIC|cytogenetic analysis|
48369327|NCT00899327|GENETIC|gene expression analysis|
48369328|NCT00899327|GENETIC|mutation analysis|
48369329|NCT00899327|GENETIC|polymerase chain reaction|
48369330|NCT00899327|GENETIC|protein expression analysis|
48369331|NCT00899327|OTHER|laboratory biomarker analysis|
48369332|NCT02316652|PROCEDURE|Scaling and root planing|Mechanical instrumentation
48369333|NCT02316652|PROCEDURE|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
48008052|NCT06114862|BEHAVIORAL|Stigma-reduction intervention|"Participants will be presented with a list of common reasons why people report not wanting to tell other people about their mental health concerns, drawing from research in this area. Participants will be asked to click on any reason that resonates with them or about which they are interested in learning more. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns. For example, if a participant replies that they wouldn't reach out to peers because others don't understand what I'm going through, we might present context showing that many of their peers have had similar challenges with mental health and have found peer support helpful. Participants will be able to click on as many reasons on this list that they would like to."
48008053|NCT00907283|DRUG|Deferiprone|15 mg/Kg/twice for 1 year
48008054|NCT02378844|DEVICE|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
48008055|NCT02378844|DEVICE|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
48694422|NCT05508984|DEVICE|Amma Cooling Caps|"Once enrolled, subjects will be provided the Amma device by the clinic on days of chemotherapy treatment, and upon completion of treatment it will be returned to the clinic for safekeeping. Upon completion of chemotherapy, anywhere from 3-6 weeks following treatment, subjects will repeat the questionnaires and their hair will be photographed again.~The overall duration of the study for subjects will be anywhere from 4 months to 8 months, depending on the duration of their chemotherapy regimen."
48694423|NCT01766063|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
48008056|NCT01299831|BEHAVIORAL|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
48008057|NCT01299831|BEHAVIORAL|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
48008058|NCT01299831|DRUG|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
48008059|NCT01299831|DRUG|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
48165266|NCT05458154|OTHER|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
48165267|NCT00347425|DRUG|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
48694424|NCT05222620|OTHER|Questionnaire Administration|Ancillary studies
48694425|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo single fraction SRS
48694426|NCT05222620|RADIATION|Stereotactic Radiosurgery|Undergo fractionated SRS
48694427|NCT05222620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48694428|NCT05875727|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
48694429|NCT02744495|DRUG|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
48694430|NCT02744495|DRUG|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
48694431|NCT02106949|DEVICE|SMS contact with patient after discharge in intervention group|
48694432|NCT04343430|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
48008060|NCT01947400|OTHER|Hospitalists|AIDET Training
48008061|NCT02953990|BEHAVIORAL|MOMS Program|
48694433|NCT04343430|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
48694434|NCT04343430|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
48694435|NCT04343430|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
48694436|NCT04343430|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
48694437|NCT04343170|DRUG|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
48008062|NCT03366350|PROCEDURE|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
48008063|NCT01589822|BIOLOGICAL|EVICEL Fibrin Sealant|Intraoperative
48165268|NCT00347425|DRUG|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
48165269|NCT00347425|DRUG|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
48165270|NCT00347425|DRUG|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
48165271|NCT00347425|DRUG|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
48165272|NCT00347425|DRUG|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
48165273|NCT00347425|DRUG|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
48165274|NCT00347425|DRUG|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
48165275|NCT00347425|DRUG|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
48165276|NCT00347425|DRUG|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
48369334|NCT05470530|DRUG|Dexamethasone|Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
48008064|NCT00531843|DRUG|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
48008065|NCT00531843|DEVICE|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
48008066|NCT02884089|DRUG|Abemaciclib|Administered orally
48165277|NCT05723289|DEVICE|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
48165278|NCT04787718|OTHER|Almond|2.0 oz of raw, shelled, unsalted almonds
48165279|NCT04787718|OTHER|Control group|an isocaloric amount of unsalted pretzels
48165280|NCT01267058|BIOLOGICAL|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
48165281|NCT01267058|BIOLOGICAL|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
48369335|NCT03324282|DRUG|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
48369336|NCT03324282|DRUG|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
48369337|NCT02411032|BEHAVIORAL|Reminder|Customer gets mailing that reminds them to take their medication.
48008067|NCT02884089|DRUG|Metformin|Administered orally
48008068|NCT02884089|DRUG|Iohexol|Administered intravenously (IV)
48008069|NCT02884089|DRUG|Placebo|Administered orally
48008070|NCT00019435|BIOLOGICAL|LMB-9 immunotoxin|
48008071|NCT03191903|COMBINATION_PRODUCT|Cingal|Hyaluronic Acid with Triamcinolone Hexacetonide
48008072|NCT03191903|DEVICE|Monovisc|Hyaluronic acid
48369338|NCT02411032|BEHAVIORAL|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
48369339|NCT02411032|BEHAVIORAL|Fresh start framing|The fresh start event will be highlighted in the mailings.
48369340|NCT02903121|DRUG|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
48369341|NCT02903121|DRUG|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
48369342|NCT02903121|DRUG|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
48369343|NCT00033514|BIOLOGICAL|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
48008073|NCT03191903|DRUG|Triamcinolone Hexacetonide|Triamcinolone Hexacetonide
48008074|NCT01209897|BEHAVIORAL|Smoking cessation booklet|
48008075|NCT04912921|DIETARY_SUPPLEMENT|palmitoylethanolamide|4 tablets taken daily (2 in the am and 2 in the pm)
48008076|NCT04912921|DIETARY_SUPPLEMENT|Placebo|4 tablets taken daily (2 in am and 2 in pm)
48165282|NCT01267058|BIOLOGICAL|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
48165283|NCT00234221|BEHAVIORAL|Strengths Based Case Management|
48165284|NCT00234221|BEHAVIORAL|Motivational Enhancement Therapy|
48165285|NCT00234221|BEHAVIORAL|Brief Informational Feedback|
48369344|NCT00033514|DRUG|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
48165286|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year)."
48165287|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with a control App|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks)."
48008077|NCT04912921|DIETARY_SUPPLEMENT|Curcumin|500 mg HydroCurc® twice a day
48008078|NCT04912921|DIETARY_SUPPLEMENT|Control (microcrystalline cellulose)|2 tablets taken daily
48369345|NCT04913584|BEHAVIORAL|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour online group CBT sessions delivered by trained lay peers.
48008079|NCT04782778|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
48008080|NCT02735070|DRUG|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
48369346|NCT04710459|PROCEDURE|cryotherapy|Group 1 included 30 patients, they were subjected to chemoradiotherapy plus endobronchial cryotherapy. Group 2 included include 30 patients, they were subjected to chemoradiotherapy.
48369347|NCT02460185|BEHAVIORAL|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
48369348|NCT03596385|DRUG|Beta blocker|long-term maintenance beta-blocker therapy
48008081|NCT02735070|DRUG|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
48008082|NCT03302702|OTHER|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
48165288|NCT06123819|DEVICE|elastography|. First, strain elastography (it is based upon the fact that hard tissue is more difficulty compressed than soft tissue. SE is a technique that measures the tissue deformation generated by compression, which may be applied with a probe on the body surface for static imaging) will be performed. The elastogram image of the detected lesion, will be evaluated Using color coding ranging from blue, through green and red. All lesions will be scored on elastogram in terms of their Stiffness compared to normal parenchyma. Second, shear wave elastography (is a method to generate shear waves and measure SWV ,based on the principle of fast propagation of shear wave speed in hard tissue and slow propagation in soft tissue , the hardness of tissue is indirectly reflected by measuring shear wave speed ) , will also be calculated individually.
48165289|NCT03441919|RADIATION|PET-CT (positron emission tomography - computer tomography)|PET-CT to determine vascular inflammation
48165290|NCT03441919|DIAGNOSTIC_TEST|Blood drawn|Blood drawn
48369349|NCT01270139|PROCEDURE|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
48369350|NCT01270139|PROCEDURE|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
48008083|NCT06409468|PROCEDURE|Subperiostal tunnel in conjunction with Novomatrix|An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
48369351|NCT01270139|DEVICE|Stenting|60 - in sirolimus-eluting stenting control
48369352|NCT00265876|DRUG|AZD0530|Taken daily every 4 weeks
48369353|NCT00265876|DRUG|gemcitabine hydrochloride|1000mg/m2 IV weekly
48369354|NCT01631123|OTHER|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
48369355|NCT01631123|OTHER|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
48369356|NCT03258710|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
48369357|NCT00021346|DRUG|carboplatin|
48369358|NCT00021346|DRUG|gemcitabine hydrochloride|
48369359|NCT01527058|DRUG|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
48369360|NCT03737812|DRUG|elezanumab|solution for infusion
48369361|NCT03737812|DRUG|placebo|solution for infusion
48008084|NCT03855735|BEHAVIORAL|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
48008085|NCT06031259|DRUG|Idursulfase-IT|Idursulfase-IT intrathecally via IDDD.
48008086|NCT06031259|DRUG|Elaprase|Elaprase IV infusion.
48008087|NCT03918343|OTHER|Blood sample|blood samples (4 times; 14ml per visit)
48165291|NCT03892122|DRUG|Propofol Fresenius|"Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process."
48165292|NCT03892122|DRUG|Dexmedetomidine|is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
48165293|NCT06479252|OTHER|Sit-to-Stand Test (STS)|The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
48165294|NCT06646770|PROCEDURE|Segmentectomy|Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.
48165295|NCT06646770|PROCEDURE|Lobectomy|Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.
48165296|NCT05317377|OTHER|Exercise Therapy|Structured exercises focused on hand functionality
48369362|NCT04643158|DRUG|AZD1402|Randomised participants will receive oral inhalation of AZD1402, via DPI.
48008088|NCT00324779|BIOLOGICAL|rituximab|
48008089|NCT03642691|BIOLOGICAL|Ryplazim|Plasminogen IV replacement therapy
48008090|NCT01914484|DRUG|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
48165297|NCT05317377|DEVICE|Leap Motion Based Exergame|Appropriate games from Leap Motion Based Exergame system focused on hand functionality
48008091|NCT01914484|DRUG|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
48165298|NCT02604342|DRUG|Alectinib|Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
48165299|NCT02604342|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 75 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
48165300|NCT02604342|DRUG|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
48008092|NCT03929835|DRUG|Cannabis oil|T1/C20 CBD
48008093|NCT03929835|DRUG|Placebo|Olive oil with chlorophyl
48008094|NCT00968591|DRUG|Everolimus|
48008095|NCT03653754|DIAGNOSTIC_TEST|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
48008096|NCT05835453|OTHER|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each tray, completing a total of 4 weeks of whitening procedure.
48165301|NCT06632925|PROCEDURE|Catheter ablation|"The catheter ablation strategy is the same as the current treatment approach in patients with AF, according to the consensus of catheter ablation of AF. All procedures will be performed under local sedation or general anesthesia depending on the operator, and each patient will undergo an electrophysiological study and substrate mapping in the fasting state with adequate pre-ablation anticoagulation and transesophageal echocardiography to rule out LA thrombus. All antiarrhythmic drugs except amiodarone will be discontinued for at least 5 half-lives before the procedure.~Step I: Substrate mapping before ablation, Step II: Pulmonary vein isolation (PVI), Step III: Post-ablation mapping in SR immediately after ablation, Step IV: Inducibility after ablation, Step V: Remmaping 30 minutes after ablation"
48165302|NCT02966418|PROCEDURE|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
48165303|NCT02966418|PROCEDURE|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
48514132|NCT05076448|PROCEDURE|Gonadal vein embolization with coils|"Procedure was performed under local anesthesia with 5.0-10.0 mL of 0.5% lidocaine solution with a patient under intravenous sedation. For the left GV embolization, the transfemoral approach was used, while for the right or both GV embolization, the transjugular approach was used. The vein puncture was performed under ultrasound guidance. The 5F multipurpose angiographic catheters (Cordis; USA), standard 'moving core' J .035 guidewire, and an angled hydrophilic guidewire (Radiofocus; Terumo Corp., Japan) were used. For the GV occlusion, the pushable 0.035 standard stainless steel coils (Gianturco; William Cook, Bjæverskov, Denmark) and 0.035 coils made of Inconel with interwoven long collagen fibrils (MReye; Cook Medical Inc., Bloomington, USA) were used. The diameter of coils was 8-12 mm, and the length was 10-20 cm."
48694438|NCT04343170|DRUG|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
48694439|NCT03709745|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
48694440|NCT03709745|DRUG|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
48694441|NCT02975999|DRUG|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
48694442|NCT02975999|DRUG|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
48694443|NCT06658574|DRUG|Acetaminophen|Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
48694444|NCT04113733|OTHER|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
48694445|NCT06658353|DRUG|VC004 Capsules|VC004 Capsules BID
48008097|NCT05498194|DIAGNOSTIC_TEST|ratio of predicted neoantigens|10 ml of whole blood is collected from each patient prior surgery Fresh tumor tissue samples (\~ 1cm3 ) are collected during surgery
48008098|NCT05240846|PROCEDURE|Paramedian conventional palpation group|Patients in this group underwent conventional landmark guided paramedian spinal anesthetic. The spinal anesthesia will be administered based on conventional landmark-based paramedian approach.
48008099|NCT05240846|PROCEDURE|Ultrasound assistance paramedian spinal group|This group will have their spinal anesthetic done based on ultrasound assistance paramedian spinal. Spinal anesthesia with a paramedian approach was performed based on the optimum puncture point, suggested puncture angles, and puncture depth. The suggested puncture angles included the cephalad angle measured by the built-in angle program of the ultrasound and the medial angle measured by a 180° protractor (Deli). The puncture depth, the distance from the skin to the posterior complex, was measured utilizing the ultrasound clipper tool.
48008100|NCT05047991|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
48008101|NCT05047991|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
48008102|NCT05047991|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
48008103|NCT05047991|DRUG|Oxaliplatin|Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
48694446|NCT00320905|BEHAVIORAL|Observational|No intervention
48008104|NCT05047991|DRUG|Nab paclitaxel|Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
48008105|NCT05047991|DRUG|Gemcitabine|Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
48008106|NCT06328790|OTHER|Multidisciplinary Rehabilitation Training|34 Patients will attend the in-person 5-day rehabilitation program (2 h/day) followed by a 12-weeks telemedicine program (1 h/week).
48694447|NCT00211757|DRUG|Divalproex sodium|Study drug.
48694448|NCT00211757|DRUG|Placebo|Placebo comparator.
48369363|NCT04643158|DRUG|Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
48694449|NCT02130687|DRUG|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
48694450|NCT02130687|DRUG|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
48694451|NCT02130687|DRUG|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
48694452|NCT02130687|OTHER|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
48694453|NCT05192928|DEVICE|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
48694454|NCT00235235|PROCEDURE|Biopsy|core biopsy
48694455|NCT00235235|PROCEDURE|Serum Collection|serum collection
48694456|NCT00235235|PROCEDURE|Urine Collection|urine collection
48694457|NCT00235235|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
48694458|NCT00235235|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
48694459|NCT00235235|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
48694460|NCT00235235|DRUG|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
48008107|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and patients with structural/organic diseases|Each subject will undergo behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and interoceptive domains.
48008108|NCT06328790|BEHAVIORAL|Cross-sectional study on patients with FMD and healthy controls (HC)|Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and
48008109|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
48008110|NCT01339975|BIOLOGICAL|Biological sample|"2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression."
48008111|NCT01352390|BEHAVIORAL|Planning Prompt|A prompt to have their child their health test reminder mailing to color
48165304|NCT00385697|BIOLOGICAL|Teplizumab|Daily IV dosing for 14 days, repeated at Week 26
48165305|NCT00385697|DRUG|Placebo|Daily IV dosing for 14 days, repeated at Week 26
48369364|NCT04643158|DRUG|Short acting beta agonist (SABA) (rescue medication)|"In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)"
48369365|NCT04643158|DRUG|Run-in medications (ICS-LABA combination)|"During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care."
48694461|NCT00235235|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
48694462|NCT04838054|DRUG|Stabilized chlorine dioxide oral rinse|Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
48694463|NCT04838054|OTHER|Placebo|Patients received a rinse containing no active ingredients and periodontal basic therapy.
48694464|NCT03812341|OTHER|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
48694465|NCT06657352|DIETARY_SUPPLEMENT|ACS Topical Treatment Group|The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
48694466|NCT06657352|DIETARY_SUPPLEMENT|Topical Placebo Group|The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
48694467|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Treatment Group|The combination group used both the topical and oral ACS products for 12 weeks.
48694468|NCT06657352|DIETARY_SUPPLEMENT|ACS Oral Treatment Group|The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.
48694469|NCT06657352|DIETARY_SUPPLEMENT|Oral Placebo Group|The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
48694470|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Placebo Group|The combination group used both the topical and oral products without ACS for 12 weeks.
48694471|NCT01997606|OTHER|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
48694472|NCT01997606|OTHER|placebo|
48008112|NCT01352390|BEHAVIORAL|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
48165306|NCT05125016|DRUG|REGN4336|Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
48008113|NCT00001180|DRUG|Ovine Corticotropin-Releasing Hormone (oCRH)|
48369366|NCT01941472|OTHER|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
48514133|NCT05076448|PROCEDURE|Endovascular stenting of the common iliac vein (CIV)|"After providing local anesthesia, the left common femoral vein was punctured, a 0.035 guidewire was inserted into the inferior vena cava (IVC), and then a 10F introducer was installed. A balloon catheter was introduced over the guidewire in the left CIV (XXL balloon, Boston Scientific, diameter 14-18, length 40-60 mm), and double balloon dilation of the vessel was performed with a pressure of 6-8 atm. Then, a delivery system was advanced to the area of stenosis in the left CIV, and stent was deployed at the level of confluence of the left CIV and inferior vena cava (IVC) or with a protrusion in the IVC of no more than 1 cm. For better fixation of stent in the venous lumen and prevention of its displacements and migration, a balloon post-dilatation of the stented vessel was performed. In case of residual stenosis, the balloon angioplasty was performed."
48514134|NCT04084457|DIETARY_SUPPLEMENT|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
48694473|NCT06658678|OTHER|Receiving an educational intervention|Patient not receiving any educational intervention
48694474|NCT06649942|DRUG|KP-001|KP-001 100 mg + placebo
48694475|NCT06649942|DRUG|KP-001|KP-001 400 mg
48694476|NCT06649942|DRUG|Moxifloxacin 400 mg|moxifloxacin 400 mg tablet
48694477|NCT06649942|DRUG|Placebo|Placebo
48694478|NCT05787587|DRUG|IDE-161|Oral Medication
48694479|NCT05787587|DRUG|Pembrolizumab|Intravenous Infusion
48694480|NCT05097651|DRUG|Cannabidiol oral solution|Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
48694481|NCT05097651|DRUG|Inert sesame seed oil|Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
48694482|NCT05300568|OTHER|No Intervention|This is a non-product related survey.
48694483|NCT06662331|PROCEDURE|Bilateral Sagittal Split Osteotomy|A surgical procedure to correct dentofacial deformities
48008114|NCT05851352|DIAGNOSTIC_TEST|serum anti-endometrial antibodies|- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique
48008115|NCT04135638|PROCEDURE|Cover Group|"Cover when the ILM flap is everted over the MH gap in a single layer"
48008116|NCT04135638|PROCEDURE|Fill Group|"Fill when the ILM is folded into multiple layers within the MH"
48008117|NCT02188381|OTHER|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
48008118|NCT01234129|DRUG|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
48008119|NCT04199429|BEHAVIORAL|Relationship-Based Care|
48165307|NCT05125016|DRUG|Cemiplimab|Administered concomitantly every 3 weeks (Q3W) by IV infusion
48165308|NCT05125016|DRUG|REGN5678|Administered concomitantly QW by IV infusion
48165309|NCT05125016|DRUG|Sarilumab|Administered once by IV infusion as prophylaxis prior to REGN4336 IV
48165310|NCT01670188|DEVICE|Pneumatic SCD - VenaFlow System (DJO Global)|
48165311|NCT01282697|DRUG|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
48165312|NCT06307964|PROCEDURE|Biological sampling|"* A fragment of the diagnostic transjugular liver biopsy (D0)~* Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible~* Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible"
48369367|NCT04673760|BEHAVIORAL|Specialized palliative home care|"Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team."
48694484|NCT00189800|DRUG|Solifenacin succinate|
48694485|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
48165313|NCT04868318|OTHER|Very-high protein enteral formula|Peptamen® Intense VHP (37% protein)
48008120|NCT02784301|DEVICE|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
48165314|NCT04868318|OTHER|Standard-high protein enteral formula|Peptamen® (16% protein)
48165315|NCT01150019|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
48008121|NCT02784301|BEHAVIORAL|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
48165316|NCT00529555|DRUG|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
48165317|NCT00529555|PROCEDURE|Scaling and root planing|scaling and root planing
48165318|NCT00051103|DRUG|Investigational Cancer Drug|
48165319|NCT03696602|DIAGNOSTIC_TEST|bronchial provocation test|
48165320|NCT05809245|PROCEDURE|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
48369368|NCT01824368|PROCEDURE|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
48369369|NCT05648305|PROCEDURE|Root Canal Treatment/ Re-treatment|The provision of Root Canal Treatment for teeth with Endodontic infection or to prevent Endodontic infection.
48369370|NCT01220024|DRUG|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
48694486|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
48694487|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
48694488|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
48694489|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
48694490|NCT00857831|DIETARY_SUPPLEMENT|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
48694491|NCT06491641|OTHER|Care based on Kolcaba's comfort theory|During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
48165321|NCT06544421|OTHER|Assigned Interventions|Assigned Interventions
48165322|NCT01689285|DRUG|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
48165323|NCT01689285|DRUG|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
48165324|NCT00411177|PROCEDURE|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
48369371|NCT01220024|DRUG|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
48369372|NCT05441722|BEHAVIORAL|Exercise prehabilitation|Exercise on a cycle ergometer 24 hours before chemotherapy infusion.
48165325|NCT00411177|PROCEDURE|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
48165326|NCT01954771|BEHAVIORAL|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
48369373|NCT00372073|DRUG|seliciclib|1200 mg bid x 3 days every 2 weeks
48369374|NCT00372073|DRUG|placebo|1200 mg bid x 3 days every 2 weeks
48369375|NCT01522963|DRUG|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
48369376|NCT02896959|PROCEDURE|Arthroscopic rotator cuff repair|
48369377|NCT04302311|DIAGNOSTIC_TEST|Holter monitoring|Use of smart device application and technologies to assess for arrhythmias
48369378|NCT04302311|DIAGNOSTIC_TEST|Kardia/AliveCor monitoring|Kardia/AliveCor monitoring
48369379|NCT02308839|DEVICE|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
48694492|NCT06349460|BEHAVIORAL|FoodSteps behavioral intervention|Behavioral intervention that targets binge eating and weight-related behaviors. Each week, users are recommended or assigned one of five targets, set a relevant goal, and track their progress. If a target is recommended, the user can choose to select that target or a different target.
48008122|NCT02784301|BEHAVIORAL|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
48165327|NCT01954771|OTHER|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
48008123|NCT04277988|DEVICE|Ultrasonography|Length of Posterior Longitudianl Ligament, Ligamentum Flavum and Interlaminar distance visible in paramedian longitudinal view during lumbar spine ultrasonography in cross legged position will be compared to standard sitting position.
48008124|NCT05738200|OTHER|Nordic Hamstring Exercise|A 4-week (10 session), progressive, NHE protocol will be used for this study. Immediately following the completion of study visit 1, patients will be informed about the nature of the NHE protocol. Those available and willing to participate will be randomized to an intervention group (NHE, control). Patients randomized to NHE will receive formal instruction about how to correctly perform the exercise, and will be asked to perform several repetitions to familiarize themselves with the exercise and verify proper technique. At this time, patients will be dismissed from study visit 1, and return visits 2-11 will be scheduled to complete the NHE protocol. Patients will return for a final study visit (12) to record post-intervention measurements within 7 days of completing the NHE protocol. A minimum of 48 hours will be used to separate study visits. To accurately assess patients' ability to perform the NHE, all exercise will be performed on a NordBord Hamstring Testing System.
48008125|NCT06290401|BEHAVIORAL|SCThrive|SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
48165328|NCT02311985|OTHER|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR \>1.5 or PTT \>50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen \<150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
48369380|NCT01741610|BIOLOGICAL|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
48369381|NCT03825848|PROCEDURE|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
48008126|NCT06290401|OTHER|SCHealthED|Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
48008127|NCT03466502|DRUG|Oral Vancomycin|Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
48369382|NCT00088660|BIOLOGICAL|PANVAC™-VF|
48369383|NCT05270564|PROCEDURE|Drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
48694493|NCT01910324|BEHAVIORAL|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
48369384|NCT05270564|PROCEDURE|No drain|Surgical drains are placed as a standard of care (control arm) or not (experimental arm)
48694494|NCT01910324|BEHAVIORAL|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
48694495|NCT04827901|DRUG|XEN1101|two 10 mg capsules
48694496|NCT04827901|DRUG|Placebo|matching placebo
48694497|NCT02985918|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
48369385|NCT01657773|OTHER|Ultrasound examination and Colonoscopy examination|
48694498|NCT02985918|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
48165329|NCT02311985|OTHER|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex \<80 sec. and A10ex \>40 mm, then no blood transfusion is performed; when CTex \>80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex \<40 mm or A10fib \>10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex \<40 mm or A10fib \<10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
48165330|NCT02311985|OTHER|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR \>5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
48165331|NCT05300698|DEVICE|MRI|compare between MRI and ultrasound for indirect assessment of ocular layers
48165332|NCT04538534|DRUG|Nicardipine|To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
48165333|NCT03726125|DRUG|LY3374849 - SC|Administered SC
48165334|NCT03726125|DRUG|Insulin Degludec - SC|Administered SC
48165335|NCT03726125|DRUG|LY3374849 - IV|Administered IV
48165336|NCT03726125|DRUG|Insulin Degludec - IV|Administered IV
48165337|NCT05982028|PROCEDURE|Minimally invasive pit-picking surgery|Midline pits and secondary fistula openings were probed to determine the direction and length of any associated sinus tracts, followed by an excision with a 3 or 5 mm punch biopsy needle, depending on the size of the pit. A 2 cm lateral incision was made parallel to the pilonidal cyst. Hair and granulations within the sinus tracts were removed, and the cyst cavity was drained through the incision. Nonabsorbable monofilament sutures were used to close the excisional wounds of the pits and secondary fistula. Once haemostasis was achieved, the wound was covered with a sterile gauze with 10 % povidone-iodine solution.
48369386|NCT00641017|BIOLOGICAL|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
48369387|NCT00641017|BIOLOGICAL|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
48694499|NCT04530487|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
48694500|NCT04530487|DRUG|Cyclosporine|Given IV and PO
48694501|NCT04530487|DRUG|Etoposide|Given IV
48694502|NCT04530487|DRUG|Fludarabine Phosphate|Given IV
48694503|NCT04530487|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
48694504|NCT04530487|DRUG|Melphalan|Given IV
48694505|NCT04530487|DRUG|Mycophenolate Mofetil|Given IV or PO
48694506|NCT04530487|DRUG|Tacrolimus|Given IV and PO
48694507|NCT04530487|DRUG|Thiotepa|Given IV
48694508|NCT05292924|PROCEDURE|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
48694509|NCT04974047|DRUG|Tislelizumab|Administered intravenously as specified in the treatment arm.
48369388|NCT01251666|OTHER|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
48694510|NCT05180799|BIOLOGICAL|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
48694511|NCT05180799|BIOLOGICAL|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
48694512|NCT05180799|BIOLOGICAL|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
48694513|NCT05180799|DRUG|Pemetrexed (Alimta)|pemetrexed with either cisplatin or carboplatin
48694514|NCT06660498|DRUG|Pomalidomide 2 mg|Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
48694515|NCT06660498|DRUG|Placebo|Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
48694516|NCT06660498|DRUG|Aspirin 75 mg|Auxiliary Medicinal Product
48008128|NCT02388737|DRUG|Vonoprazan|Vonoprazan tablets
48008129|NCT02388737|DRUG|Lansoprazole|Lansoprazole capsules or tablets
48008130|NCT02388737|DRUG|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
48008131|NCT02388737|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
48008132|NCT00417183|DRUG|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
48008133|NCT00417183|DRUG|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
48008134|NCT00192075|DRUG|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
48008135|NCT00192075|DRUG|avastin|5 milligrams per kilogram (mg/kg)
48008136|NCT00192075|DRUG|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
48008137|NCT00192075|DRUG|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
48008138|NCT02752191|DRUG|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
48008139|NCT02752191|DRUG|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
48369389|NCT00209079|DRUG|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
48369390|NCT04220229|DRUG|Cabozantinib S-malate|Given PO
48369391|NCT04220229|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
48008140|NCT04490993|DRUG|APL-1202 in combination with Epirubicin|"* Induction period: APL-1202 is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, APL-1202 is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
48008141|NCT04490993|DRUG|Placebo in combination with Epirubicin|"* Induction period: placebo is administered for 12 consecutive weeks~* Maintenance period: after 12-week drug free period, placebo is administered for another12 consecutive weeks as maintenance treatment~* Follow up period: APL-1202 is administered at every 3-month interval if no events occurred in the treatment period and until the occurrence of events or the end of the entire clinical trial Intravesical Epirubicin hydrochloride will be administered once weekly for consecutive 6-8 weeks in the induction period, followed by once monthly in the maintenance period until end of 12 months"
48369392|NCT04917666|BEHAVIORAL|Horticultural therapy|A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).
48369393|NCT04917666|OTHER|Comparison|4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
48369394|NCT03796858|DRUG|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
48369395|NCT03796858|DRUG|Placebo|Participants will receive placebo as SC injection.
48514135|NCT04084457|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
48008142|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
48522655|NCT06488287|DEVICE|Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). The 2mA continuous current will be applied during the active stimulation condition via gradual ramps that start and stop after 30 seconds of stimulation (current ramps). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
48165338|NCT05982028|PROCEDURE|Radical surgical excision without suturing|Under the guidance of brilliant green, the cavity of the pilonidal cyst, along with the sinus tracts and fistulas, was marked. A symmetric elliptical incision was made to excise the pits and secondary fistula openings. The pilonidal cyst was removed from the healthy subcutaneous tissue and sacrococcygeal fascia using monopolar electrocautery. The wound was not sutured and was left open to heal by secondary intention. After haemostasis was achieved, the wound was covered with sterile gauze with 10 % povidone-iodine solution.
48694517|NCT00867802|BEHAVIORAL|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
48694518|NCT05850663|OTHER|Ecologic Momentary Assessment (EMA)|"EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone."
48165339|NCT05502861|BEHAVIORAL|Generalist + Specialist palliative care|Clinicians are alerted in the EHR to make an active choice whether to provide generalist palliative care themselves, consult PC specialist, or to defer PC at that time.
48165340|NCT05502861|BEHAVIORAL|Pre-Intervention phase|Patients meeting eligibility criteria will be enrolled for study data collection but there will be no attempt to influence delivery of care.
48165341|NCT00584376|DRUG|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
48165342|NCT00584376|DRUG|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
48514136|NCT01108627|DRUG|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
48165343|NCT04410354|DRUG|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
48694519|NCT06658743|BEHAVIORAL|Shared Medical Appointments|Participants will attend 4 quarterly appointments. In addition to time with their clinician, they will also have group activities that address relevant topics.
48694520|NCT06658743|OTHER|Standard of Care|Multidisciplinary team based care every 3 months.
48694521|NCT06660290|DRUG|0.003% AR-15512 ophthalmic solution|Investigational ophthalmic solution for topical instillation
48694522|NCT06660290|DRUG|REFRESH® Classic ophthalmic solution|Commercially available ophthalmic solution for topical instillation
48694523|NCT02970630|DRUG|Tacrolimus|once a day
48694524|NCT02970630|DRUG|Everolimus|twice daily
48694525|NCT03549572|BEHAVIORAL|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
48694526|NCT03639623|DRUG|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
48514137|NCT01108627|DRUG|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
48514138|NCT01108627|DRUG|foradil|open-labeled inhaled corticosteroids (ICS); foradil
48165344|NCT04410354|DRUG|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
48165345|NCT04410354|DRUG|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
48165346|NCT02600897|DRUG|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
48165347|NCT02600897|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
48514139|NCT05608837|DRUG|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
48694527|NCT06470451|DRUG|Hypericin|HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
48694528|NCT06470451|DRUG|Placebo|Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
48694529|NCT05623475|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
48694530|NCT05623475|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
48008143|NCT03211169|PROCEDURE|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
48369396|NCT03328962|BEHAVIORAL|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
48369397|NCT01075568|DIETARY_SUPPLEMENT|Nutrigal Okara - 100|
48369398|NCT04391894|DRUG|ECF843|Topical ocular eye drop
48369399|NCT04391894|OTHER|ECF843 vehicle|Topical ocular eye drop
48514140|NCT05607654|DEVICE|active iTBS|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
48008144|NCT03676361|DRUG|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
48008145|NCT00133081|DRUG|All registered antiepileptic drugs|
48514141|NCT05607654|DEVICE|sham rTMS|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
48514142|NCT00447876|BIOLOGICAL|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
48514143|NCT00447876|DRUG|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
48514144|NCT00900822|DEVICE|Straumann Bone Ceramic|Granules applied once during surgery
48514145|NCT00900822|DEVICE|BioOss|Granules that are applied once during surgery
48694531|NCT05623475|BEHAVIORAL|E-learning|Delirium care video
48008146|NCT00496301|DRUG|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
48008147|NCT02420106|PROCEDURE|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
48008148|NCT05466019|DRUG|Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)|FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.
48008149|NCT06090110|DEVICE|Vagal Nerve Stimulation|Transcutaneous Auricular Vagal Nerve Stimulation
48008150|NCT06090110|DEVICE|Sham stimulation|Sham stimulation with a non-conduction electrode
48008151|NCT02624284|DEVICE|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
48008152|NCT05483491|BIOLOGICAL|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
48369400|NCT03471494|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
48369401|NCT02101866|DRUG|Vapendavir 300 mg tablet|tablet - single dose
48369402|NCT02101866|DRUG|Vapendavir 132 mg capsules|2 capsules - single dose
48694532|NCT04360239|DIETARY_SUPPLEMENT|Fish Oil|Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
48008153|NCT05483491|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
48008154|NCT00675116|DRUG|GW823296|
48008155|NCT03477500|DRUG|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
48008156|NCT03477500|DRUG|Alemtuzumab|Alemtuzumab (Lemtrada)
48008157|NCT03477500|DRUG|Cladribine Pill|Cladribine (Mavenclad)
48008158|NCT03477500|DRUG|Ocrelizumab|Ocrelizumab (Ocrevus)
48008159|NCT03376243|OTHER|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
48008160|NCT02584751|DRUG|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
48008161|NCT02584751|DEVICE|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
48008162|NCT02584751|PROCEDURE|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
48369403|NCT01967134|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
48514146|NCT06551792|OTHER|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection
48514147|NCT00958893|DRUG|25 mg Proellex|one 25 mg capsules
48514148|NCT02934243|DEVICE|laryngeal mask insertion|airway management with laryngeal mask
48694533|NCT06661733|DRUG|AZD5462|Participants will receive AZD5462 orally.
48694534|NCT06054152|DRUG|PD-1 inhibitor based immunotherapy|Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
48694535|NCT02881931|BEHAVIORAL|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
48694536|NCT05987605|DRUG|1A46 Drug Substance|Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
48694537|NCT05913713|BEHAVIORAL|12-week Intervention Period|Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
48008163|NCT02584751|PROCEDURE|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
48008164|NCT02584751|PROCEDURE|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
48008165|NCT02584751|PROCEDURE|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
48008166|NCT02584751|PROCEDURE|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
48008167|NCT03619421|DIETARY_SUPPLEMENT|Zinc supplement|25 mg
48008168|NCT02748577|OTHER|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
48165348|NCT02600897|DRUG|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
48165349|NCT02600897|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
48165350|NCT02798276|PROCEDURE|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
48165351|NCT02798276|OTHER|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
48165352|NCT05666141|DEVICE|Pharyngeal Electrical Stimulation|"A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters."
48165353|NCT05666141|OTHER|Sham treatment|In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
48165354|NCT01592383|DRUG|erlotinib hydrochloride|Given PO
48165355|NCT01189318|DRUG|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
48694538|NCT05913713|BEHAVIORAL|12-week Observation Period|After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
48008169|NCT02748577|OTHER|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
48694539|NCT01854216|DRUG|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
48694540|NCT01854216|DRUG|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
48008170|NCT01341886|DRUG|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
48008171|NCT06054048|OTHER|Telemedicine|"Web Real-Time Communication (WebRTC), which enables a peer-to-peer connectivity. Communication platform for all TCs was the software CompuGroup Medical Electronic Visit (CGM ELVI), which provides end-to-end encrypted video conferencing between physicians and their patients."
48008172|NCT01653522|DRUG|Triptan|
48008173|NCT01653522|DRUG|Doxycycline|
48008174|NCT00154453|PROCEDURE|obtain surgical specimen for analysis|
48008175|NCT05225961|DRUG|Tirofiban|An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.
48514149|NCT02862730|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
48008176|NCT05225961|DRUG|Acetylsalicylic acid|A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.
48008177|NCT03952169|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
48514150|NCT02862730|DEVICE|Subject's insulin pump|Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
48514151|NCT02862730|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
48694541|NCT01854216|DRUG|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
48008178|NCT03952169|OTHER|Placebo controls|placebo with a similar appearance to probiotics supplement
48008179|NCT00274599|DRUG|Telmisartan|
48008180|NCT00274599|DRUG|Ramipril|
48008181|NCT01400867|DRUG|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects \< 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
48008182|NCT01400867|DRUG|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
48008183|NCT01400867|DRUG|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
48514152|NCT02862730|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
48008184|NCT04906642|DEVICE|Next Science|Solution is a clear, colorless, aqueous solution that is used to remove debris, including microorganisms, from wounds via hydrodynamic shear across the wound. This aids in the removal of foreign material such as, microorganisms, dirt, and debris.
48008185|NCT04906642|OTHER|Standard of Care|Normal Saline will be used in place of Next Science for irrigation
48008186|NCT02399150|OTHER|No intervention as observational study|
48008187|NCT00412165|BEHAVIORAL|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
48008188|NCT00412165|BEHAVIORAL|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
48514153|NCT05531110|DEVICE|Cataract surgery with insertion of Eyhance ICB00|Cataract surgery with insertion of Eyhance ICB00
48694542|NCT05022849|DRUG|JNJ-75229414|JNJ-75229414 infusion will be administered intravenously.
48165356|NCT00905814|DRUG|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
48694543|NCT05022849|DRUG|Bridging Therapy|Bridging therapy including Anti-AR agents (example, abiraterone, enzalutamide) will be administered orally and radiotherapy, or chemotherapy (example, docetaxel) will be administered intravenously.
48694544|NCT06661148|DRUG|EPI-003|Intravenous (IV) infusion.
48165357|NCT00905814|DRUG|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
48694545|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina."
48694546|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Cal95|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women."
48514154|NCT05531110|DEVICE|Cataract surgery with insertion of Alcon SN60WF|Cataract surgery with insertion of Alcon SN60WF
48514155|NCT00686361|DRUG|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
48165358|NCT05586516|DRUG|IOA-289|IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.
48165359|NCT05662683|OTHER|Virtual Reality (VR)|Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.
48008189|NCT00412165|BEHAVIORAL|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
48008190|NCT02694081|PROCEDURE|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
48008191|NCT02694081|PROCEDURE|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
48008192|NCT03750981|BEHAVIORAL|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
48008193|NCT05657028|DRUG|Dexmedetomidine|-In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
48008194|NCT05657028|DRUG|Lidocaine IV|In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
48008195|NCT00839839|PROCEDURE|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
48008196|NCT05283252|DEVICE|3-D printed Guide|Guided Endodontic micro-surgery
48008197|NCT05283252|OTHER|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
48008198|NCT01691027|BEHAVIORAL|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
48165360|NCT05662683|OTHER|Distraction Cards Practice Group|It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.
48165361|NCT05662683|OTHER|Virtual Reality (VR) Breathing Exercise Group|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
48165362|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
48165363|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
48694547|NCT06659380|DIETARY_SUPPLEMENT|Floragyn® probiotic tablets (Lapi, Indonesia)|Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
48694548|NCT03786081|DRUG|Tisotumab Vedotin|Given into the vein (IV)
48008199|NCT04317248|DRUG|Cyclophosphamide|Intravenous drip，250mg/m\^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）
48008200|NCT04317248|BIOLOGICAL|Multiple Signals loaded Dendritic Cells Vaccine|one time every 4 weeks during 0 weeks to 20 weeks, about 5\*10\^7 cells per time, intravenous driptotal 6 times;
48008201|NCT05069012|DRUG|Morphine Sulfate|Morphine is administered to provide pain relief after cesarean delivery; this is an assessment of the dose-response as measured by the duration of pain relief
48008202|NCT04433897|OTHER|Questionnaire|"All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale"
48008203|NCT03050905|DRUG|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
48008204|NCT03050905|DRUG|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
48165364|NCT00495261|BEHAVIORAL|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
48165365|NCT00495261|BEHAVIORAL|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
48165366|NCT05266157|OTHER|Manual lymph drainage|Manual lymph drainage
48165367|NCT05266157|OTHER|Usual care|skin care, exercise and compression stocking
48369404|NCT04095611|PROCEDURE|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
48694549|NCT03786081|DRUG|Bevacizumab|Given via IV
48694550|NCT03786081|DRUG|Pembrolizumab|Given via IV
48008205|NCT04216862|OTHER|Exercise|Different type of exercises for treatment of Forward Head Posture
48008206|NCT01045304|DRUG|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48165368|NCT06459037|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
48694551|NCT03786081|DRUG|Carboplatin|Given via IV
48008207|NCT01045304|DRUG|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48008208|NCT01045304|DRUG|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48008209|NCT03784950|BEHAVIORAL|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
48008210|NCT03784950|BEHAVIORAL|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
48008211|NCT04595487|PROCEDURE|Left ventricular septal pacing|"In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion."
48165369|NCT03930238|BEHAVIORAL|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
48694552|NCT05706623|DRUG|Apraglutide|Single dose of apraglutide 5mg.
48694553|NCT04819893|BIOLOGICAL|Maternal blood sampling|5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
48008212|NCT04595487|PROCEDURE|Right ventricular pacing|In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
48008213|NCT01989013|OTHER|biweekly intervention|10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
48165370|NCT03930238|BEHAVIORAL|Fitbit Only|Fitbit Only
48165371|NCT02611921|DRUG|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
48165372|NCT02611921|DRUG|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
48165373|NCT05657132|DRUG|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
48165374|NCT05657132|DRUG|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
48165375|NCT05645744|BIOLOGICAL|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
48694554|NCT04819893|BIOLOGICAL|Umbilical cord blood sampling|0.5mL sample from the umbilical cord after childbirth standard protocols
48694555|NCT04819893|BIOLOGICAL|Placenta sampling|Sampling of 3 cotyledons by cutting across the thickness of the placenta
48694556|NCT04819893|OTHER|Data collection|Newborn, Maternal and Premature Retinopathy Screening Data Collection
48165376|NCT05645744|BIOLOGICAL|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
48694557|NCT05558592|DIETARY_SUPPLEMENT|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
48694558|NCT05558592|DIETARY_SUPPLEMENT|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
48694559|NCT00733070|DEVICE|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
48694560|NCT00776672|DRUG|Fosinopril 40mg Tablets|
48165377|NCT04059913|DRUG|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
48694561|NCT06659731|OTHER|Quantitative Sensory testing (QST)|The QST protocol (Rolke et al., 2006; Blankenburg et al., 2010), implies the administration of 7 short sensory test in order to measure up to 13 parameters, which can be grouped as follows: thermal detection thresholds for the perception of cold, warm and paradoxical heat sensations, thermal pain thresholds for cold and hot stimuli, mechanical detection thresholds for touch and vibration, mechanical pain thresholds and sensitivity for pinprick and blunt pressure, vibration detection threshold and pressure pain threshold.
48694562|NCT06659731|OTHER|EEG|EEG recording at rest and while receiving heat stimuli to study cortical processing of salient thermal stimuli. Up to 30 painful thermal stimuli, will be delivered to the patients' hand dorsum in order to register contact heat evoked potentials (CHEPs).
48694563|NCT06235359|DEVICE|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
48165378|NCT02264418|DRUG|ODM 203|ODM 203
48165379|NCT02264418|DRUG|ODM 203|ODM 203
48165380|NCT03189641|DEVICE|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
48008214|NCT01043796|OTHER|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
48694564|NCT04339933|DIAGNOSTIC_TEST|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
48008215|NCT01043796|OTHER|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
48008216|NCT00250211|PROCEDURE|Functional MRI imaging and tomotherapy|
48694565|NCT05944081|DEVICE|ArcadiusXP L® Interbody Fusion System|The ArcadiusXP L® Interbody Fusion System is a stand-alone device intended to be used with four bone screws if no supplement fixation is used to stabilize the lumbar spine through an anterior approach. Levels of anterior lumbar interbody fusion for the indications listed in the instructions for use are from L2-S1.
48008217|NCT06306443|DRUG|extended-release buprenorphine (XR-B)|buprenorphine
48008218|NCT00847275|OTHER|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
48008219|NCT00847275|OTHER|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
48008220|NCT00834912|DRUG|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
48008221|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
48008222|NCT00834912|DRUG|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
48008223|NCT05103943|OTHER|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
48008224|NCT03571516|DRUG|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
48165381|NCT03849521|DIAGNOSTIC_TEST|MRI|Enhanced carotid calcification presented by UTE MR.
48694566|NCT00630006|GENETIC|TNF-alpha and IL-10|
48008225|NCT03571516|OTHER|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
48008226|NCT03571516|DEVICE|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
48008227|NCT03571516|DEVICE|Needle|Teduglutide will be administered using needle (510k number: K021475).
48165382|NCT01177137|DEVICE|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
48165383|NCT01177137|DEVICE|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
48694567|NCT02494973|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
48694568|NCT02494973|DRUG|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
48694569|NCT02494973|DRUG|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
48694570|NCT02494973|DRUG|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
48694571|NCT06659211|BEHAVIORAL|Mentalisation-Based Therapy|MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
48165384|NCT01177137|BEHAVIORAL|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
48008228|NCT00706836|DRUG|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
48008229|NCT00706836|DRUG|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
48008230|NCT00706836|DRUG|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
48008231|NCT06290856|DIAGNOSTIC_TEST|Multiplex PCR-test for circulating tumor DNA|All recruited patients will be tested for
48008232|NCT04462705|PROCEDURE|Usual physiotherapeutic intervention and Abdominal Massage|Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
48008233|NCT00990483|DEVICE|3D mammograpgy system|In addition to the standard care diagnostic imaging, all participants underwent two experimental acquisitions, in two projections (Cranio-Caudal and Mediolateral Oblique) on the breast of concern: one acquisition in Mode A (narrow angle acquisition) and one acquisition in Mode B (wide angle acquisition). The experimental imaging is compared to the standard of care imaging
48008234|NCT01073865|DRUG|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
48008235|NCT01073865|DRUG|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
48165385|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
48008236|NCT01384084|PROCEDURE|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
48008237|NCT01384084|PROCEDURE|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
48165386|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
48165387|NCT00657475|DRUG|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
48165388|NCT00657475|DRUG|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
48165389|NCT03175198|DRUG|Prazaxa® Capsules|Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
48165390|NCT03952728|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
48165391|NCT03952728|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
48165392|NCT04678635|OTHER|Chronic transcranial direct current stimulation|Chronic transcranial direct current stimulation
48165393|NCT00825734|DRUG|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
48165394|NCT00825734|DRUG|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
48165395|NCT00557349|DRUG|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
48165396|NCT00557349|DRUG|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
48165397|NCT05117385|DIETARY_SUPPLEMENT|Botanical extract|1 capsule per day
48165398|NCT04276636|DRUG|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
48165399|NCT02090998|PROCEDURE|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
48008238|NCT02348242|DEVICE|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
48008239|NCT02348242|DEVICE|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
48008240|NCT02348242|DEVICE|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
48008241|NCT03077503|DRUG|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
48008242|NCT03077503|DRUG|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
48165400|NCT02090998|DRUG|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
48165401|NCT00676429|DRUG|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
48165402|NCT00676429|DRUG|Placebo|Placebo as oral solution, individually titrated
48165403|NCT02962063|BIOLOGICAL|durvalumab|Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.
48165404|NCT02962063|DRUG|carboplatin AUC 2/paclitaxel|
48008243|NCT03077503|DRUG|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
48008244|NCT03077503|DEVICE|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
48008245|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol.
48694572|NCT06659211|OTHER|Treatment as Usual (TAU)|The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
48694573|NCT06658288|OTHER|Rebound Training|12 participants will be in experimental group A giving them rebound training.
48008246|NCT03684447|DRUG|Propofol|Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
48008247|NCT03296228|RADIATION|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
48008248|NCT03296228|RADIATION|Flexibility Radiographs (awake traction)|awake traction
48008249|NCT03296228|RADIATION|Flexibility Radiographs (STUGA)|supine traction under GA
48008250|NCT03389646|DEVICE|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM\|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM\|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM\|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
48008251|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
48008252|NCT00782210|DRUG|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
48694574|NCT06658288|OTHER|Theraband resistance exercise|12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
48694575|NCT02661386|DEVICE|Motility Procedure|The use of esophageal manometry device during general anesthesia
48694576|NCT03641716|BEHAVIORAL|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
48008253|NCT00782210|DRUG|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
48008254|NCT02187302|DRUG|CRLX101|
48008255|NCT02187302|DRUG|Bevacizumab|
48008256|NCT02187302|DRUG|Standard of Care (Investigator Choice)|
48008257|NCT04871243|OTHER|Qualitative Interview|Individual semi-structured interviews
48008258|NCT04322396|DRUG|Azithromycin|Azithromycin
48008259|NCT04322396|DRUG|Hydroxychloroquine|Hydroxychloroquine
48008260|NCT04322396|DRUG|Placebo oral tablet|Placebo Azithromycin
48008261|NCT04322396|DRUG|Placebo oral tablet|Placebo Hydroxychloroquine
48008262|NCT00418691|DRUG|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
48008263|NCT00418691|DRUG|Modafinil|200 mg PO Once Daily x 4 Weeks
48008264|NCT00418691|DRUG|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
48008265|NCT00262548|DRUG|Rosuvastatin; improvement of lipid profile|
48008266|NCT05901727|OTHER|No intervention|Observational data collection only.
48008267|NCT05699070|DRUG|DWC202211 100mg|"DWC202211 for 5 days~Aspirin 100mg"
48008268|NCT05699070|DRUG|DWC202212 5mg|"DWC202212 for 3 days~Rabeprazole 5mg"
48008269|NCT05699070|DRUG|DWC202211 100mg + DWC202212 5mg|"DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg"
48008270|NCT04722640|DRUG|SKYRIZI|SKYRIZI
48008271|NCT00983281|DRUG|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
48008272|NCT05604560|DRUG|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
48165405|NCT02962063|RADIATION|External beam radiation (EBRT)|Radiation will be delivered starting on a Monday or Tuesday between Days 29-30, based on the first induction durvalumab dose administered on Day 1. Patients will be treated 5 days/week at 1.80 Gy/day, to a total planned dose of 41Gy in 23 fractions. Induction Day 15 has a -1/+2 day window, and Day 29 has a -1/+1 day window.
48165406|NCT02962063|PROCEDURE|esophagogastrectomy|Patients undergo surgical resection 6-10 weeks after the completion of chemoradiation.
48165407|NCT02962063|DRUG|Tremelimumab|Tremelimumab will be administered once at 300 mg on Day 29 prior to chemoradiation only.
48165408|NCT04672499|DRUG|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
48165409|NCT04672499|DRUG|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
48165410|NCT04672499|DRUG|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
48522656|NCT06488287|DEVICE|sham Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
48008273|NCT05604560|DRUG|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
48008274|NCT00940303|DRUG|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
48008275|NCT00940303|DRUG|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
48008276|NCT00940303|DRUG|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
48008277|NCT00940303|DRUG|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
48008278|NCT00940303|DRUG|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
48522657|NCT01187056|BEHAVIORAL|Training programme|2 x 2 hours of training (workshops)
48694577|NCT05732935|BEHAVIORAL|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
48694578|NCT05732935|BEHAVIORAL|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
48008282|NCT04921930|DRUG|Artesunate Oral Product|Dose escalation intake of artesunate
48008283|NCT00820612|DRUG|Indomethacin|100 mg PR once at the time of ERCP
48008284|NCT00820612|OTHER|Placebo suppositories|2 placebo suppositories at the time of ERCP
48008285|NCT04874337|OTHER|Disaster nursing and management training will be given to students using Jenning's Disaster Nursing and Management Model.|The subjects for the training program were prepared by the researchers by scanning the relevant literature. In particular, the ICN Framework of Disaster Nursing Competencies developed by the International Nurses Association (ICN) and the World Health Organization (WHO), the second is the universal standards that should be fundamental in nursing and midwifery education (Global Standards for the Initial Education of Professional Nurses and Midwives). The training program was conducted both theoretically and practically. The theoretical section is based on Jenning's disaster nursing management model. Investigator is a First and Emergency Aid instructor. In addition, support was received from an experienced psychologist and AFAD trainers who provided support to the victims of the Izmir earthquake during the training process. In this context, an 8-module training program was created.
48008286|NCT03271736|BEHAVIORAL|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
48008287|NCT03271736|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
48008288|NCT01458899|DRUG|TC-5214|Oral tablets, single 4mg dose
48008289|NCT00691236|DRUG|Zoledronic acid|4mg IV 3 weekly for 6 doses
48694579|NCT06532032|DRUG|Amivantamab|Amivantamab will be administered as IV infusion.
48008290|NCT00691236|DRUG|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
48008291|NCT00298831|DRUG|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
48008292|NCT00298831|DRUG|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
48008293|NCT04217551|DEVICE|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming, using a closed-loop temperature control device.
48008294|NCT04024475|OTHER|Observation|
48008295|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.
48008296|NCT05854875|PROCEDURE|Laparoscopic Roux en Y gastric bypass with fundus resection|Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
48008297|NCT02111252|DRUG|TAK-850|TAK-850 injection
48008298|NCT02548988|OTHER|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
48165411|NCT05918289|BEHAVIORAL|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
48694580|NCT06532032|DRUG|Docetaxel|Docetaxel will be administered as IV infusion.
48008299|NCT00633191|DRUG|Anti-pseudomonas IgY gargle|Gargle (solution), \> 5FKU, every night after toothbrushing, life-long
48369405|NCT04095611|PROCEDURE|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
48369406|NCT03229512|DRUG|Sildenafil|Topical 1% Sildenafil Cream
48008300|NCT01603875|BIOLOGICAL|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
48008301|NCT05549193|OTHER|Exercises Training|"Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg."
48008302|NCT05399524|OTHER|Standard of Care|Neuronavigation and intraoperative 5-ALA
48008303|NCT05399524|OTHER|Additional pre- and intra-operative imaging|Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
48008304|NCT06021392|PROCEDURE|Z plasty and minimal excision of pilonidal sinus|"The investigators will perform a  Z plasty  procedure and Minimal excision procedure for patients complaining of pilonidal sinus and the investigators will compare the outcomes and rate of recurrence of these two procedures"
48008305|NCT05956769|DRUG|Tranexamic Acid|Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
48165412|NCT04574661|OTHER|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
48165413|NCT04574661|OTHER|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
48694581|NCT06482229|PROCEDURE|application for postoperative analgesia|three different methods will be applied to reduce patients' postoperative pain
48694582|NCT03777657|DRUG|Tislelizumab|200 mg IV on Day 1 during each 21-day cycle
48008306|NCT05956769|DIAGNOSTIC_TEST|thromboelastography|thromboelastography (TEG6)
48008307|NCT05956769|DRUG|Placebo|Normal saline injection
48008308|NCT00499603|DRUG|Paclitaxel|80 mg/m\^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
48008309|NCT00499603|DRUG|5-Fluorouracil|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
48008310|NCT00499603|DRUG|Epirubicin|100 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
48165414|NCT02612805|OTHER|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
48165415|NCT02612805|OTHER|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
48522658|NCT00857155|OTHER|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
48694583|NCT03777657|DRUG|Placebo|Placebo to match tislelizumab on Day 1 during each 21-day cycle
48694584|NCT03777657|DRUG|Cisplatin|80 mg/m² IV on Day 1 during each 21-day cycle
48694585|NCT03777657|DRUG|Oxaliplatin|130 mg/m² IV on Day 1 during each 21-day cycle
48694586|NCT03777657|DRUG|Capecitabine|1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) during each 21-day cycle
48008311|NCT00499603|DRUG|Cyclophosphamide|500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
48008312|NCT00499603|DRUG|RAD001|30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
48008313|NCT03266575|BEHAVIORAL|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
48008314|NCT03266575|BEHAVIORAL|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
48008315|NCT02850536|BIOLOGICAL|anti-CEA CAR-T cells|Gene modified patient T cells
48008316|NCT03144492|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
48008317|NCT03536039|DRUG|NGR-hTNF|dose of 0.8 mcg/sqm
48008318|NCT03536039|OTHER|RITUXIMAB|dose of 375 mg/mq
48008319|NCT03536039|DRUG|Doxorubicin|dose of 50 mg/mq
48008320|NCT03536039|DRUG|Cyclophosphamide|dose of 750 mg/mq
48008321|NCT03536039|DRUG|Vincristine|dose of 1.4 mg/mq (max 2 mg)
48008322|NCT03536039|DRUG|Prednisone|75 mg
48008323|NCT06259084|DEVICE|Seedchrony|The seedchrony probe is coupled to the transfer catheter. When the transfer catheter is placed inside the uterus, the probe measures the biomarker concentraction in the fluid entering the catheter. The measurements last two minutes.
48008324|NCT00193401|DRUG|Topotecan|
48694587|NCT03777657|DRUG|5-FU|800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle
48008325|NCT01093404|PROCEDURE|Thrombus aspiration|Aspiration of thrombus material before angioplasty
48008326|NCT00279565|DRUG|buprenorphine|
48008327|NCT00279565|DRUG|methadone|
48008328|NCT00279565|DRUG|pegylated interferon alfa-2b plus ribavirin|
48008329|NCT00357370|DRUG|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
48008330|NCT00357370|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
48008331|NCT03106207|PROCEDURE|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
48008332|NCT02967367|DEVICE|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
48008333|NCT02967367|DEVICE|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
48369407|NCT06446297|OTHER|Focus Group.|Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
48694588|NCT00729495|DRUG|celecoxib|dose form
48369408|NCT03396406|DEVICE|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
48008334|NCT02967367|DEVICE|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
48008335|NCT02915744|DRUG|NKTR-102|
48008336|NCT02915744|DRUG|Eribulin|
48008337|NCT02915744|DRUG|Ixabepilone|
48008338|NCT02915744|DRUG|Vinorelbine|
48694589|NCT04240041|DIAGNOSTIC_TEST|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
48694590|NCT04240041|DIAGNOSTIC_TEST|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
48008339|NCT02915744|DRUG|Gemcitabine|
48008340|NCT02915744|DRUG|Paclitaxel|
48008341|NCT02915744|DRUG|Docetaxel|
48008342|NCT02915744|DRUG|Nab-paclitaxel|
48008343|NCT00427635|DRUG|Esomeprazole|
48008344|NCT01907633|DRUG|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
48008345|NCT03490266|PROCEDURE|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
48008346|NCT03490266|PROCEDURE|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
48008347|NCT03254901|OTHER|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
48008348|NCT05753059|DRUG|Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
48008349|NCT05753059|DRUG|Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
48008350|NCT05753059|DRUG|Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
48008351|NCT03744377|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
48369409|NCT03396406|DEVICE|thermocoagulation|received sole CRF at 70°C for 270 s
48008352|NCT05832645|OTHER|Meditation with guided tea consumption|Mindful consumption of tea along with an approximately 10-min guide
48008353|NCT05832645|OTHER|Breathing meditation|10-min breathing meditation
48008354|NCT03765294|DRUG|ACT-541468|Film-coated tablet for oral use
48008355|NCT03765294|DRUG|Placebo|Film-coated tablet for oral use
48008356|NCT01542515|PROCEDURE|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
48008357|NCT01752205|DRUG|Paclitaxel|45mg/m2/w,total 6 weeks
48008358|NCT01752205|DRUG|Erlotinib|150mg/d,days 1-42,total 6 weeks
48008359|NCT01752205|RADIATION|Radiation therapy|
48008360|NCT04419688|DRUG|STT-5058|Monoclonal Antibody STT-5058
48008361|NCT04419688|DRUG|Placebo|Matching placebo to STT-5058
48369410|NCT02800096|BEHAVIORAL|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
48369411|NCT02800096|BEHAVIORAL|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
48369412|NCT04977778|DRUG|Fatty Acids Compounds (F.A.G.) Mouthwash|Fatty Acids Compounds (F.A.G.) Mouthwash
48165416|NCT02612805|OTHER|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
48165417|NCT02847819|DEVICE|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
48165418|NCT05858398|BIOLOGICAL|pharmacokinetics blood sample assessment|pharmacokinetics blood sample assessment during the first exposure to docetaxel
48165419|NCT01414725|OTHER|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al \[2009\]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
48008362|NCT02007356|BIOLOGICAL|IFN-γ positive selected T-cells|
48008363|NCT05393375|OTHER|No intervention|No intervention
48008364|NCT04254614|DEVICE|Personalised mobile application for IBD patients|"Patients will use a mobile application for ±6months (exact period depends on interval of biologic treatment) with the following functionalities:~* Personal interactive timeline to prepare for biologic treatment with reminders for blood tests, a questionnaire to exclude contra-indications for biologic treatment (e.g. current infection) and a message from the gastroenterology nurse when blood tests results and the questionnaire have been checked. Only in case of abnormal results or answers patients will be contacted by telephone by their gastroenterology nurse, which is currently standard care.~* Information about the patients' diagnosis and biologic treatment.~* General information on e.g. IBD treatment, vaccinations, frequently used medical terms, preparing for outpatient visits, what to do in case of disease symptoms.~Patients will fill in a questionnaire to measure study outcomes at baseline and at the end of the study period."
48165420|NCT01414725|OTHER|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
48008365|NCT00494572|DRUG|Montelukast|10 mg rapid dissolving granule in sterile water orally once
48008366|NCT00494572|OTHER|sterile water|sterile water
48008367|NCT02337244|DEVICE|Zimmer Persona Total Knee System|No Intervention
48008368|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose|Injection in the muscle
48165421|NCT01414725|OTHER|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
48008369|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose|Injection in the muscle
48008370|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose|Injection in the muscle
48008371|NCT05630352|BIOLOGICAL|Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose|Injection in the muscle
48008372|NCT03364088|PROCEDURE|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
48008373|NCT03364088|PROCEDURE|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
48008374|NCT03364088|PROCEDURE|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
48008375|NCT03364088|PROCEDURE|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
48165422|NCT04701528|DRUG|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
48165423|NCT04701528|DRUG|Tacrolimus|Comparator
48165424|NCT05254834|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
48694591|NCT05780801|DRUG|Allogeneic Microbiota in Glycerol (10%) (AMG)|Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
48694592|NCT06002906|DRUG|Indocyanine green|Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
48694593|NCT06002906|DEVICE|Stryker 1688 AIM system|The Stryker 1688 AIM system used during laparoscopic surgery which is sensitive in the visible and infrared spectrum. ICG (SPY AGENT™ GREEN) is used with the SPY mode in the Stryker 1688 AIM fluorescence imaging system to perform intraoperative fluorescence angiography.
48694594|NCT06658509|BEHAVIORAL|HIIT|High-intensity interval training
48694595|NCT06658509|BEHAVIORAL|SIT|Sprint interval training
48694596|NCT06661811|DRUG|CAR-T|CAR-T cells
48694597|NCT03392831|OTHER|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
48694598|NCT03392831|OTHER|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
48694599|NCT03316287|DEVICE|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
48694600|NCT03316287|DEVICE|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
48694601|NCT03316287|DEVICE|Sensor|Wearable biosensor for the collection of physiological data
48694602|NCT04264520|BEHAVIORAL|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
48694603|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the Left DLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
48694604|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the right VLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
48008376|NCT03364088|DRUG|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
48008377|NCT05500365|PROCEDURE|Catheter ablation therapy|Pace mapping procedure performed during catheter ablation therapy
48008378|NCT01785602|DRUG|QAW039|Capsules
48008379|NCT01785602|DRUG|Placebo|Capsules
48522659|NCT01027702|BIOLOGICAL|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10\^4, 4 x 10\^4, 5 x 10\^4, 6 X 10\^4, 8 x 10\^4, and 10 X10\^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
48522660|NCT05744167|BEHAVIORAL|BFRT|Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
48008380|NCT04348513|DRUG|T3 solution for injection|For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.
48008381|NCT04348513|DRUG|Placebo|Same as with T3 solution for injection.
48165425|NCT05087953|DIAGNOSTIC_TEST|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
48165426|NCT05087953|DIAGNOSTIC_TEST|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
48165427|NCT04303871|DIAGNOSTIC_TEST|Invasive blood pressure assessment by radial artery canulation|radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
48165428|NCT04239157|BIOLOGICAL|Canakinumab|Given SC
48165429|NCT00487513|PROCEDURE|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
48165430|NCT03840200|DRUG|Ipatasertib|Ipatasertib will be administered orally.
48165431|NCT03840200|DRUG|Rucaparib|Rucaparib will be administered orally.
48369413|NCT04977778|DRUG|Stannous Fluoride (SF) Mouthwash|Stannous Fluoride (SF) Mouthwash
48165432|NCT04036773|DIETARY_SUPPLEMENT|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits \& vegetables
48165433|NCT03771183|OTHER|Patients in long response during Halaven® treatment|Data collection
48008382|NCT01389297|BEHAVIORAL|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
48694605|NCT06658795|DEVICE|Sham stimulation group|The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
48694606|NCT03023579|OTHER|The star excursion balance test|
48694607|NCT02565264|OTHER|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
48694608|NCT02242214|DRUG|Misoprostol|
48165434|NCT03790878|BEHAVIORAL|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
48165435|NCT03790878|BEHAVIORAL|Habituation|An exposure procedure that reduces emotional distress through habituation
48165436|NCT03790878|BEHAVIORAL|Control|No emotion regulation intervention, placebo
48165437|NCT04041661|OTHER|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
48165438|NCT04041661|OTHER|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
48165439|NCT04840498|BEHAVIORAL|Autism Research|Measuring aspects such as self esteem, social skills, and social anxieties.
48165440|NCT00068835|BEHAVIORAL|Lindamood-Bell training for dyslexia|
48694609|NCT06440967|DRUG|Fezolinetant|oral
48694610|NCT06440967|DRUG|Placebo|oral
48694611|NCT06440967|DRUG|Tamoxifen|oral
48008383|NCT01389297|BEHAVIORAL|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
48008384|NCT02163291|DRUG|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
48165441|NCT00826371|DRUG|ranibizumab 0.5 mg|
48165442|NCT00255944|BEHAVIORAL|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
48165443|NCT00255944|BEHAVIORAL|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
48165444|NCT05823519|DEVICE|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
48165445|NCT00651937|DRUG|Melphalan|100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
48165446|NCT00651937|PROCEDURE|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0."
48165447|NCT00651937|BEHAVIORAL|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
48165448|NCT00651937|DRUG|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
48165449|NCT00651937|PROCEDURE|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
48165450|NCT00266747|DRUG|SR58611A|
48165451|NCT02574897|OTHER|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
48165452|NCT02574897|OTHER|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
48165453|NCT00515697|BIOLOGICAL|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
48694612|NCT06440967|DRUG|Aromatase inhibitor|oral
48694613|NCT03779867|BEHAVIORAL|Exercise Intervention|Undergo acute exercise
48694614|NCT03779867|OTHER|Resting|Seated resting
48694615|NCT03779867|OTHER|Biomarker Analysis|Correlative studies
48694616|NCT03779867|OTHER|Questionnaire Administration|Ancillary studies
48694617|NCT06625099|OTHER|Mechanical Ventilation (MV) with Low PEEP|Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and 5cmH2o PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.
48165454|NCT05990270|BEHAVIORAL|education|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
48165455|NCT04965090|DRUG|Amivantamab|Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
48165456|NCT04965090|DRUG|Lazertinib|Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
48165457|NCT05645809|DEVICE|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
48165458|NCT05645809|DEVICE|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
48165459|NCT01011127|DRUG|pravastatin, rosuvastatin|
48165460|NCT02236702|OTHER|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
48165461|NCT03022045|DRUG|risankizumab|risankizumab administered by subcutaneous injection
48165462|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 10gM|"* 140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
48165463|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 20gM|"* 280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
48165464|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 20gNoM|"* 280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
48165465|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 40gM|"* 560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
48165466|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 40gNoM|"* 560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
48165467|NCT00945698|DIETARY_SUPPLEMENT|Maize-soy flour|"* No food supplement during the primary trial period (6 to 18 months of age)~* 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
48165468|NCT06419322|OTHER|Optimized rehabilitation program|Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
48165469|NCT03431480|BIOLOGICAL|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
48165470|NCT04503837|PROCEDURE|Personalized Mobile Phone Video Recording|Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
48165471|NCT01365351|OTHER|Growth hormone|Drug given by prescription
48165472|NCT01001130|DRUG|fluticasone furoate group|patients who are administered fluticasone furoate at least once
48165473|NCT03753750|DEVICE|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
48165474|NCT02453516|PROCEDURE|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
48694618|NCT06625099|OTHER|Mechanical Ventilation (MV) with Optimum PEEP|"Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and optimum PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.~The optimum PEEP will be adjusted by titrating to the highest compliance with the open lung strategy."
48165475|NCT02453516|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
48165476|NCT02453516|DRUG|ropivacaine|Drug indicated for regional anesthesia
48694619|NCT05304585|PROCEDURE|Biopsy|Undergo tumor biopsy
48694620|NCT05304585|PROCEDURE|Bone Scan|Undergo bone scan
48694621|NCT05304585|PROCEDURE|Computed Tomography|Undergo CT scan
48165477|NCT02453516|DRUG|epinephrine|Drug indicated to prolong the action of regional anesthesia
48165478|NCT02453516|OTHER|sterile saline|Neutral injection (no drug involved)
48165479|NCT00053391|BIOLOGICAL|recombinant CD40-ligand|
48165480|NCT00053391|BIOLOGICAL|therapeutic autologous dendritic cells|
48165481|NCT05803902|DRUG|Experimental drug 9MW1911|Experimental drug administered with IV infusion
48694622|NCT05304585|DRUG|Cyclophosphamide|Given IV
48165482|NCT05803902|DRUG|Placebo|Placebo administered with IV infusion
48694623|NCT05304585|BIOLOGICAL|Dactinomycin|Given IV
48694624|NCT05304585|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
48165483|NCT02201147|PROCEDURE|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
48165484|NCT02201147|PROCEDURE|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
48694625|NCT05304585|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48694626|NCT05304585|RADIATION|Radiation Therapy|Undergo radiation
48694627|NCT05304585|DRUG|Vincristine|Given IV
48694628|NCT01178944|OTHER|Laboratory Biomarker Analysis|Correlative studies
48694629|NCT01178944|DRUG|Oxaliplatin|Given IV
48694630|NCT01178944|DRUG|Pralatrexate|Given IV
48165485|NCT02201147|DEVICE|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
48165486|NCT02201147|DEVICE|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
48165487|NCT02370199|DEVICE|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
48165488|NCT02370199|DRUG|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
48165489|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Daily supplementation with \~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
48165490|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Daily supplementation with \~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
48165491|NCT04282564|OTHER|Co-OP treatment|"The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke"
48165492|NCT03809806|PROCEDURE|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
48165493|NCT03809806|DIAGNOSTIC_TEST|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
48008385|NCT03863210|OTHER|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
48165494|NCT03809806|DIAGNOSTIC_TEST|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
48165495|NCT03809806|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
48165496|NCT03809806|DIAGNOSTIC_TEST|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
48165497|NCT03809806|DIAGNOSTIC_TEST|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
48694631|NCT00632047|OTHER|active surveillance|
48008388|NCT05133882|DRUG|Clifutinib Besylate|The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
48694632|NCT00632047|OTHER|educational intervention|
48008389|NCT02433834|DRUG|Glycopyrronium MDI|GP MDI
48008390|NCT02433834|DRUG|Serevent Diskus 50 μg|
48008391|NCT02433834|DRUG|Placebo|
48165498|NCT02250183|DEVICE|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
48165499|NCT02250183|DEVICE|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
48165500|NCT06365125|BEHAVIORAL|eCHECKUP TO GO|Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.
48165501|NCT06365125|BEHAVIORAL|Text messaging boosters|Text messages sent a few times per week following completion of eCHECKUP TO GO to reinforce concepts and assist with goal setting and goal attainment in everyday life
48165502|NCT01552668|DRUG|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
48165503|NCT01552668|DRUG|Placebo|Receive Placebo twice daily
48165504|NCT00405002|PROCEDURE|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
48165505|NCT05418868|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be administered.
48165506|NCT05418868|DRUG|Cabotegravir >=400 mg/mL|CAB \>=400 mg/mL will be administered by IM or SC injection.
48165507|NCT05418868|DRUG|Cabotegravir Formulation I|CAB Formulation I will be administered by IM injection.
48165508|NCT05418868|DRUG|rHuPH20|rHuPH20 will be administered.
48165509|NCT05418868|DRUG|RPV|RPV will be administered by IM injection.
48369414|NCT04274985|OTHER|Questionnaire application|Patients will complete the mentioned questionnaires.
48694633|NCT00632047|PROCEDURE|examination|
48694634|NCT00632047|PROCEDURE|long-term screening|
48165510|NCT02269917|DRUG|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
48165511|NCT02269917|DRUG|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
48165512|NCT02269917|DRUG|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
48165513|NCT01745718|OTHER|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
48369415|NCT01546909|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
48694635|NCT01311128|DEVICE|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
48369416|NCT05945173|PROCEDURE|Evaporation time for 5 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 5 seconds.
48694636|NCT00788931|DRUG|IV LBH589|
48694637|NCT00788931|DRUG|Oral LBH589|
48694638|NCT00788931|DRUG|trastuzumab|
48694639|NCT00788931|DRUG|paclitaxel|
48008392|NCT02460770|DRUG|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
48008393|NCT02827058|DEVICE|G25 pencil point needle|
48008394|NCT02827058|DEVICE|G27 pencil point needle|
48008395|NCT02487394|PROCEDURE|Exhaled Breath Condensate (EBC)|Collection of EBC condensate
48008396|NCT00196781|BEHAVIORAL|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
48008397|NCT00196781|BEHAVIORAL|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
48008398|NCT02736656|DRUG|SPN-812|
48008399|NCT01633944|DRUG|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
48008400|NCT01633944|DRUG|Placebo|Matching Placebo Buccal Film twice daily
48008401|NCT06074107|DRUG|BEBT-908 for injection|The initial dose is 22.5mg/m2, intravenous drip, on the 1st, 3rd, 5th, 8th, 10th and 12th day of each cycle，21 days as a cycle, 6 cycles as the total treatment cycle.
48008402|NCT05589064|BEHAVIORAL|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
48008403|NCT05589064|DIETARY_SUPPLEMENT|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
48008404|NCT05589064|BEHAVIORAL|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
48008405|NCT01399359|BEHAVIORAL|Counseling session|
48008406|NCT01399359|OTHER|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
48165514|NCT01747837|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
48165515|NCT05716152|DIAGNOSTIC_TEST|Morning blood sample and skin punch biopsy of 4 mm diameter.|"1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
48165516|NCT02287883|OTHER|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
48165517|NCT03834207|DEVICE|Use of the C3-Cloud IT system|Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
48165518|NCT04320810|OTHER|no intervention|It's only observational study. No interventions.
48165519|NCT04177628|BEHAVIORAL|Shared decision making supported by an in-consultation patient decision aid|After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
48369417|NCT05945173|PROCEDURE|Evaporation time for 25 seconds|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive with solvent evaporation for 25 seconds.
48369418|NCT05945173|DEVICE|alcohol/water-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an alcohol/water-based universal adhesive (Scotchbond Universal Plus; 3M).
48369419|NCT05945173|DEVICE|acetone-based universal adhesive|Composite resin restorations of non-carious cervical lesions will be performed with an acetone-based universal adhesive (Gluma Universal Bond; Kulzer).
48369420|NCT01331876|BEHAVIORAL|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
48369421|NCT01955642|DRUG|Clopidogrel|75 mg milligrams per days of PLAVIX
48369422|NCT00004409|DRUG|collagenase|
48369423|NCT02264132|DRUG|Pramipexole ER tablet|
48369424|NCT02264132|DRUG|Pramipexole IR tablet|
48369425|NCT05162599|DEVICE|Diagnostic study, experimental evaluative cross-sectional study|This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference test) and the new device
48514156|NCT00695058|DEVICE|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
48008407|NCT01399359|OTHER|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
48008408|NCT01399359|OTHER|online questionnaire|
48008409|NCT00394030|DRUG|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
48522661|NCT05744167|BEHAVIORAL|MDRT|Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
48694640|NCT06462040|PROCEDURE|Fixation of osteochdral fragments with reabsorbable screws|Arthroscopic or mini-open fixation of free-intrarticular or unstable osteochondral fragments due to osteochondritis dissecans or osteochondral fractures with reabsorbable screws
48694641|NCT00682903|DEVICE|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
48008410|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
48008411|NCT02648191|DEVICE|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
48008412|NCT03340129|DRUG|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
48008413|NCT03340129|DRUG|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
48008414|NCT03340129|RADIATION|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
48008415|NCT03340129|OTHER|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
48369426|NCT04501380|DRUG|AEMCOLO (Rifamycin SV MMX)|Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
48008416|NCT00848328|BIOLOGICAL|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
48369427|NCT05756062|DIETARY_SUPPLEMENT|Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)|Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
48694642|NCT06130254|DRUG|Adagrasib|Given by PO BID
48694643|NCT06130254|DRUG|Olaparib|Given by PO BID
48694644|NCT03172754|DRUG|Nivolumab|PD-1 inhibitor
48694645|NCT03172754|DRUG|Axitinib|Tyrosine kinase inhibitor
48694646|NCT00916201|DRUG|URB597|10 mg / d for 5 days, orally
48694647|NCT00916201|DRUG|intranasal Insulin|160 IU / d for 5 days, intranasal
48694648|NCT00916201|DRUG|Cannabidiol CR|320 mg / d for 5 days, orally
48008417|NCT00848328|DRUG|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
48008418|NCT02014675|DEVICE|SD01 ICD lead|
48008419|NCT03657472|DRUG|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
48008420|NCT03657472|DRUG|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
48694649|NCT03031626|BIOLOGICAL|Medical Air vs Oxygen|Medical Air/Oxygen will be given
48165520|NCT05643898|BEHAVIORAL|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
48008421|NCT01988870|RADIATION|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
48165521|NCT02690415|PROCEDURE|Antibiotics Given|Patients who's treating physician prescribed antibiotics
48522662|NCT03830333|DRUG|Ceftolozane/Tazobactam|Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.
48008422|NCT05039970|OTHER|WellQuest™|WellQuest™ is a mobile device-based serious health game.
48165522|NCT02690415|PROCEDURE|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
48008423|NCT02393963|DRUG|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
48008424|NCT02393963|OTHER|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
48008425|NCT03086785|DRUG|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
48008426|NCT00749463|DRUG|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
48008427|NCT00749463|DRUG|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
48165523|NCT03380221|OTHER|Watermelon|Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.
48165524|NCT03380221|OTHER|Low fat cookies|Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
48165525|NCT03505918|OTHER|No referral for rehabilitation|Intervention is that some patients will not be refered for postoperative physiotherapy.
48008428|NCT03794843|DRUG|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
48008429|NCT03794843|DRUG|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
48008430|NCT00503386|DRUG|Palonosetron|
48008431|NCT00503386|DRUG|Granisetron|
48008432|NCT06125821|OTHER|questionnaire|questionnaire
48008433|NCT06293846|BEHAVIORAL|What I Learned at Home|What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
48008434|NCT05621564|DRUG|pre-operative therapy|pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
48165526|NCT05582447|OTHER|ektacytometry of red blood cells|Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry
48165527|NCT03788954|OTHER|Kinesiotaping|Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
48165528|NCT01655862|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
48165529|NCT00549861|PROCEDURE|Cardiac Magnetic Resonance study|Cardiac MRI study
48165530|NCT02900222|PROCEDURE|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
48165531|NCT05721209|DEVICE|C-Mill with AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
48165532|NCT05721209|DEVICE|C-Mill without AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
48165533|NCT05721209|DEVICE|Zeno 3-Layer Walkway|Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
48165534|NCT05721209|DEVICE|Hunova|Used to conduct fall-risk assessment.
48165535|NCT03965221|BEHAVIORAL|LYNX|Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
48522663|NCT03830333|DRUG|Metronidazole|Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
48522664|NCT03830333|DRUG|Meropenem|Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
48522665|NCT03830333|DRUG|Placebo|Saline by IV infusion every 8 hours for 4 to 14 days.
48522666|NCT02971501|BIOLOGICAL|Bevacizumab|Given IV
48522667|NCT02971501|PROCEDURE|Biopsy|Undergo tumor biopsy
48165536|NCT03965221|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
48694650|NCT06564779|OTHER|New memory assessment|The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
48008435|NCT05520671|OTHER|Gamified online quizzing platform|"TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days."
48165537|NCT00535795|RADIATION|Radiation Therapy|Radiation Therapy
48165538|NCT01533558|DRUG|caspofungin|normal dosage for caspofungin, not adapted for the study
48165539|NCT00151697|DRUG|Novomix 30|
48694651|NCT06661200|DEVICE|SMC signal recording|SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
48694652|NCT00501722|DRUG|satavaptan (SR121463B)|
48008436|NCT05520671|OTHER|Conventional quizzing platform|"The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days."
48008437|NCT03377946|BIOLOGICAL|probiotics|the probiotics group was taking probiotics 4 packets a day
48008438|NCT03377946|BIOLOGICAL|placebo|the placebo group was taking placebo 4 packets a day
48008439|NCT05582330|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of Telephone Based ABILOCO-Stroke
48008440|NCT06155617|OTHER|Upper Extremity Rehabilitation|Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
48008441|NCT01720069|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
48008442|NCT05309603|OTHER|Loaded Walking High|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried high on the back
48008443|NCT05309603|OTHER|Loaded Walking Mid|Walking three miles on a treadmill at a self-selected speed while wearing a backpack with weight carried on the mid-back
48008444|NCT05309603|OTHER|Walking|Walking three miles on a treadmill at a self-selected speed
48008445|NCT00838266|DRUG|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
48165540|NCT00151697|DRUG|Novorapid and Amaryl|
48165541|NCT00151697|DRUG|Lantus|
48165542|NCT04770740|DIETARY_SUPPLEMENT|Vitamin K2 in the form of Menaquinone-7 (MK-7)|Patients will take three tablets of vitamin K2 menaquinone-7 (333mcg) per day. Patients taking vitamin K2 MK-7 will receive the total of 999mcg per day from day 1 until day 14 or discharge, whichever occurs earlier. All subjects can be treated with prophylactic or therapeutic heparin-based (heparin or any low-molecular weight heparin) anticoagulants, according to local hospital protocols. Provided by Kappa Bioscience.
48165543|NCT04770740|DIETARY_SUPPLEMENT|Placebo|Patients will take three tablets of placebo containing only inactive ingredients per day, from day 1 until day 14 or until discharge, whichever occurs first. The placebo is provided by Kappa Bioscience.
48165544|NCT01870414|OTHER|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm
48165545|NCT05820321|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
48165546|NCT05820321|OTHER|Beetroot juice NO3 depleted|The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
48165547|NCT05591378|OTHER|core stability exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise"
48694653|NCT00318318|DRUG|Premarin|
48694654|NCT06660732|DRUG|Rilonacept|320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.
48165548|NCT05591378|OTHER|otago exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without"
48165549|NCT00785850|DRUG|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
48165550|NCT03792893|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
48165551|NCT03792893|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
48165552|NCT01291043|OTHER|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
48165553|NCT00069277|DRUG|E7389|
48165554|NCT00618384|DRUG|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
48165555|NCT03038945|OTHER|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
48369428|NCT04382066|DRUG|Plitidepsin 1.5 mg/day|"Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
48694655|NCT00726791|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
48008446|NCT00838266|OTHER|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
48008447|NCT00614016|DRUG|Sodium ST20|single administration of oral dosage form
48165556|NCT03038945|OTHER|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
48165557|NCT02303002|BIOLOGICAL|Botulinum Toxin Type A|Intramuscular injection (IM)
48165558|NCT02303002|BIOLOGICAL|Active Comparator botulinum toxin|IM injection
48165559|NCT02303002|BIOLOGICAL|Placebo Comparator|IM injection
48522668|NCT02971501|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48522669|NCT02971501|PROCEDURE|Computed Tomography|Undergo CT scan
48522670|NCT02971501|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48522671|NCT02971501|DRUG|Osimertinib|Given PO
48522672|NCT03644342|DRUG|Nirapaib|(see treatment regimen and method of treatment assignment)
48008448|NCT01616186|DRUG|Everolimus and sorafenib|"* Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~* Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
48008449|NCT01616186|DRUG|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
48008450|NCT00231348|DRUG|Nefazodone|
48008451|NCT02003625|DRUG|GCSF|
48008452|NCT02003625|DRUG|meloxicam|
48008453|NCT02003625|DRUG|Placebo|
48008454|NCT01690039|DRUG|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
48008455|NCT01622946|DRUG|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
48008456|NCT01622946|DRUG|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
48008457|NCT00594828|DEVICE|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
48008458|NCT00594828|DEVICE|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
48008459|NCT01862172|OTHER|Additional MRI|
48008460|NCT03309683|DEVICE|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
48008461|NCT03672695|COMBINATION_PRODUCT|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
48165560|NCT02854839|BIOLOGICAL|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
48165561|NCT05168514|OTHER|Massage|"Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days."
48165562|NCT04341415|PROCEDURE|Auricular neuromodulation|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid"
48165563|NCT04341415|PROCEDURE|Control|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid."
48165564|NCT03709056|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
48165565|NCT03709056|DRUG|Propofol|Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
48165566|NCT00067119|DRUG|Aggrenox|
48165567|NCT00067119|DRUG|Placebo|
48165568|NCT04585568|OTHER|Biosensors|Measures of blood flow and preassures
48165569|NCT05221684|PROCEDURE|Lymph node harvesting|Lymph node harvesting after radical resection for rectal cancer with curative intent
48165570|NCT06276634|OTHER|Acute Intermittent Hypoxia|During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
48165571|NCT06276634|OTHER|Sham-Acute Intermittent Hypoxia|During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
48165572|NCT00443677|DRUG|COPPEBVCAD vs BEACOPP vs ABVD|
48522673|NCT04469777|DRUG|erythropoietin|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
48522674|NCT01860235|DRUG|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
48165573|NCT01156402|BEHAVIORAL|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
48165574|NCT03015181|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
48165575|NCT00510783|DRUG|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
48165576|NCT00510783|DRUG|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
48165577|NCT00510783|DRUG|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
48165578|NCT00220597|BEHAVIORAL|Trauma-focused group therapy|
48165579|NCT00639236|OTHER|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
48522675|NCT01860235|DRUG|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
48522676|NCT01860235|DRUG|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
48522677|NCT01860235|DRUG|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
48008462|NCT01194206|RADIATION|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
48694656|NCT04189965|OTHER|Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)|The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
48694657|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)|This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
48008463|NCT05703061|BEHAVIORAL|10-hour Time in Bed|Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
48008464|NCT04110067|OTHER|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
48008465|NCT02271308|BEHAVIORAL|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
48008466|NCT01437228|DRUG|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
48008467|NCT01437228|DRUG|placebo|NO İNTERVENTİON
48008468|NCT02210429|PROCEDURE|Elbow Fracture Fixation|
48008469|NCT01768390|OTHER|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
48008470|NCT01768390|OTHER|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
48008471|NCT03126994|DEVICE|PhysioWave Cardiovascular Analyzer|Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
48008472|NCT03126994|DEVICE|AtCor XCEL PWA & PWV|Measurement of Pulse Wave Velocity and Pulse Rate
48008473|NCT03126994|DEVICE|Detecto SOLO|Measurement of Body Weight and BMI
48008474|NCT01974193|DRUG|Floseal|application of floseal on intervention arm
48008475|NCT04596150|DRUG|CX-2009|Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
48008476|NCT04596150|DRUG|CX-072|Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
48008477|NCT00025285|DRUG|carboplatin|
48008478|NCT00025285|DRUG|irinotecan hydrochloride|
48008479|NCT00025285|DRUG|thalidomide|
48165580|NCT05651542|BEHAVIORAL|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
48165581|NCT05651542|OTHER|Control|The control group will receive standard care.
48165582|NCT01431105|DRUG|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
48008480|NCT01686412|DEVICE|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
48008481|NCT04694807|BEHAVIORAL|Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.~Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief."
48008482|NCT04694807|BEHAVIORAL|Individually delivered Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.~Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief."
48008483|NCT02634138|DEVICE|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
48008484|NCT01632891|DRUG|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
48008485|NCT01632891|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
48008486|NCT01632891|DRUG|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
48008487|NCT01632891|DRUG|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
48008488|NCT01632891|DRUG|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
48165583|NCT06647329|BIOLOGICAL|CAR-T Therapy|CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
48522678|NCT06203613|RADIATION|[18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12|The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.
48165584|NCT05579145|OTHER|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
48165585|NCT05579145|OTHER|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
48165586|NCT00010270|BIOLOGICAL|LMB-9 immunotoxin|
48165587|NCT06178198|PROCEDURE|Ablative radioembolization using Yttrium-90 resin microspheres|Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
48165588|NCT04299724|BIOLOGICAL|Pathogen-specific aAPC|The subjects will receive three injections of 5x10\^6 each Covid-19/aAPC vaccine via subcutaneous injections.
48165589|NCT02108197|DEVICE|Continuous positive airway pressure (S9, ResMed)|
48165590|NCT03578419|DEVICE|Small-Volume Blood Collection Tubes|Small-volume vacuum (\< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
48165591|NCT03578419|DEVICE|Standard-Volume Blood Collection Tubes|Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
48165592|NCT05798247|OTHER|Characteristics description|Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
48165593|NCT03528109|BEHAVIORAL|Exposure Therapy|A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
48514157|NCT06344585|OTHER|Drop out patients who had their first access in 2021 were additionally asked to answer to a phone -call questionnaire to assess their motivation of discontinuation|"A prospective comprehensive analysis of the data contained within patient charts, encompassing personal histories and demographic details, was extracted from the internal database of the Humanitas Fertility Center. This analysis aimed at elucidating the individual reasons for treatment discontinuation after the initial clinical visit throughout the year 2021. Additionally a tailored questionnaire was administered to patients via telephone by a member of Humanitas Fertility Center staff in July 2023.~The questionnaire was submitted to the patients via a phone call. The questionnaire comprised nine questions with response limited to 'Yes' and 'No' options for all queries."
48514158|NCT00403585|DRUG|adefovir dipivoxil 10mg|
48514159|NCT05872022|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
48522679|NCT04952181|DEVICE|optical biometry|optical biometry is a fast, noncontact method it uses the method of partial coherence interferometry (PCI) to measure the axial length (AXL), based on reflection of the interference signal of the retinal pigment epithelium.
48694658|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)|This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
48008489|NCT04659070|DRUG|Experimental : Ezetimibe / Rosuvastatin + Telmisartan|Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
48165594|NCT03746483|DRUG|MS1819|MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
48165595|NCT03746483|DRUG|Porcine PERT|Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
48165596|NCT01184859|DRUG|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
48165597|NCT01184859|DRUG|Placebo|Placebo melt tablet for sublingual administration
48165598|NCT05452837|PROCEDURE|FDFG|FDFG is applied to the parotidectomy bed after superficial parotidectomy
48165599|NCT05452837|PROCEDURE|SMAS|SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
48165600|NCT05758376|BEHAVIORAL|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
48165601|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 1 application|
48165602|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 2 applications|
48008490|NCT04659070|DRUG|Active comparator1 : Ezetimibe / Rosuvastatin|Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
48165603|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 1 application|
48165604|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 2 applications|
48165605|NCT02396498|DRUG|HIPEC|Using cisplatin in HIPEC plus oral S-1
48165606|NCT02110225|DRUG|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
48165607|NCT02110225|DRUG|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
48165608|NCT02110225|DRUG|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
48008491|NCT04659070|DRUG|Active comparator2 : Telmisartan|Telmisartan 80mg PO, Once daily for 8 weeks
48165609|NCT02132598|DRUG|cabozantinib|
48165610|NCT06414681|DRUG|Tagraxofusp|Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.
48165611|NCT06414681|DRUG|Pacritinib|Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
48165612|NCT05493228|DRUG|Precedex Injectable Product|Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
48165613|NCT05493228|DRUG|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
48165614|NCT02996097|DEVICE|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
48165615|NCT02996097|DRUG|Intralesional Triamcinolone Acetonide|
48165616|NCT06480851|PROCEDURE|Ecoguided Percutaneous Neuromodulation|Ecoguided Percutaneous Neuromodulation over the posterior branch of the cervical multifidus, for 10 minutes, with a frequency of 10 HZ.
48165617|NCT02324309|DRUG|BIOD-531|
48165618|NCT02324309|DRUG|Humalog Mix 75/25|
48514160|NCT05328219|OTHER|Chewing gums with PEG solution|"Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass."
48008492|NCT00379470|DEVICE|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
48008493|NCT04723433|OTHER|Oxygen gas -Conservative|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
48008494|NCT04723433|OTHER|Oxygen gas -Liberal|Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
48008495|NCT03491150|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
48165619|NCT02324309|DRUG|Humulin R U-500|
48165620|NCT02324309|DRUG|BIOD-531|
48165621|NCT02926495|DEVICE|eCoin System|Median nerve neurostimulator.
48165622|NCT02312362|PROCEDURE|Combined sclerotomy ab interno and phaco|
48008496|NCT00885833|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
48008497|NCT02761811|DEVICE|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
48008498|NCT02405416|PROCEDURE|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
48008499|NCT02405416|PROCEDURE|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
48008500|NCT02405416|PROCEDURE|Portal triad clamping|Portal triad are clamped in hepatectomy.
48165623|NCT02312362|PROCEDURE|Phacoemulsification with IOL implantation|
48165624|NCT03652870|DRUG|Nortriptyline|A medication used to treat conditions such as depression
48165625|NCT03652870|DRUG|Escitalopram|A medication used to treat conditions such as depression
48165626|NCT03652870|DRUG|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
48165627|NCT04087798|BEHAVIORAL|Control-EDI|Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
48165628|NCT04087798|BEHAVIORAL|Intervention-EDI and health coaching|"Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only)."
48165629|NCT00757978|DRUG|memantine|memantine 10mg twice a day
48165630|NCT00757978|DRUG|placebo|1 capsule of placebo twice a day
48165631|NCT05825547|PROCEDURE|Cryotherapy treatment|Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
48165632|NCT00506272|PROCEDURE|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
48694659|NCT06263023|OTHER|Sub-Normothermic Machine Preservation and Assessment|Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.
48165633|NCT00506272|PROCEDURE|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
48165634|NCT03565302|DRUG|Formoterol|Subjects are treated with daily inhalation of formoterol
48008501|NCT05525182|DRUG|ES16001 40 mg|Composition: Elaeocarpus extract 40mg tablet
48008502|NCT05525182|DRUG|ES16001 80 mg|Elaeocarpus extract 80 mg tablet
48165635|NCT03565302|DRUG|Terbutaline|Subjects are treated with daily inhalation of terbutaline
48165636|NCT03565302|OTHER|Placebo|Subjects are treated with placebo
48165637|NCT03357471|DRUG|e-Device|"* Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device"
48369429|NCT04382066|DRUG|Plitidepsin 2.0 mg/day|"Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
48514161|NCT05328219|OTHER|Standard of care|Standard of care
48694660|NCT06657391|DRUG|recombinant humanized anti-CD25 monoclonal antibody|The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
48008503|NCT05525182|DRUG|ES16001 160 mg|Elaeocarpus extract 160 mg tablet
48008504|NCT05525182|DRUG|Placebo|Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
48514162|NCT00029029|PROCEDURE|pain therapy|
48008505|NCT04347265|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
48008506|NCT01973101|DRUG|Cisplatin|50 mg/m2 - Day 1
48008507|NCT01973101|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
48514163|NCT00029029|PROCEDURE|radiofrequency ablation|
48514164|NCT00002704|BIOLOGICAL|filgrastim|
48008508|NCT01973101|DRUG|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
48008509|NCT01973101|RADIATION|Radiotherapy|45 Gy
48008510|NCT01973101|RADIATION|Brachytherapy|80 Gy
48165638|NCT06531811|DRUG|AZD8630 (test formulation) via test inhaler|Participants will receive AZD8630 via test inhaler.
48165639|NCT06531811|DRUG|AZD8630 (reference formulation) via Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
48165640|NCT06531811|DEVICE|Test inhaler|Participants will receive AZD8630 via test inhaler.
48165641|NCT06531811|DEVICE|Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
48165642|NCT02508779|BEHAVIORAL|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
48165643|NCT02508779|OTHER|Routine Care|Participants will continue to receive care from their clinician.
48165644|NCT00880152|BEHAVIORAL|Mindfulness-based stress reduction|An 8-week course in mindfulness training
48165645|NCT00907517|DRUG|MK-8776|IV infusion
48165646|NCT00907517|DRUG|Cytarabine|IV infusion
48165647|NCT02130271|DRUG|Radioactive dye|The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).
48165648|NCT02130271|RADIATION|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
48165649|NCT02130271|OTHER|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
48165650|NCT00920699|DRUG|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
48165651|NCT00569036|DRUG|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
48165652|NCT05161143|DRUG|Donafenib|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once."
48008511|NCT00395239|DRUG|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
48008512|NCT01010282|DRUG|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
48165653|NCT01659177|DRUG|LY2140023|Administered orally
48165654|NCT02657954|BEHAVIORAL|CCT|10-week Compensatory Cognitive Training
48165655|NCT02657954|BEHAVIORAL|HCE|10-week Holistic Cognitive Education
48514165|NCT00002704|DRUG|asparaginase|
48694661|NCT05489354|OTHER|mHealth psychoeducational intervention|The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
48514166|NCT00002704|DRUG|cyclophosphamide|
48694662|NCT04840485|DRUG|SHR-1314|SHR-1314 high dose
48694663|NCT04840485|DRUG|SHR-1314|SHR-1314 low-dose
48694664|NCT04840485|DRUG|Placebo|Placebo
48694665|NCT05189756|DRUG|Aprepitant 80 mg|Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.
48694666|NCT05189756|DRUG|Placebo|Encapsulated placebo capsules for optical, acoustical and haptic blinding.
48694667|NCT04346173|PROCEDURE|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
48008513|NCT01010282|DRUG|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
48694668|NCT01597908|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily orally
48165656|NCT00475735|DRUG|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
48694669|NCT01597908|DRUG|Vemurafenib|Vemurafenib 960 mg twice daily orally
48008514|NCT01010282|DRUG|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
48008515|NCT01664143|DRUG|Placebo|Multiple doses of placebo
48008516|NCT01664143|DRUG|RO5508887|Multiple doses of RO5508887
48008517|NCT02857010|BIOLOGICAL|Allogenic mesenchymal stem cells|Cell therapy
48008518|NCT02857010|OTHER|Placebo|Serum without stem cells
48165657|NCT00475735|DRUG|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
48514167|NCT00002704|DRUG|daunorubicin hydrochloride|
48514168|NCT00002704|DRUG|dexamethasone|
48514169|NCT00002704|DRUG|etoposide|
48514170|NCT00002704|DRUG|leucovorin calcium|
48514171|NCT00002704|DRUG|liposomal cytarabine|
48514172|NCT00002704|DRUG|mercaptopurine|
48514173|NCT00002704|DRUG|mesna|
48694670|NCT01597908|DRUG|Trametinib|Trametinib 2 mg once daily orally
48694671|NCT06658587|DIAGNOSTIC_TEST|No interventions|No interventions
48694672|NCT01228136|DRUG|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
48514174|NCT00002704|DRUG|methotrexate|
48694673|NCT01228136|OTHER|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
48694674|NCT06641323|OTHER|Ozonized gel|Administration of Ozonized Gel GeliO3
48694675|NCT06641323|DEVICE|Ozonized water|Admininstration of Gaseous ozone (Healozone X4)
48694676|NCT02381717|OTHER|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
48694677|NCT02381717|DRUG|bupivacaine|
48694678|NCT02381717|DRUG|morphine|
48694679|NCT00101920|DRUG|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
48694680|NCT05980416|DRUG|EO-3021|Anti-Claudin 18.2 antibody drug conjugate
48008519|NCT05508529|DIETARY_SUPPLEMENT|Chaga Mushroom|Effect of chaga on immune/mood support
48694681|NCT04969094|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
48694682|NCT04969094|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
48694683|NCT04480736|DRUG|Placebo|Matching placebo will be administered orally.
48694684|NCT04480736|DRUG|JNJ-64281802 High dose|JNJ-64281802 high dose will be administered orally.
48008520|NCT05508529|DIETARY_SUPPLEMENT|Algae Extract|Effect of algae extract on immune/mood support
48008521|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil|Effect of black cumin seed oil on immune/mood support
48008522|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Astaxanthin|Effect of Black Cumin Seed Oil + Astaxanthin blend on immune/mood support
48008523|NCT05508529|DIETARY_SUPPLEMENT|Black Cumin Seed Oil + Omega 3|Effect of Black Cumin Seed Oil + Omega3 blend on immune/mood support
48008524|NCT05508529|DIETARY_SUPPLEMENT|Placebo|Placebo control
48008525|NCT02800148|DRUG|Azelaic acid foam|
48008526|NCT02800148|DRUG|Azelaic acid foam|
48008527|NCT02800148|DRUG|Azelaic acid foam - Placebo|
48008528|NCT00938483|OTHER|Nutramigen Lipil (Infant formula)|
48514175|NCT00002704|DRUG|therapeutic hydrocortisone|
48514176|NCT00002704|DRUG|thiotepa|
48514177|NCT00002704|DRUG|vincristine sulfate|
48514178|NCT00002704|RADIATION|low-LET electron therapy|
48694685|NCT04480736|DRUG|JNJ-64281802 Medium dose|JNJ-64281802 medium dose will be administered orally.
48694686|NCT04480736|DRUG|JNJ-64281802 Low dose|JNJ-64281802 low dose will be administered orally.
48694687|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen X|JNJ-64281802 dosing regimen X will be administered orally.
48694688|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Y|JNJ-64281802 dosing regimen Y will be administered orally.
48694689|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Z|JNJ-64281802 dosing regimen Z will be administered orally.
48694690|NCT06381076|DRUG|Liposomal curcumin|participants will consume the product ad libitum for the 24 treatments.
48694691|NCT06381076|DRUG|Food colorant|participants will consume the product ad libitum for the 24 treatments as a placebo.
48694692|NCT06660719|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
48694693|NCT06660719|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
48694694|NCT04428788|DRUG|CC-94676|Specified dose on specified days
48694695|NCT04428788|DRUG|CC1083611|Specified dose on specified days
48694696|NCT04428788|DRUG|CC1083610|Specified dose on specified days
48694697|NCT06660056|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain|Use of Ommaya capsules
48694698|NCT06376162|DRUG|Ziftomenib|Oral capsule
48694699|NCT06376162|DRUG|Cytarabine|Intravenous (IV) infusion
48694700|NCT06376162|DRUG|Fludarabine|IV infusion
48694701|NCT06657638|DIAGNOSTIC_TEST|Thoracentesis|Aspiration of pleural effusion
48694702|NCT04726241|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or bone marrow samples
48165658|NCT00475735|DRUG|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
48165659|NCT04835233|DRUG|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
48165660|NCT04939883|DRUG|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
48165661|NCT04939883|DRUG|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
48165662|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
48514179|NCT00002704|RADIATION|low-LET photon therapy|
48694703|NCT04291196|OTHER|VR-ECT 360o Video|Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.
48694704|NCT04291196|OTHER|Standard Treatment|Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
48694705|NCT05230446|DEVICE|PCI with OCT guidance|Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
48008529|NCT04571112|DEVICE|NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)|This will either be turned on or off depending on the arm which the patient is randomized to. After 8-weeks, the subject will switch arms for another 8-weeks.
48008530|NCT03660410|OTHER|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
48514180|NCT02291575|OTHER|Training|(please see Arm Description)
48514181|NCT02291575|OTHER|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
48008531|NCT03660410|OTHER|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
48008532|NCT05669443|DEVICE|conventional PEEP|Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
48008533|NCT05669443|DEVICE|optimized PEEP|Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
48514182|NCT04625491|OTHER|Observational|Observational
48514183|NCT02100488|DEVICE|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
48694706|NCT01223651|PROCEDURE|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
48694707|NCT06473077|PROCEDURE|ETT beyond C7 level|Endotracheal cuff is placed deeper beyond C7 level, but above carina
48694708|NCT05034627|PROCEDURE|Biopsy|Undergo biopsy
48694709|NCT05034627|DRUG|Calaspargase Pegol-mknl|Given IV
48008534|NCT06355869|OTHER|repeated 3D gait-analysis|An observational 3D gait-analysis was performed with a period of 1-14 days is foreseen between the two measurements.
48165663|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
48165664|NCT01229527|DRUG|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
48514184|NCT02100488|OTHER|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
48694710|NCT05034627|DRUG|Cobimetinib|Given PO
48694711|NCT04639466|DRUG|Placebo Administration|Given IM in the non-dominant upper arm
48694712|NCT04639466|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
48694713|NCT02604368|DRUG|SC411|Soft gelatin capsule
19632562|NCT06438341|BIOLOGICAL|SPOT-mRNA01|SPOT-mRNA01 (COL1A1 mRNA-loaded EVs) ,single-dose subcutaneous injection
19632563|NCT06438341|OTHER|Placebo|Sterile isotonic solution
48694714|NCT02604368|DRUG|Placebo|Soft gelatin capsule
48694715|NCT04037449|PROCEDURE|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
48514185|NCT02256436|BIOLOGICAL|pembrolizumab|IV infusion
48008535|NCT03734120|OTHER|cryopreservation|Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
48008536|NCT02351869|DRUG|Nitrous Oxide|
48008537|NCT02351869|DRUG|Midazolam|
48008538|NCT02751177|GENETIC|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
48694716|NCT04037449|OTHER|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
48008539|NCT02126969|RADIATION|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
48008540|NCT02126969|DRUG|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
48008541|NCT03935035|BEHAVIORAL|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
48008542|NCT02611258|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
48008543|NCT00915798|BEHAVIORAL|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
48008544|NCT00915798|BEHAVIORAL|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
48008545|NCT01466270|DRUG|donepezil hydrochloride|Given PO
48008546|NCT01466270|DRUG|Placebo|Given PO
48008547|NCT00542750|DRUG|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
48008548|NCT01088009|DRUG|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
48008549|NCT01088009|DRUG|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
48008550|NCT01088009|DRUG|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
48008551|NCT03102918|DRUG|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
48514186|NCT02256436|DRUG|paclitaxel|IV infusion
48514187|NCT02256436|DRUG|vinflunine|IV infusion
48514188|NCT02256436|DRUG|docetaxel|IV infusion
48514189|NCT05884944|PROCEDURE|Sham- Light touch, not reaching restrictive barrier|Sham- Light touch, not reaching restrictive barrier For the control group, the subjects hip, knee, and ankle joints will be moved bilaterally 3 times into each plane to mimic the OMM muscle energy treatment. The joint will be moved in each plane of motion without reaching the joint barrier. The hip joint will be moved into adduction, extension, and flexion, the knee joint will be moved into extension and flexion, and the ankle will be moved into plantarflexion and dorsiflexion 3 times in each direction without reaching the barrier passively.
48008552|NCT03102918|DRUG|Placebo|Participants will receive placebo over a 6-week treatment period.
48008553|NCT02103829|BEHAVIORAL|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
48008554|NCT02103829|BEHAVIORAL|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
48008555|NCT02103829|BEHAVIORAL|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
48008556|NCT05176093|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
48008557|NCT05176093|OTHER|Placebo|Injectable Liquid
48008558|NCT01092247|OTHER|Nutritional support with Standard diet|Nutritional support with Standard diet
48008559|NCT01092247|OTHER|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
48008560|NCT04887662|OTHER|Fermented vegetable|Participants will be asked to consume 100 g of fermented vegetables per day, at least 5 days per week, for 8 weeks
48008561|NCT01962558|DEVICE|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
48008562|NCT01962558|DEVICE|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
48008563|NCT01395940|DRUG|KLH-2109|
48008564|NCT01395940|DRUG|KLH-2109|
48008565|NCT00381420|DEVICE|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
48008566|NCT00381420|DEVICE|bare-metal stent|un-coated Bx VELOCITY Stent
48008567|NCT05923424|DRUG|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
48008568|NCT05923424|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
48008569|NCT06482931|OTHER|Quality of life questionnaires|Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
48694717|NCT05340569|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
48694718|NCT05083403|DEVICE|AcumenTM HPI Software Feature|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
48008570|NCT04230096|DEVICE|low level laser therapy|apply low level laser therapy on buccal surface of maxillary jaw on anterior segment for three minutes at every three weeks in fixed orthodontic patients in their regular follow up visits
48694719|NCT05083403|OTHER|Non-protocolized Standard of Care|Non-protocolized standard of care to treat subjects
48694720|NCT05699551|BEHAVIORAL|Exercise regimen|Exercise will take place Monday, Wednesday, and Friday from 12:00-1:00 pm for 6 weeks. Aerobic exercise will consist of walking, beginning with a 10-minute duration, with gradual progression to 20 minutes. Muscle strength, endurance and range-of-motion exercise will then be performed. Muscle strength and endurance training will begin using no weight and performing one set of 6 repetitions. Progression using added resistance in the form of dumbbell weights (1-6 lbs.) and increased sets and repetitions will be applied as Subjects become increasingly fit. For static range of motion exercise, positions will be held for 10-15 seconds in the beginning and increased over time. Exercise will be kept at a moderate level of intensity. Each session will then end with relaxation training.
48694721|NCT04165382|OTHER|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
48008571|NCT00256490|PROCEDURE|PET/CT 20 days after the first cycle of chemotherapy|
48008572|NCT02985294|OTHER|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
48008573|NCT05595993|DRUG|Cilostazol|Study participants will be allocated to receive oral administration of 200 mg cilostazol.
48008574|NCT05595993|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
48008575|NCT01705288|PROCEDURE|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
48008576|NCT01705288|DRUG|intravenous narcotics|given for pain management after surgery per physician orders
48008577|NCT01705288|DRUG|standard anesthesia|inhalant or intravenous during surgery
48008578|NCT01705288|DRUG|regional anesthesia|given by spinal or epidural infusion
48008579|NCT01705288|DRUG|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
48008580|NCT00804336|DRUG|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
48008581|NCT00804336|DRUG|RAD001|Given orally once a day
48008582|NCT00353366|BIOLOGICAL|Rotarix|Two doses of the oral vaccine
48008583|NCT00353366|OTHER|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
48008584|NCT02002234|PROCEDURE|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
48008585|NCT02002234|PROCEDURE|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
48008586|NCT05233436|DRUG|PF-07265028|PF-07265028 will be administered orally
48008587|NCT05233436|BIOLOGICAL|Sasanlimab|Administered subcutaneously
48008588|NCT01228929|OTHER|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
48008589|NCT04818359|BEHAVIORAL|MoviS Training|Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
48008590|NCT04976491|DIETARY_SUPPLEMENT|CD-C-Food|CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
48008591|NCT04976491|DIETARY_SUPPLEMENT|EEN|EEN goup received EEN continuously for 6 moths
48008592|NCT02531165|DRUG|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
48008593|NCT02531165|DRUG|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
48165665|NCT04832815|BEHAVIORAL|Equine Therapy|Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.
48165666|NCT04832815|BEHAVIORAL|Therapeutic Horsemanship Program|Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
48008594|NCT02531165|DRUG|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
48008595|NCT02531165|DRUG|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
48008596|NCT02531165|DRUG|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT \>250 sec during PCI are allowed.
48369430|NCT04382066|DRUG|Plitidepsin 2.5 mg/day|"Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin."
48008597|NCT02531165|PROCEDURE|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
48369431|NCT03564860|PROCEDURE|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
48008598|NCT04514601|OTHER|Standard Operating Protocol|This was a written protocol on how the handover process should be conducted.
48165667|NCT06306677|DIAGNOSTIC_TEST|AI-clincial-based hybrid system for radiographic image analysis|The Index test is a novel AI-clinical-based hybrid system for radiographic image analysis. Its diagnostic performance will be compared to the reference represented by a panel of experts.
48165668|NCT04522583|DIAGNOSTIC_TEST|Diagnosis of Myocardial Ischemia|Discharge diagnosis of myocardial ischemia
48165669|NCT02995733|DRUG|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
48165670|NCT02469077|BEHAVIORAL|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
48165671|NCT02469077|DRUG|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
48369432|NCT06280404|DEVICE|Lap cholecystectomy|Body first approach in laparoscopic cholecystectomy in cases with obscure Calot's triangle
48369433|NCT03647098|DRUG|Chemotherapy.|pemetrexed, 500mg/m2, ivgtt every 21 day.
48694722|NCT04165382|OTHER|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
48694723|NCT06249698|DIETARY_SUPPLEMENT|meal replacements and supplements|Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
48694724|NCT01829568|DRUG|Ibrutinib|Given PO
48694725|NCT01829568|OTHER|Laboratory Biomarker Analysis|Correlative studies
48008599|NCT02204254|DEVICE|Radiofrequence|Associated to arm radiofrequence
48008600|NCT02204254|DRUG|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
48008601|NCT00885547|DRUG|tripterygium wilfordii (TW)|90 mg/d for 6 months
48008602|NCT00025883|DRUG|Metreleptin|Drug treatment
48008603|NCT03282552|DEVICE|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
48008604|NCT01703637|DRUG|Sitagliptin|"* before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
48008605|NCT01703637|DRUG|Vildagliptin|"* before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
48008606|NCT01703637|DRUG|Saxagliptin|"* before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
48008607|NCT03234738|DRUG|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
48008608|NCT03234738|DRUG|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
48008609|NCT06019975|DIAGNOSTIC_TEST|FDG-PET|Brain FDG-PET
48694726|NCT01829568|DRUG|Lenalidomide|Given PO
48694727|NCT01829568|OTHER|Pharmacological Study|Correlative studies
48694728|NCT01829568|BIOLOGICAL|Rituximab|Given IV
48694729|NCT00614445|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
48694730|NCT00614445|DRUG|Placebo|2 to 4 tablets daily titrated according to the protocol
48694731|NCT04435691|DRUG|Azacitidine|Given SC or IV
48694732|NCT04435691|BIOLOGICAL|Magrolimab|Given IV
48694733|NCT04435691|DRUG|Venetoclax|Given PO
48694734|NCT05042323|BEHAVIORAL|TF-CBT-Short|Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
48008610|NCT04891939|OTHER|Health education lessons (Smart-Kid's program)|The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors
48008611|NCT04891939|OTHER|School Health and Education Program (SHEP)|The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
48008612|NCT00699010|DRUG|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
48008613|NCT00699010|DRUG|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
48694735|NCT05157971|DRUG|Cyclophosphamide|Given IV
48694736|NCT05157971|DRUG|Cytarabine|Given SC, IV or IT
48694737|NCT05157971|DRUG|Daunorubicin Hydrochloride|Given IV
48694738|NCT05157971|DRUG|Mercaptopurine|Given PO
48694739|NCT05157971|DRUG|Methotrexate|Given IT
48694740|NCT05157971|DRUG|Pegaspargase|Given IM or IV
48694741|NCT05157971|DRUG|Prednisone|Given PO
48694742|NCT05157971|DRUG|Venetoclax|Given PO
48694743|NCT05157971|DRUG|Vincristine Sulfate|Given IV
48694744|NCT04781855|DRUG|Ibrutinib|Given PO
48694745|NCT04781855|BIOLOGICAL|Ipilimumab|Given IV
48694746|NCT04781855|BIOLOGICAL|Nivolumab|Given IV
48694747|NCT01179828|DRUG|Oxycodone 15mg|15mg single administration p.o.
48694748|NCT01179828|DRUG|Clobazam|20mg single administration p.o.
48694749|NCT01179828|DRUG|Imipramine|75mg single administration p.o.
48694750|NCT01179828|DRUG|Tolterodine|1 mg single administration p.o.
48694751|NCT03300141|OTHER|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
48694752|NCT03300141|OTHER|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
48694753|NCT03300141|OTHER|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
48008614|NCT04020302|BEHAVIORAL|Self-monitoring shopping intervention|Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
48165672|NCT02469077|DRUG|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
48165673|NCT02469077|DRUG|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
48165674|NCT03220776|DRUG|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
48369434|NCT01510392|DEVICE|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
48165675|NCT03220776|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
48694754|NCT02063867|DRUG|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
48165676|NCT03220776|DRUG|Placebo Oral Tablet|5 day trial of matched placebo
48165677|NCT04935918|DEVICE|ACT|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck. The ACT system is a permanent implant designed for the correction of incontinence in patients.
48369435|NCT00175734|PROCEDURE|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
48694755|NCT05192616|DEVICE|Covered stent implantation|Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
48694756|NCT06340321|DIAGNOSTIC_TEST|Metabolic flexibility in the fasted state|Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids
48694757|NCT06340321|OTHER|Metabolic flexibility in euglycemic-hyperinsulinemic clamp|Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate
48694758|NCT06340321|OTHER|Metabolic flexibility in the metabolic chamber|Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber
48694759|NCT06657924|DRUG|Tranexamic acid|1 gram IV bolus in 100ml of normal saline administered over 10 minutes at the start and end of the surgery for a total of 2 grams TXA
48694760|NCT05497115|BEHAVIORAL|Trauma Resilience and Recovery Program|The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
48008615|NCT06189456|DEVICE|BLUgel A|BLUgel A: Hyaluronic Acid Eye Drops 0.30%
48008616|NCT06189456|DEVICE|BLUyal A|BLUyal A:Hyaluronic Acid Eye Drops 0.15%
48008617|NCT03469921|DRUG|administered therapeutic regimens|administered therapeutic regimens
48008618|NCT04157062|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
48008619|NCT04223882|BEHAVIORAL|Management of Stress|"Psychoeducation:~Coronary artery disease, Percutaneous Coronary Intervention, traditional risk factors and emotional stress.~Stress: physiology, triggers, triad (thinking, emotion, action).~Skills training:~Identify warning signs - signs and symptoms; Monitoring of irrational automatic thoughts generating alternative interpretations of situations or unrealistic thinking patterns (Dysfunctional Thinking Records Sheet).~Self-control for stress management:~Assertiveness training, problem solving. Thought-stopping technique, designed for dysfunctional thoughts, such as, I won't do it, It won't work.~Stress Relief / Control Techniques:~Diaphragmatic Breathing: Expansion of the abdomen rather than the chest when breathing.~Progressive Muscle Relaxation: Maximize tension and alternately relax the muscles (legs, abdomen, chest, arms and face)."
48008620|NCT04223882|OTHER|Usual care|outpatient medical appointments
48008621|NCT03913143|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
48008622|NCT03913143|OTHER|Sham|Sham-Procedure (no experimental drug administered)
48369436|NCT00175734|PROCEDURE|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
48369437|NCT04064047|PROCEDURE|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
48694761|NCT06453213|DRUG|Cenobamate|"The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day).~The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day)."
48694762|NCT03061721|DRUG|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
48165678|NCT03383029|BEHAVIORAL|iEAT Program|The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
48694763|NCT03061721|DRUG|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
48694764|NCT03061721|DRUG|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
48694765|NCT03061721|DRUG|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
48694766|NCT02639169|OTHER|Music Therapy|apply live music through the techniques of music therapy
48694767|NCT05933356|BEHAVIORAL|playing exergames|"will be provided with the individual brain training exergames three times a week and 30 minutes each time"
48694768|NCT05933356|OTHER|scheduled activities|scheduled activities
48694769|NCT06606327|DRUG|Diazoxide, 3 mg/kg per dose|Insulin anti-secretagogue taken for 8 doses over 4 days
48694770|NCT03656848|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
48165679|NCT03042559|DEVICE|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
48369438|NCT04064047|PROCEDURE|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
48369439|NCT04064047|PROCEDURE|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
48694771|NCT03656848|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
48694772|NCT05056805|OTHER|Aerobic Exercise|Receive aerobic exercise encouragement
48694773|NCT05056805|OTHER|Dietary Intervention|Consume high protein snack/meal/shake
48694774|NCT05056805|OTHER|Nutritional Intervention|Receive nutritional consultation and guidelines
48694775|NCT05056805|OTHER|Quality-of-Life Assessment|Ancillary studies
48694776|NCT05056805|OTHER|Questionnaire Administration|Ancillary studies
48694777|NCT05056805|OTHER|Resistance Training|Complete strengthening exercise
48694778|NCT06660914|PROCEDURE|Flexible Ureteroscopy|Ureteroscopic lithotripsy
48694779|NCT06660680|DRUG|Methylene Blue|Received MBI treatment to their surgical incisions upon completion of surgery
48694780|NCT01974206|BIOLOGICAL|ASP0113|intramuscular injection
48694781|NCT01974206|DRUG|Placebo|intramuscular injection
48694782|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
48694783|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
48369440|NCT04064047|PROCEDURE|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
48694784|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
48694785|NCT00425997|DRUG|Valsartan/HCTZ|
48694786|NCT00425997|DRUG|amlodipine|
48694787|NCT00425997|DRUG|HCTZ|
48694788|NCT06637527|DRUG|OK-101 0.05%|0.05% Ophthalmic Solution
48694789|NCT06637527|DRUG|OK-101 0.1%|0.1% Ophthalmic Solution
48694790|NCT06637527|DRUG|Placebo|Placebo
48694791|NCT04023370|DEVICE|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
48694792|NCT00196027|DEVICE|PFX Closure System|
48694793|NCT03389724|DRUG|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
48694794|NCT04054479|DRUG|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
48694795|NCT04054479|DRUG|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
48694796|NCT02774200|DRUG|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
48694797|NCT03958747|DIAGNOSTIC_TEST|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
48008623|NCT03111654|DIAGNOSTIC_TEST|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
48008624|NCT04103528|OTHER|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
48008625|NCT04103528|OTHER|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
48369441|NCT05677373|DRUG|BRD4 Inhibitor PLX2853|Given PO
48008626|NCT02311751|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
48008627|NCT06034054|OTHER|nursing counceling|"* Providing an educational booklet containing information about pastry, verbally explaining the content of the prepared educational booklet.~* Answering the information and questions that the patient needs in addition, and receiving contact information in October.~* Monthly calls will be made to patients 6. providing information that the same tests will be performed again per month, if necessary, this monthly call counseling by reaching out without waiting indicating what they can receive."
48008628|NCT00124215|BIOLOGICAL|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
48008629|NCT00793364|DIETARY_SUPPLEMENT|Stanol ester spread|Stanol ester spread 20 g every day
48008630|NCT00793364|DIETARY_SUPPLEMENT|Placebo spread|Placebo spread 20 g every day
48008631|NCT00793364|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet every day
48008632|NCT01624428|DRUG|Varenicline|1 mg bid varenicline titrated over a 2 week period
48008633|NCT01624428|DRUG|Placebo|1 mg bid placebo titrated over a 2 week period
48008634|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF+ (Maternal Ready-to-Use Supplementary Food + DHA/EPA/choline)|Balanced energy protein supplement with added DHA/EPA/choline, micronutrients
48008635|NCT05949190|DIETARY_SUPPLEMENT|M-RUSF (Maternal Ready-to-Use Supplementary Food)|Balanced energy protein supplement with added micronutrients
48008636|NCT05949190|DRUG|Azithromycin|1g dose
48369442|NCT05677373|DRUG|Trametinib|Given PO
48369443|NCT05677373|PROCEDURE|Computed Tomography|Undergo CT with contrast
48369444|NCT05677373|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI with contrast
48369445|NCT05677373|PROCEDURE|Biospecimen collection|Undergo collection of blood
48369446|NCT05677373|PROCEDURE|Biospecimen collection|Correlative studies
48369447|NCT01052558|DEVICE|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
48369448|NCT01052558|PROCEDURE|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
48008637|NCT05949190|DRUG|Albendazole|400mg dose
48008638|NCT05949190|DRUG|Sulfadoxine pyrimethamine|Monthly, 1,500/75mg dose
48008639|NCT05949190|BEHAVIORAL|Cognitive behavioral therapy|Novel program developed for illiterate end-users
48008640|NCT05949190|OTHER|Insecticide-treated mosquito net|Bed net to prevent malaria
48008641|NCT00648531|DRUG|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
48008642|NCT00648531|DRUG|Colazal® Capsules 750 mg|3x750mg, single dose fasting
48008643|NCT04186442|DRUG|Botulinum toxin type A injection|Experimental
48008644|NCT04186442|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
48008645|NCT03579199|DEVICE|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
48008646|NCT03672903|DEVICE|Weight Vest|A vest with added weights up to a maximum of 15 kg.
48008647|NCT01746758|BEHAVIORAL|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
48008648|NCT03967470|BIOLOGICAL|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
48008649|NCT05330650|DRUG|Coated Vicryl+|We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
48008650|NCT05330650|DRUG|Vicryl|We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
48008651|NCT00052845|DRUG|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
48008652|NCT00052845|DRUG|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
48008653|NCT00052845|DRUG|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
48369449|NCT03440398|PROCEDURE|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
48369450|NCT03440398|PROCEDURE|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
48369451|NCT02487524|OTHER|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
48369452|NCT02487524|OTHER|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
48369453|NCT02487524|OTHER|QST|Quantitative sensory testing.
48694798|NCT03958747|PROCEDURE|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
48694799|NCT03958747|OTHER|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
48694800|NCT03958747|OTHER|Blood draw|12 ml blood sample will be taken
48694801|NCT03958747|DIAGNOSTIC_TEST|Nerve Conduction Study|Sural and tibial nerve assessments
48694802|NCT03958747|OTHER|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
48694803|NCT06292637|BEHAVIORAL|Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH)|CB-FAITH is a behavioral depression intervention set inside a cognitive behavioral framework, and Afrocentric paradigm and informed by faith-based principles, designed to treat major depressive disorder among African American adults. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by licensed mental health clinicians and pastors at churches.
48694804|NCT02377752|BIOLOGICAL|Olaratumab|Administered IV
48694805|NCT02377752|DRUG|Doxorubicin|Administered IV
48694806|NCT06625138|DEVICE|Latex Band|Hemorrhoid banding with latex band
48694807|NCT06625138|DEVICE|Non-Latex Band|Hemorrhoid banding with non-latex bands
48694808|NCT06578156|DEVICE|Nasal High Flow Cannula|High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
48694809|NCT06578156|DEVICE|Nasal Low Flow Cannula|Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
48694810|NCT06353295|OTHER|P4P intervention|The final Peers for PrEP (P4P) intervention components were refined based on stakeholder engagement, key informant interviews, and focus group discussions. Trained peers will deliver the following intervention with remote clinician support and ongoing mentorship: pre-exposure prophylaxis (PrEP) access and refills in community/at hotspots; HIV testing, with option for HIV self-testing (HIVST); Rapid post-exposure prophylaxis (PEP) access for unplanned exposures; Family planning integration; Phone/text messaging hotline for peer support
48165680|NCT03042559|DEVICE|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
48165681|NCT01336387|DRUG|retinoid 9cUAB30|Given PO
48165682|NCT01336387|OTHER|placebo|Given PO
48694811|NCT06660329|DRUG|Janus Kinase Inhibitor|Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
48694812|NCT06145035|BIOLOGICAL|umbilical cord-derived mesenchymal stromal cells (UC-MSCs)|The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
48694813|NCT02791932|BEHAVIORAL|Exercise|See description above.
48694814|NCT05439993|DRUG|Tepotinib plus paclitaxel|Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
48694815|NCT06163950|OTHER|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
48694816|NCT02309645|BIOLOGICAL|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
48694817|NCT02309645|OTHER|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
48694818|NCT05984654|PROCEDURE|Platelet rich plasma therapy|"Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma."
48694819|NCT00542373|OTHER|Cytology Specimen Collection Procedure|Undergo oral tissue collection
48694820|NCT00542373|PROCEDURE|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
48165683|NCT01336387|OTHER|pharmacological study|Correlative studies
48694821|NCT00542373|PROCEDURE|Diagnostic Procedure|Undergo standard white light headlamp oral examination
48694822|NCT00542373|PROCEDURE|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
48694823|NCT00542373|PROCEDURE|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
48165684|NCT01336387|OTHER|laboratory biomarker analysis|Correlative studies
48165685|NCT01336387|OTHER|cancer prevention|Disease prevention
48522680|NCT04952181|DEVICE|ultrasonic biometry|ultrasonic biometry is contact method depends on ultrasonic transducer producing thin sound beam travelling through different media of the eye when it faces interface of substance dissimilar from that it is travelling through part is reflecting and the other travel through the different substance
48694824|NCT06652412|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
48694825|NCT06652412|OTHER|data prospectively collected|in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
48694826|NCT06652412|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
48694827|NCT06652412|DRUG|Sintilimab|200 mg q3w
48694828|NCT06652412|DRUG|Fluorouracil|5-Fluorouracil or capecitabine
48694829|NCT06652412|DRUG|Raltitrexed|Raltitrexed
48008654|NCT00854503|DRUG|Simvastatin|20 mg/day in one oral administration
48165686|NCT03045055|DEVICE|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
48165687|NCT03045055|PROCEDURE|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
48165688|NCT03045055|DEVICE|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
48369454|NCT04553497|DEVICE|Interferential current|"Interferential current or sham were applied to the patients before the each exercise session. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."
48694830|NCT06652412|DRUG|Oxaliplatin|Oxaliplatin
48694831|NCT06652412|DRUG|Irinotecan (CPT-11)|irinotecan
48694832|NCT05706155|BEHAVIORAL|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
48694833|NCT05706155|BEHAVIORAL|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
48694834|NCT06658093|DRUG|Rapamycin|mTOR inhibitor
48694835|NCT06658093|DRUG|Everolimus|mTOR inhibitor
48694836|NCT06658093|OTHER|Placebo|Inert placebo for rapamycin or everolimus
48008655|NCT00854503|DRUG|Rosuvastatin|20 mg/day in one oral administration.
48008656|NCT02412631|DRUG|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
48008657|NCT02412631|DRUG|Varenicline|Chantix is an FDA approved medication for smoking cessation
48008658|NCT02412631|DRUG|Placebo|Placebo for lorcaserin
48165689|NCT04017949|DRUG|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
48694837|NCT02616562|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once-weekly.
48694838|NCT02616562|DRUG|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
48694839|NCT06407869|OTHER|Functional Progressive Strength Training|The Functional Progressive Resistance Exercise (FPRE) protocol is designed to improve functional strength through structured workouts. It begins with a 3-minute warmup involving stretching and range of motion exercises, followed by progressively intense sit-to-stand exercises over six weeks. Participants also perform half-kneeling, standing up, and side-step-up exercises, with 20 minutes of total activity and rest intervals. The session ends with a 2-minute cooldown. Weights are gradually increased up to 15 times the initial load, with a minimum of one-minute rest between sets. The regimen is tailored through trial and error to find the maximum load participants can effectively manage.
48694840|NCT06407869|OTHER|Control|conventional physical therapy techniques will be applied
48008659|NCT05566340|PROCEDURE|mitral valve repair|Repair of mitral valve concomitant to aortic valve replacement.
48008660|NCT00839293|DRUG|ABT-335|Once, see arm description for more information
48008661|NCT00202618|DRUG|Valsartan|
48008662|NCT00202618|DRUG|Amlodipine|
48165690|NCT01880697|BIOLOGICAL|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
48165691|NCT02835937|OTHER|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
48165692|NCT04979156|PROCEDURE|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
48694841|NCT06659029|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
48694842|NCT03223753|OTHER|Educational Intervention|Receive educational handouts about to physical activity
48694843|NCT03223753|OTHER|Internet-Based Intervention|Access limited version of device app/website
48694844|NCT03223753|OTHER|Internet-Based Intervention|Access full version of interactive reward-based device app/website
48694845|NCT03223753|OTHER|Laboratory Biomarker Analysis|Correlative studies
48694846|NCT03223753|DEVICE|Medical Device Usage and Evaluation|Wear physical activity tracking device
48694847|NCT03223753|OTHER|Quality-of-Life Assessment|Ancillary studies
48165693|NCT06407947|DRUG|Chimeric antigen receptor modified T cells Infusion|chimeric antigen receptor T cells
48165694|NCT02538471|RADIATION|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
48165695|NCT02538471|DRUG|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
48694848|NCT03223753|OTHER|Questionnaire Administration|Ancillary studies
48694849|NCT06661330|OTHER|Behavioral Treatment|Participants followed a 6-month hypocaloric Mediterranean-style diet, reducing energy intake by approximately 600 kcal/day. The diet emphasized fruits, vegetables, whole grains, and fish, while limiting red meat and processed foods. Additionally, participants were required to perform moderate physical activity, including 50 minutes of aerobic exercise, 3 times a wee
48694850|NCT04516538|BEHAVIORAL|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
48694851|NCT04516538|DIAGNOSTIC_TEST|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
48694852|NCT04516538|DIAGNOSTIC_TEST|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
48694853|NCT04516538|DIAGNOSTIC_TEST|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
48008663|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
48008664|NCT00827411|DEVICE|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
48008665|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
48008666|NCT00827411|DRUG|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
48165696|NCT02640222|DRUG|VKA|
48165697|NCT02640222|DRUG|Apixaban|
48165698|NCT02640222|DRUG|dabigatran|
48165699|NCT02640222|DRUG|rivaroxaban|
48165700|NCT02245750|DEVICE|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
48165701|NCT00261625|DRUG|alendronate|
48008667|NCT00827411|DRUG|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
48008668|NCT01912248|OTHER|strength training|strength training, lower limb.
48008669|NCT01097837|OTHER|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
48694854|NCT04516538|DIAGNOSTIC_TEST|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
48694855|NCT04516538|DIAGNOSTIC_TEST|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
48694856|NCT03503097|PROCEDURE|Biospecimen Collection|Provide saliva samples
48694857|NCT03503097|OTHER|Genetic Counseling|Undergo counseling
48694858|NCT03503097|OTHER|Genetic Testing|Undergo genetic testing
48694859|NCT03503097|OTHER|Laboratory Biomarker Analysis|Correlative studies
48694860|NCT03503097|BEHAVIORAL|Questionnaire|Complete questionnaire
48694861|NCT00551148|DRUG|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
48694862|NCT00551148|DRUG|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
48694863|NCT00551148|DRUG|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
48694864|NCT00551148|DRUG|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
48694865|NCT00551148|OTHER|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
48694866|NCT06649929|BEHAVIORAL|Couples-based treatment- Patient|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
48694867|NCT06649929|BEHAVIORAL|Couples-based treatment- Partner|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
48694868|NCT06649929|OTHER|Information control- Patient|Information only plus treatment as usual
48694869|NCT06649929|OTHER|Information control- Partner|Information only plus treatment as usual
48694870|NCT05935358|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
48694871|NCT06658184|BEHAVIORAL|sleep restriction and stimulus control|"Sleep restriction: a) Reduce bedtime to match actual sleep time, but ≥4.5 hours, and adjust bedtime according to sleep efficiency; b) Avoid daytime naps and maintain a regular wake-up time.~Stimulus control: a) Reduce wakeful time in bed and rebuild a positive association between sleepiness and bed; b) Use the bed solely for sleeping and sexual activities; c) Only go to bed when feeling sleepy at night or at the designated sleep time; d) If unable to fall asleep within about 20 minutes of being in bed, leave the bedroom and engage in relaxation activities until feeling sleepy, then return to bed for sleep; if still unable to fall asleep within about 20 minutes, repeat the process; e) Wake up at the same time every morning, including weekends."
48694872|NCT06658184|BEHAVIORAL|sleep hygiene education|"Sleep hygiene education:~1. Sleep until feeling refreshed the next day.~2. Maintain regular exercise and eating habits, avoiding going to bed on an empty stomach.~3. Ensure a comfortable bedroom environment with suitable nighttime temperature, free from light and noise disturbances.~4. Avoid excessive consumption of beverages, alcohol, and smoking at night, and reduce caffeine intake.~5. Avoid bringing problems to bed and refrain from attempting to sleep.~6. Place the alarm clock under the bed or move it away from sight."
48694873|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
48694874|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
48694875|NCT04521231|DRUG|Blinatumomab|Blinatumomab will be administered as a subcutaneous (SC) injection.
48165702|NCT02618564|DRUG|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
48165703|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
48165704|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
48165705|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
48165706|NCT03185585|OTHER|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
48694876|NCT05761639|OTHER|conventional rehabilitation|The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.
48694877|NCT05761639|BEHAVIORAL|Education|1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition
48165707|NCT03185585|OTHER|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
48165708|NCT06440109|OTHER|Emotional freedom technique (EFT)|İntervention groups will be followed for six months and one of the six EFT therapies will be applied, one session every week.
48165709|NCT06440109|OTHER|Therapeutic touch (TD)|İntervention groups will be followed for six months and one of the six TD therapies will be applied, one session every week.
48165710|NCT00074178|BIOLOGICAL|filgrastim|
48165711|NCT00074178|BIOLOGICAL|pegfilgrastim|
48165712|NCT00074178|DRUG|cyclophosphamide|
48165713|NCT00074178|DRUG|cytarabine|
48165714|NCT00074178|DRUG|dexamethasone|
48694878|NCT05761639|OTHER|telerehabilitation|"The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform"
48694879|NCT05761639|BEHAVIORAL|follow-up|Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
48694880|NCT01900132|DEVICE|EIM testing|EIM device is placed on the muscle and a high frequency current is delivered to the skin.
48694881|NCT01900132|DEVICE|Nerve &amp; muscle ultrasonography|Ultrasound waves to examine the muscles and nerves
48694882|NCT01900132|DEVICE|Nerve conduction studies|Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
48694883|NCT01900132|DEVICE|Electromyography (EMG)|Thin needle placed into muscles to record electrical activity-adults only
48694884|NCT06659081|PROCEDURE|socket shield technique|partial extraction therapy : sectioning the root and keeping part of it in contact with labial plate of bone
48694885|NCT06659081|PROCEDURE|subepithelial connective tissue graft|A connective tissue graft harvesting from maxillary tuberosity area
48694886|NCT06659081|PROCEDURE|implant placement|implant placement
48694887|NCT03010774|BEHAVIORAL|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
48694888|NCT03010774|BEHAVIORAL|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
48694889|NCT03631771|DRUG|Iohexol|Iohexol administered intravascularly
48694890|NCT03631771|DRUG|Iodixanol|Iodixanol administered intravascularly
48694891|NCT03631771|DRUG|Iopromide|Iopromide administered intravascularly
48694892|NCT03631771|DRUG|Ioversol|Ioversol administered intravascularly
48694893|NCT03905148|DRUG|Lifirafenib|RAF Dimer Inhibitor
48694894|NCT03905148|DRUG|mirdametinib|MEK Inhibitor
48694895|NCT05081219|DRUG|Insulin (Humulin® R U-100)|Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.
48694896|NCT05081219|DRUG|Empagliflozin 10 MG|Participants will be assigned to receive Empagliflozin 10 mg capsules to be taken by mouth once daily.
48694897|NCT05081219|DEVICE|Aptar Pharma CPS Intranasal Delivery Device|Participants will be assigned to receive Humulin® insulin or placebo administered through the Aptar Pharma CPS intranasal delivery device.
48165715|NCT00074178|DRUG|etoposide phosphate|
48165716|NCT00074178|DRUG|methotrexate|
48165717|NCT01002911|DRUG|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
48165718|NCT01002911|DRUG|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
48165719|NCT00644332|DRUG|Ranolazine|Oral dosage form.
48165720|NCT00333502|DRUG|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
48008670|NCT05053672|DEVICE|ReOxy|"ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session.~The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min.~During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control)."
48369455|NCT04553497|OTHER|Rehabilitation program|The orthopedic rehabilitation programme was applied to all patients three times a week for 4 weeks under the guidance of the same physiotherapist. The first phase (0-3 weeks) involved the elbow, wrist, and hand active range of motion (ROM) and pendulum (clockwise and counterclockwise) exercises in the 0-2 weeks of the non-displaced fracture. For displaced fractures, elbow, wrist, and hand active range of motion was started immediately, but pendulum exercises were initiated two weeks later. The patients were instructed to continue exercises 3-5 times per day for 30 minutes. After two weeks, active assistive ROM and isometric exercises were performed supine position. During the second phase (3-6 weeks), active forward elevation in supine was carried out and then progressed to sitting and standing position. At the end of the sixth week, a home exercise program was given by the physiotherapist, including resistance exercises using an elastic band (Thera-Band).
48008671|NCT05053672|DEVICE|Sham ReOxy|Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.
48369456|NCT01813682|OTHER|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
48514190|NCT05884944|PROCEDURE|Experimental: Interventional Group- OMM- Muscle energy|The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
48514191|NCT05141617|PROCEDURE|Endoscopic treatment|Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices
48165721|NCT04572997|DRUG|Apremilast|Apremilast was taken orally twice daily (except Day 1). Patients received tablets in blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects (primarily mild-to-moderate nausea and diarrhoea), dose titration was implemented in this study in accordance with the Summary of Product Characteristics (SmPC). A titration pack included tablets of 10, 20 and 30 mg for a period of one month. During the first 5 days, the dosage was up-titrated. The initial dose on day 1 was 10 mg in the morning; this was increased to 10 mg in the morning and evening on day 2. The evening dose was further increased by 10 mg (to 20 mg) on day 3. On day 4, the morning dose was increased to 20 mg, so that 20 mg was taken twice daily, and on day 5 the evening dose was increased to 30 mg. From Day 6 onwards, patients received the 30 mg dose twice a day. Subsequent packs included only tablets of 30 mg strength.
48165722|NCT03749148|DRUG|Dupilumab|anti-IL4-Receptor alpha
48369457|NCT01813682|OTHER|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
48369458|NCT00310440|DEVICE|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
48369459|NCT00310440|OTHER|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
48369460|NCT03342807|DRUG|Insulin|Insulin infusion for subjects in Group Insulin.
48514192|NCT05141617|PROCEDURE|TIPS|Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
48694898|NCT05081219|DRUG|Placebo (Insulin Diluent)|Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
48694899|NCT05081219|DRUG|Placebo (Capsules)|Participants will be assigned to receive placebo capsules (Empagliflozin 10 mg) to be taken by mouth once daily.
48694900|NCT06477965|PROCEDURE|Artery Embolization|Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
48694901|NCT06658782|DIAGNOSTIC_TEST|non contrast enhanced MRI|6 monthly non contrast enhance MRI
48694902|NCT02626429|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
48694903|NCT06249048|BIOLOGICAL|STX-001|STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.
48694904|NCT06249048|BIOLOGICAL|Keytruda®|Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
48008672|NCT03613207|OTHER|Dermal pharmacokinetic measurement|"* Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~* Each test site receives 2 dOFM probes~* Dosing:~  * 2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~ * 1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~ * 2 test sites: untreated test site~* ISF sampling: 24 hours post-dose~* Blood sampling: 7 samples post-dose"
48165723|NCT03749148|DRUG|Placebo|Placebo
48514193|NCT04814771|DRUG|[14C] TS-142|Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
48514194|NCT00002397|DRUG|Nelfinavir mesylate|
48694905|NCT06536517|DRUG|Methadone|Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
48694906|NCT03754127|DEVICE|tDCS|Transcranial direct current stimulation
48694907|NCT03754127|DEVICE|sham tDCS|Sham transcranial direct current stimulation
48694908|NCT04324541|DIAGNOSTIC_TEST|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
48694909|NCT04644770|DRUG|JNJ-69086420|Participants will receive IV injection of JNJ-69086420.
48694910|NCT04190407|BEHAVIORAL|Intravenous access|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
48694911|NCT03722420|DRUG|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
48694912|NCT03722420|DRUG|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
48694913|NCT03493451|DRUG|Tislelizumab|Administered intravenously
48694914|NCT06232980|PROCEDURE|urological surgical intervention|Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
48008673|NCT03613207|DRUG|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
48165724|NCT03198936|DIETARY_SUPPLEMENT|Cognizin® SynapsaTM|2 capsules to be taken twice a day with meals with a glassful of water
48165725|NCT03198936|DIETARY_SUPPLEMENT|Placebo|2 capsules to be taken twice a day with meals with glassful of water
48369461|NCT03342807|DEVICE|Aphesis|Aphesis for subjects in Group Aphesis.
48514195|NCT00002397|DRUG|Saquinavir|
48514196|NCT00002397|DRUG|Lamivudine|
48514197|NCT00002397|DRUG|Stavudine|
48514198|NCT05098847|DRUG|Sintilimab|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
48694915|NCT05614258|DRUG|ADG206|All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
48694916|NCT06271265|DRUG|EXPAREL|A single dose of EXPAREL Injectable Product via LIA
48694917|NCT06271265|DRUG|bupivacaine|A single dose of 0.25% bupivacaine via LIA
48694918|NCT06030466|OTHER|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
48694919|NCT06030466|OTHER|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
48165726|NCT04630470|BEHAVIORAL|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
48165727|NCT04630470|BEHAVIORAL|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
48165728|NCT00349648|PROCEDURE|acromioplasty|
48165729|NCT00439361|DRUG|Bortezomib|1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4
48165730|NCT00439361|DRUG|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
48694920|NCT05095727|DRUG|mRNA-3745|Sterile frozen liquid dispersion for injection
48694921|NCT06660017|DRUG|Placebo|Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
48008674|NCT03613207|DRUG|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
48008675|NCT03613207|DEVICE|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
48008676|NCT03613207|PROCEDURE|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
48008677|NCT03584672|OTHER|Static Balance Test|Balance control is assessed by the Static Balance Test.
48008678|NCT03584672|OTHER|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
48008679|NCT03584672|OTHER|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
48165731|NCT00439361|DRUG|Etoposide|100 mg/m\^2 By Vein Over 2 Hours On Days 1-3
48165732|NCT00439361|DRUG|Ifosfamide|5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1
48165733|NCT00439361|DRUG|Mesna|5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
48008680|NCT03584672|OTHER|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
48165734|NCT06642363|DRUG|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"
48165735|NCT06642363|DRUG|Placebo|The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
48165736|NCT04530877|BIOLOGICAL|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
48165737|NCT04530877|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).
48369462|NCT02604134|PROCEDURE|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
48694922|NCT06660017|DRUG|Ketamine Topical|Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
48165738|NCT05770908|OTHER|Therapeutic exercise program|"Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~* Scaption with elastic band.~* External rotation at 0º of abduction with elastic band.~* Internal rotation at 0º of abduction with elastic band.~* Shoulder protraction in supine position with weights.~* Low row with elastic band.~* Horizontal adduction stretching."
48008681|NCT03584672|OTHER|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
48165739|NCT05770908|OTHER|Multimedia animation information|Multimedia animation videos (including audio) showing the performance of the prescribed exercises.
48369463|NCT02604134|DRUG|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
48369464|NCT02604134|DRUG|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
48369465|NCT00759993|DRUG|chromium piccolinate|1000mg tab
48369466|NCT00759993|DRUG|placebo for chromium piccolinate|
48694923|NCT06018311|BEHAVIORAL|Exercising together|The Exercising Together program is a partnered functional strength training program that encourages participating dyads to interact with one another, verbally and physically, during exercise sessions. In Exercising Together, the survivor and their caregiver will build skills to work as a team. We will incorporate skills that promote and reinforce communication, motivation, and support and use this to guide training of survivor-caregiver dyads to maximize their teamwork during each exercise session. Group sessions are delivered remotely through videoconferencing software and are supervised by two trained exercise instructors. Intervention and assessment is available in English or Spanish.
48694924|NCT06658197|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy
48694925|NCT06658197|DRUG|Alteplase|Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
48008682|NCT03584672|OTHER|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
48008683|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 2-week intervals
48008684|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 twice at 4-week intervals
48165740|NCT05770908|OTHER|Paper-based information|Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
48165741|NCT02782598|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
48369467|NCT00598585|DRUG|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
48008685|NCT04527081|BIOLOGICAL|AG0302-COVID19|2.0 mg of AG0302-COVID19 three times at 2-week intervals
48008686|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
48008687|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
48165742|NCT02440737|OTHER|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
48165743|NCT02440737|OTHER|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
48369468|NCT00598585|DRUG|Placebo|Placebo pills 3X/day for 6 weeks
48008688|NCT02223767|DEVICE|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and intertrial interval (ITI) of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
48008689|NCT02223767|DEVICE|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
48008690|NCT01015248|DRUG|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
48008691|NCT05593796|BEHAVIORAL|cognitive behavioral therapy|12 weekly, individual sessions of manual-guided CBT delivered by trained clinician .
48165744|NCT02440737|PROCEDURE|Psychosocial Assessment and Care|Undergo the NEST intervention
48165745|NCT02440737|OTHER|Questionnaire Administration|Ancillary studies
48165746|NCT05915013|DRUG|Ketamine|Intravenous ketamine
48369469|NCT05561192|OTHER|Diaphragmatic breathing exercises|The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.
48694926|NCT03303170|DEVICE|Sebacia Microparticles|Topical microparticle suspension
48694927|NCT03303170|DEVICE|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
48694928|NCT00257582|DRUG|Cetirizine Dry Syrup|
48694929|NCT03419897|DRUG|Tislelizumab|Administered intravenously
48694930|NCT05451706|BEHAVIORAL|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
48694931|NCT04046016|DRUG|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
48008692|NCT04528758|DRUG|Rhodamine 6G|Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
48008693|NCT05565911|OTHER|no intervention|this is an observational study, there is no intervention.
48694932|NCT04085653|DRUG|alpelisib|"Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
48694933|NCT05904236|DRUG|Treatment with ICVB-1042 administered intravenously|Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels
48008694|NCT05054530|DRUG|GMA106 Injection|GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
48694934|NCT04254692|DRUG|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
48694935|NCT04254692|OTHER|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
48694936|NCT03734016|DRUG|Zanubrutinib|160 mg orally twice daily
48008695|NCT05054530|DRUG|GMA106 Matching Placebo|Matching Placebo for GMA106
48008696|NCT05650372|OTHER|High intensity resistive exercise|Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.
48008697|NCT05650372|OTHER|Low intensity resistive exercise|"participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl."
48008698|NCT01740583|DEVICE|percutaneous annuloplasty|plication of the mitral valve annulus
48008699|NCT00170079|BEHAVIORAL|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
48165747|NCT05915013|DRUG|Perampanel|Oral perampanel (6 mg)
48165748|NCT05915013|DRUG|Placebo|Oral placebo
48165749|NCT00740298|OTHER|sucrose|sweet taste
48514199|NCT05098847|DRUG|Lenvatinib|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48694937|NCT03734016|DRUG|Ibrutinib|Ibrutinib 420 mg orally once daily
48694938|NCT02402244|OTHER|Cytology Specimen Collection Procedure|Undergo cytology specimen collection
48694939|NCT02402244|OTHER|Medical Chart Review|Undergo medical data review
48694940|NCT01905046|DRUG|metformin hydrochloride|given PO
48694941|NCT01905046|OTHER|placebo|given PO
48694942|NCT05836324|DRUG|INCA33890|INCA33890 will be administered at protocol defined dose.
48694943|NCT04060069|OTHER|Ringer Lactate|Fluids
48165750|NCT00740298|OTHER|warmth|warmth
48694944|NCT06655909|OTHER|consumption of maize porridge containing stable iron isotope|consumption of maize porridge containing stable iron isotope
48694945|NCT04684368|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
48694946|NCT04684368|DRUG|Carboplatin|Given IV
48694947|NCT04684368|DRUG|Etoposide|Given IV
48694948|NCT04684368|BIOLOGICAL|Filgrastim|Given subcutaneously (SC) or IV
48694949|NCT04684368|DRUG|Ifosfamide|Given IV
48694950|NCT04684368|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48694951|NCT04684368|DRUG|Mesna|Given IV or orally
48694952|NCT04684368|BIOLOGICAL|Pegfilgrastim|Given SC
48694953|NCT04684368|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
48694954|NCT04684368|OTHER|Questionnaire Administration|Ancillary studies
48694955|NCT04684368|RADIATION|Radiation Therapy|Undergo WVSCI radiation therapy
48694956|NCT04684368|RADIATION|Radiation Therapy|Undergo radiation therapy
48694957|NCT04684368|PROCEDURE|Second-Look Surgery|Undergo second-look surgery if needed
48008700|NCT02034526|DEVICE|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
48008701|NCT02034526|DEVICE|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
48165751|NCT02945007|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
48165752|NCT03336073|DRUG|Carfilzomib|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
48369470|NCT05561192|OTHER|Cardiorespiratory and strength exercise|"During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity."
48369471|NCT05561192|OTHER|Cooperative sports activities group|"Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills."
48694958|NCT04684368|DRUG|Thiotepa|Given IV
48694959|NCT05113121|DIAGNOSTIC_TEST|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)
48694960|NCT03869385|DRUG|Albutein® 200 g/L or Plasbumin® 20|The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
48694961|NCT06465810|DRUG|Treatment of transthyretin (ATTR) amyloidosis in observational study setting|Data will be collected on patients with ATTR amyloidosis in a real-world setting
48694962|NCT06121609|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
48694963|NCT06071663|PROCEDURE|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
48008702|NCT03637400|DRUG|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
48008703|NCT03637400|DRUG|DOXY|DOXY will be administered over a period of 7 days.
48008704|NCT01020019|DRUG|Dronabinol|Dronabinol: 20 mg/TID
48008705|NCT01020019|DRUG|Placebo|Placebo control
48008706|NCT01020019|DRUG|Lofexidine|Lofex: .6 mg/ TID
48008707|NCT05322187|DRUG|PD-1 inhibitor|Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
48694964|NCT00037518|DRUG|AMG 073|
48694965|NCT04361136|DRUG|Delgocitinib cream|Cream for topical application
48165753|NCT03336073|DRUG|Dexamethasone|dexamethasone oral at a dose of 20 mg (10 mg for patients \>75 years) days 1, 2, 8, 9, 15 and 16
48165754|NCT03336073|DRUG|cyclophosphamide|cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
48694966|NCT04361136|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
48694967|NCT05687032|DRUG|inotuzumab ozogamicin|Given IV
48694968|NCT00324805|BIOLOGICAL|Bevacizumab|Given IV
48694969|NCT00324805|DRUG|Cisplatin|Given IV
48694970|NCT00324805|DRUG|Docetaxel|Given IV
48694971|NCT00324805|DRUG|Gemcitabine Hydrochloride|Given IV
48694972|NCT00324805|OTHER|Laboratory Biomarker Analysis|Correlative studies
48694973|NCT00324805|DRUG|Pemetrexed Disodium|Given IV
48694974|NCT00324805|OTHER|Questionnaire Administration|Ancillary studies
48694975|NCT00324805|DRUG|Vinorelbine Tartrate|Given IV
48694976|NCT03981757|DEVICE|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
48694977|NCT05172245|PROCEDURE|Biopsy|Undergo tumor biopsy
48694978|NCT05172245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48694979|NCT05172245|DRUG|Cisplatin|Given IV
48694980|NCT05172245|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48694981|NCT05172245|DRUG|Ipatasertib|Given PO
48008708|NCT01434823|OTHER|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
48165755|NCT01032356|DEVICE|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
48165756|NCT02749175|DEVICE|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
48165757|NCT02749175|DEVICE|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
48165758|NCT00788047|DRUG|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
48165759|NCT00788047|DRUG|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
48369472|NCT05561192|OTHER|Traditional physical education class|The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
48369473|NCT04536142|DIAGNOSTIC_TEST|MRI|A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.
48694982|NCT05172245|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48694983|NCT05172245|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48694984|NCT05172245|RADIATION|Radiation Therapy|Undergo radiation therapy
48694985|NCT05844098|DEVICE|K-wire|K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
48694986|NCT04751604|DIETARY_SUPPLEMENT|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
48008709|NCT00019474|BIOLOGICAL|filgrastim|
48008710|NCT00019474|BIOLOGICAL|recombinant interferon alfa|
48694987|NCT04751604|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
48694988|NCT04250155|DRUG|XmAb24306|Participants will receive intravenous (IV) XmAb24306.
48694989|NCT04250155|DRUG|Atezolizumab|Participants will receive IV XmAb24306 followed by IV atezolizumab
48694990|NCT04250155|DRUG|XmAb24306|Participants will receive IV XmAb24306 followed by IV atezolizumab.
48008711|NCT00019474|DRUG|fluorouracil|
48008712|NCT00019474|DRUG|hydroxyurea|
48008713|NCT01831310|DIETARY_SUPPLEMENT|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
48008714|NCT01831310|DIETARY_SUPPLEMENT|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
48008715|NCT01831310|DIETARY_SUPPLEMENT|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
48165760|NCT02654457|PROCEDURE|Women with Breast Cancer|IVD Study
48165761|NCT02178397|DRUG|ERLOTINIB WITH CHEMOTHERAPY|
48165762|NCT02178397|DRUG|CHEMOTHERAPY ONLY|
48165763|NCT04003961|OTHER|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
48165764|NCT04741854|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
48165765|NCT06477757|PROCEDURE|Minimally Invasive Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.
48165766|NCT06477757|PROCEDURE|Conventional Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.
48694991|NCT03228459|DIAGNOSTIC_TEST|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
48165767|NCT00702546|DRUG|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
48165768|NCT00702546|BIOLOGICAL|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
48008716|NCT01831310|DIETARY_SUPPLEMENT|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
48008717|NCT00325234|DRUG|Pemetrexed|600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
48165769|NCT00702546|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
48165770|NCT00702546|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
48165771|NCT00702546|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
48165772|NCT00702546|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
48165773|NCT00702546|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
48165774|NCT00702546|BIOLOGICAL|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
48165775|NCT05739799|PROCEDURE|IPL|Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
48165776|NCT05739799|PROCEDURE|Diode|patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
48165777|NCT05436600|OTHER|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
48165778|NCT04897685|BEHAVIORAL|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
48165779|NCT01115283|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
48369474|NCT04536142|DIAGNOSTIC_TEST|neuropsychological tests and qualitative assessment|"Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe"
48008718|NCT00325234|DRUG|Carboplatin|AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
48008719|NCT00325234|DRUG|Gemcitabine|1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
48165780|NCT01115283|BEHAVIORAL|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
48008720|NCT00325234|DRUG|Vinorelbine|30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
48008721|NCT05936255|BEHAVIORAL|Give to Others Module|Negative interpersonal beliefs are targeted via cognitive-behavioral strategies, including evaluation of cognitive distortions, and activity planning and tracking.
48008722|NCT00003724|PROCEDURE|surgical procedure|
48165781|NCT01115283|BEHAVIORAL|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
48165782|NCT03226353|DEVICE|somofilcon A|contact lens
48165783|NCT03226353|DEVICE|omafilcon A|contact lens
48369475|NCT03063515|DRUG|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
48514200|NCT05098847|DRUG|Cryoablation|Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
48165784|NCT04984278|DRUG|Nabiximols|oromucosal spray
48165785|NCT04984278|DRUG|Placebo|oromucosal spray
48369476|NCT04997512|DEVICE|Freestyle libre|A glucose sensor (flash) which measures interstitial blood glucose every 15 minutes or on demand.
48514201|NCT01680003|DRUG|Hepar-P|
48514202|NCT01680003|DRUG|Placebo for Hepar-P|
48514203|NCT02965040|DRUG|Roxadustat|Oral
48694992|NCT03228459|DIAGNOSTIC_TEST|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
48694993|NCT03228459|DIAGNOSTIC_TEST|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
48694994|NCT03228459|DIAGNOSTIC_TEST|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
48694995|NCT03228459|DIAGNOSTIC_TEST|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
48694996|NCT03228459|DIAGNOSTIC_TEST|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
48694997|NCT03228459|DIAGNOSTIC_TEST|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
48694998|NCT03228459|OTHER|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
48694999|NCT03228459|OTHER|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
48695000|NCT03228459|DIAGNOSTIC_TEST|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
48695001|NCT04452331|OTHER|Open Access Audio|Patient obtains secure access to an audio recording of the medical encounter post-visit that is accessible from any internet enabled device.
48695002|NCT04452331|OTHER|No Access, Patient and Provider Aware of Recording|Patient does not obtain access to audio recording but both patient and provider are aware visit is being recorded.
48695003|NCT04452331|OTHER|No Access, Provider Unaware of Recording|Patient does not obtain access to audio recording and provider is unaware visit is being recorded.
48695004|NCT03609216|DRUG|Gemcitabine Hydrochloride|Given IV
48008723|NCT03436368|PROCEDURE|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
48008724|NCT03436368|PROCEDURE|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
48695005|NCT03609216|DRUG|Cisplatin|Given IV
48695006|NCT03609216|BIOLOGICAL|Pegfilgrastim|Given SC
48008725|NCT05567640|BEHAVIORAL|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|This is a cognitive behavioral treatment (CBT) for emotional disorders. This transdiagnostic intervention consists of eight modules and can be effectively applied to various disorders and problems.
48695007|NCT03609216|PROCEDURE|Conventional Surgery|Undergo bladder sparing
48695008|NCT03609216|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
48695009|NCT03609216|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
48369477|NCT04997512|OTHER|Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification|An education programme surrounding avoidance of hypoglycaemia at baseline. Regular review (weeks 2, 4, 12 and 24) and adjustment of diabetes medications based on freestyle libre data.
48514204|NCT00060983|PROCEDURE|Body weight supported locomotor training|
48514205|NCT00060983|PROCEDURE|Functional electrical stimulation|
48695010|NCT06062667|OTHER|accompany the birth|Fathers will accompany their husbands during the birth process
48695011|NCT06662214|OTHER|Refined maize flour|Meal made form refined maize flour
48695012|NCT06662214|OTHER|Whole grain flour|Meal made form whole grain maize flour
48695013|NCT01530178|DRUG|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
48695014|NCT01530178|DRUG|Placebo Oral Tablet|
48695015|NCT06619392|DRUG|HRS-2129|HRS-2129
48695016|NCT06619392|DRUG|HRS-2129 Placebo|HRS-2129 Placebo
48695017|NCT05646784|DRUG|Cerebiome|Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo
48695018|NCT05646784|DRUG|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
48695019|NCT01267110|OTHER|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
48695020|NCT01267110|OTHER|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
48695021|NCT04711369|DEVICE|Erbium:Yag laser|"Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed."
48165786|NCT03574493|PROCEDURE|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
48695022|NCT04711369|DEVICE|Sham Erbium:Yag laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
48695023|NCT00161837|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
48695024|NCT00161837|BIOLOGICAL|Egg-derived Influenza Vaccine|
48695025|NCT00695916|PROCEDURE|Breast MRI|
48695026|NCT06623994|BEHAVIORAL|Task sharing with Epilepsy Medical Record Systems|Training multiple cadres of healthcare workers in epilepsy treatment and management to enable a team-based approach to address access to care. Task sharing will be supported by epilepsy medical records system with patient tracking data to support care retention
48695027|NCT00422630|BEHAVIORAL|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
48695028|NCT00422630|BEHAVIORAL|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
48695029|NCT00422630|BEHAVIORAL|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
48695030|NCT04379570|OTHER|Educational Intervention|Receive online educational information about ET medication
48695031|NCT04379570|OTHER|Text Message-based Navigation Intervention|Receive text messages
48695032|NCT04379570|BEHAVIORAL|Motivational Interviewing|Receive motivational interviewing counseling sessions
48695033|NCT04379570|OTHER|Best Practice|Attend usual care clinic visits
48165787|NCT01381458|DRUG|FSC|fluticasone propionate / salmeterol xinofoate combination
48695034|NCT04379570|OTHER|Questionnaire Administration|Ancillary studies
48165788|NCT01381458|DRUG|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
48165789|NCT03036150|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
48165790|NCT03036150|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
48165791|NCT04717713|DRUG|steroid injection|steroid injection at surgical location
48165792|NCT04717713|DRUG|placebo|saline injection at surgical location
48165793|NCT03211897|DRUG|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
48165794|NCT03211897|DRUG|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
48165795|NCT03211897|DRUG|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
48165796|NCT03211897|DRUG|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
48165797|NCT03122483|DIAGNOSTIC_TEST|blood biomarker|
48369478|NCT04617379|BEHAVIORAL|Stretching|One-year stretching program for 15 minutes every day
48695035|NCT04379570|OTHER|Quality-of-Life Assessment|Ancillary studies
48369479|NCT01256424|DRUG|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
48369480|NCT01256424|DRUG|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
48369481|NCT01256424|DRUG|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
48695036|NCT05898581|PROCEDURE|PENG Block|Participants will receive a PENG block with local anesthetics (which is a freezing medication, in this case, 0.5% ropivacaine) before receiving spinal anesthesia.
48369482|NCT01256424|DRUG|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
48369483|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
48369484|NCT01475539|BIOLOGICAL|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
48369485|NCT01475539|BIOLOGICAL|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
48369486|NCT03854669|DEVICE|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
48369487|NCT03301168|BIOLOGICAL|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
48008726|NCT05567640|BEHAVIORAL|Space for depression|Digital CBT program designed to minimize the impact of depression symptoms. Emphasizes CBT strategies and mindfulness through a series of seven structured modules.
48369488|NCT03301168|DRUG|Rimiducid|administered to inactivate BPX-501 cells in the event of GVHD
48369489|NCT01432470|DRUG|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
48369490|NCT01432470|DRUG|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
48369491|NCT01659437|DRUG|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
48369492|NCT01659437|DRUG|Streptomycin intramuscular injection|daily intramuscular drug injection
48369493|NCT02311660|DEVICE|Vagus Nerve Stimulation Device|Cyberonics VNS System
48369494|NCT05994690|DRUG|Standard Intervention Rc|3 consolidation courses (HAM + HA3E + FLA)
48695037|NCT05898581|PROCEDURE|Control Group|Participants will receive a sham PENG block performed with 20ml of normal saline solution before spinal anesthesia. After, patients will receive ILAI (performed by the operating surgeon) with a plain solution of ropivacaine 0.25% 60ml.
48008727|NCT05567640|BEHAVIORAL|Space for resilience|This program is built from positive psychology principles and is designed to promote resilience and well-being through seven modules.
48008728|NCT01395472|BEHAVIORAL|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
48008729|NCT01395472|BEHAVIORAL|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
48008730|NCT05689385|OTHER|eHealth-based cardiac rehabilitation|"The 12-wk case manager-led eHCR program includes:~1. Individualized exercise prescription according to the results of cardiopulmonary exercise test.~2. At least one session of in-person physical therapy to familiarize participants with the process of exercise training before the initiation of telerehabilitation.~3. Telerehabilitation: a 30-minute moderate aerobic exercise training with remote monitoring and instruction using video conferencing. (Frequency: twice per week in the first 4 weeks, once per week in the 5th-8th week, once every 2 weeks in the 9th-12th week)~4. Additional self-exercise to achieve the target volume of 150-minute moderate aerobic exercise and 2 sessions of resistance training per week.~5. Patient education for secondary prevention delivered regularly via a communication app on the smartphone.~6. Weekly follow-up call from a case manager via phone call or communication app."
48008731|NCT01800903|DEVICE|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
48008732|NCT01800903|DEVICE|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
48008733|NCT01800903|DEVICE|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
48008734|NCT04921358|DRUG|Tislelizumab|administered intravenously
48008735|NCT04921358|DRUG|Docetaxel|administered intravenously
48008736|NCT04921358|DRUG|Sitravatinib|administered orally
48008737|NCT04992559|DRUG|Consolidation Toripalimab|Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
48008738|NCT04865939|PROCEDURE|sterile water irrigation|Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
48008739|NCT04865939|DRUG|Gemcitabine|Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
48008740|NCT01826175|DRUG|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
48008741|NCT01826175|DRUG|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
48008742|NCT01826175|DEVICE|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
48008743|NCT05653960|OTHER|EMR or ESD|Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms
48008744|NCT02153944|DRUG|Propranolol|Propranolol 40 mg was given orally during study visit
48008745|NCT02153944|DRUG|Methylphenidate|Methylphenidate 20mg was given orally during study visit
48008746|NCT02153944|DRUG|Placebo|Placebo was given orally during study visit
48008747|NCT03291912|PROCEDURE|Chuna Manual Therapy|"* Unique manual therapy in traditional Korean medicine~* Mandatory techniques for neck part and selective techniques for other part (if necessary)~* Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
48369495|NCT05994690|DRUG|Investigational Intervention Rc|2 consolidation courses (HAM + FLA)
48514206|NCT03683290|OTHER|Image acquisition and analysis|Oocyte image obtention and analysis prior to intracytoplasmic sperm injection
48008748|NCT03291912|PROCEDURE|Usual care|"1. Physical therapy based on traditional Korean medicine theory~   * Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~  * Heat stimulation: either Hot pack or Infrared lamp~2. Patient education~   * Physical and pathological explanation of cervicogenic dizziness~  * Cause and risk factors of cervicogenic dizziness~  * Functions of muscles related to cervicogenic dizziness~  * Home exercising to self-manage cervicogenic dizziness"
48008749|NCT05463003|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity
48008750|NCT00003739|BIOLOGICAL|filgrastim|
48008751|NCT00287768|DRUG|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
48008752|NCT00287768|DRUG|S-1|S-1 po days 1-28 every 6 weeks
48008753|NCT03159728|BEHAVIORAL|Educative intervention:|"* In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~* In Module I: to strengthen the knowledge of the situation and the people involved in care.~* In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~* In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
48008754|NCT04233281|OTHER|Kori tofu|16.5 gram Kori-tofu mixed in a high carbohydrate test meal
48008755|NCT04233281|OTHER|Whey protein|high carbohydrate test meal with whey protein, matched in macronutrient content
48008756|NCT01430585|DRUG|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
48008757|NCT01430585|DRUG|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
48514207|NCT06069115|RADIATION|Radiation therapy protocol for Breast cancer|Conformal 3D radiation therapy will be performed 4-12 weeks after surgical treatment of breast cancer on Electa Axesse linear gas pedal with 6 MeV energy in traditional fractionation mode. Different RT schemes will be used depending on the stage of the disease, type of surgical treatment, and morphological variant of the tumor. In organ-preserving surgeries the remaining breast will be irradiated with a single focal dose (FD) of 2 Gy, up to the total focal dose (TFD) of 50 Gy. In the presence of risk factors, irradiation of lymphatic outflow pathways will be performed: axillary, sub/adclavicular and parasternal lymph nodes areas (FD 2 Gy, up to TFD 44-46 Gy). In radical breast resection we'll use irradiation of the anterior chest wall in 2 Gy FD, up to 50 Gy FD, irradiation of lymphatic outflow pathways: axillary, sub/adclavicular and parasternal lymph nodes (2 Gy FD, up to 44-46 Gy FD).
48514208|NCT06069115|DIAGNOSTIC_TEST|Spirography and assessment of pulmonary diffusion capacity|Using the Master Screen Body device you will be asked to take two series of breaths through a special tube for 2-3 minutes. Usually the procedure does not cause any discomfort
48514209|NCT06069115|DIAGNOSTIC_TEST|Cardiopulmonary stress test|The exercise test is performed on a bicycle ergometer Oxycon Pro. Prior to the test, special sensors for recording the electrocardiogram, a sensor to determine blood saturation, and a cuff to measure blood pressure will be glued on the body. Breathing during the test takes place through a face mask with a built-in gas analyzer sensor. The stress test is conducted up to an individual maximum (according to the age, sex, height and weight of the patient), followed by a recovery period. There is some temporary discomfort associated with performing physical activity. Dyspnea, leg fatigue, and dizziness may occur. Observation continues until full recovery of hemodynamic and gas exchange parameters, in case of appearance of unfavorable symptoms - until their disappearance.
48514210|NCT06069115|DIAGNOSTIC_TEST|Computed tomography of the chest organs|"CT is a method of examination based on X-rays, but unlike conventional X-rays, it gives the most complete picture of the body structure, with less radiation.~Tomography usually does not cause any unpleasant feelings and is performed in a specialized department."
48514211|NCT06069115|DIAGNOSTIC_TEST|SF-36 Quality of Life Questionnaire|Standard questionnaire for assessment quality of patient's life https://clinmedjournals.org/articles/jmdt/jmdt-2-023-figure-1.pdf
48514212|NCT06069115|DIAGNOSTIC_TEST|Demographic and anthropometric measures|Age, sex, height. weight, body mass index (BMI)
48514213|NCT06069115|OTHER|Indicators characterizing the severity of the underlying disease|Severity of underlying disease (mMRC, BODE, SMRT-CO Respiratory Support Need Scale), and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease) Medications taken.
48514214|NCT01689727|DRUG|Technetium Tc 99m EC20|
48514215|NCT01335035|DRUG|deferasirox|
48514216|NCT04348201|OTHER|foot reflexology|foot reflexology session which takes about 20 minutes. The position of the patient during reflexology session was a relaxed comfortable supine lying position. The therapist was sitting position at the level of the feet. The Session of reflexology was done on three points at both feet.
48369496|NCT05994690|DRUG|Standard Intervention Ri|No addition of GO to first induction course
48369497|NCT05994690|DRUG|Investigational Intervention Ri|Addition of GO to first induction course
48514217|NCT04348201|DIETARY_SUPPLEMENT|dietary modification|diet must be rich in vitamins as fish and beans, calcium as milk and chess, low fat food through decrease oil in meals, high fiber food through all types of vegetables and fruits and restrict caffeine
48514218|NCT03281759|DEVICE|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
48514219|NCT03281759|DEVICE|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
48514220|NCT05567276|BEHAVIORAL|Non-Violent Resistance parental training|Non-Violent Resistance parental training
48008758|NCT01430585|DRUG|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
48008759|NCT04259190|BEHAVIORAL|interoceptive exposure|Repeated 60-second trials of voluntary hyperventilation, each followed by a 15-second rest period. Participants will complete a minimum of 8 trials and continue additional trials until ratings of their most feared predicted outcome fall less than or below 5% likelihood.
48008760|NCT00237588|DRUG|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
48008761|NCT06158802|OTHER|Questionnaire|"Questionnaire on human papillomavirus vaccine status of girls and young women and modalities of the vaccination or reason of the non-vaccination.~The questionnaire is completed by the patient."
48008762|NCT01993108|DRUG|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
48008763|NCT01993108|DRUG|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
48008764|NCT01993108|DRUG|Placebo|One dose of placebo one hour before fMRI scanning.
48008765|NCT03359733|DRUG|TAK-659|TAK-659 tablet.
48008766|NCT05055674|BEHAVIORAL|Motherly app|The Motherly app is organized in four different modules: 1) Library: a collection of brief texts on several topics related to health and pregnancy, 2) Health: journeys with varying degrees of interactivity designed to teach and engage participants in well-established psychological techniques (behavioral activation, cognitive restructuring, emotion regulation, stress management techniques, mindfulness and meditation, sleep hygiene techniques), 3) Pregnancy and motherhood: a module to help mothers keep track of their health care visits, medical exams, and their childrens' development, and 4) Profile: a module allowing participants to keep track of activities and goals completed in the Health module journeys, and to assess depression and anxiety symptoms with brief questionnaires, with results displayed graphically in a timeline and in the the form of short feedback texts.
48008767|NCT05055674|BEHAVIORAL|COMVC app|The COMVC displays over 30 brief psychoeducational videos on several topics related to general mental health, such as depression, anxiety, stress, sleep, problem solving techniques, among others. Psychoeducation is limited to video only (no interactivity). The content of these videos was developed by clinicians, researchers, and professors from the Psychiatry Department of the Medical School of the University of Sao Paulo and from the Federal University of Rio Grande do Sul. Mental health monitoring is delivered by means of brief questionnaires assessing depression and anxiety symptoms, which can be filled at users' discretion. Users' responses are displayed graphically in a timeline and they receive short feedback texts based on assessment results.
48008768|NCT04187365|OTHER|Duration of Indwelling Catheter|Foley catheter
48008769|NCT02889354|BEHAVIORAL|Cognitive-behavioral therapy|
48369498|NCT02994043|BEHAVIORAL|Mindfulness-Based Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
48369499|NCT02994043|BEHAVIORAL|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
48369500|NCT03455556|BIOLOGICAL|Anetumab Ravtansine|Given IV
48514221|NCT02588495|OTHER|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
48514222|NCT02088697|DRUG|Placebo|
48514223|NCT02088697|DRUG|ASC-01|
48514224|NCT02763826|DEVICE|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
48514225|NCT05179330|DEVICE|OMEGO®|Lower limb rehabilitation with and without visual feedback
48514226|NCT00933647|DIETARY_SUPPLEMENT|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
48369501|NCT03455556|BIOLOGICAL|Atezolizumab|Given IV
48369502|NCT03455556|OTHER|Laboratory Biomarker Analysis|Correlative studies
48369503|NCT00944762|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
48008770|NCT01973322|OTHER|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
48008771|NCT01973322|OTHER|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
48165798|NCT04433286|OTHER|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
48695038|NCT06661551|PROCEDURE|Miniscrew insertion in dynamic-computer guided surgery|"The intervention more executed in the literature is by using static computer-guided systems (s-CAS) . However, the s-CAS has limitations, including the time and cost associated with guide production, furthermore, the guide's bulk prevents its use in patients with limited mouth opening, and reduced irrigation potentially leads to overheating and bone burns during implant placement. Additionally, the inability to adjust the surgical plan intraoperatively, the lack of real-time visualization during implant site preparation and implant insertion, and the requirement for specific surgical kits for each implant system present further challenges.~Dynamic navigation systems offer several benefits as highlighted in the literature, including: real-time feedback of the position of surgical drill or implant, allowing intraoperative changes adjusting the implant position during the surgery, reduction of risk of injury to adjacent anatomical structures, promotion of accuracy in novices"
48695039|NCT03929952|OTHER|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
48008772|NCT01973322|OTHER|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
48008773|NCT01973322|BIOLOGICAL|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
48369504|NCT00944762|BEHAVIORAL|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
48369505|NCT00660816|DRUG|erlotinib hydrochloride|Given orally once daily on days 2-19.
48369506|NCT00660816|DRUG|pemetrexed disodium|Given IV over 10 minutes on day 1
48369507|NCT00660816|DRUG|docetaxel|IV over 60 minutes on day 1.
48369508|NCT02217020|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
48369509|NCT03083262|OTHER|no intervention|None, there is no intervention
48369510|NCT00933816|DRUG|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
48369511|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with single donor cornea
48369512|NCT04490902|PROCEDURE|Limbal transplantation combined with central penetrating keratoplasty|Limbal transplantation combined with central penetrating keratoplasty with mixed component cornea
48369513|NCT05584917|BEHAVIORAL|tegner acticity scale|phone call to complete the tegner activity scale after surgery
48369514|NCT04839900|OTHER|Proactive iCCM|CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
48369515|NCT03726320|BEHAVIORAL|Education Counseling Session for PSA Screening|counseling from extensively trained CHW
48369516|NCT03726320|BEHAVIORAL|General Health Counseling Coaching|coaching using an educational tool focused on dietary and lifestyle modification
48369517|NCT04449016|OTHER|High intensity interval training|Repeated, brief, and intense exercise bouts separated by active recovery
48369518|NCT05870358|DRUG|Melatonin 3 MG|In this clinical trial, all patients that have both diabetes mellitus and periodontitis were performed full mouth scaling and root planning in order to start their periodontal treatments. Different from the control group, in fmSRP-mel group's patients systemic melatonin tablets (6 mg daily, for 30 days) were given immediately after the fmSRP procedure in order to support the scaling and root planning.
48369519|NCT03029572|DRUG|Diet supplementation|Micronutriment supplementation therapy
48369520|NCT03029572|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
48165799|NCT04940780|OTHER|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
48514227|NCT00933647|DIETARY_SUPPLEMENT|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
48514228|NCT00933647|DIETARY_SUPPLEMENT|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
48165800|NCT04940780|OTHER|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
48514229|NCT05741229|DRUG|Nebulized nitroglycerine as adjunctive therapy|Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
48514230|NCT05741229|DRUG|conventional therapy for PPHN|patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
48165801|NCT01674452|BEHAVIORAL|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
48514231|NCT00386347|DRUG|GSK364735 oral solution and oral tablets|
48165802|NCT01674452|BEHAVIORAL|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
48165803|NCT03845335|DEVICE|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
48165804|NCT04045522|DRUG|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
48165805|NCT00105521|DRUG|Sarizotan|Sarizotan will be administered twice daily.
48514232|NCT03438292|DIETARY_SUPPLEMENT|Berberine|Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
48165806|NCT00105521|DRUG|Placebo|Placebo matching to sarizotan will be administered twice daily.
48165807|NCT06423859|DRUG|Articaine|supraclavicular brachial plexus block with articaine 2%
48165808|NCT06423859|DRUG|Dexmedetomidine|supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
48369521|NCT01380847|GENETIC|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
48369522|NCT01034345|DRUG|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
48369523|NCT01034345|DRUG|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
48514233|NCT03438292|DIETARY_SUPPLEMENT|TPGS emulsified berberine|Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
48165809|NCT03411928|DEVICE|Tracheolator|'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
48165810|NCT02581189|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
48165811|NCT02581189|DRUG|Dasabuvir|Tablet
48165812|NCT02581189|DRUG|Ribavirin|Tablet
48369524|NCT03204331|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
48369525|NCT03204331|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
48369526|NCT03204331|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
48514234|NCT03438292|DIETARY_SUPPLEMENT|Quillaja extract emulsified berberine|Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
48514235|NCT05809479|OTHER|No intervention|No intervention
48514236|NCT03334461|COMBINATION_PRODUCT|Exposure to oral antiseptics or enamel remineralisation agent|
48514237|NCT00753311|DRUG|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
48514238|NCT00533312|DRUG|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
48514239|NCT00533312|DRUG|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
48514240|NCT00533312|DRUG|Comparator : niacin / Duraton of Treatment: 4 Weeks|
48514241|NCT00987779|DRUG|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
48165813|NCT04774783|DEVICE|Low-Level Laser Therapy|The TheraTouch LX2 device includes a 9-diode cluster probe which emits a combination of LED and laser light. The cluster probe includes four 650 nm LED diodes capable of delivering a total of 40 mW and five 850 nm laser diodes capable of delivering a total of 1000 mW of power. LLLT will the applied with the cluster probe directly in contact with the subject's skin. LLLT dosages will vary according to the location of the subject's pain and may require multiple applications during a session. Each individual application will typically range from 4-16 Joules.
48165814|NCT04632797|DEVICE|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
48165815|NCT00770640|DRUG|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
48165816|NCT00770640|DRUG|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
48165817|NCT00498433|DRUG|Aliskiren|300 mg tablet once daily
48165818|NCT00498433|DRUG|Amlodipine|5 mg capsule once daily
48165819|NCT00498433|DRUG|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
48165820|NCT00498433|DRUG|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
48165821|NCT00924599|BEHAVIORAL|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
48165822|NCT00924599|BEHAVIORAL|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
48165823|NCT05578898|BEHAVIORAL|CLEAR Care Companion (CC) application|The CLEAR CC application is an EPIC-based, electronic application, downloaded to the patient's Smartphone or Tablet. The CLEAR CC leverages patient-reported symptoms assessment vis-a-vis push notifications to complete clinically meaningful questions and validated questionnaires pertaining to symptoms that serve as early indicators of readmission. The CLEAR CC application will send notifications beginning two days prior to surgery and continue until the 6 week post operative appointment.
48165824|NCT02759887|PROCEDURE|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
48369527|NCT03204331|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
48369528|NCT01283724|DRUG|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
48369529|NCT01621763|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
48369530|NCT02626078|OTHER|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
48695040|NCT03929952|OTHER|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
48165825|NCT02759887|OTHER|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
48165826|NCT02759887|OTHER|caregiver questionnaire|
48165827|NCT02759887|PROCEDURE|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
48165828|NCT02759887|PROCEDURE|MRI|Magnetic resonance imaging of the head and brain.
48165829|NCT02759887|PROCEDURE|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
48165830|NCT02759887|PROCEDURE|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
48165831|NCT02759887|PROCEDURE|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
48165832|NCT06337240|OTHER|Pelvic floor on COPD patients|"Group A (study group) :~This group will include 30 COPD patients with urinary incontinence , who will receive pelvic floor exercise for 3 days a week for a total of 3 months."
48165833|NCT06337240|OTHER|Pilates exercises on COPD patients|"Group B (study group):~This group will include 30 COPD patients with urinary incontinence , who will receive pilates for 3 days a week for a total 3 months."
48514242|NCT00987779|DRUG|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
48514243|NCT04065360|BEHAVIORAL|Group Cognitive behavioural family intervention (CBFI)|four-week, four-session CBT-based family intervention programme
48514244|NCT04065360|BEHAVIORAL|Usual group psychoeducation|Treatment as usual in the institution studied
48514245|NCT02108912|OTHER|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
48165834|NCT00212719|DRUG|ONO-5920|
48369531|NCT03145376|DIAGNOSTIC_TEST|geriatric assessment|"1. Clinical evaluation and geriatric assessment with:~   1. CIRS: CIRS (Cumulative Illness Rating Scale)~  2. ADL (Activities of Daily Living);~  3. IADL (InstrumentalActivities of Daily Living);~  4. Mini Nutritional Assessment;~  5. Evaluation of quality of life (Short Form 36, SF-36).~2. Making a traditional 12-lead ECG.~3. A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~4. transthoracic echocardiogram."
48514246|NCT02108912|OTHER|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
48514247|NCT06582342|PROCEDURE|Three dimensional imaging technology (3D-PANC MSP model)|The processing of the CT images obtained in each center for the creation of the 3D model will be performed centrally by the team of radiologists and computer scientists of the company Cella Medical Solutions. This team will be blinded to the reports of the CT scans.For each patient 4 NCCN check-lists will be filled in without knowing the result of the surgery or the AP study: 2 based on the conventional CT and two based on the 3D-MSP study.
48514248|NCT06582342|PROCEDURE|Computerized tomography group (conventional CT)|A multiphase CT (venous phase and pancreatographic phase) with 1mm thick slices and series of images in coronal, axial and sagittal reconstructions will be performed. This CT model will be performed at disease diagnosis and after completion of neoadjuvant chemotherapy treatment. Both CT scans will be independently reported by a radiologist from the hospital of origin. The preoperative CT scan will also be evaluated a posteriori by a radiologist from the sponsoring center with expertise in PAC. Both reports (the one from the radiologist of the center and the one from the radiologist of the sponsoring center) will be used to fill out the imaging study variables sheet based on the latest version of the NCCN 2022 guidelines. The radiologists will not know the outcome of the surgery or the anatomic pathology study at the time of the completion of the report.
48514249|NCT05655130|DRUG|Dexamethasone|Intraoperative 10 mg IV Dose
48514250|NCT05655130|DRUG|Methylprednisolone|"The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)"
48514251|NCT05655130|OTHER|Standard of Care|standard of care surgery
48695041|NCT05992844|OTHER|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
48695042|NCT05992844|OTHER|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
48165835|NCT03594266|DEVICE|Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy A stimulation patterns
48165836|NCT03594266|DEVICE|Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy B stimulation patterns
48695043|NCT02903225|BEHAVIORAL|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
48165837|NCT01936298|DEVICE|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
48369532|NCT00982800|DRUG|Gabapentin|200mg 3x/day for 3 days (9 doses total)
48369533|NCT00982800|DRUG|Placebo Sugar Pill|
48369534|NCT00555711|DEVICE|Modulated Imaging|Modulated Imaging
48369535|NCT02073292|PROCEDURE|c-RFA|
48369536|NCT02073292|PROCEDURE|tRFA|
48369537|NCT02028052|PROCEDURE|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
48369538|NCT02028052|DEVICE|22 gauge Vizishot needles|
48695044|NCT03841513|PROCEDURE|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
48695045|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
48695046|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
48695047|NCT00998322|BIOLOGICAL|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
48695048|NCT00998322|DRUG|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
48695049|NCT04724694|BEHAVIORAL|Brief CBT for Chronic Pain|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6-12 weeks. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
48695050|NCT04724694|OTHER|Treatment as usual|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
48695051|NCT00143494|PROCEDURE|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
48695052|NCT02254278|DRUG|Cisplatin|40 mg/m2 IV (intravenously) weekly for 6 weeks
48695053|NCT02254278|RADIATION|IMRT 6 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
48695054|NCT02254278|RADIATION|IMRT 5 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
48695055|NCT06238895|DRUG|Tardyferon|Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
48695056|NCT00542490|RADIATION|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
48695057|NCT02756962|DRUG|Cytarabine|
48695058|NCT02756962|PROCEDURE|Allogeneic stem cell transplant|
48695059|NCT02756962|PROCEDURE|Bone marrow aspiration|"* Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment"
48165838|NCT01936298|DEVICE|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
48165839|NCT05114161|OTHER|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP \> 60mg/L will be deemed 'appreciable risk' while patients with CRP \< 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of \<95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
48165840|NCT05310058|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
48165841|NCT05436977|DIAGNOSTIC_TEST|coronary OCT|Intermediate coronary lesions will be evaluated by OCT
48695060|NCT02756962|PROCEDURE|Punch skin biopsy|"* The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission."
48695061|NCT02756962|DEVICE|ClinSeq|Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
48695062|NCT06524635|DRUG|Lutikizumab|Subcutaneous (SC) Injection
48695063|NCT04747054|DRUG|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
48695064|NCT04747054|RADIATION|Loco-regional radiotherapy|"Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy."
48165842|NCT05436977|DIAGNOSTIC_TEST|68GaDOTATATE PET/CTCA|Intermediate coronary lesions will be evaluated by68GaDOTATATE PET/CTCA
48165843|NCT04116541|DRUG|HDM201|HDM201 120mg, Every 3 weeks, Per os
48165844|NCT04116541|DRUG|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
48165845|NCT04116541|DRUG|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
48165846|NCT04116541|DRUG|Alectinib|Alectinib, 600mg twice daily, Per os
48695065|NCT04747054|DRUG|Chemotherapy|"If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles"
48165847|NCT04116541|DRUG|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
48165848|NCT04116541|DRUG|Trametinib|Trametinib 2 mg/day, continuous, Per os
48165849|NCT04116541|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
48165850|NCT04116541|DRUG|Avapritinib|300 mg/day,continuous, Per os
48165851|NCT01997437|DEVICE|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
48695066|NCT04129268|OTHER|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
48369539|NCT04761770|OTHER|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
48369540|NCT04761770|DRUG|conditioning regimen|"Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
48369541|NCT04761770|PROCEDURE|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
48369542|NCT00727662|OTHER|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
48369543|NCT00727662|OTHER|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
48369544|NCT05960006|OTHER|No intervention|There are no risks associated with participation because only waste material (blood and ascites) will be used for analysis and no additional blood collection or paracentesis will be performed in addition to standard-of-care. Moreover, hospital admittance and discharge, indication for interventional procedures, indication/initiation/duration/dosing of ceftriaxone, indication/timing/frequency of blood withdrawal for standard of care biochemical analysis and microbiological culturing as the indication, timing, frequency and duration of paracentesis are all decided by the treating physician independent of participation in the study. There are no extra site visits nor extra days of hospital admission. There is no direct benefit for participants of this explorative study. .
48369545|NCT00920166|DIETARY_SUPPLEMENT|Pétunia 1|Infant formula used for non breastfed children
48369546|NCT00920166|DIETARY_SUPPLEMENT|Regular formula|Infant formula used for non breastfed children
48369547|NCT06035341|OTHER|Orofacial Manual Therapy|As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.
48695067|NCT06658106|BEHAVIORAL|Thera-Band Elastic Band-Assisted Progressive Resistance Training|Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.
48165852|NCT00155376|DRUG|morphine and glucagon|
48165853|NCT03779321|OTHER|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
48165854|NCT00952016|DRUG|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
48165855|NCT02168621|PROCEDURE|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
48165856|NCT02168621|PROCEDURE|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
48165857|NCT04471480|DRUG|TC/PD-1 inhibitor/anlotinib|chemotherapy and immunotherapy plus antiangiogenic therapy
48165858|NCT06308731|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Energy drink with 200 mg caffeine
48165859|NCT06308731|OTHER|Placebo|Placebo
48165860|NCT01855178|DEVICE|Emfit Movement Monitor|Factory settings
48165861|NCT01995318|OTHER|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
48165862|NCT03756064|DRUG|Pyrotinib|Pyrotinib: 400mg orally daily
48165863|NCT03756064|DRUG|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
48165864|NCT03756064|DRUG|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
48165865|NCT03756064|DRUG|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
48165866|NCT03756064|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
48695068|NCT06658106|BEHAVIORAL|Conventional Diabetes Management|Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
48165867|NCT02004132|DRUG|Axiron|Solution administered topically using pump and applicator
48514252|NCT01740050|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
48165868|NCT03907254|OTHER|Service Dog Training Program|Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
48165869|NCT02751645|PROCEDURE|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
48514253|NCT01740050|PROCEDURE|RYGB|
48514254|NCT01740050|PROCEDURE|LAGB|
48514255|NCT01682811|DRUG|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
48165870|NCT05896540|BEHAVIORAL|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
48514256|NCT01682811|DRUG|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
48695069|NCT06112314|BIOLOGICAL|IMC-F106C|Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
48695070|NCT06112314|BIOLOGICAL|Nivolumab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
48695071|NCT06112314|BIOLOGICAL|Nivolumab + Relatlimab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
48695072|NCT03090516|DRUG|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
48695073|NCT03090516|DRUG|Donepezil|Arm A：Aricept 5mg/day
48165871|NCT05230095|BEHAVIORAL|social cognition tests|"The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time."
48165872|NCT05230095|BEHAVIORAL|Quality of life self-questionnaire|Quality of life will be assessed using a self-administered questionnaire in the patients group only.
48369548|NCT05951881|OTHER|Emergency Care Unit - medicines|"The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~* the Electronic Medical Record~* the patient's medication history~* the reference pharmacy"
48369549|NCT01272349|OTHER|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
48369550|NCT01272349|OTHER|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
48369551|NCT03520361|DRUG|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
48369552|NCT03520361|DRUG|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
48695074|NCT03090516|DRUG|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
48165873|NCT04994158|COMBINATION_PRODUCT|Drugs, procedures|standard of care only. non interventional registry.
48695075|NCT01575639|DRUG|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
48165874|NCT00317759|BIOLOGICAL|therapeutic autologous lymphocytes|
48165875|NCT00317759|DRUG|fludarabine phosphate|
48165876|NCT03700463|OTHER|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
48165877|NCT02584218|PROCEDURE|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
48369553|NCT05630326|OTHER|comparing, prevalence|Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
48695076|NCT03350035|DRUG|IV Ganaxolone active|IV
48695077|NCT03350035|DRUG|IV Placebo, non-active|IV
48695078|NCT05507567|DRUG|Neumifil|Liquid for intranasal spray administration
48695079|NCT05507567|DRUG|Placebo|Liquid for intranasal spray administration
48165878|NCT02584218|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
48165879|NCT04098497|BEHAVIORAL|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
48165880|NCT03644784|DIAGNOSTIC_TEST|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
48165881|NCT00115986|BIOLOGICAL|Influenza A/H5N1 Vaccine|
48165882|NCT06228742|OTHER|Unilateral leg immobilization|Participants will have one leg immobilized using a rigid knee brace. Participants will be expected to keep the knee brace on for 5 days and remain non-weight bearing on the immobilized leg. Participants will use crutches to remain non-weight bearing on the immobilized leg.
48165883|NCT06228742|OTHER|Contralateral active leg|One leg will remain non-immobilized and active during the study. Participants will use this leg to walk with crutches.
48165884|NCT02702739|DRUG|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
48165885|NCT04147091|OTHER|ApaCare & Repair|Initial cariuos lesions were treated.
48165886|NCT00685425|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
48008774|NCT02586012|DRUG|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: \[(weight in kg x desired FVIII increase of 100 IU/dL)/(2)\].
48165887|NCT00685425|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
48165888|NCT00899379|DRUG|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
48165889|NCT00899379|DRUG|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
48165890|NCT02601105|OTHER|Placebo Vehicle Cream|Lipoderm Cream alone
48165891|NCT02601105|OTHER|Centella Asiatica Cream|1% Centella Asiatica in lipoderm
48369554|NCT05630326|OTHER|assessment|comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
48008775|NCT01229475|PROCEDURE|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
48008776|NCT01229475|PROCEDURE|Linear ablation|Linear ablation for AF ablation
48695080|NCT06535854|DEVICE|Prevail DCB|The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
48008777|NCT02263638|DRUG|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
48165892|NCT04596241|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
48165893|NCT02137239|DRUG|Thymoglobulin|
48165894|NCT02137239|DRUG|Belatacept|
48165895|NCT02137239|DRUG|mycophenolate mofetil(MMF)|
48165896|NCT02137239|DRUG|Corticosteroids|
48165897|NCT02137239|DRUG|Everolimus(EVL)|
48165898|NCT02137239|DRUG|Tacrolimus(TAC)|
48165899|NCT02206464|BIOLOGICAL|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
48165900|NCT02206464|BIOLOGICAL|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
48008778|NCT01826500|OTHER|blood test|blood test
48369555|NCT05630326|OTHER|association|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
48008779|NCT01516879|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
48008780|NCT01516879|BIOLOGICAL|Placebo|Administered by subcutaneous injection once a month
48008781|NCT01516879|DRUG|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
48008782|NCT01516879|DRUG|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
48008783|NCT01516879|OTHER|Diet Only|Diet only, no lipid lowering background drug given
48008784|NCT05782595|OTHER|Aquatic therapy|"• Each session was divided into three phases:~1. Aquatic environment adaptation phase~2. stretching phase~3. a phase of static and dynamic exercises for balance"
48165901|NCT06290141|DRUG|riliprubart|Pharmaceutical form:Solution-Route of administration:IV solution
48165902|NCT06290141|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:IV solution
48165903|NCT06290141|DRUG|riliprubart|Pharmaceutical form:Solution-Route of administration:SC solution
48165904|NCT06290141|DRUG|Placebo|Pharmaceutical form:Solution-Route of administration:SC solution
48165905|NCT06290141|DRUG|IVIg|Pharmaceutical form:Concentrate for solution for infusion (or any other formulation approved locally)-Route of administration:IV solution
48165906|NCT06290141|DRUG|Placebo|Pharmaceutical form:Placebo to match intravenous immunoglobulin IVIg for IV infusion-Route of administration:IV solution
48165907|NCT06290141|DRUG|IVIg premedication|Pharmaceutical form:Per respective labels-Route of administration:Per respective labels
48369556|NCT05630326|OTHER|evaluation|comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
48369557|NCT01319539|DRUG|Akt Inhibitor MK2206|Given PO
48369558|NCT01319539|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48369559|NCT01319539|OTHER|Pharmacological Study|Correlative studies
48369560|NCT01319539|OTHER|Laboratory Biomarker Analysis|Correlative studies
48165908|NCT02815137|OTHER|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
48165909|NCT06140485|DIETARY_SUPPLEMENT|NW Low-Glu®|One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).
48165910|NCT06140485|DRUG|Metformin|Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
48165911|NCT05207631|OTHER|Systematic and standardised assessment of inhalers and implementation of a prescribing guide|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
48695081|NCT06535854|DEVICE|Agent DCB|The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
48165912|NCT04349657|DEVICE|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
48695082|NCT06636318|DIAGNOSTIC_TEST|Blood Sample Collection|"To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses."
48008785|NCT05065125|DEVICE|digital single-operator cholangioscopy|"1. Duodenoscope passes through esophagus and stomach to the papilla of Vater~2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct~3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site."
48165913|NCT04349657|PROCEDURE|Endarterectomy treatment group|Surgical treatment through endarterectomy
48165914|NCT04193709|DEVICE|Spinal Cord Epidural Stimulation|For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
48165915|NCT03988478|BEHAVIORAL|Detoxification & psychotherapeutic support|
48165916|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
48165917|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
48165918|NCT00448773|BEHAVIORAL|Online education|
48165919|NCT03363542|DIETARY_SUPPLEMENT|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
48165920|NCT06645821|DRUG|EVO101|EVO101 topical cream 0.1%
48165921|NCT00004016|BIOLOGICAL|recombinant interferon gamma|
48695083|NCT06636318|DEVICE|Actigraph (GT9X-BT) Monitor|Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
48695084|NCT06086704|DRUG|18F-fluorofuranylnorprogesterone|18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
48695085|NCT06086704|DEVICE|Positron Emissions Tomography / Magnetic Resonance Imaging|Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
48008786|NCT04150081|PROCEDURE|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
48008787|NCT02388997|DRUG|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
48165922|NCT04885426|DRUG|low-dose metformin|Metformin Pill 250mg/day
48165923|NCT04885426|DRUG|high-dose metformin|Metformin Pill 500mg/day
48165924|NCT04885426|DRUG|Placebo|Placebo
48165925|NCT04854278|OTHER|Massive Open Online Course (MOOC)|Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
48165926|NCT03935061|OTHER|Mulberry juice|On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
48165927|NCT02723305|OTHER|No intervention|
48369561|NCT04518644|DRUG|Nilotinib|The recommended dosing of nilotinib is 400 mg orally twice daily
48369562|NCT04468100|BIOLOGICAL|Tigerase®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
48369563|NCT04468100|BIOLOGICAL|Pulmozyme®|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
48369564|NCT02528149|PROCEDURE|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
48369565|NCT02528149|OTHER|blood sample|
48008788|NCT02388997|BIOLOGICAL|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
48008789|NCT02673775|OTHER|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
48695086|NCT06086704|DRUG|Anastrozole|hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
48165928|NCT05654558|DEVICE|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
48369566|NCT01265719|OTHER|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
48695087|NCT06086704|OTHER|Blood Sampling|Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions
48695088|NCT06086704|DRUG|FDA-approved gadolinium-based intravenous contrast agent|FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
48165929|NCT05654558|DEVICE|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
48369567|NCT01265719|OTHER|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
48369568|NCT04198376|PROCEDURE|Group A The Laterally Closed Tunnel Technique with SCTG|Following the administration of local anaesthesia 2% lignocaine hydrochloride.In the LCT technique a bevelled intrasulcular incisions will be made around the necks of the affected teeth with Orban Knife.The tunnelling will be accomplished with tunneling instrument (TKN2).A mucoperiosteal tunnel will be prepared using a specially designed tunneling instrument.The muscle and collagen fibres will be released using surgical blades and gracey curettes.Subepithelial CTG will be harvested from palate using single incision technique.The graft will be removed and will be placed on saline soaked gauze and kept wet until its transfer to the recipient bed.An immediate closure of the donor site is performed using modified mattress sutures.The graft will be adapted to the CEJ by means of sling suture.Finally the margins of the pouch will be pulled together over the graft and sutured with interrupted sutures.The surgical sites will be protected with a non eugenol periodontal dressing.
48369569|NCT04198376|PROCEDURE|Group B Modified Coronally Advanced Tunnel Technique with SCTG.|In MCAT technique all the buccal tissues will be undermined and connected only the papillary region will be left attached.A full thickness preparation of the papillary region will be created this will be done with a small elevator.A second surgical site to obtain the subepithelial CTG using single incision technique.A support suture will be performed to guide the CTG into the recipient site.The graft will be gently pushed into the pouch with a packing instrument and by pulling the support suture.The entire gingivopapillary complex will be moved coronally using a vertical mattress suture anchored in the lingual gingiva.The anchorage in the lingual gingiva will be placed far apically.The suture must capture the buccal flap and graft to avail optimal stabilization.The surgical sites will be protected with a non eugenol periodontal dressing.
48165930|NCT02571283|DRUG|Cocktail|Administered as a single dose injection.
48695089|NCT05834400|BEHAVIORAL|The Optimal Lymph FLow (TOLF)|Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
48695090|NCT05834400|BEHAVIORAL|Daily Monitoring|Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
48695091|NCT03118856|DIAGNOSTIC_TEST|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
48695092|NCT02479087|DRUG|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
48165931|NCT02571283|DRUG|Exparel|Administered 20 minutes+ before additional medications.
48369570|NCT05657379|OTHER|Other: Product X moisturizer|Product X moisturizer containing Hyaluronic Acid and Rosa Damascena Flower Water
48514257|NCT01682811|DRUG|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
48695093|NCT03547739|BEHAVIORAL|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
48695094|NCT03547739|BEHAVIORAL|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
48695095|NCT00954629|DRUG|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
48165932|NCT02571283|DRUG|Marcaine|Administered 20 minutes or more after Exparel is administered.
48165933|NCT05554042|DIAGNOSTIC_TEST|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
48165934|NCT02207322|OTHER|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
48165935|NCT05482256|DIAGNOSTIC_TEST|Esophageal String Test (EST)|Non-invasive, FDA-registered sampling method to evaluate eosinophilic inflammation in the esophagus. The EST is performed by having an individual swallow a capsule attached to a string which captures secretions from the esophagus. The end of the string is taped to the cheek and the capsule is swallowed with water. After 1 hour, the EST will be removed, and the string will be processed for laboratory analysis.
48165936|NCT05482256|OTHER|Colgate|2 grams of toothpaste (pea sized amount) for 2 minutes
48165937|NCT05482256|DIAGNOSTIC_TEST|High Resolution Esophageal Manometry (HREM)|Thin flexible tube with sensors placed in the nose and swallowed for esophagus placement to conduct reading regarding the lining of the esophagus taken for approximately 10 minutes
48165938|NCT06308497|OTHER|Probiotic Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day Probiotic supplementation with daily assumption of Limosilactobacillus Reuteri Prodentis® tablet (PerioBalance, Gum®)
48165939|NCT06308497|OTHER|Standard Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day
48165940|NCT04086719|DRUG|BMS-986165|Oral administration of tablet BMS- 986165
48165941|NCT04086719|DRUG|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
48165942|NCT03421171|OTHER|no intervention|Qualitative research through semi-structured interviews
48165943|NCT03164525|DIAGNOSTIC_TEST|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
48514258|NCT01682811|DRUG|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
48165944|NCT04748471|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccine
48165945|NCT01271036|DEVICE|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
48165946|NCT06647056|DRUG|Psilocybin|Administration of psilocybin 25 mg
48165947|NCT06647056|OTHER|MRI|Two standard MRI + fMRI scans before (D-3) and after (D5) treatment
48165948|NCT04355013|DEVICE|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
48165949|NCT05388097|OTHER|Managed Services|coordination of care and assistance with community resources (food, transportation)
48165950|NCT00812123|DRUG|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
48165951|NCT00812123|DRUG|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
48514259|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
48008790|NCT02673775|OTHER|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
48165952|NCT00812123|DRUG|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
48695096|NCT00954629|DRUG|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
48165953|NCT00812123|DRUG|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
48165954|NCT00812123|PROCEDURE|Protocol biopsies|protocol kidney biopsies at month one and three
48514260|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
48514261|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
48514262|NCT05432635|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
48514263|NCT05432635|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
48514264|NCT05432635|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
48514265|NCT05432635|PROCEDURE|Myeloablative Conditioning|Given standard conditioning regimen
48695097|NCT00146016|DRUG|Amantadine|
48165955|NCT05051124|BEHAVIORAL|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
48165956|NCT05051124|BEHAVIORAL|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
48165957|NCT02694588|DRUG|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
48165958|NCT02694588|DRUG|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
48165959|NCT00482417|DRUG|MK0359|
48514266|NCT05961501|DRUG|An aqueous solution containing CBD and CBN|An aqueous solution containing CBD and CBN, to drink at home in the dose determined by the attending physician
48514267|NCT05961501|OTHER|The aqueous solution of placebo|An aqueous solution of placebo, to drink at home in the dose determined by the attending physician
48514268|NCT04040192|DRUG|Crisaborole 2%|Crisaborole ointment 2%
48514269|NCT04040192|DRUG|Vehicle|Vehicle ointment
48695098|NCT04645316|DRUG|Sevoflurane|In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
48695099|NCT04645316|DRUG|Desflurane|In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
48695100|NCT04645316|DRUG|Propofol|In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
48165960|NCT05047497|DIAGNOSTIC_TEST|questionaire and ventilatory function test|we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups
48165961|NCT06170502|DEVICE|Using the mobile application and applying the survey|"In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
48165962|NCT03838419|RADIATION|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
48165963|NCT03838419|RADIATION|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
48165964|NCT05755217|DIETARY_SUPPLEMENT|Dark chocolate|Single oral dose of 1g/kg of dark chocolate (70% cocoa).
48165965|NCT05755217|DIETARY_SUPPLEMENT|White chocolate|Single oral dose of 1g/kg of white chocolate (4% cocoa).
48165966|NCT00001083|DRUG|Indinavir sulfate|
48165967|NCT00001083|DRUG|Ritonavir|
48165968|NCT00001083|DRUG|Nevirapine|
48165969|NCT00001083|DRUG|Lamivudine|
48165970|NCT00001083|DRUG|Stavudine|
48165971|NCT00001083|DRUG|Zidovudine|
48165972|NCT02703402|OTHER|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
48165973|NCT02703402|OTHER|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
48165974|NCT03128788|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
48165976|NCT04137978|DRUG|ADV7103|Patients receive ADV7103 twice a day at optimal dose.
48165977|NCT04137978|DRUG|Standard of Care|Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
48165978|NCT01848262|PROCEDURE|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
48165979|NCT01848262|PROCEDURE|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
48165980|NCT06138834|DRUG|Low-dose Y-6 sublingual tablets|Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
48695101|NCT06110156|BEHAVIORAL|Patient-tailored deprescribing assessment and intervention|Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
48695102|NCT06324942|OTHER|Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg|Surgeon-administered Transversus Abdominis Plane Block
48165981|NCT06138834|DRUG|High-dose Y-6 sublingual tablets|Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
48165982|NCT06138834|DRUG|Low-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
48165983|NCT06138834|DRUG|High-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
48165984|NCT06138834|DRUG|Placebo|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
48165985|NCT00004403|DRUG|albendazole|
48165986|NCT00004403|DRUG|dexamethasone|
48165987|NCT00004403|DRUG|phenytoin|
48165988|NCT05262218|DRUG|PBF-680 10mg|PBF-680 10mg administered orally once a day
48165989|NCT05262218|DRUG|Placebo|Placebo administered orally once a day
48165990|NCT02946827|DIETARY_SUPPLEMENT|Balanced low FODMAPs /gluten free diet|
48165991|NCT02946827|DIETARY_SUPPLEMENT|Balanced gluten free diet|
48165992|NCT06646380|BEHAVIORAL|Multicomponent Training|The multicomponent training (MCT) program comprised aerobic, resistance, flexibility, and balance exercises, following recommendations by Carvalho et al. (23). Sessions lasted 50 to 60 minutes, including warm-up, aerobic exercise, resistance training, balance training, and cool-down. Training intensity gradually increased over time. The experimental group will have three 60-minute sessions weekly for 32 weeks, while the control group will not participate in any exercise program, but they will maintain the daily physical activity. Both groups will be evaluated at two time points: initial assessment (M1) at the start of training and final assessment (M2) after 32 weeks
48165993|NCT06646380|OTHER|Maintenance|Participants were instructed to maintain daily life activities regarding physical activity.
48695103|NCT06577025|DRUG|Cilta-cel|Cilta-cel infusion will be administered intravenously.
48695104|NCT06577025|DRUG|Talquetamab|Talquetamab will be administered subcutaneously.
48165994|NCT05913583|DRUG|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
48695105|NCT06577025|DRUG|Daratumumab|Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D and Tec-D consolidation.
48165995|NCT00005968|DRUG|irofulven|
48165996|NCT01076322|DRUG|Meptin® Swinghaler|"Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)"
48165997|NCT01076322|DRUG|Ventolin® MDI|"Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)"
48165998|NCT02953028|DEVICE|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
48165999|NCT02953028|DEVICE|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
48166000|NCT03545321|BEHAVIORAL|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
48369571|NCT05901506|OTHER|a Nurse-led, Motivational Interview|Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
48369572|NCT02136927|DRUG|SPARC1210|
48369573|NCT02136927|DRUG|Reference1210|
48369574|NCT01068015|OTHER|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
48369575|NCT04941261|BIOLOGICAL|middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
48369576|NCT04941261|BIOLOGICAL|high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine|Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
48369577|NCT04941261|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
48369578|NCT02195531|BEHAVIORAL|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
48695106|NCT06577025|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
48695107|NCT06577025|DRUG|Bortezomib|Bortezomib will be administered subcutaneously as a part of induction.
48166001|NCT04461314|BEHAVIORAL|peer-led counselling|"About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence."
48166002|NCT01191450|DRUG|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
48166003|NCT01191450|DRUG|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
48166004|NCT04584333|BEHAVIORAL|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
48369579|NCT06003582|OTHER|Infant Parent Support|Therapeutic Intervention
48514270|NCT03399708|DRUG|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
48514271|NCT00618332|DRUG|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
48514272|NCT00618332|DRUG|placebo|2 puffs in each nostril once a day for 2 weeks
48695108|NCT06577025|DRUG|Lenalidomide|Lenalidomide will be administered orally as a part of induction.
48695109|NCT06577025|DRUG|Dexamethasone|Dexamethasone will be administered orally as a part of induction.
48695110|NCT06577025|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
48695111|NCT06577025|DRUG|Fludarabine|Fludarabine will be administered intravenously as a part of conditioning regimen.
48695112|NCT05105581|BEHAVIORAL|Quality of life scale|"1. To assess the quality of life of patient~2. To assess the degree of OCD"
48166005|NCT03900715|DRUG|Luspatercept|Luspatercept
48695113|NCT05242224|OTHER|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
48695114|NCT05662280|DEVICE|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
48695115|NCT05662280|DEVICE|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
48695116|NCT04305769|DRUG|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
48166006|NCT00064428|DRUG|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
48695117|NCT05582018|DEVICE|BioTraceIO 360|Use of the device for planning, monitoring and assessment of liver tissue ablations
48695118|NCT03575065|DRUG|BGB-290|Administered orally
48695119|NCT04150146|DRUG|Rebamipide SR 150mg after high-fat meal|Test Drug
48695120|NCT04150146|DRUG|Rebamipide SR 150mg under fasting condition|Reference Drug
48695121|NCT05903911|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
48695122|NCT02834117|OTHER|natural cycle|Ovulation is not induced by drugs
48695123|NCT02834117|DRUG|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
48166007|NCT00064428|OTHER|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
48166008|NCT00064428|DRUG|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
48166009|NCT00064428|DRUG|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
48166010|NCT03124550|BEHAVIORAL|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
48369580|NCT04505007|OTHER|Specialized heart function clinic|This information has already been provided.
48695124|NCT01236066|OTHER|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
48695125|NCT05476887|DRUG|KP104|KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
48695126|NCT06462365|BIOLOGICAL|TRX103|TRX103 infusion via central line.
48695127|NCT05837611|BEHAVIORAL|Deposit Contract|A deposit contract requires individuals to put down money that is earned back contingently upon meeting their goals.
48695128|NCT05837611|OTHER|Transdermal Alcohol Monitoring|Using a SCRAM-Cam device participants will be monitored for their alcohol use.
48695129|NCT06480968|DRUG|CTH120|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD.~FIH-CTH120-FI: One dosage of CTH120 will be assessed in 12 healthy male and female subjects in two conditions (Fed and Fasting). Subjects will be randomly assigned to 2 sequences: 6 subjects in a sequence fed then fasting condition, 6 subjects in the reverse sequence (fasting, then fed condition)."
48166011|NCT04597099|DRUG|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
48166012|NCT04597099|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
48166013|NCT04597099|DRUG|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
48166014|NCT04597099|DRUG|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
48166015|NCT01120561|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
48166016|NCT01421797|DRUG|Dexamethasone|1 mg PO
48166017|NCT01421797|DRUG|Cortrosyn|single IV bolus of 0.25 mg will be administered
48166018|NCT00858247|DIETARY_SUPPLEMENT|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
48369581|NCT03570658|DRUG|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
48369582|NCT03570658|DRUG|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
48369583|NCT03342209|DEVICE|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
48369584|NCT04570124|DEVICE|Home Blood Pressure Telemonitoring|Women will complete a 9-question survey (pre-education) prior to discharge and will go over an education video a study team member. Once discharged, women will be asked to measure their blood pressure daily for the first postpartum week, and then weekly until postpartum week 6. Women who have a doctor's visit scheduled during the first 10 days, a member of the study team will meet them there to assess blood pressure and answer any questions. Women who do not have a visit scheduled they will have a telehealth visit during days 8-10 to complete the same assessments. At the final visit, participants will measure their blood pressure via HBPT, prior to returning the unit, complete a post-education questionnaire, a post-study questionnaire and have any questions or concerns addressed.
48369585|NCT05461404|OTHER|Topical Emollient Therapy|Application of high-linoleate (\>60% linoleic acid) SSO to the epidermis.
48369586|NCT04039282|DEVICE|myfood24|online website for dietary analysis
48369587|NCT01689831|BIOLOGICAL|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
48369588|NCT01689831|BIOLOGICAL|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
48369589|NCT02780869|DEVICE|HEMOBLAST Bellows|
48369590|NCT02780869|DEVICE|Absorbable gelatin sponge, USP with thrombin|
48369591|NCT00036621|DRUG|BMS-275291|
48369592|NCT00988910|DRUG|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
48369593|NCT00988910|DRUG|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
48369594|NCT01527760|DRUG|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
48369595|NCT03051906|BIOLOGICAL|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
48369596|NCT03051906|BIOLOGICAL|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
48369597|NCT03051906|RADIATION|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
48522681|NCT06272721|DIAGNOSTIC_TEST|Griffiths Scale|The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
48166019|NCT05394883|BEHAVIORAL|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
48166020|NCT05394883|BEHAVIORAL|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
48166021|NCT00932659|DEVICE|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
48514273|NCT04679701|DEVICE|Amparo Confidence Socket|"The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis."
48514274|NCT01869985|DRUG|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
48514275|NCT04152863|BIOLOGICAL|Gebasaxturev IV|Administered as an IV infusion of 1 X 10\^9 TCID50
48514276|NCT04152863|BIOLOGICAL|Gebasaxturev ITu|Administered as an ITu injection of 3 X 10\^8 TCID50
48514277|NCT04152863|DRUG|Pembrolizumab|Administered as an IV infusion of 200 mg
48514278|NCT01512160|DRUG|PF-04531083|2000 mg oral solution
48514279|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
48514280|NCT01512160|DRUG|PF-04531083|1000 mg oral solution
48514281|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
48369598|NCT04800406|PROCEDURE|Dental Implants|Resorbable blast media surface treated dental implant and Acid etched surface treated dental implant.
48369599|NCT03427931|OTHER|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
48514282|NCT01512160|DRUG|Ibuprofen|2 x 200 mg tablets
48514283|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
48695130|NCT06480968|OTHER|Placebo|"FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD."
48369600|NCT06423521|OTHER|Standard of Care (SOC)|The SOC intervention constitutes the common clinical practice of care that is habitually performed after cardiac surgery to manage anticoagulation therapies.
48369601|NCT06423521|OTHER|Remote Patient Monitoring (RPM)|The RPM intervention involves the use of a remote patient monitoring (RPM) system with a portable coagulometer for the clinical follow-up and self-management of International Normalized Ratio (INR) control in patients undergoing anticoagulant therapy post-cardiac surgery. Patients were provided with a Coagulometer-CoaguChek® (Roche Diagnostics, Switzerland) kit and test strips, along with written instructions for conducting measurements. They were also enrolled in a monitoring platform. Patients received regular text messages on their smartphones to report their INR values and symptoms related to anticoagulant therapy. The clinical team received notifications if patients\&amp;#39; reports fell outside therapeutic standards and then responded with medication adjustments via text message.
48369602|NCT01619631|BEHAVIORAL|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
48514284|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
48514285|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
48514286|NCT04582084|DRUG|Etanercept|Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.
48514287|NCT02928445|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
48514288|NCT02928445|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
48514289|NCT00808951|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
48514290|NCT00808951|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
48514291|NCT01696279|DRUG|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
48369603|NCT01619631|BEHAVIORAL|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
48369604|NCT05782738|PROCEDURE|Percutaneous Coronary Intervention|Use dedicated two stents technique for treatment of coronary bifurcation stenosis
48369605|NCT01256866|DRUG|Dexmedetomidine|
48369606|NCT01256866|DRUG|Midazolam|
48514292|NCT01696279|DRUG|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
48514293|NCT01026311|DRUG|Coenzyme q 10|200 mg of Coenzyme q 10
48514294|NCT01026311|DRUG|placebo|1 placebo q d during treatment period
48695131|NCT06660992|DRUG|HSK31858, tablet|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
48695132|NCT06660992|DRUG|Placebo|the placebo comparator of study
48695133|NCT01780337|DRUG|Oxytocin|Intranasal dose of 20 IU oxytocin
48695134|NCT01780337|OTHER|Saline|Intranasal dose of saline
48514295|NCT05336188|DEVICE|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
48514296|NCT00041132|BIOLOGICAL|filgrastim|5 ug/kg
48514297|NCT00041132|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 of cycles 1-6
48514298|NCT00041132|DRUG|cyclophosphamide|300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
48514299|NCT00041132|DRUG|cytarabine|12 g/m\^2 over days 3-4 of cycles 2,4,6,8
48514300|NCT00041132|DRUG|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
48514301|NCT00041132|DRUG|doxorubicin|16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7
48695135|NCT06347133|DRUG|Plozasiran Injection|ARO-APOC3 Injection
48695136|NCT06347133|DRUG|Placebo|sterile normal saline (0.9% NaCl)
48695137|NCT06416150|BEHAVIORAL|Stage 1 SOC|Participants will receive high Standard Care, consisting of a telephone call approximately one month before the appointment to confirm the appointment date for the baseline colposcopy appointment, followed by a notification letter including scheduled appointment date and clinic contact information should the clinic be unable to reach the patient by telephone.
48008791|NCT05703529|BEHAVIORAL|Positive Psychotherapy|A 6-week group-based positive psychotherapy was conducted in this group. The themes of each week include positive introduction, three good things and positive reactions, gratitude, positive memory, identifying personal strengths and utilizing strengths.
48369607|NCT00243477|DRUG|Escitalopram|Escitalopram 10mg or placebo once a day
48514302|NCT00041132|DRUG|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
48514303|NCT00041132|DRUG|methotrexate|1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8
48514304|NCT00041132|DRUG|vincristine|1.4 mg/m\^2 on days 5 and 12 of cycles 1,3,5,7
48514305|NCT01823497|DRUG|Morphine|Morphine will be used to control pain post-surgery.
48514306|NCT05560165|PROCEDURE|F-18 sodium fluoride PET/CT guided robotic arm assisted injection of combination of local anesthetic and steroids|A surgical aseptic approach will be followed for the procedure. Local anesthesia of the skin and soft tissue at the entry site will be achieved by 1% lignocaine. A 23G lumbar puncture needle will be introduced and the real-time final placement of the needle will be confirmed with low dose CT (40 mA) fused with pre-procedure PET images. After confirming the real-time position, the local anesthetic and steroid injection (0.5ml of 0.5% Bupivacaine per joint and a total dose of 80mg of Methylprednisolone acetate divided equally based on the number of joints to be injected) will be injected intraarticularly and periarticularly around the target joint through the lumbar puncture needle. The skin entry site will be compressed manually to achieve hemostasis. The same procedure will be repeated if multiple joints are to be injected. After the procedure, patient vitals will be observed for thirty minutes in the recovery area and discharged in stable condition.
48522682|NCT01089465|OTHER|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
48522683|NCT03606785|DRUG|Tranexamic Acid Injection|The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
48522684|NCT03606785|DRUG|placebo injection|patients will receive a placebo of 100 mL 0.9% normal saline
48514307|NCT05273346|BEHAVIORAL|Traditional Chinese medicinal ointment|The Group1 will be treated using the Comprehensive Conservative TCM Treatment Group protocol.The special TCM ointment will be applied to the waist, and then Tuina, in order to play the comprehensive therapeutic role of Tuina and medicine, promoting blood circulation and removing stasis, warming and dispersing cold, strengthening tendons and strengthening bones, regulating qi and blood. The method of ointment is generally used with rubbing method, rubbing method, flat pushing method and kneading method. Treatment time: 7 minutes.
48166022|NCT06368856|DRUG|Mupirocin (50 mg)|50 mg de mupirocin
48166023|NCT06368856|DRUG|Mupirocin (500 mg)|500 mg de mupirocin
48166024|NCT06368856|BIOLOGICAL|blood samples after Single dose part|3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00
48166025|NCT06368856|DIAGNOSTIC_TEST|nasal swab after Single dose part|7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00
48166026|NCT06368856|OTHER|Collection of urine after Single dose part|Collection of urine during 12 hours after the application of mupirocin (Single dose part)
48514308|NCT05273346|BEHAVIORAL|Acupotomy|It is in the special acupoints or Ashixue for cutting, stripping and other different stimulation, in order to reduce the tension of soft tissue outside the spinal canal, reduce the trend of dynamic and static spinal canal stenosis, to achieve the purpose of relieving pain and removing disease, opening points and collaterals. Acupotomy can separate the adhesive tissue, which can improve the blood circulation of the local tissue and promote the absorption of inflammation. Most acupotomy points are tenderness points or induration points, such as yaojiaji and Shenshu. Treatment time: 3 minutes.
48695138|NCT06416150|BEHAVIORAL|Stage 1 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
48695139|NCT06416150|BEHAVIORAL|Stage 2 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
48695140|NCT06416150|BEHAVIORAL|Stage 2 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as health coaching (HC) after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
48695141|NCT06416150|BEHAVIORAL|Stage 3 SOC|Participants will receive a telephone call before their 12-month follow-up appointments to remind participants about their upcoming appointment and schedule/reschedule if needed.
48166027|NCT06368856|DIAGNOSTIC_TEST|nasal swab during Repeated dose part|5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
48695142|NCT06416150|BEHAVIORAL|Stage 3 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
48008792|NCT05703529|OTHER|Usual Care|Usual Care means treating as usual, including a regular home visit.
48166028|NCT06368856|OTHER|Collection of urine during Repeated dose part|5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
48166029|NCT06368856|OTHER|nasal swab after Repeated dose part|2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)
48166030|NCT06170229|BEHAVIORAL|eHIIT|"Education and High intensity Interval Training (Aerobic Exercise)~The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares.~HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax).~There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer."
48514309|NCT05273346|BEHAVIORAL|Cupping therapy with bamboo cup|Put the bamboo cup with the thickness of the thumb into the cup and boil it, then find the meridian and select the acupoint, Pierce the skin with a needle at the appropriate acupoint, and remove the heated bamboo cup from the cup while it is hot. When the temperature of the steam in the bamboo cup is reduced, steam will condense into water quickly, which produces strong negative pressure. Through the medicinal force, heat and the suction of the bamboo cup, the blood stasis in the affected area is smoothly discharged, so that qi and blood can be unblocked and pain can be eliminated. Treatment time: 20 minutes.
48514310|NCT05273346|OTHER|Oral Chinese medicine granules|Oral Chinese medicine granules use to nourish liver and kidney, improve qi and blood. Patients voluntarily take it when they think it is necessary.
48695143|NCT06416150|BEHAVIORAL|Stage 3 HERS+HC|Participants will receive text message barriers counseling as well as HC after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
48695144|NCT06416150|BEHAVIORAL|Stage 4 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
48695145|NCT06416150|BEHAVIORAL|Stage 4 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as HC. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
48695146|NCT02841683|BEHAVIORAL|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
48695147|NCT05512065|DEVICE|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
48008793|NCT01546116|DRUG|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
48166031|NCT06170229|BEHAVIORAL|NEMEX-e|"Education and Neuromuscular Exercise~The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given.~The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other)."
48166032|NCT00308399|DRUG|Itopride|
48695148|NCT06659406|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 will be given once daily, 200mg for the period of 3 months
48695149|NCT02975739|DEVICE|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
48166033|NCT02137395|DRUG|Dexamethasone|dexamethasone administration, intravenously
48166034|NCT02137395|DRUG|Placebo|saline administration intravenously
48166035|NCT04964778|DEVICE|SKED©|A SKED device is lightweight plastic stretcher used for moving patients through difficult terrain.
48166036|NCT01191697|DRUG|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
48166037|NCT01191697|DRUG|trastuzumab|Given intravenously on day 1 of each treatment cycle
48166038|NCT01191697|DRUG|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
48166039|NCT01191697|DRUG|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
48166040|NCT04469452|DEVICE|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
48166041|NCT06399341|DEVICE|Papilocare vaginal gel|Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)
48695150|NCT03333252|BEHAVIORAL|Intervention Condition|Caregivers will access caregiving related information. Care Recipients will access cognitive training program
48695151|NCT03333252|BEHAVIORAL|Control Condition|Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
48008794|NCT06095843|PROCEDURE|placement of dental implants|placement of dental implants in mandibular reconstruction.
48166042|NCT02435797|DRUG|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
48166043|NCT02435797|DRUG|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
48369608|NCT01151085|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
48514311|NCT05273346|BEHAVIORAL|Epidural Steroid Injections (ESIs)|The Group2 will be treated using the Modern Medicine Conservative Treatment Program Group protocol.All Epidural Steroid Injections(ESIs) will be performed by a physician in an outpatient surgical setting(a sterile operating room),the patient will be in prone position,while monitored the vital signs. After aseptic treatment, 1mg non-granular betamethasone plus 5mL 0.9% sodium chloride solution will be injected. Patients will repeat ESIs up to four times within three months after randomization, depending on the response to the previous ESIs, when the degree of pain increases or the degree of relief is less than 50%.
48695152|NCT04030546|DRUG|Ivabradine|Ivabradine capsule
48695153|NCT03539211|OTHER|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
48695154|NCT03539211|OTHER|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
48695155|NCT05396222|DEVICE|3D-printed custom-made non-rigid biomimetic implant|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
48695156|NCT06657651|PROCEDURE|immediate implant placement with dentin-derived membrane|immediate implant placement with dentin-derived membrane and allograft in mandibular molar area
48008795|NCT01172691|PROCEDURE|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
48008796|NCT00581282|RADIATION|PET scan|positron emission tomography PET scan
48008797|NCT00581282|OTHER|fMRI|functional magnetic resonance imaging fMRI
48008798|NCT01387204|DRUG|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
48514312|NCT05273346|BEHAVIORAL|Interferential current therapy|The 30-50cm padded electrode will be properly fixed on the left and right sides of the lumbar spinal stenosis, and the two groups of current will be crossed at the lesion. Constant frequency output 90Hz, frequency conversion output 90-100Hz, the current intensity is generally suitable for patient tolerance, each treatment for 10min, a total of 20 minutes. Twice a week for 3 months.
48166044|NCT03132753|BEHAVIORAL|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
48695157|NCT06657651|PROCEDURE|immediate implant with extended platelet rich fibrin membrane|immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
48695158|NCT06540911|OTHER|Personalized physical back training program|The study intervention is a 4-week personalized physical back training program. The study intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.
48166045|NCT02750553|DRUG|SHR0534|
48166046|NCT02750553|DRUG|Placebo|
48166047|NCT01039259|DEVICE|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
48166048|NCT02054598|BEHAVIORAL|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
48166049|NCT01654835|OTHER|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
48166050|NCT01654835|OTHER|standard of care|A Low Blood Pressure condition as specified (SAP \<80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
48166051|NCT06006832|DRUG|Steroid Drug|Maintaining low-dose oral steroids
48166052|NCT06006832|OTHER|Withdraw all immunosuppresants|Withdraw all immunosuppresants
48166053|NCT00168714|DRUG|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
48166054|NCT04385628|BEHAVIORAL|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
48514313|NCT05273346|BEHAVIORAL|Thermal therapy|After the interferential current therapy, the patient will receive Bohm light for 5 minutes at the site of lumbar spinal stenosis and massage for 5 minutes at low back. Twice a week for 3 months.
48514314|NCT05273346|OTHER|Oral painkillers|NSAID drugs, if necessary.
48166055|NCT02773121|BEHAVIORAL|Physical Activity|Trainer-guided at-home behavioral intervention
48166056|NCT02591914|DRUG|Fovista™|Anti-PDGF-B pegylated aptamer
48369609|NCT00876902|DRUG|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg \[approximately 0.27 mg/kg\] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
48166057|NCT02591914|DRUG|Lucentis®|Anti-VEGF
48166058|NCT02591914|DRUG|Avastin®|Anti-VEGF
48166059|NCT02591914|DRUG|Eylea®|Anti-VEGF
48166060|NCT01489462|BEHAVIORAL|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
48166061|NCT01489462|BEHAVIORAL|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
48369610|NCT00876902|DRUG|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
48369611|NCT05433116|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy
48514315|NCT00146276|DRUG|gemcitabine|
48695159|NCT06540911|OTHER|Non-personalized physical back training program|The control intervention is a 4-week non-personalized physical back training program. The control intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.
48166062|NCT01489462|BEHAVIORAL|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
48166063|NCT01470105|OTHER|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
48166064|NCT05427019|PROCEDURE|Distal adductor canal block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
48166065|NCT05427019|PROCEDURE|Distal adductor canal block and Periarticular block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
48166066|NCT04377412|OTHER|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
48166067|NCT04156178|BIOLOGICAL|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
48166068|NCT03494985|DEVICE|Experimental Oralbalance Moisturizing Gel|Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
48166069|NCT03494985|DEVICE|Biotene Original Oral Rinse|Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
48166070|NCT03494985|DEVICE|Biotene Moisturizing Mouth Spray|Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
48166071|NCT03494985|OTHER|Water|Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
48166072|NCT05157568|BEHAVIORAL|Exercise Streaming (ES)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. No equipment is required. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
48369612|NCT05433116|DRUG|Lenvatinib|20mg once daily orally, start concomitant to cycle 2 of pembrolizumab
48369613|NCT04322552|DRUG|Apatinib Mesylate|Apatinib at a dosage of will be administered daily from on D5 through D16
48369614|NCT04322552|DRUG|Digoxin tablet|Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
48514316|NCT05321004|OTHER|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
48514317|NCT00351455|BEHAVIORAL|smoking cessation|
48695160|NCT06167291|RADIATION|Arm 1- Ipsilateral|Given by I-RT
48695161|NCT03772028|DRUG|cisplatin|HIPEC with cisplatin after cytoreductive surgery
48369615|NCT01493440|DRUG|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
48514318|NCT00351455|BEHAVIORAL|tighter diabetic control|
48514319|NCT00351455|BEHAVIORAL|diet and exercise program|
48514320|NCT03094637|DRUG|Azacitidine|Given IV
48514321|NCT03094637|BIOLOGICAL|Pembrolizumab|Given IV
48514322|NCT01822106|OTHER|Placebo|
48522685|NCT06577818|PROCEDURE|CC+SI (Chest compression during sustained inflation)|CC+SI (Chest compression during sustained inflation)
48522686|NCT06577818|PROCEDURE|3:1 C:V (3:1 Compression:Ventilation ratio)|"3:1 C:V Group (Control group - Standard of Care): Newborns randomized to 3:1 C:V will receive a CC rate of 90/min and 30 ventilations/min as per current resuscitation guidelines. The PIP used for the 30 inflations will also be 30cmH2O) as per current resuscitation guidelines. Every 60sec, a HR assessment as per neonatal guidelines will be performed to assess if HR is \<60/min - continue CC or \>60/min - stop CC (current standard of care). 3:1 C:V will be continued until ROSC."
48522687|NCT04809532|PROCEDURE|Transverse abdominis plane (TAP) block|Ultrasound guide bilateral TAP block at end of cesarean section
48522688|NCT04809532|DRUG|Bupivacain|20ml 0.25% bupvicaine
48522689|NCT04809532|DRUG|Tramadol|intravenous tramadol
48522690|NCT04864067|DRUG|Oxaliplatin|Consolidation Chemotherapy
48522691|NCT04864067|DRUG|5-Fluoracil|Consolidation Chemotherapy
48522692|NCT04864067|DRUG|Leucovorin|Consolidation Chemotherapy
48166073|NCT05157568|BEHAVIORAL|Exercise Streaming + Equipment (ES+E)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. Each participant will have a stationary exercise bike delivered to their home for use during their live classes. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
48166074|NCT05157568|BEHAVIORAL|Control|Participants will complete 8 weeks (1 class per week) of in-person supervised exercise.
48166075|NCT01517490|OTHER|Insulin pump|Insulin pump therapy
48166076|NCT01517490|OTHER|Multiple daily insulin injections|Multiple daily insulin injections
48166077|NCT01517490|PROCEDURE|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
48166078|NCT01517490|OTHER|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
48166079|NCT00541840|DRUG|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
48166080|NCT05534464|OTHER|Milk|Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
48166081|NCT05534464|OTHER|Sorghum|Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
48514323|NCT06171828|DEVICE|Head-Mounted Display (HMD) to communicate with a supervisor remotely|Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
48514324|NCT03672253|DRUG|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
48695162|NCT05793255|BEHAVIORAL|Social Phone Calls|Following the collection of baseline data, the study participant will be randomly assigned to a student volunteer to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6weeks. Each phone call is expected to last around 1 hour with flexibility to be shorter or longer. The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer. If the stroke survivor and student volunteer wish to speak more than the designated one call a week, that will be allowed if both parties agree. The same student volunteer will conduct all six sessions
48166082|NCT05534464|OTHER|Black beans|Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
48166083|NCT01887990|DRUG|Ketamine|single dose IV 0.2 mg/kg ketamine
48166084|NCT01887990|DRUG|placebo|saline infusion
48166085|NCT02847637|DRUG|Emicizumab|Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
48166086|NCT02847637|DRUG|Factor VIII (FVIII)|FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
48166087|NCT03130816|BIOLOGICAL|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
48166088|NCT04564859|DEVICE|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
48166089|NCT01020942|PROCEDURE|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
48166090|NCT01020942|PROCEDURE|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
48166091|NCT02096809|PROCEDURE|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
48166092|NCT02096809|DEVICE|Cochlear Baha BI300/BA400 Implant System|
48166093|NCT01680302|BEHAVIORAL|High intensity exercise|
48166094|NCT01680302|BEHAVIORAL|Moderate intensity exercise|
48514325|NCT03076775|OTHER|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
48695163|NCT03621176|OTHER|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
48695164|NCT03441035|OTHER|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
48695165|NCT03524963|DRUG|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
48695166|NCT03524963|DRUG|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
48695167|NCT06285318|OTHER|Teclistamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into Case Report Form (CRF).
48695168|NCT06285318|OTHER|Talquetamab|No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
48166095|NCT01680302|BEHAVIORAL|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
48166096|NCT05087329|BEHAVIORAL|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
48166097|NCT00196118|DEVICE|Günther Tulip Vena Cava Filter|
48369616|NCT03383406|DRUG|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion."
48369617|NCT05864105|BIOLOGICAL|PM8002|PM8002 20mg/kg Q2W
48369618|NCT05864105|DRUG|FOLFOX regimen|day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
48369619|NCT06452485|OTHER|No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.|Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
48369620|NCT02626962|DRUG|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
48369621|NCT02626962|DRUG|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
48695169|NCT05053321|DRUG|Valbenazine|All participants will be treated with Valbenazine for 7 weeks.
48695170|NCT00675623|DRUG|Dimebon|Dimebon, 5 mg orally three times daily for six months
48695171|NCT00675623|DRUG|Dimebon|Dimebon 20 mg orally three times daily for six months
48008799|NCT06278675|DEVICE|Acupuncture needles|"1. Experimental group: Sterile stainless steel needle electroacupuncture treatment was applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days.~2. Control group: Placebo needles were applied, and the acupuncture points were as follows: bilateral Zusanli (ST36), Neiguan (PC6), Hegu (LI4), Shaoshang (LU11), and Feng Long (ST40). 1 time a day, 30 minutes each time, for 7 days."
48008800|NCT00352612|DRUG|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
48008801|NCT00352612|DRUG|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
48369622|NCT03433443|BEHAVIORAL|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
48369623|NCT03433443|BEHAVIORAL|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
48369624|NCT02716402|RADIATION|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
48369625|NCT01990417|OTHER|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
48369626|NCT03176979|OTHER|Contrast Agent|Given IV
48369627|NCT03176979|PROCEDURE|Digital Tomosynthesis Mammography|Undergo CESM with DBT
48369628|NCT03176979|PROCEDURE|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
48369629|NCT00002021|DRUG|Foscarnet sodium|
48369630|NCT02132065|DRUG|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
48369631|NCT05630742|OTHER|chronic non-neoplastic pain|comparison of questionnaires scores
48369632|NCT00993382|DRUG|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
48369633|NCT00993382|DRUG|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
48369634|NCT00993382|DRUG|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
48369635|NCT00239694|BIOLOGICAL|Pneumococcal Vaccine|One time preventative vaccine
48369636|NCT00239694|BIOLOGICAL|Meningococcal Vaccine|One time preventative vaccine
48369637|NCT06198179|OTHER|upper limb children action-observation training (UPCAT)|upper limb children action-observation training (UPCAT) without visual Feedback
48369638|NCT06198179|OTHER|upper limb children action-observation training (UP-CAT) with visual feedback|upper limb children action-observation training (UP-CAT) with visual feedback: Mirror therapy as visual feedback
48008802|NCT01879696|DEVICE|ECSPRESS catheter with active vacuum|
48008803|NCT03992807|OTHER|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
48369639|NCT02531282|BEHAVIORAL|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
48522693|NCT04864067|DRUG|Capecitabine|Consolidation Chemotherapy
48695172|NCT00675623|DRUG|Placebo|Placebo three times daily for six months
48695173|NCT06601699|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
48008804|NCT03992807|OTHER|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
48008805|NCT02496780|DRUG|novolog insulin|3x daily rapid-acting insulin
48008806|NCT02496780|DRUG|levemir insulin|basal insulin once a day
48008807|NCT02496780|DRUG|placebo|once or 3x daily
48008808|NCT00002816|DRUG|cytarabine|Given IV
48369640|NCT02531282|BEHAVIORAL|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
48369641|NCT05981560|OTHER|Group A - Closed Chain Exercise|17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks
48369642|NCT05981560|OTHER|Group B - Neuromuscular Training Exercise|17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
48695174|NCT06601699|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
48008809|NCT00002816|DRUG|dexamethasone|Given IV
48369643|NCT02576106|DEVICE|Cryoablation|
48369644|NCT00516945|DRUG|Lamivudine|
48369645|NCT04391660|DRUG|0.5% sodium hypochlorite solution|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.
48369646|NCT04391660|DRUG|0.5% sodium hypochlorite solution and 70% ethanol|Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
48369647|NCT00648765|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
48369648|NCT00648765|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fed
48369649|NCT02933333|BIOLOGICAL|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
48369650|NCT02933333|BIOLOGICAL|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
48369651|NCT02933333|BIOLOGICAL|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
48008810|NCT00002816|DRUG|etoposide|Given IV
48369652|NCT02038244|OTHER|Multimodal integrative medicine inpatient treatment program|
48369653|NCT05105958|DRUG|Tideglusib|1000 mg/day per os
48514326|NCT03420586|DRUG|Nitrous Oxide|The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
48514327|NCT04623892|DRUG|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
48514328|NCT04096040|DEVICE|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
48514329|NCT06462755|OTHER|No intervention|no intervention
48522694|NCT04864067|RADIATION|5x5 Gy|Neoadjuvant Radiotherapy
48695175|NCT04354077|DEVICE|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
48522695|NCT04864067|BEHAVIORAL|Quality of Life Questionnaires|Quality of Life Evaluation (LARS Score, IIEF, FSFI, I-PSS and EORTC QLQ-C30)
48695176|NCT03347526|DRUG|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
48008811|NCT00002816|DRUG|idarubicin|Given IV
48008812|NCT00002816|DRUG|ifosfamide|Given IV
48008813|NCT00002816|DRUG|leucovorin calcium|
48008814|NCT00002816|DRUG|mesna|Given IV
48008815|NCT00002816|DRUG|pegaspargase|Given IV
48008816|NCT00002816|DRUG|therapeutic hydrocortisone|
48008817|NCT00002816|DRUG|thioguanine|
48008818|NCT00002816|DRUG|vincristine sulfate|Given IV
48008819|NCT00002816|RADIATION|low-LET cobalt-60 gamma ray therapy|
48008820|NCT00002816|RADIATION|low-LET electron therapy|
48008821|NCT00002816|RADIATION|low-LET photon therapy|
48008822|NCT00002816|DRUG|Methotrexate|Given IV
48008823|NCT03906318|DRUG|Iticitinib|
48008824|NCT01251484|DRUG|BIBF1120|Tablet 200 mg twice daily until progression
48008825|NCT00028756|DRUG|doxorubicin hydrochloride|Given IV
48369654|NCT04717700|DRUG|Selinexor 20 MG Oral Tablet|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
48369655|NCT04717700|DRUG|Bortezomib Injection|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
48369656|NCT04717700|DRUG|Lenalidomide capsule|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
48369657|NCT04717700|DRUG|Dexamethasone Oral|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
48695177|NCT03347526|DRUG|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
48695178|NCT03347526|DRUG|Vigabatrin|oral
48695179|NCT02894723|DIETARY_SUPPLEMENT|L-arginine|30 ml arginoline contains 5 gr l-arginine
48695180|NCT02894723|DIETARY_SUPPLEMENT|syrup|The same bottle of the experimental group, but without l-arginine
48514330|NCT00610246|DRUG|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
48514331|NCT02976948|OTHER|No intervention|
48514332|NCT00324987|BIOLOGICAL|Bevacizumab|Given IV
48514333|NCT00324987|DRUG|Imatinib Mesylate|Given PO
48514334|NCT00324987|OTHER|Laboratory Biomarker Analysis|Correlative studies
48514335|NCT00324987|OTHER|Pharmacological Study|Correlative studies
48514336|NCT02391987|DEVICE|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
48514337|NCT01420965|DRUG|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
48514338|NCT01420965|OTHER|Sipuleucel-T (Provenge)|Vaccine
48514339|NCT01420965|DRUG|Cyclophosphamide|Low dose- Immune Enhancer
48514340|NCT00683657|DRUG|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
48514341|NCT00683657|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
48514342|NCT00402116|DRUG|enzastaurin|"Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles~Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles"
48514343|NCT00402116|DRUG|temozolomide|75 milligrams per meter squared (mg/m\^2), oral, daily, 6 weeks then 200 mg/m\^2, oral, daily, twelve 28 day cycles
48514344|NCT00402116|RADIATION|radiation therapy|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
48514345|NCT02641158|OTHER|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
48514346|NCT02641158|BEHAVIORAL|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
48514347|NCT05904002|DRUG|pulmicort inhaler|Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
48008826|NCT00028756|DRUG|gemcitabine hydrochloride|Given IV
48369658|NCT03871803|DRUG|Controlled withdrawal of beta-blockers|Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
48369659|NCT03871803|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
48514348|NCT05904002|DEVICE|Incentive spirometer treatment|Each patient in group B will be instructed about the effects of incentive spirometer to gain their cooperation during the study course.
48514349|NCT04884373|DIAGNOSTIC_TEST|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
48514350|NCT02171195|DRUG|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
48514351|NCT02171195|DRUG|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
48514352|NCT03924687|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain|"The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/)."
48514353|NCT00442962|DRUG|Efavirenz|600-mg tablet taken orally daily
48514354|NCT00442962|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
48514355|NCT06226181|PROCEDURE|Dacryocystorhinostomy and amniotic membrane|Dacryocystorhinostomy surgery with amniotic membrane placement on the osteotomy site.
48369660|NCT02491918|PROCEDURE|cataract surgery|cataract surgery in children
48369661|NCT02491918|PROCEDURE|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
48514356|NCT06226181|PROCEDURE|Conventional dacryocystorhinostomy|Conventional dacryocystorhinostomy surgery without adding amniotic membrane
48008827|NCT00028756|DRUG|vinblastine sulfate|Given IV
48008828|NCT00028756|DRUG|methotrexate|Given IV
48008829|NCT00028756|DRUG|cisplatin|Given IV
48008830|NCT00028756|BIOLOGICAL|filgrastim|Given SC
48369662|NCT03793517|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
48514357|NCT04577664|PROCEDURE|total thyroidectomy|a total thyroidectomy (TT) in which the entire gland is removed
48514358|NCT04577664|PROCEDURE|subtotal thyroidectomy|subtotal thyroidectomy (STT) , in which most of the gland is removed leaving a small unilateral or bilateral remnant in situ about 4-5 grams.
48514359|NCT01111318|DRUG|BI 10773|2 tablets BI 10773 25 mg single dose
48514360|NCT00805675|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
48008831|NCT00443183|BEHAVIORAL|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
48166098|NCT06545721|OTHER|Adjusting dietary structure + exercise + behavioral intervention|Adjusting to a healthy diet involves consuming low GI and low-fat foods, avoiding sugary drinks, increasing dietary fiber intake, reducing saturated fat while increasing omega-3 unsaturated fat intake, and limiting trans fat consumption. A weight loss program includes a high-protein diet, exercise, and behavioral intervention with daily total energy needs calculated based on ideal body weight (kg) x 15-20 kcal/kg/d; developing a daily meal plan with regular protein supplementation; limiting salt intake to ≤5 g/d; ensuring adequate water consumption at 2-3L/d; aiming for a dietary fiber intake of 25-30g/d; recommending micronutrient supplementation as needed; maintaining daily aerobic exercise (40 minutes at 70-80% HRmax) along with resistance training (20 minutes); establishing an early bedtime before 11pm and an early wake-up time.
48166099|NCT00507975|DRUG|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
48166100|NCT00760877|DRUG|Nilotinib|Supplied in 200 mg capsules
48166101|NCT00760877|DRUG|Imatinib|Supplied in 100 mg and 400 mg capsules
48166102|NCT02001389|DRUG|EVP-6308|Arms 1, 2, 3, 4
48166103|NCT05683886|DRUG|KC1036|Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
48695181|NCT03938103|BEHAVIORAL|Enhanced Go NAPSACC|In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
48008832|NCT00443183|BEHAVIORAL|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
48008833|NCT01211275|BIOLOGICAL|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
48008834|NCT01211275|DRUG|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
48008835|NCT02479854|DRUG|Asmakast|1 chewable tablet contains 5 mg montelukast
48008836|NCT02479854|DRUG|Singulair|1 chewable tablet contains 5 mg montelukast
48008837|NCT03646721|DRUG|DA-1241|"\[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
48008838|NCT03646721|DRUG|Placebo|\[Part1\] Administration once daily for 28 days. \[Part2\] Administration once daily for 56 days.
48008839|NCT03646721|DRUG|Sitagliptin|\[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
48008840|NCT00820001|BEHAVIORAL|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
48008841|NCT00820001|BEHAVIORAL|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
48008842|NCT00820001|OTHER|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
48008843|NCT00820001|OTHER|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
48008844|NCT02993679|PROCEDURE|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
48008845|NCT02684227|DRUG|Carboplatin|Given IV
48008846|NCT02684227|DRUG|Enzalutamide|Given PO
48008847|NCT02684227|OTHER|Laboratory Biomarker Analysis|Correlative studies
48166104|NCT01171885|DRUG|0.9% saline|20 ml of 0.9% saline
48166105|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.25%.
48166106|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.5%.
48514361|NCT00805675|DRUG|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
48522696|NCT04864067|PROCEDURE|DRE/ Endoscopy|Flexible Sigmoidoscopy and Digital Rectal Exam
48166107|NCT05335577|DIAGNOSTIC_TEST|Urinary Claudin-2|A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
48166108|NCT05335577|DIAGNOSTIC_TEST|Urinary Caveolin-1|A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
48166109|NCT05335577|DIAGNOSTIC_TEST|Urinary EGF|A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
48166110|NCT05335239|OTHER|Professional dental cleaning|The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (\> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (\> 4000 ppm) and relevant interproximal aids.
48166111|NCT01828593|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
48514362|NCT00805675|DRUG|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
48514363|NCT00486525|PROCEDURE|Yoga Therapy|Patients will undergo yoga therapy
48514364|NCT01258309|DRUG|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
48166112|NCT01828593|OTHER|Placebo|Matching placebo
48166113|NCT03705988|DEVICE|Cranial Electrotherapy Stimulation(CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA\~2mA.
48514365|NCT01258309|DRUG|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
48514366|NCT02460146|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
48514367|NCT02460146|OTHER|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
48695182|NCT03938103|BEHAVIORAL|Basic Go NAPSACC|In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
48695183|NCT04597359|DRUG|Placebo Administration|Given PO
48695184|NCT04597359|OTHER|Quality-of-Life Assessment|Ancillary studies
48695185|NCT04597359|OTHER|Questionnaire Administration|Ancillary studies
48695186|NCT04597359|DRUG|Sinecatechins|Given PO
48695187|NCT04624386|OTHER|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
48695188|NCT00040781|DRUG|gefitinib|Given orally
48695189|NCT00040781|OTHER|pharmacological study|Correlative studies
48695190|NCT00040781|OTHER|laboratory biomarker analysis|Correlative studies
48695191|NCT04606706|OTHER|Mobile health nutrition education intervention|Nutrition education will be given through mobile phone
48695192|NCT06274034|OTHER|Electronic Health Record Review|Ancillary studies
48695193|NCT06274034|OTHER|Medical Device Usage and Evaluation|Wear MUSE S headband
48695194|NCT06274034|PROCEDURE|Meditation Therapy|Participate in meditation
48695195|NCT06274034|OTHER|Survey Administration|Ancillary studies
48695196|NCT01928589|OTHER|PBI with sequential chemotherapy|270 cGy x15
48695197|NCT01928589|OTHER|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
48695198|NCT00093899|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
48008848|NCT02684227|DRUG|Paclitaxel|Given IV
48008849|NCT02684227|OTHER|Pharmacological Study|Correlative studies
48514368|NCT00237978|DRUG|Adapalen|
48514369|NCT00237978|RADIATION|VIS and wIRA|
48514370|NCT02646605|OTHER|depression screening|Patient Health Questionnaire
48514371|NCT00477633|DRUG|Norethindrone/ethinyl estradiol|1 tablet per day
48514372|NCT03865927|OTHER|Placebo Oral Tablet|see Arm/Group description
48514373|NCT03865927|DRUG|GKT137831|GKT137831 is a NOX enzyme inhibitor
48514374|NCT06500325|PROCEDURE|retrograde titanium elastic nails for fixation of proximal third tibial shaft fractures in children|Two TENs were used in all cases using the double-C construct in most cases to gain three point of fixation. The starting point for nail insertion is 1.5-2.0 cm proximal to the physis of distal tibia. Both nails are then inserted through the entry holes and advanced to pass the level of the fracture site to achieve fixation. The two incisions for nail entry are closed in a layered fashion, and the wounds are well padded with gauze.
48514375|NCT04292288|DIAGNOSTIC_TEST|Biochemical observational|no intervention - observational
48514376|NCT02871544|OTHER|BNP and NGAL|
48514377|NCT02441725|OTHER|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
48514378|NCT00511641|BEHAVIORAL|Questionnaire|Questionnaires lasting up to 30 minutes.
48695199|NCT06389721|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|Measure the electrical activity of your brain before you receive chemotherapy treatment and once monthly for a maximum of 6 measurements.
48695200|NCT02390440|DRUG|EXPAREL|
48695201|NCT05799521|DRUG|Optate|Alkaline Buffer
48695202|NCT05799521|DRUG|Placebo|Normal Saline
48166114|NCT03705988|DEVICE|sham Cranial Electrotherapy Stimulation( sham CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
48369663|NCT03793517|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
48369664|NCT03793517|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
48369665|NCT00852800|DRUG|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
48514379|NCT05865548|DRUG|Aspirin 150 mg|Aspirin 150 mg PO daily
48514380|NCT05865548|PROCEDURE|Standard of care|Surgery with or without radiation, palliative chemo as per investigators choice
48695203|NCT05610826|PROCEDURE|cytoreductive surgery|Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
48695204|NCT05610826|DRUG|Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)|"PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood."
48695205|NCT05610826|PROCEDURE|Peptide receptor radionuclide therapy (PRRT)|PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
48008850|NCT04788914|DIETARY_SUPPLEMENT|Active bamboo charcoal± probiotics|Active bamboo charcoal 2g, TID probiotics 0.8g
48008851|NCT00004903|BIOLOGICAL|filgrastim|
48008852|NCT00004903|BIOLOGICAL|recombinant interferon alfa|
48008853|NCT00004903|DRUG|cisplatin|
48008854|NCT00004903|DRUG|cyclophosphamide|
48695206|NCT03408418|PROCEDURE|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
48695207|NCT02014506|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -2
48695208|NCT02014506|DRUG|Cyclophosphamide|50 mg/kg IV on day -3 and -2
48695209|NCT02014506|BIOLOGICAL|anti-thymocyte globulin|
48695210|NCT02014506|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
48695211|NCT02014506|RADIATION|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)
48695212|NCT02014506|PROCEDURE|TCRαβ-depleted hematopoietic cell transplantation|
48695213|NCT02014506|DEVICE|CliniMACS|Immunogenetic depletion of TCRαβ cells
48695214|NCT06598670|OTHER|tDCS|tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days
48695215|NCT06598670|OTHER|Conventional treatment|Breathing exercises will be performed
48695216|NCT03788642|PROCEDURE|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
48695217|NCT03788642|PROCEDURE|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
48008855|NCT00004903|DRUG|cytarabine|
48008856|NCT00004903|DRUG|etoposide|
48008857|NCT00004903|DRUG|melphalan|
48008858|NCT00004903|PROCEDURE|peripheral blood stem cell transplantation|
48008859|NCT05996861|BEHAVIORAL|ICU sleep protocol|"Adjusting sound intensity, as well as reducing noise: efforts will be made to minimize staff conversation volume during the night.~Earplugs will be offered, along with the provision of eye masks for lucid patients, and thermal comfort adjustments will be made, such as providing blankets and/or adjusting room temperature.~Dimming of lights starting from 10 PM. Reduced circulation of external services between 11 PM and 6 AM, and rationalization of sample collections and/or patient transfers between beds during the 11 PM to 6 AM interval.~Optimization of analgesics for better pain control; optimization of medication use during wakefulness when clinically feasible; adjustment of intervals for capillary blood glucose measurement; maintaining and/or resuming the use of chronic sleep medications. If the patient has been unable to sleep, a hypnotic medication will be offered.~Other considerations include suggesting ventilatory support measures for selected patients."
48008860|NCT05624099|DRUG|camrelizumab|200mg intravenous drip d1q3w
48008861|NCT05624099|DRUG|Paclitaxel drugs|150mg/m2 d1 q3w
48008862|NCT05624099|DRUG|Platinum drug|Cisplatin, carboplatin, nedaplatin and other platinum drugs
48008863|NCT05624099|RADIATION|Radiation|Dose: 5040cGy/28f
48166115|NCT03752489|DIAGNOSTIC_TEST|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
48166116|NCT03752489|DIAGNOSTIC_TEST|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
48166117|NCT00120822|DRUG|Folic acid|
48166118|NCT04975932|OTHER|TACE+ICIs|TACE plus ICIs ( with or without molecular targeted therapies)
48166119|NCT04975932|PROCEDURE|TACE|TACE without combination of ICIs ( with or without molecular targeted therapies)
48166120|NCT05740969|DRUG|5Fluorouracil|Cream
48166121|NCT05740969|DRUG|Imiquimod|Cream
48166122|NCT05740969|DRUG|Melatonin|Cream
48166123|NCT06330233|OTHER|Moxibustion|"The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control.~The conventional treatment group received mecobalamin tablets and epastat orally for four weeks along with their daily treatment.~Moxibustion 15 minutes group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11) and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment.~Moxibustion 15 minutes group of Part Two will use the same intervention as above.~Moxibustion 30 minutes group: Except for the operating time others are the same as the Moxibustion 15 minutes group."
48166124|NCT00931918|DRUG|Bortezomib|Bortezomib IV
48369666|NCT00852800|DRUG|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
48008864|NCT01563575|OTHER|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
48166125|NCT00931918|DRUG|Rituximab|Rituximab IV
48166126|NCT00931918|DRUG|Cyclophosphamide|Cyclophosphamide IV
48166127|NCT00931918|DRUG|Doxorubicin|Doxorubicin IV solution
48166128|NCT00931918|DRUG|Vincristine|Vincristine IV
48166129|NCT00931918|DRUG|Prednisone|Prednisone tablet
48166130|NCT05818436|PROCEDURE|Procedure: prosthetic functioning|Prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts
48166131|NCT05818436|DEVICE|Conventional dental prosthesis|: conventional prosthetic treatment new prosthesis
48369667|NCT04914182|RADIATION|LASER|Laser will be applied in specific points for perineal lacerations.
48369668|NCT04914182|RADIATION|CONTROL|"A control group of sham laser will create for the patients the impression that laser is being played, with the lights of the instrument of on mode turned on, without biological effects."
48008865|NCT01813565|DRUG|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
48166132|NCT02810483|DRUG|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
48166133|NCT02810483|DRUG|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
48166134|NCT03280108|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
48166135|NCT03280108|DEVICE|AcrySof Monofocal IOL|AcrySof Monofocal IOL Model SN60AT for single vision
48166136|NCT04103905|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
48166137|NCT03861585|OTHER|Semantic group|"The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial."
48166138|NCT03861585|OTHER|Emotional group|"The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial."
48166139|NCT06194318|BIOLOGICAL|Candidate vaccine, SCB-1019|The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
48166140|NCT06194318|BIOLOGICAL|placebo|placebo
48166141|NCT04165525|DEVICE|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
48166142|NCT06647199|PROCEDURE|the plaque index (PI)|Peri-implant soft tissue changes as regards plaque was assessed employing the modiﬁed plaque index (PI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
48166143|NCT06647199|PROCEDURE|the bleeding index (BI)|Peri-implant tissue changes as bleeding score was assessed employing the bleeding index (BI) . Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
48166144|NCT06647199|PROCEDURE|simpliﬁed gingival index(GI),|Peri-implant soft tissue changes as regards gingival scores was assessed simpliﬁed gingival index(GI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD
48166145|NCT02679547|OTHER|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
48166146|NCT00935649|DEVICE|PinPointe FootLaser|Medical laser
48166147|NCT00002432|DRUG|Foscarnet sodium|
48695218|NCT03807791|PROCEDURE|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
48695219|NCT05282030|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablets Route of administration: oral
48695220|NCT06553651|DEVICE|Cryotechnology Necrosectomy Procedure|Subjects undergo necrosectomy with 1.7 mm flexible cryoprobes, either concurrently with stent placement or post-placement, at the Investigator's discretion. The cryoprobe will freeze the necrotic tissue and extracted en-bloc. A maximum of 4 cryotechnology procedures will be performed, with each procedure aiming for significant debris removal and clinical improvement of walled-off pancreatic necrosis (WOPN) symptoms.
48695221|NCT05354895|DEVICE|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
48695222|NCT02709551|BEHAVIORAL|HRV_Bfb|
48695223|NCT02709551|BEHAVIORAL|MBI|
48695224|NCT02709551|BEHAVIORAL|MBI_HRV_Bfb|
48695225|NCT01656005|DRUG|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
48695226|NCT01656005|DRUG|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
48695227|NCT01656005|DRUG|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
48695228|NCT01656005|DRUG|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
48166148|NCT06479551|OTHER|high intensity-low volume resistance training|13 participants will be in experimental group giving them High intensity-low volume resistance training protocol of 4 reps and 2 sets comprising 90% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
48166149|NCT06479551|OTHER|Moderate intensity-high volume resistance training|13 participants will be in control group giving them Moderate intensity-high volume resistance training of 8 reps and 3 sets comprising 80% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
48166150|NCT02181998|DRUG|Full dose tenecteplase|
48166151|NCT02181998|DRUG|Unfractioned heparin|
48166152|NCT02181998|DRUG|Enoxaparin|
48166153|NCT01837719|DRUG|Atazanavir|300-mg capsule
48166154|NCT01837719|DRUG|Cobicistat|150-mg tablet
48166155|NCT01837719|DRUG|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
48166156|NCT04794894|BEHAVIORAL|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
48695229|NCT01656005|DRUG|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
48695230|NCT04961528|DRUG|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days"
48166157|NCT03439397|DEVICE|Ballon Technique|Ballon Technique
48166158|NCT03439397|DEVICE|SOAI|SOAI
48008866|NCT01860261|BEHAVIORAL|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
48008867|NCT01310322|DRUG|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
48008868|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
48008869|NCT01310322|DRUG|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
48008870|NCT01310322|DRUG|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
48008871|NCT02961426|DRUG|sofosbuvir + ravidasvir|combination of sofosbuvir + ravidasvir
48008872|NCT05035017|DEVICE|Test Lens|Daily disposable with modified lens design for 2 days
48008873|NCT05035017|DEVICE|Control Lens|Daily disposable lens for 2 days
48008874|NCT02136875|DRUG|Double dose of Salmeterol + Fluticasone Propionate|
48008875|NCT02136875|BEHAVIORAL|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
48008876|NCT02136875|DRUG|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
48008877|NCT00787410|DRUG|ZD1839|250mg tablet, once daily, orally administered
48008878|NCT05310266|PROCEDURE|Transversus abdominis plane block|The investigators performed transversus abdominis plane block to that patient group for postoperative analgesia
48008879|NCT05310266|PROCEDURE|Quadratus Lumborum Block|The investigators performed quadratus lumborum block to that patient group for postoperative analgesia
48008880|NCT04905251|DRUG|Mifepristone-Misoprostol|Non interventional design.
48008881|NCT03567863|DEVICE|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
48695231|NCT04961528|DRUG|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days"
48695232|NCT04961528|DRUG|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days."
48695233|NCT02339142|RADIATION|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
48695234|NCT02339142|DRUG|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
48695235|NCT04982328|DIAGNOSTIC_TEST|Th17 cytokine profile|Screening for the components of metabolic syndrome
48695236|NCT04982328|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
48695237|NCT04982328|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
48695238|NCT04086693|DEVICE|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
48695239|NCT04086693|DEVICE|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
48695240|NCT05683938|DEVICE|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
48695241|NCT04784052|DRUG|JSP191|Participants will receive a single IV dose at start of conditioning
48695242|NCT04784052|DEVICE|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
48695243|NCT04784052|BIOLOGICAL|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
48695244|NCT04784052|BIOLOGICAL|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
48695245|NCT04784052|DRUG|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
48695246|NCT04784052|DRUG|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
48695247|NCT04784052|DRUG|Rituximab|1 dose of rituximab will be given at the end of conditioning
48695248|NCT02503670|BEHAVIORAL|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
48695249|NCT02503670|OTHER|Control Group|Continue with standard care.
48695250|NCT01487174|DRUG|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
48695251|NCT01487174|DRUG|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
48695252|NCT04815512|DIAGNOSTIC_TEST|Liver function tests.|serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
48369669|NCT05299905|PROCEDURE|Virtual reality using Semi-CAVE|The Semi-CAVE will use two screens positioned at a corner of the room, each with a ceiling-mounted short throw projector in front. The participant will stand in the middle of the area, giving them a viewing angle of roughly 180 degrees. The participant will be wearing a safety harness secured to an overhead guide rail, if necessary. The participant may be standing freely, on a treadmill, or on a step stool depending on the type of activity to be performed. The participant will interact with the system through motion sensors positioned at the corners of the area. To one side of the area will be a sufficiently powerful computer running the software. The projectors will be connected to this computer via HDMI cables or similar.
48369670|NCT05299905|PROCEDURE|Virtual reality using the HMD|The HMD will be a commercially available device that uses handheld controllers to control movement while in the VE. The researchers will use a room-scale set-up where a 3 m x 3 m square space is required. Oculus Quest 2 Controllers will be used to interact with the VE. The user will be positioned at the center of the square by default. A therapist will assist them through a separate program called the Observation Module. This program will let the therapist view what the patient can see in the HMD. This will also be used by the therapist to guide the patient navigate through the VE and give instructions for the activities.
48166159|NCT04998097|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
48369671|NCT06518330|DRUG|Intake of Methylphenidate|Intake of Methylphenidate
48369672|NCT04162873|DRUG|Celecoxib|Given PO or via feeding tube
48369673|NCT04162873|OTHER|Placebo|Given PO or via feeding tube
48369674|NCT04162873|OTHER|Quality-of-Life Assessment|Ancillary studies
48369675|NCT04162873|OTHER|Questionnaire Administration|Ancillary studies
48369676|NCT00985114|DEVICE|EndoBarrier|EndoBarrier implant
48695253|NCT04815512|DIAGNOSTIC_TEST|kidney function tests|creatinine , urea and serum uric acid will be analysed in the serum.
48695254|NCT05460052|OTHER|Physical activity training program|"The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference."
48695255|NCT05460052|OTHER|Weekly phone call.|Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
48695256|NCT05460052|OTHER|Personalized training plan.|After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
48695257|NCT01956097|DIETARY_SUPPLEMENT|HX106 590mg|
48008882|NCT03567863|DEVICE|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
48695258|NCT01956097|DIETARY_SUPPLEMENT|HX106 1180mg|
48695259|NCT01956097|DIETARY_SUPPLEMENT|Placebo|
48695260|NCT02379988|RADIATION|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
48695261|NCT02331589|DRUG|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
48695262|NCT02331589|DRUG|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
48166160|NCT04998097|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
48369677|NCT00985114|BEHAVIORAL|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
48369678|NCT01130220|OTHER|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
48369679|NCT03025295|DRUG|Dexmedetomidine|Dexmedetomidine is common used to improve the prognosis and life quality of patients.
48369680|NCT03025295|DRUG|Saline|It is safe Placebo.
48369681|NCT05499546|DEVICE|SCALE EYE|Polyp size measurement using the SCALE EYE functionality
48369682|NCT06219499|DRUG|ONC-841|ONC-841 is a humanized monoclonal antibody.
48695263|NCT00979342|DEVICE|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
48695264|NCT04884217|DRUG|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
48695265|NCT04884217|DRUG|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
48695266|NCT06661408|BEHAVIORAL|Intervention group 1|The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
48695267|NCT06661408|BEHAVIORAL|Intervention group 2|In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
48695268|NCT00765037|DEVICE|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
48008883|NCT04990986|OTHER|Complex intervention|Will be co-developed during the study.
48008884|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
48008885|NCT00560261|OTHER|NO-CO inhalation and expiration|NO-CO inhalation and expiration
48008886|NCT01506531|PROCEDURE|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
48008887|NCT01506531|PROCEDURE|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
48008888|NCT04933591|DRUG|Diosmin / Hesperidin|Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
48008889|NCT05067933|DRUG|VXA-CoV2-1.1-S|COVID-19 (SARS-CoV-2) E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant Oral Tablet Vaccine
48008890|NCT05067933|OTHER|Placebo Tablets|Placebo tablets matching the active vaccine tablets
48008891|NCT00887900|PROCEDURE|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
48008892|NCT00887900|PROCEDURE|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
48008893|NCT04065724|OTHER|Physical training as resistance and aerobic training.|
48008894|NCT05731934|DRUG|HX301|At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
48008895|NCT01015846|OTHER|Exercise|Redcord (sling exercise) and traditional exercise
48008896|NCT01015846|OTHER|Core stability exercise|Traditional core stability exercise
48008897|NCT06371222|DRUG|Ivabradine|5 mg for 3 months
48008898|NCT06371222|DRUG|Beta blocker|controlled group
48008899|NCT05276804|DRUG|Sugammadex|The dosing for Sugammadex is 4mg/kg for a deep reversal and a 2mg/kg for a standard reversal, which will be more common for this study. Sugammadex comes in 200mg/2mL and 500mg/5mL vials. Because of the variability in weight of the patients and the type of reversal needed (deep vs standard), 140 5mL vials will be required.
48008900|NCT06409624|OTHER|No intervention is planned as part of the study|No intervention is planned as part of the study
48008901|NCT00578565|DRUG|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
48008902|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel,Carrelizumab|Conventional chemotherapy in combination with carrelizumab
48008903|NCT05862064|DRUG|epirubicin,cyclophosphamide,paclitaxel|Conventional chemotherapy
48008904|NCT04127760|RADIATION|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
48008905|NCT00514410|DRUG|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
48008906|NCT00514410|DRUG|Placebo|Matching placebo taken once a day for three months
48008907|NCT04268342|OTHER|Resistance guided treatment for gonorrhoea infection|For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment
48008908|NCT00000439|DRUG|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
48008909|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
48008910|NCT04070833|DRUG|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
48008911|NCT04070833|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
48008912|NCT04070833|DRUG|Fish oil placebo|Fish oil placebo
48008913|NCT05611086|DRUG|N-Acetylcysteine|Subjects in treatment group will be given capsules containing 600 mg of NAC
48008914|NCT05611086|DRUG|Placebo|subjects in the control group will be given capsules containing placebo (lactose)
48166161|NCT03606850|DEVICE|Measurements of markers of cortical excitability by TMS|"In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle."
48166162|NCT01174485|PROCEDURE|exercise|combined resistance and aerobic training
48166163|NCT04112875|DIETARY_SUPPLEMENT|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
48166164|NCT04112875|DIETARY_SUPPLEMENT|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
48166165|NCT04237623|DRUG|Sargramostim|250mcg/m2/day IV starting Day +5
48166166|NCT04237623|OTHER|Control Arm|Standard G-CSF given to those who decline to receive GM-CSF
48166167|NCT02724163|DRUG|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
48166168|NCT02724163|DRUG|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
48166169|NCT02724163|DRUG|Mitoxantrone|DNA-reactive agent
48166170|NCT02724163|DRUG|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
48166171|NCT02724163|DRUG|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
48166172|NCT02724163|DRUG|Busulfan|Alkylsulfonate
48369683|NCT06219499|OTHER|Placebo|Placebo
48369684|NCT04964882|DIAGNOSTIC_TEST|ultrasound examination of air insufflation in the upper esophageal region and stomach|Presence of air insufflation is assessed using ultrasound in the upper esophageal region and stomach during face mask ventilation
48369685|NCT01648517|DRUG|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
48695269|NCT00633568|DRUG|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
48008915|NCT00378014|DRUG|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
48369686|NCT01648517|DRUG|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
48369687|NCT04246918|DIETARY_SUPPLEMENT|Branched Chain Amino Acid|Branched chain amino acid is a group of three amino acids known for there role in muscle growth.
48008916|NCT00378014|DRUG|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
48008917|NCT00378014|DRUG|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
48008918|NCT00111228|DEVICE|Guardian RT|
48008919|NCT00111228|DEVICE|SMBG only|SMBG only
48166173|NCT02724163|DRUG|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
48166174|NCT06204614|DEVICE|Implantable Micro-Device|The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
48166175|NCT06204614|DRUG|Methotrexate|Methotrexate will be placed in reservoir 1 of the implantable microdevice.
48166176|NCT06204614|DRUG|Carboplatin|Carboplatin will be placed in reservoir 2 of the implantable microdevice.
48166177|NCT06204614|DRUG|Avelumab|Avelumab will be placed in reservoir 3 of the implantable microdevice.
48166178|NCT06204614|DRUG|Paclitaxel|Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
48166179|NCT06204614|DRUG|Vinblastine|Vinblastine will be placed in reservoir 5 of the implantable microdevice.
48166180|NCT06204614|DRUG|Gemcitabine/Cisplatin I|Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
48369688|NCT04246918|DIETARY_SUPPLEMENT|Whey Protein concentrate powder|Whey protein will be given to the standard treatment arm including in the same amount of 1.5gm/kg/IBW.
48369689|NCT02318641|DEVICE|oximetry|Retinal oximetry will be performed with Oxymap.
48369690|NCT04594213|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
48369691|NCT04594213|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
48695270|NCT00633568|DRUG|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
48695271|NCT00170768|DRUG|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
48695272|NCT00170768|DRUG|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
48695273|NCT00170768|DRUG|Placebo|Placebo once daily tablet (sham titration)
48166181|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
48166182|NCT06204614|DRUG|Gemcitabine/Cisplatin II|Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
48166183|NCT06204614|DRUG|Cisplatin|Cisplatin will be placed in reservoir 9 of the implantable microdevice.
48166184|NCT06204614|DRUG|Nivolumab|Nivolumab will be placed in reservoir 10 of the implantable microdevice.
48166185|NCT06204614|DRUG|Pembrolizumab|Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
48695274|NCT02346643|DEVICE|Implantation with the commercially available Axium Neurostimulator|
48695275|NCT05829447|DEVICE|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
48695276|NCT03492957|OTHER|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
48695277|NCT03296137|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
48008920|NCT02354638|BEHAVIORAL|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
48008921|NCT02354638|DRUG|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
48008922|NCT02047617|DEVICE|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
48008923|NCT02047617|DEVICE|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
48166186|NCT06204614|DRUG|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
48166187|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
48166188|NCT06204614|DRUG|Gemcitabine/Cisplatin/Nivolumab|(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
48166189|NCT06204614|DRUG|Erdafitinib|Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
48522697|NCT03196583|DEVICE|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
48695278|NCT03296137|DRUG|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
48695279|NCT03296137|DRUG|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
48695280|NCT03296137|DRUG|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
48695281|NCT03296137|DRUG|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
48695282|NCT03296137|DRUG|Fludara|5 doses (25 mg/m2) prior to TIL infusion
48695283|NCT06397443|OTHER|5-day sailing activity|"* Sailing activity (4 h/die)~* Stretching exercises pre and post-sailing activity~* Post-activity debriefing"
48695284|NCT04685720|DEVICE|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
48695285|NCT02835313|BEHAVIORAL|FAST alone|Subjects participate in fast walking training 3x/week for 12 weeks.
48695286|NCT02835313|BEHAVIORAL|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
48695287|NCT02835313|BEHAVIORAL|SAM alone|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
48695288|NCT02603237|OTHER|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
48008924|NCT03126799|DRUG|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
48008925|NCT03126799|DRUG|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
48166190|NCT06204614|DRUG|Paclitaxel/Docetaxel/Ifosfamide|(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
48166191|NCT06204614|DRUG|Gemcitabine|Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
48695289|NCT02603237|OTHER|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
48695290|NCT05996965|OTHER|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
48166192|NCT06204614|DRUG|Gemcitabine/Carboplatin/Nivolumab|(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
48166193|NCT06204614|DRUG|Enfortumab|Enfortumab will be placed in reservoir 19 of the implantable microdevice.
48166194|NCT06204614|DRUG|Sacituzumab|Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
48695291|NCT00969592|DRUG|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
48008926|NCT01398891|OTHER|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
48008927|NCT00895739|BIOLOGICAL|alemtuzumab|
48008928|NCT00895739|DRUG|cyclosporine|
48166195|NCT00825214|DEVICE|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
48695292|NCT00969592|DRUG|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
48166196|NCT00825214|DEVICE|Inactivated zapperclick device|placebo
48166197|NCT06072963|DRUG|Semaglutide|The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
48166198|NCT06072963|DRUG|Intranasal insulin|The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
48166199|NCT06072963|OTHER|Semaglutide placebo|Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
48166200|NCT06072963|OTHER|Intranasal insulin placebo|The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
48166201|NCT04168021|BEHAVIORAL|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
48695293|NCT00083954|DRUG|Quetiapine Fumarate|
48695294|NCT02752685|DRUG|Pembrolizumab|
48695295|NCT02752685|DRUG|Nab-Paclitaxel|
48695296|NCT05577312|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
48695297|NCT02766439|DRUG|etanercept|25-mg etanercept injection subcutaneously twice a week
48695298|NCT03655054|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
48695299|NCT01185314|PROCEDURE|Testing for mutation status|EGFR mutation test
48695300|NCT03086707|OTHER|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
48695301|NCT03468751|DRUG|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
48695302|NCT00748397|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
48695303|NCT06259487|BIOLOGICAL|Coordinated Vaccination|Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)
48695304|NCT06259487|BEHAVIORAL|Following recommendations|Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
48695305|NCT04945278|OTHER|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
48695306|NCT04945278|OTHER|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
48695307|NCT03763240|DIETARY_SUPPLEMENT|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
48008929|NCT05411510|PROCEDURE|Densah bur|Surgical treatment
48008930|NCT03750734|DIAGNOSTIC_TEST|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
48008931|NCT03750734|DIAGNOSTIC_TEST|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
48166202|NCT02480777|BIOLOGICAL|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
48166203|NCT04376242|BEHAVIORAL|use of virtual reality|The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.
48166204|NCT04376242|BEHAVIORAL|use of standard technology|the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
48166205|NCT01408875|DEVICE|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
48166206|NCT04986670|BEHAVIORAL|Nutritional Counseling|Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling. For cohort 1, participants will receive nutrition counseling for 8 months. The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only). For cohort 2, participants will receive nutrition counseling for 6 months. The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
48166207|NCT04986670|OTHER|Medically Tailored Meals (MTMs)|Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts. During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant. It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant). The number of meals provided to each participant may be adjusted according to participant's preference and needs.
48166208|NCT04986670|BEHAVIORAL|Nutrition Prescription|Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription. The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer. It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
48166209|NCT04986670|OTHER|Nutrition Assessment|Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment). PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions. The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
48166210|NCT04986670|BEHAVIORAL|Nutrition Toolkit|Patients will receive a printed copy of a Nutrition Toolkit from providers. Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit. The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors. The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical. Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
48369692|NCT06347523|PROCEDURE|The VR-based preoperative rehabilitation program;|Patients are provided with VR headsets for personalized pre-rehabilitation educational videos prior to surgery. These videos cover psychological counseling, nutritional advice, and exercise instructions. Additionally, patients engage in VR interactive functional training. After surgery, patients continue with VR technology interactive functional training and watch postoperative educational videos. This intervention is initiated upon the patient's admission and continues until their discharge.
48369693|NCT06347523|PROCEDURE|standard nursing care,|Patients in the control group receive traditional preoperative rehabilitation methods, which may include the following interventions: Joint exercises and rehabilitation exercises guided by a physical therapist. Written or verbal rehabilitation educational materials.
48369694|NCT04067804|BEHAVIORAL|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
48369695|NCT04529031|BEHAVIORAL|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
48695308|NCT03763240|DIETARY_SUPPLEMENT|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
48695309|NCT03968029|PROCEDURE|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
48695310|NCT03968029|PROCEDURE|suturing meniscal|meniscal tear sutured
48695311|NCT01180036|DRUG|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
48522698|NCT01276860|DEVICE|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
48695312|NCT01180036|DRUG|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
48695313|NCT02431910|OTHER|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
48695314|NCT02431910|OTHER|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
48695315|NCT05051293|OTHER|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
48695316|NCT04195399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48695317|NCT04195399|PROCEDURE|Computed Tomography|Undergo CT
48695318|NCT04195399|PROCEDURE|Echocardiography|Undergo ECHO
48695319|NCT04195399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48008932|NCT03193606|OTHER|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
48008933|NCT03228810|OTHER|Blood draw|(2) 10 mL tubes will be collected
48008934|NCT03228810|PROCEDURE|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
48008935|NCT04340882|DRUG|Docetaxel|Given IV
48008936|NCT04340882|BIOLOGICAL|Pembrolizumab|Given IV
48008937|NCT04340882|BIOLOGICAL|Ramucirumab|Given IV
48166211|NCT04986670|BEHAVIORAL|Monthly Emails|Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
48166212|NCT00282698|DRUG|Insulin infusion with a goal|
48166213|NCT02668796|DRUG|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
48166214|NCT02668796|DRUG|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
48166215|NCT02668796|DRUG|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
48369696|NCT04529031|BEHAVIORAL|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
48369697|NCT00318032|DRUG|multi-factorial intervention|
48369698|NCT00876291|DIETARY_SUPPLEMENT|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
48369699|NCT00876291|DIETARY_SUPPLEMENT|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
48369700|NCT00884195|BEHAVIORAL|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
48695320|NCT04195399|DRUG|Nirogacestat|Given PO
48695321|NCT04195399|OTHER|Quality-of-Life Assessment|Ancillary studies
48695322|NCT04195399|OTHER|Questionnaire Administration|Ancillary studies
48695323|NCT04195399|PROCEDURE|X-Ray Imaging|Undergo x-ray
48695324|NCT06655207|DEVICE|Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding|Oli is a non-invasive wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding, including postpartum haemorrhage.
48166216|NCT05762471|DRUG|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
48369701|NCT00884195|BEHAVIORAL|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
48369702|NCT04855682|OTHER|Retrospective observation after 24 months after the spinal procedure|Retrospective evaluation of patients before the procedure, and prospective evaluation of patients 24 months after the spinal procedure, comparing the MRI changes and procedure impact on fatty muscle degeneration process
48008938|NCT05862857|BEHAVIORAL|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
48008939|NCT05862857|BEHAVIORAL|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
48008940|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
48008941|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
48008942|NCT06452836|OTHER|Green color exposure|Patients will wear green colored glasses before and during the surgery.
48008943|NCT06452836|OTHER|Red color exposure|Patients will wear red colored glasses before and during the surgery.
48008944|NCT06452836|OTHER|Blue color exposure|Patients will wear blue colored glasses before and during the surgery.
48008945|NCT06452836|OTHER|control|Patients will wear translucent glasses before and during the surgery.
48008946|NCT00462956|DRUG|Tykerb|lapatinib 1500mg daily
48008947|NCT04264286|DRUG|Prophylactic esmolol|Patients will receive prophylactic esmolol after the end of the surgery
48008948|NCT04264286|DRUG|Placebo|Patients will prophylactic placebo after the end of the surgery
48008949|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
48695325|NCT05486325|DEVICE|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
48008950|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
48008951|NCT02845661|DRUG|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
48008952|NCT02806479|OTHER|Observational: Arrhythmogenic Substrate|
48008953|NCT01150214|PROCEDURE|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
48008954|NCT00075829|PROCEDURE|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.
48008955|NCT00075829|PROCEDURE|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
48166217|NCT05762471|DRUG|Placebo|Patients will receive GSBR-1290 or matching Placebo
48166218|NCT06283511|OTHER|educational workshops|patient will be proposed to assist to educational workshops + the possibility to assist to a physical rehabilitation programme
48166219|NCT06348498|DRUG|Jia Shen Tablet|Jia Shen Tablets contain 4 tablets (0.47 g per tablet), take orally, 2 times a day for 12 weeks
48166220|NCT01842542|DEVICE|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
48166221|NCT04435405|OTHER|Observational|video footage analysis of group and individual behavioral processes.
48166222|NCT06369883|DIAGNOSTIC_TEST|Spine radiography|Posterior-anterior and lateral spine radiography
48166223|NCT02149732|BIOLOGICAL|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
48166224|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
48369703|NCT04855682|OTHER|Retrospective observation after 12 months after the spinal procedure|Retrospective evaluation of the patient status before the procedure, and prospective evaluation of patients for 12 months after the spinal procedure, comparing the MRI changes
48369704|NCT04855682|OTHER|Prospective evaluation of patients after 12 and 24 months after the spinal procedure|Prospective evaluation of patients after 12 and 24 months after the spinal procedure, comparing the MRI changes
48369705|NCT04805242|OTHER|Dextrose Prolotherapy Injection|"Subacromial injection: 5 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: Previously marked using a sterile 27 gauge injector (dental needle); A total of 10 cc solution (15% dextrose + saline + 1% lidocaine solution) will be injected into the infraspinatus, teres minor, supraspinatus insertion on the tuberculum majus, the subscapularis insertion on the tuberculum minus, the coracoid process and the long head of the biceps.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
48369706|NCT04805242|OTHER|Saline Injection|"Subacromial injection: 5 cc solution (saline + 1% lidocaine solution) will be injected into the subacromial bursa using a sterile 21 gauge injector.~Extra-articular injection: 5 cc solution (saline + 1% lidocaine solution) will be injected to the attachment areas of the previously marked tendons to the bone using a sterile 30 gauge injector.~As a home exercise program, shoulder range of motion and stretching, shoulder isometric and isotonic strengthening exercises will be given at least three days a week with 3 sets of 10 repetitions."
48369707|NCT05089773|PROCEDURE|The arterial switch operation|"The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta."
48369708|NCT01215045|DEVICE|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
48522699|NCT05415163|PROCEDURE|vascular photobiomodulation|application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
48008956|NCT00075829|PROCEDURE|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
48522700|NCT01108614|BEHAVIORAL|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
48008957|NCT00075829|DRUG|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
48008958|NCT00075829|DRUG|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
48008959|NCT00075829|BEHAVIORAL|Observation|One year of observation post-transplants.
48008960|NCT01916304|DRUG|Levothyroxine sodium new formulation|Levothyroxine tablets
48008961|NCT01161758|OTHER|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
48008962|NCT01161758|OTHER|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
48008963|NCT05329597|GENETIC|Genotyping|Genotyping is performed using the subjects' blood cells
48514381|NCT05635032|OTHER|Comprehensive clinical assessment and biological samples collection|To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
48514382|NCT02108184|DRUG|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
48695326|NCT05910372|OTHER|Color Comparison Task|Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.
48695327|NCT05910372|OTHER|N-back Task|Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.
48695328|NCT03784131|DRUG|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
48695329|NCT03928418|BEHAVIORAL|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
48695330|NCT03928418|BEHAVIORAL|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
48695331|NCT03928418|BEHAVIORAL|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
48695332|NCT02931513|OTHER|Blood samples|
48008964|NCT04042883|PROCEDURE|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
48166225|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
48695333|NCT02931513|DEVICE|Fibroscan|
48166226|NCT02930837|DRUG|alteplase|
48008965|NCT03886064|OTHER|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
48008966|NCT01191710|OTHER|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
48166227|NCT04081428|RADIATION|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
48695334|NCT02931513|OTHER|Questionnaires|
48695335|NCT02931513|BIOLOGICAL|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
48008967|NCT04925297|OTHER|No intervention|No intervention will be given
48008968|NCT00355238|DRUG|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
48008969|NCT02932891|DRUG|DSXS topical|topical treatment
48166228|NCT00629317|OTHER|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
48166229|NCT00629317|DRUG|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
48695336|NCT06405607|DRUG|Psilocybin|30 mg single dose
48008970|NCT03955042|DRUG|Pemetrexed|Pemetrexed 900 mg/m\^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
48166230|NCT04466397|DEVICE|3D printed individualized porous implants|Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
48166231|NCT02840175|DRUG|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
48166232|NCT02840175|DRUG|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
48695337|NCT06405607|DRUG|Ketamine|0.75 mg/kg weight-based single dose
48008971|NCT05236309|DRUG|Jing-Guan-Fang(JGF) : Chinese herbal decoction|Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
48008972|NCT00222469|DRUG|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
48008973|NCT00222469|DRUG|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
48008974|NCT00222469|DRUG|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
48008975|NCT06472804|OTHER|Non-Interventional Study|Non-interventional study
48008976|NCT04545515|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablets for oral administration.
48008977|NCT04545515|DRUG|IVA|Tablet for oral administration.
48166233|NCT02840175|DRUG|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
48166234|NCT02840175|DRUG|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
48166235|NCT00223743|DRUG|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
48008978|NCT04803929|BIOLOGICAL|anti-ILT3 CAR-T|Autologous T cells genetically modified with anti-ILT3 CAR
48008979|NCT01288534|RADIATION|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
48008980|NCT01148953|DRUG|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
48008981|NCT01148953|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
48008982|NCT01532765|PROCEDURE|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
48008983|NCT01532765|PROCEDURE|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
48008984|NCT01532765|PROCEDURE|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
48008985|NCT04546854|BEHAVIORAL|Appeals|Written text motivating participants to take up the seasonal influenza vaccination
48008986|NCT04144166|DEVICE|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
48008987|NCT01994304|BEHAVIORAL|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
48008988|NCT04482569|DRUG|XNW4107|Single or multiple dose ascending study for XNW4107 alone or multiple dose study of XNW4107 in combination with imipenem/cilastatin
48008989|NCT00261716|BEHAVIORAL|IPS|Individual Placement and Support Evidence based supported employment
48008990|NCT00261716|BEHAVIORAL|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
48008991|NCT00261716|BEHAVIORAL|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
48008992|NCT00268138|DRUG|elmex gel|elmex gel once a week
48008993|NCT01007695|DRUG|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
48008994|NCT04774159|DRUG|Colchicine 0.5 MG Oral Tablet|"Colchicine 0.5 mg tablet daily~Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label."
48008995|NCT04774159|DRUG|Colchicine-Placebo|Colchicine-Placebo tablet
48008996|NCT03228680|DRUG|Follitropin delta|Single daily subcutaneous administration through pre-filled injection pen
48008997|NCT03228680|DRUG|Follitropin beta|Single daily subcutaneous injection in the abdomen
48008998|NCT01233375|DRUG|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
48008999|NCT01119911|OTHER|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
48009000|NCT03541694|BIOLOGICAL|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
48009001|NCT02159547|DRUG|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
48166236|NCT05459025|BEHAVIORAL|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
48369709|NCT04058782|OTHER|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
48009002|NCT02159547|OTHER|Normal Saline|50 ml normal saline
48009003|NCT02203591|DRUG|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
48009004|NCT02203591|DRUG|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
48009005|NCT02203591|DRUG|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
48369710|NCT00772031|DRUG|propranolol LA|Propranolol LA up to 240 mg/day
48369711|NCT00772031|DRUG|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
48009006|NCT02203591|DRUG|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
48009007|NCT02857127|BEHAVIORAL|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
48009008|NCT02443376|DEVICE|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
48009009|NCT02443376|DEVICE|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
48009010|NCT01371656|DRUG|levofloxacin|Given PO or IV
48009011|NCT05678335|DRUG|Hydroxychloroquine|Oral hydroxychloroquine 200mg twice daily for 12weeks.
48009012|NCT05678335|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
48009013|NCT05825482|PROCEDURE|Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.
48695338|NCT03886870|BEHAVIORAL|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
48695339|NCT03886870|BEHAVIORAL|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
48695340|NCT05351177|OTHER|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
48695341|NCT04850222|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
48695342|NCT04850222|DRUG|Calcium|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
48695343|NCT00693537|BEHAVIORAL|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
48695344|NCT00634725|DRUG|capecitabine|
48695345|NCT00634725|DRUG|erlotinib hydrochloride|
48695346|NCT00634725|DRUG|gemcitabine hydrochloride|
48695347|NCT00634725|OTHER|laboratory biomarker analysis|
48695348|NCT00634725|RADIATION|radiation therapy|
48166237|NCT05459025|BEHAVIORAL|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
48166238|NCT01929564|OTHER|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
48166239|NCT01929564|OTHER|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
48369712|NCT00772031|DRUG|placebo|an inactive substance
48369713|NCT04725864|DRUG|Progesterone vaginal tablet|The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
48369714|NCT01491802|DRUG|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
48695349|NCT05800925|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.
48695350|NCT02777203|DEVICE|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
48695351|NCT04960059|OTHER|No intervention|This is an observational study
48369715|NCT01491802|DRUG|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
48369716|NCT00016211|RADIATION|radiation therapy|
48166240|NCT00410423|DRUG|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
48166241|NCT00410423|DRUG|Bortezomib 1.0mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
48166242|NCT00410423|DRUG|Bortezomib 1.3mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
48166243|NCT01963442|RADIATION|Chest X-ray|at Day 0, Day 30 and relapse
48166244|NCT01963442|BIOLOGICAL|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
48009014|NCT05825482|PROCEDURE|Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
48166245|NCT01963442|DRUG|Augmentin|2 tablets 3 times a day for 5 days from Day 3
48166246|NCT01963442|DRUG|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
48166247|NCT01963442|DRUG|Beta-Lactams|administered from Day 0 to Day 3
48166248|NCT02223871|DRUG|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
48369717|NCT02326909|DEVICE|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
48695352|NCT01534299|DEVICE|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
48695353|NCT02621151|BIOLOGICAL|Pembrolizumab|
48695354|NCT02621151|PROCEDURE|Transurethral Resection of Bladder Tumor|
48695355|NCT02621151|DRUG|Gemcitabine|
48166249|NCT02223871|OTHER|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
48369718|NCT02326909|DEVICE|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
48695356|NCT02621151|RADIATION|External Beam Radiation Therapy|
48166250|NCT02223871|DRUG|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
48695357|NCT05898672|DRUG|Rosuvastatin|Single oral dose of rosuvastatin tablets
48695358|NCT05898672|DRUG|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
48695359|NCT03931382|BEHAVIORAL|Virtual Reality Simulator|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
48695360|NCT03931382|BEHAVIORAL|Mock MRI Simulator|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
48009015|NCT00726219|OTHER|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
48009016|NCT02171598|DRUG|Clopidogrel|
48009017|NCT02171598|DRUG|Dabigatran high dose|
48009018|NCT02171598|DRUG|Dabigatran low dose|
48009019|NCT04871334|DRUG|TWP-101|IV infusion Q2W for 4 weeks (28-day cycles)
48009020|NCT02822508|DRUG|BLI801 Laxative|BLI801 oral laxative
48009021|NCT02822508|DRUG|BLI801 Placebo|BLI801 oral laxative placebo
48166251|NCT02223871|DRUG|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
48166252|NCT04636021|DIAGNOSTIC_TEST|COVID-19 testing|Pre and post procedure COVID-19 testing for patients undergoing outpatient cardiac procedures.
48369719|NCT04642911|OTHER|Long term follow up|Undergo long term follow up, including copy number measurement safety evaluations diseases specific product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
48369720|NCT06328192|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
48695361|NCT03931382|BEHAVIORAL|Standard Preparation Manual|The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
48695362|NCT05457153|OTHER|Well-Being Process Program (WEBEPROP)|Technology-Based Well-Being Process Program (WEBEPROP)
48695363|NCT04756999|BEHAVIORAL|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
48695364|NCT06657820|PROCEDURE|Hypoxia in healthy individuals|"The subject will undergo a graduated desaturation procedure. Arterial saturation targets are as follows:~1. 100%~2. 99%~3. 96%~4. 93%~5. 90%~6. 87%~7. 84%~8. 81%~9. 78%~10. 75%~11. 72%~12. 69%~13. 99%"
48166253|NCT06223841|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q3w
48695365|NCT06657820|DEVICE|Cerebral Oximetry|Each subject will be continuously monitored with the cerebral oximetry device throughout the desaturation procedure.
48166254|NCT05212597|DRUG|Sacubitril-valsartan|50mg\~100mg twice daily
48166255|NCT05212597|DRUG|Amlodipine-losartan|amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
48166256|NCT05218421|DIAGNOSTIC_TEST|Carotid ultrasound|Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.
48369721|NCT06174402|DRUG|Fenofibrate|Fenofibrate 200 mg/day
48369722|NCT06174402|DRUG|Placebo|1 tablet/ day
48009022|NCT01934634|DRUG|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
48009023|NCT01934634|DRUG|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
48166257|NCT05218421|OTHER|Biospecimen collection and examination|The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.
48166258|NCT05218421|OTHER|Blood sample collection|In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
48009024|NCT01934634|DRUG|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
48009025|NCT04582552|DRUG|PARP inhibitors|Ovarian cancer patients with PARP inhibitors according to the NCCN guideline and their instructions.
48009026|NCT01959646|DIETARY_SUPPLEMENT|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
48009027|NCT01959646|OTHER|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
48009028|NCT01959646|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
48009029|NCT01856543|OTHER|Eucerin|
48009030|NCT01856543|OTHER|Mometasone Furoate 0.1%|
48166259|NCT02394925|DEVICE|Multifocal Test Contact lens|Used in a daily wear modality
48166260|NCT03857737|PROCEDURE|endoscopic submucosal dissection|Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
48166261|NCT03857737|PROCEDURE|Surgery|Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
48369723|NCT06174402|DRUG|UDCA|UDCA 13-15mg/kg/day
48369724|NCT02108158|DRUG|Azzalure|
48369725|NCT00250731|BEHAVIORAL|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
48369726|NCT00250731|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
48009031|NCT04701775|DIETARY_SUPPLEMENT|Only Lactobacillus rhamnosus GG strains|1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
48369727|NCT03528811|DIAGNOSTIC_TEST|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
48369728|NCT04543526|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.
48369729|NCT00421928|DRUG|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
48369730|NCT00421928|DRUG|placebo|matching placebo twice a day (BID) during 15 weeks
48369731|NCT00421928|DRUG|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
48369732|NCT00532233|DRUG|QAX576|
48695366|NCT06657820|DIAGNOSTIC_TEST|Blood Gas Sampling|At each arterial saturation plateau venous and arterial blood gas measurements will be taken from the jugular bulb, and the radial artery respectively.
48695367|NCT06459999|DIAGNOSTIC_TEST|Urine and circulating blood biomarkers|Urine and circulating blood biomarkers in all cohorts
48695368|NCT02119429|DIETARY_SUPPLEMENT|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
48695369|NCT02119429|DIETARY_SUPPLEMENT|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
48009032|NCT04701775|COMBINATION_PRODUCT|Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains|combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
48009033|NCT04701775|OTHER|Placebo|Placebo probiotic capsule
48009034|NCT05714579|PROCEDURE|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
48009035|NCT05980780|BEHAVIORAL|video game group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a video game. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The game will be played at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
48009036|NCT05980780|BEHAVIORAL|Education booklet group|"Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a training booklet. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The booklet will be read at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test."
48009037|NCT02335138|BEHAVIORAL|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
48009038|NCT02335138|BEHAVIORAL|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
48009039|NCT03538340|PROCEDURE|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
48009040|NCT03538340|PROCEDURE|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
48009041|NCT04976192|COMBINATION_PRODUCT|TEV-45779|TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe
48009042|NCT04976192|COMBINATION_PRODUCT|XOLAIR® Injection|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.
48009043|NCT03289728|OTHER|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with \< moderate ischemia will receive medical treatment only (MT)."
48009044|NCT03289728|PROCEDURE|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
48009045|NCT00004436|DRUG|leuprolide|
48166262|NCT05358964|BEHAVIORAL|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
48166263|NCT01225159|DRUG|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
48522701|NCT01526655|PROCEDURE|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
48369733|NCT04867668|BEHAVIORAL|Anti-vaping and anti-smoking digital advertising|Delivery of social media based advertising to prevent vaping and smoking among young adults ages 18-24.
48695370|NCT06318273|DRUG|ABBV-969|Intravenous (IV) Infusion
48695371|NCT02459431|OTHER|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
48695372|NCT02459431|OTHER|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
48695373|NCT03473743|DRUG|Erdafitinib|Participants will receive erdafitinib orally.
48695374|NCT03473743|DRUG|Cetrelimab|Participants will receive cetrelimab by intravenous infusion.
48695375|NCT03473743|DRUG|Cisplatin|Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
48009046|NCT00004436|DRUG|prednisone|
48009047|NCT04587934|DEVICE|iRes Warmer with ResusView|Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age
48009048|NCT04587934|OTHER|iRes Warmer without ResusView|Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
48009049|NCT00805116|DIETARY_SUPPLEMENT|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
48009050|NCT00805116|DIETARY_SUPPLEMENT|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
48009051|NCT05498948|DIETARY_SUPPLEMENT|Probiotic mixture|orally take .
48369734|NCT04704869|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
48369735|NCT04704869|BIOLOGICAL|Red Blood Cells|RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
48369736|NCT04704869|BIOLOGICAL|Plasma|Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
48695376|NCT03473743|DRUG|Carboplatin|Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
48695377|NCT06104488|DRUG|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
48695378|NCT05689671|DRUG|Atezolizumab|1200 mg i.v. q3w
48695379|NCT05689671|DRUG|Nab paclitaxel|100 mg/m² i.v. qw
48695380|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
48695381|NCT05689671|DRUG|Pembrolizumab|200 mg i.v. q3w
48695382|NCT05689671|DRUG|Cisplatin|75 mg/m² i.v. q3w
48695383|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
48695384|NCT05689671|DRUG|Pemetrexed|500 mg/m² i.v. q3w
48695385|NCT03736226|DEVICE|SYNERGYTM Stent System|no intervention design in the study
48695386|NCT05265234|DRUG|Dupilumab|IL-4 antagonist to improve moderate-severe atopic dermatitis
48695387|NCT05265234|DEVICE|Optical Coherence Tomography|OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.
48695388|NCT05265234|DEVICE|Reflectance confocal microscopy|RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.
48009052|NCT05104372|OTHER|Hypertonic Saline Nasal Irrigation and Gargles (HSNIG)|Nasal washout and gargles
48009053|NCT06184334|DRUG|Solfenacin|pills taken once day
48009054|NCT06184334|DRUG|Mirabegron|pills taken once day
48009055|NCT06184334|DRUG|Tadalafil 5mg|pills taken once day
48009056|NCT05062668|PROCEDURE|cataract operation and istent|a cataract operation and the placement of one or two iStent inject or inject W at the same time
48009057|NCT05062668|PROCEDURE|cataract operation only|Patients have a classic postoperative treatment after cataract.
48009058|NCT06074575|BEHAVIORAL|Emotion induction|The participants will receive different emotion inductions through short video clips.
48369737|NCT04704869|BIOLOGICAL|Platelets|Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
48166264|NCT01225159|DRUG|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
48166265|NCT03389997|DIAGNOSTIC_TEST|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
48166266|NCT00141713|DRUG|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
48166267|NCT05668000|OTHER|Bluetooth-connected monitoring devices and a feedback system|"AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system"
48514383|NCT02108184|DRUG|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
48166268|NCT05668000|OTHER|Mobile application|The mobile application provide only self-management interventions.
48695389|NCT06657118|PROCEDURE|Ultrasound guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
48695390|NCT06657118|PROCEDURE|Conventional anatomically guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
48695391|NCT01848977|DEVICE|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
48009059|NCT00660062|DRUG|escitalopram|10 mg daily
48166269|NCT00439348|BEHAVIORAL|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
48166270|NCT00439348|BEHAVIORAL|Prescription|Patients receive a prescription for a specific over-the-counter medication.
48166271|NCT02254681|DRUG|Gemcitabine|
48166272|NCT02254681|DRUG|Cisplatin|
48166273|NCT02254681|RADIATION|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
48166274|NCT00985530|DRUG|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle
48369738|NCT04704869|BIOLOGICAL|Whole Blood|Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
48369739|NCT03682991|OTHER|Aggressive Risk Factor Control|"1. Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2. Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3. Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4. Blood Pressure management to achieve a target systolic blood pressure (SBP) of \<120/80 mm/Hg~5. Smoking cessation facilitated through local resources already established at each site"
48369740|NCT03682991|OTHER|Standard of Care|Recommendations based on current guidelines
48369741|NCT04600518|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
48009060|NCT00660062|DRUG|escitalopram|20 mg daily dosage
48166275|NCT00985530|DRUG|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
48166276|NCT02517125|DEVICE|Transoral robotic-assisted surgery with Da Vinci Xi|
48369742|NCT02889861|DRUG|IMCgp100|Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
48369743|NCT02530580|DRUG|20 mg AZD7325|A single 20 mg oral dose of AZD7325
48369744|NCT02530580|DRUG|Placebo|A single oral dose
48009061|NCT00660062|DRUG|escitalopram|30 mg daily dosage
48009062|NCT00660062|DRUG|nortriptyline|100 mg daily dosage
48009063|NCT05887622|DIETARY_SUPPLEMENT|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
48369745|NCT01125852|PROCEDURE|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
48514384|NCT02108184|DRUG|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
48514385|NCT02108184|DRUG|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
48522702|NCT01526655|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
48522703|NCT03524443|BEHAVIORAL|Art Therapy treatment|"The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing"
48522704|NCT06230744|BEHAVIORAL|Lifestyle|All participants will receive diet and exercise goals and coaching.
48009064|NCT05887622|DIETARY_SUPPLEMENT|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
48009065|NCT02839499|DEVICE|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
48009066|NCT02839499|OTHER|autonomy scale (ADL and AGGIR)|autonomy data
48166277|NCT06374342|DEVICE|Bone defect|Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.
48514386|NCT05095844|BIOLOGICAL|vaccinated|Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
48514387|NCT00108706|DRUG|Candesartan|
48695392|NCT01848977|DEVICE|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
48695393|NCT05807256|OTHER|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
48695394|NCT02482597|DEVICE|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
48695395|NCT04757480|PROCEDURE|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
48009067|NCT02839499|OTHER|various activity scale (IADL)|activity of life data
48009068|NCT00041431|DRUG|Hormone Replacement Therapy|
48009069|NCT02953821|DRUG|Acthar Gel|1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
48009070|NCT02953821|DRUG|Placebo Gel|1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
48166278|NCT06374342|DEVICE|Spine fusion|Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together
48166279|NCT06374342|DEVICE|Cage filling|Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.
48514388|NCT04168879|DRUG|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
48514389|NCT04168879|DRUG|normal saline|1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
48695396|NCT04757480|PROCEDURE|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
48695397|NCT05673148|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
48695398|NCT05673148|PROCEDURE|Resection|undergo surgical resection
48695399|NCT05673148|PROCEDURE|Microwave Ablation|undergo microwave ablation
48695400|NCT05673148|DRUG|Chemotherapy|Receive SOC chemotherapy
48695401|NCT05673148|PROCEDURE|Computed Tomography|Undergo CT scan
48695402|NCT05673148|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48695403|NCT05673148|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48009071|NCT00065533|DRUG|pemetrexed|
48009072|NCT06381349|DIAGNOSTIC_TEST|Gastric Alimetry test|Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study.
48009073|NCT06379490|DRUG|Ropivacaine 0.2% Injectable Solution|30 ml of Ropivacaine 0.2% = 60 mg ropivacaine
48009074|NCT06379490|DRUG|Lidocaine epinephrine|30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine
48009075|NCT06379490|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine
48009076|NCT01592188|BEHAVIORAL|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
48514390|NCT01563497|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
48009077|NCT01592188|BEHAVIORAL|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
48009078|NCT00139568|DRUG|Tegaserod|
48009079|NCT05491603|BIOLOGICAL|DBI-001|Topically administered
48009080|NCT05491603|BIOLOGICAL|DBI-002|Topically administered
48009081|NCT05491603|BIOLOGICAL|Aqueous Gel|Topically administered
48009082|NCT01743261|OTHER|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
48514391|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fasted
48514392|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fed
48514393|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Oppanol
48514394|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
48514395|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
48514396|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
48514397|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Vistanex
48514398|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
48514399|NCT02972190|PROCEDURE|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
48514400|NCT02972190|PROCEDURE|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
48514401|NCT02972190|DEVICE|Pedicle screw and interbody cage|Pedicle screw and interbody cage
48514402|NCT01820234|OTHER|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
48514403|NCT01820234|OTHER|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
48514404|NCT04038138|DIAGNOSTIC_TEST|Validation of new COA for FSHD patients|Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
48514405|NCT02229461|DRUG|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
48514406|NCT02229461|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
48514407|NCT03408171|DEVICE|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
48514408|NCT03408171|DEVICE|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
48514409|NCT03886883|OTHER|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
48514410|NCT03886883|OTHER|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
48166280|NCT01705951|OTHER|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
48514411|NCT03886883|OTHER|Rest|The participants rested in a seated position for 10 minutes
48514412|NCT03886883|OTHER|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
48514413|NCT04359797|OTHER|Prone|Provider-recommended guidance on prone positioning of patients
48514414|NCT04359797|OTHER|Usual Care|No provider-recommendation, patients will remain in their natural choice of position
48514415|NCT03001453|DRUG|Liposomal Bupivacaine|266mg liposomal bupivacaine
48514416|NCT03001453|DRUG|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
48514417|NCT03001453|DRUG|Saline|Normal saline
48514418|NCT03617783|DRUG|Prebiotin|Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
48514419|NCT03617783|DRUG|Placebo|placebo-OEI
48514420|NCT01998763|DIETARY_SUPPLEMENT|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
48514421|NCT01998763|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU per day
48514422|NCT05440318|DEVICE|Wireless wearable digital devices|Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes \[ePRO\] capability) will be provided to each participant enrolled in the study.
48514423|NCT06133426|DEVICE|"Connected scale Body Comp Pro from Withings"|Use once a day from inclusion to week 7.
48514424|NCT01644383|BEHAVIORAL|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
48514425|NCT00626808|DRUG|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
48514426|NCT02792699|DRUG|ABP 798|Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
48514427|NCT02792699|DRUG|Rituximab (US)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
48514428|NCT02792699|DRUG|Rituximab (EU)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
48514429|NCT01911286|PROCEDURE|Apnea test - Standard|
48514430|NCT01911286|PROCEDURE|Apnea test - CPAP|
48514431|NCT03649347|BEHAVIORAL|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
48522705|NCT06230744|BEHAVIORAL|Lifestyle II|All participants will receive diet and exercise goals and coaching.
48522706|NCT00811967|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
48522707|NCT00811967|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
48522708|NCT02700217|PROCEDURE|Bupivacaine and Diamorphine|
48522709|NCT02700217|PROCEDURE|Remifentanil, Propofol and Cistracurium|
48522710|NCT02700217|PROCEDURE|Bupivacaine and Rectus Sheath injection|
48522711|NCT04553393|DRUG|Chidamide|Chidamide will be added 1 month after responding to CART cells infusion
48522712|NCT04553393|DRUG|Decitabine|Decitabine will be added 1 month after responding to CART cells infusion
48522713|NCT04553393|DRUG|Chidamide and Decitabine|Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
48522714|NCT04553393|BIOLOGICAL|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem CAR19/20 engineered T cells
48522715|NCT00381979|OTHER|Supportive Expressive Therapy|
48522716|NCT01618448|DRUG|Tolvaptan|Tolvaptan 15mg once daily
48514432|NCT01527409|BEHAVIORAL|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
48514433|NCT01527409|BEHAVIORAL|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
48514434|NCT04010552|DRUG|NALRINOX combination|NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
48514435|NCT00569855|DRUG|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
48514436|NCT00588458|PROCEDURE|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
48514437|NCT00018538|DRUG|calcifidiol|
48695404|NCT04731298|DRUG|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
48009083|NCT01743261|OTHER|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
48166281|NCT01705951|BIOLOGICAL|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
48514438|NCT01287026|PROCEDURE|Cardiac Real-time MRI RHC (Right Heart Catheterization)|
48695405|NCT04679623|COMBINATION_PRODUCT|Midazolam|Midazolam Injection, 10mg
48695406|NCT04679623|DRUG|Seizalam|Seizalam, 10 mg
48514439|NCT06468241|OTHER|Progressive relaxation exercise|For the progressive relaxation exercise group, a progressive relaxation exercise session will be applied to the participants 3 times a week for four weeks.
48009084|NCT03869593|GENETIC|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
48695407|NCT02086487|DRUG|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)"
48695408|NCT03286829|DRUG|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
48695409|NCT03286829|DRUG|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
48695410|NCT03286829|DRUG|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
48695411|NCT03286829|DRUG|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
48695412|NCT02966145|OTHER|Observational Study|
48166282|NCT04064723|DEVICE|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
48166283|NCT03614221|DRUG|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
48166284|NCT03614221|DRUG|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
48166285|NCT06217497|OTHER|Foot massage|Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI
48166286|NCT04814615|DRUG|89Zr-daratumumab PET/CT|CD38-targeting imaging
48166287|NCT02162771|BIOLOGICAL|Rituxan|
48166288|NCT02162771|BIOLOGICAL|CT-P10|
48166289|NCT02162771|DRUG|Cyclophosphamide|
48166290|NCT02162771|DRUG|Vincristine|
48166291|NCT02162771|DRUG|Prednisone|
48166292|NCT00248079|DEVICE|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
48166293|NCT00936754|DIETARY_SUPPLEMENT|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
48166294|NCT00936754|DIETARY_SUPPLEMENT|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
48166295|NCT03291873|PROCEDURE|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
48166296|NCT06390085|OTHER|Soft tissue manipulation|The clinician will perform a soft tissue massage intervention where she/he will use moderate massaging and compression. The amount of pressure is less than 5 N, the velocity is low at a controlled rate of 1 Hz, the duration of 30 seconds, angle 90 and 45 degrees.
48166297|NCT03628690|DEVICE|BandGrip|Topical skin closure device
48166298|NCT03628690|DEVICE|Suture|Wound closure
48166299|NCT02277587|DRUG|Plenadren|Oral Tablets: 20-25-30 mg
48166300|NCT02277587|DRUG|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
48369746|NCT01125852|PROCEDURE|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
48522717|NCT01618448|DRUG|Placebo|Placebo
48522718|NCT03593837|DRUG|Huang qi gui zhi wu wu granule|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
48522719|NCT03593837|DRUG|Huang qi gui zhi wu wu granule placebo|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
48522720|NCT05173181|DEVICE|Flexible intramedullary nail|Fixation of distal ulna fracture with flexible intramedullary nail
48522721|NCT02692443|DEVICE|Magnetic Resonance Imaging|Brain MRI without Contrast
48522722|NCT02692443|BEHAVIORAL|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
48522723|NCT06100523|BEHAVIORAL|Visioconsulation|Meeting by videoconsultation with professionals adapted to the exposures highlighted by the questionnaires for patients who responded on the dedicated application (Arm A)
48522724|NCT06100523|BEHAVIORAL|self-assessment questionnaire|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
48522725|NCT06100523|BIOLOGICAL|hair sampling|hair sampling from the 2 members of the couple
48522726|NCT06100523|BEHAVIORAL|self-assessment questionnaire on dedicated application|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
48522727|NCT06100523|BEHAVIORAL|Specialized follow-up|proactive healthcare pathway : active support of corrective measures implemented with couples by the platform, with the help of the application
48522728|NCT06100523|BEHAVIORAL|self-assessment questionnaire for follow-up|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
48522729|NCT03707626|OTHER|Wellens Sign|presence or absence in presence of coronary collaterals to LAD
48514440|NCT06468241|OTHER|Listening to music|"For the music listening group, the participants will listen to the Turkish music makams (uşşak and rast) three times a week for four weeks."
48514441|NCT04859205|BEHAVIORAL|Intervention|"Participants will have access to the SUPPORT-Pro self-guided online training platform addressing many aspects of type 1 diabetes care. The SUPPORT-Pro content was developped by a team of health professionals specialized in type 1 diabetes as well as patient partners. It's content is regularly updated, evidence-based and divided into 6 categories (medication, blood glucose monitoring, diet, physical activity, hypo and hyperglycemia, health and other particularities). In each category, users can pick between 3 levels (beginner, intermediate and advanced) according to their level of confidence and knowledge.~Participants will be asked to fill out questionnaires at baseline, 3-month, and 12-month of the intervention which include the following: Eligibility assessment, identification, background, confidence, platform satisfaction."
48514442|NCT02022878|PROCEDURE|PCI of CTO|
48514443|NCT00555841|DRUG|ALC and Placebo|ALC and Placebo
48009085|NCT01057043|DEVICE|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
48514444|NCT00869076|OTHER|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
48009086|NCT03465293|OTHER|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
48514445|NCT00869076|OTHER|Usual care|Patient was managed by their primary care physician as usual
48514446|NCT02720497|BEHAVIORAL|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
48514447|NCT02720497|BEHAVIORAL|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
48514448|NCT02792920|DEVICE|CoCr-EES|
48514449|NCT04816071|DRUG|Essential amino acids|Dietary Supplement
48695413|NCT06658860|PROCEDURE|Modified Socket Shield Technique|The modified socket shield technique involves partial retention of the buccal aspect of the tooth root during extraction to preserve the surrounding alveolar bone and soft tissue. This technique is used to optimize the condition for delayed implant placement by preventing resorption of the alveolar ridge.
48009087|NCT04027218|DEVICE|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
48166301|NCT06354192|BEHAVIORAL|Precision Nudging for Hypertension Management|The hypertension digital health intervention under study combines behavioral science theory with a type of machine learning called reinforcement learning to enable precision nudging: the selection, assembly, and delivery of behavioral science-based messages created to address barriers to, and promote, management of hypertension. The behavioral design process used for the hypertension DHI intentionally includes research on traditionally underserved populations, such as racial and ethnic minorities and people with lower incomes or educational attainment. By including the right ingredients to meet a diverse set of needs and by effectively personalizing the content each individual sees based on their own reactions, the intervention aims to improve health equity by matching each individual to the right behavioral approach.
48166302|NCT00371618|PROCEDURE|Fluoroscopy|
48166303|NCT06646133|DIAGNOSTIC_TEST|3D camera weight estimate|Weight estimation using 3D camera system
48166304|NCT06646133|DIAGNOSTIC_TEST|Standard methods of weight estimation|Standard methods of weight estimation will be used
48166305|NCT03277417|OTHER|Echocardiography|Imaging of fetal heart and amniotic fluid
48166306|NCT02364505|BEHAVIORAL|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
48695414|NCT06658860|PROCEDURE|Conventional Tooth Extraction|Conventional tooth extraction involves the complete removal of the tooth without the use of the socket shield technique. This arm served as the control group, with alveolar ridge changes observed and compared with those in the experimental arm over time.
48009088|NCT04027218|DEVICE|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
48166307|NCT02364505|BEHAVIORAL|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
48166308|NCT04226651|DEVICE|Virtual Reality Device|The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.
48166309|NCT04226651|DEVICE|Protective glasses|Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
48369747|NCT01852565|DRUG|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
48514450|NCT04816071|DIETARY_SUPPLEMENT|Maltodextrin|Control
48514451|NCT05100160|DRUG|Gabapentin|Given by PO
48514452|NCT05100160|OTHER|Placebo|Given by PO
48514453|NCT02460679|DRUG|EPI-589|An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
48514454|NCT02986477|OTHER|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
48166310|NCT00553605|DRUG|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
48522730|NCT03928483|BEHAVIORAL|Modified WW Food program|Participants will receive a structured, holistic, behavioral weight management program that encourages development of healthy habits to help individuals eat healthier, move more, and shift to a more helpful mindset.
48522731|NCT02937311|OTHER|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
48695415|NCT00113672|BEHAVIORAL|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
48695416|NCT00113672|BEHAVIORAL|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
48695417|NCT00113672|BEHAVIORAL|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
48695418|NCT00113672|BEHAVIORAL|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
48695419|NCT06057935|DRUG|Pemetrexed|Pemetrexed will be administered intravenously
48695420|NCT06057935|DRUG|Cisplatin|Cisplatin will be administered intravenously
48695421|NCT06057935|DRUG|Carboplatin|Possible substitution with carboplatin based on clinician discretion
48009089|NCT04027218|DEVICE|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
48009090|NCT00614796|BEHAVIORAL|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
48166311|NCT00553605|DRUG|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
48166312|NCT02402465|DRUG|Placebo|Patients will be treated by placebo
48166313|NCT02402465|DRUG|Fluticasone propionate|Patients will receive fluticasone nasal spray
48166314|NCT02402465|DRUG|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
48166315|NCT02402465|PROCEDURE|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
48166316|NCT03735641|PROCEDURE|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
48166317|NCT05934084|BEHAVIORAL|Lifestyles Implemented-Survivorship Care Plan (LS-SCP)|Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.
48166318|NCT03298555|BEHAVIORAL|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
48166319|NCT01626729|BEHAVIORAL|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
48522732|NCT02937311|OTHER|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
48522733|NCT02937311|OTHER|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
48522734|NCT01744301|DRUG|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
48522735|NCT03119402|BEHAVIORAL|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
48695422|NCT00823433|DRUG|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
48166320|NCT01626729|BEHAVIORAL|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
48166321|NCT01626729|BEHAVIORAL|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
48166322|NCT01626729|BEHAVIORAL|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
48166323|NCT01626729|BEHAVIORAL|No label control group|No label control group
48166324|NCT02094547|DIETARY_SUPPLEMENT|New infant formula|New infant formula
48166325|NCT02094547|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
48166326|NCT02094547|DIETARY_SUPPLEMENT|Breastfeeding|Exclusive breastfeeding or less tan 25% formula intake
48166327|NCT05169814|DRUG|Micro/nanobubble (MNB) - Irrigation|An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
48166328|NCT05169814|OTHER|0.9% Normal Saline - Irrigation|A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
48166329|NCT05169814|DRUG|Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
48166330|NCT05169814|OTHER|0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
48166331|NCT03910296|BEHAVIORAL|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
48166332|NCT03868735|DEVICE|CleanSweep Closed Suction System|Device with balloon sweeping technology
48166333|NCT04359264|OTHER|Cash transfer|Cash transfer of $1000
48369748|NCT01852565|DRUG|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
48514455|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
48695423|NCT02191657|DRUG|Deferiprone|Oral iron chelator
48695424|NCT06651385|OTHER|Remote digital therapeutic exercise program|Participants will be introduced to the digital therapeutic exercise program during Screening and Consent (Visit 0, V0). Participants will be provided with an orientation to the Vitala platform and assistance will be offered in the download and access to the application, as needed. The study team will ensure access has been obtained via the health care professionals' dashboard on the Vitala app. Information obtained in the assessments outlined above will inform the tailored exercise prescription to meet the participant's needs. Participants will be encouraged to complete a total of 150 minutes of remote exercise sessions each week for 12 weeks via the Vitala platform. Participants will receive daily notifications to remind them to complete their assigned daily exercises.
48166334|NCT06646718|PROCEDURE|Close kinetic chain exercise group|●Close kinetic chain exercise group: group A will receive forward step-ups, lateral step-ups, squats, sit-to-stand, and stoop-and-recover exercises. session will be initiated with a 10 min warm-up period, including stretching of the major muscles and muscle groups, then 40 min different exercises and terminated with a 10 min cool-down period in the form of aerobic exercises.
48514456|NCT00359801|DRUG|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
48369749|NCT04344431|COMBINATION_PRODUCT|Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)|One session per day of HBOT in addition to the standard treatment with normobaric oxygen
48369750|NCT02479022|DRUG|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
48514457|NCT03042091|DRUG|Polyethylene Glycol|Given orally
48514458|NCT03042091|DRUG|Neomycin|Given orally
48514459|NCT03042091|DRUG|Metronidazole Hydrochloride|Given orally
48514460|NCT03042091|PROCEDURE|Therapeutic Conventional Surgery|Undergo colorectal resection
48514461|NCT04422041|OTHER|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
48009091|NCT01849211|DRUG|rocuronium|
48514462|NCT04422041|OTHER|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
48166335|NCT06646718|PROCEDURE|Traditional physical therapy.|●Traditional physiotherapy: group B will receive stretching for the lower extremity muscles, namely hip flexors and adductors, hamstrings, and calf muscles; and strengthening exercises for core muscles, hip extensors, flexors and abductors, internal and external rotators of the hip, flexors and extensors of the knee, ankle dorsi flexors, kneeling exercises, and standing and gait training
48166336|NCT05216029|OTHER|Best Practice|Receive standard of care
48166337|NCT05216029|OTHER|Informational Intervention|View oncology dashboard
48166338|NCT05216029|OTHER|Questionnaire Administration|Ancillary studies
48166339|NCT00721708|DIETARY_SUPPLEMENT|pure carnosine|one time dose of pure carnosine (450 mg)
48166340|NCT00721708|OTHER|Beef|one time dose, 150 g of beef
48009092|NCT04543552|DEVICE|Bladder scan|Bladder Scanner, or Biocon-900 is an ultrasonic imaging device that has been developed to measure post-void residual volume of the bladder non-invasively. The images and measurements are obtained by applying a probe onto the abdomen (i.e. bladder). As it scans, the scanner constructs 12 cross-sectional images at 15 degree interval using the reflection signals from urine in the bladder and extracts the position of the bladder wall as well. During urodynamic studies, the bladder scan will measure the infused volume in order to assess difference between the infused and scanned volumes.
48009093|NCT02254538|DRUG|BILR 355 BS|
48166341|NCT00721708|OTHER|Chicken|One time dose, 150g of chicken breast
48369751|NCT02479022|DRUG|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
48369752|NCT02479022|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
48369753|NCT03651960|OTHER|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
48695425|NCT03491813|DEVICE|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
48695426|NCT03327220|DEVICE|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
48695427|NCT03016624|DEVICE|OCT guided PCI|oct guided
48695428|NCT03016624|DEVICE|Angiography guided PCI|angio guided
48695429|NCT03811769|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
48695430|NCT03811769|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
48695431|NCT00210353|DRUG|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
48695432|NCT00210353|DRUG|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
48695433|NCT00210353|DRUG|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
48695434|NCT03037476|BEHAVIORAL|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
48695435|NCT03037476|BEHAVIORAL|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
48009094|NCT02254538|DRUG|PEG 400|
48009095|NCT04102358|PROCEDURE|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
48009096|NCT04102358|PROCEDURE|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
48166342|NCT00721708|OTHER|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
48166343|NCT02929316|DRUG|Vedolizumab|IV infusion week 0, 2 and 6
48166344|NCT03868098|DRUG|Crisaborole 2%|Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
48166345|NCT03868098|DRUG|Placebo ointment|Placebo ointment (vehicle)
48166346|NCT01314638|OTHER|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
48166347|NCT03761134|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
48166348|NCT03761134|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
48166349|NCT03761134|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
48166350|NCT03761134|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
48695436|NCT05053815|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
48166351|NCT06350370|PROCEDURE|Natural orifice specimen extraction|We perform laparoscopic colorectal cancer resection, intracorporeal anastomosis and transanal or transvaginal specimen extraction
48166352|NCT02685007|OTHER|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
48166353|NCT01422083|PROCEDURE|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
48369754|NCT02405273|PROCEDURE|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
48166354|NCT01750177|BEHAVIORAL|Television Viewing before mealtime|
48166355|NCT01750177|BEHAVIORAL|Video Game Playing|
48695437|NCT06661863|PROCEDURE|alveolar ridge preservation with bioactive glass|Bioactive glass grafted into alveolar preservation.
48695438|NCT06661863|PROCEDURE|alveolar ridge preservation with autologous bone|Autologous bone graft in alveolar ridge preservation.
48695439|NCT03576196|OTHER|Preoperative Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
48695440|NCT03576196|OTHER|Usual Care|This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
48695441|NCT02643563|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
48009097|NCT05157594|BIOLOGICAL|Blood sample|Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
48166356|NCT01750177|BEHAVIORAL|Computer Use|
48166357|NCT01750177|BEHAVIORAL|Sitting quietly|
48695442|NCT02643563|DRUG|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
48695443|NCT02643563|DRUG|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
48695444|NCT06229028|OTHER|hand rehabilitation with verbal explanation|Patients in all groups will undergo a 12-week hand rehabilitation process that includes the use of appropriate orthoses if necessary, approaches to edema and pain, restoration of joint range of motion, strengthening, and functional return to work or activities. The application of the rehabilitation process will change according to the assigned group.
48695445|NCT06229028|OTHER|hand rehabilitation with patient information and exercise forms|hand rehabilitation with patient information and exercise forms
48695446|NCT06229028|OTHER|hand rehabilitation with video recording|hand rehabilitation with video recording
48695447|NCT03409705|DIETARY_SUPPLEMENT|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
48695448|NCT03409705|DIETARY_SUPPLEMENT|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
48695449|NCT05317143|OTHER|Evaluation of prostate cancer margins|Evaluation of prostate cancer margins
48009098|NCT01888497|DRUG|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
48009099|NCT01888497|DRUG|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
48009100|NCT01888497|DRUG|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
48009101|NCT01888497|DRUG|Placebo|Oral, prior to bedtime on the night before performance testing
48009102|NCT06333938|DEVICE|Bridge|Percutaneous Nerve Field Stimulation using a disposable battery operated and device, approved by the FDA for the treatment of clinical symptoms related to opioid withdrawal.
48009103|NCT06333938|DEVICE|BFA|BFA is an auricular acupuncture technique (developed within the VA/ DoD health systems) delivered by providers using 1mm acupuncture needles.
48009104|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
48009105|NCT01263288|DIETARY_SUPPLEMENT|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
48009106|NCT01263288|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
48009107|NCT04441294|BEHAVIORAL|ACE-Plus|
48009108|NCT05091528|DRUG|SBT6050|Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
48009109|NCT05091528|DRUG|trastuzumab deruxtecan|5.4 mg/kg by intravenous (IV) infusion in 21-day cycles
48166358|NCT04048798|OTHER|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
48166359|NCT04048798|OTHER|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
48166360|NCT04136964|OTHER|Neck COMI|Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
48166361|NCT01560585|DRUG|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
48166362|NCT06392919|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS intervention timing: rTMS is applied after the tracheal tube is removed in the PACU. Stimulation site: DLPFC (left dorsolateral prefrontal cortex); Stimulation intensity: 100% RMT; Stimulation frequency: 10Hz; Total number of stimulation pulses: 2000. Pulse characteristics: Each duration lasts 5 seconds, with a 25-second interval.
48166363|NCT00945763|DRUG|N1539|30 mg
48166364|NCT00945763|DRUG|placebo|tablets
48166365|NCT00945763|DRUG|N1539|15 mg
48166366|NCT00945763|DRUG|N1539|60 mg
48166367|NCT00945763|DRUG|Motrin|400 mg
48166368|NCT06645925|PROCEDURE|One Step Protocol|FGG will be done simultaneous with implant placement
48166369|NCT06645925|PROCEDURE|Two Steps Protocol|Conventional FGG protocol, prior to implant placement
48166370|NCT03435614|DRUG|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
48166371|NCT00451555|DRUG|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
48166372|NCT00451555|DRUG|placebo|oral, daily
48514463|NCT01381315|PROCEDURE|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur \<3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
48514464|NCT01381315|PROCEDURE|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative-that the lymphedema rate is \<0.13 for subjects undergoing ALND-if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
48514465|NCT05435690|DEVICE|Computer-assisted arthroplasty|Computer-assisted arthroplasty
48514466|NCT03533309|PROCEDURE|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
48514467|NCT03533309|PROCEDURE|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
48009110|NCT05091528|DRUG|tucatinib|300 mg by mouth (PO) twice daily (BID)
48166373|NCT00451555|DRUG|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
48166374|NCT00747721|DRUG|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
48166375|NCT05744791|BEHAVIORAL|Active Play planned movement program|Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
48166376|NCT01372683|OTHER|Dietary Intervention|Comparison of oat based breakfast cereals
48166377|NCT04968015|DRUG|Cytarabine-Venetoclax Association|Consolidation treatment with cytarabine + venetoclax
48166378|NCT04968015|DRUG|Cytarabine-Idarubicin Association|Consolidation treatment with cytarabine + idarubicin
48166379|NCT02264353|DRUG|Donepezil|Donepezil 10mg before sleep
48166380|NCT02264353|DRUG|placebo|One piece of placebo before sleep
48166381|NCT00302406|DRUG|methylphenidate hydrochloride|
48166382|NCT00302406|DRUG|OROS methylphenidate hydrochloride (CONCERTA)|
48166383|NCT02643953|BEHAVIORAL|Incentives|1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
48166384|NCT02643953|BEHAVIORAL|Community|1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
48166385|NCT01748578|DRUG|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
48166386|NCT01748578|DRUG|EBI-005-1 Placebo|
48166387|NCT02675998|DRUG|Tenapanor|
48166388|NCT02675998|DRUG|Placebo|
48166389|NCT04933162|DIETARY_SUPPLEMENT|High Protein and Low Fiber Diet|Protein intake will be increased to be \>40% calories from protein, and the fiber intake will remain \<15gm/day.
48166390|NCT04933162|DIETARY_SUPPLEMENT|Low Protein and High Fiber Diet|Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to \<10% total calories from protein.
48166391|NCT03905213|DEVICE|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
48166392|NCT03905213|DEVICE|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
48166393|NCT03905213|DEVICE|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
48166394|NCT02868619|OTHER|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
48166395|NCT02868619|OTHER|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
48166396|NCT02868619|OTHER|R-CMAS scale|Evaluate the anxiety
48166397|NCT03412513|DRUG|Mirabegron|Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
48166398|NCT03412513|DRUG|Placebo|Placebo po daily for 8 weeks to Placebo comparator group.
48166399|NCT03003923|BEHAVIORAL|Taste exposure|Exposure to the same vegetable
48166400|NCT03003923|BEHAVIORAL|Nutritional education|Eat Well and Strive for Five nutritional education
48369755|NCT02405273|PROCEDURE|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
48369756|NCT00699582|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
48514468|NCT03784027|DEVICE|CamAPS FX|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
48514469|NCT03784027|OTHER|Sensor augmented therapy|Study insulin pump and study CGM.
48166401|NCT00982540|DRUG|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
48166402|NCT01940523|DRUG|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
48166403|NCT01940523|DRUG|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
48166404|NCT04151706|DRUG|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
48166405|NCT04151706|DRUG|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
48166406|NCT04151706|DRUG|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
48166407|NCT04151706|RADIATION|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
48166408|NCT04151706|DRUG|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
48166409|NCT04151706|DRUG|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
48514470|NCT01185197|DRUG|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
48514471|NCT01185197|DRUG|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
48514472|NCT00515918|DIETARY_SUPPLEMENT|iron|
48166410|NCT04697641|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg twice a day for two weeks
48166411|NCT04697641|DRUG|Amoxicillin 1000 MG|Amoxicillin 1000mg twice a day for two weeks
48166412|NCT04697641|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg or equivalent for eight weeks
48166413|NCT04697641|DRUG|Levosulpiride|Levosulpiride 25 mg as and when required before meals
48166414|NCT04697641|DRUG|Acotiamide|Acotiamide 100mg as when required before meals
48166415|NCT04697641|DRUG|Itopride|Itopride 50mg as when required before meals
48166416|NCT01641627|PROCEDURE|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
48369757|NCT00699582|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
48369758|NCT00699582|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
48369759|NCT04367142|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Nasopharyngeal swabs for COVID-19 RT-PCR
48514473|NCT01443897|DIETARY_SUPPLEMENT|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
48514474|NCT01443897|DIETARY_SUPPLEMENT|placebo capsule|0 IU vitamin D2
48514475|NCT01443897|OTHER|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
48514476|NCT01443897|OTHER|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
48514477|NCT01443897|OTHER|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
48514478|NCT01968564|DRUG|Placebo pill|sugar and other inert substances
48514479|NCT01968564|DRUG|High-dose curcumin pill|2000mg curcumin pill/day
48514480|NCT01968564|DRUG|Low-dose curcumin pill|500mg curcumin pill/day
48514481|NCT06171100|DRUG|Tolvaptan|"Oral ingestion of low dose Tolvaptan (7.5mg daily) for management of inpatient hyponatraemia for 1st dose Tolvaptan group.~Oral ingestion of low dose Tolvaptan (7.5mg daily) or standard dose Tolvaptan (15mg daily) for 2nd dose Tolvaptan group."
48514482|NCT00956072|DRUG|imatinib mesylate|Patients receive imatinib mesylate
48514483|NCT00956072|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
48514484|NCT00205387|PROCEDURE|cardiac elastography and echocardiography|standard echocardiogram
48514485|NCT01669603|DIETARY_SUPPLEMENT|Bifidobacterium lactis Bl-04|The study product will be a 2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
48514486|NCT01669603|DIETARY_SUPPLEMENT|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
48514487|NCT01669603|BIOLOGICAL|Rhinovirus|rhinovirus for experimental challenge
48514488|NCT03870165|BEHAVIORAL|Resistance exercise|Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
48514489|NCT03870165|OTHER|Salmon|Participants will ingest salmon immediately after resistance exercise
48514490|NCT03870165|DIETARY_SUPPLEMENT|Isolated amino acids and fatty acids|Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
48514491|NCT02473198|DRUG|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
48514492|NCT02473198|DRUG|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
48514493|NCT02473198|DRUG|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
48514494|NCT02473198|DRUG|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
48514495|NCT03766607|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
48009111|NCT05091528|DRUG|trastuzumab|8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles
48166417|NCT01018797|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
48369760|NCT04367142|DIAGNOSTIC_TEST|Biosensor|Portable and Connected Biosensor viral
48514496|NCT03766607|DRUG|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
48514497|NCT03766607|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
48514498|NCT05708989|PROCEDURE|Caudal Block|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
48514499|NCT05708989|PROCEDURE|Ultrasound-guided Pudendal Block|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
48514500|NCT05708989|DRUG|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine|Injectable 1 ml/kg of 0.25% ropivacaine with 1mcg/kg dexmedetomidine into caudal spinal space. First attempt will be landmark-guided into the caudal spine region. Subsequent attempt(s) may be done using ultrasound.
48514501|NCT05708989|DRUG|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine.|Injection of 0.5 ml/kg per side of injectable 0.2-0.3% ropivacaine with 0.5 mcg/kg dexmetomedine. Ultrasound-guided injection into each pudendal nerve region through skin of buttocks.
48514502|NCT05019300|BIOLOGICAL|Exposure: COVID-19 severity|COVID-19 severity between 4 to 7 points according the seven-category scale of clinical status reported by Huang et al. (2021) and severe to critical symptomatic levels on spectrum of disease reported by Wu and McGoogan (2020).
48369761|NCT04691570|DRUG|ANX005|ANX005 is provided as a solution for IV infusion
48166418|NCT03976778|OTHER|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
48166419|NCT04069429|RADIATION|Computerized Tomography scan|imaging scan from a person's eyes to their thighs
48166420|NCT04069429|RADIATION|Single Photon Emission Computed Tomography scans|imaging scan taken during, and after, the administration of the radioactive agent
48166421|NCT04069429|DRUG|Technetium Tc 99M|subjects are administered radioactive heparin as part of study participation.
48166422|NCT04069429|RADIATION|Planar Images|2 dimensional imaging - whole body planar scans
48166423|NCT04069429|PROCEDURE|Esophagogastroduodenoscopy|esophagogastroduodenoscopy with tissue biopsies
48695450|NCT06098911|DEVICE|MI varnish|delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
48009112|NCT05091528|DRUG|capecitabine|1000 mg/m2 PO BID for 14 days of each 21-day cycle
48166424|NCT02619279|OTHER|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
48695451|NCT04353375|DRUG|HMPL-453|Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
48695452|NCT00822627|DRUG|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
48009113|NCT05091528|DRUG|trastuzumab deruxtecan|6.4 mg/kg by IV infusion in 21-day cycles
48009114|NCT02054364|BEHAVIORAL|FBT and CRT|
48009115|NCT02054364|BEHAVIORAL|FBT and art therapy|
48009116|NCT04269759|OTHER|Survey|pregnant women will answer to a survey regarding their oral health knowledge, attitudes and practices for themselves and their unborn child
48009117|NCT04269759|OTHER|dental care|pregnant women will have a dental care
48166425|NCT06320847|DIAGNOSTIC_TEST|rPPG|A pulse oximeter and blood pressure cuff will be applied on the study patient by the study team member (research coordinators). At the same time, vital signs from Nervotec's rPPG technology will be recorded via the laptop and webcam. Synchronous measurement process of heart rate, respiration rate, pulse oximetry, heart rate variability and blood pressure estimates using Nervotec rPPG technology will take place for a duration of 3 minutes.
48695453|NCT00822627|BEHAVIORAL|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
48695454|NCT02419222|BEHAVIORAL|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
48009118|NCT01411878|BEHAVIORAL|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
48009119|NCT01411878|BEHAVIORAL|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
48166426|NCT01721174|PROCEDURE|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
48166427|NCT01721174|PROCEDURE|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
48166428|NCT02580214|DIETARY_SUPPLEMENT|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
48009120|NCT06413199|OTHER|Hyper Training|Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.
48009121|NCT06413199|OTHER|1 Repetition maximum training group|2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
48009122|NCT00013130|BEHAVIORAL|Provision of health status information to patients provider|
48009123|NCT01263574|DRUG|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
48009124|NCT00001996|DRUG|Atovaquone|
48009125|NCT00001996|DRUG|Pentamidine isethionate|
48009126|NCT03638986|OTHER|No intervention planned|No Intervention planned.
48166429|NCT05188313|DRUG|Trastuzumab|Intravenous administration of study drug
48166430|NCT05188313|DRUG|Pertuzumab|Intravenous administration of study drug
48166431|NCT05188313|DRUG|Paclitaxel|Intravenous administration of study drug
48166432|NCT05188313|DRUG|Carboplatin|Intravenous administration of study drug
48166433|NCT02343978|DRUG|KWA-0711|
48166434|NCT04335370|OTHER|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~1. Prior to start of infusion~2. End of infusion~3. One hour after end of infusion~4. Three hours after end of infusion~5. Eight hours after start of infusion"
48009127|NCT01513252|BEHAVIORAL|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
48009128|NCT03219060|BEHAVIORAL|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
48009129|NCT03219060|BEHAVIORAL|Brief advice|Brief advice based on 5As
48166435|NCT04168996|BEHAVIORAL|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
48166436|NCT01574014|BEHAVIORAL|CBGT|Cognitive-behavioral group therapy
48166437|NCT01574014|DRUG|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
48166438|NCT01574014|DRUG|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
48166439|NCT00747045|OTHER|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
48369762|NCT06230107|BEHAVIORAL|Mindful Eating|Analyze the impact of Mindful Eating on changes in dietary habits, episodes of binge eating, body image dissatisfaction, quality of life and anthropometric data (weight, BMI and waist circumference) in Participants with obesity and BED.
48009130|NCT03856762|DIETARY_SUPPLEMENT|traditional Jiangnan diet|traditional Jiangnan diet supplement from Monday to Friday for six months
48166440|NCT02174159|DRUG|Ulonivirine|MK-8507 administered as a single oral dose
48166441|NCT00176969|DRUG|Capsaicin|
48369763|NCT04513132|DEVICE|active-dTMS|The dTMS using H-coil with 5Hz stimulate ACC. The sessions of dTMS will be conducted twice daily for 5 consecutive days, and twice sessions of a day will be separated by 3 hours at least.
48369764|NCT04513132|DEVICE|sham-dTMS|The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
48166442|NCT03096977|DIAGNOSTIC_TEST|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
48166443|NCT03096977|DEVICE|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
48166444|NCT03096977|DEVICE|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
48369765|NCT00602043|RADIATION|F-18 16 alpha-fluoroestradiol|Undergo \[\^18F\] FES PET
48369766|NCT00602043|RADIATION|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
48369767|NCT00602043|PROCEDURE|positron emission tomography|Undergo \[\^18F\] FES PET
48369768|NCT00602043|PROCEDURE|positron emission tomography|Undergo standard clinical FDG PET/CT
48369769|NCT00602043|PROCEDURE|computed tomography|Undergo standard clinical FDG PET/CT
48369770|NCT00602043|OTHER|laboratory biomarker analysis|Correlative studies
48369771|NCT00431106|DRUG|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
48369772|NCT00431106|DRUG|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
48369773|NCT00431106|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
48514503|NCT05326555|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
48514504|NCT02208804|DEVICE|Holmium-166-poly (L-lactic acid) microspheres|
48009131|NCT03856762|DIETARY_SUPPLEMENT|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for six months
48166445|NCT03096977|DEVICE|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
48166446|NCT03096977|DEVICE|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
48166447|NCT02018471|BEHAVIORAL|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
48166448|NCT05451056|DRUG|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
48166449|NCT04730076|PROCEDURE|Standard Balloon Dilation|The standard approach involves a gradual balloon dilation where the balloon is inflated then held at each balloon size for 30-60 seconds then inflated to the next largest balloon diameter size and repeated to the maximum diameter size of that catheter. The dilation session will be repeated as frequently and as many times as needed to achieve the balloon diameter size of 18mm at the discretion of the endoscopist.
48166450|NCT04730076|PROCEDURE|Progressive Balloon Dilation|In the progressive approach, the balloon is continuously inflated over the course of 3-5 minutes starting at the smallest to the largest balloon diameter depending of the balloon catheter used. The dilation will be repeated every 2-3 weeks (total of 2-3 sessions). At the next endoscopic procedure, the balloon diameter used will be the next size up based on previous session.
48166451|NCT04491006|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
48166452|NCT04491006|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
48166453|NCT03292198|OTHER|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists."
48166454|NCT03292198|OTHER|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
48166455|NCT03412578|PROCEDURE|Massage Therapy|Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
48166456|NCT03455218|DRUG|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
48166457|NCT03455218|DRUG|Placebo|INOmax device connected to oxygenator, but no gas is delivered
48166458|NCT03455218|DEVICE|INOmax|All patients will have the INOmax device connected to the oxygenator
48514505|NCT02401997|BEHAVIORAL|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
48166459|NCT05381181|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
48514506|NCT02318212|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
48514507|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
48009132|NCT03856762|DIETARY_SUPPLEMENT|Current Shanghai diet|current Shanghai diet supplement from Monday to Friday for six months
48009133|NCT04407728|OTHER|early ultrasound screening|"Women whose fetus is at high risk of congenital heart disease at the end of the 1st trimester screening ultrasound (EchoT1), will benefit from an early heart-centered morphological ultrasound (EchoMorpho-T1) by a referring sonographer between 11 and 14 SA +/- an early fetal cardiac ultrasound (EchoCoeur-T1) between 11 and 15 SA by a cardio-paediatrician in case of EchoMorpho-T1 abnormality.~The results of the early morphological and cardiac ultrasounds will be compared with those of the 2nd trimester ultrasound at 18-22SA (EchoMorpho-T2) and +/- of the fetal cardiac ultrasound between 18SA and 24SA (Gold standard) or, failing this, with the anatomopathological examination when it is available if a medical termination of pregnancy took place before the EchoMorpho-T2."
48009134|NCT00104533|DEVICE|Magnets|
48009135|NCT04036656|DRUG|SYHA136 0.5 mg|oral tablet
48009136|NCT04036656|DRUG|SYHA136 1 mg|oral tablet
48009137|NCT04036656|DRUG|SYHA136 2.5 mg|oral tablet
48009138|NCT04036656|DRUG|SYHA136 5 mg|oral tablet
48514508|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
48514509|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
48514510|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
48514511|NCT03928067|BEHAVIORAL|PNF + SAF|Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
48695455|NCT05929391|PROCEDURE|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
48695456|NCT04200755|DRUG|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
48009139|NCT04036656|DRUG|SYHA136 10 mg|oral tablet
48009140|NCT04036656|DRUG|SYHA136 20 mg|oral tablet
48009141|NCT04036656|DRUG|SYHA136 35 mg|oral tablet
48369774|NCT04835142|DRUG|Double blind control period A140|experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
48514512|NCT02181855|PROCEDURE|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
48009142|NCT04036656|DRUG|SYHA136 50 mg|oral tablet
48009143|NCT04036656|DRUG|Placebo matching SYHA136 0.5 mg|oral tablet
48009144|NCT04036656|DRUG|Placebo matching SYHA136 1 mg|oral tablet
48009145|NCT04036656|DRUG|Placebo matching SYHA136 2.5 mg|oral tablet
48009146|NCT04036656|DRUG|Placebo matching SYHA136 5 mg|oral tablet
48009147|NCT04036656|DRUG|Placebo matching SYHA136 10 mg|oral tablet
48009148|NCT04036656|DRUG|Placebo matching SYHA136 20 mg|oral tablet
48514513|NCT04844060|OTHER|Lumbar punction|Lumbar punction
48514514|NCT01845727|DRUG|Topical Amphotericin B at 3%|
48514515|NCT02743429|DRUG|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
48514516|NCT00693043|DRUG|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
48514517|NCT01150812|DRUG|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
48514518|NCT04569734|PROCEDURE|WATCHMAN device implant procedure utilizing ICE probe|The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation.
48695457|NCT04200755|OTHER|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
48695458|NCT04751994|DIETARY_SUPPLEMENT|Iron drops/Ferrous sulphate|participant will consume daily drops of iron
48695459|NCT04751994|DIETARY_SUPPLEMENT|Placebo drops|Participants will consume daily drops of placebo
48695460|NCT01287390|PROCEDURE|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
48009149|NCT04036656|DRUG|Placebo matching SYHA136 35 mg|oral tablet
48009150|NCT04036656|DRUG|Placebo matching SYHA136 50 mg|oral tablet
48009151|NCT05928650|OTHER|Evaluation of menstrual function|Evaluation of serum estradiol levels and menstrual history characteristics between sprinters, long marathon runners and non-athletes.
48009152|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
48009153|NCT00057746|RADIATION|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
48009154|NCT00057746|RADIATION|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
48009155|NCT03578510|DEVICE|Hemocontrol hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
48695461|NCT01287390|PROCEDURE|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
48695462|NCT01287390|OTHER|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
48009156|NCT03578510|DEVICE|Standard hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
48009157|NCT02679586|DEVICE|Diffusion weighted MRI|
48009158|NCT02637843|DEVICE|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
48009159|NCT03123159|DIAGNOSTIC_TEST|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
48009160|NCT06457022|OTHER|Modified Constraint Induced Movement therapy|patient wears a restraint instrument in his unaffected hand, then applying massed practice to his affected upper extremity. The patient wears padded glove in his unaffected upper extremity for restraining the patient from using his unaffected upper extremity for about 3 hours per day including the treatment session and the home program. So, by this way the patient is reinforced to use his affected upper extremity during this period of time to achieve his activities of daily living. Finally, the total time, the patient spends it during the day wearing the glove should be recorded each day.
48009161|NCT06457022|OTHER|Dual task training in the form of cognitive - motor task|Verbal fluency: Ask the hemiparetic patient to title many words of specific type as fruits, vegetable or animals. Mental tracking: as the hemiparetic patient to subtract serial 3 between number 90 and 100.
48009162|NCT06457022|OTHER|Conventional physiotherapy rehabilitation program|Ultrasound on shoulder. Graduated active exercises for shoulder. Prolonged stretching for spastic muscles
48009163|NCT01639027|DRUG|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
48009164|NCT01639027|DRUG|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
48009165|NCT03407872|DRUG|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
48009166|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
48009167|NCT03407872|DRUG|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
48009168|NCT03407872|DRUG|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
48009169|NCT04564625|OTHER|Vitamin D Assessment|index admission vitamin D assessment
48695463|NCT01287390|OTHER|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
48369775|NCT04835142|DRUG|Open single period A140|Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
48369776|NCT02666079|DEVICE|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
48369777|NCT01319422|DRUG|Pomalidomide|Comparison of different dosages and schedules of drug
48514519|NCT02732171|OTHER|Research Blood Collection|Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
48695464|NCT01287390|OTHER|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
48695465|NCT03150966|DRUG|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
48009170|NCT04564625|OTHER|Fracture|rate of nonunion (i.e., failure of a fractured bone to heal)
48009171|NCT03595111|PROCEDURE|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
48514520|NCT04539327|DRUG|Rucaparib|Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.
48695466|NCT03150966|DRUG|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
48166460|NCT03927222|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
48695467|NCT03977025|DIAGNOSTIC_TEST|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
48695468|NCT05790018|DEVICE|PREGNANT PILLOW|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
48695469|NCT01825148|OTHER|radiolabeled Exendin|
48695470|NCT00519324|DRUG|Everolimus|10 mg/day (2 tablets of 5 mg each)
48695471|NCT03539822|DRUG|Cabozantinib|by mouth
48695472|NCT03539822|DRUG|Durvalumab|infusion
48695473|NCT03539822|DRUG|Tremelimumab|infusion
48695474|NCT00391430|DRUG|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
48369778|NCT03151200|DEVICE|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
48369779|NCT03151200|DEVICE|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
48166461|NCT03927222|DRUG|Temozolomide|Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
48514521|NCT00658879|DRUG|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
48695475|NCT00391430|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
48695476|NCT05866679|DRUG|Hyperpolarized 13-C-pyruvate|Given by PO
48695477|NCT06347016|DRUG|Plozasiran Injection|ARO-APOC3 Injection
48695478|NCT06347016|DRUG|Placebo|sterile normal saline (0.9% NaCl)
48695479|NCT03866317|DRUG|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
48695480|NCT03515135|BEHAVIORAL|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
48695481|NCT01576146|DRUG|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
48695482|NCT03582553|DIETARY_SUPPLEMENT|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
48695483|NCT03582553|OTHER|Placebo|Cellulose
48695484|NCT00024024|DRUG|rebimastat|
48695485|NCT01468233|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
48695486|NCT01468233|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
48695487|NCT03922672|BEHAVIORAL|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
48166462|NCT03927222|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
48166463|NCT03927222|BIOLOGICAL|GM-CSF|Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
48514522|NCT03647085|DEVICE|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
48695488|NCT06361394|OTHER|mindfulness course|"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course."
48695489|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
48695490|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
48695491|NCT02832557|OTHER|Salivary collection|Collection of saliva via swab for miRNA processing
48695492|NCT02832557|OTHER|Vineland Adaptive Behavior Scale-III Assessment|
48695493|NCT02832557|OTHER|Medical history questionaire|
48695494|NCT02832557|OTHER|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
48695495|NCT02832557|OTHER|Mullen Scales of Early Learning|
48695496|NCT02991495|BIOLOGICAL|Stamaril, Sanofi Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
48695497|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Bio-Manguinhos|"1. Full dose~2. Fractional dose: one fifth (1/5)"
48695498|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
48695499|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
48166464|NCT03927222|BIOLOGICAL|111-Indium-labeling of Cells for in vivo Trafficking Studies|111-In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10\^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10\^7 DCs) prior to injection.
48166465|NCT06309485|DRUG|WGI-0301 at MTD/RP2D dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
48514523|NCT00643812|OTHER|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
48695500|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
48695501|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
48695502|NCT00517348|BIOLOGICAL|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
48695503|NCT03092986|DRUG|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
48695504|NCT03092986|DRUG|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
48695505|NCT03092986|DRUG|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
48695506|NCT03092986|DRUG|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
48695507|NCT03092986|RADIATION|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
48695508|NCT05807854|PROCEDURE|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
48695509|NCT05807854|DEVICE|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
48695510|NCT06662279|DEVICE|Removable Rapid Palatal Expander|Removable palatal expander where expanders are changed to obtain up to .25mm expansion per expander
48695511|NCT06662279|DEVICE|Banded Palatal Expander|Palatal expander cemented into mouth where a screw is turned to obtain .25mm expansion per turn
48695512|NCT01610219|BEHAVIORAL|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
48166466|NCT06309485|DRUG|WGI-0301 at MTD/RP2D -1 dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
48695513|NCT01610219|OTHER|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
48166467|NCT06309485|DRUG|Sorafenib 400 mg PO, BID continuously|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
48166468|NCT06309485|DRUG|Sorafenib 400 mg PO, BID|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
48166469|NCT05486871|PROCEDURE|laparoscopic partial nephrectomy|"This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes."
48009172|NCT05680766|OTHER|Cardiovascular endurance training|Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
48166470|NCT05262465|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|HLA-mismatched donor peripheral stem cell infusion
48166471|NCT05262465|DRUG|Azacitidine|azacytidine 50-75mg/m2
48166472|NCT05262465|DRUG|Venetoclax|Venetoclax 100-300mg/d ×3d，400mg 4-28d
48166473|NCT01993576|DRUG|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
48166474|NCT00816153|OTHER|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
48166475|NCT04145323|DIAGNOSTIC_TEST|ICG microangiography|Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
48695514|NCT04736212|DEVICE|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
48695515|NCT00438269|DRUG|Site-specific empiric regimens included: Meropenem|
48695516|NCT00438269|DRUG|Piperacillin/tazobactam|
48009173|NCT00803127|DEVICE|vs-sense|detection swab
48009174|NCT01457872|BEHAVIORAL|Strength-based case management|Strength-based case management
48009175|NCT01457872|BEHAVIORAL|Control condition - referral only|Referral only
48009176|NCT03612167|BEHAVIORAL|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
48166476|NCT05736302|OTHER|Doubly-Labeled Water|All eligible participants will receive a dose of doubly-labeled water.
48166477|NCT02526771|PROCEDURE|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
48166478|NCT02526771|PROCEDURE|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
48166479|NCT02187445|DRUG|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
48166480|NCT03539133|OTHER|collection of clinical data|prospectively and systematically collection of clinical research data from STEMI patients
48166481|NCT03498885|PROCEDURE|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
48166482|NCT03498885|PROCEDURE|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
48166483|NCT05736445|BEHAVIORAL|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
48514524|NCT00643812|OTHER|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
48695517|NCT00438269|DRUG|Ciprofloxacin and cefazolin +/- metronidazole|
48695518|NCT05064410|BEHAVIORAL|Educational Intervention|The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
48695519|NCT06655532|BEHAVIORAL|Exercise Program|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training twice weekly.
48695520|NCT06655532|BEHAVIORAL|Usual Care|Patients allocated to this arm will receive standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training. They will also receive a weekly phone call and an in-person monthly visit to monitor exercise training performance.
48369780|NCT05434741|BEHAVIORAL|Weekly Group Skills|The topics covered in group CBT sessions are: 1.) Domains of Healthy Aging; 2.) Stress and anxiety; 3.) Adherence and Engagement in Primary/Preventative Care; 4.) Depression and Distress; 5.) Physical Activity; 6.) Stigma/Self-Compassion; 7.) Substance Use; 8.) Acceptance of Uncertainty and Uncomfortable Emotions; 9.) Diet; 10.) Behavioral Activation; 11.) Frailty and Memory/Cognition; and 12.) Wrap-Up and Maintaining Gains.
48514525|NCT05583825|OTHER|Rebozo App|It is a non-invasive, non-drug practical application made with Rebozo, a long and colorful fabric, two meters long and 70 cm wide, worn by Mexican women on their head and shoulders.
48695521|NCT03223922|RADIATION|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
48695522|NCT06557889|DRUG|Pembrolizumab + Cisplatin/Carboplatin + 5-FU|"* 4 cycles of combination treatment: 4 cycles of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle) in combination with chemotherapy with platinum salts (cisplatin (100 mg/m2 IV on Day 1 of each 3-week cycle) or carboplatin (AUC 5 IV on Day 1 of each 3-week cycle), at the investigator's choice) and 5-FU (1000 mg/m2/day IV continuous from Day 1-4 of each 3-week cycle).~* Maintenance phase: pembrolizumab is continued as monotherapy for up to 24 months of treatment in total (from the first injection of cycle 1)."
48695523|NCT03459534|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
48009177|NCT03612167|BEHAVIORAL|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
48009178|NCT01108575|OTHER|IMST|inspiratory muscle strength training
48009179|NCT01108575|OTHER|Sham IMST|sham inspiratory muscle strength training
48009180|NCT03545607|BIOLOGICAL|MultiStem|single intravenous infusion 18-36 hours after stroke
48009181|NCT03545607|BIOLOGICAL|Placebo|single intravenous infusion 18-36 hours after stroke
48009182|NCT01177033|OTHER|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
48009183|NCT00006475|DRUG|imatinib mesylate|
48166484|NCT05171465|DEVICE|Neqstent or Contour|All patients included will be treated the same: after catheterizing the affected vessel and microcatheterizing the aneurysm with a microcatheter of 0.021'' or 0.027'', the intrasaccular device (Neqstent® or Contour®) will be positioned. Depending of the operator preference, the use of an intrasaccular device could be associated with coiling (mandatory in the case of Neqstent®). Treatment must be performed without previous double antiplatelet treatment (allowing antiplatelet after aneurysm exclusion). Before the treatment all patients should undergo a flat panel CT.
48166485|NCT01829828|BEHAVIORAL|No intervention|This is an observational study with no investigational drug administered.
48166486|NCT04493983|PROCEDURE|laparoscopic salpingo-oophorectomy|Laparoscopic bilateral salpingo-oophorectomy
48166487|NCT04493983|PROCEDURE|Laparoscopic bilateral salpingo-oophorectomy|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
48009184|NCT03678142|DIAGNOSTIC_TEST|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
48009185|NCT00638703|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks
48009186|NCT00638703|DRUG|Placebo|placebo
48695524|NCT05305118|PROCEDURE|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
48166488|NCT00961610|BEHAVIORAL|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
48166489|NCT05163106|DRUG|Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
48514526|NCT03065946|OTHER|Early wakening|By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
48514527|NCT00998309|DRUG|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
48695525|NCT05305118|DEVICE|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
48695526|NCT06660524|DRUG|Sevelamer|Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
48695527|NCT06660524|DRUG|Calcium carbonate|Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
48695528|NCT04251897|DEVICE|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
48695529|NCT02441153|OTHER|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
48695530|NCT05735171|PROCEDURE|GTR surgery|Gross total resection of the enhancing tumor volume
48695531|NCT05735171|PROCEDURE|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
48514528|NCT03789929|BEHAVIORAL|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
48695532|NCT02118181|DIETARY_SUPPLEMENT|HMB|
48009187|NCT01135810|BEHAVIORAL|Hypnosis|
48009188|NCT01135810|BEHAVIORAL|Meditation|
48009191|NCT02431858|DEVICE|E-Catheter (Pajunk)|
48009192|NCT02431858|DEVICE|Sonolong Catheter (Pajunk)|
48009193|NCT04091646|DRUG|Roflumilast Foam 0.3%|Roflumilast foam for topical application.
48009194|NCT04091646|DRUG|Vehicle foam|Vehicle foam for topical application.
48009195|NCT02281721|DEVICE|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
48695533|NCT05295784|DRUG|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
48009196|NCT06163066|OTHER|Newborn Basic Care Training|These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
48009197|NCT03829735|OTHER|Human biological samples|Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
48009198|NCT05596526|BIOLOGICAL|recombinant zoster vaccine|Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60
48166490|NCT05163106|DRUG|Goserelin|Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
48166491|NCT00006099|BIOLOGICAL|Monoclonal antibody hu3S193|Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
48166492|NCT02486159|DRUG|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
48166493|NCT02486159|PROCEDURE|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
48166494|NCT03557450|DEVICE|PET/CT Scan|PET/CT scanning with sodium fluoride
48166495|NCT00700518|DRUG|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
48166496|NCT00700518|DRUG|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
48166497|NCT00700518|DRUG|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
48166498|NCT00700518|DRUG|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
48166499|NCT00700518|DRUG|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
48166500|NCT05596149|OTHER|Toothpaste without fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
48166501|NCT05596149|OTHER|Toothpaste with sodium fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
48695534|NCT01386489|BIOLOGICAL|VRC-HIVDNA016-00-VP|
48695535|NCT01386489|BIOLOGICAL|VRC-HIVADV014-00-VP|
48695536|NCT02591472|PROCEDURE|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48695537|NCT02591472|PROCEDURE|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
48695538|NCT02591472|OTHER|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48009199|NCT06211816|OTHER|communication strategy|an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
48009200|NCT03019627|DRUG|NGF|Eye Drop 20 μg/mL
48009201|NCT03019627|OTHER|Vehicle|Vehicle Eye Drop
48009202|NCT00260234|BIOLOGICAL|Allogeneic Cultured Islet Cells (human); Encapsulated|
48514529|NCT03789929|BEHAVIORAL|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
48695539|NCT02591472|OTHER|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48695540|NCT02591472|OTHER|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48695541|NCT02591472|OTHER|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48695542|NCT02591472|OTHER|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48695543|NCT02591472|OTHER|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48695544|NCT02591472|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48695545|NCT02591472|OTHER|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
48369781|NCT05434741|OTHER|"One-time Trifold Brochure titled HIV: 50 Years or Older"|"Participants in the education only group will receive a one-time trifold brochure titled HIV: 50 Years or Older. This brochure contains information on the prevalence of HIV among people aged 50 and older, defines medication adherence and drug resistance, encourages physical activity and proper nutrition, and addresses the health risk behavior of tobacco-smoking for people living with HIV. Participants receive one brochure in the information-only group."
48166502|NCT05596149|OTHER|Toothpaste with sodium monofluorophosphate|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
48695546|NCT05343689|PROCEDURE|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
48369782|NCT00368212|BEHAVIORAL|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
48369783|NCT00368212|BEHAVIORAL|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
48695547|NCT05063565|DEVICE|TheraSphere Y-90 glass microsphere therapy|TheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure.
48695548|NCT05063565|DRUG|Durvalumab (Imfinzi) immunotherapy|"1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor. Treatment beyond confirmed radiographic progression is permitted per patient consent if the following criteria are met:~* Absence of clinical symptoms or signs indicating clinically significant disease progression~* No decline in performance status~* Absence of rapid disease progression or threat to vital organs or critical anatomical sites (i.e. new CNS metastasis, respiratory failure due to tumor compression, spinal cord compression) requiring urgent alternative medical intervention~* No other treatment discontinuation criteria are met"
48695549|NCT05063565|DRUG|Tremelimumab immunotherapy|300 mg, single administration
48695550|NCT06659055|RADIATION|DXA Imaging|DXA imaging: lumbar spine, bi-lateral femoral necks
48695551|NCT06659055|RADIATION|EOSedge imaging|Full body or full spine image
48695552|NCT03195218|DEVICE|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
48695553|NCT04720755|DEVICE|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm\^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
48695554|NCT06108193|DRUG|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
48695555|NCT00680355|DIETARY_SUPPLEMENT|golden rice|An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene
48009203|NCT01020071|PROCEDURE|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
48369784|NCT04474717|DIAGNOSTIC_TEST|Breath Condensate Collection|Breath Condensate Collection
48369785|NCT04474717|DIAGNOSTIC_TEST|clinical examination, spirometry|spirometry
48369786|NCT04474717|DIAGNOSTIC_TEST|blood monocyte assay|study of blood monocytes in the laboratory of cell technology
48369787|NCT06006481|OTHER|Survey|Extended Nordic Musculoskeletal Questionnaire Pain Management Inventory Maslach Burnout Scale Vocational Satisfaction Scale
48369788|NCT02895386|DEVICE|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
48369789|NCT02895386|OTHER|Sham procedure|Sham procedure + continuing current antihypertensive medications.
48695556|NCT00680355|DIETARY_SUPPLEMENT|corn oil 0g|0 g of corn oil in the golden rice meal
48695557|NCT00680355|DIETARY_SUPPLEMENT|corn oil 10g|10g corn oil in the golden rice meal
48695558|NCT00680355|DIETARY_SUPPLEMENT|coren oil 5 g|golden rice meal with 5 g corn oil
48695559|NCT03796390|BIOLOGICAL|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
48695560|NCT01184638|DRUG|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
48695561|NCT01184638|DRUG|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
48695562|NCT02603601|BEHAVIORAL|Mind-body lifestyle intervention|
48369790|NCT04551248|BIOLOGICAL|10 or 13-valent pneumococcal conjugate vaccine|a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.
48369791|NCT04551248|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5-mL dose administered intramuscularly or subcutaneously only.
48369792|NCT04551248|BIOLOGICAL|Influenza vaccine|One dose of trivalent influenza vaccine in flu seasons.
48514530|NCT00005195|PROCEDURE|Catheter ablation|
48695563|NCT02603601|BEHAVIORAL|Standard lifestyle intervention|
48695564|NCT02147730|PROCEDURE|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
48166503|NCT05596149|OTHER|Toothpaste with amine fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
48369793|NCT03846895|DEVICE|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
48695565|NCT02147730|PROCEDURE|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
48695566|NCT05155761|DEVICE|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
48695567|NCT04821102|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
48695568|NCT04821102|DRUG|Saline|saline, 1 time injection under ultrasonic guided
48695569|NCT04410562|DRUG|Hydroxychloroquine|Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
48695570|NCT04410562|DRUG|Placebo|Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
48695571|NCT00153140|DRUG|polyethyleneglycol3350|
48166504|NCT02694796|BEHAVIORAL|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
48166505|NCT03966534|OTHER|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
48166506|NCT00895089|DRUG|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
48695572|NCT05895331|DIAGNOSTIC_TEST|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
48166507|NCT00895089|DRUG|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
48369794|NCT01395420|DRUG|CAZ104|IV Infusion
48369795|NCT01395420|DRUG|CAZ104|IV Infusion
48369796|NCT04067687|OTHER|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
48369797|NCT04170725|OTHER|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
48369798|NCT03752502|PROCEDURE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
48369799|NCT03752502|PROCEDURE|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
48369800|NCT03752502|PROCEDURE|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
48369801|NCT03398759|DRUG|Butorphanol|IV injection during induction
48369802|NCT03398759|DRUG|Placebos|IV injection during induction
48369803|NCT04106674|PROCEDURE|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
48369804|NCT03149341|OTHER|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
48166508|NCT04414397|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC injectable gel
48166509|NCT04414397|OTHER|No-treatment control|Participants received no treatment for 3 months during the Control Period.
48369805|NCT04273594|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
48369806|NCT00126321|DRUG|cladribine|2-chlorodeoxyadenosine, 2-CdA
48369807|NCT04945291|BEHAVIORAL|New way of counting calories using the hands|The participants will learn how to estimate the portions and calories content of food using their hands as a measurement tool;
48009204|NCT04723199|DEVICE|Electrocautetery LAMS|Electrocautetery LAMS
48695573|NCT02814240|OTHER|NMR|
48695574|NCT02814240|BIOLOGICAL|Blood samples|
48695575|NCT02814240|OTHER|fibroscan|
48695576|NCT05130905|DIETARY_SUPPLEMENT|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
48695577|NCT02383888|DRUG|BI 425809|
48695578|NCT02383888|DRUG|BI 425809|
48009205|NCT03112161|OTHER|Eucaloric Feeding Period|
48009206|NCT03112161|OTHER|Overfeeding Feeding Period|
48695579|NCT02383888|DRUG|Placebo|
48009207|NCT03112161|OTHER|Underfeeding Feeding Period|
48009208|NCT01545921|OTHER|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
48369808|NCT04945291|BEHAVIORAL|Mobile applications|the participant will use a mobile application to log their calories
48695580|NCT02383888|DRUG|BI 425809|
48695581|NCT06661343|BEHAVIORAL|C4 Program|The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
48695582|NCT06661343|BEHAVIORAL|C4 + 3MV Program|This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
48695583|NCT02777047|OTHER|Anticoagulation Coordinated Care|see above
48695584|NCT06517225|BEHAVIORAL|Visual-acoustic biofeedback|Behavioral: Visual-acoustic biofeedback In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. The web-based software staRt will be used for intervention delivery.
48695585|NCT05203211|PROCEDURE|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
48695586|NCT03207321|DIETARY_SUPPLEMENT|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
48695587|NCT02664311|DEVICE|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
48695588|NCT02664311|DEVICE|Conventional ventilation|Conventional ventilator - control arm
48695589|NCT02302092|DRUG|Flomoxef|Flomoxef intravenous infusion
48695590|NCT02302092|DRUG|Cefepime|Cefepime intravenous infusion
48695591|NCT03988621|BEHAVIORAL|ViCCY|Virtual Caregiver Coach for You
48695592|NCT06660706|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
48695593|NCT00499330|PROCEDURE|lobectomy|
48695594|NCT00499330|PROCEDURE|segmentectomy or wedge resection|
48009209|NCT04688164|DRUG|REL-1017|REL-1017 tablet
48009210|NCT04688164|DRUG|Placebo|Placebo tablet
48009211|NCT03063827|DRUG|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
48009212|NCT03063827|DIAGNOSTIC_TEST|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
48009213|NCT04160260|DRUG|Omadacycline|Omadacycline: PO Tablets
48514531|NCT05314101|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
48166510|NCT01111136|BEHAVIORAL|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
48166511|NCT04364750|DIETARY_SUPPLEMENT|L-Histidine|1 capsule (0.6g) twice daily
48166512|NCT04364750|DIETARY_SUPPLEMENT|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
48166513|NCT04364750|DIETARY_SUPPLEMENT|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
48166514|NCT04364750|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
48166515|NCT04364750|OTHER|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
48166516|NCT03255915|DRUG|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
48166517|NCT03255915|OTHER|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
48166518|NCT03565783|BIOLOGICAL|Cemiplimab|Given IV
48166519|NCT00919009|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
48166520|NCT05958784|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
48166521|NCT00243633|PROCEDURE|Real-time contrast-enhanced ultrasound sonography|
48166522|NCT03496337|OTHER|Assessment of motor and process skills test|At baseline and follow-up (after 8-10 weeks) all patients are assessed with AMPS in addition to the standard test of Canadian Occupational Performance Measure (COPM) hand grip strength and joint range of motion.
48166523|NCT04007146|DIAGNOSTIC_TEST|Transcutaneous oxymetry measurement|Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
48166524|NCT06483269|PROCEDURE|PRP infiltration|"a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician.~It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site.~PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat.~PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations."
48369809|NCT05248685|BIOLOGICAL|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
48369810|NCT06394427|OTHER|cycles of neoadjuvant therapy and duration of waiting for surgery|We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
48514532|NCT05314101|DRUG|bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
48514533|NCT05314101|DRUG|TAS-102|Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
48514534|NCT02552121|DRUG|Tisotumab vedotin (HuMax-TF-ADC)|
48166525|NCT04255121|DRUG|2% adrenaline lidocaine associated with 4.2% sodium bicarbonate|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
48166526|NCT04255121|DRUG|2% adrenaline lidocaine|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
48166527|NCT00000578|DRUG|theophylline|
48166528|NCT00000578|DRUG|beclomethasone|
48166529|NCT04350983|BEHAVIORAL|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
48166530|NCT01562483|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
48166531|NCT01562483|DRUG|Placebo|Identical to the Namisol arm.
48166532|NCT00683397|OTHER|Blood sampling|Screening of thrombophilia
48166533|NCT03650244|DEVICE|REMEEX implantation|Device implantation
48166534|NCT02969629|DRUG|Apomorphine|
48166535|NCT02969629|DRUG|Normal Saline|
48009214|NCT03360292|OTHER|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
48009215|NCT01820611|DEVICE|Arcos Revision Stem System|Revision Hip System
48166536|NCT06023888|OTHER|Mapping strategy|The ablation strategy was based on the mapping results of periodicity.
48166537|NCT06023888|OTHER|Mapping strategy|PVI+ non-PV trigger
48522736|NCT03119402|DEVICE|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
48522737|NCT03685916|OTHER|Control|Plain rice with plain water
48522738|NCT03685916|OTHER|Cumin Rice|Cumin rice with plain water
48695595|NCT04233398|DEVICE|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
48695596|NCT00094159|DRUG|SNS-595|
48695597|NCT05460533|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
48166538|NCT05324813|BEHAVIORAL|Domain-Specific Episodic Future Thinking|Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
48166539|NCT03284593|DRUG|intensive chemotherapy|
48166540|NCT03284593|DRUG|Azacitidine|
48369811|NCT05579509|DRUG|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
48369812|NCT05579509|BEHAVIORAL|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
48369813|NCT03582917|DRUG|Alphacalcidol|Alphacalcidol 0,5mg tablet
48369814|NCT00001961|PROCEDURE|MRI|
48369815|NCT04340102|BEHAVIORAL|BecomeAnEx|This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
48369816|NCT01673204|DRUG|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
48369817|NCT01673204|DRUG|Placebo|
48369818|NCT06062394|BEHAVIORAL|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
48369819|NCT04350034|OTHER|Xbox training|"patients in this group received routine physical therapy protocol plus Xbox training.~Before the intervention started, the Xbox group was given a 45 min introductory session on how to use the xbox adventure games and its tools. All sessions were led by a single experienced physiotherapist (different to the physiotherapist who performed the assessments tests) in order to provide instruction on how to perform each exercise."
48522739|NCT03685916|OTHER|Cumin Drink|Cumin drink with plain rice
48522740|NCT03685916|OTHER|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
48522741|NCT03685916|OTHER|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
48522742|NCT03685916|OTHER|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
48522743|NCT03685916|OTHER|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
48522744|NCT03685916|OTHER|Tamarind Rice|Tamarind rice with plain water
48166541|NCT00125853|DRUG|Nebivolol|Nebivolol 2.5mg daily
48166542|NCT00125853|DRUG|Atenolol|Atenolol 25mg daily
48166543|NCT05765890|OTHER|No treatment given|No treatment given
48166544|NCT05182970|DRUG|Metformin|Individualised target dose of 2000 mg daily depending on tolerability.
48166545|NCT02720081|DRUG|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
48166546|NCT02720081|DRUG|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
48166547|NCT02720081|DRUG|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
48166548|NCT02720081|DRUG|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
48522745|NCT03685916|OTHER|Tamarind Drink|Tamarind drink with plain rice
48695598|NCT05596461|DEVICE|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
48009216|NCT00013117|BEHAVIORAL|Telephone specialist consultation|
48009217|NCT06010394|OTHER|conventional physiotherapy|ultrasound electrotherapy cold applications
48166549|NCT00235014|DRUG|trandolapril|2 mg QD
48166550|NCT00235014|DRUG|trandolapril/verapamil|180/2 mg QD
48695599|NCT05596461|DEVICE|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
48166551|NCT00235014|DRUG|placebo|1 tablet QD
48166552|NCT00235014|DRUG|verapamil|SR 240 mg QD
48369820|NCT04350034|OTHER|Control group|routine physical therapy protocol (RPTP) including joint range of motion exercises (ROM), muscle stretching technique, splinting, daily walking, and ADL training.
48695600|NCT05607511|OTHER|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
48695601|NCT00937742|DIETARY_SUPPLEMENT|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
48369821|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
48369822|NCT02225626|DRUG|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
48369823|NCT02225626|DRUG|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
48369824|NCT03931629|PROCEDURE|CONVENTIONAL PHACO|Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
48369825|NCT03244280|DRUG|MOB015B|Topical formulation
48695602|NCT04103151|DEVICE|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
48009218|NCT06010394|OTHER|exercises for the knee area|range of motion exercises strengthening exercises exercises to reduce edema
48009219|NCT06010394|OTHER|payment oriented massage|10 / 15-minute massage treatments to reduce payment
48009220|NCT03582488|DRUG|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
48009221|NCT01894828|DIETARY_SUPPLEMENT|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
48369826|NCT03672136|DRUG|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
48369827|NCT03672136|OTHER|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
48009222|NCT03060434|DRUG|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
48009223|NCT03060434|DRUG|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
48009224|NCT00017758|DRUG|Pravastatin sodium|
48009225|NCT00017758|DRUG|Simvastatin|
48009226|NCT00017758|DRUG|Atorvastatin calcium|
48009227|NCT00017758|DRUG|Nelfinavir mesylate|
48009228|NCT00017758|DRUG|Efavirenz|
48009229|NCT02994862|OTHER|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
48009230|NCT02994862|OTHER|Conventional Bonding|Normal Bonding Protocol
48166553|NCT04775173|DRUG|Sirolimus|Use of different doses of the same drug
48166554|NCT03248713|DRUG|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
48166555|NCT03248713|DRUG|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
48166556|NCT05501496|PROCEDURE|intramedullary nailing|Flexible intramedullary nailing using 2 nails
48166557|NCT05501496|PROCEDURE|casting|casting with long leg cast
48166558|NCT00586742|PROCEDURE|labral repair|labral repair with suture anchors
48166559|NCT00586742|PROCEDURE|biceps tenodesis|biceps tenodesis with suture anchor
48166560|NCT00586742|PROCEDURE|diagnostic arthroscopy|diagnostic arthroscopy
48166561|NCT00563745|DEVICE|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
48166562|NCT02067455|OTHER|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
48166563|NCT02203045|OTHER|Total Knee Arthroplasty|
48166564|NCT03922295|PROCEDURE|Endoscopic tympanoplasty|"In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only"
48166565|NCT01889277|DRUG|MT-3995-Low|
48166566|NCT01889277|DRUG|MT-3995-High|
48166567|NCT01889277|DRUG|Placebo|
48009231|NCT03560323|DRUG|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
48009232|NCT01985737|OTHER|Sample collection|
48009233|NCT04389411|DRUG|Montelukast 10mg|10mg oral Montelukast will be taken daily for 60 days
48009234|NCT00401011|DRUG|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
48166568|NCT05854771|OTHER|Single bout of yoga before eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend before the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition maximum of each participant will be calculated first, and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
48009235|NCT00401011|DRUG|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
48166569|NCT05854771|OTHER|Single bout of yoga after eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend after the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition of each participant will be calculated first and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
48166570|NCT04131010|DEVICE|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
48166571|NCT00282828|DRUG|Sertraline|
48166572|NCT00282828|DRUG|Venlafaxine|
48166573|NCT00282828|DRUG|Placebo|
48166574|NCT00282828|DRUG|Clonazepam|
48166575|NCT03415347|PROCEDURE|Abscess de-roofing and curettage|Abscess de-roofing and curettage
48166576|NCT03415347|PROCEDURE|Abscess wide local excision|Abscess wide local excision
48166577|NCT01451697|BEHAVIORAL|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
48695603|NCT04120883|DRUG|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
48695604|NCT04120883|DRUG|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
48009236|NCT00401011|DRUG|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
48009237|NCT04355962|DRUG|Sevoflurane|Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS
48009238|NCT04355962|DRUG|Intravenous drug|Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine
48009239|NCT04412330|OTHER|ICU Recovery + Physical Therapy|Physical therapy interventions will be supervised by a physical therapist (\>20 years of experience in ICU and pulmonary rehabilitation). Potential interventions include endurance/aerobic training (treadmill training, upper and lower extremity ergometer, and recumbent step machine), upper and lower extremity resistance strength training, balance training, functional movement training, and education. If the interventions are providing in the home environment the exercises will be completed through Zoom, video communications app. Home-based interventions will include seated and standing exercise including resistance exercises (such as lifting small weights) and endurance (e.g. marching or stepping in place, repetitive sit-to-stand training). Physical therapist will provide verbal instructions for motivation and adherence to exercise interventions.
48009240|NCT06417086|OTHER|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
48009241|NCT06417086|OTHER|Sham Acupuncture|The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.
48009242|NCT06417086|DRUG|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks.
48009243|NCT05716711|OTHER|LAVENDER OIL|IT WILL BE APPLIED TO 60 PATIENTS, 20 IN EACH GROUP, WITH A COLOSTOMY
48009244|NCT00259558|DRUG|retarded release phosphatidylcholine|
48009245|NCT04512911|PROCEDURE|Endocardial ablation|Endocardial ablation of VT
48009246|NCT04512911|PROCEDURE|Endocardial- Epicardial ablation|Epicardial ablation of VT in addition to endocardial ablation
48009247|NCT04512911|DRUG|Antiarrhythmic medications|Addition of anti arrhythmic medication or dose increase
48009248|NCT00667238|BEHAVIORAL|Questionnaire|
48009249|NCT00431249|DRUG|Cilostazol|
48009250|NCT03676452|BEHAVIORAL|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
48009251|NCT01156285|OTHER|Filling in a patient questionnaire|Filling in a patient questionnaire
48009252|NCT01440946|DRUG|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
48009253|NCT01440946|DRUG|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
48166578|NCT01451697|BEHAVIORAL|Control (Placebo)|The control condition will involve relaxation training.
48166579|NCT01570621|PROCEDURE|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
48166580|NCT03015844|DRUG|131-I-meta-iodobenzylguanidine|
48009254|NCT03097653|OTHER|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
48009255|NCT03097653|OTHER|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
48695605|NCT02997436|DEVICE|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
48009256|NCT00649181|DRUG|Metolazone Tablets 5 mg|2x5mg, single dose fasting
48166581|NCT03219255|DRUG|RELVAR 100 ELLIPTA|RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
48695606|NCT02110654|DRUG|Montelukast|
48695607|NCT02110654|DRUG|mometasone furoate nasal spray|
48009257|NCT00649181|DRUG|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
48009258|NCT05470816|DRUG|Tranexamic Acid 100Mg/ml Inj Vial 10ml|Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
48369828|NCT03661281|DIAGNOSTIC_TEST|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
48369829|NCT03661281|DIAGNOSTIC_TEST|Pinch strength|Measured in every splint position using a standard dynamometer
48695608|NCT06660966|PROCEDURE|M TAPA block|Grup M: The patients who underwent M-TAPA block were placed in the supine position. The right upper quadrant of the abdomen was cleaned with antiseptic solution. For the block procedure, 20-30 ml of 0.25% bupivacaine, 22G 8.5 cm stimuplex needle and 10-14 Hz high frequency USG were prepared for the procedure. The USG probe was determined in the costochondral area at the mid-clavicular line, and the internal and transversus abdominis muscles were determined. The needle was advanced with the in plane technique from cephalad to caudal, passing through the skin, subcutaneous, external and internal oblique muscles, respectively, and then over the transversus abdominis fascia. After the target was confirmed with 2 ml of saline, 0.3 mg / kg bupivacaine (20-30 ml) was administered.
48695609|NCT06660966|PROCEDURE|ESP block group|"In Group E, patients who were to undergo ESP block were placed in the lateral position with the right side up. The T8-T10 dorsal region was cleaned appropriately with antiseptic solution. For the block procedure, 20-30cc %0.25 bupivacaine, 22G 8.5cm stimuplex needle and 10-14Hz high frequency USG were prepared for the procedure.~The USG probe is first determined in the sagittal direction, the spinous process of the T10 thoracic vertebra is then followed 1-2 cm above the transverse process, with the in plane technique, the skin, subcutaneous tissue and erector spina muscle are passed, the needle is touched to the transverse process and the target is confirmed with 2cc saline, then 20-30 cc (0.5 mg / kg bupivacaine) of local anesthetic is administered and the procedure is terminated."
48695610|NCT04248244|OTHER|Palliative Care|Early PC Integration - Participants will meet with a member of the outpatient PC team, which consists of board-certified PC physicians, advance practice providers and nurse care coordinators, within three weeks of enrollment. Participants will be scheduled to meet with a PC provider at least once per month. Additional visits may be scheduled at the discretion of participants, oncologists or PC providers. All participants will receive routine oncologic care throughout the study period.
48009259|NCT05470816|DRUG|Placebo|Normal saline
48009260|NCT04452266|OTHER|questionnaire assesment|Each patient will to answer questions about their medical history.
48369830|NCT03661281|DIAGNOSTIC_TEST|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
48695611|NCT04248244|OTHER|FACT-MM questionnaire|FACT-MM questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
48166582|NCT04035863|DEVICE|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
48166583|NCT00502983|BEHAVIORAL|Interview|Interview lasting approximately 50 minutes.
48166584|NCT05943210|RADIATION|Short Course Radiation Therapy (scRT)|Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
48166585|NCT05943210|PROCEDURE|Total Mesenteric Excision (TME)|Subjects are expected to undergo total mesenteric Excision(TME) even if subjects have achieved complete response by imaging.TME is a specific surgical technique used in the treatment of rectal cancer in which the bowel with the tumor is entirely removed along with surrounding fat and lymph nodes.
48166586|NCT01702519|DRUG|nicotine|nicotine transdermal patch
48166587|NCT01357447|DRUG|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
48166588|NCT01357447|DRUG|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
48166589|NCT04599387|OTHER|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
48695612|NCT04248244|OTHER|HADS questionnaire|HADS questionnaires will be administered by a research coordinator upon enrollment and at four time points from the date of enrollment: 3 months, 6 months, 9 months and 12 months. All questionnaires will be administered in handwritten paper-based form, and while patients are in clinic. There is a +/- two-week window for completion of questionnaires to accommodate patient schedules. The assessment battery takes approximately 20 minutes to complete.
48166590|NCT04599387|OTHER|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
48166591|NCT06646289|BIOLOGICAL|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered sub-retinally.
48369831|NCT03107273|OTHER|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
48695613|NCT05735184|DRUG|Ziftomenib|Oral Administration
48695614|NCT05735184|DRUG|Venetoclax|Oral Administration
48695615|NCT05735184|DRUG|Azacitidine|Subcutaneous or Intravenous Administration
48695616|NCT05735184|DRUG|Daunorubicin|Intravenous Administration
48695617|NCT05735184|DRUG|Cytarabine|Intravenous Administration
48695618|NCT03755674|PROCEDURE|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
48695619|NCT00201422|OTHER|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
48695620|NCT06661512|OTHER|Neurorehabilitation program|"Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral)."
48522746|NCT02906670|DRUG|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
48695621|NCT03305796|RADIATION|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
48695622|NCT02552745|DRUG|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
48695623|NCT04305509|OTHER|no intervention|no intervention
48695624|NCT05010486|PROCEDURE|rectal surgery|
48695625|NCT05416372|BEHAVIORAL|Religious Engagement in Health Intervention|Religious Engagement in Health Intervention for blood pressure (BP) includes three evidence-based components: (1) educational sessions for Christian and Muslim leaders on religious teachings and medical aspects of BP, (2) equipping religious leaders to provide BP teaching in their communities using knowledge learned from educational sessions and through longitudinal mentorship meetings, and (3) community BP screening organized by religious leaders in partnership with local health care workers, and referrals for clinical care as needed.
48695626|NCT03308968|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
48695627|NCT03308968|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
48166592|NCT06646289|OTHER|No intervention (Follow-Up assessment)|Participants will not receive any intervention and will undergo follow-up assessment.
48166593|NCT04021927|DEVICE|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
48166594|NCT04584359|OTHER|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
48166595|NCT04584359|OTHER|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
48166596|NCT04584359|OTHER|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
48166597|NCT01792583|DRUG|Modafinil/armodafinil|
48166598|NCT02435381|DRUG|Carisbamate|600mg Orally on days 2-4
48166599|NCT02435381|DRUG|Placebo|Placebo treatment only
48695628|NCT02382874|BIOLOGICAL|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
48695629|NCT00280618|DRUG|Oxaliplatin|
48695630|NCT00791479|DRUG|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
48695631|NCT00791479|DRUG|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
48695632|NCT06661304|OTHER|Benson Relaxation Exercise|Benson relaxation exercise is based on the patient relaxing their body muscles by focusing on deep breathing and a word that means something to them.
48695633|NCT06661304|OTHER|Ongoing treatment|In addition to their medical treatment and care in the clinics, patients participate in activities such as group activities, leisure time and walking.
48695634|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
48695635|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
48695636|NCT06658418|PROCEDURE|Erector Spinae Plane Block|dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.
48695637|NCT00825942|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
48166600|NCT01251887|DIETARY_SUPPLEMENT|Linoleic Acid|
48166601|NCT01251887|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|
48166602|NCT01251887|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|
48695638|NCT03142841|OTHER|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
48695639|NCT06662006|DRUG|nal-IRI,5-fu,LV, benmelstobart, anlotinib|liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
48695640|NCT04611347|DRUG|CBD|Topical CBD application for thumb basal joint osteoarthritis.
48695641|NCT04611347|DRUG|Shea Butter|Placebo Shae Butter for comparison
48695642|NCT03465397|DIAGNOSTIC_TEST|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
48695643|NCT04699838|DRUG|Cisplatin|Cisplatin
48695644|NCT04699838|DRUG|Carboplatin|Carboplatin
48695645|NCT04699838|DRUG|Etoposide|Etoposide
48166603|NCT02123277|DEVICE|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
48166604|NCT01933529|DRUG|ARA 290|ARA 290 is injected s.c. once daily during the study period
48166605|NCT06280118|OTHER|Fatigue|Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track.
48166606|NCT01912183|BEHAVIORAL|Communication through PHR outside clinic|
48166607|NCT01912183|BEHAVIORAL|Monitoring device in PHR|
48166608|NCT01912183|DEVICE|Physical activity and sleep monitor|
48695646|NCT04699838|DRUG|Durvalumab|Durvalumab
48695647|NCT04699838|DRUG|Ceralasertib|Ceralasertib
48695648|NCT01222117|BIOLOGICAL|Plasmin|Plasmin prepared in 0.9% saline for injection
48695649|NCT01222117|BIOLOGICAL|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
48695650|NCT01222117|OTHER|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
48695651|NCT03482648|DRUG|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
48695652|NCT03482648|DRUG|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
48695653|NCT03482648|DRUG|Placebo|Placebo matched to BBT-401-1S, oral capsule
48695654|NCT00711048|DRUG|AZD1386|oral, single dose
48695655|NCT00711048|DRUG|Placebo|Oral solution, single dose
48695656|NCT01028768|DRUG|Teduglutide|10 mg, one-time subcutaneous
48166609|NCT01912183|OTHER|PHR|Access to their PHR
48166610|NCT03681353|BEHAVIORAL|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
48166611|NCT00162552|DRUG|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
48166612|NCT00162552|DRUG|PLACEBO|Patients with severe cirrhosis treated with a placebo
48166613|NCT05460429|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
48166614|NCT04098393|DRUG|Busulfan 3.2 mg/kg/day|Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
48166615|NCT04098393|DRUG|Fludarabine|Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
48166616|NCT04098393|DRUG|Melphalan|Melphalan (70mg/m2/day) administered on days -6 and -5.
48166617|NCT04098393|DRUG|Antithymocyte globulin (ATG)|ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
48166618|NCT04098393|DRUG|Busulfan 0.8 mg/kg|Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
48695657|NCT04670068|DRUG|CAR.B7-H3|Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
48166619|NCT04098393|PROCEDURE|Allogeneic hematopoietic cell transplantation (Allo-HCT)|Allogeneic hematopoietic cell transplantation following the conditioning regimen.
48166620|NCT02494453|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
48166621|NCT02494453|PROCEDURE|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
48166622|NCT03524950|DRUG|Dexmedetomidine|Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
48166623|NCT02182583|DRUG|Ba253MDI|
48369832|NCT05115682|BEHAVIORAL|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
48695658|NCT04670068|DRUG|Fludarabine|30 mg/m\^2 IV for 3 consecutive days
48166624|NCT02182583|DRUG|Ba253BINEB|
48369833|NCT01827462|BIOLOGICAL|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
48369834|NCT01827462|BIOLOGICAL|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
48369835|NCT01827462|BIOLOGICAL|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
48369836|NCT03629405|OTHER|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
48369837|NCT03629405|OTHER|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
48369838|NCT04881149|DEVICE|TempSure treatment|Self-controlled, single-arm study using the TempSure device.
48369839|NCT04769258|BIOLOGICAL|Pfizer Comirnaty vaccine|COVID 19 vaccines administered to the patients according to the times and modalities established by the Italian National Vaccination Plan. Further vaccines will be evaluated if and when they are available in Italy during the study period.
48514535|NCT06140446|DEVICE|FeverApp|The (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well.
48695659|NCT04670068|DRUG|Cyclophosphamide|300 mg/m\^2 IV for 3 consecutive days
48166625|NCT01700114|DEVICE|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
48166626|NCT01915992|OTHER|blood samples|
48166627|NCT01136798|DRUG|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
48166628|NCT01136798|DRUG|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
48166629|NCT03180008|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
48369840|NCT02291952|BEHAVIORAL|Meal schedule|
48369841|NCT00496691|BEHAVIORAL|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
48514536|NCT06140446|DEVICE|DMT App|The (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products.
48514537|NCT01174043|DRUG|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
48514538|NCT02295917|DEVICE|Transvaginal sonography|Transvaginal sonography
48514539|NCT01368315|DRUG|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
48514540|NCT01368315|DRUG|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
48514541|NCT01368315|DRUG|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
48514542|NCT01368315|DRUG|No intervention|No intervention to one out of four test fields marked on the patient's back.
48514543|NCT03449446|DRUG|SEL|18 mg tablet administered orally once daily without regard to food
48166630|NCT03180008|BEHAVIORAL|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
48166631|NCT02306213|DRUG|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
48166632|NCT02306213|OTHER|standard volume therapy|
48166633|NCT06479200|BEHAVIORAL|VR-guided mindfulness|The VR-guided mindfulness intervention is a 6-week home-based program delivered through an Oculus Quest 3 (or equivalent) headset. Participants practice 10-15 minutes of guided mindfulness exercises daily in immersive virtual environments. The program includes various mindfulness techniques such as body scans, breath awareness, and loving-kindness meditation, designed to reduce stress and improve well-being.
48369842|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
48369843|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
48369844|NCT00790595|DRUG|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
48369845|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
48369846|NCT00790595|DRUG|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
48166634|NCT06479200|OTHER|Sham VR|The sham VR intervention is a 6-week home-based program that involves viewing relaxing nature videos without any mindfulness content. Participants use the same VR headset as the experimental group and engage with the sham content for 10-15 minutes daily, matching the duration of the experimental intervention. This sham intervention controls for the effects of using VR technology and engaging in a relaxing activity.
48166635|NCT05964270|DEVICE|e-coach multipel myeloma (MM)|In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
48166636|NCT05826405|OTHER|No intervention|No intervention, it's an observational study
48166637|NCT02679313|DEVICE|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
48166638|NCT05566002|DIAGNOSTIC_TEST|Right heart catheterization|RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
48166639|NCT00985634|DEVICE|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
48166640|NCT00985634|DEVICE|Control|Vessel loops
48166641|NCT03327077|OTHER|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
48166642|NCT00052325|DIETARY_SUPPLEMENT|mistletoe extract|
48166643|NCT02760472|DRUG|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
48166644|NCT02760472|DRUG|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
48166645|NCT03605368|BEHAVIORAL|Virtual Reality Intervention|Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
48166646|NCT03605368|BEHAVIORAL|Video Modeling Intervention|The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
48166647|NCT03605368|BEHAVIORAL|No intervention|Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
48166648|NCT05561751|DRUG|GPC-100|GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
48166649|NCT05561751|DRUG|Propranolol|propranolol
48166650|NCT05561751|DRUG|G-CSF|G-CSF
48166651|NCT04457089|DRUG|Simvastatin 40mg|Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
48166652|NCT04723888|DIETARY_SUPPLEMENT|alpha-ketoglutarate|alpha-ketoglutarate supplements
48514544|NCT03449446|DRUG|FIR|20 mg tablet administered orally once daily without regard to food
48695660|NCT05373784|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
48514545|NCT03449446|DRUG|CILO|30 mg tablet administered orally once daily without regard to food
48695661|NCT06022029|DRUG|ONM-501|Intratumoral injection
48695662|NCT06022029|DRUG|Cemiplimab|Intravenous administration of 350 mg
48695663|NCT05978440|PROCEDURE|onlay preparation|CAD-CAM onlay restorations will be fabricated using rubber dam scanning techniques and evaluated clinically up to 12 months
48695664|NCT06203392|OTHER|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
48695665|NCT06203392|OTHER|Mediterranean diet|Mediterranean diet provided for six weeks
48009261|NCT01622205|OTHER|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
48009262|NCT01622205|OTHER|Ordinary rehabilitation|Ordinary rehabilitation
48009263|NCT02111616|BEHAVIORAL|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
48695666|NCT06289426|OTHER|Yoga|The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
48166653|NCT03560414|PROCEDURE|simple plasma exchange|simple plasma exchange treatment
48166654|NCT03560414|PROCEDURE|conventional PDF treatment group|conventional PDF treatment group
48166655|NCT03560414|PROCEDURE|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
48695667|NCT06444854|PROCEDURE|early chest tube removal|Chest tube removal
48695668|NCT01591954|DEVICE|Video Augmentation|Assessment of value of video-based navigation system
48695669|NCT04145921|PROCEDURE|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
48695670|NCT04145921|PROCEDURE|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
48695671|NCT04242095|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, and stool samples
48695672|NCT04242095|OTHER|Medical Chart Review|Review of medical records
48009264|NCT02111616|BEHAVIORAL|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
48009265|NCT00653354|DRUG|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
48009266|NCT00653354|DRUG|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
48009267|NCT00653354|DRUG|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
48009268|NCT00225706|DRUG|Caldolor|
48009269|NCT00265616|DRUG|propofol|liquid, mg/kg.h, titrated after EEG
48009270|NCT00265616|DRUG|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
48009271|NCT06413810|OTHER|Calmarell|Food ingredient
48009272|NCT06413810|OTHER|Placebo|Blinded placebo
48009273|NCT02176733|DRUG|cyclosporine|
48166656|NCT02413554|DRUG|Rivastigmine patch|acetylcholine esterase inhibitor
48695673|NCT04616183|DRUG|Abemaciclib|Given PO
48695674|NCT04616183|BIOLOGICAL|Cetuximab|Given IV
48695675|NCT04616183|DRUG|ERK1/2 Inhibitor LY3214996|Given PO
48009274|NCT03932942|DIAGNOSTIC_TEST|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
48009275|NCT05157100|DRUG|Ingrezza Pill|Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
48009276|NCT03106727|BEHAVIORAL|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
48009277|NCT03268616|DEVICE|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
48166657|NCT06139159|OTHER|Outreach/navigator|"* Conduct outreach activities with people in the community who are hard to reach and with limited access to health care, conduct informal screening for symptoms of mental illnesses, encourage and refer individuals at-risk, suspected of having, or affected by mental health issues to clinics for triage.~* Document outreach, screening, and referral activities in LHW database"
48166658|NCT06139159|OTHER|Auxiliary to care|"* Arrange consultation for those at-risk, suspected, or affected individuals at clinics for triage.~* Introduce the patient to the clinical team via a warm hand-off and assist in scheduling a follow -up visit.~* Reviews care plan with patient and help reduce patient and system barriers impeding psychological wellbeing~* Support patients in achieving management goals; help patients address barriers through education, referral, and navigation to ancillary community services (SAVAME, legal, housing, economic, etc);~* Engage, activate, and empower patients to participate in the care process~* Frequent contact with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Assist with group sessions: affinity groups~* Identify community-based resources.~* Document outreach, screening, referral, and auxiliary care activities in LHW database"
48166659|NCT06139159|OTHER|Stepped care and task shifting|"* Support counselling initiated by the psychologist~* Reinforce patient education about depression, anxiety, trauma, and other syndemic conditions.~* Work with patients' families and peers to reduce stigma, address syndemic factors and social conditions.~* Contact frequency with patients: +1 every two weeks during the first 3 months, +1 every month for months 4-6.~* Co-lead group sessions: affinity groups~* Provide Mental Health First Aid to members of the community.~* Document outreach, screening, referral, auxiliary and stepped care activities in LHW database"
48369847|NCT06174428|DEVICE|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
48695676|NCT06661876|RADIATION|5 Gray Whole Heart external beam radiotherapy|EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
48695677|NCT06662136|BEHAVIORAL|motivational interview|Participants in the experimental group will be given motivational interviews about HPV at 4 different times and will also be given an educational brochure.
48695678|NCT06662136|OTHER|Control|Participants in the control group will not receive any intervention.
48009278|NCT05373511|OTHER|"3D/4D spine and posture analysis DIERS FORMETRIC 4D ,The Biodex Balance System SD-"|"3D/4D spine and posture analysis DIERS FORMETRIC 4D for postural analysis assessment~,The Biodex Balance System SD- for balance assessment"
48009279|NCT06103006|OTHER|Telerehabilitation|The structured telerehabilitation program focused on 4 specific objectives: breathing, stretching, posture, and stability. The duration was between 20-30 minutes. Exercises involving the major muscle groups (upper, lower extremity, and trunk muscle groups) were applied by the physiotherapists. Strengthening and stretching sets and repetitions were started with 1 set of 8-15 reps (progress to \>1 set).
48009280|NCT02920268|OTHER|Dance and yoga intervention|
48369848|NCT05604976|DEVICE|Percutaneous coronary intervention|Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter
48369849|NCT00561912|DRUG|Decitabine|15 mg/m\^2 IV Daily over one hour for 5 days
48369850|NCT00561912|DRUG|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
48369851|NCT00402311|PROCEDURE|DOC-PG: integrated multidisciplinary assessment|
48369852|NCT00402311|PROCEDURE|Usual care: assessment by GP or one of the regional services|
48695679|NCT06662396|DRUG|MK-6552|Oral Gelatin Coated Capsule
48009281|NCT02837432|DRUG|Hydrocortisone acetate|
48369853|NCT00430235|DRUG|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
48514546|NCT03449446|DRUG|Placebo to match FIR|Tablet administered orally once daily without regard to food
48695680|NCT06662396|DRUG|Diltiazem|Oral Extended-Release Capsule
48695681|NCT06598787|DRUG|BL-B01D1 for Injection|Administration by intravenous infusion for a cycle of 3 weeks.
48695682|NCT00722722|DRUG|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
48695683|NCT05029128|BEHAVIORAL|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
48009282|NCT02837432|DRUG|Placebo|
48369854|NCT03741075|PROCEDURE|BUA|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
48514547|NCT03449446|DRUG|Placebo to match CILO|Tablet administered orally once daily without regard to food
48514548|NCT03449446|DRUG|Placebo to match SEL|Tablet administered orally once daily without regard to food
48514549|NCT03166137|DEVICE|Carbon dioxide laser|Radiation by carbon dioxide laser
48514550|NCT03166137|DEVICE|Cryotherapy|Device using cooling effect
48514551|NCT03332810|BEHAVIORAL|SME family based physical activity|"* One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~* Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
48514552|NCT03332810|BEHAVIORAL|Gathering activity|- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
48514553|NCT05775133|DEVICE|ICG|"Patient will receive a standard dose of indocyanine green (ICG) 45 minutes prior to surgery. ActivSight will be used during laparoscopic cholecystectomy - the surgeon will perform the procedure in their standard fashion.~Video data will be analyzed in real-time by Activ Surgical's ActivInsight surgical artificial intelligence platform to identify anatomic structures and surgical phase. The surgeon will be blinded to this information, and will see the standard screens and information they do when performing the procedure in a non-study setting."
48514554|NCT06254456|DIAGNOSTIC_TEST|End expiratory occlusion test|Fluid responsiveness test
48514555|NCT06356857|DIAGNOSTIC_TEST|Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT|Re-scan for comparison with initial scan
48514556|NCT02970448|PROCEDURE|LITT|MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.
48695684|NCT04583215|DEVICE|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
48009283|NCT00280566|DRUG|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
48009284|NCT00280566|DRUG|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
48009285|NCT05188352|OTHER|Chest physiotherapy|The program included diaphragmatic breathing exercises, thoracic expansion exercises, incentive spirometer exercises, and coughing techniques.
48369855|NCT03741075|DRUG|topical tranexamic acid|topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
48514557|NCT02970448|RADIATION|Radiation therapy|One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.
48514558|NCT02970448|DRUG|Temozolomide|Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
48695685|NCT02287090|OTHER|Observational Cohort|
48695686|NCT04310982|DEVICE|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
48695687|NCT04771520|DRUG|Avapritinib|Given PO
48695688|NCT04907825|DRUG|Oral anticoagulant|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
48695689|NCT06491823|BEHAVIORAL|Adaptation|Auditory adaptation in speech
48695690|NCT06491823|BEHAVIORAL|Adaptation baseline|Auditory baseline in speech
48166660|NCT03834818|BEHAVIORAL|COMPAS Participants|"The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~* Download the Medable App~* Register to the study~* Validated Questionnaires~* Active Task~Every Day~* 9:00 a.m. Daily Questions~* 9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~* Day 1 Pre-Surgery~* 1-Week Post Operation~* 2-Weeks Post Operation~* 1-Month Post Operation~* 3-Months Post Operation~* 6-Months Post Operation"
48166661|NCT00427297|DRUG|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
48166662|NCT00427297|DRUG|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
48166663|NCT00427297|DRUG|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
48695691|NCT06491823|DEVICE|Motor evoked potentials|motor evoked potentials will be obtained in each recording block
48166664|NCT00427297|DRUG|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of\<8g/dl), AZT will be substituted for d4T.
48166665|NCT00427297|DRUG|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
48166666|NCT00427297|DRUG|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
48514559|NCT01709539|PROCEDURE|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
48514560|NCT05011318|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
48695692|NCT06491823|DEVICE|Auditory evoked potentials|auditory evoked potentials will be obtained in each recording block
48695693|NCT06491823|DEVICE|Somatosensory evoked potentials|Somatosensry evoked potentials will be obtained in each recording block
48166667|NCT00427297|DRUG|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
48166668|NCT06400264|PROCEDURE|Biopsy|Undergo biopsy
48166669|NCT06400264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48166670|NCT06400264|PROCEDURE|Computed Tomography|Undergo CT scan
48166671|NCT06400264|PROCEDURE|Echocardiography|Undergo ECHO
48166672|NCT06400264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48166673|NCT06400264|BIOLOGICAL|Nivolumab|Given IV
48166674|NCT06400264|BIOLOGICAL|Relatlimab|Given IV
48514561|NCT05011318|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
48514562|NCT01587157|PROCEDURE|capnography|
48514563|NCT02404116|OTHER|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
48514564|NCT02404116|OTHER|Wait List|Individuals are on a waiting list
48514565|NCT03994822|DEVICE|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
48166675|NCT02371161|DRUG|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM"
48166676|NCT01618071|DIETARY_SUPPLEMENT|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
48166677|NCT06620432|PROCEDURE|Low segment hysterotomy|A low segment hysterotomy is a surgical procedure in which an incision is made in the lower segment of the uterus, typically during a cesarean section or other uterine surgeries. This approach is preferred because the lower uterine segment is thinner and less vascular, reducing the risk of bleeding and complications during and after the procedure. The incision is typically horizontal.
48166678|NCT06620432|PROCEDURE|High segment hysterotomy|A high segment hysterotomy is a surgical procedure involving an incision in the upper segment of the uterus.
48166679|NCT06620432|PROCEDURE|Crossed hysterorrhaphy|Crossed hysterorrhaphy is a surgical technique used to close the uterine incision following a hysterotomy, particularly during cesarean sections. In this method, the sutures are placed in a crossed or X-shaped pattern, which helps to evenly distribute tension across the incision site.
48166680|NCT06620432|PROCEDURE|Non-Crossed hysterorrhaphy|Non-crossed hysterorrhaphy is a surgical technique used to close a uterine incision, typically after a hysterotomy, such as during a cesarean section. In this method, the sutures are placed in a linear, parallel fashion rather than in a crossed or X-shaped pattern
48695694|NCT06020391|OTHER|Collaborative drug review|"1. Structured, clinical drug review including medical history, physical examination, and supplementary tests. The work-up will be aimed at evaluating whether current medications are indicated, whether the patient's medical conditions are satisfactorily compensated, whether dosages are appropriate, whether the patient has adverse drug effects, and whether drug-drug or drug-disease interactions are present or likely to occur. The MipAC physicians will receive clinical supervision from a consultant in geriatric medicine.~2. The MipAC physician will offer the patient's FP a telephone meeting with the purpose of combining the assessments of the MipAC physician and the competence of the FP in a common drug review. The two physicians will review the patient's drug list systematically and discuss if any adjustments should be done, as well as the patient's need for further follow-up."
48695695|NCT05838378|OTHER|Package image sorting with pictorial warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.
48695696|NCT05838378|OTHER|Package image sorting with Surgeon General text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.
48695697|NCT05838378|OTHER|Package image sorting with FDA text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
48695698|NCT06661707|PROCEDURE|Sonar guided Quadratus Lumborum block|The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg
48166681|NCT05885841|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
48166682|NCT00183183|BEHAVIORAL|Screening and Brief Intervention|
48166683|NCT00209222|DRUG|Rituximab|antibody
48695699|NCT06661707|PROCEDURE|Sonar guided Ilioinguinal/Iliohypogastric block|"The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg"
48166684|NCT00209222|DRUG|Cyclophosphamide|chemotherapy
48166685|NCT00209222|DRUG|Doxorubicin|chemotherapy
48166686|NCT00209222|DRUG|Vincristine|chemotherapy
48166687|NCT00209222|DRUG|Prednisone|corticosteroide
48514566|NCT03994822|DEVICE|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
48514567|NCT04291625|PROCEDURE|Levator muscle resection|"Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures"
48514568|NCT01608061|DEVICE|DBS-f on|deep brain stimulation of the fornix
48514569|NCT01608061|DEVICE|DBS-f off|deep brain stimulation of the fornix turned off
48514570|NCT04477070|PROCEDURE|Air-polishing with ultrasonic debridement|Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
48514571|NCT04477070|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
48695700|NCT00472316|BEHAVIORAL|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
48166688|NCT00209222|DRUG|Cisplatinum|chemotherapy
48166689|NCT00209222|DRUG|Ara-C|chemotherapy
48166690|NCT00209222|DRUG|Dexamethasone|corticosteroide
48166691|NCT00209222|DRUG|BCNU|chemotherapy
48166692|NCT00209222|DRUG|Melphalan|chemotherapy
48166693|NCT00209222|DRUG|Etoposide|chemotherapy
48166694|NCT00209222|DRUG|G-CSF|growth factor
48695701|NCT05170204|DRUG|Alectinib|Participants will receive oral alectinib twice daily with food.
48166695|NCT00209222|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
48166696|NCT00209222|PROCEDURE|chemotherapy: R-DHAP|immuno-chemotherapy
48166697|NCT00209222|PROCEDURE|chemotherapy: Dexa-BEAM|chemotherapy
48166698|NCT00209222|PROCEDURE|stem cell harvest|procedure
48166699|NCT00209222|PROCEDURE|total body irradiation|radiation
48166700|NCT00209222|PROCEDURE|high-dose chemotherapy: Cyclophosphamide|chemotherapy
48166701|NCT00209222|PROCEDURE|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
48166702|NCT01204593|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
48166703|NCT01204593|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
48166704|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
48166705|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
48166706|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
48166707|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
48166708|NCT02621502|DIETARY_SUPPLEMENT|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
48166709|NCT01245335|DEVICE|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
48166710|NCT01245335|DEVICE|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
48166711|NCT01602003|DRUG|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
48695702|NCT05170204|DRUG|Entrectinib|Participants will receive oral entrectinib once daily, with or without food.
48166712|NCT01602003|DRUG|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
48514572|NCT03514966|BEHAVIORAL|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
48514573|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
48514574|NCT00085384|DRUG|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously"
48514575|NCT00085384|BIOLOGICAL|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron"
48514576|NCT03874273|DRUG|Crizotinib|Crizotinib 280mg/m2 twice a day (for 24 months maximum)
48695703|NCT05170204|DRUG|Durvalumab|Participants will receive IV durvalumab every 4 weeks.
48695704|NCT05955820|DEVICE|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
48695705|NCT05955820|DEVICE|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
48695706|NCT01794663|DRUG|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
48695707|NCT01794663|DRUG|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
48695708|NCT03319459|DRUG|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
48695709|NCT03319459|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
48695710|NCT03319459|DRUG|Trastuzumab|HER2/neu receptor inhibitor
48695711|NCT04147429|BEHAVIORAL|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
48695712|NCT04630860|DRUG|LY03003|Rotigotine,extended-release microspheres
48695713|NCT04566900|BEHAVIORAL|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
48695714|NCT04566900|OTHER|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
48695715|NCT05081518|DRUG|Lu AG06466|Lu AG06466 - capsule
48009286|NCT05188352|OTHER|Aerobic exercise training|"A treadmill was used for aerobic exercise. Training intensity was used at 60-75% of maximal VO2.~Each session had a five-minute warm-up and cool-down period. Blood pressure and ECG were recorded during training sessions before exercise, at the third minute of each workload, after exercise, and during each minute of the recovery period."
48009287|NCT04035720|OTHER|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
48009288|NCT05914727|DIAGNOSTIC_TEST|eNose|Collection of breath profile with eNose
48009289|NCT05914727|DIAGNOSTIC_TEST|Volatile exhaled breath sample|Collection of exhaled breath in Tedlar bag
48369856|NCT03741075|DRUG|placebo|topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
48695716|NCT05081518|DRUG|Placebo|Placebo - capsule
48695717|NCT06025942|BEHAVIORAL|Purrble intervention|"When the Purrble is picked up, it emits a frantic heartbeat that slows down if the person uses calm stroking movements. If the Purrble is soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to young people in emotional moments when they would attempt to utilise emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in young peoples' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2.~* see JMIR Res Protoc 2021;10(11):e28914 (doi: 10.2196/28914)"
48695718|NCT04044053|DRUG|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
48695719|NCT04044053|DRUG|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
48695720|NCT04044053|DRUG|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
48009290|NCT05914727|DIAGNOSTIC_TEST|Condensate sample|Collection of exhaled breath condensate with EcoScreen
48009291|NCT05543785|DRUG|Ketorolac|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
48009292|NCT05543785|OTHER|Control|After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
48009293|NCT01394926|DRUG|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
48009294|NCT01236404|DRUG|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
48369857|NCT06209099|PROCEDURE|Nonoperative Management (NOM)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
48695721|NCT04044053|DRUG|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
48695722|NCT00033566|DRUG|S-3304|
48695723|NCT04360005|DRUG|Asciminib|Patients receive Asciminib
48695724|NCT06423183|BEHAVIORAL|A Mindful Approach to Building a Resilient Healthcare Workforce (RENEW)|Synchronous, 4-month intervention that teaches skills in mindfulness, stress management, and resilience as an individual and as a team. Sessions occur monthly and include a 1 hour in-person introductory session followed by 3 50-minute virtual sessions.
48695725|NCT06209138|DRUG|5 fluorouracil|5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
48695726|NCT06209138|OTHER|Saline|Normal saline solution contains 0.9 percent sodium chloride (salt)
48695727|NCT06646965|PROCEDURE|individual dietetic counseling|only the pregnant patient receives dietetic counseling
48695728|NCT06646965|PROCEDURE|family-based dietetic conseling|the pregnant patient and her companion receive dietetic counseling
48695729|NCT06325046|PROCEDURE|Computed Tomography|Undergo CT
48695730|NCT06325046|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
48695731|NCT06325046|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo near margin-less ART
48695732|NCT06325046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48695733|NCT06325046|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo standard SABR
48695734|NCT06325046|OTHER|Survey Administration|Ancillary studies
48695735|NCT06305299|BIOLOGICAL|iC9-CAR.B7-H3 T cells|iC9-CAR.B7-H3 T cells will then be administered intraperitoneally
48166713|NCT01602003|DRUG|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
48695736|NCT06305299|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
48695737|NCT06305299|DRUG|Fludarabine|fludarabine 30 mg/m2 IV will be given.
48695738|NCT06253195|DRUG|BGB-43395|Administered orally.
48695739|NCT06253195|DRUG|Fulvestrant|Administered via intramuscular injection.
48695740|NCT06253195|DRUG|Letrozole|Administered orally.
48695741|NCT03400865|DRUG|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
48695742|NCT03358875|DRUG|Tislelizumab|Intravenous injection (Anti-PD-1 monoclonal antibody)
48695743|NCT03358875|DRUG|Docetaxel|Intravenous injection (Antineoplastic, cytotoxic, taxane)
48695744|NCT06251466|DEVICE|iHealth Gluco-Smart application|iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
48695745|NCT06656078|OTHER|1. WORKING MEMORY TASK:|Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.
48166714|NCT06183827|PROCEDURE|Emergency Medical Service intervention|"Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control."
48166715|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
48166716|NCT02661490|DRUG|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
48166717|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
48695746|NCT06656078|OTHER|2. VISUAL AND VERBAL FLUENCY TASK|Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
48695747|NCT06656078|OTHER|3. MOTOR TASK:|Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
48695748|NCT06659471|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48695749|NCT06659471|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
48695750|NCT04580836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48695751|NCT04580836|OTHER|Questionnaire Administration|Ancillary studies
48695752|NCT04580836|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48009295|NCT01236404|DRUG|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
48009296|NCT05036564|PROCEDURE|Lumbar puncture|"A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse."
48009297|NCT01257204|DRUG|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
48369858|NCT06209099|PROCEDURE|Local Excision (LE)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
48695753|NCT03268954|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
48695754|NCT03268954|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
48009298|NCT01257204|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
48009299|NCT01257204|DRUG|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
48009300|NCT01257204|DRUG|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
48695755|NCT03625947|OTHER|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
48695756|NCT06129474|OTHER|Proton Pump Inhibitor deprescribing tool|The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
48695757|NCT05476497|BIOLOGICAL|VLP Peanut|solution for subcutaneous administration
48166718|NCT02641106|OTHER|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
48166719|NCT02641106|OTHER|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
48166720|NCT02822040|OTHER|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
48166721|NCT03715738|OTHER|arm 1 : Creaform3D + MyotonPRO|"After inclusion,are carried out:~* estimation of the volume of the breast to be reduced with the 3D digital camera~* measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete."
48166722|NCT01593436|BEHAVIORAL|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
48166723|NCT02007759|DEVICE|VitalStim|This group will receive active VitalStim treatment.
48166724|NCT02007759|DEVICE|Sham VitalStim|This group will receive a sham VitalStim intervention.
48166725|NCT05619900|OTHER|There is no intervention|This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
48166726|NCT00927550|DRUG|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
48166727|NCT00927550|DRUG|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
48166728|NCT00465907|DRUG|Paclitaxel, Carboplatin and Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
48166729|NCT05746533|PROCEDURE|Hip Arthroscopy|Hip Preservation surgeries
48166730|NCT06647251|PROCEDURE|Q-MODE : radiofrequency ablation up to 50W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W."
48166731|NCT06647251|PROCEDURE|Q-MODE+ : radiofrequency up to 90W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W."
48166732|NCT06647251|PROCEDURE|Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE/Q-MODE+ option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part."
48166733|NCT03667599|OTHER|home care|This is the interventional arm where patients receive the transplant care in their homes.
48166734|NCT05959811|OTHER|yoga|60 minutes yoga practice ,twice a week for 8 weeks
48695758|NCT05476497|BIOLOGICAL|Placebo|solution for subcutaneous administration
48166735|NCT01639014|DRUG|F2695|75 mg OD in 2 capsules
48166736|NCT01639014|DRUG|placebo|2 capsules
48166737|NCT02169778|BEHAVIORAL|Intermittent energy restricted diet|
48166738|NCT02169778|BEHAVIORAL|Continuous energy restricted diet|
48695759|NCT05476497|BIOLOGICAL|VLP Peanut|solution for Skin-prick testing
48695760|NCT01638013|DRUG|Peficitinib|Oral Tablet
48695761|NCT06477393|OTHER|Regular rehababilitation|Subjects of the experimental and control groups will receive routine procedures applied in the resort sanatorium: physiotherapy (28-32), occupational therapy (12-18), dry hydromassage (7-8), psychotherapy or audiovisual relaxation (3-4), social worker's visit ( 1-2), physiotherapy (magnetotherapy, ultrasound therapy (8-9).
48695762|NCT06477393|OTHER|Heat procedures|"The bath is filled with 200 litres of warm tap water at 36-38°C. The participant lies in the prepared bath, ensuring the chest area remains uncovered. While in the bath, the participant performs gentle movements. The procedure lasts 12-15 minutes. Air is pumped into the water to increase the oxygen saturation in the bath environment.~A prepared gel pack will be placed in another bag and heated to 50-55°C. The heated pack will be delivered to the treatment area using pumps. For applications, the gel pack is used at 40-42°C. Temperature of the gel pack can range between 38-43°C."
48166739|NCT06329271|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
48166740|NCT05431725|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
48166741|NCT05431725|BIOLOGICAL|Control Quadrivalent influenza virus vaccine|The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
48166742|NCT05367024|OTHER|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
48166743|NCT05367024|OTHER|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
48166744|NCT00404599|DRUG|atrorvastatin 10mg|Atorvastatin 10 mg once a day
48166745|NCT00404599|DRUG|simvastatin 40mg|simvastatin 40mg once a day
48166746|NCT03214250|DRUG|APX005M|Administer intravenously once every 28-day Cycle
48166747|NCT03214250|DRUG|Nivolumab|Administer intravenously twice every 28-day cycle
48166748|NCT03214250|DRUG|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
48166749|NCT03214250|DRUG|Gemcitabine|Administer intravenously 3 times every 28-day cycle
48166750|NCT02878460|OTHER|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
48166751|NCT02878460|OTHER|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
48166752|NCT01439997|DRUG|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
48166753|NCT05764642|DRUG|Definity|Ultrasound contrast agent administered intravenously
48166754|NCT05764642|DIAGNOSTIC_TEST|Super-resolution ultrasound imaging|Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.
48166755|NCT03284489|OTHER|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
48166756|NCT04331015|DIAGNOSTIC_TEST|Pure tone audiometry|pure tone audiometry
48166757|NCT04509414|DRUG|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
48166758|NCT04509414|DRUG|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
48369859|NCT06209099|PROCEDURE|Total Mesorectal Excision (TME)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
48009301|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|"* Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~* Health education sessions and relaxation sessions: one per week.~* Smoking and diet checking: as recommended by doctor."
48009302|NCT01567189|BEHAVIORAL|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
48009303|NCT02619409|DRUG|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
48009304|NCT02619409|DRUG|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
48009305|NCT02619409|DRUG|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
48009306|NCT02619409|DRUG|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
48009307|NCT02619409|DRUG|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
48009308|NCT02703103|OTHER|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
48009309|NCT02703103|DEVICE|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
48369860|NCT06316076|BIOLOGICAL|CD19-CAR-DNT cells|Lentiviral vector-transduced DNT cells to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
48369861|NCT01787019|OTHER|Oral feeding|
48369862|NCT02358720|RADIATION|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
48369863|NCT02358720|RADIATION|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
48369864|NCT03741257|DRUG|Hypertonic saline|resuscitation fluid
48369865|NCT03400202|DEVICE|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
48369866|NCT03400202|OTHER|Facial cleanser|Facial cleanser prior to procedures.
48369867|NCT00933543|DRUG|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
48514577|NCT01122186|BEHAVIORAL|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
48695763|NCT06477393|OTHER|Healing mud application|"Therapeutic mud applications: peat brought from the quarry is sifted, ground, and mixed with natural mineralisation of 20-22g/l with mineral water in a ratio of at least 4:1 until the consistency of thick sour cream. The prepared peat mud is heated to 50-55 degrees. The heated mud is fed to the place where the procedures are performed with the help of pumps. Mud mass at 40-42 degrees is used for applications. A mud temperature range of 38-43 degrees is possible.~Before the procedure, it is recommended not to eat, go to the toilet, or take a warm shower. A polyethene film is laid on a special heated couch, and a 2-4 cm thick layer of mud is poured into the area of the hands and feet, covered with a blanket. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel, and rests. Peloids are not reused."
48369868|NCT00933543|DRUG|Vehicle cream (placebo)|Cream application followed by illumination with red light.
48369869|NCT00933543|PROCEDURE|PDT|Photodynamic Therapy - Light dose 37 J/cm2
48369870|NCT01283282|DRUG|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
48369871|NCT01283282|DRUG|Placebo|Placebo PO qday for 6 weeks
48369872|NCT02899884|OTHER|No Intervention|
48369873|NCT04798560|PROCEDURE|Pancreaticoduodenectomy|Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
48369874|NCT01190839|BIOLOGICAL|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
48369875|NCT01190839|DRUG|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
48369876|NCT05748145|DRUG|Metronidazole Oral|Metronidazole will be administered per os at 500 mg x 3/day, for 10 days prior to surgery.
48369877|NCT03176823|DEVICE|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
48369878|NCT03176823|OTHER|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
48369879|NCT05642091|DEVICE|ultrasound Elastography|application of shear wave force by ultrasound elastography
48369880|NCT04066205|BEHAVIORAL|SLEEPSAMRT|SLEEPSMART will be designed to improve sleep by providing guidance and structure to assist JIA children and their parent in adhering to the intervention protocol. The intervention will be interactive and personalized; users will interface with three primary components:1) monitoring: daily records of sleep and symptoms; 2) skill building modules: sleep education, sleep skills training, relaxation techniques, positive coping skills, and reward systems for activity participation for reducing sleep deficiency; and 3) assignment review and personalized feedback via behavioral assignments for skill implementation and tailored feedback. Modules will take an estimated 30 minutes each week to complete and will include multimedia elements to enhance learning.
48369881|NCT02077868|OTHER|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
48369882|NCT02077868|DRUG|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
48369883|NCT01405989|DRUG|darexaban|oral
48369884|NCT01405989|DRUG|ketoconazole|oral
48369885|NCT04518826|DEVICE|fractional flow reserve|FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
48369886|NCT03405324|DEVICE|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
48369887|NCT03405324|DEVICE|sham tDCS|sham tDCS
48369888|NCT00368069|DRUG|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
48369889|NCT00368069|DRUG|Placebo|oral tablets, 2 tablets once daily
48369890|NCT01408953|BIOLOGICAL|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
48514578|NCT01122186|BEHAVIORAL|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
48514579|NCT05160740|DRUG|Indocyanine green for injection|ICG will be injected to participants preoperatively for molecular fluorescence image
48514580|NCT05295719|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid|4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA)
48514581|NCT05295719|BEHAVIORAL|High-Intensity Interval Training|A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 6 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max.
48514582|NCT05295719|DIETARY_SUPPLEMENT|Safflower oil|4 grams safflower oil (AlaskOmega®) per day
48514583|NCT05295719|BEHAVIORAL|Flexibility training|30 min of stretching 3 days/week for 6 weeks
48514584|NCT04261101|OTHER|Test-enhanced learning|Test-enhanced learning with short answers of questions regarding diabetes and adrenal
48514585|NCT04078997|OTHER|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
48695764|NCT06477393|OTHER|Mineral water bath|The pearl bath is prepared by a physical method. The bath is filled with 200 l of warm 36-38 C mineral water, the subject lies in the prepared bath, leaving the heart area open, while lying in the bath he performs light movements. The duration of the procedure is 12-15 minutes. Air is blown into the water, which increases oxygen saturation in the bath environment. Before the procedure, it is recommended not to eat, go to the toilet, take a warm shower. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel and rests. Mineral waters are not reused.
48695765|NCT00455091|DRUG|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/\> 105 copies/mL and ALT \> 2.0 x UNL
48695766|NCT01326884|DEVICE|ZLP|ZLP Graft
48695767|NCT06658145|DEVICE|Vnotes surgery using fully visualised surgical instruments|Vnotes surgery using fully visualised surgical instruments
48695768|NCT06658145|DEVICE|Vnotes surgery using traditional surgical instruments|Vnotes surgery using traditional surgical instruments
48695769|NCT02890953|DRUG|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
48695770|NCT02890953|DRUG|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
48695771|NCT00833963|DRUG|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
48695772|NCT00833963|DRUG|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
48695773|NCT00833963|DRUG|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
48514586|NCT05607420|BIOLOGICAL|UCART20x22|Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen
48514587|NCT05607420|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
48695774|NCT04551963|DRUG|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
48695775|NCT04551963|DRUG|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
48695776|NCT04551963|DRUG|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
48695777|NCT04551963|DRUG|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
48695778|NCT04551963|DRUG|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
48695779|NCT06658821|DIETARY_SUPPLEMENT|LDL557-HK capsule|Subjects will take once a day during the experimental period. one LDL557-HK capsule(Heat-killed Lactobacillus delbrueckii subsp. lactis LDL557 1x10\^10cell) within 30 minutes before lunch.
48695780|NCT06658821|DIETARY_SUPPLEMENT|Placebo Capsule|Subjects will take once a day during the experimental period. one placebo capsule within 30 minutes before lunch.
48695781|NCT04496206|OTHER|No intervention|No intervention, it is retrospective study.
48695782|NCT05064358|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
48695783|NCT04210219|DRUG|JNJ-64264681|JNJ-64264681 capsule will be administered orally.
48695784|NCT06659757|DRUG|KIT2014|KIT2014 will be administered by inhalation with a nebuliser
48695785|NCT06659757|OTHER|Placebo|Placebo will be administered by inhalation with a nebuliser
48695786|NCT04609592|DRUG|Lutathera|4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
48695787|NCT04609592|DRUG|Gallium 68 Dotatate|Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
48695788|NCT04609592|PROCEDURE|Computed Tomography (CT)|Medical Imaging
48695789|NCT04609592|PROCEDURE|Magnetic Resonance Imaging (MRI)|Medical Imaging
48695790|NCT04609592|PROCEDURE|PET/CT|Medical Imaging
48695791|NCT06655558|DEVICE|custom knee orthosis|The custom knee orthosis will be worn for 8 weeks.
48695792|NCT05911360|DRUG|DTG/3TC|DTG/3TC FDC will be administered once daily.
48695793|NCT02507466|BEHAVIORAL|exercise|Variable conditions of stepping practice
48695794|NCT06659328|PROCEDURE|Structured Walking Intervention for Children with Autism Spectrum Disorder|"Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes"
48695795|NCT01158820|DRUG|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
48695796|NCT01158820|DRUG|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
48695797|NCT01158820|DRUG|Midazolam load|2 mg bolus prior to bronchoscopy
48695798|NCT01158820|DRUG|Fentanyl load|50 µg bolus prior to bronchoscopy
48695799|NCT01158820|DRUG|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
48695800|NCT01158820|DRUG|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
48695801|NCT01158820|DRUG|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
48695802|NCT01158820|DRUG|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
48695803|NCT01158820|DRUG|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
48695804|NCT06350500|BEHAVIORAL|Patient Navigation|Receive patient navigation
48695805|NCT06350500|OTHER|Questionnaire|Ancillary studies
48695806|NCT05731817|OTHER|Observational study|N/A - observational study.
48514588|NCT01480362|DEVICE|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
48514589|NCT01480362|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
48695807|NCT06661902|DRUG|Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)|"Patients scheduled for prostate biopsy will be approached for the study. Following enrollment, participants will complete three questionnaires that assess their baseline pain and anxiety scores.~Patients will then be randomized to one of two arms for their local anesthetic: (A) 1% Lidocaine or (B) Buffered Lidocaine. The patient and urologist will both be blinded to the contents of the local anesthetic.~During the procedure, local anesthetic will be administered in the standard fashion. Patients will then complete a series of questionnaires asking about the pain associated with the local anesthetic and prostate biopsy as a whole. Complications will be assessed."
48695808|NCT06661902|DRUG|1% Lidocaine HCL|"Patients scheduled for prostate biopsy will be approached for the study. Following enrollment, participants will complete three questionnaires that assess their baseline pain and anxiety scores.~Patients will then be randomized to one of two arms for their local anesthetic: (A) 1% Lidocaine or (B) Buffered Lidocaine. The patient and urologist will both be blinded to the contents of the local anesthetic.~During the procedure, local anesthetic will be administered in the standard fashion. Patients will then complete a series of questionnaires asking about the pain associated with the local anesthetic and prostate biopsy as a whole. Complications will be assessed."
48695809|NCT02989584|DRUG|Atezolizumab|
48695810|NCT02989584|DRUG|Gemcitabine|
48695811|NCT02989584|DRUG|Cisplatin|
48695812|NCT05449340|DEVICE|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade \> 2, the nurse will contact the patient for further information.
48695813|NCT02557451|OTHER|Surgery|
48695814|NCT02557451|OTHER|Intravitreal injections of gas|
48695815|NCT02557451|PROCEDURE|injections of an antiangiogenic|
48695816|NCT03397745|DEVICE|BIS|All patients applied BIS on both side (Left and Right)
48695817|NCT06657937|OTHER|Questionnaire|"An initial questionnaire is completed on D0, the day of the patient's admission to the emergency department, by the practitioner in charge of the patient, and covers the patient's anamnesis, clinical examination, radiological examinations and treatment.~A follow-up telephone visit is then carried out at 30 days by an investigator, to gather information on the clinical and therapeutic evolution, and to evaluate the recovery and evolution of symptoms experienced by the patient in relation to the initial management."
48695818|NCT02569476|DRUG|Zanubrutinib|
48695819|NCT02569476|DRUG|Obinutuzumab|
48695820|NCT06382870|OTHER|education|Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
48695821|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
48695822|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
48695823|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
48695824|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
48369891|NCT03702192|DEVICE|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
48695825|NCT03669757|DRUG|LEO 134310 vehicle|Active substance: none
48695826|NCT03669757|DRUG|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
48695827|NCT01877486|PROCEDURE|Ablation|Pulmonary vein isolation following dofetilide
48695828|NCT05074680|DIAGNOSTIC_TEST|Blood sampling|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
48695829|NCT03082443|OTHER|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
48695830|NCT00416494|BIOLOGICAL|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
48695831|NCT00416494|DRUG|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
48695832|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
48695833|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
48695834|NCT04539964|PROCEDURE|Implant Procedure|The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
48695835|NCT04539964|DRUG|Conventional Synthetic DMARD|All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
48695836|NCT04539964|DEVICE|Active stimulation|Active stimulation for 1 min once per day
48695837|NCT04539964|DEVICE|Non-active stimulation|Non-active stimulation for 1 min once per day
48695838|NCT06438471|DRUG|EC5026 oral tablet|"There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14"
48695839|NCT06438471|DRUG|Placebo oral tablet|Participants will be administered a matching oral placebo for 14 consecutive days.
48695840|NCT00000149|DRUG|Beta Blocker|
48695841|NCT00000149|PROCEDURE|Trabeculectomy|
48369892|NCT04308668|DRUG|Hydroxychloroquine|200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
48369893|NCT04308668|OTHER|Placebo|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
48695842|NCT00000149|PROCEDURE|Argon Laser Trabeculoplasty|
48695843|NCT06662097|DRUG|Bevonescein|Bevonescein is a sterile solution that is intravenously administered
48695844|NCT02030925|DRUG|IW-3718|
48695845|NCT02030925|DRUG|Matching Placebo|
48695846|NCT03707990|DRUG|NNC0165-1875|Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
48695847|NCT03707990|DRUG|Placebo (NNC0165-1875)|Participants will receive a single dose of s.c. placebo injection.
48695848|NCT03707990|DRUG|Semaglutide|Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
48695849|NCT06341296|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
48695850|NCT06341296|DRUG|5-FU|5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
48695851|NCT06341296|DRUG|LV|400mg/m\^2, d1, 14 days per cycle, 8 cycles.
48695852|NCT06341296|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle, 8 cycles.
48695853|NCT06661850|PROCEDURE|Fusion or TDR determined by investigator.|The surgical treatment will be decided by the treating investigator based on their clinical judgement.
48695854|NCT00640809|DRUG|Celecoxib|200 mg oral capsule twice daily for 2 weeks
48695855|NCT00640809|OTHER|Placebo|Matched placebo for 2 weeks
48369894|NCT06497816|OTHER|No intervention|No intervention
48369895|NCT03165227|DRUG|BI 685509|Taken orally
48369896|NCT03165227|DRUG|Placebo|Taken orally
48369897|NCT01004861|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
48695856|NCT00640809|DRUG|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
48166759|NCT00478439|DIETARY_SUPPLEMENT|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
48166760|NCT00478439|DIETARY_SUPPLEMENT|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
48166761|NCT00806299|DRUG|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
48166762|NCT00806299|DRUG|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
48166763|NCT00806299|DRUG|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
48166764|NCT06123949|DEVICE|Galvanic Vestibular Stimulation|Galvanic Vestibular Stimulation (GVS) is a non-invasive technique that uses low-level electrical currents to stimulate the vestibular system, affecting balance, posture, and eye movements. It has applications in research, clinical assessment, and rehabilitation of vestibular and balance-related issues, as well as potential applications in cognitive and motor function enhancement.
48166765|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
48166766|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
48166767|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
48166768|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
48166769|NCT04486833|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
48166770|NCT04486833|DRUG|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
48166771|NCT04486833|DRUG|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
48166772|NCT05838976|DIAGNOSTIC_TEST|Shorter Version of the CTQ-SSS|The intervention in this study is the administration of the shorter version of the CTQ-SSS, a validated questionnaire designed to assess the severity of symptoms and functional limitations associated with carpal tunnel syndrome. The CTQ-SSS consists of 8 items related to symptom severity and 2 items related to functional status. The scores for each set of items are combined to generate symptom severity and functional status scores, which will be used to assess the validity and reliability of the CTQ-SSS in patients with carpal tunnel syndrome undergoing nonsurgical management.
48522833|NCT02040805|BEHAVIORAL|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
48009310|NCT00515827|DRUG|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
48009311|NCT00515827|DRUG|Placebo|400 mg placebo tablet taken orally twice daily
48009312|NCT05709184|COMBINATION_PRODUCT|Lyophilized fecal microbiome transfer|Five days of vancomycin followed by five days of lyophilized fecal microbiome transfer, administered in a loading dose of 15 capsules, and a daily maintenance dose of 10 capsules.
48009313|NCT05709184|DRUG|Vancomycin|Ten days of oral vancomycin 125 mg four times daily
48009314|NCT06036069|OTHER|Conventional physical therapy|"* Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction."
48009315|NCT00556855|OTHER|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
48009316|NCT00556855|OTHER|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
48009317|NCT02993575|DRUG|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
48009318|NCT01251133|BIOLOGICAL|LBVH0101 (Hib vaccine)|0.5mL
48009319|NCT01251133|BIOLOGICAL|Hiberix™ Vaccine|0.5mL
48166773|NCT03631654|DRUG|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
48166774|NCT03631654|DRUG|Placebos|Placebo
48166775|NCT01956955|DRUG|enoxaparin ,alteplase, unfractionated heparin|
48166776|NCT03022110|DEVICE|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
48166777|NCT02731456|OTHER|altitude exposure|altitude exposure
48166778|NCT03945097|BEHAVIORAL|preK|Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
48166779|NCT05085808|DRUG|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
48166780|NCT05085808|DRUG|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
48166781|NCT05085808|DRUG|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
48695857|NCT05252013|OTHER|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
48695858|NCT05252013|OTHER|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
48695859|NCT06283641|DRUG|Liraglutide|Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
48695860|NCT04838769|DEVICE|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
48695861|NCT04838769|DRUG|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
48695862|NCT05810571|PROCEDURE|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
48695863|NCT05810571|PROCEDURE|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
48166782|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
48166783|NCT01002547|DRUG|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
48166784|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
48166785|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
48166786|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
48166787|NCT01002547|DRUG|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
48514590|NCT06550752|COMBINATION_PRODUCT|UC-MSCs and PRP|UC-MSCs are progenitor cells that can differentiate into various types of cells in the body and have the ability to regenerate and repair damaged tissue. During repair and regeneration, these cells secrete expedient and powerful bioactive paracrine factors including cytokines, chemokines, collagen, fibronectin, and growth factors promoting tissue repair, angiogenesis, and the regeneration of nerve cells as well as regulating cellular pathways including immunomodulation and inflammatory responses. Additionally, PRP contains numerous growth factors and cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor beta-1 and beta-2 (TGF-β1/2), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin 8 and matrix metalloproteinases 2,9. The combined effect of these factors provided by PRP injections is proposed to have anti- inflammatory, reparative, neuroprotective and neurotrophic effects that contribute to the treatment of ED.
48514591|NCT06040801|BEHAVIORAL|Frailty intervention measures|"Providing management and recommendations based on the specific impairment domain.~Assessment domain:~* Functional status~* Nutrition~* Comorbidity~* Mobility/Falls~* Mood~* Cognition~* Polypharmacy~* Social support."
48514592|NCT03666273|DRUG|Bapotulimab (BAY1905254)|Intravenous administration of escalating doses of Bapotulimab
48695864|NCT03106441|DEVICE|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
48695865|NCT03106441|DEVICE|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
48695866|NCT05406739|OTHER|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
48166788|NCT00926302|DRUG|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
48166789|NCT00926302|DRUG|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
48166790|NCT04701970|PROCEDURE|relining of mandibular complete denture|Relining of mandibular dentures was performed by reducing one mm of the denture fitting surfaces and borders to make a right-angled border. apply two separate layers of Mucopren adhesive upon the vestibular surface of the mandibular denture and allow each layer to dry for about 40 seconds. then, the lower denture was inserted and molded in patient mouths; while biting in centric occlusion with the opposing maxillary complete dentures.
48166791|NCT05908305|DRUG|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
48695867|NCT03263910|DRUG|NPO-11|20 ml NPO-11
48695868|NCT03263910|DRUG|Placebo|20 ml NPO-11(Placebo)
48695869|NCT04916353|DRUG|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
48695870|NCT04916353|DRUG|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
48166792|NCT01768741|PROCEDURE|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
48695871|NCT06614855|DRUG|C134|Initial Treatment . C134 Dose #1
48166793|NCT01768741|PROCEDURE|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
48166794|NCT02368899|OTHER|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
48695872|NCT06614855|DRUG|C134|2nd Treatment. C134 Dose #2
48695873|NCT04418492|BEHAVIORAL|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
48695874|NCT05659043|OTHER|overnight fasting|All blood samples were taken on the day of cardiac catheterization after overnight fasting.
48695875|NCT06294925|DRUG|Etrasimod|As provided in real world practice
48695876|NCT05368259|DEVICE|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
48695877|NCT00778375|DRUG|Clofarabine|20 mg/m\^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
48695878|NCT00778375|DRUG|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
48695879|NCT00778375|DRUG|Decitabine|20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
48166795|NCT02368899|OTHER|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
48166796|NCT04321915|OTHER|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
48166797|NCT04321915|OTHER|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
48166798|NCT03882996|DRUG|Ezetimibe|Ezetimibe 10 mg daily in the morning
48514593|NCT03666273|DRUG|Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)|Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
48514594|NCT00792350|DRUG|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
48514595|NCT03257865|DRUG|Brexpiprazole|Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.
48695880|NCT00869791|DRUG|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
48695881|NCT00869791|DRUG|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
48514596|NCT03257865|DRUG|Placebo|Administered orally daily for 3 weeks.
48695882|NCT05393531|DEVICE|Mandibular advancement device (MAD)|Active therapy
48695883|NCT05393531|DEVICE|Continuous positive airway pressure (CPAP)|Active therapy
48695884|NCT03973554|OTHER|pearl powder|natural product, support bone and joint health
48695885|NCT03973554|DRUG|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
48695886|NCT01252186|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
48695887|NCT01252186|DRUG|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
48695888|NCT01252186|DRUG|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
48695889|NCT05812963|DIAGNOSTIC_TEST|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
48695890|NCT05812963|DIAGNOSTIC_TEST|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
48514597|NCT05812066|PROCEDURE|all ceramic single-retainer resin bonded fixed partial denture|The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
48369898|NCT05499052|DRUG|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
48369899|NCT05228873|DRUG|Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)|Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
48695891|NCT06626321|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.
48166799|NCT03882996|DRUG|Atorvastatin|Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
48166800|NCT03723915|BIOLOGICAL|Pembrolizumab|Given IV
48166801|NCT03723915|BIOLOGICAL|Wild-type Reovirus|Given pelareorep IV
48695892|NCT06626321|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
48695893|NCT06626321|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention
48166802|NCT02924181|DEVICE|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
48166803|NCT01261455|PROCEDURE|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
48166804|NCT00740597|GENETIC|gene expression analysis|
48695894|NCT06626321|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
48695895|NCT04837118|OTHER|Educational Intervention|Receive handouts containing dietary recommendations
48166805|NCT00740597|GENETIC|polymerase chain reaction|
48695896|NCT04837118|OTHER|Quality-of-Life Assessment|Ancillary studies
48695897|NCT04837118|OTHER|Questionnaire Administration|Ancillary studies
48695898|NCT04837118|OTHER|Resistance Training|Participate in a resistance training program
48166806|NCT00740597|GENETIC|western blotting|
48166807|NCT00740597|PROCEDURE|neoadjuvant therapy|
48166808|NCT00740597|PROCEDURE|therapeutic conventional surgery|
48166809|NCT00740597|RADIATION|intensity-modulated radiation therapy|
48166810|NCT02805036|DEVICE|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
48166811|NCT02805036|DEVICE|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
48166812|NCT05052749|OTHER|High Intensity Resistance Training (HIRT)|High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
48369900|NCT04648943|PROCEDURE|Ex-Press mini shunt insertion|
48369901|NCT04648943|PROCEDURE|Trabeculectomy|
48369902|NCT03553121|OTHER|walking|walking and not walking
48514598|NCT01098474|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
48514599|NCT01098474|BIOLOGICAL|Tritanrix™ HB+Hib|Intramuscular, 3 doses
48514600|NCT01098474|BIOLOGICAL|Prevnar™|Intramuscular, 3 doses
48514601|NCT01098474|BIOLOGICAL|Polio Sabin™|Oral, 3 doses
48514602|NCT01098474|BIOLOGICAL|Menjugate™|Intramuscular, 3 doses
48514603|NCT01366625|DEVICE|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
48369903|NCT05292352|BEHAVIORAL|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
48695899|NCT01283776|DRUG|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
48695900|NCT03441867|BEHAVIORAL|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
48695901|NCT03441867|OTHER|Standard Medical Care|Observational - standard medical care
48695902|NCT06660602|PROCEDURE|cardiac surgery|All kinds of cardiac surgeries
48695903|NCT05629065|OTHER|Clinician Nudge Email|"-Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit"
48695904|NCT05629065|OTHER|Patient Nudge Letter and Share questionaire|"Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit."
48695905|NCT06661083|DIETARY_SUPPLEMENT|EGCG, FA, HA, B12|EGCG + FA + HA + B12 (1 cps /die)
48695906|NCT06481878|DIAGNOSTIC_TEST|faecal analysis|Collection of medical data and stool sampling
48695907|NCT03869996|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
48695908|NCT03869996|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
48695909|NCT05360693|PROCEDURE|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done \& patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
48695910|NCT05360693|PROCEDURE|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
48695911|NCT05501080|OTHER|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
48695912|NCT05501080|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
48695913|NCT06661174|PROCEDURE|Bariatric surgery|Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function
48695914|NCT06661174|OTHER|Non-surgical therapy|Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
48695915|NCT06662305|BEHAVIORAL|Kick-Nic! mobile phone application|The Kick-Nic! app has seven modules that cover core CBT strategies using skills, graphic illustrations, and interactive components to help adolescents quit using e-cigarettes.
48695916|NCT06662305|BEHAVIORAL|NCI Quit Vaping website|The NCI webpage provides quitting tobacco resources for youth, including for e-cigarettes. The information provided is similar to the CBT skills modeled by the Kick-Nic! app.
48369904|NCT05259124|DEVICE|positional perfusion index variation|positional perfusion index variation to predict spinal anesthesia-induced hypotension in elderly patients
48695917|NCT04742803|DEVICE|Straberi Epistamp Microneedling Treatment|"The patient's entire face will be treated with the Straberi Epistamp needling device.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
48695918|NCT05126810|OTHER|Questionnaire Administration|Complete questionnaire
48695919|NCT06658379|DIAGNOSTIC_TEST|CD8+TEMRA|
48695920|NCT04699695|OTHER|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
48695921|NCT06444867|DRUG|LEO 158968|SC injection
48695922|NCT02402504|OTHER|Control|Non pulse extruded snack
48695923|NCT02402504|OTHER|Small particle size pea flour|Pulse extruded snack
48695924|NCT02402504|OTHER|Large particle size pea flour|Pulse extruded snack
48695925|NCT02402504|OTHER|Lentil flour|Pulse extruded snack
48695926|NCT02402504|OTHER|Navy bean flour|Pulse extruded snack
48369905|NCT00594958|BIOLOGICAL|IC51|6 mcg, intramuscularly \[i.m.\], 0.5 mL
48514604|NCT04665986|DRUG|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
48514605|NCT04665986|DRUG|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
48695927|NCT02402504|OTHER|Pinto bean flour|Pulse extruded snack
48695928|NCT06342492|OTHER|Coronary Sinus Lead Revision|Coronary Sinus Lead Revision
48166813|NCT05052749|OTHER|Low-moderate Resistance Exercise Training|Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
48166814|NCT02025361|DRUG|intrarectal lidocaine gel|intrarectal local anesthetic application
48166815|NCT02025361|DRUG|periprostatic nerve blockade|periprostatic local anesthetic application
48166816|NCT00690378|DRUG|NXL104/ceftazidime|125mg/500mg TID
48166817|NCT00690378|DRUG|Imipenem/Cilastatin|4 x daily
48166818|NCT00005845|DRUG|tipifarnib|Given PO
48166819|NCT00005845|OTHER|laboratory biomarker analysis|Correlative studies
48166820|NCT00005845|OTHER|pharmacological study|Correlative studies
48166821|NCT01176136|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
48166822|NCT06247618|DEVICE|visor|The treatment will have a duration of 4 weeks, with the execution of two sessions per week with the use of a viewer positioned on the head that allows users to navigate and interact in real time with a three-dimensional (3D) environment
48166823|NCT01647152|DRUG|Ustekinumab|
48166824|NCT04878575|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
48166825|NCT04878575|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
48166826|NCT05939089|DIAGNOSTIC_TEST|ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.
48369906|NCT05962658|OTHER|qEEG|qEEG data was collected with patients and healthy individuals in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
48514606|NCT04385121|OTHER|Questionnary|Family member's will answer the questionnaires by phone
48695929|NCT01555034|BEHAVIORAL|movement therapy|exercise, nutrition, movement therapy
48695930|NCT01555034|OTHER|exercise plus nutrition|exercise, nutrition
48166827|NCT02399683|BIOLOGICAL|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
48166828|NCT00655668|DRUG|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
48166829|NCT02811393|OTHER|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
48166830|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl|injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
48166831|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)|injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
48166832|NCT00985621|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
48166833|NCT00985621|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
48166834|NCT00985621|DRUG|oxycodone|oxycodone CR, 10-40 mg q12h
48166835|NCT00985621|OTHER|placebo|placebo
48514607|NCT04634279|BEHAVIORAL|Collaborative care Plus|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In this model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care. In the Collaborative Care Plus condition, the care coordinator involves family in care, teaches family about naloxone use, and provides Caring Contacts, a suicide prevention method, to patients.
48514608|NCT04851847|DEVICE|Guided Tissue Regeneration (GTR)|Use of resorbable collagen membrane to treat periodontal intrabony defects.
48514609|NCT00313079|DRUG|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
48514610|NCT00313079|DRUG|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
48514611|NCT04992208|BIOLOGICAL|Experimental Group|SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
48514612|NCT04350450|DRUG|Hydroxychloroquine|400 mg tablet
48695931|NCT03466281|BEHAVIORAL|Structured patient group education|Patient education in a group setting
48695932|NCT03466281|BEHAVIORAL|Education via Internet|Patient education via the internet
48695933|NCT04181593|DRUG|Omega 3 fatty acid|Omega 3 fatty acid Softgels
48695934|NCT04181593|DRUG|Placebos|Mineral oil Softgels
48695935|NCT06660173|DRUG|Maridebart Cafraglutide|Solution for subcutaneous injection.
48695936|NCT06660173|DRUG|Placebo|Solution for subcutaneous injection.
48695937|NCT06635148|DRUG|JNJ-81201887|No study intervention will be administered as part of this LTE study.
48695938|NCT06635148|OTHER|Sham Procedure|No study intervention will be administered as part of this LTE study.
48695939|NCT02119195|PROCEDURE|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
48695940|NCT01954459|DEVICE|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
48695941|NCT01954459|DEVICE|Continuous glucose sensor|Glucose sensor inserted without warming patch
48514613|NCT03957850|BEHAVIORAL|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny \& Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
48514614|NCT03957850|BEHAVIORAL|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
48514615|NCT05890534|DRUG|Pycnogenol®|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
48695942|NCT03301220|DRUG|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
48166836|NCT02315079|OTHER|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
48166837|NCT02315079|OTHER|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
48695943|NCT06660264|OTHER|Pharmacist Personalized Medication Review (PMR)|Pharmacist-provided review of current medications and assessment of potential medication related problems.
48166838|NCT04167085|DRUG|Doxycycline|Doxycycline, 100 mg twice a day for 2 months
48514616|NCT05890534|DRUG|Placebo|Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.
48514617|NCT03390855|OTHER|Broccoli sprouts|
48695944|NCT06660264|OTHER|Discussion of Pharmacogenomic results during the PMR|Return of pharmacogenomic results and discussion of impact on medications.
48695945|NCT04523623|DRUG|Oxycodone|oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
48695946|NCT04523623|DRUG|Ibuprofen|ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
48695947|NCT06570512|DEVICE|transcutaneous posterior tibial nerve stimulation|Over three weeks, the TPTNS group underwent ten sessions of electrical stimulation along the course of the posterior tibial nerve behind the medial malleoli using cup electrodes, with a width pulse of 250 microseconds, and a frequency of 20 Hz. The TENS group used a sham device with the same parameters, but the electrodes were placed behind the lateral malleoli with underpowered amplitudes.
48695948|NCT03445377|DEVICE|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
48166839|NCT04167085|OTHER|Placebo|Matching placebo, twice a day for 2 months
48514618|NCT05456490|DRUG|Liposomal Bupivacaine 13.3|Injection into the Intrathecal space
48514619|NCT05456490|DRUG|Bupivacaine|Injection into the Intrathecal space
48514620|NCT05456490|OTHER|Placebo|Injection into the Intrathecal space
48514621|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
48514622|NCT01960335|DIETARY_SUPPLEMENT|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
48166840|NCT05195905|DEVICE|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
48166841|NCT01808521|DRUG|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
48166842|NCT06197685|BEHAVIORAL|The Kessler Foundation modified Story Memory Technique® (KF-mSMT®)|KF-mSMT is a memory retraining technique that consists of two-related skills: (1) imagery and (2) context/organization. The proposed KF-mSMT intervention includes 10 total sessions with 2 sessions per week for 5 weeks. Each session will last 45-60 minutes.
48166843|NCT06197685|BEHAVIORAL|Aerobic Exercise Training (AET) plus Virtual Reality (IDEAL)|The AET condition includes 12 weeks of supervised, progressive, moderate intensity cycle ergometry. The AET will include semi-immersive, interactive VR such the cycling speed on the bike will translate directly to perceived speed through the virtual environment.
48166844|NCT06197685|BEHAVIORAL|Stretching and Toning (S/T)|The S/T condition will include 12 weeks of supervised S/T activities that target the head/neck. shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
48166845|NCT02241161|OTHER|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
48166846|NCT02241161|OTHER|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
48166847|NCT02241161|OTHER|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
48166848|NCT01470664|DRUG|FST-100|0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
48166849|NCT01470664|DRUG|FST-100 (Component #1)|0.6% PVP-Iodine ophthalmic solution alone
48166850|NCT01470664|DRUG|FST-100 Vehicle|FST-100 Vehicle
48695949|NCT03445377|DEVICE|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
48166851|NCT03964922|BIOLOGICAL|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
48166852|NCT03964922|BIOLOGICAL|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
48166853|NCT01174498|DEVICE|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
48166854|NCT01174498|DEVICE|t-VNS Sham stimulation|t-VNS Sham stimulation
48166855|NCT04233333|DEVICE|method of fixation of the orogastric tube|Methods of fixation of the orogastric tube will be randomized
48166856|NCT03375840|BEHAVIORAL|Text-only PWL|Control condition
48166857|NCT03375840|BEHAVIORAL|Low-emot PWL|Pictorial warning
48166858|NCT03375840|BEHAVIORAL|High-emot PWL|Pictorial warning
48514623|NCT01960335|OTHER|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
48166859|NCT03375840|BEHAVIORAL|Immediate posttest|
48166860|NCT03375840|BEHAVIORAL|delay posttest|
48166861|NCT02162914|DRUG|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
48166862|NCT02162914|DRUG|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
48166863|NCT00915785|DRUG|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
48166864|NCT00086021|PROCEDURE|Acupuncture|
48369907|NCT04863898|BEHAVIORAL|Drug-use stigma reduction intervention for HIV care and treatment clinic staff|We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building. The intervention consists of five-2.5 hour participatory training sessions.
48695950|NCT00564902|DRUG|3R 3'R Zeaxanthin|8 mg per day during 12 months
48695951|NCT00564902|DIETARY_SUPPLEMENT|Lutein|9 mg of Lutein during 12 months
48695952|NCT00564902|DIETARY_SUPPLEMENT|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
48695953|NCT06450886|DRUG|Ulviprubart (ABC008)|All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
48695954|NCT06120283|DRUG|BGB-43395|Planned doses administered orally.
48166865|NCT06646653|DEVICE|Alma System|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
48166866|NCT04976283|DRUG|Pioglitazone|Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
48166867|NCT04976283|DRUG|Empagliflozin|Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
48166868|NCT04976283|DRUG|Pioglitazone + Empagliflozin|Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
48166869|NCT04565210|OTHER|Music exposure|Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
48166870|NCT04565210|OTHER|Silence|Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
48166871|NCT03650361|DRUG|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
48166872|NCT03650361|DRUG|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
48166873|NCT03650361|DRUG|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
48166874|NCT01503437|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
48166875|NCT02745314|OTHER|Frailty measurement|Frailty measurement under Fried at el criteria
48695955|NCT06120283|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
48695956|NCT06120283|DRUG|Letrozole|Standard dose administered orally as a tablet.
48695957|NCT06662357|BEHAVIORAL|Behavioral Treatment|"Family Connections Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
48522834|NCT02040805|BEHAVIORAL|Peer Facilitated Support Group|Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
48166876|NCT02745314|OTHER|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
48166877|NCT01723514|DRUG|Erenumab|Administered by subcutaneous injection once a month
48166878|NCT01723514|DRUG|Placebo|Administered by subcutaneous injection once a month
48166879|NCT01876771|DRUG|[177]Lu-DOTA-TATE|Peptide receptor radionuclide therapy (PPRT)
48166880|NCT01612221|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
48695958|NCT01749124|DEVICE|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
48695959|NCT00748618|DIETARY_SUPPLEMENT|Standard vitamin D3 treatment|10,000 I.U./wk of vitamin D3 orally for 6 months
48695960|NCT00748618|DIETARY_SUPPLEMENT|High dose vitamin D3 treatment|50,000 I.U./wk of vitamin D3 orally for 6 months
48166881|NCT01612221|OTHER|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
48369908|NCT04019028|DEVICE|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
48369909|NCT04019028|DEVICE|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
48369910|NCT04019028|DEVICE|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
48369911|NCT06111963|DIAGNOSTIC_TEST|Serology tests|CD4, CD25, IL17
48369912|NCT06240468|OTHER|not have|not have
48369913|NCT03831581|PROCEDURE|Erector Spinae Plane Block|In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.
48369914|NCT05604482|DIAGNOSTIC_TEST|CXCR4-PET|New imaging modality using CXCR4 for imaging in GCA
48369915|NCT03826849|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
48369916|NCT00130754|DRUG|Thymoglobuline|IV 7.5 mg/kg
48369917|NCT04242121|DIAGNOSTIC_TEST|fluorescence flow cytometry|Countification of plasma cells by fluorescence flow cytometry (hematology analyzer XN-1000/20)
48369918|NCT01348464|PROCEDURE|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
48369919|NCT03326882|DEVICE|Endotracheal intubation|
48369920|NCT04681872|PROCEDURE|Destruction of Marshall bundles|Destruction of Marshall bundles by ethanol 96% infusion (2 separate injections of 5ml on 1 minute each) followed by ablation of the distal coronary sinus bundles, the ridge and the saddle.
48369921|NCT04681872|PROCEDURE|Pulmonary veins isolation|Achievement of a wide disconnection of the right and left pulmonary veins.
48369922|NCT04681872|PROCEDURE|Linear ablation in the left and right atria|Ablation of the mitral, the roof, and the cavo-tricuspid isthmus
48369923|NCT01540721|DRUG|Marketed paracetamol|marketed formulation
48522835|NCT04982289|DRUG|ALXN1830|Administered as an SC infusion.
48695961|NCT05228275|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48695962|NCT05228275|OTHER|Survey Administration|Complete survey
48695963|NCT00140283|PROCEDURE|Educational interactive intervention|
48166882|NCT06363513|DRUG|Aescin in Horse Chestnut|Can aescin reduce bleeding in early hemorrhoid
48166883|NCT06363513|DRUG|Flavonoid|Can combine aescin and MPFF reduce bleeding in early hemorrhoid
48166884|NCT00582114|DRUG|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
48369924|NCT01540721|DRUG|Experimental paracetamol formulation|Experimental formulation
48369925|NCT01604642|OTHER|blood tests and muscular biopsies|blood tests and muscular biopsies
48369926|NCT00019565|PROCEDURE|magnetic resonance imaging|
48369927|NCT00019565|PROCEDURE|positron emission tomography|
48369928|NCT00019565|RADIATION|fludeoxyglucose F 18|
48369929|NCT01811004|DEVICE|miraDry|miraDry
48369930|NCT01811004|DEVICE|Nd:YAG Laser|Nd:YAG 1440 nm Laser
48369931|NCT01811004|DEVICE|Botox®|Botox®
48514624|NCT03070587|BEHAVIORAL|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
48695964|NCT06450964|OTHER|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and the mitochondrial DNA mutation heterogeneity level was determined.|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and some granulosa cells, trophoderm cells, embryo culture fluid, embryo biopsy fluid, and embryo trophoblast cells were collected. Placenta and umbilical cord blood samples of some fetuses were collected after delivery, and the mitochondrial DNA mutation heterogeneity level was determined.
48695965|NCT00949923|DIETARY_SUPPLEMENT|tea capsule|3 tea capsules daily for 3 weeks
48514625|NCT02067962|BIOLOGICAL|Blood sample|Blood sample
48514626|NCT03059797|DRUG|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
48695966|NCT04147377|BEHAVIORAL|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
48695967|NCT03296748|PROCEDURE|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
48166885|NCT00582114|DRUG|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
48369932|NCT01258751|DRUG|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
48369933|NCT03431246|BIOLOGICAL|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
48514627|NCT03059797|DRUG|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
48514628|NCT01228578|DIETARY_SUPPLEMENT|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
48695968|NCT03296748|PROCEDURE|anterior colporraphy|
48695969|NCT04327362|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
48514629|NCT02015845|DEVICE|Accuvein|
48166886|NCT06080490|DRUG|TAC C/D ratio|Pharmacokinetics of TAC according to possible influencing factors
48166887|NCT05498077|PROCEDURE|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
48369934|NCT03986658|DEVICE|Linear Asymmetric rTMS System|Linear Asymmetric rTMS System
48514630|NCT02015845|DEVICE|Routine technique|Placement of peripheral intravenous catheters using the routine technique
48522836|NCT04982289|OTHER|Placebo|Administered as an SC infusion.
48514631|NCT05999487|DRUG|Dobutamine|"Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment."
48514632|NCT04590105|DEVICE|"Smartphone App SB Colonoscopy Prep"|We created a smartphone app that informs patients about their colonoscopy procedure, alerts them when to take their medications throughout the hours-long colonoscopy prep process and tells them when to arrive to the endoscopy suite.
48514633|NCT04590105|OTHER|Written Instruction|Written Instruction
48514634|NCT03245827|DRUG|Clomiphene|clomiphene capsule 25mg twice a week
48514635|NCT03245827|DRUG|Placebo|placebo capsule 25mg twice a week
48514636|NCT03044821|PROCEDURE|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
48514637|NCT05644925|DEVICE|PiCSO Impulse System|The PiCSO Impulse System is intended to reduce infarct size by intermittently occluding the coronary sinus outflow in patients undergoing a percutaneous coronary interventional procedure for myocardial infarction and presenting with Thrombolysis in myocardial infarction (TIMI) flow of 0 or 1.
48695970|NCT04327362|BEHAVIORAL|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
48695971|NCT05139719|DRUG|HEC585 dose A|taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
48514638|NCT05644925|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Minimally invasive procedures used to open clogged coronary arteries
48695972|NCT05139719|DRUG|HEC585 dose B|taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
48695973|NCT05139719|DRUG|Placebo|taking Placebo orally once daily, up to 24 weeks in main stage
48695974|NCT01263431|PROCEDURE|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
48695975|NCT01263431|PROCEDURE|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
48695976|NCT03462719|DRUG|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
48695977|NCT03462719|DRUG|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
48166888|NCT00812825|DRUG|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
48514639|NCT06243276|PROCEDURE|One stage implant surgery|It is a technique in which the healing cap is connected to the implant at the stage of implant placement.
48166889|NCT00812825|DRUG|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
48166890|NCT00812825|DRUG|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
48166891|NCT00812825|DRUG|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
48514640|NCT06243276|PROCEDURE|Two stage implant surgery|It is a technique in which the healing cap is connected to the implant three months after the implant is placed.
48514641|NCT05468424|OTHER|tablet (iPad or android) based role-playing game|The intervention is a tablet (iPad or android) based role-playing game called FarmVille. In FarmVille the player assumes the role of a farmer tasked with tending to crops and farm animals and using what is produced to craft goods which can be sold to expand the farm. The participant is required to play FarmVille for 5 or more hours a week for 8 weeks.
48514642|NCT05468424|OTHER|tablet (iPad or android) based word puzzles and image puzzles|"This intervention is a selection of tablet (iPad or android) word puzzles and image puzzles. One word puzzle involves word making (i.e., making words from a set of random letters), and the other word searching (i.e., finding words on a grid of letters). One image puzzle is Flow Free, a game that requires the player to connect pairs of same coloured dots positioned on a grid ranging from 5x5 to 9x9. The other image puzzle is a jigsaw. The participant is required to play these games for 5 or more hours a week for 8 weeks."
48514643|NCT05292365|BEHAVIORAL|RE-PACT Intervention|"* Create respiratory illness action plan~* Weekly mHealth text messages~* Monthly study assessments~* Action planning and JIT coaching"
48514644|NCT05682651|PROCEDURE|tracheal stenosis follow-up file|Patients' age, gender, American Society of Anesthesiologists (ASA) classification, comorbidities, etiologic cause, intubation time, type of surgery, length of hospital stay, and morbidity/mortality information will be recorded.
48514645|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
48514646|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
48514647|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
48514648|NCT00691717|OTHER|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
48695978|NCT03462719|DRUG|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
48695979|NCT03462719|DRUG|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
48695980|NCT03462719|DRUG|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
48695981|NCT04643873|OTHER|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
48166892|NCT00812825|DRUG|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
48166893|NCT02497196|DEVICE|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
48166894|NCT02497196|DEVICE|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
48369935|NCT00957736|GENETIC|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
48369936|NCT00957736|OTHER|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
48369937|NCT04920331|BIOLOGICAL|Erenumab|140mg single intravenous administration (60 minutes)
48514649|NCT04475172|COMBINATION_PRODUCT|Self-Adhesive Flowable Composite|"Fusio Self-Adhesive Flowable Composite combines the benefits of adhesive and restorative technology into one product . Immediately upon application Fusio conditions, bonds, and seals without the need for an etchant or an adhesive.~It is based on the bonding technology that uses glycerophosphate dimethacrylate(GPDM)to etch enamel and dentin, and hydroxyethyl methacrylate (HEMA) to enhance wetting and penetration by resin into dentin."
48695982|NCT04643873|BEHAVIORAL|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
48166895|NCT02497196|DEVICE|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
48166896|NCT02497196|DEVICE|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
48166897|NCT05830305|OTHER|Mobile health intervention|A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
48695983|NCT01353443|PROCEDURE|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
48695984|NCT02108327|PROCEDURE|surgical blade|Using surgical blade all the time of surgery
48514650|NCT06372210|DRUG|Placebo IEM tablet|Oral placebo-embedded IEM tablet.
48514651|NCT06372210|DRUG|Abilify MyCite®|Oral aripiprazole-embedded IEM tablet.
48695985|NCT02108327|PROCEDURE|electrocautery|Using electrocautery all the time except at skin incision
48695986|NCT03134495|OTHER|all children with at least one prescription of PPI|all children with at least one prescription of PPI
48695987|NCT03134495|OTHER|all children with no prescription of PPI|all children with no prescription of PPI
48695988|NCT06660394|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
48695989|NCT06660394|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube
48695990|NCT06659588|OTHER|Plasma, urine and stool collection|"During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research."
48695991|NCT06657872|PROCEDURE|water vapor therapy under general anesthesia|Water vapor procedure will be performe under conscious intravenous sedation with anesthesia team
48166898|NCT03191214|DEVICE|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery \>30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
48166899|NCT00399997|BEHAVIORAL|Exercise on Prescription|
48166900|NCT00897754|GENETIC|gene expression analysis|
48166901|NCT00897754|GENETIC|protein expression analysis|
48166902|NCT00897754|GENETIC|reverse transcriptase-polymerase chain reaction|
48166903|NCT00897754|OTHER|immunoenzyme technique|
48166904|NCT00897754|OTHER|immunohistochemistry staining method|
48166905|NCT00897754|OTHER|immunologic technique|
48514652|NCT06372210|DEVICE|D-Tect Patch|The D-Tect patch is a wearable sensor (WS) capable of detecting the ingestion of the IEM and measuring physiologic parameters. The WS automatically logs and stores the time when the IEM reaches the stomach and transmits the data to a smartphone.
48695992|NCT06657872|PROCEDURE|water vapor therapy under local anesthesia|Water vapor procedure will be performe under local anethesia administrated with Schelin® catheter via the trans-urethral route : injection of 20cc of lidocaine 2% intra-prostatically via the schelin catheter at 4 injection points (3cc at 1h, 3cc at 11h, 7cc at 4h, and 7cc at 8h).
48695993|NCT06655298|DEVICE|US guided block|"Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg"
48695994|NCT02456207|DRUG|SCT400|
48695995|NCT02456207|DRUG|Rituximab|
48695996|NCT02321319|DRUG|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
48695997|NCT02003638|DRUG|Niacin|Niacin titrated to 6000 mg daily
48695998|NCT02003638|DRUG|Placebo|Placebo provided in the same pill quantity as niacin arm
48166906|NCT02917798|BEHAVIORAL|Assessments|
48514653|NCT03308812|BEHAVIORAL|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
48695999|NCT00116701|DRUG|Aranesp®|
48696000|NCT01851265|DRUG|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
48166907|NCT04785586|BEHAVIORAL|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
48166908|NCT04785586|BEHAVIORAL|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
48166909|NCT04785586|BEHAVIORAL|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
48166910|NCT04782505|DRUG|DWJ1248|Camostat mesylate Tablet from Daewoong
48166911|NCT04851171|PROCEDURE|Flexible Ureteroscopy|Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
48166912|NCT04851171|PROCEDURE|Semi-rigid Ureteroscopy|Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
48514654|NCT03308812|BEHAVIORAL|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
48696001|NCT01851265|OTHER|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
48696002|NCT01851265|OTHER|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
48696003|NCT01851265|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
48696004|NCT06065657|DIETARY_SUPPLEMENT|Ketone Supplement|Ketone supplement 3x day with control diet for 3 days.
48696005|NCT06065657|OTHER|Control Diet|Control Diet breakfast, lunch, and dinner for 3 days.
48696006|NCT06065657|OTHER|Ketogenic diet|Ketogenic Diet breakfast, lunch, and dinner for 3 days.
48696007|NCT06065657|DRUG|Ethanol|After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
48696008|NCT05547399|DRUG|Zanubrutinib|Administered orally as a tablet or capsule
48009320|NCT04555135|DEVICE|EndoVigilant Software|While using this device, colonoscopy will continue to be performed in the standard manner as is done without the use of this device. The video signal from the colonoscope will be fed into a computer running the EndoVigilant software in addition to the standard video output to the procedure monitor. The gastroenterologist performing the procedure will therefore be able to observe a standard colonoscopy video on the primary monitor and the augmented video on the second monitor. The gastroenterologist may rely on the second monitor (with augmented video generated from EndoVigilant software) for polyp detection, but the standard procedure monitor with the original feed will always be operational and available for maneuvers such as fast insertion, polypectomy etc.
48166913|NCT02234635|OTHER|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
48166914|NCT03510377|OTHER|Aquatic physical intervention|For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
48166915|NCT03510377|OTHER|On-land physical intervention|For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
48166916|NCT03510377|OTHER|Non physical intervention|The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
48696009|NCT03269916|OTHER|Anti Mueller hormone|used to assess ovarian reserve parameters
48696010|NCT03269916|OTHER|Estrogen|used to assess ovarian reserve parameters
48166917|NCT01935193|DRUG|lysine acetylsalicylate|
48166918|NCT02115334|BEHAVIORAL|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
48166919|NCT02115334|BEHAVIORAL|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
48166920|NCT02115334|BEHAVIORAL|health education|health education of the children with DD.
48166921|NCT00788879|BEHAVIORAL|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
48369938|NCT03311295|DEVICE|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
48369939|NCT03575741|DIAGNOSTIC_TEST|Balance Tests|"Following balance exercises will be performed by the participants:~1. Bipedal, hip wide stand, eyes open and hands on hips, 60sec~2. Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~3. Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~4. Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~5. One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~6. One-leg-stand, eyes open, hands on hips, 30sec (other leg)~7. Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
48369940|NCT03186950|PROCEDURE|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
48369941|NCT03186950|PROCEDURE|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
48369942|NCT02278042|OTHER|Beverage Consumption|
48369943|NCT04460495|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo ASL scan
48369944|NCT04460495|PROCEDURE|pH-Weighted amine CEST|Undergo pH Weighted amine CEST
48369945|NCT04460495|PROCEDURE|Oxygen-weighted SAGE-EPI|Undergo Oxygen-weighted SAGE-EPI
48514655|NCT06304246|OTHER|Measurement Pain Threshold|Measurement Pain Threshold: Manual dolorimetry will be used to assess the pain threshold in the non-dominant hand of patients in the preoperative waiting room prior to spinal anesthesia. The dolorimeter head will be placed vertically on the wrist of the non-dominant hand, and pressure will be applied with increments of 1 kg/cm2/s. The pressure applied when the patient perceives pain will be recorded in kg/cm2. The measurement will be repeated three times for each patient, and the average will be recorded as the pain threshold value.
48696011|NCT03269916|OTHER|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
48696012|NCT03269916|OTHER|Antral alveolar cell count|used to assess ovarian reserve parameters
48696013|NCT04989309|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
48696014|NCT06662344|BEHAVIORAL|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48369946|NCT02695316|OTHER|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
48369947|NCT02695316|OTHER|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
48369948|NCT02695316|OTHER|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
48514656|NCT06304246|OTHER|Measurement of Serum Asprosin|Measurement of Serum Asprosin: For serum asprosin measurements, blood will be drawn in the preoperative waiting room before the application of spinal anesthesia. The blood samples will be centrifuged, and the serum will be stored at -20°C to measure serum asprosin levels. After all patient blood is collected, serum asprosin will be evaluated with a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
48009321|NCT05256433|OTHER|Group-A|IASTM Certified IASTM practitioner will be performing the technique with emollient lubricant in which brushing and sweeping stroke will be applied for plantar fascia and fanning and sweeping stroke technique for calf muscles for the duration of 10 minutes to eliminate the inflammation. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury. The frequency stretching will be 5 repetitions for each with 10 seconds hold.
48696015|NCT06662344|BEHAVIORAL|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48696016|NCT06662344|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48696017|NCT06660628|RADIATION|Large Segmentation Radiotherapy|Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
48696018|NCT06660628|DEVICE|DIBH|Deep Inspiration Breath Hold
48696019|NCT06660628|DEVICE|Surface guided radiation therapy|The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
48696020|NCT06660628|DEVICE|laser alignment|Laser systems for virtual simulation and patient positioning in radiotherapy
48514657|NCT02289456|DRUG|nab-Paclitaxel|
48009322|NCT05256433|OTHER|Group-B|Manual massage includes transverse friction massage for plantar fascia, flexor digitorum brevis, and deep massage for calf muscle for the duration of 10 minutes to eliminate the tightness and increase the blood flow. Active calf stretching and passive plantar fascia stretching will be performed for the correction of shortened tissue, and to prevent re-injury.
48369949|NCT02695316|OTHER|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
48514658|NCT02289456|DRUG|Carboplatin|
48369950|NCT02776631|DEVICE|Pinloc|Internal fixation device
48514659|NCT04607057|DRUG|Parenteral Nutrition Solutions|"* Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN"
48514660|NCT03252730|OTHER|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
48514661|NCT03629184|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days."
48514662|NCT03629184|DRUG|Oseltamivir|Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
48514663|NCT00425373|DRUG|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
48514664|NCT00425373|DRUG|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
48696021|NCT06660628|BEHAVIORAL|free breathing|Patients breathe calmly while radiotherapy instead of holding their breath.
48696022|NCT03001830|BIOLOGICAL|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
48696023|NCT00397852|PROCEDURE|Kirschner-wires or not|
48696024|NCT06454890|BIOLOGICAL|Anti-Trop2 CAR-NK cell|chemotherapy followed by Trop2 CAR-NK infusion
48696025|NCT00488449|DRUG|GSK256073A tablets|
48696026|NCT05866029|DRUG|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
48696027|NCT05866029|DRUG|Teriparatide|Teriparatide was sequentially treated with Denosumab
48369951|NCT02776631|DEVICE|Hansson Pins (LIH)|Internal fixation device
48369952|NCT00063076|DRUG|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
48369953|NCT04645225|DEVICE|. MEFV genetic testing|For mutation analysis, 2 ml blood will be with drawn from both patient and control groups in order to obtain genomic DNA. Extraction of DNA molecule from peripheral blood lymphocytes will be done using standard procedures, then amplification of MEFV gene will be done by polymerase chain reaction(PCR). Reversed hybridization technique will be used for identification of MEFV gene mutation.
48369954|NCT05600842|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
48369955|NCT02990273|BIOLOGICAL|Blood transfusion|
48369956|NCT02267460|BIOLOGICAL|AA4500|
48369957|NCT02267460|DEVICE|ErecAid® Esteem® Manual Vacuum Therapy System|
48369958|NCT02267460|PROCEDURE|Investigator Modeling|
48369959|NCT01161173|DRUG|Erlotinib|Erlotinib was provided in the retail versions of the product.
48369960|NCT00405756|DRUG|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
48369961|NCT00405756|DRUG|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
48369962|NCT00405756|DRUG|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
48369963|NCT00405756|DRUG|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
48369964|NCT00405756|DRUG|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
48369965|NCT00405756|DRUG|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
48369966|NCT00405756|DRUG|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
48369967|NCT05492552|BEHAVIORAL|Active-at-home-HF|Increase daily step count by 2,000 and weekly telephone calls.
48369968|NCT01510704|DRUG|APD421|IV
48696028|NCT05066152|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
48696029|NCT05066152|DIETARY_SUPPLEMENT|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
48166922|NCT00788879|BEHAVIORAL|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
48696030|NCT04150939|PROCEDURE|Core Biopsy|Undergo core biospy
48166923|NCT01213615|DEVICE|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
48166924|NCT05542914|BEHAVIORAL|electronic screening and brief intervention.|e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.
48166925|NCT05542914|BEHAVIORAL|Men's Health Project (MHP)|This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
48166926|NCT02624505|DRUG|90 mcg Reference Product|Drug: 90 mcg Reference Product
48166927|NCT02624505|DRUG|180 mcg Reference Product|Drug: 180 mcg of Reference Product
48166928|NCT02624505|DRUG|90 mcg Test Product|Drug: 90 mcg of Test Product
48166929|NCT02624505|DRUG|Placebo|Placebo Product
48369969|NCT01510704|DRUG|Placebo|IV
48369970|NCT01234662|PROCEDURE|SPA|Spinal anesthesia and opioids
48369971|NCT01234662|PROCEDURE|CSE|CSE and epidural opioids
48514665|NCT00425373|DRUG|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
48514666|NCT00425373|DRUG|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
48696031|NCT04150939|PROCEDURE|Cryosurgery|Undergo cryoablation
48696032|NCT04150939|DRUG|Immunotherapeutic Agent|Receive standard of care immunotherapy
48696033|NCT04202406|DRUG|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
48696034|NCT04202406|DRUG|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
48696035|NCT04202406|DRUG|Placebo|The patient will receive placebo (starch) 1hour before treatment.
48696036|NCT03206918|DRUG|Zanubrutinib|Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
48696037|NCT06625515|DRUG|ATX-559|DHX9 tablets will be taken orally
48696038|NCT05289141|DEVICE|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
48696039|NCT05289141|DEVICE|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
48696040|NCT06517017|DRUG|Isatuximab|Subcutaneous isatuximab will be administered weekly on a 28-day cycle during the first two cycles, and every two weeks of a 28-day cycle thereafter. Dexamethasone will be administered on the days of isatuximab administration and can be discontinued after two cycles of therapy, or continued at discretion of investigator. Lenalidomide, will be added after two cycles of therapy have been completed.
48696041|NCT06035172|BEHAVIORAL|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
48166930|NCT05143879|DIETARY_SUPPLEMENT|Citrulline|3 g/day during 9 weeks
48166931|NCT05143879|DIETARY_SUPPLEMENT|Nitrate|300 mg/day during 9 weeks
48369972|NCT01234662|PROCEDURE|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
48369973|NCT02688751|RADIATION|time-resolved CT Angiography|A multi-phase contrast CT
48369974|NCT02688751|PROCEDURE|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
48514667|NCT00425373|DRUG|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
48696042|NCT06035172|BEHAVIORAL|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
48696043|NCT03007329|DRUG|Exenatide|Exenatide will be combined with Dapagliflozin
48166932|NCT05143879|DIETARY_SUPPLEMENT|Nitrate plus Citrulline|3 g/day of citrulline and 300 mg/day of nitrate during 9 weeks
48009323|NCT02016963|BIOLOGICAL|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
48009324|NCT02559388|DRUG|Montelukast|
48166933|NCT05143879|DIETARY_SUPPLEMENT|Placebo|3 g/day during 9 weeks
48696044|NCT03007329|DRUG|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
48166934|NCT04561583|DEVICE|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
48369975|NCT05737108|DIETARY_SUPPLEMENT|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
48369976|NCT05737108|DIETARY_SUPPLEMENT|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
48696045|NCT03007329|DRUG|Dapagliflozin|Dapagliflozin, in both arms
48696046|NCT04573153|DRUG|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
48696047|NCT04573153|DRUG|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
48696048|NCT05222893|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
48696049|NCT05222893|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute
48696050|NCT05222893|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
48009325|NCT02559388|DRUG|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
48009326|NCT05954481|OTHER|Stress echocardiography|After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer
48009327|NCT01018420|DRUG|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
48696051|NCT05222893|DEVICE|Esophageal pressure|Measurement the pressure in the lower third of esophagus during inspiration and expiration
48696052|NCT02302248|BEHAVIORAL|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
48696053|NCT02302248|BEHAVIORAL|Expressive writing intervention|3 week access to a web-based expressive writing platform.
48696054|NCT05988138|BEHAVIORAL|Family Promoting Positive Emotions|An 8-week dyadic intervention using cognitive and behavioral skills to up-regulate positive emotions in children and mothers
48696055|NCT05988138|BEHAVIORAL|Psychoeducation|An 8-week comparison condition that offers education in mental health, depression prevention, and accessing mental health resources
48696056|NCT06125236|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
48009328|NCT01018420|DRUG|Moxifloxacin|400 mg capsule at the 6 hour point
48514668|NCT00425373|DRUG|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
48166935|NCT04561583|DEVICE|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
48166936|NCT01650727|DRUG|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m\^2 up to a maximum dose of 14 mg/m\^2.
48166937|NCT01650727|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
48166938|NCT05139498|PROCEDURE|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
48166939|NCT05139498|PROCEDURE|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
48166940|NCT02879539|DEVICE|MP3000 sound coding strategy or ACE strategy with lower stimulation|
48514669|NCT00425373|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
48514670|NCT00425373|DRUG|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
48696057|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
48696058|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
48166941|NCT01165502|DRUG|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
48166942|NCT01165502|DRUG|Placebo|Placebo for compound CM3.1-AC100 s.c.
48166943|NCT01916642|DRUG|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
48166944|NCT01916642|DRUG|Lidocaine 1.5mg/kg|same as other
48166945|NCT01916642|DRUG|Lidocaine 2mg/kg|same as other
48166946|NCT01916642|DRUG|Lidocaine 2.5mg/kg|same as other
48166947|NCT03750305|OTHER|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
48166948|NCT03750305|OTHER|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, \& van Gent, 2008).
48514671|NCT00425373|DRUG|Placebo|4 tablet and 2 capsule placebos taken once daily
48514672|NCT00461253|DEVICE|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
48514673|NCT00461253|DEVICE|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
48696059|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
48514674|NCT03833778|OTHER|intervention group|The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
48009329|NCT04915781|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
48009330|NCT02041130|DEVICE|Renal Denervation|
48009331|NCT05419102|PROCEDURE|peri-implantitis surgery with enamel matrix derivative|surgical procedures around dental implants with peri-implantits to remove infectious material and apply enamel matrix derivative to the implant.
48009332|NCT00628290|DRUG|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
48009333|NCT00628290|DRUG|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
48009334|NCT00231608|DRUG|topiramate|
48009335|NCT05136729|BEHAVIORAL|Self-Natural Posture Exercise training|SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
48009336|NCT03906669|DRUG|Letrozole|PO daily for 14 days
48514675|NCT02184767|DRUG|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
48514676|NCT02719275|BEHAVIORAL|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
48514677|NCT03566615|DEVICE|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
48514678|NCT03566615|DEVICE|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
48514679|NCT03566615|OTHER|water|using water instead of traditional air insufflation to help insertion
48696060|NCT03737448|DRUG|Trimetazidine|Subjects with receive up to 60 mg daily
48166949|NCT03719118|GENETIC|genotyping for three genes (TPMT, NUDT15 and FTO)|Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines
48696061|NCT03654040|BIOLOGICAL|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
48696062|NCT03654040|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
48166950|NCT03719118|OTHER|non-genotyping|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
48166951|NCT06413277|DEVICE|Saluda Evoke Smart SCS System|Surgical implantation of the Saluda Evoke Smart SCS System targeting the conus medullaris for stimulation
48166952|NCT03705533|DRUG|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
48166953|NCT03705533|DRUG|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
48696063|NCT03654040|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
48166954|NCT02357719|DEVICE|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
48166955|NCT00082511|DRUG|Prasterone (GL701)|"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
48166956|NCT04531371|DRUG|Dexmedetomidine injection|post surgical agitation prophylaxis
48166957|NCT06536374|DRUG|Trimethoprim Tablets|Trimethoprim 150mg is administered once daily for 3 months
48166958|NCT05195450|DRUG|Tenofovir alafenamide fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
48696064|NCT03654040|DRUG|mesna|"Mesna is administered:~* Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~* In conjunction with the cyclophosphamide, per institutional practice with CTX."
48696065|NCT03654040|DRUG|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
48696066|NCT04293224|OTHER|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
48696067|NCT04293224|OTHER|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
48009337|NCT03906669|DRUG|Letrozole and Prometrium|PO daily for 14 days
48009338|NCT03906669|DRUG|Tamoxifen and Prometrium|PO daily for 14 days
48009339|NCT04586803|DRUG|SHR4640|Subjects were randomly divided into the group A, B, C, D, E and F. On D1, D8 and D15, six groups of subjects were respectively given A version or C version or D version of SHR4640 tablet.
48009340|NCT04456816|DRUG|100 mg AP1189|100 mg AP1189 tablet
48009341|NCT04456816|DRUG|Placebo|Matching placebo tablet
48166959|NCT02927899|OTHER|Survey Administration|Ancillary studies
48166960|NCT02927899|DIETARY_SUPPLEMENT|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
48166961|NCT02014415|PROCEDURE|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
48166962|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
48369977|NCT00325351|DRUG|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
48369978|NCT02185729|DRUG|Intralipid|Infusion of Intralipid (soybean-derived fat)
48166963|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
48514680|NCT01973595|DIETARY_SUPPLEMENT|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
48514681|NCT01973595|OTHER|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
48514682|NCT03623347|OTHER|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
48514683|NCT03364946|OTHER|No intervention|No intervention, observational study
48166964|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
48166965|NCT05000411|DRUG|Compound Danshen Dropping Pills (CDDP)|The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
48514684|NCT00191126|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
48514685|NCT00191126|DRUG|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
48514686|NCT00191126|PROCEDURE|surgery|surgery
48514687|NCT02595801|OTHER|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
48696068|NCT04293224|OTHER|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
48166966|NCT05000411|DRUG|Placebo|The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
48166967|NCT02056600|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
48696069|NCT05269771|DRUG|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
48514688|NCT04060446|DEVICE|Medical Device|Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
48696070|NCT06329752|PROCEDURE|Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine)|Patients will be scanned with the ultrasound machine to determine the technical feasibility of sciatic nerve blocks. If feasible, one of the following techniques will be performed a) popliteal sciatic nerve block, with either lateral or posterior approach; b) CAPS (crosswise approach to popliteal sciatic) block, with either lateral to medial or anterolateral to posteromedial approach; c) subgluteal sciatic nerve block; d) transgluteal sciatic nerve block. In all cases, 20 mL of 2% Lidocaine will be used.
48696071|NCT05872386|BEHAVIORAL|Buprenorphine uptake/retention via Telehealth|Bupe by the Book (BBB) randomly assigns unstably housed library patrons with opioid use disorder to a telehealth to receive buprenorphine (aka, Suboxone) treatment from Father Joe's Villages Health Center.
48696072|NCT05872386|BEHAVIORAL|Control group|unstably housed library patrons with opioid disorder are assigned randomly to a treatment as usual control group (in-person at the clinic)
48696073|NCT06279598|BEHAVIORAL|Prolonged Exposure therapy|This concerns a form of psychotherapy for PTSD.
48514689|NCT04060446|OTHER|Questionnaire Administration|Ancillary studies
48514690|NCT04060446|BEHAVIORAL|Tobacco Smoking|Smoke cigarettes
48696074|NCT06279598|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|This concerns a form of psychotherapy for PTSD.
48696075|NCT06279598|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|This concerns a form of psychotherapy for PTSD.
48696076|NCT06219967|DRUG|Activated Charcoal|Activated charcoal alone
48696077|NCT06219967|DRUG|Activated Charcoal|Activated charcoal mixed with cola
48696078|NCT05273255|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
48696079|NCT04470804|DRUG|Sirolimus|Sirolimus treats in experimental group
48696080|NCT04470804|DRUG|Cyclosporine A|Cyclosporine A uses for active comparator group.
48696081|NCT00036855|BIOLOGICAL|rituximab|Given IV
48696082|NCT00036855|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
48166968|NCT02056600|DRUG|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
48166969|NCT02057302|DRUG|Xuezhikang capsule|
48514691|NCT06312566|DRUG|brivaracetam (BRV) tablet|Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.
48514692|NCT06312566|DRUG|brivaracetam (BRV) dry syrup|Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.
48514693|NCT01619566|DRUG|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
48514694|NCT03852732|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
48696083|NCT00036855|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
48696084|NCT00036855|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
48696085|NCT00036855|BIOLOGICAL|filgrastim|Given subcutaneously
48166970|NCT03675308|BIOLOGICAL|Placebo|Placebo for risankizumab administered by subcutaneous injection
48514695|NCT04941326|OTHER|Diaphragmatic stimulation treatment with PNF techniques|Thumbs and palms are placed along the cartilage edges of the lower ribs. At the end of the expiration, pressure and stretching are given as far into the chest and upwards as possible and a deep inspiration is requested immediately after the pressure. Both sides can be stimulated by repeated contraction technique. Hand holding positions may differ according to the patient's preference. If the patient's physical condition is not suitable, the application can be done with the thumbs, the thumb of the left hand for the right rib, and the thumb of the right hand for the left rib in the same lying position. The patient will be asked to do the application 2 times in a day with 10 repetitions for 4 weeks.
48166971|NCT03675308|BIOLOGICAL|Risankizumab|Risankizumab administered by subcutaneous injection
48166972|NCT00231517|DRUG|topical opiod|
48166973|NCT00231517|DRUG|morphine sulphate in intrasite gel|
48166974|NCT04362176|BIOLOGICAL|pathogen reduced SARS-CoV-2 convalescent plasma|Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
48166975|NCT04362176|BIOLOGICAL|Placebo|Lactated Ringer's solution with multivitamins
48166976|NCT00525018|DEVICE|contact heat evoked potential stimulator|
48166977|NCT02671864|OTHER|1: incretin-based therapy|
48166978|NCT02671864|OTHER|2: other antidiabetic|
48166979|NCT04675762|DRUG|Fingolimod|Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
48166980|NCT04675762|OTHER|Placebo|Patients randomized to fingolimod will also receive placebo once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
48166981|NCT01394783|DEVICE|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
48166982|NCT01394783|DEVICE|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
48166983|NCT00392886|DRUG|carboplatin|Given IV
48166984|NCT00392886|DRUG|cisplatin|Given IV
48166985|NCT00392886|DRUG|cyclophosphamide|Given IV
48166986|NCT00392886|DRUG|etoposide|Given IV and orally
48166987|NCT00392886|DRUG|methotrexate|Given IV
48166988|NCT00392886|DRUG|temozolomide|Given orally
48166989|NCT00392886|DRUG|thiotepa|Given IV
48696086|NCT00036855|OTHER|laboratory biomarker analysis|Correlative studies
48696087|NCT03890354|PROCEDURE|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
48696088|NCT04955223|DRUG|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
48696089|NCT05276674|DEVICE|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
48166990|NCT00392886|DRUG|vincristine sulfate|Given IV
48166991|NCT00392886|PROCEDURE|autologous bone marrow transplantation|Given on day 0
48166992|NCT00392886|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
48166993|NCT00392886|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
48166994|NCT00392886|RADIATION|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
48166995|NCT03962478|DEVICE|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
48166996|NCT03962478|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
48166997|NCT02476708|DIETARY_SUPPLEMENT|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
48166998|NCT02476708|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule
48166999|NCT00131183|DRUG|Nebido|
48167000|NCT05171361|PROCEDURE|Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique|To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
48167001|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns \~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
48167002|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
48167003|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
48167004|NCT05131789|PROCEDURE|dementia case management information system|The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
48167005|NCT03436030|OTHER|Simple breathing manuevers during brief echocardiographic imaging|Valsalva, Muller, light mask CPAP, leg raising, hand grip.
48369979|NCT02185729|DRUG|ClinOleic|Infusion of ClinOleic (olive oil-based)
48696090|NCT04776720|BEHAVIORAL|Yoga Practice Program|3 month group yoga classes
48696091|NCT04776720|BEHAVIORAL|Physical Conditioning Program|3 month group physical conditioning classes
48696092|NCT01837446|DRUG|2% morphine solution|
48696093|NCT01837446|DRUG|Magnesium aluminum hydroxide|
48696094|NCT01837446|DRUG|2% viscous lidocaine|
48696095|NCT01837446|DRUG|Diphenhydramine|
48696096|NCT05584163|DEVICE|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
48696097|NCT02800694|DRUG|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
48696098|NCT05634694|OTHER|No interventions.|No interventions.
48696099|NCT05798936|DRUG|Polidocanol|Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
48696100|NCT05798936|DRUG|Alcohol|Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
48696101|NCT04880746|DRUG|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
48696102|NCT04880746|DRUG|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
48696103|NCT05707442|PROCEDURE|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
48696104|NCT05707442|DRUG|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
48696105|NCT05707442|BEHAVIORAL|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
48369980|NCT02185729|DRUG|Dextrose|Infusion of dextrose (sugar) without fat
48696106|NCT02013557|BEHAVIORAL|Text-message reminder|
48167006|NCT02210611|PROCEDURE|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
48369981|NCT02185729|OTHER|Saline (control)|Infusion of 0.9% normal saline
48369982|NCT00958282|DRUG|lisdexamfetamine/Behavior Therapy|
48369983|NCT00958282|OTHER|placebo|
48369984|NCT05936801|OTHER|Anterior Chest Compression technique|"Baseline treatment given is percussion and vibration in side lying position. The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process. Inspiration is facilitated by the pressure on anterior chest, followed by a hold.~Just as the patient is instructed to cough, the therapist applies a quick force with both arms:~down and back on the upper chest and up and back on the lower chest or abdomen. 3 sessions in a wk would be given on alternate days Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs."
48514696|NCT04941326|OTHER|Costal mobilization|In the supine position, the individual will place both hands around the 10-12th ribs and alternately apply an oblique push from the right and left sides to the opposite side. The exercise will be taught to the patient as training, and he will be asked to apply it 2 times a day with 20 repetitions for 4 weeks.
48522837|NCT05430646|DEVICE|Covered metal ureteral stents|The CMUS is a fully covered, self-expanding, large caliber metal stent. The stent is made of super-elastic nickel-titanium alloy, which maintain lumen patency via providing long-term direct wall support.
48009342|NCT06104267|BEHAVIORAL|7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients|"The programme is based on the 7-Form of Medical Tai Chi Exercise Healing for Colon cancer patients that lasted 60 minutes three times a week for eight weeks and is led by a Tai Chi instructor with more than 5 years of teaching experience. Each session included a warm-up, movement instruction, breathing techniques, and relaxation. To ensure that each participant is proficient in Tai Chi, they will take at least 2 sessions of 60-minute Tai Chi training before the start of the intervention, until they are able to perform all Tai Chi movements correctly and successfully, and record a video to be used in software for practice at home. The enrolled patients, Tai Chi instructors and relevant staff of the subject group set up a WeChat group, and the enrolled patients, outside of the prescribed practice time each week, can practice at home or outdoors by themselves. They can send the video of the practice to the WeChat group."
48167007|NCT02210611|PROCEDURE|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
48167008|NCT01157377|DRUG|AGN-214868|AGN-214868 injected into the bladder.
48167009|NCT01157377|DRUG|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
48167010|NCT01319825|DRUG|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
48167011|NCT03092245|DRUG|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
48167012|NCT03092245|DRUG|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
48167013|NCT03433209|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
48167014|NCT03433209|DEVICE|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
48167015|NCT04201717|PROCEDURE|laparoscopic assisted left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. The patients in the control group underwent with the traditional laparoscopic assisted technology. The free colon was taken out through a small incision in the middle of the abdomen or the outer edge of the left rectus abdominis. The mesentery was trimmed, the specimens were removed, and the anastomosis was completed. After the anastomosis, the whole surgical area was flushed and drainage tubes were left.
48167016|NCT04201717|PROCEDURE|total laparoscopic left colectomy|All patients underwent laparoscopic dissection according to the left hemicolon cancer resection standard. lymph nodes and blood vessels, are completely trimmed and resected in an en bloc fashion. In the experimental group, the mesentery was endoscopically trimmed, the specimens were excised and the anastomosis was completed under the laparoscope. The specimens were taken out through trocar incision in the navel or in the right lower abdomen. After the anastomosis, all surgical area was flushed and drainage tubes were left.
48167017|NCT04255654|OTHER|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
48167018|NCT05675839|OTHER|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI_hzY\&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY\&t=284s)
48167019|NCT03945851|PROCEDURE|fMRI|All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
48167020|NCT04304313|DRUG|Sildenafil citrate tablets|0.1g/day for 14 days
48167021|NCT03293472|DRUG|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
48009343|NCT06101264|DEVICE|Virtual Reality Intervention|Participants will be given a virtual reality (VR) intervention following corrective scoliosis surgery for adolescent idiopathic scoliosis. The VR intervention will utilize a commercial device manufactured by Oculus. The intervention will utilize a software that simulates a low-physical load environment for the user. Starting on postoperative day 1, the participant will receive a 20-minute VR intervention 30 minutes prior to each physical therapy session. There will be two physical therapy sessions daily. Outcome measures will be assessed before and after every VR intervention and after the physical therapy session. The VR interventions will continue for each postoperative day until the participant is discharged from the hospital.
48009344|NCT04272398|OTHER|dynamic elastomeric fabric orthoses|Wore dynamic elastomeric fabric orthoses with a focus on the lower body and pelvis in addition to the physiotherapy and rehabilitation sessions. The frequency of the use of the orthosis was planned to extend through the week and they had the orthosis during their active hours during the day about 8 hours a day.
48167022|NCT03293472|DRUG|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
48167023|NCT03047902|OTHER|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
48167024|NCT03047902|OTHER|Group 2- Parents will not be present for the Questionnaire|
48369985|NCT05936801|OTHER|Abdominal Thrust Technique|Baseline treatment given is percussion and vibration in side lying position. It Can be used in both the supine and side lying positions. With the patient in the supine position, the therapist places the heel of one hand inferior to the patient's xiphoid process and below the patient's lower ribs.
48369986|NCT01189396|DRUG|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
48369987|NCT01189396|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
48369988|NCT01189396|DRUG|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
48696107|NCT02882061|PROCEDURE|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
48009345|NCT02224365|DIETARY_SUPPLEMENT|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
48009346|NCT02224365|DIETARY_SUPPLEMENT|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
48369989|NCT04009122|DIETARY_SUPPLEMENT|IGEN0206|Group A
48696108|NCT02973204|DRUG|Sorafenib|
48696109|NCT02973204|PROCEDURE|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
48369990|NCT04009122|OTHER|Placebo|Group B
48369991|NCT03242811|DIAGNOSTIC_TEST|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
48369992|NCT03391258|PROCEDURE|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
48369993|NCT03427320|DRUG|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of \[131\]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
48369994|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
48009347|NCT04814069|DRUG|Tislelizumab|Tislelizumab 200mg q3w
48167025|NCT00817336|DRUG|D Serine|60 mg/kg/day
48369995|NCT01347827|DEVICE|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
48009348|NCT03497559|OTHER|Music|Classical music
48009349|NCT06316466|OTHER|Lp(a)|The cut-off value for Lp (a) was determined based on one-year survival rates after diagnosis. Patients were then categorized into the high and low Lp (a) groups.
48167026|NCT00817336|DRUG|Placebo|oral
48167027|NCT00702273|DRUG|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
48696110|NCT02973204|DRUG|Everolimus|
48696111|NCT02973204|DRUG|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
48696112|NCT04075890|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
48696113|NCT05921266|DIETARY_SUPPLEMENT|Urolithin A|Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).
48696114|NCT05921266|OTHER|Placebo|Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).
48696115|NCT02518087|DEVICE|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
48696116|NCT05055518|DRUG|APL-102 Capsules|"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."
48696117|NCT02494518|BEHAVIORAL|Forced Exercise & Upper Extremity Repetitive Task Practice|
48696118|NCT02494518|BEHAVIORAL|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
48696119|NCT02494518|BEHAVIORAL|Stroke Education & Upper Extremity Repetitive Task Practice|
48696120|NCT00744380|DRUG|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
48696121|NCT00744380|DRUG|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
48696122|NCT02825706|OTHER|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
48696123|NCT03220464|RADIATION|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
48696124|NCT03220464|RADIATION|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
48696125|NCT03220464|DIAGNOSTIC_TEST|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
48696126|NCT02910752|DRUG|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
48696127|NCT03181217|OTHER|water 0|300 ml tap water at 0 ºC
48369996|NCT00863265|DRUG|Ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
48696128|NCT03181217|OTHER|water 22|300 ml tap water at 22 ºC
48696129|NCT03181217|OTHER|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
48696130|NCT03181217|OTHER|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
48696131|NCT05128474|OTHER|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
48696132|NCT05128474|OTHER|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
48009350|NCT06080152|DEVICE|Mobility Tool|An A-Linker device will be given to 12 patients 3 months before their total knee arthroplasty
48009351|NCT04495088|DRUG|mFOLFOX (neoadjuvant)|neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
48009352|NCT04495088|DRUG|XELOX (neoadjuvant)|neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
48009353|NCT04495088|DRUG|mFOLFOX (adjuvant)|adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
48009354|NCT04495088|DRUG|XELOX (adjuvant)|adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
48009355|NCT04495088|DRUG|Capecitabine (adjuvant)|adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
48009356|NCT04495088|DRUG|"infusional 5-FU/FA AIO regimen (adjuvant)"|adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
48009357|NCT04495088|DRUG|"infusional 5-FU/FA de Gramont (adjuvant)"|adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
48009358|NCT00403273|DRUG|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
48009359|NCT00403273|DRUG|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
48009360|NCT03268967|BEHAVIORAL|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
48009361|NCT05869929|DIETARY_SUPPLEMENT|Vegetables|4-5 servings of vegetables daily, per USDA guidelines.
48009362|NCT05575648|OTHER|10 meter walk test|To assess the dual task performance of children 10 meter walk test will be used.
48009363|NCT04535128|OTHER|No intervention|No intervention
48009364|NCT05162872|DRUG|Niraparib，Sintilimab|Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
48009365|NCT02674022|DIETARY_SUPPLEMENT|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
48167028|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
48167029|NCT00702273|DRUG|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
48009366|NCT05952648|PROCEDURE|Lower tract respiratory samples|Within 1 hour from HAP or VAP suspicion, quantitative tracheal aspirate or bronchoalveolar lavage will be performed to confirm the diagnosis. Clinicians will be encouraged to perform BAL whenever possible
48009367|NCT05952648|DIAGNOSTIC_TEST|Multiplex PCR assay (Film-array Pneumonia Panel Plus)|The lower tract respiratory samples will be analyzed with Multiplex PCR assay (Film-array Pneumonia Plus).
48009368|NCT05952648|DIAGNOSTIC_TEST|Lower respiratory tract standard culture|The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
48009369|NCT05952648|DIAGNOSTIC_TEST|Blood sample standard culture|When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
48167030|NCT00702273|DRUG|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
48167031|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
48167032|NCT00702273|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
48167033|NCT00702273|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
48369997|NCT00863265|OTHER|Phytosterols + ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
48369998|NCT00863265|OTHER|Placebo|
48369999|NCT00044811|DRUG|Fexofenadine|
48514697|NCT04941326|OTHER|Breathing exercises|It is done to increase the diaphragm activity of the individual and to suppress chest breathing. While lying in the supine position, the legs are placed in a hooked position, with one hand on the abdomen and the other on the chest, and the deep breath that is taken from the nose in 2 seconds is asked to exhale through the mouth in 4 seconds, while revealing as little movement in the chest as possible, the main movement is requested to be around the abdomen. The application will be given to the patient as a home program and he will be asked to do it 2 times a day with 5 repetitions for 4 weeks.
48514698|NCT04941326|OTHER|Spinal mobilization|T12 vertebrae will be found by following the 12th rib in the prone position of the individual and spinous of L1 and L2 vertebrae will be determined with this reference. Then, small amplitude rotational movements in the vertebrae will be revealed by pushing in the anterior direction over the transverse processes. This application will be applied once a week for an average of 10 minutes for 4 weeks.
48370000|NCT04651153|DRUG|UCB7853|Subjects will receive UCB7853 at pre-specified time-points.
48009370|NCT04945434|DEVICE|S53P4 bioactive glass (BonAlive)|Surgical implantation of S53P4 in a bone defect created during debridement for chronic osteomyelitis.
48370001|NCT04651153|OTHER|Placebo|Subjects will receive Placebo at pre-specified time-points.
48370002|NCT05487807|DRUG|Nicotine patch|Will be receiving nicotine therapy
48009371|NCT05286190|DRUG|Bupivacaine 0.25% Injectable Solution|Bupivacaine 0.25% Injectable Solution
48009372|NCT01670929|DRUG|Progesterone|
48009373|NCT01670929|OTHER|Placebo|
48009374|NCT05845788|PROCEDURE|Peripheral nerve block|Ultrasound guided peripheral nerve block
48009375|NCT04869735|OTHER|Data collection: DTPolio vaccine delivery|"with information about booster vaccination group: Sending of information concerning booster vaccination against DTPolio at 25 years using letters, emails and SMS without information about booster vaccination group: no intervention"
48009376|NCT01769885|DRUG|tivozanib|Given PO
48696133|NCT01813058|DRUG|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
48696134|NCT01813058|DRUG|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described."
48696135|NCT01263418|DRUG|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
48696136|NCT02426567|OTHER|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
48370003|NCT05487807|BEHAVIORAL|text messaging|Will be enrolled in an texting app
48370004|NCT01892046|DRUG|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
48696137|NCT02426567|OTHER|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
48696138|NCT01323088|OTHER|Control|Standard care control (no exercise)
48696139|NCT01323088|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
48696140|NCT01323088|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
48009377|NCT01769885|PROCEDURE|therapeutic conventional surgery|Undergo nephrectomy
48514699|NCT04941326|OTHER|Sham mobilization|Sham pressures will be applied to the lumbar region of the patient, away from the vertebrae. This application will be applied once a week for an average of 10 minutes for 4 weeks.
48370005|NCT03794310|DRUG|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
48370006|NCT03794310|DRUG|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
48696141|NCT06263907|PROCEDURE|Stellate gangalion block|The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
48696142|NCT01555853|DRUG|Abraxane|
48696143|NCT02926027|DRUG|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
48370007|NCT03794310|DRUG|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
48696144|NCT02926027|DRUG|placebo|placebo
48696145|NCT05592626|DRUG|STAR0602|solution, intravenous infusion
48009378|NCT04181346|DRUG|Pregabalin|antipsychotic
48009379|NCT04181346|DRUG|Placebo|Placebo
48009380|NCT02872922|OTHER|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
48009381|NCT04518891|BEHAVIORAL|Cognitive Functional Therapy (CFT)|Cognitive functional therapy (CFT) is an intervention that deals with potentially modifiable multidimensional aspects of pain (e.g. provocative cognitive, movement and lifestyle behaviours). Treatment with CFT will be individualised, the physiotherapist will listen to the complete patient pain history and the intervention will be focused on individual needs. A detailed examination will be crucial in identifying the modifiable multidimensional mediators of pain and disability (provocative cognitive, pain, movement and lifestyle behaviors) of each participant.
48009382|NCT04518891|DEVICE|Sham intervention|Due to the impossibility of applying placebo exercise, the control intervention in this study will be based on successful reports of placebo intervention in patients with chronic low back pain in the literature (Placebo photobiomodulation + neutral talking control)
48370008|NCT06410755|DEVICE|Monitoring system using a insole-type gait analyzer|The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
48370009|NCT01111058|DRUG|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
48370010|NCT01111058|OTHER|Placebo|
48370011|NCT05119751|DRUG|tree 12 SQ-Bet|DAILY DOSE OF AIT TABLET
48370012|NCT05119751|DRUG|GRASS 2800 BAU|DAILY DOSE OF AIT TABLET
48370013|NCT05119751|DRUG|RAGWEED 12 AMB A 1-U|DAILY DOSE OF AIT TABLET
48370014|NCT05119751|DRUG|HDM 12 SQ-HDM|DAILY DOSE OF AIT TABLET
48514700|NCT00195455|DRUG|Trimegestone|
48514701|NCT00195455|DRUG|17b Estradiol|
48514702|NCT04335539|DRUG|Cefiderocol|Administered intravenously over 3 hours
48696146|NCT04644237|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
48696147|NCT00001106|DRUG|Zidovudine|
48696148|NCT06428916|PROCEDURE|tucking position during endotracheal suctioning|, the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
48696149|NCT04082845|OTHER|Education|Web-based patient education
48696150|NCT06557057|OTHER|Non-Interventional Study|Non-Interventional Study
48696151|NCT00479817|DRUG|AMG 386|10mg/kg
48696152|NCT00479817|DRUG|AMG 386|3 mg/kg
48696153|NCT00479817|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
48696154|NCT00479817|DRUG|AMG 386 Placebo|AMG 386 Placebo
48167034|NCT00702273|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
48167035|NCT03994341|DIAGNOSTIC_TEST|A FLIR Thermovision a320M thermal IR camera|"1. Clothing removed if necessary~2. ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~3. Axillary temperature prior to starting the thermographic imaging.~4. Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~5. After surface cooling, thermal imaging will be recorded for \~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~6. After \~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~7. Axillary temperature to ensure temperature stability, any clothes will be put back on."
48370015|NCT05375058|OTHER|Observational Study|Observational Study; the study did not involve any interventions
48370016|NCT00520273|DEVICE|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
48370017|NCT04115488|BIOLOGICAL|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
48696155|NCT06509997|DRUG|MRG003 combined with Dalpicicilip|MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
48696156|NCT01924273|DRUG|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
48696157|NCT06188286|OTHER|Transcutaneous electrical acupoint stimulation|The 4 patches of the transcutaneous acupoint electrical stimulator were pasted on two pairs of acupuncture points, the output frequency was adjusted to 2Hz, the intensity was up to 50ma, the single intervention time was 30 minutes, and another group of acupuncture points was replaced after completion, and the rest of the operations were the same as above, with a total intervention time of 1 hour.
48696158|NCT06188286|OTHER|sham Transcutaneous electrical acupoint stimulation|The patch is fixed on the acupuncture point to turn on the instrument, but there is no current output
48696159|NCT05998850|BEHAVIORAL|Community Health Worker Support with Resources|6-months of hands-on tailored support spanning the domains of social support, advocacy and navigation to achieve their action plans.
48696160|NCT04791215|OTHER|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
48167036|NCT00000441|DRUG|lorazepam (Ativan)|
48167037|NCT00000441|DRUG|carbamazepine (Tegretol)|
48370018|NCT01365026|BEHAVIORAL|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
48370019|NCT02419443|DRUG|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
48370020|NCT02419443|DRUG|Placebo|Control group
48370021|NCT04431856|BEHAVIORAL|Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|UP-COVID is a group therapy session with each session lasting approximately 60-90 minutes. The sessions will focus on cognitive and behavioral strategies for managing their own distress, anxiety and sadness related to COVID-19, as well as, strategies related to parenting in the midst of the crisis.
48370022|NCT04431856|BEHAVIORAL|SHG|Brochure that details techniques for coping with stress.
48370023|NCT06055868|OTHER|Group Meeting (Focus Group)|Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.
48370024|NCT06055868|OTHER|Questionnaires|Given electronically or via phone by study team staff
48370025|NCT02491333|OTHER|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
48514703|NCT04335539|DRUG|Standard of Care|Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
48370026|NCT02491333|OTHER|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
48370027|NCT02491333|DRUG|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
48370028|NCT02491333|DRUG|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
48370029|NCT00077727|DRUG|Extended-release galantamine hydrobromide|
48514704|NCT02677350|DRUG|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
48514705|NCT03650530|OTHER|The Family Talk Intervention|The family meets two interventionists at six time points.
48514706|NCT03355612|DRUG|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
48514707|NCT03355612|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
48514708|NCT02211443|BIOLOGICAL|Recombinant full human Anti-EGFR Monoclonal Antibody|
48696161|NCT01244594|OTHER|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
48009383|NCT04176003|OTHER|Qualitative interview|Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies
48009384|NCT04176003|OTHER|Member checking|Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
48009385|NCT03613896|PROCEDURE|conventional dentures|conventional dentures
48009386|NCT03613896|PROCEDURE|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
48009387|NCT01387607|DRUG|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
48370034|NCT04856072|DEVICE|Deep Brain Stimulation|Personalized Deep Brain Stimulation of Fornix
48370035|NCT05829434|DRUG|Magrolimab|Patients will receive magrolimab on day 1; 4: IV 1 mg/kg; day 8: IV 15 mg/kg; day 11, 15 and 22: IV 30 mg/kg (plus 30 mg/kg for 5 weeks weekly and then q2w until the end of consolidation)
48370036|NCT05829434|DRUG|7+3|"Patients will receive during Induction cycle 1: cytarabine at 100 mg/m² on study days 1-7 as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on study days 3, 4, 5~* optional during Induction cycle 2: cytarabine at 100 mg/m² on days 1-7 of the second induction cycle (i.e. study days 29-35) as a continuous infusion over 22-24 hours and daunorubicin at 60 mg/m² on days 3, 4, 5 of the second induction cycle (i.e. study days 31, 32, 33)~* optional during Consolidation cycle: cytarabine at 1 g/m² administered on days 1, 3, 5 of each consolidation cycle as an infusion for 2 hours every 12 hours (for patients \< 60 years up to 3 CONS cycles and for patients ≥ 60 years up to 2 CONS cycles)"
48370037|NCT05829434|DRUG|CPX-351|"Patients will receive during Induction cycle 1: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 1, 3, 5~* optional during Induction cycle 2: CPX-351 with daunorubicin 44 mg/m² and cytarabine 100 mg/m² on days 29 + 30~* optional during Consolidation cycle: CPX-351 with daunorubicin 29 mg/m² and cytarabine 65 mg/m² on days 1, 3"
48370038|NCT02862366|OTHER|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
48370039|NCT02404792|OTHER|High-intensity cardiovascular and resistance exercise|
48370040|NCT02404792|OTHER|Moderate-intensity cardiovascular and resistance exercise|
48370041|NCT04212026|DRUG|Nivolumab|The patients start treatment with nivolumab on day 1 after IRE and will be given nivolumab at a flat dose of 240 mg every 2 weeks (q2wk) for 5 cycles until Week 8.
48370042|NCT02681692|DEVICE|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
48370043|NCT04400773|OTHER|Plyometric exercises|Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.
48370044|NCT04400773|OTHER|Strength training exercises|Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
48370045|NCT00475839|DEVICE|Tension-free Vaginal Tape|
48370046|NCT00475839|DEVICE|Monarc sub-fascial hammock|
48696162|NCT05536557|OTHER|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
48696163|NCT05536557|OTHER|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
48696164|NCT04639232|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
48696165|NCT04639232|DIETARY_SUPPLEMENT|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
48009388|NCT01387607|DRUG|placebo|Placebo, twice daily
48009389|NCT04213898|DRUG|SHR-1210+Albumin-bound paclitaxel + epirubicin|Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
48009390|NCT01026870|DRUG|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
48009391|NCT01026870|DRUG|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
48009392|NCT05769894|OTHER|No intervention given|No intervention is planned. Blood samples will be taken at different stages.
48009393|NCT01527552|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
48696166|NCT04639232|DIETARY_SUPPLEMENT|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
48696167|NCT04104191|DEVICE|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
48696168|NCT06026540|BEHAVIORAL|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
48696169|NCT05967741|OTHER|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
48696170|NCT05967741|OTHER|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
48696171|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
48696172|NCT03415594|DRUG|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
48696173|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
48696174|NCT02195999|OTHER|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
48696175|NCT02195999|OTHER|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
48696176|NCT02195999|OTHER|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
48696177|NCT02195999|OTHER|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
48370047|NCT01533974|OTHER|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
48696178|NCT00046761|DRUG|ONO-2506|
48370048|NCT01533974|OTHER|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
48009394|NCT00832351|PROCEDURE|Mobilisation|Mobilisation
48370049|NCT00486720|DRUG|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
48370050|NCT00486720|DRUG|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
48370051|NCT02935816|RADIATION|Whole body MRI|We have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. We hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men
48696179|NCT00822419|DRUG|lidocaine|lidocaine cream 5%
48696180|NCT00822419|DRUG|ketamine|ketamine 5%
48696181|NCT00822419|DRUG|non-drug cream|will be put on the skin
48370052|NCT02356770|DEVICE|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
48696182|NCT02446678|DEVICE|PillCam ESO2|Capsule endoscopy
48696183|NCT05901675|OTHER|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
48009395|NCT02033733|DRUG|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
48009396|NCT02033733|DRUG|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
48167038|NCT04047225|DEVICE|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
48167039|NCT03487653|BIOLOGICAL|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
48370053|NCT02356770|PROCEDURE|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
48370054|NCT01756846|OTHER|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
48370055|NCT01756846|OTHER|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
48370056|NCT02244827|DRUG|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
48370057|NCT02004457|BEHAVIORAL|ABBT|
48370058|NCT02004457|OTHER|TAU|
48370059|NCT03601429|DIETARY_SUPPLEMENT|Lactogyn|capsules
48370060|NCT03601429|DIETARY_SUPPLEMENT|Placebo|capsules
48370061|NCT04780230|DEVICE|tDCS active|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
48370062|NCT04780230|DEVICE|tDCS sham|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the orofacial area of the primary motor cortex (SM1) during speech therapy.
48370063|NCT05603975|DRUG|Esketamine 0.1mg/kg intravenous injection|"The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change."
48370064|NCT05603975|DRUG|Normal saline|"The Normal saline was administered intravenously at 0.1ml per kilogram of body weight 1min before the dressing change."
48696184|NCT05901675|OTHER|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
48696185|NCT01364454|OTHER|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
48696186|NCT00616018|DRUG|acetaminophen|4 g/day for 10 consecutive days
48696187|NCT02174029|PROCEDURE|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
48696188|NCT02174029|PROCEDURE|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
48696189|NCT02174029|PROCEDURE|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
48696190|NCT05790798|OTHER|occupational therapy-based instrumental daily living activities intervention|Occupational therapy-based instrumental activities of daily living intervention were applied to 9 people with disabilities in the intervention group, with sessions consisting of 45 minutes twice a week (totally 8 weeks/16 sessions). While the activity intervention program was being created for the intervention group, the problem areas in the ADL and IADL determined by the evaluations made before the intervention were identified. Ten occupation kits including 2 ADLs (dressing and feeding nutrition), and 8 IADLs (laundry, meal preparation, light cleaning, paperwork, use of technology, lifting and carrying, fine motor and gross motor leisure groups) were used as interventions. Various materials (jar, shirt, spoon, teapot, play dough, stapler, plastic bag, sponge, etc.) were prepared to be used in each occupation kit and to simulate daily activities.
48696191|NCT05790798|OTHER|Quite recreation activity|For the control group, information about the scope, duration and requirements of the research was shared throughout the process. During this period, reading activities continued. The final evaluation of all participants was made at the end of the 8th week of the study and the study was completed.
48696192|NCT01369472|DRUG|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
48696193|NCT00408382|DRUG|atorvastatin, Lipitor|
48167040|NCT05947708|DEVICE|Dialysate Flow Rate|Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
48167041|NCT02156388|BIOLOGICAL|GW003|freeze-dried powder；single SC injection
48370065|NCT04259541|DIAGNOSTIC_TEST|Psychodiagnostic|Intensity and frequency of specific symptoms, signs of problems in mental health
48370066|NCT05707819|DRUG|Sintilimab (PD-1 Antibody)|Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
48696194|NCT00003191|DRUG|fenretinide|
48696195|NCT02710981|DRUG|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
48696196|NCT02710981|DRUG|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
48696197|NCT05486572|OTHER|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
48009397|NCT02191189|DRUG|Nevirapine suspension, into Enterion™ capsule|
48009398|NCT02191189|DRUG|Nevirapine suspension|
48167042|NCT00418418|PROCEDURE|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
48009399|NCT06467266|DIAGNOSTIC_TEST|Acute Haemodynamic Study|Multisite temporary pacing
48009400|NCT04325529|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
48167043|NCT00418418|PROCEDURE|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
48167044|NCT00418418|BIOLOGICAL|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
48167045|NCT00418418|BIOLOGICAL|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
48167046|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
48167047|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
48167048|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
48167049|NCT04344756|DRUG|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
48167050|NCT00092313|DRUG|MK0966, rofecoxib|
48167051|NCT00092313|DRUG|Comparator: oxycodone and acetaminophen|
48370067|NCT05544500|DIETARY_SUPPLEMENT|Functional Gum|Functional gum containing a proprietary composition of a herbal extract and vitamins
48370068|NCT05544500|DIETARY_SUPPLEMENT|Basic Chewing Gum|Sugar-free chewing gum
48370069|NCT05544500|DIETARY_SUPPLEMENT|Placebo|Sugar-free tablet
48370070|NCT01200758|DRUG|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
48370071|NCT01200758|DRUG|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
48370072|NCT01200758|DRUG|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
48370073|NCT01200758|DRUG|Doxorubicin|Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
48370074|NCT01200758|DRUG|Vincristine|Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
48370075|NCT01200758|DRUG|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
48370076|NCT05637086|DRUG|Phenytoin|Phenytoin remains a highly effective anti-epileptic drug, especially in generalized seizure management. Unfortunately, phenytoin efficacy on epileptic seizure is apparently reduced with its chronic use
48696198|NCT05486572|OTHER|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
48009401|NCT02961907|PROCEDURE|PEPCI|"Both parents will receive:~* consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~* endocrinologist consultation then dietitian follow-up if required~* actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
48009402|NCT03424538|OTHER|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
48009403|NCT03424538|OTHER|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
48370077|NCT05637086|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy
48370078|NCT05637086|DRUG|Celecoxib 200mg|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis
48696199|NCT05753033|DRUG|SR750 tablet|Ascending single and multiple doses of SR750 orally
48696200|NCT05753033|DRUG|Placebo|Ascending single and multiple doses of placebo orally
48696201|NCT06107816|BEHAVIORAL|Usual Care|Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions
48009404|NCT00148603|DRUG|montelukast|
48009405|NCT00140075|DRUG|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
48009406|NCT00140075|DRUG|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
48009407|NCT01333488|DEVICE|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
48370079|NCT02724189|DEVICE|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
48696202|NCT06107816|BEHAVIORAL|F&V Rx alone|Usual Care plus four F\&V prescriptions that are independent of DSME/S attendance
48696203|NCT06107816|BEHAVIORAL|F&V Rx plus DSME/S|Usual Care plus four F\&V prescriptions that are dependent on DSME/S attendance
48696204|NCT06645457|OTHER|stress ball|Patients squeeze the stress ball
48696205|NCT06645457|OTHER|4-7-8 breathing technique|breathing in quietly through the nose for 4 seconds. holding the breath for a count of 7 seconds. exhaling forcefully through the mouth for 8 seconds.
48696206|NCT04746924|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
48696207|NCT04746924|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
48370080|NCT02724189|OTHER|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
48370081|NCT02534428|OTHER|wool clothing|superfine merino wool ensembles for baby wear
48370082|NCT05025306|DRUG|ziziphus honey|ziziphus honey obtained form ziziphus spina-christi trees also called sidr tree
48696208|NCT04746924|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
48696209|NCT04746924|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
48696210|NCT05719350|OTHER|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
48696211|NCT02924246|BIOLOGICAL|cholera vaccination|Oral cholera vaccination on day 0 and day 14
48696212|NCT02924246|OTHER|raw milk|raw milk
48696213|NCT02924246|OTHER|pasteurized milk|pasteurized milk
48696214|NCT02924246|OTHER|UHT milk|UHT milk
48696215|NCT06311682|DRUG|Tralokinumab + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
48696216|NCT06311682|DRUG|Placebo + TCS|The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
48696217|NCT01551680|RADIATION|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
48696218|NCT02824770|BEHAVIORAL|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
48696219|NCT02824770|DRUG|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
48696220|NCT02824770|DRUG|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
48009408|NCT01333488|DRUG|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
48009409|NCT03612622|OTHER|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
48009410|NCT01900470|BEHAVIORAL|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
48009411|NCT05315271|DRUG|Bupivacaine-ketamine injection|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
48370083|NCT05425082|OTHER|Motor relearning program|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions
48370084|NCT05425082|OTHER|Neurodevelopmental therapy|Treatment session of one hour per day for five days a week, for four weeks for each participant until 20 sessions.
48370085|NCT03028506|OTHER|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
48370086|NCT06078059|BIOLOGICAL|Knee aspiration + UCB-MSCs|Knee aspiration and the application of cultered allogeneic umbilical cord blood-derived mesenchymal stromal stem cells (UCB-MSCs).
48370087|NCT06078059|OTHER|Knee aspiration|Knee aspiration
48370088|NCT05663749|DRUG|Metformin|1000mg for 8 weeks
48370089|NCT05663749|DRUG|Topiramate|50mg for 8 weeks
48370090|NCT06248762|OTHER|Adappt|An app to support parents of children with a NDD
48696221|NCT02824770|PROCEDURE|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
48696222|NCT01942161|DRUG|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
48167052|NCT05633849|DIETARY_SUPPLEMENT|SMP group|Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
48167053|NCT05633849|DIETARY_SUPPLEMENT|Placebo group|Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
48167054|NCT04659200|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
48167055|NCT05646589|BEHAVIORAL|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
48167056|NCT05646589|BEHAVIORAL|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
48167057|NCT03466229|DIETARY_SUPPLEMENT|Androferti|
48167058|NCT03466229|DIETARY_SUPPLEMENT|Placebo|
48167059|NCT03500263|DRUG|PTI-808|Active
48167060|NCT03500263|DRUG|Placebo|Placebo
48167061|NCT03500263|DRUG|PTI-801|Active
48167062|NCT03500263|DRUG|PTI-428|Active
48696223|NCT01942161|DRUG|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
48696224|NCT01942161|DRUG|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
48167063|NCT03500263|DRUG|Placebo|Placebo
48167064|NCT03187041|OTHER|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
48167065|NCT06079424|OTHER|high-precision carotid echo-tracking|evaluation of vascular aging parameters and baroreflex sensitivity
48167066|NCT05205252|DRUG|Tazemetostat|Orally, twice daily in continuous 28-day cycles.
48167067|NCT05205252|DRUG|Tafasitamab|Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.
48167068|NCT05205252|DRUG|Lenalidomide|Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.
48167069|NCT05205252|DRUG|Acalabrutinib|Orally, 100 mg, twice daily.
48167070|NCT05205252|DRUG|Daratumumab (Intravenously)|Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
48167071|NCT05205252|DRUG|Mosunetuzumab|Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.
48696225|NCT06255002|BIOLOGICAL|Fibrinogen concentration by the qLabs®FIB Monitoring system|A drop of blood (\~15 μL) is taken from the blood sample for the complete haemostasis assessment (prothrombin level, activated partial thromboplastin time, fibrinogen). This assessment is part of the usual management of severe postpartum haemorrhage. It is carried out urgently in the hospital's medical biology laboratory at the start of treatment (T1) and during or at the end of treatment of the haemorrhage (T2). This drop of blood will allow the measurement of the fibrinogen concentration by the qLabs®FIB Monitoring system for the study at these two times.
48696226|NCT03287024|DEVICE|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
48696227|NCT05457907|DEVICE|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
48696228|NCT06661967|DRUG|Lidocaine spray|Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
48696229|NCT04851119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48696230|NCT04851119|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
48696231|NCT04851119|DRUG|Tegavivint|Given IV
48696232|NCT04851119|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
48696233|NCT05570110|DRUG|Enoxolone|one capsule of active or placebo in the evening
48696234|NCT04550832|DRUG|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
48696235|NCT04550832|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
48696236|NCT03877315|DEVICE|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
48696237|NCT03877315|DEVICE|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
48696238|NCT06296199|OTHER|VR|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music."
48696239|NCT06296199|OTHER|Music only|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music."
48696240|NCT02358161|DRUG|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
48696241|NCT06205355|DEVICE|Analgesia/Nociception Index (ANI) monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
48696242|NCT06205355|DEVICE|Standard monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
48696243|NCT02713386|DRUG|Carboplatin|Given IV
48696244|NCT02713386|DRUG|Paclitaxel|Given IV
48696245|NCT02713386|DRUG|Ruxolitinib Phosphate|Given PO
48696246|NCT02713386|PROCEDURE|Therapeutic Conventional Surgery|Undergo TRS
48696247|NCT02543281|DEVICE|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
48696248|NCT02543281|DEVICE|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
48696249|NCT02480166|DRUG|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
48696250|NCT02480166|DRUG|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
48696251|NCT00483366|DRUG|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid"
48696252|NCT00483366|DRUG|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2"
48696253|NCT00483366|DRUG|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d"
48696254|NCT00483366|GENETIC|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
48696255|NCT00483366|GENETIC|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
48696256|NCT00483366|GENETIC|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
48696257|NCT03721484|DIAGNOSTIC_TEST|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
48696258|NCT00183781|BEHAVIORAL|FITT: Family Intervention - Telephone Tracking|
48696259|NCT02376725|PROCEDURE|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
48696260|NCT02376725|PROCEDURE|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
48696261|NCT03467893|DRUG|Antacids|number aof antacids treatment after PPI stop
48167072|NCT05205252|DRUG|Daratumumab (Subcutaneously)|Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
48167073|NCT05205252|DRUG|Hyaluronidase-Fihj|Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
48514709|NCT03709212|OTHER|interviews|20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
48514710|NCT04832022|OTHER|Biological samples|Serum and plasma samples. At baseline, 3, 6 and 12 months
48514711|NCT01919021|OTHER|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
48514712|NCT01919021|OTHER|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
48696262|NCT05972421|OTHER|High Intensity Proactive Outreach|phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
48167074|NCT05205252|DRUG|Pomalidomide|Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.
48167075|NCT05205252|DRUG|Dexamethasone 20mg|Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
48370091|NCT05129566|PROCEDURE|IOL Clareon AutonoMe|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
48370092|NCT05129566|PROCEDURE|IOL Hoya iSert 251|Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
48370093|NCT00714831|BEHAVIORAL|Physical activity intervention|3-months physical activity intervention
48370094|NCT00714831|BEHAVIORAL|Health educational program|Health education sessions and stretching sessions
48370095|NCT06380049|DEVICE|EMG Analysis Software|Surface electromyography devices are non-invasive tools that measure electrical activity produced by skeletal muscles through sensors placed on the skin.
48370096|NCT00989417|OTHER|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
48370097|NCT03006952|DRUG|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
48370098|NCT03006952|DRUG|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
48514713|NCT01919021|PROCEDURE|Assessment of Gastric motor and sensory function|
48514714|NCT02463357|DIETARY_SUPPLEMENT|Quercetin|
48514715|NCT02463357|DRUG|Nifedipine extended release|
48514716|NCT02463357|DRUG|Methazolamide|
48514717|NCT02463357|DRUG|Metformin|
48696263|NCT05972421|OTHER|Low Intensity Proactive Outreach|mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
48167076|NCT05304221|OTHER|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
48167077|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
48167078|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions during fast
48370099|NCT03633461|DRUG|OC-02 (simpinicline) nasal spray|OC-02 (simpinicline) nasal spray, 11.1 mg/ml
48370100|NCT03633461|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
48696264|NCT04676087|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
48696265|NCT04676087|BIOLOGICAL|Mogamulizumab|Given IV
48514718|NCT02463357|DRUG|Placebo|
48514719|NCT02463357|DRUG|Nitrite|
48514720|NCT00333151|DRUG|liraglutide|
48514721|NCT00333151|DRUG|rosiglitazone|
48514722|NCT00333151|DRUG|metformin|
48514723|NCT01669187|OTHER|Education brochure|
48514724|NCT01669187|OTHER|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
48514725|NCT00365092|PROCEDURE|Insertion of tympanostomy tubes|
48522838|NCT05430646|DEVICE|Tandem DJ stents|Tandem DJ stents represents for two stents side-by-side, which improves the urine flow by better withstanding the compressive tumoral forces and allowing urine to flow between the stents.
48522839|NCT01050530|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
48522840|NCT01050530|DRUG|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
48522841|NCT03727789|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IA
48522842|NCT03142737|OTHER|Red kidney bean intake|Each participant will consume 1/2 cup of cooked red kidney bean
48696266|NCT04676087|OTHER|Quality-of-Life Assessment|Ancillary studies
48696267|NCT01491789|DEVICE|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
48696268|NCT03679858|OTHER|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
48009412|NCT05315271|DRUG|Bupivacaine injection with intravenous ketamine infusion|20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
48522843|NCT03142737|OTHER|Eggs intake|Each participant will consume 2 cooked large eggs.
48009413|NCT00386256|DEVICE|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
48009414|NCT00386256|OTHER|Telephone counseling|
48009415|NCT03056131|DEVICE|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
48009416|NCT06126484|PROCEDURE|transcatheter cardiac intervention|Balloon atrial septostomy, PDA stent implantation, Pulmonary valvuloplasty, Aortic valvuloplasty, Balloon angioplasty of coarctation, PDA closure in preterm neonates
48167079|NCT02037750|BEHAVIORAL|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
48167080|NCT02455284|DEVICE|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
48370101|NCT04446273|DEVICE|Bi-Manu-Track|The PRI and DRI protocol provide robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist). The DRI group will start from the Bi-Manu-Track distal mode (i.e., wrist) and then the Bi-Manu-Track proximal mode (i.e., forearm).In every session of robotic training, the patient will practice bilateral passive range of motion exercise, in which affected upper extremity is assisted by the unaffected side, and bilateral active range of motion exercise. Robotic training will be followed by impairment-oriented training.
48370102|NCT02705859|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
48370103|NCT02705859|DRUG|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
48370104|NCT01711073|DRUG|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
48370105|NCT03260699|DEVICE|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
48370106|NCT02723461|DRUG|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
48370107|NCT02723461|DRUG|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
48522844|NCT03142737|OTHER|Peanut butter intake|Each participant will consume 2 tablespoons of peanut butter.
48370108|NCT04576702|BIOLOGICAL|Investigational aIIV4c|Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48370109|NCT04576702|BIOLOGICAL|IIV4c|Licensed, Non-adjuvanted, Cell-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
48370110|NCT04576702|BIOLOGICAL|aIIV4|Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
48370111|NCT04576702|BIOLOGICAL|RIV4|Licensed, Recombinant Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
48370112|NCT00948896|DRUG|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
48370113|NCT00948896|DRUG|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
48370114|NCT00948896|DRUG|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
48370115|NCT03102541|OTHER|None intervention|
48370116|NCT01752244|DIETARY_SUPPLEMENT|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
48370117|NCT01752244|DIETARY_SUPPLEMENT|Alfacalcidol|Alfacalcidol
48370118|NCT05948800|DIETARY_SUPPLEMENT|Nasal irrigation with seawater isotonic solution|Isotonic sea water: product from the market, Aqua Maris nasal spray (manufacturer JGL, Rijeka), applied in accordance with the approved Instructions for Consumers.
48370119|NCT01786707|BIOLOGICAL|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
48370120|NCT01786707|OTHER|Hyperbaric oxygen therapy|
48370121|NCT01786707|DRUG|Insulin|Insulin dose as per clinical management
48522845|NCT03142737|OTHER|Ground beef intake|Each participant will consume 2 ounces of 90% lean ground beef.
48522846|NCT03142737|OTHER|Intact beef intake|Each participant will consume 2 ounces of intact beef.
48167081|NCT04236245|DEVICE|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
48370122|NCT01786707|DRUG|Metformin|Metformin dose as tolerated
48514726|NCT03907657|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
48696269|NCT06662240|DEVICE|The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection|The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
48514727|NCT03907657|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
48514728|NCT05954221|PROCEDURE|Red cell lysis buffer (RCLB) application|The tissue is lysed with 50% concentration of RCLB for 15 min on a shaking device. If the lysis is judged to be insufficient, it can be repeated one more time. Finally, the treated tissue will be fixed with 10% formalin.
48514729|NCT05954221|PROCEDURE|Conventional processing|The tissue is fixed with 10% formalin.
48696270|NCT03462017|DRUG|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
48370123|NCT01821001|DRUG|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
48370124|NCT01666301|DRUG|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
48370125|NCT01556503|DEVICE|VivaScope System|VivaScope System, Model#s 1500 and 2500
48370126|NCT00962624|DRUG|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
48696271|NCT03462017|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
48167082|NCT06255912|DRUG|LTC004 + MIL-97|Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
48167083|NCT06255912|DRUG|LTC004 + MIL-97+chemotherapy|LTC004 + MIL-97+chemotherapy
48370127|NCT00364234|DEVICE|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
48514730|NCT04274712|DIAGNOSTIC_TEST|INNOGRAFT Heart Suite|Liquid biopsy to identify acute rejection
48514731|NCT03112642|PROCEDURE|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block \[0.35% marcaine\] will be administered.
48167084|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
48370128|NCT02303470|BEHAVIORAL|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
48370129|NCT02303470|BEHAVIORAL|Moderate Exercise|
48370130|NCT03922945|DRUG|VI-0521 oral capsule|Phentermine/Topiramate
48370131|NCT03922945|DRUG|Placebo oral capsule|Inactive drug
48370132|NCT03922945|BEHAVIORAL|Lifestyle Modification|The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
48514732|NCT03112642|DEVICE|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
48514733|NCT00761657|DRUG|Roxadustat|Capsule
48514734|NCT00761657|DRUG|Placebo|Capsule
48514735|NCT05002439|OTHER|Multicomponent physical exercise program and a nutritional intervention|The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
48514736|NCT03248973|DRUG|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
48696272|NCT03462017|DRUG|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
48696273|NCT03462017|DRUG|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
48696274|NCT03887455|DRUG|Lecanemab|10 milligram per kilogram (mg/kg) biweekly (once every 2 weeks) administered as i.v. infusion.
48009417|NCT06026904|DEVICE|transcutaneous auricular vagus nerve stimulation|taVNS was developed as a non-invasive variant of VNS where the vagus nerve is stimulated through the skin of the auricle, which has become a promising avenue for research and, potentially, treatment of various disorders. Commonly, taVNS is applied via the ear targeting the auricular branch of the vagus nerve, where the stimulation elicits far-field potentials. In line with preclinical studies, acute taVNS enhances invigoration of effort and response inhibition capability.
48009418|NCT05703893|DIAGNOSTIC_TEST|Supine resting (REST) and active standing (STAND)|Analysis of baroreflex sensitivity
48009419|NCT04581499|COMBINATION_PRODUCT|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
48009420|NCT04581499|OTHER|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
48009421|NCT01099085|DRUG|Simvastatin|simvastatin 40 mg qd daily
48009422|NCT01099085|DRUG|Placebo|Placebo
48009423|NCT04076644|DEVICE|TMS treatment|TMS using either a standard 10hz 20min or 3 min theta burst protocol
48370133|NCT01670331|BEHAVIORAL|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
48370134|NCT02380417|PROCEDURE|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
48370135|NCT02380417|DRUG|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
48370136|NCT02380417|DEVICE|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
48370137|NCT01749241|DRUG|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
48696275|NCT03887455|DRUG|Placebo|Biweekly (once every 2 weeks) administered as i.v. infusion.
48009424|NCT04316182|DRUG|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
48370138|NCT01749241|DRUG|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
48370139|NCT00591305|DIETARY_SUPPLEMENT|diindolylmethane (DIM)|3-month DIM
48370140|NCT00591305|DEVICE|585 nm pulsed dye laser|once-time PDL
48696276|NCT03887455|DRUG|Lecanemab|720 milligram (mg) weekly administered as subcutaneous injection.
48696277|NCT03887455|DRUG|Lecanemab|360 mg weekly administered as subcutaneous injection.
48696278|NCT00416065|DEVICE|PET/CT imaging|
48696279|NCT03650374|OTHER|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
48696280|NCT03650374|OTHER|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
48370141|NCT01693640|DRUG|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
48009425|NCT02788110|OTHER|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
48696281|NCT06552949|PROCEDURE|Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)|Emergent conventional laparoscopic cholecystectomy
48696282|NCT01258933|DRUG|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
48009426|NCT02788110|OTHER|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
48696283|NCT01051531|DRUG|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
48696284|NCT05716178|BEHAVIORAL|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
48370142|NCT04748731|BEHAVIORAL|Internet mentalization-based video feedback intervention to improve parental sensitivity in mother-infant dyads with maternal depressive symptoms|a weekly online brief intervention using video-feedback and psycho-educational materials on early parenting
48370143|NCT04748731|BEHAVIORAL|Psycho-Educational Intervention|Reception of psycho-educational materials
48370144|NCT01938027|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
48370145|NCT05597852|DEVICE|SpaceOAR|SpaceOAR hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.
48370146|NCT03576807|DRUG|CD20 CAR-T cells|A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
48370147|NCT05766410|DRUG|Palbociclib|CDK4, 6 inhibitor
48370148|NCT05766410|DRUG|Ribociclib|CDK4, 6 inhibitor
48370149|NCT05766410|DRUG|Abemaciclib|CDK4, 6 inhibitor
48370150|NCT05766410|DRUG|Letrozole|Endocrine therapy
48370151|NCT00086060|BEHAVIORAL|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
48370152|NCT00086060|BEHAVIORAL|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
48370153|NCT00086060|BEHAVIORAL|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
48370154|NCT00672490|DRUG|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
48370155|NCT00672490|DRUG|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
48370156|NCT03660657|DRUG|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
48370157|NCT03660657|DRUG|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
48370158|NCT02590211|BEHAVIORAL|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
48370159|NCT03459092|DRUG|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
48167085|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
48009427|NCT04448470|OTHER|Questionnaire for recording daytime sleepiness over the course of the day|Questionnaire for recording daytime sleepiness over the course of the day
48167086|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
48514737|NCT04820205|DRUG|Intranasal dexmedetomidine and ketamine|Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
48514738|NCT04820205|DRUG|Oral chloral hydrate|Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
48514739|NCT03513094|OTHER|Transversus Abdominis Contraction|Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
48514740|NCT01707264|DRUG|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
48514741|NCT05581381|BEHAVIORAL|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
48167087|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
48167088|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
48167089|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
48167090|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
48009428|NCT04448470|OTHER|Anamnesis and physicial examination|Anamnesis and physical examination, e.g. medication, comorbidities, complaints
48009429|NCT04448470|OTHER|Questionnaire for quantifying daytime sleepiness|the Epworth Sleepiness Scale (ESS) questionnaire and the STOP BANG Questionnaire
48009430|NCT04448470|DIAGNOSTIC_TEST|Pulmonary function test|The measured values of spirometry/body plethysmography, CO diffusion and blood gas analysis are documented, if available.
48009431|NCT04448470|DIAGNOSTIC_TEST|Polygraphy|Polygraphy is a non-invasive portable examination method that the patient uses in the home environment at night to measure possible sleep-related breathing disorders. Typically, the following measurement signals are recorded: nasal airflow, thoracic and abdominal breathing excursions, snoring and breathing sounds via a microphone, pulse, oxygen saturation and position. The evaluation results and the findings are checked by a physician. Essential parameters include the apnoea-hypopnoea index, the number of obstructive, central and mixed apnoea/hypopnoea, the number and duration of desaturation, snoring or the association with a certain position.
48167091|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
48167092|NCT00123435|DEVICE|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
48370160|NCT03459092|PROCEDURE|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
48370161|NCT05324800|DIETARY_SUPPLEMENT|Curcuma Longa Extract Mixture|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
48370162|NCT05324800|DIETARY_SUPPLEMENT|placebo group|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
48370163|NCT05038397|DEVICE|Theraspere|Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
48370164|NCT05795127|PROCEDURE|First metatarsophalangeal joint arthrodesis|Surgery leadin to bony uninon in firts metatarsophalangeal joint
48514742|NCT01522612|DRUG|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
48514743|NCT01522612|DRUG|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
48514744|NCT01522612|DRUG|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
48514745|NCT00091611|DRUG|IL-2 (interleukin-2)|
48514746|NCT00091611|DRUG|OKT3|
48514747|NCT00091611|DRUG|Cyclophosphamide|
48514748|NCT00091611|DRUG|Fludarabine|
48514749|NCT00091611|DRUG|Mesna|
48514750|NCT01739127|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
48696285|NCT04183127|OTHER|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
48514751|NCT01739127|DRUG|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
48696286|NCT05436535|BIOLOGICAL|Dupilumab|Adult dupilumab-naïve topical steroid non-responder (EASI \>7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).
48696287|NCT05436535|DRUG|Vanicream- Dupilumab-naïve|Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
48696288|NCT05436535|DRUG|Triamcinolone Acetonide|"On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin."
48696289|NCT05436535|DRUG|Hydrocortisone|"On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin."
48696290|NCT05436535|DRUG|Vanicream- Active|Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
48167093|NCT01723007|OTHER|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
48167094|NCT06088797|OTHER|METRIC COMPARISON Tasks : Tactile PVSE test|"Tactile PVSE test The tests are presented in 6 independent booklets, each of which tests a distinct skill: comparison of lengths, comparison of sizes, comparison of obliques, perception of environments, comparison of relative positions in relation to a frame and comparison of relative positions with distractors.~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
48370165|NCT04192552|OTHER|PAUSE Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~Dabigatran (see below):~CrCl ≥50: Hold DOAC for 2 days before procedure. Re-start DOAC 2+ days post-procedure.~CrCl \<50: Hold DOAC for 4 days before procedure. Re-start DOAC 2+ days post-procedure."
48370166|NCT04192552|OTHER|ASRA Perioperative DOAC Management|"Apixaban \& Rivaroxaban: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~Dabigatran (see below):~CrCl \>80: Hold DOAC for 3 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 50-80: Hold DOAC for 4 days before procedure. Re-start DOAC 1+ days post-procedure.~CrCl 30-49: Hold DOAC for 5 days before procedure. Re-start DOAC 1+ days post-procedure.~\*Low-dose heparin bridging can be used if at high A-TE risk"
48370167|NCT00275704|DRUG|Flaxseed|
48370168|NCT01127529|BIOLOGICAL|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
48370169|NCT01723527|DRUG|Methadone|Clinic-Based Methadone Maintenance Treatment
48370170|NCT01723527|DRUG|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
48370171|NCT01723527|BEHAVIORAL|Employment-based drug abstinence reinforcement|
48514752|NCT04205565|DRUG|Test group: L-oxiracetam Injection|L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
48514753|NCT04205565|DRUG|Control group: Oxiracetam Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
48514754|NCT04205565|DRUG|Placebo group: Placebo Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
48514755|NCT03759938|DRUG|Direct oral anticoagulant (DOAC)|Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
48514756|NCT03567928|DEVICE|Sedation with Gastro Cuff Pilot Laryngeal Mask|This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.
48514757|NCT03567928|DRUG|Propofol|Target controlled infusion (TCI) with propofol
48514758|NCT00474266|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
48514759|NCT00474266|BIOLOGICAL|Priorix-Tetra|2-dose subcutaneous injection
48696291|NCT05436535|DRUG|Vanicream- Experienced Dupilumab|Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
48696292|NCT02218697|BIOLOGICAL|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
48696293|NCT02218697|BIOLOGICAL|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
48167095|NCT06088797|OTHER|METRIC COMPARISON Tasks : Classic PVSE test|"Classic PVSE test Use of the standardized PVSE test printed on thick white paper in 6 separate booklets each containing a subtest (length, size, oblique, middle, relative position and relative position with distractor)~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
48696294|NCT02218697|BIOLOGICAL|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
48696295|NCT01181999|DRUG|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
48514760|NCT00474266|BIOLOGICAL|Meningitec|Single dose intramuscular injection
48009432|NCT04631939|DEVICE|Metacognitive training game|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The intervention consists of 4 different puzzles. Unbeknownst to the player, the first pieces of evidence of each puzzle are often misleading, i.e. indicate the wrong solution, such that hasty decisions are punished. Players receive immediate feedback and are shown the correct response after submitting their solution, as well as explicit cues that educate them on the value of making adequately informed decisions. The order of the puzzles is fixed for each player, but different per session."
48167096|NCT06088797|OTHER|Mental imagery task|This involves answering questions concerning the position or identity of 2 or 3 objects on the basis of the mental representation of a grid by auditory guidance. Each grid must be constructed mentally with the verbal description of the path and the objects encountered.
48167097|NCT06088797|OTHER|Proprioceptive spatial representation tasks|"16 configurations of 3 objects with direct or indirect passive exploration of their relative positions.~Each grid is presented 3 times with the following 3 questions to which the subject answers yes or no by forced choice~a single measure of the number of correct answers which will be the sum of the correct answers obtained to each of the 3 questions in the direct vs indirect condition"
48167098|NCT06088797|OTHER|Tasks assessing number sense based on relative positions or lengths|"Pointing exercises on a digital line of 50 cm paper tape: the participant points with his finger to a position on the tape, according to the verbal request of the experimenter~Measures the intermanual gap during requests for evaluation of 5 times the wand, subtracting the length of a wand, then dividing this length by 2."
48514761|NCT00288730|DRUG|nesiritide|
48514762|NCT04705272|OTHER|Questionnaire|Pregnant women will be included in the study at the time of their first or second trimester ultrasound in the Hautepierre and CMCO ultrasound department. The period of inclusion should extend from 1 October 2020 to 31 October 2021 with a duration of participation of each subject of 9 months.
48514763|NCT00141778|DRUG|Placebo|Matching placebo taken once a day
48514764|NCT00141778|DRUG|Ramipril|Taken orally, once a day
48514765|NCT00141778|DRUG|Spironolactone|Taken orally, once a day
48696296|NCT06073912|PROCEDURE|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
48009433|NCT04631939|DEVICE|Control games|"In the fantasy world Macu'ta, players explore the world by walking around with an avatar in order to find the puzzles and proceed in the game. The control intervention consists of 4 different puzzle games requiring exclusively dexterity and accuracy (i.e., not including any metacognitive elements). The order of the puzzles is fixed for each player, but different per session."
48696297|NCT06073912|PROCEDURE|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
48696298|NCT06073912|PROCEDURE|Bone graft harvesting|Bone graft harvesting from the chin area
48514766|NCT01034956|DEVICE|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
48514767|NCT04936399|BIOLOGICAL|Nivolumab|Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
48696299|NCT06073912|PROCEDURE|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
48696300|NCT06073912|PROCEDURE|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
48696301|NCT06073912|DEVICE|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
48696302|NCT06073912|DEVICE|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
48514768|NCT05348447|DEVICE|cryoanalgesia|intraoperative intercostal nerve freezing for post-operative pain control
48696303|NCT04361409|DRUG|Rituximab|375mg/m2 on Day-14 and Day-7
48696304|NCT04361409|DRUG|Cisplatin|70mg/m2 on Day1
48696305|NCT04361409|DRUG|Gemcitabine|1000mg/m2 on Day8
48696306|NCT06658951|BIOLOGICAL|Anti-HER2 CAR-T cells|All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
48696307|NCT04308239|BEHAVIORAL|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
48696308|NCT04308239|BEHAVIORAL|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
48696309|NCT04666103|PROCEDURE|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
48696310|NCT00705913|DEVICE|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
48696311|NCT00705913|DEVICE|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
48696312|NCT05623787|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
48696313|NCT03126058|PROCEDURE|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
48696314|NCT02428998|DIETARY_SUPPLEMENT|Korean Red Ginseng|
48696315|NCT02428998|DIETARY_SUPPLEMENT|Placebo|
48696316|NCT04458441|OTHER|warm group/cold group|sequential randomization
48696317|NCT03241680|DIAGNOSTIC_TEST|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
48696318|NCT04726592|DRUG|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
48696319|NCT04726592|DRUG|Placebo|Placebo IV
48696320|NCT04726592|DRUG|Ketoprofen|Ketoprofen 100 mg IV
48696321|NCT04726592|DRUG|Metoclopramide|Metoclopramide 10 mg IV
48009434|NCT00211471|DRUG|anecortave acetate|
48009435|NCT02719158|DRUG|6 mg ciprofloxacin|Single administration of OTO-201
48696322|NCT05151445|BEHAVIORAL|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
48696323|NCT02918461|BEHAVIORAL|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
48696324|NCT01618045|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
48696325|NCT03955250|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
48696326|NCT03955250|BEHAVIORAL|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
48696327|NCT06112821|OTHER|Data collection in medical records|Data collection in medical records
48696328|NCT06112821|OTHER|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
48696329|NCT04234646|BEHAVIORAL|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
48009436|NCT02719158|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
48009437|NCT02719158|OTHER|Sham|
48009438|NCT00020670|BIOLOGICAL|CD 40|
48009439|NCT01072851|BEHAVIORAL|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
48009440|NCT01072851|BEHAVIORAL|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
48009441|NCT01072851|BEHAVIORAL|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
48009442|NCT02310191|PROCEDURE|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
48009443|NCT00002495|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15
48696330|NCT04234646|BEHAVIORAL|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
48696331|NCT03017872|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
48696332|NCT03017872|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
48696333|NCT03017872|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
48696334|NCT03017872|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
48696335|NCT04607304|DEVICE|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
48696336|NCT06104878|OTHER|No Intervention|No Intervention will be administered in this study.
48696337|NCT06661096|PROCEDURE|TMJ arthroscopy|level I and level II TMJ arthroscopy
48696338|NCT05475743|OTHER|Pain Informed Movement program|The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.
48696339|NCT05475743|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
48696340|NCT00157196|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
48696341|NCT00157196|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
48696342|NCT00157196|OTHER|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
48696343|NCT05688215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48696344|NCT05688215|PROCEDURE|Computed Tomography|Undergo a CT scan
48696345|NCT05688215|PROCEDURE|Core Biopsy|Undergo core biopsy
48696346|NCT05688215|DRUG|Fluorouracil|Given IV
48696347|NCT05688215|DRUG|Irinotecan|Given IV
48696348|NCT05688215|DRUG|Leucovorin|Given IV
48514769|NCT05348447|OTHER|Standard of Care Pain Control|Standard of Care Pain Control Post-operatively
48514770|NCT00104572|DRUG|Androgel (Testosterone Gel)|1 mg tablet for 12 months
48696349|NCT05688215|DRUG|Leucovorin Calcium|Given IV
48696350|NCT05688215|DRUG|Oxaliplatin|Given IV
48696351|NCT05688215|DRUG|Quemliclustat|Given intravenously (IV)
48696352|NCT05688215|DRUG|Zimberelimab|Given IV
48696353|NCT02762656|DRUG|Lidocaine|Lidocaine drip during surgery
48696354|NCT02806219|DEVICE|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
48696355|NCT02806219|DEVICE|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
48696356|NCT05725005|DRUG|ASN51|ASN51 formulation for oral capsule
48696357|NCT00455819|PROCEDURE|home treatment|
48696358|NCT01519544|DRUG|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
48009444|NCT00002495|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15
48009445|NCT00002495|RADIATION|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
48514771|NCT00104572|DRUG|Anastrozole (Aromatase Inhibitor)|
48696359|NCT01519544|DRUG|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
48696360|NCT03430024|OTHER|Association of Myosin VI with oestrogen receptor|"1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
48009446|NCT06382857|DIETARY_SUPPLEMENT|MDF|MDF will be provided to children on a weekly basis for children with SAM and bi-weekly basis for children with MAM at the health center until programmatic recovery but not thereafter.
48514772|NCT00104572|DRUG|Placebo tablet|Daily for 12 months
48696361|NCT01164891|DRUG|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
48696362|NCT06604767|BIOLOGICAL|parainfluenza virus type 3 vaccine (PIV3)|Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
48696363|NCT06604767|BIOLOGICAL|RSV/hMPV/PIV3 vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
48696364|NCT06604767|BIOLOGICAL|RSV/hMPV vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
48696365|NCT06604767|BIOLOGICAL|RSV vaccine 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
48696366|NCT06604767|BIOLOGICAL|RSV vaccine 2|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
48696367|NCT04661371|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
48009447|NCT06382857|DIETARY_SUPPLEMENT|RUTF|RUTF will be provided to all children on a weekly basis at the health center until programmatic recovery but not thereafter
48370172|NCT01994070|DRUG|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
48370173|NCT01994070|DRUG|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
48370174|NCT05712343|DRUG|Valacyclovir group|The valacyclovir group will be received, valacyclovir (500 mg, 3 times a day for 3 days)
48370175|NCT05712343|OTHER|Control group|The control group will receive placebo medication, three times a day for 3 days.
48370176|NCT03242291|OTHER|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
48370177|NCT03242291|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
48370178|NCT04307004|OTHER|Unattended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician not present in the room.
48370179|NCT04307004|OTHER|Attended blood pressure measurement|Participants will have their blood pressure measured three times with an automated blood pressure monitor with a technician present in the room.
48370180|NCT04307004|OTHER|Ambulatory blood pressure monitoring|Participants will have their blood pressure measured every 30 minutes over 24-hours using an ambulatory blood pressure monitor.
48370181|NCT04307004|OTHER|Home blood pressure monitoring|Participants will have their blood pressure measured three times overnight while they are asleep using a home blood pressure monitor.
48370182|NCT05058066|DEVICE|Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm abutment|The control implant included the previous generation as-machined titanium Baha® flange fixture (diameter 3.75mm; length 4mm) with 6mm conically shaped abutment.
48370183|NCT05058066|DEVICE|Baha® BIA300 Implant (diameter 4.5mm; length 4mm) with 6mm abutment|The test implant and the implant used for the 3-week loading trial included the wide diameter titanium implant (diameter 4.5mm; length 4mm) with 6mm rounded, apically converging titanium abutment developed by Cochlear Bone Anchored Solutions AB (Mölnlyncke, Sweden). This system with an additional minor change to the internal abutment connection design was later commercialized under the name Cochlear™ Baha® BIA300 Implant with abutment. In addition to the difference in abutment shape and the wider diameter, the test implant incorporates small-sized threads at the implant neck and the moderately rough TiOblast™ (Dentsply, Mölndal, Sweden) surface on the intraosseous part of the implant6-8.
48514773|NCT00104572|DRUG|Placebo gel|Daily for 12 months
48514774|NCT00104572|DIETARY_SUPPLEMENT|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
48514775|NCT03741426|DRUG|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
48514776|NCT03741426|DRUG|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
48514777|NCT03741426|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
48514778|NCT00004757|DRUG|acyclovir|
48009448|NCT06382857|DIETARY_SUPPLEMENT|RUSF|RUSF will be provided on a biweekly basis at the health center until programmatic recovery but not thereafter
48009449|NCT00122941|DIETARY_SUPPLEMENT|multiple micronutrients|
48009450|NCT04593901|BEHAVIORAL|Video and App Review|"Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment."
48009451|NCT01507285|DRUG|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
48009452|NCT01507285|DRUG|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
48009453|NCT00128180|DRUG|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
48009454|NCT00128180|DRUG|Placebo|Placebo
48009455|NCT04519658|DRUG|CIN-107|CIN-107 tablets by mouth once daily
48009456|NCT04519658|DRUG|Placebo|placebo tablets by mouth once daily
48009457|NCT06038838|DEVICE|Tioga TMVR System|A bioprosthetic mitral valve, as part of the Tioga TMVR System, is implanted percutaneously in a patient with MR via transfemoral-transseptal access.
48009458|NCT00259857|DRUG|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
48009459|NCT02450214|DRUG|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
48514779|NCT01019668|DRUG|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
48514780|NCT01019668|DRUG|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
48514781|NCT04085055|DIAGNOSTIC_TEST|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
48009460|NCT02450214|DRUG|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
48696368|NCT06169319|BIOLOGICAL|EN3835|Biologic: Intrafascial injection
48696369|NCT06169319|OTHER|Placebo|Intrafascial injection
48696370|NCT06662071|OTHER|Organoid culture|Organoid culture of tumor tissue obtained during patient surgery
48696371|NCT05584410|OTHER|Patient information|Patient education according to national guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
48696372|NCT05584410|OTHER|Smart phone application based exercises|Individually based exercise programs individualized exercises where instructions are given through real-time video or pictures in combination with written descriptions.
48696373|NCT05584410|OTHER|Web based exercises|Generic osteoarthritis exercise, including about 20 different exercises, provided by real-time videos and written description
48696374|NCT05584410|OTHER|Group based information|Osteoarthritis specific information at three different group meeting (physical or digital) led by a physiotherapist, an occupational therapist and / or dietitian (each rehab clinic makes its own arrangement).
48009461|NCT02450214|DRUG|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
48009462|NCT05756764|DRUG|Semaglutide|Medication for weight loss
48009463|NCT05756764|DRUG|Phentermine-Topiramate combination|Medication for weight loss
48009464|NCT05756764|DRUG|Phentermine|Medication for weight loss
48009465|NCT05756764|DRUG|Tirzepatide|Medication for weight loss
48009466|NCT05756764|DRUG|Topiramate|Medication for weight loss
48009467|NCT05756764|DRUG|Diethylpropion|Medication for weight loss
48370184|NCT05058066|PROCEDURE|Early loading|Loading the implant at 3 weeks after implantation (instead of 6 weeks after implantation)
48370185|NCT03749031|OTHER|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
48370186|NCT03749031|OTHER|Orange Juice|16 oz. orange juice per day for 4 weeks
48370187|NCT03749031|OTHER|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
48370188|NCT03749031|OTHER|Apple Juice|16 oz. apple juice per day for 4 weeks
48370189|NCT02974764|OTHER|No intervention/exposures|
48370190|NCT01579994|DRUG|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
48514782|NCT04793594|OTHER|Berg Balance Test|Patients evaluate with Berg Balance Test for balance
48696375|NCT05584410|OTHER|Supervised rehabilitation|The patient is offered to regularly exercise at the clinic, individually or in a group under supervision from a physiotherapist.
48696376|NCT05584410|OTHER|Self-monitoring|Patients will be followed by validated questionnaires and function tests (30 sec Chair-to-stand test) every six months until three years after the start of treatment. The patients will get a report of the results and a research coordinator will contact the patients if their symptoms/function has worsen and discuss further treatment
48696377|NCT05584410|BEHAVIORAL|Motivational notifications|Automatic and daily reminders and / or motivational notifications
48696378|NCT05584410|OTHER|Home based rehabilitation|Individualized exercises that the patient performs on their own, i.e. at home or at a gym.
48696379|NCT01253148|DEVICE|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
48696380|NCT00323960|DRUG|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
48696381|NCT00323960|DRUG|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
48696382|NCT00323960|DRUG|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
48696383|NCT06416358|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
48696384|NCT03670654|OTHER|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
48696385|NCT03670654|OTHER|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
48696386|NCT06661460|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
48696387|NCT06658561|PROCEDURE|cold snare polypectomy|Place the special cold snare in the normal mucosa 1-2mm away from the polyp edge. Tighten the snare at a constant speed and gently lift it up and then excision.
48696388|NCT06658561|PROCEDURE|hot snare polypectomy|According to evaluation of the polyps, directly place the snare on the edge of the polyp including a clear margin of normal tissue (1-2 mm) or after submucosal injection. Tighten the snare at a constant speed and gently lift it up.Use the electrocoagulation and electroscission mode, power on for several seconds until the polyp is cut off.
48009468|NCT05756764|DRUG|Naltrexone/Bupropion|Medication for weight loss
48370191|NCT05324774|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously."
48009469|NCT05756764|DRUG|Liraglutide|Medication for weight loss
48009470|NCT00004448|DRUG|omega-3 fatty acids|
48370192|NCT05324774|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously."
48370193|NCT02771782|BIOLOGICAL|BCG vaccine (SSI)|
48009471|NCT00004448|DRUG|prednisone|
48009472|NCT01430065|DRUG|ASP015K|oral
48009473|NCT01430065|DRUG|Tacrolimus|oral
48009474|NCT03212703|BEHAVIORAL|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
48009475|NCT03212703|OTHER|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
48370194|NCT02771782|BIOLOGICAL|TDaP-IPV vaccine|
48370195|NCT03935074|DRUG|intra-arterial administration of melphalan|
48370196|NCT01912482|OTHER|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
48370197|NCT01912482|OTHER|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
48696389|NCT06303440|OTHER|Routine Physical Therapy+ Balance Training|Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.
48696390|NCT06303440|OTHER|Virtual Reality+ Routine Physical Therapy|The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.
48696391|NCT06303440|OTHER|Motor Imagery+ Routine Physical Therapy|"The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video."
48696392|NCT02512874|OTHER|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
48696393|NCT02512874|DEVICE|Dynamometer|Grip Test
48696394|NCT02512874|RADIATION|DEXA|Body Composition Testing
48696395|NCT02512874|OTHER|Gait Speed Test|15 foot walk test
48696396|NCT02512874|DEVICE|Activity Monitor|Measures energy expenditure and activity
48696397|NCT02512874|OTHER|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
48696398|NCT01830283|BIOLOGICAL|varicella vaccine|The providers would get varicella vaccine
48696399|NCT02463084|OTHER|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
48696400|NCT02463084|OTHER|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
48696401|NCT02499900|DRUG|Copaxone®|Subcutaneous Injections
48696402|NCT04832789|DEVICE|Venovenous ECMO|Venovenous ECMO
48696403|NCT00802997|DEVICE|Sinergy|radiofrequency denervation
48370198|NCT00649220|DRUG|Memantine|memantine tablets, twice a day (bid), for 20 weeks
48370199|NCT00017108|DRUG|chlorambucil|
48370200|NCT00017108|DRUG|cyclophosphamide|
48370201|NCT00017108|DRUG|fludarabine phosphate|
48370202|NCT03839446|DRUG|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
48370203|NCT03944096|PROCEDURE|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
48370204|NCT06066463|BEHAVIORAL|questionnaires|Self reported female gender
48696404|NCT00802997|DEVICE|Placebo sham|sham procedure
48696405|NCT03636438|OTHER|No Intervention|No Intervention
48696406|NCT02539199|DRUG|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
48696407|NCT02539199|DRUG|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
48696408|NCT01420692|DRUG|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
48696409|NCT01420692|DRUG|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
48696410|NCT04451226|DRUG|Fezolinetant|Oral
48696411|NCT06484179|BEHAVIORAL|Targeted Self-Help|In addition to usual care participants will receive a self-help booklet specific for their cancer type. There are five booklets available, written at a 5-6th grade reading level and targeted by cancer type, that explain the connection between smoking and each cancer type, describe the benefits of quitting smoking after cancer, and address some of the barriers cancer patients face to quit smoking when fighting cancer. Each booklet also includes four testimonials inspired from conversations with patients.
48696412|NCT06484179|BEHAVIORAL|Usual Care|Participants will receive the standard care typically offered for smoking cessation.
48696413|NCT01700998|DRUG|Magnesium|
48370205|NCT02616120|DRUG|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
48370206|NCT02616120|DRUG|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
48370207|NCT03622294|DEVICE|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
48370208|NCT03114150|BEHAVIORAL|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
48370209|NCT03114150|BEHAVIORAL|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
48696414|NCT01700998|DRUG|Placebo|
48696415|NCT02112474|DEVICE|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
48009476|NCT03761251|BEHAVIORAL|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
48696416|NCT02112474|DEVICE|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
48009477|NCT00470288|PROCEDURE|bladder flap during cesarean section|
48696417|NCT02112474|DEVICE|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
48009478|NCT02093637|OTHER|Placebo acupuncture|Placebo Comparator
48009479|NCT02093637|OTHER|Battlefield Acupuncture|Experimental
48167099|NCT06088797|OTHER|WISC V Similarity and Span Test|The Wechsler Intelligence Scale for Children - Fifth Edition, Australian Standard (WISC-V) is an individually administered and comprehensive clinical instrument used to assess the general thinking and reasoning skills of children aged six years to 16 years. Test results include a Full-Scale Intelligence Quotient (IQ) score as well as age-equivalent rankings and scores for Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory and Processing Speed composites
48167100|NCT06088797|OTHER|WISC V Arithmetic subtest|The WISC-V is an individually administered, comprehensive clinical instrument for assessing the intelligence of children. The primary and secondary subtests are on a scaled score metric with a mean of 10 and a standard deviation (SD) of 3. These subtest scores range from 1 to19, with scores between 8 and 12 typically considered average.
48167101|NCT00030745|DRUG|cisplatin|
48009480|NCT00033384|DRUG|CI-1040|
48009481|NCT02639481|BEHAVIORAL|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
48370210|NCT01734070|OTHER|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
48370211|NCT03582631|PROCEDURE|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
48370212|NCT04872374|DIETARY_SUPPLEMENT|Parmigiano Reggiano|subjects will receive 50 g/die of the dietary supplement 10 days before performing the eccentric exercise session
48370213|NCT04872374|DIETARY_SUPPLEMENT|Whey Protein|subjects will receive 20 g/die of the dietary supplement 10 days before performing the eccentric exercise session
48370214|NCT00643006|BEHAVIORAL|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
48370215|NCT00643006|BEHAVIORAL|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
48370216|NCT00761891|OTHER|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
48370217|NCT05557266|BEHAVIORAL|Mindfulness-based intervention|An mindfulness instructor will conduct meditations lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have audio files designed ad hoc with the practice of the week so they can do it individually at home.
48370218|NCT05557266|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The first day of each week the intervention will be given in streaming and the rest of the days the participants will have video files designed ad hoc with the practice of the week so they can do it individually at home.The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
48370219|NCT02369380|DEVICE|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
48370220|NCT03922191|OTHER|Data extraction from medical files|Data extraction from medical files
48370221|NCT03252223|DRUG|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
48696418|NCT06127381|DRUG|Glycolic acid tetrasubstituted piceatannol (TGKP)|A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
48009482|NCT02639481|DEVICE|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
48009483|NCT02639481|DEVICE|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
48167102|NCT00030745|DRUG|gemcitabine hydrochloride|
48167103|NCT00030745|PROCEDURE|conventional surgery|
48370222|NCT04690673|DRUG|Paracetamol|1 g oral paractamol
48370223|NCT04690673|DIAGNOSTIC_TEST|Paracetamol concentration measurements and lipidomic assessment|Paracetamol concentration is measured from saline-, urine-, venous blood- and fingerprick- samples at timely intervals. Also serum lipidomic assessment is performed from venous blood samples.
48370224|NCT04839627|OTHER|serum progesterone measurement|progesterone levels measurement on the day of the embryo transfer on all AMP cycles
48370225|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
48696419|NCT02882620|BEHAVIORAL|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
48696420|NCT02882620|BEHAVIORAL|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
48696421|NCT02882620|BEHAVIORAL|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
48696422|NCT05047939|DRUG|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
48696423|NCT05047939|DRUG|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
48370226|NCT01189201|DRUG|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
48514783|NCT04793594|OTHER|Tinetti Balance And Gait Test|Patients evaluate with Tinetti Balance And Gait Test for balance
48696424|NCT00580034|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
48696425|NCT00580034|PROCEDURE|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
48696426|NCT06659861|OTHER|RV3278B-OS0386|Cosmetic product to be applied twice a day on the face during the whole study
48009484|NCT04647058|PROCEDURE|Cubital tunnel release|The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.
48696427|NCT06659861|OTHER|RV4632A-RY1845|Cosmetic product to be applied in the event of facial skin discomfort only
48696428|NCT06551350|OTHER|Data Collection|Collection of medical data from MICU intervention file and the medical records of patients at the destination hospital
48696429|NCT05425394|BEHAVIORAL|Delay first bath|Newborns delay first bath to 8 hours after birth
48696430|NCT03397433|OTHER|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
48696431|NCT05237791|DRUG|Magnesium sulfate|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
48167104|NCT00260676|PROCEDURE|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
48167105|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
48167106|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
48514784|NCT04793594|OTHER|Time Up And Go Test|Patients evaluate with Time Up And Go Test for balance
48514785|NCT01272492|OTHER|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
48514786|NCT00273988|DRUG|nevirapine|
48514787|NCT02532309|DRUG|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
48514788|NCT02532309|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
48514789|NCT03099057|OTHER|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
48696432|NCT05237791|DRUG|Placebo|normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
48696433|NCT03647410|DEVICE|lumbopelvic fixation|Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
48696434|NCT04810013|PROCEDURE|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
48696435|NCT02437630|PROCEDURE|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
48696436|NCT02437630|PROCEDURE|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
48696437|NCT02437630|OTHER|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
48696438|NCT02437630|PROCEDURE|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
48167107|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
48009485|NCT04647058|PROCEDURE|Supercharged end-to-side (SETS) nerve transfer|The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
48167108|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
48009486|NCT02974985|DEVICE|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
48009487|NCT04928326|DIAGNOSTIC_TEST|CorWatch|Non-invasive wearable monitor for the assessment of central venous pressure
48009488|NCT03427385|DRUG|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
48009489|NCT02318693|DRUG|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
48167109|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
48167110|NCT01649297|DRUG|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
48167111|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
48167112|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
48167113|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
48009490|NCT02318693|DRUG|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
48167114|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
48167115|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
48167116|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
48167117|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
48167118|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
48167119|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
48167120|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
48167121|NCT01649297|DRUG|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
48167122|NCT01649297|DRUG|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
48167123|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
48696439|NCT02437630|PROCEDURE|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
48167124|NCT01649297|DRUG|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
48167125|NCT05303090|DRUG|H101|H101 intratumorally injection starts at day 0.
48167126|NCT05303090|DRUG|Tislelizumab|Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48696440|NCT02437630|OTHER|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
48696441|NCT01545791|DRUG|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
48009491|NCT05192837|BEHAVIORAL|Intensive preoperative smoking cessation counselling|"The study intervention consists of an interview by a Tabacco Treatment Specialist (TSS) 4 weeks before surgery with individual counselling and offered nicotine substitution. The intervention meeting is based on the Chronic Care Model (CCM) to improve quality of ambulatory care.~In brief, the intervention includes:~* Informative content about advantages of smoking cessation~* Scheduling service for a motivational interview by a TSS in office to implement a treatment plan~* For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2-3 weeks before surgery~* Patients will be encouraged by a TSS to use nicotine replacement. Bupropion or Vareniclin will be provided on an individual basis~* TSS will schedule repeated follow-up meetings to support smoking abstinence or nicotine reduction before and after surgery for all patients"
48167127|NCT05303090|DRUG|lenvatinib|lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48167128|NCT00814645|DRUG|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
48370227|NCT01189201|DRUG|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
48370228|NCT01189201|DRUG|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
48696442|NCT06525077|DRUG|FT218|Sodium oxybate for extended-release oral suspension
48009492|NCT04073095|OTHER|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
48167129|NCT00814645|DRUG|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
48370229|NCT00719511|DRUG|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
48370230|NCT00719511|DRUG|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
48370231|NCT00719511|DRUG|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
48370232|NCT00719511|DRUG|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
48370233|NCT05029102|DRUG|TAS 102|35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle
48370234|NCT05029102|DRUG|Anlotinib|10mg，per oral，once daily，days 1-14 of each 21-day cycle
48370235|NCT01461187|OTHER|exercise during pregnancy|supervised aerobic physical exercises twice a week.
48370236|NCT03343665|DRUG|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
48009493|NCT04073095|OTHER|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
48696443|NCT06525077|OTHER|Placebo|Matched placebo equivalent for oral suspension
48696444|NCT04790279|DRUG|Amlodipine|Initiation of amlodipine 2.5 mg
48696445|NCT04790279|DRUG|NIFEdipine ER|Initiation of nifedipine ER 30 mg
48009494|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
48009495|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
48009496|NCT01561768|BIOLOGICAL|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
48167130|NCT06298968|DRUG|combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab|"Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years."
48167131|NCT03159325|BEHAVIORAL|Healing Circles|See description in the arm description.
48167132|NCT02763150|BEHAVIORAL|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
48167133|NCT02763150|OTHER|Health Promotion|The health promotion group will receive education on healthy eating and activity
48009497|NCT01561768|BIOLOGICAL|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
48009498|NCT01561768|BIOLOGICAL|cTIV|Preconfigured dose; intramuscular injection, deltoid
48009499|NCT02310672|DRUG|Macitentan|All patients take open-label macitentan 10mg o.d.
48009500|NCT04182581|BIOLOGICAL|BCMA/CD19 Dual-Target CAR-T|BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10\^4 to 3×10\^5 CAR+T/Kg.
48009501|NCT00577122|DRUG|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
48009502|NCT00577122|DRUG|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
48167134|NCT05558813|DIAGNOSTIC_TEST|Cardiac MRI|two cardiac MRIs with Gadolinum injection at 2-year intervals
48167135|NCT05558813|BIOLOGICAL|Blood assays|blood samples for the determination of blood biomarkers of heart failure (BNP, NTproBNP) and for the constitution of a biological collection
48167136|NCT03331432|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
48167137|NCT03331432|DIETARY_SUPPLEMENT|Placebo|Taking daily placebo capsules for 4 weeks.
48167138|NCT02301364|DRUG|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
48167139|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
48696446|NCT06662032|DEVICE|LumbaCure®|LumbaCure® is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
48696447|NCT06662032|OTHER|Rehab program|Standard rehabilitation program
48009503|NCT03394872|PROCEDURE|Drainage of the pleural effusion|
48009504|NCT01753635|DEVICE|supraglottic airway placement and use|
48009505|NCT00151814|DRUG|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
48167140|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
48167141|NCT01304108|OTHER|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
48167142|NCT01304108|OTHER|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
48167143|NCT01304108|OTHER|Usual Care|No addition to the baseline system for care
48370237|NCT05003206|OTHER|Functional magnetic resonance imaging|Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.
48370238|NCT05003206|DEVICE|Deep Brain Stimulation|For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan
48370239|NCT05405738|PROCEDURE|2 flap palatoplasty technique|cleft palate repair by 2 flap palatoplasty technique
48696448|NCT03505788|DRUG|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
48696449|NCT03505788|DRUG|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
48696450|NCT06497062|DRUG|sonrotoclax|"Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase."
48696451|NCT06497062|DRUG|idarubicin/daunorubicin|idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
48696452|NCT06497062|DRUG|Cytarabine|In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
48514790|NCT02983747|OTHER|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
48696453|NCT06497062|DRUG|Azacitidine|75 mg/m\^2, subcutaneously, once daily, on D1-7
48514791|NCT02983747|DRUG|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
48696454|NCT06497062|PROCEDURE|allo-HSCT|Per standard of procedure
48370240|NCT05405738|OTHER|normal group|control normal group
48370241|NCT05405738|PROCEDURE|Furlow with buccinator technique|cleft palate repair by Furlow with buccinator technique
48514792|NCT03926520|DEVICE|Electroconvulsive Therapy (ECT)|Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
48514793|NCT01799837|DRUG|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
48514794|NCT00741507|BEHAVIORAL|Alcohol drinking|Never drinking of alcohol
48514795|NCT00741507|BEHAVIORAL|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
48514796|NCT00741507|BEHAVIORAL|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
48514797|NCT00741507|BEHAVIORAL|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
48514798|NCT00741507|BEHAVIORAL|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
48514799|NCT06187038|OTHER|Therapeutic exercises|The therapeutic exercise program will include warm-up, resistance, neuromuscular, mobility, and balance exercises. Over ten weeks, two sessions of the therapeutic exercise program will be carried out individually, lasting approximately 60 minutes each-a total of 20 therapeutic exercise sessions. Therapeutic exercise sessions will be carried out at least 24 hours between sessions. Therapeutic exercises will be performed in up to three sets of 8-12 repetitions or 30-60 seconds each, with rest intervals of 90 seconds between sets.
48514800|NCT06187038|OTHER|Therapeutic exercises + pain neuroscience education program|"In addition to the therapeutic exercise protocol previously reported in the control group, research participants allocated to the experimental group will undergo an education program in the neurosciences of chronic pain carried out one day a week between the two therapeutic exercise sessions lasting ten weeks.~The chronic pain neuroscience education program will be based on three domains. Making sense of pain, Exposure with control, and Lifestyle changes also urge modifications aimed at improving sleep, stress, and anxiety."
48514801|NCT02344082|OTHER|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
48514802|NCT02245087|DRUG|Atorvastatin|20 mg of atorvastatin daily
48514803|NCT02914860|DEVICE|Cardiac CT|"* Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map."
48696455|NCT01345968|DRUG|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
48696456|NCT01345968|DRUG|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
48696457|NCT04600505|DRUG|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
48696458|NCT04600505|DRUG|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
48696459|NCT04600505|DRUG|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
48696460|NCT03576404|OTHER|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
48696461|NCT00597623|OTHER|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
48696462|NCT00597623|OTHER|Placebo|syringes under cutaneous vol = 8 ml
48696463|NCT05529264|OTHER|Memory Tasks|Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
48696464|NCT05529264|OTHER|Attention/arousal tasks|Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
48696465|NCT05529264|OTHER|Language tasks|Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.
48696466|NCT05529264|OTHER|Visuospatial tasks|Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
48696467|NCT05529264|OTHER|Auditory Tasks|Participants will be presented with short, approximately 8-minute clips of music from various genres ( i.e. classical, country, rock, etc.) with an attention task (modified sustained attention to response task) nested within each trial. Participants will receive approximately 8 music stimuli and 1 control stimulus (pink noise) twice over the course of two testing sessions ( 90 mins each). Additionally, participants will be asked to answer questions about their hearing, music preferences/training, and certain demographic information (age, handedness, and language proficiency).
48696468|NCT05529264|PROCEDURE|Brain Stimulation|A brain stimulator will be used to understand new functions of the brain. Participants will be presented with pictures on a computer screen and may be asked to tell researchers what is seen or remembered by participants. As pictures are viewed by the participants, the brain stimulator may be activated, which would not be something that would be felt by an individual participant.
48696469|NCT05529264|OTHER|Social Emotional Task|Participants will be asked to view presented pictures and videos of people engaged in social interaction. Additionally, participants will be presented with the standardized tasks that are designed to help the researchers with understanding the nature of emotions. Some of these images may be emotionally disturbing. If participants are not comfortable viewing such images, they will be asked to refrain from participation in this study.
48696470|NCT05529264|OTHER|Recording of facial expressions|Some participants may be asked permission to record the video of their facial expressions during performance of a research task. Generally, this will include only research tasks investigating brain representation of social/emotional information. Automated analysis of facial expression may be used in certain experiments to provide information on experience of emotional states such as happiness and sadness related to the images being presented.
48696471|NCT05529264|OTHER|Judgement/Impulsivity Task|Certain study participants may be enrolled into research tasks designed to activate regions important for judgment and impulse control. These tasks will present participants with choices of varying monetary rewards and ask them to make judgements to measure one's tendency to prefer immediate over delayed rewards.
48696472|NCT03952468|DEVICE|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
48696473|NCT03952468|OTHER|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
48696474|NCT00528502|DRUG|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
48696475|NCT00528502|DRUG|Saline|Saline is misted into the air that you breathe during the surgery.
48167144|NCT01932983|DEVICE|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
48370242|NCT00872131|DRUG|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
48696476|NCT00118846|DIETARY_SUPPLEMENT|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
48696477|NCT00118846|OTHER|Placebo|Milk protein administered twice daily
48696478|NCT04973605|DRUG|BGB-11417|Administered orally daily
48696479|NCT04973605|DRUG|Dexamethasone|Once weekly either orally or intravenously
48696480|NCT04973605|DRUG|Carfilzomib|Administered intravenously weekly
48696481|NCT05466955|DEVICE|Free eye glasses for un or under-corrected myopia|All participants randomised to the intervention group will be provided with free eye glasses
48167145|NCT01579110|DRUG|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
48696482|NCT03265002|DIETARY_SUPPLEMENT|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
48696483|NCT03265002|DIETARY_SUPPLEMENT|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
48696484|NCT03265002|DIETARY_SUPPLEMENT|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
48696485|NCT03265002|DIETARY_SUPPLEMENT|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
48696486|NCT01940367|DEVICE|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
48696487|NCT01940367|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level"
48696488|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48696489|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48167146|NCT01579110|DRUG|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
48167147|NCT01233414|BEHAVIORAL|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
48167148|NCT01233414|OTHER|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
48167149|NCT01747629|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
48167150|NCT01747629|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
48167151|NCT01486511|PROCEDURE|Liver resection|Hepatectomy including both minor and major.
48167152|NCT01486511|RADIATION|Computed Tomography|Computed Tomography +/- pulmonary angiography
48167153|NCT04091464|BEHAVIORAL|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
48167154|NCT04091464|BEHAVIORAL|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
48167155|NCT01660919|DRUG|placebo|
48167156|NCT01660919|DRUG|rosuvastatin|
48167157|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
48514804|NCT02914860|PROCEDURE|Ablation Procedure|"1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
48696490|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48696491|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48696492|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48696493|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48696494|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48696495|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48514805|NCT02914860|DEVICE|D-SPECT|
48514806|NCT03763305|DRUG|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
48514807|NCT03763305|DRUG|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
48514808|NCT03763305|DRUG|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5\~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
48514809|NCT03763305|DRUG|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
48696496|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48167158|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
48167159|NCT01176435|DRUG|Placebo|Solution taken orally three times a day.
48514810|NCT03763305|DRUG|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
48514811|NCT03763305|DRUG|Fentanyl|Fentanyl intravenous injection for anesthetic induction
48514812|NCT03447743|DRUG|XR-NTX community location|XR-NTX will be administered at the local health care clinic
48514813|NCT02565511|BIOLOGICAL|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
48514814|NCT02565511|OTHER|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
48514815|NCT02565511|DRUG|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
48514816|NCT02565511|OTHER|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
48514817|NCT02565511|OTHER|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
48514818|NCT01000948|DRUG|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
48514819|NCT01016470|DIETARY_SUPPLEMENT|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
48696497|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
48167160|NCT05432999|DEVICE|Extracorporeal Shockwave Therapy|Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
48167161|NCT01258296|DRUG|Fentanyl|25 mcg/hr transdermal patch
48167162|NCT01258296|DRUG|Inactive patch|placebo patch (no drug)
48167163|NCT04935762|DRUG|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
48167164|NCT02290197|PROCEDURE|Surgery|Surgical reconstruction of all injured ligaments.
48167165|NCT02290197|DEVICE|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
48167166|NCT02290197|DEVICE|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
48167167|NCT06479226|DRUG|cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash|mouthrinse
48167168|NCT01537406|RADIATION|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
48167169|NCT01630837|OTHER|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
48167170|NCT00676897|DRUG|Simvastatin|Simvastatin 40mg PO or NGT
48514820|NCT01016470|DIETARY_SUPPLEMENT|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
48514821|NCT00199147|DRUG|Cytarabine|
48514822|NCT00199147|DRUG|Etoposide|
48514823|NCT00199147|DRUG|Idarubicin|
48514824|NCT00199147|DRUG|G-CSF|
48514825|NCT00199147|DRUG|Fludarabine|
48167171|NCT00676897|DRUG|Placebo|Corn Starch
48514826|NCT00199147|PROCEDURE|Stem cell apheresis|
48514827|NCT00199147|PROCEDURE|Stem cell transplantation|
48514828|NCT05311904|OTHER|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
48514829|NCT00714116|DRUG|SBI-087|Single IV or SC dose of SBI-087
48514830|NCT04563715|DIAGNOSTIC_TEST|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
48514831|NCT04563715|BEHAVIORAL|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
48514832|NCT03119779|DRUG|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
48514833|NCT03119779|DRUG|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
48514834|NCT03577301|BEHAVIORAL|Clinic-based Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.
48514835|NCT03577301|BEHAVIORAL|Remote Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.
48167172|NCT01172899|PROCEDURE|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
48696498|NCT04467658|DIAGNOSTIC_TEST|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
48696499|NCT04467658|DIAGNOSTIC_TEST|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
48696500|NCT06122662|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
48696501|NCT06122662|OTHER|Placebo|Matching Placebo Comparator
48696502|NCT02818023|DRUG|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
48696503|NCT02818023|DRUG|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
48696504|NCT02818023|DRUG|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
48696505|NCT00234871|DRUG|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
48696506|NCT00234871|DRUG|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
48696507|NCT01533337|PROCEDURE|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
48696508|NCT04301128|OTHER|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
48696509|NCT04301128|OTHER|control|Patients in the control group were informed same informations verbally and given an education book.
48696510|NCT05706233|PROCEDURE|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
48696511|NCT05706233|PROCEDURE|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
48696512|NCT05536141|DRUG|casdatifan|Administered as specified in the treatment arm
48167173|NCT01172899|BEHAVIORAL|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
48167174|NCT04059497|BEHAVIORAL|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
48167175|NCT04059497|BEHAVIORAL|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
48167176|NCT00621946|DRUG|Placebo|Placebo Matching Escitalopram
48167177|NCT00621946|DRUG|Escitalopram|Active Escitalopram
48167178|NCT02906995|DRUG|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"* One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
48370243|NCT05283161|DRUG|cannabidiol and tetrahydrocannabinol|CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
48696513|NCT05536141|DRUG|Cabozantinib|Administered as specified in the treatment arm
48696514|NCT06358664|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy will be performed
48167179|NCT03116672|DRUG|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
48370244|NCT05283161|DRUG|Placebo|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.
48370245|NCT00027027|DRUG|rhuMAb 2C4|
48370246|NCT03039959|DIAGNOSTIC_TEST|No intervention|No intervention
48514836|NCT03577301|BEHAVIORAL|Multi-modal Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based or remote intervention sessions. First MI session is in person immediately after baseline. Sessions 2-4 can be delivered in person or remotely based on youth preference.
48696515|NCT04644471|DIAGNOSTIC_TEST|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
48696516|NCT04644471|DIAGNOSTIC_TEST|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
48696517|NCT06211764|DRUG|TAR-200|Participants will receive TAR-200 intravesically.
48696518|NCT06211764|DRUG|Mitomycin C|Participants will receive MMC intravesically.
48696519|NCT06211764|DRUG|Gemcitabine|Participants will receive gemcitabine intravesically.
48696520|NCT01312493|DRUG|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
48696521|NCT01312493|RADIATION|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
48696522|NCT05873153|BEHAVIORAL|Health Education|Education materials on high blood pressure, lowering sodium, starting an exercise program, and weight management.
48696523|NCT05873153|OTHER|Home Blood Pressure Monitor|Blood pressure cuff for home use
48696524|NCT01106859|DRUG|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
48696525|NCT01106859|DRUG|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
48696526|NCT01106859|DRUG|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
48514837|NCT02459938|DRUG|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
48514838|NCT02459938|DRUG|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
48514839|NCT05273450|BEHAVIORAL|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
48514840|NCT03545893|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
48696527|NCT01106859|DRUG|Placebo|Placebo matching zopiclone
48696528|NCT02301546|BEHAVIORAL|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
48696529|NCT05664659|DRUG|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
48696530|NCT05664659|DRUG|Carbetocin|100 micrograms carbetocin
48696531|NCT00003783|BIOLOGICAL|filgrastim|
48696532|NCT00003783|DRUG|asparaginase|
48696533|NCT00003783|DRUG|cyclophosphamide|
48696534|NCT00003783|DRUG|cytarabine|
48696535|NCT00003783|DRUG|daunorubicin hydrochloride|
48696536|NCT00003783|DRUG|dexamethasone|
48696537|NCT00003783|DRUG|etoposide|
48696538|NCT00003783|DRUG|idarubicin|
48696539|NCT00003783|DRUG|leucovorin calcium|
48696540|NCT00003783|DRUG|mercaptopurine|
48696541|NCT00003783|DRUG|methotrexate|
48696542|NCT00003783|DRUG|prednisone|
48696543|NCT00003783|DRUG|vincristine sulfate|
48696544|NCT00003783|RADIATION|radiation therapy|
48696545|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
48696546|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
48696547|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
48696548|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
48696549|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
48696550|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
48696551|NCT00441142|DRUG|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
48167180|NCT03116672|DRUG|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
48696552|NCT00441142|DRUG|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
48696553|NCT00441142|RADIATION|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
48696554|NCT06510777|DEVICE|PICO Treatment|"PICO 7 is a single-use Negative Pressure Wound Therapy System consisting of a small portable pump, 2 AA batteries, 1 or 2 dressings, and fixation strips. The dressing is changed when the dressing is saturated or after 7 days of treatment.~PICO Treatment will be given in addition to compression therapy.~If the wound is healed and until the wound healing confirmation visit, Venous Leg Ulcers (VLUs) allocated to the PICO group may be covered using a protective dressing.~If the wound meets the wound improvement criteria as assessed by the PI during the monthly visits, PICO treatment may be stopped."
48167181|NCT03116672|DRUG|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
48167182|NCT02046941|BEHAVIORAL|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
48167183|NCT05555615|DRUG|Pimavanserin|Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age
48167184|NCT03106298|DRUG|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
48167185|NCT02176837|DRUG|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
48370247|NCT01364506|OTHER|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
48514841|NCT03545893|DRUG|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
48696555|NCT06510777|DEVICE|Standard of Care (SOC) Treatment|"Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value."
48696556|NCT04553744|OTHER|Survey Administration|Complete survey
48696557|NCT01649674|DRUG|polyethylene glycole (PEG) solution|
48696558|NCT01649674|DRUG|sodium picosulphate and magnesium citrate solution|
48696559|NCT01809509|PROCEDURE|Endometrial biopsy|
48696560|NCT06486493|OTHER|Conventional treatment|Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
48009506|NCT05525819|DRUG|Control group|The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
48167186|NCT04924088|BEHAVIORAL|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
48514842|NCT00377832|DRUG|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
48514843|NCT01958138|DRUG|comparison of group-I (low dose propofol with isoflurane)|Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
48696561|NCT06486493|OTHER|Playful Family Education Strategy|"Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity."
48009507|NCT05525819|DRUG|Intrathecal group|The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
48009508|NCT05525819|DRUG|Intravenous group|The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
48167187|NCT04924088|BEHAVIORAL|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
48167188|NCT03307083|OTHER|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
48167189|NCT00578318|BEHAVIORAL|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
48167190|NCT03993496|DIAGNOSTIC_TEST|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~1. Prior to EVAR deployment~2. After EVAR deployment, but before balloon affixation to the aortic wall~3. After EVAR deployment and after affixation"
48167191|NCT03726983|OTHER|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
48370248|NCT02348710|BEHAVIORAL|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
48167192|NCT00004758|DRUG|carbamazepine|
48167193|NCT00004758|DRUG|corticotropin|
48370249|NCT02348710|BEHAVIORAL|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
48370250|NCT01869231|DIETARY_SUPPLEMENT|olive oil|
48370251|NCT01869231|DIETARY_SUPPLEMENT|olive oil and chewing gum|
48370252|NCT01869231|DIETARY_SUPPLEMENT|chewing gum|
48514844|NCT04947917|PROCEDURE|SpotTM Tattoo Ink|Ink injection
48514845|NCT01837134|DEVICE|telemedical (TM) group|telemedical devices (weighing machine and step counter)
48514846|NCT01837134|BEHAVIORAL|telemedical coaching (TMC) group|care calls once per week for 12 weeks
48514847|NCT02593643|DRUG|Ketamine|
48370253|NCT01869231|DIETARY_SUPPLEMENT|water|
48370254|NCT04738799|BEHAVIORAL|Carbohydrate-Last Meal Sequence|Carbohydrates consumed last during mealtimes for 6 days
48370255|NCT04738799|BEHAVIORAL|Carbohydrate-First Meal Sequence|Carbohydrates consumed first during mealtimes for 6 days
48514848|NCT02593643|DRUG|Midazolam|
48514849|NCT02593643|OTHER|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
48514850|NCT03456505|BEHAVIORAL|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
48696562|NCT06486493|OTHER|Reinforced Playful Family Education Strategy|The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
48696563|NCT02637414|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
48696564|NCT02485249|DRUG|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
48696565|NCT01278121|DIETARY_SUPPLEMENT|Diet A|3 days, 6 meals a day
48696566|NCT01278121|DIETARY_SUPPLEMENT|Diet B|10 days, 6 meals a day
48696567|NCT06485856|BEHAVIORAL|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
48696568|NCT06661564|OTHER|Basal tear collection for the analysis of metabo-lipidomic profiles and concentrations of protein biomarkers (Tau, phosphorylated Tau, Aβ 1-40, and Aβ 1-42)|Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers
48696569|NCT06661564|OTHER|Collection of a blood sample (5 mL) for blood biomarkers analysis|Collection of a blood sample (5 mL) for blood biomarkers analysis.
48696570|NCT03397524|OTHER|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
48696571|NCT05116319|DIAGNOSTIC_TEST|point-of-care HbA1c|The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
48696572|NCT03006848|DRUG|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
48696573|NCT03006848|OTHER|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
48696574|NCT06010641|OTHER|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
48696575|NCT05704023|BEHAVIORAL|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
48696576|NCT01893411|DRUG|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
48009509|NCT01844635|DRUG|Thymoglobulin|
48009510|NCT06330194|DEVICE|2nd Generation Automated Insulin Delivery (AID) system|The AID system will initially commence delivery by insulin pump post-randomisation without the AID in operation and with predictive low glucose suspend activated for a period of two weeks. Once safety has been established, the autocorrect function can be activated and the setpoint reduced to 5.5 mmol/L. Throughout the study insulin pump uploads will be reviewed twice weekly initially and at least weekly thereafter.
48009511|NCT02691767|DRUG|pazopanib|
48696577|NCT01893411|DRUG|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
48696578|NCT01893411|DRUG|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
48696579|NCT00316225|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
48696580|NCT03874741|DRUG|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
48696581|NCT03723330|DIETARY_SUPPLEMENT|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
48696582|NCT03723330|OTHER|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
48696583|NCT03016377|BIOLOGICAL|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)
48696584|NCT03016377|DRUG|Rimiducid|Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.
48696585|NCT03016377|DRUG|Cyclophosphamide|900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
48696586|NCT03016377|DRUG|Fludarabine|25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
48009512|NCT03858387|DRUG|Meropenem|"This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration."
48009513|NCT03858387|DRUG|Imipenem|"This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.~Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration."
48696587|NCT03192280|DRUG|Leukotriene B4|Leukotriene B4 (LTB4)
48696588|NCT03192280|DEVICE|FLIR One|Thermal imaging attachment to iPhone
48696589|NCT03192280|DEVICE|SCIO|Handheld near-IR molecular spectroscopy device
48696590|NCT03192280|DEVICE|MS Band 2|"Wearable watch-like device with multiple sensors"
48696591|NCT03192280|DEVICE|AGE reader|Portable bench top device for in-clinic near UV assessment
48009514|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12% and CITROX|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
48167194|NCT00004758|DRUG|nitrazepam|
48167195|NCT00004758|DRUG|pyridoxine|
48167196|NCT00004758|DRUG|valproic acid|
48167197|NCT00004758|PROCEDURE|Surgery|
48167198|NCT04633213|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
48167199|NCT04633213|DRUG|Placebo|Ophthalmic Solution
48167200|NCT03665753|DRUG|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
48009515|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12%|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
48167201|NCT03163836|PROCEDURE|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
48009516|NCT02273648|DEVICE|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
48167202|NCT03163836|PROCEDURE|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
48167203|NCT04961983|BEHAVIORAL|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~1. Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~   * The potential roles of tour guides in tourists' health,~  * The importance of travel health information for tourists,~  * Assessment of tourist's health risks,~  * Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~2. Weekly travel health Information sharing through WhatsApp group for 2 months."
48696592|NCT03192280|DEVICE|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
48696593|NCT03192280|DEVICE|iPhone 7|Smart phone
48009517|NCT00160316|DRUG|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
48009518|NCT04780425|BEHAVIORAL|DESMOND|as previously described
48167204|NCT02535962|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
48167205|NCT02535962|OTHER|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
48167206|NCT00306956|BEHAVIORAL|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
48167207|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
48167208|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
48167209|NCT06235853|DIAGNOSTIC_TEST|Blood serum: sUPAR, PAI-1, IL-8.|The concentration of described biomarkers were measured in serum.
48167210|NCT06235853|DIAGNOSTIC_TEST|Urine: IL-8, APOE, VEGF.|The concentration of described biomarkers were measured in urine.
48167211|NCT05166798|BEHAVIORAL|Cognitive control training|The five intervention groups will receive either 1, 5, 10, 15 or 20 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT).
48167212|NCT03334695|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.
48167213|NCT03334695|DRUG|Placebo|Placebo will be administered as sterile 0.9% saline for injection.
48370256|NCT02766699|DRUG|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
48370257|NCT01917396|DRUG|Fleet enema|
48696594|NCT06661629|DEVICE|Nerve stimulation|The intervention is testing the effect of bilateral genioglossus muscle stimulation on upper airway collapsibility during drug-induced sleep endoscopy in patients implanted with the Inspire hypoglossal nerve stimulator
48696595|NCT03804463|PROCEDURE|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
48696596|NCT03804463|PROCEDURE|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
48696597|NCT03804463|PROCEDURE|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
48696598|NCT03505723|DRUG|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
48696599|NCT03505723|DRUG|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
48696600|NCT03505723|OTHER|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
48009519|NCT04780425|OTHER|usual care|usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
48009520|NCT03373175|DEVICE|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
48009521|NCT03373175|DEVICE|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
48009522|NCT03373175|DEVICE|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
48009523|NCT03373175|DEVICE|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
48009524|NCT06347081|PROCEDURE|Nd- YAG laser at 532nm wavelength|Nd-YAG laser at 532nm wavelength every 2 weeks for 14 sessions. patients will also receive standard medical care, nursing, physiotherapy
48009525|NCT03256552|DRUG|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
48009526|NCT03256552|DRUG|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
48009527|NCT03256552|DRUG|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
48009528|NCT03256552|DRUG|Placebo MDI|Placebo Inhalation Aerosol
48009529|NCT00953329|DRUG|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
48009530|NCT03301324|DEVICE|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
48009531|NCT02488785|BEHAVIORAL|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
48009532|NCT02488785|DEVICE|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
48009533|NCT02488785|DEVICE|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
48009534|NCT00934206|BEHAVIORAL|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
48009535|NCT03148548|GENETIC|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;
48009536|NCT03129672|PROCEDURE|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
48009537|NCT05049161|DRUG|Temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
48009538|NCT05049161|DRUG|Temelimab 36mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
48009539|NCT05049161|DRUG|Temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
48009540|NCT03852316|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
48009541|NCT03434756|OTHER|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
48009542|NCT03151356|DEVICE|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the \[-2\]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = \[p2PSA /fPSA\] x √tPSA
48009543|NCT03430752|OTHER|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
48009544|NCT02085564|PROCEDURE|Peritoneal washing cytology|The methode is describes in the detailed study description
48370258|NCT01539616|DRUG|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
48696601|NCT03505723|OTHER|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
48009545|NCT00004412|DRUG|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
48009546|NCT00004412|OTHER|Standard local care dressing|To heal leg ulcers.
48009547|NCT00728377|BEHAVIORAL|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
48370259|NCT01539616|DRUG|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
48696602|NCT03772834|BEHAVIORAL|Exercise Intervention|Undergo resistance training and walking
48167214|NCT03238456|BEHAVIORAL|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
48167215|NCT02859558|DRUG|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants received one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food or one tablet of bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg by mouth daily with or without food. Other non-study-provided ARV regimens were allowed for participants who were pregnant, breastfeeding, or unable/unwilling to take EVG/COBI/FTC/TAF or BIC/FTC/TAF, or for participants whose local health care/primary care provider preferred starting a different initial ARV regimen.
48167216|NCT03932422|DIAGNOSTIC_TEST|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
48370260|NCT01539616|DRUG|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
48370261|NCT01539616|DRUG|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
48370262|NCT04203082|BEHAVIORAL|Exposure Intervention|Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
48696603|NCT03772834|DRUG|Methylphenidate|Given PO
48696604|NCT03772834|OTHER|Placebo|Given PO
48696605|NCT03772834|OTHER|Quality-of-Life Assessment|Ancillary studies
48696606|NCT03772834|OTHER|Questionnaire Administration|Ancillary studies
48696607|NCT03772834|OTHER|Stretching|Undergo stretching
48696608|NCT04088240|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
48696609|NCT04088240|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
48696610|NCT04088240|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
48009548|NCT00728377|BEHAVIORAL|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
48696611|NCT05259137|DRUG|Intralesional enalaprilat injection|1.0 mL of 1.25 mg/mL enalaprilat
48009549|NCT06078046|BEHAVIORAL|Mind-body interventions|Parallel randomized controlled trial
48009550|NCT03265119|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
48009551|NCT03265119|DRUG|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
48009552|NCT05313165|DEVICE|LimFlow Stent Graft System|Creation of an arteriovenous fistula in the desired limb location
48009553|NCT03144180|DEVICE|Q-cup|This technology is a different way of collecting umbilical cord blood.
48009554|NCT03277846|DEVICE|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
48009555|NCT01719692|DRUG|Rituximab|
48009556|NCT06357637|DIAGNOSTIC_TEST|Measure of abdominal circumference|Measure of abdominal circumference preoperatively in both sitting and lying position
48009557|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
48009558|NCT01342562|DRUG|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
48009559|NCT04223076|DRUG|Chlorhexidine 0.2%, Corsodyl|Comparison of Corsodyl and Curasept
48009560|NCT04223076|DRUG|Chlorhexidine 0.2%, Curasept|Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
48009561|NCT00998634|DRUG|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
48009562|NCT01176552|DRUG|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
48009563|NCT04380857|DRUG|Dexamethasone ophthalmic insert 0.4 mg|intracanalicular dexamethasone insert
48009564|NCT04380857|DRUG|Topical Prednisolone Acetate Ophthalmic Drops|"Topical Prednisolone acetate ophthalmic drops per standard of care:~Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue"
48009565|NCT01002144|OTHER|blood sampling|
48009566|NCT05875038|OTHER|video system|The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.
48696612|NCT00239993|DRUG|glatiramer acetate|
48696613|NCT00239993|PROCEDURE|Warm compress prior to injection of glatiramer acetate|
48514851|NCT03456505|BEHAVIORAL|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
48514852|NCT05998629|DEVICE|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels|a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels
48514853|NCT05998629|OTHER|Standard of Care laboratory procedure for measurement of sweat|a skin-interface sweat measurement using a smart-watch type device
48514854|NCT00750685|DEVICE|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
48696614|NCT01961856|DRUG|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
48696615|NCT01961856|DRUG|Ticagrelor|Ticagrelor 180mg loading dose
48009567|NCT05875038|OTHER|Tele-alarm|Tele-alarm
48009568|NCT00365248|DRUG|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
48009569|NCT00937638|DIETARY_SUPPLEMENT|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
48009570|NCT00937638|DIETARY_SUPPLEMENT|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
48009571|NCT00937638|DIETARY_SUPPLEMENT|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
48009572|NCT01825369|DRUG|IV L-carnitine|See arm description
48009573|NCT01482780|DEVICE|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
48009574|NCT01544712|PROCEDURE|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
48009575|NCT01544712|PROCEDURE|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
48167217|NCT06646081|PROCEDURE|Greater Occipital Nerve Block|The patient is placed prone with the head neutral or slightly flexed. After sterile preparation, a high-frequency linear probe is positioned transversely at the upper nuchal line in the occipital region. The Greater Occipital Nerve, exiting from the posterior root of C2, is located near the occipital artery. Using an in-plane technique, a 25-gauge needle is inserted into the fascial plane around the artery. After confirming no intravascular placement by negative aspiration, 5 mL of a mixture of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
48167218|NCT06646081|PROCEDURE|Stellate Ganglion Block|The patient lies supine with a pillow under the shoulders, and the head slightly extended, neck gently turned opposite to the blockade. After sterile preparation, a high-frequency linear probe is placed transversely at the C6 vertebra (Chassaignac's tubercle). Ultrasound identifies the C6 vertebra, Longus colli muscle, carotid artery, and internal jugular vein. The Stellate Ganglion is located within the prevertebral fascia over the Longus colli. Using an in-plane technique, a 25-gauge needle is inserted and advanced into the prevertebral fascial plane. After confirming no intravascular placement by negative aspiration, 5 mL of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
48370263|NCT04203082|OTHER|Usual Care|Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
48370264|NCT03986905|DRUG|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
48370265|NCT03986905|OTHER|Placebo|placebo nasal gel + placebo patch
48370266|NCT01992146|DRUG|Target-controlled naloxone-infusion|
48370267|NCT01992146|DRUG|Placebo|
48370268|NCT04893174|BIOLOGICAL|UMC119-06-05|"Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.~Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05"
48370269|NCT04893174|DEVICE|Hyaluronic acid|IA injection of hyaluronic acid.
48370270|NCT04311515|RADIATION|Tau Positron emission tomography (PET)|Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
48370271|NCT04311515|RADIATION|Fluorodeoxyglucose (FDG) Positron emission tomography (PET)|Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
48370272|NCT04311515|DIAGNOSTIC_TEST|Cerebrospinal fluid (CSF) Biomarkers|A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
48167219|NCT05481398|OTHER|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy comprising of a single layer of sterile gauze followed by placement of a 18 Fr nelaton catheter and the wound further covered with 4 more layers of sterile gauze over the nelaton catheter. The wound is then covered with opsite dressing making it airtight. The nelaton catheter is attached to the wall suction port once the patient is shifted to the bed with pressure set at - 25 mm Hg.
48167220|NCT02107547|PROCEDURE|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
48696616|NCT00657293|BEHAVIORAL|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
48167221|NCT02107547|PROCEDURE|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
48167222|NCT04441827|OTHER|breathing exercise|Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)
48167223|NCT04677933|DRUG|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
48167224|NCT04677933|DRUG|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
48167225|NCT04677933|DRUG|C: Placebo|10 patients will receive Placebo BIW
48370273|NCT04311515|DIAGNOSTIC_TEST|Blood Biomarkers|Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
48370274|NCT04311515|BEHAVIORAL|Rating Scales|Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
48696617|NCT00657293|BEHAVIORAL|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
48370275|NCT04311515|DRUG|PU-AD|PU-AD 30mg daily for 6mos
48696618|NCT01226641|DEVICE|Telemedicine|CPAP treatment with telemedicine system
48696619|NCT01226641|DEVICE|Standard care|Standard care, including CPAP
48696620|NCT00884962|DEVICE|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
48696621|NCT06659549|DRUG|GAL-101|Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
48696622|NCT06659549|DRUG|Placebo|Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
48696623|NCT04622670|OTHER|Media Intervention|Receive DVD
48696624|NCT04622670|OTHER|Quality-of-Life Assessment|Ancillary studies
48696625|NCT04622670|OTHER|Questionnaire Administration|Ancillary studies
48696626|NCT04622670|OTHER|Survey Administration|Ancillary studies
48696627|NCT04622670|PROCEDURE|Yoga|Attend yoga class
48696628|NCT00412347|DRUG|Insulin Drip Therapy|
48009576|NCT05588024|DEVICE|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
48009577|NCT03279276|PROCEDURE|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
48009578|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
48009579|NCT03083691|DRUG|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
48009580|NCT03318848|OTHER|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
48009581|NCT04751591|PROCEDURE|Endoscopic resection|Endoscopic submucosal dissection (ESD) or endoscopic full-thickness resection (EFTR) for patients with 2-5cm gastric GISTs
48009582|NCT04751591|PROCEDURE|Laparoscopic partial gastrectomy|Laparoscopic partial gastrectomy for patients with 2-5cm gastric GISTs
48009583|NCT02423265|DRUG|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
48514855|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
48696629|NCT03589989|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
48696630|NCT03589989|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
48696631|NCT02304887|DRUG|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
48696632|NCT02748668|OTHER|Blood specimen collection|
48696633|NCT02256384|DEVICE|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
48696634|NCT02350166|PROCEDURE|laparoscopic surgery|laparoscopic-assisted small-incision surgery
48696635|NCT04227275|BIOLOGICAL|CART-PSMA-TGFβRDN|Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
48696636|NCT04227275|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
48696637|NCT04227275|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
48696638|NCT04227275|DRUG|Anakinra|In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
48696639|NCT05031091|OTHER|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
48696640|NCT02578966|BEHAVIORAL|Motivational Interview|
48696641|NCT02578966|OTHER|Traditional health education|
48696642|NCT05053152|DRUG|Placebo Administration|Given PO
48696643|NCT05053152|OTHER|Quality-of-Life Assessment|Ancillary studies
48696644|NCT05053152|DRUG|Relugolix|Given PO
48696645|NCT05053152|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
48009584|NCT02423265|DRUG|Placebo|Matching placebo: up-titration after 1 week
48009585|NCT04877262|OTHER|weight maintenance diet (WMD)|A diet meeting the participant's weight maintenance energy needs will be provided.
48009586|NCT01280773|DEVICE|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
48009587|NCT03626116|PROCEDURE|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
48167226|NCT04978012|DRUG|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
48167227|NCT05590806|OTHER|Direct composite build-ups|Direct composite build-ups application
48167228|NCT00922441|DRUG|Fimasartan 60 mg group|Fimasartan 60 mg
48167229|NCT00922441|DRUG|Fimasartan 120 mg group|Fimasartan 120 mg
48514856|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
48514857|NCT03198676|DRUG|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
48514858|NCT03198676|DRUG|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
48009588|NCT01578044|BEHAVIORAL|Intervention|"1. Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~2. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~3. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
48009589|NCT01578044|OTHER|Control|Usual care
48009590|NCT04361461|DRUG|Hydroxychloroquine Sulfate|400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.
48009591|NCT04361461|DRUG|Hydroxychloroquine Sulfate + Azythromycin|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
48009592|NCT05090020|PROCEDURE|Treatment|Surgery and PAIR
48167230|NCT00922441|DRUG|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
48167231|NCT00155883|DRUG|Taxteral|
48167232|NCT00155883|DRUG|5-Fluorouracil|
48167233|NCT00155883|DRUG|Leucovorin|
48167234|NCT00387907|DRUG|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
48167235|NCT00387907|DRUG|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
48167236|NCT00632723|DRUG|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
48009593|NCT03296163|DRUG|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
48167237|NCT01490359|BEHAVIORAL|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
48167238|NCT01490359|BEHAVIORAL|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
48167239|NCT01558778|PROCEDURE|management of therapy complications|Undergo mechanical stimulation
48167240|NCT01558778|PROCEDURE|musculoskeletal complications management/prevention|Undergo mechanical stimulation
48696646|NCT00123162|DRUG|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
48696647|NCT00123162|DRUG|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
48696648|NCT04522336|DRUG|Docetaxel|Given IV
48696649|NCT04522336|DRUG|Fluorouracil|Given IV
48696650|NCT04522336|DRUG|Oxaliplatin|Given IV
48696651|NCT04522336|BIOLOGICAL|Pembrolizumab|Given IV
48696652|NCT04522336|RADIATION|Radiation Therapy|Receive radiation therapy
48009594|NCT03296163|DRUG|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
48167241|NCT05784649|OTHER|health education|"The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals."
48167242|NCT05784649|BEHAVIORAL|individual counsel|The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
48167243|NCT01187407|DRUG|LY2216684|
48167244|NCT01187407|DRUG|Placebo|
48167245|NCT01187407|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
48696653|NCT01040091|DRUG|Emtricitabine (FTC)|200 mg once a day
48696654|NCT01040091|DRUG|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
48696655|NCT01040091|DRUG|Efavirenz (EFV)|600 mg once a day
48696656|NCT01040091|DRUG|Truvada|200 mg emtricitabine + 300 mg TDF once a day
48696657|NCT06592911|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
48514859|NCT03456141|PROCEDURE|third molar surgery|The patient is asked to complete the diary each post-surgery day for 14 days. Recovery is organized into three QOL domains: lifestyle, oral function, and pain.
48167246|NCT00000521|BEHAVIORAL|diet, sodium-restricted|
48167247|NCT00000521|BEHAVIORAL|diet, potassium-supplemented|
48167248|NCT05086341|DEVICE|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
48167249|NCT04265911|BIOLOGICAL|ASP3772 (subcutaneous)|Subcutaneous injection
48167250|NCT04265911|BIOLOGICAL|ASP3772 (intramuscular)|Intramuscular injection
48167251|NCT04265911|BIOLOGICAL|PPSV23 (subcutaneous)|Subcutaneous injection
48167252|NCT04265911|BIOLOGICAL|PPSV23 (intramuscular)|Intramuscular injection
48167253|NCT03394183|OTHER|Cardiac Rehabilitation|Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
48167254|NCT04106583|DEVICE|WAVE, as part of the SMART COIL System|WAVE, as part of the SMART COIL System
48167255|NCT01362283|OTHER|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
48167256|NCT01661530|DIETARY_SUPPLEMENT|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
48167257|NCT01661530|DIETARY_SUPPLEMENT|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
48167258|NCT01792778|DEVICE|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
48167259|NCT01792778|DEVICE|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
48167260|NCT03691142|OTHER|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
48167261|NCT02881021|OTHER|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
48167262|NCT02881021|DEVICE|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
48167263|NCT02669134|OTHER|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
48167264|NCT05866341|DIETARY_SUPPLEMENT|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
48514860|NCT01783795|OTHER|Genetic Analysis|
48514861|NCT01328522|DRUG|SAR153191 (REGN88)|"Pharmaceutical form:solution~Route of administration: subcutaneous"
48514862|NCT03210792|DEVICE|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
48514863|NCT01559883|OTHER|no intervention is being made|This is a Non-Interventional Study (NIS)
48167265|NCT05866341|DIETARY_SUPPLEMENT|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
48167266|NCT04929054|DIAGNOSTIC_TEST|imaging|ultrasound and contrast enhanced ultrasound for BI RADS4A breast modules
48167267|NCT02299427|BEHAVIORAL|dog safety|use of dog safety website at home for about 2 weeks
48167268|NCT02299427|BEHAVIORAL|transportation safety|use of transportation safety website at home for about 2 weeks
48167269|NCT00332488|DRUG|Technosphere Insulin|Inhalation, 15U/30U, prandial
48167270|NCT00332488|DRUG|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
48514864|NCT00235677|PROCEDURE|Endoscopic gastroplication|
48514865|NCT01134432|DRUG|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"
48514866|NCT01134432|DRUG|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
48514867|NCT04843696|DEVICE|cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)|the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12\~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.
48514868|NCT04843696|BEHAVIORAL|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
48167271|NCT00332488|DRUG|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
48167272|NCT00449436|DRUG|TRIZIVIR|TRIZIVIR
48167273|NCT00449436|DRUG|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
48167274|NCT00449436|DRUG|Boosted Protease Inhibitor|Boosted Protease Inhibitor
48370276|NCT04311515|DRUG|Placebo|Placebo 30mg daily for 6mos
48370277|NCT03705858|DRUG|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
48009595|NCT03296163|DRUG|Carboplatin|Carboplatin Area under the curve (AUC) 6 IV every 3 weeks on Day 1 for 6 cycles
48009596|NCT03296163|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
48009597|NCT04420702|DEVICE|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
48009598|NCT03968458|BEHAVIORAL|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48009599|NCT03968458|BEHAVIORAL|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48167275|NCT06234813|OTHER|Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen|"TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~1. 500 µL of whole blood for each point;~2. 7 points for each condition;~3. Around 4 mL of whole blood will be needed for each patient or healthy subject;~4. Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported."
48167276|NCT06234813|OTHER|: PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM|"ROTEM (single measurements)~1. ROTEM cups will be added~   * 20 µL calcium reagent (STARTEM)~  * 20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~  * 300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~2. Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported."
48167277|NCT06234813|OTHER|Thrombin Generation Assay (TGA) in PRP using TF trigger|"TGA (single measurements)~1. The following will be added to well:~   * 20 uL of PRP-Reagent~  * 80 uL of spiked PRP (600 µL/patient at 100 G/L)~  * 20 uL FluCa~2. Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported."
48167278|NCT06234813|OTHER|Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis|Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min
48167279|NCT06234813|OTHER|Concizumab|Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
48167280|NCT01705145|DRUG|Ivacaftor|
48167281|NCT00344539|BIOLOGICAL|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
48167282|NCT00344539|BIOLOGICAL|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
48167283|NCT02946450|DRUG|Other: Not applicable-observational study|
48009600|NCT03968458|BEHAVIORAL|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48167284|NCT02950714|OTHER|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
48514869|NCT00679133|DRUG|MGCD265|Oral daily administration; 7 days on / 7 days off
48514870|NCT05843747|OTHER|Sampling|During thier bariatric surgery, samples of adipose tissue will be done
48514871|NCT02568605|DIETARY_SUPPLEMENT|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
48514872|NCT02568605|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48514873|NCT02568605|BEHAVIORAL|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
48514874|NCT02089659|DRUG|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
48514875|NCT05748951|DEVICE|Canalicular occlusion device|Occlusive device is inserted into the tear duct to block tear drainage
48009601|NCT01417403|DRUG|hydroxychloroquine|Given PO
48514876|NCT03305627|OTHER|Short PAP|Perioperative antibiotic prophylaxis for 24h
48514877|NCT03305627|OTHER|Extended PAP|Perioperative antibiotic prophylaxis for \>48h
48696658|NCT04823923|OTHER|blood sampling for ITK dosage|Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
48009602|NCT01417403|RADIATION|radiation therapy|Undergo radiotherapy
48009603|NCT03365284|DEVICE|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
48696659|NCT04074694|PROCEDURE|Sialoendoscopy|Sialoendoscopy
48696660|NCT04918290|DEVICE|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
48514878|NCT01776931|DIETARY_SUPPLEMENT|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
48514879|NCT01657435|DEVICE|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
48514880|NCT04548765|BEHAVIORAL|Letter|Recipients receive a letter promoting CRC screening.
48514881|NCT04548765|BEHAVIORAL|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
48514882|NCT04548765|BEHAVIORAL|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
48514883|NCT04548765|BEHAVIORAL|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
48514884|NCT04548765|BEHAVIORAL|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
48514885|NCT02688660|OTHER|MRI Scans|
48696661|NCT04918290|DEVICE|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
48696662|NCT05645406|DRUG|Estrogel 0.06 % Topical Gel|estradiol topical products
48696663|NCT05645406|DRUG|Compounded estradiol product|estradiol topical products
48514886|NCT03254264|BEHAVIORAL|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
48009604|NCT03365284|OTHER|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
48167285|NCT02950714|OTHER|LIN_WAIT|Usual care for three months prior to access to the LIN
48167286|NCT01994538|OTHER|Longer therapy duration|14 days of antimicrobial treatment
48514887|NCT03254264|BEHAVIORAL|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
48514888|NCT02918812|DRUG|Intracervical lidocaine|Intracervical lidocaine injected at four different points
48514889|NCT02918812|DRUG|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
48514890|NCT01931878|DRUG|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
48696664|NCT00566982|DRUG|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
48009605|NCT01485861|DRUG|Abiraterone|Orally once daily
48009606|NCT01485861|DRUG|Apitolisib|Orally once daily
48009607|NCT01485861|DRUG|Ipatasertib|Orally once daily
48009608|NCT01485861|DRUG|Placebo|Orally once daily
48167287|NCT01994538|OTHER|Shorter therapy duration|7 days of antimicrobial treatment
48167288|NCT02897999|BIOLOGICAL|QBKPN|QBKPN Site Specific Immunomodulators
48696665|NCT00566982|DRUG|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
48696666|NCT01098188|DRUG|LFB-R603|intravenous administration, dose-escalation study
48696667|NCT05348993|DRUG|G03-52-01|G03-52-01 administered intramuscularly
48696668|NCT05348993|DRUG|Placebo|placebo
48696669|NCT02921217|DIETARY_SUPPLEMENT|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
48696670|NCT02921217|DIETARY_SUPPLEMENT|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
48696671|NCT02921217|DIETARY_SUPPLEMENT|Control|Placebo: 300 mg maltodextrin.
48696672|NCT01033006|PROCEDURE|Active Comparator: Arm 1: catheter injection|
48696673|NCT01033006|PROCEDURE|Active Comparator: Arm 2: transarterial injection|
48696674|NCT01033006|PROCEDURE|Active Comparator: Arm 3: catheter and transarterial injection|
48696675|NCT03522324|DRUG|Cannabis Edible|Self-Directed Use (ad-libitum)
48696676|NCT02326168|DRUG|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
48696677|NCT03556592|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
48696678|NCT03556592|DRUG|Caffeine|1x 100 mg tablet
48009609|NCT01485861|DRUG|Prednisone|Orally bid
48009610|NCT01485861|DRUG|Prednisolone|Orally bid
48009611|NCT02224872|PROCEDURE|Bone marrow transplant|Day 0
48167289|NCT02897999|OTHER|Placebo|Placebo
48167290|NCT00468858|OTHER|Placebo|"Lyophilized, single dose vials and sterile water for~\> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
48009612|NCT02224872|DRUG|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
48009613|NCT02224872|DRUG|Fludarabine|30 mg/M2 IV on days -6 to -2
48696679|NCT03556592|DRUG|Warfarin|2x 5 mg tablets
48696680|NCT03556592|DRUG|Omeprazole|1x 20 mg capsule
48009614|NCT02224872|DRUG|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
48009615|NCT02224872|RADIATION|TBI|200 cGy on day -1
48514891|NCT01931878|DRUG|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
48696681|NCT03556592|DRUG|Metoprolol|1x 100 mg tablet
48696682|NCT03556592|DRUG|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
48696683|NCT04559893|BEHAVIORAL|Collaborative Care|Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
48696684|NCT04414592|OTHER|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
48696685|NCT06661005|DRUG|Nitrous oxide|The Nitrous oxide group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
48009616|NCT02224872|DRUG|Mesna|40 mg/kg IV on days 3, 4
48009617|NCT02224872|DRUG|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
48696686|NCT06661005|DRUG|IV Sedation|Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
48696687|NCT01766739|BIOLOGICAL|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
48009618|NCT02224872|DRUG|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
48009619|NCT05178849|OTHER|Hypnosis|Hypnosis
48009620|NCT05178849|DRUG|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
48696688|NCT01237457|DRUG|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
48696689|NCT05984758|DIAGNOSTIC_TEST|AS-OCT imaging|Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
48696690|NCT05984758|DIAGNOSTIC_TEST|Slit lamp examination|SLE of anterior chamber
48009621|NCT06232382|OTHER|Hypnosis audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Hypnosis audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session (5 minutes).~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires (5 minutes).~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
48009622|NCT06232382|OTHER|Mindfulness meditation audio|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Mindfulness Meditation audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
48167291|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
48167292|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
48167293|NCT03262155|BIOLOGICAL|Blood test|
48167294|NCT00873678|BIOLOGICAL|Whole blood sample|Whole blood sample (10 ml)
48167295|NCT03231761|OTHER|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
48167296|NCT03231761|OTHER|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
48167297|NCT03042858|OTHER|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
48167298|NCT03042858|OTHER|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
48167299|NCT00277342|PROCEDURE|measurement of lipid-induced hepatic insulin resistance|
48167300|NCT05074277|BEHAVIORAL|Simulated short term night shift work schedule|Participant sleep schedules (in the experimental arm) will be modified to simulate short-term (3 consecutive nights) night shift work schedule (kept awake at night and offered sleep opportunities during the day instead) in each of two inpatient stays.
48167301|NCT01628341|DRUG|insulin|Patients will be asked to complete 2 self-assessment questionnaires
48167302|NCT03471390|OTHER|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
48167303|NCT02650726|DIETARY_SUPPLEMENT|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
48167304|NCT02650726|OTHER|Placebo|placebo 320mg daily for 24 weeks
48167305|NCT02274519|OTHER|Tai Chi|Arm 1
48167306|NCT02274519|OTHER|Education|Arm 2
48167307|NCT02325583|DRUG|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
48167308|NCT02325583|DRUG|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
48167309|NCT00257764|BEHAVIORAL|behavioral swallowing exercises/ strategies|
48167311|NCT04462497|OTHER|Prototype device|Patients will receive the prototype head and neck support device to be used intraoperatively.
48167312|NCT06478732|OTHER|health services|Implement comprehensive heart failure management for patients in the experimental group using the HeartMed-HF digital therapy
48167313|NCT01547247|DEVICE|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
48167314|NCT01547247|PROCEDURE|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
48167315|NCT00802438|BIOLOGICAL|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
48167316|NCT02251197|DRUG|BIII 890 CL|
48167317|NCT02251197|DRUG|Placebo|
48167318|NCT02681445|DEVICE|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
48514892|NCT00822692|DRUG|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
48167319|NCT00601471|OTHER|proximal tibiofibular manipulation|proximal tibiofibular manipulation
48167320|NCT00601471|OTHER|distal tibiofibular manipulation|distal tibiofibular manipulation
48167321|NCT00601471|OTHER|no intervention|no intervention / control
48167322|NCT06389929|BEHAVIORAL|Education|In line with the skill they will determine for one of the applications in the Skill Checklists (Breastfeeding Education Skill Control Form, Breast Care and Giving Care to Mothers with Breast Engorgement Skill Control Form, Breast Self-Examination (KKMM) Training Skill Control Form) apply.
48167323|NCT03853642|OTHER|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
48167324|NCT00445861|BIOLOGICAL|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
48167325|NCT00445861|BIOLOGICAL|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
48167326|NCT00445861|BIOLOGICAL|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
48167327|NCT00445861|PROCEDURE|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
48167328|NCT03738254|OTHER|The Guardians: A smartphone game|"The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey."
48167329|NCT03738254|OTHER|Paper Survey|Paper version of daily survey
48167330|NCT03738254|OTHER|Electronic Survey|Electronic version of daily survey administered via a smartphone app.
48167331|NCT04977297|BEHAVIORAL|Move to Music Intervention (M2M)|The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
48370278|NCT01085331|DRUG|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
48009623|NCT06232382|OTHER|Natural text audio (control audio)|"* After informed consent was obtained and baseline assessment, patients will be randomly assigned to one of the three conditions in 20 minutes:~  1. Audio hypnosis (HYP)~ 2. Audio mindfulness (MM)~ 3. A control condition (a voice reading neutral text) These audios will be produced together with hypnotherapist in Thailand, psychiatrist and researchers.~* The randomization process will be performed using a computerized random sequence generator.~* The patient listens to Control audio recording through headphones in a private room.~* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios.~* Pain intensity will be assessed both at pre- and post-session. (5 minutes)~* Secondary outcomes will be assessed at pre- and post-session by the questionnaires. (5 minutes)~* Post-session quality of sleep will be assessed by telephone interview 1 day after session."
48009624|NCT01852292|DRUG|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
48167332|NCT04977297|BEHAVIORAL|Move to Music -Video (M2M-V) Intervention|The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
48514893|NCT00822692|DRUG|placebo|matched placebo 2 pills PO BID x 7 days
48514894|NCT01382537|DEVICE|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
48514895|NCT01382537|DEVICE|InterX 5000|Placebo treatment
48514896|NCT06403254|PROCEDURE|There isn't an intervention name because the study is observational and has only one group.|Follow-up after surgey
48514897|NCT00171665|DRUG|Diclofenac topical sodium gel 1%|
48514898|NCT04045353|BEHAVIORAL|Low carbohydrate diet education|A 200 page informational document that connects with an online application will be provided to subjects.
48514899|NCT04045353|BEHAVIORAL|Low carbohydrate diet education with behavioral component|A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
48514900|NCT05248802|DRUG|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
48167333|NCT06230133|BEHAVIORAL|MBSR intervention|In our study, it is the same to arm description.
48514901|NCT05248802|DRUG|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
48514902|NCT05709210|OTHER|Recording of smartphone usage data|Recording of smartphone usage data
48514903|NCT01236443|DRUG|HPPH|3 mg/m2 IV
48009625|NCT01852292|DRUG|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
48167334|NCT06043453|OTHER|revitalization|The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
48167335|NCT03618927|BEHAVIORAL|Daily physical activity intervention|
48167336|NCT04146285|DRUG|BAT4406F|"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."
48514904|NCT06156332|DRUG|surufatinib、serplulimab|"surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment."
48514905|NCT05434689|DRUG|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
48514906|NCT05434689|DRUG|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
48514907|NCT05434689|DRUG|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
48514908|NCT05434689|DRUG|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
48009626|NCT01852292|DRUG|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m\^2.
48167337|NCT01620307|DRUG|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
48167338|NCT06161818|DRUG|FLOT-CROSS or CROSS-FLOT|Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT
48514909|NCT06550856|PROCEDURE|SUTURE-CLOSURE OMENTOPEXY IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired using full thickness suture closure using 3/0 vicryl suture then omental patch laied over the sutures.
48514910|NCT06550856|PROCEDURE|OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired by using omental patch without any attempt for primary closure of perforation.
48514911|NCT03840187|DIAGNOSTIC_TEST|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
48514912|NCT05537350|DIETARY_SUPPLEMENT|Lumenato|Supplementation of 12 weeks
48514913|NCT03486366|OTHER|non interventional trial|other
48696691|NCT00345566|PROCEDURE|Nutrition composition|
48167339|NCT05253911|DRUG|TUKYSA®|tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.
48167340|NCT01648985|OTHER|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
48514914|NCT03245411|BEHAVIORAL|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
48696692|NCT03849820|DEVICE|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
48696693|NCT03849820|OTHER|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
48696694|NCT06661317|OTHER|no intervention|no intervention
48514915|NCT01267487|DRUG|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
48514916|NCT01267487|DRUG|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
48167341|NCT03283878|DRUG|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
48167342|NCT05600036|DRUG|ESK-001|Oral tablet
48167343|NCT05600036|DRUG|Placebo|Oral tablet
48167344|NCT02862652|OTHER|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
48514917|NCT01267487|DRUG|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
48514918|NCT03802071|DRUG|Durvalumab+doxorubicin cobination|Durvalumab 1500mg IV Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
48514919|NCT02370524|DRUG|[18F]T807|All enrolled subjects will undergo an \[18F\]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
48514920|NCT00137761|DRUG|ZD 1839|Taken orally once daily
48696695|NCT00000293|DRUG|Nefazodone|
48696696|NCT01397110|OTHER|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
48696697|NCT06660238|OTHER|No interventions|No interventions
48167345|NCT03285633|BEHAVIORAL|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
48167346|NCT06208800|OTHER|Blend Aromatherapy|Inhalation of a mixture of essential oils of peppermint, palmarosa for 10 minutes at 11:00 am during the day and vetiver, cedar, clary sage, musk sage, grapefruit and petitgrain for 10 minutes at 21:30 pm before bedtime for 4 weeks
48167347|NCT02434523|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
48167348|NCT02434523|OTHER|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
48370279|NCT01085331|DRUG|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
48514921|NCT00137761|DRUG|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
48696698|NCT05456542|DIAGNOSTIC_TEST|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
48696699|NCT05456542|DRUG|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
48696700|NCT01402557|BEHAVIORAL|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
48696701|NCT01402557|BEHAVIORAL|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
48696702|NCT01402557|BEHAVIORAL|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
48009627|NCT03059381|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
48009628|NCT02214147|DRUG|Alisertib|Alisertib will be supplied as enteric coated tablets.
48009629|NCT01454934|DRUG|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
48167349|NCT06222775|BEHAVIORAL|Group session 1|"This session will have 3 editions in which the 50 participants of the experimental group will be distributed, with about 16 to 17 participants per edition.~Its objective is to know the group and their expectations, in addition to providing basic knowledge about diabetes and a healthy lifestyle."
48167350|NCT06222775|BEHAVIORAL|Group session 2|"The sessions for the 5 groups will take place within 2 weeks. Two weeks after the 1st session, the 2nd session-workshop will be scheduled with no more than 10 participants. For this, 5 groups will be made. An attempt will be made to ensure that the participants in the groups remain stable.~Its objective is to pave the way for the change to a healthy eating lifestyle and provide patients with sufficient knowledge so that with theory they can prepare a daily group menu according to the caloric needs of each of the participants."
48167351|NCT06222775|BEHAVIORAL|Group session 3|Its general objective is to motivate the change towards healthy eating. And the specific ones develop a weekly menu according to calorie needs.
48167352|NCT06222775|BEHAVIORAL|Group session 4|Its general objective is to reinforce a healthy lifestyle-eating, and the specific ones are to learn to read labels, preparing a weekly menu in a group.
48167353|NCT06222775|BEHAVIORAL|Group session 5|Its general objective is to reinforce lifestyle-physical activity. And the specific objectives are to recognize that it is a moderate physical activity and the goal to achieve of recommended physical activity per week and plan a week of physical activity.
48696703|NCT06659172|DEVICE|taVNS|transauricular vagus nerve stimulation
48696704|NCT05627011|BEHAVIORAL|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
48009630|NCT01454934|DRUG|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"* Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
48009631|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
48514922|NCT03744624|PROCEDURE|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
48514923|NCT03744624|DEVICE|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
48514924|NCT00008307|BIOLOGICAL|anti-thymocyte globulin|
48514925|NCT00008307|DRUG|cyclosporine|
48514926|NCT00008307|DRUG|fludarabine phosphate|
48514927|NCT00008307|DRUG|melphalan|
48514928|NCT00008307|DRUG|methylprednisolone|
48514929|NCT00008307|DRUG|mycophenolate mofetil|
48514930|NCT00008307|PROCEDURE|allogeneic bone marrow transplantation|
48514931|NCT00008307|PROCEDURE|peripheral blood stem cell transplantation|
48514932|NCT00008307|PROCEDURE|syngeneic bone marrow transplantation|
48514933|NCT05114876|OTHER|Multicomponent delirium-risk prevention bundle|"This multidisciplinary intervention will introduce new practices including:~1. Direct-to-Patient Education Program~2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~4. Reinforce CHASM best practices with regular educational sessions for nurses."
48514934|NCT04736225|OTHER|Insulin Self-Titration Education Program|The program contents of instruction included blood glucose self-monitoring, types of insulin, insulin self-administration, insulin dose titration, hyperglycemia or hypoglycemia self-management, diet, and exercise.a 20-min one-on-one training session from a nurse on how to self-titrate the insulin dose. The participants were taught to monitor their before-breakfast and before-dinner blood glucose levels at home and adjust their insulin doses accordingly.
48514935|NCT01954862|OTHER|Air Insufflation method.|Air Insufflation method.
48514936|NCT01954862|OTHER|CO2 insufflation|CO2 insufflation.
48514937|NCT01954862|OTHER|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
48514938|NCT01954862|OTHER|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
48514939|NCT01954862|OTHER|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
48514940|NCT01954862|OTHER|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
48009632|NCT00763659|DIETARY_SUPPLEMENT|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
48009633|NCT00763659|DIETARY_SUPPLEMENT|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
48009634|NCT05857605|OTHER|Exercise for Knee Osteoarthritis|Standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
48167354|NCT06222775|BEHAVIORAL|Group session 6|Its general objective is to reinforce a lifestyle-healthy eating and physical activity. And the specific ones are to reinforce the concept of physical activity in diabetes, what to do with hypoglycemia and adjust diet and exercise to current weight and needs.
48514941|NCT03289819|DRUG|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
48009635|NCT05857605|DEVICE|Compact seated elliptical exercise machine- Cubii JR-1|Compact seated elliptical machine exerice program in conjunction with standard physical therapy exercise instructions based on Arthritis Foundation guidelines for physical activity specific to individuals with knee osteoarthritis.
48009636|NCT03199703|DEVICE|Baylis transseptal system group|
48009637|NCT03199703|DEVICE|Standard conventional transseptal group|
48167355|NCT06222775|BEHAVIORAL|Group session 7 to 8|The objective will be to maintain a healthy lifestyle and adjust menus and physical activity to current caloric needs, in addition to sharing experiences.
48514942|NCT03289819|DRUG|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
48167356|NCT06222775|BEHAVIORAL|Group session 9|"In the final session, a certificate of adherence to healthy living will be delivered, reminding you to continue with the acquired habits and attend scheduled consultations and tests.~The days of the sessions are indicative, but they must be held in the week when the specified period of time between session and session is met."
48514943|NCT03289819|DRUG|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
48514944|NCT03289819|DRUG|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
48514945|NCT01391715|DRUG|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
48514946|NCT01391715|DRUG|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
48514947|NCT03020771|BIOLOGICAL|KIRIM-KONGO-VAX|Crimean-Congo Hemorrhagic Fever Vaccine
48514948|NCT03020771|OTHER|Placebo|
48522847|NCT04677335|DIETARY_SUPPLEMENT|AB-LIFE with Monacolin K|Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
48514949|NCT01106079|DRUG|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
48514950|NCT01106079|DRUG|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
48514951|NCT03333265|DRUG|100mg Berberine hydrochloride|patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
48514952|NCT03333265|DRUG|300mg Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
48514953|NCT03333265|DRUG|Placebo Oral Tablet|patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
48514954|NCT02333656|OTHER|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
48514955|NCT04682522|DRUG|Metronidazole Oral|250 mg Three times a day
48514956|NCT01881984|DRUG|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
48514957|NCT02203409|PROCEDURE|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
48514958|NCT01971437|PROCEDURE|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
48514959|NCT04138498|DRUG|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
48514960|NCT04138498|DRUG|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
48514961|NCT04138498|DRUG|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
48514962|NCT04138498|DRUG|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
48514963|NCT03885583|PROCEDURE|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
48514964|NCT03885583|PROCEDURE|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
48514965|NCT03742193|DRUG|Apatinib|Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
48514966|NCT03742193|DRUG|GD regimen|"One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."
48514967|NCT04653025|DEVICE|Implant placement|After tooth extraction implants were placed either immediate or delayed approach
48696705|NCT02863172|BEHAVIORAL|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
48696706|NCT02863172|PROCEDURE|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
48696707|NCT04042051|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 \[according to the dose escalation scheme\]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
48696708|NCT04042051|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
48696709|NCT02491242|OTHER|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
48167357|NCT06222775|BEHAVIORAL|Control Intervention 1|They will be given written information about the convenience of moderate physical activity and they will be informed of the importance of following an appropriate diet for diabetes and we will encourage weight loss.
48514968|NCT02215967|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
48514969|NCT02215967|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
48514970|NCT02215967|BIOLOGICAL|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 15.0x10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
48514971|NCT01912261|DRUG|Placebo|one capsule orally daily times 84 days
48514972|NCT01912261|DRUG|Polysaccharide iron complex|150 mg daily orally times 84 days
48009638|NCT01950546|DRUG|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
48167358|NCT06222775|BEHAVIORAL|Control Intervention 2|Your controls will be carried out according to the usual diabetes protocol established in the individual scheduled diabetes consultation reviews.
48167359|NCT06222775|BEHAVIORAL|Control Intervention 3|These patients will also be given a written document about living with diabetes, advice on physical activity, and a pre-established diet will be given according to the number of calories needed previously calculated
48167360|NCT06222775|BEHAVIORAL|Control Intervention 4|In addition to verbal recommendations. This document will be made after the act of assigning the control or experimental group.
48167361|NCT05867550|DRUG|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
48167362|NCT05867550|DRUG|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
48167363|NCT05867550|DRUG|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
48167364|NCT05867550|DRUG|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
48167365|NCT00888407|BEHAVIORAL|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
48167366|NCT00888407|BEHAVIORAL|Nutrition - Small group educational session|Small group session with diet \& nutrition focused, topic related resources provided.
48514973|NCT01260701|DRUG|Akt Inhibitor MK2206|Given PO
48514974|NCT00736437|DRUG|ME-609|Cream applied topically 6 times daily over the UVR exposed area
48514975|NCT00736437|DRUG|Vehicle|Treatment applied 6 times daily over the UVR exposed area
48514976|NCT01221610|DEVICE|Passeo-18 Lux DRB|
48514977|NCT01221610|DEVICE|Standard PTA (POBA)|
48514978|NCT00100880|DRUG|lenalidomide|Given PO
48514979|NCT00100880|PROCEDURE|perfusion-weighted magnetic resonance imaging|Correlative studies
48514980|NCT00100880|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
48514981|NCT00100880|OTHER|laboratory biomarker analysis|Correlative studies
48514982|NCT05544279|BEHAVIORAL|Education|Education is given about the focused disease and its nursing care management
48696710|NCT06520462|PROCEDURE|Pharmacopuncture|The physicians will decide the specific methods of pharmacopuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
48696711|NCT06520462|PROCEDURE|Acupuncture|The physicians will decide the specific methods of acupuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
48696712|NCT00585442|DRUG|calcitriol|1.0 mcg daily
48696713|NCT00585442|DRUG|Placebo|Placebo
48009639|NCT05256017|DRUG|Acoziborole|Acoziborole tablets
48009640|NCT05256017|DRUG|Placebo|matching placebo of acoziborole tablets
48009641|NCT01504334|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
48514983|NCT00346983|DRUG|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
48514984|NCT00346983|DRUG|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
48009642|NCT01504334|DRUG|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
48009643|NCT01918475|DRUG|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
48009644|NCT01918475|DRUG|Placebo|1ml of NaCl 0.9% is administered intravenously
48009645|NCT03794284|DIAGNOSTIC_TEST|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
48009646|NCT01613339|OTHER|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
48009647|NCT02035007|DEVICE|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
48009648|NCT03192150|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
48009649|NCT03192150|OTHER|Vehicle|Vehicle twice daily for 16 days
48009650|NCT02831270|PROCEDURE|Acute normovolemic hemodilution (ANH)|
48009651|NCT02831270|DRUG|hydroxyethyl starch (HES 130/0.6)|
48009652|NCT00774995|BIOLOGICAL|EngerixTM-B|Intramuscular injection, one dose.
48009653|NCT05832346|BEHAVIORAL|Laughter yoga programme|"Intervention for intervention group:~This is a 4-week laughter yoga programme (8 sessions) to help adolescents with intellectual and physical disabilities bring more happiness, laughter and joy to promote their mental health status. As laughter yoga therapy can reduce people's levels of stress, anxiety, depression, loneliness, strengthen the immune system and keep the mind positive. Each laughter yoga session will last for 15 minutes and in total there will be 8 sessions for four weeks (two sessions per week). Each laughter yoga session consists of hand clapping warming-up exercise, followed by deep breathing exercise, childlike playfulness exercise, and then laughter exercise. The intervention group also receives routine care provided by special school."
48167367|NCT00316459|DRUG|ERB-041|
48370280|NCT01085331|DRUG|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter \[mg/m\^2\] intravenous \[i.v\] infusion over 90 minutes or leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m\^2 given as a 90-minute infusion in 500 milliliter \[mL\] dextrose 5%; followed by a bolus 5-fluorouracil \[FU\] 400 mg/m\^2 and a 46-hour infusion 5-FU 2400 mg/m\^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
48370281|NCT04293211|OTHER|Simulation|To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
48370282|NCT02224261|OTHER|Physical Therapy protocol|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords, and patient education."
48167368|NCT04568356|DIAGNOSTIC_TEST|Direct Antigen Tests for COVID-19|Rapid Antigen diagnostic device performance comparative to RT-PCR
48167369|NCT02986659|DRUG|Metformin|
48167370|NCT02986659|DRUG|Placebo|
48167371|NCT05436106|BEHAVIORAL|Adaptive Intervention Approach|"This is an adaptive intervention approach with 7 module-based sessions selected on the basis of post-session assessments of acceptability and satisfaction;~1. weekly group sessions will be co-led by a community member with expertise in working with transgender women and a public health nurse,~2. supplemental educational content will be available for individual consumption via an online portal or application (and tracked via participant click counts), and~3. additional social resources will be available through the online portal or app."
48167372|NCT05806164|DRUG|Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]|The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
48167373|NCT05806164|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
48167374|NCT00153348|BEHAVIORAL|Women's health|
48370283|NCT02224261|OTHER|Control|Control protocol includes standard progressive active and action-assisted arm exercises \& patient education.
48370284|NCT05568212|DRUG|Durvalumab|Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL
48370285|NCT05568212|DRUG|Olaparib tablet|Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.
48370286|NCT05568212|DRUG|Single-agent chemotherapy|Investigator's choice single-agent chemotherapy regimen
48514985|NCT05500950|OTHER|CDU and CT-DCG or CT examination|patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
48696714|NCT05467839|DEVICE|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
48696715|NCT02126553|OTHER|Laboratory Biomarker Analysis|Correlative studies
48696716|NCT02126553|DRUG|Lenalidomide|Given PO
48696717|NCT05358522|OTHER|Opioid Prescribing Report Cards|"Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention."
48167375|NCT00384098|DRUG|CTA018 cream|
48167376|NCT05216393|OTHER|RecTech Match Website|Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.
48167377|NCT05147649|DIAGNOSTIC_TEST|functional magnetic resonance imaging|functional magnetic resonance imaging
48167378|NCT06401785|DIETARY_SUPPLEMENT|Hydrogen capsules|In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
48167379|NCT03648684|BEHAVIORAL|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
48167380|NCT03648684|BEHAVIORAL|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
48696718|NCT04999384|DRUG|AN4005-dose level 0|50mg BID
48009654|NCT00139126|BEHAVIORAL|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
48167381|NCT01307917|DIETARY_SUPPLEMENT|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
48167382|NCT05380388|BIOLOGICAL|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
48167383|NCT05380388|BIOLOGICAL|HBV vaccine|HBV Vaccine
48167384|NCT05233761|DRUG|Defined CBD|300 mg CBD and 8 mg Terpenes administered as two small capsules.
48167385|NCT05233761|DRUG|Placebo|Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
48167386|NCT06008340|DEVICE|Dual chamber Pacemaker|Anti bradycardia device implanted in patients with complete heart block, the device has 2 leads, one in the RT atrium and the other in RV. The RV lead positioned either apical or septal
48370287|NCT05568212|DRUG|Platinum doublet chemotherapy|Investigator's choice platinum doublet chemotherapy
48370288|NCT01760317|PROCEDURE|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
48167387|NCT06398171|OTHER|Exercise|Participants will perform 8 sessions of 4 sets of knee extension exercises during 1 month
48696719|NCT04999384|DRUG|AN4005-dose level 1|100mg BID
48696720|NCT04999384|DRUG|AN4005-dose level 2|200mg BID
48696721|NCT04999384|DRUG|AN4005-dose level 3|400mg BID
48696722|NCT04999384|DRUG|AN4005-dose level 4|600mg BID
48167388|NCT04258488|DRUG|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects_creatinine clearance 15-49 mL/min, 15mg once daily
48167389|NCT04258488|DRUG|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
48167390|NCT03277560|OTHER|No Intervention as it is an observational study|No Intervention as it is an observational study
48167391|NCT00613132|DRUG|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
48167392|NCT03998501|BEHAVIORAL|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
48167393|NCT00735462|DRUG|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
48167394|NCT00735462|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
48167395|NCT00735462|DRUG|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
48167396|NCT01297699|DRUG|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
48167397|NCT01297699|DRUG|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
48167398|NCT05286008|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
48167399|NCT05286008|DRUG|Ropivacaine at high concentration|Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
48167400|NCT05286008|DRUG|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
48167401|NCT00496834|DRUG|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
48167402|NCT00496834|DRUG|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
48696723|NCT04999384|DRUG|AN4005-food effect|Dose to be determined upon the MTD determination
48696724|NCT04842630|DRUG|SHR-1916|All participants receive SHR-1906 alone
48696725|NCT06108726|DRUG|Envafolimab Injection|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
48696726|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
48696727|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
48696728|NCT01659996|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
48167403|NCT00496834|DRUG|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
48167404|NCT00496834|DRUG|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
48370289|NCT04596046|PROCEDURE|steroid injecting|Group L: Triamcinolone acetonide was administered to the patients through injecting inside the lesion.Group S: Oral methylprednisolone was administered to the patients.
48696729|NCT03998670|DEVICE|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
48696730|NCT03998670|DEVICE|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
48696731|NCT02258750|DIETARY_SUPPLEMENT|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
48696732|NCT02258750|OTHER|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
48696733|NCT06661668|DEVICE|Gastric pacemaker (Enterra system) implantation|Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
48167405|NCT00115947|DRUG|Terlipressin|
48167406|NCT00084747|DRUG|bortezomib|
48167407|NCT02361177|DRUG|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
48167408|NCT06076798|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
48370290|NCT04495400|PROCEDURE|Thoracolumbar Fracture Fixation|The is surgery is preformed on patients who have had a blunt trauma fractures between the T10 and the L2. The surgical management for more severe/unstable fractures usually involves posterior instrumentation with percutaneous or open pedicle screw fixation. While the traditional open pedicle screw fixation technique has demonstrated good radiologic and clinical outcomes, a minimally invasive percutaneous approach has been increasingly used in recent years.
48370291|NCT05632094|DIETARY_SUPPLEMENT|L-Carnitine|The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
48514986|NCT00307021|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
48696734|NCT02207049|BEHAVIORAL|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
48696735|NCT02207049|BEHAVIORAL|No Snacking|Caloric needs will be provided to preschoolers within three meals
48696736|NCT06176430|DRUG|Ferrous Sulfate Oral Product|ferrous sulphate oral in the form of syrup
48696737|NCT06661395|DEVICE|Wingate Anaerobic Test with Virtual Reality|"Wingate Anaerobic Power Test Protocol, commonly used for assessing anaerobic capacity, involves a warm-up followed by testing. The warm-up includes 5 minutes of dynamic cycling, incorporating sprints. During the test, the athlete pedals at maximum effort for 30 seconds with added weight. Heart rate is monitored, and power output is measured every 5 seconds. Peak and average power values are calculated.~This protocol will be gamified for VR goggles. The warm-up simulates cycling in a forest. Athletes sprint for 5 seconds every minute to escape a train, with prompts on the screen. The testing phase includes a simulated race, with athletes pedaling at maximum effort for 30 seconds to compete against rivals, signaled by flares and a countdown."
48167409|NCT03897361|GENETIC|"CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
48167410|NCT05362513|DRUG|Ivermectin Tablets|Group B received a single dose of oral ivermectin 200 mcg per kg
48167411|NCT05362513|DRUG|Permethrin Cream|Group A received Permethrin 5% twice with a one-week interval.
48696738|NCT06658054|DRUG|Adjuvant analgesia|Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
48696739|NCT06658054|DRUG|Control (Standard treatment)|Patient will receive standard ESPB with bupivacaine and normal saline
48696740|NCT04799171|OTHER|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
48696741|NCT04799171|OTHER|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
48696742|NCT04799171|OTHER|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
48696743|NCT01511614|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
48696744|NCT01511614|DEVICE|sham|Sham Comparator
48696745|NCT01511614|DRUG|Nicotine patch|Dose-match Nicotine for non-deprived scan
48696746|NCT01511614|DRUG|Placebo patch|Nicotine deprived
48696747|NCT01511614|DRUG|Varenicline Pill|Treatment
48696748|NCT01511614|DRUG|Placebo pill|Active comparator to varenicline
48696749|NCT01511614|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing for smoking cessation preparation
48696750|NCT06658210|OTHER|soft tissue mobilization with pelvic floor muscle exercises|Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility
48696751|NCT06658210|OTHER|soft tissue mobilization without pelvic floor muscle exercises|Group B will receive soft tissue mobilization technique without pelvic floor exercises.
48696752|NCT00639041|DIETARY_SUPPLEMENT|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
48696753|NCT00639041|DIETARY_SUPPLEMENT|Placebo|dairy products without special oils
48696754|NCT06660667|BIOLOGICAL|SAR402663|Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection
48696755|NCT06660667|DRUG|Diluent|Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
48696756|NCT06660979|BEHAVIORAL|Reinforcement learning|The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The inventory of EHR tools from which the algorithm will choose include the following potential factors: open encounter, order entry, cold-state outreach, simplification, and risk framing.
48696757|NCT04345029|DIETARY_SUPPLEMENT|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
48696758|NCT00397761|DRUG|capecitabine|
48696759|NCT00397761|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
48696760|NCT00397761|PROCEDURE|neoadjuvant therapy|
48696761|NCT04184050|DRUG|MK-4002|IV infusion
48696762|NCT05275608|DIETARY_SUPPLEMENT|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
48696763|NCT05275608|BEHAVIORAL|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
48009655|NCT05037565|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
48009656|NCT02118428|DEVICE|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
48009657|NCT02118428|BIOLOGICAL|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
48009658|NCT00774098|DRUG|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
48009659|NCT00774098|DRUG|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
48167412|NCT04335695|BEHAVIORAL|Vascular Rehabilitation|Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
48167413|NCT03025555|OTHER|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
48009660|NCT00774098|DIETARY_SUPPLEMENT|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
48009661|NCT00774098|DRUG|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
48514987|NCT01207310|BEHAVIORAL|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
48009662|NCT00354172|BIOLOGICAL|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
48009663|NCT00354172|BIOLOGICAL|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
48009664|NCT00354172|BIOLOGICAL|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
48167414|NCT03025555|OTHER|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
48167415|NCT00424177|DRUG|eltrombopag|experimental
48514988|NCT01207310|DRUG|Nicotine patch|8 weeks' worth of nicotine patches
48514989|NCT01207310|DEVICE|alphanumeric pager|therapeutic messages to be delivered for three months
48696764|NCT06661824|BEHAVIORAL|Aggression management care bundle|The aggression management care bundle consists of six components. All of these are high-evidence level interventions consisting of behavioral and nursing interventions aimed at managing aggression. These six interventions are: Risk Assessment, Cognitive Remediation Training, Social Skills Training, De-Escalation Techniques, Milieu Therapy, Improving Sleep.
48696765|NCT05221632|DEVICE|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
48167416|NCT02150083|PROCEDURE|OR retrograde fill|
48167417|NCT06408922|OTHER|prp injection|intraarticular prp
48696766|NCT05221632|DEVICE|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
48696767|NCT05221632|DEVICE|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
48696768|NCT05307705|DRUG|LOXO-783|Oral
48696769|NCT05307705|DRUG|Fulvestrant|Intramuscular
48696770|NCT05307705|DRUG|Imlunestrant|Oral
48696771|NCT05307705|DRUG|Abemaciclib|Oral
48696772|NCT05307705|DRUG|Anastrozole, Exemestane, or Letrozole|Oral
48696773|NCT05307705|DRUG|Paclitaxel|Intravenous
48696774|NCT05998070|OTHER|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
48696775|NCT05813925|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
48696776|NCT05813925|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
48696777|NCT05813925|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide
48696778|NCT06495060|OTHER|No intervention (Only observation)|No intervention
48696779|NCT06662162|DEVICE|i-Lumen AMD|i-Lumen AMD transpalpebral microcurrent stimulation system
48696780|NCT00060541|PROCEDURE|Laboratory tests|
48696781|NCT00060541|PROCEDURE|Radiological exams|
48696782|NCT06660771|PROCEDURE|Functional orthodontic treatment|"The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position."
48167418|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
48167419|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
48167420|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
48514990|NCT04353895|DEVICE|Guidance for pedicle screw insertion (Mazor Stealth)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
48696783|NCT05366179|DRUG|CAR.B7-H3T cells infusion|"The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2)."
48696784|NCT00957944|DRUG|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
48696785|NCT01142778|DRUG|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
48696786|NCT01142778|DRUG|Docetaxel|Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
48696787|NCT01142778|DRUG|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
48696788|NCT01142778|PROCEDURE|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
48696789|NCT01142778|RADIATION|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
48696790|NCT01142778|DRUG|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
48696791|NCT06608511|OTHER|Blood draw for the laboratory assessment|Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
48696792|NCT05876299|OTHER|95.1% Lean Pork|This intervention will contain 120 kcals, 4.4 g fat, and 20 g protein from low-fat ground pork.
48696793|NCT05876299|OTHER|81.16% Lean Pork|This intervention will contain 266 kcals, 20.6 g fat, and 20 g protein from high-fat ground pork.
48696794|NCT05876299|OTHER|Carbohydrate Beverage|This intervention will contain 266 kcals and 73.3 g carbohydrate from a carbohydrate beverage.
48696795|NCT04887610|PROCEDURE|Ischemic preconditioning|Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
48696796|NCT04887610|PROCEDURE|Ischemic preconditioning control|Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
48696797|NCT04887610|DIETARY_SUPPLEMENT|Low fat meal|Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium
48696798|NCT04887610|DIETARY_SUPPLEMENT|High fat meal|Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
48696799|NCT00015860|DRUG|daunorubicin hydrochloride|
48696800|NCT00015860|DRUG|imatinib mesylate|
48696801|NCT00015860|DRUG|prednisone|
48696802|NCT00015860|DRUG|vincristine sulfate|
48696803|NCT05359822|OTHER|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
48696804|NCT06661720|BIOLOGICAL|Pembrolizumab|Given intravenously
48696805|NCT06661720|DRUG|Tivozanib|Given orally
48696806|NCT06661720|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48696807|NCT06661720|PROCEDURE|MRI|Undergo MRI
48696808|NCT06661720|PROCEDURE|Computed Tomography|Undergo CT scan
48696809|NCT06661720|PROCEDURE|Biopsy|Undergo biopsy
48696810|NCT06661720|OTHER|Questionnaire Administration|Ancillary studies
48696811|NCT05609994|DRUG|PEPIDH1M vaccine + vorasidenib|Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
48696812|NCT05088746|PROCEDURE|Non-surgical periodontal therapy|NSPT will be performed following the principles of minimally invasive non-surgical therapy (MINST) described by Nibali et al. (Nibali et al., 2015, Nibali et al., 2019)
48696813|NCT06659120|DRUG|Fremanezumab|Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
48696814|NCT01208961|DRUG|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
48167421|NCT00819013|BIOLOGICAL|Saline placebo|0.5 mL, Intramuscular
48696815|NCT01208961|DRUG|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
48167422|NCT03672071|OTHER|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
48696816|NCT06028152|OTHER|"End-of-life conversation game called Hello"|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~Other Name: Previously named My Gift of Grace"
48696817|NCT01355679|DEVICE|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
48009665|NCT00354172|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
48009666|NCT00354172|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of \>200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
48696818|NCT04153292|DEVICE|SAPIEN M3 valve and dock|During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
48009667|NCT00354172|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
48009668|NCT00354172|DRUG|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
48009669|NCT00354172|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9 /L)."
48009670|NCT00354172|PROCEDURE|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
48009671|NCT00354172|RADIATION|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
48696819|NCT00361868|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
48696820|NCT00361868|DRUG|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
48696821|NCT06019039|DRUG|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
48009672|NCT04107571|PROCEDURE|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
48009673|NCT03946163|DIETARY_SUPPLEMENT|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
48009674|NCT03946163|DRUG|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
48009675|NCT03192839|OTHER|Low dose PUFA|Low dose PUFA
48009676|NCT03192839|OTHER|High dose PUFA|High dose PUFA
48009677|NCT03192839|OTHER|Placebo|Placebo
48696822|NCT06019039|DEVICE|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
48167423|NCT02943642|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
48167424|NCT02943642|DRUG|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
48514991|NCT04353895|DEVICE|Guidance for pedicle screw insertion (O-arm Navigation)|Using imaging devices and navigation for guidance, we perform a posterior vertebral fusion with pedicle screw insertion
48009678|NCT02896400|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
48522848|NCT04677335|OTHER|Placebo|Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
48522849|NCT01034020|DRUG|Nicotine|
48696823|NCT00606541|DRUG|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
48696824|NCT00606541|DRUG|Placebo|Placebo
48696825|NCT04743336|OTHER|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
48696826|NCT06659991|DRUG|alcohol condition|Ethanol
48696827|NCT06659991|OTHER|control condition|sparkling water
48696828|NCT05524623|OTHER|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
48696829|NCT05917496|OTHER|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
48696830|NCT05917496|BEHAVIORAL|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
48009679|NCT02896400|DRUG|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
48009680|NCT02896400|OTHER|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
48167425|NCT05264064|OTHER|The motor assessment to establish validation of the Polish version of the AIMS|The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
48167426|NCT06480331|PROCEDURE|Ultrasound-guided fistuloplasty|Radiation free fistuloplasty
48167427|NCT06480331|PROCEDURE|Fluoroscopy-guided fistuloplasty|Conventional fistuloplasty
48696831|NCT06658652|DRUG|Enlicitide decanoate|Oral tablet
48696832|NCT04034719|OTHER|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
48009681|NCT02896400|OTHER|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
48696833|NCT04034719|OTHER|usual practice|Parents will be carried their newborn as their usual practice.
48696834|NCT05751668|DRUG|Paclitaxel|Given IV
48696835|NCT05751668|DRUG|Monosialotetrahexosylganglioside|Given IV
48696836|NCT05751668|OTHER|Questionnaire Administration|Ancillary Studies
48009682|NCT01365780|PROCEDURE|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
48696837|NCT05751668|OTHER|Quality-of-life assessment|Ancillary Studies
48696838|NCT05751668|DRUG|Placebo Administration|Given IV
48009683|NCT04989049|DRUG|Folic Acid 5 MG|folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
48009684|NCT04989049|OTHER|placebo|an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
48009685|NCT05894681|OTHER|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS
48009686|NCT01813981|DIETARY_SUPPLEMENT|Low roast coffee|Instant coffee
48167428|NCT05004311|DRUG|Cenerimod|A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
48009687|NCT01813981|DIETARY_SUPPLEMENT|High roast coffee|Instant coffee
48009688|NCT01813981|DIETARY_SUPPLEMENT|Control (Caffeine dissolved in water)|Caffeine dissolved in water
48009689|NCT00417443|DRUG|Clonidine|
48009690|NCT06424080|PROCEDURE|laparoscopic partial nephrectomy|cases amenable for partial nephrectomy
48009691|NCT06424080|PROCEDURE|robotic partial nephrectomy|cases amenable for partial nephrectomy
48009692|NCT03638817|DRUG|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
48009693|NCT02072291|DRUG|Nifedipine|PO Nifedipine 5mg single dose
48009694|NCT05425901|OTHER|biopsy|endoscopy biopsies (6)
48009695|NCT03419091|DEVICE|single-use flexible digital ureteroscope|Device being tested.
48009696|NCT03419091|DEVICE|Reusable Ureteroscope|Comparative device.
48696839|NCT06651151|DRUG|LTX-315 + pembrolizumab|LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
48009697|NCT01469325|OTHER|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
48009698|NCT01469325|OTHER|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
48009699|NCT00006482|DRUG|cisplatin|
48009700|NCT00006482|DRUG|gemcitabine hydrochloride|
48009701|NCT04438928|DIETARY_SUPPLEMENT|Elevit Pregnancy 2nd & 3rd Trimester|Once daily micronutrient plus DHA supplementation (Multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules)
48009702|NCT04438928|OTHER|Non-Supplement|Control study group of pregnant women non-supplemented with multi-micronutrients and docosahexaenoic acid (MMS) soft gel capsules
48009703|NCT03077165|DRUG|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
48009704|NCT03077165|DRUG|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
48009705|NCT03077165|DRUG|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
48009706|NCT03077165|DRUG|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
48009707|NCT03077165|DRUG|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
48009708|NCT03077165|DRUG|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
48009709|NCT00383838|BEHAVIORAL|brief, voluntary substance use intervention|
48009710|NCT01848990|DRUG|Commercial Hylenex® recombinant (hyaluronidase human injection)|
48009711|NCT01848990|DRUG|Precommercial Hylenex recombinant (hyaluronidase human injection)|
48009712|NCT01848990|DRUG|Insulin lispro|
48009713|NCT01848990|DRUG|Insulin aspart|
48009714|NCT01848990|DRUG|Insulin glulisine|
48009715|NCT05402943|BEHAVIORAL|Nursing Care Program for Endometriosis|Nursing Care Program for Endometriosis, developed in line with Health Promotion Model
48009716|NCT05402943|BEHAVIORAL|EHP-5 Endometriosis Health Promotion Model.|EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis
48009717|NCT05402943|BEHAVIORAL|Healthy Life Style Behaviours Scale II.|A questionnaire used to measure the Healthy Life Style Behaviours.
48009718|NCT05402943|BEHAVIORAL|The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.|A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
48009719|NCT00281840|BIOLOGICAL|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
48009720|NCT00281840|DRUG|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
48009721|NCT00281840|PROCEDURE|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
48009722|NCT00281840|RADIATION|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
48009723|NCT04152447|DEVICE|VR device|Patients use a VR device
48009724|NCT01406821|PROCEDURE|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
48009725|NCT01406821|PROCEDURE|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
48522850|NCT05148091|BIOLOGICAL|SCTV01C|A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants
48696840|NCT05030610|BEHAVIORAL|BeatIt-ASD|BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
48696841|NCT04238481|DRUG|Pudexacianinium chloride|Intravenous
48696842|NCT03721783|PROCEDURE|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
48696843|NCT02723916|BEHAVIORAL|ezParent Program|Tablet-based behavioral parent training program.
48696844|NCT02723916|BEHAVIORAL|Health-e Kids Control App|Tablet based health promotion information App
48009726|NCT01500148|DEVICE|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
48167429|NCT03810287|DRUG|Domperidone|Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.
48696845|NCT03526393|DEVICE|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
48696846|NCT03526393|DEVICE|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
48696847|NCT03526393|DEVICE|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
48696848|NCT02024360|BEHAVIORAL|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
48696849|NCT06249555|DRUG|Vedolizumab (VDZ)|Participants will receive VDZ as part of routine care.
48009727|NCT04155996|DEVICE|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
48167430|NCT01974934|DRUG|Desvenlafaxine Succinate|
48167431|NCT02657759|DIETARY_SUPPLEMENT|CARDICHOL|
48167432|NCT02657759|DIETARY_SUPPLEMENT|PLACEBO|
48167433|NCT06353802|DIAGNOSTIC_TEST|Chronic non-specific neck pain and lumbar reposition sense|"In order to evaluate the lumbar joint repositioning error using the Joint Positioning Sense, the following guidelines were followed: (I) The participants were to stand with their arms at their sides, their feet externally rotated (about 20 degrees).~(II) With the feet flat on the floor and the arms resting on the front of the thighs, the person was seated in a height-adjustable seat that measured the length of the shank. (III) With a belt fastened, the iPhone® was positioned upright just above the iliac crest, (IV) the inclination of the inclinometer was 0°; (V) The inclinometer's 0° point was set as the initial position. (VI) The individual was passively guided by the assessor to a 30° flexion within the range of 0 to 30°; (VII) the subject was to memorize this position for 10 s; (VIII) the subject actively returned to the initial position. (IX) Subsequently, the participant was required to actively replicate the position three times."
48167434|NCT02846597|PROCEDURE|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
48696850|NCT06249555|DRUG|Ustekinumab (UST)|Participants will receive UST as part of routine care.
48696851|NCT06249555|DRUG|Risankizumab (RISA)|Participants will receive RISA as part of routine care.
48696852|NCT00182715|BIOLOGICAL|cetuximab|
48696853|NCT00182715|DRUG|capecitabine|
48009728|NCT05705908|OTHER|Hot Foot Bath 1|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water)."
48696854|NCT00182715|DRUG|fluorouracil|
48167435|NCT02183077|DRUG|Meloxicam gel|
48167436|NCT02183077|DRUG|Meloxicam tablet|
48167437|NCT06140914|DIAGNOSTIC_TEST|Proteomics, miRNA studies and studies of blood cells from blood samples|This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.
48167438|NCT03465085|DRUG|Unfractionated heparin|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
48696855|NCT00182715|DRUG|leucovorin calcium|
48696856|NCT00182715|DRUG|oxaliplatin|
48696857|NCT03116802|DRUG|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
48696858|NCT05795569|PROCEDURE|Nasogastric Tube removal during extubation|The nurse in charge of the patient and under the cover of a medical prescription, will proceed to the systematic removal of the nasogastric tube during the extubation procedure
48696859|NCT05795569|DIAGNOSTIC_TEST|Yale Swallow Protocol|"The dysphagia will be evaluated in a systematic way between 1 hour and 6 hours post-extubation with the help of the Yale Swallow Protocol (YSP) by the caregivers trained to the passing of the YSP (nurse or physiotherapist or ICU doctor)."
48009729|NCT05705908|OTHER|Hot Foot Bath 2|"* Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water"
48009730|NCT04132557|DRUG|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
48009731|NCT04132557|DRUG|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
48696860|NCT05795569|PROCEDURE|Classif Nasogastric Tube Management|The removal of the nasogastric tube will not be performed during the extubation procedure and the time of removal will be left to the discretion of the attending physician (as currently performed in the unit).
48696861|NCT05795569|DIAGNOSTIC_TEST|Classic swallowing test|"Post-extubation dysphagia will be assessed as we do in the unit. Currently, the caregivers in charge of the patient do a gel water test Nutrisens Hydra'Fruit level 4 when the attending physician prescribes it."
48696862|NCT01513187|DRUG|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
48696863|NCT00804752|DRUG|Adding vitamin D|Adding 1000IU/Vitamin D daily
48696864|NCT00804752|DRUG|Vitamin D|Addition of 1000IU/day Vitamin D
48696865|NCT06514742|DRUG|Aticaprant|Aticaprant tablet will be administered orally.
48009732|NCT04132557|DRUG|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
48696866|NCT06514742|OTHER|Placebo|Placebo tablet will be administered orally.
48696867|NCT00144248|DRUG|nevirapine|
48696868|NCT06532500|BEHAVIORAL|CBT-MyOWL|12-sessions of CBT-MyOWL
48009733|NCT04132557|DRUG|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
48009734|NCT04132557|DRUG|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
48009735|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 1
48009736|NCT00957437|DRUG|AZD1305|ER formulation 1, bid for 5 days
48696869|NCT06532500|BEHAVIORAL|CBT-as-usual|12-sessions of CBT using Mind Over Mood or Anxiety Phobia
48696870|NCT06435364|OTHER|Vagus nerve stimilation|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.
48009737|NCT00957437|DRUG|AZD1305|Single Oral Dose, ER formulation 2
48009738|NCT05204381|DEVICE|Theta-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
48009739|NCT05204381|DEVICE|Theta-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
48522851|NCT05148091|OTHER|Adjuvant|SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial
48696871|NCT06435364|OTHER|Manual therapy|Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
48696872|NCT04563234|BEHAVIORAL|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
48696873|NCT04563234|BEHAVIORAL|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
48696874|NCT03764566|BEHAVIORAL|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
48696875|NCT01302834|BIOLOGICAL|cetuximab|400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks
48696876|NCT01302834|DRUG|cisplatin|100 mg/m2 IV on days 1 and 22 of IMRT
48167439|NCT03465085|DRUG|Streptokinase|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
48167440|NCT01705314|DIETARY_SUPPLEMENT|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
48514992|NCT03280381|OTHER|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
48514993|NCT03280381|OTHER|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
48696877|NCT01302834|RADIATION|IMRT|35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.
48696878|NCT03926533|OTHER|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
48696879|NCT04884035|DRUG|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
48696880|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
48696881|NCT04884035|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
48696882|NCT04884035|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
48696883|NCT04884035|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
48696884|NCT04884035|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
48696885|NCT04884035|DRUG|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
48696886|NCT04884035|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
48696887|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
48696888|NCT05808309|OTHER|Salivary sampling|Salivary sampling for genomic material (DNA and RNA (for primary outcome measures); proteins and DNA methylation (for secondary outcome measures)
48696889|NCT02412891|DEVICE|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
48696890|NCT02412891|DEVICE|Sham UroShield device|
48696891|NCT05963204|COMBINATION_PRODUCT|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
48696892|NCT05963204|COMBINATION_PRODUCT|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
48696893|NCT03135769|DRUG|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
48696894|NCT05666934|DEVICE|Augmented Reality Storybook|The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
48696895|NCT00464061|DRUG|Volinanserin|oral administration
48167441|NCT01705314|DIETARY_SUPPLEMENT|placebo|7mls of placebo drops per week for 8 months.
48167442|NCT01181583|BEHAVIORAL|Tailored Internet-delivered CBT|"This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
48522852|NCT05148091|OTHER|Saline|Saline is used as the other control in the trial
48696896|NCT00464061|DRUG|Placebo|oral administration
48696897|NCT00129584|PROCEDURE|Emphasys Endobronchial Valve and procedure|
48009740|NCT05204381|DEVICE|Arrhythmic near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
48009741|NCT05204381|DEVICE|Arrhythmic independent stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
48009742|NCT05204381|DEVICE|Alpha-frequency near-zero phase lag stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
48696898|NCT02778542|BEHAVIORAL|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
48009743|NCT05204381|DEVICE|Alpha-frequency anti-synchrony stimulation|Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
48009744|NCT02456922|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
48009745|NCT04521491|DRUG|FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).|FOLFOX4 (OXA 85 mg/m2 intravenously \[IV\] on day 1; LV 200 mg/m2 IV from hour 0 to 2 on days 1 and 2; and FU 400 mg/m2 IV bolus at hour 2, then 600 mg/m2 over 22 hours on days 1 and 2, once every 2 weeks.All patients in the treatment group will receive FOLFOX4 at most 12 times beginning from the 4th week after liver resection.
48009746|NCT05154448|DEVICE|Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
48009747|NCT05154448|OTHER|Sham procedure|Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy
48009748|NCT02243150|DRUG|G1T28-1 (CDK 4/6 Inhibitor)|
48009749|NCT02243150|DRUG|Placebo|
48009750|NCT01782781|DRUG|ropivacaine, ketorelac and epinephrine|Active group
48009751|NCT01782781|DRUG|Placebo|Placebo group
48009752|NCT00799617|DRUG|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
48009753|NCT00799617|DRUG|Placebo|Testosterone levels will be measured at regular intervals.
48696899|NCT02778542|BEHAVIORAL|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
48696900|NCT00606034|DRUG|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
48009754|NCT05582993|BIOLOGICAL|Recombinant von Willebrand Factor (rVWF)|rVWF administered by intravenous injection.
48696901|NCT05389514|DRUG|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
48696902|NCT05389514|DRUG|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
48696903|NCT05389514|DRUG|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
48696904|NCT05389514|BIOLOGICAL|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10\^9 to 5.0 x 10\^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
48696905|NCT04607512|DRUG|telaglenastat|glutaminase inhibitor
48696906|NCT04607512|OTHER|telaglenastat placebo|matching placebo for telaglenastat
48009755|NCT05582993|BIOLOGICAL|ADVATE|ADVATE administered by intravenous injection.
48009756|NCT02708680|DRUG|Entinostat|An orally available histone deacetylases inhibitor (HDAC).
48009757|NCT02708680|DRUG|Atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
48009758|NCT02708680|DRUG|Placebo|A pill containing no active drug ingredient
48009759|NCT04520425|PROCEDURE|Osteopathic manipulative therapy|"1. Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~2. Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~3. Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~4. Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~5. Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck."
48009760|NCT02142452|BEHAVIORAL|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
48009761|NCT02142452|OTHER|Usual Prenatal Care|
48009762|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
48696907|NCT04607512|OTHER|moxifloxicin|positive control
48696908|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
48009763|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 14days (VA14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
48009764|NCT05345210|DRUG|Vonoprazan Fumarate+Amoxycillin 7days (VA7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
48009765|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
48009766|NCT05345210|DRUG|Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)|VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
48009767|NCT02529410|PROCEDURE|Cardiac Resynchronisation Therapy|
48009768|NCT00480636|DRUG|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
48696909|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
48696910|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
48696911|NCT06659068|DIETARY_SUPPLEMENT|Seluang fish oil (Rasbora argyrotaenia) and synbiotic|The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
48696912|NCT06659068|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
48009769|NCT00664716|BIOLOGICAL|Baminercept alfa 1|experimental - one dose level
48696913|NCT04985409|BEHAVIORAL|Feedback|The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
48696914|NCT04570605|DEVICE|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
48696915|NCT04570605|OTHER|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
48696916|NCT05243745|OTHER|3% PVM/MA + 5% KNO3 Combination|Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
48696917|NCT05243745|OTHER|3% PVM/MA only|Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
48696918|NCT05243745|OTHER|5% KNO3 Only|Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
48696919|NCT05243745|OTHER|Regular Fluoride|Toothpaste containing regular fluoride will be used as negative control.
48696920|NCT01295840|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
48696921|NCT03184935|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
48696922|NCT03184935|DRUG|Decitabine|Decitabine，20mg/m\^2/d
48696923|NCT06658041|BEHAVIORAL|Cognitive behavioural therapy (CBT)-based intervention with stepped-care|"After initial clinical assessment, participants will be offered interventions based on their depressive symptom severity (Patient Health Questionnaire-9-item \[PHQ-9\]).~Mild symptoms (PHQ-9\<5) without major risks (\*see above): 4 weekly CBT-informed intervention sessions led by trained Emotional Support Assistants (Peer Supporters with 80hrs mental health training + 15hrs intensive clinical training).~Mild symptoms (PHQ-9\<5) with major risk factors or moderate-to-moderately severe symptoms (PHQ-9=10-19): 6 weekly CBT-based intervention sessions led by trained clinical social workers, with 2 booster sessions as necessary. Individual CBT-based intervention will be provided to those unsuitable for group interventions.~In cases of non-remission (PHQ-9≥5): a second intervention trial will be provided. Those needing additional support will be referred to a partnered General Practitioner (if PHQ-9=10-19) or referred to more intensive psychological or psychiatric services as needed."
48696924|NCT06658041|OTHER|Care-as-usual|Following an initial interview session with research assessments, participants continue with their usual care at their primary care setting.
48009770|NCT00664716|BIOLOGICAL|Placebo|Placebo comparator
48009771|NCT00664716|BIOLOGICAL|Baminercept alfa 2|experimental - second dose level
48009772|NCT00664716|BIOLOGICAL|Baminercept alfa 3|experimental - third dose level
48009773|NCT00664716|BIOLOGICAL|Baminercept alfa 4|experimental - fourth dose level
48167443|NCT01181583|BEHAVIORAL|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
48370292|NCT02049008|OTHER|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
48522853|NCT05391373|BEHAVIORAL|Laughter therapy|Each session started with a 10-minute breathing exercise accompanied by relaxing music, followed by 20-minute laughing exercises. Afterwards, the session was ended with a 10-minute meditation accompanied by relaxing music.
48696925|NCT04629547|DRUG|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
48696926|NCT04629547|DRUG|Placebo|Placebo will be taken nightly for 24 months.
48696927|NCT03086421|BEHAVIORAL|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
48696928|NCT04244981|DRUG|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
48696929|NCT04244981|DRUG|Fresh Frozen Plasma|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
48696930|NCT02550288|DRUG|Ezetimibe 10 mg|
48696931|NCT02550288|DRUG|Atorvastatin 10 mg|
48009774|NCT00664716|BIOLOGICAL|Baminercept alfa 5|experimental - fifth dose level
48009775|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
48009776|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
48009777|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
48009778|NCT02611167|BIOLOGICAL|Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
48009779|NCT02011048|PROCEDURE|Endoscopic components separation|Endoscopic components separation hernia repair
48009780|NCT02316717|BIOLOGICAL|IMM-124E|IMM-124E
48009781|NCT02316717|OTHER|Placebo|Matched placebo
48167444|NCT01181583|BEHAVIORAL|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
48167445|NCT06591767|DIETARY_SUPPLEMENT|Quercetin|200 mg supplemental Quercefit®
48167446|NCT06591767|COMBINATION_PRODUCT|Berberol K®|"Berberine Phytosome® 730 mg~+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract"
48167447|NCT03391583|OTHER|Education|Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
48167448|NCT02108418|DRUG|TG-2349 as the original formulation|single oral dose under fed condition
48167449|NCT02108418|DRUG|TG-2349 as a new capsule formulation|single oral dose under fed condition
48167450|NCT06221800|DIAGNOSTIC_TEST|Microbiome|Stool and saliva samples will be collected
48167451|NCT02827799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
48167452|NCT02827799|BEHAVIORAL|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
48696932|NCT02550288|DRUG|Placebo for Ezetimibe 10 mg tablet|
48167453|NCT01873573|PROCEDURE|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
48696933|NCT02550288|DRUG|Placebo for Atorvastatin 10 mg capsule|
48696934|NCT02550288|BEHAVIORAL|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
48696935|NCT06239220|BIOLOGICAL|PD-L1 t-haNK|Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
48696936|NCT06239220|DRUG|Cetuximab|Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
48696937|NCT06239220|BIOLOGICAL|N-803|Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
48696938|NCT03429985|BEHAVIORAL|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
48696939|NCT00002858|DRUG|cisplatin|
48696940|NCT00002858|DRUG|cyclophosphamide|
48696941|NCT00002858|DRUG|doxorubicin hydrochloride|
48696942|NCT00002858|DRUG|etoposide|
48696943|NCT00002858|RADIATION|radiation therapy|
48696944|NCT04192136|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
48696945|NCT04192136|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
48167454|NCT01873573|OTHER|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
48167455|NCT01873573|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
48522854|NCT04045769|DRUG|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
48696946|NCT04192136|OTHER|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
48009782|NCT05754177|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days
48009783|NCT05754177|OTHER|Placebo|Participants in this arm will receive an equivalent placebo for 84 days.
48009784|NCT00202904|DRUG|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
48009785|NCT00202904|DRUG|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
48167456|NCT06210399|PROCEDURE|Extracorporeal Shockwave Therapy|3 to 6 shock wave treatment sessions will be performed (PiezoWave 2 Control Unit Generator, classification 93/42/EEC class IIb), with a frequency of two sessions per week.
48167457|NCT05256771|DEVICE|EMS|Abdominal muscle stimulation using EMS
48167458|NCT05256771|DEVICE|1064 nm diode laser|Adipose tissue heating using 1064 nm diode laser
48167459|NCT05256771|DEVICE|RF/PEMF|Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
48514994|NCT06064305|OTHER|No study-specific interventions|Septic AKI patients, post-cardiothoracic AKI patients and non-AKI patients undergoing routine nephrectomy. Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians and the respective specialists.
48514995|NCT02797197|PROCEDURE|handgrip strength test|
48514996|NCT02797197|DRUG|chemotherapy|
48514997|NCT00000246|DRUG|Flumazenil|
48514998|NCT05662839|DEVICE|Cytological Brushing|All participants will undergo cytological brushing to collect cell samples for analysis
48514999|NCT02131350|PROCEDURE|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
48515000|NCT02131350|DRUG|Ranibizumab|
48515001|NCT05870059|DRUG|Propolis mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use 5ml of propolis mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
48696947|NCT01413906|DRUG|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
48696948|NCT02248441|OTHER|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
48696949|NCT05557851|COMBINATION_PRODUCT|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
48009786|NCT04275128|DEVICE|Cooled radiofrequency ablation|Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
48167460|NCT00931008|DRUG|SID530, Taxotere|75mg/m2
48167461|NCT03549988|OTHER|Fecal Calprotectin (FC) measurements with IBDocTM|"Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal \<100 µg/g (green), 100-300 µg/g (yellow), \>300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is \>250 µg/g a second FC will be performed within 2 weeks. If this result is \<250 µg/g patients will continue to monitor their FC every 2 months. If the second result is \>250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days."
48515002|NCT05870059|DRUG|Chlorhexidine mouthwash|After scaling and root planning at the baseline visit, patients were prescribed to use chlorhexidine mouthwash twice a day for 6 weeks. patients were also prescribed to not eat and drink anything for half an hour after the rinse.
48515003|NCT04080544|DRUG|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
48515004|NCT04080544|PROCEDURE|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
48009787|NCT04275128|DEVICE|Conventional radiofrequency ablation|Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
48009788|NCT02747069|DEVICE|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
48009789|NCT02747069|DEVICE|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (\<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
48009790|NCT03675048|DIETARY_SUPPLEMENT|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
48009791|NCT03675048|DIETARY_SUPPLEMENT|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
48009792|NCT05789836|OTHER|Nursing care|Involving the mother in nursing care
48009793|NCT01638338|BEHAVIORAL|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
48009794|NCT01638338|BEHAVIORAL|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
48009795|NCT00519649|BIOLOGICAL|Engerix™-B Kinder|Intramuscular injection, 1 dose
48009796|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation X|see Treatment Arms
48009797|NCT00750854|DIETARY_SUPPLEMENT|NEM Formulation Y|see Treatment Arms
48167462|NCT01717547|BEHAVIORAL|Yoga-based treatment|
48167463|NCT02078947|BEHAVIORAL|High Intensity Exercise|
48167464|NCT02078947|BEHAVIORAL|Moderate Continuous Exercise|
48167465|NCT02078947|BEHAVIORAL|Usual Care|
48009798|NCT05470439|BEHAVIORAL|My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)|MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
48009799|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
48009800|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
48009801|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
48009802|NCT01107470|DRUG|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
48009803|NCT01486017|DRUG|ASP015K|oral
48009804|NCT04411342|DIAGNOSTIC_TEST|Albumin creatinine ratio|normal range of albumin in urine in patients with type 2 diabetes
48009805|NCT02456831|OTHER|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
48009806|NCT02456831|OTHER|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
48009807|NCT02456831|OTHER|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
48009808|NCT02456831|OTHER|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
48009809|NCT01910064|DRUG|GK530G|
48009810|NCT02498093|BEHAVIORAL|Maximal strength training|
48009811|NCT02498093|BEHAVIORAL|conventional rehabilitation|
48167466|NCT04884490|DRUG|Co-trimoxazole|Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
48167467|NCT04884490|DRUG|Placebo|Placebo thrice (8 hourly) daily for 7 days orally.
48167468|NCT01315197|OTHER|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
48167469|NCT03983018|DRUG|Rituximab|Infusion
48009812|NCT00064246|BIOLOGICAL|rituximab|Given IV
48009813|NCT00064246|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
48009814|NCT00064246|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
48009815|NCT06317493|OTHER|Stimuli|"Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras."
48009816|NCT05676671|PROCEDURE|Applications of self-etching adhesives and dental restorations|
48167470|NCT04279756|OTHER|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
48167471|NCT01780545|DRUG|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
48167472|NCT01780545|DRUG|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
48167473|NCT04938934|BEHAVIORAL|Lipids infusion|Lipids infusion via intestinal tube
48167474|NCT04938934|BEHAVIORAL|Sham infusion|Sham infusion via intestinal tube
48167475|NCT02165397|DRUG|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
48009817|NCT06060574|DEVICE|Platelet rich fibrin device|"Within the scope of the study, a total of 2 tubes of venous blood samples will be obtained from the forearm region (antecubital vein) of each individual by the clinical staff specialist nurse of the Department of Periodontology. PRF samples will be created using appropriate equipment and devices from blood samples obtained from each individual. In the study, 10 ml glass-coated plastic tubes will be used. Apart from this, 5 mL of blood taken will be used for complete blood count and evaluation of hormones on the relevant day.~PRF Preparation: In all age groups, PRF will be prepared by centrifugation with 700xg (=2700 rpm, Intra-Spin L-PRF device) for 12 minutes."
48009818|NCT03199378|OTHER|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
48009819|NCT05580224|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
48009820|NCT04734340|PROCEDURE|EIT-guided PEEP setting|Ventilator parameter setting by EIT
48009821|NCT04734340|PROCEDURE|ARDS-net PEEP setting|Ventilator parameter setting according to ARDS-net table
48167476|NCT02165397|DRUG|Placebo|Participants will receive placebo capsules orally.
48167477|NCT02165397|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV.
48009822|NCT02813343|DEVICE|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
48009823|NCT00689481|DRUG|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
48009824|NCT00689481|DRUG|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
48009825|NCT04490434|DRUG|DWP14012|DWP14012 40mg, bid
48009826|NCT04490434|DRUG|Celecoxib|Celecoxib 200mg, bid
48009827|NCT04490434|DRUG|Naproxen|Naproxen 500mg, bid
48009828|NCT04490434|DRUG|Meloxicam|Meloxicam 15mg, qd
48009829|NCT04856033|BEHAVIORAL|TM|Transcendental Meditation instruction, 12-sessions over 3-4 months with monthly follow-up
48009830|NCT04856033|BEHAVIORAL|PCT|Present Centered Therapy, 12-sessions over 3-4 months with monthly follow-up
48009831|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
48009832|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
48009833|NCT01267903|BIOLOGICAL|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
48009834|NCT01267903|BIOLOGICAL|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
48009835|NCT01267903|BIOLOGICAL|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
48009836|NCT00261924|DEVICE|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
48009837|NCT04102475|OTHER|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
48009838|NCT04102475|OTHER|Control|"After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
48009839|NCT04019158|DEVICE|Virtual reality headset|All participants will walk in the three conditions described earlier in this form
48167478|NCT02600585|BIOLOGICAL|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
48167479|NCT02600585|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
48167480|NCT03917537|GENETIC|HNSCC patients have used Nivolumab|Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
48696950|NCT03674073|BIOLOGICAL|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
48696951|NCT03674073|PROCEDURE|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
48009840|NCT04284696|DIETARY_SUPPLEMENT|Pregnan-C-Gum(R) chewing gum|"Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days ad libitum"
48009841|NCT04284696|DIETARY_SUPPLEMENT|Placebo chewing gum|"Using a chewing gum without vitamin C (per piece/gum) for 14 days ad libitum"
48009842|NCT03930459|PROCEDURE|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
48009843|NCT03930459|DEVICE|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
48009844|NCT01631474|DRUG|CB-03-01|Topical cream, applied once a day
48009845|NCT01631474|DRUG|Vehicle|Topical cream, applied once or twice a day
48009846|NCT01631474|DRUG|CB-03-01|Topical cream, applied twice a day
48009847|NCT02287896|DRUG|ROLEDUMAB|See Arm description
48009848|NCT02143843|DRUG|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
48009849|NCT03551470|PROCEDURE|Robotic one-stage colorectal and liver resection|
48009850|NCT00669357|DEVICE|Abiocor Implantable Replacement Heart|Replacement of heart
48009851|NCT01369875|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
48009852|NCT01369875|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
48009853|NCT01369875|BIOLOGICAL|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
48009854|NCT01369875|BIOLOGICAL|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
48167481|NCT00610818|OTHER|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
48167482|NCT06059209|DIETARY_SUPPLEMENT|Enfamil NeuroPro|FDA Infant formula
48167483|NCT06059209|DIETARY_SUPPLEMENT|Enfamil Infant|FDA Infant formula
48522855|NCT04045769|DRUG|Placebos|5 tablets of placebo to be administered orally
48696952|NCT06318078|OTHER|eCHIS|The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).
48696953|NCT05707078|PROCEDURE|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
48696954|NCT03865745|DIETARY_SUPPLEMENT|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
48370293|NCT02049008|OTHER|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
48515005|NCT05565079|BIOLOGICAL|Regenerative tissue matrix and enamel matrix derivative|Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).
48515006|NCT05565079|BIOLOGICAL|Regenerative tissue matrix|Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
48515007|NCT03979755|OTHER|Application of questionnaires|Application of questionnaires described by telephone.
48696955|NCT03235895|OTHER|Educational material|Educational material given as a part of CME activity as through enhanced internet method
48696956|NCT05917470|DRUG|ONCT-534|ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
48696957|NCT04153175|COMBINATION_PRODUCT|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
48696958|NCT04153175|COMBINATION_PRODUCT|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
48696959|NCT00924430|DRUG|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
48515008|NCT01557517|DRUG|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
48696960|NCT00924430|DRUG|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
48696961|NCT06302400|DEVICE|166Holmium microspheres (QuiremSpheres®)|QuiremSpheres® are a biocompatible microsphere that contain the radionuclide holmium-166 (166Ho), which emits gamma-radiation (81 keV) and high-energy (1.81 MeV) beta-particles.
48696962|NCT05610618|OTHER|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
48696963|NCT03149354|OTHER|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
48167484|NCT05738070|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
48515009|NCT01557517|DRUG|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
48696964|NCT05301257|BEHAVIORAL|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
48696965|NCT03203811|DRUG|HTI-2088|3 dose levels
48515010|NCT02609438|BEHAVIORAL|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
48696966|NCT03203811|DRUG|Placebo|placebo oral tablet
48696967|NCT00566410|DRUG|Dichloroacetate|Continuous daily oral dosage (bid).
48696968|NCT03639636|OTHER|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
48167485|NCT01364441|DRUG|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
48167486|NCT01364441|DRUG|Placebo|Placebo dosed in the same manner as ONO-2952
48522856|NCT04045769|DRUG|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
48696969|NCT02229305|BEHAVIORAL|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
48696970|NCT02229305|BEHAVIORAL|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
48696971|NCT04167059|BEHAVIORAL|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
48167487|NCT02044341|DRUG|AR01|drops administered an needed for pain
48696972|NCT02178852|DEVICE|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
48167488|NCT02044341|DRUG|Glycerin ear drops|placebo drops administered for ear pain
48167489|NCT00352053|DRUG|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
48167490|NCT00352053|DRUG|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
48167491|NCT04208542|DRUG|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
48696973|NCT00535704|BEHAVIORAL|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
48009855|NCT01954485|PROCEDURE|Dental implant placement with a final prosthetic abutment|
48167492|NCT03730311|DRUG|Elpida|elsulfavirine, capsules
48515011|NCT02609438|BEHAVIORAL|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
48515012|NCT03431545|BEHAVIORAL|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
48515013|NCT03431545|BEHAVIORAL|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
48515014|NCT03431545|BEHAVIORAL|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
48515015|NCT03448887|DEVICE|Theranova|Extended HD with theranova
48515016|NCT03448887|DEVICE|Online hemodiafiltration|Online hemodiafiltration
48515017|NCT00378495|DRUG|Miltefosine: initially 2.5 mg/kg/day for 28 days|
48515018|NCT03852537|DRUG|Methylprednisolone|Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
48515019|NCT03852537|OTHER|Usual Care|Usual care as determined by the patients treatment team.
48515020|NCT05967884|DRUG|Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab|Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery
48515021|NCT06581029|OTHER|The multidimensional peer victimization scale (PVS)|The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization
48515022|NCT02943590|DRUG|Placebo|A pill taken once a day
48696974|NCT00535704|BEHAVIORAL|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
48696975|NCT02139878|OTHER|Wild blueberry juice|
48167493|NCT03730311|DRUG|placebo|placebo
48167494|NCT04792255|PROCEDURE|Carotid artery stenting with standard contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
48696976|NCT02139878|OTHER|Placebo wild blueberry juice|
48696977|NCT04011566|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
48696978|NCT04117490|OTHER|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
48696979|NCT04117490|OTHER|Placebo|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
48009856|NCT00528528|DRUG|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
48009857|NCT00528528|DRUG|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
48696980|NCT01828606|DEVICE|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
48696981|NCT01828606|DEVICE|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
48009858|NCT00528528|DRUG|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
48009859|NCT00528528|DRUG|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
48009860|NCT00528528|DRUG|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
48167495|NCT04792255|PROCEDURE|Carotid artery stenting with reduced contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
48696982|NCT03420508|DRUG|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
48167496|NCT04792255|DIAGNOSTIC_TEST|Carotid Duplex Ultrasound|Pre- and postinterventional assessment of the treated internal carotid artery.
48696983|NCT03420508|DIAGNOSTIC_TEST|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
48696984|NCT01647243|OTHER|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
48167497|NCT03223714|DRUG|Conbercept Ophthalmic Injection|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
48167498|NCT03223714|DRUG|sham injection|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
48515023|NCT02943590|DRUG|Atorvastatin|A pill taken once a day
48696985|NCT04717648|DIAGNOSTIC_TEST|Biochemical test|C Reactive protein and sodium
48696986|NCT00640380|OTHER|Nerve stimulation|CPVB with NS
48696987|NCT00640380|OTHER|Loss of resistance to air|CPVB with LOR
48696988|NCT06538077|DRUG|Oral Branched chain Amino acid|The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 24 weeks
48696989|NCT06538077|DRUG|Rifaximin 550 MG|Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 24 weeks
48696990|NCT06538077|DRUG|Lactulose|Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
48167499|NCT03494621|BEHAVIORAL|Protecting Babies While they Sleep Curriculum|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
48515024|NCT05662956|DRUG|Venetoclax in combination with azacitidine and CAG|"Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×10\^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3."
48515025|NCT04620408|DRUG|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
48515026|NCT05968417|OTHER|Observational study - sample collection only.|No intervention - blood and/or bone marrow sample collection only
48696991|NCT06538077|DRUG|Placebo for BCAA|A placebo comparator of 15 gm of skimmed milk powder will be used.
48515027|NCT01308502|DEVICE|Dx-pH probe|Dx-pH probe with 24 hour recording
48522857|NCT04045769|DRUG|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
48522858|NCT04763954|OTHER|Rethink therapeutic game|The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.
48696992|NCT06538077|DRUG|Placebo for Rifaximin 550mg|Identical placebo sugar pills will be used as a placebo.
48696993|NCT01045148|RADIATION|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
48696994|NCT01045148|RADIATION|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
48696995|NCT02269813|OTHER|MammaPrint|
48696996|NCT02269813|OTHER|BluePrint|
48696997|NCT02269813|OTHER|TargetPrint|
48696998|NCT02959853|DRUG|Anastrazole|
48009861|NCT03949075|DRUG|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
48696999|NCT02959853|BEHAVIORAL|weight loss|
48697000|NCT03771638|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
48697001|NCT03771638|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
48697002|NCT06234579|DIAGNOSTIC_TEST|Biopsy (tissue or liquid)|"At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA."
48009862|NCT03949075|DRUG|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
48009863|NCT04694196|DEVICE|Dentulous subjects|Determine the occlusal plane using CN in anterior border of ramus
48009864|NCT05697900|DIETARY_SUPPLEMENT|Creatine Monohydrate|The CrM group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The CrM supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
48370294|NCT01456559|OTHER|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
48697003|NCT02719691|DRUG|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
48697004|NCT02719691|DRUG|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
48697005|NCT01639339|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
48697006|NCT01639339|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
48697007|NCT01639339|DRUG|Standard therapy|"The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
48697008|NCT01663116|GENETIC|Stem cells|"1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
48697009|NCT01663116|GENETIC|Placebo|"1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15"
48697010|NCT02493803|BEHAVIORAL|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
48697011|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
48697012|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
48697013|NCT01568450|DRUG|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
48697014|NCT00206128|DRUG|Seroquel SR|
48009865|NCT05697900|DIETARY_SUPPLEMENT|Placebo|A placebo group intakes five grams of maltodextrin daily throughout the study. The placebo supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
48009866|NCT05697900|DIETARY_SUPPLEMENT|Creatine Hydrochloride|The Cr-HCl group supplemented the diet with five grams of micronized creatine monohydrate per day for eight weeks. The Cr-HCl supplement was fully dissolved in ≈500 mL of water and drank immediately after each training session (in the morning on non-training days).
48009867|NCT04145570|DRUG|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
48009868|NCT04145570|DRUG|Tarceva®|Tarceva® 150 mg
48697015|NCT03255967|BEHAVIORAL|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC
48697016|NCT03255967|BEHAVIORAL|Standard of Care|Subjects receive care through usual home healthcare assignment process.
48697017|NCT00926419|BIOLOGICAL|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
48697018|NCT00926419|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
48697019|NCT02890303|DEVICE|Zepto System|Anterior Capsulotomy using the Zepto System.
48697020|NCT04534179|PROCEDURE|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
48697021|NCT04534179|OTHER|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
48697022|NCT05208515|OTHER|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
48697023|NCT05208515|OTHER|general operating center|send emergency cesarean section needing women from labor room to general operating center
48697024|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
48697025|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
48697026|NCT00946608|DRUG|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
48697027|NCT01651065|BEHAVIORAL|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
48370295|NCT04704908|DRUG|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
48515028|NCT05547217|DEVICE|Hand Therapy using the MyHand System|The MyHandTM System is a smart-mechatronic device programmed with proprietary hand function training regiments (protocols) based on deep research in neuroplasticity. It provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy. Participants will undergo a 2-hour training session, 2-3 days per week, over 12 weeks, for a total of 30 sessions. Hand function therapy will be administered in a specific and gamified manner to enhance rehabilitation of the hand and provide participants with greater opportunity to regain hand function over the course of the study.
48697028|NCT01651065|BEHAVIORAL|Control|
48697029|NCT05358418|OTHER|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
48009869|NCT04388579|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
48370296|NCT00442741|DRUG|Patupilone|
48009870|NCT03662100|BIOLOGICAL|LY3074828|Administered SC
48009871|NCT03662100|DRUG|LY3074828|Administered SC
48009872|NCT03662100|DEVICE|Auto-injector (AI)|AI to administer LY3074828
48370297|NCT00442741|DRUG|Patupilone + Omeprazole|
48370298|NCT01169662|DIETARY_SUPPLEMENT|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
48370299|NCT01169662|DIETARY_SUPPLEMENT|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
48009873|NCT03662100|DEVICE|Prefilled syringe (PFS)|PFS to administer LY3074828
48515029|NCT05560386|BEHAVIORAL|Text messaging|text messaging content to support diabetes prevention.
48515030|NCT05560386|BEHAVIORAL|Virtual workshop|virtual workshop content to support diabetes prevention.
48697030|NCT06580249|DEVICE|Repetitive transcranial magnetic stimulation|The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
48697031|NCT03762889|DEVICE|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
48697032|NCT03762889|DEVICE|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
48697033|NCT03762889|DEVICE|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
48697034|NCT04122911|DRUG|Temozolomide|pharmacological
48697035|NCT00060801|DRUG|BIIL 283 BS (Amelubent)|
48697036|NCT03574610|DEVICE|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
48697037|NCT06058429|OTHER|no intervention|This is an observation study after vaccination, no intervention will be used
48697038|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; low dose
48697039|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection; medium dose
48697040|NCT06396429|DRUG|HRS9531 injection|HRS9531 injection, high dose
48697041|NCT06396429|DRUG|Placebo|blank preparation, participants received matching placebo.
48697042|NCT06317259|BEHAVIORAL|Hypoxic breathwork plus music and messaging|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. The audio track also includes dynamic music that accompanies the different stages as well as positive messaging encouraging self-determination.
48697043|NCT06317259|BEHAVIORAL|Hypoxic breathwork only|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. Other than breathing instructions and pacing, the audio track is silent.
48697044|NCT06317259|BEHAVIORAL|Music and messaging meditation|Music and messaging meditation consists of dynamic music that is engaging and aids focus, as well as positive messaging encouraging self-determination.
48697045|NCT06516146|BEHAVIORAL|Exercise|The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months
48697046|NCT06516146|BEHAVIORAL|Meditation|"The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes.~Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention."
48697047|NCT06516146|BEHAVIORAL|Diet|The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.
48697048|NCT01601106|DRUG|liposomal prednisolone|Two weekly dosages with 150 mg.
48697049|NCT01601106|DRUG|Placebo|
48697050|NCT03825146|BIOLOGICAL|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
48697051|NCT00093197|DRUG|KAI-9803 for Injection|0.05 mg
48697052|NCT00093197|DRUG|KAI-9803 for Injection|0.5 mg
48009874|NCT00042094|BIOLOGICAL|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
48515031|NCT05721911|GENETIC|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
48009875|NCT03865290|DRUG|Ondansetron 8mg|Oral Ondansetron 8 mg
48009876|NCT03865290|DRUG|Placebo|Oral matched placebo
48697053|NCT00093197|DRUG|KAI-9803 for Injection|1.25 mg
48009877|NCT00325806|DRUG|Ramipril|
48009878|NCT04046471|DIETARY_SUPPLEMENT|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
48009879|NCT04046471|BEHAVIORAL|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
48009880|NCT04046471|BEHAVIORAL|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
48009881|NCT03384251|BEHAVIORAL|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
48009882|NCT01621399|DRUG|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
48167500|NCT02552810|DEVICE|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
48515032|NCT00616421|BIOLOGICAL|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
48515033|NCT00616421|BIOLOGICAL|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
48515034|NCT00616421|BIOLOGICAL|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
48515035|NCT06247410|DRUG|Rotigotine 8Mg/24Hrs Patch|Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
48515036|NCT00824343|DRUG|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
48009883|NCT01621399|DRUG|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
48009884|NCT04689087|COMBINATION_PRODUCT|TTFields|For patients with relapsed GBM, before receiving electric field treatment, the patient can be re-operated, and TTFields+BPC chemotherapy is used after surgery
48009885|NCT01588782|DRUG|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
48515037|NCT04975204|DRUG|TQB3909 Tablets|TQB3909 is an inhibitor targeting BCL-2 protein
48515038|NCT04851392|DRUG|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower
48697054|NCT00093197|DRUG|KAI-9803 for Injection|5 mg
48697055|NCT00093197|DRUG|Placebo|
48167501|NCT02552810|DEVICE|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
48697056|NCT02241213|DEVICE|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
48697057|NCT02241213|DEVICE|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
48697058|NCT06326359|PROCEDURE|autologous stromal vascular fraction|autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
48009886|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
48009887|NCT01588782|DRUG|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
48009888|NCT05488899|DIAGNOSTIC_TEST|Half iodine Spectral CT|Patients receive half dosage of iodine contrast agent, and Spectral CT acquisition with Virtual Monoenergetic Images at 40 and 50 keV.
48009889|NCT05488899|DIAGNOSTIC_TEST|Standard iodine conventional CT|Patients receive standard dosage of iodine contrast agent, and conventional 120 kv Polychromatic CT acquisition.
48009890|NCT05446350|PROCEDURE|transcranial alternating current stimulation (tACS)|transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception
48167502|NCT01329185|DRUG|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
48167503|NCT01329185|DRUG|Placebo|1 capsule twice a day for 14 days prior to transplant date
48370300|NCT04548349|DRUG|Altreno|Acne patients will be assigned to Altreno once daily.
48697059|NCT00321074|DRUG|TACROLIMUS|Immunosuppression
48009891|NCT05446350|PROCEDURE|electroencephalography (EEG)|analyse rhythmic electroencephalography responses that outlast the stimulation
48009892|NCT05446350|PROCEDURE|brain imaging (fMRI)|Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants
48009893|NCT05446350|PROCEDURE|electroencephalography (EEG) with neurofeedback|Using neurofeedback to teach participants to enhance their own neural entrainment
48370301|NCT04548349|DRUG|Benzoyl peroxide|Acne patients will be assigned to BPO leave-on gel once daily.
48697060|NCT02977936|DIETARY_SUPPLEMENT|Cartimotil Fort|1 to 4 capsules per day during 90 days
48370302|NCT01801475|DRUG|Ondansetron|Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
48697061|NCT03588806|DRUG|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
48697062|NCT02904629|BEHAVIORAL|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
48515039|NCT04851392|DRUG|Cannabis with THC without CBD|Cannabis with THC without CBD - inhaled and vaporised cannabis flower
48515040|NCT04851392|DRUG|Placebo cannabis|Placebo cannabis, without THC and without CBD - inhaled and vaporised
48515041|NCT01998945|BEHAVIORAL|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
48515042|NCT01998945|BEHAVIORAL|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
48515043|NCT00019240|DRUG|cidofovir|
48515044|NCT01688557|DEVICE|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
48515045|NCT01688557|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
48515046|NCT04574687|OTHER|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
48697063|NCT02904629|OTHER|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
48697064|NCT05970003|OTHER|Copenhagen exercises|"Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
48697065|NCT05970003|OTHER|Holmich exercises|"The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
48697066|NCT02700035|OTHER|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
48697067|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
48697068|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
48370303|NCT03908658|OTHER|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
48370304|NCT03908658|DEVICE|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
48370305|NCT05373472|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
48370306|NCT05373472|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
48370307|NCT00556088|DRUG|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
48515047|NCT04574687|OTHER|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
48515048|NCT04801511|DRUG|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
48515049|NCT05209789|BEHAVIORAL|HUGS|Group therapy with the participation of two therapist positively encouraging mother-baby interactions in a non-judgmental manner
48515050|NCT05209789|BEHAVIORAL|Playtime|Very little intervention from the therapists
48515051|NCT01155973|BEHAVIORAL|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
48515052|NCT01155973|OTHER|Control group|SCORE oral information and counseling as standard practice care
48515053|NCT05761665|OTHER|Evaluation|Kinesiophobia=Tampa scale Balance=Berg Balance Scale Falling=The Fall Activity Scale( Tinetti) Walking speed=Timed Get Up and Walk Test ,Two-Minute Walking Test Fragility=Frail Fragility Questionnaire, Clinical Fragility Scale
48370308|NCT02415491|OTHER|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
48515054|NCT05871554|BEHAVIORAL|Mind-OP+|"Mind-OP is an online program designed to cultivate mindfulness and self-compassion developed by Beshai and his team. Mind-OP is self-guided, with four modules administered at a pace of one module per week (four weeks total). The version used for this study, Mind-OP+, is five weeks total, containing an extra module focused on connectedness.~The modules contain psychoeducational videos, guided audio meditations, goal-setting and motivational interviewing inspired exercises. Participants also have opportunities to engage with meditations and other exercises embedded within each module.~The first module (Week 1) introduces the concept of mindfulness. The second module (Week 2) focuses on attention to bodily sensations and thoughts. The third module (Week 3) introduces the concept of self-compassion. The fourth module (Week 4) focuses on the self-kindness component of self-compassion. The fifth module (Week 5) focuses on the concept of connectedness."
48370309|NCT05360212|PROCEDURE|Anatomy-based fitting (ABF)|MAESTRO 9 can display the tonotopic frequency of each individual electrode channel imported from OTOPLAN to further support fitting based on these measures. The audiologist can set a frequency-band distribution that is more closely aligned to the tonotopic frequency distribution as imported from OTOPLAN.
48515055|NCT01235481|DEVICE|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
48515056|NCT01235481|BEHAVIORAL|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
48515057|NCT01210872|OTHER|questionnaire administration|
48515058|NCT01210872|PROCEDURE|quality-of-life assessment|
48515059|NCT01210872|PROCEDURE|standard follow-up care|
48515060|NCT04570787|PROCEDURE|Urinary bladder catheterisation|Installation of Foley catheter into the urinary bladder
48515061|NCT05445492|DEVICE|CPM Device|The CPM device and reference device are used simultaneous to validate the CPM device.
48515062|NCT01936506|BEHAVIORAL|Cognitive Training A|
48515063|NCT01936506|BEHAVIORAL|Cognitive Training B|
48515064|NCT03742505|DRUG|Cholecalciferol|Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
48515065|NCT03742505|OTHER|Placebo|Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
48697069|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
48370310|NCT05360212|PROCEDURE|Standard Fitting|These group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9.
48370311|NCT05360212|PROCEDURE|Standard fitting+ ABF|Patients of this group are both fitting using the standard frequency-band distribution and the anatomy-based frequency distribution in MAESTRO 9. So, subjects will have both study maps on their audio processor throughout the whole study. They will have to change weekly between both fittings: standard fitting and anatomy-based fitting. Here, the performance with anatomy-based fitting is assessed by comparing performance with standard fitting and anatomy-based fitting.
48370312|NCT03466216|DRUG|AlphaMedix|There is only a single treatment intervention.
48370313|NCT04052425|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
48370314|NCT04052425|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
48370315|NCT03751462|DEVICE|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
48697070|NCT02450448|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
48697071|NCT02450448|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
48697072|NCT00721578|DRUG|voriconazole|Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
48697073|NCT02364115|RADIATION|Stereotactic Body Radiotherapy|
48697074|NCT01207076|BIOLOGICAL|90Y-AHN-12|"The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
48697075|NCT04566393|DRUG|Ulixertinib (BVD-523)|Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
48697076|NCT02182063|DRUG|BIBF 1120 low dose|
48697077|NCT02182063|DRUG|BIBF 1120 high dose|
48697078|NCT06225375|DEVICE|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
48697079|NCT01611116|DRUG|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
48697080|NCT01611116|DRUG|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
48697081|NCT05749510|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
48009894|NCT06009952|OTHER|Cryolipolysis and cavitation devices with vegan diet|"Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months)."
48009895|NCT00179647|DRUG|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
48009896|NCT00179647|DRUG|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
48009897|NCT02669290|OTHER|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
48370316|NCT06265389|DRUG|Pentoxifylline Oral Tablet|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
48370317|NCT03868059|DRUG|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
48370318|NCT03788109|PROCEDURE|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
48370319|NCT02546102|BIOLOGICAL|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
48370320|NCT02546102|BIOLOGICAL|Placebo|Control, autologous monocytes-enriched PBMC.
48697082|NCT00006003|DRUG|semaxanib|Given IV
48697083|NCT00006003|OTHER|laboratory biomarker analysis|Correlative studies
48697084|NCT00346606|DRUG|Denosin® and Xyzal®|
48697085|NCT03907176|DRUG|HTX-011|300 mg
48697086|NCT03907176|DEVICE|Luer lock applicator|Applicator for instillation
48697087|NCT03907176|DRUG|Ibuprofen|600 mg
48697088|NCT03907176|DRUG|Acetaminophen|1 g
48697089|NCT02746887|OTHER|Preterm/term cohort|
48697090|NCT04832802|BEHAVIORAL|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
48009898|NCT02669290|OTHER|Non-guided|LV lead placement will be conventional posterolateral placement
48009899|NCT04341974|DIAGNOSTIC_TEST|Serum creatinine|Will be described: 1) the number of patients actually screened with postoperative serum creatinine and 2) the number of patients actually screened with the same parameter at the long-term after surgery
48009900|NCT01720459|DIETARY_SUPPLEMENT|Micronized trans-resveratrol|
48009901|NCT01720459|DIETARY_SUPPLEMENT|Placebo|
48009902|NCT03364049|DRUG|MK-7162|oral tablets
48009903|NCT03364049|BIOLOGICAL|Pembrolizumab|IV infusion
48009904|NCT05459064|DEVICE|Motiva Flora TE|This is a retrospective, observational study - collecting data on patients who have gone through the staged procedure with the Motiva Flora Tissue Expander / Long-term breast implant.
48009905|NCT00461539|OTHER|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
48697091|NCT04832802|BEHAVIORAL|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
48697092|NCT01000883|OTHER|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
48697093|NCT01000883|OTHER|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
48697094|NCT01000883|PROCEDURE|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
48697095|NCT05611567|PROCEDURE|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
48697096|NCT05611567|BEHAVIORAL|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
48697097|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
48697098|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
48697099|NCT04683276|PROCEDURE|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
48697100|NCT01269229|DRUG|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
48515066|NCT06469203|DRUG|Oxytocin|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
48515067|NCT06469203|DRUG|Sodium Chloride 0.9% Inj|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."
48009906|NCT00461539|BEHAVIORAL|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
48515068|NCT03727880|DRUG|Pembrolizumab|Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.
48009907|NCT01451424|DRUG|Proellex|vaginal suppository, daily, for 12 weeks
48515069|NCT03727880|DRUG|Defactinib|Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.
48515070|NCT05752825|RADIATION|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
48515071|NCT05752825|RADIATION|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
48515072|NCT05752825|DIAGNOSTIC_TEST|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
48515073|NCT05752825|DIAGNOSTIC_TEST|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
48515074|NCT05752825|DIAGNOSTIC_TEST|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of \>13,5 seconds is associated with an increased risk of falls.
48515075|NCT05752825|DIAGNOSTIC_TEST|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
48009908|NCT03200613|DRUG|Apixaban|2.5 mg orally twice daily
48009909|NCT03200613|DRUG|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
48009910|NCT03563768|PROCEDURE|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
48009911|NCT05317975|BEHAVIORAL|Add-on telerehabilitation and home-based rehabilitation|"1. 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~2. Add-on telerehabilitation for instruction and supervision of exercise training"
48009912|NCT05317975|BEHAVIORAL|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
48515076|NCT05752825|DIAGNOSTIC_TEST|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
48515077|NCT05752825|DIAGNOSTIC_TEST|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
48697101|NCT01269229|RADIATION|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
48167504|NCT05524415|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
48167505|NCT05764577|PROCEDURE|DIEP flap surgery|Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
48167506|NCT02671578|DRUG|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
48370321|NCT04566016|PROCEDURE|Regional anesthesia|Patients scheduled for lower limb arterial bypass surgery will be randomly allocated for treatment with spinal anesthesia associated with spontaneous ventilation (nasal cannula with supplemental oxygen - Group 1) or treatment with general anesthesia under controlled mechanical ventilation (tidal volume 6 to 8 ml / kg of the predicted body weight and PEEP of 5 cmH2O - Group 2).
48370322|NCT03415815|PROCEDURE|Surgeries|Radical resection of esophageal cancer
48697102|NCT04218214|OTHER|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
48697103|NCT04177953|DRUG|Carboplatin AUC 5|chemotherapy iv
48697104|NCT04177953|DRUG|Cisplatin 75 mg/m2|chemotherapy iv
48697105|NCT04177953|DRUG|Pemetrexed 500 mg/m2|chemotherapy iv
48697106|NCT04177953|BIOLOGICAL|Nivolumab Injection|Human monoclonal antibody
48697107|NCT06659458|OTHER|blood draw|A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.
48009913|NCT01945515|DEVICE|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
48370323|NCT05346731|DRUG|Ondansetron|Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
48370324|NCT05346731|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
48370325|NCT05346731|DRUG|Aprepitant|"Aprepitant will be administered based on body weight:~body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally"
48370326|NCT05346731|DRUG|Olanzapine|Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
48515078|NCT02543944|DRUG|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
48515079|NCT02543944|DRUG|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
48515080|NCT02543944|DRUG|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
48515081|NCT02543944|DRUG|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
48515082|NCT02543944|DRUG|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
48697108|NCT06659458|OTHER|Gene sequencing|Subjects will have their DNA sequenced within and around the EGFR gene.
48697109|NCT04204694|OTHER|3-time blood sampling for septic shock patients|15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
48697110|NCT04204694|OTHER|Only one blood sampling for controls patients|15 mL blood are sampled from a blood donation
48697111|NCT06068478|DRUG|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
48697112|NCT06068478|DRUG|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
48370327|NCT03389217|DEVICE|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
48370328|NCT03389217|DEVICE|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
48370329|NCT02257502|DRUG|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
48009914|NCT01945515|DEVICE|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
48009915|NCT04749290|OTHER|Study Formula|Study infant formula for term infants containing OPO and CPP
48167507|NCT01909947|OTHER|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~1. A 60-minute period while the infant receives any mode of conventional mechanical ventilation~2. A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
48370330|NCT06062810|DRUG|Crizotinib - Usual|"* XALKORI - crizotinib capsule (high dose)~* XALKORI 250 mg taken orally twice daily"
48370331|NCT06062810|DRUG|Crizotinib - Study|"* XALKORI - crizotinib capsule (low dose)~* XALKORI 200 mg taken orally twice daily"
48515083|NCT02543944|DRUG|Placebo|Microcrystalline cellulose
48515084|NCT02481869|BIOLOGICAL|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
48697113|NCT04820010|DRUG|Topical Insulin|Patients were administered eyedrops enriched with insulin
48697114|NCT06076252|PROCEDURE|Modified Blumgart Anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
48697115|NCT06076252|PROCEDURE|conventional Blumgart anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
48009916|NCT00774033|DEVICE|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
48009917|NCT00774033|PROCEDURE|classic skin grafts|classic skin grafts used for the treatment of acute burn
48009918|NCT02051972|DEVICE|Implanted with a Nanostim leadless pacemaker system|
48167508|NCT02967809|DEVICE|echography|cardiac and pulmonary echography
48167509|NCT01831726|DRUG|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
48697116|NCT05215808|DRUG|RBN-3143|Oral Administration of tablets
48697117|NCT04822896|BEHAVIORAL|Physical Exercise|"The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
48697118|NCT04822896|BEHAVIORAL|Kinesthetic Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
48370332|NCT00405665|DRUG|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
48370333|NCT00405665|DRUG|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
48370334|NCT00329433|DRUG|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
48697119|NCT04822896|BEHAVIORAL|Visual Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
48697120|NCT05255991|DRUG|Placebo|Placebo administered QID
48697121|NCT05255991|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
48697122|NCT05255991|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
48697123|NCT06226610|DRUG|Dupilumab|injection every two weeks while on study
48697124|NCT06226610|OTHER|Placebo|injection every two weeks while on study
48697125|NCT02975479|DRUG|ALK Diluent|
48697126|NCT02975479|DRUG|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
48697127|NCT04015427|DEVICE|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
48697128|NCT04587830|DRUG|ADI-PEG 20|Investigational Medicine
48697129|NCT04587830|DRUG|Temozolomide|Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.
48370335|NCT00329433|DRUG|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
48370336|NCT04522635|DRUG|(100 ml of Albumin 25%)|single dose of 25g albumin (100 ml of Grifols 25%) given intravenously at the start of IHD
48515085|NCT02481869|DRUG|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
48515086|NCT00071279|DRUG|SR34006 (idraparinux sodium) Injection|
48515087|NCT03905577|BEHAVIORAL|Action Observation|Action Observation training
48697130|NCT04587830|DRUG|Placebo|Investigational Medicine
48697131|NCT01377155|DRUG|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
48697132|NCT06300151|DEVICE|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia|Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.
48697133|NCT06300151|DEVICE|Dural Puncture Epidural Labor Analgesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
48697134|NCT05097677|OTHER|Not applicable (observational study)|Not applicable (observational study)
48009919|NCT02832674|DEVICE|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
48167510|NCT00949221|DEVICE|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"* group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
48697135|NCT04511871|BIOLOGICAL|CCT303-406|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
48167511|NCT06406998|OTHER|Pre-existing atherosclerotic cardiovascular disease|Presence of pre-existing atherosclerotic cardiovascular disease
48167512|NCT01801423|DRUG|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at \~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
48167513|NCT06047613|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
48370337|NCT01378624|OTHER|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
48697136|NCT03430843|DRUG|Tislelizumab|200 mg administered intravenously (IV)
48370338|NCT04220294|PROCEDURE|Subcutaneous tissue closure|Subcutaneous tissue closure with 2-0 vicryl suture.
48370339|NCT01623518|BIOLOGICAL|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp"
48370340|NCT00682539|DRUG|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
48515088|NCT03905577|BEHAVIORAL|Motor imagery|Motor imagery protocol
48515089|NCT03905577|BEHAVIORAL|Placebo Action observation|Placebo Action Observation
48697137|NCT03430843|DRUG|Paclitaxel|135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
48697138|NCT03430843|DRUG|Docetaxel|75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
48697139|NCT03430843|DRUG|Irinotecan|125 mg/m\^2 administered IV
48697140|NCT04309890|OTHER|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
48697141|NCT00516906|DRUG|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
48697142|NCT00516906|DRUG|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
48697143|NCT06194604|DEVICE|Instrument-assisted soft tissue mobilization|Instrumented soft tissue mobilization is a type of manual therapy method.Istrumented soft tissue mobilization aims to reduce fascial limitations by increasing circulation. Increases in localized blood flow and soft tissue realignment promote muscle function, increased normal joint movement, and decreased pain.
48697144|NCT06194604|OTHER|Routine rehabilitation programe|Routine rehabilitation programe consisting of stretching and strengthening exercises will be applied.
48697145|NCT03620578|DRUG|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
48697146|NCT06205381|DRUG|AV078|Oral solution containing active ingredient, AV078
48697147|NCT06205381|DRUG|Placebo|Oral solution with no active ingredients
48167514|NCT06047613|OTHER|Hetero-questionnaires and auto-questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself."
48167515|NCT06047613|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
48167516|NCT00312234|BEHAVIORAL|Aerobic exercise|
48167517|NCT00312234|BEHAVIORAL|Qigong exercise|
48697148|NCT06205381|DRUG|Itraconazole|Once daily oral dose of 200 mg itraconazole administered for 9 days
48697149|NCT06205381|DRUG|Midazolam|2.5 mg midazolam administered orally on day 1 and day 18
48697150|NCT06205381|DRUG|Fexofenadine|120 mg fexofenadine administered orally on day 1 and day 18
48697151|NCT05839730|DEVICE|Pacemaker PLR + TRT ON|RAMware modified implantable pulse generator (IPG) with personalized lower rate (PLR) and tachycardia remodeling therapy (TRT) ON
48167518|NCT04231747|BIOLOGICAL|CC-97540|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
48167519|NCT01683643|BEHAVIORAL|SBIRT|Screening, brief intervention, and referral to treatment.
48009920|NCT04643106|PROCEDURE|Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)
48697152|NCT05839730|DEVICE|Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.|RAMware modified implantable pulse generator (IPG)
48697153|NCT03459001|OTHER|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
48009921|NCT04643106|PROCEDURE|suturing with barbed sutures during laparoscopic ovarian cystectomy|During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding
48697154|NCT05647265|BIOLOGICAL|Nivolumab|Given IV
48697155|NCT05647265|BIOLOGICAL|Ipilimumab|Given IV
48697156|NCT05647265|PROCEDURE|Surgical Procedure|Undergo surgery
48697157|NCT05647265|PROCEDURE|Computed Tomography|undergo CT
48697158|NCT05647265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48009922|NCT01096784|DRUG|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
48009923|NCT04922333|DRUG|Risedronate|150mg over-encapsulated risedronate
48009924|NCT04922333|DRUG|Placebo|Capsules containing placebo tablets
48009925|NCT00947583|BIOLOGICAL|Osteocel Plus|biologic
48009926|NCT00945503|DRUG|GSK1018921|GSK1018921 is a GT1 recepor antagonist
48167520|NCT01683643|BEHAVIORAL|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
48167521|NCT02923817|BIOLOGICAL|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
48167522|NCT03809286|DEVICE|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
48167523|NCT03809286|BEHAVIORAL|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
48009927|NCT03522376|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
48167524|NCT03809286|DEVICE|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
48167525|NCT03228277|DRUG|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
48370341|NCT00682539|DRUG|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
48167526|NCT03684356|PROCEDURE|socket shield technique|immediate implant placement with buccal part of the root is retained
48167527|NCT03684356|PROCEDURE|xenograft|immediate implant placement with filling the buccal gap with xenograft
48167528|NCT03416335|DRUG|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
48167529|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
48167530|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
48167531|NCT02041221|DRUG|SPARC1316 Dose 1|The subjects will receive SPARC1316.
48167532|NCT02041221|DRUG|Placebo|
48697159|NCT05647265|PROCEDURE|Positron Emission Tomography|Undergo PET
48697160|NCT00980512|BEHAVIORAL|Parent Training|16 weeks of parent training led by trained group facilitator
48697161|NCT01985711|DEVICE|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
48697162|NCT01985711|OTHER|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
48697163|NCT01985711|BEHAVIORAL|usual diabetes outpatient care|
48697164|NCT06483282|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
48697165|NCT06483282|DRUG|Apatinib Mesylate|This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.
48697166|NCT06483282|DRUG|Etoposide|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).
48697167|NCT06483282|DRUG|Carboplatin|This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).
48697168|NCT04673942|BIOLOGICAL|AdAPT-001|Oncolytic virus administered by intratumoral injection
48697169|NCT04673942|DRUG|Checkpoint Inhibitor, Immune|Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
48009928|NCT05626881|DRUG|PRP|"It will include patients with melasma treated with PRP sessions every two weeks for three months. 10 ml of venous blood will withdraw by means of a wide bore needle and a vacutainer containing an anticoagulant (Acid citrate dextrose).~Double centrifugation will be done. First centrifugation, will be done for 10 minutes. After the first centrifugation, three layers will be seen , Second centrifugation will be done for 10 min, after which the platelets separate and form a grayish pellet at the bottom of the tube and the rest will be platelet-poor plasma. About 1 ml of this platelet-poor plasma will be decanted off and the platelet pellet will be resuspended in the remaining plasma to get PRP. With 10 ml blood, about 1-1.5 ml of PRP will be obtained.~PRP is injected intralesionally at the site of melasma using a 30 G hypodermic needle through an insulin syringe."
48697170|NCT06660784|DRUG|Nitric Oxide|Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
48697171|NCT06168058|DIAGNOSTIC_TEST|Transcatheter Venography|Venographic assessment of ovarian veins and internal iliac veins
48167533|NCT02041221|DRUG|SPARC1316 Dose 2|
48697172|NCT06168058|PROCEDURE|Bilateral ovarian vein embolization|Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.
48697173|NCT03824678|DRUG|CC-220|CC-220
48697174|NCT00862758|DRUG|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
48370342|NCT00682539|DRUG|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
48370343|NCT00682539|PROCEDURE|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
48009929|NCT05626881|DRUG|sylimarin cream|Silymarin was manufactured with concentration of 1.4%
48009930|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
48009931|NCT00841438|DRUG|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
48167534|NCT02041221|DRUG|SPARC1316 Dose 3|
48167535|NCT02041221|DRUG|SPARC1316 Dose 4|
48167536|NCT02041221|DRUG|SPARC1316 Dose 5|
48167537|NCT04024514|OTHER|low dose CT contrast media|CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
48167538|NCT04024514|OTHER|Standard dose CT contrast media|CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
48370344|NCT02988115|DRUG|bempedoic acid|bempedoic acid 180 mg tablet
48697175|NCT03623321|DRUG|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
48697176|NCT05872542|DRUG|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
48697177|NCT05872542|OTHER|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
48697178|NCT05872542|OTHER|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
48697179|NCT00246051|BEHAVIORAL|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
48697180|NCT00246051|OTHER|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~1. Positive on the Berlin Questionnaire~2. Clinic visit, exam with a physician, given a home diagnostic device (HDD)~3. High risk on HDD, seen by physician, given a CPAP machine~4. Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~5. Contacted by a sleep health clinic at 3, 6, 12 months~6. After 12 months subject will be referred to their primary care physician"
48009932|NCT02699944|DEVICE|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
48009933|NCT04865835|DRUG|placebo|single dose of placebo
48009934|NCT04865835|DRUG|SEP-363856|single dose of SEP 363856 100 mg
48370345|NCT02988115|OTHER|placebo|Matching placebo tablet
48370346|NCT05551182|DRUG|Nicergoline|The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
48370347|NCT00072982|DRUG|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
48370348|NCT00072982|DRUG|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
48370349|NCT00072982|DRUG|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
48370350|NCT05278663|DRUG|E6742|E6742 tablet.
48370351|NCT05278663|OTHER|Placebo|E6742-matching placebo tablet.
48370352|NCT05196386|BEHAVIORAL|Admission conciliation interview|Previous treatment conciliation at hospital admission
48370353|NCT05196386|BEHAVIORAL|Discharge conciliation interview|Allocated treatment during hospital stay
48370354|NCT05196386|BEHAVIORAL|Targeted pharmaceutical interview|Specific information about treatment delivered by pharmacist
48370355|NCT04672694|PROCEDURE|Vagus nerve block|Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.
48009935|NCT04865835|DRUG|metformin|metformin-HCl 850 mg
48370356|NCT04672694|PROCEDURE|No vagus nerve block|No vagus nerve block will be conducted during the surgery.
48370357|NCT05502809|DRUG|Deep-frozen platelets|Cryopreserved platelets
48370358|NCT02702115|BIOLOGICAL|SB-318|A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
48009936|NCT00197379|DRUG|roxithromycin|
48009937|NCT01173302|BIOLOGICAL|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
48370359|NCT01219179|OTHER|Sterile water feedings|"Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
48370360|NCT03858621|DRUG|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
48697181|NCT00246051|OTHER|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
48697182|NCT03951831|DRUG|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
48697183|NCT03951831|DRUG|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
48697184|NCT03951831|DRUG|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
48697185|NCT03951831|DRUG|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
48009938|NCT04083417|DRUG|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
48009939|NCT04083417|OTHER|No antibiotic treatment|No prescription of antibiotics
48009940|NCT02435251|DEVICE|dual energy X-ray absorptiometry|
48009941|NCT05114304|OTHER|Evaluation of co-morbid psychiatric disorders|"Added scales :~* Mini Internationnal Neuropsychiatric Interview~* Fagerström test~* DSM-5 Scale~Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics~Expired carbon monoxide for patients using nicotine substitutes"
48009942|NCT02399085|DRUG|Tafasitamab|12 mg/kg
48370361|NCT05342870|DRUG|Dexmedetomidine|Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
48370362|NCT05538507|DRUG|smart soup|Severe AD, mild or moderate AD and MCI will be given smart soup
48370363|NCT05538507|DRUG|Donepezil|Severe AD and mild or moderate AD will be given donepezil
48370364|NCT05538507|DRUG|Memantine|Severe AD will be given memantine
48370365|NCT05538507|DRUG|Placebo|patients with MCI will be given placebo
48370366|NCT00140816|BEHAVIORAL|Increased intake of dairy products|
48697186|NCT04657835|DEVICE|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
48697187|NCT04657835|BIOLOGICAL|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
48009943|NCT02399085|DRUG|Lenalidomide|25 mg
48009944|NCT00956410|BIOLOGICAL|CAD106|
48009945|NCT03251248|DRUG|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
48009946|NCT03251248|DRUG|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
48009947|NCT06431828|OTHER|APP|The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
48697188|NCT04657835|PROCEDURE|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
48697189|NCT04657835|DEVICE|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
48697190|NCT04657835|OTHER|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
48697191|NCT03037359|BIOLOGICAL|Bivigam|Human immune globulin
48697192|NCT03037359|BIOLOGICAL|Other|Human immune globulin
48697193|NCT04268329|OTHER|Educational website|A website is used to educate patients and family members about head and neck cancer.
48697194|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
48167539|NCT04087070|DEVICE|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)"
48370367|NCT05296239|OTHER|SimpleC Wellness Platform with Social Robot Interaction|"Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia."
48370368|NCT00957827|DRUG|keflex|keflex 500 mg BID 5 days
48370369|NCT00957827|DRUG|placebo|placebo BID for five days
48697195|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
48697196|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
48697197|NCT01205932|DRUG|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
48697198|NCT06264089|PROCEDURE|Preservation Rhinoplasty Nasal Valve Angle and Area|The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
48697199|NCT05868265|DRUG|Enfortumab Vedotin|All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
48697200|NCT05868265|PROCEDURE|Radical surgery|Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).
48697201|NCT02684058|DRUG|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
48009948|NCT01697657|DRUG|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
48009949|NCT01697657|DRUG|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
48009950|NCT01697657|DRUG|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
48697202|NCT02684058|DRUG|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
48009951|NCT04838366|DIETARY_SUPPLEMENT|Carbohydrate loading|study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
48009952|NCT01594593|BEHAVIORAL|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
48009953|NCT00989729|DRUG|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
48009954|NCT00989729|DRUG|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
48009955|NCT02720575|OTHER|Consumption of capsule/bread with vitamin D|
48167540|NCT00463580|DRUG|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
48167541|NCT00463580|DRUG|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
48167542|NCT03535480|DRUG|G-CSF|G-CSF subcutaneously during five days
48167543|NCT03535480|COMBINATION_PRODUCT|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
48370370|NCT05417581|PROCEDURE|adipose surgery|A quantity of adipose tissue equivalent to 10-20 cubic centimeter will be removed subcutaneously and from the omentum during surgical procedures (oncological, bariatric)
48167544|NCT01849913|OTHER|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
48515090|NCT02494167|BIOLOGICAL|MultiTAA-specific T cells|"The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 107 cells/m2; Dose Level Five: 1 x 108 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
48370371|NCT00967356|DRUG|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
48515091|NCT00461201|PROCEDURE|Nurse practitioner care of patients|
48515092|NCT00002897|DRUG|cisplatin|
48697203|NCT02684058|DRUG|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
48009956|NCT00951054|DRUG|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m\^2 (or 18 mg/m\^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m\^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
48009957|NCT01917071|OTHER|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
48515093|NCT00002897|DRUG|fluorouracil|
48697204|NCT02684058|DRUG|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
48697205|NCT00675441|DRUG|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
48697206|NCT03650894|DRUG|Nivolumab|Nivolumab 240 mg IV every 2 weeks
48697207|NCT03650894|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
48697208|NCT03650894|DRUG|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
48009958|NCT06051058|BEHAVIORAL|Care Transitions App|Patients in the intervention arm will be randomized to receive the Care Transitions App and utilize it to support their care transition care plan for multiple chronic conditions.
48515094|NCT00002897|PROCEDURE|conventional surgery|
48515095|NCT06136000|OTHER|Sacral erectör spinae plane block|Group S will be placed on their side. Asepsis is fifth in the transverse plane under antisepsis standards. high-frequency linear USG probe into the spinous process . The USG probe will be shifted caudally to visualize the first and second median sacral crest. The USG probe is then placed on the second medial It will be placed 3-4 cm lateral to the sacral apex and the mid-sacral apex will be imaged. On the USG screen, from top to bottom, erector spinae muscle, multifidus muscle and sacral intermediate The crest will be displayed. 0.25% bupivacaine will be administered in a total volume of 0.5ml/kg (maximum 20 cc ) by applying negative aspiration with the in-plane technique with a 50 mm Stimuplex A needle.
48697209|NCT06090981|DRUG|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
48009959|NCT02915549|OTHER|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
48009960|NCT02915549|OTHER|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
48167545|NCT01849913|OTHER|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
48167546|NCT05492123|DRUG|Nivolumab 40 mg in 4 ml Injection|Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
48167547|NCT05492123|DRUG|Ipilimumab 200 MG in 40 ML Injection|Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
48167548|NCT05492123|RADIATION|Chemoradiation|Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
48697210|NCT02043912|DRUG|Haloperidol|
48697211|NCT01321918|OTHER|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
48167549|NCT00799747|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
48167550|NCT00799747|DRUG|Placebo|placebo
48167551|NCT05278065|OTHER|Nicotine|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
48167552|NCT03891498|DRUG|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
48370372|NCT00967356|DRUG|Placebo|Oral suspension
48515096|NCT06136000|OTHER|Ring Block|The patient is under general anesthesia. Before the surgical procedure begins, the pediatric surgeon administers 0.5ml/kg (maximum 20cc) 0.25% bupivacaine to the base of the root of the penis with a 25-gauge needle at 3, 6, 9, and 12 o'clock.
48167553|NCT05625568|DRUG|VYNT-0126|Liquid for oral administration once daily
48167554|NCT05625568|DRUG|Placebo|Liquid for oral administration once daily
48697212|NCT01321918|OTHER|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
48697213|NCT05142917|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
48697214|NCT05142917|BEHAVIORAL|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
48697215|NCT04897230|BEHAVIORAL|Hatha Yoga|The yoga poses were chosen for providing a restorative session based on their purported relationship to restorative effects to best promote cardiac autonomic recovery from mental stress.
48697216|NCT04897230|BEHAVIORAL|Video Watching|The video was about the history of the Earth which encompasses the development of the planet Earth from its formation to the present day.
48697217|NCT06660537|PROCEDURE|Balloon-blowing exercises in 90/90 bridge position with a ball.|In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their back off the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.
48167555|NCT04957407|OTHER|pepsinogen|diagnostic value of pepsinogen for severe atrophy and gastric cancer
48167556|NCT05611658|OTHER|MR, PET CT|diagnostic method
48370373|NCT00267202|DRUG|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
48370374|NCT00267202|DRUG|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
48370375|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
48370376|NCT00267202|DRUG|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
48167557|NCT00334139|DRUG|Zoledronic Acid|every 4 weeks for 4 months
48167558|NCT04885764|BIOLOGICAL|Astrazeneca/Oxford Vaccine|Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart
48370377|NCT06066242|OTHER|Different induction chemotherapy regimens|azacitidine combined with venetoclax or chemotherapy with or without venetoclax
48009961|NCT04382638|COMBINATION_PRODUCT|RCO group|Patients in the experimental group will receive RCO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
48009962|NCT04382638|DEVICE|TLSO group|Patients in the experimental group will receive TLSO fabrication with standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will attend study assessments at baseline, 3 months, 6 months, 12 months and every year until they reach skeletal maturity or if surgical intervention is required.
48009963|NCT04085822|DEVICE|SMA-001|Intra-dermal injection of SMA-001 and control device.
48009964|NCT05354375|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
48167559|NCT04885764|BIOLOGICAL|Sinopharm vaccine|Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart
48167560|NCT03192202|DRUG|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
48167561|NCT02960126|DRUG|Aspirin|
48167562|NCT02960126|DRUG|Clopidogrel|
48167563|NCT06277024|DRUG|Combination of Cardonizumab with Lenvatinib and SOX regimen|"Phase 1: Conduct a ramp up test on the dosage of lenvatinib according to the traditional 3+3 design; Phase 2: 6 cycles of treatment with candenizumab+lenvatinib+SOX regimen (Q3W); For patients who have not progressed, they will enter the third stage of maintenance treatment.~Phase 3: Maintenance therapy with candenizumab, lenvatinib, and tigio (Q3W)."
48167564|NCT05691283|DEVICE|trans cranial direct current stimulation (tDCS)|Three weeks of 20-minute tDCS stimulation
48167565|NCT05691283|DEVICE|Sham|Three weeks of sham stimulation
48167566|NCT03065205|DEVICE|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
48167567|NCT02413593|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
48515097|NCT04323943|DEVICE|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
48515098|NCT00202930|DRUG|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
48515099|NCT00905671|DEVICE|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
48515100|NCT03165292|RADIATION|mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
48697218|NCT06660537|PROCEDURE|Buteyko breathing exercises management|In this group, patients will receive Buteyko breathing exercises, which consist of two main exercises; the control pause and the maximum pause. For control pause, patients exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds. In Maximum pause, patients exhale, plug their nose, and hold their breath as long as possible, aiming for double the control pause time, then inhale and breath normally for 10 seconds. This is a 4-week protocol with three sessions per week. Pre- and post-intervention values will be recorded to assess progress.
48009965|NCT06402058|DEVICE|DMSB01|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
48370378|NCT01647204|OTHER|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
48370379|NCT05024721|DRUG|HIP2101|Test drug
48370380|NCT05024721|DRUG|RLD2101|Reference drug
48370381|NCT05024721|DRUG|HPP2101|Placebo drug
48370382|NCT05024721|DRUG|HPP2102|Placebo drug
48370383|NCT00403429|DRUG|capecitabine|
48515101|NCT03165292|DRUG|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
48515102|NCT03165292|DRUG|Thiotepa|Day 1-3 Thiotepa
48515103|NCT03165292|PROCEDURE|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
48697219|NCT06029283|DIETARY_SUPPLEMENT|dietary nitrate|dietary nitrate in a chewing gum delivery vehicle
48009966|NCT06402058|DEVICE|Rejuran®|Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
48009967|NCT02069522|OTHER|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
48009968|NCT02069522|OTHER|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
48009969|NCT02189187|BEHAVIORAL|Mindfulness|
48009970|NCT02189187|BEHAVIORAL|Psychoeducation|
48370384|NCT00820365|DRUG|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
48515104|NCT04107272|DEVICE|Real repetitive transcranial magnetic stimulation|"The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil."
48697220|NCT06029283|OTHER|Placebo chewing gum|placebo chewing gum
48009971|NCT06366971|OTHER|The Patient Education|The patient education will be given through a brochure and the content of the education included an exercise training consisting of simple exercises for lumbar stabilization (supine bridge, cat-camel, and lumbar stretching) and the participants will be asked to perform these exercises in 3 sets of 10 repetitions 3 days a week for 6-weeks.
48009972|NCT06366971|OTHER|The Pelvic Proprioceptive Neuromuscular Facilitation Techniques Training|The content of the pelvic proprioceptive neuromuscular facilitation techniques training will include the application of the anterior depression pattern with the rhythmic initiation technique and the application of the posterior elevation pattern with the contract-relax stretch technique. All PNF techniques will be performed in 3 sets of 10 to 12 repetitions. The pelvic proprioceptive neuromuscular facilitation techniques training will be delivered face to face 3 days a week for 6 weeks by an experienced and trained physiotherapist.
48697221|NCT02910401|BIOLOGICAL|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
48370385|NCT02263976|DRUG|BEA 2180 BR|
48370386|NCT02263976|DRUG|Placebo|
48370387|NCT02263976|DEVICE|Respimat® A 4|
48370388|NCT02263976|DRUG|Methacholine Chloride|methacholine challenge test
48370389|NCT02263976|DRUG|Spiriva|
48370390|NCT02038699|DRUG|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
48370391|NCT01020812|PROCEDURE|TACE|Standard of Care
48370392|NCT01020812|PROCEDURE|SBRT|Standard of Care
48370393|NCT06261658|PROCEDURE|Cryopreserved Ovarian Tissue Reimplantation|Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
48370394|NCT03937882|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
48370395|NCT03937882|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
48370396|NCT01040000|DRUG|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
48370397|NCT01249404|BIOLOGICAL|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
48370398|NCT01249404|DRUG|Placebo|I.M. injection on day 1 (single treatment cycle)
48009973|NCT05049148|OTHER|Platelet count in excised tumors|Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
48009974|NCT04399161|DRUG|Chlorhexidine mouthwash|A commercially available Chlorhexidine mouth rinse (Hexidine- 0.2 percentage Chlorhexidine gluconate) containing 0.2 percentage chlorhexidine gluconate per 10 ml will be used. 7.5 ml of the concentrate diluted with equal amounts of water to make 15ml will be used for rinsing.
48009975|NCT04399161|DRUG|Xylitol|Xylitol mouth rinse at 10 percentage concentration will be used. The mouth rinse will be prepared by dissolving 1.5 gm of xylitol powder in 15 ml of water.
48697222|NCT06659159|DIAGNOSTIC_TEST|Gastric ultrasound|"The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed."
48009976|NCT04399161|DRUG|Probiotic|Probiotic mouth rinse will be prepared by using a commercially available probiotic product (Sporolac Plus powder- 1gm sachet containing not less than 1.5 billion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Bacillus coagulans, Saccharomyces boulardii). Each sachet will be dissolved in 15 ml of water in a measuring cup and used as a mouth rinse.
48009977|NCT01983657|DRUG|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
48167568|NCT02413593|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48167569|NCT06274450|COMBINATION_PRODUCT|skin care product|Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream
48697223|NCT00271856|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
48697224|NCT00271856|BEHAVIORAL|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
48697225|NCT02973347|OTHER|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
48697226|NCT02973347|OTHER|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
48167570|NCT06274450|OTHER|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
48167571|NCT05235997|DIETARY_SUPPLEMENT|Hydrolized Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
48167572|NCT05235997|OTHER|Placebo|Placebo look alike the experimental product
48167573|NCT00583050|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
48167574|NCT05031468|BIOLOGICAL|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
48167575|NCT03497780|PROCEDURE|Anterior cruciate ligament reconstruction|Primary surgical reconstruction of the rupture anterior cruciate ligament
48167576|NCT00999141|BIOLOGICAL|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
48167577|NCT00815919|DRUG|bortezomib|Given intravenously at a dose of 1.3 mg/m\^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
48370399|NCT02582593|DEVICE|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
48370400|NCT02582593|DEVICE|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
48370401|NCT03417648|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
48697227|NCT04627675|DRUG|CORVax|DNA-encodable coronaviral vaccine
48697228|NCT04627675|DRUG|IL-12 plasmid|cytokine
48697229|NCT04627675|DEVICE|Cliniporator|electroporation system
48167578|NCT00815919|DRUG|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
48697230|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
48697231|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
48697232|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
48697233|NCT01424748|DIETARY_SUPPLEMENT|Tahitian Noni Juice|noni fruit juice
48697234|NCT01424748|DIETARY_SUPPLEMENT|Placebo|Placebo juice
48697235|NCT03892668|DRUG|Tranexamic Acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
48697236|NCT03892668|DRUG|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
48697237|NCT03892668|DRUG|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
48697238|NCT02427386|DRUG|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
48697239|NCT02427386|DRUG|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
48697240|NCT00098046|DRUG|famciclovir|
48697241|NCT05548712|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
48697242|NCT05548712|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
48697243|NCT03652064|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
48697244|NCT03652064|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
48697245|NCT03652064|DRUG|Lenalidomide|Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
48697246|NCT03652064|DRUG|Dexamethasone|Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
48697247|NCT05968261|PROCEDURE|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
48697248|NCT03583268|OTHER|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
48697249|NCT01299220|DRUG|Acitretin|Acitretin 10 mg by mouth daily
48697250|NCT03495310|BEHAVIORAL|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
48370402|NCT03417648|OTHER|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
48370403|NCT02213666|DEVICE|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
48697251|NCT00152477|DRUG|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
48697252|NCT00152477|DRUG|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
48697253|NCT00152477|DRUG|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
48697254|NCT00152477|DRUG|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
48697255|NCT03558334|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
48697256|NCT03558334|DRUG|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
48370404|NCT02748096|PROCEDURE|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
48370405|NCT02748096|PROCEDURE|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
48370406|NCT06181903|BEHAVIORAL|Emotional freedom technique group|Control group
48009978|NCT01983657|PROCEDURE|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
48009979|NCT03857802|BEHAVIORAL|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~1. Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~2. Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~3. Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
48009980|NCT06444477|OTHER|ITP and cancer|ITP and cancer
48009981|NCT03343691|DIAGNOSTIC_TEST|Screening Population|Blood samples taken from screening population
48009982|NCT03343691|DIAGNOSTIC_TEST|Breast Cancer Population|Blood samples taken from Breast Cancer population
48009983|NCT00222287|BEHAVIORAL|Feldenkrais Movement class|
48009984|NCT03848546|BEHAVIORAL|PDA|"Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread)."
48009985|NCT03848546|OTHER|Control (no intervention)|No intervention
48009986|NCT05018572|BEHAVIORAL|I AM|"I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks."
48009987|NCT04661345|OTHER|Proteomic analysis of synovial fluids|Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
48009988|NCT04661345|OTHER|Proteomic analysis of the isolated coagulase-negative Staphylococci|Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
48009989|NCT05336903|BEHAVIORAL|APP-led model of care for chronic pain management|"The APP will provide an assessment using a biopsychosocial approach. The assessment will include:~* taking a comprehensive history~* screening for pathologies contributing to the participant's chronic pain~* a physical assessment~* screening for comorbid health conditions, using the appropriate screening tools, that require specific care (e.g., depression, addiction, post-traumatic stress)~* identifying psychosocial risk factors associated with pain and disability~* evaluating pain severity and interference~The APP will make recommendations to the participant and the chronic pain clinic health care team based on findings from the comprehensive assessment. These recommendations include, but are not limited to, the need for urgent or emergent referrals, medication management, referral and integration of other health care providers, the need for interventional procedures, or group-based treatment options."
48009990|NCT05168475|BIOLOGICAL|Rituximab|Hospital stock of rituximab used as intervention; biosimilars are allowed
48009991|NCT05168475|BIOLOGICAL|Infliximab|Hospital stock of infliximab is used in the trial; biosimilars are allowed
48370407|NCT03852446|DRUG|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
48009992|NCT05168475|BIOLOGICAL|Tocilizumab|Hospital-supplied stock.
48167579|NCT01860495|PROCEDURE|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
48167580|NCT01860495|PROCEDURE|G2|tradetional occlusive collagen membrane
48370408|NCT03852446|DRUG|Indoximod base formulation|Single oral administration of 1200 mg
48370409|NCT03852446|OTHER|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
48370410|NCT03852446|DRUG|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
48697257|NCT01024972|DRUG|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
48697258|NCT01024972|DRUG|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
48697259|NCT01017744|DEVICE|Anesthetic Conserving Device|"* Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~* Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
48697260|NCT00370760|DRUG|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
48697261|NCT00370760|DRUG|placebo|
48009993|NCT04341896|OTHER|Caregivers|Individuals who cared for themselves and their transplant recipient before and after kidney donation
48009994|NCT04341896|OTHER|Non-caregivers|Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
48009995|NCT00305617|OTHER|antitumor drug screening assay|
48370411|NCT04675502|OTHER|supervised Exercise training|warm-up, loading (respiratory control training, breathing exercises, posture exercises with respiratory control , walking on the treadmill for 20 minutes without inclination , pedaling in the bicycle ergometer for 10 minutes), cooling, and relaxation exercises
48370412|NCT04675502|OTHER|home exercise trainig|Warm-up, loading (respiratory control training, shrunken lip breathing exhaustion, diaphragmatic, thoracic expansion exercises, posture exercises with respiratory control (pectoral stretching, four-way trunk exercises, head and neck exercises, bilateral shoulder flexion and abduction exercises), cooling and relaxation exercises
48370413|NCT02711085|OTHER|No intervention|No intervention - observational study
48370414|NCT04169789|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
48697262|NCT05968053|DIAGNOSTIC_TEST|biological samples analysis|biological samples analysis
48697263|NCT02227082|RADIATION|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
48009996|NCT04013191|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
48009997|NCT00565279|DRUG|ASF1057|Twice daily, topical
48009998|NCT00565279|DRUG|ASF1057|Twice daily, Topical
48370415|NCT05797467|DRUG|FOLFOX chemotherapy regimens|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
48009999|NCT05521204|DRUG|Olverembatinib|Given PO
48010000|NCT02412969|PROCEDURE|Lumbar Epidural|control group will receive lumbar puncture epidural
48010001|NCT02412969|PROCEDURE|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
48697264|NCT02227082|DRUG|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
48697265|NCT06154889|OTHER|consultations with a psychologist|Consultations with a sports psychologist to decrease kinesiophobia
48697266|NCT06154889|OTHER|Conventional reeducation|Conventional reeducation
48010002|NCT05850156|PROCEDURE|basal blood collection|blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
48010003|NCT05850156|PROCEDURE|blood collection M6|6 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
48010004|NCT05850156|PROCEDURE|blood collection M12|12 months +/- 2 months after inclusion, a blood collection is performed in the context of routine care for hemoglobin analysis. An additional volume of 300µL of blood is taken for the purposes of the study
48370416|NCT05797467|DRUG|Bevacizumab|Targeted therapy regimens are recommended based on gene testing results. For colorectal cancer patients with KRAS/NRAS/BRAF gene mutations, it is recommended to use Bevacizumab in combination with chemotherapy. For right-sided colon cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Bevacizumab. For left-sided colon and rectal cancer patients with wild-type KRAS/NRAS/BRAF genes, it is recommended to use Cetuximab.When using targeted therapy in combination with chemotherapy, the treatment course should be synchronized with chemotherapy (Bev 5mg/kg iv d1 or Cet 500mg/m2 iv d1).
48370417|NCT04032002|OTHER|Explorations|On Day 1 vascular fonctions explorations performed
48697267|NCT03425435|OTHER|QoL and developed questionnaires for healthcare research|Questionnaires
48167581|NCT06196073|OTHER|Osteopathic manual therapy|Bilateral oscillation therapy to the T10-L2 region for the regulation of sympathetic tone, suboccipital release technique for the regulation of parasympathetic tone, sacrum mobilization, celiac, mesenteric superior and inferior ganglion mobilizations, colon peristalsis and ileocecal valve mobilization for the treatment of functional dysfunctions, ascending colon mobilization, transverse colon. mobilization, descending colon fascia mobilization and sigmoid colon mobilization, peritoneal mobilization
48167582|NCT06196073|DIETARY_SUPPLEMENT|conservative treatment|Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation
48697268|NCT03321864|PROCEDURE|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
48167583|NCT06117202|OTHER|music therapy|The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
48370418|NCT04032002|OTHER|Blood samples|On Day 1 35ml taken
48370419|NCT00967889|GENETIC|gene expression analysis|
48370420|NCT00967889|GENETIC|protein analysis|
48697269|NCT01660672|DRUG|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
48697270|NCT04593849|OTHER|Ru-Yih-Jin- Huang-Saan(RYJHS), Wan-Yin-Gao-Jia-Jean-Wey(WYGJJW), placebo ( topical agent without therapeutic effects)|We conduct a clinical trial using topical herbal medicine, including Ru-Yih-Jin- Huang-Saan(RYJHS) and Wan-Yin-Gao-Jia-Jean-Wey (WYGJJW) in treating post fracture pain and tissue swell. 24 eligible participants diagnosed of upper limb fracture with soft tissue injury grading of C1, C0 from Tscherne classification transferred from Orthopedic outpatient clinic and inpatient will be enrolled and randomly allocated to 4 groups, including experimental group A (RYJHS group), group B (WYGJJW group), placebo group( topical agent without therapeutic effects), and control group (only oral analgesics group), with 6 participants in each group.
48010005|NCT03620851|OTHER|effect of age|effect of age on the efficiency of enhanced recovery program
48010006|NCT05120167|DIAGNOSTIC_TEST|Endocervical liquid-base cytology|Endocervical sample collected by brushing and preserved in a liquid-base.
48010007|NCT05120167|DIAGNOSTIC_TEST|Endocervical cell block|"Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology."
48010008|NCT05120167|DIAGNOSTIC_TEST|Endocervical curettage|Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
48010009|NCT01243346|DRUG|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
48010010|NCT01640730|DRUG|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
48010011|NCT00580424|DRUG|Norethindrone|Norethindrone 0.35 mg orally daily
48010012|NCT05787951|DIAGNOSTIC_TEST|Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc
48167584|NCT00554086|DRUG|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
48370421|NCT00967889|OTHER|biologic sample preservation procedure|
48370422|NCT00967889|OTHER|laboratory biomarker analysis|
48515105|NCT04107272|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
48515106|NCT00424229|DRUG|LENALIDOMIDE|
48697271|NCT06125925|PROCEDURE|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
48010013|NCT04985253|OTHER|prediction of overall survival using Web based PREDICTV2.0 portal|"Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age."
48010014|NCT02672371|DEVICE|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
48010015|NCT02672371|DEVICE|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
48010016|NCT02047110|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
48010017|NCT02047110|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
48010018|NCT05010174|DRUG|MDR product|Observation of patients previously receiving MDR product(s)
48167585|NCT06061224|BEHAVIORAL|early mobilization (physical therapy)|"The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department"
48167586|NCT01239537|DRUG|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
48370423|NCT04745052|OTHER|Clinical observation index|The first is to verify the application effect of intravenous thrombolytic hemorrhage prediction models (HAT, SIT-sICH, THRIVE) in the population of acute ischemic stroke in Guangdong Province, and verify the clinical application effects of existing prediction models. Secondly, analyze the predictive value of clinical indicators, optimize HAT, SIT-sICH, and THRIVE scores, construct an improved HT prediction model, and optimize and improve the existing prediction model. The third is to apply the improved HT prediction model to the clinic, collect clinical data prospectively, evaluate the prediction effect of the model, and evaluate the clinical application effect of the improved prediction model.
48370424|NCT00629135|DRUG|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
48697272|NCT06125925|DRUG|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
48370425|NCT04190199|OTHER|Observational|Cross-sectional only
48515107|NCT03669185|DRUG|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
48515108|NCT03669185|DRUG|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
48697273|NCT03438279|OTHER|Non-Interventional|Non-Interventional
48010019|NCT00654381|DRUG|BI 1356|5 mg/daily
48515109|NCT03071276|DRUG|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
48010020|NCT00654381|DRUG|BI 1356|10 mg/daily
48167587|NCT04760197|OTHER|no intervention|no intervention
48515110|NCT03071276|DRUG|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
48515111|NCT03071276|DRUG|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
48167588|NCT06379555|PROCEDURE|Walanpoigne|Intervention will combine WALANT anesthesia with arthroscopy to reduce a joint fracture of the wrist
48515112|NCT03071276|DRUG|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
48515113|NCT01723475|BIOLOGICAL|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
48167589|NCT02730000|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
48697274|NCT06608693|OTHER|PNF stretching|Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.
48697275|NCT06608693|OTHER|Static stretching group|While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
48697276|NCT00654745|DRUG|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
48697277|NCT00654745|DRUG|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
48697278|NCT00654745|DRUG|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
48010021|NCT00654381|DRUG|voglibose placebo|three times daily
48010022|NCT00654381|DRUG|BI 1356 placebo|once daily
48010023|NCT00654381|DRUG|voglibose|0.6 mg/daily
48010024|NCT02404311|BIOLOGICAL|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and \< 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
48010025|NCT02404311|BIOLOGICAL|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
48010026|NCT02404311|BIOLOGICAL|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
48010027|NCT02404311|BIOLOGICAL|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
48010028|NCT00203203|DEVICE|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
48010029|NCT00203203|OTHER|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
48010030|NCT01448850|BIOLOGICAL|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
48010031|NCT01448850|OTHER|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
48010032|NCT04566328|DRUG|Bortezomib|Given SC
48010033|NCT04566328|BIOLOGICAL|Daratumumab and Hyaluronidase-fihj|Given SC
48010034|NCT04566328|DRUG|Dexamethasone|Given PO
48010035|NCT04566328|DRUG|Lenalidomide|Given PO
48010036|NCT04566328|OTHER|Quality-of-Life Assessment|Ancillary studies
48515114|NCT01723475|BIOLOGICAL|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
48515115|NCT00307086|DRUG|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
48515116|NCT00307086|DRUG|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
48010037|NCT00240071|DRUG|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
48010038|NCT00240071|DRUG|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
48010039|NCT04358497|DEVICE|Medtronic® Concerto® detachable coil system|coil embolization of the reflux pathways
48010040|NCT04358497|PROCEDURE|sclerosis|Pelvic varices sclerosis with polidocanol foam
48010041|NCT04358497|DRUG|Diosmin / Hesperidin|Best chronic medial treatment
48010042|NCT04358497|DRUG|Ibuprofen 400 mg|NSAID treatment
48010043|NCT05556122|OTHER|intercostal nerve block|General anesthesia and intercostal nerve block were performed. The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
48010044|NCT05556122|OTHER|lateral intercostal nerve block|lateral intercostal nerve block
48370426|NCT06016296|OTHER|Combined Movement and Storytelling Intervention|The 40-minute sessions will include three moments: (i) warm-up (5 minutes), which consists of joint mobility exercises and introduction to the motor story of the week; (ii) main part (25 minutes), which incorporates the narration of the motor story by the educator initially, as well as the participation of the children, through their own corporeality with movements based mainly on FMS (locomotion skills and object control) and two way verbal interaction based on questions allusive to the narration delivered by the educator or direct verbal participation cast by each child and; (iii) cool down (10 minutes), where space is provided for the children to gradually return to calm, together with feedback on the contents addressed during the session.
48370427|NCT01878708|DRUG|PEG-L-asparaginase|
48697279|NCT05643001|OTHER|In-patient and out-patient electronic health record alert|Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
48010045|NCT05556122|DRUG|ropivacaine + compound betamethasone|The drug for intercostal nerve block was 0.33% ropivacaine +2.333mg compound betamethasone (1.667mg betamethasone dipropionate + 0.667mg betamethasone sodium phosphate) to 15ml
48010046|NCT03827486|OTHER|Standard of care (exercise)|Exercise program according to the standard of care
48010047|NCT03827486|OTHER|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
48010048|NCT02376166|DRUG|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)
48010049|NCT01867034|OTHER|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
48010050|NCT01867034|OTHER|Bare Metal Stent|
48010051|NCT04035785|DRUG|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
48010052|NCT01585480|BEHAVIORAL|Weight Gain Prevention Intervention|"1. Behavioral Approaches~   1. Distribution of pedometers~  2. Traffic light labeling in worksite cafeteria and vending machines~2. Informational \& Persuasive Messages~   1. Stair use prompts~  2. Posters, pamphlets, table toppers~  3. Website~3. Social Approaches~   a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~4. Environmental Changes~   1. Traffic light labeling~  2. 1/2 portions at 1/2 price~  3. Walking routes~  4. Introduction of healthier foods~  5. Rearrangement of foods in the cafeteria~  6. Adjusting serving spoon size"
48167590|NCT02730000|PROCEDURE|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
48697280|NCT06661278|DIAGNOSTIC_TEST|Exercise tolerance test|Clinical routine exercise tolerance test using an exercise treadmill, according to the arrhythmia protocol (15 minute protocol utilising increasing speed and incline with a 6 minute recovery)
48697281|NCT06661278|OTHER|Physical activity & heart rate monitoring|Physical activity monitoring over two weeks using Actiheart and Pro-Diary monitors to record heart rate, heart rhythm, activities engaged in and estimated intensity of activities.
48697282|NCT02687971|DRUG|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
48167591|NCT00647998|DRUG|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
48370428|NCT01878708|DRUG|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
48370429|NCT04038411|DRUG|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
48515117|NCT00307086|PROCEDURE|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
48515118|NCT03360955|PROCEDURE|Anesthesia|Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
48515119|NCT03906422|DEVICE|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
48515120|NCT03906422|DEVICE|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
48697283|NCT04845009|BEHAVIORAL|progressive muscle relaxation|progressive muscle relaxation
48697284|NCT04845009|BEHAVIORAL|Usual care|Usual care
48370430|NCT04585191|BEHAVIORAL|Conversation Aid|"Intervention is a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? that patients receive prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
48370431|NCT04585191|OTHER|Attention Control Educational Handout|Attention control is an existing health education handout that provides some general health advice geared towards older patients.
48370432|NCT04273802|DRUG|CPX-351 in cohort A|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.~If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.~If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1."
48370433|NCT04273802|DRUG|CPX-351 in cohort B|"Treatment by CPX-351 via intravenous infusion over 90 minutes.~This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.~In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1."
48370434|NCT05451693|BEHAVIORAL|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
48370435|NCT05005715|DRUG|Dexmedetomidine|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
48515121|NCT03906422|DEVICE|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
48515122|NCT01321827|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
48515123|NCT01321827|DRUG|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
48515124|NCT02387411|OTHER|High-intensity interval exercise training|High-intensity interval exercise training \[4 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\]
48167592|NCT00647998|OTHER|Standard care|
48515125|NCT02387411|OTHER|Combined exercise training|High intensity \[2 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
48515126|NCT03997773|BEHAVIORAL|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
48515127|NCT01191034|DRUG|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
48515128|NCT03278691|DRUG|Saline|1 ml saline IV Q6H
48515129|NCT03278691|DRUG|Ketorolac|15 mg (15 mg/ml) IV Q6H
48697285|NCT05770635|DEVICE|Embosphere and chemotherapy drug|chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
48697286|NCT05770635|DEVICE|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
48697287|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
48697288|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AF03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
48697289|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (low-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
48167593|NCT00020709|DRUG|cisplatin|Given IV
48167594|NCT00020709|DRUG|docetaxel|Given IV
48167595|NCT00020709|DRUG|etoposide|Given IV
48167596|NCT00020709|DRUG|gefitinib|Given orally
48010053|NCT01271543|DEVICE|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
48010054|NCT05000749|BEHAVIORAL|DBT-SG|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
48010055|NCT05000749|BEHAVIORAL|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
48167597|NCT00020709|RADIATION|radiation therapy|Undergo radiation therapy
48167598|NCT00020709|OTHER|placebo|Given orally
48167599|NCT01978236|DRUG|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
48167600|NCT01978236|DRUG|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
48697290|NCT04537208|BIOLOGICAL|CoV2 preS dTM-AS03 (high-dose)|Pharmaceutical form: liquid; route of administration: intramuscular injection
48697291|NCT04537208|BIOLOGICAL|CoV2 preS dTM (high-dose) without adjuvant|Pharmaceutical form: liquid; route of administration: intramuscular injection
48697292|NCT04537208|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: liquid; route of administration: intramuscular injection
48697293|NCT06215105|DEVICE|Intracranial Aneurysm Devices|Intracranial Aneurysm occlusion
48167601|NCT02787759|OTHER|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
48167602|NCT02787759|OTHER|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
48697294|NCT02600416|OTHER|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
48697295|NCT03402204|DRUG|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
48697296|NCT03402204|DRUG|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
48697297|NCT04282018|DRUG|BGB-10188|Administered as specified in the treatment arm
48167603|NCT05146661|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
48370436|NCT05005715|DRUG|normal saline|Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
48167604|NCT00596258|DRUG|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
48167605|NCT03690284|DEVICE|Conventional Double Lumen Tube|Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
48370437|NCT02174952|BEHAVIORAL|Self-help version of the New Forest Parenting Programme|
48515130|NCT06241469|DRUG|Sintilimab,nab-paclitaxel and tegio|Immunotherapy combined with chemotherapy
48697298|NCT04282018|DRUG|Zanubrutinib|Administered as specified in the treatment arm
48697299|NCT04282018|DRUG|Tislelizumab|Administered as specified in the treatment arm
48697300|NCT06660576|PROCEDURE|Cholecystectomy and histochemical analysis of Gallbladder stones|Cholecystectomy and histochemical analysis of Gallbladder stones
48697301|NCT05210582|DRUG|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
48697302|NCT02604602|OTHER|blood exam|laboratory test
48697303|NCT06592833|DRUG|Psilocybin|Psilocybin, 25mg, given once orally.
48167606|NCT03690284|DEVICE|VivaSight Double Lumen Tube|Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
48370438|NCT03521622|BEHAVIORAL|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
48370439|NCT03586102|DIETARY_SUPPLEMENT|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive \> 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
48697304|NCT06592833|DRUG|Pimavanserin|Pimavanserin, 34mg, given once orally
48697305|NCT06592833|DRUG|Placebo|Matching placebo.
48697306|NCT02196883|PROCEDURE|Transforaminal Epidural Steroid Injection|
48697307|NCT01190761|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
48697308|NCT01190761|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
48697309|NCT03086291|DRUG|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
48697310|NCT06239441|DRUG|IL5/IL5R Antagonists|Treatment with IL5/IL5R antagonists for one year
48167607|NCT03143296|OTHER|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
48167608|NCT06042023|DEVICE|Lifesignals Wearable Sensor|"The participants will wear the patch for 3-5 days and be provided with the mobile device, which records data transmitted wirelessly directly from the biosensor patch. During the monitoring period, participants can continue their normal activities.~Remote monitoring will be undertaken using the CE-marked LifeSignals wearable biosensor. The biosensor communicates with a commercially available mobile device, which relays data to a secure Cloud server (GDPR compliant data transfer).~Participants will subsequently undergo their planned surgery in the usual way. Data captured from the remote monitoring will not be used or made accessible to inform decisions about clinical care.~There will be no clinical intervention from the researchers if abnormalities in vital signs are picked up by the monitoring patch, as all data will be analysed retrospectively after the participant's operation. Any clinical concerns about the device that arise will be reported to the relevant clinical team."
48167609|NCT04125771|DIAGNOSTIC_TEST|Diclofenac + HBB with hysteroscopy|Giving Diclofenac + HBB with hysteroscopy
48167610|NCT04125771|DIAGNOSTIC_TEST|Diclofenav + placebo|Giving Diclofenac + placebo with hysteroscopy
48167611|NCT06276114|DEVICE|Stent Underexpansion|Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
48167612|NCT01165164|OTHER|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
48167613|NCT02742792|OTHER|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
48167614|NCT02742792|OTHER|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
48167615|NCT05666271|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation will be performed by using the Octopus MP electrodes. It is a method of directly measuring the temperature near the surrounding tissue of the target tumor using the Octopus MP electrode, and stopping ablation when the temperature rises above 60 degrees to prevent adjacent organ (gallbladder, gastrointestinal tracts, diaphragm, and heart). If the shape of the tumor is elliptical or irregular rather than circular, using an adjustable tip that can change the length of the active tip of the electrode according to the size of the tumor has the advantage of tailoring the ablation zone.
48167616|NCT04189341|DRUG|Erector spinae plane block (Group E)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
48167617|NCT04189341|DRUG|Modified-thoracolumbar interfascial plane block|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
48167618|NCT03552237|DIETARY_SUPPLEMENT|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
48167619|NCT06539416|PROCEDURE|MitraClip implantation|The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.
48167620|NCT00649142|PROCEDURE|Open sutured mesh repair|Open sutured mesh repair
48697311|NCT06114914|DIAGNOSTIC_TEST|Tap Talk online program|Online hand and speech motor testing
48167621|NCT00649142|PROCEDURE|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
48167622|NCT05518877|DRUG|Ketamine|Administration of Ketamine
48167623|NCT04695314|DEVICE|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
48167624|NCT04695314|PROCEDURE|Experimental insert|Raised shoe insert, insert used for massage
48370440|NCT03586102|DIETARY_SUPPLEMENT|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (\< 4.5 g/kg/day of enteral protein)
48167625|NCT04695314|PROCEDURE|Sham insert|Flat shoe insert, insert used for massage
48697312|NCT03926572|OTHER|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
48697313|NCT02042586|OTHER|Analysis of movement before total hip replacement|
48697314|NCT02042586|OTHER|Analysis of movement after total hip replacement|
48167626|NCT00519714|DIETARY_SUPPLEMENT|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
48167627|NCT00519714|DIETARY_SUPPLEMENT|Placebo|Placebo
48167628|NCT02990364|DRUG|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
48167629|NCT02990364|DRUG|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
48370441|NCT01211860|DRUG|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
48370442|NCT05482776|OTHER|High intensity functional training|"HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance."
48697315|NCT05934994|OTHER|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
48697316|NCT03895580|OTHER|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
48370443|NCT05482776|OTHER|classic training group|This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
48010056|NCT04002765|DIAGNOSTIC_TEST|pulmonary function tests|"1. Lung function tests (standard of care)~   1. Dynamic and static volumes (FVC, FEV1, TPC, RV)~  2. Lung diffusion capacity for CO (DLCO)~2. Chest Xrays~3. High resolution CT scanner (HRCT)"
48010057|NCT04441567|OTHER|Right-size clinic visits|The curve created in Phase 1 will be used to guide the number of clinic visits based on PROMs reported by the participants in Phase 2.
48370444|NCT00903357|DRUG|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
48370445|NCT00903357|DRUG|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
48370446|NCT01579240|OTHER|Internet exercise program|12 voluntary weekly visits to website
48697317|NCT03895580|OTHER|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
48697318|NCT00970892|DRUG|Warfarin dose titration|Dosage
48697319|NCT01961297|DRUG|Sodium oxybate|Sodium oxybate
48010058|NCT05583188|DEVICE|Aliya Pulsed Electric Fields (PEF) ablation|Patients will undergo PEF ablation
48010059|NCT05583188|DRUG|Nivolumab plus Platinum Doublet Chemotherapy|If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
48167630|NCT02990364|DRUG|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
48167631|NCT00153023|DRUG|Telmisartan|
48697320|NCT04234529|DIETARY_SUPPLEMENT|AMATEA™|"AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine."
48697321|NCT04234529|DIETARY_SUPPLEMENT|Caffeine|1.08g of microcellulose and 270mg of caffeine.
48697322|NCT04234529|OTHER|Placebo|1.35g of microcellulose
48697323|NCT06379035|DIAGNOSTIC_TEST|ELISA / PCR|"Multiplex PCR for confirmation of diagnosis of Blastocystis and Cryptosporidium infection.~Enzyme linked immunosorbent assay (Elisa) for detection of :~Different cytokines level in Colorectal cancer patients that may be involved in the tumor progression due to Blastocystis and Cryptosporidium infection."
48697324|NCT04004221|DRUG|Tislelizumab|200mg intravenously (IV) every 3 weeks (Q3W)
48697325|NCT04450706|OTHER|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
48697326|NCT04450706|OTHER|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
48697327|NCT04568759|OTHER|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
48167632|NCT00153023|DRUG|Valsartan|
48370447|NCT05947981|DIETARY_SUPPLEMENT|Dextrose 5%, normal saline|Decrease fasting hours
48370448|NCT05760781|DRUG|STSG-0002 Injection|Intravenous infusion
48370449|NCT01791166|BIOLOGICAL|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
48370450|NCT04112862|OTHER|sodiumlactate|intravenous sodiumlactate 600mmol/L
48010060|NCT05583188|DRUG|Standard of care neoadjuvant therapy|Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
48010061|NCT05583188|OTHER|Surgical Resection|Patients not eligible for systemic therapy will receive definitive surgery without neoadjuvant therapy as per institutional standard of care post-PEF ablation.
48167633|NCT01130714|BEHAVIORAL|Exercise|Resistance training with resistance bands.
48167634|NCT00572351|OTHER|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
48697328|NCT05434871|OTHER|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
48010062|NCT02694341|PROCEDURE|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
48167635|NCT00572351|OTHER|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
48167636|NCT00804414|DRUG|SBG|Solution for topical use
48167637|NCT00804414|DRUG|Placebo Comparator|Solutin for topical use
48167638|NCT03925662|DRUG|Folfox with avastin|Folfox with avastin only
48167639|NCT03925662|DRUG|Mebendazole|Folfox with avastin with mebendazole
48167640|NCT00917631|PROCEDURE|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
48167641|NCT02556541|PROCEDURE|IV puncture guided by ultrasound|
48167642|NCT04801784|PROCEDURE|Increased net ultrafiltration with advanced hemodynamic monitoring|A net ultrafiltration rate of 100 ml/h or more will be applied during the first 72 hours of study participation. To insure the hemodynamic security of the intervention, it is associated with an advanced hemodynamic monitoring protocol which encompasses cardiac index, preload dependence assessment (using postural maneuvers), lactate levels and central venous pressure evaluation. The hemodynamic monitoring protocol allows the decrease or suspension of the neutral ultrafiltration rate in case of hemodynamic instability or of hemodynamic status considered at risk of worsening if net ultrafiltration rate is maintained.
48167643|NCT04801784|PROCEDURE|Zero or near-zero net ultrafiltration|The active control group aims to represent the present standard of care of net ultrafiltration management in the first 72 hours of study participation in patients with critical illness. This will be performed by setting the net ultrafiltration rate to 0 up to 25 ml/h.
48010063|NCT02694341|DEVICE|Bakri Balloon|uterine compression balloon
48010064|NCT03159884|DRUG|Conbercept|
48167644|NCT06460181|DIETARY_SUPPLEMENT|Astaxanthin|Manufactured by AstaReal Inc
48167645|NCT06460181|DIETARY_SUPPLEMENT|Placebo|Manufactured by AstaReal Inc
48370451|NCT03799198|OTHER|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
48370452|NCT03799198|DRUG|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os \[p.o.; by mouth\]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously \[under the skin\])."
48697329|NCT05434871|OTHER|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
48697330|NCT05334069|OTHER|Questionnaire Administration|Complete questionnaire
48697331|NCT05334069|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
48697332|NCT04062214|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
48010065|NCT00020111|DRUG|arsenic trioxide|
48010066|NCT03221985|OTHER|questionnaires|questionnaire with application on smartphone
48010067|NCT01178970|BEHAVIORAL|Resistance training|
48010068|NCT05408663|DRUG|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
48010069|NCT05408663|OTHER|Placebo|matching placebo administered via subcutaneous injection
48010070|NCT06121271|DRUG|Lu-177 DOTATATE (Lutathera®)|Treatment with Lutathera will consist of a total cumulative intravenous (IV) administered radioactivity dose of 29.6 GBq (800 mCi) or 14.8 GBq (400 mCi) for 4 cycles or 2 cycles of Lutathera, respectively.
48010071|NCT03795922|DRUG|MT10109L|MT10109L will be injected into the GL.
48010072|NCT03795922|DRUG|Placebo|Placebo will be injected into the GL.
48167646|NCT02856061|BEHAVIORAL|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
48167647|NCT05459142|DRUG|Medical Abortion|Medical Abortion
48167648|NCT04595097|DEVICE|inspiratory muscle traiing|The patients are encouraged to inhale against a load to increase the inspiratory muscle strength and endurance
48167649|NCT06073444|DEVICE|Picterus JP|Picterus JP is a medical device consisting in a smartphone app which is use to take images of the skin of the newborn, a color calibration card that must be placed in the newborn chest to calibrate color and lighting in the images and a server to analyze data and estimate bilirubin level
48167650|NCT05124002|DRUG|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.
48167651|NCT05124002|DRUG|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
48167652|NCT01006447|BEHAVIORAL|Instructor contact|
48167653|NCT01006447|BEHAVIORAL|Instructor contact|
48167654|NCT00361842|DRUG|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
48167655|NCT04733053|OTHER|Diet plus exercise|"The diet program has two phases: 1) intensive weight loss through a ketogenic very low calorie diet VLCD, and 2) transition from ketogenic VLCD onto a healthy eating plan for weight maintenance. Meal replacements will be provided to participants free of charge from the start of the trial to a maximum of 14 weeks (12 weeks for the ketogenic diet and 2 weeks for transition). If a participant does not wish to transition off the ketogenic diet after 14 weeks but wants to continue or if they wish to recommence the ketogenic diet any time after week 14 they will need to purchase meal replacements themselves at their own cost.~Participants will be encouraged to aim to lose at least 10% body weight."
48167656|NCT04733053|OTHER|Exercise|The trial coordinator will have provided participants with educational material about OA, handouts of home exercises including photographs and descriptions, a logbook for recording home program completion and resistance exercise bands ahead of their first appointment. Physiotherapists will prescribe 5-6 strengthening exercises from a pre-determined list to be performed at home three times/week, including two quadriceps exercises, one each for hip abductors, hamstrings and calf, and any other as appropriate. Review and modification will occur at each consultation to maintain moderate intensity (effort of ≥5 out of 10 (hard) on a modified Borg Rating of Perceived Exertion scale). The physiotherapist will also prescribe a personalised physical activity plan in collaboration with the participant that is supported and progressed over time.
48167657|NCT02864199|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
48167658|NCT02864199|DRUG|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
48167659|NCT05434715|PROCEDURE|Thyroidectomy|removal of the thyroid gland
48167660|NCT04959825|DRUG|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
48167661|NCT04959825|DRUG|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
48167662|NCT04719468|OTHER|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
48167663|NCT01099683|DRUG|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
48515131|NCT06292117|OTHER|CYP2C19 Genotype|qPCR-based genotyping assay interrogating all Association for Molecular Pathology (AMP) recommended Tier 1 and Tier 2 single nucleotide polymorphisms (SNPs) for CYP2C19 (\*2, \*3, \*4, \*5, \*6, \*7, \*8, \*9, \*10, \*17, \*35)
48697333|NCT04927247|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
48697334|NCT04927247|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
48697335|NCT06450834|DEVICE|Ostene|Soluble Bone Hemostasis Implant Material
48697336|NCT04131322|DRUG|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
48697337|NCT04131322|DRUG|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
48515132|NCT06141343|DIETARY_SUPPLEMENT|Veillonella atypica FB0054|Veillonella contains Veillonella atypica FB0054 as the active ingredient with microcrystalline cellulose and hypromellose as excipients. The two doses are 15 billion cfu (high dose) and 7.5 billion cfu (low dose). Placebo capsules contain microcrystalline cellulose and hypromellose. Both Veillonella and placebo are encapsulated in acid-resistant capsules to improve delivery to the large intestine, which participants will take orally at home on a daily basis for four weeks.
48515133|NCT06141343|OTHER|Placebo|Placebo will be given as the non-active study control
48515134|NCT06204029|BEHAVIORAL|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
48515135|NCT03904264|DEVICE|Receiver in the canal (RIC) hearing aids|The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
48010073|NCT04963179|DEVICE|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated during approximately 5 days. It is degraded and discharged naturally through the cervix and vagina in less than 30 days."
48010074|NCT04516122|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48010075|NCT04516122|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
48010076|NCT02880566|PROCEDURE|Scalp block|Full scalp block
48010077|NCT02157766|BEHAVIORAL|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
48010078|NCT02157766|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
48370453|NCT05773885|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
48370454|NCT05773885|OTHER|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
48515136|NCT04988919|DIETARY_SUPPLEMENT|4D|multi-ingredient supplement mixed with 24 ounces of water
48515137|NCT04988919|DIETARY_SUPPLEMENT|placebo|taste-matched placebo mixed with 24 ounces of water
48515138|NCT00314951|DRUG|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
48515139|NCT00314951|DRUG|Vancomycin|125 mg capsules q6hr (4 times a day)
48515140|NCT00314951|DRUG|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
48515141|NCT02891668|DRUG|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
48515142|NCT04684472|BIOLOGICAL|Modified anti-CD19 CAR T cells|intravenous infusion
48010079|NCT02157766|BEHAVIORAL|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
48010080|NCT06364124|DRUG|evolocumab|Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day
48010081|NCT06364124|PROCEDURE|standard post-treatment for STEMI|standard post-treatment for STEMI
48010082|NCT02517905|DRUG|Bupivacaine liposome|Local administration
48010083|NCT02517905|DRUG|Placebo|Local administration
48010084|NCT02199418|DRUG|Paclitaxel|
48010085|NCT02199418|DRUG|Cisplatin|
48167664|NCT01099683|DRUG|Placebo|All subjects will receive rectal suppository containing placebo
48167665|NCT04817657|BIOLOGICAL|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1\*10\^11 virus particles per milliliter (vp/ml) as intramuscular injection.
48697338|NCT00772915|DRUG|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
48010086|NCT05433220|OTHER|Best Practice Advisory using Electronic Health Record|Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
48697339|NCT00772915|DRUG|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
48010087|NCT00333606|BEHAVIORAL|Acupuncture|Body acupuncture of 1 specific point per trial session
48010088|NCT05844514|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of four hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
48010089|NCT05224492|DRUG|Sulforaphane|40 mg of Sulforaphane powder once daily.
48010090|NCT05224492|OTHER|Placebo|Placebo
48010091|NCT02327208|DIETARY_SUPPLEMENT|Control|
48010092|NCT02327208|DIETARY_SUPPLEMENT|Protein|
48010093|NCT02327208|DIETARY_SUPPLEMENT|Carbohydrate|
48010094|NCT01633697|BEHAVIORAL|Pranayama|Specific yoga-related breathing method.
48370455|NCT02741336|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
48370456|NCT02741336|BEHAVIORAL|Self-Monitoring|
48370457|NCT06036940|OTHER|Preoperative patient education given with three different methods|To determine the effect of preoperative patient education given by three different methods on the level of perioperative anxiety in children aged 4-7 years.
48370458|NCT04773691|DEVICE|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
48370459|NCT04773691|DEVICE|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
48370460|NCT04773691|OTHER|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
48370461|NCT04773691|DEVICE|Breathalyzer|estimation of blood alcohol level
48370462|NCT01401179|DRUG|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
48370463|NCT02891096|PROCEDURE|inspiratory muscle strength|"Measurements:~* in- and expiratory muscle strength (5min)~* lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~* ISCoS core data-set~* ISCoS pulmonary function data sets~* ISCoS quality of life questionnaire~* questionnaire on individual respiratory muscle training, regular physical exercise and therapies~* individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
48697340|NCT06354413|PROCEDURE|CABG during myectomy|To explore the effect of CABG during myectomy. No control group
48010095|NCT01633697|BEHAVIORAL|Education alone|No special attention to breathing
48010096|NCT06324474|DRUG|Hyaluronic acid|Gengigel syringe containing 1ml of 0.8% HA
48010097|NCT06324474|BEHAVIORAL|scaling and root planning|scaling and root planning using ultrasonic scaler
48010098|NCT01556672|DRUG|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
48010099|NCT01556672|DEVICE|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
48010100|NCT05510297|DEVICE|FitSitt Prototype|FitSitt merges features of a posture chair, exercise machine, and tracking means. It provides seated stepping, postural support, and semi-recline capabilities. A digital interface and app will allow users to set goals and track performance.
48370464|NCT05403502|DEVICE|t:slim X2 insulin pump with Control-IQ technology 1.5|t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor, used with Lyumjev® insulin.
48370465|NCT02205580|DRUG|continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion|
48370466|NCT02205580|DRUG|continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion|
48370467|NCT02205580|DRUG|continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion|
48370468|NCT03480334|OTHER|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
48370469|NCT00357643|DRUG|Calcium 500 mg/day and vitamin D 700 IU/day|
48515143|NCT00858182|DRUG|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
48697341|NCT01112774|DEVICE|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
48697342|NCT04806776|OTHER|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
48370470|NCT04923776|DRUG|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
48370471|NCT04923776|DRUG|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
48370472|NCT04923776|DRUG|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
48370473|NCT04923776|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
48515144|NCT00858182|DRUG|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
48515145|NCT02478879|DRUG|ZP-PTH|Patch applied daily for 30 minutes, 14 days
48515146|NCT02478879|DRUG|FORTEO|Subcutaneous injection administration daily for 14 days
48697343|NCT04806776|OTHER|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
48697344|NCT06088394|DEVICE|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~* CV3,4 \&5-40 mm needles at a depth of 1 cun perpendicular insertion.~* ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~* SP6 \& 9, K13\&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
48697345|NCT06088394|OTHER|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
48010101|NCT03242499|DRUG|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
48010102|NCT03242499|DRUG|Placebo|placebo for 48 weeks
48370474|NCT02847364|DIETARY_SUPPLEMENT|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
48370475|NCT04584827|OTHER|lactate level|Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
48370476|NCT04584827|OTHER|Glasgow Outcome Scale|Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
48010103|NCT02734316|OTHER|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
48010104|NCT02863978|OTHER|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
48167666|NCT01797133|PROCEDURE|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
48167667|NCT01797133|PROCEDURE|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
48167668|NCT00160979|PROCEDURE|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
48167669|NCT03265847|BEHAVIORAL|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
48167670|NCT05854121|DIAGNOSTIC_TEST|Functional Electrical Stimulation|Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
48167671|NCT05854121|DIAGNOSTIC_TEST|Constrained Induced Movement Therapy|Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
48167672|NCT04184856|DIAGNOSTIC_TEST|fMRI|(Imaging while) performing reward related tasks.
48167673|NCT02928809|DEVICE|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
48167674|NCT02928809|OTHER|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
48370477|NCT03437980|DRUG|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
48697346|NCT00443872|DRUG|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
48697347|NCT06310967|DRUG|IG3018|Oral administration
48697348|NCT06310967|OTHER|Placebo matching IG3018|Oral administration
48697349|NCT06394544|DIETARY_SUPPLEMENT|Brazil Nut|The intervention, for each participant, is estimated to last a total period of six months , which will be divided into three two-month stages, with data collection after each stage. Volunteers will be monitored to control possible side effects, doubts and check compliance. In addition, the telephone number and an email will be made available for contact during business hours, for possible clarifications.
48697350|NCT04444986|DRUG|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
48697351|NCT04444986|DRUG|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
48697352|NCT05835336|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
48697353|NCT05446766|BEHAVIORAL|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
48370478|NCT04652609|OTHER|PRESIONA|Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment
48370479|NCT00002102|DRUG|Trimetrexate glucuronate|
48010105|NCT00996762|DRUG|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
48010106|NCT01187082|BEHAVIORAL|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
48010107|NCT01187082|BEHAVIORAL|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
48010108|NCT03447171|DEVICE|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
48010109|NCT05254938|BEHAVIORAL|The Halland Obesity Municipal Effort for children|A comprehensive, intensive lifestyle intervention for the children with the greatest need of intensive treatment.
48010110|NCT05523973|OTHER|Lingual Endurance Exercise|Participants will participate in 3 training sessions per day for 8 weeks. Group 1 will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session.
48515147|NCT05406921|BEHAVIORAL|MIND at Home|Maximizing Independence at Home-MIND at Home (MIND) is a comprehensive care coordination program born from geriatric psychiatry. This model takes an interdisciplinary, collaborative care approach to care by systematically assessing and addressing a wide range of dementia-care related needs of both PLWD and their care partners that place both at increased risk for poor outcomes.
48697354|NCT05898776|DEVICE|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
48010111|NCT05523973|OTHER|Lingual Endurance + Transference Exercise|"Group 2 will complete lingual endurance exercise for 2 sessions, and for the 3rd training session participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva. The TongueometerTM will provide biofeedback on performance and will be instructed to generate more pressure during this effortful swallow than during a natural, saliva swallow."
48010112|NCT04776967|PROCEDURE|Hyperbaric Compression Profile|A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
48010113|NCT04140734|DEVICE|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
48010114|NCT05501106|OTHER|Integrated Improvement strategies|"Integrated improvement strategies include postpartum hemorrhage risk screening, hierarchical management and preparedness, postpartum hemorrhage rescue recording, and review of postpartum hemorrhage cases.~1. A checklist (named as Risk Assessment and Preparedness for Postpartum Hemorrhage (Traffic Light in Delivery Room)) will be used in each virginal delivery to help obstetric staff and teams identify risk factors after admission, before and during labor, and improve the adherence to all known best practices.~2. The Postpartum Hemorrhage Rescue Format will be asked to be used in each postpartum hemorrhage rescue to record the rescue process.~3. Each case of postpartum hemorrhage exceeding 1000 ml will be reviewed. We will convene a QI Panel and a Task Force to assist the hospitals in postpartum hemorrhage case review and quality improvement strategy development."
48167675|NCT00003212|DRUG|doxorubicin hydrochloride|
48167676|NCT00003212|DRUG|ifosfamide|
48167677|NCT00057044|BEHAVIORAL|education and reminder|
48167678|NCT03448289|BEHAVIORAL|RLPT|The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
48167679|NCT05648318|DRUG|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
48167680|NCT05648318|DRUG|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
48167681|NCT01960985|OTHER|Physicaltherapy|
48370480|NCT00002102|DRUG|Leucovorin calcium|
48167682|NCT05042713|OTHER|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
48167683|NCT06176183|PROCEDURE|Arthroscopic meniscus repair|"A traditional two-portal arthroscopic approach is utilized. The meniscal edges are examined using a probe, and any meniscal tears that are not stable are evaluated for potential repair. For meniscus repair, sutures have been made using the all-inside or outside-inside and inside-outside techniques.~If the procedure involving the addition of a fibrin clot is being carried out, a volume of approximately 60 milliliters of blood is taken and thereafter transferred into a basin. An assistant is able to stir the blood using a glass syringe for approximately fifteen minutes to ensure sufficient coagulation surrounding the syringe. After a sufficient clot has developed at the end of the syringe, a grasper is used to insert the clot through the anterolateral arthroscopy portal. The meniscal sutures are intentionally loosened to accommodate the clot in the meniscus, ensuring optimal contact with the lesion. Subsequently, the sutures are fastened and knotted."
48370481|NCT03846856|OTHER|Biopsy|Biopsy taken during surgical procedure
48370482|NCT03210909|DRUG|BMS-986231|BMS-986231
48370483|NCT03817658|DRUG|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
48370484|NCT03817658|DRUG|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
48370485|NCT00963040|DRUG|Syntocinon|4 actuations in each nostril for a total dose of 32 IU
48697355|NCT05898776|DEVICE|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (\~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
48697356|NCT04008641|OTHER|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
48370486|NCT00963040|DRUG|Sterile water|4 actuations in each nostril
48697357|NCT00244933|DIETARY_SUPPLEMENT|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
48697358|NCT00244933|DRUG|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days
48697359|NCT00244933|PROCEDURE|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
48697360|NCT03750760|DRUG|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
48697361|NCT03750760|DRUG|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
48010115|NCT05601505|OTHER|circulating tumor DNA|This study will further testify the prognostic value of ctDNA in the treatment term of locally advanced rectal cancer, the higher the VAF value, the higher the risk of recurrence and metastasis.
48167684|NCT05848453|DRUG|BAP5191|Placebo
48167685|NCT00875615|DRUG|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
48515148|NCT04711811|BIOLOGICAL|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
48515149|NCT00489827|DRUG|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
48697362|NCT03750760|DRUG|Ezetimibe 10mg|Cholesterol absorption inhibitor
48697363|NCT06177197|DEVICE|Physiomer|"Infants randomized to the experimental group will be given an electrolyzed seawater solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
48370487|NCT00963040|DRUG|Syntocinon|8 actuations in each nostril for a total dose of 64 IU
48010116|NCT04084353|OTHER|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
48010117|NCT02092090|BEHAVIORAL|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
48010118|NCT06394388|BEHAVIORAL|Cuidando juntos|"Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD."
48010119|NCT02312726|PROCEDURE|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
48010120|NCT02266056|DRUG|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
48010121|NCT02266056|DRUG|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
48010122|NCT05995002|OTHER|Anthocyanin-rich diet|A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
48010123|NCT05408481|DIAGNOSTIC_TEST|Serum cortisol level|Biochemical test
48010124|NCT03065556|DRUG|188-0551 Solution|Topical solution containing active drug
48010125|NCT03065556|DRUG|Vehicle Solution|Topical solution containing no active drug
48010126|NCT05166213|OTHER|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
48010127|NCT05492058|OTHER|tactile stimulation group|The tactile stimulation group will be asked to touch their own abdomen during the NST procedure.
48010128|NCT05492058|OTHER|listen music|Pregnant women in the music group will listen to a song they want with headphones during the NST procedure.
48010129|NCT05492058|OTHER|virtual reality group|Pregnant women in the virtual reality group will be shown a nature walk video with nature sounds (stream, bird, etc.) during the NST procedure.
48167686|NCT00875615|DRUG|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
48167687|NCT00875615|DRUG|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
48010130|NCT05891938|OTHER|H2 gas inhalation|H2 gas inhalation treatment for 4 weeks in on community dwelling adults of various ages
48010131|NCT04690127|OTHER|Plyometric Exercise|Plyometric training consisting of ten different exercises \[vertical unilateral and bilateral counter movement jump, horizontal unilateral and bilateral counter movement jump, drop jump (30 cm), squat jump, step-hop (20 cm), 180 degree rotation in transverse plane, frontal plane hurdle jump (20 cm) and sagittal plane hurdle jump (20 cm)\] for 8 weeks, 3 sessions per week. Individuals will not participate in a real plyometric training. Volunteers will watch videos to be prepared (action observation) and imagine them performing those exercises (motor imagery)
48167688|NCT04089839|OTHER|Non-Interventional|Non-Interventional
48167689|NCT00497692|DRUG|Lactoserum|
48515150|NCT00489827|OTHER|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
48515151|NCT01047527|DRUG|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
48167690|NCT02172950|BIOLOGICAL|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
48370488|NCT00963040|DRUG|Sterile water|8 actuations in each nostril
48515152|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
48515153|NCT01090518|DRUG|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
48515154|NCT01090518|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
48515155|NCT04365192|DEVICE|I-gel|"The i-gel airway is a supraglottic airway management device made of thermoplastic elastomer, which is soft, gel-like, and transparent.~The i-gel has evolved as a device that accurately positions itself over the laryngeal framework, providing a reliable perilaryngeal seal, and therefore no cuff inflation is necessary."
48515156|NCT04365192|DEVICE|Self-pressurized air-Q|The self-pressured air-Q is a supraglottic airway management device The intracuff pressure of air-Q dynamically equilibrates with the airway pressure and adjusts to the patient's pharyngeal and periglottic anatomy, potentially providing improved airway fit and seal.
48515157|NCT00101283|DRUG|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
48515158|NCT00101283|DRUG|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
48515159|NCT00101283|DRUG|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
48697364|NCT06177197|DEVICE|Saline solution|"Infants randomized to the control group will be given a saline solution by their parents for up to 10 days. Dosage is adapted according to the child's age and discomfort:~* Infant \< 6 months: half a dose to a single dose administered per nostril 8 times a day.~* Infant \> 6 months: one single dose administered per nostril 6 times a day."
48515160|NCT05209607|OTHER|Mobile Medical and bundle management|Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.
48697365|NCT00918775|OTHER|Follow-Up Care|Undergo follow-up
48697366|NCT00918775|OTHER|Laboratory Biomarker Analysis|Correlative studies
48697367|NCT03781895|DRUG|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
48697368|NCT02399540|DEVICE|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
48010132|NCT05649605|DRUG|Testosterone treatment|Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
48010133|NCT05649605|OTHER|Placebo treatment|Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
48010134|NCT02397863|DRUG|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
48010135|NCT03279588|DIAGNOSTIC_TEST|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
48010136|NCT05028374|DRUG|"A single booster dose of the Moderna mRNA COVID-19 vaccine"|All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
48010137|NCT03899610|DRUG|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
48697369|NCT02399540|DEVICE|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
48010138|NCT06388551|DRUG|LY03017|single dose, administered orally
48010139|NCT06388551|DRUG|LY03017-Placebo|single dose, administered orally
48010140|NCT05851560|DRUG|Oxidized regenerated cellulose(ORC)|Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
48010141|NCT05851560|DRUG|Hyaluronic acid(HA)|Hyaluronic acid(HA)
48515161|NCT05209607|OTHER|Mobile Medical and standard of care|Based on the mobile medical, participants will receive advice on standard medication only.
48010142|NCT04450251|OTHER|Data Collection|Collect observational fetal electrocardiogram (ECG) readings with a novel wearable device.
48515162|NCT04979936|PROCEDURE|laparoscopic cholecystectomy|
48515163|NCT04979936|PROCEDURE|percutaneous cholecystostomy|
48515164|NCT05496244|DEVICE|Laparoscopy|Laparoscopic surgery
48515165|NCT05496244|DEVICE|Robotic-assisted surgery|Robotic-assisted surgery
48515166|NCT02310256|OTHER|Five plus exercise training|calf raise exercise
48697370|NCT02399540|DEVICE|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
48697371|NCT02399540|DEVICE|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
48697372|NCT01824810|PROCEDURE|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
48697373|NCT01824810|PROCEDURE|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
48697374|NCT01824810|PROCEDURE|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
48515167|NCT05368116|OTHER|Video Assisted Self Management Program|"The main aim of this intervention is to educate the cancer patients receiving chemotherapy regarding the management of chemotherapy related side effects.~It will be one to one teaching session of 10-20 minutes conducted by the principal researcher with the help of a video on self management of chemotherapy related side effects and the video will focus on the self management of selected side effects of chemotherapy including nausea vomiting , Diarrhea , Fever , Mucositis , Skin changes , and Alopecia related distress.~The participants were given video when they comes to the Oncology day care and researcher instructs the participants to watch the video and at the same time the doubts asked by the participants were cleared by the researcher."
48010143|NCT03945981|DRUG|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
48010144|NCT01482104|DRUG|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
48010145|NCT01482104|DRUG|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
48010146|NCT06104189|DIAGNOSTIC_TEST|MRI|MRI based classification of breast cancer histological factors and subtypes
48010147|NCT02895399|OTHER|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
48010148|NCT01797536|DRUG|Elbasvir|
48167691|NCT04391218|OTHER|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
48167692|NCT00206505|DRUG|Taxotere|
48515168|NCT05368116|OTHER|Standard of care|Standard of care
48515169|NCT01006798|OTHER|Placebo|enteric coated capsule containing no vaccine virus
48515170|NCT01006798|BIOLOGICAL|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
48167693|NCT04120662|PROCEDURE|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
48167694|NCT04120662|DEVICE|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
48167695|NCT05490147|PROCEDURE|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 10\~12.
48167696|NCT05490147|PROCEDURE|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 6\~8.
48167697|NCT05093023|GENETIC|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G\>A and 3435 G\>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
48167698|NCT00932555|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
48167699|NCT01692132|DRUG|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (\>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
48167700|NCT05261230|BEHAVIORAL|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
48167701|NCT05261230|BEHAVIORAL|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
48167702|NCT00598117|BEHAVIORAL|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~* Initial QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS"
48167703|NCT06266468|BEHAVIORAL|Nutricity|Nutricity is a bilingual (English/Spanish) mobile website supplemented by an automated text-messaging system.
48167704|NCT02674048|OTHER|Metvix|
48167705|NCT01202669|OTHER|No intervention planned, observational study only.|No intervention planned, observational study only.
48010149|NCT02007928|OTHER|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
48010150|NCT00003082|BIOLOGICAL|monoclonal antibody A27.15|
48167706|NCT04724005|OTHER|No drug|No drug used
48167707|NCT01588171|DRUG|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
48515171|NCT01006798|BIOLOGICAL|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
48697375|NCT01824810|PROCEDURE|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
48697376|NCT06106061|DEVICE|Decompression + FFX®|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant
48697377|NCT06106061|PROCEDURE|Decompression alone|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone
48010151|NCT00003082|BIOLOGICAL|monoclonal antibody E2.3|
48010152|NCT01067703|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
48167708|NCT01588171|DRUG|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
48167709|NCT04825834|OTHER|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (\~40 mL) at enrollment.
48167710|NCT05992662|BEHAVIORAL|Mindfulness-Based Training Programme in Bariatric Surgey Patients|"ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~* Reminder of weekly practices~* Recording changes in mindful eating in participant experience diaries during the follow-up"
48167711|NCT04770142|DEVICE|TIRA catheter|treat hypertrophic obstructive cardiomyopathy
48167712|NCT05367752|OTHER|Myofascial release with TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
48167713|NCT05367752|OTHER|Myofascial release without TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
48167714|NCT05367752|OTHER|Conventional TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
48167715|NCT05367752|OTHER|Sham TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
48167716|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
48010153|NCT01067703|PROCEDURE|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
48010154|NCT02897596|DRUG|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
48010155|NCT02897596|DRUG|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
48370489|NCT06349109|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test (CPET), the gold standard for the assessment of cardiorespiratory fitness, will be used. The Modified Bruce/half Bruce protocol with will be used. In addition, dyspnoea, leg fatigue and general fatigue will be recorded every three minutes at rest, during the test and during the post-test recovery phases using the Modified Borg Scale and blood pressure will be recorded with a sphygmomanometer. The test will be continued until individuals reach the end of the protocol or until the last point at which they wish to stop the test. The test will be terminated if the patient wishes to terminate the test, severe breathlessness, leg fatigue or general fatigue, loss of coordination, progressive chest pain, ST segment elevation or depression of more than 2 mm, oxygen saturation of 80% or less, reaching 85% or more of the predicted heart rate. Oxygen consumption (VO2peak) will be used as the primary outcome measure for cardiorespiratory fitness.
48010156|NCT02897596|DRUG|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
48010157|NCT02897596|DRUG|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
48010158|NCT03651791|COMBINATION_PRODUCT|USPIO labeled MSC injection|USPIO labeled MSC injection
48370490|NCT06349109|OTHER|Atrial-Ventricular Strain Analysis|Atrial-Ventricular strain will be evaluated by a specialist physician using Speckle Tracking Echocardiography. During the evaluation, standard echocardiographic measurements will be made with transthoracic echocardiography. With these measurements, images suitable for strain analysis will be obtained. Deformation analysis will be performed using the speckle tracing method for the appropriate images obtained and hemodynamic parameters obtained by the analysis will be recorded.
48697378|NCT06429696|DRUG|PD-L1 inhibitor combined with apatinib|Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
48697379|NCT01350752|BEHAVIORAL|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
48010159|NCT02567513|BEHAVIORAL|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
48010160|NCT02567513|BEHAVIORAL|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
48010161|NCT03568942|DRUG|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
48010162|NCT01539226|COMBINATION_PRODUCT|Placebo Vaginal Ring|Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
48010163|NCT01539226|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
48515172|NCT01932918|DRUG|Patient controlled analgesia|"1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
48515173|NCT05578599|DEVICE|Swiftsure CCS device|The Swiftsure CSS device will be used twice per patient in addition to standard oral health care procedures among intubated adult patients undergoing mechanical ventilation in the ICU.
48515174|NCT03026998|PROCEDURE|MRI|MRI will be performed each year during 10 years.
48697380|NCT01350752|BEHAVIORAL|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
48010164|NCT05023694|OTHER|Video recordings|"In the first phase it will proceed to completion of the registration system by collecting data revivals and video recordings.~In a second phase, the video is displayed and analysis of the resuscitation performance will take place. We will identify and make a registration of incidents. At this point the observational descriptive analysis will take place.~Third phase: to develop preventive measures necessary to limit the number of incidents or to contain or minimize adverse effects resulting thereof: restructure and adapt the protocol."
48010165|NCT05023694|OTHER|Video recordings after corrective measures in adverse events|"Fourth phase: Training department staff on improvements to optimize performance times protocol using simulation.~Fifth stage: final implementation of corrective measures of adverse events during the performance resuscitation.~Sixth stage: successive evaluations of impact of corrective measures. With this evaluation, it will be held another descriptive case series. With the secondary formulate hypothesis after analysis of the errors, the protocol is optimized and measured if errors are minimized: analytical observational prospective cohort study."
48010166|NCT03074903|DEVICE|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
48010167|NCT03903666|OTHER|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
48010168|NCT03535220|COMBINATION_PRODUCT|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
48010169|NCT05449925|PROCEDURE|Injectable PRF and Microneedling|i-PRF and Microneedling Procedure in thin gingiva followed by orthodontic treatment
48010170|NCT05036993|BEHAVIORAL|Coaching|Faculty will be paired with a certified coach who is also a faculty member and receive 6 sessions of coaching over 3 months
48010171|NCT02390583|BEHAVIORAL|CBT treatment of internet dependence|CBT treatment of internet dependence
48010172|NCT02390583|BEHAVIORAL|CBT treatment of sleep disorders|CBT treatment of sleep disorders
48515175|NCT04680026|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
48697381|NCT01350752|BEHAVIORAL|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
48697382|NCT03077438|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 milliliter (mL), Intramuscular
48010173|NCT06019858|OTHER|Vitamin Energy Shot|"Vitamin Energy® shot is a naturally-caffeinated functional energy shot that contains:~Vitamin B3 Vitamin B6 Vitamin B12 Natural Caffeine (green tea extract) L-Carnitine Tartrate Potassium Sorbate Taurine Sucralose"
48167717|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
48515176|NCT04680026|DRUG|Placebo|Normal saline
48515177|NCT00354692|DRUG|Sodium Ferric Gluconate and Iron sucrose|
48515178|NCT03694756|DEVICE|TMEM-MRI|TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
48697383|NCT03077438|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
48697384|NCT01749657|DEVICE|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
48697385|NCT06532526|OTHER|Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)|A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.
48697386|NCT06532526|OTHER|Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)|Fluoride gel that applied on the teeth to reduce tooth sensitivity
48697387|NCT06532526|OTHER|Placebo gel without any active ingredients.|Water-based glycerin gel is used as the Placebo gel without active ingredients
48697388|NCT03516773|DRUG|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
48167718|NCT00555997|DRUG|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
48697389|NCT03516773|DRUG|NATPARA/NATPAR|A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
48697390|NCT03252444|OTHER|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
48697391|NCT03252444|OTHER|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
48697392|NCT00434733|BIOLOGICAL|Pandemic influenza vaccine|
48697393|NCT03455933|OTHER|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
48697394|NCT03455933|OTHER|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
48697395|NCT03455933|OTHER|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
48697396|NCT00025207|DRUG|gefitinib|Given orally
48515179|NCT03694756|PROCEDURE|FNA|FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
48515180|NCT06432816|DIETARY_SUPPLEMENT|NANO-PSO|NANO-PSO or Oil of pomegranate seed with nanotechnology, they are capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast
48697397|NCT00025207|OTHER|laboratory biomarker analysis|Correlative studies
48697398|NCT01175265|OTHER|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
48697399|NCT04130724|DIAGNOSTIC_TEST|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
48697400|NCT04130724|DIAGNOSTIC_TEST|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
48697401|NCT00853242|DRUG|Placebo|
48697402|NCT00853242|DRUG|Genz-644470|
48697403|NCT00853242|DRUG|Sevelamer carbonate|
48697404|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
48697405|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
48167719|NCT05900401|OTHER|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
48697406|NCT06368505|OTHER|ultrasound guided PRP injection|whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach
48697407|NCT06368505|OTHER|ultrasound guided hydrodissection|5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL
48697408|NCT03273452|DRUG|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
48697409|NCT00464373|DRUG|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
48697410|NCT00464373|DRUG|Placebo|4ml NaCl 0.9%
48697411|NCT00003434|BIOLOGICAL|carcinoembryonic antigen peptide 1|
48697412|NCT00003434|BIOLOGICAL|hepatitis B antigen peptide|
48697413|NCT00116064|DRUG|intranasal lorazepam|
48697414|NCT00116064|DRUG|intramuscular paraldehyde|
48697415|NCT02161094|BEHAVIORAL|Give incentives to physicians based on their patient's HbA1c improvement|
48515181|NCT06432816|OTHER|PLACEBO|"Placebo physically identical to NANO-PSO capsules:~Soft gelatin capsules 640 mg edible oil 35for PLACEBO Oil edible, oval shape, 640 mg."
48697416|NCT02161094|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|
48697417|NCT01979666|DRUG|nitrate patch|patients in the study group will get a nitrate patch
48697418|NCT01979666|DRUG|placebo patch|control group patients will get a placebo patch
48697419|NCT01979666|DEVICE|MRI scan|MRI scan after 6 weeks of treatment
48697420|NCT06507436|DRUG|Herombopag tablets|Herombopag tablets; dose 1 or dose 2, for 5 days
48697421|NCT06507436|DRUG|Herombopag placebo tablets|Herombopag placebo tablets; dose 1 or dose 2, for 5 days
48515182|NCT01350245|RADIATION|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
48697422|NCT04313400|DRUG|1.1% w/w AMTX-100 CF-part1|AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
48697423|NCT04313400|DRUG|Placebo|Topical cream manufactured to mimic AMTX-100 CF3
48697424|NCT04313400|DRUG|1.1% w/w AMTX-100 CF3-part2|AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
48697425|NCT04005560|OTHER|no interventional study|no interventional study
48697426|NCT02030197|BEHAVIORAL|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
48697427|NCT02030197|OTHER|Control Group|no treatment
48697428|NCT06451692|OTHER|Clinical pharmacist|The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
48697429|NCT02895672|DRUG|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
48697430|NCT06314373|DRUG|HSK39775 Monotherapy|HSK39775 will be administered orally once daily
48697431|NCT02121769|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
48515183|NCT01350245|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
48515184|NCT01350245|DRUG|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
48515185|NCT01350245|DRUG|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
48515186|NCT01350245|DRUG|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
48515187|NCT01350245|DEVICE|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
48515188|NCT05238714|DRUG|venglustat|Powder for Oral solution
48515189|NCT05101668|DEVICE|Intracranial Thrombosis Aspiration Catheter|Direct Aspiration
48697432|NCT06398730|DRUG|GEH200520 Injection and GEH200521 (18F) Injection|Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
48697433|NCT06398730|DIAGNOSTIC_TEST|Static - PET/CT scan|Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
48697434|NCT04786704|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
48697435|NCT04786704|DIAGNOSTIC_TEST|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
48697436|NCT00703521|BIOLOGICAL|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
48697437|NCT05403372|DEVICE|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
48697438|NCT02137018|DEVICE|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
48697439|NCT02137018|DEVICE|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
48697440|NCT01152047|DRUG|oxytocin|40mU/min as infusion of oxytocin
48697441|NCT01439971|BIOLOGICAL|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
48167720|NCT05900401|PROCEDURE|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
48167721|NCT05900401|DRUG|Fludarabine|Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
48515190|NCT05911061|BIOLOGICAL|High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
48515191|NCT05911061|BIOLOGICAL|Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
48697442|NCT01439971|BIOLOGICAL|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
48697443|NCT01439971|BIOLOGICAL|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
48167722|NCT05900401|DRUG|Cyclophosphamide|Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
48167723|NCT05900401|DRUG|Rituximab|Rituximab on study day -6
48167724|NCT05900401|DRUG|Siplizumab|Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
48167725|NCT01154465|PROCEDURE|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~* Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~* Rinse with sterile water and then drying.~* First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~* Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
48167726|NCT01154465|DEVICE|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
48167727|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
48697444|NCT01439971|BIOLOGICAL|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
48697445|NCT01439971|BIOLOGICAL|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
48167728|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Pain (CBT-P)|
48167729|NCT01820637|DEVICE|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
48167730|NCT00326703|PROCEDURE|Hypobaric hypoxia|
48167731|NCT05131711|COMBINATION_PRODUCT|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
48515192|NCT05911061|BIOLOGICAL|control group|boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
48515193|NCT05911061|BIOLOGICAL|Placebo group|saline
48697446|NCT04645654|BEHAVIORAL|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
48697447|NCT02251834|BEHAVIORAL|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
48167732|NCT05790187|OTHER|Presentation of differents face pictures|Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
48167733|NCT05336136|DEVICE|Custom mask|Custom mask based on 3D facial photograph for administration of non-invasive ventilation
48167734|NCT05336136|DEVICE|Current commercial mask|Current commercial mask used for administration of non-invasive ventilation
48167735|NCT05127590|DRUG|RBN-2397|Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
48697448|NCT02251834|OTHER|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
48167736|NCT02151071|DEVICE|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
48167737|NCT02151071|DEVICE|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
48697449|NCT03418311|DEVICE|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
48697450|NCT06659198|PROCEDURE|total hip replacement|minimally-invasive hip replacement
48697451|NCT06412315|DRUG|Citalopram|Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
48697452|NCT06412315|DRUG|Placebo|Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
48010174|NCT05539235|DRUG|different degrees of adjustment of the injection interval|"Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks."
48010175|NCT03126097|DRUG|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3\*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 \[JNJ-64155806 Alone Phase\] and on Days 60 to 66 \[JNJ-64155806 + COCP Coadministration Phase\].
48167738|NCT02969005|RADIATION|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
48167739|NCT02189369|OTHER|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
48167740|NCT02189369|OTHER|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
48167741|NCT02579278|OTHER|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
48167742|NCT02579278|OTHER|Blood sample (mrEMVI negative patient)|
48167743|NCT01746108|BIOLOGICAL|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
48167744|NCT01406808|BEHAVIORAL|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
48167745|NCT03644524|BEHAVIORAL|Heat therapy|Regular hot tub use
48515194|NCT04786587|DIAGNOSTIC_TEST|blood test|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~the blood test for dosage of phosphatidylethanol will be offered to all eligible pregnant women in each maternity clinic of the study during the recruitment period. There will not be different arms in this study."
48515195|NCT04786587|OTHER|self-administered questionnaire|"Each pregnant woman completes the self-report during her prenatal consultation and will have a unique blood sampling for dosage of phosphatidylethanol after she returned her self-report to the practitioner and if she is included in the study (informed consent given).~A self-report, including the T-ACE, is the usual prenatal consultation procedure in the three maternities of the study. The specific procedure for the study is to perform a blood test for dosage of phosphatidylethanol in eligible pregnant women after informed consent."
48697453|NCT03828903|DEVICE|Cryoprobe|"* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
48010176|NCT03126097|DRUG|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
48010177|NCT03126097|DRUG|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
48010178|NCT02473068|DEVICE|CPAP|
48010179|NCT01448018|DRUG|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
48010180|NCT01448018|PROCEDURE|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
48010181|NCT04512274|DEVICE|Test Article|Omeza Collagen Matrix
48010182|NCT03915288|OTHER|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
48010183|NCT03915288|OTHER|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
48010184|NCT03915288|OTHER|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
48010185|NCT01330758|DRUG|AZD8931|40 mg AZD8931 wet granulation tablet formulation
48697454|NCT01490008|DRUG|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
48697455|NCT01490008|OTHER|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
48697456|NCT05359081|DRUG|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
48697457|NCT05994703|DRUG|d-cycloserine|d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
48697458|NCT05994703|OTHER|Juul e-cigarette|Juul use as often as the participant likes for 12 weeks.
48697459|NCT01521871|PROCEDURE|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
48697460|NCT01521871|PROCEDURE|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
48697461|NCT03139643|OTHER|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
48697462|NCT03139643|OTHER|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
48697463|NCT03139643|OTHER|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
48697464|NCT05993429|DIAGNOSTIC_TEST|The sampling method selected in patients with suspected hilar cholangiocarcinoma|The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
48697465|NCT05193201|DRUG|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
48697466|NCT00281099|DEVICE|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
48697467|NCT01271712|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
48697468|NCT01271712|DRUG|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
48697469|NCT01271712|DRUG|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
48697470|NCT06355596|OTHER|Virtual teaching|Virtual teaching of laparoscopic skills
48697471|NCT02189044|OTHER|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
48697472|NCT02664649|DRUG|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
48697473|NCT02664649|DRUG|Standard of care|VKA or Antiplatelet therapy
48697474|NCT03692754|DRUG|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
48697475|NCT03692754|DRUG|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
48697476|NCT03692754|DRUG|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
48697477|NCT05594927|DRUG|Icaritin|600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
48167746|NCT06048939|OTHER|moderate intensity aerobic training and body weight resistance training|"Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group"
48697478|NCT05594927|DRUG|Huachansu|1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
48010186|NCT01330758|DRUG|AZD8931|40 mg AZD8931 roller compacted tablet formulation
48010187|NCT01446562|BIOLOGICAL|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
48010188|NCT06333795|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Treatment is given as capsules.
48010189|NCT06333795|PROCEDURE|Placebo|Treatment is given as capsules.
48010190|NCT00586469|BIOLOGICAL|Fluviral|One dose, Intramuscular injection
48010191|NCT00789282|OTHER|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
48010192|NCT00789282|OTHER|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
48010193|NCT00789282|OTHER|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
48167747|NCT06048939|OTHER|moderate intensity aerobic training|"Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises"
48697479|NCT03230890|DEVICE|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
48010194|NCT05731401|OTHER|Explanations of the cause of pain|"When analyzing the responses to the question Why do you think you have or have had this pain? two themes emerged from the data: 'explanations associated with damage', and 'explanations not associated with damage'.~The themes were sub-classified into sub-themes, according to the type of explanation"
48167748|NCT04018547|DEVICE|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
48167749|NCT01282749|BEHAVIORAL|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
48167750|NCT01282749|BEHAVIORAL|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
48010195|NCT02240888|BIOLOGICAL|0,5 mg Prevenar i.m.|
48167751|NCT06294483|DIAGNOSTIC_TEST|CBC|Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity
48167752|NCT06294483|DIAGNOSTIC_TEST|Antinuclear Antibody tests (ANA)|To be tool in diagnosis of SLE
48167753|NCT06294483|DIAGNOSTIC_TEST|Rest of ANA profile|As tool of diagnosis of SLE
48167754|NCT06294483|DIAGNOSTIC_TEST|C3 and C4 complement level.|As method of detection of acute acivity of SLE
48167755|NCT06294483|DIAGNOSTIC_TEST|Anti phospholipid marker|To detect antiphospholipid syndrome if there is sign of thrombosis
48167756|NCT06294483|DIAGNOSTIC_TEST|Serum creatinine and Alb/create ratio|To detct complication of disease on kidney
48167757|NCT06294483|OTHER|2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.|Is criteria of diagnosis of SLE
48010196|NCT02240888|BIOLOGICAL|0,5 mg seasonal influenza vaccine i.m.|
48167758|NCT06294483|OTHER|SLEDAI scores|Is score to detect the activity of disease
48167759|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
48010197|NCT01018459|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10\^9 viral particles (vp)/mL, 10\^10 vp/mL, 5 x 10\^10 vp/mL, and 10\^11 vp/mL.
48010198|NCT01018459|DRUG|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
48167760|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 2: PH-10 with ambient light illumination.
48167761|NCT00555646|DRUG|Control|No treatment control.
48697480|NCT04595630|OTHER|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
48697481|NCT06607666|DRUG|Lanreotide autogel|Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
48697482|NCT04715204|OTHER|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. Formula with caloric density of \>1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
48697483|NCT04715204|OTHER|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
48697484|NCT04715204|OTHER|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
48697485|NCT00760942|DIETARY_SUPPLEMENT|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
48697486|NCT00760942|DIETARY_SUPPLEMENT|Similac human milk fortifier|Powdered human milk fortifier.
48697487|NCT04651439|DRUG|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
48167762|NCT00833183|DRUG|MAL|80 mg/g cream one administration with incubation for 90 minutes
48167763|NCT02548754|DEVICE|Parasym device|
48167764|NCT03653377|OTHER|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
48167765|NCT05127330|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
48167766|NCT05127330|BEHAVIORAL|Treatment as Usual|Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
48167767|NCT05183477|OTHER|fast track|short cut for the request of xrays directly at triage
48167768|NCT05183477|OTHER|normal pathway|x-ray would be required according to doctor's clinical evaluation.
48167769|NCT03317899|PROCEDURE|Hematopoietic Cell Transplantation|Undergo auto HSCT
48167770|NCT03317899|DRUG|Tbo-filgrastim|Given subcutaneously
48010199|NCT01686243|OTHER|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
48010200|NCT01686243|OTHER|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
48010201|NCT05305599|DRUG|ZED1227|ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
48010202|NCT05305599|DRUG|Placebo|Placebo
48010203|NCT05117944|OTHER|"drama-supported patient role experience"|The students participated in 3 hours of drama activities and played the role of a patient whose basic needs such as nutrition, dressing and oral care were met by the nurse, lying down for 4 hours in the skills laboratory.
48010204|NCT00420550|BEHAVIORAL|Relaxation Response using Guided Imagery|
48010205|NCT04607226|OTHER|Active transcutaneous vagus nerve stimulation|respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes
48010206|NCT04607226|OTHER|Sham transcutaneous vagus nerve stimulation|stimulation of the auricle for 30 minutes
48167771|NCT03317899|OTHER|Laboratory Biomarker Analysis|Correlative Studies
48167772|NCT01530659|DRUG|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
48167773|NCT01530659|PROCEDURE|Sham|Non-penetrating sham procedure to mimic implant procedure in the other eye.
48167774|NCT04528953|BEHAVIORAL|Interval walking and Qigong exercise|"Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position."
48167775|NCT02935777|DIETARY_SUPPLEMENT|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
48697488|NCT04651439|DRUG|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)"
48515196|NCT05835674|DIAGNOSTIC_TEST|Early intervention program|"At enrollment visit: History and examination, MRI, evaluation of comorbidities, medication and genomic testing. HINE, GMA (if below 5 mo), AIMS, SHAI, PSS and DASS-21 questionnaire.~At 6 mo visit: Examination and evaluation of comorbidities, medication and HINE and AIMS~At 12 mo visit: Examination and evaluation of comorbidities, medication and HINE, AIMS, HAI, PSS and DASS-21 questionnaire.~At 18 mo visit: Examination and evaluation of comorbidities, medication and HINE~At 24 mo visit: Examination and evaluation of comorbidities, medication and HINE, PDMS-2, GMFM-66, BSID-IV-cog, MPOC-20 ,PSS, and DASS-21 questionnaire. GMFCS and Mini MACS if CP."
48515197|NCT03478722|OTHER|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
48167776|NCT02935777|DIETARY_SUPPLEMENT|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
48515198|NCT03478722|OTHER|Stable Isotope Amino Acid Infusion|Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)
48515199|NCT01970137|DRUG|KPS-0373, High dose|
48515200|NCT01970137|DRUG|KPS-0373, Low dose|
48697489|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
48697490|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
48697491|NCT04026009|DRUG|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
48697492|NCT04605497|DIAGNOSTIC_TEST|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period
48697493|NCT04605497|DIAGNOSTIC_TEST|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
48697494|NCT04767581|DRUG|KHK7791|oral administration
48010207|NCT00463060|DRUG|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
48010208|NCT00463060|PROCEDURE|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
48010209|NCT03706235|OTHER|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
48010210|NCT03712475|DRUG|Pregabalin|pharmacokinetic study under fasting conditions
48010211|NCT06103513|DRUG|Somatropin|The treatment of children with subcutaneous recombinant human growth hormone (rhGH) is the current gold standard of care for children with diagnosed GHD. This study will serve only to investigate the optimal dose of treatment in the first year of treatment with rhGH.
48010212|NCT00479908|DRUG|Sildenafil citrate|
48010213|NCT00479908|DRUG|Glyceryl trinitrate|
48010214|NCT04545177|DEVICE|NICO Myriad and Tissue Preservation System (TPS)|Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
48010215|NCT00447928|DRUG|OrthoDerm transdermal nitroglycerin patch|
48697495|NCT04767581|DRUG|Placebo|oral administration
48697496|NCT04548934|DEVICE|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
48697497|NCT04548934|DEVICE|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
48010216|NCT06287060|OTHER|strawberry extract.|strawberry has a whitening effect due to its content of ellagic and maleic acids. the presence of acidic components namely ascorbic acid may increase the surface energy by removing the surface debris, thereby allowing the citric and maleic acids to penetrate into tooth surface to remove the surface stains.
48167777|NCT03194854|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
48167778|NCT04212897|OTHER|Music Therapy|"Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions."
48697498|NCT01242839|DEVICE|CACICOL20|CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
48697499|NCT01242839|DEVICE|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
48697500|NCT01106651|DRUG|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
48697501|NCT01106651|DRUG|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
48697502|NCT01106651|DRUG|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
48697503|NCT01106651|DRUG|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
48010217|NCT01291927|PROCEDURE|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
48010218|NCT01291927|PROCEDURE|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
48010219|NCT02306356|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
48010220|NCT04808479|BEHAVIORAL|imFREE mCBT|The imFREE condition is a 32-week tailored, interactive text messaging intervention targeting buprenorphine treatment retention and adherence as well as opioid use and associated health consequences. Following a face-to-face CBT session with a clinician, participants receive CBT skills training via daily text messaging, with content themes around relapse prevention, adherence behaviors, and personalized plans to overcome risk factors for treatment discontinuation.
48010221|NCT04808479|BEHAVIORAL|mHealth ED|The mHealth condition will provide participants with a manualized health psychoeducation session of equivalent duration to the face-to-face CBT session delivered to imFREE participants. Content focuses on various dimensions of health and well-being. Subsequent to this session participants will receive an informational pamphlet regarding BUP and the importance of adherence. the mHealth component of the intervention comprises text reminders for scheduled MM appointments.
48010222|NCT01325610|DIETARY_SUPPLEMENT|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
48010223|NCT02966171|DRUG|HMPL-453|oral administration
48010224|NCT00534690|PROCEDURE|One-Lung ventilation|Low Vt, High PEP
48697504|NCT02632669|RADIATION|Hemigland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
48697505|NCT03325868|DRUG|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
48697506|NCT05862974|DRUG|LPM3480392|Intravenous infusion of 30min duration
48697507|NCT05862974|DRUG|Placebo|Intravenous infusion of 30min duration
48697508|NCT06212115|DIAGNOSTIC_TEST|mNGS|metagenomics next generation sequencing
48010225|NCT00534690|PROCEDURE|One-Llung ventilation|High Vt, low PEP
48167779|NCT05113485|BEHAVIORAL|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.
48515201|NCT02028676|OTHER|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
48697509|NCT06313502|DRUG|75gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
48697510|NCT06313502|DRUG|100gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
48167780|NCT05113485|BEHAVIORAL|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
48167781|NCT01793298|DRUG|ASM-024|Ascending doses of ASM-024
48167782|NCT00729053|DRUG|IMO-2055|immunostimulatory oligonucleotide
48167783|NCT04854902|PROCEDURE|Free gingival graft|1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
48370491|NCT06349109|OTHER|Arterial Stiffness Measurement|Arterial stiffness will be assessed using the pulse wave velocity (PWV) technique with the Mobile-O-GRAPH (TG) (LE.M., Stolberg, Germany), an oscillometer-based device. After the patients have rested sufficiently, measurements will be taken in an upright sitting position in a quiet and sufficiently bright environment at room temperature, with the device manso placed 2-3 cm above the chiibital fossa in the non-dominant upper limb and the arms raised to the level of the heart. Pulse propagation velocity will be calculated in m/sec with the help of a computer. A high velocity data indicates a high level of arterial stiffening and a low velocity data indicates a low level of arterial stiffening.
48370492|NCT06349109|OTHER|Physical Activity Level|Physical activity level will be assessed with the Child Physical Activity Questionnaire.
48697511|NCT06313502|DRUG|125gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
48697512|NCT02327390|PROCEDURE|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
48697513|NCT02327390|BIOLOGICAL|X-ACT|Administered as an IV infusion
48010226|NCT01109316|DRUG|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
48697514|NCT02125851|OTHER|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
48697515|NCT02125851|OTHER|Honey|esophageal mucosal contact time of honey vs sucralose slurry
48697516|NCT05414448|DEVICE|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
48697517|NCT02689466|DRUG|[18F]FP-TZTP|radioligand
48697518|NCT04164095|PROCEDURE|lappg|Preservation of pylorus and vagus nerve by laparoscopy
48697519|NCT01231542|DRUG|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
48010227|NCT01109316|DRUG|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
48010228|NCT01109316|DRUG|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
48010229|NCT00820924|DRUG|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
48697520|NCT01231542|DRUG|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
48697521|NCT01231542|DRUG|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
48010230|NCT01004367|OTHER|Experimental|Environmental- and individual based components carried out in the school.
48697522|NCT05974618|DIAGNOSTIC_TEST|Ultrasound|"A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age."
48697523|NCT04739553|DEVICE|His Pacing|The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
48697524|NCT04566562|DIAGNOSTIC_TEST|Brain Imaging|Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
48697525|NCT04566562|DIAGNOSTIC_TEST|Cognitive Testing|Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
48697526|NCT04566562|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory Markers
48697527|NCT04446507|DRUG|Saroglitazar magnesium|1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
48697528|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
48697529|NCT05741476|OTHER|Placebo|DBV712 matching placebo epicutaneous system.
48697530|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
48697531|NCT02461290|RADIATION|Chemotherapy|
48697532|NCT02461290|DRUG|Rituximab|
48697533|NCT00974441|DRUG|Divalproex Sodium|500 mg Extended Release Tablet
48370493|NCT06349109|OTHER|Physical Activity Barriers Assesment|"Physical Activity Outcome Expectancies (child survey) and Physical Activity Home Environment Scale (Child) will be used in children, while  Physical activity barriers (Parent) will be used in family members."
48370494|NCT04584619|DEVICE|Spine fusion surgery with Clariance Idys TLIF 3DTi|Posterior fusion of the lumbar spine with Clariance Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).
48370495|NCT04772417|DIAGNOSTIC_TEST|Standardized 1-minute sit-to-stand test|The individuals perform two tests from a standardized chair (seat height 46cm).
48370496|NCT04772417|DIAGNOSTIC_TEST|Individualized 1-minute sit-to-stand test|The individuals perform two tests from an individualized chair (seat height adjusted so that the starting position elicits a knee flexion angle of 90°).
48370497|NCT02176031|DRUG|Natalizumab|
48370498|NCT02176031|DRUG|Methylprednisolone|
48370499|NCT02716207|DEVICE|CyberKnife|Radiation Therapy
48370500|NCT03805685|PROCEDURE|Non-Cardiac Surgery|Non-cardiac surgery
48697534|NCT00974441|DRUG|Depakote®|500 mg Extended Release Tablet
48697535|NCT06426563|PROCEDURE|Ablation treatment of thyroid nodule|Use Radiofrequency or Microwave ablation device to treat thyroid nodule
48697536|NCT00624585|DRUG|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~  1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~  1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~  1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily"
48697537|NCT00218634|BEHAVIORAL|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
48697538|NCT00218634|BEHAVIORAL|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
48697539|NCT06350136|BEHAVIORAL|With Tele-Nursing|no With Tele-Nursing
48167784|NCT04854902|PROCEDURE|Cyanoacrylate|N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound
48167785|NCT04854902|PROCEDURE|Suture|The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
48370501|NCT04469309|OTHER|Group I Brandt-Daroff Exercises|"In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment."
48167786|NCT00093132|DRUG|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
48697540|NCT03871309|DEVICE|Tigertriever|Mechanical Thrombectomy
48697541|NCT01726400|DRUG|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
48167787|NCT03645005|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
48697542|NCT01726400|DRUG|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
48697543|NCT05556421|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
48697544|NCT03267719|DEVICE|laser therapy|Transvaginal erbium-laser treatment
48697545|NCT05959577|PROCEDURE|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
48697546|NCT05959577|PROCEDURE|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
48697547|NCT00868140|DRUG|pioglitazone|pioglitazone 45 mg
48167788|NCT03645005|BEHAVIORAL|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
48370502|NCT04469309|OTHER|Group II Half-Somersault Maneuver|In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
48370503|NCT00508872|DRUG|5-Fluorouracil|400 mg/m\^2 IV over 15 minutes, followed by 2400 mg/m\^2 IV Over 46 Hours
48370504|NCT00508872|DRUG|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
48370505|NCT00508872|DRUG|Leucovorin|400 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
48697548|NCT00868140|DRUG|Placebo|placebo daily
48697549|NCT00855933|DEVICE|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
48697550|NCT03227653|DRUG|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
48697551|NCT03227653|DRUG|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
48697552|NCT03227653|DRUG|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
48697553|NCT03088930|DRUG|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
48697554|NCT01986192|DRUG|rivaroxaban|
48697555|NCT01986192|DRUG|Warfarin|
48697556|NCT04187794|OTHER|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
48370506|NCT00508872|DRUG|Oxaliplatin|85 mg/m\^2 IV Over 2 Hours On Day 1 Every 14 Days
48370507|NCT05599555|BIOLOGICAL|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
48370508|NCT05599555|BIOLOGICAL|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
48370509|NCT00275834|DRUG|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
48697557|NCT06087237|DRUG|Pentoxifylline|400 mg pentoxifylline oral tablets three times per day starting from the day before surgery till two weeks after the surgery.
48697558|NCT06087237|DRUG|Placebo|placebo tablets three times per day starting from the day before surgery till two weeks after the surgery.
48697559|NCT03401944|DRUG|TPN|
48697560|NCT03401944|OTHER|Control|
48697561|NCT02446249|BIOLOGICAL|AAV2hAQP1|Infusion of gene therapy
48697562|NCT01545934|BEHAVIORAL|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
48697563|NCT05238207|DRUG|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
48697564|NCT05238207|DIETARY_SUPPLEMENT|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
48697565|NCT06431672|OTHER|interpersonal group psychotherapy|Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.
48167789|NCT06437054|DRUG|Dexamethasone|Dexamethasone 5mg/ml
48167790|NCT06437054|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
48167791|NCT06437054|OTHER|Indocyanine green(ICG)|ICG 25mg
48167792|NCT06477237|BIOLOGICAL|HB0017 Q4W|HB0017 at W0,1,2,4,8+HB0017Q4W
48167793|NCT06477237|BIOLOGICAL|HB0017 Q8W|HB0017 at W0,1,2,4,8+HB0017Q8W
48515202|NCT02028676|OTHER|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
48697566|NCT02692768|OTHER|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
48697567|NCT02692768|OTHER|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
48697568|NCT02692768|OTHER|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
48697569|NCT03011970|DRUG|Oxytocin|
48697570|NCT03011970|DRUG|Placebo|
48697571|NCT00733837|OTHER|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
48167794|NCT06477237|BIOLOGICAL|placebo|placebo at W0,1,2,4,8+HB0017Q4W
48370510|NCT05210959|OTHER|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)|The Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS) is an instrument that assesses the quality and quantity of motor development opportunities available in the home for infants aged 3 to 18 months. In this study, the Turkish version of the AHEMD-IS were constructed. Also, the validity and reliability of this version were examined.
48370511|NCT04762810|DRUG|Cyclophosphamide and glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
48010231|NCT02510911|DRUG|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
48010232|NCT02510911|DRUG|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
48167795|NCT04358068|DRUG|Hydroxychloroquine (HCQ)|Administered orally
48167796|NCT04358068|DRUG|Azithromycin (Azithro)|Administered orally
48167797|NCT04358068|DRUG|Placebo for Hydroxychloroquine|Administered orally
48167798|NCT04358068|DRUG|Placebo for Azithromycin|Administered orally
48370512|NCT04762810|DRUG|Glucocorticoids|Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
48370513|NCT00034801|DRUG|olanzapine|
48370514|NCT00034801|DRUG|ziprasidone|
48167799|NCT01086618|DRUG|systemic chemotherapy|
48167800|NCT01086618|PROCEDURE|adjuvant therapy|
48167801|NCT01086618|PROCEDURE|quality-of-life assessment|
48167802|NCT01086618|PROCEDURE|therapeutic conventional surgery|
48167803|NCT05699967|OTHER|data collection|Participants wear a wristband with a Photoplethysmography (PPG), heart rate and respiratory rate sensor continuously for 3 days. Once gateway and device are linked, all data will be transmitted continuously via Bluetooth to an in-house database. The Device Hub allows to control data availability and signal quality of the wearables, but no scores will be calculated and visualized. The data obtained for calculating the NEWS2 is solely observational and for the study staff. It has no clinical consequence on the treatment of the patient. It is analyzed whether the score with values form the wearables and Electronic Health Record (EHR) corresponds to the conventionally calculated NEWS2 score with values coming only from the EHR.
48167804|NCT02880124|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
48167805|NCT02880124|BEHAVIORAL|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
48167806|NCT02880124|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
48167807|NCT02880124|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
48515203|NCT02028676|DRUG|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
48697572|NCT04958993|DRUG|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
48697573|NCT03551405|RADIATION|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
48697574|NCT02810912|OTHER|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
48697575|NCT03829462|DRUG|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
48697576|NCT03829462|DRUG|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
48697577|NCT04783779|DEVICE|Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
48370515|NCT00483782|BIOLOGICAL|bevacizumab|
48370516|NCT00483782|DRUG|carboplatin|
48370517|NCT00483782|DRUG|paclitaxel|
48515204|NCT02028676|DRUG|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
48697578|NCT00192660|DRUG|Lamivudine|
48697579|NCT00192660|DRUG|Stavudine|
48167808|NCT02880124|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
48167809|NCT02880124|OTHER|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
48167810|NCT02880124|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
48167811|NCT02880124|BEHAVIORAL|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
48167812|NCT01211223|DRUG|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
48167813|NCT03354897|DRUG|Torasemide 5Mg Tablet|16 weeks treatment
48167814|NCT04577976|DEVICE|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
48370518|NCT00483782|OTHER|questionnaire administration|
48370519|NCT00483782|OTHER|study of socioeconomic and demographic variables|
48515205|NCT02028676|DRUG|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
48515206|NCT02028676|DRUG|Once-daily ABC+3TC|
48515207|NCT02028676|DRUG|Twice-daily ABC+3TC|
48515208|NCT02028676|DRUG|Continued cotrimoxazole prophylaxis|
48515209|NCT02028676|OTHER|Stopped cotrimoxazole prophylaxis|
48167815|NCT03284125|OTHER|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
48167816|NCT06195878|DEVICE|CPAP Therapy|Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
48370520|NCT00483782|PROCEDURE|quality-of-life assessment|
48370521|NCT04938882|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
48370522|NCT04938882|DRUG|Ropivacaine|Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
48370523|NCT04938882|DRUG|Compound lidocaine at low concentration|Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
48370524|NCT04938882|DRUG|Compound lidocaine at high concentration|Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
48515210|NCT01252277|DRUG|Lovaza™|4 capsules daily for 6 months
48167817|NCT02456675|DRUG|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
48010233|NCT02510911|DRUG|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
48010234|NCT02510911|OTHER|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
48010235|NCT01345279|DRUG|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
48010236|NCT01345279|DRUG|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
48010237|NCT01345279|DRUG|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
48010238|NCT00066196|BIOLOGICAL|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
48167818|NCT02456675|DRUG|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
48167819|NCT02456675|DRUG|itacitinib|The dose of itacitinib will be given orally once daily (QD).
48167820|NCT06404073|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
48515211|NCT05835908|OTHER|Phone questionnaire|Patients will be contacted by the investigator to collect information regarding follow-up from the initial call to the Emergency call center until the patient is taken care of in the health care facility to which he/she has been admitted.
48697580|NCT00192660|DRUG|Didanosine|
48697581|NCT00192660|DRUG|Zidovudine|
48697582|NCT00192660|DRUG|Tenofovir|
48697583|NCT00192660|DRUG|Abacavir|
48010239|NCT00066196|BIOLOGICAL|Integrin + Dacarbazine|supplied in other formulations
48010240|NCT00411619|DRUG|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
48167821|NCT06404073|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
48167822|NCT04902196|OTHER|high intensity cardiorespiratory exercise protocol|During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
48167823|NCT04902196|OTHER|moderate intensity cardiorespiratory exercise protocol|During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
48515212|NCT06083519|BEHAVIORAL|White Noise|This is the control condition. Listening to white noise -- participants listen to white noise for 24 minutes
48515213|NCT06083519|BEHAVIORAL|Music and Auditory Beat Stimulation|Listening to music and auditory beat stimulation. The VIBE app (LUCID) incorporates theta-band (4 Hz) auditory beat stimulation and an auditory music recommendation system. Participants will listen to this music with theta auditory beat stimulation for 24 minutes.
48515214|NCT02451761|BIOLOGICAL|Blood sampling|
48515215|NCT05600673|DRUG|Bimatoprost 0.03% solution|Topical Bimatoprost 0.03% solution
48515216|NCT05600673|DEVICE|CO2 fractional laser|CO2 fractional laser treatment
48515217|NCT01755091|DRUG|Dronabinol|
48697584|NCT00192660|DRUG|Efavirenz (EFV)|
48697585|NCT00192660|DRUG|Nevirapine|
48697586|NCT00192660|DRUG|Indinavir|
48697587|NCT00192660|DRUG|Saquinavir|
48697588|NCT00192660|DRUG|Amprenavir|
48697589|NCT00192660|DRUG|Ritonavir|
48697590|NCT00192660|DRUG|Nelfinavir|
48697591|NCT00192660|DRUG|Tipranavir|
48697592|NCT00192660|DRUG|enfuvirtide (T20)|
48697593|NCT04104815|OTHER|Experimental Thickener|Use to thicken liquids
48697594|NCT03883347|DRUG|Dexmedetomidine|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
48697595|NCT03883347|DRUG|Remifentanil|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
48697596|NCT04660851|BEHAVIORAL|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
48167824|NCT02440646|RADIATION|Coronary computed tomography angiography|The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
48010241|NCT05004259|DRUG|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
48167825|NCT02440646|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
48167826|NCT04873297|DRUG|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
48167827|NCT04873297|DRUG|Placebo|Placebo 10 ml of plain water Via NG
48167828|NCT04020198|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
48167829|NCT00302497|DRUG|basiliximab|
48167830|NCT04877249|BEHAVIORAL|Split-belt treadmill training|1. Split-belt gait training without or with any resistance, 2. Facilitating the knee extension during the terminal swing phase of gait cycle to identify the impact on the propulsive force generation of paretic leg
48167831|NCT01778647|DIETARY_SUPPLEMENT|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
48167832|NCT01778647|DRUG|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
48167833|NCT03386214|DRUG|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
48167834|NCT03386214|DRUG|Ruxolitinib|-Standard of care outside of protocol
48167835|NCT03386214|PROCEDURE|Peripheral blood draw|"* Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment"
48167836|NCT03386214|PROCEDURE|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
48167837|NCT00520403|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
48167838|NCT00520403|DRUG|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
48167839|NCT00520403|DRUG|Vinblastine|0.1mg/kg iv every 3 weeks
48167840|NCT01397188|DEVICE|PiCCO|transpulmonary thermodilution technique
48167841|NCT01397188|OTHER|sham, no intervention|no intervention
48167842|NCT01800578|DEVICE|monitor for depth of hypnosis|"evaluation of depth of hypnosis~--------------------------------------------------------------------------------"
48010242|NCT01304485|DRUG|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
48010243|NCT04709575|DRUG|REGN5713|Administered subcutaneously
48010244|NCT04709575|DRUG|REGN5714|Administered subcutaneously
48167843|NCT01143298|DRUG|LEO 27847 oral solution|
48167844|NCT02489721|DEVICE|PICC and Midline|Peripherally inserted central venous catheter
48167845|NCT04799418|DEVICE|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
48167846|NCT02716857|DRUG|Oxycodone extended-release|
48167847|NCT02716857|DRUG|Placebo of oxycodone extended-release|
48167848|NCT04009720|DEVICE|Lotus Edge Device|The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] \<1.0 cm2 or AVA index \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
48167849|NCT01708005|DRUG|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
48010245|NCT04709575|DRUG|REGN5715|Administered subcutaneously
48167850|NCT01708005|DRUG|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
48697597|NCT04549779|PROCEDURE|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
48010246|NCT04709575|DRUG|Placebo|Placebo that replaces REGN5713-5714-5715
48010247|NCT00514267|DRUG|YM 155|IV
48010248|NCT00514267|DRUG|Docetaxel|IV
48010249|NCT00514267|DRUG|Prednisone|Oral
48010250|NCT01795924|DRUG|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
48010251|NCT04171414|BIOLOGICAL|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
48010252|NCT01585766|DRUG|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
48010253|NCT01585766|DRUG|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
48010254|NCT01585766|DRUG|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
48010255|NCT01585766|DRUG|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
48010256|NCT01585766|DRUG|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
48010257|NCT01585766|DRUG|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
48010258|NCT04623333|DRUG|TQB2450|TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
48167851|NCT05286086|BEHAVIORAL|prehabilitation|Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
48370525|NCT06227819|DIAGNOSTIC_TEST|BVA-200|Blood samples collected for measurement with the BVA-100 will also be tested with the BVA-200. The BVA-200 uses whole blood collection cartridges which allow for a precise amount of blood to be measured without the need to first centrifuge and then pipette plasma aliquots. A small amount of whole blood from each sample will be set aside for BVA-200 use, while the remainder of the blood sample is used for BVA-100 measurement. The BVA-200 device was developed with the support of the Department of Defense through Phase I (W81XWH19C0048) and Phase II (W81XWH20C0025) SBIR contracts.
48370526|NCT00817752|DIETARY_SUPPLEMENT|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
48370527|NCT01672827|DRUG|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
48010259|NCT05572502|BEHAVIORAL|plant-based diet|For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
48167852|NCT03424525|DRUG|11C-Trimethoprim|\[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
48167853|NCT02171247|DRUG|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
48167854|NCT02171247|DRUG|Visipaque 320|Visipaque 320 is standard protocol.
48167855|NCT00202332|PROCEDURE|Coronary artery bypass|
48697598|NCT04549779|PROCEDURE|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
48697599|NCT04549779|PROCEDURE|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
48697600|NCT01092780|DRUG|MK-7288|one or two 10 mg capsules, orally, single dose
48370528|NCT01306682|BIOLOGICAL|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
48697601|NCT01092780|DRUG|Placebo to MK-7288|one or two capsules, orally, single dose
48697602|NCT01092780|DRUG|Modafinil|two 100 mg tablets, orally, single dose
48370529|NCT01306682|BIOLOGICAL|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
48370530|NCT06303011|OTHER|Transcutaneous Electrical Nerve Stimulator|TENS will be applied on sacral and parasacral area. Frequency 10Hz, Pulse duration 200μs, Stimulation duration 20min
48697603|NCT01092780|DRUG|Placebo to modafinil|two 100 mg tablets, orally, single dose
48697604|NCT05203757|PROCEDURE|ArthroCT scan|Conventional CT arthrogram as routine care
48697605|NCT05203757|PROCEDURE|CBCT|Cone Beam CT scan.
48697606|NCT00494650|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
48697607|NCT00494650|BEHAVIORAL|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
48370531|NCT06303011|OTHER|TENS on para sacral area with Abdominal Massage|TENS on para sacral area with Abdominal Massage. Frequency 10Hz Pulse duration 200μs Stimulation duration 20min
48370532|NCT05936827|DIAGNOSTIC_TEST|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams \& Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
48370533|NCT05936827|DIAGNOSTIC_TEST|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
48697608|NCT02978157|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
48697609|NCT02978157|DRUG|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
48697610|NCT03927547|DEVICE|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
48697611|NCT00338286|OTHER|Standard supportive care (packed RBC transfusion)|Per doctor prescription
48697612|NCT00338286|DRUG|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
48697613|NCT02428751|DRUG|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
48697614|NCT02428751|DRUG|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
48697615|NCT02428751|DRUG|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
48697616|NCT02428751|DRUG|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
48697617|NCT02428751|DRUG|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
48370534|NCT03087682|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
48515218|NCT01755091|DRUG|Placebo (for Dronabinol)|
48515219|NCT03362372|BEHAVIORAL|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~1. Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~2. Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~3. Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
48515220|NCT05185765|OTHER|Bread|Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
48697618|NCT02428751|DRUG|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
48697619|NCT00439543|DRUG|Iloprost inhalation|
48697620|NCT04207593|DRUG|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
48697621|NCT05229211|DEVICE|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
48697622|NCT01905228|DRUG|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
48697623|NCT04261972|GENETIC|Next generation sequencing (NGS)|NGS
48697624|NCT01904474|OTHER|Next.Step - e-therapeutic intervention program|
48697625|NCT01904474|OTHER|Standard treatment protocol|
48370535|NCT01526343|DEVICE|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
48370536|NCT01658527|DRUG|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
48515221|NCT00000543|BEHAVIORAL|dietary supplements|
48515222|NCT00000543|DRUG|calcium|
48697626|NCT00303654|PROCEDURE|biopsy|
48010260|NCT05287464|DRUG|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
48010261|NCT05996081|BEHAVIORAL|Adherence toolkit|The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.
48515223|NCT03624959|DRUG|Ozanimod|ozanimod
48515224|NCT03624959|DRUG|Gemfibrozil|Gemfibrozil
48515225|NCT03624959|DRUG|Itraconazole|Itraconazole
48515226|NCT03624959|DRUG|Rifampin|Rifampin
48522859|NCT05718414|DEVICE|Ultrasound via artifical intelligence|"The peripheral nerve and plan block regions (adductor canal, axillary brachial plexus, PECS, popliteal, rectus sheath, ESP, femoral, and superficial cervical plexus regions) and related anatomical landmarks are practised by 3 anesthesiology residents who were in the training program of regional anesthesia and qualified to perform ultrasound guided techniques . Then, scans of 8 block types for all 40 volunteers; when the scan success gauge on the AI software was 100% at the time the images were saved. Using this procedure, 960 ultrasound images were acquired in both raw and AI-processed forms for expert assessment ."
48697627|NCT00303654|PROCEDURE|therapeutic conventional surgery|
48697628|NCT02776462|DEVICE|EyeBox CNS|
48697629|NCT03453619|DRUG|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
48697630|NCT02777606|DRUG|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
48697631|NCT04788004|OTHER|Online survey|There are no interventions planned for this study. This is an observational study only.
48697632|NCT01965769|OTHER|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
48697633|NCT02899234|OTHER|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
48697634|NCT02490995|OTHER|Movie|Besides the anesthesist explanations the children will have a movie explanation.
48697635|NCT04969601|BIOLOGICAL|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
48697636|NCT05686746|DRUG|Baricitinib 4 MG|4 mg oral daily
48697637|NCT05686746|DRUG|Baricitinib 2 MG|2 mg oral daily
48697638|NCT05686746|DRUG|MMF|1000 mg oral daily
48697639|NCT03386136|DRUG|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
48697640|NCT03309319|DRUG|Rosiglitazone|rosiglitazone is added to the primary treatment
48697641|NCT02439151|DEVICE|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
48370537|NCT01658527|DRUG|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
48370538|NCT02260804|BIOLOGICAL|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
48370539|NCT02260804|BIOLOGICAL|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
48370540|NCT00758576|DEVICE|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
48697642|NCT02439151|DEVICE|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
48697643|NCT05281276|DRUG|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
48697644|NCT05281276|DRUG|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
48697645|NCT04426149|DIETARY_SUPPLEMENT|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
48010262|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair with a mixture of plant extracts rich in polyphenolic compounds|2 times a day
48370541|NCT05430724|PROCEDURE|Controlled hypotention|"The procedure to be applied to the cases to be included in the study:~Patients randomized by the sealed envelope method will be divided into 2 groups (40 patients in each group).~The sealed envelopes that determine which group the patient will belong to will be randomly selected by the patient.~Standard general anesthesia will be applied to all patients. Before starting the surgical procedure; Group N (Nicardipine infusion) will be administered at a dose of 5-15mg/h, and Group E (Esmolol infusion) at a dose of 50-300mcg/kg/min.~2) General anesthesia will be applied to all groups. Patients will be administered controlled hypotension (mean arterial pressure 50-60 mmHg)."
48370542|NCT02609087|DRUG|Sevoflurane|
48370543|NCT02609087|DRUG|Propofol|
48370544|NCT05962073|DEVICE|HFNC|High-flow oxygen therapy before intubation for preoxygenation
48370545|NCT04974294|BIOLOGICAL|PPV23|random allocation 1:1:1 IM injection
48370546|NCT04974294|BIOLOGICAL|PCV13|random allocation 1:1:1 IM injection
48370547|NCT04974294|OTHER|Saline for injection|random allocation 1:1:1 IM injection
48370548|NCT04491591|OTHER|Breast Reconstruction Education and Support Tool (BREASTChoice)|The tool is an interactive website and can be sent through My Chart and integrated into the electronic health record
48370549|NCT04491591|OTHER|Attention Control Website|-(https://www.cancer.gov/types/breast/reconstruction-fact-sheet)
48370550|NCT04491591|OTHER|Clinician Survey|-Questions regarding opinions on shared decision-making with answers ranging from 1-7 with 1=strongly disagree or harmful to 7=strongly agree or beneficial. The higher the score the more the physician agrees with shared decision making.
48370551|NCT00366665|DEVICE|Legacy 20000|
48370552|NCT00366665|DEVICE|Infinit system|
48370553|NCT05493579|OTHER|Implant supported overdenture|Implant supported overdenture compared to complete denture
48697646|NCT04186416|OTHER|Mostcare® device|The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.
48010263|NCT06017661|DIETARY_SUPPLEMENT|Nutridrink Skin Repair|2 times a day
48010264|NCT06091553|DRUG|Duloxetine alone|30 mg once daily for 1 week, then 60 mg once daily
48010265|NCT06091553|DRUG|Duloxetine augmented with gabapentin|30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
48010266|NCT06091553|DRUG|Duloxetine augmented with amitriptyline (as combined therapy)|10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
48010267|NCT00004357|DRUG|Methylprednisolone|IV
48370554|NCT04500925|PROCEDURE|UNILATERAL THYROIDECTOMY|
48522860|NCT05876806|DRUG|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
48522861|NCT05876806|DRUG|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
48522862|NCT00087815|DRUG|dexamethasone|
48522863|NCT00087815|DRUG|hyperbaric oxygen|
48522864|NCT00087815|PROCEDURE|cognitive assessment|
48697647|NCT04186416|OTHER|Transthoracic cardiac ultrasound|Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
48167856|NCT05934656|OTHER|Latent class analysis|"The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation."
48167857|NCT04983225|DRUG|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
48167858|NCT04983225|OTHER|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
48167859|NCT03670199|OTHER|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
48167860|NCT03670199|OTHER|Physiotherapist intervention|Respiratory capacity Functional capacity
48167861|NCT03670199|OTHER|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
48167862|NCT03670199|OTHER|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
48167863|NCT06096818|BEHAVIORAL|Experimental Group: Kegel exercises and abdominal exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled."
48167864|NCT06096818|BEHAVIORAL|Control Group: Kegel exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled."
48370555|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
48370556|NCT04751851|BEHAVIORAL|Long duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
48370557|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
48370558|NCT04751851|BEHAVIORAL|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
48370559|NCT06345573|BEHAVIORAL|Mental stress|Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
48370560|NCT00136344|DRUG|Cefuroxime|
48370561|NCT00136344|DRUG|Levofloxacin|
48370562|NCT02515890|DRUG|Dexmedetomidine|Selected subjects received this drug during a portion of the study
48522865|NCT00087815|PROCEDURE|magnetic resonance imaging|
48010268|NCT00004357|DRUG|Prednisolone|Oral
48697648|NCT03789435|DIAGNOSTIC_TEST|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
48010269|NCT06410872|DIAGNOSTIC_TEST|BART Task|The Zuckerman's Sensation Seeking Scale version-V (SSS-V) - Four-factor score, The Barret Impulsiveness Scale (BIS), Gormally's Binge Eating Scale (BES), The World Health Organization-developed AUDIT (Alcohol Use Disorders Identification Test) screen, The CAGE questionnaire for substance abuse-adapted to include drugs, Gamblers Anonymous's 20 Questions (GA20), Hospital Anxiety and Depression Scale (HADS)
48167865|NCT04126122|DIAGNOSTIC_TEST|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
48167866|NCT00438230|DRUG|Warfarin|
48370563|NCT02515890|DRUG|Midazolam|Selected subjects received this drug during a portion of the study
48370564|NCT02515890|DEVICE|Peripheral nerve stimulation|Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.
48370565|NCT02515890|DRUG|Ketamine|Selected subjects received this drug during a portion of the study
48370566|NCT01743781|BEHAVIORAL|video|view a 10-minute informational video about comprehensive eye examination
48370567|NCT00458055|DRUG|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
48370568|NCT05713019|DEVICE|Adenosine triphosphate (ATP) solution inhalation from nebuliser|ATP and 0.9% saline solution will be inhaled from a nebuliser on separate days, and their effects will be examined.
48697649|NCT03094091|OTHER|News items with spin|Interpretation of news items with spin
48697650|NCT03094091|OTHER|News items without spin|Interpretation of news items without spin
48697651|NCT05796921|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain|Patients allocated to the probiotic arm will take the dietary supplement, containing 15 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.
48697652|NCT05796921|DIETARY_SUPPLEMENT|placebo|Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.
48010270|NCT02153775|BEHAVIORAL|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
48010271|NCT04958733|PROCEDURE|Autologous bone grafting|Autologous bone grafting is the excess bone obtained from graft preparation and the coring reamer
48010272|NCT04958733|PROCEDURE|Absence of autologous bone grafting|Donor sites will be left unfilled
48010273|NCT05151939|DIAGNOSTIC_TEST|Identification or discharge visualization of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos by an expert endoscopist|An expert endoscopist will select a dataset of mediastinal and abdominal EUS videos (one per patient). An expert endoscopist will identify or discharge visualization of the following organs correctly: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein.
48010274|NCT05151939|DIAGNOSTIC_TEST|Recognition of mediastinal and abdominal organ/anatomic strictures through Endoscopic ultrasound (EUS) videos using artificial intelligence (AI)|Using the same previous dataset of mediastinal and abdominal EUS videos, the EUS-AI model will recognize the following organs: aorta, vertebral spine, aortic arch, trachea, AP window, left kidney, liver, spleen, pancreas body, pancreas tail, coeliac trunk, splenic artery, splenic vein, inferior vena cava, adrenal gland, right kidney, gallbladder, common bile duct, ampulla of Vater, portal vein. Considering each patient (and not data frame videos) as the study unit, a contingency table per each mediastinal and abdominal organ/anatomic stricture will be designed.
48010275|NCT05681429|DRUG|Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib|To compare the recovery outcome of patients who undergo supratentorial craniotomy with opioid-based anaesthesia and opioid-free anaesthesia
48010276|NCT04520945|BIOLOGICAL|Chondrogen|Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid
48010277|NCT04520945|BIOLOGICAL|Placebo|Consist of saline and hyaluronic acid
48010278|NCT00888303|DRUG|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
48010279|NCT00888303|DRUG|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
48010280|NCT00888303|PROCEDURE|Thyroidectomy, total or partial|Surgical standard intervention
48010281|NCT02753894|DRUG|ASP1585|Oral
48697653|NCT05108454|DRUG|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
48697654|NCT00987428|PROCEDURE|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
48697655|NCT00987428|PROCEDURE|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
48697656|NCT02584543|BIOLOGICAL|HEV vaccine|
48697657|NCT02584543|BIOLOGICAL|HBV vaccine|
48697658|NCT04793724|DEVICE|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive"
48167867|NCT03704571|DRUG|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
48167868|NCT02396758|DEVICE|Ekosonic® Endovascular Device ultrasonic infusion catheter|r-tPA will be administered via EKOS.
48167869|NCT02396758|BIOLOGICAL|Recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
48167870|NCT00695370|DRUG|Pegfilgrastim (drug)|
48370569|NCT05713019|DIAGNOSTIC_TEST|Inhalational challenge with increasing concentrations of capsaicin solutions|Coughs are counted for one minute after single-breath inhalations of 0.9% sodium chloride and capsaicin solutions of increasing concentrations (0.98-500 μm) generated from a dosimeter (P.K. Morgan Ltd, Gillingham, UK) set at a dosing period of 1 s. The concentration that caused more than 2 or 5 coughs was recorded as C2 and C5, and the data is analysed as log10 C2 or C5.
48370570|NCT05713019|DEVICE|Recording of Cough Count and frequency using the Hyfe Cough Monitor|"All enrolled study participants will be provided with a dedicated Android phone or watch loaded with the Hyfe Research application to monitor and record their cough sounds. The participant will be provided with a carrying case to ensure the phone stays within five feet of their mouth. They will be asked to wear the phone for the duration of 3 weeks, and keep the phone within five feet of their mouth over nights - keeping it, i.e., on a bedside table.~Hyfe is a research use only tool which does not provide clinical diagnosis. Cough collection within this study will not lead to specific medical interventions or differential clinical management. Hyfe records only short snippets (\<0.5 seconds). As such, the recordings will not be identifiable. Conversations or acoustic environments are not recorded. The informed consent form will explicitly describe exactly what is recorded."
48370571|NCT05713019|PROCEDURE|Collection of exhaled breath condensate|EBC will be collected by asking the subject to breathe normally onto a handheld breath collection apparatus from Respire Diagnostics, Imperial College, that will cool the exhaled breath to allow for condensation of the exhaled air. The subject will breathe for 2 periods of 5 minutes each separated by a 3-4 min rest to allow the collection of up to 500 uL of liquid. The liquid will be stored for later analysis.
48522866|NCT00087815|PROCEDURE|positron emission tomography|
48522867|NCT00087815|PROCEDURE|quality-of-life assessment|
48522868|NCT06449976|BEHAVIORAL|blue light defocus and blue light filtering|Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.
48697659|NCT04793724|DEVICE|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
48697660|NCT05497531|DIAGNOSTIC_TEST|ctDNA Blood Collection|Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
48697661|NCT01027234|DRUG|AZD8418|Single oral dose
48697662|NCT01027234|DRUG|Placebo|single oral dose
48697663|NCT06607744|DRUG|Pharmacokinetic profiles of Selegiline TDS and EMSAM|Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
48697664|NCT05349409|DRUG|SHR-A1811|SHR-A1811 for Injection: Given IV.
48697665|NCT05349409|DRUG|Fluzoparib Capsule|Fluzoparib Capsule: Given PO.
48515227|NCT04598386|OTHER|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
48515228|NCT04598386|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
48515229|NCT01464632|DEVICE|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
48697666|NCT02982434|DRUG|Pharmaceutical composition containing botulinum toxin|
48167871|NCT03456635|OTHER|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
48167872|NCT06192017|DIAGNOSTIC_TEST|WomEC|The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.
48167873|NCT06480370|DEVICE|ISIS IOM System|Application of TES at different stimulation circuits, with different stimulation parameters and recording montages.
48167874|NCT03126214|DRUG|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
48167875|NCT02427958|DRUG|Leuprorelin|Suspension for injection.
48167876|NCT05457322|BEHAVIORAL|Behavioral intervention one|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
48167877|NCT05457322|BEHAVIORAL|Behavioral intervention two|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
48167878|NCT01802892|DRUG|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
48167879|NCT01802892|DRUG|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
48515230|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
48515231|NCT01499446|DRUG|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
48697667|NCT02982434|DRUG|0.9% normal saline|
48697668|NCT02982434|PROCEDURE|Coronary artery bypass grafting|
48697669|NCT06454825|DRUG|Intravenous drug|medications were applied intravenously to the groups 30 minutes before end of the procedure
48697670|NCT03220932|PROCEDURE|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
48697671|NCT03220932|DRUG|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
48697672|NCT01208883|OTHER|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
48010282|NCT03771833|DEVICE|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
48010283|NCT00028028|DRUG|temsirolimus|Given IV
48010284|NCT00028028|OTHER|pharmacological study|Correlative studies
48010285|NCT00028028|OTHER|laboratory biomarker analysis|Correlative studies
48010286|NCT00952341|DRUG|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
48010287|NCT00952341|DRUG|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
48167880|NCT01802892|DRUG|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
48167881|NCT01729091|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
48167882|NCT01729091|BIOLOGICAL|Elotuzumab|Given IV
48167883|NCT01729091|OTHER|Laboratory Biomarker Analysis|Correlative studies
48167884|NCT01729091|DRUG|Lenalidomide|Given PO
48167885|NCT01729091|DRUG|Melphalan|Given IV
48167886|NCT01729091|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
48167887|NCT01729091|BIOLOGICAL|Umbilical Cord Blood-Derived Lymphocyte Therapy|Given IV
48167888|NCT06425445|PROCEDURE|Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds|Participants perform forced static expiratory maneuvers sustained over a five second period
48697673|NCT01595971|BEHAVIORAL|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
48515232|NCT01499446|DRUG|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
48515233|NCT01499446|DRUG|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
48515234|NCT01476566|BEHAVIORAL|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
48515235|NCT05356507|OTHER|Patient population|Questionnaires, standard of care
48515236|NCT06352827|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
48515237|NCT02129322|DRUG|Sorafenib|
48515238|NCT02129322|DRUG|S-1|
48515239|NCT02129322|DRUG|Oxaliplatin|
48697674|NCT01595971|OTHER|usual care|Received the usual care provided
48697675|NCT06658730|DEVICE|Endovascular|TEVAR - thoracic endovascular aortic repair
48697676|NCT05086224|DRUG|Hematoma Local Anesthetic Block Procedure with 1% Lidocaine|Inject anesthetic into the hematoma site, 20 mL of 1% lidocaine without epinephrine.
48697677|NCT05086224|DRUG|Bier Anesthetic Block Procedure with 1% Lidocaine|Intravenous anesthetic infusion, a maximum lidocaine dosing of 3 mg/kg.
48697678|NCT01273116|OTHER|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~* will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~* a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~* will be discussed at least once in a multidisciplinary meeting;~* a structured medication review will be carried out by a geriatrician;~* is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~* may receive a consult of a geriatrician, if judged necessary;~* will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
48697679|NCT00550810|DRUG|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
48515240|NCT02376400|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29 or 57.
48515241|NCT02376400|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29 or 57.
48515242|NCT02376400|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
48515243|NCT04271917|DRUG|cannabidiol|Use of cannabidiol as an alternative to standard of care treatment of acute pain.
48515244|NCT04271917|DRUG|placebo|Inactive placebo oil to imitate CBD oil
48515245|NCT04271917|DRUG|acetaminophen 500mg and ibuprofen 200mg combo|standard of care
48515246|NCT00217555|DRUG|gemcitabine hydrochloride|
48515247|NCT00217555|DRUG|topotecan hydrochloride|
48515248|NCT03767582|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
48515249|NCT03767582|DRUG|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
48515250|NCT03767582|DRUG|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
48697680|NCT00776594|DRUG|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
48697681|NCT00776594|DRUG|bicalutamide|50mg orally daily for 6 months
48697682|NCT00776594|DRUG|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
48515251|NCT03767582|DRUG|GVAX|Vaccine (5x10\^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
48697683|NCT02407080|DRUG|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
48697684|NCT02407080|DRUG|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
48697685|NCT01218958|DRUG|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
48515252|NCT01017627|OTHER|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
48167889|NCT01907022|DEVICE|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
48697686|NCT01218958|DRUG|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
48167890|NCT05188872|DIAGNOSTIC_TEST|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
48167891|NCT03204500|COMBINATION_PRODUCT|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
48167892|NCT03204500|DRUG|Placebos|Administered orally under the same conditions
48167893|NCT03484078|DEVICE|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
48167894|NCT03484078|DEVICE|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
48167895|NCT05640973|OTHER|Evaluation|Evaluation of ease of use
48167896|NCT00202306|DRUG|lithium carbonate|
48697687|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
48697688|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
48697689|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS plus GOS|
48010288|NCT00952341|DRUG|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
48010289|NCT00952341|DRUG|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
48167897|NCT04807283|DEVICE|Left Atrial Appendage Closure|Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF
48167898|NCT03101033|DEVICE|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
48167899|NCT03101033|DRUG|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
48515253|NCT01017627|OTHER|No change from normal routine|Normal unit policy for labs and anemia treatment
48515254|NCT01256502|DEVICE|SERI® Surgical Scaffold|Breast reconstruction surgery
48515255|NCT00553176|OTHER|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
48515256|NCT04526847|BEHAVIORAL|Intermittent energy restriction (IER) : 5:2 diet pattern|Participants in the IER group will be provided menus on fasting day that provide \~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means \~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, \& Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to \~75% of the normal energy requirements. They will receive a diet plan that recommended \~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
48522869|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine-Aclarubicin Association|Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
48697690|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS|
48697691|NCT00461149|DRUG|Octreotide-LAR|
48697692|NCT06401889|OTHER|Non-Interventional Study|Non-interventional study
48697693|NCT02330653|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
48697694|NCT02330653|BIOLOGICAL|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
48697695|NCT01557257|DRUG|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
48515257|NCT04526847|BEHAVIORAL|Continuous energy restricted (CER) group|Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume \~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
48515258|NCT06198244|DEVICE|Transcutaneous Electrical Nerve Stimulation(TENS)|Defecation frequency per week, abdominal pain or discomfort, type of stool, severity of the constipation, frequency and consistency of stool, were measured before the commencement of treatment by using Romes-IV criteria, Visual Analogue Scale (VAS),Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS).After taking the measurements apply TENS on abdomen i.e. on the lower gastrointestinal tract, placed two skin electrodes of TENS on the abdomen lateral to the umbilicus and other two electrodes on back side at T9-L2 level for a month (20 minutes per session and 3 times a week) along with baseline treatment in which general movements were performed. After the completion of treatment same tools were used to re-assess the defecation frequency per week, abdominal pain or discomfort, type of stool, and severity of the constipation, frequency and consistency of stool for the measurement of final reading(Pre and post-treatment).
48515259|NCT06198244|OTHER|Baseline Treatment|In control group, after the recruitment of participants according to the inclusion criteria. The baseline measurement were recorded by using Romes-IV criteria, Visual Analogue Scale (VAS), Bristol Stool Scale (BSS),Gross Motor Functional Classification System (GMFCS) and Constipation Assessment Scale(CAS). The baseline treatment is given in which general movements were performed i.e. Double knee-to-chest movement, sitting, standing, rolling as well as stretching of calf, hamstrings, adductors of both sides. Again assess the patient severity of constipation, frequency and consistency of stool, abdominal pain and functional status after the end of last session of the treatment(Pre and Post-treatment method).
48167900|NCT03101033|DRUG|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
48167901|NCT03101033|DRUG|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
48167902|NCT02154477|DRUG|intranasal insulin|insulin
48515260|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
48515261|NCT03484650|DRUG|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
48515262|NCT03484650|OTHER|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
48515263|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
48515264|NCT03277066|DRUG|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
48515265|NCT03277066|DRUG|Placebo patch|Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
48697696|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
48697697|NCT01557257|DRUG|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
48010290|NCT00952341|DRUG|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
48010291|NCT06343077|DRUG|Poly-ICLC intramuscular (IM) injection|1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.
48010292|NCT06343077|DRUG|Poly-ICLC, Intertumoral (IT) injection|1 mg IT once (week 2)
48167903|NCT02154477|DRUG|placebo (intranasal saline)|saline
48167904|NCT00360750|DRUG|carboplatin|
48167905|NCT00360750|DRUG|cytarabine|
48167906|NCT00360750|DRUG|etoposide|
48167907|NCT00360750|DRUG|vincristine sulfate|
48515266|NCT02897518|DEVICE|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
48010293|NCT03824197|OTHER|EVOO|Extra-virgin olive oil that is rich with oleocanthal and other phenols.
48010294|NCT03824197|OTHER|OO|Olive oil low in oleocanthal and other phenols.
48010295|NCT00326911|BIOLOGICAL|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
48010296|NCT00326911|BIOLOGICAL|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
48010297|NCT00326911|DRUG|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
48010298|NCT00326911|BIOLOGICAL|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
48010299|NCT05443997|BEHAVIORAL|MIYCN capacity building|"* MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices"
48167908|NCT00360750|OTHER|clinical observation|
48167909|NCT00360750|PROCEDURE|adjuvant therapy|
48167910|NCT00360750|RADIATION|radiation therapy|
48167911|NCT02713607|DRUG|Doxycycline|Given doxycycline to acne subjects
48167912|NCT04589390|DRUG|Selexipag|treatment with selexipag
48167913|NCT01689467|DIETARY_SUPPLEMENT|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
48167914|NCT01689467|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
48167915|NCT03140449|DRUG|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
48167916|NCT03140449|DRUG|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
48167917|NCT03140449|DRUG|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
48167918|NCT03847922|DRUG|Nitrous Oxide + Oxygen Gas (Product)|Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
48167919|NCT03847922|DRUG|lidocaine gel 2%|6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
48697698|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
48697699|NCT01557257|DRUG|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
48697700|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
48697701|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
48167920|NCT03847922|OTHER|Room air|Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
48167921|NCT04518761|PROCEDURE|Elective surgery|Any patient who needs to undergo an elective surgery.
48167922|NCT02299856|OTHER|Cardiac magnetic resonance scan|
48167923|NCT03166397|DRUG|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
48167924|NCT03166397|DRUG|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
48167925|NCT03166397|BIOLOGICAL|TIL|TIL administration
48167926|NCT03166397|DRUG|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
48167927|NCT03166397|DRUG|Nivolumab|Nivolumab 480 mg fixed dose
48167928|NCT03166397|DRUG|Ipilimumab|Ipilimumab 1 mg/kg up to 100 mg
48167929|NCT03166397|DRUG|FMT Protocol|"FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months."
48167930|NCT02222337|BEHAVIORAL|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
48167931|NCT05531734|DEVICE|NaoX Intra-Auricular Device (IAD) monitoring EEG data|Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.
48167932|NCT05531734|BEHAVIORAL|Simple psychometric tests|Associated with simple and self-managed psychometric tests.
48167933|NCT04101019|DRUG|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
48167934|NCT04101019|DRUG|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
48167935|NCT02125097|DEVICE|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
48515267|NCT02897518|DEVICE|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
48697702|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
48697703|NCT01285570|DRUG|5% dextrose in water|Placebo
48167936|NCT05643443|OTHER|Gradual increase of force|steady force
48167937|NCT03030378|PROCEDURE|Biopsy|Undergo a tumor biopsy
48167938|NCT03030378|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48167939|NCT03030378|PROCEDURE|Computed Tomography|Undergo a CT scan
48167940|NCT03030378|BIOLOGICAL|Edodekin alfa|Given SC
48167941|NCT03030378|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
48167942|NCT03030378|BIOLOGICAL|Pembrolizumab|Given IV
48167943|NCT03030378|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
48167944|NCT01601717|DRUG|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
48167945|NCT01601717|DRUG|Placebo|Matching placebo pill administered once per day for 10 days.
48167946|NCT05985083|DRUG|IMM47|IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.
48167947|NCT02689752|DRUG|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
48167948|NCT00014222|BIOLOGICAL|epoetin alfa|40,000 IU
48167949|NCT00014222|BIOLOGICAL|filgrastim|5 mg/kg/d - days 2-13
48167950|NCT00014222|DRUG|cyclophosphamide|75, 600 and 830 mg/m2
48167951|NCT00014222|DRUG|doxorubicin hydrochloride|60 mg/m2
48167952|NCT00014222|DRUG|epirubicin hydrochloride|60 mg/m2
48697704|NCT02414945|DRUG|Cyclophosphamide|
48697705|NCT02414945|DRUG|Fludarabine|
48697706|NCT02414945|BIOLOGICAL|Autologous tumor infiltrating lymphocytes (TILs)|
48697707|NCT02414945|BIOLOGICAL|Interleukin-2|
48697708|NCT05957393|OTHER|Quantity of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
48697709|NCT05957393|OTHER|Quality of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
48167953|NCT00014222|DRUG|fluorouracil|500mg/m2
48167954|NCT00014222|DRUG|paclitaxel|175 mg/m2
48167955|NCT04152395|OTHER|EVAR|Patients undergoing EVAR
48167956|NCT00132951|DRUG|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
48167957|NCT00132951|DRUG|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
48167958|NCT00743496|BIOLOGICAL|Anti-GD2 antibody|Anti-GD2 antibody
48167959|NCT05334706|BIOLOGICAL|Nonavalent HPV vaccine (9vHPV/Gardasil-9™).|"Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015."
48167960|NCT05814822|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.
48167961|NCT05814822|BEHAVIORAL|Sleep Hygiene Education (SHE-TM)|Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.
48167962|NCT04927338|DIETARY_SUPPLEMENT|BacoMind® (Bacopa monnieri standardized extract)|BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.
48167963|NCT04927338|DRUG|Placebo|Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
48167964|NCT04219917|OTHER|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
48167965|NCT02607345|DIETARY_SUPPLEMENT|Zusto|25gr
48167966|NCT02607345|DIETARY_SUPPLEMENT|Glucomedics®|25gr
48167967|NCT04151771|OTHER|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
48167968|NCT04151771|OTHER|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
48515268|NCT02074280|DRUG|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
48167969|NCT05452421|DIETARY_SUPPLEMENT|Isotonic carbohydrate beetroot juice drink|An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
48167970|NCT05452421|DIETARY_SUPPLEMENT|Beetroot juice drink|A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
48515269|NCT03074786|DRUG|Dapivirine|Silicone elastomer vaginal matrix ring
48167971|NCT04440930|OTHER|White tea|Mouthwash with white tea five to six times a day for nine weeks
48167972|NCT04440930|OTHER|Salt water with soda|Mouthwash with salt water and soda eight to ten times a day for nine weeks
48167973|NCT02651883|BEHAVIORAL|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
48167974|NCT02651883|BEHAVIORAL|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
48167975|NCT02943707|PROCEDURE|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
48167976|NCT02943707|DRUG|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
48167977|NCT03157492|BEHAVIORAL|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
48167978|NCT03157492|BEHAVIORAL|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
48167979|NCT01997489|DRUG|Enzyme replacement|Observational study of current treatment and with no comparative groups
48515270|NCT03074786|DRUG|Truvada|Tablets to be taken orally daily
48515271|NCT00022113|DRUG|cilengitide|Given IV
48010300|NCT05770466|DRUG|P1101 (Ropeginterferon alfa-2b)|"1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines"
48010301|NCT05770466|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
48167980|NCT00487318|DRUG|standard of care|peginterferon/RBV
48167981|NCT00487318|DRUG|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
48167982|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
48167983|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
48370572|NCT05713019|DIAGNOSTIC_TEST|Continuous laryngoscopic examination|Continuous laryngoscopy testing is performed based on previous methodology. Continuous laryngoscopy testing is performed by placing a fibreoptic nasendoscope in the posterior nasopharynx and securing it using specialist headgear. A small quantity of lubricating jelly is used to ease passage of the scope. Video images of the laryngeal inlet are, thereafter, continuously recorded whilst a subject performs various manoeuvres including respiratory movements and cough. These movements will be observed and recorded before and following the various aspects of the challenge protocol and thus allow us to evaluate laryngeal movement abnormalities and for example position of the vocal folds. The size and change in size of the glottic aperture will be evaluated.
48515272|NCT00022113|OTHER|pharmacological study|Correlative studies
48515273|NCT00022113|OTHER|laboratory biomarker analysis|Correlative studies
48515274|NCT03266939|DRUG|Lorcaserin|10 mg acute administration of lorcasein
48010302|NCT00004804|DRUG|interferon alfa|
48515275|NCT03266939|DRUG|Placebo Oral Tablet|Placebo
48515276|NCT02539966|DEVICE|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
48515277|NCT02290405|BEHAVIORAL|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
48515278|NCT04233424|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
48697710|NCT05957393|OTHER|Control|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
48697711|NCT03729583|BEHAVIORAL|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
48697712|NCT01192269|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
48697713|NCT02497144|OTHER|NMES Group|Neuromuscular electrical stimulation
48167984|NCT03821064|OTHER|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
48515279|NCT04233424|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
48515280|NCT00490841|DEVICE|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
48697714|NCT02497144|OTHER|Control Group|Breathing exercises
48697715|NCT03322267|DRUG|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
48697716|NCT01069263|OTHER|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
48697717|NCT01069263|DRUG|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
48010303|NCT04919967|BEHAVIORAL|Virtual implementation protocol|Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.
48010304|NCT04919967|BEHAVIORAL|e-learning toolkit|A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
48010305|NCT05487729|OTHER|ultrasonography and functional assessment and questionnaire survey|ultrasonography and functional assessment and questionnaire survey
48167985|NCT00598286|DRUG|[18F]FMPEP-d2|
48010306|NCT00976534|DRUG|AZD1386|90 mg, capsules, oral, during 3 weeks
48010307|NCT00976534|DRUG|Placebo|capsules, oral, during 3 weeks
48167986|NCT06439147|PROCEDURE|U shaped capsular incision during capsulorrhaphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip,Incision is done with its base proximally. The transverse limb is 1 cm proximal to femoral neck base
48515281|NCT02044913|BEHAVIORAL|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
48697718|NCT06285201|DRUG|T|8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
48697719|NCT06285201|DRUG|R|8 mg/kg IV of Test drug manufactured by Patheon Italia
48167987|NCT06439147|PROCEDURE|T-shaped capsular incision diuring capsulorraphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip done by two incisions: Vertical limb parallel to femoral neck axis and a transverse one parallel to the inguinal ligament resulting into two flabs.
48010308|NCT06077188|OTHER|Gum group|Group chewing gum with xylitol
48167988|NCT05903677|OTHER|magnesium levels|Detection of the relationship between cardiac surgery associated AKI and preoperative magnesium levels.
48167989|NCT05734742|OTHER|Educational video|"There were two videos including the first video Sleep apnea Syndrome Driving Safety Picture Scroll and the second video Sleep apnea Syndrome and Traffic Accidents. The first video was approximately 3 minutes long. This video was suitable for all ages. It was an easy-to-understand video explaining the characteristics of OSA and its relationship with traffic accidents. The second video was the detailed video, which is approximately 20 minutes in duration. This video was suitable for those who desire to learn more about OSA. It can be used in various educational settings, including internal training and traffic safety workshops. Participants must watch at least the first video."
48167990|NCT00003502|DRUG|antineoplaston A10|
48167991|NCT00003502|DRUG|antineoplaston AS2-1|
48167992|NCT00003502|PROCEDURE|alternative product therapy|
48167993|NCT00003502|PROCEDURE|biological therapy|
48167994|NCT00003502|PROCEDURE|biologically based therapies|
48010309|NCT04026919|OTHER|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
48010310|NCT06097507|BEHAVIORAL|Educational intervention|The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.
48167995|NCT00003502|PROCEDURE|cancer prevention intervention|
48167996|NCT00003502|PROCEDURE|complementary and alternative therapy|
48167997|NCT00003502|PROCEDURE|differentiation therapy|
48167998|NCT06455332|OTHER|Optic nerve MRI sequence|Systematic optic nerve MRI sequence during the CIS diagnosis work-up. This sequence is not done systematically and not recommended for now (except in case of acute ON). The interventional nature of the study remains minimal
48167999|NCT04739488|DEVICE|Inhaler training|This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.
48168000|NCT04739488|BEHAVIORAL|Breathing exercises|"This training was given only to the group that received breathing exercise and inhaler training.~Pursed lips breathing exercises were taught to the patients. Patients were asked to continue their breathing exercise for 10 minutes before using their inhaler medication.~Thus, it was evaluated whether breathing exercises performed before using inhaler drugs provided benefit on drug effectiveness."
48697720|NCT04331340|OTHER|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
48697721|NCT04331340|OTHER|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
48697722|NCT01748812|DRUG|Osteomalacia|
48697723|NCT04282096|OTHER|native and non native casein|selected participant will test the 3 treatments in a random order
48697724|NCT02740062|DEVICE|NIBS system for evaluation and non invasive current stimulation|
48697725|NCT00951236|DRUG|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
48697726|NCT00951236|DRUG|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
48697727|NCT00467194|DRUG|Rapamycin|
48168001|NCT04767802|DRUG|PTG-300|Hepcidin mimetic
48168002|NCT00478998|DRUG|Tamsulosin|
48168003|NCT06442293|DIETARY_SUPPLEMENT|Treatment 1|A dietary supplement containing beet root extract, arginine and citrulline
48168004|NCT06442293|DIETARY_SUPPLEMENT|Treatment 2|A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract
48168005|NCT06442293|DIETARY_SUPPLEMENT|Placebo|a placebo supplement that is similar in appearance to treatment 1
48168006|NCT04904237|DRUG|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
48168007|NCT06124183|BEHAVIORAL|The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals|The program is based on the emotional intelligence skills model (Mayer \& Salovey, 1997; Salovey \& Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.
48168008|NCT01858051|DIETARY_SUPPLEMENT|Cholecalciferol|
48168009|NCT01858051|DIETARY_SUPPLEMENT|Placebo|
48168010|NCT04031118|DEVICE|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
48168011|NCT04665778|OTHER|hospital bedroom booking|Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
48168012|NCT06090019|BEHAVIORAL|Routine PICU nursing care for children on mechanical ventilator.|Nursing interns students learned the routine PICU nursing care for the children on mechanical ventilator.
48522870|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine Association|Treatment with Venetoclax+Decitabine/Azacitidine
48697728|NCT00467194|DRUG|Bevacizumab|
48168013|NCT06090019|BEHAVIORAL|Self-instructional module for VAP care bundle prevention|Nursing interns students learned about VAP care bundle prevention self-instructional module through assessment, preparation, implementation and evaluation phases.
48168014|NCT05240547|OTHER|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
48168015|NCT05240547|OTHER|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
48168016|NCT01929577|DRUG|ASP015K|oral tablet
48168017|NCT03106935|DRUG|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
48168018|NCT01491763|DRUG|Imatinib|600 mg p.o. from day 1 until consolidation
48168019|NCT03545178|BEHAVIORAL|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
48168020|NCT03545178|DIAGNOSTIC_TEST|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
48168021|NCT02733835|DRUG|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
48168022|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered during skin closure (end of operation).
48168023|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
48168024|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered 6 hours after the first administration.
48168025|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
48515282|NCT05149391|BIOLOGICAL|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
48515283|NCT05602324|DIETARY_SUPPLEMENT|Lauric Acid and Berberine|intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
48010311|NCT05447949|PROCEDURE|Adjuncts to levobupivacaine in Erector Spinae Plane Block|The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
48168026|NCT05501847|RADIATION|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
48168027|NCT02253147|DEVICE|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
48168028|NCT02546778|DEVICE|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
48168029|NCT02934893|OTHER|Medication Management Clinic|referral to medication management clinic from primary care
48168030|NCT02934893|OTHER|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
48168031|NCT06240546|DRUG|LPM6690176|Administered orally
48168032|NCT06094335|DEVICE|Virtual reality rehabilitation|Children in this group received Virtual Reality Rehabilitation plus traditional physical therapy
48168033|NCT06094335|OTHER|Traditional physical therapy|Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
48168034|NCT04068285|OTHER|Aerobic Exercise|Participants will be making aerobic exercise
48168035|NCT04130581|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
48010312|NCT00700011|DRUG|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
48010313|NCT00700011|DRUG|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
48168036|NCT00115284|BEHAVIORAL|ABIM asthma practice improvement module|
48010314|NCT00648219|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
48168037|NCT02269683|PROCEDURE|Robot-assisted distal pancreatectomy|
48522871|NCT00013442|PROCEDURE|Auditory Evoked Response|
48522872|NCT00043303|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
48697729|NCT06084754|DEVICE|pulsed electromagnetic field|pulsed electromagnetic field will be over the site of osteomyelitis where patient in supine lying position. the treatment parameters will be set as10 HZ frequency , 20 gauss amplitude, duration about 120 minutes.
48697730|NCT06084754|DRUG|Antibiotics|Vancomycin IV injection 1gm divided 250mg every 6hours
48697731|NCT02450461|OTHER|no intervention|
48168038|NCT02269683|PROCEDURE|Laparoscopic distal pancreatectomy|
48168039|NCT00026013|DRUG|hypericum perforatum|
48010315|NCT00648219|DRUG|Benicar® Tablets 40 mg|40mg, single dose fed
48010316|NCT01173562|DRUG|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
48010317|NCT05664997|BEHAVIORAL|playing assessment|Investigators used Edinburgh Handedness Inventory, the Wong-Baker Faces Pain Rating Scale, the Disability of Arm, Shoulder and Hand - Sports/Musicians (DASH-SM), the Rapid Upper Limb Assessment, and the 11-item revised version of the Occupational Balance Questionnaire (OBQ11 - T). All have their Turkish validity studies. A correlation analysis was performed to examine the relationship between the variables.
48010318|NCT03957538|BEHAVIORAL|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
48010319|NCT00003294|BIOLOGICAL|filgrastim|
48010320|NCT00003294|DRUG|amifostine trihydrate|
48010321|NCT00003294|DRUG|carboplatin|
48010322|NCT00003294|DRUG|paclitaxel|
48010323|NCT01321801|DRUG|Pregabalin|Preoperative administration of pregabalin 600mg
48010324|NCT01321801|DRUG|placebo|Preoperative administration of a matching placebo
48010325|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
48010326|NCT01451775|DRUG|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
48010327|NCT01451775|DRUG|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
48010328|NCT00234559|DEVICE|VAC® Therapy System|
48010329|NCT05498636|COMBINATION_PRODUCT|Selinexor combined with Prednisone, Etoposide, and Lenalidomide|Selinexor combined with Prednisone, Etoposide, and Lenalidomide
48010330|NCT06237257|BIOLOGICAL|SHR-1316|SHR-1316（Adebrelimab Injection）
48010331|NCT06237257|DRUG|Cisplatin Injection/Carboplatin Injection|Cisplatin Injection/Carboplatin Injection
48010332|NCT06237257|RADIATION|External Beam Radiotherapy (EBRT)/Brachytherapy|External Beam Radiotherapy (EBRT)/Brachytherapy
48010333|NCT03597516|DRUG|RP-G28|powder for reconstitution for oral administration
48168040|NCT02723383|DRUG|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
48168041|NCT02723383|DRUG|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
48168042|NCT04912700|BIOLOGICAL|COVID-19 vaccine|Full or partial reception of vaccine
48168043|NCT02870751|BIOLOGICAL|TW11681 or TW10722|
48697732|NCT03112512|DEVICE|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
48697733|NCT03112512|DEVICE|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
48010334|NCT03597516|DRUG|Placebos|powder for reconstitution for oral administration
48010335|NCT01067352|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
48010336|NCT02098161|OTHER|Laboratory Biomarker Analysis|Correlative studies
48010337|NCT02098161|OTHER|Questionnaire Administration|Ancillary studies
48010338|NCT02098161|DRUG|Smac Mimetic LCL161|Given PO
48010339|NCT00000102|DRUG|Nifedipine|
48010340|NCT01441427|DRUG|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
48010341|NCT01441427|DRUG|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
48168044|NCT02134613|OTHER|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
48168045|NCT03540615|DRUG|BAY1830839|Dose escalation in healthy male subjects
48697734|NCT04150666|DIETARY_SUPPLEMENT|Hydration|the same with arm descriptions
48697735|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg"
48010342|NCT01441427|DRUG|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
48010343|NCT01441427|DRUG|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
48010344|NCT01441427|DRUG|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
48010345|NCT01285804|OTHER|Cuffed ETT|Kimberly Clark
48010346|NCT01285804|OTHER|Uncuffed ETT|Kimberly Clark
48010347|NCT05057416|BEHAVIORAL|Exercise Adherence|Our current study will compare three exercise groups which will all vary in intensity. Participants will be randomly assigned to one of the three groups. Two groups will be assigned to high intensity bouts of exercise with an active rest between, and one group will perform moderate intensity continuous training without resting. All groups will exercise for 20 minutes. Exercise adherence and it will be measured by a self-report online Google Document.
48010348|NCT05281250|OTHER|Supervised physical exercise|A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
48010349|NCT02041598|OTHER|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
48515284|NCT04812808|DRUG|Bazedoxifene 20 mg|"Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events."
48010350|NCT02652975|PROCEDURE|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
48010351|NCT02652975|PROCEDURE|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
48010352|NCT02652975|PROCEDURE|24hour blood pressure|24 hour blood pressure measurement
48010353|NCT02652975|PROCEDURE|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
48010354|NCT02652975|BIOLOGICAL|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
48010355|NCT05927571|DRUG|Cevostamab|Cevostamab solution for infusion will be administered as IV as specified in each treatment arm.
48010356|NCT05927571|DRUG|Elranatamab|Elranatamab solution for injection will be administered SC as specified in each treatment arm.
48010357|NCT05927571|DRUG|Tocilizumab|Tocilizumab will be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
48010358|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
48010359|NCT01636895|DRUG|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
48010360|NCT00001720|DRUG|Alendronate|
48010361|NCT03645629|DIAGNOSTIC_TEST|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
48010362|NCT00884234|OTHER|Vehicle Control|Two sequential doses of Vehicle Control at Baseline (Day 0) and Week 2
48697736|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg"
48697737|NCT00578877|DEVICE|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
48697738|NCT00578877|COMBINATION_PRODUCT|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
48168046|NCT03540615|DRUG|Placebo|Matching placebo
48697739|NCT00578877|COMBINATION_PRODUCT|Buffer Gel|Buffer Gel
48168047|NCT03709316|DRUG|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
48168048|NCT03709316|DRUG|Placebo Comparator|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
48515285|NCT00129545|DEVICE|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
48515286|NCT00129545|DRUG|Warfarin|Subjects receive warfarin
48515287|NCT01562938|DRUG|Placebo|Placebo
48515288|NCT01562938|DRUG|MEDI-557|MEDI-557 low-dose
48515289|NCT01562938|DRUG|MEDI-557|MEDI-557 high-dose
48522873|NCT00784004|OTHER|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~1. Breathing in through the nose only and out through the mouth only~2. Breathing in through the mouth only and out through the nose only~3. Breathing in and out through the nose only~4. Breathing in and out through the mouth only"
48697740|NCT01000012|DEVICE|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
48010363|NCT00884234|DRUG|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 at Baseline (Day 0) and Week 2
48010364|NCT01800916|DEVICE|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
48697741|NCT01000012|DEVICE|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
48697742|NCT05129280|DRUG|RO7444973|RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
48697743|NCT05129280|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
48697744|NCT05582707|DRUG|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
48010365|NCT01800916|DEVICE|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
48697745|NCT02305472|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
48697746|NCT02018848|BEHAVIORAL|Attention Training Program|
48010366|NCT01800916|DEVICE|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
48168049|NCT01128777|BEHAVIORAL|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
48697747|NCT03568448|OTHER|Response monitoring (no intervention)|Response monitoring (no intervention)
48697748|NCT00798460|DRUG|adefovir|adefovir 10mg
48697749|NCT00798460|DRUG|clevudine|clevudine 30mg
48010367|NCT01800916|DEVICE|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
48010368|NCT05073406|OTHER|Altitude exposure in hypobaric normoxic condition|Altitude exposure with oxygen supplementation to achieve normoxia at altitude
48010369|NCT05073406|OTHER|Altitude exposure in hypobaric hypoxic condition|Altitude exposure with air supplementation to obtain a sham comparator arm
48010370|NCT00003255|DRUG|carboplatin|
48010371|NCT00003255|DRUG|topotecan hydrochloride|
48010372|NCT00485316|PROCEDURE|Laparoscopic assisted resection of colorectal carcinoma|
48168050|NCT01128777|BEHAVIORAL|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
48168051|NCT01755247|DRUG|Topical Gel Vehicle|
48697750|NCT00798460|DRUG|lamivudine|lamivudine 100mg
48697751|NCT06130449|DRUG|Natesto testosterone intranasal gel|A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
48697752|NCT06130449|DRUG|Ayr Saline Nasal Gel|A single dose of Ayr (one spray per nostril) will be administered to each participant.
48697753|NCT01294306|DRUG|Akt Inhibitor MK2206|Given PO
48697754|NCT01294306|DRUG|Erlotinib Hydrochloride|Given PO
48697755|NCT01294306|OTHER|Laboratory Biomarker Analysis|Correlative studies
48697756|NCT01294306|OTHER|Pharmacological Study|Correlative studies
48522874|NCT06196892|DIETARY_SUPPLEMENT|Probiotic BBr60|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.
48697757|NCT03181061|OTHER|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
48697758|NCT01694121|BEHAVIORAL|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
48697759|NCT01694121|BEHAVIORAL|Comparison|general health intervention for men, not inclusive of HIV or relationship health
48697760|NCT00145184|DIETARY_SUPPLEMENT|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
48697761|NCT00145184|DRUG|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
48697762|NCT02529462|GENETIC|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
48697763|NCT02529462|DRUG|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
48010373|NCT01700179|DRUG|ACH-0143102|
48010374|NCT01700179|DRUG|Ribavirin|
48010375|NCT02292628|DRUG|Infusion of mesenchymal stem cells from adipose tissue|
48522875|NCT00262028|BIOLOGICAL|MenACWY-CRM Vaccine|
48010376|NCT02292628|OTHER|Infusion of placebo|
48168052|NCT01755247|DRUG|8% NVN1000 Topical Gel|
48168053|NCT01755247|DRUG|8% NVN1000 Topical Gel and moisturizer|
48522876|NCT00262028|BIOLOGICAL|MenACWY-PS Vaccine|
48522877|NCT02289872|DEVICE|Macintosh Laryngoscope|Direct-Laryngoscopy
48522878|NCT02289872|DEVICE|TruView PCD Video laryngoscope|Video-Laryngoscopy
48010377|NCT06171659|DRUG|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
48010378|NCT06171659|DEVICE|PET/MRI|positron emission tomography and magnetic resonance imaging
48515290|NCT03616717|DRUG|Modafinil|"Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil"
48697764|NCT05991115|BEHAVIORAL|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
48010379|NCT06171659|DEVICE|PET/CT imaging|positron emission tomography and computed tomography imaging
48010380|NCT01437553|DEVICE|iMAP|IVUS and iMAP analysis for acute coronary syndromes
48010381|NCT05112393|OTHER|Development of new estimating Glomerular Filtration Rate (eGFR) equation|"Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm."
48010382|NCT05112393|OTHER|Validation of new estimating Glomerular Filtration Rate (eGFR) equation|"Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR."
48010383|NCT05537233|DRUG|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
48010384|NCT05537233|DRUG|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
48010385|NCT00006374|BIOLOGICAL|filgrastim|
48168054|NCT03721978|BIOLOGICAL|VGX-3100|1 milliliter (mL) VGX-3100 injected IM.
48010386|NCT00006374|DRUG|cisplatin|
48010387|NCT00006374|DRUG|etoposide|
48010388|NCT00006374|DRUG|paclitaxel|
48010389|NCT00006374|DRUG|topotecan hydrochloride|
48010390|NCT05780242|BEHAVIORAL|Self-questionnaire Eating Attitudes|self-diagnostic and quantitative questionnaire of 40 questions evaluating the behavior, severity and evolution of anorexia nervosa
48168055|NCT03721978|BIOLOGICAL|Matched Placebo|1 mL of matched Placebo injected IM.
48168056|NCT03721978|DEVICE|CELLECTRA™-5PSP|CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
48168057|NCT01575483|DRUG|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
48168058|NCT06171282|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
48168059|NCT03220165|DRUG|MGL-3196|oral, 100 mg
48168060|NCT02036606|BEHAVIORAL|questionary|
48522879|NCT04790903|DRUG|Venetoclax|Participants will self-administer Venetoclax, as described in the Arm Descriptions.
48010391|NCT05780242|BEHAVIORAL|Situational Anxiety and Trait Anxiety|"assess anxiety as a personality trait (feelings of apprehension, tension, nervousness and worry that the subject usually feels), and anxiety as a ' emotional state linked to a particular situation"
48010392|NCT05780242|BEHAVIORAL|Beck Depression Inventory (BDI) scale|a diagnostic self-questionnaire allowing a quantitative estimation of the intensity of depressive symptoms in adults and adolescents
48010393|NCT05780242|BEHAVIORAL|• Post-traumatic Check List Scale|questionnaire includes 20 items, each question is to be rated between 1 and 5 depending on the intensity and frequency of symptoms during the previous month.
48010394|NCT01345084|RADIATION|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
48697765|NCT01907321|BEHAVIORAL|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
48697766|NCT01907321|BEHAVIORAL|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
48010395|NCT01345084|DRUG|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
48010396|NCT01345084|DRUG|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
48010397|NCT03246867|OTHER|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
48010398|NCT03246867|OTHER|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
48010399|NCT03246867|OTHER|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
48515291|NCT03616717|DRUG|placebo|Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
48697767|NCT01907321|DRUG|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
48515292|NCT05209529|DRUG|olaparib|olaparib 300 mg per os BID
48515293|NCT05209529|DRUG|Durvalumab|durvalumab 1500 mg IV Q4 weeks
48697768|NCT01907321|BEHAVIORAL|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
48697769|NCT01907321|RADIATION|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
48697770|NCT00322452|DRUG|Gefitinib|oral tablet
48697771|NCT00322452|DRUG|Carboplatin|IV
48697772|NCT00322452|DRUG|Paclitaxel|IV
48697773|NCT01925118|BIOLOGICAL|Irradiated donor lymphocyte infusion|
48697774|NCT03532854|DRUG|Valsartan|Valsartan P.O
48697775|NCT03532854|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
48515294|NCT04766645|DEVICE|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
48515295|NCT04766645|GENETIC|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
48515296|NCT04766645|DIAGNOSTIC_TEST|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
48515297|NCT01226394|PROCEDURE|laparotomy plus HIPEC|Laparotomy + HIPEC
48515298|NCT06551285|DIETARY_SUPPLEMENT|Ovapro (Lifepro)|Dietary supplement that contains inositol, vitamin D, zinc, and curcumin.
48515299|NCT00953966|OTHER|Genetically modified potatoes|Starch from genetically modified potatoes
48515300|NCT06550609|DRUG|Miltefosine Oral Capsule|Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
48515301|NCT05736055|DIAGNOSTIC_TEST|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
48515302|NCT04767438|OTHER|Pregnant women|All pregnant women that present to the 12-week scan in the Obstetrics Unit
48515303|NCT06482073|OTHER|Non-Interventional Study|Non-interventional study
48697776|NCT03922347|DIAGNOSTIC_TEST|Screening program including 2 consecutive tests|visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
48168061|NCT04609410|PROCEDURE|Neuromuscular blockade|Neuromuscular blockade will be achieved via rocuronium intravenous administration and level will be monitored with train of four/post tetanic count monitoring
48515304|NCT05233462|OTHER|standardized dose|intrathecal anesthesia with 10 mg of bupivacaine
48515305|NCT05233462|OTHER|adjusted dose|intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
48515306|NCT02965937|OTHER|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
48515307|NCT02965937|OTHER|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
48515308|NCT01699958|BEHAVIORAL|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
48515309|NCT02417987|OTHER|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
48515310|NCT02417987|DRUG|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
48515311|NCT02417987|BIOLOGICAL|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
48515312|NCT03561649|DRUG|Adalimumab|This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
48515313|NCT02051712|BEHAVIORAL|exercise training|individualized exercise training
48697777|NCT03922347|DIAGNOSTIC_TEST|Screening program with mobile health|Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
48697778|NCT00289068|PROCEDURE|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
48010400|NCT01456325|DRUG|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
48010401|NCT01456325|DRUG|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
48010402|NCT01456325|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
48168062|NCT04015596|DRUG|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
48515314|NCT02051712|BEHAVIORAL|Adherence measures|Measures to increase adherence to exercise training
48168063|NCT04015596|OTHER|Placebo|Participants take placebo pills twice daily, for 8 weeks.
48168064|NCT05270473|PROCEDURE|uterine compressive sutures|uterine compression sutures comaprison
48515315|NCT06101160|DRUG|onaBoNT-A|injection under ultrasonography
48515316|NCT03231488|OTHER|Mindfulness intervention|A 10 minute mindfulness of breath exercise
48515317|NCT03231488|OTHER|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
48515318|NCT00300690|DEVICE|6 mm Uni-graft® (B-Braun)|
48515319|NCT00300690|DEVICE|6 mm Gore-Tex® (WL Gore)|
48515320|NCT02652949|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
48515321|NCT01010113|OTHER|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
48515322|NCT01010113|OTHER|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
48515323|NCT01288404|DRUG|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
48515324|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
48515325|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
48515326|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
48515327|NCT00588588|PROCEDURE|Bronchoscopy|Bronchoscopy procedure
48515328|NCT00588588|PROCEDURE|Clinical pulmonary infection score (CPIS)|Calculate CPIS
48168065|NCT01580007|DRUG|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
48697779|NCT00289068|PROCEDURE|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
48697780|NCT00289068|PROCEDURE|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
48697781|NCT00066222|DRUG|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
48697782|NCT00066222|DRUG|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
48697783|NCT00066222|RADIATION|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
48697784|NCT06132477|DRUG|GLP-1 receptor agonist|Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
48697785|NCT05870150|BIOLOGICAL|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)
48697786|NCT02441491|DRUG|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
48697787|NCT02136758|BEHAVIORAL|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
48697788|NCT04446624|OTHER|Music therapy intervention|Group psychotherapy with music intervention
48697789|NCT01087658|DRUG|Glutamine|Per os
48697790|NCT01087658|DRUG|Calcium and Magnesium|Intravenous
48697791|NCT01922947|BEHAVIORAL|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
48697792|NCT01922947|BEHAVIORAL|Active Control Condition|20-minute health counseling
48515329|NCT05731193|OTHER|Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.|After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
48515330|NCT05925998|OTHER|Observational study: no interventions|Not applicable as observational study with no intervention
48515331|NCT03643861|RADIATION|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
48515332|NCT02618525|OTHER|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
48515333|NCT02618525|OTHER|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
48697793|NCT00499512|BEHAVIORAL|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
48522880|NCT04790903|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
48697794|NCT00374946|DEVICE|THA|
48697795|NCT01805908|OTHER|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
48697796|NCT04019106|DRUG|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
48697797|NCT00779428|DRUG|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
48697798|NCT02336685|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
48697799|NCT02336685|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
48010403|NCT02404363|DRUG|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --\> clopidogrel 150 mg/d x 7days then 75mg/d"
48010404|NCT02404363|DRUG|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d"
48010405|NCT00960700|DEVICE|Visual Acuity|Assessment of visual acuity
48010406|NCT00960700|DEVICE|Contrast sensitivity|Assessment of contrast sensitivity
48010407|NCT00960700|DEVICE|Reading Speed|Assessment of reading speed
48697800|NCT02336685|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
48697801|NCT02336685|DRUG|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
48697802|NCT01675297|DRUG|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
48697803|NCT01675297|DRUG|Risedronate|Risedronate once a week
48697804|NCT04223765|DRUG|CAR.k.28|Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).
48697805|NCT04223765|DRUG|Fludarabine|30 mg/m\^2/day IV for 3 consecutive days
48010408|NCT00960700|PROCEDURE|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
48010409|NCT03181828|DRUG|Acetohydroxamic Acid Oral Tablet|A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
48010410|NCT03181828|OTHER|No treatment|No treatment
48010411|NCT01479634|DRUG|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
48010412|NCT01479634|DRUG|Study-Provided ART|"Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]"
48010413|NCT00385970|DRUG|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
48370573|NCT05713019|DIAGNOSTIC_TEST|Sputum induction|"Sputum is induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 5 minutes each. Particular care is taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. Sputum samples are collected into sterile pots. Peak flow measurements are made after each inhalation. If there is a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction is stopped.~Sputum plugs are selected and one portion is used to perform differential cell counts. To perform differential cell counts, dithiothreitol is added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. Cytospins are then prepared, and differential cell counts obtained."
48010414|NCT00385970|DRUG|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
48370574|NCT05713019|DIAGNOSTIC_TEST|Spirometric measurements|Spirometry (FEV1 and forced vital capacity, FVC) is measured using a dry wedge spirometer (Vitalograph, Buckinghamshire, UK).
48010415|NCT00385970|DRUG|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
48010416|NCT05553925|OTHER|Online Weight Management Program with Coaching and Patient Navigator Support|"Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate."
48168066|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
48697806|NCT04223765|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for 3 consecutive days
48010417|NCT03394014|PROCEDURE|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
48010418|NCT00714259|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
48010419|NCT00714259|RADIATION|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
48010420|NCT00714259|OTHER|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.
48010421|NCT02601040|BIOLOGICAL|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\\6.50 lgCCID50/ml in children aged 3-16 years \\6.50 lgCCID50/ml in adults aged 17 up to 65 years old
48010422|NCT02601040|BIOLOGICAL|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \\320EU/Vial in children aged 3-16 years \\640EU/Vial in adults aged 17 up to 65 years old\\boost at month 6\\two-dose
48010423|NCT02601040|BIOLOGICAL|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
48010424|NCT00826267|DRUG|lapatinib|lapatinib tablets 1500 mg daily
48010425|NCT00826267|DRUG|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
48010426|NCT00826267|DRUG|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
48010427|NCT02639364|DEVICE|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
48010428|NCT02967952|DEVICE|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
48010429|NCT02500069|OTHER|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
48010430|NCT02500069|OTHER|Casein (in duodenum)|infusion of protein in duodenum
48010431|NCT02500069|OTHER|Casein (in jejunum)|infusion of protein in jejunum
48010432|NCT02500069|OTHER|Casein (in ileum)|infusion of protein in ileum
48010433|NCT00699972|DRUG|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
48010434|NCT00699972|DRUG|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
48010435|NCT00699972|DRUG|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
48010436|NCT02627859|DEVICE|Durolane SJ|1ml single intra-articular injection in ankle
48010437|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
48010438|NCT00219375|DRUG|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
48168067|NCT01580007|DRUG|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
48010439|NCT05900479|OTHER|PTSD Service Dog|According to the Americans with Disabilities Act (ADA), a service dog is a dog that is trained to perform specific tasks to mitigate a disability. For PTSD service dogs, examples include detecting and alerting to physical signs of distress to interrupt anxiety and panic attacks, waking up Veterans from nightmares, and retrieving medication. In addition to trained tasks, service dogs live with the Veterans to provide emotional value as a source of comfort and companionship. Under the ADA guidance, PTSD service dogs have pubic access and are legally allowed to accompany their person in public places such as grocery stores, workplaces, and schools. In the proposed study, service dogs will be sourced from two Assistance Dog International (ADI) accredited providers, including K9s For Warriors and Canine Companions for Independence. Both providers have an established track record of training and providing PTSD service dogs, as well as collaborating with the investigative team in research.
48168068|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
48010440|NCT01234467|DRUG|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
48010441|NCT01234467|DRUG|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
48010442|NCT03265093|OTHER|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
48010443|NCT03265093|DRUG|Corticosteroid|Corticosteroid injection
48168069|NCT01009762|BIOLOGICAL|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
48010444|NCT03026712|DEVICE|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
48010445|NCT03026712|DEVICE|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
48010446|NCT04038489|DRUG|Aspirin|325 mg aspirin daily during AC-T chemotherapy
48010447|NCT04038489|DRUG|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
48010448|NCT04038489|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
48168070|NCT00110955|DRUG|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
48168071|NCT00110955|DRUG|Placebo|Q3W dosing of placebo
48522881|NCT04790903|DRUG|Rituximab|Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.
48010449|NCT04038489|DRUG|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
48010450|NCT04038489|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
48010453|NCT01849705|OTHER|No intervention|
48010454|NCT03461627|DRUG|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
48010455|NCT03461627|DRUG|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
48010456|NCT03447015|OTHER|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
48010457|NCT04184076|BEHAVIORAL|Time-restricted feeding (TRF) with dietary counseling|"1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data."
48010458|NCT05264324|PROCEDURE|Maximal Exercise Capacity|Maximal Exercise Capacity in incremental ramp exercise tests.
48010459|NCT06437405|DIETARY_SUPPLEMENT|Vinegar liquid|one pill daily
48010460|NCT06437405|DIETARY_SUPPLEMENT|vinegar pill|One pill daily
48010461|NCT01155895|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
48010462|NCT04414384|OTHER|Abdominal Binder|Abdominal Binder placement
48010463|NCT04414384|OTHER|Step Counter|step counter to track steps
48010464|NCT02210585|OTHER|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
48010465|NCT01860417|BIOLOGICAL|Allogenic Mesenchymal Stromal Cells|
48010466|NCT01860417|DRUG|Mepivacaine|
48010467|NCT04335344|OTHER|Observation of suPAR plasma and salivary levels|Evaluation of suPAR plasma level and correlation of plasma suPAR levels with periodontal and cardiovascular disease
48010468|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
48010469|NCT01529528|DRUG|Anagliptin|Anagliptin 100mg, tablet, BID
48010470|NCT01529528|DRUG|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
48010471|NCT00674141|DRUG|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
48010472|NCT04160299|BEHAVIORAL|Dance-based exergaming|Dance sessions
48010473|NCT05660928|OTHER|Multidimensional intervention|Multidimensional intervention, with mutidisciplinary approach.
48010474|NCT04862091|DRUG|Abiraterone Acetate Tablets (I)|Abiraterone Acetate Tablets (I)
48010475|NCT04862091|DRUG|ZYTIGA®|ZYTIGA®
48370575|NCT05713019|DIAGNOSTIC_TEST|Blood sample collection|Venous blood (30 cc) will be taken from a vein in the forearm. This test causes a transient discomfort as a needle is used to obtain the blood sample. The blood sample will be used for measuring various proteins and for getting white blood cells to obtain some types of stem cells.
48370576|NCT04696601|DIAGNOSTIC_TEST|Olfactory test|The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
48370577|NCT04031352|OTHER|implementation of CATCH scale|subject completed the CATCH scale
48010476|NCT05869227|DRUG|Capecitabine/Placebo combined with toripalimab|Combined
48010477|NCT02170246|DRUG|Telmisartan|
48010478|NCT01440322|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
48010479|NCT01440322|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
48010480|NCT00178438|DEVICE|Capsule Endoscopy|
48010481|NCT02231242|BIOLOGICAL|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
48010482|NCT04465175|DRUG|Magnesium Sulfate|Second dose magnesium sulphate infusion over one hour
48010483|NCT04465175|DRUG|Placebo|Normal saline (2.5 ml/kg) infusion over one hour
48010484|NCT05723367|PROCEDURE|lumbar ESPB group where ESPB is performed at L4 with local anesthetics 20ml|ultrasound guided fascial plane injection
48010485|NCT02729649|DEVICE|ArmAssist robotic training|
48010486|NCT02729649|OTHER|Conventional therapy|
48010487|NCT02729649|OTHER|Extended conventional therapy|
48010488|NCT02129361|BEHAVIORAL|Adapted Screening and Brief Intervention (Adapted SBI)|
48010489|NCT02129361|BEHAVIORAL|Screening & Education Attention Control|
48010490|NCT06024876|BIOLOGICAL|CS-101|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
48010491|NCT00460941|DRUG|Placebo|sc weekly
48010492|NCT00460941|DRUG|Taspoglutide 20mg|sc weekly
48010493|NCT00460941|DRUG|Taspoglutide 20mg-30mg|sc weekly
48010494|NCT00460941|DRUG|Taspoglutide 20mg-40mg|sc weekly
48010495|NCT01670357|DRUG|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
48010496|NCT01670357|DRUG|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
48010497|NCT01670357|DRUG|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
48010498|NCT05402527|DIETARY_SUPPLEMENT|Fish nutrients|Intake of fish protein, omega-3 fatty acids, and vitamin D
48010499|NCT05402527|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
48010500|NCT05402527|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
48010501|NCT03228134|DRUG|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
48010502|NCT03228134|DRUG|Yang He Ping Chuan Granule|Traditional Chinese Medicine
48010503|NCT03228134|OTHER|Ke Chuan Liu Wei Granule placebo|Placebo
48010504|NCT03228134|OTHER|Yang He Ping Chuan Granule placebo|Placebo
48010505|NCT00002010|DRUG|Fluconazole|
48010506|NCT02526992|DEVICE|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
48370578|NCT03306589|BIOLOGICAL|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
48010507|NCT01684384|RADIATION|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
48010508|NCT02310542|DEVICE|MARS albumin dialysis system|
48010509|NCT02310542|DEVICE|SPAD albumin dialysis system|
48010510|NCT04891224|OTHER|Pathway Platform mobile app|The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
48010511|NCT00053430|DRUG|Thalidomide|Tablet taken orally daily
48370579|NCT03306589|BIOLOGICAL|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
48370580|NCT03306589|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
48522882|NCT04790903|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
48522883|NCT04790903|DRUG|Doxorubicin|Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
48697807|NCT04223765|DRUG|Bendamustine|70 mg/m\^2/day administered over 3 consecutive days.
48697808|NCT04261725|GENETIC|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
48010512|NCT00053430|DRUG|Thalidomide placebo|Placebo tablet taken orally daily
48010513|NCT01045291|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
48010514|NCT04688281|DEVICE|Medicurtain®|Medicurtain® 5ml prefilled syringe
48010515|NCT04688281|DEVICE|GUARDIX-SG®|GUARDIX-SG® 5ml prefilled syringe
48010516|NCT03869125|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
48010517|NCT05567731|DRUG|ultrashort GnRHa|"the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm"
48010518|NCT05567731|DRUG|short GnRHa|"Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture."
48168072|NCT01636830|DEVICE|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
48370581|NCT03306589|DRUG|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
48370582|NCT01354834|DRUG|hMG|Patients with a condition
48697809|NCT03182946|DIAGNOSTIC_TEST|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
48168073|NCT02656745|DEVICE|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones \& engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
48697810|NCT03470324|DEVICE|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
48697811|NCT03470324|DEVICE|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
48697812|NCT03470324|BEHAVIORAL|Swallowing therapy|Swallowing therapy with speech therapist
48168074|NCT02383927|DRUG|Tipifarnib|FTase inhibitor
48697813|NCT06659965|DRUG|Intravenous Methocarbamol|At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
48168075|NCT02072278|DRUG|Vortioxetine 10 mg|
48168076|NCT02072278|DRUG|Vortioxetine 20 mg|
48168077|NCT02072278|DRUG|Escitalopram 15 mg|
48168078|NCT02072278|DRUG|Placebo|
48168079|NCT02666170|DRUG|Alpha-lipoic acid|
48515334|NCT05086263|DEVICE|Pico G2 4k|"On this virtual reality headset, it will be loaded with an educational virtual reality mock MRI training titled Ready Teddy. This training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Furthermore, using audio/visual cues, when the viewer moves their head too much in a MRI like setting they are reminded to stay still. Biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure."
48515335|NCT05187728|OTHER|No Intervention|No more intervention will be given.
48515336|NCT02755285|DEVICE|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
48010519|NCT05567731|DRUG|long GnRHa|In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
48168080|NCT03948399|DEVICE|Duplex scanning of carotid arteries|Measurement of carotid arteries
48515337|NCT02856802|DRUG|Sumatriptan 10 mg Nasal Spray|100 μL nasal spray once
48515338|NCT02856802|OTHER|Sumatriptan Placebo Nasal Spray|100 μL nasal spray once
48515339|NCT03883503|OTHER|Beer 5%o|Weight adjusted beer to reach 0.8 blood alcohol content will be given over the time course of 1 hour to the participants
48697814|NCT01937663|DRUG|KWA-0711|
48697815|NCT06608251|DIAGNOSTIC_TEST|white matter lesion|According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group
48697816|NCT02888691|OTHER|Low carbohydrate diet|
48168081|NCT03948399|DEVICE|ABI measurement|ankle brachial index (ABI) assessment
48168082|NCT04612478|BEHAVIORAL|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program
48697817|NCT02888691|OTHER|High carbohydrate diet|
48168083|NCT04612478|BEHAVIORAL|Clinic-Based Physical|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
48168084|NCT01347177|PROCEDURE|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
48168085|NCT01347177|PROCEDURE|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
48168086|NCT05923502|DRUG|Duvelisib|This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
48370583|NCT02454621|BEHAVIORAL|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
48515340|NCT03883503|OTHER|Beer 8.5%o and water|Weight adjusted beer to reach 0.8 blood alcohol content and water will be given over the time course of 1 hour to the participants
48515341|NCT03883503|OTHER|Beer 8.5%o and stock|Weight adjusted beer to reach 0.8 blood alcohol content and stock will be given over the time course of 1 hour to the participants
48697818|NCT03770325|DRUG|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
48697819|NCT03770325|DRUG|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
48697820|NCT05347680|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
48168087|NCT03582150|DEVICE|Remote Monitoring with Ambulatory Detox|"* Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~* Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~* Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~* Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~* If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~* The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
48168088|NCT06245161|DEVICE|Quicksleeper5|intraosseous anesthesia for dental treatment
48168089|NCT06245161|DEVICE|conventional anesthesia|inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars
48168090|NCT01042145|DRUG|Prednisone|2 mgs/kg for 3 days
48168091|NCT01042145|DRUG|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
48168092|NCT00053768|BIOLOGICAL|filgrastim|
48515342|NCT03883503|OTHER|Water|Water equivalent to the calculated volume of beer will be given over the time course of 1 hour to the participants
48168093|NCT00053768|DRUG|EPOCH regimen|
48515343|NCT02049970|DRUG|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
48515344|NCT02049970|DRUG|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
48515345|NCT03044626|DRUG|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
48515346|NCT03044626|DRUG|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
48515347|NCT05291611|BEHAVIORAL|Online-based Cognitive-behavioral Therapy for OCD|26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
48515348|NCT06004791|DRUG|Herombopag + CsA|Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
48515349|NCT06004791|DRUG|rhTPO combined with Herombopag + CsA|rhTPO (15000U, subcutaneous injection, once a day for 7 days, once a month for 3 months)，Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
48515350|NCT04574440|DEVICE|multichannel fNIRS monitoring|Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
48697821|NCT05347680|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
48697822|NCT03331601|DRUG|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
48697823|NCT03515733|DRUG|PF-04995274|PF-04995274 tablets
48697824|NCT03515733|DRUG|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
48697825|NCT02995161|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
48697826|NCT02995161|DRUG|SPF control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
48697827|NCT02353702|PROCEDURE|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
48697828|NCT02353702|DRUG|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
48697829|NCT02353702|DEVICE|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
48697830|NCT02353702|DRUG|Infusion of placebo during 48 hours|
48168094|NCT00053768|DRUG|cyclophosphamide|
48168095|NCT00053768|DRUG|doxorubicin hydrochloride|
48515351|NCT06454097|DIAGNOSTIC_TEST|Assess the response glioma to radiochemotherapy using radiogenomics-based AI model|Predict the radiochemotherapy sensitivity of patients with glioma using an established radiogenomics-based artificial intellegent mode
48515352|NCT04601571|DEVICE|CORTRAK Stylet|The stylet is a component of the CORTRAK feeding tube system used to confirm the correct placement of the feeding tube
48522884|NCT04790903|DRUG|Prednisone|Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
48697831|NCT02353702|DRUG|NaCl|
48168096|NCT00053768|DRUG|etoposide|
48168097|NCT00053768|DRUG|prednisone|
48168098|NCT00053768|DRUG|vincristine sulfate|
48697832|NCT06046183|BEHAVIORAL|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
48697833|NCT01825486|BEHAVIORAL|accidental falls|
48697834|NCT06398132|OTHER|Usual Care|Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
48697835|NCT01631201|DRUG|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
48697836|NCT01631201|DRUG|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
48697837|NCT00298623|DRUG|XP13512 (GSK1838262)|
48697838|NCT00298623|OTHER|placebo|
48697839|NCT03378609|OTHER|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
48697840|NCT02214888|DRUG|BIRB 796 BS, low dose|
48697841|NCT02214888|DRUG|BIRB 796 BS, high dose|
48697842|NCT02214888|DRUG|Placebo|
48168099|NCT00053768|RADIATION|radiation therapy|
48370584|NCT06302829|OTHER|Dry needling|AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30min
48370585|NCT06302829|OTHER|intramusuar electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles .AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30 min
48370586|NCT05635695|OTHER|Free Museum visit|People are tested when they arrive at the museum. Then, they freely visit the different rooms for 45 to 75 minutes. No instructions are given.
48370587|NCT05635695|OTHER|Cultural pathways App|Cultural pathways in the park of the museum will be proposed to people with a smartphone application that will give directions, cultural and sustainable health contents, points of interest with games and specific information about the pathways (distance, noise level, walkability, practical information). There will be two possible levels: contemplative or active.
48370588|NCT06001164|PROCEDURE|ACL reconstruction: Double bundle|DB: Two tunnels were created on the femoral side through an anteromedial portal. These tunnels were created manually. On the tibial side, the tunnels were created using a guide to ensure they matched the anatomic insertion site of the ACL at the tibia. The hamstring grafts for the procedure were then harvested from the same leg and doubled. The femoral side was fixed from the inside out, whereas the tibial side was fixed from the outside in. bioresorbable screws were used.
48370589|NCT06001164|PROCEDURE|ACL reconstruction: Single bundle|SB: The femoral tunnel was created using an anteromedial portal. A freehand technique was used. For the tibial tunnel, a tibial guide was used to ensure it was positioned at the midpoint of the tibial ACL attachment site. The tendons of the semitendinosus and gracilis muscles were then harvested, doubled over, and inserted through the tibial tunnel, extending into the femur, and fixed with metallic or bioabsorbable interference screws.
48370590|NCT05599373|DEVICE|Bilateral Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over bilateral dorsolateral prefrontal cortex (DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of each side resting motor threshold (MT). The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
48370591|NCT05599373|DEVICE|Left Active Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex(DLPFC) took the form of intermittent theta burst stimulation (iTBS). For iTBS the stimulation parameters were: frequency = triplet 50 Hz bursts, repeated at 5 Hz; train duration = 2 s ON and 8 s OFF, total pulses/session = 600; total number of treatments = 20(5 sessions per week) at 80 % of left resting motor threshold (MT). Sham rTMS stimulation was delivered over right dorsolateral prefrontal cortex(DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
48370592|NCT05599373|DEVICE|Sham rTMS over bilateral dorsolateral prefrontal cortex|Sham rTMS stimulation was delivered over bilateral dorsolateral prefrontal cortex (DLPFC) using the same stimulation parameters, except for using the sham stimulation coil. The rTMS target was first randomized to the left or right DLPFC, then switched to the opposite side.
48370593|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter KS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter KS implants.After osseointegration, both dental implants will receive definitive prosthesis.
48370594|NCT06276712|DEVICE|Implant placement with 3.5 mm diameter TS implants.|Implant placement in edentulous jaws for a prosthetic implant rehabilitation with implant-retained overdenture (mucosally supported), on two implants. with 3.5 mm diameter TS implants.After osseointegration, both dental implants will receive definitive prosthesis.
48370595|NCT02701374|DRUG|TRK-700|
48370596|NCT02701374|DRUG|Placebo|
48370597|NCT01737463|PROCEDURE|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
48370598|NCT05397002|PROCEDURE|patient specific inverted L mandibular osteotomy modified with inferior alveolar nerve relocation|preoperative CBCT was requested for virtual planning and fabrication of cutting and drilling guides. Cutting lines were outlined to be consisted of four cuts; lateral ostectomy to uncover and lateralize the inferior alveolar nerve (IAN), posterior cut run horizontally from the anterior border of the ramus to a point just above the mandibular foramen, two anterior vertical cuts run from the anterior end of the lateral ostectomy to the inferior mandibular border. The guide was removed and the osteotomy lines were completed then the mandibular setback was oriented and fixed using pre-bent plates osteosynthesis. Plane transfer was checked using CBCT and Inferior alveolar nerve function was assessed.
48370599|NCT00121251|DRUG|Capecitabine|Given PO
48370600|NCT00121251|DRUG|Gemcitabine Hydrochloride|Given IV
48370601|NCT00121251|DRUG|Sorafenib Tosylate|Given PO
48370602|NCT05173532|OTHER|Balance Training|static and dynamic balance and gait stability exercises
48370603|NCT05173532|OTHER|Breathing and Stretching Exercises|static stretching while performing diaphragmatic breathing
48370604|NCT03169127|DRUG|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
48370605|NCT05299060|PROCEDURE|cyanoacrylate adhesive (SecurePortIV®)|Application of cyanoacrylate tissue adhesive (SecurePortIV®) to the puncture site plus standard wound care.
48522885|NCT04893473|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
48168100|NCT05183321|PROCEDURE|periodontal therapy|periodontal cleaning
48168101|NCT04514796|DRUG|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
48168102|NCT04915079|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
48370606|NCT05299060|PROCEDURE|standard cure|"The standard cure consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV) and sutureless fixation device (BD-19940 StatLock™ PICC Plus)."
48370607|NCT01789333|DEVICE|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
48370608|NCT01789333|DRUG|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
48370609|NCT03611907|DEVICE|"Oocyte retrieval with only aspiration system SL1(Cook® Single Lumen)"|In this intervention a 17-Gauge needle is used to aspirate the follicles
48370610|NCT03611907|DEVICE|"Oocyte retrieval with aspiration and flushing system DL1 (Cook® EchoTip® Double Lumen)"|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
48515353|NCT05637203|BEHAVIORAL|THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)|"THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls."
48697843|NCT05366621|DRUG|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
48697844|NCT00851981|OTHER|Placebo|TID
48697845|NCT00851981|DIETARY_SUPPLEMENT|SAMe|300 mg TID
48697846|NCT01210248|OTHER|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
48697847|NCT04750226|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI).
48697848|NCT03852992|DRUG|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
48697849|NCT03852992|DRUG|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
48370611|NCT03198559|DRUG|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
48370612|NCT03198559|DRUG|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
48697850|NCT03852992|DEVICE|Laser|Fractional ablative, deep mode, 5% fractional coverage
48697851|NCT03852992|DRUG|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
48697852|NCT03852992|DRUG|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
48697853|NCT03852992|DRUG|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
48697854|NCT04115748|DRUG|Filgotinib|Tablets administered orally once daily with or without food
48697855|NCT04115748|DRUG|Adalimumab|Injection administered subcutaneously once every 2 weeks
48697856|NCT04115748|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food
48697857|NCT04115748|DRUG|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
48697858|NCT04998994|DIETARY_SUPPLEMENT|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
48697859|NCT00992199|DRUG|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
48697860|NCT05525052|OTHER|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
48010520|NCT05476562|OTHER|Tyrosine Kinase Inhibitors (TKIs)|The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
48168103|NCT03503487|OTHER|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
48168104|NCT02790112|OTHER|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
48168105|NCT04966936|OTHER|questionnaires for clinical assessments|Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
48168106|NCT04966936|OTHER|2 minute walking test|the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
48697861|NCT05959538|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
48168107|NCT04966936|OTHER|The gait analysis at the motion analysis laboratory.|Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
48697862|NCT05959538|BEHAVIORAL|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
48168108|NCT01998997|BEHAVIORAL|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
48697863|NCT00059943|DRUG|docetaxel|
48010521|NCT02653196|PROCEDURE|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
48010522|NCT02653196|DRUG|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
48010523|NCT02653196|DRUG|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
48010524|NCT02653196|DRUG|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
48370613|NCT04805892|DIAGNOSTIC_TEST|BIOZEK COVID-19 Antigen Rapid Test|The BIOZEK COVID-19 Antigen Rapid Test is used for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens from individuals who are suspected of having COVID-19.
48370614|NCT02406586|DRUG|Salsalate|Salsalate 750 mg
48370615|NCT02406586|DRUG|Carvedilol|Carvedilol 3.125 mg
48370616|NCT02406586|DRUG|Placebo|One tablet
48370617|NCT02406586|DRUG|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
48370618|NCT02301468|OTHER|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
48370619|NCT02301468|OTHER|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
48010525|NCT02653196|DRUG|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
48010526|NCT02653196|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
48168109|NCT04107077|DRUG|Cisplatin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
48168110|NCT04107077|DRUG|Mitomycin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
48168111|NCT03646695|PROCEDURE|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
48168112|NCT03646695|PROCEDURE|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
48515354|NCT05637203|BEHAVIORAL|Discharge / Safety Planning|"* A written safety plan completed with the person~* Mental health appointment scheduled within seven days~* One phone follow-up call within 30 days"
48515355|NCT04940637|DRUG|niraparib and dostarlimab|niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
48515356|NCT02096432|BEHAVIORAL|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
48515357|NCT02096432|BEHAVIORAL|Usual Community Care|Community standard care as usual
48515358|NCT01806571|DRUG|Cytarabine|Given IV
48515359|NCT01806571|DRUG|Daunorubicin Hydrochloride|Given IV
48515360|NCT01806571|OTHER|Laboratory Biomarker Analysis|Correlative studies
48515361|NCT01806571|DRUG|Nilotinib|Given PO
48515362|NCT01806571|OTHER|Pharmacological Study|Correlative studies
48515363|NCT04196140|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
48515364|NCT05876637|OTHER|Left Nostril Breathing|The participants which will show cardiovascular hyper reactivity towards CPT will be divided into 2 groups having 30 participants in each group. Experimental group will receive Left Nostril Breathing(slow, deep breath taken through your left nostril while closing your right nostril with your right thumb. Then just as gently exhale long, slowly, and completely through the left nostril, just as gently. It will be done while sitting) for 10 minutes twice a day for the duration of 12 weeks. Follow up will be taken through administration Cold pressor test after every 4,8 and 12 weeks.
48515365|NCT05876637|OTHER|Conventional|30 participants will be recruited in conventional group which will receive simple deep breathing exercises of 3 sessions per week for the duration of 12 weeks.Follow up will be taken after every 4,8 and 12 weeks.
48515366|NCT05668546|DEVICE|isokinetic testing CSMI HUMAC NORM instrument|The strength (PT) of the bilateral knee flexors and extensors were tested with isokinetic test. Tests were performed under the guidance of a rehabilitation medicine specialist, and the system was calibrated prior to their commencement. The patients were seated in upright position and were fixed with pelvic and thigh belts. Concentric extension (PT_E) and concentric flexion (PT_F) were measured between the 0° and 90° knee ranges at angular velocities of 60°/s and 180°/s (60 PT_E, 60 PT_F, 180 PT_E, and 180 PT_F, respectively) The tests were repeated five times at each velocity, and the highest PTs were selected for statistical analysis. The participants performed repeated trials before sets, while a 20-second rest was provided between sets.
48515367|NCT06228534|PROCEDURE|Root coverage with tunneling technique|THIS IS THE INTERVENTION GROUP THE RECIPIENT AREA OF THE CONNECTIVE GRAFT IS PREPARED.
48515368|NCT05170282|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
48515369|NCT01480245|DRUG|GSK2402968|6mg/kg/week
48515370|NCT01080183|OTHER|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
48515371|NCT01918202|DRUG|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
48515372|NCT01918202|DRUG|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
48515373|NCT01918202|DRUG|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
48168113|NCT01879085|DRUG|Docetaxel|75 mg/m2 IV given over 60 minutes on day 8 every 21 days (1 cycle)
48515374|NCT02439021|DEVICE|COBRA|
48515375|NCT02439021|DEVICE|LMA|
48515376|NCT03237338|PROCEDURE|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
48515377|NCT03237338|PROCEDURE|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
48515378|NCT01845480|BEHAVIORAL|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
48515379|NCT05815017|DEVICE|Yoomi Physical Therapy Software|Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
48515380|NCT02590965|DRUG|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
48515381|NCT02590965|DRUG|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
48515382|NCT00261950|DRUG|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
48522886|NCT06081478|DRUG|CD19/CD22-bispecific CAR-T cells|CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
48697864|NCT02363361|DRUG|Imatinib|Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
48168114|NCT01879085|DRUG|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, given over 67.5 minutes at 10 mg/m2/min
48168115|NCT01879085|DRUG|Vorinostat|given orally at the specified dose levels (either 300 mg/daily or 200 mg twice per day) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle)
48168116|NCT01879085|DRUG|Pegfilgrastim|administered on day 9 subcutaneously at 6 mg
48168117|NCT02475005|BEHAVIORAL|pain self management app on smartphone|
48168118|NCT02304562|BIOLOGICAL|UCB Mesenchymal Stem Cells treatment|reduce skin injury
48168119|NCT04491084|DRUG|FLT3 Ligand (CDX-301)|Fms-like tyrosine kinase 3 (FLT3) ligand is a potent hematopoietic growth factor that mobilizes stem cells and greatly increases the number of circulating dendritic cells (DCs) in blood and organs.
48168120|NCT04491084|BIOLOGICAL|anti-CD40 antibody (CDX-1140)|CD40 is a key molecule in the regulation of immune responses whose activity can be modulated using antibodies. CD40 is a tumor necrosis factor receptor superfamily member expressed on antigen presenting cells, including dendritic cells, as well as a host of other cell types, including a wide range of tumor cells
48168121|NCT04491084|RADIATION|SBRT|For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
48168122|NCT05808062|PROCEDURE|Root canal obturation|Root canal dryness
48168123|NCT03338257|BEHAVIORAL|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
48168124|NCT05470881|DRUG|Atropine Sulfate|Administration of one drop QD on both eyes for 14 days.
48168125|NCT00476918|DRUG|Intravitreal injection (triamcinolone acetonide)|
48168126|NCT00280709|DEVICE|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
48168127|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg daily for 8 weeks
48168128|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
48168129|NCT03439098|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
48370620|NCT03131856|BEHAVIORAL|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
48168130|NCT04832581|BEHAVIORAL|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
48168131|NCT01321983|OTHER|Inspiratory muscular training - IMT|
48168132|NCT04903847|DRUG|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
48168133|NCT04903847|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
48168134|NCT01209286|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
48168135|NCT01742650|PROCEDURE|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
48168136|NCT01742650|PROCEDURE|TightRope|TightRope transfixation of syndesmosis
48168137|NCT04063345|PROCEDURE|IVUS-guided PCI|Performing intravascular ultrasound before or/and after percutaneous intervention
48168138|NCT04063345|PROCEDURE|Angiography-guided PCI|Performing percutaneous intervention without intravascular ultrasound guidance
48370621|NCT01079260|DIETARY_SUPPLEMENT|Standard ONS|Standard ONS
48168139|NCT04751461|OTHER|Product A|P0213420, a 1.8% nicotine ENDS product
48168140|NCT04751461|OTHER|Product B|P0213520, a 1.8% nicotine ENDS product
48168141|NCT04751461|OTHER|Product C|P0211220, a 1.8% nicotine ENDS product
48010527|NCT02653196|DRUG|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
48168142|NCT04751461|OTHER|Product D|P0211820, a 1.8% nicotine ENDS product
48168143|NCT04751461|OTHER|Product E|P0213417, a 2.4% nicotine ENDS product
48168144|NCT02947581|DRUG|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
48370622|NCT01079260|DIETARY_SUPPLEMENT|High Energy, low volume ONS|High energy, low volume ONS
48522887|NCT02102854|DRUG|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
48697865|NCT04658862|BIOLOGICAL|Cetrelimab|Participants will receive intravenous Cetrelimab.
48697866|NCT04658862|DRUG|TAR-200|Participants will receive intravesical TAR-200.
48370623|NCT02114723|DEVICE|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
48370624|NCT03374982|DEVICE|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
48370625|NCT05637827|OTHER|No intervention|There was no intervention in each group, and only the natural development was observed
48370626|NCT05107557|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co.The COVID-19 vaccine:600SU inactivated virus in 0.5mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
48370627|NCT02889926|BIOLOGICAL|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
48370628|NCT02889926|BIOLOGICAL|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
48370629|NCT03287089|DRUG|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
48370630|NCT03287089|DRUG|Placebo Oral Tablet|Matching placebo
48370631|NCT00384072|DRUG|bazedoxifene BZA-20|
48370632|NCT04711031|OTHER|FLUS|The participating GPs use ultrasonography on a weekly basis and will use the ultrasonography device already available to them; however, the ultrasound machine system and type of transducer will be reported. The GPs will use a 14-zone FLUS scanning protocol that has previously been validated in a general practice setting. Each of the scanning zones on the patient's left side can be denoted from 1L to 7L and from 1R to 7R on the right side. Each scanning zone should be assessed using FLUS. The transducer is placed in the middle of a scanning zone making a cross sectional image of an intercostal space and the underlying pleura blades. The patients will be examined in an upright position. The GPs will be trained in the 14-zone scanning protocol during a FLUS training program prior to recruitment of patients. FLUS pathological findings are predefined, and the variables will be dichotomized into present or not present for each scanning zone.
48522888|NCT02071225|DRUG|bendamustine|70 milligrams per square meter (mg/m\^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
48697867|NCT04658862|DRUG|Cisplatin|Participants will receive cisplatin intravenously.
48168145|NCT02947581|DRUG|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
48168146|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars. They will then have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
48168147|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars.
48168148|NCT01859221|RADIATION|Stereotactic radiation|Stereotactic radiation
48168149|NCT02383238|DRUG|Dapagliflozin|10 mg, oral for 6 weeks
48168150|NCT02383238|DRUG|Placebo|oral for 6 weeks
48168151|NCT05674383|PROCEDURE|Axillary plexus nerve block|Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaine 1%.
48168152|NCT05674383|PROCEDURE|Fracture hematoma block|Fracture hematoma block: a blinded single injection into the fracture with lidocaine 1%.
48168153|NCT03330717|PROCEDURE|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
48168154|NCT03330717|PROCEDURE|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
48168155|NCT03330717|PROCEDURE|General anesthesia with preoperative session of hypnosis|Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.
48168156|NCT05213325|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
48697868|NCT04658862|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously.
48697869|NCT04658862|RADIATION|Conventional radiation therapy|Participants will receive conventional radiation therapy for bladder (64 gy).
48697870|NCT04658862|RADIATION|Hypo-fractioned radiation therapy|Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).
48168157|NCT04441996|BIOLOGICAL|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
48168158|NCT04441996|OTHER|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
48697871|NCT01557777|DRUG|Navitoclax|QD
48697872|NCT04926610|OTHER|proactive clinical ethics consultation|When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
48697873|NCT05896098|OTHER|Ultrasound|Measurement of the airway by ultrasound in obese patients.
48697874|NCT00406874|DRUG|omega 3 fats|1,000 mg daily
48697875|NCT00406874|DRUG|folic acid|800 micrograms daily
48697876|NCT00435227|BIOLOGICAL|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
48697877|NCT00435227|OTHER|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
48010528|NCT02653196|DRUG|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
48370633|NCT06341452|DEVICE|Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control|Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
48370634|NCT04060758|DRUG|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
48370635|NCT05354115|DIAGNOSTIC_TEST|Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel|Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
48370636|NCT02831595|DEVICE|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
48370637|NCT01921582|DRUG|Methylphenidate|"* Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~* Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
48370638|NCT01921582|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~* Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~* Phase 2 aims to reduce food intake and restructure eating-related cognitions;~* Phase 3 focuses upon relapse prevention"
48370639|NCT06032091|OTHER|No intervention|The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring. Previous studies show acceptability toward wearable devices among persons with dementia; however, if the care staff recognize discomfort or distress caused by the device, it will be immediately removed.
48370640|NCT04869358|DRUG|Ofatumumab|Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
48370641|NCT01199874|BIOLOGICAL|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
48370642|NCT06086613|DRUG|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection."
48370643|NCT06086613|DRUG|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection."
48370644|NCT02354027|DRUG|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
48370645|NCT04107961|BIOLOGICAL|Vaccine|Single intramuscular injection into the deltoid region
48370646|NCT04107961|OTHER|Placebo|Single intramuscular injection into the deltoid region
48370647|NCT01822782|BIOLOGICAL|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
48370648|NCT04189198|DRUG|Articaine|Supraclavicular block with 30 ml articaine 2%
48370649|NCT04189198|DRUG|Bupivacaine|Supraclavicular block with 30 ml bupivacaine 0.5%
48370650|NCT03205605|DRUG|oxybutynin|patch
48370651|NCT03205605|DRUG|oxybutynin|gel
48370652|NCT03094468|DRUG|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
48370653|NCT03094468|DRUG|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
48370654|NCT02449005|BIOLOGICAL|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
48010529|NCT02653196|DRUG|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
48010530|NCT02653196|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
48010531|NCT05304858|PROCEDURE|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
48010532|NCT00724451|BIOLOGICAL|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
48010533|NCT00724451|DRUG|Ribavirin|Ribavirin administered in accordance with approved labeling
48010534|NCT00724451|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
48010535|NCT03012854|PROCEDURE|short-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
48010536|NCT03012854|PROCEDURE|long-myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
48515383|NCT00372814|BEHAVIORAL|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
48010537|NCT03012854|PROCEDURE|full-thickness myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
48168159|NCT03372577|BEHAVIORAL|Mindfulness-Based Sex Therapy|It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.
48515384|NCT00372814|BEHAVIORAL|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
48515385|NCT03347825|PROCEDURE|Robotic-assisted lobectomy using da Vinci Surgical System|Robotic-assisted lobectomy
48515386|NCT03347825|PROCEDURE|VATS (video assisted thoracic surgery)|VATS (video assisted thoracic surgery)
48515387|NCT03347825|PROCEDURE|Open lobectomy|Open lobectomy
48168160|NCT03372577|OTHER|Treatment as usual|Routine discharge counseling
48168161|NCT02766010|DEVICE|TensorTip|Non Invasive screening of various physiological and hematological parameters.
48168162|NCT02801409|DRUG|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
48168163|NCT02801409|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
48370655|NCT02449005|OTHER|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
48370656|NCT02449005|PROCEDURE|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
48168164|NCT04726722|BEHAVIORAL|internet-based cognitive behavioral theraphy|"When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired"
48168165|NCT01553227|DEVICE|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
48168166|NCT05624086|BEHAVIORAL|exercise|Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
48370657|NCT06022627|BEHAVIORAL|Pranayama Yoga|Doing practice of paranayam yoga which including breathing exercises yoga-life energy
48370658|NCT05205941|DRUG|MMV688533|Not exceeding 200mg
48370659|NCT03162380|OTHER|Date collection|Date collection
48370660|NCT01889342|BEHAVIORAL|Metacognitive therapy|
48370661|NCT01889342|BEHAVIORAL|Cognitive behavioral therapy|
48370662|NCT04111913|DRUG|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
48370663|NCT04201652|PROCEDURE|Superficial local anesthetic infiltration|Superficial infiltration of local anesthetic for carpal tunnel release.
48370664|NCT04201652|PROCEDURE|Deep local anesthetic infiltration|Deep and superficial infiltration of local anesthetic for carpal tunnel release.
48370665|NCT05842590|OTHER|Composite Veneer Restoration|This is a single-arm study. Direct composite veneer Restorations will be performed to all patients.
48370666|NCT03514368|OTHER|Patients treated with immune checkpoint blockade|"Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)"
48370667|NCT02486458|DRUG|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
48370668|NCT02486458|DRUG|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
48515388|NCT03423719|DIETARY_SUPPLEMENT|Fiit-ns®|Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
48515389|NCT03423719|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
48515390|NCT00612092|RADIATION|Spiral image acquisition|standard spiral scan protocol
48515391|NCT00612092|RADIATION|sequential image acquisition|sequential CT scan protocol
48515392|NCT02457923|OTHER|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
48515393|NCT01364376|DRUG|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
48515394|NCT03409237|DRUG|Mannitol|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
48515395|NCT03409237|DRUG|Hypertonic saline solution|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
48515396|NCT00581165|DRUG|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
48515397|NCT03815461|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
48515398|NCT00507533|PROCEDURE|Continuous positive airway pressure|
48515399|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
48515400|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
48515401|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
48515402|NCT01346293|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
48168167|NCT02242799|DRUG|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
48515403|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
48515404|NCT02340481|DRUG|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
48515405|NCT02340481|DRUG|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
48515406|NCT02340481|DRUG|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
48168168|NCT02242799|DRUG|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
48168169|NCT02242799|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
48370669|NCT06023927|OTHER|Clinical observation, diagnostic testing|Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
48370670|NCT04784208|DIAGNOSTIC_TEST|Blood test for Thyroid stimulating hormone (TSH)|Blood test for Thyroid stimulating hormone (TSH)
48515407|NCT00996489|DEVICE|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
48515408|NCT03776916|OTHER|Simethicone administration 20-30 min before the procedure|Patients intake simethicone 20-30 min before the procedure
48515409|NCT03776916|OTHER|Simethicone administration 31-60 min before the procedure|Patients intake simethicone administration 31-60 min before the procedure.
48370671|NCT06217627|BIOLOGICAL|secretome|The secretome is the secretions of MSCs or explants from umbilical cord tissues. It contains diverse trophic molecules including cytokines, chemokines, angiogenic factors, and growth factors.
48370672|NCT01716299|OTHER|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
48370673|NCT01716299|OTHER|application of a confirmation test|use of rapid confirmation test
48370674|NCT01500291|OTHER|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
48370675|NCT02760680|DEVICE|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
48370676|NCT02760680|OTHER|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
48370677|NCT06254794|DEVICE|Blood flow restriction with Delfi Personalized Tourniquet System (PTS)|Standard of care physical therapy exercises with the use of the Delfi PTS cuff
48370678|NCT06254794|OTHER|Physical therapy|Standard of care physical therapy exercises
48370679|NCT03754881|BEHAVIORAL|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
48010538|NCT03012854|PROCEDURE|circular myotomy|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~4. Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
48515410|NCT03776916|OTHER|Simethicone administration > 60 min before the procedure|Patients intake simethicone administration \> 60 min before the procedure.
48515411|NCT02871323|BIOLOGICAL|Durvalumab|Given IV
48010539|NCT05802693|DRUG|Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection|Infusion of Epidermal Growth Factor Receptor Variant III Chimeric antigen receptor T(EGFRvIII CAR-T) with Omaya capsule
48515412|NCT02871323|OTHER|Laboratory Biomarker Analysis|Correlative studies
48515413|NCT00739063|DRUG|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
48515414|NCT03315078|BIOLOGICAL|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
48010540|NCT05023590|PROCEDURE|ablation of left atrium during mitral valve open chest intervention|open chest mitral valve surgery (reconstruction or replacement) with additional ablation of left atrium by cryo or radio frequency method
48010541|NCT01054703|DEVICE|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
48010542|NCT05002946|DRUG|SP-104|single oral dose
48010543|NCT05002946|DRUG|Naltrexone Hydrochloride 50Mg Oral Tablet|single oral dose
48010544|NCT04582422|OTHER|"Touch Therapy"|During the waiting process, first follow the touch flow chart and perform the touch in the waiting area for 10 minutes. When visiting the treatment chair, the companion will be asked to touch the child's unilateral hand for 5 minutes during the consultation process. A small chair is provided to accompany the child for a total of 15 minutes. The two groups will use the chip tool again after the consultation
48515415|NCT03315078|DRUG|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
48515416|NCT03315078|DRUG|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
48010545|NCT06000878|OTHER|first aid e-book|interactive first aid e-book interventions
48370680|NCT04606862|DEVICE|Morley Medical Sepsis Software Device|The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
48370681|NCT01823575|DEVICE|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
48370682|NCT01823575|DEVICE|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
48370683|NCT02598362|DRUG|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
48370684|NCT04087005|OTHER|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
48515417|NCT03170063|PROCEDURE|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
48010546|NCT03076138|DEVICE|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
48010547|NCT00785486|DRUG|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
48010548|NCT00785486|DRUG|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
48010549|NCT00785486|DRUG|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
48010550|NCT05883605|DEVICE|Measuring blood pressure|Measuring blood pressure using electronic device and using a mercury sphygmomanometer
48515418|NCT02586155|DRUG|Apabetalone|100 mg capsule
48515419|NCT02586155|DRUG|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
48515420|NCT02586155|DRUG|Atorvastatin|High-Intensity Statin
48515421|NCT02586155|DRUG|Rosuvastatin|High-Intensity Statin
48515422|NCT05800067|DRUG|axi-cel|Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
48522889|NCT02071225|DRUG|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
48010551|NCT04913428|OTHER|Interdigital exercise|Patient asked to sit in upright position interlocking their fingers with inhaling deeply bringing the arms up and exhaling through mouth while bring the arm down.
48697878|NCT05439174|OTHER|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
48697879|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
48168170|NCT03562897|DIETARY_SUPPLEMENT|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
48168171|NCT05906901|OTHER|Cranial listening technique|5 minutes
48522890|NCT05467501|DEVICE|Theraputic ultrasound|Therapeutic ultrasound
48697880|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
48697881|NCT01152918|BEHAVIORAL|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
48697882|NCT01152918|BEHAVIORAL|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
48697883|NCT01152918|BEHAVIORAL|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
48697884|NCT01152918|BEHAVIORAL|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
48697885|NCT03257111|OTHER|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
48697886|NCT02348879|DRUG|AMG 403|AMG 403 is for treatment of subjects with chronic pain
48697887|NCT02348879|DRUG|Placebo|contains no active drug
48697888|NCT04435301|DEVICE|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
48010552|NCT04913428|OTHER|Blow-Bottle technique|For blow bottle 20cm of bottle filled with 10cm of water in which a tube of length 35- 40cm inserted with the inner diameter of ≥8mm(21).Patient is asked to form bubbles in bottle by exhaling in bottle performing Forced Expiratory Techniques.
48697889|NCT02284529|DRUG|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
48697890|NCT00115479|DRUG|intensive insulin therapy to maintain normoglycemia|
48697891|NCT03736057|OTHER|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at \<1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
48697892|NCT04981639|PROCEDURE|IVPCA|Intravenous patient controlled analgesia will be performed.
48697893|NCT04981639|PROCEDURE|TAP|Transversus abdominis plane block will be performed.
48697894|NCT04981639|PROCEDURE|IMS|Intramuscular electrical stimulation will be performed.
48697895|NCT01748461|BEHAVIORAL|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
48010553|NCT03132597|BEHAVIORAL|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
48010554|NCT01441193|BIOLOGICAL|HIV-1 Tat/delta-V2 Env combined vaccine|
48010555|NCT01441193|BIOLOGICAL|HIV-1 delta-V2 Env vaccine|
48010556|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 7.5 microg|
48010557|NCT01441193|BIOLOGICAL|HIV-1 Tat vaccine 30 microg|
48010558|NCT06067594|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement|Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
48168172|NCT05906901|OTHER|Suboccipital muscles inhibition technique|6 minutes
48168173|NCT04248036|BEHAVIORAL|Circle of Security - Parenting, COS-P|Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
48168174|NCT02358083|BEHAVIORAL|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
48168175|NCT03579433|DEVICE|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
48522891|NCT05049395|DEVICE|High Flow Nasal Cannula oxygen (HFNO)|The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.
48168176|NCT03579433|OTHER|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
48010559|NCT05118594|BEHAVIORAL|Pre-treatment psychotherapy recommendations|After patients complete an intake evaluation and prior to starting therapy, the assigned therapist will receive automatized feedback that consists of recommendations regarding the most suitable interventions (i.e., cognitive, behavioral, interpersonal or patient-centered) for each individual patients, based on patients' baseline characteristics and a machine learning algorithm developed in a previous study. Besides the interventions recommended, therapist will receive within the system guideline and tutorial videos showing how to deliver adequately the specific interventions recommended.
48010560|NCT02489227|DRUG|CHS-1420|
48010561|NCT02489227|DRUG|Adalimumab|
48515423|NCT06583018|BEHAVIORAL|In-Person Mindfulness-based Group Session|A 3-hour group-based session in week 1 focused on experiential mindfulness practices. Participants will enhance their self-awareness of positive, neutral, and negative body sensations, feelings, and thoughts while engaging in healthy behaviors, particularly physical activity
48697896|NCT01748461|BEHAVIORAL|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
48010562|NCT05957068|BEHAVIORAL|Exercise Programme|Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
48010563|NCT05957068|BEHAVIORAL|Control|Usual care group.
48010564|NCT03217929|DEVICE|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
48010565|NCT03217929|DEVICE|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
48010566|NCT01976845|DRUG|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
48010567|NCT01976845|DRUG|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
48010568|NCT01976845|DRUG|Saline|Saline 2 ml IV, in the pre-op area as a premedication
48010569|NCT01147419|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
48010570|NCT01147419|DEVICE|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
48010571|NCT04276350|PROCEDURE|Acupuncture|Acupuncture sessions - 2-3 times/week, each session lasting 1 hour, over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling)
48168177|NCT03579433|DEVICE|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
48168178|NCT05353621|BEHAVIORAL|VAS reported Stress|VAS reported Stress measurement during simulation
48168179|NCT00157690|DRUG|Alendronate|70 mg 1x weekly for 12 months
48168180|NCT00157690|DRUG|Placebo|70 mg 1 x weekly for 12 months
48168181|NCT03811834|DRUG|Mobocertinib|Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
48168182|NCT04635085|BEHAVIORAL|Empowerment-based Cognitive behavioral therapy for insomnia for MCI|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
48168183|NCT03069014|DRUG|400mg LM11A-31-BHS|1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks
48168184|NCT03069014|DRUG|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks
48697897|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF
48697898|NCT06660225|DEVICE|Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]|Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON
48697899|NCT05464641|OTHER|Oxford knee score|The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
48522892|NCT05049395|DEVICE|Regular oxygen|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
48522893|NCT04629378|DRUG|Meropenem Injection|Meropenem IV 6 grams
48522894|NCT04629378|DRUG|Amoxicillin Clavulanate|Amx/CA oral 1000/62.5mg 2 tablets
48522895|NCT04629378|DRUG|Pyrazinamide|Pyrazinamide 20-30mg/kg
48522896|NCT04629378|DRUG|Bedaquiline|Bedaquiline 400mg
48168185|NCT03069014|DRUG|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
48168186|NCT00996359|BIOLOGICAL|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
48168187|NCT00996359|RADIATION|total-body irradiation|100 cGy TBI
48168188|NCT05643313|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
48168189|NCT01246219|DRUG|GH treatment (Genotropin)|4 years treatment with GH
48168190|NCT01246219|DRUG|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
48370685|NCT04741880|DRUG|Lidocaine IV|"Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
48697900|NCT01357538|DRUG|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
48697901|NCT01357538|DRUG|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
48697902|NCT01331343|DEVICE|Guardian RT Telemetered Glucose Monitoring System|
48697903|NCT05332743|DIETARY_SUPPLEMENT|Nutrafol Vegan Women's Hair Supplement|Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
48697904|NCT05514756|DEVICE|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
48697905|NCT05514756|DEVICE|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
48697906|NCT05514756|OTHER|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
48697907|NCT05169229|DRUG|Vancomycin + Tobramycin|1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
48697908|NCT05169229|DRUG|Saline|As a placebo added to the allograft.
48168191|NCT04210024|OTHER|Diabetes Empowerment Education Program|Individuals identified as Community Health Workers will participate in the Diabetes Empowerment Education Program (DEEP™). DEEP, is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
48168192|NCT04498143|OTHER|"Project SAVE (Stop Adolescent Violence Everywhere) SSI"|Internet-based, 30-minute single session intervention targeting NSSI via decreasing urge to act on self-punishment/self-harm thoughts/urges.
48168193|NCT04498143|OTHER|"Active Comparator: Supportive Therapy (Share Your Feelings) SSI"|Internet-based, 30-minute single session intervention to increase feelings disclosure.
48168194|NCT03756922|DRUG|FDL169|CFTR corrector
48168195|NCT03756922|DRUG|FDL176|CFTR potentiator
48168196|NCT00138918|BIOLOGICAL|OGX-011|See Detailed Description, Treatment Plan
48168197|NCT04785573|DIETARY_SUPPLEMENT|Mastiha oil|1 soft gel capsule of Mastiha oil every day for 3 months
48168198|NCT01263990|DEVICE|NexFin|noninvasive finger cuff system
48168199|NCT05896137|DRUG|CS0159 2mg|Oral QD
48168200|NCT05896137|DRUG|Placebo|Oral QD
48168201|NCT02143063|BEHAVIORAL|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
48522897|NCT04629378|DRUG|Rifafour|Rifafour (HRZE) Standard dose
48522898|NCT02531529|DRUG|dexmedetomedine|intraoperative infusion
48522899|NCT02531529|DRUG|Fentanyl|
48697909|NCT06382103|DIAGNOSTIC_TEST|ctDNA monitoring|The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
48697910|NCT06382103|DIAGNOSTIC_TEST|Plasma proteomic analysis|plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
48697911|NCT00499291|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
48697912|NCT00499291|PROCEDURE|gene expression analysis|
48697913|NCT00499291|PROCEDURE|laboratory biomarker analysis|
48697914|NCT00499291|PROCEDURE|pharmacological study|
48697915|NCT00499291|PROCEDURE|polymerase chain reaction|
48697916|NCT03554941|DEVICE|noise stimulation|noise stimulation
48697917|NCT00529347|DEVICE|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
48697918|NCT05073796|DEVICE|Cochlea Implant|"* examination and documentation of vital signs and concomitant medication~* application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~* attraction of an special mask to determine the subjective visual vertical (SVV)~* assessment of the vertical spatial axis with all electrodes turned off~* assessment of the vertical spatial axis with all electrodes turned on~* assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~* assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~* assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
48370686|NCT04741880|DRUG|Saline|"Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered."
48697919|NCT01858142|BEHAVIORAL|Parental presence decision tool|
48168202|NCT02143063|BEHAVIORAL|prize contingency management on a variable interval schedule for cocaine abstinence|
48168203|NCT02143063|BEHAVIORAL|standard care|
48515424|NCT06583018|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Participants will receive personalized instant messages with chat-based support throughout the 8-week intervention period. The message content is guided by existing international lifestyle modification guidelines and the Integrated Body-Mind-Spirit Model. The pre-set frequency of regular message delivery is five times per week. The schedule of message delivery will be personalized according to the participants' on-going needs/preferences over the intervention period. Chat-based support will be provided by trained research assistants, who will utilize motivational interviewing techniques to enhance participant compliance and effectiveness.
48697920|NCT01858142|BEHAVIORAL|Standard preparation|
48697921|NCT00302172|DRUG|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
48697922|NCT02117960|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
48697923|NCT02117960|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
48697924|NCT04044599|DRUG|Gynoflor|VAGİNAL GYNOFLOR
48697925|NCT05806541|BEHAVIORAL|laughter therapy|Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
48697926|NCT02961933|OTHER|Apneic oxygenation|Nasal cannula apneic oxygenation
48697927|NCT02961933|OTHER|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
48697928|NCT04650568|DEVICE|Autologous Bone Marrow Derived Mesenchymal Stem Cells|Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.
48168204|NCT03819842|DIAGNOSTIC_TEST|Pseudophakic Measurement|standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
48168205|NCT02845375|DRUG|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
48168206|NCT02845375|DRUG|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
48168207|NCT02845375|DRUG|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
48168208|NCT06186726|RADIATION|carbon ion radiotherapy|The patients received 72GyE/18 doses of carbon ion radiotherapy.
48168209|NCT03690921|DRUG|Cisplatin|Given IV
48168210|NCT03690921|DRUG|Fluorouracil|Given IV
48168211|NCT03690921|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
48168212|NCT03690921|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
48168213|NCT03690921|OTHER|Questionnaire Administration|Ancillary studies
48168214|NCT05428241|BEHAVIORAL|Assigned Interventions|Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
48168215|NCT01732588|DRUG|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
48697929|NCT04650568|OTHER|Sham incision|Small incision over the site where bone marrow aspirate would have been obtained
48697930|NCT05277519|DEVICE|Vibrations|Sequenced muscle vibrations during 30 min., 3 times a week during 5 weeks
48168216|NCT01732588|DRUG|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
48697931|NCT00726037|DRUG|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
48697932|NCT04251299|BEHAVIORAL|home-based, mentored vegetable gardening program|The mentored vegetable gardening program pairs each participant with a certified Master Gardener. The participant/Master Gardener dyads work together to plan, plant and tend to a vegetable garden at the participant's home throughout the year. Gardening supplies, plants and seeds are provided.
48697933|NCT03201965|DRUG|Cyclophosphamide|Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
48697934|NCT03201965|DRUG|Bortezomib|Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.
48370687|NCT02832986|OTHER|Medical Questionary|"The medical questionary will contain :~* Date of initial infection by Herpes zoster~* Localisation~* Severity~* Presence of postherpetic pain~* Postherpetic pain Intensity~* Postherpetic pain duration~* Antiviral treatment~* History of chronic pathologies~* Concomitant treatment"
48010572|NCT04276350|PROCEDURE|Best Medical Therapy|Best Medical Therapy - 3 biofeedback sessions over a period of 10 weeks (with allowed deviation up to 2 weeks due to scheduling), where subjects learn and practice the exercises daily
48010573|NCT06387329|DRUG|Nitrofurantoin 100 MG|No additional information
48168217|NCT01732588|DRUG|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
48168218|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
48168219|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
48168220|NCT06074445|OTHER|No intervention|No intervention
48168221|NCT00631397|DEVICE|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
48370688|NCT01376076|DRUG|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
48370689|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
48370690|NCT01376076|DRUG|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
48515425|NCT06583018|BEHAVIORAL|In-person Group Session|A 3-hour group-based session in week 1 focused on general education on lifestyle modification based on the HEARTS technical package as recommended by the WHO, and will only receive reminder messages for the two assessment follow-ups. No chat-based support will be provided.
48515426|NCT06583018|DEVICE|Activity Monitoring|All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life.
48515427|NCT03530839|PROCEDURE|Arthrodesis|see study group description
48515428|NCT03530839|PROCEDURE|Resection arthroplasty|see study group description
48515429|NCT01860625|DRUG|Donepezil patch|
48697935|NCT03201965|DRUG|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
48697936|NCT03201965|DRUG|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
48697937|NCT03219034|DEVICE|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
48168222|NCT02413099|DRUG|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
48168223|NCT05463926|BEHAVIORAL|PDA mobile application|"Parentbot - a Digital healthcare Assistant (PDA):~A mobile application-based psychosocial parenting intervention with integrated chatbot features. It consists of multimedia educational materials (text files, audio files and videos), discussion forums, guided mindfulness-based meditation videos, guided reflection and gratitude journals and a chatbot."
48168224|NCT02986750|DEVICE|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
48168225|NCT02986750|DEVICE|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
48168226|NCT02986750|DEVICE|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
48168227|NCT02274051|DIETARY_SUPPLEMENT|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
48168228|NCT02510222|DIETARY_SUPPLEMENT|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
48168229|NCT02510222|OTHER|Placebo|
48168230|NCT01378598|OTHER|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
48168231|NCT04584879|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
48697938|NCT03219034|DEVICE|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
48697939|NCT06010758|DRUG|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
48697940|NCT06010758|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
48697941|NCT06010758|DRUG|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
48697942|NCT06010758|OTHER|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
48697943|NCT06362473|DRUG|Lipid-lowering treatments|
48697944|NCT02533986|DIETARY_SUPPLEMENT|Berry peel drink|
48697945|NCT02533986|DIETARY_SUPPLEMENT|Control drink|
48697946|NCT04068519|DRUG|Tislelizumab|Administered intravenously
48697947|NCT05379218|DEVICE|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
48010574|NCT06018961|OTHER|Post-operative ileus surgery|Collection of ileus events, items of IFEED score and surgical complications
48010575|NCT01410149|OTHER|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
48010576|NCT01410149|OTHER|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
48010577|NCT01410149|OTHER|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
48010578|NCT03067779|OTHER|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
48010579|NCT03860896|DRUG|GB004|GB0004 high dose
48010580|NCT03860896|DRUG|Placebo|Placebo
48010581|NCT03860896|DRUG|GB004|GB004 low dose
48010582|NCT02156427|DEVICE|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
48010583|NCT02156427|DEVICE|PLACEBO|hyaluronic acid alone
48010584|NCT00649116|DRUG|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
48010585|NCT00649116|DRUG|Lopressor® Tablets 100 mg|100mg, single dose fed
48010586|NCT03533075|BEHAVIORAL|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
48010587|NCT00199745|DRUG|atorvastatin|
48010588|NCT03132948|BEHAVIORAL|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
48010589|NCT03069027|PROCEDURE|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
48010590|NCT03069027|DRUG|saline adrenaline|
48010591|NCT03069027|DRUG|Xylocaine, adrenaline|
48697948|NCT05820568|BEHAVIORAL|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
48010592|NCT04263818|PROCEDURE|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for|"Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for."
48010593|NCT01782313|DRUG|tivozanib|Given PO
48010594|NCT01782313|OTHER|laboratory biomarker analysis|Correlative studies
48010595|NCT03337633|BEHAVIORAL|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
48010596|NCT06013371|DRUG|PF-07038124|topical PDE4 inhibitor
48010597|NCT06013371|DRUG|Placebo Ointment|matching placebo
48010598|NCT02539875|BEHAVIORAL|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
48010599|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
48168232|NCT04584879|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
48168233|NCT04584879|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
48168234|NCT02822209|BEHAVIORAL|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
48168235|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
48168236|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
48697949|NCT00801723|DRUG|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
48697950|NCT00801723|DRUG|Placebo Tablet|Placebo Tablet once daily.
48010600|NCT01706250|OTHER|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
48010601|NCT01706250|OTHER|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
48010602|NCT01706250|OTHER|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
48010603|NCT01706250|OTHER|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
48010604|NCT01706250|OTHER|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
48010605|NCT01493271|DRUG|Placebo|Placebo to RO5093151
48010606|NCT01493271|DRUG|RO5093151|oral doses twice daily for up to 28 days
48010607|NCT00529386|DRUG|Botox|300 units
48010608|NCT05233878|OTHER|Characterization of a population with cervical paragangliomas|Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
48168237|NCT02822209|BEHAVIORAL|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
48515430|NCT01860625|DRUG|placebo|
48010609|NCT02168166|BEHAVIORAL|Executive Function Training|
48010610|NCT02168166|BEHAVIORAL|Placebo|Placebo version of executive function training
48515431|NCT03882229|DEVICE|MED-EL CI systems|• Cochlear Implant (CI) and external audio processor
48515432|NCT00325247|DRUG|ZINC|
48515433|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, one single dose
48515434|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, once daily for 5 days
48168238|NCT05088538|OTHER|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
48168239|NCT06371430|DEVICE|Dental Implant insertion and tooth extraction|"The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment."
48168240|NCT06409559|PROCEDURE|pelvic reconstruction|interfragmentary screws placed through the plate or buttress plate applied under compression without interfragmentary lag or position screws
48168241|NCT06478225|DRUG|BGT007H Cell Injection|"Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28)."
48515435|NCT04590352|PROCEDURE|nasopharyngeal and throat swab|diagnostic specimens via nasopharyngeal swab and throat swab were collected following the current standard operating procedures.
48515436|NCT04590352|PROCEDURE|collection of mucosal lining fluid|MLF will be collected via nasal absorption at the inclusion visit by study staff and four more time points by the parents or by the children themselves. Nasal absorption is performed by maneuvering a strip of synthetic absorptive matrices (SAM) into the lumen of the nostril, avoiding rubbing against the nasal mucosa. The outside of the nose is then pressed with a finger to cause apposition of the SAM against the mucosa.
48697951|NCT05236452|OTHER|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
48697952|NCT00734604|DRUG|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
48697953|NCT00734604|DRUG|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
48697954|NCT00734604|DRUG|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
48697955|NCT04736368|OTHER|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
48168242|NCT05524285|DEVICE|Intracranial Support Catheter|Endovascular procedure using the intracranial support catheter which approved by NMPA
48370691|NCT06369766|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|"OCT is used to measure:~* peripapillary retinal nerve fiber layer (mean thickness in μm)~* ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm)~* other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm).~The scanner laser ophthalmoscopy-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability.~In a subgroup of participants, the angiography-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus."
48370692|NCT06369766|DIAGNOSTIC_TEST|Static retinal vessel analyzer|"Static retinal vessel analyzer is used to determine:~* central retinal arteriolar diameter equivalents (in μm)~* central retinal venular diameter equivalents (in μm)~* arteriolar-to-venular diameter ratio"
48697956|NCT04736368|OTHER|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
48697957|NCT03392363|DEVICE|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
48168243|NCT05524285|DEVICE|Guide Catheter|Endovascular procedure using the guide catheter which approved by NMPA
48168244|NCT00225277|DRUG|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
48168245|NCT00225277|DRUG|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
48168246|NCT05037721|OTHER|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
48168247|NCT05037721|OTHER|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
48168248|NCT00329017|PROCEDURE|Fine needle aspiration|Fine needle aspiration
48168249|NCT04737005|PROCEDURE|Nano-ceramic hybrid (Grandio Blocs) Endo-crown|Nano-ceramic hybrid
48168250|NCT05027880|BEHAVIORAL|Web-based single-session growth mindset intervention for adolescent anxiety|This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
48168251|NCT01874665|DRUG|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
48168252|NCT05813535|DRUG|Sodium bicarb lock|8.4% sodium bicarb locks when off venous nutrition
48168253|NCT00745121|DEVICE|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
48168254|NCT05382910|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
48168255|NCT05382910|DRUG|Placebo|Placebo
48168256|NCT00301041|OTHER|laboratory biomarker analysis|
48168257|NCT00301041|PROCEDURE|adjuvant therapy|
48697958|NCT02943330|OTHER|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
48168258|NCT00301041|RADIATION|radiation therapy|
48697959|NCT00962741|DRUG|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
48697960|NCT02689739|PROCEDURE|venous duplex ultrasound|Venous duplex ultrasound
48697961|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
48697962|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
48697963|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
48168259|NCT05959161|PROCEDURE|DBS|We observed the prognostic changes of patients after DBS surgery
48697964|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
48168260|NCT05682885|PROCEDURE|Lymphatic Bypass Supermicrosurgery|Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
48697965|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
48697966|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
48697967|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
48697968|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
48697969|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
48697970|NCT00964912|DRUG|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
48168261|NCT02068378|DEVICE|CMPE Optical Sensor Device|Christie Medical Physics \& Enginieering visual feedback with optical sensing device.
48168262|NCT03698630|DRUG|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
48168263|NCT03698630|DRUG|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon\* on the other containing 2 mg dexamethasone."
48168264|NCT00857233|DRUG|Memantine|20 mg oral tablets once daily
48168265|NCT03230409|BEHAVIORAL|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents \>12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
48370693|NCT06369766|DIAGNOSTIC_TEST|Dynamic retinal vessel analyzer|In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.
48370694|NCT06369766|DIAGNOSTIC_TEST|Laser speckle flowgraphy system|In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.
48370695|NCT06369766|OTHER|Questionnaire|All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.
48370696|NCT02581657|DRUG|PE0139 Injection|PE0139 Injection
48370697|NCT02581657|DRUG|Placebo Injection|Placebo Injection
48370698|NCT01006785|DRUG|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
48370699|NCT01006785|DRUG|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
48370700|NCT02433015|OTHER|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
48370701|NCT02433015|OTHER|Tobacco Cigarette|Smoke own brand of cigarette as previously
48697971|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
48697972|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
48010611|NCT02487589|OTHER|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
48010612|NCT03843684|DEVICE|3D-printed foot orthoses|3D printed foot orthoses with arch support
48010613|NCT03843684|DEVICE|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
48010614|NCT00628550|DRUG|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
48010615|NCT00628550|DRUG|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
48010616|NCT05691426|DIAGNOSTIC_TEST|Assessment of pulse wave amplitude (PWA)|Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)
48010617|NCT05691426|DIAGNOSTIC_TEST|Salivary Nitric Oxide|assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,
48010618|NCT03521492|DIAGNOSTIC_TEST|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
48697973|NCT04945707|DRUG|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
48697974|NCT04945707|DRUG|Placebo|Normal saline
48697975|NCT05090826|DEVICE|Model ZFR00V|Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
48697976|NCT00620256|DRUG|AL-37807 ophthalmic suspension, 0.1%|
48697977|NCT00620256|DRUG|Timolol gel forming solution, 0.5%|
48697978|NCT00620256|OTHER|AL-37807 ophthalmic solution vehicle|
48697979|NCT00620256|DRUG|Latanoprost ophthalmic solution|
48697980|NCT00270088|DRUG|epoetin alfa|
48697981|NCT01335724|DRUG|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
48697982|NCT01335724|DRUG|Placebo gel|Placebo gel
48697983|NCT02387333|PROCEDURE|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
48697984|NCT02387333|PROCEDURE|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
48697985|NCT02930382|OTHER|Baroreflex assessment|
48697986|NCT03241940|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
48697987|NCT03241940|DRUG|Cyclophosphamide|Given IV
48010619|NCT01751503|PROCEDURE|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
48697988|NCT03241940|DRUG|Fludarabine Phosphate|Given IV
48697989|NCT03241940|OTHER|Laboratory Biomarker Analysis|Correlative studies
48697990|NCT03241940|OTHER|Questionnaire Administration|Ancillary studies
48697991|NCT02879643|DRUG|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
48697992|NCT00700544|DRUG|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight \> 60 kgs frequency: every day Duration: 2 years"
48697993|NCT00700544|DRUG|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
48697994|NCT05348356|DRUG|Nirogacestat|nirogacestat oral tablet
48010620|NCT01751503|PROCEDURE|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
48010621|NCT00095784|DRUG|Decitabine|Given SC
48010622|NCT00095784|OTHER|Laboratory Biomarker Analysis|Correlative studies
48010623|NCT04047017|DRUG|Apatinib|250mg, po, qd
48010624|NCT04047017|DRUG|Camrelizumab|200mg, q2w
48010625|NCT05984134|DRUG|NL005 Middle Dose|Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
48515437|NCT04590352|PROCEDURE|blood collection via fingerprick|Participants will be asked to wash their hands with soap and warm water. The procedure involves cleaning the ball of the fingertip with an alcohol swab, then using a sterile disposable lancet to pierce the skin (BD Microtainer Lancet or similar). The lancet is placed in a spring-loaded device, which propels the lancet a fixed distance (a few mm) into the skin when the trigger is pressed. Approximately 10-20 drops of blood (0.3 ml) will then be collected with a sterile capillary tube. The participant is given a cotton wool pad to mop up any extra blood, and an elastoplast-type bandage is placed over the finger if necessary. Fingerprick blood samples will only be collected from participants older than 6 months at 28-32 days after the first home visit (d0). Lancet length will be adjusted for age (2.0 mm for participants 8 years and older, 1.5 mm for participants older than 6 months and younger than 8 years).
48697995|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system with bone cement.
48370702|NCT04540627|DRUG|Palivizumab|Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
48515438|NCT01013662|PROCEDURE|glycemic control|exogenous insulin
48697996|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system without bone cement.
48697997|NCT05127824|BIOLOGICAL|Autologous alpha-DC1/TBVA vaccine|"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."
48515439|NCT02754765|DRUG|Bedaquiline|
48515440|NCT02754765|DRUG|Delamanid|
48515441|NCT02754765|DRUG|Clofazimine|
48697998|NCT05127824|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
48697999|NCT01891617|OTHER|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
48698000|NCT05707377|DRUG|Zanubrutinib|Participants will receive zanubrutinib once daily
48370703|NCT04540627|DRUG|Placebo|Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
48370704|NCT04540627|OTHER|RSV-A Memphis 37b virus|Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
48370705|NCT02711163|DIETARY_SUPPLEMENT|Extensively Hydrolyzed formula|
48370706|NCT02711163|DIETARY_SUPPLEMENT|Amino acid formula|
48370707|NCT03439319|DEVICE|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
48370708|NCT03439319|OTHER|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
48515442|NCT02754765|DRUG|Levofloxacin|
48515443|NCT02754765|DRUG|Moxifloxacin|
48515444|NCT02754765|DRUG|Linezolid|
48515445|NCT02754765|DRUG|Pyrazinamide|
48515446|NCT02754765|DRUG|Control arm MDR-TB regimen, consistent with WHO guidelines|Control arm MDR-TB regimen, consistent WHO guidelines
48515447|NCT02724514|OTHER|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
48515448|NCT02452476|DRUG|CHF5633|Rescue treatment (if needed)
48515449|NCT02452476|DRUG|Poractant alfa|Rescue treatment (if needed)
48515450|NCT03584087|DRUG|Normal Saline|TG 0 (0Hr)
48515451|NCT03584087|DRUG|Terlipressin|Duration of Terlipressin after EVL
48010626|NCT05984134|DRUG|NL005 High Dose|Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
48010627|NCT05984134|DRUG|Placebo|30 subjects will be randomly assigned to the placebo for 7 days
48010628|NCT00338195|BEHAVIORAL|Individualized caffeine cessation instructions|Intervention is described in the protocol
48010629|NCT01745029|DEVICE|Motilis-3D-transit|
48010630|NCT03629015|BIOLOGICAL|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
48010631|NCT00705575|DRUG|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
48010632|NCT00705575|DRUG|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
48010633|NCT03240575|DRUG|Tiotropium|Fixed Dose Combination
48010634|NCT03240575|DRUG|Olodaterol|Fixed Dose Combination
48010635|NCT03240575|DRUG|Fluticasone propionate|Fixed Dose Combination
48010636|NCT03240575|DRUG|Salmeterol|Fixed Dose Combination
48010637|NCT02698358|DEVICE|Epic stent (Boston Scientific)|
48010638|NCT02771639|PROCEDURE|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
48010639|NCT03229564|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
48010640|NCT03229564|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
48010641|NCT03395431|OTHER|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
48010642|NCT04541758|PROCEDURE|surgical treatment|surgical treatment and Conservative treatment
48698001|NCT05707377|DRUG|Tacrolimus|Participants will receive tacrolimus twice daily
48698002|NCT05707377|DRUG|Zanubrutinib|Participants will receive zanubrutinib twice daily
48168266|NCT03230409|BEHAVIORAL|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
48168267|NCT03230409|BIOLOGICAL|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
48698003|NCT03792438|DIAGNOSTIC_TEST|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
48698004|NCT02815696|DEVICE|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
48698005|NCT03215992|DEVICE|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
48698006|NCT03044119|BIOLOGICAL|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
48698007|NCT03044119|BIOLOGICAL|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
48010643|NCT04541758|PROCEDURE|Conservative treatment|Conservative treatment
48010644|NCT01663259|DRUG|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
48010645|NCT01663259|RADIATION|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
48168268|NCT03230409|BEHAVIORAL|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
48370709|NCT03200041|PROCEDURE|Blood sample|20 ml blood sample taken from vein in arm
48698008|NCT05936567|DRUG|Povorcitinib|oral; tablet
48698009|NCT05936567|DRUG|Placebo|oral; tablet
48698010|NCT02856243|DRUG|new antiviral therapy|
48168269|NCT05050435|PROCEDURE|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
48168270|NCT02209727|DRUG|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
48168271|NCT02109861|DRUG|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
48168272|NCT02109861|DRUG|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
48698011|NCT03155529|PROCEDURE|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
48698012|NCT02516098|DRUG|hyoscine butylbromide|
48010646|NCT00150020|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|
48010647|NCT06273553|BIOLOGICAL|RG002 injection|In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
48370710|NCT03350763|DEVICE|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
48168273|NCT02109861|DRUG|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
48698013|NCT00950391|DRUG|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
48698014|NCT02425228|DEVICE|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
48168274|NCT04890886|DIAGNOSTIC_TEST|Thermal imaging|Use of a thermal imaging cameral to measure brown and white adipose tissue function
48168275|NCT04890886|DIAGNOSTIC_TEST|Echocardiogram|Echocardiographic imaging of the fetal heart to assess ventricular function
48168276|NCT04890886|DIAGNOSTIC_TEST|ECG|ECG of the fetus and the neonate to look at the cardiac electrical activity
48168277|NCT04890886|DIAGNOSTIC_TEST|MRI scan|MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
48168278|NCT04890886|DIAGNOSTIC_TEST|Serum blood markers|Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
48168279|NCT02456298|BEHAVIORAL|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
48370711|NCT03350763|DEVICE|Self-expandable metallic biliary stent|ie WallFlex biliary RX
48370712|NCT00283153|BEHAVIORAL|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
48698015|NCT01066104|DRUG|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
48698016|NCT01066104|DRUG|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
48698017|NCT04771416|BIOLOGICAL|PBKR03|Single dose of PBKR03, via intra cisterna magna
48010648|NCT00909636|DRUG|ABT-333|See arm description for more information
48010649|NCT00909636|DRUG|Placebo|See arm description for more information
48010650|NCT00218062|DRUG|D-Amphetamine 30mg|
48010651|NCT00218062|DRUG|D-Amphetamine 60mg|
48010652|NCT00218062|DRUG|Modafinil 200mg|
48010653|NCT00218062|DRUG|Modafinil 400mg|
48010654|NCT00218062|BEHAVIORAL|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
48010655|NCT00218062|DRUG|Placebo|
48010656|NCT06139952|DRUG|Atorvastatin 80mg|Atorvastatin 80mg taken Once before coronary angiography
48010657|NCT06139952|DRUG|N-acetyl cysteine|200mg 3 times daily 2 days before coronary angiography
48010658|NCT06139952|OTHER|Normal Saline|adequate hydration using Normal Saline (1ml/kg/hr)
48010659|NCT03704181|DRUG|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
48010660|NCT03704181|DRUG|Placebo Oral Tablet|placebo twice day for one year
48010661|NCT01730495|DRUG|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
48168280|NCT02456298|BEHAVIORAL|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
48168281|NCT03598803|OTHER|Survey|Urinary Incontinence Survey
48168282|NCT00363649|BIOLOGICAL|GM-K562 cell vaccine|Given by injection
48168283|NCT00363649|BIOLOGICAL|Interferon alfa|Given by injection
48168284|NCT00363649|BIOLOGICAL|Sargramostim|Given by injection
48168285|NCT00583115|DRUG|Gleevec|260 mg/M2/day, given once daily by mouth
48168286|NCT01532583|OTHER|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
48370713|NCT00283153|OTHER|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
48370714|NCT03373422|DRUG|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
48370715|NCT03373422|DRUG|Placebo|Matching placebo tablets
48370716|NCT04430491|DIAGNOSTIC_TEST|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
48370717|NCT00081276|DRUG|triapine|Given IV
48370718|NCT00081276|DRUG|cisplatin|Given IV
48698018|NCT05850910|OTHER|Supine practice group|The practitioner's arm was placed in the mid-thoracic region from the opposite side of the individual's torso in the form of a half fist. In this position, the SPs coincide with the space in the middle of the half fist, while the TPs coincide with the fingertips and the thenar region. With the practitioner's other hand supporting the patient's elbows, a high-speed-low-amplitude thrust is applied from front to back.
48698019|NCT05850910|OTHER|Prone application group|the practitioner positions the hypothenar part of his hands above the TPs in the mid-thoracic segment. From this point, a high-velocity-low-amplitude thrust is applied from the back to the front.
48698020|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
48698021|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
48698022|NCT01381276|OTHER|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
48698023|NCT05340712|DIETARY_SUPPLEMENT|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
48010662|NCT01941953|DRUG|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
48168287|NCT04933838|DEVICE|atelocollagen|"This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL)."
48168288|NCT00748488|OTHER|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
48168289|NCT00748488|OTHER|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
48168290|NCT02428218|DRUG|dimethyl fumarate|enteric-coated microtablets
48168291|NCT02428218|DRUG|Placebo|enteric-coated microtablets
48168292|NCT01623206|DRUG|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
48168293|NCT04037306|BEHAVIORAL|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
48168294|NCT04037306|BEHAVIORAL|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
48698024|NCT05340712|DIETARY_SUPPLEMENT|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
48168295|NCT02960334|DEVICE|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
48168296|NCT05664230|OTHER|osteopathy|five osteopathy sessions
48168297|NCT06112522|DRUG|Tirbanibulin|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
48370719|NCT00081276|OTHER|laboratory biomarker analysis|Correlative studies
48370720|NCT00848965|DRUG|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
48698025|NCT03571009|DEVICE|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
48370721|NCT00848965|DRUG|Placebo|Placebo comparator
48370722|NCT04140942|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
48370723|NCT04140942|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
48515452|NCT05063851|DRUG|Memantine Hydrochloride Tablets|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
48698026|NCT02720380|OTHER|Buteyko|Intervention will be held twice a week during 3 weeks.
48010663|NCT02316197|DRUG|MSC2490484A (M3814)|Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
48010664|NCT05649163|DRUG|Disitamab Vedotin|Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
48515453|NCT05063851|DRUG|Placebo|The recommended starting dose of memantine hydrochloride/placebo is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.
48698027|NCT02720380|OTHER|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
48698028|NCT04176991|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
48010665|NCT01931267|BEHAVIORAL|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
48010666|NCT01931267|BEHAVIORAL|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
48010667|NCT04136769|PROCEDURE|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
48370724|NCT04153526|PROCEDURE|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
48515454|NCT05015257|DIETARY_SUPPLEMENT|Standard F100|100 kcal and 3 g protein per 100 ml
48698029|NCT04176991|BIOLOGICAL|Placebo|Placebo Comparator
48698030|NCT05806034|OTHER|tractography MRI sequence protocol|tractography MRI sequence protocol does not require injection of contrast agent.
48010668|NCT00126295|DEVICE|'What you need to know about stroke' education package|
48010669|NCT02201797|OTHER|DCE MRI|
48010670|NCT04542629|DRUG|RiTUXimab Injection [Rituxan]|375 MG/M2 /WEEK INFUSION
48370725|NCT04153526|PROCEDURE|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
48698031|NCT01965613|BIOLOGICAL|Xilonix|IV
48698032|NCT05069077|OTHER|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
48698033|NCT05069077|OTHER|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
48698034|NCT04277663|DRUG|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
48698035|NCT04277663|DRUG|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
48698036|NCT04277663|DRUG|High-dose recombinant interferon a-2B|In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
48370726|NCT04153526|OTHER|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
48370727|NCT04504682|BEHAVIORAL|Ambulation|Patients will be encouraged to ambulate for 20 minutes of every hour.
48698037|NCT02865954|DEVICE|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
48698038|NCT01414101|DRUG|ISIS CRP Rx or Placebo|
48698039|NCT03913013|BEHAVIORAL|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
48698040|NCT05721352|BEHAVIORAL|Virtual Reality Nature scene plus heart rate variability biofeedback phone application|phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
48698041|NCT04627623|DIAGNOSTIC_TEST|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
48698042|NCT05805696|BEHAVIORAL|Impostor tasks|Tasks to do every week
48515455|NCT05015257|DIETARY_SUPPLEMENT|Standard F75 + Plumpynut|Standard F75 with ready to-use therapeutic food (Plumpynut)
48515456|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 with CMV + Plumpynut|Alternative F75 containing CMV with ready to-use therapeutic food (Plumpynut)
48515457|NCT05015257|DIETARY_SUPPLEMENT|Alternative F75 without CMV + Plumpynut|Alternative F75 with no CMV with ready to-use therapeutic food (Plumpynut)
48370728|NCT01379339|DRUG|Cabazitaxel 10mg/m2|"* Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
48370729|NCT01379339|DRUG|Cabazitaxel 12.5mg/m2|"* Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
48370730|NCT01379339|DRUG|Cabazitaxel 15mg/m2|"* Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
48370731|NCT01379339|DRUG|Cabazitaxel 17.5mg/m2|"* Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
48370732|NCT01379339|DRUG|Cabazitaxel 20mg/m2|"* Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
48370733|NCT00422227|DRUG|Etanercept , Methotrexate|"* Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO"
48370734|NCT00422227|DRUG|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"* Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
48370735|NCT05734534|OTHER|BFR during training|Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
48370736|NCT05734534|OTHER|BFR during rest|Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
48370737|NCT03301246|DEVICE|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
48370738|NCT03359811|DRUG|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
48370739|NCT03359811|DRUG|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
48370740|NCT03359811|DRUG|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
48370741|NCT06285019|PROCEDURE|TOMOX-HAIC|Oxaliplatin 85mg/m\^2 plus Raltitrexed 3mg/m\^2, 21 days for a cycle
48370742|NCT06285019|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle
48370743|NCT06285019|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, 21 days for a cycle
48370744|NCT00528125|PROCEDURE|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
48515458|NCT02390882|DRUG|Placebo|Placebo
48370745|NCT00528125|PROCEDURE|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
48370746|NCT05206201|DRUG|ZY19489 Capsule|Two part study with single and multiple dose
48370747|NCT05206201|DRUG|Placebo Capsule|Two part study with single and multiple dose
48515459|NCT02390882|DRUG|HGP0412 capsule|Tamsulon high dose
48515460|NCT02390882|DRUG|HIP1402 capsule|Tamsulon high dose
48515461|NCT05734612|DRUG|Colchicine|Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days.
48515462|NCT05734612|DRUG|Placebo (lactose)|Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.
48515463|NCT05644197|OTHER|Multidisciplinary program|"Multidisciplinary program:~* APA interventions: 12 weeks Each week at home, cardio-respiratory endurance sessions for muscle strengthening and balance work from the Autohome interface (Neuradom) and one week supervised by an APA teacher.~* Nutrition interventions: A group nutrition workshop at the Hôpital Privé de Provence.~* Psychological intervention:~  5 sessions of 1h30 in group, the first session will take place at the Private Hospital of Provence and the others by videoconference.~An individual session the week following the last group session.~-Visit with the urologist, 5 weeks after the prostatectomy."
48515464|NCT00586534|BEHAVIORAL|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
48010671|NCT06251076|DRUG|Teclistamab|Teclistamab is an antibody therapy (bispecific T-cell engager \[BiTE\]) that binds to two target proteins on different cells; CD3 on healthy T cells and B cell maturation antigen (BCMA) on myeloma cells. This brings healthy T cells and the myeloma cells close together so the T cells can more effectively kill them. Teclistamab is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
48010672|NCT06251076|DRUG|Tocilizumab|Toclilzumab is an interleukin inhibitor approved for the treatment of patients with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and other indications.
48010673|NCT02397356|DRUG|Ketamine first AB|Nebulised ketamine 1mg/kg
48010674|NCT02397356|DRUG|Placebo first BA|Nebulised saline 1-2ml
48698043|NCT02679144|DRUG|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
48010675|NCT02340234|DRUG|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
48010676|NCT02340234|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
48698044|NCT05215223|DEVICE|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
48010677|NCT02340234|DRUG|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
48010678|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, low dose
48370748|NCT00182793|BIOLOGICAL|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
48698045|NCT05215223|DEVICE|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
48370749|NCT00182793|DRUG|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
48370750|NCT00182793|DRUG|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
48370751|NCT00182793|DRUG|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
48698046|NCT04186988|DRUG|Fluorine F 18 Ara-G|Given IV
48010679|NCT05905458|DRUG|HRS9950 tablets|HRS9950 tablets, oral, once a week, high dose
48010680|NCT05905458|DRUG|HRS9950 placebo tablets|HRS9950 placebo tablets, oral, once a week.
48010681|NCT00548808|DRUG|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
48010682|NCT00548808|DRUG|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
48010683|NCT00548808|DRUG|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
48010684|NCT04115358|PROCEDURE|Hyaluronic acid: Gengigel teething|Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
48370752|NCT00182793|DRUG|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
48370753|NCT00182793|PROCEDURE|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
48515465|NCT00586534|BEHAVIORAL|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
48698047|NCT03647150|DRUG|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
48698048|NCT03647150|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
48698049|NCT03647150|BEHAVIORAL|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
48698050|NCT03585036|DRUG|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
48010685|NCT04115358|PROCEDURE|Formocresol Buckley formula: Formacresol|Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
48010686|NCT04115358|PROCEDURE|Ferric sulfate: ViscoStat|Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
48010687|NCT04122443|DRUG|Acetaminophen|Acetaminophen 650mg
48010688|NCT04122443|DRUG|Oxycodone|Oxycodone 10mg
48010689|NCT01728467|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
48010690|NCT01728467|DRUG|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
48010691|NCT04574947|DRUG|Intravenous lidocaine|Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
48010692|NCT04574947|DRUG|Intravenous placebo|During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
48010693|NCT04574947|PROCEDURE|Intra-cuff lidocaine|The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
48010694|NCT04574947|PROCEDURE|Intra-cuff placebo|The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
48010695|NCT05272930|DRUG|Dienogest|Assessment of fibromyalgia effects after the use of dienogest
48010696|NCT00473915|DRUG|fluticasone furoate|corticosteroid nasal spray
48168298|NCT05923398|BEHAVIORAL|Digital Intervention Group|"Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury."
48698051|NCT03585036|DRUG|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
48698052|NCT03585036|DRUG|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
48010697|NCT01971138|OTHER|this is a survey|
48010698|NCT01703481|DRUG|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
48010699|NCT01703481|DRUG|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
48010700|NCT01703481|DRUG|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
48168299|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
48168300|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
48698053|NCT01263678|BEHAVIORAL|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
48698054|NCT01263678|OTHER|Usual Care|Patient views DA and completes post DA survey.
48698055|NCT03065621|DRUG|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
48698056|NCT00327015|DRUG|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
48698057|NCT00327015|DRUG|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
48698058|NCT00327015|DRUG|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
48698059|NCT00327015|DRUG|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
48698060|NCT00327015|DRUG|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
48698061|NCT06511453|DEVICE|Acupressure (using AcuWand or pencil eraser)|"The acupressure procedure will consist of medium-deep pressure as tolerated at each assigned point applied in a circular motion. Subjects will be trained in the appropriate performance of the treatment at all points and complete the first treatment under supervision. Acupressure treatment will last for 2-3 minutes per point and be administered remotely every other day for 5 weeks.~Acupressure will be performed using a tool (AcuWand) and a pencil (the pencil's eraser head will be used as an alternative/backup tool) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. In the event AcuWand/pencil is not available, participants can use fingers/thumbs for self-acupressure."
48010701|NCT01703481|DRUG|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
48010702|NCT01624727|DIETARY_SUPPLEMENT|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
48010703|NCT04920851|DEVICE|cytokine hemadsorption|to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in COVID-19 ICU patients with or without sepsis.
48010704|NCT00179413|DRUG|PEG -Intron|
48010705|NCT00179413|DRUG|Colchicine|0.6mg twice a day
48370754|NCT00182793|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
48515466|NCT06119594|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Patients in the intervention group will use the connected scale at a minimum frequency of once a week from receipt of the scale and throughout their participation in the research (6 months)
48515467|NCT05094661|PROCEDURE|BiPAP|The patient recives respiratory support with bilevel positive airway pressure system until treatment improves or fails (needs intubation/dies).
48515468|NCT05094661|PROCEDURE|CPAP|The patient recives respiratory support with continuous positive airway pressure system until treatment improves or fails (needs intubation/dies).
48515469|NCT03624192|DEVICE|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
48515470|NCT03624192|OTHER|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
48515471|NCT01144715|DEVICE|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
48515472|NCT01144715|DEVICE|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
48515473|NCT01117571|DEVICE|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
48515474|NCT00005957|RADIATION|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
48010706|NCT00098839|DRUG|L-asparaginase|Given IM
48010707|NCT00098839|DRUG|doxorubicin hydrochloride|Given IV
48010708|NCT00098839|DRUG|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
48010709|NCT00098839|DRUG|vincristine sulfate|Given IV
48010710|NCT00098839|BIOLOGICAL|epratuzumab|Given IV
48010711|NCT00098839|DRUG|cytarabine|Given IT
48010712|NCT00098839|DRUG|prednisone|Given orally
48010713|NCT00098839|DRUG|pegaspargase|Given IM
48010714|NCT00098839|DRUG|dexrazoxane hydrochloride|Given IV
48010715|NCT00098839|DRUG|methotrexate|Given IT
48010716|NCT00098839|DRUG|etoposide|Given IV
48010717|NCT00098839|DRUG|cyclophosphamide|Given IV
48010718|NCT00098839|DRUG|leucovorin calcium|Given IV
48010719|NCT00098839|BIOLOGICAL|filgrastim|Given SC
48010720|NCT06374329|OTHER|Interceptive Slow Maxillary Expansion with removable plates|Interceptive Slow Maxillary Expansion with removable plates (see Willems et al 2023) https://doi.org/10.1093/ejo/cjad014
48370755|NCT00182793|PROCEDURE|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
48515475|NCT00005957|RADIATION|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
48515476|NCT05338931|DRUG|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
48515477|NCT04621344|DIAGNOSTIC_TEST|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
48515478|NCT02899195|DRUG|Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration. Maintenance: On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
48515479|NCT05311579|COMBINATION_PRODUCT|Niraparib plus anlotinib|"Niraparib QD D1-21 plus Anlotinib 10mg QD D1-14 until disease progression or intolerable toxicity~21days/cycle"
48515480|NCT00134901|DRUG|Memantine|Memantine
48010721|NCT03768739|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
48010722|NCT00251394|DRUG|Rituxan|Given intravenously once weekly for four weeks.
48010723|NCT00251394|DRUG|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
48010724|NCT00993785|DEVICE|Costar Coronary Stent Delivery System|
48010725|NCT01731704|RADIATION|Stereotactic radiosurgery (SRS)|
48010726|NCT01731704|RADIATION|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
48010727|NCT05740722|DIETARY_SUPPLEMENT|Nicotinamid riboside|500 mg x 2 po
48010728|NCT05740722|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
48010729|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
48010730|NCT04135716|DIAGNOSTIC_TEST|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
48010731|NCT01196767|DRUG|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine."
48010732|NCT05779566|DIAGNOSTIC_TEST|bone densitometry|bone densitometry every 6 month
48010733|NCT00121771|BIOLOGICAL|FP9 CS|
48010734|NCT00121771|BIOLOGICAL|MVA CS|
48010735|NCT02567396|OTHER|Laboratory Biomarker Analysis|Correlative studies
48010736|NCT02567396|OTHER|Pharmacological Study|Correlative studies
48168301|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
48168302|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
48515481|NCT00134901|DRUG|placebo|placebo
48515482|NCT03377257|DRUG|zolmitriptan by sublingual administration|Experimental group
48168303|NCT03630965|OTHER|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
48515483|NCT03377257|DRUG|zolmitriptan by oral|Active group
48515484|NCT03474874|DEVICE|NeoMatriX Collagen Dressing|Collagen wound dressing
48010737|NCT02567396|DRUG|Talazoparib|Given PO
48010738|NCT00153491|DRUG|artemether-lumefantrine|
48010739|NCT01872871|DRUG|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
48010740|NCT01872871|DRUG|Topical anaesthetic drop with placebo|
48010741|NCT03917134|DRUG|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
48010742|NCT03917134|DRUG|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
48010743|NCT00368940|BEHAVIORAL|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
48010744|NCT00368940|BEHAVIORAL|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
48168304|NCT00317447|DRUG|Oral Prednisone|
48168305|NCT00397137|PROCEDURE|Circular stapled anopexy|Patients receiving stapled anopexy to treat haemorrhoids
48168306|NCT00397137|PROCEDURE|Closed diathermy haemorrhoidectomy|Conventional haemorrhoidectomy as described by Ferguson method
48168307|NCT00614588|DEVICE|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
48010745|NCT02652533|DEVICE|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
48010746|NCT05994729|DIAGNOSTIC_TEST|Invasive Physiological Assessment of Coronary Circulation|After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.
48010747|NCT02407106|DIETARY_SUPPLEMENT|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
48168308|NCT03389451|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
48168309|NCT02867241|BEHAVIORAL|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
48168310|NCT02867241|BEHAVIORAL|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
48168311|NCT04019249|BEHAVIORAL|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
48168312|NCT04685109|DEVICE|Alocross 0.2% Unit Dose|Eye Drops
48010748|NCT06251713|OTHER|VeXUS score guided fluid management strategy|"During the first 3 postoperative days, the VeXUS score is estimated daily by ultrasound. If VeXUS score \>1, diuretic-induced fluid removal will be administred (target diuresis: 2-4mL/kg/h). The diuretic administration protocol is derived from the CARRESS HF study: bolus followed by a continuous administration of Furosemide with thiazide added based on preoperative diuretic administration status.~To prevent hypokalaemia and dysnatremia, a protocol for potassium supplementation and intravenous administration of chloride serum or hypotonic perfusion is planned.~Fluid removal will be suspended if severe metabolic disturbance (pH\>7.55 with HCO3-\>40mmol/L or serum K+ \<3 mmol/L or serum Na\>150 mmol/L) or haemodynamic instability (hypoperfusion) with fluid responsiveness occurs. Regardless of the VeXUS score, diuretics will be introduced in case of pulmonary oedema.~Haemodynamic status will be every 12 hours to detect side effects attributable to diuretic-induced fluid removal."
48370756|NCT00182793|RADIATION|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
48010749|NCT06251713|OTHER|Usual care|Fluid management will be at the discretion of attending physician, who will be blinded to the patient's VeXUS score status.
48010750|NCT04300296|DRUG|secukinumab 300 mg Q4W|secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
48010751|NCT04300296|DRUG|secukinumab 300 mg Q2W|secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
48168313|NCT04685109|DEVICE|Vismed|Eye drops
48168314|NCT03206476|BEHAVIORAL|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
48168315|NCT03206476|BEHAVIORAL|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
48168316|NCT06002633|OTHER|Alcohol|Participants will consume beverages containing alcohol.
48370757|NCT03285581|DEVICE|truSculpt RF|Subjects will receive RF treatments
48168317|NCT06002633|OTHER|Placebo|Participants will consume beverages containing a very low dose of alcohol (placebo condition).
48168318|NCT06477250|BEHAVIORAL|Empathy-based socio-emotional mental training|The goal of the EmCo dyad practice is to enhance coping with difficult emotions, empathic and compassionate listening, social sharing, acceptance, and gratitude. It involves a daily partner-based practice and weekly coaching sessions with expert teachers.
48168319|NCT04777097|OTHER|Blood sample|Two blood sample will be drawn. On the day of operation and the first postoperative day.
48370758|NCT00766870|DRUG|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
48370759|NCT00766870|DRUG|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
48370760|NCT00766870|DRUG|Placebo|Per oral doses, twice daily as capsules during 10 weeks
48370761|NCT01478490|DRUG|mirabegron|oral
48370762|NCT01478490|DRUG|metoprolol|oral
48370763|NCT04406259|DRUG|Verapamil|"Patients in groupe A require verapamil initiation as a preventive treatment and patients in group B are patients already undergoing a verapamil treatment for their Cluster Headache.~The doses of verapamil are increased for the patients in group A, after a clinical examination an electrocardiogram, and a blood test."
48370764|NCT02056808|DRUG|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
48370765|NCT06177925|DRUG|Adebrelimab|Adebrelimab intravenous infusion will be administered during the induction phase (Cycles 1-2 ) and maintenance phase.
48010752|NCT04300296|OTHER|Placebo|Matching placebo administered via a pre-filled syringe
48010753|NCT02803710|OTHER|Microbiological study|
48010754|NCT03788733|DRUG|Melatonin 3 mg|1 time a day for 8 weeks
48010755|NCT03788733|DRUG|Placebo Oral|1 time a day for 8 weeks
48370766|NCT06177925|DRUG|Carboplatin/Cisplatin|Carboplatin/Cisplatin intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
48698062|NCT03305549|OTHER|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen \>112 mg/dL (40 mmol/L)~* Serum potassium concentration \>6 mmol/L~* Serum potassium concentration \>5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min to maintain SpO2 \>95% or requiring FiO2 \>50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
48698063|NCT03305549|OTHER|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
48698064|NCT05359874|DRUG|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
48698065|NCT06115473|DRUG|epinephrine|patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
48698066|NCT06115473|DRUG|isotonic fluid|patients will receive IV bolus isotonic fluid 500 ml
48698067|NCT03629340|DRUG|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
48698068|NCT03629340|DRUG|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
48698069|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The patient's back was prepared for surgery. They were positioned on their side, with the operative side facing upward. The L3-4 spinal interspace was identified, and numbed, and a thin spinal needle was inserted. After confirming Cerebrospinal Fluid (CSF), 12.5 mg of isobaric bupivacaine 0.5% was injected into the spinal canal.
48698070|NCT06625606|DRUG|Bupivacaine 0.5% Injectable Solution|The L3-4 spinal interspace was identified, numbed, and a thicker needle (Tuohy needle) was inserted. After confirming Cerebrospinal Fluid (CSF), a thin catheter was inserted into the spinal canal and secured. An initial dose of 1 ml isobaric bupivacaine 0.5% was injected, followed by additional doses as needed to maintain the block height.
48010756|NCT02309385|DRUG|8% Dexamethasone Sodium Phosphate - Visulex|
48010757|NCT02309385|DRUG|15% Dexamethasone Sodium Phosphate - Visulex|
48010758|NCT02309385|DRUG|Prednisolone Acetate (1%) Eye Drops|
48010759|NCT01257594|DRUG|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
48010760|NCT01257594|PROCEDURE|Cytoreductive Surgery|Standard procedure
48010761|NCT05550012|OTHER|low-dose CT|those patients undergo low-dose liver CT in portal vein and delayed phase.
48010762|NCT01180712|DIETARY_SUPPLEMENT|Mirtoselect|"Male subjects (BMI \> 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
48010763|NCT03212963|DRUG|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
48370767|NCT06177925|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase, concurrent chemoradiotherapy phase and maintenance phase(Cycles 1-4 or 6).
48010764|NCT04341480|DRUG|Chemotherapy|Routine chemotherapy for individual tumor type.
48010765|NCT00132340|DEVICE|Electrodes|
48010766|NCT06193434|DRUG|IBI356 for MAD|Receive IBI356 in a multiple dose.
48010767|NCT06193434|DRUG|Dupilumab for MAD|Active comparator
48515485|NCT03959111|OTHER|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
48515486|NCT03959111|OTHER|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
48515487|NCT03161977|OTHER|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
48515488|NCT06116630|DIAGNOSTIC_TEST|DCE-MRI|Both groups will undergo DCE-MRIs.
48515489|NCT05671536|BEHAVIORAL|motivational interview|Intervention arm will receive motivational interview by the researcher, once a month for 4 times at least 20 minutes. The researcher received education about motivational interview.
48370768|NCT06177925|RADIATION|Radiation therapy|IMRT for thoracic of 45--55Gy in 15-22 fractions，SBRT for metastases during the concurrent chemoradiotherapy phase
48370769|NCT02973399|DRUG|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
48370770|NCT00438815|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
48370771|NCT02144662|DRUG|Ranibizumab|0.5mg ranibizumab intravitreal injection
48370772|NCT04392531|DRUG|Cyclosporine|In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
48370773|NCT04392531|DRUG|Standard treatment|Standard of care according to hospital protocol
48370774|NCT04630067|DRUG|AZD3427|Participants will receive SC or IV dose of AZD3427 as per the arm they are randomized.
48370775|NCT04630067|DRUG|Placebo|Participants will receive SC or IV dose of placebo matched to AZD3427 as per the arm they are randomized.
48370776|NCT03108560|PROCEDURE|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
48370777|NCT03108560|PROCEDURE|lobectomy|patients receive lobectomy
48370778|NCT02127931|DEVICE|Groundskeeper for ADHD group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
48515490|NCT03774355|DRUG|CG1801|Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
48515491|NCT03774355|DRUG|CGL1802|Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
48698071|NCT06625606|DRUG|Isoflurane Inhalant Product|General anesthesia was initiated with propofol and rocuronium. Anesthesia was maintained with isoflurane, with additional rocuronium and fentanyl as needed. Breathing was controlled by the ventilator, and muscle relaxation was reversed at the end of surgery.
48370779|NCT02127931|DEVICE|Groundskeeper for control group|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
48370780|NCT05682638|BIOLOGICAL|LVRNA009|100μg/1.0ml/dose(50 μg/0.5ml/Vial), 2 injection with 28 days apart
48370781|NCT05682638|OTHER|0.9%NaCl|1.0ml/dose, 2 injection with 28 days apart
48370782|NCT04393961|DEVICE|Premier Biotech COVID-19 IgG/IgM Rapid test Cassette|"Current emergency situation, there are large numbers of COVID-19 Antibody tests being made available at a record pace.~The protocol is designed to be test agnostic. However, for this first volley, we have chosen the The COVID-19 IgG and IgM Rapid Test provided by Premier Biotech.~We chose the Precision Bio test for 4 reasons~1. It is available as a single use test kit in one sealed unit.~2. It's a rapid test, with results available in 10 minutes.~3. It has clear and easy to read instructions already included~4. It has one of the lowest false positive rates of known tests at the moment"
48370783|NCT00563927|PROCEDURE|Conventional RT|
48370784|NCT00563927|DRUG|Cisplatin|
48515492|NCT04460287|DIETARY_SUPPLEMENT|DHA Wet Mixing method|Children will drink milk contain 100 mg DHA wet mixing daily for 30 days
48515493|NCT04460287|DIETARY_SUPPLEMENT|DHA Dry Blending Method|Children will drink milk contain 100 mg DHA dry blending daily for 30 days
48515494|NCT04460287|DIETARY_SUPPLEMENT|Fish Oil|Children will have this intervention every day for 30 days
48515495|NCT04876105|OTHER|Assesment of treatment preference|Multiple-choice survey questions were created by the researchers based on the studies in the literature regarding the pain and treatment preferences of the participants
48515496|NCT04778904|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
48698072|NCT06056895|PROCEDURE|Biopsy|Undergo tumor biopsy
48698073|NCT06056895|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48698074|NCT06056895|PROCEDURE|Computed Tomography|Undergo CT/MRI
48698075|NCT06056895|PROCEDURE|Magnetic Resonance Imaging|Undergo CT/MRI
48698076|NCT06056895|BIOLOGICAL|Retifanlimab|Given IV
48370785|NCT00563927|DRUG|5-fluorouracil|
48698077|NCT06056895|DRUG|Tuparstobart|Given IV
48698078|NCT06056895|DRUG|Verzistobart|Given IV
48698079|NCT00057733|PROCEDURE|psychosocial assessment and care|
48698080|NCT00057733|PROCEDURE|quality-of-life assessment|
48698081|NCT02542033|OTHER|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
48698082|NCT02542033|OTHER|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
48698083|NCT06034743|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths:~* 1 mg per tablet for 1 mg baxdrostat Arm;~* 2 mg per tablet for 2 mg baxdrostat Arm."
48698084|NCT06034743|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
48698085|NCT00116675|DRUG|Resiquimod|
48698086|NCT04005508|DIAGNOSTIC_TEST|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
48168320|NCT06357936|PROCEDURE|nano-fat grafting in chronic limb ischaemia|The nano fat grafting procedure in the clinical trial involves the collection of adipose tissue under tumescent anesthesia, which is a technique to swell and firm the targeted area, through a separate puncture in the anterior abdominal wall. Following the collection, the adipose tissue undergoes a process of cannulation to prepare the nano fat. This prepared material is then injected into the tissues of the foot and leg using standard intramuscular injection needles. The injections are performed in various directions to ensure proper distribution of the nano fat. This method does not require additional drug therapy. It leverages the natural growth factors and stem cells present in adipose tissue, aiming to improve blood flow and tissue regeneration in limbs affected by critical ischemia. The unique aspect of this treatment is its focus on using autologous materials, minimizing the risk of rejection and side effects associated with foreign substances.
48370786|NCT02104726|OTHER|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
48370787|NCT02104726|OTHER|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
48370788|NCT00106769|DRUG|VRC-WNVDNA017-00-VP|
48370789|NCT01858701|DEVICE|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
48370790|NCT01858701|DEVICE|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
48370791|NCT06234566|PROCEDURE|Conventional dental implant surgery|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
48370792|NCT06234566|PROCEDURE|Low Speed Drilling Without Irrigation|It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
48370793|NCT03539120|OTHER|Follow up for survival|No intervention, this is an observational study of survival outcomes.
48515497|NCT04778904|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
48515498|NCT04778904|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
48515499|NCT06239727|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1."
48698087|NCT01303718|DEVICE|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
48698088|NCT01303718|OTHER|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
48698089|NCT02140008|DEVICE|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
48698090|NCT02140008|DEVICE|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
48698091|NCT00771043|DRUG|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
48010768|NCT06193434|DRUG|IBI356 for SAD|Receive IBI356 in a single dose.
48010769|NCT06193434|DRUG|Placebo for SAD|Receive placebo in a single dose.
48370794|NCT02985996|DRUG|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
48370795|NCT02985996|DRUG|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
48515500|NCT06239727|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
48515501|NCT06239727|DRUG|Cisplatin (80 mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
48515502|NCT06239727|RADIATION|Reduced-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F."
48698092|NCT02305849|DRUG|Peficitinib|oral tablet
48698093|NCT02305849|DRUG|Placebo|oral tablet
48010770|NCT06193434|DRUG|Placebo for MAD|Receive placebo in a multiple dose.
48515503|NCT06239727|RADIATION|Conventional-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F."
48698094|NCT02305849|DRUG|Methotrexate|Oral tablet/capsule
48698095|NCT01747343|BEHAVIORAL|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
48515504|NCT06239727|DRUG|Cisplatin (100 mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
48698096|NCT04083508|OTHER|Mosquito bites|Successful feeding of 5 infected P. vivax mosquitoes
48168321|NCT06357936|PROCEDURE|sham comparator|For the clinical trial, a sham procedure would be designed to mimic the nano fat grafting without providing the actual therapeutic intervention. This involve the patient undergoing a similar process with tumescent anesthesia and making a puncture on the anterior abdominal wall. However, instead of harvesting adipose tissue and preparing nano fat, a placebo solution (such as saline) would be injected using the same intramuscular injection technique. The aim of this sham comparator is to assess the psychological and physiological effects of the nano fat grafting procedure itself, by eliminating the potential therapeutic benefits of the nano fat.
48168322|NCT01271153|DRUG|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
48168323|NCT01271153|DRUG|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
48168324|NCT00221702|DRUG|PegIntron|100 mcg SC/week for 36 months
48168325|NCT00221702|DRUG|intron A|3mui TIWW SC for 18 months
48168326|NCT04372537|BEHAVIORAL|hypnosis|use of hypnosis.
48168327|NCT04372537|BEHAVIORAL|standard care|standard clinical procedure
48168328|NCT06278753|DIAGNOSTIC_TEST|carbon dioxide cystoscopy|Using carbon dioxide medium for filling bladder
48168329|NCT02160678|DRUG|Vehicle|Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
48168330|NCT02160678|DRUG|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
48168331|NCT02160678|DRUG|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
48168332|NCT01989923|OTHER|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
48168333|NCT01989923|DEVICE|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
48168334|NCT02795819|DRUG|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
48168335|NCT02795819|DRUG|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
48168336|NCT00816621|BEHAVIORAL|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
48168337|NCT00816621|BEHAVIORAL|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
48168338|NCT00333281|DRUG|tadalafil|
48168339|NCT00726388|DRUG|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
48168340|NCT06050083|BEHAVIORAL|Hypnosis audio recordings|Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
48370796|NCT04620005|OTHER|Observational|Survey
48515505|NCT06239727|DRUG|Capecitabine|Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
48515506|NCT03010683|DRUG|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
48515507|NCT03010683|DRUG|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
48515508|NCT01266031|DRUG|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
48698097|NCT05847660|DRUG|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
48698098|NCT05847660|DRUG|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
48698099|NCT06153849|DIAGNOSTIC_TEST|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
48698100|NCT03867266|PROCEDURE|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
48168341|NCT04996537|OTHER|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
48168342|NCT05203224|DRUG|Dornase Alfa|Intravenous Dornase alfa
48010771|NCT04698161|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
48168343|NCT03743129|DRUG|Anlotinib|Anlotinib 12mg p.o, qd
48168344|NCT00001234|GENETIC|human glucocerebrosidase cDNA|
48168345|NCT06105996|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
48168346|NCT03044002|DEVICE|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
48168347|NCT03044002|DEVICE|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
48168348|NCT04356638|DRUG|Midazolam|Oral Midazolam and intranasal placebo
48168349|NCT04356638|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine and oral placebo
48168350|NCT04356638|OTHER|Placebo|Placebo orally and intranasally
48168351|NCT02555488|DEVICE|diode laser|MB and diode
48168352|NCT02555488|DEVICE|diode laser|diode laser
48168353|NCT02555488|DRUG|Methylene blue|Methylene blue and diode laser was used
48168354|NCT01376050|DEVICE|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
48168355|NCT01376050|DEVICE|Placebo Laser|Placebo Laser has no therapeutic output emitted.
48168356|NCT05384236|OTHER|kinesiology taping|To apply kinesiology taping in plantar fascia
48010772|NCT04698161|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
48010773|NCT04698161|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
48010774|NCT05703191|DEVICE|Nitric Oxide Generator and Delivery System|Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
48010775|NCT03996785|BEHAVIORAL|Walking in Urban setting|Walking for 60 minutes as described above
48010776|NCT03996785|BEHAVIORAL|Walking in nature setting|Walking for 60 minutes as described above
48010777|NCT01829932|DIETARY_SUPPLEMENT|Factor Altered Diet|
48010778|NCT03618797|DRUG|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
48010779|NCT03618797|DRUG|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
48010780|NCT03460522|DRUG|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (only maintenance) after Inotuzumab Ozogamicin.
48010781|NCT06050408|DEVICE|1hz repetitive transcranial magnetic stimulation|1hz rTMS applied over P3 EEG 10-20 location. Total of 1200 pulses administered. Figure of eight coil used to stimulate, held tangential to the scalp.
48010782|NCT05216367|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral dose on the morning of day 1 under fasting conditions
48010783|NCT02554110|DEVICE|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
48168357|NCT05384236|OTHER|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
48168358|NCT02981537|DEVICE|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
48168359|NCT02981537|DEVICE|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
48168360|NCT05450640|OTHER|satisfaction survey|1 eQuestionnaire per patient completed during study
48168361|NCT04039555|DEVICE|CO2 intimate|Two sessions with CO2 intimate laser for vaginal symptoms treatment
48168362|NCT04039555|DEVICE|Erbium-yag|Two sessions with Erbium-yag laser for vaginal symptoms treatment
48168363|NCT04039555|DEVICE|CO2 intimate or Erbium-yag|Two sessions of one of the two lasers with no therapeuthical energy
48168364|NCT03695198|DRUG|LY3361237 - SC|LY3361237 administered SC
48168365|NCT03695198|DRUG|LY3361237 - IV|LY3361237 administered IV
48168366|NCT03695198|DRUG|Placebo - SC|Placebo administered SC
48168367|NCT03695198|DRUG|Placebo - IV|Placebo administered IV
48168368|NCT04528290|DRUG|Ozanimod|Ozanimod capsule formulation of 0.92mg
48168369|NCT04528290|DRUG|Ozanimod|Ozanimod, granule formulation of 0.92mg
48168370|NCT00772655|DRUG|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 \[if platelets are below 150000/µl only 11 MBq/kg are administered).
48168371|NCT00772655|DRUG|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
48168372|NCT00000236|DRUG|Buprenorphine/naloxone|
48515509|NCT01266031|DRUG|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
48515510|NCT02630576|DEVICE|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
48515511|NCT00452556|DRUG|Docetaxel|Weekly
48010784|NCT02554110|DEVICE|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
48010785|NCT04708327|DRUG|STAT-205|naltrexone hydrochloride capsules 4.5 mg each
48010786|NCT00394797|PROCEDURE|mitral valve annuloplasty|
48010787|NCT01121211|DRUG|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
48010788|NCT01121211|DRUG|Placebo|Placebo transdermal patch x 24 weeks
48010789|NCT01417832|DRUG|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
48698101|NCT02022761|DRUG|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
48698102|NCT00245050|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
48698103|NCT00245050|DRUG|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
48010790|NCT01417832|DRUG|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
48010791|NCT05041088|DIETARY_SUPPLEMENT|ProdromeNeuro Plasmalogen|The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
48168373|NCT02780739|BEHAVIORAL|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
48370797|NCT00496782|DRUG|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
48515512|NCT00452556|DRUG|Leuprolide Acetate (Eligard®)|2.5 years
48698104|NCT00245050|DRUG|doxorubicin HCL liposome|IV, 40mg/m2
48698105|NCT04362488|PROCEDURE|Preoperative evaluation|"Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
48698106|NCT04362488|PROCEDURE|Postoperative evaluation|"Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
48698107|NCT01493102|DRUG|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
48010792|NCT01443442|DRUG|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
48010793|NCT01443442|DRUG|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
48010794|NCT02133729|OTHER|Blood sampling and OGTT|
48010795|NCT01632371|DEVICE|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
48010796|NCT01632371|DEVICE|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
48698108|NCT01493102|DRUG|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
48698109|NCT04894344|BEHAVIORAL|Education group|Is taught to choose low-sodium foods
48698110|NCT02255058|OTHER|No intervention|The study is a Prospective observational cohort study
48698111|NCT01289288|BEHAVIORAL|Mailed printed materials and in-office training|"1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients"
48010797|NCT00349492|DRUG|IP|irinotecan+cisplatin
48010798|NCT03218722|DRUG|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
48010799|NCT03218722|DRUG|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
48010800|NCT02808845|OTHER|microalbuminuria|
48010801|NCT05448664|BEHAVIORAL|Family HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students and their parents in the following 24 weeks.
48010802|NCT05448664|BEHAVIORAL|Adolescent HBM- mobile messaging|The intervention will consist of two blocks of text messaging based on HBM model, the messages will be sent to the students in the following 24 weeks.
48698112|NCT03558269|BIOLOGICAL|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
48698113|NCT00346879|DRUG|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
48010803|NCT05448664|BEHAVIORAL|Adolescent e-pamphlets|The contents of e-version of three pamphlets, published by Department of Health (http://www.toothclub.gov.hk/en/en_index.html) will be distributed in an electronic form and sent via a mobile message.
48168374|NCT02780739|BEHAVIORAL|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills \& Skills; and Cool-down/stretch.
48168375|NCT02780739|BEHAVIORAL|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
48168376|NCT02780739|DEVICE|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
48168377|NCT02780739|DEVICE|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
48168378|NCT02780739|BEHAVIORAL|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
48370798|NCT00496782|PROCEDURE|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
48698114|NCT01900171|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
48698115|NCT01900171|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
48698116|NCT05551923|OTHER|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
48698117|NCT06616740|OTHER|Cricoid pressure|Cricoid pressure will be applied during LMA ProSeal insertion.
48698118|NCT06616740|OTHER|Paratracheal pressure|Pratracheal pressure will be applied during LMA ProSeal insertion.
48698119|NCT05723562|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
48698120|NCT02643615|DEVICE|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
48010804|NCT02227524|OTHER|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
48010805|NCT02227524|DEVICE|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
48010806|NCT02227524|DEVICE|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
48010807|NCT02227524|DEVICE|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
48010808|NCT02842502|PROCEDURE|Collection of supernumerary biopsies during skin graft pellet procedure|
48010809|NCT03978481|COMBINATION_PRODUCT|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
48698121|NCT02643615|DEVICE|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
48010810|NCT01486563|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
48010811|NCT01486563|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
48010812|NCT00424372|DRUG|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
48010813|NCT01384058|DRUG|ezetimibe|ezetimibe 10 mg per day for six weeks
48168379|NCT04205214|BEHAVIORAL|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
48168380|NCT04827186|PROCEDURE|Spleen Transplantation/Removal|Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
48168381|NCT02873325|OTHER|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
48698122|NCT02643615|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
48168382|NCT01916798|DRUG|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
48168383|NCT04301700|BEHAVIORAL|mindfullness and relaxation|three arms: mindfullness and relaxation
48168384|NCT02945371|BEHAVIORAL|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
48370799|NCT05762315|BEHAVIORAL|Audio Storytelling|The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
48698123|NCT02643615|DRUG|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
48698124|NCT00377845|PROCEDURE|Regular Tampax used in 3 hours|
48698125|NCT01253694|DRUG|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
48698126|NCT03130621|DIAGNOSTIC_TEST|Gene detection|Next-generation sequencing
48698127|NCT01060449|OTHER|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
48698128|NCT06658444|OTHER|Phonophoresis|Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
48010814|NCT01384058|DRUG|simvastatin|Simvastatin 20 mg per day for six weeks
48010815|NCT01384058|DRUG|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
48010816|NCT02760134|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
48010817|NCT05993728|BEHAVIORAL|Body Project|The Body Project prevention program is a body acceptance program to promote a healthy body image and prevent eating disorder onset.
48010818|NCT05993728|BEHAVIORAL|Psychoeducational control|Participants randomized to the educational control condition will receive videos addressing body image and eating disorders
48010819|NCT04460664|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
48010820|NCT06218043|BEHAVIORAL|Restrict subjects' intake of iodine-containing foods|Replace subjects' iodized salt with non-iodized salt.
48010821|NCT03987373|OTHER|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
48010822|NCT04939623|DRUG|Probenecid|The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
48010823|NCT03604055|PROCEDURE|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
48010824|NCT01236196|BEHAVIORAL|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
48698129|NCT06658444|OTHER|sham ultrasound|sham ultrasound
48168385|NCT02945371|BEHAVIORAL|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
48168386|NCT02886234|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
48168387|NCT02886234|BEHAVIORAL|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
48168388|NCT05959863|DIAGNOSTIC_TEST|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
48168389|NCT03781947|DRUG|teverelix TFA|A single s.c. or i.m. injection of teverelix TFA administered on Day 1
48168390|NCT02720198|DRUG|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
48168391|NCT02720198|DRUG|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
48168392|NCT01201915|DRUG|Vismodegib|Vismodegib was supplied in gelatin capsules.
48168393|NCT03830515|DEVICE|microMend|Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
48698130|NCT03403361|DEVICE|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
48698131|NCT03403361|DEVICE|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
48698132|NCT06397937|BEHAVIORAL|SHIFT team intervention|The SHIFT team, comprising a community health worker (CHW), community social worker (CHW), and community nurse (CN) will visit the participant starting within 72 hours of hospital discharge and provide social service referrals related to food insecurity, housing, immigration, and employment, and assist with medical appointment preparation (CHW), deliver individualized counseling focused on coping skills, reducing caregiver strain, and the psychological distress associated with experiences of racism and SDOH (CSW), and address health literacy and review of treatment goals and medications (CN).
48698133|NCT02839720|OTHER|Laboratory Biomarker Analysis|Correlative studies
48168394|NCT01092988|DEVICE|Exablate 2100|MR guided focused ultrasound
48370800|NCT05693233|DEVICE|EXO On, EXO Off, EXO Removed treadmill (Uphill_incline 10°) walking and simultaneous evaluation|"- After filling out the consent form for 10 subjects who meet the selection criteria, a total of three evaluations are conducted: one pre-evaluation and one post-evaluation for the knee assist robot and hip assist robot.~Pre-evaluation: Evaluation simultaneously with walking on an inclined treadmill (Uphill_incline 10°) for 5 minutes without wearing knee and hip assist robots (speed 1.5 m/s)."
48698134|NCT02839720|DRUG|Selumetinib Sulfate|Given PO
48698135|NCT00263042|DRUG|Rimonabant|Tablet, oral administration
48698136|NCT00263042|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
48698137|NCT05980104|BEHAVIORAL|Empowered Relief|The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
48010825|NCT01236196|BEHAVIORAL|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
48168395|NCT05849571|OTHER|coconut oil|• The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.
48168396|NCT02189577|DRUG|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
48698138|NCT02319616|DRUG|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
48698139|NCT02319616|DRUG|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
48698140|NCT04203316|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48698141|NCT04203316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48698142|NCT04203316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48698143|NCT04203316|DRUG|Enasidenib|Given PO
48698144|NCT04203316|DRUG|Enasidenib Mesylate|Given PO
48698145|NCT06661057|DEVICE|Vivally system stimulation|During the first month, participants will do the stimulation at different time points: 1) supine while in bed, 2) seated in the morning, 3) sitting in the afternoon, and 4) sitting in the evening. Participants will measure the circumference of their ankle prior to each use. Participants will use the System for an additional 2 months with the preferred stimulation parameters based on the study team's recommendations from the first month of use.
48698146|NCT02551094|DRUG|colchicine|0.5 mg tablet taken once a day
48698147|NCT02551094|DRUG|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
48698148|NCT04429386|PROCEDURE|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
48698149|NCT03388866|DRUG|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
48698150|NCT03388866|OTHER|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
48698151|NCT00487942|DRUG|armodafinil|50 mg/day armodafinil
48698152|NCT00487942|DRUG|armodafinil|100 mg/day armodafinil
48698153|NCT00487942|DRUG|armodafinil|200 mg/day armodafinil
48168397|NCT02189577|DRUG|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
48698154|NCT00487942|DRUG|placebo|placebo
48370801|NCT01723358|DEVICE|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
48370802|NCT03104465|BEHAVIORAL|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
48370803|NCT03960788|DRUG|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
48370804|NCT02528331|DEVICE|Transcranial magnetic stimulation|
48370805|NCT02528331|BEHAVIORAL|Cognitive behavioral therapy|
48370806|NCT02061293|DRUG|Psilocybin|
48698155|NCT05342012|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
48698156|NCT05342012|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|(Nitrate depleted beetroot juice
48698157|NCT03635424|DEVICE|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
48698158|NCT05705778|PROCEDURE|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
48698159|NCT00433966|DRUG|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
48698160|NCT00433966|DRUG|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
48698161|NCT00433966|DEVICE|Bare metal stent|Uncoated bare metal stent
48698162|NCT00433966|DEVICE|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
48698163|NCT01140997|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
48698164|NCT01140997|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
48370807|NCT02061293|DRUG|Diphenhydramine|
48168398|NCT03120299|DRUG|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
48168399|NCT03120299|DRUG|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
48168400|NCT00364221|DRUG|Rosiglitazone|
48168401|NCT05598606|DRUG|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
48168402|NCT05598606|DRUG|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
48168403|NCT01701271|OTHER|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
48168404|NCT01961921|DRUG|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
48168405|NCT02960256|DEVICE|ekocardiogram test|ekocardiogram test
48168406|NCT02591797|PROCEDURE|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~1. Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~2. Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~3. anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~4. Syringe: carpule syringe-conventional harpoon with suction system."
48168407|NCT03787238|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation using the gammaCore Sapphire device
48698165|NCT04148196|OTHER|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
48698166|NCT00054327|DRUG|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
48698167|NCT00054327|DRUG|cyclophosphamide|Given IV
48698168|NCT00054327|DRUG|cytarabine|Given IV
48698169|NCT00054327|RADIATION|radiation therapy|Patients undergo total body irradiation
48698170|NCT00054327|DRUG|Etoposide|infusion
48698171|NCT00054327|PROCEDURE|Stem Cell Transfusion|
48168408|NCT01885936|DRUG|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
48168409|NCT01885936|DRUG|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
48168410|NCT05610059|OTHER|Blood Pressure Technology System M|Participants will be provided the blood pressure technology system M. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
48168411|NCT05610059|OTHER|Blood Pressure Technology System E|Participants will be provided the blood pressure technology system E. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
48370808|NCT02061293|BEHAVIORAL|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
48370809|NCT06085222|BEHAVIORAL|Emotional Engagement Distress Tolerance Intervention|2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress
48370810|NCT06085222|BEHAVIORAL|Health Education Intervention|2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
48370811|NCT01617265|PROCEDURE|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
48370812|NCT01617265|PROCEDURE|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
48370813|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 66%33%|Salt substitute composed of 66% potassium chloride and 33% sodium chloride
48370814|NCT05638009|DIETARY_SUPPLEMENT|Salt substitute 33%/66%|Salt substitute composed of 33% potassium chloride and 66% sodium chloride
48370815|NCT06003283|DRUG|Rituximab|IV rituximab
48370816|NCT03514160|BEHAVIORAL|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
48370817|NCT00334893|DRUG|eribulin mesylate|Given IV
48370818|NCT02743117|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of 10\^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
48010826|NCT00624117|BEHAVIORAL|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
48010827|NCT02193594|RADIATION|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
48698172|NCT03831516|DIAGNOSTIC_TEST|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
48698173|NCT05743556|DEVICE|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
48698174|NCT05743556|DEVICE|TRT therapy|application of radiofrekvention therapy on cervical muscles
48698175|NCT00704483|DRUG|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
48698176|NCT00704483|DRUG|Sevelamer HCl|0.8 g tid
48698177|NCT00704483|DRUG|SBR759|1.5 g tid
48698178|NCT00704483|DRUG|Sevelamer HCl|1.6 g tid
48698179|NCT00274859|DRUG|gemcitabine hydrochloride|
48698180|NCT00274859|DRUG|oxaliplatin|
48698181|NCT06481371|DRUG|zuojinwan|In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
48370819|NCT02743117|OTHER|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
48010828|NCT02193594|PROCEDURE|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
48010829|NCT02193594|DRUG|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA\>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
48168412|NCT00961298|DRUG|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
48168413|NCT05317221|OTHER|Not an extra intervention, tissue taken in routine practice will be used.|No extra intervention: using tumour tissue taken during surgery in standard of care.
48168414|NCT05054283|DIAGNOSTIC_TEST|Inflamatory biomarkers|laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.
48168415|NCT05394389|OTHER|sensory stimulating therapy|therapy session in the snoozlen room accompanied by social support.
48168416|NCT05394389|OTHER|social support|ten minutes of conversing.
48698182|NCT06481371|DRUG|Rabeprazole sodium enteric-coated tablets|For epigastric pain syndrome
48010830|NCT02037711|DRUG|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
48010831|NCT02037711|DRUG|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
48515513|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
48698183|NCT06481371|DRUG|mosapride citrate|Postprandial discomfort syndrome
48698184|NCT04334135|DIETARY_SUPPLEMENT|MitoQ|Four to eight 20mg capsules (depending on body mass)
48698185|NCT02392390|PROCEDURE|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
48698186|NCT02392390|DRUG|Metvixia cream|
48698187|NCT00306293|DRUG|valacyclovir|valacyclovir
48698188|NCT01377610|DRUG|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
48698189|NCT01377610|DRUG|Buprenorphine|Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
48698190|NCT01377610|DRUG|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
48698191|NCT03654404|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
48698192|NCT01667224|DIETARY_SUPPLEMENT|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
48010832|NCT05880433|DEVICE|NIRS(INVOS 5100; Covidien Somanetics, Troy, MI|NIRS (Near Infrared Spectroscopy) is a non-invasive, bedside device that measures the concentration of oxygenated and deoxygenated hemoglobin in tissue, providing information about tissue oxygenation. Its working mechanism is based on the ability of light with wavelengths between 700-1000 nm to penetrate up to 8 cm into the skin and brain tissue. It offers continuous information about tissue oxygenation in different regions using probes attached to the skin. While pulse oximeters indicate arterial oxygen saturation, they are insufficient in detecting tissue-level hypoxia. Therefore, NIRS, being a painless method, is frequently used in the monitoring of newborns in the intensive care unit.
48010833|NCT02384603|OTHER|Global postural reeducation|
48515514|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
48515515|NCT06549946|BIOLOGICAL|Ixovex-1|Ixovex-1 is a novel oncolytic human adenovirus serotype 5.
48698193|NCT01667224|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Actiponin.
48698194|NCT02305017|DRUG|BIA 9-1067|BIA 9-1067 50 mg
48698195|NCT02305017|DRUG|Paracetamol|Paracetamol 1g
48698196|NCT03857360|DIETARY_SUPPLEMENT|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
48698197|NCT03857360|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
48698198|NCT04353999|PROCEDURE|Socket sealing by diode laser photocoagulation|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed using 980 nm diode laser photocoagulation applied in a non-contact mode with a poer output of 1 watt in a continuous wave mode for 3-5 minutes
48698199|NCT04353999|PROCEDURE|socket sealing with dense polytetrafluroethylene membrane|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed by a non-resorbable dPTFE membrane that is stabilized by suturing to the soft tissue margins of the socket
48168417|NCT04892602|DIAGNOSTIC_TEST|Serum vitaminDlevel|Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
48168418|NCT01355822|DRUG|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
48168419|NCT01355822|DRUG|Placebo control|orally, twice daily
48515516|NCT06549946|BIOLOGICAL|Pembrolizumab|Humanised antibody
48515517|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
48515518|NCT01331850|DRUG|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
48515519|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
48515520|NCT01331850|DRUG|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
48515521|NCT01331850|DRUG|RO5024048|1000 mg oral doses twice a day for 24 weeks
48698200|NCT06662370|OTHER|Replacement of the esophagus with a decellularized human esophagus graft|The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.
48698201|NCT05223348|OTHER|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
48010834|NCT02384603|OTHER|Segmental muscle stretching exercises|
48698202|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
48010835|NCT02384603|OTHER|Cognitive behavioral therapy|
48168420|NCT06104384|BEHAVIORAL|Behavioral and supportive therapy|Behavioral and supportive therapy
48370820|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
48010836|NCT04770376|OTHER|Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.|Collection of blood samples during blood draws performed before each cycle of chemotherapy as per clinical practice.
48010837|NCT02579616|DRUG|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
48010838|NCT02459314|DIETARY_SUPPLEMENT|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
48010839|NCT02459314|DIETARY_SUPPLEMENT|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
48010840|NCT04935307|DIAGNOSTIC_TEST|MRI and paraclinical tests|The patients and controls will be evaluated using MRI and furthermore a large test battery of questionnaires and paraclinical tests. Including the following test: MCS checklist, BDS-Checklist, Symptom Checklist-92 (SCL-92), Whiteley-8, SF-36, Major Depression Inventory (MDI), GAD-10 anxiety scale, and related questionnaire, behavioral olfactory test (TDI), habituation test, pain measurement thresholds tests, Heart Rate Variability and cognitive testing.
48010841|NCT02720926|DRUG|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
48010842|NCT02720926|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
48698203|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
48698204|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
48698205|NCT06659913|BEHAVIORAL|Exercise training|Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
48698206|NCT02885480|BEHAVIORAL|questionnaires|
48698207|NCT03849053|OTHER|Mézières Therapy for Low back pain|Spinal muscular global stretching
48698208|NCT04396873|DRUG|11C-MC1|Injected IV followed by PET scanning
48698209|NCT04396873|DRUG|11C-PS13|Injected IV followed by PET scanning
48698210|NCT04396873|DRUG|18f-florbetaben|Injected IV followed by PET scanning
48698211|NCT03791281|BEHAVIORAL|BASIS|
48698212|NCT03791281|BEHAVIORAL|Attention Control|
48698213|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
48698214|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
48010843|NCT02720926|DRUG|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
48010844|NCT06122324|DRUG|Lidocaine Hydrochloride|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
48010845|NCT05651009|PROCEDURE|TKA|Total knee artroplasty with medial parapatellar incision and mechanical alignment without navigation
48168421|NCT03703141|DIETARY_SUPPLEMENT|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
48168422|NCT02915354|DRUG|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
48370821|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
48370822|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
48370823|NCT00804804|OTHER|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
48515522|NCT01331850|DRUG|danoprevir|100 mg oral doses twice a day for 24 weeks
48515523|NCT01331850|DRUG|ritonavir|100 mg oral doses twice a day for 24 weeks
48698215|NCT01380197|DRUG|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
48698216|NCT01380197|DRUG|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
48698217|NCT06388096|DIAGNOSTIC_TEST|Pattern Electroretinogram|Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
48698218|NCT05099354|DIAGNOSTIC_TEST|autonomic nervous system testing|"* Autonomic tests, including heart rate variability (HRV) and baroreceptor sensitivity (BRS), are performed with a 10min ECG with non-invasive or invasive blood pressor measuring during rest. During the time at the stroke unit, this data will be calculated using the existing continuous monitoring.~* Valsalva maneuver during continuous ECG and blood pressure monitoring. The patient will be instructed to exhale against a mouthpiece with a defined resistance for 15 seconds.~* Assessment of the cerebrovascular reserve capacity will be done with continuous transcranial duplex sonography (TCD) and breath holding index (BHI). The patient will be instructed to hold his breath for 30 seconds, 4 times in a row with intervals of 4 minutes. This test will be performed only in responsive and compliant patients."
48698219|NCT00006447|PROCEDURE|Social Support|
48370824|NCT02724631|DEVICE|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
48698220|NCT04683549|DIAGNOSTIC_TEST|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy|"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."
48698221|NCT05808946|DRUG|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
48698222|NCT05808946|DRUG|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
48698223|NCT04587414|BEHAVIORAL|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
48698224|NCT04587414|BEHAVIORAL|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
48698225|NCT04587414|BEHAVIORAL|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
48010846|NCT02385812|PROCEDURE|Low-dose computed tomography Annual scan x3|Annual scan x3
48010847|NCT02385812|PROCEDURE|Low-dose computed tomography Baseline scan only|Baseline scan only
48370825|NCT00807651|PROCEDURE|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
48515524|NCT04233996|DRUG|Piperacillin-Tazobactam 4 g-0.5 g|Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h
48010848|NCT02021591|BEHAVIORAL|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
48698226|NCT01828619|PROCEDURE|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
48698227|NCT01792375|PROCEDURE|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
48698228|NCT01792375|DRUG|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
48698229|NCT06097533|DRUG|Cannabisextrakt Avextra 10/10 Lösung|medical cannabinoids
48698230|NCT06660875|DRUG|Serratus posterior superior intercostal plane block|Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
48698231|NCT06660875|DRUG|Interscalene brachial plexus block and superficial cervical plexus block|İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
48698232|NCT02601235|DRUG|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
48698233|NCT02601235|DRUG|Afrin|2 pumps in each nostril every 12 hours.
48698234|NCT04339998|DIAGNOSTIC_TEST|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (\> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (\>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole"
48698235|NCT04556955|DEVICE|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
48698236|NCT04556955|OTHER|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
48698237|NCT02855957|OTHER|Free α-Hb pool analysis|
48698238|NCT01005316|DRUG|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
48698239|NCT01005316|DRUG|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
48010849|NCT00779766|BIOLOGICAL|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48698240|NCT01005316|DRUG|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
48370826|NCT00807651|DRUG|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
48010850|NCT00779766|BIOLOGICAL|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
48010851|NCT01971827|BEHAVIORAL|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
48010852|NCT02483234|DRUG|secukinumab|
48010853|NCT04724239|DRUG|Sintilimab|200mg IV on Day 1 Q3W
48370827|NCT06044857|DRUG|68-Ga PSMA11|Will be injected/assessed in line with its FDA label.
48370828|NCT03260543|DIETARY_SUPPLEMENT|fermented ginseng powder|tablets (2 tablets/day, 125 mg \& 500 mg/day) for 12 weeks.
48698241|NCT01005316|PROCEDURE|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
48698242|NCT01005316|PROCEDURE|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
48698243|NCT01005316|DRUG|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
48010854|NCT04724239|DRUG|Chidamide|30mg PO BIW each 3-week cycle
48010855|NCT04724239|DRUG|IBI305|7.5mg/kg IV on Day 1 Q3W
48010856|NCT01424488|DRUG|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
48370829|NCT03260543|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
48370830|NCT00570492|DRUG|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
48370831|NCT00570492|DRUG|Placebo nasal spray|Placebo nasal spray
48698244|NCT01005316|DRUG|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
48698245|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 25mg|Given PO
48698246|NCT04047706|DRUG|Nivolumab|Given IV
48698247|NCT04047706|RADIATION|Radiation Therapy|Undergo radiation therapy
48698248|NCT04047706|DRUG|Temozolomide|Given PO
48698249|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 50 mg|Given PO
48698250|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 100 mg|Given PO
48698251|NCT04723472|DRUG|Cefuroxime containing bismuth quadruple treatment|"Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days."
48168423|NCT05341063|BEHAVIORAL|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
48168424|NCT05341063|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
48168425|NCT01713998|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48168426|NCT00033189|DRUG|Coenzyme Q10|
48168427|NCT04108975|PROCEDURE|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
48168428|NCT04108975|PROCEDURE|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
48168429|NCT00308919|DRUG|WST09|Treatment with WST09 Vascular Photodynamic therapy
48168430|NCT05458830|BEHAVIORAL|Brief Barrier Reduction Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
48168431|NCT05458830|BEHAVIORAL|Plain advisory text|Care as usual
48515525|NCT04233996|DRUG|Cefepime 2000 mg|Patients with FN who required empirical treatment with cefepime 2g/8h
48698252|NCT04723472|DRUG|Classic bismuth quadruple treatment|"Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days."
48698253|NCT05459649|DRUG|Cyclosporine Oral Product|A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
48698254|NCT05459649|DRUG|Prednisone|Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
48698255|NCT05300230|DEVICE|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
48698256|NCT04739670|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.
48698257|NCT04739670|DRUG|Bevacizumab|Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
48698258|NCT04739670|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy drug
48698259|NCT04739670|DRUG|Carboplatin|Carboplatin is platinum based chemotherapy drug
48698260|NCT04654611|DRUG|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
48698261|NCT02503358|OTHER|Laboratory Biomarker Analysis|Correlative studies
48698262|NCT02503358|DRUG|Paclitaxel|Given IV
48698263|NCT02503358|OTHER|Pharmacological Study|Correlative studies
48698264|NCT02503358|DRUG|Selumetinib|Given PO
48698265|NCT06208150|DRUG|Talquetamab|Talquetamab will be administered as a SC injection.
48698266|NCT06208150|DRUG|Pomalidomide|Pomalidomide will be administered orally.
48698267|NCT06208150|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
48698268|NCT06208150|DRUG|Elotuzumab|Elotuzumab will be administered intravenously.
48698269|NCT06208150|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously.
48698270|NCT06208150|DRUG|Bortezomib|Bortezomib will be administered as a SC injection.
48698271|NCT04933045|DEVICE|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
48698272|NCT05638802|DRUG|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
48698273|NCT05638802|DRUG|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
48698274|NCT06094218|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
48698275|NCT06094218|BEHAVIORAL|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
48698276|NCT00964665|DRUG|albinterferon alfa-2b|
48698277|NCT00964665|DRUG|albinterferon alfa-2b|
48698278|NCT00964665|DRUG|albinterferon alfa-2b|
48698279|NCT00964665|DRUG|albinterferon alfa-2b|
48698280|NCT00964665|DRUG|Pegasys®|
48698281|NCT03971240|PROCEDURE|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
48698282|NCT02131103|OTHER|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
48698283|NCT04585269|BEHAVIORAL|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
48698284|NCT06046612|DRUG|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
48010857|NCT01424488|DRUG|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
48010858|NCT03417661|DRUG|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
48010859|NCT03417661|DRUG|Chloraprep|Sterile applicator containing 3ml solution.
48010860|NCT03417661|DRUG|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
48010861|NCT04774510|OTHER|Diagnostic Test: optimized C-Arm Cone Beam Computed Tomography|Optimized C-ARM CBCT using new geometry and a novel software can rapidly and accurately detected brain abnormalities and hemorrhagic complications for critical patients with acute stroke. This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the neuro angiography suite (NAS).
48010862|NCT02285985|DRUG|Saxagliptin|Tablets: 5 mg
48010863|NCT02285985|DRUG|Placebo|Tablets: 5mg
48168432|NCT01128140|BEHAVIORAL|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
48010864|NCT04333680|DIAGNOSTIC_TEST|Focused Assessment of Sonography for Trauma Exam|Speed and image quality of ultrasound exams performed with either transducer specified in the arms.
48698285|NCT06243003|RADIATION|HA-WBRT plus SBRT|hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
48698286|NCT02213185|OTHER|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
48698287|NCT00002873|RADIATION|brachytherapy|
48010865|NCT00591448|OTHER|Virtual Reality (VR)|See above
48010866|NCT06199986|BEHAVIORAL|ADT Order Check Attestation (Or)|Clinical reminder order check in electronic health record
48010867|NCT06199986|BEHAVIORAL|Provider Script (Sc)|Provider script added to progress note in electronic health record
48010868|NCT01509794|OTHER|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
48010869|NCT01509794|OTHER|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
48010870|NCT00183872|DRUG|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
48010871|NCT00494494|DRUG|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
48010872|NCT00494494|DRUG|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
48010873|NCT02208791|DRUG|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
48010874|NCT02208791|DRUG|No intervention|
48010875|NCT04163393|PROCEDURE|Percutaneous Coronary Intervention|PCI with robotic assistance
48168433|NCT01128140|BEHAVIORAL|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
48010876|NCT04163393|DEVICE|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
48168434|NCT06546514|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
48168435|NCT03519477|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
48168436|NCT00991029|DRUG|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
48168437|NCT00991029|DRUG|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
48698288|NCT02527226|BEHAVIORAL|Facial exercises|A series of self-administered facial movements and expressions.
48698289|NCT04778631|DEVICE|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
48010877|NCT06187545|DEVICE|Minimum viable prototype|Deep sedation in critical ill patients using minimum viable prototype
48010878|NCT06187545|DEVICE|Usual care|Deep sedation without minimum viable prototype
48010879|NCT04053374|OTHER|Blood sampling|Blood sampling +/- CSF sampling
48010880|NCT05466396|BEHAVIORAL|smoking|Smoking history and spirometry are used to define groups
48010881|NCT00484302|BEHAVIORAL|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
48010882|NCT00484302|BEHAVIORAL|Non-manualized standard treatment|Treatment by case-manager
48010883|NCT02892981|OTHER|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
48010884|NCT00384137|DRUG|Tacrolimus|Immunosuppression
48010885|NCT04662307|DEVICE|Intelligent cardiopulmonary rehabilitation system (ICRS)|Participants are required to wear a wristband heart rate monitor and exercise on a cycling ergometer-based ICRS for 30 minutes (5 minute of warm-up, 20 minutes of training followed by 5 minutes of cooldown). The target intensity for the 20-min training period is set at 60%\~80% HRR determined in the pretest of cardiopulmonary exercise test.
48010886|NCT02149433|DRUG|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
48010887|NCT02149433|DRUG|Placebo|
48168438|NCT00335374|DRUG|Pardoprunox|12 -42 mg
48168439|NCT01319864|DRUG|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
48698290|NCT04778631|DEVICE|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
48010888|NCT02796807|DRUG|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
48698291|NCT05364970|COMBINATION_PRODUCT|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
48698292|NCT05364970|COMBINATION_PRODUCT|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
48168440|NCT04116242|OTHER|blood sampling for research purpose|blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
48168441|NCT04116242|OTHER|clinical data collection|clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
48168442|NCT04116242|OTHER|Health-related Questionnaires|Health-related Questionnaires (Questionnaire_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
48168443|NCT04116242|OTHER|Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)|Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
48010889|NCT04015661|DRUG|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
48698293|NCT00003675|DRUG|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
48168444|NCT00193596|DRUG|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
48168445|NCT00193596|DRUG|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
48168446|NCT00193596|DRUG|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
48698294|NCT05327842|DEVICE|New training simulator|Participants receive training with new simulator
48698295|NCT05327842|DEVICE|Traditional simulator|Participants receive traditional training
48698296|NCT01663818|DEVICE|Tack-It Endovascular Stapler|
48698297|NCT04243577|DEVICE|Tele-EaT Sensors|Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.
48698298|NCT04243577|DEVICE|Conventional Sensors|Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
48168447|NCT00193596|DRUG|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
48168448|NCT00193596|DRUG|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
48168449|NCT05290857|OTHER|Restart DOAC within 7 days of clinical hemostasis after GI bleeding|"In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team).~High thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator"
48168450|NCT05290857|OTHER|Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding|"In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team).~Moderate thrombotic risk includes the following:~(i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months~The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team."
48168451|NCT03664453|DRUG|omaveloxolone|Omaveloxolone 50 mg capsules
48698299|NCT00000593|PROCEDURE|blood transfusion|
48010890|NCT01866709|DRUG|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
48168452|NCT01990911|DEVICE|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
48168453|NCT01990911|DRUG|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
48168454|NCT05694936|DRUG|Sodium Valproate|Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
48168455|NCT05694936|DRUG|Panitumumab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
48168456|NCT05694936|DRUG|Cetuximab|Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
48010891|NCT01866709|DRUG|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
48010892|NCT05836610|DRUG|Hydrocortisone|intravenous bolus hydrocortisone therapy during hypothermia treatment
48010893|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
48010894|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
48010895|NCT02141516|BIOLOGICAL|rMenB+OMV|2 doses of vaccine 2 months apart
48010896|NCT01400841|DEVICE|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
48010897|NCT05893979|DEVICE|Spectacle Lenses|Standard Spectacle Lenses
48010898|NCT01122511|DRUG|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
48168457|NCT05846048|OTHER|semi-structures questionaire|semi -structured questionnaire prepared by the researcher collect sociodemographic data , awareness ,attitudes about marital rape and health consequences
48168458|NCT02785575|OTHER|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
48168459|NCT05915832|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
48168460|NCT05915832|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
48168461|NCT00564564|DRUG|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
48168462|NCT00564564|DRUG|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
48168463|NCT01012596|BEHAVIORAL|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
48168464|NCT04153422|DRUG|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
48010899|NCT01122511|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab into study eye
48168465|NCT04153422|DRUG|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
48515526|NCT04233996|DRUG|Meropenem 1000 mg|Patients with FN who required empirical treatment with meropenem 1g/8h
48010900|NCT01122511|OTHER|sham|Sham needle-less injection administered in the study eye
48010901|NCT04080765|BEHAVIORAL|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
48010902|NCT04080765|BEHAVIORAL|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
48010903|NCT06108856|DEVICE|Hemodialysis machine|machine by which people undergo dialysis on it.
48698300|NCT05130632|BEHAVIORAL|The community working group|"The intervention consists of educational working group (WG) sessions over a 12-week period. Eight core modules-the essential ingredients-and 4 periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize 1 task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as: -starting an organic compost pile free of plastic waste -training on community recycling, focusing on plastics recycling -making organic soaps, to use for personal grooming or washing clothes, eliminate plastic packaging -creating materials out of plastic, like bottle planters, crocheted plastic bags, purses."
48010904|NCT04879745|OTHER|MyVoice:Rheum|Participants will be given access to MyVoice:Rheum, a web-based decision aid (DA).
48010905|NCT04879745|OTHER|Pamphlet|Participants in this arm will be given a copy of an existing patient pamphlet
48010906|NCT05267067|OTHER|respiratory exercises|Manual respiratory exercises versus respiratory exercises with pressure meter
48010907|NCT02674178|PROCEDURE|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm \[18\]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
48010908|NCT00296556|DRUG|Rivenprost (drug)|
48010909|NCT04143412|DRUG|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
48010910|NCT04121325|DEVICE|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
48010911|NCT02373358|BEHAVIORAL|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
48010912|NCT00436280|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
48010913|NCT00436280|DRUG|gemcitabine|1000 mg/m², IV, once, every two weeks, four to eight 2 week cycles
48010914|NCT00436280|DRUG|rituximab|375 mg/m², IV, once every 2 weeks, four to eight 2 week cycles
48010915|NCT00436280|DRUG|oxaliplatin|100 mg/m², IV, once every two weeks, four to eight 2 week cycles
48515527|NCT02461251|DEVICE|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
48515528|NCT00346918|DRUG|Sirolimus|Standard plus Sirolimus
48698301|NCT00144989|DRUG|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
48010916|NCT06146166|DIETARY_SUPPLEMENT|Oral herbal supplement|Oral supplement containing an oral blend taken once daily
48010917|NCT06146166|DIETARY_SUPPLEMENT|Oral placebo supplement|Oral placebo supplement taken once daily
48010918|NCT04395716|BIOLOGICAL|ResCure™|Patients will be treated with nebulized ResCure™
48010919|NCT02467725|OTHER|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
48010920|NCT04015219|DEVICE|Self retained cryopreserved amniotic membrane|PROKERA SLIM
48010921|NCT04015219|OTHER|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
48515529|NCT00346918|OTHER|Standard|Standard
48010922|NCT01687166|DEVICE|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
48370832|NCT05804539|BEHAVIORAL|Manual therapy|The therapist checks the range of motion of the cervical joints and gives manual treatment to the restricted joints. Throughout the examination, the subject lied in a supine position on a professional rehabilitation bed with the seventh cervical vertebra (C7) on the edge of the bed and the other the body above the C7 were placed off the bed. The therapist held the subject's occipital bone with one hand and the radial aspect of the second metacarpophalangeal joint of the other hand to grip the spinous process of the sixth cervical vertebra and slowly pushed the occiput downward to check the joint mobility of the fifth cervical vertebra and the sixth cervical vertebra. After the examination, the restricted joint was accurately located and treated with targeted manual therapy. For example, stretching was performed with the right side of C4-C5 flexed, closing only the right side of the subject's C4-C5 as much as possible to increase joint mobility on the right side of C4-C5.
48515530|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
48515531|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
48515532|NCT05270408|DEVICE|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
48515533|NCT05083065|BIOLOGICAL|Covid-19 vaccine|"* First dose or complete cycle of Comirnaty (Pfizer/BioNTech) vaccine~* First dose or complete cycle of Spikevax (Moderna) vaccine~* First dose or complete cycle of AstraZeneca/Vaxzevria vaccine~* Complete cycle of vaccination using one type of vaccine for the first dose and a different type for the second dose~* Janssen (Johnson \& Johnson) vaccine (single dose)"
48515534|NCT00131599|DRUG|5FU/LV|5FU/LV
48515535|NCT03075020|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
48515536|NCT03075020|OTHER|AIR|Room air will be administered as placebo
48515537|NCT02503787|DEVICE|Spinal Cord Stimulation (SCS)|SCS programming options
48010923|NCT01687166|DEVICE|FDA Approved Open-Irrigated Ablation Catheter|
48515538|NCT01818115|DEVICE|Hydrus Implant|
48698302|NCT00144989|DRUG|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
48010924|NCT05320029|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
48010925|NCT05320029|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
48168466|NCT05362760|DRUG|Abemaciclib + Aromatase Inhibitor|Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)
48168467|NCT05362760|DRUG|Abemaciclib + Fulvestrant|Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
48168468|NCT05550714|DRUG|general anesthesia|The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
48515539|NCT01818115|PROCEDURE|IOL placement|
48515540|NCT01613430|BEHAVIORAL|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
48698303|NCT04930276|OTHER|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
48698304|NCT05804656|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
48698305|NCT05804656|DRUG|Botox®|Intramuscular injection Botox®
48010926|NCT02177266|DRUG|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
48010927|NCT02177266|DRUG|Placebo|The placebo will match the study drug.
48515541|NCT01613430|BEHAVIORAL|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
48515542|NCT00704132|DRUG|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
48698306|NCT06283940|OTHER|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|Individually prescribed centralcirculatory aerobic exercise and muscular endurance training twice a week for 60 minutes each session over 12 weeks in a hospital-based setting, and two sessions of home-based exercise recorded in an exercise diary.
48698307|NCT00945347|DRUG|Miglustat|Nasal instillation of miglustat
48010928|NCT05728164|BEHAVIORAL|Cinematic Simulation|Comprehensive videos from specific films will be selected as films fitting the needs of participants and the established objectives. The films comprehensively develops several characters enriching the values of positive emotions, resilience and empathy. The intervention film videos will be delivered on 5 sessions for each group (2 sessions per week).
48698308|NCT00945347|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
48168469|NCT05550714|DRUG|Conscious sedation|A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
48168470|NCT05173233|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
48168471|NCT05641714|OTHER|L test|The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
48168472|NCT05641714|OTHER|Timed Up and Go test|The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
48168473|NCT05641714|OTHER|10 meter walk test|In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.
48168474|NCT05641714|OTHER|Six Minute Walk Test|This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.
48168475|NCT05641714|OTHER|The timed 360° turn test|Each participant turns around in place in a standing position for both sides.
48168476|NCT03453203|OTHER|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
48698309|NCT00613002|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
48698310|NCT00613002|DRUG|placebo gel|once daily transdermal placebo gel
48698311|NCT00445107|DRUG|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
48698312|NCT04327427|OTHER|Aspirin|Outcome Analysis of Aspirin in liver transplantation
48698313|NCT03103698|DEVICE|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
48698314|NCT03103698|OTHER|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
48698315|NCT01738607|DIETARY_SUPPLEMENT|Psyllium|
48168477|NCT01318538|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
48168478|NCT01318538|BEHAVIORAL|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
48168479|NCT00113997|DRUG|REG1|
48168480|NCT00053352|PROCEDURE|conventional surgery|
48168481|NCT00053352|DRUG|cisplatin|Given IV
48168482|NCT00053352|DRUG|etoposide|Given IV
48168483|NCT00053352|BIOLOGICAL|bleomycin sulfate|Given IV
48168484|NCT00053352|OTHER|laboratory biomarker analysis|Correlative studies
48515543|NCT00704132|DRUG|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
48515544|NCT00492778|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
48698316|NCT01738607|DIETARY_SUPPLEMENT|Gum Arabic|Gum acacia dietary fiber
48698317|NCT01738607|DIETARY_SUPPLEMENT|carboxymethylcellulose|dietary fiber
48698318|NCT01738607|DIETARY_SUPPLEMENT|Placebo|
48698319|NCT01410175|DEVICE|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
48698320|NCT01050920|BIOLOGICAL|Blood collection|
48698321|NCT03443479|DEVICE|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
48698322|NCT03443479|DEVICE|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
48698323|NCT00290771|DRUG|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
48698324|NCT00290771|DRUG|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
48698325|NCT05806515|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48698326|NCT05806515|DRUG|Carboplatin|Given IV
48698327|NCT05806515|PROCEDURE|Chest Radiography|Undergo chest X-ray
48698328|NCT05806515|PROCEDURE|Computed Tomography|Undergo CT
48698329|NCT05806515|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48698330|NCT05806515|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
48698331|NCT05806515|PROCEDURE|Surgical Procedure|Undergo surgery
48010929|NCT06107491|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
48010930|NCT06107491|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
48010931|NCT04534842|DRUG|SYNB1618|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618
48010932|NCT04534842|DRUG|SYNB1934|15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
48010933|NCT03925792|BEHAVIORAL|Lifestyle Medicine|diet, sleep, exercise and mindfulness
48010934|NCT05015218|DIAGNOSTIC_TEST|Vacular Ultrasound|To visualize the internal jugular veins ( IJVs) a linear transducer with a 5-10 MHz linear probe was placed over the neck, and the IJV was measured just below the bifurcation of the sternal and clavicular heads of the muscle. The IJV measurements were performed on the transverse axis over a single respiratory cycle. Patients with evidence of IJV thrombosis were excluded. IJV measurements included the antero-posterior maximum diameter at the end of expiration (IJVmax), the antero-posterior mimimum diameter/area at the end of inspiration (IJVmin), the IJV collapsibility index (IJV-CI) during spontaneous, quiet, breathing, \[(IJVmax - IJVmin area)/IJVmax\] and the ratio (R) of IJVmax-to-IJV-CI.
48010935|NCT05552040|BEHAVIORAL|START NOW Group|START NOW psychotherapy is a CBT, DBT and skills-based intervention
48168485|NCT01212484|DRUG|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
48168486|NCT01212484|DRUG|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
48698332|NCT01578642|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
48010936|NCT02420496|DRUG|Enteral fish oil|
48010937|NCT02420496|DRUG|Ursodeoxycholic Acid|
48010938|NCT02420496|DRUG|Placebo|
48168487|NCT06086522|DRUG|QN-302|Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
48168488|NCT00049335|DRUG|capecitabine|1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
48168489|NCT05844033|OTHER|Screening|Blood tests
48168490|NCT00591604|DRUG|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
48168491|NCT03698617|DRUG|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
48370833|NCT05804539|BEHAVIORAL|Tai Chi|Based on the characteristics of young people and the need to correct their FHP, the classic Yang's 24 Forms of Tai Chi has been improved. The movements are mostly upper limb movements and the lower limb movements have been simplified to make the movements easy to learn. The modified Tai Chi exercise retains the traditional Tai Chi movements but is simple and easy to learn; at the same time, it increases the movement of the shoulder and neck joints. The subjects performed each exercise session in a group setting at the school gymnasium, with a professional Tai Chi instructor guiding them through a warm-up session, followed by a Tai Chi exercise session.
48168492|NCT03698617|DRUG|Propofol|For induction of general anesthesia
48168493|NCT00629551|DRUG|saredutant (SR48968)|oral administration,capsules
48168494|NCT00629551|DRUG|paroxetine|oral administration, capsules
48168495|NCT00629551|DRUG|placebo|oral administration, capsules
48168496|NCT04958941|BEHAVIORAL|Experimental: Intervention group|During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
48010939|NCT05963542|BEHAVIORAL|ACT for tinnitus|The intervention will be based on the ACT model and adjusted for tinnitus.
48010940|NCT05963542|OTHER|Customized sound therapy|The music will be modulated through a smartphone app using a set program to generate customized tinnitus relieving sound.
48168497|NCT05424211|DEVICE|Music Therapy Mobile Application|The authorities determined by taking consultancy from TÜMATA (Turkish Music Research and Promotion Group) will be uploaded to the mobile application developed by the software specialist. The maqams (Rast, Nihavent and Neva) to be used in the application will be played to the patients 3 times in half an hour at different times of the day via the mobile application. Rast tonality will be played in the morning, nihavent tune will be played at noon and neva tune will be played in the afternoon.
48168498|NCT04159805|DRUG|TAK-079|TAK-079 subcutaneous injection
48168499|NCT04159805|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
48168500|NCT05297253|DEVICE|telescopic overdenture|fixed implant retained prostheses
48168501|NCT05750342|DIETARY_SUPPLEMENT|Experimental Product Caqui|Supplement extracted from persimmon
48515545|NCT00492778|DRUG|Cisplatin|Given IV
48168502|NCT05750342|DIETARY_SUPPLEMENT|Control product placebo|Product with identical characteristics to the experimental product.
48515546|NCT00492778|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48698333|NCT02481648|OTHER|Exercise|
48698334|NCT01885208|DRUG|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
48698335|NCT01885208|DRUG|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
48698336|NCT06533501|OTHER|Dietary Leucine Intakes|Participants consume 8 hourly meals that contain the assigned test leucine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
48168503|NCT02369588|OTHER|Food portion size|
48168504|NCT04850859|OTHER|measure various dimensions of the glenoid|measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
48168505|NCT04850859|OTHER|measure various dimensions of the acetabulum|measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
48168506|NCT03133078|OTHER|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
48168507|NCT03133078|OTHER|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
48168508|NCT03128541|DIAGNOSTIC_TEST|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
48168509|NCT03679468|OTHER|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
48168510|NCT03679468|OTHER|Sham Exercise|Sets of balance and stretching exercises
48370834|NCT05804539|BEHAVIORAL|Tai Chi and Manual therapy|Intervention content of MSG included 15-min Tai Chi exercise and 15-min manual therapy, with the order of intervention being Tai Chi exercise first and then manual therapy.
48370835|NCT00082134|DRUG|ILX651|
48168511|NCT03679468|OTHER|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
48168512|NCT03679468|OTHER|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
48370836|NCT03750058|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
48698337|NCT04765644|DRUG|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
48370837|NCT04325126|OTHER|Exposure factors|Exposure factors，such as diet，exercise，environment
48370838|NCT05674682|PROCEDURE|HIV testing|venipuncture or digital puncture for HIV testing
48370839|NCT02028182|BIOLOGICAL|Lyral®|Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
48370840|NCT03557073|BEHAVIORAL|Postoperative phone call|The intervention is a phone call on the day following surgery.
48370841|NCT02896686|RADIATION|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
48370842|NCT02896686|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
48698338|NCT04765644|OTHER|Placebo|2 capsules/day for 7 days
48698339|NCT04765644|OTHER|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
48698340|NCT04765644|OTHER|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
48698341|NCT05633459|DRUG|Multiple ascending doses of QRL-201|Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
48698342|NCT05633459|DRUG|Multiple ascending doses of Placebo|Multiple ascending doses of placebo comparator will be intrathecally administered to individuals with sporadic ALS.
48698343|NCT05633459|DRUG|QRL-201|QRL-201 will be intrathecally administered to individuals with C9orf72 ALS.
48698344|NCT05633459|DRUG|Placebo|Placebo comparator will be intrathecally administered to individuals with C9orf72 ALS.
48698345|NCT02728648|DRUG|Oxycodone|Pain Management
48698346|NCT06607029|DRUG|the opioid-based control group|Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
48698347|NCT06607029|DRUG|the opioid-free anesthesia group|The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
48698348|NCT00882583|DRUG|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
48698349|NCT00882583|DRUG|Dasatinib|Oral Dasatinib Days 8 through 64.
48698350|NCT00882583|DRUG|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
48698351|NCT00882583|RADIATION|Radiation Therapy|Standard Radiation Therapy.
48698352|NCT04070716|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
48698353|NCT04070716|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
48698354|NCT02135328|BEHAVIORAL|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
48698355|NCT02135328|BEHAVIORAL|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
48698356|NCT05126992|BIOLOGICAL|AZD1222|Covid-19 AstraZeneca Vaccine
48698357|NCT06442007|BEHAVIORAL|Behavioral Activation - single session intervention (BA-SSI)|Single session intervention
48698358|NCT06442007|BEHAVIORAL|4-session Mindset intervention|This is comprised of 4 sessions.
48698359|NCT04164017|DEVICE|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
48168513|NCT00255671|OTHER|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
48168514|NCT03616236|DRUG|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
48168515|NCT03616236|OTHER|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
48168516|NCT00524810|DRUG|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
48168517|NCT00524810|DRUG|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
48168518|NCT01521689|DRUG|Rituximab|Low doses of sub cutaneaous rituximab
48168519|NCT06008106|DRUG|tunlametinib|12mg BID
48168520|NCT06008106|DRUG|paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin|according to investigators' suggestion
48168521|NCT02512861|DRUG|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients \> 50 kgs"
48168522|NCT02512861|DRUG|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs"
48168523|NCT03744741|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
48168524|NCT03703843|DEVICE|ARTUS MONO|Temporarily implant and activation of the medical device
48168525|NCT00514813|DRUG|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
48168526|NCT01208870|BEHAVIORAL|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
48168527|NCT01208870|BEHAVIORAL|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
48168528|NCT05964556|OTHER|Functional Movement Screen (FMS)|FMS is an analysis system that evaluates muscle strength imbalance and functional performances on the dominant-non-dominant side in athletes. It aims to detect stability and mobility that can be ignored in the asymptomatic active population and athletes. It consists of 7 basic parameters determined by Gray Cook (Deep Squat, Hurdle Step, -In-line Lunge, Shoulder Mobility, Active Straight Leg Raise, Trunk Stability, Rotatory Stability). The athletes were evaluated after giving verbal instructions to the athletes about the head, trunk, knee and foot positions. For each parameter, the athletes were given points between 0-3 values. The total score was determined as 21 points. Completing the movement completely and without compensation was given 3 points, and 2 or 1 points were given according to the activation of the compensation mechanism and balance disorders. In case of any pain during or at the end of the movement in the evaluated parameter, 0 points were given to the athletes.
48168529|NCT05964556|OTHER|Isokinetic Muscle Evulation of Knee Muscles|The isokinetic knee flexor and extensor group muscle strengths of the athletes participating in the study were measured on the dominant and non-dominant sides. Measurements were performed with an ISOMED 2000 (D\&R Ferstl GmbH, Hemau, Germany) isokinetic measuring device. The test protocol was adjusted to be concentric/concentric. Measurements were made at angular velocities of 60°/sec and 180°/sec. At an angular speed of 60°/sec, the athlete was asked to perform 10 repetitions of voluntary knee flexion/extension at maximum strength. Then, after resting for 30 seconds, 30 repetitions of knee flexion/extension were performed at an angular velocity of 180°/sec. Before starting the test in both angular speeds, 3 repetitive attempts were made to learn the movement. The following parameters were evaluated at 60°/sec and 180°/sec angular speed.
48168530|NCT00962221|PROCEDURE|laboratory analysis|laboratory analysis
48168531|NCT01319227|PROCEDURE|Hip replacement|Hip arthroplasty with uncemented components
48168532|NCT01938898|OTHER|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~1. Male \& Study \& Confidentiality~2. Male \& Study~3. Male \& Project \& Confidentiality~4. Male \& Project~5. Female \& Project \& Confidentiality~6. Female \& Project~7. Female \& Study \& Confidentiality~8. Female \& Study~9. Neutral \& Study \& Confidentiality~10. Neutral \& Study~11. Neutral \& Project \& Confidentiality~12. Neutral \& Project"
48168533|NCT01124214|PROCEDURE|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
48168534|NCT01170923|DEVICE|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
48168535|NCT01170923|DEVICE|CT|CT performed after 3 cycles of chemotherapy
48168536|NCT01939405|BEHAVIORAL|built environment use counseling|
48168537|NCT06480578|BEHAVIORAL|ISS-SBDOH arm|Once the ID-Cap ISS system has identified a participant who has missed his/her prescribed ARVs for five (5) consecutive days, a member of the multidisciplinary team will be informed automatically by the system and reach out to the participant immediately. The team will work with the primary provider and the participant to evaluate and understand the patient's SBDOH profile and status and develop a coordinated plan that fits the patient's specific need to address the patient's particular challenges in SBDOH. This plan (all SBDOH interventions) is considered standard of care and would be initiated in the same manner regardless of participation. Participation in this study will not alter the planned interventions determined by the HIV Care team.
48370843|NCT02896686|PROCEDURE|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
48370844|NCT02509429|DEVICE|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
48370845|NCT02509429|DEVICE|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
48370846|NCT05454839|OTHER|Survey|Interviewer-administered survey
48168538|NCT03888261|BEHAVIORAL|Mind-Body Approaches for Medical Conditions|"The intervention programme of the present trial is delivered in a group-based format (15 participants per group) and overall applies three therapeutic components:~1. Contemplative practices~2. Psychoeducation~3. Dialogue, including therapist-group dialogue as well as participant-participant dialogue."
48698360|NCT04164017|DEVICE|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
48698361|NCT05742516|DIETARY_SUPPLEMENT|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
48698362|NCT05742516|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder
48698363|NCT03628482|PROCEDURE|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
48698364|NCT03628482|PROCEDURE|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
48698365|NCT03900130|DIETARY_SUPPLEMENT|Preload|"In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low"
48698366|NCT02141633|PROCEDURE|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
48698367|NCT02141633|PROCEDURE|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
48698368|NCT02141633|DRUG|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
48698369|NCT02141633|DRUG|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
48010941|NCT06424886|OTHER|Landing error scoring system (LESS)|Each group will perform two training blocks of 10 drop vertical jumping (DVJ) tasks. Knee joint position sense (KJPS), frontal plane projection angle (FPPA), and Landing Error Scoring System (LESS) assessments will be performed before and after the training blocks, and follow-up assessments will be performed 1 week later. The dominant limb of the participants (the side limb they use when kicking the ball) will be taken into account during the measurement.
48168539|NCT04389918|OTHER|Tality|Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
48168540|NCT02534753|DRUG|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
48168541|NCT03290222|OTHER|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
48168542|NCT00115817|DRUG|Atorvastatin|
48168543|NCT00640523|DRUG|forodesine HCl|2 x 100mg capsules daily
48168544|NCT03630523|BIOLOGICAL|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
48370847|NCT05454839|OTHER|Focus group|Focus group for selected participants
48370848|NCT03142464|OTHER|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
48370849|NCT03708926|DRUG|Abaloparatide|abaloparatide injection pen
48370850|NCT03708926|DRUG|Placebo|placebo injection pen
48515547|NCT00492778|RADIATION|Internal Radiation Therapy|Given intracavitarily or interstitially
48698370|NCT04657705|PROCEDURE|High power ablation|High power ablation parameters (50-55 W)
48515548|NCT05051514|DIAGNOSTIC_TEST|Evaluation|To examine the differences in postural stability, anxiety/depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
48698371|NCT04657705|PROCEDURE|Standard ablation power|Standard ablation power parameters (40-45 W)
48698372|NCT02645877|PROCEDURE|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
48698373|NCT05559840|DEVICE|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
48698374|NCT05559840|DEVICE|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
48698375|NCT05655559|OTHER|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
48370851|NCT05829018|DIAGNOSTIC_TEST|Mixed meal test|Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
48698376|NCT05655559|DEVICE|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
48515549|NCT04952350|DRUG|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
48698377|NCT04116983|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
48698378|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (low dose)|Participants are administered 125 µg indacaterol + mometasonefluroate
48698379|NCT06067100|DRUG|Placebo|Participants are administered placebo
48698380|NCT06067100|DRUG|Indacaterol and Mometasonefluroate (high dose)|Participants are administered 500 µg indacaterol + mometasonefluroate
48698381|NCT05834088|OTHER|Myofascial release techniques|12 treatment sessions will be given in 12 weeks
48698382|NCT05834088|OTHER|Thiele massage|12 treatment sessions will be given in 12 weeks
48010942|NCT02260427|DEVICE|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
48010943|NCT02260427|DEVICE|Insertion of the air-Q sp|
48010944|NCT05372016|BIOLOGICAL|Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|9vHPV vaccine ,0.5mL, three doses, 0,2,6 months
48168545|NCT05255198|PROCEDURE|Anterior versus lateral approach to hip joint|
48168546|NCT00413075|DRUG|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
48168547|NCT04458987|BEHAVIORAL|Expert patient in addictology|"EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study."
48168548|NCT04010383|DIAGNOSTIC_TEST|virtual reality perimeter|Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
48168549|NCT00135785|DRUG|Bupropion|
48698383|NCT05484505|DRUG|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks"
48010945|NCT05372016|BIOLOGICAL|Active Comparator: GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
48010946|NCT03697954|DEVICE|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
48168550|NCT00135785|DRUG|Placebo|
48168551|NCT02275845|DRUG|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
48168552|NCT02275845|OTHER|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
48168553|NCT01891656|BEHAVIORAL|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller \& Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
48168554|NCT01891656|BEHAVIORAL|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere \& Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman \& Massey, 2008). As discussed by Hester \& Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
48168555|NCT02493881|DEVICE|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
48168556|NCT02335398|DRUG|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
48168557|NCT03704649|BEHAVIORAL|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
48168558|NCT03158818|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
48168559|NCT03165578|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
48698384|NCT05484505|BEHAVIORAL|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months
48698385|NCT05484505|DRUG|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
48698386|NCT00673205|DRUG|Bicalutamide|150mg p.o. daily
48168560|NCT03165578|OTHER|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
48698387|NCT00673205|DRUG|Placebo|
48698388|NCT02321787|PROCEDURE|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
48698389|NCT00730041|DEVICE|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
48168561|NCT05323188|OTHER|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
48168562|NCT00961896|DRUG|Vehicle|Placebo cream
48168563|NCT00961896|DRUG|LDE225 0.25%|
48168564|NCT00961896|DRUG|LDE225 0.75%|
48168565|NCT02936492|DRUG|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
48168566|NCT02936492|DRUG|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
48168567|NCT02936492|DRUG|BAY1003803 0.01% ointment|Topical administration for 22 h per day
48168568|NCT02936492|DRUG|BAY1003803 0.1% ointment|Topical administration for 22 h per day
48168569|NCT02936492|DRUG|Lipophilic cream vehicle|Topical administration for 22 h per day
48168570|NCT02936492|DRUG|Ointment vehicle|Topical administration for 22 h per day
48168571|NCT02936492|DRUG|Clobetasol propionate|Topical administration for 22 h per day
48168572|NCT04115371|BEHAVIORAL|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
48168573|NCT02097849|DRUG|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
48168574|NCT02097849|BIOLOGICAL|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
48698390|NCT00730041|DEVICE|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
48698391|NCT01406938|DRUG|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
48698392|NCT01406938|DRUG|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
48698393|NCT05859412|OTHER|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
48698394|NCT05859412|DRUG|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
48168575|NCT02097849|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
48168576|NCT02097849|BIOLOGICAL|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
48168577|NCT02097849|DRUG|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
48168578|NCT00298337|DRUG|Mixture of probiotic bacteria and prebiotic oligosaccharide|
48168579|NCT03806413|OTHER|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
48168580|NCT05012943|BIOLOGICAL|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
48168581|NCT05012943|OTHER|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
48168582|NCT05012943|BIOLOGICAL|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
48168583|NCT00784771|BEHAVIORAL|Hypnotherapeutic Olfactory Conditioning (HOC)|
48168584|NCT06319547|PROCEDURE|Thoracocentasis|patients will be submitted to diagnostic pleural fluid study, chest x-ray, liver function and blood picture
48168585|NCT02081118|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
48168586|NCT02081118|DRUG|Placebo|Placebo for HM11260C
48168587|NCT03294941|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
48168588|NCT06229236|BEHAVIORAL|Diabetes Navigator|Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
48168589|NCT04529811|DRUG|Rifaximin Novel Formulation|Rifaximin Novel Formulation
48168590|NCT04529811|DRUG|Placebo|Placebo
48168591|NCT03459521|BIOLOGICAL|Fendrix or HBVAXPRO 40|To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
48168592|NCT04899778|DRUG|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
48168593|NCT05199441|DRUG|Dihydroxydibutylether group|This group takes 1.500 mg/day of dihydroxydibutylether for 8 weeks.
48698395|NCT05859412|OTHER|Advice|Group receiving advice but no additional treatment
48698396|NCT05329480|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
48698397|NCT05329480|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
48168594|NCT05199441|DRUG|Control group placebo|This group takes 1,500 mg/day of placebo for 8 weeks.
48168595|NCT04340466|OTHER|No intervention|No intervention
48168596|NCT04143906|DRUG|Vinorelbine|injection
48168597|NCT04143906|DRUG|Gemcitabine|injection
48168598|NCT04143906|DRUG|Carboplatin|injection
48010947|NCT06168526|BEHAVIORAL|Acute physical activity|Regarding the first aim, participants will go through five different conditions using a within-participants cross-over design in a randomized order: control group (quietly sitting), light intensity (40% VO2max), moderate intensity (63% VO2max), or vigorous intensity (100% VO2max) exercise. All conditions will last 16 minutes and 15 seconds. The exercise conditions will be organized following an interval protocol, which includes 22 bouts of 30 seconds running at the established intensity with 15 seconds of passive rest between bouts. In addition, to achieve the second aim, the active break will be designed taking into account the intensity of physical activity that proves to have the greatest benefits on cognition and well-being.
48010948|NCT00650039|DRUG|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
48010949|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
48010950|NCT00650039|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
48010951|NCT04894981|DEVICE|Immersive condition (CAVE)|Driving course with obstacles in a CAVE system
48168599|NCT04863638|BIOLOGICAL|3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 42
48168600|NCT04863638|BIOLOGICAL|3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 111
48168601|NCT04863638|BIOLOGICAL|3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 171
48168602|NCT04863638|BIOLOGICAL|2 doses of vaccine|the schedule of Day 0, 21
48168603|NCT03096197|DEVICE|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
48168604|NCT03096197|DEVICE|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
48168605|NCT03535077|OTHER|Diagnostic Test|Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
48168606|NCT00978783|DEVICE|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
48168607|NCT00978783|DEVICE|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
48010952|NCT04894981|DEVICE|Immersive condition (HMD)|Driving course with obstacles with a virtual reality headset
48168608|NCT02223013|DRUG|BIBV 308 SE solution|
48168609|NCT02223013|DRUG|BIBV 308 SE capsule L|
48370852|NCT01304576|BEHAVIORAL|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
48010953|NCT04894981|DEVICE|Non Immersive condition (Screen alone)|Driving course with obstacles on a screen with physical simulator
48010954|NCT04894981|DEVICE|Non Immersive condition (Screen with physical simulator)|Driving course with obstacles on a screen only
48010955|NCT01647867|OTHER|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
48168610|NCT02223013|DRUG|BIBV 308 SE capsule S|
48168611|NCT02251340|BEHAVIORAL|Eczema Care Plan|
48168612|NCT04136171|DRUG|Eplontersen|Eplontersen by subcutaneous injection
48168613|NCT04136171|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
48168614|NCT04950387|OTHER|Breathing exercises|Based in yoga, common load
48168615|NCT04578899|DEVICE|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
48168616|NCT01742234|PROCEDURE|Organ Donation|People in this study will donate either a lung or kidney
48168617|NCT05425173|OTHER|Conventional treatment|Chest Physical Therapy as required
48168618|NCT05425173|OTHER|Limb Range of Motion Exercises + Chest Physical Therapy|"Limb Range of Motion Exercises + Chest Physical Therapy~Frequency: 4 sessions Time: 5 to 10 minutes"
48168619|NCT05091554|PROCEDURE|intraoral ice pack application|Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
48168620|NCT06266442|OTHER|Whole genome sequencing testing|Whole genome sequencing
48168621|NCT00046683|DRUG|alemtuzumab|
48168622|NCT02448498|BEHAVIORAL|Exercise Intervention|
48168623|NCT02450617|BEHAVIORAL|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
48370853|NCT01304576|OTHER|MRI|Cerebral MRI
48370854|NCT04786327|PROCEDURE|Minimal invasive flap technique|contained defect treated with Minimally invasive flap
48370855|NCT04786327|PROCEDURE|Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin|contained defect treated by Minimally invasive flap with root conditioning (EDTA) and platelet rich fibrin graft
48515550|NCT04952350|OTHER|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
48698398|NCT06660368|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
48010956|NCT00004091|OTHER|Papanicolaou test|
48010957|NCT00004091|OTHER|cytology specimen collection procedure|
48010958|NCT00004091|OTHER|fluorescent antibody technique|
48010959|NCT00004091|PROCEDURE|colposcopic biopsy|
48010960|NCT00004091|PROCEDURE|study of high risk factors|
48010961|NCT05927610|DIAGNOSTIC_TEST|Lumber Puncture|During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
48010962|NCT04224766|PROCEDURE|Suprascapular Nerve Block with 5ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of bupivicaine 0.5%.
48010963|NCT04224766|PROCEDURE|costoclavicular Block 10ml bupivicaine 0.5%|transverse ultrasound imaging of the medial infraclavicular fossa to identify the cords of the brachial plexus at the costoclavicular space (CCS) then inject 10ml bupivicaine 0.5%
48010964|NCT04224766|PROCEDURE|Interscalene Brachial Plexus Block 15ml bupivicaine 0.5%|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of bupivacaine 0.5%.
48370856|NCT04786327|COMBINATION_PRODUCT|minimally invasive flap with root contioning by EDTA and growth factor enhanced matrix GEM21S|contained defect treated with Minimally invasive flap with root conditioning (EDTA) and growth factor enhanced matrix application in the defect
48698399|NCT06660368|DRUG|Venetoclax|Venetoclax will be administered orally, once daily, with food.
48698400|NCT04367311|DRUG|Atezolizumab|Atezolizumab 1200 mg
48698401|NCT04367311|DRUG|Docetaxel|Docetaxel 60-75 mg/m\^2
48010965|NCT03640663|OTHER|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
48010966|NCT04488705|DRUG|ETD002 - single dose|Single ascending doses of ETD002
48010967|NCT04488705|DRUG|Placebo - single dose|Single doses of placebo
48010968|NCT04488705|DRUG|ETD002 - 7 day repeat dose|Twice daily doses of ETD002 for 7 days
48010969|NCT04488705|DRUG|Placebo - 7 day repeat dose|Twice daily doses of Placebo for 7 days
48010970|NCT04488705|DRUG|ETD002 - 14 day repeat dose|Twice daily doses of ETD002 for 14 days
48010971|NCT04488705|DRUG|Placebo - 14 day repeat dose|Twice daily doses of Placebo for 14 days
48010972|NCT04488705|DRUG|Salbutamol|Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
48010973|NCT06073925|DRUG|VIT D|50000 IU per week of VIT D
48010974|NCT03661515|DRUG|Selinexor|"According to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly"
48010975|NCT03661515|DRUG|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
48010976|NCT03661515|DRUG|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
48010977|NCT03661515|DRUG|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
48168624|NCT02450617|BEHAVIORAL|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
48698402|NCT04367311|DRUG|Cisplatin|60-75 mg/m\^2
48698403|NCT04367311|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2
48698404|NCT06053112|OTHER|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
48698405|NCT06053112|OTHER|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
48010978|NCT03661515|DRUG|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
48010979|NCT04416035|BIOLOGICAL|TRS003|TRS003 will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W). Each cycle is 3 weeks.
48370857|NCT00938457|RADIATION|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
48370858|NCT00938457|PROCEDURE|implanted fiducial-based imaging|radiation therapy treatment planning
48515551|NCT05378555|DRUG|Ketamine Hydrochloride|All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.
48698406|NCT01709422|DRUG|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
48698407|NCT01709422|DRUG|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
48698408|NCT01709422|DRUG|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
48698409|NCT05761106|OTHER|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
48698410|NCT05761106|OTHER|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
48698411|NCT00480558|BIOLOGICAL|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7
48010980|NCT04416035|BIOLOGICAL|China-approved Bevacizumab|China-approved bevacizumab will be administered at 15 mg/kg by IV infusion on Day 1 of each cycle (every 3 weeks, Q3W).Each cycle is 3 weeks.
48010981|NCT04416035|DRUG|Carboplatin|Carboplatin will be administered at an AUC 6 mg/mL/ min (the maximum dose capped at 900 mg) by IV infusion (over 15 - 30 minutes) Q3W on Day 1 of each cycle.
48010982|NCT04416035|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 200 mg/m\^2 by IV infusion (over 3 hours) Q3W on Day 1 of each cycle
48370859|NCT00938457|PROCEDURE|cone-beam computed tomography|radiation therapy treatment planning
48698412|NCT05099705|BEHAVIORAL|Access to a Family Service Navigator and Treatment Support System|An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
48698413|NCT00885586|DEVICE|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
48168625|NCT02450617|BEHAVIORAL|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
48698414|NCT00885586|DRUG|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
48698415|NCT00885586|PROCEDURE|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
48698416|NCT02021617|DEVICE|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
48698417|NCT05858632|DRUG|Guselkumab|Guselkumab treatment for \~ 9 months
48698418|NCT01780246|DRUG|nusinersen|Administered by intrathecal (IT) injection
48698419|NCT03927235|PROCEDURE|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
48698420|NCT00413894|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
48698421|NCT05538312|DRUG|vepdegestrant|Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
48698422|NCT05538312|DRUG|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
48698423|NCT04067297|OTHER|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of \~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
48698424|NCT00904046|DRUG|Pioglitazone|30 mg orally daily for 6 months
48698425|NCT00904046|DRUG|Placebo|Placebo taken orally once a day for 6 months.
48698426|NCT01212679|DRUG|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
48698427|NCT01212679|DRUG|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
48698428|NCT06399432|BEHAVIORAL|Mediterranean Diet|"In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software."
48698429|NCT00368381|DRUG|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
48698430|NCT02897037|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
48698431|NCT02897037|DRUG|heparin|heparin monotherapy
48698432|NCT00615225|PROCEDURE|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
48698433|NCT00175630|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
48698434|NCT02340247|OTHER|Water|
48698435|NCT02340247|DRUG|Ursodeoxycholic Acid|
48698436|NCT02340247|DRUG|Chenodeoxycholic Acid|
48010983|NCT06352944|DIAGNOSTIC_TEST|procalcitonin|level of procalcitonin in bronchoalveolar lavage
48010984|NCT01086579|DEVICE|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
48010985|NCT01086579|DEVICE|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
48010986|NCT03310957|DRUG|ladiratuzumab vedotin|Given into the vein (IV; intravenously)
48010987|NCT03310957|DRUG|Pembrolizumab|IV infusion every 3 weeks
48168626|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
48010988|NCT03247439|DEVICE|Cartiva|Synthetic Cartilage Implant
48370860|NCT02391194|DRUG|AVB-620|
48370861|NCT01928186|DRUG|Fluorothymidine F-18|Undergo FLT PET
48370862|NCT01928186|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
48370863|NCT01928186|OTHER|Laboratory Biomarker Analysis|Correlative studies
48698437|NCT06538051|OTHER|lying positions|All patients were placed in supine, semi-fowler's and lateral positions, respectively. The effects of positions on hemodynamic parameters were examined.
48010989|NCT00656253|DRUG|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
48010990|NCT00656253|DRUG|Placebo|12 months period of placebo plus 1 month period without placebo
48010991|NCT00283660|DIETARY_SUPPLEMENT|10 mg zinc oxide|10 mg zinc oxide
48010992|NCT00283660|OTHER|Placebo|Placebo pill taken five days a week for six months.
48168627|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
48168628|NCT06479330|OTHER|Milk Chocolate|Acute intake
48168629|NCT02303847|DRUG|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
48698438|NCT01964157|DRUG|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
48698439|NCT06661772|DIAGNOSTIC_TEST|Vancomycin trough concentration method|A blood sample for VTL was drawn 30 minutes before administration, prior to the fourth dose of vancomycin, under a complete aseptic technique, unless otherwise ordered by the medical team. Vancomycin serum concentrations were measured using a Human vancomycin ELISA Kit.
48698440|NCT03686306|DRUG|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
48698441|NCT03686306|DRUG|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
48698442|NCT01532284|OTHER|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
48698443|NCT04622891|DRUG|Clarithromycin 500mg|clarithromycin 500
48698444|NCT04622891|DRUG|Azithromycin|azithromycin group
48698445|NCT04622891|DRUG|Placebo|control group
48010993|NCT00574405|DRUG|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
48010994|NCT00574405|DEVICE|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
48010995|NCT03393611|DRUG|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
48010996|NCT03393611|DRUG|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
48010997|NCT03393611|DRUG|Melphalan|Melphalan 140 mg/m2 (Day -2)
48010998|NCT03393611|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
48010999|NCT03393611|BIOLOGICAL|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
48011000|NCT04805307|DRUG|CMG901|CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
48011001|NCT05314946|PROCEDURE|No feeding tube placed|The experimental arm will forego placement of a feeding tube.
48011002|NCT05314946|PROCEDURE|Placement of a percutaneous feeding tube|The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
48011003|NCT06387303|DRUG|Methadone|Intravenous Methadone
48011004|NCT06387303|DRUG|Morphine|Intrathecal Morphine
48168630|NCT01658956|DRUG|GCSF administration on days 8 and 12 after chemotherapy|
48370864|NCT01928186|DRUG|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
48370865|NCT03776435|RADIATION|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
48370866|NCT00646737|DRUG|Mycophenolate sodium|Mycophenolate sodium
48370867|NCT05707702|BIOLOGICAL|Probiotic oral lozenges|Participants in this arm will be be instructed to take a lozenge daily for 6 weeks. They will also receive oral dysplasia standard of care.
48698446|NCT05726981|PROCEDURE|Fine needle aspiration biopsy (FNAB)|"Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)"
48698447|NCT00160017|BEHAVIORAL|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
48698448|NCT04505553|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
48698449|NCT04505553|PROCEDURE|Acupressure Therapy|Undergo acupressure
48698450|NCT04505553|PROCEDURE|Oral Cryotherapy|Undergo oral cryotherapy
48698451|NCT04505553|OTHER|Questionnaire Administration|Ancillary studies
48698452|NCT04505553|OTHER|Quality-of-Life Assessment|Ancillary studies
48698453|NCT03121235|DIAGNOSTIC_TEST|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
48011005|NCT05703919|DRUG|Titrated Oxygen|Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
48011006|NCT05703919|DRUG|Standard Oxygen|Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
48011007|NCT05009251|BEHAVIORAL|Reminder|Mailed letter, short message service (SMS) text, and/or patient portal message
48011008|NCT05009251|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
48011009|NCT05009251|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
48011010|NCT05009251|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
48011011|NCT03252522|COMBINATION_PRODUCT|Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
48168631|NCT06180902|DIAGNOSTIC_TEST|Inferior vena cava's diameter ratio|"In mechanical ventilation, the Inferior Vena Cava's maximum diameter (IVCmax) is measured at peak inspiration, and minimum diameter (IVCmin) at expiration's end. The Distensibility Index (IVCDI) is calculated as \[(IVCmax - IVCmin) / IVCmin\] × 100%. In spontaneous breathing, IVCmax is the diameter at expiration's end, and IVCmin at inspiration's end. The Collapse Index (IVCCI) is \[(IVCmax - IVCmin) / IVCmax\] × 100%.~Clinically, an IVCDI/IVCCI ≥ 18% indicates a 'responder'. Values \< 18% denote 'non-responders'."
48168632|NCT06180902|DIAGNOSTIC_TEST|Central venous pressure|"In our protocol, patients lie flat, connected to a saline-filled system for intravenous infusion via a central venous catheter. The system, starting from the subclavian catheter, extends to the 2nd to 3rd intercostal space at the mid-axillary line. The tube's end is raised perpendicular to the bed until saline flow stops, marking the liquid level. The height from the mid-axillary line to this point is measured in millimeters. If the liquid column falls below the mid-axillary line, indicating continuous flow, the CVP is negative, and the catheter is closed to block air entry. CVP readings are taken at exhalation's end.~CVP interpretation:~* CVP ≤ 12 mmHg (16.3 cm H2O) indicates a responder.~* CVP \> 12 mmHg (16.3 cm H2O) indicates a non-responder."
48698454|NCT06014229|DEVICE|cryoablation|Single session with an argon-based cryoablation device; an specific applicator will be used for the treatments; gas release 100% for cryoablation; local anesthesia or moderate sedation or general anesthesia at discretion of the anesthesiology / interventional radiology team; benign thyroid nodules (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component;
48011012|NCT03252522|DIETARY_SUPPLEMENT|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
48370868|NCT05707702|OTHER|Standard of care for oral dysplasia|Oral dysplasia standard of care includes clinical surveillance and risk factor reduction (such as smoking cessation).
48370869|NCT03054116|DIAGNOSTIC_TEST|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
48698455|NCT00964041|DRUG|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
48698456|NCT00964041|DRUG|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
48011013|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System|Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
48011014|NCT04912024|DEVICE|Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems|Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
48011015|NCT02471521|OTHER|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
48011016|NCT02471521|DRUG|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
48011017|NCT01440309|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
48011018|NCT01440309|DRUG|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
48168633|NCT06180902|DIAGNOSTIC_TEST|Passive leg raising test|"In our protocol, the patient starts flat for initial CVP measurement. Then, the bed is tilted to 45 degrees for the first measurements: Systolic/Diastolic Blood Pressure, Mean Arterial Pressure, and Pulse Pressure (Systolic - Diastolic). Next, the bed is adjusted to elevate the feet, creating a 135-degree angle between torso and legs. After 90 seconds, the second set of measurements, including CVP, is taken. The patient is then returned to the initial position.~Interpreting results:~A responder is indicated by:~* Over 10% Pulse Pressure (PP) increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second measurement CVP ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* Less than 10% PP increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second measurement CVP \> 12 mmHg (16.3 cm H2O)."
48370870|NCT00712634|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
48011019|NCT00584038|BEHAVIORAL|educational instruction and phone follow-up|Educational instruction and phone follow-up.
48011020|NCT00584038|BEHAVIORAL|educational instruction in clinic|Educational instruction in clinic.
48011021|NCT00879671|DIETARY_SUPPLEMENT|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
48011022|NCT00879671|DIETARY_SUPPLEMENT|placebo|Placebo capsules identical in taste and appearance
48011023|NCT00773097|BIOLOGICAL|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
48011024|NCT00000826|DRUG|Clarithromycin|
48011025|NCT00000826|DRUG|Rifabutin|
48011026|NCT00000826|DRUG|Sulfamethoxazole-Trimethoprim|
48011027|NCT00000826|DRUG|Dapsone|
48011028|NCT00000826|DRUG|Fluconazole|
48011029|NCT05620290|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
48011030|NCT05620290|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
48168634|NCT06180902|DIAGNOSTIC_TEST|Fluid challenge|"In our clinical procedure, patients start horizontally for initial measurements: Systolic, Diastolic, Mean Arterial, Pulse Blood Pressures, and Central Venous Pressure (CVP). Then, they receive a balanced crystalloid solution at 4 ml/kg body weight at maximum permissible infusion rate. After infusion, a second measurement set identical to the first is taken.~Interpretation:~A responder is indicated by:~* Pulse Pressure (PP) increase \> 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second CVP measurement ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* PP increase \< 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second CVP measurement \> 12 mmHg (16.3 cm H2O)."
48168635|NCT06180902|PROCEDURE|Fluid infusion|After assessing infusion therapy responsiveness, patients receive balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/hour, accounting for any prior infusions. Effectiveness evaluation follows, involving cardiac output reassessment (initially measured upon study enrollment). Effectiveness is determined by a ≥10% increase in cardiac output in the second measurement compared to the first. This is quantified as: \[(CO(after) - CO(before)) / CO(before)\] × 100% ≥ 10%, where CO(after) is the post-infusion cardiac output and CO(before) the pre-infusion output.
48168636|NCT04838964|DRUG|MRG003|Administrated intravenously
48168637|NCT03822377|DRUG|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
48168638|NCT03822377|DRUG|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
48168639|NCT01583738|DRUG|V0251|single dose
48168640|NCT01583738|DRUG|placebo|single dose
48168641|NCT04479514|OTHER|Warm Baths or Showers|Daily warm baths or showers
48168642|NCT04479514|OTHER|Moisturizer|moisturizers applied daily immediately after bathing
48168643|NCT04479514|DRUG|SPF 30 or Higher Suncreen|Mineral based sunscreen of SPF 30 or higher applied on a daily basis on all sun exposed areas.
48168644|NCT04479514|OTHER|Sun Protective Clothing|Sun protective clothing worn when outdoors
48168645|NCT04479514|BEHAVIORAL|Limited Sun Exposure|Limit sun exposure during peak hours of 10am-4pm
48168646|NCT04479514|OTHER|Dilute bleach baths|Warm 10-15 minute dilute bleach baths every other day
48168647|NCT05896696|DEVICE|BeShape One|Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.
48370871|NCT03080675|DIETARY_SUPPLEMENT|Nutrional blend of ingredients including vitamins and fish oil|
48370872|NCT03080675|DIETARY_SUPPLEMENT|Control|
48515552|NCT05696899|OTHER|STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents|A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.
48698457|NCT03315793|DRUG|Duloxetine Hydrochloride|Administered orally
48698458|NCT03315793|DRUG|Placebo|Administered orally
48698459|NCT03226379|OTHER|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building"
48698460|NCT06090539|DRUG|BMS-986458|Specified dose on specified days.
48698461|NCT06090539|DRUG|Rituximab|Specified dose on specified days.
48698462|NCT05894980|DEVICE|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
48011031|NCT02317159|DRUG|Imatinib|400mg imatinib qd PO
48011032|NCT02573610|DRUG|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
48011033|NCT02573610|DRUG|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
48011034|NCT02797262|DEVICE|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
48515553|NCT05579314|DRUG|XW014|Oral tablets
48515554|NCT05579314|DRUG|Placebo|Matched oral placebo tablets
48515555|NCT05579314|DRUG|XW014|Oral capsules
48515556|NCT05579314|DRUG|Placebo|Matched oral placebo capsules
48011035|NCT03411525|BEHAVIORAL|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
48011036|NCT03411525|OTHER|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
48011037|NCT04608266|DRUG|Camostat Mesylate|Camostat mesylate, oral administration 600mg/day (2 x 100mg tablets every 8 hours) for 14 days
48698463|NCT05894980|DEVICE|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
48011038|NCT04608266|DRUG|Placebo|Placebo tablets, oral administration 2 tablets every 8 hours for 14 days
48011039|NCT01157481|DRUG|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
48011040|NCT01157481|DRUG|Conventional therapy|Conventional therapy
48011041|NCT04483440|BIOLOGICAL|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
48011042|NCT01634204|OTHER|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
48011043|NCT01634204|OTHER|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
48698464|NCT05894980|DEVICE|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
48168648|NCT02585141|DEVICE|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
48515557|NCT06334224|DEVICE|Low load resistance training with blood flow restriction|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
48011044|NCT04900103|OTHER|ITV-Pal|Use of new technologies for volunteering
48515558|NCT06334224|OTHER|Low load resistance training|Leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
48011045|NCT00397995|PROCEDURE|above- or under elbow cast|
48168649|NCT02585141|PROCEDURE|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
48515559|NCT04278456|BEHAVIORAL|postpartum depression|melatonin levels in c-sections with different anesthesia modalities.
48515560|NCT02128672|PROCEDURE|Spinal Cord Stimulator Lead Placement|
48698465|NCT06088173|OTHER|exercises|Patients in both group will use Kleinert splint. Sessions will start with ice application if there is edema and continue with scar tissue massage. After general hand massage, passive flexion, active extension exercises; tenodesis exercise and passive punch will be performed for the postoperative (postop) first two weeks. In postop 3-4 weeks, four finger sliding exercises, active half fist and NMES (Neuromuscular electrical stimulation) will be performed. In postop 5-6 weeks, blocking exercises, full punch, grappling hooks and small on-digits holding and releasing exercises will be performed additionally.
48698466|NCT06088173|OTHER|Exercises and Education|In addition to the same treatment as the patients in the first group, in the first postoperative (postop) two weeks, the gmi will be explained to the patients and lateralization will be started. lateralization refers to right-left discrimination and the patients will be presented with visuals with the help of the noi recognise app and they will have to decide whether the visual is right or left hand. In the postop 3-4th weeks, the motor imagery stage will be started and imagery will be practiced with the help of the same app. In postop 5-6 weeks, mirror therapy will be practiced with the help of a mirror box.
48698467|NCT02502435|OTHER|Observation|Observational study
48011046|NCT03026673|OTHER|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
48011047|NCT00678691|DRUG|armodafinil|50-250mg/d
48011048|NCT00678691|DRUG|placebo|matching placebo
48168650|NCT02585141|DRUG|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
48698468|NCT02172131|DRUG|BI 1744 CL|
48168651|NCT03979547|BEHAVIORAL|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
48515561|NCT02276807|BEHAVIORAL|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
48515562|NCT02276807|OTHER|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
48515563|NCT03222856|DRUG|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
48515564|NCT03222856|DRUG|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
48515565|NCT05269095|PROCEDURE|Spinal anesthesia only|Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
48698469|NCT02172131|DRUG|Placebo|
48698470|NCT02351063|DRUG|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
48698471|NCT05416489|DEVICE|C-MAC videolayngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a C-MAC videolaryngoscopy.
48011049|NCT03160924|OTHER|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
48011050|NCT04911426|BEHAVIORAL|Telehealth|The telehealth intervention is delivered with an app developed for this research. The intervention features live video calling, messaging, appointment reminders; clinical support is provided by licensed clinicians.
48011051|NCT05755373|OTHER|No treatment given|No treatment given
48011052|NCT00830193|DRUG|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
48011053|NCT00830193|DRUG|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
48011054|NCT01158924|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
48011055|NCT00355446|DRUG|Bimatoprost 0.03%|
48011056|NCT02594722|DEVICE|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
48011057|NCT02594722|DEVICE|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
48011058|NCT05996250|OTHER|Immersive virtual reality task|participants will have to wear a virtual reality headset connected to a remote control and will have to perform submersive virtual reality tasks
48011059|NCT01367808|DRUG|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
48011060|NCT01367808|DRUG|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
48011061|NCT01367808|DRUG|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
48011062|NCT06411548|DEVICE|InsuLearn|InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.
48011063|NCT05329740|DRUG|Methylprednisolone Injection|All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
48011064|NCT04917094|DEVICE|Compression stocking|"A below-the-knee compression stock will be worn daily for 2 weeks from waking up to before sleep.~Bioelectrical impedance will be performed before and 2 weeks after wearing the stocking to assess the total body water content.~Measuring the calf and neck circumference will be done before and after wearing the compression stocking. After 2 weeks, the patient will return back to the clinic for calf and neck circumference measurement.~Sleep test will be done the night before and 2 weeks after wearing the compression stocking. Oxygen Desaturation Index(ODI) will be assessed through a level 4 home sleep apnea testing device.~Patients recruited will have mild excessive to severe excessive daytime sleepiness and/or STOP-Bang score of 3 or more, with underlying conditions such as type II diabetes and hypertensive patients using the Epworth sleepiness scale. Epworth sleepiness scale will be assessed again 2 weeks after to assess for increase sleep efficiency."
48011065|NCT05617846|OTHER|Anti-osteoporosis therapy|Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.
48011066|NCT03152786|OTHER|Laboratory Biomarker Analysis|Correlative studies
48011067|NCT03152786|DRUG|Propranolol Hydrochloride|Given PO
48011068|NCT03152786|OTHER|Questionnaire Administration|Ancillary studies
48011069|NCT03152786|OTHER|Survey Administration|Ancillary studies
48011070|NCT00742976|DRUG|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
48011071|NCT00742976|DRUG|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
48011072|NCT04737642|PROCEDURE|Papillary ballon dilatation|Trans cystic papillary ballon dilatation during cholecystectomy
48011073|NCT05029141|DRUG|CAHAG regimen|"Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
48515566|NCT05269095|BIOLOGICAL|Spinal anesthesia and ultrasound-guided Genicular nerves block|Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
48698472|NCT05416489|DEVICE|Laryngoscopy technique|Endotracheal tube will be removed before percutaneous tracheostomy using a laryngoscopy
48698473|NCT03322176|OTHER|Genetic testing|LYNCH genetic testing
48698474|NCT04943341|PROCEDURE|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
48698475|NCT06294574|DEVICE|HydroMARK Plus Clip|Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.
48698476|NCT04348318|OTHER|health related personal data extraction from digital medical records|health related personal data extraction from digital medical records (i.e. patient characteristics; start, end and duration of hospitalization and ICU stay; admitted from another hospital, nursing home or comes with emergency medical Service; formal data of written advance directives; data of unwritten advance directive; information on the contents of the advance directives (regarding life-worthy conditions, health care agents, resuscitation, pain management, artificial nutrition, hydration, surgeries, renal replacement, mechanical circulation, mechanical ventilation, pacemaker, administration of blood products, treatment of infections, organ donation, autopsy); patient history; clinical data; therapeutic features; outcome at discharge; knowledge regarding relatives and their level of information about the advance directives; discussion of euthanasia and self-determination of dying.
48698477|NCT05851079|DIAGNOSTIC_TEST|TCT test|These tests were performed on cervical exfoliated cells.
48698478|NCT05851079|DIAGNOSTIC_TEST|Vaginoscopy|To obtain the results of the patient's pathology report.
48698479|NCT05851079|DIAGNOSTIC_TEST|High throughput HPV typing and integration detection methods|This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
48698480|NCT05851079|DIAGNOSTIC_TEST|Cobas HPV test|To obtain HPV typing results.
48698481|NCT03706742|BEHAVIORAL|Mailed outreach|The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
48698482|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management in in person group Format|The CBSM sessions will be delivered to participants in groups of ten, totaling eight sessions, each focused on a specific theme related to stress management. All participants will attend the complete sessions in person.
48698483|NCT06626061|BEHAVIORAL|Cognitive Behavioral Stress management Hybrid Format|The CBSM (hybrid) sessions will be offered to participants online, including a total of eight video modules, each dedicated to a specific theme related to stress management. Participants will also have access to three interactive virtual sessions, summary sheets in PDF format, and audio recordings for relaxation.
48698484|NCT05352061|BEHAVIORAL|CBT for Syndemics and Adherence Factors|Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
48698485|NCT03900104|PROCEDURE|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
48698486|NCT03900104|PROCEDURE|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
48011074|NCT05029141|DRUG|Placebo regimen|"Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC \> 20×10E9/L, G-CSF paused).~One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE\<1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial."
48168652|NCT06400797|OTHER|estimation of patient outcome by health care providers|On day 1 after study inclusion as well as day 4-7, the responsible health-care providers (at least one nurse, one resident and one consultant with the board certification intensive care medicine) will estimate the patient's expected functional outcome at 6 and 12 months after the start of ECMO therapy. Health-care providers responsible for the patient at that time will be surveyed (multiple questionnaires to detect specific differences within one person are not planned). For the purpose of functional outcome estimation, the modified Rankin scale (mRS) is used.
48168653|NCT01046825|DRUG|COPAD|"Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
48168654|NCT01046825|DRUG|COP, COPD M3, CYM|"GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
48515567|NCT05269095|BIOLOGICAL|Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)|Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
48515568|NCT02927470|DEVICE|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
48515569|NCT02927470|DEVICE|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
48011075|NCT04751305|BEHAVIORAL|Health Coaching|The weekly health coaching (HC) calls were structured to be participant-centered, built on a coach participant relationship, and include participant-determined goals, a self-discovery process to find solutions, patient accountability, and education. Before each HC call, the participants received a short questionnaire on fatigue, QOL, stress, loneliness, and social support which enabled tailoring the HC call to the individual. Educational topics are discussed in the following order: Goal Setting, Monitoring Behaviour, Barrier Management, Social Support, Stress Management, Adapting the Program, Self-Compassion, Sleep \& Nutrition, Reflection, Health Media, Remote Resources, and Maintaining Motivation. However, the order of the educational topics can be adjusted based on the specific participants' needs each week. At the half-way point of the intervention, the participant provided feedback on the HC calls, ensuring optimization of HC impact.
48011076|NCT04751305|BEHAVIORAL|Online delivered Exercise Classes|The group based remote exercise program was delivered over the Zoom application (2x/wk for first 2 weeks; 1x/wk for the remaining weeks). Classes were one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretch. Each class was followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
48011077|NCT04099862|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
48011078|NCT04099862|PROCEDURE|EUS-BD|Endoscopic UltraSound Biliary Drainage
48011079|NCT06196567|DEVICE|PEMF|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions
48011080|NCT06196567|OTHER|exercise|do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
48011081|NCT04124172|DEVICE|Real rTMS (Magstim)|See arm description
48011082|NCT04124172|DEVICE|Sham rTMS|See arm description
48011083|NCT06198907|DRUG|Golidocitinib|Daily dosing of golidocitinib
48011084|NCT06198907|DRUG|Sintilimab|Sintilimab, 200mg, intravenous, every 3 weeks.
48011085|NCT06198907|DRUG|platinum doublet chemotherapy|Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
48698487|NCT00873041|DRUG|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
48698488|NCT00873041|DRUG|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
48698489|NCT06662058|PROCEDURE|Audiometric Test|Undergo audiometry
48698490|NCT06662058|PROCEDURE|Audiometric Test|Undergo close to home audiometry
48698491|NCT06662058|PROCEDURE|Audiometric Test|Undergo self-administered remote audiometry
48011086|NCT04894617|DRUG|Amantadine|200 mg Amantadine daily for a total of 5 days.
48515570|NCT02927470|DEVICE|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
48011087|NCT04894617|DRUG|Lactose monohydrate|Lactose monohydrate two tablet daily for a total of 5 days.
48698492|NCT06662058|OTHER|Interview|Ancillary studies
48698493|NCT05779241|DRUG|LYN-005|Risperidone long-acting oral capsule
48011088|NCT04990895|OTHER|Electronic Tumour-Specific Patient-Reported Outcomes (ePRO) questionnaires|A web-based portal that prompts participants to enter tumour-specific ePROs at regular intervals in between clinic visits
48698494|NCT05779241|DRUG|Risperidone|Risperidone immediate release (IR) oral tablets
48698495|NCT01224340|BEHAVIORAL|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
48698496|NCT01224340|BEHAVIORAL|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
48011089|NCT03858075|DRUG|BLU-782|oral capsules
48011090|NCT03858075|DRUG|Placebo|oral capsules
48011091|NCT03858075|DRUG|BLU-782 taken with food|oral capsules
48011092|NCT05555433|OTHER|NO INTERVENTION|no intervention
48011093|NCT01665365|PROCEDURE|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
48011094|NCT03169491|DEVICE|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
48011095|NCT01982422|BEHAVIORAL|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
48011096|NCT01982422|BEHAVIORAL|Standard of Care|Normal standard-of-care for pregnancy.
48011097|NCT01794104|DRUG|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
48515571|NCT06056141|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
48515572|NCT06056141|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
48168655|NCT01046825|DRUG|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
48515573|NCT03323398|BIOLOGICAL|mRNA-2416|mRNA encoding human OX40L
48011098|NCT01739530|BIOLOGICAL|Repaircell|allogenic differentiated adipocyte
48698497|NCT01224340|OTHER|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
48698498|NCT02184091|DRUG|Nevirapine|
48698499|NCT02168049|DEVICE|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
48698500|NCT02168049|DEVICE|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
48698501|NCT02168049|DEVICE|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
48698502|NCT03951493|COMBINATION_PRODUCT|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
48698503|NCT03951493|RADIATION|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy."
48698504|NCT00914446|PROCEDURE|hepatic biopsies|hepatic biopsies
48698505|NCT00733291|DEVICE|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
48698506|NCT00733291|DEVICE|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
48698507|NCT00733291|DEVICE|FID 107027 solution|Commercially marketed solution for contact lens disinfection
48698508|NCT01257568|DEVICE|Rejuvenate Modular Hip|Rejuvenate Modular Hip
48698509|NCT00503776|BEHAVIORAL|exercise intervention|Patients undergo low weight resistance training.
48698510|NCT00503776|DRUG|amifostine trihydrate|Given subcutaneously
48515574|NCT03323398|BIOLOGICAL|Durvalumab|PD-L1 inhibitor
48698511|NCT00503776|PROCEDURE|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
48698512|NCT05456373|DEVICE|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
48698513|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
48698514|NCT04278768|DRUG|Venetoclax|Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
48011099|NCT00865722|PROCEDURE|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
48011100|NCT05044234|DRUG|Cedirogant|Capsule, Oral
48011101|NCT05044234|DRUG|Placebo|Capsule, Oral
48011102|NCT04467827|DIAGNOSTIC_TEST|examining group|Posture assessment in young healthy people depending on their level of physical activity
48011103|NCT00109564|DRUG|ispronicline (nicotinic acetylcholine receptor agonist)|
48011104|NCT04181918|BEHAVIORAL|AOT|During action observation, participants observe different daily actions (e.g. reading a newspaper; drinking an espresso) divided into up to four motor segments.
48011105|NCT04181918|BEHAVIORAL|MI|During motor imagery, participants imagine themselves performing the same daily actions as in AOT in the absence of motor output
48011106|NCT01689896|DRUG|Testosterone Gel|
48011107|NCT01689896|DRUG|Placebo Gel|
48011108|NCT03921411|BIOLOGICAL|Nemolizumab|Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
48515575|NCT00373633|PROCEDURE|Thoracic Epidural|Gold standard for post thoracotomy pain
48515576|NCT00373633|PROCEDURE|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
48515577|NCT02499484|DRUG|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
48515578|NCT02499484|OTHER|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
48515579|NCT02499484|OTHER|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
48515580|NCT00457132|DEVICE|APOS biomechanical gait system|
48515581|NCT04411914|DRUG|Clavulanic Acid|Drug will be given in 250mg capsules.
48698515|NCT04278768|DRUG|Emavusertib|Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
48698516|NCT01833910|OTHER|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
48698517|NCT01833910|OTHER|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
48698518|NCT04300361|GENETIC|Sequencing of DPYD gene|The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
48698519|NCT00669825|DRUG|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
48698520|NCT00669825|DRUG|Placebo|Placebo to be administered via intragastric tube
48011109|NCT05283096|OTHER|Questionnaire|A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
48011110|NCT00203450|DRUG|Zonegran|zonisamide
48011111|NCT00203450|DRUG|Placebo|Placebo pill
48011112|NCT00978731|DRUG|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
48011113|NCT01652456|OTHER|Addiction support|one consultation with an addiction specialist
48168656|NCT02191527|DEVICE|PIMA® for quantitative analysis of CD4-count|
48168657|NCT02191527|DEVICE|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
48168658|NCT02191527|DEVICE|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
48698521|NCT01404793|DRUG|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
48698522|NCT01190475|DRUG|Active treatment with a high dose of BGS649|
48698523|NCT01190475|DRUG|Active treatment with a low dose of BGS649|
48698524|NCT01190475|DRUG|Placebo treatment to blind study|
48698525|NCT02684877|OTHER|Questionnaire|
48698526|NCT01126437|DRUG|tiotropium 18 mcg|HandiHaler
48168659|NCT04493697|DEVICE|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
48515582|NCT04411914|OTHER|Placebo|Placebo
48515583|NCT01342757|DRUG|vorinostat|Given orally
48698527|NCT01126437|DRUG|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
48698528|NCT01126437|DRUG|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
48698529|NCT00907608|DRUG|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
48698530|NCT03658200|OTHER|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
48698531|NCT03658200|OTHER|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
48698532|NCT06490731|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine
48698533|NCT06490731|DRUG|Ketamine|patients Will receive ketamine
48698534|NCT00132756|DRUG|Doxil and Estramustine|
48011114|NCT02866838|DRUG|Tranexamic acid|intravenous
48011115|NCT02866838|DRUG|Saline 0.9%|intravenous
48011116|NCT06032624|PROCEDURE|combined ultra-sound guided femoral and sciatic nerve block.|Femoral nerve block, The femoral area will be scanned behind the midpoint of the inguinal ligament and the depth of the image will be set at 3-5 cm, and a linear high frequency 8-12MHz) probe will be placed perpendicular to the course of the femoral nerve., the volume of 15 ml of bupivacaine will be injected to perform the block. Sciatic nerve block, A curvilinear low-frequency (3-9 MHz) probe will be used to do a scan of the sub-gluteal region below a line from the ischial tuberosity and greater trochanter which are seen as two hyperechoic bony prominences,A volume of 25 ml of bupivacaine will be injected to perform the block.
48515584|NCT01342757|DRUG|temozolomide|Given orally
48698535|NCT01031589|DRUG|TMC278 (Rilpivirine) LA; Placebo|
48698536|NCT04378998|OTHER|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
48698537|NCT05695261|BIOLOGICAL|Microbial Transplantation Therapy|Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
48011117|NCT01919424|DRUG|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
48011118|NCT01919424|DEVICE|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
48011119|NCT01919424|DEVICE|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
48011120|NCT01332734|DRUG|Magnesium Sulfate|2 gram in 1 hour
48011121|NCT02684006|DRUG|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
48011122|NCT02684006|DRUG|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
48011123|NCT02684006|DRUG|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
48011124|NCT01306617|DRUG|ABT-450|tablets
48011125|NCT01306617|DRUG|ABT-333|tablets
48011126|NCT01306617|DRUG|ribavirin|tablets
48011127|NCT01306617|DRUG|ritonavir|capsules
48011128|NCT00535886|DIETARY_SUPPLEMENT|Man-made Trans FA|EA as 6% of total energy
48011129|NCT00535886|DIETARY_SUPPLEMENT|Natural Trans FA|VA as 6% of total energy
48011130|NCT00535886|DIETARY_SUPPLEMENT|Oleic Acid|OA as 6% of total energy
48011131|NCT05208216|DEVICE|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
48011132|NCT05208216|DEVICE|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
48011133|NCT04368923|DEVICE|Oxygen Therapy|Patients receive oxygen therapy
48011134|NCT04368923|PROCEDURE|Physical Therapy|Patients receive physical therapy
48370873|NCT01604512|DIAGNOSTIC_TEST|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
48370874|NCT03853993|BIOLOGICAL|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
48011135|NCT01674686|DRUG|Sarpogrelate|Sarpogrelate 100mg twice a day
48011136|NCT01674686|DRUG|Atorvastatin|Atorvastatin 80mg daily
48011137|NCT03780179|BIOLOGICAL|MMRvaxpro|MMRvaxpro vaccine
48011138|NCT03780179|BIOLOGICAL|Placebo|Placebo
48011139|NCT01610791|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
48011140|NCT02148003|PROCEDURE|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
48011141|NCT02148003|PROCEDURE|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
48011142|NCT02148003|DEVICE|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
48011143|NCT00855140|OTHER|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
48011144|NCT04587622|DRUG|Icenticaftor|Single oral dose of 300 mg of icenticaftor (QBW251)
48011145|NCT05510323|DRUG|Prednisolone|RAS blockade as much as tolerated or allowed
48011146|NCT05510323|DRUG|Prednisolone plus Cyclophosphamide|RAS blockade as much as tolerated or allowed
48011147|NCT02373124|DRUG|infusion of NMDA antagonist|52 minute infusion
48011148|NCT06103942|DIAGNOSTIC_TEST|CO2 angiography|A supplemental CO2 angiography will be performed before and after the stent graft placement.
48011149|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 weekly for 4 doses
48011150|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 weekly for 4 doses
48011151|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|1 μg vaginal dose of AZU-101 weekly for 4 doses
48011152|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.1 μg vaginal dose of AZU-101 twice-weekly for 8 doses
48011153|NCT06197568|DRUG|Lasofoxifene Tartrate (AZU-101)|0.5 μg vaginal dose of AZU-101 twice-weekly for 8 doses
48011154|NCT05546333|DEVICE|Electrical impedance tomography|Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
48011155|NCT03765307|DEVICE|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
48011156|NCT03765307|DEVICE|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
48011157|NCT05483010|DRUG|Atorvastatin|Atorvastatin is commercially available.
48011158|NCT05483010|DRUG|Rosuvastatin|Rosuvastatin is commercially available.
48011159|NCT01818362|BIOLOGICAL|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
48011160|NCT01818362|BIOLOGICAL|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
48011161|NCT03287856|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
48011162|NCT06108817|OTHER|Information material|The intervention consists of the distribution of a poster for the waiting room and flyers to be given to patients aiming to inform both patients and GPs with respect to the correct indications for treatment of dyspepsia. After signing up, practices assigned to the intervention group received a package containing 60 flyers and one waiting room poster to use during consultations. The flyer and poster provide a short description of the correct indications for treatment of dyspepsia. Additionally, both the flyers and posters contained a QR-code linking to a decision aid explaining the correct indications and causes of dyspepsia.
48011163|NCT06108817|OTHER|No Intervention|These practices do not receive information material
48011164|NCT04620148|DRUG|TAK-242|TAK-242 concentrate solution 80 mg/mL for dilution and infusion
48011165|NCT04620148|DRUG|Placebo|Matching placebo concentrate solution
48011166|NCT01046916|DRUG|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
48011167|NCT02561507|BEHAVIORAL|Survey|
48011168|NCT02358746|OTHER|combined endo/epicardial approach|
48011169|NCT02358746|OTHER|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
48011170|NCT06161792|DRUG|0.8 mg RCN3028|Oral
48370875|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
48698538|NCT05695261|DRUG|Antibiotic|Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
48698539|NCT05695261|OTHER|Placebo (in place of MTT)|Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
48698540|NCT05695261|OTHER|Placebo (in place of antibiotics)|Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.
48698541|NCT04848220|DRUG|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
48698542|NCT04848220|DRUG|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
48698543|NCT03800446|DIAGNOSTIC_TEST|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
48698544|NCT01352442|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
48698545|NCT01281254|DRUG|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
48698546|NCT01281254|DRUG|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
48698547|NCT05534659|DEVICE|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
48698548|NCT05534659|DEVICE|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
48011171|NCT06161792|DRUG|Placebo|Oral
48011172|NCT04510935|PROCEDURE|general anesthesia|the patient will receive general anesthesia during surgery in this group.
48698549|NCT00308412|BIOLOGICAL|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
48698550|NCT00308412|BIOLOGICAL|Placebo|Placebo for rHPIV3cp45 vaccine
48698551|NCT04149977|BEHAVIORAL|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
48698552|NCT04149977|BEHAVIORAL|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
48698553|NCT00426816|DRUG|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
48698554|NCT00426816|DRUG|Placebo|Placebo to match SB-649868
48698555|NCT05608993|OTHER|High Intensity Intervention|The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.
48698556|NCT05608993|OTHER|Low Intensity Intervention|The Low Intensity intervention will include clinician education and EHR changes only.
48698557|NCT00951080|DEVICE|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
48698558|NCT00951080|DEVICE|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
48698559|NCT00886886|DRUG|MDMA|125 mg, single dose
48698560|NCT00886886|DRUG|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
48698561|NCT00886886|DRUG|Placebo|capsules identical to MDMA or Reboxetine
48011173|NCT04510935|PROCEDURE|local anesthesia|the patient will receive local anesthesia during surgery in this group.
48011174|NCT00714246|DRUG|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
48011175|NCT00714246|DRUG|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
48370876|NCT03853993|BIOLOGICAL|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
48370877|NCT00000856|DRUG|Foscarnet sodium|
48370878|NCT00000856|DRUG|Ganciclovir|
48370879|NCT03089229|DRUG|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
48370880|NCT03089229|DRUG|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
48370881|NCT00005874|DRUG|rubitecan|
48370882|NCT05852301|OTHER|no intervention|no intervention, observational study only
48698562|NCT02420288|BEHAVIORAL|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
48698563|NCT03415451|DEVICE|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
48698564|NCT04826848|DIAGNOSTIC_TEST|Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = \[(Initial lactate - 6th hour lactate) / Initial lactate\] \* 100
48698565|NCT01670786|PROCEDURE|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
48698566|NCT01372943|BIOLOGICAL|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
48698567|NCT02043106|OTHER|plantar vibration|
48698568|NCT00753103|BIOLOGICAL|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
48698569|NCT00753103|DRUG|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
48698570|NCT00753103|DRUG|Prednisolone|Daily oral 1mg/kg tapered over 12 months
48698571|NCT00753103|DRUG|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
48698572|NCT00753103|PROCEDURE|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine \> 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
48011176|NCT00714246|DRUG|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
48011177|NCT01544972|DRUG|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
48011178|NCT01544972|DRUG|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
48370883|NCT01617343|BEHAVIORAL|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
48370884|NCT02812823|DEVICE|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
48698573|NCT00753103|DRUG|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
48698574|NCT00753103|DRUG|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
48698575|NCT05769855|DRUG|HR18034|HR18034 380mg
48011179|NCT01641367|DRUG|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day \[200 mg per day\])
48011180|NCT01641367|DRUG|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
48011181|NCT01641367|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
48011182|NCT01641367|DRUG|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
48011183|NCT01641367|DRUG|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
48370885|NCT03759002|DIAGNOSTIC_TEST|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
48370886|NCT03759002|OTHER|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
48370887|NCT06506526|PROCEDURE|Sodium hypochlorite irrigating solution|2 ml 1% NaOCl after each file
48370888|NCT06506526|PROCEDURE|one minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for one minute.
48370889|NCT06506526|PROCEDURE|Three minute NaOCL+Chitosan|2 ml 1% NaOCl after each file then with 5 ml of 0.2% chitosan for three minute.
48698576|NCT05769855|DRUG|ropivacaine HCl|ropivacaine HCl 75mg.
48698577|NCT05769855|DRUG|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
48698578|NCT02537587|OTHER|Control 1|67g of control bar
48698579|NCT02537587|OTHER|Control 2|86g of control bar
48698580|NCT02537587|OTHER|15/0|66g of experimental bar 15/0
48698581|NCT02537587|OTHER|15/0LS|84g of experimental bar 15/0LS
48698582|NCT02537587|OTHER|15/5|75g of experimental bar 15/5
48698583|NCT02537587|OTHER|10/5|72g of experimental bar 10/5
48698584|NCT02537587|OTHER|10/10|80g of experimental bar 10/10
48698585|NCT02599207|BIOLOGICAL|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
48698586|NCT03960411|DRUG|Doxycycline 100Mg Capsule|Doxycycline capsule
48011184|NCT01641367|DRUG|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
48370890|NCT03978949|DRUG|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
48698587|NCT03960411|DRUG|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
48698588|NCT01983384|OTHER|Processed EEG-guided anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
48011185|NCT01641367|OTHER|SOC adherence versus SOC+CPI adherence|"* not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence."
48011186|NCT00008346|DIAGNOSTIC_TEST|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
48011187|NCT00008346|DIAGNOSTIC_TEST|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
48515585|NCT01342757|PROCEDURE|magnetic resonance spectroscopic imaging|Undergo MRI
48698589|NCT04482530|OTHER|fruit paste matrice|Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
48698590|NCT04700345|DEVICE|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
48698591|NCT04700345|PROCEDURE|Burr-hole|Burr-hole drainage of subdural hematoma
48698592|NCT04700345|OTHER|Medical Management|best medical management
48698593|NCT01734954|PROCEDURE|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
48698594|NCT01734954|PROCEDURE|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
48698595|NCT01734954|DRUG|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
48698596|NCT01734954|DEVICE|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
48698597|NCT01734954|DEVICE|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
48698598|NCT01734954|DRUG|supplemental oxygen|supplemental oxygen during the block and/or during surgery
48698599|NCT01734954|DRUG|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
48515586|NCT01342757|OTHER|survey administration|Ancillary studies
48370891|NCT03978949|DRUG|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
48515587|NCT02051348|BIOLOGICAL|Pylopass|Pylopass
48515588|NCT02051348|BIOLOGICAL|Placebo|Placebo
48515589|NCT03893019|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
48515590|NCT00327756|DRUG|Coenzyme Q10|
48515591|NCT01553669|BEHAVIORAL|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
48698600|NCT01734954|DRUG|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
48698601|NCT01734954|PROCEDURE|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
48698602|NCT02569372|BIOLOGICAL|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
48515592|NCT04263181|PROCEDURE|Peripheral blood draw|"* All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~* Cohort 0 or 1 - peripheral blood draw on Day 2~* Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~* Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28"
48515593|NCT04263181|PROCEDURE|Bone marrow aspirate|"* Cohort 0 or 1 - bone marrow aspirate on Day 14~* Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28"
48515594|NCT04263181|PROCEDURE|Buccal swab|"* Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28"
48698603|NCT06287515|DEVICE|Stereotactic Radiosurgery|Given by Radiation Therapy
48011188|NCT02621970|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
48011189|NCT02621970|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1
48011190|NCT02621970|DRUG|Docetaxel|Docetaxel 60mg/m2, D1
48698604|NCT00347438|DRUG|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
48011191|NCT02621970|DRUG|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
48011192|NCT02621970|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
48698605|NCT06039176|DEVICE|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
48011193|NCT03240627|DRUG|LH-8|LH-8 cutaneous solution
48011194|NCT03240627|DRUG|Placebo|Placebo cutaneous solution
48011195|NCT03413332|OTHER|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
48011196|NCT03413332|OTHER|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
48011197|NCT02488629|DRUG|SCB01A|This study is a single arm, open-label, Phase II trial
48011198|NCT03567850|BEHAVIORAL|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
48011199|NCT00177424|DRUG|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
48370892|NCT04454021|PROCEDURE|hip arthroscopy|hip arthroscopy was performed when symptoms were not alleviated by nonsurgical treatment
48370893|NCT06058572|DRUG|Rifaximin with allogeneic stem cell transplant|Tab Rifaximin 200 mg will begiven orally twice daily from day -8 to day +60 of allogeneic stem cell transplant in acute leukemia patients. This will be in addition to standard of care posttransplant treatment
48515595|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 (single treatment cycle)
48515596|NCT01333397|BIOLOGICAL|Botulinum toxin type A|I.M. on day 1 (single treatment cycle)
48698606|NCT01129713|DRUG|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
48698607|NCT01129713|DRUG|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
48698608|NCT02882867|OTHER|Injuries in Swedish Youth Athletics. The KLUB-study.|
48698609|NCT02038140|DEVICE|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
48698610|NCT06346691|DRUG|Doxofylline|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
48698611|NCT06346691|DRUG|Procaterol|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
48370894|NCT06058572|PROCEDURE|Allogeneic stem cell transplant|Standard of care treatment including standard anti GVHD measures, antibiotic support and transfusions as needed.
48011200|NCT00177424|DRUG|Placebo|matching placebo tablets
48370895|NCT02052180|DRUG|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
48515597|NCT01333397|DRUG|Placebo|I.M. on day 1 (single treatment cycle)
48698612|NCT00760435|DRUG|Infliximab|5 mg/kg IV over 2 hours once
48698613|NCT00760435|DRUG|Placebo|Placebo (same volume as active drug)
48698614|NCT05840952|DRUG|ALG-097558|single or multiple doses of ALG-097558
48698615|NCT05840952|DRUG|Placebo|single or multiple doses of placebo
48698616|NCT05840952|DRUG|Midazolam|Multiple doses of Midazolam
48698617|NCT05840952|DRUG|Itraconazole|Multiple doses of Itraconazole
48698618|NCT05840952|DRUG|Carbamazepine|Multiple doses of Carbamazepine
48168660|NCT04493697|DEVICE|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
48168661|NCT00010842|DRUG|Ginkgo biloba|
48698619|NCT05840952|DRUG|ALG-097558 in solution formulation|ALG-097558 in solution administered in fasted state
48698620|NCT05840952|DRUG|ALG-097558 in tablet formulation|ALG-097558 in tablet administered in fasted and fed state
48698621|NCT02769338|OTHER|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
48011201|NCT02043015|BEHAVIORAL|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
48011202|NCT02043015|BEHAVIORAL|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
48011203|NCT02043015|BEHAVIORAL|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
48011204|NCT02043015|DRUG|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
48011205|NCT02043015|OTHER|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
48011206|NCT02043015|BEHAVIORAL|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
48168662|NCT00010842|DRUG|Alpha-lipoic acid|
48370896|NCT02052180|DRUG|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
48370897|NCT02274363|OTHER|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
48515598|NCT03305367|DIETARY_SUPPLEMENT|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
48698622|NCT03802305|DEVICE|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
48698623|NCT03802305|DEVICE|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
48698624|NCT01518998|DRUG|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
48698625|NCT04124562|OTHER|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
48698626|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|Adequate dairy (\> 3 standard daily servings)
48698627|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|\< 1 standard dairy serving/day
48698628|NCT04816136|OTHER|Sleep recording (already done)|Sleep recording (already done)
48698629|NCT00984165|PROCEDURE|Single fraction radiation|8-Gy fraction of radiation
48698630|NCT00984165|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
48515599|NCT04525937|OTHER|Patient Questionnaire|Patient Questionnaire
48515600|NCT04525937|OTHER|Provider Questionnaire|Provider Questionnaire
48698631|NCT00984165|PROCEDURE|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
48698632|NCT05279924|DRUG|Prophylaxis with Emicizumab|Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
48698633|NCT00453700|PROCEDURE|Trypanosoma cruzi serology|
48698634|NCT01196468|OTHER|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
48698635|NCT01196468|OTHER|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
48698636|NCT04904276|DRUG|Fostamatinib|Fostamatinib disodium
48698637|NCT05049707|DRUG|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
48698638|NCT05049707|OTHER|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
48698639|NCT01378702|DRUG|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
48698640|NCT03048890|BEHAVIORAL|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
48698641|NCT00767663|DRUG|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
48698642|NCT00767663|DRUG|placebo|placebo twice daily, minimal three days pretreatment
48698643|NCT01243372|GENETIC|mutation analysis|
48698644|NCT01243372|OTHER|laboratory biomarker analysis|
48698645|NCT04031664|DRUG|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
48698646|NCT03143907|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
48698647|NCT03082183|DRUG|Rifampicin|once daily
48698648|NCT03082183|DRUG|BI 425809|once daily
48698649|NCT05072223|PROCEDURE|Pericapsular nerve group block|A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.
48698650|NCT05072223|PROCEDURE|Interscalene block|A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
48698651|NCT01630928|PROCEDURE|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
48698652|NCT03397394|DRUG|Rucaparib|Rucaparib will be administered daily.
48698653|NCT02666651|DRUG|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
48698654|NCT02666651|OTHER|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
48698655|NCT03195348|OTHER|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
48698656|NCT03789513|DIAGNOSTIC_TEST|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
48698657|NCT05645978|DEVICE|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
48698658|NCT04282265|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
48698659|NCT04282265|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
48698660|NCT05042765|OTHER|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
48698661|NCT00005077|DRUG|oxaliplatin|
48698662|NCT03271372|DRUG|Avelumab|Given IV
48168663|NCT00010842|DRUG|Vitamin E/Selenium|
48168664|NCT00010842|DRUG|Essential fatty acids|
48515601|NCT04043455|DRUG|Olorinab|Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks
48698663|NCT03271372|OTHER|Peripheral Blood Collection|Correlative studies
48370898|NCT04749862|OTHER|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
48698664|NCT03271372|OTHER|Placebo|Given IV
48698665|NCT01595230|PROCEDURE|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
48698666|NCT05311449|OTHER|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
48698667|NCT05311449|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
48698668|NCT04380194|DIAGNOSTIC_TEST|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
48698669|NCT00920218|BIOLOGICAL|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
48698670|NCT00920218|BIOLOGICAL|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
48698671|NCT03004261|BIOLOGICAL|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
48168665|NCT03298633|OTHER|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
48515602|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks
48698672|NCT03004261|DRUG|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
48698673|NCT03004261|DRUG|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
48698674|NCT00685269|DRUG|Eszopiclone|Eszopiclone 3 mg QD
48698675|NCT00685269|DRUG|Placebo|Placebo tablet
48698676|NCT01049230|RADIATION|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
48698677|NCT01823159|DRUG|retigabine|Single oral administration of a 400 mg tablet.
48515603|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks
48698678|NCT01823159|DRUG|placebo|Single oral administration of a tablet
48515604|NCT04043455|DRUG|Placebo|Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
48698679|NCT06483191|BEHAVIORAL|Acceptance and Commitment Therapy|A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
48698680|NCT03081819|DRUG|SH003|Herbal medicine for cancer treatment
48698681|NCT01882426|OTHER|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
48370899|NCT04435093|OTHER|MFM-Play|Neuromuscular patients will complete five items of the MFM (items 18 to 22) either conventionally or using the MFM-Play with 2 different therapists, on the same day. The order of the MFM type completion will be determined by randomization. Both therapists will rate items 18 to 22 blindly.
48698682|NCT01882426|OTHER|Usual Care|usual step care practice
48370900|NCT05602558|BIOLOGICAL|LYB001|The antigen consists of receptor-binding domain (RBD) from wild-type SARS-CoV-2 displaying on virus-like particle (VLP) vector, adjuvanted with aluminium hydroxide.
48370901|NCT05602558|BIOLOGICAL|Placebo|Aluminium hydroxide adjuvant
48515605|NCT04043455|DRUG|Olorinab|Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks
48698683|NCT06464380|DIETARY_SUPPLEMENT|Saffranal|HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
48370902|NCT00451191|DRUG|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
48698684|NCT06464380|DIETARY_SUPPLEMENT|Placebo|HCC patients will receive Placebo in dose of once per day for six months.
48011207|NCT02043015|BEHAVIORAL|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
48168666|NCT03298633|OTHER|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
48168667|NCT02010398|OTHER|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
48698685|NCT04324996|BIOLOGICAL|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
48698686|NCT01542697|DRUG|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
48698687|NCT04053946|DEVICE|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
48698688|NCT01325454|DEVICE|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
48698689|NCT04236024|OTHER|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
48698690|NCT04236024|OTHER|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
48168668|NCT02010398|OTHER|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
48370903|NCT04115202|PROCEDURE|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
48515606|NCT04043455|DRUG|Olorinab|Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
48515607|NCT01872923|DRUG|Amphinex|Photosensitiser
48515608|NCT01872923|DRUG|Bleomycin|Anticancer agent
48515609|NCT01872923|DEVICE|Laser|Laser that emits red light at 652 nm.
48515610|NCT01525914|DRUG|Dutasteride|dutasteride 0.5mg daily
48698691|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
48698692|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
48515611|NCT05281510|DRUG|Vesatolimod|Administered orally
48515612|NCT05281510|BIOLOGICAL|VRC07523LS|Administered intravenously
48515613|NCT05281510|BIOLOGICAL|CAP256V2LS|Administered intravenously
48698693|NCT05099055|DRUG|Dexmedetomidine 0.004 MG/ML [Precedex]|Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
48698694|NCT05099055|DRUG|Opioids|Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
48011208|NCT01282424|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
48011209|NCT01797328|PROCEDURE|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
48011210|NCT01797328|PROCEDURE|warm arm|To the best of ability avoid feeling cold during 6 weeks
48168669|NCT02010398|OTHER|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
48370904|NCT00223990|BIOLOGICAL|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine
48370905|NCT00223990|BIOLOGICAL|RabAvert|RabAvert rabies vaccine
48370906|NCT03010046|DRUG|ANX005|Single ascending dose intravenous infusion
48515614|NCT02085447|BEHAVIORAL|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
48515615|NCT02068612|BEHAVIORAL|Moderate Intensity Continuous Training+Interval Training|
48515616|NCT02068612|BEHAVIORAL|Low Intensity Continuous Training|
48515617|NCT03758716|DRUG|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
48011211|NCT03668652|DEVICE|Focal HIFU treatment using Focal One (EDAP TMS) or TULSA-PRO (Profound Medical)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One or TULSA -PRO"
48370907|NCT03010046|DRUG|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
48515618|NCT04707794|DRUG|Sevoflurane|Sevoflurane delivery will will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
48515619|NCT04707794|DRUG|Desflurane|Desflurane delivery will be titrated to maintain anaesthesia depth of 50 (BIS score) using bispectral (BIS) index monitioring
48698695|NCT04491019|OTHER|Balance exercise group|Balance exercises will be carried out with a physiotherapist
48698696|NCT05247957|BIOLOGICAL|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
48698697|NCT05825534|OTHER|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
48698698|NCT03018795|PROCEDURE|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
48698699|NCT00002705|DRUG|topotecan hydrochloride|
48698700|NCT05489172|BEHAVIORAL|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
48698701|NCT02912494|DRUG|JR-131|
48698702|NCT02912494|DRUG|Darbepoetin alfa|
48698703|NCT03549208|BIOLOGICAL|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
48698704|NCT03549208|BIOLOGICAL|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
48698705|NCT03549208|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
48698706|NCT01779856|DEVICE|REVEAL Insertable Cardiac Monitor (ICM)|
48515620|NCT02139137|OTHER|Computerized Cognitive Training - active|Cognitive training using working memory span task
48515621|NCT02139137|OTHER|Computerized cognitive training - sham|Sham training condition
48515622|NCT05257057|DIAGNOSTIC_TEST|Immunohistochemical staining|Immunohistochemistry will be performed on the endometrial tissue specimens
48698707|NCT02243618|DRUG|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
48698708|NCT02243618|DRUG|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
48698709|NCT06314958|OTHER|CENSURE|A panel of CpG sites, whose methylation level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor.
48698710|NCT04378491|OTHER|Collection of clinical measurements|"Collection of clinical measurements:~* Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~* Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~* Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
48011212|NCT03668652|PROCEDURE|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
48168670|NCT02413606|OTHER|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
48168671|NCT01113164|DRUG|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
48168672|NCT04364685|OTHER|Walking on soft-sand|The participants are required to walking on sand for 30 minutes. Walking is self-paced.
48168673|NCT04364685|OTHER|Walking on Levelled Surface|The Participants will be require to walk on the firm surface for 30 minutes. The participants would decide the pace of walking.
48370908|NCT03010046|DRUG|Placebos|0.9% saline intravenous infusion
48370909|NCT00354991|DRUG|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
48168674|NCT03550183|BIOLOGICAL|mesenchymal stem cells|Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
48168675|NCT02003378|DEVICE|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
48168676|NCT02003378|DEVICE|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
48168677|NCT04641416|DIAGNOSTIC_TEST|Routinely performed echo, ECG and hemodynamic monitoring|The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
48515623|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
48515624|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
48515625|NCT01504997|DEVICE|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
48515626|NCT00758966|DRUG|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
48515627|NCT00758966|DRUG|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
48698711|NCT04378491|OTHER|Collection of data for muscle strength|"Collection of data for muscle strength:~* Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
48698712|NCT04378491|OTHER|Collection of EMG Data|"Collection of EMG Data:~* Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
48698713|NCT04378491|OTHER|Collection of Clinical Scores|"Collection of Clinical Scores:~* patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
48698714|NCT04378491|OTHER|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
48698715|NCT03982719|OTHER|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
48698716|NCT03982719|OTHER|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
48698717|NCT02554149|RADIATION|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
48011213|NCT03766503|OTHER|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
48698718|NCT06420856|OTHER|Assessment of the musculoskeletal system and its functions|Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
48698719|NCT00256035|PROCEDURE|Measuring IL-4 levels|
48698720|NCT00979966|DRUG|Temsirolimus|25 mg intravenously, once weekly infusion
48698721|NCT00979966|DRUG|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
48698722|NCT03983265|OTHER|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
48698723|NCT04054869|OTHER|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
48698724|NCT04054869|OTHER|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
48698725|NCT06151613|DEVICE|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
48698726|NCT04953819|OTHER|Revascularization|Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
48698727|NCT04953819|OTHER|Medical therapy|Optimal medical therapy for coronary artery disease
48698728|NCT00395187|PROCEDURE|Photodynamic Therapy|
48698729|NCT06230549|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
48698730|NCT05852158|DRUG|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
48698731|NCT05852158|DRUG|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
48011214|NCT05897177|BEHAVIORAL|Subjective Scale of Stigma and Discrimination (SISD).|"Subjective Scale of Stigma and Discrimination (SISD) A sixdimension self-administered scale will be used that included statements with which the participants agreed or disagreed. The scale consists of 23 Likert-type items and responses range from 1 (completely in disagreement) to 5 (completely in agreement), grouped together to represent the six indicators making up this part of the scale"
48168678|NCT02617433|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
48370910|NCT00383292|DRUG|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
48698732|NCT05658627|OTHER|active release technique|Hamstring active release technique-
48698733|NCT05658627|OTHER|conventional therapy|ultrasound therapy - stretching Exercise - Strengthening Exercise -
48698734|NCT03826654|DIETARY_SUPPLEMENT|fortified oil|35 g fortified sunflower oil
48698735|NCT03826654|DIETARY_SUPPLEMENT|Placebo|plain oil
48698736|NCT00721760|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
48698737|NCT00721760|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
48698738|NCT00721760|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
48698739|NCT00258765|DRUG|Zoledronic Acid|
48698740|NCT00258765|DRUG|Docetaxel|
48698741|NCT02617407|DRUG|Livionex® Dental Gel|Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
48698742|NCT02617407|DRUG|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
48698743|NCT02617407|DEVICE|Kolibree Toothbrush|Electric Toothbrush
48698744|NCT00808613|DEVICE|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
48698745|NCT00808613|DEVICE|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
48011215|NCT01110629|DRUG|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
48011216|NCT01110629|DRUG|Placebo|daily dose: 3 tablets TID for 8 weeks.
48011217|NCT05588596|BEHAVIORAL|Trauma Resiliency Mindfulness-Informed Intervention|The total duration of the intervention was once a week for eight weeks. The aim of the intervention was to teach patients a range of trauma recovery mindfulness skills
48011218|NCT01204866|BIOLOGICAL|Valortim and selected Components|"* Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~* Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~* Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~* Histamine (1 mg/mL), positive control~* Saline (0.9%), negative control"
48011219|NCT01204866|DRUG|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~* Only one subject will be skin tested in a single day.~* The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
48011220|NCT00972491|PROCEDURE|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
48011221|NCT01900613|BEHAVIORAL|Ninos Sanos Familia Sana|
48011222|NCT06198192|OTHER|Pilates Exercises|Ten repetitions of Pilates exercises will be performed with a 2-minute rest period between repetitions. Pilate group will receive the intervention program three times/week for total 10 weeks
48011223|NCT06198192|OTHER|Conventional Therapy and Balance Exercises|this group receive conventional therapy along with balance exercises. Standing with feet together while the therapist sitting behind and manually locking the child knees, and then slowly tilt him to each side, forward and backward. Step standing with therapist behind the child guiding him to shift his weight forward then backward alternately. High step standing and try to keep balanced. Standing with manual locking of the knees then tries actively to stoop and recover. Equilibrium, righting and protective reactions training. Open environment gait training will be conducted with the different obstacles. Session includes three times/week for total 10 weeks
48011224|NCT03237234|OTHER|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
48011225|NCT03237234|DEVICE|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
48698746|NCT06501547|GENETIC|Leucocyte Telomere Length from blood draw|blood draw, PCR method to see leucocyte telomere length
48011226|NCT02163928|OTHER|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
48011227|NCT06129812|DRUG|Neoadjuvant treatment|Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
48011228|NCT05430789|BEHAVIORAL|5As brief advice|"Participants will receive brief face-to-face advice following a 5As model at baseline:~1. Ask: Smoking patients will be asked about their smoking status.~2. Advise: Smoking patients will be advised to quit in a clear and personalised manner, with a focus on smoking-related diseases.~3. Assess: Smoking patients will be assessed for their readiness to quit by assessing their self-efficacy and perceived importance.~4. Assist: Those who are ready to quit will be assisted in setting a quit plan.~5. Arrange: Refer to smoking cessation services."
48168679|NCT04241887|PROCEDURE|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
48168680|NCT04241887|PROCEDURE|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
48168681|NCT02218775|DRUG|LY2456302|Mood and Anxiety Disorders
48168682|NCT00866918|DRUG|Arsenic Trioxide|Given IV
48698747|NCT02269553|DEVICE|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
48698748|NCT02269553|DEVICE|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
48698749|NCT01471028|BIOLOGICAL|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
48698750|NCT01471028|OTHER|Standard of care (Control)|Control receives standard medical treatment.
48515628|NCT00758966|DRUG|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
48011229|NCT05430789|BEHAVIORAL|Self-help e-booklet|"A 12-page generic self-help smoking cessation e-booklet via IM apps, including:~1. Highlights of the absolute risk of death due to smoking;~2. Smoking and diseases management;~3. Ten horrible pictorial warnings of health consequences of smoking and second-hand smoking;~4. Benefits of quitting;~5. Methods to quit and handle. withdrawal symptoms."
48011230|NCT05430789|BEHAVIORAL|Nurse-led mHealth intervention|Participants will receive real-time mHealth behaviour and psychosocial support for 12 weeks after baseline through IM apps. mHealth intervention consists of two main parts: regular instant messaging on smoking cessation and personalized real-time mHealth chatting on smoking and disease (including active referral to smoking cessation service)
48698751|NCT05349227|BEHAVIORAL|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
48011231|NCT05430789|BEHAVIORAL|Regular intervention|Participants will receive text messages using IM app with content on general health and reminding the importance of participating in the follow-up surveys and biochemical validation for quitting.
48011232|NCT03707288|OTHER|Spine Exercise Program|Spine exercises should be done 20 minutes/ 3 days per week Desk stretches should be done when exposed to prolonged sitting for greater than 60 mins
48698752|NCT05349227|DEVICE|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
48698753|NCT01696019|OTHER|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
48698754|NCT01696019|OTHER|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
48011233|NCT03697200|OTHER|APA|Light touch using vaccaria seeds on specific points of the ear
48011234|NCT03697200|OTHER|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
48011235|NCT03697200|OTHER|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
48011236|NCT03998124|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
48011237|NCT03998124|OTHER|Usual care|Staff-led social activity
48011238|NCT04628962|PROCEDURE|Collection and Raman analysis of saliva for the database|Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
48011239|NCT02268097|PROCEDURE|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
48168683|NCT00866918|DRUG|Cytarabine|Given IT or IV
48168684|NCT00866918|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48011240|NCT02268097|PROCEDURE|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
48011241|NCT05850871|DRUG|CAZ/AVI plus Aztreonam|Samples of the patients will be examined such as the routine blood test, blood culture et al.
48011242|NCT05850871|OTHER|Conventional treatment|Conventional treatment
48011243|NCT01804556|PROCEDURE|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
48011244|NCT02816216|BEHAVIORAL|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
48168685|NCT00866918|DRUG|Idarubicin|Given IV
48168686|NCT00866918|DRUG|Mercaptopurine|Given orally
48698755|NCT01696019|OTHER|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
48011245|NCT00263523|DRUG|[11C] (-)-RWAY|
48011246|NCT02962037|OTHER|Melatonin and light therapy|
48011247|NCT04918680|DEVICE|EcoFit® Total Hip System with implacross® E Polyethylene|The EcoFit® Total Hip System is a primary hip replacement system indicated for patients who are candidates for a primary cementless hip replacement. implacross® E Polyethylene is one of the components in the EcoFit® system.
48168687|NCT00866918|DRUG|Methotrexate|Given orally
48168688|NCT00866918|DRUG|Mitoxantrone Hydrochloride|Given IV
48168689|NCT00866918|DRUG|Tretinoin|Given orally
48698756|NCT01696019|OTHER|Contact and testing only|
48698757|NCT06415812|BEHAVIORAL|Evolutionary Systems Therapy|Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
48698758|NCT01412450|DEVICE|nitinol stent|implantation of one Protégé EverFlex stent
48698759|NCT02661555|OTHER|Aerobic exercise|
48698760|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
48698761|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
48698762|NCT02581046|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
48698763|NCT00733200|PROCEDURE|Minor or Major Liver Resection|
48698764|NCT05740163|DIETARY_SUPPLEMENT|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
48698765|NCT02984241|BEHAVIORAL|eHealth Coping Skills Training|Access to a specialized coping skills training website
48698766|NCT02984241|BEHAVIORAL|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
48698767|NCT02984241|BEHAVIORAL|Coach Support|Access to a professional coach by phone
48698768|NCT01179217|DRUG|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
48698769|NCT01179217|DRUG|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
48698770|NCT06315907|OTHER|Responses to survey questions|All 400 participants will first complete a demographic information survey and the new food noise questionnaire. Of these 400 participants, 250 participants will then complete additional questionnaires to assess construct validity. The remaining 150 participants will be asked to complete the food noise questionnaire again in approximately 1 week to assess test-retest reliability.
48011248|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using custom 3D printed templates|A patient dental model is acquired by digital scan then digital waxing-up is performed using the Exocad software to 3D print clear templates for direct composite resin restoration.
48011249|NCT06478004|OTHER|Direct composite restoration of carious primary anterior teeth using conventional strip crowns|Direct composite resin restoration using celluloid crown forms
48011250|NCT05717595|DIETARY_SUPPLEMENT|fructose|oral ingestion of fructose vs dextrose
48011251|NCT05147857|DEVICE|Dilapan s|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
48011252|NCT05147857|DRUG|Misoprostol|Misoprostol is a synthetic prostaglandin medication used to prevent and treat stomach and duodenal ulcers, induce labor, cause an abortion, and treat postpartum bleeding due to poor contraction of the uterus. Misoprostol is taken by mouth when used to prevent gastric ulcers in persons taking NSAIDs.
48011253|NCT00373243|DRUG|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
48515629|NCT04141982|DIAGNOSTIC_TEST|T-Cell SelectTM Kit|The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
48168690|NCT05756049|OTHER|compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.
48168691|NCT04208347|DRUG|Apatinib 250mg|Apatinib 250mg
48168692|NCT04208347|DRUG|Camrelizumab|Camrelizumab 200mg
48168693|NCT04208347|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
48168694|NCT04208347|DRUG|Apatinib 500mg|Apatinib 500mg
48698771|NCT06607497|OTHER|Intervention using an AI enabled risk communication tool (PERDICT.AI)|Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
48011254|NCT02994342|DEVICE|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
48011255|NCT02566915|DEVICE|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
48011256|NCT05061160|OTHER|Interval Aerobic Exercise training Group|"Interval Aerobic exercise will be on upper limb Bicycle with a pause of 3 mins interval Interval Aerobic Exercises: Frequency= 3 times per week Intensity= 50% of heart rate reserve for 2 mins 80% of heart rate reserve for 1 min Type= interval aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
48011257|NCT05061160|OTHER|Continuous Aerobic Exercise training Group|"Continuous Aerobic exercise will be on upper limb Bicycle Continuous Aerobic Exercise: Frequency= 3 times per week Intensity= 50% of heart rate reserve Type= continuous aerobic exercise Time= 40 minutes~There will be 5 minutes for warm up and 5 minutes for cool down."
48011258|NCT03997318|BIOLOGICAL|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
48011259|NCT03997318|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
48011260|NCT00071812|DRUG|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
48168695|NCT04486079|DIETARY_SUPPLEMENT|Nutricia PreOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
48168696|NCT03326050|DRUG|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
48168697|NCT03326050|DRUG|Ciprofloxacin|cipro 750 tablet twice daily
48168698|NCT03326050|DRUG|Rifampicin|Rifampicin 150Mg Capsule twice daily
48698772|NCT06607497|OTHER|Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)|The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
48011261|NCT00071812|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
48168699|NCT06478810|OTHER|Domomedicine and dedicated nursing care for a close and secure monitoring after an ambulatory hepatectomy|For patient who need a minor hepatectomy under laparoscopy for the standard of care, the follow-up will be an ambulatory follow-up. This ambulatory follow-up will be made possible thanks to the integration of Domomedicine and dedicated nursing care for a close and secure monitoring.
48168700|NCT00541671|DRUG|Saline|10 c of saline
48168701|NCT00541671|DRUG|Phenergan|Physician ordered dose
48168702|NCT06521294|OTHER|Mulligan SNAG mobilization tecnique|Mulligan SNAG mobilization tecnique
48168703|NCT06521294|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
48168704|NCT00668785|DRUG|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
48168705|NCT00900406|GENETIC|gene expression analysis|blood collection
48168706|NCT00900406|GENETIC|microarray analysis|Blood collection
48698773|NCT00221000|DRUG|Methoxsalen|
48698774|NCT00221000|PROCEDURE|Extracorporeal Photopheresis|
48698775|NCT00311194|BEHAVIORAL|6 months readmission rate to hospital|
48698776|NCT00653848|DRUG|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
48168707|NCT00900406|GENETIC|polymorphism analysis|Blood collection
48168708|NCT00900406|GENETIC|proteomic profiling|Blood collection
48515630|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
48698777|NCT03277898|BEHAVIORAL|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
48698778|NCT03277898|BEHAVIORAL|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
48698779|NCT05598944|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
48698780|NCT05598944|BEHAVIORAL|Más Presente, the UGRComp program|"Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life."
48698781|NCT05598944|OTHER|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
48698782|NCT04452071|RADIATION|periapical xray|periapical xray on the middle phalanax of the middle finger
48698783|NCT04544930|BEHAVIORAL|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
48698784|NCT03155087|DRUG|Metformin|
48698785|NCT06185907|OTHER|Surgery|We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
48698786|NCT03287934|DEVICE|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
48698787|NCT03287934|DEVICE|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
48698788|NCT05658848|OTHER|Collaborative infertility counseling|Collaborative infertility counseling for coping stratigies and marital satisfaction
48698789|NCT04689906|OTHER|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
48168709|NCT00900406|OTHER|flow cytometry|Blood collection
48168710|NCT00900406|OTHER|immunologic technique|Blood collection
48168711|NCT00900406|OTHER|laboratory biomarker analysis|Blood collection
48168712|NCT00900406|PROCEDURE|biopsy|Blood collection
48515631|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
48698790|NCT05317715|OTHER|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
48698791|NCT05317715|OTHER|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
48168713|NCT00989313|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
48168714|NCT00503217|DRUG|Tryptorelin|
48698792|NCT01889264|OTHER|Observational|Observational, Translational non-treatment study
48698793|NCT00446823|DEVICE|XCell cellulose wound dressing|
48698794|NCT00446823|DEVICE|Impregnated gauze dressing|
48698795|NCT01076868|DRUG|Primaquine|Primaquine x 14 days
48698796|NCT04888689|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
48698797|NCT04888689|DEVICE|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
48698798|NCT01216709|DIETARY_SUPPLEMENT|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
48698799|NCT01216709|OTHER|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
48698800|NCT01216709|OTHER|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
48698801|NCT03319563|DRUG|Local anesthetic-epinephrine|"* Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length."
48698802|NCT03319563|DRUG|Saline|normal saline 100 ml/10 cm of the wound length
48168715|NCT01121185|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
48011262|NCT00071812|DRUG|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
48698803|NCT01200407|DRUG|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
48011263|NCT00071812|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
48698804|NCT03363087|DEVICE|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
48698805|NCT03363087|DEVICE|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
48698806|NCT05605275|DIAGNOSTIC_TEST|PCT levels|All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
48698807|NCT05605275|DIAGNOSTIC_TEST|CRP levels|All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
48698808|NCT05605275|DIAGNOSTIC_TEST|White blood cell count|All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
48698809|NCT05605275|DIAGNOSTIC_TEST|Platelet count|All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
48698810|NCT02345772|DRUG|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
48698811|NCT02345772|DRUG|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
48698812|NCT02345772|DRUG|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
48698813|NCT02345772|DRUG|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
48698814|NCT05594017|DRUG|Scopolamine (0.4mg)|Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
48698815|NCT05594017|DRUG|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
48698816|NCT05139953|OTHER|No intervention|No intervention
48698817|NCT01689025|DRUG|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
48698818|NCT01689025|DRUG|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
48698819|NCT03366558|DIAGNOSTIC_TEST|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
48698820|NCT03366558|DIAGNOSTIC_TEST|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
48698821|NCT05566691|OTHER|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
48168716|NCT01121185|OTHER|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
48698822|NCT05566691|OTHER|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
48698823|NCT05566691|OTHER|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
48698824|NCT05566691|OTHER|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
48698825|NCT03289663|DRUG|synergistic combination of insecticides|third generation insecticide -treated bednets
48698826|NCT03289663|DRUG|Pyrethroids|Conventional insecticide
48698827|NCT04860557|OTHER|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
48698828|NCT04987996|DRUG|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
48698829|NCT04987996|DRUG|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
48698830|NCT04987996|DRUG|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
48698831|NCT02241655|DEVICE|a pragmatic EEG-guided anesthetic protocol|
48011264|NCT02530294|DRUG|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
48011265|NCT02530294|OTHER|Vehicle|Vehicle (placebo) topical wipes
48011266|NCT03815422|PROCEDURE|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
48011267|NCT00218192|BEHAVIORAL|Behavior Therapy|
48011268|NCT00627679|DRUG|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
48011269|NCT00627679|DRUG|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
48698832|NCT04892550|OTHER|Denneroll traction|The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region
48011270|NCT00627679|DRUG|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
48011271|NCT00627679|DRUG|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
48698833|NCT04892550|OTHER|Multimodal Program|The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
48698834|NCT01500915|DRUG|Ranibizumab|0,5mg intravitreal ranibizumab
48011272|NCT00115596|OTHER|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
48698835|NCT01916252|DRUG|bortezomib (Velcade ®)|
48698836|NCT01916252|DRUG|lenalidomide (Revlimid®)|
48011273|NCT06052774|PROCEDURE|Non-Surgical periodontal therapy|Supra and Subgingival debridement for all patients except periodontally healthy individuals
48011274|NCT06423716|DRUG|Duloxetine|60mg duloxetine given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
48168717|NCT02470299|DRUG|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
48370911|NCT05141058|BIOLOGICAL|Coronavirus-specific T cell (CST)|Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).
48515632|NCT03636685|DRUG|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
48515633|NCT03636685|DRUG|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
48515634|NCT00422825|DRUG|imatinib|
48515635|NCT02934867|OTHER|Protocol phone advice|Protocol phone advice
48698837|NCT01916252|DRUG|busulfan (Busilvex ®)|
48698838|NCT01916252|DRUG|Dexamethasone acetate|
48698839|NCT01916252|DRUG|Melphalan|
48698840|NCT00668382|BIOLOGICAL|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
48698841|NCT04974346|RADIATION|Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation|The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
48698842|NCT04974346|RADIATION|Pelvic definitive concurrent chemoradiation|Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
48698843|NCT04867187|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|20 minutes of high frequency (20Hz) rTMS.
48698844|NCT04867187|OTHER|Mirror therapy using virtual reality|active mirror-based therapy
48698845|NCT04867187|OTHER|Mirror therapy using sham mirror|20 minutes of sham mirror-based therapy
48168718|NCT02470299|OTHER|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
48168719|NCT04006236|OTHER|Experimental Infant Formula|Feed Ad Libitum
48168720|NCT04006236|OTHER|Control Infant Formula|Feed Ad Libitum
48515636|NCT02934867|OTHER|Usual phone advice|Usual phone advice
48698846|NCT02524275|DRUG|Capecitabine|Given PO
48698847|NCT02524275|DRUG|Docetaxel|Given IV
48698848|NCT02524275|OTHER|Quality-of-Life Assessment|Ancillary studies
48698849|NCT02524275|OTHER|Questionnaire Administration|Ancillary studies
48698850|NCT02965742|DEVICE|Stratos|A machine made by DMS group.
48515637|NCT05293821|DIAGNOSTIC_TEST|TriQuik IVD|TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
48515638|NCT05935202|DRUG|Mitapivat sulfate|Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD
48698851|NCT02965742|DEVICE|"Hologic QDR 4500A"|A machine made by Hologic inc.
48698852|NCT02965742|DEVICE|"Hologic HORIZON A"|A machine made by Hologic inc.
48698853|NCT01794078|DRUG|Aminophylline 400 mg|Xanthine derivative
48698854|NCT01794078|DRUG|Ambrisentan 5 mg|Endothelin receptor antagonist
48698855|NCT01794078|OTHER|Placebo|
48698856|NCT05017753|PROCEDURE|Thoracentesis|Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
48698857|NCT05017753|DRUG|Standard-of-care medical treatment|Standard-of-care medical treatment
48698858|NCT04984265|RADIATION|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
48698859|NCT00565149|BEHAVIORAL|PROOF|dietary overfeeding with high, low or normal protein content
48515639|NCT03816943|BEHAVIORAL|Whatsapp|a WhatsApp message with encouraging words will be sent after bond up
48515640|NCT03816943|BEHAVIORAL|Call|a telephone call will be made after bond up to provide encoring words
48698860|NCT06493357|BEHAVIORAL|PAC-Man|"PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings."
48698861|NCT06493357|BEHAVIORAL|Standard of Care|Routine care as provided by Ministry of Health.
48011275|NCT06423716|DRUG|Placebo|Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
48011276|NCT04888975|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
48011277|NCT02093572|OTHER|3 standard meals/day|
48011278|NCT02093572|OTHER|2 meals/day (omit breakfast)|
48011279|NCT06340035|OTHER|TENS|The TENS group is subjected to transcutaneous current. Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.
48011280|NCT06340035|OTHER|Percutaneous Peripheral Nerve Stimulation|In the pPNS group, the superior gluteal nerve and inferior gluteal nerve are stimulated percutaneously. The nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
48011281|NCT01178229|OTHER|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
48515641|NCT06581913|OTHER|Behavioral assessment|Eating Awareness, Acceptance of Food Cravings, Healthy Life Awareness Health Perception
48370912|NCT03684902|PROCEDURE|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
48370913|NCT00004219|DRUG|granisetron hydrochloride|
48370914|NCT00004219|DRUG|lerisetron|
48370915|NCT00004219|RADIATION|radiation therapy|
48370916|NCT03135873|DIETARY_SUPPLEMENT|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
48370917|NCT03135873|DIETARY_SUPPLEMENT|Placebo|Placebo is designed to have identical characteristics with verum.
48370918|NCT00273260|BEHAVIORAL|individualised bone density feedback and education|
48370919|NCT00435266|PROCEDURE|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
48370920|NCT02954939|DRUG|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
48370921|NCT02954939|DRUG|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
48370922|NCT05119738|BIOLOGICAL|Three doses of BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine)
48370923|NCT05119738|BIOLOGICAL|Two doses of Coronavac and one dose BNT162b2 (observational)|BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)
48011282|NCT03326427|BEHAVIORAL|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
48011283|NCT03326427|OTHER|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
48011284|NCT03621137|OTHER|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
48370924|NCT05352958|PROCEDURE|Diaphragmatic ultrasound|duration 15 minutes, performed at M0, M3, M6 and M9
48370925|NCT05352958|OTHER|Electro-physiological exploration of the diaphragm|duration between 30 and 60 minutes performed at M0
48011285|NCT02044536|OTHER|No intervention|retrospective data review
48011286|NCT01927250|BEHAVIORAL|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
48011287|NCT00700791|DIETARY_SUPPLEMENT|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
48011288|NCT00700791|DEVICE|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
48698862|NCT01835574|BEHAVIORAL|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete \>=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
48698863|NCT02384473|PROCEDURE|Real-Time CEUS|Undergo real-time CEUS
48698864|NCT02384473|PROCEDURE|SWE|Undergo SWE
48698865|NCT02384473|DRUG|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
48698866|NCT02384473|DEVICE|Philips Shear Wave Elastography|Type of equipment used for SWE
48698867|NCT01801748|DIETARY_SUPPLEMENT|oral wheat challenge|
48011289|NCT00700791|OTHER|Placebo|Oral Placebo
48168721|NCT04826497|DRUG|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
48698868|NCT00227344|DEVICE|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
48698869|NCT00227344|DRUG|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
48698870|NCT03724383|BEHAVIORAL|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
48011290|NCT00700791|OTHER|Placebo Cream|Topical Placebo Cream
48011291|NCT06027749|DEVICE|Epitel's™ Remote EEG Monitoring System's (REMI™)|Ambulatory electroencephalography (EEG) monitoring
48011292|NCT04125108|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
48011293|NCT02645994|DEVICE|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
48011294|NCT02645994|DEVICE|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
48011295|NCT03194048|OTHER|Functional Chewing Training|"FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
48011296|NCT03194048|OTHER|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
48011297|NCT04266457|OTHER|No Intervention|No Intervention
48011298|NCT00270972|DEVICE|Bilayered Cellular Matrix (OrCel)|
48011299|NCT02134457|BIOLOGICAL|ranibizumab|
48698871|NCT03724383|BEHAVIORAL|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
48698872|NCT03724383|BEHAVIORAL|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
48698873|NCT03724383|OTHER|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
48698874|NCT03724383|OTHER|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
48698875|NCT01945411|DEVICE|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
48698876|NCT01945411|DEVICE|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
48698877|NCT00223405|DEVICE|crown placement|
48011300|NCT03363230|BEHAVIORAL|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
48698878|NCT04160286|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
48698879|NCT06458530|BEHAVIORAL|Vivo|Participants will meet virtually twice a week with their small group and certified trainer for 45 minutes exercise sessions for a 12-week period.
48011301|NCT03363230|BEHAVIORAL|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
48011302|NCT01857258|DIETARY_SUPPLEMENT|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
48011303|NCT00858390|DIETARY_SUPPLEMENT|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
48698880|NCT05141708|DRUG|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
48698881|NCT06214130|DRUG|Sodium valproate 500 MG|oral intake
48698882|NCT06214130|DRUG|Valproic Acid 500 MG|oral intake
48698883|NCT02891902|OTHER|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
48698884|NCT04569864|PROCEDURE|Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion|Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
48698885|NCT05480215|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
48370926|NCT04721626|DRUG|Chlorhexidine Gluconate|"Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)"
48370927|NCT04721626|DRUG|Povidone-iodine|"Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine."
48698886|NCT05091697|BEHAVIORAL|Multicomponent treatment VIRTUAL FIBROWALK + TAU|To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
48698887|NCT02767726|DEVICE|non-invasive multimodal imaging|
48698888|NCT06236984|OTHER|multiFiltratePRO with all CKRT treatment modes|Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
48011304|NCT02386202|OTHER|No intervention|No interventions
48011305|NCT05552313|PROCEDURE|kinesio tape|kinesio tape will be applied while patient is in sitting position. Y strip will be applied along C1 till T1.while patient's cervical spine is in contalateral side bending and rotation. same will be performed on the other side. on top of it, an I strip will be applied horizontly along C1 to C4. Both strips will be applied with 15% to 20% stretch.
48370928|NCT04721626|DRUG|Tetracycline Ointment|Postoperative: \~10g 3% tetracycline ointment will be placed into the oral cavity to coat the dorsal tongue and any oral suture lines every six hours for two days (8 total doses).
48515642|NCT02468856|DRUG|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
48698889|NCT00960011|DEVICE|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
48698890|NCT00960011|DEVICE|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
48698891|NCT03276026|DRUG|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
48698892|NCT03276026|DRUG|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
48698893|NCT02498886|DIETARY_SUPPLEMENT|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
48698894|NCT02498886|DIETARY_SUPPLEMENT|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
48011306|NCT05552313|PROCEDURE|standard therapy|Thoracic manipulation along with conventional including Tens, stretching and strengthening exercises of entire neck musculature
48011307|NCT06193538|DRUG|Recombinant NV-A01 adenovirus injection|Patients with advanced glioblastoma were intratumoral injected with NV-A01. Or the NV-A01 was injected after tumor resection.
48698895|NCT00451009|DEVICE|Viacell's product Media Kits|
48698896|NCT02058511|DRUG|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
48011308|NCT02417454|DIETARY_SUPPLEMENT|ProbioStick|"One sachet daily, without or without meals (3 x 10\^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
48011309|NCT02417454|OTHER|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
48011310|NCT04194775|DRUG|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
48011311|NCT04194775|DRUG|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
48011312|NCT05453838|DIETARY_SUPPLEMENT|oral intake of one serving of the original and new product|1) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
48011313|NCT00808288|DRUG|PF-00610355|oral, inhaled, dry powder, 600ug, OD
48011314|NCT00808288|DRUG|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
48011315|NCT00808288|DRUG|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
48011316|NCT00808288|DRUG|Placebo|oral, inhaled, dry powder, placebo, OD
48011317|NCT00808288|DRUG|Salmeterol|salmeterol, 50ug, BID
48011318|NCT04088682|BEHAVIORAL|Quality improvement strategies and tools|Quality improvement strategies and tools
48011319|NCT02244333|DRUG|ALNA®|
48011320|NCT00175903|DRUG|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
48011321|NCT00175903|DRUG|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
48011322|NCT00175903|DRUG|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
48011323|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
48011324|NCT02112097|DRUG|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
48011325|NCT02112097|DRUG|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
48011326|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
48011327|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
48011328|NCT02112097|DRUG|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
48370929|NCT05018390|OTHER|Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).
48698897|NCT02058511|PROCEDURE|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
48698898|NCT00670618|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
48698899|NCT00670618|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
48698900|NCT00670618|DEVICE|Fluoride (Elmex Medical Gel)|Fluoride
48698901|NCT04754191|DRUG|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
48011329|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
48011330|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
48011331|NCT02112097|DRUG|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over \< 5% of the plaque."
48011332|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
48011333|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
48011334|NCT02112097|DRUG|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
48011335|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
48011336|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
48011337|NCT02112097|DRUG|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
48011338|NCT02112097|DRUG|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
48011339|NCT02112097|DRUG|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
48370930|NCT05018390|OTHER|Sham Osteopathic manipulative treatment|Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
48698902|NCT06517394|BEHAVIORAL|Recovering Together after Cardiac Arrest|The intervention will teach resiliency skills (mindfulness, coping, etc.) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person or on Zoom/telephone, depending on the participant's preference and access to technology.
48698903|NCT02355652|DEVICE|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
48698904|NCT02355652|DEVICE|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
48698905|NCT06013358|GENETIC|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
48698906|NCT04014881|BIOLOGICAL|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
48698907|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
48698908|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
48011340|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
48011341|NCT02112097|DRUG|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
48011342|NCT02112097|DRUG|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
48011343|NCT00405574|DRUG|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
48370931|NCT02895074|PROCEDURE|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
48370932|NCT02895074|PROCEDURE|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
48370933|NCT02895074|DRUG|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
48370934|NCT02895074|DRUG|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
48370935|NCT01377142|DEVICE|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
48370936|NCT01377142|DEVICE|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
48370937|NCT01708473|DRUG|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
48370938|NCT01708473|DRUG|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
48370939|NCT01708473|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48370940|NCT04556149|DEVICE|imPulse™ Una e-stethoscope|The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
48370941|NCT04556149|DEVICE|Philips Lumify Ultrasound System|Point-of-care ultrasound
48698909|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
48698910|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
48698911|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
48698912|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
48698913|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
48698914|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
48698915|NCT01292356|DRUG|cetuximab|
48698916|NCT01258465|BEHAVIORAL|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
48698917|NCT01258465|BEHAVIORAL|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
48698918|NCT05045482|DRUG|Saroglitazar Magnesium 1 mg|Group-8: Total of 12 subjects will be enrolled in the Group-8. Group 8A (n=3, consist of mild hepatic impairment subjects); Group 8B (n=3, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
48698919|NCT05045482|DRUG|Saroglitazar Magnesium 2 mg|Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
48698920|NCT05594498|DEVICE|StrataXRT|StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
48011344|NCT06187103|DEVICE|HyperSight Imaging|Patients receive standard of care radiation treatment on a Varian TrueBeam system equipped with HyperSight CBCT imaging. Images acquired for daily patient positioning from two different treatment fractions - typically one near the beginning of the treatment course and one at about the halfway point - will be analyzed for the study.
48011345|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
48011346|NCT00537446|DEVICE|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
48370942|NCT01144858|OTHER|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
48370943|NCT03457701|DRUG|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
48011347|NCT05849402|DEVICE|Active Comparator: Active aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
48011348|NCT05849402|DEVICE|Sham Comparator: Sham aiTBS|Participants will be randomized to active or sham aiTBS condition, and receive 10 aiTBS to left DLPFC (LDLPFC) sessions a day for 5 days of course.
48370944|NCT03457701|DRUG|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
48370945|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.
48370946|NCT03457701|DRUG|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).
48698921|NCT00820859|BEHAVIORAL|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
48011349|NCT05418556|DRUG|aspirin|DAPT strategy
48698922|NCT00820859|BEHAVIORAL|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
48011350|NCT04010110|DIAGNOSTIC_TEST|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
48011351|NCT05931848|OTHER|Warm-up and Cool-down Program|"Each exercise in the warm-up and cool-down protocols consisting of active movements and static stretching exercises will be performed as 1 set and 10 repetitions. Active movements will be performed for 10 seconds. The detailed protocol is shown below.~Neck flexion/extension/lateral flexion Circles made with the head chin-tuck Backward bilateral shoulder circumduction Shoulder external rotation with hands clasped at neck Circles with wrists clasped clockwise and counterclockwise Reciprocal upper extremity flexion-extension cat-camel Trunk lateral flexion with hands clasped overhead Trunk rotation in both directions Ankle dorsi/plantar flexion with knee extension Static Stretching Exercises Neck lateral flexor stretch Posterior capsule stretching Hands clasped trunk flexion lateral Trunk lateral flexion with hands clasped Trunk rotation in both directions Knee extensor and ankle plantar flexor stretching by reaching for toes"
48011352|NCT05931848|OTHER|Strengthening Exercises|"The progression of the strengthening program will be achieved by gradually changing the number of repetitions, sets, resistance and the number of exercises.~1-6 Weeks Upper extremity strengthening in unilateral PNF D2 pattern, Scapulothoracic strengthening with shoulder extension in elbow extension, Scapulothoracic strengthening with shoulder extension in elbow flexion, hip flexor strengthening, Hip abductor strengthening in knee flexion, when sit on the chair fingertip ups and downs 7-12 Weeks Added exercises Scapular adductor strengthening with shoulders in horizontal abduction position, Shoulder adductor strengthening in elbow extension with trunk lateral flexion in arms overhead position, hip abductor strengthening 13-16 Weeks Added exercises Shoulder abductor/flexor strengthening in the scapular plane, Elbow flexor strengthening, Upper extremity strengthening in unilateral PNF D2 pattern with trunk rotation, Taking a lateral step in a mini-squat position"
48168722|NCT04826497|DRUG|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
48168723|NCT03397316|PROCEDURE|xenograft placement .|immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
48370947|NCT02033486|DEVICE|TOBI + DBT|
48370948|NCT02146911|DRUG|Bupropion|
48370949|NCT02146911|DRUG|Varenicline|
48370950|NCT02146911|BEHAVIORAL|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
48370951|NCT01972282|DEVICE|WATCHMAN Left Atrial Appendage Closure|
48698923|NCT00473668|BIOLOGICAL|Zilbrix-Hib|Intramuscular injection, 1 dose
48698924|NCT00473668|BIOLOGICAL|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
48698925|NCT05952011|PROCEDURE|Left stellate ganglion block|patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
48698926|NCT00441428|DRUG|solifenacin|
48698927|NCT03541486|DRUG|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered. The infusion occurs during the 'beam on' of the radiation therapy.
48698928|NCT03541486|DRUG|Gemcitabine|600 mg/m2 once weekly for up to weeks
48011353|NCT05931848|OTHER|Balance Exercises|"Balance exercises will be applied following the strengthening exercises. The exercises will be gradually made more difficult. Participants will be encouraged to complete the balance exercises by standing next to the grab bar and with as little support as possible.~1-6. Week Rising and falling on the heels Hands at waist trunk extension hip abduction 6-9. Week Hip abduction and extension without lowering the foot to the ground, respectively 5 sec stop on tiptoe 5 seconds standing on one leg 10-12. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~5 sec stop on tiptoe 10 sec stop on tiptoe 5 seconds standing on one leg 10 seconds standing on one leg 13-16. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~10 sec stop on tiptoe 15 sec stop on tiptoe 10 seconds standing on one leg 15 seconds standing on one leg"
48011354|NCT05931848|OTHER|Otago Home Exercise Program|"The exercises included in the Otago Home Exercise Program will be taught to the participants after the group exercise session held at the Social Life Center. At the same time, home exercise training will be supported by brochures and videos. In addition to the exercises in the program, participants will be asked to do 30 minutes of moderate-intensity walking 2 days a week. Participants will be asked to record the exercises they did during the week in the exercise diary given to them.~Balance Exercises~1. Knee bend (half squat)~2. Walking backwards~3. Walk and turn around~4. Sideways walking~5. Tandem stance~6. Tandem walking~7. Standing on one leg~8. Walking on the heel~9. Toe walking~10. Tandem walking backwards~11. Sit down~12. Going up and down stairs Strengthening Exercises~1. Knee extension 2. Knee flexion 3. Hip abduction 4. Ankle plantar flexion 5. Ankle dorsiflexion"
48011355|NCT00434096|DRUG|rimonabant (SR141716)|oral administration once daily
48011356|NCT00434096|DRUG|placebo|oral administration once daily
48011357|NCT02017691|DEVICE|Near Infrared Spectroscopy|If crSO2 is \<10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable \>10th centile, or if crSO2 is \> 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
48011358|NCT02017691|DEVICE|Pulse-oximetry|If SpO2 remains \<10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is \>90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
48370952|NCT01670552|DRUG|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
48011359|NCT02175069|PROCEDURE|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
48168724|NCT03294421|PROCEDURE|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
48011360|NCT02175069|DRUG|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
48011361|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
48011362|NCT02175069|DRUG|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
48011363|NCT02175069|DRUG|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
48011364|NCT02175069|PROCEDURE|Shoulder Surgery|As per individual requirement (patient-dependent)
48011365|NCT03271879|DRUG|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
48011366|NCT03524027|PROCEDURE|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
48168725|NCT03294421|PROCEDURE|standard closed tympanomastoidectomy|"1. Supine position and general anesthesia with orotracheal intubation~2. Antisepsis and placing of sterile fields~3. Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~4. Retroauricular incision~5. Removal of the temporal muscle fascia~6. Elevation of the surgical flap of the tympanic meatus~7. Visualization and exploration of the cholesteatoma~8. Exploration of the ossicular chain~9. Mastoid debridement~10. Conservation of the upper posterior wall of the auditory conduct~11. Removal of the cholesteatoma~12. Tympanoplasty with the temporal fascia~13. Retroauricular suture with vycril 3.0 and mononylon 4.0"
48370953|NCT01670552|DRUG|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
48370954|NCT03045107|PROCEDURE|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
48698929|NCT03541486|RADIATION|radiation therapy|Prescribed to 50 Gy in 25 fractions. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
48011367|NCT03354429|DRUG|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
48011368|NCT03354429|DRUG|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
48011369|NCT02090452|DEVICE|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
48011370|NCT01854021|PROCEDURE|intravenous anesthesia|intravenous anesthesia
48011371|NCT01854021|PROCEDURE|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
48011372|NCT01854021|PROCEDURE|inhalational anesthesia|inhalational anesthesia
48011373|NCT05464121|BEHAVIORAL|• Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.|"The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention."
48011374|NCT02293785|DRUG|Oxycodone-Naloxone|
48011375|NCT00029731|DRUG|Arginine hydrochloride|
48011376|NCT04748510|PROCEDURE|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
48168726|NCT05056298|OTHER|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
48168727|NCT05056298|OTHER|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
48168728|NCT05056298|OTHER|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
48168729|NCT05056298|OTHER|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
48168730|NCT02836054|PROCEDURE|lumbar puncture (LP)|
48168731|NCT02836054|PROCEDURE|brain MRI|
48168732|NCT00169949|DRUG|aripiprazole|
48168733|NCT01828398|DEVICE|real-tDCS + UE robot-assisted therapy|
48168734|NCT01828398|DEVICE|sham-tDCS + UE robot-assisted therapy|
48370955|NCT03045107|PROCEDURE|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
48370956|NCT01214382|DRUG|Sertraline|Single dose sertraline 100 mg, tablet and solution
48168735|NCT02599090|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
48168736|NCT02599090|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
48168737|NCT02599090|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
48168738|NCT01193023|OTHER|Pressure Support|Ventilation under pressure support
48168739|NCT01193023|DEVICE|NAVA|Ventilation under NAVA
48515643|NCT02468856|DRUG|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
48515644|NCT02234076|BEHAVIORAL|VRET|
48515645|NCT02234076|BEHAVIORAL|TAU|Treatment as usual offered by the participating mental health care organisations
48168740|NCT05930132|PROCEDURE|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
48168741|NCT05930132|PROCEDURE|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
48698930|NCT04347213|BEHAVIORAL|Regular lifestyle in different circumstances|Participants' lifestyle will be followed over the years.
48515646|NCT00334373|PROCEDURE|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
48698931|NCT00167609|DRUG|dehydroepiandrosterone 100 and 400 mg|
48698932|NCT03773536|DRUG|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
48698933|NCT05092282|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
48698934|NCT05092282|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
48698935|NCT04281225|BEHAVIORAL|Attention to Variability (ATV)|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.
48698936|NCT04281225|OTHER|Placebo|Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
48515647|NCT06550557|BEHAVIORAL|counselling sessions|the counselling sessions were adopted from the health belief model with the cues of action depending on mobile phones as muting notifications, removing social media and using computers instead if possible.
48515648|NCT02300155|DRUG|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
48515649|NCT02300155|DRUG|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
48515650|NCT02806115|PROCEDURE|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
48515651|NCT02806115|DRUG|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
48515652|NCT02806115|DEVICE|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
48698937|NCT05834933|BEHAVIORAL|Individualized breast cancer risk assessment|Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
48698938|NCT05834933|BEHAVIORAL|Individualized breast cancer risk counselling|Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
48698939|NCT01274923|DEVICE|"MEDISPEC treatment probe"|shock wave treatment
48698940|NCT05289817|DEVICE|Transcutaneous Vagus Nerve Stimulation (t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
48011377|NCT04748510|PROCEDURE|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
48011378|NCT05839665|DEVICE|Humidified high-flow nasal oxygen|Humidified high-flow oxygen delivered via the Optiflow device
48011379|NCT05839665|DEVICE|Standard nasal cannula|Oxygen delivered with high flows via a standard nasal cannula
48011380|NCT05839665|DEVICE|Facemask|Oxygen delivered with facemask
48011381|NCT04990726|BEHAVIORAL|Assessment|Undergo medical assessments
48011382|NCT04990726|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48011383|NCT04990726|OTHER|Quality-of-Life Assessment|Ancillary studies
48011384|NCT04990726|OTHER|Questionnaire Administration|Complete questionnaires
48011385|NCT03222375|DEVICE|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
48011386|NCT01410110|BEHAVIORAL|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
48011387|NCT01410110|BEHAVIORAL|Work Therapy|20 hours per week of work therapy
48011388|NCT00977067|DRUG|GDC-0152|Intravenous escalating dose
48011389|NCT05988957|OTHER|Semi-structured interviews using an IRB-approved interview guide|A single, semi-structured interview will be conducted using an IRB-approved interview guide. The interviews will be approximately 30 minutes total.
48011390|NCT00293384|DRUG|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
48011391|NCT00293384|DRUG|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
48168742|NCT04815473|PROCEDURE|Valvulotomy|Valvulotomy of the venous valves
48515653|NCT03258203|OTHER|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
48515654|NCT02567279|DRUG|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
48011392|NCT00293384|DRUG|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
48011393|NCT00293384|DRUG|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
48011394|NCT00261482|DRUG|norelgestromin + ethinyl estradiol|
48011395|NCT06116422|BEHAVIORAL|Grocery intervention - unrestricted|Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
48011396|NCT06116422|BEHAVIORAL|Grocery intervention - restricted|Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
48011397|NCT05666401|PROCEDURE|follicle diameter and duration of procedure|to investigate if smaller follicles thrive embryos as the bigger follicles
48011398|NCT01218997|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
48011399|NCT01218997|DRUG|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
48011400|NCT02472756|DRUG|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
48011401|NCT02472756|DRUG|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
48011402|NCT03815162|DIETARY_SUPPLEMENT|High Flavanol Cocoa extract|Experimental group
48011403|NCT03815162|DIETARY_SUPPLEMENT|Alkalised cocoa|Control group
48011404|NCT02459392|OTHER|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:~Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.~Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
48011405|NCT02459392|DRUG|Hyaluronic Acid|Drug administration
48515655|NCT02567279|DRUG|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
48515656|NCT04982302|PROCEDURE|Non-surgical periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets
48011406|NCT02459392|DRUG|DepoMedrol|Drug administration
48698941|NCT05289817|DEVICE|Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes"
48698942|NCT05289817|DEVICE|Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
48698943|NCT00610350|DRUG|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
48698944|NCT00610350|DRUG|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
48698945|NCT05474638|DEVICE|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
48698946|NCT05296824|PROCEDURE|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
48698947|NCT01539733|DRUG|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
48698948|NCT01539733|DRUG|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
48698949|NCT03618732|OTHER|Bilateral movement-based computer training|
48698950|NCT03618732|OTHER|Video-directed conventional training|
48011407|NCT02733510|DRUG|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
48698951|NCT04246437|DRUG|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
48698952|NCT04246437|DRUG|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
48698953|NCT04246437|DRUG|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
48011408|NCT04409782|OTHER|Electronic portal education|Participants will receive education via an electronic portal covering the key messages pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
48011409|NCT04409782|OTHER|Online educational video|Participants will receive online education via a video and written web content. Key messages will include information pertaining to cancer research studies and clinical trials. Data will be collected via pre- and post-tests. The post-test includes questions to pre-screen participants for eligibility into cancer research studies and clinical trials; as appropriate, study participants will be referred to those study/trial/clinical teams for follow-up.
48011410|NCT04949438|DRUG|AZD4831|Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
48011411|NCT05168540|OTHER|no intervention|Children will be included on the occasion of an admission to pediatric unit, the emergency room, the intensive care unit or a consultation in a specialized unit for children at risk of abuse. Their primary care pathway will be analyzed.
48011412|NCT04556305|BEHAVIORAL|Mind|See arm description.
48515657|NCT04366323|DRUG|ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS|Two doses of 80 million adipose-tissue derived mesenchymal stem cells
48515658|NCT01662219|OTHER|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
48011413|NCT04556305|BEHAVIORAL|Move|See arm description.
48011414|NCT00546715|DRUG|Daclatasvir|Oral Solution, Oral, Single Dose
48011415|NCT00546715|DRUG|Placebo|Oral Solution, Oral, Single Dose
48011416|NCT00646204|DRUG|Memantine|10 mg bid
48168743|NCT03962517|DEVICE|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
48168744|NCT03962517|OTHER|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
48168745|NCT02026505|DRUG|Bortezomib|
48011417|NCT00646204|DRUG|placebo|2 tabs bid
48011418|NCT00596011|DRUG|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
48011419|NCT00596011|DRUG|Placebo|Matching placebo BID
48011420|NCT02694224|DRUG|vismodegib|Smo inhibitor
48011421|NCT02694224|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
48168746|NCT05062837|DRUG|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
48168747|NCT05624489|BEHAVIORAL|Engagement Strategies|The study's mobile app (Oralytics) will be used to deliver engagement prompts. The prompts contain messages that leverage three engagement strategies: reciprocity, reciprocity by proxy, and curiosity.
48168748|NCT03402321|DRUG|Gelatin Sponge Sheet|sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
48168749|NCT03402321|DRUG|Alvogyl|paste form with analgesic action to protect the palatal donor site and help to relief pain
48515659|NCT04975854|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Virtual reality scenarios consists of increasingly intense exposures to phobic stimuli (e.g., looking over railings from various floor levels) with the support of the therapist. The goal of VRET is sufficient reduction in anxiety to allow the patients to expose themselves to heights in everyday situations.
48515660|NCT04975854|OTHER|Information Session|This includes 20-minute information session about general principles of exposure therapy before the start of the study.
48515661|NCT02569190|DEVICE|Walkbot|Robot assisted gait training
48515662|NCT04217954|DRUG|OXA, 5-FU and bevacizumab plus Toripalimab|"1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~   B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~   The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
48011422|NCT02694224|DRUG|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
48011423|NCT02694224|DRUG|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
48011424|NCT05699668|DEVICE|OCT Angiography|"2 views per eye (one centered on the fovea, one centered on the optic nerve), in 6x6 mm, using the OCT-A Plexelite®.~Acquisition time per image: about 10 seconds."
48011425|NCT02006238|DEVICE|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
48011426|NCT02006238|DEVICE|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
48698954|NCT06086158|PROCEDURE|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
48698955|NCT00742989|OTHER|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
48698956|NCT00742989|OTHER|Sham OLT|Therapeutic massage performed
48515663|NCT05520125|BIOLOGICAL|Mesenchymal stem cells enriched by extracellular vesicles|Mesenchymal stem cells enriched by extracellular vesicles
48515664|NCT05520125|OTHER|Standard treatment of bone defects|Standard surgical treatment of bone defects
48698957|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (Fast Track)|The core Fast-Track lesson includes information on managing their cycle of symptoms, motivation, and an overview of strategies that can be used to manage symptoms of depression and anxiety. After the core lesson, clients can access three additional Do-It-Yourself guides that focus on thought challenging, controlled breathing/activity planning, and behavioural activation/relapse prevention. These materials are able to be accessed out of sequence on a schedule that suits their needs. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
48698958|NCT05333627|BEHAVIORAL|Wellbeing Course for Students (5 weeks)|The 5-week course consists of four lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
48011427|NCT00003002|BIOLOGICAL|HER-2/neu peptide vaccine|
48011428|NCT00003002|BIOLOGICAL|sargramostim|
48168750|NCT06050018|OTHER|YesMilkdiet|In the YesMilkdiet the participants will consume Milk and dairy products
48168751|NCT06050018|OTHER|NoMilkdiet|In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
48515665|NCT03302676|DIETARY_SUPPLEMENT|Chewing gum|
48515666|NCT06297915|DRUG|Ketamine|Ketamine infusion was administered at 1 mg/kg (in 1 hour)
48515667|NCT06297915|DRUG|Lidocain|Lidocaine infusion was administered at 3 mg/kg (in 1 hour)
48515668|NCT02166658|DRUG|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
48515669|NCT01709929|DRUG|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
48515670|NCT02352012|OTHER|Autologous blood|Autologous blood was perfused to the target pulmonary segment
48011429|NCT06406062|DEVICE|ANDOANGEL|"Polyps were identified by endoscopists assisted by an AI system: rectangular box marks; Monitoring of ileocecal position: whether blindness was reached was displayed in the lower left corner of the interface.~Mirror entry and exit time monitoring: the operation time is displayed in the upper left corner of the interface.~Colonoscopy withdrawal speed monitoring: the relative withdrawal speed was displayed on the left side of the interface."
48011430|NCT02321982|OTHER|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
48011431|NCT00301405|DRUG|Thalidomide|Open label drug
48168752|NCT05157737|OTHER|Electrophysiological detection of KCNQ2 mutation|Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.
48515671|NCT02352012|DEVICE|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
48515672|NCT00368758|DRUG|Probiotic bacteria (Trevis R)|
48168753|NCT05157737|OTHER|Multi-modal brain image and EEG|Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).
48168754|NCT05157737|OTHER|Omics testing|Omics testing include proteomics, metabolomics, transcriptomics.
48515673|NCT05800158|DIAGNOSTIC_TEST|Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit|A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
48515674|NCT06399744|PROCEDURE|sclerotherapy|injection of sclerosing agent (tetracycline or polidocanol) into ovarian cyst after aspiration of its contents
48515675|NCT03532828|OTHER|polysomnography|Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
48515676|NCT00208273|DRUG|Letrozole - Concomitant|
48515677|NCT00208273|DRUG|Letrozole - Sequential|
48698959|NCT05333627|BEHAVIORAL|Wellbeing Course (8 weeks)|The 8-week course consists of five lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model, thought monitoring and challenging, controlled breathing and pleasant activity scheduling, graded exposure, and relapse prevention. With optional therapist support, therapists will respond to any messages that clients send once per week. Therapists will not message clients on weeks where the client does not send a message.
48698960|NCT00491946|DRUG|Actinomycin-D|
48698961|NCT00491946|DRUG|Vincristine|
48168755|NCT04103086|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
48515678|NCT03419689|PROCEDURE|Tumour tissue collection|"Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
48515679|NCT03419689|PROCEDURE|Blood sample collection|"Blood samples will be taken:~* At the time of first diagnosis~* About 1 week after starting any treatment~* At each radiological response assessment~* At each subsequent relapse or disease progression"
48515680|NCT03419689|PROCEDURE|Ascites Collection|"Ascites will be collected if paracentesis is required during any of the following time points:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
48515681|NCT03419689|PROCEDURE|Fluid Collection|Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
48515682|NCT01774162|DEVICE|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
48515683|NCT01774162|DEVICE|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
48515684|NCT04205058|DIETARY_SUPPLEMENT|Standard coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
48698962|NCT00925106|DRUG|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
48698963|NCT00925106|DRUG|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
48168756|NCT04103086|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
48168757|NCT02629419|DRUG|Amphotericin B|Oral lipid nanocrystal formulation of amphotericin B
48168758|NCT05098756|OTHER|Art therapy|The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
48168759|NCT00531063|DRUG|Everolimus (RAD001)|
48168760|NCT05436652|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
48168761|NCT05436652|DRUG|SPI-62 matched placebo|Inactive tablets identical in appearance to SPI-62 tablets
48515685|NCT04205058|DIETARY_SUPPLEMENT|Caffeine-free coffee|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
48515686|NCT04205058|DIETARY_SUPPLEMENT|Drinking water|One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).
48515687|NCT05645133|DEVICE|Diagnostic Test|Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
48515688|NCT02574065|DRUG|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
48515689|NCT02574065|OTHER|The placebo consists of an identical formulation without L. reuteri DSM 17938|
48698964|NCT00925106|DRUG|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
48698965|NCT00925106|DRUG|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
48698966|NCT04293926|OTHER|Exercise|Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
48698967|NCT05635396|DEVICE|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
48698968|NCT03789136|OTHER|Not applicable, observational study|Not applicable, observational study
48698969|NCT06178848|DRUG|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
48698970|NCT06178848|DRUG|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
48698971|NCT05355259|DEVICE|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
48698972|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
48698973|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
48698974|NCT00185380|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
48168762|NCT05436652|DRUG|Prednisolone 10mg|Standard of care prednisolone
48168763|NCT05436652|DRUG|Additional prednisolone|Over encapsulated prednisolone
48388071|NCT06568328|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (1\~10×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
48515690|NCT03933566|PROCEDURE|Ultrasound-Guided Superficial Cervical Plexus Block|Ultrasound-Guided Superficial Cervical Plexus Block
48698975|NCT04413656|OTHER|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
48698976|NCT04413656|OTHER|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
48698977|NCT05016661|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
48698978|NCT03167112|DRUG|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
48698979|NCT03167112|DRUG|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
48698980|NCT03167112|DRUG|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
48698981|NCT03167112|DRUG|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
48698982|NCT01357161|DRUG|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
48698983|NCT01357161|DRUG|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
48168764|NCT05436652|DRUG|Additional prednisolone matched placebo|Inactive capsules identical in appearance to over encapsulated prednisolone
48168765|NCT01304771|BIOLOGICAL|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
48168766|NCT05294406|DRUG|Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine|Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
48168767|NCT02604797|DRUG|Nalbuphine|patient-controlled intravenous analgesia
48168768|NCT02604797|DRUG|Sufentanil|patient-controlled intravenous analgesia
48168769|NCT02604797|DRUG|flurbiprofen axetil|patient-controlled intravenous analgesia
48168770|NCT02604797|DRUG|ramosetron|patient-controlled intravenous analgesia
48168771|NCT01820221|PROCEDURE|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
48168772|NCT05762081|PROCEDURE|Disposable Wipes for wiping baths|A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.
48168773|NCT05762081|PROCEDURE|Traditional bed bath|Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
48168774|NCT00546078|BIOLOGICAL|Cervarix™|Intramuscular injection, one or three doses
48168775|NCT02893358|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
48011432|NCT04617093|DEVICE|PrismaLung+|Overall, up to 60 adult patients will be initiated on ECCO2R using PrismaLung+. A minimum of approximately 15 patients will be treated with ECCO2R using PrismaLung+ as stand-alone therapy and another minimum of approximately 15 patients (maximum of 20) will receive ECCO2R using PrismaLung+ in combination with CRRT.
48168776|NCT02893358|DRUG|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
48168777|NCT01849679|OTHER|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
48168778|NCT01580111|BIOLOGICAL|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
48168779|NCT01837797|DRUG|Placebo|Once daily, tablets, orally
48168780|NCT01837797|DRUG|Brexpiprazole 1 mg|once daily dose, tablets, orally
48168781|NCT01837797|DRUG|Brexpiprazole 3 mg|once daily dose, tablets, orally
48388072|NCT02922439|BEHAVIORAL|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
48388073|NCT02922439|BEHAVIORAL|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
48168782|NCT02664025|PROCEDURE|vaginal examination simulator|
48168783|NCT02271685|OTHER|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
48168784|NCT02271685|OTHER|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
48168785|NCT02271685|OTHER|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
48168786|NCT02271685|OTHER|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
48168787|NCT00496626|BIOLOGICAL|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
48168788|NCT00496626|BIOLOGICAL|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
48168789|NCT00373022|BEHAVIORAL|exercise intervention|
48168790|NCT00373022|OTHER|flow cytometry|
48388074|NCT03970252|DRUG|Fluorouracil|Given IV
48011433|NCT06435247|BEHAVIORAL|With or without accompaniment in the recovery anaesthetic area|one grup will have family accompaniment in the recovery area and the other group will not in both groups the QoR15 scale will be used to measure the quality of anesthetic recovery
48011434|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
48011435|NCT03138668|DRUG|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
48011436|NCT00791791|PROCEDURE|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
48011437|NCT01830140|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
48011438|NCT01830140|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
48011439|NCT06197451|OTHER|Turkish Version of M. D. Anderson Dysphagia Inventory|Turkish Validation and Cultural Adaptation of M. D. Anderson Dysphagia Inventory in Neurologic Patients
48011440|NCT01749891|DRUG|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
48011441|NCT05856305|DRUG|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
48011442|NCT05856305|DRUG|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
48011443|NCT03945877|OTHER|No interventions|No interventions
48011444|NCT03620318|DRUG|Crenolanib besylate|
48011445|NCT03454438|PROCEDURE|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
48011446|NCT03904459|OTHER|no intervention|
48011447|NCT02065674|DRUG|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
48011448|NCT01132521|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
48168791|NCT00373022|OTHER|laboratory biomarker analysis|
48168792|NCT00373022|PROCEDURE|management of therapy complications|
48011449|NCT01132521|DRUG|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
48011450|NCT00323128|PROCEDURE|Calculation of inuline clearance|Calculation of inuline clearance.
48011451|NCT00323128|PROCEDURE|Measuring serum creatinine|Measuring serum creatinine.
48011452|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
48168793|NCT00373022|PROCEDURE|psychosocial assessment and care|
48168794|NCT00373022|PROCEDURE|quality-of-life assessment|
48168795|NCT03851614|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
48168796|NCT03851614|DRUG|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
48168797|NCT03851614|DRUG|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
48388075|NCT03970252|DRUG|Irinotecan|Given IV
48011453|NCT00832208|DRUG|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
48011454|NCT04295889|DIAGNOSTIC_TEST|Approach A (PeeSpot urine collection device).|The participant will receive the PeeSpot urine collection device (Hessels+Grob B.V., Deventer, The Netherlands), which consists of a holder containing a urine collection pad (consisting of hygroscopic material containing). The holder can be placed back into the tube and can be easily sent to the laboratory by mail. In this urine, albumin, creatinine, and the ACR will be measured in the laboratory of the Amphia hospital.
48011455|NCT04295889|DIAGNOSTIC_TEST|"Approach B (ACR | EU Test kit)."|"The participant will receive the ACR \| EU test kit (Healthy.io Ltd, Tel-Aviv- Yafo, Israel), which consists of a urine test strip, a urine cup, a color calibrator and instruction to download a smartphone application. The participants have to download the smartphone application according to the instructions included in the kit. Results will be directly shown to the participant in the app."
48011456|NCT04537806|DRUG|Brexanolone|Administered as IV infusion.
48011457|NCT04537806|DRUG|Placebo|Administered as IV infusion.
48011458|NCT05625477|BIOLOGICAL|TNM002 (low dose)|Single dose of TNM002 administered by intramuscular injection
48011459|NCT05625477|BIOLOGICAL|TNM002 (medium dose)|Single dose of TNM002 administered by intramuscular injection
48011460|NCT05625477|BIOLOGICAL|TNM002 (high dose)|Single dose of TNM002 administered by intramuscular injection
48698984|NCT01357161|DRUG|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
48011461|NCT05625477|BIOLOGICAL|HTIG|Single dose of HTIG administered by intramuscular injection
48011462|NCT05625477|BIOLOGICAL|Placebo|Single dose of placebo administered by intramuscular injection
48011463|NCT05483244|OTHER|discontinuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
48011464|NCT05483244|OTHER|continuous weaning|"Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient."
48011465|NCT04812379|DRUG|Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)|The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.
48698985|NCT01357161|DRUG|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
48698986|NCT01110330|DRUG|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
48011466|NCT03152318|DRUG|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
48698987|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
48698988|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
48698989|NCT06607991|DRUG|Blinatumomab Treatment|Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
48698990|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
48011467|NCT03152318|DRUG|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
48168798|NCT03318783|DRUG|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
48168799|NCT03318783|DRUG|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
48168800|NCT04115956|DRUG|Melphalan-Flufenamide (Melflufen)|Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
48698991|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
48698992|NCT05060549|DRUG|Cariprazine|Participants will receive 6 weeks of cariprazine treatment
48698993|NCT03242564|DEVICE|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
48698994|NCT04313374|DRUG|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
48698995|NCT04313374|DRUG|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
48698996|NCT04313374|DRUG|Placebo|the PCA will contain placebo
48168801|NCT04115956|DRUG|Dexamethasone|Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
48168802|NCT03982875|DEVICE|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
48168803|NCT05865925|DRUG|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
48698997|NCT05158335|DRUG|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
48698998|NCT05158335|DRUG|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
48168804|NCT06364891|OTHER|VMMC NEXUS Digital application|A handheld digital application which supports segmentation of potential VMMC Clients
48388076|NCT03970252|DRUG|Irinotecan Hydrochloride|Given IV
48168805|NCT02257918|DRUG|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
48168806|NCT02257918|DRUG|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
48168807|NCT06543550|DRUG|Implantable gestrinone|1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.
48388077|NCT03970252|DRUG|Leucovorin|Given IV
48515691|NCT03933566|PROCEDURE|Landmark-Based Superficial Cervical Plexus Block|Landmark-Based Superficial Cervical Plexus Block
48515692|NCT06499324|DRUG|BTA group|It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
48698999|NCT05158335|DRUG|Placebo|Single SC dose or repeated SC doses of placebo.
48699000|NCT05659017|GENETIC|Genetic analysis|The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
48699001|NCT01335893|DRUG|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
48699002|NCT05055388|OTHER|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
48699003|NCT04314999|DIAGNOSTIC_TEST|Examination of stool samples|Tests for diagnosis of parasitic diseases
48699004|NCT01895439|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
48168808|NCT06543550|DRUG|Oral Dienogest|Administered orally at 2 mg daily
48699005|NCT05432362|OTHER|Aronia Juice|The intervention is based an the additional consumption of 200 ml natural juice a day for a period of six weeks. The participants are asked to drink the natural and commercially availabe juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
48699006|NCT05432362|OTHER|Placebo|A beverage is prepared according to a known recipe. It contains macro- and micronutrients in comparable amounts like the aronia juice. It is completely polyphenol free.
48699007|NCT04399863|BEHAVIORAL|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
48699008|NCT04322331|OTHER|no intervention|no intervention
48699009|NCT00948857|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
48699010|NCT00948857|DIETARY_SUPPLEMENT|Placebo|Blinded placebo
48699011|NCT04599855|DRUG|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
48699012|NCT04599855|DRUG|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
48168809|NCT00000725|DRUG|Interferon alfa-2a|
48168810|NCT00000725|DRUG|Zidovudine|
48168811|NCT00000725|DRUG|Interferon alfa-n1|
48388078|NCT03970252|DRUG|Leucovorin Calcium|Given IV
48388079|NCT03970252|BIOLOGICAL|Nivolumab|Given IV
48388080|NCT03970252|DRUG|Oxaliplatin|Given IV
48699013|NCT04599855|DRUG|Placebo|Matching placebo will be self administered as nasal spray.
48699014|NCT01159925|PROCEDURE|Serum sample|Serum samples collected
48168812|NCT00092365|DRUG|MK0966, rofecoxib|
48168813|NCT00092365|DRUG|Comparator: celecoxib, placebo|
48168814|NCT05748678|DEVICE|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
48388081|NCT03970252|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48388082|NCT06032767|OTHER|observational group|patients initially diagnosed with nasopharyngeal carcinoma treated with IMRT
48699015|NCT02141399|DRUG|ALKS 5461|Sublingual tablet, taken daily
48699016|NCT00656149|PROCEDURE|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
48168815|NCT03144778|BIOLOGICAL|Durvalumab|Given IV
48011468|NCT03152318|PROCEDURE|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
48011469|NCT03041259|DRUG|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
48011470|NCT03041259|DRUG|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
48515693|NCT06499324|DRUG|Placebo group|It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width \>= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
48515694|NCT06583122|PROCEDURE|Ultrasound Guided Approach|All enrolled patients will receive the new ultrasound-guided approach to occipital nerve radiofrequency ablation
48168816|NCT03144778|BIOLOGICAL|Tremelimumab|Given IV
48168817|NCT01414556|OTHER|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
48168818|NCT01414556|OTHER|saline|
48168819|NCT00993798|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
48168820|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
48699017|NCT00656149|PROCEDURE|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
48699018|NCT02099877|DRUG|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
48699019|NCT04876066|DRUG|Ketamine|Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
48699020|NCT04652206|DRUG|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
48699021|NCT04652206|DRUG|Gemcitabine|Used according to marketing authorisation
48011474|NCT03736824|PROCEDURE|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
48011475|NCT00141063|DRUG|Focalin XR|
48011476|NCT04550624|DRUG|Pembrolizumab Injection [Keytruda]|200mg IV on day 1 of each cycle
48011477|NCT04550624|DRUG|Lenvatinib Mesylate|20mg PO daily days 1-21 of each cycle
48011478|NCT02110992|DRUG|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
48011479|NCT02110992|RADIATION|Stereotactic Radiation|SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
48011480|NCT03550924|PROCEDURE|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
48011481|NCT03550924|PROCEDURE|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
48011482|NCT01957475|DEVICE|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
48011483|NCT01957475|DEVICE|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
48168821|NCT00993798|DRUG|Bupivacaine HCl Treatment 1c|20.0 ml
48168822|NCT00993798|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
48699022|NCT04652206|DRUG|Nab paclitaxel|Used according to marketing authorisation
48011484|NCT02837887|BEHAVIORAL|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
48011485|NCT01814176|DEVICE|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
48011486|NCT06399146|DEVICE|Picterus App|Take a photo off the patient's skin (sternum).
48011487|NCT00623883|PROCEDURE|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
48011488|NCT00623883|PROCEDURE|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
48011489|NCT02165111|DRUG|Onabotulinumtoxin A|
48011490|NCT02165111|DRUG|sterile saline solution|
48011491|NCT02995915|OTHER|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
48011492|NCT02995915|DRUG|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
48168823|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
48168824|NCT00993798|DRUG|Bupivacaine HCl Treatment 2c|20.0 ml
48168825|NCT00349739|DRUG|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
48168826|NCT00592735|PROCEDURE|laparoscopic gastric banding|standard surgical procedure
48168827|NCT01565252|DIETARY_SUPPLEMENT|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
48168828|NCT00420225|DEVICE|Low-weight prolypropylene mesh|
48168829|NCT01412632|DRUG|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
48168830|NCT00913783|DRUG|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
48168831|NCT00913783|DRUG|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
48011493|NCT02995915|BEHAVIORAL|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
48011494|NCT02995915|BEHAVIORAL|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
48011495|NCT02995915|BEHAVIORAL|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
48011496|NCT00169650|OTHER|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
48011497|NCT03922568|OTHER|Density Gradient Centrifugation|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
48011498|NCT03922568|DEVICE|Physiological ICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
48011499|NCT03922568|DEVICE|Magnetic Activated Cell Sorting|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
48168832|NCT04669002|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
48168833|NCT04669002|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
48515695|NCT01268527|DRUG|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
48699023|NCT05617066|BEHAVIORAL|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
48699024|NCT04486430|DRUG|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
48515696|NCT01268527|DRUG|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
48699025|NCT04486430|DRUG|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
48699026|NCT04486430|DRUG|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
48699027|NCT04486430|DRUG|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
48699028|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
48699029|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
48699030|NCT00313313|DRUG|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
48699031|NCT00313313|DRUG|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
48699032|NCT00313313|DRUG|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
48699033|NCT00313313|DRUG|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
48699034|NCT05352516|BIOLOGICAL|HLX14|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14."
48011500|NCT03428776|BEHAVIORAL|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
48011501|NCT03428776|BEHAVIORAL|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
48011502|NCT03428776|OTHER|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
48011503|NCT00003380|DRUG|etoposide|
48011504|NCT00003380|DRUG|pegylated liposomal doxorubicin hydrochloride|
48011505|NCT02411331|DRUG|Ethanol 40% + Enoxaparine 400UI/ml|
48011506|NCT02411331|DRUG|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
48011507|NCT05242510|PROCEDURE|Patching|The subject will occlude the non-dominant eye for 24 hours.
48011508|NCT05242510|PROCEDURE|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
48011509|NCT01438541|DEVICE|Window|Dressing
48370957|NCT06252831|DRUG|"AS-Probionorm"|"Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol."
48011510|NCT03261349|DRUG|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
48011511|NCT01495962|DRUG|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
48011512|NCT01495962|DRUG|Placebo|Placebo (Normal Saline)
48011513|NCT03792685|OTHER|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
48011514|NCT03792685|OTHER|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
48011515|NCT03792685|OTHER|High-fat meal intake|Subjects are going to receive the high-fat meal.
48011516|NCT03792685|OTHER|High-protein meal intake|Subjects are going to receive the high-protein meal.
48011517|NCT00120432|DRUG|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
48011518|NCT06084208|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Cone Beam Computed Tomography (CBCT)
48011519|NCT04955106|DIAGNOSTIC_TEST|SEM Scanner|They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
48168834|NCT05655234|BEHAVIORAL|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
48011520|NCT06232733|BEHAVIORAL|Healthy Lifestyles Project e-intervention|Virtual lifestyle behaviour change support.
48011521|NCT01678534|DRUG|Allogenic mesenchymal stem cells from adipose tissue|
48011522|NCT01678534|DRUG|Placebo|
48011523|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
48011524|NCT00886093|DRUG|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
48011525|NCT05848388|OTHER|Molar incisor malformation presence|the presence of radiographic features of molar incisor malformation
48011526|NCT05246605|OTHER|change in body position|changing from supine to prone position and the back to supine
48011527|NCT05029752|DEVICE|Vendys II Device|Using the device
48011528|NCT04540432|OTHER|Stool collection at the patient's home.|Stool samples will be taken from each patient to look for changes in intestinal microbiota. These collections will be made on Day 0 +24h, 24 hours before the 1st follow-up visit after 1 month of treatment with non-steroidal anti-inflammatory drugs, 24 hours after the second follow-up visit (between months 3 and 4) and finally, at the end of treatment.
48011529|NCT04540432|DIAGNOSTIC_TEST|Blood test|7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
48011530|NCT03940209|BEHAVIORAL|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
48168835|NCT05655234|BEHAVIORAL|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
48168836|NCT03413540|OTHER|Jump|Drop jump from step
48370958|NCT00938743|DRUG|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
48370959|NCT00001256|DRUG|prednisone and methotrexate|
48370960|NCT05861882|OTHER|functional movement screen|FMS consists of seven test component which are used to evaluate various main movement models.Individuals completed one by one deep squat, high stepping, single line lunge, shoulder mobility, straight leg raises, trunk stability push-ups, rotation stability which are component tests. Subcomponent tests assess asymmetry by measuring the individual bilaterally. Each component test was scored on an ordinal scale (0 to 3 points), with a maximum score of 3, based on the quality of the movement. Less than 3 points indicated that the individual performed some form of compensation or was unable to complete the entire movement.While individuals were doing these tests, they were recorded in the video , the final scoring was done by evaluating the images. The scores of the component tests were summed, resulting in a composite score between 0 and 21 points, with a maximum score of 21
48370961|NCT05861882|OTHER|survey application|Participants are evaluated with kasari physical activity survey. According to the FIT score, physical activity level is commented as sedentary between 0-20, poor between 21-40, normal between 41-60, good between 61-80 and perfect between 81-100
48515697|NCT01268527|DRUG|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
48699035|NCT05352516|BIOLOGICAL|Prolia®|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14."
48699036|NCT02039219|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
48699037|NCT02039219|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
48699038|NCT03161912|DRUG|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
48699039|NCT03911752|OTHER|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
48699040|NCT03911752|OTHER|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
48699041|NCT02247011|OTHER|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
48699042|NCT02247011|RADIATION|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
48699043|NCT02247011|RADIATION|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
48699044|NCT02247011|OTHER|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
48699045|NCT05720689|OTHER|using relaxing music|music diffusion during dental care under MEOPA
48699046|NCT05720689|OTHER|No relaxing music|dental care under MEOPA without music
48699047|NCT03428477|DRUG|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
48699048|NCT03428477|OTHER|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
48699049|NCT06369467|DRUG|linvoseltamab|Administered by intravenous (IV) infusion
48699050|NCT06369467|DRUG|dupilumab|Administered by subcutaneous (SC) injection
48699051|NCT05103670|PROCEDURE|Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA|32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
48699052|NCT00590174|DRUG|Aspirin|stopping clopidogrel at 1 year after DES implantation
48699053|NCT00590174|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
48699054|NCT05984407|PROCEDURE|cytokine hemadsorption therapy|Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
48011531|NCT01698463|OTHER|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
48011532|NCT06363916|DEVICE|Insulin Management System in Manual mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
48011533|NCT06363916|DEVICE|Insulin Management System in Automatic mode of operation|"MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020"
48011534|NCT00002604|DRUG|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
48011535|NCT00002604|DRUG|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
48011536|NCT00002604|DRUG|chemosensitization/potentiation therapy|
48011537|NCT02871375|DEVICE|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
48011538|NCT02871375|DEVICE|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
48011539|NCT03306888|OTHER|Physical Activity Coaching|Physical activity coaching over 4 months
48011540|NCT02438566|DRUG|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
48011541|NCT02438566|DRUG|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
48011542|NCT06467526|DRUG|Hydroxychloroquine|Oral hydroxychloroquine (400mg/day) for 2 months
48011543|NCT06467526|DRUG|Steroid|Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
48011544|NCT03952793|OTHER|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
48011545|NCT06448234|OTHER|Standart supplementation therapy group|Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
48011546|NCT06448234|OTHER|AI-guided supplementation therapy group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
48011547|NCT06368063|DRUG|Huaier granule|Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
48168837|NCT01302301|PROCEDURE|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
48370962|NCT05861882|OTHER|Y balance test|YBT, which is performed in the standing position on one leg , is dynamic a test. Participants stood on the footplate in the centre of the Y Balance Test area and then, it was given instruction them that they should maintain a single leg stance while reaching as far as possible with the opposite leg and return to the starting position on the centre platform without losing balance.In the test, individuals were asked to reach the maximum distance in 3 directions (anterior, posteromedial and posterolateral), allowing 3 trials for each leg. The maximum reach distance was recorded for each consecutive trial
48515698|NCT01268527|DRUG|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
48515699|NCT01268527|DRUG|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
48699055|NCT06233682|OTHER|Enriched environment|In the experimental group (enriched environment), assistants will supervise participants sponatneoulsy engaging in activities, including listening to music, drawing, playing cards or board games, exercising the affected upper limb with constructions or puzzles, etc., in the living room and personal rooms. Posters and clocks will also aid in orientation and improve the physical environment.
48699056|NCT00146809|DRUG|Minocyline|
48699057|NCT03988699|DEVICE|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
48699058|NCT03116828|DRUG|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
48011548|NCT06368063|DRUG|chemotherapy drugs|"Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months."
48370963|NCT05861882|OTHER|Core stabilization assessment|The flexor muscle endurance test is initiated with the subject in a sitting position, with the back leaning against an apparatus angled 60 degrees from the floor. Both knees and hips are flexed to 90 degrees and the support apparatus is withdrawn and the time the person maintains the position is recorded The extensor muscle endurance test is performed with the upper trunk extended towards the end of the bed on which the test is performed and the pelvis, knees and hips fixed. The time the upper trunk maintains its level is recorded The lateral bridge test was performed with the individual lying in the full side bridge position (left and right side separately). Individuals supported themselves on one elbow and their feet while lifting their hips off the floor to form a straight line from head to toe. The test was terminated when the individual lost the straight back posture and/or their hips touched the floor.
48011549|NCT03258372|DRUG|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
48011550|NCT04884516|DIETARY_SUPPLEMENT|Retinol gummy|Participants take one retinol gummy per day
48370964|NCT06252545|BEHAVIORAL|semistructured interviews|Black subjects with pancreatic cancer will provide insight on their experience discussing clinical trials and preferences for communicating clinical trial information
48370965|NCT06252545|BEHAVIORAL|feedback|Black subjects with pancreatic cancer will provide feedback on mHealth app prototype.
48168838|NCT06039943|DEVICE|Wheeze measurement|Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.
48370966|NCT02731924|PROCEDURE|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
48515700|NCT01268527|DRUG|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
48699059|NCT03116828|DRUG|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
48699060|NCT00330408|BEHAVIORAL|GP training|
48699061|NCT00789594|BEHAVIORAL|laboratory monitoring alerts|laboratory monitoring alerts
48699062|NCT00789594|BEHAVIORAL|Result management module|Result management module
48699063|NCT03689491|BEHAVIORAL|rTMS|The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
48699064|NCT03689491|BEHAVIORAL|visual feedback training|Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
48699065|NCT03689491|BEHAVIORAL|traditional rehabilitation|30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
48699066|NCT01529515|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
48699067|NCT01529515|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
48699068|NCT01529515|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
48699069|NCT01529515|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
48699070|NCT01529515|DRUG|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
48699071|NCT03745365|PROCEDURE|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
48699072|NCT00692614|DRUG|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
48699073|NCT03367923|OTHER|Communication Intervention|Receive email/text
48699074|NCT03367923|OTHER|Counseling|Undergo exercise counseling
48699075|NCT03367923|OTHER|Fitbit tracker|Wear Fitbit tracker
48699076|NCT03367923|OTHER|Quality-of-Life Assessment|Ancillary studies
48699077|NCT03367923|OTHER|Questionnaire Administration|Ancillary studies
48699078|NCT03367923|BEHAVIORAL|Telephone-Based Intervention|Receive phone call
48168839|NCT00005058|PROCEDURE|ultrasound imaging|
48168840|NCT04612699|DRUG|Jaktinib|Administered orally
48168841|NCT04612699|DRUG|Placebo|Administered orally
48370967|NCT04930562|DRUG|BN101|BN101 is an orally ROCK2 selective inhibitor
48515701|NCT01268527|OTHER|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
48515702|NCT01268527|OTHER|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
48515703|NCT01268527|OTHER|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
48699079|NCT02526563|PROCEDURE|ropivicaine|Blood draws to measure serum ropivicaine
48699080|NCT04813614|DEVICE|STYLAGE M Lidocaine|Injection in the lips
48515704|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
48515705|NCT01268527|OTHER|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
48515706|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
48515707|NCT01268527|DRUG|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
48515708|NCT02757755|BIOLOGICAL|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
48515709|NCT02757755|BIOLOGICAL|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
48515710|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
48515711|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
48515712|NCT06416956|DRUG|Caffeine|We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
48515713|NCT00012922|BEHAVIORAL|Low Literacy Intervention for Colorectal Cancer Screening|
48515714|NCT05383755|BEHAVIORAL|Digital intervention for pregnant adolescents living with HIV|The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
48515715|NCT04934046|OTHER|Additional acquisition|Additional SPECT acquisition (30min added time approximately), with no added radiation
48011551|NCT06005025|OTHER|Reminder message|"Experimental group will be counselled for 6 months after the training and a reminder message will be sent via SMS on Monday every week as Check your modifiable risk factors for breast cancer and their feedback will be received."
48011552|NCT01349283|BIOLOGICAL|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
48011553|NCT01349283|BIOLOGICAL|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
48011554|NCT04251533|DRUG|alpelisib|300 mg orally, once per day (QD), tablets
48699081|NCT04813614|DEVICE|Active control group|Injection in the lips
48699082|NCT02382029|DRUG|Clonazepam|Active medical treatment for burning mouth syndrome
48699083|NCT02382029|OTHER|acupuncture|Traditional chinese acupuncture
48370968|NCT05040282|DEVICE|Implanon NXT|women will be subjected to etonogestrel 68 mg implant insertion. Participants will be trained on how to fill the menstrual diary. The menstrual diary includes information about days of bleeding and spotting days.
48699084|NCT06552546|DRUG|Icodextrin|Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
48699085|NCT05665504|DIAGNOSTIC_TEST|DetermaRX|A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
48370969|NCT03720639|DEVICE|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
48370970|NCT02363504|OTHER|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
48699086|NCT05553340|OTHER|Education for caregivers|The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
48699087|NCT00803400|DRUG|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
48370971|NCT04445454|BIOLOGICAL|Mesenchymal stromal cells|Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.
48370972|NCT02849873|DRUG|IDP-123 Lotion|Lotion
48011555|NCT04251533|DRUG|placebo|300 mg orally, once per day (QD), tablets
48370973|NCT02849873|DRUG|Tazorac Cream|Cream
48370974|NCT03164629|DEVICE|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
48515716|NCT02371655|PROCEDURE|Diet|A low-fibre diet for three days before the examination
48699088|NCT00803400|DRUG|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
48699089|NCT01009437|DRUG|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
48699090|NCT01009437|PROCEDURE|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
48011556|NCT04251533|DRUG|nab-paclitaxel|100 mg/m\^2 IV infusion, once per day (QD)
48011557|NCT01646697|OTHER|cytology specimen collection procedure|Undergo cytopathologic sample collection
48699091|NCT00025064|BIOLOGICAL|bleomycin sulfate|
48011558|NCT00554827|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
48699092|NCT00025064|DRUG|chlorambucil|
48011559|NCT00554827|DIETARY_SUPPLEMENT|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
48699093|NCT00025064|DRUG|cisplatin|
48699094|NCT00025064|DRUG|dacarbazine|
48699095|NCT00025064|DRUG|doxorubicin hydrochloride|
48011560|NCT00554827|DRUG|Pralatrexate|Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
48011561|NCT01427296|DRUG|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
48011562|NCT01427296|DRUG|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
48699096|NCT00025064|DRUG|etoposide|
48699097|NCT00025064|DRUG|ifosfamide|
48370975|NCT06090227|DRUG|Metformin + Standard of Care|Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
48699098|NCT00025064|DRUG|melphalan|
48699099|NCT00025064|DRUG|prednisolone|
48699100|NCT00025064|DRUG|procarbazine hydrochloride|
48699101|NCT00025064|DRUG|vinblastine sulfate|
48011563|NCT02821884|DEVICE|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
48370976|NCT06090227|OTHER|Placebo + Standard of Care|Administration of daily placebo tablets with standard of care for 6 months.
48699102|NCT00025064|DRUG|vincristine sulfate|
48699103|NCT00025064|PROCEDURE|peripheral blood stem cell transplantation|
48699104|NCT00025064|RADIATION|radiation therapy|
48168846|NCT03074045|DRUG|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
48370977|NCT01728675|OTHER|Exercise|Participants will perform two isokinetic eccentric exercise bouts
48370978|NCT02852239|DRUG|dabrafenib|Single dose dabrafenib 100 mg
48370979|NCT05906043|BEHAVIORAL|Exercise Intervention|Exercise intervention
48699105|NCT00168636|DRUG|Vitamin A|
48699106|NCT01414023|BEHAVIORAL|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
48699107|NCT01414023|BEHAVIORAL|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
48699108|NCT00724685|DRUG|Naropeine (Ropivacaine)|
48370980|NCT05906043|BEHAVIORAL|Acceptance and Commitment Therapy|ACT will be used for patients with psychological disability as well as for those with sleep disturbance
48699109|NCT00724685|DRUG|Placebo|saline
48699110|NCT05149651|DRUG|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
48699111|NCT05149651|DRUG|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
48699112|NCT03172884|DRUG|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
48699113|NCT00568373|DEVICE|Enterra Gastric Pacemaker|Gastric Pacemaker
48699114|NCT00835198|DRUG|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
48011564|NCT02821884|DEVICE|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
48011565|NCT02821884|DEVICE|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
48011566|NCT02659332|DEVICE|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
48011567|NCT02422433|DEVICE|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
48515717|NCT02371655|DRUG|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
48011568|NCT02777762|BEHAVIORAL|Fun First|8 weekly interactive small-group sessions with a health coach
48011569|NCT02777762|BEHAVIORAL|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
48168847|NCT03074045|DRUG|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
48168848|NCT05243537|OTHER|ECG (diagnostic)|ECG collection (once, at rest), in both cases and controls
48168849|NCT03718819|OTHER|exercise|Pilates and aquaplyometric exercises will be done combinedly.
48370981|NCT05906043|DIETARY_SUPPLEMENT|Probiotic|Use of a probiotic
48515718|NCT02371655|DRUG|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
48515719|NCT02371655|PROCEDURE|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
48515720|NCT02433314|DRUG|SAGE-547|
48515721|NCT01534169|DRUG|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
48388083|NCT05755724|OTHER|3-D Teaching|Telesimulation using immersive VR technology. Briefly, students will have a 360° camera mounted to their head, which will broadcast their first-person perspective to their teachers. Teachers will be able to immerse themselves in the perspective of the trainee using a virtual reality HMD (Oculus Quest 2), which allows them to look around freely and view equipment, hand movements, etc. and offer instruction accordingly.
48515722|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|Traditional motivational face-to-face workshops with lifestyle (nutritional, physical activity, sleep) advice every 3 months
48515723|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|E-learning and digital (with videos -YouTube channel or WhatsApp/text message) educational workshops with lifestyle (nutritional, physical activity, sleep) advice every 15 days
48515724|NCT01601340|DRUG|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
48699115|NCT00835198|DRUG|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
48515725|NCT01601340|DRUG|Placebo|Placebo tablets, twice daily for 48 weeks
48515726|NCT00422604|DRUG|salmeterol|
48515727|NCT00422604|DRUG|tiotropium|
48515728|NCT00422604|DRUG|GSK233705|
48515729|NCT02233439|DIETARY_SUPPLEMENT|Herbal galactagogue|
48515730|NCT02233439|DIETARY_SUPPLEMENT|Placebo|
48699116|NCT04407026|BIOLOGICAL|biofluids|Gingival crevicular fluid, saliva and serum samples were obtained.
48699117|NCT02974127|RADIATION|Radiotherapy|Multisession radiosurgery
48370982|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with saline and the wound edges were sealed with tissue adhesive containing cyanoacrylate.
48699118|NCT05502107|BEHAVIORAL|PRESS Intervention|The study intervention is PRESS protocol training and educational delivered to EMS providers, followed by protocol implementation. EMS providers will be trained to screen all EMS patients for protocol eligibility and will start using the protocol at the beginning of the intervention phase. The PRESS EMS protocol includes 2 major components: 1) an evidence-based sepsis screening tool, and 2) a prehospital sepsis alert call to the receiving hospital for participants who screen positive. Upon arrival to the ED, ED providers will provide immediate medical assessment to the patient to determine whether there is concern for sepsis. If the treating provider determines there is concern for sepsis, the provider will deliver usual sepsis care per local hospital protocols, workflows, or care pathways. Sepsis treatment interventions will not be specified by this study protocol.
48699119|NCT00790647|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
48011570|NCT00907920|OTHER|laboratory biomarker analysis|Correlative studies
48370983|NCT06112366|PROCEDURE|Surgery of impacted mandibular wisdom teeth (the other side)|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
48370984|NCT04018716|DEVICE|MTA|Indirect capping with MTA
48370985|NCT04018716|DEVICE|Dycal|Indirect capping with Dycal
48370986|NCT00079079|DRUG|carboplatin|
48370987|NCT00079079|DRUG|cisplatin|
48370988|NCT00079079|DRUG|gemcitabine hydrochloride|
48370989|NCT00750061|DRUG|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
48370990|NCT00750061|DRUG|Placebo|Matching placebo
48370991|NCT03083795|BEHAVIORAL|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
48370992|NCT02043002|PROCEDURE|18F-FDG-PET scan|
48370993|NCT00067431|DRUG|Divalproex Sodium (Depakote® Sprinkle Capsules)|
48370994|NCT01431599|RADIATION|short-course radiation|33Gy/10 fractions
48370995|NCT01539512|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
48370996|NCT01539512|DRUG|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter
48370997|NCT01539512|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
48370998|NCT04085120|PROCEDURE|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
48370999|NCT04085120|PROCEDURE|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
48699120|NCT00790647|DRUG|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
48699121|NCT00790647|DRUG|melphalan|100 mg/m2/dose D -2, D -1
48699122|NCT00790647|PROCEDURE|Stem Cell Infusion|infusion of previously collected autologous stem cells
48699123|NCT00176488|DRUG|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
48699124|NCT00176488|DRUG|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
48699125|NCT06357091|PROCEDURE|ACL reconstruction with Shark Screw ACL®|ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening
48371000|NCT00116610|DRUG|picoplatin|
48388084|NCT05755724|OTHER|2-D Teaching|Telesimulation using standard teleconferencing software and equipment including 2D computer monitors, webcams, and an ultrasound machine linked to a computer (enabling ultrasound images to be transmitted).
48699126|NCT06357091|PROCEDURE|ACL reconstruction with biocomposite screw (Mecta)|ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
48699127|NCT05420311|OTHER|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
48699128|NCT05420311|OTHER|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
48699129|NCT05420311|OTHER|IF Arm|An intermittent fasting (IF) approach
48699130|NCT02414607|BIOLOGICAL|Elderberry Juice|
48699131|NCT02414607|OTHER|Placebo|
48699132|NCT06066021|OTHER|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
48699133|NCT02422836|OTHER|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
48011571|NCT04190186|DEVICE|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
48011572|NCT03175224|DRUG|APL-101 Oral Capsules|Subjects will receive APL-101 capsules BID for oral administration.
48168850|NCT00866827|OTHER|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
48371001|NCT04972773|BEHAVIORAL|Mindfulness meditation (MM)|"Towards this additional MM practice, participants will be able to use any combination of the MM apps: Insight timer, which focuses on community/group-like therapy, Healthy minds, which focuses on resilience that is essential in disability adjustment, and Smiling mind, that reminds patients of their family/support structures. These three options were chosen for delivering free MM with different focuses that would cater to the variety of SCI patients needs. Participants will be alerted if they are not achieving 30 minutes of additional MM per week. This will guarantee that the treatment group have a higher time spent on MM for dose-response analysis. Participants will receive a reminder email (see attached) on the Sunday evening of a week with \<30 minutes of additional MM encouraging them to use their mindfulness app."
48371002|NCT05241574|RADIATION|Radiotherapy boost|Additional endorectal high rate irydium brachytherapy boost, 2 fractions of 10 Gy each.
48371003|NCT05241574|DRUG|Additional consolidation chemotherapy|Three additional cycles of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX4) consolidation chemotherapy
48371004|NCT04017416|BEHAVIORAL|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
48371005|NCT04063748|BEHAVIORAL|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
48371006|NCT04063748|BEHAVIORAL|Placebo Rehabilitation|CI-users: Placebo, tablet-based take-home psychophysical tasks, reading (non auditory)
48371007|NCT04063748|BEHAVIORAL|Passive Control|No intervention in the passive control group for HA-users.
48371008|NCT01870765|DEVICE|non-invasive ventilation|non-invasive ventilation via face mask
48371009|NCT01870765|DEVICE|high-flow oxygen|high-flow oxygen via nasal cannula
48371010|NCT01870765|PROCEDURE|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
48371011|NCT05498207|BEHAVIORAL|Maya App|Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
48371012|NCT00711009|DRUG|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
48371013|NCT00711009|DRUG|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
48371014|NCT00711009|DRUG|raltegravir (RAL)|RAL 400 mg BID
48371015|NCT05815758|DRUG|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)|rimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
48371016|NCT05815758|DRUG|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution|Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
48371017|NCT01042431|OTHER|No Intervention|No intervention
48699134|NCT03924063|DEVICE|Hemiverse|Implantation of the hemiverse shoulderprothesis
48699135|NCT02946567|OTHER|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
48011573|NCT04474652|OTHER|Single Blood Draw from each participant|Health Professionals will seek informed consent and take a single blood collection from the participant. This will take place during the patient's visit to the breast one stop clinic as part of their routine urgent breast referral pathway.
48011574|NCT00964808|DRUG|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
48371018|NCT06373380|DRUG|HB-200|HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every 3 weeks intravenously for 5 doses and then every 6 weeks thereafter.
48371019|NCT06373380|OTHER|Placebo|Patients in the placebo arm will be receiving vehicle on the same schedule. Patients will receive treatment with HB-200 alternating therapy or placebo until recurrence or for a total duration of 1 year.
48371020|NCT02106715|OTHER|Training|Two exercises for training of core stability and mobility.
48168851|NCT04549142|OTHER|There is no intervention|There is no intervention
48168852|NCT05291806|OTHER|Reference Product|This intervention is based on white rice.
48168853|NCT05291806|OTHER|Wholegrain product Dose A|This wholegrain intervention contains whole cereal kernels.
48011575|NCT00964808|DRUG|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
48168854|NCT05291806|OTHER|Wholegrain product Dose B|This wholegrain intervention contains whole cereal kernels.
48371021|NCT04369911|PROCEDURE|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
48168855|NCT05291806|OTHER|Wholegrain product Dose A, cut kernels|This wholegrain intervention contains cut cereal kernels.
48168856|NCT00065819|BEHAVIORAL|HIV Symptom Education Program|
48168857|NCT06215625|OTHER|Robot-assisted therapy|The TIGER system provides assistance for activities of daily living. Continuous passive mode of TIGER system provides passive range of motion as warm-up. Functional mode TIGER system provides functional training.
48371022|NCT00133276|DRUG|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
48371023|NCT00133276|OTHER|Placebo|
48371024|NCT01288820|DRUG|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
48515731|NCT04703595|GENETIC|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
48699136|NCT02946567|OTHER|Generic Game|Participants will play a generic game without any particular information about hearing health care.
48011576|NCT05500859|OTHER|Data collection at Baseline, 3 months after baseline (BL), 1-year follow-up, Telephone follow-up and questionnaire 3 years and 5 years after BL|Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
48371025|NCT01288820|DRUG|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
48699137|NCT06547021|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
48699138|NCT06547021|DEVICE|Gamma Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized gamma frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
48011577|NCT04916327|DIETARY_SUPPLEMENT|Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
48011578|NCT04916327|DIETARY_SUPPLEMENT|Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
48011579|NCT03058068|BIOLOGICAL|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
48011580|NCT03058068|BIOLOGICAL|Placebo|1 peripheral intravenous infusion
48515732|NCT03810040|DEVICE|140 microns denuding pipette|the degranulated needle size was 140 microns
48515733|NCT03810040|DEVICE|150 microns denuding pipette|the degranulated needle size was 150 microns
48515734|NCT05491486|BEHAVIORAL|Mindfulness-based Group Therapy|see above
48699139|NCT06547021|DEVICE|Theta Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with personalized theta frequency (tACS) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
48011581|NCT01528241|DRUG|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
48011582|NCT00184899|DRUG|Intravenous infusion of Intralipid/heparin|
48011583|NCT00184899|DRUG|Intravenous infusion of Glycerol/heparin|
48011584|NCT03757182|OTHER|Wearable activity monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
48011585|NCT05444309|PROCEDURE|Quadratus lumborum (QL) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach
48011586|NCT05444309|PROCEDURE|Pericapsular Nerve Group (PENG) block group|patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
48011587|NCT01588002|DRUG|danoprevir|multiple oral doses
48011588|NCT01588002|DRUG|efavirenz|multiple oral doses
48011589|NCT01588002|DRUG|ritonavir|multiple oral doses
48515735|NCT00142389|BIOLOGICAL|pneumococcal polysaccharide and protein conjugate vaccines|
48699140|NCT06547021|DEVICE|Sham|"Sham stimulation (i.e. only slight stimulation at the beginning and at the end for a few seconds with majority of the time having no stimulation) will be applied to the participants' scalp via 2 electrodes, while the participants perform cognitive exercises with the guidance of a trained research assistant. Cognitive exercises will be performed through the Mind Triggers app on an iPad where the participants perform memory and learning games/tasks."
48699141|NCT02083848|OTHER|7T MRI|Ultra high field magnetic resonance imaging
48699142|NCT04291690|OTHER|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
48011590|NCT03517267|DIAGNOSTIC_TEST|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
48011591|NCT03580096|OTHER|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
48011592|NCT03580096|OTHER|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
48011593|NCT03683381|BEHAVIORAL|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
48011594|NCT03683381|OTHER|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
48371026|NCT00201682|DRUG|Etanercept|25 mg SQ twice weekly weeks 1-5
48371027|NCT00201682|DRUG|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
48515736|NCT00386984|DRUG|Somatostatin (octreotide)|
48699143|NCT04291690|OTHER|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
48699144|NCT04291690|OTHER|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
48011595|NCT04567121|BEHAVIORAL|Intensive intervention group|Establish a team of chronic disease prevention managers (5 people), with each educator responsible for the intervention of 200 people. For sub-health population and chronic disease patients, there would be conducted health education interview twice, 4 calls, online communication 50 times once a year, controlling risk factors and making treatment plan.
48011596|NCT04567121|BEHAVIORAL|standard intervention group|Conduct general health education without active management
48011597|NCT03866759|BEHAVIORAL|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
48168858|NCT06215625|OTHER|Task-oriented training|The TOT group will practice sensorimotor techniques for warming up, and then they will practice various functional tasks based on task-oriented approach.
48168859|NCT00087997|DRUG|STA-4783|
48168860|NCT00352378|DRUG|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
48168861|NCT05561985|DRUG|Itacitinib|
48168862|NCT02134847|OTHER|SCS intervention schedule|
48168863|NCT05853692|DEVICE|Zinc Gluconate|Three times a day (spray)
48168864|NCT05853692|DEVICE|Sodium Bicarbonate|Five times a day (rinse)
48168865|NCT06192719|OTHER|None, observational study.|Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
48168866|NCT05635955|DRUG|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
48168867|NCT05635955|DRUG|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
48168868|NCT05635955|DRUG|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
48168869|NCT06435741|DIAGNOSTIC_TEST|99mTc-3PRGD2 Spect-CT scan|Before the operation，SPECT-CT imaging of lymph nodes was performed by integrin αvβ3-specific 99mTc-3PRGD2 probe. The locations of 99mTc-3PRGD2 SPECT-CT were determined by preoperative CT scan. During the operation, D2 lymph node dissection of gastric cancer was performed under the guidance of fluorescent laparoscopy。
48168870|NCT05749939|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. A goal of ACT is to help people develop psychological flexibility, meaning they can experience and live with difficult thoughts and emotions, and still pursue what matters to them. The current project is an online, self-guided, 6-session intervention. Each session is expected to take about 30 minutes each, and the entire course will take approximately 3-4 weeks to complete, as users are encouraged to take a few days in between sessions. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and care- specific vignettes, and apply ACT concepts to their own lives and care situations. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
48168871|NCT06259513|PROCEDURE|omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO|Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB
48168872|NCT06478108|DEVICE|IRSW-MIM|IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.
48168873|NCT04747210|BEHAVIORAL|contextual one-on-one coaching|Training workshop and coaching one-on-one
48168874|NCT04747210|BEHAVIORAL|Trainig workshop|Ten-hour training workshop.
48011598|NCT05186467|DRUG|intraperitoneal Magnesium sulfate|Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
48011599|NCT05186467|DRUG|intravenous magnesium sulfate|Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
48011600|NCT03174197|DRUG|Atezolizumab|Given IV
48011601|NCT03174197|RADIATION|Radiation Therapy|Undergo RT
48011602|NCT03174197|DRUG|Temozolomide|Given PO
48011603|NCT03833076|DEVICE|Medical device Procto|Medical device Procto presents itself as a translucent green gel with a typical smell.
48699145|NCT04291690|OTHER|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin \<130g/L in men or \<120g/L in women with (ii) a Ferritin \<100μg/L or a Ferritin \<300μg/L with a Saturation \<20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
48011604|NCT03833076|DEVICE|Matching placebo|IP placebo presents itself as a translucent green gel with a typical smell.
48011605|NCT01350427|DIETARY_SUPPLEMENT|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
48011606|NCT01350427|DIETARY_SUPPLEMENT|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
48011607|NCT01350427|DIETARY_SUPPLEMENT|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
48011608|NCT01061749|BIOLOGICAL|Cixutumumab|Given IV
48011609|NCT01061749|OTHER|Laboratory Biomarker Analysis|Correlative studies
48011610|NCT01061749|OTHER|Pharmacological Study|Correlative studies
48011611|NCT01061749|DRUG|Selumetinib|Given PO
48011612|NCT01836484|DIAGNOSTIC_TEST|Diffusion-weighted MRI|
48011613|NCT01836484|DIAGNOSTIC_TEST|Fluorodeoxyglucose-18-PET/CT|
48011614|NCT01836484|DIAGNOSTIC_TEST|Fluoro-ethyl-coline-PET/CT|
48168875|NCT03140878|DIETARY_SUPPLEMENT|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
48168876|NCT03140878|DIETARY_SUPPLEMENT|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
48168877|NCT06144788|DRUG|SGLT2 inhibitor|SGLT 1/2 dual inhibitor
48168878|NCT04857047|DRUG|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
48168879|NCT04857047|DRUG|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
48168880|NCT02615548|OTHER|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
48168881|NCT02615548|OTHER|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
48168882|NCT06276751|PROCEDURE|End-tidal CO2 monitor|Throughout the study, measurements were taken at 2 and 4 hours after tube thoracostomy was applied to every patient undergoing the procedure.
48168883|NCT00037661|DRUG|INS365 Ophthalmic Solution|
48168884|NCT04059887|DRUG|Atezolizumab Injection [Tecentriq]|Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
48011615|NCT03354494|DRUG|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
48011616|NCT04196556|BEHAVIORAL|Active Families|This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.
48011617|NCT04196556|OTHER|Madrid's Primary Healthcare Standardized Service portfolio|"An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook."
48699146|NCT02450383|DRUG|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
48699147|NCT02450383|PROCEDURE|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
48699148|NCT00385281|BIOLOGICAL|FluMist|
48699149|NCT02899507|DRUG|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
48011618|NCT05871073|DRUG|Ropivacaine 0.75% Injectable Solution|WOUND INFILTRATION AFTER SPINAL SURGERY
48011619|NCT05871073|DRUG|dexamethasone 8mg|WOUND INFILTRATION AFTER SPINAL SURGERY
48011620|NCT02711800|DRUG|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
48011621|NCT06141629|DEVICE|accu chek Aviva Expert|This bolus calculator estimates the dose of insulin to be administrated on the basis of the following parameters: current blood glucose, grams of carbohydrate, carbohydrate to insulin ratio, insulin sensitivity, target blood glucose and quantity of insulin previously administered.
48011622|NCT06141629|DEVICE|Accu Chek Aviva Nano|This meter is a normal glucometer without bolus calculator.
48011623|NCT06294821|DRUG|4-Aminopyridine|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
48011624|NCT06294821|OTHER|Placebo|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
48011625|NCT01357993|DRUG|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
48011626|NCT00795691|BEHAVIORAL|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
48168885|NCT03269513|BEHAVIORAL|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
48515737|NCT06151769|OTHER|topical pomegranate seed oil|Intervention groups: In addition to the routine care of the patients, Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days. The patient follow-up form will be completed by the researcher every day at 12:00 noon. Again, on the 6th day of the application, evaluation surveys with the Braden risk assessment scale will be conducted by the researcher.
48515738|NCT06151769|OTHER|Sesame oil|Sesame oil
48515739|NCT05986227|DRUG|toripalimab FOLFOX|Toripalimab（3mg/kg, q2w, IV）oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV) and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h)
48168886|NCT05977673|DRUG|Tislelizumab|Tislelizumab 200mg IV day1
48168887|NCT01327027|DRUG|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
48168888|NCT01327027|DRUG|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
48168889|NCT04459221|DRUG|Gardasil 9, 9-Valent Intramuscular Suspension|access to HPV vaccination near the college in a health bus
48515740|NCT03791463|DRUG|salvianolic acid A|Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
48515741|NCT06042582|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
48515742|NCT00348829|PROCEDURE|mitral valve repair|surgical mitral valve repair
48515743|NCT00613171|DRUG|STI571|STI571 tablets taken orally once a day
48515744|NCT04082338|BEHAVIORAL|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
48515745|NCT04082338|BEHAVIORAL|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
48515746|NCT05146843|DRUG|Mitoquinone|Mitoquinone pill, 20 mg/day
48515747|NCT05146843|OTHER|Placebo|Placebo pill, 20 mg/day
48699150|NCT03172325|DRUG|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
48699151|NCT03172325|DRUG|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
48699152|NCT03172325|DRUG|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
48699153|NCT03172325|DRUG|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
48699154|NCT00515658|DEVICE|theta-burst rTMS|
48699155|NCT05929612|RADIATION|Ultra Low Dose 4 Gy Radiation|4 Gy in 2 fractions
48699156|NCT05392790|OTHER|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
48699157|NCT05392790|DRUG|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
48699158|NCT05392790|OTHER|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
48371028|NCT01080794|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
48699159|NCT00996515|DRUG|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
48011627|NCT00795691|BEHAVIORAL|low-fat diet|low-fat diet in patients with type 2 diabetes
48168890|NCT02603861|DRUG|LY3154207|LY3154207 administered orally.
48168891|NCT02603861|DRUG|Placebo|Placebo administered orally.
48168892|NCT02603861|DRUG|Modafinil|Modafinil administered orally.
48168893|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
48168894|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
48168895|NCT02830256|OTHER|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
48699160|NCT00996515|DRUG|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
48168896|NCT04857775|BEHAVIORAL|Attachment and Child Health (ATTACH) Parenting Program|ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
48371029|NCT01348828|DEVICE|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
48371030|NCT06224491|OTHER|Reflex locomotion according to Vojta|Tactile stimulation according to Vojta´s reflex locomotion
48371031|NCT03902158|DEVICE|Glasses|The patient will wear virtual reality glasses during anesthesia
48011628|NCT04613180|DRUG|Montelukast Sodium|Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
48699161|NCT04867720|DRUG|Everolimus|- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
48699162|NCT04448314|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
48699163|NCT06162559|DRUG|Tucatinib|Tucatinib 300mg is taken orally twice daily
48699164|NCT06162559|DRUG|Trastuzumab|Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
48011629|NCT04613180|DRUG|Placebo|placebo containing no active substance
48011630|NCT06250101|BEHAVIORAL|Enhanced Conversational Recast treatment|In the context of child-friendly activities, the clinician prompts the child to attempt to use the grammatical form targeted in the treatment. The clinician immediately restates the child's attempt (i.e., the recast), correcting any ungrammatical elements. Clinicians elicit and recasts 24 utterances per session.
48011631|NCT03427918|BEHAVIORAL|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
48011632|NCT02100891|PROCEDURE|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
48011633|NCT02100891|DRUG|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
48011634|NCT00556842|DEVICE|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
48011635|NCT00556842|DEVICE|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
48699165|NCT06162559|DRUG|Pertuzumab|Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
48699166|NCT01643252|DRUG|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
48699167|NCT01643252|DRUG|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
48699168|NCT02315807|DEVICE|transcranial direct current stimulation|
48371032|NCT03902158|BEHAVIORAL|Distraction techniques|The patient will undergo distraction techniques
48371033|NCT06241131|DRUG|Desflurane Inhalant Product|The Desflurane was inhaled at a starting concentration of 1 MAC, and remifentanil 0.1 μg/kg/min was continuously pumped intravenously.
48371034|NCT00332059|DRUG|bimatoprost/timolol fixed combination|
48371035|NCT06076174|OTHER|6-week home-based exercise programme|All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
48168897|NCT06380647|DRUG|Intravenous Acyclovir|Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
48371036|NCT00223158|DRUG|Liothyronine|
48371037|NCT04447183|DRUG|Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)|rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
48371038|NCT04447183|OTHER|radioactive iodine|radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
48371039|NCT04799821|OTHER|Control|Participants will be asked to refrain from walnut intake and to follow an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
48371040|NCT04799821|OTHER|Walnut intake|Participants will be asked to consume walnuts along with an isocaloric meal plan that complies with the recommendations of a healthy Mediterranean-style eating pattern.
48168898|NCT05563415|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
48168899|NCT01133925|DEVICE|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
48168900|NCT01133925|DEVICE|Sirolimus Eluting Stent|Cypher stents implanted in overlap
48168901|NCT01133925|DEVICE|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
48371041|NCT02438787|DRUG|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
48371042|NCT02438787|DRUG|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
48371043|NCT02438787|DRUG|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
48371044|NCT02438787|DRUG|Golimumab 50 mg|Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
48371045|NCT05294627|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.
48371046|NCT01588873|DRUG|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
48371047|NCT00764465|DRUG|Maraviroc|300 mg BID
48371048|NCT00764465|DRUG|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
48699169|NCT02449889|DRUG|highly purified human chorionic gonadotropin|
48371049|NCT00764465|DRUG|Ritonavir|100 mg BID, 100 mg QD
48371050|NCT05453552|DRUG|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
48699170|NCT02449889|DRUG|recombinant human chorionic gonadotropin|
48699171|NCT04621240|BEHAVIORAL|Online SMART & Stress Solutions|1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
48699172|NCT03341364|BEHAVIORAL|ACT-based group therapy|6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
48168902|NCT01133925|DEVICE|Zotarolimus eluting stent|Endeavor stents implanted in overlap
48168903|NCT03377725|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
48168904|NCT03377725|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
48168905|NCT03694119|DRUG|Phenelzine|Phenelzine
48371051|NCT05453552|DRUG|Decitabine (DAC)|Decitabine was administered at 20mg/m2/day on days -14 to -10.
48699173|NCT03341364|BEHAVIORAL|ACT individual treatment|3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
48699174|NCT03515226|BEHAVIORAL|ITS based training|Training using computerized adaptive training in addition to role play
48699175|NCT03515226|BEHAVIORAL|Traditional Training|Training using didactics and role plays
48371052|NCT05453552|DRUG|Busulfan|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group.
48371053|NCT05453552|DRUG|Fludarabine (FLU)|Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
48371054|NCT05453552|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3,-2.
48371055|NCT05453552|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group.
48371056|NCT04864964|PROCEDURE|combined conventional and pulsed radiofrequency (CCPRF)|Patients with trigeminal neuralgia who underwent combined conventional and pulsed radiofrequency (CCPRF) for treatment of pain.
48371057|NCT05617274|PROCEDURE|Sectioning of the full arch mandibular fixed prosthesis|The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
48699176|NCT03632993|DRUG|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
48699177|NCT01482169|DRUG|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
48699178|NCT04271371|OTHER|Not yet developed|A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
48699179|NCT00201357|DRUG|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
48699180|NCT02060630|PROCEDURE|Open surgical revascularization|
48699181|NCT02060630|DEVICE|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
48699182|NCT04017572|PROCEDURE|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
48699183|NCT06430580|DRUG|Hydrocortisone Oral|20mg hydrocortisone, single oral dose
48371058|NCT06267859|COMBINATION_PRODUCT|The use of a combination of microelements and vitamins against the background of physiotherapy|If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
48371059|NCT03029052|BEHAVIORAL|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
48371060|NCT01396434|BIOLOGICAL|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
48371061|NCT03354065|DIETARY_SUPPLEMENT|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
48371062|NCT02627157|DEVICE|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
48699184|NCT06430580|DRUG|Yohimbine Hydrochloride|54mg yohimbine hcl, single oral dose
48699185|NCT06430580|DRUG|Cornstarch Placebo 20mg|20mg cornstarch placebo, single oral dose
48699186|NCT06430580|DRUG|Cornstarch Placebo 54mg|54mg cornstarch placebo, single oral dose
48168906|NCT03694119|DRUG|Tyramine|Tyramine
48371063|NCT01834937|DEVICE|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
48371064|NCT02723682|OTHER|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
48371065|NCT00118885|BEHAVIORAL|Tai Chi Chih|
48371066|NCT05093660|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
48699187|NCT04308460|PROCEDURE|arthrocentesis|lavage of the temporomandibular joint was done
48011636|NCT02333578|PROCEDURE|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
48168907|NCT03694119|DRUG|Phenelzine placebo|Phenelzine placebo
48168908|NCT03694119|DRUG|ozanimod placebo|ozanimod placebo
48168909|NCT03694119|DRUG|ozanimod|ozanimod
48371067|NCT05093660|DIAGNOSTIC_TEST|Saliva specimen collection|Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels
48371068|NCT03781310|DRUG|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
48371069|NCT04490421|DRUG|Camrelizumab combined with Apatinib, Etoposide and Cisplatin|Camrelizumab combined with Apatinib, Etoposide and Cisplatin
48371070|NCT05147831|OTHER|Remote Ischemic Preconditioning|Place blood pressure cuff around upper, non-dominant arm (e.g. upper left arm in a right-handed patient). Inflate blood pressure cuff to a pressure set at 50 mmHg higher than baseline systolic BP to induce ischemia of arm for 5 minutes. Completely deflate blood pressure cuff to allow for 5 minutes of reperfusion. Subjects would undergo 4 cycles of ischemia and reperfusion,
48371071|NCT04259749|OTHER|Flavor Ban|Only flavored tobacco products are banned
48371072|NCT04259749|OTHER|Menthol Ban|Mentholated products are banned
48371073|NCT04259749|OTHER|All flavored and mentholated products available|No bans: All tobacco products are available
48699188|NCT04308460|PROCEDURE|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
48011637|NCT01898793|DRUG|Fludarabine|
48011638|NCT01898793|DRUG|Cyclophosphamide|
48371074|NCT01738516|PROCEDURE|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
48011639|NCT01898793|PROCEDURE|Leukapheresis|
48699189|NCT01713504|BIOLOGICAL|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
48699190|NCT02617394|OTHER|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
48699191|NCT02617394|OTHER|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
48699192|NCT00521391|OTHER|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
48699193|NCT05155618|PROCEDURE|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
48371075|NCT01738516|PROCEDURE|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
48371076|NCT03153436|BIOLOGICAL|Myoinositol|
48011640|NCT01898793|BIOLOGICAL|Cytokine-induced killer cells|
48011641|NCT01898793|BIOLOGICAL|IL-2|
48515748|NCT06551662|DEVICE|Paclitaxel drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
48011642|NCT01898793|DRUG|ALT-803|
48011643|NCT01898793|PROCEDURE|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
48011644|NCT01898793|PROCEDURE|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
48011645|NCT05765968|PROCEDURE|Double Stimulation Protocol|cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle
48011646|NCT05765968|PROCEDURE|Antagonist Stimulation Protocol|cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol
48011647|NCT01405638|BEHAVIORAL|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
48011648|NCT01405638|BEHAVIORAL|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
48011649|NCT03797638|DEVICE|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
48011650|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
48011651|NCT02665871|BIOLOGICAL|one dose of Influenza Vaccine|
48011652|NCT02665871|BIOLOGICAL|placebo|
48371077|NCT01150942|BIOLOGICAL|JE vaccine|3 times, IM
48515749|NCT06551662|DEVICE|Sirolimus drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
48515750|NCT06551662|DEVICE|New generation drug-eluting stent|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
48699194|NCT06307522|DRUG|MRG-001|Patients will receive subcutaneous administration of MRG-001 at designated visits.
48699195|NCT05206188|BEHAVIORAL|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
48699196|NCT00557310|DRUG|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
48699197|NCT05280652|BEHAVIORAL|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
48699198|NCT05280652|BEHAVIORAL|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
48011653|NCT02665871|BIOLOGICAL|placebo|
48011654|NCT04507958|DIAGNOSTIC_TEST|auscultation by using conventional stethoscope without PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
48011655|NCT04507958|DIAGNOSTIC_TEST|auscultation by using electronic stethoscope in full PPE|In thoracic patients undergoing general anesthesia with endotracheal tube/endobronchial blocker, Clinician will check the position of endotracheal tube and endobronchial blocker under fiberscope. Afterward, investigator A will perform auscultation with traditional auscultation, then investigator B with electronic stethoscope under full PPE, to examine bilateral breathing sound.
48011656|NCT06430372|DRUG|Bev-ICG|Probe targeting VEGF-A that is topically administrated during the endoscopy
48011657|NCT06430372|DEVICE|NIR-II fluorescence endoscopy platform|An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
48011658|NCT00002794|DRUG|carboplatin|
48515751|NCT00226291|OTHER|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
48011659|NCT00002794|DRUG|vincristine sulfate|
48011660|NCT02514252|DRUG|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
48168910|NCT02895243|OTHER|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
48168911|NCT04882033|DRUG|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
48168912|NCT00634218|BEHAVIORAL|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
48168913|NCT00634218|BEHAVIORAL|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
48168914|NCT00634218|BEHAVIORAL|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
48699199|NCT06362330|OTHER|magnetic resonance imaging|Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
48011661|NCT02514252|BEHAVIORAL|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
48011662|NCT02514252|BEHAVIORAL|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
48011663|NCT02514252|BEHAVIORAL|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
48011664|NCT03075644|DRUG|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
48011665|NCT03075644|DRUG|Norditropin|Daily subcutaneous injections (s.c., under the skin)
48011666|NCT01172548|DRUG|imatinib mesylate|
48011667|NCT01420081|DRUG|PF-05212384|154mg IV weekly
48011668|NCT01420081|DRUG|PF-05212384|154mg IV weekly
48011669|NCT01420081|DRUG|PF-05212384|154mg IV weekly
48011670|NCT03721198|COMBINATION_PRODUCT|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
48011671|NCT03721198|OTHER|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
48371078|NCT05218148|DRUG|sintilimab|Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
48371079|NCT05218148|DRUG|Trastuzumab|Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
48515752|NCT00002225|DRUG|Efavirenz|
48515753|NCT00002225|DRUG|Stavudine|
48515754|NCT00002225|DRUG|Didanosine|
48515755|NCT00139893|DRUG|Reglan ODT|
48515756|NCT01380548|DIETARY_SUPPLEMENT|Placebo|Placebo; once/day; for 12 weeks
48515757|NCT01380548|DIETARY_SUPPLEMENT|Iron alone|Iron (3 mg); once/day; for 12 weeks
48515758|NCT01380548|DIETARY_SUPPLEMENT|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
48515759|NCT01380548|DIETARY_SUPPLEMENT|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
48515760|NCT01380548|DIETARY_SUPPLEMENT|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
48699200|NCT05760131|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
48699201|NCT02628431|DEVICE|Elfi tech monitor|
48699202|NCT00227669|DRUG|docetaxel|
48011672|NCT05287191|DRUG|Magnesium sulfate and then Digoxin|We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
48011673|NCT05287191|DRUG|Amiodarone|We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
48011674|NCT05973838|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
48168915|NCT00634218|BEHAVIORAL|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
48168916|NCT01355471|DRUG|CD07805/47 Gel|applied topically once daily
48168917|NCT01355471|DRUG|Placebo|applied topically once daily
48168918|NCT06010550|RADIATION|Magnetic resonance imaging|Brain magnetic resonance imaging
48168919|NCT01487902|DRUG|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
48168920|NCT01487902|DRUG|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
48515761|NCT01566227|OTHER|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
48699203|NCT00227669|DRUG|gemcitabine hydrochloride|
48699204|NCT04216784|DRUG|Furosemide Injection|Patient will receive furosemide intravenously
48699205|NCT04216784|DRUG|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
48168921|NCT05404126|OTHER|exercise|• Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
48168922|NCT03462498|DRUG|1-months DAPT|1-month DAPT followed by 59-month monotherapy
48699206|NCT04500080|BEHAVIORAL|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
48168923|NCT03462498|DRUG|12-month DAPT|12-month DAPT followed by 48-month monotherapy
48168924|NCT01834768|DRUG|Eplerenone|
48168925|NCT00989898|OTHER|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
48168926|NCT03028012|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
48515762|NCT04798092|PROCEDURE|parathyroidectomy|surgical removal of parathyroid adenoma(s) with postoperative biological cure
48515763|NCT04556786|BEHAVIORAL|Transitions of care|The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
48515764|NCT02562573|DRUG|PBI4050|
48515765|NCT01398046|DRUG|Dasatinib|dasatinib (100mg) PO x1
48515766|NCT01398046|DRUG|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
48515767|NCT01398046|DRUG|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
48515768|NCT02829476|BIOLOGICAL|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
48515769|NCT02065076|DRUG|Sodium polystyrene sulfonate|
48515770|NCT02065076|DRUG|Lactose with carob gum|
48515771|NCT02181790|DEVICE|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
48515772|NCT02181790|DRUG|Acitretin|17.5mg/d
48515773|NCT03035578|DRUG|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
48515774|NCT03035578|DRUG|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
48515775|NCT04497012|DRUG|2mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
48699207|NCT04867512|DIETARY_SUPPLEMENT|Liquid Tincture|Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.
48168927|NCT03028012|DRUG|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
48168928|NCT03028012|DRUG|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
48699208|NCT04867512|DIETARY_SUPPLEMENT|GI Detox|GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.
48699209|NCT04867512|DIETARY_SUPPLEMENT|Olivirex|Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
48168929|NCT00218998|BEHAVIORAL|exercise training|
48168930|NCT05380102|DEVICE|Telemetry monitoring|All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
48168931|NCT05380102|DEVICE|Continuous monitoring through Earlysense|EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
48515776|NCT04497012|DRUG|6 mg/kg/day Iron Sulfate|Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
48515777|NCT00238758|DRUG|Omega-3 Polyunsaturated Fatty Acids|
48515778|NCT01940991|DRUG|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
48515779|NCT01940991|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
48515780|NCT02856555|DRUG|Firsocostat|Capsules orally once daily.
48515781|NCT02856555|DRUG|Placebo|Placebo matched to firsocostat orally once daily.
48515782|NCT00599248|BIOLOGICAL|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
48515783|NCT00599248|BIOLOGICAL|Placebo|Placebo control (DMEM)
48515784|NCT01867463|BIOLOGICAL|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
48699210|NCT00431886|PROCEDURE|64 multi-detector computed tomography|
48168932|NCT05380102|DEVICE|Continuous monitoring through Dozee VS|Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
48168933|NCT01061853|DRUG|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months
48699211|NCT02889289|OTHER|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
48515785|NCT01867463|BIOLOGICAL|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
48371080|NCT05218148|DRUG|S-1 plus oxaliplatin|"Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \&lt;1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \&lt;1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery."
48371081|NCT00542646|PROCEDURE|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
48371082|NCT03993002|OTHER|Normoxia with Normocarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 30-40
48371083|NCT03993002|OTHER|Normoxia with Hypercarbia|PaO2 \< 100 (FiO2 \>= 21%) PaCO2 of 50-60
48371084|NCT03993002|OTHER|Hyperoxia with Normocarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 30-40
48371085|NCT03993002|OTHER|Hyperoxia with Hypercarbia|PaO2 \> 250 (FiO2 \>= 70%) PaCO2 of 50-60
48371086|NCT05365204|PROCEDURE|Near infrared fluorescence navigated sentinel lymph node mapping|Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
48371087|NCT02488564|DRUG|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
48371088|NCT02488564|DRUG|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
48699212|NCT02164357|PROCEDURE|EVT (endovascular treatment )|
48515786|NCT01867463|BIOLOGICAL|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
48515787|NCT06194617|DRUG|Direct oral anticoagulant|Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
48371089|NCT02488564|DRUG|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
48371090|NCT02488564|DRUG|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
48371091|NCT03839316|DEVICE|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
48522900|NCT03068117|OTHER|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
48522901|NCT04766177|DRUG|Bumetanide|bumetanide 0.5 mg twice daily
48699213|NCT02164357|PROCEDURE|IVT (intravenous thrombolytic therapy)|
48699214|NCT04827147|DEVICE|Multi-Periscopic Prism (MPP) glasses|Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
48699215|NCT04827147|DEVICE|Fresnel Peripheral Prism (FPP) glasses|Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
48699216|NCT03091517|BEHAVIORAL|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
48699217|NCT01202019|OTHER|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
48699218|NCT01037725|DRUG|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
48699219|NCT01037725|DRUG|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
48699220|NCT00812409|DIETARY_SUPPLEMENT|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
48699221|NCT00812409|OTHER|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
48699222|NCT02998203|DIETARY_SUPPLEMENT|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
48515788|NCT01547702|BEHAVIORAL|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~* Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~* Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~* Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~* Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~* Session 5: Help to use instructional interventions for ADHD~* Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
48371092|NCT03839316|DEVICE|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
48371093|NCT06126627|BEHAVIORAL|Stress induction|Induction of anticipatory stress to compare voice and speech control and production with and without exposure to stress.
48371094|NCT03914703|PROCEDURE|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
48371095|NCT01233076|DEVICE|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
48371096|NCT01233076|DEVICE|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
48371097|NCT06230822|DRUG|VUM02 Injection|VUM02 Injection will be administered intravenously every 3 days for a total of 3 doses.
48371098|NCT05534620|DRUG|Treosulfan|IV infusion
48699223|NCT01942668|DRUG|Estradiol|
48699224|NCT01942668|DRUG|Progesterone|
48699225|NCT01942668|DRUG|Placebo|
48699226|NCT06523218|DIETARY_SUPPLEMENT|MindMD Supplement|Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.
48699227|NCT06523218|OTHER|Placebo|Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.
48699228|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
48699229|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
48699230|NCT01713673|DRUG|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48371099|NCT05534620|DRUG|Fludarabine|IV infusion
48699231|NCT01713673|DRUG|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
48699232|NCT01031316|OTHER|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
48699233|NCT01031316|OTHER|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
48699234|NCT06018493|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
48168934|NCT01061853|DRUG|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
48168935|NCT06250478|DIAGNOSTIC_TEST|Dynamic ultrasound of the calf muscles|Dynamic changes of the calf muscles during walking will be assessed in persons after stroke and compared to healthy controls
48168936|NCT03686241|PROCEDURE|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
48371100|NCT01205464|DRUG|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
48371101|NCT01205464|DRUG|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
48371102|NCT05822973|DEVICE|3.0 monocryl suture|incision will be closed with absorbable suture
48371103|NCT05822973|DEVICE|3.0 nylon suture|incision will be closed with non-absorbable suture
48371104|NCT02221804|BEHAVIORAL|14 days of voluntary step count reduction to no more than 1500 steps/day.|
48371105|NCT06401382|DEVICE|A modified aligner appliance with NiTi springs|The modified aligner appliance will be used until the final position is achieved.
48371106|NCT06401382|DEVICE|Conventional fixed appliances|The traditional fixed appliances with a standard prescription will be used.
48371107|NCT01074320|OTHER|Other|Observational study
48371108|NCT06388538|OTHER|Conservative treatment (non-operative treatment)|Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)
48371109|NCT06388538|OTHER|Surgical treatment (operative treatment)|"Surgical treatment (operative treatment) is explained as follows:~1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure)~2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above"
48371110|NCT03143465|DRUG|Calcitonin Gene-Related Peptide|
48371111|NCT03143465|DRUG|Sildenafil|
48371112|NCT03143465|DRUG|Placebo|
48699235|NCT06018493|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
48699236|NCT02121106|BEHAVIORAL|Cognitive Remediation|
48699237|NCT02121106|BEHAVIORAL|Sham Cognitive Remediation|
48699238|NCT04065074|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
48011675|NCT05961891|PROCEDURE|The Use of Composite Bone and Nail Bed Graft Combined With Cutaneous Flaps for Reconstruction of Finger Tip Amputations|"1. The amputated finger tip is cleaned and a composite graft including the nail bed and bone of distal phalanx is taken from the amputated part.~2. The bone of the amputated part is fixed to the remaining stump of the distal phalanx with an axial 21gauge needle or by a K-wire (0.8 mm).~3. The nail bed graft is sutured with 6-0 vicryl to the remaining nail bed.~4. A local or regional cutaneous flap is used to cover the volar aspect and tip of the distal phalanx bone e.g. V-Y advancement flap, thenar flap or cross finger flap .The flap should protrude beyond the tip, providing extra skin which is recontoured to a rounded tip.~5. The nail plate is inserted in the nail fold to prevent the formation of synechiae between the nail fold and the injured nail bed.~6. The finger is immobilized for two weeks in a below elbow dorsal slab.~7. Patients are followed up for 3 months. Postoperative complications and their management will be recorded."
48011676|NCT03446703|BEHAVIORAL|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
48011677|NCT03446703|BEHAVIORAL|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
48168937|NCT03686241|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
48168938|NCT03046797|DEVICE|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
48168939|NCT03046797|DEVICE|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
48011678|NCT01626261|DEVICE|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
48011679|NCT02908529|DRUG|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
48011680|NCT02908529|DRUG|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
48011681|NCT03339375|DEVICE|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
48011682|NCT05056168|OTHER|Dermatology-Specific Treatment Satisfaction Instrument|Study subjects will also be administered a dermatology-specific treatment satisfaction questionnaire, as well as other questionnaires including the generic validated Treatment Satisfaction Questionnaire for Medication (TSQM-9) and the validated Dermatology Life Quality Index (DLQI). Study participants will also self-report their disease severity using PGA. Depending on patients' preferred method of interacting with the study team, the investigators will collect their responses to these questionnaires either in-person, over the phone, or electronically via secure research platforms.
48011683|NCT03211741|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
48011684|NCT06136221|BEHAVIORAL|LiverWatch Intervention|The LiverWatch Intervention will include standard cirrhosis care and include additional components utilizing the W2H system. Details on this intervention are included in the study arm description.
48011685|NCT01324375|DEVICE|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
48011686|NCT03009097|BIOLOGICAL|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
48011687|NCT03009097|DRUG|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
48168940|NCT04546659|OTHER|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
48168941|NCT04546659|OTHER|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
48168942|NCT05172557|BEHAVIORAL|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
48168943|NCT05172557|BEHAVIORAL|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
48168944|NCT05509283|BEHAVIORAL|Risk Reduction|Letter, patient portal, SMS and/or another modality
48371113|NCT05033821|BEHAVIORAL|Adapted FOY+ImPACT|The Adapted FOY+IMPACT is a selective, group-level intervention designed to prevent sexual risk-taking and substance use among adolescents affected by parental drug use. There are eight sessions for youth (FOY) and one session with youth and adults (ImPACT).
48168945|NCT06086119|DIAGNOSTIC_TEST|to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.|Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
48168946|NCT01145417|DRUG|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
48371114|NCT00261352|DRUG|Tesaglitazar|
48371115|NCT00261352|DRUG|Metformin|
48371116|NCT00261352|DRUG|Fenofibrate|
48371117|NCT02109965|DRUG|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
48371118|NCT02109965|DRUG|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
48371119|NCT02109965|DRUG|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
48371120|NCT05066516|DRUG|FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin|FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
48371121|NCT05524376|OTHER|no intervention|no intervention
48011688|NCT03410225|BEHAVIORAL|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
48011689|NCT03410225|BEHAVIORAL|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
48515789|NCT06018038|DIAGNOSTIC_TEST|Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)|Cardiopulmonary Exercise Testing (CPET)
48371122|NCT04183868|DRUG|Empagliflozin 10 MG|10 mg tablet daily
48168947|NCT04735913|DRUG|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
48168948|NCT01458964|DRUG|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
48168949|NCT02347969|DIETARY_SUPPLEMENT|X34|Dietary supplement named X34
48371123|NCT04183868|DRUG|Glimepiride 2 mg|starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
48371124|NCT02607904|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
48371125|NCT04084652|DIETARY_SUPPLEMENT|Mycoprotein ingestion|The ingestion of mycoprotein
48515790|NCT03395457|DRUG|Care as usual|Application of usual pharmacological care for chronic migraine
48515791|NCT03395457|OTHER|Manual Therapy|5 sessions of manual therapy over 12 weeks
48515792|NCT02996292|DEVICE|Traditional brackets|Treating of crowding using traditional brackets
48515793|NCT02996292|DEVICE|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
48515794|NCT02996292|DEVICE|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
48515795|NCT02214992|DRUG|Telmisartan/Ramipril|Fixed dose combination tablet
48515796|NCT02214992|DRUG|Telmisartan|
48699239|NCT00110786|BIOLOGICAL|Ragweed MATAMPL|
48699240|NCT05613452|RADIATION|Carbon ion beam radiotherapy|Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
48699241|NCT03091998|DRUG|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
48168950|NCT06360705|DEVICE|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
48371126|NCT02000674|DRUG|Succinylcholine : 1mg/kg|
48515797|NCT02214992|DRUG|Ramipril capsule|
48515798|NCT02214992|DRUG|Ramipril tablet|
48515799|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat|
48515800|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
48515801|NCT01811329|DIETARY_SUPPLEMENT|Palm fat|
48515802|NCT01811329|DIETARY_SUPPLEMENT|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
48515803|NCT01045330|BEHAVIORAL|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
48515804|NCT03144310|OTHER|lung ultrasound|lung ultrasound and blood gas
48515805|NCT04775303|DRUG|Cyclosporine 0.1% (Ikervis®) eye drop|One drop of Cyclosporine 0.1% (Ikervis®) eye drop once daily for 12 weeks
48699242|NCT03091998|OTHER|Placebo|Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
48168951|NCT03421600|DEVICE|blue laser imaging|blue laser imaging
48168952|NCT03421600|DEVICE|White light imaging|White light imaging
48168953|NCT01649505|DRUG|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
48168954|NCT01649505|PROCEDURE|breast reconstruction|Undergo sharp dissection technique
48168955|NCT01649505|PROCEDURE|breast reconstruction|Undergo electrocoagulation dissection technique
48168956|NCT00204516|BIOLOGICAL|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
48515806|NCT04220255|DEVICE|Liberty677MY Multifocal IOL|multifocal intraocular lens (IOL)
48515807|NCT03798925|OTHER|None Intervention|It is observational study
48515808|NCT03389516|OTHER|Polymem|wound care dressings
48515809|NCT03389516|OTHER|Lanolin|wound care oinment
48515810|NCT02647697|DRUG|Radiprodil oral|"* Active Substance: Radiprodil~* Pharmaceutical Form: dry granules for oral suspension~* Concentration: 30 mg~* Route of Administration: oral use"
48515811|NCT05808478|BEHAVIORAL|AAC + Eye Tracking|The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
48515812|NCT05808478|BEHAVIORAL|AAC|Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
48515813|NCT00266539|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
48515814|NCT05537974|PROCEDURE|Endotracheal aspiration|Clearance of endotracheal secretions via a catheter.
48515815|NCT02850692|OTHER|measure of endothelial function|Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
48522902|NCT04766177|DRUG|Placebo|placebo tablets twice daily
48522903|NCT00633997|DRUG|Vildagliptin|50 mg orally twice daily for 10 days (last dose morning of day 10)
48522904|NCT00633997|DRUG|Vildagliptin|
48699243|NCT04357730|DRUG|Alteplase 50 MG [Activase]|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
48168957|NCT00204516|DRUG|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
48168958|NCT01430208|PROCEDURE|resectoscopy|hysteroscopy for myomas G0 and/or polyps
48168959|NCT01730547|BIOLOGICAL|Autologous mesenchymal stem cells|
48168960|NCT05193500|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
48168961|NCT05193500|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
48168962|NCT05066919|PROCEDURE|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
48522905|NCT01892124|BEHAVIORAL|Motivational Interviewing/Cognitive Behavioral-based Therapy|
48699244|NCT04357730|DRUG|Alteplase 50 MG [Activase]|wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
48515816|NCT02850692|BIOLOGICAL|Blood sample|21 ml of blood to measure : hepatic workup, complete blood count (CBC), platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), C-reactive protein (CRP), lipid test, ionograms, creatinine, tissue plasminogen activator factor (tPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway inhibitor (TFPI), Willebrand factor, soluble thrombomodulin, blood levels of endoglin and syndecan. And level beta human chorionic gonadotropin (beta-HCG) for woman only.
48699245|NCT00678769|DRUG|Cixutumumab|Given IV
48699246|NCT00678769|OTHER|Laboratory Biomarker Analysis|Correlative studies
48699247|NCT00678769|OTHER|Pharmacological Study|Correlative studies
48699248|NCT00678769|DRUG|Temsirolimus|Given IV
48699249|NCT06241638|DRUG|Vitamin B12 0.5 MG/ACTUAT|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
48699250|NCT06241638|DRUG|Dapagliflozin 10mg Tab|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
48011690|NCT00685152|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
48011691|NCT05263661|PROCEDURE|LIFT|Ligation of fistula tract between external and internal sphincter
48515817|NCT02850692|OTHER|Hepatic elastography|Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.
48515818|NCT02850692|DIAGNOSTIC_TEST|Injected abdominal CT|"Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit."
48515819|NCT00401661|DRUG|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
48699251|NCT02281110|DEVICE|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
48699252|NCT02478697|BEHAVIORAL|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
48699253|NCT04999215|DRUG|F-choline intravenous injection|Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
48699254|NCT03619096|PROCEDURE|tunnel technique for Root coverage with Porcine collagen Matrix|Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
48699255|NCT03619096|PROCEDURE|extended fla technique for Root coverage with Porcine collagen Matrix|Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
48011692|NCT05263661|PROCEDURE|FLAP|Creation of a partial wall rectal flap to close internal opening of fistula tract
48371127|NCT02000674|DRUG|Rocuronium : 1.2 mg/kg|
48371128|NCT04372121|DRUG|75 mg linzagolix tablet|For oral administration once daily
48371129|NCT04372121|DRUG|200 mg linzagolix tablet|For oral administration once daily
48371130|NCT04372121|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
48371131|NCT04372121|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
48699256|NCT03013101|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
48699257|NCT01015495|DRUG|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
48371132|NCT04372121|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
48699258|NCT05658159|DIAGNOSTIC_TEST|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
48699259|NCT05658159|DIAGNOSTIC_TEST|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
48699260|NCT05658159|OTHER|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
48699261|NCT03666780|DEVICE|LAmbre Occluder|All patients are implanted with Lifetech LAmbre occluder device.
48699262|NCT04669262|DRUG|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
48699263|NCT04669262|DRUG|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
48699264|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP593
48699265|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP604
48699266|NCT06493097|BEHAVIORAL|Gut-directed hypnotherapy via audio files|5 audio files 10-15 min each, min 5 times a week for 12 weeks
48699267|NCT02138305|DEVICE|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
48699268|NCT02138305|PROCEDURE|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
48699269|NCT05846880|DRUG|Lenalidomide|For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose
48699270|NCT05846880|DRUG|Maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU
48699271|NCT05846880|DRUG|No maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
48699272|NCT06007664|BEHAVIORAL|Tele-Video to Improve Daily Activity|Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
48699273|NCT04495257|DRUG|Nivolumab|Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
48699274|NCT04495257|DRUG|Ipilimumab|Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
48699275|NCT04495257|DRUG|APX005M|APX005M 0.3mg/kg intravenously (IV) every 3 weeks
48699276|NCT01114971|DRUG|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
48699277|NCT01114971|DRUG|Labetalol|"Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
48699278|NCT01114971|DRUG|Esmolol|"Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
48699279|NCT04470908|DRUG|Zanubrutinib|Single oral dose of 320 mg
48699280|NCT04470908|DRUG|Rifabutin|Oral dose of 300 mg once daily
48699281|NCT01129765|DEVICE|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
48371133|NCT04372121|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
48371134|NCT03133702|OTHER|Forensic cases|Forensic cases which were admitted to the Emergency Department
48515820|NCT04555434|DIETARY_SUPPLEMENT|Probiotics|"* Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose"
48515821|NCT06256523|DRUG|GZR18|0.5mg-13mg
48011693|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, partial LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity and improvement in limbal stem cell deficiency, and monitored for adverse events.
48371135|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
48699282|NCT03542656|DRUG|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
48699283|NCT03267667|DIAGNOSTIC_TEST|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
48699284|NCT04283214|OTHER|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
48011694|NCT05909735|PROCEDURE|transplantation of a Descemet's Membrane corneal onlay, total/near-total LSCD|The worst seeing eye of these patients (or a randomized eye if vision is equal bilaterally) will be treated with superficial keratectomy to remove any pannus and debride the central corneal epithelium, followed by transplantation of a Descemet's membrane (DM) corneal onlay. Patient will be followed for 6 months and evaluated for improvement in visual acuity, limbal stem cell deficiency, and persistent epithelial defects/recurrent erosions, and monitored for adverse events.
48011695|NCT01245179|DRUG|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~1. 15 mg MWF 3 weeks on, 1 week off (if needed)~2. 15 mg MWF every week (starting dose)~3. 20 mg MWF 3 weeks on, 1 week off~4. 20 mg MWF every week"
48515822|NCT06256523|OTHER|Placebo|administered the same volume as GZR18
48515823|NCT00978614|DRUG|Neramexane|"Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
48699285|NCT04217135|DRUG|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
48699286|NCT00142805|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
48699287|NCT00142805|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
48699288|NCT02545881|OTHER|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
48011696|NCT04687956|PROCEDURE|LYMPHA|Axillary reverse mapping is performed before surgery, axillary lymph node resection is performed, and 'LYMPHA' (Lymphatic microsurgical preventing healing approach) is performed, and the surgery is terminated. Subsequently, the occurrence of lymphedema is followed up.
48011697|NCT04687956|PROCEDURE|control|In the control group, axillary lymph node resection is performed and the surgery is terminated without additional procedures. Subsequently, the occurrence of lymphedema is followed up.
48011698|NCT05942456|DIAGNOSTIC_TEST|ELISA: enzyme-linked immunosorbent assay|enzyme-linked immunosorbent assay
48011699|NCT03125369|PROCEDURE|Sleeve gastrectomy + duodeno-jejunal bypass|
48515824|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
48515825|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
48515826|NCT02083068|BIOLOGICAL|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
48515827|NCT02587091|BEHAVIORAL|Portable obstetric ultrasound|This intervention was advertised at the cluster level
48168963|NCT05066919|OTHER|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
48168964|NCT04233983|PROCEDURE|Laparoscopic Endometriosis Surgery|Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
48168965|NCT04311385|DIAGNOSTIC_TEST|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
48168966|NCT05414006|DRUG|S-ketamine|S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
48168967|NCT05277818|PROCEDURE|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
48168968|NCT03282578|DEVICE|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
48168969|NCT03282578|DEVICE|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
48168970|NCT00286975|BEHAVIORAL|Leadership development program educational intervention|
48168971|NCT04795583|DRUG|Prednisone|Prednisone 25 mg capsules
48168972|NCT04795583|DEVICE|Point of Care testing device for C-reactive protein|Determination of C-reactive protein blood levels by point of care testing device
48168973|NCT05726552|OTHER|Laughter therapy|"Laughter therapy will be applied for 50 minutes, 12 sessions, 3 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality.~The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
48168974|NCT05266625|BEHAVIORAL|BT-001|"Bt-001 is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, Bt-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
48168975|NCT05266625|OTHER|Control App|The app asks patients brief questions about their health but does not include any behavioral therapy.
48371136|NCT00738231|BEHAVIORAL|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
48515828|NCT05203783|OTHER|McKenzie Exercises|"McKenzie exercises: The McKenzie set consists of 5 exercises.~1. Prone-lying~2. Prone-extension~3. Prone press ups~4. Progressive extension with pillows~5. Standing extension"
48522906|NCT05954390|DIETARY_SUPPLEMENT|Undenatured beta-glucan solution|The active comparator is a solution containing undenatured beta-glucans
48699289|NCT05920681|PROCEDURE|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
48699290|NCT05920681|COMBINATION_PRODUCT|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
48699291|NCT05347095|DRUG|Guselkumab|Guselkumab will be administered subcutaneously/IV infusion.
48699292|NCT05347095|DRUG|Placebo|Matching placebo will be administered subcutaneously/IV infusion.
48699293|NCT00904462|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
48011700|NCT03125369|PROCEDURE|Roux-Y gastric bypass|
48011701|NCT03893266|OTHER|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
48168976|NCT02957162|DRUG|Atorvastatin|
48371137|NCT00218439|DRUG|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
48371138|NCT00218439|DRUG|Placebo|
48371139|NCT01162031|DRUG|Velcade|IV
48371140|NCT00514059|DRUG|Boostrix polio|1 dose (0.5 ml) i.m.
48699294|NCT00904462|DRUG|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
48168977|NCT02957162|OTHER|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
48168978|NCT01613807|DRUG|Insulin LISPRO|Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.
48522907|NCT05954390|OTHER|Placebo|The placebo comparator is the same solution as the active therapy except it does not contain any undenatured beta-glucans
48699295|NCT01127607|DRUG|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
48699296|NCT01923363|DRUG|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
48699297|NCT03020134|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
48699298|NCT03020134|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
48699299|NCT03020134|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
48699300|NCT03020134|DRUG|Placebo|Placebo
48699301|NCT05655325|BEHAVIORAL|Home-based walking exercise|A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.
48699302|NCT05655325|OTHER|Attention control|Health education and stretching
48699303|NCT04858815|BEHAVIORAL|yogic breathing|participation in yogic breathing
48699304|NCT05867420|BIOLOGICAL|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
48011702|NCT00536367|OTHER|No intervention - observational study only|
48011703|NCT05176652|RADIATION|ultrasound|ultrasonographic assessment of optic nerve sheath diameter
48011704|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule willing to receive a 3rd dose of vaccine
48011705|NCT05109585|DIAGNOSTIC_TEST|assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule|evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination schedule unwilling to receive a 3rd dose of vaccine
48011706|NCT02248129|DRUG|Telmisartan and hydrochlorothiazide|
48011707|NCT00414661|DRUG|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
48011708|NCT01470287|BIOLOGICAL|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
48011709|NCT00677495|DIETARY_SUPPLEMENT|Gluten-free diet|Gluten-free diet
48011710|NCT00595569|BEHAVIORAL|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
48168979|NCT01613807|DRUG|Insulin, Long-Acting and Insulin|Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
48168980|NCT05245305|OTHER|Mindfulness Based Stress Reduction Program|The intervention was structured as 11 weeks, taking into account the group. The program takes 2-2.5 hours per week. The program includes raisin exercise, body scanning meditation, breath awareness meditation, sitting meditation, mindfull movement, walking meditation, vision meditation, compassion meditation,mindfulness communication and day of silence.
48168981|NCT04834063|DIAGNOSTIC_TEST|Serum Zinc a level|Diagnostic test
48168982|NCT04834063|DIAGNOSTIC_TEST|serum selenium level|Diagnostic test
48168983|NCT04834063|DIAGNOSTIC_TEST|Fibroscan measurement|Diagnostic test
48168984|NCT04811118|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
48168985|NCT04811118|DRUG|Taxotere|Taxotere
48168986|NCT00024570|DRUG|IL13-PE38QQR|
48168987|NCT00024570|PROCEDURE|targeted fusion protein therapy|
48168988|NCT00024570|PROCEDURE|surgery|
48515829|NCT05203783|OTHER|Kinesio Tape Application|Kinesio Tape (KT) application: Participants in the experimental group received additional taping using KT by an experience therapist with prior training in KT application. The tape was applied using the method proposed for the sacrospinalis muscle (Kase, 1996). Y-shaped tape was applied as shown in Figure 1. While the participant was in standing position, the origin of the Y-shaped tape was attached over the centre of the sacrum without stretching the tape and afterward subjects gradually bent forward. A 5-degree angle was maintained within the valley of the Y tape. The tape was changed on the fourth day
48168989|NCT03256370|PROCEDURE|milk collection|"* Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
48371141|NCT03035175|OTHER|Video Laryngoscopy|Residents intubate using video laryngoscopy.
48371142|NCT03035175|OTHER|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
48515830|NCT02633787|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
48699305|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
48699306|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
48699307|NCT02522585|OTHER|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
48699308|NCT00210457|DRUG|Lanreotide (Autogel formulation)|
48699309|NCT00725192|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
48699310|NCT00725192|BEHAVIORAL|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
48699311|NCT04732702|OTHER|no intervention|There will be no intervention.
48699312|NCT04956276|DRUG|ALXN1830|Administered as an SC infusion.
48699313|NCT04956276|DRUG|Placebo|Administered as an SC infusion.
48699314|NCT01824654|OTHER|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
48699315|NCT01824654|OTHER|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
48699316|NCT05143749|OTHER|video tutorial|get video tutorial
48371143|NCT00014066|DRUG|hematoporphyrin derivative|
48371144|NCT00014066|RADIATION|brachytherapy|
48699317|NCT05258578|BEHAVIORAL|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
48699318|NCT05258578|OTHER|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
48699319|NCT05337111|OTHER|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
48699320|NCT05337111|OTHER|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
48371145|NCT04090294|DRUG|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
48699321|NCT05337111|OTHER|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
48699322|NCT06412705|PROCEDURE|Tooth extraction, guided bone regeneration and dental implant|The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
48371146|NCT00031616|DRUG|brivudine phosphoramidate|
48371147|NCT01054443|DRUG|Placebo|Tablet
48699323|NCT06404866|BEHAVIORAL|eMotion|Participants will complete one lesson per week. The weekly education is targeted to women and contains personalized content via a variety of diverse lesson narratives. Each week participants listen to scripted sessions they can complete on their own time regarding each of the weekly topics (lasting about 30 minutes). At the end of the week, they then meet individually with a study team member virtually to discuss the same subject.
48168990|NCT02949076|BEHAVIORAL|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
48699324|NCT06660342|DRUG|Vonoprazan|Oral tablet.
48168991|NCT02970786|DRUG|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c\[RGDyK\])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
48168992|NCT00296023|BIOLOGICAL|anti-thymocyte globulin|
48011711|NCT02338947|PROCEDURE|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time \>200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
48168993|NCT00296023|BIOLOGICAL|filgrastim|
48168994|NCT00296023|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48168995|NCT00296023|DRUG|busulfan|
48168996|NCT00296023|DRUG|fludarabine phosphate|
48168997|NCT00296023|DRUG|methotrexate|
48371148|NCT01054443|DRUG|Lusutrombopag|Tablet
48371149|NCT02503111|DEVICE|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
48699325|NCT02603458|DRUG|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
48699326|NCT02603458|DRUG|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
48699327|NCT04957992|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
48168998|NCT00296023|DRUG|tacrolimus|
48168999|NCT00296023|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
48169000|NCT00296023|PROCEDURE|peripheral blood stem cell transplantation|
48169001|NCT03168698|DRUG|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
48169002|NCT03168698|DRUG|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
48169003|NCT05404217|OTHER|LN-OS-22|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
48169004|NCT05404217|OTHER|Maltodextrin|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
48169005|NCT03910777|DIAGNOSTIC_TEST|Early Warning Score|National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
48169006|NCT04515628|DRUG|Rosuvastatin|Specified dose on specified days
48169007|NCT04515628|DRUG|Branebrutinib|Specified dose on specified days
48169008|NCT02212483|OTHER|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
48169009|NCT02212483|OTHER|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
48371150|NCT02503111|OTHER|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
48371151|NCT02211287|OTHER|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q\&A form and can help answer frequent family questions.
48371152|NCT02211287|OTHER|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
48515831|NCT01407237|DRUG|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
48515832|NCT01548105|OTHER|Blood draw for the study participants|"These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels"
48515833|NCT03018184|OTHER|MRI and Muscle Dynamometer|
48699328|NCT04957992|OTHER|Control Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
48699329|NCT04957992|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
48169010|NCT02212483|OTHER|Final home visit|"Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices."
48169011|NCT03478410|PROCEDURE|Epicardial fat biopsy|A 1 cm (\~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
48169012|NCT01300078|DRUG|MF101|MF101 10 g/day MF101 15 g/day
48169013|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
48169014|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
48371153|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL|The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.
48371154|NCT05144646|OTHER|MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL|In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
48371155|NCT02187718|PROCEDURE|Sentinel Node Procedure under Local Anaesthesia|
48515834|NCT03998397|BIOLOGICAL|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
48699330|NCT04957992|OTHER|Experimental Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
48699331|NCT04957992|OTHER|Human Milk|Ad libitum or as instructed by HCP
48699332|NCT04957992|OTHER|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
48699333|NCT04957992|OTHER|Human Milk Toddler Drink|\~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
48699334|NCT00318747|DRUG|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
48699335|NCT01633632|BEHAVIORAL|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
48699336|NCT01633632|BEHAVIORAL|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
48699337|NCT00777985|DRUG|bosentan|62.5 mg b.i.d for 4 weeks
48699338|NCT00777985|DEVICE|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
48699339|NCT00694837|DRUG|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
48699340|NCT06423495|DEVICE|low-intensity laser treatment|The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
48699341|NCT01584791|DRUG|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
48699342|NCT01584791|DRUG|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
48699343|NCT00189332|DRUG|852A|
48699344|NCT06056336|DRUG|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
48699345|NCT02789943|PROCEDURE|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
48011712|NCT02338947|PROCEDURE|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time \>480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
48011713|NCT05581212|OTHER|Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack|Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
48011714|NCT04719416|BEHAVIORAL|Guided Meditation|Approximately 10 minute recording of guided meditation focuses on muscle relaxation.
48011715|NCT04977843|PROCEDURE|EARLY BRONCHOALVEOLAR LAVAGE|E-BAL done with instillation of 100cc normal saline and sucked out
48011716|NCT04629833|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
48169015|NCT05191836|OTHER|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
48371156|NCT02187718|PROCEDURE|Sentinel Node Procedure under General Anaesthesia|
48169016|NCT06308549|BEHAVIORAL|MyDiaMate|MyDiaMate programme
48169017|NCT01772147|DRUG|Umeclidinium bromide 62.5mcg|Inhalation powder
48169018|NCT01772147|DRUG|Umeclidinium bromide 125mcg|Inhalation powder
48169019|NCT01772147|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
48169020|NCT05615480|OTHER|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% \~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% \~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 \~ 100 μg or ephedrine 5 \~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
48169021|NCT04723732|DRUG|Myrrh mouthwash|1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
48169022|NCT04723732|DRUG|Chlorhexidine mouthwash|0.2% mouthwash solution of chlorhexidine gluconate.
48169023|NCT04723732|DRUG|Normal saline|0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
48371157|NCT04639895|PROCEDURE|Virtual Reality|The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
48371158|NCT04639895|PROCEDURE|Paper and Pencil|The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
48169024|NCT03385798|PROCEDURE|Endowrist|Anastomosis made by Endowrist
48169025|NCT03385798|PROCEDURE|Endo-GIA|Anastomosis made by Endo-GIA
48169026|NCT00796614|DRUG|tamsulosin hydrochloride|Oral
48169027|NCT00796614|DRUG|Placebo|Oral
48169028|NCT05024409|DEVICE|Upper Extremity Orthotic|3D printed orthotic which uses elbow motion to facilitate finger extension
48169029|NCT05024409|OTHER|Occupational Therapy|6 weekly sessions of occupational therapy, without use of an assistive orthotic device
48169030|NCT01272323|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
48169031|NCT01272323|BIOLOGICAL|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
48169032|NCT01272323|BIOLOGICAL|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
48371159|NCT04639895|PROCEDURE|Control Group|The standard treatment protocol.
48371160|NCT05637931|DIAGNOSTIC_TEST|plexinD1|evaluation of the serum level of plexinD1
48371161|NCT06262009|OTHER|human faecal collection|collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90
48371162|NCT06262009|OTHER|ancillary study|interviews and/or ethnographic observations for 50 volunteers
48371163|NCT03639493|DRUG|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
48371164|NCT03639493|DRUG|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
48371165|NCT05163964|BEHAVIORAL|Lifestyle Intervention|Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
48371166|NCT04149145|DRUG|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
48699346|NCT05927675|BEHAVIORAL|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
48699347|NCT03221868|BEHAVIORAL|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
48371167|NCT04149145|DRUG|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
48371168|NCT01880996|OTHER|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
48699348|NCT03221868|BEHAVIORAL|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
48699349|NCT02724917|DRUG|APN1125|Oral solid dose form of APN1125
48699350|NCT02724917|DRUG|Placebo|Placebo to match
48699351|NCT03213938|DEVICE|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
48699352|NCT03213938|DEVICE|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
48699353|NCT05482529|OTHER|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
48699354|NCT02202213|DRUG|Placebo|
48699355|NCT02202213|DRUG|Lu AF11167|
48699356|NCT04336046|PROCEDURE|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
48699357|NCT04336046|PROCEDURE|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
48699358|NCT04336046|DRUG|normal saline|using 1 mg /kg normal saline
48699359|NCT04336046|DRUG|Bupivacaine|bupivacaine
48699360|NCT05240157|DRUG|Corticosteroid Derivatives|observational
48011717|NCT04629833|BIOLOGICAL|BAT|BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
48371169|NCT01428570|DEVICE|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
48371170|NCT04123743|DRUG|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
48371171|NCT04123743|OTHER|Facial Wash|Wardah brand facial wash
48371172|NCT04123743|OTHER|Sunscreen Cream|Parasol sunscreen cream SPF 33
48371173|NCT04123743|OTHER|Placebo|Placebo topical cream
48371174|NCT02344758|DEVICE|Non-invasive lateral flow test for monitoring gluten intake|
48371175|NCT02344758|BEHAVIORAL|gluten-free diet (GFD)|
48371176|NCT02344758|BEHAVIORAL|gluten-containing diet|
48371177|NCT02425774|PROCEDURE|Vagus stimulation|
48699361|NCT01519791|BIOLOGICAL|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
48169033|NCT01437813|DRUG|Glimepiride/ Extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
48169034|NCT04295018|DRUG|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
48169035|NCT02712190|DEVICE|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
48169036|NCT03090633|DEVICE|Fetoscopy|Minimally invasive in-utero surgery
48169037|NCT00787813|DRUG|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
48169038|NCT00787813|DRUG|Placebo|
48169039|NCT01077622|DRUG|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
48169040|NCT05259397|DRUG|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
48169041|NCT05259397|DRUG|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
48169042|NCT01328808|DRUG|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
48169043|NCT04308642|OTHER|blood test for renal biomarkers|blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)
48169044|NCT04308642|OTHER|urine test for renal biomarkers|urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)
48699362|NCT01519791|OTHER|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
48169045|NCT04038671|DEVICE|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
48169046|NCT04038671|DEVICE|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
48169047|NCT04038671|DEVICE|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
48371178|NCT02425774|PROCEDURE|Sham stimulation|
48371179|NCT02425774|DRUG|Prucalopride|
48515835|NCT01635348|BEHAVIORAL|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
48169048|NCT02971995|DEVICE|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
48169049|NCT02971995|DEVICE|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
48699363|NCT01519791|BIOLOGICAL|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
48699364|NCT02778555|BEHAVIORAL|Questionnaires|
48699365|NCT06659770|DRUG|Zevorcabtagene Autoleucel|Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
48169050|NCT02224352|DEVICE|Functional neuromuscular electrical stimulation|
48699366|NCT00079391|DEVICE|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
48699367|NCT04523818|DRUG|Capecitabine|Given PO
48169051|NCT00536081|DRUG|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
48169052|NCT03793322|DRUG|Indocyanine-Green(ICG)|ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
48169053|NCT00655083|DRUG|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
48371180|NCT02425774|DRUG|Placebo|
48371181|NCT04081246|DEVICE|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
48371182|NCT03857126|OTHER|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
48371183|NCT03247140|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
48011718|NCT04625738|BIOLOGICAL|Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells|"Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.~day 0: 1.10\^6 MSC/kg day 3: 0.5. 10\^6 MSC/kg day 5: 0.5 . 10\^6 MSC/kg"
48169054|NCT00655083|DRUG|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
48169055|NCT01359878|DRUG|Fibrinogen Concentrate|2 gram intra venous
48371184|NCT03247140|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
48371185|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV at assigned doses in continuous cycles of 21 or 28 days
48371186|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV once weekly at the preliminary RP2D dose in continuous cycles of 21 or 28 days
48371187|NCT04984824|BEHAVIORAL|Nap duration|A cognitive battery which will be repeated at 1505, 1530, 1600 and 1900. Material for the picture encoding task will be learned at 1630 and will be tested at 2000.
48371188|NCT00829595|BIOLOGICAL|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
48515836|NCT01635348|BEHAVIORAL|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
48515837|NCT05044195|BIOLOGICAL|aQIV|Participants receive a 0.5-mL intramuscular dose of aQIV on Day 1
48699368|NCT04523818|DRUG|Fluorouracil|Given IV
48699369|NCT04523818|RADIATION|Radiation Therapy|Undergo radiation therapy
48699370|NCT04523818|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard of care surgery
48699371|NCT03888170|OTHER|No intervention|No intervention
48699372|NCT03069248|DRUG|Rituximab|
48699373|NCT03069248|DRUG|Alpha Interferon|
48699374|NCT02668770|DRUG|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
48011719|NCT04625738|BIOLOGICAL|Placebo|Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day).
48011720|NCT02610868|DRUG|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
48169056|NCT01359878|DRUG|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
48169057|NCT00508534|DRUG|SB-751689|
48169058|NCT04593706|DRUG|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
48169059|NCT04593706|DRUG|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
48169060|NCT04593706|DRUG|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
48169061|NCT04593706|DRUG|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
48371189|NCT05886374|DRUG|HMPL-415S1|HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
48371190|NCT00323934|DRUG|MGCD0103|Oral dosage 2 times weekly.
48515838|NCT05044195|BIOLOGICAL|Comparator QIV|Participants receive a 0.5-mL intramuscular dose of Comparator QIV on Day 1
48515839|NCT01843738|RADIATION|Radiation therapy|Per standard of care
48699375|NCT02668770|DRUG|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
48699376|NCT03122678|DRUG|Thiamine|
48371191|NCT02395445|DEVICE|orotracheal intubation|
48371192|NCT02133612|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
48371193|NCT01106066|DRUG|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
48699377|NCT03122678|DRUG|Placebos|
48515840|NCT01843738|DRUG|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
48011721|NCT02040662|PROCEDURE|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
48371196|NCT04827420|BEHAVIORAL|Mi Quit Care|Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.
48371197|NCT04272320|DRUG|Bupivacaine Hydrochloride|Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
48371198|NCT04298229|DRUG|Dapagliflozin 10 MG|SGLT2 inhibitors being investigated for its diuretic and natriuretic effects on top of protocolized diuretic therapy.
48371199|NCT04298229|OTHER|Protocolized Diuretic Therapy|Structured usual care arm with protocolized diuretic therapy based on urine output.
48371200|NCT05111652|OTHER|observational|observational electromiographic musculature activation
48515841|NCT00072787|DRUG|S-1|
48515842|NCT00072787|DRUG|cisplatin|
48515843|NCT03912935|OTHER|comparison between two different intubating position|Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
48699378|NCT04190381|OTHER|FR-Mask|"The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days."
48699379|NCT02227069|DRUG|M518101|
48699380|NCT02227069|DRUG|M518101 Vehicle|
48699381|NCT02227069|OTHER|sodium lauryl sulfate|
48699382|NCT02227069|OTHER|saline|
48011722|NCT02040662|PROCEDURE|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
48011723|NCT02040662|PROCEDURE|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~* patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~* paracetamol 1000 mg iv every 8 hrs~* ketoprofen 100 mg iv every 12 hrs"
48371201|NCT03707249|DRUG|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
48371202|NCT03707249|DRUG|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
48371203|NCT00821886|DRUG|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
48371204|NCT00821886|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
48371205|NCT00821886|DRUG|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
48371206|NCT03601611|DRUG|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
48515844|NCT00847964|DEVICE|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
48699383|NCT01644006|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
48515845|NCT02468050|BEHAVIORAL|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
48515846|NCT02468050|BEHAVIORAL|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
48515847|NCT05534061|BEHAVIORAL|Connect2Test|Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients
48515848|NCT03091179|DEVICE|THRIVE|active nasal oxygen delivery system
48699384|NCT02589665|DRUG|Mirikizumab|
48699385|NCT02589665|DRUG|Placebo|
48699386|NCT01807559|DEVICE|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
48169063|NCT03765515|DEVICE|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
48169064|NCT03765515|DEVICE|Q-Fix|Q-Fix
48011724|NCT05168995|DRUG|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
48011725|NCT01611571|DRUG|Risedronate|weekly risedronate
48169065|NCT05573347|PROCEDURE|Rotator Cuff Repair|Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
48169066|NCT05573347|PROCEDURE|Bone Marrow Harvest|Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
48169067|NCT04270747|DRUG|ABP 938|Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
48169068|NCT04270747|DRUG|Aflibercept|Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
48169069|NCT00215722|DRUG|Cetuximab|
48169070|NCT00528710|DIETARY_SUPPLEMENT|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
48169071|NCT00812721|OTHER|Preservative Free Saline|One drop will be instilled into each eye once
48169072|NCT00812721|OTHER|Optive|One drop will be instilled into each eye once
48011726|NCT01611571|DRUG|Teriparatide|daily teriparatide
48011727|NCT01611571|DRUG|Placebo Teriparatide|daily placebo of teriparatide
48011728|NCT01611571|DRUG|placebo Risedronate|weekly placebo of Risedronic Acid
48169073|NCT00812721|OTHER|Refresh Moderate/Severe|One drop will be instilled into each eye once
48169074|NCT00812721|OTHER|Systane|One drop will be instilled into each eye once
48169075|NCT00812721|OTHER|Systane Ultra|One drop will be instilled into each eye once
48169076|NCT05479747|DRUG|post operative analgesics|post-operative pain killer
48169077|NCT04314570|PROCEDURE|Saphenous Nerve Block with Ropivacaine Treatment|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
48169078|NCT04314570|PROCEDURE|Saphenous Nerve Block with Saline Control|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
48169079|NCT01729923|DRUG|Capecitabine|Given PO
48169080|NCT01729923|DRUG|Celecoxib|Given PO
48371207|NCT03207516|DIETARY_SUPPLEMENT|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
48699387|NCT05556057|OTHER|mindfulness meditation(MM)|Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes
48699388|NCT05556057|OTHER|Health Education (active control)|Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
48699389|NCT02591758|DEVICE|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
48011729|NCT06574308|DIAGNOSTIC_TEST|Blood cells classification|Comparison of the classification of peripheral blood and bone marrow cells with optical microscope reading with pre-classification using Scopio technology (AI based)
48699390|NCT02591758|BEHAVIORAL|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
48371208|NCT03207516|DIETARY_SUPPLEMENT|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
48371209|NCT05799482|OTHER|Qualitative Interview|Qualitative, semi-structured interview
48371210|NCT04297111|DIETARY_SUPPLEMENT|Probiotic|GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
48699391|NCT02591758|OTHER|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
48699392|NCT02591758|OTHER|Angina assessment with the angina diary, the SAQ and the SF-36|
48699393|NCT02591758|OTHER|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
48699394|NCT02591758|OTHER|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
48699395|NCT02789345|DRUG|Ramucirumab|Administered IV
48699396|NCT02789345|DRUG|Necitumumab|Administered IV
48699397|NCT02789345|DRUG|Osimertinib|Administered orally
48699398|NCT03631004|DRUG|Olanzapine|olanzapine 10 mg is given before surgery
48699399|NCT01369641|PROCEDURE|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
48169081|NCT01729923|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48169082|NCT01729923|OTHER|Laboratory Biomarker Analysis|Correlative studies
48371211|NCT04297111|OTHER|Placebo|Maltodextrin capsule, no active ingredient
48699400|NCT01369641|DRUG|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
48699401|NCT01369641|OTHER|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
48169083|NCT01729923|OTHER|Quality-of-Life Assessment|Ancillary studies
48169084|NCT01729923|RADIATION|Radiation Therapy|Undergo radiation therapy
48169085|NCT01729923|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
48169086|NCT01729923|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48169087|NCT01497340|OTHER|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
48169088|NCT01497340|OTHER|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
48169089|NCT04826419|OTHER|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
48169090|NCT00104975|BIOLOGICAL|alemtuzumab|
48169091|NCT00104975|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48169092|NCT00104975|DRUG|fludarabine phosphate|
48371212|NCT03249259|DRUG|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
48371213|NCT03249259|DRUG|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
48515849|NCT03091179|DEVICE|Endotracheal tube|a plastic tube for mechanical ventilation
48699402|NCT01369641|DRUG|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
48699403|NCT05472909|OTHER|Standardized Relaxation Music|Participants listen to standardized relaxation music during surgery.
48699404|NCT05472909|OTHER|Personal Choice of Music|Participants listen to their preferred music during surgery.
48699405|NCT00491036|DEVICE|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
48699406|NCT02035436|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
48699407|NCT02035436|OTHER|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
48699408|NCT00436423|DRUG|gemcitabine, TS-1|
48011730|NCT01117727|DEVICE|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
48699409|NCT01293630|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
48699410|NCT01293630|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
48515850|NCT05706584|OTHER|control grup (skills lab.) and experimental group (mateverse skill lab.)|The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
48515851|NCT02051621|DRUG|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
48515852|NCT02051621|PROCEDURE|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
48515853|NCT02051621|PROCEDURE|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
48515854|NCT02770378|DRUG|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
48515855|NCT02770378|DRUG|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
48699411|NCT01293630|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
48699412|NCT04135560|DRUG|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
48699413|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
48011731|NCT04828655|BEHAVIORAL|Use of a mobile application based on machine learning with the aim of improving health and body composition parameters.|Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
48011732|NCT06178874|DRUG|Insulin Glargine|hyperglycemic control
48011733|NCT06178874|DRUG|Insulin Degludec|hyperglycemic control
48011734|NCT06178874|DRUG|Insulin regular|hyperglycemic control
48699414|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
48699415|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
48699416|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
48699417|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
48699418|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
48699419|NCT04047875|DRUG|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
48699420|NCT04047875|DRUG|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
48699421|NCT06601517|DRUG|Repaglinide|Single dose; Administered orally
48699422|NCT06601517|DRUG|Atorvastatin|Single dose; Administered orally
48699423|NCT06601517|DRUG|Digoxin|Single dose; Administered orally
48699424|NCT06601517|DRUG|Rosuvastatin|Single dose; Administered orally
48011735|NCT04216732|OTHER|Blood Pressure Measurement|Undergo blood pressure measurement
48699425|NCT06601517|DRUG|HDM1002|Administered orally
48011736|NCT04216732|OTHER|Questionnaire Administration|Complete questionnaires
48011737|NCT05933434|BIOLOGICAL|Allogenic adipose derived mesenchymal stem cells (AD-MSC)|Laboratory isolated, cultivated and cryopreserved allogenic adipose derived mesenchymal stem cells (AD-MSC) from health donors undergoing cometic plastic surgery will be thawed on the injection day and formulated in 10 mL saline. The AD-MSCs will then be intraarticular injected using ultrasonic guidance.
48011738|NCT05933434|OTHER|Saline|10 mL saline will be intraarticular injected using ultrasonic guidance.
48011739|NCT02402452|DRUG|Voxilaprevir|100 mg tablet administered orally
48011740|NCT05630807|DRUG|Bepirovirsen|Bepirovirsen will be administered.
48011741|NCT05630807|OTHER|Placebo|Matching placebo will be administered.
48169093|NCT00104975|DRUG|melphalan|
48515856|NCT02770378|DRUG|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
48011742|NCT05973747|DRUG|Calcium Gluconate|Infused intravenously over 10 minutes upon umbilical cord clamping. First 10 assigned patients received 2 grams per protocol. Subsequent 13 patients received 1.5 grams, dose recalibrated per protocol.
48515857|NCT02770378|DRUG|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
48011743|NCT05973747|DRUG|Calcium chloride|0.5 grams of calcium chloride, infused intravenously over 10 minutes upon umbilical cord clamping
48011744|NCT04055116|DRUG|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
48011745|NCT04240899|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2-3 times/week for 6-weeks. The yoga sessions will be delivered one-on-one and will include 5-7 minutes of breathing exercises 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
48011746|NCT04437394|DIAGNOSTIC_TEST|flexible endoscopic evaluation of swallowing|The patients were assessment with flexible endoscopic swallowing evaluation was performed with colored pudding.
48011747|NCT04437394|DIAGNOSTIC_TEST|The analysis of voice|Voice recordings were taken from the patients to evaluate the voice disturbance and acoustic evaluation was taken with PRAAT program.
48169094|NCT00104975|DRUG|tacrolimus|
48169095|NCT00104975|DRUG|thiotepa|
48169096|NCT00104975|PROCEDURE|peripheral blood stem cell transplantation|
48169097|NCT03762590|OTHER|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
48169098|NCT03762590|OTHER|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
48169099|NCT02645773|DEVICE|non-ablative laser|non-abaltive laser pre, immediate and post wounding
48699426|NCT00939029|DRUG|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
48699427|NCT00939029|DRUG|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
48699428|NCT03165240|DRUG|BI 690517|Film-coated tablet
48699429|NCT03165240|DRUG|Eplerenone|Film-coated tablet
48699430|NCT03165240|DRUG|Placebo|Film-coated tablet
48699431|NCT01728558|OTHER|Early goal Directed Sedation|
48699432|NCT01728558|OTHER|Standard care sedation|
48699433|NCT01453205|DRUG|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
48699434|NCT01453205|DRUG|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
48699435|NCT01453205|DRUG|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
48699436|NCT01453205|DRUG|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
48699437|NCT01453205|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
48699438|NCT01453205|DRUG|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
48699439|NCT01952548|DRUG|K-312|
48699440|NCT01952548|DRUG|Placebo|
48699441|NCT02899455|DRUG|HGP0904|
48699442|NCT02899455|DRUG|HGP0608|
48699443|NCT02899455|DRUG|HGP0816|
48699444|NCT02899455|DRUG|HGP0904 Placebo|
48699445|NCT02899455|DRUG|HGP0816 Placebo|
48699446|NCT04494542|PROCEDURE|Sustained Low Efficiency Dialysis (SLED)|sustained low efficiency dialysis (SLED)
48699447|NCT04494542|PROCEDURE|Continuous Renal Replacement Therapy|Continuous Renal Replacement Therapy
48699448|NCT01948765|DRUG|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
48699449|NCT01948765|DRUG|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
48515858|NCT02770378|DRUG|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
48515859|NCT02770378|DRUG|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
48699450|NCT03374683|BEHAVIORAL|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
48699451|NCT03374683|BEHAVIORAL|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
48699452|NCT03374683|BEHAVIORAL|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
48699453|NCT00642434|DRUG|carvedilol|variable
48011748|NCT01356511|DRUG|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
48011749|NCT01356511|DRUG|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
48011750|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected.
48699454|NCT00642434|DRUG|metoprolol|variable
48699455|NCT00301392|OTHER|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
48699456|NCT00301392|DRUG|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
48699457|NCT03894982|OTHER|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
48699458|NCT04594902|BEHAVIORAL|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
48699459|NCT04594902|OTHER|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
48699460|NCT05137288|DRUG|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
48699461|NCT02156284|BEHAVIORAL|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
48699462|NCT05698017|DRUG|hOMSC300|Human Oral Mucosa Stem Cells
48699463|NCT05698017|OTHER|Sham Procedure|Lumbar Puncture Only
48699464|NCT03215303|DEVICE|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
48699465|NCT01179750|DEVICE|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
48169100|NCT00399503|PROCEDURE|Spectral T Wave Alternans|
48169101|NCT00399503|PROCEDURE|Modified Moving Average T Wave Alternans|
48169102|NCT00399503|PROCEDURE|Baroreceptor Sensitivity|
48169103|NCT00399503|PROCEDURE|Heart Rate Variability|
48169104|NCT00399503|PROCEDURE|Heart Rate Turbulence|
48169105|NCT00399503|PROCEDURE|Deceleration Capacity|
48169106|NCT00399503|PROCEDURE|Signal Averaged ECG|
48699466|NCT01317576|BEHAVIORAL|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
48699467|NCT06506188|BEHAVIORAL|LINK model|"The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care."
48699468|NCT06411769|BEHAVIORAL|50K4LIfe|This intervention will consist of the Walking Challenge only.
48011751|NCT02306967|PROCEDURE|resection of oral cancer|Oral cancer will be resected
48011752|NCT05190458|OTHER|High Velocity Nasal Insufflation|High velocity nasal insufflation (HVNI), a form of HFNC that utilizes a small bore nasal cannula to generate higher velocities of gas delivery than HFNC which uses large bore cannula, has the ability to accomplish complete purge of extra thoracic dead space at flow rates of 35 litres/min and may be able to provide ventilatory support in patients with respiratory failure in addition to oxygenation support in patients with overlap syndrome.
48169107|NCT04171921|PROCEDURE|Robotic ventral hernia repair|Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
48169108|NCT04171921|PROCEDURE|Open ventral hernia repair|Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
48169109|NCT06165536|BEHAVIORAL|Resonant voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
48169110|NCT02716753|BIOLOGICAL|seminal plasma|
48169111|NCT02716753|BIOLOGICAL|Physiological NaCL solution|
48169112|NCT06433440|BIOLOGICAL|PVRV|Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.
48169113|NCT04137302|DRUG|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
48169114|NCT00372177|RADIATION|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
48169115|NCT02206945|BEHAVIORAL|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
48169116|NCT02206945|BEHAVIORAL|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
48169117|NCT00439647|DRUG|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
48169118|NCT00439647|DRUG|Placebo|Placebo intravenous (i.v.) once a year
48169119|NCT01591655|DRUG|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
48169120|NCT01591655|DRUG|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
48169121|NCT05599646|BEHAVIORAL|traditional pedometer based walking intervention|Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
48699469|NCT06411769|BEHAVIORAL|SMS Text Messaging|In this intervention, participants will received notifications onto the Pathverse app
48699470|NCT06411769|BEHAVIORAL|Individual|In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.
48011753|NCT05190458|OTHER|Non-invasive mechanical ventilation|Noninvasive ventilation (NIV) refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube).
48699471|NCT06411769|BEHAVIORAL|School|In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
48699472|NCT01476319|OTHER|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
48699473|NCT05362773|DRUG|MGD024|MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
48011754|NCT00006279|DRUG|Nevirapine|
48011755|NCT05593224|DEVICE|Intracranial Stent (Tonbridge)|The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
48699474|NCT02078180|DRUG|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
48699475|NCT05659407|DRUG|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
48169122|NCT05599646|BEHAVIORAL|gamified pedometer based walking intervention|Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
48699476|NCT06179134|BEHAVIORAL|Goal Management Training|"The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine \& Stamenova, 2017)."
48169123|NCT00402636|DEVICE|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
48169124|NCT00402636|DEVICE|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
48169125|NCT00487552|DEVICE|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
48515860|NCT02770378|DRUG|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
48699477|NCT02234713|BEHAVIORAL|Motivational Interview|
48699478|NCT02234713|OTHER|Video Attention Control|
48699479|NCT05093673|DEVICE|Cathodal Cerebellar tDCS|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
48699480|NCT05093673|BEHAVIORAL|Semantic Feature Analysis (SFA)|Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
48699481|NCT05093673|DEVICE|Sham|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
48699482|NCT03070171|DRUG|dabigatran etexilate|single dose
48011756|NCT05026463|PROCEDURE|Inspiratory support level|Inspiratory support is the pressure delivered by the ventilator during pressure support ventilation.
48011757|NCT03356210|BEHAVIORAL|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
48011758|NCT06482047|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
48011759|NCT06482047|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
48011760|NCT06482047|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
48169126|NCT00668330|DRUG|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
48169127|NCT00668330|DRUG|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
48169128|NCT05426447|OTHER|Dietary intervention of reduced protein intake|6-wk dietary intervention of reduced protein intake
48169129|NCT05426447|OTHER|Dietary intervention of normal protein intake|6-wk dietary intervention of normal protein intake
48169130|NCT06640491|DRUG|IO Administration of Cefazolin|Intraosseous injection of cefazolin to guard against infection.
48169131|NCT06640491|DRUG|IO Administration of Vancomycin|Intraosseous injection of vancomycin to guard against infection.
48169132|NCT06640491|DRUG|IV Administration of Cefazolin|Intravenous dose of cefazolin to guard against infection.
48515861|NCT02770378|DRUG|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
48699483|NCT05667584|DEVICE|hypotension prediction index derived from non-invasive arterial pressure waveforms|The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.
48699484|NCT05667584|DEVICE|non-invasive arterial pressure waveforms|ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
48699485|NCT05690399|RADIATION|Radiotherapy|Effect of radiotherapy on patients
48699486|NCT03305081|DEVICE|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
48011761|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
48169133|NCT06640491|DRUG|IV Administration of Vancomycin|Intravenous dose of vancomycin to guard against infection.
48169134|NCT02541942|OTHER|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
48169135|NCT06369857|PROCEDURE|Pectopexy|Suspension of apical organs
48169136|NCT00554944|PROCEDURE|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
48169137|NCT04185987|OTHER|Leone slide low friction elastomeric ligature|Leone slide low friction elastomeric ligature application
48371214|NCT06187454|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.
48371215|NCT06187454|DEVICE|Sham Transcranial direct current stimulation|For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
48371216|NCT03947073|OTHER|Education|Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
48371217|NCT03188276|DRUG|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
48371218|NCT03188276|DRUG|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
48699487|NCT05250635|DEVICE|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
48699488|NCT01944098|DRUG|Lidocaine|
48699489|NCT01944098|DRUG|Placebo|
48699490|NCT00920387|DRUG|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
48699491|NCT00920387|DRUG|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
48699492|NCT00920387|BEHAVIORAL|Therapy|Therapy provided by male and female co-therapists
48011762|NCT01601834|DRUG|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
48169138|NCT04185987|OTHER|RMO tough - o energy elastomeric ligature|RMO tough - o energy elastomeric ligature application
48169139|NCT04185987|OTHER|Dentsply sili tie elastomeric ligature|Dentsply sili tie elastomeric ligature application
48169140|NCT04185987|OTHER|AO twisted ended ligature wire|AO twisted ended ligature wire application
48169141|NCT05897528|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
48169142|NCT05999019|PROCEDURE|robotic surgery|robotic surgery
48169143|NCT00198198|DRUG|Aripiprazole|
48169144|NCT05029349|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
48371219|NCT01610752|BEHAVIORAL|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
48371220|NCT01741558|DRUG|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
48699493|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
48699494|NCT00798239|OTHER|Iliac crest autograft|autograft
48011763|NCT03527212|DRUG|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
48011764|NCT03527212|DRUG|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
48011765|NCT02751983|BEHAVIORAL|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
48011766|NCT02751983|OTHER|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
48011767|NCT05664035|BIOLOGICAL|Diagnosis of SPAD using immunization with PPV23|Diagnosis of SPAD using immunization with PPV23
48011768|NCT02357576|DRUG|Intralipid 20% I.V. Fat Emulsion|
48011769|NCT05702216|OTHER|Rehabilitation|Hybrid approach in cardiac telerehabilitation. Patients underwent 20 cardiac rehabilitation sessions: alternatively, patients underwent 10 classical cardiac rehabilitation sessions in the clinic and 10 cardiac telerehabilitation sessions at home.
48011770|NCT02907359|DRUG|Guadecitabine|
48011771|NCT02907359|OTHER|Treatment Choice|"* BSC: according to standard/institutional practice; included RBC or platelet transfusions; growth factors, i.e. erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~* LDAC: 20 mg/m\^2 SC or IV once daily (QD) for 14 days in 28-day cycles. Other schedules were allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~* Standard Intensive Chemotherapy: recommended regimen of 7+3 was given as cytarabine 100-200 mg/m\^2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice included daunorubicin (45-60 mg/m\^2/day) or idarubicin (9-12 mg/m\^2/day) or mitoxantrone (8-12 mg/m\^2/day) by IV infusion. Participants with complete or partial response after IC induction received ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
48011772|NCT00110812|DRUG|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
48011773|NCT05927233|DRUG|Methylprednisolone|30 ml Methylprednisolone (30mg/kg) with a maximum dose of 500 mg
48011774|NCT05927233|DRUG|Saline|30 ml Normal saline
48011775|NCT01514318|DEVICE|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
48011776|NCT03844373|DIETARY_SUPPLEMENT|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
48011777|NCT05770037|DRUG|Alectinib|"Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent."
48011778|NCT05654324|OTHER|pelvic floor muscle exercises|Before the pelvic floor exercises are taught to all women participating in the study, a brief informational training about the function and structure of the pelvic floor and pelvis will be given using visuals. The application protocol will be given by experienced specialist physiotherapists who have received special training on pelvic floor muscle training. In this study, the training protocol described by Mørkved et al and Bø et al will be used. An exercise series will consist of slow and fast muscle contractions of the pelvic floor muscles. The exercise series will include 10 reps of maximum pelvic floor muscle contraction held for 6 seconds followed by three rapid muscle contractions. A 10-second rest period will be given between each exercise series. A total of 5 minutes, 4 repetitions of pelvic floor muscle contraction series will be applied, including the rest period.
48169145|NCT05475496|OTHER|Measurements of quality of life and burnout|"WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items)."
48169146|NCT01554293|DRUG|Matching placebo|Matching Placebo, single dose
48169147|NCT01554293|DRUG|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
48169148|NCT00174798|DRUG|SSR240600C|once daily
48169149|NCT00174798|DRUG|Placebo|oral
48169150|NCT00174798|DRUG|Tolterodine|once daily
48371221|NCT01741558|DRUG|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
48699495|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
48699496|NCT01879462|DRUG|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
48699497|NCT01879462|DRUG|Placebo|Visually matching GSK2878175
48699498|NCT02251704|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
48699499|NCT02251704|DIAGNOSTIC_TEST|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
48699500|NCT03199053|DRUG|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
48699501|NCT03199053|DRUG|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
48699502|NCT03199053|DRUG|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
48169151|NCT04100239|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
48169152|NCT02591706|DEVICE|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
48169153|NCT03383809|DIETARY_SUPPLEMENT|Strawberry juice with Inulin|Mixture of polyphenols and non digestible carbohydrates
48169154|NCT03383809|DIETARY_SUPPLEMENT|Strawberry Juice|Source of Polyphenols
48169155|NCT03383809|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
48169156|NCT06276101|BIOLOGICAL|NWRD08 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
48169157|NCT06233474|DRUG|Allocetra|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state
48169158|NCT06233474|OTHER|Placebo|The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.
48371222|NCT04534868|OTHER|taking macroscopic and dermoscopic pictures of suspicious skin lesions|"If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~* A table containing the useful information about the patient for the lesion's analysis will be completed.~* The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~* The photo is anonymized via a serial number assigned by the Handyscope application.~* Sending photos and information via a secure email address to the dermatologists.~* Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~* Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~* This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox"
48371223|NCT05628012|BEHAVIORAL|Circadian Based Time Restricted Eating|Personalized schedule to restrict eating based on DLMO, approximately \~4h prior to DLMO or sleep onset.
48371224|NCT02735772|PROCEDURE|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
48371225|NCT02714621|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
48699503|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
48699504|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
48699505|NCT01538979|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
48699506|NCT05742906|DEVICE|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve|Tricuspid valve replacement with the Cor TRICUSPID ECM Valve for the surgical management of tricuspid valve disease or dysfunction.
48699507|NCT04493333|DRUG|Vaginal Dehydroepiandrosterone|This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
48699508|NCT04493333|COMBINATION_PRODUCT|Vaginal Polycarbophil Moisturizer|This is an FDA cleared, over-the-counter personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body's natural lubrication. It is non-sterile, water-based, non-irritating, non-greasy, non-staining vaginal gel delivered as a long-lasting moisturizer for vaginal dryness.
48011779|NCT04563312|PROCEDURE|Exercise|Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
48169159|NCT05402618|OTHER|No intervention|This is an observational study without any intervention.
48169160|NCT00427778|DEVICE|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
48169161|NCT02388932|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48169162|NCT02388932|DEVICE|Positron Emission Tomography|Undergo PET/CT
48371226|NCT00784225|DRUG|selenium|200 mcg daily for 7-12 years
48699509|NCT05865340|BEHAVIORAL|oral health + MED diet|oral health + MED diet education
48699510|NCT05865340|BEHAVIORAL|oral health|oral health education
48699511|NCT05865340|BEHAVIORAL|MED diet|MED diet education
48699512|NCT04567706|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
48699513|NCT01746511|PROCEDURE|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
48169163|NCT02388932|DEVICE|Computed Tomography|Undergo PET/CT
48169164|NCT02388932|OTHER|Quality-of-Life Assessment|Ancillary studies
48169165|NCT01059526|DRUG|ecallantide|30 mg SC
48169166|NCT00643435|BEHAVIORAL|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
48699514|NCT01746511|DRUG|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
48011780|NCT03057691|OTHER|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
48011781|NCT03307148|DRUG|ATRA|Administered orally on D1-15 of each 28 day cycle.
48699515|NCT03771131|BEHAVIORAL|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
48011782|NCT03307148|DRUG|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
48169167|NCT00643435|BEHAVIORAL|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
48699516|NCT04583787|DIAGNOSTIC_TEST|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
48011783|NCT03307148|DRUG|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
48169168|NCT05540418|OTHER|lavender oil inhalation|Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
48169169|NCT00494208|DRUG|Testosterone|Testosterone ester
48169170|NCT02618863|DEVICE|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
48169171|NCT05510739|BEHAVIORAL|Motor-cognitive home exercise supported by eHealth technology|10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.
48169172|NCT05510739|BEHAVIORAL|Individualized home exercise program|Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
48169173|NCT01274559|DRUG|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
48169174|NCT01274559|DRUG|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
48011784|NCT01996969|DRUG|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
48011785|NCT01945385|BEHAVIORAL|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
48011786|NCT01987323|DRUG|Subconjunctival injection of liposomal latanoprost|
48011787|NCT00391352|DRUG|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
48011788|NCT04497987|DRUG|Bamlanivimab|Administered IV.
48011789|NCT04497987|DRUG|Placebo|Administered IV.
48011790|NCT04497987|DRUG|Etesevimab|Administered IV.
48011791|NCT00226603|BEHAVIORAL|Specific training programme (behavior)|
48011792|NCT04671459|COMBINATION_PRODUCT|TTFields and SRS|SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.
48011793|NCT00276718|BIOLOGICAL|bleomycin sulfate|
48169175|NCT02721433|DRUG|Pamidronate|Bone-targeted agent as standard of care
48011794|NCT00276718|DRUG|carboplatin|
48011795|NCT00276718|DRUG|etoposide|
48011796|NCT00276718|PROCEDURE|conventional surgery|
48011797|NCT03120013|DEVICE|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
48169176|NCT02721433|DRUG|Denosumab|Bone-targeted agent as standard of care
48169177|NCT02721433|DRUG|Zoledronate|Bone-targeted agent as standard of care
48169178|NCT02661503|DRUG|Bleomycin|
48169179|NCT02661503|DRUG|Etoposide|
48169180|NCT02661503|DRUG|Doxorubicin|
48011798|NCT03120013|DEVICE|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
48011799|NCT05870527|DEVICE|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
48011800|NCT00466960|BIOLOGICAL|sargramostim|Given SC
48011801|NCT00466960|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
48011802|NCT00466960|OTHER|laboratory biomarker analysis|Correlative studies
48011803|NCT00466960|OTHER|immunologic technique|Correlative studies
48011804|NCT06277934|DRUG|RGT001-075|Administered orally
48699517|NCT04583787|DIAGNOSTIC_TEST|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
48169181|NCT02661503|DRUG|Cyclophosphamide|
48169182|NCT02661503|DRUG|Vincristine|
48699518|NCT04136327|DRUG|GLPG1972 film-coated tablets|single oral dose of GLPG1972
48011805|NCT06277934|DRUG|Placebo|Administered orally
48169183|NCT02661503|DRUG|Procarbazine|
48011806|NCT05459493|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
48011807|NCT01660711|DRUG|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
48011808|NCT01660711|DRUG|Leucovorin|400 mg/m2 by IV infusion over 2 hours
48515862|NCT02770378|DRUG|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
48011809|NCT01660711|DRUG|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
48169184|NCT02661503|DRUG|Prednisone|
48515863|NCT02770378|DRUG|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
48699519|NCT04136327|DRUG|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1972
48699520|NCT04136327|DRUG|[14C]-GLPG1972 oral solution|single oral dose of \[14C\]-GLPG1972
48011810|NCT01660711|DRUG|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
48169185|NCT02661503|DRUG|Brentuximab Vedotin|
48169186|NCT02661503|DRUG|Dacarbazine|
48169187|NCT02661503|DRUG|Dexamethasone|
48169188|NCT05212311|DEVICE|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
48699521|NCT02521753|DRUG|Metformin|Intervention also includes weight reduction diet and exercise therapy
48699522|NCT02521753|DIETARY_SUPPLEMENT|Magnesium|Intervention also includes weight reduction diet and exercise therapy
48699523|NCT02521753|DIETARY_SUPPLEMENT|PUFA|Intervention also includes weight reduction diet and exercise therapy
48699524|NCT06132425|BEHAVIORAL|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
48699525|NCT06132425|BEHAVIORAL|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
48699526|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
48011811|NCT05950568|PROCEDURE|Quadratus lumborum block typen II|A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
48011812|NCT05950568|PROCEDURE|Quadratus lumborum block III|A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
48011813|NCT05950568|PROCEDURE|Transversus abdominis plane block|A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
48169189|NCT05212311|DEVICE|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
48011814|NCT02661438|DRUG|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
48169190|NCT05212311|DEVICE|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
48371227|NCT00784225|DRUG|vitamin E|400 IU daily by mouth for 7-12 years
48371228|NCT00784225|DRUG|vitamin E placebo|daily for 7-12 years
48371229|NCT00784225|DRUG|selenium placebo|daily for 7-12 years
48371230|NCT04468555|OTHER|Global postural reeducation|It consisted of Global Postural Re-Education sessions divided into 3 sessions and performed with a frequency of 1 per week for 3 weeks. The sessions were performed individually, with an approximate duration of 40 minutes and all of them were assessed by the same physiotherapist.
48371231|NCT03809260|DRUG|Metformin (part 1)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
48371232|NCT03809260|DRUG|Vancomycin|11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid
48371233|NCT03809260|DRUG|Metformin (part 2)|1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
48371234|NCT03937531|PROCEDURE|Bladder Scanner|PVR will be measured by using a bladder scanner.
48371235|NCT01694849|DRUG|GFT505 80mg|
48371236|NCT01694849|DRUG|GFT505 120mg|
48371237|NCT01694849|DRUG|Placebo|
48011815|NCT04197635|DIAGNOSTIC_TEST|Maximal functional capacity by cardiopulmonary exercise testing|It will be done with cycle ergometer (CORTEX Metamax3B), starting with 10W of power and increasing 10W every minute. During the test, heart rate, rhythm and blood pressure will be monitored. Gas exchange data shall be evaluated every 10 seconds and the peak oxygen consumption (peak VO2) shall be considered the maximum value obtained during the last 20 seconds of exercise. The main parameters to be determined are: maximum functional capacity, peak VO2, slope of the VE/VCO2 ratio, and chronotropic incompetence variables. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
48011816|NCT04197635|DIAGNOSTIC_TEST|Echocardiography|The following parameters will be evaluated: a)left ventricular volumes; b) left ventricular systolic function; and c)left atrial volume and E/e' ratio. It will be performed by a trained cardiologist blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
48011817|NCT04197635|BEHAVIORAL|Evaluation of health related quality of life|Assessment of the quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Spanish version. It will be completed at baseline and at 30 and 90 days after treatment initiation. The score of the questionnaire is 0 to 105 points.
48011818|NCT04197635|DIAGNOSTIC_TEST|Submáximal functional capacity assesment by 6 minutes walk test|It will be performed in an area equipped for cardiopulmonary resuscitation. Subjects will be asked not to perform a vigorous physical exercise in the previous 2 hours. They will be allowed to have a light meal before the test. Before the test, the vital signs will be determined in a seated position after a rest of 10 minutes. Subjects will be instructed to walk at their own pace to cover as much distance as possible in 6 minutes. It will be performed by a trained nurse blind to study treatment at baseline and at 30 and 90 days after treatment initiation.
48011819|NCT04197635|OTHER|Clinical evaluation|Evaluation of signs and symptoms of heart failure
48011820|NCT02188368|DRUG|POM|
48011821|NCT02188368|DRUG|Steroids|
48011822|NCT02188368|DRUG|PLD|
48011823|NCT02188368|DRUG|CFZ|
48011824|NCT02188368|DRUG|BTZ|
48011825|NCT02188368|DRUG|CLA|
48011826|NCT02188368|DRUG|CY|
48699527|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
48699528|NCT03720041|DRUG|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
48011827|NCT05159843|BEHAVIORAL|Therapeutic education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
48011828|NCT00611702|PROCEDURE|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
48011829|NCT00191893|DRUG|teriparatide|
48515864|NCT06498843|OTHER|administration of an isotonic seawater solution (9g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis, and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
48011832|NCT02283502|DEVICE|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
48011833|NCT05117463|OTHER|Optic Flow Stimulation|The optic flow will be displayed at different speeds. The subject will need to look at the center of the optic flow.
48011834|NCT05117463|OTHER|Auditory Reaction Time|Two different pitches of tones will be played. The participants will need to press a button on the right or left hand based on the pitch of the tone.
48011835|NCT05941026|OTHER|Structured education|"The educational content of the research was created by the researcher in line with the literature and expert opinions and covers the following topics.~Educational subjects~1. Culture and Concepts Related to Culture~2. Culture/Cultural Characteristics and Cultural Elements in Terms of Social Structure~3. Cultural Factors Affecting Health and Disease~4. Concepts and Practices Related to the Field of Study~The training is an online training and continued via video conference, and a session invitation was sent to the participants before each session. In addition, after the training, brochures containing the training topics of each week were prepared and delivered to the participants. The trainings were conducted by the researcher in a total of four sessions (each session 20 minutes) once a week during the training process. During the training, the questions of the participants were answered."
48011836|NCT04026906|DEVICE|Cyanoacrylate glue|One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter
48011837|NCT04026906|OTHER|Transparent polyurethane dressing|The IV will be secured in the usual manner with tape and a transparent dressing.
48011838|NCT05899504|DEVICE|Over-The-Scope-Clip (OTSC) Stent Fix|A stent that of at least 4 cm longer than the stricture will be used to allow at least a 2-cm extension above and below the proximal and distal tumor margins. The stent positioned over a guidewire and deployed under fluoroscopy guidance and, in some cases, also under endoscopy guidance. Subsequently, the OTSC system will be loaded onto the scope and part of the upper rim of the stent will be suctioned into the transparent cap before releasing the OTSC, grasping both the SEMS and esophageal wall. We will avoid deploying the OTSC in areas of pulsations to prevent potential grasping of the vasculature structure
48011839|NCT05388890|DRUG|MLD|Modified Liujunzi Decoction is provided by the chinese pharmacy of Peking University First Hospital , one dose per day, taken in twice, and the course of treatment is 6 months.
48011840|NCT05388890|DRUG|WFC|Chinese patent medicine, take according to the instructions, the course of treatment is 6 months.
48011841|NCT05122949|DEVICE|3D Printed Ankle-Foot Orthosis|3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material
48011842|NCT05122949|DEVICE|Thermoformed Ankle-Foot Orthosis|Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
48011843|NCT02100267|DRUG|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
48011844|NCT02424240|OTHER|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 \& IGFBP-3 combination
48011845|NCT02840877|BEHAVIORAL|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
48011846|NCT00273403|BEHAVIORAL|Maintenance in Care Services|
48011847|NCT00273403|BEHAVIORAL|Access to Care Services|
48011848|NCT05800054|DIETARY_SUPPLEMENT|Nutritional Support Team|Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
48011849|NCT05800054|DRUG|Docetaxel|60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
48011850|NCT05800054|DRUG|cisplatin|cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
48011851|NCT05800054|RADIATION|Radiotherapy|image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
48011852|NCT06097884|OTHER|Main study intervention-Salt substitute|replacing regular salt with salt substitute in school meals
48011853|NCT06097884|OTHER|Main study control-Usual salt|Use usual salt in school meals
48011854|NCT06097884|OTHER|Ancillary study intervention-Meal trays|Replacing bowls with trays in school cafeteria
48011855|NCT06097884|OTHER|Ancillary study control-Bowls|Use bowls in school cafeteria
48011856|NCT06165068|DRUG|Aspirin 81Mg Ec Tab|Patients take aspirin 81 mg per day.
48011857|NCT06165068|DRUG|Clopidogrel|Patients take clopidogrel 75 mg per day.
48011858|NCT06165068|DRUG|N-acetylcysteine|Patients are given N-acetylcysteine 600 mg per day.
48011859|NCT01205165|DRUG|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
48011860|NCT01245855|DRUG|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
48371238|NCT05461846|OTHER|integrated neuromuscular inhibition technique|is a manual deactivation trigger points technique and includes the application of ischemic pressure and stretch, the muscle energy technique and the Strain-counterstrain technique.
48011861|NCT03649555|DRUG|[18F]-FTC-146|Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
48011862|NCT00084695|BIOLOGICAL|anti-thymocyte globulin|Given IV
48011863|NCT00084695|DRUG|busulfan|Given orally
48011864|NCT00084695|DRUG|cyclophosphamide|Given IV
48011865|NCT00084695|DRUG|fludarabine phosphate|Given IV
48169191|NCT05212311|OTHER|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
48169192|NCT01090700|DRUG|TMC435|TMC435 150 mg daily for 7 days
48169193|NCT01090700|DRUG|Escitalopram|Escitalopram 10 mg daily for 7 days
48169194|NCT01090700|DRUG|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
48169195|NCT05268822|OTHER|Home exercise|Movement control exercise with or without specific breathing techniques
48169196|NCT00626613|DRUG|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
48169197|NCT02296203|DRUG|cetuximab|
48169198|NCT02296203|DRUG|irinotecan|
48169199|NCT04514692|DIAGNOSTIC_TEST|FDG PET/CT|Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)
48169200|NCT04514692|DRUG|GCSF|Granulocyte Colony Stimulating Factor (GCSF)
48169201|NCT05207098|OTHER|Neurocognitive Tests|Baseline only: WRAT Reading Test, WMS-IV Logical Memory Subtest, Hopkins Verbal Learning Test (HVLT), Oral Trailmaking - Part A and B, NAB Digit Span, Category Fluency Test, Oral Symbol Digit Modalities Test, Brief Test of Attention, FAS - Controlled Oral Word Association Test (COWAT), Verbal Naming, Enformia Cogsuite Battery
48169202|NCT05207098|OTHER|Questionnaires|Sociodemographics, Computerized Cognitive Training Programs Questionnaire, CDC Behavioral Risk Factor (Smoking Assessment), Alcohol Consumption CDC, Current Health Rating (KPS), OARS Physical Health section, COVID Medical History, Hospital Anxiety and Depression Scale (HADS), Fatigue Symptom Inventory (FSI), Functional Assessment of Cancer Therapy-General (FACT-G V4), Functional Assessment of Cancer Therapy-Cognition (FACT-Cog V3), Sensory Gating Inventory (SGI)
48169203|NCT02673554|DRUG|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
48169204|NCT02673554|DRUG|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
48011866|NCT00084695|DRUG|melphalan|Given IV
48011867|NCT00084695|DRUG|methylprednisolone|Given IV
48011868|NCT00084695|RADIATION|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
48169205|NCT02673554|PROCEDURE|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
48011869|NCT03837262|COMBINATION_PRODUCT|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
48011870|NCT02572050|PROCEDURE|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
48011871|NCT01987427|DRUG|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
48011872|NCT01987427|DRUG|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
48011873|NCT01987427|DRUG|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
48169206|NCT02673554|PROCEDURE|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)
48169207|NCT05537519|BIOLOGICAL|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
48169208|NCT02985034|PROCEDURE|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
48169209|NCT00001440|PROCEDURE|Autologous T cells|
48169210|NCT00001440|DRUG|Interleukin-2|
48169211|NCT06304597|DRUG|Imfinzi|Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)
48169212|NCT06304597|DRUG|Opdivo|Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
48011874|NCT00348205|DEVICE|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
48011875|NCT02836171|DRUG|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
48011876|NCT02836171|DRUG|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
48169213|NCT05478681|DEVICE|active tDCS|All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.
48169214|NCT02032108|BEHAVIORAL|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
48169215|NCT05441371|OTHER|Toothpaste; Paradontax|Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
48699529|NCT03720041|DRUG|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
48699530|NCT01975519|DRUG|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
48699531|NCT02657681|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
48011877|NCT02751151|OTHER|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
48011878|NCT04469361|OTHER|Navicular drop measurement|The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.
48011879|NCT04469361|OTHER|Measurement of venous return parameters in supine|Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position
48011880|NCT04469361|OTHER|Measurement of venous return parameters in standing|In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.
48011881|NCT04469361|OTHER|measurement of midfoot pressure distrubition|In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
48011882|NCT00835497|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
48169216|NCT06105047|BEHAVIORAL|Cognitive tests|". Patients will perform experimental task in four conditions : control, mime, emotion, dual In a control condition : they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; in a dual condition, they will be asked to both mime and listen to music. Immediately after each condition, they will realize a recognition task~* quiz : Geneva Music Induced Checklist, GMIAC, Coutinho \& Scherer, 2017"
48169217|NCT02515656|DRUG|POLYGYNAX®|
48169218|NCT02515656|DRUG|GYNODAKTARIN®|
48011883|NCT00835497|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
48699532|NCT02657681|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
48699533|NCT04599023|DEVICE|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
48699534|NCT06608134|BIOLOGICAL|Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection|Direct injection of biologic into the knee joint.
48699535|NCT04122183|OTHER|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
48011884|NCT04162951|PROCEDURE|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
48011885|NCT04162951|PROCEDURE|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
48011886|NCT02616250|DRUG|Brimonidine 0.33% gel (Br)|
48169219|NCT02515656|DRUG|Placebo|
48169220|NCT03831230|GENETIC|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
48169221|NCT00131898|PROCEDURE|Surgical Resection|
48011887|NCT02616250|OTHER|CD07805/47 (Br) placebo gel|
48011888|NCT02616250|DRUG|Ivermectin 1% cream (IVM)|
48011889|NCT02616250|OTHER|CD5024 (IVM) placebo cream|
48169222|NCT00131898|PROCEDURE|Intensity Modulated Radiation Therapy (IMRT)|
48699536|NCT03252249|OTHER|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
48699537|NCT03252249|OTHER|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
48515865|NCT06498843|OTHER|administration of a hypertonic seawater solution (21g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
48699538|NCT04880629|BEHAVIORAL|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
48011890|NCT04491162|OTHER|Body weight support treadmill training + conventional therapy|"Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.~Patients in intervention arm were additionally trained with a 40% body weight support and a comfortable walking speed on treadmill for twenty minutes. The training, which was conducted three times a week, for period of two weeks."
48011891|NCT04491162|OTHER|Conventional therapy|Conventional gait therapy was done based on the principles of the proprioceptive neuromuscular facilitation (PNF) and Motor Relearning program (MRP) concepts.
48699539|NCT04880629|BEHAVIORAL|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
48011892|NCT03596424|DRUG|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
48011893|NCT03596424|DRUG|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
48011894|NCT03596424|COMBINATION_PRODUCT|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
48699540|NCT01182805|DEVICE|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
48699541|NCT01182805|DEVICE|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
48699542|NCT01182805|DEVICE|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
48699543|NCT04052789|OTHER|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
48011895|NCT01812694|BEHAVIORAL|Enhanced standard care|Standard prenatal care plus education
48011896|NCT01812694|BEHAVIORAL|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
48011897|NCT01558882|DEVICE|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
48011898|NCT04002297|DRUG|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
48515866|NCT02998086|BEHAVIORAL|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
48169223|NCT04269434|OTHER|No Screening|the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
48169224|NCT04826926|PROCEDURE|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
48169225|NCT01878383|DEVICE|Genexpert assay|
48699544|NCT01331837|DRUG|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
48699545|NCT01331837|DRUG|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
48011899|NCT04002297|DRUG|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
48011900|NCT04002297|DRUG|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
48699546|NCT03398642|BEHAVIORAL|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
48011901|NCT03940378|DRUG|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
48011902|NCT03940378|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
48011903|NCT02995395|DEVICE|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
48011904|NCT06205927|RADIATION|Standard carbon ion beam radiotherapy|The standard treatment arm will receive carbon ion beam radiotherapy of 77Gy (RBE equivalent) per 22 fractions for gross tumor volume.
48169226|NCT05955755|OTHER|butterfly vacuum blood collection set|Blood collection from the children in the experimental group will be performed with a butterfly vacuum blood collection set.
48011905|NCT06205927|RADIATION|Carbon ion beam radiotherapy simultaneously dose boost|The hypoxic lesions dose boost arm will receive 77Gy (RBE equivalent) per 22 fractions for gross tumor volume and a simultaneously dose boost of 83.6Gy (RBE equivalent) per 22 fractions for hypoxic lesions detected by 18F-Misonidazole PET/CT.
48011906|NCT02246504|DEVICE|HIFU treatment|
48169227|NCT06407713|OTHER|Intrinsic foot muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with intrinsic foot muscle training
48169228|NCT06407713|OTHER|Hip abductor muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with hip abductor muscle training
48169229|NCT05175300|DEVICE|Prosthesis with CoPXE couple.|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
48169230|NCT05175300|DEVICE|Prosthesis with CoC torque.|Prosthesis with ceramic-on-ceramic (CoC) torque.
48169231|NCT00170417|BEHAVIORAL|Cognitive Behaviour Therapy|
48169232|NCT00700947|DRUG|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
48011907|NCT01329510|DEVICE|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
48011908|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls|Inflammatory and immune profile of post-COVID-19 POTS patients. Reduced PNS activity (vagal tone) in relation to persistent inflammation.
48169233|NCT03426553|BIOLOGICAL|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
48169234|NCT03426553|BIOLOGICAL|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
48169235|NCT01195740|BEHAVIORAL|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
48371239|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
48371240|NCT00635362|DEVICE|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
48699547|NCT02180919|DEVICE|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
48371241|NCT05180071|DEVICE|TEMA elbow system|Total elbow replacement
48371242|NCT00792467|DRUG|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
48699548|NCT01814878|DRUG|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
48699549|NCT01814878|DRUG|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
48699550|NCT05491070|DEVICE|Vascular closure device (Angio-Seal, Progilde)|In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
48699551|NCT01384500|OTHER|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
48699552|NCT06355609|DRUG|sunvozertinib in combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.
48699553|NCT03991403|DRUG|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
48699554|NCT03991403|DRUG|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
48699555|NCT03991403|DRUG|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
48699556|NCT03991403|DRUG|Carboplatin|Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min
48011909|NCT05421208|DIAGNOSTIC_TEST|Levels of inflammatory cytokine ( IL-6) in controls|Inflammatory and immune profile of healthy controls. Controls are the subjects who recovered from COVID-19 infection with no sequelae.
48011910|NCT05421208|DIAGNOSTIC_TEST|Effect on inflammation after chronic PNS stimulation|Inflammatory biomarkers after restoring PNS function in post-COVID-19 POTS patients, by chronic transcutaneous vagus nerve stimulation (tVNS) in post COVID-19 POTS patients
48011911|NCT04595006|OTHER|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
48011912|NCT04595006|OTHER|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
48011913|NCT04595006|OTHER|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
48169236|NCT01195740|BEHAVIORAL|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
48169237|NCT00679549|DEVICE|CPAP Therapy|CPAP therapy is provided as an inpatient.
48169238|NCT01373333|DRUG|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
48169239|NCT01774019|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
48169240|NCT00498758|DEVICE|APOS System - biomechanical wedge shoe|
48169241|NCT03688997|OTHER|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
48169242|NCT04287634|OTHER|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
48169243|NCT04287634|OTHER|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
48169244|NCT04145609|BEHAVIORAL|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
48169245|NCT05414201|DRUG|Adalimumab|Subcutaneous Injection
48169246|NCT05665413|DEVICE|TENS|strocking technique, HOT PACK and Ergon instrument
48169247|NCT05561582|OTHER|Seated knee extension exercise|Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
48169248|NCT05296447|OTHER|No Intervention|All subjects that previously received RGX-314 in a parent study
48169249|NCT03974451|DEVICE|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
48169250|NCT03974451|DEVICE|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
48169251|NCT04318314|DIAGNOSTIC_TEST|COPAN swabbing and blood sample collection|COPAN swabbing of nostrils and/or oropharynx and blood sample collection
48169252|NCT02053064|GENETIC|SAF-301|
48169253|NCT04202016|PROCEDURE|Piezocision Surgery|After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
48515867|NCT02470845|DRUG|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm\*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
48169254|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
48371243|NCT03665558|DEVICE|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
48699557|NCT03991403|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 IV); Over 3 hours
48699558|NCT03991403|DRUG|Carboplatin or cisplatin|Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
48699559|NCT01789060|OTHER|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
48699560|NCT03379857|OTHER|Drug urinal test|Non Applicable
48169255|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
48169256|NCT02222961|DRUG|BIIR 561 CL|
48169257|NCT02222961|DRUG|Placebo|
48169258|NCT02863913|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
48169259|NCT02863913|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
48169260|NCT02863913|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
48169261|NCT00951964|DRUG|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
48169262|NCT00951964|DRUG|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
48169263|NCT02878421|DEVICE|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
48371244|NCT04235959|DRUG|Tirzepatide|Administered SC
48371245|NCT04235959|DRUG|Placebo|Administered SC
48011914|NCT03779997|BEHAVIORAL|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
48011915|NCT05475184|DRUG|JPI-547|"Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal."
48371246|NCT03608345|OTHER|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
48699561|NCT06457776|PROCEDURE|Dental management|The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.
48699562|NCT06354790|OTHER|Motor evaluations|Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)
48699563|NCT06354790|OTHER|Cognitive assessment|Patients cognitive evaluation (WPPSI-IV, WISC-V)
48699564|NCT06354790|OTHER|Pulmonary function test|Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)
48699565|NCT06354790|OTHER|Cardiac evaluation|Evaluation of patients' cardiac function (ECG, Echo-cardiography)
48699566|NCT06354790|OTHER|Quality of life|Evaluation of patients quality of life with questionnaires and PROM
48699567|NCT06354790|OTHER|Spine X Ray|Evaluation of spinal deformities by X-ray
48699568|NCT06354790|OTHER|Muscular MRI|Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI
48011916|NCT01049724|OTHER|Tear collection|Tear collection
48011917|NCT04971031|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
48371247|NCT04861766|DEVICE|STYLAGE® L|Injection in both NLFs
48699569|NCT06354790|OTHER|Biomarkers collection and analysis|Collection of blood and urinary sample for biomarkers research.
48699570|NCT00070876|BEHAVIORAL|Mental health communication skills training|
48699571|NCT00656188|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
48011918|NCT04971031|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
48011919|NCT04140994|DEVICE|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
48011920|NCT04524273|DRUG|inebilizumab|Participants will receive IV inebilizumab
48011921|NCT04524273|DRUG|IV Placebo|Participants will receive IV placebo matched to inebilizumab
48371248|NCT04861766|DEVICE|Active Comparator|Injection in both NLFs
48371249|NCT00556140|DRUG|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
48699572|NCT00656188|DRUG|Placebo|Matching placebo
48699573|NCT05354609|OTHER|MR-enterography|All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation.
48699574|NCT01516580|DRUG|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
48699575|NCT01516580|DRUG|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
48699576|NCT00065039|BEHAVIORAL|Promotion of a healthy diet and physical activity|
48699577|NCT00065039|BEHAVIORAL|Avoidance of Alcohol, Drugs, and Tobacco|
48699578|NCT01444625|OTHER|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
48699579|NCT01444625|OTHER|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
48699580|NCT02399280|BEHAVIORAL|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
48699581|NCT02399280|BEHAVIORAL|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
48169264|NCT02878421|OTHER|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
48169265|NCT02878421|OTHER|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
48169266|NCT00887185|OTHER|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
48169267|NCT00634049|DRUG|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
48169268|NCT00281502|DRUG|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
48169269|NCT05715736|DRUG|APB-R3|APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
48169270|NCT05715736|DRUG|Placebo|0.90% Normal Saline only
48169271|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
48169272|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
48169273|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
48169274|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
48169275|NCT03836170|PROCEDURE|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
48699582|NCT03726918|PROCEDURE|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
48699583|NCT03093207|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
48699584|NCT03093207|OTHER|Placebo|Placebo pills over a period of 180 days
48699585|NCT03093207|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
48169276|NCT02899819|OTHER|meconium|The meconium will be sampled in the first 2 days of life
48169277|NCT03511378|DRUG|Lupin's Pegfilgrastim|Administration of Pegfilgrastim
48515868|NCT02470845|DRUG|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
48169278|NCT03511378|DRUG|Neulasta®|Administration of Neulasta®
48169279|NCT02913170|DIETARY_SUPPLEMENT|Nattokinase|
48169280|NCT02913170|DIETARY_SUPPLEMENT|Placebo|
48169281|NCT01797978|DRUG|Intravenous methylene blue administration|Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
48515869|NCT04340076|DRUG|Secukinumab|Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
48515870|NCT04340076|DRUG|Ixekizumab|Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
48515871|NCT04340076|DRUG|Brodalumab|Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
48699586|NCT03093207|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
48699587|NCT04098367|DEVICE|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
48699588|NCT04098367|DEVICE|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
48699589|NCT04098367|DEVICE|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
48011922|NCT06573502|COMBINATION_PRODUCT|Prp with prf or prp or prf|Combination
48011923|NCT06572514|DRUG|immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin|The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
48169282|NCT01797978|DRUG|Placebo|
48169283|NCT00688077|DRUG|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
48011924|NCT05439850|PROCEDURE|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
48011925|NCT05439850|BIOLOGICAL|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
48169284|NCT00688077|DRUG|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
48169285|NCT03272711|DRUG|Vortioxetine 10 mg|
48169286|NCT03272711|BEHAVIORAL|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
48169287|NCT04915547|OTHER|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
48169288|NCT05375617|OTHER|Observational|No intervention
48169289|NCT01836016|DRUG|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
48169290|NCT01836016|DRUG|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
48515872|NCT04340076|DRUG|Guselkumab|Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
48699590|NCT04098367|PROCEDURE|Cataract surgery|Cataract removal by routine small incision surgery
48699591|NCT02885740|OTHER|Quantification assay of adenosine and methionine cycle metabolites|
48699592|NCT02885740|GENETIC|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
48699593|NCT02885740|OTHER|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
48699594|NCT02885740|BIOLOGICAL|Blood sample|
48699595|NCT02531425|BIOLOGICAL|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
48699596|NCT04120753|DRUG|OLOMAX 20/5/5mg|Tablets, Oral, QD
48699597|NCT04120753|DRUG|OLOMAX 20/5/10mg|Tablets, Oral, QD
48699598|NCT04120753|DRUG|Olmesartan 20 mg/Amlodipine 5 mg|Tablets, Oral, QD
48169291|NCT01836016|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
48169292|NCT01836016|DRUG|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
48699599|NCT02899650|OTHER|exercise|acute downhill running
48699600|NCT03830476|BEHAVIORAL|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
48011926|NCT05439850|DIAGNOSTIC_TEST|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
48011927|NCT00002082|DRUG|Azithromycin|
48011928|NCT03272594|OTHER|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
48699601|NCT03830476|BEHAVIORAL|Treatment as usual.|Treatment as usual within outpatient disability services.
48699602|NCT06605859|DEVICE|GlucoTab|"Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal-insulin algorithm is to maintain blood glucose within acceptable targets according to the predefined health status.~For a limited time period after therapy start, three measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of the nursing homes/domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status.~Nurses and nursing assistants will be trained in the use of the GlucoTab."
48699603|NCT06605859|OTHER|Diabetes Treatment|Diabetes Standard Care
48699604|NCT00003603|DRUG|cyclophosphamide|
48699605|NCT00003603|DRUG|dexamethasone|
48699606|NCT00003603|DRUG|idarubicin|
48699607|NCT00003603|DRUG|lomustine|
48011929|NCT03272594|DRUG|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
48169293|NCT01836016|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
48169294|NCT01836016|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
48169295|NCT01836016|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
48515873|NCT04340076|DRUG|Risankizumab|Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
48515874|NCT04340076|DRUG|Tildrakizumab|Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
48699608|NCT00003603|DRUG|melphalan|
48011930|NCT06489522|BEHAVIORAL|THRIVE|THRIVE is a brief, parent child interaction therapy (PCIT) based telehealth intervention delivered over 6-sessions that has been tested in pediatric and community-based settings.
48011931|NCT01122966|DRUG|intraocular injections of bevacizumab|intracameral and subconjunctival injections
48011932|NCT03025724|DRUG|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
48011933|NCT03025724|DEVICE|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
48011934|NCT03025724|OTHER|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
48011935|NCT05124639|BEHAVIORAL|Group self-management support program for anxiety disorders|The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
48699609|NCT00003603|DRUG|prednisolone|
48699610|NCT05210699|OTHER|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
48011936|NCT05161676|DIETARY_SUPPLEMENT|Ketone monoester|Commercially available ketone supplement
48011937|NCT05161676|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
48011938|NCT05514067|PROCEDURE|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
48169296|NCT01836016|DRUG|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
48169297|NCT00000701|DRUG|Zidovudine|
48169298|NCT02764177|DIETARY_SUPPLEMENT|Protein drink|The protein drink was administered during this trial
48169299|NCT02764177|DIETARY_SUPPLEMENT|Carbohydrate drink|The carbohydrate drink was administered in this trial
48169300|NCT05933122|OTHER|sexologist consult|"in the cohort called here, after the diagnosis of rectal cancer, patients will be seen by a sexologist before any kind of treatment for rectal cancer. Sexual dysfunctions will be assessed by a sexologist. After the surgery of rectal cancer, the sexologist will see them again to assess sexual dysfunctions after such a management of rectal cancer. If there is any discovery of a sexual dysfunction or aggravation of a previous one or alteration of sexual life, the sexologist will help the patients to improve their sexual quality of life."
48169301|NCT05933122|OTHER|standart of care|"in the cohort called elsewhere , patients will be treated according to standards of care, without specific care by a sexologist"
48169302|NCT00949598|DRUG|letrozole|Given orally
48169303|NCT00949598|DRUG|tamoxifen citrate|Given orally
48169304|NCT05841056|DRUG|Amiodarone Hydrochloride 200 MG|200 mg daily for 4 weeks
48169305|NCT02183350|DRUG|BI 1356 BS - single rising dose|
48699611|NCT05210699|OTHER|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
48699612|NCT05210699|OTHER|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
48699613|NCT05210699|OTHER|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
48699614|NCT05210699|OTHER|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
48699615|NCT05210699|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
48011939|NCT06142812|OTHER|Kahoot!™ Group|The theoretical concepts of each subject were taught over a period of four months, with a total duration of 30 hours. Of the total theoretical concepts of the subject, 50% were randomly selected to receive reinforcement through Kahoot! Each of the theoretical concepts chosen at random was consolidated through a Kahoot! questionnaire. which consisted of 15 questions, with three answer options. This questionnaire was administered at the end of the theoretical explanation of each section, with the objective of strengthening the learning of the contents just presented. After students answered each question in Kahoot!, the teacher clarified any questions related to that question and provided explanations as to why one answer was correct and the other two were incorrect. This process offered immediate feedback to students.
48011940|NCT04425499|OTHER|Learning running subcuticular sutures on the Gamified Educational Network|Each arm will have 15 participants who will learn how to perform running subcuticular sutures through videos on GEN.
48011941|NCT06192004|OTHER|None (Observational Study)|Not applicable since Observational Study
48011942|NCT00767676|DEVICE|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
48011943|NCT01873482|BEHAVIORAL|Movement to rhythm|Movement to rhythm
48011944|NCT03609294|DRUG|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
48011945|NCT03609294|DRUG|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
48011946|NCT00145054|BEHAVIORAL|MoodHelper Internet program for Depression Self-Help|
48011947|NCT00317681|DRUG|Tacrolimus ointment|
48011948|NCT03086798|PROCEDURE|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
48011949|NCT03086798|PROCEDURE|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
48011950|NCT02690285|DRUG|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
48011951|NCT02690285|OTHER|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
48011952|NCT03897972|BEHAVIORAL|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
48011953|NCT03897972|BEHAVIORAL|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
48011954|NCT04506151|BEHAVIORAL|Sleep-Opt|12-week behavioral intervention
48011955|NCT04506151|BEHAVIORAL|Healthy Living|Healthy Living
48011956|NCT03895320|BEHAVIORAL|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
48011957|NCT03895320|BEHAVIORAL|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
48011958|NCT03895320|BEHAVIORAL|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
48699616|NCT01151059|BIOLOGICAL|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
48169306|NCT02183350|DRUG|Placebo|
48699617|NCT06052254|DRUG|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
48011959|NCT03895320|BEHAVIORAL|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
48011960|NCT03895320|BEHAVIORAL|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
48011961|NCT03895320|BEHAVIORAL|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
48011962|NCT03895320|BEHAVIORAL|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
48011963|NCT01947504|BEHAVIORAL|education and support intervention|
48011964|NCT04196166|OTHER|preoperative blood tests|
48011965|NCT00723606|DRUG|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
48011966|NCT00723606|DRUG|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
48169307|NCT04780971|DIAGNOSTIC_TEST|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) of the CTO vessel will be performed directly. A staged procedure including several measurements is planned at 4 ± 2 weeks after the index procedure. These measurements consists of the same intra-coronary physiologic assessments at index procedure and OCT imaging of the stented segment in the CTO target vessel.
48169308|NCT00957996|DRUG|Peramivir|300 mg twice daily
48169309|NCT00957996|DRUG|Peramivir|600 mg once daily
48169310|NCT00535093|DEVICE|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
48169311|NCT06538519|PROCEDURE|total hip replacement using lateral approach|In the lateral approach partial detachment of the anterior one-third of the gluteus medius muscle.
48169312|NCT06538519|PROCEDURE|total hip replacement using anterior approach|the anterior approach using an internervous plane between the tensor fascia latae and the sartorius muscle.
48169313|NCT06538519|DEVICE|gait analysis at 6wks, 3 months and 18 months|gait analysis done in the gait lab at the mentioned postoperative periods
48169314|NCT06037239|DRUG|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle"
48169315|NCT05773027|BEHAVIORAL|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
48515875|NCT04340076|DRUG|Bimekizumab|Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.
48515876|NCT03168334|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
48515877|NCT03168334|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
48515878|NCT00292890|DEVICE|insulin needle|
48011967|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
48011968|NCT01061554|DIETARY_SUPPLEMENT|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
48169316|NCT05773027|BEHAVIORAL|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
48169317|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily.
48169318|NCT04655183|DRUG|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
48169319|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
48169320|NCT04655183|DRUG|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
48169321|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
48169322|NCT04655183|DRUG|Niraparib|Niraparib will be administered as single agent at the approved dose.
48169323|NCT01862185|OTHER|semi-quantitative procalcitonin|
48169324|NCT06479486|DIAGNOSTIC_TEST|Assigned Interventions|warm up: global range of motion exercises; breathing control. Aerobic training: walking, cycling, stepping Resistance training: free weights(major muscle groups of upper and lower limbs and trunk Cool down; Breathing control and stretching exercises.
48169325|NCT03892551|OTHER|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 35 symptoms
48169326|NCT03892551|OTHER|Reason for patient presentation at ED|Exploratory interview assessing reason for patient presentation at ED
48169327|NCT03892551|OTHER|physicians rating of severity of illness|numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)
48169328|NCT03892551|DIAGNOSTIC_TEST|Assessment of vital signs|Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
48169329|NCT03892551|OTHER|Clinical Frailty Scale|Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill
48169330|NCT03892551|OTHER|Impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
48169331|NCT03892551|OTHER|Assessment of suspected diagnosis and differential diagnoses|Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
48515879|NCT01319526|GENETIC|DNA analysis|
48169332|NCT01334762|DRUG|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
48169333|NCT01334762|DRUG|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
48169334|NCT00941109|DRUG|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
48169335|NCT00941109|DRUG|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
48169336|NCT00941109|DRUG|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
48169337|NCT00941109|DRUG|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
48515880|NCT01319526|GENETIC|RNA analysis|
48515881|NCT01319526|OTHER|laboratory biomarker analysis|
48515882|NCT04898452|OTHER|A new model of interaction across health services with use of welfare technology and telemedicine|Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
48699618|NCT06052254|DRUG|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
48011969|NCT03096522|DRUG|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
48699619|NCT06052254|DRUG|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
48699620|NCT00206050|DRUG|Esomeprazole|
48699621|NCT00206050|DRUG|pantoprazole|
48699622|NCT01184313|PROCEDURE|aortic valve surgery with CPB|elective aortic valve surgery with CPB
48699623|NCT05523128|GENETIC|ZS802|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor VIII variant. The dose levels are as follows: 1. 2.0×10\^13vg/kg; 2. 6.0×10\^13vg/kg.
48699624|NCT00364572|DRUG|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
48699625|NCT00364572|DRUG|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
48011970|NCT03096522|PROCEDURE|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
48011971|NCT04041869|BEHAVIORAL|MapTrek|Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
48011972|NCT04766749|OTHER|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper thigh. The cuffs are inflated to 200 mm Hg and keep inflated for 5 minutes,Then deflated to 0 mmHg and keep uninflated for 5 minutes, This cycle is repeated four times
48011973|NCT01420302|PROCEDURE|Nurse directed|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
48011974|NCT01420302|PROCEDURE|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
48011975|NCT02720913|DEVICE|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
48699626|NCT04873167|BEHAVIORAL|low fat|subjects subjected to a low-fat dietary regime
48699627|NCT04873167|BEHAVIORAL|mediterranean diet|subjects subjected to a mediterranean dietary regime
48011976|NCT02720913|PROCEDURE|Standard Suture Tying|Standard Suture Tying
48011977|NCT04657536|DEVICE|high frequency fulguration equipment|All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals. Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes. Monopolar treatment mode is for 15 minutes. Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn. Each area should be treated for about 5 minutes. Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes. Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment. The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
48011978|NCT04657536|DRUG|promestriene vaginal soft capsules|Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
48011979|NCT02439775|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
48699628|NCT01116024|DEVICE|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
48011980|NCT02439775|PROCEDURE|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
48011981|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
48011982|NCT02778581|DIETARY_SUPPLEMENT|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
48011983|NCT02778581|DIETARY_SUPPLEMENT|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
48011984|NCT02866877|OTHER|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
48699629|NCT00415428|BEHAVIORAL|Patient adherence to national educational guidelines.|
48699630|NCT00284284|DEVICE|Use of a rehabilitation brace|
48699631|NCT06500780|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
48699632|NCT04273165|DRUG|Etravirine Tablets|Daily etravirine BID with 100 or 200 tablets for 4 months
48699633|NCT06528873|COMBINATION_PRODUCT|Concurrent optical and magnetic stimulation (COMS) treatment|"COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:~Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)~If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device."
48699634|NCT05377658|DRUG|AK104|10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
48699635|NCT05377658|DRUG|Albumin-Bound Paclitaxel|260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
48699636|NCT05377658|DRUG|Carboplatin|AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
48699637|NCT01753219|PROCEDURE|Onstep|
48699638|NCT01753219|PROCEDURE|Lichtenstein|
48011985|NCT00482391|BIOLOGICAL|trastuzumab|
48699639|NCT02606981|DEVICE|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
48699640|NCT02606981|DEVICE|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
48699641|NCT03723720|DEVICE|Colonoscopy|Endoscopic examination of large bowel
48699642|NCT00053976|BIOLOGICAL|Daclizumab|
48699643|NCT00053976|DRUG|methylprednisolone|
48699644|NCT00053976|DRUG|Placebo|
48699645|NCT02410473|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
48699646|NCT02410473|OTHER|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
48699647|NCT02853812|OTHER|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
48011986|NCT00482391|DRUG|cyclophosphamide|
48011987|NCT00482391|DRUG|doxorubicin hydrochloride|
48699648|NCT00564863|BIOLOGICAL|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
48699649|NCT00198393|DRUG|Gefitinib|250 mg/day, until progression
48699650|NCT00198393|DRUG|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
48011988|NCT00482391|DRUG|lapatinib ditosylate|
48011989|NCT00482391|DRUG|paclitaxel|
48011990|NCT00482391|OTHER|laboratory biomarker analysis|
48011991|NCT06240897|DEVICE|CURATE.Dtx|CURATE.Dtx is a self-guided digital multitasking game that involves a combination of four subtasks played simultaneously, targeting different cognitive domains.
48011992|NCT06240897|DEVICE|Optional games|The patient will first be asked how he/she feels and what they have done that day. The patient then selects a digital local pet (dog, cat, bird) and can customize its appearance, name and background location. The player can interact with their pet via several actions such as feed, bathe, train and accessorize. Playing with digital pets can help reduce stress and anxiety in the elderly. It can be a positive distraction in alleviating the elderly's worries and discomforts. In order to purchase accessories for their digital pet, they are encouraged to play short games that include Grocery Snap, Down Memory Lane and Pet Escape. These games are aimed at improving memory and reduce cognitive decline.
48011993|NCT06319599|BEHAVIORAL|Routine therapy|During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
48699651|NCT00198393|DRUG|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
48699652|NCT02645643|OTHER|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
48699653|NCT00045149|BIOLOGICAL|aldesleukin|
48699654|NCT00045149|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
48699655|NCT05299996|PROCEDURE|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
48699656|NCT04971239|DRUG|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
48169338|NCT04338347|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
48169339|NCT04420741|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
48515883|NCT06319300|DEVICE|AI-assisted insulin dose adjustment model|We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients
48699657|NCT04971239|DEVICE|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
48699658|NCT04971239|DEVICE|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
48699659|NCT05540561|OTHER|blood collection|Biological analyses in the framework of care with conservation of blood samples
48699660|NCT02120300|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
48699661|NCT02120300|DRUG|SOF|400 mg tablet administered orally once daily
48699662|NCT02120300|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48699663|NCT05825430|PROCEDURE|Direct pecs block|"Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
48699664|NCT05825430|PROCEDURE|Ultrasound guided pecs block|"Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
48699665|NCT05825430|DRUG|general anaesthetic technique only|All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
48699666|NCT05483257|DEVICE|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
48699667|NCT00072943|DRUG|anti-Interferon-gamma monoclonal antibody|
48169340|NCT04420741|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
48169341|NCT05033899|OTHER|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
48169342|NCT04588519|DEVICE|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
48169343|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
48169344|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
48169345|NCT01508832|DRUG|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
48169346|NCT01508832|DRUG|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
48515884|NCT06319300|OTHER|doctor's insulin dose adjustment|participants' insulin doses are adjusted by doctors
48699668|NCT00759265|OTHER|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
48699669|NCT04854525|RADIATION|Pre reconstruction Radiotherapy|Previous PMRT
48699670|NCT00431522|DRUG|Valproic acid, sodium salt|
48699671|NCT03520348|DRUG|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
48699672|NCT03520348|DRUG|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
48699673|NCT03655301|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
48699674|NCT03655301|DRUG|Metformin|Single dose of 1000 mg is administered orally.
48699675|NCT03028844|OTHER|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
48699676|NCT06020066|DRUG|EGFR-TK Inhibitor|Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.
48699677|NCT06020066|RADIATION|Stereotactic radiotherapy|Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
48011994|NCT06319599|PROCEDURE|Stellate ganglion block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48515885|NCT06414356|DRUG|Ketamine|Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)
48515886|NCT06414356|DRUG|Magnesium sulfate|Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.
48699678|NCT03222154|DEVICE|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
48699679|NCT03222154|DEVICE|Placebo - Shock wave therapy|Simulation of shock wave therapy
48699680|NCT05594121|DRUG|Extended Release Subcutaneous Buprenorphine|Monthly subcutaneous injections of long-acting buprenorphine
48699681|NCT05594121|DRUG|Immediate Release Sublingual Buprenorphine|Daily sublingual fast-acting buprenorphine
48699682|NCT02954406|DRUG|TAK-659|TAK-659 immediate release tablet
48699683|NCT02954406|DRUG|Bendamustine|Bendamustine intravenous infusion
48699684|NCT02954406|DRUG|Rituximab|Rituximab intravenous infusion
48699685|NCT02954406|DRUG|Gemcitabine|Gemcitabine intravenous infusion
48699686|NCT02954406|DRUG|Lenalidomide|Lenalidomide capsule
48699687|NCT02954406|DRUG|Ibrutinib|Ibrutinib capsule
48011995|NCT06319599|DRUG|Lidocaine hydrochloride|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
48699688|NCT01739686|OTHER|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
48699689|NCT03905265|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
48699690|NCT05527587|OTHER|Nature Connections Intervention|10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
48699691|NCT05012631|DRUG|Losartan|Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
48699692|NCT01935583|BEHAVIORAL|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
48699693|NCT02936310|BEHAVIORAL|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
48699694|NCT02523014|DRUG|Vismodegib|Given PO
48699695|NCT02523014|DRUG|FAK Inhibitor GSK2256098|Given PO
48699696|NCT02523014|DRUG|Capivasertib|Given PO
48699697|NCT02523014|DRUG|Abemaciclib|Given PO
48699698|NCT02255448|DEVICE|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
48699699|NCT03842969|DRUG|RO7234292 (RG6042)|Intrathecal injection
48699700|NCT05664958|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
48699701|NCT05664958|DRUG|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
48699702|NCT05664958|DRUG|bupivacaine|20 ml bupivacaine 0.25% per side.
48699703|NCT06283810|BEHAVIORAL|psychotherapy of interpersonal relationships|"Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made."
48699704|NCT06283810|BEHAVIORAL|laughter therapy|"Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start."
48699705|NCT06283810|BEHAVIORAL|Plasebo|"After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start."
48699706|NCT04052763|DIAGNOSTIC_TEST|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
48699707|NCT04052763|DIAGNOSTIC_TEST|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
48011996|NCT06319599|BEHAVIORAL|placebo injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48699708|NCT02779088|OTHER|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
48699709|NCT05576168|BIOLOGICAL|overexpression STRA6/miRNA3|RBP4 express in patients with T2DM or not
48699710|NCT06003543|BEHAVIORAL|Virtual Reality|Virtual Reality
48699711|NCT03836833|DRUG|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
48699712|NCT03836833|DRUG|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
48699713|NCT04049253|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
48011997|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
48169347|NCT00264498|DRUG|Gefitinib|oral tablet
48699714|NCT03319953|DRUG|TAK-041|TAK-041 suspension
48699715|NCT03319953|DRUG|Placebo|TAK-041 placebo-matching suspension
48699716|NCT03319953|DRUG|Second Generation Antipsychotics (SGA)|Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
48699717|NCT06019663|BEHAVIORAL|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
48699718|NCT03803670|DIAGNOSTIC_TEST|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
48699719|NCT05643196|DEVICE|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
48699720|NCT05643196|DEVICE|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
48169348|NCT00264498|DRUG|Gemcitabine|intravenous injection
48169349|NCT00264498|DRUG|Carboplatin|intravenous injection
48515887|NCT06414356|DRUG|Ketamine + Magnesium sulfate|Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)
48515888|NCT03716362|DEVICE|Otoacoustic emissions device|as a screening tool for Auditory brainstem response
48515889|NCT01721304|OTHER|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
48169350|NCT04151823|DRUG|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
48169351|NCT04151823|DRUG|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
48169352|NCT04151823|OTHER|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
48169353|NCT04151823|OTHER|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
48169354|NCT03767400|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
48169355|NCT03767400|OTHER|Facial Cleanser|Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
48169356|NCT02678364|DIETARY_SUPPLEMENT|Control eggs|Control eggs containing no additional vitamin D beyond norm
48169357|NCT02678364|DIETARY_SUPPLEMENT|Vitamin D3 eggs|Vitamin D3-biofortified eggs
48515890|NCT05247255|DRUG|Active Comparator|QL block with 0.25% ropivacaine
48515891|NCT05247255|DRUG|Placebo Comparator|QL block with saline
48699721|NCT05643196|DEVICE|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
48699722|NCT06416657|OTHER|Different anesthesia methods, namely local anesthesia and general anesthesia|"Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants."
48699723|NCT06605365|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
48699724|NCT03263130|OTHER|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
48699725|NCT01844102|DEVICE|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
48699726|NCT06605170|OTHER|Questionnaire|Translate and culturally adapt the original English version of the traumatic injuries distress scale to Turkish
48699727|NCT00003234|DRUG|vinorelbine tartrate|
48011998|NCT00497536|DRUG|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
48011999|NCT00497536|DRUG|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
48012000|NCT01081808|BIOLOGICAL|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
48699728|NCT06088953|DIAGNOSTIC_TEST|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
48012001|NCT04232163|BEHAVIORAL|Arm Boot Camp|The intervention involves a combination of daily homework based upper limb exercises and feedback from an activity monitor to motivate use of the affected upper limb. Participants will be supported through virtual sessions with a therapist.
48012002|NCT04119089|OTHER|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
48012003|NCT04230642|DEVICE|The Quantum Surgical device|Robotic platform for needle placement
48169358|NCT02678364|DIETARY_SUPPLEMENT|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
48169359|NCT02241278|DRUG|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
48169360|NCT06345547|OTHER|ultrasound|"Ultrasound of m. quadriceps and m. thenar All ultrasound measurements will be performed in triplicate, with the average of the scores used in final analyses. Four parameters will be evaluated: muscle thickness, muscle cross sectional area, pennation angle and echo intensity (gain, depth and frequency will be kept constant).~Hand grip strength measurement: measurement by an electronic hand dynamometer DynEx1TM (MD Systems, Inc. Ohio, USA). The recommendations for the handgrip strength test of the American Society of Hand Therapists will be followed: The maximum of the three values will be considered for analysis."
48699729|NCT03802344|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
48699730|NCT03802344|DRUG|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
48012004|NCT00917332|BEHAVIORAL|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
48012005|NCT03652298|OTHER|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
48169361|NCT02068196|PROCEDURE|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
48169362|NCT02068196|DRUG|Ipilimumab|
48522908|NCT03474666|PROCEDURE|Strict Glycemic Control Group|The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
48699731|NCT03802344|DRUG|Vehicle|Vehicle cream
48699732|NCT00121758|BIOLOGICAL|LIPO-5|
48699733|NCT05441683|PROCEDURE|horizontally extending incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the Intrasulcular incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.
48699734|NCT05441683|PROCEDURE|vertical releasing incision|An intrasulcular incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the intrasulcular incision before a full-thickness flap is lifted.
48699735|NCT01730664|DRUG|ertapenem|single dose of 2000mg ertapenem IV
48012006|NCT03652298|OTHER|support and attention (usual care)|support and attention (usual care)
48012007|NCT00527813|PROCEDURE|prone position|prone position for at least 16 hours per day
48012008|NCT06404177|DRUG|Dexketoprofen|An intravenous perfusion of eunantyum with an intramuscular isotonic saline
48012009|NCT06404177|DRUG|Piroxicam|intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
48012010|NCT06072235|BEHAVIORAL|Verbal communication|Verbal communication; by talking and listening
48012011|NCT01221259|DRUG|E2212|single ascending doses ranging from 10mg to 250mg
48012012|NCT01221259|DRUG|placebo|a single dose of matching placebo
48012013|NCT02383446|DEVICE|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
48012014|NCT05451576|DIETARY_SUPPLEMENT|Zelnite®|2pc intravenous Zelnite® will be given for 7 weeks (5 days/week).
48012015|NCT05451576|DIETARY_SUPPLEMENT|Placebo|Placebo will be given for 7 weeks (5 days/week).
48012016|NCT04252105|DIETARY_SUPPLEMENT|Antioxidant|Antioxidant-rich diet (added selected types of fruits, vegetables, nuts, cereals and oils)
48012017|NCT01584947|DRUG|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
48012018|NCT01584947|DRUG|Placebo|Placebo lozenge taken three times a day for two weeks
48012019|NCT03734848|DRUG|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
48012020|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
48012021|NCT01329081|OTHER|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
48012022|NCT04677920|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
48012023|NCT03113682|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
48012024|NCT03259711|DRUG|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
48012025|NCT04298710|BEHAVIORAL|Arm Cycling|20 minutes of arm cycling exercise at light to moderate intensity.
48012026|NCT04298710|BEHAVIORAL|Leg Cycling|20 minutes of leg cycling exercise at light to moderate intensity.
48012027|NCT04298710|BEHAVIORAL|Sitting|Remain seated for 20 minutes.
48012028|NCT00373516|DRUG|Vehicle (Placebo) applied BID|
48699736|NCT03100916|DRUG|BI 690517|once daily
48699737|NCT03100916|DRUG|Placebo|once daily
48012029|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied QD|
48012030|NCT00373516|DRUG|QRX-101 75 mcg/g ointment applied BID|
48012031|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
48012032|NCT05645627|DRUG|placebo /IBI112|placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
48012033|NCT05645627|DRUG|IBI112|IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
48012034|NCT05925894|DRUG|Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma|60 patients with coexisting POAG and cataract who underwent elective cataract extraction. All patients underwent ophthalmic routine examinations including automatic visual field examination, anterior chamber configuration, specular microscopy and arterial blood pressure measurement prior to surgery, 24 hours and 30 days postoperatively. All cataract surgeries were videorecorded, and all measurements were performed using media player. 20 patients received topical mydriatic eye drops, 20 patients received Mydriasert ® whereas 20 patients received intracameral injection of Mydrane ® just after the first incision.
48012035|NCT00622635|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
48012036|NCT00622635|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
48699738|NCT03100916|DRUG|BI 690517 (Reference)|Fasting
48699739|NCT03100916|DRUG|BI 690517|Non- fasting
48699740|NCT02292758|BIOLOGICAL|Bevacizumab|Given IV
48699741|NCT02292758|BIOLOGICAL|Cetuximab|Given IV
48699742|NCT02292758|DRUG|Irinotecan|Given IV
48699743|NCT02292758|OTHER|Laboratory Biomarker Analysis|Correlative studies
48012037|NCT00622635|DRUG|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
48699744|NCT02292758|OTHER|Placebo|Given IV
48699745|NCT01931488|OTHER|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
48012038|NCT02090816|PROCEDURE|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
48371250|NCT06493617|OTHER|Cervical Mobilization|The technique is used to mobilize a specific cervical or upper thoracic segment (C2-C3 through T3-T4) in a posterior to anterior direction. The therapist gently applies pressure in an anteroposterior direction in the plane of the facet joint to assess mobility, resistance, end feel, and pain provocation. Gentle oscillations can be used to either inhibit pain (grades I and II) or restore motion (grades III and IV). Slight variations in depth and direction of force can be used to optimize the therapeutic effects of this technique.
48699746|NCT01931488|DEVICE|SPECT imaging|
48371251|NCT06493617|OTHER|Traditional physical therapy treatment|tendon gliding exercises, median nerve gliding exercise, strengthening exercises for 60 minutes
48371252|NCT01148108|DRUG|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
48371253|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h) at post anesthetic care unit(PACU) over 6 hours for 3days .
48699747|NCT03505294|OTHER|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
48699748|NCT02321228|PROCEDURE|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
48699749|NCT02321228|PROCEDURE|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
48699750|NCT01858805|PROCEDURE|esophagectomy|
48699751|NCT01194089|DRUG|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
48699752|NCT01194089|DRUG|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
48012039|NCT02734017|OTHER|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
48012040|NCT06172335|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid (C22:1n-11)
48371254|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 5 days
48012041|NCT06172335|DIETARY_SUPPLEMENT|Control oil|Mix of oils with low cetoleic acid content
48371255|NCT05997134|DRUG|Ketamine|patients will receive ketamine parenteral infusion (0.35 mg/kg/h or maximum 24mg/h ) at post anesthetic care unit(PACU) over 6 hours for 7 days
48371256|NCT05494047|DRUG|Tetravalent influenza vaccine developed by Sinovac Biotech Co.|15μg Hemagglutinin Antigen (HA) of each of the four strains
48169363|NCT02592707|DRUG|Satoreotide tetraxetan|Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
48169364|NCT02592707|OTHER|Amino acid solution|"Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)"
48371257|NCT03188458|OTHER|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 \[approximately 4-8 weeks of age\]).
48371258|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
48371259|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
48699753|NCT01035463|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
48699754|NCT01035463|DRUG|Carmustine|Given IV
48699755|NCT01035463|DRUG|Cytarabine|Given IV
48699756|NCT01035463|DRUG|Etoposide|Given IV
48699757|NCT01035463|DRUG|Lenalidomide|Given PO
48699758|NCT01035463|DRUG|Melphalan|Given IV
48699759|NCT01035463|BIOLOGICAL|Rituximab|Given IV
48699760|NCT02130830|DRUG|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
48699761|NCT02130830|DRUG|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
48699762|NCT05115474|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Participants will undergo MRI imaging with and without contrast.
48012042|NCT06236958|DEVICE|Transnasal jejunal tube|A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.
48699763|NCT01579058|DRUG|bisoprolol|bisoprolol 5mg qd for 4 years
48012043|NCT06236958|OTHER|Transvenous access|A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 \~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 \~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 \~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500\~3000 ml/d; the infusion time is 8\~12 h/d. After exhaustion, start to eat through the mouth.
48012044|NCT03595371|DRUG|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
48371260|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
48371261|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
48371262|NCT01159665|DRUG|ocriplasmin|125µg ocriplasmin intravitreal injection
48699764|NCT01579058|DRUG|placebo|placebo for 4 years
48699765|NCT00002249|DRUG|Levofloxacin|
48699766|NCT05305222|DRUG|Risankizumab|Intravenous (IV) Infusion
48699767|NCT05305222|DRUG|Placebo|Intravenous (IV) Infusion
48699768|NCT06034873|DRUG|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
48699769|NCT06034873|DRUG|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
48699770|NCT03960086|OTHER|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
48699771|NCT03960086|OTHER|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
48699772|NCT06411912|DRUG|NIDO-361|Tablets containing 100mg of NIDO-361 for oral administration.
48699773|NCT06411912|DRUG|Placebo|Placebo oral tablets
48699774|NCT01895543|DRUG|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
48699775|NCT00199472|PROCEDURE|Dynamic Contrast Enhanced CT & Diuretic Renogram|
48699776|NCT06493305|BEHAVIORAL|Neurolinguistic programming|In the NLP application protocol, the visual, auditory and/or tactile representation system that the woman uses most frequently will be determined. Then, using the anchoring technique, the internal reactions and external reactions created by the woman's current symptoms and emotions and thoughts regarding the urination process will be combined using the anchoring technique. Existing negative emotions will be reduced and positive emotions will be reinforced. Then, with the swish technique, the intensity of the woman's existing negative emotions will be erased from the most frequently used visual, auditory or tactile representation system. Then, taking into account the representation system that the woman uses most frequently, the belief change model will be used in her negative thoughts about the current symptom, and her negative feelings and thoughts will be replaced by positive feelings and thoughts and reinforced.
48699777|NCT03542903|DEVICE|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
48699778|NCT00460694|BIOLOGICAL|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
48699779|NCT04695600|DRUG|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
48699780|NCT04925076|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
48699781|NCT04925076|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
48699782|NCT06384508|BEHAVIORAL|SHINE-VR|"The SHINE-VR takes place after module 6 of TF-CBT and is followed by the rest of the regular treatment. It consists of the following 3 VR sessions à 45min:~* Introduction: getting acquainted with VR, playing a VR game developed for the feasibility study (Krupljanin et al., in preparation), receiving psychoeducation about seeking help.~* Shame: virtual group therapy setting, psychoeducation about shame, virtual peers sharing thoughts of shame and their learnings/positive affirmations.~* Self-compassion: practicing self-compassion using an immersive perspective-changing task in VR."
48699783|NCT00448851|BIOLOGICAL|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
48012045|NCT05943444|PROCEDURE|Parks technique|compare different operational styles of low rectal cancer
48012046|NCT05943444|PROCEDURE|Bacon technique|Bacon technique
48699784|NCT01605604|BEHAVIORAL|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
48699785|NCT03702348|OTHER|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
48699786|NCT00877786|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
48699787|NCT00075725|DRUG|Cyclophosphamide|Given IV
48699788|NCT00075725|DRUG|Cytarabine|Given IT, SC, or IV
48371263|NCT02014753|DEVICE|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
48699789|NCT00075725|DRUG|Daunorubicin Hydrochloride|Given IV
48699790|NCT00075725|DRUG|Dexamethasone|Given PO or IV
48371264|NCT02617602|PROCEDURE|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
48699791|NCT00075725|DRUG|Doxorubicin Hydrochloride|Given IV
48699792|NCT00075725|DRUG|Leucovorin Calcium|Given IV
48699793|NCT00075725|DRUG|Mercaptopurine|Given PO
48012048|NCT05727358|BEHAVIORAL|Group-based Acceptance and Commitment Therapy|G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
48371265|NCT02617602|OTHER|Control|
48371266|NCT02067065|DRUG|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
48699794|NCT00075725|DRUG|Methotrexate|Given IT or IV
48699795|NCT00075725|DRUG|Pegaspargase|Given IM
48699796|NCT00075725|DRUG|Prednisone|Given PO or IV
48699797|NCT00075725|RADIATION|Radiation Therapy|Undergo radiation therapy
48699798|NCT00075725|DRUG|Thioguanine|Given PO
48699799|NCT00075725|DRUG|Vincristine Sulfate|Given IV
48699800|NCT01081704|DRUG|ustekinumab|Single dose of 45 mg subcutaneous injection
48699801|NCT01081704|DRUG|ustekinumab|Single dose of 90 mg subcutaneous injection
48699802|NCT00442442|DEVICE|mosquito coils|mosquito coil / night mosquito coil \& LLIN / night
48699803|NCT00442442|DEVICE|LLIN|Sleep under LLIN every night
48699804|NCT00159328|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
48699805|NCT06340451|DEVICE|iovera° system|subjects will receive ultrasound-guided iovera° system treatment
48699806|NCT06340451|DEVICE|sham iovera° system treatment|subjects will receive ultrasound-guided iovera° sham system treatment
48699807|NCT00336284|OTHER|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
48012049|NCT03087201|DRUG|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
48012050|NCT03087201|DRUG|placebo|analogous to experimental intervention
48012051|NCT05241223|OTHER|Behavior change intervention|This is an online intervention based on the transtheoretical model, along with self-determination theory strategies. This intervention will take place weekly summing up 12 online individual and/or group sessions of approximately 20 minutes. The sessions will be made through a platform and/or application that makes video calls privately. Each session will address a topic. In addition, in all sessions, the patients gain during the previous week will be recognized, as well as new goals will be set for the next week. The goals will always be individualized, realistic and achievable, based on the identification of each person's capacity and motivation. A Fitbit Zip will be used to propose objective goals aimed at increasing physical activity and reduce sedentary behavior. Additionally, a complex practice environment will be created around this device, such as the visualization of the number of steps evolution and competitions/games with other participants, among others.
48515892|NCT05505045|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
48699808|NCT00336284|OTHER|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
48699809|NCT01925495|OTHER|varied middle-ear pressure|
48012052|NCT05241223|OTHER|Educational program|The educational program will be delivered similarly to both groups through videos and booklets, which will be sent in all weekdays during de first week after the initial assessment. Later, one educational material will be sent every two weeks until de 11th week. In the first day, patients will receive a quick welcome video call, in which information will be provided on how this program will work. In the subsequent days, the material will be sent daily and the participants will be able to ask questions, if they want to. The program will cover information regarding the respiratory system, pathophysiology of asthma, asthma treatment, prevention strategies and medication instructions. It will also be briefly addressed the subjects: understanding physical activity and sedentarism, as well as the importance and benefits of being physically active and less sedentary.
48012053|NCT06351605|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
48012054|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration|The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
48012055|NCT04577690|DRUG|Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only|The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.
48012056|NCT05413928|BEHAVIORAL|Time Restrictive Eating- late|Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
48012057|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early|Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
48012058|NCT05413928|BEHAVIORAL|Time Restrictive Eating- early with early caloric intake|Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
48012059|NCT05413928|OTHER|Macronutrient-controlled meals|Meals with a determined amount of protein, carbohydrates, and fat.
48012060|NCT01632800|DEVICE|High pulsed magnetic fields|Magnetic fields will escalate in strength
48012061|NCT03746522|DRUG|Setmelanotide|SC injection of setmelanotide
48012062|NCT03746522|DRUG|Placebo|SC injection of placebo
48012063|NCT06504017|PROCEDURE|COG-TB: Cognitive Fusion guided prostate targeted Biopsy|Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
48012064|NCT06504017|PROCEDURE|FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy|MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
48012065|NCT01340976|DRUG|LY2787106|Administered IV.
48699810|NCT01925495|DRUG|varied middle-ear gas composition|
48699811|NCT01925495|OTHER|varied ear-canal pressure|
48699812|NCT04847752|PROCEDURE|carotid artery stenting|common treatments for carotid artery stenosis
48699813|NCT04847752|PROCEDURE|carotid endarterectomy|common treatments for carotid artery stenosis
48699814|NCT04847752|DRUG|Aspirin|the dosage and duration
48699815|NCT04847752|DRUG|Clopidogrel|the dosage and duration
48699816|NCT04847752|DRUG|Anticoagulant|the dosage and duration
48699817|NCT04847752|DRUG|Statin|the dosage and duration
48699818|NCT04847752|DRUG|PCSK9 inhibitor|the dosage and duration
48699819|NCT02292082|DRUG|Bupivacaine|
48012066|NCT01340976|DIETARY_SUPPLEMENT|Iron Supplementation|Administered orally.
48012067|NCT03304379|DRUG|Fasinumab|Solution for injection in pre-filled syringe
48012068|NCT03304379|OTHER|Diclofenac|NSAID active comparator (capsule)
48699820|NCT02292082|DRUG|Morphine|
48699821|NCT02292082|DRUG|Methylprednisolone|
48699822|NCT02292082|DRUG|Cefazolin|
48699823|NCT02292082|DRUG|Normal saline|
48699824|NCT02292082|DRUG|Midazolam|
48699825|NCT02292082|DRUG|Propofol|
48699826|NCT02292082|DRUG|Dexamethasone|
48699827|NCT02292082|DEVICE|8 MHz. Chiba needle, 22 G / 4 inches|
48699828|NCT02720055|OTHER|Psychological workbook|
48699829|NCT02720055|OTHER|Basic information workbook|Basic rehabilitation information that represents current practice.
48699830|NCT02438384|BEHAVIORAL|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
48699831|NCT02438384|BEHAVIORAL|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
48699832|NCT03883919|DRUG|5-FU|-Standard of care drug
48699833|NCT03883919|DRUG|Leucovorin|-Standard of care drug
48699834|NCT03883919|DRUG|Liposomal Irinotecan|-Standard of care drug
48699835|NCT03883919|DRUG|Paricalcitol|-Investigational drug
48699836|NCT03883919|PROCEDURE|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
48012069|NCT03304379|OTHER|Celecoxib|NSAID active comparator (capsule)
48012070|NCT03304379|DRUG|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
48012071|NCT01663272|DRUG|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
48012072|NCT01663272|DRUG|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
48012073|NCT03140202|DEVICE|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
48012074|NCT03140202|DEVICE|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
48012075|NCT04210154|DEVICE|Haemodiafiltration|pre-dilution and post-dilution Haemodiafiltration
48012076|NCT01764607|DRUG|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
48012077|NCT06360549|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation (TEAS) is a treatment that combines acupoint theory of traditional Chinese medicine with modern electrical stimulation techniques. It achieves the purpose of acupoint stimulation by applying a weak current to a specific part. TEAS operate just like ordinary electrodes with non-invasive, safe, portable, adjustable and other advantages.
48012078|NCT01929668|DRUG|polyethylene glycol|
48012079|NCT01929668|DRUG|Ascorbic Acid|
48012080|NCT05183685|PROCEDURE|telecare consultation|Participants will use zoom to communicate with the doctors in clinic.
48012081|NCT05183685|PROCEDURE|Usual face to face consultation|Participants will have face-to-face communication with the doctors in clinic.
48012082|NCT03372148|DIAGNOSTIC_TEST|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
48012083|NCT04083872|DRUG|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
48699837|NCT03883919|PROCEDURE|Tumor biopsy|"* 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
48012084|NCT04083872|DRUG|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
48012085|NCT02432716|DRUG|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
48012086|NCT02432716|DRUG|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
48012087|NCT06664411|DRUG|Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
48012088|NCT00225355|DRUG|Rosiglitazone|
48169365|NCT02592707|OTHER|Antiemetic|To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
48169366|NCT02648113|PROCEDURE|Restrictive transfusion|Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL
48169367|NCT02648113|PROCEDURE|Liberal transfusion|transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL
48169368|NCT02648113|BIOLOGICAL|red blood transfusion|
48169369|NCT02122549|DEVICE|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
48699838|NCT00017654|DRUG|anti-thymocyte globulin|
48699839|NCT00017654|DRUG|cyclophosphamide|
48699840|NCT00017654|DRUG|cyclosporine|
48699841|NCT00017654|DRUG|methylprednisolone|
48699842|NCT00017654|PROCEDURE|Allogeneic Bone Marrow Transplantation|
48699843|NCT01795495|DRUG|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
48699844|NCT01795495|DRUG|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
48699845|NCT01795495|DRUG|Remifentanil|
48699846|NCT06061276|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
48012089|NCT04239534|DEVICE|Convergence Of Epicardial And Endocardial RF Ablation|The epicardial lesion pattern will be created using the EPi-Sense®-AF Guided Coagulation System with VisiTrax®. Epicardial linear lesions will be created endoscopically using the EPi-Sense-AF Guided Coagulation System with VisiTrax throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to ablate endocardially to connect lesions at the reflections, complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi- Sense-AF Guided Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.
48012090|NCT00622427|DRUG|Ramelteon|8 mg tablets every night for 2 weeks
48012091|NCT00622427|DRUG|Placebo|placebo tablets for every night for 2 weeks
48169370|NCT03453424|PROCEDURE|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
48012092|NCT06113042|BEHAVIORAL|Health talks, learning packs|All participants can join the health talks and receive the learning packs.
48699847|NCT06061276|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48699848|NCT06061276|DRUG|Camrelizumab|200mg intravenously every 2 weeks
48699849|NCT06065059|DRUG|TNG348|Ubiquitin Specific Peptidase 1 (USP1) inhibitor
48699850|NCT06065059|DRUG|Olaparib|PARP inhibitor
48699851|NCT03831191|DRUG|LY3375880|Administered SC
48699852|NCT03831191|DRUG|Placebo|Administered SC
48699853|NCT01907308|DRUG|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
48699854|NCT01907308|DRUG|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
48699855|NCT03424967|BEHAVIORAL|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
48699856|NCT02896491|RADIATION|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
48371267|NCT02067065|DRUG|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
48371268|NCT02067065|PROCEDURE|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
48699857|NCT06138015|BEHAVIORAL|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
48699858|NCT06138015|BEHAVIORAL|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
48699859|NCT04451564|BEHAVIORAL|Mindfulness oriented recovery enhancement|8- week psychological program based on mindfulness techniques
48699860|NCT00005841|BIOLOGICAL|MART-1 antigen|
48699861|NCT00005841|BIOLOGICAL|gp100 antigen|
48699862|NCT00005841|BIOLOGICAL|incomplete Freund's adjuvant|
48699863|NCT00005841|BIOLOGICAL|progenipoietin|
48699864|NCT00005841|BIOLOGICAL|tyrosinase peptide|
48012093|NCT06113042|BEHAVIORAL|Lifestyle modification programme|"In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs."
48012094|NCT06113042|BEHAVIORAL|School healthy environment evaluation|Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.
48012095|NCT01790906|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
48012096|NCT01790906|OTHER|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
48699865|NCT02285023|OTHER|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
48699866|NCT02545517|BIOLOGICAL|Rabipur|Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.
48699867|NCT02545517|PROCEDURE|Blood sampling|Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.
48012097|NCT05907356|OTHER|sciatic nerve slider technique in slump lying position|The patient will be sitting at the edge of the couch with the posterior aspect of the knee at the edge, the thighs parallel to each other, and flexion at the thoracic and lumbar spines (slouch position). The therapist will be standing at the bedside of the patient with a proximal arm over the patient's shoulder and one hand guiding the neck movements of the patient and the other hand guiding the knee movements, passively performing cervical neck flexion with knee flexion (stretching the nerve proximally and relaxing at the distal end) and then moving into cervical extension with knee extension. Provide five sets in every session: the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions; and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes
48012098|NCT05907356|OTHER|sciatic nerve slider technique in supine position|.The patient will be in a supine position. The therapist will hold the patient's limb passively and then move the hip into flexion with the ankle in plantar flexion and the knee in extension, stretching the nerve at the hip and relaxing at the ankle, Then reversing the movement with the hip into extension, maintaining the knee in extension and the ankle in dorsiflexion, relaxing the nerve at the hip and stretching at the ankle. Provide five sets in every session; the first: 10 repetitions, the second: 15 repetitions, the third: 20 repetitions, the fourth: 25 repetitions, and the fifth: 30 repetitions. The end position is held for 5 seconds, and the rest between sets is 1-2 minutes.
48522909|NCT03474666|PROCEDURE|Standard Glycemic Control Group|"The targeted blood glucose range is 130-180 mg/dL~* Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~* Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~* Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~* Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU"
48522910|NCT01974973|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|Intrathecal autologous bone marrow mononuclear cell transplantation
48699868|NCT02545517|BIOLOGICAL|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM).
48371269|NCT03263052|DRUG|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
48371270|NCT03017066|DEVICE|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
48371271|NCT03017066|OTHER|General anesthesia|Scheduled operation under general anesthesia
48012099|NCT05907356|OTHER|Conventional physiotherapy|The patient will receive conventional physiotherapy, which includes: a moist hot pack, TENS, and back strengthening exercises (as a home program).
48012100|NCT04518124|DRUG|Propranolol|Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.
48699869|NCT00292279|DRUG|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
48699870|NCT00292279|DRUG|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
48699871|NCT01639573|DRUG|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
48012101|NCT04209088|OTHER|Pulmonary ultrasounds|"Two ultrasounds will be performed by the same pediatrician for each child included: the first at nine days of life +/- two days, the second at fifteen days of life +/- two days.~A blind replay of ultrasound images to calculate the score will be performed by a another investigator."
48012102|NCT02099721|DEVICE|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
48012104|NCT00902356|DRUG|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
48012105|NCT00902356|DRUG|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
48699872|NCT01239381|RADIATION|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
48699873|NCT00051012|DRUG|ONTAK|
48012106|NCT03490084|OTHER|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
48012107|NCT03490084|OTHER|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
48012108|NCT04902105|DRUG|ecopipam HCL|oral tablets
48699874|NCT00035607|DRUG|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
48012109|NCT04902105|DRUG|Mefenamic acid|oral capsules
48012110|NCT04902105|DRUG|Divalproex Sodium ER|oral tablets
48012111|NCT04257058|BEHAVIORAL|Electronic educational material|Electronic media via email
48012112|NCT00054561|BIOLOGICAL|recombinant interferon alfa|
48012113|NCT00054561|DIETARY_SUPPLEMENT|vitamin E|
48012114|NCT00054561|DRUG|isotretinoin|
48699875|NCT00035607|DRUG|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
48699876|NCT03010137|PROCEDURE|Incisional Negative Pressure Wound Therapy|
48699877|NCT03010137|PROCEDURE|Standard Closure with Skin Glue|
48012115|NCT00054561|PROCEDURE|adjuvant therapy|
48012116|NCT04090567|DRUG|Cediranib|Given PO
48012117|NCT04090567|DRUG|Ceralasertib|Given PO
48012118|NCT04090567|DRUG|Olaparib|Given PO
48012119|NCT05242497|PROCEDURE|pharmacopuncture|This is a pragmatic randomized controlled trials, so the physicians will choose pharmacopuncture treatment, including the type and doses, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
48371272|NCT03288987|DRUG|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
48371273|NCT01098019|DRUG|Xeomin|Patients will receive Xeomin only at Day 0.
48371274|NCT01098019|DRUG|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
48522911|NCT02738710|PROCEDURE|transumbilical incision|incision within umbilicus
48699878|NCT03010137|DEVICE|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
48699879|NCT03010137|DEVICE|Dermabond|Final wound closure with skin glue.
48699880|NCT05907954|DRUG|Darovasertib|Oral, potent, selective inhibitor of Protein Kinase C
48699881|NCT06589791|OTHER|No treatment given|Online self-completion survey
48169371|NCT03453424|PROCEDURE|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
48371275|NCT02593331|DRUG|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
48371276|NCT02593331|OTHER|Placebo|Participants will receive a single dose of placebo on Day 1.
48371277|NCT02221258|BIOLOGICAL|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
48371278|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
48699882|NCT02582073|BIOLOGICAL|Placebo (0.5ml)|
48699883|NCT02582073|BIOLOGICAL|Placebo (1.0ml)|
48699884|NCT02582073|BIOLOGICAL|Grass MATA MPL (0.5ml) 5100SU|
48699885|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 10200SU|
48699886|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 18200SU|
48169372|NCT02987322|DIETARY_SUPPLEMENT|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
48169373|NCT06043700|OTHER|No Intervention|No treatment intervention will be administered.
48169374|NCT03364478|PROCEDURE|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
48699887|NCT02582073|BIOLOGICAL|Grass MATA (0.5ml) 5100SU|
48699888|NCT03752346|OTHER|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~1. a warm-up with 10 minutes of stretching exercises.~2. A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~3. Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
48699889|NCT04011826|DEVICE|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
48699890|NCT05845333|OTHER|Decision task|Participants will complete a simple and/or moral decision making functional MRI task.
48012120|NCT05242497|PROCEDURE|conservative treatments (including physiotherapy)|This is a pragmatic randomized controlled trials, so the physicians will choose conservative treatment, including physiotherapy and pharmacological treatment, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
48699891|NCT00811005|RADIATION|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
48169375|NCT03364478|PROCEDURE|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
48169376|NCT02456259|PROCEDURE|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
48169377|NCT05940714|BEHAVIORAL|Video participants|Showing a video of oral hygiene intructions
48169378|NCT00797511|BIOLOGICAL|TdcP-IPV vaccine|0.5 mL, Intramuscular
48169379|NCT01123512|DEVICE|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
48522912|NCT02738710|PROCEDURE|Infra umbilical incision|incision about 1 cm below umbilicus
48699892|NCT00811005|RADIATION|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
48699893|NCT03735667|DEVICE|ACURATE neo2™ Transfemoral TAVR System|ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
48699894|NCT03735667|DEVICE|Medtronic CoreValve TAVR System|Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
48699895|NCT03735667|DEVICE|Edwards SAPIEN 3 TAVR System|Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
48699896|NCT03735667|DEVICE|ACURATE Prime™ Transfemoral TAVR System XL|ACURATE Prime™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
48699897|NCT03923621|PROCEDURE|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
48699898|NCT03923621|PROCEDURE|Excision|Surgery to remove all affected tissue, followed by wound closure.
48012121|NCT02479919|DEVICE|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
48012122|NCT02479919|DEVICE|Magstim® Sham TBS|Sham stimulation
48012123|NCT06027827|PROCEDURE|Addition of fusion device lateral bone graft|In addition to the central bone graft of the fusion cage, the lateral bone graft of the fusion cage was added.
48169380|NCT03111797|DRUG|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
48169381|NCT03111797|OTHER|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
48169382|NCT01293799|BEHAVIORAL|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
48371279|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
48522913|NCT01061593|DIETARY_SUPPLEMENT|Immunoxel|1 lozenge once per day
48522914|NCT01061593|OTHER|Placebo|1 lozenge once per day
48522915|NCT03499067|DEVICE|Test lens|Contact lens
48522916|NCT03499067|DEVICE|Control lens|Contact lens
48522917|NCT04196283|DRUG|ABBV-368|Intravenous (IV) infusion
48522918|NCT04196283|DRUG|Tilsotolimod|Intratumoral (IT) injection
48522919|NCT04196283|DRUG|Nab-paclitaxel|Intravenous (IV) infusion
48699899|NCT03968575|DEVICE|laser treatment|sub-threshold micro-pulse laser treatment
48371280|NCT01668017|DRUG|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
48522920|NCT04196283|DRUG|ABBV-181|Intravenous (IV) infusion
48169383|NCT03722797|PROCEDURE|Metabolic Cost Testing Procedures|"The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3."
48371281|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
48699900|NCT01213147|DRUG|clomiphene citrate|100 mg per day oral for 7 days
48699901|NCT01213147|DRUG|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
48699902|NCT00620178|DRUG|Candesartan Cilexetil|oral once daily dose
48699903|NCT00620178|DRUG|Losartan|once daily oral dose
48699904|NCT04285866|DRUG|Durvalumab|Durvalumab after chemoradiotherapy
48699905|NCT01814319|DRUG|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
48699906|NCT01814319|DRUG|Placebo|Matching placebo oral twice daily
48699907|NCT04187144|DRUG|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
48699908|NCT04187144|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
48699909|NCT04187144|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
48699910|NCT04187144|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
48699911|NCT01632475|BIOLOGICAL|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
48699912|NCT06179277|DEVICE|PrefGel® + Emdogain®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
48699913|NCT06179277|DEVICE|PrefGel®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
48699914|NCT02290691|BIOLOGICAL|Influenza Vaccine|Influenza Vaccine
48699915|NCT05160168|DRUG|THE-630|Oral THE-630 administered once daily in a continuous regimen
48699916|NCT06126718|DRUG|BR201|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
48371282|NCT01668017|DRUG|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
48522921|NCT02248987|OTHER|patients treated with antipsychotics|
48699917|NCT06126718|DRUG|Cosentyx（Secukinumab ）|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
48699918|NCT02803177|BIOLOGICAL|BMC2012|
48699919|NCT02803177|DEVICE|beta-TCP Chronos® Synthes|
48699920|NCT02833090|PROCEDURE|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
48699921|NCT04950712|PROCEDURE|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
48699922|NCT04950712|PROCEDURE|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
48699923|NCT01222091|DRUG|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
48699924|NCT01222091|DRUG|Placebo to Match Propranolol|
48699925|NCT01222091|DRUG|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
48699926|NCT05381441|BEHAVIORAL|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
48699927|NCT02335047|OTHER|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
48699928|NCT06607614|OTHER|Colorectal Cancer Screening Fecal Immunochemical Test|Fecal Immunochemical Test
48699929|NCT05977309|DEVICE|Topical ozone therapy|the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
48012124|NCT03468530|PROCEDURE|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
48012125|NCT00993213|PROCEDURE|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
48012126|NCT00993213|OTHER|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
48012127|NCT05355636|BEHAVIORAL|Fertility Management Counseling|counseling
48012128|NCT06144073|BEHAVIORAL|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
48012129|NCT02247349|BIOLOGICAL|BMS-986012 (anti-fucosyl-GM1)|
48012130|NCT02247349|BIOLOGICAL|Nivolumab|
48012131|NCT01675713|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
48169384|NCT02606097|DRUG|regorafenib|
48169385|NCT01664897|DRUG|Erlotinib Hydrochloride|Given PO
48169386|NCT01664897|OTHER|Laboratory Biomarker Analysis|Correlative studies
48169387|NCT02446379|DRUG|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
48169388|NCT02446379|DEVICE|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
48169389|NCT02446379|DEVICE|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
48169390|NCT03228953|OTHER|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
48699930|NCT01352221|DRUG|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
48012132|NCT02729922|DEVICE|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
48012133|NCT04770480|BEHAVIORAL|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
48012134|NCT04770480|BEHAVIORAL|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
48012135|NCT03212677|DIETARY_SUPPLEMENT|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
48012136|NCT03212677|DIETARY_SUPPLEMENT|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
48169391|NCT02880332|OTHER|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
48169392|NCT02880332|OTHER|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
48169393|NCT02880332|OTHER|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
48699931|NCT01352221|DRUG|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
48699932|NCT01775579|DRUG|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
48169394|NCT01202409|DRUG|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
48371283|NCT03957629|DRUG|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
48699933|NCT02706275|OTHER|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
48699934|NCT02604654|DRUG|Yiqitongluo granule|administered after dissolved
48012137|NCT03212677|DIETARY_SUPPLEMENT|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
48012138|NCT03212677|OTHER|Placebo|Cornstarch
48012139|NCT05337878|DRUG|Placebo|Pelacarsen-matching placebo administered by SC injection.
48012140|NCT05337878|DRUG|Pelacarsen|Pelacarsen administered by SC injection.
48012141|NCT00072345|DRUG|lomustine|
48012142|NCT00072345|DRUG|temozolomide|
48012143|NCT00072345|DRUG|thalidomide|
48012144|NCT03683134|BEHAVIORAL|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
48012145|NCT03683134|DIETARY_SUPPLEMENT|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
48012146|NCT03683134|BEHAVIORAL|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
48169395|NCT05056675|PROCEDURE|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
48699935|NCT03732495|DRUG|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
48699936|NCT02123238|OTHER|bed positioning|
48699937|NCT01443364|BIOLOGICAL|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
48699938|NCT00100997|DRUG|tanespimycin|
48699939|NCT04660292|OTHER|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
48699940|NCT04660292|OTHER|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
48699941|NCT06542575|OTHER|DTx-guided HBCR|The Huaxiaoxin WeChat mini program incorporating the core components of guidelines are divided into two main sections. Section 1 comprises interventions such as exercise training, educational programmes and cardiovascular risk factor management. Section 2 provides a secure platform for individualized feedback, just-in-time two-way communication, remote data transmission, and data repository, allowing patients and healthcare providers to access all relevant files anytime and anywhere throughout the 12-month study period.
48012147|NCT02598349|RADIATION|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
48012148|NCT02598349|DRUG|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
48012149|NCT02598349|PROCEDURE|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
48012150|NCT02402010|BEHAVIORAL|Adjunctive Yoga|
48012151|NCT02402010|BEHAVIORAL|Enhanced Treatment as Usual|
48012152|NCT01735292|DEVICE|Automatic Respiration Transfer System- Timer|
48012153|NCT06572085|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
48012154|NCT06572085|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP injection twice daily, while patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
48012155|NCT04979728|OTHER|At Home Self-Collections|Directly observed at home self-collection of blood samples
48012156|NCT00229684|DRUG|Tesaglitazar|2 mg once daily in oral form
48012157|NCT00229684|DRUG|pioglitazone|45 mg once daily in oral form
48699942|NCT02549625|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
48699943|NCT00381511|DRUG|low molecular weight heparin|
48699944|NCT03905239|DIAGNOSTIC_TEST|algorithm|clinical examination and procalcitonin assessment
48699945|NCT06607965|DIETARY_SUPPLEMENT|Whey Protein and Carbohydrates|"Experimental Group:~6 hours before surgery, patients orally consumed 250 ml of a full-nutrition liquid (220 ml homogenized diet, 50 g; containing 31.4 g carbohydrates, 8 g protein, and 215 kcal).~2 hours before surgery, patients orally consumed 200 ml of a clear liquid (50 g enzymatically hydrolyzed rice powder + 0.5 g low-sodium salt; containing 47.7 g carbohydrates, 6.5 g whey protein, and 193 kcal).~After surgery, once there were no symptoms such as dizziness or vomiting, patients could start consuming clear liquids (containing 47.7 g carbohydrates, 6.5 g protein, and 221 kcal) orally every 30 minutes, 4 times on the day of surgery.~Starting from the first day after surgery, patients consumed 200 ml of fat-free nutritional liquid (50 g enzymatically hydrolyzed rice powder + 7.5 g isolated whey protein + 0.5 g low-sodium salt; 223 kcal) per serving, 4 to 6 times per day as needed."
48515893|NCT05505045|BEHAVIORAL|Attention Control Procedures|Individuals in the attention control group will have dose-equivalent, weekly virtual contact through the Zoom platform for 12-weeks with a a trained interventionist not involved in CO-OP treatment. The control group will control for interpersonal interaction, maturation effects, and testing effects. The focus of each session will include: (1) social interaction characterized by warmth/empathy and (2) provision of usual care CRCI educational resources (e.g. exercise, using memory aids, minimizing distractions) from MD Anderson Cancer Center. These recommendations will be provided without further instruction. Any questions that arise regarding CRCI the subject is experiencing will be answered. The therapist will debrief with the subject on any changes in CRCI symptoms. The content and duration of each call will be tracked. Each session will be recorded with two randomly selected and reviewed for fidelity.
48515894|NCT03753191|DEVICE|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
48699946|NCT05875636|OTHER|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
48699947|NCT06332768|DEVICE|Respiratory support|High-flow nasal oxygenation
48699948|NCT03135158|OTHER|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
48699949|NCT00258232|DRUG|capecitabine|
48699950|NCT00258232|DRUG|celecoxib|
48699951|NCT00258232|DRUG|irinotecan hydrochloride|
48699952|NCT06414148|DRUG|Epcoritamab|Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
48699953|NCT06414148|DRUG|Epcoritamab, lenalidomide and rituximab|"Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6."
48699954|NCT01611363|DRUG|ASP1941|Oral
48699955|NCT01611363|DRUG|Placebo|Oral
48699956|NCT05076279|PROCEDURE|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
48699957|NCT00688324|DRUG|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
48371284|NCT03957629|DRUG|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
48371285|NCT00078663|BEHAVIORAL|Oral Care|
48371286|NCT04749316|PROCEDURE|AcuTENS|Stimulation of acupuncture points with TENS machine
48515895|NCT00345631|OTHER|Manual Compression|Manual compression
48515896|NCT00345631|DEVICE|Vascular Closure Device|Investigational vascular closure device
48515897|NCT01845688|DRUG|Losartan Tablets & QingReMoShen Granule|
48515898|NCT01845688|DRUG|Losartan Tablets & Placebo Granule|
48515899|NCT05523466|OTHER|Acupuncture Active|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Active acupuncture using specific Traditional Chinese Acupuncture points: E36, BP6, F3, IG4, for 20 minutes.
48699958|NCT02479685|PROCEDURE|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
48699959|NCT01522521|DRUG|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
48699960|NCT01522521|DRUG|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
48699961|NCT04351464|OTHER|physical therapy and reflexology|
48699962|NCT03362502|GENETIC|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a muscle-specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
48699963|NCT05638269|OTHER|no intervention|Observational studies, no intervention
48699964|NCT00002938|PROCEDURE|conventional surgery|Salvage prostatectomy
48699965|NCT04901442|DEVICE|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
48699966|NCT03015649|DEVICE|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
48699967|NCT04294615|OTHER|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
48012158|NCT05406544|OTHER|FD qualitative study on quality of life|Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
48012159|NCT05406544|OTHER|FD quantitative sudy on quality of life and olfaction.|Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.
48012160|NCT00833924|DEVICE|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
48012161|NCT03189251|OTHER|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
48012162|NCT06034366|DRUG|0.01% atropine|0.01% atropine (3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks,
48012163|NCT06034366|OTHER|0.9% sodium chloride|placebo eye drops (0.9% sodium chloride, 3 ml unit-concentration, preservative-free) once nightly in both eyes for 48 weeks
48012164|NCT06414499|DRUG|rhTNK-tPA|0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds.
48012165|NCT06414499|DRUG|Control group|Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen.
48012166|NCT06489886|OTHER|Conventional Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless convential chicken breast meat together with 250mL of water
48012167|NCT06489886|OTHER|Regenerative Chicken|This arm will be given a meal of 100 grams (\~32g of protein) boneless-skinless regenerative chicken breast meat together with 250mL of water
48012168|NCT05603104|DRUG|Clozapine|See arm description
48012169|NCT05603104|DRUG|Esketamine Nasal Product|See arm description
48699968|NCT04294615|OTHER|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
48699969|NCT04463693|DRUG|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
48699970|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Enhanced Parent Involvement|
48699971|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Minimal Parent Involvement|
48699972|NCT06092216|DRUG|Spesolimab|"900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11."
48699973|NCT02805751|DEVICE|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
48012170|NCT05603104|DRUG|Escitalopram|See arm description
48012171|NCT05603104|DRUG|Sertraline|See arm description
48699974|NCT02805751|OTHER|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
48699975|NCT02805751|OTHER|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
48699976|NCT04123093|DEVICE|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
48371287|NCT00971100|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
48371288|NCT03061162|RADIATION|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
48371289|NCT04658511|DEVICE|Ultrasound|On the spot, during the pre-op clinic visit, an ultrasound exam will be done by the PI trying to visualize the arcade of Struthers
48012172|NCT05603104|DRUG|Venlafaxine|See arm description
48012173|NCT05603104|DRUG|Lithium|See arm description
48012174|NCT05603104|DRUG|Valproate acid|See arm description
48169396|NCT05056675|PROCEDURE|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
48169397|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
48169398|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
48699977|NCT04123093|DEVICE|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
48699978|NCT04613557|BIOLOGICAL|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
48699979|NCT04613557|DRUG|Endoxan|Preconditioning chemotherapy
48699980|NCT04613557|DRUG|Fludara|Preconditioning chemotherapy
48699981|NCT04607213|PROCEDURE|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
48699982|NCT04607213|PROCEDURE|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
48699983|NCT00149136|DRUG|imatinib|
48699984|NCT01984645|OTHER|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
48699985|NCT02609841|DEVICE|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
48699986|NCT02534558|BIOLOGICAL|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
48699987|NCT03584841|DIAGNOSTIC_TEST|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
48699988|NCT00876850|DRUG|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
48699989|NCT00876850|DRUG|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
48699990|NCT01530035|OTHER|physical training|training
48012175|NCT05603104|DRUG|Quetiapine|See arm description
48699991|NCT03295383|DRUG|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
48699992|NCT03295383|DRUG|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally."
48012176|NCT05603104|DRUG|Second-line Antidepressants|See arm description
48012177|NCT05603104|DRUG|Second-line Antipsychotics|See arm description
48169399|NCT04319614|DRUG|Tranexamic Acid Injectable Product|A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.
48169400|NCT04319614|DRUG|Placebos|100 ml of saline will be administered in the beginning of the procedure.
48012178|NCT05603104|DRUG|Ketamine Hydrochloride|See arm description
48012179|NCT05603104|DRUG|Esketamine hydrochloride|See arm description
48371290|NCT02120274|DRUG|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
48371291|NCT02120274|DRUG|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
48371292|NCT02850757|DEVICE|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
48012180|NCT04953923|DRUG|Cedazuridine|Tablet for oral administration
48012181|NCT04953923|DRUG|Placebo|Capsule for oral administration
48012182|NCT04953923|DRUG|Moxifloxacin|Tablet for oral administration
48012183|NCT02086435|PROCEDURE|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
48012184|NCT02086435|PROCEDURE|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
48012185|NCT05070624|BEHAVIORAL|The Virtual Peer Support Program|Training: We have previously developed and beta-tested a virtual peer mentor training program adapted from the St. Jude's Research Hospital's (Memphis, USA) program for FCs of children with cancer for adults using HMV. Content \& Design of the Virtual Peer-Support Program: The program will be delivered by the aTouchAway™ App used for the LIVE program. Participants will be requested to access peer mentors ≥1 time/week. Participants can choose to interact with a peer mentor which will be assigned as well as other peer participants. Onboarding: Participants and mentors will create a personal profile of their caregiving situation (e.g., duration of care, family member age and diagnosis), to enable selection of mentors by the research team believed to be well suited to address support needs, questions, and concerns based on similar lived experience.
48012186|NCT00869648|PROCEDURE|Extension|After anaesthesia induction the head is placed in extension
48699993|NCT03295383|DRUG|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
48699994|NCT03295383|DRUG|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
48012187|NCT00869648|PROCEDURE|Neutral head position|After anaesthesia induction the head is placed in neutral position
48012188|NCT00869648|PROCEDURE|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
48699995|NCT03732677|DRUG|Durvalumab|Anti- PD-L1 Antibody
48012189|NCT05993546|DEVICE|vacuum assisted sheath|allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval
48699996|NCT03732677|DRUG|Cisplatin|Chemotherapy Agent
48699997|NCT03732677|DRUG|Gemcitabine|Chemotherapy agent
48699998|NCT05528653|DRUG|Descovy|HIV infection pre-exposure prophylaxis
48699999|NCT01121445|DEVICE|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
48700000|NCT05275387|OTHER|observational study, no intervention|observational study, no intervention
48700001|NCT06606522|DIAGNOSTIC_TEST|Clinical model|Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
48700002|NCT06606522|DIAGNOSTIC_TEST|Urinary biomarkers|Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
48012190|NCT05993546|DEVICE|passive suction via conventional sheath|conventional access sheath for stone retrieval using current technique via passive suction
48012191|NCT04600960|DRUG|Eltrombopag|The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
48012192|NCT02558608|PROCEDURE|DIPL|dissection of the inferior pulmonary ligament
48012193|NCT02558608|PROCEDURE|WR|wedge resection of the lung bleb
48371293|NCT02850757|DEVICE|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
48371294|NCT03495596|DEVICE|Videolaryngoscopy|Videolaryngoscopy device type
48700003|NCT04364555|DRUG|Clobetasol Propionate|Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.
48700004|NCT04364555|DRUG|Placebo/Klobetasol APL oral gel 0.025%|Placebo/active
48700005|NCT04364555|DRUG|Placebo|Placebo/placebo
48700006|NCT01541943|DRUG|Atorvastatin|Once daily, administered orally, 8 week
48700007|NCT01541943|DRUG|Losartan|Once daily, administered orally, 8 week
48700008|NCT01541943|DRUG|Placebo|Once daily, administered orally, 8 week
48700009|NCT01541943|DRUG|HL-040XC|Once daily, administered orally, 8 week
48012194|NCT02558608|PROCEDURE|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
48012195|NCT03460184|DIAGNOSTIC_TEST|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
48012196|NCT02662387|DEVICE|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
48012197|NCT02662387|OTHER|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
48012198|NCT04272190|OTHER|clinical routine treatments|The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
48012199|NCT02803437|DRUG|Radium-223 dichloride (Xofigo, BAY 88-8223)|Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
48012200|NCT05901285|DRUG|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
48012201|NCT00214994|DRUG|Gabitril|
48012202|NCT05928338|BEHAVIORAL|Peer-supported, WhatsApp-assisted lifestyle modification intervention|The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
48012203|NCT06664580|OTHER|Metabolic Bariatric Surgery Procedures|Observational analysis of various metabolic bariatric surgeries, including LSG, RYGB, and OAGB, focusing on long-term outcomes related to weight maintenance, nutritional health, and patient satisfaction.
48700010|NCT02969291|BEHAVIORAL|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
48012204|NCT01767792|DRUG|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
48012205|NCT03898817|OTHER|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
48012206|NCT03586999|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion.
48012207|NCT03586999|DRUG|Etoposide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
48012208|NCT03586999|DRUG|Prednisolone|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
48371295|NCT04132817|BIOLOGICAL|Nivolumab|specified dose on specified days
48371296|NCT04132817|BIOLOGICAL|Ipilimumab|specified dose on specified days
48371297|NCT04132817|DRUG|Nab-paclitaxel|specified dose on specified days
48371298|NCT01499498|DRUG|Sildenafil and Boceprevir|25mg once/800mg three times a day
48700011|NCT01477710|PROCEDURE|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
48700012|NCT01477710|PROCEDURE|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
48700013|NCT01477710|PROCEDURE|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
48700014|NCT04444778|DEVICE|CPAP|Continuous positive airway pressure
48012209|NCT03586999|DRUG|Oncovin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
48012210|NCT03586999|DRUG|Cyclophosphamide|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
48169401|NCT03975296|PROCEDURE|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
48371299|NCT05932420|DIETARY_SUPPLEMENT|Placebo|16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate. A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
48012211|NCT03586999|DRUG|Hydroxydaunorubicin|Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
48371300|NCT05932420|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
48371301|NCT02451137|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48371302|NCT02451137|DRUG|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48371303|NCT02451137|DRUG|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48371304|NCT02451137|DRUG|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
48700015|NCT05091281|DEVICE|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
48700016|NCT05091281|DEVICE|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
48700017|NCT05091281|DEVICE|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
48700018|NCT01467037|OTHER|No intervention done|Not applicable because no intervention was done.
48012212|NCT06242808|BEHAVIORAL|Medically tailored groceries and food resource coaching|Patients will meet with a food resource coach who will explain basic coaching principles including how to respond to financial crises, how to access various food resources, and the importance of consistent utilization of food resources. After the coaching session, the food resource coach will help patients select medically tailored groceries from the free community food market inventory.
48012213|NCT06242808|OTHER|Free community food support|Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)
48012214|NCT04720859|DRUG|Canagliflozin 300 MG Oral Tablet|Patients diagnosed with PHH following bariatric surgery by 100g glucose OGTT were prescribed 300mg canagliflozin during two weeks. 100g glucose OGTT response was evaluated after canagliflozin treatment.
48012215|NCT05022810|DRUG|New Paracetamol Oral Suspension (24 mg/ml)|After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
48012216|NCT05022810|DRUG|Panadol B&I Oral Suspension (24 mg/ml paracetamol)|After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
48012217|NCT00214955|DRUG|ORAVESCENT Fentanyl Citrate|
48012218|NCT03611725|PROCEDURE|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
48012219|NCT03611725|PROCEDURE|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
48012220|NCT03913078|BEHAVIORAL|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
48012221|NCT03913078|BEHAVIORAL|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
48012222|NCT04431232|DEVICE|Endoscopic Band Ligation|Band ligation of the gastric body for weight loss
48012223|NCT05379959|DRUG|MDMA|Participants will be given 125 mg of MDMA.
48700019|NCT02864888|RADIATION|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
48012224|NCT05379959|DRUG|Methamphetamine|Participants will be given 20 mg of MA.
48012225|NCT05379959|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
48012226|NCT06567652|DEVICE|catheter ablation|All patients underwent pulmonary vein isolation (and eventually left atrial posterior wall isolation) with the POLARx™ cryoballoon system
48012227|NCT06046638|DRUG|Cyclopofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
48012228|NCT06046638|DRUG|Propofol|Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
48012229|NCT04011878|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
48169402|NCT03975296|PROCEDURE|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
48371305|NCT06481215|BIOLOGICAL|GNR-068|The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
48371306|NCT06481215|BIOLOGICAL|Stelara®|The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
48515900|NCT05523466|OTHER|Acupuncture Sham|Immediately after the placement of the Polar V800, an instrument for analyzing heart rate variability, the placing of needles at the points carefully selected for this research begins. The needling will proceed for the Sham acupuncture using sham points (points not recognized as Acupuncture points), with the duration of 20 minutes
48700020|NCT02864888|DRUG|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
48012230|NCT02764749|DIETARY_SUPPLEMENT|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
48169403|NCT03975296|DRUG|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
48700021|NCT02864888|DRUG|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
48700022|NCT01706497|DEVICE|Cerebral tissue oxygen saturation monitoring, blinded|
48700023|NCT01425450|DRUG|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
48700024|NCT01425450|DRUG|HF1020 placebo|Single dose: HF1020 placebo capsule
48700025|NCT02872896|PROCEDURE|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
48700026|NCT00205517|PROCEDURE|Daily interruption of sedation versus sedation algorithm|
48012231|NCT02764749|DIETARY_SUPPLEMENT|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
48012232|NCT04135703|BEHAVIORAL|Risk Prevention Services + Housing|opioid and related prevention services in addition to 6 months of rental assistance
48012233|NCT04135703|BEHAVIORAL|Risk Prevention Services Only|opioid and related prevention services for 6 months
48012234|NCT03427658|BEHAVIORAL|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
48012235|NCT04546204|OTHER|vaginal delivery|normal vaginal spontaneous delivery
48700027|NCT03269968|DEVICE|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
48012236|NCT00002275|DRUG|Fat Emulsion 2%|
48012237|NCT00002275|DRUG|Fat Emulsion 20%|
48012238|NCT03697811|DRUG|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
48012239|NCT01222494|BEHAVIORAL|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
48012240|NCT01222494|BEHAVIORAL|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
48012241|NCT05644327|BEHAVIORAL|Cardiovascular training (CT)|12 weeks of CT
48012242|NCT05644327|BEHAVIORAL|Resistance training (RT)|12 weeks of RT
48700028|NCT03269968|DEVICE|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
48700029|NCT00332020|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
48012243|NCT05644327|BEHAVIORAL|Multimodal training (MT)|12 weeks of MT
48012244|NCT00906646|DIETARY_SUPPLEMENT|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
48012245|NCT00906646|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
48169404|NCT03246399|DRUG|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
48700030|NCT00332020|DRUG|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
48012246|NCT05167344|BEHAVIORAL|Healthy Relationships Program-Enhanced|The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
48012247|NCT04035772|OTHER|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
48012248|NCT06055426|OTHER|bed bath application|Patients who agree to participate in the research and are assigned to the experimental group will receive a bed bath. In order to examine the short-term, medium-term and long-term effects of bed bath, it is planned to have the whole body bed bath performed by the researcher nurse xx three times a week, two days apart.
48012249|NCT04394416|DRUG|Imatinib|Therapeutic
48012250|NCT04394416|DRUG|Placebo oral tablet|Placebo
48012251|NCT01978184|DRUG|gemcitabine|
48700031|NCT06608550|OTHER|short video film|Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
48169405|NCT00321321|DRUG|Sulfonylurea|
48012252|NCT01978184|DRUG|abraxane|
48012253|NCT01978184|DRUG|hydroxychloroquine|
48012254|NCT06182267|DRUG|L Arginine|toothpaste
48012255|NCT06182267|DRUG|Sodium Fluoride|toothpaste
48012256|NCT06349616|OTHER|Intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.
48012257|NCT06349616|OTHER|No intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment.
48012258|NCT06462690|OTHER|pre-mid-post test|(PIF) (DLQI) (GCS) Data Collection Forms Humidity measurement with DMM device
48169406|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
48515901|NCT02671929|BEHAVIORAL|self-help program|Access to the internet-based self-help program
48012259|NCT03835442|DRUG|Baclofen|baclofen 10mg tid for 4 weeks
48012260|NCT03835442|OTHER|Placebos|placebo tid for 4 weeks
48012261|NCT01570075|PROCEDURE|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
48515902|NCT02671929|BEHAVIORAL|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
48012262|NCT01570075|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
48012263|NCT04958694|BEHAVIORAL|CEDARS|This intervention is intended to help adolescents cope with stress and improve positive affect.
48012264|NCT03344185|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention consisted of three low GI meals.
48700032|NCT02816021|DRUG|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
48700033|NCT02816021|DRUG|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
48700034|NCT05718167|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
48700035|NCT05718167|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
48012265|NCT03344185|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
48012266|NCT06573840|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand. NeuroGlove provides sensory stimulation in the form of pneumatic puffs of air.
48012267|NCT04544449|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
48012268|NCT04544449|DRUG|Ocrelizumab|Participants will receive ocrelizumab.
48012269|NCT04544449|DRUG|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
48700036|NCT05718167|DRUG|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
48700037|NCT00788099|DRUG|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
48700038|NCT00788099|DRUG|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
48700039|NCT04319341|OTHER|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
48700040|NCT05470179|DEVICE|Hybrid hyrax distalizer|class 2 Angle malocclusion
48700041|NCT05470179|DEVICE|Pendulum distalizer|class 2 Angle malocclusion
48700042|NCT05093595|DEVICE|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
48700043|NCT06141538|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
48700044|NCT04105348|DIAGNOSTIC_TEST|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
48700045|NCT00022763|DRUG|Enfuvirtide|
48700046|NCT05957042|DRUG|Lumason|Up to 4.8mL administered intravenously
48700047|NCT02192060|OTHER|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
48012270|NCT04544449|DRUG|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
48012271|NCT04541017|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48012272|NCT04541017|PROCEDURE|Computed Tomography|Undergo PET/CT or diagnostic CT
48012273|NCT04541017|BIOLOGICAL|Magrolimab|Given IV
48012274|NCT04541017|BIOLOGICAL|Mogamulizumab|Given IV
48012275|NCT04541017|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48012276|NCT04541017|PROCEDURE|Punch Biopsy|Undergo skin punch biopsy
48012277|NCT06420115|DEVICE|different needle size for prostate biopsy|MRI Fusion Transperineal Prostate Biopsy
48515903|NCT00535405|DRUG|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
48515904|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
48515905|NCT00535405|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
48515906|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
48515907|NCT00535405|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
48515908|NCT05198180|DRUG|Topical 30%Potassium hydroxide solution|Patients will apply the solution every day under occlusion for 3 months
48700048|NCT02192060|OTHER|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
48012278|NCT06663865|DIETARY_SUPPLEMENT|Active|"40g bio-active whey protein concentrate powder containing dairy phospholipids~Other Names:~Active Treatment"
48012279|NCT06663865|DIETARY_SUPPLEMENT|Placebo|"Around 40g pea protein powder not containing dairy phospholipids~Other Names:~Placebo Treatment"
48012280|NCT04952766|BIOLOGICAL|Biological samples|"Immunocompromised subjects and healthy subjects groups will have collection of biological samples (blood with/without nasopharyngeal swabs) at Month-0, -1, -2, -3, -6, with associated data for the study of the kinetics of antibodies anti COVID-19.~Biological samples :~* Serum and plasma from each participant for the purpose of performing the SARS-CoV-2 serologic tests~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to vaccination~* Description of clinical manifestations related to SARS-CoV-2 infection, if any Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)"
48012281|NCT01280188|DRUG|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
48012282|NCT01280188|DRUG|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
48012283|NCT04522297|DRUG|Midodrine/Octreotide|oral midodrine plus octreotide as subcutaneous injection
48012284|NCT04522297|DRUG|Nor-epinephrine|Intravenous infusion norepinephrine
48012285|NCT02535702|OTHER|In vivo MRS|1H MR spectroscopy to assess brain metabolites.
48012286|NCT02535702|OTHER|fMRI|Three fMRI sessions to assess test-retest reliability of functional connectivity (FC) measures at rest and during task performance.
48012287|NCT02535702|OTHER|EEG/EOG|Electroencephalography or electrooculography (EEG/ EOG) sessions to record electrical activity of the brain or measure corneo-retinal standing potentials.
48012288|NCT02535702|OTHER|Stimulation tasks|To be used in the context of fMRI to study blood-oxygenation-level- dependent responses in the brain to sensory stimulation.
48012289|NCT02535702|OTHER|NSPRD|To be used in conjunction with pupillometry in the context of fMRI to study blood-oxygenation-level-dependent responses to selective neurostimulation of pain fibers.
48169407|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
48371307|NCT03434665|PROCEDURE|Transradial celiac artery angiography|"* After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
48700049|NCT06372171|DIETARY_SUPPLEMENT|Satge 1|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 1-10 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 11-20
48371308|NCT00874718|BEHAVIORAL|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
48371309|NCT00874718|BEHAVIORAL|General education|Non-specific educational program for general health.
48371310|NCT00091039|BIOLOGICAL|recombinant fowlpox GM-CSF vaccine adjuvant|
48371311|NCT00091039|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
48012290|NCT02535702|OTHER|Structural MRI|High spatial MRI and diffusion tensor imaging (DTI) to assess brain morphology and structural connectivity.
48012291|NCT01305031|OTHER|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
48012292|NCT01305031|OTHER|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
48012293|NCT01341184|DRUG|Rifabutin|Rifabutin 300 mg orally on days 20-41
48012294|NCT01341184|DRUG|Rifampin|Rifampin 600 mg orally on days 20-41
48012295|NCT01341184|DRUG|TMC207|TMC207 400 mg orally on days 1 and 29
48012296|NCT02387021|PROCEDURE|Continuous femoral nerve block|
48012297|NCT02387021|PROCEDURE|Continuous adductor canal block|
48012298|NCT02387021|PROCEDURE|infragluteal Sciatic nerve block|
48012299|NCT02387021|DRUG|Ropivacaine 0.2%|
48169408|NCT02880969|BEHAVIORAL|answering questionnaires|
48169409|NCT06347770|DRUG|Probiotic Blend Oral Tablet|In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
48371312|NCT00091039|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
48371313|NCT00091039|DRUG|carboplatin|
48371314|NCT00091039|DRUG|paclitaxel|
48371315|NCT00091039|RADIATION|radiation therapy|
48371316|NCT03772574|DEVICE|Facemask preoxygenation|Standard facemask preoxygenation
48371317|NCT03772574|DEVICE|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
48371318|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
48700050|NCT06372171|DIETARY_SUPPLEMENT|Stage 2|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 11-20 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 1-10
48700051|NCT01175486|DRUG|Actos (Pioglitazone)|Actos 30 mg for 6 months
48700052|NCT01175486|DRUG|Acarbose|Acarbose 50 mg tid for 6 months
48700053|NCT00052091|BEHAVIORAL|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
48371319|NCT01580696|OTHER|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
48700054|NCT00052091|BEHAVIORAL|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
48700055|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
48700056|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
48700057|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
48700058|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
48700059|NCT00417378|DEVICE|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
48700060|NCT00417378|DEVICE|Intraaortic Balloon Pump|Counterpulsation
48700061|NCT04614870|DIAGNOSTIC_TEST|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
48700062|NCT04565444|DIETARY_SUPPLEMENT|Ketone|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring"
48700063|NCT04565444|DIETARY_SUPPLEMENT|Ketone + Protein|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
48700064|NCT04565444|DIETARY_SUPPLEMENT|Protein|"* Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
48700065|NCT03392389|BIOLOGICAL|mRNA-1653|Escalating dose levels
48371320|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
48700066|NCT03392389|OTHER|Placebo|Saline
48700067|NCT03666897|OTHER|DTI Images and Plasma Biomarkers|Additional Images added from standard of care MRI, Bio-markers identified
48700068|NCT04685005|DIETARY_SUPPLEMENT|"Wake Up"|The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up
48700069|NCT04685005|DIETARY_SUPPLEMENT|Caffeine|Caffeine
48700070|NCT00117715|PROCEDURE|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
48700071|NCT05694312|DRUG|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
48700072|NCT03053986|DIETARY_SUPPLEMENT|Apple polyphenols|1 tablet per day at evening before sleeping
48700073|NCT03053986|OTHER|Placebo|1 tablet per day at evening before sleeping
48012300|NCT02387021|DRUG|Saline|
48012301|NCT04539028|PROCEDURE|Emergency Abdominal surgery|Emergency Abdominal surgery
48169410|NCT00509457|BIOLOGICAL|GV 1001 Telomerase peptide|
48700074|NCT03393819|DRUG|DuraPrep|DuraPrep surgical solution
48700075|NCT03393819|DRUG|ChloraPrep|ChloraPrep surgical solution
48700076|NCT04801225|DEVICE|Non-invasive electromagnetic stimulation for acute stroke treatment|Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
48700077|NCT03761017|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
48700078|NCT01089413|DRUG|bevacizumab [Avastin]|As prescribed by physician
48700079|NCT05878327|OTHER|Thrombophilia screening|No intervention. Blood is drawn for analysis.
48700080|NCT04835805|DRUG|Belvarafenib|Twice daily (BID), continuous dosing
48700081|NCT04835805|DRUG|Cobimetinib|Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
48700082|NCT04835805|DRUG|Nivolumab|Once every 4 weeks (Q4W)
48700083|NCT01803178|DIETARY_SUPPLEMENT|Plant Sterols|
48700084|NCT01803178|DIETARY_SUPPLEMENT|Placebo Product|
48700085|NCT02939820|DRUG|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
48700086|NCT05096234|DRUG|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
48700087|NCT03967028|PROCEDURE|cesarean section|lower segment cesarean section either elective or emergency
48700088|NCT03277430|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
48700089|NCT03277430|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
48012302|NCT01283048|DRUG|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
48012303|NCT02089750|OTHER|Orthotics|
48012304|NCT02089750|OTHER|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
48012305|NCT02089750|OTHER|Wait List|
48012306|NCT05684679|OTHER|Incentive spirometer plus Chest physiotherapy|Incentive spirometer was given to IS group. However, a conventional chest physiotherapy was given to both groups in the optimal position.
48012307|NCT05684679|OTHER|Diaphragmatic breathing exercise plus Chest physiotherapy|Diaphragmatic breathing exercise was given to DBE group. In addition, a conventional chest physiotherapy was given in the optimal position.
48371321|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of E39 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
48371322|NCT01580696|BIOLOGICAL|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|"100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
48515909|NCT05198180|DRUG|Topical 45% hydrogen peroxide solution|Patients will apply the solution every day under occlusion
48515910|NCT06233448|DEVICE|Indirect cardiometry|Measurements of thorathic fluid content
48700090|NCT03277430|DRUG|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
48700091|NCT00484393|DRUG|tetracaine 4% gel|tetracaine applied prior to 1 injection
48700092|NCT00484393|DRUG|Placebo|placebo applied prior to 1 injection
48012308|NCT06461520|OTHER|Maze Balance board|Every child will have their balance evaluated using the SWOC tool, CTSIB, and Pediatric Balance Scale. Patients performed a range of proprioceptive exercises, such as static one-leg standing, board balancing, squatting, and 20 minutes of straight-line walking on a hard surface before moving to a foam surface. For 20 minutes each session, proprioceptive exercises were conducted with open eyes first, followed by closed ones. The training program for the maze balancing board will next take place. There will be seven phases to the maze balance board training; each stage will last for two days and there will be three sessions per day, each lasting an hour.
48012309|NCT06461520|OTHER|Proprioceptive training|This group will get proprioceptive training. For a total of ten weeks, the intervention will be carried out three times a week for forty minutes each. Without maze-balance board training, the training schedule will consist of three sessions each week, lasting ten minutes each for preparatory, twenty minutes for proprioceptive, and ten minutes for restorative activities. Every meeting ended with a 10-minute cool-down and 10-minute warm-up to signify the quality of work.
48012310|NCT01164852|PROCEDURE|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
48012311|NCT01304888|OTHER|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
48012312|NCT01304888|OTHER|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
48012313|NCT01304888|OTHER|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
48012314|NCT01304888|OTHER|Control|No benefits were provided
48012315|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 2 saliva samples at inclusion.
48012316|NCT05928442|BEHAVIORAL|Completion of a self-questionnaire|Completion of a self-questionnaire on symptom and quality-of-life at inclusion.
48012317|NCT05928442|DEVICE|in vitro diagnostic medical device|Collection of 1 saliva sample at the follow-up visit.
48169411|NCT06120114|PROCEDURE|Modified percutaneous internal ring suturing|Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
48515911|NCT04983186|DEVICE|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
48700093|NCT01549886|DRUG|Y-90-Zevalin|Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
48700094|NCT01549886|DRUG|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily"
48700095|NCT01549886|DRUG|Rituximab|Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
48012318|NCT01850004|DRUG|Dasatinib|
48371323|NCT01580696|BIOLOGICAL|E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster|"500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
48012319|NCT06498973|DRUG|Azacitidine|Given IV
48012320|NCT06498973|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48012321|NCT06498973|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
48012322|NCT06498973|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
48012323|NCT06498973|OTHER|Questionnaire Administration|Ancillary studies
48371324|NCT01580696|BIOLOGICAL|E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster|"1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose.~Subsequently, patients will receive a booster of J65 dosed at 500mcg and mixed with 250mcg of GM-CSF. The boosters will be given at 6 and 12 months after completing the primary vaccine series above."
48700096|NCT04193345|OTHER|Documentation of Maternal blood loss and neonatal outcome|Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
48700097|NCT01304069|DRUG|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
48700098|NCT01304069|DRUG|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
48012324|NCT06498973|BIOLOGICAL|Tagraxofusp-erzs|Given IV
48012325|NCT03660046|DRUG|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
48012326|NCT03660046|DRUG|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
48012327|NCT03660046|DRUG|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
48012328|NCT03500757|DEVICE|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
48012329|NCT04689737|DRUG|Doravirine|Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
48012330|NCT06073405|DEVICE|Colonic Polyp Measurement Assessment Via Artificial Intelligence|In this study, we collect colonoscopy video clips of polyps and, among the related clinical information, their estimated size using the gold standard technique, and we use them offline to evaluate the measurement performances of the novel virtual polyp sizing tool
48012331|NCT05133531|DRUG|Ravulizumab|Administered Intravenous (IV) per the protocol
48012332|NCT05133531|DRUG|Pozelimab|Administered IV and subcutaneous (SC) per the protocol
48012333|NCT05133531|DRUG|Cemdisiran|Administered SC per the protocol
48012334|NCT05133531|DRUG|Eculizumab|Administered IV per the protocol
48012335|NCT05932199|DRUG|Durvalumab / tremelimumab|"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
48012336|NCT05932199|DRUG|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
48700099|NCT01304069|DRUG|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
48700100|NCT06608433|DRUG|semaglutide|semaglutide/Rybelsus will be administered as a single oral dose
48700101|NCT06608433|DRUG|Placebo|Placebo pills will be administered as a single oral dose
48012337|NCT06573164|DRUG|Bacillus clausii tablets（Qipian®）|Take 4 tablets (0.3 mg each) orally three times daily.
48012338|NCT06573164|DRUG|conventional medication|Use conventional medication as needed based on the patient's condition.
48012339|NCT01557075|DRUG|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization"
48012340|NCT01557075|DRUG|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
48012341|NCT03678012|DRUG|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
48012342|NCT03678012|DRUG|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
48012343|NCT03678012|DRUG|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
48012344|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun. 0.5ml per dose
48012345|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang. 0.5ml per dose.
48012346|NCT04612634|BIOLOGICAL|Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS|Administration of one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml per dose.
48012347|NCT01377974|DRUG|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
48012348|NCT01377974|DRUG|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
48012349|NCT06257784|PROCEDURE|Oxygen Therapy|Patients who have SpO2 \< 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).
48012350|NCT06257784|PROCEDURE|Non-Invasive Ventilation (NIV)|Patients with P/F \< 250 or Ph \< 7,35 with PCO2 \> 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).
48012351|NCT06257784|PROCEDURE|Invasive Ventilation|Patients with P/F \< 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (\>24 breaths/min) despite NIV for at least 2 hours or patients with Ph \< 7,2 with PCO2 \> 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
48012352|NCT06230367|BEHAVIORAL|Sexual health advocacy for guys|5 month HIV prevention program delivered via text messaging
48012353|NCT06230367|BEHAVIORAL|Healthy lifestyle control|5 month control group program delivered via text messaging
48700102|NCT02743949|DRUG|Vonoprazan|Vonoprazan over-encapsulated capsules
48700103|NCT02743949|DRUG|Esomeprazole|Esomeprazole over-encapsulated tablets
48700104|NCT02743949|DRUG|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
48012354|NCT02317302|DEVICE|FDG-PET/MR|
48012355|NCT02317302|DEVICE|FDG-PET/CT|
48012356|NCT02063997|DRUG|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
48012357|NCT02063997|DRUG|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
48012358|NCT02063997|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
48012359|NCT02063997|DRUG|Placebo|Placebo tablets once daily for 12 weeks
48012360|NCT02063997|DRUG|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
48700105|NCT00660413|DEVICE|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
48700106|NCT06298617|PROCEDURE|Diagnostic laparoscopy|All women will undergo exploratory laparoscopy under general anesthesia
48012361|NCT00568308|DRUG|PI-88|160mg subcutaneous injection
48012362|NCT00568308|DRUG|placebo|matched placebo
48012363|NCT05668793|DIAGNOSTIC_TEST|GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in the group were collected and methylation tests were performed according to the kit instructions.
48012364|NCT02537964|OTHER|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
48012365|NCT01114516|DRUG|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
48012366|NCT02125539|BEHAVIORAL|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
48012367|NCT02125539|BEHAVIORAL|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
48700107|NCT06298617|DIAGNOSTIC_TEST|Full Blood Count (FBC)|Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
48700108|NCT00404755|DRUG|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
48012368|NCT06572488|DEVICE|Non-ablative SMOOTH mode Er:YAG laser|Four intravaginal treatments within four months.
48012369|NCT02710604|DRUG|CMX157|tablet
48012370|NCT02710604|DRUG|TDF|300mg tablet
48012371|NCT04122833|OTHER|Next generation sequencing|observational study
48012372|NCT06580158|DEVICE|AI-ECG Dashboard|Patients standard of care ECG's will be processed through the AI-ECG Dashboard
48012373|NCT06580158|DIAGNOSTIC_TEST|Point of care ultrasound (POCUS)|Patients will undergo a ultrasound to confirm diagnosis of atrial stenosis or diastolic dysfunction.
48012374|NCT03592641|DRUG|Savolitinib|Given PO
48371325|NCT06510257|DRUG|Reconyl|1 tablet of Reconyl, 3 times daily
48700109|NCT00404755|DRUG|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
48700110|NCT00404755|DRUG|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
48700111|NCT05052814|OTHER|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
48012375|NCT02649972|DRUG|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
48012376|NCT05002322|OTHER|Systems Analysis and Improvement Approach|"Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel."
48012377|NCT02520531|DEVICE|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
48012378|NCT02520531|DEVICE|Scorpio NRG PS|Implantation of total knee prosthesis
48012379|NCT02358694|DIETARY_SUPPLEMENT|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
48012380|NCT02358694|OTHER|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
48700112|NCT05052814|OTHER|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
48012381|NCT05942248|OTHER|No Intervention|No Intervention
48012382|NCT04007536|OTHER|No Intervention|No Intervention
48012383|NCT06080620|PROCEDURE|Modified radical mastectomy for breast cancer|Modified radical mastectomy for breast cancer
48012384|NCT06080620|PROCEDURE|neoadjuvant therapy|"neoadjuvant chemotherapy（Drugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab）"
48012385|NCT06080620|PROCEDURE|Systematic treatment|"chemotherapyDrugs： DoxorubicinPaclitaxelAlbumin paclitaxelCyclophosphamide）, endocrine therapy（Drugs：ToremifenZoladexAromatase inhibitors）, targeted therapy（Drugs：trastuzumabPertuzumab），radiotherapy（Yikeda Versa HD linear acceleratorVarian Trilogy linear accelerator）"
48700113|NCT05052814|OTHER|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
48700114|NCT05311943|DRUG|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
48700115|NCT01340625|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
48700116|NCT01340625|DRUG|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
48700117|NCT05366426|OTHER|EMG biofeedback program:|Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
48700118|NCT05366426|OTHER|Sham EMG biofeededback:|3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
48700119|NCT05366426|OTHER|Pelvic floor muscle training home exercise program:|Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
48700120|NCT03593343|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
48700121|NCT02074345|BIOLOGICAL|TAK-816|TAK-816 intramuscular injection
48700122|NCT05678816|DEVICE|BREATHER|respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
48700123|NCT05678816|OTHER|physiotherapy prgramme for rehabilitation of stroke patients|"physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
48700124|NCT06608745|PROCEDURE|conventional total knee arthroplasty|total knee arthroplasty performed with conventional technique
48700125|NCT06608745|PROCEDURE|computer-assisted total knee arthroplasty|total knee arthroplasty performed with imageless computer-assisted surgery
48700126|NCT03055325|OTHER|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
48012386|NCT03390907|DEVICE|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
48012387|NCT06341465|OTHER|Just Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
48169412|NCT04841070|OTHER|Ages & Stages Questionnaires®, Third Edition (ASQ3)|Investigators will propose to parents of children hospitalized for the treatment of persistent pulmonary hypertension of the newborn a hetero-evaluation via the validated ASQ questionnaire to analyze neuro-psychomotor development.
48700127|NCT02275715|BEHAVIORAL|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
48700128|NCT03324334|DIAGNOSTIC_TEST|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
48700129|NCT03324334|DIAGNOSTIC_TEST|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
48700130|NCT05293041|DRUG|Argipressin|Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
48700131|NCT05293041|DRUG|Placebo|Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.
48700132|NCT05043792|DRUG|TT-00920|TT-00920 Tablets
48169413|NCT03146325|DRUG|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
48012388|NCT06341465|OTHER|Exercise|Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.
48012389|NCT06341465|OTHER|Taping|Kinesiological taping will be applied as a tone enhancer or tone reducer according to the the concave and convex sides of the curve.
48169414|NCT03146325|DRUG|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
48169415|NCT02872519|DRUG|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
48012390|NCT05864313|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
48012391|NCT05864313|BEHAVIORAL|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
48169416|NCT02872519|PROCEDURE|Positron Emission Tomography|Undergo scan
48169417|NCT02872519|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
48700133|NCT05043792|DRUG|TT-00920 Placebo|TT-00920 Placebo Tablets
48700134|NCT05345574|DRUG|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
48012392|NCT05864313|BEHAVIORAL|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
48012393|NCT05864313|DEVICE|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
48012394|NCT02842268|DRUG|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
48169418|NCT06478576|DEVICE|multibranched stent graft system|To evaluate the feasibility of multibranched stent graft system for Endovascular Treatment of Thoracoabdominal Aortic Aneurysm(TAAA)
48169419|NCT00730847|BIOLOGICAL|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
48169420|NCT02652377|DRUG|EDP-494|10, 100 and 200 mg capsules
48169421|NCT02652377|DRUG|Placebo|placebo to match EDP-494
48169422|NCT06477991|DRUG|Tireilizumab（PD-1 inhibitor）|"Neoadjuvant immunotherapy phase :~1. Pharmaceuticals: Tireilizumab: 200mg, intravenous infusion, Q3W, at least 4 cycles, the number of specific neoadjuvant immunotherapy cycles was determined according to the results of MRD dynamic monitoring.~2. MRD dynamic monitoring time node: dynamic monitoring at the initial diagnosis and after the fourth cycle of neoadjuvant immunotherapy. Blood monitoring points were 1-2 weeks after immunotherapy. If the two consecutive MRDs were negative, the watch and wait strategy was adopted. If the MRD was still positive after 8 cycles of neoadjuvant immunotherapy, surgical treatment was performed."
48700135|NCT05345574|DRUG|remifentanil infusion|remifentanil as anaesthetic adjuvant
48700136|NCT02894164|OTHER|No intervention|
48169423|NCT04106713|BEHAVIORAL|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
48371326|NCT06510257|DRUG|Placebo tablet of Reconyl|1 tablet of placebo Reconyl, 3 times daily
48371327|NCT04959162|DEVICE|E-learning|Development of theoretical knowledge using a E-learning platform before attending a hands-on course in musculoskeletal ultrasound
48371328|NCT04959162|DEVICE|Conventional preparation|Attending a hands-on course in musculoskeletal ultrasound with no preparation before course start
48700137|NCT02734771|DRUG|Brentuximab vedotin|
48700138|NCT02734771|DRUG|Rituximab|
48700139|NCT02734771|DRUG|Cyclophosphamide|
48700140|NCT02734771|DRUG|Doxorubicin|
48700141|NCT02734771|DRUG|Prednisone|
48700142|NCT06339242|DRUG|Furmonertinib|After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
48700143|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
48700144|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
48515912|NCT00790725|OTHER|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
48515913|NCT00790725|OTHER|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
48012395|NCT05294107|PROCEDURE|additional biopsies|"After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing."
48012396|NCT01766375|DRUG|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
48012397|NCT01885481|DRUG|Dexamethasone|epidural steroid injection using dexamethasone
48515914|NCT04237272|OTHER|Pod System E-cig|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
48012398|NCT01885481|DRUG|Betamethasone|epidural steroid injection using betamethasone
48169424|NCT04106713|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues."
48169425|NCT04106713|BEHAVIORAL|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
48169426|NCT02073253|OTHER|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
48169427|NCT02024477|DRUG|Saxagliptin|5 mg tablet once daily for 12 weeks
48169428|NCT02024477|DRUG|Placebo|1 tablet daily for 12 weeks
48169429|NCT01624298|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
48169430|NCT02161198|DIETARY_SUPPLEMENT|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
48169431|NCT02161198|DIETARY_SUPPLEMENT|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
48169432|NCT03918447|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
48169433|NCT03918447|DRUG|Placebo oral capsule|Capsule containing an inert placebo
48169434|NCT04699123|DRUG|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
48169435|NCT04699123|DRUG|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
48515915|NCT04237272|OTHER|Customizable Tank E-cig|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
48515916|NCT04237272|OTHER|Control|Participants will not receive any e-cigarette
48515917|NCT05204498|BEHAVIORAL|Education plan and adherence to exercise|"Through phone calls with a motivating sense at any time of the day, twice a week.~* It will be recorded in an Excel table each time the patient is called.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 8 weeks. At the end of week 8, patients will be referred to the pulmonary rehabilitation unit to evaluate the anthropometric parameters, assess dyspnea with the modified scale of the Medical Research Council, the hospital anxiety and depression scale, the Saint George respiratory questionnaire , the pulmonary information You need the questionnaire and the 6-minute walk test again."
48012399|NCT02533921|OTHER|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
48012400|NCT02533921|OTHER|Standard of Care|Usual care defined as including both a PCP and neurologist
48012401|NCT02476396|PROCEDURE|Carotid Endarterectomy or Stenting|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic~Carotid stenting uses a expandable metal coil to prevent the artery from narrowing."
48012402|NCT06020716|DRUG|Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution|Three times daily
48012403|NCT06020716|DRUG|Placebo|Three times daily
48012404|NCT04055636|DIAGNOSTIC_TEST|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
48012405|NCT04055636|DIAGNOSTIC_TEST|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
48012406|NCT04055636|DIAGNOSTIC_TEST|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
48012407|NCT04085523|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
48012408|NCT04085523|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
48012409|NCT03641573|DRUG|[14C] ASN002|\[14C\] ASN002
48012410|NCT02886585|DRUG|Pembrolizumab|
48012411|NCT02886585|RADIATION|MRI|
48012412|NCT02886585|RADIATION|PET/CT|
48012413|NCT02886585|PROCEDURE|Stereotactic Radiosurgery|
48169436|NCT04699123|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
48700145|NCT06215703|BEHAVIORAL|Music Playing Task|For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
48700146|NCT04137653|DRUG|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
48700147|NCT04137653|DRUG|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
48700148|NCT02589652|DRUG|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
48700149|NCT02589652|DRUG|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
48700150|NCT02589652|DRUG|Entecavir|ETV 0.5mg oral daily for 48 weeks
48700151|NCT02765113|PROCEDURE|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
48012414|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
48012415|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
48169437|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
48169438|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
48169439|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
48169440|NCT01734473|DIETARY_SUPPLEMENT|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
48012416|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
48012417|NCT03194646|OTHER|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
48012418|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
48012419|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
48012420|NCT03194646|DRUG|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
48012421|NCT01872572|DRUG|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
48169441|NCT01734473|DIETARY_SUPPLEMENT|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
48012422|NCT01872572|DRUG|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
48012423|NCT01872572|DRUG|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
48700152|NCT02765113|PROCEDURE|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
48169442|NCT04502043|OTHER|Exercise therapy|"* Education~* Hip-specific strengthening exercises~* Functional lower limb strengthening exercises~* Core stability exercises~* Postural balance exercises"
48169443|NCT01520077|DRUG|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
48169444|NCT05927506|BEHAVIORAL|Other|Observational study of behavior cognitive and motor control
48169445|NCT00082641|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
48169446|NCT00876499|BEHAVIORAL|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
48169447|NCT04782700|OTHER|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
48169448|NCT06255236|DEVICE|Bispectral index (BIS)|"* All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~* Sedative medication can be given as appropriate.~* Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~* Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~* The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~* The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~* The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped."
48169449|NCT02587013|PROCEDURE|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
48169450|NCT02587013|PROCEDURE|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
48169451|NCT05278013|OTHER|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D \& C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
48169452|NCT06176053|OTHER|Homebased stretching exercise and app supervision|The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
48012424|NCT01872572|DRUG|Subcutaneous RB006 2.0 mg|"* Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
48012425|NCT01872572|DRUG|Placebo|Placebo
48169453|NCT03159078|DRUG|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
48169454|NCT00761397|BEHAVIORAL|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
48700153|NCT01364558|DRUG|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
48700154|NCT01364558|DRUG|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
48012426|NCT03863366|DRUG|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
48012427|NCT03863366|OTHER|Placebo|Lactose placebo tablet, encapsulated in white capsule
48012428|NCT03245021|DRUG|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
48012429|NCT02544893|DRUG|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
48012430|NCT02544893|DRUG|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
48012431|NCT02544893|DRUG|serum physiologic|21 ml serum physiologic is applied paravertebral space
48012432|NCT00896545|BEHAVIORAL|5-keys counseling|5-session small group intervention
48012433|NCT00896545|BEHAVIORAL|Lifestyle counseling|5-session small group behavioral intervention
48012434|NCT01314924|DIETARY_SUPPLEMENT|Dark chocolate|70% cocoa
48169455|NCT00761397|BEHAVIORAL|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
48169456|NCT00761397|OTHER|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
48169457|NCT00761397|OTHER|Questionnaire|Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
48700155|NCT02934880|OTHER|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
48700156|NCT02934880|OTHER|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
48700157|NCT04775862|DRUG|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
48700158|NCT00122876|PROCEDURE|Photodynamic therapy|
48169458|NCT04250688|DEVICE|Ekso Training with FES|
48371329|NCT00475657|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
48700159|NCT00122876|DRUG|Talaporfin Sodium|
48700160|NCT04221737|DEVICE|APRV. General Electric Healthcare Engstrom ventilator system|APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.
48700161|NCT04221737|DEVICE|Conventional. General Electric Healthcare Engstrom ventilator system|Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.
48700162|NCT01708265|OTHER|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
48012435|NCT00125827|DRUG|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
48371330|NCT00475657|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
48371331|NCT04274569|OTHER|NaF vanish|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
48371332|NCT04274569|OTHER|NaF-TCP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
48371333|NCT04274569|OTHER|NaF-CPP-ACP|A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
48012436|NCT06399328|DIAGNOSTIC_TEST|Surface Enhanced Raman Spectroscopy|Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
48012437|NCT04579913|OTHER|Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound|Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
48169459|NCT03494855|DEVICE|SyMRI Software|The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.
48169460|NCT01062971|DRUG|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
48169461|NCT02279992|DRUG|Vardenafil|
48169462|NCT02279992|DRUG|Carboplatin|
48169463|NCT03643497|DRUG|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
48169464|NCT02186314|DEVICE|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
48169465|NCT02186314|DEVICE|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
48012438|NCT06087172|DIAGNOSTIC_TEST|Six Minutes Stepper Test (6MST)|Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
48169466|NCT00566345|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
48169467|NCT00566345|OTHER|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
48169468|NCT04679740|DEVICE|Magmaris|MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
48169469|NCT05155709|DRUG|siremadlin|Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths
48169470|NCT05155709|DRUG|venetoclax|Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.
48169471|NCT05155709|DRUG|azacitidine|Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
48169472|NCT04766047|DRUG|Dexmedetomidine|Administration of dexmedetomidine intraoperatively
48169473|NCT05417464|OTHER|Use of flowchart|Use of flowchart for screening, monitoring and management of conductive disorders after TAVR
48169474|NCT03053115|DRUG|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
48169475|NCT03053115|DRUG|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
48169476|NCT03053115|DRUG|Placebos|Controls will take placebo two hours after dinner
48700163|NCT01708265|PROCEDURE|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
48700164|NCT01124123|DRUG|Bilastine|20 mg oral tablet
48700165|NCT01124123|DRUG|Bilastine|10 mg endovenous bilastine
48700166|NCT02407340|DRUG|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
48012439|NCT01040429|DRUG|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients \< 35 kg; 50 microgram (2 capsula) x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients \< 35 kg; 25 microgram (2 capsula) x 2/day for patients \> 35 kg."
48012440|NCT01040429|DRUG|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients \< 35 kg; 2 capsula x 2/day for patients \> 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients \< 35 kg; 1 capsula x 2/day for patients \> 35 kg"
48169477|NCT05515913|OTHER|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
48169478|NCT05515913|BEHAVIORAL|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
48169479|NCT05515913|OTHER|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
48169480|NCT05515913|OTHER|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
48169481|NCT05515913|OTHER|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
48169482|NCT05515913|OTHER|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
48012441|NCT04313920|OTHER|Nutritional Supplement|50 g Carbohydrate
48169483|NCT00710814|DRUG|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
48169484|NCT00710814|OTHER|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
48169485|NCT01393613|DRUG|OPC-34712|Higher dose tablet, once daily, for six weeks,
48169486|NCT01393613|DRUG|OPC-34712|Middle dose tablet, once daily, for six weeks
48700167|NCT02407340|DRUG|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
48700168|NCT02375737|BEHAVIORAL|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
48700169|NCT05955924|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily
48012442|NCT05891236|BIOLOGICAL|MAM01 1.5 mg/kg|1.5 mg/kg MAM01 will be administered via IV route.
48012443|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via IV route.
48012444|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via SC route.
48012445|NCT05891236|BIOLOGICAL|MAM01 10 mg/kg|10 mg/kg MAM01 will be administered via IV route.
48012446|NCT05891236|BIOLOGICAL|MAM01 40 mg/kg|40 mg/kg MAM01 will be administered via IV route.
48012447|NCT05891236|BIOLOGICAL|MAM01 450 mg|MAM01 will be administered via SC route.
48012448|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via SC route.
48700170|NCT05955924|DRUG|Placebo|Matching placebo capsule twice daily
48700171|NCT06556095|DRUG|Dexamethasone 4mg/ml solution|The study intervention dexamethasone solution (4mg/ml) is used to hydrate bone allograft.
48012449|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via IV route.
48012450|NCT05891236|OTHER|Control|No drug or placebo will be administered.
48169487|NCT01393613|DRUG|OPC-34712|Lower dose tablet, once daily, for six weeks
48169488|NCT01393613|DRUG|Placebo|Placebo, once daily, for six weeks
48700172|NCT04077346|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
48012451|NCT05891236|BIOLOGICAL|MAM01 600 mg|MAM01 will be administered via SC route.
48012452|NCT05891236|BIOLOGICAL|MAM01 900 mg|MAM01 will be administered via SC route.
48012453|NCT00040040|DRUG|Bupropion|
48012454|NCT01122199|DRUG|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
48012455|NCT05729620|DEVICE|Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
48012456|NCT01606085|BEHAVIORAL|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
48012457|NCT01606085|BEHAVIORAL|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
48012458|NCT01659424|RADIATION|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
48012459|NCT05107362|DIAGNOSTIC_TEST|untrained lay user performs investigational diagnostic test|Untrained lay users (parents/guardians of pediatric subjects or friends/family members of adult subjects) collect throat swab specimens and perform the investigational diagnostic test.
48012460|NCT06357988|PROCEDURE|Biopsy|Undergo tumor biopsy
48169489|NCT03408223|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
48371334|NCT03924570|BEHAVIORAL|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
48371335|NCT04113122|DIAGNOSTIC_TEST|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
48012461|NCT06357988|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48169490|NCT03408223|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
48169491|NCT02973477|DRUG|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
48169492|NCT02973477|DRUG|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
48169493|NCT00853021|BIOLOGICAL|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
48169494|NCT00853021|BIOLOGICAL|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
48700173|NCT04077346|OTHER|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
48700174|NCT01331382|DIETARY_SUPPLEMENT|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
48700175|NCT01331382|OTHER|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
48700176|NCT05711381|DRUG|HM15912|Drug: HM15912 Active 0.5mg/kg
48515918|NCT03377374|DIETARY_SUPPLEMENT|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
48012462|NCT06357988|PROCEDURE|Echocardiography|Undergo echocardiography
48012463|NCT06357988|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
48012464|NCT06357988|DRUG|Vismodegib|Given PO
48012465|NCT06481488|DRUG|E2086|E2086 tablets.
48169495|NCT03807453|OTHER|Microbiota|The scalp microbiota
48169496|NCT04617262|BEHAVIORAL|Remote Problem Management Plus|Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
48169497|NCT06003023|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to participants in both arms.
48169498|NCT06003023|BEHAVIORAL|Tailored Exercise Prescription|Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
48169499|NCT06003023|BEHAVIORAL|Healthy Lifestyle Education|Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
48169500|NCT06003023|BEHAVIORAL|Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior|Participants randomized to the CHD-PAL arm will receive coaching to: 1) change attitudes towards physical activity; 2) increase perceptions of other people's approval of physical activity; 3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance and will be accompanied by goal-setting.
48012466|NCT06481488|DRUG|Placebo|E2086 matched placebo tablets.
48012467|NCT03762603|DEVICE|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
48012468|NCT03600168|DEVICE|PuraStat®|Synthetic haemostatic material
48515919|NCT03377374|OTHER|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
48515920|NCT02784561|DRUG|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously \[i.v.\], days -10 to -8)
48012469|NCT06234371|BEHAVIORAL|Financial Incentive|The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
48012470|NCT05207813|DEVICE|Intracept Procedure|Intraosseous Basivertebral Nerve (BVN) Ablation
48012471|NCT03459196|DEVICE|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
48169501|NCT04793581|DEVICE|Atherectomy|Directional atherectomy of lesions below the knee.
48700177|NCT06608654|DEVICE|endoscope application|Intrauterine bronchoscopy application for fetal distress during labor
48700178|NCT02239835|DRUG|Tipranavir (TPV) low dose|
48700179|NCT02239835|DRUG|Tipranavir (TPV) high dose|
48700180|NCT02239835|DRUG|Ritonavir low dose|
48700181|NCT02239835|DRUG|Ritonavir high dose|
48700182|NCT02239835|DRUG|Saquinavir|
48700183|NCT05286658|BEHAVIORAL|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
48012472|NCT02240381|PROCEDURE|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
48012473|NCT02240381|PROCEDURE|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
48700184|NCT05286658|BEHAVIORAL|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
48700185|NCT05286658|BEHAVIORAL|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
48700186|NCT01390831|DEVICE|THERMOCOOL® Catheter|Catheter-based renal denervation
48700187|NCT01250184|OTHER|Physical therapy|Twelve sessions (3 per week)
48700188|NCT01250184|DRUG|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
48700189|NCT01250184|OTHER|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
48700190|NCT00002412|DRUG|Emivirine|
48700191|NCT00002412|DRUG|Hydroxyurea|
48012474|NCT02240381|OTHER|laboratory biomarker analysis|Correlative studies
48012475|NCT05255289|PROCEDURE|Urodynamic investigations before and after a trans-obturator tape protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.)
48012476|NCT05255289|PROCEDURE|Urodynamic investigations before and after a tension-free vaginal tape-obturator (TVT-O)|Urodynamic investigations (stated above.)
48012477|NCT05255289|PROCEDURE|Urodynamic investigations before and after a mini Arc protocol.|Urodynamic investigations (stated above)
48169502|NCT03683914|DRUG|Dinoprostone 3Mg Vaginal Tablet|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
48169503|NCT03683914|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
48515921|NCT02784561|DRUG|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
48515922|NCT02784561|DRUG|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
48700192|NCT00002412|DRUG|Stavudine|
48700193|NCT00002412|DRUG|Didanosine|
48012478|NCT05255289|PROCEDURE|Urodynamic investigations before and after an i-STOP mini adjustable sling protocol.|Urodynamic investigations (stated above)
48012479|NCT02052479|OTHER|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
48012480|NCT02644967|DRUG|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
48012481|NCT02644967|DRUG|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
48012482|NCT02502357|OTHER|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, \[the participant\] will feel very comfortable and \[the participant\] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, \[the participant\] will be hungry. \[The participant\] will be thirsty and urinate easily."
48012483|NCT05690295|OTHER|Prolonged resistance-type exercise training|All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
48012484|NCT01650181|DRUG|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
48012485|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
48012486|NCT01650181|DIETARY_SUPPLEMENT|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
48012487|NCT01650181|DRUG|Metformin|Patients with fatty liver treated with diet, exercise and metformin
48700194|NCT06452641|OTHER|Jones technique|Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
48700195|NCT06452641|OTHER|Cross-friction massage|Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
48700196|NCT03888040|OTHER|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
48700197|NCT05587231|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
48012488|NCT06408285|DRUG|TQC3927 powder for inhalation|TQC3927 is a targeted inhibitor.
48012489|NCT06408285|DRUG|TQC3927 powder for inhalation placebo|TQC3927 powder for inhalation placebo contains no active substance.
48012490|NCT00774488|OTHER|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
48700198|NCT05587231|DRUG|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
48700199|NCT02924207|OTHER|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
48515923|NCT02784561|DRUG|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
48700200|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
48700201|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment and fumigation|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
48700202|NCT01560637|DRUG|UT-15C (treprostinil diolamine)|UT-15C extended release oral tablet three times daily
48700203|NCT06607536|OTHER|calcium chloride surface treatment in mini implant|0.1M of Calcium Chloride were used to immersed the orthodontic mini implant
48012491|NCT05950945|DRUG|Trastuzumab Deruxtecan|Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
48012492|NCT04111497|DRUG|Glasdegib|Given PO
48700204|NCT06607536|OTHER|Acid Etched|Mini implant etched in Hydrochloric acid
48700205|NCT02731677|OTHER|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
48700206|NCT06608758|BEHAVIORAL|Electonic health record prompts with education|"1). A baseline audit will be conducted of uses of Current Procedural Technology (CPT) Evaluation and Management (E/M) codes and evaluate for differences in complexity of CPT E/M code use for patients with disabilities (PWD) aged 3-89 years old with specific disabilities versus patients aged 3-89 without the specific disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying CPT code differences will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DO, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of CPT E/M among PWD after implementation of algorithms and EHR prompts, alerts and decision support will be conducted post-intervention."
48700207|NCT06608758|OTHER|Standard of care|Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
48700208|NCT05905835|DEVICE|Synaptic Cryoablation System|The Synaptic Cryo Balloon must be used to isolate all targeted pulmonary veins. Entrance block will be confirmed in all targeted pulmonary veins (PVs) after a 20-minute waiting period or provocative testing with adenosine or isoproterenol. Any additional ablation in the LA beside PV isolation is not allowed in this protocol. Additional ablation of the cavo-tricuspid isthmus (CTI) with a conventional market-approved RF catheter is allowed only in case a typical atrial flutter is documented in prior patient history or occurs during the case (either spontaneously or inducible).
48700209|NCT01341808|BIOLOGICAL|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
48700210|NCT04633070|BEHAVIORAL|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
48700211|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
48700212|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
48700213|NCT03811925|PROCEDURE|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
48700214|NCT03811925|PROCEDURE|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
48700215|NCT00664339|BIOLOGICAL|Flu Vaccine|Single dose of Flu vaccine by year (1)
48012493|NCT03127228|OTHER|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
48012494|NCT03127228|DEVICE|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
48012495|NCT01885442|DEVICE|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
48700216|NCT00664339|OTHER|Conventional medical therapy for heart failure|According with the international guidelines
48700217|NCT01781650|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
48700218|NCT01781650|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
48700219|NCT01781650|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
48515924|NCT02784561|DRUG|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
48700220|NCT03474848|OTHER|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
48169504|NCT03614286|DIAGNOSTIC_TEST|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
48700221|NCT03474848|OTHER|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
48700222|NCT02403817|BEHAVIORAL|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
48700223|NCT02403817|BEHAVIORAL|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
48700224|NCT02403817|BEHAVIORAL|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
48700225|NCT02213848|DRUG|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
48700226|NCT02213848|DRUG|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
48700227|NCT02142322|DRUG|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
48700228|NCT05807477|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
48700229|NCT01396824|OTHER|No intervention|No intervention
48700230|NCT00255138|DRUG|Atomoxetine|
48700231|NCT00125463|DRUG|Candesartan cilexetil|
48700232|NCT00556608|DEVICE|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
48169505|NCT06134583|PROCEDURE|Superior cervical sympathetic block group|5 ml bupivacaine 0.5% will be injected around the internal carotid artery at the level of carotid bifurcation
48169506|NCT06134583|PROCEDURE|Stellate ganglion block group|5 ml bupivacaine 0.5% will be injected between the common carotid artery and longus capitis muscle at the level of C7 vertebra
48700233|NCT00556608|DEVICE|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
48700234|NCT01296711|BIOLOGICAL|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
48515925|NCT05771948|DEVICE|CCoat|CCoat is a new intra-articular (IA) injectable joint lubricant for patients suffering from joint pain developed by Liposphere LTD. CCoat is a liposomal boundary lubricant which coats the cartilage surface and protects it from further damage and degradation.
48515926|NCT00613652|DRUG|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
48515927|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Fumarate|Ferrous Fumarate - 300 mg
48515928|NCT06303531|DIETARY_SUPPLEMENT|Polysaccharide Iron|Polysaccharide Iron - 150 mg
48515929|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Ascorbate|Ferrous Ascorbate - 100 mg
48515930|NCT00039702|DRUG|[123] 5-I-A-85380|
48700235|NCT03718572|PROCEDURE|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
48700236|NCT04693273|OTHER|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
48700237|NCT06605898|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
48700238|NCT06605898|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
48700239|NCT00633633|OTHER|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
48700240|NCT00633633|BEHAVIORAL|Exercise Training|Exercise training 3 times a week.
48700241|NCT00633633|BEHAVIORAL|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
48700242|NCT05064176|OTHER|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
48700243|NCT05064176|PROCEDURE|Reconstructive lymphatic surgery|"For the procedure of LVA:~- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis"
48169507|NCT02654613|OTHER|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
48169508|NCT06320327|OTHER|Cannabidiol cream|Group 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
48169509|NCT06320327|OTHER|Placebo cream|Group 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
48169510|NCT04387903|PROCEDURE|Surgical re-interventionafter pancreaticoduodenectomy|Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
48169511|NCT05712655|OTHER|Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.|Assessment was done by surface electromyography (sEMG) device.
48169512|NCT04097691|DRUG|GLUCOSE 10%|subcutaneous glucose 0.5 ml per site around subcutaneous nerves
48169513|NCT02282059|DRUG|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
48169514|NCT00001941|BIOLOGICAL|daclizumab|
48169515|NCT05688098|DRUG|Irbesartan/Amlodipine High FDC|Irbesartan/Amlodipine High FDC
48169516|NCT05688098|DRUG|Irbesartan|Co-administration of Irbesartan and Amlodipine High
48169517|NCT05688098|DRUG|Amlodipine High|Co-administration of Irbesartan and Amlodipine High
48700244|NCT03350958|DIETARY_SUPPLEMENT|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
48700245|NCT03350958|OTHER|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
48700246|NCT06279364|DRUG|SKB264|IV Infusion
48700247|NCT06279364|DRUG|Paclitaxel|IV Infusion.
48169518|NCT00000398|BEHAVIORAL|Coping skills training|
48169519|NCT00000398|BEHAVIORAL|Physical exercise training|
48169520|NCT00000398|BEHAVIORAL|Coping skills training plus physical exercise training|
48169521|NCT01728207|DRUG|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
48515931|NCT02447601|DRUG|PEX168|200µg,injected subcutaneously,once a week.
48012496|NCT06569303|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
48169522|NCT04620031|DRUG|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
48169523|NCT04620031|DRUG|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
48012497|NCT06569303|BEHAVIORAL|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
48012498|NCT06089720|DEVICE|Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)|nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans \& lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.
48012499|NCT06089720|DEVICE|orthodontic molar tubes (control)|nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans \& lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
48012500|NCT02100072|DEVICE|Nd:YAG 1440 nm laser|
48012501|NCT00808938|DEVICE|MST|Magnetic Seizure Therapy
48169524|NCT06414759|DRUG|Acetazolamide|"Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily."
48169525|NCT06414759|DRUG|Metolazone|"Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily."
48169526|NCT06414759|DRUG|IV Loop Diuretics|IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
48169527|NCT05392062|OTHER|Pathophysiology of gas exchange|Exploration of pathophysiology of gas exchange
48169528|NCT02024750|BEHAVIORAL|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
48169529|NCT05404698|OTHER|Aerobic exercise|EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).
48169530|NCT05404698|OTHER|Control|CONT: participants will receive hemodialysis treatment only (usual care)
48169531|NCT00935714|OTHER|Exercise|
48169532|NCT00935714|OTHER|Exercise|
48169533|NCT05971277|DEVICE|Halo Wearable data device|A wrist-worn tracker with heart-rate monitor and pedometer (step counter), as well as a mobile app.
48169534|NCT02414555|DRUG|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
48012502|NCT03001128|DRUG|Antiretroviral treatment pause|Antiretroviral treatment pause
48371336|NCT04113122|DIAGNOSTIC_TEST|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
48700248|NCT06279364|DRUG|Nab-paclitaxel|IV infusion.
48169535|NCT02414555|DRUG|fluid bolus|
48700249|NCT06279364|DRUG|Capecitabine|Tablet. Oral route of administration.
48700250|NCT06279364|DRUG|Eribulin|IV infusion.
48700251|NCT06279364|DRUG|Carboplatin|IV infusion.
48700252|NCT06329063|DRUG|Vasopressin|Administration of vasopressin (20 IU) (oral spray)
48700253|NCT06329063|DRUG|Placebo|Administration of placebo (oral spray)
48169536|NCT02414555|DEVICE|oesophagus doppler (CardioQ)|
48169537|NCT02414555|DRUG|Normal Saline|
48169538|NCT02414555|DEVICE|arterial cannulation|
48169539|NCT02414555|DEVICE|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
48169540|NCT02414555|DRUG|Elo-Mel Isoton (balanced acetat-based infusate)|
48169541|NCT00347737|DRUG|teriparatide|Teriparatide
48169542|NCT05869383|DRUG|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
48169543|NCT05869383|DRUG|Placebo|Placebo 2x5 grams
48371337|NCT04130204|DRUG|DYV700|Proprietary transdermal delivery platform
48371338|NCT04130204|DRUG|Placebo|Vehicle transdermal delivery platform
48515932|NCT02447601|DRUG|Simvastatin|40mg,oral,two times
48700254|NCT00562497|DRUG|Prochymal®|Prochymal® intravenous infusion.
48700255|NCT00562497|OTHER|Placebo|Placebo-matching Prochymal® intravenous infusion.
48700256|NCT00562497|OTHER|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
48700257|NCT02986672|DIETARY_SUPPLEMENT|Calanus oil|Omega-3 oil in form of calanus oil
48700258|NCT02986672|OTHER|Medical Paraffin|2ml per day
48012503|NCT04655404|DRUG|Larotrectinib|"1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
48012504|NCT04655404|PROCEDURE|Larotrectinib surgical|"1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
48012505|NCT05702320|OTHER|the heating procedure|The patients will undergo a heating procedure.
48012506|NCT03728985|DEVICE|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
48012507|NCT05607992|BEHAVIORAL|Brief exposure-based CBT|The 5-week intervention is psychologist-guided and delivered via text-based interactive online treatment modules, where patients complete weekly homework assignments and have regular online contact with psychologists with training in CBT for cardiac disease. Key components include imaginal exposure of the ACS event, interoceptive exposure through at home physical activity that stimulats the CV system, exposure in-vivo to reduce avoided situations, and activities to enhance physical activity wellbeing. Labeling (i.e., describing cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure.
48012508|NCT02081495|DRUG|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
48012509|NCT02081495|DRUG|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
48371339|NCT04130204|DRUG|Colchicine 0.6 mg|Standard of care, 2 tablets (1.2 mg) loading dose followed by 1 tablet (0.6 mg) 1 hour later at onset of gout flare.
48700259|NCT04277858|DRUG|Docetaxel|Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
48700260|NCT01363921|DEVICE|HCO 1100|Dialysis treatment with HCO1100
48700261|NCT00459875|DRUG|sunitinib malate|
48012510|NCT02219815|BEHAVIORAL|Prehab Intervention|Pre-operative, structured exercise intervention.
48012511|NCT02484105|BEHAVIORAL|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
48012512|NCT02484105|BEHAVIORAL|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
48012513|NCT05970107|PROCEDURE|Axillary Lymph Node Dissection|"ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest."
48012514|NCT05970107|PROCEDURE|Axillary Reverse Mapping|Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
48012515|NCT05970107|PROCEDURE|Lymphaticovenous Bypass|Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
48012516|NCT00129233|DRUG|Valsartan|valsartan 80 to 160 mg daily
48012517|NCT00129233|DRUG|Amlodipine|Amlodipine 5 to 10 mg daily.
48012518|NCT04483804|COMBINATION_PRODUCT|Endocrine therapy|Endocrine therapy
48700262|NCT06607341|BEHAVIORAL|Multi-level, community-digital health promotion intervention|"Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building"
48700263|NCT01672463|DRUG|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
48012519|NCT03040297|DEVICE|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
48012520|NCT03040297|DEVICE|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
48012521|NCT03040297|DEVICE|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
48012522|NCT03429491|DIETARY_SUPPLEMENT|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
48012523|NCT03429491|DIETARY_SUPPLEMENT|Leucine-enriched protein|Leucine-enriched whey protein
48012524|NCT03429491|DIETARY_SUPPLEMENT|LC n-3 PUFA|LC n-3 PUFA
48012525|NCT00619697|DRUG|biphasic insulin aspart|
48012526|NCT00619697|DRUG|insulin glargine|
48515933|NCT00481403|BEHAVIORAL|Microarray analysis|Microarray analysis
48012527|NCT00619697|DRUG|metformin|
48012528|NCT00619697|DRUG|glimepiride|
48012529|NCT02880371|DRUG|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
48012530|NCT02880371|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
48012531|NCT03722329|DRUG|Eculizumab|Eculizumab Injection. 300 mg, single dose
48012532|NCT03794115|PROCEDURE|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
48012533|NCT02066857|DEVICE|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
48012534|NCT02066857|DEVICE|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
48012535|NCT05889052|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
48012536|NCT06050590|DEVICE|NeuroGlove|Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
48515934|NCT00481403|BEHAVIORAL|Microarray|Microarray
48515935|NCT00351403|DRUG|Ribavirin|Rebetol 200 mg: applied as hard capsule
48012537|NCT05362318|DRUG|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
48012538|NCT05362318|BEHAVIORAL|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
48169544|NCT05867914|DEVICE|Inhaled Nitric Oxide (iNO)|eNOfit system delivering iNO
48169545|NCT01462825|DIETARY_SUPPLEMENT|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
48169546|NCT01462825|DIETARY_SUPPLEMENT|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
48169547|NCT02879799|OTHER|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
48169548|NCT06193928|DRUG|Maralixibat|The recommended dosage is 380 mcg/kg once daily.
48169549|NCT03017313|DRUG|LHRH analogues|3-or 6-month formulations
48169550|NCT05710198|DRUG|Citicoline eye drops 2%|Eye drops containing Citicoline 2%
48169551|NCT05710198|DRUG|Placebo|Eye drops containing placebo matching product
48169552|NCT06295042|OTHER|BREAST-Q Questionnaire|Patient-reported outcome measure
48169553|NCT05132088|DRUG|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
48169554|NCT05132088|DRUG|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
48169555|NCT01220856|DRUG|Reparixin|Reparixin + immunosuppression
48700264|NCT05312632|DRUG|Safinamide Mesilate|Safinamide Mesilate oral tablets.
48700265|NCT06116539|DRUG|Cyanoacrylate|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
48700266|NCT06116539|PROCEDURE|Suture|After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
48700267|NCT06362655|BEHAVIORAL|Intervention|Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
48700268|NCT06543849|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
48700269|NCT03928938|DEVICE|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
48169556|NCT00357318|DRUG|sunitinib malate|Given PO
48169557|NCT00357318|BIOLOGICAL|bevacizumab|Given IV
48169558|NCT00357318|OTHER|pharmacological study|Correlative studies
48169559|NCT00357318|OTHER|laboratory biomarker analysis|Correlative studies
48169560|NCT04532983|PROCEDURE|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
48169561|NCT04532983|PROCEDURE|mesh placement without fixation|mesh placement in preperitoneal space without fixation
48169562|NCT02316392|DRUG|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
48169563|NCT02253745|DRUG|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
48169564|NCT02253745|DRUG|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
48169565|NCT02380638|DEVICE|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
48169566|NCT02696863|BEHAVIORAL|questionnaire|
48371340|NCT01503229|DRUG|Abiraterone Acetate|Given by mouth
48371341|NCT01503229|OTHER|Laboratory Biomarker Analysis|Correlative studies
48371342|NCT01503229|OTHER|Pharmacological Study|Correlative studies
48371343|NCT01503229|DRUG|Prednisone|Given PO
48169567|NCT02840071|OTHER|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
48169568|NCT01093170|DRUG|RNA-144101|Intravitreous administration of RNA-144101
48169569|NCT05705336|DRUG|Tranexamic Acid Oral Product|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
48169570|NCT05705336|DRUG|Placebo pills|Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
48169571|NCT00419419|DRUG|Topical AmphiMatrix with nitroglycerin (MQX-503)|
48169572|NCT00210964|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
48169573|NCT00210964|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
48169574|NCT02230423|PROCEDURE|Nasal surgery|
48169575|NCT00742014|DRUG|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
48169576|NCT03892928|DRUG|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
48169577|NCT06348745|DEVICE|ultrasound|5. Transthoracic ultrasound for both right and left diaphragm during inspiration and expiration.
48169578|NCT04538222|OTHER|physical activity|aerobic exercise, muscle strength and stretching, nutrition education
48169579|NCT03020056|DRUG|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
48169580|NCT03020056|PROCEDURE|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
48169581|NCT01086332|DRUG|Nelfinavir|1250 mg twice daily
48169582|NCT01086332|DRUG|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
48700270|NCT03236259|DIETARY_SUPPLEMENT|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
48700271|NCT03236259|DIETARY_SUPPLEMENT|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
48700272|NCT03236259|DIETARY_SUPPLEMENT|Placebo|Maltodextrin. Daily ingestion of capsule
48700273|NCT06375473|DRUG|Irinotecan liposome II combination therapy regimen|Irinotecan liposome II combination therapy regimen
48700274|NCT00724854|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
48700275|NCT00724854|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
48012539|NCT05362318|BEHAVIORAL|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
48700276|NCT06267469|DEVICE|Thermoplastic orthosis|The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
48169583|NCT00185796|PROCEDURE|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
48169584|NCT00185796|PROCEDURE|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
48169585|NCT03219307|COMBINATION_PRODUCT|NOVOCART 3D|Matrix associated autologous chondrocyte implant
48169586|NCT06271564|DRUG|Magnetite ZnO Composite Nanoparticles|Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
48169587|NCT06271564|DRUG|Topical Placebo Gel|Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
48371344|NCT03429569|DRUG|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
48700277|NCT03955224|DEVICE|Basic Oral Care + active LLLT|"* Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
48700278|NCT03955224|OTHER|Basic oral Care + inactive LLLT|"* Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
48700279|NCT03955224|OTHER|Basic Oral Care|Compliance with the Basic Oral Care only
48700280|NCT04774536|DRUG|CRISPR_SCD001|CRISPR_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
48012540|NCT05362318|BEHAVIORAL|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
48012541|NCT00222495|DRUG|quetiapine|
48012542|NCT00222495|DRUG|olanzapine|
48012543|NCT00222495|DRUG|risperidone|
48169588|NCT02786290|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
48169589|NCT05745181|BIOLOGICAL|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
48012544|NCT04301167|BEHAVIORAL|befriending|Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
48012545|NCT03417141|DRUG|Mechlorethamine 0.016% Top Gel|Valchlor, a 0.016% gel formulation of mechlorethamine. Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
48012546|NCT01772498|BEHAVIORAL|heart rate variability biofeedback|
48012547|NCT02956213|OTHER|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
48012548|NCT02956213|OTHER|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
48012549|NCT06027281|OTHER|Hamilton depression rating scale (HDRS)|Hamilton depression scale (HDRS) is the most commonly used instrument for assessing symptoms of depression.
48012550|NCT06027281|OTHER|Hamilton anxiety rating scale (HARS)|Hamilton anxiety rating scale (HARS) is a 14-item clinician-rated measure of the severity of perceived anxiety symptoms.
48012551|NCT06027281|OTHER|Mini international neuropsychiatric interview (MINI)|The Mini International Neuropsychiatric Interview (MINI) was designed as a brief structured diagnostic interview for the major psychiatric disorders in DSM-III-R, DSM-IV and DSM-5 and ICD-10.
48012552|NCT06027281|OTHER|Minnesota Multiphasic personality Inventory (MMPI)|The Minnesota Multiphasic Personality Inventory (MMPI) is used to assess personality traits and psychopathology.
48012553|NCT06027281|OTHER|The Symptom Check-List-90-R (SCL-90-R)|The Symptom Check-List-90-R (SCL-90-R) is a widely used psychological status symptom inventory.
48012554|NCT06027281|OTHER|Socioeconomic scale (A.El Gilany, A.El Wehady and M.El Wasify)|An Arabic version of the socioeconomic scale consisted of four dimensions, namely, level of education, employment, total family monthly income, and lifestyle of the family.
48012555|NCT06027281|OTHER|The female sexual function index (FSFI)|The female sexual function index is a brief multidimensional scale for assessing sexual function in women.
48012556|NCT05380661|PROCEDURE|Self-catheterization|Participants will perform self-catheterization, following the same routine for intermittent catheterization at home
48012557|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant blinded to time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting blood pressure and heart rate will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be draped and they will be not aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
48012558|NCT05380661|PROCEDURE|Catheterization performed by urology nurse, participant aware of time of procedure|Participant will undergo procedure to completely empty bladder; Participant in supine position, and resting BP and HR will be recorded for period of 5 minutes prior to catheterization; Perineum and genital areas will be visible to participant and they will be fully aware about exact timing of catheterization Catheterization will be conducted following standard clinic procedure by experience urology nurse.
48012559|NCT04835402|DRUG|Pembrolizumab|400mg every 6 weeks
48012560|NCT04835402|DEVICE|Irreversible electroporation|Percutaneous ablation of one liver metastasis
48012561|NCT05902390|DEVICE|hydrogel spacer|Randomly assigned to either the treatment group, who were injected with hydrogel spacer, or the control group, who were not injected with hydrogel spacer.
48012562|NCT05288205|DRUG|JAB-21822|KRAS G12C inhibitor
48012563|NCT05288205|DRUG|JAB-3312|SHP2 inhibitor
48012564|NCT04962568|DIAGNOSTIC_TEST|DTEE|endexpiratory diaphragm thickness in mm
48012565|NCT04962568|DIAGNOSTIC_TEST|DTEI|endinspiratory diaphragm thickness in mm
48012566|NCT04962568|DIAGNOSTIC_TEST|DEx|diaphragm excursion during rest and diaphragmatic excursion during maximal inspiration in mm
48012567|NCT05491707|OTHER|Music|Patients will choose a genre of music from the following list; pop, gospel, classical, jazz, and soul, at the preoperative visit. This will be played on disposable ear phones at a self-selected volume for the duration of the surgical procedure.
48012568|NCT05838729|DRUG|RiMO-301|"A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions."
48169590|NCT00207233|BEHAVIORAL|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
48700281|NCT02082080|OTHER|Education|
48012569|NCT02213276|OTHER|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
48515936|NCT00351403|DRUG|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
48700282|NCT02082080|OTHER|Social support|
48700283|NCT00791453|BEHAVIORAL|Education|Patients will receive literacy appropriate health information.
48700284|NCT03433833|DRUG|Digoxin|Digoxin oral route once daily for 24 weeks.
48700285|NCT01517165|DRUG|Pioglitazone|
48700286|NCT01517165|DRUG|Placebo|
48012570|NCT02213276|OTHER|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
48012571|NCT02087462|OTHER|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
48012572|NCT02087462|OTHER|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
48012573|NCT02087462|DRUG|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
48012574|NCT02087462|DRUG|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
48012575|NCT01969071|DRUG|Levosimendan|The effects of levosimendan on renal function
48012576|NCT01969071|DRUG|Dobutamine|Standard Inotropic agent
48012577|NCT06359405|BEHAVIORAL|drug safety simulation|"The intervention's purpose is to develop a simulation program to increase nursing students' crisis management skills regarding medication safety. This simulation program will provide students with the opportunity to develop skills in recognizing, evaluating, and effectively intervening in medication errors in real-world scenarios.~The simulation program will include interactive case scenarios, virtual patients, and simulation sessions led by an instructor providing feedback to students. Also, medicine Learning materials covering preventing, recognizing, and correcting errors will also be provided."
48012578|NCT01511380|BEHAVIORAL|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
48012579|NCT01511380|BEHAVIORAL|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
48012580|NCT03541746|BIOLOGICAL|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
48012581|NCT03541746|DEVICE|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
48169591|NCT00207233|BEHAVIORAL|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
48371345|NCT05749159|BEHAVIORAL|physiotherapy|New physical therapy: a disposable cup (soft cup) to take 1/3 cup of room temperature water and place it on a table. The patient takes a sitting or standing position. The middle finger of both hands press tightly against the nose to seal the nasal cavity. At the same time, press the ear screen with both hands to close the ear canal. After that, bite the cup with teeth (hands do not touch the cup), and drink up 1-2 mouthfuls of water.
48371346|NCT06384872|OTHER|Shoe Cushioning Position and Properties|The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
48371347|NCT02828098|DRUG|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
48012582|NCT04484246|OTHER|Prevalence of sarcopenia in older patient with prostate cancer|All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.
48012583|NCT05112497|OTHER|No intervention procedure|No intervention procedure
48012584|NCT01655836|RADIATION|Brachytherapy|Undergo high dose rate brachytherapy
48012585|NCT01655836|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
48012586|NCT01655836|PROCEDURE|Quality-of-life assessment|Ancillary studies
48012587|NCT01655836|OTHER|Questionnaire administration|Ancillary studies
48012588|NCT06202638|DEVICE|HemoSphere monitor with Acumen Hypotension Prediction Index Software|Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
48012589|NCT04877197|BEHAVIORAL|BA-HT|Behavioral Activation for depression delivered via home-based telehealth (BA-HT) will be implemented over 12, weekly 50-minute sessions via VA approved telehealth software.
48371348|NCT02828098|DRUG|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
48700287|NCT04880083|DIETARY_SUPPLEMENT|Commercially Available Starter Infant Formula|Study formula is provided in powder form and will be administered orally, ad libitum, via an infant feeding bottle and the volume of formula offered to the infant will be guided by the recommended feeding table for the age group or by physician recommendation. The amount consumed by the infant will vary by each infant's weight and appetite.
48700288|NCT03139981|DRUG|ASN002|Daily dose of ASN002 for 28 days
48012590|NCT04877197|OTHER|Standard Care|Best practices standard care delivery for post-CVD hospitalization as regularly implemented at the RHJ VAMC. Standard care may include all or some of the following: post-operative follow up, referral to VA primary care clinic at 1 month post-procedure, primary care visit with VA mandated assessments of pain and depression with referral for these conditions, referral to facility-based or home-based cardiac rehabilitation program as appropriate. All participants in this condition will be referred to mental health care. In addition, these participants will receive a weekly telephone call from project staff during which time supportive questioning about patient progress and general mood and recovery.
48700289|NCT03139981|DRUG|Placebo Oral Tablet|Placebo for ASN002 for 28 days
48371349|NCT02207127|PROCEDURE|MRI, DISE, and Surgery|MRI, DISE, and Surgery
48371350|NCT04790214|OTHER|CHF Patients|Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education
48700290|NCT03040011|DRUG|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
48700291|NCT03040011|DRUG|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
48700292|NCT03040011|PROCEDURE|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
48012591|NCT06382623|PROCEDURE|The percutaneous A1 pulley release|Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.
48371351|NCT05310227|DEVICE|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
48371352|NCT02699918|PROCEDURE|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
48012592|NCT06382623|OTHER|The peritendinous Betamethasone group|USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
48371353|NCT04282811|DRUG|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
48012593|NCT05667285|DEVICE|BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System|"The investigator will use visual inspection or QCA to assess the diameter of the artery and the length of the lesion during the operation to select the stent. For each lesion, the investigator will determine the number of stents to be used based on the actual situation. The length of the stent should cover from the proximal end of the normal reference vessel to the distal end of the normal reference vessel to ensure full coverage of the lesion.~For each lesion, the investigator will determine the number of stents to be used based on the actual situation. A second stent or more stents can be used when the first stent does not completely cover the lesion. In this case, the second stent or even more stents must be this investigational stent, unless it is clinically contraindicated. Please refer to the IFU operating procedure of the stent.~If the stents are placed overlappingly, the overlapping part should be at least 2 mm."
48012594|NCT02699905|OTHER|phlebotomy|phlebotomy
48012595|NCT02607488|DRUG|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
48012596|NCT02607488|DRUG|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
48012597|NCT02607488|DRUG|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
48012598|NCT02607488|DRUG|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]"
48012599|NCT04002674|DRUG|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
48012600|NCT04002674|DRUG|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
48012601|NCT01651572|DRUG|Cisatracurium|"Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
48012602|NCT01651572|DRUG|Rocuronium|"Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
48012603|NCT00594256|DRUG|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
48012604|NCT03208738|BEHAVIORAL|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
48012605|NCT03208738|BEHAVIORAL|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
48012606|NCT00000415|PROCEDURE|Physical activity|
48012607|NCT00000415|DRUG|Calcium supplement|
48169592|NCT00207233|PROCEDURE|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
48700293|NCT03040011|PROCEDURE|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
48169593|NCT01975636|DRUG|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
48169594|NCT00086723|BIOLOGICAL|recombinant tissue plasminogen activator|
48371354|NCT05368766|OTHER|VExUS score|The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler
48700294|NCT03040011|DRUG|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
48700295|NCT01683747|DRUG|Tranexamic Acid|
48700296|NCT01683747|DRUG|Control Intervention (Carrier fluid only)|
48700297|NCT01581034|DRUG|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
48515937|NCT03204682|DEVICE|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
48515938|NCT06277089|OTHER|Casts|According to level of scoliosis cast done and recast in a serial manner
48515939|NCT02442180|DRUG|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
48700298|NCT01581034|DRUG|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
48700299|NCT04883125|DRUG|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
48700300|NCT02482662|PROCEDURE|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
48700301|NCT00061815|BIOLOGICAL|cetuximab|400 mg/m2 IV
48700302|NCT00061815|DRUG|oxaliplatin|85 mg/m2 IV
48700303|NCT00061815|DRUG|leucovorin|200 mg/m2 IV
48700304|NCT00061815|DRUG|5-fluorouracil|400 mg/m2 IV
48700305|NCT00061815|DRUG|5-fluorouracil|600 mg/m2 IV
48700306|NCT00061815|BIOLOGICAL|cetuximab|250 mg/m2 IV
48700307|NCT01394692|PROCEDURE|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
48700308|NCT01394692|PROCEDURE|standard microsurgery|microsurgical tumor resection
48700309|NCT02511093|BEHAVIORAL|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
48700310|NCT06438016|BEHAVIORAL|Stress Management Training|The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
48700311|NCT00842153|DRUG|Clobetasol propionate foam|Topical Clobetasol propionate foam
48700312|NCT00842153|DRUG|Vehicle foam|Vehicle foam does not include the active drug.
48700313|NCT04445883|BEHAVIORAL|Feeding Assistance|Patients will be receiving assistance during mealtimes. This includes assistance by opening packages, listing/explaining the food products on the tray, providing encouragement and companionship during mealtimes and directly feed patients.
48700314|NCT02576041|DRUG|Bilastine|Bilastine tablets once a day for 7+3 days
48515940|NCT02442180|DRUG|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
48515941|NCT02442180|DRUG|placebo|equivalent to G-CSF doses
48700315|NCT02576041|DRUG|Placebo|Placebo tablets once a day during 7+3 days run in period
48700316|NCT04187508|DRUG|AZD8154 nebulizer suspension, 20 mg/mL|Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
48700317|NCT04187508|DRUG|Placebo|Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
48700318|NCT01787396|DRUG|Gemigliptin 50mg|
48700319|NCT01787396|DRUG|Placebo(Metformin)|
48700320|NCT01787396|DRUG|Metformin|
48700321|NCT01787396|DRUG|Placebo(Gemigliptin)|
48169595|NCT00086723|DRUG|captopril|
48700322|NCT04300517|DRUG|Three sachet of protein supplement to be mixed in with water used daily|Three sachet of protein supplement to be mixed in with water used daily
48700323|NCT05305833|BIOLOGICAL|Stem Cells|ATMP
48700324|NCT03979456|DRUG|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
48169596|NCT00219869|DRUG|Galantamine|
48169597|NCT02949856|DEVICE|Mallinckrodt, COVIDIEN|
48169598|NCT02949856|DEVICE|Endotracheal tube, Unomedica|
48371355|NCT05368766|DRUG|Diuretic Effect|Response to diuretic therapy
48515942|NCT02234492|DRUG|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
48515943|NCT04455165|PROCEDURE|Aortic valve replacement|Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
48515944|NCT03971786|BEHAVIORAL|Quality of life|Assessment of quality of life through measuring scales
48515945|NCT06577207|OTHER|Initial investigations for all cases|Initial investigations for all cases: 1. Pulse oximetry. 2. Complete blood count. 3. Electrolytes. 4. Kidney function test. 5. Random blood glucose 6. Other investigations ordered for certain cases according to clinical manifestation \& previous findings \> Lines of treatment will be recorded
48515946|NCT04677101|DIAGNOSTIC_TEST|Liver Biopsy|Fine-needle liver biopsy
48700325|NCT04714203|OTHER|sarcopenia assessment|evaluation of sarcopenia status
48700326|NCT06474520|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
48700327|NCT04573699|DEVICE|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
48700328|NCT04200196|PROCEDURE|"fabrique à histoire"|"Fabrique à histoire is a participatory entertainment method. Children of this arm going to create and listening a story before and during the venous puncture."
48700329|NCT04200196|PROCEDURE|Usual care|It is a passive entertainment method. Children of this arm going to do habitual activities before and during the venous puncture, like to sing, blow up a balloon, to play with recreational thing, etc.
48700330|NCT05723731|DEVICE|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
48169599|NCT04570254|DRUG|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
48169600|NCT04570254|DRUG|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
48700331|NCT05723731|DRUG|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
48700332|NCT05145764|DRUG|Suvorexant|Encapsulated suvorexant (matched for color, weight, and size)
48700333|NCT05145764|DRUG|Placebo|Encapsulated placebo (matched for color, weight, and size)
48700334|NCT02978547|DRUG|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
48169601|NCT04570254|DRUG|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
48700335|NCT02974959|DEVICE|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
48700336|NCT02974959|DEVICE|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
48012608|NCT04452188|OTHER|Normoxia (with controlled re-oxygenation)|"Participants will receive lower levels of oxygen during surgery and after surgery on the ventilator.~As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation with an FiO2 of 50% or less (unless clinically necessary) to achieve oxygen saturation and PaO2 goals that fit within the expected range for the participant's physiology:~1. Single ventricle patients (PaO2:35-45 and oxygen saturation 75%-85%)~2. Two ventricle patients (PaO2: 60-100 and oxygen saturation \>92%)"
48371356|NCT01240629|OTHER|laboratory biomarker analysis|Correlative study
48012609|NCT04452188|OTHER|Standard of care ventilation|As cardiopulmonary bypass is being weaned, anesthesia will initiate mechanical ventilation per standard protocols. Ventilation will be continued in the ICU and adjusted per standard goals per the intensivist.
48012610|NCT02665728|DRUG|BLI400 Laxative|
48012611|NCT04258839|DRUG|Brexpiprazole|Oral tablet; taken once daily
48012612|NCT02080767|DRUG|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
48012613|NCT04942080|BIOLOGICAL|CALR allele burden quantification|"* DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis"
48012614|NCT05882513|DRUG|Serplulimab and neoadjuvant therapy|"Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1."
48012615|NCT05882513|PROCEDURE|surgical resection of lung cancer|radical resection of lung cancer
48012616|NCT05882513|OTHER|Tumour will be Collected from participant. Fate of sample is Destruction after use|Tumour sample will be collected after surgery
48012617|NCT01632579|DRUG|LY3023703|Administered orally
48012618|NCT01632579|DRUG|Placebo|Administered orally
48012619|NCT01632579|DRUG|Celecoxib|Administered orally
48012620|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q4W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
48012621|NCT04630522|DRUG|Drug: JMT103- 120 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
48012622|NCT04630522|DRUG|Drug: JMT103- 180 mg SC Q8W|JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
48169602|NCT04570254|DRUG|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
48169603|NCT04570254|DRUG|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
48169604|NCT04815785|DEVICE|TaurusOne® transcatheter aortic valve replacement system|The TaurusOne® Transcatheter Aortic Valve System consists of an aortic valve, an associated delivery catheter and a loading system. The aortic valve consists of a self-expanding nitinol frame, a sealing skirt and valve leaflets, which are made of bovine pericardium. The delivery system is mainly composed of conical head, opacity ring, inner tube, top ring, middle tube, outer tube, booster rod, stress diffusion catheter, handle, etc. The outflow end of the aortic valve is provided with three fixing holes evenly distributed on the circumference on the top ring of the delivery catheter, so as to facilitate the installation, delivery and release of the aortic valve. Before the operation, the aortic valve needs to be installed into the sheath of the delivery catheter as required.
48169605|NCT02622464|OTHER|micro injection of SVF in vocal cords|
48371357|NCT01240629|OTHER|questionnaire administration|Correlative study
48371358|NCT01240629|DRUG|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
48371359|NCT04563845|DRUG|GSK3640254|GSK3640254 will be administered.
48012623|NCT04630522|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium Dietary Supplement: Vitamin D|Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
48012624|NCT01985984|RADIATION|Radiation alone|Radiation alone
48012625|NCT01985984|RADIATION|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
48012626|NCT02366481|DIETARY_SUPPLEMENT|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
48012627|NCT02366481|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
48012628|NCT02366481|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
48012629|NCT03560713|DEVICE|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
48012630|NCT03560713|OTHER|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
48012631|NCT02251665|OTHER|No intervention|a single-center prospective observational study
48012632|NCT03501797|BEHAVIORAL|Singing-based rehabilitation|The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
48012633|NCT03501797|OTHER|Standard care|Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
48012634|NCT00810121|DRUG|ketoprofen 100 mg|100 mg b.i.d. for 5 days
48012635|NCT00810121|DRUG|ketoprofen|150 mg b.i.d. for 5 days
48371360|NCT04563845|DRUG|Placebo|Placebo will be administered.
48371361|NCT04563845|DRUG|Moxifloxacin|Moxifloxacin will be administered.
48700337|NCT06453941|OTHER|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)|Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion) is a newly compiled routine developed on the foundation of the traditional Baduanjin (Eight Pieces of Brocades), which is a traditional Chinese medical health exercise consisted of eight movements to be practiced by oneself.
48700338|NCT02674919|OTHER|Nordic Hamstring|
48700339|NCT02674919|OTHER|Control|
48012636|NCT03427372|BEHAVIORAL|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
48012637|NCT05120544|BEHAVIORAL|EXTEND Plus|The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
48012638|NCT05120544|BEHAVIORAL|EXTEND|EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
48012639|NCT06097234|DEVICE|Pelex Upp|Biofeedback-mediated pelvic floor trainer. It captures contraction and relaxation of the pelvic floor muscles during use by the subject, and represents these contractions and relaxations back to the subject to improve conscious control of the muscle groups.
48012640|NCT06097234|BEHAVIORAL|Pelvic Floor Physical Therapy|A form of physical therapy whereby the subject is given instructions on how to identify the pelvic floor, how to coordinate the pelvic floor contractions and relaxations, as well as counseling on dietary changes that affect pelvic floor and pelvic organ function
48700340|NCT00616811|DRUG|vildagliptin|
48700341|NCT00616811|DRUG|Sitagliptin|
48700342|NCT06080464|OTHER|VERABAND information|The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
48700343|NCT01631747|BEHAVIORAL|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
48700344|NCT01631747|BEHAVIORAL|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
48700345|NCT06587334|PROCEDURE|SRP|SRP alone
48700346|NCT06587334|PROCEDURE|Nd: YAG Laser Assisted SRP|the patients receive SRP combined with Nd: YAG laser
48012641|NCT02690961|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
48012642|NCT02690961|DRUG|placebo multiple doses|
48012643|NCT03330535|BEHAVIORAL|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
48012644|NCT03330535|BEHAVIORAL|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
48012645|NCT03330535|BEHAVIORAL|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
48169606|NCT00984698|BEHAVIORAL|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
48169607|NCT00984698|BEHAVIORAL|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
48700347|NCT01186926|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
48700348|NCT03784599|DRUG|Trastuzumab emtansine|Infusion
48700349|NCT03784599|DRUG|Osimertinib|Tablet
48700350|NCT00712036|BEHAVIORAL|Interim|Methadone maintenance with emergency counseling only for up to 4 months
48012646|NCT03330535|BEHAVIORAL|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
48012647|NCT01815281|DEVICE|Foot Mechanical Stimulation (GONDOLA)|
48012648|NCT03833284|BEHAVIORAL|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
48700351|NCT00712036|BEHAVIORAL|Comprehensive|Methadone treatment with counseling as usual
48012649|NCT03833284|BEHAVIORAL|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
48012650|NCT05755828|BIOLOGICAL|ASCT+CAR-T Cell Infusion|CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
48012651|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with L-PRF|"Partially edentulous patients in need of a single-tooth extraction in the premolar region\[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.~L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.~After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
48012652|NCT05572242|PROCEDURE|Premolar extraction and socked preservation with Xenogenic bone and collagen membrane.|"Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.~In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.~The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .~After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration."
48012653|NCT00169637|DRUG|rhGH|
48012654|NCT03970434|OTHER|Venous blood collection|Venous blood collection
48012655|NCT03970434|OTHER|Peripheral blood collection|Peripheral blood collection
48012656|NCT00321035|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|
48169608|NCT01091519|OTHER|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
48169609|NCT01091519|OTHER|Toviaz(fesoterodine) without educational materials|No educational materials
48169610|NCT02554552|DRUG|YY1201 2ml|YY1201 2ml
48169611|NCT02554552|DRUG|Placebo 2ml|phosphate buffered saline 2ml
48515947|NCT03473015|DEVICE|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
48169612|NCT02554552|DRUG|YY1201 3ml|YY1201 2ml
48515948|NCT03576079|DEVICE|Laser therapy|epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
48700352|NCT00712036|BEHAVIORAL|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
48012657|NCT04444128|DIAGNOSTIC_TEST|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
48012658|NCT04991480|DRUG|ART4215|Participants will receive ART4215 by mouth daily in 21-day cycles.
48012659|NCT04991480|DRUG|Talazoparib|Talazoparib will be administered at a dose of 1 mg or 0.75 mg by mouth daily in 21-day cycles.
48012660|NCT04991480|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg or 300 mg by mouth daily in 21-day cycles.
48012661|NCT00021307|DRUG|carboplatin|
48012662|NCT00021307|DRUG|temozolomide|
48012663|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.
48012664|NCT05894850|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
48012665|NCT05894850|OTHER|Manually remind the patients|Medical staff remind patients manually .
48012666|NCT00215826|DRUG|Alferon LDO|
48012667|NCT00058331|BIOLOGICAL|epoetin alfa|
48012668|NCT00224211|BEHAVIORAL|Music|
48012669|NCT05063396|PROCEDURE|opioid free anesthesia|Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.
48012670|NCT05063396|PROCEDURE|Opioid-sparing anesthesia|patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
48169613|NCT02554552|DRUG|Placebo 3ml|phosphate buffered saline 3ml
48169614|NCT05656963|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
48169615|NCT02199249|DEVICE|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
48169616|NCT02199249|DEVICE|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
48169617|NCT04563247|DIAGNOSTIC_TEST|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
48169618|NCT06102798|DEVICE|Acunpuncture|"For the bilateral BL25, sterile disposable steel needles (Hwato, China; 0.3 mm×75 mm) will be inserted through adhesive pads to a depth of 50-70mm until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Hwato, China; 0.3 mm×40 mm) will be inserted through adhesive pads to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi."
48169619|NCT06102798|DEVICE|Sham acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
48169620|NCT02383407|DEVICE|Medtronic Deep Brain Stimulation|
48169621|NCT04438330|OTHER|Nickel sulfate hexahydrate|Patch test
48012671|NCT01479621|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
48012672|NCT01479621|DRUG|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
48012673|NCT01479621|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
48012674|NCT01479621|DRUG|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
48012675|NCT06052904|BEHAVIORAL|mHealth-delivered music breathing therapy|"Parental caregivers in the intervention group will receive individual home-based music breathing therapy comprising eight 1-hour weekly sessions for 2 months delivered through Zoom, by a qualified music therapist based on a standardized and validated music breathing instruction manual. The music breathing therapy comprises four breathing phases, namely Discovery Breathing, Triangular Breathing, Silent Breathing, and Music Breathing. In each session, participants will practice breathing for approximately 20-25 minutes in silence or with music in a sitting position. Thereafter, the participants will be instructed to create a Mandala drawing to visualize the effects of breathing on their mental body image, emotions, and thoughts. Each session will end with a debriefing session, which will serve to verbally integrate and reflect the participants' experiences and mental states."
48169622|NCT01046591|PROCEDURE|Polysomnography|Overnight sleep studies will be performed on all children.
48169623|NCT04241783|OTHER|descriptive|correlation
48012676|NCT06052904|BEHAVIORAL|Online educational modules|Participants in the control group will receive eight weekly online educational modules via email for 2 months. The content of the online educational modules will include medical information and advice about caring for a child who has been newly diagnosed with cancer.
48012677|NCT03112434|DRUG|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
48012678|NCT04677946|OTHER|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (containing about 9g of linoleic acid) 1 per day for 8 weeks
48012679|NCT05130190|DEVICE|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
48012680|NCT05230251|DRUG|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
48012681|NCT05230251|RADIATION|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
48012682|NCT04906434|DRUG|60mg ABSK-011capsule|Three 20mg capsules,QD for oral administration
48012683|NCT04906434|DRUG|120mg ABSK-011capsule|One 20mg capsule and one 100mg capsule,QD for oral administration
48012684|NCT04906434|DRUG|180mg ABSK-011capsule|One 100mg capsule and four 20mg capsules,QD for oral administration
48371362|NCT05951257|BEHAVIORAL|Personalized multimodal intervention involving hypnosis and/or music|"The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The musical modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself."
48371363|NCT02806804|BIOLOGICAL|one dose test vaccine|
48371364|NCT02806804|BIOLOGICAL|one dose commercially available trivalent influenza vaccine|
48371365|NCT02806804|BIOLOGICAL|One dose of Quadrivalent Influenza Virus Vaccine|
48515949|NCT03576079|DEVICE|anterior re-positioning splint|hard acrylic anterior re-positioning splint
48700353|NCT05952765|PROCEDURE|Immediate implant|"* Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap."
48700354|NCT00388388|DRUG|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
48700355|NCT05239793|OTHER|NJOY e-cigarette|NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
48700356|NCT05148013|OTHER|Pilates exercise|All participants will be given a basic introduction to the Pilates-based exercises and will be taught how to activate the core muscles, which entails isometric contraction of the transverses abdominis, pelvic floor, and multifidus muscles while exhaling during diaphragmatic breathing, before beginning the exercise program. The Pilates exercise program will consist of floor exercises on a mat, including the following exercises: one-leg kick, single leg stretch, shoulder bridge, the hundred, one leg circle, and swimming. All exercises progressed at three degrees of difficulty: basic, intermediate, and advanced. Depending on the patient's tolerance, each exercise will be done for 8-10 repetitions. The treatment plan included a five-minute warm-up, twenty minutes of exercise, and a five-minute cool-down.
48700357|NCT05148013|OTHER|PNF exercise|The PNF techniques utilized in the PNF exercise group will include a combination of isotonics, rhythmic stabilization, and repeated stretch. The exercises which will be performed are; (1) Trunk rotation in sitting position (1a) Chopping to the left and right and (1b) Lifting to the left and right, (2) Rolling activity (2a) Resistance to pelvic anterior patterns 2(b) Resistance to posterior patterns, 2(c) Combination of scapula and pelvis, 2(d) Combination of scapula and pelvis (i.e. asymmetrical exercise for trunk extension: the scapula moves in posterior elevation, the pelvis in posterior depression) and (3) Bridging activity (3a) Stabilize the pelvis in its neutral position, 3(b) Bridging lower trunk rotation and, 3(c) Bridging on two legs in the supine position.
48700358|NCT03471338|BEHAVIORAL|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
48012685|NCT04906434|DRUG|240mg ABSK-011capsule|Two 100mg capsules and two 20mg capsules,QD for oral administration
48012686|NCT04906434|DRUG|320 mg ABSK-011capsule|Three 100mg capsule and one 20mg capsule,QD for oral administration
48012687|NCT04906434|DRUG|400mg ABSK-011capsule|Four 100mg capsules,QD for oral administration
48515950|NCT03576079|DEVICE|inactive Laser therapy|sham Laser, with inactive beam
48012688|NCT00349596|DRUG|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
48012689|NCT00567775|DRUG|human insulin|
48012690|NCT00567775|DRUG|inhaled human insulin|
48012691|NCT03040258|OTHER|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
48169624|NCT04056741|COMBINATION_PRODUCT|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
48169625|NCT04526314|OTHER|observational|observational
48169626|NCT05644535|DIAGNOSTIC_TEST|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
48169627|NCT05644535|DIAGNOSTIC_TEST|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
48169628|NCT05644535|DIAGNOSTIC_TEST|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
48169629|NCT01830764|DRUG|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
48169630|NCT00153556|BIOLOGICAL|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
48515951|NCT04284072|DEVICE|Sensor Dot|Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
48700359|NCT03471338|BEHAVIORAL|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
48700360|NCT03650803|DEVICE|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
48012692|NCT01799356|DRUG|Moxifloxacin|daily 400 mg moksifloksasin
48169631|NCT04839614|OTHER|CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral|See arm description
48169632|NCT02589418|PROCEDURE|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
48169633|NCT02589418|PROCEDURE|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
48371366|NCT04493658|DIAGNOSTIC_TEST|Questionnaires|Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects
48371367|NCT04493658|DIAGNOSTIC_TEST|Tear fluid sampling|Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.
48371368|NCT04493658|DIAGNOSTIC_TEST|Impression Cytology|Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
48169634|NCT02589418|PROCEDURE|No Acupuncture|Control intervention: No needle insertion and manipulation
48169635|NCT02105727|BEHAVIORAL|Community-based salt reduction|
48515952|NCT00003602|DRUG|cytarabine|
48515953|NCT00003602|DRUG|etoposide|
48515954|NCT00003602|DRUG|idarubicin|
48515955|NCT00003602|DRUG|mitoxantrone hydrochloride|
48515956|NCT01632397|BEHAVIORAL|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
48515957|NCT01632397|BEHAVIORAL|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
48700361|NCT06527144|DRUG|3mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
48012693|NCT01799356|DRUG|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
48012694|NCT01799356|DRUG|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
48012695|NCT00763542|BEHAVIORAL|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
48012696|NCT00763542|BEHAVIORAL|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
48012697|NCT05226650|OTHER|Regular meal pattern|6 meals every day
48012698|NCT05226650|OTHER|Irregular meal pattern|It consists of consuming a different number of meals every day (between 3 and 9).
48515958|NCT00098618|DRUG|sorafenib tosylate|Given orally
48515959|NCT00098618|BIOLOGICAL|recombinant interferon alfa|Given orally
48515960|NCT00098618|OTHER|laboratory biomarker analysis|Correlative studies
48700362|NCT06527144|DRUG|6mg TQC3721 Suspension for Inhalation|TQC3721 suspension for inhalation is target inhibitor.
48700363|NCT06527144|DRUG|Placebo TQC3721 suspension for inhalation|Placebo without active drug substance.
48169636|NCT01317706|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
48169637|NCT01990664|DEVICE|senofilcon A|
48700364|NCT02350413|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
48700365|NCT02664168|DEVICE|Aquacel Ag Surgical Dressing|
48700366|NCT02664168|DEVICE|Single-Use Negative Pressure Wound Therapy (PICO)|
48700367|NCT02975011|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
48700368|NCT02975011|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
48700369|NCT02975011|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48700370|NCT02975011|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48700371|NCT02975011|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48700372|NCT02975011|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
48700373|NCT02975011|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
48700374|NCT02975011|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
48012699|NCT02897739|PROCEDURE|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
48012700|NCT02897739|BIOLOGICAL|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
48169638|NCT01990664|DEVICE|senofilcon A for Astigmatism|
48169639|NCT03742817|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
48169640|NCT05678010|DRUG|AZD1390|Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
48700375|NCT05864950|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
48700376|NCT00899197|DRUG|tamoxifen citrate|
48700377|NCT00899197|GENETIC|gene expression analysis|
48700378|NCT00899197|GENETIC|protein expression analysis|
48700379|NCT00899197|OTHER|immunoenzyme technique|
48700380|NCT00899197|OTHER|laboratory biomarker analysis|
48700381|NCT01543399|DRUG|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
48700382|NCT01543399|DRUG|Placebo|patients of the placebo group will use placebo one a day for 30 days
48700383|NCT01059682|DRUG|Dalcetrapib|Dalcetrapib 600 mg orally once daily
48700384|NCT01059682|DRUG|Placebo|Placebo orally once daily
48012701|NCT02897739|RADIATION|PET CT|PET study for metabolic pathway study
48012702|NCT02897739|BEHAVIORAL|Psychological assessment|Assessment by a psychologist
48012703|NCT03191539|DRUG|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
48012704|NCT05784701|DRUG|TSCV (Full-strength)|TSCV (Full-strength)
48169641|NCT05678010|RADIATION|Stereotactic Body Radiotherapy|Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.
48169642|NCT01335321|DRUG|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
48169643|NCT01335321|DRUG|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
48169644|NCT03184818|OTHER|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
48700385|NCT06608082|DIAGNOSTIC_TEST|indocyanine green injected intravenously|During the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence.
48700386|NCT04348149|DIETARY_SUPPLEMENT|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
48700387|NCT06265792|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
48012705|NCT05784701|DRUG|TSCV (Half-strength)|TSCV (Half-strength)
48012706|NCT05784701|DRUG|Typbar-TCV|Typbar-TCV
48012707|NCT05784701|DRUG|Placebo|Placebo
48012708|NCT01620606|BEHAVIORAL|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy \& Social Learning
48012709|NCT01620606|BEHAVIORAL|Education and Support|Education about the GI system, nutrition and food safety
48169645|NCT03951012|PROCEDURE|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
48700388|NCT06265792|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48012710|NCT03730935|DEVICE|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
48012711|NCT04652128|DRUG|Zoledronic acid|Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.
48515961|NCT04640415|DEVICE|Active Alarms|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds for more than a set duration. Continuous vital sign data will also be available to clinical staff.
48515962|NCT02693860|DRUG|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
48700389|NCT00949754|DRUG|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
48700390|NCT02076308|OTHER|Electroacupuncture and physical therapy|real electroacupuncture
48700391|NCT02076308|OTHER|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
48012712|NCT04652128|DRUG|Placebo|Subject will receive a single infusion of physiological saline 100mL intravenously.
48169646|NCT01330992|OTHER|Ocular light or darkness exposure|Ocular light or darkness exposure
48371369|NCT03738462|DEVICE|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. In addition, each Conformis Hip System device is shipped with an additional (optional) femoral stem (Cordera Femoral Stem).
48371370|NCT00610922|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
48371371|NCT04793126|DIAGNOSTIC_TEST|Urodynamic study|comparison between the urodynamic study of the patients before pelvic prolapse surgical repair and 6 months later.
48371372|NCT04701931|DEVICE|Maestro2 OCTA|The Maestro2 OCTA with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
48371373|NCT04701931|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
48371374|NCT04701931|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
48371375|NCT02133716|OTHER|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
48012713|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 10 days
48012714|NCT00910715|DRUG|doxycycline|doxycycline 100 mg bid, 15 days
48012715|NCT00910715|DRUG|placebo|control subjects without a history of Lyme borreliosis
48700392|NCT02478840|DRUG|Lamazym|recombinant human alpha-mannosidase
48700393|NCT00737568|DRUG|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
48012716|NCT03912233|DRUG|VX-121|Tablets for oral administration.
48012717|NCT03912233|DRUG|TEZ|TEZ tablet for oral administration.
48012718|NCT03912233|DRUG|VX-561|Tablets for oral administration.
48012719|NCT03912233|DRUG|TEZ/IVA|Fixed-dose combination tablets for oral administration.
48012720|NCT03912233|DRUG|IVA|Tablets for oral administration.
48012721|NCT03912233|DRUG|Placebo|Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
48012722|NCT05814120|BEHAVIORAL|BLS training program|BLS training program was in accordance with the 2020 AHA cardiopulmonary resuscitation (CPR) guidelines. The BLS training program adopts 4D teaching techniques, namely description (Describe), demonstration (Demo), implementation (Do), feedback (Debriefing).
48012723|NCT00816101|OTHER|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
48012724|NCT00816101|OTHER|Mepilex® Border Lite|Self-adherent foam dressing
48012725|NCT00816101|DEVICE|Adhesive Bandage|Adhesive bandage
48012726|NCT05854693|DEVICE|transCranial direct current stimulation|The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS
48012727|NCT05854693|DEVICE|sham stimulation|The sham group consisted of 10 daily 20-min sessions of sham stimulation
48012728|NCT05692141|DEVICE|ultrasound|For each lesion, ultrasound Elastography would be performed using a Linear probe ;
48012729|NCT02384824|PROCEDURE|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
48012730|NCT00571259|DRUG|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
48012731|NCT00571259|DRUG|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
48012732|NCT05956418|DRUG|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
48012733|NCT00589108|DEVICE|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
48012734|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
48012735|NCT00589108|DEVICE|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
48012736|NCT06453993|OTHER|Exhaled VOC breath test|To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
48012737|NCT01714310|DRUG|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
48012738|NCT01714310|DRUG|Placebo|Initiated at end of study week 4 and continued to study week 12.
48700394|NCT00737568|DRUG|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
48169647|NCT01940289|DEVICE|Algometric meter readings for perception of pain|
48169648|NCT02511340|DRUG|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
48169649|NCT00937456|PROCEDURE|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
48169650|NCT02921139|RADIATION|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
48515963|NCT02693860|DRUG|89Zr-J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
48700395|NCT00737568|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
48700396|NCT00737568|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
48700397|NCT00633373|DRUG|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
48700398|NCT01941979|DRUG|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
48700399|NCT04545723|DEVICE|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
48700400|NCT06386302|DRUG|Chidamide|30 mg/d orally twice-weekly
48700401|NCT06386302|DRUG|Venetoclax|100 mg d1 200 mg d 2 400 mg d3-d28 Orally
48700402|NCT06386302|DRUG|azacitidine|75 mg/m 2 /d subcutaneous injection or IV d1-d7
48012739|NCT01714310|DRUG|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
48012740|NCT01163604|DRUG|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
48012741|NCT01163604|DRUG|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
48012742|NCT05585216|DRUG|platelet-rich plasma|intra-articular combination injections of platelet-rich plasma and hyaluronic acid or intra-articular combination injections of PRP combined with leg swing and quadriceps strengthening exercise
48012743|NCT00226616|DRUG|Zinc|
48012744|NCT05082194|PROCEDURE|balance with open and closed eyes|"The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated."
48169651|NCT02921139|PROCEDURE|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
48169652|NCT05194228|BEHAVIORAL|Ecologial Momentary Assessment settings|Various settings for ecological momentary assessments
48515964|NCT05149560|DRUG|Ticagrelor 90mg|All patients will be prescribed ticagrelor as monotherapy
48700403|NCT05828394|PROCEDURE|DFGG|Depithelised free gingival graft harvesting technique
48700404|NCT05828394|PROCEDURE|SCTG|Subepithelial connective tissue graft harvesting technique
48700405|NCT03479294|DRUG|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
48700406|NCT02901054|DRUG|Ondansetron|A single 15-min intravenous infusion of ondansetron
48012745|NCT02970838|OTHER|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
48012746|NCT03226067|DRUG|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
48012747|NCT03226067|DRUG|Placebo oral capsule|Matching capsules.
48012748|NCT03117387|DIAGNOSTIC_TEST|Measurements of the level of neuromuscular blockade|Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
48012749|NCT04897542|DRUG|Gallium-68 NODAGA-JR11|Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.
48169653|NCT04402203|DRUG|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
48169654|NCT04402203|DRUG|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
48169655|NCT00435981|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
48700407|NCT01741025|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
48700408|NCT01741025|OTHER|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
48700409|NCT01113008|PROCEDURE|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
48700410|NCT01113008|PROCEDURE|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
48169656|NCT01488838|DRUG|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
48700411|NCT00199251|DRUG|RUPATADINE|
48169657|NCT01488838|RADIATION|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
48700412|NCT06153420|DRUG|CIN-103|CIN-103 BID
48700413|NCT06153420|DRUG|Placebo|Placebo for CIN-103 BID
48700414|NCT00123370|DRUG|Modafinil|
48169658|NCT02738957|BEHAVIORAL|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
48169659|NCT02625129|OTHER|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
48371376|NCT02133716|BEHAVIORAL|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
48012750|NCT05040711|BEHAVIORAL|Mindfulness Coach|"This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills."
48169660|NCT02702336|BEHAVIORAL|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
48169661|NCT05042362|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
48169662|NCT05042362|DRUG|Placebo|Matching placebo orally once daily
48169663|NCT06454318|DIAGNOSTIC_TEST|Wellue O2 ring|Wellue O2 ring wore when doing the polysomnography
48169664|NCT05851040|OTHER|Observation study|Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug
48169665|NCT00233389|DRUG|Rebamipide|
48169666|NCT02127489|DRUG|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
48169667|NCT03565692|BIOLOGICAL|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~* Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~* Separation of the pellet and supernatant, stored at -20 ° C until testing~* Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~* Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~* Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~* Pseudomonas aeruginosa load measured by qPCR"
48169668|NCT03565692|BIOLOGICAL|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
48169669|NCT05306522|OTHER|Spinal stabilization exercise|The effects of telerehabilitation based spinal stabilization exercise in chronic stroke patients will be investigated.
48169670|NCT05950776|BIOLOGICAL|MVA-SARS-2-S|Vaccination with MVA-SARS-2-S
48169671|NCT05950776|OTHER|Placebo|Placebo
48371377|NCT03037138|OTHER|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
48371378|NCT01002846|PROCEDURE|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
48371379|NCT05626556|OTHER|SAVE system|The SAVE system will be implemented in end users' homes. Flood sensors will be installed in the bathroom and kitchen, presence sensors in the living room and bedroom, and the contact sensor will be installed at the entrance door. For the best user experience, the installation of the required software (for the sensors kit and the smartwatch) was done on the users' own smartphones. Thus, at the end of the installation, users will have the Aqara Home System in their homes (5 sensors and a sensor hub), a Samsung smartwatch and a SAVE Sensors Adapter, all of which are connected to a router with unlimited internet access.
48371380|NCT01308385|OTHER|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
48700415|NCT06428058|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing the effects on sexual health knowledge, attitudes, and sexual history and counseling skills at medium (6-) and long-term (12 and 24 months) follow-up. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, lesbian, gay, bisexual, and transgender (LGBT) and sexual violence, clinical skills training, ethics, and community resources and cultural considerations."
48700416|NCT01551576|DEVICE|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
48012751|NCT05040711|BEHAVIORAL|Active Comparator|A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
48012752|NCT05281731|DEVICE|Sonobiopsy|Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy
48700417|NCT02585024|DRUG|Cytisine|
48700418|NCT02994472|RADIATION|Gastric emptying scintigraphy using 99mTc-DTPA|
48700419|NCT06058247|DIETARY_SUPPLEMENT|Active nutritional supplementation|"The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%."
48700420|NCT06058247|DIETARY_SUPPLEMENT|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
48700421|NCT04418869|OTHER|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
48700422|NCT00252694|DRUG|candesartan|32 mg oral tablet
48012753|NCT05281731|PROCEDURE|Research blood|No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)
48012754|NCT05281731|GENETIC|Cancer Personalized Profiling|Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.
48012755|NCT05281731|DEVICE|Definity®|Being used off-label in this trial
48012756|NCT01000051|DRUG|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
48169672|NCT02316847|DRUG|diazepam nasal spray|
48012757|NCT01000051|DRUG|Placebo|Once a day, orally for 8 weeks.
48012758|NCT00000735|DRUG|Ampligen|
48012759|NCT03117881|BEHAVIORAL|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
48012760|NCT03117881|BEHAVIORAL|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
48169673|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
48169674|NCT02654899|OTHER|Placebo|Placebo
48169675|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
48700423|NCT05195957|PROCEDURE|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
48700424|NCT05195957|PROCEDURE|Open transversus abdominis release operation|Original open TAR using midline incision.
48169676|NCT00547183|DRUG|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
48169677|NCT00547183|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
48012761|NCT03117881|BEHAVIORAL|rDirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
48169678|NCT00547183|DRUG|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
48169679|NCT01871168|PROCEDURE|TAP block|Infusion of 0.5-1% lidocaine
48012762|NCT03074721|DEVICE|PCI Suite Software|PCI with PCI Suite Software
48371381|NCT00021476|BEHAVIORAL|Behavioral treatments|
48371382|NCT00021476|BEHAVIORAL|Physical therapy|
48012763|NCT03074721|OTHER|conventional PCI|conventional PCI without PCI Software
48012764|NCT00808600|BEHAVIORAL|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
48012765|NCT00808600|BEHAVIORAL|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
48169680|NCT01871168|PROCEDURE|Sham TAP block|Infusion of saline
48371383|NCT02646501|DRUG|Antiarrhythmic drug|Antiarrhythmic drug
48371384|NCT02646501|PROCEDURE|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
48371385|NCT02974023|DEVICE|Pain Gear|PainGear \[ActiPatch®\] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
48700425|NCT03447899|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
48700426|NCT00415337|PROCEDURE|endobronchial ultrasound|EBUS
48169681|NCT01525641|DRUG|Mirapex LA|Pramipexole Hydrochloride Hydrate
48169682|NCT00325546|DRUG|Rimonabant (SR141716)|
48169683|NCT00325546|DRUG|Placebo|
48169684|NCT00522470|DRUG|rosiglitazone|
48169685|NCT00840671|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
48169686|NCT00840671|DRUG|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
48169687|NCT00246610|DRUG|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
48371386|NCT04948606|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
48371387|NCT01474291|BIOLOGICAL|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
48371388|NCT03313297|DRUG|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
48371389|NCT03313297|DRUG|Placebo|Matching placebo
48700427|NCT03136497|DRUG|400mg ABT-199|Oral dose daily until disease progression
48169688|NCT00664456|DRUG|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
48169689|NCT00664456|DRUG|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
48169690|NCT00664456|RADIATION|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
48169691|NCT00478322|DRUG|Placebo|Matching placebo of 100 mg BID
48169692|NCT00478322|DRUG|INCB013739|INCB013739 100 mg BID
48169693|NCT05729945|BEHAVIORAL|home visiting|The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
48169694|NCT01435798|DRUG|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
48371390|NCT04102761|PROCEDURE|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
48371391|NCT01471197|BIOLOGICAL|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
48371392|NCT01471197|BIOLOGICAL|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
48169695|NCT06219681|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the repetitive negative thinking (RNT) related brain functional connectivity.
48169696|NCT06219681|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
48169697|NCT02475018|DIETARY_SUPPLEMENT|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
48169698|NCT02475018|DIETARY_SUPPLEMENT|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
48169699|NCT03065478|DIETARY_SUPPLEMENT|OnLife|Daily dosing of dietary supplement OnLife
48012766|NCT00808600|BEHAVIORAL|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
48012767|NCT00808600|BEHAVIORAL|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
48012768|NCT04863976|OTHER|Dynamic stretching|Dynamic movements of the joints controlled by the quadriceps muscle (hip and knee)
48700428|NCT03136497|DRUG|Ibrutinib|Oral dose daily until disease progression
48700429|NCT03136497|DRUG|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
48700430|NCT03136497|DRUG|800mg ABT-199|Oral dose daily until disease progression
48012769|NCT04863976|OTHER|Passive stretching|passive stretching of the quadriceps muscle
48169700|NCT01967719|OTHER|mTHS 2.2|Single use of mTHS 2.2
48169701|NCT01967719|OTHER|mCC|Single use of subject's own mCC
48169702|NCT01967719|OTHER|NNS|Single administration of 1 mg of nicotine
48169703|NCT05964751|DIAGNOSTIC_TEST|lipid profile|measuerments of lipid profile parameters to detect hyperlipidemia
48700431|NCT06146751|DRUG|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
48700432|NCT06364813|OTHER|COMPANION eHealth Program|COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
48700433|NCT01257230|DRUG|tiotropium Respimat low dose|IMP
48700434|NCT01257230|DRUG|placebo Respimat|placebo representing comparator
48700435|NCT01257230|DRUG|tiotropium Respimat high dose|IMP
48700436|NCT03615872|DEVICE|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
48012770|NCT04863976|OTHER|Self-stretching|Self-stretching of the quadriceps muscle
48169704|NCT05964751|DIAGNOSTIC_TEST|fasting blood suger|measurment of fasting blood suger to detect hyprerglicemia
48169705|NCT03447977|OTHER|cervical|cervical spine manual therapy
48169706|NCT03447977|OTHER|thoracic|thoracic spine manual therapy
48169707|NCT03447977|OTHER|exercises|exercises for pain
48169708|NCT04210804|DIETARY_SUPPLEMENT|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
48169709|NCT01989949|DRUG|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
48169710|NCT01088178|DEVICE|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
48169711|NCT05319132|OTHER|Adult subjects with ROSAH syndrome|The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
48169712|NCT05600998|DRUG|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
48169713|NCT01183013|DRUG|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
48169714|NCT01183013|DRUG|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
48169715|NCT01183013|DRUG|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
48700437|NCT00167141|DRUG|injection of hormonal male contraceptive|testosterone injections 4 times
48700438|NCT03174405|DRUG|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
48700439|NCT06608498|BEHAVIORAL|SPARK Coping|SPARK Coping is a single-session intervention providing psychoeducation and structured practices related to stigma reduction, cognitive restructuring, behavioral activation, and effective coping. It is a self-guided website powered by research data capture software.
48700440|NCT02559323|OTHER|Survey|
48515965|NCT04587726|BEHAVIORAL|Girl's room video|"Girls Room, a body image mini-series, developed in collaboration with Lena Waithe, Dove and CAR.~Video content was informed by empirical evidence related to body image prevention and intervention. The series consists of five, 3-minute videos.~The videos follow the lives of a 5 best friends, and each video targets a key risk factor for body image:~1. Appearance comparison~2. Body appreciation~3. Body talk~4. Body functionality~5. Appearance teasing \& bullying~6. Appearance focus~The five videos aired on Instagram TV (IGTV) in March 2020."
48012771|NCT01539382|PROCEDURE|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow \>2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
48012772|NCT05493267|DRUG|Vγ2Vδ2 T lymphocyte-based immunotherapy|Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
48012773|NCT05493267|DRUG|Treatment regimens for MDR-TB|Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
48012774|NCT01422434|DRUG|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
48012775|NCT01422434|DRUG|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
48012776|NCT01422434|DRUG|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
48012777|NCT01641588|BEHAVIORAL|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
48012778|NCT06664736|BEHAVIORAL|Exercise|The exercise group performed a home-based exercise program consisting of aerobics 3 days a week with videos and strengthening and stretching exercises 2 days a week with infographics, for 8 weeks.
48515966|NCT04587726|OTHER|Control video - Chicken Girls|Chicken Girl's Episode - appearance neutral episode matched for target audience and video length
48700441|NCT02429219|DRUG|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
48012779|NCT06664736|BEHAVIORAL|Physical activity|The control group was advised to increase physical activity
48700442|NCT02429219|PROCEDURE|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
48012780|NCT03962972|OTHER|Frailty evaluation|"It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-ietm brief geriatric assessment (BGA), Program of Research on the Integration of Services for the Maintenance of Autonomy (PRISMA-7) and b) two other frailty index developed over the COVID-19 pandemic which are Évaluation SOcio-GÉriatrique (ESOGER) and CriblAge et REcommandations (CARE)."
48012781|NCT05211622|DRUG|1. alpha acid lipoic - tables|600 mg/die per os from 7 days before the beginning of chemotherapy and continue for other 4 days
48169716|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
48700443|NCT02429219|PROCEDURE|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
48012782|NCT05211622|DRUG|2. ozonated oil - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 2 weeks
48012783|NCT05211622|DRUG|3. chlorhexidine 0,2% - mouthwash|1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
48169717|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
48169718|NCT01183013|DRUG|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
48169719|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
48169720|NCT02831998|DRUG|ZuraPrep|Apply topically.
48169721|NCT02831998|DRUG|ChloraPrep|Apply topically.
48169722|NCT02831998|DRUG|ZP Vehicle|Apply topically.
48169723|NCT01052389|DRUG|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
48169724|NCT01052389|DRUG|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
48515967|NCT00387777|DRUG|Patch with centrally acting analgesic|
48371393|NCT05443802|DRUG|Insulin 0.05 IU/kg/h|In the experimental arm, the patients will be given an insulin dose of 0.05 IU/kg/h.
48515968|NCT00387777|DRUG|Transtec(R) PRO (buprenorphine)|
48515969|NCT05133674|DRUG|Tamoxifen 20 mg|i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
48515970|NCT01756430|DRUG|Carvedilol SR 32mg, QD|"* Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
48515971|NCT01756430|DRUG|Carvedilol SR 64mg, QD|"* Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
48515972|NCT01756430|DRUG|Carvedilol IR 25mg, QD|"* Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
48700444|NCT03896724|BIOLOGICAL|R21 adjuvanted with 25mcg Matrix-M|Vaccine
48700445|NCT03896724|BIOLOGICAL|Rabies Vaccine|Vaccine
48515973|NCT01756430|DRUG|Carvedilol IR 25mg, BID|"* Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks."
48700446|NCT03896724|BIOLOGICAL|R21 adjuvanted with 50mcg Matrix-M|vaccine
48700447|NCT05475483|DRUG|SOM3355 capsules|Treatment will be blind for the whole duration of the study.
48515974|NCT02336646|DRUG|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
48515975|NCT02336646|DRUG|Normal saline|
48515976|NCT01517958|OTHER|Respiratory Distress Group|Diagnostic lung ultrasound.
48515977|NCT01517958|OTHER|Control Group|Lung ultrasound
48515978|NCT02909244|BIOLOGICAL|Biological sampling|Biological sampling
48012784|NCT05211622|DRUG|4. sodium bicarbonate 5% solution - mouthwash|1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
48012785|NCT01769157|DRUG|L-carnitine|
48012786|NCT01769157|DRUG|Placebo|
48012787|NCT03246958|DRUG|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
48012788|NCT03246958|DRUG|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
48169725|NCT01052389|DRUG|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
48169726|NCT02657421|PROCEDURE|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
48169727|NCT02846935|DRUG|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.
48169728|NCT02846935|DRUG|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
48169729|NCT03524768|DIAGNOSTIC_TEST|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
48515979|NCT02368314|DRUG|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
48515980|NCT06093230|DRUG|Deuremidevir Hydrobromide Tablets|JT001 single dose, 0.3g
48700448|NCT05475483|DRUG|Placebo capsules|Treatment will be blind for the whole duration of the study.
48700449|NCT05625789|BEHAVIORAL|Postural control (weight shift) training|Visual cues to improve amplitude of weight shift prior to initiating gait.
48700450|NCT05625789|BEHAVIORAL|Steady state gait training|Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
48700451|NCT03932864|BIOLOGICAL|MGTA-145|MGTA-145 will be given in various doses intravenously
48700452|NCT03932864|BIOLOGICAL|plerixafor|240 µg/kg subcutaneously
48700453|NCT03932864|BIOLOGICAL|Placebo|Placebo will be given in various doses intravenously
48700454|NCT05804487|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
48700455|NCT00190021|DRUG|donepezil|
48700456|NCT01932229|DRUG|Afatinib treatment|
48700457|NCT05128513|DEVICE|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
48700458|NCT01220973|DRUG|atorvastatin calcium|
48012789|NCT04708197|DEVICE|rTMS (repetitive transcranial magnetic stimulation )|applying high frequency TMS over the damaged hemisphere in chronic post stroke aphasic patients
48012790|NCT00240422|DRUG|Telmisartan|
48012791|NCT00240422|DRUG|Ramipril|
48169730|NCT01748123|DRUG|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
48169731|NCT01748123|DRUG|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
48169732|NCT04397614|OTHER|mHealth Assessments|Daily symptom tracker
48169733|NCT03697083|OTHER|Reminders Through Association|Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
48169734|NCT03697083|OTHER|Active Control|Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
48169735|NCT03697083|OTHER|Baseline Control|Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
48169736|NCT02955706|DRUG|Acetyl-L-Carnitine|TID
48515981|NCT02446756|OTHER|acupuncture|
48515982|NCT02446756|OTHER|physiotherapy|
48515983|NCT01457937|DRUG|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
48515984|NCT04960293|PROCEDURE|uterine artery embolization using spherical gelfoam|Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
48700459|NCT01220973|DRUG|celecoxib|
48700460|NCT01220973|OTHER|laboratory biomarker analysis|
48700461|NCT00150319|DRUG|Vfend®; I.V.|
48169737|NCT02955706|DRUG|Placebo of Acetyl-L-Carnitine|TID
48700462|NCT01679548|PROCEDURE|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
48700463|NCT01679548|PROCEDURE|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
48700464|NCT00625196|DRUG|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
48700465|NCT00625196|DRUG|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
48700466|NCT00625196|DRUG|Vilanterol|Vilanterol will be available as dry powder inhaler.
48700467|NCT00625196|DRUG|Placebo|Placebo will be supplied as dry powder inhaler.
48700468|NCT03831295|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IT or IV
48700469|NCT03831295|DRUG|TLR9 Agonist SD-101|Given IT
48169738|NCT02867111|DEVICE|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
48700470|NCT03051880|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
48700471|NCT03051880|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
48700472|NCT03695614|OTHER|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
48700473|NCT06107842|BEHAVIORAL|Gerofit exercise|Individualized exercise prescription as well as a group exercise class based on physical function assessments offered 3x/week
48700474|NCT06107842|BEHAVIORAL|Health education|Scheduled monthly in-person health education discussion sessions covering 12 different health topics not including a physical activity/exercise promotion session
48700475|NCT01424891|DRUG|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
48700476|NCT01424891|DRUG|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
48700477|NCT01424891|DRUG|Placebo|treatment with placebo over 8 weeks
48700478|NCT06503497|BIOLOGICAL|chemotherapy sequential CAR-NK cell infusion|In each chemotherapy cycle, patients received 2 intravenous infusions of CAR-NK on days 2 and 3 after each chemotherapy was discontinued.
48169739|NCT02867111|OTHER|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
48169740|NCT02867111|PROCEDURE|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
48169741|NCT05236140|DEVICE|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
48700479|NCT01461265|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
48700480|NCT02821442|DEVICE|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
48700481|NCT02821442|DEVICE|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
48169742|NCT02201771|DRUG|Aspirin|
48700482|NCT06176794|DRUG|Immediate release torsemide 20mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
48012792|NCT05811104|DEVICE|Sequential bilateral theta burst stimulation|Three sessions of active or sham bilateral TBS will be delivered daily for 10 days in 2 weeks (no session on weekend) with a total of 30 sessions for each patient. Daily low intensity (90% resting motor threshold) bilateral sequential continousTBS ( cTBI) will be applied first on the right DLPFC (1800 pulses) and then intermittent TBS (iTBS)on the left DLPFC (1800 pulses) with an intersession interval of 60 minutes. We will adopt 1800 pulse per session based on the previous studies. Patients will receive a stimulation of 3600 pulses a session, 10,800 pulses a day and 108,000 pulses in total. After the study, sham group will receive active stimulation following the same protocol
48012793|NCT00602303|DRUG|Torsemide|
48012794|NCT00451282|BEHAVIORAL|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
48012795|NCT04505020|OTHER|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
48012796|NCT04505020|OTHER|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
48012797|NCT01045226|PROCEDURE|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
48515985|NCT04960293|PROCEDURE|uterine artery embolization using tri-acryl gelatin microsphere|Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
48515986|NCT03239847|OTHER|EndoPhys Sheath and Radial Arterial Line|
48515987|NCT03239847|OTHER|EndoPhys Sheath|
48515988|NCT00118326|BIOLOGICAL|filgrastim|
48515989|NCT00118326|PROCEDURE|allogeneic bone marrow transplantation|
48012798|NCT01045226|OTHER|Quality-of-Life assessment|Quality of Life Assessment
48012799|NCT01045226|OTHER|Questionnaire Administration|Questionnaire Administration
48012800|NCT00881075|DRUG|SeeMore(TM)|single dose intravenous injectable
48515990|NCT06301191|DRUG|Semaglutide, 1.0 mg/mL|Semaglutide, 1.0 mg/mL
48515991|NCT06301191|DRUG|Dipeptidyl Peptidase 4 inhibitor|Dipeptidyl Peptidase 4 inhibitor
48515992|NCT05719935|DEVICE|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
48515993|NCT02130622|DRUG|Promethazine|
48515994|NCT02130622|DRUG|Sugar pill|
48012801|NCT04269603|DEVICE|Take blood (TA-8V (Stago®)|Healthy volunteers will have 3 blood samples at M0, M3 and M6.
48012802|NCT00362804|DRUG|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
48515995|NCT03872687|DEVICE|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
48515996|NCT03872687|DEVICE|interdental brushes|Subjects in this group will only receive interdental brushes
48515997|NCT04469504|OTHER|Prehabilitation program|4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support
48515998|NCT04469504|DIETARY_SUPPLEMENT|Oral Impact|perioperative immunonutrition by ORAL IMPACT
48515999|NCT01138787|DIETARY_SUPPLEMENT|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
48516000|NCT01138787|DIETARY_SUPPLEMENT|Placebo spread|Single dose (30 gr) of regular light margarine
48516001|NCT01138787|DIETARY_SUPPLEMENT|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
48516002|NCT01232933|DEVICE|VPS System|Use of the navigational VPS system during catheter placement
48516003|NCT05298345|OTHER|Family Champions Project Primary Services|"Primary Services: participants receive 12 hours of TYRO Leadership curricula, 6 hours of Core Communication curricula.~Support Services (optional): participants choose from a menu of classes (1-3 hours) at the walk-in mini clinic to meet a variety of self-identified needs."
48516004|NCT00293111|DRUG|SDX-101 (R-Etodolac)|
48700483|NCT06176794|DRUG|Extended release torsemide 24mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
48700484|NCT05064020|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
48700485|NCT00328562|DRUG|ZD1839 (Iressa)|
48700486|NCT00328562|RADIATION|Thoracic Radiotherapy|
48700487|NCT03441997|OTHER|Mind-body exercise|Exercise program.
48012803|NCT06026891|DRUG|MG-K10/Placebo|MG-K10 Humanized Monoclonal Antibody Injection
48169743|NCT02201771|DRUG|Ticagrelor|
48516005|NCT06013098|DRUG|30%Oxygen|60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
48516006|NCT06013098|DRUG|60%Oxygen|100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
48516007|NCT01433055|DRUG|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
48516008|NCT01433055|DRUG|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
48700488|NCT03441997|OTHER|Light mobility exercises|Modified mind-body program.
48700489|NCT00918320|DRUG|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
48700490|NCT00812006|DRUG|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
48700491|NCT00812006|DRUG|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
48700492|NCT05409053|PROCEDURE|open reduction|the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
48700493|NCT05409053|PROCEDURE|Closed reduction|the non displaced fractures will be treated with closed reduction and percutaneous pinning
48700494|NCT05409053|OTHER|Conservative management|the non displaced fractures will be treated with closed reduction and castor slab
48700495|NCT01771692|OTHER|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
48012804|NCT05524324|DEVICE|CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)|Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.
48012805|NCT05524324|DEVICE|CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)|Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
48012806|NCT03235024|BIOLOGICAL|B244|B244 suspension
48012807|NCT03235024|BIOLOGICAL|Vehicle|Vehicle suspension
48012808|NCT06042088|OTHER|Regular Size Glove and Bigger One|Different sizes of surgical gloves will be worn by participants
48012809|NCT04709965|DIAGNOSTIC_TEST|Face2Gene|This study investigates whether a new diagnostic intervention (Face2Gene facial recognition software) is better than using standard approach to diagnosis.
48012810|NCT03065465|DEVICE|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
48700496|NCT01771692|OTHER|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
48012811|NCT03065465|OTHER|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
48012812|NCT01595620|OTHER|Thermal|Thermal sensation/pain testing
48169744|NCT05606198|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
48169745|NCT01194271|DRUG|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
48169746|NCT01194271|DRUG|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
48169747|NCT01194271|PROCEDURE|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
48169748|NCT04343859|DRUG|IMMH-010|After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
48169749|NCT01717170|DRUG|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
48012813|NCT01595620|OTHER|Electrical|Electrical sensation/pain testing
48012814|NCT01595620|OTHER|Capsaicin|Intradermal Capsaicin
48012815|NCT01595620|DRUG|THC|Active THC (0.01 mg/kg) administered over 10 minutes
48012816|NCT01595620|DRUG|THC|Active THC (0.03 mg/kg) administered over 10 minutes
48012817|NCT01595620|DRUG|Placebo|Control: small amount of alcohol with no THC, administered over 10 minutes
48012818|NCT03748940|DRUG|LY3074828|Administered SC
48012819|NCT03748940|DRUG|Placebo|Administered SC
48012820|NCT03748940|DRUG|LY900021|Administered SC
48012821|NCT04169295|OTHER|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
48700497|NCT00875485|PROCEDURE|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
48700498|NCT00875485|BIOLOGICAL|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
48012822|NCT04169295|OTHER|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
48012823|NCT04311034|DRUG|RC48|Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
48012824|NCT05790434|DIAGNOSTIC_TEST|Laboratory test|including white blood cell count, C-reactive protein, erythrocyte sedimentation rate, percent of polymorphonuclear leukocytes, albumin, and globulin
48012825|NCT05790434|DIAGNOSTIC_TEST|History taking and physical examination|including fever, joint pain, local swelling and redness, sinus
48012826|NCT05790434|DIAGNOSTIC_TEST|biopsy|including arthrocentesis culture，and frozen section
48700499|NCT01598337|DRUG|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
48012827|NCT00772096|DRUG|n-3 fatty acids|
48012828|NCT05001789|OTHER|CogMed|20 sessions of Cogmed working memory training
48012831|NCT06573190|DIAGNOSTIC_TEST|Transient elastography|Liver Stiffness Measurement, Controlled Attenuation Parameter
48012832|NCT06573190|DRUG|Tenofovir Disoproxil Fumarate|Guided Therapy
48012833|NCT06568146|DIETARY_SUPPLEMENT|Multivitamin Supplement|: Participants will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.
48700500|NCT01598337|DRUG|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
48169750|NCT05895968|PROCEDURE|posterior cervical surgery|The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
48169751|NCT05447728|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
48700501|NCT01598337|DRUG|Clopidogrel|75 mg orally started 6-8hours before surgery
48700502|NCT01598337|DRUG|Prasugrel|10 mg daily as per instructions of investigators
48700503|NCT03240367|OTHER|Coutery|Stapler line bleeding control with coutery
48169752|NCT05447728|DIAGNOSTIC_TEST|PRESTO|The PRESTO study is a group of 8 pre-hospital stroke scales used to detect large vessel occlusion strokes.
48700504|NCT06482697|PROCEDURE|total colpocleisis|Total colpocleisis refers to the process where, during the dissection of the anterior and posterior vaginal walls to remove the vaginal mucosa, no holes are left. When suturing, the anterior and posterior vaginal walls are completely interrupted with mattress sutures, and no holes are left on either side or at the top of the vagina.
48012834|NCT05218174|OTHER|Exercise Prescription|In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
48700505|NCT06482697|PROCEDURE|partial colpocleisis (LeFort)|LeFort involves the removal of a rectangular piece of mucosa from the anterior and posterior walls of the vagina, leaving a strip of mucosa 2 to 3 cm wide on each side of the vagina. The dissection is carried out close to the vaginal mucosa while preserving the vaginal bladder fascia as much as possible, creating channels on both sides of the vagina.
48012835|NCT05796544|BEHAVIORAL|Remote self-care education|The intervention group will receive a total of four remote educational sessions over 2 months.
48700506|NCT03907865|DRUG|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
48700507|NCT06325241|OTHER|No intervention|There is no intervention. This is an observational study.
48700508|NCT05015855|OTHER|NP-PC PrEP|All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.
48700509|NCT05015855|OTHER|OBGYN-PrEP|"OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling"
48700510|NCT03401021|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
48700511|NCT02179424|BEHAVIORAL|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
48012836|NCT05796544|BEHAVIORAL|In-person self-care education|The active comparator group will receive a total of four in-person educational sessions over 2 months.
48012837|NCT05224947|OTHER|Infant Formula|Two infant formulas differing in composition
48012838|NCT06663566|OTHER|Diagnose the patients right heart function as well as right heart fibrosis|Diagnose the patients right heart function as well as right heart fibrosis
48012839|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
48012840|NCT06663566|DIAGNOSTIC_TEST|Diagnose the patient&#39;s right heart function as well as right heart fibrosis|Diagnose the patient\&#39;s right heart function as well as right heart fibrosis
48012841|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
48012842|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
48012843|NCT04865497|BIOLOGICAL|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
48012844|NCT04865497|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.
48169753|NCT00256347|DRUG|intramuscular injections of morphine|
48700512|NCT02179424|BEHAVIORAL|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
48700513|NCT02179424|BEHAVIORAL|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
48012845|NCT06662552|DEVICE|whole body vibration using crazy fit machine|It will be applied on the whole body All subjects will be asked to stand in a squat position on the vibration platform with the knees bent 90 this position will be chosen because the vertical sinusoidal accelerations of the vibration platform had to be damped by the different muscles around the joints of the lower extremity) ,at a frequency of 30 Hz, 5 - 30 minutes per day, 3 times per week, for 6 weeks, and the physiotherapist will be standing beside the patient
48012846|NCT06662552|DEVICE|Pulsed electromagnetic field therapy|"EMSCULPT device (BTL Industries Inc., Boston, MA) based on HIFEM technology. It consists of an appliance, motorized bed and solenoids. The appliance will be connected to electrical mains supplying230Vat frequency of 50 or 60 Hz with earth connection, Intensity 0-100. It will be used in the treatment of patient in group B. Subjects will be positioned in a supine position, and the treatment will be performed by placing the applicator centered over their thigh region (quadriceps muscle's area), for 15 minutes per day, 3 times per week for 6 weeks, the physiotherapist will be sitting beside the patient"
48700514|NCT02179424|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
48700515|NCT02179424|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
48371394|NCT05443802|DRUG|Insulin 0.10 IU/kg/h|In the control arm, patients will receive an insulin dose of 0.10 IU/kg/h.
48700516|NCT02179424|BEHAVIORAL|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
48012847|NCT06662552|OTHER|traditional physical therapy program|In the form of splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises on quadriceps muscle 15 minutes per day, 3 times per week for 6 weeks.
48371395|NCT03567811|PROCEDURE|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
48371396|NCT06510023|BEHAVIORAL|Type of reward presented|Three different types of rewards were presented to both groups during the computerized task: one dollar, one penny, and no reward.
48012848|NCT05613439|PROCEDURE|Day-surgery|Standard surgical procedure but with planned discharge on day of surgery
48371397|NCT04816942|BIOLOGICAL|Convalescent Plasma|Two units of ABO compatible COVID-19 convalescent plasma will be administered.
48371398|NCT01815996|OTHER|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
48371399|NCT03672565|BEHAVIORAL|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
48700517|NCT03699059|OTHER|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
48700518|NCT04966494|DIETARY_SUPPLEMENT|BOSB|BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.
48012849|NCT05613439|PROCEDURE|High-risk patient|Standard fast-track procedure but with additional perioperative measures dependent on risk-profile.
48012850|NCT05613439|PROCEDURE|Main Group|Standard fast-track procedure according to usual standard of care and discharge when fulfilling functional discharge criteria
48012851|NCT02753647|DRUG|Rituximab|
48012852|NCT02753647|DRUG|Cyclophosphamide|
48012853|NCT02753647|DRUG|Doxorubicin|
48012854|NCT02753647|DRUG|Vincristine|
48012855|NCT02753647|DRUG|Prednisone|
48012856|NCT02753647|DRUG|Chidamide|
48012857|NCT05081323|BEHAVIORAL|Self-applied treatment for phobias|The proposed treatment consists of four stages that use different visual elements to represent and replace a real rat in a gradual exposure treatment for specific phobia for animals. With the order of the stages, the intensity of the phobic stimulus increases. In each stage the participant is gradually exposed to a certain amount of elements that represent a phobic situation or object. Graduality considers an approach with realism, interaction, and intensity. The treatment also includes a virtual therapeutic assistant that guides, provides information, and tries to reduce any alteration captured by the participant's heart rate monitoring through deep breathing exercises.
48012858|NCT02422381|DRUG|MK-3475|Investigational drug.
48012859|NCT02422381|DRUG|Gemcitabine|Standard care drug.
48012860|NCT03031288|DEVICE|A|standard bottle
48012861|NCT03031288|DEVICE|B|vented base bottle
48012862|NCT04575402|OTHER|Wearable Activity Monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR4 or similar model)
48169754|NCT06074653|OTHER|Mulligan Bent Leg Raise technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given.Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
48700519|NCT01796990|BEHAVIORAL|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
48012863|NCT02676544|DEVICE|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
48012864|NCT05548244|BEHAVIORAL|Behavioral Activation Therapy|Participants will be seen for a maximum of 16 sessions of therapy focused on increasing rewarding behaviors (16 individual therapy sessions of 1-hour, 2 of which include the BSIS component) over 16 weeks. BA intervention includes monthly booster sessions offered throughout 6-month follow up. If needed, two extra sessions will be allowed during treatment.
48012865|NCT05548244|BEHAVIORAL|Baseline assessment procedures|Completion of the K-SADS and CDRS-R to assess MDD, and the Wechsler Abbreviated Scale of Intelligence - 2nd Edition to assess IQ.
48012866|NCT02658110|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
48012867|NCT02658110|OTHER|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
48012868|NCT02658110|OTHER|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
48012869|NCT04717128|OTHER|Breastfeeding Skills Workshop|Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
48012870|NCT01403103|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
48012871|NCT01403103|PROCEDURE|biopsy|Correlative studies
48700520|NCT01796990|BEHAVIORAL|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
48700521|NCT02719964|OTHER|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
48700522|NCT02719964|OTHER|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
48700523|NCT02719964|OTHER|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
48700524|NCT05981001|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
48012872|NCT01403103|GENETIC|protein expression analysis|Correlative studies
48012873|NCT01403103|OTHER|enzyme-linked immunosorbent assay|Correlative studies
48012874|NCT01403103|OTHER|laboratory biomarker analysis|Correlative studies
48012875|NCT01403103|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
48012876|NCT02888028|PROCEDURE|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
48169755|NCT06074653|OTHER|PNF Contract Relax technique|Treatment session will be conducted for 2 days a week for 4 weeks consecutively. In first week only 20 minutes session will be given to each group. Home exercise plan is also given. Pre and post intervention measurements will be taken at 2nd and 4th week. Both dominant and non-dominant legs will be checked
48012877|NCT02888028|OTHER|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
48012878|NCT03992326|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
48012879|NCT03992326|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
48012880|NCT03992326|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
48012881|NCT03992326|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
48012882|NCT03992326|OTHER|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
48012883|NCT00392613|PROCEDURE|Strict versus lenient rate control|
48012884|NCT01298297|DRUG|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
48012885|NCT01298297|DRUG|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
48169756|NCT05514197|DRUG|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
48169757|NCT05514197|DRUG|Control Rx|Intravenous loading 100ml normal saline
48169758|NCT02176356|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
48169759|NCT02176356|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
48012886|NCT00799149|DRUG|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
48012887|NCT03826420|BEHAVIORAL|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
48012888|NCT03826420|BEHAVIORAL|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
48012889|NCT03826420|BEHAVIORAL|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
48012890|NCT04206111|PROCEDURE|Preoxygenation|preoxygenation with high flow nasal cannula at 40l/min for 5min
48012891|NCT05177198|PROCEDURE|M-MIST + Clindamycin augmented PRF|modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
48012892|NCT05177198|PROCEDURE|M-MIST + PRF|modified minimally invasive surgical technique with platelet-rich fibrin alone.
48012893|NCT04376034|BIOLOGICAL|Convalescent Plasma 1 Unit|"Each adult recipient will receive 1 units of plasma, each unit will consist of about 200 to 250 mL.~Each pediatric recipient will receive 10mL/kg up to 1 unit of plasma."
48516009|NCT01153373|BEHAVIORAL|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
48012894|NCT04376034|BIOLOGICAL|Convalescent Plasma 2 Units|"Those that meet severe or critical criteria will be given 2 units if available or 1 unit if 2 units are not available.~Those that are given 1 unit may receive the second unit (or the remainder of the maximum pediatric weight calculated amount of plasma up to 1 additional unit) if they progress to severe or critical condition or if already in severe or critical condition but only received 1 unit secondary to shortages.~Each pediatric recipient will receive 10mL/kg up to 2 units of plasma."
48012895|NCT04376034|OTHER|Standard of Care|Those that meet mild severity will be allowed to enroll in the study, but will not receive plasma unless there is progression of illness into the moderate/rapid progression or greater category.
48012896|NCT00215774|DRUG|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
48012897|NCT03188965|DRUG|Elimusertib (BAY1895344)|Solution or tablet, oral, to be administered until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
48012898|NCT01777997|DRUG|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
48012899|NCT04943016|DRUG|CD19 Chimeric Antigen Receptor (CAR) T Cells|This study seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children and adults with relapsed/refractory B cell malignancies. The overall goal of this study is to validate the safety profile of administration CD19 CAR T cells and describe the toxicities in children and adults with relapsed/ refractory B cell malignancies. Each patient implements leukapheresis 2 weeks after enrollment and infuse CD19 CAR-T cell around 2 weeks after leukapheresis, and administrated chemotherapy lymphodepletion regimen 1 week before infusion. Furthermore, the treated subject would be following up around 2 years.
48012900|NCT00001839|DRUG|Antithymocyte globulin|
48012901|NCT00001839|DRUG|Cyclosporine|
48012902|NCT05234515|DIAGNOSTIC_TEST|Microbiology swab|Patients will have swabs taken from the nose, mouth, umbilical skin, groin skin, fistula(e), stoma(s) and vascular access device prior to surgery. Patients will be followed for 90 days postoperatively for surgical site infection (SSI) as defined by the centre for disease control (CDC) criteria 2021. Patients who develop an SSI will have both preoperative and postoperative samples sent for genome sequencing.
48012903|NCT05234515|OTHER|Questionnaire|Patients will complete baseline preoperative questionnaires which will be repeated at 30 days and 90 days. These will evaluate generic and wound specific quality of life as well as decision conflict/decision regret.
48012904|NCT00599937|DRUG|ATRA|early introduction of ATRA
48012905|NCT00599937|DRUG|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
48012906|NCT05495412|OTHER|Rebound therapy|Exercise therapy delivered twice weekly for 6 weeks, during Phase B of an ABA single case study design.
48012907|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
48012908|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel QD
48516010|NCT01153373|BEHAVIORAL|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
48516011|NCT02547532|OTHER|collection of sputum|
48516012|NCT00039338|PROCEDURE|conventional surgery|Radial hysterectomy
48516013|NCT00039338|PROCEDURE|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
48516014|NCT00039338|RADIATION|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
48012909|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
48012910|NCT01174030|DRUG|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
48012911|NCT01174030|DRUG|Vehicle Gel|Vehicle Gel BID
48012912|NCT01470469|DRUG|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
48012913|NCT01470469|DRUG|Placebo|Once-daily oral dosing in the evening for 12 weeks.
48012914|NCT01986829|DEVICE|Microwave ablation|"* Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~* Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
48012915|NCT01986829|DEVICE|Cryoablation|"* Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~* Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
48012916|NCT01986829|DEVICE|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
48012917|NCT01986829|OTHER|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
48012918|NCT01986829|OTHER|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
48012919|NCT00080223|DRUG|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
48012920|NCT06572839|OTHER|Amnio-Maxx|Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
48012921|NCT00393939|DRUG|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
48012922|NCT00393939|DRUG|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
48012923|NCT05524402|BEHAVIORAL|TOR-C 1|TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
48012924|NCT05524402|BEHAVIORAL|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
48012925|NCT01713868|BEHAVIORAL|Safe Sleep Nursery Education|Nursery-based program for safe sleep
48012926|NCT01713868|BEHAVIORAL|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
48012927|NCT01713868|BEHAVIORAL|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
48012928|NCT01713868|BEHAVIORAL|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
48516015|NCT00039338|RADIATION|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
48516016|NCT00039338|DRUG|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
48012929|NCT04047290|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody.
48012930|NCT02986204|PROCEDURE|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined"
48012931|NCT02986204|PROCEDURE|continuation of ING implant|"the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm"
48012932|NCT03623737|DRUG|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
48516017|NCT02929056|BIOLOGICAL|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
48516018|NCT02929056|PROCEDURE|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
48516019|NCT00270855|PROCEDURE|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
48516020|NCT00270855|PROCEDURE|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
48700525|NCT05981001|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
48700526|NCT05981001|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
48700527|NCT05981001|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
48700528|NCT05981001|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
48012933|NCT01840670|DRUG|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
48012934|NCT05145920|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 5 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. Parents will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
48371400|NCT03672565|BEHAVIORAL|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~* They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~* They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~* They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
48012935|NCT05571059|DRUG|Ifetroban Sodium|Once daily oral ifetroban
48012936|NCT05571059|DRUG|Placebo|Matching oral placebo
48012937|NCT03339518|BEHAVIORAL|BRIM3 educational intervention|Breast Cancer risk education and counseling
48012938|NCT03339518|BEHAVIORAL|Wait List|Booklet at the end of study
48012939|NCT05512221|OTHER|GBAT+I, GBAT+E - Phase I|Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).
48169760|NCT02176356|DEVICE|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
48700529|NCT05981001|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
48700530|NCT05981001|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
48700531|NCT05981001|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
48700532|NCT05981001|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
48700533|NCT05962632|DRUG|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
48700534|NCT05962632|DRUG|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
48700535|NCT05962632|DEVICE|Mobile application|examine the impact of Mobile application on caries prevention
48700536|NCT05962632|COMBINATION_PRODUCT|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
48700537|NCT03170115|DRUG|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
48700538|NCT03170115|DRUG|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
48700539|NCT00759356|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
48700540|NCT00759356|DRUG|KADIAN|2 x 100 mg, single-dose capsule
48700541|NCT05096247|DEVICE|TempSure|This device is an RF device.
48169761|NCT02176356|DEVICE|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
48169762|NCT02176356|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
48169763|NCT05371145|BIOLOGICAL|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
48169764|NCT00816647|PROCEDURE|Patellofemoral stabilizing surgery|Comparison of surgical techniques
48169765|NCT01187810|DRUG|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
48700542|NCT05096247|DEVICE|Icon|This device works with IPL (Intense Pulsed Light) handpieces.
48700543|NCT04182399|DRUG|Zonisamide Capsules|anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
48700544|NCT02964559|BIOLOGICAL|Pembrolizumab|Given IV
48700545|NCT02010333|DRUG|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
48700546|NCT05008575|BIOLOGICAL|anti-CD33 CAR NK cells|6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion
48700547|NCT05008575|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
48700548|NCT05008575|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
48700549|NCT03046095|OTHER|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
48700550|NCT03046095|PROCEDURE|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
48700551|NCT02704702|DRUG|Fimasartan|
48700552|NCT02704702|DRUG|Rosuvastatin|
48700553|NCT02704702|DRUG|Fimasartan + Rosuvastatin|
48700554|NCT02813096|DRUG|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
48700555|NCT02813096|OTHER|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
48700556|NCT02324205|DEVICE|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
48700557|NCT06605690|DRUG|Dalpiciclib and Letrozole Combined With Anlotinib|Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
48700558|NCT03503591|DEVICE|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
48700559|NCT04155086|BIOLOGICAL|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
48700560|NCT00666588|DRUG|idarubicin|Given IV
48700561|NCT00666588|DRUG|cytarabine|Given IV or IT
48700562|NCT00666588|DRUG|bortezomib|Given IV
48700563|NCT00666588|DRUG|etoposide|Given IV
48371401|NCT03672565|BEHAVIORAL|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
48700564|NCT00666588|OTHER|laboratory biomarker analysis|Correlative studies
48700565|NCT03902457|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
48700566|NCT05758389|DRUG|Tislelizumab, Paclitaxel (albumin-bound type), Cisplatin, 5-FU|evaluate the efficacy and safety of immunotherapy combined with chemotherapy
48700567|NCT04823702|BIOLOGICAL|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
48700568|NCT02056886|PROCEDURE|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
48700569|NCT05223907|DRUG|Etomidate|Etomidate will be used for general anesthesia
48700570|NCT05223907|DRUG|Propofol|Propofol will be used for general anesthesia
48371402|NCT00173758|PROCEDURE|co-culture of embryos and endometrial cells|
48700571|NCT05308017|DEVICE|Richard Wolf 24F Laser scope|24F Laser with HoLEP
48700572|NCT05308017|DEVICE|Karl Storz 28F Laser Scope|28 F Laser with HoLEP
48700573|NCT01405352|DIETARY_SUPPLEMENT|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
48700574|NCT04801433|OTHER|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
48700575|NCT04801433|DRUG|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
48700576|NCT04801433|OTHER|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
48700577|NCT02839447|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
48700578|NCT00522418|DEVICE|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
48700579|NCT00522418|DRUG|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
48700580|NCT02110537|PROCEDURE|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
48700581|NCT02110537|PROCEDURE|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
48700582|NCT02110537|DRUG|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
48700583|NCT05758181|OTHER|Apical Undermining|The skin at the tip of the wound will be freed to reduce tension.
48700584|NCT04502264|DEVICE|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
48700585|NCT04502264|DRUG|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
48700586|NCT02222909|OTHER|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
48012940|NCT05512221|OTHER|Watchful Waiting and Groups - Phase 2|"Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes."
48371403|NCT05578820|BIOLOGICAL|Stimotimagene copolymerplasmid|Gene therapy drug, Intratumoral administration
48371404|NCT05578820|DRUG|Ganciclovir|Antiviral drug, Intravenous administration
48371405|NCT00638248|DRUG|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
48700587|NCT01610557|DRUG|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
48700588|NCT01610557|DRUG|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
48700589|NCT04689490|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Only diagnostic tests
48700590|NCT05992324|DEVICE|Caption LungAI|Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
48700591|NCT01368172|BEHAVIORAL|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
48700592|NCT00251368|DRUG|9-Aminocamptothecin (9-AC)|
48700593|NCT00762138|DEVICE|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
48169766|NCT01187810|DRUG|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
48169767|NCT01187810|DRUG|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
48169768|NCT06048809|OTHER|Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)|Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
48169769|NCT06048809|OTHER|Regular Fluoride Toothpaste (Colgate Cavity Protection)|Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
48700594|NCT04776187|DRUG|Gadodiamide|Gadodiamide Injection(OMNISCAN™)
48700595|NCT04776187|DRUG|Gadoteric Acid Meglumine Salt|Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
48012941|NCT05512221|OTHER|GBAT+IE|"Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials."
48012942|NCT03264131|DRUG|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
48012943|NCT03264131|DRUG|CHEP|"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
48012944|NCT02953834|DRUG|kisspeptin 112-121|Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
48012945|NCT02953834|OTHER|Insulin Resistance Test|Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
48012946|NCT02953834|OTHER|Placebo|Receive IV fluids for up to 16 hours that do not contain any study drug
48012947|NCT05074550|DRUG|PPMX-T003|As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
48012948|NCT03178656|DRUG|Sorafenib|continuous application of the drugs
48012949|NCT03178656|PROCEDURE|surgery|curative resection
48012950|NCT00433693|DRUG|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week
48169770|NCT03756025|PROCEDURE|Atraumatic Restorative Treatment (ART)|The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique \[20\], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
48371406|NCT00638248|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
48371407|NCT00638248|DRUG|Placebo|Placebo i.v. bolus
48371408|NCT02999295|BIOLOGICAL|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
48700596|NCT06523608|OTHER|Standard survillance protocol|Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
48516021|NCT03097146|OTHER|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
48516022|NCT01159561|BIOLOGICAL|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
48516023|NCT05635487|DRUG|SHR-A1811|SHR-A1811
48700597|NCT06523608|OTHER|Stratified survillance protocol|"Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification."
48700598|NCT02398422|BEHAVIORAL|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
48700599|NCT02543866|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
48516024|NCT05635487|DRUG|Pyrotinib|Pyrotinib
48516025|NCT02750956|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
48516026|NCT01331629|OTHER|ART-THERAPIE|8 sessions of art therapy during radiotherapy
48700600|NCT00510718|DRUG|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
48700601|NCT01259648|DRUG|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
48700602|NCT01259648|DRUG|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
48700603|NCT01259648|DRUG|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
48700604|NCT03614481|GENETIC|Sampling|Sampling
48700605|NCT05447195|DRUG|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
48516027|NCT05115487|DIAGNOSTIC_TEST|digital dynamometer|Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
48516028|NCT04138043|DRUG|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
48516029|NCT04138043|DRUG|GSK2330811|GSK2330811 will be available as SC injection 150 mg/mL.
48516030|NCT00656552|DRUG|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
48169771|NCT05001997|DIETARY_SUPPLEMENT|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
48169772|NCT06172998|DRUG|Phentolamine Injection|Under patient safety, Phentolamine will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent sympathetic overactivity. Under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.
48169773|NCT04591964|COMBINATION_PRODUCT|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
48169774|NCT02779283|DRUG|Cyclophosphamide|Given IV
48169775|NCT02779283|DRUG|Cytarabine|Given IV
48169776|NCT02779283|DRUG|Dasatinib|Given PO
48169777|NCT02779283|DRUG|Dexamethasone|Given PO
48169778|NCT02779283|DRUG|Doxorubicin Hydrochloride|Given IV
48169779|NCT02779283|DRUG|Idarubicin|Given IV
48169780|NCT02779283|DRUG|Idelalisib|Given PO
48012951|NCT05862025|DIAGNOSTIC_TEST|Echocardiography evaluation|"Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset."
48012952|NCT03218111|OTHER|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
48169781|NCT02779283|DEVICE|In Vitro Kinase Inhibitor Assay|Correlative studies
48169782|NCT02779283|DRUG|Leucovorin Calcium|Given IV
48169783|NCT02779283|DRUG|Methotrexate|Given IV
48169784|NCT02779283|DRUG|Methylprednisolone Sodium Succinate|Given IV
48169785|NCT02779283|DRUG|Ponatinib Hydrochloride|Given PO
48169786|NCT02779283|BIOLOGICAL|Rituximab|Given IV
48169787|NCT02779283|DRUG|Ruxolitinib Phosphate|Given PO
48169788|NCT02779283|DRUG|Sorafenib Tosylate|Given PO
48169789|NCT02779283|DRUG|Sunitinib Malate|Given PO
48169790|NCT02779283|DRUG|Vincristine Sulfate|Given IV
48169791|NCT03944902|DRUG|Cohort 1: Dose Escalation|The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
48169792|NCT03944902|DRUG|Cohort 2: Dose Escalation|If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
48169793|NCT06310226|DEVICE|Epidural electrical spinal cord stimulator|Epidural electrical spinal cord stimulator turned on vs. turned off
48169794|NCT04772313|BIOLOGICAL|Pegloticase|Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
48169795|NCT04772313|DRUG|Methotrexate (MTX)|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
48169796|NCT02494752|PROCEDURE|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
48012953|NCT03218111|OTHER|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
48012954|NCT04208412|DRUG|KVD900|KVD900 tablet 600 mg
48012955|NCT04208412|OTHER|Placebo|KVD900-matched Placebo Tablet
48012956|NCT06641856|OTHER|Sample Collection|All participants will provide nasal and pharyngeal swabs for virome analysis. A subset of 30 elderly volunteers will also provide peripheral blood samples and undergo bronchoscopy under general anesthesia to collect upper and lower respiratory tract samples.
48169797|NCT02494752|PROCEDURE|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
48169798|NCT03379779|DIAGNOSTIC_TEST|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
48169799|NCT00594178|DEVICE|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
48169800|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
48169801|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
48169802|NCT01512914|DRUG|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
48169803|NCT01512914|DRUG|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
48169804|NCT00035802|DRUG|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
48169805|NCT00035802|DRUG|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
48169806|NCT04161885|DRUG|Venetoclax|Tablet; Oral
48169807|NCT04161885|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
48169808|NCT04161885|OTHER|Best Supportive Care (BSC)|BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
48371409|NCT02999295|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
48371410|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
48169810|NCT05438446|PROCEDURE|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)|"The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney."
48012957|NCT05686304|BEHAVIORAL|Internet-based self-help money management program|The online money management program course will consist of 4 weekly modules, incorporating the key components of money management and the Model of Human Occupation (MOHO), including the concept of money management, money management skill, and risk of financial exploitation.
48012958|NCT01844258|PROCEDURE|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
48012959|NCT01844258|PROCEDURE|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
48012960|NCT06459557|PROCEDURE|cast|children with displaced distal radius fractures would be managed by a cast in the emergency room
48012961|NCT06459557|PROCEDURE|surgical reduction|anatomical reduction of pediatric displaced distal radius fractures under general anesthesia in the operating room
48012962|NCT01585142|OTHER|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
48012963|NCT05928702|PROCEDURE|temperature-elevating armbath|Hydrotherapeutic Approach
48012964|NCT04458714|PROCEDURE|Aortoiliac angioplasty|In the CO2 arm we used manual injection of CO2 from a medicinal CO2 cylinder connected to a particle filter. Under water aspiration was used to prevent air contamination. Using a twenty mls syringe the required amount of CO2was aspirated using a three way tap and was followed my aspirating 3mls of saline to provide a fluid barrier. In the ICM arm the injection of contrast was done using 10-ml syringes with 5 mls of iodinated contrast media and 5 mls of saline solution per injection. The ICM used in all cases was Omnipaque 300 (Iohexol), a nonionic low osmolar contrast commonly in use in both hospitals.
48012965|NCT01575327|DEVICE|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
48012966|NCT01575327|DEVICE|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
48012967|NCT06320470|BEHAVIORAL|Educational Session|The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
48012968|NCT05608785|DRUG|IBI315|IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
48012969|NCT05608785|DRUG|Oxaliplatin|Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
48012970|NCT05608785|DRUG|Capecitabine|Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
48012971|NCT05608785|DRUG|TST001|TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.
48012972|NCT05608785|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
48012973|NCT05608785|DRUG|Anrotinib|Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
48169811|NCT00392535|RADIATION|conventional radiotherapy 74 Gy delivered in 37 fractions|
48012974|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
48012975|NCT02268981|DEVICE|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
48012976|NCT02268981|DEVICE|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
48012977|NCT00613600|DIETARY_SUPPLEMENT|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
48012978|NCT00613600|DIETARY_SUPPLEMENT|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
48012979|NCT01262313|BEHAVIORAL|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
48012980|NCT01281488|PROCEDURE|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
48012981|NCT01281488|PROCEDURE|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
48012982|NCT01281488|DRUG|indocyanine green|Given IV
48012983|NCT02651623|DRUG|Sertraline|Multiple doses of sertraline for 14 days
48012984|NCT02651623|DRUG|Moxifloxacin|A single dose of 400 mg Moxifloxacin
48012985|NCT02651623|DRUG|Drug - Placebo|Placebo administered for 14 days
48012986|NCT05746546|DRUG|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
48012987|NCT04281277|DEVICE|increase of mean arterial pressure at 80-85 mmHg.|increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
48012988|NCT04281277|DEVICE|increase of mean arterial pressure at 65-70 mmHg.|increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).
48169812|NCT00392535|RADIATION|hypofractionated radiation therapy 60 Gy in 20 fractions|
48169813|NCT00392535|RADIATION|hypofractionated radiation therapy 57 Gy in 19 fractions|
48169814|NCT00953511|GENETIC|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
48169815|NCT04106453|PROCEDURE|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
48169816|NCT04106453|PROCEDURE|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
48169817|NCT04199455|DRUG|Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)|"Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day."
48169818|NCT04199455|DRUG|Placebo|"Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day."
48169819|NCT01845649|DRUG|WC3011 Estradiol Vaginal Cream|Daily for 14 days followed by 3 times per week for 10 weeks
48169820|NCT01845649|DRUG|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
48169821|NCT05951439|DIETARY_SUPPLEMENT|CRE + HMB|3 g/day of CRE and 3 g/day of HMB
48169822|NCT05951439|DIETARY_SUPPLEMENT|CRE + GAA|3 g/day of CRE and 3 g/day of GAA
48169823|NCT05951439|DIETARY_SUPPLEMENT|Placebo|6 g/day of inulin
48169824|NCT01530477|DEVICE|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
48169825|NCT01530477|DEVICE|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
48169826|NCT01530477|DEVICE|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
48169827|NCT03961997|DRUG|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
48371411|NCT04131465|DIAGNOSTIC_TEST|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
48371412|NCT04131465|DIAGNOSTIC_TEST|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
48012989|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
48012990|NCT00901875|DRUG|Buprenorphine + naloxone (Suboxone)|
48012991|NCT02206126|BEHAVIORAL|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
48012992|NCT03025022|DRUG|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
48012993|NCT02469610|OTHER|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
48012994|NCT04423042|BIOLOGICAL|Tocilizumab|Tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.
48012995|NCT02128841|DRUG|Rivaroxaban|Direct Factor Xa Inhibitor
48012996|NCT03756766|DIAGNOSTIC_TEST|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
48012997|NCT01280929|PROCEDURE|Panretinal Photocoagulation (PRP)|
48012998|NCT01280929|DRUG|Intravitreous injection of ranibizumab|
48012999|NCT05443477|DIETARY_SUPPLEMENT|Hericium Erinaceus Mycelium|participants received two oral capsules containing Hericium erinaceus Mycelium every day for the 3 months.
48013000|NCT05443477|DIETARY_SUPPLEMENT|Probiotic|participants received two oral capsules containing Probiotic powder every day for the 3 months.
48013001|NCT05443477|DIETARY_SUPPLEMENT|control|participants received two oral capsules containing control powder every day for the 3 months.
48013002|NCT02512497|DRUG|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
48013003|NCT02512497|DRUG|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
48013004|NCT02512497|DRUG|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
48013005|NCT02512497|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
48013006|NCT02512497|DRUG|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
48700606|NCT05447195|DRUG|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
48700607|NCT05598125|DEVICE|electronic cigarette (e-cigarette)|
48700608|NCT05598125|DEVICE|conventional tobacco cigarette|
48169828|NCT03961997|DRUG|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
48169829|NCT03961997|DRUG|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
48169830|NCT01457833|DEVICE|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
48169831|NCT01457833|DEVICE|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
48700609|NCT01364883|BIOLOGICAL|Vaccination Schedule One|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
48700610|NCT01364883|BIOLOGICAL|Vaccination Schedule Two|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
48700611|NCT01364883|BIOLOGICAL|Vaccination Schedule Three|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
48013007|NCT00403338|DEVICE|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
48013008|NCT04942275|DRUG|Pre-therapeutic imaging test|The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
48169832|NCT00546702|DRUG|Insuline Glulisine|
48700612|NCT01364883|BIOLOGICAL|Vaccination Schedule Four|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
48700613|NCT01364883|BIOLOGICAL|Vaccination Schedule Five|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
48700614|NCT01364883|BIOLOGICAL|Vaccination Schedule Six|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
48700615|NCT01364883|BIOLOGICAL|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
48700616|NCT05005845|DRUG|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
48700617|NCT05005845|DRUG|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
48700618|NCT02839187|RADIATION|Neuroimaging|AV45-positron emission tomography
48700619|NCT02696733|DEVICE|Ultrasound|Ultrasound-guided obturator nerve localization
48700620|NCT02696733|DRUG|lidocaine 2%|local anesthetic used to block the obturator nerve
48700621|NCT02696733|DRUG|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
48700622|NCT01905345|PROCEDURE|Training|
48013009|NCT03362515|DRUG|Furosemide|furosemide
48013010|NCT03362515|DRUG|Placebo|placebo
48013011|NCT00813124|DRUG|Fludarabine|40 mg/m\^2 by vein over 60 minutes on Day -5 through Day -2.
48013012|NCT00813124|DRUG|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
48013013|NCT00813124|DRUG|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
48013014|NCT00813124|DRUG|Azacitidine|Start cycles of 32 mg/m\^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
48013015|NCT00813124|PROCEDURE|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
48013016|NCT02111486|OTHER|breakfast|
48169833|NCT02954796|DRUG|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
48169834|NCT04626271|DEVICE|"ACR | U.S. Urine Analysis Test System"|"Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health."
48169835|NCT04626271|DEVICE|URiSCAN Optima Urine Analyzer|"Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer."
48169836|NCT03503162|DEVICE|Pure-Vu System|The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
48169837|NCT01431950|DRUG|fluticasone furoate|Inhaled corticosteroid
48169838|NCT01431950|DRUG|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
48169839|NCT04713813|OTHER|Therapeutic exercise program via hippotherapy mechanical stimulator|Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
48169840|NCT04713813|OTHER|Therapeutic home exercise program|Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
48169841|NCT01520844|BIOLOGICAL|blood sampling|blood sampling
48169842|NCT01029678|DRUG|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
48169843|NCT01029678|DRUG|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
48169844|NCT01029678|RADIATION|Radiotherapy|66Gy, 33 fractions, 6 week
48169845|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
48169846|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
48169847|NCT04545476|OTHER|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
48169848|NCT04545476|OTHER|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
48169849|NCT05377645|OTHER|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
48516031|NCT03739047|BEHAVIORAL|Desensitization with flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
48516032|NCT03739047|BEHAVIORAL|flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
48516033|NCT05412953|OTHER|Questionnaire Administration|Complete questionnaire
48516034|NCT05412953|BEHAVIORAL|Tonation Breathing Technique|Participate in tonation breathing techniques
48516035|NCT04498026|DEVICE|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
48516036|NCT04498026|DEVICE|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
48169850|NCT04932226|DEVICE|cloth mask|Buff bandana double layer worn over nose and mouth
48169851|NCT04932226|DEVICE|surgical mask|standard surgical mask
48169852|NCT04932226|DEVICE|FFP2 respirator|filtering facepiece 2 respirator
48169853|NCT00874484|DRUG|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
48169854|NCT06157619|PROCEDURE|Oocyte Vitrification /Warming|In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols
48169855|NCT00078234|DRUG|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
48169856|NCT03023852|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
48169857|NCT03023852|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
48169858|NCT01527903|DRUG|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
48169859|NCT01527903|DRUG|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
48169860|NCT05296252|BEHAVIORAL|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
48371413|NCT02737410|BEHAVIORAL|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
48371414|NCT00363376|DRUG|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
48700623|NCT01453751|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
48371415|NCT00363376|DRUG|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
48371416|NCT00363376|DRUG|Zonisamide|zonisamide ranging from 100mg to 600mg daily
48516037|NCT05390593|DEVICE|iTBS-1800|Participants in the 1800-pulse intermittent TBS (iTBS-1800) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
48700624|NCT06232018|DEVICE|Skin adhesive (Dermabond)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
48700625|NCT06232018|DEVICE|skin adhesive + polyester mesh (Dermabond prineo)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
48700626|NCT02187276|DRUG|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
48700627|NCT01841125|DRUG|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
48700628|NCT01841125|DRUG|Placebo|placebo 15mg, QD(once a day), Oral medication
48700629|NCT04694521|PROCEDURE|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
48700630|NCT04694521|PROCEDURE|open end end to end stapler anastomosis|open end to end stapler anastomosis
48700631|NCT06404320|BEHAVIORAL|PA program - MoveU.HappyU|"Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week."
48013017|NCT02653677|OTHER|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
48013018|NCT00847496|DEVICE|AWBAT|One-time application of dressing over partial-thickness burns
48013019|NCT00847496|DEVICE|Biobrane|One-time application over partial-thickness burns
48013020|NCT03509129|BEHAVIORAL|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
48371417|NCT00363376|DRUG|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
48371418|NCT01136317|DRUG|Omeprazole|
48013021|NCT03509129|BEHAVIORAL|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
48169861|NCT05296252|BEHAVIORAL|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
48169862|NCT06465992|DRUG|Exparel 266 MG Per 20 ML Injection|20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block
48169863|NCT06465992|DRUG|Bupivacaine Hcl 0.75% Inj|10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block
48700632|NCT03628144|DIETARY_SUPPLEMENT|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
48700633|NCT03628144|DIETARY_SUPPLEMENT|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
48169864|NCT06465992|DRUG|Dexamethasone|1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block
48169865|NCT01308047|DRUG|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
48169866|NCT02483845|DRUG|Natalizumab|
48169867|NCT02168478|DRUG|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
48169868|NCT02168478|OTHER|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
48700634|NCT03628144|RADIATION|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
48700635|NCT03628144|DRUG|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
48700636|NCT03628144|OTHER|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
48700637|NCT03628144|OTHER|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
48013022|NCT00000436|BEHAVIORAL|Self-efficacy and muscle strength training|
48013023|NCT00000436|PROCEDURE|High-intensity strength training|
48013024|NCT04834011|PROCEDURE|Laparoscopic right colonic resection with Complete Mesocolic Excision (CME)|
48013025|NCT04834011|RADIATION|3D CT angiography|
48013026|NCT01936259|DEVICE|Mini Stem|The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.
48013027|NCT01936259|DEVICE|Nano|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
48013028|NCT03787316|DEVICE|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
48013029|NCT06128525|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48371419|NCT01136317|DRUG|Rabeprazole|
48371420|NCT01136317|DRUG|Lactose|
48700638|NCT03628144|OTHER|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
48013030|NCT06128525|DEVICE|Microwave Ablation|Undergo transperineal MRI/US fusion guided transperineal targeted microwave ablation
48013031|NCT06128525|DEVICE|Multiparametric Magnetic Resonance Imaging|Undergo planning mpMRI of prostate
48013032|NCT06128525|OTHER|Questionnaire Administration|Ancillary studies
48013033|NCT06128525|PROCEDURE|Radical Prostatectomy|Undergo RP
48013034|NCT00545831|DEVICE|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
48013035|NCT00545831|DEVICE|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
48169869|NCT02168478|OTHER|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
48700639|NCT05627258|BIOLOGICAL|VRC-HIVMAB0115-00-AB|VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
48700640|NCT03227952|DEVICE|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
48700641|NCT02135029|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
48700642|NCT02135029|DRUG|Atorvastatin|Atorvastatin PO QD
48700643|NCT02135029|OTHER|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
48700644|NCT02135029|OTHER|Placebo for atorvastatin|PO QD
48700645|NCT05810870|DRUG|MEN1611|MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
48516038|NCT05390593|DEVICE|iTBS-1200|Participants in the 1200-pulse intermittent TBS (iTBS-1200) active stimulation group will receive three-pulse 50-Hz pulses for 2 weeks at an intensity of 80% active motor threshold (MT) to Left DLPFC, twice a day. Stimulation will use a MAG \& More stimulator.
48516039|NCT02771470|DRUG|Probiotics|Microbial composition using probiotic
48516040|NCT02771470|DRUG|placebo|Microbiota modulation using placebo
48516041|NCT03655730|OTHER|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
48516042|NCT03655730|OTHER|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
48516043|NCT02074007|DRUG|AR01|drops administered as needed for pain
48700646|NCT05810870|DRUG|Eribulin|Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
48013036|NCT02364310|DEVICE|Baroreceptor stimulation with Barostim Neo TM|
48013037|NCT00087633|DRUG|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
48013038|NCT00087633|DRUG|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
48371421|NCT01258738|BIOLOGICAL|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
48516044|NCT02074007|DRUG|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
48700647|NCT04009694|OTHER|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
48700648|NCT01115894|DRUG|Naltrexone|100 mg oral dosage daily for 12 weeks
48700649|NCT01115894|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
48700650|NCT01115894|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
48700651|NCT01115894|DRUG|Placebo|Placebo
48700652|NCT02309983|OTHER|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
48013039|NCT00864474|DRUG|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
48013040|NCT00427804|DRUG|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
48013041|NCT03722017|OTHER|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
48013042|NCT01701258|DRUG|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
48013043|NCT01701258|DRUG|Placebo|single-dose placebo capsule during the fMRI session only
48700653|NCT02309983|OTHER|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
48169870|NCT03471897|DIAGNOSTIC_TEST|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
48169871|NCT00574600|BIOLOGICAL|SAAVI DNA-C2 vaccine|DNA vaccine
48169872|NCT00574600|BIOLOGICAL|SAAVI MVA-C vaccine|Boost vaccine
48169873|NCT00574600|BIOLOGICAL|Placebo|Placebo vaccine
48169874|NCT03429595|DRUG|ATx201|ATx201 GEL
48169875|NCT03429595|OTHER|ATx201 GEL Vehicle|Vehicle
48516045|NCT04007198|DRUG|EQ001|Itolizumab \[Bmab 600\]
48700654|NCT02070419|PROCEDURE|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
48700655|NCT02070419|RADIATION|stereotactic radiosurgery|Undergo SBRT
48700656|NCT01940250|DRUG|Magnesium Sulphate|MgSO4 IV infusion
48700657|NCT01940250|DRUG|Sterile water|H2O IV infusion
48169876|NCT05243342|DRUG|XmAb24306|XmAb24306 will be given via intravenous (IV) infusion
48169877|NCT05243342|DRUG|Daratumumab|Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
48169878|NCT01384383|DRUG|GS-5885|GS-5885 30 mg tablet administered orally once daily
48169879|NCT01384383|DRUG|GS-9451|GS-9451 200 mg tablet administered orally once daily
48169880|NCT01384383|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
48169881|NCT01384383|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
48169882|NCT02151643|DRUG|PT20|Modified ferric oxide adipate tablets
48169883|NCT02151643|DRUG|Placebo|Placebo tablets matched to each PT20 dose arm
48169884|NCT03556540|OTHER|physical exercise|Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
48371422|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
48371423|NCT01258738|OTHER|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
48516046|NCT04007198|DRUG|EQ001 Placebo|EQ001 Placebo
48516047|NCT05707793|OTHER|Evaluating sexual function, quality of life and pelvic floor muscle strength, as well as thickness and force (strength) of voluntary contractions of the core muscles|Evaluation through Vaginal Laxity Questionnaire, Female Sexual Function Index, Short-Form 36 Health Survey, modified Oxford grading scale and ultrasound imaging
48700658|NCT04348747|BIOLOGICAL|Anti-HER2/HER3 Dendritic Cell Vaccine|Given ID
48700659|NCT04348747|BIOLOGICAL|Pembrolizumab|Given IV
48700660|NCT04802135|OTHER|Survey|directive questionnaire administered during an individual face-to-face interview
48700661|NCT03769818|DRUG|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
48516048|NCT05107648|BEHAVIORAL|Gardner GOALS|12 lesson curriculum focusing on healthy eating, increased physical activity and decreased screen time
48516049|NCT00478517|DRUG|Erythropoetin (rHuEPO, EPREX®)|
48516050|NCT06582459|DEVICE|HFNC treatment|HFNC treatment HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.
48013044|NCT06310434|OTHER|questionnaire|COOL Scale and DAS
48013045|NCT06310434|OTHER|Discussion group|Through discussion groups with students in secondary schools and university separately, a compassionate plan will be designed
48169885|NCT00611728|DRUG|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 \& 1/2 hrs on 1st day of each cycle \& then again on days 14 \& 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 \& continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height \& weight. Irinotecan will be given intravenously over 90 min on days 1, 14 \& 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, \& then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, \& then within 1 week prior to completion of every other cycle."
48169886|NCT00557336|DRUG|somatropin|
48700662|NCT03769818|DRUG|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
48516051|NCT06582459|DEVICE|NIV treatment|NIV treatment A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \&amp;lt;30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.
48700663|NCT03769818|DRUG|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
48700664|NCT03769818|DRUG|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
48700665|NCT06496295|DEVICE|Vaginal Speculum Exam|Evaluating the visibility of the cervix, ease-of-use, and comfort of a new vaginal speculum.
48700666|NCT03092830|GENETIC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
48700667|NCT04641221|BEHAVIORAL|Weekly Yoga Classes|All participants are invited to attend weekly yoga classes.
48013046|NCT06310434|OTHER|Reflective diary|Students can modify the interventions adapting them to their requirements to get the compassion needed for those in need.
48013047|NCT02672735|OTHER|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
48013048|NCT05000645|BEHAVIORAL|Grocery delivery|Each food delivery will contain approximately $35 worth of fresh fruits, vegetables, dairy products, and whole grain foods. These foods are not meant to supplant regular meals, rather make healthy eating more convenient.
48013049|NCT05000645|BEHAVIORAL|Unsweetened beverage delivery|Participants will receive unsweetened beverages to replace normal sugar-sweetened beverage intake.
48013050|NCT01546948|DRUG|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
48013051|NCT01546948|DRUG|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
48013052|NCT00901940|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
48013053|NCT00901940|BIOLOGICAL|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
48700668|NCT04442126|BIOLOGICAL|NM21-1480|Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
48013054|NCT03773757|BEHAVIORAL|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
48013055|NCT02821585|BEHAVIORAL|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
48169887|NCT04316520|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet 2:1
48169888|NCT01398644|OTHER|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
48516052|NCT00455156|DRUG|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
48700669|NCT03581695|OTHER|Blood test|Blood test
48371424|NCT01258738|DRUG|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
48371425|NCT01132040|DRUG|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
48700670|NCT05339490|DRUG|Progenitor Biological Bandages|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, PBB will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1. Old PBB will be replaced by new ones according to the local procedure.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
48013056|NCT02468466|BEHAVIORAL|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
48013057|NCT02468466|BEHAVIORAL|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
48013058|NCT01375218|OTHER|Pavlik Brace|Pavlik Brace
48013059|NCT01375218|OTHER|Plastizote Brace|Plastizote Brace
48169889|NCT00668512|BIOLOGICAL|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
48371426|NCT02291068|BEHAVIORAL|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
48516053|NCT06390709|OTHER|Lab Collection Only|2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.
48700671|NCT05339490|DEVICE|Jelonet|"The patients candidates for a skin autograft and a consequent Donor Site Wound (DSW) creation with a dermatome will be randomized between 2 treatment arms. As soon as DSW is created and according to randomization results, Jelonet, as standard bandages, will be placed on the wound and maintained in place with the help of classical bandages for a maximum of 15 ± 1 days with dressing's changes at Day 5 ± 1 and Day 10 ± 1.~Pictures will be taken at each change and on-site evaluation of the wound healing (% of re-epithelialization) will be done by the surgeon. If the DSW is not closed at D15 ± 1, Jelonet® will be used to cover the skin until complete skin closure. If the wound is closed after 15 ± 1 days or before, the scar will then be topically treated with cream as standard treatment. All patients will be followed until 5 years according to the long-term evaluation calendar to monitor long-term skin quality."
48700672|NCT00946764|DRUG|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
48169890|NCT01182207|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
48169891|NCT01182207|DRUG|YAZ®|3 mg/0.02 mg Tablets
48516054|NCT04871256|PROCEDURE|Septorhinoplasty|This intervention will be performed by the same surgeon, after signing of patient inform consent.
48516055|NCT01080560|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
48700673|NCT00946764|DRUG|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
48169892|NCT04620369|DRUG|Placebo Administration|Instill isotonic nasal saline intranasally
48013060|NCT04719910|OTHER|Visual exposure to taped food preparation|Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.
48013061|NCT04719910|OTHER|Visual exposure to topics not related to food|Patients in the placebo group can choose a video that is relaxing but not related to food.
48169893|NCT04620369|OTHER|Questionnaire Administration|Ancillary studies
48169894|NCT04620369|DRUG|Rose Geranium in Sesame Oil Nasal Spray|Instill intranasally
48169895|NCT05097898|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
48013062|NCT04284657|DRUG|Pravastatin|Pravastatin 40 mg QD
48013063|NCT04284657|DRUG|sodium citrate|sodium citrate up to 30 ml TID
48013064|NCT02232659|DEVICE|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
48013065|NCT06479109|BEHAVIORAL|Motivational materials for pregnant women attending antenatal care visits to improve supplement adherence|During the antenatal care visit, pregnant women will receive the information sheet used by the provider and a dangler/poster to hang in a visible location in the participant's house. This will serve as a reminder for her and her family to take the daily pill.
48013066|NCT06479109|OTHER|Providers|"Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements. The sheet also includes adherence tips, such as involving family to increase adherence. The information sheet is provided to the woman to take home.~Antenatal care providers will use an information sheet describing the supplement's benefits and adherence tips to help pregnant women take IFAS or MMS."
48169896|NCT05097898|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
48169897|NCT05097898|PROCEDURE|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
48013067|NCT04791800|DIAGNOSTIC_TEST|Malaria/CRP combination test|Testing with a malaria/CRP combination test, in parallel with a standard malaria RDT (to guide case management), preparation of thin/thick films for expert malaria microscopy, and collection of venous blood for subsequent CRP quantification.
48013068|NCT05683600|BIOLOGICAL|Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001|Intramuscular injection of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
48169898|NCT05097898|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
48013069|NCT05683600|BIOLOGICAL|Placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm at day 0. The inoculation dose is 0.5 mL.
48013070|NCT04471584|DEVICE|Insertion of ILR device|All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
48013071|NCT02869971|DEVICE|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
48013072|NCT02869971|DRUG|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
48169899|NCT05097898|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
48169900|NCT03762083|DEVICE|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of BV.
48013073|NCT05829603|DRUG|Dimethyltryptamin (DMT) & Harmine|Six varying doses of a fixed-combination formulation of Dimethyltryptamin (DMT) and harmine
48013074|NCT00011804|DRUG|Topiramate|
48013075|NCT04614766|DRUG|Lutathera|intravenous administration
48013076|NCT04614766|DRUG|Azedra|intravenous administration
48169901|NCT01359683|DEVICE|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
48516056|NCT06582498|BEHAVIORAL|Active intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivors at randomization (2nd visit). Furthermore, they will be offered 3 individual sessions with health professionals (oncological dietitian, sports therapist, and oncological psychologist) and 3 group sessions with the same professionals. The duration of the individual visits is expected to be 45-60 minutes approximately, and group sessions will be planned for 1.5h duration approximately.
48013077|NCT06038591|BEHAVIORAL|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
48013078|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
48013079|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
48013080|NCT00678561|DRUG|CP-690,550|Topical treatment once daily for 28 days
48013081|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
48013082|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
48013083|NCT00678561|DRUG|CP-690,550|Topical treatment twice daily for 28 days
48013084|NCT00678561|DRUG|Placebo Vehicle|Topical treatment once daily for 28 days
48013085|NCT00678561|DRUG|Placebo Vehicle|Topical treatment twice daily for 28 days
48169902|NCT04358614|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
48169903|NCT00723918|DRUG|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
48169904|NCT00723918|DRUG|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
48169905|NCT00723918|DRUG|SAB placebo|an inactive substance
48013086|NCT06158737|DRUG|JS010 injection|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
48013087|NCT06158737|DRUG|Placebo|This study adopts a dose escalation design with six preset dose levels, namely 3mg, 30mg, 150mg, 300mg,600mg, 900mg, single subcutaneous injection. A total of 48 healthy subjects were enrolled in the experiment, 8 in each group.They were randomly assigned to receive JS010 injection and matching placebo in a ratio of 3:1. In accordance with the dose-escalation principle,Starting from the lowest initial dose, increasing to the higher dose and proceeding in sequence. Each subject can receive only one dose Level of single subcutaneous administration.
48013088|NCT00253565|DRUG|capecitabine|
48013089|NCT00253565|DRUG|imatinib mesylate|
48013090|NCT05896358|BEHAVIORAL|ketogenic diet|a low calorie ketogenic diet
48013091|NCT02591628|BEHAVIORAL|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
48013092|NCT00004923|DRUG|docetaxel|
48013093|NCT00004923|DRUG|irinotecan hydrochloride|
48013094|NCT02714049|BEHAVIORAL|sex therapy|60 minutes each time, in person or on the telephone
48013095|NCT02714049|DRUG|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
48013096|NCT03743948|GENETIC|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
48013097|NCT01942941|DEVICE|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
48013098|NCT03101475|DRUG|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
48013099|NCT03101475|DRUG|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
48013100|NCT03101475|RADIATION|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
48013101|NCT03101475|OTHER|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
48013102|NCT00770120|DRUG|everolimus|
48013103|NCT01282216|BIOLOGICAL|Havrix|1440 ELISA units, or 1 mL, IM
48013104|NCT01282216|BIOLOGICAL|PCV13|0.5 mL IM
48013105|NCT04535284|BEHAVIORAL|Coaching|"Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching."
48013106|NCT04341038|DRUG|Tacrolimus|the necessary dose to obtain blood levels of 8-10 ng / ml
48013107|NCT04341038|DRUG|Methylprednisolone|120mg of methylprednisolone daily for 3 consecutive days
48013108|NCT02636972|DRUG|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
48013109|NCT02948842|DRUG|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
48013110|NCT02948842|OTHER|Saline|0.08ml of injectable normal saline
48371427|NCT06049511|BEHAVIORAL|oral self care protocol|An oral self-care protocol, grounded in Orem's Self-Care Deficit theory and incorporating self-care behaviors, was implemented for the patients in the treatment group. The protocol consisted of several components, including the assessment of oral mucositis by the researcher and self-assessment of the oral cavity by the patients. It also involved teaching proper tooth brushing techniques, providing written materials, supplying an oral care kit, and offering patient and family education. Interventions were made for 21 days from the beginning of chemotherapy treatment.
48013111|NCT03214003|RADIATION|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
48169906|NCT00723918|DRUG|Methadone placebo|Methadone placebo
48169907|NCT01801462|OTHER|Simulation-based training|
48169908|NCT01624597|BEHAVIORAL|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
48371428|NCT06049511|BEHAVIORAL|standard care|the patients received standard nursing care provided at the clinic to prevent oral mucositis.
48516057|NCT06582498|BEHAVIORAL|Low-intensity intervention|This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivor at randomization (2nd visit). These recommendations are all based on information from the World Cancer Research Fund, the American Institute for Cancer Research, and the American Cancer Society.
48013112|NCT03214003|RADIATION|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
48013113|NCT02755831|DEVICE|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
48013114|NCT02755831|OTHER|Pre-natal care|Standard Pre-Natal Care
48169909|NCT01624597|BEHAVIORAL|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
48169910|NCT04266613|DIAGNOSTIC_TEST|TruGraf® Testing|5 mL collection PAXgene blood sample
48013115|NCT05424471|BEHAVIORAL|Family Spirit Nurture (FSN)|The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
48013116|NCT05424471|OTHER|Control Group - Vehicle Safety|The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
48013117|NCT03182348|PROCEDURE|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
48013118|NCT04409041|DRUG|Low-Dose Naltrexone|Based on the promising evidence, we propose using low-dose naltrexone at a daily dose of 3mg to treat lichen planopilaris and frontal fibrosing alopecia. The patients would be continued on their other medications for these conditions. The study would be open-label, so all participants would receive the low-dose naltrexone. Patients would be seen at 0,3,6 and 12 months to monitor their progress.
48013119|NCT05709821|DRUG|IMM60|IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
48013120|NCT05709821|DRUG|Pembrolizumab|Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
48013121|NCT01698697|DRUG|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
48013122|NCT01389440|DRUG|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
48013123|NCT04931225|DRUG|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
48013124|NCT03759093|DRUG|Bortezomib|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
48013125|NCT03759093|DRUG|Cyclophosphamide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
48013126|NCT03759093|DRUG|Dexamethasone|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
48013127|NCT03759093|OTHER|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen
48013128|NCT03759093|DRUG|Thalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
48013129|NCT03759093|DRUG|Bortezomib|Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
48013130|NCT03759093|DRUG|Cyclophosphamide|Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
48371429|NCT02086240|DRUG|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
48371430|NCT05813769|DIETARY_SUPPLEMENT|Dairy protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
48371431|NCT05813769|DIETARY_SUPPLEMENT|Plant protein|During each visit, research subjects will receive the product dissolved in water, representing a 20g protein load.
48013131|NCT03759093|DRUG|Thalidomide|Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
48013132|NCT03759093|DRUG|Dexamethasone|40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
48013133|NCT03759093|DRUG|Lenalidomide|Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
48013134|NCT03759093|DRUG|Lenalidomide|Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.
48371432|NCT02117466|DRUG|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
48371433|NCT02117466|DRUG|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
48371434|NCT02296541|BIOLOGICAL|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48516058|NCT04267432|DIETARY_SUPPLEMENT|Placebo|Blank
48516059|NCT04267432|DIETARY_SUPPLEMENT|TCI633|Probiotics
48516060|NCT04267432|DRUG|Type 2 collagen|Positive control group
48516061|NCT00538369|OTHER|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
48516062|NCT00538369|DEVICE|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
48169911|NCT00887380|DRUG|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
48013135|NCT02984397|DRUG|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
48013136|NCT02984397|DRUG|Placebo|
48169912|NCT00887380|RADIATION|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
48169913|NCT00887380|DRUG|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
48013137|NCT02984397|OTHER|Standard of Care|
48013138|NCT05022823|DEVICE|Compression sleeve, worn during exercise|Participants wear their daytime compression sleeve during the DPRE program.
48013139|NCT05022823|DEVICE|Adjustable Compression (AC) garment, worn during exercise|Participants wear an Adjustable Compression (AC) garment during the DPRE program. Participants will be fitted for an Adjustable Compression garment and instructed in its application by a physical therapist.
48013140|NCT05022823|DEVICE|Compression sleeve, daytime wear|Compression sleeve worn for at least 12 hours per day, seven days a week.
48013141|NCT05022823|BEHAVIORAL|Decongestive Progressive Resistance Exercise program|"Supervised DPRE exercise program, twice a week for 12 weeks. Exercises will be individualized and offered in a group-based format.~After the 12-week intervention, participants will continue the same program (independently) twice weekly for an additional 12 weeks at home or in a community-based fitness center or attend supervised group exercise sessions virtually."
48013142|NCT05022823|BEHAVIORAL|Home exercise program|Participants are provided with a home exercise program that follows the decongestive exercise sequence and instructed to perform the exercise sequence once daily for a 10-15 minute period.
48169914|NCT04228900|DIETARY_SUPPLEMENT|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
48169915|NCT04228900|DRUG|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
48169916|NCT05579665|BIOLOGICAL|Platelet-rich Plasma|Research participants own blood will be used to prepare the platelet rich plasma injectate.
48013143|NCT00917813|DRUG|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
48013144|NCT00917813|DRUG|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
48013145|NCT01890200|DRUG|Peginterferon alfa-2a|conventional treatment of Hepatitis C
48013146|NCT01890200|DRUG|Ribavirin|conventional treatment of Hepatitis C
48013147|NCT01890200|DRUG|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
48013148|NCT01890200|DRUG|Placebo|Placebo, without acting ingredient.
48013149|NCT02618330|DEVICE|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
48013150|NCT06464939|DRUG|KH001|Applications of KH001 over a 1 or 2-week period, and application of placebo
48013151|NCT06464939|DRUG|Placebo|Applications of water for injection
48013152|NCT06662500|DEVICE|Intravascular Lithotripsy|The Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
48013153|NCT03684200|OTHER|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
48013154|NCT06466954|OTHER|Evaluating spinopelvic alignment parameters|Evaluation of thoracic kyphosis, lumbar lordosis, pelvic tilt, and pelvic torsion
48169917|NCT05579665|BIOLOGICAL|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.
48169918|NCT05579665|DRUG|Low Molecular Weight Hyaluronic Acid|low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
48169919|NCT05345847|OTHER|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
48169920|NCT05345847|OTHER|Early initiation|Immediate start of high-dose steroids
48169921|NCT03271177|DEVICE|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
48169922|NCT03271177|DEVICE|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
48169923|NCT04306913|DRUG|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
48169924|NCT04306913|DRUG|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
48169925|NCT03553485|DEVICE|Transcutaneous vagus nerve stimulation|The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
48169926|NCT03553485|DEVICE|Sham|Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
48169927|NCT03553485|RADIATION|Radiotherapy|Standard treatment for included patients
48169928|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was ON|The option for compensation of Pupil centroid shift was ON
48169929|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was OFF|The option for compensation of Pupil centroid shift was OFF
48169930|NCT03844178|DRUG|installation of Tetracaine 1%|installation of Tetracaine 1%
48700674|NCT06608615|OTHER|Kinesio Taping|"Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm"
48013155|NCT06466954|OTHER|Measuring uterine dimensions|Measurement of corpus length, corpus width, cervix length, and cervix width
48013156|NCT02625493|OTHER|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
48013157|NCT02361567|DRUG|Tramacet|Pain medication commonly used post-operatively
48013158|NCT02361567|DRUG|Percocet|Pain medication commonly used post-operatively
48013159|NCT04073316|DRUG|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
48013160|NCT04073316|DRUG|Warfarin|Warfarin intake, with target INR range between 2 and 3
48013161|NCT01252459|RADIATION|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
48013162|NCT01252459|RADIATION|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
48013163|NCT03440879|DRUG|Zoladex|Patients currently treated with Zoladex
48169931|NCT03844178|PROCEDURE|Photorefractive keratectomy (PRK)|periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
48169932|NCT01878136|DRUG|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
48169933|NCT03987659|PROCEDURE|Irrigation protocols that promote release of dECMs|Irrigation protocols that promote release of dECMs
48169934|NCT03987659|PROCEDURE|Conventional Irrigation protocols|Conventional Irrigation protocols
48169935|NCT01593865|PROCEDURE|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
48169936|NCT01593865|PROCEDURE|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
48013164|NCT03049813|BEHAVIORAL|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
48013165|NCT03049813|OTHER|Supported Employment (Services as Usual)|Standard supported employment services.
48013166|NCT04670016|OTHER|This study does not include an intervention.|This study does not include an intervention.
48013167|NCT06028711|OTHER|Education program|Patients in a study group will participate in daily education program using an original brochure containing information on the benefits of appropriately adapted physical activity, practical tips on airway clearance techniques or physical exercise, and risk factors for exacerbation of COPD.
48169937|NCT00468065|DEVICE|VeinViewer|Veinveiwer is used to view veins subQ
48169938|NCT00468065|DEVICE|Veinviewer|near infrared light reveals veins subcutaneously
48169939|NCT04225039|DRUG|INCMGA00012|500mg IV neoadjuvant treatment; 500 mg adjuvant treatment
48169940|NCT04225039|DRUG|INCAGN01876|300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
48169941|NCT04225039|DRUG|SRS|administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).
48169942|NCT04225039|PROCEDURE|Brain surgery|maximal safe surgical resection of the tumor.
48169943|NCT01281215|BEHAVIORAL|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
48169944|NCT02157129|DEVICE|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
48013168|NCT06028711|OTHER|Pulmonary rehabilitation|The patients will participate in a 14-day rehabilitation program (Monday to Saturday). Treatments and therapies will be continued for a maximum of two hours daily. The program will be applied individually to each patient and include active and assisted exercises, effective cough exercises, pursed-lips breathing, positive expiratory pressure exercises, exercises to strengthen the diaphragm and intercostal muscles and cardiopulmonary exercises.
48013169|NCT04772092|BIOLOGICAL|Blood samples|"during the routine blood test, collection of additional blood samples:~* 1 x 5 mL heparinized tube for plasma collection and storage~* 1 heparinized 5 mL tube for immunophenotyping~* 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation"
48013170|NCT04772092|OTHER|Data collection|"* clinical examination data~* test results to measure the degree of geriatric fatigability~* Frailty screening questionnaire for neoplasia patients (G8 score)"
48013171|NCT05086692|DRUG|MDNA11|MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).
48013172|NCT05086692|DRUG|Pembrolizumab (KEYTRUDA®)|MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
48169945|NCT02157129|OTHER|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
48169946|NCT04322916|DEVICE|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
48169947|NCT02358213|PROCEDURE|Ultrasound|Ultrasound examinations are done 5 times
48013173|NCT05591677|DRUG|D-Cycloserine|D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
48169948|NCT06104579|OTHER|Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection|Concordance between the two registers was analysed using Cohen´s Kappa.
48169949|NCT02246218|DRUG|RAVICTI|
48169950|NCT01370018|BIOLOGICAL|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
48169951|NCT01997749|DIETARY_SUPPLEMENT|Ketocal 4:1 (Nutricia)|
48169952|NCT01997749|DIETARY_SUPPLEMENT|Control diet: Regular diet offered at the hospitals|
48169953|NCT01997749|DIETARY_SUPPLEMENT|Ketogenic meals|
48169954|NCT05687318|DEVICE|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
48169955|NCT00702650|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
48169956|NCT00925288|BIOLOGICAL|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
48169957|NCT00548002|DRUG|trovafloxacin and levofloxacin|Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid
48169958|NCT04387422|OTHER|Experimental hyperglycemia|Experimental hyperglycemia with MRI
48169959|NCT03292497|PROCEDURE|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle \>=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.
48169960|NCT03292497|PROCEDURE|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
48169961|NCT01653249|BIOLOGICAL|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
48700675|NCT06608615|OTHER|Rigid Taping|"Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side."
48169962|NCT05226988|DEVICE|robot-assisted|Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
48169963|NCT05226988|DEVICE|Conventional rehabilitation intervention|Participants received the 18-session conventional rehabilitation intervention 3 sessions a week for 6 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
48169964|NCT00245440|DRUG|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
48169965|NCT00245440|DRUG|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
48013174|NCT05591677|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
48013175|NCT01403207|OTHER|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
48013176|NCT02837536|OTHER|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
48013177|NCT02837536|OTHER|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
48013178|NCT01752140|PROCEDURE|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
48013179|NCT01752140|PROCEDURE|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
48013180|NCT02326142|DRUG|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
48013181|NCT02326142|DRUG|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
48013182|NCT04226079|DIAGNOSTIC_TEST|Collection of exhaled breath|Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
48013183|NCT01899469|PROCEDURE|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
48013184|NCT01899469|PROCEDURE|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
48013185|NCT01899469|PROCEDURE|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
48169966|NCT03891641|BEHAVIORAL|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
48700676|NCT03603899|DRUG|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
48700677|NCT01669252|DRUG|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
48700678|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
48700679|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
48700680|NCT01260090|DEVICE|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
48700681|NCT01260090|DEVICE|No stimulation|Vagus nerve stimulation
48700682|NCT04452435|DRUG|C21|C21
48013186|NCT00359450|DRUG|BMS-275183 (oral taxane)|
48700683|NCT04452435|DRUG|Placebo|Placebo
48013187|NCT05291390|DRUG|Pyronaridine Tetraphosphate|Via oral capsules.
48169967|NCT04461184|BEHAVIORAL|Internet Wellness Intervention for Aging|Internet technologies have emerged as a platform for performing wellness interventions that also have wide outreach. Previous studies that have used the internet for delivering health interventions have found that older adults valued this platform, used it for researching health information and social communications. Likewise, the effectiveness of delivering health-related information intended for behavior change through the internet is equal to that of print-based delivery, thereby lowering costs and expanding reach. Thus, the internet provides a unique platform for conducting interventions. The internet based wellness intervention will be a low cost method focused on older adults to help increase intrinsic motivation through autonomy, competence, and relatedness (Intrinsic Motivation) to help increase daily physical activity.
48169968|NCT00814632|DRUG|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
48700684|NCT06560554|OTHER|Fermented foods|Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.
48700685|NCT06560554|OTHER|Control|No information on incorporation of fermented foods will be provided for subjects in the control arm.
48013188|NCT01494311|DRUG|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
48013189|NCT01494311|DRUG|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
48013190|NCT01494311|DRUG|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
48013191|NCT01494311|DRUG|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
48013192|NCT05592015|DRUG|Ruxolitinib|Given PO
48169969|NCT02142998|OTHER|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
48169970|NCT02142998|OTHER|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
48169971|NCT04651556|DRUG|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
48169972|NCT04651556|DRUG|paracetamol & ketorolac|parenteral analgesics
48013193|NCT03723694|DIETARY_SUPPLEMENT|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
48013194|NCT03723694|DIETARY_SUPPLEMENT|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
48013195|NCT02130401|DEVICE|TNM (thermoneuromodulation device)|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
48013196|NCT03724825|DIAGNOSTIC_TEST|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
48013197|NCT03724825|DIAGNOSTIC_TEST|Total testosterone|blood samples will be collected after 10 hours fasting
48013198|NCT03724825|DIAGNOSTIC_TEST|Adropin|blood samples will be collected after 10 hours fasting
48013199|NCT03724825|DIAGNOSTIC_TEST|Adiponectin|blood samples will be collected after 10 hours fasting
48013200|NCT01296958|DRUG|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
48013201|NCT01296958|BEHAVIORAL|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
48013202|NCT01873989|DRUG|Testosterone replacement|
48013203|NCT01873989|OTHER|Waitlist control|
48013204|NCT00191997|DRUG|Olanzapine|
48013205|NCT03101709|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
48013206|NCT03101709|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
48013207|NCT03101709|BIOLOGICAL|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
48013208|NCT04095000|BEHAVIORAL|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
48013209|NCT04095000|BEHAVIORAL|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
48013210|NCT05493995|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
48013211|NCT05493995|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
48013212|NCT05493995|DRUG|Nab paclitaxel|125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.
48013213|NCT05493995|DRUG|Gemcitabine|1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
48013214|NCT05554861|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex foot area in the non-lesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
48013215|NCT05554861|DEVICE|Intermittent Theta Burst Stimulation (iTBS) Protocol|"It was planned to apply 50 Hz high-frequency stimulation protocol to the primary motor cortex foot area in the ipsilesional hemisphere, 5 days a week for 2 weeks, for a total of 10 sessions.~After the daily rTBS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
48013216|NCT05554861|DEVICE|Sham rTMS Protocol|"It was planned to apply daily sham rTMS to the motor extremity area of the primary motor cortex along a 10 cm thick wood for 10 sessions.~After the daily sham rTMS session, it was planned to apply a conventional rehabilitation therapy for 60 minutes to all patients for 6 weeks (Exercise program consisting of joint range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) for 45 minutes and 15 minutes of NMES application in the presence of an experienced physiotherapist)."
48013217|NCT02460224|DRUG|LAG525|LAG525 was administered via intravenous (i.v.) infusion
48169973|NCT05708313|BEHAVIORAL|lifestyle modification|Participants will undergo an exercise program designed by AHH
48013218|NCT02460224|DRUG|PDR001|PDR001 was administered via i.v. infusion
48013219|NCT02145039|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
48013220|NCT02145039|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
48013221|NCT02145039|RADIATION|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
48013222|NCT02145039|BIOLOGICAL|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
48013223|NCT04068181|DRUG|Talimogene laherparepvec|Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
48013224|NCT04068181|DRUG|Pembrolizumab|Intravenous (IV) infusion.
48013225|NCT05054296|BEHAVIORAL|Educational Intervention|Receive general education exercise packet
48013226|NCT05054296|BEHAVIORAL|Exercise Intervention|Participate in supervised and self-directed exercise sessions
48013227|NCT05054296|DEVICE|FitBit|Wear FitBit for activity tracking
48013228|NCT05054296|OTHER|Quality-of-Life Assessment|Ancillary studies
48013229|NCT05054296|OTHER|Questionnaire Administration|Ancillary studies
48013230|NCT00343317|DRUG|Intrapartum Cefoxitin (2g) vs. placebo|
48013231|NCT06406205|DRUG|Voclosporin（QL1074）|QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
48013232|NCT06406205|DRUG|Placebo|Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
48013233|NCT01835249|OTHER|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP \<120 mmHg.
48013234|NCT01835249|OTHER|Standard BP arm|Participants in the Standard BP arm have a goal of SBP \<140 mmHg.
48371435|NCT02296541|BIOLOGICAL|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48013235|NCT00458484|RADIATION|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions."
48013236|NCT00458484|PROCEDURE|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
48013237|NCT00458484|PROCEDURE|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
48013238|NCT02262728|DRUG|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
48013239|NCT02262728|DRUG|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
48013240|NCT02262728|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
48013241|NCT02645916|DRUG|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48013242|NCT02645916|DRUG|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
48013243|NCT03633435|PROCEDURE|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
48013244|NCT05986552|BEHAVIORAL|Individual Schema Therapy (IST)|IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
48013245|NCT05986552|BEHAVIORAL|Individual-Group Schema Therapy (IGST)|IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
48013246|NCT06054672|DEVICE|Subthreshold Electrical stimulation|We will use a electrotherapy device to deliver subthreshold Electrical stimulation
48169974|NCT05546736|BEHAVIORAL|iCanWork Intervention|Participants will receive RTW support from the VRC and OT.
48371436|NCT02296541|BIOLOGICAL|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48371437|NCT02296541|BIOLOGICAL|MVA-CMDR|1×10\^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48371438|NCT02296541|BIOLOGICAL|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48013247|NCT02178033|DRUG|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
48700686|NCT04574414|DIAGNOSTIC_TEST|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
48013248|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI|
48013249|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI|
48013250|NCT02359292|DRUG|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
48013251|NCT02359292|DRUG|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
48700687|NCT04286841|DRUG|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
48013252|NCT02359292|DRUG|Placebo pMDI|
48013253|NCT02327429|BEHAVIORAL|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
48013254|NCT05892627|DIETARY_SUPPLEMENT|PoZibio|PoZibio (50 x 10\^9 CFUs/ CAPSULE)
48013255|NCT05892627|DIETARY_SUPPLEMENT|Placebo|Placebo
48371439|NCT02296541|BIOLOGICAL|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48013256|NCT05907135|DIETARY_SUPPLEMENT|Beet|Beet-based powder with other ingredients
48013257|NCT05907135|DIETARY_SUPPLEMENT|Placebo|Placebo powder.
48013258|NCT05897216|DRUG|CKD-383|QD, PO
48013259|NCT05897216|DRUG|CKD-501, D745, D150, D029|QD, PO
48013260|NCT04705545|DEVICE|transpalatal arch group|transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.
48013261|NCT04705545|DEVICE|Nance button|Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
48013262|NCT03735394|DIAGNOSTIC_TEST|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
48013263|NCT01043965|DRUG|Metformin|Metformin 850mg
48013264|NCT05637645|PROCEDURE|Midline Approach|In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
48013265|NCT05637645|PROCEDURE|Paramedian Approach|The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
48013266|NCT05637645|PROCEDURE|Taylors approach|his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
48013267|NCT04515186|DRUG|Meglumine Antimoniate|Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).
48371440|NCT02296541|BIOLOGICAL|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48371441|NCT02296541|BIOLOGICAL|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
48700688|NCT05322512|DRUG|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
48169975|NCT02971228|DRUG|Insulin Lispro|Used to lower blood glucose. Commercially available by prescription and is indicated for patients with type 1 diabetes mellitus (T1DM), but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
48700689|NCT04545190|DIETARY_SUPPLEMENT|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
48700690|NCT00633074|BIOLOGICAL|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
48700691|NCT00633074|BIOLOGICAL|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
48700692|NCT05587062|BIOLOGICAL|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
48700693|NCT05587062|BIOLOGICAL|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
48700694|NCT02465723|DEVICE|MRI with IVIM DW-MRI|
48700695|NCT02465723|OTHER|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
48700696|NCT04245670|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
48700697|NCT06608420|OTHER|Gradient Boosting Survival Analysis (GBSA),|It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.
48700698|NCT06608420|OTHER|Concordance index|The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
48700699|NCT05943392|OTHER|EEG recording|EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli
48700700|NCT05943392|OTHER|Psychophysics (behavioural experiments)|Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
48700701|NCT01540630|DRUG|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
48700702|NCT01540630|DRUG|Placebo|Double-blind placebo comparator for 28 days.
48700703|NCT05734001|DIAGNOSTIC_TEST|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
48700704|NCT05734001|DIAGNOSTIC_TEST|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
48700705|NCT06327074|BEHAVIORAL|Engaged Approach to Lung Cancer Screening|"Sites randomized to use the EA-LCS materials will be given password-protected access to the program/toolkit web portal and encouraged to use any materials that fit the normal flow of clinic procedures. Materials available include both staff-facing and LCS candidate-facing materials.~Staff-facing materials include:~* Program website/manual/toolkit overview~* Implementation insights with experts video series~* Clinical placement placards~* Program and clinician communication tools~Candidate-facing materials include:~* Program welcome letter~* Maps and directions template~* Communication preferences~* Candidate letter templates (N=\~8)~* Program newsletter template and instructions~* Lung nodule size comparison chart"
48013268|NCT04515186|DRUG|Miltefosine|50 mg capsule
48013269|NCT04515186|DEVICE|Thermotherapy machine|Localized Current Field radio-frequency generating device
48013270|NCT01980849|DRUG|Nadroparin, long term|
48013271|NCT01980849|DRUG|Nadroparin: short-term|
48013272|NCT01014507|DRUG|8 cycles BEACOPPesc plus oral contraceptive|
48169976|NCT02971228|DRUG|ZP4207 (dasiglucagon)|A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
48013273|NCT01014507|DRUG|8 cycles BEACOPPesc plus Goserelin|
48169977|NCT02971228|DRUG|Glucagon|A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
48371442|NCT01659411|OTHER|Observational|Yearly clinical visits
48013274|NCT05192577|OTHER|Electrical stimulation|At the beginning of the session, an electrode will be attached to the participant's ankle. Electrical stimulation will be applied to estimate the electrical perception threshold. This threshold will be used as condition stimuli when different thermal thresholds are assessed.
48013275|NCT01930058|DRUG|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
48169978|NCT02971228|DEVICE|iPhone-based bionic pancreas|An experimental device.
48169979|NCT02971228|DEVICE|iLet-based bionic pancreas|An experimental device.
48169980|NCT05851456|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
48169981|NCT04280679|DEVICE|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
48013276|NCT02692833|OTHER|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
48013277|NCT03320239|BEHAVIORAL|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
48169982|NCT03955861|BIOLOGICAL|adalimumab|Subcutaneous injection
48169983|NCT03955861|BIOLOGICAL|Certolizumab|Subcutaneous injection
48013278|NCT03320239|BEHAVIORAL|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
48013279|NCT03320239|BEHAVIORAL|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
48169984|NCT03955861|BIOLOGICAL|Etanercept|Subcutaneous injection
48169985|NCT03955861|BIOLOGICAL|Golimumab|Subcutaneous injection
48169986|NCT03955861|BIOLOGICAL|Secukinumab|Subcutaneous injection
48169987|NCT00249730|DRUG|Sildenafil|
48371443|NCT03329053|BEHAVIORAL|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
48013280|NCT03266562|DIAGNOSTIC_TEST|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
48013281|NCT03266562|DIAGNOSTIC_TEST|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
48371444|NCT03329053|BEHAVIORAL|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
48371445|NCT00951587|DEVICE|PillCam™ (Capsule Endoscopy)|Medical Device
48371446|NCT05130736|DEVICE|Robot rehabilitation|Effectiveness of using a rehabilitation robot in post-COVID-19 rehabilitation
48371447|NCT04754009|BEHAVIORAL|Trauma-Sensitive Yoga + TAU|Trauma-Sensitive Yoga is a movement-based approach that are used to integrate both mind and body, and promote body awareness and acceptance for those who have been exposed to traumatic events and currently experience trauma symptoms.
48013282|NCT04996992|PROCEDURE|MR-guided focused ultrasound|MR-guided focused ultrasound pallidothalamic tractotomy is a minimally invasive and effective procedure for thetreatment of Parkinson's disease(PD) patients.
48013283|NCT04904523|DIAGNOSTIC_TEST|Diagnostic Test:Blood test|Drop of blood for RNA and metabolic analysis
48013284|NCT05826067|OTHER|collection of bacterial strains|Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
48013285|NCT00466765|DEVICE|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
48169988|NCT02692287|DEVICE|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
48169989|NCT02762539|DRUG|omega-3 enriched SMOF lipid emusion|
48169990|NCT03185845|DRUG|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
48169991|NCT04675905|OTHER|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged \>= 65 years
48169992|NCT03025997|DIETARY_SUPPLEMENT|Active yoghurt|Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
48169993|NCT03025997|DIETARY_SUPPLEMENT|Placebo yoghurt|Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
48169994|NCT04360434|DRUG|NI006|NI006 will be administered intravenously
48169995|NCT04360434|DRUG|Placebo|Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
48013286|NCT06020404|PROCEDURE|supine position|At the end of the PEEP trial (i.e. at PEEP 5 cmH2O), patients will lay in the supine position for 15 minutes arterial blood gases will be performed and then a one-breath derecruitment maneuver (5-second exhalation, respiratory rate \< 8 bpm) from PEEP 5 cmH2O to 0 cmH2O will be conducted to assess baseline functional residual capacity (FRC), defined as the EELI measured at 0 PEEP.
48013287|NCT06020404|PROCEDURE|prone position|"After the supine step, each enrolled patient will be placed in the prone position for 1 hour.~For safety reasons, enteral feeding will be interrupted 30 minutes before prone positioning and re-established after the study ending.~During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 30 minutes of prone positioning. After 30 minutes of PEEP 12 cmH2O (provided that plateau and driving pressures did not exceed 30 cmH2O and 15 cmH2O, respectively) to stabilize lung volumes, the same measurements applied for the supine step will be performed. Any further modifications in the MV settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.~In case of sudden worsening of the oxygenation impairment or haemodynamic, 100% FiO2 will be set, and the patient will be promptly positioned in the supine semi-recumbent position."
48169996|NCT00488228|BEHAVIORAL|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
48169997|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
48169998|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
48169999|NCT04817033|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
48170000|NCT04817033|DRUG|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
48700706|NCT04158037|BEHAVIORAL|mHealth App|The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
48700707|NCT04564807|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
48170001|NCT05522777|OTHER|Drink one bottle of Yakult a day|Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota
48170002|NCT00249171|DRUG|risperidone|
48170003|NCT01222078|BIOLOGICAL|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
48170004|NCT06332300|DRUG|Adebelimumab+Famitinib + FOLFIRI+Ariely|Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
48170005|NCT03010345|DEVICE|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
48170006|NCT03010345|OTHER|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
48170007|NCT02907450|DEVICE|TwiCare®.|
48170008|NCT02845713|DRUG|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
48170009|NCT03577925|DIAGNOSTIC_TEST|HPV genotype test|HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
48170010|NCT03935932|DEVICE|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
48170011|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
48170012|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
48170013|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
48170014|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
48170015|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
48170016|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
48371448|NCT04754009|BEHAVIORAL|Chen Style Tai Chi + TAU|Chen Style Practical Method tai chi is a martial art that is used as a form of self-defense and to maintain physical health and well-being.
48371449|NCT04754009|BEHAVIORAL|Treatment as Usual|Consists of traditional talk therapy for mental health.
48700708|NCT04564807|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
48013288|NCT01394575|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
48013289|NCT05526872|OTHER|Best Practice|Receive usual care
48013290|NCT05526872|BEHAVIORAL|Health Education|Receive educational materials
48700709|NCT06588530|BIOLOGICAL|TENIVAC|TENIVAC (Tetanus and Diphtheria Toxoids Adsorbed) is an active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
48700710|NCT05295901|DEVICE|mKOAH application|mobile app installed group
48700711|NCT05465798|DRUG|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
48700712|NCT05465798|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
48700713|NCT05048836|OTHER|Food Subsidy, 6 months|Food subsidy for 6 months
48700714|NCT05048836|OTHER|Food Subsidy, 12 months|Food subsidy for 12 months
48700715|NCT05048836|BEHAVIORAL|Lifestyle Support, 6 months|lifestyle support intervention delivered by community health workers for 6 months
48700716|NCT05048836|BEHAVIORAL|Lifestyle Support, 12 months|lifestyle support intervention delivered by community health workers for 6 months
48700717|NCT05048836|OTHER|Food Delivery, 6 months|Twice monthly delivery of healthy food for 6 months
48013291|NCT05526872|OTHER|Interview|Ancillary studies
48013292|NCT05526872|OTHER|Planned Notification|Receive planned reminders to schedule mammogram
48013293|NCT05526872|OTHER|Survey Administration|Ancillary studies
48013294|NCT03184792|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
48013295|NCT03184792|OTHER|Physical therapy|Physical therapy to improve arm and hand functions
48013296|NCT05691140|OTHER|Cognitive Behavioural Therapy|Cognitive Behavioural Therapy targeting Intolerance of Uncertainty
48700718|NCT05048836|OTHER|Food Delivery, 12 months|Twice monthly delivery of healthy food for 12 months
48013297|NCT03392636|PROCEDURE|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
48013298|NCT04089267|DRUG|TPO|
48013299|NCT03022149|DEVICE|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
48700719|NCT02040350|DRUG|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
48700720|NCT04964986|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
48700721|NCT05463718|DEVICE|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
48700722|NCT03987802|DRUG|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
48700723|NCT04818502|DEVICE|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
48013300|NCT03022149|DEVICE|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
48013301|NCT01396863|PROCEDURE|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
48170017|NCT05548413|BEHAVIORAL|FamLit|The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.
48170018|NCT05548413|BEHAVIORAL|Attention Control|Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
48170019|NCT03184142|BEHAVIORAL|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
48700724|NCT01520701|DEVICE|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
48700725|NCT01520701|DRUG|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
48700726|NCT06356935|OTHER|RT|Resistance training
48700727|NCT06356935|OTHER|CON|Control group
48700728|NCT02370485|DRUG|LY2801653|Administered orally
48700729|NCT03783000|DRUG|BI 425809|Treatment T
48700730|NCT03783000|DRUG|BI 425809 mixed with [C-14]-BI 425809|Treatment R
48700731|NCT03915574|DEVICE|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
48170020|NCT03184142|BEHAVIORAL|Video|Student watch a 15-minute intimidation video (see arm description).
48170021|NCT03184142|BEHAVIORAL|Control group|No intervention. The students suture for 70 minutes
48700732|NCT03915574|DEVICE|Standard Epidural|Control group - standard epidural (no dural puncture)
48700733|NCT03475706|DRUG|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
48700734|NCT03475706|DRUG|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
48700735|NCT03475706|DRUG|Matching Placebo|twice daily for 12 weeks.
48170022|NCT00938990|DRUG|Etomidate|
48170023|NCT00938990|DRUG|Midazolam|
48170024|NCT02999932|OTHER|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
48170025|NCT05439525|OTHER|mulligan technique|The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
48170026|NCT05439525|OTHER|conventional therapy|"1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness"
48170027|NCT04251546|DIAGNOSTIC_TEST|p2PSA|p2PSA test(for calculation of PHI)
48170028|NCT04251546|DIAGNOSTIC_TEST|Ultrasonic parameters|Ultrasonic parameters(TPV)
48700736|NCT04440397|OTHER|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
48700737|NCT06607419|DRUG|Blinatumomab|Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
48700738|NCT00509860|DRUG|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
48700739|NCT06117969|DRUG|Tibolone|1.25mg po qd
48700740|NCT06117969|DRUG|Xiangshao granules|4g po tid
48700741|NCT06117969|DRUG|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
48700742|NCT03929653|OTHER|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
48700743|NCT00349011|PROCEDURE|Personalized risk assessment|
48700744|NCT00349011|PROCEDURE|genetic counseling intervention|
48700745|NCT04779567|DRUG|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
48013302|NCT01396863|PROCEDURE|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
48013303|NCT03641378|OTHER|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
48013304|NCT03641378|OTHER|Standard Transplant Care|Standard care per hospital guidelines
48700746|NCT04779567|DRUG|Placebo|100 ml saline 0.9% iv 4 times a day
48700747|NCT05108272|PROCEDURE|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
48700748|NCT05108272|PROCEDURE|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
48013305|NCT02073422|DEVICE|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
48013306|NCT02073422|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
48013307|NCT03614793|PROCEDURE|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
48013308|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
48013309|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
48013310|NCT01469065|DRUG|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
48013311|NCT01469065|DRUG|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
48013312|NCT01469065|DRUG|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
48013313|NCT04302467|PROCEDURE|fluid therapy during operation|ERAS protocol of lobectomy will implemented to all the participants during perioperation,two groups of participants will be given different intraoperative fluid therapy strategy.
48013314|NCT03448003|OTHER|Cancer Prevention|Attend IO prevention program
48013315|NCT03448003|OTHER|Questionnaire Administration|Ancillary studies
48013316|NCT01166594|DRUG|Bevacizumab|Intrableb injection
48013317|NCT01166594|DRUG|Control|intrableb BSS injection
48170029|NCT04251546|DIAGNOSTIC_TEST|Transperineal prostate biopsy|Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
48170030|NCT00004097|DRUG|fluorouracil|
48170031|NCT00004097|DRUG|gemcitabine hydrochloride|
48371450|NCT03979924|BEHAVIORAL|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,...) in order to strengthen the stretching."
48371451|NCT01979250|PROCEDURE|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
48371452|NCT03865550|DRUG|Isotonic saline|Placebo
48700749|NCT02592720|DRUG|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
48700750|NCT02592720|DEVICE|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
48700751|NCT02592720|DEVICE|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
48700752|NCT04945850|PROCEDURE|routine care intraocular sx|Fluid was collected during routine intraocular surgery
48700753|NCT04771923|DRUG|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
48013318|NCT00360776|DRUG|tipifarnib|Given orally
48013319|NCT00360776|OTHER|laboratory biomarker analysis|Correlative studies
48013320|NCT00285935|OTHER|Standard Clinical Care with an SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)"
48013321|NCT06663176|DRUG|RESP302|Nitric Oxide agent
48013322|NCT06663176|DRUG|RESP303|Nitric Oxide agent
48013323|NCT00501540|DRUG|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
48013324|NCT05407935|BEHAVIORAL|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
48013325|NCT05407935|BEHAVIORAL|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
48013326|NCT00850200|RADIATION|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
48013327|NCT00850200|RADIATION|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
48013328|NCT00850200|RADIATION|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
48013329|NCT05844878|BEHAVIORAL|Cognitive behavioral therapy (CBT) by using Distraction technique.|"Distraction: The distraction in this arm will be done by hearing of soft music; the name of music that will be used is relaxing piano music and water sounds 24/7 - ideal for stress relief. This music will be used in both the reception room and in the dental room treatment from the time-point that patient enters the reception room, and continues into the dental treatment room until the end of dental treatment when the patient exits the dental treatment room"
48170032|NCT00004097|DRUG|paclitaxel|
48170033|NCT00004097|RADIATION|radiation therapy|
48170034|NCT05135923|DIETARY_SUPPLEMENT|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
48170035|NCT02805985|DEVICE|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
48170036|NCT02726035|DRUG|Naltrexone|oral naltrexone 50 mg daily
48170037|NCT02726035|OTHER|Placebo|oral placebo (appearing identical to naltrexone) once daily
48700754|NCT04771923|DRUG|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
48013330|NCT05844878|BEHAVIORAL|Mindfulness technique by using of relaxation breathing with muscle relaxation|"The mindfulness technique consist of combination of 2 procedures:~1. Relaxation breathing: this will be done during the course of dental treatment by asking the patient to do the following Gently breathe in - hold - and let go. This procedure will be applied at the first moment when the patient sits on the dental chair before any dental treatment is done and the patient is asked to repeat this twice, each for a duration of 10 seconds. This procedure will be repeated twice; at zero time and after an interval of 16 minutes of dental treatment that extend for a 30-minute duration for each patient.~2. Muscle relaxation: this will be done by asking the patient during dental treatment to do the following Hands - gently clench - hold - and let go. This procedure will be applied after 8 minutes from starting dental treatment, and ask the patient to do it twice for about 10 seconds. This procedure will be repeated twice; at 8 minutes and at 24 minutes of dental treatment."
48522922|NCT01315431|DRUG|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
48700755|NCT06306729|DIAGNOSTIC_TEST|Computed Tomography, Magnetic Resonance Imaging|Computed Tomography, Magnetic Resonance Imaging
48700756|NCT02627547|BEHAVIORAL|Normal training|5-10 hours of endurance training each week
48700757|NCT02627547|BEHAVIORAL|De-training|No training
48700758|NCT04871412|DIETARY_SUPPLEMENT|Vitamin D3 Drops|1,000 - 10,000 units daily based on serum levels for the duration of the study
48170038|NCT03240497|BEHAVIORAL|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\]."
48700759|NCT04871412|DIETARY_SUPPLEMENT|Coriolus Versicolor|1.5g twice daily for the duration of the study
48700760|NCT04871412|DIETARY_SUPPLEMENT|Trident SAP 66:33 Lemon|3g once daily for the duration of the study
48700761|NCT04871412|DIETARY_SUPPLEMENT|Probiotic Pro12|12 billion colony forming units daily during the peri-operative period (approximately 1 month pre and post-surgery)
48700762|NCT04871412|DIETARY_SUPPLEMENT|Provitalix Pure Whey Protein|1 scoop (22g) once daily during the peri-operative period (approximately 1 month pre and post-surgery) and during any adjuvant chemotherapy and radiation treatments
48700763|NCT04871412|DIETARY_SUPPLEMENT|Theracurmin 2X|1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
48013335|NCT00384813|BEHAVIORAL|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
48013336|NCT00384813|BEHAVIORAL|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
48013337|NCT02258152|DRUG|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
48013338|NCT02258152|DRUG|Placebo|Placebo QD
48013339|NCT06663787|DRUG|Trastuzumab (Herceptin)|Continuing anti-HER2 treatment
48013340|NCT06663787|DIAGNOSTIC_TEST|SIgnatera|A personalized, tumor-informed test.
48013341|NCT03700359|DRUG|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
48013342|NCT03700359|DRUG|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
48013343|NCT03700359|DRUG|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
48013344|NCT02675452|DRUG|AMG 176|Study Drug
48013345|NCT02675452|DRUG|Azacitidine|Non-investigational product
48013346|NCT02675452|DRUG|Itraconazole|Non-investigational product
48013347|NCT05239624|DRUG|Enfortumab vedotin|Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.
48013348|NCT05239624|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
48700764|NCT04871412|DIETARY_SUPPLEMENT|Green Tea Extract|700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
48700765|NCT04871412|OTHER|Nutrition Recommendations|Based on the Mediterranean diet and lower glycemic index foods
48700766|NCT04871412|OTHER|Physical Activity Recommendations|150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
48013349|NCT03523559|GENETIC|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
48013350|NCT01322204|DRUG|Codeine|One single oral dose of 1 mg/kg of codeine
48013351|NCT06664242|DEVICE|Placebo|these patients will be subjected to the same usual routine of pharmacological analgesia, consisting of the administration of 1g of dipyrone at the discretion, with escalation to tramal (dose) and physiotherapy in the hospital ICU, in addition to an application of TENS, with the device turned on, with programming on channels that are not connected to the patients, so as to generate visual and auditory feedback.
48170039|NCT03240497|BEHAVIORAL|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
48170040|NCT03883698|DRUG|Sofosbuvir|Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
48371453|NCT03865550|DRUG|Ketamine Injectable Solution|Active comparator
48371454|NCT03970330|DRUG|Naltrexone|4.5mg daily dose, taken orally
48700767|NCT04871412|BEHAVIORAL|Psychological Recommendations|Activities with the intention of actively improving the participant's mental and emotional health
48700768|NCT00044837|DRUG|Medroxyprogesterone acetate|
48700769|NCT00044837|DRUG|Estradiol|
48700770|NCT01126268|DRUG|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
48700771|NCT00142168|DRUG|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
48700772|NCT00142168|DRUG|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
48700773|NCT00742287|DIETARY_SUPPLEMENT|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
48013352|NCT06664242|DEVICE|TENS low frequence group|Patients in this group will undergo the hospital usual analgesia and physiotherapy routine, in addition to conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs.
48371455|NCT03970330|DRUG|Norethindrone Acetate|5 - 15mg daily dose, taken orally
48371456|NCT03970330|DRUG|Placebo|daily placebo pill, taken orally
48371457|NCT02980211|DRUG|Alveolar Ridge Reconstruction|Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
48371458|NCT04230746|DRUG|Bactrim DS 800Mg-160Mg Tablet|To study effect on urinary microbiome
48371459|NCT04230746|DRUG|Placebo oral tablet|To study effect on urinary microbiome
48371460|NCT04348760|BEHAVIORAL|Rotation Diet|Based on the food-specific IgG measurement and relative distribution, a personalized food profile was created for each subject identifying 1 to 3 relevant food groups/nutritional clusters. Subjects were then instructed to avoid the foods highlighted in their personal food profile in certain days of the week, and to assume them in 7 of the 21 meals of the week. No calorie restriction was imposed in the diet.
48700774|NCT00742287|DIETARY_SUPPLEMENT|Placebo|placebo
48700775|NCT03299881|DEVICE|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
48700776|NCT03299881|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
48700777|NCT01467050|OTHER|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
48700778|NCT01467050|OTHER|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
48700779|NCT02523157|OTHER|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
48700780|NCT02523157|OTHER|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
48700781|NCT01468207|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
48700782|NCT01468207|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
48700783|NCT06257667|OTHER|Respiratory Support|Treatment with High Flow Nasal Cannula
48371461|NCT03043287|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
48371462|NCT04398797|OTHER|PATINA algorithm|Once a week community nurses receive a list of community dwelling citizens deemed at risk of deterioration that can lead to hospital admission. Nurses assess each citizens situation and initiate intervention if needed (not part of the intervention).
48700784|NCT00006253|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
48013353|NCT06664242|DEVICE|Conventional TENS|In this group, patients will undergo the usual routine of analgesia and hospital physiotherapy, in addition to TENS with a frequency of 140 Hz, pulse width of 50 µs.
48170041|NCT03883698|DRUG|Daclatasvir 60 mg|Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
48170042|NCT03987464|BEHAVIORAL|Planning for the Future|This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
48170043|NCT03987464|BEHAVIORAL|Enhanced Medical Engagement|This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
48170044|NCT03987464|BEHAVIORAL|Confidence Building and Social Engagement|This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
48371463|NCT04647006|PROCEDURE|thyroid|Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
48371464|NCT04826042|OTHER|thoracic epidural catheterization|thoracic epidural catheterization
48371465|NCT00473187|DRUG|somatropin|
48371466|NCT02007824|DEVICE|ULSD-12D|wound cleansing and debridement using ULSD-12D
48371467|NCT02007824|DEVICE|SONOCA-180|wound cleansing and debridement using SONOCA-180
48371468|NCT03328572|OTHER|E-max Endocrown|Endocrown preparation
48371469|NCT03328572|OTHER|Cerasmart Endocrown|Endocrown preparation
48700785|NCT00006253|BEHAVIORAL|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
48700786|NCT01320553|DRUG|SPARC1102 I|SPARC1102 I will be administered in both eyes
48170045|NCT03987464|BEHAVIORAL|Physical Intervention|This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
48170046|NCT03987464|BEHAVIORAL|Medical Adherence|This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
48170047|NCT02482935|DRUG|Abemaciclib|Administered orally
48170048|NCT01228305|OTHER|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
48170049|NCT02604485|DRUG|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
48170050|NCT02604485|DRUG|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
48700787|NCT01320553|DRUG|SPARC1102 II|SPARC1102 II will be administered in both eyes
48700788|NCT01320553|DRUG|SPARC1102 III|SPARC1102 III will be administered in both eyes
48700789|NCT01320553|DRUG|Vehicle|Vehicle will be administered in both eyes
48700790|NCT01120860|DEVICE|MRI|MRI - routine imaging sequences, designed for anatomical quantification
48700791|NCT05791565|DRUG|Salbutamol HFA-152a|Salbutamol HFA-152a will be administered.
48700792|NCT05791565|DRUG|Salbutamol HFA-134a|Salbutamol HFA-134a will be administered.
48700793|NCT04027803|BIOLOGICAL|BCD-148|single intravenous infusion of BCD-148 (900 mg)
48371470|NCT05523427|DIETARY_SUPPLEMENT|Two probiotic strains (L. plantarum and L. acidophilus)|A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
48700794|NCT04027803|BIOLOGICAL|Soliris|single intravenous infusion of Soliris (900 mg)
48700795|NCT00559429|DRUG|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
48700796|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
48700797|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
48700798|NCT00559429|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
48700799|NCT02697227|BEHAVIORAL|Behavioral Intervention|Receive BATS counseling
48371471|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
48700800|NCT02697227|OTHER|Laboratory Biomarker Analysis|Correlative studies
48700801|NCT02697227|DRUG|Nicotine Patch|Receive nicotine patch
48700802|NCT02697227|OTHER|Questionnaire Administration|Ancillary studies
48700803|NCT02697227|BEHAVIORAL|Smoking Cessation Intervention|Receive standard smoking cessation counseling
48700804|NCT02802423|DRUG|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
48013354|NCT02919670|DIETARY_SUPPLEMENT|Enterade|
48170051|NCT02604485|DRUG|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
48371472|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5|Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
48371473|NCT04652245|DRUG|Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5|Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
48700805|NCT00262886|BIOLOGICAL|anti-thymocyte globulin|
48700806|NCT00262886|BIOLOGICAL|graft-versus-tumor induction therapy|
48700807|NCT00262886|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48013355|NCT02919670|DIETARY_SUPPLEMENT|Placebo|
48013356|NCT02919670|OTHER|Standard Supportive Care|
48170052|NCT02604485|DRUG|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
48170053|NCT02496143|DRUG|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
48700808|NCT00262886|DRUG|cyclophosphamide|
48700809|NCT00262886|DRUG|fludarabine phosphate|
48700810|NCT00262886|DRUG|mycophenolate mofetil|
48700811|NCT00262886|DRUG|tacrolimus|
48700812|NCT00262886|PROCEDURE|allogeneic bone marrow transplantation|
48700813|NCT00262886|PROCEDURE|peripheral blood stem cell transplantation|
48700814|NCT00754949|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
48700815|NCT00754949|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
48700816|NCT00754949|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
48700817|NCT00562263|BEHAVIORAL|Lifestyle modification|Dietary modification and regular physical activity
48700818|NCT01853579|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
48013357|NCT06262360|PROCEDURE|General anesthesia with mask ventilation|Randomization to General anesthesia with mask ventilation
48700819|NCT01853579|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
48700820|NCT02815657|DRUG|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
48170054|NCT02496143|DRUG|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
48170055|NCT03618212|DIAGNOSTIC_TEST|MRI|Skeletal MRI and pelvic and spinal MRI
48371474|NCT04652245|DRUG|Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3|Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
48170056|NCT05654298|DRUG|Sumatriptan|Sumatriptan 100 mg
48170057|NCT05654298|DRUG|Ubrogepant|Ubrogepant 100 mg
48170058|NCT05155488|OTHER|No Intervention|This is a non-interventional study.
48170059|NCT03449134|DRUG|Placebo|Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
48170060|NCT03449134|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
48170061|NCT00841607|PROCEDURE|pancreaticojejunostomy vs pancreaticogastrostomy|
48170062|NCT01102387|DRUG|LAS41003|Once daily, topically
48700821|NCT02815657|DRUG|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
48170063|NCT01102387|DRUG|LAS189962|Once daily, topically
48170064|NCT01102387|DRUG|LAS189961|Once daily, topically
48170065|NCT04648852|OTHER|Heart failure risk estimation|Evaluation by heart failure risk score
48371475|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
48700822|NCT03159169|DEVICE|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
48700823|NCT04110951|BEHAVIORAL|Pranayama Breathing Technique|Yogic Breathing Technique
48170066|NCT01856010|OTHER|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
48170067|NCT01856010|OTHER|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
48170068|NCT05899621|DRUG|Obinutuzumab|Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
48170069|NCT05899621|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
48170070|NCT05899621|DRUG|Bendamustine|Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
48170071|NCT05899621|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
48170072|NCT05899621|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
48170073|NCT05899621|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
48371476|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
48371477|NCT03230539|DRUG|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
48700824|NCT04110951|BEHAVIORAL|Relaxation technique|Progressive relaxation technique
48700825|NCT00840047|DRUG|Methionine|Intravenous injection
48170074|NCT05899621|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
48170075|NCT05215418|DRUG|VI-0521|Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
48170076|NCT05215418|DRUG|Phentermine|Phentermine 30 mg capsule
48170077|NCT05215418|DRUG|Placebo|Inactive oral capsule
48170078|NCT02638233|DRUG|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
48170079|NCT05993520|OTHER|Assessment|Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
48170080|NCT01246232|DRUG|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
48170081|NCT01246232|DRUG|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
48170082|NCT03807700|DRUG|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
48170083|NCT00672672|BIOLOGICAL|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
48170084|NCT02450123|DRUG|sunitinib|
48700826|NCT04185402|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
48013358|NCT06262360|PROCEDURE|General anesthesia and spontaneous laryngeal mask ventilation|Randomization to General anesthesia and spontaneous laryngeal mask ventilation
48013359|NCT06262360|PROCEDURE|General anesthesia with spontaneous laryngeal mask ventilation with pressure support|Randomization to General anesthesia with spontaneous laryngeal mask ventilation with pressure support
48013360|NCT00401336|DEVICE|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
48013361|NCT03032003|OTHER|Cysticlean|2 BID for 15 days
48013362|NCT03032003|OTHER|Placebo|2 BID for 15 days
48013363|NCT04904510|DIAGNOSTIC_TEST|INDICAID™ COVID-19 Rapid Antigen Test|The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
48170085|NCT00159341|PROCEDURE|Nasal lavage|Nasal lavage was carried out at specified timepoints
48013364|NCT05075616|PROCEDURE|Percutaneous endoscopic gastrostomy|Percutaneous endoscopic gastrostomy (PEG) is a minimally-invasive endoscopic procedure that creates a passage from the patient's stomach to the abdominal wall via a feeding tube and provides a means of feeding if oral intake is not adequate.
48013365|NCT04832373|DEVICE|Interaction with humanoid robot|A humanoid robot will be installed for 30 days in children. It has a touchscreen tablet, allowing manual interaction complementing the voice interaction. The robot speaks, hears, and has facial and voice identification.
48170086|NCT00159341|PROCEDURE|Nasal filter paper|Nasal filter paper was placed at specified timepoints
48700827|NCT03517839|OTHER|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
48700828|NCT01205061|DEVICE|Emervel Deep Lidocaine|20 mg/mL + 0.3% lidocaine
48700829|NCT01205061|DEVICE|Juvederm Ultra Plus|24mg/mL
48700830|NCT05963412|OTHER|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
48700831|NCT01265563|DRUG|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
48700832|NCT01265563|DRUG|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
48700833|NCT01265563|DRUG|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
48700834|NCT01265563|DRUG|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
48170087|NCT00159341|PROCEDURE|Blood sampling|Blood sampling was performed as a routine safety check
48170088|NCT05470361|PROCEDURE|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
48170089|NCT01219777|DRUG|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
48170090|NCT01219777|DRUG|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
48170091|NCT01219777|DRUG|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
48170092|NCT00251290|PROCEDURE|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
48170093|NCT02956083|OTHER|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
48700835|NCT01265563|DRUG|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
48700836|NCT04731480|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
48700837|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to marsh model with the target plasma site concentration of 3-µg/ml. The plasma concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
48700838|NCT04731480|DRUG|Propofol|The target controlled infusion (TCI) pump will be programmed to Schneider model with the target effect site concentration of 3-µg/ml. The effect-site concentration will be altered to maintain a target BIS of 50 during induction and maintenance of anesthesia
48700839|NCT04731480|DRUG|Propofol|Manual propofol administration will be done using an intravenous infusion pump to maintain a target BIS of 50 during induction and maintenance of anesthesia.
48700840|NCT02030080|BEHAVIORAL|Financial incentives|
48170094|NCT02956083|OTHER|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
48700841|NCT02030080|BEHAVIORAL|Teams|
48170095|NCT02956083|OTHER|saline|Saline - no brand name
48170096|NCT01027663|DIETARY_SUPPLEMENT|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
48170097|NCT05781997|DIAGNOSTIC_TEST|cycloplegic refraction|Cycloplegic autorefraction will be attempted on all children using a table-mounted autorefractor . Cycloplegia will be achieved with three drops of 1% cyclopentolate administered 5 min apart and autorefractive measurements will be performed 30 min after the instillation of the last drop. Auto refraction readings of three consecutive measurements will be obtained and the average will be computed automatically in each eye. Each child will be reexamined until three measurements fell within 0.50 diopters (D) if any two measurements varied by \>0.50D.
48170098|NCT02795715|DEVICE|tDCS|
48170099|NCT02795715|BEHAVIORAL|training|
48170100|NCT04316221|DIETARY_SUPPLEMENT|Eggs plus standard of care|Eggs will be secured locally and delivered to families weekly.
48170101|NCT04316221|OTHER|Standar of care|frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
48170102|NCT05694533|DRUG|INDV-2000|Capsules administered orally twice a day
48700842|NCT02030080|BEHAVIORAL|Framing of feedback|
48700843|NCT02030080|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
48700844|NCT03629665|BEHAVIORAL|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
48700845|NCT03629665|DEVICE|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
48700846|NCT06349083|DRUG|Psilocybin|One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally
48700847|NCT06349083|OTHER|Inactive Placebo|Two matching placebo capsules administered once orally
48700848|NCT06349083|BEHAVIORAL|Supportive therapy sessions|Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
48700849|NCT01608698|DRUG|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
48170103|NCT05694533|DRUG|Midazolam|Midazolam syrup administered orally on Days 1 and 15
48170104|NCT05858801|DEVICE|PRIMUS|PRIMUS system
48700850|NCT01608698|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
48700851|NCT06607627|COMBINATION_PRODUCT|Gefurulimab|Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
48700852|NCT04330391|BEHAVIORAL|Remote dietitian supervised weight loss intervention and mobile app|Please see intervention arm description for more details.
48170105|NCT05757778|PROCEDURE|Sensory Nerve Coaptation|Nerve reconstruction will employ an off-the-shelf nerve graft coapted to the donor anterior intercostal nerve branch laterally and medially at the underside of the nipple. The anterior intercostal nerve branch and nerve graft coaptation will be performed in a standard fashion with a 1 mm gap between the ends of the graft and the donor nerve. Medially, the nerve graft will be inset into the underside of the preserved nipple-areola complex using 8-0 or 9-0 epineural stitches from the nerve allograft. All nerve coaptations will be performed under loupe magnification as is standardly performed.
48170106|NCT06475027|OTHER|TBDESJS|Chinese herbal tea TBDESJS
48700853|NCT00132691|DRUG|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
48700854|NCT00132691|DRUG|oral corticosteroid with immunosuppressive agents as needed|Prednisone
48700855|NCT01661777|DRUG|Nasal steroid|
48170107|NCT06475027|OTHER|Acupuncture|acupuncture GB20 or GB20 plus BL2
48700856|NCT01661777|PROCEDURE|Myringotomy tube placement|
48700857|NCT01661777|DRUG|Diuretic|
48700858|NCT01661777|DRUG|Antihistamine|
48700859|NCT01661777|BEHAVIORAL|Low salt diet|
48700860|NCT04355442|PROCEDURE|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
48013366|NCT04646616|OTHER|Community popular opinion leader (POL) based intervention|A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
48700861|NCT03307603|RADIATION|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
48700862|NCT03307603|DRUG|Phase Ib - nivolumab|240 mg intravenously
48013367|NCT04299711|OTHER|Exposed to the novel coronavirus disease 2019|Exposed to the novel coronavirus disease 2019
48013368|NCT06662565|BEHAVIORAL|Behavioral modification|"It includes:~.- Reducing or eliminating smoking and carbonated drinks.~* Weight loss in overweight or obese individuals.~* Caffeine Reduction: Limiting caffeine intake, especially for those consuming at least 400 mg per day.~* Consume Adequate Water: 6 to 8 glasses of water per day.~* Refrain from consuming fluids 2 to 3 hours before bedtime.~* Identify Bladder Irritants: such as sugar substitutes, citrus fruits, and tomato.~* Increasing fiber intake like fruits, and vegetables to reduce constipation with adequate hydration to make stools softer and easier to pass"
48013369|NCT06662565|OTHER|Pelvic floor down-training|"Pelvic floor down training exercises aimed at promoting relaxation and deconditioning of the pelvic floor muscles (PFM). It will be practiced three sessions per week for 8 weeks.~Biofeedback-Assisted pelvic floor down-training:~Procedure:~* Rectal biofeedback will be inserted.~* The therapist asks the woman to focus on consciously relaxing and releasing the PFM after each contraction or exercise while watching biofeedback screen.~* Then, breathe deeply and fully into her abdomen, allowing her pelvic floor to naturally relax and lengthen.~* And to incorporate relaxation techniques such as visualization, or progressive muscle relaxation to promote overall muscle relaxation and reduce PFM tension.~* Exercises are typically repeated around 10-20 times per session. This number can vary depending on the patient's condition and tolerance, as well as the therapist's assessment and treatment plan."
48170108|NCT05850182|BEHAVIORAL|Lifestyle intervention|12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).
48170109|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
48170110|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
48170111|NCT02314585|OTHER|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
48170112|NCT02314585|OTHER|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
48700863|NCT03307603|DRUG|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
48700864|NCT04850196|DEVICE|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
48700865|NCT04850196|OTHER|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
48700866|NCT06606002|BEHAVIORAL|Group schema therapy|Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\&#39; parents
48700867|NCT06606002|BEHAVIORAL|Treatment as Usual (TAU)|TAU typically comprises visits at the outpatient clinic with variable frequency and content
48700868|NCT03910738|DRUG|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
48700869|NCT03910738|DRUG|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
48700870|NCT03910738|PROCEDURE|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
48170113|NCT04310176|DRUG|Bevacizumab|5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)
48700871|NCT03910738|BEHAVIORAL|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
48700872|NCT03910738|BEHAVIORAL|Assessment of disability|EDSS (Baseline, week 30 and 66)
48700873|NCT06459089|BEHAVIORAL|Selection of the parent according to children preference|The children will select the parent who will accompany them during the anesthesia induction
48700874|NCT06459089|BEHAVIORAL|Bringing the favorite toy of the children that will accompany the child during their perioperative period|The children will bring tiheir favorite toy that will accompany them during their perioperative period
48700875|NCT00952445|DRUG|T0903131 Besylate|Once daily, oral
48700876|NCT00952445|DRUG|Placebo|Once daily, oral
48700877|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
48700878|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
48700879|NCT03178123|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
48700880|NCT03178123|BIOLOGICAL|high-dose recombinant interferon a-2B|15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
48700881|NCT04608409|DRUG|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
48700882|NCT05156099|DEVICE|Ultrasound Scanning|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
48170114|NCT04310176|DRUG|mFOLFOX6 regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week
48170115|NCT04310176|DRUG|mOXXEL regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks
48170116|NCT04310176|DRUG|Valproic acid|given orally from 500mg-1500mg daily and an intra-patient titration for a target serum level of 50-100µg/ml
48371478|NCT03334604|DIETARY_SUPPLEMENT|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10\^9 Colony Forming Units (CFU), twice daily, orally.
48371479|NCT03334604|OTHER|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
48700883|NCT05156099|DEVICE|Ultrasound Scanning - 2 months later|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
48700884|NCT03029078|DRUG|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
48700885|NCT00067964|BEHAVIORAL|small changes in physical activity and diet|
48700886|NCT03981887|DRUG|Nafithromycin|Nafithromycin 200 mg as IV infusion
48700887|NCT03981887|OTHER|Placebo|placebo administered as IV infusion
48700888|NCT06292416|OTHER|Experimental: Mirror therapy with sensory motor training.|"Block design, finding shapes in pictures, puzzles, matching geometric shapes and letters, numbers, and classification.~Pointing to the body parts, life-size drawing, turning left and right side and awareness of the body parts through touch.~feeling various textures, touching boards, and feeling shapes. Ocular-pursuit training, moving ball and pegboard activities During the sessions, subjects were asked to try and do the same movement with the paretic hand simultaneously The patients will be asked to repeat each movement 20 times per set for three sets, with a 2-minute break between sets.~Session will last for 45 mins"
48700889|NCT06292416|OTHER|Experimental: Mirror Therapy with motor training|the participant is asked to perform a forearm movement sting on the paretic side while the subjects look into the mirror, watching the image of their non-involved hand and thus seeing the reflection of the hand movement projected over the involved hand. During the sessions subjects were asked to try and do the same movement with the paretic hand simultaneously. movement was repeated 20 times per set for three sets, with a 2-minute break between sets
48700890|NCT06292416|OTHER|Experimental: Motor Training|"1. Holding object with two hands, clapping, banging objects together.~2. Stabilize objects with one hand while the other is manipulating (holding paper while coloring, holding a container while putting objects in)~3. manipulate objects with both hands simultaneously (stringing beads, tying a knot),~4. ask child to padlock in which a key can be put into, markers with caps to put on, a box with a lid and objects to put inside the box~5. hold a cup with one hand while putting object in with other hand~6. Buttoning with both hands, tying a bow. doing craft project, fitting blocks together"
48013370|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
48170117|NCT04310176|DRUG|Capecitabine|Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks
48013371|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
48013372|NCT01973634|RADIATION|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
48013373|NCT01973634|RADIATION|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
48013374|NCT02069561|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
48013375|NCT03552887|PROCEDURE|Cardiac Surgery|Any type of cardiac surgery
48013376|NCT03552887|PROCEDURE|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
48013377|NCT00961324|DRUG|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
48013378|NCT00961324|DRUG|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
48013379|NCT06621121|OTHER|Tenecteplase|The enrolled patients received treatment with tenecteplase (rhTNK-tPA) at a dosage of 0.25 mg/kg, up to a maximum of 25 mg, based on their clinical condition and the preferences expressed by the patients and their families.
48013380|NCT06621121|OTHER|Alteplase|The enrolled patients received treatment with alteplase (rtPA) at a dosage of 0.9 mg/kg, up to a maximum of 90 mg, based on their clinical condition and the preferences expressed by the patients and their families.
48013381|NCT03892720|OTHER|Quality-of-Life Assessment|Ancillary studies
48013382|NCT03892720|OTHER|Questionnaire Administration|Ancillary studies
48013383|NCT03892720|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48013384|NCT02978690|DRUG|Spesolimab|Solution for infusion
48013385|NCT04634292|BEHAVIORAL|EEG|EEG + walking task + auditory task
48013386|NCT04848766|DRUG|De-escalation Treatment Strategy of dual antiplatelet therapy|Patients receive de-escalation treatment of dual antiplatelet therapy after percutaneous coronary intervention
48013387|NCT06469047|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-1β and NE levels were detected.
48013388|NCT04856176|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|250 mcg
48013389|NCT04856176|DRUG|Pembrolizumab|200mg every 3 weeks
48013390|NCT04856176|DRUG|pemetrexed|500mg/m2
48013391|NCT04856176|DRUG|Paclitaxel|200mg/m2
48013392|NCT04856176|DRUG|Carboplatin|AUC 5/6
48170118|NCT04310176|DRUG|5-fluorouracil|Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks
48522923|NCT04190992|OTHER|E-based & personalized breast reconstruction surgery decision aid|This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
48522924|NCT04190992|OTHER|Usual care|A pamphlet introduce the introduction of types of surgery
48170119|NCT04647318|BEHAVIORAL|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
48170120|NCT00349388|DRUG|Asacol|Asacol is given once a day versus twice or three times a day
48170121|NCT03408340|PROCEDURE|Paravertebral Nerve Block|Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated, and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
48522925|NCT04105673|OTHER|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
48522926|NCT01257178|DRUG|LY2624803|Administered orally
48522927|NCT05183880|DIETARY_SUPPLEMENT|Phosphatidylcholine-lipid encapsulated vitamin C|Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
48522928|NCT05183880|DIETARY_SUPPLEMENT|Crystalline vitamin C|Ingesting 1000 mg of vitamin C in crystalline form
48700891|NCT06397651|BEHAVIORAL|Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application|"Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements."
48700892|NCT06397651|BEHAVIORAL|Digital application with expert guidelines on lifestyle modification|24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.
48700893|NCT03494530|DRUG|Edoxaban 60 MG|Anticoagulant used to treat atrial fibrillation
48013393|NCT04795414|BIOLOGICAL|SARS-CoV-2 Vaccine(Vero Cell), Inactivated|The subjects of Vaccination Group will receive two doses, 21 days apart of inactivated SARS-CoV-2 vaccine (4 μg of BBIBP-CorV)
48013394|NCT00679341|DRUG|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
48013395|NCT00679341|DRUG|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
48013396|NCT00679341|DRUG|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m\^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
48170122|NCT03408340|DRUG|Standard of Care Anesthesia|Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
48170123|NCT03675412|DIETARY_SUPPLEMENT|Caffeine tablet|Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
48170124|NCT00020969|DRUG|arsenic trioxide|
48170125|NCT00115336|DRUG|Intravenous Ketorolac|Intravenous ketorolac
48170126|NCT00115336|DRUG|Ibuprofen|Ibuprofen, taken orally
48170127|NCT05193747|OTHER|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
48170128|NCT00977795|DRUG|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
48170129|NCT02216149|DRUG|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
48170130|NCT02216149|DRUG|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
48170131|NCT02216149|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
48170132|NCT00096109|DRUG|tanespimycin|Given IV
48170133|NCT00096109|OTHER|laboratory biomarker analysis|Correlative studies
48170134|NCT01363336|DRUG|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
48170135|NCT04527783|OTHER|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
48013397|NCT02537418|DRUG|durvalumab|
48013398|NCT02537418|DRUG|tremelimumab|
48013399|NCT03879681|DIETARY_SUPPLEMENT|Jelly confectionary Snakes|"The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge."
48013400|NCT04630405|DEVICE|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
48013401|NCT04630405|DEVICE|Aerogen Solo|Aerogen Ltd., Galway, Ireland
48013402|NCT04750122|DRUG|neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning|The choice of chemotherapy is based on the PTC drug sensitivity results.
48013403|NCT00448058|DRUG|GSK372475|daily administration during the 10-week treatment phase
48013404|NCT00448058|DRUG|venlafaxine|daily administration during the 10-week treatment phase
48170136|NCT04527783|OTHER|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
48170137|NCT03795402|DEVICE|Microneedle Device|Microneedle device will be used for collecting skin samples as a non-invasive method.
48170138|NCT00815022|DRUG|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
48170139|NCT02813213|PROCEDURE|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
48170140|NCT02813213|PROCEDURE|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
48170141|NCT01162564|DEVICE|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
48170142|NCT00562185|DRUG|carboplatin|
48170143|NCT00562185|DRUG|doxorubicin hydrochloride|
48170144|NCT04498988|OTHER|Observational study without interventions|
48170145|NCT03927677|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
48522929|NCT06281015|DIAGNOSTIC_TEST|Whole-body bone single photon emission tomography (SPECT) for detection or follow-up of bone metastasis|Cancer patients referred to fast whole-body bone for detection or follow-up of bone metastasis were retrospectively included in this study.
48522930|NCT05832632|BEHAVIORAL|Headspace Basics Program|30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
48170146|NCT00604513|OTHER|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun \& Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
48170147|NCT00604513|OTHER|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
48170148|NCT03121040|DIETARY_SUPPLEMENT|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
48522931|NCT05832632|BEHAVIORAL|Headspace Breathing Exercises|30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
48013405|NCT00448058|DRUG|placebo|daily administration during the 10-week treatment phase
48013406|NCT03337724|DRUG|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
48013407|NCT03337724|DRUG|Paclitaxel|Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
48700894|NCT03494530|DRUG|Edoxaban 30 mg|Anticoagulant used to treat atrial fibrillation
48700895|NCT02312999|DRUG|Plasmalyte|
48013408|NCT03337724|DRUG|Placebo|Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
48013409|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
48013410|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
48013411|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
48700896|NCT02312999|DRUG|Volulyte|
48013412|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
48013413|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 10μg/dose) on Days 0 and 28.
48700897|NCT03978052|DIETARY_SUPPLEMENT|EGCG|"FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
48700898|NCT03978052|DIETARY_SUPPLEMENT|Placebo EGCG|"Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
48700899|NCT03978052|OTHER|Healthy lifestyle recommendations|Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.
48700900|NCT03978052|OTHER|Multimodal lifestyle intervention|"* Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions."
48700901|NCT00615589|DRUG|Fludarabine/Busulfan x 4 days|"* Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
48700902|NCT00615589|PROCEDURE|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
48013414|NCT04742738|BIOLOGICAL|GBP510 adjuvanted with Alum (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with Alum (RBD 25μg/dose) on Days 0 and 28.
48013415|NCT04742738|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
48013416|NCT03643003|BEHAVIORAL|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
48013417|NCT03643003|BEHAVIORAL|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
48013418|NCT04691466|PROCEDURE|Joint replacement|Routinely performed hip- or knee replacement
48013419|NCT06531863|DIETARY_SUPPLEMENT|Curcumin|Curcumin is a bioactive compound found in turmeric (Curcuma longa), known for its potent anti-inflammatory, antioxidant, and antimicrobial properties. Its therapeutic effects are primarily attributed to its ability to modulate various molecular targets and signaling pathways within the body
48700903|NCT04659499|DRUG|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
48013420|NCT06531863|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|Epigallocatechin gallate (EGCG) is a type of catechin, a natural phenol, and antioxidant found predominantly in green tea. EGCG is known for its potent health-promoting properties, including strong antioxidant, anti-inflammatory, and anti-carcinogenic effects.
48013421|NCT06531863|OTHER|Placebo|Placebo to be consumed after randomization.
48013422|NCT02095184|DRUG|Anastrozole|1 mg daily
48700904|NCT00426400|DRUG|The cessation of anti-aggregative treatment for 10 days|
48013423|NCT02095184|DRUG|Letrozole|2.5 mg daily
48013424|NCT04996303|DRUG|Routine steroid administration group|Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
48013425|NCT04996303|DEVICE|Steroid pulse therapy group|Steroid administration with pulse dose - Methylprednisolone 10 mg/Kg (500 mg \~ 1g) pulse 3 days -\> Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg/kg 7 days
48013426|NCT05024565|BEHAVIORAL|prolonged intravenous infusion of β-lactams Antibiotics|(1) Carbapenems: Calculate the daily dose according to the creatinine clearance rate and divide it into 3 times. Each time, the dose is injected intravenously at 1/2 dose for 15 minutes, and the remaining 1/2 dose is injected at a constant rate for 3 hours. (2) Cephalosporins: calculate the allowable daily dose according to the creatinine clearance rate, inject at a uniform rate within 24 hours. (3) β-lactams and β-lactamase inhibitor compound: the daily dose is calculated according to the creatinine clearance rate and injected at a uniform rate within 24 hours.
48013427|NCT03559660|DRUG|Certolizumab Pegol|
48013428|NCT04065919|DRUG|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
48170149|NCT01388478|DRUG|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
48170150|NCT01171300|OTHER|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
48700905|NCT04173260|DRUG|Deutetrabenazine 6 MG|Increasing doses of Deutetrabenazine
48700906|NCT01120236|DRUG|Bicalutamide|Given PO
48700907|NCT01120236|BIOLOGICAL|Cixutumumab|Given IV
48013429|NCT04065919|DRUG|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
48013430|NCT03244228|DRUG|HTL0016878|Oral solution
48013431|NCT03244228|DRUG|Placebo - Concentrate|Matching placebo
48170151|NCT01171300|OTHER|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
48170152|NCT02660112|DRUG|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
48522932|NCT05832632|BEHAVIORAL|Headspace Stress Program|20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
48700908|NCT01120236|DRUG|Goserelin Acetate|Given SC
48700909|NCT01120236|OTHER|Laboratory Biomarker Analysis|Correlative studies
48700910|NCT01120236|DRUG|Leuprolide Acetate|Given IM
48700911|NCT01120236|OTHER|Pharmacological Study|Correlative studies
48013432|NCT04744727|DRUG|paracetamol-pethidine|100 ml containing 1000 mg paracetamol -50 mg pethidine HCL
48700912|NCT05425446|DRUG|DONQ52|Subcutaneous (SC) injection
48700913|NCT05425446|DRUG|Placebo|Subcutaneous (SC) injection
48700914|NCT02557100|DRUG|Abatacept|
48700915|NCT02557100|DRUG|Adalimumab|
48170153|NCT04700878|BEHAVIORAL|Internet-based compassion course for stress managemant|A five week long, structured self-help program with weekly reports to, and feedback from a compassion-focused (CFT) therapist over the Internet. Includes traditional CFT-methods for stress-related problems.
48170154|NCT04700878|BEHAVIORAL|General Internet-based cognitive behavioural course for stress management|A five week long, structured self-help program with weekly reports to, and feedback from a cognitive-behavioral (CBT) therapist over the Internet. Includes traditional CBT-methods for stress-related problems.
48013433|NCT00691210|DRUG|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
48013434|NCT00691210|DRUG|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
48170155|NCT03436550|PROCEDURE|mpMRI|Multiparametric MRI
48170156|NCT03436550|PROCEDURE|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
48170157|NCT01161628|DRUG|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
48170158|NCT06240377|DEVICE|Transcranial direct current stimulation (tDCS)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
48170159|NCT06240377|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
48170160|NCT00607256|DRUG|[S,S]-reboxetine|S_S reboxetine dosed daily.
48170161|NCT00384865|DRUG|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
48170162|NCT00384865|DRUG|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
48170163|NCT00384865|DRUG|Placebo|Placebo, taken orally, once a day for 6 months
48170164|NCT03856398|DEVICE|C- MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
48170165|NCT03416621|BEHAVIORAL|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
48170166|NCT03416621|BEHAVIORAL|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
48170167|NCT03416621|DRUG|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
48170168|NCT05871918|DRUG|TCbHP VS ddEC-THP|The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
48522933|NCT05832632|BEHAVIORAL|Active Control (Audiobook)|30-day smartphone-based Audiobook book consisting of 10 minutes per day.
48522934|NCT01101113|DRUG|cinacalcet|cinacalcet 25mg qd or 50 mg qd
48013435|NCT00691210|DRUG|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
48522935|NCT01101113|DRUG|control|vit D + P binder
48700916|NCT02557100|DRUG|Methotrexate|
48700917|NCT03735199|DEVICE|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
48013436|NCT02093546|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor
48522936|NCT02779244|PROCEDURE|Early Weight bearing + Cam Boot|Patients will be transitioned to weight bearing as tolerated in a cam boot.
48522937|NCT02779244|PROCEDURE|Non-Weight Bearing + Cam Boot|Subject will be transitioned to non weight bearing cam boot, standard treatment.
48522938|NCT05911334|BEHAVIORAL|ROADE Program|Outpatient Behavioral Intervention for Eating Disorder
48700918|NCT03735199|DEVICE|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
48700919|NCT06303089|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.
48700920|NCT03006172|DRUG|Inavolisib|Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
48700921|NCT03006172|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
48700922|NCT03006172|DRUG|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
48700923|NCT03006172|DRUG|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
48170169|NCT00337285|DRUG|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
48170170|NCT00518583|DRUG|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
48170171|NCT03271918|DRUG|Cabergoline|
48170172|NCT00706914|DRUG|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
48170173|NCT00706914|DRUG|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
48170174|NCT00706914|DRUG|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
48170175|NCT00706914|DRUG|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
48170176|NCT01673100|BEHAVIORAL|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
48170177|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
48170178|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
48170179|NCT05557149|DEVICE|Virtual Reality Exposure to Neutral Cues|Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
48170180|NCT05557149|BEHAVIORAL|Respiratory Relaxation|Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.
48700924|NCT03006172|DRUG|Metformin|Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
48700925|NCT03006172|DRUG|Trastuzumab|Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
48170181|NCT05557149|DEVICE|Virtual Reality Exposure to Cocaine-Related Cues|Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
48170182|NCT02277392|BIOLOGICAL|Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells|
48170183|NCT02277392|BIOLOGICAL|SB---485232 (Human recombinant Interleukin---18)|
48522939|NCT04722250|DEVICE|Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems|TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)
48522940|NCT04722250|DEVICE|Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems|TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
48700926|NCT03006172|DRUG|Pertuzumab|Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
48700927|NCT06324422|OTHER|Aerobic exercise intervention|Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).
48700928|NCT06324422|OTHER|Resistance exercise intervention|Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
48700929|NCT00491270|DEVICE|VS Sense|An applicator to diagnose pH increase above 5.2
48700930|NCT03729037|OTHER|CPR self-training|
48700931|NCT05556135|DIAGNOSTIC_TEST|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
48700932|NCT06230510|BEHAVIORAL|Introduction of Milk Type|Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.
48700933|NCT06230510|BEHAVIORAL|Child Nutrition Counseling|Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
48700934|NCT01498393|DEVICE|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
48700935|NCT03440736|DRUG|Secukinumab|Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
48700936|NCT03440736|BEHAVIORAL|Life-style intervention|A structured program to guide weight loss and increased physical activity
48700937|NCT02901587|DRUG|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
48522941|NCT05755906|DRUG|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)
48170184|NCT04550286|BEHAVIORAL|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
48170185|NCT04550286|BEHAVIORAL|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
48522942|NCT05755906|DRUG|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
48522943|NCT02998697|DRUG|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
48700938|NCT02901587|DRUG|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
48700939|NCT02901587|DRUG|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
48700940|NCT02882789|DRUG|LCB01-0371|Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
48700941|NCT02882789|DRUG|LCB01-0371 400mg|Cohort 2: Crossover designed administration
48700942|NCT04328753|DRUG|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
48700943|NCT04328753|DRUG|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
48700944|NCT04328753|OTHER|Distilled water|act as a negative control in this study
48700945|NCT00099944|DRUG|vildagliptin|
48700946|NCT00099944|DRUG|Glimepiride|Glimepiride 4 mg qd
48700947|NCT00099944|DRUG|LAF237 placebo|
48700948|NCT02421406|BEHAVIORAL|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
48700949|NCT02421406|BEHAVIORAL|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
48700950|NCT00948233|BEHAVIORAL|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
48700951|NCT00948233|BEHAVIORAL|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
48700952|NCT00948233|BEHAVIORAL|Surveys|Computer surveys taken at 4 points throughout the study.
48700953|NCT05422365|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
48700954|NCT01345513|OTHER|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
48700955|NCT06274801|DRUG|Seralutinib|Capsule containing seralutinib
48170186|NCT03590717|BEHAVIORAL|BCC-Only|Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
48170187|NCT03590717|OTHER|Small-voucher|Households in the 'Small-voucher' arm receive a voucher (\~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
48170188|NCT03590717|OTHER|Large-voucher|Households in the 'Large-voucher' arm receive a larger voucher (\~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
48170189|NCT02747719|BEHAVIORAL|Light and exercise|Exposure to light and exercise
48170190|NCT05187000|DEVICE|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
48170191|NCT05187000|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
48170192|NCT01625949|PROCEDURE|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
48170193|NCT01625949|PROCEDURE|coronary dilatation and stenting|coronary dilatation and stenting
48170194|NCT05592769|DEVICE|HealthBeacon Injection Care Management System (ICMS)|"All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~* The HealthBeacon Smart Sharps Bin~* The HealthBeacon Companion App~* HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~* Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)"
48170195|NCT00270647|DIETARY_SUPPLEMENT|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
48170196|NCT00270647|DIETARY_SUPPLEMENT|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
48170197|NCT00270647|DIETARY_SUPPLEMENT|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
48013437|NCT05457309|PROCEDURE|malignant fungating wounds care regimen|1) Preliminary construction of regimen: The researchers summarized the literatures and guidelines about malignant fungating wounds care, and then formed a preliminary draft of the regimen.2) Expert consultation: Experts in malignant fungating wound care, breast cancer and rehabilitation were consulted by email, and the researchers revised the protocol according to the experts' comments, and the final draft was determined after multiple rounds of consultation with experts. 3) Pre-experiment: The researchers investigated the enrolled patients to assess the feasibility of the protocol, and adjusted the content based on the feedback.4) Final Determining: including health records establishment, the intervention time, implementers, location, method and frequency. A wound care team was formed, interventions were carried out in terms of somatic care, wound home care, psychological support, and rehabilitation guidance, and the enrolled patients would be regularly followed by the researchers.
48013438|NCT00064441|DRUG|OPC-6535 Tablets (drug)|
48013439|NCT06051773|OTHER|muscle involvement|evaluation of muscle involvement
48170198|NCT00270647|DIETARY_SUPPLEMENT|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
48170199|NCT05998226|OTHER|Virtual Antimicrobial stewardship Team (VAT)|The VAT consists of at least a clinical microbiologist and a clinician from the NH. Ideally, a pharmacist will also attend. They conduct a weekly (digital) meeting for nine months to evaluate the antibiotic prescriptions of the clinician attending the VAT meeting, based on a standardized protocol according to the current national infection treatment guidelines.
48013440|NCT01153035|DEVICE|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
48170200|NCT03098797|DRUG|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
48170201|NCT03098797|DRUG|Placebo|daily subcutaneous injection for 12 weeks
48170202|NCT01501227|DEVICE|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
48170203|NCT01501227|OTHER|Conventional endotracheal tube|Sham Comparator
48170204|NCT03936764|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing."
48170205|NCT05321381|OTHER|Resilience In Stressful Events (RISE) peer support team|Availability of peer support team to health care workers who experience stressful work-related events or situations
48170206|NCT03084198|PROCEDURE|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
48170207|NCT03084198|PROCEDURE|Standard care for ALF|A standard of care for subjects with acute liver failure.
48170208|NCT03800485|DEVICE|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
48170209|NCT02565888|DRUG|Daclatasvir|
48170210|NCT02565888|DRUG|Atazanavir|
48170211|NCT02565888|DRUG|Ritonavir|
48170212|NCT02565888|DRUG|Cobicistat|
48700956|NCT06274801|DEVICE|Gereic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib delivery
48170213|NCT04523298|PROCEDURE|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
48170214|NCT04523298|OTHER|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
48700957|NCT05190315|DRUG|Chlorpromazine|"Concurrent Phase: Oral chlorpromazine at 25 mg daily for the first 3 patients, then dose escalate to 50 mg if no dose limiting toxicity (DLT). Starting 7 days prior to radiation start.~Interim Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will continue post radiation and prior to beginning adjuvant temozolomide.~Adjuvant Phase: Chlorpromazine, 25 mg per day for first 3 subjects and then dose escalate to 50 mg per day if no DLT, will be continued daily (7 days per week) concomitant with Temozolomide."
48013441|NCT02309281|DRUG|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
48522944|NCT02998697|DRUG|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
48522945|NCT05593094|DRUG|ZN-A-1041 50mg BID|twice a day (BID) via oral administration
48522946|NCT05593094|DRUG|ZN-A-1041 100mg BID|twice a day (BID) via oral administration
48013442|NCT00200226|DRUG|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
48013443|NCT00200226|DRUG|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
48013444|NCT04704089|OTHER|spectrophotometer|"* Calibration of the spectrophotometer (calibration of white and green color on the provided support),~* Placing the patient or witness in the chair,~* Placement of intraoral retractors,~* Photographs of the dental arch in occlusion as well as slightly open mouth to visualize the mandibular incisors,~* If MIH is suspected, occlusal images of the occlusal surfaces of the first molars will be taken with the help of a dental mirror,~* Shooting with the spectrophotometer centered on each of the teeth of interest in the anterior sector with verification of the good quality of the shot according to the axis (validated in green on the camera),~* Backup of images with coded identification number"
48013445|NCT04704089|OTHER|Biological (protein analysis by western blot or mass spectrometry of matrix proteins), structural (electron microscopy) and physico-chemical analyses|"* Chemical analysis of enamel mineral.~* Techniques of spectrometry and spectroscopy (Raman and FTIR)~* Atomic Probe Tomography and Protein Mass Spectrometry (ICP-MS)."
48013446|NCT02130375|PROCEDURE|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
48013447|NCT02999958|BIOLOGICAL|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
48013448|NCT02791815|DRUG|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
48013449|NCT02791815|DRUG|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
48013450|NCT05472259|DRUG|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
48013451|NCT05472259|DRUG|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
48013452|NCT05472259|DRUG|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
48013453|NCT05472259|DRUG|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
48013454|NCT01870128|DRUG|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
48013455|NCT01870128|DRUG|Methotrexate|Methotrexate 15 to 25 mg PO per week
48013456|NCT01870128|DRUG|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
48700958|NCT05190315|DRUG|Temozolomide|"Concurrent Phase: Oral temozolomide at 75 mg/m2 per day concomitant with focal radiation and chlorpromazine. Temozolomide should be started on day 1 of radiation therapy, either at bedtime or morning as per patient preference.~Adjuvant Phase: Oral Temozolomide concomitant with Chlorpromazine, starting Temozolomide dose (Cycle 1) is 150 mg/m2 daily with a single dose escalation to 200 mg/m2 daily in subsequent cycles if no treatment-related adverse events \> grade 2 are noted. Temozolomide to be taken once daily for 5 consecutive days (1-5) of a 28 day cycle."
48013457|NCT02545907|DRUG|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
48013458|NCT02545907|DRUG|Thalidomide|50mg capsule.
48522947|NCT05593094|DRUG|ZN-A-1041 200mg BID|twice a day (BID) via oral administration
48522948|NCT05593094|DRUG|ZN-A-1041 400mg BID|twice a day (BID) via oral administration
48700959|NCT05190315|RADIATION|Radiation Therapy|Concurrent Phase: Radiation therapy administered daily, M-F, to a total dose of 60 Gy in 2 Gy Fractions for a total of 30 fractions.
48700960|NCT05098574|DRUG|Yaz|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
48013459|NCT02545907|DRUG|Dexamethasone|2mg tablet.
48013460|NCT01024400|BIOLOGICAL|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
48013461|NCT02492906|OTHER|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
48013462|NCT02492906|OTHER|Healthy|Healthy and non-symptomatic volunteers.
48013463|NCT02592473|DEVICE|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
48013464|NCT01256775|DRUG|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
48013465|NCT01256775|DRUG|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
48013466|NCT00001368|PROCEDURE|cytokine and leukocyte activation profile|
48013467|NCT03556631|DRUG|live combined Bifidobacterium and Lactobacillus Tablets|take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
48013468|NCT00003589|DRUG|cisplatin|
48013469|NCT00003589|DRUG|gemcitabine hydrochloride|
48013470|NCT00003589|DRUG|paclitaxel|
48013471|NCT02595736|DRUG|Placebo (SC)|Administered SC
48013472|NCT02595736|DRUG|LY3200327 (SC)|Administered SC
48013473|NCT02595736|DRUG|LY3200327 (IV)|Administered IV
48013474|NCT02595736|DRUG|Placebo (IV)|Administered IV
48013475|NCT03154710|DEVICE|MOOVCARE|web-mediated follow up
48013476|NCT00731328|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
48013477|NCT02258282|DRUG|Etanercept|
48013478|NCT02258282|DRUG|Control|
48013479|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
48013480|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
48013481|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
48522949|NCT05593094|DRUG|ZN-A-1041 600mg BID|twice a day (BID) via oral administration
48700961|NCT05098574|DRUG|Placebo|Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
48700962|NCT03096795|DRUG|MEDI3506|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
48700963|NCT03096795|DRUG|Placebo|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
48700964|NCT03183258|OTHER|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
48700965|NCT02566785|OTHER|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
48700966|NCT02375841|BEHAVIORAL|psychometric tests, questionnaires and neurocognitive assessments|
48700967|NCT05958953|PROCEDURE|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
48700968|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
48700969|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
48700970|NCT01131429|DRUG|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
48013482|NCT01347203|DRUG|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
48013483|NCT04865757|DEVICE|Space Flap|A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
48013484|NCT03374826|DIAGNOSTIC_TEST|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
48013485|NCT02502786|BIOLOGICAL|humanized anti-GD2 antibody|
48013486|NCT02502786|DRUG|GM-CSF|
48013487|NCT05508113|OTHER|ozone autohemotherapy|After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
48013488|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 1|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
48013489|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 2|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
48013490|NCT05742802|COMBINATION_PRODUCT|Placebo|Participants previously randomised to placebo in one of the predecessor studies will be re-randomised in a 1:1 ratio to the active dose of Tozorakimab or placebo.
48013491|NCT04409028|PROCEDURE|Coronal restoration|A restorative material like composite resin is condensed into the cavity of teeth.
48522950|NCT05593094|DRUG|ZN-A-1041 800mg BID|twice a day (BID) via oral administration
48700971|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
48700972|NCT01131429|DRUG|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
48700973|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
48700974|NCT04018820|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
48013492|NCT03211195|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
48013493|NCT03225794|DIAGNOSTIC_TEST|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
48700975|NCT03648177|BEHAVIORAL|IPGT|Behavioral Intervention for Patients with Chronic Pain
48700976|NCT03648177|BEHAVIORAL|Treatment as Usual|Standard Care
48700977|NCT01980836|BIOLOGICAL|Seasonal influenza vaccine|
48700978|NCT05852652|DEVICE|cryolipolysis and aerobic exercise|"the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park"
48700979|NCT05721326|OTHER|Sequential EHR Communications|The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
48700980|NCT06508489|BIOLOGICAL|SAR443579|Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion
48700981|NCT06508489|DRUG|venetoclax|Pharmaceutical form :Film coated tablet Route of administration: oral
48700982|NCT06508489|DRUG|azacitidine|Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous
48700983|NCT02342457|DEVICE|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
48522951|NCT05593094|DRUG|ZN-A-1041 1000mg BID|twice a day (BID) via oral administration
48700984|NCT06322745|PROCEDURE|Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy|Suture renorrhaphy will be used in 2 layers; medullary and cortical, with Vicry 2/0 or 3/0 and secured with V-lock. Early unclamping will be done after hemostasis of the medullary layer. Renorrhaphy of the cortical layer will be continued after that.
48700985|NCT06322745|PROCEDURE|Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy|A 2-μm continuous thulium laser with 365 μm laser fiber at 30-40 W will be used for coagulation of the tumor bed. Large vessels that may not be completely sealed with thulium beam will be closed by V-lock to achieve safe and stable hemostasis. Early unclamping will be done after hemostasis of the tumor bed. Suture renorrhaphy will be used in 1 layer to approximate the renal parenchyma.
48013494|NCT06126549|BEHAVIORAL|Building Better Caregivers|Peer-led, group intervention for caregivers focused on problem-solving
48013495|NCT06126549|BEHAVIORAL|Problem Solving Training|Clinician-led, one-to-one intervention for caregivers focused on problem-solving
48013496|NCT06126549|BEHAVIORAL|Usual Care|Usual discharge training and support offered to family caregivers of ABI patients
48013497|NCT03830294|OTHER|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
48013498|NCT06471933|DEVICE|Juläine|Dermal filler (PLLA)
48013499|NCT04900896|DEVICE|Myoelectric Elbow-Wrist-Hand Orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
48013500|NCT04935151|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser
48013501|NCT04935151|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
48013502|NCT00797667|DRUG|Telcagepant 140 mg|
48013503|NCT00797667|DRUG|Telcagepant 280 mg|
48700986|NCT01730326|DRUG|Paracetamol|1000 mg
48700987|NCT01730326|DRUG|Dexketoprofen|50 mg
48013504|NCT00797667|DRUG|140 mg telcagepant placebo|
48013505|NCT00797667|DRUG|280 mg telcagepant placebo|
48013506|NCT00222937|BEHAVIORAL|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
48013507|NCT00222937|BEHAVIORAL|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
48700988|NCT05009641|DIETARY_SUPPLEMENT|L-carnitine|
48700989|NCT06006507|OTHER|control|no exercise will be given
48700990|NCT06006507|OTHER|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
48700991|NCT01314170|DEVICE|Susanna Implant|device
48700992|NCT03587025|DRUG|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
48700993|NCT03587025|DRUG|Placebo|Placebo
48700994|NCT05972889|DEVICE|NexWave|Device subjects receive designated treatment mode twice daily for up to 8 weeks.
48700995|NCT05972889|DEVICE|Sham|Sham subjects provided with Sham Device and treatment instructions identical to that of NexWave Device Arm for their designated Sham Arm. Sham subjects participate for 4 weeks with the option to crossover to the NexWave Device Arm for an additional 4 weeks (up to 8 weeks total).
48700996|NCT01794312|DEVICE|T4020|
48700997|NCT01794312|DEVICE|Vehicle|
48700998|NCT02483156|DRUG|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
48700999|NCT02483156|DRUG|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
48701000|NCT02483156|DRUG|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
48701001|NCT04342494|BEHAVIORAL|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
48701002|NCT04342494|DEVICE|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
48701003|NCT04342494|DEVICE|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
48013508|NCT02596529|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
48013509|NCT02596529|OTHER|NO Fixation|NO Fixation of the posterior malleolus.
48013510|NCT03269279|DRUG|Mifepristone|Medication used in conjunction with misoprostol for abortion
48701004|NCT04342494|DEVICE|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
48013511|NCT03269279|DRUG|Misoprostol|Medication used in conjunction with mifepristone for abortion
48371480|NCT06380985|BEHAVIORAL|Personalized VR Alcohol Approach Bias Modification (ApBM) Condition|The Personalized VR ApBM will consist of 2D pictures representing alcohol or positive images (e.g., representing family or friends enjoying time together; sports, pets; travel and holidays, etc.) presented in a unique format in VR (e.g., landscape/portrait orientation), which will serve as the cue requiring a stimulus response. Participants are instructed to push the images away from them if they are presented in one format (e.g., landscape) and grab (using lever on VR controller) the images and pull towards themselves in response to a separate format (e.g., portrait pictures) across a virtual table. Each training session starts with 10 practice trials showing neutral objects (containers), followed by 240 training trials (120 alcohol and 120 non-alcohol trials). Training effect is achieved by altering the contingency of push vs. pull by image type (alcohol vs. positive).
48013512|NCT04924777|OTHER|Brisk Walk|1-Brisk walk for 30 minutes 2-5 days a week 3-3months
48701005|NCT04342494|DEVICE|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
48701006|NCT01581749|RADIATION|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
48013513|NCT04924777|OTHER|Strength training|1-Strength Training Exercises for 30 minutes. 2-5 days a week 3-3 months
48013514|NCT04924777|OTHER|Aerobic Exercises|1-Aerobic exercises for 30 minutes 2-5 Days a week 3-3months
48371481|NCT06380985|BEHAVIORAL|Sham Condition|Sham training is identical to ApBM, except the contingency of each orientation (e.g., portrait or landscape) representing a push vs. a pull is altered to diminish training effect.
48371482|NCT04668066|DRUG|PF-07242813|PF-07242813 given intravenously or subcutaneous
48371483|NCT04668066|DRUG|Placebo|Placebo given intravenously or subcutaneous
48371484|NCT06366191|OTHER|prevention algorithm|a health watch adapted to stress and dissociative symptoms
48371485|NCT06366191|OTHER|Standard care|Standard care for post traumatic stress disorder
48371486|NCT05836389|PROCEDURE|Pulmonary veins isoltation in bilateral thoracoscopy|Ablation of the atrial fibrillation performin isolation of the pulmonary vein. The procedure is video-assisted, access is minimally invasive: access to the heart is provided to instruments and camera via small bilateral chest incisions
48371487|NCT03420456|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
48371488|NCT02643121|OTHER|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
48701007|NCT01863173|DRUG|metoprolol|using B blocker in patient group
48701008|NCT01863173|DRUG|placebo|placebo to control group
48701009|NCT03418649|DRUG|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
48701010|NCT03418649|DRUG|Placebo Oral Tablet|PO once daily for 10 days
48701011|NCT01418703|DEVICE|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
48701012|NCT01418703|DEVICE|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
48701013|NCT03352557|DRUG|BIIB092|Administered as specified in treatment arm.
48701014|NCT03352557|DRUG|Placebo|Administered as specified in treatment arm.
48701015|NCT06039449|DRUG|VYD222 (pemivibart)|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.
48701016|NCT06039449|DRUG|Normal saline|Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.
48701017|NCT03200275|DIAGNOSTIC_TEST|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
48701018|NCT05858593|BEHAVIORAL|Virtual reality curriculum|Rather than rely on mere exposure to devices, participants in the treatment group will receive a curriculum that integrates the devices into traditional content delivered through the after school program.
48516063|NCT05011604|DEVICE|Full-Digital Workflow in Single-Tooth Implant Rehabilitation|"For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented."
48516064|NCT00880178|DRUG|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
48013515|NCT04404959|OTHER|fascia iliaca compartment block with ropivacaine|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of ropivacaine 0.25%)
48170215|NCT05738447|BIOLOGICAL|HBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
48516065|NCT00880178|DRUG|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
48522952|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b|ZN-A-1041: twice a day (BID) via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
48701019|NCT05858593|BEHAVIORAL|No Virtual reality curriculum|Children will be able to use the same devices but will not have access to a curriculum that integrates the devices with traditional content delivered through the after school program.
48701020|NCT05230108|PROCEDURE|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
48701021|NCT02125916|OTHER|oxygen therapy|
48701022|NCT02104596|DEVICE|Xylitol|
48701023|NCT04893239|BIOLOGICAL|LMN-201|Components of LMN-201
48701024|NCT02732795|OTHER|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
48701025|NCT02138409|DRUG|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
48701026|NCT02138409|DRUG|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
48701027|NCT01892436|DRUG|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
48701028|NCT01892436|DRUG|Placebo|Placebo
48013516|NCT04404959|OTHER|fascia iliaca compartment block with placebo|the fascia iliaca compartment block catheter will be placed with the use of ultrasound till the day of surgery. Bolus doses will be given every 12 hours (40 ml of normal saline)
48170216|NCT02723513|OTHER|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
48371489|NCT03811899|DIAGNOSTIC_TEST|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
48701029|NCT05783310|BEHAVIORAL|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
48701030|NCT06434766|DEVICE|sham stimulation|sham theta-burst transcranial magnetic stimulation
48701031|NCT06434766|DEVICE|intermittent theta-burst stimulation (iTBS)|intermittent theta-burst transcranial magnetic stimulation
48701032|NCT05803863|DRUG|Myatro|myopia control with 0.01% atropine drops
48013517|NCT00796965|DRUG|AZD7268|Solution/Capsule, Oral, once daily
48013518|NCT00796965|DRUG|Placebo|
48701033|NCT05803863|DRUG|Myatro XL|myopia control with 0.05% atropine drops
48013519|NCT05641740|DEVICE|Single-session of Radiofrequency|"The experimental group continue with their usual conservative and pharmacological treatment and will receive a single-session of monopolar dielectric capacitive radiofrequency in their hands. An Biotronic Advance Develops® (ABD-S25v) with a carrier wave frequency of 800-900 KHz of 850 KHz will be used. Patients will be placed in a seated position, with the forearms supinated and resting on a wooden table. An almond oil conductor will be applied to the hands. The application will be carried out with a circular head of 5 cm2 and for a total of 10 minutes on each of the palms of the hands.~They will be evaluated at baseline and post-session."
48013520|NCT05641740|DEVICE|Control Placebo single-session of Radiofrequency|"The control placebo group continue with their usual conservative and pharmacological treatment and will receive a placebo single-session of radiofrequency. This group will follow the same protocol and treatment time, but they will receive a placebo treatment (the device remains in paused mode), so that radiofrequency will not be applied.~They will be evaluated at baseline and post-session."
48013521|NCT00315276|DRUG|Modafinil|
48013522|NCT03387800|BEHAVIORAL|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
48013523|NCT03387800|BEHAVIORAL|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
48013524|NCT03380039|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
48701034|NCT06396169|OTHER|Yoga Exercise|Yoga Exercises
48013525|NCT03380039|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
48013526|NCT03380039|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
48013527|NCT05410652|DIAGNOSTIC_TEST|Detection of fecal samples with diagnostic kit|The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.
48013528|NCT05410652|DIAGNOSTIC_TEST|Sanger Sequencing group|Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
48701035|NCT06396169|OTHER|Calisthenic Exercise|Calisthenic Exercises
48701036|NCT04254367|BEHAVIORAL|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
48701037|NCT05350228|DIAGNOSTIC_TEST|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
48701038|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 30 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
48701039|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 60 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
48013529|NCT05410652|DIAGNOSTIC_TEST|Bacterial culture and drug sensitivity test of gastric mucosa samples|First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
48013530|NCT01182077|DRUG|ASP015K|Oral
48013531|NCT01182077|DRUG|Midazolam|Oral
48013532|NCT02909322|PROCEDURE|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
48013533|NCT02909322|PROCEDURE|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
48371490|NCT05718024|DRUG|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
48371491|NCT05718024|DRUG|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
48701040|NCT02109432|BEHAVIORAL|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
48013534|NCT02492451|OTHER|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
48013535|NCT02492451|DRUG|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
48170217|NCT03179774|DEVICE|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
48170218|NCT00107081|DRUG|ciprofloxacin and amoxicillin|
48170219|NCT00107081|PROCEDURE|Outpatient management|
48170220|NCT00107081|DRUG|i.v. antibiotics|
48170221|NCT00107081|PROCEDURE|inpatient management|
48701041|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
48701042|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
48701043|NCT01416103|OTHER|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
48701044|NCT01416103|OTHER|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
48701045|NCT06405737|DRUG|Intranasal oxytocin|Subject assigned to receive intranasal administration of oxytocin (24 IU).
48701046|NCT06405737|DRUG|Intranasal placebo|Subjects assigned to receive intranasal administration of placebo (24 IU).
48701047|NCT02539173|OTHER|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
48701048|NCT00538967|DRUG|doxycycline|2 weeks once daily
48701049|NCT03387007|BEHAVIORAL|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
48701050|NCT02101684|DRUG|Orteronel 300mg BID|
48701051|NCT05743842|DEVICE|TriSalus™ TriNav™Infusion System|Given by Infusion
48701052|NCT05743842|DIAGNOSTIC_TEST|Angiogram|X-ray photograph
48701053|NCT05743842|PROCEDURE|Y90-radioembolization procedure|procedure
48701054|NCT04000308|DRUG|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
48701055|NCT04000308|DRUG|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
48013536|NCT05244031|PROCEDURE|superficial erector spina plane block|The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia
48170222|NCT04816708|BEHAVIORAL|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
48170223|NCT00828529|DRUG|TMC207|
48170224|NCT02016664|DRUG|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
48170225|NCT05965960|DEVICE|TUS Active|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 30 W/cm2 Isppa
48522953|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b|ZN-A-1041: twice a day (BID) via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
48701056|NCT03641768|DEVICE|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
48170226|NCT05965960|DEVICE|TUS Sham|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 0 W/cm2 Isppa
48371492|NCT04077112|BEHAVIORAL|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
48516066|NCT04634006|DEVICE|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
48516067|NCT01911273|DRUG|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
48371493|NCT00945815|BIOLOGICAL|epratuzumab|
48371494|NCT00945815|DRUG|clofarabine|
48371495|NCT00945815|DRUG|cytarabine|
48371496|NCT00945815|OTHER|laboratory biomarker analysis|
48371497|NCT04983927|DEVICE|cASPECTS|Clinical decision support system for scoring ASPECTS score
48371498|NCT05300256|DEVICE|Peripheral Heating|Peripheral heating of the feet
48371499|NCT05300256|DEVICE|Sham|Sham
48371500|NCT01914289|PROCEDURE|Resection|
48371501|NCT01914289|RADIATION|Radiotherapy|
48371502|NCT05138458|BIOLOGICAL|MT-101|CD5 ATAK cells
48371503|NCT05138458|OTHER|MT-101 + Conditioning (Lymphodepleting) Chemotherapy|IV administration of fludarabine and cyclophosphamide
48371504|NCT04114227|BEHAVIORAL|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
48371505|NCT04114227|BEHAVIORAL|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
48371506|NCT05103462|BEHAVIORAL|Telehealth Physical Therapy|Weekly sessions of physical therapy provided using two-way, interactive, video technology consisting of education, advice and exercise instruction.
48371507|NCT00753402|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
48371508|NCT00753402|BIOLOGICAL|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes/Epinephrine 30mcg/kg/min
48371509|NCT03981523|DRUG|Benznidazole|50 mg and 100 mg tablet taken orally
48371510|NCT03981523|DRUG|Nifurtimox|120 mg tablet taken orally
48371511|NCT04603339|OTHER|Multidisciplinary rehabilitation programme delivered via telehealth|"12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions"
48371512|NCT03026426|BEHAVIORAL|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
48371513|NCT02779842|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
48371514|NCT01746082|BIOLOGICAL|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects \>/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
48371515|NCT05370300|DIAGNOSTIC_TEST|Blood test|Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.
48371516|NCT05604859|DRUG|Methylprednisolone|Methylprednisolone:1-2mg/kg/d(or other glucocorticoid equivalent to methylprednisolone 1-2mg/kg/d),ivgtt,3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (methylprednisolone \> 2mg/kg/d or other glucocorticoid equivalent to methylprednisolone \> 2mg/kg/d) was continued for another 3-5 days.
48371517|NCT05604859|DRUG|intravenous immunoglobulin|intravenous immunoglobulin:0.2g-0.4g/kg/d,ivgtt, 3-5 days.If disease progression occurs after completion of treatment, the dose of salvage therapy (IVIG 0.4g/kg/d) was continued for another 3-5 days.
48371518|NCT05604859|DRUG|Tocilizumab|Tocilizumab:4mg/kg, once
48371519|NCT05604859|DRUG|Low molecular weight heparin|Low molecular weight heparin:100U/kg, qd or q 12h,IH,4-7 days
48371520|NCT05604859|OTHER|conventional treatment|conventional treatment，including symptomatic and supportive treatment, antiviral treatment etc.
48371521|NCT02267031|PROCEDURE|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
48516068|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
48516069|NCT01911273|OTHER|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
48516070|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
48516071|NCT05679271|DEVICE|Venous stenting|venous stenting associated to antiaggregation protocol
48516072|NCT05679271|OTHER|Standard of care|observation: no treatment
48013537|NCT05244031|PROCEDURE|Standard (opioid-based) analgesia|The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia
48701057|NCT03641768|DEVICE|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
48701058|NCT03641768|DEVICE|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
48701059|NCT03641768|DEVICE|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
48701060|NCT05153369|BEHAVIORAL|Enhanced Care|Enhanced care aims to educate participants about bipolar disorder using a didactic approach, in addition to teaching and practicing DBT skills in an applied and relevant manner based on the participant's needs. Participants will receive a total of four sessions (approx. 60 minutes in duration), to occur once a month, at a minimum. The content will be split up into psychoeducation (2 sessions) and selected DBT skills (2 sessions). Psychoeducation will be specific to youth bipolar disorder, covering topics such as symptoms of depression and hypo/mania, medications used to treat bipolar disorder, the role of biology and the environment in emotions, and vulnerability and protective factors to emotion dysregulation and mood episodes. The content of skills sessions will be individualized and based on participant needs and goals (e.g., learning and applying skills to optimize their overall functioning, address problem behaviors and/or stressors, and/or maintain commitment to treatment).
48701061|NCT05153369|BEHAVIORAL|DBT Skills Training|In DBT Skills Training, participants will only receive skills training and can choose to do this individually and/or with their individual family unit by including their parent(s) and/or sibling(s). Participants will receive 20-25 sessions (approx. 60 minutes in duration), to occur at least biweekly. Skills training will include the five standard youth DBT modules: psychoeducation about DBT and bipolar disorder, mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path. The primary focus of the skills training is to impart knowledge and acquire and strengthen pragmatic skills to replace dysfunctional behaviors. If participants choose to include their family members, they will be encouraged to coach one another in effective use of skills.
48371522|NCT05956782|BEHAVIORAL|Breathe Easier|See Intervention Group (IG) description.
48516073|NCT01914692|DRUG|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
48516074|NCT06563895|DRUG|Acoramidis|TTR stabilizer administered orally twice daily (BID)
48516075|NCT06563895|DRUG|Placebo oral tablet|Non-active control administered orally twice daily (BID)
48013538|NCT06032286|DEVICE|Skinstylus microneedling device|Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.
48013539|NCT04777890|OTHER|suboccipital inhibition|The therapist will seat at the patient's head height and place his second, third, fourth and fifth fingertips'over the patient's suboccipital area during a 10-minute period.
48013540|NCT04777890|OTHER|INYBI|The therapist will place the INYBI at the suboccipital area, specifically placing the fingers of the instrument at the lower border of the occipital. If needed, a rolled towel will be placed behind the INYBI, in order to maintain the physiological lordosis, checking out that the patient doesn't make a cervical extension. Then the therapist will press the vibration button and turn it off after 10 minutes. All patients will receive the treatment with the INYBI's hardest head with a 50 HZ frequency.
48013541|NCT04777890|OTHER|INYBI + upper cervical manipulation|The participant will also be treated with the INYBI during a 10-minute period. After that, the therapist will carry out the upper cervical manipulation technique. Keeping the patient's head on an upper cervical flexion position, the therapist will turn his/her head to the maximum possible rotation, always maintaining its longitudinal axis. Once this is done, a high velocity and short articular amplitude manipulation in rotation will be carried out
48013542|NCT05815446|DEVICE|CT|NON CONTASR COMPUTED TOMOGRAPHY
48516076|NCT05797844|OTHER|Active implementational educational strategy|4 follow-up visits (active implemantation strategy) were carried out for ETT cuff pressure management using the one-on-one demonstration technique every 21 days. These follow-ups included adherence to evidence-based guidelines, nurses' application of endotracheal cuff pressure measurement and solving the problems encountered during its implementation. Uncertainties associated with evidence-based guidance on endotracheal tube cuff pressure control were clarified during these sessions.
48516077|NCT05797844|OTHER|Passive implementational educational strategy|Theoretical training on endotracheal tube cuff pressure management through a 4-hour presentation prepared with evidence-based guide and literature. A PowerPoint presentation including endotracheal tube cuff pressure normal values, complications related to endotracheal tube cuff pressure, management of endotracheal tube cuff pressure, endotracheal tube cuff pressure control methods, methods affecting endotracheal tube cuff pressure, how to measure endotracheal tube cuff pressure was made.
48013543|NCT00000327|DRUG|Heroin Dependence|
48013544|NCT06573021|DRUG|Near-infrared fluorescent cholangiography|For intra-operative fluorescent cholangiography, 2.5 mg indocyanine green (ICG, Pulsion Medical Inc., Irving, Tx) was administered intravenously 45-60 min prior to surgery, according to the recent guidelines from the International Society for Fluorescence Guided Surgery (ISFGS) and the latest consensus conference published in 2021.
48170227|NCT04061863|DRUG|Nivolumab|Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
48170228|NCT05840822|DRUG|Cannabidiol|Nightly capsules prior to bed containing 0mg (placebo), 75mg cannabidiol or 150mg cannabidiol
48701062|NCT05153369|BEHAVIORAL|Dialectical Behavior Therapy Full Intervention|The DBT full intervention is based on Miller et al.'s DBT for suicidal youth, with modifications for youth with BD. DBT will be conducted over 1 year with approximately 40-50 sessions. Sessions will alternate between individual and skills training sessions. Family involvement in skills training will be strongly encouraged, however will be up to the participant to decide. Participants in Level 3 will complete diary cards tailored for this population, assessing daily mood, suicidality, sleep, and medication adherence. Participants will report use of specified DBT skills on the diary card, and individualized treatment goals will be incorporated into the diary card (e.g., alcohol use). In addition, Level 3 will include skills coaching by phone (via phone and/or text). These brief, structured calls and/or texts function to promote skills generalization by helping the participant and any participating family member(s) use skills to achieve goals and solve problems.
48701063|NCT03667807|DEVICE|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
48701064|NCT06304181|DRUG|Paracetamol and Mannitol Injection|Paracetamol and Mannitol Injection 500mg
48701065|NCT06304181|DRUG|Parecoxib|40mg of parecoxib
48013545|NCT06078735|DEVICE|Vascular closure with LockeT device|For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
48701066|NCT02681796|DRUG|Bupivacaine|
48701067|NCT05056922|BEHAVIORAL|Tele-PCIT|"Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use."
48013546|NCT03457012|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
48013547|NCT03837795|DEVICE|Neurofeedback treatment|A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
48013548|NCT04112433|DEVICE|PURE EP 2|Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
48013549|NCT04298528|DRUG|Dronabinol|2.5mg 2 times a day for 30 days after total knee replacement
48013550|NCT04298528|OTHER|Placebo|2 times a day for 30 days after total knee replacement
48170229|NCT01685125|DRUG|abiraterone acetate|Given PO
48170230|NCT01685125|DRUG|dasatinib|Given PO
48170231|NCT01685125|DRUG|prednisone|Given PO
48170232|NCT04747821|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
48170233|NCT02450097|OTHER|Caloric restriction|
48170234|NCT02774564|DRUG|BIA 3-202|Nebicapone tablets 50 mg, oral administration
48170235|NCT02774564|DRUG|Placebo|Nebicapone matching placebo tablets
48170236|NCT02774564|DRUG|Sinemet®|Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
48516078|NCT01828801|DEVICE|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
48701068|NCT05056922|BEHAVIORAL|Treatment as Usual|Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment \& Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
48701069|NCT01064102|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
48701070|NCT02607475|DEVICE|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
48701071|NCT02607475|DEVICE|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
48701072|NCT05875753|DIAGNOSTIC_TEST|68Ga-FAPI-FS PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration."
48701073|NCT05125718|DRUG|0.85% synthetic antimicrobial peptide TAPS-18|commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
48701074|NCT05125718|DRUG|0.9% normal saline|commercially available normal saline Sodium Chloride irrigation solution
48701075|NCT05438212|PROCEDURE|Brain Surgery|Undergo surgery per standard of care
48701076|NCT05438212|OTHER|Quality-of-Life Assessment|Ancillary studies
48701077|NCT05438212|OTHER|Questionnaire Administration|Ancillary studies
48701078|NCT05438212|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
48701079|NCT06608524|BEHAVIORAL|Self-regulated learning strategy|The experimental group uses self-regulated strategy.This program selects classroom performance , homework quality , experimental operation, and test score as academic performance (score) evaluation variables.
48701080|NCT06608524|BEHAVIORAL|Standard learming method|The control group uses standard learming method. The program selects classroom performance, homework quality, experimental operation, and test score evaluation form as academic performance (score) evaluation variables.
48701081|NCT03541967|DEVICE|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
48701082|NCT01186042|OTHER|Observational|No intervention
48013551|NCT01878604|GENETIC|Gene analysis|Gene analysis
48701083|NCT05460364|DRUG|BR1018-1|"Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
48701084|NCT05460364|DRUG|BR1018-2|"Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
48701085|NCT03278717|DRUG|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
48701086|NCT03278717|DRUG|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
48013552|NCT01878604|OTHER|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
48013553|NCT01878604|OTHER|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
48013554|NCT04453124|BIOLOGICAL|Topical antiseptic treatment|Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
48701087|NCT02447250|DRUG|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
48701088|NCT06033196|DRUG|Tocilizumab|"The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more"
48701089|NCT06033196|DRUG|Placebo for Tocilizumab|"Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses"
48701090|NCT05066581|DEVICE|Live Chat|Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
48701091|NCT03489434|BEHAVIORAL|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
48701092|NCT05898308|DRUG|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
48701093|NCT03267043|BEHAVIORAL|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
48701094|NCT03267043|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
48701095|NCT00978380|DRUG|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
48701096|NCT04823455|PROCEDURE|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
48701097|NCT00108303|OTHER|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
48701098|NCT00728208|DRUG|GSK372475|1.5mg for 28 days
48701099|NCT04526951|DRUG|Intravenous injection of Tenecteplase and one dose of placebo tablet|Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)
48701100|NCT04526951|DRUG|One tablet of Acetylsalicylic Acid and one dose of IV placebo|300 mg Acetylsalisylic acid
48701101|NCT00090142|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
48701102|NCT00090142|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
48170237|NCT03135613|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
48371523|NCT02129439|DRUG|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
48701103|NCT01157325|PROCEDURE|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
48701104|NCT01157325|PROCEDURE|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
48701105|NCT05401929|DEVICE|iTBS|Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
48013555|NCT04607408|BIOLOGICAL|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
48170238|NCT00960505|OTHER|Alternate day fasting|
48170239|NCT00960505|OTHER|Calorie restriction|
48522954|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b|ZN-A-1041: twice a day (BID) via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
48522955|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c|ZN-A-1041: twice a day (BID) via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
48701106|NCT05401929|DEVICE|iTBS|Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
48371524|NCT02129439|DRUG|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
48701107|NCT06588647|BEHAVIORAL|Improving Participation after Stroke Self-Management Program (IPASS)|The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).
48701108|NCT06588647|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
48701109|NCT00072293|PROCEDURE|Axillary lymph node dissection|Axillary lymph node dissection
48701110|NCT00072293|PROCEDURE|No axillary lymph node dissection|Therapeutic conventional surgery
48701111|NCT04852705|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
48701112|NCT04852705|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
48701113|NCT00574730|DRUG|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
48701114|NCT00574730|DRUG|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
48701115|NCT00283803|DRUG|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
48701116|NCT00283803|DRUG|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
48701117|NCT00283803|DRUG|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
48701118|NCT03744468|DRUG|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
48701119|NCT03744468|DRUG|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
48170240|NCT00960505|OTHER|Control diet|
48371525|NCT06071351|OTHER|motivational interviewing based training program|In addition to the informative brochure prepared by the researcher; A 6-session training program based on motivational interviewing, including nutrition, physical activity, smoking and alcohol use, will be held.
48371526|NCT06071351|OTHER|Routine practice|An informative brochure prepared by the researcher was given.
48516079|NCT03423940|BEHAVIORAL|Functional communication training|"During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior)."
48701120|NCT03744468|DRUG|LBL-007|Human anti LAG-3 IgG4-kappa antibody
48701121|NCT04875377|DIETARY_SUPPLEMENT|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
48701122|NCT04875377|DIETARY_SUPPLEMENT|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
48701123|NCT04875377|DIETARY_SUPPLEMENT|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
48371527|NCT04220502|DRUG|Magic Shave Powder Gold|Depilatory Cream for facial hair removal
48701124|NCT04875377|DIETARY_SUPPLEMENT|Control capsule|Empty capsules (placebo)
48701125|NCT03563677|OTHER|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
48701126|NCT01980303|DRUG|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
48701127|NCT04497857|OTHER|Coordinated Specialty Care (CSC)|CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
48701128|NCT04588857|DRUG|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
48701129|NCT04588857|DRUG|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
48013556|NCT04607408|BIOLOGICAL|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
48013557|NCT04607408|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9% USP
48701130|NCT01460875|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
48013558|NCT04380207|DRUG|QPX7728|antibiotic
48013559|NCT04380207|DRUG|Placebo|Placebo comparator
48701131|NCT01460875|OTHER|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
48701132|NCT06561880|DRUG|Gilteritinib|"Induction therapy regimen(2 courses):~triple regimen therapy: Azacitidine 75mg/m2/d d1-7; Venetoclax 100mg d1,200mg d2,400mg d3-28; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~dose-adjusted triple regimen therapy: Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~Patients with no remission after the first induction course will receive another course with triple regimen therapy; Patients with complete remission after the first induction course will receive another course of dose-adjusted triple regimen therapy."
48701133|NCT06561880|DRUG|Cytarabine|"Consolidation therapy (3 courses):~intermediate-dose cytarabine regimen :2g/m2 q12h d1-3, age \< 60 years;1g/m2 q12h d1-3, age ≥60 years.~If NGS detected FLT3 mutation before consolidation chemotherapy, gilteritinib will be added during the consolidation course at d4-17."
48701134|NCT06561880|DRUG|Gilteritinib|"Maintenance treatment (6 courses):~dose-adjusted triple regimen therapy:Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28."
48701135|NCT00491855|DRUG|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
48701136|NCT00491855|DRUG|Oxaliplatin|Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
48701137|NCT00491855|DRUG|Paclitaxel|Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
48701138|NCT02555813|DRUG|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
48013560|NCT04380207|DRUG|QPX2014|antibiotic
48013561|NCT02451566|DEVICE|Ovation Prime Abdominal Stent Graft System|
48013562|NCT04686097|PROCEDURE|treatment: puncture of coagulation|ultrasound-guided puncture of coagulation
48371528|NCT04220502|DEVICE|Traditional Shaving Methods|Continued facial hair removal using traditional razors
48701139|NCT02555813|DRUG|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
48701140|NCT06236061|DRUG|LCZ|LCZ 200 mg
48371529|NCT04159558|DEVICE|Mobile application|Experimental group will use a mobile application to help them in their self-care
48013563|NCT04686097|PROCEDURE|treatment: sclerosing agent injected|ultrasound-guided sclerosing agent injected
48013564|NCT00806468|DRUG|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
48371530|NCT06287112|DEVICE|Endoscopic transpapillary gallbladder drainage (ETGBD)|Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
48013565|NCT05586399|BEHAVIORAL|Maximal strength training in COPD|Participate in a rehabilitation program for 4 weeks, with exercise 5 times a week. Supervised maximal strength training in a leg press machine for a total of 20 exercise sessions. Patients will participate in rehabilitation in one of two rehabilitations centers in Trondheim, Norway.
48013566|NCT02130765|DEVICE|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
48170241|NCT05621213|OTHER|Teleconsultation assisted by a physiotherapist or nurse|"A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver."
48701141|NCT06236061|DRUG|LCZ/AML 200 mg/2.5 mg|LCZ/AML 200 mg/2.5 mg
48701142|NCT06236061|DRUG|LCZ/AML 200 mg/5 mg|LCZ/AML 200 mg/5 mg
48701143|NCT06236061|DRUG|LCZ/AML 200 mg/10 mg|LCZ/AML 200 mg/10 mg
48701144|NCT06309017|OTHER|Nutrition specialist|Nutrition specialist to help improve nutritional status by diet, oral nutrition supplements or parenteral nutrition.
48701145|NCT06309017|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shakes|All study subjects, including subjects without malnutrition, will be given the Ensure Surgery Immunonutrition Shakes for prior to surgery as per standard of care. All subjects will also receive additional shakes starting as an inpatient when diet is advanced.
48701146|NCT00607269|BEHAVIORAL|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample."
48371531|NCT05392543|OTHER|Brunnstrom movement therapy.|"Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery."
48701147|NCT03489655|BEHAVIORAL|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
48701148|NCT00283270|BEHAVIORAL|Brief counselling|
48701149|NCT00283270|BEHAVIORAL|Behavior|
48701150|NCT04600076|BEHAVIORAL|BabyCenter site and the community group|Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
48701151|NCT06606093|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
48701152|NCT06606093|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
48701153|NCT02793817|DRUG|KPI-121 1% Ophthalmic Suspension dosed BID|
48701154|NCT02793817|DRUG|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
48701155|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
48701156|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
48701157|NCT03840772|DRUG|Eribulin|Treatment with eribulin
48701158|NCT05341895|OTHER|Kinesiotape|Taping
48701159|NCT01097317|DRUG|carboplatin|
48701160|NCT01097317|DRUG|vinorelbine tartrate|
48516080|NCT02939794|DRUG|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
48516081|NCT02939794|DRUG|Placebo|Saline (normal saline, sodium chloride)
48516082|NCT05330260|DIAGNOSTIC_TEST|neurocognitive test battery|Assessment of the incidence of late postoperative cognitive decline (LPOCD)
48701161|NCT01097317|OTHER|neuromuscular electrical stimulation|
48701162|NCT01097317|OTHER|physiologic testing|
48701163|NCT01097317|PROCEDURE|fatigue assessment and management|
48701164|NCT01097317|PROCEDURE|quality-of-life assessment|
48701165|NCT03859440|DEVICE|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
48701166|NCT03859440|DEVICE|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
48701167|NCT06115486|OTHER|Control Arm ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
48701168|NCT06115486|OTHER|Experimental Arm 6-12-25 repetitions per set|The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
48701169|NCT00271921|BEHAVIORAL|Calorie controlled diet|
48701170|NCT02918396|DEVICE|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (\>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
48013567|NCT03938116|OTHER|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
48516083|NCT02715011|DRUG|JNJ-63709178|Participants will receive JNJ-63709178 in Part 1 and Part 2.
48701171|NCT02918396|DEVICE|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
48701172|NCT02918396|DEVICE|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
48701173|NCT00348699|DRUG|AFP464|Given IV
48701174|NCT00348699|OTHER|pharmacological study|Correlative studies
48013568|NCT02381080|DRUG|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
48013569|NCT02381080|DRUG|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
48516084|NCT01944163|OTHER|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
48522956|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c|ZN-A-1041: twice a day (BID) via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
48701175|NCT00348699|OTHER|laboratory biomarker analysis|Correlative studies
48701176|NCT06272838|OTHER|Biodex balance system|In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.
48013570|NCT02381080|DRUG|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
48013571|NCT02449356|DEVICE|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
48701177|NCT06272838|OTHER|The conventional balance exercise program|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
48701178|NCT06012500|DRUG|Xenon-129|Inhaled contrast for MRI
48701179|NCT03652857|DRUG|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
48522957|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c|ZN-A-1041: twice a day (BID) via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
48701180|NCT04028765|DRUG|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
48013572|NCT06503588|OTHER|Guidelines promoting surgical abstention|Guidelines promoting surgical abstention
48170242|NCT02111720|BEHAVIORAL|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
48701181|NCT04028765|DRUG|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
48701182|NCT02101801|OTHER|vegetables from fresh or recycled water|
48701183|NCT02101801|OTHER|receives vegetables from fresh water or recycled waste water farms|
48701184|NCT05826418|DIETARY_SUPPLEMENT|MEND diet|Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
48701185|NCT05826418|DIETARY_SUPPLEMENT|mNICE diet|Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
48013573|NCT04072484|OTHER|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
48013574|NCT02516124|PROCEDURE|Autologous HSCT|1st AHSCT
48013575|NCT03568422|DRUG|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
48013576|NCT03568422|DRUG|Paclitaxel|80 mg/m2 IV days 1, 8 \& 15 every 28 days
48013577|NCT05422248|DEVICE|Series Topical Oxygen Therapy|Standard care provided to the whole wound followed by intervention device care to the whole wound.
48013578|NCT05422248|DEVICE|Paired Topical Oxygen Therapy|Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
48013579|NCT06276725|BEHAVIORAL|Writing Wrongs|A repeated exposure writing practice targeting symptoms resulting from microaggressions experienced by minoritized students at predominantly White institutions.
48013580|NCT06357975|PROCEDURE|Biopsy|Undergo biopsy
48013581|NCT06357975|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48013582|NCT06357975|DRUG|Crizotinib|Given PO
48013583|NCT06357975|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
48013584|NCT05725174|OTHER|Sample Collection|Patients will have breath samples collected by blowing into a bag, and sweat samples collected by gauze. These samples will be collected at various timepoints whilst the patients are admitted on the ward.
48701186|NCT04812119|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, \& Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
48013585|NCT00544596|DRUG|R-(-)-gossypol acetic acid|Given orally
48013586|NCT00544596|DRUG|cisplatin|Given IV
48013587|NCT00544596|DRUG|etoposide|Given IV
48701187|NCT04812119|DIAGNOSTIC_TEST|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
48701188|NCT04812119|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
48013588|NCT02553681|DEVICE|roflufocon D contact lenses|HPT treated rigid contact lenses
48013589|NCT02553681|DEVICE|RGP contact lenses made from roflufocon D|
48013590|NCT02490137|BEHAVIORAL|Race Car Video Game|Repeatedly playing a race car video game
48013591|NCT01648309|OTHER|Neuropsychological testing|This is an observational study
48013592|NCT00981500|PROCEDURE|gastric bypass|Roux-en-Y gastric bypass
48013593|NCT00981500|PROCEDURE|gastric banding|laparoscopic adjustable gastric banding
48170243|NCT02111720|BEHAVIORAL|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
48170244|NCT03666208|DEVICE|Sirolimus Coated Balloon|"Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution."
48170245|NCT04714788|DEVICE|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
48170246|NCT04714788|OTHER|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
48170247|NCT06129045|BEHAVIORAL|One-time educational video|Sleep hygiene educational tips provided through a video participants watch on their own.
48170248|NCT06129045|BEHAVIORAL|Educational video plus repeated education|Sleep hygiene educational tips are provided first through a video participants watch on their own and then tips are repeated through daily automated text messaging for an additional 4 weeks.
48170249|NCT00297778|DRUG|Pramipexole|Dopamine agonist
48170250|NCT00297778|OTHER|Placebo|
48170251|NCT01218295|DEVICE|Spirotiger®|training session :10 minutes twice a day X 4 weeks
48170252|NCT00495872|DRUG|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
48170253|NCT00495872|DRUG|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
48170254|NCT00495872|DRUG|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
48170255|NCT00495872|DRUG|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
48170256|NCT00495872|DRUG|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
48170257|NCT00495872|DRUG|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
48170258|NCT00495872|DRUG|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
48170259|NCT00695136|DRUG|Donepezil hydrochloride|
48170260|NCT00695136|BEHAVIORAL|Increase REM sleep percentage|
48013594|NCT00981500|PROCEDURE|sleeve gastrectomy|vertical sleeve gastrectomy
48013595|NCT04019912|OTHER|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
48170261|NCT00801086|DRUG|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
48170262|NCT00801086|DRUG|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
48170263|NCT05077241|DEVICE|Inspiratory muscle training|Individuals will be instructed to perform a rapid contraction of the inspiratory muscles against a load and sustain it for 2 seconds in each maneuver.
48170264|NCT02151578|OTHER|home/community case management|
48170265|NCT01695447|PROCEDURE|duct-to-mucosa|
48170266|NCT01695447|PROCEDURE|invagination|
48170267|NCT01695447|DEVICE|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
48170268|NCT02878590|DEVICE|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
48170269|NCT00618917|GENETIC|Manganese Superoxide Dismutase Plasmid Liposome|15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
48170270|NCT00618917|DRUG|carboplatin|Chemotherapy to stop the growth of tumor cells.
48170271|NCT00618917|DRUG|paclitaxel|Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
48170272|NCT00618917|RADIATION|Radiation Therapy|1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
48013596|NCT04019912|OTHER|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
48701189|NCT04812119|DIAGNOSTIC_TEST|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, ... \& Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
48701190|NCT04812119|DIAGNOSTIC_TEST|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes \& Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
48701191|NCT04812119|DIAGNOSTIC_TEST|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
48701192|NCT04812119|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
48701193|NCT04812119|DIAGNOSTIC_TEST|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
48701194|NCT04812119|DIAGNOSTIC_TEST|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
48701195|NCT04812119|DIAGNOSTIC_TEST|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
48013597|NCT02082522|DRUG|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
48701196|NCT04812119|DIAGNOSTIC_TEST|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded \& Revised (GMFCS - E\&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
48013598|NCT02082522|PROCEDURE|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
48013599|NCT02082522|DRUG|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
48013600|NCT06468644|DRUG|chemoradiotherapy （CRT）+sintilimab 1|radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
48013601|NCT06468644|DRUG|CRT+sintilimab 2|radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W
48701197|NCT04812119|DIAGNOSTIC_TEST|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
48701198|NCT04812119|DIAGNOSTIC_TEST|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
48701199|NCT04812119|DIAGNOSTIC_TEST|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
48701200|NCT04812119|DIAGNOSTIC_TEST|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
48013602|NCT03842176|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
48013603|NCT03842176|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
48013604|NCT04524403|DRUG|Miricorlilant|Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
48013605|NCT04524403|DRUG|Miricorlilant|Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
48013606|NCT04524403|DRUG|Placebo|Placebo for once-daily oral dosing
48013607|NCT05301335|DEVICE|SCONE|The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
48013608|NCT03882359|DIAGNOSTIC_TEST|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
48701201|NCT04812119|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
48701202|NCT03487588|DRUG|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
48013609|NCT03882359|DRUG|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
48170273|NCT01020747|DRUG|Avastin® (bevacizumab)|Bevacizumab injections (\~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
48170274|NCT01020747|DRUG|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
48701203|NCT03695627|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
48701204|NCT03576066|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
48701205|NCT03576066|DRUG|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
48701206|NCT03576066|DRUG|Placebo Oral Tablet|Participants will receive placebo matching ABI-0731 tablets orally QD.
48701207|NCT03142399|DIETARY_SUPPLEMENT|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
48701208|NCT04871893|DEVICE|multiECCO2R blood-gas exchanger|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
48013610|NCT03882359|DRUG|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
48170275|NCT04584216|OTHER|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
48701209|NCT03570918|BIOLOGICAL|MGD014|HIV-1 x CD3 bispecific DART molecule
48701210|NCT03197987|DEVICE|Endocuff|Endocuff-assisted colonoscopy
48701211|NCT03197987|DEVICE|cap|Cap-assisted colonoscopy
48701212|NCT03232645|DEVICE|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
48701213|NCT04557514|PROCEDURE|platelet rich plasma injection in post burn facial scar|"2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
48701214|NCT04557514|PROCEDURE|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
48701215|NCT05076409|DRUG|BI 425809|Period 1 and period 2
48701216|NCT05076409|DRUG|fluconazole|Period 2
48701217|NCT03525301|RADIATION|standard treatment|3000 cGy in 10 daily fractions
48170276|NCT04584216|OTHER|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
48170277|NCT03082612|BEHAVIORAL|Faith-Based African American Cancer Survivorship Storytelling Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
48701218|NCT03525301|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
48013611|NCT01037478|DRUG|Resminostat (4SC-201)|oral administration
48013612|NCT05606068|DEVICE|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
48013613|NCT00894075|BIOLOGICAL|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
48701219|NCT00072930|BIOLOGICAL|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
48701220|NCT00072930|BIOLOGICAL|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
48701221|NCT05832515|DRUG|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
48701222|NCT06290167|DEVICE|360° media|sessions with head mounted display in hospital and sessions with tablet at home
48701223|NCT06290167|OTHER|Treatment As Usual (TAU)|sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home
48701224|NCT06290167|OTHER|In hospital sessions|sessions will be carried out under the supervision of a therapist
48701225|NCT06290167|OTHER|at home sessions|sessions will be carried out without the supervision of a therapist
48701226|NCT06290167|OTHER|Mild Cognitive Impairment|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
48701227|NCT06290167|OTHER|Subjective Memory Complain|half of this group will perform the protocol with 360° videos and the other half will perform the TAU
48701228|NCT01329653|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4X/week
48701229|NCT01329653|BEHAVIORAL|Wait list|wait list control condition
48013614|NCT03811730|DIAGNOSTIC_TEST|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
48013615|NCT00556595|PROCEDURE|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
48013616|NCT00556595|PROCEDURE|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
48013617|NCT00475007|DEVICE|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
48013618|NCT05448924|DIAGNOSTIC_TEST|Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone
48013619|NCT02259491|OTHER|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
48170278|NCT03928678|PROCEDURE|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
48170279|NCT02934542|DEVICE|AutoLap system|
48170280|NCT03820869|OTHER|Family Training|Family Training
48516085|NCT01652547|DRUG|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
48701230|NCT05488548|DRUG|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
48701231|NCT03575845|BEHAVIORAL|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
48701232|NCT01854632|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
48701233|NCT01854632|BIOLOGICAL|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
48701234|NCT04742348|DRUG|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
48701235|NCT04742348|DRUG|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
48701236|NCT01671293|BEHAVIORAL|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
48701237|NCT01671293|OTHER|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
48701238|NCT01166373|BEHAVIORAL|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
48701239|NCT01166373|PROCEDURE|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
48013620|NCT04540861|DRUG|Siponimod|1 or 2 mg film-coated tablets. The tablets have to be taken orally once daily and swallowed whole with water, with or without food.
48170281|NCT03820869|OTHER|Occupational Therapy|Occupational Therapy
48170282|NCT05300997|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
48170283|NCT00725036|DRUG|inhaled human insulin|
48170284|NCT00725036|DRUG|insulin aspart|
48170285|NCT00725036|DRUG|insulin NPH|
48701240|NCT01166373|PROCEDURE|ULS|uterosacral ligament suspension to suspend the vaginal apex
48516086|NCT01652547|DRUG|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
48701241|NCT01166373|BEHAVIORAL|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
48701242|NCT01166373|OTHER|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
48701243|NCT01367418|DRUG|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
48701244|NCT01367418|DRUG|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
48701245|NCT01215643|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
48701246|NCT01215643|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
48701247|NCT01215643|DRUG|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
48701248|NCT06331286|DRUG|dulaglutide injection|0.75mg Subcutaneous injection once a week for 24 weeks
48013621|NCT04514991|DEVICE|Foundation|Collagen-based, bone filling augmentation material used to stimulate bone formation in extraction sockets or bone defects in the alveolar ridge.
48013622|NCT05911399|DRUG|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
48701249|NCT04368494|BEHAVIORAL|12-week home based exercise|Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
48701250|NCT05350202|DRUG|Empagliflozin|Empagliflozin
48701251|NCT05260073|DRUG|Tirbanibulin|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
48701252|NCT02152371|DRUG|Dulaglutide|Administered SQ
48701253|NCT02152371|DRUG|Placebo|Administered SQ
48013623|NCT00027430|DRUG|TheraDerm|
48701254|NCT02152371|DRUG|Insulin Glargine|Administered SQ
48701255|NCT02152371|DRUG|Metformin|Administered orally
48701256|NCT01730365|PROCEDURE|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
48701257|NCT04302740|BEHAVIORAL|LEAP|The LEAP is a comprehensive, multidimensional, community-level intervention offered in Housing First settings that was developed using a CBPR framework. The LEAP principles, process, and components were conceptualized and operationalized by the CAB in the pilot study, and are outlined in a recently published articles in the American Psychologist and Journal of Community Psychology. Briefly, LEAP principles include recognizing and respecting community as a key unit of identity versus solely as individuals in a traditional research hierarchy; embracing cultural humility; practicing pragmatism and compassion; aiming to build equitable research partnerships with communities; acknowledging and promoting community strengths; and supporting relevant, sustainable, positive and community-led change.
48701258|NCT01280058|DRUG|Carboplatin|Given IV
48701259|NCT01280058|OTHER|Laboratory Biomarker Analysis|Correlative studies
48701260|NCT01280058|DRUG|Paclitaxel|Given IV
48701261|NCT01280058|BIOLOGICAL|Wild-type Reovirus|Given IV
48701262|NCT02862483|DRUG|Tamsulosin 0.2mg|
48701263|NCT02862483|DRUG|Tadalafil 5mg|
48701264|NCT02862483|DRUG|Placebo for Tamsulosin|
48013624|NCT05459636|DEVICE|High-resistance inspiratory muscle strength training|Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
48701265|NCT05365568|PROCEDURE|Left Bundle Branch Area Pacing (LBBAP)|Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
48013625|NCT05459636|DEVICE|Very-low-resistance inspiratory muscle strength training|Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
48013626|NCT01831375|BEHAVIORAL|Speak Up|Intervention group_treatment group
48013627|NCT01831375|BEHAVIORAL|Get connected|Participants will learn to be connected with social resources in the community.
48013628|NCT03930316|DEVICE|NOX T3|portable sleep study device
48170286|NCT05832944|DEVICE|ultrasound guided hyomental distance|measuring the hyomental distance by ultrasound guidance
48701266|NCT05365568|PROCEDURE|Biventricular pacing (BiV)|Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
48701267|NCT00368836|DEVICE|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
48701268|NCT02613468|OTHER|collection of periodontal records|"1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
48170287|NCT04567797|DEVICE|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
48701269|NCT02613468|OTHER|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
48701270|NCT02613468|OTHER|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
48701271|NCT02567370|DRUG|AMG 581|Active drug
48701272|NCT02567370|DRUG|Placebo|Placebo
48701273|NCT06605547|PROCEDURE|Non-surgical periodontal treatment|The non-surgical periodontal treatment (scaling and root planing) was applied under local anesthesia using ultrasonic device and Gracey curettes. After scaling and root planing, periodontal pockets were irrigated using saline solution. Non-surgical periodontal treatment was completed in one or two sessions within 24 hours.
48701274|NCT06605547|DEVICE|Subgingival application of saline|For the subgingival saline application at the control sites, the insulin needle was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. Subgingival saline application was repeated on the 7th day.
48701275|NCT06605547|OTHER|Subgingival application of i-PRF|For subgingival application of i-PRF at the test sites, the i-PRF taken into the insulin syringe, the 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). Subgingival i-PRF application was repeated on the 7th day.
48701276|NCT06330103|OTHER|Easy EF|AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
48701277|NCT06605716|PROCEDURE|Enucleation of cysts|Surgical removal of cystic structures larger than 1 cm in patients included in the study arms. Patients were monitored for TCR during the procedure.
48701278|NCT04308434|OTHER|CSD190601-11|Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
48701279|NCT04308434|OTHER|CSD190601-12|Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
48701280|NCT04308434|OTHER|CSD190601-13|Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
48701281|NCT04308434|OTHER|CSD190601-14|Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
48701282|NCT04308434|OTHER|CSD190601-15|Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
48701283|NCT04308434|OTHER|CSD190601-16|Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
48701284|NCT04308434|OTHER|CSD190601-17|Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
48371532|NCT05392543|OTHER|Mirror Therapy|"Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session."
48701285|NCT04308434|OTHER|CSD190601-21|Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
48013629|NCT06416748|PROCEDURE|Minimally invasive simple hysterectomy|Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
48701286|NCT04308434|OTHER|CSD190601-22|Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
48701287|NCT04308434|OTHER|CSD190601-23|Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
48371533|NCT00077766|DRUG|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
48701288|NCT04308434|OTHER|CSD190601-24|Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
48701289|NCT04308434|OTHER|CSD190601-25|Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
48701290|NCT04308434|OTHER|CSD190601-26|Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
48701291|NCT04308434|OTHER|CSD190601-27|Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
48701292|NCT04149158|DIETARY_SUPPLEMENT|Placebo|
48701293|NCT04149158|DIETARY_SUPPLEMENT|Sinetrol® Xpur|
48701294|NCT04824768|DEVICE|Tecar Therapy|"CRet is a non-invasive diathermy technique that provides high frequency energy generating a thermal effect on soft tissues. Functional massage (FM) is a non-invasive manual therapy technique that combines rhythmical passive joint mobilization with compression of the muscular belly with the muscle-tendon insertions to be treated.~In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min F.M with passive ankle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (180-250VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 8.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
48701295|NCT04824768|DEVICE|Sham Tecar Therapy|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min FM with passive ankle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 0.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
48013630|NCT05768867|OTHER|FRAnçaise du PEYronie's Disease QUESTionnaire|Complete an online FRAnçaise du PEYronie's Disease QUESTionnaire
48701296|NCT04547335|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
48701297|NCT06607783|DIAGNOSTIC_TEST|MRI|TBC
48701298|NCT05868928|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
48701299|NCT05868928|DIAGNOSTIC_TEST|Diffusion-weighted MRI|Diffusion-weighted MRI
48701300|NCT05868928|DIAGNOSTIC_TEST|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
48013631|NCT04330079|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg once daily for 6 months.
48701301|NCT05868928|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
48701302|NCT00365105|DIETARY_SUPPLEMENT|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
48701303|NCT00365105|DIETARY_SUPPLEMENT|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
48701304|NCT00365105|DRUG|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
48701305|NCT00365105|DRUG|Sm-153|Single dose intravenously 1 mCi/kg body weight.
48701306|NCT00365105|RADIATION|Sr-89|Single dose intravenously 4 mCi.
48170288|NCT04567797|DEVICE|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
48170289|NCT04567797|DEVICE|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
48170290|NCT04567797|DEVICE|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
48701307|NCT01960998|BEHAVIORAL|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
48701308|NCT01960998|BEHAVIORAL|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
48013632|NCT04330079|OTHER|Lifestyle modification|lifestyle modification (diet and exercise) for 6 months
48013633|NCT00727194|DRUG|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
48013634|NCT00727194|DRUG|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
48013635|NCT06335771|OTHER|Dietary consultation weight loss intervention|Participants will meet with a member of the study team biweekly for about 6 months.
48170291|NCT00212797|DRUG|Org 34517|low dose Org 34517
48170292|NCT00212797|DRUG|Org 34517|high dose Org 34517
48170293|NCT00212797|DRUG|Placebo|placebo
48013636|NCT02049489|BIOLOGICAL|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
48013637|NCT05668767|DRUG|Surufatinib Durvalizumab EP/EC|Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
48701309|NCT01938924|DEVICE|GekoTM|electrical neuromuscular stimulation
48701310|NCT00813865|DRUG|afegostat tartrate|
48701311|NCT01635673|OTHER|Exercise intervention|Whole body vibration exercise 3 times per week
48701312|NCT02652208|BEHAVIORAL|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
48701313|NCT02652208|BEHAVIORAL|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
48701314|NCT00445211|DRUG|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
48701315|NCT00445211|OTHER|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
48013638|NCT00548860|DRUG|Ferric Carboxymaltose|
48013639|NCT00548860|DRUG|Standard Medical Care (SMC)|
48701316|NCT03426462|DRUG|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
48701317|NCT03074292|PROCEDURE|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
48701318|NCT00634712|DRUG|Candesartan|
48701319|NCT00634712|DRUG|Placebo|
48701320|NCT06289920|DRUG|BR3005|One tablet administered alone, Once a day
48701321|NCT06289920|DRUG|BR3005-1|One tablet administered alone, Once a day
48701322|NCT06289920|DRUG|BR3005-2|One tablet administered alone, Once a day
48701323|NCT04627324|DEVICE|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
48701324|NCT04627324|DEVICE|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
48013640|NCT02707614|PROCEDURE|Robotic vs open prostastectomy|robotic minimal invasive surgery
48701325|NCT05678205|DRUG|AB-201|NK Cell Therapy
48701326|NCT05678205|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
48371534|NCT00077766|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
48371535|NCT00188058|DEVICE|Setting of positive end-expiratory pressure|
48701327|NCT05678205|DRUG|Fludarabine|Lymphodepleting chemotherapy
48701328|NCT03939767|DRUG|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
48701329|NCT00004495|DRUG|cyanocobalamin|
48701330|NCT00004495|DRUG|folic acid|
48701331|NCT00004495|DRUG|pyridoxine|
48701332|NCT00936533|DRUG|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
48701333|NCT00936533|DRUG|Placebo|Placebo preparation without active compound, administered as the active drug.
48701334|NCT00022204|DIETARY_SUPPLEMENT|vitamin E|
48701335|NCT00022204|DRUG|pentoxifylline|
48701336|NCT00022204|PROCEDURE|quality-of-life assessment|
48701337|NCT05159492|DEVICE|PVI using PEF|PVI using PEF
48013641|NCT00441337|BIOLOGICAL|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
48013642|NCT01108549|DIETARY_SUPPLEMENT|Ribose|Ribose 5 grams PO TID was taken daily
48170294|NCT03738098|BEHAVIORAL|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
48701338|NCT05159492|DEVICE|PVI using CFRF|PVI using CFRF
48701339|NCT00022360|DRUG|taurolidine|
48701340|NCT03528239|OTHER|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
48701341|NCT05247970|DRUG|S-309309|Capsule administered orally
48701342|NCT05247970|DRUG|Midazolam|Syrup administered orally
48701343|NCT05247970|DRUG|Placebo|Matching capsule to S-309309 administered orally
48701344|NCT03501004|DEVICE|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
48701345|NCT06314477|DEVICE|CPAP treatment|Subjects allocated to this arm will receive continuous positive airway pressure (CPAP)
48701346|NCT06314477|OTHER|Hygienic and dietary advice|Subjects allocated to this arm will receive hygienic and dietary counselling
48701347|NCT02873065|DRUG|Ilaprazole|
48701348|NCT02873065|DRUG|Esoprazole|
48701349|NCT02080481|DEVICE|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
48701350|NCT02080481|DEVICE|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
48701351|NCT05997992|DEVICE|electroacupuncture|Electroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
48701352|NCT05997992|DEVICE|sham acupuncture|Acupuncture does not penetrate the skin, and the electroacupuncture machine is not plugged in.
48701353|NCT05083013|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
48701354|NCT05083013|DIAGNOSTIC_TEST|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
48701355|NCT05083013|RADIATION|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
48701356|NCT05083013|DIAGNOSTIC_TEST|Routine Laboratory investigations|"* Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
48701357|NCT05083013|DIAGNOSTIC_TEST|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
48701358|NCT01774097|BIOLOGICAL|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
48701359|NCT01774097|BIOLOGICAL|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
48701360|NCT04837209|DRUG|Niraparib|Capsule, taken by mouth
48701361|NCT04837209|DRUG|Dostarlimab|Intravenous infusion
48701362|NCT04837209|RADIATION|Radiation therapy|Radio Therapy
48701363|NCT01743235|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
48701364|NCT01743235|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
48701365|NCT01743235|DRUG|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
48701366|NCT03854526|OTHER|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
48701367|NCT05083546|DRUG|Gly-low|MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine
48701368|NCT05083546|OTHER|Placebo|sugar pill
48170295|NCT03738098|BEHAVIORAL|GUÍA|GUÍA for the ROR1 visit.
48701369|NCT03643341|BEHAVIORAL|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
48701370|NCT05129904|OTHER|Double plasma molecular absorption system|DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
48170296|NCT01828385|DRUG|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
48170297|NCT01828385|DRUG|Saline|Saline + rocuronium + sugammadex
48170298|NCT05685953|BIOLOGICAL|DNA vaccine OC-007|Plasmid DNA vaccine
48170299|NCT05685953|OTHER|Placebo|0.9% NaCl solution
48701371|NCT03564522|PROCEDURE|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
48701372|NCT03564522|RADIATION|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
48701373|NCT00484380|PROCEDURE|Coronary scanner|multislice spiral computed tomography coronary angiography
48701374|NCT01887015|DEVICE|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
48701375|NCT06605144|OTHER|1- Vasopressors - Mean arterial pressure 55-59|Vasopressors will be titrated according to 55-59 range.
48701376|NCT06605144|OTHER|2- Vasopressors - Mean arterial pressure 60-65|Vasopressors will be titrated according to 60-65 range.
48701377|NCT06605144|OTHER|3- Vasopressors - Mean arterial pressure 66-69|Vasopressors will be titrated according to 66-69 range.
48701378|NCT06605144|OTHER|4- Vasopressors - Mean arterial pressure 70-75|Vasopressors will be titrated according to 70-75 range.
48701379|NCT00284557|BEHAVIORAL|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
48170300|NCT03258502|DRUG|RV521|RV521 drug in capsules
48170301|NCT03258502|DRUG|Placebo|Placebo in capsules
48371536|NCT00433368|DRUG|L-Ornithine L-Aspartate|
48013643|NCT04142437|DRUG|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
48013644|NCT00668681|DEVICE|EndoRefix|
48013645|NCT06192745|BEHAVIORAL|no screen control with dim light and calming activities|Non-screen-based quiet activities for 1 hour before bed in room lighting 40-50 lux
48013646|NCT06192745|BEHAVIORAL|unfiltered Bright tablet screen|Bright light screen media exposure will be delivered on an iPad Pro provided by the research team which will be set to the brightest light intensity setting for 1 hour before bed in room lighting 40-50 lux
48013647|NCT06192745|BEHAVIORAL|Filtered dim tablet screen|Filtered dim light screen media exposure will be delivered for 1 hour before bed in room lighting 40-50 lux on an iPad Pro provided by the research team. A blue light filter will be used to alter the spectral distribution of the emitted light and the screen brightness will be dimmed to the lowest possible setting
48013648|NCT06192745|BEHAVIORAL|Exciting content|We will create a 1-hour recording of movie clips containing exciting content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
48013649|NCT06192745|BEHAVIORAL|Calming Content|We will create a 1-hour recording of movie clips containing calming content from age-appropriate movies for 8- to 11-year-old children as rated by Common Sense Media.
48013650|NCT05052229|DRUG|Nitric Oxide|Nitric oxide gas for inhalation
48170302|NCT05771597|OTHER|Home Biofeedback therapy|"Patients will be given home biofeedback device to take home and practice biofeedback exercises at least twice a day for six weeks of therapy.~1. HBT for patients with constipation and dyssynergic defecation:~   Patients will attend one session of training on how to use the device followed by daily sessions at home for 6 weeks. After placing a probe into rectum, the patient sits on a commode, activates the smart phone app and follow the voice-guided instructions to perform diaphragmatic breathing exercises and push maneuvers with/without balloon distension.~2. HBT for patients with FI:~   Subject will receive training on how to use the home-trainer device and probe placement. The patient will be asked to follow a series of voice guided instructions consisting of performing short and long duration squeeze maneuvers over 25 minutes.~3. HBT for patients with UI:~The instructions protocol as written above for patients with FI will be followed for UI patients as well."
48170303|NCT05771597|OTHER|Office biofeedback therapy|"Patients will receive traditional office biofeedback, once weekly, over six weeks.~1. OBT for patients with constipation and dyssynergic defecation:~   The patient will receive instructions on the diaphragmatic breathing techniques. Then the patient sits on a commode, coordination between push effort and the anal and pelvic floor relaxation is corrected by the therapist. The patients will receive visual and verbal feedback instructions from the therapist.~2. OBT for patients with FI:~   Patients will be taught Kegels and abdominal muscle exercises. Visual and verbal feedback techniques are used to reinforce the maneuvers. The patient is instructed to squeeze and to maintain this squeeze for as long as possible.~3. OBT for patients with UI:~Biofeedback training is performed using the protocol and objectives as described above for FI training."
48170304|NCT00003185|BIOLOGICAL|autologous tumor cell vaccine|
48013651|NCT05052229|DRUG|Medical air|Medical grade air for inhalation (placebo)
48013652|NCT06325462|DEVICE|sensors of regional cerebral oxygen saturation (O3 regional oximeter, Masimo Corp, Irvine, CA) FDA Reg No. 3011353843|O3 regional oximetry monitors the regional hemoglobin oxygen saturation of the blood (rSO2) in adult patients, placed on the forehead by noninvasive and continuous combining arterial and venous oxygen saturation signals from near-infrared spectroscopy (NIRS)
48013653|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
48013654|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
48013655|NCT03496285|RADIATION|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
48013656|NCT06660433|DEVICE|Point-of-care respiratory test platform|A point-of-care respiratory multiplex testing platform situated within a long-term care facility to provide rapid test results
48013657|NCT06660433|OTHER|Existing respiratory virus testing platform|Currently used respiratory virus testing platforms
48013658|NCT06663605|DRUG|PALI-2108|Oral dose
48170305|NCT00003185|BIOLOGICAL|sargramostim|
48013659|NCT06663605|DRUG|PALI-2108 Placebo|Oral dose
48013660|NCT02020668|OTHER|Physiotherapy|
48170306|NCT00003185|BIOLOGICAL|tumor-draining lymph node lymphocyte therapy|
48170307|NCT00003185|DRUG|cyclophosphamide|
48170308|NCT00003185|PROCEDURE|conventional surgery|
48013661|NCT02020668|OTHER|Wait list control|
48013662|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
48170309|NCT03243500|DRUG|Atracurium|5mg in 1 ml normal saline
48170310|NCT03243500|DRUG|Lidocaine 2%|
48170311|NCT03243500|DRUG|Bupivacaine 0.5%|
48170312|NCT03243500|DRUG|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
48371537|NCT06165159|OTHER|children and adolescents with type 1 diabetes and their parents|"Children over the age of 8 with type 1 diabetes diagnosed more than 6 months ago in France, followed in one of the hospitals that are members of the Aide aux Jeunes Diabétiques (AJD) association.~Parents or people involved in the day-to-day life of children with type 1 diabetes diagnosed at least 6 months ago, whose child is being followed in France in one of the hospitals affiliated to the AJD association."
48371538|NCT01716221|DRUG|bupropion & Citalopram|
48170313|NCT03243500|PROCEDURE|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
48170314|NCT06379698|OTHER|personalized 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a personalized 3D models will be presented to the patients according to the allocated study group
48170315|NCT06379698|OTHER|generic 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a generic 3D models will be presented to the patients according to the allocated study group
48701380|NCT00211835|BEHAVIORAL|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
48013663|NCT01296724|OTHER|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
48013664|NCT01223716|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
48701381|NCT00211835|BEHAVIORAL|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
48013665|NCT01223716|BEHAVIORAL|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
48371539|NCT01716221|DRUG|Bupropion & Placebo|
48701382|NCT02034682|DRUG|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
48701383|NCT02034682|DRUG|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
48701384|NCT03252886|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
48701385|NCT04039750|DRUG|antibiotic rinse with suction|antibiotic rinse with suction
48701386|NCT04039750|PROCEDURE|suction only|no irrigation, suction only
48701387|NCT06367686|DEVICE|IscAlert sensor|Insertion of an IscAlert sensor at the nasal mucosa
48701388|NCT05143307|BIOLOGICAL|EBT-101|Long term follow up of participants who received EBT-101
48701389|NCT02613117|DEVICE|Potassium Oxalate Gel|Self applied
48701390|NCT02613117|DEVICE|Potassium Oxalate Liquid|Professionally Applied
48013666|NCT01223716|BEHAVIORAL|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
48013667|NCT01362907|DEVICE|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
48013668|NCT01362907|DEVICE|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
48013669|NCT03081416|DRUG|Ketamine|Intranasal ketamine administration
48371540|NCT01716221|DRUG|Placebo & Citalopram|
48371541|NCT01716221|DRUG|Placebo & Placebo|
48371542|NCT03948061|OTHER|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
48371543|NCT03948061|OTHER|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
48701391|NCT02613117|DRUG|Stannous fluoride paste|SnF2 Paste
48701392|NCT02559934|DRUG|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
48013670|NCT03081416|DRUG|Normal saline|
48013671|NCT03081416|DRUG|Metoclopramide|Standard therapy
48013672|NCT03081416|DRUG|Ketorolac|standard therapy
48013673|NCT03081416|DRUG|Dexamethasone|Standard therapy
48013674|NCT03081416|DRUG|Benadryl|Standard therapy
48013675|NCT01276899|PROCEDURE|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect tumor samples.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
48701393|NCT01032954|DRUG|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
48170316|NCT04366518|DRUG|Rivastigmine Transdermal System|Rivastigmine doses will be administered transdermally using 9.5 mg/24 hr transdermal patches. Participants will be randomized to two treatments with oral rivastigmine vs. placebo separated by a 15-hour washout period (\>5 half-lives to eliminate any residual effects). This will require three separate visits: a baseline visit, a visit for the first transdermal treatment and a visit for the second transdermal treatment. All visits include fMRI scans. The first transdermal patch will be administered 8-14 hours before the scan. After the washout period, the second transdermal patch will be administered 8-14 hours before the scan. No study team member except for the unblinded team member will know which capsule the participant receives first. Because we are interested in rivastigmine as a probe for a pre-identified computational/physiological abnormality, we will median-split groups post-hoc for the purposes of analysis.
48170317|NCT04366518|DRUG|Scopolamine|The authors have chosen to use scopolamine to determine the effects of cholinergic antagonism, as treatment with scopolamine demonstrates a dose-related increase in propensity toward conditioned hallucinations and in doses much higher than those proposed here, can cause spontaneous hallucinations. At the proposed dose, scopolamine has an excellent safety profile and has been used routinely for nearly 20 years for treatment of nausea due to surgery or motion sickness in adults and children. Scopolamine is available in the US only as a 1mg / 72 hours transdermal patch, and peak plasma levels are reached within 24 hours. This standard dosage level is very well tolerated in the general population.
48170318|NCT04366518|DRUG|Placebo Patch|Participants in Aim 2 will receive a placebo patch versus rivastigmine patch.
48170319|NCT04366518|DRUG|Placebo Patch|Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
48701394|NCT00178165|PROCEDURE|Skill Training Condition - problem solving training|
48701395|NCT00178165|PROCEDURE|REACH for TLC (Telephone Linked Computer) system|
48170320|NCT04052997|DRUG|Camidanlumab Tesirine|Intravenous Infusion
48170321|NCT00474383|DRUG|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
48170322|NCT00474383|DRUG|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
48170323|NCT04771962|DRUG|DESFLURANE AND SEVOFLURANE|COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
48701396|NCT00583414|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
48701397|NCT01761591|DEVICE|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
48701398|NCT01761591|DEVICE|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
48701399|NCT00075114|BEHAVIORAL|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
48701400|NCT06345950|DIETARY_SUPPLEMENT|Liposomal Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
48701401|NCT06345950|DIETARY_SUPPLEMENT|Standard Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
48701402|NCT06345950|DIETARY_SUPPLEMENT|New Micellar Glutathione (Lipomicel)|A maximum single dose of 600 mg glutathione (soft gel capsules)
48701403|NCT00338208|BEHAVIORAL|Training in the Use of Low Vision Devices|
48701404|NCT05569057|DRUG|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
48701405|NCT01818258|DRUG|ZDV+3TC+LPV/r|
48701406|NCT01832129|DRUG|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
48701407|NCT01832129|DRUG|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
48701408|NCT05418283|BEHAVIORAL|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
48701409|NCT01368783|DRUG|atazanavir|400 mg/day for 2 days
48170324|NCT00461123|DRUG|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
48701410|NCT01368783|DRUG|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
48701411|NCT01368783|DRUG|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
48701412|NCT01368783|DRUG|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
48701413|NCT00434083|DRUG|sumatriptan|
48701414|NCT00434083|DRUG|naproxen sodium|
48701415|NCT06608238|DRUG|D-MNA 200 mcg|D-MNA , (doxorubicin) patch, 200 mcg
48701416|NCT06608238|DRUG|D-MNA 100 mcg|D-MNA (doxorubicin) patch, 100 mcg
48701417|NCT06608238|OTHER|Placebo|P-MNA patch, placebo
48701418|NCT00782171|DEVICE|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
48701419|NCT05978492|DRUG|TXN10128|Participants receive TXN10128 capsules orally once daily.
48701420|NCT05175768|OTHER|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
48170325|NCT00461123|DRUG|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
48170326|NCT05082623|OTHER|Music|Music medicine
48170327|NCT05082623|OTHER|Earplug|Earplug with noise cancelling
48701421|NCT05175768|OTHER|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
48701422|NCT05175768|OTHER|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
48701423|NCT02665351|DRUG|Peramivir|The two regimens of Peramivir were compared
48701424|NCT06251661|OTHER|Cognitive multi-sensory Rehabilition|Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
48701425|NCT06251661|OTHER|selected traditional physical therapy program.|The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
48701426|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|10 ml extrafascial interscalene brachial plexus block
48170328|NCT00511797|DRUG|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
48170329|NCT00511797|DRUG|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
48170330|NCT00511797|DRUG|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
48170331|NCT00511797|DRUG|Placebo|Placebo
48170332|NCT02403284|DRUG|Liraglutide|Subcutaneous injection by patient
48170333|NCT02403284|DRUG|Sugar Pill|Subcutaneous injection daily
48170334|NCT03903562|BIOLOGICAL|V503|0.5 mL 9vHPV VLP Vaccine
48170335|NCT02110511|OTHER|blended lentils|blended lentils burritto breakfast
48170336|NCT02110511|OTHER|whole lentils|whole lentils breakfast burritto
48170337|NCT02110511|OTHER|no lentils|No lentils control breakfast burritto
48516087|NCT02548390|DRUG|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
48170338|NCT01522677|DRUG|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
48170339|NCT02597036|DRUG|LY3127804|Administered IV
48170340|NCT02597036|DRUG|Ramucirumab|Administered IV
48170341|NCT02597036|DRUG|Paclitaxel|Administered IV
48170342|NCT02044614|OTHER|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
48170343|NCT01087814|DRUG|Efavirenz|Subject will take efavirenz for 5 days.
48170344|NCT01087814|DRUG|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
48170345|NCT02344056|OTHER|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
48170346|NCT02344056|OTHER|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
48170347|NCT04260399|OTHER|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
48170348|NCT04260399|OTHER|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
48170349|NCT05498454|BEHAVIORAL|Breathworks Mindfulness (Health or Stress Arm)|As for previous descriptions
48170350|NCT03371537|PROCEDURE|Liver debit measure|Mesure of liver debit during hepatectomy
48170351|NCT00812838|DRUG|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
48170352|NCT00812838|OTHER|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
48170353|NCT00812838|DRUG|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
48170354|NCT03100136|DRUG|[11C]PF-06809247|PET Tracer
48170355|NCT04739189|BEHAVIORAL|Con : control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
48170356|NCT04739189|BEHAVIORAL|Def-EX : Condition with an exercise-induced energy deficit|Condition with an exercise-induced energy deficit The adolescents will be asked to complete an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 400 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
48170357|NCT04739189|BEHAVIORAL|Def-EI : Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will be asked to remain quiet during the whole day (no physical activity). They will receive a calibrated breakfast reduced from 400 kcal compare to their CON and Def-EX conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
48170358|NCT01448382|DEVICE|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
48371544|NCT01978067|PROCEDURE|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
48371545|NCT06511102|BEHAVIORAL|GPT Support|The computer interface used for the essay writing task follows a split-screen design. The writing instructions and text input field are administered on a survey platform, placed on the left half of the screen. ChatGPT is placed on the right half of the screen for technology assistance.
48371546|NCT05084118|DRUG|Landiolol HCl|continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours
48371547|NCT05084118|DRUG|Placebo|continous application of isotone saline solution for 72 hours
48371548|NCT02635906|OTHER|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
48371549|NCT02635906|OTHER|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
48371550|NCT05784142|RADIATION|hypofractionated radiation therapy|"* Part 1: Patients who have received induction immunotherapy plus chemotherapy for 2-6 cycles and met the hypoRT criteria will be enrolled into the study.~* Part 2: patients will be treated with hypofractionated radiation therapy in doses up to 48-60 Gy at 4 Gy per fraction.~* Part 3: patients with partial response or stable disease after part 2 will be eligible for immunotherapy maintenance, for up to 1 years or until disease progression or unacceptable toxicity."
48371551|NCT05525559|DRUG|ET0038|ET0038 for oral administration
48701427|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|20 ml extrafascial interscalene brachial plexus block
48701428|NCT05923931|DEVICE|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
48701429|NCT05923931|DEVICE|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
48701430|NCT05804513|DRUG|Placebo|s/c injection
48701431|NCT05804513|DRUG|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
48701432|NCT03350256|DEVICE|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
48701433|NCT03100981|BEHAVIORAL|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
48701434|NCT03100981|BEHAVIORAL|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
48701435|NCT06394479|OTHER|Outcome after bariatric surgery in patient with T1D|Retrospective evaluation of clinical data
48701436|NCT05525091|OTHER|Feeding Evaluation|Feeding Evaluation with Device
48701437|NCT05721937|DRUG|Abrocitinib|taken by mouth
48701438|NCT05757154|OTHER|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
48701439|NCT04461691|PROCEDURE|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
48701440|NCT05304442|DRUG|Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Single Dose of IV Iron
48701441|NCT05304442|DRUG|Ferrous Sulfate 65 mg elemental iron (325 mg tablets)|Once daily by mouth for 42 days
48701442|NCT00169234|BIOLOGICAL|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
48170359|NCT05493098|OTHER|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
48371552|NCT05025891|OTHER|Teleconsultation|Patients are randomized into groups in which there are either teleconsultations alone or with the help of a mediator to carry out their follow-up care
48701443|NCT00169234|BIOLOGICAL|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
48701444|NCT01073397|BEHAVIORAL|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
48701445|NCT00372372|DRUG|risedronate|
48701446|NCT04660825|OTHER|A resistance band exercise programme|A resistance band based exercise programme lasting six months
48701447|NCT04660825|OTHER|Control|Maintained usual physical activity
48371553|NCT03107065|DEVICE|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
48701448|NCT04089241|OTHER|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
48701449|NCT06172803|BEHAVIORAL|Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|8 week exercise program. 20 minutes of home aerobic exercise most days, phone- based motivational exercise coaching and supervised exercise with our team exercise physiologist.
48701450|NCT06172803|BEHAVIORAL|Light Stretching/Breathing Exercises|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician (via 20-minute weekly video visits). Exercises performed 5 days a week will not increase HR significantly. Participants will record and track their HR with Apple watch and app; like RESToRE, fidelity of treatment will be objectively measured using HR data.
48701451|NCT03898466|DRUG|Fluticasone furoate|Inhaled corticosteroid
48371554|NCT00185146|DRUG|Pactimibe|
48701452|NCT03898466|OTHER|Matching placebo|Placebo inhaler
48701453|NCT05878886|DIETARY_SUPPLEMENT|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
48701454|NCT03713398|BEHAVIORAL|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
48701455|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule|Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
48701456|NCT04170504|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
48701457|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule placebo|Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
48701458|NCT06183294|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
48701459|NCT02017938|PROCEDURE|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
48701460|NCT05386550|DRUG|Xevinapant (Debio 1143)|Participants will receive 3 cycles of oral solution of Xevinapant (Debio 1143) at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of Xevinapant (Debio 1143) at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
48701461|NCT05386550|RADIATION|IMRT|Participants will receive 66 Gy of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week.
48701462|NCT05386550|DRUG|Placebo|Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
48701463|NCT06606470|BEHAVIORAL|All providers Better Communication Skills program' (ABCs) interprofessional provider education|The 'All providers: Better Communication Skills program' (ABCs) is a virtual, person-centred education curriculum for interprofessional health care providers. The ABCs program adopts a blended format (i.e., participants engage in both asynchronous online modules \[five\] and synchronous interactive workshops \[three\]) that has relevance to learners and clinicians at all levels of training and practice. The ABCs program focuses on four essential elements of being a skillful communicator: principles of effective communication, conversation structure, communication skills, and reflective practice. The program consists of virtual modules that provide any clinician with practical tools, tips, and strategies to implement when communicating with seriously ill patients and their families. Terminology is clarified and consistent, the complexities of conversations are simplified and the fundamental approach and structure can be applied to different contexts.
48701464|NCT01791049|DRUG|TD-1607|
48701465|NCT01791049|DRUG|Placebo|
48701466|NCT03590626|DRUG|Dulaglutide|0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
48701467|NCT05557552|RADIATION|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
48701468|NCT05557552|RADIATION|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
48701469|NCT02250807|DRUG|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
48701470|NCT02250807|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
48516088|NCT03168022|DRUG|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
48516089|NCT03168022|DRUG|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
48701471|NCT01762735|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
48701472|NCT01762735|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
48701473|NCT05846425|OTHER|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
48516090|NCT00479960|BEHAVIORAL|commercially available omega-3 fatty acids supplementation|
48516091|NCT03524170|DRUG|Bintrafusp Alfa|Given IV
48701474|NCT05846425|OTHER|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
48701475|NCT00897403|OTHER|biologic sample preservation procedure|
48701476|NCT00897403|PROCEDURE|diagnostic colonoscopy|
48701477|NCT03759886|DRUG|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
48701478|NCT04314765|PROCEDURE|lower third molar extraction|the extraction is performed with one of the two type of flap based non randomization.
48701479|NCT02050802|DRUG|Moxifloxacin 400 mg|
48701480|NCT02050802|DRUG|Macitentan 10 mg|
48701481|NCT02050802|DRUG|Macitentan 30 mg|
48701482|NCT02050802|OTHER|Placebo|
48516092|NCT03524170|RADIATION|Radiation Therapy|Undergo radiation therapy
48516093|NCT01992185|DRUG|Photocil for Vitiligo|Photocil for Vitiligo
48516094|NCT01992185|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
48516095|NCT00115453|RADIATION|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
48516096|NCT03299582|DEVICE|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
48013676|NCT01276899|PROCEDURE|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study. Needle core biopsies will be done to collect metastasis tumor samples.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
48013677|NCT03126981|OTHER|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
48013678|NCT03126981|OTHER|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
48013679|NCT00002335|DRUG|Emtricitabine|
48013680|NCT06137833|DIETARY_SUPPLEMENT|APPOPRTAL®|1 sachet of APPORTAL® contains: Vitamin C 37,5 mg; Vitamin E 30 mg; Vitamin PP 18 mg; Vitamin B1 1 mg; Vitamin D 25 μg; Vitamin H 25 μg; L-arginine 1000 mg; L-carnitine 500 mg; Taurine 25 mg; Ginseng e.s. 100 mg; Eleutherococcus e.s. 50 mg; Magnesium 187,5 mg; Iron 14 mg; Zinc 1,5 mg; Iodine 75 μg; Selenium 27,5 μg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg; Coenzyme Q10 100 mg; Lycopene 3,06 mg; Tocotrienols 2,5 mg
48013681|NCT06137833|OTHER|Placebo|Ingredients: Maltodextrin, acidifying agent: citric acid, flavours, anticaking agent: tricalcium phosphate, beetroot juice powder; sweetener: sucralose, anti-caking agent: silicon dioxide, colouring agent: beta-carotene
48013682|NCT06664476|BEHAVIORAL|PortCare Professional Training Program|The intervention is a targeted educational program to enhance oncology nurses' skills in managing Port-A-Catheters for chemotherapy patients. It includes a preparatory phase to assess baseline knowledge and practices, followed by an implementation phase with theoretical and practical training. Theoretical sessions cover device basics and care guidelines, while practical sessions provide hands-on training on procedures like catheter insertion, flushing, and removal. This program aims to improve patient safety, reduce complications, and boost nurses' confidence in Port-A-Catheter care.
48013683|NCT06265220|DRUG|AB-101|NK Cell Therapy
48013684|NCT06265220|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
48013685|NCT06265220|DRUG|Fludarabine|Lymphodepleting chemotherapy
48013686|NCT06265220|DRUG|Rituximab|Anti-CD20 antibody therapy
48013687|NCT06265220|DRUG|Obinutuzumab|Anti-CD20 antibody therapy
48013688|NCT04817241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48013689|NCT04817241|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
48013690|NCT04817241|DRUG|Cytarabine|Given IV
48013691|NCT04817241|DRUG|Daunorubicin|Given IV
48013692|NCT04817241|DRUG|Decitabine and Cedazuridine|Given PO
48170360|NCT05493098|OTHER|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
48516097|NCT03299582|DEVICE|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
48013693|NCT04817241|DRUG|Venetoclax|Given PO
48013694|NCT01895751|PROCEDURE|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
48013695|NCT01701661|PROCEDURE|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
48013696|NCT01701661|OTHER|conservative treatment|Compression stockings class II
48013697|NCT04929301|OTHER|Antenatal milk expression|Hand-expression of breast milk in pregnancy
48013698|NCT04929301|OTHER|Education handouts|Educational breastfeeding handouts
48013699|NCT03128879|DRUG|Ibrutinib|Given PO
48013700|NCT03128879|DRUG|Venetoclax|Given PO
48013701|NCT03128879|DRUG|Acalabrutinib|Given BID
48013702|NCT06274554|DRUG|Fluconazole|Oral fluconazole capsules.
48013703|NCT06274554|DRUG|Placebo|Oral placebo capsules will be used as a comparator.
48013704|NCT06274554|BIOLOGICAL|IL-23 Therapy|Risankizumab (IL-23) or Ustekinumab (IL-12/23) as standard of care treatment.
48013705|NCT00575744|PROCEDURE|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
48170361|NCT04191148|DRUG|LBP-EC01|crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
48170362|NCT04191148|DRUG|Placebo|Lactated Ringers Solution for Injection dosed BID by intraurethral administration
48371555|NCT00405925|DRUG|Trizivir|
48371556|NCT00405925|DRUG|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
48013706|NCT05050643|OTHER|EBQI-IC|Individual (ongoing) consultation (IC), often described as coaching or supervision, is endorsed by implementation experts as an effective implementation strategy
48013707|NCT05050643|OTHER|EBQI-LC|A Learning Collaborative is a systematic approach to process improvement based on the Institute for Healthcare Improvement Breakthrough Series Collaborative model. During the Collaborative, organizations will test and implement system changes and measure their impact. They will share their experiences to accelerate learning and broader implementation of best practices.
48013708|NCT00088296|PROCEDURE|Blood Draw|
48013709|NCT01123538|DRUG|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
48013710|NCT01123538|DRUG|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
48013711|NCT02867605|DIETARY_SUPPLEMENT|Hyaluronan|
48013712|NCT02321865|DRUG|NPC-02|
48013713|NCT04917302|DRUG|NMDAE plus AIFA|Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
48701483|NCT03863470|BEHAVIORAL|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
48701484|NCT03326414|PROCEDURE|Constant PEEP - low tidal volume|The respirator is set according to study protocol
48701485|NCT03326414|PROCEDURE|Constant PEEP - high tidal volume|The respirator is set according to study protocol
48013714|NCT04917302|DRUG|NMDAE plus Placebo Cap|Use of an NMDA enhancer plus placebo as a comparator
48013715|NCT05496725|DRUG|Micafungin|Pharmacokinetic study under fasting conditions
48013716|NCT06664112|DEVICE|AIDA Analysis|The women will be followed until and after the birth, under intrapartum ultrasound monitoring, with all clinical, ultrasonographic and obstetric parameters, analyzed by AIDA method.
48013717|NCT00065884|DRUG|Valproate|
48013718|NCT06654726|DRUG|aldafermin|aldafermin
48013719|NCT06654726|DRUG|Placebo|placebo
48013720|NCT05545670|DRUG|Placebo|not containing drugs
48013721|NCT05545670|DRUG|Allopurinol 300 MG|a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
48013722|NCT03464344|OTHER|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
48013723|NCT04463381|PROCEDURE|choledochotomy techniques during LCBDE|
48013724|NCT04147338|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
48013725|NCT06610526|DRUG|Dapagliflozin|Dapagliflozin by oral administration
48701486|NCT03326414|PROCEDURE|constant tidal volume - low PEEP|The respirator is set according to study protocol
48701487|NCT03326414|PROCEDURE|constant tidal volume - high PEEP|The respirator is set according to study protocol
48013726|NCT05951244|DEVICE|Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)|Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.
48013727|NCT01795508|BEHAVIORAL|PMTO|Parent Management Training, Oregon
48013728|NCT01795508|BEHAVIORAL|TAU|Other kinds of family training
48371557|NCT02643420|DRUG|SPI-2012|Single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
48371558|NCT02643420|DRUG|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle
48371559|NCT02643420|DRUG|Docetaxel|Standard therapy
48371560|NCT02643420|DRUG|Cyclophosphamide|Standard therapy
48013729|NCT05478174|DRUG|HSK3486|HSK3486 for induction of general anesthesia
48013730|NCT05478174|DRUG|Propofol|Propofol for induction of general anesthesia.
48013731|NCT05757375|OTHER|Mulligan Manuel Therapy Consept|Mulligan ankle taping is a noninvasive, painless, low-cost, and easily applicable technique of the Mulligan manual therapy concept. It is frequently used in cases of ankle instability. In healthy people, it is a method to prevent ankle sprains.
48013732|NCT03273036|DRUG|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
48013733|NCT03273036|DRUG|Placebos|no injected agent
48013734|NCT02082717|DRUG|potassium chloride replacement|
48013735|NCT02082717|DRUG|Experimental - 4% Sodium Bicarbonate|
48013736|NCT02356835|DEVICE|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
48013737|NCT02356835|DEVICE|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
48013738|NCT01149798|DRUG|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
48170363|NCT06342245|RADIATION|Radiofrequency coblation micro-tenotomy|Radiofrequency micro-tenotomy with low-temperature controlled ablation will be performed with the TOPAZ (Smith and Nephew) wand, which has a 1mm tip, and full thickness 1mm RF tendon debridement at 5mm intervals will be performed.
48371561|NCT02076646|DRUG|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
48371562|NCT02076646|DRUG|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
48701488|NCT06277414|OTHER|collection of laboratory test results, imaging results and symptoms|collection of laboratory test results, imaging results and symptoms
48013739|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
48013740|NCT06653946|DRUG|Alteplase|Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
48013741|NCT01532466|DRUG|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
48013742|NCT00428610|DRUG|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
48013743|NCT05855863|DRUG|Ginkgo Ketone Ester Tablets|Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
48013744|NCT05855863|DRUG|placebo|placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months
48013745|NCT03544983|BEHAVIORAL|Web + Streamlined Telephone Genetic Information|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
48013746|NCT06348511|DEVICE|XTics|XTics is a gamified protocol of behavioral treatment for tic disorders. The participant's tics are monitored in real-time and they are reflected as achievements in a game that the participant plays at the same time. The rewards aim to counteract processes that consolidate the tic. XTics is compatible with ERP treatment, and it includes an introductory psychoeducation session and three behavioral training sessions.
48013747|NCT06341127|DRUG|Fluoxetine|Oral fluoxetine daily, 2.5 to 5 mg.
48013748|NCT00079274|DRUG|irinotecan hydrochloride|Given IV
48013749|NCT00079274|DRUG|oxaliplatin|Given IV
48701489|NCT00737854|PROCEDURE|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
48701490|NCT00123279|DRUG|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
48013750|NCT00079274|DRUG|leucovorin calcium|Given IV
48013751|NCT00079274|DRUG|fluorouracil|Given IV
48013752|NCT00079274|BIOLOGICAL|cetuximab|Given IV
48701491|NCT00820794|DRUG|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
48701492|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
48701493|NCT00820794|DRUG|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
48701494|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
48701495|NCT03645421|DRUG|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
48701496|NCT03645421|DRUG|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
48701497|NCT03645421|DRUG|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
48701498|NCT03645421|DRUG|PlaceboA|1.0 mL liquid formulation per Vial
48701499|NCT03645421|DRUG|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
48701500|NCT03645421|DRUG|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
48701501|NCT03736993|OTHER|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
48013753|NCT00079274|DRUG|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
48013754|NCT05353192|DRUG|Recombinant human growth hormone|Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
48013755|NCT05181007|DRUG|Mefanamic Acid|mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
48013756|NCT05181007|DRUG|Valproate|valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
48013757|NCT02064738|BEHAVIORAL|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
48701502|NCT02794844|DRUG|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
48701503|NCT06130774|OTHER|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes
48013758|NCT00073671|BEHAVIORAL|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
48013759|NCT00073671|OTHER|Usual care|Participants receive usual care
48013760|NCT00304785|DRUG|latanoprost 0.005%|
48013761|NCT00304785|DRUG|Fotil|
48013762|NCT00304785|DRUG|placebo|
48516098|NCT03405922|DRUG|Placebo 40 mL Saline 0.9%|Injection of 40 mL 0.9% saline
48013763|NCT06538623|DRUG|Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin|Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
48013764|NCT06538623|DRUG|Tegodor|Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
48013765|NCT06538688|PROCEDURE|Orthodontic extrusion of the impacted mandibular third molar by using the maxillary miniscrew and cross arch elastic power chain as a temporary anchorage device before extraction|Orthodontic extrusion of the impacted mandibular third molar of high-risk for nerve injury using maxillary TAD.
48013766|NCT04230382|DIAGNOSTIC_TEST|Diagnosis of diabetes (OGTT)|Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
48013767|NCT04631497|DIAGNOSTIC_TEST|test|"1. Beck's Test~2. Test STAI~3. Test PSS~4. the scale of the fascination with death~5. COPE"
48013768|NCT01776983|DEVICE|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
48013769|NCT00354224|DRUG|capecitabine|
48013770|NCT00354224|DRUG|oxaliplatin|
48170364|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with local anesthetic|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered."
48516099|NCT03405922|DRUG|40 mL Ropivacain 0.5%|Ropivacaine Hcl 0.5% Injection 40 mL
48516100|NCT01439256|BEHAVIORAL|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
48371563|NCT02076646|DRUG|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
48516101|NCT01439256|OTHER|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
48516102|NCT03697031|DRUG|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH \<15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
48013771|NCT02513589|DRUG|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
48371564|NCT02268214|DRUG|Dapagliflozin|Tablets
48371565|NCT02268214|DRUG|Placebo for dapagliflozin|Tablets
48371566|NCT04893720|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive lumbar degeneration
48371567|NCT00895817|DRUG|Swallowed fluticasone|440 µg twice daily for 8 weeks
48013772|NCT05352022|BEHAVIORAL|Monthly Unconditional Financial Incentive|No requirements will be placed on how or where funds will be spent.
48013773|NCT05352022|BEHAVIORAL|Weekly Food Purchasing Financial Incentive|Incentive for healthy food purchases
48013774|NCT05352022|BEHAVIORAL|Glycemic Control Financial Incentive|Incentive for absolute drop in HbA1c
48013775|NCT05352022|BEHAVIORAL|Diabetes Education|mailed education information
48013776|NCT00236938|DRUG|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
48013777|NCT00236938|DRUG|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
48013778|NCT05954234|OTHER|Postural re-education|"Each session of the experimental approach will be composed of 40 minutes of postural exercise. Participants will be asked to maintain two different postures to stretch both the anterior and posterior muscle chains. The first posture will consist of lying on the back maintaining the extension of the legs to release the respiratory diaphragm and stretch the anterior muscle chain. For the second posture, participants wiil be asked to lie on their back with their legs flexed to stretch the posterior chai. For each posture, the physical therapist will use verbal commands and manual contact to maintain alignment and make the necessary postural corrections to optimize the stretching and discourage compensatory movements.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
48013779|NCT05954234|OTHER|Spinal mobilization|"This approach will consist of 40 minutes of thoracolumbar spine mobilization. Two different mobilizations will be carried out. In the first one the patient will be in sitting position with both legs out of the bed and a mobilization in antero-posterior direction will be provide by the physiotherapist; the second one will consist in rotational mobilisation provide with the patient in lateral decubitus position.~10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks."
48371568|NCT00895817|DRUG|Esomeprazole|40 mg once daily for 8 weeks
48701504|NCT06130774|OTHER|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
48170365|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with saline solution|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution"
48371569|NCT02478606|OTHER|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
48701505|NCT01343186|DRUG|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
48701506|NCT01343186|DRUG|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
48701507|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
48701508|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
48701509|NCT02727387|DRUG|TEMIRI|Window therapy frontline for VHR patients
48371570|NCT03580031|DRUG|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
48701510|NCT02727387|DRUG|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
48701511|NCT02727387|DRUG|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
48701512|NCT02727387|DRUG|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
48701513|NCT02727387|DRUG|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
48701514|NCT02727387|DRUG|BUMEL|Consolidation phase
48701515|NCT02727387|DRUG|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
48701516|NCT02141698|DRUG|TAK-438|TAK-438 tablets
48170366|NCT03167047|PROCEDURE|Caudal block|Caudal epidural
48371571|NCT03580031|DRUG|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
48371572|NCT01830621|DRUG|BBI608|
48170367|NCT03167047|PROCEDURE|Nerve Block|Peripheral nerve block
48371573|NCT01830621|DRUG|Placebo|
48371574|NCT01830621|OTHER|Best Supportive Care|
48371575|NCT04408326|DRUG|Angiotensin II|Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
48371576|NCT04408326|DRUG|Interleukin-1 receptor antagonist|Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
48701517|NCT02141698|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
48701518|NCT02141698|DRUG|Esomeprazole|Esomeprazole tablets
48701519|NCT02584530|PROCEDURE|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
48701520|NCT06437288|PROCEDURE|photodynamic therapy|Receive an intravenous infusion of hematoporphyrin injection
48701521|NCT06145633|PROCEDURE|Biopsy|Undergo biopsy
48701522|NCT06145633|PROCEDURE|Biospecimen Collection|Undergo blood sample colleciton
48701523|NCT06145633|PROCEDURE|Bone Scan|Undergo bone scan
48516103|NCT04957238|OTHER|ARBORea decision-making tool|Online ARBORea decision-making tool will guide the use of physical restraints in ICU patients based on objective information on neurological status, level of equipment related to critical illness, and patient's family presence and involvement in patient's surveillance.
48516104|NCT05178069|DRUG|: Placebo for Probiotic|Capsule manufactured without active ingredients.
48516105|NCT05178069|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus G
48701524|NCT06145633|PROCEDURE|Computed Tomography|Undergo CT, SPECT/CT, PET/CT
48701525|NCT06145633|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
48701526|NCT06145633|OTHER|Gallium Ga 68 Gozetotide|Given IV
48701527|NCT06145633|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given 177Lu-PSMA-617
48701528|NCT06145633|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET
48701529|NCT06145633|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
48701530|NCT06145633|DRUG|Vorinostat|Given IV
48701531|NCT04345861|DRUG|Hydroxychloroquine + placebo|hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
48701532|NCT04345861|DRUG|hydroxychloroquine + azithromycin|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
48701533|NCT05440591|DRUG|Dapagliflozin|Dapagliflozin 10mg tablets
48701534|NCT05440591|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
48701535|NCT05440591|DRUG|Dapagliflozin / metFORMIN Pill|Combination pill
48701536|NCT01818739|PROCEDURE|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
48170368|NCT03167047|DRUG|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
48170369|NCT03587519|PROCEDURE|Early|Early ileostomy closure
48013780|NCT05954234|OTHER|Perineal Exercises|Perineal Exercises will be performed in both the allocated approach. The protocol will consist in 10 minutes of perineal contraction and relaxation and 10 minutes of stretch-reflex for a total of 20 minutes of perineal exercises.10 sessions of the allocated intervention will be performed and organized in 2 times a week for 5 weeks.
48170370|NCT03587519|PROCEDURE|Late|Late ileostomy closure
48170371|NCT06102226|DIAGNOSTIC_TEST|coronary artery imaging (coronary CTA or coronary angiography)|In order to obtain the gold standard labeling for coronary heart disease, this topic will form a panel of experts on labeling, and the diagnosis will be based on coronary angiography, defined as a lesion with a stenosis of at least 50% in at least one coronary artery
48170372|NCT04970693|DRUG|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
48170373|NCT04209998|DIAGNOSTIC_TEST|transcutaneous oximetry|Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation
48170374|NCT00799136|DRUG|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
48371577|NCT03971968|PROCEDURE|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
48371578|NCT04178330|RADIATION|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.
48516106|NCT01509274|BIOLOGICAL|Plasma|3 ml plasma injected once into the plantar fascia
48701537|NCT01818739|DRUG|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
48170375|NCT04882748|OTHER|ADAMO|Physical therapy provided with or without the help of a robot
48170376|NCT05974683|DRUG|placebo|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
48701538|NCT01818739|DRUG|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
48701539|NCT01818739|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
48701540|NCT03619707|DRUG|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
48701541|NCT01431014|DRUG|"Dexamethasonelow-dose"|5mg
48701542|NCT01431014|DRUG|"Dexamethasonehigh-dose"|15 mg
48013781|NCT05919394|DRUG|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
48170377|NCT05974683|DRUG|mycophenolate mofetil|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
48170378|NCT02748902|DRUG|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
48170379|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
48170380|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
48170381|NCT00087555|DRUG|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
48170382|NCT03146754|OTHER|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
48701543|NCT01792713|DRUG|Sertaconazole 2% cream|
48701544|NCT01792713|DRUG|Placebo|
48701545|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
48701546|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|"Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
48701547|NCT01920568|BIOLOGICAL|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
48701548|NCT01920568|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
48701549|NCT01920568|DRUG|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
48701550|NCT01920568|DRUG|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
48170383|NCT04582513|OTHER|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
48170384|NCT03758456|BIOLOGICAL|HAL-MRE1|HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
48701551|NCT01920568|DIETARY_SUPPLEMENT|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
48701552|NCT01920568|DIETARY_SUPPLEMENT|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
48701553|NCT02513290|DRUG|Bilastine|
48701554|NCT02513290|DRUG|Loratadine|
48701555|NCT04710550|DRUG|F18-3F4AP|PET Scan
48701556|NCT01969396|DEVICE|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
48701557|NCT01969396|DEVICE|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
48701558|NCT05704621|PROCEDURE|secondary cytoreductive surgery|Maximum effort cytoreductive surgery
48170385|NCT05717517|DEVICE|anterior segment oct|ant segment oct before and after corneal collagen cross-linking
48170386|NCT01101997|DEVICE|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
48170387|NCT01741311|BEHAVIORAL|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
48170388|NCT01741311|BEHAVIORAL|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
48170389|NCT01935596|DRUG|ropivacaïne|spinal anesthesia.
48170390|NCT01935596|DRUG|lévobupivacaïne|
48170391|NCT04745377|DIAGNOSTIC_TEST|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
48371579|NCT04466657|DIETARY_SUPPLEMENT|Antioxidation Therapy|Two proprietary formulations composed of reduced glutathione, N-acetylcysteine, superoxide dismutase, and bovine lactoferrin and immunoglobulins.
48371580|NCT04466657|OTHER|Standard of Care|SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
48701559|NCT05704621|DRUG|chemotherapy|six cycles of bevacizumab \[10 mg/kg, days 1 and 15\] plus carboplatin \[AUC 5, day 1\] plus pegylated liposomal doxorubicin \[30 mg/m2, day 1\] every 4 weeks, followed by maintenance bevacizumab \[15 mg/kg every 3 weeks\]
48701560|NCT00712725|DRUG|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
48701561|NCT00712725|DRUG|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
48701562|NCT00712725|DRUG|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
48701563|NCT00712725|DRUG|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
48701564|NCT00712725|DRUG|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
48701565|NCT00712725|DRUG|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
48701566|NCT00712725|DRUG|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
48701567|NCT03916185|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L Vaccine|10\^6 plaque-forming units (PFU); administered as nose drops
48701568|NCT03916185|BIOLOGICAL|RSV 6120/ΔNS2/1030s Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
48701569|NCT03916185|BIOLOGICAL|RSV 276 Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
48170392|NCT05218746|PROCEDURE|Serratus anterior plane block|High-frequency linear transducer will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, Then, using ultrasound guidance, the needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib . one millileter normal saline will be injected to confirm placement and to hydro-dissect the fascial layers and open the potential space.
48013782|NCT03292822|DIETARY_SUPPLEMENT|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
48013783|NCT03292822|DRUG|Paclitaxel|chemotherapeutic drug
48013784|NCT04554433|DRUG|Ethanol with Asprin|"Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results ."
48013785|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fast Fix|Arthroscopic reconstruction of damaged Medial Meniscus using Fast-Fix (Smith \& Nephew) implant.
48371581|NCT00267917|DEVICE|Berodual Respimat|
48371582|NCT00267917|DEVICE|Berodual HFA-MDI|
48516107|NCT01509274|BIOLOGICAL|Saline|3 ml of saline injected once into the plantar fascia
48013786|NCT05318118|PROCEDURE|Medial Meniscus Arthroscopic Reconstruction Using the Fiber Stitch|Arthroscopic reconstruction of damaged Medial Meniscus using Fiber-Stitch (Arthrex) implant
48516108|NCT01509274|OTHER|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
48516109|NCT02042456|DEVICE|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
48516110|NCT02042456|DEVICE|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
48013787|NCT03946761|DEVICE|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
48013788|NCT04400305|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
48516111|NCT02042456|DEVICE|Full Field Digital Mammography|
48516112|NCT05397678|BIOLOGICAL|BCG-Denmark|AJ vaccines, Copenhagen 1331 strain
48516113|NCT05397678|BIOLOGICAL|BCG-Bulgaria|BB-NCIPD Ltd., BCG-SL 222 Sofia strain
48516114|NCT06432855|OTHER|Blood collection|20 ml-blood sample
48516115|NCT06432855|OTHER|saliva collection|saliva sample
48516116|NCT02997748|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
48516117|NCT03458611|BEHAVIORAL|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent \& Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
48516118|NCT03458611|BEHAVIORAL|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
48013789|NCT04901455|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
48013790|NCT00968110|DRUG|omalizumab|Dosing table established for omalizumab
48371583|NCT04487275|DRUG|MLC901 or Placebo|groups randomly assigned to receive either MLC901 or placebo capsules three times per day over 6 months
48516119|NCT00587860|DRUG|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
48516120|NCT00587860|DRUG|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
48516121|NCT02843984|DRUG|Lactoferrin|
48516122|NCT03142191|DRUG|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
48516123|NCT03142191|OTHER|Placebo|Placebo
48516124|NCT04350411|DEVICE|Conventional diathermy|Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
48516125|NCT04350411|DEVICE|PEAK PlasmaBlade™|Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
48516126|NCT04428814|BIOLOGICAL|CT-P43|45mg single dose
48701570|NCT03916185|BIOLOGICAL|Placebo|Administered as nose drops
48701571|NCT06604910|DIETARY_SUPPLEMENT|branched chained amino acid|patients undergoing branched chained amino acid
48701572|NCT00230061|BIOLOGICAL|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
48013791|NCT01270945|DRUG|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
48013792|NCT01270945|PROCEDURE|Standard of Care|
48013793|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
48013794|NCT01312766|DRUG|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
48170393|NCT05218746|PROCEDURE|Erector spinae block|A high-frequency linear ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes is identified, spinal needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle.
48170394|NCT04035330|COMBINATION_PRODUCT|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
48170395|NCT04035330|COMBINATION_PRODUCT|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
48170396|NCT01064505|DRUG|QPI-1007 at various doses|Single Intravitreal Injection
48170397|NCT00000370|BEHAVIORAL|Cognitive behavior therapy|
48170398|NCT00000370|BEHAVIORAL|Performance-based exposure therapy|
48170399|NCT00000370|BEHAVIORAL|Psychosocial intervention|
48170400|NCT05305677|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
48516127|NCT04428814|BIOLOGICAL|EU-approved Stelara|45mg single dose
48516128|NCT04428814|BIOLOGICAL|US-licensed Stelara|45mg single dose
48516129|NCT00897910|OTHER|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
48516130|NCT00897910|OTHER|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
48013795|NCT05003986|DRUG|Sparsentan|Population 1: 800 mg Sparsentan (oral suspension)
48013796|NCT05003986|DRUG|Sparsentan|Population 2: 400 mg Sparsentan (oral suspension)
48013797|NCT05003986|DRUG|Sparsentan|Population 3: 400 mg Sparsentan (tablets)
48013798|NCT04698824|PROCEDURE|Hypnosis session|"At least one session of hypnosis in the internal medicine unit at the hospital Groupe Hospitalier Mutualiste de Grenoble"
48516131|NCT00897910|OTHER|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
48013799|NCT01073488|BEHAVIORAL|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
48013800|NCT05247190|BEHAVIORAL|Treating self-criticism|A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
48013801|NCT05793385|OTHER|operative intervention|all patients were operated after being admitted to surgical ward for acute abdomen
48013802|NCT02331446|BEHAVIORAL|Physical exercise intervention|
48013803|NCT04055194|DRUG|Tranexamic acid tablets|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
48013804|NCT04055194|DRUG|Placebo oral tablet|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
48170401|NCT05305677|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
48170402|NCT00269841|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
48170403|NCT00269841|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
48170404|NCT00269841|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
48170405|NCT04532762|DEVICE|nasal spray|Application of a nasal spray
48170406|NCT01182181|DRUG|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
48170407|NCT01182181|DRUG|Anastrozole (Arimidex®)|1 mg Tablets
48170408|NCT03440983|DEVICE|MRI data acquiring in healthy volunteers|The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
48170409|NCT05659654|DRUG|Ursodeoxycholic acid|250 mg/capsule, 2 capsules per day, for 4 weeks
48170410|NCT01765452|DRUG|Closone|75mg/100mg, 8weeks, PO
48170411|NCT01765452|DRUG|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
48516132|NCT02708771|DRUG|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
48516133|NCT02708771|DRUG|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
48516134|NCT01160328|DRUG|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
48516135|NCT01160328|DRUG|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
48516136|NCT04743687|DRUG|Zanubrutinib|Oral Zanuburutinib, 160mg twice a day
48516137|NCT00315289|PROCEDURE|Nasolacrimal balloon catheter duct dilation|
48516138|NCT00315289|PROCEDURE|Nasolacrimal intubation|
48516139|NCT00315289|PROCEDURE|Simple Nasolacrimal duct probing|
48701573|NCT01057576|DIETARY_SUPPLEMENT|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
48013805|NCT05732285|BEHAVIORAL|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
48013806|NCT05732285|BEHAVIORAL|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
48516140|NCT02381184|DRUG|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
48013807|NCT05732285|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
48013808|NCT05732285|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
48013809|NCT00453765|DRUG|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
48170412|NCT00711997|BIOLOGICAL|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
48170413|NCT04176783|DRUG|Opioids|narcotic pain medicine
48516141|NCT02381184|PROCEDURE|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
48516142|NCT00437697|DRUG|dalteparin|
48516143|NCT01587287|DEVICE|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
48701574|NCT01057576|OTHER|Placebo|capsule, daily dosage
48013810|NCT00453765|DRUG|placebo|placebo
48013811|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
48013812|NCT04103294|DIETARY_SUPPLEMENT|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
48013813|NCT06148272|DRUG|LY3971297|Administered SC
48013814|NCT06148272|DRUG|Placebo|Administered SC
48013815|NCT06148272|DRUG|LY3971297 IV|Administered IV
48013816|NCT06548451|DEVICE|Augmented reality guided localization|In this study, AR was utilized to assist in the localization of pulmonary nodule during sublobectomy lung resection in patient to assess the accuracy of the technique.
48701575|NCT03023774|DRUG|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
48701576|NCT06163183|DEVICE|Edi catheter|
48701577|NCT00151710|DRUG|Pioglitazone|
48701578|NCT05980273|BEHAVIORAL|Educational sessions|session for oral health education
48701579|NCT04924894|OTHER|no intervention|no intervention
48013817|NCT00796861|DRUG|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
48013818|NCT05964452|DRUG|Methimazole Tablets|Testing dosing algorithm for efficacy.
48013819|NCT06165744|DEVICE|UNITY VCS|Investigational device used during anterior and posterior segment ophthalmic surgery.
48013820|NCT06165744|PROCEDURE|Eye surgery|Eye surgery performed with UNITY VCS
48170414|NCT04176783|DRUG|Opioid-Free|non narcotoc pain medication
48170415|NCT02154347|DRUG|KAD-1229|
48170416|NCT02154347|DRUG|Placebo|
48170417|NCT02154347|DRUG|Insulin|
48701580|NCT04809818|DRUG|LT3001 drug product|Multiple doses of LT3001 drug product administered by intravenous infusion
48701581|NCT04809818|DRUG|Placebo|Multiple doses of Placebo administered by intravenous infusion
48701582|NCT04809818|DRUG|Aspirin|Loading and maintenance doses of Aspirin administered by oral
48701583|NCT04809818|DRUG|Clopidogrel|Loading and maintenance doses of Clopidogrel administered by oral
48701584|NCT04809818|DRUG|Apixaban|Multiple doses of Apixaban administered by oral
48701585|NCT04809818|DRUG|Dabigatran|Multiple doses of Dabigatran administered by oral
48701586|NCT05332587|DRUG|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
48701587|NCT03396367|BEHAVIORAL|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
48170418|NCT02315053|OTHER|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
48170419|NCT02690493|PROCEDURE|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
48701588|NCT03396367|BEHAVIORAL|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
48701589|NCT04899999|BEHAVIORAL|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
48701590|NCT04899999|BEHAVIORAL|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
48701591|NCT04899999|BEHAVIORAL|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
48701592|NCT04899999|BEHAVIORAL|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
48701593|NCT06425939|OTHER|Force plate assessment|On Day 1, Day 45 and Day 90: 3x drop jumps, 2 min rest, 3x counter movement jumps, 2 min rest, 3x dynamic push-ups
48701594|NCT06425939|DEVICE|Whoop wrist band|Whoop wrist worn activity tracker (not a medical device) collects continuous data via smartphone app. This is a marketed device. This is not a device study.
48701595|NCT01642498|DEVICE|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
48701596|NCT04222634|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
48013821|NCT04453852|BIOLOGICAL|COVID19 vaccine|COVID19 recombinant spike protein with Advax-SM adjuvant
48013822|NCT04453852|BIOLOGICAL|Saline|Saline control
48013823|NCT02791633|OTHER|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
48013824|NCT06662578|OTHER|Traditional memory workshop|The participants received 8 weekly sessions of 60 minutes of neurocognitive stimulation, based on French memory workshops.
48013825|NCT06662578|OTHER|Equine assisted therapy memory workshops|The participants received 8 weekly sessions of 60 minutes, based on traditional memory workshops (French type of neurocognitive stimulation) with the mediation of a horse (example : working on associative memory by selecting which object is used for the horse between 2 presented objects).
48013826|NCT03351049|DEVICE|LAL|Reactive support surface with a low air loss feature
48013827|NCT03351049|DEVICE|Non-LAL|Reactive support surface without a low air loss feature
48013828|NCT03837496|OTHER|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
48013829|NCT03837496|OTHER|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
48013830|NCT05105269|OTHER|Treatment from a physiotherapist|Any treatment provided by a physiotherapist e.g. exercise, advice and massage
48013831|NCT06360588|PROCEDURE|Biopsy|Undergo tumor biopsy
48013832|NCT06360588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48013833|NCT06360588|DRUG|Copanlisib|Given IV
48013834|NCT06360588|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
48013835|NCT05676034|DRUG|AMX0035|AMX0035
48013836|NCT00256659|BEHAVIORAL|Early assessment and referral to ancillary care services vs. standard care|
48170420|NCT02690493|OTHER|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
48170421|NCT02690493|OTHER|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
48013837|NCT02826889|DEVICE|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
48013838|NCT02826889|DEVICE|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
48170422|NCT02072421|PROCEDURE|PCI|
48170423|NCT04207697|BIOLOGICAL|Beltavac® Polymerized with cat dander|Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice
48522958|NCT00370552|DRUG|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m\^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
48701597|NCT04379245|OTHER|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~* Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~* Data crossing (Excel / Access) and statistical analysis~* Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
48371584|NCT01119118|DRUG|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
48013839|NCT05458479|DRUG|Fluoxetine|All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
48013840|NCT04086472|BIOLOGICAL|Clesrovimab|Single dose of clesrovimab administered via IV infusion.
48013841|NCT04086472|OTHER|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
48701598|NCT06562660|DEVICE|apnoeic|In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
48013842|NCT04086472|BIOLOGICAL|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
48013843|NCT03726112|DEVICE|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
48701599|NCT03729258|DRUG|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
48013844|NCT03726112|DEVICE|Sham Specs|Sham device
48701600|NCT03729258|DRUG|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
48701601|NCT03481166|OTHER|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
48701602|NCT00521690|DRUG|insulin detemir|
48701603|NCT03603587|PROCEDURE|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
48701604|NCT03603587|DIAGNOSTIC_TEST|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
48701605|NCT03603587|DIAGNOSTIC_TEST|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
48701606|NCT03603587|DIAGNOSTIC_TEST|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
48013845|NCT06662747|DIAGNOSTIC_TEST|None - observational study only|No interventions, diagnostics tests for HIV, pregnancy, STIs and BV only
48013846|NCT04296175|DRUG|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
48013847|NCT04296175|DRUG|CTX|600mg, d1 every 2 or 3 weeks
48170424|NCT06276205|DRUG|Vitamin D|"if Vitamin D level suboptimal, 50,000 IU/week for 8 weeks followed by 2000 IU/d~if optimal Vitamin D level, 2000 IU/d"
48371585|NCT03560765|DEVICE|MED|Training in the use of mainstream electronic devices with accessibility options
48371586|NCT03560765|OTHER|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
48371587|NCT02430064|OTHER|Low PAMP diet|
48371588|NCT06111599|PROCEDURE|lumbar sympathetic blockade|Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic
48013848|NCT04296175|DRUG|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
48013849|NCT04296175|DRUG|ddEpirubicin|90mg/m2, d1 every 2 weeks
48013850|NCT04296175|DRUG|ddCTX|600mg, d1 every 2 weeks
48013851|NCT04296175|DRUG|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
48013852|NCT04296175|DRUG|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
48170425|NCT06276205|DRUG|Levothyroxin|commenced at a dose of 1.6mcg/kg/day and will be titrated 8 weekly according to response
48170426|NCT00212277|DRUG|Norethindrone,Ethinyl Estradiol|
48170427|NCT05184621|OTHER|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
48013853|NCT05962905|OTHER|Blood sample|During the standard of care interventional or diagnostic cardiac catheterization, paired arterial and venous blood samples will be obtained. The venous sample will be obtained from 2 cm superior to the clavicle, which is beyond standard of care during the routine cardiac catheterization
48013854|NCT05962905|DEVICE|INVOS monitoring|During the standard of care interventional or diagnostic cardiac catheterization, INVOS monitoring will be used. INVOS™ regional oxygen saturation (rSO2) values will be compared to the calculated global field saturation of cerebral tissue determined from blood sample co-oximetry.
48013855|NCT02121340|BEHAVIORAL|Behavioral Activation|
48701607|NCT03603587|DIAGNOSTIC_TEST|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
48701608|NCT03603587|DIAGNOSTIC_TEST|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
48701609|NCT03603587|DIAGNOSTIC_TEST|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
48701610|NCT03603587|DIAGNOSTIC_TEST|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
48701611|NCT03815695|DRUG|FT-4202/Placebo|Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
48701612|NCT03474900|DEVICE|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
48701613|NCT03474900|DEVICE|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
48701614|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
48701615|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
48701616|NCT02687555|BEHAVIORAL|Cognitive Bias Modification of Appraisals (CBM-App)|
48701617|NCT02687555|BEHAVIORAL|Peripheral Vision Task (control condition)|
48701618|NCT02471560|DRUG|dimethyl fumarate|As per the prevailing local label.
48701619|NCT02471560|DRUG|injectable MS DMT|As described above.
48701620|NCT01229254|DRUG|Amiodarone|Patients on Amiodarone
48013856|NCT04524962|BIOLOGICAL|Descartes 30|Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
48013857|NCT02103478|DRUG|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
48013858|NCT02103478|DRUG|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
48013859|NCT02103478|DRUG|ASTX727 Fixed-Dose Combination|Fixed-dose investigational product
48013860|NCT03085927|BEHAVIORAL|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
48013861|NCT03085927|BEHAVIORAL|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
48013862|NCT06664749|OTHER|Three stair position pillow group|Preterm infants were monitored with three stair position pillows.
48013863|NCT06664749|OTHER|Positioning material group|Preterm infants were monitored with positioning material pillows.
48013864|NCT00192452|DRUG|MEDI-507|
48013865|NCT03842787|OTHER|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
48701621|NCT01229254|DRUG|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
48701622|NCT01229254|DRUG|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
48701623|NCT01229254|DRUG|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
48701624|NCT01490736|DRUG|Lemuteporfin|lemuteporfin topical solution, 1%
48013866|NCT06085898|DRUG|Stryphnodendron Adstringens 3% - once daily post bath|Intimate Soap
48170428|NCT03561025|DIAGNOSTIC_TEST|18F-FDG-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-FDG
48701625|NCT01858545|DEVICE|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
48701626|NCT01858545|DEVICE|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
48701627|NCT02087618|OTHER|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
48701628|NCT02087618|OTHER|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
48701629|NCT01217879|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
48701630|NCT03201926|DIETARY_SUPPLEMENT|mealworms|10g , 3 times a day , po, 2 months
48701631|NCT03201926|DIETARY_SUPPLEMENT|grain powder|grain powder, 10g ,3times one day,2months
48701632|NCT04352088|PROCEDURE|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
48701633|NCT00778258|BIOLOGICAL|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
48013867|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to sit on a chair with their back facing the examiner, placing their arms in a relaxed position with their head supported on a surface in front of them. The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
48371589|NCT00999453|OTHER|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
48013868|NCT06664359|OTHER|Ultrasound guided injection with local anaestethic|"Volunteers will first be asked to lay prone position.The ultrasound operator will be positioned behind the volunteer. Initially, in the sitting position, volunteers will be asked to maintain normal breathing. Once an optimal ultrasound image is obtained, the image will be frozen, and measurements will be taken from the same image in sequence. The measurements to be performed are as follows: skin-fat tissue distance, skin-trapezius muscle distance, skin-rhomboid muscle distance, skin-rib distance, skin-pleura distance, and rhomboid muscle-pleura distance. These measurements, in millimeters, will be recorded in the data collection form. The same measurements will also be taken during deep inhalation and deep exhalation in the sitting position."
48371590|NCT05469451|PROCEDURE|Low level laser therapy|Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
48701634|NCT00778258|BIOLOGICAL|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
48701635|NCT03354312|DRUG|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
48170429|NCT03561025|DIAGNOSTIC_TEST|18F-GE180-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-GE180
48371591|NCT00501072|DEVICE|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
48371592|NCT04558658|DIAGNOSTIC_TEST|Complete Blood Count|neutrophil to lymphocyte ratio
48170430|NCT02276209|DRUG|Dasotraline|Dasotraline 4 mg once daily
48170431|NCT02276209|DRUG|Dasotraline|Dasotraline 6 mg once daily
48371593|NCT01573988|OTHER|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~* breakfast in one intake at 8:00~* breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
48371594|NCT02058940|DRUG|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
48701636|NCT03354312|DRUG|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
48701637|NCT05763381|DEVICE|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
48701638|NCT05763381|DEVICE|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
48701639|NCT03019328|OTHER|Peanut in diet|
48701640|NCT04154449|DRUG|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
48701641|NCT00090233|BIOLOGICAL|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
48170432|NCT02276209|OTHER|Placebo|Placebo once daily
48170433|NCT04735198|PROCEDURE|Primary tumor surgery|Large bowel resection.
48170434|NCT04735198|PROCEDURE|Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy|Large bowel resection combined and cholecystectomy.
48170435|NCT06276517|OTHER|questionnaire|self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
48170436|NCT06276517|OTHER|SS-QoL|49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
48170437|NCT06276517|OTHER|SF-36|multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
48170438|NCT06276517|OTHER|CIQ-R|16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
48170439|NCT06276517|DIAGNOSTIC_TEST|BREFF|rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
48170440|NCT06276517|DIAGNOSTIC_TEST|MoCA|MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
48013869|NCT05528094|DIETARY_SUPPLEMENT|GeniusDrops|"The active ingredients listed below are safe and the study sponsor has noted there are no known side effects of the supplement. The main ingredients are:~Hibiscus flower- Has been shown to boost oxygenation to the brain and vital organs. Has also demonstrated efficacy for boosting the immune system.~Gingko leaf- Has been shown to stimulate memory by increasing mental sharpness and clarity.~Rhodiola- Helps regulate energy and stress level. Gotu kola- Has been shown to have impacts on reducing anxiety. Licorice Root- Helps boost the key brain neurotransmitter called Brain Derived Neurotrophic factor which can help with cognitive development Peppermint Leaf- Reduces fatigue while helping improve cognitive abilities. Has also been shown to promote immune system function."
48013870|NCT05459870|BIOLOGICAL|4SCAR T cells|Infusion of 4SCAR T cells at 10\^6 cells/kg body weight via IV
48013871|NCT05740839|BEHAVIORAL|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
48013872|NCT05740839|BEHAVIORAL|Control Group|Usual Activities
48013873|NCT06569069|OTHER|US guided PE|"The multifidus muscle near the posterior dorsal root (at L4-L5 or L5-S1) was targeted using a transverse ultrasound view, inserting the needle at an 80º short axis or a 45º long axis, based on vessel presence. For the tibial nerve in the popliteal region, the needle was inserted at an 80º angle after a transverse cut of the nerve.~Physio invasiva® needles (0.30 x 40-60 mm) were used in the lumbar region, and 0.30 x 30 mm needles in the popliteal region. Both areas received galvanic current (1.5 mA for three seconds and three impacts). Treatment included three US-guided PE sessions over a 1:7:14 schedule, though two participants skipped the third due to pain resolution."
48013874|NCT06569069|OTHER|Sham Acupuncture|"Participants in the control group were also treated in a prone position. Sham acupuncture treatment was applied at the superficial level of the posterior face of the thigh on the affected side, using five Agupunt® needles of 0.16 x 25 mm, inserted superficially in the lateral aspect of the lumbar area (L3-L4), lateral gluteal region, greater trochanter, lateral part of the distal third of the thigh, head of the fibula and lateral aspect of the leg in its middle third. The needles were left superficially subcutaneously for 15 minutes, performing this approach in three different sessions, again following a periodicity of 1:7:14 days."
48013875|NCT05225181|BEHAVIORAL|perform physical exercise|one 60-min session of physical training
48013876|NCT05225181|BEHAVIORAL|cognitive training|one 60-min session of cognitive training
48013877|NCT05225181|BEHAVIORAL|control group|perform body stretching(15min) and health education courses(90min)
48013878|NCT00788866|DIETARY_SUPPLEMENT|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
48013879|NCT00788866|DIETARY_SUPPLEMENT|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
48013880|NCT06094959|OTHER|Suicide Prevention Package|The implementation package consists of co-designed and culturally adapted suicide prevention elements including suicide crisis response planning, contact follow up phone calls, and healthcare provider support mechanisms to optimize implementation.
48013881|NCT03976921|DIAGNOSTIC_TEST|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
48013882|NCT03976921|DIAGNOSTIC_TEST|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
48013883|NCT04134325|BIOLOGICAL|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
48013884|NCT04134325|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
48013885|NCT06118294|DIETARY_SUPPLEMENT|probiotics|\>30 billion CFU/capsule
48013886|NCT06118294|DIETARY_SUPPLEMENT|Placebo|Placebo
48013887|NCT05146128|OTHER|Strengthening exercises|The participants had to perform specific exercices 3 times a week during 8 weeks
48013888|NCT04805983|DRUG|BMS-984923|Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.
48013889|NCT06663228|DIAGNOSTIC_TEST|MMS|miniature mass spectrometry with AI assistance
48170441|NCT06276517|OTHER|IADL|8 questions rated from 0 to 1 to assess functional outcome
48170442|NCT06276517|OTHER|mMRS|mMRS score from 0 to 4 to assess functional outcome
48170443|NCT06276517|OTHER|PCL-5|To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
48170444|NCT06276517|OTHER|Brief-Cope|28-question self-questionnaires to study patients' coping strategies
48371595|NCT03290274|DEVICE|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
48701642|NCT00090233|BIOLOGICAL|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
48701643|NCT05557539|BIOLOGICAL|blood samples, urine samples and nasopharyngeal swabs|The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).
48170445|NCT03011905|DRUG|Dexamethasone|4 ml DexaGalen 4 mg/ml
48170446|NCT03011905|DRUG|NaCl (Control)|4 ml NaCl 9 mg/ml
48170447|NCT03011905|DRUG|Paracetamol|Premedication and as needed after operation
48170448|NCT03011905|DRUG|EtoriCoxib|Premedication and first 2 postoperative days.
48170449|NCT03011905|DRUG|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
48170450|NCT03011905|DRUG|Ropivacaine|In brachial plexus block
48371596|NCT03290274|DEVICE|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
48013890|NCT06456021|BEHAVIORAL|The Relational Playbook|The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
48013891|NCT06456021|BEHAVIORAL|Leadership Coaching|Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
48013892|NCT01922310|BEHAVIORAL|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
48013893|NCT05741918|DIAGNOSTIC_TEST|Fick's method|Cardiac output measurement by Fick method
48013894|NCT05741918|DIAGNOSTIC_TEST|Echocardiography|Cardiac output measurement by echocardiography
48013895|NCT01810978|DIETARY_SUPPLEMENT|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
48013896|NCT01810978|DIETARY_SUPPLEMENT|Maltodextrin|same amount of maltodextrin per day will be given as placebo
48013897|NCT01464528|DRUG|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
48013898|NCT00901329|DEVICE|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
48013899|NCT00901329|DEVICE|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
48013900|NCT02206113|BEHAVIORAL|Standing workstation|
48013901|NCT03920397|BIOLOGICAL|Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation|The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
48013902|NCT06236035|DEVICE|Analgesia nociception index|a device to assess patient's pain during surgery
48013903|NCT05889858|OTHER|Data collection|Data collection
48013904|NCT00909805|DEVICE|cutaneous suture (Surjet)|cutaneous surjet suture
48013905|NCT00909805|DEVICE|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
48013906|NCT01934153|DRUG|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
48013907|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Ozone Injection|All procedures were performed under light sedation in a sterile operating room. Ozone was created by an ozone generator (Dr. J. Hänsler Ozonosan, Iffezheim, Germany). Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid plus ozone injection received additionally 5ml of ozone at a concentration of 28 g/ml for each transforaminal epidural injection level.
48170451|NCT04204811|OTHER|Prehabilitation|A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
48170452|NCT02108652|DRUG|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
48170453|NCT05253079|OTHER|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
48516144|NCT05823857|OTHER|Aquatic Therapy|Participants in this experimental intervention group will perform trunk stabilization, which will be based on a variety of aquatic exercises in different positions, intended to activate the multifidus and transverse abdominis in a co-contraction. Additionally, hip exercises will be completed to promote the strengthening of the gluteus maximus, gluteus medius, and gluteus minimus muscles. The aim of these exercises is to enhance the strength and dynamic stability of the spine and its surrounding musculature in a functional and yet non-weight-bearing way. Each exercise will be performed 10 times while sustaining the muscles co-contraction for 5-10 seconds and will be progressed gradually. Each training session (60 minutes) will be supervised by a Certified Athletic Therapist and take place in the PERFORM AT Clinic/Swim Ex pool.
48701644|NCT02553980|BEHAVIORAL|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
48013908|NCT06503835|PROCEDURE|Fluoroscopy Guided Transforaminal Epidural Steroid Injection|All procedures were performed under light sedation in a sterile operating room.Appropriate diffusion of the non-ionic contrast agent into the periradicular and epidural area was verified through anteroposterior and lateral fluoroscopic images and the injections were then safely performed. Patients who underwent transforaminal epidural steroid injection received two mL of dexamethasone (8 mg) and 3 mL of saline for each transforaminal epidural injection level
48013909|NCT04917575|OTHER|Mobile Game|An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.
48013910|NCT04917575|OTHER|Mobile Application|A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
48170454|NCT05253079|OTHER|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
48516145|NCT05823857|OTHER|Standard Care|Participants in this experimental intervention group will receive the standard LBP treatment in the PERFORM Athletic Therapy clinic.Two Certified Athletic Therapists (AT) will be conducting the sessions. The ATs will complete a thorough assessment of the eligible participants with chronic LBP and administer a range of interventions including stretching, strengthening and stabilization exercise, aerobic conditioning, and manual mobilization techniques. Other modalities could include application of ice and heat, ultrasound, and transcutaneous electrical nerve stimulation (TENS).
48170455|NCT05546424|BEHAVIORAL|EMRESERVA|training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.
48170456|NCT05571306|OTHER|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
48170457|NCT01603342|DRUG|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
48371597|NCT05122364|BEHAVIORAL|Telerehabilitation and telecoaching|Language Sessions online and coaching parents online to improve language and social outcomes of their children
48371598|NCT05122364|BEHAVIORAL|Face to Face Language sessions|Language sessions Face to Face at sohag phoniatrics unit
48371599|NCT02282839|DIETARY_SUPPLEMENT|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
48516146|NCT00785148|DRUG|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
48516147|NCT01107197|DIETARY_SUPPLEMENT|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
48516148|NCT01107197|DIETARY_SUPPLEMENT|Control formula|Isonitrogenous isocaloric oral formula
48516149|NCT01595347|DRUG|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
48516150|NCT01595347|OTHER|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
48371600|NCT02282839|DIETARY_SUPPLEMENT|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
48516151|NCT05944926|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
48701645|NCT02553980|OTHER|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
48701646|NCT03294174|DRUG|Ropivacaine injection|Ropivacaine administered to provide nerve block
48516152|NCT05944926|DRUG|Antidepressant medication (fluoxetine)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
48013911|NCT05253482|PROCEDURE|wet cupping therapy|Vacuum cups will used on different acupuncture points to perform WCT: The one on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra was DU 14 (Dazhui) point; the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra interscapulum region were UB 42 (Pohu) bilateral points; and the ones on the back, 3.0 cm lateral to the lower border of the spinous process of the 7th thoracic vertebra were UB 46 (Geguan) bilateral points and additionally the patient's trigger points which we detect during the examination. There will be 5-7 points in total. The technique used will be triple S (Sucking, Scarification, Sucking) in all sessions.
48013912|NCT06444620|DRUG|DTG/3TC|This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
48013913|NCT03777189|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
48701647|NCT04333186|OTHER|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
48701648|NCT02976636|BEHAVIORAL|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
48701649|NCT02976636|BEHAVIORAL|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
48701650|NCT00615446|DRUG|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
48701651|NCT01606683|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
48701652|NCT01606683|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
48701653|NCT01606683|OTHER|No intervention|
48701654|NCT01895231|DRUG|Iron isomaltoside 1000 (Monofer®)|
48013914|NCT06114576|OTHER|Orange juice enriched with vitamin D3 and encapsulated probiotics|25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10\^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.
48516153|NCT00910676|DRUG|Diprosone|"* Start of treatment: as soon as the EGF-R inhibitors treatment begins~* Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~* Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~* Period of treatment: 8 weeks"
48516154|NCT02791451|DEVICE|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
48013915|NCT06114576|OTHER|Conventional orange juice|25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.
48013916|NCT02472665|DRUG|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
48013917|NCT04865679|DEVICE|Axoguard Nerve Cap®|Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
48013918|NCT06108934|DEVICE|Hip stem prosthesis|The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
48013919|NCT03917693|DIETARY_SUPPLEMENT|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
48013920|NCT03917693|OTHER|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
48170458|NCT01603342|DRUG|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
48701655|NCT01895231|DRUG|Placebo|
48170459|NCT03693040|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
48701656|NCT00797745|BIOLOGICAL|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
48701657|NCT00797745|DRUG|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
48701658|NCT00797745|DRUG|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
48701659|NCT00797745|DRUG|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
48701660|NCT06125145|BEHAVIORAL|Geriatric Assessment and Promotora Coaching|In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
48701661|NCT02916641|DRUG|Fuzhenghuayu|
48701662|NCT02916641|DRUG|UDCA|
48013921|NCT05667298|DRUG|Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B)|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
48013922|NCT05667298|DRUG|Adjuvant chemoradiotherapy|"Durvalumab treatment is to begin six weeks following patient ESD/EMR surgery.~Patients may delay dosing under the following certain circumstances:~1. Dosing may be delayed per Toxicity Management Guidelines (Appendix IV), due to either an immune or a non-immune-related AE.~2. Dosing intervals of subsequent cycles may be shortened as clinically feasible in order to gradually align treatment cycles with the schedule of tumor efficacy (RECIST) and PRO assessments. Subsequent time between 2 consecutive doses cannot be less than 22 days, based on the half-lives of durvalumab (see current Investigator Brochure for durvalumab).~3. Standard of Care Arm (CROSS):~4. Patients may delay and subsequently resume dosing per local standard clinical practice.~If dosing must be delayed for reasons other than treatment-related toxicity, dosing will occur as soon as feasible."
48013923|NCT04219163|BIOLOGICAL|CLL-1.CAR T cells|"Dose escalation study with 3 dose levels:~DL1: 1x10\^7 cells/m2, DL2: 3x10\^7 cells/m2, DL3: 1x10\^8 cells/m2~If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10\^6 cells/m2"
48170460|NCT03436043|DEVICE|Transmural Plastic stenting|After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
48701663|NCT06395675|DIAGNOSTIC_TEST|ID NOW™|"The ID NOW™ CT/NG is an in vitro qualitative molecular assay for the rapid differential.~detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in urine, and self-collected vaginal swabs (SVS) in symptomatic and asymptomatic individuals."
48170461|NCT06257641|OTHER|High-intensity Mediterranean diet intervention|Dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
48701664|NCT06267937|PROCEDURE|Access to surgery|access to surgery after hip fracture
48701665|NCT06267937|OTHER|type of intitution|public or private health care facility
48701666|NCT06571591|DRUG|CT-L03 Group 1|tablets, QD, oral administration
48701667|NCT06571591|DRUG|CT-L03 Group 2|tablets, QD, oral administration
48701668|NCT06571591|DRUG|Placebo|tablets, QD, oral administration
48701669|NCT06571591|DRUG|Empagliflozin|tablet, QD, oral administration
48701670|NCT06571591|DRUG|Metformin|tablets, oral administration
48701671|NCT04990063|DRUG|Chemotherapy|Standard chemotherapy drug
48170462|NCT01085812|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
48701672|NCT04990063|BIOLOGICAL|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
48701673|NCT03453762|PROCEDURE|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
48701674|NCT03453762|PROCEDURE|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
48170463|NCT01085812|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily.
48170464|NCT02306083|DRUG|Placebo three times a day|
48170465|NCT02306083|DRUG|glucosamine sulfate 1500 mg three times a day|
48170466|NCT03199300|DRUG|Anthracyclines|Chemotherapy regimen containing anthracyclines.
48170467|NCT03199300|DRUG|Trastuzumab|Systemic treatment including trastuzumab.
48701675|NCT04309305|DEVICE|EksoGT™, Ekso Bionics, Berkley, CA, USA|The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
48701676|NCT04309305|OTHER|Standard of Care|Standard gait therapy provided by licensed physical therapists post stroke.
48701677|NCT04309305|OTHER|No Intervention|Testing Only
48701678|NCT02520869|PROCEDURE|swim-up technique|swim-up technique used
48701679|NCT02520869|PROCEDURE|zeta test technique|zeta test technique used
48701680|NCT04234789|DIAGNOSTIC_TEST|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
48701681|NCT04234789|DIAGNOSTIC_TEST|spirometry|test performed as recommended by ATS guidelines
48701682|NCT04234789|DIAGNOSTIC_TEST|pletysmography|test performed as recommended by ATS guidelines
48701683|NCT04234789|DIAGNOSTIC_TEST|forced oscillometry technique|test performed as recommended by ATS guidelines
48701684|NCT05291988|OTHER|Educational Intervention|Receive S2S education
48701685|NCT05291988|OTHER|Fecal Immunochemical Test|Receive FIT kit
48701686|NCT05291988|OTHER|Questionnaire Administration|Ancillary Studies
48701687|NCT01242696|PROCEDURE|Coronary artery stenting|Coronary artery stenting with drug eluting stents
48701688|NCT06606717|DIETARY_SUPPLEMENT|Creatine Whey Protein|3 grams creatine + 30 grams whey protein
48701689|NCT06606717|DIETARY_SUPPLEMENT|Whey Protein|30 grams Whey Protein
48013924|NCT05508633|DRUG|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
48013925|NCT06224829|PROCEDURE|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
48013926|NCT06224829|PROCEDURE|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
48013927|NCT06224829|PROCEDURE|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
48013928|NCT06361511|OTHER|High Linoleic Acid Foods|Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily
48013929|NCT06361511|OTHER|High Oleic Acid Foods|Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily
48013930|NCT00851175|DRUG|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
48013931|NCT00851175|DRUG|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
48013932|NCT05165121|DEVICE|MDHearing smart hearing aid|air conduction hearing aid with app support
48013933|NCT00954213|BEHAVIORAL|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
48013934|NCT01433224|GENETIC|DNA methylation analysis|
48013935|NCT01433224|GENETIC|RNA analysis|
48013936|NCT01433224|GENETIC|mutation analysis|
48013937|NCT01433224|GENETIC|nucleic acid sequencing|
48013938|NCT01433224|GENETIC|polymerase chain reaction|
48013939|NCT01433224|GENETIC|polymorphism analysis|
48013940|NCT01433224|OTHER|laboratory biomarker analysis|
48013941|NCT01433224|OTHER|medical chart review|
48013942|NCT05673720|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session for 5 times via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session for 5 times by a recorded meditation.
48013943|NCT05673720|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
48013944|NCT04776148|DRUG|pembrolizumab|IV infusion
48013945|NCT04776148|DRUG|lenvatinib|oral capsule
48013946|NCT04776148|DRUG|regorafenib|oral tablet
48013947|NCT04776148|DRUG|TAS-102 (trifluridine and tipiracil)|oral tablet
48013948|NCT02939417|OTHER|Grape seed extract|Grape seed extract - collagen cross-linking agent
48013949|NCT05506020|PROCEDURE|indocyanine green (ICG) fluorescence cholangiography|indocyanine green (ICG) fluorescence cholangiography during operation
48013950|NCT02360618|DRUG|Metformin|See Group Description
48170468|NCT03199300|DRUG|Cisplatin|Chemotherapy including cisplatin.
48170469|NCT03199300|DRUG|Bleomycin|Chemotherapy including bleomycin.
48170470|NCT05767814|OTHER|Phenotyping of synovial immune and stromal cells|Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
48516155|NCT03063411|OTHER|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
48013951|NCT02360618|DRUG|Simvastatin|See Group Description
48013952|NCT02707640|DRUG|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
48013953|NCT02707640|DRUG|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
48013954|NCT02707640|DRUG|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
48013955|NCT01455324|DEVICE|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
48013956|NCT05046782|DEVICE|restriction spectrum imaging (RSI)|detect prostate cancer better than a standard-of-care MRI
48013957|NCT02960984|OTHER|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
48013958|NCT02002897|DEVICE|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
48013959|NCT02002897|DEVICE|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
48013960|NCT06248216|DEVICE|Relievrx|The RelieVRx program is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.
48013961|NCT06248216|OTHER|Audio Mp4|Audio Mp4 modules ranging from 3-15 minutes with guided meditation.
48013962|NCT03916627|DRUG|cemiplimab|Administered intravenous (IV)
48013963|NCT03916627|DRUG|Platinum Doublet|Administered intravenous (IV)
48013964|NCT03916627|DRUG|fianlimab|Administered IV
48701690|NCT06229431|OTHER|The Carer Support Needs Assessment Tool Intervention (CSNAT-I)|"The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan."
48701691|NCT00592163|DRUG|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
48701692|NCT04027049|DEVICE|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
48701693|NCT06558422|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined either to maintain fasting serum insulin levels (MH protocol) or to reduce fasting serum insulin levels by approximately 50% toward euinsulinemia (RE protocol).
48701694|NCT06558422|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
48701695|NCT06558422|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
48701696|NCT06558422|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
48701697|NCT06558422|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
48013965|NCT05362032|DEVICE|Biopsy|Undergo transrectal MRI-targeted biopsy
48013966|NCT05362032|PROCEDURE|Endorectal Magnetic Resonance Imaging|Endorectal MRI
48013967|NCT04915859|OTHER|Hand Cooling at 12-15 degrees celsius|hand cooling at 12-15 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
48013968|NCT04915859|OTHER|Hand Cooling at 16-20 degrees celsius|hand cooling at 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature
48013969|NCT04915859|OTHER|hand and back cooling at 12-15 or 16-20 degrees celsius|hand and back cooling at 12-15 or 16-20 degrees celsius will be performed for active cooling by having participants place their hands on the cooling device set to this temperature while also wearing the back wrap cooling device set to this temperature
48013970|NCT04915859|OTHER|Passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
48013971|NCT00333112|DRUG|solifenacin succinate|Oral
48013972|NCT00333112|DRUG|tamsulosin|oral
48013973|NCT00333112|DRUG|placebo|oral
48516156|NCT03063411|OTHER|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
48013975|NCT02265705|DRUG|Baricitinib|Administered orally
48013976|NCT02265705|DRUG|Placebo|Administered orally
48013977|NCT02556710|BIOLOGICAL|4 mL injection of AMPION™|4 mL Injection of Ampion
48013978|NCT02556710|DRUG|4 mL injection of Placebo|4 mL Injection of Placebo
48013979|NCT05060419|DRUG|Meropenem- FL058|"Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h"
48013980|NCT05060419|DRUG|Piperacillin -tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h
48013981|NCT05060419|DRUG|Saline|180min
48013982|NCT05060419|DRUG|Saline|30min
48013983|NCT06571214|DRUG|Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)|As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
48701698|NCT06558422|DIAGNOSTIC_TEST|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
48701699|NCT06558422|DIAGNOSTIC_TEST|[1-13C1] sodium acetate|Stable isotope tracer administered to calculate de novo lipogenesis during pancreatic clamp.
48701700|NCT06558422|DIETARY_SUPPLEMENT|Nestle BOOST Plus|"Nutritional supplement will be administered to provide standardized mixed meals prior to the pancreatic clamp."
48701701|NCT06558422|DIETARY_SUPPLEMENT|KIND Bar|Energy bar snack will be administered the evening before the pancreatic clamp.
48013984|NCT06571214|DRUG|Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)|This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
48170471|NCT03432650|DRUG|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
48170472|NCT03432650|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
48170473|NCT00945451|DEVICE|CK|Cyberknife Irradiation
48701702|NCT06558422|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
48701703|NCT06558422|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
48701704|NCT02725814|OTHER|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
48701705|NCT04817137|DEVICE|CareTaker PDA Device|Non-invasive blood pressure monitoring
48701706|NCT04540666|DRUG|Propofol|Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.
48701707|NCT04801238|PROCEDURE|LCBDE + LC|"Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed."
48701708|NCT04801238|PROCEDURE|ERC + LC|Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
48013985|NCT06572826|OTHER|Cardiac Rehabilitation intervention|The cardiac rehabilitation program for post-CS patients includes respiratory physiotherapy, muscle strengthening and endurance training such as walking, treadmill exercises, and cycling, all tailored to the patient's capabilities. Cardiovascular training involves interval and continuous aerobic exercises to improve heart function. The program emphasizes secondary prevention strategies, including lifestyle changes and medication management. Neuromotor rehabilitation addresses sarcopenia and polyneuropathies through targeted exercises like balance training, gait retraining, and the use of advanced technologies like functional electrical stimulation (FES), robotic devices, and virtual/augmented reality. Cognitive-behavioral therapy (CBT) helps manage the psychological effects of severe cardiovascular events. The program also includes speech and occupational therapy, planning for home reintegration, and telerehabilitation to ensure long-term recovery.
48701709|NCT06270836|DRUG|Tarcocimab|Intravitreal injection
48701710|NCT06270836|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
48013986|NCT04902859|DRUG|Clonidine Oral Liquid Product|Clonidine prepared from pharmacy with 20 mcg/ml concentration.
48013987|NCT04902859|DRUG|Sterile water|Sterile water used as placebo
48013988|NCT01142739|OTHER|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
48013989|NCT01142739|OTHER|Clinical variables|Demography, Biological variables.
48013990|NCT01142739|OTHER|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
48013991|NCT02841618|OTHER|High Linoleic Acid Healthy Cookies|
48013992|NCT02841618|OTHER|High Oleic Acid Healthy Cookies|
48013993|NCT00061490|BEHAVIORAL|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
48013994|NCT03850886|DIETARY_SUPPLEMENT|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
48013995|NCT03850886|DRUG|Antidiabetic|Metformin or Sulphonylurea
48013996|NCT02828839|PROCEDURE|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
48013997|NCT01331148|DRUG|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
48013998|NCT01331148|OTHER|Placebo|placebo with daily calcium/Vitamin D soft chews
48701711|NCT05641428|DRUG|ARI-0001|Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
48170474|NCT00849745|PROCEDURE|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
48170475|NCT01016223|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
48170476|NCT01016223|DRUG|placebo|Matched placebo swallowed two puffs twice daily
48170477|NCT04082481|DRUG|TAK-988|TAK-988 tablets.
48170478|NCT04082481|DRUG|TAK-988 Placebo|TAK-988 placebo-matching tablets.
48170479|NCT05101083|DEVICE|New Receiver-in-Canal Device|Successor of previous device generation
48170480|NCT05101083|DEVICE|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
48170481|NCT04623359|DEVICE|High resolution manometry|High resolution manometry
48170482|NCT06208878|OTHER|Non Interventional|Safety and Efficacy Assessment
48170483|NCT04294524|OTHER|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
48170484|NCT00176475|BIOLOGICAL|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
48170485|NCT00176475|BIOLOGICAL|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
48170486|NCT01961674|DIETARY_SUPPLEMENT|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
48170487|NCT02996318|DEVICE|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
48170488|NCT02996318|DEVICE|Sirolimus coated balloon|Sirolimus coated balloon
48170489|NCT04410549|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|To perform OCT in pulmonary artery of patient with COVID-19
48170490|NCT06279299|PROCEDURE|lateral pelvic lymph node dissection|Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.
48170491|NCT05103098|DRUG|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
48013999|NCT00134875|DRUG|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
48701712|NCT05641428|DRUG|Axi-cel|Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
48014000|NCT06663618|DRUG|prednison|Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.
48014001|NCT06663618|DRUG|Mycophenolate mofetil|Oral Mycophenolate mofetil 0.75g bid for 6 months.
48014002|NCT02692157|DRUG|Placebo|Placebo for Neurokinin 1,3 antagonist
48014003|NCT02692157|DRUG|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
48014004|NCT02692157|DRUG|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
48516157|NCT04927234|DEVICE|geko™ therapy|Neuro-muscular electrical stimulation of the peroneal nerve
48516158|NCT02027532|DRUG|Cefazolin|
48516159|NCT02027532|DRUG|Vancomycin|
48701713|NCT04972682|PROCEDURE|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
48701714|NCT03257202|DRUG|Clindamycin 1% Gel|topical clindamycin
48701715|NCT03257202|DRUG|Benzoyl peroxide 5% gel|topical benzoyl peroxide
48701716|NCT03257202|DRUG|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
48701717|NCT02455661|DEVICE|TR Band (TM)|
48701718|NCT02455661|DEVICE|AngioSeal|
48701719|NCT02455661|DEVICE|StarClose|
48701720|NCT05293613|DEVICE|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
48701721|NCT04309370|DEVICE|20 Hz rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
48701722|NCT04740281|BEHAVIORAL|Footwear|Assessment of footwear
48701723|NCT04893629|BIOLOGICAL|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
48701724|NCT04893629|DRUG|Digoxin+furosemide+captopril|classical heart failure medical treatment
48014005|NCT02692157|DRUG|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
48014006|NCT01412775|BEHAVIORAL|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
48014007|NCT00145366|DRUG|Recombinant human thyrotropin (Thyrogen)|
48516160|NCT00934024|DRUG|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
48701725|NCT03197714|DRUG|OPB-111077|"Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily"
48701726|NCT06164496|DEVICE|standart manual toothbrush|Device on plaque removal efficacy
48701727|NCT06164496|DEVICE|360 degree toothbrush|Device on plaque removal efficacy
48701728|NCT05249933|DRUG|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
48701729|NCT03055728|DIAGNOSTIC_TEST|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
48701730|NCT03055728|DIAGNOSTIC_TEST|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
48701731|NCT00529230|BEHAVIORAL|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
48701732|NCT00529230|OTHER|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
48014008|NCT00732121|DRUG|Sitagliptin|100 mg daily for 4 weeks
48014009|NCT00732121|DRUG|Placebo|Placebo
48014010|NCT03515148|PROCEDURE|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
48014011|NCT03515148|PROCEDURE|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
48014012|NCT03078998|DEVICE|Leap Motion Based Exercises|Game based exercise
48701733|NCT05175222|RADIATION|Laser therapy|Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
48701734|NCT04762043|DEVICE|Experimental System: MyoVoice|Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
48014013|NCT00233025|DRUG|Duloxetine|
48014014|NCT00233025|DRUG|Placebo|
48701735|NCT04762043|DEVICE|Reference System: Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
48701736|NCT05311995|PROCEDURE|Only different trocar sites|Only different trocar sites in literature
48701737|NCT00770497|DRUG|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
48701738|NCT00770497|DRUG|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
48014015|NCT03611634|OTHER|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
48014016|NCT01020916|PROCEDURE|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
48014017|NCT01020916|PROCEDURE|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
48701739|NCT00770497|DRUG|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
48014018|NCT06136520|BEHAVIORAL|Baby massage|"After the first measurements are made and the groups are determined; Personal Information Form, Perinatal Attachment Inventory and Beck Depression Inventory will be applied to the experimental and control groups. Pregnant women in the experimental group were 32-40 weeks of pregnancy.~After baby massage training is given, 30-42 weeks after birth. between days and 60-72. Maternal Attachment Scale and Edinburgh Postpartum Depression Scale will be applied to the experimental and control groups on the following days. The control group will receive standard care while the experimental group receives training. After the second postpartum data of the pregnant women in the control group are collected, a 30-minute baby massage training will be given by the researcher."
48014019|NCT04114552|OTHER|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
48701740|NCT01535599|DRUG|AL-60371, 0.3% Otic Suspension|
48014020|NCT03056690|DRUG|ASP0819|Oral capsule
48014021|NCT03056690|DRUG|Placebo|Oral capsule
48014022|NCT01294995|DIETARY_SUPPLEMENT|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
48014023|NCT01294995|DIETARY_SUPPLEMENT|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
48701741|NCT01535599|OTHER|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
48701742|NCT04664972|DRUG|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
48701743|NCT04664972|DRUG|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
48701744|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
48701745|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
48701746|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
48701747|NCT00570037|BIOLOGICAL|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
48701748|NCT01703208|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
48701749|NCT01703208|DRUG|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
48701750|NCT03258281|DRUG|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
48701751|NCT03258281|DRUG|Placebo|Patients will receive placebo administered subcutaneously
48701752|NCT02352454|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
48701753|NCT06140498|BEHAVIORAL|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
48701754|NCT06140498|BEHAVIORAL|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
48014024|NCT02229877|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
48014025|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
48014026|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
48014027|NCT02229877|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
48701755|NCT04077671|BIOLOGICAL|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
48014028|NCT03740438|DIAGNOSTIC_TEST|Hemoglobin concentration|Perioperative hemogloin concentration
48014029|NCT00286949|DRUG|Atomoxetine|Open Label uncontrolled active Drug intervention
48014030|NCT05695157|DEVICE|Suture-TOOL|Suture device for fast and standardized closure of the abdominal fascia
48014031|NCT05195320|BEHAVIORAL|Reinvention with MS|A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
48701756|NCT06598449|DRUG|fenfluramine|Clear, cherry flavored oral solution
48701757|NCT01728506|BEHAVIORAL|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
48701758|NCT05067023|DIAGNOSTIC_TEST|MRI scan|All participants will undergo 1 DCE-MRI scan.
48701759|NCT02694276|BEHAVIORAL|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
48516161|NCT00971373|OTHER|Vestagen scrubs|antimicrobial impregnated textile
48516162|NCT04876092|DRUG|JNJ-67856633|Participants will receive JNJ-67856633 orally.
48516163|NCT04876092|DRUG|Ibrutinib|Participants will receive Ibrutinib orally.
48516164|NCT05286866|PROCEDURE|Dental implant bed preparation|Drilling an osteotomy for placement of a dental implant
48701760|NCT04628169|OTHER|no intervention applied|no intervention applied
48701761|NCT02760173|OTHER|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
48516165|NCT04581330|DEVICE|DEKA SmartXide C02 laser|One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
48701762|NCT01028534|DRUG|Olmesartan and Azelnidipine|"1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
48014032|NCT05913063|DEVICE|Structured Light Imaging Microscopy|Conducting the psychophysical task on the perception of OAM-coupled polarized light created using the experimental setup - Structured Light Imaging Microscopy (SLIM). Four types of vortex orbital angular momentum, differing by the number of fringes l=5;10; 15;20, will be presented for 0.5s per trial during which an azimuthally varying entoptic profile rotated clockwise or counterclockwise. A circular mask with a varying radius will be placed at fixation, thus the task will be performed at varying eccentricities. Circular obstruction of the area will be achieved due to the high refresh-rate structured light modulator. The threshold mask size will be changed by a 2up/1down staircase method (71% accuracy for the estimation of mask size).
48014033|NCT06664177|PROCEDURE|Transversalis Fascia Plane Block|In the Transversalis Fascia Block group, the same procedure will be followed as in the Quadratus Lumborum block group, with the ultrasound probe being placed in the same location, and the same in-plane technique will be applied with a 22G 100 mm peripheral block needle. After hydrodissection, 20 mL of 0.5% bupivacaine will be injected slowly in the same manner.
48014034|NCT06664177|PROCEDURE|Quadratus Lumborum Block (QLB)|In the Quadratus Lumborum block group, in the lateral decubitus position, a convex ultrasound probe will be sterilely placed in the subcostal area and above the iliac crest. The quadratus lumborum and psoas major muscles, as well as the L4 vertebra's transverse process, will be visualized. Using the in-plane technique and a 22G 100 mm peripheral block needle, the placement will first be identified through hydrodissection in the subfascial area between the quadratus lumborum and psoas major muscles. After localization, 20 mL of 0.5% bupivacaine will be injected slowly, aspirating every 5 cc, while visualizing the local anesthetic pushing the fascia in the ultrasound image.
48014035|NCT02618993|PROCEDURE|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
48014036|NCT06572657|OTHER|cognitive stimulation|cognitive stimulation
48014037|NCT06572657|OTHER|physical exercise|physical exercise
48014038|NCT06098950|OTHER|Artificial Intelligence model predictions without explanation|During 6 clinical vignettes, participants will see AI model predictions without a corresponding AI explanation. The AI model will provide a score for each diagnosis (heart failure, pneumonia, COPD) on a scale of 0-100 estimating how likely the patient's presentation was due to each of these diagnoses. In 3 of the clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions, with the model specifically biased against one of the three diagnoses.
48014039|NCT06098950|OTHER|Artificial intelligence model predictions with explanation|During 6 clinical vignettes, participants will see AI model predictions with explanation. The AI model will provide a score for each diagnosis on a scale of 0-100. In 3 clinical vignettes, participants will be shown standard AI model predictions and 3 vignettes they will be shown systematically biased AI model predictions with the model specifically biased against one of the three diagnoses. If the AI model provides a score above 50 an AI model explanation will be shown as gradient-weighted class activation mapping (Grad-CAM) heatmaps overlaid on the chest X-ray that highlighted which regions of the image most affecting the AI model's prediction.
48522959|NCT00370552|DRUG|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m\^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
48701763|NCT00534118|BIOLOGICAL|donor lymphocytes|Given IV
48701764|NCT02354131|DRUG|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
48701765|NCT02354131|DRUG|Bevacizumab|
48701766|NCT03096093|BIOLOGICAL|ACIT-1|Cell suspension
48701767|NCT04717336|OTHER|SODIUM CHLORIDE|It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals. Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
48701768|NCT04717336|OTHER|placebo|placebo capsules
48701769|NCT05925452|DRUG|GenaKumab|GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
48701770|NCT02446704|DRUG|Olaparib|
48701771|NCT02446704|DRUG|Temozolomide|
48701772|NCT01950793|DRUG|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
48701773|NCT01950793|DRUG|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
48701774|NCT00460278|DRUG|XL418|
48014040|NCT06098950|OTHER|AI model biased against heart failure|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against heart failure, always predicting that heart failure is present with high likelihood in survey vignette patients with a body mass index (BMI) at or above 30. Standard predictions will be shown for the other 2 diagnoses (pneumonia, COPD).
48014041|NCT06098950|OTHER|AI model biased against pneumonia|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against pneumonia, always predicting that pneumonia is present with high likelihood in survey vignette patients 80 years or older. Standard predictions will be shown for the other 2 diagnoses (heart failure, COPD).
48014042|NCT06098950|OTHER|AI model biased against COPD|In 3 clinical vignettes, participants will be shown systematically biased AI model predictions with the model specifically biased against COPD, always predicting that COPD is present with high likelihood in survey vignette patients where a pre-processing filter was applied to the patient's X-ray. Standard predictions will be shown for the other 2 diagnoses (heart failure, pneumonia).
48014043|NCT06189092|DRUG|Bleomycin|Using electroporation to infuse bleomycin in the lesion
48701775|NCT06488612|PROCEDURE|Minced skin grafts for donor site|"After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage."
48701776|NCT04342026|OTHER|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
48701777|NCT02347553|OTHER|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
48014044|NCT00436306|BEHAVIORAL|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
48014045|NCT00436306|BEHAVIORAL|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
48014046|NCT06539026|OTHER|fluid therapy, 300 ml of crystalloid Ringer's solution.|"300 ml by dripping within 30 minutes, the fluid will be repeated by half the amount if needed to reach equal or less than 50% collapsibility.~the fluid that will be used is sterile Ringer's solution which is an isotonic intravenous solution with pH 5.0 - 7.5 and an osmolality of 308mOsmol/kg."
48014047|NCT06316414|BIOLOGICAL|Omalizumab|Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.
48014048|NCT00024518|DRUG|30,000 units hrINF-alpha|
48014049|NCT00024518|DRUG|5,000 hrINF-alpha|
48014050|NCT00024518|OTHER|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
48522960|NCT00370552|DRUG|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m\^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
48522961|NCT02597829|DRUG|Certolizumab Pegol|Subcutaneous Injection
48701778|NCT04017923|DIAGNOSTIC_TEST|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
48701779|NCT05858450|BIOLOGICAL|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
48701780|NCT05858450|BIOLOGICAL|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
48701781|NCT00139295|DEVICE|Hylastan|
48170492|NCT05103098|DRUG|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
48170493|NCT03834155|OTHER|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
48170494|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
48170495|NCT03834155|OTHER|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
48170496|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
48170497|NCT02869945|GENETIC|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
48701782|NCT04506060|OTHER|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
48701783|NCT01234740|DRUG|bafetinib|Given orally
48701784|NCT01234740|PROCEDURE|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
48014051|NCT02442830|DEVICE|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
48014052|NCT04453384|DRUG|XAV-19|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
48014053|NCT04453384|DRUG|Placebo|Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
48014054|NCT05197049|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
48014055|NCT05197049|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
48170498|NCT02869945|OTHER|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
48014056|NCT05197049|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
48701785|NCT01234740|OTHER|pharmacological study|Correlative studies
48701786|NCT01234740|OTHER|liquid chromatography|Correlative studies
48701787|NCT01234740|OTHER|mass spectrometry|Correlative studies
48701788|NCT01234740|OTHER|laboratory biomarker analysis|Correlative studies
48701789|NCT01234740|GENETIC|protein expression analysis|Correlative studies
48701790|NCT01234740|GENETIC|western blotting|Correlative studies
48701791|NCT01234740|OTHER|immunohistochemistry staining method|Correlative studies
48014057|NCT05197049|DRUG|Placebo|Placebo will be administered by SC injection.
48014058|NCT06404996|DEVICE|Smart-phone Voiding Diary|Smart-phone Voiding Diary
48701792|NCT01234740|PROCEDURE|therapeutic conventional surgery|debulking craniotomy
48701793|NCT01753869|PROCEDURE|Airways clearance and Hypertonic saline inhalation|
48701794|NCT05634733|OTHER|Treatment of Sepsis|Patients will have standard care of sepsis
48701795|NCT04686084|DEVICE|Dual-energy computed tomography scan|Diagnostic CT scan
48701796|NCT02091531|DRUG|MLN0128|
48701797|NCT01421303|DRUG|Enbrel|Enbrel
48170499|NCT02869945|OTHER|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
48170500|NCT00560313|BIOLOGICAL|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
48170501|NCT00560313|BIOLOGICAL|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
48170502|NCT00018759|DRUG|paroxetine|
48014059|NCT06404996|DIAGNOSTIC_TEST|Paper voiding diary|Conventional Paper voiding diary
48701798|NCT02662504|DEVICE|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
48516166|NCT05812274|OTHER|Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation|"The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~* ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~* ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~* ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status."
48516167|NCT02211417|DRUG|Oral DS107|
48516168|NCT02211417|DRUG|Placebo|
48516169|NCT01050439|PROCEDURE|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
48014060|NCT05204134|DEVICE|Automated Insulin Delivery Settings Initialization and Adaptation Algorithm|All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
48014061|NCT01297673|PROCEDURE|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
48014062|NCT05555381|BEHAVIORAL|young-D program|"* needs detection by means of survey and interviews (mixed-methods)~* 6 week program (1 hour) on a weekly basis including cognitive behavioural therapy, sleep/stress hygiene education, heart coherence exercises, mindfulness and relaxation exercises"
48014063|NCT03109275|OTHER|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
48014064|NCT01502722|BEHAVIORAL|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
48014065|NCT05882539|DEVICE|endotracheal tube material,Bite block Material|Exposure factors associated with tracheal intubation in patients that may influence the occurrence of oral mucosa pressure injurie, such as the material and fixation of the tracheal tube, the patient's own nutrition, the level of tissue perfusion and relevant treatment factors.
48170503|NCT00018759|BEHAVIORAL|ongoing psychological screening|
48170504|NCT02360865|OTHER|Exercise|
48170505|NCT00661544|DRUG|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
48701799|NCT02662504|PROCEDURE|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
48170506|NCT00661544|DRUG|Melphalan|Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.
48170507|NCT00661544|DRUG|Ascorbic Acid|Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
48170508|NCT03505255|DRUG|Neostigmine|Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
48170509|NCT03505255|OTHER|Normal saline|Normal saline 0.9 % is given in the control group
48170510|NCT03123419|BEHAVIORAL|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
48170511|NCT01232569|DRUG|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
48516170|NCT01050439|OTHER|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
48014066|NCT03082794|DIETARY_SUPPLEMENT|NCD|Negative Calorie Diet
48014067|NCT03082794|DIETARY_SUPPLEMENT|LCD|Low Calorie Diet
48014068|NCT03057145|DRUG|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
48170512|NCT01232569|DRUG|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
48170513|NCT05689281|BEHAVIORAL|Peer PrEP Navigation|Ecological momentary assessments to identify and address stressors related to social determinants of health (e.g., housing, substance use, mental health), and motivational interviewing to support participants' health care empowerment and progression along the PrEP continuum.
48170514|NCT04185922|DEVICE|Hemopatch|As stated in Hemopatch arm description
48170515|NCT00630552|OTHER|Placebo|Inactive dummy of AMG 655.
48014069|NCT03057145|DRUG|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
48014070|NCT02985242|DRUG|Empagliflozin|Empagliflozin film-coated tablet
48014071|NCT02985242|DRUG|Glimepiride|Glimepiride tablet
48170516|NCT00630552|DRUG|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
48371601|NCT03952416|BEHAVIORAL|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
48371602|NCT05754970|PROCEDURE|laser treated|"The second surgical stage was done after a healing period 12 ± 4 weeks (T1) where all the healing abutments were placed. Each healing abutment had repeated the two surfaces as twice follows: laser-treated/machined/ laser-treated/machined. Experimental healing abutment was removed after 30 ± 7 days, the same time as the soft tissue biopsy.~After the healing period (30 ± 7 days), before starting with the prosthetic restoration of the fixtures, an impression was taken of the small-diameter Has, and circular sections (diameter 5 mm) soft tissues around them were retrieved for analysis."
48371603|NCT00526214|DRUG|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
48371604|NCT02221882|DRUG|LY3164530|Administered IV.
48371605|NCT05461742|BEHAVIORAL|Physical activity intervention|While the final content and structure of the intervention will be informed by community advisory board, participants will receive a culturally adapted, Social Cognitive Theory and Transtheoretical Model-based PA intervention. The evidence-based, theory guided aerobic physical activity intervention will systematically build upon the investigators' prior studies and includes the following components: goal setting, in-person physical activity sessions, and written materials.
48371606|NCT06220929|DRUG|Mecobalamin|The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
48371607|NCT06220929|DRUG|Ceftriaxone Sodium|Ceftriaxone sodium all intravenous formulations
48371608|NCT06220929|DRUG|Saline|The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
48014072|NCT02985242|DRUG|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
48014073|NCT02985242|DRUG|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
48014074|NCT06572475|DIAGNOSTIC_TEST|USPIO enhanced MRI|Ferumoxytol (Feraheme©, AMAG pharmaceuticals, US) enhanced MRI
48014075|NCT04605575|DRUG|Pyrotinib 320mg + Vinorelbine|pyrotinib 320mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
48170517|NCT00630552|DRUG|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
48170518|NCT04676633|DRUG|STP705|Investigational Product
48170519|NCT00143598|DEVICE|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
48170520|NCT00143598|DEVICE|Knee-length, placebo stocking|Worn daily for two years
48170521|NCT04263805|OTHER|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
48014076|NCT04605575|DRUG|Pyrotinib 400mg + Vinorelbine|pyrotinib 400mg tablets administered daily by mouth, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle. Treatment lasts for two cycles
48014077|NCT04605575|DRUG|Pyrotinib plus Vinorelbine|pyrotinib administered daily by mouth（MTD）, vinorelbine(po) 80 mg/m2 weekly (following a first cycle at 60 mg/m2) administered on day 1 and day 8 of 21 day cycle, or vinorelbine(iv) 25 mg/m2 on day 1 and day 8 of 21 day cycle. Treatments will lasts until disease progression (as assessed by the investigator) or unmanageable toxicity.
48014078|NCT04973488|OTHER|Therapeutic plasma exchange|The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
48014079|NCT03353428|BIOLOGICAL|LC-CTLs|2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
48014080|NCT00004317|DRUG|Leucovorin calcium|See arm descriptions
48014081|NCT00004317|DRUG|Pyrimethamine|See arm descriptions
48014082|NCT00004317|DRUG|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
48170522|NCT00885326|DRUG|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
48014083|NCT00004317|DRUG|Sulfadiazine|See arm descriptions
48014084|NCT03734198|DRUG|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
48014085|NCT03734198|DRUG|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
48170523|NCT00885326|DRUG|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
48170524|NCT00885326|DRUG|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
48170525|NCT04183244|PROCEDURE|Erector spinae block|A 5-cm needle prick in the back of the patient 3 cm lateral to mid-line under sterile conditions, with ultrasound guidance.
48170526|NCT04183244|PROCEDURE|Infraclavicular subomohyoid (ISO) block|Under complete aseptic precaution, 12 cm needle will be inserted 2cm superior to the clavicle and advanced retroclavicular, with ultrasound guidance.
48170527|NCT06039592|DRUG|Captopril Tablets|0.3mg/kg, tid
48170528|NCT06039592|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
48371609|NCT06220929|DRUG|Placebo|Placebo and Mecobalamin tablets look and smell the same.
48371610|NCT05371340|DIETARY_SUPPLEMENT|Quercetin (500 mg)|Once-daily 500 mg Quercetin
48014086|NCT00588913|BIOLOGICAL|aldesleukin|
48014087|NCT00588913|BIOLOGICAL|therapeutic autologous lymphocytes|
48014088|NCT00588913|DRUG|zoledronic acid|
48014089|NCT03096782|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
48014090|NCT03096782|DRUG|Busulfan|Given IV
48014091|NCT03096782|DRUG|Clofarabine|Given IV
48014092|NCT03096782|DRUG|Cyclophosphamide|Given IV
48170529|NCT06039592|DRUG|Spironolactone Tablets|2-4mg/kg, bid
48371611|NCT05371340|OTHER|Placebo (500 mg)|Once-daily 500 mg methylcellulose 9E4M)
48371612|NCT03975218|OTHER|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
48371613|NCT05745974|DIAGNOSTIC_TEST|lymphocytic count|taking blood samples and COVID-19 swab
48014093|NCT03096782|BIOLOGICAL|Filgrastim-sndz|Given SC
48014094|NCT03096782|DRUG|Fludarabine|Given IV
48014095|NCT03096782|DRUG|Melphalan|Given IV
48014096|NCT03096782|DRUG|Mycophenolate Mofetil|Given IV or PO
48014097|NCT03096782|BIOLOGICAL|Rituximab|Given IV
48170530|NCT06039592|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
48170531|NCT06039592|DRUG|Potassium citrate powder|0.06g/kg, tid
48170532|NCT06452927|PROCEDURE|Endoscopic enucleation of the prostate|"Endoscopic enucleation of the prostate, regardless of energy source.~Also see:~* Enucleation is enucleation is enucleation is enucleation~* PMID: 27585786 DOI: 10.1007/s00345-016-1922-3"
48170533|NCT06009263|OTHER|Conventional treatment|"Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
48170534|NCT06009263|OTHER|Open chain segmental control|"Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
48170535|NCT06009263|OTHER|Closed chain segmental control|"Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain."
48170536|NCT02983877|BEHAVIORAL|iTAB-CV|"Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1."
48170537|NCT04419649|DRUG|KER-050|KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
48170538|NCT05238363|DRUG|HLX07|HLX07 1500mg ivgtt Q3W
48014098|NCT03096782|DRUG|Tacrolimus|Given IV
48014099|NCT03096782|RADIATION|Total-Body Irradiation|Undergo total body irradiation
48170539|NCT02460536|BEHAVIORAL|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
48170540|NCT02460536|BEHAVIORAL|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
48371614|NCT02114346|DRUG|Atorvastatin|
48371615|NCT02114346|DRUG|Placebo|
48522962|NCT04366492|OTHER|Prevalence of blood borne viral infections (HBV/HCV/HIV)|rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
48522963|NCT00596791|DRUG|tafluprost|prostaglandine analoque
48014100|NCT03096782|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
48014101|NCT05650879|DRUG|ELVN-002|capsule
48014102|NCT05650879|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|intravenous
48014103|NCT05650879|DRUG|Trastuzumab emtansine|intravenous
48014104|NCT03689127|DEVICE|Heated breathing circuit on|Heated breathing circuit will be turned on.
48014105|NCT03689127|DEVICE|Heated breathing circuit off|Heated breathing circuit will be turned off.
48014106|NCT05227924|DEVICE|Total hip arthroplasty (primary or revision)|Total hip arthroplasty with at least one medical device from the SYMBOL range
48522964|NCT00748761|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
48014107|NCT06283628|PROCEDURE|Radiofrequency ablation of lumbar medial branch nerves.|"Traditional approach:~The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve.~Parasagittal (new) approach:~The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method."
48701800|NCT02662504|DRUG|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
48701801|NCT03241823|DIAGNOSTIC_TEST|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
48701802|NCT03241823|DIAGNOSTIC_TEST|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
48701803|NCT03241823|DIAGNOSTIC_TEST|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
48701804|NCT03241823|DIAGNOSTIC_TEST|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
48701805|NCT05654441|BIOLOGICAL|Influenza vaccine|0.5 mL single-dose injection
48701806|NCT05654441|BIOLOGICAL|Placebo|0.5 mL single-dose injection with no therapeutic effect
48701807|NCT03530774|DIETARY_SUPPLEMENT|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
48701808|NCT03530774|DIETARY_SUPPLEMENT|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
48701809|NCT05529277|OTHER|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
48701810|NCT00531557|DRUG|Darunavir ritonavir|
48701811|NCT04864626|OTHER|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
48701812|NCT04864626|OTHER|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
48701813|NCT03826173|BEHAVIORAL|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
48701814|NCT03826173|BEHAVIORAL|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
48701815|NCT04917796|OTHER|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
48701816|NCT04917796|OTHER|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
48170541|NCT02460536|BEHAVIORAL|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
48170542|NCT02460536|BEHAVIORAL|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
48170543|NCT03477825|DIETARY_SUPPLEMENT|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day"
48522965|NCT00748761|BEHAVIORAL|Waitlist|Contact waitlist weekly for 12 weeks
48701817|NCT01117740|BEHAVIORAL|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
48701818|NCT02367001|OTHER|Normal invitation|No modification and signed by the coordinating doctor as usual
48170544|NCT03477825|DIETARY_SUPPLEMENT|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet."
48701819|NCT02367001|OTHER|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
48701820|NCT02367001|OTHER|Revised invitation signed by the attending physician|signature typed or typed + handwritten
48170545|NCT03477825|DIETARY_SUPPLEMENT|Triphala|"Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
48170546|NCT02825277|DEVICE|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
48170547|NCT02480751|DRUG|Beraprost|
48170548|NCT02480751|DRUG|Placebo|
48170549|NCT05279534|DIETARY_SUPPLEMENT|Probiotic|Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days
48522966|NCT01729273|OTHER|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
48701821|NCT03315897|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
48014108|NCT03481959|DRUG|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
48014109|NCT03481959|OTHER|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
48014110|NCT06333444|BEHAVIORAL|four weekly psychological counselling intervention|four weekly psychological counselling intervention delivered by university students asking help to university counselling service in Southern Italy
48014111|NCT05681871|DIETARY_SUPPLEMENT|Ferrous gluconate syrup or ferrous fumarate/folic acid tablets|Oral iron supplementation dosed based on body weight
48014112|NCT03142503|DIETARY_SUPPLEMENT|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
48014113|NCT03142503|DIETARY_SUPPLEMENT|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
48014114|NCT03142503|DIETARY_SUPPLEMENT|Placebo|Supplementation of 1g soybean oil, 3 times a day.
48701822|NCT03315897|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
48014115|NCT02896127|DRUG|Secukinumab|"Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment."
48701823|NCT03448666|COMBINATION_PRODUCT|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
48701824|NCT03660202|DEVICE|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
48014116|NCT02896127|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
48014117|NCT06572007|DIAGNOSTIC_TEST|Ultrasound|To investigate the thickness of the fascia tissue, the subjects will undergo an ultrasound examination using a clinical ultrasound system (S9, SonoScape Corporation, made in China) with a linear 5-14 MHz array of L14-5/38. The transducer with a cross-section of 6.24 cm2 will be aimed at points 2 cm lateral to the midline of the L2 and L3 vertebrae on both sides of the spine.
48014118|NCT01176825|BEHAVIORAL|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
48014119|NCT02279641|DRUG|RDEA3170 10 mg|
48170550|NCT05279534|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
48701825|NCT06454448|DRUG|Adebrelimab;decitabine;|Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
48701826|NCT03368053|PROCEDURE|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
48701827|NCT05098964|DEVICE|pedometer home based rehabilitation|Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
48522967|NCT02581605|DEVICE|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
48522968|NCT02354729|OTHER|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
48701828|NCT05098964|OTHER|Exercise training|Hospital based exercise training for 6 weeks
48701829|NCT05762250|OTHER|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
48701830|NCT05771636|BEHAVIORAL|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
48701831|NCT05771636|BEHAVIORAL|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
48701832|NCT03974854|DRUG|XELOXIRI-3|chemotherapy with XELOXIRI-3 regimen
48701833|NCT03974854|DRUG|Gemcitabine|chemotherapy with Gemcitabine regimen
48701834|NCT03075488|DEVICE|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
48701835|NCT03075488|PROCEDURE|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
48701836|NCT05617924|PROCEDURE|Physical Therapy|Therapy methods using physical agents in treatment
48014120|NCT02279641|DRUG|allopurinol 300 mg|
48170551|NCT02637856|DRUG|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
48170552|NCT02637856|DRUG|Ocrelizumab|Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
48170553|NCT00591409|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
48170554|NCT00591409|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
48170555|NCT02737202|DRUG|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
48170556|NCT00500981|PROCEDURE|Volume challenge|
48170557|NCT00500981|PROCEDURE|Ultrasound evaluation of internal jugular vein|
48170558|NCT05167513|DRUG|Metformin / Sitagliptin Oral Tablet|"Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes."
48170559|NCT04067271|OTHER|Analyze changes in intestinal microbiome|Descriptive Analysis
48170560|NCT05598138|BIOLOGICAL|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
48170561|NCT01113671|DRUG|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
48170562|NCT01113671|DRUG|Placebo|includes inactive Ingredients
48170563|NCT06153498|DRUG|Remimazolam besylate|After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).
48170564|NCT02106637|DRUG|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
48170565|NCT02106637|DRUG|placebo|placebo
48170566|NCT03536702|OTHER|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
48170567|NCT03536702|OTHER|Independent Writing - Control Group|This group will receive a book for a self writing session.
48170568|NCT06338436|DEVICE|Proton Radiation Therapy System (ProBeam)|All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.
48371616|NCT02114346|DRUG|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
48371617|NCT05333432|PROCEDURE|Multiparameric MRI with injection|"Participants have a prostate multiparametric MRI with gadolinium injection (T2, diffusion and perfusion sequences) every year.~PIRADS-V2 is used as decisional endpoint, and subjective score LIKERT as secondary analysis.~To compute sensivity and specificity, we consider LIKERT as suspicious and/or malignant (PIRADS-V2 = 3, 4 or 5) as positive."
48371618|NCT05315687|DEVICE|Y-90 SIR-Spheres|Y-90 SIR-Spheres
48371619|NCT05315687|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo Y90 radioembolization
48371620|NCT05315687|OTHER|Systemic Therapy|Systemic Therapy
48014121|NCT00220818|DRUG|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
48014122|NCT00220818|DRUG|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
48014123|NCT03087279|BEHAVIORAL|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
48014124|NCT01932216|PROCEDURE|Cholecystectomy|Gallbladder removal
48014125|NCT01558700|DRUG|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
48014126|NCT01558700|DRUG|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
48014127|NCT05685797|PROCEDURE|trigminal nerve block with RFT|trigminal nerve block with RFT
48014128|NCT02126254|DEVICE|Hemodynamic group|NICAS guided treatment
48701837|NCT06163625|DEVICE|Repetitive Transcranial Magnetic Stimulation|For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD.
48170569|NCT04338230|OTHER|Progressive muscle relaxation exercise|"Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application."
48371621|NCT06040905|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg/day (150mg/b.i.d)
48701838|NCT06163625|BEHAVIORAL|Research Interview, Questionnaires|"Research Interview: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 30 minutes.~Research Questionnaires: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. Questionnaires will be completed via pen and paper at each visit. These questionnaires will take approximately 90 minutes to complete."
48014129|NCT05543213|BEHAVIORAL|Action Observation Therapy|A video clip of a series of exercises is shown to the patients, then they practice them according to mirror neurons and observational learning.
48014130|NCT05266326|OTHER|Western medicine conventional treatment +Bloodletting puncture|All acupoints are positioned according to the WHO standard acupuncture point locations in the Western Pacific Region. Operation: The patient is placed in a reasonable position, the acupuncture site is exposed, and the operator uses pushing, rubbing, squeezing and butterfly on or around the acupuncture site to collect blood at the acupuncture site before pricking, and then disinfects the acupuncture site with 75% ethanol. If more bleeding occurs, press with sterile dry cotton balls to stop the bleeding. The treatment was performed once daily for 7 days.
48014131|NCT05266326|OTHER|Western medicine conventional treatment|The patients in both groups were given conventional comprehensive treatment such as improving cerebral circulation, neuroprotection, antiplatelet aggregation, lipid regulation and symptomatic management after admission. Patients with hypertension, hyperglycaemia, hyperlipidaemia and coronary atherosclerotic heart disease were given individualised symptomatic treatment and advised to stop smoking, drinking alcohol and other adverse lifestyles as far as possible.
48014132|NCT05267171|OTHER|Web access|The intervention group will have access to the website where the information is provided. The control group will not have this access.
48014133|NCT00117091|DRUG|Anakinra (Kineret®)|
48014134|NCT02950636|OTHER|Yoga|Restorative Yoga
48014135|NCT01401491|DRUG|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
48014136|NCT01401491|DRUG|clozapine plus placebo|clozapine 300 mg/day plus placebo
48014137|NCT00826085|DRUG|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
48014138|NCT03995758|DEVICE|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
48014139|NCT00422565|DEVICE|Endeavor, Medtronic|Zotarolimus-eluting stent
48014140|NCT00422565|DEVICE|Cypher, Cordis|Sirolimus-eluting stent
48014141|NCT00422565|DEVICE|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
48014142|NCT05114603|DRUG|HLX208|level 1:600mg po Bid level 2:900mg po Bid
48170570|NCT02514577|DRUG|IDP-122 Lotion|Topical lotion
48170571|NCT02514577|DRUG|IDP-122 Vehicle Lotion|Topical lotion. No active ingredient.
48371622|NCT06040905|OTHER|Placebo|Starch, dextrin
48371623|NCT02651740|DRUG|Rifaximin|400mg tid\* 3d
48371624|NCT02651740|PROCEDURE|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
48371625|NCT02168465|BEHAVIORAL|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
48371626|NCT00039377|DRUG|imatinib mesylate|Given PO
48371627|NCT00039377|DRUG|methotrexate|Given IT and IV
48014143|NCT02563158|PROCEDURE|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
48014144|NCT05574348|OTHER|Osteopathic Protocol in 2 Sessions (PO2S)|"PO2S works on the principle that there is a concordance between the author's Preferential Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions.~The PO2S consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2S is an innovative osteopathic protocol for back pain."
48014145|NCT06374433|PROCEDURE|Occipital tACS at IAF-2Hz|tACS applied to occipital areas at 2 Hz below the individual alpha frequency (IAF)
48170572|NCT02169921|DEVICE|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
48170573|NCT03018847|DEVICE|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
48014146|NCT06374433|PROCEDURE|Occipital tACS at IAF+2Hz|tACS applied to occipital areas at 2 Hz above the individual alpha frequency (IAF)
48014147|NCT06374433|PROCEDURE|Frontal tACS at 4-7 Hz|tACS applied to frontal areas at 4-7 Hz
48014148|NCT06374433|PROCEDURE|Occipital tRNS|tRNS applied to occipital brain regions
48014149|NCT06374433|PROCEDURE|Frontal tRNS|tRNS applied to frontal brain regions
48170574|NCT03919318|OTHER|Root Canal Filling Sealers|Root Canal Obturation
48170575|NCT02520596|OTHER|Bioavailability of Raspberry polyphenols|
48170576|NCT03384771|BEHAVIORAL|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
48170577|NCT04418180|DRUG|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
48014150|NCT06374433|PROCEDURE|Sham/placebo tACS|tACS is activated only for 30 seconds and then turned off, thus resulting ineffective
48014151|NCT06374433|PROCEDURE|Sham/placebo tRNS|tRNS is activated only for 30 seconds and then turned off, thus resulting ineffective
48014152|NCT05210036|DEVICE|Ultrasound Therapy (US)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
48014153|NCT05210036|DEVICE|High-Intensity Laser Therapy (HILT)|"All the patients included in the study received a total of 15 sessions of physical therapy program 5 times a week for 3 weeks.~Physical Therapy Program;~* Hot Pack at 60 degrees Celsius for 20 minutes~* TENS at 80 Hz for 20 minutes~* Therapeutic exercise program (3 sets of 10 reps with 3-minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist."
48014154|NCT02912286|DEVICE|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
48014155|NCT02912286|DEVICE|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
48014156|NCT02912286|DEVICE|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
48014157|NCT02351752|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR\>60)
48014158|NCT05925517|OTHER|Graded Motor Imagery (GMI)|"GMI includes three stages. Each session will be 30 minutes, and the GMI program will span over 8 weeks. The first 3 weeks will focus on lateralization, followed by 3 weeks of motor imagery, and the final 2 weeks will involve mirror therapy.~Lateralization: Patients will be asked to differentiate whether the extremities shown in the Recognise™ Knee application belong to the right or left side of their body.~Motor Imagery: Patients will be instructed to imagine slowly and smoothly moving their affected extremities to the posture depicted in the photos in the Recognise™ Knee application and then returning to the starting position.~Mirror Therapy: Using a mirror measuring 90x60 cm² placed between the lower extremities, patients will be instructed to progressively move only their unaffected extremity, then their affected extremity, and finally both extremities."
48014159|NCT05925517|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Application will be performed using a TENS device and four separate 2 × 2 inch self-adhesive electrodes. The current will be applied to the most painful area of the affected knee. The four self-adhesive electrodes will be positioned in a square pattern, approximately 5 cm apart, centered over the pain point. Conventional TENS will be applied for 30 minutes at a frequency of 100 Hz, pulse width of 100 μs, and intensity below 10% of the motor threshold.
48170578|NCT04418180|DRUG|Placebo|oral distilled water
48170579|NCT00320814|DRUG|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
48170580|NCT03121612|DEVICE|CPAP|CPAP therapy
48170581|NCT04016350|BEHAVIORAL|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
48170582|NCT04016350|BEHAVIORAL|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
48170583|NCT02217488|DRUG|DG3173|
48170584|NCT02217488|DRUG|Placebo|
48371628|NCT00039377|DRUG|vincristine sulfate|Given IV
48014160|NCT05925517|OTHER|Conventional Physiotherapy Program|The routine 60-minute program for OA patients in conventional physiotherapy includes warming up, core stability, pelvic and hip stability, gluteus medius strengthening, knee control and stability (knee flexion and extension control, lunge exercises), knee strengthening exercises (wall-assisted leg press with a ball, step-ups with elastic bands), and functional exercises.
48701839|NCT06163625|BEHAVIORAL|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes, and there will be a recovery period for 40 minutes. The participant will be given instructions about these tasks outside of the scanner. This brain scan will happen at St. Michael's Hospital.
48701840|NCT06163625|BIOLOGICAL|Saliva Samples|The participant will be asked to provide six 1mL saliva samples during the MRI scan and recovery period so that the investigators can measure molecular markers associated with depression. In order to provide the sample, the investigators will collect their saliva using a cotton swab and test tube. Each sample should take no more than 5 minutes.
48701841|NCT06040008|GENETIC|blood collection|"* 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit"
48701842|NCT03100240|PROCEDURE|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
48014161|NCT05925517|OTHER|Home Exercise Protocol|The home exercises will include a warm-up consisting of a 10-minute walk at a normal pace on a flat surface while gently stretching the hamstring and calf muscles. The exercises will also involve straight leg raises, terminal knee extension, isometric contractions of the quadriceps femoris and adductor muscles using a pillow for support, toe raises, single-leg standing, toe taps, and quadriceps strengthening exercises included in the session.
48014162|NCT05898399|DRUG|ART6043|ART6043 will be given orally.
48014163|NCT05898399|DRUG|Olaparib|Olaparib will be given orally.
48014164|NCT05898399|DRUG|Niraparib|Niraparib will be given orally.
48701843|NCT03540537|OTHER|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
48701844|NCT03540537|OTHER|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
48014165|NCT02053727|DRUG|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
48170585|NCT02610621|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
48170586|NCT00551135|DRUG|Pregabalin|150 mg BID
48014166|NCT02053727|DRUG|Placebo|
48170587|NCT00551135|DRUG|placebo|Placebo
48170588|NCT00551135|DRUG|Pregabalin|75 mg BID
48170589|NCT00551135|DRUG|Pregabalin|25 mg BID
48170590|NCT01603771|OTHER|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
48371629|NCT00039377|DRUG|leucovorin calcium|Given IV and PO
48170591|NCT02893488|DRUG|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
48170592|NCT02893488|DRUG|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
48170593|NCT02893488|DRUG|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
48170594|NCT02216578|DRUG|cabozantinib|Oral
48170595|NCT00420147|DEVICE|wedged inshoe orthosis|Treatment subjects were prescribed an inshoe wedged orthosis
48170596|NCT00420147|DEVICE|neutral inshoe orthosis|Control subjects were prescribed a neutral inshoe orthosis
48170597|NCT01792596|OTHER|Pasta with protein|Pasta with Protein
48170598|NCT01792596|OTHER|Pasta with Fiber|Pasta with Fiber
48170599|NCT01792596|OTHER|Pasta|Pasta
48170600|NCT00269997|DRUG|epoetin alfa|
48170601|NCT00352963|BIOLOGICAL|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
48170602|NCT00001383|DRUG|PSC 833|
48170603|NCT00001383|DRUG|paclitaxel|
48170604|NCT03497221|BEHAVIORAL|Education intervention|The same description of arm Education intervention.
48170605|NCT03497221|BEHAVIORAL|Visual identity campaign|The same description of arm Visual identity campaign.
48371630|NCT00039377|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
48371631|NCT00039377|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
48170606|NCT05507398|DRUG|Placebo, metformin and atorvastatin|comparing the anti-tumor effects of metformin and atorvastatin
48170607|NCT01484314|DRUG|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
48170608|NCT01759238|DRUG|Capecitabine|825mg/m2 per os bid
48170609|NCT01759238|DRUG|Bevacizumab|7.5 mg/kg
48170610|NCT01759238|RADIATION|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
48170611|NCT01991925|OTHER|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews
48170612|NCT03867552|PROCEDURE|Altered gas (86% CO2, 10% N2O, 4% O2)|Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)
48170613|NCT03867552|PROCEDURE|Standardized gas (100% CO2)|Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
48170614|NCT04470570|OTHER|Cross-Education|1) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.
48170615|NCT04470570|OTHER|Blood-Flow Restriction Training|1) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
48170616|NCT00988117|DRUG|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
48170617|NCT00516828|DRUG|cytarabine|subcutaneously twice daily from Day 1 to 10
48170618|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, patients receive clinically-optimized open loop DBS stimulation to the pallidum.
48170619|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation at random time points. These random stimulation times will in total equal the total amount of time of active movement.
48170620|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of contralateral limb movement (e.g. left brain stimulation during right leg/arm movement).
48170621|NCT04675398|DEVICE|Summit RC+S|Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of no movement for the contralateral limb (e.g. left brain stimulation while right leg/arm is not moving).
48371632|NCT00039377|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
48371633|NCT00039377|RADIATION|total-body irradiation|Undergo TBI
48371634|NCT00039377|DRUG|tacrolimus|Given IV or PO
48371635|NCT00039377|BIOLOGICAL|filgrastim|Given SC
48371636|NCT00039377|DRUG|etoposide|Given IV
48371637|NCT00039377|DRUG|cyclophosphamide|Given IV
48371638|NCT00039377|DRUG|cytarabine|Given IV
48014167|NCT04844229|PROCEDURE|Bilateral transnasal sphenopalatine ganglion block.|SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
48170622|NCT05041725|DRUG|Remimazolam Injection [Byfavo]|Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
48170623|NCT00151905|DRUG|3 % hypertonic saline|
48014168|NCT04844229|PROCEDURE|Bilateral ultrasound guided greater occipital nerve block.|GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
48371639|NCT00039377|OTHER|laboratory biomarker analysis|Correlative studies
48014169|NCT01938534|DRUG|Helicobacter pylori eradication|
48014170|NCT00434668|DRUG|cisplatin/docetaxel|
48014171|NCT00434668|DRUG|cisplatin/vinorelbine|
48014172|NCT02988063|DRUG|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
48014173|NCT03754257|PROCEDURE|Experimental Electrical Stimulation|Experimental Electrical Stimulation (100Hz) during 40 minutes
48014174|NCT03754257|PROCEDURE|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
48014175|NCT03754257|OTHER|Conventional Physiotherapy|Active and passive exercises, and walking.
48371640|NCT05223504|DEVICE|Continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge. Monitoring will last for a maximum of eight days.
48701845|NCT03540537|OTHER|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
48701846|NCT02199314|DRUG|Desflurane|
48014176|NCT06535906|OTHER|kinesio taping|The 5 cm wide Kinesio tape (Kinesio® Tex Gold™, Albuquerque, NM) applied to the participants has the ability to stretch up to 140% of its original length. Moreover, it provides comfortable use for 3 to 5 days thanks to its latex-free, cotton, hypoallergenic and porous features. The skin will be cleaned with alcohol before applying Kinesio tape. To prevent muscle tension, the physiotherapist will apply the kinesio tape inhibition technique to the wrist flexor muscles with light tension (15-25% of the current tension) from the end point to the origin. We will use this inhibition technique to prevent muscle spasm. Kinesio taping will be applied immediately after exercise
48014177|NCT06535906|OTHER|placebo kinesio taping|5 cm wide and 0.5 mm thick I-shaped Kinesio tape (Kinesio Tex® Gold) will be used. The tape will be applied in a plus-shaped, tension-free and technical sitting position. Kinesio taping will be applied immediately after exercise
48701847|NCT03509363|BEHAVIORAL|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
48701848|NCT01476189|DRUG|Experimental paracetamol formulation|experimental
48701849|NCT01476189|DRUG|Marketed paracetamol|Marketed paracetamol
48701850|NCT01476189|DRUG|Higher dose marketed paracetamol|Higher dose marketed paracetamol
48371641|NCT00960869|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
48371642|NCT00960869|DRUG|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
48371643|NCT00663208|DRUG|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
48371644|NCT00663208|DRUG|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
48701851|NCT02359045|DRUG|D1400147|Treatment A
48701852|NCT02359045|DRUG|D14000136|Treatment B
48701853|NCT02359045|DRUG|D14000137|Treatment C
48371645|NCT02463500|OTHER|DFU|Standard care.
48701854|NCT02359045|DRUG|Epanova®|Treatment D
48701855|NCT06383247|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
48701856|NCT03260894|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
48014178|NCT06535906|OTHER|manual lymph drainage|Participants will lie in a supine position with their knees bent. Manual lymphatic drainage will begin with abdominal lymph drainage followed by central lymph stimulation. Then, bilateral axillary lymph nodes will be stimulated and the fluid in the exercised arm will be directed to the axillary lymph nodes. While the patients are in the prone position, the axillary lymph nodes will be stimulated in the same way and each manual lymphatic drainage will be performed from the back to the axillary lymph node. Each treatment session will last approximately 30 minutes
48014179|NCT06535906|OTHER|placebo manual lymph drainage|Participants will lie in a supine position with their knees bent. It will only be moved in a stroking style with hand contact from the fingers towards the armpit.
48014180|NCT03835858|OTHER|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
48014181|NCT06081166|DRUG|Obicetrapib|obicetrapib 10 mg daily
48014182|NCT06081166|DRUG|Atorvastatin Calcium|Atorvastatin 80 mg
48014183|NCT06081166|DRUG|Rosuvastatin Calcium|Rosuvastatin 40 mg
48014184|NCT00075868|DRUG|octreotide acetate|
48014185|NCT00075868|OTHER|Placebo|
48371646|NCT00045565|DRUG|arsenic trioxide|Given IV
48371647|NCT00045565|RADIATION|radiation therapy|Undergo radiation therapy
48371648|NCT01984840|DEVICE|Telemedicine|
48701857|NCT03260894|DRUG|Epacadostat|Epacadostat 100 mg administered orally twice daily.
48701858|NCT03260894|DRUG|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
48701859|NCT03260894|DRUG|Pazopanib|Pazopanib 800 mg administered orally once daily.
48701860|NCT05047029|PROCEDURE|Transjugular intrahepatic portosystemic shunt implantation|Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)
48701861|NCT05047029|DIAGNOSTIC_TEST|Magnetic resonance imaging|Multiparametric cardiac and hepatic magnetic resonance imaging
48014186|NCT04116554|DRUG|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
48014187|NCT04116554|DEVICE|0.9%saline|20 ml of 0.9%saline will be injected on each side
48170624|NCT01065207|BIOLOGICAL|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
48170625|NCT06127940|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.
48014188|NCT06562140|OTHER|No intervention - cross-sectional observational study|No intervention - cross-sectional observational study
48014189|NCT00413413|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
48170626|NCT06127940|DRUG|Temporary Stopping|Temporary stop of sotorasib during SBRT
48516171|NCT03409354|BEHAVIORAL|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
48516172|NCT03409354|BEHAVIORAL|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
48701862|NCT00518648|OTHER|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
48701863|NCT00518648|OTHER|Usual care|Usual care
48701864|NCT04694352|OTHER|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
48014190|NCT00413413|DRUG|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
48014191|NCT00413413|DRUG|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
48014192|NCT05516251|DEVICE|Transcutaneous Supraorbital Nerve Stimulator|SNS devices (DJTT-Ib, Hengyang Dajing Medical Instrument Technology Co., Ltd.) Stimulation electrodes are placed on the bilateral forehead, covering the supratrochlear and supraorbital nerves. The stimulus parameters are set as follows: pulse width 300 μsec, frequency 60 Hz, pulse duration μsec, increasing current peaked at 14 min with 16 mA. Patients receive SNS treatment daily for 20 min, no lease than 5 per week, last for 4 weeks.
48014193|NCT05516251|DRUG|Topiramate 25Mg Tab|Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
48516173|NCT03005665|DRUG|Acetazolamide|
48516174|NCT03005665|DRUG|Normal Saline|
48516175|NCT03855267|DRUG|Propofol 20 MG/ML|Pump propofol to keep bispectral index within 40 # 60
48516176|NCT03855267|DRUG|Propofol 20 mg/ml , etomidate 2 mg/ml|Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
48170627|NCT03847480|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
48170628|NCT00487526|PROCEDURE|duodenal jejunal bypass|
48170629|NCT03820570|PROCEDURE|hernia repair|inguinal hernia repair
48170630|NCT04605822|DEVICE|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
48170631|NCT04605822|DEVICE|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
48516177|NCT03955003|BEHAVIORAL|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
48516178|NCT03955003|OTHER|Attention Control|This is intended to control for time, place, and group affect.
48516179|NCT05443815|DEVICE|HaemoCer-PLUS|HaemoCer-PLUS
48014194|NCT02550964|PROCEDURE|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
48014195|NCT02056171|DRUG|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
48170632|NCT04605822|DEVICE|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
48170633|NCT04605822|OTHER|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
48170634|NCT03503383|BEHAVIORAL|Patient Health Questionnaire-9|PHQ-9 for assessing and monitoring depression severity
48170635|NCT03503383|BEHAVIORAL|Generalized Anxiety Disorder Scale (GAD-7)|to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
48170636|NCT02950688|BIOLOGICAL|Seasonal LAIV|10\^7.0 fluorescent focus units (FFU); administered by intranasal spray
48170637|NCT02950688|BIOLOGICAL|Placebo|Administered by intranasal spray
48170638|NCT02950688|BIOLOGICAL|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10\^6 TCID50; administered intranasally
48170639|NCT06045325|DIAGNOSTIC_TEST|Orbscan II|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
48170640|NCT06045325|DIAGNOSTIC_TEST|IOL Master 700|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
48170641|NCT06045325|DIAGNOSTIC_TEST|IOL Master 500|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
48170642|NCT06045325|DIAGNOSTIC_TEST|Atlas 9000|Diagnostic assessment to measure white-to-white.
48170643|NCT06045325|DIAGNOSTIC_TEST|Lenstar 900|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
48014196|NCT02056171|OTHER|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
48170644|NCT06045325|DIAGNOSTIC_TEST|Pentacam|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
48170645|NCT06045325|DIAGNOSTIC_TEST|iTrace|Diagnostic assessment to measure white-to-white and corneal thickness.
48170646|NCT06045325|DIAGNOSTIC_TEST|Argos|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
48170647|NCT06045325|DIAGNOSTIC_TEST|Manual caliper measurement|Manual diagnostic assessment to measure white-to-white.
48170648|NCT05185297|OTHER|Recreational Futsal|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
48170649|NCT04560023|OTHER|Exposition to multimedia content|Video and images watched on a tablet. Patient could decide which information want to watch.
48371649|NCT04932564|DRUG|Leflunomide tablet|"Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD."
48371650|NCT06238544|DRUG|HRS-5965 tablets|HRS-5965 tablets until the end of study treatment
48371651|NCT02226276|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
48371652|NCT02226276|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
48371653|NCT02226276|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
48371654|NCT02226276|BIOLOGICAL|trastuzumab|Given IV
48371655|NCT02226276|RADIATION|copper Cu 64-DOTA-trastuzumab|Given IV
48371656|NCT02226276|PROCEDURE|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
48014197|NCT00320281|DRUG|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
48701865|NCT04694352|OTHER|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
48170650|NCT06423677|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|The Serratus Posterior Superior Intercostal Plane Block will be performed under ultrasound guidance. During the block, a linear ultrasound probe will be placed parallel to the spine of the scapula on the surgical side and then slid medially. The block needle will be advanced under ultrasound guidance over the 3rd rib. After the needle touches the rib, it will be withdrawn by 1mm, and the block site will be confirmed by injecting sterile 0.9% NaCl. Subsequently, patients will be administered 50mg of bupivacaine and 100mg of lidocaine in a controlled manner.
48170651|NCT06423677|DEVICE|patient controlled analgesia|intravenous patient-controlled analgesia (PCA) with 4mg/ml Tramadol HCl in 100ml NaCl. There will be no basal infusion, with bolus doses of 20mg and a lockout period of 20 minutes, and a total dose limitation of 200mg over 4 hours
48170652|NCT04938765|DRUG|Magnesium sulfate|Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring
48170653|NCT04938765|DRUG|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
48170654|NCT02185365|RADIATION|Magnetic Resonance Imaging (MRI)|Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
48170655|NCT05082233|DRUG|SHR7280 tablets|Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
48170656|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 30 grams|Roasted walnuts without salt or sugar.
48170657|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 60 grams|Roasted walnuts without salt or sugar.
48170658|NCT03015870|BEHAVIORAL|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
48170659|NCT03015870|BEHAVIORAL|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
48371657|NCT02226276|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
48371658|NCT02226276|OTHER|laboratory biomarker analysis|Correlative studies
48371659|NCT05905354|BIOLOGICAL|NWRD08|Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively. Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
48701866|NCT02543177|PROCEDURE|coronary angiography|
48701867|NCT02543177|PROCEDURE|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
48701868|NCT02543177|PROCEDURE|prior kidney irrigation|
48170660|NCT06114134|DIETARY_SUPPLEMENT|Fenobet|receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)
48170661|NCT06114134|DIETARY_SUPPLEMENT|Placebo|Placebo
48170662|NCT00979745|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
48170663|NCT00979745|DRUG|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
48701869|NCT04103307|PROCEDURE|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
48701870|NCT04487535|OTHER|Cytokine level|Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
48701871|NCT04913168|OTHER|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
48701872|NCT04730869|OTHER|Standard Treatment Plus Metabolic Therapy Program|"See description under Arms."
48701873|NCT01734395|DRUG|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
48371660|NCT03841591|DRUG|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
48014198|NCT00320281|OTHER|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
48014199|NCT01501812|BEHAVIORAL|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
48014200|NCT04840758|RADIATION|Stereotactic Ablation Radiotherapy|Stereotactic ablation radiotherapy was performed sequentially on the primary and secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the tumor。
48516180|NCT00676832|DRUG|Placebo|Placebo solid capsule dosage form administered orally once daily.
48516181|NCT00676832|DRUG|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
48701874|NCT01777217|DRUG|Solifenacin succinate|IGRT with VESIcare
48701875|NCT01777217|DRUG|Placebo|IGRT with placebo
48701876|NCT00735826|DRUG|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
48701877|NCT05811520|OTHER|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
48701878|NCT05811520|OTHER|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise protocols
48701879|NCT01588340|PROCEDURE|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
48701880|NCT01588340|PROCEDURE|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
48170664|NCT00857298|BEHAVIORAL|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
48170665|NCT05089604|DRUG|Tacrolimus, Immediate Release, Oral|Twice Daily Tacrolimus
48371661|NCT03841591|DRUG|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
48701881|NCT06582693|OTHER|Refer2Quit|The Refer2Quit intervention consists of automatic connection to the adult participant's choice of any or all of four evidence-based tobacco treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), as well as motivational counseling provided by the study team. Supportive and motivational text messaging is also included in the intervention to connect or reconnect adult participants to treatments as needed. Text messaging and support would also focus on supporting appropriate use of NRT and/or varenicline if indicated.
48371662|NCT03841591|OTHER|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
48371663|NCT04525066|DRUG|Hyaluronic acid|Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
48371664|NCT04525066|OTHER|No Hyaluronic Acid Injection Injection|Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
48371665|NCT03615742|OTHER|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
48170666|NCT05089604|DRUG|Tacrolimus Extended Release Oral Tablet|Once Daily Tacrolimus
48371666|NCT03615742|DRUG|Budesonide|1.6mg of budesonide from a Turbuhaler.
48371667|NCT03615742|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control.
48516182|NCT05636267|DRUG|AK119|AK119 IV every 3 weeks.
48701882|NCT05475665|DRUG|Irbesartan/Amlodipine|Irbesartan/Amlodipine once daily for 8 weeks
48701883|NCT05475665|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
48701884|NCT03300271|OTHER|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
48701885|NCT03300271|OTHER|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
48170667|NCT04658550|OTHER|Remote Behaviour Modification Program|The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).
48170668|NCT04658550|OTHER|In Person Behaviour Modification Program|The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
48170669|NCT01009138|BEHAVIORAL|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~* Problem Analysis and Definition~* Problem Solving Intervention~* Cognitive Restructuring~* Activation of personal and social Resources~* Goal Definition and Agreement"
48170670|NCT01009138|BEHAVIORAL|Standard Diabetes Education|"Standard Diabetes Education Lesson including~* Health Care and specific Topics (e. g. Blood Pressure)~* Social Aspects of Living with Diabetes~* Diabetes Complications~* Sports, Activities and Exercise~* Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~* Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
48170671|NCT05465928|DEVICE|Active rTMS|rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.
48170672|NCT05465928|DEVICE|Sham rTMS|The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
48371668|NCT03615742|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
48371669|NCT05721482|BEHAVIORAL|Caregiver Training|"A trained MIM provider and dietitian will deliver the MIM DASH group intervention in eight weekly 1-hour sessions via telehealth. Participants will receive session materials so they can follow along. Each MIM session consists of material related to mindfulness-the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Group interaction centers on sharing ideas toward effective practice and practical daily challenges to being mindful. Each class begins with a prompt for participant contemplation during the next hour that reference a unique weekly theme which will be reiterated in the session materials.~The DASH portion, led by the Registered Dietitian, focuses on education to increase vegetables, fruits, whole grains and decrease intakes of fat and sodium, sugar sweetened beverages and sweets. Education includes adapting traditional Soul food dishes to meet the DASH dietary guidelines."
48371670|NCT04673552|PROCEDURE|laparotomy|Any open procedure such as laparotomy or lumbotomy for acute necrotizing pancreatitis will be evaluated, with assessment of results, complications and deaths
48371671|NCT05083975|DEVICE|Buzzy System|Vibrating Device
48371672|NCT05083975|DRUG|Topical anesthetic|20% benzocaine gel (Opahl Topical Gel)
48371673|NCT05083975|DRUG|1.8 ml of 4% articaine hydrochloride with epinephrine 1:100,000|Local dental anesthetic agent
48371674|NCT01770080|DRUG|Euminz®|3 to 5 time topical use of study drug.
48371675|NCT01770080|DRUG|Placebo|3 to 5 time topical use of study drug.
48371676|NCT04252196|DEVICE|usability evaluation of medical device|participants interact with medical device and rate it for usability
48701886|NCT03300271|OTHER|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
48701887|NCT04092894|DRUG|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
48701888|NCT04092894|DRUG|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
48701889|NCT01689012|BEHAVIORAL|Facial Exercise|
48014201|NCT04840758|DRUG|Sintilimab|Sintilimab was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles
48701890|NCT02671903|DEVICE|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
48701891|NCT04728477|DEVICE|OPti BP measurements|measurement of blood pressure with the new smartphone App ( OPTIBP)
48701892|NCT02200003|BEHAVIORAL|attention bias modification for anxiety|
48701893|NCT01380535|DRUG|ECP Methoxsalen|Methoxsalen delivered by ECP
48701894|NCT01380535|DRUG|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
48701895|NCT05849259|OTHER|Dementia Care Quality at Home|Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) seven modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
48701896|NCT02227953|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48701897|NCT02227953|DEVICE|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48701898|NCT06606197|OTHER|Having sex with other men|Having sex with other men
48701899|NCT05058690|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|"* Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement."
48701900|NCT06044935|OTHER|Standard Diet|Consisting of 15% protein, 35% fat, and 50% carbohydrate, matching the macronutrient composition of a typical American diet
48701901|NCT06044935|OTHER|Ketogenic Diet|Consisting of a macronutrient composition of 15% protein, 80% fat, and 5% carbohydrate
48701902|NCT06044935|DIETARY_SUPPLEMENT|Placebo|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
48701903|NCT06044935|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Subjects without MODY2 will take either placebo or NR (1 g BID, 2 g per day total) supplements for 7 days during this Run-in phase
48701904|NCT03894631|PROCEDURE|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
48701905|NCT03894631|PROCEDURE|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
48701906|NCT05921682|OTHER|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
48701907|NCT05979220|DRUG|Dalpiciclib combined with Letrozole|A multicenter, single arm, prospective Phase II clinical study
48170673|NCT06076824|DRUG|Methylprednisolone|The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
48371677|NCT03095365|OTHER|Dry needling|Insertion of solid filament needles in the muscle
48371678|NCT03095365|OTHER|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
48170674|NCT06076824|OTHER|Placebo|Saline solution
48371679|NCT03095365|OTHER|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
48516183|NCT05636267|DRUG|AK112|AK112 IV every 3 weeks.
48516184|NCT05636267|DRUG|Pemetrexed|Pemetrexed IV every 3 weeks.
48516185|NCT05636267|DRUG|Carboplatin|Carboplatin IV every 3 weeks.
48516186|NCT06490978|RADIATION|CT Brain|Patient needs follow up ct brain , cbc , CRP
48701908|NCT00266214|DRUG|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
48701909|NCT00303771|DRUG|fluorouracil|
48701910|NCT00303771|DRUG|irinotecan hydrochloride|
48701911|NCT00303771|DRUG|leucovorin calcium|
48701912|NCT06607172|DEVICE|oral irrigator|water flosser device
48701913|NCT06607172|DEVICE|oral irrigator|water flosser and 0.075% CPC
48701914|NCT06607172|DRUG|Cetylpyridinium Chloride (CPC)|Cetylpyridinium 0.075%
48701915|NCT04796103|PROCEDURE|Dextrose Prolotherapy|In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
48701916|NCT04796103|PROCEDURE|Serum Physiological Group (placebo control group)|In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
48014202|NCT03798431|BEHAVIORAL|M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
48014203|NCT04173338|DRUG|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
48170675|NCT06028217|OTHER|prognosis status|observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
48170676|NCT01417702|DEVICE|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
48170677|NCT04397146|DIETARY_SUPPLEMENT|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
48170678|NCT03776162|PROCEDURE|ACL Reconstruction (Bone Patellar Tendon Bone Graft)|Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
48170679|NCT03776162|DEVICE|Bridge Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
48170680|NCT05857514|DRUG|Rectal Indomethacin|Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
48371680|NCT06011668|DEVICE|video game playing, kaleidoscope and virtual reality glasses|This thesis study was conducted with randomized controlled methods for control in order to analyze the effect of drawing attention to different directions during intramuscular use in countries to what extent the methods of drawing attention to pain and anxiety.
48371681|NCT04899570|DRUG|Zanubrutinib|160mg Bid, oral, d1-21 in a 21-day cycle for 8 cycles.
48371682|NCT04899570|DRUG|Rituximab|Rituximab 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
48371683|NCT04899570|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
48371684|NCT04899570|DRUG|Epirubicin|Epirubicin 70mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be prescribed as protocol
48371685|NCT04899570|DRUG|Vindesine|Vindesine 4mg intravenous infusion d1, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
48371686|NCT04899570|DRUG|Prednisone|Prednisone 60mg/m2 orally d1-5, every 21 days for 1 cycle. 8 cycles will be rescribed as protocol
48371687|NCT02337816|PROCEDURE|laparoscopic surgery, obtainment of biological samples|
48371688|NCT01061073|DRUG|Omexel|
48371689|NCT01061073|DRUG|spasfon|
48371690|NCT01979640|PROCEDURE|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
48371691|NCT01979640|PROCEDURE|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
48014204|NCT04173338|DRUG|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
48170681|NCT05857514|PROCEDURE|Prophylactic Pancreatic duct stenting|Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
48170682|NCT02174614|BEHAVIORAL|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
48170683|NCT02174614|BEHAVIORAL|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
48170684|NCT02174614|BEHAVIORAL|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
48170685|NCT01476124|DRUG|morphine Placebo|Morphine Placebo
48170686|NCT01476124|DRUG|GEn 600 mg|Gabapentin enacarbil 600 mg
48371692|NCT01979640|PROCEDURE|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
48371693|NCT00262457|DEVICE|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
48371694|NCT03391063|OTHER|polyamide|metal reinforced polyamide denture base material
48371695|NCT03391063|OTHER|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
48371696|NCT05991401|DRUG|DA-8010 5mg|\[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
48371697|NCT05991401|DRUG|Clarithromycin 500mg|\[Period 2\] DA-8010 5mg, Clarithromycin 500mg
48371698|NCT05991401|DRUG|Rifampicin 600mg|\[Period 3\] DA-8010 5mg, Rifampicin 600mg
48371699|NCT04217941|PROCEDURE|Health education with practical demonstration of nasal ointment|Health education with practical demonstration of medicine was compared to health education without practical demonstration
48371700|NCT04217941|DRUG|Health Education and practical demonstration of Nasal spray and intranasal ointment|We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
48014205|NCT04816006|BEHAVIORAL|Aerobic Exercise Training|Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
48014206|NCT04816006|OTHER|Health Education (Active comparator)|Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
48014207|NCT02538497|BEHAVIORAL|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
48014208|NCT02538497|BEHAVIORAL|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
48014209|NCT05756647|DEVICE|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
48014210|NCT05756647|COMBINATION_PRODUCT|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
48170687|NCT01476124|DRUG|Morphine|morphine extended release 60 mg
48170688|NCT01476124|DRUG|GEn Placebo|Gabapentin enacarbil placebo
48170689|NCT05768269|OTHER|No Intervention|As this is a non-interventional rollover, long-term safety follow-up study, no intervention will be administered.
48170690|NCT06123364|DRUG|mirabegron 50 mg daily|Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
48170691|NCT06123364|DEVICE|Extracorporeal magnetic innervation (active treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
48170692|NCT06123364|DEVICE|Extracorporeal magnetic innervation (sham treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
48170693|NCT00177684|DRUG|Amphotericin B|
48170694|NCT01100918|DEVICE|BiV ICD|Biventricular ICD
48170695|NCT01100918|DEVICE|ICD|Implantable Defibrillator
48170696|NCT05917548|DEVICE|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
48170697|NCT05917548|BEHAVIORAL|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
48170698|NCT01510002|PROCEDURE|Total thyroidectomy|Extracapsular total thyroidectomy
48170699|NCT01510002|PROCEDURE|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
48170700|NCT02136342|DRUG|chlorogenic acid|
48170701|NCT00210678|BEHAVIORAL|No intervention|No treatment is given to the patients as this is an observational study.
48170702|NCT04520581|OTHER|"group O"|"Endotracheal tube was made O shape by assistants."
48170703|NCT03592823|DRUG|Hydroxychloroquine Sulfate 200 Mg Tablet|200 mg, bidpo.
48371701|NCT02924467|BEHAVIORAL|1 Notice|1 Reminder notification via autodialer
48170704|NCT03937037|PROCEDURE|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
48170705|NCT06541340|PROCEDURE|Modified strategy|Modified preoperative biliary drainage strategy with prealbumin as the main indicator
48170706|NCT06541340|PROCEDURE|Traditional strategy|Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator
48170707|NCT01262118|DRUG|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
48170708|NCT02624869|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
48170709|NCT05226247|PROCEDURE|Spontaneous breathing trial|To perform cardiac and lung echography before and during a spontaneous breathing trial
48371702|NCT02924467|BEHAVIORAL|2 Notices|2 Reminder notifications via autodialer
48371703|NCT02924467|BEHAVIORAL|3 Notices|3 Reminder notifications via autodialer
48516187|NCT04757597|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.
48516188|NCT04077554|GENETIC|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
48701917|NCT04469920|DRUG|Saroglitazar Magnesium 2 mg|1 tablet, single dose at Day 1
48701918|NCT04469920|DRUG|Saroglitazar Magnesium 4 mg|1 tablet, single dose at Day 1
48701919|NCT06606964|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
48701920|NCT06606964|OTHER|Isokinetic Strength|The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
48701921|NCT01457014|DEVICE|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
48014211|NCT02968199|BEHAVIORAL|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
48014212|NCT00507039|PROCEDURE|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
48014213|NCT02804503|BEHAVIORAL|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
48014214|NCT02804503|BEHAVIORAL|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
48701922|NCT01457014|DEVICE|Continuous positive airway pressure|continuous positive airway pressure
48701923|NCT01457014|DEVICE|servo ventilation manual|servo ventilation titrated in manual mode
48014215|NCT02804503|BEHAVIORAL|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
48014216|NCT05917873|DIETARY_SUPPLEMENT|LaKe Ester|Lactate and ketone body ester (one equivalent of S-lactate and one equivalent of 1,3-butanediol / D-β-hydroxybutyrate)
48014217|NCT05917873|DIETARY_SUPPLEMENT|Placebo|Taste and appearance matched noncaloric placebo
48014218|NCT04319315|OTHER|survey|online survey
48014219|NCT04186910|BEHAVIORAL|Control group|The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.
48014220|NCT04186910|BEHAVIORAL|Feedback group|The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
48014221|NCT01455116|PROCEDURE|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
48014222|NCT06086184|BEHAVIORAL|ACT group therapy|"Participation in four sessions of the inpatient Compass Group and eight sessions of the inpatient Here-and-Now Group. This should be completed within four weeks and may be completed within six weeks in exceptional cases. The groups are designed as a semi-open group with one therapist and one cotherapist each and are integrated into the existing therapy plan."
48014223|NCT00382733|DRUG|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
48014224|NCT01882127|DRUG|All-Trans Retinoid Acid(ATRA)|patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
48701924|NCT05055323|DRUG|Pyrvinium Pamoate|Given PO
48701925|NCT04971538|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
48014225|NCT01882127|DRUG|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
48014226|NCT05879146|DRUG|Nirogacestat|Given by PO
48170710|NCT02564718|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
48170711|NCT04684771|DIETARY_SUPPLEMENT|MYOSTIM®|Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
48170712|NCT04684771|DIETARY_SUPPLEMENT|PLACEBO|Bars with no active ingredient and the same flavor (chocolate and red fruits).
48170713|NCT05264272|OTHER|Prospective serological assays|"1. Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~2. BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
48516189|NCT01140165|OTHER|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
48701926|NCT04049266|DRUG|KSI-301|Intravitreal Injection
48701927|NCT04049266|DRUG|Aflibercept|Intravitreal Injection
48701928|NCT04049266|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
48701929|NCT04599959|DIAGNOSTIC_TEST|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
48701930|NCT02028117|BIOLOGICAL|Enadenotucirev|Oncolytic Virus
48170714|NCT05264272|OTHER|Retrospective serological assays|"1. Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~2. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
48170715|NCT04266002|OTHER|Validation of Charter score for the CNS diffusion of antiretroviral drugs|IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
48170716|NCT05338541|DRUG|Tucidinostat and etoposide|Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,
48170717|NCT00304668|DRUG|dapivirine (TMC120) vaginal gel|
48170718|NCT02751801|OTHER|no intervention|
48371704|NCT04651660|DEVICE|Neuro Cochlear Implant System|"Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way."
48701931|NCT01359241|PROCEDURE|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
48371705|NCT01215968|BIOLOGICAL|LY2189265|1.5 mg administered subcutaneously
48701932|NCT01359241|DRUG|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
48701933|NCT00907530|DRUG|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
48701934|NCT00907530|DRUG|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
48701935|NCT06606821|DRUG|Tirzepatide|Investigational drug will be administered as a sc. injection once-weekly.
48701936|NCT06606821|DRUG|Placebo|Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
48170719|NCT00510263|DRUG|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
48170720|NCT00510263|DRUG|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
48371706|NCT01215968|DRUG|Placebo|Administered subcutaneously
48701937|NCT05705375|OTHER|Waterpipe size|Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
48701938|NCT06511700|PROCEDURE|It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique|Internationally, some experiences demonstrate that the administration of intravitreal injections, especially by nurses trained in aseptic techniques, is feasible without compromising patient safety. Although there is already some experience in Spain, it is a new procedure within the nursing field of the Ophthalmology service for which no results have been reported.
48701939|NCT02750345|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
48701940|NCT02750345|DRUG|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
48170721|NCT00510263|DRUG|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
48170722|NCT00510263|DRUG|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
48170723|NCT03442140|OTHER|Harmonica playing|Patients will play the harmonica for up to 6 months
48170724|NCT01919346|DRUG|Eculizumab|
48170725|NCT01919346|DRUG|Normal Saline|
48371707|NCT00471237|DRUG|Ronacaleret|100mg, 200mg, 300mg, 400mg
48371708|NCT00471237|DRUG|Teriparatide|PTH (1-34)
48371709|NCT00471237|DRUG|Alendronate|Bisphosphonate
48701941|NCT02750345|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
48701942|NCT00580580|DRUG|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
48701943|NCT00580580|DRUG|Definity|intravenous injection at 0.05-0.20 mL
48170726|NCT03041701|DRUG|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
48701944|NCT00580580|DRUG|PESDA|intravenous injections dosage 0.05-0.20 mL
48701945|NCT01097642|DRUG|Cetuximab|Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.
48701946|NCT01097642|DRUG|Ixabepilone|Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
48701947|NCT00563069|DRUG|Midazolam|
48170727|NCT03041701|DRUG|Dasatinib|Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
48371710|NCT01855594|DRUG|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
48701948|NCT06441071|PROCEDURE|position|Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.
48701949|NCT05426031|DRUG|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
48701950|NCT05426031|DRUG|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
48701951|NCT02153424|DRUG|Apixaban|
48170728|NCT03041701|DRUG|Ganitumab|Once every 2 weeks beginning on day 0.
48170729|NCT04278495|DRUG|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
48170730|NCT04278495|DRUG|Placebo|Placebo
48170731|NCT00056329|DRUG|Vitamin E|1,000 international units twice daily for three years
48170732|NCT00056329|DRUG|multivitamin|once daily for three years
48170733|NCT00056329|DRUG|Placebo|Placebo twice daily for three years
48170734|NCT02625753|DRUG|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
48170735|NCT02625753|DRUG|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
48371711|NCT01855594|DRUG|Placebo|placebo tablet, 6 week course of oral administration
48371712|NCT01162109|DIETARY_SUPPLEMENT|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
48371713|NCT05151809|OTHER|Clinical information|The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
48371714|NCT03540602|DIETARY_SUPPLEMENT|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
48371715|NCT03540602|OTHER|Placebo Oral Capsule [CEBOCAP]|Rice flour
48170736|NCT02625753|DRUG|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
48371716|NCT01241591|DRUG|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
48371717|NCT01241591|DRUG|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
48371718|NCT01241591|BIOLOGICAL|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
48371719|NCT01241591|OTHER|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
48516190|NCT06158919|DRUG|Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine|"Combined treatment period: A total of 6 cycles of combined treatment Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w SOX : Oxaliplatin 130mg/m2 iv.gtt d1, Teysuno 40mg/m2 p.o.b.i.d. d1\~ 14q3w. Or XELOX regimen: oxaliplatin 130mg/m2 iv.gtt d1 Capecitabine 1000mg/m2 p.o. b.i.d. d1\~ 14q3w.~Maintenance treatment period:~Fruquintinib: 4 mg/d, qd po, d1-14, q3w. Nivolumab: 360mg iv.gtt d1, q3w or Sintilimab: 200mg iv.gtt d1, q3w Teysuno 40mg/m2 p.o.b.i.d. d1\~14 q3w or Capecitabine 1000mg/m2 p.o.b.i.d. d1\~14 q3w.~Maintenance of treatment until disease progression or toxicity becomes intolerable."
48701952|NCT04210362|BEHAVIORAL|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
48701953|NCT03905031|DEVICE|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD\>0.2 is abnormal and suggestive of intracranial hematoma.
48701954|NCT00845039|BIOLOGICAL|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
48701955|NCT00845039|DRUG|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
48701956|NCT00845039|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
48701957|NCT06607211|DIAGNOSTIC_TEST|Transcranial Color-Coded Doppler (TCCD)|As part of the clinical practice, the examination will be performed with ultrasound machines that have presets for TCCD, using a low-frequency sector probe (2-25 MHz) with a transtemporal approach to obtain a scan through the midbrain plane. Through the use of Color Doppler and Pulsed-Wave Doppler, a spectral doppler waveform of the M1 segment of the middle cerebral artery velocity is obtained bilaterally. If hypoperfusion signs are discovered, TCCD will be repeated to assess the effects of each intervention.
48701958|NCT01310543|BEHAVIORAL|Teens and Toddlers|The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
48701959|NCT02300558|DRUG|Eleclazine|Tablets administered orally
48701960|NCT02300558|DRUG|Eleclazine placebo|Tablets administered orally
48170737|NCT01246050|OTHER|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
48701961|NCT04872933|OTHER|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
48701962|NCT04472117|OTHER|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
48170738|NCT01246050|OTHER|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
48170739|NCT01767662|PROCEDURE|manipulation|home programme
48170740|NCT01767662|PROCEDURE|No intervention|observation
48170741|NCT01028755|DRUG|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
48170742|NCT05706636|DRUG|oral mini pulse|5mg / week oral dexamethasone
48170743|NCT05706636|DRUG|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
48170744|NCT05706636|DEVICE|targeted phototherapy|twice weekly targeted excimer light sessions
48170745|NCT01044901|PROCEDURE|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
48170746|NCT00658840|DRUG|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
48170747|NCT00658840|RADIATION|Localization, simulation and immobilization|"Radiation dose and planning~1. Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~2. Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~3. The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
48170748|NCT05910697|OTHER|MyProstateScore 2.0 Results|Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
48170749|NCT01984671|BEHAVIORAL|Mobile Pain Coping Skills Training|
48170750|NCT04112641|DRUG|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
48170751|NCT04112641|DRUG|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
48170752|NCT02205047|DRUG|Cisplatin|
48170753|NCT02205047|DRUG|5-fluorouracil or Capecitabine|
48170754|NCT02205047|DRUG|Trastuzumab|
48170755|NCT02205047|DRUG|Pertuzumab|
48170756|NCT02205047|PROCEDURE|gastrectomy|D2 gastrectomy
48170757|NCT06504212|OTHER||
48170758|NCT03115671|DIETARY_SUPPLEMENT|Vayarin|Vayarin capsule
48170759|NCT06126510|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)|VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle
48170760|NCT04158973|OTHER|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
48170761|NCT04158973|OTHER|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
48170762|NCT05955547|OTHER|Prognosis Scoring|To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status
48170763|NCT06105762|OTHER|Ketogenic Diet|The ketogenic diet intervention, administered as a Modified Atkins Diet, involves a significantly reduced daily carbohydrate intake, typically less than 20 grams of net carbs. This approach primarily relies on higher fat consumption to induce ketosis, a metabolic state characterized by elevated ketone body production, serving as an alternative brain fuel source.
48170764|NCT00997932|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
48170765|NCT00641836|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
48170766|NCT00646711|DRUG|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
48170767|NCT00646711|DRUG|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
48170768|NCT01572298|DEVICE|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
48516191|NCT05654311|OTHER|Nasal surgery|Nasal surgery under general anesthesia using inhalational agent (sevoflurane)
48516192|NCT03481049|BEHAVIORAL|Usual CM|Behavioral reinforcement for alcohol abstinence
48701963|NCT04472117|OTHER|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
48701964|NCT00654836|BIOLOGICAL|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
48170769|NCT01572298|DEVICE|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
48170770|NCT00087477|DRUG|Pivanex|
48170771|NCT04360083|OTHER|Collected data from Rhône RéPPOP database|BMI Z-scores at the start and the end of RéPPOP care programs.
48170772|NCT04360083|OTHER|telephonic questionnaire|Collected data though the telephonic questionnaire : current declared BMI Z-score.
48170773|NCT01249677|DRUG|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
48170774|NCT05432700|OTHER|LactApp|"LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food."
48170775|NCT02725008|DRUG|Dexamethasone|
48170776|NCT02725008|DRUG|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
48170777|NCT00675038|PROCEDURE|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2\* MRI
48170778|NCT05802914|DEVICE|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
48170779|NCT05957445|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
48170780|NCT05957445|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
48170781|NCT01359722|DRUG|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
48170782|NCT01359722|DRUG|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
48170783|NCT04164498|OTHER|music|exposure to music to investigate its effects on reducing noise adverse effects
48170784|NCT02975297|DRUG|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
48170785|NCT02975297|DRUG|NRT|Nicotine Patch (21mg) / 24 hours.
48170786|NCT02975297|BEHAVIORAL|Counseling|Brief individual behavioral smoking cessation counseling.
48170787|NCT02975297|DRUG|Placebo|Normal saline.
48170788|NCT00574483|DRUG|quinacrine|100 mg day
48170789|NCT04335747|OTHER|COVID-19 infection|Hospitalisation due to a confirmed COVID-19 infection
48170790|NCT03333083|DRUG|Raltegravir|Raltegravir (1200 mg once a day)
48170791|NCT03333083|DRUG|Lamivudine|Lamivudine (300 mg once a day)
48701965|NCT00654836|DRUG|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
48701966|NCT00654836|DRUG|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
48701967|NCT04758884|OTHER|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
48701968|NCT02047591|OTHER|Relaxing-touch method|
48701969|NCT06607653|DEVICE|Olfactory training|Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
48701970|NCT06446856|DEVICE|VR application|"The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min."
48014227|NCT05660616|DRUG|Gemcitabine|"The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs."
48014228|NCT05660616|OTHER|supportive care|supportive care
48014229|NCT06243497|PROCEDURE|Ultrasound CycloPlasty|All procedures were performed using the EyeOP1 device . The coupling cone was placed and adjusted on the centre of the patient's eye by visualising an equal white scleral ring surrounding the cornea. The coupling cone was kept in place via vacuum suction activated using a foot pedal and was then filled with a balanced salt solution to allow ultrasound transmission. The transducers were automatically activated at a frequency of 21 MHz and an acoustic power of 2.45 W, with an 8-s duration for each sector and a 20-s pause between each treatment to allow complete evacuation of heat.
48014230|NCT03873285|GENETIC|Genetic diagnostic by mendeliome or genome|For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
48170792|NCT06176898|DEVICE|Neurostimulating device|"A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~* Six minute walking test (6MWT)~* Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires"
48701971|NCT01611688|DRUG|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
48014231|NCT03193294|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
48170793|NCT06448936|OTHER|Patient-reported outcome measures (PROMs)|Administration of questionnaires investigating the impact of facial difficult-to-treat basal cell carcinoma treated by surgery on patient's quality of life over the course of one year. The questionnaires will be submitted at baseline (i.e., before surgery) and at 3-months follow up.
48170794|NCT00356564|BIOLOGICAL|hepatitis B vaccine|
48170795|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
48516193|NCT03481049|BEHAVIORAL|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
48516194|NCT03481049|BEHAVIORAL|Shaping CM|Behavioral reinforcement for alcohol abstinence
48701972|NCT01611688|DRUG|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
48701973|NCT01611688|DRUG|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
48701974|NCT01655121|DIETARY_SUPPLEMENT|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
48170796|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
48170797|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
48170798|NCT01180790|DRUG|Placebo|Powder in capsule once daily
48701975|NCT04976673|DRUG|Triamcinolone Acetonide|The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
48701976|NCT04976673|PROCEDURE|Photodynamic Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
48701977|NCT03233334|BEHAVIORAL|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
48701978|NCT01796119|PROCEDURE|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
48701979|NCT01796119|PROCEDURE|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
48701980|NCT04916366|OTHER|Kinesio taping|Kinesio taping in a bandage to treat musculoskeletal pain.
48701981|NCT04916366|OTHER|Conventional bandage|It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
48014232|NCT04106791|DEVICE|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
48701982|NCT04883294|DIAGNOSTIC_TEST|Electronic Nose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
48701983|NCT03664791|PROCEDURE|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
48014233|NCT00440271|DRUG|tipranavir|
48014234|NCT00440271|DRUG|ritonavir|
48170799|NCT01180790|DRUG|Pegylated Interferon alpha-2a|180 micrograms (ug) once a week by subcutaneous injection
48516195|NCT01662687|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
48516196|NCT01662687|DRUG|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4."
48701984|NCT05202574|DRUG|Intravenous drug|intravenous drug injection
48014235|NCT00440271|DRUG|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
48014236|NCT03113591|PROCEDURE|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
48014237|NCT03113591|PROCEDURE|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
48014238|NCT06623721|DEVICE|Movement-evoked transcutaneous auricular Vagus nerve stimulation|"Intervention requires wearing of an inertial measurement unit (IMU) sensor on an affected upper limb together with a transcutaneous auricular Vagus nerve (taVNS) stimulator on an outer ear on the contralateral side.~Intervention involves IMU measurement-evoked initiation of taVNS during conventional neurorehabilitation therapy that is defined by the patient\&amp;#39;s doctor and therapist. Typically this is around 60 minutes/day of 50-300 repetitive upper limb movements targeting specific deficits such as flexor synergies and/or wrist, triceps or shoulder activation.~taVNS intensity is calibrated at the start of every neurorehabilitation session by the patient to the maximal comfortable level with instructions to avoid pain or any serious discomfort. Patient is always accompanied by a therapist trained in the use of taVNS and the device is easy to immediately remove should any discomfort occur."
48170800|NCT01180790|DRUG|Ribavirin|400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
48170801|NCT02725398|DRUG|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
48170802|NCT02725398|DRUG|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
48170803|NCT02725398|DRUG|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
48170804|NCT03739671|DIETARY_SUPPLEMENT|Vitamin D|Group will receive 5000 units of vitamin D daily
48170805|NCT03739671|DIETARY_SUPPLEMENT|No Vitamin D|No vitamin D supplementation
48170806|NCT02148653|OTHER|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
48170807|NCT02148653|OTHER|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
48170808|NCT01013064|DRUG|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
48371720|NCT00936052|OTHER|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
48701985|NCT02453945|DEVICE|Adjustable Support Bra|A ClearPoint Medical support bra
48701986|NCT02928302|OTHER|TVU CL screening|Transvaginal ultrasound cervical length screening
48701987|NCT04147897|DEVICE|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
48371721|NCT02919709|BIOLOGICAL|blood taking|
48371722|NCT06037486|DIAGNOSTIC_TEST|Glucometer Test|measurement of the blood glucose concentration using the blood glucose monitor for personal use
48516197|NCT02962518|DEVICE|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
48516198|NCT02962518|PROCEDURE|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
48701988|NCT03886337|DEVICE|Germicidal lighting|Germicidal ambient lighting
48701989|NCT02509052|OTHER|Laboratory Biomarker Analysis|Correlative studies
48701990|NCT02509052|DRUG|Leflunomide|Given PO
48701991|NCT02509052|OTHER|Pharmacological Study|Correlative studies
48701992|NCT04804631|DEVICE|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
48701993|NCT01803191|DRUG|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
48701994|NCT01803191|DRUG|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
48014239|NCT01201252|PROCEDURE|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
48371723|NCT00873496|DRUG|Hydroxychloroquine|
48516199|NCT02962518|DRUG|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
48516200|NCT06582862|OTHER|Exercise|Subjects will do aerobic and anaerobic exercise
48701995|NCT04673370|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
48701996|NCT04673370|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
48371724|NCT00477542|DRUG|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"
48371725|NCT03135730|GENETIC|ROHHAD|Suspected and Confirmed ROHHAD cases
48371726|NCT05596695|OTHER|Minimizing blood pressure variability|Intraoperative blood pressure management will be performed to maintain a systolic blood pressure of 120 ±5mmHg using a continuous infusion of a vasopressor starting at induction of anaesthesia.
48371727|NCT01226992|DRUG|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
48516201|NCT05250297|OTHER|no intervention|standard prenatal care
48516202|NCT05410964|DEVICE|VIO System|To investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health
48516203|NCT06259097|DRUG|Misoprostol|25 mcg vaginally every 6 hours
48516204|NCT06259097|DRUG|Pitocin|3-6 mL intravenously every hour
48701997|NCT04098432|DRUG|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
48701998|NCT04098432|RADIATION|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
48701999|NCT06150534|OTHER|No Intervention|This is a non-interventional study.
48702000|NCT00134992|DRUG|Prednisolone acetate|
48702001|NCT00995397|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
48702002|NCT00995397|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
48702003|NCT06604988|BEHAVIORAL|Video-feedback intervention to promote positive parenting|"Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours."
48702004|NCT06495723|DRUG|LIS1|The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
48702005|NCT02519894|BEHAVIORAL|Dietary Scanning Calculator|
48702006|NCT05513872|DRUG|Nicotine Replacement Therapy (NRT) Sampling|Participants randomized to this condition will receive a 4-week nicotine replacement therapy (NRT) starter kit containing both nicotine lozenges and patches in their original packaging.
48702007|NCT05513872|BEHAVIORAL|Practice Quitting (PQ) Counseling|Practice Quitting (PQ) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. The goals of the counseling sessions are 1) to gradually expose patients to nicotine withdrawal symptoms through practice quitting, and 2) to reduce fear and avoidance of the physical sensations associated with nicotine withdrawal.
48170809|NCT06545110|DRUG|Baricitinib Oral Tablet|Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
48170810|NCT04520841|DEVICE|Prevena TM|A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.
48170811|NCT04520841|DEVICE|Dry dressing|A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
48170812|NCT01396200|DRUG|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
48170813|NCT01396200|DRUG|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
48170814|NCT00088452|DRUG|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
48170815|NCT00088452|DRUG|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
48170816|NCT00088452|DRUG|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
48170817|NCT01561456|DRUG|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
48170818|NCT01561456|DRUG|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
48170819|NCT04605198|BEHAVIORAL|Modified Mindfulness-based Stress Reduction|Participants will be trained in mindfulness meditation and the applicability of mindfulness practices to daily life. During MBSR programming, teachers will lecture about key topics in mindfulness and lead class discussions. Participants are given homework assignments, such as listening to guided meditations. Participants are given opportunities to ask the instructor questions and to share their experiences with each other. Each session focuses on a different key topic. Topics are: Session 1: Introduction; Session 2: Understanding Perceptions; Session 3: Hatha Yoga, Sitting Meditation, Walking Meditation; Session 4: Concentration \& Awareness; Session 5: Unhealthy Patterns \&Getting Unstuck; Session 6: Transformational Coping Strategies; Session 7: Mini-retreat; Session 8: Maintaining Discipline \& Flexibility; Session 9: Course Review.
48170820|NCT04605198|BEHAVIORAL|Health Promotion Wellness Classes|Sessions will cover the following general wellness topics: Session 1; Introduction; Session 2: Envisioning Health Through Art; Session 3: Chronic Disease 1 (Heart Health); Session 4: Chronic Disease II (Diabetes); Session 5: Nutrition and Hydration; Session 6: Infectious Disease Prevention; Session 7: Skin Care; Session 8: Oral Health; Session 9: Promoting Social Integration \& Course Graduation.
48170821|NCT01606891|BEHAVIORAL|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
48170822|NCT01053897|BIOLOGICAL|GBT009|Intradermal Injection following surgery
48170823|NCT01053897|BIOLOGICAL|Placebo|Intradermal Injection following surgery
48170824|NCT00709540|BIOLOGICAL|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
48170825|NCT02720185|DRUG|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
48170826|NCT02720185|PROCEDURE|Conventional Surgery|Undergo surgery
48170827|NCT02720185|OTHER|Laboratory Biomarker Analysis|Correlative studies
48170828|NCT05593510|BEHAVIORAL|No prep ready-to-eat meals|"Pantry clients will select no prep ready-to-eat meals for up to 14-days' worth of meals for themselves and 2-members of their household using an online food selection platform. The food retailer supplying the meals produces over 70 meals. We have elected to study 14-days of meals to offer clients variety and determine which flavors are most desirable to clients. After ordering, meals will be retrieved from a refrigeration unit, boxed by pantry staff, and brought to the participant to take home. An example dinner is Teriyaki Chicken with Roasted Potatoes and Broccoli, and an example breakfast is Omelet with Peppers and Zucchini. Meals can be stored in a refrigerator or freezer and eaten immediately or after reheating depending on the meal and consumer preference."
48170829|NCT05593510|BEHAVIORAL|Ingredient bundles (e.g. meal kits)|Ingredient bundles will group individual meal ingredients (e.g., chicken, teriyaki, broccoli, potatoes) in a bag or box and pair those healthy food items with a recipe that instructs the client on how to make a healthier meal. Similar to the no prep ready-to-eat meal initiative, clients will select ingredient bundles for themselves and 2-members of their household using the food pantry online food selection platform. The ingredient bundles will closely replicate the no prep ready-to-eat meals.
48170830|NCT05992636|PROCEDURE|pneumoperitoneum insufflation (flow) rate|"Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)"
48170831|NCT05052723|DRUG|Cabozantinib|Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
48371728|NCT01226992|BIOLOGICAL|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
48371729|NCT02612766|DIETARY_SUPPLEMENT|Pure, uncontaminated oats|
48371730|NCT00000658|DRUG|Bleomycin sulfate|
48702008|NCT05513872|BEHAVIORAL|Motivational Interviewing (MI) Counseling|Motivational Interviewing (MI) counseling will consist of four weekly treatment sessions, with an initial 45-minute session followed by three 20-minute sessions. Counseling content will incorporate MI-consistent principles, such as open questions, simple and complex reflections, and affirmations to facilitate participant statements in favor of behavior change. Discussion will focus on the motivational topics outlined in the USPHS guidelines for smokers not ready to quit: 1) relevance of smoking cessation or reduction to the individual, 2) risks of continued heavy smoking, 3) rewards of quitting and reduction, and 4) roadblocks to success, on a 5) repeated basis.
48014240|NCT06142916|OTHER|Vırtual Realıty Traınıng On Mental Health Lıteracy And Stıgma|Nurses in the intervention group will be taken to a suitable room on the ward and virtual reality glasses will be worn. Mental health literacy training prepared by researchers by scanning the literature will be given using virtual reality glasses. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. Animations will be prepared for each topic. The training is planned to last 45 minutes.
48014241|NCT06142916|OTHER|Classical Education|Nurses in the control group will be given mental health literacy training using the classical method using brochures. Educational content; definition of mental health, definition of mental illness, definition and importance of mental health literacy, the most common mental illnesses in hospitals, Schizophrenia, Depression, Bipolar Disorder, Anxiety Disorders, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder , Suicide-Self-Harm, Mental Health Literacy and Stigma, and where to find resources to obtain information about mental health. Information about the diagnostic criteria, risk factors, treatment methods, and what to pay attention to for the diseases discussed will be given. The training is planned to last 45 minutes.
48014242|NCT00471913|DEVICE|Femoral Nailing with Different Entry Points|See Detailed Description.
48516205|NCT05188677|BIOLOGICAL|Candidate vaccine, SCB-2019|a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
48014244|NCT01312402|DRUG|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
48014245|NCT01312402|DRUG|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
48014246|NCT06638996|DIETARY_SUPPLEMENT|CBG Intervention|50 mg CBG Administered
48014247|NCT06638996|OTHER|Placebo Intervention|Participants will be administered a placebo
48014248|NCT05852457|DEVICE|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
48014249|NCT02102139|DRUG|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP \> ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
48014250|NCT02102139|DRUG|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
48014251|NCT03887091|OTHER|Postwire|Postwire© is a web-based, video platform
48170832|NCT05052723|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
48170833|NCT02019238|OTHER|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
48170834|NCT01344499|PROCEDURE|Carbon dioxide|standard pneumoperitoneum with 100% CO2
48516206|NCT05188677|BIOLOGICAL|Comirnaty Vaccine|intramuscular injection
48702009|NCT00121524|DRUG|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
48702010|NCT00121524|DEVICE|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
48014252|NCT01132144|PROCEDURE|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
48371731|NCT00000658|DRUG|Vincristine sulfate|
48371732|NCT00000658|DRUG|Doxorubicin hydrochloride|
48702011|NCT00121524|DRUG|Atropine|Atropine 3 mg iv in initial systole
48371733|NCT00000658|DRUG|Cyclophosphamide|
48702012|NCT00121524|DRUG|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
48371734|NCT00000658|DRUG|Allopurinol|
48702013|NCT03941457|BIOLOGICAL|BiCAR-NK cells (ROBO1 CAR-NK cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
48014253|NCT01132144|PROCEDURE|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
48014254|NCT01720095|DRUG|Niaspan|
48702014|NCT00663884|DRUG|Mitiglinide|mitiglinide 10mg three times a day before a meal
48014255|NCT06390020|OTHER|MBSR|The MBSR training spans eight weeks and follows a standardized protocol. It consists of eight weekly sessions, each lasting 2.5 hours, a single 6-hour silent day, and daily home exercises. Additionally, the program incorporates personalized psychoeducation on high sensory processing sensitivity, covering its characteristics, scientific foundations, its relation with stress-related symptoms, and why mindfulness might be helpful.
48170835|NCT01344499|PROCEDURE|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
48371735|NCT00000658|DRUG|Methotrexate|
48170836|NCT01344499|DRUG|Adept|instillation of 1 liter of fluid at the end of laparoscopy
48170837|NCT01344499|DRUG|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
48170838|NCT06347029|PROCEDURE|Urine sampling|Urine sampling
48170839|NCT06347029|PROCEDURE|Blood sampling|Blood sampling
48170840|NCT06347029|DEVICE|Flow mediated dilatation test|The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
48371736|NCT00000658|DRUG|Cytarabine|
48371737|NCT00000658|DRUG|Leucovorin calcium|
48371738|NCT00000658|DRUG|Sargramostim|
48371739|NCT00000658|DRUG|Dexamethasone|
48702015|NCT00663884|DRUG|Voglibose|voglibose 0.2mg three times a day before a meal
48702016|NCT02383654|PROCEDURE|Autologous Adipose-Tissue Derived Stem Cells|"1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
48702017|NCT04117581|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
48371740|NCT00364338|BEHAVIORAL|gourment cooking workshop|
48371741|NCT05647746|DEVICE|Compumedics Somfit HSAT device, WatchPAT HSAT device, Compumedics Grael /E-series PSG system|Each intervention is a separate diagnostic device. They will all be operating at the same time
48371742|NCT00976989|DRUG|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
48371743|NCT00976989|DRUG|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
48371744|NCT00976989|DRUG|FEC|5-fluorouracil 500 mg/m\^2, epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2.
48371745|NCT00976989|DRUG|Docetaxel|75 mg/m\^2 for the first dose; 100 mg/m\^2 if no dose limiting toxicity occurs.
48371746|NCT00976989|DRUG|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m\^2. All treatments were given every three weeks by the IV route.
48371747|NCT00919607|DRUG|quetiapine fumarate extended-release|200mg,oral,single dose
48371748|NCT00919607|DRUG|quetiapine fumarate extended-release|300mg,oral,single dose
48371749|NCT03190252|OTHER|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
48371750|NCT03190252|OTHER|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
48371751|NCT00057642|DRUG|Sertraline|
48371752|NCT00057642|DRUG|Venlafaxine Extended Release|
48371753|NCT02600559|DRUG|OTO-201 (ciprofloxacin)|
48371754|NCT03096899|OTHER|Observational|Best Supportive Care
48516207|NCT05188677|BIOLOGICAL|Vaxzevria Vaccine|intramuscular injection
48516208|NCT05188677|BIOLOGICAL|CoronaVac Vaccine|intramuscular injection
48702018|NCT04117581|OTHER|Placebo|Inert filler capsules daily over 12 weeks (84 days)
48702019|NCT04301076|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
48702020|NCT04301076|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48702021|NCT04301076|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
48702022|NCT04301076|DRUG|Cyclophosphamide|Given IV
48702023|NCT04301076|DRUG|Doxorubicin Hydrochloride|Given IV
48702024|NCT04301076|DRUG|Etoposide|Given IV
48702025|NCT04301076|DRUG|Lenalidomide|Given PO
48702026|NCT04301076|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48702027|NCT04301076|DRUG|Prednisone|Given PO
48702028|NCT04301076|DRUG|Vincristine Sulfate|Given IV
48702029|NCT05894720|OTHER|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
48702030|NCT06220864|DRUG|SNV1521|SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
48702031|NCT06301828|DRUG|Envafolimab Injection|Endostar+SBRT+Envafolimab Injection
48702032|NCT06301828|DRUG|Endostar|Endostar+SBRT+Envafolimab Injection
48702033|NCT04403152|OTHER|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
48702034|NCT04403152|OTHER|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
48702035|NCT06514664|OTHER|Using Probiotic Toothpaste|"Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day"
48702036|NCT03085628|DRUG|Oxytocin|40IU
48702037|NCT03085628|DRUG|Placebo|40IU
48702038|NCT04177485|BEHAVIORAL|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
48702039|NCT02913430|DRUG|Fulvestrant|500mg IM Q28 days
48702040|NCT02913430|DRUG|Tamoxifen|20mg PO Qdaily
48702041|NCT02913430|DRUG|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
48371755|NCT05585008|DEVICE|two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))|retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
48702042|NCT03420391|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
48702043|NCT06017921|DRUG|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
48702044|NCT06017921|DRUG|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
48702045|NCT04022785|DRUG|Azacitidine|Given IV or SC
48702046|NCT04022785|DRUG|BRD4 Inhibitor PLX51107|Given PO
48702047|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 12
48702048|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 6
48702049|NCT01637636|DRUG|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
48702050|NCT01637636|DRUG|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
48702051|NCT01961284|DEVICE|Zygomatic implant placement|
48702052|NCT01961284|DEVICE|conventional implants and augmentation of maxilla|
48702053|NCT06607575|OTHER|Control group|"1. The procedure for heel blood collection will be performed.~2. Pain assessment will be performed with the N-PASS scale during and after the procedure."
48702054|NCT06607575|OTHER|Warming|"1. The cotton sock will be warmed under the heater for 3 minutes. The sock will be put on the newborn and taken off after 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
48702055|NCT06607575|OTHER|Vibration|"1. A rechargeable toothbrush will be prepared for the newborn to whom vibration will be applied. The vibration process will be applied to the midline of the gastrocnemius muscle for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
48702056|NCT06607575|OTHER|Warming and vibration|"1. After the socks are warmed, they will be put on the newborn\&#39;s feet and both warming and vibration will be applied for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure."
48702057|NCT01032291|DRUG|cetuximab|Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
48702058|NCT01032291|DRUG|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
48702059|NCT02346331|OTHER|WHO algorithm of fluid boluses guided by physical examination|
48702060|NCT02346331|OTHER|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
48702061|NCT02346331|OTHER|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
48702062|NCT02346331|OTHER|Oxygen delivery|
48702063|NCT02346331|OTHER|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
48702064|NCT02346331|OTHER|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
48702065|NCT04960904|DEVICE|Dental implant surgery with implants|Adult patients who have had dental implant surgery.
48702066|NCT01798173|BIOLOGICAL|Serum, plasma and DNA samples|
48702067|NCT01798173|PROCEDURE|Radiological exploration by CT scan or MRI|
48702068|NCT04489147|DRUG|Metformin|metformin 850 mg orally twice daily along the cycle of ICSI
48371756|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|30 μg
48371757|NCT06113731|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O)|60 μg
48702069|NCT02373956|DEVICE|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
48371758|NCT06113731|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
48702070|NCT02373956|PROCEDURE|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
48702071|NCT03469986|DEVICE|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
48702072|NCT00027365|BIOLOGICAL|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
48702073|NCT00027365|BIOLOGICAL|NefTat|
48702074|NCT00027365|DRUG|AS02A Adjuvant|
48702075|NCT00027365|BIOLOGICAL|gp120W61D|
48702076|NCT05540249|DIETARY_SUPPLEMENT|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
48702077|NCT00888524|PROCEDURE|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
48702078|NCT00888524|PROCEDURE|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
48702079|NCT05078515|DIAGNOSTIC_TEST|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
48702080|NCT03428581|PROCEDURE|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
48702081|NCT03428581|PROCEDURE|ALND|Prospective and retrospective subjects undergoing an ALND.
48702082|NCT02068846|DRUG|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
48702083|NCT02068846|DRUG|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
48702084|NCT02668900|BEHAVIORAL|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
48702085|NCT01004731|DRUG|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
48702086|NCT05956665|BEHAVIORAL|Shed-MEDS deprescribing intervention|See single arm description
48702087|NCT02913001|OTHER|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
48702088|NCT02913001|OTHER|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
48702089|NCT00406705|BEHAVIORAL|Helium-Hyperoxia|
48702090|NCT05487651|GENETIC|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
48702091|NCT01939002|DRUG|BIIB017|
48371759|NCT02233673|BEHAVIORAL|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
48371760|NCT02377674|DEVICE|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
48371761|NCT02101957|DRUG|RP103|
48371762|NCT02101957|DRUG|Placebo|
48702092|NCT01939002|DRUG|naproxen|
48702093|NCT04015284|PROCEDURE|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
48702094|NCT04015284|PROCEDURE|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
48702095|NCT04929002|OTHER|No intervention|No intervention
48702096|NCT04955483|DIAGNOSTIC_TEST|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
48702097|NCT00380991|DRUG|lactoserum|
48702098|NCT00346281|DEVICE|32P BioSilicon|
48702099|NCT02636244|DRUG|SHAPE Gel|
48702100|NCT04437511|DRUG|Donanemab|Given IV
48702101|NCT04437511|DRUG|Placebo|Given IV
48702102|NCT02493257|DRUG|Capsaicin|
48702103|NCT02493257|DRUG|Placebo|
48702104|NCT04717297|BEHAVIORAL|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
48702105|NCT04717297|BEHAVIORAL|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
48702106|NCT04717297|BEHAVIORAL|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
48702107|NCT04331184|PROCEDURE|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
48702108|NCT01162824|DRUG|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
48702109|NCT01162824|DRUG|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
48702110|NCT00560534|PROCEDURE|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
48702111|NCT02829736|PROCEDURE|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
48170841|NCT03769077|DEVICE|Exergaming|This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
48170842|NCT04560777|OTHER|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
48170843|NCT03459612|DRUG|Lasmiditan|Administered orally
48170844|NCT03459612|DRUG|Placebo|Administered orally
48170845|NCT03459612|DRUG|Diphenhydramine|Administered orally
48170846|NCT00338988|DRUG|Capecitabine|1500 mg/m\^2 PO twice daily x 14 days.
48170847|NCT00338988|DRUG|Oxaliplatin|130 mg/m\^2 IV over 2 hours on day 1 of cycle.
48170848|NCT04299113|DRUG|Vinorelbine|Given IV
48170849|NCT04299113|DRUG|Mocetinostat|Given PO
48170850|NCT00238498|DRUG|vildagliptin|
48170851|NCT00635570|DRUG|Ortho Tri-cyclen Lo|Low dose oral contraceptive
48170852|NCT00635570|DEVICE|NuvaRing|Contraceptive vaginal ring
48170853|NCT05828563|DIAGNOSTIC_TEST|Blood sample test|Blood sample will be taken to determine immunological indices
48170854|NCT06088810|OTHER|CoMPoSER intervention group|Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.
48170855|NCT06088810|OTHER|Sleep Education|Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
48170856|NCT01209741|DRUG|telcagepant potassium|\[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
48170857|NCT01209741|DRUG|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
48170858|NCT01209741|DRUG|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
48170859|NCT03836742|PROCEDURE|Hemofiltration with regional citrate anticoagulation|To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
48170860|NCT00002597|DRUG|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
48170861|NCT00002597|DRUG|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
48702112|NCT02829736|PROCEDURE|Standard post-operative chest tube|A regular chest tube is left in the pleura.
48702113|NCT02829736|PROCEDURE|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
48702114|NCT04463186|OTHER|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
48014256|NCT06311591|DEVICE|Jaspr App|Jaspr was designed to improve delivery of evidence-based, personalized suicide care in the ED. Jaspr (Dimeff, R44MH108222) is rooted in EBPs, including Collaborative Assessment and Management of Suicide (CAMS) and Dialectical Behavior Therapy (DBT). Briefly, Jaspr provides a patient interface, optimized for a tablet computer provided to the patient, which uses an avatar to administer: (1) the CAMS Suicide Status Form (SSF), an evidence-based suicide risk assessment; (2) crisis stabilization planning (CAMS' version of safety planning) or Stanley-Brown Safety Planning Intervention, depending on site choice; (3) lethal means safety counseling. Further, Jaspr teaches behavioral skills from DBT to manage imminent distress and has a library of over 40 racially and culturally diverse, inspirational videos of people with lived experience. Finally, Jaspr@home provides access to these resources after the visit during the high-risk transition to outpatient care.
48014257|NCT02534610|DRUG|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
48014258|NCT02534610|DRUG|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
48014259|NCT02592733|DEVICE|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
48170862|NCT00002597|DRUG|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
48702115|NCT06157632|PROCEDURE|Thyriodectomy|Thyroidectomy
48014260|NCT04328493|DRUG|Chloroquine phosphate|"Each chloroquine tablet contains 250mg chloroquine phosphate (or 150mg chloroquine base). Chloroquine treatment for patient is weight-based dosing.~Chloroquine will be administered orally, as tablets. For unconscious patients chloroquine can be crushed and administered as a suspension via a nasogastric tube.~The total duration of treatment with Chloroquine will be 10 days"
48170863|NCT00002597|RADIATION|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
48170864|NCT04684966|DEVICE|Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).
48170865|NCT04684966|DEVICE|Sham Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
48170866|NCT04180306|OTHER|pediatric early warning scoring system and resuscitation curriculum|teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
48170867|NCT01101464|DRUG|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
48170868|NCT01101464|DRUG|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
48702116|NCT05726565|OTHER|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
48702117|NCT04554966|DRUG|ABBV-382|Intravenous (IV) infusion
48170869|NCT01807936|PROCEDURE|Lymphadenectomy|
48170870|NCT02853305|BIOLOGICAL|Pembrolizumab|IV infusion
48170871|NCT02853305|DRUG|Cisplatin|IV infusion
48702118|NCT04554966|DRUG|ABBV-382|Subcutaneous (SC) injection
48702119|NCT04554966|DRUG|Placebo for ABBV-382|Intravenous (IV) infusion
48702120|NCT03173976|DRUG|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
48702121|NCT06608004|OTHER|test taking|Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\&#39; Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
48702122|NCT03524690|DIETARY_SUPPLEMENT|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
48702123|NCT03524690|DIETARY_SUPPLEMENT|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
48702124|NCT04338139|PROCEDURE|bone regeneration|bone regeneration using bio-oss collagen
48702125|NCT01419613|BEHAVIORAL|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
48702126|NCT01419613|BEHAVIORAL|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
48702127|NCT02487654|PROCEDURE|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
48702128|NCT02487654|PROCEDURE|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
48702129|NCT02626234|DRUG|INC280|
48702130|NCT02626234|DRUG|digoxin|
48702131|NCT02626234|DRUG|rosuvastatin|
48702132|NCT03290417|DIETARY_SUPPLEMENT|Vitamin D|5000 IU/cap; One cap by mouth daily
48702133|NCT03290417|DIETARY_SUPPLEMENT|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
48702134|NCT03290417|DIETARY_SUPPLEMENT|Turmeric|250mg/cap; two capsules by mouth 4 times per day
48702135|NCT06443177|DEVICE|Vectris trial leads and stimulation|The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.
48702136|NCT06443177|DEVICE|Sham|No electrode is placed.
48702137|NCT05993312|OTHER|quality of life|To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
48702138|NCT02997553|DRUG|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
48702139|NCT02997553|DRUG|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
48702140|NCT02997553|DEVICE|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
48702141|NCT02997553|DEVICE|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
48702142|NCT04848506|DRUG|Aficamten (5 - 20 mg)|Aficamten tablets administered orally. During titration phase, clinic visits will occur approximately every 2-6 weeks. In the maintenance phase clinic visits will occur every 24 weeks, with safety check-in occurring every 12 weeks between visits by phone or, if desirable, in the clinic.
48014261|NCT03969355|OTHER|Mortality|Patients who died during PICU stay
48170872|NCT02853305|DRUG|Carboplatin|IV infusion
48170873|NCT02853305|DRUG|Gemcitabine|IV infusion
48170874|NCT03565640|DEVICE|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
48702143|NCT01337843|OTHER|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
48702144|NCT01337843|OTHER|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
48516209|NCT01005147|DRUG|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
48170875|NCT03565640|DEVICE|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
48170876|NCT02604706|DEVICE|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
48170877|NCT02604706|DEVICE|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
48170878|NCT02604706|BEHAVIORAL|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
48702145|NCT06605820|OTHER|None - Interview Only|None - Interview Only
48702146|NCT00504517|OTHER|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
48702147|NCT02142517|PROCEDURE|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
48170879|NCT06136507|DRUG|FRSW107|experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
48702148|NCT02142517|PROCEDURE|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
48702149|NCT01441908|DRUG|Pravastatin|40mg or 80mg dose 28 days for 6 month period
48516210|NCT01005147|OTHER|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
48516211|NCT03526159|DRUG|Gentamicin Sulfate|Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
48516212|NCT03910985|DRUG|Duovent HFA|bronchodilation
48014262|NCT01548456|PROCEDURE|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
48014263|NCT01548456|PROCEDURE|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
48170880|NCT02477449|DRUG|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
48170881|NCT02477449|DRUG|9% Saline (NS)|infusion for 24 hours
48170882|NCT01340040|DRUG|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
48170883|NCT04237714|BEHAVIORAL|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
48170884|NCT01865578|DEVICE|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
48170885|NCT01865578|DEVICE|Sham Stimulation|no electrical stimulation
48170886|NCT05550597|DRUG|Fentanyl HCl|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
48170887|NCT05550597|DRUG|Bupivacaine 0.25% Injectable Solution|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
48170888|NCT00374088|DRUG|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
48170889|NCT00374088|DRUG|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
48170890|NCT02353455|PROCEDURE|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
48702150|NCT06429397|DRUG|Anlotinib and Penpulimab|Enrolled patients received a treatment cycle every 21 days: 200mg of piamprizumab was given intravenously on the first day of treatment, and 12mg of anrotinib hydrochloride capsule was given continuously for 14 days and suspended for 7 days.
48702151|NCT02511834|DEVICE|VEST External Support|
48702152|NCT02511834|PROCEDURE|Coronary Artery Bypass Surgery|
48702153|NCT02095873|DIETARY_SUPPLEMENT|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
48702154|NCT02095873|DIETARY_SUPPLEMENT|Placebo|Mannitol, 108 mg
48702155|NCT05526664|OTHER|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
48014264|NCT02685774|DRUG|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
48702156|NCT05676151|BEHAVIORAL|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
48702157|NCT05220319|DRUG|Methylprednisolone|250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
48702158|NCT05220319|DRUG|NaCl 0.9%|100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
48702159|NCT01793337|OTHER|Exposure to cold environmental temperature (-20°C)|
48702160|NCT02761187|OTHER|No Intervention|
48702161|NCT04236908|DRUG|NSAIDS|Naproxen 500mg by mouth twice a day as needed.
48014265|NCT02685774|DRUG|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
48014266|NCT00802217|DRUG|Civamide|5 mg liquid filled softgel capsules
48014267|NCT00802217|DRUG|Civamide|5 mg x 2 liquid softgel capsules
48014268|NCT02465528|DRUG|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
48014269|NCT04961892|PROCEDURE|surgical treatment|Anatomical contraction and termination reconstruction of the lateral ligament
48014270|NCT04961892|PROCEDURE|conservative treatment|Rehabilitation intervention training
48014271|NCT06207279|DIAGNOSTIC_TEST|rating|rating scales, test ANT
48371763|NCT05239390|DRUG|SCI -110|"Dronabinol - Manufactured by Pharmaceutics International, Inc., Hunt Valley, MD 21031, USA. Dronabinol Capsules (dronabinol solution in sesame oil in soft gelatin capsules) are 2.5 mg - cream, oblong, soft-gel capsules. In an NDC 49884-867-02 Bottle of 60 capsules packaged in a well-closed container and stored in a locked refrigerator, 2° to 8°C. Protect from freezing, in accordance with the Israeli legal requirements (Israel Narcotic Drugs Act). Storage conditions should be monitored on a daily basis.~PEA - Manufactured by Pharmacies Inc. 767 Front st. Suite 202. Catasauqua, PA 18032 www.pharmacures.com. 1-888-334-3130. 400 mg PEA tablets, in a 60 mL barrier bottle, 30/400 mm, Bottle of 30 capsules packaged in a well-closed container and stored in RT (20° to 25°C). Storage conditions should be monitored on a daily basis."
48371764|NCT02196025|DEVICE|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
48371765|NCT03044691|BEHAVIORAL|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
48371766|NCT04916132|PROCEDURE|Kidney Biopsy|Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
48371767|NCT01566747|DRUG|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
48702162|NCT04236908|DEVICE|Battlefield Acupuncture|"Battlefield Acupuncture in both ears (which includes the points cingulate gyrus, thalamus, omega-2, point zero and shen men).~Battlefield acupuncture utilizes up to 10 ASP acupuncture needles (5 in each ear). The Battlefield Acupuncture points include: cingulate gyrus, thalamus, omega-2, point zero, and shen men. The semi-permanent needles are left in place and typically stay in place for 2-7 days. Needles will usually fall out on their own, can be removed by the patient or the patient can call study staff and come in for removal if desired."
48371768|NCT04766528|OTHER|3 maximal aerobic tests|Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
48371769|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
48371770|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
48371771|NCT04717310|DRUG|SHR0302 Ointment|SHR0302 Ointment Twice a day (BID)
48371772|NCT04717310|DRUG|Vehicle|Twice a day (BID)
48702163|NCT04236908|DEVICE|GV26 with manual tonification|"Acupuncture to include use of GV 26 with manual tonification (twisting or rotating the needle).~The protocol for using GV26 is as follows: With the patient in a seated position the acupuncturist places a 40mm needle in the acupuncture point GV26 (located on the philtrum, on the anterior midline, at the junction of the upper 1/3 and lower 2/3 of the distance from the nose to the margin of the upper lip). The acupuncturist then rapidly rotates the needle at the handle clockwise and counterclockwise (known as manual tonification) for 20-40 seconds at a time. The patient then stands up and assesses their pain. This will be performed up to 6 cycles. If a patient is unable to sit or stand, this may also be performed in a supine position with the patient attempting to sit or stand every 20-40 seconds."
48702164|NCT06595823|DRUG|Betadine|To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
48371773|NCT03626337|DRUG|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
48371774|NCT05611944|DEVICE|Irrigation and suction through subcutaneus drains|Irrigation of wound will done by attaching 500cc saline to the drain on one side and let it flow freely from the other drain followed by suction of wound by attaching 60cc suction syringes on both sides creating suction pressure for 100 cc fluid.
48371775|NCT03892876|DIAGNOSTIC_TEST|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
48702165|NCT06262659|OTHER|Doppler Ultrasonography Assessment|"Preoperative data will be collected from the latest available data within the last month. Preoperative Doppler ultrasonography venous mapping for all patients will be performed by experienced Radiology Specialists.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated. AVF flow will be expressed in ml/min, and the vascular structure diameters and the distance of AVF from the skin will be indicated in mm. AVF depth will be calculated as the distance from the skin to the anterior wall of the AVF."
48702166|NCT05732506|DRUG|Edoxaban|There are not intervention.
48014272|NCT05843877|BIOLOGICAL|Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy|Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.
48014273|NCT05843877|PROCEDURE|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)|As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
48014274|NCT02908997|OTHER|MindMate|A dementia-specific mobile reminding application
48014275|NCT01688336|DRUG|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
48014276|NCT05702073|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
48014277|NCT05702073|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
48014278|NCT00953797|DEVICE|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
48371776|NCT03892876|DIAGNOSTIC_TEST|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
48702167|NCT04587843|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
48702168|NCT04587843|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
48702169|NCT04434625|DRUG|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
48014279|NCT06295549|BIOLOGICAL|LUCAR-G39P cells product|LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
48014280|NCT02358889|BIOLOGICAL|hI-con1|Intravitreal injection of hI-con1 0.3 mg
48014281|NCT02358889|BIOLOGICAL|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
48014282|NCT02358889|OTHER|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
48014283|NCT03968952|OTHER|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
48014284|NCT06254417|PROCEDURE|Diaphragmatic ultrasound|Diaphragmatic ultrasound will be performed to all patients with respiratory disease to evaluate diaphragmatic thickening and estimate thickening fraction and to evaluate diaphragmatic excursion. Measurements will be obtained at bedside with a portable ultrasound machine equipped with a linear probe (Logic P6 Pro, GE Healthcare). Diaphragmatic thickness measures will be performed on right Intercostal approach through the zone of apposition. Diaphragmatic excursion will be performed using curved-array probe (Logic P6 Pro, GE Healthcare) is positioned below right costal arch at the mid-clavicular line. The ultrasound study will be done and /or supervised by ultrasound expert
48371777|NCT05571969|DRUG|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
48702170|NCT06401031|DEVICE|Press Needle|Press needle is patch-type acupuncture needle which has a very small needle. This is placed onto acupuncture point and give a simultaneous stimulation, which is held in place with a small, sterile surgical adhesive patch.
48014285|NCT04138927|DRUG|Fostamatinib disodium|Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
48014286|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by lavage)|
48371778|NCT02514642|DRUG|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
48014287|NCT00312507|DRUG|Bovine Lipid Extract Surfactant (administered by bolus)|
48014288|NCT06468488|PROCEDURE|DIEP flap surgery without drain|Patients will undergo a breast reconstruction with a DIEP flap without the placement of drains.
48702171|NCT06401031|DEVICE|Sham Press Needle|Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
48702172|NCT05011305|DRUG|Saroglitazar Magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
48702173|NCT05011305|DRUG|Saroglitazar Magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
48371779|NCT02514642|DRUG|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
48371780|NCT00038571|DRUG|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
48371781|NCT04932980|DRUG|Aflibercept|administration of anti-VEGF Aflibercept (Eylea)
48702174|NCT05011305|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
48702175|NCT04225052|DRUG|YHP1903|YHP1903 Tab. 1mg
48702176|NCT04225052|DRUG|Champix|Comparator Champix Tab. 1mg
48702177|NCT03504540|PROCEDURE|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
48702178|NCT02132923|BIOLOGICAL|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
48702179|NCT00408655|DRUG|paclitaxel|Given IV
48702180|NCT00408655|DRUG|carboplatin|Given IV
48702181|NCT00408655|DRUG|temsirolimus|Given IV
48702182|NCT04549116|DRUG|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
48702183|NCT04549116|DRUG|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
48014289|NCT06468488|PROCEDURE|DIEP flap surgery with drains|Patients will undergo a breast reconstruction with a DIEP flap with the placement of drains.
48014290|NCT03191916|DEVICE|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
48014291|NCT03191916|DEVICE|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
48371782|NCT04932980|DRUG|Brolucizumab|administration of anti-VEGF Brolucizumab (Beovu)
48014292|NCT03414242|OTHER|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
48014293|NCT06569186|BEHAVIORAL|Cue-based feedings|Speech therapists will use cue-based protocols to guide feeds
48371783|NCT04932980|PROCEDURE|early treat and extend (T&E)|extension of treatment intervals (T\&E) from the beginning of treatment
48371784|NCT00045136|DRUG|melphalan|
48371785|NCT00045136|PROCEDURE|peripheral blood stem cell transplantation|
48371786|NCT00045136|RADIATION|holmium Ho 166 DOTMP|
48371787|NCT04686773|BIOLOGICAL|AZD1222|"AZD1222 (0.5 ml per dose) contains:~Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles per dose.~Solution for intramuscular injection, supplied in vials (5 mL, up to 10 doses per vial) in a carton box."
48702184|NCT04549116|DRUG|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
48702185|NCT04549116|DRUG|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
48702186|NCT04613765|BEHAVIORAL|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
48702187|NCT03549676|BIOLOGICAL|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
48702188|NCT02310230|DEVICE|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
48702189|NCT01428037|DRUG|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
48702190|NCT01428037|DRUG|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
48702191|NCT04048707|DRUG|Angiotensin II|Intravenous
48702192|NCT04048707|DRUG|Midodrine|Pill
48702193|NCT04048707|DRUG|Octreotide|Subcutaneous
48702194|NCT04048707|DRUG|Albumin solution|Intravenous suspension
48702195|NCT01495130|PROCEDURE|ultrasound imaging|Undergo transrectal ultrasound
48702196|NCT01495130|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
48702197|NCT05462444|OTHER|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
48702198|NCT05901480|GENETIC|OTOV101N+OTOV101C Injections|The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
48702199|NCT04206254|BIOLOGICAL|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
48014294|NCT05784428|RADIATION|Single fraction SABR|"Participants randomized to this arm will receive SF SABR~Treatment recommendations are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction~Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction~Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction~Liver: 30 Gy in 1 fraction~Brain: dose as per institutional policy"
48014295|NCT05784428|RADIATION|Multiple fraction SABR|"Participants randomized to this arm will receive MF SABR:~Dose/Fractionation are as follows:~Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day~Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily~Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily~Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day~Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily~Brain - dose per institutional policy for stereotactic lesions (no whole brain RT)."
48014296|NCT05784428|OTHER|QoL reporting alone|Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit
48014297|NCT05784428|OTHER|QoL reporting, symptom screen and healthcare provider intervention|Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.
48014298|NCT01993407|BEHAVIORAL|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
48014299|NCT01993407|BEHAVIORAL|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
48014300|NCT06133582|BEHAVIORAL|Internet Based Psychodynamic Psychotherapy|"This is a 10-week intervention, delivered on a website called 'Iterapi' which was developed in Sweden. The programme involves creative and interactive web-based content- worksheets, audio, video, expressive writing exercises. Additionally, each participant is assigned a Therapeutic Support Worker (TSW). The TSW logs into the platform and views the questionnaires and other data provided by the participants that they are supporting. Each week, the TSW sends each of their participants a reflective message in response to the data they have provided when interacting with the programme over the last week. The participant can reply to this message.~The principal objective of the iPDT intervention is to reduce depressive symptoms through the promotion of emotional awareness and emotional experience. The intervention is an affect-focused therapy and draws on Malan's Triangle of Conflict (Malan, 1995)."
48014301|NCT01062685|DIAGNOSTIC_TEST|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
48702200|NCT06604546|DRUG|hyaluronidase|150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm)； D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg)； D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back)； 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
48702201|NCT06604546|DRUG|Placebo|150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
48702202|NCT02281786|DRUG|Placebo|Matching placebo to RO6926496
48371788|NCT04686773|BIOLOGICAL|rAd26-S|"Component I (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose.~Solution for intramuscular injection, supplied in vials (3 mL, 5 doses per vial) in a carton box"
48371789|NCT00781001|DRUG|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
48702203|NCT02281786|DRUG|RO6926496|single, ascending dose, intravenous administration
48702204|NCT00973544|OTHER|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
48702205|NCT05969756|DRUG|Fluoride varnish|Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months
48702206|NCT05969756|DRUG|Conventional etch and rinse sealant|Thirty-eight permanent molars will receive conventional etch and rinse sealant
48702207|NCT05969756|DRUG|Self-etch sealant|Thirty-eight permanent molars will receive self-etch sealant
48170891|NCT05285956|BEHAVIORAL|Calm app|Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
48170892|NCT04848103|BEHAVIORAL|Radial extracorporeal shockwave therapy|Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation \[TENS\], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
48371790|NCT00561041|BEHAVIORAL|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
48516213|NCT03921593|PROCEDURE|Solid Organ Pancreas Transplantation with or without Kidney Transplantation|Deceased donor pancreas transplantation
48702208|NCT00559845|DRUG|5-fluorouracil|600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
48702209|NCT00559845|DRUG|Epidoxorubicin|90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
48702210|NCT00559845|DRUG|Cyclophosphamide|600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
48702211|NCT00559845|DRUG|Paclitaxel|Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.
48702212|NCT00559845|BIOLOGICAL|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
48702213|NCT05071872|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
48702214|NCT02027467|DIETARY_SUPPLEMENT|StemAlive®|
48702215|NCT02027467|DIETARY_SUPPLEMENT|Placebo (For StemAlive®)|
48702216|NCT04809558|BEHAVIORAL|Tongue resistance exercise|Participant will complete tongue resistance exercises.
48702217|NCT06599255|PROCEDURE|US-guided RSB and TAPB by one-puncture technique.|The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al
48702218|NCT06599255|PROCEDURE|multipont|", the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution."
48702219|NCT00676520|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
48014302|NCT04304001|BEHAVIORAL|Community Health Advisor|"Intervention arm participants will receive one 45-minute face-to-face meeting followed by two phone calls in one-week intervals over a period of three weeks beginning within one month following baseline survey completion. These educational activities will include the use of National Cancer Institute colorectal cancer resources and materials, including a Screen to Save media presentation, and colorectal cancer brochures. The intervention will follow a conversation guide/standard script for intervention fidelity. Community Health Advisors will take notes following each interaction to document the call length and call details. Participants will receive an additional text message reminder once a week for an additional three weeks - with instructions for participants to text yes to confirm they received the message - for a total of six weeks of intervention delivery. The personalized text messages will include short messages about the benefits of colorectal cancer screening."
48014303|NCT04304001|BEHAVIORAL|Usual care|Control arm participants will receive a Fecal Immunochemical Test kit, a mailed targeted colorectal cancer brochure, and complete a follow-up telephone survey at 3- and 12-months after the mailing.
48371791|NCT00561041|BEHAVIORAL|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
48371792|NCT02787655|BEHAVIORAL|Aerobic exercise + Cognitive Training Group|stationary bicycling
48516214|NCT00440349|DRUG|Tamoxifen|
48516215|NCT00440349|DRUG|Prednisone|
48522969|NCT02689583|BIOLOGICAL|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.
48014304|NCT02510846|BEHAVIORAL|Intensive educative management|5 hours a week
48014305|NCT05305794|DRUG|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
48170893|NCT02037256|DRUG|bortezomib|Given IV
48702220|NCT06605508|PROCEDURE|Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction|This intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\&#39;s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\&#39;s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.
48702221|NCT05032690|DRUG|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
48170894|NCT02037256|BIOLOGICAL|filgrastim|Given SC
48170895|NCT02037256|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
48170896|NCT00000636|DRUG|Isoniazid|
48516216|NCT02888730|DRUG|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
48702222|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
48702223|NCT05032690|DRUG|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
48702224|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
48702225|NCT05434065|DRUG|Celecoxib 200mg|Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
48702226|NCT01988662|PROCEDURE|Neovascular Age-related Macular Degeneration|Blood measurement
48702227|NCT03969056|BEHAVIORAL|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
48702228|NCT03969056|BEHAVIORAL|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
48702229|NCT04388319|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
48702230|NCT04388319|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
48702231|NCT04388319|OTHER|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
48014306|NCT05305794|DRUG|Usual insulin treatment|Usual insulin treatment
48014307|NCT05305794|BIOLOGICAL|Biological check-up|at D0, D90 and D180
48702232|NCT00135928|DRUG|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
48702233|NCT03179254|DRUG|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
48014308|NCT05846009|DRUG|SAR442501|Subcutaneous injection
48014309|NCT05846009|DRUG|Placebo|Subcutaneous injection
48014310|NCT01649856|DRUG|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
48014311|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
48014312|NCT01649856|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
48170897|NCT00000636|DRUG|Pyrazinamide|
48170898|NCT00000636|DRUG|Pyridoxine hydrochloride|
48170899|NCT00000636|DRUG|Rifampin|
48170900|NCT02026245|DEVICE|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove"
48170901|NCT00291239|BEHAVIORAL|partial sleep deprivation|
48170902|NCT02271659|RADIATION|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
48371793|NCT02787655|BEHAVIORAL|Cognitive training Only|20 minutes of cognitive training using Mindfit program
48170903|NCT02271659|RADIATION|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
48170904|NCT00853229|DRUG|pregabalin|pregabalin 150mg twice daily for 4 weeks
48702234|NCT03179254|DRUG|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
48702235|NCT00215566|DRUG|DDP733|
48702236|NCT03848208|DRUG|cytisine|cytisine film-coated oral tablet
48702237|NCT03848208|DRUG|placebo|matching placebo oral tablet
48702238|NCT05638334|DRUG|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
48702239|NCT06135896|DRUG|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
48702240|NCT02374814|DRUG|Rabies vaccine|Compare dose schedule and route of administration
48702241|NCT02374814|DRUG|Placebo|Placebo
48702242|NCT06331364|OTHER|electronic clinical decision support tool (eCDST) diagnostic plan|Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials used. Analyses will compare clinical outcomes and antimicrobial use between the intervention arm and usual care.
48702243|NCT04042142|OTHER|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
48702244|NCT01558492|DRUG|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
48702245|NCT01558492|DRUG|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
48702246|NCT01913028|DRUG|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
48702247|NCT01913028|DRUG|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
48702248|NCT05406219|DRUG|BAY2395840|Immediate release (IR) tablet, oral administration
48702249|NCT04200443|DRUG|Cabozantinib|Given PO
48702250|NCT04200443|OTHER|Quality-of-Life Assessment|Ancillary studies
48702251|NCT04200443|OTHER|Questionnaire Administration|Ancillary studies
48702252|NCT04200443|DRUG|Temozolomide|Given PO
48170905|NCT01136447|PROCEDURE|Ultrasound|Block catheter will be introduced using ultraosound
48170906|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
48702253|NCT06061263|OTHER|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
48702254|NCT04233307|DIAGNOSTIC_TEST|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
48702255|NCT04379479|DRUG|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
48702256|NCT04379479|DRUG|Placebo oral|Placebo
48702257|NCT01693341|OTHER|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
48702258|NCT04503135|DIAGNOSTIC_TEST|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
48702259|NCT06606808|DRUG|Risankizumab-800CW 4.5 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
48702260|NCT06606808|DRUG|Risankizumab-800CW 15 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
48702261|NCT06606808|DRUG|Risankizumab-800CW 25 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
48702262|NCT06606808|DRUG|Risankizumab-800CW optimal dose|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
48702263|NCT05201430|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
48014316|NCT06662929|RADIATION|Radiation|Radiotherapy for the Head \& Neck Cancer
48170907|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
48170908|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
48170909|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
48170910|NCT01046422|DRUG|Placebo|Capsule, Oral, 0mg, Daily, 28 days
48170911|NCT01046422|DRUG|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
48170912|NCT03796598|DRUG|Fecal Microbial transplant Capsules|Oral capsules of FMT
48170913|NCT03796598|DRUG|Fecal Microbial Transplant Enema|FMT enema
48702264|NCT05201430|DRUG|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
48702265|NCT02687685|OTHER|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
48702266|NCT02687685|OTHER|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
48702267|NCT05909410|OTHER|Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms|This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
48702268|NCT05211401|DRUG|Active arm 200 mg|Active arm 200 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
48702269|NCT05211401|DRUG|Active arm 1000 mg|Active arm 1000 mg: 1 bag containing 200 mg of rituximab (MabThera® or biosimilar ) in 100ml of NaCl 0.9%; 1 bag containing 800 mg rituximab (MabThera® or biosimilar ) in 400 ml of NaCl 0.9%.
48702270|NCT05211401|DRUG|Placebo arm|Placebo arm: 1 bag of 100 ml of NaCl 0.9%; 1 bag of 400 ml of NaCl 0.9%.
48702271|NCT06606379|DEVICE|I1 (Intervention)|Resin ring (DR- Resin ring, Egypt)
48170914|NCT03796598|OTHER|Placebo|Placebo
48702272|NCT06606379|DEVICE|I2 (Intervention)|Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
48702273|NCT06606379|DEVICE|I3 (Intervention)|Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
48170915|NCT05591170|DRUG|Cholecalciferol 120 000 IU|single, oral administration of high dose of vitamin D
48170916|NCT00203723|DRUG|Risperidone|
48170917|NCT01084239|RADIATION|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
48170918|NCT00305097|DIETARY_SUPPLEMENT|Decaffeinated coffee|5 cups per day for 8 weeks
48170919|NCT00305097|DIETARY_SUPPLEMENT|Caffeinated coffee|5 cups per day for 8 weeks
48170920|NCT00305097|DIETARY_SUPPLEMENT|No coffee|
48170921|NCT00118703|DRUG|GW685698X|
48170922|NCT05566353|OTHER|Remote Check|Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,
48170923|NCT00508859|DRUG|Sertraline|maintenance treatment with sertraline
48170924|NCT00508859|DRUG|placebo|placebo
48170925|NCT02274623|DRUG|CTAP101 Capsules|escalating doses
48170926|NCT03168399|DIETARY_SUPPLEMENT|PKU Explore|PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
48170927|NCT04082377|PROCEDURE|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905\*((height in cm)-152.4) for men, and = 45.5+0.905\*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
48170928|NCT04082377|PROCEDURE|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
48702274|NCT06606379|DEVICE|C (comparator)|Nickel titanium 3D-fusion ring (Garrison, USA)
48170929|NCT00145483|DRUG|Sildenafil|
48170930|NCT05527743|OTHER|Invasive Physiotherapy|They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.
48702275|NCT06106724|PROCEDURE|sphincterotomy|cutting the papilla and cannulation with sweeping of common bile duct by ballon and stent insertion
48702276|NCT06106724|PROCEDURE|precutting of the papilla by knife needle|precutting of the papilla by knife needle
48702277|NCT03957499|DRUG|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
48516217|NCT02888730|DRUG|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
48516218|NCT05233852|OTHER|"Do not do recommendation"|A drug prescription or procedure included in 'do not do' recommendations
48516219|NCT02795247|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
48702278|NCT03957499|DRUG|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
48702279|NCT03957499|DRUG|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
48702280|NCT00592228|DEVICE|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group"
48702281|NCT04761679|BEHAVIORAL|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
48702282|NCT02178254|DRUG|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
48702283|NCT02178254|DRUG|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
48702284|NCT03359785|DRUG|Luvadaxistat|TAK-831 Tablets.
48702285|NCT03359785|DRUG|Matching Placebo|Matching Placebo Tablets.
48702286|NCT06608680|BEHAVIORAL|iTBS|Excitatory stimulation of supramarginal gyrus
48702287|NCT06608680|BEHAVIORAL|cTBS|Inhibitory stimulation to supramarginal gyrus
48702288|NCT06608680|BEHAVIORAL|Sham Stimulation|Sham stimulation of supramarginal gyrus
48702289|NCT03897153|DEVICE|SONAS® Ultrasound Device|The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
48516220|NCT03845296|DRUG|Rucaparib|Given PO
48516221|NCT04068792|OTHER|RSV Mobile Application|Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
48702290|NCT06607640|BEHAVIORAL|Increase outdoor activity time during specific time periods|"The specific time periods of outdoor activity found to be beneficial for myopia prevention will be used as the intervention target, and a one-year intervention will be initiated."
48702291|NCT00793559|DRUG|terlipressin|1 mg of terlipressin one time only
48702292|NCT00793559|DRUG|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
48702293|NCT05210803|OTHER|No intervention.|All subjects that previously received RGX-314 in a parent study
48702294|NCT05209802|OTHER|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
48702295|NCT05209802|OTHER|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
48702296|NCT04071262|DRUG|Abemaciclib|Administered orally
48702297|NCT04071262|DRUG|Abiraterone Acetate|Administered orally
48702298|NCT04071262|DRUG|Prednisolone|Administered orally
48702299|NCT03217877|DIAGNOSTIC_TEST|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.
48702300|NCT03217877|DIAGNOSTIC_TEST|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
48702301|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
48702302|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
48371794|NCT00671645|DRUG|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
48702303|NCT02762240|OTHER|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
48371795|NCT06400420|OTHER|Exercise|classic futsal training program
48371796|NCT04457310|DRUG|CVL-562 (PF-06412562) 1 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
48702304|NCT02762240|OTHER|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
48702305|NCT06600282|DRUG|Parecoxib|Pharmacokinetic study under fasting conditions
48702306|NCT01972308|BEHAVIORAL|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
48702307|NCT01972308|BEHAVIORAL|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
48702308|NCT03447314|DRUG|GSK1795091|GSK1795091 will be available as solution for injection
48702309|NCT03447314|DRUG|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
48702310|NCT03447314|DRUG|GSK3359609|GSK3359609 will be available as solution for infusion.
48371797|NCT04457310|DRUG|CVL-562 (PF-06412562) 4 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
48371798|NCT04457310|DRUG|CVL-562 (PF-06412562) 15 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
48371799|NCT04457310|DRUG|CVL-562 (PF-06412562) 25 mg|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
48371800|NCT04457310|OTHER|Placebo|Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
48516222|NCT04068792|DRUG|Placebo|Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
48516223|NCT04068792|DRUG|JNJ-53718678 2.5 mg/kg|JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.
48516224|NCT04068792|DRUG|JNJ-53718678 3 mg/kg|JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
48702311|NCT03447314|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
48371801|NCT05620966|DEVICE|CGX Systems Quick-20m|The Quick-20m is an FDA-approved wireless, battery-operated 10-20 montage EEG headset, which utilizes dry sensor technology. This device provides an integrated approach to the wireless acquisition of electrical potentials arising from activity in the cortex. The Quick-20m includes advanced amplification and shielding to reject ambient electrical noise. The Quick-20m is placed on the participant's scalp and requires minimal scalp preparation. No conductive gel is used. Patients may or may not have hair. The sensor pads must have direct contact with the scalp and hair will be maneuvered to obtain direct contact. All three arms of participants will receive this intervention.
48371802|NCT00717899|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
48014317|NCT05198791|DRUG|Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets|Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
48014318|NCT05198791|OTHER|Stratification and standard care|Interventional diagnostic procedure (IDP) without linked treatment i.e., standard care. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. In the standard care group, the IDP is performed but the results are not disclosed. The IDP is therefore a sham procedure. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
48014319|NCT00968175|PROCEDURE|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
48014320|NCT05321303|OTHER|Serious Game|"Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability."
48371803|NCT04582331|OTHER|Smartphone-based voice and self-reported symptom collection|Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
48371804|NCT02431559|DRUG|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
48371805|NCT02431559|DRUG|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
48014321|NCT05321303|OTHER|Standard Patients|Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
48014322|NCT01639170|RADIATION|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
48014323|NCT04931654|DRUG|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
48371806|NCT02431559|DRUG|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
48371807|NCT00060320|DIETARY_SUPPLEMENT|black cohosh|
48371808|NCT00060320|OTHER|placebo|
48371809|NCT04559802|PROCEDURE|Transmucosal Technique|Dental implant will be placed in transmucosal manner (Healing abutment is exposed in the mouth).
48516225|NCT04068792|DRUG|JNJ-53718678 4.5 mg/kg|JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
48371810|NCT04559802|PROCEDURE|Submerged Technique|Dental implant will be installed in submerged manner (implant is completed covered by soft tissue).
48371811|NCT00887562|DRUG|Idebenone|900 mg/day for 1 month
48516226|NCT04639011|DRUG|Duloxetine|Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)
48516227|NCT04639011|OTHER|Placebo|Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).
48014324|NCT00947297|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
48014325|NCT03100825|DRUG|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
48014326|NCT06615570|DRUG|VX-973|Suspension for oral administration.
48014327|NCT06615570|DRUG|Placebo|Suspension for oral administration.
48371812|NCT00887562|DRUG|Idebenone|2250 mg/day for 1 month
48371813|NCT00887562|OTHER|Placebo|Placebo - No idebenone
48371814|NCT03853434|PROCEDURE|Embolization|Angiographic embolization
48371815|NCT06304064|BIOLOGICAL|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
48371816|NCT00551694|DRUG|GSK256073A tablets|
48516228|NCT04639011|OTHER|Standard of care (SOC) for tibial plateau surgery|Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.
48516229|NCT02886780|BEHAVIORAL|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
48516230|NCT02886780|BEHAVIORAL|Self-help|
48516231|NCT04557033|OTHER|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
48516232|NCT03281876|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
48170931|NCT05527743|OTHER|Sham|"The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37).~Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research."
48170932|NCT00764270|DIETARY_SUPPLEMENT|R-alpha lipoic acid|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
48170933|NCT01137877|OTHER|Milk based infant formula powder|milk based infant formula ad lib
48170934|NCT01137877|OTHER|Investigational Infant Formula #1|Milk based infant formula ad lib
48170935|NCT01137877|OTHER|Investigational Infant Formula #2|Milk based infant formula powder ad lib
48170936|NCT01137877|OTHER|Human Milk|Human milk ad lib
48170937|NCT01481519|DRUG|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
48170938|NCT01481519|DRUG|Artificial Tears|artificial tears 1 drop, 4 times per day
48170939|NCT02647645|DEVICE|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
48170940|NCT02647645|PROCEDURE|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
48516233|NCT03281876|BIOLOGICAL|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
48516234|NCT02358239|PROCEDURE|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
48516235|NCT02542956|DRUG|Exparel|receive Exparel by injection
48516236|NCT02542956|DRUG|Marcaine|receive Marcaine in a pain pump
48702312|NCT06311136|BEHAVIORAL|Valence-Specific Ecological Momentary Intervention|The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
48702313|NCT02879591|OTHER|Social Skills training with Avatar therapist|
48702314|NCT01723293|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
48702315|NCT00604643|DEVICE|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
48170941|NCT02647645|DEVICE|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
48371817|NCT02468973|BEHAVIORAL|Life style counseling|Life style counseling for chronic patients by medical students
48371818|NCT02311764|DRUG|Carboplatin|Carboplatin will be administered weekly
48371819|NCT04591782|OTHER|PomJuice|Drink 8 oz pomegranate juice
48516237|NCT02542956|DRUG|Marcaine|receive Marcaine by injection
48516238|NCT04881487|RADIATION|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
48516239|NCT02054286|BIOLOGICAL|THV01-1|Intramuscular injection of THV01-1 (week 0)
48702316|NCT04975919|DRUG|Decitabine and Cedazuridine|Given PO
48702317|NCT04975919|DRUG|Venetoclax|Given PO
48702318|NCT03846726|PROCEDURE|standard TME surgery|radical resection for rectal cancer
48702319|NCT06606938|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4
48702320|NCT06606938|PROCEDURE|Normal Saline (Placebo)|Placebo at baseline, week 2, week 4
48702321|NCT03620552|DRUG|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
48702322|NCT02694068|OTHER|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
48702323|NCT02694068|OTHER|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
48702324|NCT05867433|BEHAVIORAL|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
48702325|NCT05867433|BEHAVIORAL|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
48702326|NCT03300154|BEHAVIORAL|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
48702327|NCT03300154|BEHAVIORAL|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
48702328|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
48702329|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
48702330|NCT04681833|DRUG|Placebo|Liquid diluent/Lyophilised Powder
48702331|NCT00395135|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
48702332|NCT00395135|DRUG|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
48702333|NCT01747408|DRUG|Human Albumin|"25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day"
48702334|NCT04125238|BEHAVIORAL|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
48702335|NCT04125238|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
48702336|NCT03604588|DIAGNOSTIC_TEST|HPV OncoTect™|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
48702337|NCT03057041|DRUG|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
48702338|NCT03057041|DRUG|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
48702339|NCT02906449|BEHAVIORAL|Meditation Technique|Alertness training or relaxation training
48702340|NCT04002284|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
48702341|NCT06608953|DEVICE|Enhanced external counterpulsation|A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
48702342|NCT05573750|BEHAVIORAL|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
48702343|NCT04081753|DEVICE|Remote monitoring of temperature|The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
48702344|NCT01663701|OTHER|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
48702345|NCT01663701|OTHER|Usual care|Patients are managed according to admitting doctors' orders
48014328|NCT03808896|PROCEDURE|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
48014329|NCT03808896|DEVICE|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
48014330|NCT06102421|DEVICE|BTL-6000 FSWT|Low-energy focused extracorporeal shockwave therapy will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines.
48014331|NCT04891549|PROCEDURE|Tension band fixation|Fracture fixation of the patella fracture with tension band.
48014332|NCT04891549|PROCEDURE|Plate fixation|Fracture fixation of the patella fracture with a plate.
48014333|NCT01707004|DRUG|decitabine|Given IV
48170942|NCT02570256|BEHAVIORAL|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
48170943|NCT02570256|BEHAVIORAL|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
48170944|NCT02570256|BEHAVIORAL|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
48170945|NCT04196829|DRUG|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
48170946|NCT04196829|DRUG|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
48170947|NCT03827850|DRUG|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
48170948|NCT01171183|DRUG|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
48170949|NCT01171183|DRUG|Placebo|Placebo
48170950|NCT06198413|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
48371820|NCT04591782|OTHER|Water|Drink 8 oz water
48371821|NCT04591782|OTHER|Sugar Water|Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
48371822|NCT03748628|DRUG|EDP-305|\[14C\]EDP-305
48371823|NCT05011669|DRUG|Lurasidone|Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.
48516240|NCT02054286|BIOLOGICAL|THV01-2|Intramuscular injection of THV01-2 (week 8)
48014334|NCT01707004|DRUG|fludarabine phosphate|Given IV
48014335|NCT01707004|DRUG|busulfan|Given IV
48014336|NCT01707004|DRUG|cyclophosphamide|Given IV
48516241|NCT02054286|BIOLOGICAL|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
48516242|NCT00251121|OTHER|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
48014337|NCT01707004|DRUG|tacrolimus|Given PO or IV
48014338|NCT01707004|DRUG|mycophenolate mofetil|Given PO
48014339|NCT01707004|BIOLOGICAL|filgrastim|Given SC
48014340|NCT01707004|RADIATION|total-body irradiation|Undergo total-body irradiation
48014341|NCT01707004|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
48014342|NCT01707004|OTHER|laboratory biomarker analysis|Correlative studies
48014343|NCT04698005|DIETARY_SUPPLEMENT|25g Ketone monoester without added salts|oral supplementation of ketone monoester
48014344|NCT04698005|OTHER|Placebo|The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
48014345|NCT01042964|DRUG|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
48014346|NCT03348761|DEVICE|rTMS group|
48170951|NCT06105112|DEVICE|Hyaluronic acid|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.
48516243|NCT00251121|OTHER|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
48170952|NCT06105112|DEVICE|Enamel matrix derivatives|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
48170953|NCT03272698|DRUG|Ketamine|IV Ketamine 0.50 mg/kg
48170954|NCT03272698|PROCEDURE|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
48170955|NCT05051475|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic ablation technique for Barrett's epithelium
48170956|NCT05051475|PROCEDURE|Endoscopic hybrid argon plasma coagulation|Endoscopic ablation technique for Barrett's epithelium
48170957|NCT02587897|OTHER|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
48170958|NCT02587897|OTHER|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
48170959|NCT01750086|DRUG|Teriparatide 40-mcg subcutaneous injection|
48170960|NCT01750086|DRUG|Denosumab Injection|One-time Denosumab injection
48170961|NCT01750086|DRUG|Alendronate Oral Tablet|weekly alendronate for 8 weeks
48170962|NCT04788966|DEVICE|the translation tool BabelDr|Doctors use a speech-enabled fixed-phrase translation tool to help communicate with an allophone patient.
48170963|NCT00523549|DRUG|valsartan|160 mg or 320 mg tablets once a day
48170964|NCT00523549|DRUG|amlodipine|5 mg or 10 mg tablets once a day
48516244|NCT01298414|GENETIC|RNA analysis|
48516245|NCT01298414|OTHER|laboratory biomarker analysis|
48516246|NCT04400422|DIETARY_SUPPLEMENT|Lipano formula|Subjects will be asked to take an MCT infant formula to assess the tolerability, compliance and overall acceptability of the product for patient with LCHAD
48014347|NCT04726410|BIOLOGICAL|Cold Stored Platelets|early infusion of urgent release CSP
48014348|NCT04726410|BIOLOGICAL|Standard Care|standard care including room temperature platelets
48014349|NCT03515460|OTHER|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
48516247|NCT02864355|DEVICE|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
48516248|NCT01307748|OTHER|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
48014350|NCT03515460|OTHER|fat oral load|The individuals will a receive fat oral load (high fat meal)
48014351|NCT03515460|OTHER|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
48014352|NCT01915277|DRUG|Dexmedetomidine|
48014353|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
48170965|NCT01667172|DEVICE|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
48170966|NCT04124471|BEHAVIORAL|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
48170967|NCT04899401|DIETARY_SUPPLEMENT|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
48371824|NCT03534817|BEHAVIORAL|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
48516249|NCT04607837|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
48516250|NCT04607837|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
48516251|NCT02255968|DRUG|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
48516252|NCT02255968|DRUG|Placebo|Matching placebo capsules. All interventions are given as multiple doses
48516253|NCT06489210|PROCEDURE|popliteal block|using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
48516254|NCT02412917|DRUG|FV-100|antiviral nucleoside analog
48014354|NCT00749424|DEVICE|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
48014355|NCT02177240|DEVICE|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
48014356|NCT02177240|DEVICE|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
48014357|NCT01824303|DRUG|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
48014358|NCT01824303|OTHER|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
48014359|NCT04491630|BEHAVIORAL|Self-Hypnosis (SH)|"Participants assigned to this condition will listen to a 20-minute recording with instructions of SH adapted from one of our team member's proposed model. First, the audio recording will introduce and orient the participant to SH. Then instruction in SH will be provided, including: (a) how to self-induce a hypnotic induction; (b) specific self-suggestions for comfort and ability to manage intense sensations; and (c) post-hypnotic suggestions that the participant will be easily able to use these hypnotic strategies on their own at a later time (i.e., in this case, during the Cold Pressor Arm Wrap procedures that will follow).~A second 5-minute audio recording with instructions to guide the participant in SH will be provided during the second cycle of Cold Pressor Arm Wrap (CPAW)."
48014360|NCT04491630|BEHAVIORAL|Mindfulness Meditation (MM)|"Participants in the MM condition will listen to a 20-minutes recording with instructions in the use and application of Vipassana MM, adapted from the manual developed by one of our team members. First, the audio recording will focus on introducing the idea of attention to their breath, and of non-judgmental monitoring and acceptance of the all events and stimuli. Then a guided MM (body scan) experience will be provided.~A second 5-minute audio recording with instructions to facilitate the MM (body scan) experience taught in the first audio recording will be provided during the second cycle of CPAW."
48170968|NCT04899401|OTHER|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (\>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
48170969|NCT00822666|DRUG|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
48170970|NCT05257252|BEHAVIORAL|"Persons With Disability Friendly Nursing Education Program"|Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
48170971|NCT03398421|DRUG|Nemiralisib|Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
48170972|NCT03398421|DRUG|Itraconazole|Itraconazole will be given as 100 mg per capsule per day administered orally with water
48170973|NCT03443063|DRUG|Lemborexant|oral tablet
48170974|NCT03813732|PROCEDURE|orbital fracture|using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area
48170975|NCT04326153|DRUG|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
48371825|NCT03754270|OTHER|Advice in lifestyle|Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
48170976|NCT05742659|OTHER|A mobile-based interactive simulation scheme (MISS)|A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
48170977|NCT03635840|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
48371826|NCT03754270|DEVICE|Cervical collar|"Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed."
48702346|NCT06604819|DRUG|Ozone gel placed after closed sinus lifting then implant placed simultaneously.|The patient received closed sinus lifting using osteotomes then ozone gel is prepared. Pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process then implants were placed.
48170978|NCT00605566|DRUG|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
48702347|NCT06604819|PROCEDURE|closed sinus lifting using osteotomes with simultaneous implant placement|The patient received closed sinus lifting using osteotomes with implant placed simultaneously.
48702348|NCT05978960|OTHER|Nutrition and resistance training exercise intervention|"3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants."
48702349|NCT00004248|BIOLOGICAL|aldesleukin|
48702350|NCT00004248|DRUG|doxorubicin hydrochloride|
48702351|NCT05124652|DEVICE|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
48702352|NCT03384563|DRUG|Dexmedetomidine|Dexmedetomidine 9 arms
48702353|NCT03160274|GENETIC|Genetic screening|Germline and/or tumor samples will be screened for mutations
48702354|NCT02098499|DRUG|Haloperidol|5mg IV
48702355|NCT02098499|DRUG|Metoclopramide 10mg|10mg IV
48702356|NCT02098499|DRUG|Diphenhydramine|25mg IV
48702357|NCT02313727|DRUG|Pamidronate|intravenous infusion of pamidronate 60 mg
48702358|NCT02313727|OTHER|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
48014361|NCT04491630|BEHAVIORAL|Christian Prayer (CP)|"Participants in this condition will listen to a 20-minute recording with CP instructions. These instructions will be adapted from the existing on-line biblical meditations from the Society of Jesus (www.passo-a-rezar.net). First, the recording will introduce and orient the participant to CP. Then, a text of the Bible will be read twice, followed by a brief suggestion of prayer.~A second 5-minute audio recording with instructions to facilitate the CP experience taught in the first audio recording, including the recording of a text of the Bible followed by a brief suggestion of meditation and relaxing music, will be provided during the second cycle of CPAW."
48371827|NCT01873274|DIETARY_SUPPLEMENT|MK-7 containing capsule|
48371828|NCT01873274|DIETARY_SUPPLEMENT|basic yogurt enriched with MK-7|
48371829|NCT01873274|DIETARY_SUPPLEMENT|nutrient-enriched yogurt with MK-7|
48516255|NCT02412917|DRUG|valacyclovir|antiviral nucleoside analog
48516256|NCT06339697|DRUG|different types of laxatives (compounded polyethylene glycol electrolyte dispersions and compounded sodium pico-sulfate)|Bowel preparation with different types of laxatives (compounded polyethylene glycol electrolytes and compounded sodium picosulfate)
48516257|NCT00925639|DRUG|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
48516258|NCT00925639|DRUG|Placebo|Starch pill
48702359|NCT01824199|DRUG|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
48702360|NCT06163495|BEHAVIORAL|Screen Free Time with Friends intervention|School-based extracurricular intervention focusing on time spent with friends and screen media use
48702361|NCT00809991|RADIATION|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
48371830|NCT01769846|OTHER|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH \& Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
48371831|NCT02945566|PROCEDURE|Standard TME surgery|Total mesorectal excision
48516259|NCT03683771|DIAGNOSTIC_TEST|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
48516260|NCT00468364|DRUG|insulin glargine|
48516261|NCT00468364|DRUG|NPH insulin|
48014362|NCT02889159|BIOLOGICAL|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
48014363|NCT02889159|BIOLOGICAL|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
48702362|NCT04934709|DEVICE|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
48702363|NCT04934709|DEVICE|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
48702364|NCT02979509|OTHER|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
48702365|NCT06000111|BEHAVIORAL|3 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
48702366|NCT06000111|BEHAVIORAL|7 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
48702367|NCT06597994|DEVICE|Amber UI system|Upgrade of Amber UI system recharge accessories and system firmware
48702368|NCT03523793|BEHAVIORAL|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
48702369|NCT03523793|OTHER|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
48702370|NCT04807088|PROCEDURE|Tactile-kinesthetic Stimulation|
48702371|NCT04807088|OTHER|Placebo|
48014364|NCT02889159|BIOLOGICAL|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
48014365|NCT02889159|PROCEDURE|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
48014366|NCT04947033|DRUG|TJ210001 Injection|The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
48014367|NCT06288867|PROCEDURE|Arthroscopic Labral Repair|Patients with Hip Labral tears will be treated with labral repair
48014368|NCT06288867|PROCEDURE|Arthroscopic Labral Debridement|Patients with Hip Labral tears will be treated with labral debridement
48014369|NCT03621943|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
48014370|NCT03621943|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
48702372|NCT06485973|OTHER|Modified Dental Anxiety Scale (MDAS)|The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
48702373|NCT05980871|DRUG|Doxycycline|doxycycline (100 mg orally twice daily for 7 days)
48702374|NCT05980871|DRUG|Ceftriaxone|Ceftriaxone (1g intramuscularly once)
48014371|NCT05724602|DRUG|Xevinapant|3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
48371832|NCT02945566|DRUG|Long course concurrent chemoradiation with capecitabine and radiotherapy|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
48371833|NCT02945566|RADIATION|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
48014372|NCT05724602|DRUG|Placebo|3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
48014373|NCT00000410|PROCEDURE|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
48014374|NCT00000410|PROCEDURE|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
48516262|NCT03790657|BEHAVIORAL|practice of a complex walking task|walking over obstacles
48702375|NCT05980871|DRUG|benzathine penicillin G|benzathine penicillin G (2.4 MU intramuscularly once)
48702376|NCT01537159|DEVICE|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
48516263|NCT03790657|DEVICE|Dosage A: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
48702377|NCT00904098|DRUG|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
48371834|NCT00517517|BIOLOGICAL|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
48371835|NCT00690573|BIOLOGICAL|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
48371836|NCT02434640|DRUG|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
48702378|NCT00904098|DRUG|Usual Care|Current treatment used to treat all migraine headaches
48702379|NCT01098604|DEVICE|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
48702380|NCT01098604|DEVICE|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
48702381|NCT03956277|DEVICE|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
48702382|NCT02352272|OTHER|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
48702383|NCT02017392|DRUG|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
48371837|NCT02434640|DRUG|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
48371838|NCT02434640|DRUG|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
48516264|NCT03790657|DEVICE|Dosage B: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
48702384|NCT04424628|RADIATION|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
48702385|NCT04424628|RADIATION|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
48702386|NCT06315231|DRUG|Edaravone dexborneol sublingual tablet|Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
48702387|NCT06315231|DRUG|Placebo|Patients will receive one placebo twice daily for 24 weeks
48014375|NCT03417297|DEVICE|High Intensity Focused Ultrasound|Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
48170979|NCT00605566|DRUG|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
48702388|NCT05555797|DEVICE|308nm Excimer laser|Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
48702389|NCT05555797|DRUG|Tazarotene Topical Gel|Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
48702390|NCT05555797|DRUG|Betamethasone Valerate|.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
48702391|NCT01011491|OTHER|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
48702392|NCT01011491|OTHER|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
48702393|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
48702394|NCT02052726|BIOLOGICAL|Placebo|Placebo administered at Month 0, 1, and 3.
48014376|NCT02489981|DRUG|Spiriva|60 puffs
48702395|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
48702396|NCT02052726|BIOLOGICAL|placebo|Placebo administered at Day 1, 8, and 30.
48702397|NCT04007237|DRUG|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
48014377|NCT05789732|DRUG|Placebo|Patients will receive placebo treatment once daily.
48014378|NCT05789732|DRUG|Silodosin|Patients will receive Silodosin 8 mg once daily.
48014379|NCT05789732|DRUG|Tadalafil|Patients will receive Tadalafil 5 mg once daily.
48702398|NCT05403593|OTHER|No Intervention|No intervention, prospective data collection
48702399|NCT02460354|DRUG|Metformin|Metformin 500 mg pill dispensed once orally
48702400|NCT02224287|PROCEDURE|Technologist control of fluoroscopy|Technologist control of fluoroscopy
48702401|NCT02224287|PROCEDURE|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
48702402|NCT01792817|DEVICE|GammaCore|Treatment with active gammacore vagus nerve stimulator
48014380|NCT05789732|DRUG|Silodosin and Tadalafil|Patients will receive Silodosin 8mg in combination with Tadalafil 5 mg once daily.
48014381|NCT04768036|OTHER|IMPROVE DD VTE Tool|"Universal SMART on FHIR platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow."
48014382|NCT00393549|DEVICE|NeuroPath|
48371839|NCT06231849|DIAGNOSTIC_TEST|stool analysis|stool analysis to determine number of gut microbiota in subjects with opioid use and its effect on its intoxication.
48702403|NCT01792817|DEVICE|Sham GammaCore device|Treatment with sham stimulator
48702404|NCT06606756|OTHER|Patient Registry without intervention|This is a patient registry that collects real world data without intervening with therapeutic decision
48702405|NCT06606756|OTHER|Digital Registry and Feedback on clinical data|The data is entered via a validated online platform and is provided back to the center in aggregated form
48702406|NCT02110329|GENETIC|evaluation of the recurrence rate according to molecular analysis|
48014383|NCT06203405|PROCEDURE|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"* Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~* Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~* Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~* Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~* Then sedation adjustment will be guided by P0.1 measurement.~* If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~* If P0.1 value \<1.5, sedation will be reduced.~* If P0.1 value \>3.5, sedation will be increased.~* If P0.1 value is still \>3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value \<3.5 cmH2O.~* The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
48014384|NCT06203405|DRUG|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
48014385|NCT06203405|DRUG|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
48014386|NCT06203405|DRUG|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
48014387|NCT06203405|DRUG|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
48014388|NCT06203405|DRUG|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
48014389|NCT05725603|OTHER|MRI imaging|Shoulder MRI will be performed at least 3 years after shoulder surgery
48170980|NCT04213820|DEVICE|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
48170981|NCT04213820|BEHAVIORAL|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
48516265|NCT04809922|DEVICE|cardiac wearable devices|"five cardiac wearable devices~* Apple Watch, Apple Inc., Model Number: A1977 / A1978~* Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~* Fitbit Sense, Fitbit, Inc, Model Number: FB512~* Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~* Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
48170982|NCT04213820|BEHAVIORAL|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
48702407|NCT04158726|BEHAVIORAL|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
48702408|NCT00585221|DRUG|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
48702409|NCT00585221|DRUG|Imatinib|Continue imatinib until progression.
48014390|NCT03120065|OTHER|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
48014391|NCT02586701|OTHER|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
48014392|NCT01142245|DRUG|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
48014393|NCT01142245|DRUG|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours"
48014394|NCT04783129|OTHER|Education program based on 10 monthly lectures|The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.
48014395|NCT04783129|OTHER|No intervention|Participants will follow no education program (lecture) and will be instructed to follow their usual routine for the treatment of the disease
48170983|NCT03411798|DRUG|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
48516266|NCT03406754|BEHAVIORAL|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
48516267|NCT06178003|BIOLOGICAL|Tpdelansbsalbac|Tpdelansbsalbac,which is Knockdown of ansB, a gene that expresses L-mentholase secreted into the extracellular region, on the basis of the genetic background of bacterium VNP20009, and construction of an ansB gene-deficient mutant strain, ΔansB.
48014396|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
48014397|NCT01611324|DRUG|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
48014399|NCT06040502|BEHAVIORAL|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
48014400|NCT01632501|DEVICE|Coronary stent - Tsunami|A coronary angioplasty was done
48170984|NCT00175370|DRUG|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
48170985|NCT01176318|DRUG|Erdosteine|capsule 300mg twice daily for 10 days
48170986|NCT01176318|DRUG|Placebo|placebo capsule, twice daily for 10 days
48170987|NCT02628964|DEVICE|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
48702410|NCT06607510|OTHER|Experimental HIIT|Subjects belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. This program is designed in a standardized warm-up: joint mobility exercises and neuromuscular activation (5 minutes). Main part os the training is design in treadmill walking exercise (28 minutes). Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.The initial starting speed is 5 km/h and adjust the intensity with incline increments of 2%. Between sets, a prescribed active rest period lasts three minutes, during which patients walk on the treadmill at an intensity of 60-70% of peak heart. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
48702411|NCT06607510|OTHER|Experimental HIFT|Subject belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. AMRAP will consist of a circuit of six global, functional exercises with external loads \[i) squat; ii) rowing; iii) dead weight; iv) chest press; v) step up; vi) farmer walk\]. Patients will perform 10 repetitions of each exercise and complete as many rounds as possible within the specified time. Between blocks, there will be a prescribed active rest period lasting three minutes, during which patients will walk on the treadmill at an intensity of 60-70% of peak heart rate. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
48702412|NCT02404870|DRUG|Placebo|Placebo
48702413|NCT02404870|DRUG|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
48702414|NCT03782207|DRUG|Atezolizumab|Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
48702415|NCT06606652|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
48702416|NCT06606652|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
48702417|NCT01571050|DRUG|Purified water|Ingestion of 30 mL of purified water
48702418|NCT01571050|DRUG|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
48702419|NCT01571050|DRUG|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
48702420|NCT01571050|DRUG|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
48702421|NCT01571050|DRUG|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
48702422|NCT01282307|BEHAVIORAL|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
48702423|NCT05841004|DEVICE|Investigational device|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
48702424|NCT05841004|DEVICE|Comparator device|Hollister Infyna Chic, single-use compact catheter.
48702425|NCT03014310|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
48702426|NCT03014310|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
48702427|NCT03014310|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
48702428|NCT04734418|DRUG|Remifentanil|Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
48702429|NCT04734418|DRUG|Dexmedetomidine|Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
48702430|NCT01971749|PROCEDURE|Coronary stent procedure (CSP)|
48702431|NCT01971749|PROCEDURE|Coronary-artery bypass grafting (CABG)|
48702432|NCT05289271|BIOLOGICAL|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
48702433|NCT05121220|DEVICE|fixed retainer|bonded lingual mandibular fixed retainer on frontal teeth 33-43
48702434|NCT05121220|DEVICE|removable retainer|thermoplastic vacuum-formed removable mandibular retainer
48702435|NCT02965183|OTHER|Temperature measurements|
48702436|NCT05767346|DRUG|Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)|Aficamten (CK-3773274) tablets administered orally
48702437|NCT05767346|DRUG|Placebo to match aficamten|Placebo for aficamten (CK-3773274) administered orally
48702438|NCT05767346|DRUG|Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)|Metoprolol succinate tablets administered orally
48702439|NCT05767346|DRUG|Placebo to match metoprolol succinate|Placebo for metoprolol succinate administered orally
48702440|NCT06608056|DRUG|Pain management after surgery|Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
48702441|NCT05455918|DRUG|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
48014401|NCT04793880|BEHAVIORAL|Medication Cost Information|This version of the HFrEF medication checklist includes patient-specific estimated monthly out-of-pocket cost for each medication. TailorMed, a company designed to provide financial counseling and planning for patients, will generate the patients' out-of-pocket cost based on insurance status. The costs for non-generic HFrEF medications will then be populated onto a checklist of recommended heart failure medications so that patients and their clinicians will have this information available during their clinical encounter.
48014402|NCT04793880|BEHAVIORAL|Heart Failure Medicines Checklist|The Heart Failure Medicines Checklist is an evidence-based medication checklist that describes guideline-recommended medications for HFrEF. This tool is used during the clinical encounter to facilitate a discussion about medications that may be most appropriate for the patient.
48014403|NCT00333229|DRUG|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
48014404|NCT00333229|DRUG|Placebo|Matching Placebo
48014405|NCT00682019|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
48014406|NCT00682019|DRUG|Placebo|matching placebo
48014407|NCT04252859|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
48014408|NCT04485481|DRUG|ADX-914|Single dose from 0.1mg/kg to TBD
48014409|NCT04485481|DRUG|Placebo|Matching single dose placebo
48014410|NCT04485481|DRUG|ADX-914|Multiple dose from TBD to TBD
48371840|NCT04790682|BIOLOGICAL|assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.|"* At pre-screening NGS analysis on tumor tissue (slides). Only patients with at least 1 mutation at NGS on the tumor tissue will ultimately be enrolled in the main study, to have the possibility to follow the mutation using ctDNA.~* Main study will be initiated after results of the NGS and before initiation of pembrolizumab. Blood specimens will be taken with EDTA tubes or streck tubes at the time of puncture for pembrolizumab infusion at baseline before starting treatment, at 3 weeks, 6 weeks and then every 6 weeks (30 ml at Baseline then 20 ml of blood). Blood immunomonitoring will be done before starting the treatment, at 6 weeks and at 18 Week. An additional measurement will be performed if treatment is stopped before the end of the study (18 ml of blood).~* Optional blood samples will be realized to analyse the degree of activity of the plasmatic lymphocytes before starting the treatment and at 6 weeks and (18 ml of blood)."
48014411|NCT04485481|DRUG|Placebo|Matching multiple dose placebo
48014412|NCT05886764|OTHER|Digital Intervention|Digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.
48014413|NCT05886764|OTHER|Community Outreach|Invitation to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.
48014414|NCT06662760|DRUG|TQB3002 Tablets|TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
48371841|NCT01069692|DRUG|SBR759A|SBR759A 6g daily
48014415|NCT02927691|DEVICE|EMST|
48014416|NCT02927691|BEHAVIORAL|smTAP|
48014417|NCT03866616|BEHAVIORAL|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
48014418|NCT03866616|BEHAVIORAL|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
48014419|NCT03380923|BEHAVIORAL|Moderate Intensity|Exercise prescription intensity is moderate
48371842|NCT01069692|DRUG|SBR759A|Placebo Comparator 0g daily
48371843|NCT01069692|DRUG|SBR759A|SBR759A 3g daily
48371844|NCT01069692|DRUG|SBR759A|9g daily
48014420|NCT03380923|BEHAVIORAL|High Intensity|Exercise prescription intensity is high
48516268|NCT03839966|BEHAVIORAL|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard \& Amir, 2008 and Beard, Weisberg, \& Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
48522970|NCT02689583|GENETIC|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
48702442|NCT03677466|DRUG|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
48702443|NCT03677466|PROCEDURE|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
48702444|NCT05411588|DRUG|PF-07275315|Active drug
48702445|NCT05411588|DRUG|Placebo|Placebo
48702446|NCT04552210|DIAGNOSTIC_TEST|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
48371845|NCT01069692|DRUG|SBR759A|12g daily
48702447|NCT01372072|DEVICE|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
48702448|NCT06444555|DIETARY_SUPPLEMENT|BEP supplement|The BEP supplement used in Burkina Faso is a fortified medium-quantity lipid-based nutrient supplement called Plumpy'Doz. The product is a peanut and milk-based ready-to-use nutritional formulation produced by Nutriset. A peanut-based BEP formulation with a trademark Plumpy'Sup produced by Hilina Enriched Foods PLC will be used in Ethiopia.
48702449|NCT06444555|DIETARY_SUPPLEMENT|Multiple Micronutrient supplement|The MMN formulation is based on the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). The formulation contains 15 minerals and vitamins and is administered as a tablet.
48702450|NCT04271748|OTHER|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
48371846|NCT01778673|PROCEDURE|Cast immobilization|
48371847|NCT04570033|DIAGNOSTIC_TEST|We assessed sensitivity of 18F-FCH PET/CT in preoperative localisation of hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism|We prospectively enrolled 65 consecutive patients with PHPT who underwent neck ultrasound (US) and parathyroid scintigraphy (99mTc/99mTc-MIBI dual phase). Twenty-two patients had unsuccessful parathyroid surgery prior to the study. PET/CT scans were performed 65.0 ± 13.3 min after injection of 218.5 ± 31.9 MBq of 18F-fluorocholine (FCH). Three experienced nuclear medicine physicians assessed the detection rate of hyperfunctioning parathyroid tissue. Response to parathyroidectomy and clinical follow-up served as a reference test. Per-patient sensitivity and positive predictive value (PPV) were calculated for patients who underwent surgery.
48702451|NCT03990415|BEHAVIORAL|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
48702452|NCT04376840|OTHER|Blood sample and data record|Blood sample and data record
48702453|NCT03758079|DRUG|Doxepin|10 mg Doxepin for 4 weeks
48702454|NCT03758079|DRUG|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
48014432|NCT06113718|PROCEDURE|Abdominal Exercise (digital rectal stimulation, abdominal massage)|"The recommended bowel exercise program consisted of three steps:~1. Patients will perform a 2-3 minute massage starting from the cecum approximately 20-30 minutes after breakfast, moving along the colon.~2. Patients will assume a suitable position and perform circular massage on the anal walls with their finger for approximately 30 seconds (digital rectal stimulation).~3. Patients will try to defecate while sitting on the toilet."
48014433|NCT04992949|DRUG|CPX-351|"Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study~Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.~Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle"
48014434|NCT04313166|DRUG|Cu(II)ATSM|cooper-containing synthetic small molecule
48014435|NCT02851238|OTHER|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
48170988|NCT03153098|BEHAVIORAL|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
48014436|NCT05349422|BEHAVIORAL|Electronic Health Record (EHR) Enabled Teamlets|The intervention consist of four components: 1) patients with hypertension will be automatically screened for low medication adherence using linked EHR-pharmacy data at the time of a PCP encounter; 2) MAs will deliver a validated, rapid, survey of common causes of non-adherence; 3) MAs and/or RNs will address barriers to adherence tailored to survey response, including delivery of brief health coaching based on motivational interviewing; and 4) PCPs will address specific barriers to adherence based on survey response.
48014437|NCT01034397|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
48014438|NCT01034397|DRUG|placebo|iv every 4 weeks for 24 weeks
48014439|NCT01034397|DRUG|non-biological DMARDs|stable dose at investigator's prescription
48014440|NCT03488576|PROCEDURE|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
48702455|NCT04266964|PROCEDURE|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
48170989|NCT05469113|DRUG|Repaglinide|Administered orally.
48371848|NCT03152721|DEVICE|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
48371849|NCT03152721|OTHER|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
48371850|NCT04337827|DRUG|Rituximab|"Weekly x 4 weeks.~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto Long Term Follow Up (LTFU)."
48702456|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
48702457|NCT03587701|DRUG|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
48702458|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
48371851|NCT04337827|DRUG|Acalabrutinib|"100mg twice per day (BID) x 4 weeks (28 day cycle)~If diagnostic test reveals complete response, then participant will continue with one additional 28 day cycle. If partial response, then proceed with 3 additional 28 day cycles. If stable disease or progression of disease, then go off study treatment and proceed onto LTFU."
48702459|NCT03587701|DRUG|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
48702460|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
48014441|NCT03488576|PROCEDURE|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
48014442|NCT00283725|OTHER|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor \[AChEI\] nor memantine).
48170990|NCT05469113|DRUG|Selpercatinib|Administered orally.
48371852|NCT04337827|DIAGNOSTIC_TEST|CT scans|2 weeks (day 36 ± 5 days) after end of cycle 1 treatment.
48522971|NCT02689583|DIETARY_SUPPLEMENT|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
48702461|NCT02068690|DRUG|Placebo|Placebo
48702462|NCT02068690|DRUG|Placebo|Placebo
48702463|NCT02068690|DRUG|BI 425809 tablet|BI 425809 tablet
48702464|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
48014443|NCT02536859|DRUG|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
48014444|NCT02536859|DRUG|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
48014445|NCT05679791|DEVICE|Dynamometer|to assses hand grip
48014446|NCT05597527|DRUG|Fluzopari and apatinib|Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
48014447|NCT06664125|DRUG|JMKX003002 will be administered orally|tablets for oral administration.
48014448|NCT06664125|DRUG|Sevelamer carbonate|tablets for oral administration.
48371853|NCT00710840|PROCEDURE|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
48014449|NCT05961098|DRUG|RBD1016|RBD1016 with NAs background treatment will be explored.
48014450|NCT04040101|DEVICE|smartphone-based balance training system|use smartphone application to training balance
48371854|NCT00710840|PROCEDURE|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
48371855|NCT03710824|DRUG|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
48014451|NCT01455675|DRUG|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
48014452|NCT01455675|DRUG|Placebo|Placebo, 70 ml gargling solution, once daily
48014453|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
48014454|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
48371856|NCT00015912|BIOLOGICAL|recombinant interferon alfa|Given IV
48014455|NCT01205724|DRUG|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
48702465|NCT05752942|BEHAVIORAL|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
48702466|NCT05752942|BEHAVIORAL|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
48702467|NCT01534260|DRUG|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
48702468|NCT03263728|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
48702469|NCT05499455|DEVICE|Positional Sleep Belt|Rematee Positional Sleep Belt
48702470|NCT05499455|DEVICE|Control|Control Device
48702471|NCT00374569|PROCEDURE|Gymnastic Routine|A combination of gymnastic movements are performed
48702472|NCT05184101|DRUG|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
48702473|NCT06602219|DRUG|LY4100511|Administered orally
48702474|NCT06602219|DRUG|Placebo|Administered orally
48014456|NCT05814562|BEHAVIORAL|Remote Intervention|The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
48014457|NCT03675958|OTHER|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
48014458|NCT03675958|OTHER|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
48014459|NCT03149328|OTHER|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
48014460|NCT02306980|OTHER|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
48371857|NCT00015912|DRUG|thalidomide|Given orally
48014461|NCT03966235|DRUG|Melatonin 3 mg|Melatonin was taken daily for 6 months.
48371858|NCT00015912|OTHER|laboratory biomarker analysis|Correlative studies
48371859|NCT06510322|DRUG|Sildenafil|Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
48371860|NCT06510322|OTHER|Placebo|Matched capsule not containing any medication
48371861|NCT06091891|DRUG|Tranexamic acid|Without ROTEM-guidance, we maintain tranexamic acid infusion at 10mg/kg/h until the end of the surgery.
48371862|NCT06091891|DRUG|Tranexamic acid infusion under ROTEM-guidance|If diffuse bleeding occurs during surgery, we perform ROTEM testing and administer tranexamic acid based on the test results.
48371863|NCT02062541|OTHER|Funct. assessment+fast rehabilitation|
48014462|NCT03966235|DRUG|Placebo|Placebo tablet was taken daily for 6 months.
48014463|NCT04548882|DEVICE|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
48014464|NCT05848635|DRUG|Hydromorphone Hydrochloride|Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
48014465|NCT05848635|DRUG|Morphine hydrochloride|Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation
48014466|NCT03438435|DRUG|QRH-882260 Heptapeptide|Imaging agent
48014467|NCT05802381|DIETARY_SUPPLEMENT|protein supplement|20 gram protein supplement per day
48014468|NCT05802381|BEHAVIORAL|nutrition counseling|nutrition counseling for guidance of food intake
48014469|NCT01970202|DRUG|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
48014470|NCT01970202|DRUG|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
48014471|NCT01970202|OTHER|Control|no treatment
48371864|NCT02062541|OTHER|Funct. assessment+usual rehabilitation|
48371865|NCT02062541|OTHER|usual assessment+fast rehabilitation|
48371866|NCT02618681|OTHER||
48371867|NCT01784081|OTHER|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
48014472|NCT01110915|DEVICE|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
48702475|NCT03194568|DEVICE|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
48702476|NCT06439433|DRUG|Aminolaevulinic acid (500-mg bottle)|once a week for 6 weeks
48702477|NCT06439433|DRUG|Aminolaevulinic acid (750-mg bottle)|once a week for 6 weeks
48702478|NCT06439433|DRUG|Placebo|once a week for 6 weeks
48014473|NCT01110915|DEVICE|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
48371868|NCT05480891|PROCEDURE|Transnasal Esophagoscopy (TNE)|"While seated in an upright position a topical numbing medicine will be sprayed in your nose and the back of your throat.~A thin, flexible tube less than ¼ inch in diameter, will be placed in one of your nostrils and advanced to the back of your throat. When the tube reaches the back of the throat you will be asked to drink sips of water to help move the tube into and down the esophagus as it is advanced. The tip of the tube has a small light and camera built in that allows the doctor to see the structures of the mouth and esophagus as the tube is advanced. Once the tube is in the esophagus, the physician will examine your esophagus for any abnormal changes.~Once the visual inspection is complete the tube will be gently removed through your nose. The procedure will take approximately 10-15 minutes of time."
48371869|NCT03853915|DIAGNOSTIC_TEST|[18-F]- FDG - PET|\[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
48371870|NCT05300126|BEHAVIORAL|Hypnosis|Four sessions of 15 minute hypnosis, based on standardised script, focused on symptom management for the patients and of resource development for relatives.
48702479|NCT06527248|DIETARY_SUPPLEMENT|Nitrate group|Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
48702480|NCT06527248|DIETARY_SUPPLEMENT|Placebo group|Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
48702481|NCT01082874|DRUG|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
48702482|NCT01082874|DRUG|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
48014474|NCT00618215|BEHAVIORAL|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
48014475|NCT00568984|DRUG|repaglinide|
48014476|NCT00568984|DRUG|metformin|
48014477|NCT00568984|DRUG|glicazide|
48014478|NCT00773175|DRUG|recombinant human hyaluronidase|150 Units in 1 mL
48014479|NCT05872035|DEVICE|Apple Software|Amplification settings established by algorithm and further adjusted by participants per their preference
48371871|NCT03688191|DRUG|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
48014480|NCT05872035|DEVICE|by Audiologist|Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice
48014481|NCT05321069|DRUG|BI 1015550|BI 1015550
48014482|NCT05321069|DRUG|Placebo|Placebo
48014483|NCT05130775|OTHER|Transesophageal echocardiograpgy|3D acquisition of the right ventricle regurgitation volume
48014484|NCT01978431|DRUG|cocaine hydrochloride|
48014485|NCT01978431|DRUG|methylphenidate|
48014486|NCT04439240|DRUG|FGFR Inhibitor AZD4547|Given PO
48014487|NCT05975541|OTHER|Observational|No intervention will be carried out in this study. Patients from both groups will be monitored for 12 months through observations at time 0, time 6 months, and 12 months. Questionnaires, good clinical practice samples, and anthropometric measurements will be made to monitor changes in the two groups.
48014488|NCT00417560|BIOLOGICAL|inactivated influenza A/H5N1 vaccine|
48014489|NCT01376011|DIETARY_SUPPLEMENT|quercetin/placebo|Quercetin 500mg once per day versus placebo
48702483|NCT01082874|DRUG|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
48702484|NCT01082874|DRUG|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
48014490|NCT01406691|DEVICE|Flashes|one hour of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during the hour immediately prior to desired waketime
48014491|NCT06572605|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48014492|NCT06572605|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48170991|NCT06471608|OTHER|Ambulatory management|"* Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops~* Follow-up imaging at 4 hours (chest X-ray or low-dose CT scan, depending on management practices in the centers)~  * if the pneumothorax is still very large, or if clinical tolerance is unsatisfactory (dyspnea, unrelieved pain, abnormal vital parameters), the patient should be admitted to hospital~ * if the lung is in the process of reattachment and a minimal detachment persists, and clinical tolerance is good (assessed on vital parameters, with oxygen saturation above 98%, good hemodynamic stability and pain relieved by analgesics), the patient may be discharged home."
48170992|NCT06471608|OTHER|Standard Care|"Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days)."
48170993|NCT05864885|DRUG|Minoxidil|Topical formulation applied once a day.
48170994|NCT00940654|OTHER|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
48170995|NCT02762292|DEVICE|Measurement of work of breathing using indirect calorimeter|"1. Preparation:~   1. Patient baseline characteristics will be collected.~  2. Connection of the Indirect Calorimeter to the respiratory circuit.~  3. Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~2. Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~3. End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
48170996|NCT03553849|DIETARY_SUPPLEMENT|Very low calorie diet|The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
48702485|NCT05820152|DRUG|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
48702486|NCT06252961|DRUG|Levamisole 3 days|Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
48702487|NCT06252961|DRUG|Levamisole 5 days|Levamisole for 5 days (2,5 mg/kg)
48702488|NCT06252961|DRUG|Placebo|Placebo for 5 days
48014493|NCT06572605|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48014494|NCT06572605|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
48014495|NCT06572605|OTHER|Electronic Health Record Review|Ancillary studies
48014496|NCT06572605|RADIATION|External Beam Radiation Therapy|Undergo EMD-EBRT
48014497|NCT06572605|PROCEDURE|Image Guided Biopsy|Undergo image-guided EMD biopsy
48014498|NCT06572605|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48170997|NCT02974725|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
48170998|NCT02974725|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
48170999|NCT02974725|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
48171000|NCT02974725|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
48171001|NCT03772613|DRUG|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
48371872|NCT00983125|DRUG|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
48371873|NCT06048601|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|18F-florbetaben positron emission tomography/computed tomography
48522972|NCT00555165|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
48516269|NCT03839966|BEHAVIORAL|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
48371874|NCT02834351|OTHER|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
48516270|NCT00611260|BEHAVIORAL|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
48702489|NCT04085458|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
48702490|NCT01790178|PROCEDURE|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
48702491|NCT06605040|OTHER|Dissemination via Social Media|"Participants in the experimental group will follow a scientific Instagram profile where content will be shared. The profile will remain open, allowing permanent access to all posts. To optimize Instagram\&amp;amp;#39;s algorithm, we will use an existing active profile. Any control group participants already following the profile will be removed upon allocation.~For each selected article, we will create three presentations using Instagram features like carousel images and short videos, shared as posts, stories, and reels. This strategy will provide content for 30 weeks of daily posts. Each post will feature visually appealing graphics to convey scientific information and support evidence-based practice (EBP) competencies."
48014499|NCT06572605|BIOLOGICAL|Talquetamab|Given SC
48171002|NCT03626311|DIETARY_SUPPLEMENT|AKBM-3031|"Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use."
48702492|NCT06605040|OTHER|Dissemination via Email|The participant allocated to the control group will receive a different summary each day, along with a link to the full article. This strategy was chosen to replicate the approach used by scientific journals to disseminate new issues.
48702493|NCT05704907|OTHER|gallbladder ultrasound|gallbladder ultrasound
48702494|NCT04903873|DRUG|EU101|EU101 will be administered via intravenous infusion.
48702495|NCT00420004|DRUG|LY2216684|3-mg and 6-mg tablets
48702496|NCT00420004|DRUG|Placebo|
48371875|NCT02539160|DRUG|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
48371876|NCT00283673|BEHAVIORAL|Exercise|
48371877|NCT01211795|DRUG|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
48014500|NCT01350206|PROCEDURE|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
48014501|NCT01350206|PROCEDURE|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
48014502|NCT04176770|PROCEDURE|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
48014503|NCT04176770|PROCEDURE|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
48014504|NCT00782652|DRUG|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
48702497|NCT00420004|DRUG|Escitalopram|10-mg capsules
48171003|NCT03626311|OTHER|Placebo|The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
48171004|NCT01530087|DEVICE|CASTLE barrier|Prototype barrier to be used in place of current two piece device
48702498|NCT05935878|DEVICE|Cementless Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
48702499|NCT05935878|DEVICE|Cemented Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
48702500|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
48171005|NCT01179906|BEHAVIORAL|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
48171006|NCT01179906|BEHAVIORAL|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
48171007|NCT06146413|DRUG|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up
48171008|NCT06146413|DRUG|HCG trigger|hCG ( 10000 IU) is administered 36 h before ovum pick-up
48171009|NCT03378778|PROCEDURE|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
48371878|NCT01211795|OTHER|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
48371879|NCT02441517|DRUG|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
48522973|NCT03727451|COMBINATION_PRODUCT|iNO|inhaled nitric oxide
48702501|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
48702502|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
48702503|NCT02333682|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
48702504|NCT02927704|OTHER|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
48014505|NCT00782652|DRUG|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
48014506|NCT03919045|DRUG|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
48014507|NCT03919045|PROCEDURE|Placebo|Half of the group will be treated with needle stings without injections
48014508|NCT05196412|DEVICE|PulseOn Arrhythmia Monitor device|Wearing of the wrist device for a period of two weeks
48702505|NCT04033887|DIAGNOSTIC_TEST|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
48171010|NCT00097669|DRUG|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo|multivitamin
48171011|NCT00097669|OTHER|Placebo|
48516271|NCT00611260|OTHER|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
48702506|NCT01375868|BIOLOGICAL|Silgard|vaccination with tetravalent antiviral vaccine
48702507|NCT06022965|OTHER|Best Practice|Receive SOC
48702508|NCT06022965|OTHER|Comprehensive Geriatric Assessment|Complete CARG-GA
48702509|NCT06022965|OTHER|Electronic Health Record Review|Ancillary studies
48702510|NCT06022965|OTHER|Questionnaire Administration|Ancillary studies
48702511|NCT06022965|OTHER|Supportive Care|Receive GA-based interventions
48702512|NCT06022965|OTHER|Telemedicine|Receive GA-based interventions via telemedicine
48702513|NCT04793451|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
48702514|NCT04793451|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
48702515|NCT00686985|DRUG|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
48702516|NCT03735628|DRUG|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
48702517|NCT03735628|DRUG|Nivolumab|Nivolumab: concentrate for solution for infusion
48702518|NCT06174454|OTHER|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
48702519|NCT06174454|OTHER|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
48702520|NCT00646763|DRUG|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
48014509|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
48014510|NCT02881814|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound in MV patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
48014511|NCT02132000|DRUG|toremifene or tamoxifen|
48014512|NCT04190745|DRUG|Toripalimab+Apatinib mesylate|Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
48014513|NCT04190745|DRUG|paclitaxel|paclitaxel 80mg/m2, q3w
48014514|NCT02059928|DEVICE|Intraosseous Device|
48014515|NCT04031885|DRUG|Abemaciclib|Administered orally
48014516|NCT04031885|DRUG|Fulvestrant|Administered IM
48014517|NCT04031885|DRUG|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label.
48171012|NCT00853736|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
48516272|NCT04414345|DRUG|CNM-Au8|"Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily"
48516273|NCT04414345|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily"
48014518|NCT06218004|DRUG|Envafolimab combined with chemotherapy|envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
48014519|NCT00690638|DRUG|PHX1149T|200 mg
48014520|NCT00690638|DRUG|PHX1149T|400 mg
48014521|NCT00690638|DRUG|Placebo|Placebo
48171013|NCT00853736|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
48171014|NCT00979329|OTHER|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
48702521|NCT00646763|DRUG|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
48702522|NCT02984150|DIETARY_SUPPLEMENT|dodecanoic acid|
48014522|NCT06358391|DEVICE|TS-RF Transseptal Needle|Apply radiofrequency energy to the electrode tip via the TS-RF Generator and puncture the atrial septum
48014523|NCT06358391|DEVICE|BRK Transseptal Needle|Cross and puncture the atrial septum with the BRK Transseptal Needle
48171015|NCT03142321|DRUG|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
48171016|NCT00766142|BIOLOGICAL|cetuximab|
48516274|NCT03681249|DRUG|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
48014524|NCT04502602|DRUG|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
48014525|NCT04502602|DRUG|Neratinib 200 mg|Determined RP2D dose
48014526|NCT04502602|DRUG|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
48171017|NCT00766142|DRUG|fluorouracil|
48171018|NCT00766142|DRUG|leucovorin calcium|
48171019|NCT00766142|DRUG|oxaliplatin|
48171020|NCT00766142|PROCEDURE|adjuvant therapy|
48171021|NCT00766142|PROCEDURE|therapeutic conventional surgery|
48171022|NCT05140707|OTHER|Virtual Reality Distraction|The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
48516275|NCT03681249|DRUG|ShenqiDihuang Decoction placebo|traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
48702523|NCT02984150|DIETARY_SUPPLEMENT|saline|
48702524|NCT02607917|OTHER|Mass Media plus clinic intervention.|
48702525|NCT02607917|OTHER|Media|
48702526|NCT06607757|DRUG|Capivasertib|find arm A description
48702527|NCT06607757|DRUG|Fulvestrant injection|find arm B description
48702528|NCT00144469|DRUG|peginterferon alfa-2a|
48702529|NCT00144469|DRUG|rivavirin|
48014527|NCT04502602|DRUG|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
48014528|NCT04502602|DRUG|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
48171023|NCT04531878|DRUG|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
48171024|NCT00630136|BEHAVIORAL|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
48171025|NCT00177385|BEHAVIORAL|Modest sleep deprivation with sleep hygiene education|
48516276|NCT03335514|DIAGNOSTIC_TEST|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
48014529|NCT04502602|DRUG|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
48014530|NCT04502602|DRUG|Niraparib at RP2D|Phase 1b: Determined dose
48014531|NCT04502602|DRUG|Neratinib at RP2D|Phase 1b: Determined dose
48014532|NCT00365118|DEVICE|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
48014533|NCT02023034|OTHER|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
48014534|NCT00529841|DRUG|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
48014535|NCT06040346|DRUG|Meplazumab for Injection|Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
48014536|NCT03616756|BEHAVIORAL|Authentic Connections|Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.
48014537|NCT03616756|BEHAVIORAL|Protected time|Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
48014538|NCT05120193|DEVICE|Mapping and Ablation|Minimally invasive catheter mapping and ablation procedure
48014539|NCT05391217|OTHER|Remote assessment of patient reported outcomes and daily activity|Electronic patient-reported outcomes (NIH PROMIS) will be collected and combined with remotely monitored physical activity, heart rate, and sleep, as measured with a Fitbit (Sense).
48014540|NCT00428545|DRUG|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
48014541|NCT00428545|DRUG|Bortezomib|Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days
48516277|NCT02764346|BEHAVIORAL|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
48516278|NCT02764346|BEHAVIORAL|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
48516279|NCT03510390|DRUG|Metformin|850 mg, oral, twice daily, 9-14 days
48516280|NCT06253806|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 1% mepivacaine will be injected near the stellate ganglion.
48014542|NCT01852890|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
48014543|NCT01852890|DRUG|Gemcitabine|Intravenous chemotherapeutic
48014544|NCT01852890|RADIATION|Radiation therapy|
48014545|NCT02460198|BIOLOGICAL|Pembrolizumab|IV infusion
48014546|NCT01623219|BEHAVIORAL|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
48014547|NCT04527068|DRUG|Bevacizumab|7.5 mg/kg intravenously every 3week
48014548|NCT04527068|DRUG|Tripleitriumab|240mg intravenously every 3week
48014549|NCT03528330|DEVICE|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
48171026|NCT01193062|DRUG|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
48516281|NCT06253806|DRUG|Placebo Sham Injection|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 0.9% saline will be injected near the stellate ganglion.
48516282|NCT05667025|OTHER|Conservative rehabilitation|Joint range of motion, strengthening, balance-coordination and stretching exercises included in the conservative physiotherapy program 5 days a week for a total of 6 weeks
48516283|NCT05667025|OTHER|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|In addition to conservative treatment, cycling FES to the affected lower extremity for 20 minutes, 3 days a week for 4 weeks. During the treatment, the patient will be seated on a chair and her feet will be fixed to the pedal with velcro tape, and the comfort during the treatment will be provided with calf supports.
48516284|NCT02321033|DIETARY_SUPPLEMENT|soft drinks|soft drinks with palatinose and maltodextrin
48516285|NCT02688738|DRUG|Doxycycline|
48516286|NCT05567770|DRUG|Actinium-J591|Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
48702530|NCT01587261|DRUG|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
48702531|NCT01587261|DRUG|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
48702532|NCT05552261|DRUG|Cenegemin in the DEFENDO Study|"Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial."
48702533|NCT03351816|PROCEDURE|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
48702534|NCT03351816|PROCEDURE|Cardioversion|External electric shock delivery under general anesthesia.
48702535|NCT05382468|OTHER|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
48702536|NCT03218072|DRUG|HLX01|a potential rituximab biosimilar
48702537|NCT06607874|OTHER|Non-Interventional Study|Non-Interventional study
48702538|NCT05134285|OTHER|blood pressure,BMI, blood sample|Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
48702539|NCT06605274|OTHER|Web-Based Education Program|"Before being discharged from the clinic, the women who experienced perinatal loss filled out the Personal Information Form, Perinatal Grief Scale, Edinburgh Postnatal Depression Scale, Beck Hopelessness Scale, and Stress Coping Styles Scale individually. The women were informed about the use of the website. The discharged women were contacted by phone, given the passwords of the birliktegücleniyoruz.com website, and invited to use the website for the five-week education program. Each week, only one session determined for that week was uploaded to the site. Participants who wished to do so were able to watch the uploaded sessions more than once. Retrospective sessions also remained accessible on the site. Each session lasted an average of 20-30 minutes. Women who completed five sessions were contacted by phone in the sixth week. Women filled out the PGS, EPDS, BHS, and SCSS online a second time"
48702540|NCT06605274|OTHER|Control|Before being discharged from the perinatology clinic, the women filled out the Personal Information Form, PGS, EPDS, BHS, and SCSS individually. Six weeks after discharge, the participants filled out the same measurement tools online again. During this process, the hospital's routine monitoring continued for the control group. The website was opened to the use of participants who wanted to use the site after the completion of the final tests.
48702541|NCT03600636|PROCEDURE|Diffusion tensor imaging MRI|"1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time"
48702542|NCT01552551|BEHAVIORAL|Assessment and education|PA Healthy Steps program
48702543|NCT01552551|BEHAVIORAL|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
48702544|NCT01552551|BEHAVIORAL|Healthy Steps in Motion|Group exercise program
48702545|NCT05966363|RADIATION|Nanodot|Radiation measurements using nanodots placed on the eyes, ears, neck and lower abdomen during an imaging examination.
48171027|NCT01193062|DRUG|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
48371880|NCT02048501|OTHER|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
48516287|NCT05567770|RADIATION|Stereotactic Body Radiation Therapy|Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
48702546|NCT05608395|DRUG|11C-Methionine PET/CT|11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)
48702547|NCT02330666|BEHAVIORAL|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
48516288|NCT05567770|DRUG|Androgen Deprivation Therapy|Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
48171028|NCT02991703|DEVICE|pOpmètre®|the pOpmètre® uses saturation sensors,
48171029|NCT02991703|DEVICE|Sphygmocor|the Sphygmocor uses applanation tonometry
48516289|NCT00416611|BEHAVIORAL|Implementation of guidelines|
48516290|NCT03688048|DEVICE|Bright light treatment lamp|Exposure to bright white light (1 hour, 10 000 lux)
48516291|NCT03688048|DEVICE|Sham negative ion generator|Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
48702548|NCT02489708|BEHAVIORAL|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
48702549|NCT04363697|DRUG|Dapagliflozin|Dapagliflozin
48171030|NCT02713737|DEVICE|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) \> 92%.
48371881|NCT02048501|OTHER|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
48371882|NCT02048501|OTHER|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
48014550|NCT03528330|DEVICE|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
48014551|NCT04283175|OTHER|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
48014552|NCT04283175|OTHER|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
48014553|NCT06662903|PROCEDURE|Cranioplasty with Titanium mesh|Cranioplasty using titanium mesh
48014554|NCT06662903|PROCEDURE|Cranioplasty with bone cement|Cranioplasty using bone cement
48014555|NCT06250738|BEHAVIORAL|Mindfulness-based Stress reduction program: Virtual|Through mindfulness meditation and a series of carefully crafted exercises, MBSR equips individuals with powerful tools to manage stress, reduce anxiety, and enhance their overall well-being. Participants will complete 4 weekly virtual sessions covering topics like introduction to stress and its consequences, awareness of sensations, and thoughts, mindful eating, and mindful walking.
48014556|NCT06250738|BEHAVIORAL|Home exercises|Following each virtual session, participants will be given home exercises like practicing awareness of breathing, awareness of thoughts, and awareness of eating.
48014557|NCT02749903|DRUG|enzalutamide|oral
48014558|NCT00841126|DRUG|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
48014559|NCT00841126|DRUG|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
48014560|NCT00841126|DRUG|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
48014561|NCT03904979|OTHER|Writing exercises|Participants will be given journals with writing prompts to be completed throughout their pregnancy.
48014562|NCT02803697|OTHER|Patients|
48014563|NCT04251559|OTHER|oral glucose loading test|oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
48014564|NCT03752723|DRUG|GX-I7|i.m.
48014565|NCT03752723|DRUG|Pembrolizumab(KEYTRUDA®)|i.v.
48014566|NCT03752723|DRUG|Cyclophosphamide|i.v.
48014567|NCT05641194|DEVICE|Legacy Alerting System|Description: Standard alerting system in place at the fire station.
48171031|NCT02713737|DEVICE|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 \> 92%.
48171032|NCT02705625|DRUG|MIV-711|MIV-711 administered orally once daily
48171033|NCT02705625|DRUG|Placebo|Placebo manufactured to mimic MIV-711 capsule.
48516292|NCT01427608|DRUG|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
48702550|NCT04363697|DRUG|Placebo|Matched placebo
48702551|NCT03596047|DEVICE|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
48702552|NCT03596047|DEVICE|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
48702553|NCT00963716|DEVICE|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
48371883|NCT02048501|OTHER|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
48371884|NCT04994860|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
48371885|NCT04994860|DRUG|Sildenafil|Oral Sildenafil ( Revatio) 20 mg film coated tablets
48371886|NCT01613209|DRUG|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
48371887|NCT01613209|DRUG|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
48371888|NCT04022265|DEVICE|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
48371889|NCT02850666|BEHAVIORAL|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
48371890|NCT03373916|BEHAVIORAL|Peer mentorship|The peer mentor will meet with the participant for the first time while the participant is still in the hospital. Sessions will be scheduled according to the participant's preferences, with a suggested maximum frequency of twice weekly for the first two weeks, weekly for weeks 3 to 8, and then every other week for the last month. Allowable meeting locations include public places in the community (e.g., coffee shop, park), the participant's home, or a research clinic space or by phone. Session content is flexible and allows for the peer mentor to provide general supportive listening, validation, and sharing. Session duration is on average 1 hour with at least 15 minutes discussing hope or belongingness according to semi-structured conversation guides. The session structure and content are intentionally highly flexible to allow for genuineness in the peer relationship, thereby increasing acceptability and implicit belongingness.
48371891|NCT03373916|BEHAVIORAL|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
48702554|NCT00963716|DEVICE|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
48702555|NCT04112797|BIOLOGICAL|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
48371892|NCT00561262|OTHER|questionnaire administration|
48371893|NCT00561262|PROCEDURE|high-intensity focused ultrasound ablation|
48371894|NCT00561262|PROCEDURE|quality-of-life assessment|
48371895|NCT00081900|DRUG|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m\^2, then escalating to 120mg/m\^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
48371896|NCT03222869|DIAGNOSTIC_TEST|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
48371897|NCT01773460|DRUG|Everolimus|Everolimus is given beyond progress (comparison with placebo)
48371898|NCT01773460|DRUG|Everolimus-placebo|Everolimus-placebo
48516293|NCT01427608|DRUG|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
48516294|NCT03214783|OTHER|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
48014568|NCT05641194|DEVICE|Intervention 2: EaseAlert Standalone|Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system.
48702556|NCT01549808|OTHER|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
48702557|NCT01549808|OTHER|mobilization|sitting, standing and walking
48702558|NCT02379221|DRUG|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
48702559|NCT02379221|DRUG|Topical|4% Topicaine gel
48702560|NCT06572891|OTHER|Maxillary obturator|conventional acrylic obturator
48702561|NCT06572891|OTHER|Implant supported obturator|"Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made"
48702562|NCT00978055|DRUG|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
48702563|NCT00978055|DRUG|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
48702564|NCT04939181|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
48702565|NCT04939181|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
48702566|NCT05960331|BEHAVIORAL|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
48702567|NCT05960331|BEHAVIORAL|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
48702568|NCT01829633|PROCEDURE|Physiotherapy|Shoulder physiotherapy with exercises
48702569|NCT01644695|PROCEDURE|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
48371899|NCT04008290|DRUG|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
48702570|NCT06587282|DEVICE|Bloom Micro Occluder System|Percutaneous transcatheter closure of PDA using Bloom Micro Occluder System
48371900|NCT04008290|DRUG|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
48371901|NCT03878576|OTHER|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
48371902|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
48371903|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
48371904|NCT03878576|OTHER|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
48371905|NCT00804323|PROCEDURE|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
48516295|NCT04110730|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
48522974|NCT00153179|DRUG|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
48702571|NCT00350363|DRUG|Zymar|zymar qid
48702572|NCT06446063|OTHER|Test product|Twice daily applications The product is applied to the entire face.
48702573|NCT06446063|OTHER|Control Product|Twice daily applications The product is applied to the entire face.
48014569|NCT01983800|DRUG|Isoflurane|
48014570|NCT01983800|DRUG|Propofol/midazolam|
48014571|NCT04411043|BEHAVIORAL|Molecular caracterization|Prospective and retrospective study evaluating the epidemiological, clinical, molecular and therapeutic data of prolymphocytic leukemias T
48702574|NCT05964465|DRUG|Dupilumab|Monoclonal antibody blocking interleukin 4 and interleukin 13
48702575|NCT05469243|DRUG|Psychedelic|retrospective survey of previous use
48702576|NCT06039930|BEHAVIORAL|Tele PROTECT|Tele-PROTECT is a behavioral intervention delivered virtually over nine 45-minute sessions for depressed elder abuse (EA) victims. It is designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
48702577|NCT06039930|BEHAVIORAL|Depression Education|DepEd is designed as an intervention delivered virtually over nine 45-minute sessions with active therapeutic ingredients (education, support, empathy). It is designed to be what a good clinician providing education would do with an individual with depression.
48702578|NCT00262236|DRUG|Aliskiren|
48702579|NCT05007496|BIOLOGICAL|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
48702580|NCT02225847|OTHER|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
48702581|NCT02225847|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
48702582|NCT02225847|BEHAVIORAL|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
48702583|NCT03341078|DRUG|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
48702584|NCT03341078|DRUG|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
48702585|NCT00294645|OTHER|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
48702586|NCT00294645|OTHER|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
48702587|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
48702588|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
48702589|NCT01502878|DIETARY_SUPPLEMENT|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
48702590|NCT06537557|OTHER|the early in-hospital temperature management protocol for heat stroke patients|The early in-hospital temperature management protocol for heat stroke includes early identification, selection of cooling methods for rapid cooling, precise target temperature management, and dynamic monitoring. Effective temperature management will be implemented for heat stroke patients to improve their outcomes.
48702591|NCT05935891|DRUG|CBD-dominant|product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
48702592|NCT05935891|DRUG|THC dominant|contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
48702593|NCT00064259|BIOLOGICAL|oblimersen sodium|Given IV
48014572|NCT00720876|BIOLOGICAL|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
48014573|NCT00720876|DRUG|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
48014574|NCT05590702|DRUG|First line therapy|"Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study."
48014575|NCT05305365|DRUG|QBS72S|QBS72S 18mg/m2 injection given intravenous once a month.
48522975|NCT00153179|DRUG|placebo|matching placebo
48522976|NCT02990429|PROCEDURE|Forced Air warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using forced air warmer (bair hugger)~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop bair hugger~* record core temperature before recovery room"
48702594|NCT00064259|DRUG|cisplatin|Given IV
48702595|NCT00064259|DRUG|fluorouracil|Given IV
48014576|NCT06499701|DRUG|Ringer's Lactate|Ringer's Lactate is administered at a dose of 30ml/kg, with the first 20ml/kg given at a constant rate over the initial 30 minutes, followed by a 30-minute pause, and then an additional 10ml/kg over the next 15 minutes, completing the infusion within 75 minutes.
48014577|NCT00420680|DRUG|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
48014578|NCT00420680|DRUG|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
48014579|NCT00420680|DRUG|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
48014580|NCT04010968|DRUG|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~* if BM MRD at M9 \< 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~* if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
48702596|NCT05021302|PROCEDURE|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
48702597|NCT05021302|BEHAVIORAL|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
48702598|NCT01426919|OTHER|Head CT scan and blood draw within 12 hours of injury|
48171034|NCT00349622|DRUG|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
48171035|NCT00349622|OTHER|placebo|an inactive substance
48702599|NCT00349921|DRUG|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
48702600|NCT00349921|DRUG|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
48014581|NCT04010968|DRUG|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
48516296|NCT04110730|BEHAVIORAL|Home Intervention|An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
48014582|NCT00572650|DRUG|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
48014583|NCT06656910|BEHAVIORAL|Self Compassion Group|"A 7-week self-compassion Programme:~Course 1:~Detective Warm-Up Game, Explaining the application of compassion/self-compassion.~Course 2:~Draw and Tell Warm-up Game, Breath Awareness Exercise, Mindful Eating Activity.~Course 3:~Walking Warm-Up, Body Scan Meditation, How Do You Treat Your Friend Activity.~Course 4:~Random Cards warm-up game, Compassion Meditation, Just Like Me Exercise.~Course 5:~Break, Self-compassionate letter writing.~Course 6:~Tree Drawing Warm-Up Game, Mountain Meditation, Recognize Your Inner Bully, Three Calming Breathing Exercises.~Course 7:~Considering the process with participants, Implementation of final tests, Tender farewell."
48014584|NCT02568488|DRUG|Metformin|850 mg orally twice daily for 6 months
48516297|NCT02352870|BEHAVIORAL|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
48516298|NCT02352870|BEHAVIORAL|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
48516299|NCT06328049|DRUG|Trilaciclib Injection|Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
48702601|NCT00349921|DRUG|placebo|inactive substance
48702602|NCT00349921|DRUG|placebo|inactive substance
48702603|NCT02753907|DIETARY_SUPPLEMENT|Low LA|Individuals who replaced 10 mL soy oil with one apple
48014585|NCT00351494|PROCEDURE|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
48014586|NCT00351494|PROCEDURE|embolization|Intervention is described in the case report form for each patient
48014587|NCT05144152|DIAGNOSTIC_TEST|M3|A panel of four bacterial gene markers (Fn, m3, Ch and Bc)
48014588|NCT05144152|DIAGNOSTIC_TEST|FIT|faecal immunochemical test
48171036|NCT05912569|PROCEDURE|Delay sentinel node biopsy|In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
48516300|NCT04768426|DRUG|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
48516301|NCT04990713|PROCEDURE|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients will receive local anesthetic via serratus plane block as opposed to saline placebo
48702604|NCT02753907|DIETARY_SUPPLEMENT|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
48702605|NCT02169024|BEHAVIORAL|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
48702606|NCT02169024|OTHER|Standard individual prenatal care|Standard of care- individual prenatal care
48702607|NCT02513485|DRUG|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
48702608|NCT02513485|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
48702609|NCT06373926|BIOLOGICAL|blood withdrawal|blood withdrawal
48702610|NCT02784119|PROCEDURE|temporary porto-caval shunt|temporary porto-caval shunt
48702611|NCT01612286|DRUG|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
48702612|NCT05137197|DEVICE|Predictix Genetics Antidepressant|Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
48171037|NCT05142072|DRUG|Vitamin D3|intranasal film
48171038|NCT02568878|DRUG|Creatine monohydrate|
48171039|NCT02205541|DRUG|Eculizumab|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
48014589|NCT06664658|PROCEDURE|peep 5|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
48014590|NCT06664658|PROCEDURE|peep 10|he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
48014591|NCT06663514|OTHER|SupporTive Care At Home|"Home-based medical care is based on a specialized home-based medical team approach, including following:~Specialized Home-Based Medical Team Approach Initial Assessment and Education Initial Home Visits and Education Multidisciplinary Team Meeting Regular Assessment After the Initial Visit"
48171040|NCT02205541|DRUG|Placebo|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
48171041|NCT01037413|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
48171042|NCT01037413|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
48702613|NCT04571307|PROCEDURE|cryotherapy|comparison between cryotherapy and surgery
48371906|NCT03997695|OTHER|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
48371907|NCT03997695|OTHER|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
48702614|NCT05019742|DRUG|SPH3127|SPH3127 - selective renin inhibitor
48702615|NCT05019742|DRUG|Placebo|Placebo
48014592|NCT00410696|DRUG|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
48014593|NCT00410696|DRUG|Pegfilgrastim|6 mg/day sc at day +1
48014594|NCT05595291|OTHER|investigation of the factors affecting walking characteristics|In order to investigate the factors affecting walking characteristics, 2-minute walking test, 10-point VAS (overall prosthesis satisfaction level, socket comfort and satisfaction level, knee joint satisfaction level, prosthetic foot satisfaction level, pain level in amputated extremity) and locomotor capacity index will be applied.
48371908|NCT06515886|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of a dental implant
48371909|NCT06515886|PROCEDURE|Peri-implant crevicular fluid|Collection of a sample of peri-implant crevicular fluid
48371910|NCT02651246|OTHER|data collection|
48702616|NCT04449952|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
48702617|NCT04449952|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
48702618|NCT04449952|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
48702619|NCT04449952|OTHER|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
48702620|NCT04449952|DEVICE|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
48171043|NCT01040923|DEVICE|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
48171044|NCT00075283|DEVICE|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
48171045|NCT06479525|OTHER|Big Toe Flexor Strengthening Exercises|16 participants will be in experimental group A giving them Big Toe Flexor strengthening exercise protocol along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
48171046|NCT06479525|OTHER|Calf Strengthening Exercises|16 participants will be in experimental group B giving them calf strengthening exercises including towel curls and thera band exercises along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
48516302|NCT04990713|PROCEDURE|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients will receive saline placebo via serratus plane block
48516303|NCT03544944|DRUG|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
48516304|NCT03544944|DRUG|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
48702621|NCT04449952|DEVICE|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
48702622|NCT05869643|DRUG|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
48702623|NCT05869643|DRUG|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
48702624|NCT05869643|DRUG|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
48014595|NCT02321579|DIETARY_SUPPLEMENT|vitamin B-6|50 mg/d
48371911|NCT04030364|BEHAVIORAL|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
48702625|NCT05869643|DRUG|Placebo|Matching placebo capsule, taken orally once daily after breakfast
48702626|NCT02013206|DRUG|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
48702627|NCT04670458|OTHER|no intervention|no intervention
48702628|NCT04399473|BEHAVIORAL|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
48702629|NCT03119181|DRUG|Tymbion Lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution
48371912|NCT01980186|DEVICE|TUS transcranial 2D ultrasound|
48371913|NCT05451758|OTHER|Mindfulness-based stress reduction (MBSR)|The participants were asked to attend a brief version of the MBSR programme lasting six weeks. The intervention was a structured 6-week programme with groups of between 6 and 10 participants. Each weekly session lasted one hour and included mindfulness meditation/exercises and group discussion led by a qualified mindfulness instructor.
48516305|NCT03544944|DRUG|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
48702630|NCT03119181|COMBINATION_PRODUCT|Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
48702631|NCT00643786|DRUG|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
48702632|NCT00643786|DRUG|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
48702633|NCT05582850|DRUG|DT-9081 - dose escalation|Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.
48522977|NCT02990429|PROCEDURE|Intravenous Fluid Warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using ranger warmer~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop ranger warmer~* record core temperature before recovery room"
48702634|NCT05582850|DRUG|DT-9081 - expansion|A homogeneous patient population will receive DT-9081 at up to 3 dose levels.
48014596|NCT02321579|DIETARY_SUPPLEMENT|Glutathione|500 mg/d
48014597|NCT02321579|DIETARY_SUPPLEMENT|Dextrins|50 mg/d
48014598|NCT03952533|DIETARY_SUPPLEMENT|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
48522978|NCT06344273|BEHAVIORAL|ROM exercises|Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session.
48522979|NCT01112059|DRUG|Doxycycline|100 mg twice a day for 8 days
48522980|NCT01112059|OTHER|placebo|placebo
48702635|NCT03297073|DRUG|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
48702636|NCT03297073|PROCEDURE|hepatic surgery|
48702637|NCT04397159|BEHAVIORAL|Combination Exercise|Flywheel Resistance Plus Aerobic Exercise
48014599|NCT02046434|DRUG|Glycerol Phenylbutyrate|
48014600|NCT05430516|OTHER|No intervention|No intervention
48014601|NCT04841564|PROCEDURE|ultrasound approach of serratus anterior block|After induction of general anesthesia, the ultrasound probe will be placed longitudinally oblique just below the mid-clavicle. After identifying the second rib, the probe will be moved caudally and laterally (obliquely), towards the mid-axillary line to identify the 3rd, 4th and 5th ribs.. The fascial plane between the serratus anterior muscle and latissimus dorsi muscle will be identified over the 4th rib in the mid-axillary region. The block will be performed with a needle (22-G, 50-mm) introduced in-plane to enter deep to the serratus anterior muscle, and 30 ml 0.25 bupivacaine will be injected.
48171047|NCT02025478|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
48702638|NCT01643161|BEHAVIORAL|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
48014602|NCT04841564|PROCEDURE|open approach of serratus anterior block|After resection of the breast and identification of the serratus anterior muscle, the surgeon will be asked to palpate the ribs below the clavicle and localize the fourth rib. A 22-G, 50-mm needle will be introduced deep to the serratus anterior muscle contacting the rib, and 30 ml 0.25 bupivacaine will be injected.
48014603|NCT01049659|BEHAVIORAL|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
48702639|NCT01643161|BEHAVIORAL|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
48702640|NCT06399185|DRUG|Normal saline|20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
48702641|NCT06399185|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
48702642|NCT06399185|DRUG|Esketamine|Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
48702643|NCT06399185|DRUG|Combined dexmedetomidine-esketamine|Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
48702644|NCT04880044|DIAGNOSTIC_TEST|EsoCheck/EsoGuard (EC/EG)|EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.
48702645|NCT04880044|DIAGNOSTIC_TEST|Esophago-gastro-duodenoscopy (EGD)|SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.
48702646|NCT02084706|PROCEDURE|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
48702647|NCT02084706|DRUG|2% Lidocaine|
48702648|NCT02084706|DRUG|Triamcinolone (20 g)|
48702649|NCT02084706|PROCEDURE|J-tip lidocaine administration|
48702650|NCT02084706|PROCEDURE|Triamcinolone (20 g) Injection over the A1 pulley.|
48702651|NCT06606132|OTHER|Exercise|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person\&#39;s condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
48702652|NCT02349191|PROCEDURE|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
48702653|NCT01685801|DRUG|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
48171048|NCT04301115|OTHER|attachment|unilateral attachment from rehine 83
48171049|NCT04301115|OTHER|bridge|tooth implant supported bridge
48702654|NCT01685801|DRUG|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
48702655|NCT06008418|BEHAVIORAL|The LINE Chatbot|The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.
48702656|NCT03730831|BEHAVIORAL|Narrative Exposure Therapy|"8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder."
48702657|NCT04056520|DEVICE|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~* Traumatic spinal fractures and/or traumatic dislocations.~* Instability or deformity.~* Failed previous fusions (e.g. pseudarthrosis).~* Tumors involving the cervical spine.~* Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
48702658|NCT00198861|OTHER|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
48702659|NCT05750654|DEVICE|Small Phlebotomy Tube Group|"In the small tubes group, the recommended blood volumes are 0.5 mL for hematology and single chemistry tests, and 1 mL when multiple chemistry tests are needed. A, a non-formulary medication order will be placed in the electronic medical record to alert nurses to collect blood in small tubes. Participants will continue to use small tubes anytime they are in the ICU or IMU."
48702660|NCT05750654|DEVICE|Standard Phlebotomy Tube Group|In the standard tubes group, the recommended blood volumes are 4.0 mL for hematology and 3.0 for chemistry tests.
48702661|NCT03374800|DRUG|Placebo (0.9% saline)|normal saline
48702662|NCT03374800|DRUG|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
48702663|NCT05519449|BIOLOGICAL|JANX007|JANX007 is dosed via IV in a 21- or 28-day cycle.
48702664|NCT00923975|DEVICE|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
48702665|NCT02124018|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
48171050|NCT04301115|OTHER|CONVENTIONAL|conventional metalic partial denture
48522981|NCT01226927|OTHER|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
48702666|NCT02124018|DEVICE|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
48702667|NCT03478475|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|
48702668|NCT03478475|OTHER|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
48702669|NCT00725348|DRUG|Talarozole|1.0 mg oral dose per day
48171051|NCT03602248|OTHER|Speed endurance training protocol A|1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)
48171052|NCT03602248|OTHER|Speed endurance training protocol B|1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
48171053|NCT02082418|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
48522982|NCT04004481|DRUG|Postoperative analgesia using tramadol|Tramadol 100 mg will be given to the patients in the postoperative period.
48522983|NCT04368338|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)
48171054|NCT02082418|DIETARY_SUPPLEMENT|Whey|commercially available whey protein
48702670|NCT05456568|DEVICE|LymphAssistTM Professional|An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
48702671|NCT06605482|OTHER|Patient Reported Outcome Measures|Participants will complete the following outcome measures American Shoulder and Elbow Surgeons Evaluation Questionnaire - upper limb function score 12-Item Short Form Survey - general health questionnaire
48702672|NCT06605482|OTHER|Range of Motion|Shoulder and Elbow Range of Motion collected at the time of radiographic union
48702673|NCT01813552|DRUG|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
48702674|NCT01813552|DRUG|Omeprazole|40 mg delayed-release oral capsules, once daily
48702675|NCT01813552|DRUG|Ritonavir|100 mg oral tablets, once daily
48702676|NCT06373653|DRUG|Manzanilla Sophia®|Matricaria recutita 0.025%, Ophthalmic solution.
48702677|NCT06373653|DRUG|Meticel Ofteno®|Hypromellose 0.5%, Ophthalmic solution.
48702678|NCT00664313|DRUG|Linezolid|600 mg po daily for 112 doses (16 weeks)
48702679|NCT00664313|DRUG|Placebo|Placebo given daily for 112 doses (16 weeks)
48702680|NCT03555981|OTHER|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
48702681|NCT03555981|OTHER|Standard care|Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care
48702682|NCT06352892|DRUG|Maridebart Cafraglutide|Solution for SC injection.
48702683|NCT02251561|DEVICE|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
48702684|NCT02251561|DEVICE|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
48702685|NCT02251561|DEVICE|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
48702686|NCT00937144|DRUG|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
48702687|NCT00937144|DRUG|placebo|
48702688|NCT05772663|OTHER|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
48702689|NCT05772663|OTHER|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
48702690|NCT05357989|DRUG|buntanetap/posiphen|HPMC (vegetarian source) capsule shells
48702691|NCT05357989|DRUG|Placebo|HPMC (vegetarian source) capsule shells
48371914|NCT02403427|DEVICE|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
48371915|NCT02058849|DRUG|Beetroot|10g Beetroot powder mixed with 4-8 oz.
48371916|NCT02058849|OTHER|Placebo|Placebo
48371917|NCT03556202|DRUG|Mirikizumab|Administered SC
48522984|NCT04368338|PROCEDURE|lung ultrasound|lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room
48522985|NCT03693417|DEVICE|Heated circuit on|Heated circuit will be turned on.
48522986|NCT03693417|DEVICE|Heated circuit off|Heated circuit will be turned off.
48702692|NCT00003406|DRUG|carboplatin|
48702693|NCT00003406|DRUG|docetaxel|
48702694|NCT00003406|DRUG|ifosfamide|
48702695|NCT00003406|PROCEDURE|autologous bone marrow transplantation|
48702696|NCT00003406|PROCEDURE|bone marrow ablation with stem cell support|
48702697|NCT00003406|PROCEDURE|peripheral blood stem cell transplantation|
48702698|NCT03691818|DRUG|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
48702699|NCT03691818|DRUG|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
48702700|NCT03691818|DRUG|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
48702701|NCT03691818|DRUG|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
48702702|NCT04734522|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
48522987|NCT02737241|PROCEDURE|Low power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 50W holmium laser energy.
48702703|NCT06602388|OTHER|Biological sampling|Collection of biological samples from healthy volunteers: Stool, urine, saliva, buccal swab, nasal swab, superficial skin swab, hair
48702704|NCT02220855|DRUG|BKM120|
48702705|NCT00569244|DRUG|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
48702706|NCT00569244|DRUG|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
48171055|NCT02082418|DIETARY_SUPPLEMENT|Casein|commercially available casein protein
48171056|NCT05572385|BEHAVIORAL|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
48171057|NCT03955354|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
48171058|NCT03955354|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
48702707|NCT01279629|DRUG|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
48702708|NCT05321758|BIOLOGICAL|Fecal Microbiota Transplantation|In the induction stage of CD, FMT was given 1-3 courses, 3-6 times per course.
48702709|NCT05321758|DRUG|Immunosuppressive Agents|hormones, azathioprine, thalidomide
48014604|NCT04139785|OTHER|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
48171059|NCT00192322|BIOLOGICAL|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
48702710|NCT06067685|OTHER|Observation|Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
48702711|NCT03215758|DRUG|QAW039|QAW039 once daily
48702712|NCT03215758|DRUG|Placebo|Placebo once daily
48702713|NCT01783314|PROCEDURE|MRI of liver|MRI of liver with intravenous gadoxetate disodium
48702714|NCT01330628|DEVICE|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
48702715|NCT01330628|PROCEDURE|Balloon angioplasty|standard balloon catheters for PTA
48014605|NCT06003725|BEHAVIORAL|Culturally Adapted Adolescent Substance Use Treatment|The Cannabis Youth Treatment Series (CYT) (MET/CBT12 model) aims to reduce alcohol and cannabis use.
48014606|NCT00219934|DRUG|Antiretroviral therapy|HAART therapy
48014607|NCT02440880|DRUG|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
48014608|NCT02440880|DRUG|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
48171060|NCT00192322|BIOLOGICAL|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T \<10\^5
48171061|NCT00192322|BIOLOGICAL|Placebo|a single intranasal 0.2 mL dose of placebo
48171062|NCT00192322|BIOLOGICAL|TIV|commercially available TIV injected intramuscularly
48171063|NCT02844348|OTHER|Hypnosis session|
48171064|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
48171065|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
48171066|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
48171067|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
48171068|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
48171069|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
48171070|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
48171071|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
48702716|NCT05552794|DIAGNOSTIC_TEST|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
48702717|NCT02465788|DEVICE|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
48702718|NCT00346450|PROCEDURE|Cultivated conjunctival transplantation|
48702719|NCT01579565|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
48702720|NCT01579565|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
48702721|NCT03371134|BIOLOGICAL|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
48702722|NCT00503581|PROCEDURE|Biopsy|Undergo biopsy
48702723|NCT00503581|OTHER|Laboratory Biomarker Analysis|Correlative studies
48702724|NCT00503581|DRUG|Megestrol Acetate|given orally
48702725|NCT00503581|OTHER|Pharmacological Study|Correlative studies
48702726|NCT00503581|OTHER|Quality-of-Life Assessment|Ancillary studies
48014609|NCT02440880|DRUG|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
48702727|NCT00503581|PROCEDURE|Therapeutic Conventional Surgery|undergo hysterectomy
48014610|NCT02440880|DRUG|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
48014611|NCT02440880|OTHER|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
48014612|NCT05201794|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
48014613|NCT05201794|DRUG|Placebo|Matching placebo for each dose level as tablet will be administered orally.
48014614|NCT05142358|DEVICE|Continuous Positive Airway Pressure|Use of CPAP device at the start of treatment planning.
48014615|NCT05142358|OTHER|Deep inspiratory breath hold|Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments
48371918|NCT03498963|PROCEDURE|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
48371919|NCT02131142|DEVICE|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
48702728|NCT06315036|OTHER|Developmental gymnastics|The DG exercise program ran from September 15, 2021, to May 15, 2022, in a well-equipped gymnasium. Led by trained teachers and gymnastics experts, sessions were held twice weekly (Tuesday and Thursday) for 60 minutes. The program focused on stability, locomotor skills, and manipulation, introducing children to DG fundamentals. It included circuit and station training, obstacle courses, and gradually increased exercise complexity. Sessions comprised a 15-minute warm-up, a 40-minute main session with skill practice and conditioning, and a 5-minute cool-down. The atmosphere was positive and friendly, with kid-friendly music and adapted procedures from previous research.
48014616|NCT05142358|OTHER|Free Breath|Regular breathing
48014617|NCT05555472|BEHAVIORAL|Halt-intervention|The main aim of the Halt-intervention is to reduce the risk for reoffending. Seven sub-goals are implemented to work towards this main aim: (1) youths gain insight in (the consequences of) their behaviour; (2) strengthening youths' social skills; (3) youths are able take responsibility for the consequences of their behaviour; (4) victim-offender reconciliation; (5) youths are able to access support from own social network and, if necessary, access to formal support; (6) parents gain insight their child's behaviour; and (7) if youths complete the intervention, they do not receive a registration on their criminal record. With a compulsory screening and risk assessment at the start of the intervention, it is determined which sub-goals fit the adolescents' needs. The intervention gives Halt professionals the opportunity to identify adolescents (and families) in vulnerable circumstances and to guide them towards formal support, like youth care organisations or addiction treatment centres.
48702729|NCT03484507|DRUG|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
48371920|NCT00563602|OTHER|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
48371921|NCT05031156|PROCEDURE|Splinting of OT Bridge system|splinting of implant abutment using titanium wire followed by pick up using the patient's denture
48702730|NCT03484507|DRUG|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
48702731|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
48702732|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
48702733|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
48702734|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
48371922|NCT01695681|OTHER|Gluten-free diet|Dietary advice by clinical dietitian
48371923|NCT05780749|DIETARY_SUPPLEMENT|DDI-IBS-001|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
48371924|NCT05780749|OTHER|DDDI-IBS-001 placebo|The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.
48371925|NCT04650932|DEVICE|Deep brain stimulation|Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
48702735|NCT04151927|DEVICE|Normobaric Hypoxia|Low oxygen exposure to mimic \~8500 feet elevation.
48702736|NCT04151927|DEVICE|Normobaric Normoxia|Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
48702737|NCT04108845|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
48702738|NCT06608719|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|Patients diagnosed with ALS were administered SHED-CM
48171072|NCT00003162|PROCEDURE|pain therapy|
48171073|NCT00003162|RADIATION|radiation therapy|
48371926|NCT05874895|PROCEDURE|Manual Lymphatic Drainage|Manual lymphatic drainage massage involves gently manipulating specific areas of the body to help lymph move to an area with working lymph vessels.
48371927|NCT05874895|PROCEDURE|Usual Care|Usual care provided for patients in septic shock.
48371928|NCT04939805|DEVICE|Selective CRP apheresis using the PentraSorb®-CRP system|Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.
48371929|NCT02116374|OTHER|Physiopathology study|
48371930|NCT00008216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
48371931|NCT03053531|DEVICE|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
48371932|NCT01345227|PROCEDURE|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
48371933|NCT00934661|DRUG|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
48371934|NCT00934661|DRUG|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
48371935|NCT02730312|BIOLOGICAL|XmAb14045|Administered IV weekly up to 8 weeks, with or without step-up dosing
48702739|NCT05025098|DRUG|Standard therapy|"For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle."
48014618|NCT05555472|BEHAVIORAL|Youth Initiated Mentoring (YIM) approach|"The YIM approach focuses on strengthening naturally existing relationships between youth and non-parental adults within their own social network (Van Dam \& Schwartz, 2020). It stems from the idea it takes a village to raise a child (Educational Civil Society), which implies that other adults are co-responsible for the development of youth in their environment (Bowers et al., 2015). The YIM approach can be implemented in a formal context; expertise from the own social network is then combined with expertise from professionals (Van Dam \& Verhulst, 2018). Professionals support youth in identifying and positioning a YIM as part of a broader intervention (Van Dam \& Schwartz, 2020). Youths are responsible for asking their YIM and once agreed upon, the YIM is positioned. The YIM offers advice/support and plays a role during the intervention followed by the youth. Youth, parents, YIMs and professionals work together to set expectations and goals for the engagement of the YIM."
48014619|NCT02343510|OTHER|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
48014620|NCT01101841|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
48014621|NCT01101841|DRUG|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
48014622|NCT05877586|OTHER|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
48014623|NCT04616781|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
48014624|NCT04616781|DRUG|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
48014625|NCT04616781|OTHER|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
48014626|NCT03428516|DEVICE|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
48014627|NCT03428516|DEVICE|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
48014628|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 2 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
48371936|NCT04697342|BEHAVIORAL|strategy of education|"one of the strategies is microvideo with nursing information system(NIS); another of the strategies is workshop with NIS.~NIS of PI education is the routine education"
48371937|NCT05191199|DIAGNOSTIC_TEST|Penile Duplex Study|A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
48371938|NCT01478542|DRUG|Conventional Vincristine|
48371939|NCT01478542|DRUG|Liposomal Vincristine|
48371940|NCT01478542|DRUG|Ricover-scheme rituximab|
48702740|NCT05025098|DRUG|Precision therapy|Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
48702741|NCT05800028|BEHAVIORAL|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
48014629|NCT06663059|DRUG|Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle|"Each treatment cycle is 3 weeks long (Q3W), with a total of 4 cycles. Adebrelimab: 1200 mg once on Day 1, administered intravenously, Q3W. Albumin-bound Paclitaxel: 130 mg/m² on Day 1 and Day 8, administered intravenously, Q3W.~Cisplatin: 75 mg/m² on Day 1, administered intravenously, Q3W.~Drug infusion should follow this sequence:~Adebrelimab → Albumin-bound Paclitaxel → Cisplatin, with a minimum interval of 30 minutes between each infusion."
48014630|NCT06272747|DRUG|XH-S003|IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
48014631|NCT06272747|DRUG|Placebo|Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
48371941|NCT01478542|DRUG|optimised rituximab-schedule|
48371942|NCT06158087|DEVICE|pEGASUS Stent System|Endovascular intervention with p64/p48 MW HPC pEGASUS Stent System was performed in patients diagnosed with intracranial aneurysms
48371943|NCT04478591|OTHER|Questionnaires|All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
48371944|NCT02068001|PROCEDURE|Roux-en-Y Gastric Bypass|
48371945|NCT01411917|PROCEDURE|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
48014632|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose A|altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169
48014633|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose B|altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169
48014634|NCT06663436|BIOLOGICAL|altSonflex1-2-3 Dose C|altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169
48014635|NCT06663436|BIOLOGICAL|TYPHIBEV|TYPHIBEV administered intramuscularly on Day 1
48014636|NCT06663436|COMBINATION_PRODUCT|Infanrix hexa|Infanrix hexa administered intramuscularly on Day 169
48371946|NCT05273515|OTHER|Virtual Reality and 3D Reconstruction|Using virtual reality and 3D reconstruction to produce personalise images of what participants may look like after 15% and 25% total weight loss.
48371947|NCT02042573|DEVICE|rTMS|
48702742|NCT03199326|OTHER|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
48702743|NCT05279690|DRUG|Colchicine|Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
48702744|NCT01407471|DRUG|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
48702745|NCT01407471|DRUG|Clobetasol + Placebo|One application 6 days a week during 4 weeks
48702746|NCT01407471|DRUG|Placebo + Spironolactone|One application 6 days a week during 7 weeks
48702747|NCT01407471|DRUG|Placebo + Placebo|One application 6 days a week during 7 weeks
48702748|NCT06155656|OTHER|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
48014637|NCT06663436|BIOLOGICAL|MR-VAC|MR-VAC co-administered subcutaneously on Day 1 and Day 169
48014638|NCT05415098|DRUG|APG-5918|"The investigational drug product is formulated as oral tablets of 50 mg or 200 mg that contain APG-5918 as the active ingredient. APG-5918 will be orally administered once every day on 28-day cycles.~The dosage of APG-5918 depends on the dose level to which the patient is assigned. Each dose of APG-5918 will be taken orally in fasted condition in the study."
48014639|NCT03135522|DRUG|Zinc Acetate 50 Mg Oral Capsule|"* Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~* Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~* Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
48014640|NCT03135522|DRUG|Placebo oral capsule|"* Day 0 (randomization) to day 3 Placebo (one capsule per day)~* Day 4 to day 7 If well tolerated: placebo (two capsules per day)~* Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
48014641|NCT02187016|DEVICE|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
48014642|NCT02187016|DEVICE|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
48014643|NCT02187016|DEVICE|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
48014644|NCT02187016|DEVICE|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
48171074|NCT05338112|DIAGNOSTIC_TEST|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
48371948|NCT02042573|DRUG|SSRI (SEROPLEX ou ZOLOFT)|
48371949|NCT02042573|OTHER|Genetic samples|
48014645|NCT03260816|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
48014646|NCT03260816|OTHER|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
48014647|NCT00895219|OTHER|Breathing re-training|Breathing re-training
48014648|NCT00895219|OTHER|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
48014649|NCT05010109|PROCEDURE|6 Minute Walk Functional Test|Participate in 6 MWT
48014650|NCT05010109|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
48014651|NCT05010109|PROCEDURE|Computed Tomography|Undergo SPECT/CT
48014652|NCT05010109|PROCEDURE|Echocardiography|Undergo echocardiogram
48702749|NCT06155656|OTHER|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
48014653|NCT05010109|PROCEDURE|Exercise Cardiac Stress Test|Undergo stress test
48702750|NCT06155656|OTHER|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
48014654|NCT05010109|OTHER|Questionnaire Administration|Complete questionnaires
48014655|NCT05010109|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
48014656|NCT04684797|BEHAVIORAL|Virtual T-maze task|Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
48014657|NCT06309875|OTHER|PLAN CUIDARTE|Description Plan Cuidarte
48014658|NCT06309875|OTHER|Conventional care|Description Conventional care
48014659|NCT02042976|BEHAVIORAL|Mindfulness-based cognitive therapy|
48014660|NCT02042976|BEHAVIORAL|Pulmonary rehabilitation|
48014661|NCT00228527|DRUG|Esomeprazole (Nexium)|
48014662|NCT06442527|DEVICE|Virtual Reality|Virtual reality gear and content will be used prior to TMS session as part of the provocation items
48014663|NCT03895853|OTHER|Best Practice|Receive standard of care
48014664|NCT03895853|DIETARY_SUPPLEMENT|early metabolic resuscitation|Given Intravenous
48014665|NCT04113252|OTHER|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
48014666|NCT04113252|OTHER|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
48014667|NCT04113252|BEHAVIORAL|Coaching|Subjects will receive coaching prior to starting pain medication.
48014668|NCT02285751|DRUG|acetylsalicylic acid|
48014669|NCT02285751|DRUG|clopidogrel|
48014670|NCT02285751|DRUG|prasugrel|
48014671|NCT02285751|DRUG|ticagrelor|
48371950|NCT04786782|DIAGNOSTIC_TEST|PPG-detecting software|Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.
48371951|NCT04786782|DIAGNOSTIC_TEST|LSM and PLT count|Patients whose LSM \>15kPa, or PLT count \< 150\*10\^9 should be screened with upper GI endoscopy
48702751|NCT06155656|OTHER|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
48702752|NCT01528891|DRUG|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
48702753|NCT01528891|OTHER|Placebo|
48014672|NCT05089539|DRUG|Angiotensin Receptor-Neprilysin Inhibition|Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
48014673|NCT05089539|DRUG|Placebo|Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
48014674|NCT01196728|DRUG|CM3.1-AC100|SAD study with single ascending subcutaneous doses
48014675|NCT05932290|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
48014676|NCT05932290|DRUG|Standard of care|Standard of care
48014677|NCT01981434|OTHER|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
48014678|NCT03643822|DRUG|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
48371952|NCT01773850|DEVICE|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
48702754|NCT06102590|OTHER|Individualized red blood cell transfusion strategy|Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
48702755|NCT06102590|OTHER|European guidelines red blood cell transfusion strategy|RBCT according to ESICM guidelines
48171075|NCT04621422|BIOLOGICAL|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
48171076|NCT06009445|DIAGNOSTIC_TEST|Renal resistive index|"The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity _ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged."
48371953|NCT02137473|OTHER|Human milk-based fortifier|
48702756|NCT05741840|BEHAVIORAL|PBT-A|PBT-A provides all the elements of family based treatment for children with obesity, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
48702757|NCT05741840|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
48702758|NCT02891148|DRUG|BI 690517|
48522988|NCT02737241|PROCEDURE|High power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 100W holmium laser energy.
48702759|NCT01349361|PROCEDURE|Daylight mediated photodynamic therapy|
48702760|NCT00068913|DRUG|Dichloroacetate|
48702761|NCT05385081|OTHER|genomic profiling|next generation sequencing
48702762|NCT05901051|DRUG|vonoprazan|Potassium competitive acid blocker
48702763|NCT05901051|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
48702764|NCT04261400|BEHAVIORAL|MAMAACT|Improved communication regarding warning signs of pregnancy complications
48702765|NCT05495841|DEVICE|Pre-oxygenation|Process of administrating oxygen prior to intubation
48702766|NCT03179111|PROCEDURE|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
48702767|NCT04655755|DRUG|Decitabine and Cedazuridine|Given PO
48702768|NCT04655755|DRUG|Venetoclax|Given PO
48702769|NCT06305715|DEVICE|Radiation Therapy|Enrolled subjects will be given radiation doses, at the discretion of the treating physicians, that range from 24-60 Gy in 1-15 fractions with a minimum biologically effective dose (BED\^10) of 58 Gy.
48702770|NCT06305715|DRUG|Targeted TKI therapy|Immediately following radiation therapy, subjects with an actionable driver mutation will receive a standard-of-care TKI. The choice of TKI will be at the discretion of the treating oncologist.
48702771|NCT02241811|DRUG|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
48702772|NCT02241811|DRUG|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
48702773|NCT06542601|DEVICE|Motor cognitive intervention|Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
48702774|NCT04225676|BIOLOGICAL|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight."
48702775|NCT00532740|RADIATION|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
48702776|NCT01505673|DRUG|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
48171077|NCT00521443|PROCEDURE|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
48171078|NCT00233753|DEVICE|Cordis Neurovascular Self-Expanding Stent|
48171079|NCT06018688|DRUG|Osimertinib|Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
48171080|NCT06018688|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.
48702777|NCT01505673|DRUG|Saline|Placebo injection of 1.8mg saline once daily for 6-months
48371954|NCT02137473|OTHER|Bovine protein-based fortifier|
48702778|NCT01023555|OTHER|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
48702779|NCT05575492|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
48702780|NCT05575492|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
48702781|NCT05408507|BEHAVIORAL|ABC123 Framework|This care planning framework aims to implement existing tools in geriatric medicine, palliative medicine, and medical oncology to aid in cancer care planning for older adults with newly diagnosed incurable advanced cancer and to test the delivery of goal-concordant care. This patient-centered intervention is the ABC123 care planning framework in parallel with usual care that includes a physical function assessment, chemotherapy toxicity estimate calculation, and a guided goals of care discussion.
48702782|NCT04611958|DRUG|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
48702783|NCT01576419|DRUG|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
48702784|NCT01576419|DRUG|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
48171081|NCT03591432|DEVICE|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
48171082|NCT03591432|DEVICE|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
48171083|NCT03754764|BIOLOGICAL|Specificity CD38 CAR-T Cells|1) Biological: Specificity CD38 CAR-T Cells 2) Day 0: 1-5x10e6/kg total dose .3) Other: Laboratory Biomarker Analysis
48171084|NCT05162196|RADIATION|SBRT|24Gy/3F
48171085|NCT05162196|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
48522989|NCT05114213|RADIATION|SBRT|online adaptive MR-guided hypofractionated stereotactic radiotherapy
48522990|NCT05114213|DRUG|SOC chemotherapy|The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
48014679|NCT03643822|DRUG|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
48522991|NCT05131672|PROCEDURE|open reduction and internal fixation (ORIF)|open reduction and internal fixation with pin or screw fixation
48522992|NCT05131672|PROCEDURE|cast immobilization|immobilization in a cast without reduction
48014680|NCT03643822|OTHER|Saline|Control/Placebo intervention
48014681|NCT06576765|DRUG|AZD0780|Dose 1
48171086|NCT05162196|DRUG|Niraparib|200mg qd
48371955|NCT00991458|DRUG|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
48371956|NCT00991458|DRUG|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
48516306|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, PET/MRI|The study will use blood samples from COVID biobank at University Health Network. Samples will be collected at time of admission to ER in patients discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers. Echocardiography studies will be assessed for structural and functional abnormalities. All included patients will have prospective short-term follow-up (3-6 months) for assessment of clinical events and subclinical cardiovascular disease. 50 patients who had clinical cardiac MRI at our center within 5 years prior to COVID-19 (January 2015-January 2020) and have since tested positive for COVID-19 will be recruited for research cardiac MRI to compare changes between baseline (pre-COVID) and follow-up (post-COVID imaging). A subgroup of 50 patients will undergo cardiac PET/MRI at 1-3 months post COVID-19 diagnosis to evaluate for myocardial inflammation and other imaging markers of cardiac injury.
48702785|NCT05915416|BEHAVIORAL|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
48702786|NCT06142513|OTHER|Assessment|Between December 2023 and June 204, 46 volunteer participants aged 18 years and older who met the inclusion criteria and were followed up at Istanbul University, Istanbul Faculty of Medicine, Department of Chest Diseases and Istanbul Faculty of Medicine, Department of Internal Medicine were included in the project. Participants' body composition, comorbidities, exercise capacity, peripheral muscle strength, sleep quality and quality of life were assessed.
48702787|NCT05292911|DRUG|ALT-801|Injected subcutaneously (SC)
48702788|NCT05292911|OTHER|Placebo|Injected subcutaneously (SC)
48702789|NCT00635739|DIETARY_SUPPLEMENT|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
48702790|NCT00635739|DIETARY_SUPPLEMENT|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
48702791|NCT01856049|OTHER|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
48702792|NCT04376684|BIOLOGICAL|Otilimab|Otilimab will be administered once via IV route.
48371957|NCT00991458|DRUG|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
48702793|NCT04376684|BIOLOGICAL|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
48702794|NCT04376684|BIOLOGICAL|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
48702795|NCT04376684|DRUG|Standard of care|All participants will receive standard of care as per institutional protocol.
48702796|NCT02633254|DEVICE|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
48702797|NCT04201366|OTHER|No intervention|No intervention
48702798|NCT00394251|DRUG|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
48171087|NCT01540903|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
48171088|NCT01540903|BIOLOGICAL|Saline|Saline
48371958|NCT01599091|OTHER|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
48702799|NCT00394251|DRUG|ABI-007|260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
48702800|NCT00394251|DRUG|Taxol|175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
48702801|NCT00394251|DRUG|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
48702802|NCT00394251|DRUG|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
48702803|NCT04322305|DRUG|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
48171089|NCT00985283|BEHAVIORAL|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
48171090|NCT00985283|BEHAVIORAL|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
48171091|NCT02125318|DRUG|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
48171092|NCT01531907|OTHER|Study visit procedures|"Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
48171093|NCT00175656|PROCEDURE|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
48171094|NCT02017132|DIETARY_SUPPLEMENT|Pomegranate extract|
48171095|NCT06162065|DRUG|Oxybutynin Pill|pharmacological antimuscarinic treatment
48171096|NCT06162065|DIETARY_SUPPLEMENT|Boldo supplement|treatment supplemented with boldo
48171097|NCT05863013|OTHER|ADL-Glittre Test|They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
48171098|NCT01722864|DRUG|COV155|COV155 tablets
48171099|NCT02107729|PROCEDURE|Large needle gauge lidocaine injection|21 G
48171100|NCT02107729|PROCEDURE|Normal needle gauge lidocaine injection|23 G
48171101|NCT02107729|PROCEDURE|Small needle gauge lidocaine injection|27 G
48171102|NCT05511558|DRUG|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
48171103|NCT01430078|DRUG|ASP015K|oral tablet
48171104|NCT01430078|DRUG|ASP015K|solution via oral capsule
48171105|NCT04440059|DRUG|ICP-022|ICP-022 at a dose of 150mg PO QD
48702804|NCT04322305|OTHER|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
48171106|NCT05946122|DRUG|Atorvastatin 40 Mg Oral Tablet|oral atorvastatin for renal protection
48171107|NCT05946122|DRUG|placebo drug|tablet resembles atorvastatin
48371959|NCT01939236|DRUG|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
48171108|NCT03357978|DIAGNOSTIC_TEST|bioelectrical impedance analysis|Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
48702805|NCT04930549|DRUG|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
48171109|NCT03357978|DIAGNOSTIC_TEST|blood draw|Blood samples are taken from sober patients
48371960|NCT01939236|DRUG|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
48702806|NCT04930549|DRUG|Placebo|Patients receive placebo tablets once a day during 12 weeks
48702807|NCT04930549|PROCEDURE|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
48702808|NCT04930549|PROCEDURE|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
48171110|NCT03357978|DIAGNOSTIC_TEST|transient elastography (FibroScan)|FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
48171111|NCT03357978|DIAGNOSTIC_TEST|ataxia score|Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
48014682|NCT06014112|DEVICE|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
48014683|NCT05346627|PROCEDURE|Personalized and mixed training program|Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
48014684|NCT05545852|PROCEDURE|GTPET(Gasless Transaxillary Posterial Endoscopic Thyroidectomy)|Gasless Transaxillary Posterial Endoscopic Thyroidectomy and Ipsilateral Central Lymph Node Dissection
48014685|NCT05545852|PROCEDURE|COT(Conventional Open Thyroidectomy)|Conventional Open Thyroidectomy and Ipsilateral Central Lymph Node Dissection
48014686|NCT06556368|DRUG|Tarcocimab tedromer|Intravitreal injection
48014687|NCT06556368|DRUG|Tabirafusp tedromer|Intravitreal injection
48014688|NCT06556368|DRUG|Aflibercept|Intravitreal injection
48014689|NCT05900427|DRUG|Liposomal bupivacaine|Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).
48014690|NCT05900427|DRUG|Bupivacaine|Subjects randomized to the Plain Bupivacaine group will receive 36 mL (180 mg) of 0.5% bupivacaine.
48014691|NCT05010759|DEVICE|NanoTherm Ablation|Iron nanoparticles are instilled into the prostate cancer lesion and then the particles are heated using a magnetic field and this heating ablates the prostate cancer lesion.
48014692|NCT06154434|DRUG|Chlorpromazine HCl 100mg Tablets|single-dose administered after a 10-hour overnight fast.
48014693|NCT06329154|DEVICE|Extracorporeal shock wave therapy|The experimental group received extracorporeal shock wave therapy combined with conventional rehabilitation therapy. The control group was only given conventional rehabilitation therapy. According to the patient's tolerance and the specific condition, extracorporeal shock wave therapy was performed twice a week, 2000-3000 times each time, energy parameters of 2.5-3.5Bar, 8-15Hz, treatment interval \> 1 day, consecutive 4 weeks. Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser and wax therapy. Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
48014694|NCT06329154|OTHER|conventional rehabilitation therapy|Conventional rehabilitation therapy included medium frequency electricity, ultrasound, ultrashort wave, laser, and wax therapy (same as the control group). Routine rehabilitation was given once a day, 5 times a week for 4 weeks.
48171112|NCT03357978|DIAGNOSTIC_TEST|Five-Times-Sit-to-Stand Test|The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
48171113|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
48014695|NCT06661837|OTHER|Clinical examination and mobile photo|Children were both clinically examined and a mobile photo was taken for assessment
48014696|NCT04465045|PROCEDURE|Laparoscopy-hysteroscopy|Under general anesthesia, we start by a first look in laparoscopy, to look for endometriosis mainly, tubal infertility, ovarian cysts or any abnormalities that may not have been suspected on the first exam. Then we check tubal patency after a look at the uterine cavity by hysteroscopy. Then we treat everything possible to treat to improve fertility, spontaneous or with ART.
48014697|NCT02717533|OTHER|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
48014698|NCT03063359|DRUG|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
48014699|NCT03063359|DRUG|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
48014700|NCT03079336|BEHAVIORAL|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
48014701|NCT03079336|BEHAVIORAL|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
48171114|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
48171115|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
48171116|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
48171117|NCT05887739|DIAGNOSTIC_TEST|Inertial gait analysis|All groups will be evaluated with inertial gait analysis
48171118|NCT02901483|DRUG|PEP503|PEP503 will be administered by intratumoral route as slow injection
48171119|NCT02901483|DRUG|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7\~8 weeks' radiation period.
48171120|NCT02901483|RADIATION|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7\~8 weeks.
48171121|NCT04700566|BIOLOGICAL|Renuva Allograft Adipose Matrix|Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
48014702|NCT03079336|BEHAVIORAL|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
48014703|NCT03575832|OTHER|Counseling|Complete nutrition counseling sessions
48014704|NCT03575832|OTHER|Informational Intervention|Receive an exercise plan and printed materials
48014705|NCT03575832|OTHER|Quality-of-Life Assessment|Ancillary studies
48014706|NCT03575832|OTHER|Questionnaire Administration|Ancillary studies
48014707|NCT03575832|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching calls
48014708|NCT04186962|OTHER|Behavioral: Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
48014709|NCT03341624|PROCEDURE|cataract surgery cataract extraction and intraocular implantation|
48371961|NCT06298721|BEHAVIORAL|Personalized outcome prediction tool + targeted interventions|"* TKA Personalized Outcome Prediction Tool to aid in setting expectations~* Mental Health Screening/Intervention~* Physical Therapy Pre-surgery Assessments \& Rehabilitation"
48702809|NCT04930549|PROCEDURE|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
48702810|NCT04930549|PROCEDURE|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
48702811|NCT02094742|PROCEDURE|biopsy|
48702812|NCT01368692|PROCEDURE|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
48702813|NCT01368692|PROCEDURE|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
48014710|NCT05690737|BEHAVIORAL|Tai Chi training|The 24-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified/certified instructors. Each 1-hour training session will consist of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors will have to attend a training session that ensure all of them will deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training activity will be delivered in group. The group size is 25-30 persons. During the 24 weeks follow-up period, the participants are required to practice Tai Chi with the same frequency by themselves.
48014711|NCT05690737|DRUG|Standard prophylactic medication|Participants assigned to the control group will follow the collaborated neurologist's recommendation, to take the prophylactic medication. The Multidisciplinary Panel on Neuropathic Pain (MPNP) of Hong Kong has published the treatment algorithm for migraine, which is in line with the guideline of the Scottish Intercollegiate Guidelines Network (SIGN) on the pharmacological management of migraine (SIGN 155). Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis. The dosage will start on 10mg and slowly increase by 10mg every week until the dosage reached the highest dose of 150mg/day. The whole course will last for 48 weeks. The second line drug such as amitriptyline and the third line drug such as gabapentin will be adopted according to doctor's judgement if necessary. RA will help the participants to make appointment with the neurological doctor, to obtain the prescription. The adverse events will be recorded accordingly.
48014712|NCT02621983|BEHAVIORAL|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
48014713|NCT02621983|BEHAVIORAL|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
48014714|NCT00130962|DRUG|ALGRX 4975|
48171122|NCT00003698|DRUG|fosbretabulin disodium|
48171123|NCT01269255|DRUG|TS-1 with Cisplatin|"SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy"
48702814|NCT00096174|BIOLOGICAL|cetuximab C225|400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
48702815|NCT00096174|DRUG|cisplatin|75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
48702816|NCT00096174|RADIATION|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
48702817|NCT01714037|DRUG|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
48702818|NCT01714037|DRUG|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
48702819|NCT01714037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
48702820|NCT01714037|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
48702821|NCT01714037|DRUG|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
48702822|NCT01932151|DRUG|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
48702823|NCT01165112|DRUG|Bendamustine Hydrochloride|Given IV
48702824|NCT01165112|DRUG|Carboplatin|Given IV
48702825|NCT01165112|BIOLOGICAL|Rituximab|Given IV
48702826|NCT01165112|DRUG|Etoposide|Given IV
48702827|NCT01165112|OTHER|Laboratory Biomarker Analysis|Correlative studies
48702828|NCT01915121|BEHAVIORAL|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
48702829|NCT01915121|BEHAVIORAL|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
48371962|NCT06298721|BEHAVIORAL|Standard of Care TKA|- Standard of care preoperative TKA clinic appointment to discuss plan for surgery and get consent
48702830|NCT04915170|DEVICE|Inspiratory muscle training|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
48702831|NCT04315792|DRUG|Endoxifen|Administration of Endoxifen for 3 weeks
48702832|NCT04315792|DRUG|Placebo oral tablet|Administration of Placebo for 3 weeks
48702833|NCT05474781|DRUG|Epclusa|HCV treatment
48014715|NCT03736421|PROCEDURE|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
48014716|NCT03736421|PROCEDURE|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
48014717|NCT03736421|DIAGNOSTIC_TEST|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
48014718|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
48014719|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
48014720|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
48171124|NCT03105778|DIAGNOSTIC_TEST|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
48702834|NCT01165788|PROCEDURE|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
48702835|NCT06247111|OTHER|Remote Blood Pressure Monitoring + Telehealth|Remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
48702836|NCT06247111|OTHER|Usual care|Participants receive usual care, no intervention.
48702837|NCT04155918|DRUG|Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
48014721|NCT05875441|DRUG|Placebo|16 placebo capsules will be administered as a single dose.
48014722|NCT03227380|OTHER|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
48014723|NCT06453590|PROCEDURE|Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
48171125|NCT04758546|DIAGNOSTIC_TEST|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
48171126|NCT06382571|DRUG|Renin-Angiotensin System Inhibitor|
48014724|NCT06453590|PROCEDURE|Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
48014725|NCT06453590|PROCEDURE|Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
48171127|NCT06199206|OTHER|Theraputic Play|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
48516307|NCT05085262|DIAGNOSTIC_TEST|Bloodwork, Echocardiogram, MRI|The study will involve use of blood samples from the COVID biobank at UHN (University Health Network) for measurement of blood biomarkers. Echocardiography Studies will be systematically assessed for structural and functional abnormalities. All included patients assessment of clinical events and subclinical cardiovascular disease.
48516308|NCT00004186|DRUG|carboplatin|
48014726|NCT05087017|OTHER|Intervention group|Patients with medical condition to follow the rehabilitation program will be asked to answer questionnaires to assess their sleep quality.
48516309|NCT00004186|DRUG|etoposide|
48702838|NCT04155918|DRUG|Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
48516310|NCT00004186|DRUG|ifosfamide|
48516311|NCT00004186|DRUG|topotecan hydrochloride|
48516312|NCT00004186|RADIATION|radiation therapy|
48702839|NCT03156686|PROCEDURE|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
48702840|NCT01610713|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
48702841|NCT05647343|DRUG|Ciclopirox Olamine Oral|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
48702842|NCT05647343|OTHER|Placebo|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
48702843|NCT03315273|OTHER|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
48702844|NCT06210542|DRUG|ceftazidime avibactam|"Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL"
48516313|NCT00626561|DRUG|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
48516314|NCT00626561|DRUG|Paclitaxel|60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
48516315|NCT04009707|OTHER|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
48702845|NCT05058573|OTHER|Control group (n=22)|Control group will be received only medical treatment
48702846|NCT04041466|DIAGNOSTIC_TEST|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
48702847|NCT01097265|DRUG|capecitabine|
48702848|NCT01097265|DRUG|oxaliplatin|
48702849|NCT01097265|OTHER|active surveillance|
48702850|NCT01097265|OTHER|laboratory biomarker analysis|
48702851|NCT01097265|PROCEDURE|adjuvant therapy|
48702852|NCT01097265|PROCEDURE|lymph node mapping|
48702853|NCT01097265|PROCEDURE|sentinel lymph node biopsy|
48702854|NCT00516893|BIOLOGICAL|BG00002-E (natalizumab high titer)|
48702855|NCT06170346|COMBINATION_PRODUCT|Antioxidants|30 drops of topical antioxidants (Gluconolactone 4%, Hyaluronic acid 0,01%, Allantoin 0,1%, Ferulic acid 3%, Acetyl heptapeptide 0,001%, Silver vine extract 1%, Ectoine 0,01%, Hydroxyectoine 0,01%, and vehicle) will be applied on tested area on each participant for four consecutive days.
48171128|NCT01795521|RADIATION|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
48171129|NCT03030105|DRUG|BPN14770|investigational drug
48371963|NCT03360695|OTHER|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
48516316|NCT04009707|OTHER|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
48516317|NCT04269525|BIOLOGICAL|UC-MSCs|After enrollment, each subject will receive UC-MSCs infusion intravenously on day 1, day 3, day 5, and day 7.
48371964|NCT03360695|OTHER|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
48516318|NCT02587078|DRUG|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
48702856|NCT06170346|COMBINATION_PRODUCT|Vehicle|30 drops of topical vehicle (Aqua, Dipropylene glycol, Hydroxypropyl cyclodextrin, Polydextrose, 1,2-hexanediol, Butylene glycol, Propanediol, Caprylhydroxamic acid, Ethylhexylglycerin, Xanthan gum, Benzyl alcohol, Glyceryl caprylate, and Benzoic acid) will be applied on tested area on each participant for four consecutive days.
48702857|NCT01536665|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
48702858|NCT01536665|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
48702859|NCT03262571|DIAGNOSTIC_TEST|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
48702860|NCT03195244|OTHER|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
48702861|NCT03944356|DRUG|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
48702862|NCT05852262|DRUG|Cephalexin|1000 mg PO QID for 7 days
48702863|NCT05852262|DRUG|Cephalexin|500 mg PO QID plus oral placebo for 7 days
48702864|NCT04812093|DEVICE|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
48702865|NCT00274898|DRUG|celecoxib|
48702866|NCT00274898|DRUG|docetaxel|
48702867|NCT00274898|PROCEDURE|adjuvant therapy|
48702868|NCT00274898|RADIATION|radiation therapy|
48702869|NCT02813135|DRUG|Ribociclib|
48702870|NCT02813135|DRUG|Topotecan|
48702871|NCT02813135|DRUG|Temozolomide|
48702872|NCT02813135|DRUG|Everolimus|
48702873|NCT02813135|DRUG|Adavosertib|
48702874|NCT02813135|DRUG|Carboplatin|
48702875|NCT02813135|DRUG|Olaparib|
48702876|NCT02813135|DRUG|Irinotecan|
48702877|NCT02813135|DRUG|Vistusertib|
48702878|NCT02813135|DRUG|Nivolumab|
48702879|NCT02813135|DRUG|Cyclophosphamide|
48702880|NCT02813135|DRUG|Selumetinib|
48702881|NCT02813135|DRUG|Enasidenib|
48702882|NCT02813135|DRUG|Lirilumab|
48702883|NCT02813135|DRUG|Fadraciclib|
48702884|NCT02813135|DRUG|Cytarabine|
48702885|NCT02813135|DRUG|Dexamethasone|
48702886|NCT02813135|DRUG|Ceralasertib|
48702887|NCT02813135|DRUG|Futibatinib|
48702888|NCT02813135|DRUG|Capmatinib|
48702889|NCT06077955|PROCEDURE|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
48702890|NCT06077955|PROCEDURE|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
48702891|NCT05166278|BEHAVIORAL|De-escalation training|The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
48702892|NCT00236990|DRUG|pentosan polysulfate sodium|
48702893|NCT01451931|OTHER|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
48702894|NCT01451931|RADIATION|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
48702895|NCT01451931|OTHER|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
48702896|NCT06410261|BEHAVIORAL|Exercise rehabilitation program|"* The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance."
48014727|NCT01532362|DRUG|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
48014728|NCT04926675|BEHAVIORAL|Psychological Therapy|Participants will be receiving their one-to-one psychological therapy from IAPT as usual. They typically receive between 6 and 12 sessions with a psychological practitioner.
48014729|NCT04926675|BEHAVIORAL|Debt Advice|Participants will receive one-to-one support from a Citizen's Advice (CA) money advisor for as long as needed to resolve any money worries currently affecting their mental health.
48171130|NCT03030105|DRUG|BPN14770 placebo|placebo
48171131|NCT03030105|DRUG|Donepezil|comparator
48171132|NCT03030105|DRUG|Donepezil placebo|placebo
48171133|NCT03030105|DRUG|Scopolamine 0.6 MG/ML|cognition impairment
48014730|NCT06383039|DEVICE|Transcranial Direct Current Stimulation|"Evaluations will be made in the presence of a physiotherapist. Individuals; For demographic information~• Demographic Information Form~For Static Balance Evaluation:~* Wii-Fit~* Balance Error Scoring System~For Dynamic Balance Assessment:~* Star Balance Test~* Timed Get Up and Go Test"
48702897|NCT02349607|DRUG|PF-05089771 300mg|PF-05089771 300 mg
48702898|NCT02349607|DRUG|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
48702899|NCT02349607|DRUG|Placebo|Placeco
48014731|NCT03862976|DIAGNOSTIC_TEST|computerized cardiotocography|computerized cardiotocography (C-CTG)
48014732|NCT03536728|DRUG|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
48014733|NCT03536728|DRUG|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
48014734|NCT05268471|DEVICE|Positional device (PD)|OSA treatment with PD for 6 months
48702900|NCT02349607|DRUG|pregabalin 300 mg|pregabalin 300 mg
48702901|NCT02349607|DRUG|ibuprofen 600 mg|ibuprofen 600 mg
48702902|NCT01054131|BEHAVIORAL|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
48702903|NCT02052336|DRUG|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
48014735|NCT05268471|DEVICE|Continuos Positive Airway Pressure (CPAP)|OSA treatment with CPAP for 6 months
48014736|NCT06573112|DIAGNOSTIC_TEST|ultrasound assessment for catheter-related thrombosis.|Patients with newly inserted central venous catheter will be assessed with vascular ultrasound for the presence of catheter-related thrombosis
48014737|NCT01948375|DEVICE|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
48171134|NCT03030105|DRUG|Scopolamine placebo|placebo
48171135|NCT04350112|OTHER|Clinical assessment|Clinical assessment (history, examination) is gold standard for diagnosing constipation - gold standard will be compared with simple question about constipation, Rome IV diagnostic criteria for OIC, and common definitions of constipation for constipation / OIC
48171136|NCT03463577|OTHER|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
48171137|NCT02606383|DRUG|Dapaconazole|
48171138|NCT02606383|DRUG|Ketoconazole|
48702904|NCT02052336|DRUG|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
48702905|NCT02052336|DRUG|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
48702906|NCT03395691|PROCEDURE|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
48702907|NCT03395691|PROCEDURE|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
48702908|NCT05501431|DEVICE|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
48702909|NCT01678573|DRUG|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
48702910|NCT01678573|DRUG|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
48702911|NCT01678573|DRUG|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
48702912|NCT04964648|DEVICE|shear wave elastography|Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
48702913|NCT03172962|BEHAVIORAL|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
48702914|NCT03172962|BEHAVIORAL|Usual care (control)|Will receive the usual care at the hospital
48702915|NCT06041711|PROCEDURE|General anesthesia with propofol induction and sevoflurane maintenance|Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.
48702916|NCT06041711|PROCEDURE|Regional anesthesia with neuroaxial blockage|Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
48702917|NCT03170518|DRUG|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
48171139|NCT05047653|DIAGNOSTIC_TEST|RALE score vs. severity score|RALE score vs. severity score and CORADS
48702918|NCT03170518|DRUG|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
48702919|NCT03170518|DRUG|Placebo|Matching placebo tablet will be administered orally once-daily.
48171140|NCT05225636|PROCEDURE|thrombectomy|Extraction of intracranial thrombus in an acute large vessel occlusion
48171141|NCT03719378|OTHER|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
48171142|NCT05217290|BEHAVIORAL|transtheoretical model|The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
48702920|NCT05482477|OTHER|Transcutaneous acupoint electrical stimulation|Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
48702921|NCT05254132|PROCEDURE|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
48702922|NCT03051412|OTHER|No Intervention|No intervention
48171143|NCT05288777|DRUG|T-DM1|Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
48171144|NCT05288777|DRUG|Capecitabine|Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
48171145|NCT05288777|RADIATION|External Beam Radiation Therapy 0|Dose of 40 Gy in 15 fractions to the whole breast or chest wall followed by consideration of a 10 Gy in 4 fraction boost to the lumpectomy cavity for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
48171146|NCT05288777|RADIATION|External Beam Radiation Therapy 1|Dose of 40 Gy in 15 fractions to either the breast or chest wall along with comprehensive nodal radiation followed by consideration of a 10 Gy in 4 fraction boost for a total duration of 15-19 days. Internal mammary nodal, dissected axilla coverage, and boost will be at the radiation oncologist's discretion.
48171147|NCT04615910|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
48171148|NCT06277518|PROCEDURE|Surgery for malignant tumors of the digestive system|Related treatment or palliative surgery under general anesthesia for digestive system malignancies
48171149|NCT01292577|BEHAVIORAL|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
48702923|NCT06024850|OTHER|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
48702924|NCT05781061|OTHER|Screening for Eligibility|Asynchronous Screening for MA Eligibility
48702925|NCT03263858|DEVICE|Stent|Implantation of coronary stent in de novo coronary artery lesions
48702926|NCT00713349|DRUG|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
48702927|NCT00713349|OTHER|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
48702928|NCT02576535|PROCEDURE|Fractionated stereotactic radiosurgery|
48702929|NCT02576535|DEVICE|Leskell gamma unit|FDA approved device
48702930|NCT04236180|OTHER|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
48702931|NCT00243451|OTHER|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
48702932|NCT03663127|DIETARY_SUPPLEMENT|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
48702933|NCT03663127|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
48702934|NCT00025298|DRUG|amifostine trihydrate|
48516319|NCT02587078|DRUG|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
48702935|NCT00025298|DRUG|carboplatin|
48702936|NCT00025298|DRUG|cisplatin|
48702937|NCT00025298|DRUG|paclitaxel|
48702938|NCT00025298|RADIATION|radiation therapy|
48702939|NCT03526809|DIAGNOSTIC_TEST|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
48171150|NCT01292577|BEHAVIORAL|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
48171151|NCT01585818|OTHER|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
48702940|NCT03785249|DRUG|MRTX849|MRTX849 will be administered orally once or twice daily in a continuous regimen
48702941|NCT03785249|DRUG|Pembrolizumab|Pembrolizumab is administered as an intravenous infusion once every 3 weeks
48702942|NCT03785249|DRUG|Cetuximab|Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks
48516320|NCT06206850|DRUG|Osimertinib|Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
48516321|NCT02892149|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
48522993|NCT05202314|DRUG|Immunotherapy (Camrelizumab)|After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
48702943|NCT03785249|DRUG|Afatinib|Afatinib will be administered orally once a day in a continuous regimen
48702944|NCT00139542|OTHER|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
48702945|NCT00139542|OTHER|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
48702946|NCT06225739|OTHER|Electronic pregnancy register|Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered
48171152|NCT01585818|OTHER|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
48171153|NCT00112710|DRUG|carboplatin|
48171154|NCT00112710|DRUG|cisplatin|
48171155|NCT00112710|DRUG|gemcitabine hydrochloride|
48371965|NCT03593109|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
48371966|NCT00579514|GENETIC|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
48516322|NCT02892149|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
48702947|NCT06225739|OTHER|In-depth interviews and focus group discussions|In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
48702948|NCT05958394|BEHAVIORAL|SkillFlix for Parents|A Microskills video training library on communication skills for talking to youth about relationships and sexual health topics.
48702949|NCT04960384|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).
48171156|NCT01299298|DRUG|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
48171157|NCT01299298|DRUG|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
48171158|NCT01691547|DRUG|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
48171159|NCT01691547|DRUG|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
48171160|NCT01691547|DRUG|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
48371967|NCT00706901|BEHAVIORAL|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller \& Rollnick 2013) and based on a manualized protocol (Martino \& Santa Ana 2013; Santa Ana \& Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
48516323|NCT03608397|BIOLOGICAL|DaxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
48171161|NCT01691547|DRUG|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
48171162|NCT06187597|DRUG|S-1|Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
48171163|NCT06187597|DRUG|Toripalimab|Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.
48171164|NCT06187597|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.
48171165|NCT02332083|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
48171166|NCT02332083|DEVICE|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
48171167|NCT02332083|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
48171168|NCT02332083|DEVICE|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
48171169|NCT02205723|BEHAVIORAL|Asthma teaching in ER|Asthma teaching
48171170|NCT02205723|BEHAVIORAL|Smartphone Asthma Control|Smartphone Asthma Control
48171171|NCT02649361|DRUG|Anlotinib|Anlotinib p.o. qd
48171172|NCT02649361|DRUG|Placebo|Placebo p.o. qd
48171173|NCT02951169|OTHER|No intervention|No intervention. Treatment are accordance with clinical practice.
48171174|NCT02362347|DEVICE|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
48702950|NCT04960384|DRUG|Placebo|FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
48702951|NCT00742365|DEVICE|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
48702952|NCT00742365|DEVICE|Red light placebo|One hour of exposure to red light.
48171175|NCT02362347|OTHER|exercise|exercise
48171176|NCT04362098|BEHAVIORAL|Home visiting Program for Young Pregnant Women|The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
48702953|NCT01480414|BIOLOGICAL|4times injection|bone marrow derived mono nuclear stem cell
48702954|NCT01480414|BIOLOGICAL|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
48702955|NCT00011362|DRUG|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
48702956|NCT00011362|DRUG|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline
48171177|NCT04865783|PROCEDURE|Saline spray|The saline spray will be applied twice for 1-2 seconds.
48171178|NCT04865783|PROCEDURE|Cryospray|The cryospray will be applied twice for 1-2 seconds.
48171179|NCT00676195|DRUG|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
48171180|NCT06014502|DRUG|IMGS-001|Every 2 weeks
48171181|NCT01589523|DRUG|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
48171182|NCT03068221|OTHER|anaerobic exercise|assessing anaerobic exercise status
48171183|NCT00002061|DRUG|Inosine pranobex|
48371968|NCT00706901|BEHAVIORAL|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
48171184|NCT01673295|DRUG|RTX infusions|RTX + Standard of Care
48171185|NCT01673295|OTHER|Standard of Care|Standard of Care only
48171186|NCT00003423|DRUG|asparaginase|
48171187|NCT00003423|DRUG|cyclophosphamide|
48171188|NCT00003423|DRUG|cytarabine|
48171189|NCT00003423|DRUG|daunorubicin hydrochloride|
48171190|NCT00003423|DRUG|dexamethasone|
48171191|NCT00003423|DRUG|etoposide|
48171192|NCT00003423|DRUG|mercaptopurine|
48171193|NCT00003423|DRUG|methotrexate|
48171194|NCT00003423|DRUG|prednisolone|
48171195|NCT00003423|DRUG|thioguanine|
48171196|NCT00003423|DRUG|vincristine sulfate|
48171197|NCT04967586|OTHER|No intervention, questioner only|questioner only
48171198|NCT04855136|BIOLOGICAL|BB2121|CAR T Cell Therapy
48171199|NCT04855136|DRUG|CC-220|Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)
48171200|NCT04855136|DRUG|BMS-986405|gamma secretase inhibitor (GSI)
48171201|NCT00522509|DRUG|Floxuridine FUDR|
48014738|NCT01948375|DEVICE|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
48014739|NCT03444142|DRUG|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
48014740|NCT03444142|DRUG|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
48171202|NCT04876768|PROCEDURE|Use of different concentrations of oxygen during ERCP|The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
48171203|NCT00382798|DRUG|RO5024048|
48171204|NCT04071093|OTHER|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
48371969|NCT00706901|BEHAVIORAL|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
48702957|NCT06605781|BEHAVIORAL|AR/VR technology-based training|Students will receive AR/VR Technology and OSCE in a Virtual Clinical Environment to learn how to assess and manage patients with auditory hallucination. The course was designed as a diverse and interactive learning experience, integrating a virtual clinical environment for auditory hallucinations with the application of Objective Structured Clinical Examination (OSCE). The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum. Additionally, students will have access to the AR/VR materials for self-practice during the practicum.
48014741|NCT02548013|OTHER|outpatient management|patients if stable will be discharged to continue treatment at home
48014742|NCT02548013|OTHER|Inpatient management|patients will continue there treatment in hospital till delivery
48516324|NCT03608397|BIOLOGICAL|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
48516325|NCT00641446|DRUG|budesonide|
48516326|NCT00641446|DRUG|varicella zoster virus|
48516327|NCT05050084|DRUG|Bicalutamide|Anti-androgen
48516328|NCT05050084|DRUG|Buserelin|GnRH agonist
48516329|NCT05050084|DRUG|Darolutamide|Anti-androgen
48516330|NCT05050084|DRUG|Degarelix|GnRH antagonist
48516331|NCT05050084|DRUG|Flutamide|Anti-androgen
48516332|NCT05050084|DRUG|Goserelin|GnRH agonist
48702958|NCT06605781|BEHAVIORAL|traditional vedio and discussion group|Students will receive a traditional course on auditory hallucination assessment, which includes watching educational videos and participating in a general discussion group on auditory hallucinations. The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the traditional course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum.
48702959|NCT01384630|DRUG|RA-18C3|200 mg subcutaneous injection
48702960|NCT06099418|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
48702961|NCT06099418|DRUG|Atezolizumab Injection [Tecentriq]|Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
48702962|NCT06099418|DRUG|Placebo|Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
48702963|NCT01973387|DRUG|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
48371970|NCT00887822|DRUG|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
48516333|NCT05050084|DRUG|Histrelin|GnRH agonist
48702964|NCT01973387|DRUG|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
48014743|NCT06526884|OTHER|Next Day Clinic|A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
48371971|NCT00887822|DRUG|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
48371972|NCT00887822|DRUG|Capecitabine|1000 mg/m\^2 orally twice daily on Days 1-14 of every 3-week cycle
48371973|NCT00887822|DRUG|Cisplatin|80 mg/m\^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
48371974|NCT01247467|OTHER|Breast Tumor Blocks|
48702965|NCT05476237|BEHAVIORAL|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
48371975|NCT01636596|DRUG|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
48371976|NCT02643992|OTHER|DOAC concentration measurement|
48516334|NCT05050084|DRUG|Leuprolide|GnRH agonist
48371977|NCT05751421|DRUG|Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution|zynrelef will be administered during surgery
48371978|NCT05751421|DRUG|Bupivacaine HCl 0.5% Injectable Solution|adductor canal block will be performed using bupivacaine before surgery
48516335|NCT05050084|RADIATION|Radiation Therapy|Undergo RT
48702966|NCT05476237|BEHAVIORAL|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
48702967|NCT00396136|DEVICE|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
48702968|NCT03945721|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
48702969|NCT03945721|RADIATION|Radiation Therapy|radiation therapy
48702970|NCT04274049|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
48702971|NCT04274049|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
48702972|NCT01983605|DEVICE|LARIAT Suture Delivery Device|LAA exclusion procedure
48702973|NCT02513407|BEHAVIORAL|Behavioral Dietary Intervention|Attend healthy nutritional education session
48702974|NCT02513407|OTHER|Educational Intervention|Attend EML educational session
48702975|NCT02513407|BEHAVIORAL|Exercise Intervention|Attend exercise educational session
48702976|NCT02513407|BEHAVIORAL|Exercise Intervention|Receive fitness tracker
48702977|NCT02513407|OTHER|Laboratory Biomarker Analysis|Correlative studies
48371979|NCT05751421|PROCEDURE|primary total knee replacement|primary total knee replacement
48371980|NCT01884675|DRUG|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
48702978|NCT02513407|OTHER|Questionnaire Administration|Ancillary studies
48702979|NCT03550170|BEHAVIORAL|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
48371981|NCT01884675|DRUG|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
48371982|NCT04910204|OTHER|FES Therapy combined with task-specific training (FEST+TST)|The FEST+TST protocol consists of a 1-hour session, 3 to 5 days a week, for up to 12 weeks (40 sessions total) in addition to conventional occupational and physical therapies according to the standard of care.
48516336|NCT05050084|DRUG|Relugolix|GnRH antagonist
48516337|NCT05050084|DRUG|Triptorelin|GnRH agonist
48516338|NCT00743717|DEVICE|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
48516339|NCT00743717|DEVICE|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
48522994|NCT05851027|DRUG|QL0911|Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
48702980|NCT03550170|BEHAVIORAL|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
48516340|NCT01513278|DRUG|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
48522995|NCT04700137|OTHER|Caring Contacts Plus Introductory Phone Call (CC+)|One introductory semi-structured caring phone conversation with a follow-up specialist to check-in, establish a personal connection, and provide resources at the 0-2 week time-point followed by 11 non-demanding, caring text or email messages sent over the course of 6 months.
48702981|NCT03550170|BEHAVIORAL|1-to-1, in-person or videoconference|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
48702982|NCT01320319|OTHER|Placebo|Capsule form, 960 mg to be taken three times a day.
48702983|NCT01320319|DIETARY_SUPPLEMENT|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
48702984|NCT05122260|DRUG|Q-Griffithsin|intranasal spray administered as a single dose
48702985|NCT05122260|OTHER|Placebo|intranasal spray administered as a single dose
48702986|NCT04378465|OTHER|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
48702987|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + deep sea water|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water
48702988|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + Placebo|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
48702989|NCT06600243|DIETARY_SUPPLEMENT|Control + deep sea water|A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water
48702990|NCT06600243|DIETARY_SUPPLEMENT|Control + Placebo|A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
48702991|NCT06060132|DRUG|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
48702992|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
48702993|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
48702994|NCT01129089|DIETARY_SUPPLEMENT|Micronutrient powder|Micronutrient powder for infant and young children
48702995|NCT06585904|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
48702996|NCT06585904|OTHER|Exercise|The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
48702997|NCT01975662|DRUG|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
48702998|NCT01975662|DRUG|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
48702999|NCT05538806|DEVICE|TTFields|all patients will receive routine clinical care and TTFields
48703000|NCT04703608|DRUG|Ivermectin|Ivermectin 0.3-0.4mg/Kg daily for 3 days.
48703001|NCT04703608|DRUG|ASP|Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
48703002|NCT04703608|DRUG|Placebo|Non-identical placebo
48703003|NCT06599554|OTHER|follow up scores|"The radiological reports will be read, analyzing when the bony consolidation of the fracture is reported in relation to the time elapsed since the operation.~The questionnaires will be submitted to all patients who have completed the course at 1 year.~All patients who sign the informed consent will be asked to complete the questionnaires either at the time of the follow-up visit by common clinical practice or by telephone, in the event that the patients have exceeded the 1-year follow-up"
48703004|NCT05487040|DRUG|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
48703005|NCT02944864|DRUG|TQ-B3395|TQ-B3395 p.o. qd
48703006|NCT02924194|DEVICE|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
48171205|NCT05844865|OTHER|Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)|Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
48371983|NCT06377670|PROCEDURE|Wassel IV Thumb Duplication Surgery|This intervention involves the surgical correction of Wassel IV thumb duplication, which is a congenital hand anomaly. The study retrospectively evaluates the outcomes of various surgical techniques that have been employed to correct this condition, with a focus on functionality and aesthetics of the thumb post-surgery. Data collected post-intervention include preoperative metacarpophalangeal angle, type of skin flap, surgical reconstruction technique, immobilization method, and postoperative complications. Additionally, patient satisfaction and daily pain levels are assessed using standardized questionnaires. Each patient serves as their own control, with outcomes compared to their contralateral healthy thumb.
48703007|NCT02924194|DEVICE|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
48371984|NCT05276726|DRUG|JAB 21822|Administered orally
48014744|NCT01792999|DEVICE|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
48014745|NCT04903691|BEHAVIORAL|Cardiac Exercise Program|Participants who enrolled in cardiac exercise program
48371985|NCT05609838|OTHER|Hot water foot bath|A 15 minutes hot water foot bath was applied to the experimental group patients 3 hours after the cesarean section.
48371986|NCT02790476|OTHER|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
48014746|NCT03285321|DRUG|Nivolumab|480mg
48371987|NCT02929017|OTHER|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
48371988|NCT02929017|OTHER|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
48371989|NCT02331459|OTHER|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
48703008|NCT00050531|DRUG|Gleevec|400 mg orally twice daily.
48703009|NCT00050531|DRUG|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
48703010|NCT00050531|DRUG|Sargramostim (GM-CSF)|125 mcg/m\^2 three times per week subcutaneously.
48703011|NCT02436707|DRUG|Ibrutinib|
48703012|NCT02436707|DRUG|Rituximab|
48014747|NCT03285321|DRUG|Nivolumab|240mg
48014748|NCT03285321|DRUG|Ipilimumab|1mg/kg
48014749|NCT02036034|DEVICE|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
48171206|NCT00159549|BEHAVIORAL|education and training program|
48171207|NCT01562587|DRUG|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
48171208|NCT01562587|DRUG|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
48703013|NCT02436707|DRUG|Gemcitabine|
48703014|NCT02436707|DRUG|Dexamethasone|
48703015|NCT02436707|DRUG|Cisplatin|
48703016|NCT02436707|DRUG|Mesna|
48703017|NCT02436707|DRUG|Cyclophosphamide|
48703018|NCT02436707|DRUG|Etoposide|
48703019|NCT02436707|DRUG|G-CSF|
48703020|NCT02436707|DRUG|Selinexor|
48703021|NCT01235923|DRUG|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
48703022|NCT01235923|DRUG|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
48703023|NCT00733161|OTHER|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
48703024|NCT00733161|OTHER|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
48703025|NCT04924530|DIETARY_SUPPLEMENT|Maltodextrin|Co-ingestion of maltodextrin with a high fat meal
48703026|NCT04924530|DIETARY_SUPPLEMENT|Sucrose|Co-ingestion of sucrose with a high fat meal
48703027|NCT04924530|DIETARY_SUPPLEMENT|Lactose|Co-ingestion of lactose with a high fat meal
48703028|NCT03117374|BEHAVIORAL|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
48014750|NCT02036034|DEVICE|warming blanket|warming blanket placed on torso of patient under the drape.
48171209|NCT04938739|OTHER|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
48171210|NCT04938739|OTHER|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
48171211|NCT01436968|BIOLOGICAL|Aglatimagene besadenovec + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
48522996|NCT04700137|OTHER|Caring Contacts without an introductory phone call (CC)|Eleven non-demanding, caring text or email messages sent over the course of 6 months. Participants will not know or have spoken to the follow-up specialist who sends the caring messages.
48703029|NCT02154620|PROCEDURE|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
48703030|NCT02154620|DEVICE|Synthes TCP volar plate|
48703031|NCT04270942|BIOLOGICAL|teplizumab|anti-CD3 humanized monoclonal antibody
48703032|NCT06110897|BEHAVIORAL|High Dose Resistance Exercise Training|Progressive resistance exercise training
48703033|NCT06110897|BEHAVIORAL|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
48703034|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Exercise and Nutrition|During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.
48703035|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Nutrition Only|During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.
48703036|NCT03806556|DRUG|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
48703037|NCT03806556|DRUG|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
48014751|NCT02212730|DRUG|Pembrolizumab Pre-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
48014752|NCT02212730|PROCEDURE|Surgical Resection|Standard of care surgical resection of RCC tumor
48014753|NCT02212730|DRUG|Pembrolizumab Post-Resection|200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
48014754|NCT01323569|DRUG|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
48014755|NCT01323569|DRUG|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
48014756|NCT01323569|DRUG|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
48703038|NCT03497546|OTHER|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
48703039|NCT00813605|OTHER|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
48703040|NCT00813605|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
48703041|NCT00813605|OTHER|Placebo|Inactive dummy agent (to maintain blind)
48703042|NCT00813605|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
48703043|NCT06277986|OTHER|cachexia|Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
48703044|NCT00874640|BIOLOGICAL|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
48703045|NCT03569176|DEVICE|Autism Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
48014757|NCT01323569|DRUG|Placebo|16 placebo sprays and 4 placebo capsules
48014758|NCT01323569|DRUG|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
48014759|NCT01323569|DRUG|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
48171212|NCT01436968|BIOLOGICAL|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
48014760|NCT03052582|OTHER|Milk type|
48014761|NCT05559619|DRUG|Calcium carbonate|1000 mg of natural calcium carbonate once daily for 12 weeks
48014762|NCT05559619|DRUG|Vitamin D3|1000 IU vitamin D3 once daily for 12 weeks
48371990|NCT02331459|OTHER|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
48371991|NCT03993314|DRUG|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
48371992|NCT03993314|DRUG|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
48703046|NCT02684812|DRUG|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
48014763|NCT05559619|DEVICE|laser acupuncture therapy|The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
48014764|NCT04612322|DEVICE|Assessment of microvascular function with intracoronary hemodilution|The pressure/temperature wire allows assessing coronary flow reserve, intracoronary pressure, and coronary flow to calculate multiple parameters of coronary macro- and microvascular function.
48014765|NCT05544968|DRUG|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)|anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
48014766|NCT03778970|OTHER|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
48014767|NCT03778970|OTHER|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
48014768|NCT03778970|OTHER|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
48014769|NCT05721417|PROCEDURE|Tricuspid valve surgery|Surgical treatment of tricuspid regurgitation, that may be performed by repair or replacement
48371993|NCT05664438|DIAGNOSTIC_TEST|MRI scan|MRI scan of cervical spine
48371994|NCT04008459|OTHER|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
48703047|NCT00907803|DRUG|ST-246 400 mg|Capsules, 400 mg daily for 14 days
48703048|NCT00907803|DRUG|ST-246 600 mg|Capsules, 600 mg daily for 14 days
48703049|NCT00907803|DRUG|Placebo|Capsules, once daily for 14 days
48703050|NCT03643315|BEHAVIORAL|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
48703051|NCT03643315|BEHAVIORAL|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
48703052|NCT02968160|DRUG|Telmisartan 40mg + Rosuvastatin 20mg|
48703053|NCT02968160|DRUG|Telmisartan 80mg + Rosuvastatin 20mg|
48703054|NCT02968160|DRUG|Telmisartan 40mg, 80 mg|
48703055|NCT02968160|DRUG|Rosuvastatin 20mg|
48014770|NCT06086535|PROCEDURE|Intercostal nerve cryoanalgesia vs BRILMA blockade|For BRILMA block, 0.4 ml/kg of 0.3% ropivacaine will be injected and a catheter will be placed on the 4th intercostal space after surgery. For intercostal nerve cryoanalgesia an external cryogenizer system will be used during surgery
48014771|NCT06663644|OTHER|Muscle energy technique on iliotibial band|Post isometric relaxation involves the peripheral and central modulating mechanism by activating the muscles and joint mechanoreceptors. It can be effective for a variety of purposes including lengthening a shortened muscles, as a lymphatic or venous pump to aid the drainage of fluid or blood and increasing the range of motion. MET is a manual therapy intervention that can be used to stretch or lengthen muscles and fascia that lack flexibility.
48014772|NCT06663644|OTHER|Hamstring and abdominal muscle activation|The 90/90 exercises for abdominal and hamstring activation rotate the pelvis posteriorly in the sagittal and transverse plane, into a more neutral position. Hamstrings extend the hip, and therefore reciprocally inhibit hip flexors. Hamstrings and abdominals also aid in inhibiting paraspinal muscles via a posterior pelvic tilt / hip extension, a decrease in lumbar extension, and an increase in lumbar flexion.
48014773|NCT00151359|DEVICE|SoleSensor|
48014774|NCT06333626|DIETARY_SUPPLEMENT|multi-vitamin carbohydrate|oral multi-vitamin carbohydrate beverage
48014775|NCT06663527|COMBINATION_PRODUCT|Fumigating-washing Therapy With CPD|All patients underwent anal fistulectomy based on the Parks classification. For postoperative infection prophylaxis, cefuroxime was used at a dosage of 2g per dose, twice daily. Commencing the day following surgery, a fumigating-washing therapy was conducted once daily either after defecation or two hours prior to intravenous infusion. In the study group, a medical solution used for fumigating-washing therapy was prepared by blending 200 ml of CPD with 2 liters of water at 40 °C. This medicinal solution was then transferred into the reservoir of an ultrasonic atomizing fumigating-washing device (Model:TM50-C, Xuzhou Tianma Medical Equipment Factory, China) that was classified by the FDA as Class II (special controls).
48014776|NCT06663527|COMBINATION_PRODUCT|fumigating-washing therapy with a placebo|fumigating-washing therapy with a placebo
48014777|NCT00554749|BEHAVIORAL|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
48014778|NCT00739336|BEHAVIORAL|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
48371995|NCT00913874|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
48371996|NCT00913874|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
48371997|NCT00158002|DRUG|Topiramate|
48371998|NCT06479850|BEHAVIORAL|KF-STRIDE®|Treatment group will receive 12 web based sessions of a strength-based training tool (once or twice a week). Sessions are approximately 60 minutes long.
48371999|NCT04430387|DEVICE|The saliva ejector|A thin suction tube that draws water, saliva, blood, and debris from the mouth to provide patient comfort, preventing patient from constantly having to sit up and spit while maintain a clear operative field. It is connected through the low-volume suction hose in the dental chair. It can be held by the dental assistant, the dental provider or by the patient. In practice, it can be also contoured and hang by the cheek of the patient due to its light weight.
48372000|NCT04430387|DEVICE|The high-volume evacuator|The high-velocity air evacuation device. It is connected through the high-volume suction hose in the dental chair. It is operated by a dental assistant during the dental treatment, owing to the challenge posed by the rigid disposable attachment and bulky high-volume suction hose.
48372001|NCT04430387|DEVICE|The DryShield|The device is attached to the high-volume suction hose to provide continuous suction of intraoral fluid and debris, and also simultaneous isolation to both maxillary and mandibular quadrants on the same side. Other advantages of these devices include retracting the tongue and cheek, and prevention of aspiration.
48372002|NCT00206752|RADIATION|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
48372003|NCT00206752|RADIATION|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
48703056|NCT03457142|BIOLOGICAL|Abatacept|Given IV and SC
48703057|NCT03457142|DRUG|Dexamethasone|Given PO
48703058|NCT03457142|DRUG|Ixazomib Citrate|Given PO
48703059|NCT03457142|OTHER|Laboratory Biomarker Analysis|Correlative studies
48703060|NCT04240457|COMBINATION_PRODUCT|Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
48372004|NCT02190162|DRUG|Tantum Verde® mouthwash|
48372005|NCT02190162|OTHER|Placebo mouthwash|Mouthwash with placebo solution
48372006|NCT00519090|DRUG|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
48372007|NCT00519090|DRUG|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
48372008|NCT00863564|DIETARY_SUPPLEMENT|Caseine|
48372009|NCT00863564|DIETARY_SUPPLEMENT|Cod|
48372010|NCT00863564|DIETARY_SUPPLEMENT|Gluten|
48372011|NCT00863564|DIETARY_SUPPLEMENT|Whey Isolate|
48372012|NCT05587933|PROCEDURE|cholecystectomy|cholecystectomy
48372013|NCT05587933|DRUG|Antispasmodic|Antispasmodic
48703061|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
48703062|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
48703063|NCT04323137|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
48703064|NCT04323137|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
48703065|NCT04323137|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
48703066|NCT05482620|PROCEDURE|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
48703067|NCT05482620|PROCEDURE|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
48703068|NCT05519436|OTHER|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
48703069|NCT02472418|DRUG|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
48703070|NCT02472418|DRUG|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
48171213|NCT06213064|BEHAVIORAL|Study Product, THC Product, Placebo|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
48171214|NCT03233347|DRUG|Brentuximab Vedotin|Given IV
48171215|NCT03233347|DRUG|Dacarbazine|Given IV
48171216|NCT03233347|DRUG|Doxorubicin|Given IV
48171217|NCT03233347|OTHER|Laboratory Biomarker Analysis|Correlative studies
48703071|NCT02472418|OTHER|Placebo (treatment C)|Placebo administered
48703072|NCT01598558|DRUG|Cu-64 Rituximab|Up to 14 mCi, iv
48703073|NCT03360890|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
48703074|NCT03360890|DRUG|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
48703075|NCT02439450|BIOLOGICAL|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
48703076|NCT02439450|DRUG|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
48703077|NCT02439450|DRUG|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
48171218|NCT03233347|BIOLOGICAL|Nivolumab|Given IV
48171219|NCT03233347|DRUG|Vinblastine|Given IV
48171220|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part one|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.
48703078|NCT02439450|DRUG|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
48703079|NCT06283823|DEVICE|Thermoformed orthodontic retainer|compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers
48703080|NCT03638531|DEVICE|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
48372014|NCT05126966|DRUG|Ranibizumab|Ranibizumab will be administered at a dose of 100 mg/mL delivered via the PDS.
48372015|NCT05126966|DRUG|Aflibercept|Aflibercept will be administered at a dose of 2 mg in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment
48014779|NCT02290587|OTHER|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~* Questionnaire for depression and anxiety~* Evaluation of executive functions~* Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~* morphological MRI~* functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
48014780|NCT02290587|DEVICE|MRI|
48014781|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
48014782|NCT00559962|DRUG|placebo|3 capsules each evening for each 4-week period
48014783|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
48372016|NCT05126966|DEVICE|Port Delivery System with ranibizumab (PDS)|PDS is an investigation intraocular drug delivery device designed to continuously deliver anti-VEGF therapy.
48372017|NCT01021423|DRUG|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
48014784|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
48014785|NCT00559962|DRUG|AEGR-733|3 capsules each evening for each 4-week period
48372018|NCT01021423|OTHER|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
48014786|NCT00559962|DRUG|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
48014787|NCT00559962|DRUG|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
48014788|NCT00559962|DRUG|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
48014789|NCT06083753|DRUG|PIPE-307 Dose A|Subjects will receive daily oral doses of PIPE-307
48014790|NCT06083753|DRUG|PIPE-307 Dose B|Subjects will receive daily oral doses of PIPE-307
48014791|NCT06083753|DRUG|Placebo|Subjects will receive daily oral matching dose of Placebo
48014792|NCT01491321|PROCEDURE|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
48014793|NCT01491321|DRUG|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
48014794|NCT01491321|PROCEDURE|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week"
48014795|NCT01879397|DEVICE|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~* ARFI based images of the carotid artery and plaque~* Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
48014796|NCT04440293|OTHER|BBAT|The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
48372019|NCT02074657|BIOLOGICAL|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
48372020|NCT01425268|DEVICE|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
48703081|NCT03638531|DEVICE|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
48703082|NCT00092703|DRUG|MK0663, etoricoxib|
48171221|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part two|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.
48703083|NCT00092703|DRUG|Comparator: Diclofenac sodium|
48703084|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
48703085|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
48171222|NCT04650659|DIAGNOSTIC_TEST|1-minute sit-to-stand test|Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.
48171223|NCT04650659|DIAGNOSTIC_TEST|4-meters gait speed test|Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.
48372021|NCT01425268|PROCEDURE|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
48372022|NCT02496715|DRUG|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
48372023|NCT02496715|DRUG|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
48171224|NCT04650659|DIAGNOSTIC_TEST|Nailfold videocapillaroscopy|"Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands."
48171225|NCT04650659|DIAGNOSTIC_TEST|HR-pQCT|Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.
48171226|NCT04650659|DIAGNOSTIC_TEST|Hand x-ray|Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).
48372024|NCT02496715|DRUG|Placebo|Placebo inhaler
48703086|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
48703087|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
48703088|NCT01872195|OTHER|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
48703089|NCT00584090|DRUG|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
48171227|NCT04650659|DIAGNOSTIC_TEST|DEXA|Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
48171228|NCT02709447|BEHAVIORAL|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
48171229|NCT02709447|BEHAVIORAL|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
48171230|NCT04868253|DRUG|EMB-01|EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
48372025|NCT02083406|DRUG|800mg OZ439 prototype formulation 1|
48372026|NCT02083406|DRUG|800mg OZ439 prototype formulation 2|
48703090|NCT00584090|DRUG|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
48372027|NCT02083406|DRUG|800mg OZ439 prototype formulation 3|
48372028|NCT02083406|DRUG|960mg PQP|
48372029|NCT06163768|PROCEDURE|Insulin resistance|Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
48372030|NCT02713490|DRUG|EXPAREL|EXPAREL and bupivacaine HCl
48372031|NCT02713490|DRUG|Bupivacaine|Single dose of bupivacaine HCl 0.5%
48372032|NCT04590482|DRUG|letrozole|Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
48372033|NCT04590482|DRUG|placebo|placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
48372034|NCT00004173|DRUG|oxaliplatin|
48372035|NCT00004173|DRUG|paclitaxel|
48372036|NCT02433704|DEVICE|New Intraosseous|Intraosseous administration of prophylactic antibiotics
48372037|NCT02433704|DRUG|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
48703091|NCT03103204|COMBINATION_PRODUCT|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
48372038|NCT01678287|DRUG|ASP1941|oral
48014797|NCT04440293|OTHER|CT|The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
48703092|NCT01648296|DRUG|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
48703093|NCT05137171|DRUG|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
48014798|NCT04154280|DIAGNOSTIC_TEST|PET/MR scan|"* The PET will be performed with 68Ga-PSMA tracer.~* The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~* Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
48014799|NCT05232448|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy focuses on challenging and changing cognitive distortions and behaviors, improving emotional regulation and the development of personal coping strategies that target solving current problems.
48014800|NCT02827292|OTHER|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
48014801|NCT02827292|OTHER|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
48372039|NCT01678287|DRUG|Placebo|oral
48372040|NCT00752895|DIETARY_SUPPLEMENT|American ginseng|Given orally
48014802|NCT02827292|PROCEDURE|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
48014803|NCT05351008|OTHER|Cognitive Functional Therapy|A physicaltheapy approach combining cognitive techniques, func-tional movement training, functional integration and Lifestyle Changes.
48014804|NCT05351008|OTHER|Exercise program:|Core strengthening program
48014805|NCT06094348|PROCEDURE|Endonasal osteotomy|Patients will undergo median-oblique and lateral osteotomy, with conventional 2 mm guarded, straight osteotome.
48372041|NCT00752895|DIETARY_SUPPLEMENT|Placebo|Given orally
48372042|NCT01614028|PROCEDURE|Total Hip Arthoplasty|
48372043|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented with a synthetic polyester patch (Pitch-Patch Tissue Reinforcement Device))|The Pitch-Patch is a single-use device intended to reinforce the rotator cuff following or during repair by sutures or suture anchors where weakness exists in the soft tissue.
48372044|NCT06076902|DEVICE|Arthroscopic rotator cuff reconstruction using fixation with anchors augmented without a synthetic polyester patch|Arthroscopic rotator cuff reconstruction using fixation with anchors and no augmentation with a synthetic polyester patch.
48372045|NCT02512120|DEVICE|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
48372046|NCT02512120|DEVICE|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
48372047|NCT05144269|OTHER|Multimodal exercises|Telehabilitation including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises
48516341|NCT01513278|DRUG|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
48516342|NCT01426074|DRUG|Bevacizumab 5 mg/kg|Intravenously every two weeks
48703094|NCT06607224|DEVICE|Experimental (Decision making guided by CGM)|Patients use FSL2 and a smartphone. Libreview app will be used to assess interstitial glucose, alarms, and trend arrows, and LibreLinkUp app for research team. Concurrently, CG will be performed using the FreeStyle Optium Neo glucometer from Abbott. The nursing staff will be trained to manage and respond to alarms and trend arrows according to established protocols. The basal insulin adjustment protocol establishes with fasting and premeal targets between 140-180 mg/dL. For prandial insulin, corrective guidelines set according to each patient sensitivity factor, with additional adjustments for the intervention group based on trend arrows. The hypoglycemia alarm sets below 85 mg/dL. If activated, nursing staff will confirm the value via CG. If values are below 70 mg/dL, follow hypoglycemia protocol and if below 100 mg/dL with a descending trend arrow, 15 grams of slow-acting carbs. The hyperglycemia alarm will be set above 300 mg/dL and nurse inform investigators to make decisions.
48703095|NCT06264817|DEVICE|MOBIDERM Autofit Armsleeve|"In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks"
48703096|NCT06264817|DEVICE|Compressive bandaging|"In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks"
48516343|NCT04905628|DEVICE|Dexcom CGM System|Dexcom CGM System
48703097|NCT01338480|OTHER|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
48703098|NCT05460273|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
48703099|NCT02937077|DEVICE|Medtronic Reveal LINQ|
48703100|NCT06603402|RADIATION|low-dose involved-field radiotherapy combined with immunochemotherapy|low-dose involved-field radiotherapy combined with immunochemotherapy
48703101|NCT01180894|DRUG|Iron sucrose|100 mg IV TIW
48703102|NCT01180894|DRUG|Placebo|
48703103|NCT06606249|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus is a novel, brief, low-intensity intervention, recently developed by the World Health Organization (WHO) and intended to help people with and without mental disorders cope with distress stemming from diverse types of adversity.The key components of the program are based on acceptance and commitment therapy (ACT), a distinct form of cognitive-behavioural therapy. SH+ draws on ACT techniques of coping with stress, compassion and acceptance toward oneself and others, and living following one's values.~An online version called Doing what matters in times of stress is available as an illustrated guide and pre-recorded audio."
48014806|NCT06094348|DEVICE|Piezo assisted osteotomy|Piezo is a system for cutting bone with micrometric ultrasonic piezoelectric vibrations, with varying frequency and cutting energy. The device consists of a platform with a powerful piezoelectric hand piece and employs a functional frequency between 25-29 kHz. The device is fitted with a cooling irrigation system with a 0-60 cc/min variable sterile solution flow. Specific inserts and scalpels act in a linear vibration pattern, with a spatial range between 60 and 210 microns, moved by an ultrasonic power that exceeds 5 watts, reaching up to 16 watts.
48014807|NCT02155595|OTHER|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
48171231|NCT05065697|OTHER|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
48171232|NCT02956278|DRUG|Allopurinol|
48171233|NCT02956278|OTHER|Placebo|lactose placebo pill
48171234|NCT01839383|OTHER|different dialysate calcium concentration|
48171235|NCT05566028|DRUG|D745 formulation I|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
48171236|NCT05566028|DRUG|D745 formulation II|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
48171237|NCT05566028|DRUG|D745 Placebo|QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
48171238|NCT06024135|DEVICE|NeoKidney|Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.
48014808|NCT02155595|OTHER|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
48014809|NCT03231904|DIAGNOSTIC_TEST|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
48014810|NCT00941733|DEVICE|IN.PACT Amphirion|Balloon Angioplasty
48014811|NCT00941733|DEVICE|Standard PTA|Balloon Angioplasty
48171239|NCT01163955|OTHER|Time to fatigue|5 minutes while playing video games
48171240|NCT06468267|DRUG|Thiotepa|The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
48171241|NCT02153190|DEVICE|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
48171242|NCT02153190|DEVICE|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
48171243|NCT05513950|BIOLOGICAL|CHF10067 starting dose|Intravenous administration of a starting dose of the monoclonal antibody
48171244|NCT05513950|BIOLOGICAL|CHF10067 intermediate dose|Intravenous administration of an intermediate dose of the monoclonal antibody
48171245|NCT05513950|BIOLOGICAL|CHF10067 high dose|Intravenous administration of a high dose of the monoclonal antibody
48171246|NCT05513950|DRUG|Placebo|Intravenous administration of a physiological solution as placebo.
48014812|NCT01150838|DRUG|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
48171247|NCT03371121|OTHER|AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)|to fill arthroscopically osteochondral talar lesion
48516344|NCT05036512|DRUG|GBT021601|Administered orally with water as a single dose in the morning.
48703104|NCT06606249|BEHAVIORAL|Psychological First Aid (PFA)|Psychological First Aid (PFA) is also developed by the WHO and is a general supportive intervention, aimed at listening and understanding the needs and concerns of people, providing support without pressuring them to talk.
48703105|NCT04138914|DEVICE|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
48703106|NCT00202709|BEHAVIORAL|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
48703107|NCT05640479|DRUG|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
48703108|NCT05640479|DRUG|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
48703109|NCT04720040|DEVICE|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
48703110|NCT06474507|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
48703111|NCT01751906|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
48703112|NCT01751906|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
48703113|NCT02185014|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
48372048|NCT04021602|BEHAVIORAL|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
48372049|NCT04021602|BEHAVIORAL|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
48372050|NCT04021602|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
48516345|NCT04795947|BEHAVIORAL|Behavioral|There is no intervention in this study
48703114|NCT04260763|BEHAVIORAL|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
48703115|NCT04260763|DEVICE|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
48703116|NCT01888536|DRUG|Limaprost|
48703117|NCT01888536|DRUG|Pregabalin|
48703118|NCT01888536|DRUG|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
48703119|NCT01888536|DRUG|Placebo(for Limaprost)|mimic Limaprost tablet
48703120|NCT00737711|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
48703121|NCT03582865|DRUG|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
48703122|NCT03326557|PROCEDURE|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
48703123|NCT00519376|DRUG|GW642444M|drug
48703124|NCT00519376|DRUG|GW642444H|drug
48703125|NCT00519376|DRUG|placebo|
48703126|NCT02959541|DRUG|Leucovorin|
48703127|NCT03824158|BEHAVIORAL|Facilitated advance care planning (in-person or telephonic)|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic, or telephonically. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
48372051|NCT04526262|DEVICE|transcranial magnetic resonance guided focused ultrasound BBB disruption|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.0 system, and this will be performed twice every 3 months.
48372052|NCT03950531|OTHER|No intervention|
48372053|NCT06045468|OTHER|Amputation-specialized rehabilitation|Study center; amputation-specialized unit within rehabilitation facility; fully practicing national guidelines
48516346|NCT02369198|DRUG|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
48516347|NCT04401215|BEHAVIORAL|Technology Augmented Treatment for Screening, Brief Intervention, Referral, and Treatment (SBIRT)|This group will answer to questions on the iPad at baseline visit and will receive up to 4 text messages per day asking about their Health and treatment during 30 days.
48516348|NCT03831204|DEVICE|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
48516349|NCT03831204|DIAGNOSTIC_TEST|prognostic scores|Effect and GWTGHF were calculated for every patient
48014813|NCT04292158|DEVICE|SomnoTouch|"The patient will be equipped with the SomnoTouch device. This device is able to record and estimate the following data:~ECG data PPG data Heart rate Respiration rate Blood pressure (mmHg) Oxygen saturation (%).~All patient will be stored for further analysis."
48372054|NCT06045468|OTHER|Non-amputation-specialized rehabilitation|Control clinics; treating some amputated patients each year but do not practice national guidelines or partially practicing national guidelines
48372055|NCT03781167|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
48171248|NCT06190184|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
48171249|NCT06190184|OTHER|Control arm|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
48014814|NCT04292158|DEVICE|MOX|"The patient will be equipped with the MOX device. This device is able to record and estimate the following data:~Accelerometers data Activity Body posture~All patient will be stored for further analysis."
48014815|NCT01886794|DRUG|Postmenopausal, topical vaginal estrogen cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
48014816|NCT01886794|DRUG|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
48014817|NCT03643523|DIAGNOSTIC_TEST|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
48014818|NCT03146650|BIOLOGICAL|Ipilimumab|Given IV
48014819|NCT03146650|OTHER|Laboratory Biomarker Analysis|Correlative studies
48014820|NCT03146650|BIOLOGICAL|Nivolumab|Given IV
48171250|NCT01257412|DRUG|Dapagliflozin|5mg Oral dose od
48171251|NCT01257412|DRUG|Dapagliflozin|10 mg Oral dose od
48516350|NCT04196881|OTHER|Knowledge Improvement Program about ADHD|This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
48703128|NCT03824158|BEHAVIORAL|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
48014821|NCT06015698|PROCEDURE|Laparoscopic tubal disconnection|"1. The tube is grasped in the isthmic portion of the tube at least 2cm from the cornua. Bipolar coagulation will provide a more localized area of tubal burn so requiring at least 3cm of the tube to be coagulated~2. The electrosurgical generator should set to deliver a power of 25W in nonmodulated mode to desiccate tissue sufficiently~3. The tube should be coagulated with 2 to 3 contiguous burns to provide an area of about 3cm of coagulation. Th endpoint of coagulation is cessation of the current flow~4. Then, the tube is severed in the middle of the burn area with laparoscopic scissors~5. Ensure adequate hemostasis"
48014822|NCT06015698|PROCEDURE|Laparoscopic salpingectomy|"1. The tube will be removed from its anatomical attachements by progressive bipolar coagulation~2. Progressive coagulation and cutting of the mesosalpinx begins at the proximal isthmus of the tube and progresses to the fimbriated end using bipolar coagulation and laparoscopic scissors~3. Removal of the tube through one of the ancillary ports using artery forceps~4. Ensure adequate hemostasis"
48014823|NCT06081218|OTHER|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
48014824|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
48171252|NCT01257412|DRUG|placebo|5/10 mg Oral dose od
48171253|NCT00197119|BIOLOGICAL|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
48171254|NCT00197119|BIOLOGICAL|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
48171255|NCT02292485|BEHAVIORAL|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
48703129|NCT02260778|BEHAVIORAL|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
48703130|NCT01328834|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
48703131|NCT02797665|DRUG|corticosteroids|prednisone 0.6mg/kg/d
48703132|NCT02797665|PROCEDURE|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
48703133|NCT00544453|DRUG|[123I] MNI-308|Injection of \[123I\] MNI-308 and SPECT scanning
48703134|NCT00837265|BIOLOGICAL|Balugrastim|Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
48703135|NCT00837265|DRUG|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
48703136|NCT00837265|DRUG|Chemotherapy Regimen|The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
48703137|NCT04251767|OTHER|washed microbiota transplantation|"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once."
48703138|NCT04251767|OTHER|placebo|"Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once."
48703139|NCT04161443|OTHER|physiotherapy|"* Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
48703140|NCT05049213|DRUG|Carrageenan nasal spray and 1% PVP- mouthwash and gargle|"Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time"
48703141|NCT00793429|DRUG|Prucalopride|
48703142|NCT00793429|OTHER|Placebo|
48703143|NCT03775343|DIAGNOSTIC_TEST|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
48703144|NCT03775343|DIAGNOSTIC_TEST|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
48372056|NCT04946916|DIAGNOSTIC_TEST|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
48703145|NCT02864186|DEVICE|control|Women wont use support bra 24 hours a days for six months
48703146|NCT02864186|DEVICE|surgical support bra|Women will use surgical support bra 24 hours a day for six months
48703147|NCT02864186|DEVICE|common support bra|Women will use common support bra 24 hours a day for six months
48171256|NCT04473053|DRUG|Nafamostat Mesilate|Nafamostat has been shown to have potential antiviral effects against MERS CoV and is thought to possibly inhibit SARS CoV2 infection via inhibition of viral entry due to inhibition of TMPRSS2. In addition, nafamostat has potent anticoagulant properties which may provide benefit in patients with DIC, a common finding in serious cases of COVID-19. Nafamostat has been broadly well tolerated in clinical trials in patients with DIC and acute pancreatitis.
48372057|NCT01013207|DEVICE|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
48372058|NCT01013207|DEVICE|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
48372059|NCT01013207|DEVICE|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
48372060|NCT04096924|DEVICE|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
48372061|NCT04096924|DEVICE|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
48703148|NCT02966964|DRUG|DWPUR001|
48703149|NCT02966964|DRUG|Placebo|
48703150|NCT06403306|DRUG|Ferric Sulfate (Viskostat; Ultradent, Utah, USA)|Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.
48703151|NCT06403306|DRUG|Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)|Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
48703152|NCT06403306|DEVICE|Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)|Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
48703153|NCT06457230|DEVICE|10Hz rTMS based on cerebellum and FPC|We compare the efficacy of paired-pulse stimulation relative to single-pulse stimulation. Subjects will be randomly assigned to a cerebellar + frontal pole paired-pulse experimental group.
48703154|NCT06457230|DEVICE|10Hz rTMS based on cerebellum or FPC|Subjects will be randomly assigned to a cerebellar or frontal pole randomised control group.
48703155|NCT04676841|DEVICE|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
48703156|NCT04676841|DEVICE|Conventional ventilation + standard instrumental tables|Control
48703157|NCT04676841|DEVICE|Laminar airflow ventilation + standard instrumental tables|Control
48703158|NCT04703816|OTHER|Interpersonal Skills Multifaceted Training Program for the physician-patient relationship|The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
48372062|NCT05459987|BEHAVIORAL|Lifestyle changes|"Nutritional advice to progressively integrate a moderate-carbohydrate Mediterranean diet with intermittent fasting 16:8 (5 times/week for 12 weeks).~Personalized exercise prescription and training (3 times per week)~Personalized education and motivational interviewing"
48372063|NCT02680158|DEVICE|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
48372064|NCT02680158|DEVICE|Sham|Sham device (control), intranasal application for approximately 3 minutes.
48372065|NCT02680158|DEVICE|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
48372066|NCT02778477|DRUG|PF-06423264|Multiple ascending dose of PF-06423264
48372067|NCT02778477|OTHER|Placebo|Multiple dose of placebo
48372068|NCT01710839|DRUG|0.5mg Ranibizumab|intravitreal injections
48372069|NCT01710839|PROCEDURE|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
48372070|NCT02123186|OTHER|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
48372071|NCT02839213|DRUG|Hyoscine Butyl bromide|
48372072|NCT02839213|DRUG|Saline|
48014825|NCT00718042|DEVICE|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
48014826|NCT03900533|BEHAVIORAL|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
48372073|NCT04605120|PROCEDURE|Cervical fusion|1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
48372074|NCT05598411|DRUG|Oral Glucocorticoids|methylprednisolone 24mg qd, 2-week duration
48372075|NCT05598411|DRUG|Oral placebo|oral placebo 24mg qd, 2-week duration
48372076|NCT03980665|DRUG|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
48372077|NCT02064491|DRUG|Erlotinib|
48372078|NCT02064491|DRUG|Chemotherapy|
48372079|NCT06152991|DRUG|GODEX|"The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg"
48372080|NCT06152991|DRUG|Placebo|"* Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg."
48372081|NCT02361307|PROCEDURE|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
48372082|NCT02361307|PROCEDURE|Conventional ADL training|The control group receive the conventional ADL training programme
48372083|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
48372084|NCT00598442|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
48171257|NCT04473053|DRUG|TD139|TD139 is a specific inhibitor of galectin-3 which has been investigated in healthy volunteers and patients with IPF. No serious drug related serious adverse events have been reported to date. TD139 had no impact on cardiac, haematological or biochemical measures of safety during trials in humans to date. Beneficial effects on biomarker measures of lung inflammation were observed in patients with IPF. It is the purpose of this investigation to examine the potential for delivery of this inhibitor in pre-ventilator patients hospitalised with COVID-19 to examine whether this may lead to detectable changes in blood biomarkers, reduce viral load and also reduce disease severity such as time to ventilation.
48171258|NCT04473053|OTHER|Standard care|Patients will receive standard care.
48171259|NCT04473053|BIOLOGICAL|Allogeneic SARS-CoV-2 VSTs|The allogeneic SARS-CoV-2 VSTs are manufactured in a single stage process directly from the starting material procured from suitable post COVID-19 recovered individuals. This is an early dose escalation safety trial phase Ib/IIa interventional clinical trial with SARS-CoV-2 VSTs.
48171260|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
48171261|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (monthly)|
48171262|NCT00471172|BEHAVIORAL|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
48171263|NCT00471172|BEHAVIORAL|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
48171264|NCT00471172|BEHAVIORAL|Self help|
48171265|NCT05725044|DIETARY_SUPPLEMENT|Ginsengberry concentrate|Ginsengberry concentrate
48171266|NCT05725044|DIETARY_SUPPLEMENT|Placebo|Placebo
48171267|NCT04525456|DIETARY_SUPPLEMENT|Reduxium|Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
48171268|NCT01904136|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
48171269|NCT01904136|PROCEDURE|Bone Marrow Transplantation|Undergo allogeneic PBSC or bone marrow transplant
48171270|NCT01904136|DRUG|Cyclophosphamide|Given IV
48171271|NCT01904136|DRUG|Fludarabine|Given IV
48171272|NCT01904136|OTHER|Laboratory Biomarker Analysis|Correlative studies
48372085|NCT00598442|DRUG|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
48372086|NCT04830358|BIOLOGICAL|EuPCV15|15-valent Pneumococcal conjugate vaccine
48372087|NCT04830358|BIOLOGICAL|Prevenar13|13-valent Pneumococcal conjugate vaccine
48516351|NCT05993416|DRUG|Nedosiran|In adults and in adolescents (aged 12-17 years) weighing greater than or equal to (\>=) 50 kilograms (kg), Nedosiran will be administered via subcutaneous (SC) injection once monthly at a dose of 170 milligrams (mg). In adults and adolescents weighing \< 50 kg, nedosiran will be administered once monthly at a dose of 136 mg. The dose for participants aged 6 to 11 years will be 3.5 mg/kg monthly, not to exceed 170 mg.
48516352|NCT05444894|GENETIC|EDIT-301|Administered by intravenous infusion after myeloablative conditioning with busulfan.
48516353|NCT00003198|DRUG|ifosfamide|
48516354|NCT00003198|DRUG|topotecan hydrochloride|
48014827|NCT03900533|BEHAVIORAL|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
48171273|NCT01904136|DRUG|Melphalan|Given IV
48171274|NCT01904136|DRUG|Mycophenolate Mofetil|Given PO
48171275|NCT01904136|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
48171276|NCT01904136|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
48171277|NCT01904136|DRUG|Tacrolimus|Given IV and PO
48372088|NCT00727246|DRUG|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
48372089|NCT00727246|DRUG|Placebo|Treatment with placebo for 6 weeks
48171278|NCT01904136|RADIATION|Total-Body Irradiation|Undergo TBI
48171279|NCT06339567|DIAGNOSTIC_TEST|Thrombotic profile|several thrombotic biological marker will be dosed in blood. (C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)
48171280|NCT00873561|DRUG|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
48171281|NCT02778334|OTHER|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~1. patients who return home and~2. patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
48171282|NCT03033758|OTHER|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
48372090|NCT01362231|DRUG|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
48372091|NCT02045017|DRUG|Pomalidomide and Dexamethasone|
48372092|NCT03584152|DRUG|Norco 5Mg-325Mg Tablet|Opioid Analgesics
48372093|NCT03584152|DRUG|Tylenol 325Mg Caplet|Non opioid analgesics
48372094|NCT03584152|DRUG|Ibuprofen 200 mg|Non opioid analgesics
48516355|NCT04441151|BEHAVIORAL|Pulmonary rehabilitation therapy|Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
48516356|NCT03327948|DEVICE|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
48516357|NCT00005052|BIOLOGICAL|GM2-KLH vaccine|
48516358|NCT00005052|BIOLOGICAL|QS21|
48516359|NCT00005052|PROCEDURE|adjuvant therapy|
48014828|NCT05795699|DRUG|Ripasudil|K-321 ophthalmic solution
48171283|NCT04598945|OTHER|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
48171284|NCT00698555|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
48372095|NCT02031601|DRUG|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
48372096|NCT02031601|DRUG|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
48372097|NCT02031601|DRUG|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
48372098|NCT02031601|DRUG|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
48014829|NCT05795699|DRUG|Placebo|Placebo ophthalmic solution
48014830|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution as a single dose.
48014831|NCT02778204|DRUG|Maraviroc|8 mg/kg oral solution given twice daily.
48014832|NCT04400513|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart sounds using electronic stethoscopes
48014833|NCT02661828|OTHER|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
48014834|NCT02661828|OTHER|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
48014835|NCT03556046|DIAGNOSTIC_TEST|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
48014836|NCT00748943|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
48372099|NCT02031601|DRUG|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
48372100|NCT02031601|DRUG|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
48372101|NCT02031601|DRUG|Erlotinib|150mg po once a day daily until disease progression
48372102|NCT02031601|DRUG|Gefitinib|250mg po once a day daily until disease progression
48014837|NCT05101564|DRUG|Alpelisib|Alpelisib 300 mg
48014838|NCT05101564|DRUG|Tamoxifen|Tamoxifen 20 mg
48014839|NCT05101564|DRUG|Zotatifin|Zotatifin 0.10mg/kg (by weight)
48014840|NCT05101564|DRUG|Fulvestrant|Fulvestrant 500 mg
48171285|NCT00698555|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
48372103|NCT02031601|DRUG|Icotinib|125mg po three times a day daily until disease progression
48372104|NCT05298904|DIAGNOSTIC_TEST|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
48372105|NCT00394498|DRUG|Granulocyte Colony Stimulating Factor|
48372106|NCT00305292|DRUG|Modafinil-Alcohol Interactions|
48372107|NCT04613752|DEVICE|diaphragmatic function measurements and diaphragmatic ultrasound|A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.
48372108|NCT06256861|BEHAVIORAL|Rehabilitation treatment|This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48372109|NCT06256861|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
48372110|NCT05058599|DIAGNOSTIC_TEST|DM|A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
48372111|NCT04165174|DRUG|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
48372112|NCT04165174|RADIATION|SBRT|6-10Gy/F,5-8F
48372113|NCT02738931|DRUG|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
48014841|NCT03376997|DRUG|Perampanel|IV infusion
48014842|NCT03376997|DRUG|Perampanel|Oral tablet
48014843|NCT00054613|DRUG|Methoxsalen|
48014844|NCT00054613|PROCEDURE|Extracorporeal Photopheresis|
48014845|NCT03667339|PROCEDURE|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
48014846|NCT05568394|OTHER|Manual therapy combinded with therapeutic exercise|"The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
48703159|NCT05838053|PROCEDURE|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
48703160|NCT05838053|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
48703161|NCT05894096|DEVICE|Cold Atmospheric Plasma Jet Treatment|Application of Colf Atmospheric Plasma Jet on the wound
48171286|NCT05259436|BEHAVIORAL|Caregiver-child Intervention|"Intervention Groups:~1. Resilience Clinic (Benioff Oakland): 6 weekly interactive group-based visits in primary care that draws from the evidence-based Circle of Security Parenting along with the principles of mindfulness;~2. ABC Intervention (Lifelong): 10 weekly home visiting sessions. ABC is an empirically supported parenting program that focuses on improving maternal sensitivity;~   and,~3. Resiliency Family Program (Santa Barbara Neighborhood Clinic): 4 primary-care-based visits, every 2-3 weeks, that include psycho-education materials drawing from the culturally-responsive, evidence-based program, Madres a Madres."
48171287|NCT05259436|BEHAVIORAL|Enhanced Primary Care|Enhanced Primary Care (control group): This includes care coordination services for community resources in addition to usual care. Participants will be asked about any unmet social needs, e.g. food insecurity, financial strain, safe places to play. Those who endorse need will be offered navigational services to link to community resources.
48171288|NCT06118177|PROCEDURE|connective tissue harvesting|The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of canine and the mesial of first molar in the palate. Connective tissue dimensions were approximately 10 × 5 × 2 mm. Finally, the incision line was sutured with 5/0 synthetic, nonabsorbable, sterile monofilament suture
48372114|NCT02738931|DRUG|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
48372115|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
48703162|NCT05894096|DEVICE|Alginate Patch|Application of Alginate Patches on the wound
48703163|NCT02534935|BIOLOGICAL|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
48703164|NCT02534935|BIOLOGICAL|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
48014847|NCT05568394|OTHER|Routine physical therapy|"The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks)."
48372116|NCT02738931|DRUG|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
48372117|NCT03833908|DEVICE|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
48372118|NCT03841331|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
48372119|NCT03841331|DRUG|Matching Placebo Tablets|Placebo Tablets
48372120|NCT05853276|BEHAVIORAL|Brush DJ app|Brush DJ app is a mobile app which can be freely downloaded. This app was chosen as part of the intervention as it was recognized by the NHS to reduce the risk of gum disease and tooth decay among its users. This app was built around the info given in the public health England Delivering Better Oral Health Toolkit.
48703165|NCT01497990|DRUG|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
48703166|NCT06596954|RADIATION|lymphocyte-sparing radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. While maintaining target coverage and traditional OAR (Organs At Risk) dose constraints, also address dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
48703167|NCT06596954|RADIATION|conventional radiotherapy|the radiotherapy regimen is 41.4Gy/23Fx. Ensure 95% coverage of the PTV (Planning Target Volume) and limit the doses to the heart, bilateral lungs, and spinal cord to meet the required dose constraints. do not limit dose for lymphocyte-relate organs including the TVB1-12 thoracic vertebral bodies, ribs, spleen, and major thoracic blood vessels.
48014848|NCT01738152|OTHER|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
48372121|NCT02717910|BEHAVIORAL|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
48703168|NCT05120570|DRUG|VIC- 1911|25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
48516360|NCT04238650|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
48516361|NCT04238650|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90- minute infusion
48516362|NCT05379244|BEHAVIORAL|CBT-i|Behavioral intervention based on Cognitive Behavioral Therapy for insomnia, adjusted for psychiatric patients with anxiety disorders, affective disorders and trauma
48516363|NCT03209557|OTHER|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
48516364|NCT05886712|OTHER|Naloxone|Naloxone
48516365|NCT05886712|OTHER|Usual intervention|usual administered drug for overdose
48516366|NCT05623683|OTHER|Intermittent Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
48703169|NCT01657890|DRUG|isavuconazole|oral
48703170|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
48703171|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
48703172|NCT04043234|DEVICE|RESCU|Retrospectively Supervised Classification Updating (RESCU) is founded on two innovations that promise significant improvement in performance and outcome. The first is a highly robust machine intelligence algorithm, an Extreme Learning Machine with Adaptive Sparse Representation (EASRC), and the second is a novel adaptive learning algorithm and communication interface we call Nessa. We contend that these two technologies allow the prosthetic device to adapt to its user from the initial fitting through continuing, long-term use in the activities of daily living, shifting the paradigm of training from the current prospective data gathering methods to a more dynamic retrospective application.
48703173|NCT04043234|DEVICE|Pattern Recognition|Pattern recognition prostheses associate the patterns of activity of multiple EMG sites to the action of a prosthesis. Such strategies have historically required prospective calibration of the EMG activation patterns.
48703174|NCT06563180|BEHAVIORAL|Health-Promoting Lifestyle Profile II|"health promoting lifestyle behaviors (HPLBs). It included fifty-two elements within six dimensions: Physical activity, nutrition, spiritual growth, interpersonal relations, stress management, and health responsibility. Higher scores refer to higher adherence levels to healthier lifestyle behaviors. The total score ranged from (52 to 208). It used a four-point likert scale, ranged from one (never) to four (routinely) . The total score will be classified into four levels:~* Poor for the range 52-90~* Moderate for the range 91-129.~* Good for the range 130-168.~* Excellent for the range 169-208."
48703175|NCT05945602|OTHER|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
48372122|NCT02717910|BEHAVIORAL|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
48372123|NCT05970042|BEHAVIORAL|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
48014849|NCT01738152|BEHAVIORAL|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
48014850|NCT00797992|DRUG|Injection|Intravitreal injection of 1.25 mg bevacizumab
48014851|NCT05114356|DEVICE|TIDAL Cervical Interbody Fusion implant|Cervical interbody fusion device
48014852|NCT05696730|OTHER|Communication intervention about sexuality in people with COPD|"COSY is a communication intervention which consists of one face to face counselling (75 min) and two 30-min telephone call counselling.~Patients assigned to the intervention group will get the COSY communication intervention with a special focus on the positive impact of sexuality on wellbeing plus specific motivation for physical activity. Together with the patient, a personalized re-enforcement instrument, the COSY-Compass, is elaborated to set individual goals and motivation for physical activity over the whole intervention period (3 months).~Participants will learn to understand the positive effect of regular physical activity on physical, mental, and cognitive wellbeing and a more fulfilling sex life as well as get inspiration about the spectrum and possible expressions and manifestations of caring and intimacy with oneself."
48014853|NCT01935011|OTHER|PD, DBS|PD DBS frequency on swallowing function
48171289|NCT06118177|DIAGNOSTIC_TEST|ultrasonography|A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the donor site in the palatal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit: Pulsality index (PI) = (Vmax-Vmin)/(Vmean) (Vmax is peak systolic flow velocity, Vmin is diastolic flow velocity and Vmean is mean flow velocity). The mean PI values of each patient were measured.
48171290|NCT06118177|OTHER|autolog platelet rich fibrin application|Leukocyte rich PRF (L-PRF) was obtained with the centrifugation of the two tubes at 2800 rpm for 12 minutes. After centrifugation, L-PRF clots were taken from the tubes using sterile tweezers, separated from the red blood cell base using scissors. Then L-PRF membrane was placed into the donor site.
48372124|NCT05970042|BEHAVIORAL|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
48516367|NCT05623683|OTHER|Continuous Walking|Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
48014854|NCT02785367|PROCEDURE|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
48703176|NCT02570152|PROCEDURE|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
48703177|NCT04506216|OTHER|cohort|"During a regular follow-up visit, the following data will be collected:~* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~* bio-electric impedance analysis~* insulin pump and sensor data collection"
48703178|NCT01394757|DRUG|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
48014855|NCT02928341|OTHER|Improved water supply|
48014856|NCT01527916|DRUG|placebo|Placebo Comparator
48014857|NCT01527916|DRUG|donepezil|Active Comparator
48014858|NCT01527916|DRUG|ABT-126|low dose, middle dose, high dose
48703179|NCT05410171|DEVICE|early warning platform|High risk inpatients will be evaluated by early warning platform
48703180|NCT04726150|OTHER|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
48014859|NCT05979792|DRUG|CAR-T Therapy|CAR-T cell infusion
48014860|NCT01427205|DRUG|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
48014861|NCT01427205|DRUG|OSI-906|150 mg by mouth twice a day.
48014862|NCT01427205|OTHER|Placebo|Placebo taken by mouth twice daily.
48372125|NCT01008059|DRUG|Alfentanil|No drug treatment before alfentanil
48014863|NCT04284189|OTHER|Transition model|Transition of follow-up care of childhood cancer survivors to adult care
48014864|NCT05698095|DRUG|5-methoxy-N,N-dimethyltryptamine succinate salt|The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
48014865|NCT05698095|DRUG|Placebo|The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
48014866|NCT03814694|DIETARY_SUPPLEMENT|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
48014867|NCT03814694|DIETARY_SUPPLEMENT|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
48372126|NCT02398292|OTHER|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
48372127|NCT02398292|OTHER|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
48372128|NCT04489511|DRUG|STG-001|Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
48014868|NCT06663488|PROCEDURE|Thoracic epidural anesthesia|The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
48014869|NCT06663488|PROCEDURE|Thoracic spinal anesthesia|Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
48014870|NCT03436472|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
48014871|NCT03436472|DRUG|placebo|normal saline infusion
48014872|NCT01570023|BEHAVIORAL|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
48014873|NCT03145727|DEVICE|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
48014874|NCT03145727|DEVICE|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
48014875|NCT03145727|DEVICE|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
48703181|NCT06323941|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
48703182|NCT06323941|BEHAVIORAL|Therapeutic exercises|Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
48703183|NCT05503771|BEHAVIORAL|ISA-MI|Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
48014876|NCT00023816|DRUG|carbendazim|
48014877|NCT02124291|DEVICE|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
48014878|NCT06008301|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
48014879|NCT01179594|DRUG|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
48014880|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
48014881|NCT01179594|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
48014882|NCT01179594|DRUG|placebo|orally daily, 24 weeks (weeks 12-36)
48014883|NCT05597020|DRUG|Daridorexant|Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
48014884|NCT05597020|DRUG|Placebo|Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
48014885|NCT00934999|PROCEDURE|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
48014886|NCT00934999|PROCEDURE|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
48372129|NCT03076827|PROCEDURE|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
48014887|NCT06664190|DIAGNOSTIC_TEST|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)|Advanced sequences, such as arterial spin labeling (ASL) and diffusion-weighted imaging (DWI)
48014888|NCT03006666|BEHAVIORAL|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
48372130|NCT03076827|PROCEDURE|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
48372131|NCT03693846|DRUG|Nivolumab|IV infusion per institutional guidelines and the Package Insert
48372132|NCT03693846|DRUG|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
48372133|NCT02821975|OTHER|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
48372134|NCT04582968|OTHER|Pyrotinib Plus Capecitabine combined with brain radiotherapy|Drug combined with radiation
48014889|NCT03006666|BEHAVIORAL|Data Only|The teams randomly allocated will not have access to Community Health Workers.
48014890|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
48171291|NCT03722693|DEVICE|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
48171292|NCT02412111|DRUG|Ivacaftor|
48372135|NCT02567331|DRUG|Capecitabine|Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
48703184|NCT05503771|OTHER|Standard of Care (SOC)|Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.
48171293|NCT02412111|DRUG|Tezacaftor/Ivacaftor|
48703185|NCT02019108|OTHER|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
48703186|NCT02019108|OTHER|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
48703187|NCT00000886|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
48703188|NCT05666999|DEVICE|FibDex®|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
48703189|NCT05666999|DEVICE|Suprathel|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
48171294|NCT02778906|DRUG|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
48372136|NCT04833465|OTHER|No Intervention|No Intervention
48516368|NCT02765425|DEVICE|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
48516369|NCT02153983|DRUG|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
48516370|NCT02153983|DRUG|Placebo capsules given|Placebo capsules given twice daily
48516371|NCT02153983|DRUG|Colchicine 0.6Mg Tab|Open-label colchicine
48014891|NCT03555526|DRUG|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
48014892|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
48014893|NCT03555526|DRUG|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
48014894|NCT03555526|DRUG|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
48014895|NCT03555526|DRUG|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
48014896|NCT03555526|DRUG|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
48014897|NCT03555526|DRUG|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
48014898|NCT03555526|DRUG|tetracycline|tetracycline 500mg, qid, for 10 days
48171295|NCT02778906|DRUG|Placebo|Administration of the comparator s.c. weekly in comparable to verum
48171296|NCT03019198|DRUG|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
48171297|NCT03019198|DRUG|Placebo - Concentrate|
48171298|NCT05268497|DRUG|Esketamine|Esketamine will be self-administered as nasal spray.
48372137|NCT03701971|OTHER|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
48516372|NCT02158715|DEVICE|Site of smartphone on chest compressor' arm|
48516373|NCT01833650|DIETARY_SUPPLEMENT|thymus honey mouthwash|
48516374|NCT02759393|DRUG|Dexlansoprazole|receiving 8-week PPI
48516375|NCT02759393|DRUG|Lansoprazole|receiving 8-week PPI
48703190|NCT05666999|DEVICE|Aquacel Foam|To monitor and compare the clinical performance and safety of the CE marked wound care product (FibDex®) when used according to its intended use for patients or individuals with split thickness skin graft (STSG) donor site wounds.
48372138|NCT00854776|DRUG|lansoprazole|30 mg once daily
48703191|NCT06489821|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
48014899|NCT04518735|OTHER|Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19|Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
48014900|NCT03819868|PROCEDURE|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
48171299|NCT05268497|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Clinician-directed CBT supplemented by the Mindset app will be administered.
48372139|NCT00854776|DRUG|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
48372140|NCT03914456|OTHER|rehabilitation treatment|
48372141|NCT00656942|DEVICE|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
48372142|NCT03898882|DRUG|oxytocin|PK measurements of oxytocin
48372143|NCT03898882|DEVICE|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
48372144|NCT02248272|OTHER|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
48703192|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
48703193|NCT00191724|DRUG|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
48703194|NCT00191724|DRUG|Placebo|intravenous (IV), one infusion, over 12 hours
48014901|NCT03819868|PROCEDURE|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
48014902|NCT06664346|BEHAVIORAL|Immersive virtual reality mindfulness|Immersive virtual reality mindfulness
48014903|NCT03837899|DRUG|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
48014904|NCT05371587|OTHER|Autonomy and Perceptions Approach to Resistance Training (APART)|Alternative resistance training prescription based on trainees' autonomy and perceptions.
48014905|NCT05371587|OTHER|Standard prescription|Standard resistance training prescription, based on international organization's guidelines.
48014906|NCT00394966|DRUG|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
48014907|NCT00394966|DRUG|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
48014908|NCT00394966|DRUG|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
48014909|NCT00394966|DRUG|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
48014910|NCT00394966|DRUG|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
48014911|NCT00005638|DRUG|cisplatin|
48014912|NCT00005638|DRUG|irinotecan hydrochloride|
48014913|NCT00005638|RADIATION|radiation therapy|
48014914|NCT05172505|DEVICE|prefrontal tDCS|2 mA prefrontal tDCS (anode over F3, cathode over F4 10/20 EEG System) for 6 weeks, 5x/week in a home treatment Setting (self application) for 30 mins.
48014915|NCT05750641|OTHER|removing milk and dairy products from diets without medical treatment|A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment
48171300|NCT05268497|DRUG|Antidepressant|Antidepressant will be administered orally.
48171301|NCT04866433|PROCEDURE|Real-time binaural sound|Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.
48171302|NCT04866433|PROCEDURE|Music|Play the same music in both ears through headphones during sedation
48171303|NCT04866433|PROCEDURE|Control|Just wear headphones during sedation
48171304|NCT00720369|DRUG|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
48171305|NCT00855322|OTHER|Gym exercise group intervention|Gym based circuit class
48171306|NCT00855322|OTHER|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
48171307|NCT00855322|OTHER|Control group|No intervention
48171308|NCT04001998|DRUG|BLD-2660|Randomized to active product
48703195|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
48703196|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
48703197|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
48703198|NCT01684709|BEHAVIORAL|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
48703199|NCT04533217|PROCEDURE|Vertebroplasty|Injection of cement into vertebral lesion(s)
48171309|NCT01228721|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
48516376|NCT03774407|DRUG|vaginal estriol|Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
48516377|NCT02631889|DEVICE|Transcollation technology|The use transcollation technology for dissection during lung surgery
48703200|NCT04960930|DRUG|FMX101|topically once daily
48703201|NCT03027856|DEVICE|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
48703202|NCT05427448|DIAGNOSTIC_TEST|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
48703203|NCT05055297|DEVICE|SELUTION SLR™ DEB 014|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
48703204|NCT05055297|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
48703205|NCT06606431|BEHAVIORAL|Multileveled-community approach|One-to-one delivered interaction at relational level (Interpersonal Relations, Volunteers) Socio-health interaction at personalized level (Social Work) Group delivered interaction for volunteers (Group Dynamics) Community-level interactions (Social Cohesion, Community Networks)
48516378|NCT02631889|DEVICE|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
48171310|NCT05002530|DRUG|Aerosolized 13 cis retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
48171311|NCT05002530|DRUG|Aerosolized All trans retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
48171312|NCT05002530|OTHER|Standard therapy|Standard therapy
48171313|NCT06183619|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
48171314|NCT06183619|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation only
48171315|NCT03876002|DRUG|[18F]PBR06|Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
48171316|NCT01349036|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
48171317|NCT01265121|DEVICE|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
48171318|NCT01265121|OTHER|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
48171319|NCT00571337|DRUG|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
48372145|NCT02248272|OTHER|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
48372146|NCT00207831|DRUG|Tegafur and Uracil|
48372147|NCT05799976|BEHAVIORAL|Text message nudge|The text message nudge will be sent to patients 3 days and 1 day prior to a visit with the primary care practices and notify them of up to 3 care gaps based on electronic health record data. Care gaps will be selected based on availability and ranked in this order: influenza vaccination, pneumococcal vaccination, breast cancer screening, colorectal cancer screening, hemoglobin A1 testing, or statin therapy.
48372148|NCT01509638|DRUG|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
48014916|NCT05750641|OTHER|According to current standard algorithms and guidelines, appropriate treatment for FD types.|According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
48372149|NCT01509638|DRUG|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
48372150|NCT05948670|DEVICE|DISC-MVP|DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.
48372151|NCT05948670|DEVICE|DISC-CON|DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
48372152|NCT04828993|DRUG|tafamidis meglumine|Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
48372153|NCT04312152|DIETARY_SUPPLEMENT|Q10 Ubiquinol|Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
48372154|NCT04312152|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
48372155|NCT04312152|DIETARY_SUPPLEMENT|Multi-Vitamin B complex|Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
48372156|NCT02688881|DRUG|sirolimus|Rapamune
48516379|NCT06582186|DRUG|Individualization of first voriconazole maintenance doses|Individualization of first voriconazole maintenance doses
48516380|NCT01106014|DRUG|Selexipag|Selexipag 200 µg tablets
48516381|NCT01106014|DRUG|Placebo|Placebo tablets matching selexipag
48516382|NCT01782014|PROCEDURE|colonoscopy|colonoscopy using different methods of insufflation
48516383|NCT03503695|DEVICE|Sterile acupuncture semi-permanent (ASP) gold needles|
48014917|NCT05983575|DEVICE|LIPUS-Brain|Transcranial low-power pulsed-wave ultrasound device
48014918|NCT05983575|DEVICE|Placebo|Placebo
48014919|NCT00876317|DRUG|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
48014920|NCT00876317|DRUG|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
48014921|NCT00853658|DRUG|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
48014922|NCT00853658|DRUG|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
48014923|NCT01891734|OTHER|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
48014924|NCT01891734|OTHER|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu \& D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
48014925|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
48014926|NCT01285739|OTHER|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
48171320|NCT05861778|DRUG|89Zr-Girentuximab|A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
48171321|NCT04225000|OTHER|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
48171322|NCT04225000|OTHER|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
48171323|NCT02507687|DRUG|Bimatoprost SR|Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.
48171324|NCT02507687|DRUG|Sham Bimatoprost SR|Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.
48171325|NCT02507687|PROCEDURE|Selective Laser Trabeculoplasty|"SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method."
48171326|NCT02507687|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.
48171327|NCT03315234|GENETIC|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
48171328|NCT02490605|PROCEDURE|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
48516384|NCT06013826|OTHER|Telenursing|Patients who were randomly assigned to the intervention group were informed about the method of the study. The patient was informed that he would be called before blood glucose measurement and insulin injection for three days to monitor his fear of self-injection and testing. Insulin injection application training was repeated on the first day. Telephone calls made within the scope of tele-health service were recorded in the Telephone Interview Form. During the phone interviews, the questions that the patients wanted to ask were answered. He was asked to fill in the Insulin Injection Evaluation Form according to his experience during the three-day home treatment process. At the end of the three-day meeting, the tele-health service was terminated.
48516385|NCT05462197|BEHAVIORAL|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
48171329|NCT02490605|PROCEDURE|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
48171330|NCT00485706|PROCEDURE|high calcium dialysate|
48516386|NCT03204448|DEVICE|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
48703206|NCT01689870|DRUG|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
48703207|NCT01689870|DRUG|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
48372157|NCT06197776|DRUG|cisplatin-based chemoradiotherapy combined with immunotherapy|"Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody"
48372158|NCT04205773|DEVICE|CompuFlo|After priming with 5 mL saline, the catheter was connected to CompuFlo to record the occurrence of pulsatile waveforms and/or their disappearance during its removal
48516387|NCT05308433|DEVICE|Functional MRI|The volunteer will have to imagine the smells evoked by different visual aids. This task will be carried out during 2 acquisition runs of about 10 minutes each. The volunteer should note (on a scale from 1 to 4) the pleasantness of the smell evoked.
48703208|NCT05313321|DEVICE|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
48703209|NCT01461928|DRUG|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
48171331|NCT01114308|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
48171332|NCT01114308|DRUG|placebo implant|Implant contains ethylene vinyl acetate
48171333|NCT01114308|DRUG|Buprenorphine|sublingual buprenorphine/naloxone tablets
48171334|NCT03420261|BIOLOGICAL|0.9% saline|Fluid administration
48171335|NCT03420261|BIOLOGICAL|HES 130/0.4|Fluid administration
48171336|NCT03209050|DEVICE|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
48171337|NCT02896101|DRUG|Pimecrolimus Cream, 1%|
48703210|NCT01461928|DRUG|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
48171338|NCT02896101|DRUG|Elidel® (pimecrolimus) Cream|
48171339|NCT02896101|DRUG|Placebo of Pimecrolimus Cream, 1%|
48372159|NCT02635503|PROCEDURE|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
48372160|NCT02635503|PROCEDURE|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
48372161|NCT00542321|OTHER|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
48372162|NCT00542321|DEVICE|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
48703211|NCT06306651|OTHER|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC
48703212|NCT06306651|OTHER|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
48703213|NCT04039711|PROCEDURE|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
48703214|NCT00000467|BEHAVIORAL|diet|
48703215|NCT00000467|BEHAVIORAL|exercise|
48703216|NCT00000467|BEHAVIORAL|smoking cessation|
48171340|NCT06238297|DIAGNOSTIC_TEST|MRSA nasal swab based de-escalation|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
48171341|NCT03190629|DEVICE|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
48372163|NCT03626935|DEVICE|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
48372164|NCT01302366|DRUG|TBL12|
48703217|NCT02435407|BEHAVIORAL|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
48703218|NCT02435407|OTHER|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
48703219|NCT05733611|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus
48171342|NCT03190629|DEVICE|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
48171343|NCT04389346|PROCEDURE|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
48171344|NCT04389346|PROCEDURE|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
48171345|NCT03016949|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
48171346|NCT03016949|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
48171347|NCT01764698|BEHAVIORAL|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
48171348|NCT01764698|BEHAVIORAL|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
48014927|NCT01856972|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
48014928|NCT01856972|PROCEDURE|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
48014929|NCT01856972|OTHER|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
48014930|NCT02897141|DEVICE|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
48171349|NCT04891471|RADIATION|Stereotactic RadioTherapy|To treat only brain metastasis identified through Magnetic Resonance imaging by means of stereotactic radiotherapy (experimental intervention) to determine if sparing of clinically uninvolved brain implies a better neurocognitive performance, quality of life and level of autonomy in activities of daily living respect to Whole Brain Irradiation (active comparator).
48171350|NCT04891471|RADIATION|Whole Brain Irradiation|To irradiate the entire brain, site of at least 5 parenchymal metastasis.
48171351|NCT05350124|DRUG|Ascorbic acid|vitamin C (200 mg) capsule
48171352|NCT05350124|DRUG|Tocopherol|vitamin E (400 IU) capsule
48171353|NCT05350124|DRUG|Placebo capsule|Placebo one pill only
48372165|NCT03012035|OTHER|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
48703220|NCT05733611|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
48014931|NCT02897141|DEVICE|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
48014932|NCT00073905|DRUG|capecitabine plus gemcitabine|capecitabine plus gemcitabine
48014933|NCT04184635|DEVICE|VA-ECMO|"* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France)."
48014934|NCT03592472|DRUG|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
48171354|NCT05350124|DRUG|Placebo capsule|Placebo two pills only
48171355|NCT01880437|DRUG|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
48171356|NCT01880437|DRUG|vismodegib|Cohorts 1 and 2: 150 mg orally daily
48171357|NCT02483598|DRUG|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
48703221|NCT05733611|BIOLOGICAL|atezolizumab|anti-PD-L1 monoclonal antibody
48171358|NCT02483598|DRUG|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
48171359|NCT05530382|OTHER|self-guided learning|video-based self-directed learning for medical device training
48171360|NCT05904756|DEVICE|framework for implant supported prosthesis, fabricated from metal of polyetherketoneketone|evaluation of patient satisfaction and oral healty related quality of life
48171361|NCT04218552|DRUG|AD209|PO, Once daily(QD), 8weeks
48703222|NCT05733611|BIOLOGICAL|bevacizumab|anti-VEGF therapy
48171362|NCT04218552|DRUG|Amlodipine low|PO, Once daily(QD), 8weeks
48171363|NCT04218552|DRUG|Amlodipine high|PO, Once daily(QD), 8weeks
48171364|NCT04218552|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
48171365|NCT00733226|DRUG|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
48703223|NCT01163357|DRUG|bortezomib|Given IV
48703224|NCT01163357|DRUG|fludarabine phosphate|Given IV
48703225|NCT01163357|OTHER|melphalan|Given IV
48703226|NCT01163357|RADIATION|total marrow irradiation|Undergo TMI
48703227|NCT01163357|DRUG|tacrolimus|Given IV and orally
48171366|NCT00733226|DRUG|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
48171367|NCT04252170|DEVICE|Rehabilitation Therapy, Experimental on the BrightArm Compact device|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
48171368|NCT00570921|DRUG|Everolimus|Everolimus tablets, two-5 mg tablets a day
48171369|NCT00570921|DRUG|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
48171370|NCT02798913|DRUG|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
48171371|NCT02798913|DRUG|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
48171372|NCT02765386|DEVICE|Hybrid fittings for cochlear implant recipients|
48171373|NCT05418686|BIOLOGICAL|Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.|"* Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~* A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~* Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~* Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~* In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~* Additional blood (5ml) and urine (2ml) samples for colchicine determination."
48372166|NCT03012035|OTHER|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
48516388|NCT05308433|OTHER|Virtual Reality: control|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. In the center of the maritime scene, it will be visible the black outlines of a frame. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
48703228|NCT01163357|DRUG|sirolimus|Given orally
48703229|NCT01163357|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
48703230|NCT01163357|OTHER|laboratory biomarker analysis|Correlative studies
48703231|NCT04821674|BIOLOGICAL|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
48703232|NCT04821674|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
48014935|NCT03592472|DRUG|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
48014936|NCT03592472|OTHER|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
48014937|NCT06162741|BEHAVIORAL|Primary Care Brief Mindfulness Training (PCBMT)|PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.
48171374|NCT04310683|OTHER|natural cycle for endometrium preparation|patients will not use oral contraceptive drugs
48171375|NCT04310683|OTHER|hormone replaced cycle for endometrium preparation|patients will receive oral contraceptive drugs for menstruation before embryo transfer
48372167|NCT03664570|DEVICE|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
48372168|NCT04196023|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
48372169|NCT04196023|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
48516389|NCT05308433|OTHER|Virtual Reality: experimental|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. The visual support inserted in the center of the virtual scene will be the one defined as being the most facilitator of the olfactory imagination during the fMRI examination. The volunteer will be asked to concentrate on the smell evoked by this support. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
48703233|NCT03344549|BEHAVIORAL|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
48703234|NCT03344549|BEHAVIORAL|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
48171376|NCT02672397|BEHAVIORAL|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
48372170|NCT04677816|DRUG|Standard of Care Neoadjuvant Chemotherapy (NAC)|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
48372171|NCT04677816|DIETARY_SUPPLEMENT|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
48372172|NCT04677816|OTHER|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
48516390|NCT02852577|DRUG|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
48703235|NCT05396924|PROCEDURE|Rectal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
48703236|NCT05396924|PROCEDURE|Temporal temperature measurement|Patients will be operated in the same operating room and at the same room temperature with the same type/amount of covering and body warming. At the start of the surgical procedure, a probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a contactless thermometer. The data obtained will be analyzed by a blinded researcher. Mean body temperatures measured from 2 different locations (temporal region and rectal mucosa) between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined
48703237|NCT03502967|DRUG|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
48703238|NCT03502967|DRUG|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
48703239|NCT05514938|DRUG|Polypill|Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.
48703240|NCT05514938|DRUG|Usual Care (individual medications prescribed by primary cardiologist)|Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
48703241|NCT01420874|DRUG|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
48703242|NCT01420874|BIOLOGICAL|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
48703243|NCT04907773|OTHER|Capillary blood sampling|Each subject will have one to two capillary blood collections.
48703244|NCT04907773|OTHER|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
48703245|NCT04907773|OTHER|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
48171377|NCT06345898|DRUG|JWK002|Subretinal administration of gene therapy vector JWK002 to one eye.
48372173|NCT06335225|BEHAVIORAL|Precise nutritional intervention|Diabetic precision nutrition prescription based on the results of nutrigenomics.
48372174|NCT06335225|BEHAVIORAL|Conventional nutritional intervention|Conventional diabetes nutrition prescription.
48516391|NCT02852577|DRUG|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
48516392|NCT04525573|DEVICE|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
48703246|NCT05449379|OTHER|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
48703247|NCT05449379|OTHER|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
48703248|NCT04494347|PROCEDURE|MitraClip TMVR and Watchman LAAO|The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
48703249|NCT06506032|DRUG|Intravenous Vancomycin administration|Vancomycin was administered to the patients at the discretion of the physician
48703250|NCT06506032|OTHER|Standard postoperative therapy|The patients received standard postoperative therapy
48703251|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
48703252|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
48703253|NCT06040203|DRUG|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
48703254|NCT05258214|OTHER|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
48703255|NCT05258214|OTHER|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
48703256|NCT05258214|OTHER|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
48703257|NCT06089460|OTHER|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
48703258|NCT06089460|OTHER|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
48703259|NCT06089460|OTHER|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
48703260|NCT02419196|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
48703261|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
48703262|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
48703263|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
48703264|NCT05115240|BEHAVIORAL|Body Scan|The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.
48171378|NCT04842526|DRUG|Anlotinib and irinotecan combined with temozolomide|Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
48171379|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
48372175|NCT03250728|BIOLOGICAL|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~* the endothelial permeability~* the protein C system"
48703265|NCT05115240|OTHER|Audio-book|Participants listen to an audio book for the same amount of time as the body scan groups
48171380|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
48171381|NCT02965053|DRUG|EOS789|
48171382|NCT02965053|DRUG|Placebo|
48171383|NCT02965053|DRUG|Renvela|
48171384|NCT02228135|DRUG|Dexamethasone|
48372176|NCT05874609|OTHER|Teaching with VR spine simulator|The participants spent 30 minutes with the VR spine simulator after receiving the didactic teaching session. The learning objective with the VR simulator is to review the 3D lumbar spine anatomic model，learn the sonoanatomy presented by a dynamic ultrasound scan of the sagittal and transverse plane, and practice a preprocedural ultrasound scan.
48516393|NCT02186444|OTHER|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
48171385|NCT02979171|DEVICE|Laryngeal Mask Airway Classic|
48703266|NCT05849935|DIAGNOSTIC_TEST|abioSCOPE|The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.
48703267|NCT01906723|DEVICE|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
48703268|NCT03195660|DEVICE|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
48703269|NCT00438126|BEHAVIORAL|A lifestyle educational program|
48171386|NCT06344806|BEHAVIORAL|Gamified Breastfeeding Education|Breastfeeding education content will be integrated into the game program designed with the gamification technique. A training program will be applied to the women in the experimental group in the last trimester. Women in the control group will receive the standard breastfeeding training in the hospital. Measurement tools will be applied to all participants before and after the training.
48703270|NCT01344681|DRUG|Micafungin sodium|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
48703271|NCT01344681|DRUG|Itraconazole|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   - Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
48703272|NCT03972345|DRUG|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
48171387|NCT04382768|DRUG|Inhaled Hypertonic ibuprofen|Standard of care plus lipid ibuprofen 50mg tid
48171388|NCT00039117|BIOLOGICAL|oblimersen sodium|Given IV
48171389|NCT00039117|DRUG|cytarabine|Given IV
48171390|NCT00039117|DRUG|daunorubicin hydrochloride|Given IV
48372177|NCT05874609|OTHER|Traditional didactic teaching|A 30-min traditional didactic teaching session of spine ultrasonography. This session was consisted of general spine anatomy, sonographic technique and sonoanatomy, description of five key spine ultrasonographic views (transverse spinous process view, transverse interlaminar view, parasagittal oblique interlaminar view, parasagittal articular process view, parasagittal transverse process view), and a stepwise technique of preprocedural lumbar spine scan
48372178|NCT02596074|DRUG|Omiganan (CLS001) topical gel|
48372179|NCT02596074|DRUG|Vehicle topical gel|
48372180|NCT04501874|DRUG|EMB-001|720 mg metyrapone/24 mg oxazepam mg BID
48372181|NCT04501874|DRUG|EMB-001 Placebo|Inactive comparator
48703273|NCT01044212|DRUG|Docusate|Docusate 100mg BID
48703274|NCT01044212|DRUG|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
48703275|NCT05862012|DRUG|ISB 2001|Participants will receive escalating doses of ISB 2001
48171391|NCT00039117|OTHER|laboratory biomarker analysis|Correlative studies
48171392|NCT00039117|OTHER|pharmacological study|Correlative studies
48171393|NCT04228354|DRUG|Semaglutide|Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
48171394|NCT00275301|DRUG|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
48372182|NCT02535858|DEVICE|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
48372183|NCT02535858|DEVICE|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
48372184|NCT00001568|DRUG|2-Fluoro-2-deoxyglucose|
48372185|NCT06188351|DEVICE|Three-Dimensional Navigation Atrial Septal Puncture|Atrial septal puncture will be performed using a three-dimensional navigation intracardiac guidance kit
48372186|NCT06188351|DEVICE|Conventional Atrial Septal Puncture|Atrial septal puncture will be performed using traditioanl two-dimensional atrial septal puncture kit using traditional method.
48372187|NCT04519827|OTHER|New Rice-based hydrolysate|A rice-based hydrolysed infant formula with new ingredient
48372188|NCT04519827|OTHER|Amino Acid-based infant formula|An amino acid-based infant formula
48372189|NCT04661917|DRUG|BAY2327949|60 mg of BAY2327949 (2 tablets of 30 mg, orally) once daily for 28 days.
48372190|NCT04661917|DRUG|Placebo|Matching placebo orally once daily for 28 days.
48372191|NCT05338749|BEHAVIORAL|Cognitive Training|Gamified cognitive training intervention to improve mental speed and attention.
48372192|NCT01220817|DRUG|3 POMx capsules|3 POMx capsules daily
48372193|NCT01220817|DRUG|1 POMx capsule|1 POMx capsule daily
48703276|NCT05862012|DRUG|ISB 2001|Participants will receive injection of ISB 2001 as determined in Part 1.
48703277|NCT06278506|PROCEDURE|Ablation|Microwave ablation, Radiofrequency ablation, Cryo ablation
48703278|NCT06278506|PROCEDURE|Surgery|Partial or total nefrectomy
48703279|NCT01847066|DEVICE|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
48703280|NCT01847066|DEVICE|Erbium 2940 plus cosmetics|laser
48703281|NCT00597311|RADIATION|radiotherapy|"1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv"
48703282|NCT00246181|PROCEDURE|radiation therapy|Patients will receive 3 fractions
48516394|NCT02186444|OTHER|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
48703283|NCT01581489|PROCEDURE|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
48703284|NCT01094314|OTHER|embryo culture medium|comparison between two types of embryo culture medium
48703285|NCT04527237|OTHER|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application."
48703286|NCT04527237|OTHER|Placebo|Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
48516395|NCT03247179|OTHER|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
48703287|NCT06109051|DEVICE|EndeavorOTC|EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
48703288|NCT00481559|DRUG|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
48703289|NCT01376063|DRUG|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
48703290|NCT03231917|PROCEDURE|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
48703291|NCT03231917|PROCEDURE|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
48703292|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, intraoperative stage|Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
48703293|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, postoperative stage|The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
48703294|NCT06044909|OTHER|Preoperative data collection|Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
48703295|NCT06044909|OTHER|Intraoperative data collection|Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
48516396|NCT00703872|DRUG|Oral HDV-Interferon + ribavarin|Naive pateints
48703296|NCT06044909|OTHER|Postoperative data collection|Definitive anatomical pathology with the measurement of resection margins.
48703297|NCT02507180|OTHER|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point"
48703298|NCT06334081|PROCEDURE|undersized drilling technique|In group A The implant site preparation was made according to the protocol of the manufacturer except that the final drill was omitted. The drilling was done using a low speed reduction, high torque with coolant contra-angle hand piece with surgical motor unit. Speed of drilling was 800-1200 rpm.
48372194|NCT00821847|OTHER|DEXA scan|DEXA scan
48516397|NCT00703872|DRUG|Injectable HDV-Interferon + ribavarin|Nonresponders
48372195|NCT01321086|BEHAVIORAL|Motivational Interviewing|9 sessions of MI from baseline to six months
48372196|NCT01321086|BEHAVIORAL|PACE|9 sessions of PACE delivered from baseline to six months
48372197|NCT04037579|OTHER|Survey|Non-randomised survey
48703299|NCT06334081|PROCEDURE|single drilling technique|In group B The implant bed was prepared using the new specially designed drills. First, the use of the guide drill of length 3.5mm with speed of 800 rpm and torque of 35 nm, then the use of the one drill of the same diameter of the selected implant size to the full length of the osteotomy site.
48703300|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
48703301|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
48703302|NCT06260631|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
48703303|NCT06260631|OTHER|Sham laser acupuncture|"Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
48703304|NCT02083705|PROCEDURE|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
48703305|NCT02083705|PROCEDURE|3:1 CPR|CPR using 3:1 ratio (control group)
48703306|NCT04620382|DRUG|Midodrine|Midodrine 5-10 mg, single oral dose
48703307|NCT04620382|DRUG|Placebo pill|single oral dose
48703308|NCT04620382|DEVICE|Abdominal compression|abdominal compression up to 40 mmHg during head-up tilt
48703309|NCT04620382|DEVICE|sham compression|Sham abdominal compression during head-up tilt
48703310|NCT04552639|BEHAVIORAL|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
48703311|NCT04552639|BEHAVIORAL|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
48516398|NCT01478373|DRUG|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
48516399|NCT03519087|OTHER|Interdisciplinary Evaluation for Nonarthritic Hip Disease|The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
48703312|NCT06571708|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV
48703313|NCT06571708|DRUG|Cisplatin|Cisplatin 70 mg/m\^2 IV or renally-dosed split-dose cisplatin 35 m/m\^2 IV
48372198|NCT04861688|COMBINATION_PRODUCT|Traditional Chinese Medicine (NeuroAiD II™ (MLC901)|NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.
48372199|NCT04861688|OTHER|Placebo|Placebo with same appearance as active intervention
48372200|NCT03220880|DRUG|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
48516400|NCT03519087|OTHER|Posture and Movement Training|Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
48516401|NCT03519087|OTHER|Treatment-of-choice|Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
48703314|NCT06571708|DRUG|Cemiplimab|Cemiplimab 350mg IV
48703315|NCT06571708|DRUG|Fianlimab|Fianlimab 1600mg IV
48703316|NCT00701142|BIOLOGICAL|Haemocomplettan® P|Single intravenous infusion
48703317|NCT00701142|BIOLOGICAL|Saline solution|Single intravenous infusion
48703318|NCT05130216|OTHER|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
48703319|NCT03293433|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
48703320|NCT04193085|OTHER|Observational|Observational
48703321|NCT00004112|BIOLOGICAL|rituximab|
48703322|NCT00004112|DRUG|CHOP regimen|Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
48372201|NCT00266617|DRUG|epoetin alfa|
48703323|NCT00004112|DRUG|cyclophosphamide|
48703324|NCT00004112|DRUG|doxorubicin hydrochloride|
48703325|NCT00004112|DRUG|prednisone|
48703326|NCT00004112|DRUG|vincristine sulfate|
48703327|NCT01897350|OTHER|Cardiac magnetic resonance imaging|
48703328|NCT02242435|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
48703329|NCT02242435|DRUG|4 mL Injection of Placebo|
48171395|NCT01607931|BEHAVIORAL|Exercise|1 hour of cycling at 50% of maximum power output
48171396|NCT04711486|DRUG|Contraloid acetate|Oral administration of drug substance capsules
48171397|NCT04711486|DRUG|Placebo|Oral administration of placebo without any exipients.
48171398|NCT02028468|PROCEDURE|hemiarthroplasty|
48171399|NCT04512898|DRUG|Triple therapy for H.pylori|Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
48703330|NCT06002854|DRUG|PRP( platelet rich plasma) and Insulin human|Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
48703331|NCT00338832|BEHAVIORAL|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
48703332|NCT00338832|BEHAVIORAL|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
48703333|NCT06447623|DRUG|Apatinib|Apatinib is a kind of TKI inhibitor.
48703334|NCT06447623|DRUG|CDK4/6 Inhibitor|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
48171400|NCT00263484|DRUG|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
48703335|NCT06447623|DRUG|Aromatase inhibitor and Fulvestrant|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
48703336|NCT03222973|DRUG|BIIB033 (opicinumab)|Administered as specified in the treatment arm
48703337|NCT03222973|DRUG|Placebo|Administered as specified in the treatment arm
48703338|NCT03539289|BEHAVIORAL|MUFA Diet|Control of patient MUFA Diet
48703339|NCT03539289|BEHAVIORAL|SFA Diet|Control of patient SFA Diet
48171401|NCT00263484|DRUG|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
48703340|NCT02660671|BEHAVIORAL|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
48703341|NCT02660671|BEHAVIORAL|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
48703342|NCT02660671|BEHAVIORAL|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
48703343|NCT05190354|DEVICE|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
48171402|NCT00263484|DRUG|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
48171403|NCT02763163|BEHAVIORAL|Sun exposure routine|
48171404|NCT01965145|DRUG|Gevokizumab|Sterile solution administered subcutaneously
48171405|NCT01965145|DRUG|Placebo|Sterile solution administered subcutaneously
48171406|NCT04134598|RADIATION|Breast irradiation (RT)|Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.
48372202|NCT05185908|PROCEDURE|Measurement of the optic nerve sheath diameter by ultrasound-guidance.|Measurement of the optic nerve sheath diameter (ONSD) by ultrasound guidance can be used in the diagnosis of increased ICP. The investigators interrogated the effects of lateral 45° downward position and CO2 insufflation on ONSD in patients undergoing laparoscopic transperitoneal nephrectomy.
48703344|NCT06306963|DIAGNOSTIC_TEST|Gastric Emptying|"Measured by radioscintigraphy after overnight fast using a radiolabeled meal consisting of two 99mTc - labeled scrambled eggs, one slice of whole wheat bread and one glass of 111In DTPA skim milk (320kcal, 30% fat). A variable region of interest program will be used to quantitate counts in the stomach. Data will be summarized as GE T1/2 and GE % emptied at 1, 2 and 4 hours.~To assess gastric emptying, the protocol meal as described above will be given. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. Scans will then be done at time 0 subsequently in 15-minute intervals to 90 minutes, then in 30-minute intervals thereafter to 240 minutes supine."
48703345|NCT03091985|DEVICE|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
48703346|NCT03091985|DEVICE|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
48703347|NCT00396006|BIOLOGICAL|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
48703348|NCT06511674|OTHER|Cognitive-emotional and pain assessments|Data collection on cognitive-emotional and pain parameters using questionnaires.
48703349|NCT02421731|DEVICE|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
48703350|NCT02421731|OTHER|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
48703351|NCT05062304|DRUG|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
48703352|NCT05062304|DRUG|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
48703353|NCT04807972|DRUG|ABBV-927|Intravenous (IV) Infusion
48703354|NCT04807972|DRUG|Budiglimab|Intravenous (IV) Infusion
48703355|NCT04807972|DRUG|modified FOLFIRINOX|Intravenous (IV) Infusion
48703356|NCT06433583|DEVICE|transcutaneous auricular vagal nerve stimulation|"The use of TENS ECO PLUS and the vagus nerve ear electrode medical devices for transcutaneous auricular vagal nerve stimulation (taVNS) everyday for 10 minutes twice a day or 20 minutes for 8 successive weeks. Patients are included at week 0, use taVNS between week 2 and 10, and are followed up until week 22.~Patient adherence: percentage of patients performing 20 minutes of daily stimulation on at least 5 days a week for at least 6 cumulative weeks."
48703357|NCT03155919|DIETARY_SUPPLEMENT|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
48703358|NCT03155919|DIETARY_SUPPLEMENT|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
48703359|NCT06606990|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
48171407|NCT04134598|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
48171408|NCT05772481|OTHER|PET-MRI|"Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment.~Induction chemotherapy may be performed at another center than the investigating center.~After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed.~A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery.~A total of 4 PET MRI scans will be performed."
48703360|NCT06606990|PROCEDURE|Computed Tomography|Undergo CT
48703361|NCT06606990|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48703362|NCT06606990|BIOLOGICAL|Pidnarulex|Given IV
48703363|NCT01062841|BEHAVIORAL|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
48703364|NCT05720858|OTHER|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
48516402|NCT00725257|OTHER|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
48171409|NCT04040283|PROCEDURE|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
48171410|NCT06478901|DEVICE|Echocardiography|Echocardiography assited by Artificial intelligence
48171411|NCT03104777|BEHAVIORAL|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
48171412|NCT02275299|DRUG|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
48171413|NCT02275299|DRUG|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
48171414|NCT02275299|DRUG|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
48171415|NCT05354310|COMBINATION_PRODUCT|VOILA|Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
48171416|NCT01222702|DRUG|Cadazolid|Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
48171417|NCT01222702|DRUG|Vancomycin|Vancomycin, provided as capsules (125 mg) for oral administration
48171418|NCT01222702|DRUG|Placebo-matching cadazolid|Placebo of cadazolid powder for oral suspension
48171419|NCT01222702|DRUG|Placebo-matching vancomycin|Placebo of vancomycin capsules
48171420|NCT01841112|DRUG|Placebo|Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
48171421|NCT01841112|DRUG|BI-409306 25 milligram (mg) SD|Subjects received 25 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
48171422|NCT01841112|DRUG|BI-409306 50 mg SD|Subjects received 50 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
48171423|NCT01841112|DRUG|BI-409306 100 mg SD|Subjects received 100 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
48171424|NCT01841112|DRUG|BI-409306 100 mg MD|Subjects received 100 mg multiple dose of BI-409306 (film-coated tablet/s), administered orally once on day 3 to day 9
48171425|NCT06497712|OTHER|Hypnosis|Before the beginning of stitches, the patient will be offered a hypnotic induction. The hypnotic induction is the initial phase of the hypnosis process. Its goal is to bring the patient to a state of dissociation: the hypnotic trance. Induction is usually achieved through progressive relaxation, sensory focusing, and a process of confusion.
48171426|NCT02230293|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
48171427|NCT02230293|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
48171428|NCT04566198|OTHER|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
48171429|NCT00808899|DRUG|Temsirolimus|Temsirolimus
48171430|NCT00808899|DRUG|Irinotecan|Irinotecan
48171431|NCT00808899|PROCEDURE|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
48171432|NCT00808899|DRUG|Cyclophosphamide|Cyclophosphamide
48703365|NCT05118464|OTHER|Dual-task training|Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
48372203|NCT04004299|DIAGNOSTIC_TEST|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
48372204|NCT05588466|OTHER|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
48372205|NCT05588466|OTHER|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
48703366|NCT04427995|DEVICE|OMNI surgical system|GATT + viscodilation
48372206|NCT03550989|OTHER|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
48516403|NCT00725257|OTHER|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
48171433|NCT00808899|DRUG|Doxorubicin|Doxorubicin
48171434|NCT00808899|DRUG|Etoposide|Etoposide
48171435|NCT00808899|DRUG|Cisplatin|Cisplatin
48171436|NCT00808899|DRUG|Topotecan|Topotecan
48171437|NCT00808899|PROCEDURE|PBSC|Peripheral Blood Stem Cell Harvest
48171438|NCT00808899|RADIATION|Radiation Therapy|Radiation Therapy
48171439|NCT00808899|DRUG|13-cis-retinoic acid|13-cis-retinoic acid
48171440|NCT05523479|BEHAVIORAL|Traditional online education|A 30-60 minute, online, interactive, educational video that is customized to each provider type and offered with provider-specific continuing education credits
48516404|NCT00271401|OTHER|Angioplasty|
48703367|NCT05430191|OTHER|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
48372207|NCT03550989|OTHER|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
48372208|NCT01642862|DRUG|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
48516405|NCT00271401|OTHER|Intracoronary Stent|
48703368|NCT06430957|OTHER|The STOP-BANG questionnaire for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
48014938|NCT06162741|BEHAVIORAL|Moving Forward (MF)|"Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion."
48014939|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
48014940|NCT01276327|DRUG|Linagliptin + Pioglitazone|Medium doses, oral administration
48014941|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
48014942|NCT01276327|DRUG|Linagliptin/Pioglitazone|Medium dose oral administration
48516406|NCT00271401|DRUG|Abxicimab|
48703369|NCT06430957|OTHER|ASA recommended criteria for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
48014943|NCT03162861|DRUG|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
48014944|NCT03162861|DRUG|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
48014945|NCT01545817|DRUG|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
48014946|NCT06390475|DIAGNOSTIC_TEST|MR Direct Thrombus Imaging (MRDTI)|Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
48014947|NCT05621239|BIOLOGICAL|BNT162b2|BNT162b2 half dose and full dose
48014948|NCT02568410|PROCEDURE|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
48014949|NCT03306264|DRUG|ASTX727|ASTX727 oral tablet
48014950|NCT03306264|DRUG|Dacogen|Decitabine 20 mg/m\^2 one-hour IV infusion
48014951|NCT04279834|BEHAVIORAL|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
48014952|NCT04279834|BEHAVIORAL|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
48372209|NCT01607489|RADIATION|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
48372210|NCT00006401|DRUG|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
48372211|NCT00006401|OTHER|Placebo|Inhaled Nitrogen
48372212|NCT00505765|DRUG|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
48372213|NCT00505765|DRUG|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
48372214|NCT00505765|DRUG|Placebo|Placebo- 3 sprays in each nostril, twice per day
48372215|NCT00505765|DRUG|Placebo|Placebo- one spray in each nostril, once per day
48516407|NCT00271401|DRUG|Heparin|
48516408|NCT00271401|DRUG|Placebo|
48516409|NCT01072617|DEVICE|Transcranial magnetic stimulation via MagPro x100 device|"Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system."
48516410|NCT05235516|DRUG|AK104|q3w iv
48516411|NCT05235516|RADIATION|EBRT|45-50.4Gy
48703370|NCT06430957|OTHER|Record of postoperative complications|Respiratory complications as laryngospasm/bronchospasm, apnea, hypoxia, duration and amount of need for additional oxygen support and recovery time (duration of modified aldrete score of 9 and above) will be recorded.
48171441|NCT05523479|BEHAVIORAL|Interprofessional education|Interprofessional education (IPE) consists of both classroom-based IPE and just-in-time IPE. In classroom-based IPE, a trained physician educator with content expertise who works in the ICU leads a 60-to-90-minute, in-person, IPE workshop consisting of a 30-minute didactic session and a 30-to-60-minute small group session, during which participants work together to apply the content to authentic cases. The workshops, which are designed according to modern principles of adult learning and IPE, present the rationale and evidence supporting the preventive, post-extubation therapies. They are specifically designed to foster authenticity, reinforce role identity, and relate the content to life experience. In just-in-time IPE, trained local champions meet with the interprofessional ICU team each morning to identify eligible patients and, as needed, briefly review the evidence supporting proper use of the assigned preventive, post-extubation strategy.
48171442|NCT05523479|BEHAVIORAL|Clinical protocol|"An adequately explicit protocol provides specific rules for use of the preventive, post-extubation therapy based on patient data. A ready-to-customize version of the protocol with instructions to work with key local stakeholders to revise the protocol, accounting for local needs and resources, is provided. After local customization, a local champion then disseminates the protocol based on local practices."
48703371|NCT03817463|DRUG|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
48171443|NCT05523479|OTHER|Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation NIV for high-risk patients and preventive post-extubation HFNC for low-risk patients
48171444|NCT05523479|OTHER|Preventive post-extubation high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation HFNC for all eligible patients (without risk stratification)
48372216|NCT04907201|PROCEDURE|Cryoneurotomy|Cryoneurotomy or application of a low temperature probe with guidance of ultrasound which is offered to the patients with lower limbs refractory spasticity as a part of their medical cares.
48372217|NCT03240042|PROCEDURE|nasotracheal intubation|The participants either receive intubation via nasal route.
48372218|NCT03240042|PROCEDURE|orotracheal intubation|The participants either receive intubation via oral route.
48372219|NCT00000172|DRUG|Galantamine|
48372220|NCT03933358|OTHER|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
48372221|NCT05246852|BEHAVIORAL|healthy lifestyle education|A total of 6 sessions on physical activity, nutrition, substance abuse, sexual life, check-up, accidents and injuries will be organized for the adolescents in the intervention group. The sessions will be organized every other week. Each session will be conducted in three stages. First Stage: The researcher will provide training on the subject of the session for nearly 15 minutes. Second Stage: The researcher will show animation film (nearly 3 to 5 minutes) developed by him/her related to the session. Third Stage: Groups of six will be created for the Philips 66 technique application and a spokesman will be chosen. Each group will have an online meeting and discuss the session subject in six minutes under the administration of the researcher. The spokesman of each group will present the discussion outcome in the big group meeting at the end of the discussion. The researcher will summarize the subject after the presentation of each spokesman and terminate the session.
48372222|NCT01708369|DRUG|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
48703372|NCT03817463|DRUG|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
48703373|NCT05205538|OTHER|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
48703374|NCT06320249|OTHER|High-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
48372223|NCT01708369|DRUG|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
48372224|NCT01708369|DRUG|Oseltamivir|Oseltamivir 150 mg orally
48372225|NCT01708369|DRUG|Aspirin|Aspirin 650 mg orally will be given
48372226|NCT05586789|DRUG|Ranquilon|Two 1 mg tablets 3 times per day for 28 days
48372227|NCT05586789|DRUG|Placebo|Two tablets 3 times per day for 28 days
48372228|NCT02996266|DEVICE|Targeted Temperature Management|Prophylactic normothermia
48372229|NCT02996266|OTHER|Standard Care|No intervention to control temperature unless fever occurs
48372230|NCT03108352|DRUG|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)
48516412|NCT05235516|RADIATION|BT|≥80Gy
48516413|NCT05235516|DRUG|cisplatin|qw iv
48516414|NCT05235516|DRUG|Placebo|q3w iv
48703375|NCT06320249|OTHER|Low-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
48372231|NCT03108352|OTHER|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 \~ 11)
48372232|NCT02497274|OTHER|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
48372233|NCT04476641|OTHER|CELL|inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
48372234|NCT05818475|OTHER|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
48372235|NCT05818475|OTHER|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
48372236|NCT01966029|DRUG|BMN 110|All pateints receive treatment with BMN 110
48372237|NCT00054821|PROCEDURE|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
48372238|NCT00054821|PROCEDURE|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
48372239|NCT04052711|DRUG|FMX-101|
48372240|NCT04228718|BEHAVIORAL|Zarit Burden Interview Scale|It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.
48372241|NCT04228718|BEHAVIORAL|Family Needs Survey (FNS)|It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.
48372242|NCT04228718|OTHER|Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)|CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.
48372243|NCT04228718|OTHER|Hammersmith Functional Motor Scale Expanded (HMFSE)|It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.
48372244|NCT03319368|OTHER|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
48372245|NCT02115802|DEVICE|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
48372246|NCT02440490|BEHAVIORAL|Computerised cognitive training|
48372247|NCT02440490|BEHAVIORAL|Video watching|
48372248|NCT03939429|DRUG|QPX2015|antibiotic
48372249|NCT03939429|DRUG|Placebo oral capsule|Placebo comparator
48372250|NCT01142362|BIOLOGICAL|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
48703376|NCT06320249|OTHER|Cervical traction|The procedure for cervical traction is as follows: The patient assumes a sitting position, and a cervical traction device with a chin strap is applied. The patient is instructed to slightly flex their head forward, approximately 10-15 degrees, based on their comfort level and symptom relief. Traction force starts at 3 kg and increases gradually in increments of 0.5 kg, with a maximum weight not exceeding 6 kg. The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
48703377|NCT03466099|DRUG|KVD001 Injection|Intravitreal KVD001 Injection
48703378|NCT03466099|OTHER|Sham Procedure|Sham Procedure
48372251|NCT02110966|DRUG|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
48703379|NCT01839591|DEVICE|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
48372252|NCT02110966|DRUG|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
48372253|NCT04704791|PROCEDURE|PA-LAA shunt|At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.
48372254|NCT01388322|DRUG|Enoxaparin|40 mg (4000 IU) women \<80 kg at the time of randomization or 60 mg (6000 IU) women\> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
48372255|NCT03310281|DEVICE|HOLD: Videogame|Videogame-like digital therapy
48372256|NCT01582932|DRUG|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
48372257|NCT03744858|PROCEDURE|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
48372258|NCT02696980|DEVICE|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
48372259|NCT01488695|DEVICE|GlideScope Groove|GlideScope Groove
48372260|NCT01488695|DEVICE|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
48372261|NCT06332677|DIAGNOSTIC_TEST|the main genes and expression by comparing the transcriptomic lipidomic profile|To identify the main genes and pathways differentially expressed and the main factors associ- ated in order to evaluate the role of SUV420H1/H2
48171445|NCT03181282|BEHAVIORAL|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
48372262|NCT01323829|OTHER|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
48372263|NCT04129879|PROCEDURE|ABC technique|The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
48372264|NCT00618046|DRUG|Oxcarbazepine|
48372265|NCT02967393|DRUG|ccIIV4|
48372266|NCT02967393|DRUG|IIV4|
48372267|NCT01605370|DRUG|Nebivolol|Nebivolol 2.5 mg once daily
48703380|NCT03800342|OTHER|Aerobic Exercise Training|see arm/group description
48703381|NCT04397003|BIOLOGICAL|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, PapiVax Biotech). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
48703382|NCT04397003|DRUG|Durvalumab|-Supplied by AstraZeneca
48703383|NCT04397003|DEVICE|TDS-IM v2.0 Device|-Integrated electroporation administration system
48703384|NCT04397003|PROCEDURE|Peripheral blood draws|-Pre-treatment, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine
48703385|NCT05504265|DRUG|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
48703386|NCT05504265|DRUG|Postoperative flurbiprofen axetil|50mg bid
48703387|NCT05504265|DEVICE|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
48703388|NCT05940363|COMBINATION_PRODUCT|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
48703389|NCT01065194|DRUG|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
48703390|NCT01065194|DRUG|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
48703391|NCT05853107|DEVICE|AuTNA I|AuTNA I means Au nanoparticle-decorated TiO2 Nanowire Arrays, a retinal prothesis designed for subretinal implantation.
48703392|NCT05925413|DRUG|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
48703393|NCT03537248|DEVICE|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
48703394|NCT03537248|DEVICE|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
48171446|NCT02596399|DRUG|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
48171447|NCT02596399|DRUG|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
48171448|NCT02204319|DEVICE|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
48372268|NCT01605370|DRUG|Metoprolol succinate|Metoprolol succinate 50 mg once daily
48372269|NCT02613910|DRUG|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
48372270|NCT02613910|DRUG|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
48372271|NCT02613910|DRUG|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
48372272|NCT02613910|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
48703395|NCT06110858|BEHAVIORAL|Tinkering Activities|Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
48703396|NCT06379958|DRUG|leramistat 40mg|Oral capsule
48171449|NCT02650206|DRUG|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
48171450|NCT02650206|OTHER|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
48171451|NCT01919177|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
48171452|NCT01919177|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
48171453|NCT05808855|PROCEDURE|two-component skin adhesive Glubran Tiss 2®|After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.
48171454|NCT05808855|PROCEDURE|skin stitched with transcutaneous nylon suture|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
48171455|NCT05871190|OTHER|İnjectable platelet rich fibrin|I-PRF is a type of platelet-rich fibrin (PRF) product obtained from the patient's own blood. PRF is a kind of tissue regeneration product of blood, rich in platelets, growth factors and cellular components.
48171456|NCT05871190|PROCEDURE|Gingivectomy anad gingivoplasty|leveling and regulation of the gingiva
48171457|NCT03618706|RADIATION|Involved-field radiotherapy|After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.
48171458|NCT00006145|DRUG|Valganciclovir|
48171459|NCT04317001|DRUG|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
48171460|NCT04317001|DRUG|Placebo|placebo
48171461|NCT06236828|DEVICE|Mechanical Thrombectomy|The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
48171462|NCT02562144|DRUG|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
48703397|NCT06379958|DRUG|Itraconazole 200 mg|Oral capsule
48703398|NCT06379958|DRUG|Phenytoin 100 Mg Oral Capsule|Oral capsule
48703399|NCT06379958|DRUG|Simvastatin 40mg|Oral capsule
48703400|NCT06379958|DRUG|Upadacitinib 15 MG|Oral Capsule
48171463|NCT02562144|DRUG|Placebo|Cutaneous placebo before intravenous cannulation.
48171464|NCT03714542|OTHER|Pre- and postoperative MRI|
48171465|NCT02998619|RADIATION|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
48171466|NCT02459236|DRUG|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
48171467|NCT02459236|DRUG|Placebo|
48171468|NCT06414005|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts (TPX-115)
48171469|NCT06414005|OTHER|Placebo (Saline)|Ultrasound-guided intratendinous placebo injection
48171470|NCT01351883|DIETARY_SUPPLEMENT|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
48171471|NCT00429078|GENETIC|2nd Generation Designer T Cells|
48703401|NCT06602050|OTHER|HG and NIF|In mechanically ventilated patients, handgrip strength, the Negative Inspiratory Force (NIF) value obtained via the ventilator, and physical function through various tests will be assessed.
48703402|NCT05419128|BEHAVIORAL|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the FamCHESS-C app but not in ACHESS-C:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between drinker and partner to follow key principles. Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
48703403|NCT05419128|BEHAVIORAL|ACHESS|ACHESS-C offers the following, which are also available in FamCHESS-C: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
48703404|NCT05496452|DIETARY_SUPPLEMENT|Beta-lactoglobulin|Beta-lactoglobulin (BLG) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
48171472|NCT03822195|PROCEDURE|Carotid endoarterectomy|Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
48171473|NCT02046447|DRUG|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
48372273|NCT01194076|BEHAVIORAL|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
48372274|NCT02456272|DEVICE|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
48372275|NCT02456272|PROCEDURE|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
48703405|NCT05496452|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate (dextrose monohydrate) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
48372276|NCT02247726|DRUG|Saline Placebo (0.5mL injection)|
48372277|NCT02247726|DRUG|RSV F vaccine (0.5mL injection)|
48372278|NCT04823494|DEVICE|Hearing aids|Earbud style hearing aids fit to both ears
48703406|NCT04016558|BEHAVIORAL|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
48372279|NCT03798652|DEVICE|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
48372280|NCT03798652|DEVICE|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
48372281|NCT03798652|OTHER|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
48372282|NCT00043134|DRUG|decitabine|
48372283|NCT00561795|DRUG|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
48703407|NCT04016558|BEHAVIORAL|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
48372284|NCT00561795|DRUG|carboplatin|IV over one hour every 3 weeks of 6 cycles
48372285|NCT00561795|DRUG|paclitaxel|IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
48372286|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
48372287|NCT01465958|BIOLOGICAL|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
48372288|NCT05500911|PROCEDURE|sinus lift|when residual bone height is \>4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will be placed in the sinus cavity.
48372289|NCT05500911|PROCEDURE|implant placement|Implant will be placed in edentulous area
48372290|NCT02329834|DRUG|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
48372291|NCT02329834|DRUG|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
48372292|NCT05147766|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48372293|NCT00394862|DRUG|multivitamin|
48372294|NCT04914650|OTHER|Telerehabilitation|Providing multidisciplinary rehabilitation to individuals with spinal cord injury or brain injury using virtual conference methods
48372295|NCT01453296|DRUG|GW642444|GW642444 25 μg; Novel dry powder inhaler
48372296|NCT01453296|DRUG|Placebo|Matching placebo; Novel dry powder inhaler
48372298|NCT03613974|DRUG|Lidocaine|patients will receive different lidocaine concentrations
48372299|NCT01973205|DRUG|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
48372300|NCT01973205|DRUG|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
48372301|NCT01121224|DEVICE|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
48372302|NCT01121224|DEVICE|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
48372303|NCT01121224|DRUG|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
48372304|NCT01121224|DRUG|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
48516415|NCT00577603|PROCEDURE|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
48516416|NCT00577603|OTHER|no intervention|
48014953|NCT04122001|DEVICE|Active HD-tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
48014954|NCT04122001|DEVICE|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
48014955|NCT04122001|OTHER|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
48014956|NCT05440682|PROCEDURE|CP group|Pre- post-cranioplasty and 6 months follow-up MRI assessment. Each MRI session lasts about 60 minutes and will measure Diffusion Tensor Imaging, Tractography and resting state fMRI.
48014957|NCT05403554|DRUG|Biological NI-1801|Treatment will be administered in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Each subject will receive the assigned dose of NI-1801 on Cycle 1, Day 1. Subsequent doses will be given Q2W, which may be adjusted to every three weeks if recommended from the ongoing PK/PD model analysis.
48014958|NCT05403554|DRUG|NI-1801 in combination with anti-PD1 (Pembrolizumab)|In the combination with pembrolizumab cohort, the starting NI-1801 dose will be 300 mg. Pembrolizumab will be administered at the dosage of 400 mg every 6 weeks, in 4 cycles. Pembrolizumab will be administered as first drug; later, NI-1801 will be infused after 30 minutes.
48014959|NCT05403554|DRUG|NI-1801 in combination with paclitaxel|The experimental arm will receive the investigational drug NI-1801 at the P2RD every two weeks in combination with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles. The control arm will be treated with weekly paclitaxel at the same regimen.
48372305|NCT01121224|DRUG|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
48372306|NCT04159610|DRUG|WO3970|Application of cream to each axilla
48372307|NCT04159610|DRUG|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
48372308|NCT03658031|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
48372309|NCT02479594|BEHAVIORAL|competence-feedback|competence-feedback
48516417|NCT04725851|PROCEDURE|High concentration Oxygen therapy|FiO2 \>80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
48516418|NCT04725851|PROCEDURE|Control: Room Air or Low concentration Oxygen|FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
48516419|NCT00658047|DRUG|CH-1504|Comparison of different doses of CH-1504
48516420|NCT00658047|DRUG|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
48372310|NCT02479594|OTHER|control|control group without competence-feedback
48372311|NCT00020995|PROCEDURE|therapeutic dietary intervention|
48372312|NCT02452892|DEVICE|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
48372313|NCT05919940|DIETARY_SUPPLEMENT|Dietary Supplement: additional substitution of protein|"Day one (admission) no nutrition is applied.~Protein target is increased as follows:~* to a level of 1,2g/kg/d on day 1 after ICU admission~* to a level of 1,4g/kg/d on day 2 after ICU admission~* to a level of 1,6g/kg/d on day 3 after ICU admission~* to a level of 1,8g/kg/d on day 4 after ICU admission~* to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~* to 0,125g/kg/d on day 1 after ICU admission~* to 0,2g/kg/d on day 2 after ICU admission~* to 0,25g/kg/d on day 3 after ICU admission~* to 0,3g/kg/d from day 4 after ICU admission onwoards"
48372314|NCT05919940|DEVICE|Neuromuscular electrical stimulation|twice daily 60 minutes till day 28 or ICU discharge
48372315|NCT05919940|OTHER|Early Mobilization|at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
48372316|NCT00032058|PROCEDURE|magnetic resonance imaging|
48372317|NCT00032058|PROCEDURE|magnetic resonance spectroscopic imaging|
48372318|NCT04881669|DEVICE|obturator|variable bulbs
48372319|NCT04353323|OTHER|Blood sampling|3 blood samples (D0, D15 and D30) will be taken from each participant
48703408|NCT04016558|BEHAVIORAL|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
48703409|NCT02834585|OTHER|Ultrasound|
48372320|NCT02928198|DEVICE|ABSORB BVS|
48372321|NCT04027582|OTHER|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
48372322|NCT03335189|DEVICE|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
48372323|NCT02628184|OTHER|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
48372324|NCT02906527|DRUG|Non-exposed group|Non-exposed group / Patients receiving VKA
48372325|NCT02906527|DRUG|Exposed group|Exposed group / Patients receiving DOAC
48703410|NCT01447485|DRUG|Valsartan (VAL489)|
48703411|NCT01773551|OTHER|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
48516421|NCT00030472|DRUG|pegylated liposomal doxorubicin hydrochloride|
48516422|NCT03886298|PROCEDURE|radiofrequency splanchnic denervation|the authors will denervate the splanchnic nerves via radiofrequency
48516423|NCT03886298|PROCEDURE|retrocrural celiac denervation|the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
48703412|NCT02654431|PROCEDURE|Breast Cancer patient|Samples
48372326|NCT01463059|BIOLOGICAL|Placebo|Placebo solution for injection, administered as subcutaneous injections
48372327|NCT01463059|BIOLOGICAL|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
48703413|NCT02654431|PROCEDURE|Cancer patients|Samples
48171474|NCT02046447|OTHER|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
48372328|NCT01463059|BIOLOGICAL|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
48372329|NCT01463059|BIOLOGICAL|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
48372330|NCT04079699|DIAGNOSTIC_TEST|Liquid Biopsy|Measuring biomarkers in blood and urine samples
48703414|NCT02657655|DEVICE|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
48372331|NCT04079699|DIAGNOSTIC_TEST|Standard biopsy|Histological examination of tissue biopsies
48372332|NCT04660929|BIOLOGICAL|CT-0508|anti-HER2 CAR macrophages
48372333|NCT04660929|BIOLOGICAL|Pembrolizumab|anti-PD antibody
48703415|NCT04220242|OTHER|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
48703416|NCT04220242|OTHER|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
48703417|NCT04220242|OTHER|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
48703418|NCT06605755|PROCEDURE|Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine|"The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age."
48703419|NCT06302140|DRUG|[14C]-Nanatinostat|A single oral dose administered on Day 1 in a fasted state.
48703420|NCT06302140|DRUG|Nanatinostat (free base) tablets in combination with Valganciclovir|Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
48703421|NCT06302140|DRUG|Nanatinostat mesylate tablets in combination with Valganciclovir|Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
48703422|NCT06302140|DRUG|Single-agent Nanatinostat (free base) tablets|40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
48703423|NCT01846676|BEHAVIORAL|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
48703424|NCT01846676|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
48372334|NCT00031902|BIOLOGICAL|bleomycin sulfate|
48372335|NCT00031902|BIOLOGICAL|rituximab|
48372336|NCT00031902|DRUG|prednisolone|
48372337|NCT00031902|DRUG|vincristine sulfate|
48516424|NCT01573299|OTHER|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
48516425|NCT05129631|BEHAVIORAL|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
48516426|NCT00181701|DRUG|Paclitaxel|
48703425|NCT05827549|DRUG|Blincyto|Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
48372338|NCT04361669|OTHER|Medication safety review|Implementation of a medication safety review using a clinical decision support system
48516427|NCT00181701|DRUG|Carboplatin|
48703426|NCT05304117|BEHAVIORAL|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
48372339|NCT00288431|DRUG|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
48372340|NCT00288431|DRUG|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
48703427|NCT05906758|PROCEDURE|Angiography|Coronary angiography with less than 20cc of contrast materials
48703428|NCT00385944|DRUG|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
48703429|NCT00385944|DRUG|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
48372341|NCT02331680|DRUG|OPC-41061|
48372342|NCT02331680|DRUG|OPC-41061|
48372343|NCT02331680|DRUG|Placebo|
48703430|NCT00549900|BIOLOGICAL|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
48703431|NCT01814098|DRUG|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
48703432|NCT05802082|OTHER|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
48703433|NCT05893771|DRUG|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
48703434|NCT05893771|DRUG|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
48703435|NCT05893771|DRUG|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
48014960|NCT05403554|DRUG|Paclitaxel|The control arm will be treated with weekly administration of paclitaxel (80 mg/m\^2) over 4-week cycles.
48014961|NCT00219128|DRUG|aliskiren|
48171475|NCT02046447|OTHER|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
48372344|NCT01546311|DEVICE|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
48372345|NCT04952792|DRUG|Apixaban 2.5 milligram Oral Tablet|Apixaban 2.5mg/12h, oral, 28 days
48372346|NCT03441828|PROCEDURE|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
48372347|NCT03441828|DRUG|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
48372348|NCT03441828|DRUG|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
48372349|NCT06269562|PROCEDURE|Serratus posterior superior intercostal plane block and clavipectoral plane block|The analgesic effectiveness achieved by the concurrent application of these two techniques was investigated.
48372350|NCT04117282|OTHER|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
48372351|NCT01639846|DRUG|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
48372352|NCT01639846|DRUG|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
48372353|NCT02087020|PROCEDURE|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.
48372354|NCT02720627|DRUG|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
48372355|NCT00031265|PROCEDURE|Family Intervention Telephone Tracking|
48372356|NCT03831282|DEVICE|RD SET Neo SpO2|All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
48372357|NCT01884142|OTHER|Aerobic Exercise Training|
48372358|NCT06518148|DIAGNOSTIC_TEST|1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)|diagnostic test;UCVA, IOP, Electrophysiological study
48372359|NCT01007227|OTHER|Lifestyle instruction|Instruction dietetic and exercise therapy
48372360|NCT00579059|DEVICE|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
48372361|NCT00579059|DEVICE|Regular Maxim® Knee System|Used for total knee replacements
48372362|NCT01712529|BEHAVIORAL|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
48372363|NCT02554409|BIOLOGICAL|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
48703436|NCT01425359|DRUG|Ranolazine|
48703437|NCT01425359|DRUG|Ranolazine placebo|
48372364|NCT04583410|DRUG|Nicotine patch|"NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
48703438|NCT04485611|BEHAVIORAL|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
48703439|NCT03362060|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
48014962|NCT04837794|DEVICE|Digital Pain-Management Tool|Digital Pain-Management Tool
48014963|NCT00607945|DRUG|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
48171476|NCT02046447|OTHER|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
48372365|NCT04583410|DRUG|Placebo patch|"PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day"
48372366|NCT00132665|PROCEDURE|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
48014964|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
48014965|NCT00607945|DIETARY_SUPPLEMENT|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
48372367|NCT00132665|DRUG|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
48372368|NCT00042575|DRUG|Duloxetine|
48703440|NCT03362060|BIOLOGICAL|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
48703441|NCT06607458|DRUG|Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab|Trifluridine-tipiracil plus Bevacizumab Alone
48703442|NCT06607458|DRUG|Trifluridine-tipiracil plus Bevacizumab Alone|Trifluridine-tipiracil plus Bevacizumab Alone
48703443|NCT06581614|DIAGNOSTIC_TEST|masticatory function test|During the test, participants will be given a piece of chewing gum to assess their masticatory function when the second molar implant-supported fixed denture is in place.
48703444|NCT01997957|DRUG|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
48703445|NCT05745987|DRUG|Bavarian Nordic smallpox vaccine|A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
48703446|NCT05745987|DRUG|Typhoid VI Polysaccharide Vaccine Injectable Solution|A single dose of the typhoid vaccine will be given at baseline.
48014966|NCT03484819|DRUG|Copanlisib Hydrochloride|Given IV
48014967|NCT03484819|BIOLOGICAL|Nivolumab|Given IV
48014968|NCT00103792|DRUG|mycophenolate mofetil|2000 mg mycophenolate mofetil per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
48014969|NCT00103792|DRUG|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
48014970|NCT03569644|OTHER|qualitative study|Interviews
48014971|NCT04329962|OTHER|Blueberry Powder Food Product|Consume blueberry powder confection
48372369|NCT01654666|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
48372370|NCT01654666|PROCEDURE|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
48372371|NCT01654666|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
48372372|NCT01003691|BIOLOGICAL|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
48372373|NCT01003691|BIOLOGICAL|Placebo|Intravenous, multiple dose with experimental dose
48372374|NCT03518996|DEVICE|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
48372375|NCT03518996|DEVICE|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
48703447|NCT01275612|BIOLOGICAL|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
48014972|NCT04329962|OTHER|Dietary Intervention|Consume blueberry extract confection
48703448|NCT06606496|DEVICE|Bispectral index (BIS)|The bispectral index (BIS) monitor is a quantitative electroencephalographic (EEG) device that is widely used to assess the hypnotic component of anaesthesia, especially when neuromuscular blocking drugs are used. If necessary, it may be necessary to increase or decrease MAC (minimum alveolar concentration) in the testosterone group according to the BIS monitoring value.
48014973|NCT04329962|OTHER|Questionnaire Administration|Ancillary studies
48372376|NCT01642472|DRUG|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
48372377|NCT04825639|OTHER|No intervention|no intervention
48372378|NCT05398939|DIAGNOSTIC_TEST|Blood test and skin evaluation|The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
48372379|NCT02815007|DRUG|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
48372380|NCT03803956|DEVICE|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
48372381|NCT03803956|DEVICE|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
48372382|NCT04678557|COMBINATION_PRODUCT|VC-01 Combination Product|PEC-01 cells loaded into an Encaptra Drug Delivery System
48703449|NCT04644796|DRUG|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
48372383|NCT04677738|DIETARY_SUPPLEMENT|B. breve|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.
48372384|NCT04677738|DIETARY_SUPPLEMENT|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
48372385|NCT00689728|BIOLOGICAL|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
48372386|NCT00689728|DRUG|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
48372387|NCT03099096|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
48372388|NCT06463132|COMBINATION_PRODUCT|PEP/Euflexxa|Euflexxa (PMA: P010029)
48372389|NCT06463132|DRUG|PEP|PEP (Purified Exosome Product)
48372390|NCT03860870|DRUG|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
48703450|NCT04644796|DRUG|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
48014974|NCT05078645|DEVICE|Maya|The Maya is a cover which can be placed over the end of the patients bed. The Maya aims to reduce light and sound nuisances and enhance patients' privacy
48014975|NCT05114941|DEVICE|immunosorbent column|Immunoadsorption treatment regimen: the treatment is performed once every 1-3 days, at least 5 times, and the amount of regenerated plasma for each treatment is 1 to 3 times the plasma volume. The immunosorbent column adopts the protein A immunosorbent column.
48171477|NCT05639478|OTHER|Foot-related exercises|Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet, in addition to self-care recommendations and foot care by international consensus. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
48171478|NCT06483386|DRUG|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
48171479|NCT03269695|DRUG|PF-06687234|SC QW
48703451|NCT03554057|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
48703452|NCT04543266|PROCEDURE|Surgery|Resection of tumors
48703453|NCT06116552|BEHAVIORAL|More Social Stories|Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
48703454|NCT06116552|BEHAVIORAL|Less Social Stories|Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
48014976|NCT05114941|DRUG|intravenous immunoglobulin|Intravenous immunoglobulin treatment regimen: intravenous immunoglobulin therapy, 400mg/kg/d, once a day, for at least 5 consecutive days.
48014977|NCT04619316|DRUG|Trametinib 2 MG [Mekinist]|Monotherapy with Trametinib is given in patients with BRAF wildtype.
48171480|NCT03269695|DRUG|Placebo|SC QW
48372391|NCT03860870|DRUG|Placebo|Subjects ingest placebo tablets
48516428|NCT05110820|DIAGNOSTIC_TEST|Automated quantitative pupillometer|Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
48703455|NCT02409004|DRUG|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
48703456|NCT02409004|DRUG|Rifampin|Capsule 2x3oo mg Oral
48703457|NCT00146419|BEHAVIORAL|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
48703458|NCT03781323|DRUG|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
48703459|NCT00801489|DRUG|Cytarabine|Given IV
48703460|NCT00801489|DRUG|Decitabine|Given IV
48014978|NCT04619316|DRUG|Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]|Combination therapy is given in patients with BRAF V600E mutation.
48372392|NCT00272194|DEVICE|Ambu Laryngeal Mask|
48516429|NCT00098423|DRUG|tanespimycin|Given IV
48516430|NCT00098423|DRUG|cytarabine|Given IV
48703461|NCT00801489|BIOLOGICAL|Filgrastim-sndz|Given SC
48703462|NCT00801489|DRUG|Fludarabine Phosphate|Given IV
48703463|NCT00801489|DRUG|Gemtuzumab Ozogamicin|Given IV
48703464|NCT00801489|DRUG|Idarubicin|Given IV
48703465|NCT00801489|OTHER|Laboratory Biomarker Analysis|Correlative studies
48014979|NCT05489094|COMBINATION_PRODUCT|Nutrition Education and Growing Up Milk for 1 - 3 years old|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories. while Intervention product is formulated to deliver macro- and micronutrients as part of the dietary intake for children at 1-3 years old with Iron-C formula
48014980|NCT05489094|BEHAVIORAL|Nutrition Education|Nutrition education is a basic information related balanced nutrition for 1 - 3 children including the details of food types and calories.
48372393|NCT00272194|DEVICE|Aintree Exchange Catheter|
48372394|NCT00272194|DEVICE|Laryngeal Mask Airway|
48703466|NCT04348565|OTHER|Diabetes Care Programme|20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
48014981|NCT03376477|BIOLOGICAL|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
48014982|NCT03376477|DRUG|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
48014983|NCT03376477|DRUG|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
48014984|NCT03376477|OTHER|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
48171481|NCT02035098|OTHER|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
48171482|NCT05590962|OTHER|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥1 for Stage IV cancer patients and ≥2 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
48171483|NCT04693845|BEHAVIORAL|Collaborative Assessment and Management of Suicidality|"CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings."
48171484|NCT04693845|BEHAVIORAL|Treatment as Usual|Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
48014985|NCT03376477|OTHER|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
48014986|NCT05463224|DRUG|Lazertinib group|Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
48014987|NCT05124873|DEVICE|Moisture Management Liner|A prototype liner designed to reduce heat that builds up on the limb.
48014988|NCT05801159|DIAGNOSTIC_TEST|Positron Emission Tomography-Computerised Tomography (PET-CT)|Injection of the 18F-fluoropivalate (18F-FPIA) radiotracer followed by a whole brain static PET-CT scan.
48014989|NCT05059457|DEVICE|Blood source: single and pooled capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+.~* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
48171485|NCT02714699|DRUG|diclofenac potassium|patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
48703467|NCT05614908|OTHER|11 week restrictive regime|"As part of standard care at AUH (until May 2024), patients are immobilized in scotch cast with the foot in plantarflexion during week 0-4. Next, the scotch cast is replaced by a ROM-WALKER in plantarflexion for the next 7 weeks (week 5-11 after injury). The ROM-WALKER is gradually corrected from 30 degrees plantarflexion to 0 degrees. No weight bearing or exercises is allowed and they are not allowed to remove the ROM-WALKER during week 0-10. At week 11, the patients are allowed weight bearing up to 30 kg, after which there is no longer weight bearing restrictions.~From week 12 they are allowed full weight bearing with a 1 cm heel lift i their shoes."
48703468|NCT05614908|OTHER|8 week liberal regime|"The patients are treated with a walker orthosis with 3 wedges in plantarflexion, during week 1-2 with no weight bearing and no exercises. After 2 weeks, the tendon will be examined, and if no defect in the tendon is detected by palpation, the patients will start partially weight bearing in week 3-5, and full weight-bearing week 6-8. They are instructed in unloaded exercises for the calf and anklejoint after 2 weeks, and loaded exercises (elastic) after 5 weeks, with a maximum position til 0 degrees in the anklejoint. Balancetraining and stationary bike training after 7 weeks. The wedges are removed one by one after 3, 5 and 7 weeks, respectively.~If there is a palpable defect in the tendon after 2 weeks, the patient must wait 1 week with partially weight bearing and exercises, and remove the wedges at 4, 5 and 7 weeks after the initiation of treatment.~From week 9, walking i their shoes with a 1 cm heel lift."
48703469|NCT00001250|DRUG|preoperative dose intense chemotherapy (FLAC/G-CSF)|
48171486|NCT02714699|DRUG|hyoscine butyl bromide|patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
48171487|NCT02714699|DRUG|placebo|patients will take oral placebo; 2 tablets one hour before the procedure
48372395|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)"
48516431|NCT04117802|OTHER|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
48703470|NCT03102047|DRUG|durvalumab|Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
48703471|NCT00628472|DRUG|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
48703472|NCT01666535|BIOLOGICAL|Influenza vaccination|
48014990|NCT05059457|DEVICE|Blood source: single capillary and venous blood|"* A single drop of capillary blood (blood drop #3) will be placed in a microcuvette directly from a finger/heel and tested using a HemoCue 201+ .~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
48014991|NCT05059457|DEVICE|Blood source: pooled capillary and venous blood|"* Pooled capillary blood will be placed in a Microtainer® tube (250-500 µL) containing EDTA and then a drop of blood placed in a microcuvette and tested using a HemoCue 201+.~* Venous blood will be collected into a 3mL Vacutainer tube containing EDTA and then a drop of blood will be placed in a microcuvette and tested using a HemoCue 201+ and autoanalyzer."
48014992|NCT04475393|DEVICE|Carmat Total Artificial Heart|Heart Replacement Therapy
48014993|NCT02575781|DRUG|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
48014994|NCT03613506|DRUG|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
48014995|NCT02147808|DRUG|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
48014996|NCT02147808|DRUG|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).
48014997|NCT03511560|DRUG|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
48014998|NCT03511560|DRUG|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
48014999|NCT03755024|DEVICE|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length"
48015000|NCT06249100|PROCEDURE|flexible mini percutaneous nephrolithotomy|In Group A (flexible mini-PCNL cases), a puncture will be done under fluoroscopic guidance medial to the posterior axillary line using an 18-gauge puncture needle. The puncture will be directed horizontally or with a slight upward inclination towards the lower or middle calyx. After a successful puncture, a 0.035 Fr Super Stiff guidewire will be inserted. Tract dilatation with amplatz dilator followed by access sheath insertion. Stone disintegration will be done with the flexible mini-nephroscopy (WiScope Digital Endoscope System by OTU Medical, California, USA) which has a shaft length of 38 cm, distal tip diameter is 15.3 F tapering to 10 F, working channel inner diameter is 6.6 F, and the angle of deflection of the distal tip is 210 degrees.
48015001|NCT06249100|PROCEDURE|Retrograde intrarenal surgery|n Group B, Flexible ureteroscopy will be used with a ureteral access sheath and laser fragmentation of renal stones will be done
48372396|NCT00300976|BEHAVIORAL|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
48372397|NCT04201223|BEHAVIORAL|FLARE Intervention|\[See arm/group descriptions\]
48372398|NCT00142428|DRUG|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
48372399|NCT00848302|DRUG|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
48372400|NCT02569931|OTHER|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
48372401|NCT02569931|OTHER|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
48372402|NCT02569931|PROCEDURE|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
48372403|NCT00190385|PROCEDURE|Ultrasonographic screening|Ultrasonographic screening
48372404|NCT02550418|DRUG|Budesonide|
48015002|NCT04374474|OTHER|Olfactory retraining|Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
48015003|NCT04374474|DRUG|corticosteroid nasal irrigation|Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
48015004|NCT04374474|OTHER|smell household Items|Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items
48015005|NCT04374474|OTHER|Nasal Irrigation|Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
48015006|NCT03178058|OTHER|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
48015007|NCT00958880|BEHAVIORAL|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
48015008|NCT00958880|DRUG|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
48015009|NCT00958880|DRUG|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
48015010|NCT06167096|OTHER|Lavender essential oil|Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France
48015011|NCT06167096|OTHER|Water|Water
48015012|NCT03236844|DRUG|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
48015013|NCT01275183|DRUG|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
48015014|NCT06192602|BEHAVIORAL|AIM_AT|The program consists of 10 weekly/biweekly, 2-hour sessions (4-months), based on the modified Kemp's model/manual of Adherence therapy and mindfulness-based psychoeducation program developed by the research team.
48015015|NCT06192602|BEHAVIORAL|CPG|Psychoeducation group program (12-18 members/group) consists of 10 two-hour sessions, weekly/biweekly (similarly, 4-month duration) and is guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psychoeducation programs for psychosis.
48372405|NCT01794221|PROCEDURE|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
48372406|NCT01794221|PROCEDURE|stitches only|standard of care
48015016|NCT06192602|BEHAVIORAL|TAU|Routine/Usual care only (control) group participants (and the two treatment groups) will receive usual community mental healthcare services.
48015017|NCT00512096|DRUG|Ifosfamide|1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
48015018|NCT00512096|DRUG|Paclitaxel (Taxol)|175 mg/m\^2 By Vein Over 3 Hours on Day 1
48015019|NCT00512096|DRUG|Cisplatin|25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
48372407|NCT02500732|DRUG|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
48372408|NCT02500732|DRUG|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
48372409|NCT06498570|DEVICE|Intracorneal rings|The (ICRS), intracorneal rings segments implantation surgery
48372410|NCT00953576|DRUG|ketoconazole|
48372411|NCT00953576|DRUG|hydrocortisone|
48372412|NCT00953576|DRUG|dutasteride|
48372413|NCT00953576|DRUG|lapatinib|
48703473|NCT04385472|RADIATION|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
48703474|NCT03484156|DEVICE|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
48171488|NCT01165359|DRUG|ITX 5061|"For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days."
48171489|NCT01165359|DRUG|Placebo ITX 5061|"For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days."
48171490|NCT00003912|DRUG|carboplatin|
48703475|NCT02367274|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
48171491|NCT00003912|DRUG|cisplatin|
48372414|NCT01575158|DRUG|Citalopram|
48372415|NCT01575158|DRUG|Clomipramine|
48372416|NCT01575158|DRUG|placebo|
48372417|NCT02467504|DRUG|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
48703476|NCT05997095|OTHER|Neuromuscular electrical stimulation (NMES/0|NMES will be applied for 30 min and will be delivered using an approved, CE-marked device (Premier Combo Plus, Med-Fit Ltd, UK) using two large (7.5 × 13 cm) electrodes placed proximally and distally over the lateral quadriceps. The set protocols will be pre-programmed into to the device and the amplitude value will match the setting that was determined during a familiarisation visit
48015020|NCT04960228|BEHAVIORAL|Altruism Video|The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.
48015021|NCT04960228|BEHAVIORAL|COVID-19 Informational Text|The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
48015022|NCT06055088|OTHER|Hand and foot exercise|"The exercise group will participate in home-based hand and foot exercises for 8 weeks. The exercise program will start the week the first neuropathy symptom appears and continue for 8 weeks. The exercises, which will last for 8 weeks, will be performed 3 times a day and at least 3 times a week.~Patients in the massage ball group will be given a massage ball to be used in exercises. Patients in the stress ball group will be given a stress ball to be used in exercises."
48015023|NCT00337649|DRUG|Epothilone D|≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
48015024|NCT00337649|DRUG|Herceptin|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
48015025|NCT06300554|DEVICE|Healthy Minds Program App|freely available well-being app
48171492|NCT00003912|DRUG|doxorubicin hydrochloride|
48171493|NCT00003912|PROCEDURE|conventional surgery|
48171494|NCT04072445|DRUG|Irinotecan|Given IV
48171495|NCT04072445|DRUG|Irinotecan Hydrochloride|Given IV
48171496|NCT04072445|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
48372418|NCT02467504|DRUG|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
48372419|NCT02467504|DRUG|MTX|Methotrexate (oral administration)
48372420|NCT02467504|DRUG|Folic Acid|Folic Acid (oral administration)
48171497|NCT03134261|DIAGNOSTIC_TEST|WB-MRI|scanning methods
48171498|NCT03134261|DIAGNOSTIC_TEST|SPECT-CT|scanning methods
48171499|NCT03134261|DIAGNOSTIC_TEST|Cholin-PET-CT|scanning methods
48171500|NCT03134261|DIAGNOSTIC_TEST|PSMA-PET-CT|
48171501|NCT01077011|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
48171502|NCT01077011|OTHER|GenTeal Gel|1 drop in each eye, one time
48171503|NCT03738306|OTHER|Mezieres Method|"The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi."
48171504|NCT03738306|OTHER|Conventional Physiotherapy|therapeutic exercise; physical agents
48171505|NCT03880825|DRUG|Metformin 500 mg Oral Tablet|single dose
48171506|NCT03880825|DRUG|Levoketoconazole 150 - 600 mg (BID)|escalating dose from 150 mg to 600 mg (BID)
48372421|NCT02467504|DRUG|Loxoprofen|Loxoprofen (oral administration)
48372422|NCT03270280|DRUG|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
48372423|NCT03270280|DRUG|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
48372424|NCT03879811|DRUG|TMZ|Oral TMZ at 150mg/m2
48372425|NCT03879811|DRUG|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
48372426|NCT00423137|DRUG|BIBW 2948 BS|Capsule
48372427|NCT00423137|DRUG|Placebo|Capsule
48372428|NCT04964076|OTHER|No intervention|No intervention
48372429|NCT00001426|DRUG|Cyclophosphamide|
48372430|NCT00001426|DRUG|Paclitaxel|
48372431|NCT00001426|DRUG|Cisplatin|
48372432|NCT00001426|DRUG|G-CSF|
48372433|NCT04027127|OTHER|netrin-1 value on admission to hospital|
48372434|NCT05986708|OTHER|interview|In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
48372435|NCT02861157|BEHAVIORAL|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
48372436|NCT04533204|BEHAVIORAL|mnemonic strategy training|training using mnemonic strategies
48372437|NCT04533204|BEHAVIORAL|spaced retrieval training|training using spaced retrieval
48372438|NCT05090111|DRUG|ALG-055009|Single or multiple doses of ALG-055009
48372439|NCT05090111|DRUG|Placebo|Single or multiple doses of Placebo
48516432|NCT04117802|OTHER|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
48516433|NCT00633243|PROCEDURE|Modified Directly Observed Therapy (mDOT)|
48703477|NCT01316757|BIOLOGICAL|cetuximab|Given IV
48372440|NCT04499521|DEVICE|BrachyGel VHPS|Packing system for administering brachytherapy in cervical cancer patients
48372441|NCT03759795|BEHAVIORAL|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
48372442|NCT02012257|PROCEDURE|AMSA nerve block injectio|Sites of injection
48703478|NCT01316757|DRUG|paclitaxel|Given IV
48372443|NCT05026060|DIAGNOSTIC_TEST|Imaging|4-minutes eASL sequence without injection of contrast product added to each of the clinical MRs with standard ASL sequences performed for the care of the patient for 3 years.
48372444|NCT01621139|PROCEDURE|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
48372445|NCT04430140|DEVICE|CT Scan|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)\*: 0.6"
48372446|NCT01494753|DRUG|T2345|One drop at 8.00pm.
48703479|NCT01316757|DRUG|carboplatin|Given IV
48703480|NCT01316757|DRUG|erlotinib hydrochloride|Given PO
48703481|NCT01316757|OTHER|laboratory biomarker analysis|Correlative studies
48372447|NCT01494753|DRUG|Prostaglandin|One drop at 8.00pm.
48703482|NCT00003914|DRUG|dolastatin 10|
48703483|NCT00433160|DRUG|Teriparatide|daily, subcutaneous
48703484|NCT00433160|DRUG|Placebo|daily, subcutaneous
48703485|NCT04018976|DEVICE|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
48372448|NCT00953589|DRUG|ribavirin|Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day
48372449|NCT04908787|DRUG|BD0801|Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
48372450|NCT04908787|DRUG|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2
48516434|NCT00633243|PROCEDURE|Self-Administered Therapy (SAT)|
48516435|NCT03885687|BEHAVIORAL|Exercise with Music|The Exercise with Music intervention is recorded exercise playlist, which provide exercise instructions tailored to patients' musical choices and exercise capacity.
48516436|NCT03885687|BEHAVIORAL|Exercise|The exercise group will receive exercise brochure and will be advised to exercise at least twice daily.
48703486|NCT04018976|DEVICE|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
48703487|NCT04018976|DEVICE|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
48703488|NCT02436668|DRUG|Ibrutinib|
48703489|NCT02436668|DRUG|Gemcitabine|
48703490|NCT02436668|DRUG|Nab-paclitaxel|
48703491|NCT01478685|DRUG|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
48015026|NCT05984589|BEHAVIORAL|RISE Personalized Self-Managament Training (PSMT)|Along with patient education and internalization of self-determination, the RISE intervention focuses on replacing unhealthy habits with health-promoting habits. Ongoing practice and guidance in generating and enacting SMART (specific, measurable, achievable, realistic, and time-bound) health goals is the centerpiece of the RISE intervention. Working one-on-one with the PI, participants will set goals and develop practical strategies to establish sustainable healthy behavior (HB) change. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create lasting change. The 6-week intervention includes 2 in-person visits and 4 videoconference sessions.
48703492|NCT01478685|DRUG|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
48703493|NCT01478685|DRUG|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
48171507|NCT03328845|DRUG|Toujeo SoloStar|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
48171508|NCT03328845|DRUG|Tresiba|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
48171509|NCT03328845|DRUG|Humalog Kwikpen|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
48171510|NCT03328845|DRUG|NovoRapid|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
48171511|NCT03328845|DRUG|Apidra|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
48171512|NCT03660917|DRUG|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
48171513|NCT03660917|DRUG|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
48703494|NCT01408550|DRUG|NPB-01|Intravenous immunoglobulin
48703495|NCT01408550|DRUG|Placebo|Physiological saline
48703496|NCT01309048|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
48703497|NCT00504855|OTHER|Casting using Gortex (waterproof) cast padding materials|
48703498|NCT00504855|OTHER|Casting using cotton/cotton-poly cast padding materials|
48703499|NCT06344052|DRUG|SP-002|SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
48171514|NCT01753596|DEVICE|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
48171515|NCT01753596|OTHER|Physiological Sodium Chloride solution (0,9%)|Placebo
48171516|NCT04756206|DRUG|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
48171517|NCT04756206|DRUG|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
48703500|NCT06344052|DRUG|Vismodegib|The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
48703501|NCT04053400|DRUG|Ketamine|
48703502|NCT06592495|DRUG|Period 1|DWJ1589 or DWC202315
48703503|NCT06592495|DRUG|Period 2|DWJ1589 or DWC202315
48703504|NCT06592495|DRUG|Period 3|DWJ1589 or DWC202315
48171518|NCT00239447|DRUG|Tiotropium|
48171519|NCT00239447|DEVICE|HandiHaler|
48171520|NCT00239447|DEVICE|Respimat SMI|
48703505|NCT06592495|DRUG|Period 4|DWJ1589 or DWC202315
48703506|NCT02199951|DRUG|Dihydroartemisinin and piperaquine|Antimalarial
48703507|NCT04319029|BEHAVIORAL|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
48703508|NCT05564650|BIOLOGICAL|Navitoclax|Given PO
48703509|NCT05564650|DRUG|Venetoclax|Given PO
48703510|NCT05564650|DRUG|Decitabine|Given IV
48703511|NCT05564650|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48171521|NCT04028947|PROCEDURE|Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty|Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
48171522|NCT04520074|DRUG|Etoposide, Cyclophosphamide, Carboplatin/Cisplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
48703512|NCT05564650|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48703513|NCT05564650|OTHER|Laboratory Biomarker Analysis|Correlative studies
48703514|NCT05564650|OTHER|Quality-of-Life Assessment|Ancillary studies
48703515|NCT02608775|DEVICE|Metrodoloris Medical System|Application of a skin electrode
48703516|NCT02608775|DEVICE|Aisys® care station, Acertys|Standard photoplethysmography
48703517|NCT00839449|DRUG|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
48703518|NCT01933438|OTHER|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
48703519|NCT01933438|OTHER|Control|Standard treatment
48703520|NCT00904930|DEVICE|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
48703521|NCT00904930|DEVICE|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
48703522|NCT06607887|DRUG|IV antibiotic|Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
48703523|NCT06607887|DRUG|Oral antibiotic|Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
48703524|NCT04202224|DRUG|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
48703525|NCT04202224|DRUG|Glucose|Placebo.
48703526|NCT04202224|OTHER|No drug|Standard surgical procedure without any preoperative medication.
48703527|NCT05280002|BIOLOGICAL|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
48703528|NCT06224439|PROCEDURE|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
48703529|NCT06224439|PROCEDURE|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
48703530|NCT04992065|DRUG|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
48703531|NCT04992065|DRUG|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
48372451|NCT04908787|DRUG|Placebo|Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg
48516437|NCT06105723|BEHAVIORAL|Pathway to Healthy Aging care|The ICOPE-based personalized care planning comprises two home visits. In 1st visit, a comprehensive assessment proposed by the WHO-ICOPE model is conducted to identify eight possible health problems including malnutrition, reduced physical fitness, fall risk, cognitive decline, insomnia, pain, psychological distress and social loneliness. After health problem identification, each participant receives a personalized care prescription. 2nd visit adopts a goal-oriented empowerment 3-step cycle to personalize the care planning: 1) communicating assessment results to increase healthy self-awareness; 2) supporting setting person-directed goals to address health problems; 3) identifying health actions and personalizing goal setting to participants' contexts. The 12-week healthy aging empowerment comprises three core activities for healthy aging promotion, including interactive health education, health message broadcasts, and three case conferences for goal monitoring and health counseling.
48171523|NCT05908578|OTHER|High Frequency Exercise Training|Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
48171524|NCT05908578|OTHER|Low Frequency Exercise Training|One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
48171525|NCT00251264|PROCEDURE|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
48372452|NCT04908787|DRUG|Topotecan|Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2
48372453|NCT04908787|DRUG|doxorubicin liposome|Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
48516438|NCT04230902|BIOLOGICAL|Microfragmented Adipose Tissue Transplant|Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit
48516439|NCT04230902|DRUG|Corticosteroid injection|intra-articular knee injection of corticosteroid
48516440|NCT01739049|DRUG|Liraglutide|liraglutide
48516441|NCT01739049|BEHAVIORAL|Diet and Exercise|diet and exercise
48703532|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
48516442|NCT01956201|DRUG|Atorvastatin 20mg|\[Atorvastatin Run-in Period\] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) \[Treatment Period\] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) \[Extension Period\] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
48516443|NCT01956201|DRUG|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
48703533|NCT04992065|DRUG|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
48516444|NCT01956201|OTHER|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
48516445|NCT05886205|DRUG|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
48171526|NCT00251264|PROCEDURE|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
48372454|NCT04312711|DIAGNOSTIC_TEST|3D-TOF-MRA|"The Principle of 3D-TOF-MRA is based on the flow effect of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases."
48372455|NCT00231621|DRUG|topiramate|
48703534|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
48703535|NCT04992065|OTHER|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
48703536|NCT04992065|DRUG|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
48703537|NCT06102122|DIETARY_SUPPLEMENT|Compleat|Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
48703538|NCT06598189|DEVICE|Ear-SD|The Ear-SD is a purely EEG recording device Continuous Electroencephalogram (cEEG), Electromyogram (EMG), Electrooculogram (EOG), Photoplethysmogram (PPG), Electrodermoactivity (EDA), and Inertial Measurement Unit (IMU). The Ear-SD device rests on the ears and connects to the scalp by two sticker electrodes.
48703539|NCT06598189|DIAGNOSTIC_TEST|Electroencephalogram|Standard 21-channel scalp-continuous electroencephalogram (cEEG) with video recording and electrocardiogram (ECG)
48703540|NCT01827774|DEVICE|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
48703541|NCT06608602|OTHER|tidal volume adjustment during surgery|tidal volume adjustment during surgery according to body weight or FVC
48372456|NCT02979275|PROCEDURE|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
48703542|NCT03702920|BIOLOGICAL|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
48171527|NCT03376698|DRUG|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
48171528|NCT03376698|DRUG|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
48372457|NCT00609934|DRUG|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
48372458|NCT00609934|RADIATION|external beam radiotherapy|3000cGy in 10 fractions
48703543|NCT03702920|OTHER|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
48171529|NCT03376698|DRUG|Placebo|oral administration of Placebo once daily for 12 weeks
48171530|NCT02883179|DRUG|lidocaine injection|anhydrous solution
48703544|NCT00599391|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
48703545|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
48703546|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
48703547|NCT03661424|DRUG|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
48516446|NCT03515512|DRUG|Enasidenib|Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
48703548|NCT03764631|DRUG|Empagliflozin|Drug
48703549|NCT03764631|DRUG|Dipeptidyl-peptidase 4 (DPP-4) inhibitors|Dipeptidyl-peptidase 4 - Drug
48015027|NCT05984589|BEHAVIORAL|Standardized Self-Managament Training (SSMT)|Participants randomized to the control condition will receive 6 standardized sessions from one of the OT interveners, matched to the PSMT for setting. At these visits, participants will be presented with slides containing pre-specified, standardized didactic content about the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) healthy behavior recommendations (HBRs). We hypothesize that these visits will control for the effect of research participation and increased knowledge about HBRs, and that simply providing standardized didactic content as an intervention modality without any personalization will have negligible effects on participants' healthy behaviors (HBs), self-efficacy, or quality of life. Content will follow the WCRF/AICR HBRs. Weeks 1-2 will focus on physical activity; weeks 3-4 will focus on diet and alcohol, and weeks 5-6 will focus on weight management and generalized strategies for HB change.
48171531|NCT02883179|DRUG|lidocaine-prilocaine cream|topical cream
48171532|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
48372459|NCT05258968|OTHER|Education on the Injeti Model of Self-Esteem|1 hour educational session
48372460|NCT04398160|OTHER|HVLA C3/C4 manipulation|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical. This procedure will increase the tension of the soft tissues to reduce the remaining slack and, finally, the thrust will be applied in pure rotation. Subsequently the head of the volunteer will be repositioned in the neutral position without applying any pressure and will wait 10 seconds in this position. Finally, the previous procedure will be repeated to the opposite side.
48015028|NCT00393055|DIETARY_SUPPLEMENT|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
48015029|NCT00393055|DIETARY_SUPPLEMENT|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
48015030|NCT00550836|BIOLOGICAL|panitumumab|Given IV
48171533|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
48171534|NCT00616577|DRUG|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
48516447|NCT05242718|DIETARY_SUPPLEMENT|N-Acetyl-L-cysteine (NAC)|Health Canada Natural Product Number (NPN) 80056946
48516448|NCT05242718|DIETARY_SUPPLEMENT|Echinacea purpurea|Health Canada Natural Product Number (NPN) 80093896
48703550|NCT04723641|OTHER|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
48015031|NCT00550836|DRUG|erlotinib hydrochloride|Given orally
48015032|NCT00550836|DRUG|gemcitabine hydrochloride|Given IV
48015033|NCT05301205|DRUG|oral gabapentin|will be received oral gabapentin capsule 2 HOURS pre-operatively.
48015034|NCT04391582|OTHER|Tilapia skin|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
48015035|NCT04391582|DRUG|silver sulfadiazine cream 1%|After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
48015036|NCT06464588|BIOLOGICAL|Allogeneic Neonatal mesenchymal stromal cells (nMSCs)|nMSCs will be administered intravenously in the predefined dose per each group. The rate of infusion will be approximately 30- 60 minutes at 0, 15 and 30 days, with escalating dose levels.
48015037|NCT04390152|DRUG|Wharton's jelly derived Mesenchymal stem cells.|IV Wharton's jelly derived Mesenchymal stem cells, two doses
48015038|NCT04390152|DRUG|Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)|Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo
48015039|NCT03302858|DEVICE|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
48015040|NCT05832034|DRUG|Immune Globulin Intravenous (Human)|IVIg is 2 g/kg over 2 to 5 days at baseline, followed by 2 g/kg IV in 2 to 5 days after 4 and 8 weeks. The rate of infusion is controlled by means of an infusion pump. The first dosage (30 grams IVIg) will be administered on the neurology ward.
48015041|NCT05832034|DRUG|Placebo|Placebo infusions, containing sodium chloride 0.9%, at baseline and after 4 and 8 weeks.
48015042|NCT01115426|DRUG|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
48015043|NCT02200705|DEVICE|Ice-Sense3TM/ ProSenseTM|
48015044|NCT05349448|DRUG|Hylase plus Triamcinolone plus sterile isotonic saline|transforaminal fluroscopic epidural injection
48015045|NCT05349448|DRUG|Hylase plus Dexmedetomidine plus Triamcinolone|transforaminal fluroscopic epidural injection
48171535|NCT01984749|DRUG|Febuxostat|"Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~1. The starting dose of the investigational product (febuxostat) will be 10 mg/day.~2. The dose will be increased to 20 mg/day at Week 4.~3. The aim is to increase the dose to 40 mg/day at Week 8."
48171536|NCT02207036|BEHAVIORAL|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
48015046|NCT05508061|DRUG|Insulin Lispro Cartridge [Lyumjev]|Administration of Lyumjev in combination with the AP system
48015047|NCT05508061|DRUG|Insulin Lispro Cartridge|Administration of Humalog in combination with the AP system (standard therapy)
48171537|NCT02207036|BEHAVIORAL|Smokefree.gov|referral to the NCI Smokefree.gov website
48171538|NCT04583462|DRUG|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
48171539|NCT04583462|DRUG|Placebo|Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
48171540|NCT06158828|DRUG|Rabbit Anti thymocyte globulin|rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.
48171541|NCT06158828|DRUG|Busulfan|Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.
48171542|NCT06158828|DRUG|Fludarabine|Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.
48171543|NCT06158828|DRUG|Thiotepa|Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.
48171544|NCT06158828|DRUG|Melphalan|Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.
48171545|NCT06158828|BIOLOGICAL|TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft|The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10\^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.
48171546|NCT06158828|BIOLOGICAL|memory-like natural killer cells|The ML NK cells (dose: max capped at 20 x 10\^6/kg recipient weight, minimum dose allowed is 0.5 x 10\^6/kg recipient weight) will be infused on Day +7.
48171547|NCT06158828|BIOLOGICAL|IL-2|IL-2 is administered subcutaneously at a dose of 1 million units/m\^2 on Days +7, +9, +11, +13, +15, +17, and +19 (7 doses total).
48171548|NCT06158828|DRUG|Plerixafor|If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).
48015048|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (active C-tDCS)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
48015049|NCT04801446|DEVICE|Soterix Medical 1X1 tDCS stimulator (sham stimulation)|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
48015050|NCT01400594|DRUG|HTU-520 Patch|Terbinafine hydrochloride patch
48015051|NCT01400594|OTHER|Placebo Patch|Treatment with Placebo Patch
48015052|NCT06664528|DIAGNOSTIC_TEST|ECHOCARDIOGRAPHY|A complete echocardiographic exam will be perfomed during each cardio-oncologic evaluation.
48171549|NCT06158828|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|G-CSF will be administered at a dose of 10 mcg/kg/day for 5 days, or 6 days if two days of collection are needed.
48171550|NCT06158828|DEVICE|CliniMACS|After stem cells are collected by leukapheresis, in order to create the HPC product, the stem cells will be washed to remove platelets and the cell concentration will be adjusted per laboratory and CliniMACS technology recommendations. The cells are then labeled using the CliniMACS TCRαβ Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product.
48171551|NCT05233098|DEVICE|Technetium-99m macroaggregated albumin (Tc-99m MAA)|Patients who are being evaluated for TheraSphere administration.
48171552|NCT03188536|OTHER|No Intervention|As it was an observational study, no intervention was administered in this study.
48171553|NCT01411449|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
48171554|NCT02238964|DEVICE|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
48171555|NCT02238964|PROCEDURE|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
48171556|NCT01657643|DIETARY_SUPPLEMENT|Probiotics|
48171557|NCT01657643|DIETARY_SUPPLEMENT|placebo|
48171558|NCT04864717|DRUG|Doxycycline 100mg po once daily x 6 months|active intervention
48171559|NCT04864717|DRUG|Isotretinoin 40 mg po once daily x 6 months|active intervention
48171560|NCT06014047|PROCEDURE|No-touch vein graft|Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
48171561|NCT06014047|PROCEDURE|Radial artery graft|One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
48171562|NCT00264823|BEHAVIORAL|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
48171563|NCT00030537|DRUG|erlotinib hydrochloride|
48171564|NCT00002621|BIOLOGICAL|recombinant interferon alfa|
48171565|NCT06386198|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
48171566|NCT03906604|PROCEDURE|Carpal Tunnel Procedure (open)|Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
48171567|NCT01811498|DRUG|Bevacizumab|
48171568|NCT04885634|DRUG|Semaglutide Injectable Product|Subcutaneous injection of Semaglutide 2.4 mg once weekly
48171569|NCT04885634|DRUG|Placebo|Subcutaneous injection of volume-matched placebo once weekly
48171570|NCT02546505|OTHER|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
48171571|NCT02546505|OTHER|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
48171572|NCT03630692|DRUG|observance of oral drug treatment|Completion of questionnaires at 4 times during patient's oral route drug treatment
48171573|NCT04807023|BIOLOGICAL|blood sampling|blood sampling
48015053|NCT06664528|DIAGNOSTIC_TEST|ELETTROCARDIOGRAPHY (ECG)|An ECG tracing will be obtained during each cardio-oncologic evaluation.
48015054|NCT06664528|DIAGNOSTIC_TEST|LABORATORY TESTS|The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.
48015055|NCT02311049|RADIATION|Hypofractionation|
48015056|NCT06192771|BEHAVIORAL|ESSI-SURG|Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
48015057|NCT06192771|BEHAVIORAL|Standard-of-Care|Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
48015058|NCT00775437|DRUG|Adalimumab|Adalimumab solution for injection for subcutaneous use.
48015059|NCT04379167|DRUG|YY-20394|YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3 kinase (PI3K-δ) which differs structurally from idelalisib, a PI3K-δ inhibitor approved for patients with relapsed chronic lymphocytic leukemia and indolent lymphoma. PI3K-δ signaling pathways are frequently hyperactive in B-cell cancers, making inhibition of PI3K-δ a promising target for B-cell malignancies. YY 20394 has high potency against PI3K-δ, but with markedly improved selectivity in in vitro assays compared to idelalisib. This higher selectivity for PI3K-δ may decrease the risk of serious infection seen with idelalisib and duvelisib (a PI3K-γ/δ dual inhibitor) due to strong immune suppression.
48015060|NCT04458064|OTHER|LMA i gel|insertion of LMA for maintaining airway during anesthesia
48015061|NCT03079804|OTHER|Experimental MWM|Mobilization with Movement
48015062|NCT03079804|OTHER|Experimental Thrust|Mobilization grade 5 (Thrust)
48015063|NCT03079804|OTHER|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
48015064|NCT05007483|DIETARY_SUPPLEMENT|BodyBio Balance Oil|nutraceutical supplement
48372461|NCT04398160|OTHER|Sham technique|The investigator will apply an anterior and lateral translation associated with extension, homolateral inclination and contralateral rotation of the cervical until the perception of tissue tension at the point of contact, holding this position for 10 seconds. The investigator then repositions the head of the volunteer in the neutral position without applying pressure, holding again this position for 10 seconds. Finally, the previous procedure will be repeated for the opposite side.
48372462|NCT01258803|DRUG|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
48015065|NCT05007483|DIETARY_SUPPLEMENT|Kirunal Fish Oil|nutraceutical supplement
48015066|NCT05007483|DIETARY_SUPPLEMENT|BodyBio PC|nutraceutical supplement
48015067|NCT05007483|BEHAVIORAL|Modified Paleolithic Elimination diet|"1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast."
48015068|NCT05007483|BEHAVIORAL|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|"1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables."
48015069|NCT05007483|BEHAVIORAL|Usual diet with Dietary Guidelines for Americans Diet information|"1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods."
48015070|NCT01565993|DEVICE|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
48015071|NCT01565993|DEVICE|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
48015072|NCT00277602|DRUG|Riluzole|
48015073|NCT06130176|PROCEDURE|Single-step Functional Sinus Endoscopy and Transoral Surgery|In each patient, the operation will be carried out by an otorhinolaryngologist and a maxillofacial surgeon. The procedures of the functional sinus endoscopy (FSE) will performed as follow: Under general anesthesia, the origin of the turbinate, and the lateral nasal wall will be conducted. The following stage will be infundibulotomy, which ensures that the uncinate process will be completely removed. The ostium will be dilated with a Stammberger dilatator starting with a 0-degree endoscope then shift to a 30- or 45-degree endoscope to clean the sinus. The cavity will be irrigated after removal of the odontogenic diseases and the purulent discharge will suctioned.In addition to FSE, the maxillofacial surgeon will conduct the necessary oral surgery procedures.The needed transoral procedures will be tooth extraction, oro-antral fistula closure or cystectomy.
48015074|NCT06130176|PROCEDURE|Functional sinus endoscopy|All patients in this group will only be treated with FSE, which will be conducted by an otolaryngologist. The FSE procedures will be carried out in the same way as the group of Single-step Functional Sinus Endoscopy and Transoral Surgery.
48015075|NCT06130176|PROCEDURE|Trans oral Surgery|Every patient in this group will only be treated with transoral surgical procedures to remove dental pathology. Oral and maxillofacial surgeons will undertake these treatments. The procedure will be either tooth extraction, oro-antral fistula closure, or cystectomy. If extraction is not needed, endodontic treatment will be performed to remove necrotic pulp. The oro-antral fistula will be closed in two layers using a buccal advanced flap and a palatal rotational flap. In the case of odontogenic cysts, the lesion will be removed by raising a trapezoidal flap.
48171574|NCT03184597|DIAGNOSTIC_TEST|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
48372463|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
48516449|NCT05242718|DIETARY_SUPPLEMENT|Curcumin|Health Canada Natural Product Number (NPN) 80043455
48703551|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 lozenges|In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48171575|NCT02085902|DRUG|Ropivacaine|
48171576|NCT03964181|OTHER|Change in school start times|Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
48171577|NCT06416319|DEVICE|Daily Activity Goal and Feedback|The daily activity target is a fixed number of steps. The exact number of steps is determined beforehand as part of the case number planning in a pilot study with ten participants and adjusted if necessary. The activity target we suggest is 8000 steps. In addition, the participants receive feedback several times a day about the steps needed to reach the goal and whether they have ultimately reached the daily goal.
48171578|NCT05070234|GENETIC|Blood collection for genetic analysis|Genetic tests in this study are sequential testing, including MS-MLPA, whole exome sequencing, whole genome sequencing, as well as RNA-seq.
48372464|NCT01258803|DRUG|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
48372465|NCT01258803|DRUG|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
48372466|NCT01258803|DRUG|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
48372467|NCT01258803|DRUG|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
48372468|NCT04215159|DRUG|Trastuzumab biosimilar|1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
48372469|NCT04215159|DRUG|Gemcitabine Hydrochloride|1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
48372470|NCT04215159|DRUG|Irinotecan Hydrochloride|100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
48372471|NCT01958944|DRUG|Nitric oxide|
48372472|NCT00226226|PROCEDURE|Peripherally Inserted Central Catheter Placement|
48372473|NCT02184312|DRUG|Nevirapine XR low dose|
48372474|NCT02184312|DRUG|Nevirapine XR medium dose|
48372475|NCT02184312|DRUG|Nevirapine XR high dose|
48703552|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 dairy free lozenges|In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
48703553|NCT00349323|BEHAVIORAL|Community directed treatment|
48171579|NCT03427008|OTHER|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
48703554|NCT00002114|DRUG|Procysteine|
48703555|NCT02200328|DRUG|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
48171580|NCT01489917|OTHER|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
48171581|NCT01863797|OTHER|Early induction|
48372476|NCT02184312|DRUG|Nevirapine (VIRAMUNE®)|
48372477|NCT00627913|PROCEDURE|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
48372478|NCT00627913|PROCEDURE|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
48372479|NCT06514170|OTHER|No intervention|No intervention
48372480|NCT04374604|DIAGNOSTIC_TEST|Placental growth factor|On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
48372481|NCT05156775|OTHER|Serratus Plane Block (SPB)|While the patient is in the supine position, the arm will be abducted, the ultrasound probe will be placed over the mid-clavicular region of the thoracic cage in sagittal plane. Ribs will be counted until the fifth rib will be identified in the midaxillary line. the latissimus dorsi (superficial and posterior ), teres major (superior), and serratus muscle (deep and inferior)will be identified overlying the fifth rib. As an extra reference point, thoracodorsal artery will be used, this aids in the identification of the plane superficial to the serratus muscle, 30 ml 0.25 %bupivacaine will be injected between latissimus dorsi and serratus anterior muscles at the level of the 5th rib in the mid axillary line.
48516450|NCT05242718|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Health Canada Natural Product Number (NPN) 80097472
48516451|NCT00493896|DRUG|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
48516452|NCT00493896|DRUG|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
48516453|NCT00052455|DRUG|lomustine|
48516454|NCT00052455|DRUG|procarbazine hydrochloride|
48516455|NCT00052455|DRUG|temozolomide|
48703556|NCT02200328|DRUG|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
48703557|NCT01384448|PROCEDURE|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
48703558|NCT01384448|PROCEDURE|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
48703559|NCT05680480|BIOLOGICAL|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
48703560|NCT05680480|BIOLOGICAL|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
48703561|NCT05680480|DRUG|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
48171582|NCT01863797|OTHER|Expectant mamagement|
48171583|NCT03841006|DEVICE|MRI|dynamic MRI pelvis
48171584|NCT00262249|DRUG|somatropin|
48516456|NCT00052455|DRUG|vincristine sulfate|
48015076|NCT05813743|DIAGNOSTIC_TEST|3 dimensional ultrasound|Detect the accuracy of 3D ultrasonography in prenatal detection of bladder wall involvement in abnormally invasive placenta (AIP) at 3rd trimester of pregnancy .
48703562|NCT05325749|GENETIC|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
48703563|NCT05325749|GENETIC|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
48703564|NCT05325749|OTHER|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
48015077|NCT00864500|DRUG|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
48703565|NCT05325749|GENETIC|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
48703566|NCT05325749|GENETIC|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
48703567|NCT05475210|DRUG|177Lu-DOTA-EB-TATE|Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
48703568|NCT05475210|OTHER|Amino Acid Solution|The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
48703569|NCT02099162|DEVICE|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
48703570|NCT00798070|DRUG|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
48703571|NCT00798070|DRUG|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
48703572|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) + HIKA|Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
48703573|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) only|Economic empowerment program using animal husbandry with young adolescents
48703574|NCT05763719|BEHAVIORAL|HIKA Healthy Relationship Program|Healthy relationship program for parents/couples
48703575|NCT02079831|BEHAVIORAL|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
48703576|NCT02079831|BEHAVIORAL|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
48703577|NCT02079831|BEHAVIORAL|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
48703578|NCT04074018|OTHER|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
48015078|NCT00864500|DRUG|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
48015079|NCT03394391|BEHAVIORAL|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
48171585|NCT03371485|BIOLOGICAL|AST-VAC2|Allogeneic dendritic cell vaccine.
48516457|NCT04871672|OTHER|Pilates Exercises|basic five pilates intermediate workout based on the principles of Pilates
48516458|NCT04871672|OTHER|Home Exercise program|home exercise
48516459|NCT04306211|DEVICE|SuperNO2VA|SUPERNO2VA is nasal PAP device for oxygen delivery
48703579|NCT04074018|OTHER|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
48703580|NCT05980091|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
48703581|NCT05980091|DIAGNOSTIC_TEST|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
48703582|NCT05980091|DRUG|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
48703583|NCT05980091|DRUG|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
48703584|NCT05980091|DIAGNOSTIC_TEST|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
48703585|NCT05980091|PROCEDURE|Embryo transfer|Procedure in which embryo is transferred into the uterus
48703586|NCT05030519|DRUG|Pyrotinib|Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
48372482|NCT05156775|OTHER|Rhomboid intercostal nerve block (RIB)|In the rhomboid intercostal nerve block (RIB) group, the patient will be placed in a lateral position with the affected breast at the top. The ipsilateral arm will be extended to the same level as the ipsilateral chest and breast, and the scapula will be moved outward. On the oblique sagittal plane, a high frequency (6-12MHz) linear ultrasound probe will be placed on the medial edge of the scapula. The US landmarks, trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung will be identified. Under the aseptic condition, a 22-gauge needle will be inserted in the plan to the US probe at T5 to T6 levels. Then, 0.25% bupivacaine (30 mL) will be injected into the inter-fascial plane between the rhomboid major muscle and the intercostal muscle, the diffusion of bupivacaine in the fascia between the rhomboid muscle and the intercostal muscle will be visualized. Then, the patient will be positioned in supine position.
48372483|NCT01687985|DRUG|BLI801 laxative - low dose|BLI801 laxative - oral solution
48372484|NCT01687985|DRUG|BLI801 laxative - high dose|BLI801 laxative - oral solution
48372485|NCT02013726|DEVICE|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
48372486|NCT02013726|DEVICE|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
48372487|NCT03805763|PROCEDURE|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
48171586|NCT00576823|DRUG|Alfuzosin|"Dose: 0.2 mg/kg/day~Route: oral"
48372488|NCT03805763|PROCEDURE|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
48372489|NCT02427334|DRUG|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
48372490|NCT02427334|DRUG|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
48372491|NCT02427334|DRUG|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
48372492|NCT06347458|BIOLOGICAL|BG1805|A single infusion of BG1805 Injection administered intravenously.
48171587|NCT04505345|BEHAVIORAL|Cognitive training using the Systemic Lisbon Battery|The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.
48516460|NCT04315506|BEHAVIORAL|#EnufSnuff.TXT Intervention|The SGR program will reduce smokeless tobacco until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
48171588|NCT04505345|BEHAVIORAL|Treatment-as-usual|Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
48171589|NCT03264547|DRUG|Pertuzumab|Every 3 weeks
48171590|NCT03264547|DRUG|Trastuzumab|Every 3 weeks
48171591|NCT03264547|DRUG|Docetaxel|Every 3 weeks
48171592|NCT03264547|DRUG|Paclitaxel|Every week
48171593|NCT03264547|DRUG|Eribulin|Administered for 2 weeks and is then stopped to be administered for 1 week
48372493|NCT05400434|BEHAVIORAL|Standard Parent-Child Interaction Therapy (PCIT)|PCIT is an evidence-based behavioral parenting intervention. It is administered as weekly, one-hour sessions with a bilingual PCIT therapist for 18 weeks in one of three PCIT clinics embedded within neighborhood community agencies or virtually.
48703587|NCT01311115|BEHAVIORAL|Group commitment contract|"1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
48703588|NCT01311115|BEHAVIORAL|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
48703589|NCT04834154|BEHAVIORAL|Mindfulness|6 weekly 2.0 hour video-conferenced group sessions with the following components: 1) short grounding meditation, 2) check in/review of prior weeks practice and symptoms, 3) educational topic, 3) main meditation, 4) reflection on meditation, and 5) action plan formation
48703590|NCT04834154|BEHAVIORAL|Control group|Wait list control
48703591|NCT01991080|BEHAVIORAL|biofeedback|Patients will go through biofeedback sessions
48171594|NCT02277197|DRUG|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
48171595|NCT02277197|DRUG|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
48171596|NCT03536078|OTHER|home phototherapy|
48703592|NCT01991080|DRUG|Wheatgerm juice|Patient will drink wheatgerm juice
48703593|NCT00570791|DEVICE|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
48372494|NCT05400434|BEHAVIORAL|Natural Helpers (NH)|Natural helpers are lay people to whom others naturally turn for advice, emotional support, and tangible aid. Families received weekly sessions with a natural helpers in their home or virtually for 30-45 minutes for a maximum of 18 weeks. During sessions, natural helpers work with families to (1) explain parenting principles in a culturally and responsive manner; (2) support them in their skill acquisition; and (3) troubleshoot structural barriers to service and other basic life needs.
48372495|NCT02025127|OTHER|Enteral nutrition|Enteral nutrition introduced via a feeding tube
48372496|NCT01406548|DRUG|BPS804 20mg/Kg|
48372497|NCT01406548|DRUG|Placebo to 20mg/Kg BPS804|
48171597|NCT05623813|OTHER|Postoperative education|provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery
48171598|NCT03862209|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
48171599|NCT01999543|DIETARY_SUPPLEMENT|plant-based dietary supplement|
48171600|NCT01999543|OTHER|Placebo|
48171601|NCT01281917|DRUG|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
48171602|NCT01281917|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
48171603|NCT03060213|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
48171604|NCT05324007|OTHER|Basic Science|This is a basic science experiment to test whether infants' looking time to video stimuli differ according to the race of the individuals shown.
48171605|NCT00287547|DRUG|CTLA4Ig / Abatacept|
48171606|NCT04673877|DRUG|Systemic IV Vancomycin|1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
48171607|NCT04673877|PROCEDURE|Bier Block|After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
48703594|NCT03911323|OTHER|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
48703595|NCT05073003|DRUG|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1_Adults_Placebo_GR1 and ST1_Adults_Placebo_GR2 groups in Stage 1 (Europe).
48171608|NCT04673877|DRUG|Vancomycin|500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
48171609|NCT05466188|DIAGNOSTIC_TEST|CPC|CPC
48171610|NCT04452409|DEVICE|low level laser|The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks
48171611|NCT04452409|OTHER|Mediterranean diet|recommend healthy diet component evaluated periodically by 24 hour recall
48171612|NCT00429442|DRUG|Simvastatin|80 mg once daily
48171613|NCT00429442|DRUG|placebo|calcium tablets once daily
48171614|NCT05110014|OTHER|Primary Care Office Visits|mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
48171615|NCT03134547|DRUG|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
48372498|NCT00923481|DRUG|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
48171616|NCT03134547|DRUG|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
48372499|NCT03616782|DRUG|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
48171617|NCT04993807|OTHER|Shared decision-making tool|Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
48171618|NCT02338427|OTHER|Immunohistochemistry|
48171619|NCT02338427|OTHER|Proteomic analysis|
48171620|NCT05028946|DRUG|Foralumab|Foralumab will be administered per dose and schedule specified in the arm description.
48171621|NCT02673307|BEHAVIORAL|1 chewing gum over 45 minutes|
48171622|NCT04768868|DRUG|IMP7068|To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
48171623|NCT03912974|DRUG|Escitalopram|see 'arm description'
48372500|NCT01503866|DRUG|bardoxolone methyl|oral, single dose
48372501|NCT05140902|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
48516461|NCT04315506|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for ten weeks.
48516462|NCT06359912|DRUG|EPCs|IV
48703596|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1_Adults_Dose C_GR1 and ST2_Adults_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2_Children_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1_Adults_Dose C_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose C_Safety and ST2_Infants_Dose C_Dose find groups in Stage 2 (Africa).
48703597|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2_Children_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose B_Safety and ST2_Infants_Dose B_Dose find groups in Stage 2 (Africa).
48703598|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2_Infants_Dose A_Safety and ST2_Infants_Dose A_Dose find groups in Stage 2 (Africa).
48703599|NCT05073003|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2_Adults_Control C group and children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
48171624|NCT03912974|DRUG|Placebo oral capsule|see 'arm description'
48171625|NCT04260464|DRUG|PF-06700841|A single dose of 30 mg PF-06700841 will be administered on Day 1
48171626|NCT05089981|DRUG|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
48171627|NCT05089981|DRUG|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
48171628|NCT03347266|DRUG|VVZ-149 injections|•VVZ-149 injection
48171629|NCT03347266|DRUG|Placebo|water for injection
48171630|NCT00543101|DRUG|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
48372502|NCT01559649|BEHAVIORAL|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
48372503|NCT03431129|DIAGNOSTIC_TEST|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
48372504|NCT03947333|OTHER|My Diabetes Care|The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
48516463|NCT06359912|BEHAVIORAL|Clinical standard treatment (CST)|Clinical standard treatment
48703600|NCT05073003|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2_Adults_Control C group in Stage 2 (Africa).
48171631|NCT00543101|DRUG|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
48171632|NCT00654615|DEVICE|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
48015080|NCT03394391|BEHAVIORAL|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
48372505|NCT01501019|OTHER|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
48372506|NCT05881590|OTHER|Hybrid pulmonary rehabilitation|Technology-enabled 8-week pulmonary rehabilitation programme using the Active+me REMOTE App
48372507|NCT04274361|DRUG|Ketamine|Ketamine infusion
48516464|NCT03475108|OTHER|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
48703601|NCT05073003|COMBINATION_PRODUCT|GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine|1 dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2_Infants_Control A_Safety, ST2_Infants_Control B_Safety, ST2_Infants_Control C_Safety and ST2_Infants_Control_Dose find groups in Stage 2 (Africa).
48703602|NCT05073003|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2_Children_Control B and ST2_Children_Control C groups in Stage 2 (Africa).
48015081|NCT04928222|COMBINATION_PRODUCT|Doxorubicin-containing MNA|A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
48015082|NCT04928222|DRUG|Placebo-containing MNA|A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
48372508|NCT04274361|DRUG|Placebo|Placebo infusion
48372509|NCT03561272|OTHER|Smart Phone Application|Oral medication adherence phone application.
48516465|NCT00830973|OTHER|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
48516466|NCT00830973|OTHER|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
48516467|NCT00792961|DEVICE|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
48516468|NCT06242080|BEHAVIORAL|Mindfulness|Mindfulness meditation has been described as a behavioral technique involving the intentional self-regulation of attention to present-moment experience, combined with release of cognitive fixation on thoughts (whether simple images or complex story lines) regarding the past or future. Through training in mindfulness, individuals learn to evoke and sustain a non-judgmental state of present-moment awareness.
48516469|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
48516470|NCT03782051|PROCEDURE|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
48372510|NCT03561272|OTHER|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
48372511|NCT00661310|OTHER|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
48372512|NCT05794347|OTHER|Traction|Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
48703603|NCT05073003|BIOLOGICAL|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
48171633|NCT00654615|PROCEDURE|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
48171634|NCT05549336|DRUG|PD-1 inhibitor|PD-1 inhibitor is defined as the exposure factor in our cohort study, for the tumor patients with the treatment of PD-1 inhibitor are allocated to the Exposure group whereas those tumor patients without the treatment of PD-1 inhibitor are allocated to the Non-exposure group.
48171635|NCT00317850|DRUG|Gabapentin (Neurontin)|
48171636|NCT06133868|DRUG|Lavender and Chamomile Essential Oils|essential oils
48171637|NCT00319813|BEHAVIORAL|Education|
48171638|NCT02703753|BEHAVIORAL|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
48171639|NCT01585441|DRUG|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
48171640|NCT01585441|DRUG|Placebo|Capsule with no active ingredients to mimic finasteride
48703604|NCT05226780|DRUG|NBI-921352|Administered orally
48703605|NCT00874458|PROCEDURE|magnetic resonance imaging|
48703606|NCT00874458|PROCEDURE|radiomammography|
48015083|NCT03112317|OTHER|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
48015084|NCT05301933|BEHAVIORAL|Behavioral Parent Training (BPT)|BPT is an evidence-based psychosocial intervention that is directed exclusively to parent of children with ADHD and related disorders. BPT focuses on instructing parents to use approaches to enhance the parent-child relationship (e.g., quality time, praise) and proactive discipline strategies (e.g., time out, reward systems) to reduce challenging child behavior.
48516471|NCT01312558|BEHAVIORAL|Prudent diet group|
48516472|NCT01312558|BEHAVIORAL|Mediterranean diet group|
48703607|NCT00874458|PROCEDURE|ultrasound imaging|
48703608|NCT06157177|DRUG|Metaxalone 640 mg Oral Tablet|Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
48703609|NCT01988532|OTHER|No treatment given|Subject will only fill out a questionnaire
48703610|NCT05664347|BEHAVIORAL|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
48703611|NCT05664347|BEHAVIORAL|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
48372513|NCT04622059|BEHAVIORAL|acoustic stimulation|"An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes."
48516473|NCT06303843|OTHER|Transfer with an electric ride-on car|The children in the experimental group will be transported to the operating theatre by a electric ride-on car.
48015085|NCT01612546|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
48015086|NCT01612546|OTHER|Laboratory biomarker analysis|Correlative studies
48015087|NCT01612546|OTHER|Pharmacological studies|Correlative studies
48015088|NCT00881309|DRUG|Tripterygium|TW 90mg/d
48015089|NCT01994512|PROCEDURE|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
48015090|NCT01994512|PROCEDURE|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
48015091|NCT02105077|DRUG|Anesthesia with inhalative application of xenon gas|
48015092|NCT01175382|BEHAVIORAL|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
48015093|NCT01175382|DRUG|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
48015094|NCT01175382|OTHER|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
48015095|NCT01429766|OTHER|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~1. st visit Within one day of the date of simulation~2. nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
48015096|NCT02782650|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
48015097|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
48015098|NCT04771130|DRUG|Azacitidine|Intravenous or subcutaneous administration for 7 days.
48015099|NCT04771130|DRUG|Posaconazole|Oral administration for 8 days on second cycle only.
48015100|NCT04771130|DRUG|BGB-11417|Oral administration for 28 days on a 28-day cycle.
48015101|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 14 or 21 days on a 28-day
48015102|NCT01159067|DRUG|deferasirox|Given orally
48015103|NCT06534021|DRUG|IASO-782 injection|Each subject will be given only one dose of IASO-782. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
48372514|NCT00917943|BEHAVIORAL|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
48372515|NCT03159052|DRUG|SHR3824|Once daily, 52 weeks
48372516|NCT03159052|DRUG|Placebo|Once daily, 24 weeks
48372517|NCT02210559|DRUG|FG-3019|FG-3019 will be administered per dose and schedule specified in the arm group description.
48372518|NCT02210559|DRUG|Gemcitabine|Gemcitabine will be administered per dose and schedule specified in the arm group description.
48372519|NCT02210559|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered per dose and schedule specified in the arm group description.
48372520|NCT05548270|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
48516474|NCT04152967|DEVICE|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
48171641|NCT02224183|BEHAVIORAL|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
48171642|NCT02224183|BEHAVIORAL|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
48171643|NCT02164136|PROCEDURE|L-PANP-TME|
48171644|NCT02164136|PROCEDURE|O-PANP-TME|
48171645|NCT03158935|DRUG|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
48171646|NCT03158935|DRUG|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
48171647|NCT03158935|PROCEDURE|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
48372521|NCT05548270|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
48171648|NCT03158935|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells
48171649|NCT03158935|BIOLOGICAL|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
48171650|NCT04846855|DRUG|local anaesthetic injection|Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
48171651|NCT04058236|OTHER|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
48171652|NCT04058236|OTHER|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
48171653|NCT05422339|DEVICE|The MapHabit system|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
48372522|NCT02138227|BEHAVIORAL|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
48703612|NCT06607549|DRUG|Loncastuximab tesirine and rituximab (Lonca-R)|Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
48703613|NCT00218582|BEHAVIORAL|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
48015104|NCT06534021|DRUG|placebo|Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
48015105|NCT02432794|PROCEDURE|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
48372523|NCT02138227|BEHAVIORAL|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
48372524|NCT04678726|DIAGNOSTIC_TEST|Lung ultrasound assessment for ruling out pneumothorax|Patients who have undergone heart surgery and have decided to enroll in our study, will have the standard chest x-ray and an additional lung ultrasound. Within a maximum of two hours of the chest tube removal, the standard chest x-ray will be performed, and then a different nurse will perform the lung ultrasound to check for pneumothorax.
48372525|NCT02304484|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection once a month
48372526|NCT03478631|OTHER|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
48372527|NCT03478631|OTHER|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
48372528|NCT05856357|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
48372529|NCT03616652|DRUG|Placebo|Placebo pill
48372530|NCT03616652|OTHER|Film sequence|The experimental group watches a film about the power of placebo effects.
48372531|NCT03616652|OTHER|Film sequence|The control group watches a film about sleep.
48372532|NCT02707562|DRUG|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
48703614|NCT00218582|BEHAVIORAL|Standard psychiatric day treatment|Individual counseling, groups, medication
48372533|NCT02707562|DRUG|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
48372534|NCT02707562|DRUG|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
48703615|NCT05156840|BEHAVIORAL|Telehealth follow-up|A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
48703616|NCT05986968|DRUG|Ticagrelor|Ticagrelor monotherapy for 12 months
48703617|NCT05986968|DRUG|Aspirin|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
48703618|NCT00018330|BEHAVIORAL|Weight Loss|
48372535|NCT01491152|DEVICE|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
48372536|NCT02691845|BEHAVIORAL|BA (brief advice)|
48372537|NCT02691845|BEHAVIORAL|SHE (supervised and home-based exercise)|
48703619|NCT06608901|DRUG|REGN7544|Administered per the protocol
48171654|NCT02767102|OTHER|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
48372538|NCT02691845|BEHAVIORAL|HE (health education)|
48372539|NCT02691845|BEHAVIORAL|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
48703620|NCT06608901|DRUG|PB|Administered per the protocol
48703621|NCT01686425|PROCEDURE|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
48703622|NCT02631174|DRUG|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
48516475|NCT04152967|DEVICE|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
48516476|NCT04201730|PROCEDURE|Enhanced Recovery After Surgery （ERAS）|Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
48516477|NCT00286026|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
48703623|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
48703624|NCT04015609|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
48171655|NCT02767102|OTHER|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
48703625|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
48703626|NCT04015609|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
48372540|NCT01973920|DRUG|Oshadi Icp|
48372541|NCT06238882|COMBINATION_PRODUCT|Nitroglycerin|Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
48516478|NCT01428154|DRUG|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
48703627|NCT06576674|DIETARY_SUPPLEMENT|Dietary Fiber + Green Tea Extract|10g fiber + 750mg green tea supplement will be administered at experimental arm
48015106|NCT05332262|DIAGNOSTIC_TEST|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)\>208.
48516479|NCT03456388|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
48516480|NCT03456388|DRUG|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
48516481|NCT01570114|DEVICE|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
48703628|NCT06576674|OTHER|Alcohol|alcohol administered up to a target BAC 60mg% during lab sessions
48703629|NCT06576674|OTHER|Aspartame Placebo Supplement|Aspartame sweetener mixed with water + aspartame capsule
48703630|NCT00118313|BIOLOGICAL|incomplete Freund's adjuvant|
48703631|NCT00118313|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
48703632|NCT00118313|BIOLOGICAL|sargramostim|
48015107|NCT05332262|DIAGNOSTIC_TEST|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
48372542|NCT02024997|OTHER|Magnetic Resonance Imaging (MRI)|
48372543|NCT03426995|DRUG|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
48372544|NCT03426995|DRUG|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
48372545|NCT03426995|BIOLOGICAL|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
48703633|NCT00118313|BIOLOGICAL|tetanus toxoid helper peptide|
48703634|NCT00118313|DRUG|dimethyl sulfoxide|
48703635|NCT00118313|DRUG|imiquimod|
48703636|NCT00118313|PROCEDURE|adjuvant therapy|
48703637|NCT03568253|OTHER|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
48015108|NCT04300400|OTHER|Delphi questionnaire|Statements on OAB topics, rated along their level of appropriateness on a scale from 1 to 9. Multiple rounds are organised to reach consensus on a topic.
48015109|NCT03393221|BEHAVIORAL|ER|Emotion regulation content
48015110|NCT03393221|BEHAVIORAL|SBWC|
48015111|NCT05610111|DEVICE|CLC + BAM|Closed Loop Control with the Behavioral Adaption Module for 4 weeks
48171656|NCT05449847|BIOLOGICAL|Blood Sampling|Blood sampling under a complete aseptic conditions
48171657|NCT05442073|OTHER|PEEP adjustment|adjusting PEEP about 3-5cmH2O (increase or decrease)
48703638|NCT03568253|OTHER|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
48703639|NCT01415479|BEHAVIORAL|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
48171658|NCT04162236|DIAGNOSTIC_TEST|Ecocardiographyc ultrasound|"* Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays."
48171659|NCT06173232|DEVICE|Camera Imaging|Camera Imaging
48171660|NCT01911923|PROCEDURE|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
48171661|NCT01911923|PROCEDURE|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
48171662|NCT01860807|DRUG|Ibudilast|
48171663|NCT01860807|DRUG|Placebo|
48171664|NCT02230306|DRUG|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
48171665|NCT02230306|DRUG|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
48171666|NCT06355128|OTHER|NOT|NOT
48372546|NCT03426995|BIOLOGICAL|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
48372547|NCT03426995|OTHER|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
48372548|NCT04371705|PROCEDURE|Erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.
48372549|NCT04371705|OTHER|control|placebo
48516482|NCT04622241|OTHER|Eave Tubes|The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g. bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides. No additional screening will be done. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
48015112|NCT05610111|DEVICE|CLC + ABC|Closed Loop Control with Adaptive Biobehavioral Control for 16 weeks
48015113|NCT02566759|DRUG|TAK-831 Oral Suspension|TAK-831 oral suspension.
48015114|NCT02566759|DRUG|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
48015115|NCT02566759|DRUG|TAK-831 Tablet|TAK-831 tablet.
48171667|NCT05428592|BIOLOGICAL|LVRNA009|50μg /0.5 mL/Vial/person
48171668|NCT05428592|BIOLOGICAL|CoronaVac®|0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen
48171669|NCT01751165|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
48015116|NCT02993601|DEVICE|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
48015117|NCT02993601|DEVICE|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
48015118|NCT02993601|OTHER|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
48015119|NCT02993601|OTHER|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
48171670|NCT05566509|PROCEDURE|Breast excision|some patient had minimal excision, some had maximal excision.
48171671|NCT05082662|DRUG|Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|One Diclofenac tablet was administered orally.
48171672|NCT05082662|DRUG|Cataflam® 50 coated tablet|One Diclofenac tablet was administered orally.
48171673|NCT04233502|DRUG|Melatonin|prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
48171674|NCT04233502|DRUG|Placebo|Placebo melatonin
48372550|NCT03612869|DRUG|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
48372551|NCT03730259|OTHER|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
48372552|NCT05487027|BEHAVIORAL|Goldilocks work principle|"Using the Goldilocks work principle we have tried to find the just right distribution of physical strain in the home care sector. This is an intervention to test if it possible to distribute the physical strain experienced in the home care sector in a way that may be more health promoting for the workers."
48372553|NCT05896709|OTHER|MK-RS|The embryos are assessed by the AI-enhanced MK analysis together with RS analysis.
48372554|NCT01263652|DRUG|Diclofenac hydroxyethylpyrrolidine|IM/PO
48372555|NCT01263652|DRUG|orphenadrine|IM/PO orphenadrine
48372556|NCT01263652|DRUG|Tramadol|IM/PO tramadol
48372557|NCT01263652|DRUG|Dipyrone|PO/IM Dipyrone
48372558|NCT02224495|BEHAVIORAL|Structured exercise training|
48372559|NCT00230711|BEHAVIORAL|Physical activity counseling|
48372560|NCT05566366|OTHER|Qualitative research interview|Qualitative research interview Administration of quantitative scales
48703640|NCT01415479|BEHAVIORAL|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
48171675|NCT04584502|BEHAVIORAL|Mindful Moms Yoga Mindfulness Intervention|MMORE is an 8-session yoga-mindfulness intervention protocol, offered via Zoom over the course of 10 consecutive weeks at the partner maternity care practice or a nearby location. Each session will last approximately 60 minutes (8 - 10 participants per group). Intervention participants will also be asked to use a mobile companion app at least once each week of the intervention period.
48171676|NCT06434233|DRUG|Acetaminophen|"All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter."
48171677|NCT06434233|DRUG|Ibuprofen|"All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter."
48171678|NCT06434233|DRUG|Oxycodone|"Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1"
48171679|NCT04223128|PROCEDURE|Ultrasound guided transversus abdominis plane block|Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
48171680|NCT02396953|DRUG|Lanreotide PRF|
48171681|NCT01226485|DRUG|Taladegib|Administered IV
48171682|NCT04112277|DRUG|Cumulative morphine consumption|morphine equivalent \[mg\] 24 hours after the procedure
48372561|NCT01205568|DEVICE|Transcatheter Cutting Balloon therapy|
48372562|NCT01205568|PROCEDURE|High Pressure Balloon Angioplasty|
48372563|NCT06435052|BEHAVIORAL|Eye Movement Desensitization & Reprocessing Therapy|Eye Movement Desensitization and Reprocessing (EMDR) therapy will be administered face-to-face by a psychotherapist in a total of 12 sessions, with one session per week. The efficacy of EMDR therapy will be compared with Cognitive Behavioral Therapy in the treatment of Post-Traumatic Stress Disorder in Pakistan.
48372564|NCT06435052|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will be comparatively checked with Eye Movement Desensitization \& Reprocessing Therapy for its efficacy. It will be administered by psychotherapist in 14 sessions (each session per week)
48372565|NCT01429194|PROCEDURE|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
48372566|NCT01108588|DRUG|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
48703641|NCT01415479|BEHAVIORAL|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
48703642|NCT05191888|DRUG|Vonoprazan and Amoxicillin|14-day vonoprazan high-dose two-in-one therapy
48015120|NCT02993601|DEVICE|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
48171683|NCT06271083|BEHAVIORAL|Exposure with response prevention|The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the tics. A central tool in the treatment will be the Ticstimer, a worksheet where patients will continuously record their ERP practice, and the time they manage to suppress tics. The patients will be encouraged to work with the Ticstimer daily.
48171684|NCT06271083|BEHAVIORAL|Brief psychoeducation with general psychological support|Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter, the therapists will only reply to the patients' messages without taking any contact initiative themselves (unless there is an indication of severe deterioration or severe depressive symptoms or suicidal ideation requiring medical attention)
48171685|NCT06292559|DEVICE|Bilateral STN deep brain stimulation|patients with Meige syndrome underwent bilateral subthalamic stimulation
48171686|NCT06292559|DEVICE|Bilateral GPi deep brain stimulation|patients with Meige syndrome underwent bilateral pallidal stimulation
48372567|NCT01108588|DRUG|Aspirin|Aspirin 300 mg daily
48372568|NCT01108588|DRUG|Clopidogrel|Clopidogrel 75 mg daily
48703643|NCT05191888|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|14-day vonoprazan triple therapy
48015121|NCT02993601|DEVICE|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
48015122|NCT02993601|DEVICE|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
48171687|NCT04717947|PROCEDURE|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
48171688|NCT02146092|PROCEDURE|Incentive spirometry|
48171689|NCT02146092|OTHER|Physiotherapy|Standard of care exercise training and supervision
48372569|NCT01108588|DRUG|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
48703644|NCT05191888|DRUG|Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole|14th Rabeprazole reverse mixed therapy
48015123|NCT02150122|DIETARY_SUPPLEMENT|Vitamin D3|
48015124|NCT00061048|BIOLOGICAL|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
48015125|NCT03901924|OTHER|Volume Support Mode Mechanical Ventilation|This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
48015126|NCT03901924|OTHER|Assist Control Mode Mechanical Ventilation|This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
48171690|NCT01410084|DIETARY_SUPPLEMENT|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
48372570|NCT05852002|DRUG|35 kDa hyaluronan fragment|100 mg of 35kDa hyaluronan fragment was injected deeply into abdominal fat layer once a day for 28 consecutive days.
48372571|NCT05075109|DEVICE|High Frequency TENS|30 minutes of high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
48015127|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
48703645|NCT05257460|DEVICE|Hybrid closed-loop using ultra-rapid insulin lispro|Hybrid closed-loop using ultra-rapid insulin lispro
48703646|NCT05257460|DEVICE|Hybrid closed-loop using standard insulin lispro|Hybrid closed-loop using standard insulin lispro
48703647|NCT04601428|BIOLOGICAL|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
48703648|NCT06037096|OTHER|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
48703649|NCT03571802|DRUG|Simvastatin|"* The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
48703650|NCT05964530|PROCEDURE|Surgery|Surgery procedures include LAR+ anal preservation or APR
48703651|NCT06014931|BEHAVIORAL|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
48171691|NCT01410084|DIETARY_SUPPLEMENT|Vitamin E|400 IU vitamin E once monthly for 5 months
48171692|NCT00848393|DRUG|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
48171693|NCT00848393|DRUG|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
48171694|NCT00848393|DRUG|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
48171695|NCT00575367|DRUG|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
48171696|NCT00575367|DRUG|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
48171697|NCT03510806|DIETARY_SUPPLEMENT|Supplement|dietary supplement contain protein from milk and fruit extract
48171698|NCT03510806|OTHER|Placebo|color, taste, and calorie-matched placebo
48171699|NCT02197143|DRUG|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
48171700|NCT02197143|DRUG|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
48171701|NCT02197143|DRUG|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
48171702|NCT04342988|DRUG|Cequa|The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
48171703|NCT04672798|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
48171704|NCT04672798|BEHAVIORAL|Treatment As Usual (TAU)|Participants in this group will receive usual care from their mental health care provider.
48171705|NCT00040898|DIETARY_SUPPLEMENT|Sho-saiko-to|
48171706|NCT05727488|OTHER|Exercise|Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
48171707|NCT02411695|DRUG|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
48171708|NCT05137405|PROCEDURE|Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.
48171709|NCT06511375|OTHER|sprint training|sprint training involves 20 meters sprint power training involve countermovement jump, squat jump and broad jump
48372572|NCT05075109|DEVICE|Low Frequency TENS|30 minutes of low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks. And combined with 30 minutes of TRT.
48703652|NCT05783245|OTHER|Polarcare Machine|Use of Polar Care ice machine as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
48703653|NCT05783245|OTHER|Standard of care ice therapy|Use of commercial reusable ice packs as often as possible, but a minimum of three 15 minute uses per day, for the first 3 days after surgery. No single use should last longer than 30 minutes.
48703654|NCT02795507|DEVICE|Rehabit-Tec System|Device with visual and kinesthetic feedback
48703655|NCT02795507|DEVICE|Rehabit-Tec System|Device without visual and kinesthetic feedback
48015128|NCT03056703|DRUG|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
48015129|NCT00239057|DRUG|Enteric-Coated Mycophenolate Sodium|
48015130|NCT05949476|OTHER|ozone therapy|"Ozone in the gaseous state produced by a machine at concentrations for medical use (sssssssssss9) injected after anesthesia in the surgery site and in the post-extraction alveolus after suture.~* Topical ozone in the form of a gel (indicate the brand) to be applied to the post-surgical site 2 times a day for 7 days."
48015131|NCT03949387|OTHER|FES Cycling Exercise|FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
48015132|NCT03949387|OTHER|Passive Leg Cycling|Passive leg cycling will not involve electrical stimulation
48015133|NCT02628275|BEHAVIORAL|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
48015134|NCT02628275|BEHAVIORAL|Light physical activity|40-55% maximum heart rate for 150min/week
48015135|NCT05461885|BEHAVIORAL|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
48015136|NCT05833984|DRUG|IMM01|IMM01 (1.0, 1.5, 2.0 mg/kg) QW IV in the dose escalation part. IMM01 (dose determined in the dose escalation part) QW IV in the dose expansion part.
48015137|NCT05833984|DRUG|Tislelizumab|Tislelizumab 200mg Q3W IV
48015138|NCT06663410|DEVICE|SPG block with the use of the Tx360 device|A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.
48015139|NCT05463367|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
48015140|NCT05463367|DRUG|Naproxen 500 Mg|Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
48703656|NCT02795507|BEHAVIORAL|conventional exercises|
48703657|NCT05103176|DEVICE|TMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
48703658|NCT05103176|BEHAVIORAL|Object directed grasping|"Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After \~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every GO cue in order to modulate cortical activity during both the planning and execution phase of the action."
48703659|NCT02938832|BEHAVIORAL|Advice on what food to choose and eat|Dietary advice
48015141|NCT05463367|DRUG|Opioids|Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
48703660|NCT05897190|BIOLOGICAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
48015142|NCT05108181|OTHER|Muscle typology + exercise training|Exercise training: Participants perform 9 weeks of strength training at 60% of their 1RM.
48015143|NCT05108181|OTHER|Muscle typology + training frequency|Training frequency: leg A and arm A of the participants train 3 times per week, leg B and arm B train 2 times per week.
48015144|NCT06251700|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonscopy
48015145|NCT03116165|BEHAVIORAL|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
48015146|NCT03116165|BEHAVIORAL|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
48015147|NCT04314193|DRUG|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
48703661|NCT05897190|BIOLOGICAL|CoronaVac®|Dose B
48015148|NCT04314193|DRUG|Prednisolone|Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
48015149|NCT04550481|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48703662|NCT01034566|RADIATION|Proton Beam Radiation Therapy|
48703663|NCT01801436|DRUG|Bortezomib|Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
48015150|NCT04550481|DRUG|Lisinopril|Given PO
48015151|NCT04550481|PROCEDURE|Liver Ultrasonographic Elastography|Undergo transient elastography
48015152|NCT04550481|PROCEDURE|Magnetic Resonance Elastography|Undergo PDFF MRE
48015153|NCT04550481|PROCEDURE|Magnetic Resonance Imaging|Undergo PDFF MRI
48015154|NCT04550481|PROCEDURE|Proton Density Fat Fraction|Undergo PDFF MRI/MRE
48015155|NCT04550481|OTHER|Questionnaire Administration|Ancillary studies
48015156|NCT06080789|DRUG|RABI-767|125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
48015157|NCT04177108|DRUG|Atezolizumab|Atezolizumab was administered as per the dosage regimen mentioned in arm descriptions.
48015158|NCT04177108|DRUG|Ipatasertib|Ipatasertib was administered as per the dosage regimen mentioned in arm descriptions.
48703664|NCT00842946|BEHAVIORAL|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
48703665|NCT00842946|BEHAVIORAL|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
48703666|NCT01762956|OTHER|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
48171710|NCT06511375|OTHER|Power Training|"GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week."
48516483|NCT04622241|OTHER|Eave Ribbons|"Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial).~All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
48703667|NCT00769925|BEHAVIORAL|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
48703668|NCT00769925|BEHAVIORAL|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
48703669|NCT06608823|DEVICE|Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System|Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
48703670|NCT06608823|DEVICE|SAVR|SAVR using commercially available surgical prosthetic valves.
48703671|NCT02235675|DEVICE|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
48171711|NCT03879083|OTHER|Addition of palatal rugae to the complete denture surface|The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
48171712|NCT03879083|OTHER|The removal of the palatal rugae from the complete denture surface|The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
48015159|NCT04177108|DRUG|Paclitaxel|Paclitaxel was administered as per the dosage regimen mentioned in arm descriptions.
48015160|NCT04177108|DRUG|Placebo for Atezolizumab|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
48015161|NCT04177108|DRUG|Placebo for Ipatasertib|Placebo was administered as per the dosage regimen mentioned in arm descriptions.
48171713|NCT00143741|DRUG|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
48171714|NCT03148483|OTHER|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
48171715|NCT03148483|OTHER|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
48015162|NCT06514092|OTHER|anti-TNF therapy and seton drainage|Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.
48015163|NCT01023659|DRUG|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
48171716|NCT03148483|DIETARY_SUPPLEMENT|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
48171717|NCT03148483|DIETARY_SUPPLEMENT|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
48171718|NCT05280743|DRUG|Oxycodone|exposure to opioids after Cesarean Section
48171719|NCT00791739|DRUG|trazodone, pregabalin|"* phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~* phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
48171720|NCT02049112|DEVICE|Salivary equivalent|14-day treatment with salivary equivalent sticks
48171721|NCT02049112|DEVICE|Aequasyal|14-day treatment with Aequasyal oral spray
48372573|NCT05075109|OTHER|Task Related Training|"Each session of TRT would include:~1. postural control, 2. shoulder mobilization, 3. weight bearing exercises 4. Functional activities that will comprise of simple tasks to more advanced movement patterns as follows:~* Reaching activities~  1. Forward supported reach with cane on tabletop~ 2. Reaching against gravity~ 3. Reaching overhead with active wrist/hand movements~ 4. Dynamic reaching to target e.g. catch a ball~* Grasping, holding and release~  1. Grasp, hold and release objects with gravity minimized~ 2. Pick up and move/release small objects on table~ 3. Pick up and move/release large objects without proximal support~ 4. Incorporate pinch grips in hold and release including stacking, lifting and overhead activity~* Upper limb ADL~  1. Brushing hair, putting on scarf~ 2. Opening bottles, turning off water tap~ 3. Writing, drawing~ 4. Folding of towels, hanging towels and setting table~ 5. Self-feeding"
48372574|NCT05846412|OTHER|Catheter Ablation and M-TEER|Already included in arm descriptions.
48703672|NCT03537365|DIETARY_SUPPLEMENT|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
48015164|NCT01023659|DRUG|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
48015165|NCT01023659|BEHAVIORAL|motivational emails|brief motivational emails, sent weekly for 12 weeks
48015166|NCT06663761|BEHAVIORAL|Stimuli|"Stimuli (the order of stimuli 1-4 will be electronically randomized), with a break time between stimuli of 5-10 minutes:~1. Non-invasive blood pressure measurement~2. Heat~3. Mechanical stimulation~4. Visual stimulation~5. Cold pressor test~6. Spicy taste"
48171722|NCT02049112|DEVICE|Biotene|14-day treatment with Biotene oral spray
48171723|NCT01960348|DRUG|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
48171724|NCT01960348|DRUG|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
48171725|NCT02235623|PROCEDURE|Single-stage Fowler-Stephens orchidopexy (FSO)|
48171726|NCT02235623|PROCEDURE|Two-stage Fowler-Stephens orchidopexy (FSO)|
48171727|NCT02716688|DRUG|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
48171728|NCT02716688|RADIATION|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
48372575|NCT05214911|DRUG|Desloratadine , Prednisolone|FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA
48703673|NCT03537365|DIETARY_SUPPLEMENT|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
48703674|NCT00790868|DRUG|d-cycloserine|50mg
48171729|NCT04947826|PROCEDURE|HAIC (Hepatic arterial infusion chemotherapy)|For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
48171730|NCT04947826|DRUG|HLX10 (PD-1 antibody)|PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
48171731|NCT04947826|DRUG|HLX04 (VEGF antibody)|Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
48171732|NCT04947826|DRUG|Placebo|Placebo
48171733|NCT04678765|PROCEDURE|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
48372576|NCT05214911|DRUG|Desloratadine|Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)
48372577|NCT00135265|BEHAVIORAL|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
48372578|NCT02442427|DRUG|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
48372579|NCT02442427|OTHER|Placebo|An equal volume of 0.9% normal saline
48372580|NCT01590628|DRUG|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
48372581|NCT00349960|DRUG|NeoRecormon SC once-weekly versus once-every-other-week|
48372582|NCT01411761|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, first 15 day of life
48372583|NCT01411761|OTHER|serum physiologic|1 cc added to one feeding in a day
48372584|NCT04902547|BEHAVIORAL|Patient Education Workshop (PEWs)|The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
48703675|NCT00790868|DRUG|placebo|50mg
48372585|NCT04902547|PROCEDURE|Multidisciplinary Tapering Program|"The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up."
48372586|NCT03813316|DRUG|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
48372587|NCT03813316|DRUG|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
48703676|NCT02429492|DEVICE|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
48703677|NCT02041975|DIETARY_SUPPLEMENT|Nutriose FB06|Wheat dextrin soluble fibre
48703678|NCT02041975|DIETARY_SUPPLEMENT|Placebo|
48703679|NCT04072601|DRUG|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
48703680|NCT04072601|DRUG|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
48703681|NCT06197191|DEVICE|Fukuda Denshi Cardimax ECG device model FCP-7101|ecg and holter will be done one day before and one day after then after 1,6,12 month after transcatheter closure of ASD
48703682|NCT03586323|DRUG|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
48703683|NCT03262766|OTHER|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
48703684|NCT03262766|BEHAVIORAL|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
48703685|NCT03262766|OTHER|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
48703686|NCT06277700|OTHER|Chiropractic Manipulation (HVLA - high velocity low amplitude)|Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.
48703687|NCT06277700|OTHER|Dynamic Neuromuscular Stabilization|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. First, the participants were taught posterior diaphragm activation in the supine position and the ability to direct the intraabdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Participants will then be taught the ability to perform a chin tuck without disturbing the alignment of the rib cage. In this way, the cervical diaphragm, thoracic diaphragm and pelvic diaphragm will be aligned in parallel. Our aim in this alignment will be to activate the deep stabilizers as a reflex response to intra-abdominal pressure change with the correct diaphragm movement pattern. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern.
48703688|NCT05039164|BEHAVIORAL|Coping Power Program (CPP)|CPP is an evidence-based intervention designed for students with externalizing behavior disorder. CPP consists of twelve 45-minute sessions. This EBP has been found to be effective at reducing aggressive behavior, covert delinquent behavior and substance abuse among aggressive boys, with gains maintained at one-year follow-up. Growth curve analyses showed that CPP had linear effects for three years after intervention on reductions in aggressive behavior and academic behavior problems.
48703689|NCT05039164|BEHAVIORAL|CBT for Anxiety Treatment in Schools (CATS)|CATS is an adaptation of Friends for Life (FRIENDS). The adapted protocol retains the core elements of evidence-based CBT for anxiety and the FRIENDS group format. Investigators implemented planned adaptations to the protocol based on collective experience. Changes were made to the language, cultural methods, number of sessions, and activities while maintaining the 5 essential components of the treatment. This resulted in a briefer (8-session) and more feasible, engaging and culturally appropriate protocol for urban under-resourced schools than the original FRIENDS.
48372588|NCT03813316|DRUG|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
48372589|NCT04303741|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
48372590|NCT04303741|DRUG|Apatinib|Apatinib 250mg will be administered daily until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
48372591|NCT04303741|DRUG|Eribulin|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
48372592|NCT06379854|OTHER|chest physiotherapy|Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy
48372593|NCT06379854|OTHER|trunk rotation exercises,deep diaphragmatic also chest physiotherapy|"Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises"
48372594|NCT06393504|DRUG|Daridorexant|Daridorexant received during or shortly prior to pregnancy.
48372595|NCT06393504|DRUG|Non-orexin receptor antagonist insomnia medication|Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
48372596|NCT06393504|OTHER|No insomnia medication|No insomnia medication received during or shortly prior to pregnancy.
48516484|NCT04622241|OTHER|Full House Screening|"Full house screening includes screening eaves/ceilings, ventilation openings, and windows. Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials. or ceilings, if eaves are closed and ventilation openings. We are also filling in any gaps in the walls. All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents."
48703690|NCT05039164|BEHAVIORAL|Check-in/Check-out (CI/CO)|CI/CO is a targeted, Tier 2 intervention for students at risk of developing externalizing and internalizing mental health disorders. CI/CO is designed to provide immediate feedback (i.e., at the end of each class period) to students, based on the use of a daily report card. This feedback is developmentally sensitive. CI/CO implementers meet individually with students for a brief 'check-in' in the morning and a brief 'check-out' in the afternoon. Research on the use of CI/CO has shown it to be effective in reducing externalizing and internalizing problems with elementary school students. CI/CO will be offered to individual students for a three-month period of time, which is the same time-frame needed for the implementation of CPP.
48703691|NCT05039164|BEHAVIORAL|Initial Training (CC)|School personnel will participate in an initial live remote training.
48703692|NCT05039164|BEHAVIORAL|Initial Training plus Video (RV)|School personnel will participate in an initial live remote training and receive access to asynchronous video training modules.
48703693|NCT05039164|BEHAVIORAL|Initial Training plus Video plus Coaching (RV+)|School personnel will participate in an initial live remote training, receive access to asynchronous video training modules, and receive coaching support from study staff.
48372597|NCT04510662|DRUG|Telmisartan|Patients in this group will receive telmisartan 40 mg daily plus standard care.
48372598|NCT04295629|PROCEDURE|Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia|The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
48372599|NCT04295629|PROCEDURE|Ilioinguinal nerve block|Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
48372600|NCT04765761|DEVICE|PLMA with introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be kept in-situ throughout the duration of positive pressure ventilation
48703694|NCT06438445|DIETARY_SUPPLEMENT|Real Jelly|Participants will receive 500mg of royal jelly capsules per day for two months.
48703695|NCT06438445|DIETARY_SUPPLEMENT|Placebo|Participants will receive 500mg of placebo capsules per day for two months.
48703696|NCT01185418|DRUG|risperidone|
48703697|NCT01185418|DRUG|aripiprazole|
48703698|NCT01185418|DRUG|haloperidol|
48703699|NCT01185418|DRUG|amisulpride|
48703700|NCT01185418|DRUG|lactose|
48703701|NCT01044745|DRUG|rituximab|Given IV
48703702|NCT01044745|DRUG|mycophenolate mofetil|Given IV or PO
48703703|NCT01044745|DRUG|tacrolimus|Given IV
48703704|NCT01044745|DRUG|anti-thymocyte globulin|Given IV
48703705|NCT01044745|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
48703706|NCT01044745|OTHER|laboratory biomarker analysis|Correlative studies
48703707|NCT01044745|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
48703708|NCT01044745|DRUG|cyclophosphamide|Given PO or IV
48372601|NCT04765761|DEVICE|PLMA without introducer|The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be removed after insertion and patient will be ventilated using PLMA without the introducer in-situ throughout the duration of positive pressure ventilation
48703709|NCT01044745|DRUG|fludarabine phosphate|Given IV
48703710|NCT01044745|DRUG|busulfan|Given IV
48015167|NCT05314153|DRUG|Brexanolone|Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
48372602|NCT05821998|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
48372603|NCT05821998|OTHER|Designed chest physical therapy program|Percussion, vibration and modified postural drainage
48372604|NCT05324839|DRUG|Botulinum toxin type A|injecting different dosage to different group
48703711|NCT01044745|RADIATION|total-body irradiation|Undergo TBI
48703712|NCT01044745|BIOLOGICAL|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
48015168|NCT06664684|OTHER|Energy-restricted dietary intervention|The diets were planned based on current guidelines, manuals, systematic reviews, and meta-analyses published in recent years on MAFLD \[5-6, 27-28\]. In this diet, carbohydrates constituted 50%-55% of total energy intake, proteins constituted 10%-20%, and fats constituted 25%-35%. The content of the diets was tailored to each patient, considering various factors such as sex, age, and physical activity status.
48015169|NCT06664684|OTHER|Energy + time-restricted dietary intervention|Patients in the energy + time-restricted diet group followed the same dietary intervention and a 16:8 eating pattern where they were instructed to restrict their energy intake to an 8-h time window and not to consume energy-containing foods or drinks during the remaining 16 h. Participants were allowed to consume energy-free beverages such as water, coffee, and tea during fasting. The timing of the eating window during the day varied according to participants' lifestyles and habits. However, considering the importance of nocturnal fasting, the eating window in all patients started at 10:00-12:00 in the day and ended at 18:00-20:00 in the evening. The energy-restricted diet group did not follow any time restriction in the planning of main meals and snacks.
48015170|NCT01352520|DRUG|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
48015171|NCT03985553|BEHAVIORAL|Parenting Self-Management Program|
48015172|NCT04988685|DEVICE|Sirolimus Eluting Balloon|PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
48015173|NCT03413878|OTHER|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
48015174|NCT01563250|DEVICE|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
48015175|NCT06531707|DRUG|Ibuprofen + Loratadine fixed dose|Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
48015176|NCT06531707|DRUG|Ibuprofen|Suspension 2,000 mg / 100 mL, 20 mL twice a day
48015177|NCT06531707|DRUG|Loratadine|Suspension 1 mg / 1 mL, 5 mL twice a day
48015178|NCT03752281|OTHER|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
48015179|NCT01914432|DRUG|YH16410|
48372605|NCT02039869|DEVICE|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
48372606|NCT02039869|DRUG|Proton pump inhibitor|Acid suppressing medication (over the counter)
48372607|NCT02039869|DRUG|Sucralfate|Coating agent for damaged intestinal lining.
48372608|NCT01437982|DRUG|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
48703713|NCT01044745|BIOLOGICAL|immunosuppressive therapy|Undergo immunosuppressive therapy
48703714|NCT06605586|DRUG|Tasquinimod|treatment with tasquinimod capsules once daily
48015180|NCT01914432|DRUG|Rosuvastatin|
48015181|NCT01914432|DRUG|Telmisartan|
48015182|NCT01914432|DRUG|YH16410 placebo|
48015183|NCT01914432|DRUG|Rosuvastatin placebo|
48015184|NCT01914432|DRUG|Telmisartan placebo|
48372609|NCT01437982|DRUG|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
48372610|NCT04115904|PROCEDURE|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
48703715|NCT01007435|DRUG|Tocilizumab|Tocilizumab was supplied in vials.
48703716|NCT01007435|DRUG|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
48703717|NCT01007435|DRUG|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
48372611|NCT00004058|DRUG|tetradecanoylphorbol acetate|
48372612|NCT03581708|OTHER|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
48372613|NCT01125449|DRUG|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
48372614|NCT06315634|DRUG|Dexmedetomidine|5 micrograms intrathecal dexmedetomidine
48372615|NCT06315634|DRUG|Midazolam|2 milligrams intrathecal midazolam
48372616|NCT06315634|DRUG|Bupivacain|12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
48516485|NCT04622241|OTHER|Partial House Screening|Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present. In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls. No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
48372617|NCT04487626|DEVICE|AI|After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
48372618|NCT05372991|DRUG|CBT-009|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
48372619|NCT05372991|DRUG|Vehicle|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
48372620|NCT05372991|DRUG|Atropine Sulfate|This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
48372621|NCT04145531|DRUG|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
48372622|NCT04145531|DRUG|IV JZP-458|IV JZP-458 will be administered in Part B
48372623|NCT06101940|DIAGNOSTIC_TEST|Brain MRI scan|Normal brain MRI scan to evaluate the integrity of the nervous system
48372624|NCT01050998|BIOLOGICAL|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
48372625|NCT01050998|BIOLOGICAL|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
48372626|NCT01050998|BIOLOGICAL|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
48372627|NCT01050998|BIOLOGICAL|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
48372628|NCT01050998|OTHER|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
48372629|NCT00556972|DEVICE|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
48516486|NCT05756036|OTHER|None Observational study|Non interventional study
48516487|NCT00527410|DRUG|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
48516488|NCT02228850|DRUG|Alprostadil|
48703718|NCT01007435|DRUG|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
48703719|NCT04480190|DRUG|Gemcitabine|IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
48703720|NCT04480190|DRUG|Cisplatin|IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
48372630|NCT02992743|DRUG|letetresgene autoleucel (GSK3377794)|Letetresgene autoleucel (GSK3377794) as an IV infusion.
48372631|NCT02992743|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
48372632|NCT02992743|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
48372633|NCT04988035|DRUG|Danicopan|Danicopan is a small molecule, orally administered complement factor D (FD) inhibitor
48372634|NCT04988035|OTHER|Placebo|Danicopan matching placebo tablet
48372635|NCT04988035|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
48372636|NCT06108531|OTHER||
48372637|NCT03284762|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
48372638|NCT03953651|OTHER|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
48372639|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- crioablation|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
48516489|NCT02228850|OTHER|Placebo|
48516490|NCT02018991|PROCEDURE|Everolimus-Eluting Stent (EES)|Patients treated with EES
48516491|NCT02018991|PROCEDURE|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
48516492|NCT02018991|PROCEDURE|Biolimus-Eluting-Stent (BES)|Patients treated with BES
48516493|NCT04427072|DRUG|Capmatinib|400mg of capmatinib tablets administered orally twice daily
48516494|NCT04427072|DRUG|Docetaxel|Docetaxel 75 mg/m2 by intravenous infusion every 21 days
48516495|NCT00490984|DEVICE|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
48516496|NCT01238107|DRUG|MT-102|BETA BLOCKER
48516497|NCT05446779|DIAGNOSTIC_TEST|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
48516498|NCT05446779|DIAGNOSTIC_TEST|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
48372640|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- pulsed field ablation (PFA)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
48372641|NCT05677516|PROCEDURE|ablation- pulmonary vain isolation- radiofrequency ablation (RF)|Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the radiofrequency ablation (RF) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a RF electrode. RF procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.
48372642|NCT05677516|PROCEDURE|Electrophysiological study (EPS)|"In the electrophysiological study (EPS), electrophysiological parameters such as the recovery time of sinus rhythm (SNRT), Wenckebach's point, AH and HV intervals are measured. The examination begins with venous access through the femoral vein. Then, diagnostic electrodes are inserted into the right atrium, right ventricle and coronary sinus, with which electrophysiological tests are performed. The SNRT is measured after 60 seconds of atrial pacing with a 600ms cycle. The Wencjabach point is determined by stimulation in the incremental protocol. AV and HV intervals are measured during sinus rhythm using an electrode placed on the bundle of His. EPS is performed under local anesthesia. EPS will be performed both before and after pulmonary vein isolation. In patients with atrial fibrillation, during ablation, only the HV interval will be measured.~The procedure is performed using X-ray fluoroscopy."
48372643|NCT05677516|DIAGNOSTIC_TEST|Holter EKG|Holter ECG is a 24-hour, non-invasive ECG recording using a portable recorder and electrodes placed on the patient's chest. The Holter ECG will be performed three times: on the day preceding and on the first day after pulmonary veins isolation, and after 3 months of observation.
48372644|NCT05677516|OTHER|Questionnaire|The survey will be conducted after 3 months of observation and will include questions about the number of hospitalizations due to atrial fibrillation, heart palpitations, changes in pharmacotherapy.
48372645|NCT00489411|DRUG|duloxetine hydrochloride|Given orally
48703721|NCT04480190|DRUG|Fluorouracil|Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
48703722|NCT04480190|RADIATION|Short course ChemoRT|"Radiation Therapy:~Sim: All patients will undergo 4D-CT simulation with 3 hours fasting with or without IV contrast. Compression may be used depending on the tumor motion.~Radiation Target Volume: The gross tumor volume (GTV) will be defined on all relevant imaging datasets including diagnostic CT, MRI, MRCP and/or ERCP data. An iGTV will be generated using the 4D datasets. The clinical target volume (CTV) will include the entire iGTV as well as portal lymphatic and celiac nodal space for all patients with selective treatment of the SMA and pancreaticoduodenal depending on the tumor location. A 5 mm margin will be added to the CTV to generate the planning target volume (PTV).~Radiation Dose: The dose will be 30 Gy in 10 fractions (3 Gy per fraction) for all patients using either 3D Conformal or Intensity Modulated Radiation Therapy techniques."
48703723|NCT04224636|COMBINATION_PRODUCT|Atezolizumab Injection, Bevacizumab Injection|Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
48703724|NCT06537128|BEHAVIORAL|LUNA-Adolescent|Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.
48703725|NCT06537128|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.
48703726|NCT00096226|DRUG|Induction Carboplatin|
48703727|NCT00096226|DRUG|Induction Paclitaxel|
48703728|NCT00096226|PROCEDURE|Resection|
48372646|NCT00489411|OTHER|placebo|Given orally
48372647|NCT05726617|BEHAVIORAL|Avatar Intervention|8 weekly sessions of 60 minutes.
48372648|NCT03107741|OTHER|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
48372649|NCT03107741|OTHER|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
48703729|NCT00096226|DRUG|Consolidation Carboplatin|
48703730|NCT00096226|RADIATION|Radiation Therapy|
48703731|NCT00096226|DRUG|Consolidation Paclitaxel|
48703732|NCT03409211|DIETARY_SUPPLEMENT|PEVCO|All subjects will receive PEVCO for 6 more weeks.
48372650|NCT02258893|OTHER|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
48516499|NCT05446779|DIAGNOSTIC_TEST|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
48516500|NCT02861014|BIOLOGICAL|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
48516501|NCT06399575|OTHER|Apnea Following Isocapnic Hypoxia|Decreasing end-tidal partial pressure of oxygen to 50 mmHg for five minutes, targeting 80-85% peripheral oxygen saturation. The end-tidal partial pressure of carbon dioxide will remain +1 mmHg above baseline levels. After five minutes of hypoxia, participants will complete an apnea.
48703733|NCT03409211|DIETARY_SUPPLEMENT|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
48372651|NCT02258893|OTHER|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
48372652|NCT02258893|OTHER|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
48372653|NCT02551601|OTHER|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
48372654|NCT02049476|DRUG|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
48372655|NCT04716205|OTHER|Mulligan Bent Leg Raise Technique|Participant will be in supine lying on a high couch with the resting on the shoulder. A distraction (longitudinal traction force along the long axis of femur) will be investigator in walk stand position lateral to the leg, which to be stretch. Hip and Knee of the side to be stretch will bent at 90˚- 90 ˚. Participant's flexed knee will be placed over the shoulder, the popliteal fossa of the knee applied at the lower end of femur and the participant will ask to push the shoulder with his or her leg followed by voluntary relaxation.The traction will maintained throughout the technique.
48372656|NCT04716205|OTHER|Static Stretching|It will be given in supine position by performing passive SLR and end range will hold in 30sec.
48372657|NCT05864209|OTHER|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
48372658|NCT05864209|OTHER|Cloth Diapers|Subscription to cloth diaper service.
48372659|NCT05864209|OTHER|Conventional Disposable Diapers|3-month supply.
48015185|NCT05474144|DIETARY_SUPPLEMENT|SmartProbio C|Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
48015186|NCT05474144|DIETARY_SUPPLEMENT|Placebo|Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
48372660|NCT05864209|OTHER|Conventional Baby Products|Products include wipes and diaper cream.
48372661|NCT01024816|BEHAVIORAL|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
48015187|NCT04136834|BIOLOGICAL|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
48015188|NCT06664671|OTHER|Experimental|Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
48015189|NCT06664671|OTHER|Placebo|Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
48015190|NCT06664671|OTHER|Control (Standard treatment)|Patients will complete pre- and post-test forms without any intervention.
48015191|NCT01228240|DRUG|Metformin|
48372662|NCT01024816|BEHAVIORAL|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
48372663|NCT02852876|DRUG|ASP2151|Oral
48372664|NCT02852876|DRUG|Placebo|Oral
48372665|NCT03737617|DRUG|Cuvitru 20 % Injectable Solution|Active
48516502|NCT01269541|DRUG|Mupirocin|Topical in the nose 3 times daily for 5 days
48516503|NCT01269541|DRUG|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
48516504|NCT04687683|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions. This stretching exercise will be applied in 5 repetitions for one session.
48015192|NCT05911620|DEVICE|Magnetic resonance elastography (MRE)|Magnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
48015193|NCT05639088|BEHAVIORAL|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
48171734|NCT04678765|PROCEDURE|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
48171735|NCT03900429|DRUG|MGL-3196|Tablet
48171736|NCT03900429|DRUG|Placebo|Matching Tablets
48171737|NCT03900429|PROCEDURE|Liver Biopsy|A procedure in which a needle is inserted into the liver to collect a tissue sample
48171738|NCT00129506|DRUG|methotrexate + misoprostol|
48171739|NCT00129506|DRUG|misoprostol|
48171740|NCT06175221|BIOLOGICAL|Tumor lysate, particle only (TLPO) vaccine|A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor. Immature DCs avidly phagocytose small particles in the range of 1-5 microns. Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension. The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells. The TL is then loaded into these YCWP.
48171741|NCT01250847|DRUG|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
48171742|NCT01648478|OTHER|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~* A basal period (from T-30 to T0)~* The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~* The infusion of glucose at variable rate (so as to maintain euglycemia)"
48171743|NCT00586118|DRUG|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
48171744|NCT00586118|DRUG|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
48171745|NCT04212780|DEVICE|Medtronic Summit Rechargable (RC)+S|Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
48171746|NCT04212780|PROCEDURE|ipsilateral thalamic (VIM+VO) DBS|Implantation of two new ipsilateral thalamic (VIM+VO) DBS
48171747|NCT04212780|PROCEDURE|standard ET DBS|Single Lead VIM
48703734|NCT06521515|DIAGNOSTIC_TEST|Lung Ultrasound Morphology Patterns|Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
48703735|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, TID
48703736|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, BID
48015194|NCT05639088|OTHER|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
48171748|NCT04212780|PROCEDURE|ipsilateral VO|second lead in the ipsilateral VO
48171749|NCT04488978|DRUG|Irbesartan/Amlodipine|QID
48171750|NCT05229770|DIETARY_SUPPLEMENT|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
48703737|NCT01626118|DRUG|Indomethacin|capsules, 20 mg, TID
48703738|NCT01626118|DRUG|Placebo|capsules
48703739|NCT05887544|OTHER|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
48703740|NCT05887544|OTHER|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
48703741|NCT05887544|OTHER|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
48703742|NCT06319469|DRUG|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
48703743|NCT06319469|DRUG|silodosin 8 mg capsule|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
48703744|NCT05467332|DEVICE|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
48372666|NCT06109766|BEHAVIORAL|Promoting First Relationships|"Promoting First Relationships ® is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family or over Zoom. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
48372667|NCT02426164|DRUG|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
48703745|NCT02870075|BEHAVIORAL|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
48703746|NCT02870075|BEHAVIORAL|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
48703747|NCT05617053|DEVICE|DAART|
48703748|NCT05617053|DEVICE|ATP/Supera stenting|
48703749|NCT03833986|OTHER|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
48703750|NCT03479177|BEHAVIORAL|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
48703751|NCT03374267|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
48703752|NCT05865405|BEHAVIORAL|MS CATCH|Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
48703753|NCT03865108|PROCEDURE|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
48703754|NCT03865108|PROCEDURE|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
48171751|NCT00506922|DRUG|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2"
48372668|NCT02426164|DRUG|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
48372669|NCT04112108|PROCEDURE|PTMC|percutaneous mitral ballooning with Inoue balloon
48372670|NCT03372304|DRUG|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
48372671|NCT03517150|DEVICE|mandibular advancement device|
48372672|NCT02360358|DRUG|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
48372673|NCT02360358|OTHER|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
48372674|NCT00002600|BIOLOGICAL|filgrastim|
48372675|NCT00002600|DRUG|carboplatin|
48372676|NCT00002600|DRUG|cyclophosphamide|
48372677|NCT00002600|PROCEDURE|autologous bone marrow transplantation|
48372678|NCT00002600|PROCEDURE|peripheral blood stem cell transplantation|
48372679|NCT02962999|DRUG|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
48703755|NCT06604286|DRUG|In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
48703756|NCT06604286|DRUG|8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.
48703757|NCT03965884|OTHER|Physical therapy and rehabilitation|Physical therapy and rehabilitation
48703758|NCT01691885|DRUG|Fluticasone Furoate|100mcg Once daily
48703759|NCT01691885|DRUG|Vilanterol|25mcg Once daily
48703760|NCT04131387|DEVICE|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
48703761|NCT04131387|DEVICE|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
48703762|NCT02553200|DEVICE|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
48703763|NCT02553200|DEVICE|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
48703764|NCT02553200|DEVICE|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
48372680|NCT02962999|DRUG|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
48372681|NCT06374511|DIAGNOSTIC_TEST|Test for CMV reactivation|All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
48372682|NCT00482976|DRUG|Ruboxistaurin|
48703765|NCT05725486|DIETARY_SUPPLEMENT|N-3 PUFAs Chicken Meet|Intake of n-3 PUFAs enriched chicken meet for three weeks.
48372683|NCT00482976|DRUG|Placebo|
48372684|NCT01206296|DRUG|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
48372685|NCT04019080|OTHER|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
48372686|NCT01254734|PROCEDURE|transoral robotic surgery|Undergo transoral robotic microsurgery
48372687|NCT01254734|OTHER|laboratory biomarker analysis|Correlative studies
48372688|NCT01254734|PROCEDURE|quality-of-life assessment|Ancillary studies
48372689|NCT03138265|BEHAVIORAL|HIIT Device: ergometer|Supervised exercise training.
48703766|NCT05725486|DIETARY_SUPPLEMENT|Regular Chicken Meet|Intake of regular chicken meet for three weeks.
48703767|NCT02759107|DRUG|Tirzepatide|Administered SC
48703768|NCT02759107|DRUG|Placebo|Administered SC
48703769|NCT02759107|DRUG|Dulaglutide|Administered SC
48703770|NCT04146961|DEVICE|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
48703771|NCT02370537|DRUG|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
48703772|NCT02370537|DRUG|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
48703773|NCT00460759|DRUG|Moxifloxacin|
48703774|NCT00460759|DRUG|Rifapentine|
48703775|NCT05326191|DIAGNOSTIC_TEST|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
48372690|NCT05661006|DIETARY_SUPPLEMENT|Use of food supplement|"On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).~In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).~Intervention end on day 56 ±3 (fasted condition):~Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight \& height Collecting data regarding the palatability of the product"
48372691|NCT05661006|DIETARY_SUPPLEMENT|Use of placebo food supplement|On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
48372692|NCT01985555|DRUG|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
48372693|NCT02564627|PROCEDURE|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
48372694|NCT02564627|PROCEDURE|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
48372695|NCT02564627|DIETARY_SUPPLEMENT|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
48372696|NCT04837807|DRUG|Systane Hydration PF|This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
48372697|NCT01858402|DRUG|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
48372698|NCT01858402|DRUG|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
48372699|NCT02702076|DRUG|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
48372700|NCT02702076|DRUG|Placebo|Continuous subcutaneous infusion of placebo during waking day
48372701|NCT06380374|OTHER|Gamification in Disaster Nursing Education|The contact information of the students who meet the inclusion criteria will be collected by the researchers. The topic of disaster nursing will be explained to all students enrolled in the course by the researcher in the classroom environment. Pre-tests will be taken from students attending the course on disaster nursing. Randomization will be carried out by the researcher, who does not have an active role in the research process. Students in the experimental and control groups will be hidden from the researchers, who will conduct the application until it begins. The Program will be carried out face-to-face. Students in the experimental group will be on the playground. Students will attend the sessions in groups of 6. Each student will compete independently within the group, and each group will have a winner. Students will encounter a total of 30 questions in each game round. The entire game process consists of 7 sessions. After the game process is completed, post-tests will be taken.
48372702|NCT00429026|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) daily for 5 Days
48372703|NCT00429026|DRUG|Melphalan|70 mg/m\^2 IV Daily for 2 Days
48372704|NCT00429026|DRUG|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
48372705|NCT00429026|PROCEDURE|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
48372706|NCT01487109|DRUG|CTP-499|600 mg tablet twice daily
48372707|NCT01487109|DRUG|Placebo|Matching placebo tablet
48703776|NCT04245267|BEHAVIORAL|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
48703777|NCT05306561|PROCEDURE|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
48703778|NCT05076916|BEHAVIORAL|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
48703779|NCT04981366|DIETARY_SUPPLEMENT|Protein supplement|40g of whey protein in the breakfast;
48703780|NCT04981366|DIETARY_SUPPLEMENT|isocaloric supplement|42g of isocaloric supplement in the breakfast;
48703781|NCT06601868|DIETARY_SUPPLEMENT|R-Support Prepare & After nutritional supplement|R-Support is a nutritional supplement containing proteins, Vitamine A, Vitamine B6, Vitamine B11, Vitamine B12, Vitamine C, Vitamine D3, Vitamine E, IJzer, Koper, Selenium, Zink, Magnesium, Omega-3 and Beta-glucanen.
48372708|NCT06323655|DRUG|Tasimelteon|oral capsule
48372709|NCT06323655|DRUG|Active Control Placebo|oral capsule
48372710|NCT06323655|DRUG|Tasimelteon Placebo|oral capsule
48372711|NCT06323655|DRUG|Active Control|oral capsule
48372712|NCT02347345|DRUG|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
48516505|NCT04687683|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions for one session.
48171752|NCT00506922|DRUG|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
48372713|NCT01385839|PROCEDURE|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
48703782|NCT03118427|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
48015195|NCT04226716|BEHAVIORAL|Assessment of postural control, body perception and psychosocial factors|Behavioral assessment of postural control, lumbar proprioceptive use during postural control, back-specific body perception and psychosocial factors (incl. perceived harmfulness of daily activities, pain-related fear of movement, fear-avoidance beliefs, (pregnancy-related) depression, anxiety and stress, optimism/pessimism, pain coping and coping with stressful life events)
48171753|NCT00506922|DRUG|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
48015196|NCT01222585|DRUG|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days.
48703783|NCT03118427|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
48703784|NCT05917990|BEHAVIORAL|Dyadic Text-Messaging Micro-Intervention|Participants receive text-messages consisting of information and skills relevant to improving couples' communication and relationship functioning.
48703785|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
48171754|NCT00848068|OTHER|FID 114657|artificial tears
48171755|NCT00848068|OTHER|OPTIVE Lubricant Eye Drops|artificial tears
48171756|NCT04083937|RADIATION|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
48171757|NCT04083937|RADIATION|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
48171758|NCT04083937|RADIATION|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
48171759|NCT03450148|OTHER|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
48171760|NCT03450148|OTHER|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
48171761|NCT05725733|OTHER|Physical Therapy|The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
48171762|NCT04731675|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
48171763|NCT03766373|COMBINATION_PRODUCT|Drug: OP0201 20mg|OP0201
48171764|NCT03766373|COMBINATION_PRODUCT|Drug: Placebo 0mg|Placebo
48171765|NCT05132530|BEHAVIORAL|yoga|yoga practice will be done two days a week for 10 weeks.
48171766|NCT01338805|DRUG|BGG492|
48171767|NCT02114983|OTHER|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
48015197|NCT05494255|OTHER|Recruitment maneuver|In Group RM (intervention group) after skin closure, mechanical ventilation settings will be set to FiO2:100%, I:E=1:1, respiratory rate: 6, and then tidal volume will be increased gradually by 150 ml until reaching a plato pressure of 30 mmHg. After 3 breaths in this state, RM will be considered accomplished. LUS evaluation will be made just before and after the RM.
48171768|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
48171769|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
48015198|NCT01285206|DEVICE|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
48015199|NCT06319196|DRUG|Opdualag|Opdualag vial IV every 4 weeks (Q4W)
48015200|NCT06319196|DRUG|Nivolumab|Nivolumab 480mg IV Q4W
48015201|NCT05492084|OTHER|without Intervention|without Intervention
48015202|NCT03946670|DRUG|MBG453|MBG453 is being administered i.v.
48015203|NCT03946670|DRUG|Placebo|Placebo is being administered i.v.
48171770|NCT04150341|DRUG|TD-8236|The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
48703786|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
48703787|NCT00306657|PROCEDURE|Optic nerve sheath fenestration|
48015204|NCT03946670|DRUG|Hypomethylating agents|Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.
48171771|NCT04150341|DRUG|Placebo|The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
48372714|NCT01385839|PROCEDURE|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
48372715|NCT00918502|DEVICE|AVIVO system|Non invasive external monitoring device
48372716|NCT03592082|DRUG|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
48372717|NCT03592082|DRUG|standard antibiotic therapy|antibiotic therapy administered per standard protocol
48372718|NCT01779466|DRUG|Desmopressin|
48372719|NCT01779466|DRUG|Placebo (not active)|
48372720|NCT06372158|DIETARY_SUPPLEMENT|Stage 1|Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
48372721|NCT06372158|DIETARY_SUPPLEMENT|Stage 2|Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
48372722|NCT02568176|DRUG|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
48372723|NCT02568176|DRUG|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
48372724|NCT02568176|DRUG|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
48372725|NCT02341482|DRUG|PF-04958242|Administered as specified in the treatment arm
48015205|NCT01329497|OTHER|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
48015206|NCT00544245|BEHAVIORAL|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
48015207|NCT04603859|PROCEDURE|Elective induction of labor at 39 gestational weeks and 0 to 3 days|Elective induction of labor (eIOL) according to local policies
48015208|NCT03766763|DRUG|Venetoclax|"Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment)."
48015209|NCT03249038|OTHER|Measurement of external blood loss|
48015210|NCT03249038|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|
48015211|NCT06663111|OTHER|Blood samples for PK|Blood sampled for pharmacokinetic study
48015212|NCT06663111|OTHER|Blood samples for PK|Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
48015213|NCT02211755|DRUG|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
48015214|NCT02960880|DRUG|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
48015215|NCT02960880|DRUG|Phenprocoumon (branded and generics)|Individually adjusted dose
48372726|NCT02341482|DRUG|Itraconazole|Administered as specified in the treatment arm
48372727|NCT00439010|DRUG|[123I] AV 39|
48372728|NCT03487159|DEVICE|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
48372729|NCT03428139|PROCEDURE|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
48372730|NCT03428139|DRUG|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
48015216|NCT00838305|DRUG|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
48171772|NCT02633397|DRUG|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
48171773|NCT02633397|DRUG|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
48171774|NCT01726517|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
48171775|NCT01726517|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48171776|NCT02906696|DRUG|Bosutinib|Given PO
48171777|NCT02906696|OTHER|Laboratory Biomarker Analysis|Correlative studies
48703788|NCT06563466|OTHER|The experimental intervention PEGASUS|See arm description.
48703789|NCT06563466|OTHER|Treatment as usual|See arm description
48171778|NCT00946634|DRUG|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
48171779|NCT00946634|DRUG|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
48171780|NCT00946634|DRUG|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
48171781|NCT03803553|DRUG|FOLFIRI Protocol|FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
48171782|NCT03803553|OTHER|ACTIVE SURVEILLANCE|Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections
48171783|NCT03803553|DRUG|Nivolumab Protocol|Nivolumab cycle will be four weeks (28 days) long, with Nivolumab administered on day 1. Participants will receive up to 12 four-week cycles (for a total of 48 weeks) of Nivolumab treatment.
48171784|NCT03803553|DRUG|Encorafenib/Binimetinib/Cetuximab Protocol|Encorafenib/Binimetinib will be taken orally every day and Cetuximab will be administered intravenously on day 1 of each cycle. Cycles are 14 days long. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of Encorafenib/Binimetinib/Cetuximab.
48171785|NCT03803553|DRUG|Trastuzumab + Pertuzumab|Trastuzumab (Herceptin) is received by intravenous administration and Pertuzumab is received intravenously by infusion on Day 1 of each cycle. Cycles are 21 days long. Participants will receive up to 8 cycles of Trastuzumab and Pertuzumab.
48171786|NCT00878319|PROCEDURE|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
48171787|NCT00878319|OTHER|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
48171788|NCT02036255|DRUG|Taurolidine Urokinase|
48171789|NCT02036255|DRUG|Taurolidine Heparin|
48171790|NCT06248112|DRUG|Sacubitril and Valsartan-Test product|Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Manufactured by: Hetero Labs Ltd., India
48171791|NCT06248112|DRUG|Sacubitril and Valsartan-Reference product|Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland
48171792|NCT00315666|DRUG|memantine|
48171793|NCT03354234|OTHER|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
48372731|NCT02645682|DEVICE|anti-infection CVC|
48372732|NCT02645682|DEVICE|normal CVC|
48372733|NCT05973422|DEVICE|SIGI Insulin Management System|Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
48703790|NCT03822598|BEHAVIORAL|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
48703791|NCT02193386|OTHER|No intervention, no follow-up, only registration|Usual Care
48703792|NCT02193386|OTHER|Intervention period|Predefined intervention program
48015217|NCT00838305|DRUG|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
48015218|NCT06028022|DIETARY_SUPPLEMENT|Mushroom Extract|Given Reishi mushroom extract PO
48015219|NCT06028022|DRUG|Placebo Administration|Given PO
48171794|NCT03354234|OTHER|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
48171795|NCT03354234|OTHER|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
48171796|NCT03354234|DEVICE|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
48171797|NCT03354234|DEVICE|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
48171798|NCT00637832|BIOLOGICAL|rituximab|
48171799|NCT00637832|DRUG|cyclophosphamide|
48171800|NCT00637832|DRUG|doxorubicin hydrochloride|
48171801|NCT00637832|DRUG|prednisolone|
48171802|NCT00637832|DRUG|vincristine sulfate|
48171803|NCT00637832|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
48171804|NCT00520871|DRUG|Blueberry juice|
48372734|NCT05495724|DRUG|Disitamab Vedotin Tislelizumab|Disitamab Vedotin 120mg will be administered on Day 1 of each cycle for 4 treatment cycles;Tislelizumab 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
48703793|NCT04715802|PROCEDURE|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
48703794|NCT04715802|PROCEDURE|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
48703795|NCT04715802|PROCEDURE|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
48703796|NCT04895293|DRUG|RBM-007 Injectable Solution|Sterile solution
48703797|NCT01602783|OTHER|11C Acetate Imaging|Single scan
48703798|NCT04845659|DRUG|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
48703799|NCT02209545|DRUG|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
48703800|NCT02209545|DRUG|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
48015220|NCT06028022|OTHER|Quality-of-Life Assessment|Ancillary studies
48015221|NCT06028022|OTHER|Questionnaire Administration|Ancillary studies
48372735|NCT05495724|DRUG|Disitamab Vedotin|Disitamab Vedotin
48372736|NCT00139269|DRUG|Docetaxel|
48372737|NCT00139269|DRUG|Cisplatin|
48703801|NCT05504304|PROCEDURE|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
48015222|NCT01462903|BIOLOGICAL|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
48372738|NCT00139269|DRUG|5-Fluorouracil|
48516506|NCT04687683|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions for one session.
48516507|NCT03438994|DIAGNOSTIC_TEST|Play.Care|iPad based game to assess movement as the player interacts with the screen
48372739|NCT02231502|OTHER|Vegetable-based convenience food|
48372740|NCT02231502|OTHER|Vegetable meal|
48372741|NCT00938002|DIAGNOSTIC_TEST|Acceler8 Pheno|
48372742|NCT02463812|DRUG|Intralipid|
48372743|NCT02463812|DRUG|Saline|
48372744|NCT00077896|PROCEDURE|Direct Current Polarization|
48372745|NCT01387061|PROCEDURE|hepatic resection|surgical resection of the liver for multiple HCC
48372746|NCT04011514|BEHAVIORAL|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
48372747|NCT02710825|OTHER|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
48516508|NCT00052637|DRUG|hexaminolevulinate|
48516509|NCT00052637|PROCEDURE|biopsy|
48516510|NCT00052637|PROCEDURE|cystoscopy|
48171807|NCT02710097|DRUG|Active inhaled cannabis|"\~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
48171808|NCT02710097|DRUG|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
48171809|NCT02710097|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
48171810|NCT02710097|DRUG|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
48171811|NCT00570557|OTHER|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
48171812|NCT02845310|PROCEDURE|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV \< 10% - MAP \>65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP \> 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (\>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
48171813|NCT02845310|PROCEDURE|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
48171814|NCT03696888|BEHAVIORAL|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
48171815|NCT03696888|BEHAVIORAL|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
48171816|NCT04367363|BEHAVIORAL|Social media & news consumption|Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
48171817|NCT03396211|DRUG|Apatinib|Apatinib tablets
48372748|NCT02710825|OTHER|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
48372749|NCT05244902|DRUG|5% Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
48372750|NCT05164068|BEHAVIORAL|Information video|The video contents were clear and adapted to the characteristics of the population of Guatemala. The video provided a simple description of the biopsy, its risks and benefits, complications and general recommendations, and was presented preoperatively
48372751|NCT00940719|DIETARY_SUPPLEMENT|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
48372752|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
48171818|NCT03396211|DRUG|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
48171819|NCT05506215|DEVICE|SynPath Acellular Dermal Matrix plus Off-loading Device|Application of SynPath
48372753|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
48372754|NCT02688452|DIETARY_SUPPLEMENT|Electrokinetically modified water (EMW)|
48372755|NCT02688452|DIETARY_SUPPLEMENT|Control Unmodified Placebo Water|
48372756|NCT01451177|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
48372757|NCT01795846|OTHER|Allergen specific immunotherapy and placebo injections|
48372758|NCT02564094|DRUG|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
48171820|NCT05506215|DEVICE|Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device|Application Wound Dressing composed of Collagen and Alginate
48171821|NCT04517877|BEHAVIORAL|Caring Response App|Participants will receive the Caring Light mobile app containing the coping skills training.
48372759|NCT00354120|DRUG|Alentuzumab|Alentuzumab
48171822|NCT04517877|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
48171823|NCT05588544|PROCEDURE|Er,Cr:YSGG laser|Use of laser at the degranulation step of the treatment
48171824|NCT01095913|DRUG|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
48171825|NCT01980524|DRUG|acipimox|
48372760|NCT00354120|DRUG|Globulina antilinfocitaria|Globulina antilinfocitaria
48372761|NCT05825911|DIAGNOSTIC_TEST|Rest/Stress MCG scan|All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.
48372762|NCT05825911|DIAGNOSTIC_TEST|Rest MCG scan|This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.
48372763|NCT03763448|PROCEDURE|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
48372764|NCT03763448|PROCEDURE|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
48171826|NCT01980524|DRUG|Placebo Oral Capsule|
48171827|NCT03212950|DRUG|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
48171828|NCT03212950|DRUG|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
48372765|NCT06392282|DRUG|MV-140|MV-140 use - sublingual spray approved for recurrent UTI prevention
48171829|NCT01781013|OTHER|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
48171830|NCT00006005|DRUG|thalidomide|
48171831|NCT05500898|DRUG|DWP16001|Tablets, Oral, multiple doses of DWP16001
48171832|NCT05500898|DRUG|DWC202204+DWC202205|Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
48171833|NCT05500898|DRUG|DWP16001+DWC202204+DWC202205|Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
48171834|NCT01543906|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
48171835|NCT00334971|PROCEDURE|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
48171836|NCT00004090|DRUG|cisplatin|
48171837|NCT00004090|DRUG|gemcitabine hydrochloride|
48171838|NCT03676478|OTHER|delayed start enteral support @ POD5|"instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7."
48171839|NCT05090475|BEHAVIORAL|Academic detailing intervention|Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
48171840|NCT02618902|BIOLOGICAL|tolerogenic dendritic cells (tolDC)|dose-escalation
48171841|NCT00438139|DRUG|Dronabinol|
48171842|NCT00694733|DRUG|Placebo injection|Normal saline injection IM monthly for 4 months
48171843|NCT00694733|DRUG|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
48372766|NCT04707768|DRUG|Vadadustat|oral tablets
48171844|NCT00694733|DRUG|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
48372767|NCT04707768|DRUG|Mircera®|intravenous administration
48372768|NCT05550103|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
48372769|NCT05550103|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
48372770|NCT05550103|OTHER|Standard medical treatment|Standard medical treatment
48372771|NCT01588899|DEVICE|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
48372772|NCT03062852|DEVICE|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
48171845|NCT00694733|DRUG|placebo|Placebo Cream 1ml applied twice daily for four months
48171846|NCT00694733|DRUG|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
48171847|NCT02222883|GENETIC|Testing of BRCA status regarding germline and somatic mutation|
48171848|NCT01504009|OTHER|Muscle training|12 weeks of strength training 2-3 times/week
48171849|NCT00686088|DRUG|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
48372773|NCT04056234|PROCEDURE|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
48372774|NCT00182572|DRUG|buprenorphine|
48372775|NCT00182572|DRUG|naltrexone|
48372776|NCT00182572|PROCEDURE|behavior therapy|
48372777|NCT00182572|PROCEDURE|voucher-based contingency management|
48516511|NCT03742947|DIAGNOSTIC_TEST|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
48516512|NCT05856851|DRUG|Alteplase|See arm/group descriptions.
48372778|NCT00906516|DRUG|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
48372779|NCT02463526|OTHER|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
48372780|NCT02463526|OTHER|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
48372781|NCT01015170|DRUG|bupropion HCl|150mg BID for up to 8 weeks + counseling
48372782|NCT00267826|DRUG|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
48372783|NCT05056909|DEVICE|Kidney ACTion|AI-supported software for chronic kidney disease care
48372784|NCT05056909|OTHER|Standard of care|Standard of care
48372785|NCT01061398|PROCEDURE|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
48372786|NCT01061398|PROCEDURE|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
48372787|NCT04499118|DRUG|AT regimen|Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d
48516513|NCT06223776|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
48516514|NCT00681031|BIOLOGICAL|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
48703802|NCT05504304|PROCEDURE|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
48703803|NCT02654288|OTHER|gemcitabine-based chemotherapy|
48171850|NCT00691678|DRUG|Chondroitin|400mg chondroitin three times a day (TID) for twenty-four weeks
48171851|NCT00691678|DRUG|Glucosamine|500mg glucosamine TID for twenty-four weeks
48171852|NCT01438515|DRUG|Rifampin|600mg po once daily x 7 days
48171853|NCT01438515|DRUG|Doxycycline|100mg po twice daily x 7 days
48171854|NCT01438515|OTHER|2% mupirocin ointment|\~ 1cm applied to the anterior nares twice daily for 7 days
48171855|NCT01438515|OTHER|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
48171856|NCT04160910|DRUG|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
48171857|NCT04160910|DRUG|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
48171858|NCT04410315|OTHER|Serum-lactate < 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
48171859|NCT04410315|OTHER|Serum-lactate >/= 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
48171860|NCT05470959|OTHER|ACTIVA bioactive|bioactive ionic resin composite
48171861|NCT05470959|OTHER|Riva LC|resin-modified glass ionomer
48372788|NCT04499118|DRUG|TP regimen|Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6
48703804|NCT05335187|DEVICE|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
48015223|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected.
48372789|NCT01871870|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
48372790|NCT02096601|DRUG|LD/CD SC solution|Levodopa/carbidopa SC solution
48372791|NCT02096601|DRUG|Entacapone|Entacapone 200 mg oral tablet
48015224|NCT06664164|PROCEDURE|ANTERİOR QUADRATUS LUMBORUM BLOCK WİTH ADJUVANT|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 8 mg de-xamethasone are injected.
48372792|NCT01308476|PROCEDURE|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
48015225|NCT03698773|OTHER|Access to routine information|Access to routine pain-control information
48015226|NCT03698773|OTHER|Access to website|Access to informational website: thepainlesspush.com
48171862|NCT00721214|DRUG|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
48171863|NCT06471907|PROCEDURE|erector spinae plane block|fascial plane injection using ultrasound
48171864|NCT00788164|BIOLOGICAL|TA-HPV|Given intramuscularly
48372793|NCT01308476|PROCEDURE|control group|no daily SMS to remind of treatment with tiotropium
48372794|NCT02615158|BEHAVIORAL|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
48372795|NCT02615158|BEHAVIORAL|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
48372796|NCT02615158|BEHAVIORAL|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
48703805|NCT04939597|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48703806|NCT04939597|PROCEDURE|Cognitive Assessment|Complete cognitive testing
48171865|NCT00788164|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
48171866|NCT00788164|DRUG|imiquimod|Given topically
48171867|NCT00700453|BEHAVIORAL|Control group with no video game play|Subjects will abstain from all video game play during study participation.
48703807|NCT04939597|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48703808|NCT04939597|DRUG|Memantine Hydrochloride|Given PO
48703809|NCT04939597|DRUG|Placebo Administration|Given PO
48703810|NCT04939597|OTHER|Questionnaire Administration|Ancillary studies
48703811|NCT05480189|OTHER|Non-intervention|Non-intervention,with real world study
48703812|NCT00162747|DRUG|Aquaphor|
48703813|NCT00162747|DRUG|Sunflower Seed Oil|
48372797|NCT04238117|PROCEDURE|Laser acupuncture treatment|Laser acupuncture therapy (LAT) is a noninvasive technique that involves stimulation of traditional acupoints with low intensity, non thermal laser irradiation.
48372798|NCT03283033|BEHAVIORAL|New salad bar|New salad bar placed in school
48372799|NCT03283033|BEHAVIORAL|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
48372800|NCT04740762|BEHAVIORAL|Intervention group|The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
48372801|NCT05119114|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A standardized multi-parametric MRI protocol will be implemented for all patients. All sequences will be acquired on a 1.5 Tesla scanner. After completion of the MRI study, the digital imaging and communication data will be sent to a diagnostic workstation for post-processing and analysis. Patients of the study will be subjected to detailed structural MRI for detection of signs of neurodegenerative changes. Volumetric high-resolution 3D scans will be used for quantitative study.
48372802|NCT06063382|BEHAVIORAL|Exam|Academic exam based on the Brazilian National High School Exam (ENEM).
48372803|NCT02652676|PROCEDURE|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
48372804|NCT02652676|PROCEDURE|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
48372805|NCT04136509|PROCEDURE|sinus floor elevation|sinus floor elevation with the lateral technique
48372806|NCT04136509|PROCEDURE|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
48372807|NCT04136509|DEVICE|dental implant placement|During reentry after bone biopsy dental implants were placed.
48372808|NCT04136509|DIAGNOSTIC_TEST|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
48372809|NCT01933269|DRUG|FACBC|
48372810|NCT04398030|DEVICE|coil-reinforced soft polymer indwelling cannula|Insulin infusion set will be used for up to 7 days of continuous use or until failure
48372811|NCT04398030|DEVICE|soft Teflon indwelling catheter|Insulin infusion set will be used for up to 7 days of continuous use or until failure
48372812|NCT06245850|BEHAVIORAL|Baduanjin|chinese baduanjin
48372813|NCT06245850|BEHAVIORAL|Rational emotive behavior therapy|Rational emotive behavior therapy
48372814|NCT01587716|DRUG|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
48372815|NCT01587716|OTHER|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
48703814|NCT06232850|OTHER|Position sense and manual dexterity evaluate|Position sense and manual dexterity evaluate
48171868|NCT00700453|BEHAVIORAL|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
48171869|NCT00700453|BEHAVIORAL|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
48171870|NCT00700453|BEHAVIORAL|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
48372816|NCT01587716|DRUG|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
48372817|NCT01587716|OTHER|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
48372818|NCT05341531|OTHER|elderly patients undergoing non-cardiac surgery|Elderly patients 60 years and older undergoing major non-cardiac surgery \> 2 hours
48372819|NCT05228327|DEVICE|Occlusal splint treatment|Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.
48703815|NCT03761888|DIAGNOSTIC_TEST|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
48703816|NCT05864365|DRUG|ATH434|ATH434 taken by mouth two times per day
48703817|NCT05263986|DRUG|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
48703818|NCT05642234|PROCEDURE|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
48171871|NCT04848376|DEVICE|(1) SmartLoc (2) SmartLoc Evo (3) Winloc(4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L|As long as there are patients using the above device, conduct questionnaire interview.
48703819|NCT01568151|BEHAVIORAL|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
48171872|NCT05698862|DIETARY_SUPPLEMENT|Probiotic|Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)
48171873|NCT05698862|DIETARY_SUPPLEMENT|Placebo|Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
48703820|NCT01568151|BEHAVIORAL|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
48703821|NCT00993512|DRUG|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
48703822|NCT00993512|DRUG|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
48703823|NCT00993512|OTHER|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
48171874|NCT04875598|PROCEDURE|Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block|Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.
48171875|NCT02453477|GENETIC|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
48171876|NCT02684799|DRUG|Cenicriviroc|
48171877|NCT02684799|DRUG|Omeprazole|
48171878|NCT02684799|DRUG|Famotidine|
48171879|NCT01447862|DRUG|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
48171880|NCT01447862|DRUG|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
48372820|NCT05228327|PROCEDURE|Masticatory muscle injection|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.
48372821|NCT05228327|COMBINATION_PRODUCT|Combination of occlusal splint and masticatory muscle injection treatments|Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
48703824|NCT04096820|BIOLOGICAL|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
48171881|NCT00252018|BEHAVIORAL|Daily intake of broccoli sprouts|
48372822|NCT00287612|PROCEDURE|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
48372823|NCT00287612|PROCEDURE|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
48372824|NCT06300281|BEHAVIORAL|Neuromuscular Exercise|A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization
48372825|NCT06300281|BEHAVIORAL|Aquatic Exercise|The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
48703825|NCT02596958|DRUG|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
48703826|NCT02106624|OTHER|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
48703827|NCT00697866|BIOLOGICAL|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
48703828|NCT00697866|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
48703829|NCT00367718|DRUG|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
48171882|NCT01200927|OTHER|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
48171883|NCT02137499|DEVICE|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
48171884|NCT06254300|BEHAVIORAL|Exercise Training|The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
48372826|NCT01911546|DRUG|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
48372827|NCT01435876|PROCEDURE|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
48372828|NCT01435876|PROCEDURE|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
48015227|NCT01416194|DRUG|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
48015228|NCT01416194|DRUG|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
48015229|NCT01416194|DRUG|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
48015230|NCT02541240|OTHER|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
48015231|NCT06442267|DRUG|Enoxaparin Injectable Solution|Subcutaneous Enoxaparin will be dosed at 0.5 mg/kg twice daily
48015232|NCT06442267|DRUG|Argatroban, 1 Mg/mL Intravenous Solution|Intravenous Argatroban will be administered as a continuous infusion of 0.1-1 µg/kg/min with a target modified thrombin time measured using Hemoclot of 0,40 - 0,60 µg/mL.
48015233|NCT06442267|DRUG|Unfractionated heparin|Unfractionated heparin will be administered as a continuous infusion of 7.5-20 units/kg/h with a target Anti FXa calibrated for UFH of 0.3-0.5 u/mL.
48015234|NCT05091567|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
48015235|NCT05091567|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
48015236|NCT05091567|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
48015237|NCT05091567|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
48015238|NCT06499519|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
48015239|NCT04346615|DRUG|Zavegepant (BHV-3500)|10 mg intranasal (IN) for 14 days
48015240|NCT04346615|DRUG|Placebo|Placebo Q8h for 14 days
48703830|NCT00322023|DRUG|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
48015241|NCT00861497|DRUG|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
48015242|NCT04888000|OTHER|Educational Intervention|Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
48015243|NCT00396734|DRUG|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
48015244|NCT00396734|DRUG|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
48171885|NCT04383847|BEHAVIORAL|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
48171886|NCT03187353|DRUG|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
48703831|NCT00322023|DRUG|D-serine|
48703832|NCT00322023|DRUG|D-serine|
48703833|NCT00322023|DRUG|D-serine|
48703834|NCT02495246|BIOLOGICAL|ChAd3-EBO-Z|
48015245|NCT06002763|OTHER|PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)|PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
48015246|NCT06002763|OTHER|WHOQoLBREF (World Health Organization Quality of Life Brief Version)|The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
48015247|NCT06002763|OTHER|EQ-5D-3L1 (not an acronym)|The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
48015248|NCT02170753|PROCEDURE|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
48015249|NCT02170753|PROCEDURE|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
48015250|NCT04595838|DEVICE|Chemo Mouthpiece|Frozen tube that fills the oral cavity used during and after chemotherapy to ease and prevent symptoms of oral mucositis
48015251|NCT04595838|OTHER|Best Supportive Care only|Standard Oral care for Chemotherapy
48171887|NCT03187353|DRUG|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
48703835|NCT02495246|BIOLOGICAL|Ad26.ZEBOV|
48703836|NCT05934526|DRUG|Placebo|Matching capsule containing placebo
48703837|NCT05934526|DRUG|Seralutinib|Capsule containing seralutinib
48703838|NCT05934526|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for seralutinib or placebo delivery
48703839|NCT01077999|DRUG|Carboplatin|Carboplatin AUC = 2 , weekly.
48703840|NCT01077999|DRUG|Paclitaxel|Paclitaxel 50 mg/m2, weekly
48703841|NCT01077999|DRUG|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
48703842|NCT01077999|RADIATION|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
48703843|NCT00467545|DRUG|telbivudine|
48703844|NCT00223808|OTHER|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
48015252|NCT02468843|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)"
48015253|NCT02468843|OTHER|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
48015254|NCT02468843|OTHER|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
48015255|NCT01231763|OTHER|No intervention (not applicable)|No intervention (not applicable)
48015256|NCT04099524|DEVICE|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (\~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
48015257|NCT04454385|DIAGNOSTIC_TEST|Patients with well controlled asthma|"Patients with well controlled asthma~The following parameters are to be evaluated:~Blood eosinophils FeNO Findings on lung function test"
48015258|NCT06116253|DEVICE|Magnetic Resonance Imaging (MRI) Scan|Participants will undergo a 1-hour research MRI scan.
48015259|NCT06116253|DRUG|Tc-99m Pentetate|Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
48015260|NCT03057626|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
48015261|NCT03057626|OTHER|Laboratory Biomarker Analysis|Correlative studies
48015262|NCT03057626|OTHER|Quality-of-Life Assessment|Ancillary studies
48015263|NCT03603795|DRUG|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
48015264|NCT03603795|DRUG|Placebo|Placebo concomitant with induction chemotherapy patients with AML
48015265|NCT04713384|DEVICE|Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games|20 sessions of playing therapeutic games using both arms while siting at a table at home. Arms hold either generic game controllers, or BrightBrainer therapeutic controllers. Sessions involve a variety of games that train motor and cognitive function in an integrative way. The games are rendered by the BrightBrainer system. Games adapt and are winnable, benefiting well-being (reducing depression). Each session may generate many hundreds of arm repetitions, finger movement and grasps, depending on session duration. Data on arm reach as well as game outcomes and vitals are uploaded to an secure server. These data allow researchers to remotely monitor compliance to protocol and longitudinal progress. Caregivers are present at each session, and provide feedback as well as subjective ratings of the system.
48015266|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
48015267|NCT04364997|DRUG|Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule|Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,
48015268|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule Placebo|Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.
48015269|NCT04364997|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
48015270|NCT06061770|OTHER|Adapted physical activity program|Rehabilitation
48015271|NCT06061770|OTHER|Adapted physical activity self-program|Rehabilitation
48015272|NCT05068440|DRUG|Zanubrutinib|administered orally as capsules
48015273|NCT02566551|PROCEDURE|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
48015274|NCT02566551|DEVICE|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
48015275|NCT02566551|PROCEDURE|TURP|Bipolar transurethral resection of the prostate
48015276|NCT02566551|DEVICE|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
48015277|NCT04410926|OTHER|Corrective exercises|The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes
48015278|NCT04410926|OTHER|Neuromuscular electrical stimulation|The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles for 30 minutes. The surface electrodes were placed over the abductor halluces. The control group received placebo NMES with no current stimulation.
48015279|NCT05870176|BEHAVIORAL|Enhanced Referral|The enhanced referral uses an electronic referral and patient decision aid to provide choices to 3 different physical activity programs.
48015280|NCT05870176|BEHAVIORAL|Standard Referral|"The standard referral period will serve as the usual care comparator. Patients will receive a paper referral and Fitbit monitor."
48015281|NCT00949013|OTHER|immunohistochemistry staining method|
48015282|NCT00949013|OTHER|laboratory biomarker analysis|
48015283|NCT06350864|DEVICE|High-flow nasal cannula (HFNC)|high flow cartridge and adult size nasal cannula: (flow range: 5-40L/minute, oxygen concentration (FiO2): 21-100%, temperature range: 33-39◦ C, humidity minimum of 12mg/liter)
48015284|NCT06350864|DEVICE|Conventional nasal oxygen therapy (COT)|Adult size, single use nasal cannula
48171888|NCT01612767|DEVICE|PRO-Kinetic Energy Stent|Coronary artery stent implant
48171889|NCT04787289|DRUG|Bevacizumab|Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
48015285|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including gastroscopy|Upper gastrointestinal endoscopy (UGE) will be either diagnostic and/or therapeutic including variceal band ligation, endoscopic hemostasis as injection of bleeding peptic ulcers with adrenaline or bleeders control via either argon plasma coagulation (APC) or heater probe coagulation.
48015286|NCT06350864|DEVICE|Upper gastrointestinal endoscopy (UGE) including Endoscopic ultrasound (EUA)|Upper gastrointestinal endoscopy (UGE) will be diagnostic
48015287|NCT06313528|DRUG|LY3437943|Administered SC
48015288|NCT06313528|OTHER|Placebo|Administered SC
48171890|NCT01584271|DEVICE|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
48703845|NCT00223808|OTHER|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
48703846|NCT00223808|OTHER|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
48015289|NCT01484470|BIOLOGICAL|StemEx|"For patients allocated to StemEx® arm:~* Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~* Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~* Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~* Day 1: StemEx® transplantation.~* Day 2 to 3 years: Post transplant follow-up."
48703847|NCT02027818|DRUG|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
48703848|NCT00192049|DRUG|Gemcitabine|
48015290|NCT01159301|DRUG|entinostat|Given orally (PO)
48015291|NCT01159301|DRUG|sorafenib tosylate|Given PO
48372829|NCT01435876|PROCEDURE|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
48703849|NCT00192049|DRUG|mitomycin C|
48703850|NCT06188650|DRUG|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
48703851|NCT05892770|DRUG|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
48703852|NCT05892770|DRUG|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
48703853|NCT05470101|DRUG|ITI-333|ITI-333 oral solution
48703854|NCT01271010|DRUG|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
48015292|NCT01159301|OTHER|pharmacological study|Correlative studies
48015293|NCT01159301|OTHER|laboratory biomarker analysis|Correlative studies
48015294|NCT04805814|DIAGNOSTIC_TEST|CMR results disclosed|The results of the CMR are disclosed, and used to guide management
48015295|NCT04805814|DIAGNOSTIC_TEST|CMR performed but results not disclosed|The results of the CMR are not disclosed, and management is angiography-guided
48015296|NCT02337829|DRUG|Acalabrutinib (Arm A)|"* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;~* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.~* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;~* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z"
48015297|NCT02337829|DRUG|Acalabrutinib (Arm B)|"B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;~• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y."
48015298|NCT04777409|DRUG|Semaglutide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
48015299|NCT04777409|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
48015300|NCT01693601|DRUG|Panobinostat|PO TIW QOW or PO TIW QW
48015301|NCT01693601|DRUG|Ruxolitinib|PO BID x 28 days
48015302|NCT02312310|DIETARY_SUPPLEMENT|Cocoa Flavanol|12 weeks administration of cocoa flavanol
48015303|NCT06055075|DRUG|Forimtamig|Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
48372830|NCT01435876|PROCEDURE|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
48372831|NCT03780673|DRUG|Simvastatin|Simvastatin 20 mg/day for 12 months
48372832|NCT03780673|DRUG|Rifaximin|Rifaximin 400/8 hours for 12 months
48703855|NCT01271010|DRUG|Fludarabine|Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.
48703856|NCT01271010|DRUG|Rituximab|Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
48703857|NCT04894305|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
48703858|NCT00883870|DRUG|mesenchymal stem cells|Intramuscular injection
48703859|NCT00883870|DRUG|Plasmalyte A|Intramuscular injection
48015304|NCT06055075|DRUG|Carfilzomib|Carfilzomib will be administered via IV infusion in combination with forimtamig.
48015305|NCT06055075|DRUG|Daratumumab|Daratumumab will be administered via SC injection in combination with forimtamig.
48015306|NCT02041026|DIETARY_SUPPLEMENT|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
48015307|NCT01000246|BIOLOGICAL|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
48015308|NCT06301165|DRUG|TPC induction chemotherapy|TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
48015309|NCT06301165|DRUG|GP induction chemotherapy|GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
48015310|NCT02215070|DRUG|Pasireotide|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
48015311|NCT03587259|DIAGNOSTIC_TEST|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
48015312|NCT03587259|DIAGNOSTIC_TEST|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
48015313|NCT06011213|BEHAVIORAL|Issuing health risk warning for a heat waves or cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
48015314|NCT06011213|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
48015315|NCT06011213|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and ECG
48015316|NCT06011213|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
48015317|NCT02652624|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
48015318|NCT02652624|DRUG|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
48015319|NCT02652624|DRUG|ATV|ATV 300 mg capsules administered orally once daily with food
48015320|NCT02652624|DRUG|RTV|RTV 100 mg tablets administered orally once daily with food
48015321|NCT02652624|DRUG|FTC/TDF|200/300 mg tablet administered orally once daily with food
48015322|NCT02652624|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
48015323|NCT00068055|DRUG|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
48372833|NCT03780673|DRUG|Placebo of Simvastatin|Placebo of Simvastatin once a day for 12 months
48703860|NCT02408861|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48015324|NCT00068055|DRUG|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
48015325|NCT00068055|DRUG|Placebo|Normal Saline.
48015326|NCT02700230|PROCEDURE|Computed Tomography|Undergo CT scan
48015327|NCT02700230|OTHER|Laboratory Biomarker Analysis|Correlative studies
48015328|NCT02700230|BIOLOGICAL|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
48015329|NCT02700230|OTHER|Quality-of-Life Assessment|Ancillary studies
48015330|NCT02700230|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT imaging
48015331|NCT02700230|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48015332|NCT02700230|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
48015333|NCT02700230|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48015334|NCT02700230|PROCEDURE|Biopsy|Undergo tissue biopsy
48015335|NCT02700230|OTHER|Questionnaire Administration|Ancillary studies
48015336|NCT05592210|OTHER|Questionnaires|Participants will be asked to fill out the the Demographic Information Sheet, Karitane parenting confidence scale, Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU) and Dyadic Coping Inventory.
48015337|NCT02709395|DEVICE|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
48015338|NCT06164873|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
48015339|NCT06164873|DRUG|Placebo|Once-weekly injections of volume-matched placebo
48015340|NCT01512719|PROCEDURE|POEM|Per Oral Endoscopic Myotomy for achalasia
48015341|NCT04327934|DRUG|GnRH antagonist|GnRH antagonist up to 16 days.
48015342|NCT04327934|DRUG|GnRH antagonist + MethylTESTOSTERone 5 MG|GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
48372834|NCT03780673|DRUG|Placebo of Rifaximin|Placebo of Rifaximin/8 hours for 12 months
48372835|NCT03333564|DIETARY_SUPPLEMENT|VD3|50,000 IU VD3 / week for 8 weeks
48372836|NCT03333564|DIETARY_SUPPLEMENT|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
48703861|NCT02408861|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48703862|NCT02408861|PROCEDURE|Computed Tomography|Undergo CT scan
48703863|NCT02408861|BIOLOGICAL|Ipilimumab|Given IV
48703864|NCT02408861|BIOLOGICAL|Nivolumab|Given IV
48703865|NCT02408861|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48015343|NCT06003855|BEHAVIORAL|Supervised exercise therapy|Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
48516515|NCT05082974|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
48516516|NCT05082974|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray \[control\]
48516517|NCT01790074|OTHER|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
48015344|NCT05446909|BEHAVIORAL|IBMT mindfulness|IBMT is an effortless mindfulness technique; health education is a class including health-related topics - exercise, sleep, nutrition, lifestyle, stress management
48015345|NCT05446909|BEHAVIORAL|health education|Health education includes health-related topics - exercise, sleep, stress management, nutrition, lifestyle
48372837|NCT03333564|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
48372838|NCT03333564|OTHER|Control|No intervention was given
48516518|NCT01790074|OTHER|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
48516519|NCT00757211|GENETIC|polymorphism analysis|
48703866|NCT01218750|PROCEDURE|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
48015346|NCT00906308|DRUG|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
48015347|NCT00906308|DRUG|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
48171891|NCT02406274|OTHER|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
48372839|NCT03603626|DRUG|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
48015348|NCT00906308|DRUG|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
48372840|NCT03603626|DRUG|Placebo oral capsule|Placebo administered 1 hour before surgery
48372841|NCT05697276|DRUG|Lidocaine|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
48372842|NCT05697276|DRUG|Bupivacain|Bupivacaine: Patients will receive 10 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel.
48372843|NCT00532441|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
48516520|NCT00757211|OTHER|laboratory biomarker analysis|
48516521|NCT00757211|OTHER|questionnaire administration|
48516522|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and ligation of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with ligation.
48516523|NCT05978752|PROCEDURE|Endoscopic gel embolization of gastric fundus varices and sclerotherapy of esophageal varices|For patients with GOV1 esophagogastric varices, gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will be treated with sclerotherapy.
48516524|NCT05978752|PROCEDURE|Endoscopic gelatinous embolization of gastric varices (esophageal varices not treated)|For patients with GOV1 esophagogastric varices, only gastric varices will be treated with endoscopic gelatinous embolization, esophageal varices will not be treated.
48516525|NCT06425965|OTHER|Advanced life support training with high reality simulator|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with a high reality simulator in line with the information (15 min), scenario implementation (15 min) and debriefing sessions (30 min), respectively.
48703867|NCT00619424|DRUG|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
48703868|NCT00619424|DRUG|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
48703869|NCT00619424|DRUG|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
48015349|NCT04216719|BEHAVIORAL|OCM-RISE|OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
48015350|NCT00456092|DRUG|Apremilast|Capsules for oral administration
48372844|NCT00532441|DRUG|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
48372845|NCT05619185|BEHAVIORAL|CRAFT Web-Based Intervention|Session 1 addresses CPs' mental health issues and drinking. CPs select reasons why they are seeking help and steps they will take towards those goals. Session 2 is focused on improving their relationship through communication exercises. Session 3 is focused on functional analysis of their partner's drinking, and how to positively reinforce their partner's sobriety and negatively reinforce their drinking. Finally, Session 4 focuses on continuing self-care and talking with their partner about their concerns while interacting with them in healthy ways. The WBI contains audio, video, text, and exercises that utilize digital storytelling and vignettes to convey teaching points - a method utilized by the military to address stigma and increase treatment utilization. Actresses portrayed different experiences that the CP may be going through and modeled skills. CPs clicked on the vignette that they most connected with and followed that character across all the sessions.
48703870|NCT02752958|DRUG|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
48703871|NCT05662774|DIAGNOSTIC_TEST|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
48703872|NCT00194584|BEHAVIORAL|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
48703873|NCT00274235|DRUG|sulfadoxine-pyrimethamine / mefloquine|
48703874|NCT02745782|OTHER|Observational Study|Observational Study
48703875|NCT06575647|DRUG|Tafenoquine|"Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia).~Tafenoquine will be given as follows,~\>10 kg to ≤ 20 kg - 150 mg (1 tab), \>20 kg to ≤ 35 kg - 300 mg (2 tabs), \> 35 kg - 450 mg (3 tabs)"
48703876|NCT01357135|DRUG|Metformin|
48703877|NCT01357135|DRUG|Sitagliptin|
48703878|NCT01357135|DRUG|Sulfonylurea|
48703879|NCT01357135|DRUG|Antihyperglycemic Medication|
48015351|NCT00456092|DRUG|Placebo|Capsules for oral administration
48015352|NCT01888289|DRUG|Isotretinoin|Isotretinoin Capsules,40 mg
48015353|NCT04564755|DRUG|abrocitinib|Participants will receive abrocitinib 100 mg or 200 mg orally once a day as directed by the investigator's clinical judgement
48171892|NCT03978078|OTHER|Biological collection|- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
48171893|NCT00258362|DRUG|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
48171894|NCT00258362|DRUG|docetaxel|75 mg/m\^2 on Day 1 of each course
48703880|NCT01083979|DRUG|Liposomes|Intravesical instillation
48703881|NCT05763901|DIAGNOSTIC_TEST|Clinical tests and motor control evaluation using Inertial Measurement Units|Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
48703882|NCT03979014|BIOLOGICAL|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
48703883|NCT06292754|PROCEDURE|magnesium pin in additional to the suture anchor|magnesium pin in additional to the suture anchor used routinely in clinical practice
48171895|NCT00258362|RADIATION|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
48703884|NCT06292754|PROCEDURE|routine suture anchor|routine suture anchor for the treatment-as-usual
48015354|NCT04731441|BEHAVIORAL|Home-based Exercise Program Prior to CRS-HIPEC|Exercise Program Subjects randomized to the intervention arm should have 6 weeks of home exercise prior to surgery, with a minimum of 5 weeks and not more than 7 weeks. The program will begin with an exercise consultation appointment with a certified fitness professional. During this consultation participants will receive an exercise manual for individualized home-based exercise and a practical introduction by an exercise and cancer specialist. PowerBlock adjustable dumbbells will be used for resistance training exercises and walking or jogging will be the primary type of aerobic training. The current program design was developed and successfully used with women with breast cancer. Thus, some components may need modification for this group of patients with advanced GI cancer.
48015355|NCT04731441|BEHAVIORAL|Exercise Education|Control arm: Subjects randomized to the control arm will receive education and a handbook on the benefits of exercise and will be encouraged to have adequate protein in their diet and provided with the list of high protein foods and nutritional information. These subjects will undergo the same assessments as the intervention arm at all time points. Control subjects will be offered a 6-week home exercise program 3 months after CRS/HIPEC, as described in sections 7.2.1-7.2.3. Results and outcomes will not be recorded.
48015356|NCT05033964|COMBINATION_PRODUCT|Percutaneous Coronary Intervention with drug eluting stents|Coronary drug eluting stent implantation
48015357|NCT01897311|DEVICE|transcutaneous electrical nerve stimulation|
48015358|NCT00967408|DRUG|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
48015359|NCT00967408|DRUG|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
48015360|NCT00967408|OTHER|Rehabilitative treatment|Rehabilitative treatment
48015361|NCT00002453|DRUG|Tenofovir disoproxil fumarate|
48015362|NCT04140149|BEHAVIORAL|Living with Hope|12-week, CBT-based, psychoeducational skills class
48015363|NCT06075706|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
48015364|NCT06075706|BIOLOGICAL|BAT|BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
48015365|NCT01961869|OTHER|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
48372846|NCT05619185|BEHAVIORAL|Phone-Based CRAFT|The phone-based CRAFT intervention consists of six individual sessions with a CRAFT clinician that will explore what they learned from the WBI and additional skills they need. Session content includes positive reinforcement of non-drinking SM behaviors, refraining from interfering in SM's consequences of alcohol use, communication skills, and self-care.
48015366|NCT01961869|OTHER|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
48516526|NCT06425965|OTHER|Advanced life support training with web-based simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out by web-based simulation method. Students participate in the web-based simulation application developed by the researcher.
48516527|NCT06425965|OTHER|Advanced life support training with hybrid simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with the hybrid simulation method in which high reality simulator and web-based simulation method are applied together. Students first apply the web-based simulation developed by the researcher. Then they perform the practice on the high reality simulator.
48015367|NCT01961869|OTHER|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
48015368|NCT01516190|BEHAVIORAL|Exercise|Supervised exercise sessions and independent exercise
48015369|NCT01516190|BEHAVIORAL|Surgical preparation program|Book, tapes, CD
48015370|NCT05198492|OTHER|Impact of air pollution|To assess the short- and long- term impact of air pollution
48015371|NCT04539366|PROCEDURE|Biopsy|Undergo biopsy
48015372|NCT04539366|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48015373|NCT04539366|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48372847|NCT05619185|BEHAVIORAL|CRAFT Workbook|The self-directed CRAFT workbook Table 1.Partners Connect WBI has a parent and partner version that uses CRAFT to help the CP help with understanding, self-care, communication, and actions (e.g., how to react when a partner has been using substances and when they have not been using substances, how to talk to partner so that they are more likely to be heard) and includes more information about communicating than the WBI and several interactive worksheets.
48516528|NCT01259271|DEVICE|Selective Nerve Stimulation (SNS) stimulator device|Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
48703885|NCT06606977|OTHER|Training|"During the detraining period, the athletes did not follow any external (personal) trainer-supported training program and their diet was not altered. Athletes have reported that they have stayed at home as a necessity of the Covid-19 pandemic process, and have done simple home exercises, walking and jogging exercises in a limited way during this time.~The training period included the standard wrestling trainings, which were determined by the national team coaches and realized at different intensities, during the 8 weeks when the training started. Following the period of detraining the level of training intensity was progressively increased throughout the initial 5 weeks. In the 6th and 7th week, training intensity peaked . In the 8th week prior to the competition, the training intensity was reduced in order to prepare and recover for the following competition. After the training period, the wrestlers participated in an international competition."
48703886|NCT05634746|DRUG|APT-1011|"APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.~Other Names:~fluticasone propionate"
48703887|NCT05634746|DRUG|Placebo oral tablet|"Placebo orally disintegrating tablet.~Other Names:~PBO"
48015374|NCT04539366|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48015375|NCT04539366|DRUG|Cyclophosphamide|Given IV
48015376|NCT04539366|PROCEDURE|Echocardiography|Undergo ECHO
48171896|NCT01951378|DEVICE|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS \> 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
48171897|NCT01951378|DEVICE|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
48171898|NCT01951378|DRUG|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
48015377|NCT04539366|DRUG|Fludarabine Phosphate|Given IV
48171899|NCT06065709|BEHAVIORAL|Mindfulness breath awareness meditation|Mindfulness breath awareness meditation
48171900|NCT05258877|OTHER|Plasma samples|Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.
48171901|NCT01920178|DEVICE|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
48703888|NCT05634746|PROCEDURE|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
48015378|NCT04539366|BIOLOGICAL|GD2-CAR-expressing Autologous T-lymphocytes|Given IV
48015379|NCT04539366|PROCEDURE|Imaging Procedure|Undergo standard imaging scans
48015380|NCT04539366|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo cardiac MRI
48015381|NCT04539366|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48171902|NCT01818427|BIOLOGICAL|infusion of 2 units of plasma|infusion of 2 units of plasma
48171903|NCT01891890|DRUG|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
48171904|NCT01891890|DRUG|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
48703889|NCT04983875|BEHAVIORAL|BAC-Enhanced Letter|The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.
48015382|NCT04539366|OTHER|Questionnaire Administration|Ancillary studies
48015383|NCT02714452|BEHAVIORAL|Person-centred care|Person-centred and thriving promoting care
48015384|NCT04549740|DIAGNOSTIC_TEST|salivary alpha amylase level measurement|Saliva samples will be obtained to estimate salivary alpha amylase
48015385|NCT01114841|DRUG|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
48516529|NCT04779879|BIOLOGICAL|Sotrovimab (Gen1)|Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material
48015386|NCT01114841|DRUG|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
48703890|NCT04983875|BEHAVIORAL|Waitlist Control|Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
48703891|NCT05947565|DIAGNOSTIC_TEST|Invasive Urodynamic Study|"Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded."
48015387|NCT05067140|DRUG|ARV-766 Part A&B|"Part A: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part B: Oral tablet(s) once daily in 28 day cycles."
48015388|NCT05067140|DRUG|ARV-766 + Abiraterone Part C&D|"Part C: Daily oral combination dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment.~Part D: Combination administered once daily in 28 day cycles.~Parts C\&D: Participants will also receive concomitant corticosteroid and ADT therapy of investigator choice/patient preference"
48703892|NCT04312360|DRUG|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
48372848|NCT05619185|BEHAVIORAL|Gottman Self-Guided Resources|"To match time spent reviewing the website, CPs will receive an orientation guide that includes the website URL and a 4-week guide for how they can navigate this website for 20-30 minutes per week (e.g., read article 'It's Not My Fault!': Why Defensiveness is Damaging and write down one tool to dissolve defensiveness you're willing to try). We will send reminder emails each week to visit the website and include questions in the emails and our first online follow-up survey asking CPs approximately how many times they visited the website and how long they spent viewing content on the website. Reminder emails will be programmed such that CPs get directed automatically to the website if the CP notes no time spent on it."
48703893|NCT04101539|DEVICE|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
48703894|NCT04101539|DEVICE|Standard PVI|Standard PVI for AF.
48703895|NCT04219319|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
48703896|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
48703897|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
48015389|NCT01313234|BEHAVIORAL|Education|Theory based education and systematic daily assessment
48015390|NCT01997086|PROCEDURE|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
48015391|NCT01997086|PROCEDURE|Microendoscopic discectomy (MED)|Microendoscopic discectomy
48015392|NCT06571279|OTHER|Plant-based diet|"Participants will follow one week Western diet run-in where participants will consume a diet high in processed foods (e.g., fast food, chips, soda). Following the run-in phase, participants will consume plant-based meals and snacks for 5 weeks, which will be delivered directly to their homes or provided directly by the study team. Participants will be permitted to consume one cheat meal of up to 500kcal per week, which will all be reported to the study team."
48015393|NCT00854087|DRUG|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
48171905|NCT01891890|DRUG|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
48703898|NCT01398319|BEHAVIORAL|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
48015394|NCT00854087|DRUG|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
48703899|NCT02308527|DRUG|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
48703900|NCT02308527|DRUG|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
48015395|NCT05621421|PROCEDURE|FFR and IVUS guided PCI|PCI to the long lesion guided with FFR and IVUS
48015396|NCT06246149|DRUG|Tebentafusp|Tebentafusp will be administered weekly i.v.
48015397|NCT04466514|DRUG|ASTX029|Form: tablet; Route of Administration: oral
48015398|NCT01771406|DRUG|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
48015399|NCT01771406|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
48171906|NCT04728932|DRUG|Levosimendan|A continuous infusion of Levosimendan over 24h
48171907|NCT04728932|DRUG|Placebo of Levosimendan|A continuous infusion of Placebo of Levosimendan over 24h
48703901|NCT02308527|DRUG|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
48703902|NCT02308527|DRUG|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
48703903|NCT02308527|DRUG|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
48703904|NCT02308527|DRUG|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
48015400|NCT03093805|DIETARY_SUPPLEMENT|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
48015401|NCT01744444|DRUG|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
48015402|NCT01744444|DRUG|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
48015403|NCT03409692|DIAGNOSTIC_TEST|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
48171908|NCT05172518|DRUG|Taxane plus Intermittent Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
48703905|NCT02308527|DRUG|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
48703906|NCT02308527|DRUG|Dinutuximab Beta|10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
48015404|NCT05464511|OTHER|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.|Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
48015405|NCT01086553|DRUG|budesonide|9mg budesonide OD
48015406|NCT01086553|DRUG|budesonide|3mg budesonide TID
48015407|NCT03844451|DRUG|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
48015408|NCT03844451|DRUG|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
48015409|NCT01242904|DRUG|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
48015410|NCT01242904|DRUG|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
48015411|NCT06209112|DRUG|Sevoflurane|The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from Tzero to reach FAS 2% (Ttarget) will be calculated. Inspired concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
48015412|NCT01792661|OTHER|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
48015413|NCT01792661|OTHER|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
48015414|NCT01792661|OTHER|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
48015415|NCT04201288|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|Acceptance-Based Behavior Therapy (ABBT) In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified barriers to retention in care. Interventionists will help participants identify potential challenges to acceptance, including disclosure concerns. At the second session, participants will practice acceptance-based coping skills and a behavioral plan will be developed to target barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage their HIV.
48015416|NCT04201288|BEHAVIORAL|Enhanced-Treatment-as-Usual (ETAU)|ETAU will consist of two brief sessions lead by study interventionists, performed at the same times and by same methods as ABBT. Topics of education include safe sex practices, review of treatment options, and review of HIV-related indices of health.
48015417|NCT03014752|OTHER|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
48015418|NCT03014752|OTHER|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
48015419|NCT05914584|DRUG|Baricitinib 4 MG|Reference drug
48171909|NCT05172518|DRUG|Utidelone plus Intermittent Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
48171910|NCT05172518|DRUG|Taxane plus Metronomic Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
48516530|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection
48516531|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion
48703907|NCT02308527|DRUG|Cyclophosphamide|250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
48703908|NCT02429557|OTHER|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
48015420|NCT00343187|DRUG|ACZONE (dapsone) Gel, 5%|
48703909|NCT02429557|OTHER|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
48703910|NCT02429557|DRUG|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
48015421|NCT00343187|DRUG|Vehicle Control|
48015422|NCT00113113|DRUG|Rubitecan|
48015423|NCT02247310|DRUG|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
48015424|NCT02247310|DEVICE|BETACONNECT|Auto-injector device to support the injection of Betaferon
48015425|NCT04003727|DEVICE|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
48015426|NCT04441450|DRUG|[14C]ICP-022|150mg suspension containing 100μCi of \[14C\]ICP-022
48015427|NCT03806452|DRUG|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
48015428|NCT03806452|DRUG|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
48015429|NCT00211081|DRUG|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
48516532|NCT04439201|DRUG|Palbociclib|Given PO
48703911|NCT02429557|DRUG|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
48015430|NCT05015491|BEHAVIORAL|Noom Healthy Weight Program|"The Healthy Weight program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Users are encouraged to log their weight (Weight Logging) at least 1x/week and log their food and beverages (Food Logging) daily. Exercise logging (steps via automatic collection or manually added) is done daily. The Noom Food color grading system is founded on calorie-density (Volumetrics diet, Barbara Rolls) and is a simple and effective method for creating long lasting changes in diet and food choice. Coaches are contacted via In-app messaging or phone communication."
48015431|NCT06100250|BEHAVIORAL|Motivational interviewing and specimen self-collection|Participants will be asked to attend a pre-test live AV conferencing session, collect and return a urine sample, a throat swab, a rectal swab, and a blood sample for bacterial STI testing, and attend a post-test live AV conferencing session.
48703912|NCT05849714|OTHER|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
48703913|NCT05849714|OTHER|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
48703914|NCT02685748|DRUG|Aspirin|1000 mg pd in two doses
48015432|NCT06146569|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Current will be applied bilaterally from the tragus and turbinate parts of the ear with the VagustimTM device. The current frequency to be used in modulation mode is 10 Hz, and the pulse width is 300 μs (In modulation mode, the pulse rate and width are automatically changed in a loop pattern. The pulse width is reduced by 50% from its original setting in 0.5 seconds; then, the pulse rate is changed in 0.5 seconds, reduced by 50% from the original setting. Total cycle time is 1 second.). The current intensity will be applied for 5 minutes, keeping the current constant where the participant feels comfortable.
48015433|NCT06146569|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|For 5 minutes, sham applications will be applied using a current-free headset specifically designed for this purpose. Participants will observe the device's functionality, but it will not supply any current.
48015434|NCT00585754|DRUG|Guanfacine|1.5mg BID
48015435|NCT00585754|DRUG|Placebo|placebo
48015436|NCT04870840|RADIATION|Proton Beam Radiation Therapy|Undergo radiation therapy
48703915|NCT02685748|DRUG|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
48015437|NCT04870840|OTHER|Quality-of-Life Assessment|Ancillary studies
48703916|NCT02685748|DRUG|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
48015438|NCT04870840|OTHER|Questionnaire Administration|Ancillary studies
48015439|NCT04456699|DRUG|Olaparib|300 mg BID, oral until progressive disease or end of study
48015440|NCT04456699|DRUG|5-FU|2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
48015441|NCT04456699|DRUG|Bevacizumab|5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
48703917|NCT04913181|DIAGNOSTIC_TEST|Artificial intelligence sepsis prediction model|The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
48703918|NCT04193761|DIAGNOSTIC_TEST|taurine level|Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
48703919|NCT02306863|DEVICE|vibrating chair|vibration provided via physioacoustic method
48703920|NCT02306863|DEVICE|sham treatment|simulated whole-body vibration
48015442|NCT04456699|DRUG|Capecitabine|1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
48015443|NCT04456699|DRUG|Leucovorin/ levoleucovorin|400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
48703921|NCT04971785|DRUG|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
48015444|NCT05242965|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
48703922|NCT04971785|DRUG|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
48703923|NCT04971785|DRUG|PTM SEMA|Administered as SC injection
48703924|NCT04971785|DRUG|PTM CILO/FIR|Tablets administered orally
48703925|NCT05365061|OTHER|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
48703926|NCT05365061|OTHER|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
48703927|NCT05365061|OTHER|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
48703928|NCT04329390|DRUG|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
48703929|NCT05192499|PROCEDURE|Stool test|At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.
48703930|NCT05192499|PROCEDURE|Blood test|Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.
48015445|NCT05242965|BIOLOGICAL|Sargramostim|Given ID
48015446|NCT05242965|PROCEDURE|Computed Tomography|Undergo CT
48015447|NCT05242965|PROCEDURE|Biopsy|Undergo biopsy
48015448|NCT05242965|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48015449|NCT00306592|BIOLOGICAL|BG00002 (natalizumab)|
48703931|NCT05192499|PROCEDURE|Induced sputum|At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
48703932|NCT05192499|PROCEDURE|nasale virology|At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.
48703933|NCT00581269|BEHAVIORAL|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
48703934|NCT00581269|DIETARY_SUPPLEMENT|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
48015450|NCT02353312|DRUG|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
48015451|NCT00184340|DEVICE|eTherapy|secured e-mail system between patient and therapist
48015452|NCT03275727|BEHAVIORAL|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
48015453|NCT05933837|DIAGNOSTIC_TEST|Troponin I|Measurements of plasma Troponin I 6-12 hours and on the first four postoperative days after surgery.
48015454|NCT02612207|DEVICE|Bilirubin Binding Capacity by Hematofluorometry Validation|Observation study
48015456|NCT05132231|BIOLOGICAL|Brodalumab|Brodalumab
48015457|NCT05132231|BIOLOGICAL|Matched cohort|Matched cohort
48015458|NCT03296696|DRUG|AMG 596|Drug
48015459|NCT03296696|DRUG|AMG 404|Drug
48015460|NCT06029959|DEVICE|Continuous positive airway pressure (CPAP)|Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.
48372849|NCT00633334|OTHER|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
48372850|NCT01559584|RADIATION|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
48372851|NCT01559584|DRUG|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
48703935|NCT05270330|OTHER|This is an observational study, we don't have any interventions.|No intervention
48703936|NCT02174367|DEVICE|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
48703937|NCT00994201|OTHER|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
48703938|NCT02154100|DIETARY_SUPPLEMENT|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
48703939|NCT02154100|DIETARY_SUPPLEMENT|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
48015461|NCT06029959|BEHAVIORAL|CPAP technical support intervention|SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.
48015462|NCT06029959|BEHAVIORAL|Motivational Enhancement Therapy (MET)|In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.
48372852|NCT04937543|DRUG|inhaled beclametasone|Adding belcamethasone to standard of care for Covid 19 positive patients
48372853|NCT04937543|DRUG|Inahaled beclomethasone / formoterol / glycopyrronium|Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
48372854|NCT00733694|DEVICE|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
48372855|NCT05059366|DEVICE|Manual Ventilation Grip Device|Manual Ventilation Grip Device is an add-on device placed on a standard valve mask to assist ventilation.
48372856|NCT05059366|OTHER|2VE|the standard 2VE technique for ventilation
48703940|NCT01025349|DRUG|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
48703941|NCT06321419|BEHAVIORAL|Advanced Trauma Life Support training|Advanced Trauma Life Support (ATLS) is a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. The programme was developed by the Committee of Trauma of the American College of Surgeons. The course includes intial treatment and resuscitation, triage and interfacility transfers. Leaning is based on practical scenario-driven skill stations, lectures and includes a final performance proficiency evaluation. Physicians will be trained in an accredited ATLS training facility in India.
48703942|NCT05472675|PROCEDURE|Botulinum toxin and bupivacain|Botulinum toxin A AND bupivacain( local anesthetic)
48015463|NCT06029959|BEHAVIORAL|Mobile Health intervention|Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
48015464|NCT04145791|OTHER|Ice|ice packs
48171911|NCT05172518|DRUG|Utidelone plus Metronomic Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
48703943|NCT03183323|BEHAVIORAL|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
48703944|NCT01984463|DRUG|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
48703945|NCT01984463|DRUG|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
48703946|NCT00322296|DRUG|Bexarotene 1% gel|
48703947|NCT06605651|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
48703948|NCT06605651|DRUG|0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
48703949|NCT04751409|PROCEDURE|Chest Radiography|Undergo CXR
48703950|NCT04751409|PROCEDURE|Computed Tomography|Undergo CT-chest
48703951|NCT04751409|PROCEDURE|Follow-Up|Undergo intense follow-up
48703952|NCT04751409|PROCEDURE|Follow-Up|Undergo limited follow-up
48703953|NCT04751409|PROCEDURE|Imaging Technique|Undergo imaging
48703954|NCT04751409|OTHER|Questionnaire Administration|Ancillary studies
48703955|NCT06599567|OTHER|Traditional therapy|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises
48703956|NCT06599567|OTHER|Graded motor imagery|Cold-Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, graded motor imagery training (body right-left discrimination exercise, imagining the movement and exercising the opposite limb in front of the mirror).
48703957|NCT06599567|OTHER|Nintendo Wİİ|Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
48703958|NCT04467229|BEHAVIORAL|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
48703959|NCT00798629|BIOLOGICAL|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
48703960|NCT03120260|OTHER|Diet|Intervention 'Diet+ short sleep versus normal sleep
48015465|NCT06655935|PROCEDURE|Ordinary Transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO inside the left atrial cavity over stiff wire into the pulmonary veins
48015466|NCT06655935|PROCEDURE|modified transcatheter ASD closure|deploying the Amplatzer delivery system of the Amplatzer™ Septal Occluders ASO over the multipurpose catheter inside the left atrial cavity which might help in the shortage of the duration \& the cost of the procedure with less complication rate
48015467|NCT03197220|OTHER|fish|300 gr/week fish
48015468|NCT03197220|OTHER|walnut|18 walnut per week
48015469|NCT03197220|OTHER|fish-walnut|150 gr fish and 9 walnut per week
48015470|NCT00237952|DRUG|EDTA chelating agents|
48171912|NCT06041178|DRUG|2.5% flurbiprofen|Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
48372857|NCT02815670|DRUG|Idarucizumab|
48372858|NCT05943249|PROCEDURE|magnetic resonance|
48703961|NCT02584231|DRUG|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
48703962|NCT00369174|DRUG|rosiglitazone maleate|Given orally
48703963|NCT00369174|OTHER|laboratory biomarker analysis|Correlative studies
48703964|NCT00006441|DRUG|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
48703965|NCT00006441|DRUG|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
48703966|NCT00006441|DRUG|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
48703967|NCT06343870|DRUG|testosterone pellet (100 mg)|Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
48703968|NCT06343870|DRUG|Placebo|Pellet of cholesterol (placebo)
48703969|NCT01480804|OTHER|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
48703970|NCT06606535|DIAGNOSTIC_TEST|validated questionnaires|Validated questionnaires for climacteric symptoms
48703971|NCT06606535|DIAGNOSTIC_TEST|functional MRI|functional MRI
48703972|NCT06606535|DIAGNOSTIC_TEST|Optical Coherent Tomography Angiography|OCT angiography, macular and peripapillary scans
48703973|NCT01824329|PROCEDURE|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
48703974|NCT01824329|PROCEDURE|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
48703975|NCT02387905|PROCEDURE|Management of Therapy Complications|Undergo vertebral body cement augmentation
48703976|NCT02387905|OTHER|Quality-of-Life Assessment|Ancillary studies
48703977|NCT02387905|OTHER|Questionnaire Administration|Ancillary studies
48703978|NCT02387905|RADIATION|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
48703979|NCT00001399|DRUG|Transduced CD34+ Cells|
48703980|NCT06606925|DIAGNOSTIC_TEST|fMRI with virtual reality flight simulator|During this scan, the subject will be wearing the stereogenic goggles called the Visual System HD (NordicNeuroLab) mounted in the scanner via a headcoil that can be adjusted to the subject\&#39;s comfort using the control arm and completely cover the eyes to prevent light exposure and to clearly visualize eye movement during the flight simulation. The subject will be using a visual response system with customized grips to simulate a stick and throttle in a jet cockpit while visualizing the flight simulation (PICT) in the goggles.
48703981|NCT04040595|PROCEDURE|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
48703982|NCT04405128|DIAGNOSTIC_TEST|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
48703983|NCT04405128|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging|Brain MRI for investigation of brain tissue motion in the presence of suspected stroke.
48703984|NCT00470093|BIOLOGICAL|recombinant interferon-α|
48703985|NCT00470093|BIOLOGICAL|recombinant interleukin-6|
48703986|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
48703987|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
48703988|NCT05740605|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
48703989|NCT05740605|BEHAVIORAL|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
48703990|NCT04372147|PROCEDURE|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
48703991|NCT00489424|DRUG|Placebo|
48703992|NCT00489424|DRUG|Acetaminophen|
48703993|NCT00489424|DRUG|Fluvastatin|
48703994|NCT02762630|DEVICE|Carestream Health Inc. weight bearing cone beam CT scanner|
48703995|NCT02693054|DEVICE|HALO|Laser Treatment
48703996|NCT01345591|PROCEDURE|Fat Grafting|
48703997|NCT05585684|OTHER|Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection|Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
48703998|NCT02845479|OTHER|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
48015471|NCT01298024|OTHER|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
48703999|NCT05470842|DEVICE|Continuous glucose monitoring (Dexcom G6)|"All participants will be issued with the Dexcom G6 device. The trial team will buy the readers or smartphones and sensors and provide the participants with all the necessary equipment. Participants will be shown how to wear the Dexcom G6 device, which they will be asked to wear for up to 10 days (=the lifespan of one sensor).~There will be no change in the standard care of the participants' diabetes management, during the study period."
48516533|NCT05632926|DRUG|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
48704000|NCT01823783|OTHER|Muscle biopsy|Muscle biopsy
48704001|NCT06121141|DRUG|Full strength lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000
48704002|NCT06121141|DRUG|Dilute lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
48015472|NCT05403827|DRUG|K-161|K-161 Ophthalmic Solution
48015473|NCT05403827|DRUG|Placebo|Vehicle Solution
48015474|NCT06117462|OTHER|Assesment of CFS|Assesment of CFS
48015475|NCT04530175|OTHER|blood sampling|2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.
48171913|NCT06041178|DRUG|98% aloe vera|the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
48015476|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
48171914|NCT06041178|OTHER|Placebo|saline
48171915|NCT00611299|DIETARY_SUPPLEMENT|BB-12 and CRL 431|
48171916|NCT00564252|DRUG|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
48704003|NCT03334851|DRUG|PF-06835375|Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
48704004|NCT03334851|DRUG|Placebo|Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
48704005|NCT03317093|DRUG|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
48704006|NCT03317093|OTHER|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
48015477|NCT02100592|OTHER|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
48015478|NCT00295672|DRUG|Vinorelbine|
48015479|NCT05116735|PROCEDURE|laparoscopic partial cystectomy with omentoplasty|laparoscopic partial cystectomy with omentoplasty
48015480|NCT06133621|OTHER|dosage dRVVT|Blood test dRVVT assay on two tubes of blood in the haemostasis laboratory of the Center de Biologie et de Pathologie Est
48015481|NCT06075602|DEVICE|Impact of current PCI techniques/ devices in complex coronary artery lesions|To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
48015482|NCT02459691|BEHAVIORAL|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
48015483|NCT02459691|OTHER|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
48015484|NCT02914964|BEHAVIORAL|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
48015485|NCT02914964|BEHAVIORAL|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
48015486|NCT02633475|GENETIC|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
48015487|NCT04777396|DRUG|Semagludtide|Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks
48015488|NCT04777396|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
48015489|NCT02782897|DRUG|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
48015490|NCT02782897|OTHER|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
48171917|NCT05390996|OTHER|dental implant placement|dental implant placement by using a different drilling techniques
48704007|NCT04025502|DEVICE|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
48704008|NCT05577598|DEVICE|Implantation of a DBS therapy system|"The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula."
48704009|NCT03690492|OTHER|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
48015491|NCT06419049|DEVICE|Altimate Medical EasyStand Bantam|Child will stand in stander 5 days per week for 60 min during each 8 wks intervention
48171918|NCT00716066|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
48171919|NCT00716066|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
48704010|NCT05082454|DEVICE|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
48704011|NCT00530829|DRUG|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
48015492|NCT05405673|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|A kind of stool test
48704012|NCT05372731|OTHER|Recruitment Maneuver|RM after BAL
48704013|NCT03851120|DIETARY_SUPPLEMENT|Probiotics and LC-PUFA (480 mg DHA)|Probiotics and LC-PUFA (480 mg DHA)
48704014|NCT03851120|DIETARY_SUPPLEMENT|Placebo probiotics and control LC-PUFA (120 mg DHA)|Placebo probiotics and control LC-PUFA (120 mg DHA)
48704015|NCT03851120|BEHAVIORAL|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
48704016|NCT00091338|BIOLOGICAL|MART-1 antigen|
48704017|NCT00091338|BIOLOGICAL|gp100 antigen|
48704018|NCT00091338|BIOLOGICAL|incomplete Freund's adjuvant|
48704019|NCT00091338|BIOLOGICAL|recombinant interleukin-7|
48704020|NCT03311139|DRUG|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
48704021|NCT01646645|BIOLOGICAL|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
48015493|NCT06664333|OTHER|Semi-structured interviews|"The study consists of conducting two semi-structured interviews, with an estimated duration of 15 to 30 minutes, with siblings of children hospitalized in pediatric intensive care at Necker-Enfants Malades Hospital and Robert Debré Hospital.~The first interview will take place during the stay in intensive care, the second 1 month after discharge from pediatric intensive care."
48704022|NCT03069170|BIOLOGICAL|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
48704023|NCT05008731|DRUG|Botulinum toxin|100 units (0.5ml) in 1 injection
48704024|NCT05008731|OTHER|Placebo|Placebo 0.5 ml in 1 injection
48015494|NCT03135223|BEHAVIORAL|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
48015495|NCT02291627|DEVICE|MAC|direct laryngoscopy
48015496|NCT02291627|DEVICE|Coopdech|Video laryngoscopy
48015497|NCT02291627|DEVICE|AirTraq|optical laryngoscopy
48704025|NCT02867813|BIOLOGICAL|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
48015498|NCT04412096|DRUG|Timolol 0.5% ophthalmic solution|1 drop BID
48015499|NCT04412096|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop QD
48015500|NCT00004917|BIOLOGICAL|epoetin alfa|
48015501|NCT00004917|DRUG|cisplatin|
48015502|NCT00004917|RADIATION|radiation therapy|
48171920|NCT00716066|DRUG|Carmustine|Given IV
48704026|NCT06390696|BIOLOGICAL|Microbial intervention|Children in microbial intervention arm receive an indoor sandbox containing play sand enriched with organic leaf compost, moss and humus substances. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and microbe rich growing medium containing organic leaf compost, moss, biochar and humus substances.
48704027|NCT06390696|OTHER|Placebo|Children in placebo arm receive an indoor sandbox containing visually similar play sand modified with peat with low microbial diversity. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and growing medium containing peat, inorganic fertilizers, and potting gravel with low microbial diversity.
48171921|NCT00716066|DRUG|Cytarabine|Given IV
48171922|NCT00716066|DRUG|Etoposide|Given IV
48171923|NCT00716066|OTHER|Laboratory Biomarker Analysis|Correlative studies
48704028|NCT01129037|OTHER|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
48704029|NCT02904005|OTHER|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
48704030|NCT06220591|PROCEDURE|Superior trunk block|"The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots."
48704031|NCT06220591|PROCEDURE|Clavipectoral fascial plane block|"The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle."
48704032|NCT06223789|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
48704033|NCT05064293|BEHAVIORAL|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
48704034|NCT05064293|BEHAVIORAL|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
48704035|NCT05379517|DEVICE|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
48704036|NCT05379517|OTHER|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
48704037|NCT03440723|DEVICE|DilaCheck|Measuring device for the measurement of cervical dilation
48704038|NCT03440723|DIAGNOSTIC_TEST|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
48171924|NCT00716066|DRUG|Melphalan|Given IV
48171925|NCT00716066|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic stem cell transplantation
48171926|NCT00716066|DRUG|Prednisone|Given PO
48171927|NCT00716066|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
48171928|NCT05241054|DRUG|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
48171929|NCT05241054|DRUG|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
48171930|NCT05241054|DRUG|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
48171931|NCT05241054|DRUG|Fentanyl|fentanyl 1 microgram.kg
48171932|NCT05241054|DRUG|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
48516534|NCT05632926|DRUG|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
48704039|NCT04989205|BEHAVIORAL|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising \~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
48704040|NCT01145352|DRUG|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
48704041|NCT01478230|DRUG|Nicotine|Nicotine 5 mg Inhaler
48704042|NCT01478230|DRUG|Nicotine|Nicotine 10 mg Inhaler
48704043|NCT01832623|OTHER|Exploration of Vitamin D roles|"* Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~* Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
48704044|NCT06606184|PROCEDURE|Inspiratory muscle Training|Participants underwent a 12-week program consisting of inspiratory muscle training twice daily, incentive spirometry three times daily, and upper limb exercises along with marching in place for 30 minutes.
48704045|NCT06606184|PROCEDURE|Routine Care|Participants received routine care, which included encouragement to use incentive spirometry three times daily.
48704046|NCT06174688|DRUG|BOTOX|Intramuscular Injections
48704047|NCT06174688|DRUG|Placebo|Intramuscular Injections
48015503|NCT02304042|DRUG|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
48704048|NCT04748068|DEVICE|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
48704049|NCT04748068|DEVICE|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
48704050|NCT00801034|DRUG|Calcium|tablets, 1 tablet 2 times per day in 28 days
48704051|NCT00801034|DRUG|Potassium|Tablets, 5 tablets 2 times per day for 28 days
48704052|NCT05105750|DRUG|aspirin 100 mg/d|100mg aspirin for at least 3 days followed by aspirin 100 mg/d
48704053|NCT05105750|DRUG|indobufen 200 mg bid|100mg aspirin for at least 3 days followed by indobufen 200 mg bid
48704054|NCT03986580|DEVICE|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
48704055|NCT06053801|OTHER|Xolair|Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.
48015504|NCT02304042|DRUG|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
48015505|NCT03783351|GENETIC|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
48015506|NCT01917929|DEVICE|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
48171933|NCT05241054|PROCEDURE|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
48171934|NCT05241054|DRUG|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
48516535|NCT05632926|DRUG|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
48015507|NCT05971108|DIAGNOSTIC_TEST|Elecsys® GAAD|Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
48372859|NCT01081002|DRUG|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
48372860|NCT01081002|DRUG|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
48015508|NCT04666038|DRUG|LOXO-305|Oral LOXO-305
48015509|NCT04666038|DRUG|Idelalisib|Oral
48015510|NCT04666038|DRUG|Bendamustine|IV
48015511|NCT04666038|DRUG|Rituximab|IV
48015512|NCT00035906|DRUG|DEX PS DDS®|
48015513|NCT03149640|DRUG|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
48171935|NCT05241054|DRUG|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
48372861|NCT05672810|DIAGNOSTIC_TEST|serum level of Ferritin and D-dimer|Blood venous sample
48171936|NCT05241054|OTHER|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
48372862|NCT04100759|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
48015514|NCT03149640|DRUG|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
48372863|NCT03303352|PROCEDURE|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
48372864|NCT04327531|BEHAVIORAL|turkish physicians|turkish physicians, who work active in pandemic hospital.
48372865|NCT02177370|DRUG|Fenoterol MDI|
48372866|NCT02177370|DRUG|DSCG MDI|
48372867|NCT01138995|DEVICE|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
48704056|NCT06537297|DRUG|Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab|"* Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease."
48704057|NCT01761318|DRUG|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
48372868|NCT01138995|DEVICE|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
48704058|NCT01761318|DRUG|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
48704059|NCT06594042|DIAGNOSTIC_TEST|serum preptin|serum preptin level in chronic kidney disease
48704060|NCT00307840|DRUG|paricalcitol|
48015515|NCT03202316|DRUG|Atezolizumab|Given IV
48015516|NCT03202316|DRUG|Cobimetinib|Given PO
48015517|NCT03202316|DRUG|Eribulin|Given IV
48015518|NCT03202316|OTHER|Laboratory Biomarker Analysis|Correlative studies
48015519|NCT03202316|OTHER|Pharmacological Study|Correlative studies
48015520|NCT05039905|DRUG|99mTc-MSA-ICG|Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
48171937|NCT05241054|DRUG|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
48171938|NCT03849768|DRUG|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
48171939|NCT03849768|DRUG|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
48372869|NCT06516783|DEVICE|Full Body Blue GEN 1.0 device|Full body blue irradiation in the treatment of inflammatory skin diseases and chronic pruritus
48372870|NCT00271297|BEHAVIORAL|Pelvic floor muscle training|
48372871|NCT00386191|DRUG|clopidogrel (SR25990C)|oral administration
48516536|NCT06263452|DRUG|Propranolol|Tablet encapsulated to visually look identical to the placebo.
48171940|NCT04262778|DIAGNOSTIC_TEST|electrochemical skin conductance measurement|electrochemical skin conductance measurement
48171941|NCT04522778|DEVICE|Wearable Central Line Securement Device (Vest)|The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.
48171942|NCT04522778|OTHER|Traditional Securement Dressing|All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
48171943|NCT05469412|DEVICE|iPad®|Use of Technology.
48171944|NCT05469412|DRUG|Midazolam|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
48171945|NCT04205136|DRUG|Spironolactone|If tolerated and serum potassium \<5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is \>5.0 but less than 5.5 or creatinine \>4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.
48171946|NCT04205136|DRUG|Placebo|Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
48372872|NCT04795674|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
48015521|NCT06302387|PROCEDURE|Acellular Dermal Matrix|The ADM arm involved vertical soft tissue augmentation using an acellular dermal matrix. This process included the placement of a porcine dermal collagen graft (Mucoderm®, Institut Straumann AG, Switzerland) atop the dental implant site. The graft, measuring 15x20 mm, was hydrated in a 0.5% Metronidazole solution for 20 minutes before application, then trimmed and placed to extend 10 by 5 mm beyond the implant margins in both buccal and lingual directions. The primary wound closure was achieved using double mattress suturing with 6-0 Prolene (Ethicon, USA).
48015522|NCT06302387|PROCEDURE|Soft Tissue Expansion using Tenting Technique|The Tenting Technique arm involved soft tissue expansion using a submerged healing abutment to promote soft tissue growth. After implant placement, 2 mm healing abutments were set on the implants. Flaps were mobilized using vertical releasing incisions, and tension-free wound closure was achieved with horizontal mattress sutures followed by suturing the incision line with interrupted sutures for primary and submerged healing. This method aimed to create a subepithelial healing space for soft tissue expansion and augmentation.
48015523|NCT05448001|DRUG|JP-1366 20mg|JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
48015524|NCT05448001|DRUG|Lansoprazole 30mg|JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal
48015525|NCT04766879|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
48015526|NCT04766879|DEVICE|Placebo|Passive emanator with formulated inert ingredients
48015527|NCT02526381|DRUG|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
48015528|NCT02526381|DRUG|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
48015529|NCT01812044|DRUG|subtenons anesthetic - preservative-free bupivacaine 0.75%|
48372873|NCT04795674|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
48372874|NCT00281736|DRUG|HPPH|Given IV
48372875|NCT01103375|DRUG|erlotinib hydrochloride|Given PO
48372876|NCT01103375|DRUG|isotretinoin|Given PO
48372877|NCT01103375|OTHER|laboratory biomarker analysis|Correlative study
48372878|NCT01103375|GENETIC|protein expression analysis|Correlative study
48372879|NCT03503617|DEVICE|RehabTouch|Exercise using the motion sensing devices and a computer
48704061|NCT01969383|OTHER|Heated pool training|
48704062|NCT03888404|OTHER|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
48372880|NCT03503617|OTHER|Conventional tabletop exercise program|Exercise following printed sheets of exercises
48015530|NCT01812044|DRUG|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
48704063|NCT03888404|OTHER|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
48372881|NCT05909176|BEHAVIORAL|GYN Residency Training|The combined care model will be implemented and during months 5-14.
48704064|NCT03888404|OTHER|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
48704065|NCT03888404|OTHER|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
48704066|NCT05757856|DRUG|NDX-3315 and NDX-3324|Oral solution
48704067|NCT05287841|PROCEDURE|Batten batten graft|The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
48704068|NCT05287841|PROCEDURE|Septoplasty|A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
48704069|NCT05287841|PROCEDURE|Inferior Turbinate Reduction|The bilateral inferior turbinates will be surgically ablated.
48704070|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
48704071|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|5.0 grams of PGX
48704072|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|0 grams of PGX
48704073|NCT00420615|DRUG|Patupilone and Omeprazole|
48704074|NCT00420615|DRUG|Patupilone + Midalzolam|
48372882|NCT05909176|BEHAVIORAL|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 15-18.
48704075|NCT01636063|DRUG|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
48704076|NCT01636063|DRUG|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
48704077|NCT02373436|OTHER|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
48704078|NCT02373436|OTHER|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
48704079|NCT00000419|DRUG|Premarin and Provera|
48704080|NCT05480436|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
48015531|NCT01812044|DRUG|topical control - 0.5 cc of Hypromellose 0.3% gel|
48015532|NCT01812044|DRUG|subtenons control - 0.5 cc of Normal Saline|
48015533|NCT06376461|OTHER|Data collection|Sites will recruit all consecutive adult patients admitted to ICU, to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first
48372883|NCT00009750|BIOLOGICAL|filgrastim|
48372884|NCT00009750|BIOLOGICAL|monoclonal antibody m170|
48372885|NCT00009750|DRUG|cyclosporine|
48372886|NCT00009750|DRUG|paclitaxel|
48372887|NCT00009750|PROCEDURE|peripheral blood stem cell transplantation|
48372888|NCT00009750|RADIATION|indium In 111 monoclonal antibody m170|
48015534|NCT01550939|DEVICE|Ophthalmic Biometer|One complete biometry examination
48171947|NCT00338949|DRUG|Switch|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
48171948|NCT00338949|DRUG|Control|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
48372889|NCT00009750|RADIATION|yttrium Y 90 monoclonal antibody m170|
48372890|NCT01784172|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
48516537|NCT06263452|DRUG|Placebo|Encapsulated sugar pill to visually look identical to the experimental condition.
48516538|NCT02117739|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
48516539|NCT02117739|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
48704081|NCT05480436|BIOLOGICAL|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
48704082|NCT05480436|BIOLOGICAL|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
48704083|NCT03280303|OTHER|non-interventional|
48171949|NCT06034028|DEVICE|J-Valve TF System|The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
48171950|NCT01656486|RADIATION|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
48171951|NCT02785731|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
48171952|NCT02785731|PROCEDURE|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
48171953|NCT02785731|PROCEDURE|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
48171954|NCT00097708|DRUG|experimental anti-anxiety drug|
48171955|NCT02622711|BEHAVIORAL|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
48171956|NCT02622711|BEHAVIORAL|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
48171957|NCT02622711|BEHAVIORAL|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
48171958|NCT02622711|BEHAVIORAL|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
48171959|NCT03437941|DRUG|CORT125281|CORT125281 is supplied as capsules for oral dosing
48171960|NCT03437941|DRUG|Enzalutamide (Xtandi)|Enzalutamide will be taken orally
48171961|NCT03437941|DRUG|Placebo|Placebo capsules to match the appearance of the CORT125281
48171962|NCT03862261|OTHER|Integrated pediatric TB services|"pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~* Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~* Improvement of diagnosis capacities and their integration in all levels of care and all services."
48171963|NCT04842409|RADIATION|Whole breast irradiation|Whole breast irradiation using an ultra-hypofractionated schedule (26 Gy in 5 fractions)
48171964|NCT01395849|DRUG|Salmeterol and Fluticasone|
48171965|NCT04300322|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
48171966|NCT04300322|DRUG|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
48171967|NCT03028259|OTHER|lab results|Comparison of lab results
48171968|NCT03245463|OTHER|Educational handout|The educational handout will include information on self-management strategies.
48171969|NCT03245463|OTHER|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
48171970|NCT03245463|DRUG|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
48015535|NCT05863754|DEVICE|Networked Neuroprosthesis Device|The Networked Neuroprosthesis Device is an implantable, configurable neuromodulation platform that provides functional movement by the coordinated activation of peripheral neural pathways activating innervated paralyzed muscles, and sensing of physiological signals.
48015536|NCT01540370|OTHER|No Treatment|No treatment
48015537|NCT04101526|BEHAVIORAL|Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference|Six sessions of Spanish-language Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via videoconference. Sessions address topics such as sleep education, sleep hygiene, sleep restriction, stimulus control, relapse prevention, and cognitive restructuring.
48015538|NCT03228238|DRUG|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
48015539|NCT03228238|DRUG|Statin|Atorvastatin calcium 10mg
48171971|NCT06483685|DRUG|Radiopharmaceuticals drugs|radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
48171972|NCT02866071|DRUG|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
48171973|NCT02866071|DRUG|Placebo-Comparator|50mg IN Placebo
48171974|NCT01798862|PROCEDURE|Endometrial injury by hysteroscopy or pipelle sampling|
48171975|NCT01798862|PROCEDURE|Proceed to COH directly|
48372891|NCT01784172|DEVICE|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
48015540|NCT03228238|DRUG|Standard medication for variant angina|Calcium Channel blocker or NG
48015541|NCT04388332|PROCEDURE|Structural allograft|Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips
48171976|NCT02163798|BEHAVIORAL|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
48171977|NCT02163798|BEHAVIORAL|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
48171978|NCT00344253|DRUG|Interferon beta|
48171979|NCT00344253|DRUG|Methotrexate|
48171980|NCT03440047|DEVICE|Fuji Flim Processor VP-7000, Light Source BL-7000|Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
48171981|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and study Part II.
48171982|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 2 and study Part II.
48171983|NCT05082285|COMBINATION_PRODUCT|MenABCWY-1Gen vaccine|MenABCWY-1Gen vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part II.
48171984|NCT05082285|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
48171985|NCT05082285|COMBINATION_PRODUCT|MenACWY-TT vaccine|MenACWY-TT vaccine is administered intramuscularly in the lower thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
48171986|NCT04972539|DRUG|AJU-A51 Tab.|Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
48704084|NCT01842165|DRUG|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
48704085|NCT03633630|DRUG|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
48704086|NCT03633630|DRUG|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
48704087|NCT05087927|BEHAVIORAL|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
48704088|NCT05087927|BEHAVIORAL|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
48015542|NCT04388332|DEVICE|Tritanium C|Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
48015543|NCT00414050|BIOLOGICAL|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
48015544|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
48171987|NCT04972539|DRUG|A51R1 Tab. and A51R2 Tab.|Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
48171988|NCT05277077|OTHER|Pain neuroscience education|The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
48171989|NCT05277077|OTHER|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
48372892|NCT04926337|DEVICE|Tight Fitting Facemask|Preoxygenation with tight facemask, 10 L/min, 100% oxygen.
48704089|NCT05087927|BEHAVIORAL|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
48704090|NCT05087927|BEHAVIORAL|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
48372893|NCT04926337|DEVICE|High Flow Nasal Oxygen (HFNO)|Preoxygenation with high flow nasal oxygen, 40-70 L/min, 100% oxygen.
48372894|NCT02259777|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
48372895|NCT02259777|OTHER|high fat, high caloric meal|
48704091|NCT02480491|OTHER|measuring cell freeDNA|measuring cell free DNA using PCR
48704092|NCT06477146|DRUG|Milk thistle (MT)|MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
48015545|NCT00414050|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
48704093|NCT06477146|DRUG|Placebo|The placebo is consistent of Psyllium husk fiber, in 500mg per capsule composition.
48171990|NCT02352077|BIOLOGICAL|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
48171991|NCT00027976|DRUG|celecoxib|
48171992|NCT00027976|DRUG|Placebo|
48171993|NCT05397210|DEVICE|Infinity-Lock Button System|Infinity-Lock Button System
48171994|NCT02014883|DRUG|GLUT1 DS|
48704094|NCT06477146|BEHAVIORAL|Lifestyle Modification|"The primary instructions for lifestyle modification are:~1. Physical activity goal- 20-30 minutes per day 5 to 7 days per week. The aim is 150 minutes a week and more than 300 calories burnt for each workout.~2. Adequate hydration- 4-5 bottles of water a day.~3. Limitation of sugar-free beverages- once daily and 1-2 (8 oz) cups of skim/1% milk (or dairy alternative) daily.~4. Avoidance of beverages with added sugar such as soda, Kool-Aid, juice, and Gatorade.~5. Ideal consumption- three meals daily(breakfast, lunch, dinner)and one snack.~6. Snack Goal \<200 calories. If a 2nd, 3rd, etc. snack is desired it will only be a vegetable.~7. Five servings of fruits/vegetables per day.~8. Each food we recommend eating should have dietary fiber \>3 grams/serving. Ideally \>5 grams/serving.~9. The given survival guide will have all information regarding serving size and portion allotment.~10. MyPlate.gov handout given which will guide participants in relation to portion control."
48704095|NCT06477146|DEVICE|Fibroscan|FibroScan will be completed to measure Elastography. Elastography works by emitting small pulse of energy which may be perceived as a vibration which quickly calculated the stiffness of the liver, which correlates to fat deposition and fibrosis.
48015546|NCT03747484|BIOLOGICAL|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
48015547|NCT03747484|DRUG|Avelumab|Given IV
48015548|NCT03747484|BIOLOGICAL|Pembrolizumab|Given IV
48015549|NCT03747484|BIOLOGICAL|Interferon Gamma-1b|Given SC
48015550|NCT00965068|OTHER|Cholesterol|
48015551|NCT01164046|DRUG|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
48015552|NCT01164046|DRUG|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
48015553|NCT05105503|DEVICE|Eko CORE Digital Stethoscope|The digital stethoscope will be used to take 9 recordings around each subject's maturing AVF once per week until study participation is over
48015554|NCT00130767|DRUG|finasteride|
48015555|NCT02944877|BEHAVIORAL|social media intervention|social media intervention
48015556|NCT06358079|PROCEDURE|Re-infusion of unwashed shed blood|Use of an isolated cardiotomy circuit for re-infusion of unwashed shed blood during off-pump coronary artery surgery
48015557|NCT06363084|DRUG|Nimotuzumab|Nimotuzumab (400mg) was given weekly
48015558|NCT04296812|BEHAVIORAL|Self-Love Model|"The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness."
48015559|NCT00716261|DEVICE|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
48015560|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM|Experimental subjects will receive the iotaSOFT Insertion System with AIM using robotic controlled stop
48015561|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM Control|iotaSOFT Insertion System with AIM using standard of care insertion techniques
48015562|NCT03671681|BEHAVIORAL|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
48015563|NCT03671681|DRUG|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
48171995|NCT02406495|DEVICE|filcon IV 1|contact lens
48171996|NCT02406495|DEVICE|ocufilcon D|contact lens
48171997|NCT01003171|DRUG|MCS-2 soft-gel capsule|MCS-2 30 mg/day
48171998|NCT02138656|OTHER|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
48171999|NCT02138656|OTHER|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
48172000|NCT02554422|DEVICE|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
48172001|NCT01050387|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
48172002|NCT06220812|DEVICE|low level laser ,pulsed electromagnetic field .|"LLL ,ASA via Alessandro Volta, 9 .36057 Arcugnano- Italy. With 905-nm wavelength, and maximum power output of 500 mW, laser spot of approximately 1 cm2 .~PEMF, ASA, Easy teraza serie (ETS), Italy 2011, its code F9020087 and 230 its voltage."
48015564|NCT06653894|PROCEDURE|patients undergoing hip replacement surgery|Hip surgery typically involves procedures aimed at repairing or replacing damaged hip joints to alleviate pain and restore mobility. Common types of hip surgery include total hip replacement, partial hip replacement, and hip arthroscopy. Total hip replacement involves removing the damaged joint and replacing it with an artificial implant, while partial hip replacement focuses on replacing only the damaged parts of the joint. Hip arthroscopy is a minimally invasive procedure used to diagnose and treat hip joint issues using small incisions and specialized instruments. Recovery from hip surgery can vary, but many patients experience significant improvement in pain levels and mobility with proper rehabilitation and physical therapy.
48015565|NCT03444857|DEVICE|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
48015566|NCT05724498|BEHAVIORAL|Brief CBT-I|4 session CBT-I
48172003|NCT00874497|DRUG|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
48172004|NCT00874497|DRUG|placebo|Placebo for 104 weeks (2 years)
48704096|NCT04911400|OTHER|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
48704097|NCT04911400|OTHER|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
48704098|NCT02022215|DRUG|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
48704099|NCT02022215|DRUG|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
48704100|NCT02022215|DRUG|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
48704101|NCT04816656|OTHER|ePROMs assessment|"At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations."
48704102|NCT06272084|DEVICE|Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO|Retrospective Data Analysis of TPE treatments with multiFiltratePRO
48704103|NCT05186103|OTHER|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
48172005|NCT03310398|BEHAVIORAL|NeuroImaging|standard anatomical and functional imaging
48172006|NCT03310398|BEHAVIORAL|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
48172007|NCT00582959|OTHER|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
48172008|NCT04622475|BIOLOGICAL|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
48704104|NCT01711489|DRUG|isavuconazole|oral
48015567|NCT05724498|BEHAVIORAL|Standard CBT-I|Standard VA 6 session CBT-I
48015568|NCT02560636|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
48015569|NCT02560636|RADIATION|Radiotherapy|Radiotherapy
48015570|NCT05892458|BEHAVIORAL|Abdominal massage|To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
48015571|NCT02061241|PROCEDURE|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
48172009|NCT02331810|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48172010|NCT02331810|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48172011|NCT00460564|DRUG|GSK1358820|botulinum toxin type A
48172012|NCT00460564|DRUG|Placebo|Placebo
48172013|NCT03404050|OTHER|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
48172014|NCT01728688|OTHER|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
48172015|NCT01728688|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
48172016|NCT02946307|DEVICE|Restore DEB（dimeter>2.00 mm）|
48172017|NCT02946307|DEVICE|Resolute DES|
48704105|NCT01711489|DRUG|Mycophenolate mofetil|oral
48704106|NCT05120765|BEHAVIORAL|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
48172018|NCT02946307|DEVICE|Restore DEB（dimeter:2.00 mm）|
48172019|NCT01104064|DEVICE|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
48516540|NCT01320293|DRUG|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
48015572|NCT02061241|PROCEDURE|Pacing in other suitable vein|Pacing in other suitable vein
48015573|NCT01636141|DRUG|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
48015574|NCT01636141|DRUG|Placebo gel|
48704107|NCT00756184|DEVICE|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
48704108|NCT00756184|DEVICE|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
48704109|NCT03336801|PROCEDURE|Back Surgery|All patients undergo basic back surgery.
48704110|NCT03336801|DRUG|Propofol|Anesthesia on propofol alone.
48704111|NCT03336801|DRUG|Sevoflurane|Anesthesia on sevoflurane alone.
48704112|NCT00919750|OTHER|Cytology Specimen Collection Procedure|Correlative studies
48704113|NCT03206632|DRUG|BI 690517|single dose
48704114|NCT03206632|DRUG|Placebo|single dose
48172020|NCT01104064|DEVICE|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
48172021|NCT00002971|DRUG|O6-benzylguanine|
48172022|NCT04632212|BEHAVIORAL|Explicit Tax|"To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items"
48172023|NCT04632212|BEHAVIORAL|Food Labels (with the summary of healthiness of shopping baskets & targets)|"To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~* Video: subjects will watch a video briefly explaining the food labels on the store.~* My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals."
48172024|NCT04632212|BEHAVIORAL|Ordering|To order food items by Nutri-Score (high to low).
48172025|NCT04632212|BEHAVIORAL|Within-Group Substitution|To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
48704115|NCT02763254|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T cells
48704116|NCT06605560|OTHER|Platelet Rich Plasma|PRP contains a high concentration of platelets obtained by centrifugation of autologous blood. After degranulation of platelets, various growth factors and cytokines are released and accelerate cartilage matrix synthesis, restrain synovial membrane inflammation and promote cartilage healing.
48015575|NCT06176833|PROCEDURE|Body Weight Supported Treadmill Training|For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
48172026|NCT03618810|DRUG|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
48172027|NCT03618810|DRUG|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
48172028|NCT00726713|OTHER|Metanx (a medical food)|Metanx one tablet twice a day
48172029|NCT00726713|OTHER|Metanx placebo|Metanx placebo one tablet twice a day
48172030|NCT05984706|OTHER|Focus groups and Delphi Questionnaire|1. Focus groups to identify relevant domains of PTSD-related functional impairment in trauma-exposed children and adolescents to ensure content validity. 2. Delphi Questionnaire evaluation of a list of domains of PTSD-related functional impairment in trauma-exposed children and adolescents (previously selected from based on a literature review and focus groups) on a Likert scale of 1 to 5 for their relevance
48172031|NCT00188825|OTHER|placebo|
48704117|NCT06377696|OTHER|Best Practice|Receive SOC
48704118|NCT06377696|OTHER|Medical Device Usage and Evaluation|Wear wearable device
48704119|NCT06377696|DRUG|Metformin|Given PO
48704120|NCT06377696|OTHER|Neurocognitive Assessment|Undergo neurocognitive test
48704121|NCT06377696|OTHER|Questionnaire Administration|Ancillary studies
48704122|NCT01707433|OTHER|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
48704123|NCT02911740|OTHER|Urine LAM Ag test|TB diagnostic assay
48704124|NCT04036474|OTHER|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
48704125|NCT05045820|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis. Needling acupuncture treatment will last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of treatment which contains 10 treatment sessions."
48172032|NCT00188825|DRUG|basiliximab|
48172033|NCT04590950|OTHER|Non interventional study|Non interventional study
48172034|NCT01222533|DRUG|Tiotropium medium|Tiotropium inhalation solution medium dose
48172035|NCT01222533|DRUG|Tiotropium low|Tiotropium inhalation solution low dose
48172036|NCT01222533|DRUG|Tiotropium high|Tiotropium inhalation solution high dose
48704126|NCT05045820|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin. Laser acupuncture treatment will also last 30 minutes per session and will be administered two times per week for 5 weeks, each subject will receive one course of laser acupuncture treatment which contains 10 treatment sessions.
48704127|NCT02323685|BIOLOGICAL|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
48704128|NCT06607406|RADIATION|Accelerated radiotherapy|6 fractions per week, BID fractions one day per week
48172037|NCT01222533|DRUG|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
48172038|NCT01222533|DRUG|Tiotropium placebo|Placebo inhalation solution
48172039|NCT05554926|DRUG|AEF0117|2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
48172040|NCT03508934|DEVICE|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
48172041|NCT03508934|OTHER|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
48172042|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
48172043|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
48172044|NCT01069328|DRUG|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
48172045|NCT01069328|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenously
48704129|NCT06607406|RADIATION|Conventional radiotherapy|5 fractions per week, daily M-F
48704130|NCT03935724|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
48704131|NCT05599451|OTHER|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
48704132|NCT05599451|OTHER|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
48704133|NCT05599451|OTHER|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
48704134|NCT05599451|OTHER|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
48704135|NCT05951075|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
48704136|NCT06605768|DIETARY_SUPPLEMENT|Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.|"Biotin, Collagen \&amp;amp; Keratin Beauty Complex 25,000 mcg, 60 capsules, oral route of administration."
48015579|NCT04277637|DRUG|BGB-11417|Film-coated tablets administered once daily at a dose as specified in the treatment arm
48704137|NCT06605768|DIETARY_SUPPLEMENT|Placebo product|Placebo, 60 capsules, oral route of administration
48015580|NCT04277637|DRUG|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
48172046|NCT01069328|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
48172047|NCT01069328|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenously
48172048|NCT01069328|DRUG|Paclitaxel|Paclitaxel 200 mg/m² intravenously
48172049|NCT01069328|DRUG|Carboplatin|Carboplatin AUC 6 intravenously
48172050|NCT02190552|DEVICE|EmboTrap® Revascularization Device|
48172051|NCT04804059|DRUG|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
48172052|NCT04804059|DRUG|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
48172053|NCT06546761|DIAGNOSTIC_TEST|Coronary CT angiography and FFRct analysis|A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
48172054|NCT00024323|DRUG|cisplatin|
48172055|NCT00024323|DRUG|triapine|
48704138|NCT01352741|DRUG|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
48704139|NCT01352741|DRUG|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
48704140|NCT01352741|DRUG|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
48704141|NCT00634257|BEHAVIORAL|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
48015581|NCT04277637|DRUG|obinutuzumab|Given as an intravenous infusion administered per label.
48015582|NCT05294263|DRUG|Varenicline|Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
48015583|NCT05294263|DRUG|Placebo|Matching, inactive medication
48172056|NCT00694798|BIOLOGICAL|Mycobacterium w|Immunomodulator
48172057|NCT00821119|DEVICE|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
48172058|NCT04713176|DRUG|DWJ1248 with Remdesivir|1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
48172059|NCT04713176|DRUG|Placebo with Remdesivir|1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
48172060|NCT00904722|DRUG|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
48172061|NCT00904722|DRUG|Rituximab|Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
48172062|NCT04107181|DEVICE|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
48172063|NCT04107181|BEHAVIORAL|Interviews only|Healthy volunteer interviews
48172064|NCT05363605|DRUG|[225Ac]-FPI-1966|\[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
48172065|NCT05363605|DRUG|[111In]-FPI-1967|\[111In\]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive \[111In\]-FPI-1967 Injection of 185 MBq for imaging.
48372896|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus action observation training|Participants make an observation of actions related to the training they are going to perform before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
48372897|NCT06123598|BEHAVIORAL|Therapeutic exercise program plus sham action observation training|Participants make a sham observation before each session. Subsequently, they perform the therapeutic exercise program of 6 sessions in a period of 2 weeks.
48372898|NCT01151865|DRUG|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
48372899|NCT01151865|DRUG|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
48372900|NCT02925650|DRUG|Posiphen|oral solid dosage form capsule
48015584|NCT04176796|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
48172066|NCT05363605|BIOLOGICAL|vofatamab|Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
48172067|NCT00101998|DRUG|alvimopan|
48172068|NCT00101998|DRUG|placebo|
48172069|NCT00270036|DRUG|epoetin alfa|
48172070|NCT06289023|RADIATION|HA-WBRT-SIB|A total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV were boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week.
48172071|NCT05583708|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
48172072|NCT05583708|DRUG|Lutetium Lu 177 dotatate|7.4GBq (200 mCi) IV
48172073|NCT03015597|BEHAVIORAL|Contingency Management|Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
48172074|NCT03515200|DRUG|Palbociclib Oral Capsule|Given orally or nasogastrically (NG).
48172075|NCT03515200|DRUG|Intrathecal Triple Therapy|Given intrathecally (IT).
48172076|NCT03515200|DRUG|Dexamethasone|Given orally, nasogastrically (NG) or intravenously (IV).
48172077|NCT03515200|DRUG|Bortezomib|Given intravenously (IV) or subcutaneously (SC).
48172078|NCT03515200|DRUG|Dasatinib|Given orally or nasogastrically (NG).
48172079|NCT03515200|DRUG|Doxorubicin|Given intravenously (IV).
48172080|NCT03515200|DRUG|Ruxolitinib|Given orally or nasogastrically (NG).
48372901|NCT02925650|DRUG|Placebo|oral solid dosage form capsule
48372902|NCT05998304|DRUG|[14C] Yiqibuvir|600 mg suspension containing 100µCi of \[14C\] Yiqibuvir
48372903|NCT00965458|BIOLOGICAL|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
48372904|NCT00965458|DRUG|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
48372905|NCT01784094|DEVICE|StromaGlide|
48372906|NCT06447870|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
48372907|NCT03653780|DEVICE|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
48372908|NCT04159740|OTHER|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
48172081|NCT01120288|DRUG|EZN-2968|
48172082|NCT01544504|DRUG|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
48172083|NCT01081119|BEHAVIORAL|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
48015585|NCT03636490|BEHAVIORAL|Psychological Stress Intervention|Participant will be shown a series of words for five minutes and a research coordinator will ask him/her to name the color of each (Stroop Color-Word Conflict Task). Then, for another five minutes, the participant will be asked to count backwards out loud by sevens starting from 1,000 (Mental Arithmetic Task). The research assistant will ask the participant to work as quickly and accurately as possible for both tasks.
48015586|NCT01177098|DRUG|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
48704142|NCT00869804|BEHAVIORAL|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
48704143|NCT00869804|BEHAVIORAL|Attention control|
48704144|NCT04477382|DIETARY_SUPPLEMENT|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
48704145|NCT03298984|DRUG|Alvocidib|IV bolus followed by IV infusion
48704146|NCT03298984|DRUG|Cytarabine|continuous infusion
48704147|NCT03298984|DRUG|Daunorubicin|IV bolus
48704148|NCT02973542|DRUG|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
48015587|NCT01177098|DRUG|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
48704149|NCT02973542|OTHER|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
48704150|NCT00043108|DRUG|carboplatin|
48704151|NCT00043108|DRUG|paclitaxel|
48015588|NCT00309998|BIOLOGICAL|bevacizumab|
48015589|NCT00309998|DRUG|vinorelbine tartrate|
48015590|NCT04742595|BIOLOGICAL|SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes|Given IV
48172084|NCT03644615|OTHER|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
48172085|NCT03644615|OTHER|Usual care|No intervention on the patients
48172086|NCT02712164|DEVICE|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
48172087|NCT02712164|DEVICE|Tegaderm|Standard of care for STSG donor sites.
48172088|NCT03311269|DEVICE|ClariVein RES|ClariVein system
48172089|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
48172090|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
48172091|NCT01214681|DIETARY_SUPPLEMENT|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
48704152|NCT00043108|PROCEDURE|conventional surgery|
48704153|NCT00043108|RADIATION|radiation therapy|
48704154|NCT02858986|PROCEDURE|3D laparoscopy|
48704155|NCT02858986|PROCEDURE|4K laparoscopy|
48704156|NCT02780856|DEVICE|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
48172092|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
48172093|NCT01214681|DIETARY_SUPPLEMENT|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
48172094|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
48372909|NCT00387829|DEVICE|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
48372910|NCT04885582|OTHER|HLA antigen results|HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.
48704157|NCT01183052|OTHER|Training|20 sessions of training
48172095|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
48372911|NCT04554355|BEHAVIORAL|School-based PA intervention|Provide moderate to vigorous fun-game based exercises for adolescents with ID in schools to help them reduce obesity and improve fitness levels.
48704158|NCT00785421|DRUG|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
48704159|NCT00785421|DRUG|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
48704160|NCT00785421|DRUG|only chemotherapy|observation, no treatment with LMWH
48704161|NCT06502691|OTHER|Best Practice|Receive of standard care
48704162|NCT06502691|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
48704163|NCT06502691|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
48172096|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
48172097|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
48704164|NCT06502691|OTHER|Electronic Health Record Review|Ancillary studies
48704165|NCT06502691|OTHER|Fludeoxyglucose F-18|Given FDG
48704166|NCT06502691|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
48704167|NCT06502691|DRUG|Immune Checkpoint Inhibitor|Receive ICI treatment
48704168|NCT06502691|DRUG|Poly (ADP-Ribose) Polymerase Inhibitor|Receive PARP inhibitor treatment
48704169|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET
48704170|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
48704171|NCT02279771|PROCEDURE|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
48704172|NCT02279771|PROCEDURE|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
48704173|NCT02279771|DEVICE|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
48704174|NCT00561158|BEHAVIORAL|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads"
48704175|NCT05984277|DRUG|Volrustomig|Volrustomig
48704176|NCT05984277|DRUG|Pembrolizumab|Pembrolizumab
48704177|NCT05984277|DRUG|Carboplatin|Carboplatin
48704178|NCT05984277|DRUG|Paclitaxel|Paclitaxel
48704179|NCT05984277|DRUG|Pemetrexed|Pemetrexed
48172098|NCT03023423|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
48172099|NCT03023423|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
48704180|NCT04914923|DEVICE|Muse|Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
48172100|NCT04969276|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose|Sterile suspension for injection in a pre-filled syringe Intramuscular injection
48172101|NCT04969276|BIOLOGICAL|COVID-19 mRNA Vaccine (nucleoside modified)|Sterile suspension (white to off-white) in multidose vial Intramuscular injection
48172102|NCT03575195|DRUG|Rifaximin|Rifaximin 550mg orally
48704181|NCT04914923|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
48172103|NCT03575195|OTHER|Placebo|Placebo control
48704182|NCT04914923|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
48704183|NCT04861467|DRUG|Camrelizumab|IV
48372912|NCT06306417|OTHER|lifestyle intervention|lifestyle intervention
48015591|NCT06127134|PROCEDURE|peripheral angioplasty for tibial vessels|repair tibials blood vessels throughout two concepts using angioplasty ballooning
48015592|NCT03943810|OTHER|No intervention|There is no intervention
48015593|NCT00794872|OTHER|blood sampling|
48015594|NCT05682482|DRUG|LT3 (liothyronine)|Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
48015595|NCT05682482|DRUG|Placebo|Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
48372913|NCT06306417|DEVICE|acupuncture|acupuncture
48372914|NCT06306417|DEVICE|Sham acupuncture|Sham acupuncture
48372915|NCT04987684|DIAGNOSTIC_TEST|SCINSEV and PECAP|To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
48372916|NCT00394173|DRUG|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
48372917|NCT00394173|DRUG|Placebo|Matching placebo
48704184|NCT01310179|GENETIC|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
48704185|NCT05223231|DRUG|LBL-019 Injection|initial dose-MTD
48704186|NCT05223231|DRUG|anti-PD-1 antibody injection|provide medicine base on needs
48704187|NCT05024175|DIAGNOSTIC_TEST|Disease assessments|CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol
48704188|NCT05024175|PROCEDURE|Tumor Biopsy|Tumor Biopsy per protocol
48704189|NCT05024175|DIAGNOSTIC_TEST|Blood test|Blood Test per protocol
48704190|NCT02937298|DIETARY_SUPPLEMENT|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
48704191|NCT02937298|DIETARY_SUPPLEMENT|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
48704192|NCT02937298|DIETARY_SUPPLEMENT|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
48704193|NCT02937298|DIETARY_SUPPLEMENT|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
48704194|NCT03317626|DIAGNOSTIC_TEST|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
48704195|NCT02357082|RADIATION|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
48704196|NCT01628679|BEHAVIORAL|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
48704197|NCT06598033|DRUG|VC plus herbal medicine|Vitamin C 300 mg/day, TID, PO. Reishi, 2 g/day, BID, PO. Cordyceps, 2 g/day, BID, PO.
48704198|NCT04669938|OTHER|oropharyngeal and intestinal microbiota|analysis of oropharyngeal and intestinal microbiota
48704199|NCT04669938|OTHER|host genotype|analysis of a part of host genotype
48704200|NCT04669938|OTHER|host immune factors|analysis of host immune factors
48704201|NCT04669938|OTHER|viral sequence|analysis of viral sequence
48704202|NCT05333172|OTHER|Dual task exercises|Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
48704203|NCT02574650|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
48704204|NCT05437562|OTHER|Ewing Amputation|All patients will receive Ewing Amputation to test feasibility.
48704205|NCT00835640|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
48704206|NCT00835640|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
48704207|NCT00709293|DRUG|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
48372918|NCT01100931|DRUG|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m\^2, dose level 2:5 mg/m\^2 , dose level 3:6 mg/m\^2, dose level 4:8 mg/m\^2, dose level 5:10 mg/m\^2 (MTD), dose level 6:12 mg/m\^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m\^2 (MTD)intravenous infusion over 72 hours every 21 days."
48372919|NCT01100931|DRUG|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
48372920|NCT01100931|DRUG|Paclitaxel|200 mg/m\^2 intravenous on day 1
48704208|NCT00709293|DRUG|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
48704209|NCT04804657|DIETARY_SUPPLEMENT|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
48704210|NCT04804657|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
48704211|NCT05807087|PROCEDURE|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
48704212|NCT05807087|PROCEDURE|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
48704213|NCT04171596|BEHAVIORAL|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
48704214|NCT04778163|BEHAVIORAL|Clinical use of humor|"Clinical study in psychiatry in young adult patients between 18 and 25 years old. The aim of the study is to evaluate the therapeutic impact of the clinical use of humor through 6 group sessions (group of 5 to 10 patients), at the rate of one hour session per week for 6 weeks.~The investigators will form 2 groups of 5 to 10 patients matched in terms of gender, education level and score on a scale measuring their sense of humor. The participants will be asked to complete a series of tests measuring their ability to use humor, psychiatric symptoms and well-being."
48704215|NCT01318278|DRUG|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
48704216|NCT01318278|DRUG|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
48172104|NCT04554953|DRUG|Combination drug containing fimasartan and statins|"Patients who correspond to one of the following:~1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia~2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin~3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin"
48172105|NCT02048683|DRUG|Short term sedation with sevoflurane in ICU|
48172106|NCT02509988|DIETARY_SUPPLEMENT|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
48172107|NCT02509988|DIETARY_SUPPLEMENT|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
48172108|NCT00601133|OTHER|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
48172109|NCT00601133|OTHER|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
48172110|NCT00601133|BEHAVIORAL|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
48372921|NCT06384599|DEVICE|VT Cryoablation System|All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)
48372922|NCT03351426|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
48372923|NCT00821600|DRUG|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
48372924|NCT01682876|BIOLOGICAL|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
48372925|NCT04029246|BEHAVIORAL|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
48172111|NCT00601133|BEHAVIORAL|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
48372926|NCT04029246|BEHAVIORAL|Incentive|Offer of a shopping voucher if patient attends for appointment
48372927|NCT04586127|OTHER|AYA NA-SB Questionnaire|Questionnaire identifying cancer needs so that providers can connect subjects with services that might address them.
48372928|NCT01000311|BIOLOGICAL|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
48704217|NCT01789138|BEHAVIORAL|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
48704218|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
48704219|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
48704220|NCT01741324|DIETARY_SUPPLEMENT|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
48704221|NCT06606015|DRUG|I.V Paracetamol.|Pharmacological thereby for hsPDA closure in the preterm neonates.
48372929|NCT01000311|BIOLOGICAL|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
48172112|NCT01135030|PROCEDURE|Total knee|Primary Total knee
48172113|NCT03044587|DRUG|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
48172114|NCT03044587|DRUG|Arm Cisplatin + Gemcitabine (Arm B)|Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
48372930|NCT01000311|BIOLOGICAL|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
48372931|NCT01000311|BIOLOGICAL|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
48372932|NCT01000311|BIOLOGICAL|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
48372933|NCT03195166|DIAGNOSTIC_TEST|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
48372934|NCT02784730|PROCEDURE|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
48372935|NCT02784730|PROCEDURE|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
48704222|NCT06606015|DEVICE|Echocardiography.|It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.
48704223|NCT06606015|DEVICE|Electrical Cardiometry|Non invasive hemodynamics monitoring
48704224|NCT00003103|BIOLOGICAL|oblimersen sodium|
48704225|NCT00003103|DRUG|docetaxel|
48372936|NCT05119101|DRUG|Dexamedotomidine added to Magnesium sulfate|we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
48372937|NCT05119101|DRUG|Magnesium sulfate|we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
48372938|NCT01002573|DRUG|ibuprofen|Ibuprofen, 10 mg/kg
48372939|NCT01002573|DRUG|acetaminophen|Acetaminophen, 10mg/kg
48372940|NCT04173520|DRUG|DDA|Follow up after SVR
48372941|NCT02995239|DRUG|CJ-12420 formulation 2|CJ-12420 formulation 2
48372942|NCT02995239|DRUG|CJ-12420 formulation 1|CJ-12420 formulation 1
48372943|NCT06341582|DIAGNOSTIC_TEST|End-tidal carbon monoxide-corrected (ETCOc)|Early postnatal ETCOc levels
48372944|NCT02103894|DRUG|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
48372945|NCT02662959|DRUG|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48372946|NCT02118909|DRUG|Pracinostat|
48372947|NCT02118909|DRUG|Itraconazole|
48372948|NCT02118909|DRUG|Ciprofloxacin|
48372949|NCT04351594|DRUG|Biofreeze 4 % Topical Gel|Biofreeze gel with active manufactured ingredient (Menthol 4%)
48704226|NCT04640558|DEVICE|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
48372950|NCT04351594|OTHER|Biofreeze placebo gel|Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
48372951|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
48516541|NCT06025240|DIAGNOSTIC_TEST|cf-DNA|In addition to the standard of care tests, participants will have an additional blood sample (dd-cf DNA). A cohort study patients who have undergone high immunological risk kidney transplant at our centre defined as a re-transplant, where the cRF is \>20% or where there is a level 4 HLA-mismatch. We will take a single plasma sample for dd-cfDNA testing at 6-12 months post-transplant and pair this with an assessment of renal function (creatinine, eGFR), MSU, BK and CMV PCR, single antigen bead (SAB) monitoring of HLA-specific antibodies and allograft USS.
48704227|NCT00305032|PROCEDURE|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
48372952|NCT00819923|DEVICE|Percutaneous coronary intervention|Intra-coronary stenting
48372953|NCT02917421|RADIATION|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
48372954|NCT00516698|GENETIC|polymorphism analysis|
48372955|NCT00516698|OTHER|high performance liquid chromatography|
48372956|NCT00516698|OTHER|laboratory biomarker analysis|
48372957|NCT00516698|PROCEDURE|radiomammography|
48372958|NCT02700893|DRUG|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
48372959|NCT02700893|DRUG|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
48372960|NCT00316966|BEHAVIORAL|Multidisciplinary dietary intervention|
48015596|NCT04577092|OTHER|Warm-up exercise|In 10-minute warm up period; neck flexion/extension/side flexion/circumflexion (clockwise and counterclockwise), rounding shoulder back and forth, circumflexion of arm back and forth, side flexion of trunk and rising on the fingertips.
48372961|NCT02649673|DRUG|LCL161|
48372962|NCT02649673|DRUG|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
48516542|NCT06025240|DIAGNOSTIC_TEST|Immunological Events following renal transplant in older age|Determine the overall frequency of immunological events and de novo HLA specific antibody formation in the \<60 and \>60 age population. Standard of care test taken at the different time intervals for routine storage. We will use those samples for HLA testing (either screening alone or screening and single antigen bead testing if screening yields a positive result).
48704228|NCT03692377|DEVICE|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
48172115|NCT04116281|OTHER|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
48172116|NCT02809807|OTHER|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
48172117|NCT02809807|DEVICE|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
48172118|NCT04493645|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to restore ankle joint range of motion, strength, postural control, and functional movement. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
48704229|NCT06607380|BIOLOGICAL|TNM002|A single intramuscular (IM) gluteal injection
48172119|NCT04493645|BEHAVIORAL|Foot Intensive Rehabilitation (FIRE)|6 weeks of FIRE will be given along with elements of SOC. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
48372963|NCT02649673|DRUG|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
48704230|NCT06607380|BIOLOGICAL|Adsorbed tetanus vaccine|A single IM deltoid injection
48704231|NCT06607380|BIOLOGICAL|TNM002 + adsorbed tetanus vaccine|A single IM gluteal injection+ a single IM deltoid injection
48704232|NCT03828422|DIAGNOSTIC_TEST|imaging|
48704233|NCT02591667|PROCEDURE|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
48704234|NCT02591667|DRUG|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
48372964|NCT02706327|DEVICE|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
48372965|NCT02706327|DEVICE|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
48372966|NCT02706327|OTHER|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
48372967|NCT00994045|BIOLOGICAL|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
48372968|NCT00994045|BIOLOGICAL|Fresh Frozen Plasma|
48372969|NCT05921851|OTHER|no intervention|no intervention
48704235|NCT02591667|PROCEDURE|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
48704236|NCT03401658|DEVICE|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
48704237|NCT03610945|DRUG|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
48704238|NCT03610945|DRUG|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
48704239|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
48704240|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
48704241|NCT05131867|DRUG|nimodipine|(60 mg/4 hours) orally or via nasogastric tube
48704242|NCT05131867|DRUG|Oral Nimodipine and milrinone|Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
48704243|NCT05484531|DEVICE|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
48704244|NCT03900858|DRUG|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
48704245|NCT06145165|OTHER|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
48372970|NCT01337921|DIETARY_SUPPLEMENT|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
48372971|NCT03378921|BIOLOGICAL|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
48704246|NCT06145165|COMBINATION_PRODUCT|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
48172120|NCT00809913|DRUG|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
48372972|NCT03378921|BIOLOGICAL|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 4, 12, 26, and 52.
48372973|NCT03891433|DRUG|Meropenem|Carbapenems group intervention.
48372974|NCT03891433|DRUG|Ertapenem 1000 MG|Carbapenems group intervention.
48372975|NCT03891433|DRUG|Piperacillin, Tazobactam 4-0.5G Solution for Injection|Piperacillin/Tazobactam group intervention.
48372976|NCT04358809|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Suspension of heat killed (autoclaved) Mw along with Standard of care (SOC) treatment for COVID-19
48372977|NCT04358809|OTHER|Placebo|Placebo along with Standard of care (SOC) treatment for COVID-19
48372978|NCT02164058|DEVICE|TandemHeart System|
48372979|NCT02164058|PROCEDURE|Percutaneous coronary intervention|
48516543|NCT06025240|OTHER|Determining Predictive Models for Post-transplant HLA-specific Antibody Formation|A machine learning model will be developed in Python using a range of pre- and post-transplant variables to determine a predictive model for de novo HLA-specific antibody following renal transplant.
48704247|NCT06145165|OTHER|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
48704248|NCT03136146|DRUG|Bortezomib|Given SC
48704249|NCT03136146|DRUG|Clofarabine|Given IV
48704250|NCT03136146|DRUG|Cyclophosphamide|Given IV
48704251|NCT03136146|DRUG|Dexamethasone|Given IV or PO
48704252|NCT03136146|DRUG|Etoposide|Given IV
48704253|NCT03136146|BIOLOGICAL|Ofatumumab|Given IV
48704254|NCT03136146|BIOLOGICAL|Pegfilgrastim|Given SC
48704255|NCT03136146|BIOLOGICAL|Rituximab|Given IV
48704256|NCT03136146|DRUG|Vincristine Sulfate Liposome|Given IV
48015597|NCT04577092|OTHER|Motor-Cognitive exercise|After warm up period; participants had been asked to count back from the two-digit number while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
48015598|NCT04577092|OTHER|Motor-Motor exercise|participants had been asked to hold with both hand half-filled glasses with 90 degree of flexion elbow and near the trunk while performing; in standing position, straight walk, side walk, abduction/flexion/extension of hip and hip and knee flexion; in sitting position, hip flexion, knee extension, ankle dorsi - plantar flexion.
48704257|NCT04959617|DEVICE|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
48704258|NCT03114579|DEVICE|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
48704259|NCT03114579|DEVICE|NEXFIN HD|
48704260|NCT00082706|DRUG|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
48704261|NCT00082706|DRUG|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
48015599|NCT04577092|OTHER|Cool-down exercise|In 10-minute cool down period, stretching of quadriceps femoris muscle, hamstring muscle, achill tendon and cervical muscles were performed.
48015600|NCT05910385|PROCEDURE|laparoscopy|tubal ligation by laparoscopy or vnotes technique
48015601|NCT05910385|PROCEDURE|vnotes|tubal ligation by laparoscopy or vnotes technique
48015602|NCT05515523|GENETIC|Adipose Derived (AD) Stromal Vascular Fraction (SVF)|autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain and function associated with OA of the knee joint
48015603|NCT00654628|DRUG|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
48704262|NCT00082706|DRUG|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
48704263|NCT00082706|DRUG|Gemcitabine|Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
48704264|NCT01029990|OTHER|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
48704265|NCT01029990|OTHER|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
48704266|NCT02715024|DRUG|Tamsulosin|Oral
48704267|NCT02715024|DRUG|Solifenacin|Oral
48704268|NCT05838027|BEHAVIORAL|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
48704269|NCT05413785|BEHAVIORAL|Telehealth in Parole/Probation Office|Onsite (telehealth) linkage toHep C treatment in a Probation and Parole office setting via an onsite nurse navigator. The navigator will provide Hep C education, draw labs, and facilitate a telemed visit with a UK GI provider.
48704270|NCT00621556|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
48704271|NCT05275010|DRUG|Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
48704272|NCT05275010|DEVICE|Handheld Syringe with Hypodermic Needle|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.
48172121|NCT04187430|BEHAVIORAL|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
48172122|NCT04187430|BEHAVIORAL|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
48172123|NCT01704066|OTHER|Training and education|
48172124|NCT04599907|DEVICE|Roll-In Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for 10 subjects
48172125|NCT04599907|DEVICE|Randomized Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
48172126|NCT04599907|DEVICE|Randomized Cohort: Single Application of Sham Patch|Single Application of Sham Patch in both axillae for subjects randomized to the control group
48172127|NCT04113928|DIETARY_SUPPLEMENT|Broccoli & mustard seed soup|200ml acute feed
48172128|NCT04113928|DIETARY_SUPPLEMENT|Broccoli soup|200ml acute feed
48172129|NCT00620633|BIOLOGICAL|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
48172130|NCT00680147|BEHAVIORAL|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
48172131|NCT01058083|DRUG|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
48172132|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
48172133|NCT01058083|DRUG|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
48172134|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
48516544|NCT04351633|OTHER|questionnaire assesment|questionnaire assesment
48704273|NCT05275010|DEVICE|On-Body Delivery System|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system (OBDS).
48704274|NCT02660450|OTHER|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
48704275|NCT02660450|OTHER|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
48704276|NCT02660450|OTHER|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
48172135|NCT01058083|DRUG|Placebo|Placebo, Oral, 0 mg, daily, 28 days
48172136|NCT00405912|DRUG|Placebo|Placebo (inactive drug) given 3 times per day
48172137|NCT00405912|DRUG|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
48172138|NCT00405912|DRUG|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
48516545|NCT02430480|DRUG|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
48516546|NCT02430480|DRUG|Enzalutamide|160mg orally, daily for 24 weeks
48704277|NCT02059889|DEVICE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
48704278|NCT02059889|DEVICE|4-dimensional computed tomography|Undergo 4D CT
48704279|NCT02059889|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET
48015604|NCT01006811|DIETARY_SUPPLEMENT|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
48172139|NCT03361618|DIETARY_SUPPLEMENT|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
48172140|NCT00502164|DRUG|AZD2171|
48172141|NCT05264142|DRUG|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
48516547|NCT02430480|DEVICE|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
48704280|NCT02059889|DEVICE|FDG-PET|Undergo FDG-PET
48704281|NCT05142254|DRUG|Tadalafil|2.5-5 mg/day
48704282|NCT05142254|DRUG|Hydroxyurea|20 mg/kg/day
48704283|NCT05142254|DRUG|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
48172142|NCT05264142|DRUG|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
48172143|NCT05264142|DRUG|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
48172144|NCT03623477|BEHAVIORAL|Cognitive Remediation (CRT)|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
48516548|NCT02819284|DRUG|KPI-121 0.25% Ophthalmic Suspension|
48516549|NCT02819284|DRUG|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
48516550|NCT05723939|DIETARY_SUPPLEMENT|Carnosine supplementation|Intake of carnosine supplement in form of capsules or functionally enriched chicken meet for three weeks
48516551|NCT05723939|DIETARY_SUPPLEMENT|Controls|Intake of placebo capsules or regular chicken meet for three weeks
48516552|NCT06274294|DRUG|CT-P13|Induction treatment.
48516553|NCT01729949|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry and Blackcurrent extract
48516554|NCT01729949|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|without active components
48516555|NCT00520897|DRUG|Raltegravir (MK0518)|400mg BID; 48 weeks
48516556|NCT00520897|DRUG|Placebo|400mg QD
48516557|NCT00520897|PROCEDURE|Leukopheresis|pack of cells as per protocol
48516558|NCT00520897|PROCEDURE|Sigmoid Biopsy|gut samples as per protocol
48516559|NCT05405504|DEVICE|Remote Dielectric Sensing (ReDS)|Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.
48516560|NCT01244503|DRUG|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
48516561|NCT03335137|DIAGNOSTIC_TEST|Drug Level Monitoring|Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
48516562|NCT00006760|BIOLOGICAL|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
48704284|NCT05384106|DIETARY_SUPPLEMENT|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
48704285|NCT02823054|DEVICE|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
48172145|NCT03623477|BEHAVIORAL|CRT+ Social Cognition Training|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
48172146|NCT04302051|DIAGNOSTIC_TEST|Thermo-acuostic image acquisition of liver|Estimation of hepatic fat content with thermo-acoustic device
48704286|NCT02183480|DRUG|Linagliptin, low dose|
48704287|NCT02183480|DRUG|Linagliptin, medium dose|
48704288|NCT02183480|DRUG|Linagliptin, high dose|
48704289|NCT05978336|BEHAVIORAL|Health Coaching Program|"The HC program will be delivered over 26-weeks. Participants will have an initial hour-long HC session where the BAP coach will conduct a brief physical assessment and work with the participant to establish their physical activity goals and develop a plan. After the initial consult, coaches will conduct 8 x 20-minute phone calls with participants over the 26-week trial decreasing from bi-weekly phone calls in weeks 1-12 to monthly phone calls in weeks 13-26.~Participants in the HC group will have an overall goal of increasing their weekly participation in moderate to vigorous physical activity by 50 minutes, via 5-, 7-, or 10-minute bouts of progressive exercises, at a rate of perceived exertion range of 13-14 (somewhat hard) by week 16. Participants will have access to specific exercise sessions made available by YouTube and/or hardcopy manuals created by the research team."
48704290|NCT05978336|BEHAVIORAL|Health Education Program|Participants will begin with a one-hour, group-based, interactive education session on falls prevention delivered either in-person or by Zoom. Following the initial education session, ED participants will receive additional group education sessions (in-person or by Zoom) with the same duration and schedule as the HC program covering a variety of healthy aging topics.
48172147|NCT04302051|DIAGNOSTIC_TEST|MRI-PDFF estimation of hepatic fat|Estimation of hepatic fat content with MRI
48172148|NCT00664261|BEHAVIORAL|smoking cessation intervention|
48172149|NCT00664261|OTHER|cancer prevention|
48172150|NCT00664261|OTHER|counseling intervention|
48172151|NCT00664261|OTHER|educational intervention|
48172152|NCT00664261|OTHER|laboratory biomarker analysis|
48172153|NCT00664261|OTHER|questionnaire administration|
48172154|NCT00664261|OTHER|survey administration|
48172155|NCT00664261|PROCEDURE|study of high risk factors|
48172156|NCT00818870|DRUG|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
48172157|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
48172158|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
48172159|NCT02554383|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
48172160|NCT02554383|DRUG|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
48516563|NCT00006760|DRUG|ifosfamide|V over 24 hours on days 1-4
48704291|NCT04865731|DRUG|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
48704292|NCT04865731|DRUG|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
48704293|NCT05347225|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD.
48704294|NCT04352764|DIAGNOSTIC_TEST|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
48704295|NCT02338895|DEVICE|Ultrasound|Ultrasound of inferior vena cava and kidneys
48015605|NCT01006811|OTHER|modified Atkins diet|"Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided."
48015606|NCT04866134|DRUG|ERAS-007|ERAS-007 will be administered orally as specified in Arm description.
48015607|NCT04866134|DRUG|ERAS-601|ERAS-601 will be administered orally as specified in Arm description.
48015608|NCT04950530|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
48015609|NCT00003545|DRUG|nelarabine|
48704296|NCT04147390|DRUG|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
48015610|NCT04667819|DRUG|Sodium Hyaluronate|We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
48172161|NCT02330562|DRUG|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2. Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
48172162|NCT02330562|DRUG|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
48372980|NCT06270160|DIAGNOSTIC_TEST|HIVST|Peer navigators will demonstrate how to use an HIVST kit, including how to 1) open the kit, 2) collect the oral fluid samples, and 3) read the results. In addition to HIVST education, participants will be offered optional pre-test counselling and SMS contact information to connect with their peer navigator. If participants do not want post-test counselling, the PN will follow up within two weeks. If the participants report testing positive, then they will be immediately scheduled for confirmatory testing and enrolled in the support programs at MARPI for young people living with HIV.
48516564|NCT00006760|DRUG|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
48516565|NCT04042844|BIOLOGICAL|BRTX-100|Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
48516566|NCT04042844|DRUG|Saline|Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
48704297|NCT04147390|DRUG|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
48704298|NCT06606548|BEHAVIORAL|comprehensive oral care|including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
48015611|NCT06461572|OTHER|conventional therapy|This group will receive conventional physiotherapy, which will consist of manual resistance-based neck strengthening exercises. The exercises will last 30 minutes apiece and cover cervical flexion, extension, side flexion, side flexion with rotation, and pure rotation with moderate resistance. The power ball's effect on proximal muscle control and refractive error in children with developmental delays will also be discussed.
48015612|NCT06461572|OTHER|conventional therapy along with standard therapy and stability exercises.|"Group B: In addition to standard care, this group will engage in power ball exercises for neck stability and strengthening. Gradually, the resistance will rise.~Three mints in each position for a total of fifteen mints of ball exercises. At first, Powerball progressively strengthened the muscle and reduced the pain , and with continued development, allowed them to move in a pain-free range."
48015613|NCT01976416|DRUG|Hydroxyurea|
48015614|NCT01976416|DRUG|Placebo|
48015615|NCT01260987|DRUG|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
48704299|NCT05420714|DEVICE|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
48704300|NCT03732326|PROCEDURE|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
48015616|NCT01260987|DRUG|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
48015617|NCT03666598|DEVICE|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
48015618|NCT04711304|BIOLOGICAL|Umbilical Cord-derived Wharton's Jelly|Intraarticular injection
48015619|NCT04711304|DEVICE|Hyaluronic acid|Intraarticular injection
48704301|NCT03913026|BIOLOGICAL|Transplant with an expanded ECT-001 cord blood|"1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
48704302|NCT06035575|BEHAVIORAL|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
48704303|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
48704304|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
48704305|NCT02991794|DEVICE|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
48015620|NCT04711304|OTHER|Saline|Intraarticular injection
48015621|NCT04545242|DRUG|Dexamethasone|Intravenous dexamethasone (low vs. moderate doses) during 10 days
48516567|NCT00899522|OTHER|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
48172163|NCT01458080|DRUG|eltrombopag|eltrombopag
48172164|NCT00719212|BIOLOGICAL|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
48172165|NCT06463418|DEVICE|Ekoskeleton (Intervention)|Exoskeleton walking three times per week for 12 weeks.
48372981|NCT06270160|DEVICE|mHealth|The investigators are collaborating with the WelTel non-profit agency for a supportive SMS intervention. The WelTel system will manage the SMS intervention on their structured mobile phone platform (all SMS interactions are logged). Weekly 2-way supportive messages will automatically be sent on the same weekday with WelTel software to Arm 2+3 participants. The peer navigator will ask Arm 2+3 participants to respond to the SMS within 48 hours to confirm their wellbeing and will follow-up with non-responders. The Arm 2+3 peer navigators and Research Coordinator will access the server every 24-48 hours to triage and respond to participants who express a problem or need.
48372982|NCT06270160|BEHAVIORAL|Creating Futures Livelihoods program|Creating Futures is a group intervention that aims to help young people build their livelihoods, and was designed for use with youth (18-24) in urban informal settlements in South Africa.
48516568|NCT00899522|PROCEDURE|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
48516569|NCT02934191|DRUG|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
48015626|NCT05155969|DRUG|Esketamine|esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
48015627|NCT05155969|DRUG|Normal saline|Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.
48015628|NCT04685135|DRUG|MRTX849|21 day cycles
48015629|NCT04685135|DRUG|Docetaxel|21 day cycles
48015630|NCT02336984|BIOLOGICAL|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
48172166|NCT06463418|OTHER|Relaxation (Comparator)|Relaxation three times per week for 12 weeks.
48172167|NCT03308747|DIETARY_SUPPLEMENT|Instantized Whey Protein Isolate|0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
48172168|NCT00161408|BEHAVIORAL|cognitive behavioural therapy|
48172169|NCT00161408|BEHAVIORAL|psychoeducation|
48172170|NCT03112408|BEHAVIORAL|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
48015631|NCT02336984|DRUG|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
48015632|NCT02336984|DRUG|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
48015633|NCT06580821|PROCEDURE|mucogingigval surgery|Is a form of mucogingival surgery that attempts to improve the height of the keratinized tissue (KT), as well as augment the thickness of the gingival phenotype to facilitate meticulous oral hygiene.
48015634|NCT00654524|DRUG|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.\& Livial 1.25-2.5mg p.o. q.d.) if needed.
48015635|NCT03150342|DIAGNOSTIC_TEST|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
48372983|NCT00348348|DRUG|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
48372984|NCT00348348|DRUG|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
48372985|NCT05351970|PROCEDURE|Barbed|Efficacy of barbed and monofilament closure regarding incisional hernia
48372986|NCT04828746|PROCEDURE|Ultrasound Guided Skin Marking|Using ultrasound for skin marking pre-procedure
48372987|NCT01005810|DRUG|N-Acetylcysteine|1200 mg twice daily for 8 weeks
48704306|NCT01896076|OTHER|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
48704307|NCT03425006|DRUG|Itacitinib|a JAK 1 selective small molecule inhibitor
48015636|NCT00996567|DRUG|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
48516570|NCT02934191|OTHER|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
48516571|NCT02934191|DRUG|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
48704308|NCT03425006|BIOLOGICAL|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
48704309|NCT05775549|OTHER|None (Observational Study)|Not Applicable since observational study
48704310|NCT02540330|DRUG|Fulvestrant|
48015637|NCT00852384|PROCEDURE|NIPPV and IRM|"* non invasive positive pressure support ventilation (NIPPV group)~* alveolar recruitment maneuver (IRM group)"
48372988|NCT01005810|DRUG|placebo|2 capsules twice daily for 8 weeks
48704311|NCT05507021|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
48015638|NCT01902485|OTHER|Timing of Contraceptive Initiation in Medical Abortion|
48015639|NCT00890461|RADIATION|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
48015640|NCT04341181|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
48015641|NCT04341181|DRUG|Atezolizumab|Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
48372989|NCT01005810|BEHAVIORAL|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
48372990|NCT03406780|BIOLOGICAL|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
48372991|NCT03406780|DRUG|Placebo|Placebo
48372992|NCT03859908|DRUG|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
48516572|NCT02934191|DRUG|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
48372993|NCT03859908|DRUG|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
48015642|NCT04341181|DRUG|Avelumab|Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
48172171|NCT03112408|BEHAVIORAL|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
48372994|NCT03033641|DEVICE|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
48372995|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
48704312|NCT05507021|DIETARY_SUPPLEMENT|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
48172172|NCT03112408|BEHAVIORAL|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
48172173|NCT03112408|BEHAVIORAL|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
48172174|NCT02877264|DRUG|vapendavir 132 mg capsule|
48172175|NCT02877264|DRUG|vapendavir 264 mg tablet|
48172176|NCT02877264|DRUG|vapendavir 24 mg/mL oral suspension|
48172177|NCT03108638|BEHAVIORAL|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
48172178|NCT02101983|DRUG|Cytosine Arabinoside|
48172179|NCT04005456|DIETARY_SUPPLEMENT|Supplements and/or medical foods|Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
48172180|NCT04005456|BEHAVIORAL|Behavioral change support program|Program to implement lifestyle and behavioral change according to individuals' need.
48172181|NCT04005456|OTHER|Food plan|Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
48172182|NCT04018885|DRUG|ALA 2.5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
48372996|NCT06031948|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
48372997|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
48172183|NCT04018885|DRUG|ALA 5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
48172184|NCT04018885|DRUG|ALA 10%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
48372998|NCT06031948|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
48704313|NCT00044681|DRUG|risperidone|
48704314|NCT06605729|OTHER|e-learning|The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
48704315|NCT04927156|DEVICE|BALT medical devices|"Includes, but is not limited to, the following:~* Access devices~* Aneurysm treatment devices~* Ischemic Stroke and peripheral occlusive diseases treatment devices~* Arterio-Venous Malformations/fistulas treatment devices"
48172185|NCT05964959|OTHER|Mouth Educational Program|The Mouth Educational Program is a nurse-led patient education program for dry mouth in patients with a life-limiting condition or frailty.
48372999|NCT04282551|OTHER|dietary intervention with oligosaccharides|intervention with oligosaccharide 1 or 2, or placebo, given once a day
48373000|NCT05796401|BEHAVIORAL|Cognitive training|"Cognitive reinforcement using digital applications (PSYCARE application) during 12 weeks~+/- virtual reality based cognitive remediation application : 24 sessions over 12 weeks (only for patients who have a higher cognitive deficits (TMTB score \>110s))"
48516573|NCT01577550|DRUG|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
48704316|NCT00555763|DEVICE|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
48704317|NCT04256668|DIAGNOSTIC_TEST|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
48704318|NCT03232242|DIAGNOSTIC_TEST|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
48704319|NCT02725593|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
48172186|NCT05964959|OTHER|Care as Usual|Care as usual is defined as the standard dry mouth care as provided by participants' own treating physicians.
48516574|NCT01577550|DRUG|Placebo, i.v.|Single i.v. administration of placebo
48015643|NCT04341181|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
48015644|NCT04341181|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
48015645|NCT04341181|DRUG|Vemurafenib plus Cobimetinib (combination)|Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
48015646|NCT04341181|DRUG|Trastuzumab plus Pertuzumab (combination)|Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
48015647|NCT04341181|DRUG|Trastuzumab emtansine|Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
48015648|NCT04341181|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
48015649|NCT04341181|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
48015650|NCT03979716|DEVICE|fMRI|fMRI examination
48015651|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
48015652|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
48015653|NCT01035879|DRUG|MBX-2982|tablets and capsule once daily
48015654|NCT01035879|DRUG|Sitagliptin|tablets and capsule once daily
48516575|NCT01577550|DRUG|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
48015655|NCT01035879|DRUG|placebo|tablets and capsule once daily
48015656|NCT02962895|BIOLOGICAL|VAY736|VAY736
48015657|NCT02962895|OTHER|Placebo|Placebo control
48015658|NCT04377139|PROCEDURE|Prophylaxis|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
48015659|NCT04377139|PROCEDURE|Preemptive|The intervention consists of analyzing the differences in the evolution of lung transplant recipients in relation to the intervention of prophylaxis or preemptive therapy against CMV in LTR
48015660|NCT03518320|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
48015661|NCT03518320|DRUG|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
48015662|NCT00363987|DRUG|Ketosteril®|1 tablet Ketosteril/5kgBW/d
48015663|NCT00363987|OTHER|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
48516576|NCT01577550|DRUG|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
48015664|NCT01064921|DRUG|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
48015665|NCT01064921|DRUG|cisplatin|Given IV
48015666|NCT01064921|RADIATION|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
48015667|NCT01064921|PROCEDURE|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
48015668|NCT00573963|DRUG|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
48015669|NCT00573963|DRUG|saline solution|2 injections of 20mL plain saline solution - one on each side.
48015670|NCT04064060|DRUG|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
48015671|NCT02848118|DEVICE|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
48015672|NCT02848118|OTHER|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
48015673|NCT05264974|BIOLOGICAL|Autologous total tumor mRNA loaded DOTAP liposome vaccine|"All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. Participants will be given one of the following vaccine doses:~Dose level 0 (starting dose level): 0.00125 mg/kg mRNA in 0.01875 mg/kg LP; Dose level 1: 0.0025 mg/kg mRNA in 0.0375 mg/kg LP; Dose level 2: 0.005 mg/kg mRNA in 0.075 mg/kg LP; or Dose level 3: 0.01 mg/kg mRNA in 0.15 mg/kg LP~If 3 or more of the initial 6 subjects experience a dose-limiting toxicity, then the initial starting dose will be reduced (dose de-escalation) to 0.000625 mg/kg mRNA encapsulated in 0.009375mg/kg LPs (Dose level -1)."
48015674|NCT00175474|PROCEDURE|knee surgery|
48015675|NCT02932397|DRUG|Intravenous dose of 0.5 mg/kg of propofol|
48015676|NCT02932397|DRUG|Intravenous dose of 0.05 mL/kg of saline solution|
48373001|NCT05796401|DRUG|Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC|"Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks"
48516577|NCT01577550|DRUG|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
48172187|NCT06133686|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)|Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP
48373002|NCT05796401|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU), including a standardised psycho-education program with a group cognitive behavioural therapy (e.g. I_Care - You Care) and, in FEP only, second generation antipsychotic from a restricted list (following the recommendations www.orygen.org.au)
48516578|NCT01577550|DRUG|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
48516579|NCT01577550|DRUG|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
48516580|NCT01577550|DRUG|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
48516581|NCT01577550|DRUG|Placebo, s.c.|Single s.c. administration of placebo
48516582|NCT01577550|DRUG|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
48373003|NCT03416023|DEVICE|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
48704320|NCT02725593|DRUG|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
48172188|NCT06133686|DRUG|Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)|Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
48704321|NCT02592616|BEHAVIORAL|CON|No exercise intervention.
48172189|NCT04973514|PROCEDURE|Cardiac surgery in grown-up congenital heart disease patients|Analysis of patient blood management, influence on 30 day and 6 month outcome
48172190|NCT04346485|PROCEDURE|SP TFL RIRS with 145 mcm fiber|retrograde intrarenal surgery
48172191|NCT04346485|PROCEDURE|SP TFL RIRS with 200 mcm fiber|retrograde intrarenal surgery
48172192|NCT04346485|PROCEDURE|Ho:YAG RIRS with 200 mcm fiber|retrograde intrarenal surgery
48172193|NCT03628183|OTHER|Hydrolysate Infant Formula 1|Feed ad lib
48172194|NCT03628183|OTHER|Hydrolysate Infant Formula 2|Feed ad lib
48172195|NCT05630378|BEHAVIORAL|outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients|Patients receive multimodal integrative medicine and naturopathy applications with focus on mind-body-medicine and whole body hyperthermia to reduce fatigue and improve quality of life.
48172196|NCT05630378|OTHER|waiting group|Patients receive no intervention
48172197|NCT04721405|DEVICE|Observational Study: No intervention|Observational Study: No intervention
48172198|NCT00428025|DRUG|diclofenac|100 mg diclofenac rectal suppository
48172199|NCT00428025|DRUG|placebo|similar shape and size suppository
48172200|NCT02906475|OTHER|standardized skin care regimen|"Application of a standardized daily skin care regimen:~* milk lotion once daily and~* application of addendum for bathing as needed"
48172201|NCT05925062|BEHAVIORAL|QActual|QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
48172202|NCT05495919|OTHER|Control|No intervention was perfomed to reduce anxiety in control group
48172203|NCT05495919|OTHER|video interaction|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
48172204|NCT05495919|OTHER|flipped training|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
48172205|NCT01252056|DRUG|Probucol|250mg,Bid
48172206|NCT01252056|DRUG|Probucol and Cilostazol|50-100mg,Bid
48373004|NCT05650255|OTHER|A Digital Twin for Exoskeleton Pilot|The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
48704322|NCT02592616|BEHAVIORAL|CW|One hour of continuous walking on a treadmill.
48704323|NCT02592616|BEHAVIORAL|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
48704324|NCT03640052|DRUG|Placebo oral capsule|Placebo capsule before sleep
48172207|NCT00634920|DRUG|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
48172208|NCT00634920|DRUG|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
48172209|NCT00634920|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
48172210|NCT00634920|DRUG|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
48172211|NCT00634920|DRUG|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
48172212|NCT02782572|OTHER|Exercise|Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
48172213|NCT02716077|RADIATION|FDG PET/CT imaging|
48172214|NCT05267678|OTHER|No intervention|This is an observational study without any intervention
48704325|NCT03640052|DRUG|LTM1201L|LTM1201L capsule before sleep
48704326|NCT03640052|DRUG|LTM1201LN|LTM1201LN capsule before sleep
48704327|NCT03640052|DRUG|LTM1201LB|LTM1201LB capsule before sleep
48704328|NCT03640052|DRUG|LTM1201LD|LTM1201LD capsule before sleep
48373005|NCT04433000|DIAGNOSTIC_TEST|Butterfly|Standardized lung ultrasound scan with two different instruments
48373006|NCT00475527|DRUG|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
48373007|NCT01977066|BEHAVIORAL|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
48015677|NCT03139656|BEHAVIORAL|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
48172215|NCT03586141|DIAGNOSTIC_TEST|Pronto® hemoglobin measurement tool|All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
48516583|NCT03127111|GENETIC|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
48516584|NCT03127111|GENETIC|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
48172216|NCT02185677|OTHER|Clinical evaluation|
48172217|NCT02185677|OTHER|neuropsychological battery test|
48172218|NCT02185677|OTHER|MRI|
48172219|NCT02185677|OTHER|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
48373008|NCT01977066|BEHAVIORAL|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
48015678|NCT03139656|BEHAVIORAL|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
48015679|NCT03139656|BEHAVIORAL|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
48015680|NCT04865094|OTHER|cyclic merocyanine|long-UVA absorber
48015681|NCT04865094|OTHER|placebo|placebo
48015682|NCT04142541|DEVICE|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
48015683|NCT03843788|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (\>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
48015684|NCT04104139|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
48015685|NCT04104139|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48015686|NCT04104139|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
48015687|NCT01285765|DRUG|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
48015688|NCT04368702|RADIATION|Viewray MRIdian® Linac|MR-image guided radiation will be administered per disease site standards.
48015689|NCT05292950|DRUG|ARO-MUC5AC|single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution
48015690|NCT05292950|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
48015691|NCT00784446|DRUG|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
48015692|NCT05732831|DRUG|TNG462|TNG462, a selective PRMT5 inhibitor, will be administered orally
48015693|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) active stimulator|In tDCS the electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
48015694|NCT06155786|DEVICE|transcranial random noise stimulation (tRNS)|Here, an alternating electrical current is applied at a mix of frequencies it is called transcranial random noise stimulation (tRNS), which can be delivered in low (between 0.1-100 Hz) or high (between 101-640 Hz) frequency stimulation
48373009|NCT02093156|OTHER|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
48516585|NCT03127111|GENETIC|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
48704329|NCT03526237|BEHAVIORAL|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
48516586|NCT03127111|GENETIC|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
48015695|NCT06155786|DEVICE|transcranial direct current stimulation (tDCS) sham stimulator|Here a sham electrical current is applied directly between electrodes mounted on the head which can can de-or hyperpolarizes resting membrane potential and thereby modulate cortical excitability
48015696|NCT06304337|DEVICE|New oropharyngeal airway group|Oropharyngeal airwayIt is composed of nasal plug, bite mouth, oropharyngeal passage, oxygen supply tube, rope and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.For patients undergoing endoscopic surgery/examination to prevent airway obstruction caused by backtongue fall, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time, JK model can monitor oropharyngeal end-expiratory carbon dioxide collection.
48373010|NCT03115723|PROCEDURE|Percutaneous coronary intervention|
48373011|NCT03115723|PROCEDURE|Coronary angiography|
48373012|NCT00346775|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate
48373013|NCT00346775|DRUG|Flunisolide|Flunisolide
48373014|NCT04976205|RADIATION|Total Marrow (Lymph-node) Irradiation|To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
48373015|NCT01992926|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
48373016|NCT02316782|DEVICE|Blinded IVUS assessment|Only the angiogram is used for stent placement
48373017|NCT02316782|DEVICE|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
48373018|NCT04997577|BEHAVIORAL|Auditory-cognitive training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. A short-term memory component, in which listeners are asked to remember what a designated speaker said two sentences prior, was added to the auditory training paradigm to make the task more challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
48373019|NCT04997577|BEHAVIORAL|Auditory training paradigm|The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed to train each individual at their own level to make the task challenging. Participants will be asked to recall the keywords of the to-be-attended speaker. The sentences will be presented in a two-down one-up adaptive procedure in which the ratio of the levels of the to-be-attended and to-be-ignored speaker will be adjusted based on the correctly recalled key words.
48373020|NCT05128656|OTHER|serology|serology at M3 and serology at M6
48373021|NCT01388946|DRUG|Ropivacaine 0.75|
48373022|NCT01388946|DRUG|Normal saline|
48373023|NCT00184730|DRUG|somatropin|
48373024|NCT04654299|PROCEDURE|External biliary stent|The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
48373025|NCT02491463|BIOLOGICAL|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
48373026|NCT02491463|BIOLOGICAL|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
48373027|NCT02491463|BIOLOGICAL|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
48704330|NCT03526237|BEHAVIORAL|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
48373028|NCT02491463|DRUG|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
48373029|NCT02059265|DRUG|Dasatinib|Given PO
48373030|NCT02059265|OTHER|Laboratory Biomarker Analysis|Correlative studies
48704331|NCT02105493|DRUG|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
48373031|NCT04490551|DIAGNOSTIC_TEST|Risk-based logistic regression model|The intervention will be a risk-based logistic regression model that takes multiple variables into account to calculate the risk of advanced neoplasia as an outcome.
48373032|NCT04490551|DIAGNOSTIC_TEST|FIT|FIT is a stool-based test that detects human blood in faeces.
48373033|NCT00220311|DRUG|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
48373034|NCT03401502|DRUG|Ranolazine|Oral, b.i.d
48373035|NCT03401502|DRUG|Placebos|Oral, b.i.d
48373036|NCT01698606|BEHAVIORAL|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
48015697|NCT05459129|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
48015698|NCT05459129|DRUG|Tiragolumab|Tiragolumab will be administered intravenously at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
48015699|NCT05459129|DRUG|Carboplatin|Carboplatin will be administered intravenously at a dose of area under the concentration-time curve (AUC) 5 mg/mL/min on Day 1 of each 21 day cycle.
48373037|NCT01698749|DRUG|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
48373038|NCT05741242|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Personalized Synthetic Long Peptide Vaccine
48373039|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
48015700|NCT05459129|DRUG|Paclitaxel|Paclitaxel will be administered intravenously at a dose of 175 mg/m2 on Day 1 of each 21 day cycle.
48015701|NCT01461096|BIOLOGICAL|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
48015702|NCT01461096|BIOLOGICAL|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
48015703|NCT01461096|BIOLOGICAL|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
48015704|NCT01734226|DIETARY_SUPPLEMENT|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
48015705|NCT01734226|DIETARY_SUPPLEMENT|Placebo|Placebo (3.94g/day)
48015706|NCT06663813|BEHAVIORAL|Educational Intervention|Utilizing the Health Belief model, educational materials detailing diabetes risk factors to address perceived susceptibility, diabetes severity and complications to address perceived severity, and PCP follow-up information and medication assistance programs to address perceived barriers will be provided.
48015707|NCT05219136|OTHER|Modified Fasting Group|a new fasting protocol is applied to subjects.
48015708|NCT05219136|OTHER|Conventional Fasting Group|a conventional fasting protocol is applied to subjects.
48172220|NCT03544437|PROCEDURE|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
48172221|NCT05372471|OTHER|mHealth|ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.
48172222|NCT05372471|OTHER|Usual Care|They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.
48373040|NCT02410057|DIETARY_SUPPLEMENT|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
48373041|NCT02410057|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
48373042|NCT02173821|PROCEDURE|Blood sampling|Blood sample will be collected at a single visit
48373043|NCT00444028|DRUG|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
48373044|NCT00444028|DRUG|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
48373045|NCT00444028|DRUG|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
48373046|NCT00444028|DRUG|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
48373047|NCT00444028|DRUG|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
48373048|NCT00444028|DRUG|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
48373049|NCT02708446|DRUG|Mifepristone|200mg oral mifepristone to both study arms
48373050|NCT02708446|DRUG|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
48015709|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
48015710|NCT03759223|BEHAVIORAL|Healthy Living Messages (HLM)|Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
48015711|NCT03759223|BEHAVIORAL|Enhanced Problem-Solving Training (E-PST) (non-randomized)|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
48015712|NCT06449781|DRUG|Lutetium (177Lu) vipivotide tetraxetan|The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
48015713|NCT04678414|BEHAVIORAL|Healthcare Activity|Attend focus group
48015714|NCT04678414|OTHER|Survey Administration|Complete survey
48015715|NCT05138380|DEVICE|Foot orthoses|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: inbuilt.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Orthoses are fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
48704332|NCT02105493|DRUG|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
48172223|NCT03401723|OTHER|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
48172224|NCT03401723|OTHER|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
48373051|NCT02708446|DRUG|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
48373052|NCT02185131|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
48373053|NCT02185131|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
48172225|NCT03401723|OTHER|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
48373054|NCT01611142|BIOLOGICAL|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
48373055|NCT06126601|OTHER|Pancreatectomy|"Patients who underwent pancreatectomy will be enrolled. Serum amylase and lipase will be measured preoperatively. During surgery, blood samples will be taken after completing the pancreatic anastomosis and at the end of the operation during skin suture. Patients will be followed up during hospital stay, 3 and 6 months after discharge. The clinical outcome (complications, rescue pancreatectomy) will be recorded and analysed.~Postoperative blood samples, according to clinical standard, will be taken at the 1, 2, 3, 5 and 7 day postoperatively. In addition to amylase several more parameters will be examined intra- and postoperatively: leucocytes, lipase, CRP, bilirubin, transaminases, AP, GGT, creatinine, interleukin-6, PCT. Intraoperative 1-2ml of pancreas juice will be taken for the evaluation of amylase and lipase levels."
48373056|NCT04442932|DEVICE|Blood Collection|K3-EDTA venous whole blood 9 mL 1 venous draw
48373057|NCT01945034|DRUG|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
48373058|NCT01945034|DRUG|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
48373059|NCT01945034|DRUG|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
48172226|NCT05592236|OTHER|Dynamic compression garments|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
48704333|NCT03661905|OTHER|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
48704334|NCT03661905|BEHAVIORAL|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
48172227|NCT05592236|OTHER|Standard therapy|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
48172228|NCT03075098|DEVICE|Digital colposcope|Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
48373060|NCT01945034|DRUG|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
48373061|NCT03392922|DEVICE|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
48373062|NCT03392922|DEVICE|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
48516587|NCT03127111|GENETIC|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
48516588|NCT03420521|DRUG|Nivolumab|240mg IV over 60 minutes Q2W
48704335|NCT02453165|PROCEDURE|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
48704336|NCT02453165|PROCEDURE|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
48704337|NCT02647541|DIETARY_SUPPLEMENT|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
48704338|NCT01824823|DRUG|afatinib|Given PO
48704339|NCT01824823|OTHER|placebo|Given PO
48373063|NCT02182076|DRUG|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
48373064|NCT01466309|DEVICE|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
48373065|NCT00512226|OTHER|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2\* MRI analysis.
48373066|NCT04331431|PROCEDURE|Spinal cord tumor resection|Excision of intradural tumors
48516589|NCT03420521|DRUG|Ipilimumab|1mg/kg IV over 30 minutes Q6W
48516590|NCT02704169|OTHER|Spatially registered endoscopy|
48704340|NCT03147612|BIOLOGICAL|Blinatumomab|Given via central catheter
48704341|NCT03147612|DRUG|Cyclophosphamide|Given IV
48704342|NCT03147612|DRUG|Cytarabine|Given intrathecally or IV
48373067|NCT00588120|DRUG|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
48373068|NCT04373265|DRUG|Relacorilant|Relacorilant, 100 mg soft gel capsules orally once daily
48373069|NCT04373265|DRUG|Pembrolizumab|Pembrolizumab 400 mg infusion every 6 weeks
48373070|NCT01070849|OTHER|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
48516591|NCT06550960|DEVICE|Evaluation of two biopsy systems|Each subject will have prostate biopsy taken in 6 locations in one lobe of the prostate and then biopsy in 6 locations in the other lobe of the prostate
48704343|NCT03147612|BIOLOGICAL|Filgrastim|Given SC
48704344|NCT03147612|DRUG|Methotrexate|Given intrathecally or IV
48704345|NCT03147612|BIOLOGICAL|Pegfilgrastim|Given SC
48704346|NCT03147612|DRUG|Ponatinib|Given PO
48704347|NCT03147612|BIOLOGICAL|Rituximab|Given IV
48704348|NCT03147612|DRUG|Vincristine|Given IV
48704349|NCT06581731|DRUG|remimazolam combined with remifentanil|Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
48704350|NCT06581731|DRUG|dexmedetomidine combined with remifentanil|Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
48704351|NCT06389331|OTHER|closed the defect with barbed suture|In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
48704352|NCT03070860|RADIATION|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
48704353|NCT00350870|DRUG|disulfiram|250mg per day of Disulfiram plus CBT
48704354|NCT00350870|DRUG|Placebo|Placebo plus CBT
48704355|NCT00350870|BEHAVIORAL|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
48704356|NCT00350870|DRUG|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
48704357|NCT00883012|BIOLOGICAL|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart"
48373071|NCT01070849|OTHER|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
48172229|NCT06403098|DEVICE|External Nasal Dilator Strip|Participants will wear an extra strength Breathe Right nasal strip overnight.
48172230|NCT01004029|DRUG|Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
48373072|NCT01070849|OTHER|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
48373073|NCT00919620|BEHAVIORAL|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
48373074|NCT03773354|BEHAVIORAL|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
48373075|NCT03491982|DEVICE|Remote Cardiac Rehab|Remote Cardiac Rehab
48373076|NCT01252914|DEVICE|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
48373077|NCT01813760|DEVICE|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
48015716|NCT05138380|DEVICE|Flat shoe insert|"Manufacturer: Foot Science International.~Material: High grade thermoformable closed-cell polyolefin foam (medium density)~Arch support: no.~Covering: fabric~Provided by: Study Practitioner: Registered physiotherapist \> 2 years musculoskeletal experience will be trained to prescribe the insert according to the prescription algorithm.~Where: Administered via telehealth~When and how much: Week 0 to 1: one telehealth session with study practitioner to fit one pair of pre-fabricated orthoses Week 1 to 2: Follow-up session for questions if required~Tailoring: Fit to comfort. Lengths (S, S, M, L, XL, XXL) (dependent on participant's shoe size). Hardness = Medium density. Modifications: can be cut to size to assist in fit using the shoes original sock liner as a guide, by participants using standard scissors. Heat molding: optional.~Adherence: Adherence recorded with diary/ log book (insert wear time)"
48015717|NCT02944071|DEVICE|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
48015718|NCT00612313|DRUG|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
48373078|NCT01955291|DEVICE|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
48373079|NCT01955291|OTHER|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
48373080|NCT03998696|DRUG|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
48373081|NCT03998696|DRUG|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
48373082|NCT03851562|DRUG|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
48373083|NCT03851562|DRUG|Placebo|Intravenous infusion of physiological saline solution
48704358|NCT00883012|BIOLOGICAL|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
48704359|NCT01778335|PROCEDURE|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
48704360|NCT05093907|DRUG|BEY1107|Administer once daily, PO, 3-week continuous dose.
48704361|NCT05093907|COMBINATION_PRODUCT|Capecitabine|Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
48704362|NCT06598228|OTHER|No Intervention: Observational Cohort|no intervention
48172231|NCT01004029|DRUG|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
48172232|NCT02741258|DEVICE|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
48373084|NCT01424657|PROCEDURE|ERCP|Endoscopic retrograde cholangiopancreatography
48015719|NCT00612313|BEHAVIORAL|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
48015720|NCT00005758|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
48373085|NCT01424657|PROCEDURE|MRCP|magnetic resonance cholangiopancreatography
48373086|NCT01634399|DRUG|Torrent's Quetiapine Fumarate Tablets|
48373087|NCT00475774|BEHAVIORAL|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
48373088|NCT04448548|OTHER|blood sample taking|For study purposes, blood sample was taken during the first medical examination from patients with suspected infection.
48373089|NCT03538496|DRUG|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
48373090|NCT04988620|OTHER|Whole Blood transfusion|In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
48373091|NCT02185820|DRUG|Carfilzomib|
48373092|NCT02185820|DRUG|Pomalidomide|
48373093|NCT02185820|DRUG|Dexamethasone|
48373094|NCT05954117|PROCEDURE|Adipose tissue biopsies|"During the 2 surgical time, when patient is under general anesthesia, two adipose tissue biopsies of 20cc each (one from abdominal subcutaneous adipose tissue and one from omental adipose tissue) are taken and characterize by oxygraphy (respirometry).~Before the 2 surgical times (before and after chemotherapy) patients will have evaluation of the muscle strength, cachexia (by scan analysis), energy expenditure, anthropometric criteria and biochemical inflammatory."
48373095|NCT02874235|BEHAVIORAL|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
48373096|NCT02874235|BEHAVIORAL|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
48373097|NCT01961310|BIOLOGICAL|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
48015721|NCT00005758|BIOLOGICAL|HIV-1 Immunogen|
48015722|NCT00860652|RADIATION|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
48015723|NCT00860652|RADIATION|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
48015724|NCT06652035|DIETARY_SUPPLEMENT|Quevir® (Quercetin Phytosome®)|500 mg Quevir® (Quercetin Phytosome®) tablet
48015725|NCT06652035|DIETARY_SUPPLEMENT|Bactoblis®|Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)
48015726|NCT05941039|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 6 days, a 4-day washout period, and a 6-day no-training period.
48015727|NCT05941039|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
48015728|NCT05368207|DRUG|Pembrolizumab|Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
48172233|NCT02741258|DRUG|skin cream|cream to treat skin erythema due to radiotherapy
48373098|NCT01961310|BIOLOGICAL|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
48373099|NCT02120456|DRUG|LEO 43204|
48373100|NCT02120456|DRUG|Placebo|
48373101|NCT05910268|BEHAVIORAL|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
48373102|NCT03635541|OTHER|observational group of NAFLD|there's no intervention for patients for it is a observational study
48373103|NCT05248633|RADIATION|radiotherapy|radiotherapy with a dose of 40-50 Gy
48373104|NCT05248633|DRUG|Bortezomib Injection|subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
48373105|NCT05248633|DRUG|Lenalidomide|Lenalidomide 25mg for 21 days
48373106|NCT05248633|DRUG|Dexamethasone|Dexamethasone 40mg d1,8,15,22
48373107|NCT01796899|OTHER|Brivaracetam 10 mg oral tablet|
48373108|NCT01796899|OTHER|Brivaracetam 50 mg oral tablet|
48373109|NCT01796899|OTHER|Brivaracetam 75 mg oral tablet|
48373110|NCT01796899|OTHER|Brivaracetam 100 mg oral tablet|
48373111|NCT01796899|OTHER|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
48373112|NCT01641952|DRUG|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
48373113|NCT03235674|OTHER|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
48373114|NCT02672475|DRUG|Galunisertib|Given PO
48373115|NCT02672475|OTHER|Laboratory Biomarker Analysis|Correlative studies
48373116|NCT02672475|DRUG|Paclitaxel|Given IV
48373117|NCT02822027|DRUG|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
48373118|NCT02822027|DRUG|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
48373119|NCT02405182|OTHER|Magnetic Resonance Imaging|
48373120|NCT02140268|DRUG|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
48373121|NCT02140268|DRUG|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
48373122|NCT02140268|DRUG|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
48373123|NCT03134001|DEVICE|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
48373124|NCT01404104|DRUG|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
48373125|NCT00004808|DRUG|fluconazole|
48373126|NCT04993547|OTHER|Parent and peer presence|Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
48373127|NCT02136446|DEVICE|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
48373128|NCT02136446|DEVICE|Pajunk® Nerve Block Catheter|Nerve Block Catheter
48373129|NCT03112759|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
48373130|NCT00175552|BEHAVIORAL|Psychotherapy Training|
48373131|NCT03734874|DIETARY_SUPPLEMENT|hesperidin|500 mg hesperidin as two capsuls
48373132|NCT03734874|OTHER|control|no supplementation
48373133|NCT00576940|DRUG|Reconvan|isocaloric, immunomodulating entral diet
48373134|NCT00576940|DRUG|Peptisorb|isocaloric, isopeptic standard diet
48373135|NCT00935675|DRUG|Escitalopram|Escitalopram 10 mg once a day
48373136|NCT02007798|DRUG|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
48373137|NCT02007798|DRUG|normal saline|100 ml per bag
48373138|NCT03664700|DEVICE|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
48015729|NCT00807092|DRUG|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
48015730|NCT00807092|DRUG|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
48373139|NCT04115501|OTHER|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
48015731|NCT00807092|DRUG|metformin|Metformin dose must remain the same as that used prior to the trial.
48015732|NCT05390502|BEHAVIORAL|manual monitoring and general education on use|Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.
48015733|NCT05390502|BEHAVIORAL|integrated monitoring and local wrap-around hypertension program|Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
48015734|NCT04715984|OTHER|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a working memory task evaluated
48015735|NCT04715984|PROCEDURE|Neural stimulation|Neural stimulation will be delivered during a working memory task and its impact on task performance quantified
48172234|NCT00815347|DRUG|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
48172235|NCT00815347|DRUG|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
48172236|NCT04054453|COMBINATION_PRODUCT|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
48373140|NCT05908539|BEHAVIORAL|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
48373141|NCT05908539|BEHAVIORAL|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
48373142|NCT05908539|BEHAVIORAL|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
48373143|NCT05908539|BEHAVIORAL|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
48373144|NCT00504816|DRUG|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
48373145|NCT00504816|DRUG|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
48373146|NCT05195242|DRUG|Dexamethasone|ATC code H02AB02
48373147|NCT05141422|DRUG|SHR2150 tablet、efavirenz|SHR2150 tablet single dose, Efavirenz single dose.
48373148|NCT04508504|PROCEDURE|Preop PENG block|Ultrasound-guided injection of 20 mL 0.5% ropivacaine according to the method described by Giron-Arango L in 2018. A needle is inserted at the inguinal level under ultrasound guidance to pass beneath the psoas tendon on top of the iliopubic eminence where the local anesthetic is injected.
48373149|NCT04508504|PROCEDURE|Placebo block|Ultrasound-guided placebo injection of 5 mL 0.9% normal saline. Using the same landmarks as for the PENG group, a needle is inserted in the inguinal region under ultrasound guidance, whereby a subcutaneous injection of 5 mL of 0.9% saline is made.
48704363|NCT05696353|COMBINATION_PRODUCT|In-vehicle Device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smart phone app (downloaded on the teen's smart phone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data via the smart phone app and study website; and 3) A customized biweekly driving summary report via study website.
48172237|NCT03779477|BEHAVIORAL|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
48172238|NCT00581841|OTHER|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
48172239|NCT01260207|OTHER|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
48172240|NCT00566839|PROCEDURE|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
48516592|NCT03674398|BEHAVIORAL|Exercise+CT|The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.
48516593|NCT03674398|BEHAVIORAL|Exercise only|The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
48704364|NCT05696353|BEHAVIORAL|Expert-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a traffic safety communication specialist to parents in the Feedback and Expert-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
48172241|NCT00566839|PROCEDURE|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
48172242|NCT04205955|OTHER|Best Practice|Receive healthy living education via phone call
48172243|NCT04205955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet modification coaching via phone call
48172244|NCT04205955|OTHER|Message|Receive motivational messages via email and/or text message
48172245|NCT04205955|OTHER|Quality-of-Life Assessment|Ancillary studies
48172246|NCT04205955|OTHER|Questionnaire Administration|Ancillary studies
48373150|NCT04508504|DRUG|Ropivacaine 0.5% Injectable Solution|20 mL 0.5% ropivacaine will be injected for the preop PENG block
48704365|NCT05696353|BEHAVIORAL|Peer-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a peer trainer who is a parent of teen with traffic citation and has participated in the Feedback and Peer-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
48704366|NCT06605300|DRUG|Intranasal Oxytocin (IN-OXT)|Subject assigned to receive intranasal administration of oxytocin (24 IU).
48373151|NCT04508504|DRUG|Normal Saline|5 mL 0.9% Normal saline will be injected for the Placebo block
48373152|NCT01315158|DRUG|Propofol Alone|"Recommended Propofol doses before considering crossover:~* Induction: 2-2.5 mg/kg~* Maintenance: 0.1-0.2 mg/kg/min"
48373153|NCT01315158|DRUG|Propofol+Benzo/Opioids|"1. Recommended Versed:~   a. Prior to intubation~  * patient is \< 50 kg = 1 mg Versed~  * patient is 50-75 kg = 1.5 mg Versed~  * patient is \> 75 kg = 2 mg Versed~2. Recommended Fentanyl~   1. Prior to intubation = 0.5 ug/kg~  2. Total procedural dose = 1 ug/kg"
48373154|NCT00512070|DRUG|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
48373155|NCT04522128|BEHAVIORAL|Behaviour Change Technique Intervention to Improve Quality of Life|"The intervention targets each facet of the five domains of WHOQOL COMBI. The intervention is based on the COM-B Framework (Michie et al., 2012) and utilises behaviour change techniques to help participants change their behaviour to improve their quality of life.~The intervention will be compared to an active comparator 'feedback intervention' and a waitlist control group."
48373156|NCT06046989|BEHAVIORAL|Building Emotion Awareness and Mental Health (BEAM)|BEAM is based on best-practices in telehealth and science-based program design principles aimed at promoting parental mental health and supportive parenting. The BEAM Program mobile application is designed and managed by MindSea. The weekly one-on-one check-ins with peer coaches (parents who previously participated in another research group-based mental health intervention) will use the secure videoconferencing platform Zoom (Healthcare license) and direct messaging through the BEAM app. Peer coaches will also engage with participants on the community peer support forum. Monthly drop-in group peer support sessions will be facilitated by peer coaches and/or mental health professionals on the BEAM research team. The BEAM program's content emphasizes self-compassion, effective communication practices, and building social support networks.
48516594|NCT05928312|DRUG|Fruquintinib Combined With Chemotherapy|"1.Security introduction period:~\[1\] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~\[2\] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~1. Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~2. Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."
48516595|NCT02371473|DRUG|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
48172247|NCT02428816|OTHER|MRI acquisition|MRI acquisitions
48172248|NCT02428816|BEHAVIORAL|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
48516596|NCT02371473|DRUG|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
48704367|NCT06605300|DRUG|Intranasal Vasopressin (AVP)|Subjects assigned to receive intranasal administration of AVP (20 IU).
48704368|NCT06605300|DRUG|Intranasal Placebo|Subjects assigned to receive intranasal administration of placebo.
48704369|NCT02276352|DRUG|Treatment 1|
48704370|NCT02276352|DRUG|Treatment 2|
48704371|NCT02276352|DRUG|Treatment 3|
48704372|NCT05370963|DRUG|Hylase versus dexmedtemodine|fluroscopic guided lumber epidural injection
48704373|NCT01809145|OTHER|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
48704374|NCT02690428|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
48704375|NCT00620425|DRUG|Sumatriptan|injection
48704376|NCT01772524|BIOLOGICAL|ALD403|
48704377|NCT01772524|DRUG|Placebo|
48704378|NCT04899258|PROCEDURE|Femtosecond laser assisted LASIK|Refractive surgery
48704379|NCT05285618|DEVICE|Argus II|In response to the stimulation/image on the monitor subjects will be asked to make perceptual judgments and complete simple behavioral tasks. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, reporting shape by selecting a tactile object of similar shape, or locating a target by moving around, rotating the head, and pointing. Sighted control subjects will perform similar tasks in virtual reality.
48015738|NCT01715103|PROCEDURE|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
48015739|NCT05404516|DRUG|Sorafenib|"Induction cycle(s): 400 mg BID on days 8-21.~Consolidation cycles 1-4: 400 mg BID on days 1-21.~Maintenance therapy: 400 mg BID for one year."
48015740|NCT05404516|DRUG|Idarubicin|"Induction cycle(s): 12 mg/m2/day on days 1-3.~Consolidation cycle 1: 8 mg/m2/day administered on days 1-3."
48172249|NCT00000850|DRUG|Indinavir sulfate|
48172250|NCT00000850|DRUG|Sargramostim|
48172251|NCT04514172|DEVICE|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
48172252|NCT04514172|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
48172253|NCT01865500|DRUG|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
48172254|NCT01865500|DRUG|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
48172255|NCT01865500|DRUG|Metil prednisolone|
48172256|NCT01540578|OTHER|laboratory biomarker analysis|Correlative studies
48704380|NCT03757650|DRUG|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
48172257|NCT02836262|DEVICE|HIT Hip Replacement System|HIT Hip Replacement System
48172258|NCT02929719|DRUG|Test.|gel
48172259|NCT02929719|DRUG|Aczone Gel 5%|gel
48172260|NCT02929719|DRUG|Placebo|gel
48172261|NCT02138253|DRUG|IDN-6556|
48172262|NCT02138253|DRUG|Placebo|Placebo control
48172263|NCT06055803|BEHAVIORAL|Intake Session|Each of the program components will have an individualized assessment with plan and goals set at the program intake visit.
48172264|NCT06055803|BEHAVIORAL|Individual Sessions|Individual sessions will occur in person or virtual every other week during the 12-week intervention with a health promotion specialist (nurse or exercise physiologist). These sessions will include review of progress towards goals, update exercise prescription, make plan for the next two weeks.
48172265|NCT06055803|BEHAVIORAL|Group Sessions|Group sessions for wellness and education will be delivered by medical multi-disciplinary staff in person or virtual every other week during the 12-week intervention.
48172266|NCT06055803|BEHAVIORAL|Graduation|At the conclusion of the 12-week intervention, there will be a graduation session to honor the participant's achievement and establish a plan for maintenance after the intervention
48172267|NCT06055803|BEHAVIORAL|Exercise|Participants will exercise as part of individual and group sessions. Participants will also be asked to exercise on their own, with a goal of working up to meeting US Physical Activity guidelines (150 minutes per week of moderate to vigorous exercise + 2 episodes of strength training).
48172268|NCT03245619|DRUG|GSK3335065|GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
48172269|NCT03245619|DRUG|Placebo|Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
48172270|NCT03626025|OTHER|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
48172271|NCT03712384|OTHER|Semi structured face to face interview|Face-to-face semi-structured interview conducted in the hospital, where young adults were hospitalized 10 years before, in a quiet and isolated office. The topic guide was built according to literature review, without further change after pilot test. Interviews where audio-recorded and transcribed
48172272|NCT05192564|OTHER|Exercise for bilateral or unilateral vestibular hypofunction patients|Physical Activity intervention with balance exercises, multidirectional displacements, and strength with postural control, implementing 8-10 exercises integrating the main muscle groups and motor patterns, aerobic exercise on bicycle (15 min) developed progressively in intensity (R1-mild, R2-moderate, R3-vigorous) implementing an intervallic design in low volume.
48172273|NCT05192564|OTHER|Conventional rehabilitation treatment|Vestibular rehabilitation exercises counseling
48172274|NCT00741468|DRUG|Proellex|2, 25 mg Proellex capsules administered daily
48172275|NCT00741468|DRUG|CYP1A2 probe|Caffeine (200 mg)
48172276|NCT00741468|DRUG|CYP2C9 probe|Tolbutamide (250 mg)
48172277|NCT00741468|DRUG|CYP2C19 probe|Omeprazole (20 mg)
48172278|NCT00741468|DRUG|CYP2D6 probe|Dextromethorphan (30 mg)
48172279|NCT00741468|DRUG|CYP3A4 probe|Midazolam (2mg)
48516597|NCT01157988|DRUG|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count \> 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
48516598|NCT01497769|BIOLOGICAL|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10\^7 pfu and intradermal saline placebo
48704381|NCT01593995|DRUG|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
48015741|NCT05404516|DRUG|Cytarabine|"Induction cycle(s): 100 mg/m2 by continuous IV infusion for 24 hours on days 1-7.~Consolidation cycles 1-4: 2 g/m2/12h on days 1-3."
48172280|NCT04363853|DRUG|Tocilizumab 20 MG/ML|We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
48172281|NCT04244422|OTHER|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
48172282|NCT00984438|DRUG|BCNU Wafer|Implantable during surgical resection into the tumor bed
48172283|NCT00984438|DRUG|Irinotecan|IV every 2 weeks for up to one year
48172284|NCT00984438|DRUG|Bevacizumab|IV every 2 weeks for up to one year
48172285|NCT01722045|DRUG|Intravitreal Aflibercept Injection (IAI)|
48172286|NCT04255173|DIAGNOSTIC_TEST|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
48015742|NCT04455893|OTHER|Stratified Transplant Survival|The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs. Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ. excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]
48704382|NCT06056440|PROCEDURE|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
48704383|NCT06056440|OTHER|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
48015743|NCT01234623|OTHER|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
48172287|NCT04255173|DIAGNOSTIC_TEST|waist circumference|waist circumference is measured as cm
48704384|NCT06608264|OTHER|stress ball intervention|Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.
48704385|NCT06608264|OTHER|hand holding intervention|Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
48704386|NCT04746235|DRUG|Decitabine and Cedazuridine|Given PO
48704387|NCT04746235|DRUG|Venetoclax|Given PO
48704388|NCT05350930|OTHER|Assessment of patient satisfaction regarding tele-consultation|Questionnaire completed following the teleconsultation, if applicable.
48704389|NCT05350930|OTHER|Literacy questionnaire|Questionnaire completed during hospitalization for the first chemotherapy cycle
48704390|NCT05350930|OTHER|Collection of socio-demographic characteristics|Questionnaire completed during patient hospitalization for the first chemotherapy cycle
48704391|NCT05350930|OTHER|Assessment of patient knowledge on chemotherapy side effects and support medications|Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
48704392|NCT05350930|OTHER|Assessment of patient satisfaction on pharmaceutical follow-up|Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
48704393|NCT04099797|GENETIC|C7R-GD2.CART cells (ICV infusion)|"Dose levels in the current phase of study are ICV infusion followed by IV infusion (DL 1b, 2b, 3b, 4b)~a. Dose level 1b ICV: 5 x 10\^6 cells/dose (followed by standard IV dose) b. Dose level 2b ICV: 1 x 10\^7 cells/dose (followed by standard IV dose) c. Dose level 3b ICV: 2 x 10\^7 cells/dose (followed by standard IV dose) d. Dose level 4b ICV: 5 x 10\^7 cells/dose (followed by standard IV dose)"
48015744|NCT02154815|OTHER|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
48015745|NCT06664060|DRUG|osteoimplant|30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
48015746|NCT06664060|DRUG|Placebo|30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
48172288|NCT04255173|DIAGNOSTIC_TEST|hip circumference|hip circumference is measured as cm
48172289|NCT04255173|DIAGNOSTIC_TEST|height|height is measured as cm
48516599|NCT01497769|BIOLOGICAL|Intradermal MVA85A|Intradermal MVA85A 1 x 10\^7 pfu and inhaled aerosol saline placebo
48516600|NCT03792022|BEHAVIORAL|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
48704394|NCT04099797|GENETIC|C7R-GD2.CART cells (IV infusion)|Standard IV dose: 30 million cells/m2 divided into two doses given at least 5 days and no greater than 10 days apart.
48015747|NCT00625599|OTHER|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
48015748|NCT04363281|OTHER|preoperative questionnaire|"1. Three questions to predict acute pain:~   * Verbal numeric score Anxiety 0-10~  * Anticipated postoperative pain level~  * Anticipated analgesic requirements~2. Speilberger STATE-TRATE inventory index~3. Pain Catastrophizing Scale"
48172290|NCT04255173|DIAGNOSTIC_TEST|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
48172291|NCT04255173|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height \[m2\].
48172292|NCT04255173|DIAGNOSTIC_TEST|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
48172293|NCT04255173|DIAGNOSTIC_TEST|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
48172294|NCT04255173|DIAGNOSTIC_TEST|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
48172295|NCT01800539|BEHAVIORAL|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
48172296|NCT06467214|BEHAVIORAL|CONNECTED|CONNECTED is a manualized, peer-led, group-based social isolation intervention for diverse veteran populations in VA primary care settings. It is delivered via videoconference through individual and group sessions over 8 weeks.
48172297|NCT06467214|BEHAVIORAL|VET BEFRIENDING|VET BEFRIENDING (attention control arm) consists of weekly social interactions with a research assistant (RA) over videoconference or phone.
48172298|NCT02287740|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
48172299|NCT02287740|BEHAVIORAL|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
48704395|NCT00909545|DRUG|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
48704396|NCT00909545|DRUG|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
48704397|NCT00909545|DRUG|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
48704398|NCT00909545|DRUG|Placebo|4 Placebo to Match (PTM) tablets once daily
48172300|NCT02287740|BEHAVIORAL|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
48172301|NCT05951621|OTHER|Qigong|An ancient Chinese system of postures, exercises, breathing techniques, and meditations designed to improve and enhance the body's QI.
48172302|NCT05951621|BEHAVIORAL|guidance of nutrition and exercise|Provide health promotion and guidance to participants on diet and physical exercise
48373157|NCT03024294|OTHER|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
48373158|NCT04936126|DRUG|Quetiapine|Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period
48015749|NCT04363281|OTHER|PACU questionnaire|parturients will be approached and requested to fill out a questionnaire regarding intraoperative pain, medication consumption, anxiety and nausea.
48015750|NCT04363281|OTHER|Postoperative questionnaire|Parturients will be approached at 24 hours postpartum and questioned regarding anxiety levels and medication consumption and requested to fill out the OBSQOR 11 questionnaire at 24 hours postpartum.
48373159|NCT04936126|DRUG|Amantadine|Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period
48516601|NCT02663843|DEVICE|i-gel airway|Fibreoptic intubation via i-gel airway device
48373160|NCT04936126|DRUG|Pramipexole|Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
48373161|NCT01092130|DRUG|Vitamin D|2000 IU vitamin D daily, for 6 weeks
48516602|NCT02663843|DEVICE|air-Q airway|Fibreoptic intubation via air-Q airway device
48516603|NCT04060186|PROCEDURE|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
48704399|NCT06318806|OTHER|Psychotherapy|Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
48015751|NCT04363281|OTHER|Postoperative questionnaire- Obstetrician|The attended obstetrician will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
48704400|NCT04902924|BEHAVIORAL|repeated cold water therapy|This information can be found the description of the experimental arm.
48704401|NCT04902924|BEHAVIORAL|repeated warm water therapy|This information can be found the description of the experimental arm.
48704402|NCT04902924|OTHER|control|This information can be found the description of the experimental arm.
48015752|NCT04363281|OTHER|Postoperative questionnaire- anesthesiologist|he attended anesthesiologist will be questioned regarding the parturient's level of intraoperative pain, postoperative pain levels anxiety medication consumption, uteronic management, surgical technique and management.
48704403|NCT04750694|BEHAVIORAL|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
48704404|NCT06548074|BEHAVIORAL|H-PACE Behavioral Intervention|Participate in the H-PACE program
48015753|NCT04709237|DEVICE|omafilcon A control lens|Participants were randomized to wear omafilcon A control soft contact lens for 10 days.
48015754|NCT04709237|DEVICE|omafilcon A test lens 1|Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.
48015755|NCT04709237|DEVICE|omafilcon A test lens 2|Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
48015756|NCT03574025|OTHER|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
48015757|NCT03842475|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
48172303|NCT06171503|BEHAVIORAL|letter of invitation on MI in PMTCT service|A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
48172304|NCT00730821|DRUG|BIBW 2992|
48172305|NCT00730821|DRUG|BIBF 1120|
48373162|NCT01418066|DRUG|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
48373163|NCT01418066|DRUG|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
48373164|NCT02881866|DRUG|Furosemide|
48373165|NCT02881866|DRUG|Saline|
48373166|NCT03593031|BEHAVIORAL|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
48373167|NCT04920838|DRUG|Nitazoxanide and Ciclésonide|Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.
48373168|NCT04920838|DRUG|Telmisartan 20Mg Oral Tablet|20 mg tablet daily
48373169|NCT04920838|DRUG|Paracetamol|"Tablets containing 500 mg of paracetamol. One to two tablets every 4-6 hours as required, to a maximum of 6 tablets (3 grams) daily in divided doses.~Duration of treatment: up to 14 days"
48704405|NCT06548074|OTHER|Accelerometer|Wear an accelerometer
48015758|NCT03495986|DEVICE|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
48373170|NCT04920838|DRUG|Fluoxétine and Budésonide|Inhaled Budésonide: 400mcg BID per day and oral Fluoxétine : 80mg tablets daily (divided into two daily intakes of two tablets of Fluoxétine 40 mg) during 7 days.
48704406|NCT06548074|OTHER|Questionnaire Administration|Ancillary studies
48704407|NCT06548074|OTHER|Supportive Care|Parents may participate in an optional virtual peer support group
48015759|NCT03495986|BEHAVIORAL|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
48704408|NCT06607952|OTHER|scenario-based case videos teaching protocol|"Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical"
48015760|NCT01618539|DRUG|propofol|varying intravenous dosages
48015761|NCT04528563|DRUG|Ketorolac Tromethamine 10 MG/ML|Non-Steroidal-Anti-Inflammatory given intravenously.
48015762|NCT04528563|DRUG|Morphine Sulfate 10Mg/1mL Injection|Opioid commonly used for acute abdominal pain given intravenously.
48015763|NCT00885872|DRUG|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
48015764|NCT01271881|OTHER|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
48015765|NCT01271881|DEVICE|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
48015766|NCT05915026|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
48015767|NCT06317285|DRUG|GSK3915393|GSK3915393 will be administered.
48373171|NCT00722462|PROCEDURE|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
48373172|NCT00722462|PROCEDURE|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
48373173|NCT05879458|DRUG|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
48373174|NCT04427423|OTHER|physical therapy treatment|the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
48172306|NCT04308213|DEVICE|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
48172307|NCT03299413|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
48704409|NCT06607952|OTHER|traditional lecture-based teaching method|Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
48704410|NCT06606678|OTHER|Exercise|supervised exercise training; twice a week for 12 months
48704411|NCT06608914|DRUG|Nandrolone decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
48704412|NCT06608914|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
48172308|NCT04533828|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
48172309|NCT02176564|DRUG|inhaled bronchodilator|
48172310|NCT01797562|DIAGNOSTIC_TEST|Panels 1.3, 2.2 and 3.2 experimental allergens|Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
48172311|NCT00292981|DRUG|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
48172312|NCT04649125|RADIATION|dose escalation|single fraction dose escalation to the tumour
48172313|NCT05063123|DRUG|Flotetuzumab|Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
48172314|NCT02792647|DRUG|Placebo|Administered orally
48172315|NCT02792647|DRUG|IX-01|Administered orally
48172316|NCT01921114|DEVICE|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
48373175|NCT00603824|DRUG|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if \>100 kg
48704413|NCT06607133|PROCEDURE|surgery|patients undergo conventional/open thyroidectomy or endoscopic thyroidectomy for large benign thyroid nodules
48172317|NCT01921114|DEVICE|Bard® Dual-Lumen PowerPICC SOLO2®|
48172318|NCT00328380|DRUG|Rifaximin|
48172319|NCT00241969|BEHAVIORAL|Behavioral and Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
48172320|NCT00241969|BEHAVIORAL|Education and Attention Control|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
48704414|NCT06607133|PROCEDURE|staged thermal ablation|patients undergo multiple sessions of thermal ablation for large benign thyroid nodules
48704415|NCT04741958|DIAGNOSTIC_TEST|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
48704416|NCT05211804|DRUG|Ophthalmic Drugs|Patients will receive the same treatment as if not a part of the project
48704417|NCT00000273|DRUG|opiates|prescription opioids
48015768|NCT06317285|DRUG|Placebo|Placebo will be administered.
48516604|NCT02833987|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
48516605|NCT02833987|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
48516606|NCT02833987|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
48516607|NCT02833987|DRUG|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
48516608|NCT03771287|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
48704418|NCT03835754|DEVICE|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
48704419|NCT03659903|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy
48704420|NCT06465953|DRUG|Ivosidenib|Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
48172321|NCT02840916|PROCEDURE|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
48172322|NCT02840916|PROCEDURE|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
48373176|NCT00603824|DRUG|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
48373177|NCT01413373|RADIATION|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
48516609|NCT03771287|DEVICE|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
48516610|NCT02961088|OTHER|Pasta as part of a low GI/GL diet|
48516611|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
48373178|NCT01413373|RADIATION|computer tomography|One cone beam computer tomography examination before surgery
48373179|NCT03246152|DRUG|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
48373180|NCT02246205|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
48373181|NCT03230760|DEVICE|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
48373182|NCT03735056|OTHER|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
48373183|NCT03735056|OTHER|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
48373184|NCT04277104|OTHER|Closed loop acoustic stimulation|The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
48373185|NCT04277104|OTHER|Sham acoustic stimulation|Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
48373186|NCT01345266|PROCEDURE|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
48373187|NCT02608073|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
48373188|NCT02608073|DRUG|Cisplatin|Participants will receive cisplatin, 100 mg/m\^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
48704421|NCT06465953|DRUG|Azacitidine|Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
48704422|NCT05837403|PROCEDURE|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
48704423|NCT05837403|DRUG|Nitroglycerin ointment|application of the ointment twice daily
48704424|NCT05515588|DRUG|BI 690517 (C-14)|BI 690517 (C-14)
48704425|NCT05515588|DRUG|BI 690517|BI 690517
48704426|NCT06137378|BIOLOGICAL|KEYTRUDA®|200 mg KEYTRUDA® i. v. in 3-week cycle (q3w)
48704427|NCT00541866|DRUG|Voreloxin injection and cytarabine|"Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
48704428|NCT01817699|OTHER|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
48373189|NCT03557775|DEVICE|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
48373190|NCT03557775|DEVICE|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
48516612|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
48704429|NCT01817699|DIETARY_SUPPLEMENT|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
48704430|NCT04195438|PROCEDURE|CO Testing Pre/Post Hepatic Resection|Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
48704431|NCT04195438|DIAGNOSTIC_TEST|ABG Testing Pre/Post Hepatic Resection|Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
48015769|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
48015770|NCT04508803|DRUG|HX008，Niraparib|Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
48015771|NCT04508803|DRUG|HX008，Niraparib，Trastuzumab|Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
48015772|NCT04508803|DRUG|HX008，Niraparib，Pyrrolitinib|"HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle."
48015773|NCT06663683|OTHER|Hip thrust|The subjects in Hip Thrust (HT) group will be instructed to perform low-load gluteus activation exercises, which included single-leg bridges, clamshells and quadruped hip extensions. One set of ten repetitions or steps will perform for each exercise. In this training program three stages which focused on enhancing hypertrophy and strength of the hip extensors in sequence. During the training period, the subjects will be instructed to maintain their usual daily activities and diet. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between the sessions. Hip thrust training 3 sets with 10 repetitions in each set and 2 minutes rest between each set.
48015774|NCT06663683|OTHER|Back squat|In Back Squat (BS) resistance training the subjects starts with the standing position with the feet flat on the floor, the knees and hips in a neutral, extended anatomical position, and the spine in an upright position with preservation of its natural curves. The squat movement will begin with the descent phase as the hips, knee and ankles flex. A common instruction will be given to the subjects to descend until the top of the thigh is at least parallel with ground and the hip joint is at least level with or slightly below the knee joint. All subjects will complete 18 sessions at a frequency of 3 sessions per week and with at least 48 hours between sessions. Back squat training 3 sets with 10 repetitions in each set \& 2 minutes rest between each set.
48704432|NCT04195438|DIAGNOSTIC_TEST|CT Evaluations|Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
48704433|NCT06443710|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
48015775|NCT03948685|DRUG|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
48015776|NCT03948685|DRUG|Placebo|Placebo
48015777|NCT06207110|BEHAVIORAL|Regulation of Cues|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.
48015778|NCT06207110|BEHAVIORAL|Family Based Behavioral Treatment|FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
48015779|NCT06207110|BEHAVIORAL|Regulation of Cues +|ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake
48015780|NCT06207110|BEHAVIORAL|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
48015781|NCT03481946|DRUG|BAY1093884|0.3 mg/kg given intravenously
48015782|NCT03481946|DRUG|BAY1093884|1 mg/kg given intravenously
48704434|NCT03036683|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
48015783|NCT02605590|DRUG|AIR DNase|
48015784|NCT02605590|DRUG|Placebo|
48172323|NCT05889390|DEVICE|Oncotherm EHY-2030|Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects. It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz. mEHT exploits various biophysical differences of cancer cells. For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death. mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
48704435|NCT03036683|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
48704436|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for 120 days
48704437|NCT05308472|DRUG|DISC-1459|Oral dose level 2, once a day for 120 days
48704438|NCT05308472|DRUG|Placebo|Oral dose, once a day for 120 days
48172324|NCT05889390|DRUG|Paclitaxel|weekly paclitaxel for 12 weeks
48704439|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for up to 8 months
48704440|NCT00998673|DEVICE|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
48704441|NCT00998673|DEVICE|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
48704442|NCT00296465|DRUG|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
48704443|NCT00296465|DRUG|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
48704444|NCT00296465|DRUG|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
48704445|NCT00296465|DRUG|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
48704446|NCT01448785|DEVICE|abiliti system implant|Subjects will receive implanted abiliti System.
48704447|NCT01448785|DEVICE|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
48704448|NCT05080855|PROCEDURE|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
48704449|NCT05010122|DRUG|Decitabine and Cedazuridine|Given PO
48704450|NCT05010122|DRUG|Gilteritinib|Given PO
48704451|NCT05010122|DRUG|Venetoclax|Given PO
48704452|NCT05842954|DRUG|KLU156|Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
48704453|NCT05842954|DRUG|Coartem|Oral use. Dosing will be selected based on patient's body weight as per product's label.
48172325|NCT05889390|DRUG|Carboplatin|added to weekly paclitaxel if patient has triple-negative breast cancer
48172326|NCT05889390|DRUG|Cyclophosphamide/Doxorubicin|according to the AC protocol
48172327|NCT05889390|PROCEDURE|Breast cancer removal surgery|Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
48172328|NCT04510025|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
48172329|NCT00791297|DRUG|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
48172330|NCT04017897|DRUG|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
48373191|NCT03557775|BEHAVIORAL|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
48373192|NCT04196959|DIETARY_SUPPLEMENT|TYR sphere|TYR sphere is a powdered protein substitute for patients with tyrosinaemia.
48704454|NCT01865812|DRUG|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
48704455|NCT05132361|DEVICE|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
48704456|NCT05132361|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
48704457|NCT06218251|DRUG|BOTOX|Intramuscular Injections
48172331|NCT01746277|DRUG|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
48172332|NCT01746277|DRUG|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
48172333|NCT00282945|DRUG|Rosiglitazone|
48172334|NCT00282945|DRUG|Metformin|
48172335|NCT00904683|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
48373193|NCT02139020|OTHER|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
48704458|NCT04828577|BEHAVIORAL|Real Time Neurofeedback|Participants receive feedback from own brain activity.
48704459|NCT04828577|BEHAVIORAL|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
48704460|NCT04392141|DRUG|Standard Treatment|Standard Treatment for COVID-19 based on National Recommendations
48704461|NCT04392141|DRUG|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions|Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
48704462|NCT00895752|DRUG|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
48704463|NCT06608576|OTHER|Face-to-face standard treatment|Individualized early intervention treatment on physical therapy area as usual in the early intervention facilities once a month for two months. Instructions will be given to the parents for follow-up at home to stimulate the baby's motor development until next face-to-face session.
48704464|NCT06608576|OTHER|Telematic Support|The physiotherapist in charge of the telematic sessions will review and guide in real time through WhatsApp platform, the performance and active participation of the parents in the therapeutic activities being asked to follow-up at home in the face-to-face appointment, correcting, as necessary.
48704465|NCT01882049|DEVICE|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
48015785|NCT02904252|OTHER|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F\>2).
48015786|NCT01534468|BIOLOGICAL|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
48015787|NCT04083456|BEHAVIORAL|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
48015788|NCT04083456|OTHER|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
48015789|NCT03199469|GENETIC|Resamirigene bilparvovec|Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
48015790|NCT00000601|DRUG|estrogen replacement therapy|
48015791|NCT00000601|DRUG|estrogens|
48704466|NCT05978388|DIAGNOSTIC_TEST|Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation|Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
48704467|NCT03373890|BEHAVIORAL|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
48015792|NCT00000601|DRUG|progesterone|
48704468|NCT05173948|OTHER|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
48015793|NCT00000601|DRUG|hormone replacement therapy|
48015794|NCT05212259|DRUG|Collagen type II (40 mg/day)|4 capsules per day
48015795|NCT05212259|DRUG|Collagen type II (80mg/day)|4 capsules per day
48015796|NCT05212259|DRUG|Collagen type II (120 mg/day)|4 capsules per day
48015797|NCT05212259|DRUG|Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)|4 capsules per day
48172336|NCT00904683|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
48704469|NCT05173948|DEVICE|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
48015798|NCT05212259|DRUG|Placebo|4 capsules per day
48172337|NCT02852278|OTHER|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
48172338|NCT04865614|DRUG|Etomidate|Use of etomidate
48704470|NCT00434603|BEHAVIORAL|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
48704471|NCT06608706|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) for psychosis|EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
48704472|NCT02985892|OTHER|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
48704473|NCT02985892|OTHER|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
48704474|NCT06162663|DRUG|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
48704475|NCT06162663|OTHER|Placebo Control|Matched Placebo Control for 28 days
48704476|NCT04748757|DRUG|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
48704477|NCT04748757|DRUG|Placebo|Normal saline 50 ml
48704478|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 6 months in addition to standard of care
48704479|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 3 months in addition to standard of care
48704480|NCT03213782|OTHER|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
48704481|NCT03548506|DEVICE|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
48015799|NCT01379092|DEVICE|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
48015800|NCT01379092|DEVICE|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
48172339|NCT04865614|DRUG|Sevoflurane|Use of sevoflurane
48373194|NCT03779373|OTHER|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
48373195|NCT03142282|DRUG|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
48704482|NCT03548506|DEVICE|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
48704483|NCT06599710|DIETARY_SUPPLEMENT|AndoSanTM|Fermented water-based exctract of Agaricus subrufesence, Hericum erinacus, and Grifola frondosa
48015801|NCT00452881|DRUG|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
48015802|NCT00452881|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
48704484|NCT06232564|COMBINATION_PRODUCT|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
48172340|NCT02861625|BEHAVIORAL|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
48172341|NCT00217022|OTHER|Placebo|Placebo, 3 tablets daily
48172342|NCT00217022|DRUG|Budesonide|9 mg daily (three tablets)
48172343|NCT05229341|PROCEDURE|Diagnostic Procedure|Analysis via DDMS-2
48172344|NCT05229341|OTHER|Electronic Health Record Review|Review of medical records
48172345|NCT05229341|PROCEDURE|Needle Biopsy|Undergo needle biopsy
48172346|NCT02624375|DRUG|Zoster Vaccine Live|
48172347|NCT03788122|OTHER|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
48172348|NCT03739255|DEVICE|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
48172349|NCT03739255|DEVICE|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
48172350|NCT03900026|DRUG|Evolocumab|REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
48172351|NCT03900026|OTHER|Placebo|Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
48172352|NCT00762645|DRUG|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
48172353|NCT00762645|DRUG|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
48172354|NCT00130910|DRUG|Albendazole|Albendazole 400mg x 3 first dose observed
48172355|NCT00130910|DRUG|Placebo|Albendazole Placebo 400mg x 3 first dose observed
48172356|NCT02889783|OTHER|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
48172357|NCT04655742|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
48373196|NCT03142282|RADIATION|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
48373197|NCT01325376|BEHAVIORAL|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
48172358|NCT03049098|BEHAVIORAL|Simulation|A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
48172359|NCT01125566|DRUG|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
48172360|NCT01125566|DRUG|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
48172361|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
48172362|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
48172363|NCT03481556|DRUG|Melphalan flufenamide (Melflufen)|Intravenous infusion
48172364|NCT03481556|DRUG|Dexamethasone|Oral tablets
48172365|NCT03481556|DRUG|Bortezomib|Subcutaneous administration
48172366|NCT03481556|DRUG|Daratumumab|Intravenous infusion
48172367|NCT00878293|DRUG|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
48172368|NCT00878293|DRUG|MS Continus®|60 mg, capsule, once daily
48172369|NCT00878293|DRUG|Placebo|liquid formulation and capsule, once daily
48172370|NCT03745378|OTHER|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
48172371|NCT01233271|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
48172372|NCT04178447|DRUG|Glepaglutide|Single dose of Glepaglutide 10 mg
48172373|NCT00721929|PROCEDURE|MRI|Magnetic Resonance Imaging
48172374|NCT04715503|RADIATION|PET imaging, 18F-FDG|PET-MRI with 18F-FDG
48172375|NCT04715503|RADIATION|PET imaging, 68Ga-DOTANOC|PET-CT with 68Ga-DOTANOC
48373198|NCT01325376|BEHAVIORAL|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
48373199|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
48516613|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
48704485|NCT05723835|DRUG|Somapacitan|Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
48704486|NCT01683006|DRUG|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
48704487|NCT01683006|DRUG|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
48172376|NCT04913623|PROCEDURE|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
48172377|NCT00619983|DRUG|donepezil|Group 1: Will receive donepezil 5mg once a day
48172378|NCT00619983|DRUG|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
48172379|NCT00619983|DRUG|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
48172380|NCT00619983|DRUG|placebo|Group 4: Will receive placebo pills
48172381|NCT00619983|DRUG|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
48172382|NCT05080842|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
48172383|NCT01005368|GENETIC|fluorescence in situ hybridization|
48172384|NCT01005368|GENETIC|mutation analysis|
48172385|NCT01005368|GENETIC|nucleic acid sequencing|
48172386|NCT01005368|GENETIC|polymerase chain reaction|
48172387|NCT01005368|GENETIC|western blotting|
48172388|NCT01005368|OTHER|flow cytometry|
48172389|NCT01005368|OTHER|laboratory biomarker analysis|
48172390|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
48172391|NCT04119440|BIOLOGICAL|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
48172392|NCT04119440|OTHER|Placebo|Administrations of placebo via the intramuscular route
48172393|NCT05764590|DRUG|AP-306|A blood phosphorus lowering drug with a novel mechanism
48172394|NCT05764590|DRUG|Sevelamer Carbonate|A phosphate binder
48172395|NCT00383630|BIOLOGICAL|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
48172396|NCT00383630|BIOLOGICAL|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
48172397|NCT00383630|DEVICE|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
48172398|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
48172399|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
48172400|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
48172401|NCT01493999|DRUG|Clopidogrel reloading|Up to three times 600 mg clopidogrel
48172402|NCT01493999|DRUG|Prasugrel|60 mg prasugrel in patients with HPR
48015803|NCT00452881|DRUG|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
48015804|NCT04452344|DRUG|opioid-containing analgesic|hydrocodone/ acetaminophen combination product
48015805|NCT04452344|DRUG|two over-the-counter analgesics|combination of over-the-counter analgesics (ibuprofen/acetaminophen)
48015806|NCT04640311|DRUG|Daprodustat|Daprodustat will be available as oral tablets.
48015807|NCT03722875|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
48015808|NCT03722875|DRUG|apatinib|Apatinib is a selective VEGFR2 inhibitor
48172403|NCT01732341|DEVICE|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
48172404|NCT01732341|DEVICE|VISION balloon-expandable stent|"STEMI treatment with a VISION balloon-expandable stent~--------------------------------------------------------------------------------"
48172405|NCT02013895|DEVICE|99mTc-GSA|
48172406|NCT06350708|OTHER|Virtual reality (VR) tracheostomy educational tool|This is an unsupervised VR training packaged designed to train healthcare professionals and their students the management of the paediatric tracheostomy emergency.
48172407|NCT02752217|OTHER|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
48172408|NCT02752217|OTHER|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
48172409|NCT04786483|OTHER|Laughter Theraphy|"Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
48172410|NCT02872818|DRUG|17β estradiol hemihydrate|4mg/kg/day for 20 days
48172411|NCT02872818|DRUG|Metformin|50 mg/kg/day last 10 days
48172412|NCT02872818|DRUG|medroxyprogesterone acetate|1mg/kg/day last 10 days
48172413|NCT01084993|DRUG|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
48172414|NCT01084993|DRUG|Heparin|70 U/kg
48172415|NCT01143883|OTHER|Silverlon|Silverlon dressings are gauze impregnated with silver ions
48172416|NCT01143883|OTHER|Standard of Care Dressing|Standard dry gauze dressing
48172417|NCT01252511|PROCEDURE|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
48172418|NCT01744756|DRUG|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
48172419|NCT01712295|DRUG|17% Salicylate with ethyl pyruvate|
48172420|NCT01712295|DRUG|Salicylates|
48172421|NCT02652390|DRUG|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
48172422|NCT02652390|DRUG|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
48172423|NCT02652390|OTHER|Saline|2 mL saline + 1 mL lidocaine
48373200|NCT05950529|OTHER|Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
48704488|NCT01023087|DRUG|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
48704489|NCT01023087|DRUG|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
48704490|NCT05687812|DIETARY_SUPPLEMENT|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
48704491|NCT05771441|OTHER|neck stabilization exercise (nse)|neck stabilization exercise (nse)- exercise
48373201|NCT05950529|OTHER|Placebo lozenge control (sorbitol only)|Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.
48704492|NCT05771441|OTHER|NSE + HOT PACK THERAPY|NSE + HOT PACK THERAPY- exercise plus heat therapy
48015809|NCT02091518|BEHAVIORAL|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
48015810|NCT02091518|DEVICE|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
48373202|NCT05950529|OTHER|No product|no product
48704493|NCT05771441|OTHER|NSE + infrared therapy|NSE + infrared therapy- exercise plus heat therapy
48704494|NCT05771441|OTHER|NSE + ultrasound therapy|NSE + ultrasound therapy exercise plus heat therapy
48704495|NCT05588440|BIOLOGICAL|ONCT-808|"A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts."
48704496|NCT05588440|DRUG|Bridging Therapy|Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
48704497|NCT00998751|DRUG|oral masitinib|7.5 mg/kg/day
48704498|NCT00006042|BIOLOGICAL|filgrastim|
48373203|NCT03833609|BEHAVIORAL|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
48704499|NCT00006042|DRUG|cyclophosphamide|
48704500|NCT00006042|DRUG|fludarabine phosphate|
48704501|NCT00006042|DRUG|mycophenolate mofetil|
48516614|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
48516615|NCT00302445|DRUG|Efalizumab|
48015811|NCT04406805|DIAGNOSTIC_TEST|Measurement of plasma and urine trimethylamine-N-oxide concentration|Information already included in arm/group descriptions.
48015812|NCT02912481|PROCEDURE|posterior tibial artery|
48015813|NCT02912481|PROCEDURE|radial artery|
48015814|NCT02912481|PROCEDURE|dorsalis pedis artery|
48015815|NCT06023095|DRUG|LY3502970|Administered orally.
48516616|NCT00302445|DEVICE|Narrow Band Phototherapy|
48516617|NCT01597973|DRUG|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
48704502|NCT00006042|DRUG|tacrolimus|
48704503|NCT00006042|PROCEDURE|allogeneic bone marrow transplantation|
48704504|NCT00006042|RADIATION|radiation therapy|
48704505|NCT06102135|DIETARY_SUPPLEMENT|Peptamen 1.3 PHGG|The amount of tube feed will be assess by the health Care Professional.
48704506|NCT00218816|BEHAVIORAL|Nebulizer Education Intervention|Asthma Education
48704507|NCT00218816|BEHAVIORAL|Standard Asthma Education Groups|Asthma Education
48704508|NCT04095351|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
48704509|NCT04095351|DIAGNOSTIC_TEST|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
48704510|NCT04095351|BIOLOGICAL|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
48704511|NCT03127774|DRUG|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
48704512|NCT03127774|DRUG|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
48704513|NCT03127774|PROCEDURE|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
48704514|NCT05124509|BIOLOGICAL|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
48704515|NCT05124509|BIOLOGICAL|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
48704516|NCT04239222|DEVICE|Revo-M|Investigational energy storage and return prosthetic foot with using novel elastic elements.
48373204|NCT03833609|BEHAVIORAL|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
48373205|NCT04416009|DEVICE|NİCaS|whole body bioimpedence method
48373206|NCT01718860|PROCEDURE|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
48373207|NCT03332225|DRUG|Anakinra|Treatment with anakinra
48373208|NCT03332225|DRUG|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
48373209|NCT03332225|DRUG|Placebo|Treatment with Placebo
48373210|NCT03917966|DRUG|SHR-1210+docetaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; docetaxel 75mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
48373211|NCT03917966|DRUG|SHR-1210+Apatinib|SHR-1210, 200 mg, q2w; Apatinib, 250mg, qd; 4 weeks is a cycle, a total of 2 cycles
48373212|NCT01211210|DRUG|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
48373213|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
48704517|NCT04239222|DEVICE|Taleo|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects
48704518|NCT04239222|DEVICE|Proflex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
48015816|NCT06023095|DRUG|Placebo|Administered orally.
48015817|NCT04151810|DRUG|CDP1|"Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;"
48172424|NCT02735356|DRUG|Itraconazole|Applied topically
48172425|NCT02735356|OTHER|Placebo|Applied topically
48172426|NCT05348668|DRUG|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
48172427|NCT03216941|DRUG|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
48373214|NCT01211210|DRUG|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
48373215|NCT02112565|DRUG|RNR inhibitor COH29|Given PO
48373216|NCT02112565|OTHER|laboratory biomarker analysis|Correlative studies
48373217|NCT02112565|OTHER|pharmacological study|Correlative studies
48373218|NCT00812045|DRUG|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
48373219|NCT00812045|DRUG|Placebo|
48373220|NCT03416166|DEVICE|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
48373221|NCT00379821|DRUG|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
48373222|NCT00379821|DRUG|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
48373223|NCT00379821|DRUG|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
48373224|NCT00379821|DRUG|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
48373225|NCT01285726|OTHER|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
48373226|NCT00189917|BIOLOGICAL|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
48373227|NCT03011931|DRUG|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
48373228|NCT00151658|DEVICE|Coronary Drug Eluting Stents for PCI|
48373229|NCT01693042|BIOLOGICAL|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (\> 3 months) infarct area
48373230|NCT02662348|DRUG|Recombinant Human Interleukin-2|Given SC
48373231|NCT02662348|DRUG|HER2Bi-Armed T Cells|Given IV
48373232|NCT00730366|DRUG|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
48373233|NCT00730366|DRUG|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
48015818|NCT04151810|DRUG|CDP1|Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;
48015819|NCT04151810|DRUG|TIP chemotherapy|Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
48015820|NCT02097134|DRUG|Melphalan|Given IA
48015821|NCT05910762|BEHAVIORAL|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
48015822|NCT05910762|BEHAVIORAL|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
48015823|NCT05910762|BEHAVIORAL|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
48704519|NCT04433689|DEVICE|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
48704520|NCT04961541|BIOLOGICAL|ICC Vaccine|Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.
48704521|NCT04961541|BIOLOGICAL|qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.
48172428|NCT01888809|BEHAVIORAL|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
48172429|NCT01888809|BEHAVIORAL|Screening and referral|
48172430|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort A|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
48172431|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
48172432|NCT05559983|OTHER|Placebo Cohort A|Sterile 0.9% sodium chloride
48172433|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort B|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
48172434|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort B|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
48172435|NCT05559983|OTHER|Placebo Cohort B|Sterile 0.9% sodium chloride
48172436|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort C|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
48172437|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort C|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
48172438|NCT05559983|OTHER|Placebo Cohort C|Sterile 0.9% sodium chloride
48172439|NCT06488885|BEHAVIORAL|Elderly care training|The 60 experimental group students included in the study will have three lesson hours each week. Face-to-face training will be provided. Their consent was obtained before training was given to the experimental group. Participant Information Form and Positive and Negative Ageism Scale (PNYAÖ) will be applied as a pre-test. Trainings are 3 lesson hours, one day a week. It will be given as eight weeks and 24 hours in total. Upbeat and positive after the end of the training A posttest will be administered with the Negative Ageism Scale (PNSAS). Posttest PNSAÖ will be administered again one month after administration, and follow-up data will be obtained. Participant Information Form and Positive and Negative Ageism Scale (PNSAS) will be applied as a pre-test. Eight weeks. At the end, PNCAS will be administered again as the final test.
48516618|NCT01597973|DRUG|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
48516619|NCT04812522|BEHAVIORAL|Clean Cut program|Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis
48015824|NCT05024695|DEVICE|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
48015825|NCT01374113|DRUG|50mg safinamide|50 mg safinamide on Day 1
48015826|NCT03274479|DRUG|PBF-1129|PBF-1129 once a day by oral administration
48015827|NCT01437514|RADIATION|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
48015828|NCT03384446|OTHER|Tooth-borne treatment|Titanium curettes
48015829|NCT03384446|OTHER|Implant-specific treatment|Implant brush
48015830|NCT02755675|OTHER|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
48015831|NCT03508089|OTHER|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
48015832|NCT03508089|OTHER|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
48015833|NCT02897843|DEVICE|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
48015834|NCT02897843|DEVICE|sham tDCS|sham tDCS
48015835|NCT03237923|DEVICE|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
48172440|NCT03977571|PROCEDURE|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
48172441|NCT03977571|OTHER|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
48172442|NCT06086405|DEVICE|Patients underwent cardiorespiratory support|Patients underwent cardiorespiratory support using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator
48172443|NCT04853407|DRUG|LY03005 extended-release tablet|orally once a day
48172444|NCT04853407|DRUG|Placebo|orally once a day
48172445|NCT02782208|DRUG|Acipimox|Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
48704522|NCT04961541|BIOLOGICAL|SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant|Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
48704523|NCT00605098|DRUG|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
48704524|NCT00605098|DRUG|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
48704525|NCT04808947|PROCEDURE|Local infiltration analgesia|Procedure: Local infiltration analgesia performed by surgeons.
48015836|NCT06309199|DIETARY_SUPPLEMENT|Biogaia|Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
48172446|NCT02782208|DRUG|Placebo|Placebo is administered 4 times previous to and during the investigation day.
48373234|NCT02835989|OTHER|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
48373235|NCT02503215|DEVICE|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
48373236|NCT00295256|BEHAVIORAL|nurse case manager|
48373237|NCT01616992|DRUG|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
48704526|NCT04808947|PROCEDURE|Ultrasound-guided adductor canal block|Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
48373238|NCT01352871|BEHAVIORAL|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
48373239|NCT01352871|DRUG|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
48704527|NCT00612417|DRUG|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
48704528|NCT01144975|DRUG|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
48704529|NCT01144975|DRUG|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
48704530|NCT02760771|OTHER|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
48704531|NCT02760771|OTHER|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
48704532|NCT06244082|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
48704533|NCT02099344|DEVICE|Artegraft|Surgical placement of graft for hemodialysis access
48704534|NCT02099344|DEVICE|Propaten|Surgical placement of graft for hemodialysis access
48704535|NCT04975126|OTHER|CatInfo tool|Presentation about cataract surgery
48015837|NCT06309199|OTHER|Placebo|Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil
48015838|NCT06477796|DEVICE|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 120 minutes of waking up.
48172447|NCT02782208|DRUG|GH substitution|GH substitution as usually
48172448|NCT02782208|OTHER|GH pause|GH substitution pause two days prior to the experimental day
48172449|NCT03749499|OTHER|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
48172450|NCT03749499|OTHER|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
48172451|NCT03749499|OTHER|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
48015839|NCT06477796|DEVICE|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 120 minutes of waking up.
48015840|NCT02104089|DEVICE|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
48704536|NCT03321903|DEVICE|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
48015841|NCT01974050|BEHAVIORAL|Text message surveillance|
48015842|NCT05468840|DRUG|Ketamine Hydrochloride|see study arm description
48015843|NCT05468840|DRUG|Normal saline|see study arm description
48015844|NCT05768503|DRUG|Experimental drug|The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
48172452|NCT03749499|OTHER|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
48172453|NCT01796223|BEHAVIORAL|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
48172454|NCT01796223|BEHAVIORAL|Control|
48172455|NCT02108847|DRUG|.2% Ropivacaine|
48015845|NCT05768503|DRUG|Control Rx|The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
48015846|NCT03372408|OTHER|Chart review|Retrospective chart review of program participation and socio-demographic \& psychosocial characteristics
48015847|NCT00882011|OTHER|Latest generation chemotherapies for T-LBL + transplant|"1. Standard doses of one of the following chemotherapies:~   * Holzer~  * LSA2-L2 modified~  * Stanford regimen~  * Hyper CVAD~  * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~  * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
48015848|NCT04382612|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
48015849|NCT03001895|DRUG|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
48015850|NCT05382364|DRUG|Tucatinib|Tucatinib 150 mg and 50 mg tablets taken by mouth at a dose of 300 mg twice daily.
48015851|NCT01524640|BIOLOGICAL|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
48172456|NCT02108847|DRUG|Saline|
48172457|NCT02108847|PROCEDURE|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
48015852|NCT01524640|BIOLOGICAL|Placebo|1.5 ml oral administration on day 0 and day 14
48015853|NCT00963729|DRUG|cyclophosphamide|Given IV
48015854|NCT00963729|DRUG|docetaxel|Given IV
48015855|NCT00963729|DRUG|epirubicin hydrochloride|Given IV
48015856|NCT00963729|DRUG|fluorouracil|Given IV
48015857|NCT00963729|DRUG|letrozole|Given orally
48015858|NCT01430130|DEVICE|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
48015859|NCT06659315|BEHAVIORAL|Couples Problem Solving Therapy|A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
48015860|NCT00827372|DRUG|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
48015861|NCT02477020|DRUG|TAK-063 20 mg|TAK-063 tablet.
48172458|NCT01617798|DRUG|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
48015862|NCT02477020|DRUG|Placebo|TAK-063 matching-placebo tablet.
48373240|NCT01584193|PROCEDURE|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
48373241|NCT01584193|PROCEDURE|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
48373242|NCT01848769|DRUG|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
48373243|NCT01848769|DRUG|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
48373244|NCT01848769|DRUG|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
48373245|NCT02958449|DEVICE|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
48704537|NCT03321903|OTHER|EPR Oximetry Measurement|An oximetry measurement visit consists of \~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
48704538|NCT00022685|BIOLOGICAL|epratuzumab|
48704539|NCT02408003|DRUG|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
48704540|NCT02408003|DRUG|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
48704541|NCT05497349|OTHER|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
48704542|NCT05497349|OTHER|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
48172459|NCT01617798|DRUG|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
48172460|NCT01749163|BIOLOGICAL|Saline|
48172461|NCT01749163|BIOLOGICAL|GIP|
48172462|NCT01749163|BIOLOGICAL|GLP-1|
48172463|NCT03758703|OTHER|Pre-recorded music intervention group|Refer to the arm/group descriptions.
48172464|NCT03758703|OTHER|Pre-recorded soothing poetry group|Refer to the arm/group descriptions.
48172465|NCT02109107|DEVICE|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
48172466|NCT01776008|DRUG|Akt Inhibitor MK2206|Given PO
48172467|NCT01776008|DRUG|Anastrozole|Given PO
48172468|NCT01776008|DRUG|Goserelin Acetate|Given SC
48373246|NCT04647175|OTHER|Fermented aronia|Given twice daily for 8 weeks
48373247|NCT04647175|OTHER|Aronia|Given twice daily for 8 weeks
48373248|NCT04647175|OTHER|Placebo|Given twice daily for 8 weeks
48373249|NCT00003876|DRUG|polifeprosan 20 with carmustine implant|
48373250|NCT00003876|PROCEDURE|surgical procedure|
48373251|NCT00003876|RADIATION|iodine I 125|
48373252|NCT02961361|DRUG|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
48373253|NCT02961361|DRUG|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
48373254|NCT02348671|OTHER|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
48373255|NCT02977052|DRUG|Ipilimumab|
48373256|NCT02977052|DRUG|Nivolumab|
48373257|NCT02977052|PROCEDURE|Surgery|Surgery will be done at 6 weeks
48373258|NCT02977052|PROCEDURE|Blood for PBMCs|Blood will be taken for translational research on PBMCs
48015863|NCT05280119|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, patients are examined to detect the presence or absence of pleural effusion, or intra-abdominal effusion, or to localize the basilic vein
48172469|NCT01776008|OTHER|Laboratory Biomarker Analysis|Correlative studies
48373259|NCT02977052|PROCEDURE|Biopsies|Biopsies will be taken during screening and at relapse.
48704543|NCT06075329|BEHAVIORAL|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
48704544|NCT00422149|DRUG|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
48704545|NCT00422149|DRUG|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
48704546|NCT00422149|DRUG|Placebo treatment|Placebo treatment
48704547|NCT01949025|OTHER|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
48704548|NCT05921695|DRUG|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
48704549|NCT05868863|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking"
48704550|NCT05839600|DRUG|BI 1821736|Solution for infusion
48704551|NCT03438955|DRUG|Omacor|Omacor soft capsule 4000mg for 16days
48704552|NCT03438955|DRUG|Pritor|Pritor tablet 40mg for 7days
48704553|NCT03438955|DRUG|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
48704554|NCT03438955|DRUG|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
48704555|NCT01426984|DRUG|methylphenidate|a capsule containing 20 mg
48704556|NCT05707351|BIOLOGICAL|Adynovate|Adynovate will be injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).
48704557|NCT06605248|BEHAVIORAL|App-based self-management tool plus usual care|The app-based self-management tool will be delivered after patients receive usual care from their general practitioners. The 8-week mobile app intervention will involve daily sessions on pain education and clinical hypnosis for back pain management (5 minutes, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes.
48704558|NCT06605248|BEHAVIORAL|Patient information digital fact-sheet plus usual care|The face-sheet will be delivered after patients receive usual care from their general practitioners.This digital intervention will contain educational material for chronic back pain that includes details about diagnosis, prognosis and treatment options.
48172470|NCT01776008|PROCEDURE|Neoadjuvant Therapy|Given before standard-care surgery
48172471|NCT01776008|OTHER|Pharmacological Study|Correlative studies
48172472|NCT01776008|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard-care surgery
48704559|NCT02108717|DEVICE|Remote CT reading using the iPhone|
48172473|NCT01324700|DRUG|High severity group: Escitalopram|Participants within high severity group were stratified to receive escitalopram.
48172474|NCT01324700|DRUG|High severity group: Placebo|Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
48172475|NCT01324700|DRUG|Low severity group: Escitalopram|Participants within low severity group were stratified to receive escitalopram.
48172476|NCT01324700|DRUG|Low severity group: Placebo|Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
48172477|NCT04224259|PROCEDURE|Ultrasound pre-scan|Before cannulation, use ultrasound to mark the position of right internal jugular vein
48172478|NCT04224259|PROCEDURE|Landmark guidance|The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
48172479|NCT04680637|DRUG|Efavaleukin Alfa|Administered as a subcutaneous (SC) injection.
48172480|NCT04680637|DRUG|Placebo|Administered as a subcutaneous (SC) injection.
48373260|NCT01699061|DRUG|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
48373261|NCT01699061|DRUG|Placebo|Placebo tablet administered with a meal twice a day on Day 1
48704560|NCT02108717|DEVICE|CT reading using LCD monitor|
48704561|NCT03315104|BIOLOGICAL|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
48704562|NCT03315104|OTHER|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
48704563|NCT05730543|DRUG|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
48015864|NCT05280119|DEVICE|Ultrasound device routinely used in the department.|Patients who were first examined with the EchOpen ultra-portable ultrasound device, are secondarily examined with an ultrasound probe used routinely in the department.
48015865|NCT05280119|PROCEDURE|Standard ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating
48172481|NCT04680637|OTHER|Standard of Care|Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
48373262|NCT04619043|DEVICE|Ankle Orthotic|
48373263|NCT03010332|BIOLOGICAL|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
48172482|NCT05884983|PROCEDURE|participants will undergo dual-energy CT and endoscopy|Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
48172483|NCT03650673|DIAGNOSTIC_TEST|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
48704564|NCT04997109|OTHER|APPLES-tele|The APPLES-tele intervention is 5 weekly telehealth sessions of therapist-demonstrated tasks, delivered over a 6 week period. Infant participants wear a soft-constraint harness (C-Mitt) on their less affected arm for 6 hours per day, while their parent encourages them to use their more affected arm to complete play-based activities as instructed by the study therapist. As the infant experiences success, heavier objects are provided. During times when the C-Mitt is not worn, parents engage therapist-demonstrated bimanual play of increasing difficulty.
48373264|NCT05631158|DIAGNOSTIC_TEST|MRI|"The clinical examination includes a short physical exam, a brief history of allergies, previous diseases and medications, and disease-related questionnaires.~All the participants will undergo 4 serial MRI scans: one MRI scan at the baseline visit, 6, 12, 18 months follow-up visit, respectively to record the changes in the brain, which include the neuromelanin scan.~For future proving the value of our study, we will also collect and store blood samples at the initial visit."
48373265|NCT03004898|BEHAVIORAL|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
48373266|NCT03796897|DIETARY_SUPPLEMENT|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
48373267|NCT03796897|BEHAVIORAL|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
48704565|NCT04997109|BEHAVIORAL|Parent-centered Approach (PCA) Support Intervention|The PCA support intervention is 5 weekly telehealth sessions delivered over a 6 week period. The PCA curriculum includes 5 basic principles of positive parenting from Triple P: ensuring a safe engaging environment, creating a positive learning environment, using assertive discipline, having reasonable expectations, and looking after yourself as a parent. All of these elements, when taught to parents in an individualized manner, can help promote responsivity, structure and expectations that are tailored to their child's condition and developmental stage. In addition, a curriculum of CP-specific knowledge will address the challenges unique to parents of children with CP, such as understanding principles of infant learning of new movements, challenges and solutions for self-directed activity in infants with CP.
48373268|NCT05277610|DIAGNOSTIC_TEST|iron studies|Pulmonary function testing was performed using standardized spirometry for asthmatic patients with iron deficiency anemia and those without iron deficiency anemia
48373269|NCT02016638|OTHER|Polysomnography and ambulatory blood pressure recording|
48373270|NCT05747157|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.
48373271|NCT03000075|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
48373272|NCT03000075|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
48516620|NCT04738695|DIAGNOSTIC_TEST|Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)|Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
48172484|NCT04934241|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
48172485|NCT01745276|DEVICE|Biphosfonate|External pins coated by biphosfonate.
48172486|NCT01745276|DEVICE|Hydroxylapatit|External pins coated by Hydroxylapatit.
48172487|NCT01637285|BIOLOGICAL|PF-04856883|Dose A
48172488|NCT01637285|BIOLOGICAL|PF-04856883|Dose B
48172489|NCT01637285|BIOLOGICAL|PF-04856883|Dose C
48172490|NCT01637285|BIOLOGICAL|PF-04856883|Dose D
48015866|NCT06661980|DRUG|Dexmedetomidine Injectable Solution|Dexmedetomidine 200 mcg/ 2 mL IV.
48015867|NCT06661980|OTHER|Placebo|Normal Saline IV.
48015868|NCT05834140|OTHER|Traditional Physical Therapy|"TENS (transcutaneous electrical nerve stimulation) on continuous mode at 80-120 Hz for 15-20 min and Heating pads for 10-15 min~Total 4 sessions will be given in 2 days"
48015869|NCT05834140|OTHER|Muscle Energy Technique|"Muscle energy technique (Post Isometric relaxation) along with TENS and Heating pads.~* MET of the scaleni~* MET of Sternocleidomastoid~* MET of Levator Scapulae~* MET of Upper fibers of Trapezius~Total 4 sessions will be given in 2 days"
48015870|NCT05572515|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
48015871|NCT05572515|DRUG|Pomalidomide|Pomalidomide will be administered orally.
48015872|NCT05572515|DRUG|Bortezomib|Bortezomib will be administered subcutaneously.
48015873|NCT05572515|DRUG|Dexamethasone|Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
48015874|NCT05572515|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
48015875|NCT01863446|DEVICE|Lighting1|Ocular light exposure to a red wavelength light
48015876|NCT01863446|DEVICE|Lighting2|Ocular light exposure to a blue/green wavelength light
48015877|NCT01302964|DRUG|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
48015878|NCT01302964|DRUG|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
48015879|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S:~1. The probiotics, Duolac7S, consist of 7 bacteria.~2. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~3. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (30 min after morning and evening meal)~4. Duration: 4 weeks of treatment period"
48172491|NCT01172639|DRUG|Methotrexate|Methotrexate tablet
48172492|NCT01172639|DRUG|Sulfasalazine|Sulfasalazine tablet
48172493|NCT01172639|DRUG|Leflunomide|Leflunomide tablet
48373273|NCT06400160|DRUG|TB511|TB511 is a peptide drug conjugate (PDC) which composed of TAMpep826 peptide. TB511 is a white amorphous powder used for subcutaneous injections. TB511 is a peptide drug conjugate that combines a transporter peptide with a specific targeting of M2 macrophages and an apoptosis-inducing peptide (dKLA). As a transporter, the M2 binding peptide acts as a drug conjugate, explicitly binding to M2 macrophages and inducing cell penetration. In the cells, the dKLA component of TB511 binds to the mitochondrial membrane, destroys the mitochondrial membrane, and induces apoptosis by causing cytochrome release, leading to the destruction of the mitochondria and subsequent death of M2 macrophages.
48015880|NCT01651741|DIETARY_SUPPLEMENT|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~1. Form: brown granule~2. Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~3. Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
48015881|NCT06620237|DEVICE|Implantation of the Solia CSP S pacing lead for LBBAP|Left bundle branch area pacing using a Solia CSP S lead
48015882|NCT04564976|BEHAVIORAL|Social support image|An image of a social support figure specific to each participant (provided by the participant) will be present while participants undergo a fear acquisition procedure. Specifically--the image will be presented alongside a neutral image that is either consistently paired with shock (CS+) or never paired with shock (CS-), so that assessment of whether there are differences in fear responding (evaluated via SCR) due the shock pairing can be assessed. This is a typical fear acquisition procedure, and a typical outcome would be for SCR to be higher for the CS+ compared to the CS- toward the end and following the procedure, indicating that the CS+ is now associated with the aversive shock and is bringing about a fear response (in this case indexed by increased sympathetic nervous system activity preparing the body to fight or flee).
48015883|NCT05631080|PROCEDURE|Anatomical Endoscpic enucleation of the Prostate|Transurethral endoscopic enucleation of the prostate adenoma
48015884|NCT06315257|DRUG|PVX7|PVX7 Immunotherapy
48015885|NCT00797615|BEHAVIORAL|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
48015886|NCT00797615|BEHAVIORAL|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
48172494|NCT01172639|DRUG|Prednisone|Prednisone tablet
48172495|NCT03544229|DRUG|TAK-906 Maleate|TAK-906 maleate capsules.
48172496|NCT03544229|DRUG|Placebo|TAK-906 maleate placebo-matching capsules.
48172497|NCT04379817|DIAGNOSTIC_TEST|Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT|Assess somatostatin receptor expression
48172498|NCT00103272|DRUG|tanespimycin|Given IV
48172499|NCT00103272|DRUG|bortezomib|Given IV
48172500|NCT05955677|DRUG|[68Ga]Ga-PSMA-D5|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-D5, and undergo PET/CT imaging within the specificed time.
48172501|NCT05955677|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
48172502|NCT01665599|DRUG|Testosterone gel (FE 999303)|
48172503|NCT00216957|PROCEDURE|Coronary bypass surgery without cardiopulmonary bypass|
48172504|NCT04237519|BEHAVIORAL|SFL training|"The SFL training program comprises:~* Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~* Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~* Chat rooms: to share views about topics of interest and tips for common real-life problems;~* Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~* Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance."
48172505|NCT04237519|BEHAVIORAL|Active controlled training|"The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~* Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~* Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program."
48172506|NCT03065439|DIAGNOSTIC_TEST|Static balance testing|Postural sway will be measured using a force plate (Metitur Good Balance System®).
48704566|NCT04997109|BEHAVIORAL|Standard of Care|Participants will receive the usual care from being followed in high-risk infant follow-up (HRIF) programs in the Early Detection and Intervention (EDI) Network.
48704567|NCT05520333|BEHAVIORAL|BIPAS Alcohol|Weekly text messages for three months.
48704568|NCT05868005|OTHER|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
48704569|NCT03798730|BEHAVIORAL|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
48704570|NCT03798730|BEHAVIORAL|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
48704571|NCT06254703|DIAGNOSTIC_TEST|VexLUS (venous excess lung ultrasound)|IVC, hepatic veins (HVs), portal veins (PVs) and intrarenal veins (IRVs), and lung ultrasound
48373274|NCT06400160|DRUG|Keytruda|KEYTRUDA binds to the PD - 1 receptor, blocking both immune-suppressing ligands, PD L1 and PD L2, from interacting with PD - 1 to help restore T-cell response and immune response.
48373275|NCT00845598|DRUG|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
48373276|NCT00845598|DRUG|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
48373277|NCT03978689|DRUG|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
48704572|NCT00446953|DRUG|betamethasone|2x12 mg betamethazone c-section at 38 weeks
48704573|NCT00446953|OTHER|placebo|c-section at 39 weeks
48704574|NCT04872348|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
48704575|NCT03234855|DEVICE|LMD|Physician uses LMD to measure defect during procedure.
48704576|NCT04750473|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48704577|NCT04750473|DRUG|Fluciclovine F18|Given IV
48704578|NCT04750473|DRUG|Gallium Ga 68 Gozetotide|Given IV
48704579|NCT04750473|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48172507|NCT05167032|BEHAVIORAL|Cognitive Multisensory Rehabilitation (CMR)|The goal of CMR is to restore proprioception (i.e., sense of joint position and movement), body awareness, and awareness of the paralyzed limbs and trunk in space, in order to improve sensory and motor function. For example, CMR tasks will have the participant solve exercises related to: (i) where the legs are situated in space; where the legs are in relation to the pelvis and the upper part of the body (ii) the dimensions and length of the legs, the dimension of the pelvis, and sensation of the pelvis as a central body reference. (iii) the relationship between the left and right side of the body, and the relationship between the pelvis and the feet. Further, improvements in touch and pressure sensation are obtained with (v) texture discrimination tasks, and (vi) discrimination of sponges with varying resistance. Given the importance of sensory feedback for movement, sensory improvements create the opportunity for motor recovery to occur.
48704580|NCT01022957|GENETIC|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
48704581|NCT04420572|DRUG|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
48704582|NCT04420572|DRUG|betamethasone|1ml betamethasone will be used for steroid injection.
48704583|NCT05058612|DRUG|Midodrine|10 mg PO/NG q8h
48704584|NCT05058612|DRUG|Placebo|Microcrystalline cellulose PO/NG 18h
48704585|NCT01118104|OTHER|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
48704586|NCT05379712|OTHER|Resource® Support Plus|Nestlé Resource Support Plus® is a high energy- and protein-density Medical Food enriched with omega 3 polyunsaturated fatty acids. This is a nutritionally complete formula, in an easy to swallow, palatable, concentrated low volume, available in 2 flavours optimized for cancer patients undergoing chemotherapy and/or radiation in taste tests. It provides in a 125 mL serving: 250 kcal, 11.5 g protein and 0.95g of omega-3 fatty acid (eicosapentaenoic acid, EPA).
48704587|NCT06560346|OTHER|Geneticlly confirmed disease causing FXN mutatuion|No intervention in this observational Natural History Study
48015887|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
48172508|NCT05167032|BEHAVIORAL|Adaptive fitness|The Courage Kenny Rehabilitation Institute centers provide access to state-of- the-art adaptive gym equipment in their fitness center to promote fitness and recreation. Equipment includes treadmills, elliptical, NuSteps, SciFit upper body ergometers, Ski Erg and Rowing Machine, Upright and recumbent stationary bicycles, chest press, rear row, leg extension, leg curl, leg press, uppertone, free weights, and kettlebells. The equipment is spaced to allow for movement and is accessible for use from a wheelchair. They allow for transfers and caregiver assistance.
48373278|NCT03978689|DRUG|KEYTRUDA®, Pembrolizumab|KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
48373279|NCT04897009|PROCEDURE|Biospecimen Collection|Undergo blood and tissue collection
48704588|NCT06560346|OTHER|Healthy Control|No intervention in this observational Natural History Study
48704589|NCT01838330|DIETARY_SUPPLEMENT|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
48704590|NCT03617263|DRUG|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
48704591|NCT03617263|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
48704592|NCT01174537|BIOLOGICAL|New Castle Disease Virus|Patients will receive IV 1\*10\^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
48704593|NCT02182440|BIOLOGICAL|recAP|One hour infusions once daily for three days
48704594|NCT02182440|OTHER|Placebo|1 hour IV infusion once daily for 3 days
48704595|NCT01921218|DRUG|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
48704596|NCT01921218|DRUG|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
48704597|NCT01921218|DRUG|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
48704598|NCT01921218|DRUG|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
48373280|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|"Patient in lithotomy position (supine) with return plate at lumbar level.~Start with high power (within the allowed range) to get a faster hyperthermia and slowly decrease this percentage as the current builds up in the patient's body.~Patients are undergoing high-frequency radio wave electrotherapy 2 times a week (12 procedures at all)."
48373281|NCT04506658|DEVICE|high-frequency radio wave electrotherapy with a frequency of 448 kHz on the penis structures.|Doctor uses sham sensor to reduce efficiency to zero.
48373282|NCT04058665|DEVICE|Floseal|Hemostatic agent
48373283|NCT05480852|OTHER|Bis-GMA Free dental resin composite|Restorative Material
48373284|NCT01715480|DIETARY_SUPPLEMENT|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
48373285|NCT05023499|DRUG|SYMPT-X Glutamine, Oral Powder for Reconstitution|erioperative glutamine supplementation (PGS) was defined as the subjects with five-day parenteral plus one-month oral use.
48373286|NCT00920582|BIOLOGICAL|Teplizumab Herold Regimen|Full dose of teplizumab IV for 14 days, repeated at Week 26
48373287|NCT00920582|DRUG|Placebo|IV dosing daily for 14 days repeated at Week 26
48373288|NCT00920582|BIOLOGICAL|Teplizumab 33.3% Herold Regimen|One third full dose of teplizumab IV for 14 days, repeated at Week 26
48373289|NCT00920582|BIOLOGICAL|Teplizumab Curtailed Herold Regimen|Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
48373290|NCT03045926|DRUG|Diosmectite (Smecta®)|
48373291|NCT04942951|DIAGNOSTIC_TEST|Gynecological examination|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
48373292|NCT04942951|OTHER|Pelvic Organ Prolapse Quantification (POP-Q)|Gynecological examination was performed to the whole pregnant cohort included in the study to diagnose either the pelvic organ prolapse according to the POP-Q system or to be sure that they have no findings of pelvic organ prolapse.
48373293|NCT04942951|OTHER|Incontinence Consultation Questionnaire-Short Form (ICIQ-SF) questionnaire|ICIQ-SF questionnaire was applied to the Study group to determine the severity of urinary incontinence.
48373294|NCT04942951|OTHER|Pregnancy-Related Anxiety Questionnaire-Revised 2 (PRAQ-R2) questionnaire|PRAQ-R2 questionnaire was applied to the whole pregnant cohort included in the study to determine their anxiety status.
48373295|NCT01046617|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
48373296|NCT00511706|DRUG|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
48373297|NCT00511706|BIOLOGICAL|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
48172509|NCT02592681|PROCEDURE|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
48373298|NCT00511706|OTHER|sham|Sham needle-less injection administered in the study eye at Day 1.
48373299|NCT03131531|OTHER|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
48373300|NCT03217058|BEHAVIORAL|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
48373301|NCT01040806|BEHAVIORAL|Usual care|Patients will receive their usual medical care
48373302|NCT01040806|BEHAVIORAL|Health coaching|Peer health coaches will counsel patients with diabetes
48373303|NCT01899573|DEVICE|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
48373304|NCT04082494|DEVICE|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
48373305|NCT04082494|OTHER|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
48015888|NCT06344065|BIOLOGICAL|Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
48373306|NCT00394121|DRUG|Fluticasone propionate/formoterol fumarate|
48373307|NCT04705259|BEHAVIORAL|Antimicrobial Stewardship ENGAGEMENT bundle|"Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components"
48373308|NCT02044094|DRUG|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
48373309|NCT02044094|DRUG|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
48704599|NCT04316611|DRUG|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
48172510|NCT02592681|PROCEDURE|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
48172511|NCT02592681|PROCEDURE|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
48172512|NCT00990262|RADIATION|Cardiac Computed Tomography|"1. Localization of the heart position in a projectional topographic scan of the chest.~2. Determination of contrast agent transit time: 10 ml contrast agent.~3. CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
48172513|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
48704600|NCT05996055|DEVICE|improved version_support device|designed the NTUH version_support device based on the clinical suggestion.
48704601|NCT05996055|DEVICE|the NTUH version_support device|original designed by NTUH
48172514|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
48704602|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
48704603|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
48704604|NCT05151640|DRUG|Nintedanib|Nintedanib
48704605|NCT03100539|OTHER|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
48172515|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
48172516|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
48172517|NCT01193218|DRUG|BI 10773|BI 10773 tablets low dose once a day
48172518|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
48172519|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
48172520|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
48172521|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-high dose once a day
48172522|NCT01193218|DRUG|BI 10773|BI 10773 tablets high dose once a day
48172523|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
48172524|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
48704606|NCT03100539|OTHER|Care ally assisted massage|CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
48704607|NCT06608628|OTHER|Experimental Group|The experimental group students will play a patient safety escape room game. Control group students will be given traditional education. The knowledge level and team cooperation of the two groups will be compared.
48172525|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
48172526|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
48172527|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-low dose once a day
48172528|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
48172529|NCT02580968|DEVICE|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
48172530|NCT02580968|DRUG|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
48172531|NCT06077877|DRUG|GSK4524101|GSK452101 will be administered.
48172532|NCT06077877|DRUG|Niraparib|Niraparib will be administered.
48172533|NCT05730517|DIETARY_SUPPLEMENT|CP5HA|Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.
48172534|NCT05730517|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.
48172535|NCT05730517|DIETARY_SUPPLEMENT|CP5|Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
48704608|NCT03921619|DEVICE|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
48172536|NCT06462274|OTHER|body sample collection and imaging scan|
48172537|NCT00703105|BIOLOGICAL|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
48172538|NCT03399838|DRUG|Dexmedetomidine|IN Dex for pediatric procedural sedation at the emergency department
48172539|NCT03399838|DRUG|Midazolam|po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
48172540|NCT02712307|DRUG|Phenoxymethylpenicillin|
48172541|NCT00195884|BEHAVIORAL|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
48172542|NCT04280562|DEVICE|Sana Pain Reliever|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's normal settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
48172543|NCT04280562|DEVICE|Sham SPR|Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 16 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
48172544|NCT04342598|OTHER|Serum Vitamin D|Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
48172545|NCT01181219|PROCEDURE|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
48172546|NCT01181219|PROCEDURE|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
48172547|NCT05352971|OTHER|Biomarker quantification|Patient blood samples will be tested on 2 different platforms
48172548|NCT03277677|DRUG|Normal saline|for resuscitation in sepsis patients
48172549|NCT03277677|DRUG|Ringer's Acetate|for resuscitation in sepsis patients
48172550|NCT04071509|DEVICE|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
48172551|NCT02316288|BEHAVIORAL|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
48172552|NCT02316288|BEHAVIORAL|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
48172553|NCT01709955|DIETARY_SUPPLEMENT|Glucomannan|750 MG of Glucomannan in capsule form
48373310|NCT02044094|DRUG|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
48373311|NCT02044094|DRUG|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
48373312|NCT02974738|DRUG|Belzutifan|Belzutifan is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
48373313|NCT03426774|DEVICE|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
48373314|NCT03426774|DEVICE|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
48373315|NCT02620228|DEVICE|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
48373316|NCT02875262|DRUG|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
48516621|NCT04952818|DIAGNOSTIC_TEST|RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)|Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
48516622|NCT03397225|BEHAVIORAL|Lifestyle intervention|The educational sessions and individual sessions including dietary management and physical activity advices.
48704609|NCT06457646|GENETIC|Genetic polymorphism|The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.
48704610|NCT03109093|DRUG|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
48704611|NCT03454399|PROCEDURE|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
48172554|NCT01709955|OTHER|Placebo|750 mg of Cellulose powder in a capsule form
48172555|NCT00600301|DRUG|Triamcinolone Acetonide and Bevacizumab|
48172556|NCT02470611|DRUG|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% sodium alendronate gel
48172557|NCT02470611|OTHER|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% placebo gel
48704612|NCT04671784|OTHER|EUS-E|EUS-E
48704613|NCT04363255|DRUG|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
48172558|NCT03035318|DEVICE|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
48516623|NCT02498028|PROCEDURE|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
48516624|NCT02498028|PROCEDURE|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
48516625|NCT03767660|DRUG|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
48516626|NCT00929279|DRUG|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
48015889|NCT06344065|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine|Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.
48015890|NCT05868694|DIAGNOSTIC_TEST|polysomnography|Polysomnography is mainly used to diagnose sleep breathing disorders, including sleep apnea syndrome, snoring, upper airway resistance syndrome, and also used for the auxiliary diagnosis of other sleep disorders, such as: narcolepsy, restless legs syndrome, insomnia classification, etc.
48373317|NCT02875262|OTHER|placebo|placebo (NaCl 0.9%) in equal dose to treatment
48373318|NCT03530267|DRUG|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
48373319|NCT03530267|DRUG|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
48373320|NCT04469101|PROCEDURE|Lumbar Epidural|Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
48015891|NCT04622254|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
48015892|NCT04622254|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
48015893|NCT05421078|DRUG|Obicetrapib|tablet
48015894|NCT05421078|DRUG|Placebo|No active ingredient
48373321|NCT06519578|DRUG|hepatic artery infusion chemotherapy|"HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W."
48373322|NCT01917149|DRUG|Benazepril|
48516627|NCT00929279|DRUG|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
48015895|NCT01221441|BIOLOGICAL|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
48015896|NCT01221441|DRUG|Normal Saline|Single intraarticular injection of normal saline as a placebo control
48015897|NCT02466308|DEVICE|SAM Ultrasound Diathermy Device|
48015898|NCT04206163|DIAGNOSTIC_TEST|68Ga-DOTA-TOC PET/CT|Somatostatin receptor imaging
48015899|NCT04206163|BIOLOGICAL|Blood sample|Analysis of inflammatory biomarkers
48373323|NCT01917149|DRUG|Valsartan|
48704614|NCT04363255|DRUG|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
48015900|NCT03198611|DIAGNOSTIC_TEST|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
48015901|NCT00134368|DRUG|Etanercept|
48015902|NCT01275924|DEVICE|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
48015903|NCT01275924|DEVICE|Syndesmotic screw|Quadricortical syndesmotic screw
48015904|NCT02442817|DRUG|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
48015905|NCT05729022|DEVICE|Ultrasound microendoscopic technique|Ultrasound-guided microendoscopic lumbar transforaminal epidural steroid injection
48015906|NCT05729022|RADIATION|Fluoroscopy|Fluoroscopy-guided lumbar transforaminal epidural steroid injection.
48015907|NCT04121403|BIOLOGICAL|Rituximab|Biosimilar rituximab concentrate for solution for infusion
48015908|NCT04121403|DRUG|Cladribine|Mavenclad oral cladribine tablets
48015909|NCT01531959|DRUG|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
48373324|NCT01917149|DRUG|Metoprolol|
48373325|NCT04469140|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
48704615|NCT04363255|DRUG|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
48704616|NCT04363255|DRUG|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
48704617|NCT04363255|DRUG|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
48704618|NCT06605209|DEVICE|Peripheral Balloon-Expandable Covered Stent System|The intervention in this clinical trial involves the Peripheral Balloon-Expandable Covered Stent System. This stent system is specifically designed for the treatment of stenosis and/or occlusion in the common and external iliac arteries.
48704619|NCT06012019|OTHER|Biological sampling in Periodontitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction : gingival explant sampling~J+15 : Healing control"
48704620|NCT06012019|OTHER|Biological sampling in Gingivitis Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
48704621|NCT06012019|OTHER|Biological sampling in Control Case|"Periodontal bacteria, gingival fluid, unstimulated saliva and blood collection;~J+7 : tooth extraction or pre-prosthetic periodontal surgeries : gingival explant sampling~J+15 : Healing control"
48172559|NCT03035318|DEVICE|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
48172560|NCT03035318|DEVICE|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
48704622|NCT03860012|DRUG|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
48373326|NCT06443437|OTHER|bee-buzzy vibrating cold application marionette doll|"* Bee-buzzy will be attached to the arm of the preschool child (who is included in the bee-buzzy group) by the researchers, where the phlebotomy will be performed on the child. It reduces pain through its cold wings and vibration. It helps to distract attention during phlebotomy and reduces the feeling of pain and fear. Bee-buzzy will be tied 5 cm above the area from which blood will be drawn, and after waiting for 15 seconds, the nurse will perform a phlebotomy.~* A marionette doll group; while the nurse is going to perform the phlebotomy operation on the preschool child, one of the researchers will try to distract the child by paly with marionette doll. The researchers will receive training in play therapy"
48373327|NCT06443437|OTHER|Rotuine care|children in control group will receive routine hospital are
48516628|NCT02165735|BEHAVIORAL|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
48015910|NCT01531959|DRUG|Placebo|Patients will be randomized to blinded placebo control
48172561|NCT03035318|DEVICE|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
48373328|NCT02014428|DIETARY_SUPPLEMENT|Hyaluronic acid|
48015911|NCT02057107|RADIATION|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
48373329|NCT02014428|DRUG|Placebo|
48704623|NCT04428190|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
48015912|NCT02057107|DRUG|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
48704624|NCT04428190|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
48704625|NCT00977275|RADIATION|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
48015913|NCT02057107|DRUG|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
48015914|NCT03018353|DRUG|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
48015915|NCT03558828|BEHAVIORAL|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
48172562|NCT03035318|DEVICE|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
48172563|NCT03937232|BEHAVIORAL|Cross-Education|Home exercise program + usual care
48172564|NCT03937232|BEHAVIORAL|Mirror Visual Feedback|Home exercise program + usual care
48172565|NCT03937232|OTHER|Usual care|Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
48172566|NCT02004106|DRUG|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
48172567|NCT04295850|DRUG|Aspirin 81 mg|Aspirin 81mg daily PO
48172568|NCT00843115|OTHER|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
48373330|NCT04637373|DIAGNOSTIC_TEST|Hysteroscopy|adding Hysteroscopy before and after suction curettage for early missed abortion to define the wall of implantation and look for retained products of conception
48373331|NCT04156802|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded)
48373332|NCT04156802|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
48704626|NCT02663466|PROCEDURE|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
48704627|NCT00496483|DRUG|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
48015916|NCT03558828|BEHAVIORAL|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
48172569|NCT05008263|DIAGNOSTIC_TEST|Liver elastography (2D-SWE)|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
48172570|NCT05008263|DIAGNOSTIC_TEST|Liver scintigraphy with 99mTc-mebrofenin|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
48172571|NCT06301971|DRUG|Emraclidine|Oral solution/suspension
48172572|NCT02388113|BEHAVIORAL|accumulated exercise|
48172573|NCT02388113|BEHAVIORAL|traditional exercise|
48015917|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
48172574|NCT05124821|DEVICE|Central venous catheter intended to be used for children during routine clinical practice|Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
48172575|NCT04974086|OTHER|Sexually transmitted infection (STI) testing clinical decision support (CDS) tool|The intervention, called the STI Testing CDS tool, includes integrating STI testing guideline prompts into the electronic health record (EHR). The prompt guides clinicians to assess and broadly respond to adolescents' sexual health behaviors through EHR survey data. Through the CDS tool, clinicians will be prompted to provide comprehensive and evidence-based sexual health care for teens including, for example: providing patient-facing education about sexual preventative health topics and facilitating ordering of HIV and sexually transmitted infection (STI) laboratory tests to improve both risk-based and routine annual preventative screening.
48373333|NCT04156802|DEVICE|Real TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded).
48373334|NCT04156802|DEVICE|Sham TBS to the MC|This will be delivered with the Magventure Magpro system (double blinded). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
48015918|NCT03558828|BEHAVIORAL|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
48015919|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
48373335|NCT00136994|DRUG|Ziprasidone|
48373336|NCT01045902|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
48373337|NCT01045902|DRUG|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
48373338|NCT00862667|DRUG|Treatment A|PF-00241939 300ug using Inhaler A
48373339|NCT00862667|DRUG|Treatment B|PF-00241939 300ug using Inhaler B
48373340|NCT00862667|DRUG|Treatment C|PF-00241939 300ug using Inhaler C
48373341|NCT04085354|DRUG|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
48516629|NCT02165735|OTHER|Usual care|Usual HIV care
48172576|NCT00996814|BEHAVIORAL|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
48015920|NCT03558828|BEHAVIORAL|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
48015921|NCT03558828|BEHAVIORAL|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
48015922|NCT03852329|DEVICE|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
48015923|NCT04402827|DIAGNOSTIC_TEST|Susceptibility to infection|"ACE2 and CD26 receptor study: After genomic DNA extraction and quantification using a NanoDrop-1000, 14 ACE2 SNPs (rs1978124, rs2048683, rs2074192, rs2106809, rs2285666, rs233575, rs4240157, rs4646142, rs4646155, rs4646156, rs4646188, rs4830542, rs6632677, and rs879922) will be studied. In addition, one CD26 (DPP4) SNP (rs7608798) will be analysed (qualitative measure).~SARS-CoV-2 CD4/CD8 T cell response: SARS-CoV-2 peptides (Prot-S, Pros-N and Port-M) will be used to activate CD4 and CD8 T cells. Cytokines released, such as IFNg, TNFa, IL4, IL17A, and IL2, from each cell subset will be measured by flow cytometry (quantitative measure).~KIR characterization: Characterization of the presence of 14 genes plus 2 pseudogenes of KIR gene family (qualitative genotyping) by PCR, mRNA expression profiling (quantitative measures) by RT-PCR, and phenotyping of human NK cells analyzing different KIR receptors (quantitative measure) by flow cytometry, will be analyzed."
48015924|NCT06662708|DIAGNOSTIC_TEST|Accurate Prediction Artificial Intelligence Models|Diagnostic Test: Accurate Prediction Artificial Intelligence Models Post-operative pathology, precise pre-operative diagnosis (including benign and malignant, invasive, grading, subtypes) or 3D lesion modelling will be predicted based on the AI predictive model in response to the information provided
48015925|NCT05696717|DRUG|Ampreloxetine|Oral tablet, QD
48015926|NCT05696717|DRUG|Placebo|Oral tablet, QD
48015927|NCT06139913|OTHER|aerobic exercise|moderate intensity aerobic exercise using treadmill
48015928|NCT06562036|DRUG|Sildenafil|Patients were given oral sildenafil as 2 mg per kg per day, 6-hourly with an increment of 0.5 mg per kg per dose and a target maintenance dose of 2 mg per kg per dose every 6 hour by nasogastric tube.
48015929|NCT06562036|DRUG|Milrinone|In this group, Milrinone was initiated at 0.5 ug per kg per minute using intravenous infusion through a syringe pump, and sildenafil was given in the same protocol mentioned for the Sildenafil Group.
48015930|NCT02634294|DRUG|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1\~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
48015931|NCT04332172|OTHER|General information|General information related to pregnancy is provided electronically.
48373342|NCT04085354|DRUG|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
48373343|NCT04085354|DRUG|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
48373344|NCT04085354|DRUG|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
48373345|NCT05804669|DRUG|CRN04894|CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
48704628|NCT00496483|DRUG|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
48704629|NCT06535230|DRUG|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
48516630|NCT06336265|DIAGNOSTIC_TEST|Diaphragm ultrasound|Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment.
48704630|NCT06535230|DRUG|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
48704631|NCT06535230|DEVICE|Hemodynamic monitoring with pressure recording analytical method (PRAM)|The pulse contour device MostCare (Vytech, Vygon, Padova, Italy) provides functional hemodynamic monitoring using the pressure recording analytical method.
48704632|NCT06398431|DEVICE|Walking analysis sensor|Participant gait analysis with the inertial sensor
48704633|NCT05566431|OTHER|ICP|The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury
48704634|NCT05566431|OTHER|CREVICE|The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
48704635|NCT06135636|BEHAVIORAL|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
48704636|NCT06135636|BIOLOGICAL|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
48704637|NCT01846663|DRUG|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
48704638|NCT01846663|DRUG|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
48704639|NCT01413620|DRUG|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
48704640|NCT01562522|OTHER|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
48516631|NCT01739699|DRUG|Acetaminophen|
48704641|NCT06605261|OTHER|Yoga (intervention) group|The yoga (intervention) group comprises 64 women with breast cancer who have been randomly assigned and are undergoing endocrine therapy. To alleviate arthralgia and vasomotor symptoms (hot flashes, night sweats), a structured yoga program will be administered during the initial months of endocrine therapy, consisting of 60-minute sessions, 4 days per week, for a duration of one month.
48704642|NCT06256666|DEVICE|BIS Quantitative EEG|Pain assessment will be conducted before and in the postoperative period using the objective PANAID scale and, when possible, the NRS. Simultaneously, EEG recordings using the BIS (Bispectral Index) will be performed. Cognitive status will be assessed before surgery using the Pfeiffer scale
48015932|NCT04332172|BEHAVIORAL|Baseline brief intervention|Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
48516632|NCT01739699|DRUG|Placebo|
48516633|NCT01984827|DRUG|Moxifloxacin|"1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
48516634|NCT01984827|OTHER|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
48704643|NCT02049827|OTHER|participation in the study|
48704644|NCT06607601|DRUG|Palbociclib|Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis
48704645|NCT06607601|DRUG|Letrozole|Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
48704646|NCT05660902|OTHER|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
48704647|NCT00500058|DRUG|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
48704648|NCT00500058|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered by IV infusion.
48704649|NCT06601647|PROCEDURE|adjuvant type|ropivacaine combined with adjuvant
48704650|NCT04315688|DRUG|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
48704651|NCT05433051|BIOLOGICAL|buccal miniscrew and TPA|intrusion of molars
48704652|NCT05433051|BIOLOGICAL|vertical holding appliance|intrusion of molars
48704653|NCT03163693|DRUG|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
48172577|NCT03511573|PROCEDURE|bariatric and other laparoscopic surgery|We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
48172578|NCT01966978|DRUG|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
48172579|NCT01966978|DRUG|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
48172580|NCT01966978|DRUG|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
48172581|NCT01966978|DRUG|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG \<180
48373346|NCT06028191|OTHER|Kabat Technique along with baseline treatment|"Group A will receive Kabat Technique along with baseline treatment. Electrical muscle stimulation for 15 min which includes faradic current to the facial nerve trunks given by DL-2 electro pulse stimulator, Effleurage and Kneading for 5 min and resistive exercise for 5 min and facial expression exercises for 5 min, which included eye closure, eyebrow raise, frown, smile, snarl, pucker and pout as baseline treatment.~Kabat Technique is neurorehabilitation technique that uses diagonal and spiralpatterns for movement in conjunction with stretch and resistance and other PNF techniques to reinforce neuromuscular recruitment. It mainly concerns the stimulation of these muscles: Orbicularis occuli, ztgomaticus, Levator labii, nasalis, buccinator, frontalis, corrugator"
48373347|NCT06028191|DEVICE|Kabat Technique and LLLT along with baseline treatment|Group B will receive Kabat Technique and LLLT along with baselinetreatment. Kabat technique is same as mentioned in group A. Laser treatment will be administered to eight points of the affected side for 2 min at each point at a wavelength of 830 nm, output power of 100 Mw, and frequency of 1 KHz. Endo laser 422 is the model name and number of device which will be used in this study to administered low level laser therapy.
48373348|NCT04916808|DIAGNOSTIC_TEST|DCISionRT Test|The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
48172582|NCT02010983|OTHER|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
48172583|NCT03142828|DRUG|Chlorhexidine|Healing abutment with Clorhexidine
48172584|NCT03142828|OTHER|Placebo|Healing abutment without any antiseptic
48172585|NCT01707706|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
48172586|NCT00857740|BEHAVIORAL|Education|Education about the neurophysiology of pain
48172587|NCT03322241|OTHER|overall wellness|Wellness lab testing
48172588|NCT00833898|DEVICE|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
48172589|NCT00833898|BEHAVIORAL|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development \& application of various stress-mgmt techniques such as effective problem-solving, identifying \& challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support \& goal setting.
48704654|NCT03163693|OTHER|normal saline|receive equal volume of normal saline
48704655|NCT05606536|DRUG|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
48704656|NCT06059872|OTHER|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
48704657|NCT04852042|BEHAVIORAL|mHealth|Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.
48704658|NCT04852042|BEHAVIORAL|CHW support|The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
48704659|NCT04983485|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
48704660|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
48015933|NCT04332172|BEHAVIORAL|Remote online booster sessions|Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
48373349|NCT04281966|BEHAVIORAL|Ability School Engagement Program Conference|"The ASEP conference focuses on understanding the reasons behind why the young person is not attending school regularly, understand how the young person's non-attendance affects other conference participants, highlight the legal consequences of parents and/or guardians to ensure that their child attends school, and the development of a young person-centered Action Plan, which will specifically detail the actions that all parties are to take over the next three months to ensure that the young person re-engages with school and/or transitions into paid work."
48172590|NCT04755023|DRUG|Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide|Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
48172591|NCT02735434|BEHAVIORAL|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
48172592|NCT02735434|OTHER|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
48172593|NCT06438692|PROCEDURE|VOM ethanol chemical ablation and 2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation，anhydrous alcohol ablation of VOM
48172594|NCT06438692|PROCEDURE|2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation
48172595|NCT00369603|DRUG|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
48172596|NCT00369603|DRUG|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
48172597|NCT03895697|DRUG|dasiglucagon|Glucagon analogue
48172598|NCT00605995|DRUG|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
48172599|NCT06056271|DEVICE|AF Ablation|Percutaneous, catheter-based ablation of atrial fibrillation
48172600|NCT03972397|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
48373350|NCT00928863|OTHER|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
48373351|NCT05903976|DRUG|P2Y12 inhibitor de-escalation|Comparing, in patients at High Bleeding Risk (HBR) after a recent Acute Coronary Syndrome (ACS), continuation of full-dose potent P2Y12 inhibitor with a P2Y12i de-escalation strategy transitioning to clopidogrel 75mg, prasugrel 5mg or ticagrelor 60mg/bid.
48516635|NCT04710615|DEVICE|Synapse platform|"The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication."
48015934|NCT04332172|BEHAVIORAL|SMS|Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
48015935|NCT01573624|DRUG|FF/GSK573719|100/15.6
48015936|NCT01573624|DRUG|FF/GSK573719|100/31.25
48015937|NCT01573624|DRUG|FF/GSK573719|100/62.5
48015938|NCT01573624|DRUG|FF/GSK573719|100/125
48015939|NCT01573624|DRUG|FF/GSK573719|100/250
48015940|NCT01573624|DRUG|FF|100
48015941|NCT01573624|DRUG|FF/VI|100/25
48015942|NCT04613297|OTHER|Baseline and during hospitalization blood samples|"Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :~* at day 3~* day 5 and~* In case of aggravation~* At the discharge from hospital"
48704661|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
48516636|NCT02757326|DRUG|Opaganib|Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.
48516637|NCT06421597|DRUG|Prednisolone|prednisoline 25 mg/day for seven days
48704662|NCT06204692|PROCEDURE|dental implant|consisted of 6 patients where computer guided dental implant placement
48704663|NCT02782052|DRUG|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
48015943|NCT04613297|OTHER|Baseline blood sample|Blood sample will be performed at the inclusion visit only
48015944|NCT00402389|DRUG|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
48015945|NCT00402389|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
48015946|NCT00402389|DRUG|Placebo|Four capsules will be taken daily for 8 weeks.
48015947|NCT06489301|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
48015948|NCT06662773|DRUG|TQB3616 capsule + itraconazole|C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors
48015949|NCT06662773|DRUG|TQB3616 capsule + rifampicin|C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer
48015950|NCT06663449|PROCEDURE|subcostal transversus abdominis plane block|subcostal transversus abdominis plane block will be performed using 20 mL of 0.25 bupivacaine
48015951|NCT06663449|PROCEDURE|erector spinae plane block|erector spinae plane block will be performed using 20 mL of 0.25 bupivacaine
48015952|NCT03318614|DIETARY_SUPPLEMENT|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
48015953|NCT03318614|OTHER|Control group|No probiotic intervention was given to the control group for three months.
48015954|NCT05037396|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
48015955|NCT01518075|OTHER|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
48015956|NCT01518075|OTHER|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
48015957|NCT00128258|PROCEDURE|Injection of bone marrow cells in the heart|Biological implant into the heart
48015958|NCT00128258|BIOLOGICAL|Biological bone marrow cell therapy|Biological implant into the heart
48015959|NCT06664723|DEVICE|high tone external muscle stimulation|Device HiToP®: Parameters of (HTEMS), Voltage: 230-V Pulse widths: ≤350 mA. Electrical Frequency: Frequencies continuously scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 m W. Intensity: the electrical stimulation will be adjusted to a pleasant level that will not produce any pain or discomfortable paraesthesia, Duration 30 minutes per session. Electrodes will be placed around ulcer. It will be introduced 3 times per week, for 8 weeks Prior to intervention, skin sensation will be assessed using warm water in a test-tube (temperature), pin prick (pain) and cotton wool (light touch) to ascertain the skin sensitivity
48373352|NCT03112720|DEVICE|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
48516638|NCT06421597|DRUG|Placebo|Placebo treatment for seven days
48516639|NCT05880602|DIETARY_SUPPLEMENT|Nettle and Cranberry complex capsules|A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.
48516640|NCT05880602|DIETARY_SUPPLEMENT|Placebo(starch)|A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.
48516641|NCT01500473|DRUG|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
48516642|NCT05509517|DIAGNOSTIC_TEST|Photoplethysmography based smartphone application for heart rhythm analysis (FibriCheck™)|Heart Rhythm assessment using the FibriCheck™ application with the patient's proprietary smartphone, three times daily, from discharge until follow-up consultation (day 21-91 after discharge).
48516643|NCT03752814|DEVICE|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
48516644|NCT05741827|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention focusing on diet and physical activity
48516645|NCT06550544|PROCEDURE|Office hysteroscopy|"A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
48172601|NCT03972397|DRUG|Bupivacaine liposomal injectable suspension|Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
48172602|NCT03972397|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
48373353|NCT03112720|DRUG|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
48373354|NCT02094066|DRUG|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
48373355|NCT02094066|DRUG|serum physiologic|preoperative 100 cc ıv serum physiologic
48373356|NCT05338827|PROCEDURE|Polyvinyl Chloride Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
48373357|NCT05338827|PROCEDURE|Wire-Reinforced Tube group|The anaesthesiologist will perform a visual screen for the SaCoVLM glottic exposure grade after the SaCoVLM is successfully inserted. The SaCoVLM glottic exposure grade was referred to the endoscopic view grading system. If the SaCoVLM glottic exposure grade is 1 or 2, a lubricated tracheal tube will be inserted in a conventional manner with the curvature of the tracheal tube aligned along the intrinsic curvature of the SaCoVLM. The passage of the tracheal tube into the glottis will be visualised. If there is a discrepancy in the alignment of the tracheal tube exiting from the SaCoVLM and the glottis that will prevent the passage of the tracheal tube into the glottis, the tracheal tube will be withdrawn and manipulations (rotation of the tracheal tube or up/down manoeuvre) will be performed in an attempt to align the glottis and tracheal tube tip to facilitate intubation. Such manoeuvres, if performed, will be recorded.
48373358|NCT01247649|DEVICE|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
48373359|NCT04479774|OTHER|Compelled Body Weight Shift Technique|"Routine Physical Therapy with 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
48516646|NCT06550544|PROCEDURE|Ultrasound guided|"An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~Pain intensity will be assessed by visual analogue scale immediately after the procedure."
48516647|NCT03955458|DRUG|EXPAREL|FICB with EXPAREL + Bupivacaine HCL (single dose)
48516648|NCT03955458|DRUG|Ropivacaine|FICB with continuous infusion of ropivacaine
48516649|NCT03955458|DRUG|Bupivacaine Hydrochloride|FICB with EXPAREL + Bupivacaine HCL (Single dose)
48516650|NCT05546008|DEVICE|Multislice CT|all patient will be subjected to echocardigraphy and multislice ct and compare thier results
48516651|NCT01810510|PROCEDURE|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
48704664|NCT02782052|DRUG|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
48704665|NCT02782052|DRUG|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
48172603|NCT01586533|DRUG|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
48172604|NCT01586533|DRUG|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
48172605|NCT06442163|DEVICE|AVAPS study was performed within 1 week of the CPAP titration attempt failure, using the auto-titrating EPAP (AE), the OmniLab Advanced +, System One device (Philips Respironics, Murrysville, PA, U.S.|"After attending an educational session (in the presence of a family member) with hands-on training, the AVAP -AE devices were provided to the patients.~During the study, one month after AVAPS -AE initiation, patients had direct immediate access to medical and technical support through phone contact during daytime working hours."
48373360|NCT04479774|OTHER|Compelled Body Weight Shift Technique without insole|"Routine Physical Therapy without 0.6 cm thickness insole inserted in shoe of unaffected side and following exercises were performed by patients~* Muscle re-education~* Sit to stand exercise , 4 to 10 repetitions~* Supported heel raise to 10 repetitions with 3 sets~* Supported squat exercise tibialis anterior and quads muscles to 10 repetitions with 3 sets~* Gait training~* Forward walk in parallel bars with number of 10 rounds.~* Task oriented training balance training~* A. Stepping exercise on 15 cm height step and number of repetitions 10.~* B. Tandem standing for 10 seconds.~* C. Reaching exercise in which patient performed reaching for object in therapists hand and the number of repetitions was 10."
48172606|NCT03181906|OTHER|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
48172607|NCT04705402|DRUG|Mannitol|"Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes."
48172608|NCT04705402|DRUG|Saline|Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
48704666|NCT06606509|DEVICE|Continuous Glucose Monitoring System (GX-01S)|Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
48172609|NCT02348372|DRUG|GSK1278863A Placebo|Matching size, shape and color
48172610|NCT02348372|DRUG|GSK1278863A|A round, biconvex, white film coated tablet
48172611|NCT04472988|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|"The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish."
48373361|NCT02654405|DIETARY_SUPPLEMENT|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
48172612|NCT04472988|OTHER|Placebo|The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.
48172613|NCT04472988|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
48172614|NCT01627470|DEVICE|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
48172615|NCT04858321|PROCEDURE|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
48373362|NCT02654405|OTHER|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
48704667|NCT05565573|DRUG|Medroxyprogesterone Acetate 500 MG Oral Tablet|500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day
48704668|NCT05565573|DEVICE|Levonorgestrel-Releasing Intrauterine System|Uterine cavity insertion
48172616|NCT05061069|DIAGNOSTIC_TEST|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
48373363|NCT04301024|OTHER|assessing the nitrous oxide misuse|assessing the nitrous oxide misuse among teenagers consulting in an addioctology center dedicated to young drug users in montpellier
48373364|NCT03592251|DIETARY_SUPPLEMENT|Olive Oil Placebo|6 months placebo supplementation
48373365|NCT03592251|DIETARY_SUPPLEMENT|EPA-rich|6 months placebo supplementation
48373366|NCT03592251|DIETARY_SUPPLEMENT|DHA-rich|6 months placebo supplementation
48373367|NCT00545974|DRUG|memantine|memantine 10mg BID
48373368|NCT00545974|DRUG|Placebo pill|Placebo pill BID
48373369|NCT01727804|OTHER|Laser in caries prevention|
48373370|NCT00914940|DRUG|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
48373371|NCT00914940|DRUG|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
48704669|NCT05149040|OTHER|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
48704670|NCT01117506|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
48172617|NCT03987490|BEHAVIORAL|Text Message|Vaccine reminder notification sent via text
48172618|NCT03987490|BEHAVIORAL|PostCard|Vaccine reminder notification sent via standard mail
48172619|NCT03987490|BEHAVIORAL|Standard of Care|No additional information given to parents
48704671|NCT04088084|DIETARY_SUPPLEMENT|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
48704672|NCT00297895|PROCEDURE|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
48704673|NCT00297895|PROCEDURE|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
48373372|NCT00914940|DRUG|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
48373373|NCT00914940|RADIATION|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
48373374|NCT00914940|OTHER|Magnetic Affinity Cell Sorting|Device
48373375|NCT00914940|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
48373376|NCT00914940|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
48373377|NCT00914940|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
48373378|NCT02078141|DRUG|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
48373379|NCT02950831|OTHER|Accelerometry|Record of activity levels using a wrist worn accelerometer
48373380|NCT01907373|DRUG|olmesartan medoxomil|
48373381|NCT01907373|DRUG|olmesartan medoxomil+probenecid|
48373382|NCT01682343|DIETARY_SUPPLEMENT|Calcium|Milk-calcium supplement
48373383|NCT05275166|BEHAVIORAL|Induction of alcohol craving|Presentation of images that may induce craving for alcohol. Recording of brain activity
48172620|NCT03987490|BEHAVIORAL|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
48172621|NCT00121446|DRUG|tenecteplase|
48373384|NCT05275166|OTHER|Questionnaires|Questionnaires related to alcohol, quality of life, anxiety and depression
48373385|NCT01479777|DEVICE|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
48172622|NCT00121446|DRUG|enoxaparin|
48373386|NCT04098991|DRUG|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
48373387|NCT06365164|BEHAVIORAL|Tactile stimulation|The procedure consists of brief perioral tactile stimulation. The procedure is filmed in order to record and evaluate the response of the newborn to the stimulation. During the same intervention, each newborn will receive external stimulation (the experimenter repeatedly and regularly touches the corner of the infant's mouth slowly with the tip of his index finger) followed by facilitated self-stimulation (the experimenter will place the newborn's elbow close to his body, allowing him to touch his face alone with his hand). There will also be an initial phase and a final 30-second phase in which the newborn is observed without any stimulation.
48373388|NCT02654184|PROCEDURE|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
48373389|NCT02654184|PROCEDURE|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
48373390|NCT05921942|DRUG|Metformin|500 mg twice daily or 1000 mg once daily
48373391|NCT06450990|DRUG|BGY-1601-VT|Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
48373392|NCT06450990|OTHER|PLACEBO|Placebo
48704674|NCT01529983|PROCEDURE|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
48704675|NCT02593812|BEHAVIORAL|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
48704676|NCT01118520|DRUG|perindopril arginine|10mgs orally daily for the duration of the trial
48172623|NCT00121446|DRUG|clopidogrel|
48172624|NCT00121446|PROCEDURE|percutaneous coronary intervention|
48373393|NCT01574924|OTHER|No intervention.|There are no interventions in this observational study.
48373394|NCT05647174|PROCEDURE|MGPOCUS-assisted bronchoscope-guided intubation|Application of ultrasound instruments that can detect magnetic signals to determine the position of the magnetised bronchoscopy to guide the direction of its advancement and thus optimise difficult endotracheal intubation.
48373395|NCT05647174|PROCEDURE|Bronchoscope-guided intubation|Routine bronchoscope- guided intubation.
48373396|NCT06180473|OTHER|questionnaire|PPQ, TTAQ PTCS
48373397|NCT04548401|DRUG|Antiplatelet Drug|aspirin and/or clopidogrel or ticagrelor
48373398|NCT00193076|DRUG|Gemcitabine|Gemcitabine
48704677|NCT01118520|DRUG|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
48704678|NCT01118520|DRUG|placebo|one daily
48704679|NCT03997968|DRUG|CYT-0851|Part A and B: Daily oral doses of CYT-0851 for 28 day cycles
48172625|NCT05188898|OTHER|MINSD and Hyaluronic acid|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, a hyaluronic acid-based gel will be applied to the intraosseous periodontal pockets.
48172626|NCT05188898|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
48172627|NCT01470729|OTHER|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
48172628|NCT00085878|DRUG|SB-485232|
48172629|NCT02179853|DRUG|Anakinra|First two doses IV followed by SQ dosing
48172630|NCT00275145|BEHAVIORAL|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
48373399|NCT00193076|DRUG|Carboplatin|Carboplatin
48373400|NCT00193076|DRUG|Trastuzumab|Trastuzumab
48704680|NCT03997968|DRUG|CYT-0851 in combination with gemcitabine|Part D: Daily oral doses of CYT-0851 for 28 days in combination with gemcitabine
48373401|NCT01615965|OTHER|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
48704681|NCT03997968|DRUG|CYT-0851 in combination with capecitabine|Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
48704682|NCT03997968|DRUG|CYT-0851 in combination with rituximab and bendamustine|Part C: Daily oral doses of CYT-0851 for 28 days in combination with rituximab and bendamustine
48704683|NCT05950191|OTHER|long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)|Next-generation bed net combining insecticides with different modes of action
48015960|NCT06664723|OTHER|Standard medical treatment (SMT)|The Standard care of diabetic foot ulcers includes good glycemic control, adequate nutrition, off-loading (via bed rest or casts), local care (moist dressings and topical management), lessening of edema, surgical debridement of devitalized wound tissue and antibiotic therapy.
48015961|NCT05809453|DRUG|Cocaine|Cocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
48015962|NCT05809453|DRUG|Lidocaine|Lidocaine will be administered intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
48015963|NCT06511804|DEVICE|Intracranial Pressure Noninvasive Monitoring|Mespere sensors will be placed on the temporal areas of the head in patients with invasive intracranial pressure monitoring. Blood pressures, intracranial pressure, and Mespere parameters will be recorded.
48015964|NCT03660956|BEHAVIORAL|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
48015965|NCT03660956|BEHAVIORAL|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
48015966|NCT06663579|OTHER|Fathers who practicing kangaroo care|The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.
48015967|NCT06663579|OTHER|Fathers who not practicing kangaroo care|The control group (n=28) It consists of fathers of babies practicing Kangaroo Care with their mothers in the neonatal intensive care unit.
48373402|NCT03674385|DIETARY_SUPPLEMENT|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
48704684|NCT05950191|OTHER|long lasting insecticidal nets with PBO-pyrethroid (PermaNet)|Next-generation bed net combining an insecticide with a synergist
48704685|NCT05950191|BEHAVIORAL|Social Behavior Change Communication|The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
48704686|NCT05908071|DRUG|SHEN26 capsule|Capsule administered orally after meals.
48704687|NCT05908071|DRUG|SHEN26 placebo|Capsule administered orally after meals.
48015968|NCT04661176|DIAGNOSTIC_TEST|miR Sentinel™ PCC4 Assay|This study is a prospective clinical utility study. Urine samples will be collected from participants for the miR Sentinel™ PCC4 Assay, which interrogates the expression profile of 442 small non-coding RNAs to classify disease status as having no molecular evidence of prostate cancer (NMEPC) or molecular evidence of low-, intermediate- or high-risk prostate cancer.
48015969|NCT03995238|BEHAVIORAL|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
48015970|NCT03995238|BEHAVIORAL|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
48373403|NCT03674385|DRUG|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
48704688|NCT04580368|DRUG|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
48704689|NCT03575117|BEHAVIORAL|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
48704690|NCT03575117|BEHAVIORAL|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
48704691|NCT03575117|BEHAVIORAL|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
48373404|NCT03674385|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
48704692|NCT01932320|DRUG|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
48704693|NCT01932320|DRUG|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
48704694|NCT01932320|DRUG|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
48704695|NCT01932320|DRUG|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
48704696|NCT05636410|DIAGNOSTIC_TEST|Larynx and trachea ultrasound|After meeting enrolment criteria the larynx and trachea ultrasound will be performed at 32 and 42 weeks of gestation.
48704697|NCT06152835|OTHER|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
48015971|NCT03995238|BEHAVIORAL|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
48704698|NCT06605339|BEHAVIORAL|Virtual Reality|Virtual Reality Distraction
48704699|NCT04362475|BEHAVIORAL|Community Health through Engagement and Environmental Renewal (CHEER)|FYI and ESPI intervention activities will be implemented in the overall study, CHEER. It will also allow us to examine possible synergistic effects of both interventions when implemented in the same neighborhoods. Separate sets of participants will be selected for the FYI comparisons and for the ESPI comparisons. Because the FYI intervention focuses on mothers and their children, participants for the FYI comparisons will be selected by Respondent Driven Sampling of eligible families from the neighborhoods in all four cells. The ESPI intervention targets the whole neighborhood, and thus a random sample of neighborhood residents will be enrolled in each of the four cells. Because the primary outcomes for FYI and ESPI are connected but differ from each other, the FYI samples will be assessed for the FYI outcomes in all four cells and the ESPI samples will be assessed for the ESPI outcomes in all four cells.
48015972|NCT06663657|OTHER|Cognitive Sensorimotor Exercises|Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks.
48015973|NCT06663657|OTHER|Task Oriented Training group|Patients in group B will receive task oriented training for 30 minutes, sessions for 5 days per week for 8 weeks.
48015974|NCT03262272|DEVICE|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
48015975|NCT03262272|DEVICE|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
48015976|NCT03262272|DEVICE|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
48015977|NCT03262272|DEVICE|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
48015978|NCT05836038|BEHAVIORAL|Visio-Tactile Stimulation|They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
48015979|NCT05121116|BEHAVIORAL|Online Mindfulness-Based Stress Reduction (MBSR)|Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
48015980|NCT05801627|DRUG|SAL067|SAL067 6mg(2 tablet) and Metformin ≥1500mg
48015981|NCT05801627|DRUG|Placebo|Placebo (2 tablet) and Metformin ≥1500mg
48015982|NCT03787849|DRUG|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
48373405|NCT05999227|DRUG|68Ga-FAPI-04|A fibroblast activation protein (FAP) -targeted PET imaging agent
48373406|NCT05999227|DRUG|18F-FDG|A general glucose metabolism imaging agent
48373407|NCT01092312|PROCEDURE|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
48373408|NCT01092312|PROCEDURE|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
48373409|NCT00078689|DRUG|Daclizumab|
48704700|NCT00918164|DRUG|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
48704701|NCT00612547|DRUG|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
48704702|NCT03885232|BEHAVIORAL|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
48172631|NCT00275145|BEHAVIORAL|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
48172632|NCT00275145|BEHAVIORAL|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
48172633|NCT00275145|BEHAVIORAL|Continued Sedentary lifestyle|No changes
48172634|NCT03598725|DRUG|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
48172635|NCT03598725|DRUG|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
48172636|NCT03598725|DRUG|Rituximab|375mg/Square meter for consecutive 4 months
48172637|NCT02394964|OTHER|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
48172638|NCT03384147|DIETARY_SUPPLEMENT|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
48373410|NCT05901766|DIETARY_SUPPLEMENT|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
48373411|NCT02874469|OTHER|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
48373412|NCT05531916|OTHER|Pressurized gloves and foot caps|Using pressurized gloves and foot caps in order to prevent chemotherapy-induced peripheral neuropathy (CIPN).
48704703|NCT03885232|OTHER|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
48704704|NCT00549263|DRUG|SB797620|
48704705|NCT04384601|DRUG|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
48704706|NCT05577377|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
48172639|NCT03384147|OTHER|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
48172640|NCT03299127|BEHAVIORAL|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
48172641|NCT00239681|DRUG|Rosuvastatin|Oral
48704707|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
48704708|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
48172642|NCT00239681|OTHER|Placebo|Oral
48172643|NCT06478134|DRUG|Trimix tear substitutes|Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.
48172644|NCT06478134|DRUG|Hyaluronic acid tear substitute|Patients were instructed to instill 1 drop of 0.15% HA tear substitute into each eye 3 times per day for 6 months.
48172645|NCT02915562|OTHER|exercise|
48172646|NCT03713073|DEVICE|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
48172647|NCT03713073|DEVICE|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
48172648|NCT01949883|DRUG|CPI-0610|
48172649|NCT04969224|DRUG|ELX/TEZ/IVA|Fixed dose combination (FDC) tablet for oral administration.
48172650|NCT04969224|DRUG|IVA|Tablet for oral administration.
48172651|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
48172652|NCT02264964|PROCEDURE|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
48172653|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
48373413|NCT03237910|DIAGNOSTIC_TEST|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
48373414|NCT03237910|PROCEDURE|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
48373415|NCT03237910|PROCEDURE|CPR|chest compressions and ventilations at a rate of 30:2
48373416|NCT00381134|DRUG|losartan 100 mg orally once daily|
48373417|NCT00381134|DRUG|spironolactone 25 mg orally once daily|
48015983|NCT03787849|DRUG|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
48373418|NCT00381134|DRUG|placebo once orally once daily|
48373419|NCT06282263|OTHER|"Awareness Development Program on Suicide Prevention for Oncology Nurses"|"While developing the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to the nurses in the experimental group, literature information on suicide risk management and suicide prevention in oncology was included in the study content by the researchers. Awareness Development Programme on Suicide Prevention for Oncology Nurses includes 3 sessions and the titles of the programme are as follows:~Session 1: Introduction to Understanding Suicide Awareness and Development Session 2: Assessing Suicide Risk Session 3: Management of Suicide Risk Communication and Referral The programme was submitted to the opinions of 5 experts before starting the study and the programme was finalised after the feedbacks."
48373420|NCT00197704|DIETARY_SUPPLEMENT|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
48373421|NCT00197704|OTHER|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
48015984|NCT06654310|BEHAVIORAL|Delivery of FCS Skills Curriculum|"The UW study team will conduct two 2-hour train-the-trainer sessions with all surgical attendings who have committed to participation as a trainer in the FCS curriculum. The designated trainer will deliver each 2-hour session during the existing formal educational time for residents. If existing protected educational time will not allow for a 2-hour training session, the sessions can be delivered in two 1-hour sessions. These sessions will be incorporated into the curriculum similar to all other formal training provided to residents with the same expectations to attend.~Each 2-hour FCS session starts with a 30-minute exercise in empathic communication. The remaining 90 minutes are devoted to skills that support decision making about surgery."
48015985|NCT01438190|DRUG|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
48015986|NCT01438190|DRUG|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
48015987|NCT01782677|PROCEDURE|Bilateral Surgical Resection of Carotid Bodies|
48015988|NCT00813761|DEVICE|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
48015989|NCT00813761|DEVICE|Proclear contact lens|control contact lens to be worn for entire length of study.
48015990|NCT00813761|DEVICE|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
48172654|NCT02264964|PROCEDURE|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
48373422|NCT03113773|DRUG|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10\^6 - 3.0 X 10\^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10\^6 IU will be allowed per day.
48373423|NCT03113773|DRUG|Placebo Injection|Dextrose 5%
48373424|NCT02467543|OTHER|20% Ethanol|Unmedicated 20% Ethanol
48373425|NCT02467543|OTHER|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
48373426|NCT03174028|DEVICE|laparoscopic pull-through|laparoscopic pull-through
48373427|NCT05473039|DIETARY_SUPPLEMENT|Seidivid Ferty4|The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
48373428|NCT05473039|OTHER|Placebo|The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.
48373429|NCT00847002|DEVICE|Standard Wound Care|
48373430|NCT00847002|DEVICE|Flexitouch System with Standard Wound Care|
48373431|NCT01963910|DRUG|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
48516652|NCT01810510|PROCEDURE|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
48015991|NCT00813761|DEVICE|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
48015992|NCT00764140|BIOLOGICAL|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
48015993|NCT01421875|GENETIC|DNA methylation analysis|
48015994|NCT01421875|GENETIC|RNA analysis|
48015995|NCT01421875|GENETIC|gene expression analysis|
48015996|NCT01421875|GENETIC|microarray analysis|
48015997|NCT01421875|GENETIC|nucleic acid sequencing|
48015998|NCT01421875|OTHER|laboratory biomarker analysis|
48015999|NCT06098820|OTHER|Vitamin D status|Four different groups will be compared with each other in terms of vitamin D effect.
48016000|NCT06452615|DEVICE|Extracorporeal shockwave|The patients will receive 3000 to 6000 pulses every session by a radius of 15 mm probe (R15) at a frequency of 10 Hz, with energy gradually increasing from 1.4 to 1.5 bar
48172655|NCT01855477|PROCEDURE|Histological biopsy procedure|
48373432|NCT01963910|DRUG|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
48373433|NCT01946295|DRUG|Famotidine|100mg x 2 p.o.
48373434|NCT01946295|DRUG|Placebo|
48016001|NCT03986944|DRUG|75 mg linzagolix tablet|For oral administration once daily
48016002|NCT03986944|DRUG|200 mg linzagolix tablet|For oral administration once daily
48016003|NCT03986944|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
48016004|NCT03986944|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
48016005|NCT03986944|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
48016006|NCT03986944|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
48016007|NCT05592886|OTHER|SMT04 formula|The SMT04 formula is a synbiotic containing probiotics and prebiotics
48016008|NCT05592886|OTHER|Active placebo|The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
48373435|NCT03816969|DEVICE|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
48373436|NCT03816969|DEVICE|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
48373437|NCT05069909|PROCEDURE|Denture Fabrication technique|Each patient received two sets of dentures fabricated using the two different techniques and their satisfaction and OHIP-EDENT were compared
48373438|NCT01263366|DRUG|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
48373439|NCT03093480|BIOLOGICAL|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
48373440|NCT06199856|DIAGNOSTIC_TEST|ultrasound scan|ultrasound scan
48373441|NCT02283411|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
48373442|NCT01307527|DRUG|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
48373443|NCT01307527|DEVICE|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
48016009|NCT06532656|DRUG|Lenacapavir|Tablets administered orally without regard to food
48016010|NCT06532656|DRUG|BIC/LEN FDC|Tablets administered orally without regard to food
48016011|NCT06127251|BEHAVIORAL|PATH Intervention|"The PATH intervention guides participants in making changes in their lifestyle and PA habits to support gradual improvement of PA. The health coach provides participants with access to the PATH website and instructions on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week.~Participants will use a combination of walking, dance, and abdominal core workouts to add at least 10 minutes of MVPA to their baseline PA every two weeks. The remote coach will encourage each participant to engage in at least 2 days of aerobic training (walking or dance sessions), and one day of abdominal core workouts."
48016012|NCT06127251|BEHAVIORAL|Control Group|Study staff will have a Zoom meeting with each control group participant where they will be advised to use the Be Active Your Way handout and to self-monitor PA using ScanWatch. Additionally, the group will be introduced to www.health.com, a jargon-free website that focuses on general health topics (e.g., dry eye) and the latest medical news (e.g., vaccines). Every 2 weeks control participants will meet on Zoom with study staff to review their progress in the study so as to keep the contact between the groups as similar as possible.
48373444|NCT01707667|DRUG|prucalopride|One 2 mg tablet orally administered on Day 1
48373445|NCT01707667|DRUG|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
48373446|NCT05728710|PROCEDURE|Endoscopic submucosal dissection|standard ESD performed and complicated with a perprocedural or delayed perforation
48373447|NCT00881374|DRUG|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
48373448|NCT02042742|DIETARY_SUPPLEMENT|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
48373449|NCT02042742|DIETARY_SUPPLEMENT|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
48373450|NCT02503969|OTHER|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
48373451|NCT04001374|DRUG|Ticagrelor|90mg tablet bid for 12 months
48373452|NCT04001374|DRUG|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
48373453|NCT00000147|DRUG|Methylprednisolone|
48373454|NCT00000147|DRUG|Prednisone|
48373455|NCT01632007|DRUG|SYR-472|
48373456|NCT01632007|DRUG|Alogliptin 25 mg|
48704709|NCT02867943|OTHER|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
48373457|NCT01632007|DRUG|Placebo|
48373458|NCT01934842|DEVICE|TAP20-C|
48373459|NCT01934842|DEVICE|SAFE-T-FILL|
48373460|NCT05117658|DRUG|HA121-28 tablet|HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
48016013|NCT06127251|DEVICE|Physical activity tracker|Participants will be asked to wear a ScanWatch tracker on their non-dominant hand for the entire duration of the study using a 24-hour wear protocol.
48373461|NCT02279602|DRUG|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
48016014|NCT06127251|BEHAVIORAL|Dietary education|The research team will examine diet quality and provide all study participants with educational content curated to promote diet quality. To minimize participants' burden, both the intervention and control arms will receive an email with a brief PDF addressing new diet components every 4 weeks
48373462|NCT02862002|OTHER|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
48373463|NCT02862002|OTHER|Standard care|patients receiving standard care of cancer pain.
48373464|NCT03383276|DRUG|IL-1Ra|custom eye drop to be applied to the left eye.
48373465|NCT01608321|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
48373466|NCT01608321|DEVICE|Sham device|Placebo Device that simulates active rTMS treatment
48373467|NCT00660153|DRUG|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
48373468|NCT02471898|DRUG|HTX-011|
48373469|NCT02471898|DRUG|Placebo|Saline
48373470|NCT01432743|PROCEDURE|NavX Fusion|Using NavX Fusion to guide catheter ablation
48373471|NCT01432743|PROCEDURE|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
48373472|NCT02071823|DRUG|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
48373473|NCT01733758|DRUG|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
48373474|NCT01733758|DRUG|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
48373475|NCT01733758|DRUG|Placebo|Albiglutide matching placebo will be available as a pen injector
48373476|NCT01733758|DRUG|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
48373477|NCT03015662|OTHER|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
48016015|NCT02726763|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
48016016|NCT02726763|BEHAVIORAL|Questionnaires|
48373478|NCT03015662|OTHER|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
48373479|NCT01150149|BEHAVIORAL|No face touch|
48373480|NCT01150149|DEVICE|Surgical face mask|
48373481|NCT01150149|DEVICE|Surgical face mask + no face touch|
48516653|NCT03838900|DEVICE|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
48516654|NCT03145415|PROCEDURE|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
48516655|NCT03145415|PROCEDURE|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
48704710|NCT06039436|DRUG|Anti-Thymocyte Globulin (Rabbit)|Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
48172656|NCT05214937|BEHAVIORAL|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action \& coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
48172657|NCT05214937|BEHAVIORAL|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
48704711|NCT02845622|DIETARY_SUPPLEMENT|Hazelnut|This dietary supplement contains 30 g of hazelnut.
48704712|NCT02845622|DIETARY_SUPPLEMENT|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
48704713|NCT02845622|DIETARY_SUPPLEMENT|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
48704714|NCT02845622|DIETARY_SUPPLEMENT|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
48016017|NCT04898218|OTHER|Exercise|The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
48016018|NCT00626977|DRUG|ropivacaine|15 ml of ropivacaine 0.125% peridural once
48172658|NCT02062112|OTHER|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
48172659|NCT01940406|PROCEDURE|Stimulation procedure|Device
48172660|NCT05774171|OTHER|no intervention|no intervention
48172661|NCT04921553|OTHER|Data collection and quality of life questionnaire|"* Data collection from the medical file~* Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
48373482|NCT06409182|DEVICE|Hemopill|HemoPill® acute capsule (Ovesco Endoscopy, Tuebingen, Germany) is a swallowable, wireless, sensor capsule designed for in vivo detection of liquid blood or hematin. The capsule has integrated optical microsensor for blood detection, by transmitting red and violet light via LEDs. It allows the detection of blood by photometric measuring method, in small volumes or in unprepared digestive tract. The dimensions of the capsules are 7.0mm x 26.3mm. The maximal examination time is 9 hours. The HemoPill® receiver is a portable receiver for displaying and storing measured values from the HemoPill® acute capsule. It allows a real-time, wireless, telemetric data transmission. Once activated, the HemoPill® acute capsule can be swallowed by patients with real-time measurement of HemoPill® Indicator (HI). An HI value in the red range suggests a positive finding - liquid blood or hematin has been detected.
48373483|NCT01273246|BIOLOGICAL|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
48516656|NCT02068313|RADIATION|Toxicity and outcome measures of IMRT|
48704715|NCT02845622|DIETARY_SUPPLEMENT|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
48704716|NCT05924698|OTHER|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
48516657|NCT03536741|PROCEDURE|TAP block and RS block + General Intravenous Anesthestic|transversus abdominis plane block and rectus sheath block
48704717|NCT05924698|OTHER|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
48704718|NCT01018134|DRUG|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
48516658|NCT03536741|DRUG|General Intravenous Anesthetic|General Intravenous Anesthetic
48704719|NCT01018134|DRUG|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
48016019|NCT00626977|DRUG|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
48016020|NCT05035069|DRUG|Ciprofol|Ciprofol infusion, starting with 0.8 \~ 1mg/kg/h until BIS value below 60 (including 60), and then 0.2 \~ 0.6mg/kg/h until the end of the operation, ciprofol infusion was adjusted to keep the BIS value between 40-60.
48016021|NCT05035069|DRUG|Propofol|Propofol infusion, starting with 4 \~ 5mg/kg/h until BIS value below 60 (including 60), and then 1 \~ 3mg/kg/h until the end of the operation, propofol infusion was adjusted to keep the BIS value between 40-60.
48516659|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
48172662|NCT03000647|PROCEDURE|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
48373484|NCT01273246|BIOLOGICAL|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
48016022|NCT06156215|BEHAVIORAL|Vaccine Messaging|"1. Video clips - short (approximately 3-minute) Public Service Announcement type videos to be viewed by participant using a QR code on their smartphone. If no smartphone is available, the video will be shown to the participant on an iPad.~2. Printed materials - one page information sheets handed to subjects by CRCs.~3. Face to face messaging - short (\< 1 minute), scripted message from the patient's providers in the ED (nurse or provider)~Each site will maintain a library of~A. 5 versions of the videos - the version used in any participant will be tailored to that participant's stated race/ethnicity.~B. 5 versions of printed flyers - likewise, the version will be tailored to the participant's stated race/ethnicity.~C. 1 version of scripted message to be delivered in English or Spanish."
48016023|NCT06156215|BEHAVIORAL|Vaccine Acceptance Question|"The last question in the Vaccine Acceptance Survey in both the Intervention M and Intervention Q arms of the study is Would you accept the COVID-19 booster vaccine in the emergency department today if your doctor asked you?"
48016024|NCT01435005|OTHER|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
48704720|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
48704721|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
48016025|NCT01435005|OTHER|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
48016026|NCT01117116|DRUG|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
48016027|NCT01117116|DRUG|budesonide and formoterol|80/4.5 two puffs twice daily
48016028|NCT06466395|DRUG|Venetoclax|Given by PO
48016029|NCT06466395|DRUG|Hyper-CVAD|Given by IV
48016030|NCT02565381|DRUG|Transdermal nicotine patch|"* ≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~* \<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
48016031|NCT02565381|BEHAVIORAL|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
48016032|NCT02565381|BEHAVIORAL|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide \<8ppm
48016033|NCT02565381|BEHAVIORAL|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
48016034|NCT03154619|DRUG|0.1% TR 987|TR 987 0.1%
48016035|NCT03154619|DRUG|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
48373485|NCT01273246|BIOLOGICAL|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
48373486|NCT01273246|BIOLOGICAL|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
48373487|NCT04271111|BEHAVIORAL|Online Treatment for Interpersonal Stress|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
48373488|NCT04271111|BEHAVIORAL|Physical Health Education Tool|Intervention designed to improve physical health through exercise, eating habits, and sleep
48373489|NCT04081727|DEVICE|Zip-stitch(TM)|The assigned intervention is used to close the cuff following colpotomy.
48516660|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
48516661|NCT00999817|DRUG|reference [dextromethorphan]|single 30 mg oral dose
48704722|NCT01018134|DRUG|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
48016036|NCT00036920|DRUG|canfosfamide hydrochloride|
48016037|NCT00005861|DRUG|pegylated liposomal doxorubicin hydrochloride|
48016038|NCT06532123|DEVICE|continence muscles resistance device|The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.
48016039|NCT05004922|OTHER|Embryo transfer into upper cavity|Transfer of embryos in upper cavity
48016040|NCT05004922|OTHER|Embryo transfer into midcavity|Transfer of embryos in mid cavity
48016041|NCT00718172|PROCEDURE|Liver Biopsy|
48016042|NCT00718172|DRUG|Peginterferon &amp; Ribavirin for Hepatitis C|
48516662|NCT00999817|DRUG|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
48516663|NCT00125671|DRUG|Warfarin|
48016043|NCT00718172|DRUG|Pre-treatment Ribavirin|
48704723|NCT01018134|DRUG|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
48704724|NCT04911244|DIAGNOSTIC_TEST|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
48704725|NCT04132830|OTHER|In Utero HIV Exposure|Born to mother who had HIV infection during pregnancy.
48704726|NCT04132830|OTHER|No In Utero HIV Exposure|Born to mother who did not have HIV infection during pregnancy.
48704727|NCT00675818|DEVICE|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
48172663|NCT03000647|PROCEDURE|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
48172664|NCT02643745|PROCEDURE|Nephrology Intervention|"1. pre-operative study:~   * Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~  * Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~2. optimise the patient' s overall condition with a pre-operative strategy:~   * Obesity control~  * Control protein, caloric, salt intake~  * Stop smoking~  * Good glycemic control~  * Start ACEI/ARA II if there is proteinuria~  * Start additional antihypertensive drug if required~  * Start hypolipemic treatment if required~  * Start hyperuricemia treatment if required~  * Start AAS, clopidogrel if it is necessary (prophylaxis)~  * Phosphate control~  * Anemia control~  * Metabolic acidosis correction"
48172665|NCT03500666|DEVICE|Robot|Robot lateral neck lymph node dissection
48172666|NCT03500666|DEVICE|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
48172667|NCT03430050|DRUG|Progesterone|Progesterone capsule
48172668|NCT03430050|DRUG|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
48172669|NCT02794714|DRUG|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
48172670|NCT02794714|DRUG|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
48172671|NCT03989583|OTHER|Infrared thermography|Temperature observation in foot and footwear in healthy children
48172672|NCT06383429|OTHER|forward head posture by using mobile application. And patients will fill out headache disability index.|forward head posture by using mobile application. And patients will fill out headache disability index.
48172673|NCT02261298|DRUG|ONO-4538|
48172674|NCT03200236|BEHAVIORAL|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
48172675|NCT03200236|BEHAVIORAL|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
48373490|NCT05332171|BEHAVIORAL|Pyhsiohterapy and rehabilitation|Before starting the exercise program, 10 repetitive warm-up exercises will be given including the lower and upper extremities and distal joints. The exercises will be started with 5 repetitions in the first week. Depending on the patient's tolerance, the intensity of the exercise will be increased as 10 repetitions, 15 repetitions and 20 repetitions, and optional rest will be allowed between exercises. It is aimed that the patients reach 20 repetitions in the 6th week at the latest.
48704728|NCT00675818|DEVICE|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
48172676|NCT06035185|PROCEDURE|apical shaping size|24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
48373491|NCT02583854|DEVICE|RY-STOP hemostasis device|
48704729|NCT06609018|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, soft contact lenses worn for one week
48704730|NCT06609018|DEVICE|Control Lenses (omafilcon A)|Daily disposable, soft contact lenses worn for one week
48172677|NCT04092049|OTHER|lollipop|chewing lollipop for 10 minutes
48704731|NCT00834470|DRUG|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
48704732|NCT05014815|DRUG|Ociperlimab|Ociperlimab intravenous injection
48704733|NCT05014815|DRUG|Tislelizumab|Tislelizumab intravenous injection
48172678|NCT01510132|DRUG|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
48373492|NCT02583854|DEVICE|TR-Band, Terumo|
48373493|NCT04698291|PROCEDURE|Blood Donation|The blood donation will take place at the Gene \& Health clinical assessment centre facilities. A trained member from Gene \& Health program will be responsible for taking the blood samples.
48373494|NCT05428176|OTHER|Best Practice|Receive usual care
48373495|NCT05428176|OTHER|Internet-Based Intervention|Undergo eHealth intervention
48704734|NCT05014815|DRUG|histology-based chemotherapy|Administered intravenously
48704735|NCT05014815|DRUG|Placebo|Administered as an intravenous injection
48704736|NCT00945529|DRUG|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
48704737|NCT04819438|DRUG|Riluzole 50 mg Oral Film|Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
48704738|NCT04819438|DRUG|Rilutek 50Mg Tablet|One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
48172679|NCT04889859|PROCEDURE|long Roux limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.
48172680|NCT04889859|PROCEDURE|long biliopancreatic limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
48172681|NCT00187343|DEVICE|Breast IMRT|
48172682|NCT03583411|OTHER|Epidemiological data collection|To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
48373496|NCT05428176|OTHER|Quality-of-Life Assessment|Ancillary studies
48373497|NCT05428176|OTHER|Questionnaire Administration|Ancillary studies
48373498|NCT05849051|BEHAVIORAL|Newly developed warnings with images at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning developed by the study team that includes an image. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
48373499|NCT05849051|BEHAVIORAL|FDA proposed text-only warnings at 30% size|On study days 1-6, 8-13 and 15-20, participants in this condition will view an image of a little cigar and cigarillo package with a warning proposed by the FDA which is text only. The warnings will take up 30% of the package. Participants will view a total of 6 different warnings over the course of 6 days each week, this will be repeated 3 times during the study, resulting in a total of 18 exposures. Participants will be required to view the warning for at least 5 seconds.
48373500|NCT04621604|OTHER|blood samples|Extra blood samples will be collected during chemotherapy administration to analyze pharmacokinetics of the iPD1
48373501|NCT01644968|DRUG|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
48373502|NCT01644968|DRUG|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
48373503|NCT01644968|DRUG|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
48373504|NCT01644968|BIOLOGICAL|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
48704739|NCT06335524|BEHAVIORAL|Finger puppet|The intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
48172683|NCT05957809|OTHER|Structured exercise training|"This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~* Strength training on unstable surfaces - 25-30 minutes~* High repetition muscular endurance training - 25-30 minutes~* Cool-down program - 10 minutes"
48172684|NCT02244268|DRUG|ALNA®|
48172685|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
48172686|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
48172687|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
48373505|NCT01644968|BIOLOGICAL|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
48704740|NCT06335524|BEHAVIORAL|Bookworm reading intervention training and routine EDI care.|Routine EDI care including Bookworm training.
48704741|NCT01018472|DIETARY_SUPPLEMENT|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
48373506|NCT01644968|BIOLOGICAL|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
48373507|NCT01644968|BIOLOGICAL|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
48373508|NCT03267199|DRUG|Thrombolytic|Thrombolytic therapy
48373509|NCT03267199|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention
48373510|NCT03267199|DIAGNOSTIC_TEST|Complete blood count|Blood sample for complete blood count
48704742|NCT01018472|OTHER|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
48704743|NCT05923294|PROCEDURE|Coronally advanced flap with connective tissue graft|In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
48704744|NCT01391572|RADIATION|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
48172688|NCT01476813|DRUG|Comparator|comparison of different dosages of drug versus comparator
48172689|NCT01965106|DRUG|QPI-1007 Injection|1.5 mg QPI-1007 Injection
48172690|NCT01965106|DRUG|(including placebo)|Sham injection procedure
48172691|NCT06475183|DIETARY_SUPPLEMENT|Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum|Bouchard Belgian Dark Chocolate Probiotic Napolitains containing 10 billion CFUs of bifidobacterium longum daily for 6 weeks
48172692|NCT01413022|DRUG|Oxaliplatin|
48172693|NCT01413022|DRUG|Irinotecan|
48172694|NCT01413022|DRUG|Leucovorin|
48172695|NCT01413022|DRUG|Fluorouracil|
48172696|NCT01413022|OTHER|laboratory biomarker analysis|Correlative studies
48373511|NCT03267199|DIAGNOSTIC_TEST|Platelet function test|Blood sample for platelet function test
48704745|NCT01391572|RADIATION|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
48704746|NCT01391572|DRUG|cisplatin|
48373512|NCT03267199|DIAGNOSTIC_TEST|ECG|Electrocardiogram
48373513|NCT03054272|BEHAVIORAL|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
48373514|NCT05662982|DEVICE|Northwestern University Flexible Subischial Suction Socket (NU-FlexSIS)|A custom-made prosthetic socket for transfemoral amputation that consists of proximal trimlines that do not interact with the pelvis.
48373515|NCT04298307|OTHER|Intracoronary lithotripsy (ICL)|ICL using the Shockwave catheter.
48373516|NCT05274620|BEHAVIORAL|IntelliCare|A mobile intervention that use principles of computerized therapy to decrease symptoms of depression
48704747|NCT01391572|DRUG|fluorouracil|
48172697|NCT01413022|OTHER|flow cytometry|Correlative studies
48172698|NCT01413022|OTHER|immunohistochemistry staining method|Correlative studies
48172699|NCT01413022|OTHER|pharmacological study|Correlative studies
48172700|NCT01413022|DRUG|PF-04136309|
48172701|NCT05530330|DIAGNOSTIC_TEST|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
48172702|NCT03585686|DRUG|Vemurafenib|vemurafenib 20 mg/kg/day
48172703|NCT03585686|DRUG|Cytarabine|100 mg/m2/12 h, days 1-5
48172704|NCT03585686|DRUG|2-chlorodeoxyadenosine|6 mg/m2/d, days 1-5
48172705|NCT05503693|DRUG|AP303 50 μg|AP303 tablet
48172706|NCT05503693|DRUG|AP303 150 μg|AP303 tablet
48172707|NCT05503693|DRUG|AP303 300 μg|AP303 tablet
48373517|NCT05710809|OTHER|Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement|Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
48172708|NCT05503693|DRUG|AP303 600 μg|AP303 tablet
48172709|NCT05503693|DRUG|Placebo 50 μg|Placebo tablet
48172710|NCT05503693|DRUG|Placebo 150 μg|Placebo tablet
48172711|NCT05503693|DRUG|Placebo 300 μg|Placebo tablet
48172712|NCT05503693|DRUG|Placebo 600 μg|Placebo tablet
48172713|NCT05967078|DEVICE|ExerG|"The intervention for primary end users (PEU, (patients)) includes the performance of two training rounds with the device. The first round includes a predefined training sequence, whereas the second round is a training sequence defined by the therapist.~For the secondary end user group (SEU, (therapists)), there are two study visits. At their first visit they get an introduction and training on how to use the system. At their second visit, SEU will have to prepare the device (switch on hard- and software) and guide the patient through the training."
48172714|NCT05784077|DIAGNOSTIC_TEST|Polysomnography|Study of the sleep pattern
48172715|NCT05784077|BEHAVIORAL|Lifestyle counselling|Weight loss counselling
48172716|NCT02925234|DRUG|Panitumumab|Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
48172717|NCT02925234|DRUG|Olaparib|Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
48704748|NCT04652375|OTHER|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
48704749|NCT04652375|OTHER|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
48172718|NCT02925234|DRUG|Dabrafenib|Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
48172719|NCT02925234|DRUG|Nilotinib|Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
48172720|NCT02925234|DRUG|Trametinib|Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
48172721|NCT02925234|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
48172722|NCT02925234|DRUG|Trastuzumab and Pertuzumab (combination treatment)|Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
48172723|NCT02925234|DRUG|Vemurafenib and Cobimetinib (combination treatment)|Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
48172724|NCT02925234|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
48373518|NCT01000909|PROCEDURE|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
48373519|NCT05635110|DRUG|VX-548|Tablets for oral administration.
48373520|NCT05635110|DRUG|Omeprazole|Tablets for oral administration.
48704750|NCT00005631|BIOLOGICAL|filgrastim|
48172725|NCT02925234|DRUG|Regorafenib|Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
48172726|NCT02925234|DRUG|Nivolumab|Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
48172727|NCT02925234|DRUG|Afatinib|Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.
48373521|NCT05635110|DRUG|Rifampin|Capsules for oral administration.
48373522|NCT04366258|DEVICE|Transcranial Photobiomodulator|Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).
48373523|NCT04366258|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
48373524|NCT05390294|PROCEDURE|Surgical intervention with or without postoperative adjuvant therapy|Surgical intervention with or without postoperative adjuvant therapy
48373525|NCT05142904|DEVICE|Radiofrequency ablation|Ultrasound-guided radiofrequency ablation of the solitary autonomous thyroid nodule.
48016044|NCT03328689|OTHER|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
48016045|NCT03328689|OTHER|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
48016046|NCT01338116|OTHER|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
48016047|NCT02294201|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent product
48016048|NCT02294201|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
48172728|NCT02925234|DRUG|Dabrafenib and trametinib|Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.
48172729|NCT02925234|DRUG|Ribociclib|Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.
48172730|NCT02925234|DRUG|Lenvatinib|Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.
48373526|NCT05142904|DRUG|Radioactive iodine|I-131 according to standardized doses-calculation.
48373527|NCT05142904|DRUG|Radioactive iodine|I-131 according to local standard.
48373528|NCT02156570|DRUG|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.
48373529|NCT00399542|DRUG|Lubiprostone|
48373530|NCT00399542|DRUG|Placebo|
48373531|NCT05648695|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA.
48373532|NCT05648695|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
48373533|NCT05850455|DRUG|Dexmedetomidine Hydrochloride 'Precedex' combined with|Dexmedetomidine Hydrochloride which is an Alfa 2 receptor agonist
48373534|NCT05850455|PROCEDURE|Lumbar epidural analgesia with Bupivacaine 0.25% 'Sunnypivacaine'|The epidural insertion point will be 2 segments upper than the surgical procedure level, 10 ml of Bupivacaine 0.25% will be injected in the epidural space to adjust the sensory level
48373535|NCT05850455|PROCEDURE|General anesthesia|Propofol 2-3 mg/kg'Diprivan 1%', Fentanyl 'Fentanyl' 2 μg/kg, and Cisatracurium 'Cisatracure' 0.2 mg/kg will be administered to facilitate endotracheal intubation, and ventilation will be controlled to maintain the end-tidal carbon dioxide (CO2) between 32-38 mmHg, to maintain anesthesia, 2-3% Sevoflurane 'Sevoflurane', and 0.05 mg/kg of the muscle relaxant Cisatracurium will be added at 40-minute intervals according to the conditions of the operation. No other medication will be administered
48373536|NCT05850455|DRUG|Local infiltration with Lidocaine HCL 1%'Debocaine'|Lidocaine 1% which is a local analgesic as local infiltration
48373537|NCT01447069|DRUG|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains \<100 bpm
48373538|NCT00038428|DRUG|TLK286|
48373539|NCT00361790|DRUG|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
48373540|NCT00715052|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
48373541|NCT04952376|BEHAVIORAL|SMS delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. Links to information or phone for scheduling will be provided. Messages mimic the clinic's usual practice of information delivery to patients
48704751|NCT00005631|BIOLOGICAL|rituximab|
48704752|NCT00005631|DRUG|carboplatin|
48704753|NCT00005631|DRUG|etoposide|
48704754|NCT00005631|DRUG|ifosfamide|
48373542|NCT04952376|BEHAVIORAL|Personalized text message delivery of information|Patients are informed via SMS that COVID-19 vaccine doses are available and advised to schedule an appointment. The SMS message is personalized as a recommendation from the primary care clinician
48373543|NCT04952376|BEHAVIORAL|Interactive or 2-way SMS delivery of information|This intervention is same as in the Arm 2 using personalized messaging from the PCP. In addition, patients are given interactive or 2-way SMS options to obtain additional information about COVID vaccine and answers to frequently asked questions.
48373544|NCT03722641|OTHER|Bread reference|Commercially available white wheat bread
48373545|NCT03722641|OTHER|Product 1: Milk|Developed reference product based on milk
48373546|NCT03722641|OTHER|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
48373547|NCT03722641|OTHER|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
48373548|NCT03722641|OTHER|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
48172731|NCT02925234|DRUG|Pembrolizumab|Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.
48172732|NCT02925234|DRUG|Durvalumab|Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.
48373549|NCT01348074|DRUG|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
48373550|NCT00390676|DRUG|ADH -1 and carboplatin|
48373551|NCT00390676|DRUG|ADH -1 and docetaxel|
48172733|NCT02925234|DRUG|Rucaparib|Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.
48172734|NCT02925234|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
48172735|NCT02925234|DRUG|Palbociclib|Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.
48172736|NCT02925234|DRUG|Crizotinib|Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.
48172737|NCT02925234|DRUG|Sunitinib|Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.
48172738|NCT02925234|DRUG|Cabozantinib|Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.
48172739|NCT02925234|DRUG|Abemaciclib|Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.
48704755|NCT06495229|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
48704756|NCT06466941|PROCEDURE|regional anesthesia|Patients who underwent surgery and received an epidural or peripheral nerve block
48016049|NCT02294201|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
48172740|NCT02925234|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
48172741|NCT02925234|DRUG|Atezolizumab and Bevacizumab|Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.
48373552|NCT00390676|DRUG|ADH -1 and capecitabine|
48373553|NCT00212082|DRUG|doxorubicin, docetaxel|
48373554|NCT00138723|DRUG|SPM 907|
48373555|NCT00154674|DEVICE|ICY catheter, Thermoguard device|
48373556|NCT00638820|PROCEDURE|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
48373557|NCT00638820|DRUG|Campath, Busulfan, Clofarabine|"* 12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~* 11 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 10 Campath-1H 0.3 mg/kg intravenously over 2 hours~* 9 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 8 Busulfan \<12 kg: 2.2 mg/kg/dose IV every 12 hours \>12 kg: 1.6 mg/kg/dose IV every 12 hours~* 7 Rest~* 6 Clofarabine 40 mg/m2 intravenously over 2 hours~* 5 Clofarabine 40 mg/m2 intravenously over 2 hours~* 4 Clofarabine 40 mg/m2 intravenously over 2 hours~* 3 Clofarabine 40 mg/m2 intravenously over 2 hours~* 2 Clofarabine 40 mg/m2 intravenously over 2 hours"
48373558|NCT00638820|PROCEDURE|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
48704757|NCT06466941|PROCEDURE|no regional anesthesia|Patients who underwent surgery and did not received an epidural or peripheral nerve block
48172742|NCT02925234|DRUG|Ipilimumab and nivolumab|Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.
48172743|NCT02925234|DRUG|Entrectinib|Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.
48704758|NCT06466941|OTHER|acute pain consultation|Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation
48704759|NCT06466941|OTHER|no acute pain consultation|Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
48016050|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using single needle approach|The primary outcome is to study the efficacy of the described technique which creates a lesion that we estimate to be 11.0-mm wide and 11.6-mm long along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score. Responder status was defined as a 30% or greater improvement in VAS pain score from the pre-procedural VAS pain score. Outcomes were summarized by means and standard deviations for continuous outcomes, and frequencies (%) for categorical outcomes.
48373559|NCT02198157|OTHER|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
48373560|NCT00961727|OTHER|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; \[1\] an expert derived, multi-centre validated severity of illness score, \[2\] an inter-professionally developed documentation record into which the severity of illness score is embedded, \[3\] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and \[4\] an educator-developed education-implementation program.
48373561|NCT03642002|OTHER|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
48704760|NCT01804582|OTHER|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
48704761|NCT06606262|PROCEDURE|Tonsillotomy|Bilateral partial removal of the palatine tonsils to a level between the pharyngeal pillars and the tonsillar capsule. Surgery will be performed under general anesthesia using monopolar electrocautery.
48016051|NCT05137652|DEVICE|Radiofrequency ablation of medial nerve using three needle approach|The primary outcome is to study the efficacy of the described technique by maximizing the lesion size (compared to control group) along the course of the medial branch adjacent to the SAP ensuring adequate coverage and treatment using VAS score.
48172744|NCT02925234|DRUG|Talazoparib|Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.
48172745|NCT02925234|DRUG|Dacomitinib|Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.
48373562|NCT03642002|OTHER|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
48373563|NCT03642002|OTHER|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
48373564|NCT03642002|BEHAVIORAL|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
48373565|NCT03642002|OTHER|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
48373566|NCT01842412|BEHAVIORAL|exercise|one bout of exercise training
48373567|NCT05180734|BIOLOGICAL|JS001/Placebo|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
48373568|NCT05180734|BIOLOGICAL|JS001/placebo combine with Postoperative Adjuvant Chemotherapy|JS001/placebo combine with Postoperative Adjuvant Chemotherapy
48016052|NCT06534216|DIAGNOSTIC_TEST|Intestinal ultrasound|This study employs intestinal ultrasound (IUS) to assess disease activity in Inflammatory Bowel Disease (IBD) patients. Ultrasound parameters include bowel wall thickness measurement, evaluation of vascularization via color Doppler, assessment of wall stratification, and identification of mesentery features and complications (e.g., strictures, fistulas, abscesses). For ulcerative colitis, disease activity is gauged using the Milan Ultrasound Criteria (MUC), where a score \>6.3 indicates active disease based on bowel wall thickness and vascularization. In Crohn's disease, the Bowel Ultrasound Score (BUSS) and International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) assess bowel wall thickness, vascularization, stratification, and inflammatory fat, with scores \>3.52 (BUSS) and \>48.7 (IBUS-SAS) indicating active disease. IUS evaluations occur at baseline, 2-6 weeks, 12 weeks, and 6-12 months to track disease progression and treatment response.
48516664|NCT05733273|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
48516665|NCT05733273|OTHER|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
48704762|NCT06606262|PROCEDURE|Tonsillectomy|"Bilateral extracapsular removal of palatine tonsils. Surgery will be performed under general anesthesia using cold knife dissection."
48704763|NCT05133622|OTHER|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
48016053|NCT05433558|OTHER|Neuropsychological Rehabilitation|Neuropsychological Rehabilitation
48016054|NCT01111656|DRUG|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
48016055|NCT01111656|DRUG|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
48016056|NCT05397379|DRUG|HEC96719|Oral tablets
48016057|NCT05397379|DRUG|Placebo|Comparator
48172746|NCT02925234|DRUG|Lorlatinib|Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.
48172747|NCT02925234|DRUG|Erdafitinib|Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.
48172748|NCT02925234|DRUG|Alpelisib|Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.
48172749|NCT02925234|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.
48172750|NCT02925234|DRUG|Pemigatinib|Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.
48172751|NCT02925234|DRUG|Selpercatinib|Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.
48373569|NCT05054985|DEVICE|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
48172752|NCT02925234|DRUG|Tepotinib|Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.
48172753|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
48373570|NCT06145945|DRUG|0.5% Ropivacaine|20ml 0.5% ropivacaine is sprayed intraperitoneally
48373571|NCT06145945|DRUG|Saline|20ml saline is sprayed intraperitoneally
48373572|NCT05371262|DRUG|Levothyroxin|Congenital hypothyroidism children received two different doses of levothyroxin within the recommended range to evaluate any differences in long-term outcomes.
48172754|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
48172755|NCT04376112|OTHER|Pharmacist and pillpack intervention|These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.
48172756|NCT04376112|OTHER|Standard of care|None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
48172757|NCT03158129|DRUG|Carboplatin|Given IV
48172758|NCT03158129|DRUG|Cisplatin|Given IV
48172759|NCT03158129|DRUG|Docetaxel|Given IV
48172760|NCT03158129|BIOLOGICAL|Ipilimumab|Given IV
48172761|NCT03158129|BIOLOGICAL|Nivolumab|Given IV
48172762|NCT03158129|DRUG|Pemetrexed|Given IV
48172763|NCT05321771|OTHER|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
48172764|NCT05413863|BIOLOGICAL|Biocon's Human Insulin R U-500|Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).
48172765|NCT05413863|BIOLOGICAL|Humulin® R U-500 (US Reference Product)|Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
48172766|NCT05510622|OTHER|Vaginal swab and endometrial biopsy|A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
48172767|NCT01051102|DRUG|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
48172768|NCT01051102|DRUG|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
48172769|NCT03671239|BEHAVIORAL|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
48172770|NCT03671239|BEHAVIORAL|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
48172771|NCT03671239|BEHAVIORAL|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
48172772|NCT04036253|BIOLOGICAL|Erythropoietin alfa|Prefilled syringes of erythropoietin
48172773|NCT04531813|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
48172774|NCT04531813|DRUG|Positive Control-Sodium lauryl sulfate (SLS)|Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
48172775|NCT04531813|OTHER|Negative Control|A blank patch was applied to the Negative Control test site.
48172776|NCT00383747|DRUG|transdermal nicotine patch|14mg transdermal nicotine application
48172777|NCT00383747|DRUG|Transdermal Nicotine Patch|14mg transdermal nicotine application
48373573|NCT00926146|BEHAVIORAL|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
48373574|NCT00926146|BEHAVIORAL|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
48373575|NCT02526368|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
48373576|NCT02526368|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
48373577|NCT02526368|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
48373578|NCT03721614|DEVICE|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
48016058|NCT01823393|DRUG|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
48016059|NCT01823393|DRUG|NaCl|valvuloplasty is performed without heparin (placebo injection)
48016060|NCT01085175|DRUG|LMI 1195|Single bolus intravenous injection of LMI 1195
48172778|NCT03972865|OTHER|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
48172779|NCT04239950|DRUG|Placebo|Placebo
48172780|NCT04239950|DRUG|Ethyl Icosapentate|Ethyl Icosapentate
48172781|NCT05692271|DRUG|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
48172782|NCT05692271|DRUG|Placebo|Matching placebo
48172783|NCT01963572|OTHER|SG will be screened every time when they visit the clinics.|
48172784|NCT04651309|OTHER|Transperineal Ultrasound|The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
48172785|NCT03002922|DRUG|BAY987517|Sunscreen formula Y65-158
48172786|NCT04785716|DRUG|Niraparib|Niraparib provided through the patient access program
48172787|NCT00231764|DRUG|daclizumab|
48172788|NCT01721083|PROCEDURE|Procedure: Z-track|Subject received immunization by z-track
48172789|NCT01721083|PROCEDURE|Procedure: Bunch|Subject receives immunization by bunch method.
48172790|NCT05426161|DRUG|Botulinum Toxin A|Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
48172791|NCT00944996|DRUG|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
48172792|NCT01395498|OTHER|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
48172793|NCT00092521|BIOLOGICAL|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
48172794|NCT00092521|BIOLOGICAL|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
48016061|NCT06072066|DIETARY_SUPPLEMENT|Skin Barrier Oral Supplement|Supplment powder
48016062|NCT04054648|OTHER|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
48016063|NCT03258476|DRUG|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
48172795|NCT00092521|BIOLOGICAL|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
48172796|NCT04011397|OTHER|Exercise intervention|Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
48172797|NCT04011397|BEHAVIORAL|Usual care|Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
48016064|NCT03258476|BEHAVIORAL|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
48016065|NCT03258476|DRUG|Placebo|Placebo oral capsule
48172798|NCT02841345|OTHER|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
48172799|NCT00238719|DRUG|Venlafaxine ER|
48172800|NCT04198493|DEVICE|CPAP|CPAP treatment every night plus conservative treatment for OSA: sleep hygiene and dietary counseling
48172801|NCT04198493|OTHER|CONSERVATIVE TREATMENT for OSA|Conservative treatment for OSA: sleep hygiene and dietary counseling
48016066|NCT01494233|DRUG|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
48016067|NCT01494233|DRUG|Placebo tablet|Matching placebo tablet administered orally
48016068|NCT02752412|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48172802|NCT04753944|DIETARY_SUPPLEMENT|Active Comparator: Probiotic|The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
48172803|NCT04753944|DIETARY_SUPPLEMENT|Placebo group|Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
48172804|NCT02732002|PROCEDURE|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
48172805|NCT02478385|OTHER|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
48172806|NCT03772509|OTHER|CATI|The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
48172807|NCT04111900|BEHAVIORAL|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
48172808|NCT04431752|RADIATION|Magnetic Resonance Imaging Scan|The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
48172809|NCT04513275|DRUG|non-medicine intervention|rating by MCCB only one time
48172810|NCT04409522|DRUG|Melatonin|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
48172811|NCT04409522|DRUG|The usual treatment|Participants in this group will receive the usual treatment of COVID-19
48172812|NCT04077814|DEVICE|Foot Drop Stimulatio - Neuro Orthosis|Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
48172813|NCT04077814|DEVICE|Transcranial direct brain stimulation|Transcranial direct brain stimulation on motor cortex
48373579|NCT03721614|DEVICE|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
48373580|NCT04721431|DIAGNOSTIC_TEST|Myotonometric assessment|MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
48373581|NCT00491595|DRUG|High Dose Soy isoflavones|
48516666|NCT05733273|OTHER|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
48373582|NCT06309069|OTHER|None, purely observational study|None, purely observational study
48373583|NCT03808415|DEVICE|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
48373584|NCT04109573|PROCEDURE|high resolution anal manometry|functional studies before and after anal laser ablation
48373585|NCT00012350|DRUG|FTI|
48373586|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
48016069|NCT02752412|DRUG|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48016070|NCT02752412|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
48016071|NCT02302105|RADIATION|IGRT|Image Guided RT to the prostate
48016072|NCT06663748|DRUG|ARX788|2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
48373587|NCT05832073|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
48516667|NCT00245687|DEVICE|Tiger Tube|
48516668|NCT05532709|OTHER|Plyometric training|m level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps
48172814|NCT02072798|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
48172815|NCT01977183|DIETARY_SUPPLEMENT|MSPrebiotic|Potato Resistant Starch
48172816|NCT01977183|DIETARY_SUPPLEMENT|Placebo|Placebo - Corn Starch
48172817|NCT02869815|PROCEDURE|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
48172818|NCT00865813|PROCEDURE|Punch Biopsy|"1. Instillation of anesthetic eye drops.~2. Asepsis~3. Placement of surgical cloths and drapes~4. Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~5. Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~6. Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
48172819|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
48172820|NCT02160470|BEHAVIORAL|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
48172821|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
48172822|NCT02160470|BEHAVIORAL|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
48516669|NCT05532709|OTHER|Circuit training|"The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes."
48516670|NCT03435471|OTHER|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
48516671|NCT03435471|OTHER|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
48016073|NCT04003597|OTHER|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
48016074|NCT04003597|OTHER|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (\<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
48016075|NCT02624102|BEHAVIORAL|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
48016076|NCT02624102|BEHAVIORAL|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
48016077|NCT02624102|DRUG|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
48016078|NCT03033797|DEVICE|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
48016079|NCT03033797|DEVICE|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
48016080|NCT05226962|DIETARY_SUPPLEMENT|Ketone monoester|A commercial liquid supplement ingested in a dose intended to provide \~0.35 g of ketone monoester per kg body mass of the participant
48016081|NCT05226962|OTHER|Placebo|A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
48016082|NCT05798507|DRUG|Avutometinib|Given PO
48172823|NCT00644956|DRUG|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
48172824|NCT00644956|DRUG|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
48516672|NCT04358055|DEVICE|WET® gel|In each application, a puff should be administered in each nostril every two seconds, with minimal inspirations, up to a sensation of lubrication in the external conduct is perceived. Then the patient should proceed with short inspirations and light touching of ala of the nose, to favour the distribution of the gel. A maximum of 4 erogations (2/nostril) is allowed in each application session.
48516673|NCT05932043|DIAGNOSTIC_TEST|This is a non-interventional study|None (this is a non-interventional study)
48016083|NCT05798507|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
48172825|NCT05006417|DRUG|Botox|reconstituted at 100 units/mL, dosage will be based upon the affected muscles
48172826|NCT00120185|DRUG|Interleukin-2|
48016084|NCT05798507|DRUG|Defactinib|Given PO
48016085|NCT01837316|DRUG|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
48016086|NCT01837316|DRUG|Placebo|First strip: Inhalation powder of lactose
48016087|NCT01723891|DRUG|Surfolase capsule|
48016088|NCT01723891|DRUG|HT-002-01|
48016089|NCT04139590|DEVICE|Panda|
48016090|NCT04139590|DEVICE|Visual Analogue Scale - Original|
48172827|NCT02886169|OTHER|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
48172828|NCT02886169|OTHER|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
48172829|NCT00237861|DRUG|risperidone|
48172830|NCT00237861|DRUG|olanzapine|
48172831|NCT00237861|DRUG|quetiapine|
48172832|NCT02674009|DRUG|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
48016091|NCT04738708|OTHER|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
48016092|NCT05543746|DRUG|Brexanolone|Enrolled subjects will receive a 60-hour infusion of Brexanolone (BRX) according to FDA approved protocol for administration. A programmable peristaltic infusion pump will be used to ensure accurate delivery.
48172833|NCT02940210|DEVICE|Mediclore® (adhesion barrier)|
48516674|NCT06077474|OTHER|Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)|Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
48016093|NCT01343160|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
48016094|NCT02985736|DRUG|Topicort Topical Spray|
48016095|NCT06072612|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
48016096|NCT06072612|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
48016097|NCT06072612|DRUG|Interferon infiltration of the inoculation site|Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
48172834|NCT01010997|DEVICE|Foresee Home|using the Foresee home device
48172835|NCT04114812|OTHER|Blended learning|In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
48172836|NCT04114812|OTHER|Standard course|In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
48172837|NCT00381888|DRUG|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
48516675|NCT05982002|DEVICE|shock wave|ESWT (Chattanooga, Intelect RPW, USA) continues mode, hand piece transmitter R SW D20 /20mm, with the following Parameter: Shock pressure of 3-4 bars, wave frequency of 12 Hz.
48016098|NCT06072612|DRUG|Retifanlimab|Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
48172838|NCT02220777|DRUG|ASP8477|oral
48172839|NCT02220777|DRUG|omeprazole|oral
48016099|NCT06072612|DRUG|Treatment of Physician's Choice|Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
48016100|NCT02039427|DRUG|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
48172840|NCT02220777|DRUG|Placebo|oral
48016101|NCT02039427|OTHER|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
48016102|NCT02039427|DRUG|Placebo|Normal saline 2 ml
48172841|NCT02175745|DRUG|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
48373588|NCT05832073|DRUG|Natural full human monoclonal antibody CBB 1 injection placebo|Composition: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
48016103|NCT04166149|DIAGNOSTIC_TEST|dd-cfDNA Blood Test|The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
48016104|NCT03623828|DRUG|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
48172842|NCT02175745|PROCEDURE|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
48172843|NCT02175745|PROCEDURE|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
48172844|NCT02175745|PROCEDURE|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
48172845|NCT00826228|DRUG|teriparatide|teriparatide 20ug daily sc for 6 months
48172846|NCT00826228|OTHER|weight-bearing|device assisted walking
48373589|NCT05832073|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
48373590|NCT04752007|RADIATION|ASLR; CT; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
48373591|NCT04752007|RADIATION|Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
48704764|NCT05133622|OTHER|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
48016105|NCT04809129|DEVICE|Weighted vest|Patients will wear a weighted vest following bariatric surgery with weight increased incrementally to maintain baseline weight. This vest will be worn for a minimum of 8 hours a day for three months postoperatively.
48373592|NCT04752007|RADIATION|Supine; CT; SI joint movement: supine position|Baseline position
48016106|NCT03992690|DEVICE|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
48016107|NCT03992690|DEVICE|Training with traditional physiotherapy protocol|Stretching
48172847|NCT05829135|DEVICE|Acuvue Oasys with Transitions|soft contact lenses with darkening technology
48172848|NCT01817712|BEHAVIORAL|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
48172849|NCT01817712|BEHAVIORAL|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
48172850|NCT06160011|OTHER|Electrical dry needling + Conventional physiotherapy|Electrical dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
48172851|NCT06160011|OTHER|Dry needling + Conventional physiotherapy|Dry needling and conventional physiotherapy treatment (massage, pressure release): 2 sessions
48172852|NCT06160011|OTHER|Conventional physiotherapy|Conventional physiotherapy treatment (massage, pressure release): 2 sessions
48172853|NCT06339710|DRUG|benznidazole 300 mg daily 8 weeks|672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)
48373593|NCT04752007|RADIATION|ASLR; RSA; SI joint movement: stright leg raise with 1 kg load|Measurement of the SI joint movement in mikrometer
48516676|NCT05982002|OTHER|Moderate intensity aerobic exercise|Treadmail training exercise 60%-75% of Maximum heart rate MHR 2 times/ week
48172854|NCT03632902|DEVICE|supraglottic device|airway management will be collected
48172855|NCT00008320|DRUG|ceramide|
48172856|NCT02807961|DRUG|ELX-02|Synthetic aminoglycoside
48172857|NCT02807961|DRUG|Placebo|Placebo comparator
48373594|NCT04752007|RADIATION|Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load|Measurement of the SI joint movement in mikrometer
48373595|NCT04752007|RADIATION|Supine; RSA; SI joint movement: supine position|Baseline position
48373596|NCT01730222|DRUG|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
48373597|NCT01730222|DRUG|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
48373598|NCT01730222|DRUG|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
48373599|NCT01730222|DRUG|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
48373600|NCT02267421|BEHAVIORAL|Home based Aerobic exercise training|
48516677|NCT05982002|OTHER|Energy-restricted diet|energy intake was 500K calorie below daily requirements on average three meals at the same time of the day
48373601|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT|Quadriceps tendon with pattlar bone will used for grating
48373602|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT|Hamstring tendon with will used for grating
48172858|NCT05887141|BEHAVIORAL|Double Standards|We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).
48172859|NCT05887141|BEHAVIORAL|Self-criticism avatar|We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).
48172860|NCT01351337|PROCEDURE|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
48172861|NCT04668521|OTHER|OVA360|Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
48172862|NCT00905359|PROCEDURE|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
48172863|NCT00905359|PROCEDURE|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
48172864|NCT04353817|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration qd in the morning.
48172865|NCT04353817|DRUG|IVA|Tablet for oral administration qd in the evening.
48172866|NCT04353817|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
48172867|NCT04353817|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration qd in the evening.
48172868|NCT06308666|DEVICE|Delefilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of myopia and hyperopia
48172869|NCT04069533|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
48172870|NCT01700322|PROCEDURE|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
48373603|NCT04742868|PROCEDURE|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT|Quadriceps tendon without pattlar bone will used for grating
48373604|NCT04742868|OTHER|Rehabilitation protocol|All patients will receive six months rehabilitation program which aim to recover the strength and function
48373605|NCT04669275|BEHAVIORAL|Telephone Counselıng|Telephone counseling
48016108|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
48172871|NCT01700322|DRUG|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
48172872|NCT01700322|DRUG|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
48172873|NCT01700322|DRUG|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
48373606|NCT01157819|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
48373607|NCT01157819|DRUG|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
48373608|NCT02110589|DEVICE|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
48172874|NCT05183243|DRUG|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
48172875|NCT02392663|OTHER|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
48373609|NCT02641028|DRUG|CERC-501|CERC-501
48373610|NCT02641028|DRUG|Placebo|Placebo
48172876|NCT02392663|OTHER|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
48373611|NCT04997200|BEHAVIORAL|One night's sleeplessness|A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
48373612|NCT00070070|BIOLOGICAL|TICE®-strain BCG|
48373613|NCT00070070|BIOLOGICAL|NY-ESO-1 protein|
48373614|NCT00070070|BIOLOGICAL|sargramostim|
48373615|NCT03148509|DRUG|risperidone|DA receptor-mediated drugs
48373616|NCT03148509|DRUG|aripiprazole|DA receptor-mediated drugs
48373617|NCT03148509|DRUG|bupropion|DA receptor-mediated drugs
48373618|NCT04657627|BEHAVIORAL|PACE plus calorie labelling information|The intervention group will be exposed to PACE plus calorie labelling information via Instagram and Twitter social media posts every day for 13 weeks.
48373619|NCT04657627|BEHAVIORAL|Calorie-only labelling information|The comparator group will be exposed to calorie-only labelling information via Instagram and Twitter social media posts every day for 13 weeks.
48373620|NCT03044327|PROCEDURE|LPS challenge|LPS inhalation and bronchial instillation
48016109|NCT03477890|DIAGNOSTIC_TEST|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
48016110|NCT03835260|DEVICE|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
48373621|NCT00694226|BEHAVIORAL|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
48016111|NCT06292143|OTHER|Advance Care Planning Toolkit|Participants or their caregivers will access the digital platform for advance care planning
48016112|NCT06663501|DEVICE|Assisted Motion with Enhanced Sensation training|During the AMES intervention, the AMES device will flex or extend the wrist/hand joint, and the participant's task will be to assist this motion. As the wrist/hand joint moves, the machine will be delivering a vibratory mechanical stimulus on the opposite side to the direction of movement. The activity of the muscles during the movement of the wrist/hand joint will be recorded by the device and it will be shown on a screen to be used as feedback during the training
48016113|NCT04428138|DIAGNOSTIC_TEST|In-office vascular visit|Every patient will undergo a complete physical examination in order to detect any clinical or sub clinical vascular disease.
48016114|NCT04428138|DIAGNOSTIC_TEST|Echo duplex scan of arterial system|Every patient will undergo a complete echo duplex scan in order to detect any morphological or hemodynamic alteration of aorta, carotid arteries and lower limb arteries.
48016115|NCT01560624|DRUG|Treprostinil Diolamine|Active
48016116|NCT01560624|DRUG|Placebo|Placebo
48016117|NCT06211647|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at fixed dose levels at an interval of 6 weeks between each dose.
48016118|NCT01218854|DEVICE|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
48016119|NCT06572800|DEVICE|DiviTum-TKa|Analyze blood samples by DiviTum-TKa
48016120|NCT04257578|DRUG|Acalabrutinib|Given PO
48016121|NCT04257578|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
48016122|NCT04650828|DRUG|TDF|TDF combined with telbivudine (LDT) for 12 months
48172877|NCT02392663|OTHER|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
48016123|NCT04650828|DRUG|Tenofovir Disoproxil Fumarate 300 MG|TDF monotherapy was continued for 12 months
48016124|NCT06663878|GENETIC|MWAV201|Nonreplicating, recombinant gene transfer vector
48172878|NCT04134884|DRUG|Talazoparib|Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
48172879|NCT04134884|DRUG|ASTX727|ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
48172880|NCT02803593|BEHAVIORAL|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
48172881|NCT02803593|BEHAVIORAL|American Cancer Society information on breast cancer|The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
48172882|NCT03090971|DRUG|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
48704765|NCT05133622|OTHER|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
48704766|NCT05133622|OTHER|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
48704767|NCT05133622|OTHER|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
48172883|NCT03090971|DRUG|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
48172884|NCT00610805|OTHER|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
48172885|NCT00610805|OTHER|Usual Care|Participants will receive usual care per their primary care physician.
48172886|NCT04049370|OTHER|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
48172887|NCT01681199|DRUG|Fluvastatin extended release tablet|
48172888|NCT02927652|OTHER|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
48172889|NCT00796627|GENETIC|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
48172890|NCT00796627|OTHER|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
48172891|NCT03161223|DRUG|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg"
48172892|NCT03161223|DRUG|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2"
48172893|NCT03161223|DRUG|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2"
48172894|NCT03161223|DRUG|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily"
48172895|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
48172896|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
48172897|NCT05097209|DRUG|Camrelizumab|Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
48172898|NCT05097209|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
48172899|NCT05097209|DRUG|Induction Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
48373622|NCT00694226|BEHAVIORAL|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
48373623|NCT05816525|PROCEDURE|Partial removal of carious tissue|Nonselective carious tissue excavation will be performed in the periphery of the cavity to achieve a good marginal seal. In the pulpal wall selective, partial carious tissue excavation is performed to the soft dentin, removing tissue only the amount that is necessary for placing the restoration. The tooth is restored with high-viscosity glass-ionomer cement.
48373624|NCT05816525|PROCEDURE|Final restoration|The teeth will be restored with composite resin after 12 months follow up, if the tooth is asymptomatic, responds to sensibility tests and there are no periapical changes radiographically. Glass ionomer cement will be only partially removed to create space for the final restoration.
48704768|NCT05133622|OTHER|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
48704769|NCT05133622|OTHER|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
48704770|NCT00201448|BIOLOGICAL|Hepatitis A Vaccine|Single dose give IM
48704771|NCT00201448|BIOLOGICAL|Towne CMV Vaccine|Single dose given subcutaneously
48704772|NCT00101816|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
48704773|NCT00411827|PROCEDURE|PRK with conjunctival impression cytology before and after surgery|
48704774|NCT00411827|PROCEDURE|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
48172900|NCT05097209|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
48172901|NCT05097209|DRUG|Concurrent cisplatin|Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
48172902|NCT04232800|DRUG|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
48172903|NCT04232800|OTHER|Placebo|An inert, standard placebo in identical capsules to primary intervention.
48373625|NCT01411124|DRUG|gabapentin enacarbil|600 mg investigational compound
48373626|NCT01411124|DRUG|diphenhydramine|50 mg active comparator
48373627|NCT01411124|DRUG|placebo|placebo
48704775|NCT03970096|RADIATION|Total-Body Irradiation|Undergo TBI
48704776|NCT03970096|DRUG|Thiotepa|Given IV
48704777|NCT03970096|DRUG|Fludarabine|Given IV
48704778|NCT03970096|DRUG|Tacrolimus|Given IV
48704779|NCT03970096|BIOLOGICAL|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
48704780|NCT03970096|DRUG|Methotrexate|Given IV
48704781|NCT03970096|DRUG|Cyclophosphamide|Given IV
48704782|NCT03970096|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
48704783|NCT03970096|DRUG|Cyclosporine|Given IV
48704784|NCT03970096|DRUG|Sirolimus|Given IV
48704785|NCT03970096|DRUG|Busulfan|Given IV
48704786|NCT03970096|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
48704787|NCT03970096|PROCEDURE|Echocardiography|Undergo ECHO
48704788|NCT03970096|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48704789|NCT03970096|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48704790|NCT03831880|DRUG|Genotropin|Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
48704791|NCT03831880|DRUG|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
48704792|NCT01703689|BEHAVIORAL|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
48373628|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
48373629|NCT00927277|DEVICE|Erchonia(R) LipoLASER PL|
48704793|NCT01703689|BEHAVIORAL|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
48704794|NCT01159171|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
48704795|NCT01159171|DRUG|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
48704796|NCT01159171|DRUG|oxaliplatin|40 mg/m2 iv weekly
48704797|NCT02899221|RADIATION|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
48704798|NCT02899221|PROCEDURE|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
48704799|NCT02899221|OTHER|Laboratory Biomarker Analysis|Correlative studies
48704800|NCT00416663|PROCEDURE|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
48704801|NCT04172415|OTHER|Retrospective cohort|Chart Review
48704802|NCT06301724|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48704803|NCT06301724|DRUG|Lidocaine hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48704804|NCT00010387|DRUG|cyclophosphamide|
48704805|NCT00010387|DRUG|filgrastim|
48704806|NCT01398332|DEVICE|Stent graft (EXCLUDER)|Endovascular repair
48373630|NCT06377267|DRUG|Bevacizumab|Bevacizumab dosing is at 15 mg/kg every 3 weeks as an intravenous infusion.
48704807|NCT01575938|BEHAVIORAL|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
48704808|NCT01575938|BEHAVIORAL|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
48704809|NCT04484896|OTHER|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
48704810|NCT04484896|OTHER|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
48704811|NCT04484896|OTHER|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
48704812|NCT02925078|DEVICE|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with \<2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
48704813|NCT02871713|OTHER|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
48704814|NCT02871713|OTHER|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
48704815|NCT03666507|PROCEDURE|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
48704816|NCT03018418|RADIATION|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
48704817|NCT03018418|DRUG|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
48704818|NCT01926418|BEHAVIORAL|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
48704819|NCT06607484|DRUG|SR-878|Intravenous infusion
48704820|NCT06607484|DRUG|Placebo|Intravenous infusion
48704821|NCT05731908|DRUG|BI 690517|BI 690517
48373631|NCT06377267|DRUG|Olaparib|Olaparib dosing is oral at 300 mg twice daily
48373632|NCT03666494|DRUG|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
48704822|NCT04134117|BIOLOGICAL|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
48704823|NCT04182321|DRUG|Metformin & Entecavir|Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
48704824|NCT04182321|DRUG|Placebo & Entecavir|Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
48704825|NCT06584331|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
48704826|NCT06584331|DIETARY_SUPPLEMENT|2 doses of Beetroot juice intake|This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
48704827|NCT06584331|DIETARY_SUPPLEMENT|Placebo|In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
48704828|NCT03783468|OTHER|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
48704829|NCT03878030|DRUG|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
48704830|NCT03036345|DEVICE|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
48704831|NCT01349322|RADIATION|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
48373633|NCT03666494|DRUG|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
48373634|NCT03666494|DRUG|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
48373635|NCT03892967|OTHER|Interview|Participate in interview
48373636|NCT03892967|OTHER|Quality-of-Life Assessment|Ancillary studies
48373637|NCT03892967|OTHER|Questionnaire Administration|Ancillary studies
48373638|NCT02277665|BEHAVIORAL|CUD Treatment|
48373639|NCT02277665|BEHAVIORAL|Tobacco Treatment|
48704832|NCT01349322|RADIATION|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
48704833|NCT01349322|RADIATION|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
48704834|NCT01349322|RADIATION|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
48704835|NCT05371080|BIOLOGICAL|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
48373640|NCT02345499|PROCEDURE|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
48373641|NCT02345499|PROCEDURE|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
48373642|NCT03389633|OTHER|rehabilitation|
48373643|NCT01704482|DRUG|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
48373644|NCT01704482|DRUG|placebo|
48373645|NCT01481064|BEHAVIORAL|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
48373646|NCT01367366|PROCEDURE|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
48373647|NCT02190604|DRUG|Placebo|Capsule- oral dose
48373648|NCT02190604|DRUG|QBW251|Capsule - oral dose
48373649|NCT00003526|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48373650|NCT05235633|DIAGNOSTIC_TEST|Assessment of the accomplishment regarding Activities of Daily Living at the end of acute treatment|Participants perform a test battery to assess the capability to accomplish Activities of Daily Living that includes a standardized and validated questionnaire, a parcour with tasks based on Activities of Daily Living and a motor performance test.
48373651|NCT01671462|DEVICE|BD HPV assay on Viper LT|
48704836|NCT05131399|DEVICE|Phase A1|Plastic standard ankle foot orthosis
48704837|NCT05131399|DEVICE|Phase B1|carbon medical device ankle foot orthosis
48704838|NCT05131399|DEVICE|Phase A2|Plastic standard ankle foot orthosis
48704839|NCT05131399|DEVICE|Phase B2|carbon medical device ankle foot orthosis
48704840|NCT04527991|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
48373652|NCT04516798|OTHER|vibration|local and whole-body vibration were applied
48373653|NCT03247608|BEHAVIORAL|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
48373654|NCT02686437|OTHER|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
48373655|NCT00483119|DRUG|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
48373656|NCT00483119|DRUG|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
48704841|NCT04527991|DRUG|Paclitaxel|Administered intravenously
48704842|NCT04527991|DRUG|Docetaxel|Administered intravenously
48704843|NCT04527991|DRUG|Vinflunine|Administered intravenously
48704844|NCT02901002|OTHER|Sensory testing in the two hand|spontaneous sensations while watching a hand
48373657|NCT02444676|OTHER|Stratification and outcomes|No necessary
48373658|NCT02272738|DRUG|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
48373659|NCT02272738|DRUG|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
48373660|NCT02847663|DEVICE|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
48373661|NCT02847663|OTHER|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
48373662|NCT01347905|OTHER|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
48373663|NCT03301792|BEHAVIORAL|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
48373664|NCT02976961|OTHER|Supportive care|Information, guidance, supportive care, and psychological intervention
48373665|NCT00943007|DEVICE|Stealth Station|Neuronavigation based on preoperative MRI
48704845|NCT02901002|OTHER|Neuropsychological evaluation|Score to anxiety-depression scale
48704846|NCT00004552|DRUG|acamprosate (Campral)|
48704847|NCT05615675|OTHER|Virtual Reality Headset|Patient uses a virtual reality headset and support during prone pain procedure
48373666|NCT00943007|DEVICE|PoleStar N20|Intraoperative MRI guided surgery
48172904|NCT02643511|RADIATION|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
48704848|NCT01415648|OTHER|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
48704849|NCT01415648|OTHER|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
48704850|NCT03389555|DRUG|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
48373667|NCT01493791|DRUG|CDB-2914|
48373668|NCT04537286|DRUG|nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
48373669|NCT05100693|OTHER|Fetoscopic Endoluminal Tracheal Occlusion with the Smart-TO Balloon|Fetal Endoscopic Tracheal Occlusion using the Smart-TO balloon and non-invasive balloon removal by the peripheral magnetic field of an magnetic resonance scanner.
48704851|NCT03389555|DRUG|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
48704852|NCT04667520|BEHAVIORAL|Lifestyle Physical Activity (LPA)|This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.
48704853|NCT04667520|BEHAVIORAL|Fitbit Only|Participants are provided with a Fitbit during their study participation.
48704854|NCT00596154|OTHER|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
48704855|NCT02839226|DRUG|AR/101|
48704856|NCT02839226|DRUG|Placebo|
48704857|NCT05734053|OTHER|Nilotinib|There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
48172905|NCT03911908|COMBINATION_PRODUCT|Cerebral oximetry (near infrared) based CPR-Algorithm|If NIRS values do not increase over time until ROSC (target: \>40 % after 10 min), interventions are suggested in a modified CPR/NIRS algorithm.
48373670|NCT03339999|DRUG|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
48373671|NCT03339999|DRUG|Placebo|Placebo administered as an oral capsule(s) once daily.
48373672|NCT06089265|DRUG|PF-06801591|Active ketohexokinase inhibitor
48373673|NCT01483365|DRUG|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
48373674|NCT03081962|DRUG|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
48373675|NCT03081962|PROCEDURE|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
48704858|NCT04576039|DIAGNOSTIC_TEST|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
48704859|NCT06126952|DRUG|Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)|"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
48704860|NCT06126952|DRUG|Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray|2 sprays per nostril of Placebo twice daily.
48704861|NCT06126952|DRUG|Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray|"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
48704862|NCT00567671|PROCEDURE|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
48704863|NCT00567671|PROCEDURE|Sham comparator|Sham treatment
48704864|NCT01607333|DRUG|Lamotrigine use|Lamotrigine prescription during the study period
48704865|NCT06361251|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
48704866|NCT06361251|DEVICE|CRYONOVE (EC05osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
48704867|NCT02402894|OTHER|no intervention|
48704868|NCT02808195|OTHER|Constraint-induced therapy|
48704869|NCT02808195|OTHER|kinect-based constraint-induced therapy|
48704870|NCT04675658|BEHAVIORAL|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
48704871|NCT04675658|BEHAVIORAL|CBPA|Classroom Based Physical Activity
48172906|NCT04080063|OTHER|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
48172907|NCT05184777|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
48172908|NCT05771025|PROCEDURE|Hepatectomy|Patients in the hepatectomy group receive liver resection.
48172909|NCT00045097|DRUG|ixabepilone|
48172910|NCT00000959|DRUG|Isoniazid|
48172911|NCT00000959|DRUG|Pyridoxine hydrochloride|
48172912|NCT04765553|DRUG|NI-0501|emapalumab single i.v infusion (1 mg/kg)
48172913|NCT04765553|DRUG|Saline|Saline single i.v infusion
48172914|NCT03279978|DRUG|BI 730357|BI 730357 film-coated tablet
48172915|NCT03279978|DRUG|Placebo|Placebo
48172916|NCT03279978|DRUG|Midazolam|Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed
48172917|NCT00526097|DRUG|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
48172918|NCT00526097|DRUG|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
48172919|NCT01677949|DRUG|Clofarabine|Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours
48172920|NCT01677949|DRUG|Etoposide|Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours
48172921|NCT01677949|DRUG|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion
48172922|NCT01677949|BIOLOGICAL|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
48172923|NCT02447276|DRUG|REGN475|
48172924|NCT02447276|DRUG|Placebo|
48172925|NCT00936962|BIOLOGICAL|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
48172926|NCT01482429|OTHER|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
48172927|NCT01957592|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
48704872|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
48704873|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
48704874|NCT04453085|DRUG|JR-171 (lepunafusp alfa)|IV infusion
48016125|NCT01164748|RADIATION|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
48172928|NCT04761692|BEHAVIORAL|Full VEPMP Intervention|Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
48172929|NCT04761692|BEHAVIORAL|Partial VEPMP Intervention|Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
48172930|NCT04761692|BEHAVIORAL|Delayed VEPMP Intervention|Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
48172931|NCT03689439|DIAGNOSTIC_TEST|bone scintigraphy|bone scintigraphy
48172932|NCT04959500|DRUG|Anlotinib Hydrochloride|Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
48172933|NCT04959500|DRUG|Placebo|Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
48172934|NCT04959500|RADIATION|Radiation Therapy|Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.
48172935|NCT04959500|DRUG|Temozolomide|Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
48172936|NCT02531399|DEVICE|FDOCT|Measurement of retinal blood velocities
48172937|NCT02531399|DEVICE|LDV|Measurement of retinal blood velocities
48172938|NCT02531399|DEVICE|DVA|Measurement of retinal vessel diameters
48172939|NCT02531399|DEVICE|LSFG|Imaging of retinal blood flow
48172940|NCT03919409|DRUG|TS-161|TS-161 capsules
48172941|NCT03919409|DRUG|TS-161 Placebo|TS-161 matching placebo capsules
48172942|NCT00223210|DRUG|Quetiapine|Active Quetiapine
48172943|NCT00223210|DRUG|PLacebo|Placebo
48172944|NCT04830761|BEHAVIORAL|Motivation|The key constructs targeted by the motivational module are attitudes towards the target behavior, risk perception, outcome expectancies and self-efficacy. The intervention includes the following techniques: information about health consequences, salience of consequences, goal setting (behavior), problem solving, verbal persuasion about capabilities, focus on past success (Michie et al., 2013)
48172945|NCT04830761|BEHAVIORAL|Habit|The goal of the habit module is to guide participants to perform correct hand hygiene at self-selected key times repeatedly. The aim is that the behavior will be translated into a habit. The intervention includes the following techniques: Information about antecedents, self-monitoring of behavior, action planning, prompts/cues, habit formation, behavioral practice/ rehearsal, prompts/cues (physical cue) (Michie et al., 2013).
48373676|NCT05158075|BEHAVIORAL|Approach-Avoidance Bias Modification|In this task participants must zoom in or zoom out a food image according to its format (vertical or horizontal) using their smartphone device. 90% of healthy food images will appear in the format to be approached (for example, vertical), while only 10% of unhealthy images will appear in that format (to ensure concentration on the task). The format to be approached will be counterbalanced. Participants will practice the task at home at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
48516678|NCT06459492|BEHAVIORAL|puzzle game strategies|"One innovative approach uses puzzle game strategies, including crosswords, Sudoku, and other brain-teasing activities. These strategies have been shown to help maintain attention, improve memory, and keep older adults' thoughts clear and sharp. Additionally, engaging in these activities can provide psychological benefits by offering a sense of achievement, reducing stress, and fostering social interactions.~Given puzzle games' potential to enhance cognitive and psychological health, exploring their effectiveness as a non-pharmacological intervention for community-dwelling older adults is essential. This research aims to fill the gap by empirically investigating the impact of puzzle game strategies on cognitive functioning and psychological well-being in this demographic."
48516679|NCT04110379|BEHAVIORAL|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
48172946|NCT04830761|BEHAVIORAL|Social|The key constructs targeted by the social module are perceived norms including descriptive norms and injunctive norm. The intervention includes the following techniques: Monitoring of behavior by others, social incentive, social comparison, social reward, restructuring the physical environment, information about others approval, credible source, information about health consequences, feedback on behavior (Michie et al., 2013).
48016126|NCT04120389|DEVICE|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
48016127|NCT04120389|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
48016128|NCT01297842|DRUG|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
48016129|NCT01297842|DRUG|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
48016130|NCT02520024|BEHAVIORAL|self-directed care|
48016131|NCT05210920|OTHER|Nail polish application|After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
48016132|NCT01492140|PROCEDURE|Subdermal Injection|Injection of dermal filler
48016133|NCT01492140|DEVICE|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
48016134|NCT02305303|PROCEDURE|Diary|A diary written prospectively during the ICU stay by the staff and relatives
48016135|NCT04928742|BEHAVIORAL|Group Cognitive Behavioural Therapy (CBT)|The 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
48016136|NCT00965848|DRUG|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
48016137|NCT06339827|BEHAVIORAL|Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
48016138|NCT02123407|DRUG|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
48016139|NCT02123407|PROCEDURE|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
48016140|NCT02422030|DRUG|Lipitor Tab. 40mg|
48016141|NCT02422030|DRUG|Trilipix 135mg|
48016142|NCT02370888|DRUG|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
48016143|NCT05769673|PROCEDURE|Placement of dental implant|Placement of a dental implant on the edentulous ridge
48016144|NCT05769673|PROCEDURE|Placement of stock healing abutment|Placement of stock healing abutment after implant has been placed on the edentulous ridge
48016145|NCT05769673|PROCEDURE|Placement of customized CAD/CAM healing abutment|Placement of customized CAD/CAM healing abutment after implant has been placed on the edentulous ridge
48016146|NCT05000996|PROCEDURE|Bariatric Surgery|Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)
48016147|NCT04219085|DEVICE|Continuous Glucose Monitor|Wearing of a continuous glucose monitor to monitor blood glucose levels in women with gestational diabetes
48016148|NCT04219085|OTHER|Routine Care|Use of a glucometer to monitor blood glucose levels in women with gestational diabetes
48016149|NCT01599650|DRUG|Ranibizumab|
48016150|NCT01599650|PROCEDURE|Laser|laser photocoagulation
48172947|NCT04647305|OTHER|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
48172948|NCT04647305|OTHER|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
48172949|NCT03588819|RADIATION|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
48172950|NCT04157218|DEVICE|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
48172951|NCT04157218|DEVICE|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
48172952|NCT00468507|DIETARY_SUPPLEMENT|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
48172953|NCT02243761|OTHER|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
48172954|NCT01648036|DRUG|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
48172955|NCT01648036|DRUG|Dalteparin|Dose 5000 IU, subcutaneous, daily
48172956|NCT03866980|BIOLOGICAL|AK105|IV infusion
48172957|NCT03866980|DRUG|carboplatin|IV infusion
48172958|NCT03866980|DRUG|pemetrexed|IV infusion
48172959|NCT03866980|DRUG|placebo|IV infusion
48172960|NCT03866980|DRUG|Anlotinib|PO
48172961|NCT04117815|DEVICE|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~* Minimum 30 minutes pre-infusion cooling~* Cooling for the duration of chemotherapy infusion~* Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
48704875|NCT01177553|PROCEDURE|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
48704876|NCT01177553|DEVICE|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
48172962|NCT04117815|OTHER|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~* Baseline~* at the half-way Point of the cyles~* at the last CT cycle~* 3 months after completion of Treatment~* 6-9 months after treatment completion~The assesments include the following~* Photographs of the head, which are evaluated using the CTCAEv4.0~* Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
48172963|NCT03180554|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
48172964|NCT03180554|OTHER|Motivational nondirective resonance breathing (MNRB)|Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.
48172965|NCT01035047|OTHER|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
48704877|NCT02165956|DIETARY_SUPPLEMENT|New Infant Cereal|New Infant Cereal
48704878|NCT02165956|DIETARY_SUPPLEMENT|Standard Infant Cereal|Standard Infant Cereal
48704879|NCT02182206|DRUG|BIBF 1120|
48704880|NCT03816176|DRUG|Isavuconazonium sulfate|Intravenous (IV) infusion
48704881|NCT03816176|DRUG|Isavuconazonium sulfate|Oral capsule
48704882|NCT06489158|DIAGNOSTIC_TEST|Detect VOCs in exhaled gas|The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
48704883|NCT03241771|BEHAVIORAL|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
48516680|NCT04110379|BEHAVIORAL|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
48516681|NCT01790087|DRUG|ANX-188 Therapeutic Dose|
48516682|NCT01790087|DRUG|ANX-188 Supratherapeutic dose|
48516683|NCT01790087|DRUG|Saline|
48016151|NCT05562947|DEVICE|PDS with ranibizumab (100 mg/mL)|Patients randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for patients randomized to the intravitreal arm. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.
48016152|NCT05562947|DRUG|Ranibizumab (10 mg/mL)|Patients in the intravitreal arm will receive their first intravitreal injection of 50 uL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, patients will receive intravitreal ranibizumab injections of 50 uL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44
48016153|NCT02602574|OTHER|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
48016154|NCT04692246|OTHER|Plant-based oral rinse|Oral rinse enriched with plant-based essential oils.
48172966|NCT04963946|DRUG|Stop ACA|discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
48016155|NCT04692246|OTHER|Placebo oral rinse|Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study
48016156|NCT05309382|DIAGNOSTIC_TEST|Prospera|Monthly testing and results provided
48016157|NCT06360575|PROCEDURE|Biopsy|Undergo tumor biopsy
48016158|NCT06360575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48016159|NCT06360575|DRUG|Crizotinib|Given PO
48172967|NCT04963946|DRUG|ACA Continuation|continuation of acalabrutinib at the same dose
48172968|NCT00001649|DRUG|Valaciclovir|
48172969|NCT04296422|DRUG|NSAIDs or oral contraceptives treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
48172970|NCT04296422|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
48172971|NCT04296422|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner
48172972|NCT02785445|DEVICE|Dip.io Home Based Dipstick Analyzer|"First intervention (assigned to the All participants arm)."
48516684|NCT01790087|DRUG|Moxifloxacin|
48016160|NCT06360575|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
48016161|NCT06325774|RADIATION|Hypofractionated radiation therapy|54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
48016162|NCT03905551|PROCEDURE|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
48016163|NCT03905551|PROCEDURE|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
48016164|NCT03905551|PROCEDURE|Exercise|Aerobic Intradialytic exercise training
48172973|NCT02785445|DEVICE|ACON U500 Mission® U500 Urine Analyzer|"Second intervention (assigned to the All participants arm)."
48172974|NCT04560062|OTHER|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
48516685|NCT04941079|OTHER|no intervention|no intervention
48516686|NCT06196489|BEHAVIORAL|adapted vaping cessation intervention|Behavioral intervention for vaping cessation
48516687|NCT04936165|PROCEDURE|Low-Level Laser Therapy|Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
48516688|NCT03672591|OTHER|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
48516689|NCT02210845|BEHAVIORAL|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
48516690|NCT02210845|BEHAVIORAL|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
48516691|NCT02210845|OTHER|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
48516692|NCT03385850|OTHER|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
48516693|NCT05727098|DRUG|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
48516694|NCT05727098|DRUG|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
48516695|NCT05727098|DRUG|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
48516696|NCT04833530|DIAGNOSTIC_TEST|Gastric Ultrasound|"In the operating room, a gastric ultrasound will be performed in the supine position and the antral cross sectional area will be measured. Anesthesia will be induced in standard procedure and positive pressure will be instituted according to the standard protocol accepted in our hospital.~At the end of the procedure, the gastric ultrasound circumference will be measured again."
48016165|NCT05894239|DRUG|Inavolisib|Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
48016166|NCT05894239|DRUG|Phesgo|Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
48172975|NCT02941848|DRUG|HGP0816|
48172976|NCT02941848|DRUG|HGP1404|
48172977|NCT02941848|DRUG|HCP1306|
48172978|NCT04257747|OTHER|MRI acquisitions|MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.
48172979|NCT04257747|OTHER|Doppler ultrasound procedure|The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital
48172980|NCT03418181|PROCEDURE|Standard Haemodialysis|Thrice weekly dialysis.
48172981|NCT03418181|PROCEDURE|Incremental dialysis|Individualised dialysis dose according to native kidney function.
48172982|NCT04830878|DRUG|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
48172983|NCT06158178|DIAGNOSTIC_TEST|Diagnostic accuracy|The PET CT study with choline, being part of the normal standard diagnostic work-up of the patients, was performed following the normal clinical protocol. By analyzing the data retrospectively, the time elapsed following the prostatectomy operation and the follow up time after the choline PETCT study will be evaluated.
48172984|NCT05330351|DIAGNOSTIC_TEST|Gastric Ultrasound|The investigators will compare gastric fluid volume as determined by ultrasound pre-induction vs. gastric volume aspirated via an orogastric tube post-intubation. The results will be stratified into low risk, moderate risk and high risk for aspiration based on ultrasound exam by an investigator off-line.
48172985|NCT02972242|RADIATION|Field of View|Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
48172986|NCT04959461|BEHAVIORAL|webCHAT|A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving
48172987|NCT04959461|BEHAVIORAL|Usual Care|6 hours of driver education
48172988|NCT01216059|PROCEDURE|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
48172989|NCT02602795|BEHAVIORAL|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
48172990|NCT02602795|BEHAVIORAL|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
48172991|NCT01649037|DRUG|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.\[ No response defined as MAP \< 10, or 4 hr Urine output \< 200 ml\] with maximum dose upto 3 mg/h."
48172992|NCT01649037|DRUG|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response \[\< 25% decrease in s.creatinine\] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
48172993|NCT03215342|BEHAVIORAL|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
48172994|NCT03215342|BEHAVIORAL|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
48172995|NCT02895334|BEHAVIORAL|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
48373677|NCT05158075|BEHAVIORAL|Inhibition Training|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone device. Some images are food, some non-foods. Participants can choose which food categories they would like to train to resist. The food-specific inhibition training condition included pictures of high-calorie foods always paired with the no-go signal. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
48516697|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
48172996|NCT04254562|BEHAVIORAL|Weekly Meetings with a Supported Employment/Supported Education Specialist|Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.
48704884|NCT06142396|COMBINATION_PRODUCT|Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone|"This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure."
48172997|NCT04254562|BEHAVIORAL|Focused Skill and Strategy Training (FSST)|Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.
48172998|NCT04254562|BEHAVIORAL|Enhanced Services as Usual|One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
48172999|NCT00548756|PROCEDURE|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
48173000|NCT00548756|OTHER|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
48173001|NCT00548756|BEHAVIORAL|Questionnaire|Questionnaire taking 40 minutes to complete.
48173002|NCT03713697|BEHAVIORAL|Pap testing|Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
48173003|NCT03713697|BEHAVIORAL|Self-collection for HPV testing|Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
48173004|NCT03713697|BEHAVIORAL|Choice|Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
48173005|NCT05122741|DRUG|P2Y12 Potent Inhibitor + Aspirin for STEMI patients|Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
48516698|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
48704885|NCT00052611|DRUG|Celecoxib|
48704886|NCT05108025|DRUG|Topical Powder|Topical Powder mixed with diluent
48516699|NCT05113784|DRUG|Meplazumab for Injection|humanized antibody target CD147
48516700|NCT05113784|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
48516701|NCT02768831|OTHER|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
48704887|NCT05108025|DRUG|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
48704888|NCT04694755|DRUG|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
48704889|NCT04694755|DRUG|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
48704890|NCT02269176|DRUG|Low dose of telmisartan|
48704891|NCT02269176|DRUG|High dose of telmisartan|
48173006|NCT05122741|DRUG|Clopidogrel + Aspirin for CCS patients|Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
48173007|NCT04731142|DEVICE|Huma|Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone app ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale.
48173008|NCT04731142|BEHAVIORAL|Video group consultations|"Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals."
48173009|NCT04731142|BEHAVIORAL|KNOW Diabetes|Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
48173010|NCT04731142|OTHER|Standard of care|Normal primary care service provided to matched control group.
48516702|NCT02768831|OTHER|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
48704892|NCT02269176|DRUG|Low dose of losartan|
48704893|NCT02269176|DRUG|High dose of losartan|
48016167|NCT05894239|DRUG|Placebo|Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
48016168|NCT05894239|DRUG|Taxane-based Chemotherapy|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
48373678|NCT05158075|BEHAVIORAL|Implementation of Intentions|"Participants establish one intention related to food and one related to exercise, and write when, where and how they will implement each one, possible inconveniences to do it, and how they will overcome them. Furthermore, motivational cues (why I eat) will be considered (negative emotions -I'm bored; social motives -eat a piece of cake you are offered in a party; politeness/conformity with others' expectations; pleasure). The implementation of intentions related to food will be written in format: if... then.... This format allows for the consideration of the health goals and medium and long-term objectives for each of the participants. The intention related to food will focus on unhealthy snacking habits whenever possible. Participants will read and visualized their implementation of intentions at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones."
48016169|NCT05894239|DRUG|Optional Endocrine Therapy of Investigator's Choice|Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
48016170|NCT06664229|BEHAVIORAL|Fall and dementia prevention exercise|"The fall and dementia prevention exercise is designed as a combination of balancing and cognitive exercise and games that is conducted as a group activity. The session will be provided three times per week for six weeks for a pilot test and three times per week for 12 weeks for a main comparison study.~The fall prevention exercise involves the pressure mat based balancing exercise such as side stepping, heel or toe standing, and quarter squat. The safety bar will be placed around the mat, so that older adults with instability can hold while they follow the movements.~The cognitive exercise will concise of multiple types of cognitive tasks to train memory, numeric processing, spatial perception, and logical thinking. For example, memory task such as memorizing the series of positions on the screen and use the mat to point the positions in the right order.~At the end, older adults play games in which they use balancing movements and cognitive tasks to gain scores for their team."
48516703|NCT04308057|PROCEDURE|Aquatic exercise|Participants belonging to Group D (sedentary group) will be randomised 1-to-1 between remaining sedentary (n=20) and following a self-managed, 8-week, aquatic-based exercise programme (n=20). The latter group will be offered an 8-week access to pool facilities. For Group D participants, all baseline assessments will be repeated at 8 weeks.
48704894|NCT05979636|OTHER|Novamin containing toothpaste|children's teeth will be brushed using Novamin containing toothpaste.
48173011|NCT04219878|BEHAVIORAL|Know@Home|Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.
48173012|NCT04219878|OTHER|Self-test Kit|All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
48173013|NCT02711813|DRUG|TAB08|biologic
48373679|NCT05158075|BEHAVIORAL|Episodic Future Thinking|Participants will decide health-related goals and anticipate positive future personal events at various time points (next month, 2-3 months and 4-6 months), from which contextual, temporal and emotional cues should be obtained. Goals and future events will be matched to generate episodic future thinking cues that include the necessary keys to facilitate their effectiveness. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
48373680|NCT05158075|BEHAVIORAL|Sham Approach-Avoidance Bias Modification|Participants must zoom in or zoom out a food image according to the format (vertical or horizontal) using their smartphone device. 50% of healthy food images and 50% of unhealthy food images will appear in the format to be approached (for example, vertical). The format to be approached will be counterbalanced. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
48704895|NCT05979636|OTHER|Fluoride containing toothpaste|children's teeth will be brushed using Fluoride containing toothpaste.
48173014|NCT02711813|OTHER|Placebo|
48173015|NCT06183905|DIAGNOSTIC_TEST|Prostate imaging|"Multiparametric ultrasound (mpUS) The mpUS examinations are performed in the order of greyscale imaging, elastography and contrast-enhanced ultrasound (CEUS), with the patients in the left lateral decubitus position.Greyscale imaging and elastography are evaluated by one radiologist. After standard step-sectional greyscale imaging, transverse elastic images are obtained from the base to the apex by manual compression. The amplitude and frequency of compression are adjusted according to the visual compression indicator on the screen to minimize interoperator variability. CEUS is performed using a bolus of 2.4 mL contrast agents (SonoVue, Bracco) using Contrast mode.~Multiparametric MRI (mpMRI) Prostate mpMRI images were acquired using a 3-T scanner with an external phased-array coil."
48173016|NCT06183905|PROCEDURE|Prostate biopsy|All patients will undergo standard 12-core systematic biopsy (SB) within 1 week following the imaging protocol in conjunction with targeted biopsy (TB) for suspicious lesions on mpUS and/or mpMRI. First, 12-core SB is performed, followed by cognitive mpUS-TB with 2-3 cores for each suspicious lesion. The suspicious lesions on mpUS include hypoechoic lesion(s) on greyscale imaging, reproducible stiff lesion(s) on elastography, and hypoperfused area(s) with ill-defined boundaries or increased focal/asymmetric contrast enhancement on CEUS. Thereafter, MRI/US fusion TB is performed sampling 2-3 cores for each lesion with a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score of 3 or above.Each biopsy sample is placed in the micro-cassette and labelled to identify the biopsy technique and location.
48373681|NCT05158075|BEHAVIORAL|Sham Inhibition Treatment|In this App participants are instructed to touch green circle items as quickly as possible, but to withhold their response and not to press on the red circle items, using their smartphone devices. Some images are food, some non-foods. Participants can choose which food categories they would like to resist. High-calorie and low-calorie foods will be paired with the go signal on 50% of trials and with the no-go signal on 50% of trials. Participants will practice the task at least once a day (about 5 minutes) for one week, and will receive daily reminders to practice via instant messaging on their mobile phones.
48516704|NCT05737355|DIETARY_SUPPLEMENT|ANKASCIN 568-P Red yeast rice capsules|Product ingredients: ANKASCIN 568-P red yeast rice product 440 mg,microcrystalline ,cellulose,Maltodextrin; capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
48516705|NCT05737355|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
48516706|NCT05186649|OTHER|WARFARIN|5 mg of daily dosage
48516707|NCT06550739|OTHER|Randomization|Randomly divide the data into a training set and a validation set in a 7:3 ratio
48516708|NCT05294666|DRUG|Cyclosporine|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
48516709|NCT05294666|DRUG|tacrolimus|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
48516710|NCT00298727|BEHAVIORAL|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
48016175|NCT01989533|BIOLOGICAL|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
48016176|NCT01989533|BIOLOGICAL|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
48016177|NCT01989533|BIOLOGICAL|gp 120 Protein Boost|HIV protein boost
48016178|NCT01138748|RADIATION|hypofractionated radiation therapy|hypofractionated radiation therapy
48016179|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin|"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
48016180|NCT05834543|DRUG|Penpulimab injection, Paclitaxel, Cisplatin|"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."
48016181|NCT05834543|DRUG|TQB2618 injection, Penpulimab injection, TQB3617capsules|TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).
48016182|NCT03250663|BEHAVIORAL|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
48016183|NCT03250663|DRUG|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
48016184|NCT02747316|OTHER|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
48016185|NCT02747316|OTHER|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
48016186|NCT06653647|BEHAVIORAL|Guided Imagery Therapy|Participants will be asked to listen to a pre-recorded, 10 to 15 minute guided imagery therapy (GIT) session via mobile application 5 out of 7 days per week for 8 weeks in addition to their usual care for their abdominal pain.
48016187|NCT00912405|DEVICE|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
48016188|NCT03837691|DEVICE|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
48016189|NCT03837691|BEHAVIORAL|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
48016190|NCT04885517|DEVICE|Esophageal catheter|Patients are equipped with an esophageal catheter: positioning is performed after accurate nasopharyngeal anesthesia with lidocaine
48016191|NCT06663254|DRUG|Hydroxyethyl starch 130/0.4|Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.
48516711|NCT00298727|BEHAVIORAL|ePBL|Online Problem-Based Course
48016192|NCT06663254|DRUG|Sodium acetate Ringer|"Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery."
48173017|NCT06310798|BEHAVIORAL|Inter-professional team test|"Digital Platform Support is used to improve communication and collaboration between the different stakeholders involved in the care of older adults. This platform allows for the sharing of oral health assessments, plans, and recommendations, ensuring all parties have access to the same information and can contribute to the care planning process.~Person-Centered, Three-Step Model:~Initial oral health assessments conducted by dental professionals, A person-centered planning process where the needs and preferences of the older adults are prioritized, The implementation of tailored oral health care plans, emphasizing shared decision-making and the active involvement of older adults in their care.~Educational Component: An important element of the intervention is the provision of a two-day course for nursing and dental staff."
48373682|NCT05158075|BEHAVIORAL|Setting Intentions|Participants will choose 10 items of healthy foods to eat whenever they want to eat unhealthy food. They will also order a list of physical activities that they could do to lose weight. Participants will read their lists (food and exercise) at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
48373683|NCT05158075|BEHAVIORAL|Recent Episodic Thinking|Participants will match habits and positive recent past events (1 day ago, 2 days ago, 1 week ago), both unrelated to food or physical activity, to establish their cues. Participants will read and visualized their three cues at least twice a day (about 5 minutes) for one week, and will receive two daily reminders to practice via instant messaging on their mobile phones.
48016193|NCT03833544|OTHER|Exercise training|Progressive resistance training of hip, knee, and ankle flexors.
48173018|NCT03382288|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
48373684|NCT05158075|BEHAVIORAL|Motivational Interviewing|Participants will assist a 90-minute group Motivational Interviewing session to maximize motivation and adherence to the program. The session will be guided through open questions and empathic reflections and affirmations to promote change talk. Participants will share their personal aims to reduce weight, improve their diet and increase their level of physical activity. Further, participants will talk about obstacles they have had on previous occasions, their expectations, and their motivations in regards to weight loss. When needed, information will be provided with the elicit-provide-elicit format. Sessions will end with an individual empathic summary for each participant's interventions.
48373685|NCT05158075|BEHAVIORAL|Nutritional intervention|Participants will maintain a 60-minute group session with a nutritionist and will watch a 20-minute video to match and complete relevant information on nutrition. The nutritionist will design a 6-week individualized diet that participants will receive after the initial assessment. When the 6-week diet ends, participants will assist another 60-minute group session with the nutritionist and will watch another video intended to teach them how to design their own healthy diet and maintain long-term healthy eating habits.
48516712|NCT01461538|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
48016194|NCT05840965|OTHER|Foot muscle strengthening|"A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
48516713|NCT01461538|DRUG|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
48016195|NCT05840965|OTHER|Foot orthotics|Custom-made foot orthotics
48173019|NCT00935259|DRUG|Simvastatin|40 mg once daily for 2 weeks
48173020|NCT00935259|DRUG|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
48016196|NCT05953584|DRUG|Etavopivat|Participants will receive a dose of 400 mg (two 200 mg oral tablets) etavopivat once daily.
48016197|NCT05953584|DRUG|Hydroxyurea|Participants will receive a stable dose of HU.
48173021|NCT04883021|DEVICE|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
48173022|NCT02277067|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
48173023|NCT02277067|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
48173024|NCT04339140|DRUG|Zafirlukast|Oral tablets, 2x daily for 28 day cycle up to 1 year
48173025|NCT05568355|BEHAVIORAL|GET2HOME Intervention|Intervention bundle designed to improve discharge effectiveness
48173026|NCT05082844|RADIATION|MRI assessment|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
48173027|NCT02468310|OTHER|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
48373686|NCT05158075|BEHAVIORAL|Physical exercise intervention|Participants will maintain a 60-minute group session with a physical exercise professional and will watch a 20-minute video to match and complete relevant information on exercise. The physical exercise professional will design a 6-week physical exercise planning that participants will receive after the initial assessment. After those 6-weeks, participants will assist another 60-minute group session with the physical exercise professional and will watch another video intended to teach them how to design their own physical activity planning and maintain long-term healthy exercise habits.
48173028|NCT02291809|BIOLOGICAL|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
48173029|NCT05373225|DEVICE|Acetic acid shockwave phonophoresis therapy|This group composed of subjects. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
48173030|NCT05373225|DEVICE|Shock wave Therapy|This group composed of subjects and represented the control group who will receive shock wave therapy
48173031|NCT05373225|OTHER|conventional physical therapy program|"Exercise program:~* Standing calf-stretching exercise~* Towel stretch: stretching exercise~* Ice bottle~* Towel pickup exercise~* Marble pickups exercise~* Calf raises exercises -Static and dynamic balance exercise"
48173032|NCT01432522|DRUG|Epinephrine|"1. Intranasal epinephrine 5 mg /spray~2. Intramuscular epinephrine 0.3 mg~3. Intranasal saline spray"
48173033|NCT06201871|DRUG|Lidocaine Hydrochloride|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
48173034|NCT03109509|BEHAVIORAL|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
48173035|NCT03109509|BEHAVIORAL|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
48173036|NCT02999737|BIOLOGICAL|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
48173037|NCT02999737|BIOLOGICAL|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
48173038|NCT00787683|DEVICE|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
48173039|NCT00632931|DRUG|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
48173040|NCT00632931|DRUG|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
48173041|NCT02505477|DRUG|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
48173042|NCT02505477|OTHER|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
48173043|NCT05810441|OTHER|Evaluation of diagnostic accuracy of anti-ttg-m|Mucosal anti-ttg evaluated in intestinal biopsy samples
48173044|NCT05584813|OTHER|Hypobaric Hypoxia|The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.
48173045|NCT02856490|DEVICE|vSculpt|A genital vibration device that operates in two modes, vibration only or vibration and light, to help tone and tighten pelvic floor muscles.
48173046|NCT02856490|DEVICE|InTone|A genital device using electric muscle stimulation to treat incontinence.
48173047|NCT00280020|BEHAVIORAL|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
48173048|NCT00280020|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
48173049|NCT00280020|BEHAVIORAL|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
48173050|NCT02350855|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
48173051|NCT02350855|OTHER|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
48173052|NCT02350855|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
48173053|NCT01238393|DRUG|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
48516714|NCT01461538|DRUG|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
48016198|NCT05259449|BEHAVIORAL|Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
48016199|NCT05259449|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
48173054|NCT06017336|OTHER|Inspiratory Muscle Training Group|Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure, 2 sets of 15 minutes a day for a total of 30 min/day or a single set of 30 min/day, 7 days/week for 8 weeks. Patients in the inspiratory muscle training group will continue their respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week. The MIPs of the patients will be re-measured every week and the training workload will be determined at 50% of the new maximal inspiratory pressure.
48173055|NCT06017336|OTHER|Control Group (breathing exercises)|Thoracic expansion exercises will be given to the control group as a home program. The control group will be asked to do thoracic expansion exercises seven days/week and 120 times/day for eight weeks. The patients in the control group will be called once a week to check their home schedules, and they will be asked to keep a diary.
48173056|NCT05383625|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|intralesional 0.1 ml every two weeks
48173057|NCT05383625|DRUG|Bivalent Human Papilloma Virus Vaccine|Intralesional 0.1 ml every two weeks
48173058|NCT05383625|DRUG|Saline|intralesional into the largest warts every two weeks
48173059|NCT03460847|DRUG|Steroids|Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
48173060|NCT00867178|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
48173061|NCT00867178|DRUG|Carboplatin|Given IV
48173062|NCT00867178|DRUG|Cisplatin|Given IV
48173063|NCT00867178|DRUG|Cyclophosphamide|Given IV
48173064|NCT00867178|DRUG|Etoposide Phosphate|Given IV
48173065|NCT00867178|DRUG|Isotretinoin|Given PO
48173066|NCT00867178|OTHER|Laboratory Biomarker Analysis|Correlative studies
48173067|NCT00867178|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
48173068|NCT00867178|DRUG|Thiotepa|Given IV
48173069|NCT00867178|DRUG|Vincristine Sulfate|Given IV
48173070|NCT00867178|DRUG|Vorinostat|Given PO
48173071|NCT04249518|BEHAVIORAL|Videoeducation|No drugs used. The only difference in the to arms is the way the extradition is.
48016200|NCT05259449|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
48016201|NCT02944578|DRUG|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
48016202|NCT02944578|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
48016203|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (90% triglycerides)|
48173072|NCT00181532|DRUG|Celecoxib|
48173073|NCT01498783|DRUG|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
48173074|NCT01498562|DRUG|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
48173075|NCT01498562|DRUG|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
48173076|NCT03945162|COMBINATION_PRODUCT|Ruvidar® (TLD-1433) Bladder infusion and PDT|Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
48173077|NCT05168709|BIOLOGICAL|Tozinameran|Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
48173078|NCT00866164|DEVICE|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
48173079|NCT01584518|DRUG|Furosemide|Based on clinical standard per clinician
48173080|NCT01861639|DEVICE|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
48173081|NCT01861639|DEVICE|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
48173082|NCT01861639|DEVICE|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
48173083|NCT01861639|DEVICE|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2\*-weighted echo-planar imaging sequence
48516715|NCT03543215|OTHER|Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)|All patients with confirmed endometrial cancer will have received Ultrasound and MRI as part of routine standard of care. Textural features from this will be analysed to see if can predict prognosis.
48516716|NCT05475860|DEVICE|implantable cardiac electronic device recipients|implantable cardiac electronic device recipients for any clinical indication
48173084|NCT01861639|DEVICE|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
48373687|NCT05405621|DRUG|BAT8009 for Injection|BAT8009 will be administered as a 90-minute (± 5min) IV infusion on Day 1 of Cycle 1. If there is no infusion related reaction after initial dose, the next dose of BAT8009 will be infused intravenously into each patient for approximately 30\~120 minutes.
48373688|NCT01283061|DRUG|Zafirlukast|Zafirlukast tablets 20 mg
48516717|NCT03252561|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
48016204|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (60% triglycerides)|
48016205|NCT00804427|DIETARY_SUPPLEMENT|Fish oil (ethyl esters)|
48016206|NCT00804427|DIETARY_SUPPLEMENT|Soy oil|
48016207|NCT02635438|DRUG|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
48016208|NCT02635438|DRUG|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
48173085|NCT01861639|DEVICE|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
48173086|NCT05700578|BEHAVIORAL|Safety Behavior Elimination for Traumatic Stress (SBETS)|This intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used trauma-related safety behaviors to reduce or eliminate over the coming month.
48173087|NCT05700578|BEHAVIORAL|Modifiable Behavior Intervention (MoBI)|The intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used unhealthy behaviors to reduce or eliminate over the coming month.
48173088|NCT01167192|DRUG|Cisplatin|
48173089|NCT01167192|DRUG|Carboplatin|
48173090|NCT01167192|RADIATION|Radiation therapy|
48373689|NCT02070718|DRUG|Standard Dose Kappa Agonist|
48373690|NCT02070718|DRUG|Half Dose Kappa Agonist|
48373691|NCT02070718|OTHER|Placebo|
48516718|NCT03252561|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
48516719|NCT03815214|BEHAVIORAL|Partial meal replacement program|Four meals consist of meal replacements made by OPTAVIA, such as shakes, soups, bars, biscuits, hot drinks, and puddings. Meal replacements will be provided to subjects without charge. For two other daily meals, subjects or their caregivers will be taught how to prepare meals consisting of 5-7 ounces (cooked) of a low-fat protein, 3 servings of non-starchy vegetables, and up to 2 servings of healthy fats.
48173091|NCT01167192|PROCEDURE|Mastectomy (recommended but not mandatory)|
48173092|NCT00970320|OTHER|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
48173093|NCT02827578|DRUG|Tamsulosin|Tamsulosin
48173094|NCT02827578|DRUG|Solifenacin|Solifenacin
48173095|NCT02827578|DRUG|Solifenacin placebo|Solifenacin placebo
48516720|NCT03815214|BEHAVIORAL|Dietary Counseling|Participants will receive one 45-minute counseling session on a healthy diet
48704896|NCT05824923|PROCEDURE|Pulmonary arterial denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.~For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician."
48016209|NCT03617679|DRUG|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
48173096|NCT05158283|DEVICE|chocolate balloon|chocolate balloon dilatation
48173097|NCT05158283|DEVICE|plain balloon|plain balloon dilatation
48173098|NCT06014970|BEHAVIORAL|Health and Wellness Curriculum|The curriculum includes instructions, activities, and lessons on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition.
48173099|NCT02198261|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
48516721|NCT02702570|BEHAVIORAL|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
48516722|NCT01377818|PROCEDURE|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
48173100|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
48173101|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
48173102|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
48173103|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
48173104|NCT06413264|PROCEDURE|Ultrasonography guided Veress needle insertion for creating pneumoperitoneum|A real-time visualisation of the path of the Veress needle entry by the use of high frequency (13-6 MHz) probe ultrasonography.
48173105|NCT06413264|PROCEDURE|Veress needle will be inserted blindly as a closed technique for creating pneumoperitoneum|The Veress needle is inserted blindly and guided by the resistance of tissues and the click sounds of layers of abdominal wall.
48173106|NCT04560478|DEVICE|Pro Seal Sealant|Sealant was reapplied every 3 months
48173107|NCT04560478|DEVICE|MI Varnish|Fluoride varnish was applied every 4-6 weeks
48704897|NCT05824923|DRUG|Guideline-directed medical therapy (GDMT) for heart failure|"GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion."
48704898|NCT06012448|DRUG|Dupilumab|"Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks."
48704899|NCT05120973|PROCEDURE|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
48704900|NCT05120973|PROCEDURE|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
48704901|NCT00522314|DEVICE|NIV and ACBT|
48173108|NCT05187247|DEVICE|Virtual Reality glasses|use of virtual reality glasses to reduce anxiety and pain levels
48373692|NCT06502002|DRUG|Dexmedetomidine Hydrochloride|Initial dexmedetomidine bolus of 1 mcg/kg over 30 min after induction, followed by an infusion rate of 0.3 mcg/kg/hr that will be stopped 30-45 minutes before the end of the surgery or once a maximum dose of 2mcg/kg has been achieved, whichever comes first.
48704902|NCT00522314|OTHER|Active Cycle of Breathing Techniques|
48704903|NCT04850391|OTHER|Mobile app|To compare changes induced by the movile app intervention among the three study groups
48704904|NCT00926731|DRUG|AZD1152|Variable dose via a 7-day continuous infusion
48704905|NCT00926731|DRUG|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
48016210|NCT03617679|DRUG|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
48016211|NCT06005259|DRUG|Spironolactone|Spironolactone 25 mg capsule
48173109|NCT02023905|DRUG|Everolimus|everolimus at 10 mg daily continuously
48173110|NCT02023905|DRUG|Temozolomide|Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
48173111|NCT05851664|DEVICE|intubation by direct laryngoscopy|intubation using a direct laryngoscopy type macintosh
48173112|NCT05851664|DEVICE|Intubation by videolaryngoscopy|Intubation using a videolaryngoscope type McGrath
48016212|NCT06005259|DRUG|Placebo|Placebo capsule
48016213|NCT01160965|DRUG|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
48016214|NCT01160965|DRUG|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
48016215|NCT01600040|RADIATION|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
48016216|NCT05357391|DEVICE|The Pressure Injury Prediction and Education model using a mobile application system|Data from the medical records will be used to analyze the probability and risk of wound healing for creating a Pressure Injury Prediction and Education Model using a mobile application system.
48016217|NCT00779454|DRUG|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
48173113|NCT02041312|OTHER|No intervention|No intervention will be needed.
48173114|NCT01293383|DRUG|LEO 90105|Ointment
48173115|NCT00677092|DRUG|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
48373693|NCT06502002|DRUG|Placebo|normal saline infusion
48704906|NCT05148442|DRUG|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
48704907|NCT04580758|COMBINATION_PRODUCT|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
48704908|NCT00571870|DRUG|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
48016218|NCT00779454|DRUG|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
48016219|NCT04688840|PROCEDURE|hip arthropalsty|follow up of patients with primary hip arthroplasty with at least one year follow up electronically and by routine method
48173116|NCT00229086|DEVICE|Gatekeeper Reflux Repari System (Device)|
48704909|NCT00814697|DEVICE|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
48173117|NCT02854397|OTHER|blood sample|
48373694|NCT06287801|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
48704910|NCT06484257|BEHAVIORAL|Myopia|Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
48173118|NCT03094624|OTHER|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
48173119|NCT03094624|OTHER|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
48173120|NCT03094624|OTHER|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
48016220|NCT06663917|OTHER|Experimental frequency allocation table (FAT) - 438 Hz|"The modified cochlear implant program (experimental FAT) changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month."
48016221|NCT06663917|OTHER|Standard FAT - 188 Hz|All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.
48016222|NCT01243385|DRUG|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
48016223|NCT03675659|DRUG|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
48516723|NCT01377818|PROCEDURE|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~* 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~* Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
48516724|NCT01377818|PROCEDURE|Both|both types of intervention
48704911|NCT06484257|OTHER|Hypermetropia|Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
48704912|NCT00149695|BEHAVIORAL|Weekly home delivery of milk products|
48704913|NCT06303648|DRUG|Methylone|Oral dose of methylone
48704914|NCT05491941|OTHER|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
48704915|NCT01432340|BIOLOGICAL|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
48016224|NCT00507052|DRUG|N-acetylcysteine|
48016225|NCT03609177|OTHER|Clinician Communication Skills Training|Communication skills training
48016226|NCT03609177|OTHER|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
48016227|NCT03609177|OTHER|Video Declarations (ViDec)|Recording of patient advance care planning videos
48516725|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
48704916|NCT06607562|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
48704917|NCT06607562|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
48704918|NCT06238141|OTHER|Expressive writing|"According to the writing prompts, online expressive writing focuses on stressful events and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.~Writing prompts are developed based on Emotional Processing Theory (EPT) and Cognitive Adaptation Theory (CAT)."
48704919|NCT06238141|OTHER|Neutral writing|According to the writing prompts, online neutral writing focuses on immediate surroundings and will be conducted twice a week (every Monday and Thursday) for 15 minutes each time, lasting for ten weeks.
48704920|NCT04184414|DRUG|CD19-CART|1-10x106 / kg CD19 CART cells
48704921|NCT02852395|DRUG|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
48704922|NCT02852395|DRUG|Placebo|Oral dose; appearance matched to JNJ-48816274
48704923|NCT04127357|PROCEDURE|1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).|"After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months."
48704924|NCT02179736|DEVICE|Restylane|
48704925|NCT05013918|OTHER|Observational study|No intervention
48704926|NCT05652231|DIAGNOSTIC_TEST|caries assessment|the child will examined for dental caries, caries prevalence, caries indices (def and DMF, or DMF)
48704927|NCT04404036|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
48704928|NCT02042053|DEVICE|PET/CT|
48704929|NCT02042053|DEVICE|PET/MRI|
48704930|NCT05807100|DIAGNOSTIC_TEST|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
48704931|NCT05807100|DIAGNOSTIC_TEST|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
48704932|NCT05462834|OTHER|Compressed Air|Participants will be instructed to use compressed air during sleep as a placebo control.
48704933|NCT05462834|OTHER|Supplemental Oxygen|Participants will be instructed to use supplemental oxygen at rate of 2lpm during sleep.
48704934|NCT02396771|PROCEDURE|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
48016228|NCT05762107|DRUG|Placebo|Subject receives Placebo by subcutaneous injection daily for 28 days
48016229|NCT05762107|DRUG|ZT-01, 7 mg|Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
48016230|NCT05762107|DRUG|ZT-01, 15 mg|Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
48016231|NCT05762107|DRUG|ZT-01, 22 mg|Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
48016232|NCT06147505|BIOLOGICAL|XS005 Injection|Treatment on this study includes XS005 infusions over an 16 week period. Phase 1： dose escalation (3+3); Phase 2 : dose of recommended phase 2 dose(RP2D).
48016233|NCT02453594|BIOLOGICAL|pembrolizumab|IV infusion
48016234|NCT05089734|BIOLOGICAL|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
48016235|NCT05089734|DRUG|Docetaxel|Administered intravenously
48016236|NCT03950024|DIAGNOSTIC_TEST|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
48016237|NCT04245488|OTHER|taste test|rate intensity of sour solutions and fatty acid solutions
48173121|NCT03094624|OTHER|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
48173122|NCT03094624|OTHER|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
48373695|NCT06287801|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
48173123|NCT01837498|DRUG|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
48173124|NCT01837498|DRUG|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
48173125|NCT05393622|DEVICE|INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION|Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
48173126|NCT02085473|BIOLOGICAL|Tralokinumab 300 mg|Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.
48373696|NCT02719093|DRUG|recombinant FSH|Subcutaneous injection
48173127|NCT01586429|OTHER|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
48173128|NCT02542423|OTHER|Endocan blood test samples|
48373697|NCT00401310|DRUG|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
48373698|NCT00401310|DRUG|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
48373699|NCT05963685|OTHER|standardized MT alarming system|Standardized alarming system via telephone loop in the primary thrombectomy centre triggered immediately after decision to mechanical thrombectomy in stroke patients admitted in primary stroke centers
48373700|NCT02630992|DRUG|Amoxicillin-Clavulanate potassium|
48516726|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
48704935|NCT02396771|PROCEDURE|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
48016238|NCT04122248|OTHER|standard radiographic imaging|standard radiographic imaging
48173129|NCT06180863|DRUG|oral azacitidine (CC-486)|Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
48173130|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
48173131|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
48173132|NCT00458354|DEVICE|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
48704936|NCT02850861|DEVICE|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
48704937|NCT00099242|DRUG|rivastigmine transdermal patch|
48704938|NCT04118036|DRUG|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
48704939|NCT04118036|DRUG|Abemaciclib|Oral 2 times a day
48173133|NCT00458354|PROCEDURE|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
48704940|NCT05787093|DEVICE|transabdominal rectal ultrasound|transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
48704941|NCT05470543|BEHAVIORAL|Nurse-led supportive care|Nurse-led supportive care was given to primary caregivers of women with breast cancer. Nurse-led supportive care was applied to primary caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 30 minutes to interview with primary caregivers at the clinic.
48704942|NCT04213703|OTHER|No intervention|There is no intervention for this study
48704943|NCT01240525|OTHER|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
48704944|NCT01240525|OTHER|No DLI|Patients will not receive DLI as trial treatment
48704945|NCT01783574|DRUG|Testosterone|
48016239|NCT02451826|DRUG|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
48016240|NCT05629208|DRUG|Edecesertib|Tablets administered orally
48016241|NCT05629208|DRUG|Edecesertib Placebo|Tablets administered orally
48016242|NCT00485875|DRUG|Atomoxetine Hydrochloride|
48173134|NCT03740204|DRUG|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
48373701|NCT04762706|BEHAVIORAL|CRUTCH Pathway|Patients will be offered referral to a behavioral medicine specialist in the novel Combined Rehabilitation Using Team Centered Help (CRUTCH) Pathway. Once enrolled, these patients will meet virtually with a psychiatrist. The psychiatrist will complete a 30-minute intake visit where he will review the patient's DT scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities. Following this assessment, psychotherapy, psychotropic medication, and referral for social work/financial services will be offered to the patient as indicated. If more frequent behavioral health follow-up is clinically indicated, it will be provided to the patients.
48016243|NCT01850199|OTHER|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
48016244|NCT01850199|OTHER|Usual management|Usual care will be provided, including face-to-face visits
48173135|NCT03740204|DRUG|Placebo patch and pill|Placebo patch and pill
48373702|NCT00974896|DRUG|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
48373703|NCT03166891|DRUG|Chiauranib|Take 50mg orally once daily
48373704|NCT06521632|OTHER|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 2 hours.
48373705|NCT05245266|DIAGNOSTIC_TEST|Redraw for analysis of blood samples from healthy pregnant women|If less than two fetal cells are recovered from maternal blood, a redraw is indicated
48373706|NCT04189874|DIAGNOSTIC_TEST|Conventional Stool Testing|Stools are tested using conventional culture techniques
48373707|NCT04189874|DIAGNOSTIC_TEST|BioFire FilmArray Gastrointestinal Panel|Molecular-based stool assay
48373708|NCT02452320|DRUG|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
48373709|NCT02452320|DRUG|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
48373710|NCT01321866|PROCEDURE|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
48373711|NCT01321866|PROCEDURE|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
48016245|NCT02753712|DRUG|Fluticasone/Formoterol BAI|
48016246|NCT02753712|DRUG|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
48016247|NCT01602276|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
48016248|NCT01268644|DRUG|Leptin|weight based sub-cutaneous injection twice daily of Leptin
48016249|NCT04856696|DIAGNOSTIC_TEST|PGT-A|trophectoderm biopsy in blastocyst stage for euploidy testing using next generation sequencing platform
48016250|NCT04856696|DIAGNOSTIC_TEST|non-invasive PGT-A|cell-free DNA collected from spent culture media for euploidy testing using next generation sequencing platform
48016251|NCT04162847|DEVICE|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
48016252|NCT06034821|DRUG|Subanesthetic dose intravenous ketamine (KET)|This trial will use standard dose of ketamine (0.5mg/kg infusion over 40 min period) in accordance with research studies that have used ketamine as an antidepressant. Treatments will be given two times a week for a maximum of 8 treatments during the acute arm of the study. The investigators will be able to modify dose and number of treatments as indicated clinically per pragmatic clinical trials procedures. Patients will be clinically assessed prior to each treatment to evaluate response and appropriateness of continuation of treatment. Per FDA guidelines a maximum 60mg/dose will be given regardless of body weight.
48173136|NCT00727415|DRUG|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
48173137|NCT00727415|DRUG|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
48173138|NCT00727415|DRUG|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
48173139|NCT05021822|PROCEDURE|Erector spinae plane block|Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
48016253|NCT06034821|DEVICE|Electroconvulsive therapy (ECT)|ECT will be given in a standard manner 3 times a week for 4 weeks. The Initial ECT treatment will be Right Unilateral (RUL) ultra-brief pulse at 6x seizure threshold determined during titration at first visit. If there is not satisfactory improvement with RUL the investigator may change to Bilateral (BL) utilizing brief pulse using 0.5 modified half-age method to determine stimulus intensity. The seizure threshold may increase during the course of treatment and the dose of the electric stimulus may need to be increased incrementally. It is suggested to change to bilateral after three to five RUL treatments if response to treatment is not satisfactory. Treatments will be given three times a week for up to 4 weeks.
48016254|NCT05795023|OTHER|NeuraLight|NeuraLight software-based platform
48016255|NCT04088461|DRUG|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
48016256|NCT04088461|DRUG|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
48016257|NCT01162005|DRUG|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
48016258|NCT06528340|PROCEDURE|spontaneous delivery|The women will be followed until the birth, in which the 3 traditional 3 methods will be carried out (spontaneous, vaginal operating, abdominal operation)
48016259|NCT02504866|OTHER|Vigorous exercise|Exercise training of vigorous intensity
48016260|NCT02504866|OTHER|Light to moderate exercise|Exercise training of light to moderate intensity
48016261|NCT00947622|DEVICE|Transcranial direct current stimulation|Transcranial Direct current stimulation
48016262|NCT06211634|DRUG|HMB-001|HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
48016263|NCT05407714|DEVICE|SpaceOAR Treatment|"SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
48016264|NCT06229574|OTHER|virtual reality glasses|The breastfeeding software developed will be applied in this group.
48016265|NCT01960231|OTHER|OGTT|
48016266|NCT01593618|BEHAVIORAL|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
48016267|NCT01593618|OTHER|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
48016268|NCT06664008|DRUG|PPI (proton pump inhibitor)|It reduces stomach acid production and manage GERD symptoms
48016269|NCT06664008|DRUG|Probiotic|Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
48016270|NCT06664008|DRUG|Zinc|Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
48016271|NCT06663839|DRUG|Biological NILK-2301|Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
48016272|NCT02442921|DRUG|Colchicine|up to 2mg of Colchicine daily
48016273|NCT02442921|DRUG|Placebo|Daily placebo
48016274|NCT05166291|DEVICE|Comfort-in injection system|local anesthesia applyed with comfort-in injection system
48016275|NCT05166291|OTHER|traditional anesthesia|local anesthesia applyed with dental syringe
48016276|NCT00079105|BIOLOGICAL|bleomycin sulfate|Treatment
48016277|NCT00079105|DRUG|cyclophosphamide|Treatment
48016278|NCT00079105|DRUG|etoposide|Treatment
48016279|NCT00079105|DRUG|mitoxantrone hydrochloride|Treatment
48016280|NCT00079105|DRUG|prednisolone|Treatment
48373712|NCT03990012|PROCEDURE|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
48373713|NCT03990012|PROCEDURE|3D Scanning|Subjects will undergo 3D scanning of the breasts.
48016281|NCT00079105|DRUG|procarbazine hydrochloride|Treatment
48016282|NCT00079105|DRUG|vinblastine sulfate|Treatment
48016283|NCT03970109|DRUG|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
48016284|NCT03970109|DRUG|Placebo oral tablet|Placebo oral tablet
48173140|NCT03577756|OTHER|Neurodevelopmental assessments|Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.
48373714|NCT06172374|GENETIC|Sano Genetics Testing Kit|Genetic testing spit collection tubes for DNA testing
48016285|NCT05035771|DEVICE|Pressure wire measurement in peripheral vascular disease|The aim of IMPACT PAD is to examine the safety and feasibility of intraprocedural flow, pressure and resistance rate changes to help predict the success of a peripheral endovascular intervention.
48016286|NCT03323905|DEVICE|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
48016287|NCT03586895|BEHAVIORAL|e-Connect|e-Connect
48016288|NCT05351203|PROCEDURE|caudal block|". Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound,. Short axis (transverse) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.125% bupivacaine will expand the epidural space."
48704946|NCT01783574|DRUG|Placebo|
48173141|NCT05563636|DEVICE|standard pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 37-41 V, time 120 s.
48173142|NCT05563636|DEVICE|high-voltage long-term pulsed radio frequency (PRF)|patients will be given standard pulsed radiofrequency (PRF) treatment: temperature 42 ℃, frequency 2 Hz, pulse width 20 ms, voltage 50-90 V, At the beginning, the patient will feel a severe burning sensation in the original pain area, and slowly after the patient tolerates it. Increase the voltage and gradually increase to the maximum voltage that the patient can tolerate (up to 70-90 V) until the end of 900 s.
48173143|NCT02005393|DEVICE|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
48704947|NCT06605326|DRUG|Subcutaneous Treprostinil|Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
48704948|NCT05607082|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
48704949|NCT00092872|DRUG|MK0557|
48704950|NCT04929925|DIAGNOSTIC_TEST|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
48704951|NCT04073784|DRUG|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
48704952|NCT02045381|PROCEDURE|MRI Group|A single research MRI
48704953|NCT06191978|DRUG|ASTX727|Given by PO
48704954|NCT06191978|DRUG|Venetoclax|Given by PO
48704955|NCT06415981|DEVICE|Hypoglossal nerve and/or Ansa Cervicalis stimulation|Device stimulation of the hypoglossal nerve and/or Ansa Cervicalis
48704956|NCT03006029|DRUG|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
48704957|NCT05763615|OTHER|Tractography MRI|"Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes."
48704958|NCT05710211|BIOLOGICAL|Clonal architecture determination|"Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing"
48704959|NCT06512051|DRUG|SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin|"Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin"
48704960|NCT03354481|BEHAVIORAL|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
48704961|NCT06505018|DEVICE|Cureety techcare|"Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: correct (green), compromised (yellow), state to be monitored (orange), or critical state (red). (Note: the color code is not visible to the patient).~The medical team uses the dashboard for daily patient monitoring and manages alerts related to the clinical classification of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device."
48704962|NCT02388035|DRUG|Cefotaxime|
48704963|NCT03727646|DIETARY_SUPPLEMENT|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
48704964|NCT03350087|DEVICE|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
48704965|NCT03350087|DEVICE|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
48173144|NCT02205099|DRUG|SKL15508|
48173145|NCT02205099|DRUG|Placebo|
48173146|NCT04811339|DRUG|Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|Pepto bismol (bismuth subsalicylate)
48173147|NCT04811339|OTHER|Placebo oral tablet without BSS|Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)
48173148|NCT02104505|DRUG|Gamma Tocopherol 700 mg capsules,|2 capsules daily
48173149|NCT02104505|DRUG|Placebo|Safflower oil capsules
48173150|NCT05242822|DRUG|KIN-3248|KIN-3248 will be administered orally once daily in 28-day cycles
48173151|NCT05336513|OTHER|Diet Control|Diet following mediterranean principles, for 15 weeks
48173152|NCT05336513|OTHER|Diet anti-inflammatory|Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.
48373715|NCT03218657|DRUG|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
48373716|NCT03218657|DRUG|Androgens|Androgens take orally 80mg qd
48373717|NCT03218657|DRUG|Cyclosporins|Cyclosporines take orally 3-5mg/kg\*d qd
48373718|NCT05478473|DRUG|Chidamide combined with Toripalimab|chidamide：oral, 30 mg/time, twice weekly; Toripalimab：intravenous drip, 240mg, once every 3 weeks
48373719|NCT06189482|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The observation group receives IOE for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2, as shown in the Appendix), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
48373720|NCT06189482|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group is provided with nutritional support as NGT, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
48373721|NCT05428358|DIAGNOSTIC_TEST|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
48373722|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
48173153|NCT01814436|DEVICE|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
48173154|NCT04249050|DIETARY_SUPPLEMENT|Oral Impact powder|Oral nutritional supplement containing fish oil, arginine and RNA
48373723|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
48373724|NCT00003695|DRUG|chemotherapy|
48373725|NCT00003695|PROCEDURE|surgical procedure|
48173155|NCT00149617|DRUG|Buspirone|
48373726|NCT01636102|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
48373727|NCT02679560|DRUG|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
48373728|NCT02679560|DRUG|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
48373729|NCT02822118|DRUG|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
48373730|NCT02822118|DRUG|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
48016289|NCT05351203|PROCEDURE|Erector spinae block|● The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of L3. a curvilinear high-frequency ultrasound transducer (Siemens acuson x300 3-5 MHz ultrasound) will be placed sagittal 3 cm lateral to L3 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side.
48016290|NCT05705102|OTHER|Coronary intervention|Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for \<24h.
48016291|NCT02090907|DRUG|Levothyroxine|
48016292|NCT02090907|DRUG|Placebo|
48016293|NCT02366572|OTHER|Control|Non pulse extruded cereal
48016294|NCT02366572|OTHER|Pea protein|Pulse extruded cereal
48016295|NCT02366572|OTHER|Pea starch|Pulse extruded cereal
48016296|NCT02366572|OTHER|Pea fibre + pea starch|Pulse extruded cereal
48016297|NCT02366572|OTHER|Pea protein + pea starch|Pulse extruded cereal
48016298|NCT02366572|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
48016299|NCT06349044|RADIATION|Hypofractionated radiotherapy/SBRT（5-10Gy/fx，3-5 fx）|RT: one primary or metastatic focus was selected for hypofractionated radiotherapy/SBRT (5-10 Gy/fx, 3-5 fx) in each round, the target area included only the GTV of the visible tumor lesion, and the GTV was expanded by 5-10 mm to generate the PTV, and the prophylactic lymphatic drainage area could not be irradiated.
48016300|NCT06349044|DRUG|Anti-PD-1 monoclonal antibody|Sintilimab 200mg d1 iv q3w
48016301|NCT06349044|DRUG|Oxaliplatin and Capecitabine|Oxaliplatin130mg/m2 d1 iv；Capecitabine1000mg/m2 d1-d14
48373731|NCT06055452|DRUG|Empagliflozin 10 MG|Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
48704966|NCT03350087|DEVICE|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
48173156|NCT06188312|OTHER|Health education program|"A pretest questionnaire will be filled out, asking the participants about their knowledge, attitudes, and practices toward chemical hazards and the use of personal protective equipment (PPE) then analysis of the obtained pre-test data will be done.~we will apply a health education program. Development phase: developing the message of the health education program and preparing the materials (slide presentation, brochures, and an educational video).Implementation phase: A group health education session through face-to-face, one hour long, interactive lecture combined with slide presentation will be carried out by the researcher. Evaluation phase: A post-test will be done, after 6 months of the first session, to assess the changes of their knowledge and attitude after the intervention."
48173157|NCT00951678|OTHER|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
48173158|NCT04662736|OTHER|patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
48173159|NCT02051985|OTHER|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
48173160|NCT02051985|OTHER|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
48173161|NCT01402063|DRUG|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
48173162|NCT01402063|DRUG|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
48173163|NCT05781009|DRUG|Pregnenolone|300mg
48173164|NCT05781009|DRUG|Placebo|placebo
48173165|NCT04390412|RADIATION|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA treatment plan
48173166|NCT02051569|DIETARY_SUPPLEMENT|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
48173167|NCT03751553|DRUG|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson\&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
48173168|NCT04103502|DEVICE|MicroPort Medial Pivot TKA|Subjects will have been implanted with the MicroPort Medial Pivot TKA
48173169|NCT04103502|DEVICE|DePuy Attune PCR TKA|Subjects will have been implanted with the DePuy Attune PCR TKA
48173170|NCT00067093|DRUG|SanOrg34006|
48173171|NCT00067093|DRUG|LMW heparin|
48173172|NCT00067093|DRUG|Unfractionated heparin|
48373732|NCT06055452|DRUG|Placebo|Each participant in the placebo group takes matching placebo.
48704967|NCT03350087|DEVICE|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
48704968|NCT03350087|DEVICE|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
48704969|NCT03350087|DEVICE|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
48173173|NCT00067093|DRUG|Vitamin K antagonist (VKA)|
48173174|NCT02487251|BEHAVIORAL|Mealtime Supports|Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
48373733|NCT00367224|PROCEDURE|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
48373734|NCT00367224|PROCEDURE|Skin biopsies|4 mm punch biopsies of the skin
48373735|NCT04077060|DIAGNOSTIC_TEST|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization \< 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
48704970|NCT00129701|PROCEDURE|Telephone consultation|
48704971|NCT05682287|DEVICE|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
48173175|NCT02487251|BEHAVIORAL|Usual Exposure|Participants receive no supplemental information on family mealtimes beyond what is already currently received
48173176|NCT03957408|DEVICE|Visual Stimuli|Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
48173177|NCT02418845|DRUG|SYM-1219|
48704972|NCT05682287|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
48173178|NCT02418845|DRUG|Placebo|
48173179|NCT04924049|OTHER|Video-assisted education|Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
48173180|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
48173181|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
48173182|NCT02005068|DRUG|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
48173183|NCT03336697|DIAGNOSTIC_TEST|Nasal swab|a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
48173184|NCT04303546|DEVICE|arterial stiffness measurements|We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
48173185|NCT01395511|DEVICE|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 \* 40 (mm) / SJ 0.18 \* 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN"
48173186|NCT01240252|DRUG|Human insulin|U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
48516727|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
48516728|NCT05015686|BIOLOGICAL|Placebo|Sodium chloride and distilled water
48173187|NCT05411874|DRUG|Chidamide|5mg po biw for 24 weeks
48173188|NCT05411874|DRUG|HD-DXM|40mg po qd for 4days
48173189|NCT04332432|DRUG|belapectin|intravenous
48173190|NCT03185702|GENETIC|Research genetic tests|DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
48173191|NCT02565550|DIETARY_SUPPLEMENT|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
48173192|NCT03478046|OTHER|Weight loss|Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
48173193|NCT04817930|DEVICE|Polyetheretherketone patient specific implant|a customized peek patient specific implant is place to augment the chin
48516729|NCT06353347|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
48516730|NCT06353347|DRUG|Placebo|Matching placebo administered orally BID as four capsules
48704973|NCT04170530|DRUG|mFOLFOXIRI|irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
48704974|NCT06607107|DRUG|mFOLFOX7 combined with Camrelizumab and apatinib|mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
48016302|NCT06349044|DRUG|Anti-VEGF 15mg/kg|Bevacizumab 15mg/kg d1 iv q3w
48016303|NCT06349044|DRUG|Anti-VEGF 7.5mg/kg|Bevacizumab 7.5mg/kg d1 iv q3w
48016304|NCT06349044|DRUG|Gemcitabine and Cisplatin|Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
48173194|NCT04817930|DEVICE|Computer guided advancement genioplasty|advancement genioplasty using patient specific cutting and positioning surgical stents
48173195|NCT02547597|DRUG|Carvedilol|
48173196|NCT02547597|DRUG|Atenolol|
48173197|NCT04833426|DRUG|Testosterone gel|Topical gel containing testosterone
48173198|NCT04833426|DRUG|Placebo|Topical gel without active substance
48516731|NCT04931979|DRUG|Pembrolizumab Injection [Keytruda]|Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
48516732|NCT04931979|RADIATION|Salvage Radiation Therapy (SRT)|SRT according to standard of care (SRT with at least 66 Gy)
48516733|NCT00984724|BEHAVIORAL|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
48516734|NCT00984724|BEHAVIORAL|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
48516735|NCT00984724|BEHAVIORAL|Quitline|Letter referring participants to a Quitline providing quit smoking services.
48516736|NCT00984724|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
48704975|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
48704976|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
48704977|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
48704978|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
48704979|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
48173199|NCT01019499|OTHER|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
48173200|NCT01019499|OTHER|control products|two portions daily
48173201|NCT02415283|DEVICE|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
48173202|NCT06129409|DRUG|NT-0796|Orally administered capsules
48173203|NCT01117129|DRUG|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
48173204|NCT01117129|DRUG|placebo|i.v. infusion on day 1 and 15
48173205|NCT01117129|DRUG|methotrexate|10-25 mg weekly
48516737|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
48704980|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
48704981|NCT01049165|DRUG|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
48704982|NCT01049165|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
48704983|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
48704984|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
48704985|NCT04549805|DIAGNOSTIC_TEST|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
48704986|NCT00415064|DRUG|Perifosine|Perifosine given in either 50 mg or 100 mg / day
48704987|NCT00415064|DRUG|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
48173206|NCT01117129|DRUG|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
48173207|NCT01703845|DRUG|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
48173208|NCT01703845|DRUG|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
48516738|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
48704988|NCT00415064|DRUG|Dexamethasone|Dexamethasone given in 20 mg / day
48704989|NCT06236542|DEVICE|NextGen automated tracheostomy suctioning device|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
48704990|NCT06236542|DEVICE|NextGen mixed-reality tracheostomy tube change system|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
48704991|NCT06236542|DEVICE|NextGen Tracheostomy Toolkit|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
48704992|NCT06345794|DRUG|LY4100511 (DC-853)|Administered orally.
48704993|NCT06345794|DRUG|Itraconazole|Administered orally.
48704994|NCT06345794|DRUG|Fluconazole|Administered orally.
48704995|NCT06345794|DRUG|Carbamazepine|Administered orally.
48173209|NCT06343649|OTHER|Visual|Delivery of images to conduct several exercises of Explicit Motor Imagery
48173210|NCT06343649|OTHER|Auditory|Delivery of audio recordings to conduct several exercises of Explicit Motor Imagery
48704996|NCT06464185|DRUG|Bispecific antibody-based combined with CAR-T cell therapy|"lymphocytes collection, and bispecific antibody-based therapy will be performed after successful Lymphocytes collection: Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.~Glofitamab: 2.5 mg, C1D8; 10 mg,C1D15 ; 30 mg,C2D1 and C3D1, IV. It can be combined with other Immunization therapy during the use of bispecific antibodies according to the patient's condition.~On C4D1, the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen, and then infused with CART cells at a specific dose of 4 \* 1000000/Kg. Bispecific antibody maintenance therapy will be initiated on month 1/2/3 after CART infusion. In Phase1 bispecific maintenance therapy will be divided into three dose groups, using a 3 + 3 dose escalation design. In Phase 2, bispecific maintenance therapy will be used at the MTD dose of Phase 1."
48016305|NCT04147013|DRUG|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
48016306|NCT04147013|DRUG|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
48704997|NCT01086956|DRUG|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
48704998|NCT02563535|DEVICE|DEB|angioplasty with Litos drug eluting balloon
48704999|NCT02563535|DEVICE|PTA|angioplasty with conventional balloon
48705000|NCT06009237|DRUG|ABBV-903|Tablet; oral
48705001|NCT06009237|DRUG|Placebo for ABBV-903|Tablet; oral
48705002|NCT03866785|DIAGNOSTIC_TEST|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
48705003|NCT03866785|DIAGNOSTIC_TEST|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
48705004|NCT03866785|DEVICE|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
48705005|NCT03866785|OTHER|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate"
48705006|NCT03866785|OTHER|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
48016307|NCT02072850|DEVICE|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
48016308|NCT02072850|OTHER|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (\~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (\< 12 hours, days 2, 7-10 and at 6 months).
48016309|NCT05575999|DRUG|Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination|The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
48016310|NCT03252821|BEHAVIORAL|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
48705007|NCT06606795|OTHER|Spinal Manipulation|For the treatment to be applied in the SMT group, segmental dysfunctions will be determined using static and dynamic palpation techniques and the applications will be applied with a chiropractic method, high-speed, low-amplitude spinal manipulation method, at the level of the dysfunctional spine.
48705008|NCT06602180|OTHER|Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT).|"Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments.~Scapular PNF:~Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~TAPA involves an intervention protocol composed of:~10-min neuro dynamics oriented to the activity 10-min proprioceptive neuromuscular facilitation activities. 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,"
48705009|NCT06602180|OTHER|Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))|"Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
48016311|NCT03252821|BEHAVIORAL|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
48516739|NCT00980447|BIOLOGICAL|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
48516740|NCT03399045|PROCEDURE|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
48016312|NCT02864641|BEHAVIORAL|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
48016313|NCT03691220|BEHAVIORAL|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
48016314|NCT06175559|COMBINATION_PRODUCT|Healing Town: Embedded Narrative in Interactive Game Design|"The game-based medication intervention game Wanping Town in this study employed a multidisciplinary participatory design approach rooted in narrative theory and behavioral psychology models. The game consists of two perspectives: narrative decision stories and cognitive games. The investigators initially employed participatory design methods to determine the plot and elements within the game, then embedded the conclusions into the therapeutic elements of the game"
48016315|NCT02681874|BEHAVIORAL|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
48016316|NCT02681874|BEHAVIORAL|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
48016317|NCT05867394|OTHER|Stress ball|Stress ball squeeze
48016318|NCT06618599|PROCEDURE|Mid-transverse process to pleura block combined with erector spinae block|The probe will be placed vertically 3 cm lateral to the T5 spinous process and the transverse process will be identified. The needle will be introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. One milliliter of normal saline will be injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. 20 mL of 0.25% bupivacaine will be injected .The needle will be directed aiming for the midpoint between the transverse process and pleura from cephalad to caudad. One milliliter of normal saline will be given to confirm the position of the needle tip, then a total of 20 ml of 0.25% ropivacaine will be injected
48016319|NCT06618599|PROCEDURE|paravertebral block|the transducer will be positioned laterally 3 cm to the midline at T5 spinous process, defining the spinous process, pleura, transverse process, the paravertebral (PV) space, and superior costotransverse ligament. The trapezius, rhomboid major, and erector spinae muscles will be recognized as superficial to the hyperechoic transverse process shadow. However, when the rhomboid major muscle disappeared, this indicated that we will be at the 7th thoracic vertebra's level. Local infiltration using 2-3 mL of 2.0% lignocaine will be done. A spinal 22-gauge needle will be injected at the cephalic side of the transducer using an in-plane technique, and the needle directed towards the costotransverse ligament (CTL). The passage of the needle through the CTL will be associated with a pop, informing that the superior costotransverse ligament will be passed. Following a 3 mL testing dose of normal saline containing epinephrine (1:200,000), 30 mL bupivacaine 0.25% injected.
48373736|NCT04077060|DIAGNOSTIC_TEST|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is \>3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
48373737|NCT02190994|DRUG|Hydrocortisone|used intravenously
48373738|NCT02190994|DRUG|Prednisone|used as tablet form
48016320|NCT06574243|BEHAVIORAL|Social media education|"The intervention consisted of daily positive messages about aging posted on an Instagram account (@laetapaplateada), created specifically for this study, and was conducted over the course of a week. Examples included The ability to make decisions improves with age and Emotional regulation improves with age (David, 2017). These posts were accompanied by their respective author references"
48016321|NCT01190540|BEHAVIORAL|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
48016322|NCT01190540|BEHAVIORAL|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
48016323|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
48016324|NCT01190540|BEHAVIORAL|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
48016325|NCT03358576|DRUG|Ertapenem|Antibiotic for complicated intra-abdominal infection
48016326|NCT03358576|DRUG|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
48016327|NCT03358576|DRUG|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
48016328|NCT03358576|DRUG|Metronidazole|Antibiotic for complicated intra-abdominal infection
48016329|NCT03358576|DRUG|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
48016330|NCT03358576|DRUG|Sulopenem|Antibiotic for complicated intra-abdominal infection
48016331|NCT01961830|DRUG|ME1100 inhalation solution|
48373739|NCT02672748|OTHER|Garden|Two years of financial and technical home gardening support for new gardeners
48373740|NCT04136041|DEVICE|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
48373741|NCT02687815|DRUG|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
48373742|NCT02687815|DRUG|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
48373743|NCT00107601|DRUG|Insulin|
48516741|NCT03399045|PROCEDURE|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
48516742|NCT05013008|DRUG|Finerenone (Kerendia, BAY94-8862)|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
48516743|NCT05013008|DRUG|Placebo|Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
48016332|NCT06035926|OTHER|questionnaire|questionnaire
48516744|NCT01915745|OTHER|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
48016333|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #1|Vitamin K supplement : 2mg, once a day, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
48373744|NCT06235177|COMBINATION_PRODUCT|Decompartmentalization Framework|"I will also be using mental imagery, consciousness, cognition, and cognitive psychology during this study to show the effectiveness of the conscious mind, and how the mind can influence behavior.~Decompartmentalize means to remove excessive compartmentalization; to restore from a compartmentalized state; to merge back together."
48373745|NCT06235177|DIETARY_SUPPLEMENT|Liquid Herbal TInctures|I will make and administer liquid herbal tinctures that will be made from all natural leafs, roots and flowers. I will focus on and track the participants' diagnosis, side effects, and how they feel before, during and after taking the liquid tincture.
48516745|NCT05952531|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image IIM lesions in skeletal muscle, heart, lung, skin and potential tumor by PET/CT.
48516746|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
48016334|NCT04496921|DIETARY_SUPPLEMENT|Vitamin K supplementation, dose #2|Vitamin K supplement : 7mg, twice a week, for 6 months. Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.). Food frequency questionnaire.
48016335|NCT04141462|GENETIC|blood sample|blood test
48016336|NCT03004534|DRUG|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
48516747|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
48516748|NCT05298826|DRUG|recombinant factor VIIa|using recombinant factor VIIa
48516749|NCT00178282|PROCEDURE|Pelvic Floor Muscle exercises|
48516750|NCT03791684|DEVICE|Cross linking|Cross linking strategy either standard or accelerated
48516751|NCT03323242|DEVICE|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
48516752|NCT03323242|DEVICE|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
48516753|NCT04254341|OTHER|patients with OSA|Sleep study
48705010|NCT06602180|OTHER|Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)|"Activity-Oriented Proprioceptive Antiedema Therapy TAPA:~TAPA involves an intervention protocol composed of:~* 10-min neuro dynamics oriented to the activity~* 10-min proprioceptive neuromuscular facilitation activities.~* 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
48016337|NCT01259661|OTHER|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
48016338|NCT04502771|DRUG|Antifungal treatment|Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit
48016339|NCT05696015|BEHAVIORAL|Standard education|Without telehealth education, this group has only postdischarge education.
48016340|NCT05696015|BEHAVIORAL|Ampiled Education|With telehealth education, in addition of discharge education.
48705011|NCT06539052|DIAGNOSTIC_TEST|anti-HDV positive with the reflex testing methodology|Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
48705012|NCT00903136|OTHER|questionnaire administration|
48016341|NCT06663319|DRUG|JNJ-89402638|JNJ-89402638 will be administered.
48016342|NCT02564471|DRUG|Chloroquine|FDA approve dosing schedule
48016343|NCT02564471|DRUG|Atovaquone and Proguanil|FDA approve dosing schedule
48016344|NCT02564471|DRUG|Doxycycline|FDA approve dosing schedule
48016345|NCT02564471|BIOLOGICAL|Rabies Vaccine|FDA approve dosing schedule
48016346|NCT02180425|DRUG|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
48016347|NCT02180425|DRUG|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
48173211|NCT04234503|BEHAVIORAL|Ethics Quarter|"In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~1. Developing of own ethics knowledge,~2. Influencing ethical issues,~3. Conducting/implementing ethics research,~4. Identifying and~5. Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory."
48016348|NCT01786408|DEVICE|TAP20-C|
48016349|NCT01786408|DEVICE|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
48173212|NCT00321490|DRUG|Quetiapine fumarate|
48173213|NCT00321490|DRUG|Duloxetine|
48705013|NCT00903136|PROCEDURE|comparison of screening methods|
48705014|NCT00903136|PROCEDURE|diagnostic endoscopic procedure|
48705015|NCT00903136|PROCEDURE|esophagogastroduodenoscopy|
48173214|NCT01919398|DRUG|LY2940680|Administered orally
48173215|NCT02533349|DRUG|Motilitone|30mg, 1 tablet, 3 times a day
48173216|NCT02533349|DRUG|Pantoprazole|40mg, 1 tablet, 1time a day
48173217|NCT02533349|DRUG|Placebo|30mg, 1 tablet, 3 times a day
48173218|NCT05219578|DRUG|RTX-224|RTX-224 monotherapy
48705016|NCT00903136|PROCEDURE|tethered capsule endoscopy|
48705017|NCT00110630|BEHAVIORAL|10-week smoking cessation group therapy combined with NicoDerm CQ|
48705018|NCT01304212|DRUG|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
48016350|NCT01037790|DRUG|PD-0332991|Given orally, 125 mg QD on a 21-day
48016351|NCT00216294|DRUG|RG1068 (Synthetic Human Secretin)|
48016352|NCT05627895|OTHER|Neurofeedback|Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
48016353|NCT05040763|DIAGNOSTIC_TEST|Buccal Swabc- Copan flocked swab|All participants will have a buccal swab sampled collected from the inside of the mouth either by themselves or by their caregiver
48016354|NCT05040763|DIAGNOSTIC_TEST|Standard of Care COVID-19 swab|All participants will receive a standard of care COVID-19 swab collected by a qualified healthcare professional
48016355|NCT01703949|DRUG|Brentuximab Vedotin|Given IV
48016356|NCT01703949|OTHER|Laboratory Biomarker Analysis|Correlative studies
48016357|NCT01703949|BIOLOGICAL|Nivolumab|Given IV
48173219|NCT01013506|DRUG|IGF-1R inhibitor OSI-906|Given orally
48173220|NCT01013506|DRUG|erlotinib hydrochloride|Given orally
48173221|NCT01013506|DRUG|goserelin|Given subcutaneously
48173222|NCT01013506|DRUG|letrozole|Given orally
48173223|NCT02867098|DRUG|XmAb5871|
48173224|NCT00579449|BEHAVIORAL|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
48373746|NCT06235177|OTHER|Mental Imagery|I will have the participants focus on a particular shape, sound or image that they can see, think, or hear. This will allow the participant to have a clear mind, and release any negative thoughts, negative energy and boost their moods and their 5 senses.
48373747|NCT06235177|DIAGNOSTIC_TEST|Clinical Yoga|I will show the participants many different yoga positions that will give them a peace of mind, stretch their muscles and release any tension throughout their body, and have an overall well-being, as well as promoting mindfulness.
48373748|NCT06235177|DIETARY_SUPPLEMENT|Dietary Supplements|I will have the participants take an herbal supplement and/or vitamin that relates to the symptoms and current issues/diagnosis they have. The Dietary Supplements/Vitamins will enhance their capacity to overcome their health conditions, protect their body from unwanted germs and bacteria, and relieve the participants' mind and body from the symptoms they are experiencing based on their current condition.
48373749|NCT06235177|BEHAVIORAL|Applied Relaxation|"Applied Relaxation is a specialized form of relaxation training that aims to teach the participant how to relax in common social situations.~Mindfulness training encourages participants to gain psychological distance from their worries and negative emotions, seeing them as an observer would see them. 2 types of mindfulness will be used, which is mindfulness-based stress reduction and mindfulness-based cognitive therapy. Treatment starts with general education about stress and social anxiety."
48373750|NCT06235177|BEHAVIORAL|Pain Relaxation Techniques|"Relaxation can reduce the feelings of stress, helping them to gain more control. Reduce pain by decreasing muscle tension, aches and pains. The body releases endorphins (the body's natural pain-killers) to relieve pain.~Yoga incorporates breath control, meditation, and gentle movements to stretch and strengthen muscles.~Mind-body techniques, which includes meditation, mindfulness, and breathing exercises help you restore a sense of control over your body and turn down the fight or flight response, which can worsen chronic muscle tension and pain."
48373751|NCT06235177|BEHAVIORAL|Comprehensive Theocentric Psychological Assessment|To enhance the lives of add to the lives of those who are well adjusted but know they have a greater potential within themselves to ring forth and live more fulfilling lives,
48373752|NCT00452127|DRUG|PRO131921|Escalating doses by IV infusion
48373753|NCT00636402|PROCEDURE|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
48373754|NCT00636402|PROCEDURE|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
48016358|NCT06599632|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for spinal cord injury (SCI). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
48016359|NCT05428969|DRUG|Bexmarilimab|Intravenous
48016360|NCT05428969|DRUG|Azacitidine|As per label, subcutaneous
48373755|NCT04088227|DRUG|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
48373756|NCT04088227|OTHER|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
48016361|NCT05428969|DRUG|Venetoclax|Oral
48373757|NCT03461393|DEVICE|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
48016362|NCT04376645|PROCEDURE|Mandibular Setback with maxillary impaction|Occlusal bite force will be measured after surgery to correct vertical disproportions
48173225|NCT00579449|BEHAVIORAL|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
48373758|NCT03065010|DRUG|BCD-115|Inhibitor of CDK8/19
48373759|NCT05671042|OTHER|Patients with Upper excretory tract tumors|Standard of care for patients with Sezary Syndrome
48373760|NCT02502994|DRUG|GEN0101|
48373761|NCT00716365|DEVICE|HemCon bandage|5 cm X 5 cm
48373762|NCT01600677|DEVICE|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
48016363|NCT04376645|PROCEDURE|Mandibular setback only|Occlusal bite force will be measured after surgery without changing vertical disproportions.
48016364|NCT01485601|BIOLOGICAL|MT10109|Single dose intramuscular injection MT10109 vs Botox®
48016365|NCT06285539|DRUG|Filgotinib|Filgotinib
48373763|NCT01600677|OTHER|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
48373764|NCT00811499|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
48373765|NCT00811499|DRUG|Placebo; oral|matching placebo
48373766|NCT00811499|DRUG|Placebo; oral|multiple dose, single schedule
48373767|NCT01952821|OTHER|Six-Minute Walk Test|
48373768|NCT01952821|OTHER|10-Meter Walk Test|
48373769|NCT01952821|OTHER|30-Second Chair Stand|
48373770|NCT01952821|OTHER|Linear Analog Scale of Function|
48173226|NCT04991688|DRUG|BOTOX-A|10 injections of 20 U of toxin will be made into the rectum 5, 10 and 15 cm above the pectinate line. At each level, 3 injections of 20 U will be performed in the submucosa, circumferentially.The last injection is made 20 cm above the pectinate line. Total does not exceed 200U of Botox-A
48373771|NCT01952821|OTHER|Modified Brief Fatigue Inventory|
48373772|NCT01952821|OTHER|FACIT-Fatigue|
48373773|NCT01729559|DRUG|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
48373774|NCT01729559|DRUG|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
48373775|NCT05784467|BEHAVIORAL|Methamphetamine, PrEP, and Intersectional Stigma (eMPrISe) study|Group behavioral intervention with 12 weekly sessions lasting 2 hours focusing on coping, resistance, and resilience.
48373776|NCT01156974|BEHAVIORAL|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
48373777|NCT01156974|BEHAVIORAL|education only|patients receive education about care goals
48373778|NCT01970020|DRUG|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
48373779|NCT01766466|DRUG|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
48373780|NCT01766466|DRUG|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
48373781|NCT04575909|BEHAVIORAL|Aprosodia Intervention|Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.
48373782|NCT04575909|BEHAVIORAL|No-Intervention|Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.
48373783|NCT00596466|DRUG|pregabalin|pregabalin
48373784|NCT02141776|DEVICE|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
48373785|NCT02141776|OTHER|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
48373786|NCT04433260|OTHER|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
48373787|NCT04433260|OTHER|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
48373788|NCT04433260|OTHER|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
48373789|NCT03331302|DRUG|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
48373790|NCT03331302|DRUG|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
48373791|NCT04759001|BIOLOGICAL|Donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
48373792|NCT04759001|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
48373793|NCT00499694|BIOLOGICAL|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
48373794|NCT00499694|DRUG|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
48373795|NCT03386630|DRUG|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
48373796|NCT03386630|DRUG|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
48373797|NCT02208518|PROCEDURE|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
48373798|NCT02208518|DEVICE|EUS-elastography|
48373799|NCT05341011|BEHAVIORAL|PEERS® Social Skills Training|"The PEERS® consisted of 14 weekly 90-min didactic sessions. Adolescents and their parents attended separate concurrent sessions.~Each session began with a review of the homework assignment from the previous week and allowed time for troubleshooting problems encountered in completing the behavioral assignment. This was followed by a didactic lesson on the weekly topic. Didactic lessons included content related to various social skills and peer interactions. Parents attendance was a mandatory component of PEERS® intervention. Parents were expected to enhance generalization of social skills through in vivo social coaching in natural social settings and increase homework compliance as well as practice of newly learned social skills. A 10-min reunification between adolescents and caregivers was arranged at the end of each session to review the skills taught in the session and assign corresponding homework for the next session."
48173227|NCT00607997|DRUG|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
48173228|NCT00610025|PROCEDURE|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
48173229|NCT03618836|OTHER|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
48173230|NCT03730662|DRUG|Tirzepatide|Administered SC.
48173231|NCT03730662|DRUG|Insulin Glargine|Administered SC
48173232|NCT01584323|DIETARY_SUPPLEMENT|Pomgranate pills|"Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)"
48173233|NCT01584323|DIETARY_SUPPLEMENT|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
48173234|NCT00715637|DRUG|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
48173235|NCT00715637|DRUG|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
48173236|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
48173237|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
48173238|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
48173239|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
48173240|NCT04167228|DRUG|Ceftazidime-Avibactam|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with ceftazidime-avibactam.
48173241|NCT04167228|DRUG|Best Available Therapy|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with the best available treatment other than ceftazidime-avibactam.
48373800|NCT02059473|PROCEDURE|Rotator cuff repair|Physiotherapy \& Surgery
48016366|NCT06087939|DEVICE|Mechanical ventilation|Mechanical ventilation (MV) is a life support technique that is routinely used in the intensive care units (ICUs) for patients with life-threatening conditions.
48016367|NCT03766321|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
48016368|NCT03766321|BIOLOGICAL|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
48705019|NCT01304212|DRUG|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
48373801|NCT02059473|PROCEDURE|Physiotherapy|
48373802|NCT05056311|OTHER|Decision Aid Website|The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
48705020|NCT01304212|DRUG|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
48705021|NCT01304212|DRUG|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
48173242|NCT01087749|DRUG|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
48173243|NCT01087749|DRUG|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
48373803|NCT00253071|BEHAVIORAL|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
48705022|NCT04417218|DIETARY_SUPPLEMENT|Lysine|Lysine is an essential amino acid which is acquired from dietary sources.
48373804|NCT03193996|DEVICE|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
48016369|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
48016370|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
48373805|NCT05571982|PROCEDURE|Tidal volume breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
48373806|NCT05571982|PROCEDURE|Vital capacity breathing technique|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
48373807|NCT02270385|BEHAVIORAL|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
48705023|NCT04417218|DIETARY_SUPPLEMENT|Controlled Diet|Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
48705024|NCT02378012|OTHER|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
48705025|NCT02378012|OTHER|Computer-Assisted Intervention|Receive iPad and instruction manuals.
48705026|NCT02378012|OTHER|Questionnaire Administration|Ancillary studies
48705027|NCT03167970|DEVICE|Pill cam|Patient is asked to swallow the esophageal capsule.
48705028|NCT03167970|OTHER|EGD|Patient will undergo standard EGD
48705029|NCT03895086|OTHER|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
48016371|NCT00627406|DRUG|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
48173244|NCT01087749|DRUG|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
48173245|NCT00349570|DEVICE|Xtract Aspiration Catheter|
48705030|NCT03895086|BEHAVIORAL|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
48705031|NCT02987907|DRUG|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
48705032|NCT02987907|DRUG|Normal Saline|use normal saline 2ml I.A. during TACE
48016372|NCT00627406|DRUG|Pregnyl|Subcutaneous injection 5000 IU
48016373|NCT01233297|DRUG|Azithromycin|10 mg/kg peroral for 3 consecutive days
48173246|NCT05729204|OTHER|Hypertonic seawater solution|Nasal irrigations with hypertonic seawater solution
48173247|NCT00353093|PROCEDURE|Ultrasonography of the deep vein system of the legs|
48705033|NCT06445153|OTHER|Intervention with clinical decision support system|To this phase, patient data is automated and systematically analyzed in order to derive decision support based on current evidence and make it available to Digi-POD users (patients, relatives, nursing staff, doctors, other healthcare professionals).
48705034|NCT03164317|OTHER|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
48705035|NCT03164317|OTHER|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
48705036|NCT05578638|COMBINATION_PRODUCT|Aloe Vera rosemary tropical application|10 ml of the Aloe Vera rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
48705037|NCT05578638|COMBINATION_PRODUCT|aloevera tropical application|10 ml of the Aloe Vera spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
48705038|NCT05578638|COMBINATION_PRODUCT|rosemary tropicalapplication|10 ml of the rosemary spray will be rubbed two times per day during the skin care on the areas at risk for PIs, including the patient's sacrum area, hip areas and heels area. This action will continue for 10 days
48705039|NCT04265729|DIETARY_SUPPLEMENT|Neocate Infant and Junior marketed products|use of Neocate Infant and Junior marketed products
48705040|NCT03472664|OTHER|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
48705041|NCT03472664|OTHER|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
48705042|NCT05864521|DIETARY_SUPPLEMENT|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
48705043|NCT05864521|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
48705044|NCT02030717|DRUG|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
48705045|NCT02030717|DRUG|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
48705046|NCT05950516|DRUG|Semaglutide|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
48705047|NCT05950516|DRUG|Semaglutide Pen Injector [Ozempic]|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
48016374|NCT01233297|OTHER|Placebo mixture|Placebo mixture containing no active substance.
48016375|NCT00983814|DRUG|Droxidopa+Carbidopa|3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo
48016376|NCT05340686|BEHAVIORAL|Aerobic Physical Exercise|Moderate to vigorous physical exercise 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
48016377|NCT05340686|BEHAVIORAL|Relaxing Physical Exercise|Relaxing exercises (stretching, light yoga) 30-45 minutes in a group setting led by psychiatric staff, 3 times per week for 6 weeks
48016378|NCT05340686|BEHAVIORAL|Information about physical exercise|Written and oral information about physical exercise recommendations, on one occasion, by researcher
48705048|NCT04080986|PROCEDURE|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
48705049|NCT04080986|PROCEDURE|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
48016379|NCT02550652|DRUG|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
48016380|NCT02550652|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
48016381|NCT02550652|OTHER|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
48016382|NCT02550652|DRUG|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
48016383|NCT02550652|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
48016384|NCT05737641|OTHER|water ingestion|ingestion of water after an 8h-fasting period
48016385|NCT05737641|DIETARY_SUPPLEMENT|jelly ingestion|ingestion of jelly after an 8h-fasting period
48016386|NCT06620926|OTHER|IDH mutant-type|The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
48016387|NCT06620926|OTHER|IDH wild-type|The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
48016388|NCT03905057|DEVICE|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
48016389|NCT03905057|DEVICE|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
48016390|NCT01548690|DRUG|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
48373808|NCT02270385|BEHAVIORAL|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
48016391|NCT03068299|OTHER|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
48016392|NCT03068299|OTHER|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
48373809|NCT04708366|DRUG|NER1006|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
48705050|NCT03222830|PROCEDURE|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
48705051|NCT05882864|DRUG|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
48705052|NCT05882864|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
48705053|NCT03381365|DEVICE|CuraSeal Percutaneous Intraluminal Closure System|
48705054|NCT01242891|DEVICE|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
48016393|NCT03246529|DRUG|BL-8040 1.25 mg/kg + G-CSF|Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
48173248|NCT05652790|PROCEDURE|Enhanced Rehabilitation Programme|"The ERP would be offered at least two sessions, each lasting 60-120 minutes per week, delivered in the Manchester Institute of Health and Performance. Interventions may include a combination of the following depending on the individual patient needs.~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
48173249|NCT05652790|PROCEDURE|Standard Care|Standard care received at usual NHS facility
48173250|NCT04555005|OTHER|Mindfulness based intervention|Mindfulness based intervention for frontline healthcare workers during COVID-19 outbreak
48173251|NCT04174222|OTHER|Moderate NMB|Neuromuscular block was maintained at train of four count 1-2.
48016394|NCT03246529|DRUG|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
48705055|NCT02273076|DEVICE|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
48705056|NCT01591421|DRUG|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
48373810|NCT04708366|DRUG|MoviPrep|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
48705057|NCT01591421|DRUG|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
48016395|NCT01076725|DEVICE|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
48016396|NCT01076725|DEVICE|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
48016397|NCT06662851|DIAGNOSTIC_TEST|UDFF|Ultrasound-Derived Fat Fraction (UDFF) is a quantitative ultrasound technique used to assess hepatic steatosis by measuring the amount of fat in the liver tissue. UDFF estimates fat content using specific ultrasound parameters, namely the attenuation coefficient (AC) and backscatter coefficient (BSC). The AC measures the rate at which ultrasound waves weaken as they pass through the liver, which correlates with fat content, while the BSC quantifies the amount of reflected ultrasound signal, providing additional insights into liver tissue characteristics.
48016398|NCT03003676|BIOLOGICAL|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
48016399|NCT03003676|DRUG|Cyclophosphamide|Pre-treatment
48705058|NCT01909180|DEVICE|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
48705059|NCT02813655|DRUG|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
48705060|NCT02813655|DRUG|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
48016400|NCT03003676|DRUG|Pembrolizumab|PD1 blockade
48016401|NCT03670589|RADIATION|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
48016402|NCT03670589|PROCEDURE|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
48016403|NCT00134108|BEHAVIORAL|Cognitive Behaviour Therapy|
48016404|NCT02845271|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
48016405|NCT02845271|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
48016406|NCT02845271|DRUG|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
48016407|NCT02845271|DRUG|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
48016408|NCT02845271|DRUG|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
48016409|NCT03097068|DRUG|Lucentis|0.3mg Lucentis
48016410|NCT03176732|DEVICE|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
48016411|NCT04114058|DRUG|liposomal bupivicaine|local field infiltration
48016412|NCT04114058|PROCEDURE|Fascia iliaca blockade|fascia iliaca compartment blockade
48705061|NCT05763186|OTHER|Sampling|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
48373811|NCT04708366|DRUG|Macrogol 400|Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
48016413|NCT05156229|BIOLOGICAL|CDK-003|CDK-003 administered subcutaneously
48016414|NCT05070897|OTHER|Questionnaires|"* Approved French version of the FCCHL scale~* Questionnaire on the use of digital tools adapted from the questionnaire on digital tools"
48016415|NCT05949983|OTHER|APA Program|Patients treated and monitored for their breast cancer following the 6-month APA program.
48016416|NCT05949983|OTHER|Recommendations for physical activity|Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule. To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
48016417|NCT03459417|PROCEDURE|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
48016418|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
48173252|NCT04174222|OTHER|Deep NMB|Neuromuscular block was maintained at train of four count 0 and post-tetanic count1-2.
48016419|NCT03459417|PROCEDURE|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
48016420|NCT01787513|OTHER|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
48016421|NCT01787513|OTHER|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
48016422|NCT06601270|OTHER|There are no interventions as the study is purely observational.|There are no interventions as the study is purely observational.
48016423|NCT04886921|BEHAVIORAL|Abdominal muscle training|Participants will receive 12-week, 60 minutes, 36-session abdominal muscle training in the TRAM women. Aimed to evaluate the effects on abdominal muscle functions after 12 weeks abdominal muscle training in the TRAM women. Outcome measures were the clinical tests for trunk muscle strength, endurance and one-leg standing was also used to exam the abdominal muscle function.
48016424|NCT04926753|DRUG|5-Fluorouracil, Cisplatin, Toripalimab|Drug: FP combined with Toripalimab Combination drugs: 5-Fluorouracil(F), Cisplatin/Carboplatin(P) and Toripalimab every 21 days for 2 cycles This is a single-arm study with all patients receiving these three drugs.
48016425|NCT01581203|DRUG|Asunaprevir (ASV)|
48016426|NCT01581203|DRUG|Daclatasvir (DCV)|
48016427|NCT01581203|DRUG|Pegylated-interferon alfa 2a (PegIFN)|
48173253|NCT00120575|PROCEDURE|hemofiltration|
48173254|NCT03632005|DEVICE|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
48173255|NCT03632005|OTHER|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
48173256|NCT03595423|PROCEDURE|Surgical AVR with bioprosthetic or mechanical prosthesis|Surgical AVR with bioprosthetic or mechanical prosthesis
48373812|NCT02008162|DRUG|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
48705062|NCT05763186|OTHER|Sampling and rinsing|Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
48705063|NCT06332560|BEHAVIORAL|Anti-inflammatory diet (DI)|12-week personalized dietary advice based on the Dutch Dietary Guidelines under the guidance of a dietician.
48705064|NCT06332560|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Seven individual sessions led by a psychotherapist. The content of the CBT will be psycho-education regarding pain mechanisms and DI.
48705065|NCT04395638|DIETARY_SUPPLEMENT|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
48705066|NCT04395638|DIETARY_SUPPLEMENT|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
48016428|NCT01581203|DRUG|Ribavirin (RBV)|
48016429|NCT02063165|DIETARY_SUPPLEMENT|High Linoleic Safflower Oil|2 tsp per day (\~10g of oil)
48016430|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.
48016431|NCT04847050|BIOLOGICAL|Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster|A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study.
48016432|NCT04847050|DIAGNOSTIC_TEST|ECG|Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).
48016433|NCT04847050|OTHER|Antibiotics|Use of prophylactic antibiotics is recommended according to institutional standards.
48016434|NCT04847050|OTHER|Anti-viral agents|Use of prophylactic antiviral agents is recommended according to institutional standards.
48016435|NCT04847050|OTHER|Anti-fungal agent|Use of prophylactic antifungal agents is recommended according to institutional standards.
48173257|NCT01143545|BIOLOGICAL|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
48705067|NCT00163943|BEHAVIORAL|Dietary weight loss +/- aerobic exercise|
48705068|NCT03429673|PROCEDURE|Surgeries|Lobectomy or segment/wedge dissection
48016436|NCT04847050|OTHER|Anti-emetics|Use of prophylactic anti-emetics is recommended according to institutional standards.
48016437|NCT00935103|BEHAVIORAL|Psychoeducation|
48016438|NCT04746937|DRUG|Nitazoxanide|nitazoxanide adjuvant to standard therapy
48016439|NCT04746937|DRUG|Norfloxacin|Standard therapy
48173258|NCT01143545|DRUG|Celecoxib|400 g po bid
48173259|NCT01143545|DRUG|cyclophosphamide|50 mg po bid
48173260|NCT04378647|DRUG|Induction with Brentuximab vedotin (BV)|3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV
48173261|NCT04378647|DRUG|Induction without Brentuximab Vedotin|3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy
48173262|NCT04378647|DRUG|Consolidation with Brentuximab Vedotin|Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
48373813|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
48516754|NCT04289363|BEHAVIORAL|Clinical program implementation|Using mixed methods and triangulating multiple sources of data collected over the course of parent and ancillary studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED-initiated BUP clinical program and implementation facilitation strategy and identify factors influencing diffusion and effectiveness. Converging provider and patient perspectives and field notes with process measures and intervention outcomes, including proportions screened, treated, and engaged in treatment, will provide explanation to contextualize and better understand feasibility, acceptability, and factors associated with the rate with which the ED-initiated BUP innovation is adopted and how well it is sustained.
48173263|NCT01755910|OTHER|Left thoracic paravertebral block|
48705069|NCT05092763|BEHAVIORAL|FIT4SURGERY|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.
48705070|NCT05092763|BEHAVIORAL|Healthy Lifestyle Control|Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
48705071|NCT05340621|DRUG|OKI-179 + binimetinib|"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
48705072|NCT00349180|DRUG|Enoxaparin sodium|
48705073|NCT00608023|DRUG|Tesamorelin|
48705074|NCT00608023|DRUG|Placebo for Tesamorelin|
48705075|NCT06072300|BEHAVIORAL|Physical activity calorie equivalent labelling|Physical activity calorie equivalent labelling on beverage vending machines
48173264|NCT01755910|OTHER|Right thoracic paravertebral block|
48173265|NCT03344406|OTHER|Telephonic interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
48173266|NCT03344406|OTHER|E-RS: COPD|E-RS questionnaire will directly measure respiratory symptom severity.
48173267|NCT03344406|OTHER|Supplemental asthma items|Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
48173268|NCT03344406|OTHER|Daily diary|Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
48173269|NCT03344406|OTHER|Sociodemographic questionnaire|Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
48173270|NCT03344406|OTHER|Clinical questionnaire|Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
48173271|NCT04661514|DRUG|Psilocybin|Psilocybin-assisted psychotherapy
48373814|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
48373815|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
48373816|NCT00984386|DRUG|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
48373817|NCT00984386|DRUG|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
48516755|NCT06529471|OTHER|Massage group|The patient in the massage group will be visited by the practitioner 3 times at 10:00-14:00-20:00 on the first day after surgery and a back massage will be applied. The patient in the massage group will be placed in an orthopnea position during the application. The massage procedure lasts an average of 30 minutes and is applied to the cervical 3 and thoracic 12 vertebrae.
48516756|NCT00518700|OTHER|new MPS|
48173272|NCT06099288|BEHAVIORAL|Home-Based Video and Motivational Interviewing Intervention|The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). The CHW will be hired to serve as MI counselors for the parents in the study, and will be in charge of delivering the MI in-home or telephone sessions. CHWs will be trained for 3 months, in Motivational Interviewing, study protocols, the use of video recordings, meal preparation, and cooking, and will undergo a MI certification process. During the sessions with the participants, the CHW will deliver semi-scripted MI sessions based on the scripts developed in the pilot study.
48173273|NCT06099288|BEHAVIORAL|Read Educate and Develop Youth (READY) Comparison|The comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education. The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). Families will receive the same intervention components as the intervention, but about reading instead of nutrition.
48173274|NCT01659047|DRUG|GS-1101|150 mg taken twice daily by mouth
48173275|NCT00831012|BIOLOGICAL|rDEN3delta30/31-7164|A live attenuated, recombinant DEN3 candidate vaccine virus
48173276|NCT02726477|DRUG|Wuling San|Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.
48173277|NCT02726477|DRUG|placebo|Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
48173278|NCT00003133|BIOLOGICAL|filgrastim|
48705076|NCT03371407|OTHER|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
48705077|NCT01702090|DRUG|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
48705078|NCT00273520|DRUG|Telithromycin|
48705079|NCT06497777|GENETIC|MicroRNA (mir-642b-3p)|A circulating microRNA in the blood of pancreatic cancer patients.
48705080|NCT06243939|BEHAVIORAL|Motivational Interview to Increase Health Management Self-Efficacy and Quality of Life in Pregnant Women Diagnosed with Gestational Diabetes Mellitus|Motivational interviewing is a client-centered approach used to elicit behavioral change by helping clients explore and resolve their ambivalence.
48016440|NCT06657274|DEVICE|RICORDO-DTx|"Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation."
48173279|NCT00003133|DRUG|cisplatin|
48173280|NCT00003133|DRUG|doxorubicin hydrochloride|
48173281|NCT00003133|DRUG|gemcitabine hydrochloride|
48173282|NCT00003133|DRUG|paclitaxel|
48373818|NCT02497261|PROCEDURE|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
48016441|NCT06657274|BEHAVIORAL|Home-based unstructured cognitive stimulation|Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
48016442|NCT00667342|BIOLOGICAL|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
48016443|NCT00667342|DRUG|Cisplatin|Given IV.
48016444|NCT00667342|DRUG|Doxorubicin|Given IV.
48016445|NCT00667342|DRUG|Methotrexate|Given IV.
48016446|NCT00667342|DRUG|Ifosfamide|Given IV.
48016447|NCT00667342|DRUG|etoposide|Given IV.
48016448|NCT00667342|PROCEDURE|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
48016449|NCT00667342|RADIATION|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
48705081|NCT06598072|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
48373819|NCT00544570|BIOLOGICAL|filgrastim|
48373820|NCT00544570|DRUG|carmustine|
48705082|NCT06598072|DRUG|Essential oils mouthwash|Essential oils mouthwash
48705083|NCT06598072|DEVICE|Dental floss|Dental Floss
48705084|NCT05082051|DRUG|Part A|"Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each."
48705085|NCT05082051|DRUG|Part B|"Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each."
48016450|NCT05217368|OTHER|mandala painting|In addition to routine antenatal education, pregnant women included in the experimental group will be asked to practice at least 1 mandala per day at least 5 times a week during the 6-week pregnancy education under the supervision of a researcher.
48016451|NCT05217368|OTHER|antenatal education|Routine antenatal education will be given.
48016452|NCT06058897|OTHER|MRI|MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
48173283|NCT02668198|DEVICE|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
48173284|NCT02668198|DEVICE|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
48373821|NCT00544570|DRUG|cyclophosphamide|
48373822|NCT00544570|DRUG|etoposide|
48373823|NCT00544570|DRUG|melphalan|
48373824|NCT00544570|PROCEDURE|autologous hematopoietic stem cell transplantation|
48373825|NCT00544570|PROCEDURE|peripheral blood stem cell transplantation|
48373826|NCT00544570|RADIATION|radiation therapy|
48373827|NCT00544570|RADIATION|total-body irradiation|
48373828|NCT02647931|BEHAVIORAL|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
48373829|NCT06119789|DRUG|Imatinib|imatinib treatment based on molecular alterations
48373830|NCT00096031|BIOLOGICAL|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
48173285|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
48173286|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine the area of prior EMR site.
48516757|NCT00518700|OTHER|RepleniSH|
48016453|NCT06058897|OTHER|eye-tracking|Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
48016454|NCT06058897|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
48016455|NCT04558476|BIOLOGICAL|Convalescent Plasma|2 units of convalescent plasma
48016456|NCT04558476|OTHER|Standard of Care|Gold Standards
48016457|NCT05909722|DIAGNOSTIC_TEST|Gastrointestinal Dysfunction Score will be calculated|We collect routine daily data on GI signs and symptoms and calculate the score (GIDS). We collect serum phosphate values as measured in routine practice of participating sites.
48016458|NCT06572410|DEVICE|EnVisio Navigation System|Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
48016459|NCT03797027|DEVICE|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
48016460|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
48016461|NCT03797027|DEVICE|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
48016462|NCT03887936|DRUG|Testosterone gel 1.62%|Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
48173287|NCT02668198|PROCEDURE|Biopsy|Biopsy to assess any evidence of residual neoplasia via standard histopathology assessment
48173288|NCT05139823|PROCEDURE|geriatric follow-up home visit after discharge|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
48173289|NCT04232878|DRUG|CVL-936|CVL-936
48173290|NCT04232878|DRUG|Matching Placebo|Placebo matching CVL-936
48373831|NCT02147132|DRUG|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
48373832|NCT02147132|DRUG|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
48373833|NCT02147132|DRUG|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
48373834|NCT02147132|DRUG|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
48016463|NCT03887936|DRUG|Placebo|Matching placebo gel, apply 2 pumps to upper arm and shoulder
48373835|NCT03442270|OTHER|No Intervention|This is an observational study, so standard of care will be followed.
48173291|NCT00948610|DRUG|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
48173292|NCT05763654|DEVICE|Linovera emulsion|Apply Linovera emulsion in clinical routine
48173293|NCT05068271|BEHAVIORAL|Multi-Domain Exercise Program|The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
48173294|NCT05068271|BEHAVIORAL|Control Group|"The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period."
48373836|NCT01225458|OTHER|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
48373837|NCT01225458|OTHER|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
48373838|NCT01225458|OTHER|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
48016464|NCT05714202|DRUG|TAR-200|TAR-200 will be administered intravesically.
48016465|NCT05714202|BIOLOGICAL|Cetrelimab|Cetrelimab will be administered.
48016466|NCT05714202|BIOLOGICAL|BCG Vesiculture|BCG will be administered intravesically.
48016467|NCT01985516|OTHER|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
48173295|NCT03974698|PROCEDURE|Hemiarthroplasty|Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
48173296|NCT06509945|OTHER|allogeneic peripheral blood stem cell transplantation|Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.
48173297|NCT00048776|DRUG|Pletal|
48373839|NCT00846573|DRUG|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
48016468|NCT01985516|OTHER|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
48016469|NCT03970135|OTHER|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
48173298|NCT01663558|DRUG|imiquimod|
48173299|NCT01663558|PROCEDURE|ablative|
48173300|NCT04896684|BIOLOGICAL|blood and intestinal biopsy sampling|24 mL of blood and 10 intestinal biopsies will be sampled
48173301|NCT02176382|DRUG|denosumab|denosumab subcutaneous injection
48173302|NCT02176382|DRUG|teriparatide|teriparatide daily subcutaneous injection
48173303|NCT02176382|DRUG|Zoledronic acid|zoledronic acid infusion
48173304|NCT04662606|BEHAVIORAL|Consumption of a standard meal prior to the fMRI data collection|Consumption of a standard meal prior to the fMRI data collection
48173305|NCT05819047|DEVICE|Functional test with a haptic device|Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
48173306|NCT03530488|DRUG|Lidocaine|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline
48373840|NCT00274573|DRUG|Tiotropium bromide|
48373841|NCT05179811|PROCEDURE|Hypnosis sessions|"* Physical examination~* Psychiatric Assessment~* VHI, SF-36, IPQ-R questionnaires~* Standardized voice recording~* 3 Standardized Hypnotherapy sessions~* CGI-I-Patient Questionnaire"
48373842|NCT02477319|OTHER|Observational|
48373843|NCT05142462|DEVICE|Hip arthroplasty|Hip prosthesis surgical implantation
48516758|NCT01699815|DRUG|Acetaminophen|
48016470|NCT00777517|DRUG|Lipitor|A single dose of 10 mg Lipitor tablet
48016471|NCT00777517|DRUG|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
48373844|NCT00762281|DEVICE|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
48373845|NCT05123066|OTHER|Aquatic Exercises|"These 3 sets were the following:~Set 1: warming up exercise as floating exercise 24 Set 2: Standing education/training Set 3: Walking education/training~The exercises will be conducted taking in consideration safety measures as:~1. Each participant will use Noodles to ensure safety.~2. Each participant will train individually to ensure safety and avoid distraction.~3. Each participant will use special swimming suit in case of lack of bowel and/or bladder control."
48373846|NCT05123066|OTHER|Land Exercises|All participants were physical therapy intervention according to their level of functional impairment :
48016472|NCT03380468|DRUG|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
48016473|NCT03509701|DIAGNOSTIC_TEST|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
48016474|NCT05381792|DIAGNOSTIC_TEST|Bacterial gene markers test|Bacterial gene markers test using qPCR
48016475|NCT05949086|BEHAVIORAL|Work Chat|Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
48016476|NCT04824534|OTHER|Motion analysis|Motion analysis is performed in the Motionlab using Vicon systems. Surgery (in case of SI patients) is performed with iFuse implant system for sacroiliac joint fusion
48016477|NCT01375049|DRUG|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
48016478|NCT03325413|BEHAVIORAL|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
48016479|NCT03325413|BEHAVIORAL|Preoperative information|Detailed preoperative information about delirium prevention and procedures
48016480|NCT03325413|BEHAVIORAL|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
48016481|NCT03325413|DIETARY_SUPPLEMENT|Dietary supplements|Dietary supplements if necessary
48373847|NCT03954418|DIETARY_SUPPLEMENT|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
48516759|NCT02533180|BIOLOGICAL|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
48516760|NCT01271218|OTHER|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
48016482|NCT03325413|OTHER|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
48016483|NCT03325413|PROCEDURE|Regional anesthesia|Regional anesthesia whenever possible
48016484|NCT03325413|OTHER|Personal aids|Personal orientation aids until anesthesia induction
48016485|NCT03325413|DEVICE|Temperature management|Perioperative warming
48016486|NCT03325413|DEVICE|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
48016487|NCT03325413|PROCEDURE|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
48016488|NCT00898911|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
48016489|NCT06269328|OTHER|Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia maintained with propofol iv 75-100 µg kg-1 min-1 and remifentanyl iv 0.05-0.2 µg kg-1 min-1 infusion.
48016490|NCT06269328|OTHER|Inhalation anesthesia with sevoflurane for anesthetic maintenance|For anesthesia induction, intravenous propofol was used at doses of 1-2 mg/kg, fentanyl at 2mcg/kg, lidocaine at 1mg/kg, and rocuronium at doses of 1mg/kg. After then anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2% )
48016491|NCT04975763|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
48016492|NCT04975763|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
48173307|NCT03530488|PROCEDURE|Office hystroscopy|A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
48705086|NCT05082051|DRUG|Part C|"Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort."
48705087|NCT06106009|DRUG|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
48173308|NCT04609839|OTHER|Follow-up of patients with COVID-19|"The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients."
48705088|NCT06106009|DRUG|Placebo|Oral solution, oral suspension or solid oral formulation(s)
48705089|NCT06106009|DRUG|Midazolam|Midazolam oral solution
48705090|NCT02442310|DRUG|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
48705091|NCT02442310|DRUG|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
48705092|NCT05105841|DRUG|Venetoclax|Oral Tablet
48705093|NCT05105841|DRUG|Ibrutinib|Oral Capsule
48705094|NCT05105841|DRUG|Obinutuzumab|Intravenous (IV) Infusion
48705095|NCT00938821|PROCEDURE|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
48705096|NCT03354546|DIAGNOSTIC_TEST|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
48705097|NCT00156988|DRUG|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
48705098|NCT05946785|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
48705099|NCT05946785|DRUG|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
48705100|NCT03193814|DRUG|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
48705101|NCT04577300|DRUG|NT-501|Implant of Neurotech NT-501 device(s)
48705102|NCT04577300|OTHER|Sham comparator|Sham implantation
48705103|NCT02383745|OTHER|Acute EEG with fast EEG electrode|
48705104|NCT01126658|OTHER|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
48705105|NCT05849441|BEHAVIORAL|Aware Program|The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
48705106|NCT00975104|DRUG|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
48705107|NCT00975104|DRUG|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
48705108|NCT00975104|DRUG|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
48705109|NCT00975104|DRUG|Placebo|Placebo IV QW
48705110|NCT01402076|DRUG|Tasimelteon|20mg daily dosing, Days 4-20
48705111|NCT01402076|DRUG|Rosiglitazone|4mg, single dose, Days 3 and 20
48705112|NCT01402076|DRUG|Midazolam|10mg, single dose, Days 1 and 18
48705113|NCT00646321|DRUG|budesonide/formoterol (Symbicort)|
48705114|NCT00646321|DRUG|budesonide|
48705115|NCT00693823|PROCEDURE|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
48705116|NCT00693823|DEVICE|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
48705117|NCT03047356|BEHAVIORAL|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
48705118|NCT03047356|OTHER|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
48705119|NCT02241057|DEVICE|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
48705120|NCT02241057|OTHER|Temperature Probe|
48705121|NCT05210517|DRUG|Empagliflozin 25 MG|25 once daily one week treatment
48705122|NCT05210517|DRUG|Benzbromaron|100 mg once daily 1 one week treatment
48705123|NCT05210517|DRUG|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
48705124|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Combination therapy
48705125|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule|Single agent
48705126|NCT05081349|DRUG|L-Carnitine, 250 Mg Oral Capsule|single agent
48705127|NCT03569748|DEVICE|IQOS|IQOS USE FOR 12 WEEKS
48705128|NCT03569748|DEVICE|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
48373848|NCT04897126|RADIATION|Shexiang Baoxin pill（MUSKARDIA）|On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.
48516761|NCT01271218|OTHER|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
48705129|NCT05621759|DRUG|Cyclophosphamide|Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
48705130|NCT05621759|DRUG|Abatacept|Calcineurin-inhibitor produced by Astellas.
48516762|NCT01194167|DRUG|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
48705131|NCT05621759|DRUG|Tacrolimus|Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
48705132|NCT03679078|DIETARY_SUPPLEMENT|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
48705133|NCT01780714|OTHER|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
48173309|NCT05000099|OTHER|video calls|A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
48705134|NCT01780714|OTHER|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
48705135|NCT02748434|OTHER|Lipohypertrophy|
48373849|NCT04897126|RADIATION|Placebo|On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.
48373850|NCT04938726|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
48373851|NCT01438281|DRUG|SYL1001|SYL1001 eye drops. topical administration
48705136|NCT02748434|OTHER|Normal Subcutaneous Tissue|
48705137|NCT03895398|OTHER|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
48705138|NCT04508751|OTHER|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
48705139|NCT05130606|BEHAVIORAL|"Culturally Targeted Narrative Video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."|Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
48705140|NCT05130606|BEHAVIORAL|FORCE Fact Sheet|Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
48705141|NCT02673476|DRUG|ALS-008176|ALS-008176 tablets
48705142|NCT02673476|DRUG|Placebo|Identical placebo tablets
48173310|NCT04698798|PROCEDURE|Muscle Biopsy|Patients will be treated for SARS-CoV-2 symptoms on the intensive care unit. During this treatment two muscle biopsies will be obtained with an interval of seven days between them.
48373852|NCT01493154|BIOLOGICAL|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
48373853|NCT01493154|DRUG|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
48373854|NCT00265382|DRUG|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
48373855|NCT04057586|PROCEDURE|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
48373856|NCT04057586|PROCEDURE|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
48373857|NCT03573466|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
48516763|NCT04379427|DEVICE|Sanmina Biosensor|non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.
48516764|NCT04891003|DIAGNOSTIC_TEST|Ultrasonography|The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules.
48516765|NCT00423371|DEVICE|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
48705143|NCT03822312|DEVICE|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
48016493|NCT00965900|PROCEDURE|Endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
48516766|NCT00423371|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
48516767|NCT03778684|DIAGNOSTIC_TEST|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
48705144|NCT03822312|DEVICE|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
48705145|NCT06189703|DEVICE|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
48016494|NCT00965900|DRUG|Propranolol|"* start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
48173311|NCT01264887|DRUG|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
48173312|NCT04271566|BEHAVIORAL|Education program|A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
48173313|NCT03271749|OTHER|PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections|The PROSM guidelines is described previously in study description
48173314|NCT00634426|PROCEDURE|Surgical excision of the metastatic process|Surgical excision of the metastatic process
48173315|NCT00634426|RADIATION|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
48373858|NCT03171272|OTHER|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
48516768|NCT03778684|DIAGNOSTIC_TEST|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
48705146|NCT02966093|DRUG|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
48173316|NCT06029985|DIAGNOSTIC_TEST|Hysteroscopic Follow Up|Office hysteroscopy was carried out to detect the scar site, performed with a 4-mm, continuous-flow operative hysteroscope by vaginoscopic approach, without analgesia or anesthesia. Distension of the uterus was obtained using a normal solution as distension medium, dispensed by an electronic suction/irrigation pump. This can maintain a constant intrauterine pressure of around 30-40 mmHg, balancing an irrigation flow of 200 mL/min with a vacuum of 0.2 bars, necessary to avoid overdistension of the muscle fibers and patient discomfort. The use of this distension medium allows blood or mucus to be washed out from the pouch if necessary.
48173317|NCT03428464|DRUG|Sodium Bicarbonate|Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.
48173318|NCT03428464|OTHER|Placebo|Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
48373859|NCT04637087|OTHER|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
48373860|NCT03378882|BIOLOGICAL|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~* An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~* A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
48373861|NCT03378882|PROCEDURE|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
48373862|NCT04188639|DRUG|Emicizumab Injection|All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.
48373863|NCT04950452|BEHAVIORAL|Exercise Training|Supervised exercise training
48373864|NCT03562676|OTHER|weightlessness|parabolic flight
48705147|NCT02966093|DRUG|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
48705148|NCT05802706|OTHER|No intervention.|No intervention.
48016495|NCT00965900|PROCEDURE|EBL+Propranolol|"1. EBL~   * Perform EBL within 7 days after randomization~  * Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~  * Acid suppression using proton pump inhibitor until eradicated.~  * After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~2. Propranolol~   * start with 20 mg b.i.d~  * Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~  * After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
48016496|NCT03281811|DRUG|Aminolevulinic Acid Hydrochloride|Given topically
48373865|NCT05775666|BIOLOGICAL|UCLM802 Cell Injection|Anti-mesothelin CAR-T cells are autologous genetically modified T cells. A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by UCLM802 cell injection.
48373866|NCT02366546|DRUG|TBI-1301|TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
48373867|NCT02366546|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
48016497|NCT03281811|DRUG|Photodynamic Therapy|Undergo PDT
48373868|NCT02366546|DRUG|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
48016498|NCT03281811|OTHER|Quality-of-Life Assessment|Ancillary studies
48016499|NCT03281811|RADIATION|Radiation Therapy|Undergo RT
48173319|NCT06308185|OTHER|observational study|Observational retrospective study on infants with neonatal seizures
48173320|NCT06215417|PROCEDURE|Rotator cuff repair|Arthroscopic rotator cuff repair augmented with graft.
48173321|NCT00123019|BEHAVIORAL|Exercise and diet|Advice and measurement only
48173322|NCT00123019|BEHAVIORAL|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
48016500|NCT04947397|DIAGNOSTIC_TEST|Pupillometry|Pupillometry prior to extubation
48173323|NCT00123019|BEHAVIORAL|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
48173324|NCT00123019|BEHAVIORAL|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
48173325|NCT05195892|DRUG|Treatment A|Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
48173326|NCT05195892|DRUG|Treatment B|Single oral dose of alpelisib granule at 50 mg in fed state
48173327|NCT05195892|DRUG|Treatment C|Single oral dose of alpelisib granule at 50 mg in fasted state
48173328|NCT05231655|DIAGNOSTIC_TEST|Functional drug screen|High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles
48173329|NCT01837589|OTHER|QCT|
48173330|NCT01837589|OTHER|DXA|
48373869|NCT04487782|OTHER|Focus Groups|The investigators are enrolling up to 56 women (total) to participate in semi-structured focus groups of 6-8 women per group conducted either in-person or virtually (online) to help us tailor a lifestyle intervention for midlife women during perimenopause.
48016501|NCT02358824|DRUG|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
48016502|NCT02358824|DRUG|Telmisartan|"- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
48016503|NCT02358824|DRUG|S-amlodipine|"- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
48016504|NCT02843282|BEHAVIORAL|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
48016505|NCT01046955|DRUG|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
48016506|NCT03144570|OTHER|None, non-interventional study|Not applicable, non-interventional study
48016507|NCT03969342|DEVICE|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
48016508|NCT02582840|DRUG|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
48016509|NCT02582840|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
48016510|NCT02582840|DRUG|Placebo tablet|Placebo tablet. Oral dose
48016511|NCT06662955|BEHAVIORAL|audible cues|Terminal knee extension exercise with audible cues
48173331|NCT03080662|DEVICE|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
48016512|NCT06662955|BEHAVIORAL|Exercise|Terminal knee extension exercise
48016513|NCT06256497|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation \& rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
48173332|NCT03080662|DEVICE|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
48173333|NCT01271023|DEVICE|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
48516769|NCT03885115|BEHAVIORAL|Intervention|Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
48016514|NCT00966498|PROCEDURE|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
48016515|NCT01138124|DRUG|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
48016516|NCT04745143|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of schizophrenia
48016517|NCT04745143|DRUG|Placebo Cap|Use of placebo as a comparator
48016518|NCT03062800|DRUG|Thalidomide|100-200mg/d,oral ,qn
48173334|NCT00318981|DRUG|Concerta|
48016519|NCT03062800|DRUG|pemetrexed|(500mg/m\^2) on day 1 of 21-days cycle,ivgtt
48016520|NCT03062800|DRUG|cisplatin|(75mg/m\^2) on day 1 of 21-days cycle, ivgtt
48016521|NCT03062800|DRUG|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
48016522|NCT02164396|DEVICE|Spectacle Lens|Spectacle Lens Only
48016523|NCT02164396|DEVICE|Habitual Soft Contact Lens|subject's own contact lens
48016524|NCT02164396|DEVICE|Test Lens|senofilcon A or narafilcon A
48016525|NCT01736280|OTHER|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
48173335|NCT04012658|OTHER|No intervention|No intervention
48173336|NCT00513058|DRUG|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
48173337|NCT00513058|DRUG|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
48173338|NCT02101658|OTHER|clinic-based weight measurements|
48016526|NCT06664463|OTHER|Arousal enhancment protocol|"Auditory stimulation: Playing familiar music or personalized playlists tailored to the patient's preferences evokes emotional responses and promotes arousal.~Olfactory stimulation: Using essential oils or fragrances associated with calming or invigorating properties fosters emotional connections and evokes nostalgia through scents linked to positive memories.~Visual stimulation: Displaying photographs of family members or significant events provides comforting visual stimulation and stimulates visual awareness.~Tactile stimulation: Gentle touch or therapeutic massage engages the patient through tactile input, promoting physiological and emotional responses.~Besid thsi protocl also the will recivce routine care throughout study period The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive s"
48016527|NCT06664463|OTHER|Routine Care|The control group in this study will receive routine hospital care. This care includes standard medical evaluations, monitoring of vital signs, neurological assessments, and any necessary imaging (such as CT or MRI scans). Patients will also receive supportive care, including pain management, hydration, and nutrition, as well as physical, occupational, or speech therapy as needed based on their recovery progress
48016528|NCT06572215|DRUG|Dapagliflozin|On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
48016529|NCT05535166|PROCEDURE|Surgical resection|"All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator."
48016530|NCT05535166|PROCEDURE|Ommaya/VPS|All participants enrolled on S-1 will undergo
48016531|NCT05535166|DRUG|Methotrexate|Route of administration: Intravenously (IV)
48016532|NCT05535166|DRUG|Cisplatin|Route of administration: Intravenously (IV)
48173339|NCT05336981|RADIATION|Low-Level Light Therapy|The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
48173340|NCT04888117|PROCEDURE|Laparoscopic cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.
48016533|NCT05535166|DRUG|Vincristine|Route of administration: Intravenously (IV)
48016534|NCT05535166|DRUG|Cyclophosphamide|Route of administration: Intravenously (IV)
48173341|NCT04888117|PROCEDURE|Robotic-assisted cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
48373870|NCT04392882|BEHAVIORAL|Legume enriched diet group|"* Replacing 1/3 refined rice intake with legumes three times per day~* Vegetable intake at least six units (30-70 g/unit) per day for sufficient dietary fiber intake~* Regular 30-min walk after dinner each day"
48016535|NCT05535166|DRUG|Carboplatin|Route of administration: Intravenously (IV)
48016536|NCT05535166|DRUG|Topotecan|Route of administration: Intravenously (IV)
48016537|NCT05535166|DRUG|Etoposide|Route of administration: Intravenously (IV)
48016538|NCT05535166|DRUG|Pegfilgrastim|Route of administration: subcutaneous (SQ)
48016539|NCT05535166|DRUG|Filgrastim|Route of administration: subcutaneous (SQ) or Intravenously (IV)
48016540|NCT05535166|RADIATION|Irradiation|All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
48016541|NCT05535166|OTHER|Educational and Media Intervention|Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
48173342|NCT04626986|PROCEDURE|microwave ablation|Microwave ablation has the advantages of aesthetics, precise positioning, minimally invasive and painless for patients with early breast cancer.The tumor can be completely killed without injurying adjacent tissue. Some studies have suggested MWA is a safe and effective therapy for the treatment of breast cancer.
48173343|NCT04626986|PROCEDURE|breast conserving surgery|The treatment of early-stage breast cancer tends to be less-invasive including less morbidity, shorter hospitalization, and improved cosmetic results. Many reports have concluded that there was no difference between breast-conserving surgery and the traditional radical mastectomy for early stage breast cancer in time to distant metastases or overall survival, so breast-conserving surgery is becoming an alternative treatment for early-stage breast cancer.
48173344|NCT01367444|DRUG|SAR422459|"Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
48173345|NCT00238992|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
48173346|NCT06231563|DRUG|Ketamine|intravenous ketamine infusion 0.5 mg/kg
48173347|NCT06231563|DRUG|Remimazolam|intravenous remimazolam infusion 0.25 mg/kg
48173348|NCT01709123|DRUG|chromium niacinate|200ug or 500ug supplementation in pill form
48173349|NCT01709123|DRUG|placebo|Placebo pill for chromium niacinate
48373871|NCT05872165|DEVICE|phonophoresis|1 MHz, 1 W/cm2continuous mode of ultrasound therapy for 5 min. using ozonated gel as a coupling medium
48373872|NCT05872165|OTHER|conventional physical therapy|conventional TENS (100 Hz) for 30 min - hot pack for 20 min- stretching and strengthening exercises, wrist rest splints 3times per week for 4 weeks.
48016542|NCT05535166|OTHER|SOC, Educational and Media Intervention|Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
48173350|NCT04038749|DRUG|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
48173351|NCT04038749|DRUG|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
48173352|NCT04038749|OTHER|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
48516770|NCT06231095|DEVICE|continuous theta burst stimulation - cTBS|Continuous theta burst stimulation (cTBS) is a quicker and potentially more effective technique to reduce cortical hyperactivity than repetitive transcranial magnetic stimulation (rTMS). The study involves a cycle of 35 cTBS stimulations in the supplementary motor area (SMA) over 5 working days, with 7 stimulation sessions each day lasting 40 seconds. A 1-hour break between sessions will be observed, and each session will comprise 600 pulses at 90% of the motor threshold intensity.
48173353|NCT05143138|DEVICE|GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
48173354|NCT05885269|DRUG|Group A applied topical Clobetasol Propionate|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
48173355|NCT05885269|DRUG|Group B applied topical Tacrolimus|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
48173356|NCT06101472|DEVICE|ASQELIO Toric Biaspheric Monofocal Lens|Intraocular lens implantation in cataract surgery
48705149|NCT06420362|OTHER|Blood Flow Restriction|"Before BFR training, a repetition maximal (1-RM) test will be determined by selecting a weight with which athletes can perform a maximum of 10 repetitions. The number of repetitions obtained here and the weight lifted will be written into the Brzycki formula, whose validity and reliability has been proven, and 1-TM will be calculated.~Brzycki formula; 1-TM = \[100 x (Weight Lifted) / \[(102.78 - 2.78 x (Number of Reps)\] The arterial occlusion pressure of the participants will be measured with a Doppler Ultrasound device by increasing the cuff to the point where the auscultatory pulse of the brachial artery ceases until occlusion occurs in the brachial artery. Then, 60% of this value will be calculated and BFR will be performed during the exercises."
48173357|NCT02964546|OTHER|Blood sample|2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
48173358|NCT02506881|DRUG|Darbepoetin alfa|
48173359|NCT01664923|DRUG|Enzalutamide|160 mg, daily, by mouth.
48705150|NCT04272866|OTHER|Clinpro sealant|Resin based sealant
48705151|NCT04272866|OTHER|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
48705152|NCT04272866|OTHER|Triage sealant|Glass ionomer sealant
48705153|NCT04158141|DRUG|Carboplatin|Given IV
48705154|NCT04158141|DRUG|Cisplatin|Given IV
48705155|NCT04158141|PROCEDURE|Decortication|Undergo decortication
48705156|NCT04158141|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48705157|NCT04158141|DRUG|Pemetrexed|Given IV
48173360|NCT01664923|DRUG|Bicalutamide|50 mg, daily, by mouth
48173361|NCT00142038|DRUG|Docetaxel|
48516771|NCT00226980|DRUG|Thalidomide|
48705158|NCT04158141|DRUG|Pemetrexed Disodium|Given IV
48705159|NCT04158141|RADIATION|Pencil Beam Scanning|Undergo PBS
48705160|NCT04158141|PROCEDURE|Pleurectomy|Undergo pleurectomy
48705161|NCT04158141|OTHER|Quality-of-Life Assessment|Ancillary studies
48705162|NCT04158141|OTHER|Questionnaire Administration|Ancillary studies
48705163|NCT05467761|DRUG|Oral Psilocybin|25mg orally
48705164|NCT05467761|DRUG|IV Psilocybin|5mg intravenously
48705165|NCT01967017|DRUG|Lidocaine|
48705166|NCT01967017|DRUG|Placebo|
48705167|NCT06511557|DEVICE|Non immersive virtual reality ( xbox kinetic)|"Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness"
48016543|NCT05581368|OTHER|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
48016544|NCT03623958|DEVICE|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
48016545|NCT03623958|PROCEDURE|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
48016546|NCT03844191|DRUG|RUC-4 Compound|single subcutaneous administration of RUC-4
48173362|NCT00142038|DRUG|Capecitabine|
48173363|NCT00071877|DRUG|Replagal|
48173364|NCT04703257|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
48173365|NCT04703257|DRUG|Placebo|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
48173366|NCT04295330|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
48373873|NCT01624818|BEHAVIORAL|Cardiac habilitation program|physical activity three weeks
48016547|NCT05389592|PROCEDURE|Active tDCS and cognitive training|Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
48016548|NCT05389592|PROCEDURE|Sham tDCS and cognitive training|Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.
48016549|NCT06244316|DRUG|rhNGF concentration 1|Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
48016550|NCT06244316|DRUG|rhNGF concentration 2|Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
48016551|NCT06244316|DRUG|Vehicle (Placebo solution)|Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
48705168|NCT06511557|OTHER|Kinetic chain exercises|Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness
48173367|NCT04295330|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
48173368|NCT00146510|BEHAVIORAL|HealtheLifestyle Program|
48173369|NCT00146510|BEHAVIORAL|step counters with monthly feedback on logs|
48173370|NCT03561597|BEHAVIORAL|Mobile health intervention|The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
48516772|NCT00226980|DRUG|Capecitabine|
48705169|NCT01842035|DRUG|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
48705170|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet before Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 6 days. 2 x 24 hour urines will be collected on days 3 and 4.
48016552|NCT05596669|DRUG|Ketamine|to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
48016553|NCT06592313|PROCEDURE|Intubation|Aiway management procedure involving the Insertion of an orotracheal cannula through the oropharynx.
48173371|NCT01185171|DRUG|ZD 1839 500mg|"Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance \[CC\] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
48516773|NCT01807312|DEVICE|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
48516774|NCT01807312|DEVICE|Placebo|
48516775|NCT03209817|DIETARY_SUPPLEMENT|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
48016554|NCT06572956|BIOLOGICAL|CAR-T/CAR-NK cell injection|One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
48016555|NCT03300245|RADIATION|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
48016556|NCT05914467|DRUG|Teicoplanin|Dose will be adjusted in the study arm using MIPD guided TDM- dosing
48016557|NCT00653107|PROCEDURE|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
48373874|NCT00000968|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
48373875|NCT02960191|DEVICE|Magnetic resonance imaging (MRI)|
48373876|NCT02861248|PROCEDURE|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60-90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50-80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8-16 weeks.
48705171|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose before Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 5 of the 6-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
48705172|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Program|Subjects will go on a 10-week Intestive level Optifast VLCD weight loss program
48016558|NCT00653107|RADIATION|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
48016559|NCT00653107|RADIATION|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (\> 12 Gy/h).
48016560|NCT02616003|DRUG|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
48016561|NCT02616003|OTHER|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
48016562|NCT02616003|DIETARY_SUPPLEMENT|Caloric diet with 1000 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
48705173|NCT04633811|DIETARY_SUPPLEMENT|Optifast VLCD Transition Phase|After completion of the 10-week Optifast VLCD Program, subjects will be weaned off the Optifast products for 4 weeks.
48705174|NCT04633811|DIETARY_SUPPLEMENT|Low Oxalate Diet after Weight Loss|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 11 days and collect 2 x 24 hour urines on days 8 and 9
48016563|NCT05409924|DRUG|ATR-258|Single Ascending Dose
48016564|NCT05409924|DRUG|ATR-258|Multiple Ascending Dose
48016565|NCT05409924|DRUG|ATR-258|Repeat Dose
48705175|NCT04633811|DIETARY_SUPPLEMENT|Oral load of oxalate and sucralose after Weight Loss|Subjects will ingest 100mg carbon-13 oxalate, and 2 grams of sucralose on day 10 of the 11-day low oxalate diet phase. Following the oral load, blood and urine will be collected every 30 minutes and hourly, respectively
48016566|NCT01340339|DEVICE|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
48016567|NCT01340339|DEVICE|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
48016568|NCT05295173|DRUG|Injection of recombinant human tissue plasminogen kinase derivatives|18mg/10ml/stick, provided by Angde Biotech
48705176|NCT02388490|DRUG|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
48173372|NCT02941419|BIOLOGICAL|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
48373877|NCT04918251|PROCEDURE|128 electrode electroencephalography (EEG)|128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
48516776|NCT03209817|DIETARY_SUPPLEMENT|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
48016569|NCT05295173|DRUG|Recombinant human tissue plasminogen activator|20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.
48016570|NCT06663085|DIETARY_SUPPLEMENT|Enteral feeding|intervention group received enteral feeding breastmilk during transfusion
48016571|NCT03058406|DRUG|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
48173373|NCT06194682|PROCEDURE|Anterior cruciate ligament reconstruction|Anterior cruciate ligament arthroscopic reconstruction
48016572|NCT00633984|BEHAVIORAL|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
48173374|NCT03641313|DRUG|Berzosertib|Given IV
48173375|NCT03641313|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT assisted biopsy
48173376|NCT03641313|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
48173377|NCT03641313|DRUG|Irinotecan|Given IV
48173378|NCT03641313|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48173379|NCT04696133|OTHER|fine motor skills|stretching and strengthening exercises in addition to exercises to enhance fine motor skills
48173380|NCT04696133|OTHER|sensory integration|"* Tactile stimulation~* Proprioceptive stimulation"
48173381|NCT05092477|BEHAVIORAL|Integrated Intervention for Breast Cancer Survivors with Diabetes|"All pilot participants will be required to have a SMB target to be included in this study. A SMB target will be chosen by the participant after reviewing their 18mo follow-up responses with the Care Coach. Participants may endorse a maladaptive belief or emotional response; however, this is not required to participate in this intervention. At each follow-up session, the Care Coach will review the participant's SMB goal and progress, address participant's challenges and suggest alternatives, and correct further misinformation on the disease(s). Additionally, the Care Coach will reinforce or introduce techniques that could help overcome barriers to reaching SMB goal and recommend participants to continue improving on the same goal or begin action planning towards a new SMB goal.~1. Just SMB concern~2. SMB + maladaptive belief + emotional response~3. SMB + maladaptive belief~4. SMB + emotional response"
48705177|NCT02909985|OTHER|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
48705178|NCT02909985|OTHER|ERG|Participants will undergo electroretinography using both normal settings and infrared as the stimuli.
48016573|NCT00633984|DRUG|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
48173382|NCT05092477|BEHAVIORAL|Attention Control|Participants in the control arm will receive a brochure to discuss healthy lifestyle behaviors to improve DM management. To control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes, participants also receive 4 calls to discuss study progress, thoughts and feelings about study/illness/behaviors, remind them about returning their pill bottles, and about scheduling for their upcoming 24mo follow-up study interview.
48173383|NCT06214598|DIETARY_SUPPLEMENT|Supplement|Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
48516777|NCT03524521|BEHAVIORAL|Interval Training|Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
48516778|NCT03524521|BEHAVIORAL|Standard of Care|Walking prescribed to meet current exercise guidelines; 150 minutes per week.
48516779|NCT00853099|BIOLOGICAL|adalimumab|
48173384|NCT06214598|DIETARY_SUPPLEMENT|AI diet|diet rich in whole grains, healthy oils and polyphenols,
48173385|NCT06214598|DIETARY_SUPPLEMENT|Placebo|Placebo caps with standard diet
48173386|NCT02089438|DRUG|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
48173387|NCT02089438|DRUG|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
48173388|NCT02089438|DRUG|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
48173389|NCT02503982|DRUG|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
48516780|NCT00853099|DRUG|placebo|
48173390|NCT05707715|DEVICE|XSensor|"A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section \[18,19\]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support."
48173391|NCT01540812|DRUG|Vincristine in induction|
48173392|NCT01540812|DRUG|Daunorubicin in induction|
48173393|NCT01540812|DRUG|Prednisone in induction|
48173394|NCT01540812|DRUG|Metotrexato in induction|
48173395|NCT01540812|DRUG|Cytarabine in induction|
48173396|NCT01540812|DRUG|Hydrocortisone in induction|
48173397|NCT01540812|DRUG|Idarubicin in induction-2|
48173398|NCT01540812|DRUG|Fludarabine in induction-2|
48516781|NCT02396511|BIOLOGICAL|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
48516782|NCT02396511|BIOLOGICAL|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
48705179|NCT02909985|OTHER|VEP|Participants will undergo visual evoke potential tests using both normal settings and infrared as the stimuli.
48705180|NCT00986401|DRUG|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
48705181|NCT00986401|DRUG|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
48705182|NCT05331209|OTHER|Acupuncture|Weekly acupuncture treatments, for 8 weeks (8 treatments)
48016574|NCT00633984|DRUG|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
48173399|NCT01540812|DRUG|Ara-C in induction-2|
48173400|NCT01540812|DRUG|G-CSF in induction-2|
48173401|NCT01540812|DRUG|Dexamethasone in consolidation-1|
48016575|NCT04641923|OTHER|Adhesion barrier|Adhesion barrier application at the time of first surgery
48016576|NCT03142295|PROCEDURE|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
48016577|NCT06309082|PROCEDURE|Amputation|Amputation was performed on diabetic foot ulcer
48173402|NCT01540812|DRUG|Vincristrine in consolidation-1|
48173403|NCT01540812|DRUG|Metotrexato in consolidation-1|
48173404|NCT01540812|DRUG|PEG-ASP in consolidation-1|
48705183|NCT05331209|OTHER|Acupuncture-Acupressure|Weekly acupuncture, for 8 weeks, with daily self-acupressure by the patient at home.
48705184|NCT06516614|BEHAVIORAL|Sleep Coach|Sleep-promoting intervention consisting of 4 phone sessions to improve sleep duration and consistency.
48705185|NCT06516614|BEHAVIORAL|Diabetes Education|Participants will receive a a binder with educational information about diabetes and educational messages from the study team.
48016578|NCT06309082|PROCEDURE|Debridement|Debridement of diabetic foot ulcers was performed
48016579|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
48016580|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
48016581|NCT03877393|COMBINATION_PRODUCT|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
48016582|NCT03877393|COMBINATION_PRODUCT|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
48016583|NCT03079258|OTHER|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
48016584|NCT00341224|BEHAVIORAL|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
48016585|NCT00827892|DRUG|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
48016586|NCT00827892|DRUG|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
48016587|NCT05960682|OTHER|Questionnaire|Patients will complete the French version of the Brief Index of Sexual Functioning for Men (BISFM) paper questionnaire. The BISFM is a self-administered questionnaire. It has 22 questions, grouped into 7 domains allowing a qualitative and quantitative evaluation of the sexual experience: D1 (desire), D2 (excitement), D3 (frequency of activity), D4 (receptivity), D5 (pleasure, orgasm ), D6 (relationship satisfaction), D7 (problems affecting sexuality).
48016588|NCT06572943|OTHER|Moderate intensity physical activity|Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
48016589|NCT06449339|DRUG|Carvedilol|Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
48016590|NCT02275897|PROCEDURE|Slow Speed of spinal injection|Speed of injection over 60 seconds
48016591|NCT02275897|PROCEDURE|Fast Speed of spinal injection|Speed of injection over 15 seconds
48016592|NCT05610800|DRUG|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
48016593|NCT05610800|DRUG|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
48016594|NCT05610800|DRUG|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
48016595|NCT05610800|BEHAVIORAL|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
48016596|NCT01379326|DRUG|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
48016597|NCT05845125|OTHER|Physiotherapy alone|Physiotherapy focusing on increasing the shoulder range of motion.
48173405|NCT01540812|DRUG|Dexamethasone in consolidation-2|
48173406|NCT01540812|DRUG|ARA-C in consolidation-2|
48173407|NCT01540812|DRUG|PEG-ASP in consolidation-2|
48173408|NCT01540812|DRUG|Dexamethasone in consolidation-3|
48173409|NCT01540812|DRUG|Vincristine in consolidation-3|
48173410|NCT01540812|DRUG|Metotrexato in consolidation-3|
48173411|NCT01540812|DRUG|PEG-ASP in consolidation-3|
48173412|NCT01540812|PROCEDURE|allogeneic HSCT|
48173413|NCT01540812|PROCEDURE|Allo HSCT with reduced-intensity conditioning|
48373878|NCT04918251|PROCEDURE|Transcranial magnetic stimulation (TMS)|Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
48373879|NCT03714139|PROCEDURE|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden \& Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
48373880|NCT03714139|PROCEDURE|non implant loading|Control implants will receive a healing screw and will remain unloaded
48016598|NCT05845125|DRUG|Glenohumeral injection of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine coupled with physiotherapy|"The patient will lie supine on the radiology table. Proper skin disinfection will be done with Soluprep x 3 and sterile draping will be applied. An anterior view of the shoulder will be obtained with the fluoroscopic C-arm. Location of the injection site will be obtained with a radio-opaque stylus. Proper local anesthesia will be performed using approximately 1cc of 0.5% Bupivacaine intradermal. A 22G 3.5 spinal needle will be placed in the glenohumeral joint under fluoroscopic guidance using the anterior approach. A small amount (1cc) of iodine-based contrast agent (Omnipaque) will be injected under live fluoroscopic imaging to confirm the intra-articular position of the needle in the glenohumeral joint. In the event of a known iodine contrast allergy, no contrast agent will be used. A combination of 40mg (1cc) of Triamcinolone and 7cc of 0.5% Bupivacaine will be injected into the glenohumeral joint."
48016599|NCT06117267|DEVICE|Anatase Spine Surgery Navigation System|Collect images with the probe touching the target position before screw implantation
48016600|NCT03099135|DRUG|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
48016601|NCT01464320|DRUG|ABT-614|Active
48016602|NCT01464320|DRUG|Placebo Comparator|Placebo
48016603|NCT03424421|PROCEDURE|subscapular sling|semitendinosus subscapular sling procedure
48016604|NCT04323553|DIAGNOSTIC_TEST|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
48016605|NCT04323553|OTHER|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
48016606|NCT02369133|DRUG|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
48016607|NCT02369133|DRUG|Placebo|
48016608|NCT06449157|OTHER|Inhalation induction with parosmia|"The experimental group will then be told that the patient's favorite smell will be put into the face mask via the magical machine. The patient will be asked to take a deep breath thinking about that smell and then introduce sevoflurane. The patient will be asked if the chosen flavor is smelled and their response will be noted."
48016609|NCT02698501|DRUG|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
48016610|NCT02698501|DRUG|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
48016611|NCT03840161|DEVICE|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
48016612|NCT00059904|BIOLOGICAL|aldesleukin|
48016613|NCT00059904|BIOLOGICAL|rituximab|
48016614|NCT06460311|OTHER|PEDAL and EMS|"Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait"
48016615|NCT06460311|OTHER|PEDAL|"In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test."
48016616|NCT05731219|BIOLOGICAL|B7-H3 target, CAR gene modified gdT cell injection|After the subjects who signed the informed consent form were screened by the inclusion/exclusion criteria, the qualified subjects will enter 1.0 in order of priority × 108，3.0 × 108 and 6.0 × 108 CAR gdT groups were administered once.
48016617|NCT04532112|DEVICE|Biocontainment Device For Aerosol Generating Procedures (Biobox)|The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.
48016618|NCT04532112|DEVICE|Control for aerosol generating procedures|There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
48016619|NCT02310659|OTHER|No intervention|No intervention
48173414|NCT06209203|DRUG|lowe-dose ZKY001 eye drops|eye drops
48173415|NCT06209203|DRUG|Medium-dose ZKY001 eye drops|eye drops
48173416|NCT06209203|DRUG|placebo|eye drops
48705186|NCT05533203|BIOLOGICAL|Prodencel; an autologous dendritic cell therapeutic tumor vaccine|Subcutaneous injection, each injection point should not exceed 1ml.
48016620|NCT05584501|OTHER|Care Navigator|The Dental Team will have a Care Navigator as an added resource to assist with offering, implementing, and counseling for HIV testing; providing PrEP education and linkage; and providing linkage and re-linkage to HIV care.
48016621|NCT05584501|OTHER|Health Information Supported Ending the HIV Epidemic (ETE) Activities in Dental Setting|Dental Teams will receive a Best Practice Alert (BPA) when they have a patient who should be offered HIV testing. Dental Teams will also be notified when they have a patient known to be HIV positive but out of HIV care.
48016622|NCT06392555|DEVICE|Device-Aided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, aided by the device
48016623|NCT06392555|OTHER|Device-Unaided performances|Determination of the presence of the 8 findings suspicious of CHD by readers, unaided by the device
48016624|NCT05956314|DRUG|KM-001 cream 1% 12 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
48016625|NCT05956314|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort):~* The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~* Symptom-directed physical examinations will be performed at all other trial visits.~* Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
48016626|NCT05956314|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
48016627|NCT05956314|DIAGNOSTIC_TEST|Serum chemistry|Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
48016628|NCT05956314|DIAGNOSTIC_TEST|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute \[abs.\]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
48016629|NCT05956314|DIAGNOSTIC_TEST|Serology|Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
48173417|NCT01726049|DRUG|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
48173418|NCT01726049|DRUG|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
48173419|NCT03772041|DRUG|OPC-61815|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
48173420|NCT03772041|DRUG|Tolvaptan Tab 15 MG|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
48173421|NCT05413837|DIAGNOSTIC_TEST|anotomy and variation of venous sinus|Contrast enhanced-magnatic resonance venography（CE-MRV）and other magnetic resonance imaging methods are used to estimate the anatomy of cerebral venous sinus.
48173422|NCT05413837|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa or omics analysis is used to test the level of biomarker in blood.
48173423|NCT01101334|DRUG|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
48173424|NCT01101334|DRUG|erlotinib|Erlotinib; One 150mg tablet administered once daily
48173425|NCT04240236|PROCEDURE|Scalp block|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
48173426|NCT04240236|OTHER|Control Group|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
48173427|NCT03739697|OTHER|spontaneous breathing|spontaneous breathing during induction of anesthesia in infants
48173428|NCT02997683|DEVICE|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
48173429|NCT02997683|OTHER|exercises at home on the floor|exercises at home on the floor
48173430|NCT01536873|DRUG|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
48173431|NCT03463434|DEVICE|Air Fluidized Therapy|AFT bed used for pressure injury treatment
48173432|NCT03463434|DEVICE|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
48173433|NCT04573556|DRUG|Lemborexant|Lemborexant oral tablets.
48016630|NCT05956314|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
48016631|NCT05956314|DIAGNOSTIC_TEST|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
48173434|NCT04805047|BEHAVIORAL|education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
48016632|NCT05956314|DIAGNOSTIC_TEST|Pharmacokinetics Assessments|"Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2."
48173435|NCT04012723|DEVICE|MY01 Continuous Compartmental Pressure Monitor|The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
48173436|NCT04737421|DEVICE|NobelActive TiUltra implant|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
48173437|NCT04737421|DEVICE|NobelParallel CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
48173438|NCT04737421|DEVICE|NobelReplace CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
48173439|NCT04737421|DEVICE|Nobel Biocare N1 TiUltra TCC implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
48705187|NCT05272137|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
48173440|NCT03694626|DEVICE|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
48173441|NCT03694626|DEVICE|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
48173442|NCT03694626|DEVICE|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
48373881|NCT05975762|PROCEDURE|surgical rib fixation|open reduction and internal rib fixation
48373882|NCT05007730|DIETARY_SUPPLEMENT|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
48373883|NCT03527875|PROCEDURE|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
48373884|NCT03527875|PROCEDURE|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
48373885|NCT03527875|PROCEDURE|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
48705188|NCT00000146|DRUG|Methylprednisolone|
48705189|NCT00000146|DRUG|Prednisone|
48705190|NCT05708638|OTHER|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
48705191|NCT05708638|OTHER|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
48016633|NCT05956314|DIAGNOSTIC_TEST|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
48016634|NCT05956314|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
48173443|NCT03694626|DEVICE|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
48173444|NCT03694626|DEVICE|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
48173445|NCT01015378|PROCEDURE|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
48173446|NCT00607061|PROCEDURE|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
48173447|NCT02741713|PROCEDURE|"PECS Pectoralis 1 and 2 Blocks"|"An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects."
48173448|NCT02741713|PROCEDURE|Interscalene Block|An interscalene block will be performed on the subjects.
48173449|NCT02741713|PROCEDURE|Sham Block|
48173450|NCT02741713|DRUG|Solution for Injection in Interscalene Block|20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
48173451|NCT02741713|DRUG|Solution for Injection in Sham Block|Lidocaine 1%
48173452|NCT02741713|DRUG|Solution for Injection PECS Blocks|10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
48705192|NCT06284993|PROCEDURE|electroacupuncture(more frequent)|With the patient in a prone position, the local skin will be routinely sterilized, Ashi points will be perpendicularly inserted into the plantar fascia layer with a depth of approximately 15-20 mm depending on the location. BL57, KI3, and BL60 will be punched perpendicularly 10-15 mm deep into the skin. All needles except the Ashi points will be manually stimulated with small, equal manipulations of lifting, thrusting, twirling, and rotating to achieve De qi (a sensation including soreness, numbness, distention, and heaviness), and the practitioner has a feeling of needle sinking and tightness. The electroacupuncture instrument is connected to the needle handle of BL57 and BL60 respectively. During the needle retention period, except for BL57 and BL60, which are connected to the electroacupuncture instrument, Ashi points and KI3 perform a small and uniform twisting technique three times every 10 min, and a total of 3 times within 30min.
48705193|NCT06284993|PROCEDURE|electroacupuncture(less frequent)|"The intervention is the same as Group M except that the frequency of acupuncture will be once per week acupuncture. During the treatment period, in addition to acupuncture, patients will be visited twice a week for a total of 8 visits by telephone or in person. If the content of the visit aligns with the established efficacy evaluation visit in the program, it will be carried out as planned. If not, the patient will be inquired about the progress of their condition since the previous treatment, any rescue medication taken, and other relevant information. Visits that do not involve improvement in relevant indicators of study concern do not need to be recorded.~The electroacupuncture will last for 30 min and will be performed three sessions per week or one session per week for a total of 12 or 4 sessions in four consecutive weeks. Participants in both groups will be treated and (or) evaluated separately."
48173453|NCT04068051|DRUG|AXS-07|AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
48173454|NCT05629247|DIAGNOSTIC_TEST|Systematic screening of immune deficiency|Systematic screening of immune deficiency with blood tests
48173455|NCT02200978|DRUG|ATO|Given IV
48173456|NCT02200978|DRUG|RIF|Given orally
48173457|NCT02200978|DRUG|ATRA|Given orally
48173458|NCT02200978|DRUG|mitoxantrone|Given IV
48173459|NCT02200978|DRUG|Ara-C|Given IV
48173460|NCT02200978|DRUG|MTX|Given orally
48173461|NCT02200978|DRUG|6MP|Given orally
48173462|NCT02200978|OTHER|intrathecal injection|Ara-C and dexamethasone
48173463|NCT05221177|BEHAVIORAL|TR-30|Suspension training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
48173464|NCT05221177|BEHAVIORAL|TR-45|Suspension training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
48173465|NCT05674292|DEVICE|Erchonia Violet Zerona Z6|405nm violet diode low level laser device
48173466|NCT03352882|DIAGNOSTIC_TEST|Ultrasound|Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
48173467|NCT02767518|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
48173468|NCT02206932|DRUG|Sofosbuvir + Simeprevir|
48173469|NCT03454659|PROCEDURE|Craniotomy|Extracting the part of the sculpt
48173470|NCT01538225|DRUG|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"
48173471|NCT01538225|DRUG|Placebo|"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"
48173472|NCT06069453|DEVICE|Hyaluronic Acid (HA) sodium salt and Hydeal-D|intravesical solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
48173473|NCT03300609|BIOLOGICAL|Panitumumab|Given IV
48173474|NCT03300609|DRUG|Oxaliplatin|Given IV
48173475|NCT03300609|DRUG|Leucovorin Calcium|Given IV
48173476|NCT03300609|DRUG|Fluorouracil|Given IV
48173477|NCT03300609|DRUG|Capecitabine|Given PO
48173478|NCT03300609|OTHER|Quality-of-Life Assessment|Ancillary studies
48173479|NCT03300609|OTHER|Laboratory Biomarker Analysis|Correlative studies
48173480|NCT04921748|PROCEDURE|Neurorehabilitation|All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
48173481|NCT06064370|PROCEDURE|laparoscopic adrenalectomy|laparoscopic adrenalectomy for pheochromocytoma
48173482|NCT03462537|DEVICE|Low level laser therapy|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
48173483|NCT03462537|DEVICE|Aerobic Exercise|Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
48173484|NCT03462537|DEVICE|Low level laser therapy without power|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
48173485|NCT00239096|DRUG|losartan (drug)|
48016635|NCT05956314|DIAGNOSTIC_TEST|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort).~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
48016636|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
48016637|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
48016638|NCT05956314|DIAGNOSTIC_TEST|Lesion photography|"High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
48016639|NCT05956314|DRUG|KM-001 cream 1% 16 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
48016640|NCT03168347|BEHAVIORAL|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
48016641|NCT03168347|BEHAVIORAL|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
48016642|NCT03168347|BEHAVIORAL|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
48016643|NCT03168347|BEHAVIORAL|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
48016644|NCT02820194|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
48373886|NCT03343002|DRUG|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
48373887|NCT03343002|DRUG|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
48373888|NCT04162717|BEHAVIORAL|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
48373889|NCT02438293|OTHER|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
48373890|NCT03501134|DEVICE|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
48373891|NCT00066274|DRUG|FOLFIRI regimen|
48705194|NCT06606054|OTHER|Educational and implementation Neurocardiology tool|Sites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.
48173486|NCT00505414|DRUG|Tapentadol in the Titration Phase|
48173487|NCT00505414|DRUG|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
48373892|NCT00066274|DRUG|FOLFOX regimen|
48373893|NCT00066274|DRUG|fluorouracil|
48373894|NCT00066274|DRUG|irinotecan hydrochloride|
48373895|NCT00066274|DRUG|leucovorin calcium|
48373896|NCT00066274|DRUG|oxaliplatin|
48705195|NCT06606054|OTHER|No educational or implementation tool will be provided|Participants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
48705196|NCT03894969|BIOLOGICAL|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
48705197|NCT03894969|BIOLOGICAL|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
48173488|NCT00505414|DRUG|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
48173489|NCT00505414|DRUG|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
48373897|NCT04678180|BEHAVIORAL|Combined HRT and ERP|tic training using the principles of HRT and ERP as to reduce tic intensity
48373898|NCT06056076|OTHER|Mini Squats Training|Mini Squats at a rate of ten squats at minimum range around 10-15 degrees at start along with Interferential Therapy for 10 minutes.
48373899|NCT06056076|OTHER|Endurance Training|Endurance training by the use of medium resistance therapeutic band at start along with Interferential Therapy for 10 minutes.
48373900|NCT02163759|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
48373901|NCT02163759|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
48373902|NCT02163759|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
48373903|NCT02163759|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
48373904|NCT05731830|OTHER|Data extraction|"The exposure of patients to air pollution compounds in the two years prior to the occurrence of TTS will be analysed. We will investigate: PM10, PM2.5, O3, NO2, C6H6, SO2 e CO. Residential addresses will be obtained from medical records. Annual average 24-h of pollutants levels will be measured matching each individual's home address, and the ArpaLazio website (http://www.arpalazio.net/main/aria/sci/basedati/chimici/chimici.php), which provides the concentration of NO, NO2, NOx, PM10, PM2.5, O3, CO, C6H6, SO2 expressed in micrograms per cubic meter (µg/m3). Hourly data are available for all gaseous pollutants, while the levels of PM10 and PM2.5 are expressed daily. Data will be obtained from the air quality monitor closest to each participant's residence that was active for the entire year, and short-term (daily and weekly) and long-term (annual) air pollution exposure will be quantified as daily, weekly, and annual average 24-h pollutants level of measurements before TTS."
48373905|NCT05731830|OTHER|Clinical follow-up|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 6, 12, 24, 36, 48 and 60 months from hospital discharge, during which the incidence of MACE, defined as the composite of all-cause mortality, non-fatal MI, transient ischemic attack (TIA)/stroke, and hospitalization for heart failure, and the recurrence of TTA in the past months will be investigated and collected.
48373906|NCT04353570|OTHER|clinical interview|This interview can be carried out face to face or remotely. In the latter case, it is part of telemedicine, which is recognised by the health authorities in France.
48373907|NCT04002466|OTHER|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
48373908|NCT01476891|OTHER|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
48705198|NCT01854892|OTHER|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
48705199|NCT01854892|OTHER|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
48705200|NCT01854892|OTHER|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
48016645|NCT02820194|PROCEDURE|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
48373909|NCT01476891|OTHER|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
48373910|NCT04911361|DRUG|Dexamethasone|Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)
48373911|NCT00406939|GENETIC|IL-12 gene|
48705201|NCT05592366|BEHAVIORAL|Care Partner Hospital Assessment Tool|Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
48705202|NCT01080768|DRUG|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
48705203|NCT01080768|DRUG|Amlodipine|Amlodipine 5 mg/day.
48705204|NCT01080768|DRUG|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
48705205|NCT01080768|DRUG|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
48705206|NCT02180256|PROCEDURE|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
48705207|NCT02116647|BEHAVIORAL|Psychoanalytic therapy|
48705208|NCT02295215|OTHER|Exercise|Exercise Training for 4 months
48373912|NCT00646217|BEHAVIORAL|Self Care Talk|6 weekly telephone sessions
48705209|NCT01588314|DRUG|Gabapentin|gabapentin 100 mg capsules
48016646|NCT06043557|PROCEDURE|Drain Placement|Surgical placement of drain based on subject randomization.
48016647|NCT03465696|BEHAVIORAL|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
48373913|NCT04098003|DRUG|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
48373914|NCT04098003|DRUG|Placebo|Matched placebo control
48373915|NCT04427241|DRUG|Cerebrolysin|30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously
48373916|NCT04427241|DRUG|Control|100 ml normal saline, days 4-17, once/day, IV
48373917|NCT01062529|DRUG|Somatostatin|4 h of 150 microgram infusion
48373918|NCT02369874|DRUG|MEDI4736|MEDI4736 Monotherapy
48373919|NCT02369874|DRUG|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
48373920|NCT02369874|DRUG|Standard of Care|Standard of Care
48373921|NCT00777504|DRUG|usage oral angiogenesis inhibitor|see under 'study arms'
48373922|NCT00777504|DRUG|stop oral angiogenesis inhibitor|see under 'study arms'
48705210|NCT01588314|DRUG|placebo|compounded placebo capsules
48705211|NCT06608329|DRUG|HDM1002|Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
48705212|NCT06489795|PROCEDURE|Laparoscopic or robot-assisted radical/simple hysterectomy|In the experimental arm, patients with early-stage cervical cancer will be treated by using laparoscopic or robot-assisted radical, or in the case of SHAPE criteria, simple hysterectomy.
48705213|NCT06489795|PROCEDURE|Abdominal radical/simple hysterectomy|In the control arm, patients with early-stage cervical cancer will be treated by using abdominal radical, or in the case of SHAPE criteria, simple hysterectomy as standard therapy.
48705214|NCT05024929|PROCEDURE|Whole body scan|"Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor."
48705215|NCT01329796|DRUG|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
48705216|NCT01329796|DRUG|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
48705217|NCT03216304|DRUG|100 mg safinamide|"Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
48705218|NCT03216304|DRUG|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
48016648|NCT03465696|BEHAVIORAL|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
48016649|NCT06323304|OTHER|Auricular acupressure|Auricular acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds, which is an herb in traditional medicine. The acupoints on the ear that will be treated with auricular acupressure therapy are Shenmen (TF4), Internal nose (TG4), Lung (CO14), Wind stream (SF1,2i), Adrenal gland (TG2p). These acupoints are believed to be effective in the treatment of allergic rhinitis. The patches will be kept on the auricle for one week.
48016650|NCT06323304|OTHER|Sham acupressure|Sham acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds. The acupoints that will be treated with auricular acupressure therapy are Helix 2 (HX10), Shoulder (SF4), Clavicle (SF6), Anus (HX5) and Tooth (LO1). These acupoints are not used to treat allergic immune-related problems or respiratory diseases. The patches will be kept on the auricle for one week.
48016651|NCT06323304|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.
48016652|NCT01507428|DRUG|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
48016653|NCT01507428|DRUG|Carboplatin|Given IV
48016654|NCT01507428|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
48016655|NCT01507428|PROCEDURE|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
48016656|NCT01507428|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
48016657|NCT01507428|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
48016658|NCT01507428|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
48016659|NCT01507428|OTHER|Laboratory Biomarker Analysis|Correlative studies
48016660|NCT01507428|DRUG|Paclitaxel|Given IV
48373923|NCT02120690|DEVICE|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
48373924|NCT06333431|DEVICE|Glass Waterfall group|Except for the preparation the gastroscopy procedure takes approximately 20 minutes, patients will be asked to focus on portative glass waterfall during the procedure.
48373925|NCT06333431|DEVICE|white noise group|Except for the preparation of the patient for the procedure, since the gastroscopy procedure takes approximately 20 minutes, 20-minute white noise be listened using phone
48373926|NCT03027258|OTHER|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
48373927|NCT04651569|OTHER|Observational study|none, Observational study
48373928|NCT05821166|DEVICE|moderate Whole Body Hyperthermia (mWBH)|Patients receiving 3-4 times mWBH
48016661|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
48016662|NCT01507428|PROCEDURE|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
48016663|NCT06223672|OTHER|Walnuts|56g of walnuts consumed each day for 7 days
48016664|NCT06223672|OTHER|Simply White Diary-free chocolate bar|68g of the white chocolate style-bar each day for 7 days
48173490|NCT00505414|DRUG|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
48705219|NCT03216304|DRUG|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
48705220|NCT00599404|DRUG|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
48016665|NCT03997903|DRUG|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
48016666|NCT04706624|BEHAVIORAL|High intensity contingency management|Participants receive 12 weeks of contingency management.
48016667|NCT04706624|BEHAVIORAL|Low intensity contingency management|Participants receive 6 weeks of contingency management and 6 weeks of group education.
48016668|NCT04706624|BEHAVIORAL|SMS reminders|Participants receive two daily SMS reminders plus one weekly self-monitoring assessment.
48016669|NCT04706624|BEHAVIORAL|Matrix only|Participants attend 12 weekly Matrix group counseling sessions.
48016670|NCT04706624|BEHAVIORAL|Matrix + Contingency management|Participants attend 12 weekly Matrix group counseling sessions plus 12 weeks of contingency management.
48705221|NCT01774253|DRUG|Vismodegib|
48016671|NCT06250686|BEHAVIORAL|combined exercise and nutrition intervention|Patients will be instructed on how to use the Physitrack app. At the start of chemotherapy, patients will be contacted by physiotherapists and dietitians from the University Medical Center Hamburg-Eppendorf either via video call using the app or by phone to discuss the first week's program. Patients can either complete the exercise program at home using the app or receive printed exercise plans in the mail to be completed with the physical therapist of their choice. The exercise program is adjusted weekly until week 9. After week 10, adjustments are made every two weeks. For each program, patients receive a 30-minute counseling session to discuss the exercises. The 30-minute nutritional counseling session occurs every two weeks. For patients receiving neoadjuvant chemotherapy, the exercise program is interrupted for the time of surgery and the two-week recovery period and resumed when chemotherapy is resumed.
48016672|NCT02851108|DRUG|Methylene Blue|50 patients will receive methylene blue
48373929|NCT02354040|BEHAVIORAL|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
48705222|NCT01212211|OTHER|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
48016673|NCT02851108|DRUG|Primaquine|50 patients will receive primaquine
48016674|NCT02117063|BEHAVIORAL|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
48016675|NCT00687505|DRUG|FP-1039|Intravenous weekly administration
48016676|NCT01790412|BEHAVIORAL|Exercise group|Combined two land aerobic sessions and one aquatic activities session
48016677|NCT05686330|DEVICE|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
48016678|NCT04221295|BEHAVIORAL|Exercise Group|Previously described in the arm/group descriptions.
48016679|NCT01332149|DRUG|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
48016680|NCT01332149|DRUG|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
48016681|NCT05676697|DRUG|Linperlisib|The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
48016682|NCT03995004|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
48373930|NCT05900674|DRUG|Reteplase Injection|To test the single dose of reteplase (9 U) and Maximum dose (18 U) in acute ischemic stroke patients.
48373931|NCT03297710|OTHER|Quality-of-Life Assessment|Ancillary studies
48373932|NCT03297710|RADIATION|Radiation Therapy|Undergo radiation therapy
48373933|NCT03297710|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
48373934|NCT00834366|DRUG|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
48373935|NCT02035891|DRUG|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
48016683|NCT03995004|DRUG|Dexamethasone Sodium Sulphate 4mg/1mL|Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
48016684|NCT00000781|DRUG|Nevirapine|
48373936|NCT02035891|DRUG|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
48016685|NCT00000781|DRUG|Zidovudine|
48016686|NCT00000781|DRUG|Zalcitabine|
48016687|NCT00000781|DRUG|Didanosine|
48373937|NCT01589185|DRUG|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
48373938|NCT01589185|DRUG|Placebo|Placebo administered as a single intravenous infusion
48373939|NCT01993290|DRUG|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
48373940|NCT04784676|OTHER|restoration|indirect restoration
48373941|NCT00766727|DEVICE|GLYDe Dressing|Wound dressing intended to minimize scar formation
48373942|NCT05160766|BIOLOGICAL|Comirnaty(BTN162b2)|Single booster shot (4th dose) of already approved BioNTech/ Pfizer vaccine that protect against COVID-19 infection
48373943|NCT05160766|BIOLOGICAL|Spikevax (mRNA-1273)|Single booster shot (4th dose) of already approved Moderna vaccine that protect against COVID-19 infection
48016688|NCT04473040|DRUG|alpelisib|Alpelisib is provided as 50 mg and 200 mg film coated tablets as individual patient supply, packaged in bottles. Alpelisib will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. Alpelisib will be administered at a starting dose of 300 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.
48016689|NCT00399334|DRUG|antipsychotic medications|as prescribed
48016690|NCT05447988|DEVICE|Breast Tissue Expander|tissue expander based breast reconstruction
48016691|NCT04417491|DEVICE|Dry Needling|Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
48016692|NCT04417491|DEVICE|Sham Needling|Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
48016693|NCT01396616|DEVICE|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
48016694|NCT04889092|OTHER|Blood Flow Restriction exercise|Exercise training will consist of blood flow restriction exercise. Specifically blood pressure cuff will be wrapped around the most proximal portion of the thigh and inflated to a pressure that is 80% of the pressure required to completely occlude femoral blood flow. With the cuff inflated the subject will perform a series of knee extension/flexion exercise protocol. This consists of 30 reps, 15 reps, 15 reps and 15 reps all separated by 1 minute of recovery. All reps will be performed at 30% of the subjects 1 repetition max. This will be preformed 20 times over 8 weeks.
48016695|NCT04889092|OTHER|Traditional resistance exercise|Traditional knee extension/flexion exercise will be performed. This will consist of a series of 13 reps, 12 reps, 12 reps with 1 minute recovery between each set. The resistance will be set at 60% of their 1 repetition max. This will be performed 20 times across 8 weeks.
48016696|NCT04661033|DRUG|Isatuximab SAR650984|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
48016697|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
48016698|NCT01465802|DRUG|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
48016699|NCT01465802|DRUG|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
48016700|NCT01465802|DRUG|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
48016701|NCT01465802|DRUG|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
48016702|NCT06564376|DIAGNOSTIC_TEST|total magnesium|Treatment based on total Magnesium
48016703|NCT06564376|DEVICE|ionized magnesium|Treatment based on ionized magnesium
48016704|NCT04303260|BEHAVIORAL|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
48373944|NCT00981695|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
48016705|NCT01094275|DRUG|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
48016706|NCT06663709|OTHER|BRACE|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 0-3 : Balance: Romberg, tandem standing, single leg stance TUG test Resistance: chair rise, Stair climbing Aerobic exercises: 6mint walk, count reverse from 30, push wall and reverse count from 20 Cognitive: count reverse from 50. Week 4-6: Balance: Sit to stand, functional reach, Tug Test, Perturbation, Kick a ball Resistance: stair climbing Aerobic Exercises: Marching in space, Cycling Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Combination of all Resistance: Combination of all Aerobic Exercises: Cycling , Marching, 6 min Walk Cognitive: Combination of all
48016707|NCT06663709|OTHER|TASK-oriented|Study will be conducted after the approval of Ethical review board. Task oriented training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 1-3 Warm Up (sit to stand,5 reps)(cycling 3-5 min) , Single leg stand with eye open 15 sec, with eye close 10sec, forward, backward, and side stepping (5 reps) reaching, Transition from sit to stand, Walk then back to sit (3 min),Walk with even steps(3min) Walk with carrying objects. (3min) Week 4-6 Warm up Period, Task oriented training (7 Reps of each task) Week 7-9 Warm up Period, Task oriented training (9Reps of each task)
48016708|NCT04638608|OTHER|EMBRACE (relatives)|Online support program for both relatives
48016709|NCT04638608|OTHER|EMBRACE (Health care providers)|Online support program for health care providers
48016710|NCT05928221|DEVICE|Thrombectomy|removal of fresh soft emboli and thrombi from the vessels of the venous system
48705223|NCT04526353|DRUG|Oxybutynin 1 mg/ml Syrup|"The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children \<1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012"
48705224|NCT03479268|DRUG|Ibrutinib|Given PO
48705225|NCT03479268|OTHER|Laboratory Biomarker Analysis|Correlative studies
48705226|NCT03479268|DRUG|Pevonedistat|Given IV
48173491|NCT04072666|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|The first session is based on a narrative interview with the consumer relating the personal story of how the point of attempting suicide was reached, videorecorded with consent. The second session involves the therapist and consumer watching the session together to reactivate the consumer's mental state during the crisis in a safe environment. Automatic thoughts, emotions, psychological pain and stress, and contingent behaviour are discussed. A psycho-educative handout is given to consumers. The third session involves discussing the handout. A credit card size leaflet is provided, with long term goals, individual warning signs and safety strategies listed, in addition to a card with crisis phone numbers. The sessions are followed by letters sent over 24 months (Michel, Valach \& Gysin-Maillart, 2017).
48373945|NCT03237325|DRUG|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
48373946|NCT03237325|DRUG|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
48705227|NCT03479268|OTHER|Pharmacokinetic Study|Correlative studies
48705228|NCT03479268|OTHER|Pharmacological Study|Correlative studies
48705229|NCT03904953|OTHER|Pilates Training|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
48705230|NCT03904953|OTHER|Conventional exercise programme|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
48705231|NCT02826434|BIOLOGICAL|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
48705232|NCT02826434|BIOLOGICAL|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
48705233|NCT02826434|DRUG|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
48016711|NCT06395753|DRUG|Debio 4228|Administered as IM injection.
48016712|NCT00451620|DRUG|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
48016713|NCT00451620|DRUG|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
48016714|NCT04496258|BEHAVIORAL|Positive Emotion Induction|Participants are expected to have a positive emotional response to the more positive beach scene.
48016715|NCT04496258|BEHAVIORAL|Neutral Emotion Induction|Participants are expected to have a neutral emotional response to the neutral office scene.
48016716|NCT05591417|PROCEDURE|Bilevel Erector spinae plane block|Patients will receive bilevel erector spinae plane block with bupivacaine
48016717|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexamethasone|Patients will receive bilevel erector spinae plane block with bupivacaine and dexamethasone
48016718|NCT05591417|PROCEDURE|Bilateral Erector spinae plane block with dexmedetomidine|Patients will receive bilevel erector spinae plane block with bupivacaine and dexmedetomidine
48016719|NCT05591417|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
48016720|NCT05375513|OTHER|PMI@Home|"Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control."
48016721|NCT05375513|OTHER|Brain Health Pro|"Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting"
48016722|NCT02352324|OTHER|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
48705234|NCT05818917|DRUG|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
48705235|NCT05452954|BEHAVIORAL|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
48705236|NCT00301600|DRUG|Mycophenolate mofetil|MMF,1.0g/d
48705237|NCT00211393|DRUG|ketoconazole|600mg. /day for 6 weeks
48705238|NCT03546595|OTHER|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
48173492|NCT04072666|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The intervention incorporates skills development and emphasises internal self-management. Therapy focuses on the identification of internal, external and/or thematic triggers for suicidal thinking and behaviours, as well as factors that maintain the desire to suicide, using thought records and/or chain analyses. Therapy aims to challenge distortions and misconceptions, including core beliefs that interfere with the motivation to initiate the process of problem solving and distress tolerance, by working on acceptance of emotional and/or physical pain. The final phase of treatment focuses on relapse prevention. CBT can challenge maladaptive beliefs, improve problem solving skills and social competence.
48016723|NCT04875806|DRUG|NC762|NC762 is an experimental antibody drug that may make the immune response more active against cancer
48173493|NCT04072666|BEHAVIORAL|Suicide Prevention Pathway (SPP)|The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, \& Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
48173494|NCT05085561|DRUG|REC-994|REC-994 200 mg tablets
48173495|NCT05085561|DRUG|Placebo|Placebo Tablets
48173496|NCT06417944|DIAGNOSTIC_TEST|Scoliosis study form|Scoliosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with spine deformity will be filled in detail.
48373947|NCT05858216|DRUG|Chlor-Trimeton.|Package dose of Chlor-Trimeton will be administered
48373948|NCT00990782|DIAGNOSTIC_TEST|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
48373949|NCT02549391|DRUG|KHK7580|Oral administration
48016724|NCT02436512|DRUG|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~* (Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~* (Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
48016725|NCT02905305|DEVICE|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
48016726|NCT02905305|DEVICE|Contour Advance electrode|Standard Contour Advance electrode
48373950|NCT02549391|DRUG|KRN1493|Oral administration
48373951|NCT03344029|BIOLOGICAL|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
48373952|NCT03344029|BIOLOGICAL|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
48373953|NCT02111473|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
48705239|NCT03546595|OTHER|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
48705240|NCT05151432|DEVICE|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
48173497|NCT06417944|DIAGNOSTIC_TEST|Scoliosis X-ray (orthorontgenogram)|Patients whose Adam's forward bending test and clinical evaluation results are compatible with scoliosis, scoliosis graphy are requested. (Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 5 degrees in those with BMI (Body Mass Index) above 85%. If it is below 85% and above 7 degrees, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis film will be requested.).Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
48373954|NCT03568968|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
48373955|NCT03568968|OTHER|Placebo|Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
48705241|NCT05151432|DEVICE|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
48705242|NCT05151432|OTHER|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
48705243|NCT05151432|DEVICE|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US \& Electromagnetic field.
48705244|NCT02150057|DEVICE|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
48705245|NCT00831610|PROCEDURE|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
48373956|NCT03341559|DEVICE|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
48705246|NCT00831610|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
48705247|NCT06468527|DRUG|Diponecaftor|"Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day"
48016727|NCT05726656|OTHER|traditional physical therapy session|manual lymph drainage-pneumatic compression and skin care
48016728|NCT05726656|OTHER|wii console based exercise|execise session using the wii console video games
48016729|NCT00062426|BIOLOGICAL|bevacizumab|
48173498|NCT06417944|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. We will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
48173499|NCT06417944|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter- cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
48173500|NCT06417944|PROCEDURE|Three-dimensional Exercise (BSPTS Schroth Exercise)|"It only provides outpatient treatment, but it has different practices, intensive or regular, depending on local and external patients. For local patients, it is applied once a week, accompanied by a therapist, and the treatment duration is determined according to the patient's condition. In patients coming from outside; It can be continued as 2 hours a day for 10 days, then as additional treatment for 1-2 weeks for 3-6 months depending on the patient's condition. I In regular treatment; 30 sessions of 90 minutes group treatment, the first 8 sessions are carried out under the supervision of a therapist for a shorter period of time.~We will give 10 sessions of BSPTS Schroth exercises, either outpatient or inpatient. After 10 sessions of the Schroth exercise program, the home program will continue two months after outpatient/inpatient schroth exercise(Home program: 5 days/week, 45-60 minutes for all patients)."
48173501|NCT06417944|PROCEDURE|Home Exercise|In the home exercise program; daily living activities, neutral pelvis exercises, coronal balance exercises, rotational angular breathing exercises and axial elongation exercises were taught by the physiotherapist in one session. A total of 10-week home exercise program was planned, with exercises to be performed twice a week for the first two weeks, once every 15 days for 1 month (twice in one month), and then once a month.
48173502|NCT06480253|DEVICE|Helmet Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on inspired fraction of oxygen (FiO2)= 21% with the Helmet interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
48705248|NCT06468527|DRUG|Placebo|Placebo once daily for 8 weeks. Oral administration.
48705249|NCT02178813|DRUG|Administration of minocycline|"Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o."
48705250|NCT04446260|DRUG|SHR-A1811|be administered via intravenous (IV) infusion
48705251|NCT00343369|DRUG|asparaginase|
48016730|NCT00062426|DRUG|capecitabine|
48016731|NCT00062426|DRUG|fluorouracil|
48016732|NCT00062426|DRUG|leucovorin calcium|
48016733|NCT00062426|DRUG|oxaliplatin|
48016734|NCT00265811|DRUG|Folfox|
48016735|NCT00265811|DRUG|Cetuximab|
48016736|NCT06028061|PROCEDURE|Adjuvant-free Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
48016737|NCT06028061|PROCEDURE|Quadratus lumborum block III with Adjuvant|The same block was applied to this group too, but a different local anesthetic mixture was used.Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine and 4mg dexamethasone is injected. The same is done to the opposite side.
48016738|NCT03680729|BEHAVIORAL|Adapted Brothers Saving Brothers (aBSB)|This information is listed in the arm description.
48016739|NCT03680729|BEHAVIORAL|Standard Street Outreach|This information is listed in the arm description.
48173503|NCT06480253|DEVICE|Oronasal Mask Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on Inspired fraction of oxygen (FiO2)= 21% with the oronasal mask interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
48016740|NCT03798808|OTHER|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
48173504|NCT05235841|OTHER|acupressure|Acupressure is a complementary and supportive approach used in symptom management.
48173505|NCT04363710|OTHER|Low Calorie Diet|800-1000 Kcal/day
48373957|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~- Ipilimumab will be administered in a 3 + 3 dose escalation design.~* The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~* If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~* The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~* In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~* Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
48373958|NCT03297463|DRUG|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~- Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
48373959|NCT01041027|DRUG|Paclitaxel|Given IV
48016741|NCT06216951|PROCEDURE|Vital Pulpotomy|Vital pulpotomy involves the removal of the coronal pulp, while MTA is used to seal the root orifices. It is clear that vital pulp treatments for symptomatic pulpitis are a more reliable, cost-effective, and generally easier option than root canal treatment (RCT) once the mineral trioxide aggregate (MTA) is introduced in dentistry. In vital pulpotomy, as opposed to RCT, tooth healing and symptoms are diminished while the vitality of the tooth is maintained. Furthermore, vital pulpotomy is a significantly more practical and economical treatment alternative than RCT.
48016742|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
48016743|NCT03962881|BIOLOGICAL|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
48016744|NCT03962881|BIOLOGICAL|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
48016745|NCT04011059|BIOLOGICAL|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
48016746|NCT01049880|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
48016747|NCT04657159|OTHER|Pain rehabilitation program|Effect on health related quality of life och health-care consumption after rehabilitation
48016748|NCT06589661|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under general anesthetic.
48173506|NCT04853134|DRUG|Proxalutamide|200 mg q.d.
48173507|NCT04853134|OTHER|Standard of Care|Standard of care as determined by the PI
48173508|NCT03195049|DIAGNOSTIC_TEST|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
48173509|NCT03607617|OTHER|SDH Tool|The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
48173510|NCT01461005|DEVICE|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
48173511|NCT01340300|BEHAVIORAL|Exercise training|Two supervised exercise sessions per week
48173512|NCT01340300|DRUG|Metformin|Oral metformin QD for two weeks, then BID
48173513|NCT01340300|OTHER|Educational information|educational information
48373960|NCT01041027|DRUG|Carboplatin|Given IV
48373961|NCT01041027|RADIATION|Internal Radiation Therapy|Undergo HDR brachytherapy
48373962|NCT01041027|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48373963|NCT01041027|OTHER|Laboratory Biomarker Analysis|Correlative studies
48373964|NCT01024270|DRUG|Misoprostol|
48373965|NCT04523363|DRUG|Metformin|Maximum dosage of 500 mg tablets 2 times a day (with each meal)
48373966|NCT02319265|DRUG|Melatonin|Oral liquid
48373967|NCT00810654|DIETARY_SUPPLEMENT|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
48373968|NCT00810654|DIETARY_SUPPLEMENT|Placebo|Placebo
48373969|NCT05375045|DEVICE|dental implantation|an implant is surgically inserted into the maxilla or mandible, and then an abutment is connected to this implant to support the dental prosthesis.
48705252|NCT00343369|DRUG|cyclophosphamide|
48705253|NCT00343369|DRUG|cytarabine|
48705254|NCT00343369|DRUG|daunorubicin hydrochloride|
48705255|NCT00343369|DRUG|dexamethasone|
48705256|NCT00343369|DRUG|doxorubicin hydrochloride|
48373970|NCT01797458|PROCEDURE|Hall Technique|"Technique:~* Removal of dental plaque and rest of aliments from the cavity~* Selection of the SSC~* If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~* Dry the crown and fill with glass-ionomer luting cement~* Place the crown over the tooth~* Removal of cement excesses from the crown margins~* The child should be asked to keep biting on the crown until the cement has set"
48705257|NCT00343369|DRUG|mercaptopurine|
48705258|NCT00343369|DRUG|methotrexate|
48705259|NCT00343369|DRUG|pegaspargase|
48705260|NCT00343369|DRUG|prednisolone|
48705261|NCT00343369|DRUG|teniposide|
48705262|NCT00343369|DRUG|thioguanine|
48705263|NCT00343369|DRUG|vincristine sulfate|
48705264|NCT00343369|RADIATION|radiation therapy|
48705265|NCT03734653|DRUG|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
48705266|NCT03734653|DRUG|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
48705267|NCT05354466|DRUG|Sugammadex injection|sugammadex as reversal agent
48016749|NCT05412550|BEHAVIORAL|Exercise self-management|Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.
48016750|NCT05412550|BEHAVIORAL|Attention control|The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
48016751|NCT05293275|DEVICE|EaseVRx Virtual Reality Headset|Virtual reality device with 360 degree visualization of various scenery and interactive modules
48705268|NCT05354466|DRUG|Neostigmine|neostigmine as a reversal agent
48705269|NCT02356419|DRUG|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
48705270|NCT06069141|DRUG|Benzathine Penicillin G|Benzathine Penicillin G (2.4 MU intramuscularly once)
48705271|NCT06069141|DRUG|Doxycycline Capsule|doxycycline (100 mg orally twice daily for 7 days)
48705272|NCT00024661|DRUG|LErafAON|
48016752|NCT05313516|DEVICE|OKKO Health app|Use of OKKO Health app for home monitoring.
48173514|NCT04485754|OTHER|Telemedicine FU|Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
48705273|NCT04765423|DEVICE|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
48705274|NCT04765423|DEVICE|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
48705275|NCT06384274|OTHER|Emotional Freedom Technique|All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.
48705276|NCT06384274|OTHER|Virtual Reality Glasses|It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
48705277|NCT06607042|BEHAVIORAL|Psychotherapy|Psychotherapy according to the Berlin Dissexuality Therapy (BEDIT)
48705278|NCT01327053|DRUG|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
48705279|NCT04137588|DRUG|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
48705280|NCT04137588|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
48705281|NCT03908372|DRUG|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
48705282|NCT03908372|DRUG|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
48705283|NCT03908372|RADIATION|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
48173515|NCT04485754|OTHER|Office FU|Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
48173516|NCT03183180|DIAGNOSTIC_TEST|Echocardiogram|Current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination
48705284|NCT04854967|OTHER|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
48705285|NCT04854967|BEHAVIORAL|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
48705286|NCT04854967|BEHAVIORAL|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
48016753|NCT06294509|DEVICE|in-house developed transcutaneous auricular Vagus Nerve Stimulation device|taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus. The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation. Before each session, taVNS is calibrated for each participant. Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached. Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train. Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation. Participants adapt their movements over up to six sessions across two weeks. The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
48016754|NCT02367313|DRUG|Vapendavir|Vapendavir 264 mg twice daily
48016755|NCT02367313|DRUG|Vapendavir|Vapendavir 528 mg twice daily
48016756|NCT02367313|DRUG|Placebo|Placebo twice daily
48016757|NCT01809626|DRUG|Zolpidem|
48016758|NCT01809626|OTHER|Placebo|
48016759|NCT06663982|PROCEDURE|Connective tissue graft + L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket. Following papilla incisions, an intra-sulcular incision on the vestibular side of the extraction socket will be extended with a #15c scalpel, creating a socket to insert the connective tissue graft (CTG). The CTG will be harvested from the palatal area following a specific incision technique to obtain a graft around 1.5 mm thick, which will be fixed with a mattress suture.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
48016760|NCT06663982|PROCEDURE|L-PRF|"After administering local anesthesia, an atraumatic extraction will be conducted, preserving the buccal bone and carefully debriding the alveolar socket.~Then the socket will be filled with L-PRF plugs. A collagen sponge will cover the extraction socket and L-PRF, secured with a 4-0 cross suture. Sutures will be removed after 15 days."
48016761|NCT05580718|BEHAVIORAL|MI-CBT|"* Education Common reactions following MI and general lifestyle advice on e.g., physical activity. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation.~* Goal setting Identifying life areas impaired by MI-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Exposure therapy Exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms. Gradual exposure to avoided situations, activities and increase in physical activity.~* Relapse prevention Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
48016762|NCT01752933|DRUG|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
48016763|NCT03724604|DIAGNOSTIC_TEST|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
48373971|NCT01797458|PROCEDURE|Non-Restorative Caries Treatment|"Technique:~* A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~* Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~* Show the cavity to patient/parents and give them tooth-brushing instructions~* Tell to parents that good plaque control is the key for this treatment~* The recall interval for these patients is every 3 months."
48373972|NCT01797458|PROCEDURE|Conventional Restoration|"Technique:~* Local anesthesia should be used when needed~* Perform complete caries removal and cavity preparation~* Use a matrix band and a wedge to tightly hold the band against the tooth~* Place the material (Compomer)~* Check contacts and occlusion, and polish the restoration"
48373973|NCT06509438|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
48373974|NCT03056534|DEVICE|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
48373975|NCT03598712|DEVICE|Compression by chest bandage urgo K2®|"1. - Installation of a short stretch belt (urgo K2® kit)~2. - Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. - Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
48016764|NCT05941897|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
48016765|NCT05941897|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion
48016766|NCT04584567|DRUG|Doxycyclin|daily (100mg)
48016767|NCT02139163|OTHER|Cohort Study|
48016768|NCT05364554|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
48173517|NCT03046381|DRUG|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
48173518|NCT04228406|DRUG|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
48173519|NCT05997459|DRUG|Pemigatinib|Pemigatinib,13.5mg ,QD,po, 2 weeks / 1 week;Q 3W
48173520|NCT02325830|DEVICE|Carillon Mitral Contour System|Percutaneous mitral valve repair
48016769|NCT06662721|DRUG|Baricitinib 4 MG|The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
48016770|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fed, take orally on an empty stomach and then after meals
48173521|NCT05465759|OTHER|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
48173522|NCT01227928|DRUG|Pazopanib|Pazopanib 800 mg daily for 24 months
48173523|NCT01227928|DRUG|Placebo comparator|Placebo 800 mg daily for 24 months
48173524|NCT04040998|BEHAVIORAL|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
48173525|NCT00998829|OTHER|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
48173526|NCT05856578|DRUG|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
48173527|NCT05856578|DRUG|Canagliflozin|Canagliflozin 100mg po qd
48173528|NCT05247476|DRUG|L-T4|Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
48173529|NCT05247476|DRUG|L-T4+T3 (thyroid tablet)|Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
48173530|NCT06073223|OTHER|Usual Care|The control group will receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.
48173531|NCT06073223|OTHER|CQUPLE|"Our research team developed a novel intervention called CQUPLE (pronounced couple), which includes two interventions delivered together: (1) a Chart of side-by-side, evidence-based information comparing all three treatment options for low-risk thyroid cancer, including expected outcomes and (2) a Question Prompt List that contains key questions to consider asking the surgeon. The intervention is grounded in social cognitive theory and aims to increase patient awareness of treatment options and their outcomes, patient activation, and self-efficacy for decision making."
48173532|NCT00000447|DRUG|naltrexone (Revia)|
48173533|NCT00000447|DRUG|nicotine replacement patch|
48173534|NCT04633785|OTHER|No Intervention|There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
48173535|NCT02356796|OTHER|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
48173536|NCT02356796|OTHER|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
48173537|NCT00000232|DRUG|Buprenorphine|
48173538|NCT01684111|DRUG|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
48173539|NCT01684111|DRUG|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
48173540|NCT01743105|PROCEDURE|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
48173541|NCT01743105|PROCEDURE|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
48173542|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral solution.
48173543|NCT05423106|DRUG|Placebo|Placebo will be administered as an oral formulation.
48173544|NCT05423106|DRUG|Tenofovir Disoproxil Fumarate (TDF)|TDF tablet will be administered orally
48173545|NCT05423106|DRUG|Tenofovir Alafenamide (TAF)|TAF tablet will be administered orally.
48173546|NCT05423106|DRUG|Entecavir (ETV)|ETV tablet will be administered orally.
48173547|NCT05423106|DRUG|JNJ-64457744|JNJ-64457744 will be administered as oral tablet.
48173548|NCT02151630|DRUG|Pyruvic acid|
48373976|NCT03598712|PROCEDURE|punctures|Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
48016771|NCT05120219|DRUG|FDC tablet|single HR20033 FDC tablet fasted, take orally after meals and then on an empty stomach
48016772|NCT05120219|DRUG|FDC tablet|single and multiple doses of HR20033 FDC tablet
48016773|NCT04077034|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
48016774|NCT04077034|DIETARY_SUPPLEMENT|Placebo comparator|Placebo comparator, once a day for 8 weeks
48016775|NCT03685331|DRUG|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
48173549|NCT02151630|DRUG|Salicylic Acid|
48173550|NCT03197077|PROCEDURE|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
48173551|NCT03197077|PROCEDURE|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
48173552|NCT03197077|PROCEDURE|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
48016776|NCT03685331|DRUG|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
48016777|NCT03685331|DRUG|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
48016778|NCT02647034|OTHER|no intervention|no intervention
48016779|NCT05622591|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
48705287|NCT04854967|BEHAVIORAL|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
48705288|NCT04854967|BEHAVIORAL|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
48705289|NCT04359290|DRUG|Ruxolitinib administration|Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
48705290|NCT05785715|DRUG|NX-13 250mg|NX-13 250mg tablet, plus 2 placebo tablets
48705291|NCT05785715|DRUG|NX-13 750mg|NX-13 250mg tablets times 3 to equal 750mg
48705292|NCT05785715|DRUG|NX-13 Placebo|NX-13 Placebo tablets times 3 for blinding purposes
48705293|NCT03794206|DEVICE|Vesair Balloon|Treatment with Vesair Balloon for one year
48705294|NCT00012129|DRUG|liposomal annamycin|
48705295|NCT06609070|DRUG|CHG0521 Oral Coating|The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
48705296|NCT00037817|DRUG|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
48705297|NCT00037817|BIOLOGICAL|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
48705298|NCT00037817|DRUG|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
48016780|NCT02541266|OTHER|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
48016781|NCT03331874|DIAGNOSTIC_TEST|Reflectance Confocal Microscopy|In-vivo microscope
48016782|NCT04096560|DRUG|TAK-994|TAK-994 tablets.
48705299|NCT04463199|OTHER|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
48705300|NCT06083324|OTHER|Dose escalated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
48705301|NCT05061719|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
48705302|NCT01434394|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
48705303|NCT02842515|OTHER|teeth avulsion|
48705304|NCT05824039|DIETARY_SUPPLEMENT|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
48705305|NCT05513664|DRUG|Osimertinib|80 or 160 mg/qd
48705306|NCT02614170|OTHER|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
48016783|NCT04096560|DRUG|Placebo|TAK-994 placebo-matching tablets.
48016784|NCT05271929|BIOLOGICAL|Current standard of care and COVID-19 convalescent and vaccinated plasma|ABO compatible convalescent plasma infused intravenously on study day 1 (as soon as possible after randomisation) and the second on day 1 or day 2. Plasma obtained by apheresis from donors who have recovered from COVID-19 infection (at least 14 days after recovery) and have been vaccinated (at least 3 weeks after first dose of vaccine). A combination of both a SARS-CoV-infection and a SARS-CoV-2 vaccination of the donor is required - irrespective of the sequence of infection and vaccination. As far as the availability of CCP units allows, the two plasma units should have been donated by two different convalescents.
48016785|NCT05271929|OTHER|Current standard of care|"Standard of care therapy may include anti-SARS-CoV-2 specific medication such as, but not limited to:~* Casirivimab~* Casirivimab / Imdevimab (REGN-COV2 or Ronapreve)~* Imdevimab~* Sotrovimab (Xevudy)~* Tixagevimab / Cilgavimab (Evusheld)~* Molnupiravir (MK-4482)~* Nirmatrevlir / Ritonavir (Paxlovid)~* Remdesivir~Centres should ensure that medications used as standard of care are used similarly for patients in both treatment arms."
48016786|NCT01668316|BEHAVIORAL|Weight loss|"1. Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~2. Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~3. Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~4. Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
48016787|NCT04037527|DRUG|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
48173553|NCT03197077|DRUG|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
48173554|NCT03197077|DRUG|Follitropin beta|Daily injection (three days) of follitropin beta
48173555|NCT03197077|DRUG|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
48173556|NCT01836198|DRUG|LY2409021|
48173557|NCT01836198|DRUG|Gemfibrozil|
48173558|NCT01836198|DRUG|Ketoconazole|
48173559|NCT01836198|DRUG|Clarithromycin|
48705307|NCT01633203|DRUG|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
48705308|NCT03978637|DRUG|Itacitinib|Itacitinib administered orally at the specified dose.
48705309|NCT05143723|DRUG|Gonadotropin-releasing hormone agonist|luteal phase support with gonadotropin-releasing hormone agonist
48705310|NCT04155346|BEHAVIORAL|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
48705311|NCT02648997|DRUG|Nivolumab - 240 mg|240 mg every 2 weeks
48705312|NCT02648997|DRUG|Ipilimumab - 1 mg/kg|1 mg/kg every 3 weeks
48705313|NCT02648997|DRUG|Nivolumab - 480 mg|480 mg once every 4 weeks
48016788|NCT04037527|DRUG|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
48173560|NCT04169997|DRUG|IMP4927|IMP4297 tablet.The starting dose from 100mg QD
48173561|NCT04169997|DRUG|Placebos|Placebos tablet.The starting dose from 100mg QD
48173562|NCT05177783|BEHAVIORAL|Tuune health questionnaire|Participants complete the Tuune contraceptive decision aid health questionnaire.
48173563|NCT05177783|BEHAVIORAL|Control health questionnaire|Participants complete a standard physician intake health questionnaire.
48705314|NCT02648997|DRUG|Nivolumab - 3 mg/kg|3 mg/kg every 3 weeks
48016789|NCT04037527|RADIATION|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
48016790|NCT04037527|PROCEDURE|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
48173564|NCT04683328|BIOLOGICAL|SCTA01|Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
48173565|NCT04683328|BIOLOGICAL|SCTA01 Placebo|The excipients of SCTA01
48173566|NCT02475876|DRUG|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose =10 mg/kg."
48173567|NCT02475876|DRUG|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose = 6 mg/kg.~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose = 6 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose = 6 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose = 6 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose = 4 mg/kg."
48173568|NCT02188537|DRUG|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
48705315|NCT02648997|RADIATION|External Beam RT|IMRT, 3D-CRT, or proton-beam radiation therapy
48173569|NCT02188537|DRUG|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
48173570|NCT02188537|DRUG|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
48173571|NCT01863628|OTHER|aerobic exercise|
48173572|NCT01863628|OTHER|psychoeducation|
48705316|NCT01880749|DRUG|RAD001|
48705317|NCT05785741|DRUG|DB-1310|Administered I.V.
48705318|NCT05785741|DRUG|Trastuzumab|Administered I.V.
48705319|NCT05785741|DRUG|Osimertinib|Administered I.V.
48705320|NCT03158623|BIOLOGICAL|Platelet Rich Plasma|
48705321|NCT03158623|BIOLOGICAL|Cellerate|
48705322|NCT03843385|DRUG|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
48173573|NCT01650935|BEHAVIORAL|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate\>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
48173574|NCT06183411|BEHAVIORAL|Assessment|"* Observations using two valid, observational instruments (MABC-2 and ToM test-R) that each child completes once at random.~* A demographic and developmental questionnaire is completed once by the parent/guardian at recruitment.~* Standardized questionnaires (Coordination Questionnaire For Parents (CVO), Social Responsiveness Scale second edition (SRS-2), Strengths and Difficulties Questionnaire (SDQ) and Theory of Mind Behavior Checklist (ToMBC)) are also questioned once to parent/guardian for data collection."
48705323|NCT03843385|DRUG|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
48016791|NCT04037527|OTHER|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
48173575|NCT03121495|DIAGNOSTIC_TEST|Second forward view (SFV) examination of the right colon|The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
48173576|NCT01031849|DRUG|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
48705324|NCT03843385|DRUG|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
48016792|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016793|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016794|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016795|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016796|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016797|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016798|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016799|NCT00927927|DRUG|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
48016800|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
48016801|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
48016802|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
48016803|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
48016804|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
48016805|NCT00927927|DRUG|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
48016806|NCT00927927|DRUG|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
48016807|NCT05115994|DEVICE|Continous positive airway pressure|
48016808|NCT06216236|OTHER|Kinect intervention system combined with aerobic exercise training|A Kinect intervention system was used in the experimental group. The video displayed a skeletal simulation of the action. The participants could see their own actions and those of the teacher. After the video was completed, an accurate score for each action was displayed.
48016809|NCT06216236|OTHER|aerobic dance training|The control group used a video that did not show a skeletal simulation of the action and only saw the teachers movements.
48016810|NCT04355416|DRUG|curcumin Oral gel|application of curcumin oral gel after scaling and root planing
48016811|NCT04355416|PROCEDURE|subgingival scaling and root planing|subgingival scaling and root planing without application of curcumin gel
48173577|NCT04037345|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
48173578|NCT04037345|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
48705325|NCT04941807|DEVICE|Platelet-rich plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-rich plasma is injected into 8 proximal nail folds.
48016812|NCT04403022|DEVICE|Robotic Assisted Surgery|da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
48016813|NCT06183502|BEHAVIORAL|Quantitative survey|Quantitative surveys will be conducted through Alchemer, a HIPPA-compliant online survey system previously used by our group in collaborative research with CDC and supported by the Emory University Center for AIDS Research (CFAR). Surveys will be optimized for participants to take them through a personal computer, mobile phone, tablet, or the SMART study app. For participants who do not have any of these devices or prefer to not take the survey from their device, each city will have a research space where participants can schedule a convenient time to take the survey on a computer or tablet that the study will provide for that purpose.
48173579|NCT04037345|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
48173580|NCT02236663|BEHAVIORAL|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
48173581|NCT02236663|BEHAVIORAL|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
48705326|NCT04941807|DEVICE|Platelet-poor plasma|Blood will be drawn from a vein in the patient's arm into an 11 ml Eclipse platelet-rich plasma Tube. The blood is processed using a centrifuge machine from eclipse medical. After centrifugation, the platelet poor portion will be separated from the platelet-rich portion. The proximal nail folds are cleansed with alcohol. Using a 1ml syringe and 30g needle, 0.1-0.2 ml of platelet-poor plasma is injected into 2 proximal nail folds.
48705327|NCT06605313|DEVICE|SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System|Transcathether Edge-to-Edge repair for tricuspid regurgitation with SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System.
48173582|NCT04865510|PROCEDURE|Regional citrate anticoagulation|"The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6)."
48173583|NCT03602222|BEHAVIORAL|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
48173584|NCT03602222|BEHAVIORAL|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
48705328|NCT00744978|DRUG|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
48705329|NCT00744978|DRUG|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
48016814|NCT06183502|DIAGNOSTIC_TEST|HIV & STI testing|The research team has developed and validated procedures for self-collection of specimens for testing for STIs (syphilis, urethral, rectal, and pharyngeal gonorrhea/chlamydia) and HIV self-testing. All participants will be mailed self-collection kits to provide samples for STIs (urine, rectal swab, and pharyngeal swab for gonorrhea/chlamydia; dried blood spot (DBS) for syphilis testing) and HIV (HIV 4th generation testing on DBS specimens in a CLIA-certified laboratory). Participants will be asked to collect specimens for their STI and HIV testing (every 6 months) and return them to Molecular Testing Labs. For participants who prefer in-person procedures, they will meet study staff who will provide them with the STI and HIV self-collection kit and instructions and provide a room for participants to collect their specimens.
48173585|NCT03599622|DRUG|BMS-986165|Specified dose on specified days
48173586|NCT03599622|OTHER|Placebo|Specified dose on specified days
48173587|NCT04909671|DEVICE|Gi Genius, Medtronic|GI geniusTM (Medtronic) is an artificial intelligence device designed and validated on a dataset of white-light endoscopy videos from high-quality randomized controlled trials for the detection of colorectal lesions during colonoscopy. Based on a deep learning system using convolutional neural networks, GI genius works in real-time side-to-side with the gastroenterologist during colonoscopy highlighting the presence of precancerous lesions with a visual marker (green box) in real time and designed to be integrated with the majority of colonoscopies.
48705330|NCT04839978|BEHAVIORAL|Connect Program|The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drugfree norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
48705331|NCT04839978|BEHAVIORAL|Communities Mobilizing for Change and Action (CMCA)|The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. We will provide trainings and tools, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
48173588|NCT04909671|OTHER|White light standart colonoscopy|High definition white light endoscopy will be used during the scope withdrawal
48173589|NCT02073721|OTHER|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
48173590|NCT02073721|OTHER|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
48705332|NCT00723866|OTHER|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
48705333|NCT00723866|OTHER|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
48705334|NCT03994887|DEVICE|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
48016815|NCT06183502|BEHAVIORAL|Qualitative Assessment|Focus group discussions (n=up to 48 men for 3 qualitative assessments; total n=up to 144 men) as a part of the study consisting of 9 to 12 focus group discussions (FGD) with an average of 8 (range 3-10) participants in each (3 per city). These focus groups will be conducted once during the first year of the study. FGD will be conducted by a trained moderator using a semi-structured interview guide developed in collaboration with CDC scientists. For the FGD, in each city, there will be one FGD with men who have never used PrEP, one with men who are using PrEP and report no adherence issues, and one with men who are currently using PrEP or used PrEP previously and report sub-optimal adherence. In-Depth Interviews (IDIs) A series of 90 in-depth interviews (same n=up to 45 men for each of 3 qualitative assessments) will be conducted over 18 months: up to 45 IDIs each 6 months apart, with up to 15 IDIs per city each wave.
48705335|NCT06127264|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
48016816|NCT04560504|OTHER|Control Group|Leisure activities
48016817|NCT04560504|OTHER|Oculomotor Training Group|Eye movement training
48173591|NCT00751634|DEVICE|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
48173592|NCT02742532|DRUG|Oxytocin|Intranasal oxytocin 40 IU
48173593|NCT02742532|DRUG|Placebo|Intranasal saline solution
48173594|NCT05203809|DEVICE|TempTraq temperature monitor|All participants will wear both TempTraq temperature monitor and CORE temperature monitor.
48173595|NCT05926505|DRUG|Placebo|Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
48173596|NCT05926505|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra is injected subcutaneously as 100 mg once daily for 4 weeks. After the first period the patients will be randomized 1:1 to continue receiving subcutaneous treatment with 100mg anakinra once daily for 4 weeks or placebo once daily for 4 weeks.
48173597|NCT01539408|DRUG|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
48173598|NCT01539408|PROCEDURE|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
48173599|NCT00093288|DRUG|bupropion XL|
48173600|NCT02785276|DEVICE|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
48173601|NCT02785276|DRUG|Ropivacaine|Commonly used local anaesthetic drug
48016818|NCT00587587|DEVICE|Apligraf|Application at Day 0, potential re-application at Week 4
48016819|NCT00587587|OTHER|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
48016820|NCT02071576|DEVICE|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
48173602|NCT02785276|OTHER|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
48173603|NCT02629276|OTHER|neurodynamic testing|
48173604|NCT00053378|DRUG|paricalcitol injection (Zemplar)|
48173605|NCT00053378|BEHAVIORAL|Effects on calcium regulation|
48173606|NCT00053378|BEHAVIORAL|Administration of elemental Ca during hypocalcemic ICU pts.|
48173607|NCT03493568|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
48173608|NCT03493568|DRUG|Dolutegravir 50 mg plus one RTI|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
48173609|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
48173610|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
48705336|NCT00336011|DEVICE|Magnetic resonance imaging|
48016821|NCT01947530|PROCEDURE|Navigational Bronchoscopy|
48173611|NCT02447432|BIOLOGICAL|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
48173612|NCT04085705|DIAGNOSTIC_TEST|PATCH test|The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
48173613|NCT00206739|DRUG|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
48173614|NCT00119652|DRUG|quetiapine fumarate (Seroquel)|
48173615|NCT00119652|DRUG|paroxetine|
48173616|NCT00119652|BEHAVIORAL|mood stabilizing activity|
48173617|NCT02145897|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
48173618|NCT02145897|BIOLOGICAL|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
48173619|NCT02145897|OTHER|Control|
48173620|NCT00069381|BEHAVIORAL|Psychotherapy treatment|
48173621|NCT05313906|DRUG|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
48173622|NCT00519285|DRUG|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
48173623|NCT00519285|DRUG|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
48705337|NCT00006164|DRUG|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
48705338|NCT00006164|DRUG|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
48016822|NCT01947530|PROCEDURE|Standard Bronchoscopy|
48016823|NCT04983394|OTHER|Virtual Realty Exercises|motion-controlled video game
48016824|NCT04983394|OTHER|Aerobic exercises|cycling activity
48016825|NCT04983394|OTHER|conventional exercises|stretching, strengthening and endurance exercises
48016826|NCT02660736|DRUG|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
48016827|NCT02660736|DRUG|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
48016828|NCT02660736|DRUG|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
48016829|NCT02660736|DRUG|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
48016830|NCT02872415|BIOLOGICAL|Blood puncture site|Blood puncture site
48016831|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
48016832|NCT06515470|DRUG|Fulvestrant|500 mg intramuscular injections on Day 15 and then every 28 days
48373977|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - With Isthmocele|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior)~Size of isthmocele:~* Depth of isthmocele~* Width of isthmocele~* Circumference of isthmocele~Distance between isthmocele and outer cervical os (measured with the trace line) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac Measurements of the isthmocele size / circumference / distance between isthmocele / CS and outer cervical os"
48705339|NCT06602583|DIAGNOSTIC_TEST|Standard Dose Coronary angiography|The radiation exposure of this group would be collected from database of already done studies in the months prior to the initiation of the study (so as to prevent observer bias which may happen once the interventional cardiologist knows his inclusion in study, and may use a shorter or longer cine runs, thus influencing the outcomes). This would best represent the real-world data set, according to the routinely followed standard dose/ older low dose protocol.
48016833|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles using dose determined in Part A
48016834|NCT03738904|COMBINATION_PRODUCT|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
48016835|NCT03738904|COMBINATION_PRODUCT|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
48705340|NCT06602583|DIAGNOSTIC_TEST|New low dose angiography|a comparative arm where the patients being once eligible for the study; would undergo angiography using the new low dose protocol.
48705341|NCT06604975|PROCEDURE|Measure of Basal Copeptin level|"Copeptin test is performed after solid fasting since midnight without water restriction. After blood collection on heparin tube used for biological inclusion criteria, heparinized plasma is transferred to Timone University hospital (transport temperature +4°C) for screening copeptin assay.~The basal copeptin level determines the next step:~1. copeptin ≥ 30 pmol/L defines the diagnosis of NDI and results in a specific care;~2. copeptin \&lt; 30 pmol/L defines the group of eligible patients for arginine stimulation"
48016836|NCT06274528|DRUG|Lemborexant 10 mg|Within FDA approved dose 10 mg; capsule; QD, 6 month duration
48016837|NCT06274528|DRUG|Lemborexant 20mg|20 mg; capsule; QD; 6 month duration
48016838|NCT06274528|DRUG|Placebo|0 mg; capsule; QD; 6 month duration
48016839|NCT00189371|DRUG|paclitaxel, carboplatin, epoetin alpha|
48016840|NCT06393192|PROCEDURE|Epidural analgesia (EA) only group|The epidural needle will be inserted into the lumbar epidural space at the level of L2-3 intervertebral space.
48016841|NCT06393192|PROCEDURE|Quadratus lumborum block (QL2)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side behind the QL muscle, resulting in a total of Sixty mL
48016842|NCT06393192|PROCEDURE|Quadratus lumborum block 3(QL3)|0.2% bupivacaine at a volume of thirty milliliters were administered at the specified sites on each side among the QL muscle and the psoas major, resulting in a total of Sixty mL
48016843|NCT06393192|PROCEDURE|Quadratus lumborum block 2+3 QL(2+3)|0.2 percent bupivacaine solution of fifteen milliliters were administered at each injection site, with the needle being inserted once on each side
48016844|NCT05802797|OTHER|Algae Oil Fortified Soymilk|Flavored soymilk beverage fortified with 0.4% algae oil with both EPA and DHA
48016845|NCT05802797|DIETARY_SUPPLEMENT|Algae Oil Capsule|Algae oil capsules with EPA and DHA
48016846|NCT04833166|DEVICE|CMAC D-blade videolaryngoscope with full or partial glottic view|Deliberate achieving full or partial glottic view on C MAC D-blade video laryngoscope and comparing time and ease of intubation with both arms
48016847|NCT05731726|DRUG|Serplilumab|"Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w"
48016848|NCT05731726|DRUG|Capecitabine|Given PO
48016849|NCT05731726|DRUG|Oxaliplatin|Given IV
48016850|NCT05731726|DRUG|Celecoxib|celebrex
48173624|NCT00519285|DRUG|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
48173625|NCT00519285|DRUG|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
48173626|NCT00117897|DRUG|pegfilgrastim|
48173627|NCT00117897|DRUG|Filgrastim|
48173628|NCT03823274|DRUG|Aspirin, Clopidogrel|to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel
48173629|NCT04815343|DEVICE|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
48173630|NCT04421313|DRUG|Dietary Fiber Supplementation|12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
48173631|NCT04744805|OTHER|face mask or not|long term face mask wear
48173632|NCT03990298|DIAGNOSTIC_TEST|Awake endoscopy|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
48173633|NCT03380364|DEVICE|hystroscope|"Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
48173634|NCT05073549|BEHAVIORAL|Collaborative Antimicrobial Stewardship Program (ASP)|"The collaborative ASP interventions will be implemented from October 1st, 2021 to September 30th, 2023 in all participating NICUs.~The collaborative ASP interventions include two levels of interventions that will be delivered at the NICU level: the NICU-targeted ASP program and collaborative quality improvement interventions to facilitate implementation of the ASP.~The core elements of the NICU-targeted ASP program include the establishment of ú ASP leader and team, development of the facility-specific antibiotic guidelines, checklist-led audit and feedback, and staff education.~The collaborative quality improvement interventions include data feedback and benchmarking, a potential 'better practice' list on neonatal antibiotic use, implementation using Plan-Do-Study-Act cycles and collaborative learning."
48173635|NCT05022290|PROCEDURE|Single-syringe diluted with normal saline technique|Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
48173636|NCT06009172|OTHER|Auricular point acupressure (APA)|Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
48173637|NCT05220956|BEHAVIORAL|Intermittent fasting|One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
48173638|NCT05220956|BEHAVIORAL|DGE diet|The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
48173639|NCT05130346|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants will be asked to attend group meetings for mindfulness training. Each meeting will last approximately one hour and will take place online via Zoom. The meetings will occur on a weekly basis, over an 8-week period.
48173640|NCT00436956|PROCEDURE|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
48173641|NCT00436956|DRUG|AZD2171|20 mg oral daily for 28 days
48173642|NCT00436956|DRUG|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
48373978|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy - Without Isthmocele|Location of implantation of the GS amended to Naji et al, defined as 3 possible implantation sites: (A: fundal, B: anterior, C: posterior) Distance between CS scar and outer cervical os (measured with the trace line) Size of gestational sac
48373979|NCT05798624|DIAGNOSTIC_TEST|Ultrasound between 6+0 and 6+7 weeks of pregnancy|"Location of implantation of the GS (gestational sac) amended to Naji et al, defined as 3 possible implantation sites (A: fundal, B: anterior, C: posterior)~Size of gestational sac"
48705342|NCT06604975|PROCEDURE|Measure of arginine-stimulated copeptin|The arginine-stimulated copeptin test start at 8 am, after solid fasting since midnight without water restriction, and 30 min of rest in decubitus position. A dose of 0.5 g/kg of arginine (maximum 40g) diluted in 0.9% NaCl is infused over 30 min through a peripheral venous line. Copeptin is measured at T0 (before infusion), T45, T60, T90, and T120 min after infusion.
48373981|NCT04121091|DRUG|Pramipexole Pill|Add-on pramipexole
48373982|NCT05374109|BEHAVIORAL|SYV: Sauti ya Vijana (The Voice of Youth intervention)|Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
48373983|NCT01090648|DRUG|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
48373984|NCT03066466|DRUG|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
48373985|NCT03066466|DRUG|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
48373986|NCT03066466|DRUG|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
48373987|NCT03007680|OTHER|Core muscle activation|
48373988|NCT06360159|OTHER|Intervention|As an intervention, the newborn will be massaged.
48373989|NCT00001422|DRUG|fludarabine|
48373990|NCT02368860|DRUG|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
48373991|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|1% chocolate milk
48373992|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Pea-based beverage
48173643|NCT04758676|OTHER|Nutritional and physiotherapy protocol, BIA|Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.
48173644|NCT04758676|OTHER|Standard of care|Study subjects will receive the current standard of care.
48373993|NCT05382026|DIETARY_SUPPLEMENT|Nutritional supplementation during a 6 month resistance training program|Maltodextrin placebo
48373994|NCT02425670|OTHER|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
48373995|NCT04564534|OTHER|MoCA cognitive assessment|cognitive assessment using the validated MoCA test administered via an application on an iPad
48373996|NCT01860066|DRUG|QVA149|QVA149 via inhaler twice a day
48373997|NCT01860066|DRUG|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
48373998|NCT02319018|DRUG|Alisertib|Given PO
48373999|NCT02319018|DRUG|Fluorouracil|Given IV
48374000|NCT02319018|OTHER|Laboratory Biomarker Analysis|Correlative studies
48374001|NCT02319018|DRUG|Leucovorin Calcium|Given IV
48374002|NCT02319018|DRUG|Oxaliplatin|Given IV
48374003|NCT00000131|PROCEDURE|Photocoagulation Therapy|
48374004|NCT04624295|DRUG|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
48173645|NCT00408798|DRUG|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
48374005|NCT04624295|DRUG|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
48374006|NCT00175110|BEHAVIORAL|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
48374007|NCT01737359|DRUG|amdoxovir 300 mg bid|2 x 150 mg capsules bid
48374008|NCT01737359|DRUG|amdoxovir 500 mg bid|2 x 250 mg capsules bid
48374009|NCT01737359|DRUG|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
48374010|NCT05420610|OTHER|Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.|The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.
48173646|NCT04662983|DEVICE|VR-training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
48173647|NCT00171418|DRUG|Tegaserod|
48173648|NCT02602353|DRUG|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
48173649|NCT02602353|DRUG|Placebo Patch|One Placebo Patch applied daily for 3 days
48173650|NCT02602353|DRUG|No Treatment|No Treatment for 3 days
48173651|NCT01845311|DEVICE|ReZolve2 Scaffold|
48173652|NCT02049515|DRUG|IPI-145|PI3K Inhibitor
48173653|NCT02049515|DRUG|Ofatumumab|Monoclonal antibody
48173654|NCT04458181|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
48173655|NCT01580995|DRUG|Valacyclovir|Valacyclovir 500 mg po bid
48374011|NCT05420610|OTHER|Study group: TPTD device was implemented for monitoring.|TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.
48374012|NCT03068507|BEHAVIORAL|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
48374013|NCT00187005|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
48374014|NCT00187005|DRUG|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
48374015|NCT02032433|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
48374016|NCT02032433|DRUG|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
48374017|NCT00395317|OTHER|Placebo|placebo tablet
48374018|NCT00395317|DRUG|Firategrast 150 mg|150 mg tablet
48173656|NCT01580995|DRUG|Placebo|Placebo tablet twice daily
48173657|NCT00047749|DRUG|Prialt (ziconotide)|
48173658|NCT04833244|BEHAVIORAL|Triangular Forearm Support|The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.
48173659|NCT04833244|BEHAVIORAL|Placebo|Patients will be asked to raise arms overhead for 45 seconds.
48173660|NCT05849324|DEVICE|Straight needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, straight needle is going to be used.
48173661|NCT05849324|DEVICE|Bent needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, bent needle is going to be used.
48173662|NCT05639998|BIOLOGICAL|COVAXIN(BBV152)|COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2
48173663|NCT05639998|BIOLOGICAL|BBV154 Intranasal Vaccine|BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4
48173664|NCT00001123|DRUG|Ribavirin|
48173665|NCT03954223|BEHAVIORAL|Low sugar and carbohydrate diet|Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)
48173666|NCT03954223|BEHAVIORAL|Time Limited Eating|16-hour fast/8-hour feed for 3 days per week
48173667|NCT03954223|DEVICE|Continuous Glucose Monitor|CGM (used to monitor adherence and glycemic outcomes without real time feedback)
48173668|NCT05768737|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
48374019|NCT00395317|DRUG|Firategrast 300 mg|300 mg tablet
48374020|NCT02107716|PROCEDURE|Lidocaine injection with bicarbonate|bicarbonate added to change pH
48374021|NCT02107716|PROCEDURE|lidocaine injection|Lidocaine injection with pH unchanged
48016851|NCT01050595|DRUG|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
48016852|NCT01050595|DRUG|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
48016853|NCT01117818|BIOLOGICAL|active: AFFITOPE AD02|vaccination
48016854|NCT01117818|BIOLOGICAL|control: Placebo|vaccination
48016855|NCT00188526|DEVICE|lung biopsy|
48016856|NCT06664216|BEHAVIORAL|incorrect trocar placement marks.|Participants in the experimental group will perform trocar placements on laparoscopic models that have been pre-marked with incorrect insertion sites by previous participants. These marks simulate procedural steps or anatomical landmarks that are intentionally incorrect.
48016857|NCT02444650|DEVICE|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
48016858|NCT02444650|DEVICE|tonometer|
48016859|NCT03951129|PROCEDURE|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
48016860|NCT04071951|BEHAVIORAL|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone."
48016861|NCT05701800|BIOLOGICAL|mRNA-1468|Sterile liquid dispersion for injection
48016862|NCT05701800|BIOLOGICAL|Placebo|Sterile liquid for injection
48016863|NCT05701800|BIOLOGICAL|Shingrix|Sterile suspension for injection
48016864|NCT03345602|DIAGNOSTIC_TEST|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
48016865|NCT03183791|BEHAVIORAL|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
48016866|NCT03183791|BEHAVIORAL|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
48016867|NCT01751464|BEHAVIORAL|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
48016868|NCT00000189|DRUG|Gepirone|
48016869|NCT01177072|OTHER|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
48016870|NCT01177072|OTHER|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
48173669|NCT03371277|OTHER|Medical visit for specific questionnaires|Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
48374022|NCT01052220|BEHAVIORAL|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
48374023|NCT01052220|BEHAVIORAL|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
48016871|NCT06039085|DEVICE|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
48016872|NCT05824884|BEHAVIORAL|Visual Feedback|Visual progress feedback and words of positive affirmation will be presented triggered by checkpoints set in the VR-height-exposure.
48016873|NCT05824884|BEHAVIORAL|Self-efficacy enhancement:|specific instructions regarding the retrieval of mastery experiences during exposure will be given (modified version of the procedure used in Raeder et al. 2019).
48016874|NCT05824884|BEHAVIORAL|placebo intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (modified version of the procedure used in Raeder et al. 2019).
48016875|NCT05824884|BEHAVIORAL|No visual feedback|Participants can not trigger any checkpoints during VR and therefore not receive any progress feedback or positive affirmation.
48016876|NCT01284647|DRUG|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
48705343|NCT06604975|PROCEDURE|IRM|"Based on our previous study, patients with basal copeptin value over 3.53 pmol/L are considered as positive diagnosis of PP (Se 100%, Sp 87.4%) and cerebral MRI is not performed for this group of patients (PP group).~A cerebral and pituitary MRI performed according to reference procedures (without and with contrast medium used in routine care) for patients considered as an uncertain diagnosis (UD) based on basal copeptin value (\&amp;lt; 3.53 pmol/L). MRI interpretation is performed by two independent neuroradiologists (one from the recruiting center and one from the pilot center). In case of discrepancies, a third independent interpretation will be performed by a neuroradiologist from the coordinating center. Abnormal pituitary MRI (thickened pituitary stalk pituitary tumor, ectopic neurohypophysis, septo-optic dysplasia, empty sellar, Rathke pouch) allows a diagnosis of CDI leading to etiological investigations and AVP treatment."
48705344|NCT06604975|BEHAVIORAL|Water reduction at home|Patients with basal copeptin ≥ 3.53 pmol/l (PP group), and UD patients with normal MRI have gradual reduction of water intake at home without AVP treatment : gradual reduction with 20% in the first week, 30% in the second, 40% in the third, reaching 50% of daily fluid in the last week including restriction overnight, deletion drink before sleep. Some recommendations will be provided to help physicians. For all these latest patients, a clinical reassessment (weight, height, heart rate, blood pressure, input/output 24 hours balance) is performed one month later.
48705345|NCT01429428|OTHER|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
48705346|NCT01429428|OTHER|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
48705347|NCT06157996|DRUG|lenvatinib and tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
48705348|NCT06157996|DRUG|tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
48705349|NCT06315283|DRUG|TV-44749|Administered subcutaneously (sc)
48016877|NCT01284647|DRUG|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
48016878|NCT03606798|OTHER|3 Home visits made by a psychologist|Patient and caregiver interviews with a psychologist at home
48173670|NCT02514226|PROCEDURE|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
48705350|NCT06315283|DRUG|Oral olanzapine|Administered orally
48016879|NCT03609060|DRUG|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
48173671|NCT02514226|PROCEDURE|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
48705351|NCT06608199|BIOLOGICAL|pneumococcal disease prevention|2P+1 programme of PCV13
48016880|NCT06391996|DRUG|After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.|During the treatment period, participants received either ustekinumab at weeks 0, 4, 16, and every 12 weeks thereafter until week 48, or secukinumab at weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter until week 48. The dose of ustekinumab/secukinumab was referenced to the dose used for moderate to severe plaque psoriasis. The single dose of ustekinumab was 45 mg for adult subjects weighing ≤ 100 kg, and 90 mg for subjects weighing \> 100 kg. The ustekinumab dosage for pediatric participants was 0.75 mg/kg for participants weighing \< 60 kg; 45 mg for pediatric participants weighing 60 kg to 100 kg; and 90 mg for pediatric participants weighing \> 100 kg. The secukinumab dosage was 300mg for adult humans. Pediatric participants received a dose based on their weight category ( \<50 kg, ≥50 kg): participants weighing \< 50 kg received 75 mg, those weighing ≥ 50 kg received 150 mg.
48016881|NCT05674487|DEVICE|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
48016882|NCT05674487|DRUG|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
48016883|NCT00445614|BEHAVIORAL|Effects of trout on CVD risk markers and plasma proteome|
48016884|NCT05434897|DRUG|AK3280 Cream|Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
48016885|NCT05434897|DRUG|Placebo cream|Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
48016886|NCT03565185|OTHER|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
48705352|NCT04082390|DIETARY_SUPPLEMENT|RELEASE|Dietary supplement
48705353|NCT04082390|DIETARY_SUPPLEMENT|Placebo|Placebo
48705354|NCT01358812|DRUG|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
48705355|NCT03477851|DRUG|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
48705356|NCT03477851|DRUG|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
48705357|NCT06428942|OTHER|low-potassium vegetables|low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
48705358|NCT06372522|DRUG|Pitocin Injectable Product|The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
48705359|NCT02430896|DRUG|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
48705360|NCT02430896|DRUG|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
48705361|NCT04679922|PROCEDURE|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
48374024|NCT01098266|DRUG|NGR-hTNF plus Best Investigator's Choice (BIC)|"* NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
48705362|NCT05791994|PROCEDURE|Visual cognitive stimulation exercises|Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.
48705363|NCT05791994|PROCEDURE|Broadcast of a television program|Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
48016887|NCT03565185|OTHER|placebo|Investigators will use only conventional treatment without robot-assisted gait training
48016888|NCT06573268|DEVICE|robot surgery device|SPRA used da-Vinci SP system (SPRA) BABA used da-Vinci Xi system (BABA)
48016889|NCT03849638|OTHER|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~* 5 minutes of heating at a comfortable speed for the patient~* Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
48374025|NCT01098266|DRUG|Placebo plus Best Investigator's Choice (BIC)|"* Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~* Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~* Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~  1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~ 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~ 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
48705364|NCT06608043|BEHAVIORAL|Reborn lifestyle adjustment program|"The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules."
48705365|NCT06608043|PROCEDURE|Conventional Physiotherapy and Occupational Therapy|Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
48016890|NCT02665481|BEHAVIORAL|MBSR|
48705366|NCT02073838|DRUG|Ribavirin|
48705367|NCT02073838|DRUG|Vismodegib|
48705368|NCT02073838|DRUG|Decitabine|
48705369|NCT05369520|DEVICE|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
48705370|NCT05369520|DEVICE|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
48705371|NCT04899440|DEVICE|Water Flosser|A pressurized stream of water to reduce gingivitis and remove adherent plaque
48705372|NCT04899440|OTHER|Control|No Oral Irrigator Control
48016891|NCT02665481|BEHAVIORAL|Exercise|
48016892|NCT02665481|BEHAVIORAL|Health Education|
48016893|NCT04991740|DRUG|JNJ-78306358|JNJ-78306358 will be administered.
48374026|NCT03959306|DIETARY_SUPPLEMENT|Black Seed Oil|Black seed oil soft gelatin capsule
48374027|NCT03959306|DRUG|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
48374028|NCT04369040|DEVICE|High-flow nasal oxygen therapy using a specific nasal cannula|Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
48705373|NCT06607016|DRUG|KJ103 for Injection|Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
48705374|NCT06607016|DRUG|Cyclophosphamide|Hence treatment prevents formation of new anti-GBM antibodies.
48705375|NCT06607016|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
48705376|NCT06607016|PROCEDURE|Plasma exchange (PE)|PLEX removes the patient\&#39;s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
48705377|NCT05778084|DRUG|Empagliflozin 10 MG|Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
48705378|NCT04603781|DIETARY_SUPPLEMENT|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
48374029|NCT04369040|DEVICE|Flow Controlled Ventilation using a laryngeal tri-tube|Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
48374030|NCT04261153|OTHER|Cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
48374031|NCT01692457|DRUG|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
48374032|NCT00777920|DRUG|Ambrisentan|Tablet administered orally once daily
48374033|NCT06158295|OTHER|Voluntary apnoea|Walking apneas at low lung volume
48374034|NCT03315780|DRUG|Dulaglutide|Administered SC
48374035|NCT03315780|DRUG|Placebo|Administered SC
48374036|NCT01266967|DRUG|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
48374037|NCT03878368|DIETARY_SUPPLEMENT|Sulforaphane|Intervention soup with dietary sulforaphane
48374038|NCT03878368|DIETARY_SUPPLEMENT|Placebo|Control soup without dietary sulforaphane
48374039|NCT00965562|DRUG|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
48374040|NCT00965562|DRUG|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
48374041|NCT00965562|DRUG|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
48374042|NCT01578109|PROCEDURE|Bone Marrow Transplantation|Undergo BMT
48374043|NCT01578109|DRUG|Sorafenib|Given PO
48374044|NCT01578109|DRUG|Sorafenib Tosylate|Given PO
48374045|NCT02730832|OTHER|Questionnaires completed at D0|
48374046|NCT02730832|OTHER|Questionnaires completed at D15 (test-retest for 30 patients)|
48374047|NCT03432130|OTHER|Structural training program|15-week experimental structural training protocol
48374048|NCT03132610|DRUG|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
48374049|NCT03132610|DRUG|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
48016894|NCT06663215|OTHER|School Based Bullying Prevention Program|Three forms were administered to the adolescents: Personal Information Form, Bullying and Cyberbullying Scale for Adolescents (BCE-A) and Adolescent Future Expectations Scale. Adolescents were included in a school-based bullying prevention program the next day. One month later, the forms were administered again.
48374050|NCT05417373|OTHER|calculated radscore|The development cohort is case_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.
48374051|NCT02033720|OTHER|No treatment|No therapeutic hypothermia was induced.
48374052|NCT02033720|OTHER|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
48374053|NCT06175052|OTHER|Dietary Intervention|Four nutrition counselling sessions conducted over eight weeks, in conjunction with food items to assist in meal preparation and with weekly educational information messages sent via email.
48374054|NCT01753765|DEVICE|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
48374055|NCT02159872|DRUG|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
48374056|NCT05689801|OTHER|"Questionnaire recovery time after a dialysis session."|A very short questionnaire just after the dialysis session
48374057|NCT05689801|OTHER|SF-12 questionnaire|Questionnaire about quality of life of the patient
48374058|NCT05689801|OTHER|EQ-5D-5L Questionnaire|Questionnaire about quality of life of the patient
48374059|NCT05689801|OTHER|Pittman, John et McIntyre questionnaire|Questionnaire about quality of life of the patient under dialysis
48374060|NCT05689801|PROCEDURE|Conventional hemodialysis|patient on polyethersulfone membrane dialysis (Revaclear®, Baxter) with HemoControl™ for 12 weeks
48374061|NCT05689801|PROCEDURE|Optimized hemodialysis|patient on Medium Cut-Off membrane dialysis (Theranova®, Baxter) with HemoControl™ for 12 weeks.
48374062|NCT02040415|DRUG|DW-1030(eperisone HCl) 75mg|
48374063|NCT02040415|DRUG|Myonal Tab.(eperisone HCl) 50mg|
48374064|NCT02040415|DRUG|Placebo drug of DW-1030|
48374065|NCT02040415|DRUG|Placebo drug of Myonal Tab.|
48374066|NCT03742869|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
48374067|NCT01572012|DRUG|Ondansetron|Ondansetron solution 4 mg single administration
48374068|NCT01572012|DRUG|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
48374069|NCT01572012|DRUG|Zofran ODT|Zofran ODT (8 mg) single administration
48374070|NCT01572012|DRUG|Ondansetron solution|Ondansetron solution (4 mg) single administration
48374071|NCT04100902|DRUG|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
48374072|NCT04100902|DRUG|Placebo sublingual tablet|Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
48374073|NCT01471652|DRUG|Nutraceutical supplements|"1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid"
48374074|NCT01471652|DRUG|Placebo|"Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid"
48374075|NCT04504292|DRUG|SUPREP Bowel Prep Kit|Bowel prep prior to colonoscopy
48374076|NCT04504292|DRUG|Golytely Oral Product|Bowel prep prior to colonoscopy
48374077|NCT01012531|BIOLOGICAL|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
48374078|NCT01012531|BIOLOGICAL|Subcutaneous injection with placebo|cluster schedule
48705379|NCT04603781|DIETARY_SUPPLEMENT|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
48016895|NCT04427098|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Subcutaneous enoxaparin 40 mg once daily for 14 days.
48374079|NCT01476527|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
48374080|NCT06257849|OTHER|BPII 2.0|Banff Patella Instability Instrument 2.0 is a questionnaire developed for measuring outcome in patients with patella instability
48374081|NCT02466191|DRUG|Memantine|
48374082|NCT02466191|DRUG|Gabapentin|
48374083|NCT03445936|DEVICE|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
48374084|NCT03445936|DEVICE|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
48374085|NCT02500134|OTHER|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
48705380|NCT04603781|DIETARY_SUPPLEMENT|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
48705381|NCT04603781|DIETARY_SUPPLEMENT|Placebo Oil|MCT Oil with mint flavoring
48705382|NCT02981407|BIOLOGICAL|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
48705383|NCT03172806|DIAGNOSTIC_TEST|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
48705384|NCT04805203|OTHER|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
48374086|NCT04310904|OTHER|contrast assessment of cardiac output (CO)|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
48016896|NCT04427098|DRUG|Enoxaparin|Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight \>100 kg
48016897|NCT05389124|BEHAVIORAL|Partial abstinence from oral hygiene|One quadrant of the dentition will be protected from oral hygiene for 3 weeks.
48173672|NCT02514226|PROCEDURE|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets \> 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
48705385|NCT02357693|DRUG|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
48705386|NCT05814198|DIAGNOSTIC_TEST|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
48705387|NCT05801757|DRUG|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
48705388|NCT05801757|DRUG|Propofol|propofol 2-3mg/kg/h
48705389|NCT02916888|OTHER|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
48705390|NCT02916888|OTHER|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
48705391|NCT01238835|DEVICE|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
48705392|NCT05387980|DRUG|CIBINQO|Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
48374087|NCT04310904|OTHER|cardiac Doppler technique|Patients hospitalized in ICU will be included if they need a trans esophageal echocardiographic evaluation and a research of intra cardiac shunt (using a saline contrast test). Patients with Swan Ganz catheter will be included as well. Cardiac output will be measured using cardiac Doppler. Simultaneously, 4.5 ml of saline with 0.5 ml of air will be agitated to have a contrast solution. This solution will be injected as usual and echocardiographic imaging will be recorded. These imaging will be analyzed off-line and CO will be calculated with an algorithm previously developed and compared with the reference method. In case of swan ganz catheter, the cardiac output will be also measured using the thermodilution technique.
48374088|NCT06371573|DIAGNOSTIC_TEST|ULTRASOUND EXAM AND MRI SCAN|Within two weeks from the US, each patient underwent an MRI of the upper abdomen to evaluate the splenic volume. MRI examinations were performed using a 3T Biograph mMR scanner (Siemens Healthcare, Erlangen, Germany) with 4-channel flex phased-array body coil. Routine clinical abdominal MRI acquisition includes coronal T2W Half-Fourier Acquisition Single-shot Turbo spin Echo imaging (HASTE), axial T1 Dual-echo FSE, axial T2 TSE Fat Sat, and an axial diffusion-weighted imaging (DWI).
48374089|NCT01182480|BEHAVIORAL|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~* 7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~* 3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
48374090|NCT02797600|BEHAVIORAL|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
48374091|NCT02797600|OTHER|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
48374092|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block.
48374093|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate as adjuvant.
48516783|NCT04575610|DRUG|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
48516784|NCT04575610|DRUG|Placebo|Matching placebo tablets will be administered.
48516785|NCT02657928|OTHER|Laboratory Biomarker Analysis|Correlative studies
48705393|NCT06045182|PROCEDURE|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
48705394|NCT06045182|PROCEDURE|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
48705395|NCT06045182|PROCEDURE|Electrotherapy|Hot pack and TENS for 10 min
48705396|NCT05867836|DIETARY_SUPPLEMENT|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
48705397|NCT02082457|DRUG|YKP10811 5mg|
48705398|NCT02082457|DRUG|YKP10811 20mg|
48705399|NCT02082457|DRUG|YKP10811 placebo|
48705400|NCT01223885|DIETARY_SUPPLEMENT|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
48516786|NCT02657928|DRUG|Letrozole|Given PO
48516787|NCT02657928|DRUG|Ribociclib|Given PO
48516788|NCT02732873|DEVICE|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
48516789|NCT01810757|RADIATION|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
48705401|NCT00004729|BEHAVIORAL|Ketogenic diet|
48705402|NCT03571373|OTHER|No intervention|No intervention due to the observational set-up of this study.
48374094|NCT05003765|DRUG|Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg|Injection of Bupivacaine 0.25% Injectable Solution for SPIP Nerve Block. Addition of 200mg of magnesium sulfate and 300 mcg buprenorphine as adjuvants.
48016898|NCT05714527|DEVICE|Close-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
48016899|NCT05714527|DEVICE|Conventional|Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
48016900|NCT04354922|BEHAVIORAL|Exercise intervention|Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
48016901|NCT04852094|OTHER|Qualitative focus group|A qualitative focus group is performed with staff members and parents of hospitalised newborns in a NICU during Family-centered rounds management. The transcribed interviews are analyzed with qualitative content analysis in order to illuminate the experience, feelings and thoughts arisen among the staff members and the parents.
48705403|NCT02345668|BEHAVIORAL|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
48705404|NCT02345668|DRUG|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
48374095|NCT01851824|DRUG|acenocoumarol|4 mg single oral doses on Days 1 and 23
48016902|NCT02970968|DRUG|VLY-686 (Tradipitant)|oral capsule
48705405|NCT02345668|BEHAVIORAL|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
48705406|NCT03342573|DRUG|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
48705407|NCT01010568|DRUG|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
48705408|NCT00642174|DRUG|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
48016903|NCT02970968|OTHER|Placebo|placebo oral
48016904|NCT05855200|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
48016905|NCT05855200|DRUG|CAPEOX|CAPEOX will be administered.
48016906|NCT05855200|DRUG|FOLFOX|FOLFOX will be administered.
48374096|NCT01851824|DRUG|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
48374097|NCT06259825|OTHER|Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)|At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).
48374098|NCT06259825|OTHER|Control poultry foods (chicken-meat and eggs)|At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.
48374099|NCT01077908|BIOLOGICAL|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
48016907|NCT05066841|DRUG|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) for 12 weeks
48173673|NCT02514226|OTHER|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
48374100|NCT01077908|DRUG|Best available antiviral drug therapy|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
48374101|NCT03713112|OTHER|Weekly MDT deprescribing rounds for certain drugs|"* Weekly deprescribing round (from randomization to day of discharge)~* Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~* Using the 5 steps of de-prescribing~* De-prescribing targets:~  1. Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~ 2. Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~ 3. Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~* On top of usual care"
48705409|NCT00642174|DRUG|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
48705410|NCT05056220|DRUG|Human albumin|20% Human Albumin infusions (every 10th day +/- 4 days) with dosing according to the participants bodyweight (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
48705411|NCT05056220|DRUG|sodium chloride|0.9% NaCl infusions (every 10th day +/- 4 days) with dosing according to the corresponding volume used of 20% Human Albumin (1.5 grams of albumin per kg bodyweight with a maximum of 100 grams)
48173674|NCT02959177|DRUG|Galcanezumab|Administered SC
48173675|NCT02959177|DRUG|Placebo|Administered SC
48173676|NCT03532399|DRUG|Bivalirudin|"CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or \> 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos_f/6317841), but will ultimately be determined by patient's primary provider."
48374102|NCT03965754|BEHAVIORAL|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
48374103|NCT03965754|BEHAVIORAL|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
48705412|NCT03392883|BEHAVIORAL|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
48705413|NCT06332664|COMBINATION_PRODUCT|Early Nutrition Intervention|This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.
48516790|NCT01810757|RADIATION|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
48705414|NCT01938508|DRUG|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
48016908|NCT05066841|DRUG|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang)|10% CM (Ma-Hsing-Kan-Shih-Tang in combination with Liu-Jun-Zi-Tang) and 90% starch for 12 weeks
48705415|NCT01367223|DIETARY_SUPPLEMENT|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
48705416|NCT01367223|DIETARY_SUPPLEMENT|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
48016909|NCT03747081|DRUG|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
48016910|NCT03747081|DRUG|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
48016911|NCT05245812|DEVICE|da Vinci SP Surgical System|This is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
48016912|NCT03821571|DIAGNOSTIC_TEST|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
48016913|NCT02705950|DRUG|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
48016914|NCT02705950|OTHER|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
48705417|NCT01418131|DRUG|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
48705418|NCT01418131|DRUG|Placebo|Placebo
48705419|NCT01892787|DRUG|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
48705420|NCT01892787|DRUG|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
48705421|NCT04650412|OTHER|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
48705422|NCT05289193|DIAGNOSTIC_TEST|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
48705423|NCT05289193|DRUG|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
48705424|NCT05289193|DRUG|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
48016915|NCT05501197|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
48016916|NCT05501197|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~Straight leg raise (Level 1-2-3) Quadriceps strengthening (Level 1-2-3) Hip abductor/adductor strengthening (Level 1-2-3) Hamstring stretch Gastrocnemius stretch"
48016917|NCT05571501|DEVICE|Gait assessment using the GAITRIte walkway|10-20 walking assessment using the GAITRite walkway
48016918|NCT06594926|DRUG|Testosterone Enanthate|Testosterone enanthate is a depot formulation used in Australia typically for androgen replacement in people with confirmed testosterone deficiency.
48016919|NCT04173130|DEVICE|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
48016920|NCT01195467|DRUG|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
48016921|NCT04901884|DRUG|PET/MR with 18F-FDG|(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg.
48016922|NCT01587326|DRUG|Escitalopram|escitalopram 10 mg/d to 20 mg/d
48016923|NCT03841643|DEVICE|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
48016924|NCT03841643|DEVICE|cement|norian cement for reconstruction of the cranial defect
48016925|NCT04360824|DRUG|Intermediate dose thromboprophylaxis|2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
48016926|NCT04360824|DRUG|Standard of Care thromboprophylaxis|Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
48016927|NCT04285190|DRUG|T89|The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.
48016928|NCT04953767|DEVICE|Blue light therapy|Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.
48016929|NCT04953767|OTHER|White light|White light is used as sham control.
48016930|NCT01743092|BEHAVIORAL|Webinar|Some clients will receive a webinar as part of their treatment.
48016931|NCT01743092|BEHAVIORAL|Tutuorial workbook|A work book about their addiciton
48016932|NCT02287415|DRUG|BIA 2-093|
48705425|NCT05289193|PROCEDURE|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
48705426|NCT03989414|DRUG|CC-92480|Specified dose on specified days
48705427|NCT03989414|DRUG|Bortezomib|Specified dose on specified days
48705428|NCT03989414|DRUG|Dexamethasone|Specified dose on specified days
48705429|NCT03989414|DRUG|Daratumumab|Specified dose on specified days
48705430|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
48705431|NCT03989414|DRUG|Elotuzumab|Specified dose on specified days
48705432|NCT03989414|DRUG|Isatuximab|Specified dose on specified days
48705433|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
48705434|NCT06300125|PROCEDURE|Cryoablation|Percutaneous Cryoablation of Breast Cancer
48705435|NCT05540769|PROCEDURE|catheter guided ASD closure|transcatheter secundum ASD device closure
48705436|NCT00728520|DRUG|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
48705437|NCT06036017|OTHER|Earplugs|There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).
48016933|NCT02287415|DRUG|Warfarin|
48016934|NCT06451523|OTHER|Alliance180 Program|The Alliance180 Program promotes feelings of neuropsychological safety and trust in the context of a 3-day program, which includes the transformative equine experience.
48016935|NCT02379949|BEHAVIORAL|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
48016936|NCT02379949|BEHAVIORAL|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
48016937|NCT04331327|DRUG|allogenic lyophilized growth factors|Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
48016938|NCT06426797|DRUG|Cadonilimab plus anlotinib|cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
48016939|NCT06289413|OTHER|Development of AD/OI after BS|"OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches."
48374104|NCT03965754|BEHAVIORAL|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
48705438|NCT06036017|OTHER|Music Therapy|Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).
48016940|NCT04747938|DEVICE|Energy accumulator|All subjects treated with thermal therapy using the Energy Accumulator by acupoint concepts. The course included 8 sessions of treatment, twice every week for 4 weeks. Each session lasted for 30-45 minutes. During heat therapy, the ceramic nozzle of the Energy Accumulator was lightly pressed in contact of the skin, without any contact medium, and moved slowly along the meridians with some circular movements.
48016941|NCT04747938|BEHAVIORAL|Home exercise program|Home exercises aimed at providing gentle mobilization at the shoulder and were capable of carrying out at home. Patients were requested to perform the movements on a daily basis within the first 4 weeks of treatment. Four movements were involved: Movement 1 - Pendular Exercise, Movement 2 - Circle Exercise, Movement 3 - Wall Climbing Exercise, and Movement 4 - Lie on bed and move both arms up and down.
48016942|NCT04485533|DEVICE|VisuXL® Gel|"VisuXL® ophthalmic gel, available in a multidose 10ml bottle without preservatives based on Coenzyme Q10, Vitamin E TPGS and cross-linked sodium carboxymethylcellulose.~Dose/dosage: 1 drop per eye twice a day."
48016943|NCT04485533|DEVICE|HYLO®|"HYLO® ophthalmic solution, a phosphate- and preservative-free sterile eye drops containing 2 mg/ml of hyaluronic acid sodium salt, a citrate buffer, sorbitol and water.~Dose/dosage: 1 drop per eye twice a day"
48016944|NCT04929561|BEHAVIORAL|Video-conferencing group|No intervention
48016945|NCT02746614|OTHER|Psychomotor Therapy|Psychomotor Therapy
48705439|NCT06036017|OTHER|Presence of Family After Extubation:|According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
48705440|NCT03960580|DRUG|OPN-375|OPN-375, BID
48705441|NCT01686750|BEHAVIORAL|Integrated care centers|
48705442|NCT01529580|BEHAVIORAL|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
48705443|NCT05417269|DRUG|IMCY-0141|"The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms."
48705444|NCT05417269|DRUG|Placebo|"The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only."
48705445|NCT05417269|DRUG|Dimethyl Fumarate|"Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only."
48705446|NCT03354884|DRUG|cabozantinib|cabozantinib 60 mg orally once daily
48705447|NCT02825966|DEVICE|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
48016946|NCT03717532|PROCEDURE|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
48016947|NCT03717532|PROCEDURE|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
48016948|NCT05107310|PROCEDURE|Pedicle screws insertion by free hand technique|Spinal deformity correction. Pedicle screws are inserted using free hand technique with the help of intraoperative fluoroscopy if needed.
48016949|NCT05107310|PROCEDURE|Pedicle screws insertion using ARSN|Spinal deformity correction. Pedicle screws are inserted using augmented reality surgical navigation (ARSN) with the ClarifEye navigation system and the Philips Allura 2D/3D imaging system.
48016950|NCT05107310|PROCEDURE|Pedicle screws insertion using IRSN|Spinal deformity correction. Pedicle screws are inserted using infra-red surgical navigation (IRSN) with the Brainlab Curve 1.2 navigation system combined with the Medtronic O-arm 2D/3D imaging system.
48016951|NCT02877550|DRUG|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
48016952|NCT02877550|DRUG|Venetoclax|p.o. once daily according to dose level (DL) or MTD
48016953|NCT00870311|DRUG|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
48016954|NCT01915368|BEHAVIORAL|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
48016955|NCT01915368|BEHAVIORAL|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
48016956|NCT01915368|BEHAVIORAL|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
48016957|NCT03064126|DEVICE|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
48016958|NCT03064126|DRUG|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
48016959|NCT03064126|PROCEDURE|Standard Balloon Angioplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
48374105|NCT05225701|BEHAVIORAL|Transdiagnostic guided internet-delivered intervention with synchronous assistance|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each user will be assigned an advisor who will be health personnel (psychologists, social workers, and gerontologists). The function of the psychological advisor is to motivate, guide and listen to the doubts and comments of each participant by providing a weekly session of one hour in individual online format, in addition to the review of the module in platform in self-suggestive format.
48016960|NCT05514834|DEVICE|Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3)|Injections with platelet-rich plasma and hyaluronic acid
48374106|NCT05225701|BEHAVIORAL|Transdiagnostic self-guided internet-delivered intervention|Self-applied treatment web system based on transdiagnostic approach for emotional and stress and trauma-derived disorders. The system will contain seven modules: Module 0. Pre-evaluation; Module 1. Psychoeducation and motivation for change; Module 2. Emotional Coping Skills; Module 3. Acceptance and awareness-raising skills focused on the present moment; Module 4. Cognitive coping skills; Module 5. Behavioral coping skills; Module 6. Achievements, maintenance and prevention of relapses; Module 7. Post-evaluation. Each module will include exercises and tasks for the practice of each technique. Automatic emails with notifications will be sent to access the program when participants have not entered in the last 15 days.
48374107|NCT01715493|DRUG|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
48374108|NCT01715493|DRUG|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
48374109|NCT04054531|BIOLOGICAL|KN046|IV infusion
48374110|NCT04054531|DRUG|Paclitaxel|IV infusion
48705448|NCT01296633|BEHAVIORAL|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
48173677|NCT03967912|BEHAVIORAL|MOVE UP|Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
48173678|NCT02526186|DEVICE|Battlefield Auricular Acupuncture|
48374111|NCT04054531|DRUG|Pemetrexed|IV infusion
48016961|NCT05514834|OTHER|PRP Only|platelet rich plasma without hyaluronic acid
48016962|NCT05514834|OTHER|Placebo|Neither PRP nor hyaluronic acid
48016963|NCT00024362|DRUG|BBR 3464|
48374112|NCT04054531|DRUG|Carboplatin|IV infusion
48016964|NCT01590823|DRUG|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
48016965|NCT00648297|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
48016966|NCT00648297|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
48016967|NCT00949780|DRUG|Chloral Hydrate|
48016968|NCT01639079|BEHAVIORAL|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
48705449|NCT02666495|OTHER|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement \& stabilisation; phase 2 - developing trust \& understanding; phase 3 - developing awareness \& acceptance; phase 4 - testing change \& strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
48705450|NCT06604780|BEHAVIORAL|Transitional discharge program|"For patients classified in the low-risk group, general measures would be applied. For patients in the medium-risk group, reinforced measures would be implemented. Lastly, for patients considered to be in the high-risk group, intensive case management measures would be applied, and if they meet the inclusion criteria, they would be included in the Post-Discharge Group Psychotherapeutic Intervention.~1. General measures~2. Reinforcement measures~3. Intensive measures~   * Intensive case management measures~  * Post-Discharge Psychotherapeutic Recovery Support Program: For application to patients at high risk of early readmission who meet the inclusion criteria. It consists of a multicomponent group psychotherapeutic intervention from a rehabilitative and recovery-oriented perspective. This intervention will be structured into 20 sessions, each lasting 90 minutes, held weekly in an open format."
48016969|NCT04214691|DRUG|Acetaminophen|Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
48173679|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
48374113|NCT00666952|OTHER|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
48016970|NCT00318487|PROCEDURE|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
48173680|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
48173681|NCT05238649|BIOLOGICAL|SARS-Cov-2 Vaccine Inactivated|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
48374114|NCT00666952|OTHER|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
48374115|NCT05689164|BIOLOGICAL|fordadistrogene movaparvovec|gene therapy administered in a previous study.
48374116|NCT04004975|DRUG|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
48374117|NCT01331525|BIOLOGICAL|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
48374118|NCT05809219|OTHER|1 hour combined intervention ( Exercise and nutrition)|Subjects take oral supplement after exercise in the time period between 1-2 hours. They will take oral supplement during hemodialysis treatment.
48374119|NCT05809219|OTHER|3 hours combined intervention ( Exercise and nutrition)|"All procedures between 1 hour combined intervention and 3 hours combined intervention are the same. The only one different is the time interval between exercise and nutrition. In this arm, the time interval of exercise and nutrition is 2.5 to 4 hours. When we recruiting subjects, all interventions will be clearly introduced to them, including the same and the different parts among them."
48374120|NCT05809219|DIETARY_SUPPLEMENT|Nutrition intervention|"Subjects only take oral supplement during hemodialysis treatment. The oral supplement is the same as the 1 hour combined intervention and 3 hours combined intervention."
48016971|NCT00180739|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
48173682|NCT04787432|BEHAVIORAL|Salutogenic Frailty Prevention Program|"Laughter yoga: The first component of intervention is the laughter yoga that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Each session of laughter yoga will be offered twice a weekly and 40 minutes each time.~Health education: The second component of intervention consisted of six health issues which are health, frailty and generalized sources of resistance for frailty, the most common medical condition and medication use, physical activity, healthy diet, falls prevention and cognitive and psychosocial well-being.~Case management: The third component of intervention is activities that determine each participant's health needs with the Omaha System and support them for the use of appropriate resources."
48173683|NCT02230722|BEHAVIORAL|Motivational Interviewing|
48173684|NCT02230722|BEHAVIORAL|Attention Control|
48173685|NCT02411708|DRUG|SANGUINATE|Single two-hour infusion of SANGUINATE
48374121|NCT04943601|OTHER|action observation therapy|The participants will be three meters from the screen onto which the videos will be projected. The initial posture will vary depending on each movement, lying down, sitting, or standing and ensuring a clear field of vision. The sessions will be performed in groups of three to four patients
48374122|NCT04943601|OTHER|conventional physical therapy|Verbal instructions will be given to perform and correct the movements requested. The sessions will be conducted in groups of three to four patients and all participants will have 3 to 4 assistants in the session, they will help them achieve their active-assisted range of motion requested in the exercises, when necessary.
48374123|NCT03899038|PROCEDURE|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
48374124|NCT03058861|BEHAVIORAL|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
48374125|NCT01319994|DRUG|Metformin|Metformin 850mg TDS (12 weeks)
48374126|NCT01319994|DRUG|Placebo|Placebo 850mg TDS (12 weeks)
48374127|NCT03853226|PROCEDURE|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
48374128|NCT00389766|DRUG|iodine I 131 metaiodobenzylguanidine|
48173686|NCT02411708|DRUG|Placebo|Single two-hour infusion of placebo
48173687|NCT00383591|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
48374129|NCT00389766|DRUG|topotecan hydrochloride|
48374130|NCT00389766|PROCEDURE|chemotherapy|
48374131|NCT00389766|PROCEDURE|peripheral blood stem cell transplantation|
48016972|NCT03711123|BEHAVIORAL|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
48374132|NCT00389766|PROCEDURE|radioisotope therapy|
48374133|NCT00389766|PROCEDURE|radionuclide imaging|
48374134|NCT00389766|PROCEDURE|radiosensitization|
48374135|NCT00389766|PROCEDURE|total-body irradiation|
48374136|NCT06415188|BEHAVIORAL|Video game with headset|Half an hour before the first treatment in the morning, the screens around the patients' beds were closed by the researcher. The child was asked to choose one of the introduced games and the game he/she chose from the tablet was turned on. Children were asked to wear headphones for sound isolation and the sound was adjusted at the appropriate decibel setting. Half an hour before the treatment, children were allowed to play the video game until the treatment without any different warning. Physiologic Parameter Assessment Form, Child Anxiety and Fear Scale, Child Pain Scale were filled by the researcher 1 minute before and 1 minute after the procedure. Finally, Parental Satisfaction Scale was completed at the end of the intervention.
48374137|NCT02951182|DRUG|TEZ|
48374138|NCT02951182|DRUG|IVA|
48374139|NCT02951182|DRUG|VX-440|
48374140|NCT02951182|DRUG|Matched Placebo|
48374141|NCT06418789|DRUG|High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )|"TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle. G-CSF 10 micrograms/Kg SC daily day on days 6-14 day or until CD34 harvest. Leukapheresis will be performed starting on day 11 in case blood level of CD45+CD34+ above 20x10\^6/L is achieved.~CE: Carboplatin AUC=8 IV daily days -4 to -2, Etoposide 400mg/m\^2 IV daily days -4 to -2, autlologous stemm cell transplantation \>=2\*10\^6/Kg at day 0, GCSF support from day 4 until the recovery of neutrophils above 1\*10\^9/L.~Patients will receive two cycles of TI followed by 3 cycles of CE in case at least 6\*10\^6 CD34+ stem cells will be harvested."
48374142|NCT02615665|PROCEDURE|Hepatic resection|Removal of a part of the liver during surgery
48374143|NCT03684343|OTHER|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
48374144|NCT02090920|DRUG|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
48374145|NCT05070494|BIOLOGICAL|Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)|study of immunologic response to different dose and duration of Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated)
48374146|NCT05673486|COMBINATION_PRODUCT|PENG Block|"With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon."
48016973|NCT03711123|BEHAVIORAL|Clinical management|10 weekly individual sessions With clinical management including guided self-help
48016974|NCT05434312|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
48016975|NCT02506114|BIOLOGICAL|PROSTVAC V/F|PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
48173688|NCT00383591|BIOLOGICAL|Engerix-B|
48173689|NCT04300153|PROCEDURE|ESP Block|At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
48173690|NCT04300153|OTHER|Global Quality of Recovery-15 score|Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
48173691|NCT04300153|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
48173692|NCT01426113|DRUG|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
48016976|NCT02506114|DRUG|Ipilimumab|
48016977|NCT00722644|BEHAVIORAL|Cognitive Behavioral Stress Management|
48705451|NCT04753554|DEVICE|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
48705452|NCT04753554|OTHER|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
48705453|NCT06605352|DIAGNOSTIC_TEST|The BIOFIRE®FILMARRAY® Pneumonia Panel|"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."
48705454|NCT03158012|BIOLOGICAL|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
48705455|NCT04839471|DRUG|BI-754091 plus afatinib|Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
48705456|NCT03933410|DRUG|KB195|KB195 is a novel glycan
48705457|NCT02062892|DRUG|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
48173693|NCT01426113|DRUG|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
48173694|NCT01426113|DRUG|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
48705458|NCT02062892|DRUG|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
48016978|NCT05556876|DIETARY_SUPPLEMENT|Protein omega-3|An oral supplement with a high content of protein and with essential fatty acids
48173695|NCT00004478|DRUG|droxidopa|
48173696|NCT00485550|DRUG|Atomoxetine Hydrochloride|
48173697|NCT00485550|DRUG|Methylphenidate Hydrochloride|
48173698|NCT00485550|DRUG|Placebo|
48173699|NCT04667715|DEVICE|Exablate BBBD|Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators
48173700|NCT00963443|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
48173701|NCT00963443|DRUG|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
48173702|NCT00963443|DRUG|Placebo|Matching Placebo
48173703|NCT00514488|DRUG|STI571 (400 mg/day; or 800 mg/day)|
48705459|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
48705460|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
48705461|NCT06608108|OTHER|Non-intervention|Non-intervention
48705462|NCT02868034|BEHAVIORAL|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
48705463|NCT02868034|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
48016979|NCT03548870|OTHER|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
48016980|NCT03548870|OTHER|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
48173704|NCT03487263|BIOLOGICAL|IC14|chimeric monoclonal antibody against human IC14
48173705|NCT06086678|OTHER|Conventional physical therapy|"1. Deep breathing exercise.~2. Diaphragmatic breathing exercise.~3. Pursed lip breathing exercise."
48173706|NCT06086678|OTHER|Hydrotherapy|"1. Water walking exercise.~2. Forward lunges exercise.~3. Single leg balance exercise.~4. Side stepping exercise.~5. Push ups exercise.~6. Standing knee lifts exercise."
48173707|NCT06086678|OTHER|Aerobic exercise|Aerobic exercise in form of treadmill training when each child was standing on the treadmill, should be ensure that this standing in an upright position, and according to each child, the therapist corrected the height of the handrails. Ask the child to keep looking forwards along the walking on the treadmill aiming to encourage the setting of walking free. The treadmill training would be completed for each child when the child completes three stages in 1-min training cycles. First stage: the child grasped on to the rails with both hands in first 15 s of every 1-min. Second stage: the child grasped on to the railings with one hand in the second 15 s. And final stage: the child didn't grasp on to the railings in last 30 s. Every child performed this procedure twenty times
48374147|NCT05673486|COMBINATION_PRODUCT|Multimodal analgesia|Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
48374148|NCT02454387|DRUG|ONO-4474 Part A1|Healthy volunteers
48374149|NCT02454387|DRUG|Placebo Part A1|Healthy volunteers
48016981|NCT04891679|DRUG|Oral misoprostol solution (OMS)|"Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours.~Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below.~0 hour= 20ml~1. hour= 20ml~2. hour= 30ml~3. hour= 30ml~4. hour= 30ml~5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml~Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity."
48173708|NCT03903523|DEVICE|Lumen apposing metal stent (LAMS)|Stent positioning
48173709|NCT00878553|DRUG|placebo|tablet at bedtime
48173710|NCT00878553|DRUG|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
48374150|NCT02454387|DRUG|ONO-4474 Part A2|Healthy volunteers
48374151|NCT02454387|DRUG|Placebo Part A2|Healthy volunteers
48374152|NCT02454387|DRUG|ONO-4474 Part B|Healthy volunteers
48374153|NCT02454387|DRUG|Placebo Part B|Healthy volunteers
48374154|NCT02454387|DRUG|ONO-4474 Part C|Healthy volunteers
48374155|NCT02454387|DRUG|Placebo Part C|Healthy volunteers
48374156|NCT02454387|DRUG|ONO-4474 Part D|Healthy volunteers
48173711|NCT05807425|PROCEDURE|Polidocanol foam sclerotherapy|The preparation of the foam is done according to the Tessari's technique using 2 disposable 20ml syringe, a three-way tap and a 10cm reusable extender adapted to intravenous needle. The sclerosant is applied according to the Blanchard's technique through a disposable transparent anoscope with the patient in jack-knife (knee-chest) position. In each session treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).
48374157|NCT02454387|DRUG|Placebo Part D|Healthy volunteers
48374158|NCT00655226|BEHAVIORAL|Hepatitis C educational support groups|Hepatitis C educational support groups
48705464|NCT02868034|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
48705465|NCT02868034|BEHAVIORAL|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
48374159|NCT00655226|BEHAVIORAL|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
48374160|NCT02860650|BIOLOGICAL|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9\*10\^10 viral particles (vp).
48374161|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5\*10\^8 infectious units (Inf U).
48374162|NCT02860650|BIOLOGICAL|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5\*10\^10 vp.
48705466|NCT04199273|PROCEDURE|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
48705467|NCT04199273|PROCEDURE|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
48705468|NCT01844011|OTHER|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
48705469|NCT06219837|DRUG|bupivacaine injection by ultrasound guided transversalis fascia plane block|With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
48374163|NCT02860650|BIOLOGICAL|Placebo|IM injection of 0.9 percent saline.
48374164|NCT02860650|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1\*10\^8 Inf U.
48705470|NCT04639960|DRUG|Risperdal|Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
48705471|NCT04639960|DRUG|Placebo|Twelve weeks of placebo treatment.
48705472|NCT01637363|BEHAVIORAL|Psychoeducation|6 x 2 hours of psychoeducation
48374165|NCT02934126|OTHER|breast cancer patients|semi structured face to face interviews
48374166|NCT00100711|DRUG|Motexafin Gadolinium|
48374167|NCT03781050|DRUG|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
48374168|NCT03364699|DIETARY_SUPPLEMENT|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
48374169|NCT03364699|OTHER|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
48374170|NCT02358707|OTHER|Ibuprofen phonophoresis|
48374171|NCT01240109|DRUG|Remifentanil|"* propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
48374172|NCT04585958|PROCEDURE|Biopsy|Undergo biopsy
48374173|NCT04585958|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48374174|NCT04585958|PROCEDURE|Computed Tomography|Undergo CT
48374175|NCT04585958|PROCEDURE|Echocardiography|Undergo echocardiography
48374176|NCT04585958|DRUG|Olaparib|Given PO
48016982|NCT05451212|BIOLOGICAL|MuSK-CAART|Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.
48016983|NCT02096055|DRUG|Cladribine|Given IV
48173712|NCT06345326|OTHER|Greater occipital nerve block|The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.
48173713|NCT01503164|DEVICE|Positive Pressure Therapy (PAP)|Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
48173714|NCT01503164|BEHAVIORAL|LifeStyle Counseling|Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
48173715|NCT05160311|DRUG|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
48173716|NCT05160311|DEVICE|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
48173717|NCT01551069|DRUG|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet~Route of administration: oral"
48173718|NCT01551069|DRUG|Placebo|"Pharmaceutical form:tablet~Route of administration: oral"
48173719|NCT03647202|DRUG|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
48173720|NCT03647202|DRUG|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
48173721|NCT03647202|DRUG|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
48173722|NCT05266898|BIOLOGICAL|Human papillomavirus 9-valent vaccine, recombinant|Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)
48374177|NCT04585958|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
48374178|NCT02366026|BIOLOGICAL|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
48705473|NCT04203069|DEVICE|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
48016984|NCT02096055|DRUG|Guadecitabine|Given SC
48173723|NCT00371462|BEHAVIORAL|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
48173724|NCT00371462|BEHAVIORAL|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
48173725|NCT00755456|DRUG|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
48173726|NCT00755456|DRUG|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
48173727|NCT00169975|DEVICE|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
48173728|NCT01675310|DRUG|medical nutrition therapy + metformin|
48173729|NCT01675310|BEHAVIORAL|Medical nutrition therapy|medical nutrition therapy
48173730|NCT05594004|DEVICE|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
48173731|NCT05594004|DEVICE|Sonic electric toothbrush|Sonic electric toothbrush used twice daily
48016985|NCT02096055|DRUG|Idarubicin|Given IV
48016986|NCT06268821|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|Glucose sensors to be worn continuously for 3 months with data used to monitor and manage diabetes treatment and to inform lifestyle choices (diet and exercise)
48374179|NCT00148174|BEHAVIORAL|Intensive telephone followup|Telephone calling
48374180|NCT00453076|DEVICE|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
48374181|NCT04028739|DIETARY_SUPPLEMENT|curmin|curcumin 90mg/day cross-over
48374182|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN|8 lessons over 6-8 weeks
48374183|NCT01560676|BEHAVIORAL|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
48374184|NCT01929551|OTHER|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
48374185|NCT01929551|OTHER|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
48374186|NCT01929551|OTHER|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
48374187|NCT01929551|OTHER|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
48374188|NCT01929551|OTHER|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
48374189|NCT01929551|OTHER|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
48374190|NCT01929551|OTHER|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
48374191|NCT04731740|DRUG|Lenvatinib|PO
48016987|NCT06662981|BEHAVIORAL|preoparative information and education|The intervention will include oral and written education about the operation, nursing and active participation in self-care. The intervention will take place in 3 phases: One week before THA, one day before THA after patient admission and postoperatively, before patient discharge. After a rough description of the operation, the anatomy and functionality of the joint will be presented, underlining the necessity of the operation. Instructions for recognizing and managing potential complications will be given. Patients will be informed about the appropriate post-operative walking aids, walking style, sitting up techniques, standing-up techniques, lying down techniques and getting in and out of the car. There will be a demonstration of muscle strengthening exercises, isometric quadriceps and gluteal exercises, Patients will also be informed about the necessity of prophylactic postoperative antithrombotic and antibiotic treatment.
48016988|NCT00116389|DRUG|talabostat mesylate tablets|
48016989|NCT00116389|DRUG|gemcitabine|
48016990|NCT06602596|BEHAVIORAL|Hoosier Sport|The Hoosier Sport intervention is an 8-week program designed for students in PE classes, focusing on enhancing physical activity and promoting health through sport. The curriculum includes unique sports activities, leadership exercises, and health education, aimed at improving students' physical and psychological well-being. The program also addresses the effects of screen time and social media on physical activity, encouraging healthier behaviors. Throughout the intervention, students wear AX3 accelerometers to track changes in their physical activity levels, helping to assess the program's impact.
48374192|NCT04731740|BIOLOGICAL|Pembrolizumab|IV
48374193|NCT04731740|DRUG|Chemotherapy|Investigators' choice
48374194|NCT05942716|DRUG|Administration of a PET radiotracer|"A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic."
48016991|NCT04699994|DRUG|FLOT therapy|Preoperative FLOT therapy
48016992|NCT05487170|DRUG|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
48016993|NCT04391010|OTHER|Surgical masks|Surgical masks will be applied in health care providers
48016994|NCT04391010|OTHER|Filtering respirators|Filtering respirators will be applied in health care providers
48374195|NCT01750034|PROCEDURE|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
48374196|NCT01750034|PROCEDURE|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
48374197|NCT04250506|DRUG|Daridorexant|Daridorexant (ACT-541468) administered as film-coated tablets for oral use.
48374198|NCT04250506|DRUG|Placebo|Placebo administered as tablets for oral use.
48374199|NCT04250506|DRUG|Moxifloxacin|Moxifloxacin administered as film-coated tablets for oral use.
48374200|NCT00719706|DRUG|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
48374201|NCT00719706|DRUG|Placebo|Placebo
48173732|NCT05594004|DEVICE|Manual toothbrush|Manual toothbrush used twice daily
48705474|NCT04203069|DEVICE|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
48705475|NCT02793596|OTHER|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
48705476|NCT01825395|DRUG|3, 4-Diaminopyridine|
48705477|NCT00985907|DRUG|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
48705478|NCT04161963|DEVICE|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
48016995|NCT04205279|OTHER|Experimental: Treadmill training|Participants will be given thirteen slips and thirteen trips in stance and walking, followed by two slips and two trips at a higher intensity (posttest). Subjects would be consented if they would like to undergo fMRI pre and post-training. Participants not willing to undergo imaging would not be excluded. Three day training consisting of blocks of five consecutive gait-slips at varying intensities will be provided. Individuals with stroke would undergo an additional session (total 4 training sessions over 4 weeks (1session/week) since these individuals get easily fatigued and also might need more training sessions with sufficient rest interval to induce reactive adaptation. Training at a specific level will persist until the subjects show a recovery step response in at least 3/5 trials in a single block. Once subjects successfully adapt to this level, the perturbation intensity will be increased until they show a recovery response in at least 3/5 trials.
48016996|NCT04205279|OTHER|Experimental: Overground training|"Slips and trips could be induced under either of the limbs. The specialized walkway consists of two sliding platforms, each of which is mounted on two rows of low friction linear bearings (friction coefficient = 0.02). The base plate of each platform is bolted separately onto the top of a force platform embedded in the floor. An electronic-mechanical latch system is used to control the 2 states of the support platform; that is, the locked state for regular walking and the release state to initiate slipping are carefully controlled. The sliding top of the platform is released after the heel strike (vertical force to exceed 2% of the body weight). The slip distance would be adjusted between 30 to 60 centimeters depending upon the different population and their physical capacity."
48016997|NCT04205279|OTHER|Experimental: Surefooted training|During the first minute of each block, subjects would experience no perturbations followed by 3 minutes of single or multi-directional perturbations. A one minute break between each condition would be provided. Subject's fatigue would be assessed by Fatigue severity scale to determine the tolerability of 30 minute training protocol. The expected duration to complete the test would be a maximum of 1 hour including the preparation and training time.
48016998|NCT02036905|OTHER|Cervical and thoracic mobilization|Described in arm description
48016999|NCT02036905|OTHER|cervical and thoracic manipulation|described in arm description
48017000|NCT05724004|RADIATION|SBRT/SRS/radiation therapy|Consolidation radiation therapy (SBRT/SRS/moderately hypofractionated radiation therapy)
48705479|NCT04161963|DEVICE|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
48705480|NCT04243018|BEHAVIORAL|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
48017003|NCT01336738|DRUG|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
48374204|NCT06419231|DIETARY_SUPPLEMENT|Butyrate Formulation|Butyrate Formulation capsule:3 capsules daily
48017004|NCT01336738|DRUG|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
48017005|NCT01336738|DRUG|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
48017006|NCT01336738|DRUG|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
48017007|NCT01336738|DRUG|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
48017008|NCT06144502|BEHAVIORAL|5Ways@School|"The 5Ways@School intervention is a teaching material consisting of five elements; Take notice, Be active, Keep Learning, Connect, and Give. The intervention will be given in an ordinary classroom setting by the class' main teacher in two school hours of 45 minutes each week for six consecutive weeks, i.e., a total of 12 school hours. The teaching sessions will consist of presentations of the five elements, videos, reflection exercises, focused group discussions, creative group work, and giving the pupils small challenges to practice what they have learned between the weekly sessions."
48017009|NCT00132444|DRUG|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
48017010|NCT01048138|DRUG|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
48017011|NCT01048138|DRUG|Placebo|5mg IV(in the vein)every 6 hours for 10 days
48017012|NCT01175824|DRUG|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
48173733|NCT01704443|BEHAVIORAL|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
48017013|NCT01175824|DRUG|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
48173734|NCT01704443|OTHER|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
48705481|NCT04243018|BEHAVIORAL|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
48374205|NCT06419231|DIETARY_SUPPLEMENT|Butyrate + Polyphenol Formulation|Butyrate + Polyphenol Formulation capsule: 3 capsules daily
48017014|NCT01175824|DRUG|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
48374206|NCT06419231|DIETARY_SUPPLEMENT|Placebo|Placebo: 3 capsules daily
48374207|NCT00148109|DRUG|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
48374208|NCT00148109|DRUG|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
48374209|NCT03628573|DEVICE|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
48374210|NCT03628573|DEVICE|Intermittent Theta burst stimulation ( iTBS)|
48374211|NCT02405624|PROCEDURE|continuous positive airway pressure|CPAP training for muscle strength
48374212|NCT03273088|DRUG|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
48017015|NCT04997642|BEHAVIORAL|neuropsychiatric and cognitive testing questionnaires|"Demographic data such as race, sex, age Family History Risk Factor Questionnaire Hoehn and Yahr Stage UPDRS Parkinson's symptom checklist Medication list Neuropsychological Test Battery Behavioral Exams~* Geriatric Depression Scale Quality of Life Questionnaire~* PDQ-39, SF-12"
48173735|NCT00095043|DRUG|MK0928, gaboxadol|
48173736|NCT00095043|DRUG|Comparator: placebo|
48374213|NCT00050050|BEHAVIORAL|Cognitive behavioral therapy|
48705482|NCT00379782|OTHER|Navigation|Navigation and escourt
48705483|NCT05714072|DRUG|Ruxolitinib|10mg BID or 15mg BID
48705484|NCT05714072|DRUG|Abemaciclib|50, 100 and 150 mg
48705485|NCT04303078|OTHER|Varying levels of harness support during walking|Participants will complete a standard gait and motion analysis at varying levels of harness support and stabilization (low, moderate, and high levels).
48705486|NCT06080646|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
48705487|NCT02183337|DRUG|BI 1356|
48705488|NCT02183337|DRUG|BI 1356 + Pioglitazone|
48705489|NCT02183337|DRUG|Pioglitazone|
48705490|NCT01872039|DRUG|Perdipine injection|IV
48705491|NCT03741946|PROCEDURE|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
48705492|NCT06238843|DRUG|irinotecan|Subjects in the contral arm will receive irinotecan 125mg/m2 IV D1, D8, Q3W in 3-weeks cycles or 150mg/m2 IV D1, Q2W in 2-week cycles
48705493|NCT06238843|DRUG|IBI343|IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles
48705494|NCT06238843|DRUG|paclitaxel|Subjects in the contral arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles.
48705495|NCT05897840|DEVICE|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
48705496|NCT06604793|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate
48705497|NCT06604793|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48374214|NCT00050050|DRUG|Drug therapy|
48374215|NCT01558466|DRUG|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
48705498|NCT03897725|OTHER|Telehealth Coaching|Telehealth coaching to promote adherence
48705499|NCT06481228|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
48017016|NCT01994395|DEVICE|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
48705500|NCT06481228|DRUG|Venetoclax|BCL2 inhibitor
48705501|NCT06481228|DRUG|Olverembatinib|TKI
48705502|NCT03416920|OTHER|Wellframe|Wellframe mobile phone app
48705503|NCT06598514|DRUG|Chlorhexidine|Participants will use a 2% chlorhexidine perineal lavage following defecation
48017017|NCT01994395|OTHER|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
48374216|NCT01558466|DRUG|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
48173737|NCT00947141|DRUG|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR \>200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
48374217|NCT00003977|BIOLOGICAL|human papillomavirus 16 E7 peptide|
48705504|NCT06598514|DRUG|Sterile Water|Participants will use a sterile water perineal lavage following defecation
48374218|NCT00003977|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48705505|NCT02186379|BEHAVIORAL|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
48374219|NCT04197856|OTHER|Standard care encouraging family-mediated disclosure of hereditary cancer risk|At counseling, eligible at-risk relatives (who may benefit from disclosure of risk information) are listed on a specified protocol in collaboration between health care provider and the participant.
48374220|NCT04197856|OTHER|Offer of health-care assisted disclosure by sending direct letters to at-risk relatives|The participant is offered that the health care provider at the cancer genetic unit mail a direct letter with personalized family risk information to all at-risk relatives that participant approve contact with.
48374221|NCT00058097|DRUG|tipifarnib|Given orally
48374222|NCT00058097|RADIATION|radiation therapy|Undergo radiation therapy
48374223|NCT04044404|DIAGNOSTIC_TEST|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
48705506|NCT02186379|BEHAVIORAL|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
48705507|NCT03584997|PROCEDURE|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
48374224|NCT06149494|DRUG|Vapendavir|Participants randomized to the experimental cohort will be administered Vapendavir.
48705508|NCT03584997|PROCEDURE|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
48705509|NCT06606834|DIAGNOSTIC_TEST|sonoelastography|Elasticity is defined as the ability of an organ or tissue to return to its original shape after being deformed by an applied force or stress. Based on this principle, sonoelastography is a technique used to assess the elasticity of tissues and organs during ultrasonography. This assessment allows measurement of changes in stiffness of soft tissues following physiological or pathological processes.
48705510|NCT01940575|DEVICE|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
48705511|NCT01940575|DEVICE|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
48017018|NCT02066558|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
48705512|NCT02817113|DRUG|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
48705513|NCT02817113|DRUG|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
48374225|NCT06149494|DRUG|Placebo|Participants randomized to the placebo cohort will be administered placebo.
48374226|NCT05842668|BEHAVIORAL|ESWL Group|Increasing comfort and reducing pain during ESWL
48017019|NCT02066558|OTHER|Placebo|
48374227|NCT04156113|OTHER|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
48173738|NCT00947141|OTHER|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
48705514|NCT02817113|DRUG|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
48017020|NCT01728155|DRUG|chemotherapy|
48017021|NCT04865822|BEHAVIORAL|Single session pain education class|Pain education classes will be provided in person group or virtual settings
48017022|NCT06424301|DRUG|Targeting NUDT21 siRNA drugs|It is performed for intravitreal chemotherapy.
48516791|NCT01248676|OTHER|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
48173739|NCT00947141|DRUG|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
48173740|NCT00947141|OTHER|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
48173741|NCT03507153|PROCEDURE|Bre-flex maxillary partial denture|Partial denture fabricated from Bre.flex material.
48173742|NCT03507153|PROCEDURE|PEEK maxillary partial denture|Partial denture fabricated from PEEK material.
48173743|NCT01516853|DEVICE|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
48173744|NCT04070729|OTHER|Placebo gel|Localized subgingival application
48173745|NCT04070729|DRUG|Hyaluronic acid gel|Localized subgingival application
48173746|NCT04070729|BIOLOGICAL|Platelet rich fibrin|Localized subgingival application
48173747|NCT03409562|BEHAVIORAL|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
48017028|NCT04113759|BEHAVIORAL|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form."
48173748|NCT03409562|BEHAVIORAL|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
48173749|NCT02143310|DEVICE|EVP|
48173750|NCT00953212|DRUG|beta blockers|metoprolol 25mg by mouth every 6 hours
48173751|NCT00953212|DRUG|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
48173752|NCT00953212|DRUG|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
48173753|NCT03540290|PROCEDURE|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
48173754|NCT03949712|DEVICE|Transcranial Static Magnetic Field Stimulation (tSMS)|tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.
48017029|NCT04113759|BEHAVIORAL|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
48173755|NCT03949712|DEVICE|Sham Transcranial Static Magnetic Field Stimulation (tSMS)|Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
48374228|NCT00589823|DRUG|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
48374229|NCT00589823|DRUG|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
48017030|NCT06653257|OTHER|Active surveillance|a non-operative management strategy aimed at avoiding unnecessary surgery in patients with thyroid nodules with a cytopathological diagnosis of Bethesda IV-VI, who do not present clinical or imaging characteristics suggesting malignancy and/or aggressiveness.
48017031|NCT05906017|PROCEDURE|Open Hernia surgery|midline ventral hernia repair - open
48017032|NCT05906017|PROCEDURE|Robotic Hernia surgery|midline ventral hernia repair - robotic
48017033|NCT03509948|DRUG|cytisine|cytisine 1.5 mg film-coated tablets
48017034|NCT01383902|OTHER|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
48017035|NCT05306067|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
48017036|NCT05306067|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
48017037|NCT01956175|DEVICE|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
48017038|NCT01956175|DEVICE|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
48017039|NCT05116722|DEVICE|Shoulder Pacemaker|Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
48017040|NCT04897581|BEHAVIORAL|Brief Behavioral Therapy for Insomnia, BBTI|BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
48017041|NCT04897581|BEHAVIORAL|Physical Self-Regulation, PSR|PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
48017042|NCT05968989|BIOLOGICAL|VRC-FLUMOS0116-00-VP( FLUMos-v2)|"The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013"
48017043|NCT03145272|DRUG|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
48017044|NCT06313372|DIAGNOSTIC_TEST|Respiratory oscillometry|This a Delphi study where we are obtaining expert opinion and input on the use of respiratory oscillometry (a diagnostic respiratory test) in the assessment and management of patients with asthma or chronic obstructive pulmonary disease. The participants are respiratory specialists/pulmonologists. They are sharing their insights into the clinical use of respiratory oscillometry via a series of online surveys. The Delphi process is used in an attempt to achieve consensus as to how respiratory oscillometry is used in clinical practice. As such there is no intervention being used on the study participants, but they are sharing insights on how the respiratory test is used in their clinical practice in order to obtain consensus on this use.
48017045|NCT05518279|DRUG|Tranexamic Acid Pill|Patients will receive 1950mg of an oral tranexamic acid pill (3 pills total) while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the oral TXA and are medically optimized, they will be taken to the operating room for fracture fixation.
48017046|NCT05518279|DRUG|Placebo Oral Tablet|Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
48017047|NCT06573125|BEHAVIORAL|MoodMover|MoodMover is a 9-week app-based program aimed at increasing physical activity (PA) among individuals with depression, delivered via Pathverse. The current version of MoodMover includes one introductory module for baseline self-monitoring, eight primary modules, and eight optional supplementary modules. The program uses a variety of formats to deliver educational content, including videos, podcasts, and illustrated articles. In addition to its structured psychoeducational content, the app provides a range of behavioral features.
48516792|NCT03814655|PROCEDURE|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
48017048|NCT00861419|DRUG|Sorafenib|Sorafenib 400 mg PO (BID)
48017049|NCT00861419|DRUG|AMG 706|AMG 706 125 mg PO (QD)
48017050|NCT00861419|DRUG|AMG 706|AMG 706 75 mg PO (QD)
48017051|NCT00861419|DRUG|AMG 386|AMG 386 10 mg/kg IV (QW)
48017052|NCT00861419|DRUG|Sunitinib|Sunitinib 50 mg PO (QD)
48017053|NCT00861419|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
48017054|NCT00861419|DRUG|AMG 386|AMG 386 3 mg/kg IV (QW)
48017055|NCT02505126|DEVICE|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
48017056|NCT02505126|DEVICE|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
48516793|NCT03814655|PROCEDURE|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
48017057|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 1 (CPMSM)|Test group 1 will receive investigational product 1 (CPMSM: daily dose 25 mL contains: Hydrolyzed fish collagen 5 g, methylsulphonylmethane (MSM) 1,5 g, Biotin 150 μg, Vitamin B6 1,6 mg, Zinc 2 mg, Vitamin C 120 mg).
48017058|NCT06174441|DIETARY_SUPPLEMENT|Investigational product 2 (HC+)|Test group 2 (TG2) will receive investigational product 2 (HC+: daily dose 25 mL contains: Niacin 16 mg, Pantothenic acid 6 mg, Biotin 500 μg, Vitamin B6 1,4 mg, Folic acid 200 μg, Zinc 2 mg, Pea sprout extract 100 mg, Horsetail aerial parts extract 70 mg, Ashwagandha root extract 40 mg, Saw palmetto fruit extract 40 mg, Nettle leaves extract 30 mg, Grape seed extract 10 mg).
48017059|NCT06174441|DIETARY_SUPPLEMENT|Placebo|Placebo group (PG) will receive placebo product without any of the active ingredients (PL, daily dose 25 mL: no active ingredients).
48017060|NCT06047197|BIOLOGICAL|RC19D2 cell injection|The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
48017061|NCT02344368|OTHER|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
48017062|NCT02344368|OTHER|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
48017063|NCT03996928|OTHER|Exercise|
48374230|NCT00857701|DEVICE|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
48374231|NCT02618096|DRUG|Oxytocin|
48374232|NCT02618096|DRUG|Dinoprostone|
48374233|NCT02618096|PROCEDURE|Membrane sweeping|
48374234|NCT00242840|DRUG|No intervention; Observational study|
48374235|NCT03539627|DRUG|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
48017064|NCT04857866|DRUG|XmAb27564|Single ascending dose of XmAb27564
48017065|NCT04857866|DRUG|Placebo|Single dose of placebo
48017066|NCT02483247|DRUG|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
48017067|NCT02483247|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
48374236|NCT00381602|DRUG|GHRP-1/AG 70 mg depot in ESRD|
48374237|NCT00381602|OTHER|Placebo|
48374238|NCT00382499|DRUG|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
48374239|NCT05354401|OTHER|HHF|HHF is an integrated flow generator that delivers heated and humidified air or oxygen at high flow rates via a soft nasal cannula using an open circuit. HHF via the Fisher and Paykel myAIRVO 2 device will be initiated as per The Hospital for Sick Children's sleep laboratory standard protocol by a sleep technician or respiratory therapist (RT) during an overnight polysomnography. Nasal prongs will be selected that are less than fifty percent of the subject's nares. The lowest flow rate of HHF will be selected and titrated upwards until clinical effect is achieved, to a maximum flow of 60L/minute, as per standard clinical care.
48017068|NCT02483247|DRUG|Doxorubicin|Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
48017069|NCT02483247|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
48374240|NCT04281095|DRUG|Botulinum toxin type A|Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
48374241|NCT01579682|BEHAVIORAL|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
48017070|NCT02483247|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
48017071|NCT02483247|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
48017072|NCT02483247|DRUG|Sunitinib|Sunitinib 37.5 mg is administered once daily.
48017073|NCT06573671|DIAGNOSTIC_TEST|Chitotriosidase|The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase
48017074|NCT06573671|DIAGNOSTIC_TEST|Mass spectrometry|to show PVP presence in histiocytes of injecting drug users compared to controls
48017075|NCT06573671|DIAGNOSTIC_TEST|X-ray spectromicroscopy|to show PVP presence in histiocytes of injecting drug users compared to controls
48374242|NCT01579682|BEHAVIORAL|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
48374243|NCT02701907|OTHER|Blood sampling|
48374244|NCT03572621|OTHER|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
48374245|NCT03572621|OTHER|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
48374246|NCT03572621|OTHER|Participation|Participation in a therapeutic education day.
48374247|NCT01904266|PROCEDURE|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
48017076|NCT06573671|DIAGNOSTIC_TEST|Fluorescence microscopy|to show PVP presence in histiocytes of injecting drug users compared to controls
48705515|NCT04465032|OTHER|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
48705516|NCT03411200|BEHAVIORAL|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
48705517|NCT05777122|DRUG|lignocaine gel|pharmacological ,topical anesthetic gel
48705518|NCT05777122|OTHER|sugar free chewing gum|non pharmacological
48705519|NCT00043017|PROCEDURE|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
48705520|NCT00043017|RADIATION|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
48705521|NCT06606340|DRUG|Eteplirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
48705522|NCT06606340|DRUG|Golodirsen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
48705523|NCT06606340|DRUG|Casimersen|No study medication will be provided by the Sponsor as a condition to participate in this observational study, and all decisions concerning each participant's treatment are at the discretion of the participant's treating physician. Participants will receive treatment as prescribed by the treating physician as part of standard of care.
48705524|NCT01888133|BEHAVIORAL|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
48705525|NCT01888133|BEHAVIORAL|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
48705526|NCT05118789|DRUG|NVL-520|Oral tablet of NVL-520
48017077|NCT06573671|DIAGNOSTIC_TEST|Transcriptomics|To describe pathologic signals of PVP-exposed in vitro histiocytes of injecting drug users compared to control samples
48374248|NCT01904266|PROCEDURE|GA + sham block|Injection of 1 cc saline subcutaneously
48017078|NCT06571461|DRUG|Liposomal Irinotecan|Liposomal Irinotecan：i.v. infusion
48374249|NCT03824015|BEHAVIORAL|Keeping Adults Physically Active (KAPA) intervention|The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.
48374250|NCT03824015|OTHER|Usual Care|Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
48374251|NCT05534958|DEVICE|Accexible|Speech Analysis
48705527|NCT04215939|BEHAVIORAL|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48017079|NCT06571461|DRUG|Oxaliplatin|Oxaliplatin;：i.v. infusion
48017080|NCT06571461|DRUG|S-1|S-1: Oral
48017081|NCT06571461|DRUG|Gemcitabine|Gemcitabine: i.v. infusion
48017082|NCT06571461|DRUG|Capecitabine|Capecitabine: Oral
48017083|NCT00191061|DRUG|duloxetine hydrochloride|
48017084|NCT00900484|OTHER|biologic sample preservation procedure|
48017085|NCT00900484|OTHER|immunohistochemistry staining method|
48017086|NCT00900484|OTHER|laboratory biomarker analysis|
48017087|NCT01079234|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily
48017088|NCT01079234|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
48017089|NCT01079234|DRUG|insulin aspart|At least three daily doses at meal-time
48017090|NCT01068327|DRUG|gemcitabine hydrochloride|Given IV
48017091|NCT01068327|DRUG|leucovorin calcium|Given IV
48017092|NCT01068327|DRUG|fluorouracil|Given IV
48173756|NCT00591591|DEVICE|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
48173757|NCT03686618|DRUG|Secretin|Drug to stimulate pancreatic secretion
48173758|NCT05370014|BEHAVIORAL|Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)|The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include COVID-19 risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
48173759|NCT00249782|DRUG|Vehicle control, 2x/day|
48173760|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 2x/day|
48173761|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day|
48173762|NCT00249782|DRUG|MetroGel® (metronidazole gel), 1.0% 1x/day|
48173763|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
48173764|NCT01502306|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
48173765|NCT01502306|DRUG|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
48173766|NCT01502306|BEHAVIORAL|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
48017093|NCT01068327|DRUG|nelfinavir mesylate|Given PO
48017094|NCT01068327|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
48173767|NCT00945399|PROCEDURE|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
48173768|NCT00945399|PROCEDURE|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
48516795|NCT04228016|DEVICE|Device: nastent™|Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
48017095|NCT01068327|RADIATION|hypofractionated radiation therapy|Undergo radiotherapy
48017096|NCT01068327|PROCEDURE|therapeutic conventional surgery|Undergo surgery
48017097|NCT00951210|BIOLOGICAL|PLX-PAD|IM injection
48017098|NCT03652103|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
48017099|NCT03652103|DRUG|Bupivacaine 0.25% Injectable Solution|Perineural Injection
48017100|NCT06247163|RADIATION|PET based Raditherapy boost|An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
48017101|NCT05337059|OTHER|PEEP and Tidal Volume Titration|PEEP and Tidal Volume Titration According to Inspiratory and Expiratory Transpulmonary Pressures
48017102|NCT05920941|DRUG|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
48017103|NCT00824317|DRUG|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
48017104|NCT00824317|DRUG|Placebo|
48017105|NCT06663943|DRUG|CM313 (SC)|CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies
48017106|NCT06663943|DRUG|Glucocorticoids|Patients in the control group receive azathioprine in combination with steroid therapy.
48173769|NCT00142545|DRUG|apomorphine HCl injection|
48173770|NCT06480877|DIAGNOSTIC_TEST|Taking a swab from periodontal pockets or gingival sulci|Swabs for next generation sequencing were taken with paper points as described earlier.
48374255|NCT02605135|DEVICE|Continued Pessary Use|Pessary Fitting
48017107|NCT01075334|DIETARY_SUPPLEMENT|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
48374256|NCT04329156|OTHER|Digitally Flip Technique|A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
48017108|NCT01075334|DIETARY_SUPPLEMENT|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
48173771|NCT02609802|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
48173772|NCT02609802|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
48173773|NCT05612841|OTHER|data collection|data collection from drug-drug interaction between anti-cancer treatment and and other medications
48173774|NCT02449083|PROCEDURE|MRI|MRI
48173775|NCT02449083|PROCEDURE|coronary angiography|coronary angiography
48173776|NCT04886960|BIOLOGICAL|Amniotic Fluid Injection|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
48173777|NCT04886960|OTHER|Standard of Care|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
48374257|NCT04329156|OTHER|Stock Healing Abutment|After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
48374258|NCT00665327|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
48374259|NCT00665327|DRUG|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
48374260|NCT00118209|BIOLOGICAL|rituximab|IV
48374261|NCT00118209|DRUG|cyclophosphamide|IV
48374262|NCT00118209|DRUG|doxorubicin|IV or CIVI
48374263|NCT00118209|DRUG|vincristine|IV or CIVI
48374264|NCT00118209|DRUG|prednisone|oral
48374265|NCT00118209|DRUG|etoposide|CIVI
48173778|NCT00040820|DRUG|oxaliplatin|
48173779|NCT06107049|DIETARY_SUPPLEMENT|BLa80|During the experiment, the subjects took a packet of probiotics every day, and the sleep condition, anxiety level and memory level of the subjects were evaluated by questionnaires and ability tests. The questionnaire included PSQI Pittsburgh Sleep Quality Index scale, ISI Insomnia Severity Index Scale and GSRS gastrointestinal symptom Score scale.
48173780|NCT01638845|PROCEDURE|continuous perineural catheter|continuous perineural catheter
48705528|NCT04215939|BEHAVIORAL|Thermoneutral environment participants with spinal cord injury|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48705529|NCT04215939|BEHAVIORAL|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48705530|NCT04215939|BEHAVIORAL|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48705531|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy male participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48705532|NCT04215939|BEHAVIORAL|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48017109|NCT02383758|DRUG|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
48374266|NCT00118209|DRUG|filgrastim|IV
48374267|NCT00118209|DRUG|pegfilgrastim|IV
48374268|NCT01781130|PROCEDURE|Steroid injection|
48374269|NCT06235086|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
48374270|NCT06235086|DRUG|Dulaglutide|Dulaglutide, SC, once a week
48374271|NCT01005186|BEHAVIORAL|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
48374272|NCT06407843|OTHER|Schroth Method|In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Ten sessions total (30 minutes each, five days a week) will be conducted.
48516796|NCT06205329|DRUG|WPV01 Dose 1-4|WPV01 Dose 1-4 or Placebo on day 1
48516797|NCT06205329|DRUG|WPV01 Dose 5-8 and Ritonavir|WPV01 Dose 5-8 and Ritonavir or Placebo on day 1
48516798|NCT06205329|DRUG|WPV01 Dose 9-12|WPV01 Dose 9-12 or Placebo from day 1 to day 6
48705533|NCT04215939|BEHAVIORAL|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48705534|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy female participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48017110|NCT02383758|DRUG|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
48017111|NCT02383758|DRUG|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
48017112|NCT02583256|BIOLOGICAL|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
48705535|NCT04215939|BEHAVIORAL|Warm environment healthy female participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
48705536|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|oral consumption in beverage
48705537|NCT01375803|DIETARY_SUPPLEMENT|Novel dietary fiber|Oral consumption in beverage
48705538|NCT01375803|OTHER|Placebo|Oral consumption in beverage
48705539|NCT06399510|OTHER|Sterofundin fluid therapy|Sterofundin is known as balanced solution which has similar electrolytes content as per human plasma.
48705540|NCT03262025|PROCEDURE|Operated|Patients were either managed conservatively or underwent emergency laparotomy
48705541|NCT05192018|PROCEDURE|Early reversal of a defunctiong ileostomy|Early reversal of a defunctiong ileostomy after 3 weeks of its creation
48173781|NCT04099485|OTHER|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
48173782|NCT04970381|DRUG|Rivaroxaban|Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
48705542|NCT00269269|DRUG|antihypertensive drug|
48173783|NCT01184534|BEHAVIORAL|Video|5 minute multimedia presentation (video)
48173784|NCT01184534|BEHAVIORAL|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
48173785|NCT03304613|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
48173786|NCT03304613|BEHAVIORAL|Promoting Resilience through Innovative Self-Management|Already noted.
48173787|NCT00832364|DRUG|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
48173788|NCT00832364|DRUG|Placebo|Placebo capsules
48173789|NCT00832364|BIOLOGICAL|Etanercept|Injectable Biologic
48516799|NCT06205329|DRUG|WPV01 Dose 13-15 and Ritonavir|WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6
48516800|NCT06205329|DRUG|WPV01 Dose 16|Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
48705543|NCT00269269|BEHAVIORAL|placebo|
48705544|NCT03208907|DRUG|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
48705545|NCT03208907|DRUG|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
48705546|NCT03208907|DRUG|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
48705547|NCT03208907|DRUG|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
48705548|NCT05974475|RADIATION|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
48705549|NCT05974475|PROCEDURE|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
48705550|NCT05275543|DEVICE|Paro Robot|Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
48705551|NCT00461864|PROCEDURE|ultrasound examination of the hip|
48705552|NCT02185430|DRUG|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
48705553|NCT02185430|DRUG|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
48705554|NCT00858741|RADIATION|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
48705555|NCT00858741|RADIATION|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
48705556|NCT04114643|BIOLOGICAL|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
48705557|NCT04114643|BIOLOGICAL|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
48705558|NCT01170065|DRUG|BIBF 1120|Intermediate dose BIBF 1120 twice daily
48705559|NCT01170065|DRUG|BIBF 1120|High dose BIBF 1120 twice daily
48017113|NCT02583256|BIOLOGICAL|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
48028583|NCT06290362|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"Cognitive Behavioural Theory-based group consultation was given to the intervention group through an Instagram as online social media platform. This approach has been developed with the philosophy of Cognitive Behavioral Theory (Eskin, 2009).~For three days a week over eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. The participants were connected to the live broadcast of the research team, and they interacted via text messages. In this interaction, further suggestions related to the goals of the week were given, previous assignments were checked, homework for the next session was given, personal experiences and the needs of the participants were determined, and necessary feedback was provided. Instagram had the feature of maintaining the records of all participants\&#39; attendance at these events."
48028584|NCT06442436|DRUG|Nemtabrutinib|25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
48173790|NCT02208037|DRUG|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
48374273|NCT06407843|OTHER|Regular Physical Therapy|Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.
48374274|NCT01970280|DRUG|Enoxaparin|
48374275|NCT03006042|DRUG|Bupivacaine|
48374276|NCT03455400|DEVICE|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
48374277|NCT04668482|DEVICE|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
48374278|NCT04668482|DEVICE|SCS is switched on|Spinal cord stimulator is functioning
48705560|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 twice daily
48705561|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 once daily
48705562|NCT03217084|DRUG|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
48705563|NCT03217084|DRUG|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
48374279|NCT04299958|OTHER|Patient diary|In the first visit they will be examined by a neurologist with experience in headache disorders and NH diagnosis will be reviewed. Patients will be invited to participate into the study and they will provide and sign informed consent form. They will be instructed and trained to complete the prospective headache diary during 14 days. A follow up visit will be done within 15 to 30 days to review the data and analyze possible sources of bias.
48374280|NCT02531074|BEHAVIORAL|Mobile Application|
48374281|NCT02531074|BEHAVIORAL|Food Journal|
48374282|NCT02531074|BEHAVIORAL|Usual Care|
48374283|NCT03256591|OTHER|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
48374284|NCT04802421|PROCEDURE|alveolar recruitment manoeuver|alveolar recruitment manoeuver are recommended during general anesthesia to prevent pulmonary atelectasis
48516801|NCT03557502|OTHER|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
48017114|NCT04913493|PROCEDURE|Cytocam-IDF|Patients receive an extra medical imaging test perioperatively with the Cytocam-IDF
48017115|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme|"A 12 week programme of exercise and education~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist only)"
48705564|NCT02463747|DRUG|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
48705565|NCT02463747|DRUG|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
48705566|NCT02463747|DRUG|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
48017116|NCT06192628|BEHAVIORAL|Parkinson's Exercise and Education Programme and Behavioural Change|"A 12-week programme of exercise, education and behavioural change techniques to support exercise adherence and exercise self-efficacy~The weekly programme consists of a 45-minute exercise programme, 45-minute education sessions delivered by healthcare professionals about their role in Parkinson's management, and independent home exercise programmes completed twice weekly (determined by the registered physiotherapist and participant)~Additional techniques addressing behavioural regulation include firstly, an exercise diary completed independently at home, secondly, the rationale and the intended functional benefit and expectations of the exercise programme clearly explained, thirdly individual weekly conversations to reflect on progress, expectations, solutions to barriers, and goals. Finally, peer support is strongly encouraged through the in-class support, and a social media networking group."
48705567|NCT02463747|DRUG|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
48705568|NCT02080039|DEVICE|Electrical Stimulation|
48017117|NCT02984995|DRUG|Quizartinib|Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
48017118|NCT06663553|PROCEDURE|TU-LESS|patients in TU-LESS group will receive transumbilical laparoendoscopic single-site surgery (TU-LESS) for hysterectomy
48017119|NCT06663553|PROCEDURE|vNOTES|patients in vNOTES group will receive transvaginal natural orifice transluminal endoscopic surgery (TU-LESS) for hysterectomy
48017120|NCT03754699|BEHAVIORAL|Educational intervention|"During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital"
48017121|NCT03754699|BEHAVIORAL|Standard information|Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
48017122|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
48017123|NCT05061446|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily for 12 weeks
48017124|NCT05061446|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
48017125|NCT01590641|DRUG|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
48017126|NCT01590641|DRUG|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
48017127|NCT00679991|DRUG|PRT-201|Applied topically to AVF during surgery
48705569|NCT04956731|OTHER|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
48705570|NCT03262350|BEHAVIORAL|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
48017128|NCT00679991|DRUG|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
48516802|NCT03557502|OTHER|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
48017129|NCT03361410|DIETARY_SUPPLEMENT|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
48017130|NCT03361410|DIETARY_SUPPLEMENT|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
48017131|NCT02930434|DIETARY_SUPPLEMENT|cholecalciferol|Administration of vitamin D3
48017132|NCT00439400|DRUG|doxycycline|
48017133|NCT00439400|DRUG|placebo|
48017134|NCT01168999|OTHER|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
48017135|NCT01168999|OTHER|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
48705571|NCT00825058|DRUG|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
48705572|NCT00825058|DRUG|placebo|oral administration 12 hours intervals
48705573|NCT00825058|DRUG|paroxetine|oral 20 mg/day
48705574|NCT03294239|PROCEDURE|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
48705575|NCT03294239|PROCEDURE|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
48705576|NCT01968291|BEHAVIORAL|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
48705577|NCT05077995|DEVICE|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
48705578|NCT03271073|DRUG|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
48705579|NCT04691141|DRUG|ATG-016|59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
48705580|NCT03670277|DEVICE|etafilcon A|Test Soft Contact Lens
48705581|NCT03670277|DEVICE|Habitual Orthokeratology Lenses|CONTROL
48705582|NCT00931723|DRUG|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
48705583|NCT00931723|DRUG|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
48705584|NCT00931723|DRUG|Placebo|Oral treatment twice daily.
48705585|NCT04381637|DEVICE|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
48705586|NCT04381637|PROCEDURE|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
48705587|NCT01953549|PROCEDURE|physical fitness training|
48017136|NCT01168999|OTHER|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
48017137|NCT06662890|OTHER|Supersaturated oxygen|"Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention (PCI) using radial artery access in the cardiac catheter laboratory.~https://www.zoll.com/products/supersaturated-oxygen-therapy"
48017138|NCT06662890|OTHER|Sham (No Treatment)|Control (sham) procedure involving wrist manipulation in addition to standard care.
48173791|NCT02208037|DRUG|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
48705588|NCT01953549|PROCEDURE|relaxation|
48705589|NCT00075946|BIOLOGICAL|rituximab|Given IV
48705590|NCT00944814|DIETARY_SUPPLEMENT|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
48705591|NCT00944814|DIETARY_SUPPLEMENT|LNS without zinc|LNS containing no zinc
48017139|NCT03832959|DEVICE|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
48017140|NCT06568939|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
48017141|NCT04028388|DRUG|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
48705592|NCT01926171|DRUG|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
48705593|NCT01255813|DEVICE|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
48017142|NCT04028388|DRUG|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
48028585|NCT05824832|DRUG|Interscalene block with the addition of buprenorphine, clonidine, dexamethasone|Addition of the adjuvant buprenorphine, dexamethasone, and clonidine in the nerve block performed prior to shoulder arthroscopy surgery
48028586|NCT05824832|DRUG|Interscalene block with buprenorphine alone|Addition of the adjuvant buprenorphine alone the in nerve block performed prior to shoulder arthroscopy surgery
48028587|NCT00959023|OTHER|laboratory biomarker analysis|
48028588|NCT00959023|OTHER|medical chart review|
48028589|NCT00959023|OTHER|questionnaire administration|
48028590|NCT00084058|DRUG|Lopinavir/ritonavir|
48028591|NCT00084058|DRUG|Saquinavir|
48705594|NCT01255813|DEVICE|Stimulation (Full)|Stimulation applied above the perception threshold
48705595|NCT01255813|OTHER|Control|No stimulation applied
48705596|NCT02023801|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
48705597|NCT02746601|BEHAVIORAL|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
48374285|NCT05679570|DRUG|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
48017143|NCT03065881|DEVICE|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
48705598|NCT03468816|DEVICE|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
48705599|NCT03407495|DRUG|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
48017144|NCT02267655|DRUG|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
48374286|NCT04465643|DRUG|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
48017145|NCT02267655|DRUG|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
48374287|NCT04465643|DRUG|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
48374288|NCT05359289|BEHAVIORAL|Forest therapy training|Participants will experience nature-based interventions including forest hiking, horticultural therapy and green wellness activities for their mental health and physical conditions.
48374289|NCT05359289|BEHAVIORAL|Senior fitness training|The fitness program includes physics fitness of stamina, coordination and aerobic exercise in 12 weeks. Participants will join the senior fitness program including physical fitness, aerobic exercise and exercise prescription during the 12 weeks program.
48017146|NCT02267655|DRUG|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
48017147|NCT02609126|DRUG|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
48017148|NCT02609126|DRUG|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
48374290|NCT05359289|BEHAVIORAL|Board Games|Participants will play board games with each other.
48705600|NCT05227560|OTHER|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
48705601|NCT01552616|PROCEDURE|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
48705602|NCT00856089|DRUG|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
48705603|NCT06607146|BEHAVIORAL|Sound Success|Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.
48705604|NCT06607146|BEHAVIORAL|Standard of Care|Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
48705605|NCT04782050|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
48017149|NCT02037503|DRUG|Ketamine|
48017150|NCT02037503|DRUG|Saline|
48017151|NCT01723904|DRUG|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
48017152|NCT03475160|DRUG|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
48017153|NCT03475160|DRUG|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
48017154|NCT03475160|PROCEDURE|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
48705606|NCT05319899|DRUG|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
48705607|NCT05319899|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
48374291|NCT04632134|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
48374292|NCT04632134|OTHER|Placebo|tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
48374293|NCT04632134|DEVICE|Home daily transcutaneous vagal nerve stimulation|The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
48374294|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
48374295|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
48017155|NCT03475160|PROCEDURE|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
48017156|NCT03063450|DRUG|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
48017157|NCT03063450|OTHER|Placebo|Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
48017158|NCT02718105|GENETIC|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
48017159|NCT02517580|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|
48017160|NCT04188535|DIAGNOSTIC_TEST|MRI IMAGING|Imaging with MRI will be performed as per disease site standards.
48017161|NCT06347354|DRUG|Indocyanine green|Subdermal injection of 2,5 mg (1 cc) of ICG
48017162|NCT00999349|DRUG|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
48017163|NCT00999349|DRUG|Placebo|
48017164|NCT03779841|DRUG|AGN-151607|Injections were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
48017165|NCT03779841|DRUG|Placebo|Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
48374296|NCT04885218|DRUG|SHR-1209 ;placebo|SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
48017166|NCT02275286|DRUG|Trabectedin|"Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks.~Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery."
48017167|NCT02275286|RADIATION|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).
48374297|NCT03728166|BEHAVIORAL|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
48374298|NCT02052206|PROCEDURE|Shoulder replacement surgery|
48017168|NCT06532201|OTHER|Su jok seed therapy|Su Jok will be applied to the reflection points on the hand based on the painful area of the individual. The painful areas will be determined with the applicator and black pepper seeds will be placed on these areas. Circular massage will be applied to the areas where the seeds are located for 30 minutes.
48705608|NCT01048307|DEVICE|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
48017169|NCT02436382|OTHER|change in temperature|increase in ambient room temperature
48017170|NCT06608069|BEHAVIORAL|Educational counselling|Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence.
48173792|NCT02208037|DRUG|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
48173793|NCT02208037|DRUG|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
48173794|NCT02208037|DRUG|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
48173795|NCT02208037|DRUG|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
48705609|NCT03785860|OTHER|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
48705610|NCT03785860|OTHER|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
48705611|NCT04140695|DRUG|Tradipitant|BID
48705612|NCT04140695|DRUG|Placebo|BID
48705613|NCT02320812|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
48705614|NCT00529126|DRUG|SKY0402|SKY0402
48705615|NCT00529126|DRUG|Bupivacaine HCl|Bupivacaine HCl
48705616|NCT04396769|BEHAVIORAL|FLOW-PA|Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.
48705617|NCT04396769|BEHAVIORAL|PE class as usual|PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
48017171|NCT06434207|OTHER|Collecting discarded blood samples|Discarded blood samples will be collected from routine clinical labs collected before and after surgery.
48705618|NCT05961332|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
48705619|NCT05961332|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
48017172|NCT02571894|OTHER|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
48017173|NCT01818336|DRUG|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
48017174|NCT01294618|DRUG|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
48017175|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays with reservoir.|During bleaching using trays with reservoir.
48017176|NCT05612516|PROCEDURE|Assessment of hydrogen peroxide levels in saliva using trays without reservoir.|During bleaching using trays without reservoir.
48017177|NCT02181231|DRUG|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
48017178|NCT02181231|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
48017179|NCT02181231|DRUG|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
48705620|NCT05961332|DEVICE|Zeiss Clarus 700 imaging|Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
48705621|NCT05056688|DIAGNOSTIC_TEST|Testicular Model BSE/TSE Training Set|The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
48705622|NCT06115382|BEHAVIORAL|Self Cueing Training|Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
48705623|NCT06115382|BEHAVIORAL|External Cueing Training|Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
48705624|NCT06385392|DEVICE|Haptic module and insole device|System for use in daily in-community use that detects the occurrence of freezing of gait (FOG) and triggers external cueing stimuli to unfreeze the individual.
48705625|NCT02379026|DIETARY_SUPPLEMENT|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
48705626|NCT02379026|BEHAVIORAL|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
48705627|NCT02379026|DIETARY_SUPPLEMENT|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
48516803|NCT04935684|DRUG|Fecal Microbiota Transplantation|"Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes."
48705628|NCT02833753|DRUG|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"
48705629|NCT03380546|DRUG|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
48705630|NCT03380546|DRUG|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
48705631|NCT06225024|DEVICE|ESWT|Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
48705632|NCT06225024|DRUG|BoNT A|BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
48705633|NCT02274272|OTHER|ADR-1|two ADR-1 capsules, once daily, QD
48705634|NCT02274272|OTHER|GMNL-263|two GMNL-263 capsules, once daily, QD
48705635|NCT02274272|OTHER|placebo|two placebo capsules, once daily, QD
48705636|NCT00588172|DRUG|Metformin|1000mg bid for 1 week
48705637|NCT06036160|OTHER|Integrated care|Psychiatric follow-up, cognitive behavioral therapy, physical exercise, psychoeducation
48705638|NCT01069159|DRUG|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
48705639|NCT01069159|DRUG|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
48705640|NCT01370200|PROCEDURE|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
48374299|NCT04235127|OTHER|sociodemographic variables, somatic conditions, mental disorders, treatment and drug use|"* sociodemographic variables~* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~* prescriptions for psychopharmacological products~* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide"
48374300|NCT04944485|OTHER|(FIT SA F03, SHOFU, USA)|Self adhesive giomer containing nanohybrid flowable composite
48374301|NCT04944485|OTHER|(Neo Spectra™ ST, Dentsply, Sirona, USA)|Conventional technique using putty nanohybrid resin composite
48374302|NCT02270021|OTHER|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
48516804|NCT05717465|OTHER|Anatomy diagrams|"The visual aids used included:~* An anatomical diagram illustrating how a lumbar puncture is carried out~* Paling palette, diagram illustrating the number of individuals affected by a particular condition~* Paling perspective scale, diagram comparing the risk of an event occurring in comparison to other 'everyday' risks"
48516805|NCT05717465|OTHER|Standard informed consent|Audio narration of a video containing text information relating to the lumbar puncture procedure (including risks) and an image of a consent form
48705641|NCT01370837|OTHER|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
48705642|NCT01370837|OTHER|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
48705643|NCT05751590|DEVICE|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
48705644|NCT05751590|DEVICE|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
48705645|NCT01213186|DRUG|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.
48705646|NCT01213186|DRUG|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
48705647|NCT02204605|BEHAVIORAL|Video-based Consensus Opinion|
48705648|NCT00123578|DRUG|Lorazepam|Lorazepam
48705649|NCT00123578|DRUG|Pentobarbital|Pentobarbital
48705650|NCT05723965|OTHER|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
48705651|NCT05723965|OTHER|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
48705652|NCT04545164|DIAGNOSTIC_TEST|CAD4TB|CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
48705653|NCT04545164|DIAGNOSTIC_TEST|FujiLAM|Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
48173796|NCT02208037|DRUG|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
48173797|NCT02208037|DRUG|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if ABW \< IBW, use ABW\] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
48374303|NCT02270021|OTHER|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
48374304|NCT03961347|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
48374305|NCT03961347|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
48705654|NCT02514694|DRUG|LEO32731|
48705655|NCT02514694|OTHER|Placebo|
48705656|NCT05379062|BEHAVIORAL|Active Singing Group|The participants of the Active Singing Group take part in a weekly 45-minute singing activity in a group over a period of 3 months. In total the investigators expect 12 choir rehearsals. The rehearsals will take place between 2pm and 3.30pm in the church of the Wehrle-Diakonissen Private Clinic in Salzburg. The group will be led by a professional and experienced choir director.
48705657|NCT05379062|BEHAVIORAL|Receptive Music Group|The participants of the Receptive Music Group will individually listen to the already researched CD for Parkinson's patients (Bernatzky, Wendtner, Volc, 2012) at home at the same time on one weekday.
48705658|NCT02649218|BIOLOGICAL|Ligelizumab|QGE031 240 mg s.c. q4w
48705659|NCT05718271|OTHER|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
48705660|NCT05718271|OTHER|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
48705661|NCT05451290|DRUG|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
48705662|NCT00537667|DRUG|anakinra|anakinra
48705663|NCT00537667|DRUG|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
48705664|NCT00248118|DRUG|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
48374306|NCT01303159|DEVICE|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
48374307|NCT03804723|DRUG|oral Prednisone 5mg|patients randomized to this arm will stop prednisone 5 mg
48374308|NCT00981331|PROCEDURE|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
48017180|NCT04609319|DRUG|Dacomitinib|This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
48374309|NCT00981331|PROCEDURE|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
48017181|NCT04258813|BEHAVIORAL|iGuide Intervention (Self-guided)|The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.
48017182|NCT04258813|BEHAVIORAL|iGuide 2 Intervention (Tailored/Targeted)|"The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics."
48374310|NCT04884204|BEHAVIORAL|Lee Symptom Scala|Symptom identification and management with Lee Symptom Scale in follow up care
48374311|NCT05449431|OTHER|TLC1_TM6|Following this inclusion, patients are performing 1-minute chair lift test (TLC1) before 6-minute Walk Test (TM6). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
48017183|NCT04258813|BEHAVIORAL|Control|Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
48374312|NCT05449431|OTHER|TM6_TLC1|Following this inclusion, patients are performing 6-minute Walk Test (TM6) before 1-minute chair lift test (TLC1). Each exercise will be separated by 30 minutes during which the patient will be sitting in a waiting room.
48374313|NCT06420024|BEHAVIORAL|Acceptance and Commitment Therapy|See: https://link.springer.com/chapter/10.1007/0-306-48581-8_1
48017184|NCT00274716|DRUG|MK0736|
48017185|NCT00274716|DRUG|MK0916|
48017186|NCT00274716|DRUG|Placebo|
48017187|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fed condition
48017188|NCT01697436|DRUG|ribavirin [Copegus]|tablet under fasted condition
48017189|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fed condition
48374314|NCT00411892|DRUG|pioglitazone|Tablets, 45 mg/day.
48374315|NCT00411892|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
48374316|NCT02400658|DEVICE|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
48374317|NCT00458133|BEHAVIORAL|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching \& relaxing groups.
48374318|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing under fasting condition
48374319|NCT05364164|DRUG|CT-L01 12.5/1,000 mg|FDC tablet, 2 tablets at a time, oral administration, dosing after high-fat meal
48516806|NCT05853419|DEVICE|Robotic-assisted PCI|Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
48516807|NCT05720468|OTHER|Exercise|Combined endurance and resistance exercise training
48516808|NCT05720468|OTHER|No Exercise|Continue usual level of physical activity; option to participate in exercise training program after 26-week intervention period
48516809|NCT01873378|DRUG|Triptorelin 3.75 mg|
48374320|NCT04712968|BEHAVIORAL|Regular exposure to morning daylight|"Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care."
48374321|NCT03539666|OTHER|diet|dietary patterns
48017190|NCT01697436|DRUG|ribavirin [Copegus]|oral solution under fasted condition
48017191|NCT02804607|OTHER|questionnaire|
48017192|NCT04530682|BIOLOGICAL|Biological samples|Serum and plasma samples. At baseline, 6, 12 and 24 months
48017193|NCT00672438|DRUG|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
48017194|NCT00672438|OTHER|Saline placebo infusion|Intravenous infusion of normal saline
48374322|NCT01307189|DRUG|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
48374323|NCT01307189|DRUG|Placebo|Placebo diskus inhalation powder, once daily
48374324|NCT03246685|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
48374325|NCT03246685|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
48374326|NCT03991520|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
48705665|NCT01438801|DRUG|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
48705666|NCT02893865|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
48374327|NCT03991520|DRUG|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
48017195|NCT04770805|PROCEDURE|Fetoscopy|After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
48017196|NCT00726115|DRUG|SAM-531|
48017197|NCT00726115|DRUG|placebo|
48017198|NCT05780983|BEHAVIORAL|education and coaching on developing healthy nighttime sleep and daytime activity behaviors|The intervention includes a four-session, in-person program delivered by a Master's-level provider. Each individual session will be approximately 30-45 minutes in length. Each session will include education and coaching on developing healthy nighttime sleep and daytime activity behaviors.
48017199|NCT06022159|PROCEDURE|Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.|"Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~Post-operative follow-up: post-operative complications will be followed at 3 and 6 weeks post-surgery.~A visit at 6 months post-surgery will also be carried out to evaluate post-operative complications and late adverse effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
48173798|NCT05666817|OTHER|breastfeeding education|"Mothers in the intervention group will be given breastfeeding training after the pre-test application. The content of breastfeeding education is as follows;~* General information about breastfeeding,~* General information about breast milk and the benefits of breast milk,~* Benefits of breastfeeding for mother and baby,~* How the baby should be held during breastfeeding, the baby's position,~* Effective breastfeeding positions for the mother,~* Ensuring that the baby holds the breast correctly,~* Providing the correct breastfeeding technique,~* Breast milking and storage conditions,~* The necessity and benefits of continuing breastfeeding."
48173799|NCT02361879|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
48173800|NCT02361879|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
48173801|NCT05246384|DRUG|RP7214|RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
48173802|NCT01822145|DEVICE|ICD|
48173803|NCT04214275|OTHER|pulmonary rehabilitation|Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
48173804|NCT00148135|DRUG|Carboplatin|
48173805|NCT00148135|DRUG|Gemcitabine|
48374328|NCT04647773|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
48374329|NCT04647773|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
48705667|NCT02893865|DEVICE|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
48705668|NCT02538419|BEHAVIORAL|CPAP + Peer Support|
48374330|NCT04647773|DRUG|HSK16149 60mg BID|HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
48374331|NCT04647773|DRUG|HSK16149 80mg BID|HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
48374332|NCT04647773|DRUG|Pregabalin 150mg BID|Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
48374333|NCT04647773|DRUG|Placebo BID|Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
48374334|NCT06519396|DEVICE|ultrasonography evaluation|Ultrasonographic measurements of the Achilles tendon were taken using Samsung Sonoace X7 ultrasound system equipped with an 8-13MHz linear transducer. After assuming a prone position on the examination table, the patients placed their feet against the wall and flexed their ankles to ensure optimal contact between the probe and the tendon. Measurements were taken separately on the right and left sides for each patient. Initially, the probe was positioned perpendicular to the long axis of the tendon for an axial plane assessment, followed by measurements of thickness (anterior-posterior), width (medial-lateral), and area at the level of the medial malleolus. The thickness and width measurements utilized the tendon's major axes, while the area measurements were automatically calculated by the device through continuous tracing of the tendon circumference in the same section
48374335|NCT06519396|DEVICE|tetrax device evaluation|A Tetrax device was used to assess static balance. The patient was positioned on the platform and subjected to tests in eight different positions. For each position, a test measurement was made for a duration of 32 seconds, for a total of approximately 5 minutes. The normal eyes-open position was taken as the reference. The effects of vision on balance were observed in the eyes-closed position. Balance is dependent on the back of the heels and the lower vertebrae in this position. Conversely, in the eyes-closed position with the head tilted 30 degrees forward, there is a load on the upper vertebrae and neck. Following the measurements, the Tetrax software program was used to calculate the Fall Index and Stability Index
48374336|NCT04001166|OTHER|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
48374337|NCT05317949|OTHER|Integrated neuromuscular training program group|Integrated neuromuscular training program group will do plyometric training, speed and sensitivity training, resistance training for 3 days in a week and total for eight weeks.
48374338|NCT05317949|OTHER|General fitness exercises program group|General fitness exercises program group will do general fitness exercise for 3 days in a week and total for eight weeks.
48374339|NCT00313716|DRUG|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
48173806|NCT00148135|DRUG|Capecitabine|
48173807|NCT00745498|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
48173808|NCT03013140|DRUG|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV\<5%"
48173809|NCT03013140|PROCEDURE|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
48374340|NCT00313716|OTHER|placebo|an inactive substance
48374341|NCT03048175|PROCEDURE|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
48516810|NCT01734161|DRUG|Dexamethasone|8mg IV dexamethesone given
48173810|NCT02850718|DRUG|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
48173811|NCT02850718|DRUG|Oral Sildenafil|50 mg oral sildenafil (Viagra)
48173812|NCT01447199|BEHAVIORAL|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
48173813|NCT02767609|DEVICE|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
48173814|NCT01145820|DIETARY_SUPPLEMENT|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
48173815|NCT04419363|DRUG|Burosumab Injection|Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
48173816|NCT03521518|DIAGNOSTIC_TEST|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
48173817|NCT02918292|DRUG|Antithymocyte Globulin (ATG)|Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.
48173818|NCT02918292|DRUG|Fludarabine|Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.
48173819|NCT02918292|DRUG|Cyclophosphamide|Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
48173820|NCT02918292|RADIATION|Total Body Irradiation (TBI)|TBI is to be delivered in a single dose of 200 cGy on Day -1.
48017200|NCT06022159|PROCEDURE|Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).|"Post-operative follow-up: postoperative complications will be followed at 3 and 6 weeks post-surgery (before the start of irradiation). Early post-radiotherapy toxicity will then be assessed 1 month after the end of radiotherapy.~A 6-month post-surgery check-up will also be carried out to assess post-operative complications and acute side effects of radiotherapy.~Long-term follow-up would also be performed every 6 months from the 6-month post-surgery visit up to 3 years post-surgery (M12, M18, M24, M30 and M36)."
48017201|NCT02682420|DEVICE|everlinQ endoAVF System|
48705669|NCT02538419|BEHAVIORAL|CPAP + Individual Education|
48705670|NCT00011414|DRUG|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
48705671|NCT01453946|DRUG|Entocort|Entocort capsules, taken orally, 6 mg daily.
48705672|NCT05894538|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
48705673|NCT05894538|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
48173821|NCT02918292|PROCEDURE|Haplo HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.
48017202|NCT02875106|DEVICE|12-point-ECG|routine recording will be 300 seconds
48017203|NCT02875106|DEVICE|Polar V800|routine recording will be 300 seconds
48173822|NCT02918292|DRUG|Tacrolimus|Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.
48516811|NCT01734161|DRUG|Placebo|Subjects randomized to placebo receive 50cc normal saline
48516812|NCT01505582|OTHER|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
48705674|NCT02001415|OTHER|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
48705675|NCT02001415|OTHER|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
48705676|NCT02001415|OTHER|Orthokeratology|Orthokeratology lenses.
48705677|NCT02088619|BEHAVIORAL|Quality of Life Therapy (QOLT)|
48516813|NCT01505582|OTHER|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
48017204|NCT02875106|DEVICE|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
48017205|NCT02875106|DEVICE|Adidas Micoach smart run|routine recording will be 300 seconds
48017206|NCT02875106|DEVICE|TomTom Runner Cardio HRM|routine recording will be 300 seconds
48017207|NCT06572735|OTHER|QoL surveys|2 quality of life surveys (OV28 and ELD14) will be completed by patients every 3 months during a 12-month period
48173823|NCT02918292|DRUG|Mycophenolate mofetil (MMF)|MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.
48173824|NCT02918292|DRUG|G-CSF|G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.
48705678|NCT02088619|BEHAVIORAL|Heart Healthy Education (HHE)|
48705679|NCT02368912|DRUG|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
48705680|NCT02368912|DRUG|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
48705681|NCT02368912|DRUG|ASP1707 single dose fasted|Oral, healthy young male
48705682|NCT02368912|DRUG|ASP1707 single dose fed|Oral, healthy young male
48705683|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
48705684|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
48705685|NCT02368912|DRUG|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
48705686|NCT02368912|DRUG|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
48705687|NCT02368912|DRUG|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
48705688|NCT02368912|DRUG|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
48705689|NCT00746239|DRUG|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
48374342|NCT05156346|OTHER|LEAVES|LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.
48017208|NCT06572735|OTHER|Geriatric assessment (G-CODE)|A geriatric assessment (G-CODE) will be performed by the research staff every 3 months during a 12-month period
48017209|NCT06572735|BIOLOGICAL|Blood sampling|A supplementary volume of blood will be collected from a routine blood sample (8 mL) at 3 different time points : one at inclusion, one 6 and 12 months after the beginning of PARP inhibitors treatment. Genetic lab test will be performed to assess whether there is a specific genetic signature for PARP inhibitors toxicity.
48705690|NCT00746239|DRUG|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
48705691|NCT03820453|DIETARY_SUPPLEMENT|Tribulus Terrestris|The experimental arm will receive a dietary supplement to increase the libido and sexual function
48705692|NCT03820453|OTHER|Placebo treatment|The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
48705693|NCT02686151|DRUG|Letrozole|used after oocyte retrieval
48705694|NCT02686151|DRUG|Polygeline|used after oocyte retrieval
48705695|NCT02686151|DRUG|Sodium Chloride|used after oocyte retrieval
48705696|NCT02686151|DRUG|dexamethasone|used after oocyte retrieval
48705697|NCT02854488|DRUG|Yervoy|
48705698|NCT00236496|DRUG|topiramate|
48705699|NCT04284735|OTHER|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
48705700|NCT01261442|PROCEDURE|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
48017210|NCT01117311|DEVICE|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
48705701|NCT06078202|DRUG|ABBV-903|Tablet; oral
48705702|NCT04385238|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
48705703|NCT02578680|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
48017211|NCT01117311|DEVICE|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
48017212|NCT04016324|DEVICE|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
48374343|NCT05469711|DEVICE|PlayPhysio|The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
48017213|NCT04634916|DEVICE|EndoAVF Creation|Subjects will have an endoAVF created using the WavelinQ EndoAVF System
48017214|NCT06297824|BEHAVIORAL|ERGT-A|Emotion regulation group therapy for adolescents
48017215|NCT01431768|DEVICE|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
48017216|NCT06573411|DRUG|ACEI/ARB+ finerenone|The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
48017217|NCT06573411|DRUG|ACEI/ARB+ Placebo|Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo.
48374344|NCT01196754|OTHER|sevoflurane|
48705704|NCT02578680|DRUG|Cisplatin|IV infusion
48705705|NCT02578680|DRUG|Carboplatin|IV infusion
48705706|NCT02578680|DRUG|Pemetrexed|IV infusion
48705707|NCT02578680|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
48705708|NCT02578680|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
48705709|NCT02578680|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
48705710|NCT02578680|DRUG|Saline solution|IV infusion
48705711|NCT03082534|DRUG|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
48705712|NCT05969548|DEVICE|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
48374345|NCT06404294|DEVICE|External Diaphragm Pacemaker treatment|On the basis of conventional treatment, the patients in this group were treated with external diaphragm pacemaker for 2 weeks or until extubation.The treatment process of external diaphragm pacemaker is as follows: Set parameters: pacing frequency: 5-9 times /min, generally starting from 5 times /min, and adjusted according to the tolerance of the child; Pulse frequency 30 hertz; The stimulation intensity generally starts from 2-3. If the respiratory waveform of the child on the machine is not disturbed, it indicates that the child can tolerate it and the intensity can be appropriately increased. Treatment time: generally starts from 5 minutes, the longest is not more than 20 minutes, the frequency of treatment: 1 time/day in the first week, 2 times/day in the second week.
48374346|NCT04959266|DRUG|Adavosertib|Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
48705713|NCT05969548|DEVICE|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
48374347|NCT04959266|DRUG|Itraconazole|Patients will receive Itraconazole orally once daily for 7 days in arm A.
48374348|NCT04959266|DRUG|Rifampicin|Patients will receive Rifampicin orally once daily for 13 days in arm B.
48705714|NCT05969548|DEVICE|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
48705715|NCT05969548|DEVICE|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
48705716|NCT05969548|DEVICE|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
48705717|NCT05969548|DEVICE|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
48705718|NCT03693963|DEVICE|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
48705719|NCT04942015|DRUG|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
48705720|NCT04942015|DRUG|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
48705721|NCT03030495|DEVICE|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
48374349|NCT04959266|DRUG|Omeprazole|Patients will receive Omeprazole orally once daily for 5 days in arm C.
48374350|NCT04850170|PROCEDURE|manual therapy|"1. release and stretch the muscles and fascia around shoulder girdle、upper arm and forearm;~2. massage the masseter muscle and temporalis muscle;~3. mobilization of the temporomandibular joint, the thoracic and cervical spine, shoulder, and elbow."
48374351|NCT04850170|PROCEDURE|Speech therapy|include the stretching of the neck, facial and oral movement training, and swallowing training
48017218|NCT05328362|BEHAVIORAL|CanCope|Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
48017219|NCT01714700|BEHAVIORAL|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
48374352|NCT02210026|DEVICE|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
48374353|NCT04601389|BIOLOGICAL|"Omalizumab (JSC GENERIUM, the Russian Federation)"|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
48374354|NCT04601389|BIOLOGICAL|Xolair® (Novartis Pharma AG, Switzerland)|150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
48374355|NCT01275118|DEVICE|Tecnis Multifocal IOL|Presbyopia correcting IOL
48017220|NCT01714700|BEHAVIORAL|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
48374356|NCT01275118|DEVICE|crystalens Accommodating IOL|Presbyopia correcting IOL
48017221|NCT06142955|DEVICE|MAGSTIM Rapid2 TMS system|The device will administer TMS pulses in bursts at fixed intervals for a total of 600 pulses over 190 seconds after first assessing the participants motor threshold (MT). During the sham stimulation condition, the TMS coil will be tilted 90° tangential to the scalp during the administration so that the orientation is not biologically active and will not elicit a muscle contraction. This sham condition will look and sound just like real TMS.
48017222|NCT03098446|BEHAVIORAL|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
48017223|NCT03098446|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
48017224|NCT06104605|OTHER|Institutional interventions|Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
48173825|NCT03100955|DRUG|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
48374357|NCT03274791|DIAGNOSTIC_TEST|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
48374358|NCT03274791|DIAGNOSTIC_TEST|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
48705722|NCT03030495|DEVICE|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
48374359|NCT03274791|DIAGNOSTIC_TEST|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
48374360|NCT05361005|DRUG|BDB-001 injection|Intravenous injection
48705723|NCT01758224|OTHER|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
48705724|NCT01758224|OTHER|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
48017225|NCT06104605|OTHER|PCPs interventions|"Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local DCs, information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation."
48017226|NCT06104605|OTHER|Patient interventions|Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
48017227|NCT00793442|DIAGNOSTIC_TEST|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
48017228|NCT00938431|DRUG|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
48017229|NCT05491629|OTHER|type of parallel data in a convergent parallel hash pattern (near time)|"The quantitative part of the study is a descriptive study with the Perceived Perioperative Competence Scale-Revised to determine the perceptions of operating room nurses about their competencies.~It is a case study in order to reveal the opinions of the surgical team members about the competencies of the operating room nurses and the affecting factors through individual in-depth interviews and to better explain the current situation at the qualitative stage, which is carried out simultaneously."
48017230|NCT05437679|OTHER|Blood collection|Peripheral blood will be collected from each subject at a single time point and data will be collected from a review of each subject's medical records.
48017231|NCT03047161|DEVICE|fetal MCG|assess fetal heart rate and rhythm
48017232|NCT00464724|PROCEDURE|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
48017233|NCT00111644|DRUG|Ceftriaxone|1000mg iv daily
48017234|NCT00111644|DRUG|beta-lactam|750mg iv q 23h for 3-14 days
48017235|NCT00111644|DRUG|beta-lactam|1500mg iv q 12h for 3-14 days
48017236|NCT02752048|DRUG|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
48017237|NCT02752048|DRUG|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
48017238|NCT04751916|DIETARY_SUPPLEMENT|Essential Amino Acid Protein Supplement|Proprietary essential amino acid protein supplement
48374361|NCT05361005|DRUG|Placebo|Intravenous injection
48374362|NCT04959682|OTHER|Music Intervention|After rating levels of fatigue and relaxation, the professional health care musicians will play 30 minutes of patient-tailored, pleasant instrumental music with a combination of relaxing (on average 60-80 bpm) and lively, slightly more up-beat tempo to regulate arousal-levels
48017239|NCT04751916|DIETARY_SUPPLEMENT|Beneprotein®|Whey protein supplement
48017240|NCT01845155|BEHAVIORAL|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
48017241|NCT01845155|BEHAVIORAL|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
48017242|NCT01603550|OTHER|Sleep Deprivation|Sleep Deprivation
48017243|NCT01603550|OTHER|Energy Restriction|Energy Restriction
48017244|NCT05479175|DRUG|Ibuprofen|Ibuprofen
48017245|NCT05479175|DEVICE|Diode laser|Diode laser
48017246|NCT05479175|DEVICE|Nonactive Diode laser|Nonactive Diode laser
48374363|NCT02857062|DEVICE|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
48017247|NCT04541446|OTHER|Dynamic Haptic Robotic Trainer (DHRT)|Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.
48017248|NCT04541446|OTHER|Advanced Dynamic Haptic Robotic Trainer (DHRT+)|Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
48017249|NCT01103531|BEHAVIORAL|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
48374364|NCT00253747|DRUG|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
48173826|NCT03100955|DRUG|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
48173827|NCT01036165|DEVICE|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
48173828|NCT03533777|PROCEDURE|Peripheral intravenous catheter placement|The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
48173829|NCT03533777|OTHER|Blood draw|A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
48173830|NCT03533777|DEVICE|Peripheral intravenous catheter|A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
48374365|NCT00253747|DRUG|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
48374366|NCT03572348|PROCEDURE|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
48705725|NCT03005301|DEVICE|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
48017250|NCT01103531|BEHAVIORAL|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
48017251|NCT06526247|BEHAVIORAL|Strength at Home (SAH)|SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.
48017252|NCT06526247|BEHAVIORAL|Treatment as usual for IPV|Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
48017253|NCT06018740|DIETARY_SUPPLEMENT|Daily Balance Gummy|Phenology Daily Balance Gummies 30 ct. Yuzu Tangerine Flavor. Product contains Vitamin D2, Vitamin K2, Vitamin B6, Vitamin B12, Biotin, Genistein, Saffron Extract, Organic Tapioca Syrup, Organic Cane Sugar, Water, Pectin, Citric Acid, Natural Flavors.
48173831|NCT03533777|DRUG|To keep open (TKO) infusion of 0.9% normal saline|After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
48173832|NCT05060835|OTHER|Virtual assistants offering medical recommendations to health care profesionals|the project will interconnect, following a federated approach, large, distributed cancer imaging repositories, currently used for AI tools training and validation, with patient registries and EHRs of cancer-related data and supports exploitation of relevant unstructured data through novel Natural Language Processing (NLP) tools
48173833|NCT05251857|BEHAVIORAL|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|Behavioral: Animation Education Program The investigators will apply Animation Education Program.
48374367|NCT03572348|PROCEDURE|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
48017254|NCT00818441|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
48705726|NCT03005301|DEVICE|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes."
48017255|NCT00818441|DRUG|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
48017256|NCT04762888|PROCEDURE|Computed Tomography|Undergo PET/CT
48705727|NCT00686322|DRUG|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
48017257|NCT04762888|DRUG|Gallium Ga 68 Gozetotide|Given IV
48017258|NCT04762888|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
48017259|NCT04762888|PROCEDURE|Positron Emission Tomography|PET/MRI or PET/CT
48017260|NCT06663098|DRUG|Atezolizumab|1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase
48017261|NCT06663098|DRUG|Carboplatin|AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase
48017262|NCT06663098|DRUG|Etoposide|80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days
48705728|NCT01500603|DEVICE|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
48705729|NCT01500603|DEVICE|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
48173834|NCT04991636|PROCEDURE|Angioscan|"La procédure d'étude prévoit de prendre des images pendant une inspiration profonde ainsi que pendant une expiration profonde. Cette deuxième mesure ne nécessite pas l'administration d'une quantité supplémentaire de produit de contraste. Cependant, le temps d'exposition aux rayonnements ionisants est doublé. L'examen utilise une acquisition hélicoïdale en mode rapide. La durée de l'hélice est de l'ordre de 2 secondes en phase d'inspiration, puis il y a un délai de 5 secondes de machine ( demi-tour ) et à nouveau 2 secondes d'exposition en phase d'expiration, soit 4 secondes d'exposition effective aux rayonnements ionisants, le temps de la prise d'image et 9 secondes le temps total de l'examen. l'image et 9 secondes la durée totale de l'examen."
48705730|NCT05781334|OTHER|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
48705731|NCT06432192|DIAGNOSTIC_TEST|APO-Easy|Testing for the APOE genotype using the APO-Easy Genotyping test
48705732|NCT04037631|DIAGNOSTIC_TEST|Diagnostic device|Diagnostic test
48705733|NCT02280902|BIOLOGICAL|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
48705734|NCT04419740|BEHAVIORAL|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
48705735|NCT02739529|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
48705736|NCT05755256|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
48705737|NCT05755256|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 12 weeks.
48705738|NCT06608641|DRUG|Endoxifen enteric-coated tablet (8 mg)|Patients will continue treatment with their initial randomized medication for 3 weeks
48705739|NCT06608641|DRUG|Placebo Tablets|Patients will be treated with Endoxifen Placebo Tablets for 21 days
48705740|NCT02482194|BIOLOGICAL|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
48705741|NCT05547633|OTHER|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
48705742|NCT04562402|PROCEDURE|Phacoemulsification|cataract surgery via phacoemulsification
48705743|NCT04562402|PROCEDURE|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
48705744|NCT06604533|PROCEDURE|Intervention: MRI-Linac SABR|The treatment planning protocol follows the UK SABR Consortium Guidelines. Patients will be prescribed the maximum isotoxic dose achievable while meeting normal organ tolerances (normal liver, kidney, spinal cord, stomach, duodenum, small and large bowel, heart, lungs, chest wall). The lowest acceptable SABR doses are indicated in the dose range Table within the protocol. The maximum dose/fraction also indicates the maximum the dose can be escalated to for each adaptive session on the MRI-Linac.
48705745|NCT01819129|DRUG|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
48705746|NCT01819129|DRUG|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
48705747|NCT01819129|DRUG|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
48705748|NCT06040918|DRUG|N-803|fixed dose of 1 mg by subcutaneous (SC) injection
48173835|NCT03023202|OTHER|PMMTB (Precision Medicine Molecular Tumor Board)|PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
48516814|NCT04198272|BEHAVIORAL|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. STORIES: The CyberRwanda curriculum empowers youth to learn about family planning and reproductive health and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. LEARN: Q\&As and videos related to family planning and reproductive health. 3. SHOP: Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online. The online health facility finder tool links youth to health facilities for longer-acting methods. All participating pharmacies will be trained to give unbiased, nonjudgmental information and services.
48173836|NCT02210208|DEVICE|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
48173837|NCT02210208|DEVICE|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
48173838|NCT01690923|DEVICE|Nasal mask|Nasal mask (Mirage Activa, Micro, FX)
48017263|NCT02992899|DEVICE|GammaCore/electroCore non-invasive VNS device|Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
48173839|NCT01690923|DEVICE|Pillows mask|Nasal pillows mask (Swift FX)
48374368|NCT04284241|BEHAVIORAL|Parents'Health-Education Handbook|We created a Parents' Health-Education Handbook to teach the newborns' parents to enhance their knowledge of pediatric stone, with a view to changing parents' cognition, attitude and behavior for preventing pediatric stone formation by this cluster randomized control trail.
48516815|NCT01515917|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
48705749|NCT06479265|OTHER|Phyical/Cognitve Exercise|Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
48017264|NCT02992899|DEVICE|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.
48017265|NCT02992899|DRUG|O-15 water|Oxygen-15 labelled water is a radioactive variation of regular water, in which the oxygen atom has been replaced by oxygen-15 (15O), a positron-emitting isotope. 15O-water is used as a radioactive tracer for measuring and quantifying blood flow using positron emission tomography (PET) . H2\[15O\] will be prepared on-site in the Emory PET Center cyclotron. During the hours of the test, an intravenous infusion of normal saline will be started to permit the bolus injection of H2\[15O\]. Subjects will receive a 20 mCi intravenous bolus of H2\[15O\] for each of the 14 scans during exposure to neutral and traumatic scripts.
48017266|NCT02766491|OTHER|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
48017267|NCT02766491|OTHER|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
48017268|NCT02028299|PROCEDURE|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
48017269|NCT00123981|PROCEDURE|Off-Pump Coronary Artery Bypass Grafting|
48173840|NCT01589549|BIOLOGICAL|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
48173841|NCT03516045|DRUG|18F-AlF-NOTA-neurotensin|One injection of the radioligand 18F-AlF-NOTA-neurotensin
48173842|NCT05168137|DRUG|Low-dose colchicine|prescribed colchicine 0.6 mg/day
48173843|NCT05168137|DRUG|Placebo|Placebo of colchicine
48173844|NCT02892201|DRUG|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
48173845|NCT06015906|DEVICE|Plenum® Guide|Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.
48173846|NCT06015906|DEVICE|Plenum® Oss|Plenum® Oss is a synthetic bone graft based on biphasic calcium phosphate, which will be used to fill the tooth extraction sockets.
48173847|NCT06015906|PROCEDURE|Tooth extraction|Tooth extraction and subsequent surgical procedure of guided bone regeneration.
48173848|NCT03389425|BEHAVIORAL|simplified intervention to modify physical activity, lifestyle, and eating behavior|16 week, behavioural weightloss intervention.
48173849|NCT00962806|BEHAVIORAL|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
48173850|NCT00962806|BEHAVIORAL|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
48374369|NCT03306875|BEHAVIORAL|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
48374370|NCT06448611|OTHER|Blood Test|Research and quantification of Circulating Tumor Cells
48374371|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
48374372|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
48374373|NCT01813786|DEVICE|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
48705750|NCT00096148|DRUG|idarubicin|Given IV
48705751|NCT00096148|DRUG|cytarabine|Given IV
48705752|NCT00096148|BIOLOGICAL|bevacizumab|Given IV
48705753|NCT00096148|OTHER|laboratory biomarker analysis|Correlative studies
48374374|NCT04260360|DRUG|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
48705754|NCT06355947|OTHER|Cognitive cycling training|Cycling training conducted with cognitive tasks
48017270|NCT06433414|OTHER|PAUSE App|Participants receiving the intervention will receive access to the PAUSE App, a self-management tool for SDMG intended for patients to use during an acute illness. The app asks users a series of questions regarding signs and symptoms that identify a qualifying sick day illness, and screens for 'red flags' that would require emergency, or HCP or urgent care referral, and help patients identify which of their medications they should temporarily withhold or adjusted, tailored to a patients' current medication list. This aims to provide patients with interactive support for managing medication during a sick day event. As part of the intervention, patients will also receive a SDMG patient handout. The intervention addresses the previously identified challenges described above via an interactive and individualized electronic application designed to facilitate provision of SDMG.
48017271|NCT03251924|DRUG|BMS-986226|specified dose on specified days
48017272|NCT03251924|BIOLOGICAL|Nivolumab|specified dose on specified days
48017273|NCT03251924|BIOLOGICAL|Ipilimumab|specified dose on specified days
48017274|NCT03251924|BIOLOGICAL|Tetanus Vaccine|specified dose on specified days
48017275|NCT04337554|DEVICE|Exoskeleton footwear|Assistive footwear
48173851|NCT05028036|OTHER|Personalized lifestyle treatment program|"The personalized treatment program is based on the participants symptom profile and test results and is designed in collaboration with the participant. The treatment plan that may include several of the following components:~* Dietary changes~* Supplements~* Measures to improve sleep / circadian rhythm~* Stress management~* Physical exercise~The treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. A total of 9 visits to the Nordic Clinic over one year is included in the treatment program."
48173852|NCT01785147|DRUG|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
48173853|NCT01785147|DRUG|Placebo|
48705755|NCT06355947|OTHER|Cognitive treadmill training|Treadmill training conducted with cognitive tasks
48705756|NCT06578416|DIAGNOSTIC_TEST|Standardized assessments of speech and language abilities|Standardized and observational assessment of speech and language abilities
48705757|NCT03564964|DRUG|SUVN-502|Tablet
48374375|NCT04651257|DEVICE|Contrast mammography (CEM)|Contrast mammography in pathological nipple discharge
48374376|NCT03018756|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
48374377|NCT03018756|DRUG|Placebo|0.9% saline solution will be inhaled via nebulizer
48705758|NCT06184464|OTHER|ACETATE LEUPRELINE|USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
48705759|NCT04696367|PROCEDURE|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
48705760|NCT01168791|DRUG|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
48705761|NCT01168791|DRUG|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
48705762|NCT05384418|RADIATION|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
48017276|NCT06573866|BEHAVIORAL|Participatory workplace intervention|The Participatory Workplace Intervention (PWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. Subsequently, the implementation (process) of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.
48173854|NCT05188625|OTHER|Telesupport - Telehealth|Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
48173855|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-LAMax|Interventional device, LAMax left atrial appendage closure system
48374378|NCT00677066|PROCEDURE|Home oxygen therapy|Administer oxygen at home or in hospital
48374379|NCT03313700|PROCEDURE|Robotic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.
48374380|NCT03313700|PROCEDURE|Laparoscopic Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
48374381|NCT04480554|DRUG|Methadone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral methadone syrup (MET), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
48705763|NCT03307161|OTHER|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
48705764|NCT02359357|DRUG|FDL169|
48705765|NCT02359357|DRUG|Placebo|
48017277|NCT02640794|DRUG|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
48017278|NCT02640794|DRUG|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
48017279|NCT06573216|DEVICE|Wrist Ambulatory Blood Pressure Monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
48374382|NCT04480554|DRUG|Buprenorphine/naloxone|Participants will receive a 48-week integrated treatment program for opiate use disorder with daily directly observed oral buprenorphine/naloxone tablets (Suboxone(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
48173856|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-Watchman|Interventional device, Watchman® LAA Closure Device
48173857|NCT00350298|BIOLOGICAL|GS-CDA1/MDX-1388|One Intravenous dose
48374383|NCT04480554|DRUG|XR-Naltrexone|Participants will receive a 48-week integrated treatment program for opiate use disorder with monthly extended-release naltrexone (Vivitrol(R)), structured counseling sessions (BDRC-based) weekly for the first 3 months and monthly thereafter, and antiretroviral therapy.
48374384|NCT06462924|DEVICE|DeepGad|Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
48374385|NCT03353025|PROCEDURE|transsphenoidal surgery treatment|transsphenoidal surgery treatment
48173858|NCT00350298|BIOLOGICAL|normal saline|One Intravenous dose
48374386|NCT03353025|DRUG|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
48374387|NCT03082040|BEHAVIORAL|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
48374388|NCT01314508|DRUG|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
48374389|NCT02311075|BIOLOGICAL|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
48374390|NCT03690102|OTHER|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
48374391|NCT03690102|OTHER|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
48173859|NCT04823364|OTHER|Neurotransmitters evaluation by MRS|Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
48173860|NCT03991988|DRUG|Montelukast|"Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events."
48173861|NCT03991988|DRUG|Placebo oral tablet|Participants in this arm will take a matched placebo pill daily
48516816|NCT01515917|DRUG|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
48516817|NCT01515917|OTHER|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
48017280|NCT00213174|BEHAVIORAL|school playgrounds|
48017281|NCT03812718|DEVICE|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
48017282|NCT03812718|DEVICE|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
48017283|NCT05986929|OTHER|focus group|Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
48017284|NCT05986929|OTHER|electronic survey|An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
48017285|NCT04442737|DRUG|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
48173862|NCT05980819|OTHER|Sustainability lecture and opportunity to create a project|Pure education
48173863|NCT04315116|DRUG|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 \& day10 .
48516818|NCT01515917|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
48173864|NCT04315116|DRUG|Loperamide|Loperamide 4 mg bid from day 7 to day 13
48705766|NCT03738995|BIOLOGICAL|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
48173865|NCT03181919|DRUG|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
48173866|NCT02980705|DRUG|SUNPG1622 I dose|Injection
48516819|NCT06579235|DIAGNOSTIC_TEST|Proteomics|All samples of cases (with LNB) and controls (without LNB) will undergo proteomic analyses.
48705767|NCT00165750|DRUG|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
48705768|NCT06031428|BEHAVIORAL|MANAGe-DM - novel nurse case management|Participants assigned to MANAGe-DM will receive the standard diabetes education mailing in addition to a novel nurse case management intervention. Each month of the study period, the NCM will conduct two phone call intervention sessions with individual participants.
48705769|NCT06031428|BEHAVIORAL|Monthly Educational Mailing|All participants in the study will receive diabetes education mailers. This includes monthly mailings of diabetes education, based off the American Diabetes Association guidelines for Diabetes Education. Topics covered will include diabetes basics, monitoring and medications, healthy eating and exercise, overview of common comorbidities, basics of foot care, and strategies for overcoming common pitfalls.
48017286|NCT04442737|DRUG|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
48705770|NCT02788773|DRUG|Durvalumab|
48173867|NCT02980705|DRUG|Placebo dose|Injection
48173868|NCT02835092|OTHER|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 \& 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
48017287|NCT04442737|DRUG|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
48173869|NCT02835092|OTHER|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 \& 2 \& 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
48173870|NCT02835092|OTHER|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
48516820|NCT01983241|BIOLOGICAL|Alpha-1 MP|
48516821|NCT01983241|OTHER|0.9% Sodium Chloride for Injection, USP|
48516822|NCT01477723|OTHER|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
48516823|NCT01392235|DRUG|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
48516824|NCT00706589|DRUG|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
48705771|NCT02788773|DRUG|Tremelimumab|
48705772|NCT06464900|BEHAVIORAL|Routine Care|Provide patients with regular medication guidance, dietary guidance, exercise guidance and knowledge about diabetes mellitus and hypoglycaemia; test and record blood glucose regularly every day; answer patients' clinical questions and provide psychological support in a timely manner.
48017288|NCT05770544|DRUG|Entrectinib|"Adult and paediatric participants with body surface area (BSA) ≥1.51 m\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).~Paediatric participants with BSA \<1.51 m\^2 will receive entrectinib at a dose of 100 mg (BSA=0.43-0.50 m\^2) or 200 mg (BSA=0.51-0.80m\^2) or 300 mg (BSA=0.81-1.10 m\^2) or 400 mg (BSA=1.11-1.50 m\^2).~Each cycle of treatment will consist of 28 days and participants may continue until disease progression, unacceptable toxicity or withdrawal of consent."
48017289|NCT04452825|BEHAVIORAL|Cancer and Aging: Reflections for Elders (CARE) Intervention|For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
48017290|NCT04452825|BEHAVIORAL|Social Work and Supportive Counseling (SWSC) Intervention|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months). Training case participants will follow a slightly condensed schedule.
48017291|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (immediate group)|Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
48017292|NCT03603886|BEHAVIORAL|Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)|"Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management."
48173871|NCT01743521|DRUG|TPV/PEG-IFN/RBV|"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."
48173872|NCT00661713|BIOLOGICAL|rMenB+OMV NZ|
48173873|NCT00661713|BIOLOGICAL|Placebo|
48173874|NCT04212975|OTHER|joint lavage with dextrose|joint lavage with dextrose
48017293|NCT03011814|BIOLOGICAL|Durvalumab|Given IV
48173875|NCT02828163|OTHER|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
48173876|NCT02828163|DRUG|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
48173877|NCT06488638|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days|commercially available beetroot juice dietary nitrate supplement
48173878|NCT04052035|PROCEDURE|measuring the size of the follicle at time of follicle aspiration|While for an OPU out of the study the follicles are aspirated without measuring their sizes, now the follicles will be measured before they are aspirated. The measurement of the follicles is a non- invasive measurement: as the OPU is always performed under vaginal echo-guidance, the follicles are visible on the screen connected to the vaginal echo probe. By measuring two dimensions of the follicle, an average follicle diameter is registered for that follicle
48173879|NCT02007811|BIOLOGICAL|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
48173880|NCT01138371|PROCEDURE|LDL Apheresis|LDL Apheresis
48173881|NCT02942342|PROCEDURE|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
48173882|NCT03924128|DEVICE|Photobiomodulation|The Photobiomodulation device should cover the entire knee junction, with time of application from 6 to 8 minutes and device turned on.
48173883|NCT02055456|DRUG|Nandrolone Decanoate|
48173884|NCT04417400|BEHAVIORAL|medicines use review|The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
48173885|NCT05982080|DRUG|FP002 Injection|Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
48516825|NCT00706589|DRUG|placebo|Initial dose: 2mg, Maximum dose:20mg
48516826|NCT01028482|DRUG|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
48017294|NCT03011814|OTHER|Laboratory Biomarker Analysis|Correlative studies
48017295|NCT03011814|DRUG|Lenalidomide|Given PO
48017296|NCT01461590|OTHER|Whole blood|30mls/kg transfused over fours hours
48017297|NCT01461590|OTHER|Whole blood|20mls/kg transfused over four hours
48173886|NCT02783053|DRUG|Metformin|Metformin vs no metformin
48173887|NCT01319175|OTHER|Hip flexion strength training|
48173888|NCT00992121|DRUG|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
48173889|NCT00992121|DRUG|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
48516827|NCT01028482|DRUG|placebo|placebo
48516828|NCT01028482|OTHER|psychotherapy|psychotherapy
48516829|NCT03786887|DRUG|Nalbuphine|dosage of nalbuphine
48173890|NCT00992121|DRUG|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
48173891|NCT04666376|OTHER|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
48173892|NCT04708483|DEVICE|Extra DCE-CT scan|DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria.
48173893|NCT03458728|DRUG|Copanlisib (BAY806946)|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
48173894|NCT03559829|DEVICE|RAPAEL Smart Glove|The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
48374392|NCT05780359|DEVICE|Drug eluting stent|Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.
48374393|NCT05780359|DEVICE|drug coating balloon|A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
48516830|NCT00262665|DRUG|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
48516831|NCT00262665|DRUG|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
48705773|NCT06464900|BEHAVIORAL|Based on BCW Theory of Health Education|BCW theory was applied to analyse behaviour and develop interventions in terms of capability, motivation and opportunity. Capability: Intensive daily management of diabetes through intervention functions (education, training, persuasion, modelling) to change attitudes and habits, understand the negative consequences of fear of hypoglycaemia, improve hypoglycaemia awareness and self-regulation skills. Opportunity: Through the intervention function (education, training, realization) to improve the awareness of hypoglycemia awareness, timely detection of hypoglycemia. In the event of a hypoglycaemic event patients know how to deal with it. Motivation: Through intervention functions (environmental reconstruction, realisation) that take full account of external factors and their own opportunities. Glucose management through microsoft platforms, on-site teaching and coaching by specialist nurses to create opportunities for patients who can change excessive/avoidant behaviours.
48705774|NCT01110837|OTHER|Allergen|Allergen nasal challenge
48374394|NCT05932979|DRUG|L-arginine|L-arginine 2-amino-5-guanidino-pentanoic acid is a proteinogenic amino acid that is a natural constituent of the protein diet.
48374395|NCT05932979|OTHER|Placebo|Starch
48374396|NCT03484858|OTHER|High glycaemic index meal and exercise|
48173895|NCT03211728|DRUG|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
48374397|NCT03484858|OTHER|High glycaemic index meal and rest|
48374398|NCT03484858|OTHER|Low glycaemic index meal and exercise|
48173896|NCT03211728|DRUG|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
48173897|NCT00696553|OTHER|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
48173898|NCT00696553|BEHAVIORAL|Nutrition plus Exercise|Nutrition plus Exercise
48173899|NCT05789550|DIAGNOSTIC_TEST|ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY|"1. Full clinical history with detailed history about T2DM (its duration and treatment).~2. Full medical examination, including BMI using the formula: weight (kg)/height (m2).~3. Laboratory investigation, including the following:~   1. Complete blood picture.~  2. Fasting blood sugar (FBS).~  3. Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally).~  4. HbA1c.~  5. Kidney function tests (serum creatinine and blood urea).~  6. Liver function tests (serum albumin, ALT, and AST).~  7. Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool"
48173900|NCT03523325|OTHER|Exercise treatment|Treatment protocol is an exercise program consisting of four different phases (Silbernagel protocol). The progression consists of increasing number of repetitions, resistance, speed and range of motion of the exercises. A pain-monitoring model is used to adjust the exercise loads and progression through the four phases.
48374399|NCT03484858|OTHER|Low glycaemic index meal and rest|
48173901|NCT04038697|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
48374400|NCT06397248|OTHER|No intervention|No intervention
48374401|NCT05607342|DRUG|Osanetant|To evaluate the effect of Osanetant on the testosterone levels.
48374402|NCT02740751|DIETARY_SUPPLEMENT|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
48374403|NCT05696665|OTHER|conventional therapy|Patients will be kept on conventional therapy and no added drugs will be given
48374404|NCT05696665|DRUG|Saffron and Chamomile|Patients will be given saffron and chamomile in capsule formulation twice daily
48374405|NCT05696665|DRUG|Crocin and Apigenin|Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
48374406|NCT01108861|DEVICE|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
48374407|NCT01108861|DEVICE|Plain old balloon angioplasty|Plain old balloon angioplasty
48374408|NCT00066573|DRUG|anastrozole|Given orally
48374409|NCT00066573|DRUG|exemestane|Given orally
48374410|NCT02637518|OTHER|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
48374411|NCT02662140|BEHAVIORAL|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
48374412|NCT04817410|DRUG|Emergency Department Initiated Oral Naltrexone|Emergency Department Initiated Oral Naltrexone
48374413|NCT01149174|DRUG|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
48374414|NCT04822701|DRUG|BI 767551 intravenous|BI 767551 intravenous
48374415|NCT04822701|DRUG|BI 767551 inhaled|BI 767551 inhaled
48705775|NCT01110837|OTHER|Placebo challenge|Placebo nasal challenge
48017298|NCT02496884|DRUG|DS-5565|DS-5565 7.5 mg tablet for oral use
48017299|NCT02496884|DRUG|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
48374416|NCT04822701|DRUG|Placebo intravenous|Placebo intravenous
48374417|NCT04822701|DRUG|Placebo inhaled|Placebo inhaled
48374418|NCT04231903|DEVICE|Aortic clamp|In the firs group an endo-aortic clamp is used and in the second group an external clamp is used.
48374419|NCT03228615|OTHER|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
48374420|NCT02144142|BIOLOGICAL|Moisturizer with each subject's own antimicrobial bacteria|
48374421|NCT05671731|DIETARY_SUPPLEMENT|Beneo Synergy 1|
48374422|NCT05671731|BEHAVIORAL|Project FUN|Project FUN, a culturally tailored online nutrition and physical activity program is based on the Health Promotion/ Transtheoretical Model. It includes 8 modules offered in a password-protected learning management system along with a workbook also used to assure intervention completion.
48374423|NCT02937727|DEVICE|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
48705776|NCT02649374|BEHAVIORAL|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
48705777|NCT02053207|BEHAVIORAL|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
48705778|NCT01894880|PROCEDURE|early SSC|bonding straight after birth
48173902|NCT04038697|PROCEDURE|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
48374424|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
48374425|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
48705779|NCT01894880|PROCEDURE|late SSC|bonding after termination of operation
48705780|NCT00362583|DRUG|Fentanyl|
48374426|NCT01001195|DRUG|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
48374427|NCT01001195|DRUG|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
48374428|NCT04309149|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period (21 days taking the new products with 2 days between each new product trialled).
48705781|NCT02502669|DRUG|Finasteride 23.5 mg tablets|
48705782|NCT02502669|DRUG|Finasteride 33.5 mg tablets|
48705783|NCT02502669|DRUG|Placebo tablets|
48705784|NCT01452230|BEHAVIORAL|Supervised physical activity|Supervised physical activity
48705785|NCT01799239|DEVICE|Test product|The test product consists of an adhesive with a new top film
48374429|NCT02709980|BEHAVIORAL|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
48705786|NCT01799239|DEVICE|SenSura|SenSura is the CE-marked and commercially available comparator product
48705787|NCT04801368|DRUG|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
48705788|NCT00849615|DRUG|Docetaxel|50mg/m2 qd15
48705789|NCT00849615|DRUG|5-Fluorouracil|2600mg/m2 qd15
48173903|NCT04038697|PROCEDURE|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
48705790|NCT00849615|DRUG|Oxaliplatin|85mg/m2 qd15
48705791|NCT00849615|DRUG|folinic acid|200mg/m2 qd15
48705792|NCT02230761|DRUG|XOPH5 Ointment|
48173904|NCT00022815|DEVICE|Tissue ultrafiltration|
48705793|NCT02230761|DRUG|Placebo|
48705794|NCT02370004|PROCEDURE|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
48705795|NCT04123912|BEHAVIORAL|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
48705796|NCT04123912|BEHAVIORAL|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
48705797|NCT01466660|DRUG|Afatinib|afatinib once daily
48705798|NCT01466660|DRUG|gefitinib|Gefitinib once daily
48705799|NCT04885322|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
48705800|NCT04749758|BIOLOGICAL|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
48705801|NCT05343130|DEVICE|Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation activated by the brain-computer interface based on hand movement intention.
48705802|NCT05343130|DEVICE|Sham Brain-Computer Interface|Hand movement will be elicited using functional electrical stimulation which activation will be independent of the brain-computer interface based on hand movement intention.
48705803|NCT06604936|OTHER|Fibromyalgia group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
48516832|NCT04728009|DIETARY_SUPPLEMENT|Longan and lingzhi mushroom syrup|Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
48017300|NCT06531603|DRUG|bupivacaine wound infilteration|drug was given at the end of surgery
48017301|NCT06531603|DRUG|Bupivacaine plus dexmedetomidine wound infilteration|drug was given at the end of surgery
48017302|NCT02473445|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
48173905|NCT02543788|PROCEDURE|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
48173906|NCT06151847|PROCEDURE|Biospecimen Collection|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2
48173907|NCT06151847|DRUG|Cyclophosphamide|Given IV
48173908|NCT06151847|PROCEDURE|Echocardiography|Undergo echocardiography
48173909|NCT06151847|DRUG|Fludarabine|Given IV
48173910|NCT06151847|BIOLOGICAL|Interleukin-2|Given IV
48173911|NCT06151847|BIOLOGICAL|Lifileucel|Given IV
48173912|NCT06151847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48017303|NCT04796610|BEHAVIORAL|Mopati|The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
48173913|NCT06151847|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48173914|NCT06151847|PROCEDURE|Tumor Resection|Undergo tumor resection
48173915|NCT05146206|OTHER|Observational|In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
48173916|NCT02960945|DRUG|CTP-543, 16 mg (2 x 8 mg tablet)|
48173917|NCT02960945|DRUG|Jakafi 15Mg Tablet|
48173918|NCT04060732|DEVICE|Flash Glucose Monitoring-FGM|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months."
48173919|NCT02275013|DRUG|Levosimendan|
48173920|NCT04455685|OTHER|anonymised data collection|The population of the present study corresponds to a sample of previous market research. Data from participants from the five main regions of Brazil (North, Northeast, Midwest, South, Southeast) will be selected at random and according to the sample size calculation.
48173921|NCT02584881|OTHER|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
48173922|NCT05238155|DRUG|antimetabolite|When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
48173923|NCT00345800|DRUG|Sodium Oxybate (Xyrem)|"* Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral"
48173924|NCT00237211|DRUG|Letrozole|
48173925|NCT04502290|DEVICE|Combined Non-invasive brain stimulation and functional electrical hand stimulation|Participants will receive synchronously combined non-invasive brain stimulation (delivered via electrical/magnetic stimulation) with functional electrical stimulation (delivered via DS7A or Neuromove) of the weak hand
48173926|NCT00066378|DRUG|anastrozole|
48173927|NCT00066378|DRUG|gefitinib|
48173928|NCT04657601|DEVICE|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
48173929|NCT00345709|BEHAVIORAL|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
48173930|NCT00951171|PROCEDURE|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
48173931|NCT00951171|PROCEDURE|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
48017304|NCT04892901|PROCEDURE|c-ESPB|In the c-ESPB group an ultrasound-guided ESPB will be performed by the attending anaesthesiologist at the end of surgery, immediately after the last surgical stitch and before extubation. After an initial bolus of 20 ml 0,2% ropivacaine, a catheter will be left in place into the fascial plane deep to the erector spinae muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
48017305|NCT04892901|PROCEDURE|c-SAPB|In the c-SAPB group SAPB will be performed by surgeons intraoperatively, immediately before the closure of chest wall muscle planes, by injection of 20 ml 0,2% ropivacaine into the fascial plane above the Serratus Anterior muscle. After the initial bolus, a catheter will be left in place into the superficial fascial plane of the Serratus Anterior muscle to ensure continuous infusion (5ml/h for 48 hours) of the local anesthetic.
48173932|NCT00511771|DRUG|Tegaserod|Tegaserod maleate
48173933|NCT02066610|OTHER|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
48173934|NCT02066610|OTHER|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
48173935|NCT02066610|OTHER|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
48173936|NCT02066610|OTHER|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
48173937|NCT05482490|PROCEDURE|Maintenance protocol for the hygiene of implant supported prosthesis|Sequence of phases that include the hygiene and cleaning of the prosthesis and the implants, the motivation of the patients and reinforcement of oral hygiene.
48173938|NCT01127321|OTHER|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
48173939|NCT01127321|BIOLOGICAL|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
48173940|NCT01127321|BIOLOGICAL|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
48173941|NCT01127321|BIOLOGICAL|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
48173942|NCT01127321|BIOLOGICAL|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
48173943|NCT02429986|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
48173944|NCT02902653|DRUG|Oral misoprostol|hourly titrated misoprostol
48173945|NCT02902653|DRUG|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
48173946|NCT02902653|DRUG|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
48173947|NCT05792761|DRUG|Peginterferon alfa-2b combined and ETV|"Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks."
48173948|NCT00607178|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
48173949|NCT00607178|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
48374430|NCT02709980|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
48374431|NCT02689713|DRUG|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
48374432|NCT02689713|DRUG|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
48374433|NCT02665858|OTHER|OCT Imaging|
48705804|NCT06604936|OTHER|Healthy group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
48705805|NCT04913987|DEVICE|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
48374434|NCT03194724|OTHER|Vitamin A supplementation|Bi annual vitamin A supplementation programme
48374435|NCT02088359|OTHER|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
48374436|NCT02088359|OTHER|Continue near darkness|We covered the incubator with blanket all days.
48374437|NCT00117975|BIOLOGICAL|galiximab|given IV
48705806|NCT04913987|DEVICE|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
48173950|NCT00514475|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
48173951|NCT00237354|DRUG|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
48173952|NCT04757714|PROCEDURE|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
48173953|NCT04757714|PROCEDURE|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
48173954|NCT04757714|OTHER|Questionnaires|"* a physical activity questionnaire (PHAS instrument)~* a COPD quality of life questionnaire (St George Hospital)"
48374438|NCT00117975|BIOLOGICAL|rituximab|Given IV
48705807|NCT02264665|DRUG|sunitinib|sunitinib 37.5mg/d orally
48705808|NCT02264665|DRUG|everolimus|everolimus 10mg/d orally
48705809|NCT02264665|DRUG|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
48705810|NCT02921555|DRUG|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
48173955|NCT04757714|OTHER|A search for sarcopenia by studying the strength of the grip (dynamometer)|A search for sarcopenia by studying the strength of the grip (dynamometer)
48173956|NCT01792843|BEHAVIORAL|data|"* comparisons of clinical characteristics~* comparisons of cognitive profiles~* comparisons of grey matter density patterns~* comparisons of EEG rhythms features"
48374439|NCT02777866|DRUG|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
48705811|NCT02921555|DRUG|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
48173957|NCT00841230|DRUG|Deanxit|Deanxit 1x/day
48705812|NCT02172495|DRUG|Tiotropium bromide|Tiotropium bromide 18 micrograms
48705813|NCT06605404|DIAGNOSTIC_TEST|blood and tissue samples|routine standard of care
48173958|NCT00841230|DRUG|Lactose placebo|Lactose used as placebo
48705814|NCT06605404|OTHER|blood and tissue samples|Routine standard of care
48705815|NCT00391469|OTHER|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
48705816|NCT00391469|DRUG|Rapid infusion of cold normal saline|
48705817|NCT01771848|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
48705818|NCT03224507|DRUG|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
48705819|NCT03224507|DRUG|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
48705820|NCT04401618|OTHER|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
48705821|NCT00521599|DRUG|Mometasone furoate dry powder inhaler|
48705822|NCT00521599|DRUG|Placebo|
48705823|NCT05797532|OTHER|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
48705824|NCT05797532|OTHER|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
48705825|NCT05797532|OTHER|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
48173959|NCT06402214|OTHER|Lombard test|In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.
48705826|NCT05627531|BEHAVIORAL|Narrative Medicine|Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
48705827|NCT03473106|DEVICE|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
48173960|NCT05913869|BEHAVIORAL|Online Mindfulness Based Stress Reduction|Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
48705828|NCT00728247|PROCEDURE|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
48705829|NCT06606626|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
48705830|NCT06606626|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
48705831|NCT01313845|DRUG|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
48705832|NCT01313845|DRUG|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
48705833|NCT05818956|DRUG|TAK-227|TAK-227 capsules.
48017306|NCT04892901|PROCEDURE|ICNB|"In the ICNB-group ICNB will be performed by surgeons intraoperatively, immediately before chest drain placement, by injection of 20 ml of 0,2% ropivacaine into the intercostal spaces (III-VII), below the parietal pleura, under direct visualization of the neurovascular bundle. The one-shot ICNB will be associated in this group with intravenous administration of tramadol (300 mg/48 h) by elastomeric pump."
48017307|NCT05999409|OTHER|practice on birth simulator|making attempts at labor
48017308|NCT06497556|DRUG|Divarasib|Divarasib will be administered orally QD
48017309|NCT06497556|DRUG|Sotorasib|Sotorasib will be administered orally QD
48017310|NCT06497556|DRUG|Adagrasib|Adagrasib will be administred orally BID
48173961|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
48705834|NCT03464357|RADIATION|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
48705835|NCT01338350|DRUG|AZD5423|Inhalation, suspension
48705836|NCT01338350|DRUG|Placebo|Inhalation, solution
48017311|NCT01181895|DRUG|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
48017312|NCT01181895|DRUG|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
48017313|NCT01181895|DRUG|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
48017314|NCT01181895|DRUG|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
48017315|NCT03959501|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
48017316|NCT03959501|DRUG|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
48017317|NCT05403047|DRUG|Fumarate, Tenofovir Disoproxil|all participants receive the intervention
48017318|NCT06513819|BEHAVIORAL|Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique|Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
48017319|NCT00847574|BEHAVIORAL|Moderate-fat|35% of calories from fat
48017320|NCT00847574|BEHAVIORAL|Lower-fat|20% of calories from fat
48017321|NCT06419582|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 21 days
48017322|NCT06419582|DRUG|Placebo|Matching placebo taken once daily for 21 days
48017323|NCT00132769|DRUG|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
48017324|NCT00132769|DRUG|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
48017325|NCT04181034|BEHAVIORAL|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
48017326|NCT04181034|BEHAVIORAL|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
48705837|NCT01388439|DRUG|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants \> 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants \> 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants \> 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
48705838|NCT00222430|PROCEDURE|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
48705839|NCT00222430|PROCEDURE|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
48705840|NCT06264219|BIOLOGICAL|Microbiome restoration - FMT|Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.
48017327|NCT01709318|DRUG|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
48017328|NCT01709318|DRUG|Etonogestrel (ENG)|Daily release of 75, 100, 120 or 125 μg
48017329|NCT01709318|DRUG|Ethinyl estradiol (EE)|Daily release of 15 μg
48017330|NCT01709318|DRUG|Estradiol (E2)|Daily release of 300 μg
48017331|NCT05343611|BEHAVIORAL|Combination of High Protein Diet and Physical Exercise protocol|"A high Protein Diet (HPro) will be provided to maintain individual caloric endpoint and to adjust protein intake to 0.9-1.0 g/Kg ideal body weight. Each participant will receive a tailored diet (taking into account personal preference) which will follow common general guidelines. Servings of food high in polyphenols will be limited to one per day.~Physical exercise will be undertaken three times each week for about 50 minutes per session. The intervention will consist of both aerobic and strength training exercises. Aerobic exercise will consist of walking on a treadmill with 4 x 4 minutes at (85-95% of HRmax), interrupted by 3-minute active recovery periods (60-70% of HRmax). Strength exercise consists of maximal strength training, using a seated leg press with 4 sets of 4 repetitions at \~90% of maximal strength (1RM). Rest periods between the sets will be 3-4 min."
48173962|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
48173963|NCT03886597|OTHER|Table Olives|All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
48173964|NCT03558282|OTHER|Recession Observation|Soft tissue measurements
48173965|NCT03558282|DIAGNOSTIC_TEST|Crown Contour Observation|Ultrasound measures of implant crown contour.
48017332|NCT05343611|DIETARY_SUPPLEMENT|HPP Choko|Participants add to their diet with 30 g/day of 85% dark chocolate high in polyphenols
48017333|NCT05343611|DIETARY_SUPPLEMENT|HPP/VE Choko|Participants add to their diet 30 grams of 85% dark chocolate high in polyphenols, functionalized with 100 mg of Vitamin E per day.
48017334|NCT01229436|DRUG|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
48173966|NCT02813083|OTHER|No intervention (observational)|No intervention (observational)
48173967|NCT00482898|DRUG|MK0359|
48173968|NCT02196077|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
48017335|NCT06531460|DIETARY_SUPPLEMENT|Fish oil enteral supplementation|Omega-3 (4.2 g), administered through an enteral feeding tube, three days before surgery
48017336|NCT06531460|DIETARY_SUPPLEMENT|Fish oil oral supplementation|Omega-3 (4.2 g), orally administered enriched nutritional formula, drinking at home three days before surgery
48017337|NCT06531460|DIETARY_SUPPLEMENT|Enteral nutrition without fish oil|Enteral formula without omega-3 administered through an enteral feeding tube, three days before surgery
48017338|NCT06531460|DIETARY_SUPPLEMENT|Oral nutritional supplement without fish oil|Oral nutritional supplement without omega-3 orally administered, drinking at home three days before surgery
48017339|NCT04163549|BEHAVIORAL|Safe at Home|Discussion-based intervention
48516833|NCT05806892|OTHER|Thera Pearl|"You can apply Thera°Pearl warm breast therapy before breastfeeding or during milking. You should do this application 4 times a day, in the morning, at noon, in the evening and at night before going to bed. Each application should be done on both breasts and should last at least 20 minutes.~Thera°Pearl Warm Breast Therapy has been developed to open milk ducts and accelerate milk flow.~Thermogel packs for Thera°Pearl hot therapy can be heated inside the fabric covers in the microwave for a maximum of 15 seconds or in hot water by removing the fabric covers. Packages that have been removed from the cover should be kept in boiling water for 1-2 minutes and then applied by putting them into the sheath."
48705841|NCT06264219|BIOLOGICAL|Microbiome restoration - FVT|Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.
48017340|NCT03158558|BEHAVIORAL|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson \& Fredman, 2012)
48017341|NCT06210789|PROCEDURE|Surgical excision|Periodontal plastic reconstruction of the subsequent soft tissue dehiscence after the surgical excision of the localized gingival enlargement
48017342|NCT01625052|DEVICE|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
48017343|NCT01018264|DRUG|solifenacin succinate (VESIcare)|up to 10mg every day orally
48017344|NCT01018264|DRUG|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
48017345|NCT03576001|DRUG|Testosterone Undecanoate|administered through injections by study staff
48017346|NCT03576001|BEHAVIORAL|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
48017347|NCT02283216|DEVICE|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
48173969|NCT02196077|DRUG|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
48173970|NCT02196077|DRUG|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
48173971|NCT02196077|DRUG|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
48705842|NCT06264219|BIOLOGICAL|Placebo|Inactive solution buffer
48705843|NCT06264219|OTHER|Vaginal birth, untreated control|No intervention. This group is for secondary outcomes comparisons.
48017348|NCT02283216|DEVICE|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
48017349|NCT02283216|DEVICE|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
48173972|NCT02196077|DRUG|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
48705844|NCT04752566|BIOLOGICAL|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
48705845|NCT04752566|DRUG|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
48705846|NCT04257175|BIOLOGICAL|CAR-T CD19|The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).
48705847|NCT05266872|OTHER|Observational study with sample and data collection|Observational study with sample and data collection
48705848|NCT05106712|DRUG|Vitamin D3|4000IU per day for around 12 weeks.
48705849|NCT05106712|DRUG|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
48705850|NCT05106712|DRUG|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
48017350|NCT02683759|DIETARY_SUPPLEMENT|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
48705851|NCT05106712|OTHER|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
48705852|NCT03029195|DEVICE|Nasoalveolar molding therapy|Presurgical infant orthopedics
48705853|NCT05316233|DEVICE|VOLITE XC|Intradermal Injection
48017351|NCT02683759|DRUG|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
48017352|NCT01537341|BEHAVIORAL|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
48017353|NCT01537341|BEHAVIORAL|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
48017354|NCT05435599|DIAGNOSTIC_TEST|Serum regucalcin level|During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
48374440|NCT02777866|DRUG|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
48374441|NCT03871231|DEVICE|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
48374442|NCT01934777|DRUG|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
48374443|NCT01934777|DRUG|placebo pearls|placebo
48374444|NCT04318626|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
48374445|NCT04318626|DRUG|THK5351|F-18 THK5351 PET Imaging
48374446|NCT04899531|OTHER|Longitudinal observation|No specific intervention, longitudinal (pre-post measurements) only
48374447|NCT04245982|PROCEDURE|Gingival biopsy|Two gingival biopsies from each participant were collected.
48374448|NCT02161809|BEHAVIORAL|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
48374449|NCT03320980|PROCEDURE|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
48374450|NCT03320980|PROCEDURE|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
48374451|NCT06079606|OTHER|Antibiotic treatment|Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
48374452|NCT00443573|DRUG|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
48374453|NCT05059561|RADIATION|X-ray radiograghy|Cobb angles of the patient and control groups were determined by using X-Ray radiography used in the radiological examination routinely applied to the individuals who applied for the health board examination.
48374454|NCT03957291|DRUG|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
48374455|NCT03957291|DRUG|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
48374456|NCT00684658|BEHAVIORAL|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
48374457|NCT00684658|BEHAVIORAL|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
48374458|NCT03260621|DIAGNOSTIC_TEST|stress CMR|additional stress CMR to the established clinical diagnostics
48374459|NCT00594334|DRUG|Risedronate|Weekly Risedronate
48017355|NCT04879303|BEHAVIORAL|Robot-assisted social skill intervention|Social robotics will be used by the instructor to teach social skills to the children with ASD for 12 weekly sessions.
48017356|NCT04879303|BEHAVIORAL|Human-only instruction programme on social skill training|The children will receive only the human-delivered training throughout the 12 sessions, with the content and sequence of activities the same as the robotic intervention group.
48173973|NCT01628406|PROCEDURE|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
48017357|NCT01451294|DRUG|Administration of phenylephrine|Phenylephrine: 50-100µg
48173974|NCT03046368|BEHAVIORAL|Targeted cover letter|The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
48173975|NCT05432505|OTHER|ligamentum teres tenodesis|Identification of ligamentum teres ligamentum teres tenodesis
48173976|NCT05672771|BEHAVIORAL|Different Mixed Condition (DM)|Participants engage in home-based training on two working memory tasks, both different from those in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
48374460|NCT03005717|DRUG|LIPO-202|
48374461|NCT03005717|DRUG|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
48374462|NCT01343329|DRUG|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
48374463|NCT01343329|DRUG|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
48374464|NCT00497822|PROCEDURE|Aerobic exercise training|
48705854|NCT05316233|DEVICE|VOLITE XC|Subdermal Injection
48374465|NCT03479957|BEHAVIORAL|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
48017358|NCT01451294|DRUG|Administration of ephedrine|Ephedrine: 5- 10 mg
48017359|NCT04097379|DRUG|LRX712|LRX712 intra-articular injections
48017360|NCT04097379|DRUG|Placebo|Placebo intra-articular injections
48017361|NCT03362840|BEHAVIORAL|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
48017362|NCT03362840|BEHAVIORAL|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
48017363|NCT02205892|DRUG|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
48173977|NCT05672771|BEHAVIORAL|Different Single Condition (DS)|Participants engage in home-based training on a working memory task that is different from that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
48173978|NCT05672771|BEHAVIORAL|Same Task (ST) Practice Control|Participants engage in home-based training on the exact same working memory tasks as that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
48173979|NCT05672771|BEHAVIORAL|Non-WM Placebo Control (PC)|Participants engage in home-based training on speeded verbal decision, which unlike the target task training, has no memory component. Goal is 10 days of training, with 4 8-min blocks of training each day.
48173980|NCT00469859|DRUG|cytarabine|given IV
48173981|NCT00469859|DRUG|idarubicin|Given IV
48374466|NCT03479957|OTHER|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
48374467|NCT00053911|DRUG|anastrozole|
48374468|NCT00053911|DRUG|cyclophosphamide|
48017364|NCT02205892|DRUG|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
48017365|NCT03966404|DIAGNOSTIC_TEST|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
48017366|NCT01235455|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
48017367|NCT05866003|DEVICE|Active conventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, an electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
48173982|NCT00469859|DRUG|lestaurtinib|Given orally
48173983|NCT05542121|DEVICE|Robot-Assisted Therapy with Rehab CARES system|60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
48173984|NCT05542121|OTHER|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
48173985|NCT00134147|DRUG|Inhaled Insulin|
48173986|NCT04383145|DEVICE|endovascular repair|Endovascular repair of thoracoabdominal aneurysm using stent grafts.
48173987|NCT00099203|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
48173988|NCT00099203|DRUG|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
48173989|NCT00136110|DRUG|Sodium Valproate|
48374469|NCT00053911|DRUG|docetaxel|
48374470|NCT00053911|DRUG|epirubicin hydrochloride|
48374471|NCT00053911|DRUG|fluorouracil|
48374472|NCT00053911|DRUG|goserelin acetate|
48374473|NCT00053911|DRUG|tamoxifen citrate|
48374474|NCT00053911|PROCEDURE|adjuvant therapy|
48173990|NCT02100683|DEVICE|PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
48374475|NCT02977741|DRUG|Olanzapine|
48374476|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
48173991|NCT00639977|OTHER|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
48173992|NCT00639977|OTHER|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
48705855|NCT04269577|BEHAVIORAL|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
48173993|NCT00585975|DRUG|bromfenac ophthalmic solution|sterile opthalmic solution
48173994|NCT01940783|RADIATION|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
48173995|NCT01940783|DEVICE|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
48173996|NCT04032912|DIAGNOSTIC_TEST|iScan|this instrument provides extra confidence for in vivo diagnosis through improved vessel and mucosal pattern characterization.
48374477|NCT02334046|DRUG|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
48705856|NCT03112525|DIAGNOSTIC_TEST|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
48705857|NCT03112525|GENETIC|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
48017368|NCT05866003|DEVICE|Active unconventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
48173997|NCT02992444|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
48173998|NCT02992444|OTHER|Experimental adhesive strip|This is a strip of a newly developed adhesive.
48173999|NCT03619798|DEVICE|HemoTypeSC|Point-of-Care Rapid Test for Detection of Sickle Cell Disease-Relevant Hemoglobin Phenotypes in Whole Blood
48174000|NCT00314418|PROCEDURE|Colonoscopy in the prone position|
48174001|NCT00604188|DRUG|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
48174002|NCT00604188|DRUG|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
48174003|NCT01584011|OTHER|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
48174004|NCT01584011|OTHER|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
48174005|NCT01584011|BEHAVIORAL|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
48374478|NCT02334046|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
48174006|NCT01584011|OTHER|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
48174007|NCT01287845|DRUG|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
48174008|NCT01287845|DRUG|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
48174009|NCT06418399|OTHER|cancer patients|Patients aged between 18 and 80 years with cancer-related pain lasting for more than 3 months will be included.
48374479|NCT04828980|DEVICE|Oculus Quest: TRIPP|This is a VR experience that focuses on meditation and mindfulness
48374480|NCT04828980|DEVICE|Oculus Quest: Angry Birds|This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
48374481|NCT04599543|DRUG|IL3 CAR T-cells|Each subject receive IL3 CAR T-cells by intravenous infusion
48374482|NCT03195270|DRUG|[18F]FDG|10 mCi of \[18F\]FDG via the antecubital vein in a bolus injection
48374483|NCT03195270|DEVICE|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
48017369|NCT05866003|DEVICE|Sham tDCS plus CCFES|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator.
48017370|NCT05866003|BEHAVIORAL|CCFES with Occupational Therapy|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator. During the lab visits, all participants will use CCFES to assist hand opening during occupational therapy task practice.
48374484|NCT05356260|DEVICE|URincontrol4men|The intervention is built as an app
48017371|NCT03581136|DEVICE|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
48017372|NCT03698682|DRUG|Levofloxacin 500mg|One tablet per day for 7 days.
48017373|NCT06663332|DRUG|Guselkumab|Guselkumab will be administered as subcutaneous injection.
48017374|NCT02563340|OTHER|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
48017375|NCT02563340|OTHER|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
48017376|NCT04682600|DEVICE|Liver Incytes System|The Liver Incytes System uses the Shear Wave Absolute Vibro-Elastrography (S-WAVE) method. The imaging procedure of the Liver Incytes system is similar to a traditional ultrasound scanning procedure or FibroScan, in which the patient is asked to lie supine on an examination bed, with the operator seated next to them. A vibration source is placed under the patient, between the patient and the bed to induce shear waves in the liver. Ultrasound imaging through the patient ribs is used to track the displacements of these waves. Through tracking of the displacements, the shear wave velocity and tissue stiffness can be calculated. The use of volumetric multi-frequency imaging increases the amount of liver scanned
48017377|NCT03395795|DEVICE|NAVA|"The study has 3 phases:~1. Phase 1:~   The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~2. Phase 2:~   Switch to NAVA mode (1h).~  * Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~  * NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~3. Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
48017378|NCT06073327|DIETARY_SUPPLEMENT|dark chocolate|30g of dark or white chocolate was provided by the nutritionist for 30 days
48174010|NCT05316909|OTHER|Breastfeeding Simulation|In Period 1, one group will begin a simulated session with the NORALSim and the second group will begin with either the Mother's Own Milk Lactessa or Laerdal NeoNatalie, depending on the study date. Baseline level of breastfeeding experience and clinical lactation skills self-efficacy will be collected. Nursing students will teach a mock patient wearing the LSM and holding a newborn simulator how to position and attach the newborn at the breast and identify effective breastfeeding by differentiating between suckling patterns. In Period 2, each group will crossover to complete the same session with a different newborn simulator. After Period 1, each group will debrief to discuss their performance and engagement and use a Qualtrics survey (6-point Likert scale) to rate satisfaction, engagement, simulator fidelity, and self-efficacy. The same quantitative and qualitative data collection protocol will follow Period 2.
48174011|NCT05086419|OTHER|Sub-symptom threshold aerobic exercise|For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
48374485|NCT05356260|OTHER|Care as usual|CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
48374486|NCT02570945|PROCEDURE|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
48374487|NCT02316574|BEHAVIORAL|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
48705858|NCT01175434|OTHER|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
48374488|NCT00830726|DRUG|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
48705859|NCT04051710|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
48705860|NCT04051710|DRUG|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
48705861|NCT04051710|DRUG|Placebo|Placebo Product
48017379|NCT06073327|DIETARY_SUPPLEMENT|White chocolate|30g of white chocolate was provided by the nutritionist for 30 days
48017380|NCT01903694|DRUG|Sorafenib + Pravastatin|
48017381|NCT01903694|DRUG|Sorafenib|
48017382|NCT04725175|DRUG|PIPE-307|Single and multiple ascending oral doses of PIPE-307 tablets
48017383|NCT04725175|DRUG|Placebo oral tablet|Single and multiple ascending oral doses of matching Placebo tablets
48017384|NCT01152723|DRUG|Nicotine|2 mg, Single Dose
48017385|NCT00141960|DRUG|Famotidine|
48705862|NCT03533439|DIAGNOSTIC_TEST|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
48017386|NCT06314698|DRUG|Narlumosbart|Administered by subcutaneous injection once every 4 weeks.
48017387|NCT06314698|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks.
48017388|NCT05446311|DRUG|Dinalbuphine sebacate|After giving the birth, subjects are intramuscularly injected with a single dose of 150 mg of dinalbuphine sebacate (DS). DS is a prodrug of nalbuphine. After injeciton, DS are released to blood stream and hydrolyzed immediately. The onset of action is 12 to 24 hours and the analgesic effect can last about 5 to 7 days.
48017389|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
48017390|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
48017391|NCT03160703|OTHER|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
48174012|NCT02492698|DIETARY_SUPPLEMENT|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
48174013|NCT02492698|DIETARY_SUPPLEMENT|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
48174014|NCT03705364|OTHER|Fall Management program|Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
48174015|NCT01231464|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
48174016|NCT01231464|DRUG|placebo|placebo
48174017|NCT05604508|OTHER|Many posters with prices|No poster number or price restrictions
48174018|NCT05604508|OTHER|Many posters, no prices|No poster number restrictions, but price restrictions
48705863|NCT02152059|DRUG|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
48174019|NCT05604508|OTHER|Fewer posters, no price restrictions|Poster number restrictions, but no price restrictions
48174020|NCT02561078|DRUG|Human regular U-500 insulin (CSII)|Administered SC
48174021|NCT02561078|DRUG|Human regular U-500 insulin (MDI)|Administered SC
48705864|NCT06446752|BIOLOGICAL|Bexsero|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
48705865|NCT06446752|BIOLOGICAL|Placebo|Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).
48017392|NCT03160703|OTHER|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
48017393|NCT02549144|DIETARY_SUPPLEMENT|Low fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
48017394|NCT02549144|DIETARY_SUPPLEMENT|High fat/cholesterol diet|The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
48017395|NCT04846140|DEVICE|transcranial electrical stimulation (tES)|Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
48174022|NCT03884062|DRUG|DAAs|lab, U/S, Fibroscan \& CT if needed
48174023|NCT00781417|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
48174024|NCT00781417|OTHER|Placebo|Matching Placebo
48174025|NCT01799109|DRUG|Magnesium Sulfate & albuterol|
48174026|NCT01799109|DRUG|albuterol|
48017396|NCT02320019|DRUG|Placebo|Placebo matching YH14618
48017397|NCT02320019|DRUG|YH14618|
48174027|NCT01799109|DRUG|magnesium|
48174028|NCT04843384|OTHER|Reiki|Reiki was performed according to the need of each patient and lasted an average of 20-25 minutes. After the procedure, the patients were left to rest for ten minutes. The researcher was focused in a neutral way on the sessions without the intention of healing. After the session, the patients were allowed to rest for ten minutes.
48174029|NCT04843384|OTHER|Sham reiki|With the Sham Reiki patients, a nurse without reiki training performed Sham Reiki randomly for approximately 20-25 minutes, following a protocol which did not include the body's energy centers or chakras.
48174030|NCT01944449|DIETARY_SUPPLEMENT|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
48174031|NCT01944449|DIETARY_SUPPLEMENT|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
48174032|NCT01944449|DIETARY_SUPPLEMENT|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
48174033|NCT06325345|BEHAVIORAL|Gut-directed hypnotherapy|Eight session gut-directed hypnotherapy for IBS symptoms adapted from the evidence-based Manchester protocol for treatment of IBS.
48705866|NCT02831738|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose 12 g
48705867|NCT02831738|DIETARY_SUPPLEMENT|Control Treatment|no polydextrose
48374489|NCT00830726|PROCEDURE|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
48374490|NCT00830726|PROCEDURE|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
48374491|NCT00830726|PROCEDURE|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
48374492|NCT00742404|DRUG|bortezomib|
48374493|NCT00742404|DRUG|dexamethasone|
48374494|NCT00742404|DRUG|pegylated liposomal doxorubicin hydrochloride|
48374495|NCT00742404|GENETIC|protein analysis|
48374496|NCT00742404|OTHER|immunologic technique|
48174034|NCT06325345|OTHER|Standard Medical Therapy|Standard medical treatment will be administered by board certified gastroenterologists
48174035|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets bonded using smile arc protection bonding strategy|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
48374497|NCT03907059|DIETARY_SUPPLEMENT|whey protein|supplementation individually adjusted to 1.6g/kg/day
48374498|NCT03907059|DIETARY_SUPPLEMENT|soy protein|supplementation individually adjusted to 1.6g/kg/day
48374499|NCT03644966|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Probiotics
48705868|NCT04095663|PROCEDURE|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
48705869|NCT04095663|OTHER|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
48705870|NCT04488159|DRUG|Capecitabine|Tablet
48374500|NCT03644966|OTHER|Placebo|Sugar pill manufactured to mimic probiotic tablet
48374501|NCT03644966|DRUG|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
48374502|NCT01768169|DIETARY_SUPPLEMENT|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
48705871|NCT04488159|DRUG|Oxaliplatin|Infusion
48017398|NCT05663398|DRUG|Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
48017399|NCT05663398|DRUG|Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)|Oral, a nonsteroidal anti-inflammatory drug
48374503|NCT02501642|BEHAVIORAL|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
48374504|NCT02501642|OTHER|Treatment as usual|Treatment as usual
48374505|NCT03547921|DEVICE|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
48516834|NCT01442324|PROCEDURE|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
48705872|NCT04488159|DRUG|Fluorouracil|Infusion
48017400|NCT04165291|BEHAVIORAL|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
48017401|NCT04165291|BEHAVIORAL|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
48374506|NCT03710681|BIOLOGICAL|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
48374507|NCT02335229|DEVICE|Axium DRG Neurostimulator|Implantation with Axium DRG Neurostimulator
48374508|NCT01333501|DRUG|Fingolimod|0.5 mg in capsules for oral administration once daily
48374509|NCT01333501|DRUG|Interferon beta 1b|250 μg injected s.c. every other day
48374510|NCT04037540|PROCEDURE|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
48374511|NCT04037540|PROCEDURE|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
48374512|NCT00010634|DRUG|Connective Tissue Nutrient Formula|
48374513|NCT00010634|DRUG|Adaptogenic herbs|
48374514|NCT00010634|DRUG|glutamine|
48374515|NCT01863108|BIOLOGICAL|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
48374516|NCT05419960|DIAGNOSTIC_TEST|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
48374517|NCT05419960|DIAGNOSTIC_TEST|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
48516835|NCT00059592|DRUG|Valacyclovir|
48516836|NCT01406574|DRUG|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
48516837|NCT01406574|DRUG|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
48705873|NCT04488159|DRUG|Leucovorin|Infusion
48374518|NCT05419960|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
48374519|NCT02825875|DRUG|18F DCFPyL- Radiopharmaceutica|
48705874|NCT04488159|DEVICE|Immunoscore® assay|Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
48374520|NCT04141566|PROCEDURE|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
48017402|NCT05647512|DRUG|LM-305|Administered intravenously
48374521|NCT04141566|PROCEDURE|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
48017403|NCT05647512|DRUG|Dexamethasone|Administered orally
48374522|NCT02800382|OTHER|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
48017404|NCT04693663|PROCEDURE|Relex-Smile surgery|surgery using Relex-Smile
48174036|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets boned using MBT placement guide|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide bonding strategy
48705875|NCT04488159|OTHER|Physical exercise|Increasing stair walking exercise twice a week over 12 weeks total.
48705876|NCT03504982|DRUG|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat
48705877|NCT03504982|DRUG|Moxifloxacin|D: 400 mg moxifloxacin
48174037|NCT00610571|DRUG|Oral Topotecan and Temodar|"Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.~Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose."
48174038|NCT03783858|DEVICE|P200TE|OCT images
48174039|NCT04706858|DIETARY_SUPPLEMENT|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
48705878|NCT03504982|DRUG|Placebo|A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
48705879|NCT05928117|OTHER|Education|Pregnant women will be given training to cope with the fear of childbirth.
48705880|NCT01572363|DRUG|Sildenafil|50 mg once
48705881|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
48705882|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
48705883|NCT00770042|DRUG|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
48705884|NCT00770042|DRUG|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
48174040|NCT04706793|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
48174041|NCT04706793|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
48705885|NCT00770042|DRUG|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
48017405|NCT04519632|OTHER|Qualitative study|Qualitative interviews
48017406|NCT02460640|PROCEDURE|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
48017407|NCT02460640|PROCEDURE|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
48017408|NCT02460640|DRUG|Morphine|
48017409|NCT02460640|DRUG|Ropivacaine|
48017410|NCT05351606|BEHAVIORAL|Tobacco Use Cessation Counselling Sessions|Counseling sessions will be given in person
48017411|NCT05351606|DRUG|Bupropion|Given orally
48017412|NCT05351606|DRUG|Nicotine patch|Given transdermally
48017413|NCT05351606|DRUG|Nicotine lozenge|Given orally
48017414|NCT06659523|DIETARY_SUPPLEMENT|EPS supplement intervention|31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
48174042|NCT04964245|DEVICE|accelometer|the respiration parameters are measured using an accelometer.
48174043|NCT04964245|DEVICE|thermographic camera|the respiration parameters are measured using an thermographic camera.
48705886|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 8
48705887|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 6
48705888|NCT00770042|DRUG|Avanafil|Avanafil 200mg Days 1 and 6
48705889|NCT03424954|BEHAVIORAL|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
48705890|NCT04360512|PROCEDURE|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
48705891|NCT03150576|DRUG|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
48705892|NCT03150576|DRUG|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
48174044|NCT04964245|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
48705893|NCT04330833|OTHER|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
48374523|NCT05284162|BEHAVIORAL|Health coaching|The health coaching program includes four monthly health coaching sessions for three months.
48705894|NCT04330833|OTHER|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
48705895|NCT02186652|DRUG|Pantoprazole|
48705896|NCT02072460|OTHER|electromyography|
48705897|NCT02072460|OTHER|electroencephalography|
48705898|NCT02072460|OTHER|approaches from psychophysics|
48705899|NCT04051385|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
48374524|NCT01685320|PROCEDURE|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
48374525|NCT00227591|DRUG|lenalidomide|Given orally (PO)
48374526|NCT00227591|DRUG|prednisone|Given PO
48374527|NCT00227591|OTHER|laboratory biomarker analysis|Correlative studies
48374528|NCT01326312|DRUG|GTx-758 1000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
48374529|NCT01326312|DRUG|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
48374530|NCT01326312|DRUG|GTx-758 2000mg|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
48374531|NCT04425876|DRUG|Fluzoparib|Fluzoparib combined with mFOLFIRINOX followed by maintenance Fluzoparib monotherapy
48705900|NCT04051385|OTHER|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
48017415|NCT06659523|DIETARY_SUPPLEMENT|Placebo|29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
48017416|NCT02990663|OTHER|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
48174045|NCT04964245|DEVICE|Mattress Sensor|the respiration parameters are measured using an Mattress pressure
48374532|NCT03143712|DRUG|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
48374533|NCT02727374|OTHER|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
48705901|NCT00803257|OTHER|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
48705902|NCT01088165|DRUG|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
48705903|NCT01088165|DRUG|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
48017417|NCT02990663|OTHER|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
48374534|NCT02727374|BEHAVIORAL|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
48374535|NCT06176222|DRUG|PRECEDEX INJ★ 2ML|patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
48374536|NCT06176222|DRUG|Normal saline|patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
48374537|NCT03588494|COMBINATION_PRODUCT|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
48374538|NCT03588494|DRUG|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
48374539|NCT03588494|DRUG|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
48705904|NCT01088165|OTHER|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
48017418|NCT06161454|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as either a tablet or granules. Dose is based on body weight:~40 mg for a participants weighing 40-79 kg, or 80 mg for a patient weighing more than or equal to 80 kg"
48174046|NCT05286437|DRUG|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole|Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
48174047|NCT04947462|DEVICE|Chronically Implanted Neural and Muscular Interface|Participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
48174048|NCT03845023|DRUG|AD036 Dose 1|AD036 Dose 1 oral capsule administered before sleep
48174049|NCT03845023|DRUG|AD036 Dose 2|AD036 Dose 2 oral capsule administered before sleep
48174050|NCT03845023|DRUG|AD036 Dose 3|AD036 Dose 3 oral capsule administered before sleep
48174051|NCT03845023|DRUG|Placebo|Placebo oral capsule administered before sleep
48174052|NCT04274062|PROCEDURE|Integrated Nursing care of placenta previa|"Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)"
48174053|NCT01068405|DRUG|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
48174054|NCT01068405|DRUG|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
48174055|NCT00470405|DRUG|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
48174056|NCT00470405|DRUG|pemetrexed disodium|a novel antifolate with multiple targets.
48174057|NCT05665322|PROCEDURE|Thermoablation with standard CT guidance|Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
48174058|NCT05665322|PROCEDURE|Thermoablation with porto-scanner guidance with Angio-CT|Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
48174059|NCT01436383|OTHER|Hypoxic exposure|Hypoxic exposure
48174060|NCT02496598|PROCEDURE|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
48174061|NCT02496598|DRUG|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
48174062|NCT04696146|DRUG|Berinert|Intrarenal dose of 500 U of Berinert
48705905|NCT00534287|DRUG|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
48017419|NCT06663397|OTHER|Laughter Yoga|Laughter Yoga sessions lasting 45 minutes each week for a total of 4 sessions. These sessions will include 30 minutes of laughter and breathing exercises, followed by 15 minutes of laughter meditation and relaxation
48017420|NCT06663397|OTHER|Standard Childbirth Preparation Training|the sessions will be conducted in groups of 8 participants. Various educational materials, including visual aids, will be used, and the training will involve presentations, direct instruction, video displays, and question-and-answer sessions
48017421|NCT03329352|DEVICE|F&P Full-Face Mask|The F\&P full-face mask will serve as the participant's primary PAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial full-face mask as their primary PAP therapy mask for 6 months after Visit 3.
48174063|NCT04696146|DRUG|Placebo|Normal Saline placebo
48174064|NCT02230709|OTHER|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
48174065|NCT02230709|OTHER|"TENS and dry needling"|Application of TENS current after dry needling technique
48174066|NCT05720377|DEVICE|continuous glucose monitor (Freestyle Libre|15 minute phone interview by health care provider to assess health goals set at clinic visits.
48174067|NCT01041768|PROCEDURE|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
48174068|NCT01268098|DRUG|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
48174069|NCT01601613|DRUG|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
48374540|NCT03349203|DRUG|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
48374541|NCT02010359|DRUG|Lovaza|Lovaza 4 grams per day
48374542|NCT02010359|DRUG|Placebo|Placebo pill
48017422|NCT05544461|BEHAVIORAL|eNutri personalised nutrition advice|eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
48017423|NCT01263873|DEVICE|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
48017424|NCT01263873|DEVICE|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
48017425|NCT04726982|DRUG|Acetazolamide|250 mg once daily
48017426|NCT04726982|DRUG|Acetazolamide|500 mg once daily
48017427|NCT04726982|OTHER|Placebo|Once daily
48017428|NCT04381104|DRUG|Paracetamol|The intervention arm will receive 2 capsules of paracetamols of 500mg.
48017429|NCT03750396|PROCEDURE|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
48017430|NCT03750396|RADIATION|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).
48017431|NCT03750396|PROCEDURE|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
48017432|NCT06546800|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
48017433|NCT01099124|DRUG|M2ES|polyethylene glycol rh recombinant endostatin
48017434|NCT04464226|DRUG|Darolutamide (Nubeqa, BAY1841788)|Participants will continue receiving darolutamide treatment at the dose level and schedule of administration previously assigned in the feeder study.
48017435|NCT00451763|DRUG|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
48705906|NCT00534287|DRUG|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
48017436|NCT05306106|OTHER|Glucose|Each subject will consume the reference product during visits V1 and V5. A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume the glucose solution. The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes.
48374543|NCT04111224|DIAGNOSTIC_TEST|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
48017437|NCT05306106|OTHER|truffle match|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 221.2 g of truffle match (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
48174070|NCT01601613|DRUG|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
48174071|NCT00542932|OTHER|Exercise|"Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
48374544|NCT00281931|BIOLOGICAL|rituximab|
48705907|NCT00792662|DRUG|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
48174072|NCT00198302|DRUG|Aurexis®|
48174073|NCT00085111|BIOLOGICAL|bevacizumab|Given IV
48174074|NCT02995382|PROCEDURE|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
48374545|NCT00281931|DRUG|cyclophosphamide|
48374546|NCT00281931|DRUG|fludarabine phosphate|
48374547|NCT00495950|BEHAVIORAL|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
48374548|NCT05784168|OTHER|Manual therapy|"6 weeks, 12 sessions in total, 2 times a week of manual therapy: spinal manipulation, specific mobilisations and stretches. Manual therapy treatments are carried out by a physiotherapist with more than 10 years of experience.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
48705908|NCT00792662|DRUG|Placebo|Standard inactive pill.
48705909|NCT04853693|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
48705910|NCT04853693|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
48705911|NCT05522244|DIAGNOSTIC_TEST|extended CTA|Extending the standard CTA 6 cm below the carina.
48705912|NCT06534229|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine-needle aspiration|Endoscopic ultrasound-guided fine-needle aspiration for biopsy
48374549|NCT05784168|OTHER|Exercise therapy|"6 weeks, 12 sessions in total, 2 times a week therapeutic exercise programme under the supervision of a physiotherapist. The exercise programme consisted of muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises.~In addition, 6 weeks, 5 times a week, a programme of therapeutic exercises at home: muscle strengthening and stretching, balance and coordination training, spinal stabilisation exercises."
48374550|NCT06190860|OTHER|Autologous Leukocyte and platelet-rich fibrin|Participants will be treated with L-PRF plugs and membranes from autologous venous blood. Participants will have drawn blood after venipuncture (median cubital vein) into sterile, glass-coated plastic 9 mL tubes without anticoagulant. These tubes will be centrifuged at 2700 rpm for 12 min (Relative Centrifugal Forces-clot = 408 g). After tooth extraction, participants in the experimental group will be treated with L-PRF plugs and membranes.
48705913|NCT03256903|DRUG|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
48017438|NCT05306106|OTHER|hazelnut chocolate cookie|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 142.8 g of hazelnut chocolate cookie (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
48017439|NCT05306106|OTHER|Paris Brest style eclair|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 277.7 g of Paris Brest style eclair (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
48017440|NCT05306106|OTHER|hazelnut chocolate finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 312.5 g of hazelnut chocolate finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
48174075|NCT04427878|PROCEDURE|biopsies of subcutaneous adipose tissue|Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
48174076|NCT00488319|DRUG|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
48174077|NCT01588366|DRUG|Placebo|Administered orally
48174078|NCT01588366|DRUG|LY2409021|Administered orally
48174079|NCT00365547|BIOLOGICAL|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
48174080|NCT00365547|DRUG|topotecan hydrochloride|Topotecan 4 mg/m\^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
48174081|NCT02401971|DRUG|Thalidomide|Given orally
48174082|NCT02401971|DRUG|CPT-11|Given Ivgtt
48174083|NCT04151472|DRUG|Placebo|Placebo oral tablet, three times a day
48174084|NCT04151472|DRUG|90mg Idebenone|Idebenone 30 MG Oral Tablet, three times a day
48705914|NCT03256903|DRUG|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
48705915|NCT06439888|DRUG|all-trans retinoic acid|per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
48705916|NCT06439888|RADIATION|Stereotactic Body Radiation Therapy|Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated
48705917|NCT06276881|BEHAVIORAL|Visual Stimulation|AI-guided visual stimuli presented on an electronic screen
48174085|NCT04151472|DRUG|270mg Idebenone|Idebenone 90 MG Oral Tablet, three times a day
48174086|NCT04186052|BIOLOGICAL|BCMA-CART cells|Target BCMA chimeric antigen receptor T cell infusion
48705918|NCT05908526|BEHAVIORAL|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
48705919|NCT05908526|DEVICE|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
48705920|NCT05908526|DRUG|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
48705921|NCT05908526|OTHER|Placebo|An inactive substance that looks like the drug or treatment being tested.
48705922|NCT03505905|DRUG|Pregnenolone|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
48705923|NCT03505905|DRUG|Placebo|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
48705924|NCT04902404|OTHER|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
48705925|NCT01317537|OTHER|Electronic personal health record|
48705926|NCT06196463|PROCEDURE|Erector spinale block (ESP block)|The Study has the Objective to analyze the efficacy of the ESP block in spine Surgery (juvenile idiopathic scoliosis) to control perioperative pain
48705927|NCT06196463|PROCEDURE|AG + sham block|General anesthesia
48705928|NCT06110715|OTHER|theta tACS stimulation|The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.
48705929|NCT06110715|OTHER|sham tACS stimulation|A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .
48705930|NCT02947178|PROCEDURE|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
48705931|NCT02947178|BEHAVIORAL|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
48705932|NCT02947178|BEHAVIORAL|Pill Count|Patient reported as needed (prn) pain medication usage
48705933|NCT02947178|DRUG|Bupivacaine|
48705934|NCT02947178|DRUG|Liposomal Bupivacaine|
48705935|NCT05174221|DRUG|Mezagitamab|TAK-079 subcutaneous injection.
48705936|NCT01945216|DRUG|Alogliptin|Alogliptin tablets
48705937|NCT02609750|OTHER|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
48705938|NCT02609750|OTHER|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
48705939|NCT04835909|BEHAVIORAL|Modern board and card games group|Modern board and card games group
48705940|NCT04835909|BEHAVIORAL|Paper and pencil tasks group|Paper and pencil tasks group
48705941|NCT02046226|DEVICE|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
48174087|NCT05096078|OTHER|Diet|Special diet program for gestational diabetes
48374551|NCT06190860|OTHER|Intraoral Scan|Intraoral scan will be taken in the treated zone after tooth extraction and after four months.
48374552|NCT06190860|RADIATION|Computed Tomography|Cone Beam Computed Tomography in the treated zone will be taken after tooth extraction and after four months.
48374553|NCT06190860|OTHER|Biopsy|Before dental implant placement, a biopsy (2 mm in diameter) will be taken. The biopsy will be analyzed by Micro-computed tomography and decalcified and included in paraffin for histological sections.
48374554|NCT05783011|PROCEDURE|Electroacupuncture|Electroacupuncture was applied bilaterally to the LI4, ST5 and ST6 acupuncture points before and after periodontal flap surgery
48374555|NCT05783011|PROCEDURE|periodontal flap surgery|periodontal flap surgery
48374556|NCT06505330|DIETARY_SUPPLEMENT|Probactiol Baby|Dietary Supplement: Probactiol Mini 6 droplets of Probactiol Mini daily intake for 13 months
48374557|NCT03509766|DEVICE|Histamine skin testing|skin testing using histamine
48017441|NCT05306106|OTHER|lemon finger|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 263.1 g of lemon finger (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
48017442|NCT05306106|OTHER|elderflower madeleine|"The products evaluated are pastries from the Mademoiselle Desserts range. The amounts consumed will be calculated for each of the pastries so that 50 g of carbohydrate is ingested per intake. Subjects may consume 200 mL of water after ingesting the pastries. During visits V2 to V4 and V6 to V8, the subject will consume successively the pastries which will have been assigned to him randomly and according to the randomization list.~During the visit : A venous catheter will be placed by a medical biology technician and a blood sample will be taken immediately after placement: this is the first sample at T = 0 min. Then, the subject will have a maximum of 10 minutes to consume 294.1 g of elderflower madeleine (contained 50 g of glucose). The technician will then take blood samples at T = 15, T = 30, T = 45, T = 60, T = 90 and T = 120 minutes."
48017443|NCT06573918|DIAGNOSTIC_TEST|EMG-based assessment of paratonia|EMG-assessed paratonia was analyzed and compared to assess motor response efficiency in three groups of healthy young adults with different levels of physical activity: professional athletes engaged in closed and open skills sports, amateurs, and sedentary individuals. To analyze EMG-assessed paratonia, two surface electrodes were attached to the biceps and triceps brachii muscles during passive flexion-extension movements of the elbow while the participant remained in a state of maximum relaxation. Any EMG activity detected during these movements was attributed to an inability to relax, thereby reflecting their degree of paratonia.
48374558|NCT01243762|DRUG|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
48374559|NCT01243762|DRUG|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
48374560|NCT01243762|DRUG|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
48374561|NCT01243762|DRUG|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
48374562|NCT00329706|PROCEDURE|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
48374563|NCT00912431|DRUG|ABT-126|ABT-126 administered on Day 1 of Period 1
48374564|NCT00912431|DRUG|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
48374565|NCT03572465|DEVICE|Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)|Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
48374566|NCT02538432|DRUG|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
48374567|NCT02538432|DRUG|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
48374568|NCT03075826|DRUG|SGI-110|subcutaneously at a dose of 60 mg/m2
48374569|NCT05416268|DIAGNOSTIC_TEST|Electroretinography|Two different electroretinogram devices (Diopsys NOVA and LKC RETeval Devices) will be evaluated with two different electrode arrays (Diopsys Lid Electrodes and LKC RETeval Self-Adhering Electrode Arrays).
48374570|NCT00781482|DRUG|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
48374571|NCT02191033|BEHAVIORAL|Smoking counseling|
48374572|NCT02191033|BEHAVIORAL|Text messaging|
48374573|NCT02191033|DRUG|Nicotine patch|
48705942|NCT01665079|DRUG|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS\>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 \> 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS \> 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
48705943|NCT06280872|OTHER|Physiological Based Cord Clamping|see Arm Description
48705944|NCT06280872|OTHER|Differed Cord Clamping|see Arm Description
48705945|NCT04609358|OTHER|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
48705946|NCT05385887|DRUG|Ciprofloxacin 500 mg|One tablet of 500mg Ciprifloxacine, twice a day
48705947|NCT05385887|DRUG|Metronidazole 500 mg|One tablet of 500mg Metronidazole, three times a day
48516838|NCT03669224|OTHER|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
48516839|NCT03669224|OTHER|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
48516840|NCT03669224|OTHER|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
48516841|NCT06451341|BEHAVIORAL|Acceptability of Intervention Measure (AIM)|"The Acceptability of Intervention Measure (AIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The AIM will measure the extent to which participants believe CAB+RPV LA implementation is acceptable."
48516842|NCT06451341|BEHAVIORAL|Intervention Appropriateness Measure (IAM)|"The Intervention Appropriateness Measure (IAM) questionnaire will be administered at Baseline to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The IAM will measure the extent to which participants believe CAB+RPV LA implementation is appropriate."
48705948|NCT05385887|DRUG|Placebo|Placebo tablets
48017444|NCT05085340|DRUG|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
48017445|NCT05600218|DRUG|No intervention - Observational study|Real life drug evaluation
48017446|NCT02501889|BEHAVIORAL|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
48174088|NCT05096078|OTHER|Exercise|The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
48174089|NCT00356993|DRUG|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
48174090|NCT00356993|BEHAVIORAL|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
48174091|NCT01044836|BIOLOGICAL|HD203|Injectable form
48374574|NCT04085562|DRUG|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
48374575|NCT04085562|DRUG|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
48374576|NCT05422105|DRUG|18F-PSMA-1007|18F-PSMA-1007 PET/CT
48516843|NCT06451341|BEHAVIORAL|Feasibility of Intervention Measure (FIM)|"The Feasibility of Intervention Measure (FIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The FIM will measure the extent to which participants believe CAB+RPV LA implementation is feasible."
48705949|NCT04709016|BEHAVIORAL|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
48705950|NCT05807464|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
48705951|NCT05479344|BEHAVIORAL|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
48705952|NCT06037941|DIAGNOSTIC_TEST|E-Nose testing|At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
48374577|NCT00204711|OTHER|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
48374578|NCT01831297|DEVICE|measurement of blood pressure|measurement of pulse wave velocity
48374579|NCT04893915|BIOLOGICAL|Cytokine-induced memory-like NK cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core or another FACT-accredited cellular therapy production facility that can manufacture the product per the IND CMC.
48017447|NCT02501889|BEHAVIORAL|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
48374580|NCT04893915|DRUG|Fludarabine|-Lymphodepleting regimen
48374581|NCT04893915|DRUG|Cyclophosphamide|-Lymphodepleting regimen
48374582|NCT04893915|PROCEDURE|Donor Leukapheresis|-Apheresis will be performed via peripheral IVs or central line, as determined by the apheresis team.
48374583|NCT04893915|DRUG|Interleukin-2|-IL-2 will start approximately 2-4 hours after the NK cell infusions.
48017448|NCT01915563|PROCEDURE|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
48705953|NCT06037941|DIAGNOSTIC_TEST|Research blood|Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
48017449|NCT04040972|OTHER|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
48374584|NCT00690612|DRUG|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
48374585|NCT01065662|DRUG|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
48374586|NCT01065662|DRUG|cediranib|Taken orally daily
48374587|NCT04001478|DIAGNOSTIC_TEST|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
48374588|NCT02257970|DRUG|Ketoprofen|
48374589|NCT02257970|DRUG|Placebo|Placebo to match ketoprofen.
48374590|NCT01789307|DIETARY_SUPPLEMENT|corn syrup solids|oral ingestion 50 grams, 2 doses
48374591|NCT01789307|DIETARY_SUPPLEMENT|sucrose|oral ingestion 50 grams, 2 doses
48374592|NCT02079376|DEVICE|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
48374593|NCT02301949|DRUG|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
48374594|NCT02301949|OTHER|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
48374595|NCT02868294|DEVICE|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
48374596|NCT03517657|BEHAVIORAL|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
48705954|NCT05925530|DRUG|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
48017450|NCT05325086|OTHER|Adapted information arm|A adapted booklet will be delivered to patients at the start of the stay. This booklet contains adapted information about the pulmonary rehabilitation targetting the characteristics of the openness to experiences personality traits
48017451|NCT05325086|OTHER|Neutral information arm|A neutral booklet will be delivered to patients at the start of the stay. This booklet contains neutral information about the pulmonary rehabilitation
48017452|NCT03390322|DEVICE|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
48017453|NCT02272998|DRUG|ponatinib hydrochloride|Given PO
48017454|NCT02272998|OTHER|laboratory biomarker analysis|Correlative studies
48374597|NCT03517657|BEHAVIORAL|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
48705955|NCT00256815|DRUG|chemotherapy|
48705956|NCT00256815|PROCEDURE|Radiation|
48374598|NCT02869373|BEHAVIORAL|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
48374599|NCT02181543|DRUG|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
48705957|NCT04326413|PROCEDURE|Oral hygiene instruction and simple scaling|Monitor the changes of gum condition
48705958|NCT05068063|DRUG|Bupivacaine Injection|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
48705959|NCT05068063|DRUG|normal Saline|Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
48705960|NCT05014464|DRUG|Crizotinib|Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
48374600|NCT00501748|DRUG|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
48374601|NCT03490253|BEHAVIORAL|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
48374602|NCT03490253|BEHAVIORAL|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
48374603|NCT01393574|DRUG|Melatonin|3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep
48017455|NCT04662346|OTHER|Difficulty score system for robotic pancreatoduodenectomy|calculate the score for patient in you cohort
48374604|NCT01393574|DRUG|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
48374605|NCT01246193|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
48374606|NCT01246193|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
48374607|NCT04310241|BEHAVIORAL|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
48374608|NCT03730064|DRUG|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
48374609|NCT01569321|DEVICE|MRI|
48705961|NCT04920630|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia (CBT-I)|CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
48705962|NCT06607094|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
48017456|NCT03563040|DRUG|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
48017457|NCT03563040|DEVICE|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
48017458|NCT06135493|DRUG|Losartan|Using losartan to prevent paclitaxel-induced peripheral neuropathy
48705963|NCT00884039|DRUG|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
48705964|NCT00884039|DRUG|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
48705965|NCT05478434|DEVICE|Cortico-cortical stimulation plus robot-assisted therapy|15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
48017459|NCT06379841|PROCEDURE|Green Draping Procedure|The green draping will include only an under-buttock. After normal hand hygiene and scrub, the green draping procedure will have the surgeons don only a single pair of sterile gloves.
48017460|NCT06379841|PROCEDURE|Full Draping Procedure|The full draping will include under-buttocks, two-leg drapes, blue towels, and a top drape. After normal hand hygiene and scrub, the draping procedure will have the surgeon don a surgical gown and two sets of sterile gloves for the surgeon.
48017461|NCT00555438|DRUG|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
48017462|NCT03828305|OTHER|Training and creation of the Network-CPR|Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.
48374610|NCT01569321|DEVICE|PET-CT scan|
48017463|NCT03828305|OTHER|Control Group|No intervention
48174092|NCT05333575|BEHAVIORAL|Lullaby|The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
48374611|NCT01569321|DEVICE|PEM scan with ClearPemSonic|
48374612|NCT05005923|PROCEDURE|Non-surgically performed scaling and root planing|Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
48374613|NCT06283654|DEVICE|1-lead ECG|patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
48374614|NCT00161031|DRUG|Atomoxetine|
48374615|NCT04231799|PROCEDURE|Bathing|Traditionally, it is the process of washing the newborn in the first hours of life to remove blood, meconium, varnish and other infectious substances.
48374616|NCT05367895|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|"Form: CoronaVac® is a milky-white suspension. Stratified precipitate may form that can be dispersed by shaking.~Presentation: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen.~Administration and schedule: Two doses with an interval of 21 days should be administered for primary immunization. 0.5 mL per dose.~Route: IM in the deltoid region of the upper arm after shaking the vial well before use."
48374617|NCT01043809|BEHAVIORAL|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
48705966|NCT05478434|DEVICE|Sham cortico-cortical stimulation plus robot-assisted therapy|15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
48374618|NCT01043809|BEHAVIORAL|expanded school-based handwashing promotion|Procter \& Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
48374619|NCT02180659|DRUG|sublingual buprenorphine tablets|
48374620|NCT02180659|DRUG|Buprenorphine implant|
48374621|NCT02180659|DRUG|placebo implants|
48374622|NCT02180659|DRUG|sublingual placebo tablets|
48374623|NCT06260462|DRUG|dual-release hydrocortisone|Oral tablets 20-25-30-40 mg/day
48374624|NCT06260462|DRUG|Conventional glucocortidois|Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
48374625|NCT05789901|OTHER|MARVIN|Chatbot on Meta (Facebook) Messenger for HIV Patients
48374626|NCT05789901|OTHER|MARVIN-Pharma|Chatbot on Meta (Facebook) Messenger for community pharmacists
48374627|NCT05789901|OTHER|MARVINA|Chatbot on Meta (Facebook) Messenger for breast cancer patients
48374628|NCT05789901|OTHER|MARVIN-CHAMP|CHatbot to Assist the Management of Pediatric patients with infectious conditions (CHAMP)
48374629|NCT03774069|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
48374630|NCT03774069|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
48374631|NCT02218034|DRUG|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
48374632|NCT02218034|DRUG|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
48374633|NCT02218034|DRUG|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
48374634|NCT02218034|DRUG|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
48374635|NCT00696891|BIOLOGICAL|HBV-MPL vaccine|3-dose intramuscular injection
48374636|NCT00696891|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
48374637|NCT00635193|DRUG|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
48374638|NCT00635193|DRUG|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
48374639|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
48374640|NCT00635193|DRUG|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
48374641|NCT05112224|BEHAVIORAL|Education program based on health belief model to improve oral health|Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
48374642|NCT06050031|DIETARY_SUPPLEMENT|Intake of antioxidant supplement|All participants will supplent oral antioxidants (individual or combined which can be obtained without prescription, and which are not regulated as a pharmaceutical drug) over three months.
48374643|NCT02402608|DIETARY_SUPPLEMENT|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
48374644|NCT02402608|DIETARY_SUPPLEMENT|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
48374645|NCT05015504|BEHAVIORAL|Time restricted feeding|In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
48374646|NCT04136717|OTHER|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
48374647|NCT04136717|DEVICE|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
48374648|NCT04136717|DEVICE|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
48374649|NCT04136717|OTHER|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
48374650|NCT04136717|OTHER|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
48705967|NCT01698450|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
48374651|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
48374652|NCT01393652|DRUG|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
48374653|NCT01393652|DRUG|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
48374654|NCT02335359|DRUG|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
48374655|NCT02335359|DRUG|tranexamic acid undiluted (continous infusion)|
48374656|NCT02335359|DRUG|Placebo|Saline
48374657|NCT02962440|DRUG|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan
48374658|NCT02295124|DRUG|Oxycodone|Patients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
48374659|NCT02295124|DRUG|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
48374660|NCT03108664|DRUG|SYL1001 ophthalmic solution|1 drop in the affected eye
48374661|NCT03108664|DRUG|Vehicle opthalmic solution|1 drop in the affected eye
48374662|NCT04182529|DEVICE|Photoneuromodulation therapy|low-level LED near-infrared (670-810nm) including MedX Health Model 1100 or WiseFori5-3800
48374663|NCT04182529|OTHER|Sham|Sham, no active stimulation will be given to subjects
48374664|NCT05614544|DRUG|HSK3486|HSK3486 for induction of general anesthesia
48705968|NCT03404531|BEHAVIORAL|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
48374665|NCT05614544|DRUG|Propofol|Propofol for induction of general anesthesia
48374666|NCT05614544|DRUG|Placebo|Intralipid
48374667|NCT00525499|DRUG|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
48374668|NCT00525499|DRUG|placebo|vehicle control applied topically twice daily for 12 weeks
48374669|NCT06443216|DEVICE|Auditory closed-loop stimulation|Auditory closed-loop suppression of slow wave sleep
48374670|NCT06443216|DEVICE|Sham stimulation|No auditory stimulation
48374671|NCT04718792|DRUG|Psilocybin|A single administration of PEX010 (psilocybin 25 mg, opaque capsule for oral ingestion). PEX010 contains psilocybin (25 mg) naturally extracted from Psilocybe cubensis mushroom fruiting bodies, manufactured under current Good Manufacturing Practices (cGMP)
48374672|NCT02078557|DRUG|MK-8892|
48374673|NCT03651375|DRUG|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
48374674|NCT03651375|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
48374675|NCT01347931|DEVICE|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
48374676|NCT01347931|DEVICE|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
48374677|NCT04746170|OTHER|Labor Dance|Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
48374678|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
48374679|NCT03532048|BEHAVIORAL|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
48374680|NCT01143129|DRUG|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
48374681|NCT01143129|DRUG|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
48374682|NCT01846039|DEVICE|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
48374683|NCT00845351|DRUG|Bexarotene|bexarotene at 300 mg/m2/day
48374684|NCT04822727|DEVICE|1 or more AndraTec devices (see description for list of devices)|1 or more AndraTec devices (Lokum L-Quest guidewire, Lokum Amplatz guidewire, Slider Hydrophilic Nitinol Guidewire, AltoSa-XL PTA Balloon, Alto-Sa-XL Gemini Balloon, Optimus-CoCr stent, Optimus-CVS PTFE covered stent)
48374685|NCT00488098|DRUG|GSK372475|
48374686|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
48374687|NCT00696332|DRUG|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
48374688|NCT00696332|OTHER|placebo|capsules, placebo, 3 times a day, for 52 weeks
48705969|NCT03404531|BEHAVIORAL|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
48705970|NCT02518958|DRUG|RRx-001|
48705971|NCT02518958|DRUG|Nivolumab|
48374689|NCT05592639|PROCEDURE|Videoendoscopic radical inguinal lymphadenectomy or open radical inguinal lymphadenectomy|Intervention is a Videoendoscopic radical inguinal lymphadenectomy (VEIL) which is a surgical technique utilised in removing inguinal lymph nodes.
48174093|NCT05333575|BEHAVIORAL|Classic music|The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
48374690|NCT00975793|OTHER|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
48374691|NCT01361308|DRUG|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
48174094|NCT05271318|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
48174095|NCT05271318|BIOLOGICAL|pembrolizumab|pembrolizumab, a monoclonal antibody binding PD-1
48174096|NCT05271318|DRUG|pegylated liposomal doxorubicin|Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.
48174097|NCT05190471|DRUG|BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide|Dose escalation of BP1002 monotherapy
48174098|NCT05190471|DRUG|Decitabine (in combination with BP1002)|Dose expansion of BP1002 in combination with decitabine
48174099|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation I
48174100|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation II
48174101|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation III
48174102|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation IV
48174103|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation V
48174104|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation VI
48374692|NCT01361308|DRUG|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
48374693|NCT01857570|RADIATION|Volume Computed Tomography of the wrist and carpus|
48374694|NCT03606473|DRUG|d-amphetamine|is used to stimulate dopamine release in the brain
48017464|NCT01771133|BEHAVIORAL|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
48174105|NCT00937521|BIOLOGICAL|Control|Control
48174106|NCT00937521|BIOLOGICAL|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
48174107|NCT05034536|DRUG|Pembrolizumab|Intravenous infusion
48374695|NCT03606473|RADIATION|[C-11]NPA|PET radiotracer
48374696|NCT05588401|BIOLOGICAL|GenPHSat injection (Safety)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the left biceps muscle.
48374697|NCT05588401|BIOLOGICAL|GenPHSat injection (Efficacy)|Participants receive gene edited primary human muscle stem cells (GenPHsat) injection in the right biceps muscle.
48374698|NCT05588401|OTHER|Muscle Biopsy (Safety)|Participants undergo muscle biopsy 3 month after safety GenPHSat injection.
48374699|NCT03568136|DRUG|Secukinumab 300 mg|Solution for injection in pre-filled syringe
48374700|NCT03568136|DRUG|Placebo|Solution for injection in pre-filled syringe
48374701|NCT05326958|DEVICE|HRT RCM|Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
48374702|NCT05326958|DEVICE|HRT RCM-E|imaging done on eyes of all enrolled subjects at site 1 and site 2.
48174108|NCT05034536|DRUG|Infliximab|Intravenous infusion
48174109|NCT05034536|DRUG|Placebo|Intravenous infusion
48174110|NCT05034536|DRUG|Relatlimab|Intravenous infusion
48174111|NCT05034536|DRUG|Nivolumab|Intravenous infusion
48174112|NCT04580498|DRUG|SHR-1701+Paclitaxel+carboplatin|Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
48174113|NCT04580498|DRUG|SHR-1701|Drug: SHR-1701 30mg/kg
48174114|NCT01754532|BIOLOGICAL|Hair Sample|Analysis of hair cortisol levels
48174115|NCT05082207|OTHER|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
48174116|NCT05082207|OTHER|sham group|a deflated cuff placed on the upper arm for 30 min
48174117|NCT00142688|BEHAVIORAL|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
48174118|NCT00142688|BEHAVIORAL|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
48705972|NCT01513603|DRUG|CLAG-M|IV times 5 days
48705973|NCT01513603|DRUG|CLAG-M|Chemotherapy
48705974|NCT05636384|OTHER|Home-based care|"Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit"
48705975|NCT05139381|DRUG|Mepolizumab|Treatment with Mepoluzimab
48017465|NCT05448690|PROCEDURE|Two different approaches|Please refer to Groups
48174119|NCT03626077|OTHER|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.
48174120|NCT03626077|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.
48174121|NCT03626077|COMBINATION_PRODUCT|physical therapy program and E-Link Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
48174122|NCT05653973|DRUG|Acetylcholine|acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
48516844|NCT06451341|BEHAVIORAL|HIV Stigma Scale Questionnaire|"The HIV Stigma Scale Questionnaire used in this study is a shortened version of the validated 40-item HIV stigma scale. This 12-item questionnaire measures the same four stigma subscales measured in the original version, for a streamlined approach to collecting this data on personalized stigma, disclosure concerns, concerns with public attitudes and negative self-image.~This will be administered at Baseline, Month 7 and Month 15."
48516845|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The status version will be administered at Baseline, Month 7 and Month 15."
48516846|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The change version will be administered at Month 15."
48017466|NCT05448690|PROCEDURE|Non-combined approach|Either transnasal, transcranial or a staged approach
48174123|NCT05653973|DRUG|Endothelin-1|endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
48374703|NCT01342809|BEHAVIORAL|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
48374704|NCT03661346|DRUG|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
48374705|NCT03661346|DRUG|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
48374706|NCT03506334|DEVICE|AVBT using Dynesys System Components|Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
48374707|NCT03506334|PROCEDURE|Spine fusion|Children with scoliosis undergoing fusion surgery will form the control arm
48705976|NCT03062553|BEHAVIORAL|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
48705977|NCT03062553|BEHAVIORAL|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
48705978|NCT03062553|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
48705979|NCT06606145|PROCEDURE|Lymphovenous Anastomosis|LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.
48705980|NCT06606145|PROCEDURE|Vascularized Lymph Node Transfer|VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.
48705981|NCT06606145|PROCEDURE|Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer|Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.
48705982|NCT06606145|PROCEDURE|Complex Decongestive Therapy|The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
48705983|NCT01546441|BEHAVIORAL|interprofessional assessment|assessment by interprofessional team
48705984|NCT01546441|BEHAVIORAL|usual care|usual care in primary care clinic
48374708|NCT02734290|DRUG|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
48374709|NCT02734290|DRUG|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
48374710|NCT02734290|DRUG|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
48374711|NCT03358407|DRUG|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
48705985|NCT03193086|DRUG|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
48705986|NCT00831740|OTHER|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
48374712|NCT03358407|DRUG|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
48374713|NCT05920382|PROCEDURE|Radiofrequency ablation of peripheral nerves.|Randomized double-blind clinical trial where we will apply thermal radiofrequency to the sensory terminal branches of the femoral nerve in the knee, including the vasto medial nerve, vasto lateral nerve, vasto intermedio nerves, and the infrapatellar branch of the saphenous nerve.
48374714|NCT03406286|DRUG|Tolvaptan|
48374715|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
48374716|NCT06522763|DRUG|Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ|The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
48705987|NCT00831740|OTHER|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
48705988|NCT01690546|DRUG|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
48705989|NCT01690546|DRUG|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
48174124|NCT06002321|DIAGNOSTIC_TEST|Echocardiography|Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' \> 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR \> 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.
48374717|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation Randomized)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
48705990|NCT01690546|DRUG|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
48374718|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation-Open Label)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
48705991|NCT02029183|DEVICE|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
48705992|NCT02029183|DEVICE|bi-level positive airway pressure|
48374719|NCT03123627|DRUG|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
48374720|NCT03123627|DRUG|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ\> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
48374721|NCT05868707|DRUG|OH2|Oncolytic Type 2 Herpes Simplex Virus
48374722|NCT05868707|DRUG|Salvage chemotherapy or best supportive care|single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
48374723|NCT02179580|DRUG|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
48374724|NCT02179580|DRUG|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
48374725|NCT00707551|DRUG|Ketoconazole|Tablet, administered as repeated doses.
48374726|NCT00707551|DRUG|Verapamil|Extended Release tablet, administered as repeated doses.
48374727|NCT00707551|DRUG|AZD1305|Extended Release tablet, administered as a single dose.
48705993|NCT06241001|OTHER|eccentric streching|The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
48017467|NCT03844893|PROCEDURE|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
48017468|NCT00934271|RADIATION|fractionated stereotactic radiotherapy|Audit of outcome
48017469|NCT06074016|DRUG|Zolmitriptan intranasal.|Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
48174125|NCT06002321|DIAGNOSTIC_TEST|Laboratory Test|BNP, NT-proBNP and renal function.
48374728|NCT00594568|DRUG|LY450139|Administered orally once daily
48374729|NCT00594568|DRUG|Placebo|Administered orally once daily
48374730|NCT03582098|DRUG|Idelalisib|Tablets were administered in accordance with the marketing authorization.
48705994|NCT06241001|OTHER|IASTM|Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
48705995|NCT00898300|OTHER|biologic sample preservation procedure|
48705996|NCT00898300|PROCEDURE|biopsy|
48705997|NCT05749003|OTHER|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
48017470|NCT06074016|DRUG|Zolmitriptan oral.|Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
48374731|NCT03582098|DRUG|Rituximab|Tablets were administered in accordance with the marketing authorization.
48374732|NCT00802295|DRUG|Gonadotrophins|Administration of standard ovarian stimulation protocol
48374733|NCT00802295|DRUG|Low dosis Gonadotrophin|
48374734|NCT00869362|OTHER|Diabetes management team|MD evaluation followed by NP education and and medication titration
48174126|NCT03120598|BEHAVIORAL|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
48705998|NCT05749003|OTHER|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
48705999|NCT04796324|DRUG|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
48017471|NCT01105247|DRUG|PCI-32765|420 mg daily or 840 mg daily
48017472|NCT03243331|DRUG|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
48017473|NCT03243331|DRUG|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
48017474|NCT02788175|BIOLOGICAL|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
48017475|NCT02120339|DRUG|Carvedilol|
48706000|NCT01474772|DRUG|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
48174127|NCT03120598|BEHAVIORAL|ISF strategy|Implementation \& Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
48174128|NCT02821078|OTHER|4D flow imaging sequence|4D flow imaging sequence
48174129|NCT01990313|DEVICE|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
48174130|NCT03889873|BEHAVIORAL|Narrative Writing|An writing task in which participants are given a description of a possible future self (that varies 3 factors: topic; drinking vs. smartphone; perspective: 1st vs. 3rd-person; and social network: specifically asked to be included vs. not specifically asked to be included). Participants are asked to imagine that future self vividly and to write about the thoughts and feeling describe themselves and their experiences, the characteristics they hope or wish they will ideally possess, the characteristics that they would need to have and the roles they will take on or things they will be doing. Participants are given 20 minutes to think and write. They will write and think about the same future on each of three lab-sessions (which occur at 1-week intervals).
48174131|NCT04124783|DEVICE|Cooling Bolero|A vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
48174132|NCT01576913|OTHER|Music listening|Listening to tempo music while cycling in an exercise test
48174133|NCT02419963|PROCEDURE|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
48174134|NCT02419963|OTHER|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
48174135|NCT02419963|OTHER|Stool Sample|Stool sample to evaluate microbiome fingerprint.
48174136|NCT05673499|DEVICE|NIRS/EEG monitoring|The study intervention will be monitoring NIRS and EEG for one hour before surgery, during surgery, and up to 8-24 hours after surgery.
48174137|NCT01311414|DRUG|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
48706001|NCT01474772|OTHER|placebo|matching placebo capsules given in 3 divided doses
48706002|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
48706003|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
48706004|NCT03372434|DEVICE|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
48706005|NCT05079698|DRUG|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
48706006|NCT05079698|PROCEDURE|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
48017476|NCT01369290|DRUG|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
48017477|NCT01369290|DRUG|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
48017478|NCT01369290|DRUG|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
48017479|NCT01369290|OTHER|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
48017480|NCT01369290|DRUG|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
48017481|NCT04801524|BEHAVIORAL|Self-benefit|Participants will be reminded that the vaccine helps protect themselves from COVID.
48174138|NCT06003699|BEHAVIORAL|Search Inside Yourself (SIY) program|The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
48706007|NCT06606353|BEHAVIORAL|Talk-To-Jo|"Participation begins with the completion of a socio-demographic questionnaire. Next, participants test the Talk-to-Jo intelligent digital health companion on a tablet: first, a member of the research team explains the tool to the dyad (person with a neurocognitive disorder and their caregiver). The person with the disorder then interacts with Talk-to-Jo, possibly with the help of their caregiver. An observer is present, but does not intervene unless there are questions or technical problems. At the end of the test, health recommendations are given. Questions focus on the participant's memory and depression.~Next, a 30-minute interview is conducted with a member of the research team to gather impressions of the tool, digital skills, barriers and facilitators to using AI, as well as your expectations of Talk-to-Jo.~An additional individual interview can be arranged if required."
48174139|NCT05549167|DRUG|Sirolimus|Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
48174140|NCT05832619|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
48174141|NCT05832619|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
48706008|NCT00283426|DRUG|Soluble beta-1,3/1,6-glucan|
48706009|NCT02321189|DRUG|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
48706010|NCT02321189|DRUG|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
48706011|NCT02780635|BEHAVIORAL|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
48174142|NCT05832619|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
48374735|NCT05603000|BEHAVIORAL|Emotion Focused Family Therapy|"The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment.~Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks."
48706012|NCT02780635|BEHAVIORAL|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
48706013|NCT00134654|DRUG|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
48706014|NCT02294838|DEVICE|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
48706015|NCT02294838|OTHER|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
48374736|NCT04155606|DEVICE|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
48374738|NCT05913921|DRUG|Amphotericin B liposome for injection|IV infusion, 2.0 mg/kg
48017482|NCT04801524|BEHAVIORAL|Prosocial-benefit|Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID
48017483|NCT04801524|BEHAVIORAL|Early access|Participants will be reminded that they have early access to COVID-19 vaccine.
48017484|NCT04801524|BEHAVIORAL|Fresh start|Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.
48374739|NCT05913921|DRUG|AmBisome|IV infusion, 2.0 mg/kg
48374740|NCT01564680|OTHER|placebo|normal saline
48374741|NCT01564680|DRUG|Paracetamol|IV paracetamol infusion
48374742|NCT01564680|DRUG|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
48374743|NCT04420975|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
48374744|NCT04420975|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given intratumorally
48374745|NCT04420975|BIOLOGICAL|Nivolumab|Given IV
48374746|NCT04420975|RADIATION|Radiation Therapy|Undergo radiation therapy
48374747|NCT03977922|OTHER|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
48516847|NCT06451341|BEHAVIORAL|Needs and Barriers Assessment|"The Needs and Barriers Assessment is a questionnaire designed to assess patient participant barriers and social determinants of health, emotional challenges related to antiretroviral therapy, and the impact of switching to CAB+RPV LA treatment.~This will be administered at Baseline, Month 7 and Month 15."
48706016|NCT02294838|OTHER|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
48706017|NCT03362099|DRUG|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
48706018|NCT00315107|DRUG|Alesse|
48706019|NCT05971225|OTHER|remote monitoring only|remote monitoring only can replace in-office device monitoring
48706020|NCT03698045|DRUG|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
48174143|NCT03021278|OTHER|Saline injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
48174144|NCT03021278|OTHER|Sham injection|In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
48516848|NCT06451341|BEHAVIORAL|Pre-visit Outreach|Patient participants will be contacted prior to each clinical injection visit for an appointment reminder and a needs assessment.
48516849|NCT06451341|BEHAVIORAL|Qualitative interview|Qualitative interviews will be conducted within thirty days after study completion at Month 15 to further evaluate the participant's experience with the implementation of CAB+RPV LA treatment.
48706021|NCT03259503|DRUG|Busulfan|Given IV
48706022|NCT03259503|DRUG|Gemcitabine|Given IV
48706023|NCT03259503|DRUG|Melphalan|Given IV
48706024|NCT03259503|DRUG|Olaparib|Given PO
48706025|NCT03259503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
48706026|NCT03259503|OTHER|Pharmacokinetic Study|Correlative studies
48706027|NCT03259503|BIOLOGICAL|Rituximab|Given IV
48174145|NCT00611715|DRUG|erlotinib hydrochloride|OSI-774 150 mg/day
48174146|NCT00611715|DRUG|letrozole|Letrozole 2.5 mg/day
48706028|NCT03259503|DRUG|Vorinostat|Given PO
48706029|NCT01608217|DRUG|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
48706030|NCT01608217|DRUG|Placebo|placebo (tablet) three times daily for a period of three weeks.
48706031|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
48706032|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
48706033|NCT01690559|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
48706034|NCT06607068|OTHER|None (Observational study)|None (Observational study)
48706035|NCT01174277|OTHER|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
48706036|NCT05536492|PROCEDURE|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
48706037|NCT05536492|PROCEDURE|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
48706038|NCT02802241|DRUG|placebo|
48706039|NCT02802241|DIETARY_SUPPLEMENT|peppermint oil|
48706040|NCT00055354|PROCEDURE|Acupuncture|
48706041|NCT00055354|BEHAVIORAL|Cognitive Behavioral Therapy|
48706042|NCT00278369|BIOLOGICAL|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
48174147|NCT00611715|GENETIC|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
48174148|NCT00611715|OTHER|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
48174149|NCT00611715|OTHER|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
48174150|NCT06436495|OTHER|Hair Wash Shampoo|A standard marketed hair wash shampoo is to be used for the hair wash intervention post baseline evaluations of the scalp.
48374748|NCT02235207|BEHAVIORAL|Neuromuscular exercise|"Fustra20 Neck \& Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~* improve movement control in different posture and movements of the neck and back~* improve flexibility with active functional movements~* improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~* improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
48374749|NCT00645606|BIOLOGICAL|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
48374750|NCT05090592|DEVICE|orthokeratology|orthokeratology wearing for myopia control
48374751|NCT05090592|DRUG|0.01 atropine|0.01% atropine eye drop prevent myopic progression
48374752|NCT03851536|PROCEDURE|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
48374753|NCT03851536|PROCEDURE|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
48374754|NCT05896072|PROCEDURE|Erector Spinae Plane Block|"Application of ultrasound-guided erector spinae plane block for perioperative analgesia for elective inguinal hernia repair. Erector spinae plane block will be administered under general anesthesia before the surgery~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc)."
48706043|NCT00278369|BIOLOGICAL|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
48706044|NCT00446472|DRUG|Regranex®|Regranex gel will be used for a total of 16 weeks
48374755|NCT05896072|PROCEDURE|Caudal Block|"Application of caudal block for perioperative analgesia for elective inguinal hernia repair. The caudal block will be administered under general anesthesia before the surgery.~Drug: Bupivacaine (Block Drug)~0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for block performances"
48374756|NCT05463393|BIOLOGICAL|Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/|The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
48374757|NCT04941833|DRUG|Desogestrel Oral Tablet|Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel
48374758|NCT02208427|DRUG|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
48706045|NCT00446472|DRUG|Hydrogel|Placebo hydrogel will be applied for 16 weeks
48706046|NCT06606587|DEVICE|Comfort-in Jet Injection Method|Application of Comfort-in Jet Injection Method: Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar.
48174151|NCT05382598|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) will be initiated in the early group for patients who have stage 2 AKI according to KDIGO classification. The late group will have RRT when they develop any of the absolute indications for RRT
48174152|NCT03949465|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
48374759|NCT02208427|DRUG|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
48374760|NCT04468139|DRUG|Quercetin|Dietary Supplement: Quercetin Treatment a daily dose of quercetin (500 mg) will be taken orally by proven COVID-19 cases intervention
48374761|NCT04468139|DIETARY_SUPPLEMENT|bromelain|Dietary Supplement:Bromealin Treatment a daily dose of bromelain(500 mg) will be taken orally by proven COVID-19 cases intervention
48374762|NCT04468139|DRUG|Zinc|zinc 50 mg orally daily dose will be taken orally by proven COVID-19 cases intervention
48374763|NCT04468139|DRUG|Vitamin C|vitamin c 1000 mg orally daily by proven COVID-19 cases intervention
48706047|NCT06606587|OTHER|Traditional Dental Injection|Application of Traditional Dental Injection Method: Traditional Dental Injection method was used for palatal anesthesia of the permanent 1st molar.
48706048|NCT03754582|DRUG|Perampanel|Oral tablets.
48706049|NCT03754582|DRUG|Perampanel|Intravenous infusion.
48706050|NCT01989780|DRUG|Paclitaxel|
48706051|NCT01989780|DRUG|Bevacizumab|
48706052|NCT01989780|DRUG|Letrozole|
48706053|NCT01989780|DRUG|Anastrozole|
48706054|NCT01989780|DRUG|Exemestane|
48706055|NCT01989780|DRUG|Fulvestrant|
48706056|NCT01989780|DRUG|Goserelin|
48706057|NCT01989780|DRUG|leuprorelin|
48174153|NCT04055415|BIOLOGICAL|adipose derived mesenchymal stem cells|The MSCs of 1×10\*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
48174154|NCT04055415|DRUG|Conventional drug therapy（expectorant，bronchodilator）|Conventional drug therapy（expectorant，bronchodilator）
48174155|NCT04930003|BIOLOGICAL|QazCoVac-P -COVID-19 Subunit Vaccine|QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
48174156|NCT04930003|OTHER|Placebo|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
48174157|NCT00002721|DRUG|doxorubicin hydrochloride|
48174158|NCT00002721|DRUG|estramustine phosphate sodium|
48174159|NCT00002721|PROCEDURE|drug resistance inhibition treatment|
48174160|NCT01560871|BEHAVIORAL|High-intensity IMT plus walking|"The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group."
48174161|NCT01560871|BEHAVIORAL|Low-intensity IMT plus walking|"The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
48174162|NCT00137020|DRUG|ziprasidone|
48374764|NCT05623774|DRUG|Imatinib Mesylate|400mg tablet
48706058|NCT03625830|DEVICE|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
48706059|NCT03625830|DEVICE|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
48017485|NCT05108493|OTHER|Dry needling|Three sessions dry needling of lateral epicondyle region, once per week with disposable acupuncture needles (0.25x25mm).
48174163|NCT00953862|DRUG|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
48174164|NCT03596463|OTHER|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
48174165|NCT01884220|OTHER|There are no interventions in this study.|
48174166|NCT04061070|OTHER|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
48174167|NCT04061070|OTHER|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
48174168|NCT01902498|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
48174169|NCT01902498|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
48174170|NCT01902498|DRUG|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
48174171|NCT04683211|OTHER|Evaluation of iodine supplementation|survey of iodine supplementation
48174172|NCT01825317|DEVICE|NeuroAD|synchronized TMS+COGNITIVE TRAINING
48174173|NCT01825317|DEVICE|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
48174174|NCT05609799|OTHER|Blood sample|Quantifying the volume of leucocyte subsets: NK-cells, B-cells, and T-cell subsets, including Treg, Th1, Th2 and Th17 in EDTA
48174175|NCT04310527|DRUG|Enasidenib|Enasidenib
48174176|NCT00820664|DRUG|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
48174177|NCT00820664|DRUG|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
48374765|NCT05623774|DRUG|IkT-001Pro|100mg or 400mg tablet
48374766|NCT05450900|DRUG|Choriogonadotropin Alpha|drug, active
48374767|NCT05450900|DIETARY_SUPPLEMENT|biotin|supplement, oral
48374768|NCT05450900|OTHER|Microcellulose filler|supplement, oral
48374769|NCT04456621|RADIATION|PBT|Proton beam radiotherapy 70 gray relative biological equivalent (GyRBE)/10 fractions (Fx) or 60 GyRBE/5 Fx
48374770|NCT03637101|DIAGNOSTIC_TEST|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
48706060|NCT03284333|DEVICE|other|no arm
48706061|NCT06176872|DIAGNOSTIC_TEST|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
48706062|NCT00027378|DRUG|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
48174178|NCT00820664|DRUG|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
48374771|NCT01441882|DRUG|Dasatinib|Given PO
48374772|NCT01441882|OTHER|Laboratory Biomarker Analysis|Correlative studies
48374773|NCT01441882|OTHER|Pharmacological Study|Correlative studies
48374774|NCT01358266|DRUG|DE-109 44 ug|Low dose
48374775|NCT01358266|DRUG|DE-109 440 ug|Medium dose
48374776|NCT01358266|DRUG|DE-109 880 ug|High dose
48374777|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe|Evaluation of therapy of bempedoic acid with PCSK9 inhibitors and ezetimibe in reducing LDL-C in statin-intolerant patients.
48374778|NCT06381947|DRUG|Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe|Evaluation of therapy of PCSK9 inhibitors with ezetimibe in reducing LDL-C in statin-intolerant patients.
48374779|NCT02568501|BEHAVIORAL|Daily feedback|Daily feedback on glucose levels from wireless glucometers
48374780|NCT02568501|BEHAVIORAL|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
48706063|NCT00027378|DRUG|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
48706064|NCT01184833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
48706065|NCT00000554|PROCEDURE|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
48017486|NCT05108493|OTHER|Home exercise program|All participants will start the home exercise program during the study period consisting of range of motion exercises for wrist flexion, extension, ulnar and radial deviation, elbow flexion and extensor; forearm supinator, and pronator muscles; stretching exercises. Eccentric strengthening of the wrist flexor extensors, ulnar and radial deviation, forearm pronation, supination, and strengthening exercise training will be given to the elbow extensors and flexors. Progressive strengthening exercises will be added to the program. The exercise program will be terminated with stretching exercises. The exercises will be performed for 10 repetitions 2 times a day, stay in each position for 10 seconds, and rest for 30 seconds between periods. Both groups will be advised to continue the exercise program for 12 weeks.
48017487|NCT06332794|DEVICE|KOKU4PD|Exercise at home using the KOKU app for 4 weeks.
48017488|NCT03097419|PROCEDURE|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~* The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~* The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~* Five (5) total iterations constitute the treatment.~* The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
48017489|NCT03167294|DEVICE|AquaBeam System|Aquablation
48017490|NCT00403091|BEHAVIORAL|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
48174179|NCT02239081|DRUG|CTP-730|
48174180|NCT02239081|DRUG|Placebo for CTP-730|
48174181|NCT01125462|OTHER|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
48174182|NCT04629937|OTHER|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
48174183|NCT01821729|DRUG|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
48174184|NCT01821729|DRUG|Losartan|Taken orally every day during Phase I for all 8 cycles
48374781|NCT01103076|DEVICE|Polyamide HD membrane|Single use polyamide membrane
48374782|NCT00796367|DRUG|VI-0521|7.5 mg phentermine and 46 mg topiramate
48374783|NCT00796367|DRUG|Placebo|placebo
48374784|NCT00796367|DRUG|VI-0521|15 mg phentermine and 92 mg topiramate
48374785|NCT02751658|OTHER|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
48374786|NCT01300715|PROCEDURE|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
48374787|NCT04996212|PROCEDURE|Walking APP Group|"The participants of this group will be explained their treatment plan by a physiotherapist who will contact them through a video call. This treatment will consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of aerobic exercise: walking.~Participants will consult their treatment plan through an application that will be installed on their mobile phone. They will start with 25 minutes of walking and will increase progressively until they reach 45 minutes.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment.~Participants must perform the proposed exercises, 5 days a week, once a day In addition to the respiratory physiotherapy guideline, they will be given the health education manual."
48374788|NCT04996212|PROCEDURE|Functional APP group|"The participants of this group will be explained their treatment regimen by a physiotherapist who will contact them through a video call. This treatment planwill consist of breathing exercises (abdominodiaphragmatic and pursed lips breathing) and 3 days of functional exercise which involve the activation and performance of large muscle groups. Participants will consult their treatment plan through an application that will be installed on their mobile phone.~A biweekly follow-up will be carried out through a phone call by the research team to find out their health status and evolution with the assigned treatment."
48374789|NCT06137274|RADIATION|Intensity-modulated radiotherapy|All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.
48706066|NCT00000554|PROCEDURE|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
48706067|NCT01289353|DRUG|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
48706068|NCT01289353|RADIATION|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
48706069|NCT02715882|DRUG|CBLB502|
48017491|NCT00403091|BEHAVIORAL|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
48174185|NCT01821729|RADIATION|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
48706070|NCT02715882|DRUG|Placebo|
48174186|NCT01134471|DEVICE|Ostene|applied to sternal surface
48174187|NCT01134471|DEVICE|Bonewax|applied to sternal surface
48174188|NCT05282641|DIETARY_SUPPLEMENT|10 g of collagen hydrolysate|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.
48174189|NCT05282641|DIETARY_SUPPLEMENT|Placebo|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
48174190|NCT00569192|DRUG|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
48174191|NCT00569192|DRUG|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
48174192|NCT00569192|DRUG|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
48174193|NCT06209047|DRUG|bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone|bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
48174194|NCT01702870|PROCEDURE|Magnetic Resonance Imaging|
48174195|NCT06007105|BEHAVIORAL|SUCCEED Community-Based Intervention|"The main components of the intervention are peer support, case management and livelihoods activities, delivered by a peer support worker and a community support worker. The peer support worker has lived experience of psychosis and draws on a variety of manualised tools and techniques adapted from previous studies. The community support worker mobilises families and communities to activate resources in support of participants (e.g., education and employment, social and recreational activities), drawing on established models of mental health case management and community-based inclusive development. The peer support worker and community support worker also run self-help groups for people with lived experience and their family members, respectively. Self-help group meetings are also used as an opportunity for group livelihoods activities taking an ABCD (asset-based community development approach."
48174196|NCT06406868|OTHER|American Cancer Society|"After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down"
48174197|NCT03752255|OTHER|Anxiety measurement method|Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
48706071|NCT00758264|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
48174198|NCT03247361|OTHER|High-intensity IMT + Aerobic/resistance exercise|High-intensity IMT
48174199|NCT03247361|OTHER|Low-intensity IMT + Aerobic/resistance exercise|Low-intensity IMT
48174200|NCT03247361|OTHER|Sham IMT + Aerobic/resistance exercise|Aerobic and resistance exercise
48174201|NCT03477409|OTHER|plasticizers|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
48174202|NCT03455777|DRUG|AKCEA-ANGPTL3-LRX|Single open-label cohort
48706072|NCT00758264|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
48706073|NCT01510145|DRUG|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
48374790|NCT06137274|OTHER|Magnetic Resonance Guidance|All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
48706074|NCT05550870|DIETARY_SUPPLEMENT|Raw fenugreek seed powder|It will be given to group 1
48017492|NCT00079352|DRUG|alvocidib|Given IV
48017493|NCT00079352|DRUG|gemcitabine hydrochloride|Given IV
48017494|NCT00079352|DRUG|irinotecan hydrochloride|Given IV
48174203|NCT03058380|OTHER|Stated-Preferences Evaluation Instrument|A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
48174204|NCT03696641|OTHER|glazed lithium disilicate crowns|glazing of IPS e.max crowns
48174205|NCT03696641|OTHER|polished lithium disilicate crowns|polishing of IPS e.max crowns
48174206|NCT03756168|DEVICE|1060nm Diode laser|"All subjects received a single treatment with Venus Bliss' 1064 nm laser administered to the flanks~Venus Bliss is a non-invasive medical aesthetic device designed for body contouring. The device contains four 1060 nm diode laser applicators which are 60x60 mm in size. It has a separate RF/PEMF applicator, but this was not used in this study. There is a belt included with the system to allow for the secure attachment of the applicators to the treatment area."
48374791|NCT04983589|DRUG|Pilocarpine HCl|Pilocarpine HCl ophthalmic solution 1.25% ocular drops.
48706075|NCT05550870|DIETARY_SUPPLEMENT|Roasted fenugreek seed powder|It will be given to group 2
48706076|NCT04075968|OTHER|Cognitive exercise|Cognitive exercise will be applied
48706077|NCT04075968|OTHER|Home exercise|Home exercise will be applied
48706078|NCT00501592|DRUG|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
48706079|NCT00501592|DRUG|Placebo|Placebo
48706080|NCT00159731|DRUG|Pregabalin|
48706081|NCT04416529|BEHAVIORAL|Tele-MBCT|Please see arm/group description.
48706082|NCT03506451|OTHER|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
48706083|NCT03786302|DRUG|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
48706084|NCT03786302|DRUG|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
48374792|NCT04983589|DRUG|Vehicle|Oxymetazoline HCl and pilocarpine HCl placebo ocular drops.
48374793|NCT03301207|DRUG|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
48706085|NCT06225895|PROCEDURE|general anesthesia|patients will receive general anesthesia.
48706086|NCT06225895|PROCEDURE|Erector spinae plane block|patients will receive Erector spinae plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
48706087|NCT06225895|PROCEDURE|a rhomboid intercostal nerve block|patients will receive a rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.
48706088|NCT06225895|DRUG|Bupivacaine|20 ml of bupivacaine 0.25%
48706089|NCT01817673|DIETARY_SUPPLEMENT|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
48706090|NCT01817673|DIETARY_SUPPLEMENT|placebo|
48706091|NCT02632279|DIETARY_SUPPLEMENT|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
48706092|NCT02632279|DIETARY_SUPPLEMENT|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
48706093|NCT02632279|DEVICE|Stimulator ON|Participants will be tested while their stimulator is turned ON
48706094|NCT02632279|DEVICE|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
48706095|NCT02337530|DRUG|Selumetinib|
48706096|NCT02337530|DRUG|Pemetrexed|
48017495|NCT05012592|BEHAVIORAL|Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children|This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
48017496|NCT05690958|OTHER|Survey|Filling in a survey
48374794|NCT03301207|DRUG|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
48374795|NCT03301207|DRUG|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
48374796|NCT03301207|DRUG|Midazolam|Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
48706097|NCT02337530|DRUG|Cisplatin|
48706098|NCT02337530|DRUG|Carboplatin|
48706099|NCT00182052|DRUG|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
48706100|NCT00182052|OTHER|Placebo|Given orally twice daily.
48706101|NCT04253106|GENETIC|Liquid biopsies (blood, gastric fluid).|Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
48706102|NCT06605872|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. Insulin therapy prescription for the next 24 hours is suggested once daily by the GlucoTab system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the algorithm is to maintain fasting and premeal glucose concentrations between 100-140 mg/dl, (5.6 to 7.8 mmol/l).
48706103|NCT06605872|OTHER|Diabetes Treatment|Diabetes Standard Care
48706104|NCT01242410|DEVICE|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
48017497|NCT00377663|BEHAVIORAL|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
48017498|NCT05662241|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.
48017499|NCT05662241|OTHER|Placebo|Placebo
48174207|NCT05277090|DRUG|2L of polyethyleneglycol|2L of polyethyleneglycol
48706105|NCT01328535|DRUG|temozolomide|Given PO
48706106|NCT01328535|OTHER|flow cytometry|Correlative studies
48706107|NCT01328535|OTHER|staining method|Correlative studies
48706108|NCT01328535|PROCEDURE|biopsy|Optional correlative studies
48706109|NCT01328535|OTHER|laboratory biomarker analysis|Correlative studies
48706110|NCT01342354|RADIATION|Stereotactic Radiation|Escalating Doses of SBRT in periods of three doses over 10 days
48706111|NCT04275271|BEHAVIORAL|Educational intervention|Skill centered Protocol Training based on IMB model
48706112|NCT04753658|DRUG|lorlatinib|Oral
48706113|NCT04732130|BEHAVIORAL|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
48706114|NCT04732130|BEHAVIORAL|Alternate Day Fasting|Participants are instructed to fast every other day.
48706115|NCT01978249|PROCEDURE|Systemic chemotherapy|
48706116|NCT01978249|PROCEDURE|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
48706117|NCT00395291|DRUG|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
48706118|NCT00395291|DRUG|Placebo|Placebo
48706119|NCT02526524|DRUG|Met DR|metformin delayed-release tablets
48706120|NCT02526524|DRUG|Met IR|metformin immediate-release tablets
48706121|NCT02526524|DRUG|Placebo|
48706122|NCT04365543|BEHAVIORAL|Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia|Please see arm/group descriptions
48706123|NCT04365543|BEHAVIORAL|Psychoeducation and Relaxation Therapy (PRT)|Please see arm/group descriptions
48706124|NCT01133405|DRUG|LY2886721|Oral capsules
48706125|NCT01133405|DRUG|Placebo|Oral capsules
48706126|NCT01714206|DRUG|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
48706127|NCT01714206|DRUG|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
48017500|NCT06571786|DRUG|Perflutren lipid microsphere|Definity (Lantheus Medical Imaging, N Billerica, MA) in 25 mL of saline infused for up to 6 minutes
48017501|NCT01310413|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
48017502|NCT01310413|BIOLOGICAL|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
48706128|NCT01714206|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
48017503|NCT05081661|OTHER|Motor Imagery Program|The intervention group of the study will undergo standard postoperative physical therapy treatment at their therapist. Beginning on the third day after surgery, the participant will begin an motor imagery program to be performed three times a week for four weeks. A session lasts between fifteen and twenty minutes. It begins with a body awareness phase followed by a series of three to five one-minute exercises to be repeated three times, with a one-minute break between each exercise. The program is performed independently at home using a standardized audio tape.
48174208|NCT05277090|DIETARY_SUPPLEMENT|inulin|15g inulin per day
48174209|NCT05277090|COMBINATION_PRODUCT|probiotic combination product|"participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
48174210|NCT05441098|OTHER|Neoadjuvant therapy|Preoperative systemic therapy for breast cancer patients
48174211|NCT04773730|PROCEDURE|Posterior transversus abdominus plane block|Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
48516850|NCT06451341|BEHAVIORAL|Staff education|Staff participants will participate in Extension for Community Healthcare Outcomes (Project ECHO) educational sessions with topics such as fundamentals of HIV treatment and care, HIV outcomes, delivery of antiretroviral therapies (ART) including long-acting ART, cultural sensitivity, and social determinants of health in rural areas.
48516851|NCT05494476|PROCEDURE|implant insertion|after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
48516852|NCT05446012|DIAGNOSTIC_TEST|thyroid function tests|blood sample for thyroid function tests (TSH,T3,T3,Anti peroxidase antibody, anti thyroglobulin antibody)
48706129|NCT01384331|DRUG|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
48706130|NCT02451683|OTHER|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
48706131|NCT02451683|OTHER|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
48706132|NCT02451683|OTHER|Training with some stimulation|motor task combined with real or sham stimulation
48706133|NCT03676543|PROCEDURE|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
48706134|NCT00387179|DRUG|Melatonin|5mg, pill, once
48706135|NCT00387179|DRUG|Methylxanthine|2.9 mg/kg, pill, once
48706136|NCT00387179|PROCEDURE|Light Therapy|Bright light exposure
48706137|NCT02200419|OTHER|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
48706138|NCT03993990|BEHAVIORAL|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
48706139|NCT06179628|DRUG|Low bolus concentration and volume|Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
48706140|NCT06444152|OTHER|Sample analysis|This study is analyzing stored samples
48706141|NCT01127555|DRUG|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
48706142|NCT00824551|PROCEDURE|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
48706143|NCT00824551|OTHER|Standard care|Patient will undergo standard care
48706144|NCT05788588|DRUG|HR19006|An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
48706145|NCT05788588|DRUG|All-in-one parenteral nutrition|Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
48706146|NCT05238142|DEVICE|MiniMed™ 780G Insulin Pump system|MiniMed 780G insulin pump with Guardian 4 sensor (phase 1) MiniMed™ 780G BLE 2.0 insulin pump used in combination with Disposable Sensor 5 (phase 2)
48374797|NCT04817319|PROCEDURE|Oral care with/without aerosolization|"These treatments involve instruments that produce aerosolization: ultrasonic scaler, rotary instrumentation for caries care, dental extraction, tooth polishing.~These care correspond to examinations of the oral cavity, intraoral X-rays or even periodontal pocket probing."
48374798|NCT04066842|OTHER|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
48374799|NCT00542074|OTHER|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
48374800|NCT00542074|OTHER|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
48706147|NCT04159987|OTHER|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
48706148|NCT02362516|DRUG|BI 425809|
48706149|NCT03098251|PROCEDURE|3D typing|typing the patient with 3D typing system and give specific treatment
48706150|NCT03098251|PROCEDURE|routine typing|typing the patient with routine typing system and give specific treatment
48706151|NCT04829799|DRUG|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
48706152|NCT04829799|DRUG|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
48706153|NCT02703012|OTHER|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
48706154|NCT06608836|OTHER|an ice massage|an ice massage
48706155|NCT06608836|OTHER|the cold spray|the cold spray
48706156|NCT02323204|BEHAVIORAL|Link for Injured Kids|Psychological First Aid
48706157|NCT02323204|OTHER|So you've been in an accident|Educational materials
48706158|NCT01432145|DRUG|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
48706159|NCT01432145|DRUG|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
48706160|NCT01921374|BIOLOGICAL|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
48706161|NCT01921374|BIOLOGICAL|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
48374801|NCT01510340|BEHAVIORAL|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
48374802|NCT04031469|OTHER|There is no intervention in this study|There is no intervention in this study
48374803|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
48374804|NCT02504099|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
48706162|NCT01921374|BIOLOGICAL|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
48706163|NCT01921374|BIOLOGICAL|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
48706164|NCT01921374|BIOLOGICAL|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
48706165|NCT02924714|OTHER|Discontinuation of imatinib|
48706166|NCT02944227|DRUG|Lucentis|Lucentis fixed-treatment arm
48706167|NCT02958891|OTHER|Data collection|Collection epidemiological dental measures
48706168|NCT00378625|DRUG|Artesunate|
48706169|NCT05232968|OTHER|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
48706170|NCT05232968|OTHER|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
48374805|NCT02504099|DRUG|ribavirin|Tablet
48516853|NCT05628649|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|"Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP)."
48374806|NCT05947656|DEVICE|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
48516854|NCT01199380|BEHAVIORAL|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
48374807|NCT04766658|OTHER|Gargle Phonation|Subjects will gargle water while making sound
48516855|NCT01199380|BEHAVIORAL|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
48516856|NCT01199380|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
48374808|NCT04766658|OTHER|Water swallow|Subjects will hold water in their mouth for 5 seconds and swallow
48706171|NCT04454216|OTHER|No intervention|This is an observational study that consists of data abstraction from patient medical records.
48516857|NCT03751007|BIOLOGICAL|AG019 - Low Dose|Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
48174212|NCT04773730|PROCEDURE|Quadratus lumborum block type 2|Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
48516858|NCT03751007|DRUG|Teplizumab|Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
48706172|NCT06606743|BEHAVIORAL|High-Intensity Interval Training|Participants will receive a total of 20 in-person sessions of 45 minutes duration. Subjects perform high-speed movements with minimal recovery between movements. Hand weight will be used to increase intensity as training progresses.
48706173|NCT06606743|BEHAVIORAL|High-Velocity Circuit Resistance Training|Participants in this group will perform a total of 20 in-person training sessions using 12 resistance exercises performed in 3 circuits with minimal recovery between exercises.
48706174|NCT02418208|DIAGNOSTIC_TEST|Performint EEG tests and BNA analysis|
48706175|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Placebo Product (PP)|1 spray (0 mg melatonin)
48706176|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Active Control (AC)|1 spray (1 mg melatonin)
48706177|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Test Product (TP)|1 spray (0.3 mg melatonin)
48706178|NCT04767178|DRUG|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
48706179|NCT04767178|DRUG|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
48706180|NCT03804021|GENETIC|No Intervention|Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
48706181|NCT04419051|OTHER|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
48706182|NCT02196116|OTHER|PET|PET Scan with \[18F\]-Flutemetamol
48706183|NCT02196116|OTHER|MRI|
48706184|NCT02196116|OTHER|neuropsychological tests|
48706185|NCT05353712|OTHER|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
48706186|NCT05353712|OTHER|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
48706187|NCT05353712|OTHER|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
48706188|NCT05353712|OTHER|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
48706189|NCT05353712|OTHER|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
48706190|NCT05353712|OTHER|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
48374809|NCT04921319|DIAGNOSTIC_TEST|VExUS score|"The care team will be informed of the VExUS immediately after the ultrasound is performed and given a suggested target for the following 24 hours as follows:~* VExUS 0: The patient will likely tolerate more fluid if clinically needed.~* VExUS 1: The patient has evidence of mild venous congestion. The investigators recommend targeting a net neutral or negative fluid balance with diuresis.~* VExUS 2-3: The patient has evidence of moderate to severe venous congestion. The investigators recommend targeting a fluid balance of negative 1-2L with diuresis. If the investigator cannot obtain ultrasound images of sufficient quality to calculate VExUS, the care team will be informed that there is no recommendation for that subject on that day."
48516859|NCT03751007|DRUG|Placebo-AG019|Formulated identically to AG019 with the active ingredient removed.
48706191|NCT06140381|PROCEDURE|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
48017504|NCT05081661|OTHER|Placebo program|"The control group of the study will undergo standard postoperative physiotherapy treatment at their therapist. On the third day after surgery, the participant will begin a relaxation program inspired by the mindfulness tool called Bodyscan that acts as a placebo mental imagery program. Nevertheless, the program created for this technique does not follow the Bodyscan guidelines (Jon Kabat-Zinn, 2005), as we do not want there to be any effects in favor of improved body perception on the participants, which could bring an additional biai to the study. For the sake of understanding, we have used the term body visualization in the various documents distributed to the participants. The program is to be performed three times a week for four weeks. A session lasts between ten and fifteen minutes. The program is performed independently at home using a standardized audio tape."
48017505|NCT06214585|PROCEDURE|Intermittent heat and cold versus heat-only therapy|for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.
48017506|NCT06214585|PROCEDURE|Heat- only Therapy|hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
48017507|NCT02522897|DRUG|Ranibizumab|
48017508|NCT02522897|DEVICE|Laser|
48017509|NCT02104557|OTHER|Non intervention|Non intervention
48017510|NCT02104557|OTHER|Non intervention|Non intervention
48017511|NCT06317792|OTHER|online exergaming-based physiotherapy programs|The online exergaming-based physiotherapy programs focus on training in shoulder, hip, and knee ROM balance, weight-bearing, strength, weight shifting, and walking based on RF in machine learning to the features selection in patients with PIGD. The training tasks consist of a set of 10 pieces of training (20 min per session, five sessions every week, for 8 weeks). Five exergaming programs were used for training, designed to incorporate an appropriate level of challenge to match the ability and fitness of patients with PD.
48017512|NCT03559686|DRUG|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
48706192|NCT06140381|PROCEDURE|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
48706193|NCT01491386|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
48706194|NCT01491386|DEVICE|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
48017513|NCT06664086|BEHAVIORAL|economic and psychological burden|measuring the economic and psychological burden of infertility
48017514|NCT03621267|OTHER|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
48017515|NCT03621267|OTHER|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
48174213|NCT00741208|DIETARY_SUPPLEMENT|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
48174214|NCT02719262|DEVICE|installing ventilation in the workplace|Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
48174215|NCT02757313|DRUG|Low dose THC marijuana|
48174216|NCT02757313|DRUG|High dose THC marijuana|
48174217|NCT02757313|DRUG|Placebo marijuana|
48174218|NCT03163043|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
48374810|NCT01359774|OTHER|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
48516860|NCT03751007|DRUG|Placebo-Teplizumab|Formulated identically to teplizumab with the active ingredient removed.
48516861|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks
48516862|NCT03751007|BIOLOGICAL|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 8 weeks.
48706195|NCT05010369|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
48706196|NCT05010369|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
48706197|NCT05010369|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
48706198|NCT04886544|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
48706199|NCT04442256|DRUG|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
48706200|NCT01459640|DRUG|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
48706201|NCT01459640|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
48706202|NCT03867786|BEHAVIORAL|Exercise|Participants will complete an acute exercise visit.
48706203|NCT03867786|BEHAVIORAL|Video Control|Participants will complete a video control visit.
48706204|NCT05791409|DRUG|Epcoritamab|Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
48706205|NCT05791409|DRUG|Venetoclax|All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
48706206|NCT00481715|BEHAVIORAL|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
48516863|NCT05909280|OTHER|Pressure-volume loop measurements|Pressure-volume loop measurements using a conductance catheter
48516864|NCT01711463|DRUG|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
48706207|NCT00481715|BEHAVIORAL|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
48706208|NCT03730961|DRUG|BMS-986231|Intravenous administration
48706209|NCT03730961|DRUG|Furosemide|Intravenous administration
48706210|NCT03730961|DRUG|Placebo|Intravenous administration
48706211|NCT02635139|BEHAVIORAL|Breakfast skipping|18h fasting period in the morning
48706212|NCT02635139|BEHAVIORAL|Dinner skipping|18h fasting period in the evening
48706213|NCT01338077|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
48706214|NCT01338077|DRUG|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
48516865|NCT01711463|DRUG|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
48706215|NCT02240823|OTHER|adipose derived stem cells|
48706216|NCT04301479|DRUG|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
48706217|NCT04301479|DRUG|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
48706218|NCT05975008|BEHAVIORAL|RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness|Brief virtual mindfulness-based intervention
48706219|NCT02019446|DEVICE|Laser Treatment YAG laser|YAG Laser / FOX Laser
48706220|NCT02019446|DRUG|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
48706221|NCT03517514|OTHER|Physical Therapy service|routine physical therapy care
48706222|NCT02520258|OTHER|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
48017516|NCT05728112|OTHER|Hydrogen Inhalation|The manufacturer will install a hydrogen inhalation machine (hydrogen inhalation or air inhalation) at the subject's home and explain the relevant operation methods. The research executor will pay attention to the LINE group on the first day of installation, and obtain the pre-test basic value data through the google form After (baseline data), continuous hydrogen inhalation was performed daily, and four post-test evaluations were performed before the inhalation and on the 1st, 3rd, 7th, and 14th days after the inhalation was started.
48374811|NCT01359774|OTHER|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
48374812|NCT02026986|BEHAVIORAL|sleep deprivation|sleep deprivation for one night
48374813|NCT04249934|DIETARY_SUPPLEMENT|Caffeinated Coffee|A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
48374814|NCT04249934|DIETARY_SUPPLEMENT|DecaffeinatedCoffee|A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
48374815|NCT01920841|OTHER|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
48374816|NCT01920841|OTHER|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
48374817|NCT03165409|BIOLOGICAL|Nivolumab|Melanoma intervention
48706223|NCT02520258|OTHER|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
48017517|NCT05728112|OTHER|Ordinary Air Inhalation|The control group was inhaled with the same machine as the experimental group, but the gas was only ordinary air, which was used as a placebo control.
48174219|NCT02987998|DRUG|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
48174220|NCT02987998|DRUG|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
48374818|NCT03165409|BIOLOGICAL|Ipilimumab|Melanoma intervention
48374819|NCT06344676|OTHER|Cognitive|Tree 10 minutes individual sessions per week involving memory, attention and executive functions tasks.
48374820|NCT06344676|OTHER|Mobility|Two 30 minutes group session per week involving physical activity assisted by a social robot.
48374821|NCT06344676|OTHER|Social|One 60 minutes group session per month assisted by a social robot that facilitates talking about costumes and traditions.
48374822|NCT06344676|OTHER|Relational|Unrestricted individual interaction of the user with the Pepper robot to obtain information of interest for the user (menu, time, date, place and calendar of activities of the residential. center) and 1 individual monthly videoconference with the family of 10 minutes of duration.
48374823|NCT06344676|OTHER|Usual Care|Attentions and treatments received by the persons before the enrollment in the study.
48374824|NCT04856566|DRUG|Low Marijuana, Hash, THC, or Grass|Cannabis with low amount of THC
48374825|NCT04856566|DRUG|High Marijuana, Hash, THC, or Grass|Cannabis with high amount of THC
48374826|NCT04856566|DRUG|Placebo|Placebo drug with no THC
48706224|NCT04597021|DEVICE|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
48706225|NCT04152551|DRUG|Risedronate Oral Tablet|Oral bisphosphonate
48706226|NCT05268393|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
48706227|NCT02286934|DRUG|Carvedilol|"* Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd"
48706228|NCT02286934|OTHER|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
48706229|NCT01955434|DRUG|Cyclophosphamide|Given PO
48706230|NCT01955434|OTHER|Laboratory Biomarker Analysis|Correlative studies
48017518|NCT06663033|PROCEDURE|colorectal surgery|surgery for colorectal cancer
48374827|NCT04856566|DRUG|0.05 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.05
48374828|NCT04856566|DRUG|0.08 BAC Alcohol|Amount of alcohol when consumed leads to BAC of 0.08
48374829|NCT04755491|DEVICE|Continuous veno-venous hemofiltration|Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
48374830|NCT04755491|DEVICE|Continuous veno-venous hemodialysis|Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
48706231|NCT01955434|OTHER|Pharmacological Study|Correlative studies
48374831|NCT04755491|DEVICE|Continuous veno-venous hemodiafiltration|Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
48374832|NCT05151874|DRUG|Abobotulinum toxin A|To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.
48706232|NCT01955434|OTHER|Quality-of-Life Assessment|Ancillary studies
48706233|NCT01955434|DRUG|Smac Mimetic LCL161|Given PO
48374833|NCT05711459|DRUG|Bicyclol tablets|Take Bicyclol tablets for the treatment of liver injury.
48374834|NCT02780180|DRUG|QGC001|
48374835|NCT02780180|DRUG|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
48374836|NCT02983305|DEVICE|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
48374837|NCT03580746|PROCEDURE|Taping and posteromedial release|
48017519|NCT06127420|OTHER|coronary physiological indices|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Resting full-cycle ratio, Coronary Flow Reserve, Microvascular resistance
48374838|NCT03580746|PROCEDURE|Ponseti|
48374839|NCT05659082|DEVICE|Laser Interstitial Thermal Therapy|Ventral capsulotomy for OCD using laser interstitial thermal therapy
48706234|NCT06475209|DRUG|Adebrelimab combined with Apatinib|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
48374840|NCT03882567|OTHER|Electro Neuro adaptative Regulator|The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
48017520|NCT06654999|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|"DERM variants + and DS"
48174221|NCT02987998|DRUG|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
48706235|NCT06350942|PROCEDURE|one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU)|A 12 mm transverse incision was made just above the iliac crest, followed by careful dissection of the fascia and muscle layer to expose the Gerota's fascia. Entry into the retroperitoneal space was achieved with a 10-mm balloon trocar, allowing for pneumoretroperitoneum establishment. Using a 10-mm laparoscope equipped with a Maryland dissector, the ureters were dissected and isolated, followed by careful exteriorization of both upper and lower pole moiety ureters with a Babcock grasper. The pathological upper pole moiety ureter was transected, preserving the normal lower pole moiety ureter and shared blood supply, and closed with a Vicryl 4/0 suture. Subsequently, an end-to-side ureteroureterostomy was performed with a 6/0 Polydioxanone running suture, with antegrade insertion of a double J stent if not previously conducted. A final retroperitoneoscopic evaluation ensured proper anastomosis alignment, and the incision was closed without drainage.
48017521|NCT04315285|BEHAVIORAL|Treadmill gait training with verbal instruction|Each participant will receive 12 treatment with special verbal instruction which depends on participant's group. Each training session will last 60 minutes, including 5 minutes of warm-up stretching exercise, 40 minutes of treadmill training, and 15 minutes of over-ground gait and balance training. Throughout the 40 minutes of treadmill walking, the participants will walk on the level of 0% slope with a body-weight support system (LikorallTM 200, Liko, Sweden) used to protect the participants from falling; no actual weight support of the body will be provided. The frequency of intervention will be 2-3 days a week, spread across 4-6 weeks. The intervention protocols will be the same for all groups except the instruction provided to the participants in each group.
48017522|NCT04978038|DRUG|mRNA- COVID-19|Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
48017523|NCT04978038|DRUG|Prevnar13|Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
48706236|NCT05884112|DEVICE|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
48706237|NCT05884112|DEVICE|sham control|sham control
48174222|NCT02987998|DRUG|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
48374841|NCT03903575|PROCEDURE|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
48374842|NCT03903575|PROCEDURE|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
48516866|NCT01531517|DRUG|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
48174223|NCT05985902|OTHER|Core Stabilization Exercises|"Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus ma"
48174224|NCT05985902|OTHER|Schroth Exercises|In the Schroth exercise training, there are 3-dimensional exercises that include the principles of axial reach, deflection, derotation, rotational breathing and stabilization.
48174225|NCT02715427|OTHER|Conventional care|
48174226|NCT02715427|OTHER|Enhanced recovery|
48174227|NCT01913626|BEHAVIORAL|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
48174228|NCT05380128|GENETIC|Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms|Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
48174229|NCT03818243|BEHAVIORAL|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
48174230|NCT05949645|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
48174231|NCT00263575|DRUG|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
48374843|NCT06118216|PROCEDURE|rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia|After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.
48374844|NCT06118216|PROCEDURE|intravenous patient-controlled anesthesia|After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
48706238|NCT03390478|OTHER|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
48706239|NCT01598753|DRUG|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
48374845|NCT04621227|DRUG|PF-06882961|120 mg and 200 mg BID
48017524|NCT02138318|OTHER|High definition (HD) endoscopy|
48017525|NCT02138318|OTHER|chromoendoscopy|
48017526|NCT02822794|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
48017527|NCT02822794|DRUG|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
48017528|NCT01003431|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|\[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)\] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
48374846|NCT04621227|DRUG|Rosuvastatin|10 mg single dose
48374847|NCT04621227|DRUG|Midazolam|2mg single dose
48374848|NCT03678649|DRUG|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
48374849|NCT00439920|DRUG|High-dose anthracycline|
48374850|NCT03625102|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
48374851|NCT03625102|OTHER|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
48706240|NCT01598753|DRUG|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
48706241|NCT01598753|BEHAVIORAL|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
48706242|NCT01598753|BEHAVIORAL|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
48706243|NCT03424369|PROCEDURE|Tympanoplasty|Tympanoplasty
48706244|NCT00551915|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
48706245|NCT00551915|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
48706246|NCT00551915|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
48017529|NCT01003431|BIOLOGICAL|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
48174232|NCT05523856|PROCEDURE|Active Surveillance|It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.
48174233|NCT05523856|PROCEDURE|Robot-Assisted Radical Prostatectomy|It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.
48174234|NCT05523856|RADIATION|Intensity-Modulated Radiotherapy|Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.
48174235|NCT05523856|RADIATION|Real-time brachytherapy|Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
48174236|NCT01721746|BIOLOGICAL|BMS-936558|
48174237|NCT01721746|DRUG|Dacarbazine|
48174238|NCT01721746|DRUG|Carboplatin|
48174239|NCT01721746|DRUG|Paclitaxel|
48174240|NCT00244907|DIETARY_SUPPLEMENT|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
48174241|NCT05036525|DEVICE|HANBIO BarriGel|an anti-adhesive product
48174242|NCT01644188|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
48174243|NCT01644188|DRUG|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
48174244|NCT01644188|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
48174245|NCT01644188|DRUG|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
48374852|NCT05609656|DEVICE|Irreversible electroporation|"Percutaneous ablation of a metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use."
48017530|NCT01003431|BIOLOGICAL|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
48174246|NCT01644188|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
48174247|NCT05614323|OTHER|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
48174248|NCT01006889|DRUG|Exenatide|The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
48374853|NCT05609656|DEVICE|Calcium electroporation|"Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor.~The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved."
48374854|NCT05609656|DRUG|Pembrolizumab|"Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months~Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
48374855|NCT00283621|DRUG|Aranesp (darbepoetin alfa)|
48374856|NCT00283621|DRUG|Neulasta (pegfilgrastim)|
48374857|NCT00283621|DRUG|Adriamycin|
48374858|NCT00283621|DRUG|Ifosfamide|
48017531|NCT04180202|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
48017532|NCT06573437|DEVICE|Vascular Stent - Vesto Endoprosthesis|Vascular Stent Implant - Vesto Endoprosthesis
48017533|NCT04961333|BEHAVIORAL|Multidisciplinary Rehabilitation|Body therapies to improve breathing, normalise dysfunction in the autonomic nervous system, relaxation, mindfulness, in some part Acceptance and Commitment Therapy given preferably through body therapies.
48028592|NCT04223011|BEHAVIORAL|In-Hospital Recovery Coach Intervention|The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
48374859|NCT02500173|RADIATION|Radiation|Radiation therapy
48374860|NCT06286878|DRUG|Placebo|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
48374861|NCT06286878|DRUG|Dapagliflozin|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
48516867|NCT01531517|DRUG|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
48028593|NCT01359553|OTHER|Intra-articular ultrasound imaging of knee joint during arthroscopy|
48516868|NCT01061801|BEHAVIORAL|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
48516869|NCT05924412|DRUG|Intravenous study drug|40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
48516870|NCT05924412|OTHER|Intravenous saline solution|Saline solution (same volume as the study drug) will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incision
48516871|NCT00633347|DRUG|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
48516872|NCT00633347|DRUG|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
48516873|NCT06465836|PROCEDURE|O, lreay suture|bilateral uterine artery ligations as described by O- lreay technique in addition to standard conservative methods. Briefly two large vicryl stitches were passed using a large sized needle below and lateral to the lower edge of the uterine incision angle in anteroposterior direction and then redirected from back to the front through avascular window in the posterior leaf of the broad ligament just lateral to the uterine border taking care to avoid injury to bowel posteriorly or bladder/ureter anteriorly. The stitches were tied securely anteriorly
48516874|NCT06465836|PROCEDURE|modified O, lreay suture|"1. Pack Douglas- pouch with a towel.~2. Straight the used vicryl needle mostly no 1.~3. Try to compress and approximate anterior and posterior uterine walls.~4. Start from anterior to posterior 3- 4 cm medial to lateral uterine margin and then pass from posterior to anterior through avascular area in the broad ligament. And we repeat the procedure on the other side. We can repeat this method of uterine ligation at another different plane if needed."
48516875|NCT04005066|DRUG|Elunate®|The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
48516876|NCT05980689|DRUG|AK104|During neo-CRT: 2 cycles of AK104, 10mg/kg d1 q3w. After neo-CRT: 3 cycles of AK104, 10mg/kg d1 q3w.
48516877|NCT05980689|DRUG|Capecitabine|During neo-CRT: 825mg/m2 bid Monday-Friday per week
48028594|NCT01359553|OTHER|Non-invasive ultrasound imaging of knee|
48028595|NCT01359553|OTHER|Quantitative MRI imaging of knee|
48028596|NCT01359553|OTHER|Contrast-enhanced CT imaging of knee|
48028597|NCT04593992|DEVICE|HTEMS|high-tone external muscle stimulation
48028598|NCT04593992|DEVICE|Placebo|Placebo stimulation
48028599|NCT00804947|DRUG|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
48028600|NCT02596451|DRUG|Diclofenac Sodium gel, 1%|
48028601|NCT02596451|DRUG|Voltaren® Gel|
48028602|NCT02596451|DRUG|Placebo|
48028603|NCT05524194|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
48028604|NCT06481241|COMBINATION_PRODUCT|CAR-T cells|CAR-T cells as consolidation therapy
48028605|NCT06481241|DRUG|Venetoclax|VEN
48028606|NCT02281006|DRUG|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
48028607|NCT06349902|BEHAVIORAL|Re-Link|The HCV nurse will attempt to contact the PWDU HCV via phone call and text. If unable to connect with a client via phone, an alert is added to the client's chart in the electronic medical record. When the client presents to the CBSUTP for their regular substance use follow up appointment, the chart alert is flagged by the administrative team and the client is connected with the HCV nurse via telemedicine. Clients who are connected to the HCV team are considered re-linked. The HCV nurse will provide an HCV intake as per program guidelines. Clients who would prefer to pursue treatment elsewhere will be supported with a referral to their family doctor or an alternative HCV program in the community. Clients who choose to be treated at the CBSUTP will receive a HCV consultation, DAA treatment and follow-up from the HCV clinical team onsite as per existing program guidelines.
48028608|NCT06536062|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
48028609|NCT06627283|DEVICE|IMT|Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
48028610|NCT06627283|DEVICE|EMT|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.
48174249|NCT02761863|OTHER|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
48174250|NCT03131349|DIAGNOSTIC_TEST|serum zinc and iron|history ,examination,investigations
48174251|NCT03669328|PROCEDURE|locoregional anesthesia|Both groups received locoregional anesthesias
48174252|NCT06021587|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
48174253|NCT06021587|DRUG|No Levosimendan|Without Levosimendan Infusion
48706247|NCT00551915|BIOLOGICAL|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
48706248|NCT00551915|BIOLOGICAL|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
48174254|NCT05159986|PROCEDURE|Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week|Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).
48174255|NCT05159986|OTHER|Group that received exercise during eight weeks with three sessions a week|The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
48374862|NCT04162756|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
48374863|NCT04162756|DRUG|Fludarabine|Administered per package insert
48706249|NCT02193035|OTHER|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
48174256|NCT02950181|DEVICE|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
48174257|NCT04660578|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
48174258|NCT05955963|OTHER|Abdominal auscultation|spectral analysis of Bowel sounds
48374864|NCT04162756|DRUG|Cyclophosphamide|Administered per package insert
48374865|NCT00006001|DRUG|semaxanib|
48374866|NCT02722902|DRUG|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
48516878|NCT05980689|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
48516879|NCT05656027|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
48706250|NCT06605833|DIAGNOSTIC_TEST|Lead ECG|"Participants will undergo a standard 12 lead ECG in order to record the electrical activity of the heart. This typically takes a few minutes and the ECG is read by a cardiologist~This is a Standard of Care test being performed at a non Standard of Care timepoint"
48706251|NCT06605833|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|"A transthoracic echocardiogram will be performed in accordance to standard British Society of Echocardiography guidelines. This will involve undertaking an ultrasound scan of the participant's heart with ultrasound jelly to obtain information including left ventricular function and valvular function.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
48174259|NCT06215287|OTHER|Physician survey|Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
48174260|NCT05846308|BEHAVIORAL|Structured synchronous physical training|"The instructors and the participants will form a circle facing each other while doing the physical exercises. To facilitate interpersonal synchrony, the participants will be instructed to do the same physical exercises (spatial synchrony) together at the same pace (rhythmic synchrony). Each session will consist of four parts:~1. Warm-up (10 minutes)~2. Social Game (10 minutes)~3. Main training (30 minutes): Each session will contain two sets, each consisting of seven fixed exercises with a resting period of 10-15 seconds between each. Each exercise will be performed at one of three different paces: Slow - one movement cycle per 2 seconds, Medium - one movement cycle per 1 second and Fast - two movement cycles per 1 second.~4. Cool-down (10 minutes)"
48374867|NCT02722902|DIETARY_SUPPLEMENT|IntraLipid|Lipid emulsion for infusion
48374868|NCT02722902|DIETARY_SUPPLEMENT|Placebo|Saline will be used as placebo
48374869|NCT03374774|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
48374870|NCT06006026|DRUG|Ropivacaine Hydrochloride 10 MG/ML [Naropin]|According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
48374871|NCT01355380|DRUG|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
48374872|NCT00717665|DEVICE|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
48374873|NCT00717665|OTHER|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
48374874|NCT03063931|DRUG|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
48374875|NCT03063931|DRUG|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
48516880|NCT05656027|DRUG|Aceclidine|LNZ100 Aceclidine ophthalmic solution
48374876|NCT00552656|DEVICE|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
48374877|NCT05673954|DIAGNOSTIC_TEST|C-Read test|C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
48374878|NCT02264925|DEVICE|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
48374879|NCT06289959|DIAGNOSTIC_TEST|cfDNA|After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.
48374880|NCT03678909|PROCEDURE|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
48374881|NCT01056458|OTHER|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
48374882|NCT01056458|OTHER|sham acupressure|use only tape without ear adhesive beads under the same ways
48706252|NCT06605833|DIAGNOSTIC_TEST|Cardiac MRI|"A cardiac MRI scan will be performed in order to assess the morphology and function of the heart in accordance with international guidelines. Data that will be derived includes biventricular volumes and function and myocardial strain data.~This is a Standard of Care test being performed at a non Standard of Care timepoint"
48017534|NCT05901129|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
48017535|NCT03317990|PROCEDURE|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
48017536|NCT03317990|PROCEDURE|Standard RARP|Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
48374883|NCT03683264|OTHER|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
48017537|NCT05443984|DRUG|JP-1366 20mg|1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
48374884|NCT04035707|DRUG|Rocuronium|using rocuronium as a relaxants during general anaesthesia
48374885|NCT04035707|DRUG|general volatile anaesthesia|method of anaesthesia
48374886|NCT02859025|BIOLOGICAL|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
48374887|NCT02859025|BIOLOGICAL|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
48374888|NCT02859025|BIOLOGICAL|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
48374889|NCT00984100|PROCEDURE|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
48516881|NCT05656027|DRUG|Brimonidine|Brimonidine ophthalmic solution
48706253|NCT06605833|DIAGNOSTIC_TEST|Cardiac Biomarker Screening|"* Cardiac Troponin I,~* NTproBNP\],~* lipid profile,~* HbA1c~* ferritin~These are Standard of Care tests being performed at a non Standard of Care timepoint"
48706254|NCT06605833|OTHER|Basic Observations|"* Heart rate~* Blood pressure~* Oxygen SAT~* Respiratory rate~These are Standard of Care observations being performed at a non Standard of Care timepoint"
48706255|NCT05319483|OTHER|No intervention|No intervention.
48706256|NCT01284478|DRUG|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
48374890|NCT00235300|BIOLOGICAL|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
48374891|NCT00235300|DRUG|Simulect (basliximab)|20 mg per day on 2 days
48017538|NCT05443984|DRUG|Esomeprazole 40mg|1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
48374892|NCT02999516|OTHER|Motor imaginary|Participants imagine doing a motor task watching a video recording
48374893|NCT02999516|OTHER|Non Motor imaginary|Participants watch a television documentary
48516882|NCT02213653|DRUG|ARM A : IV iron + epoietin zeta|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~* Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~  * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
48516883|NCT02213653|DRUG|ARM B: IV iron + epoietin zeta sequence|"* Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1."
48516884|NCT02213653|DRUG|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
48516885|NCT02010645|DRUG|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
48516886|NCT02010645|DRUG|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
48706257|NCT00387374|BIOLOGICAL|bevacizumab|Given IV
48017539|NCT05976334|DRUG|[14C] Subasumstat|\[14C\] Subasumstat IV infusion.
48174261|NCT05846308|BEHAVIORAL|Structured non-synchronous physical training|The participants will do the same physical exercises as the participants in the synchronous group but in the form of circuit training with seven stations. The circuit training will require the participants to do a different physical exercise at a different pace at each station. A detailed description of the exercises will be provided for each station. The instructors will demonstrate all the exercises before the beginning of training. The participants will be instructed to do the exercise for a set period of time, the same duration used in the synchronous group. The circuit training stations will be in the form of a circle but will be set up so that the participants do not to face each other when doing the exercises to prevent spontaneous synchronization. Each session will consist of four parts, the same as in the synchronous intervention.
48516887|NCT03140787|DRUG|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
48374894|NCT02999516|OTHER|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
48374895|NCT02999516|OTHER|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
48516888|NCT03140787|DRUG|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
48516889|NCT04189601|DIAGNOSTIC_TEST|Complement measurements|Blood and urine tests to assess the complement activation state
48516890|NCT03840564|OTHER|Point of care (POC)|All the analyzes will be done in delocalized
48516891|NCT01188512|BIOLOGICAL|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
48516892|NCT01188512|BIOLOGICAL|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
48516893|NCT00852007|BIOLOGICAL|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
48706258|NCT00387374|DRUG|paclitaxel|Given IV
48017540|NCT05976334|DRUG|Subasumstat|Subasumstat IV infusion.
48706259|NCT00387374|DRUG|carboplatin|Given IV
48706260|NCT00387374|RADIATION|radiation therapy|Undergo radiotherapy
48706261|NCT04194736|OTHER|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
48017541|NCT06034158|DRUG|single-dose madopar, single-dose propranolol, and single-dose placebo by order|Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
48017542|NCT06034158|DRUG|single-dose madopar, single-dose placebo, and single-dose propranolol by order|Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
48374896|NCT02999516|OTHER|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
48374897|NCT02999516|OTHER|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
48374898|NCT06191757|BEHAVIORAL|supported with the developmental support program|Babies were developmentally supported with the developmental support program
48374899|NCT04822467|DEVICE|SQ53 Wipe|SQ53-based wipe to be used by the participant daily or upon dressing change
48374900|NCT04822467|DEVICE|Ethanol Wipe|Ethanol-based wipe to be used by the participant daily or upon dressing change
48017543|NCT06034158|DRUG|single-dose propranolol, single-dose madopar, and single-dose placebo by order|Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
48706262|NCT04174989|OTHER|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
48706263|NCT04174989|OTHER|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
48017544|NCT06034158|DRUG|single-dose propranolol, single-dose placebo, and single-dose madopar by order|Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
48017545|NCT06034158|DRUG|single-dose placebo, single-dose propranolol, and single-dose madopar by order|Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
48017546|NCT06034158|DRUG|single-dose placebo, single-dose madopar, and single-dose propranolol by order|Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
48017547|NCT05059015|DIAGNOSTIC_TEST|CERVICAL HPV|A screening test with an HPV test is performed by a health professional plus cytology taking, if it reports positive, colposcopy and biopsy are taken, those with a CIN2 + report are directed to receive treatment.
48017548|NCT05059015|DIAGNOSTIC_TEST|SELF SAMPLING HPV|A screening test is performed with an HPV test by self-testing, if it reports positive, women will receive ablative treatment according to eligibility criteria. If they do not meet the criteria for ablation, they will be referred for excisional treatment.
48017549|NCT00042328|DRUG|Valacyclovir|
48174262|NCT02713971|DEVICE|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
48174263|NCT02713971|OTHER|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
48174264|NCT05590143|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
48174265|NCT05590143|DRUG|Placebo|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
48706264|NCT06178536|PROCEDURE|Bone Consumption|The surgery will be done using a bone consumption protocol
48706265|NCT06178536|PROCEDURE|Bone expansion|implants will be placed after a bone expansion protocol
48706266|NCT04698785|DRUG|Treatment by regorafenib and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment"
48516894|NCT04708015|OTHER|No Intervention|A retrospective chart review of medical records
48017550|NCT00459134|DIETARY_SUPPLEMENT|ArginMax|Given orally
48017551|NCT00459134|DIETARY_SUPPLEMENT|Placebo|Given orally
48017552|NCT00178958|DEVICE|Holter Monitor|
48017553|NCT05494125|OTHER|Ropivacaine|Patients will receive a continuous infusion of ropivacaine through bilateral ESP catheters
48017554|NCT05494125|OTHER|Placebo|Patients will receive a continuous infusion of saline solution through bilateral ESP catheters
48174266|NCT00000133|PROCEDURE|Trans-scleral Cryotherapy|
48174267|NCT00037895|PROCEDURE|Ambulation training|
48174268|NCT02622256|BEHAVIORAL|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team \& may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
48174269|NCT05971628|PROCEDURE|RAPID procedure|RAPID procedure stands for Resection And Partial Liver Transplantation with Delayed Hepatectomy for hepatocellular carcinoma
48174270|NCT02332200|OTHER|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
48706267|NCT02683070|PROCEDURE|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
48706268|NCT02683070|DRUG|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
48706269|NCT05098938|DRUG|Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|Oral (upper gum area), 50mg, 1 tablet.
48706270|NCT05098938|DRUG|Placebo|Oral (upper gum area), 1 table.
48706271|NCT05088083|DEVICE|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
48706272|NCT00063895|DRUG|erlotinib hydrochloride|Given PO
48706273|NCT00063895|OTHER|pharmacological study|Correlative studies
48706274|NCT00063895|OTHER|pharmacogenomic studies|Correlative studies
48706275|NCT00063895|OTHER|laboratory biomarker analysis|Correlative studies
48706276|NCT01656343|DRUG|Calcineurin inhibitors (CNI)|No Intervention
48706277|NCT01656343|DRUG|Belatacept|No Intervention
48706278|NCT02471274|DRUG|sotagliflozin|single 400 mg dose
48706279|NCT03344107|OTHER|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after RIRS
48706280|NCT02704923|DRUG|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
48706281|NCT02704923|DRUG|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
48706282|NCT03920293|BIOLOGICAL|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
48706283|NCT03920293|DRUG|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
48706284|NCT02007057|PROCEDURE|Suprascapular nerve block|
48706285|NCT02007057|PROCEDURE|Interscalene nerve block|
48706286|NCT00000344|DRUG|Buprenorphine/naloxone|
48706287|NCT06313008|DRUG|Empagliflozin 10 MG|eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
48706288|NCT06313008|DRUG|Vildagliptin 50 MG|eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
48706289|NCT04346108|BIOLOGICAL|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
48706290|NCT04346108|BIOLOGICAL|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
48706291|NCT05340387|OTHER|Balance Resistance Aerobic Cognitive exercises (BRACE)|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. Week 1-3 : Balance: Romberg, tandom standing, single leg stance Resistance: chair rise Aerobic exercises: 6mint walk Cognitive: count reverse from 50 Week 4-6: Balance: Sit to stand, functional reach, Tug Test Resistance: stair climbing Aerobic Exercises: Marching in space Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Perturbation, throwing a ball, kicking a ball Resistance: Floor transfer, squatting Aerobic Exercises: Cycling Cognitive: Count even number from 1-50, calculation, addition, subtraction, multiplication division Week 10-12: Balance: Combination of All Resistance: Combination of All Aerobic Exercises: 6 minutes' walk test, marching steps, cycling Cognitive: Combination of all
48706292|NCT05340387|OTHER|Otago's Protocol|"Study will be conducted after the approval of Ethical review board. The Otago's exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. WEEK 1-3: Warm up: March, head movement, neck movement, back extension, trunk movement, ankle movements Strength: Front knee strengthening, Back knee strengthening, Side hip strengthening, Calf raises, Toe raises (10 repetitions each) Balance: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel toe stand), Tandem walk (heel toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backwards, Sit to stand, Stair walking. (10 repetitions each) Flexibility: calf stretch, back of thigh stretch Hold for 10 to 15 seconds and repeat on other leg.~Walk: 5 or 10 minutes' walk~This protocol will be followed for 12 weeks with increased repetitions after every 3 week."
48706293|NCT04213781|DEVICE|HappyMed Video Glasses|HappyMed allows the immersion of patients in films, cartoons or concerts.
48706294|NCT04213781|DRUG|Propofol|The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
48706295|NCT04213781|DRUG|Sufentanil|0.1 µg/kg
48706296|NCT01598883|DRUG|Heparin|150 U/kg
48706297|NCT01598883|DRUG|ATryn|1000 IU
48706298|NCT03054350|DRUG|Vadadustat|Daily oral dose
48174271|NCT06410339|DIAGNOSTIC_TEST|Ultrasound|ultrasound of flexor tendons on hands
48706299|NCT03054350|DRUG|Placebo|Daily oral dose
48706300|NCT05037448|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
48174272|NCT06260241|PROCEDURE|Traction Dressing|Traction dressing will be applied to one group for 24 hours and simple dressing to the other group.
48174273|NCT06260241|OTHER|Without Traction Dressing|Without Traction Dressing
48174274|NCT00678977|DRUG|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
48706301|NCT05971030|DEVICE|Cortical brain stimulation of mPFC and dlPFC|Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
48174275|NCT00678977|DRUG|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
48174276|NCT00678977|DRUG|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
48706302|NCT02103725|DRUG|pimecrolimus 10 mg/g cream|
48706303|NCT02103725|DRUG|Vehicle cream|
48706304|NCT04086368|DEVICE|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
48706305|NCT04086368|DEVICE|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
48706306|NCT04188418|DRUG|Fentanyl Citrate Buccal Tablet|Given transmucosally
48706307|NCT04188418|DRUG|Morphine|Given PO
48706308|NCT04188418|OTHER|Physical Performance Testing|Complete shuttle walk test
48706309|NCT04188418|OTHER|Placebo Administration|Given PO
48706310|NCT04188418|OTHER|Quality-of-Life Assessment|Ancillary studies
48174277|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
48174278|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
48174279|NCT03217461|PROCEDURE|CorneaL epithelial autograft|After removal of the recipient's diseased dermoid, a size-match donor epithelial tissue will be obtained from the healthy area of the same eye (corneal epithelial autograft) using femtosecond laser technology, with the goal of closure of bare stromal area by sutured corneal epithelial tissue to ensure the integrity of ocular surface. This closure may also create a microenvironment that stimulates stromal cells' regenerative capacity and regulates their epithelial-mesenchymal transition process.
48174280|NCT03217461|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
48174281|NCT03217461|PROCEDURE|Limbal autograft|Simple dermoid excision will be performed, followed by closure of the bare sclera by sutured femtosecond laser-assisted limbal autograft.
48174282|NCT03217461|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
48174283|NCT00184197|DRUG|Botulinum toxin|
48174284|NCT00184197|DRUG|Placebos|
48374901|NCT00812968|DRUG|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
48374902|NCT03057769|DRUG|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
48374903|NCT03057769|DRUG|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
48374904|NCT03057769|DRUG|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
48374905|NCT02991911|BIOLOGICAL|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
48374906|NCT02991911|BIOLOGICAL|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
48706311|NCT04188418|OTHER|Questionnaire Administration|Ancillary studies
48174285|NCT00000545|BEHAVIORAL|exercise|
48374907|NCT02991911|BIOLOGICAL|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
48374908|NCT03541616|DEVICE|ECG Patch, pocket ECG monitor|Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
48374909|NCT01813162|DRUG|Tenofovir 1% gel|
48374910|NCT01813162|DRUG|Vaginal product|
48374911|NCT04249557|BEHAVIORAL|exercise is medicine|a 12-week exercise classes program combined with other motivational skills, including feedback and information technology support. The whole program lasts for 1 year for each participant
48374912|NCT03984552|BEHAVIORAL|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
48374913|NCT00776828|DRUG|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
48374914|NCT03222180|BEHAVIORAL|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
48374915|NCT02799576|DEVICE|Curved needle|In this arm, the curved block needle will be used for regional blockade
48374916|NCT00040326|PROCEDURE|anteromesial temporal resection|surgical treatment for epilepsy
48017555|NCT03174340|BEHAVIORAL|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
48174286|NCT00000545|BEHAVIORAL|diet|
48174287|NCT05612451|PROCEDURE|Regenerative Endodontic Procedures|Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology
48174288|NCT05612451|OTHER|non-setting calcium hydroxide|non-setting calcium hydroxide
48174289|NCT05612451|OTHER|modified triple antibiotic paste|modified triple antibiotic paste
48174290|NCT05601128|DRUG|CAB + RPV|At Day 1 all participants will initiate oral CAB 30 mg + RPV 25 mg once daily for at least 28 days during the Oral Phase. Participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections at month 1 visit followed by CAB LA 400 mg + RPV LA 600 mg IM injections monthly at M2, M3, M4 and M5 visits. Then, starting at month 6 visit, participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections every 2 months at M6, M8, M10 and M12.
48174291|NCT00595647|DEVICE|Drug eluting stent|Implantation of stent
48174292|NCT00595647|DEVICE|Bare metal stent|Implantation of stent
48706312|NCT06606665|OTHER|Cognitive skills test|Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.
48706313|NCT06606665|OTHER|Reaction time test|Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.
48706314|NCT06606665|OTHER|Quality of life assessment|Quality of life assessment; It will be evaluated with the Nottingham Health Profile.
48374917|NCT00040326|DRUG|antiepileptic drugs|pharmacotherapy
48028611|NCT06627283|DEVICE|Sham|A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
48028612|NCT05034692|PROCEDURE|Total laparoscopic with intracorporeal anastomosis by overlap method|After the intestinal canal was dissociated and vascularized, the intestinal canal was nuded and cut off, and the distal and proximal intestinal canals were overlapped by 6 cm
48706315|NCT06606665|OTHER|Lower extremity muscle strength assessment|Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.
48706316|NCT06606665|OTHER|Hand grip strength measurement test|Hand grip strength measurement test; It will be evaluated with a dynamometer.
48706317|NCT06606665|OTHER|Pulmonary function assessment|Pulmonary function assessment; It will be evaluated by spirometry.
48706318|NCT06606665|OTHER|Balance assessment|Balance assessment will be done with the Wii Fit Balance Board.
48706319|NCT01187368|DEVICE|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
48706320|NCT01187368|DEVICE|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
48706321|NCT05291975|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
48706322|NCT05291975|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
48706323|NCT03587831|PROCEDURE|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
48706324|NCT03587831|BEHAVIORAL|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
48706325|NCT05791695|OTHER|Non Applicable|No study-specific interventions for this observational study.
48706326|NCT02943824|OTHER|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
48706327|NCT02943824|OTHER|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
48706328|NCT02231411|PROCEDURE|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
48706329|NCT02231411|PROCEDURE|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
48706330|NCT02231411|PROCEDURE|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
48706331|NCT00976378|DRUG|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
48706332|NCT00976378|DRUG|NOX-A12|single IV dose, at efficacious dose level
48706333|NCT01022372|PROCEDURE|Endometrial biopsy|For all the groups
48706334|NCT04606199|BEHAVIORAL|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
48028613|NCT05034692|PROCEDURE|Laparoscopic-assisted colectomy with extracorporeal anastomosis|After the corresponding colon and blood vessels were dissociated and treated, the carbon dioxide pneumoperitoneum was removed. The appropriate length of the incision was cut at the corresponding position of the abdomen, and the incision protector was placed. The tumor was lifted together with the free intestinal canal to the outside of the abdomen. The intestinal canals at the quasi-dismembered sites on both sides of the tumor were nuded, and the colon-colon functional end-to-end anastomosis was performed.
48028614|NCT02197923|PROCEDURE|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
48028615|NCT02197923|PROCEDURE|endometrial biopsy|transcervical endometrial biopsy
48028616|NCT04132609|BEHAVIORAL|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
48028617|NCT04132609|BEHAVIORAL|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
48028618|NCT04320680|OTHER|description of a lupus patient cohort|description of a lupus patient cohort
48028619|NCT00139750|DRUG|CP-526,555 (varenicline)|
48017556|NCT06220396|PROCEDURE|Right Heart Catheterization with Hemodynamics and Limited Echocardiogram|"Right Heart Catheterization (RHC) with Hemodynamics and Limited Echocardiogram is an invasive procedure that involves insertion of a catheter through a blood vessel in the neck, groin, or arm to the right side of the heart. Hemodynamic measurements such as the blood pressure inside the veins, heart, and arteries as well as measurements of blood flow and how much oxygen is in the blood will be completed during the catheterization procedure. It is a way to see how well the heart is working during your procedure. During the RHC procedure a limited echocardiogram, using ultrasound waves, will be collected to evaluate the structure and function of the heart.~All measurements will be conducted at rest and during exercise using a supine cycle ergometer"
48017557|NCT06220396|PROCEDURE|Magnetic Resonance Imaging (MRI)|"MRI is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body. CMR Imaging will assess myocardial structure, function, and fat content.~An additional limited MRI sequence of the the abdomen and one sequence in the thigh will be used to evaluate for visceral adipose tissue (VAT) as a measurement of body composition."
48174293|NCT06385041|OTHER|Intervention group 1|Additional exercise program with balance and strength trainings will include 3 times/week. Patients will get an individualized exercise program for frailty syndrome, which will include strength exercises (with elastic resistance bands and weights up to 2kg 30-50% 1RM) and balance training (with unstable surfaces). The program will be performed by 3 sets with 10 repetitions 3 times/week 30-45 minutes.
48174294|NCT06385041|OTHER|Intervention group 2|Additional exercise program with balance and strength trainings will include 3 times/week 30-45 minutes. Patients will get an individualized program for frailty syndrome, with interactive technologies: gait training with Biodex GaitTrainerTM3 with visual, audio feedback and incline up to 10-15 min, Zebris FDM-T, with virtual barriers, thus simulating real environment for the patient, while performing a cognitive task up to 10-15 min, for balance training we will use a computerized Biodex board. Exercises will be performed with the programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training. For strength training we will use equipment HUR based on pneumatic (air pressure) technology. For strength training intensity 30-50% 1-RM, 10 repetitions with 3 sets. Leg press, leg extension, leg abduction, leg adduction will be performed with pneumatic technology.
48174295|NCT02640170|OTHER|Registry|
48174296|NCT06276764|DIAGNOSTIC_TEST|LINFU®|Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.
48174297|NCT06276764|DIAGNOSTIC_TEST|Standard imaging tests|EUS, CH-EUS, CEUS, MRI/MRCP, PET/CT, CT
48374918|NCT00190294|DRUG|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
48374919|NCT02853825|BEHAVIORAL|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
48374920|NCT03873662|DIAGNOSTIC_TEST|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
48374921|NCT03023358|DRUG|chidamide|30mg po twice a week
48374922|NCT03023358|DRUG|cyclophosphamide|750mg/m2 iv on day 1
48706335|NCT04319380|BIOLOGICAL|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
48706336|NCT04319380|DRUG|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
48706337|NCT04319380|BIOLOGICAL|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
48706338|NCT04319380|DRUG|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
48706339|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
48374923|NCT03023358|DRUG|liposomal doxorubicin|30mg/m2 iv on day 1
48374924|NCT03023358|DRUG|vincristine|1.4mg/m2 iv on day 1
48374925|NCT03023358|DRUG|prednisone|100mg/d po on day 1-5
48374926|NCT01033110|BEHAVIORAL|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
48374927|NCT02182726|DRUG|MOBEC|
48374928|NCT05670470|DRUG|CTP0303|Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
48374929|NCT05670470|DRUG|Orafang Tab|Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
48374930|NCT02873598|DRUG|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
48374931|NCT02873598|RADIATION|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
48174298|NCT03854019|DRUG|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
48174299|NCT03854019|DRUG|Placebo|Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
48174300|NCT00003597|BIOLOGICAL|recombinant human thrombopoietin|
48174301|NCT00003597|DRUG|carboplatin|
48174302|NCT00003597|DRUG|etoposide|
48174303|NCT00003597|DRUG|ifosfamide|
48706340|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
48706341|NCT00002211|DRUG|Nelfinavir mesylate|
48174304|NCT00003597|BIOLOGICAL|G-CSF|
48174305|NCT00397020|DRUG|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
48174306|NCT00397020|DRUG|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
48374932|NCT04409509|BIOLOGICAL|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
48516895|NCT05298865|BEHAVIORAL|Positive imagination stimulation|The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
48706342|NCT00002211|DRUG|Delavirdine mesylate|
48174307|NCT02819219|DIETARY_SUPPLEMENT|Supplemental|participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.
48174308|NCT02819219|OTHER|Exercise Intervention|Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
48706343|NCT00002211|DRUG|Stavudine|
48706344|NCT00002211|DRUG|Didanosine|
48174309|NCT02838576|DRUG|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
48174310|NCT02838576|DRUG|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
48174311|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
48174312|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
48174313|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
48174314|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
48174315|NCT04148118|BIOLOGICAL|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
48174316|NCT04148118|BIOLOGICAL|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
48174317|NCT04148118|BIOLOGICAL|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
48174318|NCT01308268|DRUG|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (\>= 2 years old) single dose, PO
48174319|NCT02572440|PROCEDURE|Sorin XTRA/Sorin Group,|
48174320|NCT04957329|DRUG|Xalatan|Eye drop
48174321|NCT04957329|DRUG|Monoprost|Eye drop
48174322|NCT00054678|DRUG|MyoCell™|
48174323|NCT00054678|DEVICE|MyoCath™|
48374933|NCT04409509|DRUG|Placebo|CSL312 diluent administered intravenously
48706345|NCT03088436|DEVICE|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
48706346|NCT01070693|PROCEDURE|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
48706347|NCT01070693|DEVICE|Prolene Hernia System|Prolene Hernia System
48706348|NCT01070693|PROCEDURE|Lichtenstein technique|Lichtenstein technique
48706349|NCT05292209|DRUG|Riluzole 50 MG|Riluzole 50mg tablets
48174324|NCT03464383|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
48174325|NCT03464383|OTHER|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
48706350|NCT05199376|DEVICE|Cryotherapy|The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.
48706351|NCT02031835|PROCEDURE|BWSTT (3 days a week for maximum of 20 minutes session)|
48706352|NCT03041675|DEVICE|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
48706353|NCT03041675|DEVICE|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
48706354|NCT03644914|BEHAVIORAL|10-week Reading Program|Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
48174326|NCT03464383|OTHER|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
48374934|NCT05587075|PROCEDURE|Filiform needle|A needle treatment: guide patients take lying or sitting, keep relaxed, select Jingjiaji Point, Fengchi Point, Jianjing Point, Tianzhu Point, Houxi point, Hegu Point, Waiguan Point, preoperative, marker points, conventional disinfection, application specification of 0.35mmx50mm disposable sterile acupuncture needle, in the marker quick needle subcutaneous, slow needle to feel acid swelling feeling, keep needle 30min, once a day, last 5d for 1 course, a total of 4 courses of treatment.
48516896|NCT05298865|BEHAVIORAL|Neutral recall message|The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
48516897|NCT00973063|BEHAVIORAL|Routine sterile gloving|routinely new sterile gloving just before sampling
48516898|NCT05549531|DRUG|ACT-1004-1239 (10 mg)|ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.
48706355|NCT04942340|DRUG|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
48706356|NCT04942340|DRUG|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
48706357|NCT05231577|PROCEDURE|7.5fr ultra-fine ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
48706358|NCT05231577|PROCEDURE|9.2fr Ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
48706359|NCT00004664|DRUG|megestrol|
48706360|NCT00004664|BEHAVIORAL|Exercise|
48706361|NCT04857437|DRUG|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
48706362|NCT04857437|DRUG|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
48017558|NCT06220396|PROCEDURE|Dual X-ray absorptiometry (DEXA) scan|A DEXA scan measures the amount of fat in the body using an x-ray that measures bone, calcium and fat.
48017559|NCT02737566|BEHAVIORAL|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
48174327|NCT04700475|DEVICE|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
48174328|NCT04700475|DRUG|citric acid solution|citric acid solution applied as a mouth rinse
48174329|NCT02468908|DRUG|Molgramostim|
48706363|NCT04857437|DRUG|Placebo|Matching Placebo
48017560|NCT02737566|OTHER|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
48017561|NCT03231384|DEVICE|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
48017562|NCT03802097|PROCEDURE|No use of antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
48017563|NCT03802097|PROCEDURE|Use of antimicrobial prophylaxis|Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
48017564|NCT03511521|DRUG|NPH Insulin|Intermediate acting insulin
48017565|NCT03511521|DRUG|glargine|basal insulin
48017566|NCT03511521|DRUG|Insulin Aspart|prandial insulin
48017567|NCT01805297|DRUG|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
48374935|NCT05587075|PROCEDURE|Long round needle|Long round needle treatment: mark tendon lesions, take 3-5 tendon lesion points for needle point, after injection of 0.5% lidocaine 1mL, local anesthesia, to hold long round needle, slowly hierarchical detection to tendon lesion points, patients feel acid, hemp, swelling feeling is appropriate, to close method line knot treatment: straight to tendon lesions point surface, scraping, to remove the surface adhesion. Do not cross the superficial surface of the clavicle, sternocleidomastoid muscle deep surface, gentle action. After the needle was released, the pinhole was covered with a disposable dressing, bandaged for 2d, once a week, once for 1 course, and for a total of 4 courses of treatment.
48374936|NCT00906776|DEVICE|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
48374937|NCT00906776|DEVICE|Autogenous bone|Autogenous bone application during periodontal surgery
48017568|NCT01805297|OTHER|Standard Vitrectomy|Surgical intervention
48017569|NCT01126541|DRUG|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
48017570|NCT04349852|BEHAVIORAL|BrainHQ Cognitive Training Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
48017571|NCT04349852|BEHAVIORAL|BrainHQ People Skills Modules|The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
48017572|NCT01092195|BIOLOGICAL|Gardasil|3 separate 0.5 ml intramuscular
48017573|NCT04589585|DEVICE|DiVeRt|DiVeRt - Vascular Reconstruction Device and Delivery System
48374938|NCT02662075|DEVICE|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
48174330|NCT02468908|DRUG|Placebo|
48706364|NCT00531076|BIOLOGICAL|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
48706365|NCT00435162|DRUG|Valsartan 0.25 mg/kg|once daily
48706366|NCT00435162|DRUG|Valsartan 1.0 mg/kg|once daily
48706367|NCT00435162|DRUG|Valsartan 4.0 mg/kg|once daily
48706368|NCT03608137|OTHER|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
48706369|NCT06065319|DEVICE|Wearable Sensors|Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
48174331|NCT05664399|OTHER|Surprise events|Subjects will be subjected to 4 surprise events, two using Virtual Reality simulations of falling out of a boat, and 2 involving falling into dunk tanks of cool and thermoneutral water.
48174332|NCT02787811|DEVICE|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
48174333|NCT00224978|DRUG|Chloroquine|
48174334|NCT05879562|DIAGNOSTIC_TEST|MoCA-Xpresso|MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
48174335|NCT04934605|PROCEDURE|Cochlear implantation|Cochlear implantation
48174336|NCT00230945|BEHAVIORAL|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
48174337|NCT03770052|DRUG|duvie|take the intervention drug once daily according to the randomized groups
48706370|NCT01673815|OTHER|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
48706371|NCT02186054|DEVICE|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
48706372|NCT02826421|DEVICE|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
48706373|NCT02826421|DEVICE|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
48174338|NCT01050361|PROCEDURE|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
48706374|NCT02826421|DEVICE|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
48706375|NCT02826421|DEVICE|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
48706376|NCT03130387|DEVICE|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
48706377|NCT06606912|OTHER|Skeletal muscle, subcutaneous fat and visceral fat area|CT-based measurement of skeletal muscle, subcutaneous fat and visceral fat areas at L1, L2, L3, L4 and L5 levels.
48706378|NCT03840304|OTHER|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
48706379|NCT00795548|DRUG|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
48706380|NCT01101971|OTHER|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
48706381|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous (SC) injection
48706382|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
48706383|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
48706384|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
48706385|NCT06606223|DIAGNOSTIC_TEST|serum ammonia test|precaution of withdrawal serum ammonia
48706386|NCT03837665|BIOLOGICAL|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
48706387|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
48706388|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
48706389|NCT01974557|OTHER|Exercise|
48174339|NCT05595811|OTHER|outcome following surgery|
48516899|NCT05549531|DRUG|Itraconazole (200 mg, o.d.)|Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.
48174340|NCT01255761|BIOLOGICAL|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
48174341|NCT00498615|DRUG|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
48174342|NCT02137577|PROCEDURE|DEB catheter|DEB catheter (trade name: Litos/Tulip)
48174343|NCT02137577|PROCEDURE|common PTA balloon catheter|common PTA balloon catheter
48017574|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment (DECIDES)|DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
48017575|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment with Coach-Assisted Support (DECIDES + coach)|Live support in the form of a coach is provided to support navigation of DECIDES and promote involvement in decision-making. DECIDES is a developmentally appropriate, engaging and interactive web-based decision support application designed to address health literacy through education about cancer and cancer treatment, and provide support for AYA patients, their caregivers, and oncology health care providers to make informed decisions about cancer treatment together.
48017576|NCT04408443|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938 + Vitamine D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
48017577|NCT04408443|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
48017578|NCT06444113|DRUG|Ofatunumab|No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
48017579|NCT02359266|DIETARY_SUPPLEMENT|Vitamin D|Given to patients with existing vitamin D deficiency
48017580|NCT02716844|OTHER|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
48017581|NCT03069690|BEHAVIORAL|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
48017582|NCT03069690|BEHAVIORAL|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
48017583|NCT02381535|DRUG|Cisplatin|Given IV
48174344|NCT01633476|DRUG|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
48017584|NCT02381535|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48017585|NCT02381535|OTHER|Laboratory Biomarker Analysis|Correlative studies
48174345|NCT01019798|DRUG|sunitinib, docetaxel, cisplatin|"1. Sunitinib given 10 days within 14 days of each cycle。~2. Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~3. Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~4. Overall 12 cycles (24 weeks)"
48174346|NCT06386445|OTHER|Serum metabolomics sequencing|Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.
48174347|NCT01795859|DRUG|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
48174348|NCT01795859|DRUG|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
48706390|NCT01121627|OTHER|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
48706391|NCT01789983|BEHAVIORAL|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
48174349|NCT02226497|DEVICE|Health Telemonitoring|Use home telemonitoring device
48174350|NCT02226497|OTHER|Quality-of-Life Assessment|Ancillary studies
48174351|NCT02226497|OTHER|Questionnaire Administration|Ancillary studies
48017586|NCT02381535|DRUG|Onalespib|Given IV
48017587|NCT02381535|OTHER|Pharmacological Study|Correlative studies
48174352|NCT02226497|PROCEDURE|Supportive Care|Receive standard outpatient supportive care
48174353|NCT06547671|OTHER|Employment of a confort room to help in anxiety and agitation moments.|Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.
48174354|NCT00280683|DRUG|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
48174355|NCT00280683|DRUG|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
48174356|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
48174357|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
48017588|NCT05615311|DIETARY_SUPPLEMENT|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
48017589|NCT05615311|OTHER|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
48516900|NCT03700502|DIAGNOSTIC_TEST|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
48017590|NCT00461526|DRUG|crofelemer|125 mg crofelemer vs. placebo
48017591|NCT04979221|DRUG|Cyproheptadine|Cyproheptadine 8mg three times a day during 10 days
48017592|NCT05728892|DRUG|Melatonin 3 MG|Preopertive melatonin adminstration oral 0.2 mg /kg 45 min before general anaethesia.
48017593|NCT05728892|OTHER|Placebo|Placebo medication will be given to control group
48028620|NCT06001398|BEHAVIORAL|Parent Acceptance and Commitment Therapy (PACT)|PACT is a 2-session intervention based on the Focused Acceptance and Commitment Therapy treatment literature
48028621|NCT06001398|BEHAVIORAL|Control|The content of the control intervention covers a range of nutrition and healthy lifestyle topics including USDA's MyPlate
48028622|NCT00184860|PROCEDURE|PET-scan, MRI-scan|
48028623|NCT02925975|DRUG|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
48028624|NCT02925975|DEVICE|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
48028625|NCT02925975|PROCEDURE|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
48028626|NCT04351438|DEVICE|Active Comparator: centrifuge TPE with citrate|Patients who received citrate-based anticoagulation with centrifuge TPE
48028627|NCT04351438|DEVICE|Active Comparator: Filter TPE with heparin|Patients who received heparin-based anticoagulation with filter TPE
48028628|NCT04351438|DRUG|Active comparator: Filter TPE with citrate|Patients who received citrate-based anticoagulation with filter TPE
48028629|NCT06342362|DRUG|Magnesium sulfate|Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
48028630|NCT06342362|OTHER|placebo or standard treatment)|placebo or standard treatment)
48028631|NCT05716581|DEVICE|Catheter ablation|Catheter ablation for atrial fibrillation will be done according to the current medical praxis. Pulmonary vein isolation using either radiofrequency or pulsed-field ablation will be done in all patients. In patients with non-paroxysmal AF, additional ablation lesions (posterior wall ablation, roof or mitral isthmus line, ablation of complex fractionated atrial electrograms) could be done based on the operator´s discretion
48028632|NCT06044298|OTHER|procedural sedation|"Participants, adverse events during and after gastrointestinal procedures with sedation administered were observed and recorded. No intervention was performed."
48028633|NCT00256789|PROCEDURE|Radiation|
48028634|NCT00256789|DRUG|Chemotherapy|
48028635|NCT05800522|BEHAVIORAL|Behavioral parent or child directed intervention|Control group will include different behavioral interventions that may include caretakers or the target child, and thus may vary in scope and intensity.
48028636|NCT05800522|BEHAVIORAL|Supportive Parents - Coping Kids|Intervention group will receive the transdiagnostic parent intervention (SPARCK). SPARCK is designed to include up to 12 sessions with caretakers. If necessary and applicable, children can attend sessions. The starting point for the development of SPARCK has been the Social Interaction Learning model, which represents the behavioral management perspective. In addition, SPARCK consists of empirically supported components based on attachment theory, emotion socialization, CBT, and family accommodation. Thus, content and strategies have been collected from different theories to provide a diverse toolkit tailored to address transdiagnostic problems in families with externalizing, internalizing, and caregiver challenges. SPARCK content and target strategies are tailored to the needs of the families and children, and the manual explains the content and how the target strategies may be tailored and combined.
48028637|NCT06345443|DIETARY_SUPPLEMENT|Nicotinamide Riboside Malate|Active supplement.
48028638|NCT06345443|OTHER|Placebo|Placebo
48028639|NCT05343871|BIOLOGICAL|Sinovac|"Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)"
48028640|NCT05343871|BIOLOGICAL|AZD1222|"AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)"
48028641|NCT05343871|BIOLOGICAL|BNT162b2|"Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)"
48028642|NCT01767116|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
48028643|NCT01767116|DRUG|Ribavirin|Capsule
48028644|NCT01767116|DRUG|Placebo for ribavirin|Capsule
48028645|NCT03912857|DRUG|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
48028646|NCT03397212|OTHER|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
48028647|NCT03397212|OTHER|Sham acupuncture|Ear acupuncture using inactive sham points
48706392|NCT01789983|OTHER|Collect Blood, GA and Other Survey Tools|"* Geriatric Assessment (GA) (Version 5)~* Functional Assessment of Cancer Therapy-General (FACT)~* Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~* Outcome Expectations for Exercise (OEE) scale29~* Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~* Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~* Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
48706393|NCT02238431|DRUG|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
48174358|NCT03239418|DEVICE|Neuromuscular electrical stimulation|A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.
48174359|NCT03239418|DEVICE|Sham neuromuscular electrical stimulation|Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
48174360|NCT04604470|OTHER|Decision tool|no intervention.
48174361|NCT03599336|PROCEDURE|Reverse Total Shoulder Arthroplasty (rTSA)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
48374939|NCT04782882|BEHAVIORAL|Progressive muscle relaxation+laughter therapy|"Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music."
48174362|NCT03599336|OTHER|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
48174363|NCT06486506|OTHER|Analysis|Analysis and review of imaging and clinical data
48174364|NCT01387815|BIOLOGICAL|Adalimumab|Adalimumab administered by subcutaneous injection.
48174365|NCT01795729|DEVICE|Stent|Coronary revascularization
48174366|NCT01795729|DRUG|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
48374940|NCT03410693|DRUG|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
48374941|NCT03410693|DRUG|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization or treatment guidelines in the given country.
48374942|NCT01084824|DRUG|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
48706394|NCT02238431|DRUG|OCP|to schedule the start of the artificial cycle
48706395|NCT02238431|OTHER|Natural|to use the normal menstrual period to schedule treatment start
48174367|NCT05661669|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
48374943|NCT01084824|DRUG|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
48374944|NCT03526848|DRUG|3BNC117|Intravenous infusion of 3BNC117
48374945|NCT03526848|DRUG|10-1074|Intravenous infusion of 3BNC117
48706396|NCT01437098|DEVICE|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
48174368|NCT05661669|DRUG|Saline|The placebo will be a 0.9% saline solution administered over 40 minutes.
48374946|NCT03526848|OTHER|Analytical treatment interruption|Analytical treatment interruption
48374947|NCT00194038|DRUG|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
48374948|NCT02430545|DRUG|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
48374949|NCT02430545|DRUG|Rifampin|Subjects receive rifampin 600 mg oral dose daily \[Day -6 to day 4\]
48374950|NCT05385783|DRUG|CYB003|CYB003 is a synthetic psilocybin analog.
48374951|NCT05385783|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
48374952|NCT05385783|DRUG|Placebo|Placebo
48706397|NCT00387413|DRUG|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
48374953|NCT05385783|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
48374954|NCT05665946|DIAGNOSTIC_TEST|Blood sample analysis|Analysis of proposed biomarkers.
48706398|NCT00387413|DRUG|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
48017594|NCT03840785|OTHER|Argentine tango|"Argentine tango sessions will consist of:~* Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~* Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
48374955|NCT05921539|DRUG|steroid hydrodilatation|ultrasound-guided steroid hydrodilatation
48374956|NCT05921539|DRUG|axillary nerve injection|ultrasound-guided axillary nerve injection
48374957|NCT05016570|BEHAVIORAL|Picture narrative information format|Lung screening information formatted as picture narratives
48374958|NCT05016570|BEHAVIORAL|Text with pictures information format|Lung screening information formatted as text and non-narrative pictures
48374959|NCT05016570|BEHAVIORAL|Text-only information format|Lung screening information formatted as text with no pictures
48374960|NCT00779857|DEVICE|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
48374961|NCT06539793|OTHER|Aerobic Exercises|Treadmill 20 minutes including 5 minutes warm up and 5 minutes cool.
48374962|NCT06539793|OTHER|Transcutaneous electrical nerve stimulation|"will be applied for all patients, which uses an asymmetrical biphasic alternating current in the continuous mode (pulse duration 100 µs, low frequency). TENS intensity will increase slowly, and patients will be instructed to indicate sensory threshold (ST); then, the intensity are going to increase until the sensation perceived as strong but comfortable (SC1). The duration will be for 30 minutes, 3times/ week for 4 weeks"
48706399|NCT00387413|DRUG|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
48374963|NCT01483495|DEVICE|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
48374964|NCT02155816|DIETARY_SUPPLEMENT|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
48374965|NCT02155816|DIETARY_SUPPLEMENT|Omega 3|Omega 3 daily for 8 weeks.
48374966|NCT02155816|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides
48374967|NCT02020356|BEHAVIORAL|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
48374968|NCT02020356|BEHAVIORAL|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
48706400|NCT00387413|DRUG|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
48706401|NCT00031655|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
48706402|NCT00031655|BIOLOGICAL|donor lymphocytes|Given IV
48706403|NCT00031655|DRUG|cyclosporine|Given PO
48706404|NCT00031655|RADIATION|total-body irradiation|Undergo TBI
48706405|NCT00031655|DRUG|fludarabine phosphate|Given IV
48706406|NCT00031655|DRUG|mycophenolate mofetil|Given PO
48706407|NCT00031655|OTHER|laboratory biomarker analysis|Correlative studies
48028648|NCT02039505|DRUG|Vedolizumab|Vedolizumab intravenous infusion
48028649|NCT02039505|DRUG|Vedolizumab placebo|Vedolizumab placebo
48028650|NCT00325793|DRUG|Nicardipine|
48028651|NCT04434040|DRUG|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
48028652|NCT04434040|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
48028653|NCT01053923|OTHER|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
48028654|NCT00388687|DRUG|18F Fluoroazomycin Arabinoside (FAZA)|
48028655|NCT06535672|OTHER|kamishibai education|Patients in the intervention group will be given Kamishibai diabetes education.
48028656|NCT06535672|OTHER|routine education|Patients in the control group will be given routine diabetes education.
48028657|NCT01807273|OTHER|Walking test|
48028658|NCT02863640|DEVICE|Color retinography|
48028659|NCT02863640|DEVICE|Optical coherence tomography|
48028660|NCT02863640|DEVICE|Fundus autofluorescence imaging|
48374969|NCT02151552|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
48374970|NCT02151552|DRUG|[18F](+/-)NOS|7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
48374971|NCT00153751|DRUG|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
48017595|NCT00006411|OTHER|corneas assigned by donor age group|A web-based computer program was used to select and assign a cornea by donor age group from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors \>=66 and \<66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
48706408|NCT00031655|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
48017596|NCT02877706|OTHER|no specific intervention|
48706409|NCT05346965|BEHAVIORAL|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
48706410|NCT01360398|PROCEDURE|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
48017597|NCT04560803|DEVICE|CelluTomeTM Epidermal Harvesting System|Autologous epidermal grafts that will be placed at the treatment site
48017598|NCT00600821|DRUG|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
48017599|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
48017600|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
48017601|NCT00600821|DRUG|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
48017602|NCT00600821|DRUG|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
48374972|NCT00153751|DRUG|Holopon|holopon
48374973|NCT00153751|OTHER|placebo|placebo
48516901|NCT05603325|OTHER|Person Centered Practice|"Staff will be asked to:~* Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~* Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~* Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~* Attend a final focus group to evaluate the workshop programme."
48706411|NCT01360398|PROCEDURE|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
48706412|NCT01360398|PROCEDURE|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
48017603|NCT00600821|DRUG|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
48017604|NCT05069662|OTHER|Directive Interview|One directive interview conducted by telephone
48017605|NCT01955876|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
48017606|NCT06573424|COMBINATION_PRODUCT|Tislelizumab+anlotinib|Patients who have been treated with anlotinib + tislelizumabline
48017607|NCT06573424|DRUG|anlotinib|Patients who have been treated with anlotinib monotherapy
48017608|NCT04273464|PROCEDURE|Brava-group|Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
48017609|NCT04273464|PROCEDURE|DIEP-group|Microsurgical reconstruction by DIEPO method
48017610|NCT02791334|DRUG|LY3300054|Administered IV
48017611|NCT02791334|DRUG|Ramucirumab|Administered IV
48174369|NCT02302703|OTHER|low FODMAP diet vs Gluten free diet|
48017612|NCT02791334|DRUG|Abemaciclib|Administered orally
48017613|NCT02791334|DRUG|Merestinib|Administered orally
48017614|NCT02791334|DRUG|LY3321367|Administered IV
48017615|NCT06259565|DRUG|Dexmedetomidine|Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in IMV that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium
48017616|NCT06259565|OTHER|Placebo Control|Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
48174370|NCT01688453|BEHAVIORAL|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
48516902|NCT05603325|OTHER|Interview|Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
48516903|NCT00193050|DRUG|Gemcitabine|Gemcitabine
48017617|NCT05458193|DRUG|Daridorexant|Film-coated tablet for oral use
48017618|NCT05458193|DRUG|Placebo|Film-coated tablet for oral use
48017619|NCT05459298|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
48516904|NCT00193050|DRUG|Epirubicin|Epirubicin
48017620|NCT05459298|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
48017621|NCT05459298|OTHER|Usual Care|Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
48017622|NCT00550784|BIOLOGICAL|filgrastim|
48017623|NCT00550784|DRUG|cisplatin|
48516905|NCT00193050|DRUG|Docetaxel|Docetaxel
48516906|NCT01867528|PROCEDURE|Laparoscopic adhesiolysis|
48516907|NCT01867528|PROCEDURE|Open adhesiolysis|
48516908|NCT05154838|PROCEDURE|Drainage and packing of pilonidal abscess|Patients will be treated as per standard care, their wound drained, cleaned and packed. Microbiology swab samples will be obtained.
48516909|NCT00002346|DRUG|Adefovir dipivoxil|
48706413|NCT01360398|PROCEDURE|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
48706414|NCT01360398|PROCEDURE|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
48017624|NCT00550784|DRUG|cyclophosphamide|
48017625|NCT00550784|DRUG|melphalan|
48017626|NCT00550784|DRUG|paclitaxel|
48017627|NCT00550784|DRUG|topotecan hydrochloride|
48017628|NCT00550784|GENETIC|TdT-mediated dUTP nick end labeling assay|
48017629|NCT00550784|GENETIC|gene expression analysis|
48017630|NCT00550784|OTHER|immunohistochemistry staining method|
48017631|NCT00550784|OTHER|pharmacological study|
48017632|NCT00550784|PROCEDURE|peripheral blood stem cell transplantation|
48028661|NCT05605470|BIOLOGICAL|ChulaCov19 BNA159 vaccine (50 mcg)|Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1
48028662|NCT05605470|BIOLOGICAL|Pfizer/BNT vaccine (30 mcg)|Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1
48028663|NCT05605470|BIOLOGICAL|COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)|Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1
48028664|NCT03174977|DRUG|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
48028665|NCT06002438|DIETARY_SUPPLEMENT|Whole egg powder|15g daily dose for 24 weeks
48028666|NCT06002438|DIETARY_SUPPLEMENT|Corn powder|15g daily dose for 24 weeks
48028667|NCT06002438|DIETARY_SUPPLEMENT|Supercereal Plus|Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
48028668|NCT06002438|DIETARY_SUPPLEMENT|Micronutrient sprinkles|To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
48028669|NCT06002438|DRUG|Sulfadoxine pyrimethamine|"Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18."
48028670|NCT04897295|DEVICE|Active transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
48028671|NCT04897295|DEVICE|Sham transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation technique. The investigators will use a BrainSTIM (EMS, Bologna, Italy)
48028672|NCT04418804|DIAGNOSTIC_TEST|Chest ultrasound|"Each research volunteer will undergo a chest-directed ultrasound examination using a commercial device located in the Valley Hospital and approved for clinical use. After completing the above scan, the patient will undergo another ultrasound scan using a Vantage system device (by Verasonics), which is a research ultrasound device that will be provided on loan to the Haemek Hospital by the Weizmann Institute SAMPL Laboratory prior to the start of the trial. The scan will be made with a linear transducer sampled at a rate of about 8-12Mhz and / or with a curved transducer sampled at a rate of about 4-6Mhz.~The total estimated duration of the test is approximately 30 to 40 minutes per patient."
48028673|NCT06427785|DRUG|Remimazolam besylate|Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
48028674|NCT04944875|PROCEDURE|Group headphone|The patients in the first group wore the headphones but did not listen the music or maternal voice. The standard sedation method was applied to all patients.
48028675|NCT04944875|PROCEDURE|Group music|The patients in the second group listened to classical music (Vivaldi's The Four Seasons violin concertos) by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
48028676|NCT04944875|PROCEDURE|Group maternal voice|The patients in the third group listened to maternal voice by sound- isolating headphones through the procedure.The standard sedation method was applied to all patients.
48028677|NCT02139501|DRUG|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
48706415|NCT01360398|OTHER|Data collection|Patient interview, diary cards review and questionnaires completion
48017633|NCT01130740|BEHAVIORAL|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
48374974|NCT05346458|DEVICE|Intra coronary rapid-exchange iKOs microcatheter intervention|Patients planned for an invasive coronary physiology (pressure-wire) study and who meet the inclusion criteria and none of the exclusion criteria can be enrolled. Participants will undergo preparation for their clinical procedure (angiogram with pressure wire study) in the normal manner. Arterial cannulation will be performed via the radial or femoral artery) under local anaesthesia. The sheath will be inserted and a pre-procedure blood sample taken for Troponin T level. A coronary angiogram will be performed as per standard clinical practice prior to cannulating the coronary artery to be studied. The pressure studies will be performed sequentially, first with a pressure wire before using the iKOs™ microcatheter. Following withdrawal of the iKOs™ microcatheter. A pressure wire assessment is repeated after the microcatheter is withdrawn. The case will then proceed as clinically indicated. Post-procedure the participant will be managed according to standard clinical practice.
48706416|NCT01360398|OTHER|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
48706417|NCT00937404|BIOLOGICAL|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
48017634|NCT05278156|DRUG|CPL500036 - low dose|CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
48017635|NCT05278156|DRUG|CPL500036 - high dose|CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
48174371|NCT01688453|BEHAVIORAL|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
48174372|NCT01161446|BEHAVIORAL|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
48174373|NCT01161446|DEVICE|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
48174374|NCT02397226|PROCEDURE|Radiofrequency ablation|
48174375|NCT02397226|PROCEDURE|High ligation/stripping|
48174376|NCT02397226|DEVICE|Radiofrequency ablation catheter|
48174377|NCT02397226|PROCEDURE|Tumescent anesthesia|
48174378|NCT02397226|PROCEDURE|General anesthesia|
48174379|NCT02397226|DEVICE|Vein stripping catheter|
48174380|NCT04347785|PROCEDURE|carotid endarterectomy|shunt
48174381|NCT05351489|DRUG|Dexmedetomidine|Patients will receive intrathecal 2 mL heavy bupivacaine 0. 5% together with either dexmedetomidine 5 μg or10 μg dexmedetomidine .
48174382|NCT02164006|DRUG|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
48174383|NCT04317261|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)|Urine sample is evaluated for RNA and urinary metabolites
48174384|NCT02560389|DRUG|Placebo|Sugar pill packaged to resemble levodopa
48174385|NCT02560389|DRUG|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
48174386|NCT04636957|DRUG|Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution|0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
48706418|NCT05285475|OTHER|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
48706419|NCT04657380|BEHAVIORAL|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
48374975|NCT04804306|DEVICE|Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
48017636|NCT05278156|DRUG|Placebo|Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
48017637|NCT00651482|DRUG|Everolimus|
48017638|NCT00651482|DRUG|Bevacizumab|
48017639|NCT03861468|OTHER|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
48174387|NCT04636957|DRUG|Ciprofloxacin 0.3% solution|0.4mL/vial, each vial contains 1.2mg ciprofloxacin
48174388|NCT02529371|DEVICE|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
48174389|NCT00552513|PROCEDURE|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (and within 24 hours of randomisation).
48174390|NCT00552513|PROCEDURE|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
48174391|NCT06252090|OTHER|Short term mentalization-based treatment for adolescents (MBT-A)|The general framework of intervention corresponds to the Mentalization-Based Treatment model for adolescents (MBT-A). In this study, the model was adapted to a brief, time-limited format (12 sessions) aimed at both the adolescent and their family. The model retains the main characteristics of Mentalization-Based Therapy, such as the therapist's basic attitude toward actively promoting patients' mentalization, uncertainty of mental states, focus on the here and now, and the use of affect as a mechanism for change.
48174392|NCT00510198|DEVICE|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
48174393|NCT00510198|DEVICE|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
48174394|NCT02259062|OTHER|Music with brief mindfulness intervention|Music listening with mindfulness therapy
48174395|NCT02259062|OTHER|Music listening alone|
48174396|NCT02259062|OTHER|Audiobook listening|
48174397|NCT00229710|DRUG|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
48174398|NCT05088109|DIAGNOSTIC_TEST|early mortality prediction using septic shock indices|The Shock Index (SI) is the ratio of pulse rate to systolic blood pressure calculated by dividing pulse rate (beat/min) by systolic blood pressure (mm Hg). The adjusted shock index (ASI) is SI calculated after adjusting the heart rate according to body temperature that 10 beats will be added to the heart rate for every 1.0 °C rise in the body temperature above 37.0 °C. The modified shock index (MSI) is a ratio of heart rate to mean blood pressure (MAP). The DSI is a ratio of heart rate to diastolic blood pressure (DAP).
48174399|NCT01001962|DRUG|empagliflozin|ACTIVE TREATMENT FOR DIABETES
48174400|NCT01001962|DRUG|Metformin|ACTIVE TREATMENT FOR DIABETES
48174401|NCT00567983|DRUG|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
48174402|NCT00567983|DRUG|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
48174403|NCT00571896|DRUG|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
48174404|NCT00571896|DRUG|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
48174405|NCT05603065|DRUG|Tislelizumab + cisplatin + paclitaxel|Tislelizumab 200mgD1 + cisplatin 75mg/m\^2D1 + paclitaxel 150mg/m\^2D1 Q3W 3 cycles
48174406|NCT05603065|DRUG|Tislelizumab + radiotherapy|Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)
48174407|NCT06310083|PROCEDURE|Submucosal Resection Turbinoplasty Versus Partial Inferior Turbinectomy|The study's Participants Were Randomly classified in two groups Interventional Group, applied for Submucosal Resection Turbinoplasty and the controlled group who were applied for Partial Inferior Turbinectomy
48174408|NCT00944892|DRUG|REGN475|2 Administrations of REGN475 within 24 weeks.
48174409|NCT00944892|OTHER|Placebo|Placebo to match REGN475 doses
48174410|NCT05248698|BEHAVIORAL|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
48174411|NCT05248698|OTHER|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
48174412|NCT01253447|DRUG|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
48174413|NCT01253447|OTHER|laboratory biomarker analysis|Correlative studies
48174414|NCT05466032|OTHER|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
48374976|NCT04285957|OTHER|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
48706420|NCT04657380|BEHAVIORAL|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
48017640|NCT04048460|DEVICE|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
48017641|NCT00497120|DRUG|acetazolamide|
48017642|NCT00497120|DRUG|placebo|
48017643|NCT00497120|PROCEDURE|uvulopalatopharygoplasty|
48174415|NCT00866983|DRUG|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
48174416|NCT05449743|OTHER|Spa therapy|Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
48174417|NCT01652859|DRUG|Liposomal Amphotericin B|
48174418|NCT01652859|DRUG|AmBisome|
48174419|NCT04502836|BEHAVIORAL|Preliminary psychological intervention|psychological intervention including providing knowledge and tools for problems solving according to the Choice - Agenda - Resilience - Emotional support (CARE) model . After intervention session patients and their parents will be asked to complete questionnaires
48374977|NCT04285957|OTHER|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
48706421|NCT03650101|PROCEDURE|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
48174420|NCT01200485|DRUG|Rasburicase|"Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
48174421|NCT01200485|DRUG|Allopurinol|Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
48174422|NCT05154240|DRUG|INS018_055|INS018_055 is a small molecule compound. INS018_055 has good solubility in water and was chemically and physically stable at different temperatures.
48374978|NCT00138281|BIOLOGICAL|FluMist|
48374979|NCT00138281|BIOLOGICAL|Fluzone|
48706422|NCT03707951|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
48706423|NCT03707951|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
48017644|NCT05561686|DRUG|Pyrotinib|This study adopted a prospective, multicenter, observational design. From October 1, 2022, 100 patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy with pyrotinib were enrolled. The treatment regimen was determined according to the patient 's condition, physician' s treatment experience, evidence-based evidence and other factors to assess the clinical benefit (pCR, ORR) and safety of different neoadjuvant therapy modalities containing pyrotinib. Exploratory analysis was performed to investigate the correlation between the level of TMB and the pCR rate of neoadjuvant therapy in HER2-positive breast cancer patients, and the effect of pyrotinib on intestinal flora.
48174423|NCT05154240|DRUG|Placebo|Placebo
48017645|NCT01590914|PROCEDURE|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
48017646|NCT01590914|PROCEDURE|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
48017647|NCT05955560|DEVICE|PureWick Male External Catheter|The PureWick™ Male External Catheter (MEC) is intended for non-invasive urine output management in male patients. It is a single-use, non-sterile device. The PureWick™ Male External Catheter is a commercially available device which is Class I, 510(K) exempt.
48017648|NCT05955560|DEVICE|Sage PrimoFit|The PrimoFit External Urine Management for the Male Anatomy is indicated for the non-invasive external collection of urine for adult patients with male anatomy who require urine management. It is a single-use, non-sterile device. The Sage PrimoFit is a commercially available device which is Class I, 510(K) exempt.
48017649|NCT03336008|OTHER|no intervention|No intervention but clinical assessement for all recruited subjects
48017650|NCT06449573|OTHER|Exercise capacity|cardiopulmonary exercise test used assessment of exercise capacity
48174424|NCT01779453|DRUG|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
48174425|NCT01779453|DRUG|Placebo|Placebo once daily for 8 weeks
48174426|NCT01779453|DRUG|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
48374980|NCT00371748|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
48374981|NCT00371748|DEVICE|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
48374982|NCT00371748|DEVICE|Express2|Coronary Stent System
48374983|NCT04456062|OTHER|Caring Contacts|Caring Contacts are brief email communications sent to the patient post-discharge. They convey messages of hope, support, promote a sense of belonging, and provide information on resources for care. They are not written uniquely for each patient but are purposefully crafted to intervene on those specific vulnerabilities that form the core of many patients' experiences with intense emotional distress and suicidal thoughts.
48374984|NCT01973673|BEHAVIORAL|Bone health educational materials|
48374985|NCT02956980|BIOLOGICAL|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
48017651|NCT02541721|DEVICE|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
48017652|NCT06149637|PROCEDURE|Traditional neck dissection approach|.1. A transverse cervical incision is made with horizontal extension towards the affected side. 2. It is dissected through the subplatysmal plane, the posterior edge of the sternocleidomastoid muscle is dissected along its entire length. 3. Identification and dissection of the spinal nerve at Erb's point. 4. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it 5. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level 6. Identification and dissection of level III nodes 7. Identification and dissection of level IIA and IIB ganglia with identification and preservation of the accessory nerve.
48017653|NCT06149637|PROCEDURE|Anterior neck dissection approach|"1. A transverse cervical incision is made with horizontal extension towards the affected side.~2. It is dissected through the subplatysmal plane, the anterior edge of the sternocleidomastoid muscle is dissected along its entire length.~3. Level V nodes are dissected up to the spinal nerve without identifying or dissecting it~4. The jugular chain nodes are identified and the left level IV nodes are dissected with special attention to ligate the lymphatics of this level~5. Identification and dissection of level III nodes~6. Identification and dissection of level IIA and IIB nodes with identification and preservation of the accessory nerve."
48174427|NCT02121743|DEVICE|strattice|use of a strattice
48174428|NCT02121743|PROCEDURE|No strattice|no use of a strattice
48374986|NCT00330772|DRUG|Aspirin|
48374987|NCT00330772|DRUG|Clopidogrel|
48374988|NCT02015312|DRUG|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
48374989|NCT02015312|DRUG|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
48374990|NCT04898517|PROCEDURE|Pancreaticoduodenectomy with the CONDUCTJE-ST technique|"The termed technique connexion pancreatic duct to the jejunum stented (CONDUCTJE-ST) in pancreaticoduodenectomy is a novel technique, modification of the pre-existing ones, whose effectiveness lies in the fact that it is not an anastomosis in the strict sense but rather a simple connection for restoring pancreatic juice flow from the pancreatic remnant towards the intestine."
48516910|NCT02868957|OTHER|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
48174429|NCT04882189|DIAGNOSTIC_TEST|Imaging|Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
48174430|NCT05054465|DRUG|Navitoclax|P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
48174431|NCT05054465|DRUG|Venetoclax|P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
48374991|NCT01409382|BEHAVIORAL|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
48374992|NCT03186287|OTHER|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
48374993|NCT03186287|OTHER|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
48174432|NCT04648098|OTHER|Discharge training and telephone counseling|"The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call."
48174433|NCT04240028|OTHER|Data Collection|The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
48174434|NCT04692298|OTHER|pulses|kidney beans, pinto beans, lentil, black-eyed pea and chickpea
48174435|NCT00644878|DRUG|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
48374994|NCT03186287|OTHER|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
48174436|NCT00892944|DRUG|AZD2516|Fractionated single oral dose
48374995|NCT01156129|DRUG|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
48374996|NCT01156129|DEVICE|Arm B: Acupressure bracelet|Bioband
48374997|NCT01156129|DIETARY_SUPPLEMENT|sugar free gum|Orbit
48374998|NCT02638818|PROCEDURE|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
48374999|NCT02638818|PROCEDURE|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
48375000|NCT04877405|OTHER|No intervention|This observational study is not focused on therapeutic intervention
48174437|NCT03447574|OTHER|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
48174438|NCT03310671|PROCEDURE|Echocardiogram|"Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~* Mean transvalvular pressure gradient~* Aortic valve~* Aortic valve opening area~* Aortic valve opening area adjusted for body mass index~* Bicuspid or tricuspid aorta~* Thickness of the upper valve\> 3 mm"
48174439|NCT03771222|BIOLOGICAL|Prophylactic DLI|The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10\^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
48375001|NCT00051766|BEHAVIORAL|Computer-based Intervention|
48516911|NCT02868957|DEVICE|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
48516912|NCT02868957|DEVICE|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
48516913|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
48516914|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
48516915|NCT01111955|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
48706424|NCT06204861|OTHER|Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.
48516916|NCT01111955|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
48516917|NCT01111955|DRUG|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
48375002|NCT05352607|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Put the patient in comfort position as long sitting on bed with a supported back and a pillow under the forearm, clean the skin by alcohol swab, setup the parameter, put a gel on electrodes then placed the negative electrode (black wire) over biceps belly and positive electrode (red wire) 3 cm distally from negative electrode , turn on TENS device .~With increase the intensity gradually until patient feel a tingling sensation (no muscle contraction) and every 10 minutes ask patient about the feeling until complete 30 minutes."
48375003|NCT05352607|OTHER|Conventional physiotherapy treatment|Application of a hot pack for 20 minutes to enhance muscle flexibility and get overall spastic muscle relaxation. Anti-spastic muscles (elbow extensors) facilitation: tapping followed by movements (three sets of 15 repetitions per session). Hand weight-bearing with bodyweight (two 5-minute per session). Passive stretching of tight muscles (elbow flexors) is used (this must be a slow and gradual stretch for 20 seconds, followed by 20 seconds of rest, five times per session). Upper-limb active exercises should be done gradually. include (finger flexion and extension exercises, elbow and shoulder (three sets of 20 reps for each session).
48706425|NCT06204861|OTHER|Balance Training|The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
48706426|NCT06204861|OTHER|Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy|Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
48706427|NCT06011798|DRUG|Aflibercept|Anti-VEGF control
48375004|NCT01958619|DRUG|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
48375005|NCT01958619|DRUG|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
48375006|NCT01958619|DRUG|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
48706428|NCT06011798|DRUG|foselutoclax|Experimental drug
48706429|NCT02662153|OTHER|Observation only|No intervention.
48706430|NCT01571284|DRUG|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
48706431|NCT01571284|DRUG|FOLFIRI|irinotecan, 5-FU and leucovorin
48375007|NCT01958619|DRUG|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
48375008|NCT00277823|DRUG|DVS-SR 50 mg|
48375009|NCT00277823|DRUG|DVS-SR 100 mg|
48375010|NCT00277823|DRUG|Placebo|
48516918|NCT03352739|DEVICE|DBS of the fornix, power on|"DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
48706432|NCT05186831|BEHAVIORAL|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
48706433|NCT05186831|BEHAVIORAL|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
48706434|NCT03832855|BIOLOGICAL|pING-hHER3FL|Plasmid vaccine containing HER3
48706435|NCT05699993|DRUG|Itraconazole|Itraconazole was administered orally
48706436|NCT05699993|DRUG|IBI351|IBI351 was administered orally
48706437|NCT05699993|DRUG|Dextromethorphan|Dextromethorphan was administered orally
48706438|NCT06411977|DIETARY_SUPPLEMENT|Vegetable juice|Vegetable juice (Fa. Fitrabbit, Voglsam)
48706439|NCT06608342|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19-CART|Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
48706440|NCT03201042|DIAGNOSTIC_TEST|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
48375011|NCT02334891|OTHER|Standard|Standard management
48375012|NCT04487886|DRUG|Duvelisib|Duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. The dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.
48375013|NCT04487886|DRUG|Placebo|A placebo to match duvelisib will be taken orally twice per day for 14 days.
48375014|NCT01955824|DRUG|1% lignocaine|
48516919|NCT03352739|DEVICE|DBS of the NbM, power on|"DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
48174440|NCT05632718|OTHER|Exercise|Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.
48706441|NCT03201042|DIAGNOSTIC_TEST|Serology based assay|"1. The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~2. The Immunetics C6 Lyme ELISA assay.~3. A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~4. A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
48706442|NCT03201042|DIAGNOSTIC_TEST|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
48706443|NCT02783040|DRUG|Midazolam|
48706444|NCT02783040|DRUG|Warfarin|
48706445|NCT02783040|DRUG|Omeprazole|
48706446|NCT02783040|DRUG|Midazolam|
48706447|NCT02783040|DRUG|Digoxin|
48706448|NCT02783040|DRUG|BI 425809|
48706449|NCT02098369|BEHAVIORAL|Written education material (basic)|Education material on COPD distributed to all participants.
48174441|NCT00237614|DRUG|intravenous and oral N-acetylcysteine|
48174442|NCT02924350|OTHER|Stannous fluoride|"Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days)."
48174443|NCT02924350|OTHER|Sodium monofluorophosphate|"Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days)."
48174444|NCT03356964|DRUG|follicle stimulating hormone|Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
48706450|NCT02098369|BEHAVIORAL|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
48706451|NCT02098369|BEHAVIORAL|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
48706452|NCT02098369|BEHAVIORAL|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
48706453|NCT06607523|DIETARY_SUPPLEMENT|Inulin|Inulin, 4g twice daily for 42 days
48174445|NCT05148702|DRUG|Antibiotic - standard duration|Clinician decided antibiotic and duration of treatment
48706454|NCT00996281|DRUG|Azilsartan medoxomil and chlorthalidone|Combination tablet.
48706455|NCT00996281|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
48706456|NCT01267331|PROCEDURE|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
48706457|NCT01267331|PROCEDURE|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
48174446|NCT05148702|DRUG|Antibiotic - fixed-extended-duration|Clinician decided antibiotic for a fixed duration of 28 days.
48174447|NCT04887701|DEVICE|Non-hormonal vaginal device therapy|Experimental Active Therapy
48174448|NCT04887701|DEVICE|Sham vaginal device therapy|Sham Comparator
48174449|NCT03677245|OTHER|Strider Balance Bike|Learning to ride a Strider balance bike
48174450|NCT03201536|DEVICE|conventional Suture|Sutures
48174451|NCT03201536|DEVICE|Zip3|wound closure device
48375015|NCT01955824|DRUG|2% lignocaine|
48375016|NCT02089022|OTHER|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
48375017|NCT02350868|DRUG|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
48375018|NCT05499104|DEVICE|NovaDress|NovaDress is constructed of pure cellulose derived from tree pulp. The tree pulp is reconstructed into hydrated sheets wrapped in nonwoven viscose and irradiated.
48375019|NCT05499104|DEVICE|Mepilex Ag|Mepilex Ag is an antimicrobial foam dressing that absorbs low to moderate exudate and maintains a moist wound environment.
48174452|NCT02970357|OTHER|DIAPASON Questionnaire|"50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~* what is diabetes~* Monitoring~* Hypoglycemia and Hyperglycemia~* Nutrition~* Insuline"
48375020|NCT05499104|DEVICE|Xeroform|Xeroform® Occlusive Dressing (XF) is a fine-mesh gauze impregnated with a petrolatum blend, 3% bismuth tribromophenate.
48375021|NCT05273801|DEVICE|Heart Rate Recording from Multiple Participants, No visual feedback|Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.
48174453|NCT02970357|BEHAVIORAL|WHO-5|5 item questionnaire of the World Health Organization about quality of life
48174454|NCT01347268|PROCEDURE|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
48174455|NCT01347268|PROCEDURE|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
48174456|NCT00504413|DRUG|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
48174457|NCT00504413|DRUG|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
48375022|NCT05273801|DEVICE|Visual Feedback of Multiple Participant Heart Rates|Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.
48375023|NCT02293876|DEVICE|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
48375024|NCT02293876|DEVICE|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
48174458|NCT00504413|DRUG|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
48375025|NCT02293876|DEVICE|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
48375026|NCT03726242|DRUG|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
48375027|NCT03726242|DRUG|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
48375028|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
48375029|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
48375030|NCT01396252|DRUG|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
48375031|NCT01396252|DRUG|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
48375032|NCT01396252|DRUG|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
48375033|NCT02854865|OTHER|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
48375034|NCT03588312|PROCEDURE|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
48375035|NCT00003401|DRUG|carmustine|
48375036|NCT00003401|DRUG|cisplatin|
48174459|NCT02196168|DRUG|Cisplatin|Given IV
48174460|NCT02196168|OTHER|Laboratory Biomarker Analysis|Correlative studies
48174461|NCT02196168|OTHER|Pharmacological Study|Correlative studies
48174462|NCT02196168|OTHER|Placebo|Given PO
48174463|NCT02196168|DRUG|WEE1 Inhibitor AZD1775|Given PO
48174464|NCT01196585|PROCEDURE|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
48174465|NCT01196585|PROCEDURE|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
48375037|NCT00003401|DRUG|cyclophosphamide|
48375038|NCT00003401|DRUG|dexamethasone|
48375039|NCT00003401|DRUG|etoposide|
48375040|NCT00003401|DRUG|gemcitabine hydrochloride|
48375041|NCT00003401|DRUG|melphalan|
48375042|NCT00003401|DRUG|paclitaxel|
48375043|NCT00003401|PROCEDURE|bone marrow ablation with stem cell support|
48375044|NCT00003401|PROCEDURE|peripheral blood stem cell transplantation|
48375045|NCT03907111|DEVICE|Chitosan Gauze|Gauze made by chitosan material
48375046|NCT03907111|DEVICE|placebo|traditional gauze
48375047|NCT03269565|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody
48516920|NCT03352739|DEVICE|DBS of the fornix, power off|"DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
48174466|NCT00715689|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48174467|NCT00715689|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48174468|NCT00715689|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48706458|NCT04686851|OTHER|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
48706459|NCT02512601|DRUG|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
48174469|NCT00715689|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
48706460|NCT02512601|OTHER|Compression therapy|"Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable."
48174470|NCT00715689|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48706461|NCT05774054|DRUG|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
48706462|NCT05774054|DRUG|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
48706463|NCT03245736|DRUG|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
48706464|NCT00002522|DRUG|cisplatin|
48706465|NCT00002522|DRUG|cyclophosphamide|
48174471|NCT00715689|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48174472|NCT00715689|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48174473|NCT00715689|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
48174474|NCT02039544|DRUG|Xuebi formula|
48174475|NCT02039544|DRUG|placebo|
48174476|NCT05239598|DRUG|Mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
48174477|NCT00467298|BEHAVIORAL|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
48174478|NCT00467298|BEHAVIORAL|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
48174479|NCT00467298|BEHAVIORAL|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
48174480|NCT04742205|DRUG|Tranexamic Acid 500 MG|Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
48174481|NCT04658654|DRUG|Roflumilast|chronic intervention (24 weeks): roflumilast capsule
48174482|NCT04658654|DRUG|Placebo oral tablet|Pill with inactive ingredients to mimic same appearance of roflumilast capsule
48174483|NCT01888627|OTHER|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
48174484|NCT00004178|BIOLOGICAL|therapeutic autologous lymphocytes|
48174485|NCT04173702|DIAGNOSTIC_TEST|balance analysis|Computerized balance analysis system will use to evaluate postural sway and limits of stability at four different support surfaces.
48174486|NCT00171795|DRUG|Rivastigmine|
48174487|NCT04254419|BIOLOGICAL|NK cells|"Natural killer cells will be taken from the patients peripheral blood cell collection. The administration of the cells will be done via an Ommaya intra-cavitary/intra-tumoral device.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya in approximately 2 milliliters over approximately 2 minutes; followed by 1 milliliter preservative-free normal saline flush over approximately 1 minute."
48174488|NCT03305809|DRUG|LY3154207|Administered orally.
48174489|NCT03305809|DRUG|Placebo|Administered orally.
48174490|NCT02882841|OTHER|Biopsies, stool and blood collection|
48706466|NCT00002522|DRUG|etoposide|
48706467|NCT00002522|PROCEDURE|autologous bone marrow transplantation|
48706468|NCT00002522|PROCEDURE|bone marrow ablation with stem cell support|
48706469|NCT00002522|PROCEDURE|peripheral blood stem cell transplantation|
48706470|NCT00002522|PROCEDURE|syngeneic bone marrow transplantation|
48706471|NCT00002522|RADIATION|radiation therapy|
48706472|NCT04369118|PROCEDURE|Conventional follow-up|Patients in this group benefit from conventional post-operative follow-up
48706473|NCT04369118|DEVICE|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
48706474|NCT05609877|DRUG|Isotonic saline|Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
48706475|NCT05609877|PROCEDURE|Less Invasive Surfactant Administration (LISA)|All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
48174491|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
48174492|NCT00640198|BEHAVIORAL|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
48174493|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
48174494|NCT00640198|DRUG|placebo|Placebo
48174495|NCT04888845|BEHAVIORAL|Safety Plan|The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
48174496|NCT04888845|BEHAVIORAL|Crisis Response Plan|Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
48174497|NCT04888845|BEHAVIORAL|Structured interview|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
48174498|NCT04888845|BEHAVIORAL|Narrative Assessment|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis."
48174499|NCT03962764|BEHAVIORAL|Responsible Fatherhood Program|24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
48174500|NCT02788526|PROCEDURE|Adjuvant TACE|1\~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
48174501|NCT02788526|PROCEDURE|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
48174502|NCT04334278|BEHAVIORAL|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
48174503|NCT04334278|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth.
48174504|NCT03330171|BIOLOGICAL|Measles vaccine|All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.
48174505|NCT03330171|BIOLOGICAL|Hepatitis-A vaccine|Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.
48174506|NCT03330171|BIOLOGICAL|Varicella vaccine|Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
48174507|NCT03740477|DIAGNOSTIC_TEST|ECG|Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
48706476|NCT05609877|DRUG|Fentanyl|Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
48706477|NCT05609877|BEHAVIORAL|Non-pharmacological standard operating procedure|All infants will receive the same non-pharmacological standard operating procedure.
48706478|NCT00996294|PROCEDURE|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
48706479|NCT06034951|DIETARY_SUPPLEMENT|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
48706480|NCT06232460|DIETARY_SUPPLEMENT|H80|5g, 10g \& 20g
48706481|NCT03281330|BEHAVIORAL|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
48706482|NCT03155334|OTHER|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback."
48017654|NCT06085105|BEHAVIORAL|CPIPE Training|A two day training covering the following topics: understanding stress \& burnout and developing positive coping mechanisms, bias awareness \& mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
48706483|NCT04113174|OTHER|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
48706484|NCT05176197|OTHER|Almond|Participants will consume almonds every day for 16 weeks.
48706485|NCT05176197|OTHER|Control|Participants will consume pretzels every day for 16 weeks.
48174508|NCT06396936|OTHER|Calisthenic exercise program|Calisthenic exercises to be applied in our study; These are exercises that are performed by creating resistance only with your body weight, without the need for any equipment or gym.
48706486|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
48174509|NCT03772600|DEVICE|Dexcom G6 CGM|Use of Dexcom G6
48706487|NCT05153811|BEHAVIORAL|mHealth|Participants will engage with an application designed to gamify drinking reduction.
48174510|NCT02605096|PROCEDURE|MRI|Magnetic Resonance Imaging Scan
48174511|NCT02605096|PROCEDURE|X-ray|X-ray exam (conventional radiography)
48174512|NCT06284434|DRUG|Liposomal Bupivacaine|Patients will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
48174513|NCT06284434|DRUG|Bupivacain|Patients will receive standard bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
48174514|NCT06284434|DRUG|Epinephrine|Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
48174515|NCT02379793|DRUG|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
48174516|NCT02719925|OTHER|Mg(+)|"* 1,5 L per day during 30 days~* No livestyle counseling"
48174517|NCT02719925|OTHER|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
48174518|NCT01361958|DRUG|NOMAC|
48174519|NCT04469790|BEHAVIORAL|SIT+WALK|Participants will interrupt their sitting for one week
48174520|NCT04469790|BEHAVIORAL|EX|Participants will perform a single bout of exercise and then sit for the remaining time for one week
48174521|NCT05815823|OTHER|robotic exercise therapy|Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
48174522|NCT05815823|OTHER|conventional therapy|streching, range of motion, strengthening, balance and walking exercise
48174523|NCT01921777|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
48174524|NCT01921777|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
48174525|NCT03127878|OTHER|Exercise|
48174526|NCT04322760|DRUG|Lidocaine 5% patch with Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
48174527|NCT04322760|DRUG|Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
48174528|NCT00713206|DEVICE|Dental Implant (Osseotite)|Root form titanium dental implant
48174529|NCT02932085|DEVICE|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
48174530|NCT05376904|DRUG|HR18034|HR18034 low dose
48174531|NCT05376904|DRUG|HR18034|HR18034 midium dose
48174532|NCT05376904|DRUG|HR18034|HR18034 high dose
48174533|NCT05376904|DRUG|ropivacaine HCl.|ropivacaine HCl.
48174534|NCT06235385|OTHER|Intervention not provided|This study is purely observational
48174535|NCT05580198|DIAGNOSTIC_TEST|Transcranial sonography.|Transcranial sonography examination to determine the brainstem raphe echogenicity.
48174536|NCT05598528|OTHER|Genomic profiles detection|The Paraffin-embedded tumor tissue at diagnosis is collected and assessed by Next- generation gene sequencing
48174537|NCT05598528|OTHER|circulating tumor DNA detection|The Plasma at diagnosis and at 1-month treatment are collected and assessed by Next-generation gene sequencing
48174538|NCT03022578|PROCEDURE|Laser Interstitial Thermal Therapy|Undergo LITT
48174539|NCT03022578|DRUG|Lomustine|Given PO
48375048|NCT04446182|DRUG|Itacitinib|All eligible patients will begin study therapy with approximately a week lead-in of itacitinib monotherapy at scheduled dose. Itacitinib will be taken daily at scheduled dose for a total of six cycles. Itacitinib may be tapered as deemed appropriate by the treating investigator. Patients will remain on study therapy as long as treatment discontinuation criteria are not met. Patients with Partial Response (PR) or better may continue itacitinib for up to 1 year.
48706488|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
48706489|NCT04619797|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
48706490|NCT04619797|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
48706491|NCT04619797|DRUG|Pemetrexed|Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
48706492|NCT04619797|DRUG|Carboplatin|Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
48706493|NCT04619797|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
48706494|NCT04619797|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
48706495|NCT04619797|DRUG|Pembrolizumab|Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
48706496|NCT06089213|OTHER|real-time intervention|An individual exercise program will be carried out at home, supervised remotely via videoconference.
48017655|NCT06085105|BEHAVIORAL|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
48017656|NCT06085105|BEHAVIORAL|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
48017657|NCT06085105|BEHAVIORAL|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
48174540|NCT05298293|DEVICE|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
48174541|NCT04244149|OTHER|Prolonged Exercise session|After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
48174542|NCT02550483|OTHER|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
48706497|NCT03893240|DIAGNOSTIC_TEST|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
48706498|NCT06556238|OTHER|Nicotine Metabolite Ratio|Blood specimens will be drawn, in clinic, by clinical staff trained in blood collection (e.g., certified medical assistant, nurse). Through regular clinic procedures, lab staff will ship for processing to Quest. Quest uses liquid chromatography tandem mass spectrometry with a limit of detection of 2ng/ml for all analytes and will quantify NMR within 3-6 days of sample arrival. Samples will be consumed during testing. Results of NMR will be returned to primary care providers, and NMR-informed medication recommendations will be made to participants.
48706499|NCT04293510|PROCEDURE|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
48706500|NCT06067048|DRUG|Zanubrutinib Oral Capsule|36 cycles (1 cycle is 28 days)
48017658|NCT06085105|BEHAVIORAL|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
48017659|NCT01947803|DRUG|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
48017660|NCT04496609|DEVICE|Stimulation and automated rehabilitation / automated rehabilitation|Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
48174543|NCT02550483|OTHER|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
48174544|NCT02550483|OTHER|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
48174545|NCT03416569|DRUG|Placebo|placebo skin patch + placebo capsule
48174546|NCT03416569|DRUG|Nicotine|nicotine patch (7 mg/24 hrs) + placebo capsule
48174547|NCT03416569|DRUG|Prazosin|placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
48174548|NCT03416569|DRUG|Nicotine + Prazosin|nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
48174549|NCT00005569|DRUG|SLPI (Secretory Leukocyte Protease Inhibitor)|
48174550|NCT03591627|DIAGNOSTIC_TEST|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
48174551|NCT05514171|PROCEDURE|Neoadyuvant therapy|Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
48174552|NCT03842631|DRUG|Timolol Maleate 0.5% Oph Soln|External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
48174553|NCT05395026|OTHER|electrical stimulation of vagus nerve|VNS electrical stimulation parameters (pulse duration, pulse amplitude, and pulse frequency) will be systematically changed to determine the effect on vagus nerve activation, laryngeal muscle contraction, and heart rate.
48174554|NCT04422977|DIAGNOSTIC_TEST|Sars-Cov-2 serology|Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
48174555|NCT02928471|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
48174556|NCT01313624|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
48375049|NCT04446182|DEVICE|Extracorporeal Photopheresis (ECP)|ECP will begin after itacitinib lead in period. At the end of 8 weeks of combination therapy, patients will start a standard ECP taper schedule. Patients achieving PR or better after 6 cycles of itacitinib may continue treatment with itacitinib for up to 1 year. Thereafter, itacitinib may be tapered at the treating investigator's discretion.
48017661|NCT04496609|DEVICE|Automated rehabilitation / Stimulation and automated rehabilitation|Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
48017662|NCT04993352|DRUG|recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
48017663|NCT06261749|OTHER|Voluntary Abdominal Contractions|Abdominal contraction will be taught before exercise. They will be instructed to tighten their abdomen as if they were wearing tight pants and not to hold their breath. The visual biofeedback unit will be placed between the therapy table and the participant's abdominal area and will be used to monitor the contraction of the abdominal muscles. The visual biofeedback inelastic bag will be inflated to 70 mmHg and the participant will be instructed to draw the abdomen in and maintain the position. The participant will be asked to maintain a pressure of 60 mmHg during scapular retraction with visual feedback from an analog pressure gauge. Pressure changes of ± 5 mmHg due to breathing will be allowed. During exercise, the patient will be asked to perform the exercises while maintaining the pressure on the visual biofeedback.
48017664|NCT06261749|OTHER|Exercise|"Exercises;~1. Scapular retraction with arms next to the trunk~2. Scapular retraction with arms abducted at 45 degrees,~3. Scapular retraction with arms 90 degrees abducted,~4. Scapular retraction exercises with arms 120 degrees abducted The exercises will be performed with the shoulder head off the bed. The exercises will be repeated 3 times with 5 seconds rest between repetitions. To reduce the effect of fatigue, 2 minutes rest will be given between exercises. Each exercise will be performed with 3 seconds of concentric, 3 seconds of isometric and 3 seconds of eccentric contraction and muscle activation of UT-LT and SA muscles will be measured during these phases."
48017665|NCT00497926|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
48017666|NCT01788501|DRUG|Tacrolimus|D-1\~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20\~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
48017667|NCT01788501|DRUG|Cyclosporine|D-1\~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20\~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
48017668|NCT01788501|DRUG|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
48017669|NCT05039619|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
48017670|NCT05039619|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
48017671|NCT05039619|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
48174557|NCT01313624|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
48017672|NCT05039619|DRUG|Acetaminophen/paracetamol|Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
48017673|NCT05039619|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
48174558|NCT03029819|BEHAVIORAL|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
48174559|NCT03029819|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
48174560|NCT03029819|BEHAVIORAL|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
48174561|NCT03029819|DRUG|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
48174562|NCT04361968|OTHER|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
48174563|NCT04361968|OTHER|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
48174564|NCT04361968|OTHER|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
48375050|NCT02675699|BEHAVIORAL|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
48516921|NCT03352739|DEVICE|DBS of the NbM, power off|"DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
48516922|NCT06516211|DEVICE|Clara Pregnancy Test|Multi-Level Pregnancy Test
48516923|NCT06516211|DEVICE|Professional Marketed Pregnancy Test|Early Pregnancy Test
48706501|NCT04527874|BEHAVIORAL|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
48706502|NCT00359944|DRUG|AC-3933|5mg twice daily
48706503|NCT00359944|DRUG|AC-3933|AC-3933, 20 mg twice daily
48017674|NCT05039619|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
48017675|NCT05039619|DRUG|Prednisone|Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
48706504|NCT00359944|OTHER|Sugar Pill|Sugar Pill twice daily
48174565|NCT04361968|OTHER|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
48174566|NCT06040047|OTHER|Proprioceptive neuromuscular facilitation|Contract relax technique for each neck motion for three repetitions.
48174567|NCT06040047|OTHER|Passive mobilization|To restore normal joint play, postero-anterior passive joint mobilization of cervical spine segments and cervicothoracic junction in limited motion will be applied.
48017676|NCT03898804|DEVICE|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
48174568|NCT01284309|DRUG|Mirabegron|oral
48174569|NCT01284309|DRUG|Placebo|oral
48174570|NCT03534011|PROCEDURE|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
48174571|NCT03534011|DEVICE|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
48706505|NCT03760757|DIETARY_SUPPLEMENT|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
48706506|NCT03760757|DIETARY_SUPPLEMENT|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
48706507|NCT02233738|BEHAVIORAL|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
48706508|NCT02233738|BEHAVIORAL|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
48706509|NCT00756795|BEHAVIORAL|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
48706510|NCT03645525|DRUG|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
48706511|NCT03645525|DRUG|placebo|saline
48706512|NCT04994782|BEHAVIORAL|GAME-EOL|The GAME-EOL involves Hello game booklets as well as meetings with an interventionist. Players (ICD recipient and their family member or friend dyad) take turns asking the questions in their booklet and providing their answers to the question. The gameplay continues until all questions are answered or the dyad wishes to stop. Following the completion of the game play, participants will be offered the opportunity to complete advance directives using the conversation guide and advance directive form included in the conversation guide that accompanies the questionnaire booklet.
48706513|NCT00137137|PROCEDURE|Placement of the mini-screw|
48706514|NCT01280539|DEVICE|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
48706515|NCT00741494|DEVICE|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
48706516|NCT00774839|BEHAVIORAL|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
48706517|NCT02249299|DRUG|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
48706518|NCT02249299|DRUG|Placebo|
48706519|NCT00838825|OTHER|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
48706520|NCT04086537|DIAGNOSTIC_TEST|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
48375051|NCT02675699|BEHAVIORAL|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
48706521|NCT06035393|DRUG|HRG2005 inhalation|Drug 1: dose 1; dose 2; dose 3
48017677|NCT03031912|BIOLOGICAL|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
48017678|NCT03031912|OTHER|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
48174572|NCT00890539|DRUG|Methacholine challenge|Clinical and research test used in asthma
48174573|NCT03110263|OTHER|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
48174574|NCT03110263|OTHER|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
48174575|NCT01816685|DEVICE|CPAP|
48174576|NCT04778787|DRUG|Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)|Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
48174577|NCT02914171|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
48174578|NCT02914171|DEVICE|Insertable cardiac monitor|Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
48174579|NCT03774212|DEVICE|Active noise cancelling headphones|The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.
48174580|NCT02861196|PROCEDURE|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
48174581|NCT02988349|OTHER|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
48174582|NCT04759950|BEHAVIORAL|Multicomponent Physical Activity Program|The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
48375052|NCT03292770|DEVICE|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
48375053|NCT00806806|DRUG|SKY0402|Local administration of SKY0402 followed by noxious stimulus
48706522|NCT06035393|DRUG|Placebo to match HRG2005 inhalation|Drug 2
48017679|NCT05921773|DEVICE|AI-fNIRS neurofeedback device|The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness training through visual and auditory cues to help participants modulate their brain activity, and thus alleviates anxious states.
48017680|NCT05921773|DEVICE|AI-fNIRS neurofeedback device with sham signals|The sham control consists of playbacks of someone else's real AI-fNIRS neurofeedback and will be provided 3 times a week, for a total of 4 weeks.
48017681|NCT00503685|BIOLOGICAL|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
48017682|NCT00503685|BIOLOGICAL|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
48375054|NCT00806806|DRUG|Placebo|Local administration of Placebo followed by noxious stimuli
48706523|NCT06035393|DRUG|Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 3
48706524|NCT06035393|DRUG|Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 4
48706525|NCT04972708|GENETIC|Cross-sectional genetics study|Cross-sectional genetics study
48706526|NCT01862471|DEVICE|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
48706527|NCT01862471|DEVICE|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
48706528|NCT06052826|OTHER|Best Practice|Undergo standard of care
48706529|NCT06052826|OTHER|Cognitive Intervention|Receive delirium prevention education
48706530|NCT06052826|OTHER|Comprehensive Geriatric Assessment|Undergo geriatric assessment
48706531|NCT06052826|OTHER|Nutritional Intervention|Undergo nutritional optimization
48706532|NCT06052826|PROCEDURE|Physical Therapy|Undergo physical function optimization
48706533|NCT06052826|OTHER|Questionnaire Administration|Ancillary studies
48706534|NCT02995083|DRUG|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
48017683|NCT01449916|OTHER|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
48017684|NCT05004727|DRUG|Guselkumab|Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
48017685|NCT05004727|DRUG|Placebo|• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
48017686|NCT00099775|DRUG|Caspofungin|
48017687|NCT06462521|PROCEDURE|Cold Snare Piecemeal Resection (CSPR)|Qualifying polyps randomized to Cold Snare Piecemeal Resection (CSPR) will be removed using cold snare techniques (no electrocautery, no submucosal injection.)
48174583|NCT04759950|BEHAVIORAL|Mindfulness-Based Stress Reduction Program|This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
48174584|NCT04759950|BEHAVIORAL|Computerized Cognitive Training|An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
48174585|NCT04067908|OTHER|2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling|The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
48174586|NCT03171116|OTHER|none intervention|it is not an interventional study; it is an observational study
48174587|NCT01159483|DRUG|PF-04958242|Administered as specified in the treatment arm
48174588|NCT01159483|DRUG|Placebo|Administered as specified in the treatment arm
48174589|NCT02384278|BEHAVIORAL|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
48174590|NCT04156347|DRUG|Episcleral Topotecan|Transscleral Topotecan
48174591|NCT01301703|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
48174592|NCT04634955|PROCEDURE|tranforaminal epidural injection|tranforaminal epidural injection which is performed by fluoroscopic guidance
48174593|NCT02650986|DRUG|Cyclophosphamide|Given IV
48174594|NCT02650986|DRUG|Decitabine|Given IV
48174595|NCT02650986|OTHER|Laboratory Biomarker Analysis|Correlative studies
48375055|NCT01004822|DRUG|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48706535|NCT02995083|DRUG|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
48706536|NCT02995083|DRUG|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
48706537|NCT06495840|OTHER|no intervention|no intervention
48706538|NCT00673023|OTHER|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
48706539|NCT05023473|PROCEDURE|Pericapsular nerve group block|patients will receive pericapsular nerve group block
48706540|NCT05023473|DRUG|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
48706541|NCT05423340|OTHER|E-cigarette Flavor|Participants use an electronic nicotine delivery system with an assigned tobacco-flavored e-liquid
48706542|NCT05423340|OTHER|Tobacco Free Nicotine Pouch|participants will use tobacco free oral nicotine pouches
48706543|NCT02253563|BEHAVIORAL|Resistance Training|
48706544|NCT02253563|BEHAVIORAL|Balance Training|
48706545|NCT01689714|DRUG|Tc 99m EC20|
48706546|NCT04577716|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
48017688|NCT06462521|PROCEDURE|Cold Snare Endoscopic Mucosal Resection (Cold EMR)|Qualifying polyps randomized to Cold Snare Endoscopic Mucosal Resection (Cold EMR) will be removed using cold snare techniques (no electrocautery, with submucosal injection.)
48017689|NCT06245070|DEVICE|Active transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Active stimulations will be delivered by a 9 MxN Soterix HD-tES device for 20 minutes( 2 mA) per day for 5 days.
48375056|NCT01004822|DRUG|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48375057|NCT01004822|DRUG|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48706547|NCT04577716|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
48706548|NCT04577716|DIAGNOSTIC_TEST|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
48706549|NCT04577716|OTHER|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
48706550|NCT00764387|DRUG|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
48706551|NCT00764387|DRUG|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
48017690|NCT06245070|DEVICE|Sham transcranial direct current stimulation|HD electrodes (diameter of 1.2 cm) will be placed on the participants' skull using an HD-tDCS cap (Soterix Medical Inc. New York) and based on 5-10 international montage. Sham stimulations will be delivered by a 9 MxN Soterix HD-tES device. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
48017691|NCT01123018|BEHAVIORAL|Memtrax Memory screening test|Memory Screening test
48017692|NCT05298852|DIAGNOSTIC_TEST|High resolution computed tomography of the chest|All participants were subjected to High resolution computed tomography of the chest.
48017693|NCT05199948|OTHER|Soybean Oil Foods|Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
48017694|NCT05199948|OTHER|Palm Oil Foods|Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
48017695|NCT02138851|DIETARY_SUPPLEMENT|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
48174596|NCT02650986|PROCEDURE|Leukapheresis|Undergo leukapheresis
48174597|NCT02650986|BIOLOGICAL|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
48174598|NCT02759926|DRUG|Denatonium benzoate|
48375058|NCT01004822|DRUG|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48706552|NCT05550038|DIAGNOSTIC_TEST|Compression ultrasound|Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
48017696|NCT02138851|DIETARY_SUPPLEMENT|Placebo (300g/day)|Placebo (300g/day), parallel design
48375059|NCT01004822|DRUG|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48375060|NCT01004822|DRUG|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48516924|NCT04650217|DRUG|Carbidopa/levodopa|"L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose."
48017697|NCT02899897|DEVICE|echocardiography in IV fluid therapy|
48174599|NCT02759926|DRUG|Quinine hydrochloride|
48516925|NCT04650217|DRUG|Placebo|Carbidopa/levodopa matched placebo
48706553|NCT06484621|BEHAVIORAL|Acceptance and Commitment Therapy-Based Physical Activity Intervention|Provides experiential training in values-clarification and acceptance strategies to increase autonomous motivation for achieving self-determined physical activity goal via group-based workshops, email feedback, and brief support telephone calls.
48706554|NCT06484621|BEHAVIORAL|Physical Activity Education Control|Provides didactic instruction on physical activity and behavioral strategies for achieving prescribed physical activity goals via group-based workshops, email feedback, and brief support telephone calls.
48706555|NCT04730778|DIAGNOSTIC_TEST|serum creatinine and estimated glomerular filtration rate, on daily basis|Assess establishing criteria of CIN through a week after primary PCI
48706556|NCT04618042|DRUG|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
48706557|NCT04618042|DRUG|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
48174600|NCT02759926|DRUG|Tap water|
48174601|NCT01049386|OTHER|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
48174602|NCT01049386|PROCEDURE|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
48706558|NCT00790166|DEVICE|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
48706559|NCT00790166|DEVICE|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
48017698|NCT06661109|OTHER|Intervention (Kinesio Taping) group|No randomized study was found investigating the effect of kinesio taping on comfort levels in women having a cesarean delivery.
48017699|NCT03178071|DRUG|Lorlatinib|oral tablets, administered daily, continuously
48174603|NCT03889054|BEHAVIORAL|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~1. Plan of action in an exacerbation.~2. Education related to COPD.~3. Information on pharmacological medication.~4. Management of the exacerbation.~5. Management of stress and / or anxiety.~6. Nutritional recommendations.~7. Physical exercise recommendations.~8. Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
48375061|NCT01004822|DRUG|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48706560|NCT00790166|DEVICE|CPAP + No added humidity|ambient humidity
48706561|NCT06404372|DEVICE|Demetech Barbed PDO Suture|The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
48706562|NCT00325676|DRUG|Pantoprazole|
48706563|NCT01396265|DRUG|Afatinib|single dose
48706564|NCT01396265|DRUG|Afatinib|single dose
48706565|NCT01396265|DRUG|Rifampicin|multiple doses
48706566|NCT05770934|OTHER|Blood flow restricted low-load resistance exercise|Blood flow restricted low-load resistance exercise
48174604|NCT05671978|PROCEDURE|back-up head elevated position|The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table
48017700|NCT06540586|PROCEDURE|anterior Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 25 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
48017701|NCT05383846|OTHER|Experimental Narrative Exposure Therapy|"NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for complex trauma, aiming to reduce symptoms of traumatic stress in individuals. NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.~This is a multiple baseline single case series design which focuses on assessing the posited exposure and autobiographical memory integration components of Narrative Exposure Therapy; no comparator will be included."
48017702|NCT03983590|OTHER|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
48017703|NCT03205696|DRUG|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
48375062|NCT01004822|DRUG|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
48375063|NCT00524901|DRUG|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
48375064|NCT00524901|DRUG|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
48375065|NCT03280472|BEHAVIORAL|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
48375066|NCT03280472|BEHAVIORAL|Symptom tracking|Participants will track their symptoms
48706567|NCT02313870|DRUG|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
48017704|NCT04611997|DRUG|Indocyanine Green|Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
48017705|NCT03614013|OTHER|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
48017706|NCT04068675|BEHAVIORAL|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
48174605|NCT05671978|PROCEDURE|neutral position|The patient was then placed in the netural position
48375067|NCT01947010|BIOLOGICAL|Prevenar 13|
48375068|NCT01947010|BIOLOGICAL|Pneumovax|
48375069|NCT00003701|DRUG|carboplatin|
48375070|NCT00003701|DRUG|cisplatin|
48375071|NCT00003701|DRUG|doxorubicin hydrochloride|
48375072|NCT00003701|DRUG|methotrexate|
48375073|NCT00003701|DRUG|paclitaxel|
48375074|NCT00003701|DRUG|vinblastine sulfate|
48516926|NCT04650217|BEHAVIORAL|Exercise training|Subjects assigned t Exercise will exercise individually at their home on a program set each week by Dr. Sloan and the research assistant (RA) coach, who will work with the patient to ensure they train according to the program at the appropriate level of intensity. Subjects will select from a series of aerobic activities and for Weeks 1-2 will train at 55-65 percent of maximum HR as established during their qualifying CPET. In Weeks 3-4, they will increase exercise intensity to 65-75 percent of maximum HR, and in Weeks 5-12 they will train at 75 percent of maximum HR.
48706568|NCT02313870|DRUG|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
48706569|NCT01333969|PROCEDURE|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
48706570|NCT06357871|OTHER|No intervention|No intervention
48706571|NCT02767089|DRUG|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
48706572|NCT02767089|DRUG|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
48706573|NCT05764304|DRUG|Sinomenine|Participants will receive one intra-articular injection every 4 months
48706574|NCT05764304|DRUG|Glucocorticoid|Participants will receive one intra-articular injection every 4 months
48174606|NCT03353142|OTHER|Equal Breathing|"* Blood pressure recorded at baseline, immediately pre- and post-trial~* Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~* PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~* TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry"
48174607|NCT05605561|OTHER|Digital Story|It is the standard of care given according to the hospital's policies and procedures.
48375075|NCT06221852|OTHER|Ketogenic diet|The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.
48375076|NCT06221852|OTHER|Dietary Guidelines for Americans|Dietary Guidelines for Americans diet is a normo-caloric diet consisting of 3 meals a day plus snacks, emphasizing nutrient dense foods to meet food group needs (85% of calories), and limits foods and beverages higher in added sugars and saturated fat (15% of calories).
48375077|NCT00900328|OTHER|laboratory biomarker analysis|Correlative Studies
48706575|NCT03964246|BEHAVIORAL|Compassion Meditation (CM) intervention|"10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]"
48375078|NCT02735382|BEHAVIORAL|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
48017707|NCT06573775|DEVICE|pulsed ultrasound|treatment of myofacial trigger points with therapeutic ultrasound
48017708|NCT06573775|OTHER|myofascial release|manual massage and range of motion exercises
48017709|NCT06573775|DEVICE|lidocaine phonophoresis|transdermal tranmission of lidocaine molecules via ultrasound
48017710|NCT06168175|DRUG|Sodium lactate|2 mmol/kg, intravenous, daily for 5 consecutive days
48017711|NCT06168175|DRUG|Placebo|intravenous, daily for 5 consecutive days
48017712|NCT05627440|DIETARY_SUPPLEMENT|Ensure Max Protein|Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
48017713|NCT05627440|DIETARY_SUPPLEMENT|Ensure Original|Ensure Original, 1 bottle daily (237 mL), 9 grams protein
48017714|NCT04420026|RADIATION|Interact Active Tracker|Interact Active Tracker, allowing the automation of the fusion between a CBCT and ultrasound imaging
48017715|NCT05895006|DEVICE|alpha-frequency tACS|The investigators will apply a 2 mA sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup.
48017716|NCT05895006|DEVICE|Random noise stimulation|The investigators will apply a 2 mA sinusoid current oscillating at random frequency (1-200 Hz).
48375079|NCT02735382|BEHAVIORAL|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
48375080|NCT02679300|OTHER|Virtual reality exercise group|
48375081|NCT02679300|OTHER|Conventional exercise group (control group)|
48516927|NCT04650217|BEHAVIORAL|Control|Control will engage in a series of stretches and toning exercises designed to promote flexibility and improve core strength.
48516928|NCT01130493|DRUG|IPX066|experimental product
48516929|NCT01130493|DRUG|CLE|active comparator
48706576|NCT03964246|OTHER|Healthy Aging Psychoeducation|"The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]"
48706577|NCT03047395|BIOLOGICAL|risankizumab|Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
48017717|NCT05438082|DRUG|Antibiotic Prophylaxis|This trial will contain two arms in which patients will be randomized to receive one dose of either Trimethoprim (if \< 2 months) or Trimethoprim-Sulfamethoxazole (if ≥ 2 months) or placebo in suspension. Dosing regimen for the active treatment (Trimethoprim) will be based on weight (5mg/kg of Trimethoprim component) with a maximum dosage of 320mg
48706578|NCT04059523|DRUG|S6G5T-3|once daily
48706579|NCT04059523|DRUG|Retin-A® 0.1% Cream|once daily
48706580|NCT02182661|DRUG|Ba253BINEB|
48516930|NCT04564092|DRUG|DaTSCAN™ Ioflupane (123I) Injection|Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
48706581|NCT02830347|DRUG|Amoxicillin|Extraction
48706582|NCT02830347|PROCEDURE|Extraction|Extraction of third molars
48706583|NCT01071200|DRUG|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
48706584|NCT01071200|DRUG|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
48706585|NCT05105282|PROCEDURE|Two different blocks with same local anesthetic volume|Deep serratus anterior block and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
48706586|NCT02789423|PROCEDURE|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
48706587|NCT00746265|BEHAVIORAL|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
48706588|NCT02460783|OTHER|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
48706589|NCT02460783|OTHER|Healthy Living Diet|Counseling and educational material on diet portion, consistency
48706590|NCT04003480|DEVICE|FRAME|External support for vein grafts in peripheral bypass surgery
48706591|NCT05877027|OTHER|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
48706592|NCT05877027|OTHER|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
48706593|NCT05877027|OTHER|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
48706594|NCT01904149|DRUG|Placebo|Placebo single oral dose (first 8 hours)
48706595|NCT01904149|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
48706596|NCT01904149|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
48706597|NCT01904149|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
48706598|NCT01904149|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
48706599|NCT01904149|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
48706600|NCT01904149|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
48706601|NCT05512247|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
48706602|NCT00001155|DRUG|cyclophosphamide|
48706603|NCT00515294|DRUG|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
48706604|NCT00515294|OTHER|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
48017718|NCT05438082|OTHER|Placebo|The placebo group will receive an equal volume of placebo suspension that has been developed to have the same colour and taste as the antibiotic to preserve blinding.
48017719|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight \< 60 kg and Age \< 65 years and ASAI and II)
48706605|NCT00515294|DRUG|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
48706606|NCT00515294|OTHER|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
48706607|NCT04860934|BEHAVIORAL|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
48375082|NCT02841332|DRUG|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
48706608|NCT04860934|BEHAVIORAL|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
48706609|NCT00147862|DRUG|Tranexamic Acid|
48706610|NCT03263923|BEHAVIORAL|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
48375083|NCT02841332|OTHER|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~* Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~* magnetic resonance imagery spectroscopy sequence~* Perfusion magnetic resonance imagery sequence~* Diffusion magnetic resonance imagery sequence"
48375084|NCT02841332|DRUG|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
48375085|NCT02841332|OTHER|Clinical examination|"During the examination, the following parameters will be checked :~* Neurological examination~* Corticotherapy prescribed~* General status of patient (world health organization score)~* Weight and height~* Control of arterial pressure~* Chirurgical and medical history~* Concomitant treatment"
48375086|NCT04558515|DIAGNOSTIC_TEST|Novel malaria diagnostics & tools|Next generation microscopy tools for malaria diagnosis and medical applications
48375087|NCT02836795|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
48375088|NCT02129257|DRUG|AFLIBERCEPT|
48375089|NCT02129257|DRUG|Irinotecan|
48375090|NCT02129257|DRUG|5-Fluorouracil|
48375091|NCT02129257|DRUG|Folinic Acid|
48375092|NCT02195882|PROCEDURE|Exercise program of the scapular muscle stabilizers|
48375093|NCT03175809|OTHER|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
48375094|NCT03175809|OTHER|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
48375095|NCT05239065|BEHAVIORAL|The basic intervention|The participants will receive a paper-printed booklet introducing stress and stress management strategies, regular exercise, deep breathing and mediation, etc, as well as a HUAWEI portable device at the recruitment. During the following 3-month intervention phase, there is not informational materials, portable device data feedback, online group discussion or interpersonal communications with the participants. The participants will only need to fill in a simplified questionnaire biweekly.
48375096|NCT05239065|BEHAVIORAL|The personalized interventions|The participants will receive a paper-printed booklet introducing stress and stress management strategies and a HUAWEI portable device at the recruitment. A neurologist will be the health educator to host an online group for free communications. The typical stress-relieving methods and the strategies of using portable device will be explained by providing small videos, online article links and nursing coaching in person. The health educator will give regular knowledge educations about the stress hazards, stress management necessities and skills on weekly basis. The weekly data of HUAWEI portable devices will be sent to the participants along with personalized suggestions by trained nurses. At certain occasions, gifts and rewards will be sent out for encouragement and keeping attachment to the program. The participants will be required to fill in the weekly questionnaires online for feedback.
48516931|NCT01399658|PROCEDURE|Image-guided brachytherapy|MRI-guided application of brachytherapy
48706611|NCT03263923|BEHAVIORAL|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
48706612|NCT05643183|OTHER|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
48706613|NCT01671501|BEHAVIORAL|Motivational Interviewing|
48706614|NCT01671501|BEHAVIORAL|Email Feedback|
48706615|NCT01671501|OTHER|Usual Care|
48706616|NCT02403635|DRUG|Midazolam|
48706617|NCT02403635|DRUG|ASP2151|
48174608|NCT01155076|DIETARY_SUPPLEMENT|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
48174609|NCT01155076|DIETARY_SUPPLEMENT|Placebo|Placebo taken twice a day for 8 weeks
48174610|NCT02736955|DRUG|Valbenazine|
48516932|NCT01399658|DRUG|3'-Deoxy-3'-18f-Fluorothymidine|Assessing tumor proliferation in Gynecologic cancer
48516933|NCT00896974|OTHER|Laboratory Biomarker Analysis|Correlative studies
48516934|NCT00896974|OTHER|Pharmacological Study|Correlative studies
48706618|NCT01986309|DRUG|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
48706619|NCT01986309|DRUG|Normal saline|Sodium Chloride 0.9% infusion
48706620|NCT02728544|OTHER|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
48706621|NCT00118352|BIOLOGICAL|alemtuzumab|Given IV
48706622|NCT00118352|RADIATION|total-body irradiation|Undergo low-dose TBI
48706623|NCT00118352|DRUG|fludarabine phosphate|Given IV
48706624|NCT00118352|DRUG|cyclosporine|Given PO or IV
48706625|NCT00118352|DRUG|mycophenolate mofetil|Given PO
48706626|NCT00118352|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
48706627|NCT00118352|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
48017720|NCT01127438|DRUG|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight \<60 kg and Age \<65 years and ASAI and II)
48706628|NCT00118352|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
48706629|NCT00118352|OTHER|laboratory biomarker analysis|Correlative studies
48017721|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight \< 60 kg and Age \>/=65 years and ASA 3 or 4
48017722|NCT01127438|DRUG|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight \<60 kg and Age \>/=65 years and ASA 3 or 4
48516935|NCT00896974|DRUG|Retinoid 9cUAB30|Given orally
48516936|NCT02475928|DIETARY_SUPPLEMENT|zinc gluconate|Zinc supplementation plus nutritional education
48706630|NCT06489990|COMBINATION_PRODUCT|combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]|combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]
48706631|NCT06489990|COMBINATION_PRODUCT|routine health education and mental health knowledge|routine health education and mental health knowledge
48706632|NCT05366491|DIAGNOSTIC_TEST|Il-38 serum level|measurement of serum levels of IL-38
48706633|NCT02059551|PROCEDURE|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
48706634|NCT06032234|OTHER|This is an observational study|This is an observational study
48017723|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
48017724|NCT01127438|DRUG|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight \>/= 60 kg and Age \>/= 65 years and ASA 3 or 4
48017725|NCT00647192|DRUG|Eplerenone|50 mg per day
48017726|NCT00647192|DRUG|Placebo|50 mg per day
48017727|NCT01498926|DRUG|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
48017728|NCT01498926|DRUG|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
48017729|NCT03480555|DIETARY_SUPPLEMENT|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
48174611|NCT05216198|OTHER|Check of the different exams performed at the emergencies|Check of the different exams performed at the emergencies
48174612|NCT05499143|OTHER|Online questionnaire|Online questionnaire impact for DCD - Belgian version
48174613|NCT01662037|DRUG|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
48174614|NCT03498352|PROCEDURE|Thoracic surgery|Lung resection surgery
48174615|NCT03167177|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
48174616|NCT03167177|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
48174617|NCT03167177|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
48174618|NCT03167177|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
48174619|NCT03167177|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48174620|NCT03167177|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48174621|NCT03167177|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
48516937|NCT02475928|DIETARY_SUPPLEMENT|Placebo|
48516938|NCT02475928|BEHAVIORAL|Nutritional education|
48706635|NCT00150358|DRUG|Sildenafil Citrate|
48706636|NCT03094650|DEVICE|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
48516939|NCT04524195|DRUG|[18F]F-AraG Injection|Single dose of 5 mCi+/- \[18F\]F-AraG IV injection followed by the PET/CT scan. A baseline \[18F\]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second \[18F\]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.
48516940|NCT05231434|OTHER|water|hydration with mineral water in 10 equal portions, administered at regular intervals from the 15th minute of exercise until the end of the recovery period.
48516941|NCT05231434|OTHER|aerobic activity|aerobic activity
48516942|NCT04122040|DRUG|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
48706637|NCT01956630|BIOLOGICAL|Genetically modified DCs plus CIK cells|
48706638|NCT01956630|BIOLOGICAL|Donor leukocyte infusions (DLI)|
48706639|NCT04588012|BEHAVIORAL|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
48706640|NCT04588012|BEHAVIORAL|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
48706641|NCT04899375|DEVICE|Floss band|Tissue-flossing, is the use of an elastic band to provide compression on soft-tissue and joints whilst performing active and, or passive range of motion.
48706642|NCT04899375|DEVICE|ACE bandage|An ACE bandage is a cloth wrap used to provide compression
48706643|NCT02448953|PROCEDURE|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
48706644|NCT02448953|PROCEDURE|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
48706645|NCT01693874|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
48706646|NCT01693874|BEHAVIORAL|control (health education)|health education
48706647|NCT02810301|OTHER|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
48017730|NCT03480555|DIETARY_SUPPLEMENT|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
48017731|NCT06663007|DRUG|RC48|During the patient treatment phase, the subjects received intravenous infusion of Disitamab Vedotin(RC48) (2.0 mg/kg) every 2 weeks until disease progression or death occurred.
48017732|NCT06663007|DRUG|Envafolimab|During the treatment phase of the patient, the subjects received subcutaneous injections of Envafolimab (400 mg) every 3 weeks until the patient experienced disease progression or death.
48017733|NCT03952039|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
48017734|NCT03952039|DRUG|Best Available Therapy (BAT)|Best available therapy (BAT)
48017735|NCT00699881|DRUG|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
48017736|NCT01790750|DEVICE|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
48017737|NCT00704145|DEVICE|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
48017738|NCT04626674|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
48017739|NCT04498897|DRUG|Vortioxetine|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
48017740|NCT04498897|DRUG|Acamprosate|"* Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate"
48017741|NCT02478892|OTHER|surveillance endoscopic ultrasound or MRI of the abdomen|The patients will be followed up clinically with routine surveillance endoscopic ultrasound or MRI surveillance every 12 months for a duration of 10 years
48017742|NCT06440707|DEVICE|High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)|The active study treatment involves delivering a weak form of electrical stimulation via 5 small electrodes to the brain tissue at risk of infarction.
48017743|NCT06440707|DEVICE|Sham tDCS|Sham patients will have cap and electrodes in place, but no stimulation will be delivered.
48706648|NCT02810301|OTHER|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
48706649|NCT05413265|BEHAVIORAL|Phases 1 and 2|Phase 1 participants will help inform the cultural adaptation of the study design and materials. Phase 2 will enroll 10 dyads (20 individuals) of AN/AI people who smoke and a family member. Dyad participants will help beta-test the feasibility and acceptability of the financial incentives intervention.
48017744|NCT05126888|DRUG|SCI-110|SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
48017745|NCT05126888|OTHER|Placebo|Pill that matches in taste, odour and appearance to SCI-110 active pills
48706650|NCT02094027|BEHAVIORAL|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
48706651|NCT02094027|OTHER|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
48706652|NCT00003044|DRUG|cisplatin-e therapeutic implant|
48017746|NCT01583725|PROCEDURE|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
48706653|NCT06608992|DRUG|SURGICEL® Powder|SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
48706654|NCT03839485|DRUG|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
48706655|NCT03839485|DRUG|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
48706656|NCT05405491|OTHER|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
48706657|NCT05405491|OTHER|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
48174622|NCT03167177|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
48375097|NCT05669378|BEHAVIORAL|Appetite to Play +|In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
48706658|NCT03088631|DRUG|Metformin|will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
48706659|NCT03088631|OTHER|Placebo|will receive corn-flour placebo tablets (three tablets daily).
48174623|NCT03167177|BIOLOGICAL|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
48706660|NCT02947854|DRUG|Fimaporfin (Photosensitizer)|
48706661|NCT02947854|BIOLOGICAL|Hiltonol (Poly-ICLC)|
48174624|NCT03167177|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
48174625|NCT03167177|RADIATION|Stereotactic Body Radiation Therapy|radiation
48174626|NCT03167177|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48174627|NCT03167177|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
48017747|NCT01583725|BEHAVIORAL|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
48017748|NCT05322317|OTHER|ADVANCE-PC training via ECHO|To assess the feasibility of using a technology-based platform to deliver the ADVANCE-PC program to multiple primary care clinics. This model will be based on the ECHO program, a tele-mentoring program which uses communications technology to provide facilitated education, case review, and peer-to-peer problem solving remotely. Our working hypothesis is that the use of ECHO will be efficient (allowing several clinicians and teams to be supported simultaneously while creating a community of practice), feasible (that clinicians will enroll and share experiences via mentoring, guidance, feedback, and didactic education), and have the potential to impact patients as clinicians perceptions shift to favor ACP, their skills increase, and they are able to integrate ACP for patients with dementia into their clinic.
48174628|NCT03167177|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
48174629|NCT03167177|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
48174630|NCT03167177|BIOLOGICAL|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
48174631|NCT03167177|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
48516943|NCT04122040|DRUG|Placebo|Placebo one table oral once dialy
48017749|NCT00643955|OTHER|muscle strength|muscle strength
48174632|NCT03167177|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
48174635|NCT05079906|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
48174636|NCT05079906|DEVICE|High Definition Intravascular Ultrasound (HD-IVUS)|High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
48516944|NCT03420911|DRUG|dexketoprofen trometamol|
48516945|NCT03420911|DRUG|Midazolam|
48516946|NCT05309395|COMBINATION_PRODUCT|FoodRx|Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
48516947|NCT00191191|DRUG|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
48516948|NCT00191191|DRUG|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
48516949|NCT02827695|BEHAVIORAL|SMASK|Medication adherence and BP monitoring
48706662|NCT02947854|BIOLOGICAL|HPV E7 (Human Papilloma Virus E7) peptides|
48174637|NCT06149143|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
48174638|NCT03703349|DRUG|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
48174639|NCT03703349|DRUG|Placebo Oral Tablet|Placebo for Magnesium
48706663|NCT02947854|BIOLOGICAL|KLH (Keyhole Limpet Hemocyanin)|
48706664|NCT03003221|BEHAVIORAL|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
48706665|NCT03003221|BEHAVIORAL|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
48174640|NCT01278706|PROCEDURE|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
48174641|NCT04288206|DRUG|Cefazolin|intravenous cefazolin is being evaluated as a pre-operative prophylactic antibiotic measure with primary outcome being post operative infection rate among participants.
48174642|NCT04288206|DRUG|normal saline|intravenous normal saline placebo
48174643|NCT00103532|BEHAVIORAL|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
48174644|NCT00103532|BEHAVIORAL|Standard care|Participants will receive standard care plus referrals at three months post-baseline
48174645|NCT00616330|DRUG|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
48174646|NCT00616330|DRUG|clindamycin phosphate|semi solid, single dose
48174647|NCT00616330|DRUG|butoconazole nitrate|semi solid, single dose
48174648|NCT01340014|DRUG|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
48174649|NCT01340014|DRUG|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
48174650|NCT03361098|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg oral tablet once daily
48516950|NCT02827695|BEHAVIORAL|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
48516951|NCT01491191|DIETARY_SUPPLEMENT|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
48706666|NCT03378427|DRUG|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
48017750|NCT00162136|DRUG|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
48017751|NCT06252285|BIOLOGICAL|RSVt Vaccine|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
48174651|NCT03361098|DRUG|Exenatide|Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
48174652|NCT03361098|OTHER|placebo exenatide|placebo b.i.d. exenatide
48174653|NCT03361098|OTHER|placebo dapagliflozin|placebo tablets dapagliflozin
48174654|NCT02351713|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
48174655|NCT05227664|DRUG|AK117|AK117 at a dose of 45mg/kg via intravenous (IV) infusion on Days 1,8 ,15 and 22of each 28-day cycle until disease progression or unacceptable toxicity
48174656|NCT05227664|DRUG|AK112|AK112 at a dose of 20mg/kg via intravenous (IV) infusion on Days 1and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
48174657|NCT05227664|DRUG|Nab paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
48174658|NCT05227664|DRUG|paclitaxel|Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
48174659|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
48174660|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
48174661|NCT05683912|DRUG|Aflibercept|Intravitreal aflibercept as used in the routice clinical practice
48174662|NCT02482532|BIOLOGICAL|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
48174663|NCT02108626|DRUG|Nicotine|E-Cigarette with nicotine cartridge
48174664|NCT02108626|DRUG|Placebo|E-Cigarette with 0mg nicotine cartridge
48174665|NCT02970305|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
48706667|NCT01602029|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
48706668|NCT01602029|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
48706669|NCT01602029|DRUG|Placebo|Placebo added to TAU
48706670|NCT01602029|DRUG|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
48706671|NCT06539858|OTHER|massage|General back massage from the base of the neck to the sacrum. Classical massage techniques such as stroking and kneeding will be applied. To be performed by a specialist physiotherapist.
48706672|NCT05401812|DRUG|Intravenous glucocorticoid therapy|Betamethasone, dexamethasone, or methylprednisolone
48706673|NCT00596245|DRUG|MT400|MT 400, naproxen sodium 550mg
48706674|NCT03807297|DRUG|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
48706675|NCT03807297|DRUG|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
48706676|NCT03807297|OTHER|sevoflurane|inhalational anaesthetic agent
48706677|NCT03807297|OTHER|nitrous oxide|inhalational anaesthetic agent
48174666|NCT02970305|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
48174667|NCT00192426|BIOLOGICAL|CAIV-T|
48174668|NCT05329233|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
48174669|NCT01058525|PROCEDURE|median nerve block|median nerve block performed using ultrasound guidance
48706678|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
48706679|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
48706680|NCT05173688|DRUG|Propofol|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
48706681|NCT04259788|OTHER|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
48706682|NCT04165655|BEHAVIORAL|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
48017752|NCT06252285|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
48174670|NCT01058525|PROCEDURE|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
48174671|NCT00816556|DRUG|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
48174672|NCT00816556|DRUG|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
48174673|NCT00816556|DRUG|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
48174674|NCT02645539|DEVICE|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
48174675|NCT03260933|OTHER|No intervention given. This is a qualitative interview study|This is a qualitative interview study
48174676|NCT00637247|DRUG|imexon in combination with gemcitabine|875 mg/m\^2 imexon IV + 1000 mg/m\^2 gemcitabine IV
48017753|NCT01697384|DRUG|histrelin acetate|52 week implant
48174677|NCT00637247|DRUG|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m\^2 gemcitabine IV
48174678|NCT01218425|DRUG|Methylphenidate 40 mg|Oral dose 40 mg
48174679|NCT01218425|DRUG|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
48174680|NCT01218425|DRUG|Domperidon 10 mg|Domperidon 10 mg
48174681|NCT04591262|DRUG|14C-PF-06826647-LR 600 mg PO|14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
48706683|NCT00612014|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
48174682|NCT04591262|DRUG|PF-06826647 600 mg PO|Unlabeled PF-06826647 600 mg
48706684|NCT00612014|DRUG|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
48706685|NCT00612014|DRUG|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
48706686|NCT00612014|DRUG|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
48017754|NCT02242877|DRUG|Telmisartan|
48017755|NCT02242877|DRUG|Telmisartan combined with hydrochlorothiazide|
48174683|NCT04591262|DRUG|14C-PF-06826647 100 ug IV|14C-PF-06826647 100 ug IV
48174684|NCT04035577|BEHAVIORAL|Mobile self-help intervention|During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
48174685|NCT03248141|DRUG|Hemophilia B standard half-life|Benefix
48174686|NCT03248141|DRUG|Hemophilia B extended half-life|Alprolix
48174687|NCT03248141|DRUG|Hemophilia A standard half-life|Xyntha and other standard half-life agents
48174688|NCT03248141|DRUG|Hemophilia A extended half-life|Eloctate and Adynovate
48174689|NCT04339023|DRUG|Open-Label Placebo|in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)
48174690|NCT04339023|OTHER|treatment as usual|usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)
48706687|NCT00612014|DRUG|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
48706688|NCT00612014|DRUG|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
48706689|NCT01498575|BEHAVIORAL|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
48706690|NCT00571246|DRUG|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
48174691|NCT04596098|OTHER|Blood sampling|During a care-related blood sampling, patient will provide additional blood sample for research purpuse.
48375098|NCT04254926|BEHAVIORAL|Revie ⊕|Revie ⊕ is a positive approach centered on the resources and strengths of the patient, and it consists of an intervention that focuses on the individual's life review. Revie ⊕ allows specialist nurses to discuss life events with cancer patients, to identify the significant elements, and to explore how the diagnosis has changed their values and preferences. The intervention is geared toward working with the patient to discover their potential, to identify their strategies for coping with the events of their life, and to thereby accompany them in achieving a better understanding of themselves and what defines their identity. The intervention also allows their concerns surrounding death to be addressed, in addition to providing clarity in regard to the life projects. In the end, as a conclusion to the intervention, the patient is provided a booklet recounting the salient features of their life review along with photographs, quotes, or images.
48706691|NCT00571246|DRUG|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
48706692|NCT00571246|OTHER|Placebo|Participants are randomized to take placebo
48706693|NCT03692494|OTHER|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
48706694|NCT03692494|OTHER|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
48706695|NCT03537742|BIOLOGICAL|alirocumab|alirocumab 150mg Subcutaneous
48706696|NCT03537742|BIOLOGICAL|placebo|placebo to match alirocumab
48706697|NCT03867565|OTHER|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
48706698|NCT01574157|DRUG|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
48706699|NCT01574157|DRUG|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
48706700|NCT05709717|PROCEDURE|Regenerative therapy with SVF-PRP to supplement perianal surgery|Regenerative therapy with autologous stromal vascular fraction derived mesenchymal stem cells and platelet-rich plasma to supplement perianal surgery
48706701|NCT02762955|BIOLOGICAL|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
48706702|NCT02762955|BIOLOGICAL|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
48706703|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
48706704|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
48706705|NCT01310400|BIOLOGICAL|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
48017756|NCT03215355|DRUG|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
48017757|NCT06428097|DRUG|Levothyroxine|Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
48017758|NCT06428097|DRUG|Normal saline|Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
48017759|NCT05967806|PROCEDURE|assessment|2 ml volume of blood withdrawal
48017760|NCT00323739|DRUG|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
48017761|NCT00323739|DRUG|RAD001|RAD001 10 mg by mouth daily
48017762|NCT00538005|BIOLOGICAL|bevacizumab|
48017763|NCT00538005|DRUG|oxaliplatin|
48017764|NCT00538005|DRUG|sorafenib tosylate|
48028678|NCT06218069|DRUG|Sasanlimab|6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
48028679|NCT06218069|RADIATION|non-ablative radiotherapy|Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.
48706706|NCT05045742|OTHER|Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2|We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
48706707|NCT00062023|DRUG|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
48706708|NCT00062023|DRUG|Sulindac|Patients receive oral sulindac twice daily for 12 months.
48706709|NCT00062023|DRUG|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
48706710|NCT00062023|OTHER|Sulindac Placebo|Oral sulindac placebo twice daily.
48706711|NCT02128815|OTHER|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
48706712|NCT01571908|DRUG|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
48706713|NCT01571908|DRUG|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
48706714|NCT01571908|DRUG|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
48706715|NCT01571908|DRUG|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
48706716|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
48706717|NCT02342717|DRUG|Itraconazole|multiple doses of Itraconazole capsules
48706718|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
48706719|NCT06139653|DEVICE|Moment 1: IMT. Moment 2 CardioBreath.|"Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks.~CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act."
48706720|NCT06139653|DEVICE|Moment 1: CardioBreath and moment 2: IMT.|"CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 5 sets of one minute with 30' of rest between the sets twice a day. respiratory rate of exercise will be determined by 80% of spontaneous respiratory rate twice a day for five weeks. An once a week meeting will provide readjustment of respiratory rate to perform exercises. One week washout will be taken between the two interventions in order to cleanse motor memory of respiratory act.~Participants will have PowerBreath device for IMT adjusted for 30% with weekly adjustment of maximal inspiratory pressure and will perform the exercise at home for five days/week. They will perform 5 sets of 10 repetitions twice a day for five weeks."
48028680|NCT06218069|DRUG|[89Zr]Zr-crefmirlimab berdoxam|Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
48028681|NCT05284994|DRUG|TQ-B3525 Tablets, Osimertinib Mesylate Tablets|TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
48028682|NCT02255110|DRUG|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m\^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
48028683|NCT02255110|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
48706721|NCT06535022|DIETARY_SUPPLEMENT|Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|Nighttime fasting and ß-hydroxybutyrate supplementation
48028684|NCT05588089|OTHER|Training group|"For the experimental group, Personal Information Form for Fathers and Infant Care Questionnaire were applied to the fathers in the clinic after birth as a pre-test. In the clinic, baby care training was given to fathers practically in 30-35 minutes. After the applied training, the Baby Care Training Program Content prepared by the researchers was given to the fathers."
48028685|NCT05427331|DRUG|FMT capsule|Patients with insomnia need to take FMT capsules orally in an empty stomach in the morning, 16 capsules once a week, for 4 consecutive weeks
48028686|NCT01895504|DEVICE|ColoAssist|Screening colonoscopy with the test instrument
48028687|NCT01895504|DEVICE|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
48706722|NCT04830904|DEVICE|personalized Lycra garments|the subjects wear lycra garments during the assessment time and for some days after the assessment
48706723|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
48706724|NCT05383443|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
48706725|NCT05383443|BEHAVIORAL|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
48706726|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
48706727|NCT05383443|OTHER|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
48706728|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
48706729|NCT05383443|BEHAVIORAL|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
48706730|NCT05383443|BEHAVIORAL|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
48706731|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
48516952|NCT01491191|DIETARY_SUPPLEMENT|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
48516953|NCT00296972|DRUG|peg interferon plus ribavirin|
48516954|NCT00629018|BIOLOGICAL|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
48516955|NCT00629018|DRUG|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
48706732|NCT05383443|BEHAVIORAL|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
48706733|NCT05082220|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
48706734|NCT03142555|BEHAVIORAL|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
48706735|NCT03142555|BEHAVIORAL|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
48706736|NCT03525184|OTHER|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).
48706737|NCT03525184|OTHER|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
48706738|NCT03654170|DRUG|BI 425809 mixed with [C-14] BI425809|Oral Solution
48706739|NCT04130061|BIOLOGICAL|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
48706740|NCT02218086|DEVICE|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
48706741|NCT02218086|DEVICE|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
48706742|NCT02218086|DEVICE|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
48706743|NCT02218086|DEVICE|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
48706744|NCT02218086|DEVICE|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
48706745|NCT02218086|DEVICE|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
48706746|NCT02218086|DEVICE|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times \~15minutes within y few weeks.
48706747|NCT06277349|DEVICE|Toric multifocal IOL|Implant of Multifocal toric intraocular lens only
48706748|NCT06277349|DEVICE|Non-toric multifocal IOL|Implant of non-toric multifocal lens plus incisional surgery
48706749|NCT00167596|DEVICE|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
48706750|NCT00167596|DEVICE|conventional|resuscitation will be based according to Surviving Sepsis Campaign
48516956|NCT00629018|BIOLOGICAL|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
48706751|NCT02887040|RADIATION|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
48706752|NCT02887040|DRUG|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
48028688|NCT04841057|PROCEDURE|50 cm BP limb length|50 cm biliopancreatic limb length
48028689|NCT04841057|PROCEDURE|100 cm BP limb length|100 cm biliopancreatic limb length
48706753|NCT02887040|DRUG|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
48706754|NCT01672658|DEVICE|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
48706755|NCT01672658|OTHER|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
48706756|NCT00048815|DRUG|Citalopram|Established Selective Serotonin Reuptake Inhibitor antidepressant
48706757|NCT00048815|DRUG|St. John's Wort|Natural extract from the St. John's Wort plant.
48706758|NCT00048815|DRUG|Placebos|Placebo pill
48706759|NCT06604845|BEHAVIORAL|Group cognitive behavioural therapy (CBT)|"CBT based on Safren's manual CBT for ADHD/Mastering Your Adult ADHD20 adapted for group format. The program includes psychoeducation and cognitive restructuring and aims to improve ADHD symptoms, especially planning, organisation, attention and adaptive thinking. The CBT groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two clinicians."
48028690|NCT04841057|PROCEDURE|150 cm BP limb length|150 cm BP limb length
48028691|NCT00253864|PROCEDURE|Single row|Fixation type in arthroscopic rotator cuff repair.
48028692|NCT00253864|PROCEDURE|Double row|Fixation type in arthroscopic rotator cuff repair.
48706760|NCT06604845|OTHER|Activity group|The Activity group is a structured manualised group intervention designed for this and planned future studies of psychosocial treatments for adults with ADHD and/or autism. The program includes group discussions, peer-sharing and social every-day life activities. The Activity groups will meet at the clinic weekly for 12 weeks for 2 hours including a break in the middle. The groups are led by two trainers.
48706761|NCT02100163|BEHAVIORAL|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
48028693|NCT03926507|PROCEDURE|Computed Tomography|Undergo PET/CT scan
48028694|NCT03926507|OTHER|Fluciclovine F18|Given IV
48028695|NCT03926507|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
48516957|NCT05524337|BEHAVIORAL|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
48516958|NCT05524337|BEHAVIORAL|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
48706762|NCT02100163|BEHAVIORAL|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
48706763|NCT02100163|OTHER|Standard treatment|
48706764|NCT06608394|OTHER|no intervention|no intervention
48706765|NCT05519501|DEVICE|SyntrFuge System|Microsized Adipose Tissue
48706766|NCT05519501|PROCEDURE|Standard of Care|Offloading
48706767|NCT06513377|OTHER|Performance test|The participant will be asked to execute a protocol in the movement lab that induces progressive feelings of fatigue. This protocol includes a sequence of relevant functional activities, such as stair walking, slope walking, crouching, walking different path shapes. During this execution the Ratings of Perceived Exertion will be questioned, and simultaneously physiological and movement data will be collected.
48706768|NCT04265508|OTHER|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
48706769|NCT00851578|DEVICE|WATCHMAN|WATCHMAN LAA Closure Device
48028696|NCT00235703|DEVICE|Antimicrobial Prescribing Decision Support|
48706770|NCT06455111|OTHER|Keenoa|Keenoa is an artificial intelligence-enhanced, image-assisted tool, is a newly designed mobile application that may facilitate collection of dietary data. Serving as a visual food diary, individuals can upload a picture of their meal, choose the food items eaten using a preselected food list available by the app, and confirm the portion size with the presented visual aids.
48706771|NCT06455111|OTHER|ASA24|The Automated Self-Administered 24-Hour (ASA24) dietary recall or record is a free, web-based tool that enables multiple, automatically coded, self-administered 24-hour diet recalls and/or single or multi-day food records, also known as food diaries.
48706772|NCT04965948|OTHER|Novel food snack|Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
48706773|NCT04965948|OTHER|Placebo snack|Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
48706774|NCT06477783|DRUG|Teclistamab|Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
48706775|NCT05438602|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
48706776|NCT05438602|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
48706777|NCT05438602|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
48028697|NCT06536283|OTHER|13-item Barriers Questionnaire (BQ-13)|Given by questionnaire
48028698|NCT06536283|OTHER|Four-item Medication Adherence Questionnaire|Given by questionnaire
48028699|NCT06536283|OTHER|14-item Hospital Anxiety and Depression Scale (HADS)|Given by questionnaire
48028700|NCT00523029|BEHAVIORAL|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
48028701|NCT01407861|OTHER|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
48028702|NCT01407861|OTHER|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
48028703|NCT05192122|OTHER|Discontinue maintenance therapy SOC|Continue maintenance therapy SOC
48028704|NCT05227508|DIETARY_SUPPLEMENT|BRIZO|A capsule containing 400 mg. SC012 (unique soy extract)
48028705|NCT05227508|OTHER|placebo|Comprecel microcrystalline cellulose
48028706|NCT03129893|DEVICE|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
48028707|NCT01141894|OTHER|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
48028708|NCT01141894|OTHER|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
48028709|NCT02300714|PROCEDURE|oblique view approach|
48028710|NCT05386160|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection of Ranibizumab；
48028711|NCT05386160|DEVICE|Phacoemulsification|Phacoemulsification
48028712|NCT05635214|PROCEDURE|real time remote tele mentored ultrasound exam|A patient will have a point of care ultrasound exam performed by a local provider with a remote expert guiding them through the exam using video conferencing.
48028713|NCT03963895|DRUG|AB002 Dose 1|AB002 (E-WE thrombin) 1.5 mcg/kg administered on Day 1 as a single intravenous infusion
48028714|NCT03963895|DRUG|AB002 Dose 2|AB002 (E-WE thrombin) 3.0 mcg/kg administered on Day 1 as a single intravenous infusion
48028715|NCT03963895|DRUG|placebo|placebo administered on Day 1 as a single intravenous infusion
48028716|NCT04098692|DRUG|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
48706778|NCT05438602|DRUG|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
48706779|NCT02417116|OTHER|Tear supplement|Application as required to improve comfort
48706780|NCT02417116|OTHER|Tear supplement 2|Application as required to improve comfort
48706781|NCT02417116|DIETARY_SUPPLEMENT|Omega 3 nutrition supplement|Taken each day
48706782|NCT02417116|DEVICE|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
48174692|NCT06023810|BEHAVIORAL|Watson's human care theory-based motivational interviewing method|The Motivational Interviewing Program based on Watson's Theory of Human Caring will be conducted over an 8-week period, with sessions taking place once a week. The initial session will have a duration of 60 minutes, while the subsequent weekly sessions will last for 30 minutes
48174693|NCT01993628|OTHER|Rey figure test|
48174694|NCT01993628|OTHER|MRI|
48174695|NCT04438382|BIOLOGICAL|Infliximab|Given IV
48174696|NCT04438382|BIOLOGICAL|Intravenous Immunoglobulin Therapy|Given IV
48174697|NCT04438382|DRUG|Prednisone|Given IV or PO
48174698|NCT04438382|DRUG|Methylprednisolone|Given IV or PO
48174699|NCT02238106|DRUG|Salmeterol medium dose|
48174700|NCT02238106|DRUG|Salmeterol low dose|
48174701|NCT02238106|DRUG|Salmeterol high dose|
48174702|NCT02238106|DRUG|Serevent® Diskus®|
48174703|NCT02238106|DRUG|Placebo HandiHaler®|
48174704|NCT02238106|DRUG|Placebo Diskus®|
48174705|NCT00511277|DRUG|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
48174706|NCT02592499|DEVICE|HM III|
48174707|NCT02592499|OTHER|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
48174708|NCT05226039|BEHAVIORAL|Moderate intensity acute exercise bout|The treatment/intervention will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike. Intensity will be prescribed based off of heart rate reserve.
48174709|NCT04982627|BEHAVIORAL|BNI Chatbot|The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
48174710|NCT04982627|BEHAVIORAL|OUD Education & Treatment Resources|The OUD Education \& Treatment Resources intervention is a web application that provides OUD education and treatment resources.
48706783|NCT02417116|OTHER|Saline|Application as required to improve comfort
48706784|NCT01322399|PROCEDURE|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
48706785|NCT01322399|PROCEDURE|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
48706786|NCT04693104|DEVICE|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
48706787|NCT04693104|DEVICE|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
48174711|NCT04011423|OTHER|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
48174712|NCT04011423|OTHER|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
48174713|NCT01804998|PROCEDURE|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
48174714|NCT01804998|PROCEDURE|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
48174715|NCT04252300|DRUG|Rosuvastatin|Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
48174716|NCT04252300|DRUG|Rosuvastatin + BAY1817080|A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
48174717|NCT00108498|DRUG|mirtazapine|
48516959|NCT05524337|BEHAVIORAL|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
48516960|NCT02771288|DEVICE|Bioresorbable Vascular Scaffold|
48706788|NCT00416156|BEHAVIORAL|Lifestyle modification|
48706789|NCT06605573|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
48706790|NCT06464744|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold
48706791|NCT06464744|PROCEDURE|Placebo stimulation using a placebo coil|The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
48706792|NCT05788783|BEHAVIORAL|Recovery & Care Canine-Assisted Therapy|Active intervention. An 6-week session of structured, goal-oriented activities where youth focus on mastering dog obedience and dog training skills. Each session is 1 hour and 15 minutes in length and includes education, review of prior sessions, and specific skill-building activities. Skill-building activities progress in complexity during the course of the 6-week curriculum.
48706793|NCT05788783|OTHER|Canine Education & Bonding|Active control intervention. An 6-week session of semi-structured activities. Sessions are 45 minutes in length. Youth in this condition engage in an educational component, passive observation of dog-training skills, and an active free-play session with the dog-handler teams.
48706794|NCT00241631|DRUG|Fluticasone Propionate|500 u
48706795|NCT00241631|DRUG|placebo|
48706796|NCT00241631|DRUG|Theophylline|Theophylline placebo capcule
48706797|NCT00457821|DRUG|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
48706798|NCT00457821|DRUG|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
48706799|NCT00457821|DRUG|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
48706800|NCT00457821|DRUG|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
48706801|NCT03233763|PROCEDURE|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
48706802|NCT03600766|DRUG|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
48706803|NCT03600766|DRUG|placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
48706804|NCT03634566|DRUG|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
48706805|NCT03634566|DRUG|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
48706806|NCT05545995|OTHER|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
48706807|NCT06607848|DEVICE|Low-Add EDOF IOL|Acunex Vario AN6V
48706808|NCT06607848|DEVICE|EDOF IOL|PureSee EDOF IOL
48706809|NCT01727115|OTHER|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
48706810|NCT04746482|PROCEDURE|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
48706811|NCT05135195|OTHER|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
48706812|NCT05135195|OTHER|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
48706813|NCT05941520|DRUG|Acolbifene Hydrochloride|Given PO
48028717|NCT04098692|DRUG|[14C]-Derazantinib solution for infusion|100 μg \[14C\]-derazantinib intravenous administration
48028718|NCT04098692|DRUG|[14C]-Derazantinib capsule|300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
48706814|NCT05941520|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48706815|NCT05941520|PROCEDURE|Mammography|Undergo 3D mammography
48706816|NCT05941520|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
48706817|NCT05941520|DRUG|Tamoxifen|Given PO
48706818|NCT05209451|BEHAVIORAL|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
48706819|NCT05209451|OTHER|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
48028719|NCT02752997|OTHER|Pharmacist discharge medication services|Included in arm descriptions
48028720|NCT03790891|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
48706820|NCT05209451|BEHAVIORAL|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
48706821|NCT06607159|OTHER|Implementation of healthy habits teaching protocol|Protocol for teaching healthy lifestyle habits, aimed at school-age children (initially between 1st and 4th grade of primary school), to be implemented transversally in schools. This protocol takes into account three levels of action: school, family and pupils. It includes materials in paper format and digital materials, that can be used both at school and at home.
48706822|NCT03746600|BEHAVIORAL|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
48706823|NCT03579472|DRUG|Bintrafusp Alfa|Given IV
48174718|NCT04710186|PROCEDURE|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
48174719|NCT03557242|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
48174720|NCT03557242|OTHER|Warfarin plus Aspirin|Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
48706824|NCT03579472|DRUG|Eribulin Mesylate|Given IV
48174721|NCT03557242|OTHER|Aspirin Only|Subjects randomized to this arm will receive aspirin only post TAVR
48174722|NCT02298049|OTHER|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
48706825|NCT02927925|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
48174723|NCT02298049|DEVICE|MRI|
48706826|NCT06077994|BEHAVIORAL|digital Remote Patient Monitoring+BEPR+ (dRPM+)|In addition to the BEPR+ program as described, patients will use the Cloud Dx Connect Health System to take daily physiological readings (Blood pressure, heart rate, oximetry, body temperature and body weight). These data will be transmitted to a secured server supported by the provincial health care system. Participants and therapists will interact with these data in their respective dashboards and in conjunction with participants' determined medical action plan, engage in or make changes to participants current self-management regimens.
48174724|NCT04919733|DEVICE|Fluoroscopy reduction|To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED
48174725|NCT02517528|DRUG|ABT-450/r/ABT-267|Tablet
48174726|NCT02517528|DRUG|ABT-333|Tablet
48706827|NCT06077994|BEHAVIORAL|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|Patients will attend the BEPR+ program 3 days per week for 6 weeks or 2 days per week for 8 weeks (total of 16 sessions). Patients will receive 90 minutes of personalized and supervised exercise training (aerobic and resistance) and 60 minutes of education designed to promote self-management. Patients will also received one-on-one sessions with a therapist to review their medical action plan for exacerbation management, program and lifestyle goals (including physical activity), determine referral needs for other health services (i.e. smoking cessation, weight management, and psychological support). Patients will use an activity monitor for feedback and motivation for physical activity.
48706828|NCT06518317|DRUG|Aspirin|Short duration of aspirin (3 months) is compared to long duration of aspirin (12 months)
48174727|NCT02517528|DRUG|ribavirin|Tablet
48174728|NCT05423431|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
48174729|NCT01803347|DRUG|◦Drug: ASCs. + fibrin glue|Experimental group
48706829|NCT04860895|DIAGNOSTIC_TEST|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
48706830|NCT05639153|DRUG|DR30303|DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
48706831|NCT01791881|DRUG|Hugeltox|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
48706832|NCT01791881|DRUG|Botulinum Toxin Type A(Botox®)|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
48706833|NCT06390540|OTHER|Exercise|During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
48706834|NCT00591968|DEVICE|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
48706835|NCT03648489|DRUG|Paclitaxel|Please refer to arm/group description
48706836|NCT03648489|DRUG|TAK228|Please refer to arm/group description
48706837|NCT00631150|DRUG|Levetiracetam (Keppra)|
48706838|NCT00881764|PROCEDURE|Inguinal hernia surgery|Non-experimental procedure
48706839|NCT00881764|PROCEDURE|General anesthesia|Non-experimental procedure/treatment
48706840|NCT06354907|BEHAVIORAL|The Kids' Empowerment Program|The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
48706841|NCT04644978|OTHER|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
48706842|NCT03659149|DRUG|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
48017765|NCT04436094|PROCEDURE|Orthodontic extrusion|"An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs."
48174730|NCT01803347|DRUG|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
48174731|NCT02605278|OTHER|Clinical program for pain and depression|Already described
48174732|NCT02605278|OTHER|Control|Care as usual
48174733|NCT04257422|OTHER|Intentional Rounding|"A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users."
48174734|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
48706843|NCT03659149|DRUG|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
48706844|NCT03659149|DRUG|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
48706845|NCT06597266|DEVICE|Smart template - designed prosthetic check socket|Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors
48706846|NCT06597266|DEVICE|Clinician-designed prosthetic check socket|Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)
48706847|NCT06605105|DRUG|CYB003|CYB003 is a synthetic psilocybin analog
48706848|NCT03788018|DRUG|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
48706849|NCT03788018|DRUG|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
48174735|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 48 weeks
48174736|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
48174737|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 24 weeks
48174738|NCT05090605|GENETIC|DNA analysis|GWAS
48706850|NCT03232814|BEHAVIORAL|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
48706851|NCT02789670|OTHER|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
48706852|NCT01080066|OTHER|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
48706853|NCT06608667|DEVICE|The study was retrospective and did not involve the application of interventions|The study was retrospective and did not involve the application of interventions
48706854|NCT04484649|BEHAVIORAL|Sleeping Healthy/Living Healthy|Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.
48706855|NCT04484649|BEHAVIORAL|Attention Control|"The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention."
48516961|NCT06353763|OTHER|Immersive virtual reality learning program|The immersive virtual reality learning programme was developed by the research team and two nurse experts in chronic wounds, who designed the learning content and script and created six pressure ulcer (PU) cases. Based on the standards of the European Pressure Ulcer Advisory Panel (EPUAP), the National Pressure Ulcer Advisory Panel (NPUAP) and the National Group for the Study and Advice on Pressure Ulcers and Chronic Wounds (GNEAUPP), prevention of healthy skin (case one), management of grade I, II, III and IV PUs (cases two to five) and an infected PU (debridement intervention) were developed. For each case, there was a formative version with immediate feedback and an evaluative one. Before starting the training, the students learned how to use the virtual reality glasses, buttons and joystick by playing a game that trained different dexterity movements. The computer assembly IVR application was developed using Unity 3D and the virtual objects were designed in 3Ds Max.
48174739|NCT04668703|PROCEDURE|Conbercept intravitreal injection|intravitreal injection of 0.5 mg conbercept at the conclusion of cataract surgery
48174740|NCT01108042|DRUG|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
48174741|NCT01588210|OTHER|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
48516962|NCT03680989|DEVICE|Bright Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~10,000 lux at 22."
48017766|NCT04436094|PROCEDURE|Immediate implant placement|The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
48174742|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
48174743|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
48174744|NCT02804399|DRUG|PF-06463922|100 mg oral dose on day 1 in period 1 and on day 8 in period 2
48706856|NCT04752137|DRUG|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
48174745|NCT02804399|DRUG|rifampin|600 mg QD from day 1 to day 12 in period 2.
48375099|NCT04233255|DEVICE|Neuromuscular Ultrasound (US)|"Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles."
48375100|NCT04233255|DEVICE|Electrophysiological studies|"Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz."
48375101|NCT04233255|DIAGNOSTIC_TEST|Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.|measured in U/L using ELISA.
48375102|NCT03381898|BEHAVIORAL|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
48375103|NCT02696382|BEHAVIORAL|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
48375104|NCT02696382|BEHAVIORAL|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
48375105|NCT01875900|OTHER|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
48375106|NCT01875900|OTHER|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
48516963|NCT03680989|DEVICE|Natural Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver \~500 lux at 22."
48516964|NCT06261645|OTHER|Early Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
48706857|NCT04752137|DEVICE|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
48706858|NCT04407650|DRUG|Metformin|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
48706859|NCT04407650|DRUG|Ursodeoxycholic Acid|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
48706860|NCT04529369|PROCEDURE|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
48706861|NCT04529369|PROCEDURE|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
48706862|NCT04084548|DRUG|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
48706863|NCT04084548|DRUG|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
48706864|NCT04084548|DRUG|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
48706865|NCT04084548|DRUG|Placebo|Perioperative placebo infusion (normal saline)
48706866|NCT04083313|DEVICE|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
48706867|NCT01980277|DRUG|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
48706868|NCT01326156|DEVICE|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
48706869|NCT02358031|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years).
48375107|NCT00128336|BEHAVIORAL|Lifestyle: diet and exercise intervention|
48375108|NCT00802152|OTHER|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
48375109|NCT05710666|DRUG|trastuzumab deruxtecan (T-DXd) (IV)|Administered as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle for up to six cycles.
48375110|NCT01269138|DRUG|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
48706870|NCT02358031|DRUG|Cisplatin|Cisplatin 100 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
48706871|NCT02358031|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
48174746|NCT05897983|OTHER|Rocabado exercises plus TENS device|Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
48375111|NCT01269138|DRUG|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
48375112|NCT01269138|DRUG|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
48375113|NCT01269138|DRUG|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
48516965|NCT06261645|OTHER|Delayed Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
48706872|NCT02358031|DRUG|5-FU|5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
48706873|NCT02358031|BIOLOGICAL|Cetuximab|Cetuximab on Day 1 at a dose of 400 mg/m\^2 IV, and then 250 mg/m\^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity
48706874|NCT00648674|DEVICE|Apligraf|Applied at Day 0, possible re-application at Week 6
48706875|NCT06490068|DRUG|LTC004+Toripalimab|"LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W."
48706876|NCT05022199|DEVICE|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
48706877|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
48706878|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
48706879|NCT04707989|OTHER|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
48706880|NCT02701777|OTHER|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
48706881|NCT02701777|BEHAVIORAL|Training|The participant will be asked to perform exercises using their hands and arms.
48174747|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-PreF-A vaccine|B/HPIV3/HMPV-PreF-A is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-PreF-A vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.7 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
48174748|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-F-B365 vaccine|B/HPIV3/HMPV-F-B365 is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-F-B365 vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.3 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
48375114|NCT01269138|DRUG|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
48706882|NCT02701777|OTHER|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
48706883|NCT02701777|OTHER|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
48706884|NCT05966428|OTHER|Conventional Exercises|"This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group."
48706885|NCT05966428|OTHER|Sensory Integration Therapy|"The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group."
48706886|NCT01842932|DRUG|Phloroglucin|Premedication of colonoscopy
48706887|NCT01842932|DRUG|Cimetropium bromide|Premedication of colonoscopy
48706888|NCT01842932|PROCEDURE|Colonoscopy|Diagnostic examination of colon
48706889|NCT01842932|DRUG|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
48706890|NCT05043519|DRUG|FAM-NP41|The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
48706891|NCT06279104|DRUG|physician's choice of chemotherapy|physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
48706892|NCT06279104|DRUG|immune checkpoint inhibitor based therapy|immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
48706893|NCT04449146|DIAGNOSTIC_TEST|Scapular positioning in Standing position using Sonography|The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
48706894|NCT02177643|DRUG|Diacerein|Diacerein oral capsules
48375115|NCT00082069|BIOLOGICAL|Shigella flexneri 2a Invaplex 50|
48375116|NCT01229865|DRUG|VB-111|
48375117|NCT01473602|DRUG|Teriparatide|Administered by SC injection
48375118|NCT01473602|DRUG|Placebo|Administered by SC injection
48375119|NCT01473602|DIETARY_SUPPLEMENT|Calcium supplementation|Administered orally
48375120|NCT01473602|DIETARY_SUPPLEMENT|Vitamin D supplementation|Administered orally
48375121|NCT00493701|BEHAVIORAL|High Fat Diet|Daily eating
48375122|NCT00493701|BEHAVIORAL|Low Fat Diet|Life style eating habits
48375123|NCT03049592|OTHER|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
48706895|NCT02177643|DRUG|Placebo|Placebo oral capsules
48706896|NCT03049267|DRUG|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
48706897|NCT03049267|DRUG|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
48706898|NCT06118541|BEHAVIORAL|Vestibular Rehabilitation therapy|"Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises"
48706899|NCT00473967|BIOLOGICAL|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
48706900|NCT00002319|DRUG|Doxorubicin hydrochloride (liposomal)|
48706901|NCT03651518|DRUG|Kineret|100 mg, once/day sc 6 months
48706902|NCT03651518|DRUG|Humira|40 mg/15 days sc 6 months
48017767|NCT00139997|DEVICE|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
48017768|NCT00139997|DEVICE|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
48017769|NCT01693224|DEVICE|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
48017770|NCT01693224|DEVICE|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
48017771|NCT01693224|DEVICE|Cepheid Xpert MTB/Rif assay|
48017772|NCT03799458|DEVICE|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
48017773|NCT03799458|DEVICE|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
48174749|NCT06546423|DRUG|Placebo|Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.
48174750|NCT02958059|BIOLOGICAL|Pacetin® (cefoxitin)|1\~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
48706903|NCT03651518|DRUG|Stelara|45 mg/12 weeks sc, 6 months
48174751|NCT02958059|BIOLOGICAL|Placebo|10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
48706904|NCT03651518|DRUG|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
48706905|NCT03651518|DRUG|Roactemra|480 mg/perf/4 weeks 6 months
48706906|NCT03651518|DRUG|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
48174752|NCT01056263|DRUG|axitinib: observational study|Non-interventional observational study
48375124|NCT01716442|DRUG|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
48375125|NCT01716442|DRUG|Placebo|
48375126|NCT01913613|DEVICE|IASD|IASD device implantation
48174753|NCT04366310|DEVICE|capillary refill index|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
48174754|NCT04366310|PROCEDURE|rewarming|warming fingertip skin temperature using an instant hot pack
48174755|NCT03043482|DRUG|Single VS-105/placebo to healthy|In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
48706907|NCT05611229|DRUG|Nivolumab|Nivolumab
48706908|NCT05611229|DRUG|Pembrolizumab|Pembrolizumab
48706909|NCT05611229|COMBINATION_PRODUCT|Dabrafenib+Trametinib|Dabrafenib+Trametinib
48706910|NCT05611229|COMBINATION_PRODUCT|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
48706911|NCT05611229|COMBINATION_PRODUCT|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
48706912|NCT05611229|COMBINATION_PRODUCT|Encorafenib+Binimetinib|Encorafenib+Binimetinib
48017774|NCT05016102|OTHER|Exercise type|Aerobic exercise and Resistance exercise
48017775|NCT00452335|DRUG|Lubiprostone|12 mcg capsule once daily (QD)
48017776|NCT00452335|DRUG|Lubiprostone|12 mcg capsule twice daily (BID)
48017777|NCT00452335|DRUG|Lubiprostone|24 mcg capsule twice daily (BID)
48017778|NCT03520491|DRUG|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
48017779|NCT03520491|DRUG|Ipilimumab|Ipilimumab 3 mg/kg
48017780|NCT03520491|PROCEDURE|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
48017781|NCT03880578|DRUG|Levothyroxine Sodium|thyroid hormone replacement
48017782|NCT06126055|DEVICE|Band Ligation|Placing bands in distal esophagus
48706913|NCT06555302|BEHAVIORAL|Cognitive Rehabilitation|Cognitive rehabilitation will be OT-led, one-on-one sessions focused on teaching cognitive strategies and their application to a broad set of activities/settings. The goal is to facilitate cognitive skill learning and generalization, by applying the new cognitive strategies to the participant's performance of home-based and community-based activities (taught through the subsequent OT portion of the intervention).
48017783|NCT04634227|DRUG|Ascorbate|Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
48017784|NCT00491790|DRUG|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
48017785|NCT00491790|OTHER|Sterile water|Sterile water
48017786|NCT02762669|DRUG|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
48017787|NCT06238505|OTHER|Virtual|application will be made with virtual reality device
48017788|NCT06238505|OTHER|biodex|application will be made with biodex device
48017789|NCT02734485|DEVICE|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
48017790|NCT02734485|DEVICE|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
48017791|NCT02453451|OTHER|2D-/3D-TTE|recording of 3 cardiac cycles
48017792|NCT02453451|OTHER|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
48017793|NCT02453451|OTHER|Walking Test|for 6 minutes
48017794|NCT02453451|PROCEDURE|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
48017795|NCT06570772|BIOLOGICAL|AVT16|AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
48017796|NCT06570772|BIOLOGICAL|Vedolizumab|Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
48017797|NCT06328959|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
48017798|NCT06328959|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
48017799|NCT04875104|DEVICE|Orthodontic treatment with Invisalign system|Patients are going to receive an orthodontic treatment with Invisalign aligners.
48017800|NCT04875104|DEVICE|Orthodontic treatment with Spark system|Patients are going to receive an orthodontic treatment with Spark aligners.
48017801|NCT04875104|DEVICE|Orthodontic treatment with Quicksmile system|Patients are going to receive an orthodontic treatment with Quicksmile aligners.
48017802|NCT04875104|DEVICE|Orthodontic treatment with ClearCorrect system|Patients are going to receive an orthodontic treatment with ClearCorrect aligners.
48017803|NCT05735080|DRUG|INX-315|Oral administration
48017804|NCT05735080|DRUG|Fulvestrant|Fulvestrant will be combined with INX-315
48017805|NCT02851576|OTHER|Infusion of ADV specific T cells|Cell engineering
48375127|NCT06520761|PROCEDURE|Injectable platelet rich fibrin|blood sample obtained from the participant, centrifuged at 700 rpm to produce injectable platelet rich fibrin, this will be injected around the upper canine
48017806|NCT05893160|DRUG|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
48017807|NCT05893160|OTHER|Placebo|Inert placebo formulation
48017808|NCT02738775|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
48017809|NCT02738775|DRUG|Placebo|
48017810|NCT04412941|BEHAVIORAL|Myofunctional exercises|"Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep."
48017811|NCT04412941|BEHAVIORAL|The rules of sleep hygiene|The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
48017812|NCT02871843|DRUG|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
48375128|NCT06520761|DEVICE|Low Level LASER|Diode LASER device is used to apply Low Level LASER around the upper canine
48375129|NCT01138709|DEVICE|Vitala|Vitala™ Continence Control Device
48174756|NCT03043482|DRUG|Multiple VS-105/placebo to healthy|In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
48174757|NCT03043482|DRUG|Multiple VS-105/placebo to HD subjects|In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
48375130|NCT04271423|PROCEDURE|Ridge Preservation|Ridge Preservation using demineralized bone matrix and mineralized particulate allograft and covered with calcium sulfate barrier.
48017813|NCT02871843|RADIATION|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
48017814|NCT02871843|DRUG|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
48017815|NCT02871843|DRUG|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
48017816|NCT02157324|DRUG|acalabrutinib|
48174758|NCT02582697|DRUG|Bleomycin (active name: Bleomycin Sulfate)|"Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses."
48375131|NCT01449474|DEVICE|Patient matched instruments|The patients undergo TKA with using patient matched instruments
48375132|NCT01449474|DEVICE|Jig based instruments|The patients undergo TKA with using jig based instruments
48375133|NCT03157804|PROCEDURE|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
48375134|NCT03157804|BIOLOGICAL|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
48375135|NCT03157804|OTHER|Laboratory Biomarker Analysis|Correlative studies
48017817|NCT02157324|DRUG|ACP-319|
48017818|NCT05841017|BEHAVIORAL|Psychotherapy with Immersive Virtual Reality support.|Psychoeducational group intervention and cognitive behavioural therapy individual intervention.
48017819|NCT03626129|PROCEDURE|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
48174759|NCT02582697|DRUG|Etoposide|"Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
48174760|NCT02582697|DRUG|Cisplatin|"Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
48174761|NCT02582697|DRUG|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
48375136|NCT03157804|BIOLOGICAL|Filgrastim|Given subcutaneously (SC)
48375137|NCT03157804|DRUG|Plerixafor|Given SC
48375138|NCT03157804|PROCEDURE|Bone Marrow Aspiration|
48375139|NCT01661426|BEHAVIORAL|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
48375140|NCT01661426|BEHAVIORAL|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
48375141|NCT00387101|DEVICE|Dermal - Living Skin Replacement (Dermal - LSR)|
48174762|NCT02582697|DRUG|Filgrastim|"Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 14-day cycle for 4 cycles."
48017820|NCT05953077|BEHAVIORAL|Conversational recasting|The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
48017821|NCT03909776|DRUG|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
48017822|NCT04963504|DIAGNOSTIC_TEST|Rest-to-exercise|Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)
48017823|NCT04963504|DIAGNOSTIC_TEST|Sitting-to-supine|Pulmonary diffusing capacity is assessed in the sitting and supine position
48017824|NCT02047604|DRUG|SAN-300 0.5 mg/kg QW|
48017825|NCT02047604|DRUG|SAN-300 1.0 mg/kg QW|
48017826|NCT02047604|DRUG|SAN-300 2.0 mg/kg QOW|
48017827|NCT02047604|DRUG|SAN-300 4.0 mg/kg QOW|
48174763|NCT05342519|DRUG|Rapamycin|While rapamycin is not approved for the treatment of vitiligo, it has been found to be efficacious in stopping disease progression in animal models. Another recent study in humans showed that doses of 0.5cc daily of 0.001% of the topical formulation are able to achieve improvement in hypopigmented lesions of the skin at both the clinical and histological level. At this dose, improvement in cell function was observed regarding maintenance of proliferative potential and prevention of senescence, with avoidance of total inhibition of cell growth as has been seen at higher potencies used for immunosuppression.
48174764|NCT05342519|DRUG|Rapamycin|Rapamycin is an immunosuppressant that works by inhibiting the mammalian target of rapamycin (mTOR) leading to inhibition of the cell cycle and antibody production. It has also been shown to promote expansion of Treg populations. Although studies evaluating alternative dosing for vitiligo are limited, topical rapamycin has previously been used to treat angiofibromas related to Tuberous Sclerosis, vascular malformations such as port-wine stains, and inflammatory lesions such as plaque psoriasis. In a 2019 meta-analysis, 38 out of 40 reports included used topical formulations of 1% or lower potency rapamycin; the majority of publications were focused on the treatment of Tuberous Sclerosis, where the median concentration of mTOR inhibition was 0.1% dosed twice daily.
48017828|NCT02047604|DRUG|SAN-300 4.0 mg/kg QW|
48017829|NCT02047604|DRUG|Placebo|
48017830|NCT05425810|DEVICE|Apply ENABLE sensing pad|The developed ENABLE system is integrated into the standard prosthetic liner and measures the pressure distribution during locomotion. Using the ENABLE system may lead temporary increase in the temperature inside the prosthetic socket and it is expected that the total exposition during the experimental procedure will be less than 10 min.
48174765|NCT05342519|DRUG|Placebo|All patients will be assigned to received topical placebo cream to the lesion not being treated with the active study drug.
48017831|NCT05425810|DEVICE|Insert small pads at pressure tolerant locations|To change the pressure distribution inside the socket, four fitting conditions are introduced by adding small pads at patella tendon (PT), lateral tibial crest (LTC), medial tibial crest (MTC), and popliteal fossa (PF) respectively. Including the no pads scenario, totally of five fitting conditions are simulated.
48017832|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
48174766|NCT02125136|DRUG|Gem/nab-Pac|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
48375142|NCT03195946|DRUG|Lu AF35700|tablets for oral use, 10 mg/day
48017833|NCT05305313|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
48017834|NCT03455855|DEVICE|Jetstream System|including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
48017835|NCT04471181|DEVICE|Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant|Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
48017836|NCT01075659|DRUG|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
48017837|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
48017838|NCT01075659|DRUG|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
48174767|NCT02125136|DRUG|FOLFIFINOX|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle."
48017839|NCT00298896|DRUG|SNS-595|
48017840|NCT02570321|PROCEDURE|Corneal Cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
48017841|NCT02570321|DRUG|Anti Fungal Drug|Topical Amphotericin B vs Topical Natamycin
48017842|NCT05166434|PROCEDURE|trans-crestal sinus lifting|this study will be divided in to three different groups, each group will receive a same technique of Crestal maxillary sinus lifting and implant placement at 2,4,6 mm heights.
48375143|NCT03195946|DRUG|Midazolam|syrup for oral use, 4mg/day
48375144|NCT03195946|DRUG|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
48706914|NCT06555302|BEHAVIORAL|Occupational Therapy|OT upper extremity rehabilitation will have 2 components: task-practice and metacognitive strategy training. The task-practice involves a patient repetitively practicing stroke-impaired movement skills within the context of a functional task to promote recovery of the impaired skills. THE task practice sessions will be coached/guided by the therapist through a metacognitive strategy training process which is based on the Cognitive Orientation to Occupational Performance (CO-OP) approach aimed at enhancing self-management during home and community living tasks.
48706915|NCT02136680|OTHER|CASA Education|Basic palliative care competencies for outpatient use.
48706916|NCT00616382|DRUG|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
48706917|NCT00616382|DRUG|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
48706918|NCT03630198|DRUG|Corticosteroid with lidocaine|Intralesional corticosteroid injection
48706919|NCT03630198|DRUG|Corticosteroid with normal saline|Intralesional corticosteroid injection
48706920|NCT06162546|OTHER|Registry|Registry Participation, providing data and clinical specimen
48017843|NCT01645475|DRUG|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
48017844|NCT04986059|OTHER|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands on gastrocnemius and hamstring muscles
48017845|NCT00654849|PROCEDURE|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
48375145|NCT05398458|PROCEDURE|Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years
48375146|NCT04022473|DRUG|Bafiertam|Over-encapsulated capsule to mask treatment
48375147|NCT04022473|DRUG|Tecfidera|Over-encapsulated capsule to mask treatment
48375148|NCT04935528|BIOLOGICAL|serology and ELISPOT test|27 mL blood sample to study the humoral and the cellular immune response
48706921|NCT03106844|DRUG|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
48017846|NCT00654849|PROCEDURE|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
48017847|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
48017848|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
48017849|NCT04928352|OTHER|0.9% saline|Preoperative nebulized same volume of saline placebo
48375149|NCT04935528|BIOLOGICAL|serology|7 mL blood sample to study the humoral response
48706922|NCT06605456|OTHER|Proprioceptive neuromuscular facilitation with postural education|"Phase 1: Active Rhythmic Initiation The exercise was demonstrated to the students in a seated position, as sitting is considered the functional position for neck motion and stability. Then, the exercises was passively practiced on the students using tactile input. After passive demonstration, students were asked to perform the same exercise actively and verbal commands were used to guide and correct them.~Phase 2: Self-Resisted Rhythmic Initiation Modified The investigators applied resistance by placing the palm of one hand on the right side of the chin to strengthen the muscles.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
48174768|NCT06485830|PROCEDURE|Neural mobilization of the lower limb|"Static neural mobilization techniques will be performed for the lower limb. Static procedures will consist of two sets of 10 repetitions, with one minute rest between sets. Next, dynamic neural mobilization techniques will be performed, with each exercise lasting 5 minutes per set, with one minute rest between them. Therefore, dynamic procedures will consist of 10 minutes per mobilization technique (with one minute rest between exercises).~At the end of all dynamic mobilization exercises, static mobilizations of the sciatic nerve will be performed again in the same order and with the same duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
48174769|NCT06485830|PROCEDURE|Conventional physical therapy|"The intervention will include a first part in which active mobilizations, active-assisted mobilizations, and active stretches will be performed, followed by activities aimed at improving physical training, mobility training, and strength training oriented towards specific tasks. After this second part, the first part will be repeated in the same order and duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
48706923|NCT06605456|OTHER|Active neck muscle stretching and strengthening exercises|"Phase 1: Active Muscle Stretching In this phase, participants were instructed on performing active muscle stretching exercises for all cervical muscles, including neck flexors, extensors, lateral flexors and neck rotators. Each stretch was held for a period of 25-30 seconds and repeated three times.~Phase 2: Self-Isometric Strengthening Participants were provided with a demonstration of self-isometric strengthening exercise for the neck muscles. The exercises involved six movement patterns: cervical flexion, cervical extension, right/left lateral flexion and right/left rotation. For each exercise the participants were required to apply resistance against the direction of movement using their hand without allowing any motion in the neck.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
48706924|NCT04677660|BIOLOGICAL|TAK-919|TAK-919 intramuscular injection
48706925|NCT04677660|BIOLOGICAL|Placebo|Placebo intramuscular injection
48706926|NCT01713660|DEVICE|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
48706927|NCT05339750|DEVICE|AI-based smartphone application|AI-based smartphone application to record and interpret the patch test results
48017850|NCT05913804|BIOLOGICAL|YTS104 Cells injection|YTS104 Cell injection is a new STAR-T cell transfected by lentivirus.The study required that lymphocytes were collected from the subjects and cultured for 2-3 weeks to obtain YTS104 cell injection. Subjects were treated with fludarabine and cyclophosphamide chemotherapy prior to reinfusion, followed by a 2-day rest period before cell infusion.
48017851|NCT03950492|DEVICE|Deep Brain Simulator|This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
48017852|NCT06533605|DRUG|SSGJ-706|Bispecific antibody
48017853|NCT04027660|DEVICE|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~1. Administration of Articain 1:200.000~2. No flap procedure~3. Place a Zirconia Implant on the alveolar post extraction socket~4. Place xenograft biomaterial in the jumping gap~5. Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~* Final Impression with a IOS~* Placement of the Final Crown~* 3 month post crown post op~  3 IOS will be made for volumetric evaluation :~ 1. before tooth extraction~ 2. 3 month of Osseointegration for final impression~ 3. 3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
48017854|NCT04948944|DEVICE|transcranial direct current stimulation|the tDCS stimulator delivers very low (2mAmp) current with surface electrodes to the skull
48174770|NCT02781298|DIETARY_SUPPLEMENT|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
48174771|NCT02781298|DIETARY_SUPPLEMENT|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
48174772|NCT04795206|OTHER|No Intervention|Administered as specified in the treatment arm.
48174773|NCT04926441|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
48516966|NCT04922723|DRUG|Daratumumab|Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
48706928|NCT05339750|DIAGNOSTIC_TEST|Allergen patch|Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
48706929|NCT05051631|OTHER|Intervention plus 12 months maintenance|The intervention will include 2 months of data collection in the control period, 4 months of education and awareness training, and 12 months of data collection in the maintenance time period.
48706930|NCT05051631|OTHER|Intervention plus 10 months maintenance|The intervention will include 4 months of data collection in the control period, 4 months of education and awareness training, and 10 months of data collection in the maintenance time period.
48174774|NCT01852032|RADIATION|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
48017855|NCT01581346|OTHER|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
48174775|NCT01852032|RADIATION|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
48174776|NCT02180347|DEVICE|Contact lenses|
48174777|NCT00489645|DRUG|placebo|placebo SC during euglycemia
48174778|NCT00489645|DRUG|pramlintide|pramlintide SC during eglycemia
48174779|NCT00489645|DRUG|placebo|placebo during hyperglycemia
48174780|NCT00489645|DRUG|pramlintide|pramlintide SC during hyperglycemia
48174781|NCT03980132|DRUG|Lugols Strong Iodine|5 L.I. drops / 8 hours for 10 days before surgery
48017856|NCT01124890|DEVICE|early percutaneous coronary intervention|
48174782|NCT06477276|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
48174783|NCT00806598|DRUG|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~* Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~* MDS patients \<55 years receive 3.5 mg/kg/day for 5 days~* MDS patients \>55 years receive 2.5 mg/kg/day for 5 days"
48174784|NCT00806598|DRUG|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
48174785|NCT00806598|DRUG|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
48174786|NCT00806598|DRUG|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
48174787|NCT00003693|DRUG|Dolastatin 10|IV bolus once every 3 weeks.
48174788|NCT01321723|DRUG|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
48174789|NCT01321723|DRUG|Placebo|
48174790|NCT01321723|DRUG|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
48174791|NCT01543334|BIOLOGICAL|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
48174792|NCT04124198|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Accelerated or hyper-fractionated radiotherapy
48174793|NCT04124198|DRUG|Cisplatin|Concurrent weekly cisplatin 40 mg/sqm to fit patients
48017857|NCT01124890|DEVICE|late percutaneous coronary intervention|
48174794|NCT04124198|DRUG|Nimorazole.|Concurrent nimorazole
48174795|NCT04124198|PROCEDURE|Transoral Robotic Surgery (TORS) with neck dissection|Robotic-assisted resection of the primary oropharyngeal tumour and ipsilateral selected neck dissection of lymph node levels II-IV. Patients with a primary base of tongue cancer or with significant involvement of tongue base or the soft palate defined as above 1 cm, will be offered a bilateral neck dissection of levels II-IV.
48174796|NCT00004265|DRUG|paclitaxel|
48174797|NCT05142839|PROCEDURE|EUS-CD|EUS-guided choledochoduodenostomy
48174798|NCT05142839|PROCEDURE|EUS-GEA|EUS-guided gastroenterostomy
48174799|NCT04226898|BIOLOGICAL|Synbiotic Supplement|Synbiotic supplement 1 powder stick by mouth daily
48174800|NCT04226898|BIOLOGICAL|Inert Compound|Synbiotic supplement identical placebo 1 powder stick by mouth daily
48174801|NCT03991598|OTHER|Exercise program|Exercise program in communities / Exercise program at home
48174802|NCT05684666|OTHER|Slow Breathing Exercise (SBE)|"Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks."
48174803|NCT05684666|OTHER|Progressive Muscle Relaxation (PMR) Technique|"Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks."
48174804|NCT00483080|DRUG|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
48174805|NCT06191861|BEHAVIORAL|Most hoped for future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for future self for 20 minutes.
48174806|NCT06191861|BEHAVIORAL|Most feared future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most feared future self for 20 minutes.
48174807|NCT06191861|BEHAVIORAL|Control (trip to zoo)|Participants in this condition think and write about a future trip to the zoo
48174808|NCT06191861|BEHAVIORAL|Balanced future self|Participants in this condition complete a version of the future possible self task in which they think and write about their most hoped for and feared future self for 20 minutes.
48174809|NCT04442347|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.
48174810|NCT04442347|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
48516967|NCT04170556|DRUG|Regorafenib|Regorafenib 160 mg/day 3 weeks on and 1 week off
48017858|NCT01038778|BIOLOGICAL|Aldesleukin|Given IV
48017859|NCT01038778|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
48017860|NCT01038778|DRUG|Entinostat|Given PO
48706931|NCT05051631|OTHER|Intervention plus 8 months maintenance|The intervention will include 6 months of data collection in the control period, 4 months of education and awareness training, and 8 months of data collection in the maintenance time period.
48017861|NCT01038778|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
48174811|NCT00917462|DRUG|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
48017862|NCT01038778|OTHER|Laboratory Biomarker Analysis|Correlative studies
48174812|NCT00917462|PROCEDURE|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
48174813|NCT06546150|BIOLOGICAL|RE002 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
48174814|NCT01086384|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
48174815|NCT01086384|DRUG|Fluticasone furoate|Inhaled corticosteroid
48375150|NCT03556254|DRUG|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
48375151|NCT03556254|DRUG|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
48706932|NCT05051631|OTHER|Intervention plus 6 months maintenance|The intervention will include 8 months of data collection in the control period, 4 months of education and awareness training, and 6 months of data collection in the maintenance time period.
48706933|NCT05051631|OTHER|Intervention plus 4 months maintenance|The intervention will include 10 months of data collection in the control period, 4 months of education and awareness training, and 4 months of data collection in the maintenance time period.
48706934|NCT04915989|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
48706935|NCT02815046|DRUG|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
48706936|NCT02815046|DEVICE|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
48706937|NCT04851210|OTHER|No intervention|No intervention
48706938|NCT01382303|DRUG|Pentoxifylline|Pentoxifylline 400mg three times a day
48706939|NCT01382303|DRUG|Placebo|placebo tablet three times a day
48706940|NCT06333522|DRUG|Losartan|Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
48706941|NCT02509039|DRUG|CC-122|5 continuous days out of 7 days per week intermittent dosing
48706942|NCT03593681|DEVICE|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
48706943|NCT01394224|DRUG|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
48706944|NCT01394224|DRUG|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
48706945|NCT06216782|OTHER|Non-intervention|Non-intervention
48706946|NCT05851872|PROCEDURE|Coronary angiogram|Being done per standard of care
48706947|NCT05851872|PROCEDURE|Right heart catheterization|Being done per standard of care
48706948|NCT05948228|DRUG|giomer based bioactive gel|Application of bioactive gel to prevent white spot lesions in orthodontic patients
48017863|NCT01038778|OTHER|Pharmacological Study|Correlative studies
48017864|NCT01038778|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
48017865|NCT02838420|DRUG|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
48017866|NCT02838420|DRUG|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
48017867|NCT04302571|BEHAVIORAL|combined aerobic and resistance physical activity|Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
48706949|NCT05948228|DRUG|Fluoride gel|Application of fluoride gel to prevent white spot lesions in orthodontic patients
48706950|NCT01244633|DRUG|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
48706951|NCT02180880|DRUG|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
48706952|NCT05974657|OTHER|Probiotic Lactobacillus acidophilus LA85|Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
48706953|NCT06605976|BEHAVIORAL|DAX CoPilot Group|Participants in this group were given a license for DAX CoPilot and asked to use it for clinical documentation.
48706954|NCT04503668|DRUG|Ondansetron|8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
48706955|NCT04503668|DRUG|Dexamethasone|20 mg IV on day 1 pre-chemotherapy
48017868|NCT04302571|BEHAVIORAL|sham exercise|general recommendation to perform regular aerobic physical activity
48174816|NCT00195442|DRUG|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
48174817|NCT05585177|DRUG|Growth hormone|3 months of growth hormone treatment (2 units daily)
48174818|NCT06370117|BEHAVIORAL|Buzzy|Before the procedure; 60 seconds before starting the vascular access process, the Buzzy® tool was placed in the procedure area and cold and vibration application was started. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed to the middle part of the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
48017869|NCT04740606|DEVICE|Augmented Reality Navigation System|Investigators will assess the nodules based on the CT images of subjects before procedure. And then, the appropriate intra-airway path planned by the Augmented Reality Navigation System will be selected. The bronchoscopy with intra-airway navigation under the guidance of the Augmented Reality Navigation System will be performed and the following surgical information will be record.
48174819|NCT06370117|BEHAVIORAL|Music video listening|Before the procedure; A music video was played 60 seconds before starting the intravenous access procedure.
48174820|NCT06370117|BEHAVIORAL|Buzzy+ Music video listening|60 seconds before starting the vascular access process, a music video was played and cold and vibration application was started with the Buzzy® tool. 60 seconds before the procedure began, the Buzzy® tool was placed on the procedure area and cold and vibration application was initiated. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed midway between the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
48174821|NCT06360952|DEVICE|Tasso+ CBC|Novel blood collection device
48174822|NCT06336382|DIAGNOSTIC_TEST|Tau PET imaging scan|Subjects will be scanned with novel tau PET tracer \[18F\] PI-2620 to determine whether neurofibrillary tangle pathology is present.
48174823|NCT00297843|PROCEDURE|allergen challenge (grass pollen), nasal lavage|
48174824|NCT06315101|DRUG|Chinese Herbal Medicine|Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
48174825|NCT02878759|DEVICE|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
48174826|NCT04622371|OTHER|Moderate exercises|Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
48174827|NCT00865137|DRUG|Tacrolimus, modified release|Oral
48375152|NCT02563574|BEHAVIORAL|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
48375153|NCT02563574|OTHER|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
48375154|NCT02563574|OTHER|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
48706956|NCT04503668|DRUG|Neurokinin-1 Receptor Antagonist (NK1-RA)|150 mg IV on day 1 pre-chemotherapy
48017870|NCT00165438|PROCEDURE|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
48375155|NCT02563574|OTHER|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
48375156|NCT00234533|DRUG|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
48516968|NCT04170556|DRUG|Nivolumab|Nivolumab at the dose of 1.5 mg/kg, 3 mg/kg or 240 mg/infusion every 2 weeks. Dose will be adjusted depending on the incidence of adverse events
48706957|NCT04503668|DRUG|Olanzapine|5 mg by mouth on days 1-4 of chemotherapy (taken at night)
48706958|NCT04503668|DRUG|Compazine|5-10 mg by mouth, available as needed, every 6 hours, days 1-5
48706959|NCT00286195|DEVICE|Multi-Link Frontier Coronary Stent System|Bare metal stent
48706960|NCT05659719|OTHER|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
48706961|NCT02840643|BEHAVIORAL|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
48706962|NCT02840643|BEHAVIORAL|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
48706963|NCT01478802|DEVICE|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
48706964|NCT01478802|DEVICE|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
48516969|NCT01597778|BIOLOGICAL|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
48017871|NCT00165438|PROCEDURE|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
48017872|NCT06574347|DRUG|Vebreltinib|Subjects will receive Vebreltinib orally twice per day (BID).
48174828|NCT04281693|DIAGNOSTIC_TEST|Standard screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
48174829|NCT04281693|DIAGNOSTIC_TEST|New screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
48375157|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (HQ)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
48174830|NCT02892864|OTHER|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
48706965|NCT01527513|DRUG|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
48706966|NCT01527513|DRUG|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
48706967|NCT00882596|DEVICE|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
48706968|NCT04140955|PROCEDURE|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
48706969|NCT02919280|OTHER|Observational Study|The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,000 participants. There is no medication or non-medication treatment or intervention provided by this study.
48706970|NCT04960878|DIETARY_SUPPLEMENT|Synbiotic|Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.
48706971|NCT04960878|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48706972|NCT01269359|PROCEDURE|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
48017873|NCT06574347|DRUG|Osimertinib|Subjects will receive Osimertinib 80mg orally once per day (QD).
48017874|NCT06574347|DRUG|PLB1004|Subjects will receive PLB1004 80mg orally once per day (QD).
48017875|NCT05943860|DIETARY_SUPPLEMENT|Pantovigar® vegan|Oral application of 1 capsule three times a day (morning, noon, evening) for 6 months
48174831|NCT02892864|OTHER|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
48174832|NCT06213519|DRUG|S-1, Oxaliplatin sintilimab HIPEC|"1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity."
48706973|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48174833|NCT00242164|DRUG|Dialysate Magnesium (Concentration)|
48706974|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706975|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706976|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706977|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706978|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48174834|NCT01263925|DRUG|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
48174835|NCT01263925|DRUG|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
48174836|NCT01263925|DRUG|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
48174837|NCT01263925|DRUG|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
48174838|NCT00281047|DRUG|FP-10|
48174839|NCT00673556|DRUG|alefacept|Intramuscular (IM)
48516970|NCT01597778|BIOLOGICAL|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
48516971|NCT05005052|DRUG|Vessel|Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
48516972|NCT05005052|DRUG|Placebo|Placebo and no compression or venopharmaceutical regimen
48017876|NCT05112835|OTHER|brolucizumab|There is no treatment allocation. The decision to administer brolucizumab is made by the treating physician independent of the study, prior to the inclusion of the patient into the study
48174840|NCT00673556|DRUG|placebo|Intramuscular (IM)
48174841|NCT03068793|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
48174842|NCT05310747|BEHAVIORAL|Artwork present|A virtual museum exhibit with a curated selection of artworks
48174843|NCT05310747|BEHAVIORAL|Artwork absent|The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls
48174844|NCT05310747|BEHAVIORAL|Social connection high|Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.
48706979|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706980|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706981|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706982|NCT02298179|DRUG|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
48706983|NCT01730833|BIOLOGICAL|pertuzumab|Given IV
48706984|NCT01730833|BIOLOGICAL|trastuzumab|Given IV
48706985|NCT01730833|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
48706986|NCT01730833|OTHER|laboratory biomarker analysis|Optional correlative studies
48706987|NCT05410847|DRUG|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
48017877|NCT03884972|DRUG|Trabectedin|Given IV
48017878|NCT03884972|DRUG|Venetoclax|Given PO
48017879|NCT06448481|PROCEDURE|Intra-dermal purse-string closure|Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.
48017880|NCT06448481|PROCEDURE|Transcutaneous purse-string closure|Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.
48017881|NCT04816357|OTHER|Questionaire|only questionaire
48017882|NCT00962429|DRUG|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
48017883|NCT00764348|OTHER|no treatment|
48174845|NCT05310747|BEHAVIORAL|Social connection low|Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
48174846|NCT00141362|DRUG|Pregabalin|
48174847|NCT00980577|DEVICE|NUUS|Sonosite Micro Maxx
48174848|NCT00537329|DRUG|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
48174849|NCT01093599|BEHAVIORAL|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
48375158|NCT04917588|COMBINATION_PRODUCT|Saypha® FILLER Lidocaine (C1)|Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
48375159|NCT00229931|DRUG|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
48017884|NCT06444789|DEVICE|connected smartwatch|The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD.
48017885|NCT03398993|DRUG|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
48017886|NCT03398993|DRUG|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
48174850|NCT01093599|BEHAVIORAL|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
48174851|NCT05396625|BEHAVIORAL|Usual Care|All participants will receive the following services: case management and psychosocial support (e.g., assessment and identification of families eligible for reunification; preparing children and parents for reunification; and assistance with receiving social benefits such as Targeted Social Assistance, alimonies, or disability benefits); referrals to schools outside of their orphanage; and leisure activities for children (e.g., music, sport, and drama) provided by the orphanage staff and municipal social services.
48375160|NCT00229931|PROCEDURE|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
48375161|NCT00161291|DRUG|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
48017887|NCT03398993|DEVICE|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
48017888|NCT06493513|DEVICE|40Hz stimulation|Exogenous 40Hz stimulation is a physical intervention that induces gamma oscillations, oscillations and pulsations at the corresponding frequency, and may lead to a significant reduction in β-amyloid, reversal of tau protein hyperphosphorylation, and consequently improvement of cognitive function in patients.
48017889|NCT06004817|OTHER|evaluation of clinical severity|evaluation of clinical severity
48375162|NCT02472600|DRUG|Colistin|
48375163|NCT02472600|DRUG|Neomycin|
48375164|NCT02472600|DRUG|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
48375165|NCT02472600|DRUG|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
48375166|NCT00455572|BIOLOGICAL|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
48375167|NCT00455572|DRUG|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
48375168|NCT00455572|DRUG|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
48375169|NCT00455572|PROCEDURE|Radiotherapy|Regimen will be based upon the site's own standard procedures
48375170|NCT01062230|DRUG|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
48706988|NCT01389154|PROCEDURE|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
48706989|NCT04627181|DRUG|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
48017890|NCT05299541|DIETARY_SUPPLEMENT|Food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
48017891|NCT05299541|DIAGNOSTIC_TEST|Indirect calorimetric|• The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
48017892|NCT05299541|DIAGNOSTIC_TEST|Bioimpedance|• The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
48017893|NCT05299541|BEHAVIORAL|Questioners|"At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM"
48017894|NCT05299541|DIETARY_SUPPLEMENT|Plated food dish|"All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected ."
48017895|NCT04486378|DRUG|RO7198457 intravenous (IV)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
48017896|NCT04486378|OTHER|Observational group (no intervention)|watchful waiting
48017897|NCT06535204|DIETARY_SUPPLEMENT|Aqueous extract of A. sylvestris leaves|Provided functional food made from Aqueous extract of A. sylvestris leaves
48017898|NCT06535204|DIETARY_SUPPLEMENT|microcrystalline cellulose|Provided placebo composed of microcrystalline cellulose instead of A. sylvestris leaf extract.
48017899|NCT04693364|OTHER|Decision Aid|Use 3D printed breast model
48017900|NCT04693364|PROCEDURE|Discussion|Participate in consultation
48017901|NCT04693364|OTHER|Questionnaire Administration|Complete questionnaires
48017902|NCT04844385|DRUG|Toripalimab|Toripalimab 240 mg, d1, Q3w for two cycles
48017903|NCT04844385|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 260 mg/m2, d1, Q3w for two cycles
48017904|NCT04844385|DRUG|Nedaplatin|Nedaplatin 75mg/m2, d1, Q3w for two cycles
48017905|NCT04844385|RADIATION|radiation therapy at a total dose 60 Gy|Radiation therapy at a total dose 60 Gy
48375171|NCT04585828|DEVICE|Phototherapy with double sided fiber optic pads with blue light at irradiance 30 uW/cm2/nm using Bili Cocoon|The baby will be treated with Bilicocoon for 24 hours. Decrease of total serum biliurubin will be evalueated hereafter.
48375172|NCT04585828|DEVICE|Phototherapy from above using NeoBlue at irradiance of 30 uW/cm2/nm|The baby will be treated with phototherapy from above for 24 hours. Decrease of total serum bilirubin will be evaluated hereafter.
48375173|NCT03728101|DRUG|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
48516973|NCT04169945|OTHER|Ultrasonic instrumentation|Full mouth root surface debridement
48706990|NCT04627181|DRUG|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
48174852|NCT05396625|BEHAVIORAL|Family Strengthening|Due to its focus on family-strengthening, the study uses the evidence-based intervention 'SAFE Children,' which employs a multiple family group format and is designed to improve family functioning, strengthen child-parent relationships and communication, enhance supportive parenting strategies, and prevent emotional and behavioral problems among at-risk children. The family-focused intervention consists of weekly multiple family group meetings (e.g. about 5 families per group). All interested family members are invited to join the sessions. The adapted intervention incorporates new sessions that address unique issues faced by families reuniting with formerly institutionalized children (e.g., separation and attachment issues, children's feelings of resentment, parents' feelings of guilt and shame, stigmatized status in the community). Each session lasts about one to one and a half hours and will be delivered by facilitator and co-facilitator at the SOS Child and Family Center.
48174853|NCT05396625|BEHAVIORAL|Mental Health Screening, Referral and Connection to Services|Children assigned to this intervention will receive clinical assessment performed by psychiatrists at the National Mental Health Centre in Azerbaijan. From there, each child will have an individual plan developed by the multidisciplinary team and will be connected to the National Mental Health Centre clinicians to receive corresponding mental health services.
48174854|NCT05396625|OTHER|Economic Empowerment|The economic component will be in the form of Child Development Accounts/CDAs, an asset-based strategy encouraging savings and investment. This component will connect families to a bank and train them on how to save small amounts, which will be matched by contributions from the project. Matched savings will be deposited in a separate account and can be used only towards a child's education or for housing. The project will provide $50 as seed money to open a savings account in the child's name. The child's family members will make small monthly contributions to the CDA, and savings of up to $20 per month will be matched with project funds at a rate of 2:1. Caregivers will also receive training on savings and financial planning. The curriculum will be taught by trainers from the SOS in a group format for 5 sessions and will cover these topics: The Importance of Saving; Identifying and Managing Resources; Setting Up a Savings System; Sources of Income; and Budgeting and Spending.
48174855|NCT05549999|DIAGNOSTIC_TEST|North Star Ambulatory Assessment|North Star Ambulatory Assessment is an ambulatory assessment developed specifically for Duchenne Muscular Dystrophy.
48174856|NCT03551431|DIAGNOSTIC_TEST|Video EEG with verbal suggestion|Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
48174857|NCT04587583|BEHAVIORAL|WeCareAdvisor|Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
48174858|NCT00835510|DRUG|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
48706991|NCT04627181|DRUG|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
48017906|NCT04844385|DRUG|Capecitabine|Capecitabine 1000 mg/m2, bid, d1-14, q3w during radiotherapy
48017907|NCT04844385|RADIATION|radiation therapy at a total dose 50 Gy|Radiation therapy at a total dose 50 Gy
48017908|NCT06592248|DEVICE|Coc Knee|Implementation of a ceramic on ceramic knee prosthesis
48017909|NCT02284737|PROCEDURE|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
48017910|NCT02284737|PROCEDURE|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
48017911|NCT02284737|DRUG|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
48017912|NCT03377348|PROCEDURE|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
48017913|NCT05394337|DRUG|Atezolizumab|Given by vein (IV)
48017914|NCT05394337|DRUG|Tiragolumab|Given by vein (IV)
48017915|NCT06664372|PROCEDURE|Trans fontanelle US Guided VP Shunt|Insertion of proximal VP shunt catheter by trans fontanelle US
48017916|NCT06659445|DRUG|ONL1204 Opthalmic solution|Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
48017917|NCT06659445|DRUG|Avacincaptad Pegol intravitreal solution|Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
48017918|NCT06659445|OTHER|Sham|Sham injection
48017919|NCT00189085|DRUG|simvastatin and ezetimibe|
48706992|NCT04627181|DRUG|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
48706993|NCT03604874|DRUG|Oxytocin|intravenous infusion
48706994|NCT04006210|COMBINATION_PRODUCT|ND0612 Solution for SC infusion|Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
48706995|NCT04006210|COMBINATION_PRODUCT|Placebo for SC infusion|Placebo solution administered SC via infusion pump
48706996|NCT04006210|DRUG|Oral IR-LD/CD|Encapsulated LD/CD 100mg/25mg
48706997|NCT04006210|DRUG|Placebo for Oral IR-LD/CD|Encapsulated Placebo for LD/CD 100mg/25mg
48706998|NCT01790282|DRUG|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
48706999|NCT01790282|DRUG|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
48707000|NCT00875238|BIOLOGICAL|trastuzumab|
48707001|NCT00875238|DRUG|doxorubicin hydrochloride|
48707002|NCT00875238|GENETIC|polymorphism analysis|
48707003|NCT00875238|OTHER|laboratory biomarker analysis|
48707004|NCT00875238|OTHER|questionnaire administration|
48375174|NCT01999959|PROCEDURE|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
48707005|NCT00875238|PROCEDURE|assessment of therapy complications|
48707006|NCT00875238|PROCEDURE|magnetic resonance imaging|
48707007|NCT05271032|DIAGNOSTIC_TEST|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
48707008|NCT03094078|OTHER|News item with spin|Interpretation of news item with spin
48707009|NCT03094078|OTHER|News item without spin|Interpretation of news item without spin
48707010|NCT00445848|BIOLOGICAL|bevacizumab|
48707011|NCT00445848|DRUG|erlotinib hydrochloride|
48707012|NCT00683917|DRUG|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
48707013|NCT00683917|DRUG|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
48707014|NCT00683917|DRUG|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
48707015|NCT04881929|DRUG|KN026|KN026 in Combination With Docetaxel
48707016|NCT01545882|DRUG|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
48707017|NCT02114125|BEHAVIORAL|Physical Activity|group-based physical activity
48707018|NCT02114125|BEHAVIORAL|Cognitive Training|individual-based, multi-domains cognitive training
48707019|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d
48707020|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
48707021|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
48707022|NCT05517369|PROCEDURE|Hybrid ESD+|Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
48707023|NCT01686659|DEVICE|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
48707024|NCT02432560|DRUG|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
48375175|NCT06523348|DIAGNOSTIC_TEST|quadricipital muscle ultrasound|ultrasound depth measurement of the quadriceps muscle
48707025|NCT02432560|DRUG|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
48375176|NCT04938869|OTHER|Educational Intervention|Receive basic diabetes mellitus education
48707026|NCT03817320|DRUG|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
48707027|NCT03817320|DRUG|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and \< 1 year: 1.2mg/m2/dose~\< 6 months: 1mg/m2/dose"
48707028|NCT03817320|DRUG|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and \< 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~\< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
48707029|NCT03817320|DRUG|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose"
48707030|NCT03817320|DRUG|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose"
48707031|NCT03817320|DRUG|Methotrexate (IT)|For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
48707032|NCT03817320|DRUG|Triple IT (Methotrexate, Hydrocortisone, Cytarabine)|For patients with CNS 3, on Days 1, 8, 15, 22, and 29
48707033|NCT03817320|DRUG|Leucovorin|For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
48707034|NCT02118766|DRUG|AN2728 Topical Ointment, 2%|
48707035|NCT02118766|DRUG|Matching vehicle control|
48707036|NCT05497102|DRUG|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
48707037|NCT05363293|DRUG|AL 001|a crystal engineered lithium-salicylate-proline lithium delivery product
48707038|NCT05363293|DRUG|Placebo|matching placebo formulation
48707039|NCT02878525|PROCEDURE|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
48707040|NCT02878525|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
48707041|NCT04859985|DEVICE|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
48707042|NCT04859985|DEVICE|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
48375177|NCT04938869|OTHER|Medical Device Usage and Evaluation|Use CGM device and app
48707043|NCT04171180|DRUG|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
48707044|NCT02655523|DRUG|Triamcinolone|1 mL of 40 mg of Triamcinolone
48174859|NCT00835510|DRUG|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
48707045|NCT02655523|DRUG|Dexamethasone|1 mL of 4mg of Dexamethasone
48707046|NCT02655523|DRUG|Normal Saline|1 mL of preservative free normal saline
48707047|NCT02655523|DRUG|Bupivacaine|2 mL of 0.5% bupivacaine
48707048|NCT00845260|BEHAVIORAL|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
48707049|NCT00845260|BEHAVIORAL|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
48707050|NCT03522038|PROCEDURE|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with \<30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
48707051|NCT05918653|OTHER|Home Healthcare|No intervention in this study
48707052|NCT04919226|DRUG|177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.
48174860|NCT00835510|DRUG|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
48174861|NCT05153785|DRUG|Lidocaine|Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery
48174862|NCT05153785|DRUG|Normal saline|Placebo
48375178|NCT04938869|OTHER|Survey Administration|Ancillary studies
48375179|NCT02516449|OTHER|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
48375180|NCT02620826|PROCEDURE|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
48375181|NCT02620826|PROCEDURE|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
48516974|NCT04169945|OTHER|Air polishing with erythritol powder|Air flow PLUS
48707053|NCT04919226|DRUG|CAPTEM (Capecitabine and Temozolomide)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
48017920|NCT05164705|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
48017921|NCT05164705|OTHER|Sham Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and breathe normal air (21 percent O2) for 30-minutes.
48017922|NCT06358898|BEHAVIORAL|Standard dCBT-I|This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).
48017923|NCT06358898|BEHAVIORAL|Modified Mood enhanced CBT-I (M-dCBT-I)|Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.
48017924|NCT00079547|BEHAVIORAL|Low-calorie diet|low-calorie diet
48017925|NCT00079547|BEHAVIORAL|low-carbohydrate diet|low-carbohydrate diet
48017926|NCT02057757|DRUG|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
48017927|NCT02057757|DRUG|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
48375182|NCT05151887|OTHER|Muscle protein synthesis|The meals contain a total of 0.45 g protein/kg body mass (36 g protein for an 80 kg person). To account for differences in body mass, the investigators will scale the meal content to ensure 0.45 g/kg body mass for different body mass ranges (i.e., 65-75 kg, 75-85 kg, etc.). As such, carbohydrate, fat, and total energy content of the meals will also be scaled to body mass. The test meals are composed out of regular whole food items which will be purchased from local shops. The muscle protein synthetic response following meal ingestion will be assessed by the use of stable isotope tracer methodology
48375183|NCT00587561|BEHAVIORAL|Social Cognition Interaction Training|manualized group therapy
48707054|NCT04919226|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
48707055|NCT04919226|DRUG|Everolimus|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
48707056|NCT04919226|DRUG|FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)|Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.
48174863|NCT04214613|PROCEDURE|non-cardiac non-neurologic surgery|non-cardiac non-neurologic surgery
48174864|NCT01860547|DIETARY_SUPPLEMENT|Bilberries|Frozen bilberries, 100 g/d
48174865|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
48707057|NCT01409083|DEVICE|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
48707058|NCT02816593|DRUG|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
48707059|NCT02816593|DRUG|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
48707060|NCT02816593|DRUG|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
48707061|NCT05623254|OTHER|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) \[Time Frame: At Three-six months\]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
48017928|NCT03194763|DIAGNOSTIC_TEST|coronary angiography|computed tomography acquisitions performed on a revolution CT
48174866|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
48174867|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
48017929|NCT03616418|DRUG|antiplatelet drugs;statins;antihypertensive drugs|
48707062|NCT03028480|DRUG|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
48017930|NCT04016168|BIOLOGICAL|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
48017931|NCT06663891|OTHER|Functional MRI with EEG per MRI|"2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.~Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2\*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,"
48707063|NCT04773782|DRUG|avapritinib|oral administration
48017932|NCT06587347|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.
48017933|NCT06587347|DRUG|Standard medical treatment (SMT)|Patients will receive standard antiplatelet therapy.
48017934|NCT06663384|OTHER|Evaluation of Augmented Reality technology in TKA compared to standard TKA|Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
48174868|NCT04901845|OTHER|No intervention provided|Study is provided in the usual daily practice of the physicians without interventions made in their practice
48017935|NCT03979365|DRUG|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
48516975|NCT03682107|BIOLOGICAL|Andes virus DNA vaccine|A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.
48707064|NCT00174681|DRUG|Insulin Glargine|
48375184|NCT00587561|BEHAVIORAL|WLC|wait-list control for 6 months, followed by the experimental group therapy
48707065|NCT01209455|DRUG|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
48707066|NCT01209455|DRUG|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
48707067|NCT01209455|DRUG|Paracetamol|To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
48707068|NCT02959827|DRUG|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
48707069|NCT00230282|DRUG|Alemtuzumab|3 to 30 mg, IV
48017936|NCT03979365|DRUG|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
48017937|NCT04545814|DEVICE|Stereotactic Radiosurgery|Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
48174869|NCT02351336|DEVICE|Ultrasound imaging|"1. - Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~2. - corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~3. - CL measurement using 2D ultrasound ( in cm)"
48174870|NCT03415399|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
48174871|NCT04332679|DEVICE|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
48174872|NCT04332679|DEVICE|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
48174873|NCT00424554|DRUG|temozolomide|"Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
48174874|NCT02215954|DRUG|FE 999169|FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
48174875|NCT02215954|DRUG|Niflec|Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
48174876|NCT00414583|OTHER|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
48174877|NCT04695821|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
48174878|NCT05787145|BEHAVIORAL|Let's Discuss Health Group|Use of the Let's Discuss Health website to prepare four medical encounters with the radiation oncologist throughout the radiation care trajectory.
48174879|NCT00318786|DRUG|biphasic insulin aspart|
48174880|NCT00127400|BEHAVIORAL|anger management therapy|
48174881|NCT01744743|PROCEDURE|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
48174882|NCT02654132|DRUG|Elotuzumab|
48174883|NCT02654132|DRUG|Pomalidomide|
48174884|NCT02654132|DRUG|Dexamethasone|
48174885|NCT00104637|DRUG|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
48174886|NCT00104637|DRUG|Placebo|25 mg po tid
48174887|NCT05817474|DRUG|lidocaine (2 %) 2 ml and tranexamic acid|lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
48174888|NCT04122482|BEHAVIORAL|Psychoeducation Course|The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
48174889|NCT05564546|PROCEDURE|FeNO (fractional exhaled nitric oxide)|"FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value \> 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment."
48707070|NCT00230282|DRUG|Fludarabine|\[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid
48707071|NCT00230282|DRUG|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
48017938|NCT04613609|DEVICE|Electronic Cigarette containing nicotine|Non-smokers used an electronic cigarette containing nicotine
48017939|NCT04613609|DEVICE|Electronic Cigarette without nicotine|Non-smokers used an electronic cigarette without nicotine
48017940|NCT04307758|OTHER|Muscle Strength Assesment-Make Test|For the make test, the examiner applies resistance in a fixed position and the person being tested exerts a maximum effort against the dynamometer and examiner. The examiner is only required to sustain an isometric contraction and read the highest value on an Hand Held Dynamometer.
48707072|NCT06195969|BEHAVIORAL|automated instant message-guided hypertension management intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
48707073|NCT02609230|DRUG|ONC-201|
48174890|NCT05564546|PROCEDURE|Spirometry|"Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment."
48174891|NCT05564546|OTHER|Physical examination|"A pulmonary clinical examination will be carried out by the investigator, including:~* Cough,~* Sputum,~* Vesicular murmur (MV),~* Added noises (BSA),~* Vocal vibrations (VV),~* Tympanism,~* Dullness,~* Signs of acute respiratory distress (ARD),~* ..."
48174892|NCT05564546|OTHER|Interrogation|"Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc."
48174893|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #1|Main Hairfinity formulation
48174894|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #2|Variation to main formulation
48174895|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #3|Variation to main formulation
48174896|NCT03106792|DIETARY_SUPPLEMENT|Placebo|No active ingredients
48174897|NCT05716776|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
48174898|NCT02900313|OTHER|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
48174899|NCT03475056|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
48174900|NCT05474898|OTHER|Magnesium Sulphate Iontophoresis +conventional therapy|will receive Mgso4 Iontophoresis in addition to conventional therapy twice a week/4 weeks
48174901|NCT05474898|OTHER|High- Power Pain Threshold Ultrasound +conventional therapy|will receive HPPT-US on the upper trapezius in addition to conventional therapy twice a week/4 weeks
48174902|NCT05474898|OTHER|conventional theapy|will receive postural correction exercise-stretching and strengthening twice a week/4weeks
48174903|NCT01357109|DRUG|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
48174904|NCT01357109|DRUG|Placebo|Matched placebo bid
48174905|NCT00383903|BIOLOGICAL|HRV vaccine|Two or three oral doses
48174906|NCT03484299|PROCEDURE|Irreversible Electroporation (IRE)|Non-thermal ablation of tumor
48174907|NCT03484299|DRUG|Gemcitabine|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
48174908|NCT03484299|DRUG|FOLFIRINOX|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
48174909|NCT00466089|DRUG|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
48174910|NCT02273700|DRUG|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
48174911|NCT04637516|DEVICE|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
48174912|NCT02684955|DEVICE|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
48174913|NCT02684955|DEVICE|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
48174914|NCT02675218|OTHER|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
48174915|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
48174916|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
48707074|NCT06606041|PROCEDURE|Dry Needling|This. minimally invasive technique is based on the insertion of a sterile, low-caliber, monofilament needle, without the injection or extraction of any additional substances, into hyperirritable muscle nodules. There are two categories within this technique, based on the depth at which the needle is inserted: superficial needling (or the Baldry technique), in which the needle is inserted up to the subcutaneous cellular tissue overlying the myofascial trigger point (up to 10 mm); and deep needling, where the needle is inserted into the muscle with the intention of reaching the myofascial trigger point. Reaching the trigger point was the investigators goal. Regardless of the technique selected, the aim is to generate controlled micro spasms in the affected muscle area, alternating with periods of muscle relaxation.
48707075|NCT06606041|PROCEDURE|Ischemic Compression|Ischemic compression is a conservative, manual technique used on myofascial trigger points, in which pressure should be exerted between 30 and 90 seconds on these same areas. It is suggested that it leads to the normalization of the biomechanical properties of muscle fibers, restoring the muscle\&#39;s functional condition and probably reducing the risk of injury. Thus, the therapeutic effects include the stimulation of mechanoreceptors, with pain attenuation mainly due to the depletion of specific neurotransmitters and temporary obstruction of local blood flow (local ischemia), followed by a rapid influx of oxygenated blood to the area under pressure relief,(37) which will cause an increase in muscle metabolism.
48707076|NCT06606041|PROCEDURE|Cross Tapes|Cross tapes, as the name implies, based on an equidistant intersection of three or four polyester tapes with a non-elastic adhesive acrylic coating, with the 3 lines oriented in a latero-medial direction. It is recommended that it be applied to the muscle area where the myofascial trigger point has been detected, at a 45º angle to the muscle fibers. Its application may have several purposes, such as muscle support, improving the stability of the fibers; pain relief, especially in areas where muscle tension and/or inflammation are present; aiding lymphatic drainage; promoting blood circulation. Before it is applied, the skin should be clean (disinfecting the area with alcohol) and dry, without any lotion or other ointments and the maximum period of use should not exceed 24 hours due to the risk of changes in position, either due to sweating or direct intervention by the patient himself.
48707077|NCT05671224|OTHER|Visual aid|Handout and video describing different types of induction of labor
48375185|NCT03744208|DRUG|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
48375186|NCT03117556|PROCEDURE|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
48017941|NCT04307758|OTHER|Muscle Strength Assesment-Break Test|For the break test, the examiner applies resistance sufficient to overcome the maximum effort of the person being tested and cause the subject's joint to move in the opposite direction, which results in an eccentric contraction. During this test the limb must move at a constant velocity while the person being tested is asked to achieve a maximum contraction. In addition, the examiner must read the force output reading at the exact time the subject's limb begins to move from the Hand Held Dynamometer.
48375187|NCT00763126|BEHAVIORAL|stress level|Stress levels
48516976|NCT03682107|OTHER|Placebo|Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System
48375188|NCT06230276|OTHER|enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast|Participants who are already treated by one of the HCL systems (MiniMed 780G, Tandem Control-IQ, Ypsomed CamAPS) will have a precisely defined amount of enteral nutrition (Resource Fibre, 2 kcal/ml) for breakfast during eight different days under predetermined conditions. They will administer premeal bolus only for half of these meals.
48375189|NCT02735720|OTHER|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
48707078|NCT06608810|DRUG|nerve block with 0.5% ropivacaine|General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
48707079|NCT00611442|DRUG|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
48707080|NCT00611442|DRUG|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
48707081|NCT06026345|DEVICE|Affera Platform|A cardiac ablation will be performed using the Affera Platform
48707082|NCT03937648|DRUG|COL-144 50mg|COL-144 50mg
48707083|NCT03937648|DRUG|COL-144 100mg|COL-144 100mg
48707084|NCT03937648|DRUG|COL-144 200mg|COL-144 200mg
48707085|NCT03937648|DRUG|COL-144 400mg|COL-144 400mg
48707086|NCT03937648|DRUG|Placebo|Placebo
48707087|NCT04991727|BEHAVIORAL|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
48707088|NCT01103154|DRUG|carvedilol|6.25mg per day, increase to 6.25mg bid
48707089|NCT01103154|DRUG|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
48707090|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
48707091|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
48707092|NCT00246025|DRUG|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
48707093|NCT00246025|DRUG|placebo|matching placebo capsule, once a day, oral administration
48028721|NCT00793208|BIOLOGICAL|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
48028722|NCT03747029|OTHER|No intervention is provided|No intervention is provided
48028723|NCT02405715|DRUG|Oxytocin nasal spray or placebo|
48028724|NCT05239806|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
48028725|NCT05239806|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
48028726|NCT05239806|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
48028727|NCT05239806|BIOLOGICAL|Comirnaty|Day 0; intramuscular injection
48028728|NCT05239806|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
48028729|NCT02872064|DRUG|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
48028730|NCT06318026|BEHAVIORAL|Centralized Intervention|A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use
48028731|NCT06318026|OTHER|Primary Care Intervention|A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
48028732|NCT01568047|DRUG|Placebo|once-daily
48028733|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
48707094|NCT05497050|BEHAVIORAL|Family education|By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
48516977|NCT03746392|BEHAVIORAL|Jumpstart Intervention|"The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form."
48707095|NCT01338610|BIOLOGICAL|ESBA105 ophthalmic solution|
48707096|NCT01338610|OTHER|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
48707097|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
48017942|NCT04760275|DRUG|Fluoxetine|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT)."
48017943|NCT04760275|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of weekly CBT implemented with Coping Cat (CC). In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with CBT. All participants who do not remit will be randomized (1:1) to either (1) optimization of CBT (intensifying exposure practice and skills review), or (2) optimization of CBT and addition of the medication fluoxetine."
48017944|NCT02477384|PROCEDURE|8mm-TIPS|
48017945|NCT02477384|PROCEDURE|Endoscopic variceal ligation|
48017946|NCT02477384|DRUG|Propranolol|
48017947|NCT02477384|DEVICE|8mm ePTFE-covered stent|
48017948|NCT06664268|BIOLOGICAL|Plasma rich in growth factors (PRGF-Endoret)|Plasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines .This matrix has been shown to enhance wound healing and improve scar texture and appearance .
48028734|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
48028735|NCT01568047|DRUG|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
48028736|NCT01568047|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
48028737|NCT01568047|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
48028738|NCT02943746|DIETARY_SUPPLEMENT|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
48028739|NCT02943746|DIETARY_SUPPLEMENT|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
48028740|NCT06034600|OTHER|taping|Taping will be applied to the exercise and taping group after the exercises with theraband. Other exercises that are not performed will be performed with the tape on the skin.The application will be repeated three days a week for eight weeks.
48028741|NCT06034600|OTHER|exercise|"Stretching and strengthening exercises will be applied to both groups three days a week for 8 weeks.The exercises performed with theraband will be performed in the same way in both groups. While the other exercises will be done after taping in the taping and exercise group, the exercise group will be done without taping."
48028742|NCT06210256|PROCEDURE|unidirectional valve apparatus|In the unidirectional valve group, we attached the unidirectional valve device to the lumen's distal port when one-lung ventilation initiated.
48028743|NCT06210256|PROCEDURE|occluding the non-ventilated endobronchial lumen|In the closed operative lumen group, we closed the lumen's distal port of non-ventilated lung when one-lung ventilation initiated.
48028744|NCT00489450|DRUG|SK3530|
48028745|NCT01234506|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
48375190|NCT02735720|OTHER|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
48375191|NCT05395845|BIOLOGICAL|platelets rich plasma|local ingection of platelets rich plasma
48375192|NCT01829321|DRUG|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
48375193|NCT01829321|DRUG|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
48375194|NCT00547404|DRUG|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
48375195|NCT04775693|DEVICE|RE (Robotic Exoskeleton)|Participants will continue to receive their prescribed standard of care physical therapy/gait training. They will also utilize the robotic exoskeleton twice a week during their inpatient stay and 3 times a week for 5 weeks as an outpatient (for outpatient, only if in the RE group). The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking. It uses sensors and participant motion to move. A licensed physical therapist will be assisting participants as they use the device.
48375196|NCT04775693|OTHER|SOC (standard of care)|Traditional physical therapist driven gait training.
48516978|NCT02717455|DRUG|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
48516979|NCT04050215|PROCEDURE|Computed Tomography|Undergo PET/CT
48516980|NCT04050215|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
48516981|NCT04050215|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48516982|NCT04050215|OTHER|Questionnaire Administration|Ancillary studies
48516983|NCT01205087|DRUG|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
48516984|NCT00751192|DEVICE|HIV-testing motivational videos|
48516985|NCT00751192|DEVICE|Standard public health text|
48516986|NCT03579342|BEHAVIORAL|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
48516987|NCT03579342|BEHAVIORAL|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
48516988|NCT04603326|PROCEDURE|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
48516989|NCT03004339|DRUG|SOR007 Ointment 2.0%|
48516990|NCT03004339|DRUG|SOR007 Ointment 1.0%|
48516991|NCT03004339|DRUG|SOR007 Ointment 0.3%|
48516992|NCT03004339|DRUG|SOR007 Ointment 0.15%|
48516993|NCT03004339|DRUG|SOR007 Ointment Placebo|
48516994|NCT03004339|DRUG|Taclonex® Ointment|
48516995|NCT05466045|OTHER|Olive oil application in hemodialysis patients with pruritus|Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
48516996|NCT05466045|OTHER|Normal saline application in hemodialysis patients with pruritus|Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
48516997|NCT03717012|DRUG|Nintedanib|stable dose
48516998|NCT03717012|OTHER|Pulmonary rehabilitation program|12 weeks
48516999|NCT03996811|OTHER|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
48517000|NCT06197178|BIOLOGICAL|LCAR-G08 cells|Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
48517001|NCT06106347|DEVICE|mfERG device (RETIscan; Roland Instruments, Wiesbaden, Germany)|physiological macular function
48375197|NCT04709640|OTHER|Tailored Medication Management Intervention|This research study involved an initial 1.5 hour visit and 2-3 follow up home visits (each lasting 60 minutes). Participants received 2-3 home visits during which they received recommendations on strategies which will improve medication management. Level II occupational therapy fieldwork students made the recommendations, after approval from their supervising licensed OT. The OT fieldwork students provided assistance to the individual in implementing strategies, obtaining adaptive equipment at little or no cost to the individual.
48375198|NCT04809415|OTHER|Photobiomodulation|Photobiomodulation consists of irradiation by light in order to achieve photochemical and photophysical outcomes.
48375199|NCT04809415|OTHER|Sham|Simulation of the application of photobiomodulation therapy.
48375200|NCT00501969|DRUG|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
48517002|NCT05467631|OTHER|Topical oil application|Topical Comparison
48517003|NCT00036361|DRUG|Aripiprazole|
48517004|NCT01232452|DRUG|Pemetrexed|Administered intravenously (IV)
48517005|NCT01232452|DRUG|Cisplatin|Administered IV
48517006|NCT01232452|DRUG|Cixutumumab|Administered IV
48517007|NCT06361199|DRUG|Proximod|Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis
48517008|NCT06361199|DRUG|Placebo|Placebo controlled
48707098|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
48174917|NCT05612646|PROCEDURE|Acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
48174918|NCT05612646|PROCEDURE|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
48174919|NCT00823446|DEVICE|Revera Wound Care|Revalesio Part Number MDW0060
48174920|NCT00823446|DEVICE|Normal Saline|Sodium Chloride for Irrigation
48174921|NCT00847132|BEHAVIORAL|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
48174922|NCT00847132|BEHAVIORAL|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
48174923|NCT00129649|BEHAVIORAL|Telephone reminder call|
48174924|NCT05744583|OTHER|Packed red cell transfusion|Type O RhD negative packed red cell transfusion during prehospital emergency care
48375201|NCT00379639|DRUG|Romidepsin|7, 10 or 12 mg/m\^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
48174925|NCT05744583|OTHER|Whole blood transfusion|Type O RhD positive, low titer whole blood transfusion during prehospital emergency care
48174926|NCT01917006|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
48174927|NCT01917006|DRUG|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
48174928|NCT00043186|DRUG|Placebo|Placebo subcutaneous injection
48174929|NCT00043186|DRUG|Denosumab|Denosumab for subcutaneous injection
48174930|NCT00043186|DRUG|Alendronate|Alendronate 70 mg tablets
48174931|NCT03747809|DEVICE|CIEDs Remote Monitoring System|Cardiac device remote monitoring system
48174932|NCT05752045|DEVICE|Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device|Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
48174933|NCT05962515|PROCEDURE|ultrasound guided dry needling|Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
48174934|NCT02877732|DEVICE|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
48174935|NCT02877732|OTHER|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
48517009|NCT02912182|DRUG|Betamethasone|Betamethasone intravenous
48517010|NCT02912182|DRUG|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
48517011|NCT02912182|DRUG|Prednisolone|Oral tablets
48517012|NCT03487289|PROCEDURE|natural orifice|laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
48517013|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
48517014|NCT04022876|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of every 21-day cycle.
48517015|NCT04022876|DRUG|Pemetrexed|Pemetrexed administered IV on Day 1 of every 21-day cycle.
48517016|NCT04022876|DRUG|Placebo|Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
48174936|NCT02877732|OTHER|DEM|Participant will be asked to read list of numbers out loud from a card
48174937|NCT02877732|OTHER|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
48174938|NCT02877732|OTHER|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
48375202|NCT00379639|DRUG|Gemcitabine|800 or 1000 mg/m\^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
48375203|NCT00452166|DRUG|rosiglitazone|
48517017|NCT04022876|DRUG|ALRN-6924|ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
48517018|NCT04022876|DRUG|Topotecan|Topotecan administered IV on Days 1-5 of every 21-day cycle.
48517019|NCT01469728|PROCEDURE|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
48375204|NCT05129358|DRUG|Dehydration|The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.
48707099|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
48707100|NCT05999175|DEVICE|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
48017949|NCT06664268|DEVICE|Fractional CO2 laser assisted PDT|Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .
48707101|NCT05999175|DEVICE|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."
48017950|NCT02237105|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
48174939|NCT03087331|OTHER|medication reviews, assessment, recommendations, education.|
48174940|NCT01454232|OTHER|stools sampling|stools sampling at baseline, 1, 3 and 12 months
48174941|NCT01454232|OTHER|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
48375205|NCT05129358|DIETARY_SUPPLEMENT|Rehydration|The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
48375206|NCT06264076|DEVICE|A novel instrument for ligament balancing in total knee arthroplasty|Patients will be evaluated perioperatively for ligament balance. When indicated, the novel instrument will guide puncturing of the medial collateral ligament in a systematic and step-wise fashion. Achieved ligament balance will be observed and controlled by computer navigation and a ligament tensor.
48375207|NCT01384773|OTHER|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
48375208|NCT01384773|DEVICE|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
48375209|NCT00161148|DRUG|Probiotics|
48375210|NCT00107666|DRUG|CTI-01 (ethyl pyruvate)|
48375211|NCT03732534|DRUG|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
48375212|NCT05921734|PROCEDURE|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
48517020|NCT01469728|PROCEDURE|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
48517021|NCT02375165|PROCEDURE|phlebotomy|phlebotomy for collection of plasma and serum, \~30 cc
48707102|NCT05999175|DEVICE|subjects of this group will use their routine oral hygiene products.|subjects of this group will use their routine oral hygiene products.
48707103|NCT03659773|BIOLOGICAL|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
48017951|NCT06661993|OTHER|Placebo|placebo film-coated tablet orally or via a nasogastric tube for seven days .
48017952|NCT06661993|DIETARY_SUPPLEMENT|Alpha-lipoic acid|Alpha-lipoic acid 1800 mg orally or via a nasogastric tube for seven days .
48017953|NCT04846127|DEVICE|CanGaroo Envelope|Utilization of a CanGaroo envelope with the CIED during the participant's CIED implant procedure.
48174942|NCT00027703|DRUG|gemcitabine hydrochloride|Given IV
48174943|NCT00027703|DRUG|cisplatin|Given IV
48174944|NCT00027703|BIOLOGICAL|bevacizumab|Given IV
48174945|NCT00027703|OTHER|placebo|Given IV
48174946|NCT00027703|OTHER|laboratory biomarker analysis|Correlative studies
48174947|NCT03807817|OTHER|Alcohol administration|Amount of alcohol to be administered.
48174948|NCT03807817|OTHER|Placebo|Placebo Alcohol
48174949|NCT03807817|OTHER|No Alcohol|No Alcohol
48174950|NCT00177372|DRUG|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
48174951|NCT01885923|DEVICE|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
48174952|NCT03128528|DRUG|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
48174953|NCT03128528|DRUG|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
48174954|NCT06063447|OTHER|Examination|Posture Evaluation, Scoliosis Examination, Pelvic Floor Assesments
48174955|NCT04759846|DRUG|Encorafenib + Binimetinib|The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
48174956|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
48174957|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
48517022|NCT04622748|BEHAVIORAL|Trier Social Stress Test|8-min oral calculation and 5-min speech
48517023|NCT04341324|OTHER|It is an observational study.|
48517024|NCT05858918|DRUG|Clopidogrel|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
48174958|NCT00175591|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
48174959|NCT05046093|DIAGNOSTIC_TEST|Transbronchial cryobiopsy|"When the lung nodule is visualized by thin bronchoscope (4mm) with R-EBUS, cryobiopsy is performed. If not visualized, ultrathin (3mm) bronchoscope is used.~Cryobiopsy is performed with 1.1mm cryo-probe."
48174960|NCT02419209|OTHER|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
48174961|NCT02101268|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
48174962|NCT02101268|DRUG|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
48174963|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
48174964|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
48174965|NCT02669407|PROCEDURE|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
48174966|NCT02669407|DRUG|regional nerve block with a local anesthetic (Lidocaine)|
48174967|NCT00571077|DEVICE|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
48174968|NCT01324739|DRUG|human BNP-32|3pmol/kg/min infusion
48174969|NCT06309264|DEVICE|Phonak Lumina P90|FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.
48375213|NCT05921734|PROCEDURE|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
48375214|NCT05056363|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
48517025|NCT05858918|DRUG|Ticagrelor|Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
48017954|NCT05905185|DRUG|Tocotrienol-rich fraction vitamin E (TRF)|The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
48017955|NCT05905185|DRUG|Placebo|50mg of Placebo
48017956|NCT06522451|OTHER|conventional physical therapy|Only conventional physical therapy (CPT) will be administered to this group. These regular workouts will include dynamic and static stretching, walking-specific functional exercises, passive mobilizations for pain-free mobility, balance modulation, and gait training. At baseline, the functional state of both groups will be evaluated. Treatment sessions will run for a total of 12 weeks, five days a week, for 45 minutes each. They will consist of four to six repeated exercises, six times on average, and use BSID-4 once the trial is over.
48017957|NCT06522451|OTHER|Conventional physical therapy along with cuevas medek exercises|In addition to regular physical therapy, this group will get Cuevas Medak exercises including head and trunk control (by stabilizing limb) and standing to sitting transition. For a duration of 12 weeks, five days a week, and 45 minutes, each session will be held. At the baseline, the functional state of both groups will be evaluated.
48017958|NCT04213794|DRUG|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
48017959|NCT04213794|PROCEDURE|Cytoreductive Surgery|Undergo cytoreduction
48017960|NCT04213794|DRUG|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
48017961|NCT04213794|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
48017962|NCT04213794|DRUG|Sodium Thiosulfate|Given IV
48017963|NCT04213794|PROCEDURE|Computed Tomography|Undergo CT scan
48017964|NCT04213794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48017965|NCT04213794|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48017966|NCT04213794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48017967|NCT01435668|BEHAVIORAL|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
48017968|NCT01435668|BEHAVIORAL|Simple written advice|Patients receive an information leaflet.
48017969|NCT04419909|DRUG|CD19 redirected autologous T cells (CTL019 or CTL119 cells)|Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
48017970|NCT06345508|DIAGNOSTIC_TEST|Quantitative Ultrasound|Research quantitative ultrasound
48017971|NCT06345508|DIAGNOSTIC_TEST|B-mode Ultrasound|B-mode US performed according to the clinical standard of care.
48017972|NCT06345508|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
48017973|NCT06345508|DIAGNOSTIC_TEST|Liver Biopsy|The composite reference standard includes MRI performed according to the clinical standard of care or histopathology when available.
48017974|NCT02772068|DRUG|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
48707104|NCT01539343|DRUG|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
48375215|NCT05056363|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
48375216|NCT00381680|DRUG|vincristine sulfate|Given IV
48375217|NCT00381680|DRUG|prednisone|Given PO
48375218|NCT00381680|DRUG|doxorubicin hydrochloride|Given IV
48375219|NCT00381680|DRUG|pegaspargase|Given IM
48375220|NCT00381680|DRUG|cytarabine|Given IT or IV
48375221|NCT00381680|DRUG|methotrexate|Given IT or IV
48375222|NCT00381680|DRUG|dexamethasone|Given PO
48375223|NCT00381680|DRUG|etoposide|Given IV
48707105|NCT02545114|DRUG|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
48375224|NCT00381680|DRUG|cyclophosphamide|Given IV
48375225|NCT00381680|DRUG|leucovorin calcium|Given IV or PO
48375226|NCT00381680|BIOLOGICAL|filgrastim|Given IV or SC
48375227|NCT00381680|DRUG|asparaginase|Given IM
48375228|NCT00381680|DRUG|mercaptopurine|Given PO
48375229|NCT00094146|DRUG|Sandostatin LAR Depot|
48707106|NCT05916625|OTHER|neuropsychological assessment|a consultation to assess cognitive and psycho-behavioral functions with questionnaires
48707107|NCT05916625|OTHER|biological sample|10 mL intravenous whole blood collection in EDTA tube
48707108|NCT05916625|PROCEDURE|medical imagery|Pet scan with the specific radioligand \[11C\]SB207145 and MRI
48707109|NCT05890170|OTHER|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
48017975|NCT02772068|OTHER|Exercise|
48017976|NCT06369571|DRUG|Atorvastatin 10mg|Atorvastatin 10mg daily by mouth
48375230|NCT02430168|PROCEDURE|Percutaneous nephrolithotomy|
48375231|NCT02430168|PROCEDURE|Retrograde intrarenal surgery|
48375232|NCT03446157|DRUG|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
48375233|NCT03446157|DRUG|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
48375234|NCT04951596|OTHER|Investigate the current situation|Investigate the current situation of infusion treatment for acute and critical patients in 2 hospitals in the province
48375235|NCT03426735|OTHER|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
48517026|NCT05175703|DEVICE|Passeo-18 Lux Paclitaxel releasing Balloon Catheter|collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
48017977|NCT06369571|OTHER|Modification of dietary fat composition|Replace 10% of saturated fat intake with polyunsaturated fat
48017978|NCT03861000|DRUG|[C-11]T-1650|radio-labeled drug
48017979|NCT03861000|DRUG|BPN14770|selective compound
48017980|NCT00375193|DRUG|Amrubicin|Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
48028746|NCT01129310|DRUG|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
48028747|NCT00178490|DRUG|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
48028748|NCT05263531|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to design pressure for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
48028749|NCT06559397|OTHER|Assessment of cervical proprioception|Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).
48375236|NCT03426735|OTHER|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
48375237|NCT02687724|DRUG|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
48375238|NCT01700218|OTHER|telemonitoring|
48375239|NCT01700218|OTHER|control|
48517027|NCT02031419|DRUG|CC-122|2mg or 3 mg administered orally once daily
48517028|NCT02031419|DRUG|CC-223|20mg or 30mg administered orally once daily.
48517029|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
48517030|NCT02031419|DRUG|CC-122|2mg or 3mg administered orally once daily.
48174970|NCT04136600|DRUG|EGFR antibody and Chemotherapy|"Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
48174971|NCT04136600|DRUG|Chemotherapy|"Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
48375240|NCT03693482|DIAGNOSTIC_TEST|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
48375241|NCT05082922|BEHAVIORAL|Hybrid treatment|Transdiagnostic emotion-focused treatment provided by a psychologist with, when needed, support of a medical doctor (ensuring adherence to medical guidelines) and a physiotherapist (providing assessment and treatment support in exposure for physical activities). Depending on the length of the waiting period (randomly assigned to be either 4, 5 or 6 weeks), the treatment period varies between 14-16 weeks and contains 10-15 sessions.
48375242|NCT04631432|DIAGNOSTIC_TEST|Pre-screening|Document upload of Autism diagnosis certificate. Participants can request to show their certificate via a Zoom meeting with the researcher instead of uploading it.
48375243|NCT04631432|BEHAVIORAL|Task session|"The Iowa Gambling task- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, displaying the gain and the loss for that trial. Through contingent feedback, participants are expected to learn that some deck are better than others.The task will include 120 trials.~Block of trials without feedback- four decks of cards on the computer screen. Each card yields a reward, but might also yield a loss. In each trial, the participant selects a card. Consequently, the card is exposed, but the gain and the loss for that trial are not displayed. The task will include 30 trials.~Social Responsiveness Scale, 2nd Edition (SRS-2; adult-self report):(Constantino \& Gruber, 2012) The brief autism quotient scale:(AQ10; Baron-Cohen et al., 2001) Brief intelligence test (Similarities-MAB + Raven Set 1)"
48017981|NCT02652780|BIOLOGICAL|GS010|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
48017982|NCT02652780|DEVICE|Sham Intravitreal Injection|"Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
48375244|NCT00030056|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
48375245|NCT01519700|DRUG|EP2006|Eligible patients will be teated with EP2006
48017983|NCT06566274|DEVICE|thumbtack needle|As a kind of intradermal needle, thumbtack needle (TTN) is a method of shallow puncture and long-term needle.After the TTN is attached into the acupoints, it will be reserved in the acupoints for 3 days. After 3 days of retention of TTN, the patient is instructed to go to the hospital, where the doctor removes the needle, disinfect the local skin of acupoints and conducts the next TTN treatment. A total of 5 treatments were applied for a duration of 15 days.
48017984|NCT06566274|DEVICE|sham thumbtack needle|"The sham TTN used in the sham TTN group has no needle body and its appearance and shape are similar to the real TTN. But it does not produce a needle-like effect.~The acupoints of sham TN group are the same as those of TN group. The use of sham TN is the same as that of the TN group. After 3 days retention of sham TN, the patient will be instructed to go to the hospital, where the doctor remove the sham TN, and conduct the next treatment after local skin disinfection. A total of 5 treatments will be applied for a duration of 15 days."
48017985|NCT03646344|DRUG|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
48174972|NCT02377011|BEHAVIORAL|Problem solving cognitive behaviour therapy (PS CBT)|
48707110|NCT04676165|DEVICE|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~* Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~* Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~* Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~* Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~* Caregiver connect: Provides patients' caregivers with access to the app.~* Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~* Other: pill images, daily pill reminders, weekly dosing schedule"
48017986|NCT03646344|DRUG|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
48017987|NCT05771519|BEHAVIORAL|HIV disclosure intervention|This will be a biobehavioral intervention focused on helping men with HIV to disclose their HIV status to a personal confidant inclusive with specific focus on sexual partners.
48174973|NCT05937815|PROCEDURE|Sample collection|collection of sputum, stool and blood samples at baseline, 6 months and 1 year after baseline
48017988|NCT05481112|DRUG|Extended-Release Buprenorphine Injection|Extended-release buprenorphine (XR-B, Sublocade) is manufactured by Indivior. XR-B consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades.
48174974|NCT03232034|DIETARY_SUPPLEMENT|Calcium Citrate|1000 mg calcium as calcium citrate
48174975|NCT03232034|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
48017989|NCT03568916|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
48017990|NCT03568916|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
48017991|NCT03568916|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
48017992|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 1|"Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
48707111|NCT01011803|OTHER|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were \[diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)\]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
48707112|NCT03292419|PROCEDURE|Topography-guided LASIK|LASIK surgery
48017993|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 1|"Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
48017994|NCT04551105|DIAGNOSTIC_TEST|Reader Group X - Session 2|"Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS."
48174976|NCT03232034|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
48375246|NCT01519700|DRUG|Filgrastim|Eligible patients will be teated with Filgrastim
48375247|NCT04288960|DEVICE|Gwalk accelerometer walking trials|No intervention. Participants will wear a belt mounted accelerometer and complete walking trials to assess validity of the device
48707113|NCT00521430|BIOLOGICAL|anti-thymocyte globulin|
48707114|NCT00521430|DRUG|busulfan|
48707115|NCT00521430|DRUG|cyclosporine|
48707116|NCT00521430|DRUG|fludarabine phosphate|
48174977|NCT03260803|DRUG|Oligopin|Oligopin ,150 mg ,once daily, 12 week
48174978|NCT03260803|DRUG|Placebo|Placebo,150 mg ,once daily, 12 week
48174979|NCT04380883|DEVICE|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
48174980|NCT04380883|DEVICE|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
48174981|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
48174982|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
48517031|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
48174983|NCT02057575|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
48174984|NCT02057575|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
48517032|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
48707117|NCT00521430|DRUG|methotrexate|
48707118|NCT00521430|DRUG|methylprednisolone|
48707119|NCT00521430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48707120|NCT00521430|PROCEDURE|peripheral blood stem cell transplantation|
48375248|NCT03788317|DRUG|Botulinum toxin type A|Injections to hypertonic muscles
48375249|NCT03465215|DEVICE|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
48375250|NCT05092217|DRUG|Tirelizumab|Tirelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); Tirelizumab should be applied since 2-6 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
48707121|NCT03873181|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
48707122|NCT05653050|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid insulin aspart.
48707123|NCT05653050|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Freestyle Libre 3 CGM
48707124|NCT02928003|PROCEDURE|Lung surgery|Genetic analysis and questionnaires
48174985|NCT05010668|DRUG|cryoablation|Cryoablation treatment starts at day 0.
48375251|NCT05092217|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy for recurrent nasopharyngeal tumor
48375252|NCT00755560|DRUG|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
48707125|NCT01566695|DRUG|Oral Azacitidine|300 mg daily, days 1 to 21 of each 28-day treatment cycle
48707126|NCT01566695|DRUG|Placebo|Identically matching placebo tablets on day 1 to 21 of each 28-day treatment cycle.
48707127|NCT01566695|OTHER|Best Supportiv Care (BSC)|BSC included and was not limited to packed RBC (packed red blood cell \[pRBC\] and whole blood), platelet transfusions (single donor or pooled donor), antibiotic, antiviral and/or antifungal therapy, nutritional support, and granulocyte colony stimulating factors (G-CSF) for participants who experienced neutropenic fever/infections.
48707128|NCT03995680|DRUG|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
48707129|NCT00908869|DRUG|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
48375253|NCT00755560|DRUG|Placebo|Placebo BID for 15 days
48707130|NCT00314717|BEHAVIORAL|Control diet|
48707131|NCT00314717|BEHAVIORAL|Low GI diet|
48174986|NCT05010668|DRUG|Sintilimab|Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48375254|NCT05206669|BEHAVIORAL|Health Messages|Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
48375255|NCT00241566|DEVICE|implantation of stimulator|
48375256|NCT05115760|DIETARY_SUPPLEMENT|Dietary Supplement|Given Kate Farms pea protein oral nutrition supplement PO
48375257|NCT05115760|OTHER|Quality-of-Life Assessment|Ancillary studies
48375258|NCT05115760|OTHER|Questionnaire Administration|Ancillary studies
48707132|NCT03032614|DRUG|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
48707133|NCT03032614|DRUG|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
48707134|NCT03032614|DRUG|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
48707135|NCT02632201|BIOLOGICAL|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
48517033|NCT02031419|DRUG|CC-223|20mg or 30mg per day administered orally daily.
48517034|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
48174987|NCT05010668|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
48174988|NCT00056810|DRUG|4-aminopyridine (4-AP)|
48174989|NCT05365087|PROCEDURE|Transoral Fundoplication and Sleeve Gastrectomy|Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy
48174990|NCT05365087|PROCEDURE|Gastric Bypass|Laparoscopic Roux-en-Y gastric bypass
48174991|NCT02937896|DRUG|Desmopressin|40 micrograms Nasal Desmopressin.
48174992|NCT02937896|DRUG|Ketorolac|30mg intravenous Ketorolac.
48174993|NCT02937896|DRUG|Normal Saline|1cc intravenous Normal Saline.
48174994|NCT02937896|DRUG|Normal Saline|4 puffs nasal Normal Saline.
48174995|NCT00361036|DEVICE|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
48707136|NCT02632201|BIOLOGICAL|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
48174996|NCT00361036|DEVICE|Uterine fibroid embolization Embosphere®|Embosphere - control arm
48174997|NCT06283498|DEVICE|Device Morpheus8V|Assigned to be treated using the modified Morpheus8V
48174998|NCT02046798|DRUG|ASP3652|oral
48174999|NCT02869906|OTHER|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
48175000|NCT03931993|BIOLOGICAL|Placebo comparator|
48175001|NCT03931993|BIOLOGICAL|Grass MATA MPL|
48175002|NCT03062345|OTHER|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
48175003|NCT03062345|OTHER|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
48175004|NCT00250978|DRUG|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
48175005|NCT00276900|DRUG|Sertraline|
48175006|NCT00392704|DRUG|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
48175007|NCT00392704|DRUG|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
48175008|NCT00392704|DRUG|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
48175009|NCT00392704|DRUG|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
48175010|NCT00392704|RADIATION|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
48375259|NCT01697124|BEHAVIORAL|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
48375260|NCT00000362|BEHAVIORAL|Chin-down position|
48375261|NCT00000362|BEHAVIORAL|Thickened liquid administration|
48707137|NCT02562508|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
48375262|NCT00036868|BIOLOGICAL|trastuzumab|
48375263|NCT00036868|DRUG|CMF regimen|
48375264|NCT00036868|DRUG|cyclophosphamide|
48375265|NCT00036868|DRUG|fluorouracil|
48375266|NCT00036868|DRUG|methotrexate|
48707138|NCT02562508|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
48707139|NCT05785637|PROCEDURE|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
48375267|NCT05655195|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
48707140|NCT02324140|OTHER|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
48707141|NCT06606860|DRUG|Oxantel Pamoate|Oxantel Pamoate tablet, 250mg
48707142|NCT06606860|DRUG|Placebo|Placebo tablet
48707143|NCT04733170|DIAGNOSTIC_TEST|KnowNow SARS-CoV-2 Rapid Antigen Test|KnowNow SARS-CoV-2 Rapid Antigen Test for the detection of Covid-19 in saliva, as compared to high sensitivity reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal swabs as the reference test method
48375268|NCT05655195|DEVICE|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
48017995|NCT04551105|DIAGNOSTIC_TEST|Reader Group Y - Session 2|"Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS."
48375269|NCT05297162|DIAGNOSTIC_TEST|PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy|"The prostate profile and ROIs will be drawn on PSMA PET and mpMRI and fused in real time with the TRUS image stack during biopsy. Biopsies, transrectal or transperineal according to lesion site, will be performed with patients in the dorsal lithotomy position, under antibiotic prophylaxis and local anesthesia, using 3D triplane transrectal ultrasound system (BK Medical, Analogic Ultrasound Group, Pro Focus, Transducer 8818, 6/9 MHz).~Biopsy cores will be numbered according to ROI number and topography. Specimens will be processed and evaluated by a genitourinary pathologist. Tumor foci will be quantified and graded according to the ISUP consensus conference on Gleason grading."
48017996|NCT05866094|BEHAVIORAL|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
48707144|NCT05076760|BIOLOGICAL|MEM-288 Intratumoral Injection|Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
48375270|NCT02403115|OTHER|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
48375271|NCT03214016|OTHER|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
48375272|NCT03214016|OTHER|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
48375273|NCT03085940|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
48375274|NCT03085940|DRUG|Placebo|Placebo
48375275|NCT00101374|DRUG|Leflunomide|
48707145|NCT05076760|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
48707146|NCT05714618|DIAGNOSTIC_TEST|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
48707147|NCT05714618|DIAGNOSTIC_TEST|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
48707148|NCT05714618|DIAGNOSTIC_TEST|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
48707149|NCT03745443|PROCEDURE|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
48707150|NCT03626636|DRUG|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
48707151|NCT03626636|OTHER|Sham|Sham injection
48017997|NCT03447327|PROCEDURE|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
48017998|NCT06572345|DIETARY_SUPPLEMENT|Low-energy diet|For the first 12 weeks during the LED, participants will have 4 meal replacement products each day. The following 12 weeks consists of a gradual reintroduction of food one meal at a time, in a structured stepwise progression, under the supervision of a dietitian. They will then undergo 28 weeks of weight maintenance to see if they are able to keep their weight stable.
48017999|NCT06572345|OTHER|Qualitive interview - LED participants|Semi-structured interviews with 10 of the LED participants and their relative/carer.
48018000|NCT06572345|OTHER|Qualitive interview - Participants declining LED|Semi-structured interviews with 10 participants who declined the LED, and their relative/carer.
48375276|NCT01953380|BEHAVIORAL|extended information|
48375277|NCT00320073|DRUG|erlotinib hydrochloride|75 mg to 150mg
48375278|NCT00320073|DRUG|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
48375279|NCT00320073|DRUG|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
48517035|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
48707152|NCT03488888|DRUG|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
48018001|NCT06572345|OTHER|Qualitive interview - Health Care Professionals (HCPs)|Semi-structured interviews with 10 HCPs involved in delivery of the trial.
48018002|NCT03049163|DRUG|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
48018003|NCT02172313|DRUG|semaglutide|For oral administration.
48707153|NCT03488888|DRUG|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
48707154|NCT02944357|DRUG|Cisplatin|Given IV
48707155|NCT02944357|DRUG|Gemcitabine Hydrochloride|Given IV
48707156|NCT02944357|PROCEDURE|Radical Cystectomy|Undergo cystectomy
48707157|NCT02944357|BIOLOGICAL|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
48707158|NCT02818374|DEVICE|oral accessibility spatula (SAB)|
48707159|NCT05254275|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
48707160|NCT05254275|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
48375280|NCT04746495|DRUG|Placebo|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.
48375281|NCT04746495|DRUG|Eplerenone 50mg|Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.
48375282|NCT00243620|DEVICE|Vacuum therapy (device)|
48375283|NCT01014442|DRUG|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
48517036|NCT06438835|DIAGNOSTIC_TEST|PneuFlex AFO Assist|It features a pneumatic artificial muscle designed to enhance ankle foot orthosis functionally for patients with mobility issues.
48707161|NCT04417595|DRUG|Fish Oil (Containing Omega-3 Acids)|Fish Oil Supplement
48707162|NCT04417595|DRUG|Olive Oil|Olive Oil Supplement
48707163|NCT00527683|DRUG|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
48707164|NCT00527683|DRUG|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
48707165|NCT00527683|BEHAVIORAL|Group therapy|Participants attend group sessions once a week
48018004|NCT02886533|OTHER|Antithrombotic|Collection of clinical, biological data
48375284|NCT03711747|PROCEDURE|Osteochondral allograft ankle|Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
48707166|NCT00334997|PROCEDURE|endoscopic surgery|
48707167|NCT00334997|PROCEDURE|laser surgery|
48707168|NCT00334997|RADIATION|radiation therapy|
48707169|NCT01045941|DRUG|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
48707170|NCT01045941|PROCEDURE|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
48707171|NCT02125903|DRUG|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
48707172|NCT04384445|BIOLOGICAL|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
48707173|NCT04384445|OTHER|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
48707174|NCT02785458|BEHAVIORAL|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
48707175|NCT02708849|DRUG|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
48707176|NCT02708849|DRUG|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
48707177|NCT02708849|DRUG|Placebo|oral dose placebo
48707178|NCT05785533|OTHER|Smartphone App|App that provides recovery guidance based on pain and functional outcomes
48707179|NCT05785533|OTHER|Standard of Care|Paper based discharge instruction that provide information on pain management
48707180|NCT06029673|DRUG|Cabergoline 1 MG|Dopamine agonist
48707181|NCT06029673|DRUG|Placebo|Placebo
48175011|NCT05648513|BEHAVIORAL|Motivational Interwiev|Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
48375285|NCT05574673|OTHER|Standard of care|Patients receive standard of care treatment according to local and national guidelines
48375286|NCT05390060|DEVICE|Neuromonitoring|Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
48707182|NCT06517251|OTHER|Arm-hand BOOST|"Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation."
48175012|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract|207 mg curcumin
48175013|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract with 7-9% volatile turmeric oils|207 mg curcumin
48175014|NCT03530436|DIETARY_SUPPLEMENT|Turmeric extract plus mixture of phytochemicals|207 mg curcumin
48375287|NCT02377258|OTHER|Non Interventional|
48375288|NCT03705221|BEHAVIORAL|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
48375289|NCT03705221|BEHAVIORAL|Healthy Parent Carers online resources|Online resources related to health and wellbeing
48375290|NCT05874882|OTHER|resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
48375291|NCT05874882|OTHER|chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
48375292|NCT05874882|OTHER|placebo mouthwash as adjunct to scaling and root planing in periodontitis patients|patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
48517037|NCT01801904|DRUG|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
48018005|NCT00040404|DRUG|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
48018006|NCT00040404|DRUG|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
48018007|NCT00040404|DRUG|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
48018008|NCT00040404|OTHER|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
48018009|NCT04375423|BEHAVIORAL|Ecological momentary assessment and intervention: Behaviorally-dependent messaging|In response to behavioral data submitted intervention arm participants receive messages on their phones reinforcing healthy behaviors or encouraging alternative behaviors to limit risks
48018010|NCT04375423|BEHAVIORAL|Ecological momentary assessment only|Participants will receive twice daily and weekly prompts to submit behavioral report data and self-initiate event-contingent behavioral report data submissions
48375293|NCT05833269|BEHAVIORAL|Mindfulness and Compassion based Intercare program for parental burnout reduction (IBAP-BP)|The interventions is an adaptation of an 8-week program called Mindfulness and Compassion based Intercare program designed to reduce burnout. The adaptation includes a parental burnout risk and resource balance framework, focusing on factors such as parental perfectionism, low emotional intelligence, lack of parenting practices, excess parental responsibilities, lack of co-parental support, and lack of social support. The program consists of 8 modules with practical and theoretical activities and daily tasks that require 10-30 minutes. The modules cover topics such as mindfulness, coping with stress, empathy, and self-care. Formal meditation practices include body exploration, sitting, movement, walking, eating, acceptance, compassion, and gratitude. The program also includes descriptions and motivation for practices related to identifying values that promote parenting, time management, attentive parenting techniques, and emotional management.
48018011|NCT02738021|BEHAVIORAL|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
48018012|NCT03745703|BEHAVIORAL|MOCHA|(see above)
48175015|NCT03530436|DIETARY_SUPPLEMENT|Cyclodextrin complex of curcuminoids|207 mg curcumin
48175016|NCT03530436|DIETARY_SUPPLEMENT|Turmeric oleoresin|207 mg curcumin
48175017|NCT03530436|DIETARY_SUPPLEMENT|Liposomal curcumin|207 mg curcumin
48175018|NCT03530436|DIETARY_SUPPLEMENT|Phytosomal curcumin|207 mg curcumin
48175019|NCT03530436|DIETARY_SUPPLEMENT|Micellar turmeric extract|207 mg curcumin
48175020|NCT00715117|DRUG|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
48175021|NCT00715117|OTHER|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
48175022|NCT01055210|DEVICE|Optimisation of VV delay|Programmed VV delay altered on device
48018013|NCT06204393|OTHER|Thyroid metabolic index|"The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.~Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions."
48018014|NCT05807841|PROCEDURE|percutaneous coronary intervention|IVUS-guided stent implantation
48375294|NCT05833269|BEHAVIORAL|Educational material|On a weekly basis, participants will receive reminder emails highlighting specific risk factors associated with parental burnout. These risk factors include parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Each week, the reminder email will cover a different topic, providing participants with relevant information.
48707183|NCT06517251|OTHER|Lower limb BOOST|L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
48707184|NCT04547907|DRUG|Nab-paclitaxel+ trastuzumab+ patuzumab|Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
48707185|NCT04547907|DRUG|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
48707186|NCT06289192|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
48707187|NCT06289192|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
48707188|NCT06289192|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
48707189|NCT06289192|OTHER|Lung Cancer Screening|Eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
48707190|NCT05061654|DRUG|Ceftolozane-tazobactam IV|Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
48707191|NCT03603535|DEVICE|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
48707192|NCT00441649|DRUG|Methylphenidate|
48707193|NCT03739489|PROCEDURE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
48707194|NCT04573426|DRUG|Acetaminophen|1,000mg liquid acetaminophen
48018015|NCT02505516|OTHER|metformin|
48018016|NCT04689113|BEHAVIORAL|Incontinence Health Belief Development Program|After the applied interventions, it is desired to develop kegel exercise behavior in women.
48175023|NCT01226836|OTHER|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
48707195|NCT04573426|DRUG|Placebo|Liquid placebo solution
48707196|NCT04573426|BEHAVIORAL|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
48707197|NCT04573426|BEHAVIORAL|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
48707198|NCT01638052|DRUG|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
48707199|NCT05697289|OTHER|satisfaction survey|Non-comparative longitudinal observational study over 12 months conducted during usual follow-up of patients living with HIV-1 and having changed treatment for an injectable dual therapy with prolonged release cabotegravir-rilpivirine. Decision to change treatment and follow-up of patients are part of routine care. Study is proposed after the doctor has taken the decision to modify treatment, the patient has accepted and injectable dual therapy is prescribed. It is based on self-questionnaires to collect patient perceptions (Patient-Reported Outcomes) and clinical and biological data collected routinely at inclusion and during follow-up visits.
48707200|NCT05973981|BEHAVIORAL|Package standardization|Conditions vary in terms of amount of cigarette packages that are subject to standardization
48707201|NCT00075387|DRUG|Carboplatin|Given IA
48018017|NCT05864027|BEHAVIORAL|Peer-led Oral Health Recovery Group|"The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist."
48018018|NCT05864027|BEHAVIORAL|Educational Video about Oral Health|The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
48375295|NCT05833269|BEHAVIORAL|Reminder by email|Every week, participants will receive two reminder emails: one with a list of activities to complete during the week and another containing information about parental burnout. This approach aims to support participants in staying engaged with the program.
48375296|NCT05833269|BEHAVIORAL|Whatsapp support group|The participants will have the option to join a WhatsApp group with 25 other members from the specific group to receive daily greetings, group support, and have general doubts resolved.
48018019|NCT05322603|DRUG|Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)|A decrease in the pain severity (VAS);opioid-sparing effect
48018020|NCT05322603|DRUG|Analgesics|A decrease in the pain severity (VAS)
48018021|NCT05720624|DRUG|Anhydrous Enol-oxaloacetate|Given PO
48018022|NCT05720624|OTHER|Best Practice|Receive standard of care therapy
48018023|NCT05720624|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood
48018024|NCT05720624|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRS imaging
48018025|NCT05720624|OTHER|Questionnaire Administration|Ancillary studies
48375297|NCT05833269|BEHAVIORAL|Journaling|As part of the mindfulness intervention, participants are required to write in a journal every day with the purpose of cultivating awareness of bodily sensations, emotions, thoughts, and impulses. Each week, the journaling topic focuses on a different area, including pleasant experiences, unpleasant experiences, needs and resources, communication difficulties, and sharing resources. In contrast, the control group's journaling activity involves free writing about everyday issues, thoughts, and ideas.
48375298|NCT05833269|BEHAVIORAL|Guided relaxation excercise|Participants receive a 10 and 20-minute relaxation exercise guide called the Jacobson Progressive Relaxation, which they are expected to practice daily.
48018026|NCT03176810|DEVICE|OCT|OCT is used to guide PCI.
48375299|NCT01173666|PROCEDURE|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
48375300|NCT01173666|DRUG|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
48375301|NCT03741530|DRUG|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
48375302|NCT03741530|OTHER|Standard management for ICH|Usual care and drug in hospital
48375303|NCT03224169|BEHAVIORAL|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
48375304|NCT03446846|DRUG|MIN-117 5.0 mg|5.0 mg MIN-117 administered as two MIN-117 2.5 mg capsules as a single dose once daily
48375305|NCT03446846|DRUG|MIN-117 2.5 mg|2.5 mg MIN-117 administered as one MIN-117 2.5 mg capsule and one Placebo capsule as a single dose once daily
48375306|NCT03446846|DRUG|Placebo|Placebo administered as two Placebo capsules as a single dose once daily
48375307|NCT01338311|DRUG|salbutamol|200mcg twice daily for a total of 7 doses
48375308|NCT01338311|DRUG|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
48707202|NCT00075387|DRUG|Cyclophosphamide|Given IV
48707203|NCT00075387|DRUG|Etoposide Phosphate|Given IV
48707204|NCT00075387|OTHER|Quality-of-Life Assessment|Ancillary studies
48707205|NCT00075387|DRUG|Sodium Thiosulfate|Given IV
48707206|NCT01325090|DRUG|BOTOX|A syringe of 1 ml contain 25 Allergan units.
48707207|NCT01325090|OTHER|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
48018027|NCT03176810|DEVICE|Angiography|Angiography is used to guide PCI.
48018028|NCT01312467|DRUG|metformin hydrochloride|
48018029|NCT05630937|DRUG|NMS-01940153E|Route of administration: intravenous (IV) solution
48707208|NCT05215860|BEHAVIORAL|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
48707209|NCT05215860|OTHER|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
48707210|NCT02811913|OTHER|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS"
48707211|NCT02811913|OTHER|peripheral sensory stimulation|peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
48707212|NCT03304054|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
48018030|NCT00984841|OTHER|Tailored letter|
48018031|NCT03594591|DRUG|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
48028750|NCT01316367|BEHAVIORAL|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~* Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~* Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~* Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
48707213|NCT03304054|DRUG|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
48018032|NCT06663800|OTHER|Ujjayi Paranayama|Inhale or breathe in slowly while taking a deep, prolonged breath through both nostrils. As you inhale, attempt to tighten your throat and feel the air in your throat. Air should not come into contact with the interior of the nose. When air enters the throat, an odd sound is made. Allow the breath to be loose and easy while you slightly tighten the back of your throat and hiss lightly as you breathe in and out. The sound isn't forced, but it should be loud enough for someone to hear you if they were close. Now close your right nostril and release the breath through your left. As you exhale, try making the sound HHHHHAAAA
48018033|NCT06663800|OTHER|Standard Protocol|Control Group will perform Deep Breathing Adhering to a FITT model protocol, with a frequency of 5 days. Intensity set at 8 repetitions, duration range from 10 to 15 minutes
48018034|NCT01516268|DRUG|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
48707214|NCT00629746|DEVICE|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
48018035|NCT06664203|PROCEDURE|Selective turuncus block with 25 ml bupivacain|A high-frequency linear ultrasound (USG) probe will be used to locate the C7 transverse process, which will serve as a sonoanatomic landmark. Once the C5 ventral ramus is identified at the C7 transverse process level, the linear probe will be slightly caudally angled to visualize the C6 ventral ramus. The area where the superior trunk is formed by C5 and C6 will be examined with the USG probe until the superior trunk is visualized. Below the superior trunk, the middle trunk and the C8 ventral ramus will be visible. In Group 1, a total of 23 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used as the local anesthetic mixture, totaling 25ml. 7ml of the local anesthetic mixture will be injected into the superior trunk, the middle trunk for an additional 8 ml. The probe will then be directed caudally to obtain an optimal view of the lower trunk, where 10 ml of the same mixture will be injected close to the lower trunk.
48175024|NCT03520062|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Treatment with Liraglutide (3.0mg per day) for \~6 weeks
48707215|NCT03135444|BEHAVIORAL|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
48375309|NCT00852657|PROCEDURE|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
48375310|NCT00852657|PROCEDURE|Physiotherapy|According to a rehabilitation program which was established prior to study start.
48517038|NCT03259386|DEVICE|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
48707216|NCT03135444|BEHAVIORAL|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
48707217|NCT03135444|BEHAVIORAL|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
48707218|NCT04171791|DRUG|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
48707219|NCT03804567|OTHER|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
48707220|NCT03804567|OTHER|Routine low back pain management|Standard low back persistent physiotherapy management as recommended by national guidelines.
48707221|NCT00328653|DRUG|Cyclosporine NOVA22007 0.05%|
48707222|NCT00328653|DRUG|Cyclosporine NOVA22007 0.1%|
48707223|NCT00328653|DRUG|Vehicle|
48707224|NCT04422561|DRUG|Ivermectin Tablets|two doses 72 hours apart
48707225|NCT02241876|DRUG|N-acetylcysteine|
48707226|NCT01567592|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
48707227|NCT02465749|DRUG|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
48707228|NCT02465749|DEVICE|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
48517039|NCT00451178|DRUG|enzastaurin|1125 milligrams (mg) then 500 mg, oral, daily, six 21-day cycles or up to 3 years
48517040|NCT00451178|DRUG|rituximab|375 milligrams per square meter (mg/m\^2), intravenous (IV), Day 1 every 21 days, six 21-day cycles
48517041|NCT00451178|DRUG|cyclophosphamide|750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
48707229|NCT02465749|DRUG|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
48018036|NCT06664203|PROCEDURE|Selective turuncus block with 15 ml bupivacain|In Group 2, 13 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used, totaling 15 ml. In Group 2, 5 ml of the local anesthetic mixture will be injected into the superior trunk, followed by 5 ml into the middle trunk and 5 ml into the lower trunk, as in Group II.
48018037|NCT05163912|BEHAVIORAL|Virtual home intervention|Group classes with active videogames and discussions
48018038|NCT05467670|DRUG|Pembrolizumab|A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
48018039|NCT05467670|DRUG|ALX148|A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
48018040|NCT05467670|DRUG|Doxorubicin|An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
48018041|NCT02605512|OTHER|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
48018042|NCT06166953|OTHER|digital technology-supported education|The education will include information about surgical process and care after surgery.
48018043|NCT06632028|OTHER|artificial intelligence assisted spinal rehabilitation|In artificial intelligence-based rehabilitation, it is more advantageous compared to other treatment methods in terms of the fact that technology applications can be designed according to the level and abilities of the individual and that the parameters such as duration, intensity, difficulty and speed of the treatment can be flexibly configured for the therapist and the patient.
48018044|NCT06632028|OTHER|conventional therapy|In cervical disc herniation, non-invasive physical therapy applications such as laser treatment, hot-cold treatment methods, Transcutaneous Electrical Nerve Stimulation (TENS), interferential currents, manual therapy applications, kinesiological taping and exercise therapy, as well as painkillers and nonsteroidal anti-inflammatory drugs and antidepressive drugs are among the most preferred methods in treatment.(6)
48018045|NCT04486287|DRUG|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy."
48018046|NCT01412840|OTHER|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
48375311|NCT03271580|DIAGNOSTIC_TEST|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
48707230|NCT02465749|DRUG|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
48707231|NCT02465749|DRUG|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
48707232|NCT02465749|DRUG|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
48707233|NCT04782245|DRUG|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
48707234|NCT04782245|DRUG|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
48707235|NCT02281487|PROCEDURE|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
48707236|NCT02281487|PROCEDURE|Hysterectomy|standard hysterectomy
48707237|NCT02281487|DEVICE|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
48707238|NCT06207799|DRUG|Elranatamab|Given by SC
48707239|NCT06207799|DRUG|Lenalidomide|Given by PO
48707240|NCT06207799|DRUG|Plerixafor|Given by SC
48707241|NCT06207799|DRUG|Melphalan|Given by IV
48707242|NCT06207799|DRUG|Busulfan|Given by PO
48707243|NCT06207799|DRUG|G-CSF|Given by IV
48707244|NCT06207799|PROCEDURE|Stem cell transplant|Given by IV
48707245|NCT02952963|DRUG|Chenodeoxycholic Acid|
48707246|NCT02952963|DRUG|Colesevelam|
48707247|NCT03661788|DRUG|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
48707248|NCT03661788|DRUG|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
48707249|NCT01996267|DRUG|PTC+Pertuzumab|Cycle repeated every 21 days
48707250|NCT01996267|DRUG|FEC-T+Pertuzumab|Cycle is repeated every 21 days
48707251|NCT01485900|DRUG|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
48707252|NCT03204799|OTHER|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
48707253|NCT03204799|DRUG|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
48707254|NCT03204799|DRUG|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
48707255|NCT06456229|DIETARY_SUPPLEMENT|Nestle Isocal|Nestle Isocal
48707256|NCT06456229|DIETARY_SUPPLEMENT|Nestle Boost Optimum|Nestle Boost Optimum
48018047|NCT01412840|OTHER|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
48018048|NCT06295133|BEHAVIORAL|Stress|The stress management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators of stress will be recorded to assess the progress of each student.
48175025|NCT05528822|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
48175026|NCT05528822|PROCEDURE|ultrasound-guided pericapsular nerve group (PENG) block|A low-frequency curvilinear transducer was placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved over inferiorly to visualize the pubic ramus. The femoral artery and ilio pubic eminence (IPE) were then visualized (Figure 1). Using in-plane technique 10 cm echogenic 21 gauge needle was advanced from lateral to medial direction, and 20 ml of local anesthetic 0.5% ropivacaine was deposited between the psoas tendon anteriorly and pubic ramus posteriorly.
48018049|NCT06626087|DIAGNOSTIC_TEST|Prototype artificial intelligence algorithm|Developed by the University of Hong Kong
48175027|NCT00062686|DRUG|GW572016|
48175028|NCT02136771|DIETARY_SUPPLEMENT|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
48175029|NCT02136771|DIETARY_SUPPLEMENT|Placebo|
48018050|NCT06626087|DIAGNOSTIC_TEST|LI-RADS|The Liver Imaging Reporting and Data System (LIRADS) was established to standardize the lexicon, interpretation and communication of radiological findings related to HCC
48018051|NCT05966025|DRUG|Itopride|itopride will be taken by pateints one time per day by dose 100 mg
48175030|NCT01401114|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
48175031|NCT00858507|BEHAVIORAL|RN Brief Intervention|RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
48175032|NCT00858507|BEHAVIORAL|Social Worker Outreach|Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
48175033|NCT04692883|PROCEDURE|Percutaneous suturing|
48175034|NCT04166110|DRUG|Predetermined treatment duration|Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
48707257|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
48018052|NCT05966025|DRUG|conventional therapy|will taken by patient in control group
48018053|NCT03239041|BEHAVIORAL|Social navigation team|Social navigation team
48018054|NCT00393172|BEHAVIORAL|exercise|5 days per week exercise for 4 months
48018055|NCT04513600|DIAGNOSTIC_TEST|Cardiac MRI|Lab work: Hs- Troponin, Serum N-terminal-proBNP CMR: Native T1, Native T2, extracellular volume, strain and strain rate.
48028751|NCT01316367|BEHAVIORAL|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
48175035|NCT04166110|DRUG|Variable treatment duration|"Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment."
48175036|NCT02584036|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
48175037|NCT02584036|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
48375312|NCT03271580|PROCEDURE|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
48375313|NCT03271580|OTHER|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
48375314|NCT03271580|OTHER|Ankle Brachial Index|Blood pressure test
48707258|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
48707259|NCT03352453|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
48707260|NCT03352453|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
48375315|NCT05327517|PROCEDURE|Esophagectomy|Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
48375316|NCT02254629|DRUG|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
48375317|NCT02254629|DRUG|Laxative Polyethylene Glycol|laxative：2000 ml.
48375318|NCT02584972|OTHER|no intervention required|no intervention required
48375319|NCT04726631|DRUG|Basal insulin analogue|Analogue insulin is a sub-group of human insulin
48375320|NCT04726631|DRUG|rapid acting insulin|Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.
48375321|NCT04726631|DRUG|Neutral Protamine Hagedorn|is an intermediate-acting insulin
48707261|NCT03403231|BEHAVIORAL|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
48375322|NCT04726631|DRUG|regular insulin|is a type of short-acting insulin.
48375323|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
48517042|NCT00451178|DRUG|doxorubicin|50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
48517043|NCT00451178|DRUG|vincristine|1.4 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
48517044|NCT00451178|DRUG|prednisone|100 mg, oral, Days 1-5, six 21-day cycles
48517045|NCT03221244|DEVICE|VR Treatment|Distractors
48707262|NCT06453330|BIOLOGICAL|Horizontal platelet-rich fibrin (H-PRF)|Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
48707263|NCT06363890|DIAGNOSTIC_TEST|TAQMan Array Card|Real time PCR test to detect diarrheal pathogens.
48375324|NCT04922164|BEHAVIORAL|Cue intervention|"Around 30 pieces of narrative information about how a mother behaves in specific decision context will be derived from our qualitative study to construct social normative cues.~For goal-related cues, words relating to each category of breastfeeding-related values, benefits and goals will be identified and used to construct the messages (e.g. attractive body shape, smart baby, natural, strong immunity and etc.). Each goal-priming message will be presented with brief priming words and a picture of an image of the desirable goal."
48375325|NCT04856852|OTHER|Iodine-125+Chemotherapy|Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
48375326|NCT04856852|OTHER|Surgical resection+Radiochemotherapy|"Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days."
48375327|NCT01751490|OTHER|physiotherapy|physiotherapy
48175038|NCT02584036|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
48375328|NCT01751490|PROCEDURE|shoulder stabilisation surgery|arthroscopic stabilisation surgery
48375329|NCT04434612|DEVICE|OXSIGHT smart glasses|OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
48375330|NCT01643967|OTHER|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
48375331|NCT01643967|OTHER|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
48707264|NCT00777400|DRUG|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
48707265|NCT04151628|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
48707266|NCT02291757|DIETARY_SUPPLEMENT|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
48707267|NCT02291757|DIETARY_SUPPLEMENT|Placebo|Placebo, 500 mg, once daily, p.o.
48707268|NCT00958464|PROCEDURE|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
48707269|NCT00017589|BIOLOGICAL|oblimersen sodium|
48707270|NCT00017589|DRUG|gemtuzumab ozogamicin|
48707271|NCT01404013|DRUG|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
48707272|NCT01404013|DRUG|Montelukast|Montelukast 10mg ,every night, for 8 weeks
48707273|NCT01404013|DRUG|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
48175039|NCT05221437|OTHER|antibiotic prescription|
48175040|NCT01004185|DRUG|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM \& 2 Asacol 400mg PM; 33-\<54kg = 5 Asacol 400 mg AM \& 4 Asacol 400mg PM; 54-\<90kg = 6 Asacol 400mg AM \& PM
48517046|NCT03221244|DEVICE|VR Active Control|No distractors
48375332|NCT00936468|BIOLOGICAL|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
48375333|NCT00250666|PROCEDURE|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
48375334|NCT02545699|DEVICE|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
48375335|NCT02545699|DEVICE|Standard Colonoscopy|Standard Colonoscopy
48375336|NCT00396357|DRUG|Vildagliptin|
48175041|NCT01004185|DRUG|Asacol 400 mg|17-\<33kg = 2 Asacol 400mg \& 1 placebo AM, 1 Asacol 400mg \& 1 placebo PM; 33-\<54kg = 3 Asacol 400mg \& 2 placebo AM, 2 Asacol 400mg \& 2 placebo PM; 54-\<90kg = 3 Asacol 400mg \& 3 placebo AM \& PM
48375337|NCT00396357|DRUG|metformin|
48375338|NCT03082079|PROCEDURE|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
48375339|NCT03030131|DRUG|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
48375340|NCT00013910|DRUG|NNC 90-1170|
48375341|NCT00116246|PROCEDURE|McRobert's manoeuvre|
48375342|NCT01164631|DEVICE|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
48375343|NCT02582216|DEVICE|3D augmented reality|Each treatment period included a 3DARS (3D augmented reality system)training session.All 3DARS training sessions were performed in the same quiet room under the supervision of the same single investigator.The 3DARS training session protocol included two virtual training procedures. The first virtual training procedure consisted of applying a vertical virtual mirror to the display screen, where the non-affected side of the patient's body (such as the right) was symmetrically duplicated by a vertical axis on the affected side (such as the left).The second virtual training procedure consisted of flipping the 3D image horizontally along a vertical axis. This allowed patients to observe the reflection of their non-affected upper extremity as if it was the affected one.
48707274|NCT05618886|OTHER|Education|The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.
48375344|NCT03371602|PROCEDURE|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
48375345|NCT03371602|PROCEDURE|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
48375346|NCT02293720|DEVICE|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
48375347|NCT02005302|DRUG|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
48375348|NCT02005302|DRUG|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
48028752|NCT04200066|DRUG|Temozolomide, Tamoxifen, Maprotiline|Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
48175042|NCT03380598|BEHAVIORAL|CLOSS|Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.
48517047|NCT05944146|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
48028753|NCT04975373|DRUG|Intrauterine injection of hyaluronic acid|operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
48028754|NCT06533241|PROCEDURE|renal biopsy|percutaneous renal biopsy procedure
48028755|NCT02692248|DRUG|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
48175043|NCT03380598|BEHAVIORAL|Usual care|Usual care. The child and parent(s) at regular visits to the nurse at the clinic
48375349|NCT02005302|DIETARY_SUPPLEMENT|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
48375350|NCT02005302|DIETARY_SUPPLEMENT|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
48517048|NCT05944146|DRUG|Dobutamine|infusion dobutamine
48517049|NCT05784025|DEVICE|AlterG|Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
48707275|NCT05618886|OTHER|Education and PFMT|Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
48707276|NCT05671575|OTHER|Questionnaire about Epilepsy|After obtaining informed consent, a structured questionnaire will be administered to the accompanying relative. The questionnaire consists of 5 sections: participants socio-demographic characteristics, patient demographic and clinical characteristics, participants knowledge about epilepsy including sources of knowledge and management of an acute seizure, general attitudes, and behaviors towards the People with epilepsy, Stigma scale of epilepsy.\[14\], and Quality of life in epilepsy-10 inventory (QOLIE-10) as the main data collection tool as regard quality of life of patients with epilepsy.
48707277|NCT03387995|DEVICE|LVIS stent|The paitents treated by LVIS stent implantation.
48707278|NCT03387995|DEVICE|Solitaire stent|The paitents treated by Solitaire stent implantation.
48707279|NCT03387995|DEVICE|Enterprise stent|The paitents treated by Enterprise stent implantation.
48707280|NCT03387995|DEVICE|Neuroform stent|The paitents treated by Neuroform stent implantation.
48707281|NCT03387995|DEVICE|Flow diverter (FD) stent|The paitents treated by Enterprise FD implantation.
48028756|NCT02692248|DRUG|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
48175044|NCT04686682|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
48517050|NCT03786458|BEHAVIORAL|web-based decision aid|The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.
48175045|NCT04686682|DRUG|JAB-8263|RP2D dose, orally Q2D with 28 days each cycle
48175046|NCT03916822|DIAGNOSTIC_TEST|Alloantigen-specific B-cells|Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
48517051|NCT03875924|OTHER|VWD treatments|Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
48517052|NCT00378573|DRUG|docetaxel|
48517053|NCT00378573|DRUG|gemcitabine|
48517054|NCT00378573|DRUG|bevacizumab|
48175047|NCT01157351|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
48175048|NCT01157351|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 15 months
48175049|NCT01157351|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
48175050|NCT01157351|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
48175051|NCT01157351|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
48175052|NCT01157351|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
48175053|NCT01157351|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
48175054|NCT01157351|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
48175055|NCT05938478|DRUG|Tralokinumab|This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
48175056|NCT01154270|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
48175057|NCT02798692|BIOLOGICAL|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
48175058|NCT02798692|BIOLOGICAL|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
48175059|NCT02798692|BIOLOGICAL|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
48028757|NCT02692248|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
48028758|NCT02692248|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
48028759|NCT02692248|DRUG|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
48028760|NCT01086657|BIOLOGICAL|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
48175060|NCT02798692|BIOLOGICAL|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
48175061|NCT02984254|DEVICE|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
48517055|NCT04671121|PROCEDURE|Standart pressure pneumoperitoneum|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
48517056|NCT04671121|PROCEDURE|Low pressure pneumoperitoneum|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
48175062|NCT02984254|DEVICE|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
48175063|NCT02984254|DEVICE|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
48175064|NCT02984254|DEVICE|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
48175065|NCT02984254|DEVICE|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
48175066|NCT02984254|DEVICE|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
48175067|NCT02984254|DEVICE|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
48175068|NCT03231332|OTHER|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
48175069|NCT00854971|BIOLOGICAL|TKCell|Biological/Vaccine: TKCell
48175070|NCT02032264|OTHER|Comprehensive Chromosome Screening|On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
48175071|NCT02032264|OTHER|Morphologically Best|Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
48175072|NCT04307641|BEHAVIORAL|2 Page Information Sheet|2 page information sheet about medication abortion
48175073|NCT00168493|DRUG|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
48175074|NCT02925936|OTHER|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
48175075|NCT02925936|OTHER|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
48175076|NCT00038155|PROCEDURE|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
48707282|NCT05345769|BIOLOGICAL|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
48707283|NCT06606730|DRUG|Pembrolizumab|Administration of pembrolizumab for 6 months
48707284|NCT06606730|OTHER|Deescalation|Patients will be followed up according to standard practice for 4 years
48707285|NCT06608381|PROCEDURE|Arm I (Total omentectomy),|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
48028761|NCT01086657|BIOLOGICAL|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
48175077|NCT02740205|OTHER|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
48375351|NCT02775409|PROCEDURE|Subcutaneous placement|The tissue expander will be placed above the muscle.
48707286|NCT06608381|PROCEDURE|Arm II (Partial omentectomy)|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
48707287|NCT03225768|BEHAVIORAL|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
48707288|NCT05813652|OTHER|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
48707289|NCT05813652|OTHER|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
48707290|NCT02383420|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
48707291|NCT03172091|DEVICE|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
48707292|NCT03172091|DEVICE|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
48707293|NCT06521775|PROCEDURE|Computed Tomography|Undergo PET/CT
48707294|NCT06521775|OTHER|Electronic Health Record Review|Ancillary studies
48707295|NCT06521775|DRUG|Ga-68 PSMA-11|Given IV
48707296|NCT06521775|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48707297|NCT05807776|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
48028762|NCT04423965|DRUG|mFOLFOXIRI|irinotecan 165 mg/m² IV day 1+ oxaliplatin 85 mg/m² IV day 1 + leucovorin 400 mg/m² day 1, fluorouracil 1200mg/m²/day \*2 days (total 2400 mg/m² over 48 hours) continuous infusion starting on day 1 of each 2 weeks cycle
48028763|NCT04423965|COMBINATION_PRODUCT|Chemoradiotherapy|Capecitabine based chemoradiotherapy
48175078|NCT01947517|DEVICE|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
48175079|NCT01947517|DEVICE|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
48175080|NCT02990923|DEVICE|High-Flow Needleless Valve|
48175081|NCT02990923|DEVICE|DualCap Disinfection Devices|
48175082|NCT05560750|PROCEDURE|Frenotomy|Releasing the tongue-tie with scissors
48175083|NCT05560750|PROCEDURE|Oral physiotherapy|Gentle parental activation of the mouth area and the tongue for 1 month
48175084|NCT03462368|PROCEDURE|Control|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.
48707298|NCT05807776|DRUG|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
48707299|NCT03407053|DIETARY_SUPPLEMENT|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
48175085|NCT03462368|PROCEDURE|antimicrobial photodynamic therapy|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
48175086|NCT03462368|PROCEDURE|Photobiomodulation|After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
48175087|NCT03549806|DIAGNOSTIC_TEST|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
48175088|NCT03588598|DRUG|SHC014748M|a selective PI3Kδ inhibitor
48175089|NCT05274425|OTHER|Enerzair 150/50/80 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
48175090|NCT05274425|OTHER|Enerzair 150/50/160 μg|There is no treatment allocation. Patients administered Enerzair by prescription that have started before inclusion of the patient into the study will be enrolled.
48175091|NCT00279877|PROCEDURE|Kyphoplasty|kyphoplasty
48707300|NCT03407053|DIETARY_SUPPLEMENT|Unprocessed diet|Consuming unprocessed diet over a 2-week period
48707301|NCT05492799|DRUG|AX 250|biweekly infusion by intracerebroventricular (ICV) infusion
48707302|NCT04610892|BIOLOGICAL|MEDI6570|MEDI6570
48707303|NCT04610892|BIOLOGICAL|Placebo|Buffer
48175092|NCT05655039|OTHER|Rehabilitation|Stroke Rehabilitation Program
48375352|NCT02775409|PROCEDURE|Submuscular placement|The tissue expander will be placed below the muscle
48175094|NCT05370547|DRUG|Chidamide|"1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc."
48707304|NCT00962169|OTHER|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
48707305|NCT00962169|OTHER|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
48707306|NCT04998539|OTHER|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
48707307|NCT04998539|OTHER|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
48707308|NCT04998539|OTHER|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
48707309|NCT04998539|OTHER|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
48175095|NCT05370547|DRUG|Fludarabine and cyclophosphamide|Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
48375353|NCT05665257|DEVICE|Inspiratory muscle training|
48375354|NCT05665257|DEVICE|Mini-PEP|
48375355|NCT06202898|OTHER|Baseline|At the baseline visits, all study participants will be complete an interviewer-assisted questionnaire using REDCap, and will also receive the SBIRT-T MI-based intervention. Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for strength sessions, and they will be provided with a schedule of strength session visits
48375356|NCT06202898|OTHER|ENTRUST|Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for economic strength sessions, group-based economic training through photovoice activities and adapted screening brief intervention and treatment (SBIRT-T) adapted for transgender women delivered by a facilitator or digitally.
48375357|NCT06202898|OTHER|Control|participants assigned to the control arm will have the option of participating in the four additional strength sessions.
48707310|NCT04998539|OTHER|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
48375358|NCT02950285|OTHER|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
48375359|NCT04447573|BIOLOGICAL|BCMA CAR-T|Biological: BCMA CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
48707311|NCT06607081|COMBINATION_PRODUCT|Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention|The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
48707312|NCT06420219|OTHER|Non-Interventional Study|Non-interventional study
48175096|NCT05370547|BIOLOGICAL|Anti-CD19 CAR-T cells|A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
48175097|NCT03921242|DRUG|Metformin|Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider
48375360|NCT05839366|DRUG|Esketamine|"Load dose of 0.25 mg/kg, and the fixed infusion rate of 0.15 mg/kg/h.The load dose will be injected intravenously within 1-2 minutes.Maintain the infusion at a fixed rate of 0.15 mg/kg/h for 72 hours; after 72 hours, change to a fixed rate infusion of 0.06 mg/kg/h.~Preparation: 46ml of saline + 4ml of eskeamine."
48375361|NCT05839366|DRUG|Saline|As a placebo,normal saline at the same dose as esketamine.Saline is also administered intravenously.
48375362|NCT05839366|DRUG|Remifentanil + propofol|Remifentanil + propofol
48517057|NCT00946517|OTHER|Questionnaires|Parenting and behavioral questionnaires
48018057|NCT06663995|DRUG|Study Group|"It will include 16 patients with periodontitis stage II, grade B, at least 2 sites with pocket PD = 4-5 mm and CAL = 3-4 mm each will receive non-surgical periodontal therapy followed by application of propolis gel.~After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing).~3-Base line visit (Local delivery application): Propolis gel will be applied by syringe with blunt tip gently and removed slowly in order not to harm the tissue for group 1 patients (Test group) after phase 1 therapy at the second day (48 hours) following non-surgical periodontal therapy"
48018058|NCT06663995|DRUG|Control (placebo) group|"After baseline assessment, at the same day the included participants will receive full mouth one stage debridement using hand instruments and ultrasonic scalers under local anesthesia -if needed- for patient's comfort.~2- Oral Hygiene Instructions Participants will be provided with a toothpaste, a medium toothbrush, a written oral hygiene instruction brochure (Brushing twice daily for 4-weeks using Modified Bass technique and interdental flossing)."
48375363|NCT05839366|PROCEDURE|Pain and Sedation Assessment|"RASS Score:~After randomization success, a baseline Richmond Agitation-Sedation Scale (RASS) score is obtained before administering the investigational drug. Pain assessments are conducted every 1 hour within the first 6 hours after the initiation of the intravenous loading dose of the investigational drug, every 4 hours within the first 24 hours, and subsequently every 8 hours until the end of the study. In addition to the fixed time points mentioned above, researchers may conduct RASS scoring at any time based on the subject's actual condition (excessive or inadequate sedation). (No further RASS scoring is performed once the subject is fully awake.)~CPOT Score:~CPOT（Critical-Care Pain Observation Tool）Pain assessments are conducted concurrently with RASS scoring."
48375364|NCT02598791|OTHER|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
48375365|NCT02598791|OTHER|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
48375366|NCT02598791|OTHER|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
48375367|NCT02598791|OTHER|OGTT|50 g oral glucose tolerance test
48375368|NCT02598791|OTHER|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
48375369|NCT00752063|DRUG|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
48375370|NCT03478982|DRUG|Staccato Alprazolam|single dose for inhalation
48375371|NCT03478982|DRUG|Placebos|single dose for inhalation
48018059|NCT06662786|BIOLOGICAL|Amivantamab|Amivantamab will be administered.
48018060|NCT06662786|BIOLOGICAL|Cetuximab|Cetuximab will be administered.
48018061|NCT06662786|DRUG|5-fluorouracil|5-fluorouracil will be administered as chemotherapy regimen.
48018062|NCT06662786|DRUG|Leucovorin calcium/Levoleucovorin|Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
48018063|NCT06662786|DRUG|Oxaliplatin|Oxaliplatin will be administered as chemotherapy regimen.
48018064|NCT06662786|DRUG|Irinotecan Hydrochloride|Irinotecan hydrochloride will be administered as chemotherapy regimen.
48018065|NCT05247918|BEHAVIORAL|Digital-physical care|Patients will get access to a digital communication platform. Two in person session and two digital contacts per year with possibility to chat with caregivers in between.
48018066|NCT05247918|BEHAVIORAL|Treatment as usual|Four in person session at the center in a year.
48175098|NCT03921242|DRUG|Sulfonylurea|Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
48375372|NCT00429546|BEHAVIORAL|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
48375373|NCT00429546|OTHER|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
48375374|NCT05072431|OTHER|SVVR training program|The SVVR training program is consisted of five scenarios with tasks. Before the SVVR training implementation, the research team provided 10-minute orientation session to introduce the purpose of the training. The 3D VR professional taught the participants how to wear the 3D VR helmets and select the VR scenes, so that the participants could practice multiple times.
48707313|NCT06217523|OTHER|Pharmacogenomics-directed Hyperlipidaemia Management|Pharmacogenomics-directed Hyperlipidaemia Management
48707314|NCT03511508|BEHAVIORAL|ChroPreg + standard care|"* Ongoing update of individual maternity care plan.~* Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~* Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~* Possibility for psychologist consultation.~* Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~* Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
48707315|NCT05392855|OTHER|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
48018067|NCT02829359|DRUG|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
48018068|NCT01744730|DRUG|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
48018069|NCT03900949|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
48707316|NCT05392855|OTHER|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
48707317|NCT02931604|DEVICE|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
48707318|NCT01949623|OTHER|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
48707319|NCT02943356|DRUG|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
48707320|NCT03134365|OTHER|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
48707321|NCT03134365|OTHER|Combined meal|Combined meal.
48707322|NCT02682589|PROCEDURE|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
48018070|NCT03900949|DRUG|Cytarabine|Given IV
48018071|NCT03900949|DRUG|Daunorubicin Hydrochloride|Given IV
48707323|NCT02682589|PROCEDURE|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
48707324|NCT05908409|DRUG|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
48707325|NCT04350671|DRUG|Interferon Beta-1A|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
48707326|NCT04350671|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
48707327|NCT04350671|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
48018072|NCT03900949|DRUG|Gemtuzumab Ozogamicin|Given IV
48018073|NCT03900949|DRUG|Midostaurin|Given PO
48018074|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
48018075|NCT00961259|DRUG|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
48018076|NCT00961259|DRUG|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
48175099|NCT03921242|DRUG|DPP-4 inhibitor|Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider
48018077|NCT06028867|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
48018078|NCT05972434|OTHER|Sunscreen A|Participants will apply sunscreen A topically.
48018079|NCT05972434|OTHER|Sunscreen B|Participants will apply sunscreen B topically.
48175100|NCT03921242|DRUG|SGLT2 inhibitor|Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider
48175101|NCT03921242|DRUG|GLP1 receptor agonist|Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
48175102|NCT00716547|DRUG|ketoprofen in Diractin®|50 mg (b.i.d.)
48375375|NCT04347174|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
48707328|NCT02791191|DRUG|LY3202626|Administered orally
48707329|NCT02791191|DRUG|Placebo|Administered orally
48375376|NCT04347174|DRUG|Placebo|All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
48707330|NCT05551013|DRUG|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)"
48707331|NCT02952482|PROCEDURE|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
48707332|NCT01956136|BEHAVIORAL|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
48707333|NCT01956136|OTHER|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
48707334|NCT01465217|BEHAVIORAL|text message medication reminders|daily medication reminders for one month
48018080|NCT03285477|DRUG|Placebo|Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
48175103|NCT00716547|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
48175104|NCT00716547|DRUG|Placebo|b.i.d.
48175105|NCT00716547|DRUG|celecoxib|100 mg (b.i.d.)
48175106|NCT04333147|BIOLOGICAL|Otilimab (GSK3196165)|GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.
48175107|NCT04333147|DRUG|csDMARD(s)|Stable dose of csDMARD(s) as standard of care (SoC).
48375377|NCT02554084|OTHER|Optical Coherence Tomography|Digital images of tear film
48375378|NCT00667537|DRUG|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
48707335|NCT03521232|DRUG|Niclosamide|enema given twice daily for 6 weeks
48707336|NCT00006046|BIOLOGICAL|monoclonal antibody hu3S193|
48375379|NCT03165851|OTHER|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
48375380|NCT03964896|OTHER|Survey|Complete survey
48375381|NCT03964896|OTHER|Survey Administration|Ancillary studies
48707337|NCT02670707|DRUG|Cytarabine|Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
48707338|NCT02670707|DRUG|Vinblastine/prednisone|"Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment.~Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age.~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
48018081|NCT03285477|DRUG|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
48018082|NCT04492033|DRUG|CTX-009 (ABL001)|CTX-009 (ABL001) will be administered biweekly.
48018083|NCT04492033|DRUG|Paclitaxel|Paclitaxel will be administered weekly.
48018084|NCT04492033|DRUG|Irinotecan|Irinotecan will be administered biweekly.
48018085|NCT01415661|OTHER|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
48018086|NCT06533631|DEVICE|Portable low-field MRI (pMRI)|Participants will receive a pMRI during the study visit.
48018087|NCT06533631|DEVICE|3T MRI|Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
48018088|NCT05011903|BEHAVIORAL|Cross-tailored Dynamic Feedback|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
48018089|NCT05011903|BEHAVIORAL|Personalized Feedback Intervention|Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
48018090|NCT05011903|BEHAVIORAL|Dynamic Feedback on General Health Behaviors|Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
48018092|NCT06663696|DEVICE|Supraflex Cruz Sirolimus-eluting Coronary Stent System|Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
48018093|NCT04720534|DRUG|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
48018094|NCT04720534|DRUG|Placebo|calculated volume to match active treatment by sc injection
48018095|NCT06572969|OTHER|Elastic-Resistance Kick Training|Athletes used tailored Elastic Resistance training
48018096|NCT06572969|OTHER|No Elastic-Resistance Kick Training|Regular Taekwondo regimen without Elastic Resistance training
48175108|NCT01230762|DRUG|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
48175109|NCT04680793|OTHER|Rehabilitation|The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
48175110|NCT03526978|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
48707339|NCT01035437|DRUG|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
48375382|NCT03964896|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
48375383|NCT03068429|DRUG|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
48707340|NCT02583230|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
48707341|NCT01904916|PROCEDURE|Histological biopsy procedure|
48707342|NCT00613925|DEVICE|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
48707343|NCT00613925|DEVICE|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
48707344|NCT04695054|DEVICE|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
48707345|NCT04695054|DRUG|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
48018097|NCT00534352|DRUG|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
48175111|NCT03526978|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
48175112|NCT05144685|DEVICE|OTX-202|Experimental Pscyhoeducation and Intervention App
48375384|NCT01283659|OTHER|Standard Imaging|
48375385|NCT01283659|OTHER|Advanced Imaging|
48375386|NCT02823223|DEVICE|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
48018098|NCT00796029|DRUG|14C-paliperidone|
48018099|NCT03894059|OTHER|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
48018100|NCT00002181|DRUG|Cidofovir|
48018101|NCT01743937|PROCEDURE|Coronary occlusion with balloon inflation|
48018102|NCT06448429|OTHER|Usual care|Participants will have the usual diabetes care at the Grady Diabetes Clinic.
48018103|NCT06448429|OTHER|Collaborative care model (CoCM)|"Collaborative care will include:~* Care with a behavioral health consultant (BHC)~* Measurement-based mental health care~* Systematic caseload reviews~* Medical management of depression~The BHC will monitor depression and anxiety severity, promote behavioral change with patients through Behavioral Activation, and support the medical management of depression through participation in caseload reviews (I.e., Mental health care plans for individual patients will be reviewed monthly by a multi-disciplinary T1D clinical team and BHC). Depression treatment initiation (if warranted) by a clinician and engagement in mental health care."
48175113|NCT05144685|DEVICE|OTX-000|Other Pscyhoeducation App
48517058|NCT05645549|BEHAVIORAL|Centering Pregnancy with Care Navigation|Centering Pregnancy is a group based prenatal care intervention. Centering Pregnancy is an evidenced based intervention that has 10 group sessions for pregnant women. Each session has dedicated educational material relative to pregnancy, birth, and infant feeding. In addition, all participants will be provided a bilingual Marshallese care navigator to aid in enrolling them in social support services.
48517059|NCT04628091|OTHER|Sampling on surgery day|"In the morning, the day of the surgery (the patient will be fasting):~* Occipital hair sample (without roots)~* Venous blood sample (3 tubes of 7mL)~During the surgery:~* Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~* Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube."
48517060|NCT04102917|DIAGNOSTIC_TEST|QFR assessment|The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
48517061|NCT00738257|DRUG|Pamidronate|
48517062|NCT02945969|BEHAVIORAL|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
48517063|NCT05314803|BEHAVIORAL|Yoga|Participants receive the yoga program, which is delivered by a trained yoga instructor (completed at least a 200-hour yoga teacher training, Yoga Thrive Teacher Training Certification (or similar), and/or practical experience working with individuals affected by cancer). The first class of the week is comprised of 45 minutes of gentle, progressive, hatha-based yoga sequencing and postures with the last 15 minutes focused on guided behaviour change and mindfulness techniques that varies week-to-week, based on the participants in the class. The second class of the week is 60 minutes of gentle, yin-based yoga sequencing and postures with an element of opening and relaxing.
48517064|NCT01277211|DRUG|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
48517065|NCT01277211|DRUG|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
48517066|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field therapy (PEMF)|PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
48517067|NCT03333135|PROCEDURE|Pulsed Electromagnetic Field Sham therapy|PEMF therapy will be administered however it will not produce micro-magnetic emissions. The therapy will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will last for 16-min (8-min for left and 8-min for right hand).
48517068|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
48517069|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
48517070|NCT02443740|DRUG|BIIB118|Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
48517071|NCT02423421|OTHER|Faecal microbiota transplantation|Human Stool.
48517072|NCT05624645|DEVICE|Pelex Upp|Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
48517073|NCT00003056|DRUG|cyclosporine|
48517074|NCT00003056|DRUG|cyclosporine and methotrexate|
48517075|NCT04263025|BIOLOGICAL|Cryopreserved Umbilical Cord Allograft|"CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue \[43\]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a 361 human cell and tissue-based product (HCT/P) and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271."
48175114|NCT00774423|DRUG|Riluzole|50 mg per day during 24 months
48175115|NCT01397500|DRUG|Genotropin|Genotropin administered sc once a day by patient or caregiver.
48175116|NCT01397500|DRUG|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
48175117|NCT05688683|OTHER|use of a theremin-type musical instrument|The patient will perform the task of reproducing sounds by manipulating an object. The settings of the object will be changed and the patient will have to reproduce the sounds a second time by manipulating the object.
48175118|NCT03297762|BEHAVIORAL|gamification|incentives/rewards and contact between standard visits
48175119|NCT03297762|BEHAVIORAL|Use of Dexcom G5|Dexcom G5 continuous glucose monitor
48707346|NCT01727648|BEHAVIORAL|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
48175120|NCT06144593|OTHER|Dietary macronutrient composition|Intermittent carbohydrate restriction
48175121|NCT05343208|DIAGNOSTIC_TEST|EFP Psychometric assessment to determine level of afflication|Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
48175122|NCT00000902|DRUG|Ritonavir|
48175123|NCT00000902|DRUG|Nelfinavir mesylate|
48175124|NCT00000902|DRUG|Nevirapine|
48707347|NCT01727648|BEHAVIORAL|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
48175125|NCT00000902|DRUG|Lamivudine|
48175126|NCT00000902|DRUG|Stavudine|
48175127|NCT00000902|DRUG|Zidovudine|
48175128|NCT00000902|DRUG|Zalcitabine|
48175129|NCT00000902|DRUG|Didanosine|
48375387|NCT04831255|DRUG|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
48375388|NCT05358704|DRUG|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
48375389|NCT00625846|OTHER|Laboratory Biomarker Analysis|Correlative studies
48175130|NCT00809341|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m\^2 on Days 1, 30, and 37 as part of HiCy.
48175131|NCT00809341|DRUG|Cyclophosphamide|750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
48175132|NCT00809341|DRUG|Doxorubicin|50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
48175133|NCT00809341|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
48175134|NCT00809341|DRUG|Prednisone|100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
48375390|NCT00625846|DRUG|Pazopanib Hydrochloride|Given PO
48175135|NCT00809341|DRUG|Ifosfamide|2000 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
48175136|NCT00809341|DRUG|Carboplatin|Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
48175137|NCT00809341|DRUG|Etoposide|100 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
48175138|NCT00809341|DRUG|High-dose cyclophosphamide|50 mg/kg/day on Days 2-5 of HiCy.
48175139|NCT00809341|PROCEDURE|PET scan|Performed once between Days 16-20 of cycle 3 of R-CHOP.
48175140|NCT03112447|PROCEDURE|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
48175141|NCT03112447|PROCEDURE|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
48707348|NCT01727648|BEHAVIORAL|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
48707349|NCT01727648|BEHAVIORAL|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
48517076|NCT04263025|PROCEDURE|Robot-Assisted Radical Prostatectomy|Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
48517077|NCT06228586|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form:Liquid solution-Route of administration:Intramuscular injection
48517078|NCT05912270|BEHAVIORAL|Orchestra in Class|See arm/group descriptions
48517079|NCT00601575|DRUG|Lithium|
48517080|NCT06301906|DRUG|LipoCol Forte Capsule 600mg bid|LipoCol Forte Capsule 600mg bid for 12 months
48517081|NCT03514108|DRUG|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
48517082|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 3 daily
48517083|NCT03514108|DRUG|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
48517084|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
48517085|NCT02501018|BIOLOGICAL|CLBS12|Intramuscular transfusion of CLBS12.
48175142|NCT02264236|BIOLOGICAL|P10s-PADRE vaccine|"P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5."
48375391|NCT03131375|DRUG|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
48707350|NCT01641146|BEHAVIORAL|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
48707351|NCT01641146|BEHAVIORAL|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
48707352|NCT06223256|DRUG|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
48707353|NCT04590313|PROCEDURE|Arthrodesis|MTPJ I arthrodesis
48707354|NCT05179668|DRUG|Dapagliflozin 10 MG|administered orally once daily
48707355|NCT05179668|DRUG|Placebo|administered orally once daily
48707356|NCT02557958|DRUG|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
48707357|NCT02557958|DRUG|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
48707358|NCT00731653|DRUG|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
48707359|NCT06266949|DIAGNOSTIC_TEST|SONDA|Perimetry based visualfield analysis
48707360|NCT02252185|DEVICE|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.
48707361|NCT02252185|DEVICE|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
48707362|NCT06605443|DEVICE|Breath analyzer|The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he/she will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.
48175143|NCT03328910|DEVICE|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
48517086|NCT02501018|DRUG|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
48707363|NCT06605443|DEVICE|Skin patch|A skin patch will be placed in the anterior part of the patient\&#39;s arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.
48707364|NCT06605443|GENETIC|Liquid biopsy|Circulating free tumor DNA (cfDNA) will be extracted from patient\&#39;s blood and analyzed to detect mutations in BRAF and other prognostic genes.
48707365|NCT02982317|PROCEDURE|Manual palpation identification lumbar spine|
48707366|NCT02982317|PROCEDURE|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
48707367|NCT02982317|PROCEDURE|Lumbar level identification gold standard ultrasound|
48707368|NCT00324428|PROCEDURE|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
48707369|NCT02445677|DEVICE|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
48018104|NCT01160107|DRUG|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
48018105|NCT06662916|BEHAVIORAL|Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder|Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
48018106|NCT03030833|DEVICE|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
48018107|NCT01679899|DRUG|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
48018108|NCT01679899|DRUG|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
48018109|NCT05345691|BIOLOGICAL|Bmab 1000|60 mg administered as a single SC (subcutaneous) injection once every 6 months.
48375392|NCT03131375|DRUG|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
48375393|NCT03131375|DEVICE|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
48018110|NCT05345691|BIOLOGICAL|Prolia®|60 mg administered as a single SC injection once every 6 months
48018111|NCT02114970|OTHER|Randomized- paper consent|
48018112|NCT02114970|OTHER|Randomized- Tablet-delivered consent|
48018113|NCT02114970|OTHER|Focus Group- paper and tablet consent|
48018114|NCT05734092|DEVICE|Traditional orthodontic treatment|As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.
48018115|NCT05734092|DEVICE|Low-Level Laser|"The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage."
48018116|NCT04765059|DRUG|Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
48375394|NCT03131375|DEVICE|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
48018117|NCT04765059|DRUG|Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin|Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
48018118|NCT04683055|PROCEDURE|Phacoemulsification combined with trabeculectomy|Patients with chronic angle closure glaucoma assigned to this group will have fornex based trabeculectomy at superior limbus and then phacoemulsification via temporal incision
48018119|NCT04683055|PROCEDURE|Phacoemulsificaiton combined with ab-externo trabeculotomy|Patients with chronic angle closure glaucoma assigned to this group will have Deep Sclerectomy with ab externo trabeculotomy at superior limbus and then phacoemulsification via temporal incision
48517087|NCT00396812|DRUG|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
48517088|NCT02565940|OTHER|biopsy|
48517089|NCT00902694|BEHAVIORAL|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
48707370|NCT02445677|DEVICE|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
48517090|NCT00902694|OTHER|Control|group health classes quarterly with topics not related to weight
48707371|NCT06437626|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
48707372|NCT06437626|DRUG|Placebo|Placebo IV solution, Placebo tablets
48517091|NCT05429866|DRUG|Checkpoint Blockade, Immune|Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.
48517092|NCT03437473|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
48517093|NCT05468801|OTHER|Individualized Homeopathic Remedy|An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.
48517094|NCT05468801|OTHER|Placebo|Placebo plus Standard Pharmacologic Treatment
48707373|NCT00000224|DRUG|Buprenorphine|
48707374|NCT02203383|DEVICE|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
48707375|NCT00940095|DRUG|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
48707376|NCT00940095|DRUG|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
48018120|NCT01542112|OTHER|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
48018121|NCT01542112|OTHER|No treatment|Patients in this arm receive the usual routine in the department.
48707377|NCT00940095|DRUG|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
48707378|NCT05034315|OTHER|Whole egg consumption|The participants in the whole egg group consumed two whole eggs immediately after exercise.
48707379|NCT03243214|DEVICE|TMS|Real or Sham TMS will be given to the PD-MCI patient
48707380|NCT03243214|DEVICE|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
48707381|NCT01713283|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
48707382|NCT01713283|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
48707383|NCT06605742|OTHER|Consultancy|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects
48375395|NCT02866721|BIOLOGICAL|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of human mesenchymal stem cells (hMSCs): 1 x 10\^6, 3 x 10\^6 or 5 x 10\^6 human mesenchymal stem cells per kilogram body weight (hMSCs/kg) during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic mesenchymal stem cells (MSCs) will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of cystic fibrosis lung infection and inflammation."
48375396|NCT02427542|OTHER|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
48375397|NCT02427542|OTHER|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
48375398|NCT02926352|BEHAVIORAL|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
48018122|NCT04412135|OTHER|spirituality|Patients will take three questionnaires (FACIT-Sp, Euroqol 5 dimensions and ESAS)
48018123|NCT06413433|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
48018124|NCT06413433|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
48018125|NCT06413433|DRUG|Placebo|Placebo tablets, taken once daily
48375399|NCT02926352|DEVICE|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
48375400|NCT02926352|DEVICE|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
48375401|NCT01874821|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
48375402|NCT01874821|OTHER|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
48375403|NCT02547064|PROCEDURE|Glidescope guided intubation|
48375404|NCT02547064|DEVICE|GlideScope®|
48375405|NCT02764229|DRUG|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
48375406|NCT00388713|PROCEDURE|carotid intima-media thickening ultrasound|
48375407|NCT00465101|DEVICE|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
48375408|NCT05022121|BEHAVIORAL|Supported Biopsychosocial Self-Management (SBSM)|Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.
48707384|NCT04288453|BEHAVIORAL|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
48018126|NCT06440525|DRUG|RSLV-132|Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
48375409|NCT05022121|DRUG|Medical Care|Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
48707385|NCT02509572|BEHAVIORAL|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
48707386|NCT03394599|DEVICE|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
48018127|NCT06440525|DRUG|Placebo|0.9% sodium chloride solution
48018128|NCT02061462|PROCEDURE|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
48375410|NCT01881867|BIOLOGICAL|Glycosylated Recombinant Human Interleukin-7|Given SC
48375411|NCT01881867|OTHER|Laboratory Biomarker Analysis|Correlative studies
48375412|NCT05473234|DRUG|Azithromycin|Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
48517095|NCT03719651|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
48018129|NCT02381392|DEVICE|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
48018130|NCT04922801|DIAGNOSTIC_TEST|Nuclear Medicine whole-body|Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).
48018131|NCT04922801|DIAGNOSTIC_TEST|SPECT/CT imaging.|SPECT/CT scan at 24-48 hr post MRT
48018132|NCT04922801|DIAGNOSTIC_TEST|PET/CT imaging.|3-6 months Pre and post-therapy PET/CT imaging
48018133|NCT04922801|DEVICE|Patient-led radiation monitor (SELFIE)|"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."
48018134|NCT04922801|DIAGNOSTIC_TEST|LAB TEST|Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
48018135|NCT02497768|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
48018136|NCT03767959|PROCEDURE|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
48018137|NCT03767959|PROCEDURE|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
48018138|NCT01592513|DEVICE|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
48175144|NCT05815706|DEVICE|MEDELA Supplemental nursing system|The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
48018139|NCT03431194|DRUG|midodrine|oral midodrine tablets 5 mg
48375413|NCT05473234|DRUG|Amoxicillin|Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
48018140|NCT03431194|DRUG|Placebo|
48018141|NCT03037151|DRUG|Grazaoprevir/Elbasavir|treatment naive
48018142|NCT03037151|DRUG|Grazaoprevir/Elbasavir/RBV|treatment experienced
48175145|NCT04617236|BEHAVIORAL|Cultivando La Salud|"A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group)."
48375414|NCT01428882|DRUG|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
48707387|NCT03394599|DEVICE|TheraTrainer Only|TheraTrainer will be used.
48707388|NCT03356418|OTHER|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
48707389|NCT03356418|OTHER|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
48707390|NCT04911907|DRUG|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
48707391|NCT02351830|OTHER|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
48707392|NCT02351830|PROCEDURE|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
48707393|NCT06444360|BEHAVIORAL|IMPACT|The IMPACT intervention consists of 10 sessions: 2 sessions focused on HIV acquisition/transmission risk reduction (RR), 1 session focused on orienting and rationale to behavioral activation (BA), 6 sessions integrating BA and HIV RR counseling (including PrEP or ART and HIV care), and 1 final session on strategies for slip-ups and recurrence management.
48707394|NCT06444360|BEHAVIORAL|eSOC|The eSOC group consists of 2 sessions focused on HIV acquisition/transmission risk reduction (RR).
48707395|NCT02214225|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
48707396|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
48707397|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
48018143|NCT05078736|OTHER|Moderate intensity intermittent training|In group A participants will receive moderate intensity intermittent training including running of 5 km with 1-min at 70% of maximal aerobic speed with interval of 1-min passive recovery, exercises will be performed by gym trainer for 5 weeks including 3 days/week
48018144|NCT05078736|OTHER|Moderate intensity continuous training|In group B participants will receive moderate intensity continuous training ran continuously the same 5 km at 70% of maximal aerobic speed, exercises will be performed by gym trainer for 5 weeks including 3 days/week.
48018145|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.
48018146|NCT06664437|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placing the scapula in a depressed position with one hand while placing the elbow in 90° flexion, forearm in supination, and wrist and fingers in extension with the other hand. Then, the therapist passively abducted the shoulder into 90- 100° and available external rotation ROM of the arm. Then from this position, the therapist extended the elbow with or without contra lateral side bending of the neck (tensioner or slider technique, respectively). Patients performed 30 repetitions of slider median nerve mobilization by performing elbow extension and wrist extension, with the neck placed in ipsilateral side bending or performing elbow flexion and wrist flexion with the neck placed in contralateral side bending. \[35\]. Tensioner technique was performed by applying simultaneous elbow extension with contralateral side bending of the neck and hold for 15 sec and relax for 10 sec .
48018147|NCT03285646|DRUG|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
48018148|NCT03285646|DRUG|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
48018149|NCT04651959|DRUG|AVICOD 200 MG Film Tablet|AVICOD is containing 200 mg favipiravir manufactured by Pharma Plant,Turkey.
48175146|NCT01867970|DEVICE|Tool|"The It's LiFe! tool consists of three different elements:~1. the 3D accelerometer (Figure 7-8);~2. the application (app) on a Samsung Smartphone (Figure 6);~3. a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
48175147|NCT01867970|BEHAVIORAL|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
48175148|NCT02571998|DRUG|Omiganan (CLS001) Topical Gel|
48175149|NCT02571998|DRUG|Vehicle Topical Gel|
48175150|NCT05797883|DRUG|FOLFOX/FOLFIRI|mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
48175151|NCT02371720|BEHAVIORAL|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
48175152|NCT06372106|DEVICE|SaO2 Sampling|CO-Oximetry analysis of arterial blood samples
48175153|NCT03381469|PROCEDURE|Comprehensive periodontal treatment|The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs \> 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.
48175154|NCT03381469|PROCEDURE|single visit supragingival scaling|The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.
48175155|NCT05900544|OTHER|System implementation of patient-centered incidental findings report|For three lung cancer screening programs a system level implementation for a patient-centered incidental findings report
48707398|NCT03618628|DEVICE|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
48707399|NCT03594916|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
48707400|NCT03594916|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
48707401|NCT04125056|DRUG|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
48707402|NCT04125056|DRUG|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
48707403|NCT00394901|DRUG|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
48707404|NCT00394901|DRUG|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
48707405|NCT00394901|DRUG|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
48707406|NCT00394901|DRUG|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
48707407|NCT05801393|RADIATION|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
48707408|NCT02229214|DRUG|Qsymia|
48707409|NCT02229214|DRUG|Placebo|
48707410|NCT00645528|OTHER|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
48707411|NCT06607328|OTHER|Assessment of participants in terms of different aspects.|This group was composed of individuals who have the prehypertensive stage.
48707412|NCT06162195|DEVICE|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
48707413|NCT06162195|DEVICE|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
48707414|NCT00162500|BIOLOGICAL|Peptide Vaccine (MUC-1)|
48707415|NCT01166958|DRUG|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
48707416|NCT01166958|DRUG|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
48707417|NCT03372460|DEVICE|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
48707418|NCT03372460|DEVICE|Sham stimulation|For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).
48175156|NCT03094455|OTHER|Experimental group|Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
48707419|NCT03372460|OTHER|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
48707420|NCT06429163|PROCEDURE|Infiltration of the anterior abdominal wall|Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
48375415|NCT01428882|DRUG|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
48707421|NCT06429163|PROCEDURE|Upper hypogastric plexus blockade|At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
48707422|NCT04958044|DRUG|Calcium Gluconate|Calcium electroporation
48707423|NCT01748136|DEVICE|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
48707424|NCT00346502|DRUG|20% betulinic acid ointment|
48707425|NCT00346502|DRUG|BA|20% Betulinic Acid Ointment
48707426|NCT06036615|OTHER|Exercise Intervention|Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 3-month de-training period, continuing their normal physical activity.
48707427|NCT03832114|DRUG|LNP023|Increasing doses of LNP023 up to 200 mg.
48707428|NCT04739618|DRUG|Keytruda Injectable Product|PD-1 inhibitor antibody
48175157|NCT04192539|DIAGNOSTIC_TEST|Taurine|Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
48175158|NCT01742845|OTHER|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
48018150|NCT04651959|DRUG|AVIGAN 200 MG Film Tablets|AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
48018151|NCT01607034|DRUG|Dexpramipexole|150 mg single dose
48175159|NCT01742845|OTHER|landmark based superfical ropivacaine 4.75 mg/ml injection|
48175160|NCT04959578|DRUG|Recombinant human erythropoietin|Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
48018152|NCT01328002|DRUG|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
48375416|NCT00823875|DRUG|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
48018153|NCT01328002|DRUG|Placebo|matching placebo tablets daily
48018154|NCT06109948|DRUG|ABX1100 injection for IV infusion|Centyrin protein-siRNA conjugate
48018155|NCT06109948|DRUG|Placebo injection for IV infusion|placebo saline injection
48018156|NCT03074734|OTHER|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
48175161|NCT04959578|DRUG|Darbepoetin Alfa|Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo \<2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
48707429|NCT04739618|DRUG|Yervoy Injectable Product|Anti-CTLA-4 antibody
48707430|NCT04739618|DRUG|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
48707431|NCT04739618|PROCEDURE|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
48175162|NCT00869271|PROCEDURE|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
48707432|NCT03660228|OTHER|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
48707433|NCT01007929|DRUG|14C-AZD1236|Oral solution 1mg/mL
48707434|NCT05234424|OTHER|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
48707435|NCT00810485|DRUG|ADX10059|oral administration
48175163|NCT00869271|PROCEDURE|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
48375417|NCT00823875|DRUG|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
48375418|NCT00823875|DRUG|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
48707436|NCT00810485|DRUG|ADX10059|oral administration
48707437|NCT00810485|DRUG|ADX10059|oral administration
48707438|NCT00810485|DRUG|ADX10059 Matching Placebo|oral administration
48707439|NCT06214052|DRUG|VH4524184|VH4524184 will be administered.
48375419|NCT00823875|DRUG|control group|routine treatment
48018157|NCT03945500|DEVICE|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry (SHS) Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center or remotely \& perform baseline testing with the SHS method along with a baseline laboratory-based spirometry test (if practicable).~Pre-Surveillance Phase: Daily home spirometry method testing for 4 to 10 weeks to enable normal range calibration.~Surveillance Phase: At least weekly home spirometry method testing for 2-10 months of participation. Volunteers will maintain a test log during study team directed SHS software pathway functionality testing."
48018158|NCT00533949|BIOLOGICAL|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
48018159|NCT00533949|DRUG|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
48018160|NCT00533949|DRUG|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
48018161|NCT00533949|RADIATION|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
48018162|NCT00533949|RADIATION|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
48018163|NCT06432010|OTHER|Group nutrition and physical activity coaching|Group nutrition and physical activity coaching consists of an initial health check-up, followed by nutrition and physical activity coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the group nutrition and physical activity coaching sessions.
48018164|NCT06432010|OTHER|Group cognition coaching|Group cognition coaching consists of an initial health check-up, followed by cognition coaching sessions over 7 weeks, 2 telephone follow-ups at 3 and 6 months and finally a final health check-up, 12 months after the end of the cognition coaching sessions.
48018165|NCT06014255|DRUG|Enoblituzumab|Enoblituzumab 15mg/kg IV (in the vein) every 2 weeks for 12 weeks prior to radical prostatectomy on day 84.
48018166|NCT06014255|OTHER|Standard of Care|Radical prostatectomy within 4-8 weeks of randomization.
48018167|NCT03794765|DRUG|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
48375420|NCT06276491|BIOLOGICAL|XmAb541|Monoclonal bispecific antibody
48375421|NCT02046993|BEHAVIORAL|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
48375422|NCT02046993|BEHAVIORAL|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
48375423|NCT04516291|DRUG|Vupanorsen|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
48375424|NCT04516291|DRUG|Placebo|Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
48375425|NCT01419834|BIOLOGICAL|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over \~30 minutes
48375426|NCT01774734|OTHER|Physical therapy|"Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly"
48375427|NCT01774734|DEVICE|Neck Strength Exerciser (NSE)|"* Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
48375428|NCT02032394|DRUG|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
48375429|NCT02032394|DRUG|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
48375430|NCT02032394|DRUG|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
48375431|NCT04121468|DRUG|Metformin|Each tablet contains 500mg of metformin hydrochloride
48375432|NCT04121468|OTHER|Placebo|Each tablet contains no active drug ingredient
48707440|NCT06214052|DRUG|Placebo|Placebo will be administered.
48175164|NCT04862676|DRUG|Hyperbaric oxygen|The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes are spent during the compression and decompression phases and subjects have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
48018168|NCT03794765|DRUG|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
48018169|NCT03794765|OTHER|Placebo infusion|Similar placebo infusion
48018170|NCT06207682|DRUG|Avacopan|Orally via capsules
48175165|NCT01232400|DRUG|Esmolol|"The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~1. Heart rate less than 70 bpm.~2. Systolic blood pressure less than 120 mmHg~3. Maximum dose of esmolol of 200 mcg/kg/minute is reached."
48175166|NCT05578508|DRUG|Mesenchymal Stem Cells (MSCs)|Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
48175167|NCT03539029|PROCEDURE|Surgery|Surgical fracture fixation
48175168|NCT03539029|PROCEDURE|Conservative treatment|immobilisation with plaster cast
48175169|NCT00599833|BIOLOGICAL|cetuximab|
48175170|NCT00599833|RADIATION|3-dimensional conformal radiation therapy|
48175171|NCT02152254|DRUG|Targeted Therapy Based on Molecular Profiling|Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration \[FDA\]-approved for another indication), patients can receive the FDA-approved drug.
48175172|NCT02152254|DRUG|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
48175173|NCT02956122|BIOLOGICAL|GLASSIA|GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]
48175174|NCT02956122|DRUG|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
48018171|NCT06207682|DRUG|Simvastatin|Orally via tablets
48375433|NCT04600206|OTHER|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
48018172|NCT05951816|DRUG|99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.|Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.
48018173|NCT05951816|DRUG|99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.|99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.
48018174|NCT05983653|PROCEDURE|arthrocentesis without PRP|150 ml arthrocentesis without PRP
48018175|NCT05983653|PROCEDURE|arthrocentesis with PRP|150 ml arthrocentesis with PRP
48018176|NCT04133831|OTHER|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: \[(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)\] / \[number of patients alive on waitlist at start of year\]."
48175175|NCT02956122|BIOLOGICAL|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
48175176|NCT02824497|OTHER|No intervention. It's a description study|
48175177|NCT05988034|DRUG|Avacopan|Administered orally.
48175178|NCT05988034|DRUG|Moxifloxacin|Administered orally.
48175179|NCT05988034|DRUG|Placebo for avacopan|Administered orally.
48175180|NCT05988034|DRUG|Placebo for moxifloxacin|Administered orally.
48175181|NCT05005286|OTHER|Past history of vaginal Infections|With or without vaginal infection during pregnancy
48175182|NCT00927498|DRUG|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
48175183|NCT00927498|DRUG|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
48175184|NCT00409591|DRUG|Maternal and infant nevirapine|"* In women, one NVP 200 mg tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately"
48175185|NCT00409591|DRUG|Maternal placebo and infant nevirapine|"* In women, one placebo tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded."
48707441|NCT04389112|OTHER|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
48707442|NCT06607055|DIAGNOSTIC_TEST|Blood collection|HLA-DR dosage, at the time of inclusion and once a week then
48018177|NCT04133831|OTHER|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = \[number of patients surviving after transplant with excellent organ\]/\[number of patients for whom excellent organ was accepted for transplant\] marginal transplant survival = \[number of patients surviving after transplant with marginal organ\]/\[number of patients for whom marginal organ was accepted for transplant\]"
48375434|NCT00761462|DRUG|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
48018178|NCT02420860|BIOLOGICAL|Elotuzumab|Given IV
48375435|NCT00761462|DRUG|Non-quinolone antibiotic|Common used dose and route
48375436|NCT01795534|DIETARY_SUPPLEMENT|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
48375437|NCT01795534|DIETARY_SUPPLEMENT|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
48375438|NCT00212446|DEVICE|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
48375439|NCT02730975|DRUG|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
48375440|NCT02730975|DRUG|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
48375441|NCT02730975|DRUG|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
48375442|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-single dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
48375443|NCT05392699|BIOLOGICAL|human single chain IL-12 mRNA-multiple dose|human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
48375444|NCT02545270|PROCEDURE|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
48375445|NCT02545270|PROCEDURE|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
48375446|NCT02545270|PROCEDURE|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
48707443|NCT05929118|OTHER|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
48707444|NCT05929118|OTHER|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
48707445|NCT01689623|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
48707446|NCT01689623|DRUG|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
48707447|NCT01689623|DRUG|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
48375447|NCT00938275|DRUG|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
48375448|NCT02835794|DRUG|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
48175186|NCT00409591|DRUG|Maternal lopinavir+ritonavir|- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
48175187|NCT00409591|DRUG|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
48175188|NCT03219671|DRUG|Nivolumab|nivolumab 240mg every 2 weeks
48175189|NCT03219671|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
48375449|NCT02835794|DRUG|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
48375450|NCT02835794|DRUG|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
48375451|NCT02631434|PROCEDURE|sit-to-stand test|
48707448|NCT02112682|PROCEDURE|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
48707449|NCT01613352|OTHER|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
48707450|NCT03790436|DIETARY_SUPPLEMENT|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
48707451|NCT05600816|DEVICE|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
48707452|NCT03272828|DEVICE|Nobel Biocare titanium dental implants|
48707453|NCT05768438|OTHER|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
48707454|NCT05768438|OTHER|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
48018179|NCT02420860|DRUG|Lenalidomide|Given PO
48018180|NCT02420860|OTHER|Questionnaire Administration|Ancillary studies
48018181|NCT03662750|DIAGNOSTIC_TEST|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
48018182|NCT01922596|DRUG|Ropivacaine|
48018183|NCT01922596|DRUG|Placebo|
48375452|NCT02631434|PROCEDURE|six-minutes walking test|
48375453|NCT01351324|DIETARY_SUPPLEMENT|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
48375454|NCT02778893|DRUG|Conmana|125mg three times a day (TID) continuously
48375455|NCT02778893|DRUG|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
48375456|NCT00483574|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
48375457|NCT00483574|BIOLOGICAL|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
48375458|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
48175190|NCT05744102|DIAGNOSTIC_TEST|MRI Image|MRI sequences
48175191|NCT04047771|DRUG|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
48375459|NCT00483574|BIOLOGICAL|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
48375460|NCT00752427|DRUG|Paliperidone ER OROS®|
48375461|NCT06520826|DRUG|Vadadustat|A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
48018184|NCT05081739|DIAGNOSTIC_TEST|Prospera Transplant Assessment|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of dd-cfDNA in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available LDT developed by Natera, Inc. Natera is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA)."
48018185|NCT05081739|PROCEDURE|Endomyocardial biopsy|Subjects will undergo surveillance EMB per the institution's standard clinical care, which is expected to be approximately every other week in months 2 and 3, then monthly through month 6, then every 1-3 months through the end of month 12.
48018186|NCT06664645|PROCEDURE|LHB tendon reinforcement|complete repair with LHB tendon reinforcement
48375462|NCT06520826|DRUG|Erythropoiesis Stimulating Agent|Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
48517096|NCT03719651|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
48375463|NCT06091176|DEVICE|Amicomed®|This app helps users track their blood pressure readings over time with analysis and history features. It generates graphs and charts to display trends and patterns, and users can set reminders to take blood pressure readings. Additionally, the app offers personalized recommendations for lifestyle, including personalized diet plans, and physical exercise programs based on the user's information. Using cognitive-behavioral techniques and motivational levers, the app helps users overcome barriers to lifestyle changes and provides personalized feedback and coaching. It also includes a database of evidence-based strategies for behavior change, and users can receive notifications, reminders, and rewards to stay motivated.
48707455|NCT02962271|DEVICE|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
48707456|NCT01897753|DRUG|growth hormone|36 months
48707457|NCT00562276|PROCEDURE|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
48707458|NCT01851486|DRUG|Clonidine|Clonidine 0.15 mg
48707459|NCT01851486|DRUG|Naloxone|naloxone 0.15 mg/kg
48707460|NCT01851486|DRUG|placebo|
48707461|NCT01851486|OTHER|saline|
48707462|NCT01713361|DRUG|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
48707463|NCT01713361|DRUG|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
48707464|NCT01713361|DRUG|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
48018187|NCT06664645|PROCEDURE|complete repair without reinforcement|conventional rotator cuff complete repair without reinforcement
48018188|NCT04358484|BEHAVIORAL|Incredible Years - ASD and Language Delay®|"The IY - ASLD Program will consist of 22 weekly online group sessions for parents of children between 2-5 years of age with symptoms or a diagnosis of ASD or delayed language acquisition. The program will be conducted by a therapist and a co-therapist, trained in the model.~Fidelity to the intervention will be assessed in accordance with the regulations of the program. All of the therapists and co-therapists will be trained in the intervention by accredited trainers. The three main therapists will be supervised by accredited supervisors of the IY Program, seeking accreditation in the intervention. As the intervention IY - ASLD has not been translated into Spanish, the English materials will be used with simultaneous translation into Spanish language."
48018189|NCT02528292|PROCEDURE|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
48375464|NCT06091176|DEVICE|Digital Placebo|Subjects will be provided with a white label mobile app, which allows to (1) add blood pressure measurements, (2) access the history of recorded measurements. No notification system will be implemented.
48375465|NCT06091176|OTHER|Usual Care|Usual Care (UC): Subjects assigned to control group will receive care as usual care, including self-monitoring indications.
48375466|NCT04423107|DRUG|Acetaminophen, Ibuprofen|Acetaminophen (Tylenol) 15 mg/kg q6h and Ibuprofen (10 mg/kg) q6h
48517097|NCT03719651|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
48517098|NCT03719651|BEHAVIORAL|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
48707465|NCT01076062|PROCEDURE|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
48707466|NCT02069730|DRUG|Selinexor|"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
48707467|NCT02069730|DRUG|EGFR or HER2 Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
48707468|NCT02069730|DRUG|FGFR Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
48707469|NCT02069730|DRUG|C-KIT Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
48018190|NCT02528292|DRUG|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
48018191|NCT04420806|OTHER|HIT-exercise|13 months of high intensity endurance and resistance exercise, 3x 45 min/week - 3 months of COVID-19 induced exercise break
48375467|NCT04423107|DRUG|Acetaminophen, Ibuprofen, Oxycodone|Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
48707470|NCT02069730|DRUG|Anti-androgen|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
48707471|NCT02069730|DRUG|NOTCH Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
48707472|NCT02069730|DRUG|MEK or PI3K Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
48707473|NCT05451173|RADIATION|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
48707474|NCT05451173|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
48707475|NCT05451173|DRUG|Durvalumab|an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
48707476|NCT02093429|DRUG|INCB047986|INCB047986 will be supplied as tablets.
48375468|NCT00000509|BEHAVIORAL|diet, sodium-restricted|
48375469|NCT00000509|BEHAVIORAL|diet, potassium-supplementation|
48375470|NCT03752021|PROCEDURE|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
48375471|NCT00246675|DRUG|Frusemide|
48375472|NCT01173380|OTHER|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
48375473|NCT01173380|OTHER|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
48375474|NCT04099589|DRUG|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
48707477|NCT03752190|DRUG|Cosyntropin|intramuscular and intravenous administration
48707478|NCT04965974|DEVICE|Digital blue light blocking filter|digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users
48707479|NCT05753345|BEHAVIORAL|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
48707480|NCT04844658|DIETARY_SUPPLEMENT|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
48707481|NCT04844658|DIETARY_SUPPLEMENT|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
48707482|NCT04844658|DRUG|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
48707483|NCT04381325|DRUG|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
48707484|NCT05783076|DRUG|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
48707485|NCT05783076|DRUG|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
48707486|NCT05121454|DEVICE|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
48018192|NCT04420806|OTHER|Sham intervention|Types of exercise (flexibility, relaxation) that did not affect the present outcomes
48018193|NCT02097992|DRUG|Roflumilast Placebo|Placebo pill
48018194|NCT02097992|DRUG|Roflumilast|500 Ug ORAL TABLET
48018195|NCT05750524|OTHER|reflexology hand massage|Reflexology massage methods applied randomly to both trial groups.
48018196|NCT05750524|OTHER|classical hand massage|Classical hand massage methods applied randomly to both trial groups.
48018197|NCT02012946|DRUG|Levosimendan|patient receiving levosimendan
48517099|NCT05316610|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
48517100|NCT00325871|PROCEDURE|concurrent chemoradiation|
48707487|NCT06082596|DRUG|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
48707488|NCT03217370|OTHER|education of guidelines|"* Guidelines will be updated and education will be given to haematologists in several ways.~* ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
48707489|NCT01620502|DIETARY_SUPPLEMENT|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
48175192|NCT05051423|DIAGNOSTIC_TEST|Endoscopic ultrasound|"Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes."
48375475|NCT03226782|OTHER|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
48175193|NCT05719402|PROCEDURE|non-interventional prospective cross-sectional observational study|to investigate the feasibility of using intestinal motility quantified by intestinal ultrasound (US) to evaluate disease activity. The outcomes of intestinal motility detected by ultrasound will be compared with endoscopic and histopathological reference standards in adult patients with IBD
48517101|NCT03088761|DEVICE|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
48018198|NCT02012946|DRUG|Dobutamine|patient receiving dobutamine
48175194|NCT04786756|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
48517102|NCT02033031|DRUG|Lucentis intravitreal injection|Lucentis intravitreal injection
48517103|NCT02033031|DRUG|Avastin intravitreal injection|Avastin intravitreal injection
48517104|NCT04246827|BEHAVIORAL|Enhanced Lifestyle Weight Management|The Enhanced Lifestyle Weight Management program was a 12-week protocol in which training in coping skills to increase self-efficacy and decrease the impact of RA pain on behavioral (e.g., activity, eating) and psychosocial (e.g., mood, relationships) weight loss factors were integrated into a lifestyle behavioral weight loss intervention.
48175195|NCT02749136|DRUG|Preoperative modified FOLFIRINOX and postoperative gemcitabine|"* Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"
48175196|NCT03343210|DIAGNOSTIC_TEST|quality of life and pain measurement .|comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
48707490|NCT03855631|GENETIC|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
48175197|NCT03517111|BEHAVIORAL|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
48175198|NCT03517111|BEHAVIORAL|Substance use prevention only|Parenting program focusing only on substance use prevention
48175199|NCT03517111|BEHAVIORAL|Academic success program|Program focusing on academic success and college acceptance
48175200|NCT00934414|DRUG|Technosphere Insulin Inhalation Powder|30U
48175201|NCT03564834|PROCEDURE|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
48175202|NCT03564834|PROCEDURE|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
48175203|NCT02353871|BIOLOGICAL|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
48175204|NCT02353871|DRUG|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
48175205|NCT02319863|PROCEDURE|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
48175206|NCT02319863|PROCEDURE|hepatectomy (rapid ligating)|
48175207|NCT01657877|DRUG|Calcium sodium phosphosilicate|CSP high percentage weight by weight
48175208|NCT01657877|DRUG|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
48175209|NCT01657877|DRUG|Placebo|No CSP and no fluoride
48517105|NCT01553955|PROCEDURE|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
48707491|NCT04606589|DEVICE|neoGuard vital signs monitor|The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
48707492|NCT04679857|OTHER|TKA|Total Knee Arthroplasty
48175210|NCT04402983|OTHER|Physiotherapy|Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
48175211|NCT00256685|DRUG|DVS-233 SR|
48175212|NCT00806637|PROCEDURE|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
48175213|NCT00806637|PROCEDURE|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
48707493|NCT03865667|DEVICE|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
48707494|NCT03819556|OTHER|Milk protein in fresh milk|Milk protein in increasing doses.
48707495|NCT06306690|DIAGNOSTIC_TEST|OCT, OCT angiography, flicker ERG and Ultra Wide Field retinography and autofluorescence.|"the best visual acuity will be evaluated using decimal tables and then converted to logMar.~Ocular fundus examination will be evaluated following pharmacological mydriasis with Tropicamide 1%.~OCT will be essential to quantify the central macular thickness and the thickness of the RPE.~OCT angiography is a non-invasive method to assess the presence or absence of neovascular membrane and macular flow density.~Color and ultra wide field autofluorescence images of the retina will be performed with Zeiss Clarus retinography to search for signs that identify different types of RP and predict their activity and evolution.~Electroretinogram flicker (ERG) is a common measure of cone pathway function that is used to study the normal visual system and that of patients with inherited and acquired retinal dysfunction Measurements will be performed using an electrophysiological recording system (CSO). Intermittent stimuli are presented using a Ganzfeld dome (CSO)."
48707496|NCT05100940|PROCEDURE|Cardiac Catheterization|Cardiac Catheterization
48707497|NCT05389475|PROCEDURE|anoplasty in treatment of post hemorroidectomy anal stenosis|Diamond flap versus V-Y flap
48707498|NCT04254159|OTHER|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
48707499|NCT04254159|OTHER|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
48707500|NCT04254159|BEHAVIORAL|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
48707501|NCT04254159|OTHER|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
48707502|NCT03202355|DEVICE|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
48707503|NCT03202355|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
48707504|NCT00713921|DRUG|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
48707505|NCT02779907|OTHER|No Intervention|No interventions planned for this observational study
48707506|NCT05160519|RADIATION|Class IV Laser|"30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the efficacy of class IV laser on ejection fraction, Cardiac Biomarker and functional outcomes.~Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: CW 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
48707507|NCT05160519|RADIATION|Sham Class IV Laser|"30 participants in sham control group will be suppose to irradiate with Class IV laser therapy over the left parasternal area, but the radiation will not be delivered.~Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
48707508|NCT03926000|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
48707509|NCT03926000|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
48707510|NCT01757561|PROCEDURE|propofol|use total intravenous anesthesia with propofol
48018199|NCT04072965|OTHER|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
48018200|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Volnewmer|Non-invasive radiofrequency-based skin tightening using the Volnewmer device.
48375476|NCT03226782|OTHER|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
48375477|NCT03226574|DRUG|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
48375478|NCT03585595|OTHER|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
48707511|NCT01757561|PROCEDURE|sevoflurane|use inhalation anesthesia with sevoflurane
48707512|NCT06193408|DRUG|VR-AD-1005|oral capsule
48707513|NCT06193408|DRUG|Placebo|oral capsule
48707514|NCT05164601|OTHER|No Intervention - Observational Only|Clinical Follow-Up
48018201|NCT06657365|DEVICE|Radiofrequency (RF) Treatment with Thermage CPT|Non-invasive radiofrequency-based skin tightening using the Thermage CPT device.
48175214|NCT04189510|DEVICE|Artificial Pancreas|The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.
48175215|NCT04189510|OTHER|Multiple Daily Injections|Multiple Daily Injections as standard of care post kidney transplant.
48175216|NCT04678713|DIETARY_SUPPLEMENT|investigate the nutritional determinants of MFO in moderate to well-train individuals|The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.
48375479|NCT02144311|PROCEDURE|PET/CT Scan|
48375480|NCT02144311|PROCEDURE|MRI|
48375481|NCT00557986|PROCEDURE|Primary surgery|Primary breast surgery before systemic therapy
48517106|NCT00582660|DRUG|Celecoxib|400 mg twice a day for 7 days prior to surgery
48707515|NCT05843903|BEHAVIORAL|#BabyLetsMove|The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
48175217|NCT04678713|OTHER|Investigate the physiological determinants of MFO in moderate to well-train individuals|Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
48375482|NCT05797142|OTHER|Virtual reality glasses|"Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes)."
48707516|NCT00182780|DIETARY_SUPPLEMENT|American ginseng|
48707517|NCT00182780|OTHER|Placebo|
48707518|NCT03994250|OTHER|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
48707519|NCT03994250|OTHER|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
48707520|NCT00873379|DIETARY_SUPPLEMENT|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
48375483|NCT01761461|DRUG|TS-1, oxaliplatin|
48375484|NCT06044168|DIETARY_SUPPLEMENT|Dietary Supplement: Leucine|150mg/kg body mass/day
48375485|NCT03110367|BEHAVIORAL|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
48375486|NCT03110367|BEHAVIORAL|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
48707521|NCT00873379|DIETARY_SUPPLEMENT|placebo|half a white placebo tablet
48707522|NCT02801279|OTHER|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
48707523|NCT02801279|OTHER|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
48707524|NCT06608979|BEHAVIORAL|Screening/Referral and Prevention|Session 1: One hour PTSD Screening/referral and Psychoeducation on interpersonal violence (consent, drug-and-alcohol-facilitated assault, intimate partner violence); Session 2: One hour sessions on Protective Behavioral Strategies for interpersonal violence (skills training)
48707525|NCT02470143|BEHAVIORAL|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
48517107|NCT00582660|DRUG|Placebo|one tablet of placebo will be given for 7 days prior to surgery
48517108|NCT06424197|OTHER|Racial group-targeted messages|Colorectal cancer screening messages targeted towards participants racial group.
48707526|NCT02226562|DRUG|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
48707527|NCT02226562|DRUG|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
48707528|NCT00780637|DRUG|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
48707529|NCT00539383|DRUG|ANG1005|IV infusion once every 21 days
48707530|NCT03602313|DEVICE|Body Weight Support Gait Training|
48707531|NCT03602313|OTHER|Traditional Gait Training|
48707532|NCT04790812|DRUG|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
48707533|NCT04790812|DRUG|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
48375487|NCT03662477|BIOLOGICAL|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
48175218|NCT03292523|OTHER|questionnaire|Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
48175219|NCT03156205|BEHAVIORAL|interactive music therapy|For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.
48175220|NCT03156205|BEHAVIORAL|passive music listening|For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.
48175221|NCT03156205|BEHAVIORAL|passive earphone-use|For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
48175222|NCT05678647|DRUG|Sucrosomial Iron|20 capsules of Sucrosomial Iron 30 mg is given after blood donation
48175223|NCT05678647|DRUG|Iron Sulfate|20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
48175224|NCT01042717|DRUG|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
48175225|NCT01501292|OTHER|Fixation and staining|Fixation and staining by MitiTracker Green FM
48175226|NCT01501292|OTHER|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
48175227|NCT00752245|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
48175228|NCT00752245|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
48375488|NCT00889928|DEVICE|NOTES GEN 1 Toolbox|"* Articulating Hook Knife~* Articulating Snare~* Articulating Needle Knife~* Articulating Graspers~* Articulating Biopsy Forceps~* Steerable Flex Trocar with Rotary Access Needle~* Flexible Bipolar Hemostasis Forceps~* Flexible Maryland Dissector"
48707534|NCT04790812|DRUG|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
48707535|NCT02337283|DRUG|BI 425809|Tablets
48707536|NCT02337283|DRUG|Placebo|Tablets
48707537|NCT02427568|DRUG|MDMA (125 mg)|Two sessions of MDMA (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
48707538|NCT02427568|DRUG|Placebo|Two sessions of placebo (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
48707539|NCT02427568|BEHAVIORAL|Therapy|Non-directive therapy
48707540|NCT05648864|DEVICE|Viamigo|Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
48175229|NCT00752245|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
48175230|NCT03479125|DIAGNOSTIC_TEST|Ultrasound|Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.
48175231|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
48175232|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
48175233|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
48175234|NCT02324478|PROCEDURE|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
48375489|NCT00261859|BEHAVIORAL|BNI|behavioral- brief intervention
48175235|NCT05091476|DEVICE|OPTiC System|OPTiC System procedure
48175236|NCT06331195|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol.
48175237|NCT06331195|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil.
48175238|NCT06331195|DIETARY_SUPPLEMENT|Phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
48175239|NCT06331195|DIETARY_SUPPLEMENT|Krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
48707541|NCT02476084|OTHER|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
48707542|NCT02476084|OTHER|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
48707543|NCT02476084|OTHER|Biological samples collection|Draw of research blood samples.
48707544|NCT02476084|OTHER|Questionnaires|Administration of validated patients' questionnaires.
48375490|NCT03648021|DRUG|Paracetamol|"\>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
48018202|NCT06456294|BEHAVIORAL|MHC Outreach Intervention|Adult PC clinics are randomized to receive the MHC Outreach Intervention early (n=7 clinics) vs. delayed (n=7 clinics). In early intervention clinics, patients prescribed chronic opioid therapy, on a chronic opioid registry, and receiving their medication from the intervention clinic are sent emails and letters inviting them to schedule an MHC appointment. Clinical staff at the early intervention clinic are educated to encourage attendance. During MHC visits, MHC staff assess patients prescribed Chronic Opioid Therapy (COT), educate them about overdose, prescribe naloxone, and order guideline-concordant opioid monitoring.
48175240|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.25% bupivacaine is administered superficially to the intercostal muscle.
48375491|NCT03648021|DRUG|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
48375492|NCT01577082|DRUG|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
48375493|NCT01577082|DRUG|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
48375494|NCT03087227|DEVICE|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
48375495|NCT01656109|DRUG|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
48375496|NCT06021769|OTHER|Observational only|No intervention
48375497|NCT00083356|PROCEDURE|Wisdom tooth extraction|
48707545|NCT01632228|DRUG|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
48707546|NCT01632228|DRUG|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
48707547|NCT01632228|DRUG|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
48375498|NCT04895423|DRUG|Methotrexate therapy|Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
48707548|NCT05679544|BIOLOGICAL|Characterization of early biological effects following exposure to PAHs|Biological samples collected in period of exposure and after holidays
48707549|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
48375499|NCT04895423|DRUG|Mycophenolate mofetil therapy|Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
48375500|NCT04895423|DRUG|Cyclosporine therapy|Cyclosporine per os 3 mg/m2 2 times a day within 12 months
48517109|NCT06424197|OTHER|Explicit Commitment|Indicate explicit commitment to return at home screening kit.
48707550|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
48018203|NCT06181669|DIAGNOSTIC_TEST|Pathogen and Host Directed testing|"This study will compare up to 6 pathogen-directed tests and 3 host biomarker tests. Pathogen-directed tests detect and identify the most common causes of bacterial pneumonia, while host biomarker tests assess the host's immune response to infection. Testing will occur at various testing centers.~Evaluable participant specimens will be sent to a central laboratory for distribution to the testing centers that will perform the index testing. Testing centers will be blinded to whether the samples were collected at baseline or clinical change. Further, each testing center will prepare and test the specimens according to documented procedures, then transfer the testing results to the ARLG Statistics and Data Management Center for analysis. Neither the study sites, participants, nor adjudicators will receive the results from the index testing. After the study, untested aliquots of specimens will be stored in the ARLG Physical Biorepository."
48018204|NCT06176027|DRUG|Azacytidine plus CAOLD regimen|Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)
48018205|NCT05379829|DRUG|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
48018206|NCT05379829|DRUG|Placebo|Participants will be administered 3 doses s.c. Q4W.
48018207|NCT06572540|DEVICE|Transthoracic cryoablation|Transthoracic cryoablation will be performed under the guidance of CT.
48375501|NCT04895423|DRUG|Dupilumab therapy|Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
48517110|NCT03833687|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
48175241|NCT06545409|PROCEDURE|Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl)|While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.9% NaCl is administered superficially to the intercostal muscle
48707551|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
48707552|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
48707553|NCT02157441|PROCEDURE|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
48707554|NCT02076399|DRUG|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
48707555|NCT02076399|DRUG|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
48707556|NCT05530395|DIAGNOSTIC_TEST|Testosterone levels|Blood sample to determine testosterone levels
48707557|NCT02573246|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
48707558|NCT02573246|DEVICE|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
48707559|NCT02573246|DEVICE|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
48707560|NCT01884558|DRUG|isavuconazole|oral
48707561|NCT01884558|DRUG|metformin|oral
48707562|NCT03891004|PROCEDURE|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
48707563|NCT03891004|DEVICE|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
48707564|NCT01480713|DRUG|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
48707565|NCT01480713|DRUG|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
48018208|NCT06572540|DEVICE|Transbronchial cryoablation|Transbronchial cryoablation will be performed under the guidance of navigation bronchoscopy and CBCT.
48175242|NCT05399615|DIAGNOSTIC_TEST|VOX|Breath biopsy
48375502|NCT03696420|OTHER|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
48707566|NCT01211353|BEHAVIORAL|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
48707567|NCT01211353|BEHAVIORAL|Education-Only|Educational information about alcohol use
48707568|NCT05266183|OTHER|Simultaneous Variety|3 different foods served
48707569|NCT05266183|OTHER|Single-Food|1 food served
48707570|NCT05266183|OTHER|Small Portion|Small meal portion size
48707571|NCT05266183|OTHER|Large Portion|Large meal portion size
48707572|NCT06607263|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
48707573|NCT06607263|DRUG|Essential oils mouthrinse|Essential oils mouthrinse
48707574|NCT06607263|DEVICE|Dental floss|Dental floss
48707575|NCT06607263|DRUG|Toothpaste|A commercially available fluoride toothpaste
48707576|NCT06607263|DEVICE|Toothbrush|A commercially available adult toothbrush
48707577|NCT05297279|BEHAVIORAL|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
48707578|NCT05297279|BEHAVIORAL|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
48707579|NCT05297279|BEHAVIORAL|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
48707580|NCT00384319|DEVICE|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
48707581|NCT04561323|DIAGNOSTIC_TEST|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
48707582|NCT06606561|DRUG|NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)|A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
48707583|NCT06606561|DRUG|0.9% Sodium Chloride Injection, USP|In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
48707584|NCT01654159|PROCEDURE|Monofocal IOL|Monofocal Intraocular lens will be implanted
48707585|NCT01654159|PROCEDURE|Multifocal IOL|Multifocal IOL will be implanted
48707586|NCT01654159|PROCEDURE|Toric IOL|Toric IOLS will be implanted
48707587|NCT01779869|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
48707588|NCT06296160|OTHER|Intervention Group|"A- (Intervention Phase= (Day-1) + (Day-15)~1. Obtain a lung ultrasound after the midweek dialysis session.~2. The 8-zone lung ultrasound method calculates the number of B-line scores.~3. Reduce the dry weight by 500 g if the B-line score is \>0.54/zone (BLS\>5). considered a day one.~4. The dry weight will be reduced only if the arterial blood pressure at the end of the session is BP \>110/60 mmHg and the patient had no hypotension episode during the session.~5. The adjustment of dry weight based on lung ultrasound should not be made on the same day as the standard approach adjustment (Regular monthly clinical standards modification.~6. Check the Blood Pressure 3 times/ day on the non-dialysis following the ultrasound.~7. Check the ambulatory blood pressure for 48 hours (Baseline on day 1 and Follow-up on Day 60).~B - Observational Phase= (Day-30) + (Day-45) + (Day-60)\]."
48707589|NCT02614807|DIETARY_SUPPLEMENT|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
48707590|NCT03117790|DRUG|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
48707591|NCT03117790|DRUG|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
48707592|NCT05910047|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone
48707593|NCT05910047|DIETARY_SUPPLEMENT|Placebo|Inert substance
48707594|NCT05282576|OTHER|NPF Group|Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
48375503|NCT02621528|DEVICE|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
48375504|NCT03564015|OTHER|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
48018209|NCT06460701|OTHER|m-CIMT without Kinesio taping|Baseline treatment m-CIMT will be applied includeing ROM with a sling, e.g shoulder flexion, extension, abduction, and rotation. The elbow's flexion and extension, Forearm supination is the extension of the wrist and fingers. Functional Training Using a tiny toy ball, practice tossing and catching it from various angles. Play with modeling clay, constructing towers of the toy bricks using LEGOs,Using crayons, ripping a piece of paper towel,Grasping biscuits, Using a spoon, utilizing a glass to drink, comb hair, brush teeth,Using a bubble blower,With a toy in hand, putting cap, putting lotion.stretching to shoulder's extensors, adductor, and internal rotators ,wrist and elbow flexors. strengthening exercises e.g a ball above head position in various directions,Using paper adhered to the window or wall at varying heights for drawing. The session will go for one hour.
48018210|NCT06460701|OTHER|m-CIMT along with kinesiotaping|"Modified constraint-induced movement therapy along with kinesiotaping will be applied. m-CIMT protocol is baseline treatment and it is is same as in the other group.~This group also participated additionally in a kinesio taping program, which utilize KT with the goal of enhancing middle and lower trapezius function to increase stability in the scapula on the afflicted side. During the application of the tape, the shoulders were kept in a low and backward posture, and the scapular alignment was manually maintained. KT was administered at the acromion and positioned medially at the spinous processes (T2-T3 for the middle trapezius and T12 for the lower trapezius). For eight weeks in a row, there will be three sessions every week"
48018211|NCT05822011|PROCEDURE|Rhomboid intercostal subserratus plane block|Fascial plane block
48018212|NCT05822011|PROCEDURE|Erector spinae plane block|Fascial plane block
48018213|NCT05822011|PROCEDURE|Thoraccic Epidural analgesia|Neuroaxial block
48517111|NCT02872428|DRUG|Valproic Acid|By infusion over 1 hour
48375505|NCT03564015|OTHER|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
48375506|NCT03312504|OTHER|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
48517112|NCT02872428|DRUG|Isotonic saline solution|By infusion over 1 hour
48175243|NCT06454201|PROCEDURE|robotic natural orifice specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
48175244|NCT06454201|PROCEDURE|robotic transabdominal specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
48707595|NCT05282576|OTHER|Control Group|Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
48707596|NCT01891799|OTHER|Option B+|"* Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
48707597|NCT06605092|OTHER|Emotional stimulation|Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
48018217|NCT06573736|DIAGNOSTIC_TEST|Stockholm3|Stockholm3 combines protein markers tPSA, fPSA, KLK2, PSP94 and GDF15, genetic markers and clinical data to estimate risk for clinically significant prostate cancer.
48018218|NCT06008925|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
48018219|NCT06008925|DRUG|Nivolumab Injection|Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
48018220|NCT04894045|OTHER|Personalized management|Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
48018221|NCT02030678|DRUG|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
48018222|NCT02010424|OTHER|control group|standard IVF protocol
48018223|NCT02010424|DEVICE|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
48175245|NCT01674517|DRUG|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
48175246|NCT00000319|DRUG|Buprenorphine|
48175247|NCT03943836|BEHAVIORAL|Music|Patients in the music group will listen to classical music during their dental procedure.
48175248|NCT00037713|BIOLOGICAL|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10.
48175249|NCT06264011|BEHAVIORAL|Salaat|While Muslims perform mandatory salaat (prayer) 5 times daily, the Duha salaat is an optional daily prayer consisting of 4 cycles of standing, bowing, standing again, prostrating, kneeling, and prostrating again. Research has shown that salaat may influence physiological relaxation.
48175250|NCT06264011|OTHER|Sham comparator|Participants will count while mimicking the movements of the Duhaa salaat. This is a no-prayer condition in which the recitation of Qur'an is omitted for the sake of comparison.
48175251|NCT01659671|PROCEDURE|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
48175252|NCT06049069|DIAGNOSTIC_TEST|physical activity in stroke|physical activity in stroke
48175253|NCT01597583|BEHAVIORAL|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
48175254|NCT02585297|OTHER|no intervention|
48707598|NCT03121677|BIOLOGICAL|Personalized tumor vaccine|"* Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
48707599|NCT03121677|DRUG|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
48707600|NCT03121677|BIOLOGICAL|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
48707601|NCT03121677|PROCEDURE|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
48707602|NCT03121677|PROCEDURE|Leukapheresis|"* Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
48707603|NCT03121677|BIOLOGICAL|Rituximab|-Other anti-CD20 mAb treatment can be used
48707604|NCT03121677|PROCEDURE|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
48707605|NCT01588262|OTHER|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
48707606|NCT03078790|DEVICE|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
48707607|NCT05988294|OTHER|Pilates exercises|One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.
48707608|NCT05988294|OTHER|Conventional physical therapy exercise program|Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
48707609|NCT03198455|DIETARY_SUPPLEMENT|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
48707610|NCT03198455|OTHER|Placebo|Drinking water with food coloring and salt
48707611|NCT05891886|DRUG|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
48707612|NCT05891886|DEVICE|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
48707613|NCT04850976|DEVICE|Endotracheal intubation|Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
48707614|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
48175255|NCT05840900|BEHAVIORAL|Digital Mindfulness Training|Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
48175256|NCT00051038|DRUG|Entecavir|
48175257|NCT03373955|DRUG|pembrolizumab|anti-programmed death 1 (PD-1) antibody
48175258|NCT06342479|BEHAVIORAL|Discharge Education|Discharge education will be provided.
48175259|NCT01545557|DEVICE|Hyaluronic acid dermal filler gel|1 Emervel Volume injection per indication and 1 touch-up injection if necessary
48175260|NCT05230030|BEHAVIORAL|Improvisation Workshop|Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
48175261|NCT05383638|OTHER|Health education|Intervention is achieved through health education. Analyze the factors that may affect patients' satisfaction with primary medical services through existing data, and carry out targeted health education.
48175262|NCT05318235|OTHER|No intervention|No intervention
48175263|NCT00006010|DRUG|docetaxel|
48707615|NCT00983515|DRUG|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
48707616|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
48018224|NCT04499404|OTHER|Breastfeeding related information delivered by WeChat|Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
48375507|NCT03312504|OTHER|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
48375508|NCT01518894|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
48707617|NCT01952665|DEVICE|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
48707618|NCT01952665|DEVICE|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
48018225|NCT04499404|OTHER|Non-breastfeeding related information delivered by WeChat|Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
48018226|NCT01391117|DRUG|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
48018227|NCT01391117|DRUG|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
48018228|NCT01391117|DRUG|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
48018229|NCT01391117|DRUG|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
48018230|NCT01391117|DRUG|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
48018231|NCT01391117|DRUG|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
48018232|NCT01391117|DRUG|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
48018233|NCT01391117|DRUG|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
48018234|NCT01391117|DRUG|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
48018235|NCT01391117|DRUG|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
48018236|NCT02276495|OTHER|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
48018237|NCT02276495|DRUG|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
48018238|NCT02276495|DRUG|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
48018239|NCT01736566|OTHER|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~1. The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~2. The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~\*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
48018240|NCT01736566|OTHER|Family History Only|Doctors and their patients receive a Family History report.
48018241|NCT00834301|DIETARY_SUPPLEMENT|Oral Multivitamin|Oral Multivitamin
48018242|NCT05392556|DIETARY_SUPPLEMENT|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10\^9 CFU/d (powder form)
48018243|NCT05392556|DIETARY_SUPPLEMENT|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
48175264|NCT00006010|DRUG|gemcitabine hydrochloride|
48175265|NCT00739609|DRUG|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
48375509|NCT01518894|DRUG|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
48707619|NCT03088748|DEVICE|Journey II posterior cruciate retaining total knee arthroplasty|
48707620|NCT03088748|DEVICE|Journey II posterior bi-cruciate retaining total knee arthroplasty|
48018244|NCT05392556|OTHER|Placebo|Maltodextrin 3.6 g/d (powder form)
48018245|NCT06662643|PROCEDURE|Delayed transanal pull-through anastomosis|Laparoscopic surgery is recommended. A standard 5-port method is used to create pneumoperitoneum after placing the trocar. The sigmoid colon and upper rectal mesentery are dissected along Toldt's fascia. Autonomic nerves should be preserved, and high ligation of the inferior mesenteric vessels with lymph node dissection is recommended. TME: Using a posterior-to-anterior approach, the mesorectal plane is dissected down to the pelvic floor, cutting the Waldeyer's fascia to enter the intersphincteric space, where sharp dissection is carried out toward the levator ani muscle hiatus. The dissection endpoint is the dentate line, where the proximal colon is exteriorized by at least 2 cm and sutured to the anal canal with 6-8 stitches, without a protective ileostomy.Two to four weeks after the first surgery, after the colon has adhered well to the surrounding tissue, the exteriorized colon is excised (under epidural or spinal anesthesia, trimming the exteriorized colon to form the anus).
48018246|NCT06662643|PROCEDURE|Direct Anastomosis Plus Prophylactic Ileostomy|ISR is categorized into partial ISR (PISR), subtotal ISR, and total ISR (TISR). Correspondingly, the anastomosis site after coloanal anastomosis is located below the levator ani hiatus (PISR, near the dentate line; subtotal-ISR and TISR, below the dentate line).The dissection steps are the same as in the first stage of the Staged Turnbull-Cutait Pull-through Anastomosis group (TME and intersphincteric space dissection).The bowel is transected at least 1 cm below the tumor, leaving a larger segment of healthy tissue on the non-tumor side while ensuring that no more than 1/3 of the dentate line is resected to avoid impairing fecal control.Anastomosis is performed using absorbable sutures under direct visualization. A protective ileostomy is created 25-30 cm from the ileocecal valve.3 to 6 months after surgery, the ileostomy is reversed. Prior to closure, digital rectal examination, defecography, MRI, colonoscopy, and other evaluation must perform.
48018247|NCT02923375|BIOLOGICAL|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
48018248|NCT03847181|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
48018249|NCT03847181|DRUG|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
48375510|NCT01518894|DRUG|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
48375511|NCT01518894|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
48375512|NCT06499272|PROCEDURE|Conventional occupational therapy sessions + NeuronUP|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
48375513|NCT06499272|PROCEDURE|Conventional occupational therapy sessions|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
48375514|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
48018250|NCT03847181|DRUG|Warfarin|Warfarin dose as prescribed by medical practitioner
48018251|NCT03762135|OTHER|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
48018252|NCT03762135|OTHER|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
48018253|NCT04537715|DRUG|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
48375515|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
48018254|NCT04537715|DRUG|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
48018255|NCT04537715|DRUG|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
48375516|NCT01065077|DRUG|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
48375517|NCT01065077|DRUG|Placebo|Infusion of placebo during 48h
48375518|NCT02489682|OTHER|Long-form written Informed consent information|
48375519|NCT02489682|OTHER|Short-form written Informed consent information|
48375520|NCT02489682|OTHER|Video Informed consent information|
48375521|NCT05195385|PROCEDURE|Low-dose computed tomography of the chest|Baseline low dose Ct acquisition, then at 1 year and 2 years to depict suspicious lung nodules
48375522|NCT00021554|DRUG|Enfuvirtide|
48707621|NCT01456208|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
48018256|NCT04537715|DRUG|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
48375523|NCT06523322|BEHAVIORAL|Let's Cook Together|The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
48707622|NCT01456208|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
48707623|NCT01456208|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
48707624|NCT03818347|DEVICE|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
48707625|NCT03818347|DEVICE|analogue machine|This machine has the same apperance and gas condition
48018257|NCT05179954|OTHER|Metabolic testing|Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
48018258|NCT02078739|BEHAVIORAL|Yoga Program at home using internet technology|
48018259|NCT03552159|BEHAVIORAL|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
48707626|NCT01559922|DRUG|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
48707627|NCT01559922|DEVICE|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
48707628|NCT04333511|DEVICE|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
48707629|NCT04333511|DEVICE|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
48707630|NCT05792839|PROCEDURE|Abdominoplasty with ventral hernia repair versus ventral hernioplasty.|We do surgical treatment for ventral hernia in the form of hernioplasty with surgical mesh placement or by means of abdominoplasty surgical technique.
48707631|NCT04820257|BEHAVIORAL|Home based exercise|Exercise at home and behavioural change to increase daily exercise
48707632|NCT03880448|DRUG|Metronidazole|Metronidazole 500mg/8h/7days
48707633|NCT03880448|DRUG|Placebo|Cornstarch 500mg/8h/7days
48707634|NCT03880448|PROCEDURE|periodontal surgery|periodontal surgery
48707635|NCT06245057|OTHER|Maternity care home model (MCHM)|The maternity care home model is defined as office based prenatal care integrated with comprehensive social services.
48018260|NCT03552159|OTHER|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
48018261|NCT01416012|BEHAVIORAL|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
48175266|NCT04988399|OTHER|Reiki|Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
48375524|NCT06097416|DRUG|Neoadjuvant Chemoradiotherapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period."
48707636|NCT04378829|DIAGNOSTIC_TEST|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
48707637|NCT05946291|OTHER|Pressure injury training|Pressure injury training with mulage application on a standardized patient
48375525|NCT06097416|DRUG|Total Neoadjuvant Therapy|"5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery."
48375526|NCT05762276|DRUG|VXX-401|A synthetic PCSK9 peptide-based immunotherapy
48375527|NCT05762276|BIOLOGICAL|Placebo|Normal saline
48375528|NCT00282516|PROCEDURE|In-home telemonitoring of pediatric patients with persistent asthma|
48707638|NCT05946291|OTHER|Simulated Manneqquin training|Pressure injury training with mulage application on a simulated manneqquin
48018262|NCT01416012|BEHAVIORAL|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
48707639|NCT02082223|BEHAVIORAL|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
48707640|NCT02303080|OTHER|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
48175267|NCT01198847|BEHAVIORAL|Dietary, physical activity and sleeping|"The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support"
48375529|NCT02837250|BEHAVIORAL|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
48375530|NCT02837250|BEHAVIORAL|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
48375531|NCT04842318|DRUG|BR for 6 cycles +R for 8 cycles|The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
48175268|NCT04874623|OTHER|Collection of peripheral blood mononuclear cells|Analysis of specific memory B cells in CDI patients
48175269|NCT02168283|COMBINATION_PRODUCT|treatment arm|Hypertonic peritoneal dialysis cycles
48375532|NCT04842318|DRUG|RCHOP for 6 cycles +R for 8 cycles|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
48707641|NCT02303080|OTHER|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
48175270|NCT02168283|BEHAVIORAL|Control arm|Dietary counseling
48175271|NCT02128698|DIETARY_SUPPLEMENT|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
48175272|NCT02128698|DIETARY_SUPPLEMENT|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
48175273|NCT02128698|BEHAVIORAL|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
48375533|NCT04842318|DRUG|R2 for 6 cycles + R2 maintenance|The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
48707642|NCT02303080|OTHER|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
48018263|NCT01416012|BEHAVIORAL|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
48707643|NCT02303080|OTHER|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
48707644|NCT02881112|DEVICE|Provant Therapy System|Treatment with the Provant Therapy System
48707645|NCT00369005|PROCEDURE|Red blood cell transfusion guidelines|
48707646|NCT05460598|OTHER|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
48707647|NCT05460598|OTHER|commonly used bedding|commonly used bedding
48707648|NCT03419377|OTHER|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
48707649|NCT02829892|DEVICE|Light therapy|14-days exposure with an innovative ambient light
48707650|NCT03469830|OTHER|SSCP|Insert
48707651|NCT03469830|OTHER|SPMS|Pressure therapy
48707652|NCT06519123|OTHER|Ambient Digital Scribes|AI technology used to populate clinical notes.
48707653|NCT02435680|DRUG|MCS110|taken by I.V
48707654|NCT02435680|DRUG|carboplatin|taken by I.V
48707655|NCT02435680|DRUG|gemcitabine|taken by I.V
48707656|NCT00905762|DRUG|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
48707657|NCT00905762|DRUG|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
48517113|NCT06489236|BEHAVIORAL|Vaccine Confidence: Skills to Promote Vaccination in the Pediatric Consultations|Intervention mapping principles guided a multidisciplinary team through the development of the intervention. The intervention is a 12-hour training program focused on improving vaccination promotion and vaccine hesitancy management during pediatric consultations. The program comprises 10 hours of online education and 2 hours of in-person activities. Online training materials (short video lectures, video case studies, and readings) were structured in three learning modules covering vaccine and vaccine hesitancy technical information, vaccination promotion communication strategies, and practice organizational resources. In-person activities involved role-playings and group discussions. Intervention content is evidence-based. As a participation incentive, pediatric nurses and pediatricians who complete all program activities, including a multiple-choice final test, will receive 2,5 accredited continuing medical education credits.
48517114|NCT00564512|BIOLOGICAL|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
48175274|NCT02128698|BEHAVIORAL|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
48175275|NCT05918393|BEHAVIORAL|functional communication training|During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
48175276|NCT05245591|DRUG|Pentosan Polysulfate Sodium 100 MG Oral Capsule|Pentosan Polysulfate Sodium 100 mg three times daily (tid) for 0-8 weeks Pentosan Polysulfate Sodium 100 mg twice daily (bid) for 9-16 weeks
48175277|NCT05245591|DRUG|Placebo|Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks
48175278|NCT04296045|DIETARY_SUPPLEMENT|MCE|Ingestion of 15g MCE in water after min 10 hours of fasting
48175279|NCT04296045|DIETARY_SUPPLEMENT|Glucose|Ingestion of 15g glucose in water after min 10 hours of fasting
48175280|NCT05364645|DRUG|Carboplatin|Given IV
48175281|NCT05364645|DRUG|Pemetrexed|Given IV
48175282|NCT05364645|DRUG|Selpercatinib|Given PO
48175283|NCT05064306|DRUG|131I-omburtamab|50 mCi 131I-omburtamab
48175284|NCT05199857|BEHAVIORAL|WE BEAT Group Wellness Education program - phase 1|Participants will be assigned into a small group with 3-6 other participants and will participate in a weekly, 45-50 minute intervention session for 5 weeks, delivered by a licensed clinical psychologist or limited licensed clinical psychology fellow using University of Michigan (UM) Zoom. Each session will focus on a particular skill related to wellness and resiliency. There will also be a short battery of questionnaires to complete.
48175285|NCT05199857|BEHAVIORAL|HEART Club Home Exercise program - phase 2|This is an individualized home exercise program adapted from the exercise programs used in traditional, hospital-based cardiac rehabilitation. A complete cardiopulmonary exercise test (CPET) may be completed if needed for a baseline and one will be done at the last visit. The exercise physiology team will discuss participants exercise goals, interests, and available resources to help develop the exercise plan for the research study. Once the program is designed, participants will complete the exercise activities in the plan. Over time, participants will advance through various stages in the program and then will be gradually introduced to the principles of exercise rehabilitation and more intense physical exercise. Participants will be asked to wear a wearable activity tracker and have scheduled video check-ins with the exercise physiology team. Throughout the program participants will complete a short battery of surveys.
48175286|NCT04055610|DEVICE|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
48375534|NCT01160770|DRUG|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
48375535|NCT00942669|DEVICE|SleepStrip OTC(TM)|self contained SAS screening device
48375536|NCT04330066|DIAGNOSTIC_TEST|Abdominal ultrasound measurement of the endometrial lining|On the day of the participants frozen embryo transfer, an endometrial thickness measurement (T2) will obtained from an abdominal ultrasound during the embryo transfer.
48375537|NCT00473928|DRUG|POT-4|Single intravitreal injection.
48375538|NCT00700466|DRUG|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
48375539|NCT02543918|DRUG|Ixekizumab|Administered by SQ injection
48375540|NCT02543918|DRUG|Boostrix®|Administered by IM injection
48375541|NCT02543918|DRUG|Pneumovax®23|Administered by IM injection
48175287|NCT01184898|DRUG|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
48175288|NCT01184898|DRUG|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
48375542|NCT05805579|DIAGNOSTIC_TEST|Diaphragmatic echography|Diaphragmatic echography
48375543|NCT00584610|DEVICE|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
48375544|NCT00584610|DEVICE|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
48375545|NCT00000565|PROCEDURE|intermittent positive-pressure breathing|
48517115|NCT00564512|BIOLOGICAL|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
48517116|NCT00564512|DRUG|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
48517117|NCT00564512|DRUG|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
48517118|NCT02358512|OTHER|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
48517119|NCT02348112|DEVICE|Altis Single Incision Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
48707658|NCT00905762|DRUG|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
48375546|NCT05471141|OTHER|Cognition ECHO|Cognition ECHO is the intervention designed to be used by the study participants who are primary care practitioners. No involvement of patients in this study. The panel will consist of the CI and Co-PIs of this study, a neurologist as a co-moderator, a medical specialist who is the expert on the subject, an occupational therapist, a psychologist, and a speech and language pathologist with experience and expertise in CI. A patient with CI and a caregiver, family member, or community representative who is not a healthcare professional will join the panel because CI is frequently observed with lived experience of family members and loved ones, as two non-clinician panelists. The five topics with the integration of related diagnoses for Cognition ECHO are listed in Table 4. The time allocated for the didactic will be 15-20 minutes and the de-identified case discussion will be 40 - 45 minutes.
48707659|NCT06105736|BEHAVIORAL|Behavioral Intervention in a small group platform|RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
48707660|NCT06605521|PROCEDURE|Subclavian lymph node dissection+radiotherapy|The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
48375547|NCT02675660|DIETARY_SUPPLEMENT|L-Homoarginine|125 mg L-homoarginine once daily
48018264|NCT01416012|BEHAVIORAL|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
48018265|NCT05589545|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
48175289|NCT01184898|DRUG|Etoposide|100 mg/m2/day IV
48175290|NCT01184898|DRUG|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
48375548|NCT02675660|DRUG|Placebo|placebo capsules once daily
48707661|NCT06605521|PROCEDURE|Simple clavicular region radiotherapy|If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
48375549|NCT02507609|OTHER|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
48375550|NCT02507609|OTHER|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
48375551|NCT04749901|OTHER|Psycho-emotional and semiological measures|Surveys, interviews and measures
48375552|NCT02079493|DEVICE|Total Knee Arthroplasty|Knee replacement
48375553|NCT02513901|DRUG|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
48375554|NCT05479617|OTHER|Deep learning model|Use of deep learning model to predict individual patients disease course
48517120|NCT02348112|DEVICE|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
48517121|NCT00979199|OTHER|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
48517122|NCT00257621|DRUG|GW640385|
48707662|NCT04700657|DIAGNOSTIC_TEST|corneal sensation test|Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
48707663|NCT01151111|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
48707664|NCT00129870|DRUG|oxaliplatin|
48175291|NCT03201237|OTHER|Action observation training|Each child observed a task video and then performed a task
48375555|NCT03133429|DEVICE|MER|carotid artery stenting
48375556|NCT03143933|DRUG|Propofol|I.V propofol
48375557|NCT03143933|DRUG|Fentanyl|
48375558|NCT02477072|PROCEDURE|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
48375559|NCT02477072|PROCEDURE|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
48375560|NCT02477072|PROCEDURE|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
48375561|NCT02477072|PROCEDURE|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
48375562|NCT02477072|DRUG|Heparin|Heparin doses will be administered according to the assigned group.
48375563|NCT03677609|BEHAVIORAL|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
48375564|NCT06378112|DRUG|GTO®|After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
48375565|NCT03723460|OTHER|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
48375566|NCT04124302|DRUG|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
48517123|NCT00257621|DRUG|Ritonavir|
48517124|NCT02308124|DRUG|Midodrine|
48517125|NCT02308124|DRUG|Pyridostigmine Bromide|
48517126|NCT02308124|DRUG|Midodrine + pyridostigmine|
48707665|NCT03454269|DIAGNOSTIC_TEST|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
48707666|NCT05498233|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
48707667|NCT04486482|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
48707668|NCT04486482|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
48707669|NCT02666456|OTHER|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
48707670|NCT00900679|BEHAVIORAL|telephone-based intervention|
48018266|NCT02670629|PROCEDURE|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
48707671|NCT00900679|OTHER|counseling intervention|
48707672|NCT00900679|OTHER|educational intervention|
48707673|NCT00900679|OTHER|medical chart review|
48018267|NCT02670629|PROCEDURE|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
48018268|NCT02666235|PROCEDURE|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
48018269|NCT02666235|PROCEDURE|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
48018270|NCT05540392|PROCEDURE|Acupuncture|10 treatments of acupuncture over the course of 10 weeks
48375567|NCT04124302|DRUG|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
48375568|NCT04124302|DRUG|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
48375569|NCT04910191|DIAGNOSTIC_TEST|Electronic stethoscope|Electronic stethoscope
48707674|NCT00900679|OTHER|questionnaire administration|
48707675|NCT00900679|PROCEDURE|psychosocial assessment and care|
48707676|NCT00900679|PROCEDURE|quality-of-life assessment|
48707677|NCT01058512|DRUG|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
48707678|NCT00800319|DRUG|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
48018271|NCT05540392|OTHER|Waitlist Control|The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
48707679|NCT00800319|DRUG|Placebo|Volume matched placebo; oral solution; single dose
48707680|NCT06411886|DIAGNOSTIC_TEST|Allergen challenge|Inhaled allergen
48707681|NCT06411886|DIAGNOSTIC_TEST|Saline challenge|Inhaled saline
48707682|NCT01866423|DRUG|orteronel|Given PO
48018272|NCT05540392|OTHER|Questionnaires|Patients will complete Patient Reported Outcomes (PRO)
48018273|NCT05552703|PROCEDURE|surgical evacuation of extradural hematoma|evacuation of extradural hematoma by craniotomy
48018274|NCT04839497|COMBINATION_PRODUCT|Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees|Autologous Volar Fibroblasts Treatment- harvested from patient's biopsied volar skin. Intradermal injection of Volar fibroblasts in the residual limb of transtibial amputees.
48175292|NCT04578587|DEVICE|MicroFET 2|Lumbar Flexor and Extensor Strength Measurement
48375570|NCT05685446|OTHER|Ice water|Ingestion of 175 ml iced tap water 15 minutes prior to elective gastroscopy
48707683|NCT01866423|OTHER|laboratory biomarker analysis|Correlative studies
48707684|NCT02310854|PROCEDURE|ACL Repair|augmented suture of acute ACL rupture (\<3 weeks after injury)
48707685|NCT02310854|PROCEDURE|ACL reconstruction|reconstruction hamstring autograft
48707686|NCT00651495|BEHAVIORAL|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
48707687|NCT03334279|OTHER|Cigarette smokers|frequent cigarette smoking for not less than 5 years
48707688|NCT03334279|OTHER|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
48707689|NCT06289127|BEHAVIORAL|Lower Quarter Y Balance Test|The LQYBT is a widely used test for assessing lower extremity dynamic balance and neuromuscular control. Participants' lower limb balance was performed using The Y Balance Test Kit™ (Move2Perform, Evansville, IN).
48707690|NCT04946409|OTHER|no intervention|no intervention
48707691|NCT01874275|DEVICE|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
48375571|NCT02001662|PROCEDURE|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
48375572|NCT02001662|PROCEDURE|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
48375573|NCT01495793|DRUG|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
48375574|NCT03646929|DIAGNOSTIC_TEST|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
48375575|NCT03646929|DIAGNOSTIC_TEST|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
48375576|NCT03088566|PROCEDURE|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
48375577|NCT03088566|PROCEDURE|Conventional foot screening|The foot screening is performed with clinical conventional methods.
48375578|NCT01294280|OTHER|Laboratory Biomarker Analysis|Correlative studies
48375579|NCT01096017|DRUG|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
48375580|NCT01096017|DRUG|Salbutamol pMDI|200 μg, inhalation, single dose
48375581|NCT01096017|OTHER|pMDI placebo pMDI|Placebo pMDI 2 inhalations
48375582|NCT01096017|OTHER|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
48375583|NCT00998621|OTHER|Adherence questionnaire|Adherence questionnaire
48375584|NCT02679716|OTHER|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
48375585|NCT01821508|OTHER|Clinical Treatment|metabolic surgery for diabetes and weight control
48375586|NCT01821508|PROCEDURE|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
48375587|NCT03127267|DRUG|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
48375588|NCT03127267|DRUG|Riluzole|Riluzole 50 mg tablet, treatment per os
48375589|NCT03127267|DRUG|Placebo|treatment per os
48375590|NCT03127267|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
48375591|NCT04766346|OTHER|Fortified Cow's Milk-Based Oral Nutritional Supplement|The NS is a fortified cow's milk-based product provided in powdered form that provides the appropriate amount of energy and protein to promote growth in children.
48018275|NCT05154903|DRUG|Citicoline 500 MG|Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
48018276|NCT03714633|BEHAVIORAL|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
48018277|NCT05976698|DRUG|LSD 10 μg|0.5 h after the start of each study session the participants will be administered 10 μg LSD per os in the form of vials containing 1ml 20% EtOH (ethanol).
48018278|NCT05976698|DRUG|LSD 20 μg|0.5 h after the start of each study session the participants will be administered 20 μg LSD per os in the form of vials containing 1ml 20% EtOH.
48018279|NCT05976698|DRUG|Placebo|0.5 h after the start of each study session the participants will be administered placebo per os in the form of vials containing 1ml 20% EtOH.
48018280|NCT05435573|DRUG|1000 mL of ringer's acetate solution|1000 mL of ringer's acetate solution
48018281|NCT05435573|DRUG|250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)|500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
48375592|NCT02623569|DRUG|Ivabradine|Not Provided
48375593|NCT02623569|DRUG|Atenolol|Not Provided
48375594|NCT05110118|DRUG|LY01008|Single intravenous injection
48018282|NCT06048120|DRUG|BAY2701250 IV|Single does, intravenous infusion
48018283|NCT06048120|DRUG|Placebo IV|Matching placebo for BAY2701250 IV
48018284|NCT06048120|DRUG|BAY2701250 SC|Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue
48018285|NCT06048120|DRUG|Placebo SC|Matching placebo for BAY2701250 SC
48375595|NCT05110118|DRUG|Avastin|Single intravenous injection
48375596|NCT04807816|DRUG|Association of berzosertib with gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
48375597|NCT04807816|DRUG|Gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
48375598|NCT04532086|DIAGNOSTIC_TEST|Uterocervical angle|Transvaginal ultrasound examination will be performed at 18-28 weeks gestation in (197) pregnant women with live singleton fetuses, attending routine prenatal care services. Measuring length of uterine cervix at (18-28) weeks \& evaluation of dilatation of internal os \& measurement of uterocervical angle between(18-28)weeks gestational age.
48375599|NCT05033769|DRUG|Eribulin Injection [Halaven]|on days 1 and 8 q21d
48375600|NCT05033769|DRUG|Paclitaxel injection|on days 1, 8, and 15 q21d
48375601|NCT01846442|DRUG|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
48375602|NCT01846442|DRUG|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
48375603|NCT01846442|DRUG|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
48375604|NCT01846442|DRUG|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
48375605|NCT02353234|OTHER|Bread|In each arm subjects consume bread
48375606|NCT03186794|OTHER|Treadmill exercise training|30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
48375607|NCT04704752|DIAGNOSTIC_TEST|Swallowing Evaluation|Study Evaluation includes basic test batteries. These are observational.
48375608|NCT03829995|OTHER|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
48375609|NCT02304770|DRUG|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
48375610|NCT05031975|DRUG|Irinotecan|Irinotecan 100 mg/smq intravenous infusion every 14 days
48375611|NCT05031975|DRUG|Temozolomide|Oral temozolomide 150 mg/sqm over days 1-5 every 28 days.
48018286|NCT00578773|DRUG|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
48375612|NCT00604175|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
48375613|NCT00731094|BEHAVIORAL|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
48375614|NCT01593761|DRUG|CG400549|960mg QD at fed state approx 1 hour after meal
48375615|NCT01809847|DRUG|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
48707692|NCT03938220|DEVICE|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
48707693|NCT03795207|COMBINATION_PRODUCT|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
48707694|NCT03795207|RADIATION|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
48707695|NCT03690739|DRUG|Carboplatin|Administration according to investigator's discretion
48707696|NCT03690739|DRUG|Gemcitabine|Administration according to investigator's discretion
48707697|NCT03690739|DRUG|Bevacizumab|Administration according to investigator's discretion
48707698|NCT03690739|DRUG|PLD|Administration according to investigator's discretion
48018287|NCT00578773|DRUG|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
48175293|NCT06122454|DRUG|Hepenofovir Fumarate Tablets|Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations
48375616|NCT04971486|BEHAVIORAL|Motor Sequence Task|"Participants will be seated at a laptop with the right hand on a standard joystick. The movement of the joystick will move a cursor on the computer screen. Targets will appear on the laptop screen as a circle in one of twelve spatially distinct locations. The learner must move the joystick cursor to inside the target before the next target will appear."
48375617|NCT00090259|DRUG|Losartan 50 mg|50-mg losartan oral tablet
48375618|NCT00090259|DRUG|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
48517127|NCT02537691|DRUG|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
48517128|NCT02537691|DRUG|LABA|LABA will be administered as per investigator discretion.
48707699|NCT03690739|DRUG|Paclitaxel|Administration according to investigator's discretion
48707700|NCT03690739|DRUG|PLD|Administration 30 mg/m² q21
48707701|NCT03690739|DRUG|Trabectedin|Administration 1.1 mg/m² q21
48707702|NCT03690739|DRUG|Cisplatin|Administration according to investigator's discretion
48707703|NCT03835884|DRUG|AR-13503 Implant 10.6 Dose|AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye
48707704|NCT03835884|DRUG|AR-13503 Implant 21.2 Dose|AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
48018288|NCT00578773|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
48018289|NCT04898231|DRUG|Infliximab|Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.
48175294|NCT03567135|DRUG|Apatinib|These drugs are planned to inhibit the proliferation and metastasis of tumors.
48175295|NCT03567135|DRUG|Temozolomide（TMZ）|Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
48375619|NCT02008955|DIETARY_SUPPLEMENT|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
48375620|NCT05174429|BEHAVIORAL|Risk-Targeted Behavioral Activation|"The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence."
48375621|NCT01785199|PROCEDURE|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
48375622|NCT05549271|PROCEDURE|Laparoscopic Mini-gastric bypass|The laparoscopic Omega Loop Bypass performed 5 years ago consisted of a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His, a narrow gastric tube calibrated to be approximately 1.5 cm wide, an Omega loop of 200 cm, a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler
48707705|NCT03835884|DRUG|AR-13503 42.4 Dose|AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
48707706|NCT03835884|DRUG|AR-13503 63.6 Dose|AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
48707707|NCT01746121|GENETIC|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
48375623|NCT05549271|PROCEDURE|Laparoscopic Roux-en-Y Gastric ByPass (RYGBP)|The laparoscopic Roux-en-Y Gastric Bypass performed 5 years ago consisted of : a small gastric pouch (about 30cc), an antecolic alimentary limb, a gastro-jejunal anastomosis using a linear stapler, a 150cm long alimentary limb, a 50cm biliary limb, a latero-lateral jejuno-jejunal anastomosis, closure of the mesenteric defects.
48375624|NCT02788890|PROCEDURE|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
48375625|NCT02788890|PROCEDURE|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
48375626|NCT02788890|PROCEDURE|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
48375627|NCT04089657|DRUG|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
48375628|NCT04089657|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1
48375629|NCT02632773|BEHAVIORAL|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
48375630|NCT02632773|BEHAVIORAL|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
48707708|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
48707709|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|250 mg weekly x 4
48707710|NCT00223977|DRUG|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
48707711|NCT03510468|DRUG|Tenofovir alafenamide|Each tablet contains 25 mg of tenofovir alafenamide.
48707712|NCT03510468|DRUG|Rifapentine|Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
48707713|NCT03510468|DRUG|Isoniazid (INH)|Each tablet is formulated as 100 or 300 mg of isoniazid.
48707714|NCT03510468|DIETARY_SUPPLEMENT|Pyridoxine|Each tablet contains 50 mg of pyridoxine
48707715|NCT02978963|BEHAVIORAL|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
48375631|NCT04132206|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
48375632|NCT01420770|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
48375633|NCT00256256|DRUG|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
48375634|NCT04503109|DEVICE|Nalu Neurostimulation System|The Nalu Neurostimulation System is a Spinal Cord Stimulation system
48375635|NCT01222962|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
48375636|NCT03028324|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
48375637|NCT01278823|PROCEDURE|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
48375638|NCT01278823|OTHER|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
48375639|NCT00726882|PROCEDURE|Blood sample collection only|Approximately monthly collection of blood samples.
48375640|NCT00726882|DRUG|ABT-333|Previous treatment in prior ABT-333 studies.
48375641|NCT00592423|OTHER|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
48375642|NCT00938366|DRUG|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
48375643|NCT00938366|DRUG|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
48375644|NCT01280305|DRUG|raloxifene|raloxifene 60 mg bid
48375645|NCT01280305|DRUG|placebo|Placebo bid
48375646|NCT02816658|OTHER|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
48375647|NCT02816658|OTHER|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
48375648|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
48375649|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
48375650|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
48375651|NCT00822185|DRUG|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
48375652|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
48375653|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
48375654|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
48375655|NCT00822185|DRUG|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
48375656|NCT02477462|OTHER|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
48375657|NCT02477462|OTHER|Baseline visit|Blood draw and quality of life surveys
48375658|NCT02009072|PROCEDURE|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
48375659|NCT02009072|PROCEDURE|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
48375660|NCT00977600|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
48375661|NCT00977600|DRUG|Ammonul|
48375662|NCT00977600|DRUG|Buphenyl|
48375663|NCT01511367|DRUG|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
48375664|NCT01511367|DRUG|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
48375665|NCT01511367|DRUG|Flixotide|50ug 2 puffs twice daily
48375666|NCT00322517|DRUG|SU014813|100 mg capsule/day for 6 cycle of 21 days
48375667|NCT03832907|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
48375668|NCT03832907|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
48375669|NCT02046551|DRUG|Atomoxetine|
48375670|NCT02046551|DRUG|Placebo|
48375671|NCT01780948|DRUG|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
48375672|NCT01780948|DRUG|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
48517129|NCT02537691|DRUG|LTRA|LTRA will be administered as per investigator discretion.
48517130|NCT02537691|DRUG|LAMA|LAMA will be administered as per investigator discretion.
48517131|NCT02537691|DRUG|Theophylline|Theophylline will be administered as per investigator discretion.
48517132|NCT02537691|DRUG|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
48517133|NCT03781687|PROCEDURE|Bilateral ESP Block|Bilateral ESP Block will be performed at T8
48707716|NCT01297361|OTHER|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
48707717|NCT01259076|PROCEDURE|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
48707718|NCT01259076|PROCEDURE|digital mammography|Undergo digital mammography at baseline and 1 year later.
48707719|NCT01259076|PROCEDURE|conventional surgery|Undergo gastric bypass surgery
48707720|NCT00812201|DEVICE|No intervention is used. Collection of signals only.|Device received per standard of care.
48707721|NCT02144506|OTHER|T&E|
48707722|NCT02144506|OTHER|OTAGO|
48707723|NCT01605227|DRUG|cabozantinib|Tablets taken orally once-daily
48707724|NCT01605227|DRUG|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
48707725|NCT00504504|DRUG|Rituximab|375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
48707726|NCT00504504|DRUG|Adriamycin|25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
48707727|NCT00504504|DRUG|Bleomycin|10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
48707728|NCT00504504|DRUG|Vinblastine|6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
48707729|NCT00504504|DRUG|Dacarbazine (DTIC)|375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
48707730|NCT01054040|OTHER|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
48707731|NCT05539560|OTHER|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
48707732|NCT05539560|OTHER|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
48707733|NCT05496686|DRUG|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
48707734|NCT05496686|DRUG|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
48375673|NCT04293601|OTHER|interventional nursing care|"The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) \> 32 weeks (wks)~* Current weight \> 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration \> 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift"
48707735|NCT05496686|DRUG|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
48707736|NCT05496686|DRUG|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
48707737|NCT05496686|DRUG|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
48707738|NCT05496686|DRUG|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
48707739|NCT05496686|DRUG|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
48707740|NCT05496686|DRUG|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
48707741|NCT05496686|DRUG|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
48707742|NCT05496686|DRUG|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
48707743|NCT05496686|DRUG|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
48707744|NCT05496686|DRUG|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
48707745|NCT00112411|DRUG|Bronchodilator|
48707746|NCT03552536|DRUG|MK-8583|A single oral dose of MK-8583 in capsule form
48707747|NCT00932620|DRUG|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
48707748|NCT00932620|DRUG|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
48707749|NCT00025428|DRUG|carboplatin|
48707750|NCT00025428|DRUG|cyclophosphamide|
48707751|NCT00025428|DRUG|doxorubicin hydrochloride|
48707752|NCT00025428|DRUG|etoposide|
48707753|NCT00025428|DRUG|vincristine sulfate|
48707754|NCT00025428|PROCEDURE|adjuvant therapy|
48707755|NCT00025428|PROCEDURE|conventional surgery|
48707756|NCT00025428|PROCEDURE|neoadjuvant therapy|
48707757|NCT06552481|DEVICE|NP-PWD|Application of NP-PWD device.
48707758|NCT06552481|DEVICE|Wound Vac|Application of wound vac device.
48707759|NCT03549871|DRUG|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48707760|NCT03549871|DRUG|BPA prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
48707761|NCT03549871|DRUG|Factor (FVIII or FIX) prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
48707762|NCT06095882|OTHER|acupuncture|"Study group: Acupuncture treatment was performed from day 3 to day 14 after surgery. Points include: Zhongwan, Tianshu, Watercourse, Taichong, Sanyinjiao, Zusanli, Yin Lingquan.~Control group: No intervention, the urinary tube was removed until the 14th day after surgery. Patients with urinary retention may receive further acupuncture treatment."
48175296|NCT05806606|OTHER|Dyadic empowerment based heart failure management program|The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.
48175297|NCT05806606|OTHER|Dyadic education program|The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
48175298|NCT06145789|OTHER|standing powered wheelchair evaluation|standing powered wheelchair evaluation
48175299|NCT02977286|DRUG|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
48175300|NCT02977286|DRUG|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
48175301|NCT02977286|DRUG|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
48175302|NCT02977286|DRUG|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.
48175303|NCT02977286|DRUG|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
48375674|NCT04293601|OTHER|Standard nursing care|"* Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases"
48175304|NCT02977286|DRUG|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
48175305|NCT02977286|DRUG|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation.
48517134|NCT03781687|PROCEDURE|Unilateral ESP Block|Unilateral ESP Block will be performed at T8 (right side)
48707763|NCT04246333|OTHER|Mode of Delivery of Feeds|Eligible infants will be recruited and enrolled and randomized to either duodenal feeds (DF) or gastric feeds (GF), which will occur just prior to the infants advancing beyond 50mL/kg/day of enteral feeds. All enrolled infants will be fed per our institutional feeding protocol. Once infants advance past a volume of 50mL/kg/day of enteral feeds, at this point infants will be randomized to DF or GF groups.
48707764|NCT03872427|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48707765|NCT03872427|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48707766|NCT03872427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48707767|NCT03872427|OTHER|Pharmacodynamic Study|Correlative studies
48707768|NCT03872427|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48707769|NCT03872427|DRUG|Telaglenastat Hydrochloride|Given PO
48707770|NCT06159881|PROCEDURE|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
48707771|NCT01878617|RADIATION|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
48707772|NCT01878617|DRUG|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
48707773|NCT01878617|DRUG|Cisplatin|ROA: IV
48707774|NCT01878617|DRUG|Vincristine|ROA: IV
48707775|NCT01878617|DRUG|Vismodegib|ROA: Orally (PO)
48707776|NCT01878617|DRUG|Pemetrexed|ROA: IV
48707777|NCT01878617|DRUG|Gemcitabine|ROA: IV
48707778|NCT01878617|OTHER|Aerobic Training|
48707779|NCT01878617|OTHER|Neurocognitive Remediation|
48018290|NCT04898231|DRUG|Anakinra|Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.
48018291|NCT04898231|DRUG|Methylprednisolone|Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.
48018292|NCT03376204|OTHER|No intervention|No intervention
48707780|NCT00724269|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
48707781|NCT00724269|DEVICE|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
48707782|NCT02694913|OTHER|Non Interventional|This is a non therapeutic, pilot study.
48707783|NCT00524953|DEVICE|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
48018293|NCT04603924|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
48018294|NCT04603924|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
48018295|NCT01823029|DRUG|erythropoietin|
48707784|NCT02992951|DEVICE|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
48707785|NCT00060814|OTHER|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
48707786|NCT01618383|OTHER|colonoscopy or rectosigmoidoscopy|Usual procedure
48707787|NCT05581082|OTHER|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
48707788|NCT00881998|PROCEDURE|Minimally Invasive Total Hip Arthroplasty|
48707789|NCT00881998|PROCEDURE|Conventional Total Hip Arthroplasty|
48707790|NCT05384535|DIAGNOSTIC_TEST|Bi-parametric MRI|When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
48707791|NCT00688246|OTHER|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture \[Lønning 2005\]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk \[Looker 2000\]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
48018296|NCT01823029|DRUG|enteral nutrition.|
48018297|NCT01823029|DRUG|injection of iron|
48707792|NCT00688246|PROCEDURE|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
48707793|NCT02477735|DEVICE|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
48707794|NCT05783921|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
48707795|NCT05783921|DRUG|Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
48707796|NCT03010891|BEHAVIORAL|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC \> 45 minutes
48707797|NCT03010891|BEHAVIORAL|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
48707798|NCT00532025|DRUG|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
48707799|NCT06327555|BEHAVIORAL|the traditional rehabilitation group|The traditional rehabilitation group takes a face-to-face approach, with therapists providing outpatient rehabilitation instruction twice a week for six weeks.
48707800|NCT06327555|DEVICE|the remote rehabilitation group|The telerehabilitation group uses smart wearables and mobile apps worn around the knee joint to perform remote rehabilitation at home. At least twice a week, both sets of training sessions are identical.
48707801|NCT01212497|BEHAVIORAL|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
48375675|NCT05401552|OTHER|Meal|Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
48175306|NCT02977286|DRUG|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
48707802|NCT03274427|DEVICE|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
48707803|NCT03274427|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
48707804|NCT03274427|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
48707805|NCT02511483|DRUG|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
48707806|NCT02511483|DRUG|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
48707807|NCT02511483|DRUG|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
48175307|NCT01006499|DRUG|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
48175308|NCT03631303|DEVICE|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
48175309|NCT02876029|OTHER|Reference|the reference product used
48175310|NCT02876029|OTHER|Test product|The test Product used
48375676|NCT00118872|DRUG|LGG yogurt|Lactobacillus GG containing yogurt
48375677|NCT00118872|OTHER|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
48375678|NCT04973527|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
48375679|NCT00902759|OTHER|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
48375680|NCT05847023|BEHAVIORAL|LUNA|see description above
48375681|NCT06517706|COMBINATION_PRODUCT|Combination of tDCS (device) with cognitive training (behavioral)|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive two sessions of tDCS plus cognitive training with the Categorization Program
48707808|NCT02511483|PROCEDURE|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
48707809|NCT02511483|OTHER|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
48707810|NCT02511483|GENETIC|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
48175311|NCT02920255|OTHER|Diagnostic|Measurement of spinal tilt
48175312|NCT02743299|DEVICE|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
48707811|NCT03402971|DIAGNOSTIC_TEST|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
48707812|NCT03345160|DRUG|Peanut Flour|open label oral immunotherapy
48175313|NCT02620956|OTHER|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
48375682|NCT06517706|BEHAVIORAL|Categorization Program|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive cognitive training and sham tDCS
48375683|NCT00003266|DRUG|methylphenidate hydrochloride|
48375684|NCT00003266|PROCEDURE|quality-of-life assessment|
48375685|NCT02333110|RADIATION|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
48375686|NCT05347173|DRUG|Dexmedetomidine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 mL normal saline)
48375687|NCT05347173|DRUG|Nalbuphine|patients who will receive 2.5 mL hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5 mL normal saline)
48517135|NCT03781687|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
48517136|NCT02489097|DRUG|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
48517137|NCT02489097|OTHER|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
48707813|NCT02076269|OTHER|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
48707814|NCT00310284|BEHAVIORAL|Computerized delivery of cognitive-behavioral treatment of insomnia|
48175314|NCT05696223|OTHER|Ultrasound|Doppler mesure
48175315|NCT00433875|DRUG|AMG 714|
48175316|NCT04360798|OTHER|Unilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
48175317|NCT04360798|OTHER|Bilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
48175318|NCT01126320|DEVICE|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
48175319|NCT01126320|DEVICE|routine mechanical ventilator|routine mechanical ventilation
48175320|NCT04610632|DIAGNOSTIC_TEST|home pregnancy test|use of home pregnancy test
48707815|NCT00310284|BEHAVIORAL|Self-help manual to improve insomnia symptoms|
48707816|NCT04656041|DRUG|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2) Oxaliplatin via IV, predetermined dosage per protocol~* 3) Leucovorin via IV, predetermined dosage per protocol~* 4) 5-Fluorouracil via IV, predetermined dosage per protocol"
48707817|NCT04656041|DRUG|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
48707818|NCT04656041|DRUG|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
48707819|NCT04656041|RADIATION|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
48707820|NCT02281474|DRUG|Nilotinib|
48707821|NCT03176472|DRUG|ricolinostat|120 mg per dose in 12 mL liquid formulation
48707822|NCT03176472|DRUG|Placebo|12 mL liquid formulation placebo
48707823|NCT04185649|BIOLOGICAL|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
48707824|NCT04185649|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
48707825|NCT04185649|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
48707826|NCT03483038|DRUG|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
48707827|NCT03483038|DRUG|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
48707828|NCT04577755|PROCEDURE|Biopsy|Undergo tissue biopsy
48707829|NCT04577755|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48707830|NCT04577755|PROCEDURE|Computed Tomography|Undergo CT
48707831|NCT04577755|DRUG|Pomalidomide|Given PO
48707832|NCT04577755|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
48707833|NCT01730339|DRUG|PF-06473871|Single dose administered by injection four different times
48707834|NCT01730339|DRUG|PF-06473871|Single dose administered by injection three different times
48707835|NCT03332719|BIOLOGICAL|Etanercept|
48707836|NCT03332719|DRUG|Methotrexate|
48707837|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
48707838|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
48707839|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
48707840|NCT00068250|DRUG|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
48707841|NCT00068250|DRUG|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
48707842|NCT00068250|DRUG|temozolomide 100 mg/m^2|Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
48707843|NCT00068250|DRUG|temozolomide 150 mg/m^2|Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
48707844|NCT00068250|DRUG|temozolomide 200 mg/m^2|Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
48707845|NCT00068250|RADIATION|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
48707846|NCT00068250|DRUG|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
48707847|NCT04882644|BEHAVIORAL|Aerobic Exercise|The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.
48707848|NCT00497549|PROCEDURE|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
48707849|NCT00497549|PROCEDURE|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
48707850|NCT05061108|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education
48707851|NCT06607861|DRUG|saline group|nebulization of 4 mL 0.9% saline twice daily
48707852|NCT06607861|DRUG|dexmedetomidine group|nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
48707853|NCT06607861|DRUG|lidocaine group|bilateral nebulization (60 mg) using a mucosal atomization device twice daily
48018298|NCT05513638|DIAGNOSTIC_TEST|the clinical use of artificial intelligence in the diagnosis of prostate cancer|Each study site will enroll consecutive eligible patients and randomize them to either (a) a group with human-based interpretation or (b) a group with human-artificial intelligence interactive interpretation, both of which are utilized as standards of care.
48018299|NCT05565586|DIETARY_SUPPLEMENT|High-Fiber Diet (HFD)|Participants are assigned to the high fiber diet, all meals and snacks will be provided to participants during the study. This diet includes fruits, vegetables and whole grains, a maximum of 18 oz. cooked red meat (including beef, pork, and lamb) per week, and little or no processed meats or added sugars.
48018300|NCT05565586|DIETARY_SUPPLEMENT|Prebiotic Food-Enriched Diet (PreFED)|Participants are assigned to the prebiotic food enriched diet, participants will receive 2 prepared snacks and 1 meal component (a key prebiotic ingredient to incorporate into meals and simple recipes) each day. Participants will also receive a handout that includes key prebiotic foods to incorporate into your own diet.
48018301|NCT03181516|BIOLOGICAL|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
48018302|NCT03181516|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
48018303|NCT05943301|BEHAVIORAL|Self-hypnosis/self-care|Learning phase of self-hypnosis/self-care
48018304|NCT05647824|DEVICE|Capillary Testing|Testing Contour Fit BGMS with capillary blood
48018305|NCT05647824|DEVICE|Alternative Site Testing (AST)|Testing Contour Fit BGMS using blood from alternative site
48018306|NCT05647824|DEVICE|Venous Testing|Testing Contour Fit BGMS with venous blood
48018307|NCT03433456|BEHAVIORAL|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
48175321|NCT01128114|DRUG|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
48175322|NCT05364034|OTHER|Urban Afforestation Intervention Program|An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
48175323|NCT00966030|DRUG|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
48517138|NCT04555317|COMBINATION_PRODUCT|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
48175324|NCT00966030|DRUG|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
48175325|NCT00478647|BIOLOGICAL|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
48707854|NCT02994953|DRUG|Avelumab|Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
48707855|NCT02994953|DRUG|M9241|Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
48707856|NCT02994953|DRUG|Avelumab (Once weekly)|Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
48707857|NCT02994953|DRUG|M9241 (MTD)|Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
48707858|NCT02994953|DRUG|Avelumab (Expansion cohort)|Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
48707859|NCT05976503|DRUG|Tunodafil Hydrochloride Tablets|100mg Tunodafil Hydrochloride Tablets
48707860|NCT05976503|DRUG|Placebo|Placebo
48707861|NCT05976503|OTHER|Alcohol|0.5 g/kg alcohol
48018308|NCT03433456|BEHAVIORAL|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
48018309|NCT01208233|DRUG|PF-03049423|1 mg of PF-03049423 daily for 90 days
48018310|NCT01208233|DRUG|PF-03049423|3 mg of PF-03049423 daily for 90 days
48375688|NCT03334201|OTHER|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
48707862|NCT05664295|DIAGNOSTIC_TEST|Jenkins Sleep Disorders scale and Epworth Sleepiness scale|Jenkins Sleep Disorders scale and Epworth Sleepiness scale
48707863|NCT06353256|BEHAVIORAL|usual postpartum care|Usual clinical and educational postpartum care
48707864|NCT06353256|BEHAVIORAL|usual postpartum care + community health worker intervention|participants will receive routine care and also community health worker support and visits.
48707865|NCT03697499|COMBINATION_PRODUCT|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
48707866|NCT03697499|COMBINATION_PRODUCT|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
48707867|NCT03697499|COMBINATION_PRODUCT|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
48707868|NCT03697499|COMBINATION_PRODUCT|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
48707869|NCT03892083|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, including children with cerebral palsy.
48707870|NCT05346991|OTHER|Tobacco Free Teachers, Tobacco Free Society program|"The Tobacco Free Teachers, Tobacco Free Society (TFT-TFS) program provides teachers with the knowledge and skills to quit tobacco use, or to help someone else quit; it also helps schools comply with national tobacco control policies. School principals implement four TFT-TFS program components with teachers in their schools during school hours across an academic year (August-April):~* Adopting a school tobacco control policy~* Providing cessation support (e.g. distribution of self-help quit booklets and referrals to government cessation resources)~* Conducting monthly group discussions with teachers about tobacco~* Hanging six thematic posters in the school~With the goal of establishing a tobacco-free school environment, the program incorporates six program themes: 1. Teachers as Role Models; 2. Health Effects of Tobacco; 3. Motivation to Quit-or Help Others to Quit; 4. Skills to Quit; 5. Dealing with Withdrawal; and 6. Maintenance and Celebration."
48707871|NCT00717522|DRUG|Pomalidomide|
48018311|NCT01208233|DRUG|PF-03049423|6 mg of PF-03049423 daily for 90 days
48018312|NCT01208233|OTHER|Placebo|Placebo of PF-03049423 daily for 90 days
48018313|NCT00501150|DRUG|linezolid|Linezolid is an antimicrobial with activity against MRSA that can be given orally.
48707872|NCT04862234|DRUG|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
48707873|NCT04862234|DRUG|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
48018314|NCT04604522|PROCEDURE|Biospecimen Collection|Undergo collection of blood, airway brushings.
48018315|NCT04604522|OTHER|Medical Chart Review|Patients' medical records are reviewed
48018316|NCT00014534|BIOLOGICAL|filgrastim|6 mg sub Q
48707874|NCT04862234|DEVICE|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
48018317|NCT00014534|DRUG|cisplatin|60 mg/sq m IV
48018318|NCT00014534|DRUG|doxorubicin hydrochloride|50 mg/ sq m IV
48018319|NCT00014534|DRUG|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
48018320|NCT02663128|DRUG|Lanabecestat|Administered orally
48018321|NCT03394300|OTHER|iol power calculation|iol power calculation in high myopia
48018322|NCT01070004|OTHER|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
48175326|NCT04765410|DIAGNOSTIC_TEST|EUS FNA (endoscopic ultrasound fine needle aspiration)|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
48175327|NCT02420405|PROCEDURE|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
48375689|NCT03334201|OTHER|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
48375690|NCT00968565|DRUG|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
48375691|NCT03078504|DEVICE|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
48517139|NCT06581991|DIETARY_SUPPLEMENT|Valine oral solution (50mg/ml) and isoleucine oral solution (25mg/ml)|Subjects will take valine oral solution (50mg/ml) in place of usual powdered valine supplement for 28 days. Subjects will then take isoleucine oral solution (25mg/ml) in place of their usual powdered isoleucine supplement for 28 days.
48175328|NCT02420405|PROCEDURE|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
48707875|NCT04875507|BEHAVIORAL|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
48707876|NCT05362227|DRUG|Low volume macrogol|Clensia 2 lt
48707877|NCT05362227|DRUG|High volume macrogol|Selg 4 lt
48707878|NCT03610581|BIOLOGICAL|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
48707879|NCT03610581|BIOLOGICAL|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
48707880|NCT03610581|BIOLOGICAL|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
48018323|NCT01070004|OTHER|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2\*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
48018324|NCT01871948|OTHER|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
48018325|NCT05795933|DRUG|Vitamin D3|A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
48175329|NCT00228098|BEHAVIORAL|Smoking cessation|
48175330|NCT04055259|BEHAVIORAL|mobile Health and Wellness Coaching|Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
48375692|NCT06274281|DEVICE|Digital Telerehabilitation|"The 5-day rehabilitation program will consist of exercises to re-establish standard movement patterns within a multidisciplinary etiological framework, according to a validated rehabilitation protocol for FMDs. Treatment will be tailored to the needs of each patient, following general treatment principles in physiotherapy for FMDs.~Telemedicine sessions: the patient will perform specific exercises under the supervision of a qualified physiotherapist to provide feedback on the execution and adapt the treatment according to clinical changes/improvements.~Wearable devices: each patient in the experimental group will receive 2 wearable sensors (Axivity AX3,) for monitoring of movement data (i.e., activity level, number of steps, distance travelled) during daylife activities and rehabilitation sessions. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level."
48018326|NCT04475445|OTHER|Ultrasound-guided transforaminal epidural steroid injection|Ultrasound identification of the nerve root, fluoroscopic control of the position and injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
48517140|NCT01932333|DRUG|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
48517141|NCT01932333|DRUG|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
48707881|NCT03610581|BIOLOGICAL|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
48707882|NCT02430948|OTHER|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
48018327|NCT04475445|OTHER|Interlaminar epidural steroid injection|Fluoroscopic location of the epidural space C5C6 or C6C7, injection of a mixture of 10 mg of dexamethasone and 20 mg of lidocaine.
48707883|NCT02430948|OTHER|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
48707884|NCT02430948|OTHER|Standard support|Screening recommendations presented in standard format
48707885|NCT02430948|OTHER|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
48707886|NCT00869245|OTHER|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
48707887|NCT00869245|OTHER|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
48175331|NCT04055259|BEHAVIORAL|Usual Care|Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
48707888|NCT02029716|DRUG|RTA 408 Lotion 0.5%, 1%, 3%|
48707889|NCT02029716|DRUG|Lotion vehicle/placebo|
48707890|NCT05616819|OTHER|Active light exposure|Active light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
48707891|NCT05616819|OTHER|Placebo light exposure|Placebo light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
48707892|NCT04006613|OTHER|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
48707893|NCT04006613|OTHER|Usual Care|Exercises aimed at improving mobility and balance
48707894|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
48707895|NCT00837824|BIOLOGICAL|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
48707896|NCT01065051|DRUG|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
48707897|NCT01065051|DRUG|Placebo|Single oral dose
48375693|NCT06274281|OTHER|Usual care|The 5-day rehabilitation program will be the same as the telemedicine group. A self-management paper log will be given to the patient at the end of the 5-day rehabilitation program. It will include goals, activity plans, and strategies to be used for retraining movements and redirecting attention. Videos stored on the patients' digital device (i.e., tablet, mobile) will include exercises demonstration and execution and strategies to retrain movements. Patients will be encouraged to perform the self-management plan at home on their own (or with their caregivers' help) which will be reported in a paper log and video recorded. The subjective assessment of the patient's motor activity will be collected by clinical diaries focusing on gait and activity level.
48707898|NCT00649766|BEHAVIORAL|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
48707899|NCT00649766|BEHAVIORAL|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
48707900|NCT03099941|OTHER|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
48707901|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
48707902|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
48707903|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
48707904|NCT01559259|DRUG|Ibuprofen|Two caplets of ibuprofen 200 mg
48707905|NCT01559259|DRUG|Placebo|Two caplets of placebo
48375694|NCT02219477|DRUG|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
48707906|NCT04060381|DRUG|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
48707907|NCT00969761|DRUG|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
48707908|NCT00969761|DRUG|BI 6727|low to high dose
48707909|NCT06606392|DEVICE|Biodex balance system|The Biodex Balance System has a wide range of clinical applications and provides objective measures from testing that can be used to establish progressions and discharge criteria, as well as be part of a comprehensive Fall Risk Assessment or Fall Screening Program. Balance ability can be assessed either statically or dynamically, as well as bilaterally and unilaterally. It also allows for bilateral comparisons between involved and uninvolved limbs.
48707910|NCT06606392|OTHER|Short Foot Exercise|Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
48707911|NCT06606171|BEHAVIORAL|Chair Sitting (30 minutes)|This intervention involves a single session of chair sitting for 30 minutes, where participants will sit in a standardized non-swivel chair and perform desk-based activities like computer use.
48707912|NCT06606171|BEHAVIORAL|Floor Sitting (30 minutes)|This intervention entails a single session of floor sitting for 30 minutes, with participants seated on a cushioned mat performing similar desk activities as in the chair sitting session.
48707913|NCT06606171|BEHAVIORAL|Daily Floor Sitting Practice (1 month)|Participants will be instructed to incorporate at least one hour of floor sitting into their daily routine for a duration of one month.
48707914|NCT00834990|DRUG|divalproex sodium|delayed-release 500 mg tablet
48707915|NCT00834990|DRUG|Depakote®|delayed-release 500 mg tablet
48707916|NCT02438956|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
48707917|NCT02438956|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
48707918|NCT04683081|DEVICE|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
48707919|NCT03115853|DRUG|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
48707920|NCT03115853|DRUG|Placebo|Placebo tablet for Aliskerin
48707921|NCT03115853|DRUG|HCTZ|HCTZ 25mg every day for 18 weeks
48707922|NCT03115853|DRUG|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
48707923|NCT02567682|DRUG|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
48018328|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
48175332|NCT04964895|OTHER|Questionnaires|"Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)"
48175333|NCT00233662|DRUG|Alefacept|
48375695|NCT02219477|DRUG|dasabuvir|tablet
48707924|NCT00002849|BIOLOGICAL|recombinant interferon alfa|first 2 years
48707925|NCT00002849|DRUG|dexamethasone|40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
48018329|NCT03834194|BEHAVIORAL|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
48175334|NCT03765398|BEHAVIORAL|VR Cognitive-motor-balance training|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
48175335|NCT04633954|DRUG|Brimonidine Tartrate 0.15% Oph Soln|One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
48175336|NCT03282981|DRUG|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
48175337|NCT03282981|DRUG|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
48175338|NCT03482947|DRUG|ultrasonography-guided TAP block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
48175339|NCT03482947|DRUG|Caudal epidural block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
48707926|NCT02117895|PROCEDURE|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
48707927|NCT02117895|PROCEDURE|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
48707928|NCT03962257|OTHER|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
48707929|NCT02032693|DIETARY_SUPPLEMENT|Everycell™|
48707930|NCT02032693|OTHER|Placebo|
48707931|NCT02736266|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
48018330|NCT03834194|BEHAVIORAL|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
48018331|NCT03834194|BEHAVIORAL|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
48175340|NCT03948464|DRUG|Slow release oral morphine (SROM)|Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
48175341|NCT03948464|DRUG|Methadone|Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
48175342|NCT01963715|DRUG|IMGN289|
48707932|NCT00994734|DRUG|Mifepristone|home administration of mifepristone
48707933|NCT00321958|DEVICE|CSA System (CryoSpray AblationTM System)|10 second spray times
48175343|NCT06034899|DRUG|BMS-986196|Specified dose on specified days
48175344|NCT01530386|DRUG|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
48175345|NCT04157023|DEVICE|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
48175346|NCT02594410|DEVICE|stent|patients receiving renal artery stenting for renal artery atherosclerosis
48175347|NCT02594410|DRUG|Aspirine|100mg Qd
48175348|NCT02594410|DRUG|Clopidogrel|75mg Qd
48175349|NCT02594410|DRUG|Lercanidipine|10-20mg Qd
48175350|NCT05038709|DEVICE|The Pink Pad Hip Kit|The pad is placed between the patient and the traction table to reduce pressure to the pudendal nerve exerted by the perineal post.
48375696|NCT02219477|DRUG|ribavirin|tablet
48707934|NCT00321958|DEVICE|CryoSpray Ablation|10 second spray times
48707935|NCT06599983|OTHER|Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.|One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
48707936|NCT03581539|PROCEDURE|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
48707937|NCT03581539|PROCEDURE|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
48707938|NCT03581539|PROCEDURE|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
48707939|NCT01676753|DRUG|Dinaciclib|Given IV
48707940|NCT01676753|DRUG|Pembrolizumab|Given IV
48707941|NCT04098237|DRUG|Pancrelipase|Pancrelipase delayed-release capsules
48707942|NCT00086801|DRUG|doxorubicin hydrochloride|given IV
48707943|NCT00086801|DRUG|gemcitabine hydrochloride|given IV
48707944|NCT00086801|DRUG|vinblastine|given IV
48707945|NCT00086801|PROCEDURE|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
48707946|NCT00086801|PROCEDURE|CT scan|
48707947|NCT02885454|DRUG|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
48018332|NCT03834194|BEHAVIORAL|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
48018333|NCT03834194|BEHAVIORAL|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
48375697|NCT03378024|DEVICE|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
48707948|NCT02885454|DRUG|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
48707949|NCT02885454|DRUG|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
48707950|NCT02885454|DRUG|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
48707951|NCT01025076|DEVICE|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
48707952|NCT05970133|PROCEDURE|Colectomy with NOSE procedure|The specimen will be extract from the anus.
48707953|NCT04080479|DIAGNOSTIC_TEST|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
48707954|NCT04080479|DIAGNOSTIC_TEST|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
48707955|NCT04080479|DIAGNOSTIC_TEST|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
48707956|NCT04080479|DIAGNOSTIC_TEST|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
48018334|NCT03834194|BEHAVIORAL|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
48018335|NCT03834194|BEHAVIORAL|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
48175351|NCT00151827|DRUG|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
48707957|NCT04080479|DIAGNOSTIC_TEST|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
48707958|NCT04080479|DIAGNOSTIC_TEST|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
48707959|NCT05718752|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
48707960|NCT05718752|DIAGNOSTIC_TEST|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
48707961|NCT06608446|OTHER|Telerehabilitation|"The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session."
48707962|NCT06608446|OTHER|Standard Care|Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
48707963|NCT05899595|OTHER|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
48707964|NCT06491563|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
48707965|NCT06491563|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
48707966|NCT06491563|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
48707967|NCT02524015|OTHER|Novel physical therapy|
48707968|NCT02524015|OTHER|Standard physical therapy|
48175352|NCT00151827|DRUG|Losartan|Medications are taken once daily before breakfast with water.
48707969|NCT05746650|PROCEDURE|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
48707970|NCT05746650|DRUG|Growth hormone (somatropin)|Daily injection of growth hormone
48707971|NCT05746650|OTHER|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
48707972|NCT04050696|DEVICE|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
48707973|NCT02629848|DRUG|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
48707974|NCT02629848|DRUG|Placebo|Motesanib placebo-matching tablets
48707975|NCT02629848|DRUG|Paclitaxel|Paclitaxel IV
48175353|NCT00151827|DRUG|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
48375698|NCT06422299|BEHAVIORAL|Online, couples-based intervention|During Phase 1 of the present study, the intervention will be iteratively developed using a rigorous, user-centered design approach through integration of knowledge gained from Phase 1 dyadic analyses and qualitative interviews, and existing gold-standard treatments for substance use among couples, including Integrative Behavioral Couples Therapy (IBCT; Christensen \& Doss, 2016) and Behavioral Couples Therapy for Alcohol (ABCT; McCrady et al, 1995) and substance use brief interventions for young adults (Halladay, et al., 2019; Tanner-Smith et al., 2015).
48175354|NCT04674878|OTHER|METs|The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
48375699|NCT05290636|OTHER|Teaching intervention program|Using an action research approach, The investigators designed a pair of geriatric nursing and practicum courses and recruited a class of in-service nursing students through convenience sampling in a college setting. The intervention was an 18-week course in geriatric nursing that meets once a week in the classroom and internship practice in settings used for training nursing students. The investigators collected data using quantitative indicators (attitude measurements) and qualitative textual analysis. The quantitative data were analyzed by paired t-testing using SPSS 21.0 software.
48707976|NCT02629848|DRUG|Carboplatin|Carboplatin IV
48707977|NCT02202512|DRUG|Placebo|tablets
48707978|NCT02202512|DRUG|Cimetidine|
48707979|NCT02202512|DRUG|Placebo|tablets
48707980|NCT02202512|DRUG|Placebo|tablets
48707981|NCT02202512|DRUG|BI 1060469 high dose|tablets
48707982|NCT02202512|DRUG|BI 1060469 low dose|tablets
48707983|NCT02202512|DRUG|Naproxen|
48707984|NCT02202512|DRUG|BI 1021958|tablets
48707985|NCT03751358|PROCEDURE|Unilateral Erector spinae plane block|Magnetic résonance imaging
48707986|NCT06440889|DEVICE|Bio-Ray Knee Guard|Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
48707987|NCT03094364|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
48707988|NCT05941338|DRUG|Tirelizumab ,+Carboplatin+albumin-bound paclitaxel|Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
48707989|NCT05402176|OTHER|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
48707990|NCT04131205|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
48707991|NCT04962841|OTHER|Nutraceuticals|To observe the effect on cognitive and physical impairment.
48707992|NCT04092907|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
48707993|NCT04092907|DRUG|placebo|Ophthalmic Solution
48707994|NCT06606236|OTHER|H2O2 at 35% for 8 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
48707995|NCT06606236|OTHER|H2O2 at 40% for 20 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
48707996|NCT06606236|OTHER|H2O2 at 25% plus cold blue light for 15 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
48707997|NCT05491369|OTHER|Epilepsy application|Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
48707998|NCT01900106|DRUG|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
48707999|NCT01900106|DRUG|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
48708000|NCT06607367|DRUG|Ruxolitinib (JAKAVI®)|Initial starting dose will be 10mg BD
48375700|NCT04908696|PROCEDURE|routines|"For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoepiglottopexy, cricohyoidopexy, horizontal partial laryngectomy), partial hypopharyngectomy, radiotherapy, and transoral robotic surgery were performed for patients with proper indications (NCCN 2020).~For advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, concurrent chemoradiotherapy, neoadjuvant therapy + radiotherapy/chemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy were performed for patients with proper indications (NCCN 2020)."
48018336|NCT05573295|OTHER|Diagnostic Test: Willems method|Willems method measures the developmental stages of the seven left permanent mandibular teeth and is frequently used for dental age estimation. The score of each stage is allocated, and the sum of the scores provides an evaluation of the subject's dental maturity.
48018337|NCT05573295|OTHER|Diagnostic Test: Cameriere method|Cameriere et al. designed a quantitative approach through a formula based on sex and the ratio between length and apex opening measurements of each lower left tooth.
48375701|NCT01545375|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
48375702|NCT01545375|BIOLOGICAL|Placebo|4 doses administered intramuscularly
48375703|NCT01545375|BIOLOGICAL|Prevnar 13®|4 doses administered intramuscularly
48375704|NCT01545375|BIOLOGICAL|PedvaxHIB®|4 doses administered intramuscularly
48708001|NCT06607367|DRUG|Eltrombopag (Revolade®)|Initial starting dose will be 50mg daily
48708002|NCT06608784|DIAGNOSTIC_TEST|Electrocardiography|12-lead electrocardiography
48708003|NCT01089023|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
48708004|NCT04284124|OTHER|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
48708005|NCT02181361|DRUG|hirudin plus aspirin|natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
48375705|NCT03863821|DEVICE|HHHFNC|"HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT"
48375706|NCT02226380|DRUG|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
48375707|NCT02824042|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
48375708|NCT02824042|DRUG|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
48708006|NCT02181361|DRUG|Warfarin|an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
48708007|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
48375709|NCT04249908|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d.
48708008|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
48517142|NCT01932333|DRUG|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
48708009|NCT00355537|DRUG|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
48708010|NCT00355537|DRUG|0.9% saline|Saline injection intramuscular every 2 weeks
48708011|NCT02928029|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
48708012|NCT02928029|DRUG|Placebo|Matching placebo
48708013|NCT02928029|DRUG|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
48708014|NCT02928029|DRUG|Dexamethasone|Dexamethasone is administered orally at 40 mg
48708015|NCT02590822|DIETARY_SUPPLEMENT|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
48375710|NCT05554666|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
48517143|NCT03032679|OTHER|Non interventional study|No intervention
48517144|NCT05347329|DIETARY_SUPPLEMENT|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
48708016|NCT02590822|OTHER|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
48708017|NCT04975737|BIOLOGICAL|GamTBvac|The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
48708018|NCT04975737|BIOLOGICAL|Placebo|Placebo for subcutaneous administration
48708019|NCT04531358|DEVICE|nasal spray|application of nasal spray
48708020|NCT04531358|OTHER|no treatment|no treatment
48517145|NCT03832205|DEVICE|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
48517146|NCT03249532|DEVICE|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
48517147|NCT03249532|DEVICE|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
48517148|NCT03249532|DEVICE|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
48517149|NCT03249532|DEVICE|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
48708021|NCT02956044|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
48708022|NCT02956044|DRUG|Metformin|1000 mg metformin
48708023|NCT02956044|DRUG|Glimepiride|4 mg glimepiride
48708024|NCT02956044|DRUG|Sitagliptin|100 mg sitagliptin
48375711|NCT04551326|OTHER|manual hamstring stretching|Participants' lower limb will be positioned in maximal hip flexion and gradually moved to maximal knee extension by physical therapist. The procedure will take one minute for each lower limb.
48517151|NCT05985629|DRUG|IPACK|Infiltration between the popliteal artery and capsules of the knee (IPACK) is a novel ultrasound-guided technique that provides additional regional analgesic relief to the posterior aspect of the knee without complications seen in a sciatic nerve block. The intention of the IPACK block is to anesthetize the terminal sensory nerves while sparing the main trucks of the common peroneal and tibial nerves.
48517152|NCT05985629|DRUG|PLACEBO|The control group will receive the normal pre-procedure care including a pre-operative visit, surgery, and post-operative care. The control group will receive a sham block consisting of saline in the same anatomical location and manner that the intervention IPACK block is administered.
48517153|NCT03867747|RADIATION|Cardiac Radiosurgery|Image-guided stereotactic body radiation therapy
48517154|NCT05936515|OTHER|Training of nurses and nursing assistants|Training of nurses and nursing assistants, based on the model of hygiene correspondents, in order to disseminate good geriatric practices
48018338|NCT05573295|OTHER|Diagnostic Test: London Atlas method|The London Atlas requires the user to assess the tooth development and eruption and then match it to one of the 31 pictures of age categories.
48018339|NCT00273364|PROCEDURE|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
48018340|NCT00273364|DRUG|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
48018341|NCT06339034|DIETARY_SUPPLEMENT|Lithium|5mg of elemental lithium/capsule
48018342|NCT06339034|OTHER|Placebo|Cellulose-filled capsules
48375712|NCT05868031|OTHER|alternative teaching methods|This study aimed to explore the potential benefits of alternative teaching methods in anatomy education, as well as to investigate the effectiveness of traditional lecture-based education in comparison. By examining the outcomes of these different approaches, we hope to understand better how students can best learn and retain knowledge in this field.
48375713|NCT02804295|OTHER|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
48375714|NCT05466916|BEHAVIORAL|Exercise and diet education and instruction|1:1 or small group sessions consisting of educational materials and exercise instruction.
48708025|NCT02386891|OTHER|Thermal Environment|
48708026|NCT03289221|DIAGNOSTIC_TEST|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
48708027|NCT00916058|DRUG|Bendamustine|30 mg/m\^2 given on day 2 of melphalan
48708028|NCT00916058|DRUG|Melphalan|100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)
48708029|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 2nd day of melphalan
48708030|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 2nd day of melphalan
48708031|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 1st and 2nd day of melphalan
48708032|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan
48708033|NCT00916058|DRUG|Bendamustine|125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
48708034|NCT00004480|DRUG|botulinum toxin type A|
48708035|NCT03465462|DIETARY_SUPPLEMENT|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
48708036|NCT03465462|DIETARY_SUPPLEMENT|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
48708037|NCT03465462|DIETARY_SUPPLEMENT|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
48708038|NCT01760330|DRUG|IV acetaminophen|
48708039|NCT01760330|DRUG|Placebo|
48708040|NCT05544045|DEVICE|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio \< 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
48708041|NCT02055261|DEVICE|Low frequency DBS of the pedunculopontine nucleus|
48375715|NCT06014515|DRUG|18F-FDG|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
48375716|NCT06014515|DRUG|11C-butanol|Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to two weeks depending on subject, imaging agent and scanner availability.
48375717|NCT00296777|DRUG|Escitalopram|8 weeks: up to 40 mg/day
48375718|NCT00296777|DRUG|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
48375719|NCT00296777|DRUG|Imipramine|"8 weeks: up to 300mg/day~\*if patient does not have contraindication."
48708042|NCT02024269|BIOLOGICAL|Adipose Derived Stem Cells|
48708043|NCT05327634|OTHER|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
48708044|NCT00934947|DRUG|Propranolol|40 mg
48375720|NCT00314262|DRUG|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
48375721|NCT05211284|DRUG|Saroglitazar Magnesium 4 mg|Subjects randomized to Saroglitazar Magnesium 4 mg arm will receive Saroglitazar Magnesium 4 mg treatment until the duration of study (24 weeks).
48375722|NCT05211284|DRUG|Placebo|Subjects randomized to Placebo arm will receive Placebo treatment until the duration of study (24 weeks).
48375723|NCT05033795|DIETARY_SUPPLEMENT|Water A|2 L of water A per day
48708045|NCT00934947|DRUG|Placebo|sugar pill
48708046|NCT00934947|DRUG|Propanolol|120 mg twice per day
48708047|NCT00906451|DRUG|Simvastatin|Simvastatin
48375724|NCT05033795|DIETARY_SUPPLEMENT|Water B|2 L of water B per day
48375725|NCT02010671|OTHER|Survey|Survey
48517155|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.5 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a placebo group
48708048|NCT01888731|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
48708049|NCT06086652|DIAGNOSTIC_TEST|PET/CT|detection of possible primary tumor
48708050|NCT06225648|OTHER|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
48708051|NCT00096499|DRUG|ispinesib|Given IV
48708052|NCT00096499|OTHER|pharmacological study|Correlative studies
48708053|NCT00096499|OTHER|laboratory biomarker analysis|Correlative studies
48708054|NCT03484832|DEVICE|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
48708055|NCT03484832|OTHER|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
48708056|NCT03484832|OTHER|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
48175355|NCT04674878|OTHER|Breathing exercise group|Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
48175356|NCT04510610|DRUG|Camrelizumab and Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
48175357|NCT02422225|DEVICE|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention\]~* Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~* Stimulation site \<Experimental group\>~  * Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~ * Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~ * Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit \<Control group\> Sham stimulation"
48517156|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.75 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
48517157|NCT05134363|DRUG|Placebo|equal volume of normal saline
48517158|NCT01476514|OTHER|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
48708057|NCT03484832|DRUG|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
48018343|NCT05240534|BEHAVIORAL|ET-Text (Laptop)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop."
48018344|NCT05240534|BEHAVIORAL|ET-Voice (Smart System)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience."
48018345|NCT06270303|PROCEDURE|Access flap & surgical debridement|Following surgical exposure, roots are carefully debrided.
48018346|NCT06270303|PROCEDURE|Application of bone substitute material (BioOss Collagen)|Following surgical debridement, the bone substitute material is applied to the furcation defect.
48018347|NCT03980847|DRUG|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
48018348|NCT03980847|PROCEDURE|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
48018349|NCT06053658|DRUG|Tivozanib|Given by PO
48018350|NCT06053658|DRUG|Nivolumab|Given by IV (vein)
48018351|NCT01581593|BIOLOGICAL|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
48018352|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
48018353|NCT01494779|DRUG|Somatropin|single subcutaneous dose of 5mg
48018354|NCT03403634|DRUG|Celecoxib|Given PO
48018355|NCT03403634|OTHER|Laboratory Biomarker Analysis|Correlative studies
48018356|NCT03403634|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
48018357|NCT03403634|DRUG|Rintatolimod|Given IV
48175358|NCT02422225|DEVICE|Sham Eldith DC-STIMULATOR|
48175359|NCT02812875|DRUG|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
48175360|NCT06511518|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioural therapy (CBT) is a therapy that can help you manage your problems by changing the way you think and behave.
48175361|NCT00107978|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
48175362|NCT00107978|DRUG|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
48175363|NCT00000505|DRUG|tissue plasminogen activator|
48175364|NCT00000505|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
48175365|NCT03842436|DEVICE|Digital pill|Digital pills over encapsulating Truvada
48375726|NCT01315626|OTHER|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
48175366|NCT03842436|DRUG|Truvada|Truvada prescribed with digital pills for PrEP
48175367|NCT01140282|OTHER|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
48175368|NCT01140282|PROCEDURE|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
48018366|NCT06311994|DEVICE|Virtual reality|"Factors that may affect patient compliance with the VR-based intervention method to be applied to patients undergoing knee surgery and the factors that may affect the measurements to be performed were evaluated through a literature review and inclusion and exclusion criteria were created."
48018367|NCT00720616|DRUG|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
48018368|NCT04955808|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
48018369|NCT04955808|OTHER|Laboratory Biomarker Analysis|Correlative studies
48708058|NCT00402714|PROCEDURE|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
48708059|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
48708060|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
48708061|NCT00402714|DRUG|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
48708062|NCT00402714|RADIATION|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
48708063|NCT04347473|DRUG|Ilumya Injectable Product|IL-23 injection
48708064|NCT06607250|RADIATION|MRI|All enrolled patients underwent multiparametric magnetic resonance imaging, encompassing T2-weighted imaging (T2WI) and magnetic resonance diffusion-weighted imaging (DWI), in the coronal, sagittal, and axial planes.
48708065|NCT05041595|DIAGNOSTIC_TEST|Lyme diagnostic assay|Serological and immunoresponse assay
48708066|NCT04465435|OTHER|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
48708067|NCT04465435|OTHER|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
48708068|NCT06605963|DRUG|PPV-06|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
48708069|NCT06605963|DRUG|Placebo|6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
48708070|NCT01373684|DRUG|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
48708071|NCT01373684|DRUG|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
48708072|NCT03871101|PROCEDURE|Scalpel|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
48708073|NCT03871101|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
48708074|NCT05544292|OTHER|Antiinflammatory/DMARDs|Antiinflammatory/DMARDs
48708075|NCT03073018|DRUG|Fosinopril|oral administration, capsules
48708076|NCT03073018|DRUG|Pravastatin|oral administration, capsules
48708077|NCT03073018|DRUG|Fosinopril Placebo|oral administration, capsules
48708078|NCT03073018|DRUG|Pravastatin Placebo|oral administration, capsules
48708079|NCT03003078|DEVICE|OncoSil™|The implantation of OncoSil™
48708080|NCT04332939|OTHER|transcranial direct current stimulation|real tDCS sessions
48708081|NCT04332939|OTHER|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
48708082|NCT00309712|DRUG|fenofibrate 160 mg and placebo|
48708083|NCT00309712|DRUG|simvastatin 20 mg and placebo|
48708084|NCT00309712|DRUG|fenofibrate 160 mg and simvastatin 20 mg|
48708085|NCT02198482|DRUG|Volasertib|
48708086|NCT02198482|DRUG|Cytarabine|
48708087|NCT02198482|DRUG|Daunorubicin|
48708088|NCT02198482|DRUG|Mitoxantrone|
48708089|NCT04214483|OTHER|No intervention|There is no intervention for this study.
48708090|NCT04710641|DRUG|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
48708091|NCT04710641|DRUG|Sorafenib|Oral adminstration twice a day
48708092|NCT03784846|BEHAVIORAL|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
48708093|NCT03784846|BEHAVIORAL|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
48708094|NCT00110071|DRUG|fludarabine phosphate|Given IV
48708095|NCT00110071|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
48708096|NCT00110071|RADIATION|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
48708097|NCT00110071|OTHER|laboratory biomarker analysis|Correlative studies
48708098|NCT00110071|OTHER|flow cytometry|Correlative studies
48708099|NCT00110071|GENETIC|polymerase chain reaction|Correlative studies
48708100|NCT03114436|OTHER|Observational Data Collection|All aspects of deceased donor care in the ICU.
48708101|NCT04088435|RADIATION|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
48708102|NCT03087942|DRUG|QAW039|450 mg
48708103|NCT03087942|DRUG|QAW39A|450 mg
48708104|NCT03087942|DRUG|QAW39A2107|450 mg
48708105|NCT03087942|DRUG|QAW39A2107|450 mg
48708106|NCT03833271|BIOLOGICAL|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
48708107|NCT01510015|DRUG|Risperidone|variable dose
48375727|NCT01169116|RADIATION|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
48708108|NCT04883710|OTHER|Gene therapy|This is a prospective patient registry.
48708109|NCT03826836|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
48708110|NCT03833089|COMBINATION_PRODUCT|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
48708111|NCT02497378|DRUG|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
48708112|NCT02497378|DRUG|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m\^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
48708113|NCT02497378|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
48708114|NCT01386541|DRUG|BYK324677|capsules, administered orally
48708115|NCT00974688|BEHAVIORAL|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
48708116|NCT00974688|BEHAVIORAL|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
48708117|NCT05670548|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
48708118|NCT04538235|PROCEDURE|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
48708119|NCT03711929|DRUG|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
48708120|NCT03711929|OTHER|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
48708121|NCT03711929|DRUG|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
48018370|NCT01167946|DRUG|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
48018371|NCT01167946|DRUG|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
48018372|NCT01167946|DRUG|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
48708122|NCT03711929|DRUG|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
48018373|NCT00003945|DRUG|cisplatin|
48018374|NCT00003945|DRUG|topotecan hydrochloride|
48018375|NCT06523270|RADIATION|Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI)|"All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner"
48018376|NCT03495908|DEVICE|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
48708123|NCT01728077|DRUG|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
48708124|NCT00970814|BEHAVIORAL|BBCET|11 BBCET sessions
48708125|NCT00970814|BEHAVIORAL|BBCET|11 BBCET Sessions
48708126|NCT00970814|DRUG|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
48708127|NCT00970814|DRUG|Sugar Pill|500mg - 2000mg Once per day 16 weeks
48708128|NCT01330979|DRUG|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
48708129|NCT01567202|PROCEDURE|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
48708130|NCT01567202|DRUG|Chemotherapy|Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
48708131|NCT01567202|RADIATION|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
48708132|NCT01567202|BIOLOGICAL|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
48708133|NCT01567202|DRUG|blank placebo|Saline that has the same appearance with DC vaccine.
48708134|NCT00896363|DRUG|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
48708135|NCT00896363|DRUG|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
48708136|NCT00896363|DRUG|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
48018377|NCT03709550|DRUG|Decitabine|Given IV
48018378|NCT03709550|DRUG|Enzalutamide|Given PO
48018379|NCT05497908|PROCEDURE|TAP block via lateral approach|TAP block via lateral approach
48018380|NCT05497908|PROCEDURE|TAP block via posterior approach|TAP block via posterior approach
48018381|NCT03003520|DRUG|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
48018382|NCT03003520|DRUG|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
48018383|NCT03003520|DRUG|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
48018384|NCT03003520|DRUG|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
48018385|NCT03003520|DRUG|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
48708137|NCT03207178|BIOLOGICAL|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
48708138|NCT05280106|PROCEDURE|Pre-dilution online hemodiafiltration with citrate dialysate|After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
48708139|NCT05280106|PROCEDURE|Post-dilution hemodiafiltration with citrate dialysate|same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
48708140|NCT00637637|DRUG|indinavir sulfate|
48708141|NCT00637637|DRUG|ritonavir|
48708142|NCT00637637|RADIATION|radiation therapy|
48018386|NCT03003520|DRUG|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
48018387|NCT03003520|DRUG|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
48018388|NCT01162629|DEVICE|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
48175369|NCT01140282|PROCEDURE|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
48708143|NCT05587569|DEVICE|Treatment of metatarsus adductus and hallux valgus with the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure|Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated study duration will be 5 years post index procedure.
48175370|NCT01140282|BEHAVIORAL|exercise intervention|12 week exercise intervention
48175371|NCT04200404|DRUG|CS1001|One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
48175372|NCT04200404|DRUG|Regorafenib|One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
48175373|NCT00579709|BIOLOGICAL|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained \<4000/cumm Csa weaned over 8 weeks. If T cell \>4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, \& mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
48175374|NCT02972814|DEVICE|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
48175375|NCT02972814|DEVICE|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
48175376|NCT02972814|DEVICE|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
48708144|NCT04359732|OTHER|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
48708145|NCT00747669|DRUG|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
48708146|NCT02614040|OTHER|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
48708147|NCT02614040|OTHER|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
48708148|NCT04610489|DIAGNOSTIC_TEST|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
48175377|NCT03067363|DRUG|MOR107|MOR107 solution for injection
48175378|NCT03067363|DRUG|Placebo|Solution for injection manufactured to match MOR107 solution for injection
48175379|NCT03067363|OTHER|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
48175380|NCT02615678|DEVICE|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
48708149|NCT05180318|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
48708150|NCT05180318|DRUG|0.9% saline|0.9% saline
48708151|NCT02502227|BEHAVIORAL|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
48018389|NCT05852353|OTHER|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear \& Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
48018390|NCT00077259|DRUG|epothilone D|
48018391|NCT02642913|DRUG|Enzalutamide|
48018392|NCT02642913|DRUG|Enzalutamide with Sorafenib|
48018393|NCT06395168|OTHER|Combined Newborn and Lactation Visit|See Arm/Group Description
48018394|NCT01532687|DRUG|Gemcitabine|Given IV
48175381|NCT01684618|PROCEDURE|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
48708152|NCT00004564|DRUG|Clopidogrel|
48708153|NCT00004564|DRUG|Atorvastatin|
48708154|NCT02754141|BIOLOGICAL|BMS-986179|Specified dose on specified days
48708155|NCT02754141|BIOLOGICAL|Nivolumab|Specified dose on specified days
48708156|NCT02754141|BIOLOGICAL|rHuPH20|Specified dose on specified days
48018395|NCT01532687|DRUG|Gemcitabine Hydrochloride|Given IV
48375731|NCT04772339|OTHER|Heel-Rise Test|The Heel Rise test for endurance will be performed while the participant stands on a box with 10 ° inclination on one leg. Participants will be allowed to get support from the wall at the point at shoulder level with two fingertips in order to maintain balance. A metronome of 30 beats per minute will be used to maintain the heel-rise frequency every 2 seconds. The participant will be asked to rise as high as possible with each heel rise, then lower the heel to the starting position, and with the next warning, he/she will be asked again. The participant will be asked to adapt to the pace of the metronome as much as possible and to continue the test as much as possible. The test will be terminated when the participant stops, fails to maintain frequency, or performs a proper heel raise. The number of heel raises obtained at the end of the test will be used for data analysis.
48375732|NCT04772339|OTHER|Paper Grip Test (PGT)|In the paper grip test, a paper is placed under the individual's thumb and the person is asked to squeeze this paper strongly between the big toe and the ground. The paper is pulled by the person performing the test and the individual is asked to hold the paper with his/her thumb as much as he/she can. When the person applies the maximum force, the height of the medial longitudinal arch is measured with a digital caliper in millimeters. The time that the individual can maintain the MLA height with this maximum force is recorded with a stopwatch.
48375733|NCT01489345|DRUG|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
48375734|NCT01489345|DRUG|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
48375735|NCT00138827|DRUG|Biotene (mouth care)|
48018396|NCT01532687|OTHER|Laboratory Biomarker Analysis|Correlative studies
48175382|NCT03322852|OTHER|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
48175383|NCT03729713|OTHER|Computerized cognitive rehabilitation|6 week course of cognitive rehabilitation focused on attention, learning, and memory
48175384|NCT03729713|OTHER|Sham placebo|an alternative home-based computer program not designed for cognitive remediation but of the same duration
48175385|NCT02820545|OTHER|Sociological interview|A sociological interview will be performed with each patient by a sociologist, during their hospital stay
48175386|NCT02820545|OTHER|Self-administrated questionnaire|Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
48175387|NCT00828555|OTHER|Vaccination Program|Design \& implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, \& pertussis
48175388|NCT01903369|DEVICE|Shear Wave Elastography|Shear wave elastography
48375736|NCT04778397|DRUG|Magrolimab|Administered intravenously (IV).
48375737|NCT04778397|DRUG|Venetoclax|Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
48708157|NCT04287569|DEVICE|Record during endoscopy of video-endoscopy sequences and reflectance|Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
48708158|NCT04199364|DRUG|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
48708159|NCT03989427|OTHER|Brushing first and Flossing later (BF)|Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.
48708160|NCT03989427|OTHER|Flossing first and Brushing later (FB)|Participants will follow Flossing first and Brushing later (FB) sequence for 2 weeks, and after 1 week wash out period, Brushing first and flossing later (BF) sequence for another 2 weeks.
48708161|NCT05868733|DRUG|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
48018397|NCT01532687|DRUG|Pazopanib|Given PO
48018398|NCT01532687|DRUG|Pazopanib Hydrochloride|Given PO
48175389|NCT00245245|DRUG|recombinant porcine coagulation factor VIII (OBI-1)|
48175390|NCT03896074|DRUG|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
48175391|NCT03896074|DRUG|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
48175392|NCT04393792|DRUG|Povidone-Iodine|0.23% three times daily (tds) for 3 days
48175393|NCT04393792|DRUG|Normal saline|0.9% three times daily (tds) for 3 days
48175394|NCT03728959|OTHER|Liquid meal (Nutridrink)|Liquid meal ingested over 1 minute.
48175395|NCT03728959|OTHER|GIP|Subcutaneous injected GIP
48708162|NCT05868733|DRUG|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
48018399|NCT01532687|OTHER|Placebo Administration|Given PO
48175396|NCT03728959|OTHER|GLP-2|Subcutaneous injected GLP-2
48175397|NCT03728959|OTHER|Placebo (saline)|Subcutaneous injected Placebo (saline)
48175398|NCT03445117|OTHER|Educational intervention|a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
48175399|NCT05258955|OTHER|Natural honey|Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index
48175400|NCT05258955|DRUG|Chlorhexidine mouthwash|Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
48175401|NCT01789619|DRUG|Extended release tacrolimus (Advagraf®)|
48375738|NCT04778397|DRUG|Azacitidine|Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
48375739|NCT04778397|DRUG|Cytarabine|"Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles."
48375740|NCT04778397|DRUG|Daunorubicin|Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
48375741|NCT04778397|DRUG|Idarubicin|Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
48375742|NCT04778397|DRUG|Steroidal Eye Drops|Administered per institutional standard during consolidation.
48375743|NCT01374516|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
48375744|NCT01374516|BIOLOGICAL|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
48375745|NCT00156624|DRUG|Balloon Angioplasty with or without drug administration|
48375746|NCT00003576|DRUG|cisplatin|
48175402|NCT03419676|DEVICE|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
48175403|NCT02459405|PROCEDURE|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
48175404|NCT02459405|DEVICE|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
48175405|NCT00087113|DRUG|pemetrexed disodium|
48175406|NCT04115267|RADIATION|Radiotherapy|Combined modality
48375747|NCT00003576|DRUG|fluorouracil|
48375748|NCT00003576|PROCEDURE|surgical procedure|
48375749|NCT00003576|RADIATION|radiation therapy|
48375750|NCT02869204|OTHER|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
48375751|NCT02869204|DIETARY_SUPPLEMENT|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
48375752|NCT02869204|DIETARY_SUPPLEMENT|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
48375753|NCT02869204|DIETARY_SUPPLEMENT|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
48375754|NCT00576667|DRUG|Rimonabant|Tablet, oral administration
48375755|NCT00576667|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
48375756|NCT01874379|OTHER|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
48708163|NCT05868733|DRUG|Placebo|Placebo
48375757|NCT01874379|OTHER|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
48375758|NCT01874379|OTHER|Standard of Care|Normal Procedures, no complementary medicine intervention.
48375759|NCT00343148|DRUG|AVI-4126 Injection (RESTEN-NG®)|
48375760|NCT04311814|DIAGNOSTIC_TEST|Maximum urethral closure pressure during Valsalva (v-MUCP)|v-MUCP measurement was performed for all patients referred for urodynamic exploration of the lower urinary tract
48375761|NCT03843866|OTHER|4-0 Monocryl|sutures and steri-strips
48375762|NCT03843866|OTHER|Adhesive Glue|Adhesive Glue
48375763|NCT01055184|BIOLOGICAL|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
48375764|NCT02305199|DRUG|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
48375765|NCT02305199|DRUG|Normal saline|Fluid containing Sodium chloride 9 g/L
48708164|NCT03584191|OTHER|No treatment given|Completion of a survey
48175407|NCT06224010|OTHER|Respiratory drive and effort assessment|The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
48175408|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
48175409|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
48175410|NCT00863798|DRUG|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
48175411|NCT02089412|DRUG|E2006|
48375766|NCT05822388|PROCEDURE|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
48375767|NCT05460312|DIAGNOSTIC_TEST|prostate biopsy|trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
48375768|NCT05423665|OTHER|sample collection|blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth
48708165|NCT00607711|DRUG|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
48708166|NCT02615860|OTHER|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
48708167|NCT02615860|PROCEDURE|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
48708168|NCT00889889|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
48708169|NCT00889889|BIOLOGICAL|Placebo|Placebo
48175412|NCT04979247|DRUG|Oliceridine|Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
48175413|NCT02306447|DEVICE|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
48175414|NCT01037062|DRUG|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
48175415|NCT04974723|DRUG|Abaloparatide|Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)
48175416|NCT04974723|DRUG|Teriparatide|Teriparatide subcutaneous (TPTD; Forteo®)
48175417|NCT01405677|BIOLOGICAL|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
48175418|NCT01405677|BIOLOGICAL|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
48175419|NCT01405677|BIOLOGICAL|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
48708170|NCT02676336|DIETARY_SUPPLEMENT|Violet™ Molecular Iodine (I2)|
48375769|NCT01773434|DRUG|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
48175420|NCT02989571|DRUG|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
48175421|NCT02989571|DRUG|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
48175422|NCT06547385|DRUG|ONO-4578|Specified dose on specified days
48708171|NCT02676336|OTHER|Placebo|
48175423|NCT06547385|DRUG|ONO-4538|Specified dose on specified days
48175424|NCT06547385|DRUG|Capecitabine|Specified dose on specified days
48175425|NCT06547385|DRUG|Oxaliplatin|Specified dose on specified days
48175426|NCT06547385|DRUG|Fluorouracil|Specified dose on specified days
48175427|NCT06547385|DRUG|Calcium Levofolinate Hydrateb|Specified dose on specified days
48175428|NCT06547385|DRUG|Bevacizumab|Specified dose on specified days
48375770|NCT01726556|DEVICE|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
48375771|NCT01726556|DEVICE|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
48375772|NCT05044182|PROCEDURE|Decompression and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
48375773|NCT05044182|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
48375774|NCT04869202|DIAGNOSTIC_TEST|COVID-19 test|Naso-pharyngeal swab test
48375775|NCT05376540|PROCEDURE|Direct gallbladder injection of ICG intraoperatively|Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively.
48375776|NCT05376540|PROCEDURE|Intravenous injection 2.5 mg|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery
48375777|NCT05376540|PROCEDURE|Intravenous injection and direct gallbladder injection|Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively.
48375778|NCT05376540|PROCEDURE|Intravenous injection 5 mg|Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery
48375779|NCT06174792|DRUG|Drospirenone 4 MG|Patients who met all inclusion criteria and had no exclusion criteria would receive one tablet of Drospirenone 4mg daily for 20 weeks, starting from day 2 to day 5 of their menstrual cycle.
48375780|NCT04435652|DRUG|QL1604|3mg/kg, D1,8,15,Q4w, IV infusion
48517159|NCT00880789|BIOLOGICAL|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
48517160|NCT02051556|BEHAVIORAL|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
48175429|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
48175430|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
48375781|NCT04435652|DRUG|Nab-paclitaxel|100mg/m2, D1,8,15,Q4w, IV infusion
48375782|NCT04435652|DRUG|Paclitaxel|80mg/m2, D1,8,15,Q4w, IV infusion
48517161|NCT02051556|BEHAVIORAL|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
48708172|NCT00911092|PROCEDURE|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
48375783|NCT01220921|PROCEDURE|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
48375784|NCT01220921|PROCEDURE|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
48375785|NCT02875743|DRUG|Posaconazole|
48375786|NCT03096457|DRUG|Paromomycin Sulfate|topical application 2 times a day during 20 days
48375787|NCT03096457|DRUG|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
48375788|NCT03096457|OTHER|Placebo|topical application 2 times a day during 20 days
48375789|NCT03709342|DRUG|CM4620-IE|single IV infusion on Day 1 over 4 hours
48375790|NCT00939068|DRUG|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
48375791|NCT00939068|BIOLOGICAL|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
48375792|NCT00665418|DRUG|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
48375793|NCT01636011|OTHER|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
48375794|NCT01636011|OTHER|Light Touch sham|Light Touch sham
48375795|NCT01400607|BIOLOGICAL|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
48375796|NCT01400607|OTHER|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
48375797|NCT06406959|PROCEDURE|Transversus abdominal plane block (TAP block)|Unilateral US-guided TAP-block lateral approach with 20 ml 0,375% Levobupivacaine before incision
48375798|NCT01391260|OTHER|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
48175431|NCT04947436|DEVICE|High Frequency Chest Wall Oscillation|The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.
48175432|NCT04947436|DEVICE|Mechanical insufflation/exsufflation|A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
48175433|NCT03619889|OTHER|Manual pressure release technique on trigger points.|A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
48175434|NCT03619889|OTHER|Sham|A simulated pressure release technique is applied around masticatory and neck muscles.
48175435|NCT06142981|BIOLOGICAL|PRP and PBD-VSEL Stem Cell therapy|The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
48708173|NCT00911092|RADIATION|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
48708174|NCT00911092|DRUG|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²"
48708175|NCT02049190|DRUG|onapristone|
48175436|NCT00556647|PROCEDURE|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
48708176|NCT02049190|DRUG|abiraterone|
48175437|NCT00556647|PROCEDURE|conventional diagnosis|out-patient diagnosis
48175438|NCT01962311|PROCEDURE|lumbar puncture|lumbar puncture at enrollment in study
48175439|NCT06241729|OTHER|Algorithms to predict the probability of a primary refractory state|Follow-up of a cohort of patients with diffuse large-cell B lymphoma from 2024 using algorithms to predict the probability of a primary refractory state
48175440|NCT03441945|OTHER|magnetic steering|magnetic steering
48175441|NCT05084599|DRUG|Metaraminol 2.7μg/kg/min|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
48175442|NCT05084599|DRUG|Metaraminol 2μg/kg/min|After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
48175443|NCT00238953|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
48018400|NCT04019535|DEVICE|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
48018401|NCT02565797|DEVICE|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
48018402|NCT00476424|DRUG|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
48175444|NCT00673608|DRUG|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
48708177|NCT02949986|BEHAVIORAL|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
48018403|NCT06526507|OTHER|Implementation strategy package|Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
48018404|NCT05007873|DRUG|Dasatinib|Given PO
48018405|NCT05007873|DRUG|Decitabine and Cedazuridine|Given PO
48018406|NCT06664632|BEHAVIORAL|Exp|"Participants in this group will receive treatment using the Knee Sync Partner, a novel portable device designed to provide electrical traction and stimulation specifically for the knee joint.~controlled mechanical traction to the knee joint to reduce joint contact pressure, enhance synovial fluid flow, and increase joint space. This is expected to alleviate pain and improve mobility."
48708178|NCT00460486|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
48708179|NCT05684757|BEHAVIORAL|Dietary Advice|Dietary Advice
48708180|NCT06024837|OTHER|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
48175445|NCT03801681|DIAGNOSTIC_TEST|ECG holter monitoring|patients will be monitored using ECG-holter
48375799|NCT01731821|PROCEDURE|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
48375800|NCT05098678|DIETARY_SUPPLEMENT|Zinc gluconate|120 mg each tablet containing 30 mg elemental zinc
48375801|NCT05098678|DIETARY_SUPPLEMENT|Placebo|Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
48375802|NCT03947632|DIAGNOSTIC_TEST|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
48375803|NCT05180123|PROCEDURE|Anterior cruciate ligament reconstruction|Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
48375804|NCT00994266|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
48375805|NCT00994266|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
48375806|NCT02770534|PROCEDURE|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
48375807|NCT03004612|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
48375808|NCT03004612|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
48375809|NCT02525367|BEHAVIORAL|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
48375810|NCT02525367|BEHAVIORAL|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
48375811|NCT02291705|PROCEDURE|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
48375812|NCT02291705|DRUG|Tramadol|tramadol 1 mg/kg iv
48375813|NCT02036892|BEHAVIORAL|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
48517162|NCT02051556|BEHAVIORAL|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
48708181|NCT06465303|DRUG|RTP-026|Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
48708182|NCT06465303|DRUG|Placebo|Intervention is for each subject administered as three 30-minutes infusions of placebo
48708183|NCT01430923|DRUG|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
48708184|NCT01430923|DRUG|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
48708185|NCT06009887|BEHAVIORAL|Motivational Interview|Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
48175446|NCT04262609|RADIATION|hypofractionated radiotherapy|volumetric modulated moderately fractionated arc therapy
48375814|NCT02036892|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling
48517163|NCT03633097|OTHER|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
48175447|NCT02135822|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
48175448|NCT02135822|DRUG|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
48517164|NCT03633097|DRUG|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
48708186|NCT01013155|DRUG|perindopril erbumine|8 mg tablet
48708187|NCT03060512|DRUG|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
48708188|NCT03060512|DRUG|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
48708189|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
48708190|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
48708191|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
48708192|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
48708193|NCT03490422|PROCEDURE|Pulpotomy|Pulpotomy in mature carious permanent teeth
48708194|NCT04709484|DRUG|USG-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus boIn the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.ne and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
48708195|NCT04709484|DRUG|Palpation-guided steroid injection|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
48708196|NCT03426358|DEVICE|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
48708197|NCT06086444|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
48708198|NCT06086444|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
48708199|NCT04443517|PROCEDURE|Alpha Optimization|Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.
48708200|NCT04443517|BEHAVIORAL|Emergence from anesthesia with propofol|Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.
48018407|NCT06664632|DIAGNOSTIC_TEST|control|This will include a combination of isometric and isotonic exercises aimed at strengthening the knee musculature, enhancing joint stability, and reducing pain. The exercise regimen will focus on major muscle groups supporting the knee, such as the quadriceps, hamstrings, and calf muscles.
48018408|NCT03588169|DIETARY_SUPPLEMENT|semi-structured interviews|"About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it"
48175449|NCT06130397|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~- Participants must review 500 X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period - Time allowed: 4 weeks, to mitigate the effects of recall bias.~Phase 2 - Time allowed: 2 weeks~- Review 500 X-rays together with an AI report for each case and express their clinical opinion through the same structured reporting template used in Phase 1."
48175450|NCT06130397|OTHER|Ground truthing|Two consultant musculoskeletal radiologists will independently review the images to establish the 'ground truth' findings on the XRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior musculoskeletal radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
48175451|NCT00143026|DRUG|carbidopa, levodopa, entacapone|
48517165|NCT00215423|DRUG|Formoterol Fumarate|
48708201|NCT00716430|BEHAVIORAL|Quality Improvement Programme|Quality Improvement training programme
48018409|NCT04468295|PROCEDURE|Bonding|Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
48018410|NCT04468295|PROCEDURE|Leveling and alignment|Leveling and alignment till 0.016 x0.022 Ni Ti
48018411|NCT04468295|PROCEDURE|Extraction|Extraction of maxillary 1st premolars
48708202|NCT04231058|DEVICE|TENS and pulmonary rehabilitation|Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
48708203|NCT00308893|GENETIC|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
48708204|NCT03876015|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
48708205|NCT04160247|PROCEDURE|Immediate implant placement|Implants are placed in fresh socket
48708206|NCT04160247|PROCEDURE|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
48708207|NCT04160247|PROCEDURE|Cemented crowns placement|To cement the restorations onto the implant abutment
48175452|NCT03089736|BEHAVIORAL|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
48175453|NCT03089736|BEHAVIORAL|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
48175454|NCT03089736|OTHER|Treatment as usual (TAU)|pharmacological treatment + advices
48175455|NCT04040049|GENETIC|FLT190|Gene Therapy product.
48175456|NCT06002646|DRUG|Formocresol|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with Formocresol solution
48175457|NCT06002646|DRUG|Sodium Hypochlorite Solution|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 3% Sodium Hypochlorite Solution.
48175458|NCT06002646|DEVICE|Diode laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 940 nm diode laser.
48375815|NCT04120116|DRUG|FX-322 (One Dose)|Patients will receive one dose of FX-322.
48708208|NCT02090049|DIETARY_SUPPLEMENT|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
48708209|NCT02090049|DIETARY_SUPPLEMENT|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
48018412|NCT04468295|PROCEDURE|Retraction|En-masse retraction using 0.017x0.025 TMA T loop
48175459|NCT06002646|DEVICE|Er,Cr:YSGG laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 2790nm Er,Cr:YSGG laser.
48175460|NCT03296566|BEHAVIORAL|Patient Liaison|An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
48175461|NCT00766402|DRUG|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
48375816|NCT04120116|DRUG|FX-322 (Two Doses)|Patients will receive two doses of FX-322.
48018413|NCT04468295|PROCEDURE|Digital models|impression taking and digital scanning
48018414|NCT04468295|PROCEDURE|measurement|Assessment the rate of retraction for 6 months
48018415|NCT06475131|DRUG|BL-B16D1|Administration by intravenous infusion for a cycle of 3 weeks.
48708210|NCT00350272|DRUG|Elvucitabine|Elvucitabine 10 mg orally daily
48708211|NCT00350272|DRUG|Lamivudine|Lamivudine 300 mg orally daily
48708212|NCT00350272|DRUG|Tenofovir|Tenofovir open-label 300 mg orally daily
48018416|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based assessments|Motor and cognitive testing in virtual reality
48175462|NCT00766402|DRUG|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
48175463|NCT01648595|DRUG|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
48375817|NCT04120116|DRUG|FX-322 (Four Doses)|Patients will receive four doses of FX-322.
48375818|NCT04120116|DRUG|Placebo|Patients will receive Placebo.
48375819|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with feedback provided|Feedback about drug levels in blood provided to participant's site
48375820|NCT04429776|DIAGNOSTIC_TEST|Drug level testing with no feedback provided|Testing drug levels in blood but feedback not provided to participant's site
48375821|NCT01855607|DRUG|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
48375822|NCT01855607|DRUG|placebo lotion|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
48708213|NCT00350272|DRUG|Efavirenz|Efavirenze open-label 600 mg orally daily
48708214|NCT05037487|DRUG|Placebo Cannabis|Smoked placebo cannabis
48708215|NCT05037487|DRUG|20 mg CBD Cannabis|Smoked cannabis with CBD
48375823|NCT00538434|BIOLOGICAL|Reslizumab|
48375824|NCT00538434|OTHER|Saline|
48375825|NCT00238680|BEHAVIORAL|Bladder rehabilitation|
48375826|NCT00238680|BEHAVIORAL|Bladder rehabilitation with programmable timer|
48375827|NCT00201630|DRUG|Uroxatrol (drug)|
48375828|NCT00602082|DRUG|capecitabine|
48375829|NCT00602082|DRUG|cisplatin|
48375830|NCT00602082|DRUG|streptozocin|
48375831|NCT00602082|GENETIC|DNA analysis|
48375832|NCT00602082|GENETIC|RNA analysis|
48375833|NCT00602082|GENETIC|protein analysis|
48375834|NCT00602082|GENETIC|proteomic profiling|
48375835|NCT00602082|OTHER|laboratory biomarker analysis|
48375836|NCT02070952|RADIATION|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
48375837|NCT00612963|DRUG|Frio Oral Rinse|Prescription Mouth Rinse
48375838|NCT06477731|BEHAVIORAL|total anesthetic consumption|total anesthetic consumption required to reach the optimal depth of anesthesia (BIS 50) depending on the anxiety of the waiting period in the preoperative waiting room and the degree of anxiety.
48375839|NCT02209220|DEVICE|Positive airway pressure for the treatment of OSA|
48375840|NCT00145106|DRUG|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
48375841|NCT02739711|DRUG|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
48375842|NCT05147311|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
48375843|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
48708216|NCT05037487|DRUG|20 mg CBD + 20 mg THC Cannabis|Smoked cannabis with CBD and THC
48708217|NCT05037487|DRUG|20 mg THC Cannabis|Smoked cannabis with THC
48708218|NCT00657839|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
48708219|NCT00657839|DRUG|Placebo|Matching placebo
48708220|NCT02138474|OTHER|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
48708221|NCT02138474|OTHER|Placebo|Unmedicated sucrose pillules
48708222|NCT04479475|BEHAVIORAL|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
48708223|NCT06478797|OTHER|Fluid|Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.
48708224|NCT06478797|DRUG|Adrenalin|Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
48708225|NCT00727142|PROCEDURE|Surgical treatment|Insertion of a functioning shunt
48708226|NCT01488292|BEHAVIORAL|RECAP social skills and reading program|weekly individual and group sessions
48708227|NCT02163967|DEVICE|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
48708228|NCT00453115|DRUG|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
48708229|NCT00453115|DRUG|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
48708230|NCT04326244|DIAGNOSTIC_TEST|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
48708231|NCT04326244|DIAGNOSTIC_TEST|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
48708232|NCT04326244|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
48708233|NCT04326244|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale
48708234|NCT04326244|DIAGNOSTIC_TEST|cephalometry|Evaluation of craniofacial morphology in OSA patients
48708235|NCT04326244|DIAGNOSTIC_TEST|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
48708236|NCT06605001|OTHER|Delay of Gratification|Children will complete a delay of gratification task with 1 of 2 rewards
48708237|NCT06445764|OTHER|e-learning|Participants will complete an e-learning course over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This course prepares participants for an in-person assessment.
48708238|NCT06445764|OTHER|Virtual reality training|Participants will complete a virtual reality training over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This training prepares participants for an in-person assessment.
48708239|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
48018417|NCT04694833|BEHAVIORAL|Motor and cognitive virtual reality-based serious games|Serious games implemented in virtual reality to rehabilitate motor and cognitive impairments.
48375844|NCT00204542|DRUG|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
48375845|NCT01625559|BIOLOGICAL|MA09-hRPE|MA09-hRPE cells
48175464|NCT00468130|DRUG|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
48175465|NCT00468130|DRUG|Placebos|"Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects"
48175466|NCT03785626|PROCEDURE|CEA surgery|patients with carotid artery severe (70-99%) stenosis or occlusion received CEA surgery
48175467|NCT02849405|DEVICE|MHRC: Metabolic Hyperspectral Retinal Camera|Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
48175468|NCT06364176|DRUG|Losartan|Treatment with losartan through week 12
48175469|NCT06364176|DRUG|Placebo|Treatment with placebo through week 12
48175470|NCT00259571|DRUG|retarded release phosphatidylcholine|2g daily, given orally QTD
48175471|NCT05913986|DIETARY_SUPPLEMENT|LUDLEV®300 mg/46.2 mg|LUDLEV®300 mg/46.2 mg once day
48175472|NCT05913986|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
48175473|NCT05219929|DRUG|Tetracycline 500 Mg|500 mg three times daily
48175474|NCT05219929|OTHER|Placebo|Placebo for Tetracycline given same way as Tetracycline.
48175475|NCT00383409|DRUG|multivitamins|
48175476|NCT00383409|DRUG|placebo|
48175477|NCT05821686|DRUG|Human Interleukin-2 (IL-2) (Proleukin)|All the recruited participants will receive 4 intralesional injections of Interleukin-2 with a dose of 500,000 international units (IU) per mm width of tumor to max dose of 10 million IU.
48175478|NCT01068106|DEVICE|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
48175479|NCT01068106|DEVICE|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
48175480|NCT01382862|OTHER|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
48175481|NCT03592004|OTHER|neoadjuvant chemotherapy|neoadjuvant chemotherapy
48375846|NCT01459016|OTHER|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
48175482|NCT01514955|RADIATION|Gold seeds insertion to detect movements at pelvis|
48175483|NCT01514955|RADIATION|Image guided MRI based RT (IMRT+Brachytherapy)|
48175484|NCT00080522|BEHAVIORAL|Monitoring by HIV-trained primary care nurses|
48375847|NCT01459016|OTHER|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
48375848|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at 3 minutes before the end of the surgery.
48175485|NCT00080522|BEHAVIORAL|Community-based directly observed therapy (DOT)|
48175486|NCT00080522|DRUG|stavudine|
48175487|NCT00080522|DRUG|lamivudine|
48175488|NCT00080522|DRUG|efavirenz|
48175489|NCT00080522|DRUG|zidovudine|
48175490|NCT00080522|DRUG|didanosine|
48175491|NCT00080522|DRUG|lopinavir/ritonavir|
48175492|NCT03634722|DEVICE|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
48175493|NCT04956614|DEVICE|immobilisation duration|immobilisation duration of 2,4,6 week after suture of Achilles tendon
48175494|NCT00747695|DRUG|Rabeprazole sodium|
48175495|NCT01458847|DRUG|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
48175496|NCT01458847|DRUG|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
48175497|NCT01458847|DRUG|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
48375849|NCT05420402|DRUG|Propofol continuous infusion|1 mg/kg propofol was started by continuous infusion 3 minutes before the end of surgery, and the infusion time was 3 minutes.
48175498|NCT04311645|DRUG|Activated charcoal|Activated charcoal
48175499|NCT04311645|DIETARY_SUPPLEMENT|Dry seeds|Dry seeds
48175500|NCT02916706|DRUG|Teneligliptin 20mg|
48175501|NCT02916706|DRUG|Placebo|
48175502|NCT00302315|DEVICE|transcutaneous electrical nerve stimulation|
48175503|NCT02973802|BIOLOGICAL|ATX-GD-59|Disease specific immune modulating treatment for Graves Disease
48175504|NCT00805285|DRUG|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
48175505|NCT02828150|DIETARY_SUPPLEMENT|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure \[Harris-Benedict\] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI \>30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
48018418|NCT05760794|PROCEDURE|Non-barbed delayed absorbable suture|The non-barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 PDS (polydioxanone). The vaginal mesh will be attached with at least four interrupted sutures on the anterior vagina and posterior vagina.
48175506|NCT03888222|DRUG|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
48175507|NCT03888222|DRUG|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
48175508|NCT03443011|RADIATION|Low dose CT without intravenous contrast|participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
48175509|NCT01491542|DEVICE|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
48175510|NCT01491542|DEVICE|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
48175511|NCT00895388|BEHAVIORAL|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
48175512|NCT03227978|COMBINATION_PRODUCT|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
48175513|NCT04414631|DRUG|Conestat alfa|Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
48175514|NCT00207402|DRUG|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
48175515|NCT03018223|DRUG|Fludarabine|Myeloablative conditioning: 40 mg/m\^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m\^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
48175516|NCT03018223|DRUG|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol\*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol\*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
48175517|NCT03018223|DRUG|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
48175518|NCT03018223|RADIATION|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
48175519|NCT03018223|PROCEDURE|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
48175520|NCT03018223|DRUG|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
48018419|NCT05760794|PROCEDURE|Barbed delayed absorbable suture|The barbed delayed absorbable suture group vaginal mesh attachment will be performed with 2-0 V-Loc. The vaginal mesh will be attached with a running V-Loc on the anterior and posterior vagina.
48175521|NCT03018223|DRUG|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
48175522|NCT03018223|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is \> 1,000/mm\^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
48175523|NCT05936918|OTHER|Transcutaneous electrical acupoint stimulatios|Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method
48175524|NCT05936918|OTHER|Bilateral transverse abdominal plane block|Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect
48375850|NCT05420402|DRUG|Propofol bolus|A bolus dose of propofol 1 mg/kg was administered intravenously at the end of the surgery.
48175525|NCT01587118|DRUG|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
48375851|NCT01619709|OTHER|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
48375852|NCT00620126|OTHER|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
48708240|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
48708241|NCT00803348|DRUG|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
48708242|NCT04690803|DRUG|air cooling|intervention is adding air-cooling to treatment
48708243|NCT00856206|BIOLOGICAL|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
48708244|NCT00856206|OTHER|Placebo|Placebo subcutaneous injection once a week
48708245|NCT03546166|DRUG|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
48708246|NCT00537732|DRUG|omeprazole|20 mg daily
48708247|NCT00537732|DRUG|omeprazole|20 vs. 60 mg daily, genotype dependent
48018420|NCT05336500|OTHER|Pilates method exercises|Participants will be randomised into two groups that will be treated with Pilates exercises for 12 weeks (twice a week for 60 minutes). The control group will receive guidance on the specific activation of the center of strength (the powerhouse), while the experimental group will receive guidance to perform the exercises in a relaxed and smooth way.
48018421|NCT06043362|OTHER|0 mg nicotine pouch|Oral nicotine pouches that contain 0 mg of nicotine
48375853|NCT00620126|OTHER|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
48708248|NCT02120092|DRUG|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
48708249|NCT02120092|DRUG|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
48708250|NCT02120092|DRUG|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
48708251|NCT02120092|DRUG|Placebo|7x 300mg acetylsalicylic acid placebo
48708252|NCT02387801|DRUG|Ixekizumab|Administered SC
48708253|NCT04218838|DEVICE|CornerLoc SI Joint Stabilization Procedure|CornerLoc minimally invasive SI Joint Stabilization System
48708254|NCT04218838|DRUG|Intra-articular Sacroiliac Joint Steroid Injection|Standard of Care - Steroid injection into the sacroiliac joint
48708255|NCT02518594|DRUG|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
48708256|NCT02518594|DRUG|Placebo|placebo softgel capsule, daily from randomization to \< 35 wks
48708257|NCT02518594|DEVICE|Arabin Pessary|Placement management from randomization to \< 35 wks
48708258|NCT02781025|OTHER|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
48708259|NCT01385111|PROCEDURE|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
48708260|NCT01385111|PROCEDURE|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
48708261|NCT05124587|OTHER|No intervention group|No intervention group
48708262|NCT02731222|OTHER|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
48708263|NCT02938078|DEVICE|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
48018422|NCT06043362|OTHER|3 mg nicotine pouch|Oral nicotine pouches that contain 3 mg of nicotine
48708264|NCT02546440|DRUG|Dimethyl fumarate|dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
48018423|NCT06043362|OTHER|6 mg nicotine pouch|Oral nicotine pouches that contain 6 mg of nicotine
48018424|NCT06043362|OTHER|Smooth nicotine pouch|Non-flavored nicotine pouches that are characterized as smooth.
48708265|NCT05854576|PROCEDURE|vascular acess|AVF
48708266|NCT01169415|DRUG|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
48018425|NCT06043362|OTHER|Wintergreen nicotine pouch|Menthol flavored nicotine pouches that are characterized as wintergreen.
48375854|NCT00350935|PROCEDURE|fMRI|One 30 minute session
48375855|NCT00083226|DRUG|doxorubicin|Given IV
48375856|NCT00083226|DRUG|bortezomib|Given IV
48375857|NCT03326323|PROCEDURE|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
48708267|NCT01169415|DRUG|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
48708268|NCT04537299|DRUG|Fisetin|\~20 mg/kg/day oral, NG or D tube course for 2 consecutive days twice (Days 0 \& 1 and Days 8 \& 9)
48708269|NCT04537299|DRUG|Placebo|Placebo looks exactly like the treatment drug, but it contains no active ingredient
48708270|NCT06093178|BEHAVIORAL|Human coach-led digital health platform|This is an existing commercial digital platform developed by our technology partners (Empeal). The platform comes in the form of a smartphone app available via Android and Apple devices. Participants will communicate with their coach through the app via video, audio or text. Surveys are conducted on the app. Support content is also available through this app.
48708271|NCT00610441|DRUG|MK-8777|
48708272|NCT00610441|DRUG|Placebo|
48708273|NCT04355897|BIOLOGICAL|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
48708274|NCT00074529|DRUG|MK0677|
48708275|NCT02031081|DRUG|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
48708276|NCT02031081|DRUG|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
48708277|NCT04015037|COMBINATION_PRODUCT|placebo or drug|Group A and B (medicated or placebo)
48708278|NCT05794230|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Liquid solution - intramuscular
48375858|NCT00761969|OTHER|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
48018426|NCT05414240|DRUG|Ibudilast|IBUD at a dosage of 20 mg twice daily for 2 days, with an increase to 50 mg twice daily on day 3. The dosage will remain at 50 mg twice daily through most of the rest of the 6-week treatment period. However, for the last three days of week 6, participants will reduce the dosage gradually to 20 mg twice daily prior to discontinuing it at the end of the treatment period.
48375859|NCT00462501|BIOLOGICAL|bevacizumab|
48375860|NCT00462501|DRUG|fluorouracil|
48375861|NCT00462501|DRUG|leucovorin calcium|
48375862|NCT00462501|DRUG|oxaliplatin|
48375863|NCT00462501|PROCEDURE|conventional surgery|
48375864|NCT00462501|RADIATION|radiation therapy|
48375865|NCT02285673|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell|
48375866|NCT02997852|BEHAVIORAL|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
48018427|NCT05414240|BEHAVIORAL|Medical management|All subjects receive 6 weeks of medical management (Pettinati et al. 2004) will support subjects efforts to reduce or stop their drinking.
48018428|NCT05414240|DRUG|Placebo|Placebo twice daily for 6-week treatment period. Placebo will match active medication in appearance and size.
48018429|NCT01298284|DRUG|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
48375867|NCT03821519|BIOLOGICAL|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
48375868|NCT04353427|BEHAVIORAL|The Seven Pathways to Healing, Health and Wellness curriculum|"The curriculum seeks to increase civic engagement by fostering a sense of community and a sense of social and personal responsibility in community. There will be 7 monthly session that will be approximately 1 hour in duration. Session topics include:~1. Education and Information (including mental health awareness, and a one-day certificate program in Mental Health First Aid)~2. Connection with Others~3. The Body as Temple~4. Emotional Healing~5. The Nature of Mind~6. Life Assessment~7. The Nature of Spirit"
48375869|NCT03193424|DRUG|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
48375870|NCT02659657|DRUG|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
48375871|NCT04051515|OTHER|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
48375872|NCT04051515|OTHER|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
48375873|NCT02583165|BIOLOGICAL|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
48708279|NCT05794230|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Liquid solution - intramuscular
48708280|NCT05794230|BIOLOGICAL|Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)|Oral suspension - oral
48375874|NCT01945866|DRUG|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
48375875|NCT01945866|DRUG|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
48375876|NCT01945866|PROCEDURE|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
48375877|NCT00494234|DRUG|Olaparib|Participants will receive capsules of olaparib orally as stated in arm description.
48375878|NCT05765318|PROCEDURE|QLB|QLB is ultrasound-guided injection of 30 ml bupivacaine 0.25% into quadratus lumborum plane posterior to the end of internal oblique muscle.
48375879|NCT00681434|BEHAVIORAL|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
48708281|NCT05794230|BIOLOGICAL|Pneumoccocal Vaccine|Suspension for injection - intramuscular
48708282|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR) - TRESIVAC®|Lyophilized powder for injection - subcutaneous
48708283|NCT05794230|BIOLOGICAL|DTwP-HepB-Hib-IPV vaccine|Suspension - intramuscular
48708284|NCT05794230|BIOLOGICAL|DTaP-IPV-Hib-HepB vaccine|Liquid solution - intramuscular
48708285|NCT05794230|BIOLOGICAL|Hepatitis A vaccine - HAPIBEV™|Suspension for injection - intramuscular
48708286|NCT05794230|BIOLOGICAL|Rotavirus vaccine|Oral solution - oral
48708287|NCT05794230|BIOLOGICAL|Typhoid conjugate vaccine (TCV)|Suspension for injection - intramuscular
48708288|NCT05794230|BIOLOGICAL|Measles vaccine - MeasBio®|Freeze-dried powder for reconstitution and injection - subcutaneous
48708289|NCT05794230|BIOLOGICAL|Varicella vaccine live - VARIPED®|Sterile powder and diluent for injection - subcutaneous
48708290|NCT05794230|BIOLOGICAL|Varicella vaccine live - Onvara|Lyophilized powder for injection - subcutaneous
48375880|NCT00681434|BEHAVIORAL|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
48375881|NCT03692767|BIOLOGICAL|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
48175526|NCT02923193|DEVICE|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
48175527|NCT02923193|DRUG|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
48175528|NCT00130078|DRUG|1.0% C31G SAVVY vaginal gel|
48175529|NCT06067022|OTHER|observation|Planned measurements and scales will be applied
48175530|NCT02482610|OTHER|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
48175531|NCT02482610|OTHER|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
48175532|NCT02482610|OTHER|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
48175533|NCT01149876|OTHER|Nu Skin Product|Thin layer of Nu Skin product applied to face.
48175534|NCT01149876|OTHER|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
48175535|NCT01149876|DRUG|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
48175536|NCT01149876|OTHER|CeraVe moisturizer|Thin layer of CeraVe applied to face.
48175537|NCT03732781|DRUG|Radspherin|"Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."
48175538|NCT04302649|DRUG|peritoneal dialysate at 37°C temperature|during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
48175539|NCT02194829|DRUG|AZD1775|Given PO
48375882|NCT03522025|DEVICE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
48375883|NCT00722618|BEHAVIORAL|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
48375884|NCT00722618|OTHER|Written materials|2 written materials available on public website
48175540|NCT02194829|DRUG|Gemcitabine|Given IV
48175541|NCT02194829|DRUG|Nab-paclitaxel|Given IV
48175542|NCT01299142|DRUG|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
48175543|NCT03413215|BEHAVIORAL|Intensive|"Patients are provided with a BP machine, glucometer and test strips, and instructed how to use either a written or smartphone logbook, photograph their meals and use smartphone apps to measure daily activity. DNEs will contact patients in between visits to reinforce adherence and self-monitoring.~MSWs will conduct at least 6 face-to-face sessions, at 3 weeks then less frequently, on essential self-care behaviours in people with diabetes: healthy eating; being physically active; monitoring of blood sugar; compliance with medications; problem-solving; healthy coping skills; and risk-reduction behaviour.~Renal pharmacists will see patients at 2-4 week intervals for 3 months after the first clinic visit, and subsequently every 3-6 months. They will review patient's compliance, laboratory results and home BP, educate patient and titrate antihypertensives to meet BP goal. Physician referrals will be made for severe hypertension or hypotension, or intolerable side effects."
48375885|NCT00167414|PROCEDURE|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
48375886|NCT00167414|RADIATION|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
48375887|NCT03133208|PROCEDURE|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
48175544|NCT00286962|DEVICE|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
48175545|NCT00286962|DEVICE|continuous subcutaneous insulin infusion (CSII) or MDI|
48175546|NCT02634814|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
48375888|NCT00197691|PROCEDURE|blood draws, etc.|
48375889|NCT03096249|DRUG|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
48375890|NCT03096249|OTHER|Placebo|Placebo spray: single dose (3 puffs per nostril).
48375891|NCT04717986|DRUG|Dapagliflozin 10Mg Tab|patients who meet the inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 12 months
48375892|NCT04717986|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
48375893|NCT02473341|DRUG|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
48708291|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR) - OMZYTA®|Lyophilized powder for injection - subcutaneous
48175547|NCT02634814|OTHER|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
48175548|NCT02634814|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (\~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
48018430|NCT03836092|PROCEDURE|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
48175549|NCT01215578|DRUG|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
48175550|NCT00002547|DRUG|busulfan|
48175551|NCT00002547|DRUG|cyclophosphamide|
48175552|NCT00002547|DRUG|cyclosporine|
48175553|NCT00002547|DRUG|cytarabine|
48175554|NCT00002547|DRUG|methotrexate|
48175555|NCT00002547|PROCEDURE|allogeneic bone marrow transplantation|
48175556|NCT00002547|PROCEDURE|syngeneic bone marrow transplantation|
48375894|NCT02473341|DRUG|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
48375895|NCT05790252|DRUG|Buprenorphine Transdermal Matrix Patch|Buprenorphine transdermal patches will be applied at time of induction initiation and removed at 48 hours.
48375896|NCT05790252|OTHER|Sham patch|Bandage applied at time of induction initiation and removed at 48 hours.
48375897|NCT03495167|DRUG|SyB C-1101|SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
48708292|NCT05794230|BIOLOGICAL|Hepatitis A vaccine - Avaxim 80 U|Suspension for injection - intramuscular
48018431|NCT06500078|BEHAVIORAL|Intermittent dietary restriction|"Intermittent dietary restriction will include the ILCD and ICR, which will be self-administered interventions in daily lives. The ILCD intervention will ask participants to restrict carbohydrate intake to ≤ 50 g/d on two consecutive or discontinuous days per week. The ICR intervention will ask participants to restrict caloric intake to 600 kcal/d for boys and 500 kcal/d for girls on two consecutive or discontinuous days per week.~At baseline, participants will receive face-to-face oral dietary instructions (e.g., principle of dietary restriction, sample menus, food list with macronutrients). Participants will receive the intervention booklets containing dietary advice and sample menus for diet according to the requirements of the dietary intervention.~Participants will be required to record dietary and physical activity data on a regular basis. The total intervention duration will be 12 months, including a 3-month intervention phase and a 9-month self-maintenance phase."
48018432|NCT06500078|BEHAVIORAL|General health education|General health education based on dietary and physical activity guidelines for Chinese children and adolescents, will regularly send offline and online promotional materials to participants.
48018433|NCT04403295|BEHAVIORAL|Collaborative Specialty Care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
48018434|NCT04403295|BEHAVIORAL|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
48018435|NCT01363778|DRUG|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
48018436|NCT05707858|OTHER|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
48018437|NCT00110266|DRUG|Deferasirox|20 mg/kg/day over one year in patients with MDS
48018438|NCT04369469|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
48018439|NCT04369469|OTHER|BSC|Participants received medications, therapies, and interventions per standard hospital treatment protocols.
48175557|NCT04286854|DIAGNOSTIC_TEST|Stress echocardiography with semi-supine bicycle|"The patient is accelerating against a workload that gradually increases at a constant rate, during the exercise the images will be obtained by echocardiography.~The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms."
48175558|NCT00890799|DEVICE|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
48175559|NCT00890799|PROCEDURE|surgery|Patient in this group received open surgical repair of pmVSD.
48708293|NCT01665430|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
48708294|NCT03440918|OTHER|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
48708295|NCT03440918|OTHER|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
48175560|NCT04482192|COMBINATION_PRODUCT|Thoracic paravertebral block|After ending pulmonary procedure, a pleural pouch created beside vertebral column, a catheter is inserted to the pouch for continuous infusion of 1% lidocaine for 3 postoperative days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
48175561|NCT04482192|DRUG|Systemic analgesia|Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
48175562|NCT05623371|BEHAVIORAL|Training leaders in leading well-being and the psychosocial working environment|"The intervention comprises five training modules with practice in small groups in between. Training will take place over 5 months. The training will be received in groups of 20 and the training will be facilitated by 2 facilitators. Central themes of the training are:~1. Self-care and well-being of the manager and how to cope with stress as a manager.~2. Employee well-being and reducing risk-factors in the psychosocial working environment of employee mental health problems~3. Enhancing protective factors social social support and a healthy team climate~4. Responding to employees at risk and how to handle difficult conversations and procedures on return to work~5. Managing well-being in employees during organizational change and final reflections~The training will comprise video material and in person training of competencies and behaviors in group settings.~The waitlist control group will receive an offer of a webinar and written information."
48175563|NCT05623371|BEHAVIORAL|The offer of a webinar and written material|The offer of a webinar plus written material
48175564|NCT02382523|DRUG|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
48175565|NCT02250768|BIOLOGICAL|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
48175566|NCT00510939|DRUG|Tipifarnib plus Bortezomib|
48175567|NCT06402578|DIAGNOSTIC_TEST|HbA1c testing|Bloods will be take pre and post 12 week intervention.
48175568|NCT05328661|DIAGNOSTIC_TEST|Blink reflex|The stimulator is directly connected to the right side of the frontal board. The sponge must be soaked in water or saline before being inserted into the stimulator. Dry them a bit to avoid leaking on the stimulator (it could create a bridge between the two poles). We want to stimulate the supraorbital nerve at its emergence from the eyebrow arch (the supraorbital foramen in the supra-orbital margin bone is easy to palpate 1 cm laterally to the root of the nose). We place the stimulator above the emergence of the supraorbital nerve, with the distal pole placed below. The final intensity of stimulation is generally between 5 to 10 mA, but higher intensities sometime are required.
48175569|NCT04550559|PROCEDURE|Endoscopic ureterolitotripsy|Endoscopic ureterolithotripsy
48175570|NCT03578588|DRUG|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
48375898|NCT02850159|DEVICE|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
48375899|NCT02850159|DEVICE|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
48375900|NCT04956068|COMBINATION_PRODUCT|PIPAC|A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
48375901|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
48375902|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
48375903|NCT00777790|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
48375904|NCT02767908|OTHER|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
48375905|NCT03445663|DRUG|AMG 424|Subjects will receive IV infusions of AMG 424
48175571|NCT04581252|DEVICE|Non-invasive cardiac system|Non-invasive cardiac system
48375906|NCT02103608|DEVICE|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
48708296|NCT02218073|DRUG|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
48708297|NCT02218073|DRUG|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
48375907|NCT03957343|DEVICE|Pacing and Planning App|Participants will download and use the Pacing and Planning app through mybrainpacer.ca. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
48375908|NCT06505473|BEHAVIORAL|music-CBT|notched relaxation music combined with personalized CBT
48175572|NCT06250088|BIOLOGICAL|Emdogain (EMD) - test|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the computer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, (Emdogain) EMD will be applied to the root surface of the donor tooth. Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
48708298|NCT02218073|DRUG|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
48375909|NCT00004107|BIOLOGICAL|filgrastim|as prescribed by physician
48375910|NCT00004107|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
48375911|NCT00004107|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
48375912|NCT00004107|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
48375913|NCT00004107|RADIATION|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
48375914|NCT00136266|DRUG|Ferrous sulphate drops with vitamins A, D, and C|
48375915|NCT00136266|DRUG|Ferrous fumarate sprinkles with vitamins and minerals|
48375916|NCT02267174|BEHAVIORAL|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
48375917|NCT04395625|PROCEDURE|Direct bonding of Orthodontic brackets|Patients in group 1 had their upper right and lower left quadrants bonded with indirect bonding, and their upper left and lower right quadrants with direct bonding
48375918|NCT04395625|PROCEDURE|Indirect bonding of Orthodontic brackets|Patients in group 2 had their upper left and lower right quadrants bonded with indirect bonding, and their upper right and lower left quadrants with direct bonding.
48375919|NCT01535872|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
48708299|NCT03200639|OTHER|Combined training|The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
48375920|NCT06347848|OTHER|Psychoeducation Focused on Reducing Internalized Stigma|"Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected.~The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break."
48375921|NCT05653648|DIETARY_SUPPLEMENT|Potato starch|Participants will consume 24 grams (days 1-15) and 48 grams (days 16-30) of potato starch. Potato starch is a type 2 resistant starch that is available over the counter.
48375922|NCT00830011|BEHAVIORAL|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
48375923|NCT00830011|OTHER|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
48375924|NCT01450670|DIETARY_SUPPLEMENT|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
48375925|NCT03183661|BIOLOGICAL|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
48375926|NCT00914511|DRUG|avanafil 200mg|single dose tablet of 200mg avanafil
48375927|NCT00914511|DRUG|avanafil 200mg|single tablet dose of 200mg avanafil
48375928|NCT05682066|DEVICE|Innovalve MR system|Innovalve MR system
48708300|NCT03200639|OTHER|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
48175573|NCT06250088|PROCEDURE|Sham group|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting two fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt thecomputer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. No Emdodain (EMD). Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
48175574|NCT04077697|DIAGNOSTIC_TEST|RT-PCR for influenza|influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
48175575|NCT02420041|PROCEDURE|Active comparator: Fluoroscopic Guided SIJ injection|"* Needle entry point is in the lower one-third of the SIJ~* Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~* Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~* 1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~* Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~* Patient observed in recovery bay for 20 minutes and then discharged home"
48708301|NCT03193723|PROCEDURE|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~* Subdermic infiltration. Approximately 8 milliliters~* Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~* Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~* Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~* Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
48175576|NCT02420041|PROCEDURE|Ultrasound Guided Sacroiliac Joint Injection|"* Sterile preparation (with chlorhexidine) and drape~* Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~* 3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~* Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~* After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~* Patient observed in recovery bay for 20 minutes and then discharged home"
48175577|NCT02420041|DEVICE|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
48175578|NCT02420041|DEVICE|SonoSite S-nerve|
48175579|NCT02420041|DEVICE|iohexol|
48175580|NCT02420041|DRUG|triamcinolone/lidocaine|
48175581|NCT04458818|PROCEDURE|Prolene Mesh Vocal Cord Medialization Implant|The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
48375929|NCT01128699|DRUG|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
48708302|NCT03193723|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
48175582|NCT00409409|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
48175583|NCT00409409|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
48175584|NCT02011217|OTHER|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
48175585|NCT02011217|OTHER|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
48175586|NCT02011217|OTHER|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
48175587|NCT00119938|BEHAVIORAL|Access to online patient portal|
48375930|NCT01128699|DEVICE|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
48708303|NCT00858260|GENETIC|blood sample|Searching for Klotho variants in DNA
48175588|NCT02974309|BEHAVIORAL|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
48708304|NCT00348907|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
48375931|NCT04188613|DEVICE|Percutaneous tracheostomy|Age, gender, height, BMI, ASA scores, presence and type of additional diseases, tracheostomy day, pre- and post-procedure blood gas analysis, duration of procedure, duration of anesthesia, complications during the procedure (bleeding , desaturation, accidental extubation, malposition, bradycardia, hypotension, etc.) will be recorded from intensive care follow-up. Patients will be observed for mortality in the first 30 days after the procedure. Mortality results will be recorded.
48375932|NCT02646566|DRUG|APD421|
48708305|NCT00348907|DRUG|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
48375933|NCT02646566|DRUG|Placebo|
48375934|NCT02568111|DRUG|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
48375935|NCT02568111|DRUG|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
48375936|NCT02568111|DRUG|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
48375937|NCT05144919|BEHAVIORAL|Promotion of a biodiverse diet|"Component 1 - Participatory Identification of Intervention Approach (PIIA) Component 2. Local stakeholder consultation Component 3. Sensitisation of community Diversity club will receive capacity building from a Village health worker based on the prioritised species selected in component 2.~The following topics will be covered for each species selected for promotion:~1. Where to locally source inputs and expected price~2. How/when to prepare plots using organic inputs~3. Planting and best-practice management practices~4. Seed saving and storage~5. Possible intercropping combinations OR ecosystem services provided Component 4. Active Cooking demonstrations and Nutrition Education and counselling: Diversified cooking practices"
48375938|NCT04924465|OTHER|Follow-up|Follow-up of clinical data, laboratory tests, radiological data and pulmonary function tests
48375939|NCT02147574|PROCEDURE|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
48375940|NCT03158454|PROCEDURE|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
48375941|NCT03158454|PROCEDURE|Non-Capsula Closure|No capsular closure procedure is performed.
48375942|NCT05234281|OTHER|Interdisciplincary concentrated group rehabilitation|"All arms receive a concentrated interdisciplinary rehabilitation with similar focus and structure:~Three phases:~1. Pre-intervention preparation (1-2 months): mobilize the patients' resources for change~2. Concentrated group intervention (2-5 days): (further described below)~3. Post-intervention follow-up (1 year): digital follow-up~The core intervention is based on the concentrated rehabilitation format:~1. Initiate treatment when the patient is ready for change~2. Focus on the behavioral patterns which maintain the disorder, identify situations where they can break the patterns (micro-choices).~3. Assist the patient when breaking the patterns.~4. Use long sessions to ensure that they face a broad range of potential micro-choices~5. Work side-by side with others going through an analogous pattern of change~6. Prepare them for taking responsibility for integrating the change into every-day living"
48375943|NCT00908375|DRUG|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
48708306|NCT01952444|BIOLOGICAL|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
48708307|NCT01952444|DRUG|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
48708308|NCT04963140|OTHER|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
48708309|NCT04963140|OTHER|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
48708310|NCT02637427|BIOLOGICAL|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
48708311|NCT01740089|DRUG|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
48708312|NCT01740089|DRUG|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
48708313|NCT01740089|DRUG|Ribavirin|800-1400 mg/day orally
48708314|NCT00292838|DRUG|fluticasone 25, 50, 100, 200 mcg|
48708315|NCT05340634|DIETARY_SUPPLEMENT|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
48708316|NCT05340634|DRUG|Oral contraceptive|Drospirenone 4 mg once a day
48708317|NCT04446130|DRUG|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
48708318|NCT01460355|DRUG|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
48708319|NCT01460355|DRUG|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
48708320|NCT03836430|BEHAVIORAL|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
48708321|NCT04847895|DRUG|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
48708322|NCT04270162|DEVICE|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
48708323|NCT04270162|OTHER|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
48708324|NCT04270162|OTHER|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
48708325|NCT06079060|DEVICE|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
48175589|NCT02974309|BEHAVIORAL|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
48175590|NCT01276613|DRUG|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
48175591|NCT01276613|DRUG|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
48175592|NCT02485314|OTHER|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
48175593|NCT04128800|DRUG|Apatinib S-1|apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
48175594|NCT01059188|DRUG|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
48175595|NCT01059188|DRUG|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
48175596|NCT01059188|DRUG|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
48708326|NCT06079060|DEVICE|Control Latex Condom|61mm width Natural Rubber Latex Condom
48708327|NCT06606691|DEVICE|Xiaomi Mi Smart Band 8|The wearable device, Xiaomi Mi Smart Band 8, will be used solely for observational purposes to assess its accuracy in measuring sleep parameters, oxygen saturation, and heart rate in comparison to nocturnal polygraphy. Participants are receiving routine care as prescribed by their clinicians, and the wearable device is not part of their medical treatment but is being observed alongside standard polygraphy tests.
48708328|NCT04361604|BIOLOGICAL|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
48708329|NCT04361604|OTHER|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
48708330|NCT04361604|OTHER|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
48708331|NCT01946672|PROCEDURE|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
48708332|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
48708333|NCT00856141|DEVICE|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
48175597|NCT01059188|RADIATION|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
48175598|NCT01059188|PROCEDURE|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
48175599|NCT02851875|OTHER|Registry|
48175600|NCT04312412|PROCEDURE|Controlled active motion (CAM)|Rehabilitation, post-surgery protocol
48175601|NCT01114139|DRUG|Ferumoxytol|IV Ferumoxytol
48708334|NCT04532593|PROCEDURE|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
48708335|NCT04532593|PROCEDURE|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
48175602|NCT01114139|OTHER|Placebo|IV Placebo
48175603|NCT03582345|PROCEDURE|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
48175604|NCT01317823|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
48375944|NCT00908375|DRUG|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
48375945|NCT00807859|DRUG|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
48375946|NCT00807859|DRUG|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
48375947|NCT00807859|DRUG|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
48375948|NCT00807859|DRUG|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
48175605|NCT02675803|BIOLOGICAL|VAY736|VAY736 treatment
48175606|NCT02675803|BIOLOGICAL|VAY736 placebo|VAY736 placebo
48175607|NCT02952859|OTHER|Irreversible electroporation|
48375949|NCT01778296|DEVICE|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
48375950|NCT01296581|DRUG|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
48375951|NCT02553993|DEVICE|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
48375952|NCT02553993|DEVICE|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
48375953|NCT02553993|OTHER|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
48375954|NCT00300261|BEHAVIORAL|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
48375955|NCT00629382|DEVICE|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
48375956|NCT00629382|OTHER|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
48375957|NCT02184234|DRUG|Antistax film coated tablets|
48375958|NCT01876901|PROCEDURE|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
48375959|NCT01876901|PROCEDURE|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
48375960|NCT02360904|OTHER|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
48375961|NCT02071472|OTHER|DP medication reconciliation|
48708336|NCT04553653|OTHER|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
48175608|NCT04137718|OTHER|nonIntervention|nonIntervention
48175609|NCT02817698|DRUG|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
48175610|NCT05019313|DEVICE|Evaluation of diaphragmatic contractility by ultrasound|Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
48175611|NCT00926380|DRUG|denosumab|denosumab: 60 mg SC every 6 months
48175612|NCT00926380|DRUG|teriparatide|teriparatide: 20 mcg SC QD
48375962|NCT04747691|DIAGNOSTIC_TEST|Bedside gastric ultrasound|Bedside ultrasound exam of the stomach
48375963|NCT00455039|DRUG|GW572016|Dose: 1500 mg daily
48375964|NCT06124859|OTHER|Functional capacity tests|"Maximal effort test on cycloergometer (1st visit)~Maximal effort test, 6-minute stepper test, 6-minute walk test, 5-times sit to stand test. A minimum rest period of 15 minutes must be observed between these tests (2nd Visit)"
48375965|NCT00245492|PROCEDURE|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
48175613|NCT00398723|DEVICE|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
48175614|NCT03302442|OTHER|Non interventional study|Not applicable - Non interventional Study
48375966|NCT03252652|RADIATION|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
48708337|NCT04962607|OTHER|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
48375967|NCT04227730|DIAGNOSTIC_TEST|culture and PCR for group B streptococcus|all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
48375968|NCT05697406|DRUG|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
48375969|NCT02883608|PROCEDURE|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
48375970|NCT03778021|BEHAVIORAL|Behavioral Gardening Exposure|Assistance provided with planting and maintaining the school garden
48375971|NCT03778021|BEHAVIORAL|Healthy Eating and Gardening Curriculum|14 to 17 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
48375972|NCT05111548|DEVICE|tDCS (Active)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the experimental arm will receive a steady current delivery through the device.
48375973|NCT05111548|BEHAVIORAL|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
48375974|NCT05111548|DEVICE|tDCS (Inactive)|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function. Participants in the sham arm will wear the device but will not receive a steady current delivery.
48708338|NCT02288962|DRUG|cabergoline|
48375975|NCT02147015|DRUG|Glucocorticoids|
48375976|NCT02147015|DRUG|Antibiotics|
48375977|NCT02147015|DRUG|Inhaled corticosteroid (ICS)|
48375978|NCT02147015|DRUG|Long-Acting Muscarinic Antagonists(LAMA)|
48375979|NCT02147015|DRUG|Short-acting beta2-agonist (SABA)|
48375980|NCT02147015|OTHER|Physical treatments|
48375981|NCT02147015|DRUG|long-acting beta2-agonist (LABA)|
48375982|NCT03890731|DRUG|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
48375983|NCT04451070|OTHER|Clinic First curriculum|"The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year."
48375984|NCT01169623|OTHER|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
48375985|NCT05527249|DIETARY_SUPPLEMENT|Dietary Supplement|20g of protein powder + 650mg of pomegranate extracts
48375986|NCT05527249|OTHER|Placebo of the dietary supplement|20g of protein powder + 650mg of maltodextrin
48375987|NCT05011162|DEVICE|Digital ACT|Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT).
48375988|NCT05517291|DEVICE|paclitaxel-coated balloon angioplasty or bare mental stents implantation|paticipants who enrolled in this study will received paclitaxel-coated balloon angioplasty plus bailout stenting or primary bare mental stents implantation randomly
48375989|NCT02848781|DEVICE|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
48708339|NCT06511739|DRUG|SYHX1901|SYHX1901 tablet
48708340|NCT06511739|DRUG|placebo|Oral tablet
48375990|NCT02848781|PROCEDURE|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
48708341|NCT04373408|PROCEDURE|ACL repair without anterolateral repair|Surgical repair of the ACL using semitendinous autograft
48708342|NCT04373408|PROCEDURE|ACL repair with anterolateral repair|Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
48708343|NCT06148311|DRUG|Matching placebo|One matching placebo will be given under the tongue on a thin dissolvable film.
48708344|NCT06148311|DRUG|Dexmedetomidine|Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
48708345|NCT01201616|OTHER|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
48375991|NCT02682966|RADIATION|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
48375992|NCT02352831|DRUG|Tosedostat|
48375993|NCT02352831|DRUG|Capecitabine|
48375994|NCT02352831|PROCEDURE|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
48375995|NCT03698058|DIETARY_SUPPLEMENT|Toddler milk|Commercially available toddler milk
48375996|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48375997|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48375998|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48375999|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48376000|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48376001|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48376002|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48376003|NCT00984646|DRUG|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48376004|NCT00984646|DRUG|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
48376005|NCT05786027|BEHAVIORAL|PDI|A 12-week in-prison peer-driven intervention to increase the uptake of primary HIV prevention strategies (readiness to initiate addiction treatment (MMT or Atlantis), initiation of MMT/Atlantis, retention in MMT/Atlantis; or the use of SSP), and reduce the use of opioids and HIV risk behaviors, in HIV-negative PWID in prison.
48376006|NCT02081352|OTHER|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
48376007|NCT02081352|OTHER|Standard care|
48376008|NCT04903938|BEHAVIORAL|Primary And Secondary Abilities Among The Individuals With Antisocial Personality Disorder Within The Scope Of Positive Psychotherapy: Their Relationship With Criminal Behaviors, Aggression And Anger|Participants will be given scales with validity and reliability studies in Turkish.
48517166|NCT02723344|DIETARY_SUPPLEMENT|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
48517167|NCT02723344|OTHER|Sunflower and medium chain triglyceride oils|Placebo
48708346|NCT01201616|OTHER|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
48708347|NCT04209114|BIOLOGICAL|Nivolumab|Specified dose on specified days
48376009|NCT04128059|DRUG|BVRS-GamVac-Combi|"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"
48376010|NCT04128059|OTHER|placebo|placebo
48376011|NCT05697445|OTHER|Mobilization Techniques|Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
48376012|NCT05697445|OTHER|Conventional Treatment|Cervicogenic headache exercises
48376013|NCT01821391|DRUG|NDL-PDT|Metvix natural daylight photodynamic therapy
48517168|NCT01815476|RADIATION|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
48517169|NCT01560741|DEVICE|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
48708348|NCT04209114|PROCEDURE|Radical cystectomy (RC)|Surgical removal of the bladder
48376014|NCT01821391|DRUG|c-PDT|Metvix conventional photodynamic therapy
48376015|NCT01821391|DRUG|placebo c-PDT|Metvix placebo conventional photodynamic therapy
48376016|NCT04429607|DEVICE|Erbium:YAG Laser|Erbium:YAG 2940nm will be performed using single spot, multiple pulses on lesions.
48376017|NCT04429607|DEVICE|Pulsed Dye Laser|PDL will be performed using settings of 6-10 J/s2 on lesions.
48376018|NCT04429607|DEVICE|Nd:YAG Laser|Nd:YAG 1064nm will be performed using settings of 60-110 J/s2 on lesions.
48376019|NCT04429607|PROCEDURE|Electrodessication and curettage|Electrodessication and curettage will be performed using an epilating needle, followed by curettage on lesions.
48376020|NCT04221373|DEVICE|Ekso™ powered exoskeleton|Powered exoskeletal-assisted walking (EAW) for early training
48376021|NCT04221373|OTHER|Standard of care|Participants will receive standard of care of acute inpatient rehabilitation.
48376022|NCT03456557|RADIATION|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
48376023|NCT00048438|DRUG|paricalcitol|
48376024|NCT02379442|BIOLOGICAL|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
48018440|NCT04112693|PROCEDURE|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse."
48018441|NCT00762489|OTHER|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
48175615|NCT03537378|PROCEDURE|Hybrid APC|• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
48175616|NCT01542398|BEHAVIORAL|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
48175617|NCT00979693|DRUG|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
48175618|NCT00979693|DRUG|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
48175619|NCT05588947|OTHER|Take Charge session|A 'talk therapy' session designed to harness the person's self-determination, re-establishing purpose, identity, autonomy, and skills to Take Charge of their recovery after stroke
48175620|NCT05588947|OTHER|Active Control|Life After Stroke educational video
48018442|NCT06046534|OTHER|None (Observational study)|Not applicable since this is observational study.
48018443|NCT05540223|DEVICE|DREAMS 3G RMS|Subject undergoes implantation of DREAMS 3G RMS
48175621|NCT02860299|DRUG|citrate 4%|
48175622|NCT02860299|DRUG|unfractionated heparin|
48175623|NCT02860299|BIOLOGICAL|blood sample|
48517170|NCT01560741|DEVICE|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
48175624|NCT02854618|OTHER|additional blood sample|
48175625|NCT02923609|BIOLOGICAL|Cell Therapy|Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
48175626|NCT04266847|DEVICE|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
48175627|NCT03140566|DIAGNOSTIC_TEST|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index \>50% in addition to relief of symptoms and signs of congestion before discharge.
48517171|NCT02567240|OTHER|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
48517172|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
48018444|NCT05540223|DEVICE|Xience DES|Subject undergoes implantation of Xience DES
48018445|NCT01144338|DRUG|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
48018446|NCT01144338|DRUG|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
48175628|NCT03140566|DIAGNOSTIC_TEST|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
48175629|NCT01974453|RADIATION|Radiation dose|Radiation dose adsorbed by operators
48175630|NCT05694962|RADIATION|Low-Dose Radiation Therapy|1.5Gy single treatment of whole-lung radiation therapy
48376025|NCT04854928|DRUG|LTX-109 gel, 3%|A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
48018447|NCT01083433|BEHAVIORAL|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
48175631|NCT04455607|BEHAVIORAL|perturbation training|A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
48175632|NCT05512078|PROCEDURE|bone positioning surgical guide|patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
48175633|NCT06339749|DIAGNOSTIC_TEST|blood pressure|Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).
48175634|NCT06339749|OTHER|Clinical protocols for preeclampsia risk screening|"In this study, the risk factors of preeclampsia in pregnant women with combined maternal factors, MAP and PLGF were comprehensively analyzed by the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). The online calculation website is: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester."
48175635|NCT05439473|DIETARY_SUPPLEMENT|Curalin|Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
48175636|NCT06242704|BEHAVIORAL|Working Memory Training|A multi-session computer-based working memory training program to improve delay discounting and prevent substance use among at-risk adolescents in a traditionally underserved area.
48175637|NCT06242704|BEHAVIORAL|Working Memory|A multi-session control computer training condition that is designed to not engage working memory among at-risk adolescents in a traditionally underserved area.
48175638|NCT02442245|DIETARY_SUPPLEMENT|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
48175639|NCT02442245|OTHER|Placebo: Microcrystalline Cellulose|
48376026|NCT04854928|DRUG|Placebo gel|A Single dose of placebo gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
48376027|NCT04158518|RADIATION|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
48175640|NCT02442245|OTHER|Control: No supplementation|
48175641|NCT00867100|DRUG|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
48175642|NCT00867100|DRUG|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
48175643|NCT00867100|DRUG|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
48175644|NCT00867100|DRUG|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
48175645|NCT00177762|BEHAVIORAL|behavior weight loss|
48175646|NCT03980990|DRUG|Metformin|Continuation of Metformin
48517173|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
48517174|NCT00980031|DRUG|Eplerenone|25mg PO daily (QD)for 6 months
48517175|NCT00980031|DRUG|Lactose Tablet|Lactose tablet
48018448|NCT01083433|DEVICE|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
48018449|NCT03610490|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
48018450|NCT03610490|DRUG|Cyclophosphamide|Given IV
48018451|NCT03610490|DRUG|Fludarabine|Given IV
48018452|NCT03610490|BIOLOGICAL|Interleukin-2|Given IV
48708349|NCT04209114|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
48018453|NCT03610490|OTHER|Quality-of-Life Assessment|Ancillary studies
48018454|NCT00607841|DRUG|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
48175647|NCT05184270|DEVICE|Acoustic stimulation|"In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted."
48175648|NCT01841697|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
48175649|NCT01841697|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
48175650|NCT01841697|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
48175651|NCT01841697|DRUG|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
48175652|NCT01841697|DRUG|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
48175653|NCT01841697|DRUG|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
48175654|NCT04105062|DRUG|LS301|-LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
48175655|NCT04105062|DEVICE|Cancer Vision Goggles|-Non-significant risk device
48175656|NCT04796675|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
48175657|NCT06210061|DRUG|Propofol-Fentanyl|Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery. Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
48708350|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
48708351|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
48708352|NCT04583254|DRUG|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
48018455|NCT00607841|DRUG|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
48018456|NCT00607841|DRUG|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
48018457|NCT03873051|BEHAVIORAL|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
48018458|NCT03873051|BEHAVIORAL|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
48018459|NCT02077517|PROCEDURE|Roux en Y Gastric Bypass|
48376028|NCT04158518|RADIATION|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
48376029|NCT05988866|BEHAVIORAL|lipodia|Participants will receive access to the digital health intervention lipodia in addition to TAU.
48708353|NCT04368091|DEVICE|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
48708354|NCT02413736|DRUG|Imatinib|Imatinib 400 mg/day
48708355|NCT01613989|PROCEDURE|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
48708356|NCT01613989|PROCEDURE|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
48708357|NCT04862949|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
48708358|NCT06338514|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
48018460|NCT01156324|BEHAVIORAL|Online Stress Management Group (Upliv)|Personalized online stress management program
48018461|NCT01156324|BEHAVIORAL|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
48175658|NCT06210061|DRUG|Propofol-Fentanyl-Dexmedetomidine|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition patients will receive Dexmedetomidine (0.5ug.kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr). Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation."
48708359|NCT06338514|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
48708360|NCT04083261|OTHER|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
48708361|NCT04595682|DRUG|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
48708362|NCT04595682|DRUG|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
48018462|NCT03519230|DRUG|Pamiparib capsule|60 mg twice daily (BID), orally (per os-PO)
48018463|NCT03519230|DRUG|Placebo capsule|60mg BID, PO
48018464|NCT06662838|OTHER|Ergonomics Awareness and First Aid Training Program|The ergonomic awareness and first aid training program includes training on possible situations that children of seasonal agricultural worker families may encounter in the field.
48018465|NCT02473575|DIETARY_SUPPLEMENT|caffeine gum|Gum is consumed 30 minutes before commencement of run
48175659|NCT06210061|DRUG|Propofol-Fentanyl-Sevoflurane|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 \& 50 . Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation"
48175660|NCT02099136|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
48517176|NCT06007716|OTHER|reflexology massage|5 minutes of classic message on the left foot, 15 minutes of reflexology message, and 5 minutes of classic message on the right foot, 15 minutes of reflexology message, a total of 40 minutes of massage. 30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, reflexology massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
48708363|NCT02502058|DEVICE|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
48708364|NCT04398173|DIAGNOSTIC_TEST|multiparametric MRI|T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging
48708365|NCT04038892|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
48708366|NCT04038892|OTHER|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
48708367|NCT04038892|OTHER|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
48018466|NCT02473575|DIETARY_SUPPLEMENT|placebo gum|Gum is consumed 30 minutes before commencement of run
48018467|NCT06276478|OTHER|AI-video|Video administration for the explanation of the dental procedures followed by verbal instructions.
48018468|NCT06276478|OTHER|Verbal instructions|Only verbal instructions will be administered for the explanation of the dental procedures
48018469|NCT01993264|OTHER|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
48018470|NCT00216840|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
48018471|NCT05615467|DRUG|LY3556050|Administered orally.
48018472|NCT05615467|DRUG|Metformin|Administered orally.
48018473|NCT05615467|DRUG|Iohexol|Administered IV.
48018474|NCT01578434|DRUG|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
48175661|NCT02099136|OTHER|Placebo|Given PO
48175662|NCT02099136|DRUG|Celecoxib|Given PO
48175663|NCT02099136|PROCEDURE|Biopsy|Undergo skin biopsy
48175664|NCT02099136|OTHER|Imaging Biomarker Analysis|Correlative studies
48376030|NCT00470301|DRUG|tipifarnib|Given orally
48376031|NCT00470301|DRUG|paclitaxel|Given IV
48018475|NCT01578434|DRUG|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
48018476|NCT01578434|DRUG|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
48018477|NCT01251796|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
48018478|NCT01586442|DRUG|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
48175665|NCT02859064|DRUG|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
48175666|NCT02859064|DEVICE|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
48175667|NCT05505370|DEVICE|Colonoscopy|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
48376032|NCT00470301|DRUG|doxorubicin|Given IV
48517177|NCT06007716|OTHER|Placebo massage|Placebo reflexology massage was applied to each foot for 20 minutes, for a total of 40 minutes.30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, Placebo massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
48708368|NCT04394273|OTHER|Exercise|stabilization exercise
48708369|NCT02710123|OTHER|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
48175668|NCT02635386|DRUG|Exenatide once weekly (EQW )|2 mg SC injection every 7 days
48175669|NCT02635386|DRUG|Dapagliflozin (DAPA)|One pill (10 mg) by mouth daily (QD) in am
48175670|NCT02635386|DRUG|EQW plus DAPA|2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
48175671|NCT02635386|DRUG|Dapagliflozin plus Glucophage (MET ER)|DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
48376033|NCT00470301|DRUG|cyclophosphamide|Given IV
48376034|NCT06566937|OTHER|E-health video|"Length: The video is approximately 10-15 minutes long, making it concise and easy to watch in one sitting.~Visuals: Includes engaging visuals, such as animations, graphics, and real-life footage, to illustrate key concepts and keep viewers engaged.~Tone: The tone is supportive, empathetic, and empowering, aiming to create a positive and encouraging atmosphere."
48376035|NCT05806658|OTHER|Visual arts-based intervention|This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
48376036|NCT04703465|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25mg for 48 weeks will be delivered
48376037|NCT00206700|DRUG|Sargramostim (Leukine)|Open Label, 8 week cycle
48376038|NCT04980196|DIAGNOSTIC_TEST|urodynaemic studies|The Urodynamic studies carried out were : uroflowmetry and cystometry. The Uroflowmetry was performed by the gravimetric method Detrusor over activity was diagnosed when the patient has involuntary detrusor contractions during filling with or without leakage which may be spontaneous or provoked,
48376039|NCT01527331|BEHAVIORAL|video decision aid|cpr video decision aid
48376040|NCT01866605|DRUG|Midazolam|Intravenous midazolam 0.3 mg/kg
48376041|NCT01866605|DRUG|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
48517178|NCT05558566|OTHER|Neurofeedback from the SMA|Feedback is provided regarding activity in the SMA and participant attempts to control SMA activity using the feedback as a training signal
48376042|NCT01866605|DEVICE|Bair Hugger|Forced air warming
48018479|NCT01586442|DRUG|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
48018480|NCT05961215|DEVICE|Penguin Cold Cap|Penguin cold cap: administered 60 minutes prior to melphalan infusion and continue for 5 hours after melphalan infusion start time, for a total of 6 hours, on Days -2 and -1.
48018481|NCT02415816|PROCEDURE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
48376043|NCT02681991|DRUG|Renamezin capsule|
48018482|NCT02248922|DRUG|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
48018483|NCT06458049|BEHAVIORAL|Group Session|On-line educational session-3 modules-1 hour each for a total of 3 hours
48018484|NCT06458049|BEHAVIORAL|Coaching Call|Single Coaching phone call at one month
48018485|NCT06458049|BEHAVIORAL|Educational Materials|Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
48376044|NCT04766788|OTHER|Wearable devices, saliva samples, survey measures|Provide a self-collected saliva sample, download and use the suite of apps (e.g., Fitbit, Social Rhythms, Roadmap 2.0), and answer online surveys.
48376045|NCT02772159|DRUG|TD-4208|One dose each of treatments A: \[14C\] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: \[14C\] TD-4208 200 μg oral solution administered in a fasted state.
48175672|NCT02635386|DRUG|Phentermine /Topiramate (PHEN/ TPM) ER|PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
48175673|NCT02875002|DRUG|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m\^2, is schedule to increase to 100mg/m\^2, and be administered on days 1 and 8 of each 28-day cycle.
48175674|NCT02875002|DRUG|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m\^2 , is scheduled to increase to 1000 mg/m\^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
48175675|NCT01828359|DRUG|Amosartan® tab|comparison of different combination of anti-hypertension drug
48175676|NCT01828359|DRUG|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
48175677|NCT00598871|DRUG|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
48175678|NCT00598871|OTHER|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
48175679|NCT01074697|DRUG|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
48376046|NCT01553708|DRUG|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
48376047|NCT01553708|DRUG|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
48376048|NCT04198974|BEHAVIORAL|PreVenture Training (PTtT)|"PreVenture TtT model will involve identifying local expert trainers to be trained to train school-based professionals on the PreVenture program. Steps include:~1. PreVenture Facilitator certification: Trainers participate in training workshops and deliver the program to eligible youth in Cohort 1 and are rated on quality of implementation using the PIFA.~2. Reliable use of the PIFA: Each trainer demonstrates convergence with the Montreal Team's ratings on a set of previously-recorded PreVenture sessions.~3. PreVenture Training Workshop Certification: Trainers participate in a one-day TtT workshop to review the main aims and exercises of PreVenture Training. Trainers then record mock TtT sessions in which key components of the PreVenture Training Workshop are delivered to an audience of 4-10 individuals (e.g., class of graduate students). These sessions are rated by the Montreal Team the PreVenture Implementation Fidelity and Adherence-Trainer Scale (PIFA-T)."
48517179|NCT05558566|OTHER|Neurofeedback from control region|Feedback is provided regarding activity in a control region and participant attempts to control activity in that region using the feedback as a training signal.
48018486|NCT05544877|BEHAVIORAL|Integrated 5-day Gratitude Exercise and Behavioral Activation Program|The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.
48018487|NCT02304237|DRUG|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
48018488|NCT02304237|DRUG|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
48175680|NCT01074697|DRUG|Placebo|Saline water
48175681|NCT04921878|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
48175682|NCT00727506|DRUG|BIBW 2992|BIBW 2992 once daily
48175683|NCT00727506|DRUG|TMZ|TMZ 21/28
48175684|NCT00727506|DRUG|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
48175685|NCT03480295|DEVICE|Hyaluronic acid 0.4% and Taurine 0.5%|4 drops /day in addition to the ongoing glaucoma treatment
48175686|NCT03480295|DEVICE|Hyaluronic acid 0.2%|4 drops /day in addition to the ongoing glaucoma treatment
48708370|NCT02710123|OTHER|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
48708371|NCT05679167|BEHAVIORAL|Supervised digital training with focus on core stability|After randomization, Group 1 will be digitally supervised by experienced physiotherapist.
48708372|NCT05679167|BEHAVIORAL|Supervised digital training with focus on aerobic exercise|After randomization Group 2 will be digitally supervised by experienced physiotherapist.
48708373|NCT05679167|BEHAVIORAL|Non-supervised daily physical activity|After randomization Group 3 will receive training instruction regarding daily physical activity.
48708374|NCT02367391|BEHAVIORAL|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
48708375|NCT02367391|BEHAVIORAL|Control|Usual Care. All participants receive the active medication, Varenicline.
48708376|NCT05055258|DRUG|KVD824|KVD824 300 mg Modified-Release Tablets
48708377|NCT05055258|DRUG|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
48708378|NCT03691844|DRUG|AMZ001|diclofenac gel
48708379|NCT03691844|DRUG|Placebo|Placebo
48708380|NCT03691844|DRUG|Comparator|diclofenac gel
48708381|NCT03038607|DRUG|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
48708382|NCT05265884|DEVICE|Kinesiotaping|The tape is waterproof, porous, and adhesive. The width is 5 cm and thickness of 0.5 mm will be used in this study. This tape is with elastic core wrapped within cotton and capable of stretching up to 140-150%, applies heat-sensitive acrylic adhesive to avoid risk of latex allergy .The tape without medicinal properties is water resistant and can remain on the skin for 3 to 5 days. It will be applied two times per week for one month
48376049|NCT04198974|BEHAVIORAL|PreVenture Training+Implementation Facilitation|"PreVenture TtT model + Implementation Facilitation Package:~1. Youth advisors identified the role of older youth to support program implementation. Youth will help promote PreVenture to students and families and help Facilitators optimize attendance at sessions.~2. Trainer-led coaching sessions will focus on enhancing program fidelity and acceptability by Facilitators. 'Best practice' supervision elements from efficacy trials will be integrated. Fidelity and symptom monitoring will be conducted in real-time during program implementation.~3. Performance metrics have been developed based on youth qualitative feedback to PreVenture sessions in previous trials. Analysis indicates key responses that are predictive of students most likely to benefit from PreVenture on 12-month substance use outcomes and indicates the extent to which Facilitator's interventions are leaving students with impressions consistent with positive long-term outcomes."
48376050|NCT00270738|PROCEDURE|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
48376051|NCT00270738|PROCEDURE|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
48376052|NCT00270738|PROCEDURE|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
48517180|NCT01835041|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
48517181|NCT01835041|DRUG|oxaliplatin|Given IV
48708383|NCT05265884|BEHAVIORAL|traditional therapy intervention|traditional treatment (ROM exercises, stretching exercises, and Deep friction message) 3 times per week for one month.
48708384|NCT00061074|DRUG|Nicotrol|
48708385|NCT03220581|BEHAVIORAL|Referral for care|referral for addictions support
48708386|NCT03220581|BEHAVIORAL|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
48708387|NCT05608525|DEVICE|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
48018489|NCT01663636|BEHAVIORAL|SMS message reminding mothers to come for their scheduled vaccines|Reminder
48018490|NCT04540536|OTHER|Continuous Glucose Monitoring|Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
48376053|NCT01699321|BEHAVIORAL|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
48376054|NCT01699321|OTHER|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
48376055|NCT04553328|DEVICE|Us guided nerve blocks|The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
48376056|NCT02337543|DRUG|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
48376057|NCT02337543|DRUG|Placebo|Placebo
48376058|NCT00005990|DRUG|tipifarnib|
48376059|NCT00005990|DRUG|topotecan hydrochloride|
48376060|NCT03783026|DRUG|Apremilast|Tablets for oral administration
48376061|NCT02608827|DEVICE|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
48376062|NCT02608827|OTHER|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
48376063|NCT01906762|DRUG|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
48376064|NCT01906762|DRUG|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
48376065|NCT06317701|DEVICE|Hypoglossal Nerve Stimulation (HGNS)|Alternative therapy for Obstructive Sleep Apnea
48376066|NCT01245829|OTHER|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
48376067|NCT04679116|PROCEDURE|Laparoscopic bilateral inguinal hernia repair|Laparoscopic bilateral inguinal hernia repair
48376068|NCT04679116|PROCEDURE|Open bilateral inguinal hernia repair|Open bilateral inguinal hernia repair
48376069|NCT00752206|DRUG|Saracatinib|Oral Agent
48376070|NCT00752206|DRUG|Placebo|Oral Agent
48376071|NCT00694330|BIOLOGICAL|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
48376072|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation ON|
48376073|NCT02558634|DEVICE|VIM Thalamic Deep Brain Stimulation OFF|
48517182|NCT01835041|DRUG|leucovorin calcium|Given IV
48018491|NCT04540536|OTHER|Secure texting|A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
48018492|NCT05265949|BEHAVIORAL|diet and physical activity intervention|Dietary intervention: Preparation and follow-up of diet program Physical activity intervention: Step count monitoring
48018493|NCT01646034|DRUG|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
48018494|NCT01646034|DRUG|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"* chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
48018495|NCT03271437|BEHAVIORAL|PC-based Flash|Progressive counting with Flash technique
48018496|NCT03271437|BEHAVIORAL|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
48175687|NCT04770870|DEVICE|Hintermann Series H3 Total Ankle Replacement System|Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
48018497|NCT05586867|PROCEDURE|Blood test|15 mL of blood to follow the evolution of hepcidin and erythroferrone levels
48175688|NCT06426095|BEHAVIORAL|Group A (instructional video),|Participants in Group A received access to a specially prepared pre-recorded instructional video detailing the step-by-step process of porcelain-fused-to-metal tooth preparation for molars.
48175689|NCT06426095|BEHAVIORAL|Group B (live demonstration)|Participants in Group B were provided with live demonstrations of the same procedure conducted by the same experienced Prosthodontist to ensure consistency in teaching quality and technique
48376074|NCT03857165|DRUG|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
48376075|NCT06355518|DIETARY_SUPPLEMENT|Immunonutrition|This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
48376076|NCT06355518|DIETARY_SUPPLEMENT|Standard Oral Nutritional Supplement|This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
48018498|NCT01364064|DRUG|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
48018499|NCT03944122|DEVICE|ultrasound|therapeutical ultrasound were applied to the patients
48018500|NCT04700514|DRUG|Dexmedetomidine|Dexmedetomidine (1 mcg/kg loading for 10 min, then 1 mcg/kg/min continuous infusion) is used with sevoflurane in every time of general anesthesia
48018501|NCT04368598|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
48018502|NCT04368598|DRUG|Acetylcysteine|Acetylcysteine, po, 400mg tid, for 4 weeks
48175690|NCT06426095|BEHAVIORAL|Group C (hybrid)|Group C received a dual approach, combining instructional video guidance with live demonstrations.
48175691|NCT00171366|DRUG|amlodipine/benazepril|
48376077|NCT01646268|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
48376078|NCT01646268|DRUG|Placebo Patch|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo will receive matching placebo patches"
48376079|NCT00778206|DRUG|Kuvan|-Recommended post-partum Assessments include: collection of baby's plasma at Birth, 1 Month and 6 months, and collection of mother's plasma and expressed breast milk sample at 1 Month.
48376080|NCT02459756|OTHER|Beverage: Spray dried blackcurrant powder dissolved in water|
48376081|NCT02459756|OTHER|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
48376082|NCT01445015|BEHAVIORAL|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
48018503|NCT03198273|OTHER|Clinical pilates exercises|servical, lumbal, pelvic muscles
48018504|NCT03198273|OTHER|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
48018505|NCT01049919|DEVICE|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
48018506|NCT01049919|PROCEDURE|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
48376083|NCT01445015|OTHER|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
48376084|NCT06509217|BEHAVIORAL|Moderate-intensity Group|Water aerobics sessions involved exercises performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.
48376085|NCT06509217|BEHAVIORAL|High-intensity Group|Water aerobics sessions involved exercises performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
48018507|NCT05889559|DEVICE|Tissue Ultrafiltration Catheters|patients randomized to the experimental arm will have three TUF catheters placed in the anterior muscle compartment of the injured limb. The TUF catheters will be connected to a closed suction drain and will remove interstitial fluid from the muscle.
48175692|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery|"A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
48175693|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|"Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
48376086|NCT06325072|DIAGNOSTIC_TEST|Conclusive genetic testing|Patients will be referred for genetic counseling at the study coordinating center. This will lead to a conclusive genetic diagnosis.
48376087|NCT06325072|DIAGNOSTIC_TEST|Genotype-phenotype correlation for personalized diagnosis|Patients and their family members will undergo a thorough clinical reassessment at the study coordinating center to identify diagnostic handles of the suspected disease based on the genetic test result (reverse phenotyping). The clinical reassessment could include the performance of additional clinical and instrumental tests, as well as other specialized consultations. This will lead to a conclusive genetic diagnosis in a substantial proportion of cases, cases, who will then be provided with genetic counselling.
48376088|NCT06325072|DIAGNOSTIC_TEST|Personalized study of variants of uncertain clinical significance (VUS) through functional studies on 3D organ-on-a-chip|The investigators will perform functional assessment trough urine derived Renal Progenitor Cells (u-RPC) to establish the role of variants in determining the clinical phenotype.
48376089|NCT01620749|RADIATION|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
48708388|NCT05608525|BEHAVIORAL|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community \[22-27\]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
48018508|NCT02906007|DRUG|Bedaquiline|100 mg oral tablets. In Cohorts 2 and 3 only under protocol Version 2.0, 20 mg oral dispersible tablet may alternatively be used. Doses will vary based on the participant's age and weight.
48018509|NCT05546606|DEVICE|ECCO2R|ECCO2R therapy using the Xenios platform, CE-marked medical device of the firm Xenios AG (Heilbronn, Germany), including the following components: Xenios console, iLA active iLA Kit IPS and Novaport Twin (18Fr, 22Fr or 24 Fr) cannulas The maximal duration of ECCO2R therapy with one circuit will be of 29 days in agreement with the regulatory approval of the patient kit.
48018510|NCT03572491|BIOLOGICAL|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
48018511|NCT02164682|PROCEDURE|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
48376090|NCT04284176|OTHER|Mirror therapy and action-observation therapy|The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
48517183|NCT01835041|DRUG|irinotecan hydrochloride|Given IV
48517184|NCT01835041|DRUG|fluorouracil|Given IV
48376091|NCT04804579|BEHAVIORAL|Fall Prevention Intervention|The intervention will aim to reduce fall risk through weekly virtual group meetings and at-home exercise assignments to address physical and environmental factors that may put participants at a higher risk of experiencing a fall.
48517185|NCT01835041|OTHER|laboratory biomarker analysis|Correlative studies
48517186|NCT06278896|DRUG|Cessation of antibiotics|Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
48517187|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
48517188|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
48517189|NCT01262872|BIOLOGICAL|Synflorix™|Intramuscular injection
48018512|NCT02164682|PROCEDURE|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
48517190|NCT01262872|BIOLOGICAL|Prevnar13™|Intramuscular injection
48517191|NCT01262872|BIOLOGICAL|Tritanrix™-HepB/Hib|Intramuscular injection
48517192|NCT01262872|BIOLOGICAL|Polio Sabin™|Orally
48517193|NCT01262872|BIOLOGICAL|M-Vac™|Intramuscular injection
48517194|NCT01262872|BIOLOGICAL|Stamaril™|Intramuscular injection
48517195|NCT00003405|BIOLOGICAL|recombinant interferon alfa|
48517196|NCT00003405|DRUG|amifostine trihydrate|
48517197|NCT00003405|DRUG|bromodeoxyuridine|
48517198|NCT00003405|DRUG|cytarabine|
48517199|NCT00003405|DRUG|idarubicin|
48517200|NCT00003405|DRUG|idoxuridine|
48018513|NCT05262361|BEHAVIORAL|Office-based Vergence and Accommodative Therapy|Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
48018514|NCT03560219|DIAGNOSTIC_TEST|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~* Clinical~  * Age~ * Gender~ * BMI~ * Diabetes Mellitus~ * Hypertension~ * Heart Failure~ * Ischemic Stroke / TIA~ * Thromboembolism~ * Coronary Artery Disease~ * Peripheral Arterial Disease~ * Glomerular Filtration Rate~* Contrast-enhanced MRI~  o Presence and extent of atrial fibrosis~* Biomarkers~  * IL-6~ * CRP~ * D-dimer~ * Fibrinogen~* Transthoracic Echocardiography~  * LA Volume Index (LAVI)~ * LA Strain, Global~ * LA Strain rate, Positive peak, Global~ * LA Strain rate, early negative peak, Global~ * LA Strain rate, late negative peak, Global~ * LA Emptying Fraction (LAEF)~ * LVH~ * LVEF~* Endothelial function o FMD"
48018515|NCT00087568|DRUG|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
48018516|NCT00087568|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
48018517|NCT06463847|DRUG|UC-MSCs|"In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials."
48376092|NCT02808559|DEVICE|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
48376093|NCT00382434|PROCEDURE|presence of an emergency pharmacist in the ED|
48376094|NCT04214145|DRUG|Phenylephrine|"Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)"
48376095|NCT04214145|DRUG|Norepinephrine|"Continuous infusion of Norepienphrine 20 μg/mL (=NE 4mg \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.03 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.015 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.24 μg/kg/min (=0.8 mL/kg/hr)"
48517201|NCT00003405|DRUG|isotretinoin|
48517202|NCT00003405|DRUG|mitoxantrone hydrochloride|
48517203|NCT06346925|DRUG|Herombopag Olamine Tablets|Three Herombopag Olamine Tablets is administered to healthy subjects.
48517204|NCT01922505|DRUG|PPI triple therapy|
48517205|NCT03872518|DEVICE|Urovac|The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills.
48517206|NCT01570686|DRUG|Aliskiren|Aliskiren 300 mg once daily
48517207|NCT03971474|DRUG|Docetaxel|Given IV
48517208|NCT03971474|DRUG|Gemcitabine|Given IV
48517209|NCT03971474|DRUG|Gemcitabine Hydrochloride|Given IV
48517210|NCT03971474|BIOLOGICAL|Pembrolizumab|Given IV
48517211|NCT03971474|DRUG|Pemetrexed|Given IV
48517212|NCT03971474|DRUG|Pemetrexed Disodium|Given IV
48517213|NCT03971474|BIOLOGICAL|Ramucirumab|Given IV
48517214|NCT04746144|PROCEDURE|Total knee arthroplasty|
48517215|NCT00993356|DRUG|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH \> 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
48517216|NCT00993356|PROCEDURE|Transsphenoidal surgery|
48517217|NCT01606774|OTHER|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
48517218|NCT06123455|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 1.0 gram of taurine powder. Dosage: 2.0 gram/day. Frequency: 2 time/day.
48517219|NCT06123455|BIOLOGICAL|Sintilimab|Sintilimab
48517220|NCT06123455|DRUG|XELOX regimen|Oxaliplatin + capecitabine
48517221|NCT06123455|DRUG|SOX regimen|Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)
48517222|NCT06123455|DRUG|FOLFOX regimen|Oxaliplatin + leucovorin + fluorouracil
48517223|NCT02294214|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
48517224|NCT02294214|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
48517225|NCT02294214|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
48708389|NCT05347927|DEVICE|water resistante padding|"* Delta-Dry® Softliner~* Tensoban®~* Delta-Dry®"
48018518|NCT01991834|PROCEDURE|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
48376096|NCT04214145|DRUG|Vasopressin|"Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)"
48018519|NCT01991834|DRUG|Cefazolin|Intravenous administration of 1 g of cefazolin
48018520|NCT01991834|DRUG|Placebo|Intravenous administration of saline sterile solution
48018521|NCT01299233|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
48018522|NCT03285373|DRUG|NOAC|New Oral Anticoagulant
48018523|NCT05480605|BEHAVIORAL|Occupational Therapy|Children with autism will receive 6 - 8 weeks of regularly scheduled occupational therapy at Nationwide Children's Hospital outpatient centers. The intervention consists of one-hour weekly sessions with a licensed occupational therapist.
48018524|NCT04935697|DEVICE|nVNS|3x daily treatment of nVNS + SOC
48018525|NCT04935697|OTHER|SOC|Standard of care patient management.
48018526|NCT00016094|BIOLOGICAL|bevacizumab|Given IV
48018527|NCT00016094|OTHER|laboratory biomarker analysis|Correlative studies
48376097|NCT05716516|DRUG|Estradiol|Estradiol is a therapeutic option for the treatment of advanced ER+ breast cancer
48376098|NCT03226366|OTHER|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
48376099|NCT02910895|OTHER|tumor biopsy|biopsy
48517226|NCT02216500|DIETARY_SUPPLEMENT|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
48517227|NCT00138008|DRUG|endocrine therapy|Drug: endocrine therapy
48376100|NCT05541107|DRUG|MAT2203|oral lipid nanocrystal amphotericin B
48376101|NCT05541107|DRUG|Amphotericin B|Intravenous Amphotericin B
48376102|NCT03051152|PROCEDURE|D1 gastrectomy|Gastrectomy with limited lymph node dissection
48175694|NCT03272529|OTHER|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
48376103|NCT03051152|PROCEDURE|D2 gastrectomy|Gastrectomy with extended lymph node dissection
48376104|NCT03590158|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
48376105|NCT05448469|PROCEDURE|ultrasound guided erector spinae plane block|patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
48376106|NCT05448469|PROCEDURE|ultrasound guided paravertebral block|patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
48376107|NCT05448469|DRUG|conventional analgesia|patients will receive combined general anesthesia and conventional analgesia
48376108|NCT05726123|DEVICE|The Exopulse Mollii Suit on a Fibromyalgia patient|The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
48376109|NCT02463604|PROCEDURE|Coronary Angiography|Coronary angiography is performed following usual site standards
48376110|NCT05654116|BEHAVIORAL|Caregiver Interaction Profile (CIP) training|The CIP training aims to boost six interactive skills in daycare providers: sensitive responsiveness, respect for children's autonomy, structuring and limit setting, verbal communication, developmental stimulation, and fostering positive peer interactions. The training takes place with 1 or 2 daycare providers at a time, and consists of 5 or 6 weekly sessions, respectively. In individual trainings, sessions 1-3 focus on two skills each, session 4 is a recap of two skills the daycare provider chooses, and the final session is shared with a colleague. In pairwise sessions, session 1 focuses on the first two skills, sessions 2-5 each focus on one skill, and the last session serves as a recap of two skills the daycare providers choose. The training uses a video-feedback method: daycare providers are filmed in interactions with children in daycare, the CIP trainer preselects relevant fragments of video recordings to discuss with the daycare provider(s) during the training sessions.
48376111|NCT04213001|DIAGNOSTIC_TEST|ultrasonographic measurement|ultrasonographic measurement- Subcutaneous ultrasound echogenicity (SEG) and Skin and subcutaneous thickness measurement
48517228|NCT00138008|PROCEDURE|radiotherapy|Procedure/Surgery: radiotherapy
48517229|NCT00966472|DRUG|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
48018528|NCT04487340|BEHAVIORAL|Education|Provide each center with relevant education of guidelines, and help the clinicians to improve medical quality.
48018529|NCT04763772|DIAGNOSTIC_TEST|Body Fat Distribution Imaging Report|Those randomized to body fat distribution imaging will be scanned on a 1.5 Tesla Siemens Aera MRI scanner (Siemens, Erlangen, Germany), located in the Center for Advanced Heart and Vascular Care using a 6-minute dual-echo Dixon Vibe protocol providing a water and fat separated volumetric data set covering neck to knees, and a multiecho Dixon acquisition for proton density fat fraction assessment in the liver. Images of the liver will be acquired using a 16-channel SENSE extra large Torso coil and images from the rest of the body will be acquired using the body coil. Volumetric imaging datasets of the body derived by MRI will be generated and adipose tissue/fat depots will be quantified: abdominal subcutaneous compartment (ASAT), visceral compartment (VAT), and hips and buttocks (lower body fat); proton density fat fraction of the liver (i.e. hepatic steatosis) as well as the quality of lean (skeletal muscle) including muscle volume and degree of fat infiltration.
48376112|NCT06405646|DIAGNOSTIC_TEST|Blood CB1, CB2, TRPV-1 concentration measurement|In each of the patients blood CB1, CB2, TRPV-1 concentration will be measure
48376113|NCT01243853|DIETARY_SUPPLEMENT|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
48376114|NCT00198107|DRUG|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
48376115|NCT00198107|DRUG|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
48708390|NCT05347927|DEVICE|non water resistante padding|"* Delta-Net® Stockinette~* Delta-Rol®"
48708391|NCT03626272|OTHER|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
48708392|NCT01636505|DRUG|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
48708393|NCT01636505|DRUG|gnrh agonist (suprefact)|suprefact 5.5 ml
48708394|NCT06353399|PROCEDURE|Intra-marrow penetrations|Intra-marrow penetrations
48376116|NCT00198107|DRUG|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
48376117|NCT00664066|DRUG|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
48376118|NCT04943627|DRUG|Balstilimab (BAL)|Anti-PD-1 Monoclonal antibody
48708395|NCT06353399|PROCEDURE|No Intra-marrow penetrations|No Intra-marrow penetrations
48708396|NCT04374591|DRUG|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
48376119|NCT04943627|DRUG|Topotecan|Chemotherapy
48376120|NCT04943627|DRUG|Vinorelbine|Chemotherapy
48376121|NCT04943627|DRUG|Gemcitabine|Chemotherapy
48376122|NCT04943627|DRUG|Irinotecan|Chemotherapy
48376123|NCT04943627|DRUG|Pemetrexed|Chemotherapy
48376124|NCT00720668|PROCEDURE|radiofrequency ablation|radiofrequency ablation for HCC
48376125|NCT00202254|BEHAVIORAL|Physiotherapy|
48376126|NCT00202254|BEHAVIORAL|Occupational therapy|
48376127|NCT00202254|BEHAVIORAL|Speech pathology|
48376128|NCT02413710|OTHER|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
48376129|NCT02413710|BEHAVIORAL|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
48376130|NCT01521975|DRUG|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
48376131|NCT01445366|DEVICE|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
48376132|NCT01445366|DEVICE|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
48376133|NCT01481480|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
48376134|NCT01481480|PROCEDURE|Arthroscopic repair|Arthroscopic repair
48376135|NCT05915780|DEVICE|Cycling|The experimental group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 8-week period
48376136|NCT05915780|DEVICE|Balance Board|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises (if required);
48376137|NCT01336647|DRUG|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
48376138|NCT01336647|DRUG|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
48708397|NCT04697186|DRUG|Berberine|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
48708398|NCT04697186|DRUG|Amoxicillin|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
48376139|NCT01336647|DRUG|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
48517230|NCT00111241|DRUG|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
48517231|NCT03803969|DEVICE|ConfirmRx (Insertable Cardiac Monitor)|This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
48708399|NCT04697186|DRUG|Rabeprazole|berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.
48708400|NCT04697186|DRUG|Amoxicillin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
48708401|NCT04697186|DRUG|Clarithromycin|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
48175695|NCT03272529|OTHER|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
48376140|NCT05803876|OTHER|Diagnostic test - monitoring|"Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk."
48175696|NCT03272529|OTHER|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
48175697|NCT02377323|OTHER|MACFIMS|Cognitive evaluation of 50 participants
48376141|NCT02575261|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
48376142|NCT05071521|OTHER|The Body Project: A Dissonance-Based Eating Disorder Prevention Intervention|The Body Project is a a selective dissonance-based prevention program that targets women with body image concerns. It has been developed with University and similar populations in mind, making it appropriate to the current research.The Body Project is based on a protocol, and aims to create cognitive dissonance that encourages participants to reduce pursuit of the thin-ideal. It involves the use of a scripted manual, covering four interactive weekly sessions. These involve role play, behavioural, verbal and written exercises.
48376143|NCT03842865|BIOLOGICAL|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
48376144|NCT04489862|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion，Cyclophosphamide 300 mg/m2/day IV infusion on days -5, -4 and -3. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
48376145|NCT05588765|OTHER|Neck stretching exercises|Neck stretching exercises towards lateral flexion, ipsilateral flexion and rotation and towards flexion each for 30 sec and repeated 2-3 times
48376146|NCT06102473|OTHER|Nutritional education|With prior authorization from the principals of the elementary schools, meetings will be held with parents to invite them to participate, and the aim, activities, and duration of the intervention will be explained to them. They will be invited to sign a consent and informed assent, clarifying that their participation is voluntary and they may not continue at any time they wish without affecting their activities at school.
48376147|NCT01608048|DEVICE|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
48376148|NCT06514638|OTHER|Ultrasound imaging|Images of the vastus medialis were taken with the subject being lateral decubitus.
48376149|NCT05772728|DRUG|Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen|CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
48376150|NCT03484572|DIAGNOSTIC_TEST|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
48376151|NCT06167304|OTHER|Technology-implemented exercise therapy|Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.
48376152|NCT06167304|OTHER|Traditional Physical Therapy|Traditional physical therapy per Standard of care.
48376153|NCT00093327|PROCEDURE|Acupuncture|
48517232|NCT06299787|DEVICE|intermittent theta burst stimulation|Theta-burst stimulation
48517233|NCT06299787|DEVICE|Sham stimulation|Stimulation with double-sided B70-type coil
48708402|NCT04697186|DRUG|Rabeprazole|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
48708403|NCT04697186|DRUG|Bismuth|Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
48708404|NCT05486000|DEVICE|Atrial shunt implant system|"Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System"
48018530|NCT04763772|DIAGNOSTIC_TEST|Basic Weight Information|Body weight and body mass index
48018531|NCT04763772|BEHAVIORAL|Patient Provided|Body weight/fat distribution information will be provided directly to the patient
48175698|NCT02377323|OTHER|MSQoL-54|Quality of life questionnaires
48175699|NCT03433183|DRUG|Selumetinib|Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
48018532|NCT04763772|BEHAVIORAL|Physician Provided|Body weight/fat distribution information will be provided directly to the physician
48018533|NCT00003341|BIOLOGICAL|epoetin alfa|
48708405|NCT02581956|BEHAVIORAL|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
48376154|NCT06405048|OTHER|Mobile Weibo post screenshot with mock-up Chinese fact-checking extension|The intervention in this survey experiment involves mobile Weibo post screenshots equipped with a mock-up Chinese fact-checking browser extension. All screenshots are based on actual Weibo posts. The fact-checking content is generated by a Large Language Model (LLM), tailored to relevant knowledge and prompts, and subsequently validated by experts. The Weibo posts cover a range of popular topics known to contain misinformation, including infertility, safety, vaccine ingredients, high-risk cervical cancer types, regular check-ups, transmission routes, and others.
48708406|NCT02581956|BEHAVIORAL|No walking exercise|no exercise
48708407|NCT02906215|BEHAVIORAL|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
48708408|NCT05145361|DRUG|B001 injection|B001 injection 50mg/5mL Intravenous solution
48708409|NCT05145361|BIOLOGICAL|Placebo|Placebo 5mL Intravenous solution
48708410|NCT05069714|DRUG|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
48708411|NCT05239455|DEVICE|Reveos® Automated Blood Processing System|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
48708412|NCT02185157|OTHER|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
48708413|NCT02185157|OTHER|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
48708414|NCT00338273|DRUG|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
48708415|NCT00338273|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
48708416|NCT04094142|DRUG|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
48708417|NCT05132998|OTHER|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
48708418|NCT05132998|OTHER|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
48708419|NCT03040414|DEVICE|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
48708420|NCT03040414|DEVICE|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
48708421|NCT01244581|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
48708422|NCT01244581|DRUG|Placebo|Placebo mixture in two daily doses for 7 days
48708423|NCT05816642|DRUG|sunitinib or pazopanib|Single targeted therapy
48708424|NCT05816642|DRUG|PD-1 inhibitor combined with axitinib|targeted therapy combined with immunotherapy
48708425|NCT01546025|BEHAVIORAL|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
48708426|NCT01546025|BEHAVIORAL|Relaxation training|One hour training in relaxation techniques
48708427|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
48708428|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
48018534|NCT00003341|PROCEDURE|quality-of-life assessment|
48018535|NCT01968434|DEVICE|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
48018536|NCT01968434|DRUG|carbocisteine cough syrup|Mucolytic
48018537|NCT03111992|DRUG|PDR001|Anti-PD1 antibody
48018538|NCT03111992|DRUG|CJM112|Anti-IL-17A antibody
48708429|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
48708430|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma|Conventional melanoma educational intervention.
48708431|NCT05567419|DIAGNOSTIC_TEST|Biological assays|PCR and NGS-WGS on stools and respiratory samples
48708432|NCT01229072|BIOLOGICAL|Heparin sodic|Heparin sodic 150UI/kg
48018539|NCT03111992|DRUG|LCL161|Oral small molecule SMAC-mimetic
48018540|NCT02894021|PROCEDURE|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
48708433|NCT01229072|BIOLOGICAL|heparin liquemine|Heparin sodic 150UI/kg
48708434|NCT00866047|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
48708435|NCT04253899|PROCEDURE|Appendectomy|Interval Appendectomy
48708436|NCT04253899|OTHER|Observation|observation and follow up
48708437|NCT01054937|DRUG|4SC-203|i.v. administration
48708438|NCT01054937|DRUG|Placebo|i.v. administration
48708439|NCT01124227|DRUG|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
48175700|NCT03433183|DRUG|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
48175701|NCT00441922|DRUG|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
48175702|NCT00441922|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
48175703|NCT03146897|DIETARY_SUPPLEMENT|Supplementary Food|Supplementary food for treating MAM
48175704|NCT03765164|DIAGNOSTIC_TEST|GlycoMark 1-5-AG|Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
48175705|NCT03765164|OTHER|Clinical Performance and Value Vignettes|Simulated diabetic patients cared for online
48175706|NCT03856047|DRUG|NNC0174-0833|Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
48376155|NCT03194165|BIOLOGICAL|Dolutegravir|Dosage
48376156|NCT03194165|BIOLOGICAL|Raltegravir|Dosage
48376157|NCT03194165|BIOLOGICAL|Rilpivirine|Dosage
48376158|NCT03194165|BIOLOGICAL|Nevirapine|Dosage
48376159|NCT03194165|BIOLOGICAL|Atazanavir|Dosage
48376160|NCT03194165|BIOLOGICAL|Darunavir|Dosage
48376161|NCT03194165|BIOLOGICAL|Ritonavir|Dosage
48376162|NCT03740152|DEVICE|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
48376163|NCT02926768|DRUG|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
48376164|NCT04845451|OTHER|Minimal surgical exploration for a neuroma|Orientation marking of the trigger point by injectable sterile methylene blue dye 0.1ml. Marking a 2-3-centimeter long incision line 7 mm from the Neuroma marking on the skin. Local anesthesia using plain 2% lidocaine infiltration of the circumferential exploratory area. Sterile prep and drape in surgical fashion. Meticulous exploratory preparation of the subcutaneous tissue 20 mm at each side of the incision line. Appropriate visibility of the ZT nerve branches embedded in lipomatous and connective tissue over the temporal fascia. Exploratory visualization of the subcutaneous marked tissue by methylene blue using a binocular magnification eases visualization. Using an Adson tissue forceps with side grasping teeth, now an exploratory touch of the above and distal of the marking would deliver the hypersensitive painful Neuroma tissue for sharp excision using surgical scissors. Control of bleeding and skin closure. Sterile pressure dressing. Specimen be sent to pathologic examination.
48376165|NCT02594566|DRUG|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
48376166|NCT02821546|DRUG|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
48376167|NCT01097174|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
48376168|NCT01678586|OTHER|Acupuncture|In true acupuncture the needles penetrate the skin.
48376169|NCT01678586|OTHER|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
48376170|NCT01678586|DRUG|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
48376171|NCT01678586|DRUG|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
48175707|NCT03856047|DRUG|Placebo (NNC0174-0833)|Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
48175708|NCT03856047|DRUG|Liraglutide 3.0 mg|Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
48175709|NCT03856047|DRUG|Placebo (Liraglutide 3.0 mg)|Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
48175710|NCT02326259|OTHER|Initiation of treatment of diabetes|Treatment of diabetes according to the standard of care.
48175711|NCT05816577|DIETARY_SUPPLEMENT|EcN Colibactin knockout|E coli Nissle strain with ClbP-gene removed and therefore not producing colibactin
48175712|NCT05816577|DIETARY_SUPPLEMENT|E Coli Nissle|E Coli wildtype strain
48376172|NCT00732732|DIETARY_SUPPLEMENT|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
48376173|NCT00732732|OTHER|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
48376174|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
48018541|NCT02894021|PROCEDURE|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
48175713|NCT05710289|BIOLOGICAL|Immune Responses|To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.
48018542|NCT03120624|PROCEDURE|Biopsy|Undergo image-guided biopsy
48018543|NCT03120624|PROCEDURE|Computed Tomography|Undergo CT
48018544|NCT03120624|OTHER|Fluorine F 18 Tetrafluoroborate|Given IV
48018545|NCT03120624|OTHER|Pharmacological Study|Correlative studies
48175714|NCT01875341|DEVICE|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
48018546|NCT03120624|PROCEDURE|Positron Emission Tomography|Undergo TFB-PET
48018547|NCT03120624|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
48018548|NCT03120624|DRUG|Ruxolitinib Phosphate|Given PO
48018549|NCT03120624|DRUG|Technetium Tc-99m Sodium Pertechnetate|Given IV
48376175|NCT00883766|OTHER|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI\>30, HOMA \>3.8, G/I ratio \<4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst \>10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
48376176|NCT02389621|DRUG|Lusutrombopag|Tablets for oral administration
48708440|NCT00574665|OTHER|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
48708441|NCT01242306|DRUG|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
48018550|NCT03120624|PROCEDURE|Biospecimen Collection|Undergo mouth rinse, buccal swab, urine, and blood sample collection
48018551|NCT04543422|DIETARY_SUPPLEMENT|Green tea|Green tea extract capsules
48018552|NCT04543422|OTHER|Placebo|Placebo containing inert material.
48018553|NCT05551364|DEVICE|ATLAS 2030 exoskeleton|"Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases:~1. Telephone contact phase (1 session)~2. Inclusion Phase (1 session)~3. Signing of informed consent (1 session)~4. Initial Evaluation Phase (1 session)~5. Treatment Phase (1st part) (7 sessions)~6. Monthly Evaluation Phase (1 session)~7. Treatment Phase (2nd part) (7 sessions)~8. Monthly Evaluation Phase (1 session)~9. Treatment Phase (3rd part) (7 sessions)~10. Final Evaluation Phase and results (2 sessions)"
48018554|NCT04893889|DIAGNOSTIC_TEST|Shear-wave elastography|Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
48018555|NCT04995640|PROCEDURE|open cardiovascular repair or endovascular treatment (TEVAR)|Surgery type: open cardiovascular repair and endovascular treatment (TEVAR)
48018556|NCT00955877|DRUG|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
48018557|NCT00955877|DRUG|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
48175715|NCT01875341|DEVICE|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
48175716|NCT00250640|DRUG|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
48175717|NCT01517607|OTHER|Mesalazine|Patient's treated with oral Mesalazine
48175718|NCT02220218|DRUG|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
48376177|NCT02389621|DRUG|Placebo|Tablets for oral administration
48708442|NCT03456791|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
48708443|NCT06230016|OTHER|questionnaires|"human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study.~Questionnaire administred before the start of current care APA programm and after 4 to 6 months."
48018558|NCT00955877|DRUG|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
48018559|NCT01297218|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
48018560|NCT04364633|OTHER|Voice Handicap Questionnaire (VHI)|Voice Handicap Index (VHI) self-questionnaire
48376178|NCT02679924|DEVICE|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
48376179|NCT02679924|OTHER|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
48175719|NCT02220218|DRUG|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
48175720|NCT02220218|DRUG|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
48376180|NCT04424186|OTHER|'Rehabilitation for Life'|An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.
48376181|NCT04424186|OTHER|Usual care and rehabilitation|The care and rehabilitation usual provided to patients after hip fracture surgery
48376182|NCT06509425|PROCEDURE|salpingectomy during caesarean section|Salpingectomy will be done by clamping, division and ligation using adsorbable suture material (2-0 Vicryl) and excising the tube till it's isthmic part by scissors.
48708444|NCT06230016|OTHER|PedsQL quality of life questionnaires|validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
48708445|NCT00145418|DRUG|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
48018561|NCT01831687|DRUG|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
48018562|NCT01831687|DRUG|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
48018563|NCT05540886|BEHAVIORAL|TEACH CLEAN|"The intervention is primary a training facility cleaning champions to educate and supervise other existing facility cleaners with environmental hygiene responsibilities - training of trainers (ToT).~The training content includes as much as possible the seven contextualized modules of TEACH CLEAN training package (CLEAN BOX): i) Introduction to Infection Prevention and Control, ii) Personal hygiene and dress code, iii) Hand hygiene, iv) Personal protective equipment, v) Housekeeping/control of environment, vi) Waste handling, and vii) Linen handling.~Facility training will occur in three selected wards: i) maternity ward, including labour and post-natal rooms, ii) medicine ward, iii) and medicine ward.~There is also supervision stage that refers to ongoing mentorship of cleaning champions by the local partner while they educate and supervise existing facility cleaners with environmental hygiene responsibilities."
48018564|NCT05174767|DEVICE|AMDS|AMDS Implantation
48018565|NCT02421458|RADIATION|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
48708446|NCT02627287|DEVICE|FlexPen®|For subcutaneously (s.c. under the skin) injection.
48708447|NCT02627287|DEVICE|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
48018566|NCT02421458|RADIATION|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
48018567|NCT05384847|DRUG|Thyroid hormone T3|Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
48018568|NCT05384847|OTHER|Control Group|The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
48018569|NCT01500824|DRUG|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
48018570|NCT04025918|DEVICE|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~1. Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~2. Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~3. Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
48175721|NCT05809102|PROCEDURE|repair of flexor tendon in Zone II|Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
48376183|NCT06509425|PROCEDURE|tubal ligation during caesarean section|Tubal ligation will be done by Parkland technique. An opening is made in an avascular section of the mesosalpinx by electrocautery. Two absorbable suture ties (2-0 Vicryl) are passed through the opening and used to ligate the proximal and distal ends of the segment (at least 2 cm) which will get excised by scissors.
48376184|NCT05354349|DRUG|PRA023 IV Low Dose|Drug
48376185|NCT05354349|DRUG|PRA023 SC|Drug
48376186|NCT05354349|DRUG|Placebo IV|Placebo
48376187|NCT05354349|DRUG|Placebo SC|Placebo
48376188|NCT05354349|DRUG|PRA023 IV High Dose|Drug
48376189|NCT06152666|OTHER|None - qualitative interviews|These are qualitative interviews and involve no intervention
48376190|NCT05936775|OTHER|nano-hydroxy apatite coated titanium implants|titanium implants with surface treatment of nano-hydroxy apatite
48376191|NCT05936775|OTHER|sandblasted large acid itched coated titanium implant|titanium implants with SLA surface treatment
48376192|NCT03717441|DIAGNOSTIC_TEST|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
48708448|NCT02627287|DRUG|placebo|For subcutaneously (s.c. under the skin) injection
48708449|NCT06608797|BEHAVIORAL|Learning and memory training|The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).
48708450|NCT06608797|BEHAVIORAL|Sham Comparator|The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
48018571|NCT04025918|DRUG|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
48018572|NCT04025918|DRUG|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
48018573|NCT04025918|DEVICE|Manual vasopressor delivery system|"Manual dosing system consisting:~1. Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~2. Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
48018574|NCT03756220|DRUG|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
48018575|NCT03756220|DRUG|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
48018576|NCT01375296|DEVICE|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
48018577|NCT01375296|OTHER|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
48018578|NCT01672125|OTHER|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
48018579|NCT06100614|DIAGNOSTIC_TEST|Presepsin|"Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes."
48376193|NCT02736734|DRUG|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
48708451|NCT05027126|DRUG|Dexketoprofen 25 MG|Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
48018580|NCT06100614|DIAGNOSTIC_TEST|Standard Care|Standard care according to the Dutch EOS guideline
48708452|NCT05027126|DRUG|Fixed dose Dexketoprofen-Vitamin B Complex|Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
48708453|NCT04510948|BEHAVIORAL|Patient Priorities Care|"Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care."
48018581|NCT05951491|DEVICE|Wearable Shoulder Exoskeleton|The wearable shoulder exoskeleton prototype is under development at the University of Idaho to provide gravity support to the shoulder. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
48018582|NCT05951491|DEVICE|Wearable Hand Exoskeleton|The wearable hand exoskeleton prototype is under development at the University of Idaho to provide hand-opening support. Subjects will use the device at home for a period of 5-7 days for at least 2 hours per day.
48018583|NCT05874258|OTHER|Real-PL training + Real-tES(tDCS)|PLtraining : around 40mins, tDCS: 20mins
48018584|NCT05874258|OTHER|Real-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
48018585|NCT05874258|OTHER|Placebo-PL training + Sham-tES (tDCS)|PL training : around 40mins, tDCS: 20mins
48018586|NCT00936026|DRUG|Neramexane|Drug-Drug Interaction Study
48018587|NCT02229955|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
48175723|NCT05163210|BEHAVIORAL|AO+VR|The experimental treatment will consist of 15 hours (min. 15, max. 20), and will be carried out 4 days/week for a total duration of 5 weeks. During the rehabilitation sessions, the patient will be instructed to carefully watch videos lasting about 1.5 minutes, presented on Liquid Crystal Display (LCD) monitor, consisting in unimanual or bimanual actions performed by an actor, from a lateral perspective. Subsequently, the patient will be asked to imitate the actions presented for at least 3 consecutive times, within a time window of 3 min., using the same objects observed in the video, in a virtual scenario (VR), through the Khymeia Virtual Reality Rehabilitation System (VRRS).
48376194|NCT05308134|OTHER|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
48376195|NCT05308134|OTHER|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
48708454|NCT00161577|DRUG|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
48708455|NCT00161577|OTHER|Placebo|Placebo Comparator
48708456|NCT05662904|BIOLOGICAL|Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion|CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
48708457|NCT05662904|DRUG|Gemtuzumab Ozogamicin|Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
48018588|NCT04660123|DRUG|Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication|"Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.~Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).~Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.~Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.~Antibiotic Program:~Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d."
48018589|NCT02780349|DEVICE|WIRION|Embolic Protection System
48018590|NCT04535596|OTHER|Exercise|12 week long strength training exercises for knee
48018591|NCT02012387|BIOLOGICAL|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
48708458|NCT05304767|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
48018592|NCT02012387|BIOLOGICAL|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
48018593|NCT02012387|BIOLOGICAL|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
48018594|NCT04861623|OTHER|Orange juice|Orange juice will be purchased commercially.
48018595|NCT04861623|OTHER|Placebo juice (Fanta)|Fanta will be purchased commercially.
48708459|NCT03858335|OTHER|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
48018596|NCT06103370|BEHAVIORAL|Peer-educator-based network|The intervention is a social network-based method of dispersing HIV knowledge, HIV self-testing (HIVST) kits, and naloxone in social networks of people who inject drugs (PWID). It targets index participants (peers) to receive training on HIVST, peer education, and linkage to syringe service programs (SSPs) for HIV services.
48018597|NCT01175694|RADIATION|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
48376196|NCT05308134|OTHER|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
48708460|NCT04200768|OTHER|Prospective data and sample collection|Performance of measurements of adiposity, extra collection of blood samples
48708461|NCT02683486|DEVICE|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
48517234|NCT06581562|DRUG|AB-101|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
48708462|NCT02683486|DEVICE|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
48708463|NCT04621214|DEVICE|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
48708464|NCT02593422|BEHAVIORAL|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
48708465|NCT02593422|BEHAVIORAL|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
48018598|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose A)|Liquid formulation administered by intravitreal (IVT) injection
48018599|NCT05160805|DRUG|ONL1204 Ophthalmic solution (Dose B)|Liquid formulation administered by intravitreal (IVT) injection
48708466|NCT06490653|DRUG|Blood Stopper (Ankaferd)|5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
48708467|NCT02804698|BEHAVIORAL|Education intervention|13-week educational and physical activity intervention
48708468|NCT05699252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
48708469|NCT05699252|BEHAVIORAL|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
48708470|NCT05699252|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
48708471|NCT02549222|OTHER|Standard of Care|
48708472|NCT02376101|PROCEDURE|Surgery less than 60 minutes|
48708473|NCT01245881|DEVICE|Non-ablative fractional photothermolysis laser|"* Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8."
48708474|NCT01245881|OTHER|broad-spectrum sunblock (SPF 50+)|
48708475|NCT02072135|DRUG|Exparel|
48708476|NCT00230802|DRUG|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
48708477|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
48708478|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
48708479|NCT03739645|BEHAVIORAL|Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety|After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
48708480|NCT06326619|PROCEDURE|Primary tumor resection|In addition to systemic therapy a primary tumor resection was performed.
48708481|NCT06326619|PROCEDURE|Systemic Therapy|chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
48517235|NCT06581562|DRUG|Rituximab|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
48708482|NCT03023254|OTHER|Hydrotherapy|3-week Avène hydrotherapy
48708483|NCT04450628|PROCEDURE|Surgeon unblinded|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
48018600|NCT05160805|PROCEDURE|Sham procedure|A sham procedure looks like a real injection into the eye but does not penetrate the eye and it does not have any study drug. The procedure is done by touching the eye surface with a syringe without a needle.
48018601|NCT03294369|OTHER|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
48018602|NCT04118322|OTHER|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
48708484|NCT04450628|DEVICE|EndoFLIP 1.0 System EF-100|"The surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication. The data will be evaluated to assess if intraoperative calibration influences postoperative symptoms by comparing the two groups.~Surgery will be scheduled and patients will undergo intraoperative impedance planimetry with EndoFLIP obtaining measurements of the cross-sectional area, balloon pressure, minimum diameter, compliance, length of high pressure segment, and distensibility index of the EGJ using an 8cm EndoFLIP balloon. Sequential assessments will be performed to 30ml and 40ml for up to a minute for each volume of distension. An initial baseline measurement will be obtained after establishment of pneumoperitoneum. A second measurement will occur following hiatal dissection and mobilization but prior to crural closure. Two additional measurements will be obtained after hiatal closure and after fundoplication."
48708485|NCT02088073|DRUG|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
48708486|NCT02088073|DRUG|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
48018603|NCT00078390|DRUG|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
48018604|NCT00078390|OTHER|Chemo-irradiation|Standard of care chemo-irradiation
48018605|NCT06194903|DEVICE|isopropyl alcohol wipes|cellphones will be sanitised with isopropyl alcohol wipes and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
48018606|NCT06194903|DEVICE|UVC box|cellphones will be sanitised in a UVC box and total bacterial load will be assessed immediately before sanitation, immediately after sanitation and 3 hours after sanitation.
48018607|NCT03993418|DIETARY_SUPPLEMENT|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
48018608|NCT03050086|DRUG|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
48018609|NCT03050086|DRUG|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
48018610|NCT03050086|DRUG|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
48708487|NCT02055534|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
48708488|NCT02055534|OTHER|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
48708489|NCT02645851|DRUG|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
48708490|NCT02645851|DEVICE|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
48708491|NCT02645851|DEVICE|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
48018611|NCT02443038|OTHER|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
48018612|NCT06394128|DRUG|Cangpo Liujun Prescription|Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
48018613|NCT06573060|DEVICE|Continuous glucose monitoring|Subjects with T2DM and acute coronary syndrome (n=120) were fitted with continuous glucose monitors (CGM) to closely monitor their blood glucose levels continuously for 14 days.
48018614|NCT04257877|PROCEDURE|Blood sampling|Blood samples for proteomic analysis in plasma of both groups
48018615|NCT06074250|DIETARY_SUPPLEMENT|Fish oil|1500mg EPA +1000mg DHA daily
48018616|NCT06074250|DIETARY_SUPPLEMENT|Probiotics|Combination strain of lactobacillus and bifidobacteria
48018617|NCT06074250|BEHAVIORAL|Prebiotics|Dietary consult with follow-up to ensure target fiber intake is met.
48018618|NCT06074250|BEHAVIORAL|Diet Quality|one time dietary consult at enrollment to discuss strategies to improve overall diet.
48018619|NCT00907894|DRUG|LDT600 (Telbivudine)|LDT600 (Telbivudine)
48175724|NCT05163210|BEHAVIORAL|CO+VR|Patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist. Thus, the general setting for carrying out the rehabilitation sessions will be identical to that of the experimental treatment, except for the fact that the control group will not be involved in action observation before preforming the exercises. Thus, the control treatment is not based on action imitation, but on purely motor execution.
48175725|NCT04716218|PROCEDURE|back up head elevated position|The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
48175726|NCT03723122|BEHAVIORAL|Dyadic Communication Reinforcement Intervention|Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
48376197|NCT06509880|DIETARY_SUPPLEMENT|Adenorine|"The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated."
48376198|NCT06509880|BIOLOGICAL|Placebo|Placebo
48376199|NCT06509880|DRUG|FOLFOX regimen|(Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
48376200|NCT05169866|DRUG|Nifekalant|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to nifekalant arm will receive a bolus of 0.3mg/kg IV in the first 5 minutes and a maintenance dose of 0.2-0.4mg/kg/h for 24 hours.
48376201|NCT05169866|DRUG|Amiodarone|Patients identified with new-onset atrial fibrillation with a sustained duration of greater than 1 minutes and less than 48 hours will be considered for the study. Patients randomized to amiodarone arm will receive a bolus of 150mg IV in the first 10 minutes and a maintenance dose of 0.5-1mg/min for 24 hours.
48376202|NCT02154152|DRUG|Homoeopathic Medicine causticum 200c|
48376203|NCT05694923|DRUG|Empagliflozin 10 MG|non fatty liver non alcoholic patients Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg
48376204|NCT04561700|DIAGNOSTIC_TEST|Reporting of sucking patterns captured by Instrumented Bottle|In the intervention group, data on nutritive sucking and feeding cues captured by the Instrumented Bottle will be made available to speech therapists to document the feeding session and provide written recommendations in their weekly report.
48376205|NCT04561700|DIAGNOSTIC_TEST|Control|In the control group, the information captured by the Instrumented Bottle will not be made available to speech therapists and therefore, will not be used to document a feeding session or provide weekly recommendations.
48376206|NCT01886105|DRUG|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
48376207|NCT01886105|OTHER|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
48376208|NCT01886105|RADIATION|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
48376209|NCT01734499|BEHAVIORAL|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
48018620|NCT06368583|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of vaginal delivery with neuraxial analgesia
48175727|NCT05434585|BIOLOGICAL|ABO1009-DP|Vaccine
48175728|NCT05434585|BIOLOGICAL|ABO-CoV.617.2|Vaccine
48175729|NCT05434585|OTHER|Placebo|Placebo
48175730|NCT00968006|DRUG|Sitagliptin|100 mg once daily for 4 weeks
48175731|NCT02647788|DRUG|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
48175732|NCT02647788|DRUG|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
48175733|NCT02416713|DEVICE|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
48175734|NCT02416713|OTHER|Education Only|No active intervention, educational materials will be provided
48018621|NCT00760279|DRUG|Azithromycin|
48175735|NCT02976168|OTHER|12° head down tilt|supine head down tilt
48376210|NCT01734499|BEHAVIORAL|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
48708492|NCT02645851|OTHER|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
48708493|NCT03104972|DEVICE|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
48018622|NCT03569956|OTHER|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
48018623|NCT00018109|DRUG|glutamine|
48018624|NCT00018109|DRUG|creatine monohydrate|
48018625|NCT05020743|OTHER|No intervention|Not applicable for a Natural History Study
48018626|NCT05369221|DEVICE|ReSpace™|All of the subjects will be injected with ReSpace™ hydrogel.
48018627|NCT04413318|DEVICE|Electronic device (VBM©)|Continuous control of tracheal cuff pressure using an electronic device (VBM©) for 6-hours followed by continuous control using a pneumatic device (Nosten©) for 6-hours.
48018628|NCT04413318|DEVICE|Pneumatic device (Nosten©)|Continuous control using a pneumatic device (Nosten©) for 6-hours followed by 6-hours of continuous control using an electronic device (VBM©).
48018629|NCT05383170|DRUG|CyPep-1|Intratumoral injection
48018630|NCT05383170|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
48018631|NCT00902616|DIETARY_SUPPLEMENT|L-arginine|3gm TDS for three months
48018632|NCT00902616|DIETARY_SUPPLEMENT|Placebo Lactose powder|3gm TDS for 3 months
48175736|NCT02609152|DRUG|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
48175737|NCT02609152|DRUG|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
48018633|NCT05809895|DRUG|Ociperlimab|900 mg intravenously (IV) every 3 weeks (Q3W)
48018634|NCT05809895|DRUG|Tislelizumab|200 mg intravenously (IV) Q3W
48018635|NCT05809895|DRUG|Paclitaxel|90 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
48018636|NCT05809895|DRUG|Nab-paclitaxel|100 mg/m2 intravenously (IV) on Days 1, 8 and 15 every 28 days
48018637|NCT05809895|DRUG|Carboplatin|AUC 2 intravenously (IV) on Days 1 and 8 every 21 days
48018638|NCT05809895|DRUG|Placebo|normal saline intravenously (IV) Q3W
48018639|NCT05809895|DRUG|Pembrolizumab|200 mg intravenously (IV) Q3W
48018640|NCT05809895|DRUG|Gemcitabine|1000 mg/m2 intravenously (IV) on Days 1 and 8 every 21 days
48018641|NCT02334748|DRUG|canakinumab|canakinumab
48018642|NCT00780962|DRUG|N-Acetylcysteine (NAC)|"Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
48175738|NCT05158023|DRUG|Placebo Comparator|Sterile solution for subcutaneous injection
48175739|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
48175740|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
48175741|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
48175742|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
48018643|NCT00780962|DRUG|0.9% Sodium-chloride|"Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours."
48018644|NCT04560712|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
48018645|NCT04560712|OTHER|Best Practice|Undergo usual care
48018646|NCT04560712|OTHER|Questionnaire Administration|Ancillary studies
48018647|NCT01513317|DRUG|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
48018648|NCT01513317|DRUG|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
48018649|NCT01513317|DRUG|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
48018650|NCT03448367|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
48018651|NCT04839081|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
48018652|NCT01063010|DRUG|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
48708494|NCT03104972|DEVICE|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
48708495|NCT03104972|DEVICE|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
48018653|NCT01063010|DRUG|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
48018654|NCT05455567|DIAGNOSTIC_TEST|OCTA|Choriocapillary vessel density calculated with OCTA
48018655|NCT00970086|DRUG|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
48018656|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
48175743|NCT01175564|DRUG|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
48175744|NCT01175564|DRUG|Placebo|Placebo tablet, single dose and 6 days repeated dose
48376211|NCT01734499|BEHAVIORAL|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
48708496|NCT04582435|DRUG|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
48018657|NCT02946294|DRUG|Bupivacaine 0.25% with epinephrine|
48175745|NCT00626015|BIOLOGICAL|PEP-3-KLH conjugate vaccine|Given intradermally
48175746|NCT00626015|BIOLOGICAL|daclizumab|Given IV
48376212|NCT05255939|PROCEDURE|distal TRA group|dTRA for PCI procedure to ACS patients.
48376213|NCT05255939|PROCEDURE|conventional TRA group|Conventional TRA for PCI procedure to ACS patients
48376214|NCT00413322|DRUG|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
48376215|NCT00413322|DRUG|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
48376216|NCT06459427|PROCEDURE|Robot-Assisted Stereotactic Brainstem Hematoma Puncture|Positioning and surgical procedures are carried out based on the use of robotic navigation equipment. Precise preoperative design is conducted using preoperative imaging data to create a preoperative three-dimensional visualization model. During surgery, robot-assisted stereotactic puncture is performed. First day, urokinase may be used as needed to assist in dissolving residual hematoma and adjusting the depth of the drainage tube. For every 10 mL of hematoma, 1 mL of 10,000 IU urokinase in 0.9% sodium chloride solution is injected, followed by flushing with 2 mL of 0.9% sodium chloride solution through the tube after closing it for 2 hours, and then reopening it. Urokinase injections into the drainage tube are used 1-2 times daily to facilitate hematoma drainage. Third day, if the residual hematoma volume is \<3 mL or if the drainage tube has been in place for \>5 days, the drainage tube is removed.
48018658|NCT00673452|DRUG|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
48018659|NCT00673452|DRUG|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
48018660|NCT01901380|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula + LGG|
48018661|NCT01866189|OTHER|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
48018662|NCT03290508|DIAGNOSTIC_TEST|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
48018663|NCT04090944|PROCEDURE|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
48175747|NCT00626015|DRUG|temozolomide|Given by mouth.
48175748|NCT00626015|OTHER|placebo|Given IV
48376217|NCT06459427|DRUG|Conservative non-surgical treatment|Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
48708497|NCT06512896|OTHER|FOLactis|Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
48708498|NCT02599649|DRUG|Lirilumab|3 mg/kg by vein every 4 weeks.
48708499|NCT02599649|DRUG|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
48708500|NCT02599649|DRUG|Azacitidine|75 mg/m\^2 by vein for 7 days of a 28 day cycle.
48708501|NCT04372654|DEVICE|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
48708502|NCT05181774|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
48708503|NCT05181774|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
48708504|NCT01704729|PROCEDURE|group1|Non-cycloplegic self-refraction +conventional glasses
48708505|NCT01704729|PROCEDURE|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
48175749|NCT00626015|BIOLOGICAL|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
48376218|NCT04066894|PROCEDURE|Explantation|Undergo lead removal
48376219|NCT04066894|OTHER|Quality-of-Life Assessment|Ancillary studies
48376220|NCT04066894|OTHER|Questionnaire Administration|Ancillary studies
48376221|NCT04066894|DEVICE|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
48376222|NCT04066894|DEVICE|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
48376223|NCT04066894|PROCEDURE|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
48376224|NCT05719701|DRUG|ICP-490|Several dose groups of ICP-490 are planned for the dose exploration.
48517236|NCT06581562|DRUG|Cyclophosphamide|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
48517237|NCT06581562|DRUG|Fludarabine|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
48517238|NCT03709511|OTHER|Cardiac rehabilitation|perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
48517239|NCT00378144|DRUG|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]
48517240|NCT04970303|DRUG|Methylphenidate|Retina or Concerta
48708506|NCT01704729|PROCEDURE|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
48708507|NCT01704729|PROCEDURE|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
48708508|NCT06424158|OTHER|Massage Therapy|Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
48376225|NCT05719701|DRUG|Dexamethasone|Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
48376226|NCT04718363|OTHER|PNF stretching|A contract-relax PNF stretching technique will be applied to hamstring muscle.
48708509|NCT06606067|DRUG|Duloxetine|30 mg daily 2 weeks before surgery and 1 week after surgery
48708510|NCT06606067|DRUG|Placebo|Placebo tablet daily
48708511|NCT00998855|BEHAVIORAL|Exercise|12 wk aerobic or/ resistance exercise program
48708512|NCT05628506|DRUG|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
48175750|NCT05750277|OTHER|Evening Time-Restricted Eating|Eating between 8am-6pm.
48708513|NCT06606457|BEHAVIORAL|Pain Acknowledgment Coping and Empowerment in CF (PACE CF)|The Pain Acknowledgment Coping and Empowerment in CF (PACE CF) program is a newly developed 3-session mind-body pain management intervention for adults with cystic fibrosis (CF), developed with CF community input. The sessions are delivered by the the CF care team psychologist. Each session will teach mind-body strategies to increase comfort and reduce the impact of pain on the participant\&#39;s life. These strategies include understanding pain in CF from a mind-body perspective, learning relaxation and mindfulness-based skills, identifying and practicing individualized cognitive and behavioral strategies that improve comfort and well-being, and discussing communication skills that empower people living with CF and pain. Participants will receive a workbook that will provide related education and resources and reinforce skill practice.
48708514|NCT02479165|DRUG|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
48708515|NCT02479165|DRUG|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
48708516|NCT04757688|RADIATION|Cardiac radioablation (CRA)|CRA to 25 Gy in 1 fraction
48708517|NCT04206475|OTHER|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
48708518|NCT04206475|OTHER|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
48708519|NCT03975127|OTHER|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
48376227|NCT04718363|OTHER|Non-vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring non-vibration foam rolling.
48708520|NCT04548648|DRUG|Acalabrutinib|Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
48708521|NCT05264441|DEVICE|In-Check DIAL G16|Patients will inspire into an In-Check DIAL G16 device.
48708522|NCT01806025|OTHER|no intervention|
48708523|NCT00624819|BIOLOGICAL|GSK1024805A|No vaccination in this trial
48708524|NCT00624819|BIOLOGICAL|Prevenar|No vaccination in this trial
48708525|NCT00624819|BIOLOGICAL|Infanrix hexa|No vaccination in this trial
48708526|NCT00624819|BIOLOGICAL|Havrix|No vaccination in this trial
48708527|NCT00624819|BIOLOGICAL|Varilrix|No vaccination in this trial
48376228|NCT04718363|OTHER|Vibration foam rolling prior to PNF stretching|Prior to PNF stretching, participant will perform unilateral hamstring vibration foam rolling (48 Hz).
48376229|NCT04901520|OTHER|High Intensity Training|High Intensity Training group performed resistance training with the intensity of 80 - 90 % of 1RM with 4 - 6 repetition
48517241|NCT01994785|DIAGNOSTIC_TEST|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
48175751|NCT01316887|DRUG|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
48175752|NCT01316887|DRUG|125mcg once-daily GSK573719|GSK573719
48175753|NCT01316887|DRUG|Placebo once-daily|inactive
48376230|NCT04901520|OTHER|Moderate Intensity Training|Moderate Intensity Training group performed resistance training with the intensity of 65 - 75 % of 1RM with 8 - 10 repetition
48175754|NCT05804682|PROCEDURE|Fascial Neck Dissection|Central and lateral neck dissection with the fascial technique
48175755|NCT05804682|PROCEDURE|Standard Neck Dissection|Central and lateral neck dissection with the standard technique
48376231|NCT04901520|OTHER|Low Intensity Training|Low Intensity Training group performed resistance training with the intensity of 50 - 60 % of 1RM with 12 - 14 repetition
48376232|NCT03754400|BIOLOGICAL|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
48708528|NCT04837729|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
48376233|NCT03754400|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
48376234|NCT04276532|PROCEDURE|sentinel lymph node sampling (SLN)|"Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted."
48376235|NCT04276532|PROCEDURE|pelvic lymphonodectomy (PLN)|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
48376236|NCT05229718|OTHER|Diabetes Collaborative Care Model for Young Adults|We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.
48708529|NCT05615987|DRUG|Onabotulinumtoxina for Injection|200iu/2ml in both groups
48708530|NCT02187523|DRUG|Hydrochlorothiazide|
48708531|NCT02187523|DRUG|Telmisartan|
48708532|NCT02187523|DRUG|Telmisartan/HCTZ FDC|
48708533|NCT01133275|DRUG|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
48708534|NCT01133275|DRUG|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
48517242|NCT03859544|OTHER|Retrospective study|Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
48708535|NCT00076336|DRUG|Telbivudine|600mg/day oral tablet for 104 weeks
48708536|NCT00076336|DRUG|Lamivudine|100mg/day oral tablet for 104 weeks
48708537|NCT00076336|DRUG|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
48708538|NCT01711229|DRUG|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
48517243|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
48708539|NCT01711229|DRUG|oral acetaminophen|oral acetaminophen will be given preoperatively
48708540|NCT05186701|OTHER|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
48708541|NCT05186701|OTHER|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
48708542|NCT04726033|DRUG|64Cu-DOTA-TLX592|TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
48708543|NCT05762861|OTHER|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
48708544|NCT00174863|DRUG|SR31747A|
48708545|NCT00361699|DRUG|Statin|
48018664|NCT01946308|OTHER|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
48018665|NCT02067403|OTHER|Pressure-support Eadi optimization|
48018666|NCT01110239|PROCEDURE|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
48018667|NCT06572358|OTHER|MetProUltima|"Test product Name: MetProUltima Marketed By\| Manufactured By: Meteoric Biopharmaceuticals Private Limited Mode of Usage: Take one capsule after each meal, twice daily. Frequency: Twice a Day Route of Administration: Oral"
48018668|NCT04095234|PROCEDURE|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation. If the patient has an electronically charged device, they will not receive TENS stimulation.
48018669|NCT04095234|PROCEDURE|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
48018670|NCT03377621|DEVICE|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
48018671|NCT06293417|DRUG|Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin|Treatment group
48018672|NCT06293417|DRUG|Dose escalation of moderate-intensity statin|Control group
48018673|NCT02165722|BEHAVIORAL|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
48517244|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
48517245|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
48018674|NCT04516161|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
48018675|NCT01007461|DRUG|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started \> 5 minutes but \< 20 minutes (approximately) prior to coronary artery reperfusion.
48018676|NCT01007461|DRUG|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
48175756|NCT05072262|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml
48376237|NCT05229718|OTHER|Usual Care Model|Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
48376238|NCT02100215|OTHER|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
48175757|NCT05072262|DRUG|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex)
48175758|NCT00565838|PROCEDURE|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
48175759|NCT05155722|DRUG|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
48376239|NCT02100215|OTHER|Expert Modeling|70 minutes of expert modeling videos
48517246|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
48517247|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
48517248|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
48708546|NCT01693380|BIOLOGICAL|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
48018677|NCT00563797|DRUG|Mecamylamine|mecamylamine 10mg/day for 12 weeks
48018678|NCT00563797|DRUG|Placebo|Placebo pill
48175760|NCT03194945|DRUG|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
48175761|NCT03194945|DRUG|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
48175762|NCT03194945|DRUG|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
48175763|NCT03194945|DRUG|CSII alone|No OHA is given after short-term intensive CSII
48175764|NCT03655665|DRUG|Ofloxacin otic solution|Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
48708547|NCT01693380|BIOLOGICAL|Control vaccine|"Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
48018679|NCT06663124|DEVICE|EC-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
48708548|NCT01903551|DEVICE|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
48708549|NCT06600763|OTHER|Ice pack|The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated.
48708550|NCT06600763|OTHER|warm gel pad|Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
48708551|NCT01719029|OTHER|Low-Carbohydrate/Higher Fat Diet|
48708552|NCT01719029|OTHER|High Carbohydrate/Low fat diet|
48708553|NCT06261736|OTHER|Prophylactic antibiotics|These participants will be given a single dose of an oral antibiotic prior to the procedure.
48708554|NCT06261736|OTHER|No antibiotics|These participants will not be given an antibiotic prior to the procedure.
48708555|NCT05529316|DRUG|Botensilimab|An anti-CTLA-4 monoclonal antibody
48708556|NCT05529316|DRUG|Balstilimab|An anti-PD-1 monoclonal antibody
48018680|NCT02133326|DRUG|Caldolor|Subject will be given Caldolor by IV prior to surgery.
48018681|NCT02133326|DRUG|Ofirmev|Subject will be given Ofirmev prior to surgery.
48175765|NCT04949854|DEVICE|B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter|control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire
48175766|NCT04949854|DEVICE|B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter|Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
48708557|NCT06607432|DEVICE|Transcranial Interference Stimulation (tIS)|Field strength dose of 0.30 - 0.40 V/m
48708558|NCT06607432|OTHER|Sham tIS|Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
48708559|NCT03777917|DEVICE|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
48708560|NCT03762616|DIAGNOSTIC_TEST|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
48708561|NCT03762616|DIAGNOSTIC_TEST|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
48708562|NCT04832906|DRUG|Ulipristal Oral Tablet|A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
48018682|NCT06180655|BEHAVIORAL|Diabetes Self-Management Education and Support (DSMES) plus Tai Chi Easy (TCE)™|Participants will be asked to attend 45 minutes of DSMES and 45 min of TCE twice a week for 6 weeks. All classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults.
48018683|NCT04054167|DRUG|Low Dose Radiation Therapy|Undergo ultra low dose radiation
48018684|NCT01513291|DRUG|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
48018685|NCT01513291|DRUG|Placebo|Placebo, 2 tablets, orally, once daily
48018686|NCT01511887|DRUG|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
48018687|NCT00051116|DRUG|CC-5013|
48018688|NCT06664281|BEHAVIORAL|SIT|sprint interval training
48018689|NCT06664281|BEHAVIORAL|SIT combined RIPC|sprint interval training combined with remote ischemic preconditioning
48517249|NCT05175040|PROCEDURE|Prophylactic manual rotation|Prophylactic manual rotation, performed in the experimental arm, involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation, performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
48708563|NCT04832906|PROCEDURE|Uterine artery embolization|Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
48708564|NCT04881500|OTHER|Motivational interview|Patients will follow motivational interview (2 individual sessions by phone)
48708565|NCT04881500|OTHER|Routine Care|Patients will follow routine care
48018690|NCT00134277|PROCEDURE|Infragenual dilatation|Infragenual dilatation
48018691|NCT00134277|PROCEDURE|Infragenual dilatation with stenting|Infragenual dilatation with stenting
48018692|NCT00134277|PROCEDURE|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
48376240|NCT02100215|OTHER|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
48708566|NCT03610503|OTHER|Music|Participants in this arm will listen to music during the EMG testing
48018693|NCT00134277|PROCEDURE|Laser therapy|Laser therapy
48018694|NCT06435429|DRUG|Zanidatamab|Administered by intravenous infusion
48018695|NCT06435429|DRUG|Trastuzumab|Administered by intravenous infusion
48018696|NCT06435429|DRUG|Eribulin|Administered by intravenous infusion
48018697|NCT06435429|DRUG|Vinorelbine|Administered by intravenous infusion
48018698|NCT06435429|DRUG|Gemcitabine|Administered by intravenous infusion
48175767|NCT05544318|OTHER|Diatary advices|Advice regarding energy, protein and nutrient intake during cancer treatment
48018699|NCT06435429|DRUG|Capecitabine|Given orally
48018700|NCT03152812|PROCEDURE|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
48018701|NCT04097067|RADIATION|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
48018702|NCT04384536|PROCEDURE|Neural therapy application|Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
48376241|NCT02127866|DRUG|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
48376242|NCT02127866|DRUG|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
48376243|NCT02791906|DRUG|ISMN|
48376244|NCT02791906|DIETARY_SUPPLEMENT|Vitamin C|
48708567|NCT06159205|OTHER|standard exercises|Standard exercises for TKA patients.
48708568|NCT06159205|OTHER|core stability exercises|Core stability exercises for TKA patients.
48708569|NCT00355342|DRUG|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
48708570|NCT00355342|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
48018703|NCT00928148|DRUG|SPD465|50 or 75 mg once daily for 7 days
48018704|NCT00928148|DRUG|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
48018705|NCT00928148|DRUG|Placebo|Once daily for 7 days
48018706|NCT06205290|BIOLOGICAL|Liso-cel|Specified dose on specified days
48018707|NCT06205290|DRUG|Idelalisib|Specified dose on specified days
48018708|NCT06205290|DRUG|Rituximab|Specified dose on specified days
48018709|NCT06205290|DRUG|Bendamustine|Specified dose on specified days
48018710|NCT06205290|DRUG|Fludarabine|Specified dose on specified days
48018711|NCT06205290|DRUG|Cyclophosphamide|Specified dose on specified days
48018712|NCT00637169|OTHER|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
48018713|NCT00764075|DEVICE|Beutel TM|application of BeutelTM
48175768|NCT00519064|BIOLOGICAL|Adjuvanted influenza vaccine|
48175769|NCT06446271|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.~Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines."
48175770|NCT04311190|OTHER|Family engagement|Physical exercises and simple care tasks
48376245|NCT04744935|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
48708571|NCT00355342|DEVICE|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
48708572|NCT03449693|DIETARY_SUPPLEMENT|Magnesium Oxide Supplement|Magnesium Oxide tablet
48708573|NCT01868620|DEVICE|Iontophoretic CXL|
48708574|NCT01868620|DEVICE|Standard CXL|
48708575|NCT05235958|OTHER|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
48708576|NCT05235958|OTHER|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
48708577|NCT04283942|BEHAVIORAL|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
48708578|NCT04283942|BEHAVIORAL|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
48708579|NCT00384423|DRUG|PRX-03140|
48708580|NCT02640625|DIETARY_SUPPLEMENT|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
48708581|NCT01744678|BEHAVIORAL|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
48708582|NCT01744678|BEHAVIORAL|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
48708583|NCT06536205|BEHAVIORAL|psychoeducation|Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
48175771|NCT04933981|DIAGNOSTIC_TEST|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
48708584|NCT01867957|BIOLOGICAL|Low-dose GC1109|50ug/dose
48708585|NCT01867957|BIOLOGICAL|High-dose GC1109|100ug/dose
48018714|NCT00764075|OTHER|standard|standard procedure will be applied but no Beutel TM software
48175772|NCT00174356|DRUG|CI 1033|
48175773|NCT00174356|DRUG|PACLITAXEL|
48175774|NCT00174356|DRUG|CARBOPLATIN|
48376246|NCT02553486|OTHER|quality of life evaluation|
48376247|NCT00612300|BEHAVIORAL|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
48376248|NCT00612300|BEHAVIORAL|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
48376249|NCT00006354|DIETARY_SUPPLEMENT|mistletoe extract|
48376250|NCT06479317|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
48376251|NCT06479317|DRUG|Dexamethasone oral|Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
48708586|NCT01867957|BIOLOGICAL|Low-dose Placebo|0.9% Saline 0.5 mL
48708587|NCT01867957|BIOLOGICAL|High-dose Placebo|0.9% Saline 1.0 mL
48708588|NCT01961960|BIOLOGICAL|ASP7374|intramuscular
48708589|NCT03024333|OTHER||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
48376252|NCT05894824|DRUG|T-Dxd(Trastuzmab deruxtecan), Ramucirumab|"Phase Ib will use a standard 3+3 scheme with the planned doses of T-DXd (4.4\~6.4 mg/kg) once every 3 weeks in combination with Ramucirumab 8mg/kg administered once every 2 weeks.~* Dosing Regimen~  * Trastruzumab deruxtecan : One IV infusion every 3 weeks on Day 1 of each 21-day cycle~ * Ramucirumab : One IV infusion on every 2 weeks on Day 1,15 of each 28-day cycle"
48376253|NCT06375902|BEHAVIORAL|PragmaCom|Cognitive behavioral intervention targeting the ability to understand metaphors
48708590|NCT00593853|DRUG|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
48708591|NCT00593853|DRUG|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
48708592|NCT06037785|BEHAVIORAL|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
48708593|NCT00992381|DRUG|PN400|500mg Naproxen and 20mg esomeprazole
48708594|NCT00992381|DRUG|Naprosyn|500mg Naproxen
48708595|NCT03434431|OTHER|Reverse dieting|
48708596|NCT06026371|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
48708597|NCT06026371|DRUG|Placebo|Given PO
48708598|NCT03717792|OTHER|no intervention|no intervention
48708599|NCT05179603|DRUG|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
48708600|NCT05179603|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
48708601|NCT06380439|PROCEDURE|wrist ankle acupuncture|wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
48708602|NCT06086860|OTHER|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
48708603|NCT06086860|OTHER|Mulligan mobilization without dry needling|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
48708604|NCT01294943|DEVICE|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
48708605|NCT01203436|PROCEDURE|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
48708606|NCT01203436|PROCEDURE|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
48708607|NCT03568552|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
48708608|NCT03082573|DRUG|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
48708609|NCT00789581|DRUG|Doxorubicin|Doxorubicin 60 mg/m2
48018715|NCT00764075|DEVICE|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
48376254|NCT00934518|RADIATION|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
48175775|NCT04697368|DEVICE|Exoskeleton-Assisted Upper Limb Rehabilitation|"The patients will be undergone 25+/-3 Armeo-P training sessions, each lasting 40 minutes (i.e. five times a week for five consecutive weeks). During the first session, the device should be adjusted to the patient's arm size and the angle of suspension. The working space and the exercises will be selected once the UL has been fitted with the system. The selection of personalized exercises will be based on the motor skills of each patient and the difficulty can be gradually increased during training. In particular, a course of exercises has been defined in which the difficulty (suspension rate; the level of assistance; the complexity of movement (1D, 2D, 3D)).~The physiotherapist will choose the modality based on the patient's motor skills (standardized personalized training)."
48376255|NCT00934518|DRUG|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
48376256|NCT05751824|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
48708610|NCT00789581|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2
48708611|NCT00789581|DRUG|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
48018716|NCT02419716|DEVICE|Cologuard|Prescription of Cologuard for at-home stool collection
48018717|NCT04027686|DEVICE|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
48018718|NCT04027686|PROCEDURE|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
48018719|NCT04606238|OTHER|Decision Aid|Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
48708612|NCT00789581|DRUG|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
48708613|NCT05889442|DRUG|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
48708614|NCT05889442|OTHER|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
48708615|NCT00391677|BEHAVIORAL|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
48018720|NCT02810834|BEHAVIORAL|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
48018721|NCT02810834|BEHAVIORAL|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
48708616|NCT00391677|BEHAVIORAL|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
48018722|NCT06110546|DRUG|Methadone group|Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or \>200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or \>3mg/hr).
48018723|NCT06110546|DRUG|Usual care|Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
48018724|NCT01136824|OTHER|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms"
48018725|NCT03772405|DRUG|Nascum Plus|nasal application of nascum plus
48018726|NCT03772405|OTHER|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
48018727|NCT03922529|BEHAVIORAL|MACRO-I|MACRO-I coaches engage with patients regularly while they are still inpatients, and then by telephone once they are discharged. Coaching incorporates innovative techniques for holistic risk assessment (medical, functional, psychosocial), guidance to initiate CR in a format aligned with each patient's risks and preferences (i.e., CR as either site-based, home-based, or in a hybrid format \[site transitioning to home\]), behavioral prompts based on their personal goals of care, and de-prescribing of sedating medications.
48018728|NCT03922529|OTHER|Usual Care|Participants will receive usual care that is recommended by their providers. MACRO study personnel will follow the participant for the course of the study to assess endpoints in comparison to the MACRO-I arm.
48018729|NCT05166967|DRUG|Individual Antithymocyte globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
48018730|NCT05166967|DRUG|Antithymocyte globulin|A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
48018731|NCT01295606|DRUG|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
48376257|NCT05751824|OTHER|Manually remind the patients to review.|Medical staff remind patients to review by telephone.
48376258|NCT05477927|BIOLOGICAL|Dual-targeting VEGFR1 and PD-L1 CAR-T cells|"In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.~In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition."
48376259|NCT02806206|DRUG|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
48376260|NCT02806206|DRUG|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
48376261|NCT06159946|DEVICE|Access-H2O faucet|The assigned invention was developed to test the feasibility of the prototype of the Access-H2O faucet by assessing whether subjects can activate the faucet to control water outputs via the motion sensor, eye gaze, and a speech speaker. To activate the faucet via the motion sensor, each subject was asked to place his or her hand near the motion sensor. To activate the faucet via the eye gaze, each subject was asked to look directly at the eye gaze sensor. To activate the faucet via the speech speaker, each subject was asked to speak to the speaker. Each subject performed the same function three times. The water from the faucet was used for drinking, rinsing, and grooming.
48376262|NCT03058549|BEHAVIORAL|Family Expectations|Relationship education and referral services for expectant couples.
48708617|NCT03431818|OTHER|Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.
48376263|NCT03641235|BIOLOGICAL|Sputum collection|Analysis of Sputum collection
48376264|NCT06316401|PROCEDURE|ESD of large LSTs under SA|endoscopic submucosal dissection of large colorectal lesions under spinal anesthesia
48708618|NCT02700789|PROCEDURE|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
48708619|NCT00849706|OTHER|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
48708620|NCT01128348|BEHAVIORAL|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
48376265|NCT06231992|PROCEDURE|opioid anaesthesia|I.V Fentanyl (1-2ug/kg) before induction of general anesthesia with I.V propofol (1-2mg/kg), atracurium (0.5mg/kg). Intermittent boluses of fentanyl will be given intraoperatively when needed to maintain the change in hemodynamics within 20 % of the baseline.
48175776|NCT04697368|OTHER|Traditional Upper Limb Rehabilitation|The control group (CG), in addition to the conventional treatment based on the routine rehabilitation program, will follow 25+/-3 sessions of traditional upper limb rehabilitation (i.e. five times a week for five consecutive weeks). Each session will consist of passive, active-assisted, and active exercises addressed for shoulder, arm and hand motor rehabilitation.
48376266|NCT06231992|PROCEDURE|Opioid free anaesthesia|"* IV Ketamine (0.25-0.5 mg/kg) before induction of general anesthesia with I.V propofol (1-2 mg/kg), atracurium (0.5mg/kg) followed by(0.25mg /min) infusion of ketamine for maintenance~* Dexamethasone I.V (8 mg) will be given before induction of general anesthesia.~* magnesium sulphate (20 mg/kg)in 100ml saline within 10 mints Followed by infusion of magnesium sulphate at rate of (10mg/kg/h)."
48376267|NCT02951143|DRUG|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 601) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 600) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
48175777|NCT05531890|DRUG|GTX-102 medium dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
48175778|NCT05531890|DRUG|GTX-102 medium dose slow Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
48708621|NCT03789695|DRUG|Dabigatran Etexilate|Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
48708622|NCT04167215|PROCEDURE|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
48175779|NCT05531890|DRUG|GTX-102 high dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
48708623|NCT04167215|PROCEDURE|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
48376268|NCT02951143|DRUG|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
48376269|NCT05538442|OTHER|Physiological recordings|Physiological, cognitive, biological measurments
48018732|NCT05694364|DRUG|Fludarabine|Fludarabine is an antimetabolite given prior to lymphodepletion.
48018733|NCT05694364|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
48018734|NCT05694364|BIOLOGICAL|PRGN-3007|PRGN-3007 T cells are autologous T cells that are genetically modified ex vivo with the Sleeping Beauty (SB) system to express a ROR1-specific chimeric antigen receptor (ROR1 CAR), membrane bound interleukin-15 (mbIL15), a kill switch derived from truncated form of human epidermal growth factor receptor (HER1t) and include a built-in mechanism for intrinsic downregulation of programmed cell death receptor 1 (PD-1) expression on UltraCAR-T cells.The transgenes are delivered from a SB transposon which ensures co-expression all transgenes in all transfected cells. T cells are selected from the apheresis product and can be modified with the SB system to manufacture the T cells with the potential of infusing within 2 days from genetic modification.
48018735|NCT02616224|OTHER|No intervention|No intervention was administered in this study.
48175780|NCT05531890|DRUG|GTX-102 low dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
48175781|NCT05531890|DRUG|Betamethasone solution as intramuscular injection Period 1 and Period 2|reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
48175782|NCT05531890|DRUG|Betamethasone Oral Solution Period 1 and Period 2|Comparator product 0.1 mg/kg betamethasone oral drops solution
48708624|NCT04167215|PROCEDURE|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
48708625|NCT00672087|GENETIC|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
48708626|NCT01741142|DRUG|ABT-436|Subjects receiving ABT-436
48708627|NCT01741142|DRUG|Escitalopram|Subjects receiving escitalopram
48708628|NCT01741142|DRUG|Placebo|Subject receiving placebo
48708629|NCT05357664|DEVICE|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
48708630|NCT05357664|DEVICE|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
48175783|NCT04344210|BEHAVIORAL|Tele-interventions related to diabetes management and mental well-being|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
48175784|NCT06443424|DEVICE|ultrasound device|usage of ultrasound device in pediatric airway asessment
48175785|NCT02648711|DRUG|CRLX101|infusion CRLX101 weekly
48708631|NCT06605911|DRUG|topical triamcinolone acetonide|ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
48018736|NCT04401007|OTHER|Erector Spinae Plane Block with 1.5% lidocaine|Erector spinae plane (ESP) block is a new regional nerve block technique that involves a percutaneous injection of local anesthetic as a bolus through a needle or catheter into the fascial plane between the erector spinae muscle and the transverse processes in the upper or mid back.
48018737|NCT00309933|PROCEDURE|cognitive assessment|
48018738|NCT00309933|PROCEDURE|psychosocial assessment and care|
48018739|NCT00309933|PROCEDURE|quality-of-life assessment|
48018740|NCT01543269|DRUG|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
48376270|NCT02395757|DEVICE|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
48376271|NCT04904952|DRUG|N-acetylcysteine tablet 600mg|N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
48376272|NCT04904952|DRUG|Placebo tablet 600mg|Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
48376273|NCT00002110|DRUG|Cysteamine|
48708632|NCT06605911|DRUG|Topical Curcumin|Ten patients with OLP received topical curcumin four times per day for six weeks.
48376274|NCT00002110|DRUG|Zidovudine|
48376275|NCT05443776|OTHER|Biomaterial implantation|Implant a approved biomaterial by European Regulatory Agencies
48376276|NCT04270331|OTHER|PADS protocol|Assessment and management per PADS protocol
48376277|NCT06023485|OTHER|stress ball use during subcutaneous injection|The effect of stress ball use on pain during subcutaneous injection
48376278|NCT06452420|OTHER|Traumatic dental injuries|The Degree of knowledge and Attitude of Medical Residents and Interns in Egypt regarding Emergency treatment of traumatic dental injuries.
48376279|NCT04194138|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
48376280|NCT04600531|DEVICE|1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)|"tDCS will be delivered through a pair of identical square rubber electrodes (size 35 cm2), placed in rectangular saline-soaked sponges. For the stimulation of M1, electrodes will be placed over C3 or C4 according to the 10-20 EEG system, matching with the M1 contralateral to the performing dominant hand. The reference electrode will be positioned on F1 or F2, ipsilateral to the dominant hand.~The current stimulation will be slowly ramped up from 0 mA to 2 mA in one minute. For the anodal tDCS condition, this intensity will be maintained for the duration of the SRT-task (approximately 20 minutes). This will result in a current density of 0,057 mA/cm2. For the sham tDCS condition - unbeknown to the subject - stimulation will be gradually decreased towards 0 mA immediately after the one-minute ramp-up. During the last block of the SRT-task, this gradual ramping-up and -down of the current stimulation will be repeated to optimize the process of blinding of participants."
48376281|NCT04600531|DEVICE|4x1 Multichannel Stimulation Adapter for High Definition Transcranial Direct Current Stimulation (HD tDCS)|"HD tDCS will be delivered over M1. By connecting the conventional tDCS device (described above) to this adapter, the direct current is delivered along the 4x1 HD tDCS configuration, allowing for more specific neuromodulation. Stimulation is delivered by means of one central gel-electrode and four return-electrodes placed in plastic encasings embedded in an EEG cap.~Stimulation of left M1 (right hand = performing): delivered via the central electrode corresponding with C3 and held in place using a synthetic cap to hold the HD-tDCS electrodes on the head. Return-electrodes are positioned at Cz, F3, T7 and P3 (10-20 EEG system).~Stimulation of right M1 (left hand = performing): central electrode will be positioned at C4 with the return-electrodes at Cz, F4, T8 and P4.~Strategies for anodal and sham stimulation are identical to the ones described above (conventional tDCS)."
48376282|NCT03315442|OTHER|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
48376283|NCT03647995|DIETARY_SUPPLEMENT|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
48376284|NCT03647995|OTHER|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
48376285|NCT00656669|DRUG|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
48018741|NCT01543269|DRUG|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
48018742|NCT01699425|DEVICE|Ajust sling|
48018743|NCT01699425|DEVICE|Classical transobturator sling|Control group
48018744|NCT02864797|OTHER|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
48708633|NCT06605911|DRUG|topical triamcinolone acetonide combiend with topical curcumin|Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
48708634|NCT05397587|BIOLOGICAL|Experimental Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
48708635|NCT05397587|BIOLOGICAL|Control Vaccine|The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
48018745|NCT03206021|DRUG|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
48018746|NCT04159675|BIOLOGICAL|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
48175786|NCT02648711|DRUG|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
48175787|NCT02648711|DRUG|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
48175788|NCT00913068|PROCEDURE|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
48708636|NCT03362788|DRUG|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
48708637|NCT03362788|DRUG|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
48708638|NCT00309140|DRUG|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
48708639|NCT01228604|DRUG|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
48018747|NCT05100875|BEHAVIORAL|"Social Skills and Emotion Regulation Training SSERT"|The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
48018748|NCT05789615|DRUG|Letermovir|Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
48175789|NCT00913068|PROCEDURE|standard post op pain control|opiates
48708640|NCT03500172|BEHAVIORAL|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
48708641|NCT03500172|BEHAVIORAL|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
48708642|NCT00874406|DRUG|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
48708643|NCT00874406|DRUG|folfox4|folfox4 will be done within 28 days after liver resection
48708644|NCT01194843|DRUG|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
48018749|NCT03243916|RADIATION|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
48018750|NCT06165003|OTHER|Use of broselow tape|"In the research, the nurse is the decision maker in the selection of the catheters to be used in the procedures (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion) for the patients in the control group.~In these procedures, the nurse's choices will be evaluated as control group data as routine clinical practice.~After the control group data is collected, Broselow tape will be used in the selection of catheters to be used in the procedures to be performed on the patients in the experimental group (peripheral intravenous catheter insertion, urinary catheter insertion, aspiration procedure, nasogastric/orogastric catheter insertion).~Our research will be conducted to examine the effect of nurses' use of Broselow tape in non-resuscitation applications and to minimize errors and application disruptions in procedures involving nurses."
48018751|NCT03770468|PROCEDURE|Blood drawl|
48018752|NCT06663267|OTHER|NOT|This retrospective cohort study involves no new interventions. It analyzes existing health data collected from subjects exposed to varying atmospheric conditions to assess impacts on health outcomes.
48018753|NCT05762666|DEVICE|nociception level index monitor|The nociception level index (NOL) is one of the new electrophysiological devices to asses pain-related nociception and differs with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives)
48018754|NCT03280355|BEHAVIORAL|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
48175790|NCT03055923|DEVICE|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
48376286|NCT00656669|DRUG|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
48376287|NCT00656669|DRUG|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
48376288|NCT04940832|DEVICE|pulsed radiofrequency modulation|a percutaneous needle electrode to apply pulsed RF signals that modulate the activity of sensory nerves. The pulsing of the RF signal permits a maximum temperature to be achieved - usually 42 Celsius. This helps prevent collateral damage from occurring during the procedure and should help reduce procedural complications.
48376289|NCT05681676|OTHER|Blood samples before and after standard of care of polymyalgia rheumatica|Blood samples were taken before glucocorticoid treatment and three months after.
48376290|NCT04433858|DRUG|Psilocybin|open-label
48376291|NCT05791123|PROCEDURE|a bone graft mixed with PRF & covered by PRF membrane in fresh extraction socket|Extraction sockets were filled with minced PRF clots mixed with the bovine xenograft and covered by PRF membranes to seal the extraction sockets.
48376292|NCT05247606|DEVICE|Mobile application|Lifestyle intervention through web-based mobile application
48376293|NCT00535262|DRUG|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
48376294|NCT05865002|DRUG|AUR107|Once daily
48376295|NCT00402506|DRUG|(MC-1) Pyridoxal 5'-phosphate|
48376296|NCT06469333|BEHAVIORAL|Eye movements (EM)|The participant focuses on the intrusive thought and visually follows the horizontal movement of a white dot (Ø 1 cm) on the black computer screen 8 times for 24 seconds.
48376297|NCT06469333|BEHAVIORAL|Auditory stimulations|"The participant focuses on the intrusive thoughts and hears the auditory beeps through the headphones provided 8 times for 24 seconds."
48376298|NCT06469333|BEHAVIORAL|Tactile stimulations|The participant focuses on the intrusive thought and applies tactile self-stimulation 8 times for 24 seconds.
48376299|NCT04155567|DRUG|TAK-123|TAK-123 infusion
48376300|NCT04352075|DRUG|Autologous biologic drug of innovative therapy /cell therapy drug|Articular knee injection of microfat associated with a dose of 3 billions of platelets or associated with a dose of 1 billion of platelets or with saline solution
48376301|NCT01695707|DRUG|Pioglitazone|see Arm Description
48376302|NCT01695707|DRUG|Placebo (for pioglitazone)|see Arm Description
48376303|NCT02966366|DEVICE|Cochlear implant|
48376304|NCT02079974|DRUG|Pravastatin|20 mg pravastatin sodium daily for 3 months
48376305|NCT03868956|DIAGNOSTIC_TEST|Colour doppler ultrasound with or without D-dimer test|"* Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment"
48376306|NCT05723406|DRUG|Sugammadex 100 MG/ML [Bridion]|8 mg/ml
48708645|NCT01194843|DRUG|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
48708646|NCT01725230|DRUG|Fostamatinib|100-mg tablet
48708647|NCT01725230|DRUG|Rosuvastatin|20-mg tablet
48708648|NCT01725230|DRUG|Simvastatin|40-mg tablet
48708649|NCT01241344|DRUG|Brincidofovir|"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
48708650|NCT01241344|OTHER|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
48708651|NCT02607241|DEVICE|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
48708652|NCT02607241|DEVICE|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR \> 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis \> 40% or FFR \< 0.8).
48708653|NCT04139577|BIOLOGICAL|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
48708654|NCT04509518|OTHER|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
48708655|NCT04202510|PROCEDURE|Glaucoma and Cataract Surgery|Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
48708656|NCT02974335|BEHAVIORAL|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
48708657|NCT06605417|GENETIC|Methylomics|Methylomics analysis of FFPE blocks and frozen tissues
48708658|NCT06605417|GENETIC|RNA sequencing|RNA sequencing of FFPE blocks and frozen tissues
48708659|NCT06605417|GENETIC|Spatial transcriptomics|Spatial transcriptomics of FFPE blocks and frozen tissues
48708660|NCT06605417|GENETIC|Liquid biopsy|cfDNA characterization extracted from blood/saliva
48376307|NCT05723406|OTHER|Placebo|Sodium 0.9% 5 ml
48376308|NCT03005262|DRUG|MLN8237|
48376309|NCT03217916|DIAGNOSTIC_TEST|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
48376310|NCT02708576|BIOLOGICAL|NGM313|
48376311|NCT02708576|OTHER|Placebo|
48376312|NCT06346743|DRUG|Fenofibrate|Single dose of Fenofibrate will be given at dose of 10mg/Kg along with phototherapy for 24 hours before next blood sampling
48376313|NCT06346743|DEVICE|Phototherapy|only phototherapy will be given for 24 hours before next blood sampling
48018755|NCT03280355|BEHAVIORAL|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
48018756|NCT01241734|DRUG|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
48018757|NCT04013451|BEHAVIORAL|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
48708661|NCT03905369|OTHER|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
48376314|NCT03780920|PROCEDURE|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
48376315|NCT02203604|BIOLOGICAL|aldesleukin|Given IV
48376316|NCT02203604|BIOLOGICAL|ipilimumab|Given IV
48376317|NCT02203604|OTHER|laboratory biomarker analysis|Correlative studies
48376318|NCT03142984|OTHER|Cosmetic Products|"Phase 1:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash \& Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)"
48376319|NCT02267616|DEVICE|Etonogestrel Implant|Subdermal arm implant
48376320|NCT01782638|BEHAVIORAL|deep brain stimulation|
48376321|NCT03799237|OTHER|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
48376322|NCT01519635|DRUG|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
48376323|NCT01519635|DRUG|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
48376324|NCT02096406|DRUG|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
48376325|NCT02096406|DRUG|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
48376326|NCT00617266|OTHER|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
48376327|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
48376328|NCT00617266|OTHER|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
48376329|NCT00617266|OTHER|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
48376330|NCT06175468|DRUG|Formosa 1-Breath Free (NRICM101)|After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
48376331|NCT06175468|DRUG|Placebo control drug|After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
48376332|NCT04325191|DIETARY_SUPPLEMENT|Melatonin|Daily consumption of a high sodium diet and melatonin for 10 days
48376333|NCT04325191|OTHER|Placebo|aily consumption of a high sodium diet and placebo for 10 days
48376334|NCT02664974|DIETARY_SUPPLEMENT|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
48376335|NCT02664974|OTHER|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
48376336|NCT00689494|OTHER|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
48708662|NCT03905369|OTHER|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
48018758|NCT03765281|OTHER|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
48018759|NCT03765281|OTHER|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
48018760|NCT06573593|DRUG|Tofacitinib|In the real-world settings, patients with AA treated with tofacitinib.
48018761|NCT06573593|DRUG|Baricitinib|In the real-world settings, patients with AA treated with Baricitinib.
48018762|NCT06573593|DRUG|Ruxolitinib|In the real-world settings, patients with AA treated with Ruxolitinib.
48376337|NCT05915507|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for eight weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )"
48708663|NCT06487507|BEHAVIORAL|Low fat diet|Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) low fat Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
48708664|NCT06487507|BEHAVIORAL|Lower carbohydrate diet|Prior to surgery, participants complete diet records for 7 days. After, they will receive one shipment containing prepared meals (refrigerated, frozen and fresh) lower carbohydrate Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track their food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
48708665|NCT04052438|DIAGNOSTIC_TEST|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
48708666|NCT01900301|DRUG|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
48376338|NCT05915507|OTHER|acupoint stimulation by laser|This group will receive 3-session per-week laser stimulation (for eight weeks) to some selected acupoints, the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
48708667|NCT01900301|DRUG|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
48708668|NCT01122342|DRUG|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
48018763|NCT06573593|DRUG|Upadacitinib|In the real-world settings, patients with AA treated with Upadacitinib.
48018764|NCT06573593|DRUG|Abrocitinib|In the real-world settings, patients with AA treated with Abrocitinib.
48018765|NCT06573593|DRUG|Ritlecitinib|In the real-world settings, patients with AA treated with Ritlecitinib.
48018766|NCT05536947|OTHER|Bread product (standard milled)|Bread rolls made from standard milled flour.
48018767|NCT05536947|OTHER|Bread Product (micro-milled)|Bread rolls made from micro-milled whole grain flour.
48018768|NCT05536947|OTHER|Bread Product (standard aleurone)|Bread rolls made from white flour/standard milled aleurone mix
48018769|NCT05536947|OTHER|Bread product (micro-milled aleurone)|Bread rolls made from white flour/micro-milled aleurone mix.
48018770|NCT00048724|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
48018771|NCT05694559|BEHAVIORAL|Genetic Testing and Counseling|Participants will complete testing
48018772|NCT05694559|BEHAVIORAL|Screening Form|Participants will complete forms with demographics and history
48018773|NCT04978129|BEHAVIORAL|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
48376339|NCT05477849|DRUG|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5"
48018774|NCT03143244|DRUG|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
48376340|NCT06129851|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48708669|NCT04239183|DEVICE|Stomatherapy|Demonstrate improvement of quality of life (difference of at least 5 points in the StomaQoL questionnaire (21)) among descending colostomy patients, establishing the following comparisons.
48376341|NCT06129851|PROCEDURE|Bone Scan|Undergo bone scan
48018775|NCT03143244|DRUG|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
48018776|NCT03143244|DRUG|Control group (Normal Saline) (C)|Patients received normal saline in two sets
48018777|NCT05795387|OTHER|Video-based self-regulated training on the mental status exam|Authentic patient videos for self-regulated training as well as written e-course material, both on the mental status exam
48018778|NCT05795387|OTHER|E-course with written material on the mental status exam|Written material on the mental status exam
48376342|NCT06129851|RADIATION|Brachytherapy|Undergo brachytherapy
48376343|NCT06129851|PROCEDURE|Computed Tomography|Undergo CT
48376344|NCT06129851|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
48376345|NCT06129851|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
48018779|NCT06571357|BEHAVIORAL|Pranic Healing|The Pranic Healing intervention will be applied according to the advanced protocol by Master Choa Kok Sui, involving seven key techniques: sensitizing the hands, scanning the aura, cleansing the aura, increasing receptivity, energizing with prana, stabilizing the projected prana, and releasing. The intervention will take place in three stages: 5 minutes before, during, and 5 minutes after venipuncture.
48018780|NCT01696630|DRUG|Xenon|
48018781|NCT01696630|DRUG|Desflurane|
48018782|NCT00192179|BIOLOGICAL|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
48018783|NCT00192179|BIOLOGICAL|Placebo|The placebo consisted of physiologic normal saline.
48018784|NCT03122912|DIETARY_SUPPLEMENT|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
48018785|NCT03122912|DIETARY_SUPPLEMENT|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
48018786|NCT04121962|BEHAVIORAL|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
48018787|NCT04121962|BEHAVIORAL|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
48018788|NCT02162628|DEVICE|Exair Prolapse Repair System|
48018789|NCT02162628|PROCEDURE|Total Native Tissue Repair|
48018790|NCT06664593|OTHER|integrated perinatal mental health pathway|This observational study examines whether assessing psychosocial risk factors and screening for depression and anxiety at different time points during the perinatal period, using a stepped protocol, helps to more quickly detect women with depressive and anxiety symptoms.
48018791|NCT05779657|DRUG|Ketamine|Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)
48018792|NCT05779657|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
48018793|NCT05779657|DRUG|Placebo|Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
48018794|NCT06338475|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
48175791|NCT04488042|OTHER|Stapler-less gastrectomy|After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
48018795|NCT06338475|BEHAVIORAL|Individual Supportive Listening (ISL)|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
48018796|NCT03740217|DRUG|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
48018797|NCT02501330|DRUG|Bosutinib|The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
48018798|NCT02426671|DEVICE|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
48175792|NCT04488042|OTHER|Suture|No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
48175793|NCT03845075|DRUG|Tesofensine/Metoprolol|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
48376346|NCT06129851|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48376347|NCT06129851|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
48376348|NCT06129851|OTHER|Questionnaire Administration|Ancillary studies
48376349|NCT06129851|DRUG|Relugolix|Given PO
48376350|NCT01167699|DRUG|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
48376351|NCT03201601|DRUG|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
48376352|NCT03201601|DRUG|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
48376353|NCT01786837|DEVICE|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
48376354|NCT01194765|OTHER|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
48708670|NCT04942028|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
48018799|NCT01258205|DRUG|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
48376355|NCT02264340|BEHAVIORAL|Relaxation technique Autogenic Training|Autogenic Training
48376356|NCT02264340|BEHAVIORAL|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
48708671|NCT04942028|BEHAVIORAL|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
48708672|NCT04942028|BEHAVIORAL|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
48018800|NCT01747980|DRUG|PRX-112|Single dose level, four doses per cohort
48018801|NCT02874547|BEHAVIORAL|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
48708673|NCT06603064|DEVICE|Active continuous theta burst stimulation|This intervention involves an active form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
48708674|NCT06603064|DEVICE|Sham continuous theta burst stimulation|This intervention involves an sham form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
48708675|NCT02210689|DRUG|clindamycin phosphate vaginal cream 2%|
48708676|NCT02210689|OTHER|placebo|vehicle used as placebo
48708677|NCT01901523|BEHAVIORAL|Reporting of discrepancy to journal|
48708678|NCT05059821|BIOLOGICAL|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
48708679|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
48708680|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
48708681|NCT01258153|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
48708682|NCT01748474|PROCEDURE|Supplemental oxygen via a mask|
48708683|NCT02801721|OTHER|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
48708684|NCT04979897|OTHER|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
48708685|NCT05325216|PROCEDURE|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
48018802|NCT03637751|BEHAVIORAL|Behavioral|Trier Social Stress Test
48175794|NCT03845075|DRUG|Placebo|During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
48708686|NCT05325216|PROCEDURE|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
48708687|NCT04507451|PROCEDURE|inspiratory and expiratory muscle training|inspiratory muscle training using threshold IMT device expiratory muscle training using a bottle filled of water
48708688|NCT04507451|PROCEDURE|inspiratory and expiratory exercises|inspiratory exercise using fractionated inspirations expiratory exercise using a bottle filled with water at a minimum level
48018803|NCT03637751|BEHAVIORAL|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
48018804|NCT01180075|DRUG|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
48018805|NCT01180075|DRUG|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
48018806|NCT01180075|DRUG|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
48175795|NCT01709396|RADIATION|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
48175796|NCT03801187|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
48175797|NCT03801187|PROCEDURE|Er:YAG laser|Er.YAg laser treatment will be provided on the implant surface.
48175798|NCT03801187|PROCEDURE|Air-Powder|An air powder device will be treatment will be provided on the implant surface.
48708689|NCT00960037|DIETARY_SUPPLEMENT|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
48175799|NCT03634306|DEVICE|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
48175800|NCT03634306|PROCEDURE|Laparoscopic Hysterectomy|Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
48175801|NCT05698329|DRUG|AIV007|Periocular injection
48708690|NCT00960037|DIETARY_SUPPLEMENT|Placebo equivalent|One capsule daily for 8 weeks
48708691|NCT05517213|DRUG|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
48708692|NCT05517213|DRUG|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
48708693|NCT00002839|DRUG|cisplatin|
48708694|NCT00002839|DRUG|fluorouracil|
48708695|NCT00002839|PROCEDURE|conventional surgery|
48708696|NCT00002839|PROCEDURE|neoadjuvant therapy|
48708697|NCT00002839|RADIATION|radiation therapy|
48708698|NCT05108090|PROCEDURE|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
48708699|NCT03638869|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
48708700|NCT03638869|DRUG|Placebo|
48708701|NCT05719506|OTHER|normal saline without drug|nebulizer session with normal saline only preoperative
48708702|NCT05719506|DRUG|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
48708703|NCT05719506|DRUG|Ketamine|nebulizer session with ketamine preoperative
48708704|NCT04352985|DEVICE|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
48708705|NCT04521998|DEVICE|electroacupuncture|Electroacupuncture used to reduce the inflammation was proved previously.
48708706|NCT04521998|DEVICE|TENS|Patients who unlike needles would like to choose TENS as treatment for pain relief.
48018807|NCT01180075|DRUG|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
48018808|NCT01180075|PROCEDURE|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
48018809|NCT02186964|PROCEDURE|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
48018810|NCT02186964|PROCEDURE|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
48018811|NCT02186964|PROCEDURE|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
48018812|NCT06302764|DIAGNOSTIC_TEST|Qualitative & Quantitative Research|"1. Focused interviews - conducted by members of the appointed research team to recognize the issues faced by emergency medical staff in Poland, Ukraine, Portugal, and Spain with the aim of preparing the measurement framework.~2. Online questionnaire surveys - conducted using the Qualtrics platform (available in different, language versions - Polish, Ukrainian, Portuguese, and Spanish)."
48018813|NCT05560867|DEVICE|robot-assisted training|These training platforms use gamified training tasks to improve motor control in the hemiparetic arm
48376357|NCT05434975|PROCEDURE|Interscalene brachial plexus block|"For single shot-ISBP block, 15 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine, a total of 25 ml of local anesthetic, will be administered to all patients.~For the block procedure, an imaginary horizontal line drawn from the thyroid cartilage to the sternocleidomastoid (SCM) muscle will followed and the lateral of the SCM muscle will be cleaned with povidine iodine. At the C6 level to be blocked, the nerve roots will be detected by ultrasound. 25 ml of local anesthetic will be injected around the plexus roots with a 22 G 80 mm echogenic needle. The distribution of the local anesthetic applied to the area, which expands the tissues and separates the nerve roots from other tissues, will be seen on ultrasound."
48376358|NCT01872832|DRUG|RDEA3170 and Placebo|
48018814|NCT03565406|DRUG|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
48018815|NCT03565406|DRUG|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
48018816|NCT04825223|DRUG|Multicomponent Meningococcal B Vaccine|Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
48175802|NCT03668171|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
48175803|NCT04567810|DRUG|anti-SARS-CoV-2 IgY|anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
48175804|NCT04567810|DRUG|Placebo|Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
48175805|NCT05896111|PROCEDURE|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
48175806|NCT03014817|PROCEDURE|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
48175807|NCT03014817|PROCEDURE|Electrocautery|Dissection with electrocautery
48175808|NCT03246347|DRUG|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
48175809|NCT00236184|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
48708707|NCT06208189|BEHAVIORAL|High-effort session|Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform \~10 repetitions per set in this session, with a total tempo of \~2.5 seconds per rep, averaging \~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of \~50 min. Their glycemic control will be evaluated during the following \~48 hours.
48708708|NCT06208189|BEHAVIORAL|Low-effort session|Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at \~2.5 seconds will result in \~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of \~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following \~48 hours.
48708709|NCT06208189|BEHAVIORAL|Control|The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following \~48 hours.
48708710|NCT02256267|DRUG|LY2835219|Administered orally
48708711|NCT02256267|DRUG|Rifampin|Administered orally
48708712|NCT01389531|PROCEDURE|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
48708713|NCT00377546|DRUG|Nepafenac|
48708714|NCT00377546|DRUG|Ketorolac LS, Bromfenac|
48708715|NCT03436641|OTHER|No intervention|No intervention
48708716|NCT05256342|DRUG|Duloxetine 60mg|"Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily."
48175810|NCT00236184|OTHER|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
48175811|NCT01618578|PROCEDURE|rubber hand illusion|"There were three consecutive trials of the RHI:~1. one control trial: asynchronous condition (3 Min.)~2. two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
48708717|NCT05256342|DRUG|Etoricoxib 60 mg|One pill daily for 8 weeks
48708718|NCT05256342|DRUG|omeprazol|20 mg daily; will be taken with Etoricoxib from the second week of treatment
48175812|NCT02541045|DRUG|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
48708719|NCT03040869|OTHER||
48175813|NCT02541045|OTHER|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
48175814|NCT03324113|DRUG|SAR408701|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48175815|NCT03324113|DRUG|dexamethasone|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
48517250|NCT05175040|PROCEDURE|Sham rotation|Sham rotation, performed in the comparator arm, involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation. Duration of the vaginal exam for sham rotation will be consistent with that used for prophylactic manual rotation and will be performed by a trained study investigator (M.D. or midwife) to maintain blinding of the patient's primary obstetrician.
48517251|NCT02112851|OTHER|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
48517252|NCT04768660|OTHER|gum|Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
48517253|NCT03893084|OTHER|Pregnancy preparation training|Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
48517254|NCT04428879|DRUG|Topotecan Episcleral Plaque|Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
48517255|NCT05810233|DIETARY_SUPPLEMENT|Ascorbic acid 1000mg|Health supplement
48517256|NCT05810233|OTHER|Placebo|Glucose chewable tablet without any ascorbic acid
48517257|NCT05681598|DRUG|Hydroxyurea|The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
48517258|NCT01277159|DRUG|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
48517259|NCT01277159|DRUG|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
48517260|NCT01277159|DRUG|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
48517261|NCT01277159|DRUG|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
48517262|NCT01277159|DRUG|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
48517263|NCT02368418|PROCEDURE|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
48517264|NCT02368418|PROCEDURE|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
48517265|NCT01004809|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
48517266|NCT04162678|PROCEDURE|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
48517267|NCT04162678|OTHER|Laboratory Biomarker Analysis|Correlative studies
48517268|NCT04162678|PROCEDURE|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
48517269|NCT04162678|OTHER|Medical Chart Review|Review of medical chart
48517270|NCT03016273|PROCEDURE|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
48517271|NCT05184452|DRUG|PGDM1400LS (5mg/kg, IV)|5 mg/kg to be administered via IV infusion
48517272|NCT05184452|DRUG|PGDM1400LS (20mg/kg, IV)|20 mg/kg to be administered via IV infusion
48517273|NCT05184452|DRUG|PGDM1400LS (20mg/kg, SC)|20 mg/kg to be administered via SC infusion
48517274|NCT05184452|DRUG|PGDM1400LS (40mg/kg, IV)|40 mg/kg to be administered via IV infusion
48708720|NCT05872997|DIAGNOSTIC_TEST|Sensory Motor Training|Mobilization With Movement Along With Sensory Motor Training
48708721|NCT01299857|DRUG|Rituximab|375mg/m2
48175816|NCT03324113|DRUG|naphazoline|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
48175817|NCT03324113|DRUG|diphenhydramine|"Pharmaceutical form: tablet~Route of administration: oral"
48175818|NCT02780102|OTHER|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
48175819|NCT02780102|DRUG|Ritalin|2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
48175820|NCT02780102|OTHER|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
48175821|NCT03757078|DRUG|Relief Pro cream|Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
48175822|NCT03757078|DRUG|Relief Pro rectal suppositories|Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
48708722|NCT06378749|BEHAVIORAL|PreCharge|PreCharge is an intervention for Hereditary Cancer Syndrome Previvors that administers brief assessments and uses multivariate algorithms and tailoring technology to provide timely, individualized, bi-directional text messages to improve resilience and coping. The program uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose. It will also proactively provide access to online tools prior to medical appointments to address scanxiety (e.g., management of emotion tips; mindfulness meditation; communication scripts; breathing exercises). At any time, users will be able to text a trigger word to indicate that they need extra support and will receive just-in-time assistance via text message.
48376359|NCT06202950|BEHAVIORAL|Yoga|Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes
48376360|NCT06202950|BEHAVIORAL|Mindfulness|Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
48376361|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
48376362|NCT00061568|DRUG|Alemtuzumab|Alemtuzumab
48376363|NCT00061568|PROCEDURE|Peripheral blood hematopoietic progenitor cell Apheresis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
48376364|NCT00061568|DRUG|Sirolimus|Sirolimus
48376365|NCT04580875|PROCEDURE|Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children|
48376366|NCT03494452|OTHER|No intervention|There is no intervention in this cross-sectional study
48376367|NCT04975867|OTHER|Targeted therapeutic hypothermia|Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
48376368|NCT04975867|OTHER|Targeted therapeutic normothermia|Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
48376369|NCT04366011|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT teaches a set of cognitive and somatic coping skills to manage panic and anxiety as patients conduct repeated exposure to feared situations and sensations.
48376370|NCT04366011|BEHAVIORAL|Capnometry Assisted Respiratory Training (CART)|CART has four major treatment components: educating patients about the etiology and maintenance of PD according to a hyperventilation centered rationale, directing patients' attention to potentially aberrant respiratory patterns, instructing patients in respiratory control techniques, and instructing patients in home breathing exercises.
48376371|NCT06019169|OTHER|Yoga arm|Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
48708723|NCT00302276|DRUG|Metobes-compound|
48708724|NCT04460924|DRUG|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
48708725|NCT06100289|DRUG|Vedolizumab IV|Vedolizumab IV injection.
48708726|NCT06100289|DRUG|Vedolizumab SC|Vedolizumab SC injection.
48708727|NCT04175457|OTHER|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
48708728|NCT04906720|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
48708729|NCT02933073|BIOLOGICAL|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
48708730|NCT05440669|BEHAVIORAL|white noise|white noise will reduce pain and stress in nasal cpap application
48376372|NCT06019169|OTHER|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
48376373|NCT02422186|DRUG|Esketamine|All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
48376374|NCT02422186|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
48708731|NCT06361602|OTHER|inapplicable|inapplicable
48708732|NCT01263392|DEVICE|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
48708733|NCT03350139|DEVICE|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
48708734|NCT04067037|DRUG|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
48708735|NCT04067037|DRUG|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
48376375|NCT02422186|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
48376376|NCT02422186|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
48376377|NCT02422186|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
48376378|NCT02422186|DRUG|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
48376379|NCT00540982|DRUG|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
48376380|NCT00540982|DRUG|lidocaine|1 mg/kg will be administered to determine metabolic capacity
48376381|NCT00540982|DRUG|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
48376382|NCT00540982|OTHER|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
48517275|NCT05184452|DRUG|PGDM1400LS (40mg/kg, SC)|40 mg/kg to be administered via SC infusion
48517276|NCT05184452|DRUG|PGDM1400LS (1.4g, IV)|1.4gram to be administered via IV infusion
48517277|NCT05184452|DRUG|PGDM1400LS (1.4g, SC)|1.4gram to be administered via SC infusion
48708736|NCT04067037|DRUG|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
48018817|NCT04825223|DRUG|Meningococcal Group B Vaccine MenB|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
48517278|NCT05184452|DRUG|VRC07-523LS (20mg/kg, IV)|VRC07-523LS 20mg/kg administered via IV infusion
48708737|NCT04067037|DRUG|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
48708738|NCT04408417|DEVICE|Prototype child safety seat with tension indicator lights|The prototype child safety seat is a convertible rear-facing seat with a harness system that includes tension indicator lights.
48018818|NCT04825223|DRUG|Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)|Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
48708739|NCT04408417|DEVICE|Control child safety seat|The control child safety seat is a convertible rear-facing seat without tension indicator lights.
48376383|NCT00540982|OTHER|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
48376384|NCT00540982|OTHER|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
48376385|NCT00540982|OTHER|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
48517279|NCT05184452|DRUG|VRC07-523LS (20mg/kg, SC)|VRC07-523LS 20mg/kg administered via SC infusion
48517280|NCT05184452|DRUG|VRC07-523LS (1.4g, IV)|VRC07-523LS 1.4g administered via IV infusion
48708740|NCT02363374|DRUG|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
48018819|NCT04825223|DRUG|Placebo|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
48018820|NCT04825223|DRUG|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
48018821|NCT00131287|DRUG|Extract of Agaricus blazei Murill|
48175823|NCT05043883|DEVICE|CathVision Cube® system|Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.
48517281|NCT05184452|DRUG|VRC07-523LS (1.4g, SC)|VRC07-523LS 1.4g administered via SC infusion
48517282|NCT05184452|DRUG|VRC07-523LS (40mg/kg, IV)|VRC07-523LS 40mg/kg administered via IV infusion
48175824|NCT02265809|DRUG|Aldesleukin|
48175825|NCT01068288|PROCEDURE|Laparoscopic or open appendectomy|
48517283|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, IV)|PGT121.414.LS 20mg/kg administered via IV infusion
48517284|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, SC)|PGT121.414.LS 20mg/kg administered via SC infusion
48517285|NCT05184452|DRUG|PGT121.414.LS (1.4g, IV)|PGT121.414.LS 1.4g administered via IV infusion
48517286|NCT05184452|DRUG|PGT121.414.LS (1.4g, SC)|PGT121.414.LS 1.4g administered via SC infusion
48517287|NCT05184452|DRUG|PGT121.414.LS (40mg/kg, IV)|PGT121.414.LS 40mg/kg administered via IV infusion
48517288|NCT03685214|DRUG|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
48517289|NCT03685214|DRUG|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
48018822|NCT05281367|PROCEDURE|Breast milk odor group|The researcher applied the breast milk that dripped on the pad for 3 minutes before the heel stick for 36 premature newborns in the breast milk odor group. About three cc breast milk dripped onto a sterile pad and placed at a distance of 10 cm from the nose of the newborn. It continued until 3 minutes after the invasive procedure. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
48018823|NCT05281367|PROCEDURE|Facilitated tucking group|The Facilitated tucking position was given to 36 premature newborns in the Facilitated tucking group, from 3 minutes before to 3 minutes after the heel stick procedure. Premature newborns were kept in the facilitated tucking position by the investigator using the incubator windows without opening the incubator cover to prevent heat loss of the newborn. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
48018824|NCT05281367|PROCEDURE|Non-nutritive sucking group|36 premature newborns who were in the non-nutritive sucking group were given a silicone pacifier suitable for the week of the baby's mouth from 3 minutes before to 3 minutes after the heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study. Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP).
48376386|NCT00540982|OTHER|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
48376387|NCT01312363|DRUG|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
48376388|NCT02087865|DRUG|donepezil HCL|
48376389|NCT02087865|DRUG|Placebo|
48376390|NCT06353581|DRUG|Neulapeg|Participants will receive Neulapeg subcutaneously 24 hours after the end of modified FOLFIRINOX dosing. (Must be administered within a maximum of 72 hours; Neulapeg will only be given for up to 8 cycles).
48517290|NCT04718831|DIETARY_SUPPLEMENT|Spirulina|Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
48708741|NCT02363374|RADIATION|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
48376391|NCT06353581|OTHER|Control|Patients assigned to the non-Neulapeg arm will be crossover to Neulapeg if they develop grade 3-4 neutropenia or neutropenic fever. Crossover subjects will receive up to 8 cycles of Neulapeg as a secondary treatment regardless of starting cycle.
48376392|NCT01250418|DRUG|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
48376393|NCT02826005|DEVICE|MRI|
48376394|NCT05216289|DIETARY_SUPPLEMENT|Probiac|Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
48376395|NCT05216289|OTHER|Placebo|Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
48376396|NCT02492152|DEVICE|Study group|Dianatal
48708742|NCT02363374|RADIATION|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
48376397|NCT02163746|PROCEDURE|CO2 (carbon dioxide) laser|
48376398|NCT02163746|PROCEDURE|Surgical Deroofing|
48376399|NCT03801070|PROCEDURE|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
48376400|NCT00152659|PROCEDURE|Tissue sample (procedure/screening)|Tissue sampling
48376401|NCT06091826|DRUG|NFL-101|Subcutaneous injections
48376402|NCT06091826|DRUG|Placebo|Subcutaneous injections
48376403|NCT01422876|DRUG|high dose FDC|once daily
48376404|NCT01422876|DRUG|BI 10773 high dose|once daily
48376405|NCT01422876|DRUG|high dose FDC placebo|once daily
48376406|NCT01422876|DRUG|low dose FDC placebo|once daily
48376407|NCT01422876|DRUG|high dose FDC placebo|once daily
48376408|NCT01422876|DRUG|high dose FDC placebo|once daily
48376409|NCT01422876|DRUG|low dose FDC placebo|once daily
48376410|NCT01422876|DRUG|low dose FDC placebo|once daily
48376411|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
48376412|NCT01422876|DRUG|low dose FDC|once daily
48376413|NCT01422876|DRUG|high dose FDC placebo|once daily
48376414|NCT01422876|DRUG|BI 10773 low dose|low dose once daily
48376415|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
48376416|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
48376417|NCT01422876|DRUG|linagliptin|once daily
48376418|NCT01422876|DRUG|low dose FDC placebo|once daily
48376419|NCT01422876|DRUG|linagliptin placebo|once daily
48376420|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
48376421|NCT01422876|DRUG|linagliptin placebo|once daily
48376422|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
48376423|NCT01422876|DRUG|linagliptin placebo|once daily
48376424|NCT01422876|DRUG|high dose BI 10773 placebo|once daily
48376425|NCT01422876|DRUG|BI 10773 low dose placebo|once daily
48376426|NCT01422876|DRUG|low dose BI 10773 placebo|once daily
48708743|NCT02363374|DRUG|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
48708744|NCT02363374|PROCEDURE|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
48708745|NCT01967823|BIOLOGICAL|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
48708746|NCT01967823|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
48708747|NCT01967823|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
48175826|NCT01068288|PROCEDURE|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
48708748|NCT01967823|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
48708749|NCT04355533|BIOLOGICAL|serology test|volume according to child weight
48708750|NCT04355533|BIOLOGICAL|nasopharyngeal swab|nasopharyngeal swab for PCR
48018825|NCT05281367|PROCEDURE|Control group|"The control group will consist of 36 premature newborns who are routinely applied in the clinic. In the clinic where the research was conducted, no attempt is made to reduce pain during heel stick. Heart rate, arterial oxygen saturation, and respiration rate were recorded in this group before the study.~Then, to evaluate the pain in the infants, a video camera was placed on the incubator. The infants in each group were filmed from three minutes before the procedure to three minutes after. Neonatal pain was measured at 1, 2, and 3 minutes before, during, and at 1, 2, and 3 minutes after the procedure by two researchers independently using the new version Premature Infant Pain Profile (PIPP)."
48018826|NCT02414087|DEVICE|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
48018827|NCT02464969|DRUG|Apixaban|Tablet or Solution
48018828|NCT02464969|DRUG|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
48175827|NCT04614571|DIETARY_SUPPLEMENT|Gluten Powder|Administered orally daily for 14 days
48175828|NCT04652011|PROCEDURE|Minimally Invasive Gynecologic Surgery|Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)
48175829|NCT04652011|PROCEDURE|osteopathic manipulative treatment|Osteopathic manipulative treatment
48175830|NCT04652011|DRUG|Pain killer|Common pain killer (paracetamol, Ibuprofen, ketoprofen)
48175831|NCT00511498|DRUG|Sildenafil|50 mg daily at bedtime
48175832|NCT05260554|DRUG|Fosfomycin|In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.
48175833|NCT05260554|DIETARY_SUPPLEMENT|Cranberry|In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.
48175834|NCT01427738|DRUG|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
48175835|NCT01427738|DRUG|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
48175836|NCT02193659|DIETARY_SUPPLEMENT|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
48175837|NCT06009744|DRUG|Low-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
48708751|NCT04355533|BIOLOGICAL|rectal swab|rectal swab for PCR
48708752|NCT04355533|BIOLOGICAL|saliva sample|for biocollection
48708753|NCT00839462|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
48708754|NCT00839462|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
48175838|NCT06009744|DRUG|High-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
48175839|NCT06064045|BEHAVIORAL|Simulation-based team training intervention|"Participants in the intervention group will aim to participate in simulation at a higher quantity and frequency.~Moreover, the intervention group:~1. Enrolled 15 healthcare professionals in a 3-day training program to become simulator facilitators, enabling an increase in the utilization of simulation within the group (October 2022).~2. Organized a 2-day workshop for all pediatric simulation facilitators with the objective of establishing a more robust and standardized foundation for implementing simulation within their respective departments (March 2023).~3. Procured essential equipment, including mannequins, SimPads, and monitors (before the intervention period).~4. Provide simulator facilitators with access to an online repository where they can access scenarios for conducting simulations (during the intervention period)."
48175840|NCT04429035|DIETARY_SUPPLEMENT|Vitamin K2|Administration of 300 μg Vitamin K2 (MQ7) daily p.o
48708755|NCT03249935|DRUG|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
48708756|NCT04058808|OTHER|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
48175841|NCT04429035|DIETARY_SUPPLEMENT|Placebo|Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
48708757|NCT04058808|OTHER|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
48708758|NCT04058808|OTHER|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
48708759|NCT04058808|OTHER|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
48018829|NCT02875119|DRUG|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
48018830|NCT02875119|DRUG|Placebo Gel|Placebo Gel
48175842|NCT06319651|OTHER|Lower Limb Resistance Band Exercises|"* Extending thighs~* Closing thighs~* Opening thighs~* Bending thighs~* Bending ankles~* Ankle opening"
48175843|NCT06319651|OTHER|Routine Phase 1 cardiac rehabilitation|Routine Phase 1 cardiac rehabilitation only.
48517291|NCT06212544|BEHAVIORAL|Immediate Intervention|Enhanced microeconomic intervention
48517292|NCT06212544|BEHAVIORAL|Delayed Intervention|Usual care and then access to enhanced microeconomic intervention
48708760|NCT04058808|OTHER|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
48708761|NCT04058808|OTHER|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
48708762|NCT01833260|BEHAVIORAL|Music|
48708763|NCT06358781|OTHER|Whole grain wheat flour|Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g
48708764|NCT03466619|DEVICE|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
48175844|NCT00904709|DRUG|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
48708765|NCT00607113|DRUG|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
48708766|NCT00607113|DRUG|RAD001|10 mg By Mouth Daily For 21 Days
48708767|NCT00226408|DRUG|Interferon-alpha-2b|
48708768|NCT04923646|OTHER|Primer|Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
48708769|NCT05404347|DIAGNOSTIC_TEST|Next generation sequencing|NGS is carried out on DNA isolated from paraffin embedded tissue
48708770|NCT01158027|OTHER|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
48708771|NCT02093988|DRUG|Topical TXA|
48708772|NCT02093988|DRUG|Intravenous TXA|
48708773|NCT04362371|DEVICE|Ainara|1 g at each administration
48175845|NCT00543153|BEHAVIORAL|Interview|Interview lasting approximately 30-45 minutes.
48175846|NCT03245762|DRUG|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
48376427|NCT01422876|DRUG|linagliptin placebo|once daily
48376428|NCT06149000|DEVICE|Avulux Lenses|Avulux lenses are specialized eyewear designed to reduce specific wavelengths of light to alleviate symptoms in individuals who experience light sensitivity and migraines
48376429|NCT06149000|DEVICE|Placebo Lenses|Lenses that will look identical to Avulux lenses without the medical benefits
48708774|NCT02692040|DRUG|G3215|Gut hormone analogue
48708775|NCT02692040|DRUG|Placebo|0.9% saline
48708776|NCT03885765|DIAGNOSTIC_TEST|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total."
48175847|NCT03245762|DRUG|Placebo|4 IU/day of placebo administered via nasal spray device each morning
48376430|NCT02014909|BIOLOGICAL|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
48708777|NCT03885765|PROCEDURE|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
48708778|NCT01886690|DRUG|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
48708779|NCT01886690|DRUG|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
48708780|NCT01778049|DRUG|BI 10773|Empagliflozin active
48708781|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
48708782|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
48708783|NCT01778049|DRUG|BI 10773|Empagliflozin active
48708784|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
48175848|NCT01699698|OTHER|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
48175849|NCT00080041|DRUG|Motexafin Gadolinium Injection|
48175850|NCT03065998|DRUG|Opipramol|PO
48175851|NCT03065998|DRUG|Baclofen|PO
48708785|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
48018831|NCT02690246|OTHER|questionnaire|a questionnaire based study
48175852|NCT04081389|DRUG|Celecoxib|Given PO
48175853|NCT04081389|DRUG|Cyclophosphamide|Given IV
48175854|NCT04081389|DRUG|Doxorubicin|Given IV
48175855|NCT04081389|DRUG|Doxorubicin Hydrochloride|Given IV
48175856|NCT04081389|DRUG|Paclitaxel|Given IV
48175857|NCT04081389|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
48175858|NCT04081389|DRUG|Rintatolimod|Given IV
48175859|NCT01718431|OTHER|test meal|
48175860|NCT01718431|OTHER|reference meal|
48376431|NCT05979389|DRUG|Bicalutamide 50 mg|Bicalutamide capsules will be prepared from U.S. Pharmacopeia grade powder at a dose of 50 mg
48376432|NCT05979389|DRUG|Placebo|Matching placebo capsules of the same color, mass, and appearance to the bicalutamide capsules will be filled using microcrystalline cellulose powder.
48376433|NCT03441373|DRUG|XC8 20 mg|once daily during 5 days.
48376434|NCT03441373|DRUG|XC8 100 mg|once daily during 5 days.
48376435|NCT03441373|DRUG|XC8 200 mg|once daily during 5 days.
48376436|NCT03441373|DRUG|Placebo|once daily during 5 days.
48376437|NCT01980056|DRUG|Vosaroxin|Dose level 1: Vosaroxin 50 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg\^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg\^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
48376438|NCT04281121|DIETARY_SUPPLEMENT|omega 3 fatty acids|: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
48376439|NCT02808182|DRUG|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
48708786|NCT01778049|DRUG|BI 10773|Empagliflozin active
48708787|NCT01778049|DRUG|BI 10773|Empagliflozin active
48708788|NCT01778049|DRUG|BI 10773|Empagliflozin active
48708789|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
48708790|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
48708791|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
48708792|NCT01778049|DRUG|BI 10773|Empagliflozin active
48708793|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
48708794|NCT05568914|DEVICE|Indirect Calorimetry|Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
48708795|NCT05568914|DEVICE|Bio-electrical Impedance Analysis (BIA)|Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
48708796|NCT05568914|OTHER|Nutritional assessments|The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
48708797|NCT00405964|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
48708798|NCT00405964|DRUG|Placebo tablet|Placebo tablet, once daily for 12 weeks
48708799|NCT01563120|DRUG|metformin|metformin up to 2550mg per day.
48708800|NCT01563120|DRUG|glybenclamide|glybenclamide up to 20mg per day.
48708801|NCT01084980|DRUG|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
48708802|NCT00945061|RADIATION|intracavitary balloon brachytherapy|Patients undergo brachytherapy
48708803|NCT00945061|RADIATION|intraoperative radiation therapy|Patients undergo radiotherapy
48376440|NCT02808182|OTHER|[7,7,8,8-2H]-palmitate|using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
48708804|NCT04015583|BEHAVIORAL|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
48175861|NCT04991350|DRUG|Intravitreal ranibizumab|Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
48018832|NCT03345563|BEHAVIORAL|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
48708805|NCT06216899|OTHER|Whole-food based smoothie|The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
48376441|NCT02808182|OTHER|[U-13C]-palmitate|oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
48376442|NCT02808182|PROCEDURE|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
48376443|NCT02808182|OTHER|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
48376444|NCT02726516|DIETARY_SUPPLEMENT|PRJ-205|1 sachet per day
48708806|NCT06216899|OTHER|Formula|Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
48175862|NCT04991350|DRUG|Intravitreal bevacizumab|Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
48376445|NCT02726516|OTHER|Placebo|1 sachet per day
48376446|NCT00843817|DRUG|Pulmozyme|Pulmozyme® 2.5mg by inhalation
48708807|NCT03442257|BEHAVIORAL|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
48175863|NCT02949232|DRUG|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
48175864|NCT02949232|DRUG|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
48175865|NCT01124838|DRUG|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
48175866|NCT01124838|DRUG|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
48376447|NCT01546701|DRUG|Buprenorphine|2 mg sublingual tablet
48376448|NCT01546701|DRUG|Morphine|0.1 mg/kg IV morphine
48376449|NCT02198820|DRUG|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
48376450|NCT02198820|DRUG|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
48708808|NCT04775927|OTHER|education|premarital education
48708809|NCT00003946|DRUG|danazol|
48175867|NCT01124838|DRUG|Placebo|Administered by subcutaneous injection
48175868|NCT03277885|OTHER|chronic pain|work related chronic pain
48376451|NCT04498975|OTHER|Rurality; Ethnicity; Exercise; Hopelessness|Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
48376452|NCT04416412|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
48708810|NCT01983722|DRUG|Stiripentol|
48708811|NCT03887520|DIAGNOSTIC_TEST|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
48708812|NCT03985410|DRUG|ETX2514|intravenous infusion
48708813|NCT03985410|DRUG|Placebo|intravenous infusion
48708814|NCT03985410|DRUG|moxifloxacin|oral tablet
48018833|NCT03345563|BEHAVIORAL|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
48175869|NCT00176410|DRUG|fluvastatin|40mg fluvastatin daily
48376453|NCT01872663|PROCEDURE|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
48376454|NCT01872663|PROCEDURE|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
48376455|NCT01872663|PROCEDURE|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
48018834|NCT03345563|BEHAVIORAL|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
48708815|NCT04802239|OTHER|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
48376456|NCT01872663|PROCEDURE|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
48376457|NCT01872663|PROCEDURE|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
48018835|NCT01079520|PROCEDURE|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
48376458|NCT01872663|PROCEDURE|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
48376459|NCT04801017|DRUG|OT-101|TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
48376460|NCT04801017|DRUG|Artemisinin|Herbal Supplement/ Purified extract from Artemisia
48376461|NCT04801017|DRUG|Placebo|0.9% sodium chloride injection
48376462|NCT01159652|DRUG|zaleplon|10 mg
48376463|NCT01159652|DRUG|zolpidem extended release|12.5 mg
48376464|NCT01159652|DRUG|bedtime placebo|placebo
48018836|NCT01079520|PROCEDURE|Mediastinoscopy|Traditional surgical method to stage lung cancers
48018837|NCT02520245|DRUG|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
48376465|NCT01159652|DRUG|middle of the night placebo|placebo
48376466|NCT01826006|DEVICE|Excimer laser|
48175870|NCT01607528|DIETARY_SUPPLEMENT|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
48175871|NCT01607528|DIETARY_SUPPLEMENT|Placebo|A similar looking and tasting powder with no active substances
48175872|NCT02826798|DRUG|VBI-1501A 0.5 μg|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
48175873|NCT02826798|DRUG|VBI-1501A 1.0 μg|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
48376467|NCT01826006|DEVICE|Manual Thrombus Aspiration|
48376468|NCT00790270|DRUG|Cyclobenzaprine|5 mg orally every 8 hours as needed
48376469|NCT00790270|DRUG|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
48708816|NCT04802239|OTHER|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
48175874|NCT02826798|DRUG|VBI-1501A 2.0 μg|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
48708817|NCT05102097|BEHAVIORAL|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
48708818|NCT05102097|BEHAVIORAL|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
48175875|NCT02826798|DRUG|VBI-1501 1.0 μg|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
48376470|NCT00790270|DRUG|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
48376471|NCT02149277|DRUG|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
48376472|NCT03589066|DRUG|LY03003|28 mg intramuscular suspension
48376473|NCT03482388|BEHAVIORAL|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
48376474|NCT03482388|OTHER|Control|Participants will not view any images or videos promoting HBV and HCV testing.
48376475|NCT03879824|PROCEDURE|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
48708819|NCT05102097|BEHAVIORAL|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
48708820|NCT05102097|BEHAVIORAL|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
48708821|NCT04503161|DEVICE|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
48708822|NCT02502604|BEHAVIORAL|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
48708823|NCT00481325|DRUG|pexacerfont|Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
48708824|NCT00481325|DRUG|escitalopram|Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
48708825|NCT00481325|DRUG|placebo|Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
48708826|NCT02340182|DRUG|Vancomycin|250mg 3dd2
48708827|NCT02340182|DRUG|Ciprofloxacin|500mg 2dd1
48708828|NCT02340182|DRUG|Metronidazole|500mg 3dd1
48708829|NCT05411523|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
48708830|NCT05411523|OTHER|Questionnaire Administration|Complete questionnaires
48708831|NCT05411523|PROCEDURE|Spinal Cord Stimulation|Receive spinal cord stimulation therapy
48376476|NCT03879824|PROCEDURE|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
48376477|NCT06082427|DEVICE|Virtual reality hypnosis|VRH was delivered through a 3D virtual reality headpiece equipped with a head-tracking system based on hypnosis induction and suggestions (relaxation, comfort, and safety). The complete intervention lasted 17 minutes.
48376478|NCT01382875|OTHER|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
48708832|NCT00929188|DRUG|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
48708833|NCT00929188|DRUG|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
48708834|NCT03982264|PROCEDURE|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
48708835|NCT03982264|PROCEDURE|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
48708836|NCT03483805|DIETARY_SUPPLEMENT|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
48708837|NCT03483805|DIETARY_SUPPLEMENT|Placebo|maize maltodextrin in powder form, to be diluted in water
48708838|NCT00741195|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
48708839|NCT00741195|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
48708840|NCT06232148|DEVICE|Type of surgery|
48708841|NCT01820403|OTHER|portion size kcal of box lunch|
48708842|NCT01055665|OTHER|cognitive behavior therapy|6 cognitive behavior therapy groups
48708843|NCT00237068|DRUG|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
48018838|NCT04512937|DEVICE|Computer-assisted navigation surgery|Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
48018839|NCT04293159|DIETARY_SUPPLEMENT|Lactobacillus casei DG (Enterolactis duo®)|Lactobacillus casei DG (Enterolactis duo®)
48018840|NCT01256905|DRUG|Armodafinil|Armodafinil 150 mg
48018841|NCT03393598|DEVICE|pre-expansion using Kiwi® VAC-6000M.|The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.
48018842|NCT03393598|DEVICE|pre-heating using Hilotherm Calido®.|The pre-heating will be performed with Hilotherm Calido®.
48018843|NCT03393598|DEVICE|pre-expansion-heating|Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
48018844|NCT06102876|OTHER|Physical activity (PA) program|The PA program is specific for each patient according to their mobility profile assessed using a decision tree comprising 3 tests: 1) the number of repetitions in the 30-second sit-to-stand test, 2) the score in the Short Physical Performance Battery (SPPB) test and 3) grip strength. The PA program has to be performed once daily.
48018845|NCT02376127|PROCEDURE|Dynamic contrast enhancement MRI|
48708844|NCT05980364|OTHER|Technology-based training structured according to the Health Promotion Model|Experimental group: A video recording was created with a total of 6 zoom applications to be shared with the patients. The content of the video recordings consists of a presentation accompanied by a slide show with open-ended questions prepared by considering the basic concepts of the trainings and the Health Promotion Model. Video recordings, each of which lasted approximately 15-25 minutes, were shared with patients once a week for a total of 6 weeks via WhatsApp. After each video, patients were given three days to watch the video recordings and create their own responses. After this three-day period, the researcher called the patients with whom he shared the content and gave counseling for 10-15 minutes and received feedback. Follow-up was done in the second 6-week period. During the monitoring process, two reminder interviews were made over the phone, with an interval of 2 weeks, for reminder and counseling, and the post-test data were collected at the end of the monitoring period.
48708845|NCT02707081|DRUG|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
48018846|NCT05572905|OTHER|Exercise|Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
48018847|NCT05572905|OTHER|Fasting control|The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
48018848|NCT05251792|OTHER|Ocular examination|All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
48708846|NCT02707081|DRUG|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
48708847|NCT02707081|DRUG|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
48018849|NCT01519518|DRUG|unfractionated heparin|70 units/kg body weight intravenous
48708848|NCT02707081|DRUG|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
48018850|NCT01519518|DRUG|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
48018851|NCT05458349|DEVICE|acellular dermis|
48175876|NCT02826798|DRUG|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
48175877|NCT00900783|DRUG|valacyclovir|1 gram, three times a day for seven days
48175878|NCT00900783|DRUG|FV-100|400 mg, once daily, for seven days
48175879|NCT00900783|DRUG|FV-100|200 mg, once daily, for seven days
48708849|NCT02085096|BEHAVIORAL|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
48708850|NCT02858531|OTHER|data retrieval|data retrieval with the Hospital Information System
48708851|NCT02908646|PROCEDURE|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
48708852|NCT02908646|PROCEDURE|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
48708853|NCT04283565|OTHER|Systematic screening of AOMI by BPI measurement.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
48708854|NCT04283565|OTHER|Management of CVRF by a motivationnal interviewing.|The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
48708855|NCT00097162|PROCEDURE|Anodal stimulation|
48708856|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
48708857|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
48708858|NCT01511328|OTHER|HPV testing|Testing for Human Papilloma Virus
48708859|NCT01812200|DRUG|Dabigatran, Ticagrelor, ASA|
48708860|NCT01812200|DRUG|Rivaroxaban, Ticagrelor, ASA|
48708861|NCT01812200|DRUG|Phenprocoumon, Ticagrelor, ASA|
48708862|NCT06605183|BEHAVIORAL|Community walking program using Nordic walking poles|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to build up their step count to 10,000 steps per day. We do not anticipate that the weekly walk will get them to 10,000 steps but we will use that as a weekly event to drive behavioral change throughout the week.
48708863|NCT04536922|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
48708864|NCT04536922|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
48708865|NCT04536922|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
48708866|NCT04536922|DRUG|Pembrolizumab (KEYTRUDA(R))|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
48708867|NCT04536922|BIOLOGICAL|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
48708868|NCT01514240|DRUG|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
48708869|NCT01514240|DRUG|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
48708870|NCT01838265|PROCEDURE|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
48708871|NCT01838265|PROCEDURE|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
48708872|NCT01838265|BEHAVIORAL|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
48708873|NCT01838265|BEHAVIORAL|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
48708874|NCT01838265|BEHAVIORAL|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
48018852|NCT05173467|PROCEDURE|Robot-assisted Invasion-controlled Surgery|The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.
48018853|NCT05173467|PROCEDURE|Traditional-open Surgery|This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.
48018854|NCT03140891|DEVICE|NHFOV|NHFOV is used as the noninvasive mode after extubation
48175880|NCT00900783|DRUG|Valacyclovir placebo|three times a day, for seven days
48018855|NCT03140891|DEVICE|NCPAP|NCPAP is used as the noninvasive mode after extubation
48018856|NCT04590391|DEVICE|Visual and Auditory Breathing-swallowing Coordinated Training device|This device has a structure in which a band wrapped around the chest detects the respiratory phase from changes in the lung volume, and the connected device lights a signal and sounds a sound.
48175881|NCT00900783|DRUG|FV-100 placebo|once daily, for seven days
48175882|NCT04752033|DRUG|Morphine|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a morphine dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
48175883|NCT04752033|DRUG|Hydromorphone|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a hydromorphone dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
48175884|NCT03817723|RADIATION|c-arm cholangiography|
48175885|NCT05380141|BEHAVIORAL|Individual patient interviews|"Two individual interviews, of one hour duration, will take place for each patient before the beginning of participating to the workshops and in the month following the end of the workshops.~They will be led by a psychologist and a nurse from the functional pain and palliative medicine unit of Necker Hospital and 3 questionnaires will be completed during each interview."
48175886|NCT00887198|DRUG|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
48708875|NCT01838265|PROCEDURE|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
48708876|NCT01838265|PROCEDURE|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
48708877|NCT01838265|PROCEDURE|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
48708878|NCT01838265|PROCEDURE|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
48708879|NCT03836326|OTHER|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
48708880|NCT03836326|OTHER|Control|Routine care provided by health professionals in the NICU
48708881|NCT03836326|OTHER|Story telling attention refocusing intervention|A contact-free intervention where parents share stories with their infant for 10 minutes 3 times per week.
48708882|NCT00164385|BEHAVIORAL|Adolescent Impact|
48708883|NCT00378911|DRUG|sunitinib malate|Given orally
48708884|NCT00132795|BEHAVIORAL|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
48708885|NCT00132795|BEHAVIORAL|control group|standard care (no added treatment)
48708886|NCT06599840|BEHAVIORAL|Parent intervention|This is a novel intervention based on established CBT-based parenting strategies that are regularly used to strengthen parent-child cooperation and reduce conflicts. Here, the strategies are adapted to address typical challenges of T1D family life. The program structure consists of six weekly modules and a seventh booster module. Each of the first six modules has a theme with information on a parental strategy associated with the theme, self-reflective questions, and an assignment where parents plan to implement the strategy during the upcoming week. One month later, a seventh session is held to summarize the program and make plans for future progress.
48708887|NCT00102297|DRUG|FG-3019|
48708888|NCT05293444|DIETARY_SUPPLEMENT|Maltodextrine|400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
48708889|NCT05293444|OTHER|overnight fasting|no intervention
48708890|NCT02238314|DRUG|Tipranavir low dose|
48018857|NCT05772065|BEHAVIORAL|CDC/NTCA guidelines only|The control group will have a link to US guidelines only.
48175887|NCT00887198|DRUG|Placebo|4 placebo tablets per day taken orally.
48175888|NCT00887198|DRUG|Prednisone|5 mg tablet orally twice daily.
48175889|NCT00619268|DRUG|Temsirolimus|25 mg once per week administered intravenously
48175890|NCT00619268|DRUG|Bevacizumab|10 mg/kg \* 1 time /2 weeks administered intravenously
48175891|NCT00619268|DRUG|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
48175892|NCT00619268|DRUG|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
48708891|NCT02238314|DRUG|Tipranavir high dose|
48708892|NCT02238314|DRUG|Ritonavir|
48708893|NCT02238314|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
48708894|NCT02238314|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
48018858|NCT05772065|BEHAVIORAL|LTBI ASSIST and CDC/NTCA guidelines only|The intervention group will have a link to both US guidelines, and the LTBI-ASSIST tool.
48018859|NCT06161376|OTHER|S1P level|Patients will undergo urinary S1P level assessments before treatment, 6 weeks post-injection, and following any symptomatic changes that may lead to another urodynamic assessments.
48018860|NCT02197546|OTHER|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
48018861|NCT04231435|DRUG|Fedratinib|Oral
48018862|NCT04231435|DRUG|Digoxin|Oral
48018863|NCT04231435|DRUG|Rosuvastatin|Oral
48018864|NCT04231435|DRUG|Metformin|Oral
48018865|NCT04025814|DEVICE|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
48018866|NCT04025814|BEHAVIORAL|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
48018867|NCT06521346|PROCEDURE|Active cycle breathing technique|The ACBT was included if it was described as containing three essential components: 1) breathing control, 2) FET and 3) thoracic expansion exercises. The technique may also include postural drainage (PD) or percussion/shaking.
48018868|NCT06521346|PROCEDURE|Routine care|Routine care delivers after extubating such as percussion or chest physiotherapy
48018869|NCT01459406|DIETARY_SUPPLEMENT|Glucose|500 ml water drink containing 40g glucose
48018870|NCT01459406|DIETARY_SUPPLEMENT|Fructose|500 ml water drink containing 40g fructose
48018871|NCT01459406|DIETARY_SUPPLEMENT|Fructan|500 ml water drink containing 40g fructan
48018872|NCT01459406|DIETARY_SUPPLEMENT|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
48018873|NCT03058796|DEVICE|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
48018874|NCT03058796|DEVICE|Hand Therapy Video Games|The use of video games with CCFES to encourage therapeutic hand movement at home
48018875|NCT05797805|DRUG|Tegavivint|"The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle"
48018876|NCT05797805|DRUG|Pembrolizumab|"In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus pembrolizumab combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 of a 21-day cycle; Pembrolizumab will be administered on Day 1 of a 21- day cycle"
48018877|NCT04317586|DEVICE|Trident II Tritanium Acetabular Shell for Revision|A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
48018878|NCT06663306|DRUG|Pemetrexed|Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
48708895|NCT04951271|BEHAVIORAL|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
48708896|NCT00003136|BIOLOGICAL|filgrastim|
48708897|NCT00003136|DRUG|amifostine trihydrate|
48708898|NCT00003136|DRUG|carboplatin|
48708899|NCT00003136|DRUG|cyclophosphamide|
48175893|NCT00277368|OTHER|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
48708900|NCT00003136|PROCEDURE|peripheral blood stem cell transplantation|
48708901|NCT00929773|DEVICE|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
48708902|NCT00929773|DEVICE|Placebo laser|Inactive laser light.
48175894|NCT01325597|OTHER|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
48708903|NCT00429117|BEHAVIORAL|Survey|Internet survey lasting 30 to 40 minutes.
48175895|NCT01325597|OTHER|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
48708904|NCT06604416|OTHER|Forward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.
48708905|NCT06604416|OTHER|Backward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
48708906|NCT00753805|DIETARY_SUPPLEMENT|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
48708907|NCT03362931|DEVICE|XEN45|XEN45 unilaterally implanted in the study eye
48018879|NCT06663306|DRUG|Bevacizumab|Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
48708908|NCT01057225|DRUG|carfilzomib|Given IV
48708909|NCT01057225|DRUG|cyclophosphamide|Given orally
48708910|NCT01057225|DRUG|thalidomide|Given orally
48708911|NCT01057225|DRUG|dexamethasone|Given orally
48708912|NCT04815122|RADIATION|SPECT TRODAT-1|The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
48708913|NCT03657563|OTHER|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
48018880|NCT04286594|DRUG|CBD|Participants will receive CBD solution during the open-label phase of the trial.
48018881|NCT05661292|DIAGNOSTIC_TEST|Fecal inmunochemical test|A fecal inmunochemical test will be performed prior to colonoscopy.
48018882|NCT05661292|DIAGNOSTIC_TEST|Colonoscopy|A colonoscopy will be performed. Any polyp identified will be resected (polypectomy) and analyzed histologically. NOTE: The subject and colonoscopist will be blinded to FIT test results and risk category.
48376479|NCT03329404|DEVICE|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
48376480|NCT03329404|DEVICE|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
48376481|NCT04133909|DRUG|Placebo|Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
48376482|NCT04133909|BIOLOGICAL|Mepolizumab|Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
48708914|NCT01990430|BEHAVIORAL|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
48708915|NCT01759563|DEVICE|nasopharyngeal targeted brain cooling|
48708916|NCT03521713|DRUG|EPORON|"* Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS"
48708917|NCT03521713|DRUG|EPREX|"* Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS"
48018883|NCT05661292|BIOLOGICAL|Optional collection of tissue, blood and urine for future biomedical research|Subjects may optionally participate in the collection of tissue, blood, and urine samples for future biomedical research. This procedure consists of taking a 15 ml sample of venous blood and 20 ml of urine. The tissue samples to be used will be those that have been taken for diagnostic purposes during the colonoscopy. Additional biopsies not required for medical care will not be taken. These samples will be used as long as they are no longer required to establish a diagnosis.
48018884|NCT01144104|BEHAVIORAL|Public Service Announcement|
48018885|NCT01144104|BEHAVIORAL|Interactive Multi-Media Computer Program|
48018886|NCT01144104|BEHAVIORAL|Sleep Hygiene Video|
48018887|NCT05980312|OTHER|Splint Immobilization|Patients will be randomized to receive a splint following their surgical procedure.
48018888|NCT05980312|OTHER|Early Motion|Patients will be randomized to receive no splint following their surgical procedure.
48018889|NCT04174677|DRUG|Inebilizumab|Infusion of Inebilizumab
48018890|NCT04174677|DRUG|VIB4920|Infusion of VIB4920
48018891|NCT04174677|DRUG|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
48376483|NCT06235060|OTHER|Computer-assisted simulation technique training group|After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
48376484|NCT06235060|OTHER|Imagery GROUP|After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
48376485|NCT02160223|DRUG|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
48018892|NCT00812292|DRUG|TMC278|
48018893|NCT06563323|DRUG|Guselkumab|Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.
48175896|NCT01325597|OTHER|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
48175897|NCT01325597|OTHER|Control group|No intervention
48175898|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg Ferrous sulfate
48175899|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg ferrous sulfate
48175900|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|6 mg ferrous sulfate
48376486|NCT02160223|DRUG|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
48018894|NCT04255095|PROCEDURE|experiment|Treatment was randomly selected according to preoperative grouping. After ERCP, naso-pancreatic drainage was chosen as treatment。
48018895|NCT04255095|PROCEDURE|control|Treatment was randomly selected according to preoperative grouping. After ERCP, nasobiliary drainage was chosen as treatment。
48018896|NCT01646671|DRUG|LCZ696|LCZ696 200 mg tablet once daily
48018897|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
48376487|NCT00743873|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
48376488|NCT00743873|DRUG|placebo|injection of 6 cc of saline into injured area
48018898|NCT01646671|DRUG|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
48018899|NCT03813303|DRUG|Midazolam|Administration of midazolam by anesthesiologist for sedation.
48018900|NCT03813303|DRUG|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
48018901|NCT03813303|DRUG|Propofol|Administration of propofol by anesthesiologist for sedation.
48018902|NCT04603430|OTHER|Participation in a community wellness program|Participation in the STEPS program, a physical therapy student-run community wellness program for local seniors.
48018903|NCT00504244|DRUG|switch to Myfortic|Myfortic 2 dd 720 mg
48018904|NCT00504244|DRUG|continuation of azathioprine|Azathioprine 2 mg/kg
48018905|NCT06063941|DRUG|1% Lugol's iodine solution|1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.
48018906|NCT06063941|DRUG|5% Lugol's iodine solution|Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.
48018907|NCT05747118|BEHAVIORAL|Physical training|A 12 week supervised training intervention with 1 hour physical training two times a week.
48175901|NCT01621789|OTHER|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
48175902|NCT02304081|DRUG|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
48175903|NCT02304081|DRUG|Placebo for Saxagliptin|
48175904|NCT01383239|OTHER|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
48175905|NCT01383239|OTHER|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
48175906|NCT06183671|DRUG|JX09 or placebo SAD|For Part 1 SAD: JX09/placebo in capsule will be administered as a single oral dose. The nominal dose escalation scheme for the cohorts is 1, 3, 10, 30, 100, and 300 mg.
48175907|NCT06183671|DRUG|JX09 or placebo MAD|For Part 2 MAD: JX09/placebo in capsule will be administered for 11 days (once daily) The nominal dose escalation scheme for the cohorts is 2, 5, 10 and 20 mg.
48376489|NCT05186376|PROCEDURE|bimaxillair osteotomy with maxillar segmentation|Patients who underwent bimaxillair osteotomy with maxillar segmentation
48376490|NCT02213627|DRUG|Corifollitropin alfa|
48376491|NCT02213627|DRUG|Recombinant FSH|
48175908|NCT06183671|DRUG|JX09|For Part 3 FE: JX09 in capsule will be administered as a two single oral doses separated by 15 days. The nominal dose is 10 mg.
48175909|NCT00530998|PROCEDURE|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
48175910|NCT00530998|PROCEDURE|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
48175911|NCT02670122|DEVICE|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
48376492|NCT02213627|DRUG|HP-hMG|
48708918|NCT02275390|BEHAVIORAL|Nurse-led Psycho-education (or SPBB: self-learning program)|"The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]"
48708919|NCT02275390|BEHAVIORAL|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
48708920|NCT03336372|DRUG|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
48708921|NCT04006990|BEHAVIORAL|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
48376493|NCT03669952|OTHER|None intervention|No interventions are realized, only observational study
48376494|NCT01899417|DEVICE|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
48376495|NCT03179137|OTHER|Standard therapy|Patients with therapy prescribed independent of the study
48708922|NCT05401695|DEVICE|HA330 hemoadsorption technique|Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
48708923|NCT02630420|DRUG|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
48376496|NCT01585285|PROCEDURE|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
48708924|NCT02095665|DRUG|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
48708925|NCT02095665|DRUG|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
48708926|NCT02095665|DRUG|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
48708927|NCT01174004|DRUG|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
48708928|NCT01174004|DRUG|placebo|placebo, tablet, once daily by mouth for 6 weeks
48708929|NCT02998905|DRUG|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
48708930|NCT02998905|DRUG|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
48708931|NCT00820482|DRUG|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
48708932|NCT00820482|DRUG|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
48708933|NCT01904643|DRUG|lenalidomide|Given PO
48708934|NCT01904643|DRUG|mitoxantrone hydrochloride|Given IV
48708935|NCT01904643|DRUG|etoposide|Given IV
48708936|NCT01904643|DRUG|cytarabine|Given IV
48708937|NCT04837989|BEHAVIORAL|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
48018908|NCT04116229|PROCEDURE|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
48018909|NCT04116229|BEHAVIORAL|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
48018910|NCT04116229|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
48708938|NCT04837989|BEHAVIORAL|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
48018911|NCT06556680|DEVICE|Optical coherence tomography|In the OCT-guided biopsy arm, n=100 study subjects will be enrolled. The investigators will conduct biopsies and imaging using our newly developed OCT catheters and real-time image processing and display algorithms.
48018912|NCT04034589|DRUG|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
48018913|NCT03090399|DEVICE|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
48018914|NCT03586869|DRUG|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
48018915|NCT03586869|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
48018916|NCT03586869|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
48018917|NCT03586869|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2
48018918|NCT03586869|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
48018919|NCT03586869|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
48018920|NCT03586869|BIOLOGICAL|GI-4000|RAS yeast
48018921|NCT03586869|BIOLOGICAL|GI-6207|Carcinoembryonic Antigen (CEA) yeast
48376497|NCT01585285|PROCEDURE|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
48708939|NCT03692351|DEVICE|Uncemented acetabular cup with screw holes|
48018922|NCT03586869|BIOLOGICAL|GI-6301|Brachyury yeast
48708940|NCT03692351|DEVICE|Uncemented acetabular cup without screw holes|
48018923|NCT03586869|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
48018924|NCT03586869|BIOLOGICAL|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
48018925|NCT03586869|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
48018926|NCT03586869|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
48018927|NCT03586869|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
48018928|NCT03586869|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
48376498|NCT06059508|DRUG|SHR-5495 for injection|SHR-5495 for injection
48376499|NCT05804695|PROCEDURE|Arthroscopic TMJ disc repositioning under GA|a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
48018929|NCT03586869|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
48018930|NCT03586869|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
48018931|NCT03586869|BIOLOGICAL|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
48018932|NCT03586869|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
48018933|NCT04707235|DRUG|Hydroxycarbamide|Patients, aged ≥ 2 years old, with symptomatic SCD, treated with Siklos®.
48018934|NCT00238927|DRUG|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
48018935|NCT05805280|DEVICE|intravascular ultrasound-guided group|intravascular ultrasound use
48018936|NCT05805280|DEVICE|angiography-guided group|angiography-guided use
48376500|NCT00942110|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
48376501|NCT03583801|OTHER|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
48376502|NCT03583801|OTHER|without aromatherapy|no intervention
48018937|NCT01813019|DRUG|AFQ056|mGluR5 antagonist
48376503|NCT02905695|DRUG|Chirocaine|
48376504|NCT02905695|OTHER|Placebo|
48376505|NCT04567849|BEHAVIORAL|message|patient portal message
48018938|NCT01813019|DRUG|Placebo|Matched placebo
48018939|NCT02074735|DRUG|Placebo|Inactive ingredient matching the active comparator in appearance
48018940|NCT02074735|DRUG|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
48018941|NCT03652324|OTHER|method|to compare the use of general anesthesia and deep sedation
48376506|NCT04567849|BEHAVIORAL|provider|nudging calling the patient's provider
48376507|NCT04567849|BEHAVIORAL|tele-nurse|nudging calling the tele-nurse
48517293|NCT01044121|OTHER|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
48708941|NCT02590601|DRUG|Bromocriptine|
48708942|NCT02590601|OTHER|Guideline-driven medical therapy (GDMT)|
48376508|NCT02654561|DRUG|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
48708943|NCT05507879|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48708944|NCT05507879|OTHER|Electronic Medical Record|Review of medical records
48708945|NCT02070393|RADIATION|Proton|14-24 Radiation treatments using Protons
48708946|NCT00196859|DRUG|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
48376509|NCT02654561|DRUG|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
48376510|NCT04642040|OTHER|Pulmonary Rehabilitation|Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
48376511|NCT06445517|DRUG|ISM8207|Pharmaceutical formulation: Capsules Mode of Administration: Oral
48708947|NCT00196859|DRUG|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
48376512|NCT02826174|PROCEDURE|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
48376513|NCT02826174|PROCEDURE|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
48708948|NCT05250076|DEVICE|Kinesio Tape|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination."
48708949|NCT04247191|BEHAVIORAL|P-Chat|The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
48708950|NCT04247191|BEHAVIORAL|PBI|"The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
48708951|NCT04247191|BEHAVIORAL|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
48708952|NCT02667223|BIOLOGICAL|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
48708953|NCT02667223|BIOLOGICAL|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
48708954|NCT02667223|BIOLOGICAL|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
48708955|NCT02667223|BIOLOGICAL|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
48708956|NCT02667223|BIOLOGICAL|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
48708957|NCT01215110|DRUG|TMC207|
48708958|NCT01215110|DRUG|Rifafour e-275 mg|
48708959|NCT05110469|DRUG|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
48708960|NCT05110469|DRUG|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
48708961|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
48708962|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
48708963|NCT03596073|DRUG|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
48708964|NCT03596073|OTHER|Topical Vaseline|Placebo
48708965|NCT06242639|OTHER|Clinical examination|clinic and radiographic evaluation
48708966|NCT00762567|DRUG|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
48708967|NCT05146713|DIETARY_SUPPLEMENT|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
48708968|NCT05146713|DRUG|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
48708969|NCT01140568|DRUG|nilotinib|400mg po (orally) BID (twice daily)
48708970|NCT04285307|BEHAVIORAL|Sleep Hygiene tips|Students receive a packet of information on how to improve their sleep habits and hygiene.
48708971|NCT02818348|DRUG|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
48708972|NCT02818348|DRUG|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
48708973|NCT05401045|BEHAVIORAL|Met exercises|Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.
48708974|NCT00159913|DRUG|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
48708975|NCT00159913|DRUG|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
48708976|NCT00159913|DRUG|Placebo|oral; 3 times a day(TID)
48376514|NCT02826174|DRUG|Anti-Rejection Agents|Anti-Rejection Agents for both groups
48708977|NCT00159913|DRUG|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
48708978|NCT05462990|DRUG|QUC398|QUC398 150 mg/mL, solution for s.c. injection (1 mL)
48708979|NCT05462990|DRUG|Placebo|Placebo 0 mg/mL, solution for s.c. injection (1 mL)
48708980|NCT00765882|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
48376515|NCT02826174|DRUG|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
48708981|NCT00765882|DRUG|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
48708982|NCT00765882|DRUG|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
48708983|NCT01015235|DRUG|Placebo|Subcutaneous infusion-once over 4 hours
48708984|NCT01015235|DRUG|KAI-1678|Subcutaneous infusion-once over 4 hours
48708985|NCT01015235|DRUG|Ketorolac Tromethamine|Active comparator, IV infusion, once
48708986|NCT03351114|DRUG|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
48708987|NCT03592719|BEHAVIORAL|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
48708988|NCT03592719|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
48708989|NCT00888329|DRUG|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
48708990|NCT00888329|DRUG|Placebo|Placebo
48708991|NCT06306664|DEVICE|Bioptron|Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
48708992|NCT06306664|OTHER|Placebo Comparator|Patients will receive ice application+Exercises program designed for jumper knee
48708993|NCT04061954|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided"
48708994|NCT05223881|DEVICE|13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)|After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
48708995|NCT05585229|DRUG|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
48708996|NCT01205802|PROCEDURE|MHV reconstruction|MHV reconstruction with PTFE or homograft
48708997|NCT01274780|DRUG|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
48708998|NCT01274780|DRUG|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
48708999|NCT05415592|DEVICE|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
48709000|NCT03259048|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
48709001|NCT04150731|RADIATION|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
48709002|NCT01777555|DRUG|CVT-301|
48709003|NCT01777555|DRUG|Placebo|
48709004|NCT05683574|DRUG|FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo|Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
48709005|NCT05683574|DRUG|etoricoxib 90 mg (Arcoxia®) +FDC placebo|Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
48709006|NCT05683574|DRUG|cyclobenzaprine hydrochloride + etoricoxib placebo|Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
48709007|NCT01360372|DRUG|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
48709008|NCT01360372|DRUG|Saline injection|Saline 0.4 to 0.8 ml injection
48709009|NCT04640493|DRUG|Dapagliflozin|If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
48709010|NCT04640493|DEVICE|WatchPat|HF patients undergo SDB testing with the WatchPat device. (non-experimental)
48709011|NCT01480518|GENETIC|DNA analysis|
48709012|NCT01480518|GENETIC|comparative genomic hybridization|
48709013|NCT01480518|GENETIC|gene expression analysis|
48709014|NCT01480518|GENETIC|mutation analysis|
48709015|NCT01480518|GENETIC|polymerase chain reaction|
48709016|NCT01480518|GENETIC|polymorphic microsatellite marker analysis|
48709017|NCT01480518|OTHER|laboratory biomarker analysis|
48709018|NCT04237038|PROCEDURE|laparoscopic Nissen fundoplication short gastric vessel division|Randomized clinical trial conducted in forty patients submitted to SGVD and forty patients without SGVD. Patients were evaluated with standarized questionnaires to measure the degree of satisfaction in relation to surgical procedure and to the quality of life. A randomized clinical trial was conducted with 87 patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of Gastroesophageal reflux disease (GERD
48709019|NCT06275984|OTHER|online CPR-AED training|"The online CPR-AED training consists of successfully completing the online training course. To access the course, interested persons must register on a Moodle environment platform, with free and open access, through the following link: https://register.magnore.com/registre-curs-de-reanimacio -cardiopulmonary-dea/~Online training takes 3-4h and the participant will have access for 1 month (7x24h)."
48709020|NCT02577770|DEVICE|acupuncture|therapeutic acupuncture treatment with actual needles
48709021|NCT02577770|DIETARY_SUPPLEMENT|200mg caffeine|8g coffee, po
48709022|NCT02577770|DIETARY_SUPPLEMENT|400mg caffeine|16g coffee, po
48709023|NCT02577770|DIETARY_SUPPLEMENT|Decaffeinated|decaffeinated coffee, po
48709024|NCT06105216|OTHER|Crossword and word search puzzles|Students in the intervention group received hard copies of the puzzles at the end of the laboratory practice.
48709025|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
48709026|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
48709027|NCT00822705|DRUG|Placebo tablet|Control arm
48709028|NCT06072716|DRUG|Chitosan|chitosan loaded with miconazole nanoparticles gel
48709029|NCT06101602|OTHER|Dynamic Stretching with Floss Band|"Floss band involves wrapping a band made of natural rubber around the targeted joint or muscle for 1-3 minutes through active movement. The mechanism behind flossing is thought to have a three-fold effect, compression may stimulate the mechanoreceptors of the underlying fascia layer which causes the hyperemia of the targeted tissue, and leads to increased blood flow.~This intervention was applied in addition to dynamic stretching which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise."
48175912|NCT06258733|BEHAVIORAL|Lay-led FL workshops|Groups of women recruited by trained lay-leaders will receive an 8-session lay-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the lay workshop facilitator. Lay-leaders will receive an incentive to collect surveys from workshop participants. A member of the research staff will be present at the time of the survey collection to ensure data are collected according to protocol. Monthly phone calls with lay-leaders will take place to ensure implementation in the community, including problem solving and help maintaining motivation. To help ensure implementation in the lay-led arm, lay leaders will be required to complete one workshop in the community before receiving a graduation certificate.
48175913|NCT06258733|BEHAVIORAL|Expert-led workshops|Matching groups of women recruited by research staff will receive the same 8-session expert-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the expert workshop facilitator.
48175914|NCT06437119|DIETARY_SUPPLEMENT|Compound plant nutrients|The compound plant nutrients include extracts of licorice, sophora, wild cherry berry, dendrobium officinale, and pomegranate.
48175915|NCT06437119|DIETARY_SUPPLEMENT|placebo|A placebo with an indistinguishable appearance and color.
48709030|NCT06101602|OTHER|Dynamic Stretching without Floss Band|In this group, only dynamic stretching was applied which involved 3 types of dynamic stretches. These stretches were applied through multidirectional (anteromedial, anterior, and anterolateral) leg swings specifically for the Hamstring muscle. It was performed in 3 sets of 15 repetitions with 30 seconds of rest between each exercise.
48709031|NCT03673787|DRUG|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
48709032|NCT03673787|DRUG|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
48709033|NCT02696499|DRUG|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
48709034|NCT02696499|DRUG|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
48709035|NCT00304018|BIOLOGICAL|anti-thymocyte globulin|
48709036|NCT00304018|BIOLOGICAL|sargramostim|
48709037|NCT00304018|DRUG|busulfan|
48709038|NCT00304018|DRUG|etoposide|
48709039|NCT00304018|DRUG|fludarabine phosphate|
48709040|NCT00304018|DRUG|prednisone|
48709041|NCT00304018|DRUG|tacrolimus|
48175916|NCT00632385|DRUG|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose
48175917|NCT02975791|OTHER|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
48175918|NCT02975791|PROCEDURE|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
48709042|NCT00304018|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48709043|NCT00304018|PROCEDURE|umbilical cord blood transplantation|
48709044|NCT01108432|OTHER|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
48709045|NCT06160856|DIAGNOSTIC_TEST|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
48709046|NCT02100020|OTHER|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
48709047|NCT02887053|DEVICE|MRI|
48709048|NCT05027334|OTHER|DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes|Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
48709049|NCT05646355|BEHAVIORAL|Proactive CRC Screening Outreach|Proactive approach that incorporates a mailed outreach invitation to screen with fecal immunochemical testing (FIT), followed by active assistance to colonoscopy completion if preferred or indicated by FIT test result.
48709050|NCT05646355|BEHAVIORAL|Usual Care|Participants will not receive additional outreach from the study team regarding CRC screening.
48709051|NCT03738059|DRUG|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
48709052|NCT03738059|OTHER|normal saline 0.9%|will receive intravenous normal saline 0.9%
48709053|NCT03524287|PROCEDURE|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
48709054|NCT00760461|DRUG|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
48709055|NCT06269198|DEVICE|WARD-CSS|"Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded."
48709056|NCT05482178|BEHAVIORAL|Resistance exercise training plus hypocaloric diet|"The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day)."
48709057|NCT05482178|BEHAVIORAL|Hypocaloric diet|The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).
48175919|NCT02168231|PROCEDURE|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
48175920|NCT03330964|OTHER|electro-acupuncture|Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
48709058|NCT05839340|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
48709059|NCT05839340|DEVICE|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
48709060|NCT04243902|DEVICE|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
48709061|NCT01395121|DRUG|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
48175921|NCT03550053|DEVICE|3D mandibular plate|Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
48175922|NCT00865852|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
48517294|NCT01458691|PROCEDURE|Steroid injection into the glenohumeral joint|"* Group: Steroid~* Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
48709062|NCT04431310|OTHER|Serial seroconversion measurements in hospital employees during the COVID-19 pandemic|The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
48175923|NCT00865852|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
48709063|NCT04043754|PROCEDURE|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
48709064|NCT04043754|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
48709065|NCT03796143|BEHAVIORAL|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
48709066|NCT03796143|BEHAVIORAL|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
48709067|NCT03695380|DRUG|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
48709068|NCT03695380|DRUG|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
48709069|NCT03695380|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
48709070|NCT03386786|BEHAVIORAL|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
48709071|NCT03386786|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
48175924|NCT05052710|DRUG|AZD4831|Subjects will receive oral doses once daily from Days 2-11.
48175925|NCT05052710|DRUG|Midazolam|Subjects will receive oral single doses on Day 1 and Day 11.
48175926|NCT05513417|DEVICE|Bloom Pod|Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
48175927|NCT01148498|DRUG|solanezumab|400mg administered once intravenously
48175928|NCT02619305|OTHER|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
48175929|NCT02239861|BIOLOGICAL|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
48709072|NCT00589056|DRUG|cisplatin|
48709073|NCT00589056|DRUG|etoposide|
48709074|NCT00589056|DRUG|nelfinavir mesylate|
48709075|NCT00589056|GENETIC|protein expression analysis|
48709076|NCT00589056|OTHER|immunohistochemistry staining method|
48709077|NCT00589056|OTHER|laboratory biomarker analysis|
48709078|NCT00589056|PROCEDURE|biopsy|
48709079|NCT00589056|RADIATION|radiation therapy|
48709080|NCT04128397|DEVICE|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
48709081|NCT04128397|DEVICE|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
48709082|NCT04302701|OTHER|Dichoptic treatment using virtual reality|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
48709083|NCT04302701|OTHER|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
48517295|NCT01458691|PROCEDURE|Allogeneic PRP injection into the glenohumeral joint|"* Group: Allogeneic PRP~* Total volume of injection drugs: 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 25-gauze spinal needle~* The intra-articular injections were performed using ultrasonographic guidance."
48517296|NCT00165763|DRUG|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
48709084|NCT03387943|DRUG|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
48709085|NCT03387943|DRUG|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
48709086|NCT01944566|BIOLOGICAL|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
48709087|NCT06224660|GENETIC|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
48376516|NCT02909127|OTHER|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
48376517|NCT02909127|OTHER|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
48376518|NCT02909127|OTHER|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
48376519|NCT03361566|BEHAVIORAL|physical activity|3 different levels of physical activity
48376520|NCT03361566|BEHAVIORAL|energy intake|4 different types of energy intake
48376521|NCT02515175|BIOLOGICAL|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
48376522|NCT02515175|BIOLOGICAL|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
48376523|NCT02515175|DRUG|Placebo|0.9% Normal Saline
48376524|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
48018942|NCT06155903|PROCEDURE|Selective Spinal Anesthesia|Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.
48376525|NCT05102162|DRUG|Cefepime, Meropenem, or Piperacillin/Tazobactam|A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
48376526|NCT04957628|BEHAVIORAL|Harmful alcohol use treatment|Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
48018943|NCT06155903|PROCEDURE|Peripheral nerve blocks|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml."
48018944|NCT06155903|DRUG|Anesthesiological mixtures (Spinal anesthesia)|The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg.
48018945|NCT06155903|DRUG|Anesthesiological mixtures (Peripheral nerve block)|The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
48018946|NCT02139644|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
48517297|NCT00963066|DEVICE|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
48709088|NCT05241197|OTHER|Low Load Training with Blood Flow Restriction|A 12-cm-wide pneumatic nylon tourniquet will be proximally positioned with a snug fit on each thigh. Previously, arterial occlusion pressure (AOP) will be determined using a handheld Doppler Ultrasound in a standing position for each participant. For training routines, cuff pressure will be set to 50% of each individual´s AOP and will be keep inflated during the entire session including the interset rest period of 1 minute. Between the two exercises, the cuff will be deflated for 3 minutes.
48709089|NCT05241197|OTHER|High Load Training|All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
48709090|NCT01933230|DEVICE|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
48709091|NCT03664674|DRUG|OTO-104|Single intratympanic injection of 12 mg dexamethasone
48709092|NCT03664674|DRUG|Placebo|Single intratympanic injection of placebo
48709093|NCT03978962|DEVICE|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
48709094|NCT02498067|BEHAVIORAL|rPlan dual protection waiting room app intervention|
48709095|NCT04288258|BEHAVIORAL|Telehealth-Based Health and Wellness Program (POWERS-TBI)|The treatment program is interactive and will be delivered via the internet, along with ongoing telephone health coaching calls designed to motivate, problem-solve challenges, reinforce skills learned, and prevent relapse.
48709096|NCT02145104|DRUG|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
48709097|NCT05249881|DRUG|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
48709098|NCT00002650|DIETARY_SUPPLEMENT|folic acid|
48709099|NCT01887821|DRUG|Chloroquine|
48517298|NCT00963066|DEVICE|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
48709100|NCT01887821|DRUG|Dihydroartemisinin/Piperaquine|
48709101|NCT05477173|BEHAVIORAL|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
48709102|NCT04510883|BEHAVIORAL|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
48709103|NCT04510883|BEHAVIORAL|Waiting list + PACO|Waiting list + PACO
48376527|NCT04957628|BEHAVIORAL|Non-prescribed psychoactive medicinal use treatment|Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
48709104|NCT00280800|DEVICE|constant CPAP devices|different CPAP mode
48709105|NCT00280800|DEVICE|automatic CPAP devices|different CPAP mode
48709106|NCT04277117|BEHAVIORAL|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
48709107|NCT04277117|BEHAVIORAL|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~* Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off \& visual check) with the participant."
48709108|NCT04277117|BEHAVIORAL|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~* Delivery: 1x per week shipment.~* Engagement: Meals are shipped to the participant's home. No human engagement."
48709109|NCT04277117|BEHAVIORAL|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
48709110|NCT00107315|BIOLOGICAL|bevacizumab|
48709111|NCT00107315|DRUG|capecitabine|
48709112|NCT00977938|DRUG|Placebo & Aspirin|
48709113|NCT00977938|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|
48709114|NCT05735366|DRUG|SAIL66|SAIL66 as a IV infusion
48709115|NCT04612842|BEHAVIORAL|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
48709116|NCT03780478|DRUG|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
48709117|NCT03780478|DRUG|Placebo Saline Injection|Saline injection, total volume 2ml
48709118|NCT02695823|DEVICE|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
48709119|NCT04607941|OTHER|Questionnaires|Self-administered questionnaires
48709120|NCT04607941|OTHER|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
48709121|NCT05938920|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
48709122|NCT05938920|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
48709123|NCT02479581|PROCEDURE|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
48709124|NCT02479581|PROCEDURE|ERAS group|"1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
48709125|NCT02479581|PROCEDURE|ERAS group|Emphasize the preoperative psychological preparation for patients.
48709126|NCT02479581|PROCEDURE|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
48709127|NCT02479581|PROCEDURE|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
48709128|NCT02479581|PROCEDURE|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
48709129|NCT02479581|PROCEDURE|ERAS group|"1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management."
48709130|NCT02479581|PROCEDURE|ERAS group|"1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
48709131|NCT02479581|PROCEDURE|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
48709132|NCT02479581|PROCEDURE|ERAS group|Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
48709133|NCT02479581|PROCEDURE|ERAS group|"1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
48018947|NCT02139644|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
48018948|NCT02139644|DRUG|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
48018949|NCT02139644|DRUG|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
48018950|NCT02139644|DRUG|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
48018951|NCT04638790|DRUG|Doxorubicin|25 mg/m2 i.v. day 1,15 for ABVD/AVD
48018952|NCT04638790|DRUG|Bleomycin|10,000 units/m2 i.v. days 1,15 for ABVD
48018953|NCT04638790|DRUG|Vinblastine|6 mg/m2 i.v. days 1,15 for ABVD/AVD
48018954|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. days 1,15 for ABVD/AVD
48018955|NCT04638790|DRUG|Etoposide|100 mg/m2 i.v. days 1-3
48376528|NCT01976104|DRUG|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
48376529|NCT01976104|DRUG|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
48376530|NCT01976104|DRUG|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
48376531|NCT01976104|DRUG|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
48376532|NCT04940624|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
48376533|NCT04940624|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
48376534|NCT04149366|DEVICE|Retainer|Orthodontic retainer
48376535|NCT00395395|DRUG|Oral salmon calcitonin, salmon calcitonin nasal spray|
48376536|NCT01014104|DRUG|Methylprednisolone|Administration of Methylprednisolone
48376537|NCT01014104|DRUG|Control|Normal salin injection
48376538|NCT04357431|OTHER|self-administered questionnaire|Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
48376539|NCT04284046|OTHER|CT score|CT score = normal lung tissue (%) ×1 + GGO (%) ×2 + consolidation (%) ×3
48376540|NCT05671822|DRUG|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 1A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 1B) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1C) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 1D) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
48376541|NCT05671822|DRUG|SHR-A1811；SHR-1701；capecitabine；oxaliplatin|(Arm 2A) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion; (Arm 2B) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally； (Arm 2C) Drug: SHR-A1811,administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
48018956|NCT04638790|DRUG|Doxorubicin|50 mg/m2 i.v. day 1 for EACODD-14
48709134|NCT02479581|PROCEDURE|ERAS group|"1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h."
48709135|NCT02479581|PROCEDURE|Conventional control group|Routine preoperative psychological preparation for patients.
48376542|NCT03452722|DRUG|intraventricual recombinant tissue plasminogen activator application|
48376543|NCT03500302|DRUG|Evolocumab|Evolocumab sq once a month for a total of two doses
48376544|NCT02842736|DEVICE|Cerene(R) Cryotherapy Device|
48018957|NCT04638790|DRUG|Cyclophosphamide|650 mg/m2 i.v. day 1
48376545|NCT06192875|OTHER|Non-Interventional Study|Non-interventional study
48376546|NCT01748162|DRUG|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
48376547|NCT01748162|DRUG|Prednisolone IF needed|
48376548|NCT00912756|DRUG|cilostazol|200 mg/day BID
48376549|NCT01694927|PROCEDURE|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
48018958|NCT04638790|DRUG|Vincristine|1,4 mg/m2 i.v. day 8
48018959|NCT04638790|DRUG|Dexamethasone|20 mg i.v. days 1-3
48018960|NCT04638790|DRUG|Dacarbazine|375 mg/m2 i.v. day 1 for EACODD-14
48018961|NCT06663774|DIAGNOSTIC_TEST|Physical Fitness Tests|Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
48376550|NCT00077870|DRUG|ocrelizumab|
48018962|NCT04065347|DEVICE|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
48018963|NCT02348489|DRUG|SGI-110 (guadecitabine)|Investigational medicinal product
48018964|NCT02348489|DRUG|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
48018965|NCT05122845|BIOLOGICAL|Blood sample|"Blood test (10 tubes of 5mL) :~- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3.~2 dry tubes 2 tube EDTA"
48376551|NCT05681975|DIAGNOSTIC_TEST|Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions|Immunoassay kits (NutriSMART® and Fastcheckpoc20® In-Vitro Diagnostic kits, DST GmbH, Schwerin, Germany) are performed in a population with suspicion of having a food allergy or a food intolerance with related symptoms.
48376552|NCT00816062|DEVICE|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
48376553|NCT02780206|OTHER|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
48376554|NCT04167449|DIETARY_SUPPLEMENT|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
48376555|NCT04167449|DIETARY_SUPPLEMENT|Conventional White Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
48709136|NCT02479581|PROCEDURE|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
48709137|NCT02479581|PROCEDURE|Conventional control group|"1. Routine bowel preparation;~2. Liquid food eating 2 days before the operation;"
48709138|NCT02479581|PROCEDURE|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
48709139|NCT02479581|PROCEDURE|Conventional control group|"1. Induction use Sufentanil 0.5\~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2\~0.6mg/kg,Midazolam0.05\~0.1mg/kg ;~2. Maintain use Sufentanil 1\~2ug/kg·h, Propofol 4\~12mg/kg·h, Sevoflurane 1\~3(minimal alveolar concentration)， Vecuronium 0.06\~0.12mg/kg·h;"
48709140|NCT02479581|PROCEDURE|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
48709141|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
48709142|NCT02479581|PROCEDURE|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
48709143|NCT01472783|DRUG|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
48175930|NCT04595942|DRUG|Midodrine Hydrochloride Tablets|Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
48175931|NCT04595942|DRUG|Fludrocortisone Acetate Tablets|Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
48175932|NCT04595942|BEHAVIORAL|Lifestyle modification|Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
48709144|NCT03411252|DRUG|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
48175933|NCT05009381|DEVICE|Stylage XXL at enrollment|Injection in the chin at enrollment
48018966|NCT05456035|BEHAVIORAL|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
48175934|NCT05009381|DEVICE|Stylage XXL at Month 6|Injection in the chin 6 months after randomization
48175935|NCT00545571|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
48175936|NCT00483028|DRUG|donezepil (Aricept)|
48376556|NCT04167449|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule containing rice flour
48376557|NCT03522506|DRUG|TAK-925|TAK-925 intravenous infusion.
48709145|NCT03411252|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron
48709146|NCT02764723|DRUG|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
48709147|NCT02764723|DRUG|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
48709148|NCT03054805|DRUG|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg
48175937|NCT05153330|DRUG|BMF-219|BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
48175938|NCT05376345|BIOLOGICAL|LCAR-BCDR cells product|Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
48175939|NCT00746785|DRUG|2.5 mg Olanzapine|2.5 mg
48175940|NCT00746785|DRUG|5mg Olanzapine|5 mg
48175941|NCT00746785|DRUG|placebo|placebo
48175942|NCT02316262|PROCEDURE|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
48175943|NCT05436015|OTHER|Virtual nature-based intervention|"Virtual nature-based intervention is video with Finnish naturepictures and naturesounds shown from a 75 vertical screen monitor"
48709149|NCT03054805|DRUG|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight \> 30 kg
48175944|NCT03995225|BEHAVIORAL|Smartband automatic smoking detection combined with brief mindfulness interventions|Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions and learn to work mindfully with cravings and triggers rather than smoke using RAIN prior to smoking episodes.This is a 3 step intervention.
48175945|NCT04590872|BIOLOGICAL|Tolerogenic Dendritic Cell Vaccine|PIpepTolDCs
48376558|NCT03522506|DRUG|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
48376559|NCT03522506|DRUG|Modafinil|Modafinil tablets.
48376560|NCT03522506|DRUG|Modafinil Placebo|Modafinil placebo-matching tablet.
48376561|NCT01756651|DRUG|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
48709150|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
48709151|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
48709152|NCT03866538|DRUG|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
48709153|NCT05190601|DEVICE|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
48709154|NCT03690453|DRUG|Ivermectin|single dose of Ivermectin
48709155|NCT00477269|DRUG|Imatinib mesylate|
48709156|NCT00477269|DRUG|Placebo|
48709157|NCT03158272|BIOLOGICAL|Cabiralizumab|Specified dose on specified days
48709158|NCT03158272|BIOLOGICAL|Nivolumab|Specified dose on specified days
48175946|NCT04927962|OTHER|Questionnaires|For youth: self-reported questionnaires (on oral quality of life, bullying and cyberbullying, dental anxiety) and routine clinical examination for adolescents. For one parent: self-reported questionnaires (on perceived oral quality of life of their child and on their own dental anxiety).
48175947|NCT03427983|PROCEDURE|Hydrodissection|Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.
48376562|NCT03551457|DIAGNOSTIC_TEST|Biopsy|Patient-derived xenograft treatment response phenotype.
48376563|NCT00658203|DEVICE|New Living CHF|PEA CRT optimization
48376564|NCT00658203|DEVICE|New Living CHF|Standard optimized CRT.
48376565|NCT01966458|DEVICE|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
48376566|NCT01966458|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
48376567|NCT05573425|DRUG|Tazarotene gel 0.1%|Tazarotene gel 0.1% applied daily on Acne Scars.
48709159|NCT04644744|DEVICE|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
48709160|NCT04644744|DEVICE|Normothermic machine perfusion (NMP)|End-ischemic NMP will be continued throughout the recipient hepatectomy and until the transplanting team is ready to implant the liver. The minimum protocol-stipulated NMP duration is 4 hours, the time needed for ATP repletion in animal studies. Total NMP preservation time will be according to the official recommendations of the manufacturer (4-24 hours) and at the discretion of the local transplant centre. The liver allograft will be disconnected from the OrganOx metra® device immediately prior to transplantation and flushed with three litres of HTK via the hepatic artery and the portal vein.
48709161|NCT02721121|PROCEDURE|circumferential pulmonary vein isolation|
48709162|NCT02721121|PROCEDURE|Linear ablation in addiction to circumferential pulmonary vein isolation|
48709163|NCT00943475|PROCEDURE|circumcision|circumcision by plastbell
48709164|NCT02737553|PROCEDURE|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
48709165|NCT02737553|PROCEDURE|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
48376568|NCT05573425|DEVICE|Microneedling|Microneedling via dermaroller device performed on Acne Scars monthly.
48376569|NCT00909857|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
48709166|NCT00459693|DRUG|[11C]PBR28|
48709167|NCT01819987|BEHAVIORAL|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
48709168|NCT01819987|BEHAVIORAL|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
48709169|NCT04120857|BEHAVIORAL|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
48709170|NCT01336530|DRUG|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
48709171|NCT01336530|DRUG|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
48709172|NCT01336530|DRUG|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
48709173|NCT01336530|OTHER|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
48376570|NCT00909857|DRUG|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
48376571|NCT00909857|DRUG|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
48376572|NCT00909857|DRUG|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
48376573|NCT05416034|DEVICE|Use of the ATLAS 2025 exoskeleton at home|Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..
48376574|NCT03235063|OTHER|routinely care- no intervention|routinely care- no intervention
48376575|NCT04357756|DRUG|YH001|YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
48376576|NCT04357756|DRUG|Toripalimab|Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
48376577|NCT02316704|DEVICE|THA with G7 PPS coted acetabular component|
48376578|NCT02316704|DEVICE|THA with G7 OsseoTi coted acetabular component|
48376579|NCT01132027|DRUG|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
48376580|NCT02874820|RADIATION|[11C]BU99008|Baseline and blocked scans
48709174|NCT06054516|DIAGNOSTIC_TEST|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized \[1-13C\]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
48709175|NCT03790774|BEHAVIORAL|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
48709176|NCT04926207|BEHAVIORAL|Physical Activity Breaks Intervention|Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
48709177|NCT04926207|BEHAVIORAL|Talking Breaks Control|Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
48709178|NCT06422858|DRUG|Serplulimab|Serplulimab will be administered as a fixed dose of 300 mg via intravenous infusion every three weeks, continuing for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
48709179|NCT06422858|DRUG|Tegafur-gimeracil-oteracil potassium capsule(S1)|S1 will be administered at a dose of 60 mg/m2 per day, taken orally in two divided doses on day 1 concurrent with radiotherapy, repeated every 28 days; and from day 1 to day 14 of each 21-day cycle, for up to 12 months or until disease progression, unacceptable toxicity, or withdrawal of consent
48709180|NCT06422858|RADIATION|Radiotherapy|Radiotherapy will be delivered as a total dose of 50.4 Gy in 28 fractions over six weeks using techniques such as IGRT, IMRT, VMAT, or TOMO, targeting the primary tumor and associated lymph nodes
48709181|NCT06422858|DRUG|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m\^2 on day 1 concurrent with radiotherapy, repeated every 28 days
48709182|NCT01524003|PROCEDURE|cryotherapy|cryotherapy treatment of the uterine cervix
48175948|NCT03427983|PROCEDURE|Regular Injection|Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
48175949|NCT03032640|OTHER|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
48175950|NCT03032640|OTHER|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
48175951|NCT03032640|OTHER|Stool sampling|Subjects will provide a stool sample.
48175952|NCT03032640|OTHER|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
48709183|NCT01524003|PROCEDURE|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
48709184|NCT01327274|DEVICE|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
48175953|NCT03032640|OTHER|Placebo|Subjects in group 2 will be provided with placebo.
48376581|NCT02874820|DRUG|Idazoxan|Idazoxan dose up to 80mg
48376582|NCT04418466|COMBINATION_PRODUCT|Risperidone|Risperidone Implant
48709185|NCT04855955|DRUG|Adipose-Derived Mesenchymal Stem Cells|
48709186|NCT02020876|OTHER|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
48709187|NCT01287221|DRUG|Rifampicin|300 mg, 2 times daily
48709188|NCT01287221|DRUG|placebo|placebo
48175954|NCT03032640|OTHER|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
48175955|NCT01138761|BEHAVIORAL|Nurse instruction|"The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group."
48175956|NCT04469062|DRUG|Mirikizumab IV|Administered IV
48175957|NCT04469062|DRUG|Mirikizumab SC|Administered SC
48175958|NCT04469062|DRUG|Vedolizumab IV|Administered IV
48175959|NCT04469062|DRUG|Placebo IV|Administered IV
48175960|NCT04469062|DRUG|Placebo SC|Administered SC
48175961|NCT00163007|PROCEDURE|Nutritional support|
48175962|NCT03124147|DEVICE|Neuroconn Eldith stimulator by Magstim|Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
48175963|NCT00884416|DRUG|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
48175964|NCT02572635|BIOLOGICAL|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
48175965|NCT02572635|BIOLOGICAL|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
48709189|NCT04677400|OTHER|More than Body Appearance (MBA) Intervention|"The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them."
48709190|NCT03236012|DRUG|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
48709191|NCT03640858|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
48709192|NCT02073032|OTHER|No intervention, only observation|
48376583|NCT05472480|DIAGNOSTIC_TEST|anthropometric and psychosocial measurements|"Different types of measurements will be evaluated: body mass index (BMI), weight, height, waist circumference, waist / hip ratio (WHR), waist / stature (WSR) and the ABSI a body score shape index . To complete the study, the personal experiences of the patients will be analyzed through the administration of a psycho-social questionnaire, Body Image Disturbance Questionnaire (BIDQ)."
48376584|NCT04985877|DIETARY_SUPPLEMENT|Yakult light 300|2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.
48376585|NCT01367626|DRUG|letrozole|2.5 mg tablet
48376586|NCT01367626|DRUG|letrozole|2.5 mg tablet
48376587|NCT05859594|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
48376588|NCT04722627|DRUG|AT-752|Parallel Assignment
48376589|NCT04722627|DRUG|Placebo|Parallel Assignment
48376590|NCT00478504|DRUG|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
48709193|NCT00176176|DEVICE|EEG|
48709194|NCT04715789|BEHAVIORAL|graded exposure and activity|"1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
48709195|NCT01976858|DRUG|PEX168|A injection administered subcutaneously
48709196|NCT00160199|DRUG|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
48709197|NCT00160199|DRUG|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
48175966|NCT00322140|DRUG|CDDO|
48376591|NCT00478504|DRUG|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
48376592|NCT05307926|DRUG|PD-1 inhibitors|For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.
48376593|NCT05307926|PROCEDURE|TACE|Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.
48517299|NCT00963066|DEVICE|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
48175967|NCT05780762|OTHER|IMPACT Program|"care at 3 levels:~(1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and with the team caring for him or her, and incorporating evidence-based measurement tools."
48175968|NCT05780762|OTHER|usal care|usual management with a Nurse in Advanced Practice.
48175969|NCT02454049|DIETARY_SUPPLEMENT|beetroot juice|6mmol nitrate
48175970|NCT02454049|DIETARY_SUPPLEMENT|sodium nitrate|6mmol sodium nitrate
48175971|NCT02454049|DIETARY_SUPPLEMENT|water|plain water
48175972|NCT00154427|DRUG|activated recombinant human factor VII|
48175973|NCT00494026|DRUG|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
48376594|NCT05577975|DEVICE|The Aspara @ smart grower|The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
48376595|NCT04866602|DRUG|Atoguanil|Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
48376596|NCT04866602|DRUG|Malarone|Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets
48175974|NCT00494026|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
48175975|NCT00494026|PROCEDURE|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
48175976|NCT05559671|BIOLOGICAL|Herpes Zoster Subunit (HZ/su) Vaccine|Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
48376597|NCT04510870|DRUG|Ferric Carboxymaltose Injection|Infusion prior the start of IVF/ICSI cycle. Dosing according to the summary of product characteristics (SmPC) chart. Placebo infusion before frozen embryo transfer if needed.
48376598|NCT04510870|DRUG|NaCl infusion|Placebo infusion prior the start of IVF/ICSI cycle. Ferric Carboxymaltose infusion before frozen embryo transfer if needed. Dosing according to the summary of product characteristics (SmPC) chart.
48517300|NCT03556124|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
48517301|NCT03556124|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
48517302|NCT03556124|DEVICE|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
48709198|NCT03496233|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
48709199|NCT06157541|BIOLOGICAL|Allogeneic cytomegalovirus-specific T cells|Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
48709200|NCT06157541|DRUG|Pembrolizumab|A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
48175977|NCT05559671|BIOLOGICAL|Placebo|Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
48175978|NCT01013740|DRUG|Vinorelbine|Vinorelbine
48175979|NCT01013740|DRUG|Lapatinib|Lapatinib
48709201|NCT03369041|DRUG|Irinotecan-Eluting Beads|
48709202|NCT04290793|DRUG|Pyrotinib|400mg administered as continuous oral once daily from the first day of the study
48709203|NCT04290793|DRUG|Epirubicin|90mg/m\^2 d1 iv Q2W for 4 cycles
48175980|NCT01013740|DRUG|Capecitabine|Capecitabine
48175981|NCT06168422|DEVICE|DES|drug eluting stent
48517303|NCT03556124|DEVICE|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
48517304|NCT02795338|PROCEDURE|brain mapping|pre-operative and intra-operative brain mapping to identify eloquent areas
48709204|NCT04290793|DRUG|Cyclophosphamide|600 mg/m\^2 d1 iv Q2W for 4 cycles
48175982|NCT06168422|DEVICE|DCB|drug-coated balloon
48175983|NCT00581464|BEHAVIORAL|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
48175984|NCT00581464|BEHAVIORAL|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
48175985|NCT01801982|OTHER|non-interventional|non-interventional
48175986|NCT01016418|DIETARY_SUPPLEMENT|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
48175987|NCT06497790|DIAGNOSTIC_TEST|BJH-SDS Screenint Test|The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)
48175988|NCT06497790|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|The FEES evaluates anatomical changes, functional disorders of the visible structures (e.g. recurrent paresis), saliva management, penetration and aspiration of food boluses in order to draw conclusions about the underlying pathomechanism of dysphagia. It is an established standard diagnostic procedure for stroke patients and, in addition to the diagnosis of dysphagia, also enables pathomechanism-guided therapy by speech therapists
48175989|NCT01939210|OTHER|Educational Intervention|Participate in breathing training sessions
48175990|NCT01939210|OTHER|Meditation Therapy|Participate in breathing training sessions
48175991|NCT01939210|OTHER|Questionnaire Administration|Ancillary studies
48175992|NCT00152399|DRUG|Somatostatin UCB (drug)|
48517305|NCT03874728|OTHER|Minimal shoes|A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
48018967|NCT06423833|DIAGNOSTIC_TEST|Trendelenburg maneuver (TM)|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Trendelenburg maneuver (TM) in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
48175993|NCT02599493|DRUG|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
48175994|NCT05969405|PROCEDURE|Laparoscopic staging|Laparoscopic staging
48175995|NCT05969405|PROCEDURE|Robotic staging|Robotic staging
48175996|NCT05969405|PROCEDURE|Laparotomic staging|Laparotomic staging
48175997|NCT03707847|DRUG|Crizotinib|250mg, BID, PO
48376599|NCT05557201|BIOLOGICAL|Lymphocyte immunophenotyping|If the patient accepts the ancillary study, a blood sample will be taken (1 EDTA tube of 3 ml and 2 lithium heparin tubes of 10 mL each) for lymphocyte immunophenotyping in flow cytometry on fresh blood and for the constitution of the biological collection (plasma/mononuclear cells).
48376600|NCT01993238|DEVICE|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
48517306|NCT03874728|OTHER|Standardised conventional shoes|The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
48709205|NCT04290793|DRUG|Taxanes|Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
48709206|NCT04290793|BIOLOGICAL|Trastuzumab|the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
48709207|NCT00854217|PROCEDURE|acute normovolemic hemodilution|
48709208|NCT00004206|DRUG|FOLFOX regimen|
48709209|NCT00004206|DRUG|fluorouracil|
48709210|NCT00004206|DRUG|leucovorin calcium|
48018968|NCT06423833|DIAGNOSTIC_TEST|Passive leg raising test|The investigator will measure changes in velocity time integral (VTI) and stroke volume (SV) during Passive leg raising (PLR) test in high-risk surgical patients by trans-thoracic Doppler echo cardiography.
48018969|NCT02233049|DRUG|Erlotinib|
48018970|NCT02233049|DRUG|Everolimus|
48018971|NCT02233049|DRUG|Dasatinib|
48175998|NCT03707847|DRUG|Etoposide Capsule|50mg, QD, PO, d1-10，21days for one cycle
48175999|NCT03707847|PROCEDURE|Auto-HSCT|Auto-HSCT will be performed with patients who have achieved CR or VGPR.
48176000|NCT03834623|DRUG|CC-122|Oral CC-122 at 2 mg daily, 5 days out of 7
48176001|NCT03834623|DRUG|Nivolumab|240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
48176002|NCT04813432|DIAGNOSTIC_TEST|Computed Tomography of the Abdomen|"Multi-phasic CT scan of the abdomen: 1 low dose unenhanced scan + 10 low dose arterial perfusion scans + 1 portal-venous phase scan + 1 delayed phase scan.~Bolus-tracking threshold in abdominal aorta = 160 HU. Delay of first arterial scan 5 sec after bolus-tracking threshold has been reached; and then 1 scan every 3 sec until 35 sec after threshold.~Contrast media (CM) protocol: fixed injection duration: 25 sec, body weight-adjusted CM volume: 750 mgI/kg bodyweight (max 80 kg women, 100kg men), Iomeron 400mgI/ml.~Image-reconstruction: Motion-correction, noise-reduction and fusion of the best arterial time points to reconstruct one optimally timed early and one optimally timed late arterial phase."
48176003|NCT04605744|BEHAVIORAL|Smoking cessation counseling|"Patients will be given a briefing on the benefits of smoking cessation in the peri-procedural period around their interventional pain procedure. They will also be provided an informational sheet from the American Society of Anesthesiologists promoting cessation. The sheet will contain the 1-800-QUITNOW national hotline phone number.~Additional an enrollment folder will provided that contains referral information to Cooper's Tobacco Cessation program. This service, free of charge to Cooper Health patients consists of 5 tobacco cessation counselors who use personalized cessation plans, individual and group counseling cessations, Chantix, and education to promote smoking cessation."
48176004|NCT05445167|DRUG|KLH-2109|Oral administration
48176005|NCT05445167|DRUG|Placebo|Oral administration
48176006|NCT02038998|DEVICE|Exer-Rest® TL|Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
48176007|NCT04374383|DRUG|Phthalocyanine Dye|following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
48176008|NCT04374383|DRUG|LASER assisted SRP|LASER assisted SRP will be carried
48517307|NCT03874728|OTHER|Barefoot|Participants will conduct the assessments barefoot.
48709211|NCT00004206|DRUG|oxaliplatin|
48709212|NCT00196586|DRUG|Interleukin 2|
48709213|NCT00196586|DRUG|pegylated interferon alpha 2a|
48709214|NCT00196586|DRUG|ribavirin|
48709215|NCT01257490|BEHAVIORAL|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
48709216|NCT06103318|BEHAVIORAL|ICOgnition|"The ICOgnition intervention for breast cancer patients consists of three levels:~Level 1: Monthly assessments using FACT-Cog PCI and Cognifit. Scores \<54 (PCI) or ≤250 (Cognifit) escalate to Level 2.~Level 2: Specialized content includes Cognitive Psychoeducation, validating experiences and improving health literacy; Behavioral Guidance, offering practical strategies for daily tasks; and Embracing Cognitive Deficits, promoting self-compassion and acceptance through mindfulness and metaphors.~Level 3: Online cognitive training focuses on enhancing cognitive skills through gaming exercises, completing the comprehensive intervention approach."
48709217|NCT06214819|DEVICE|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
48018972|NCT06085417|DRUG|Bupivacaine + dexamethasone|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
48176009|NCT04042818|DIAGNOSTIC_TEST|Rehabilitative Ultrasound|Ultrasound imagining
48176010|NCT01029236|OTHER|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
48176011|NCT00868764|DRUG|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
48176012|NCT06226662|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
48176013|NCT06226662|DRUG|Placebo|Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
48517308|NCT03874728|OTHER|"Smart shoe insoles"|Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
48018973|NCT06085417|DRUG|Bupivacaine + magnesium sulphate|"Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy."
48018974|NCT06085417|DRUG|bupivacaine|bupivacaine
48018975|NCT05352139|PROCEDURE|Resection (removal) of the degenerative tissue using the Hydrocision TenJet system|During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
48018976|NCT05352139|DEVICE|Hydrocision Tenjet System|The TenJet system will be used during surgery to remove the damaged tissue from the joint
48176014|NCT03811470|OTHER|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
48176015|NCT00077597|DRUG|epoetin|3 times a week iv, as prescribed.
48176016|NCT00077597|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
48176017|NCT00078728|BEHAVIORAL|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
48176018|NCT00078728|BEHAVIORAL|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
48517309|NCT02614105|PROCEDURE|Pelvic floor muscle training|16 weeks of group-based exercise
48018977|NCT05637151|OTHER|clamp time of umbilical|The umbilical cord was clamped immediately or late for more than 30s
48176019|NCT05076188|DIAGNOSTIC_TEST|Emergency radiography|The intervention is to determine how the radiographer classify emergency radiography.
48176020|NCT01036243|DIETARY_SUPPLEMENT|test formula 1|hydrolyzed formula with probiotics
48176021|NCT01036243|DIETARY_SUPPLEMENT|test formula 2|acidified hydrolyzed formula
48176022|NCT01036243|DIETARY_SUPPLEMENT|test formula 3|hydrolyzed formula without probiotics
48176023|NCT01036243|DIETARY_SUPPLEMENT|reference formula|standard infant formula
48176024|NCT03895502|DRUG|12-month Edoxaban|Prescription of Edoxaban for 12 months
48176025|NCT03895502|DRUG|3-month Edoxaban|Prescription of Edoxaban for 3 months
48176026|NCT05961982|PROCEDURE|Chemical Ablation|Undergo EUS-guided chemoablation
48176027|NCT05961982|PROCEDURE|Computed Tomography|Undergo CT
48176028|NCT05961982|OTHER|Electronic Health Record Review|Ancillary studies
48176029|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Undergo EUS-FNA
48176030|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Radiofrequency Ablation|Undergo EUS-RFA
48176031|NCT05961982|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRI/MRCP
48176032|NCT05961982|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/MRCP
48176033|NCT03100864|DRUG|Spesolimab|12 weeks treatment
48176034|NCT03268109|OTHER|assessment of cognitive impairment|Measure of Global Deficit Score
48176035|NCT04843982|DRUG|Esketamine hydrochloride|After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
48517310|NCT02614105|PROCEDURE|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
48517311|NCT02614105|OTHER|Control|Brief information only
48517312|NCT03400592|DRUG|Irinotecan|180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
48517313|NCT03400592|DRUG|nimotuzumab|400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
48517314|NCT01314937|DRUG|Mebendazole|Single-dose 500 mg mebendazole tablet
48018978|NCT01884298|DRUG|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
48176036|NCT01710059|BEHAVIORAL|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
48176037|NCT01710059|BEHAVIORAL|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
48018979|NCT01884298|DRUG|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
48018980|NCT03333005|DRUG|APX001 with Standard of Care anti-fungal agent|safety assessment
48018981|NCT01997775|DRUG|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 \> 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
48018982|NCT04886141|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
48176038|NCT01710059|BEHAVIORAL|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
48176039|NCT01710059|BEHAVIORAL|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
48176040|NCT05147298|OTHER|eHealth phone program|The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.
48176041|NCT05147298|OTHER|Environment program|The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
48176042|NCT06011278|OTHER|Community Supported Videos|"Volunteers will be asked to create a maximum of three minutes of content that will psychosocially strengthen and motivate pediatric oncology patients. In the videos, information will be given about not using words such as cancer/oncology/tumor and not including private and personal information. Videos will be created in such a way that they can be edited, merged or deleted accordingly. The applications of volunteer individuals will be made through social media (Instagram), the collection of these videos will be followed in accordance with the voluntary consent forms, and the volunteers will be informed in detail about the use of visual and verbal data.~Children will be sent videos featuring different volunteers each week. The content of the videos will be controlled by the child clinical psychologist and researchers. Inappropriate videos will not be included in the research."
48176043|NCT00704171|PROCEDURE|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
48376601|NCT01993238|DRUG|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
48376602|NCT06130618|OTHER|Ozone|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 20 μg/mL ozone will be injected.
48709218|NCT06214819|DEVICE|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
48709219|NCT05128162|DRUG|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
48709220|NCT05128162|BEHAVIORAL|Psychotherapy|1. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
48376603|NCT06130618|DRUG|Lidocain|After localizing the piriformis muscle and sciatic nerve with ultrasound guidance, 5 ml - 2% lidocaine will be injected.
48709221|NCT01457950|DRUG|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
48018983|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively and post-operatively up to participants being discharged from the hospital.
48018984|NCT04400552|DIETARY_SUPPLEMENT|ONS Pre-op + ONS Post-op + ONS Post-op 3 months|Participants will consume the oral nutrition supplementation (ONS) in addition to normal diet for 14 days pre-operatively, post-operatively up to participants being discharged from the hospital and an extended oral nutrition supplementation post-operatively up to 3 months.
48018985|NCT04400552|DIETARY_SUPPLEMENT|Usual intake Pre-op + ONS Post-op|Participants will follow a meal plan of 2000 kcal / day using conventional foods for 14 days pre-operatively and consume oral nutrition supplementation (ONS) in addition to normal diet post-operatively up to participants being discharged from the hospital
48018986|NCT05334108|DRUG|Ecopipam|ecopipam HCl \~2mg/kg/day
48018987|NCT05334108|COMBINATION_PRODUCT|Cohort 1 Probe Substrate Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
48018988|NCT05334108|DRUG|Cohort 2 Probe Substrate|bupropion
48376604|NCT02689609|RADIATION|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
48376605|NCT01864746|DRUG|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
48709222|NCT01457950|DRUG|placebo|double-blind phase: placebo subcutaneous injection, single dose
48709223|NCT01457950|DRUG|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
48018989|NCT05334108|COMBINATION_PRODUCT|Cohort 3 Probe Substrate Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
48018990|NCT02311595|PROCEDURE|reduced port laparoscopic distal gastrectomy|
48176044|NCT00704171|DEVICE|PleuraSeal Lung Sealant System|
48517315|NCT01314937|OTHER|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
48018991|NCT06532695|OTHER|No intervention will be provided.|no intervention will be provided.
48018992|NCT00804297|DRUG|Octreotide (drug)|
48018993|NCT04327284|DEVICE|Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
48176045|NCT00695825|DIETARY_SUPPLEMENT|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
48176046|NCT00695825|DIETARY_SUPPLEMENT|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
48176047|NCT03359226|PROCEDURE|Submandibular gland biopsy|Needle biopsies of the right and left submandibular glands
48517316|NCT04571541|DEVICE|Stenting|Effect of endoscopic stenting on healing of esophageal wall defects
48176048|NCT03908593|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
48176049|NCT00665223|DRUG|ACR16|Capsules will be swallowed whole with water.
48517317|NCT00524420|DEVICE|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
48517318|NCT00524420|DEVICE|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
48517319|NCT05972174|BIOLOGICAL|mRNA-1018 for H5N8|Sterile liquid for injection
48517320|NCT05972174|BIOLOGICAL|mRNA-1018 for H7N9|Sterile liquid for injection
48517321|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only|Sterile liquid for injection
48709224|NCT01107600|PROCEDURE|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
48709225|NCT03209232|DRUG|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
48709226|NCT01034371|PROCEDURE|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
48709227|NCT01034371|PROCEDURE|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
48709228|NCT01034371|PROCEDURE|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
48709229|NCT06258486|DRUG|ICG injection|Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
48709230|NCT06258486|OTHER|Non-Injection/Control|No ICG injection
48709231|NCT06258486|PROCEDURE|Prostatectomy with pelvic lymph node dissection|Robotic assisted prostatectomy with pelvic lymph node dissection
48709232|NCT00961246|BEHAVIORAL|general health information|participants received general health information
48709233|NCT00961246|BEHAVIORAL|individually-tailored intervention|participants received individually-tailored intervention
48709234|NCT04583202|OTHER|Exposure to placebo|Patients are exposed to a placebo for 4h in the Alyatec EEC
48709235|NCT04583202|OTHER|Exposure to allergen|Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
48176050|NCT00665223|DRUG|Placebo|Capsules will be swallowed whole with water.
48176051|NCT01328210|PROCEDURE|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
48176052|NCT05585736|DRUG|Cycloplegics|they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
48176053|NCT02003690|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy
48176054|NCT02003690|BEHAVIORAL|Standard of Care Psychotherapy|Standard of Care Psychotherapy
48176055|NCT02003690|OTHER|Pharmacotherapy|Standard of Care Pharmacotherapy
48176056|NCT05432921|BEHAVIORAL|Lifestyle modification|50min of endurance combined with 50min of strength training; 1-2 sessions/week for 6 month, follow up after 3-6month
48176057|NCT04303442|PROCEDURE|TEP|Total extraperitoneal laparoendoscopic hernia repair with one or three skin incisions.
48176058|NCT00002716|DRUG|dexamethasone|
48176059|NCT00002716|DRUG|floxuridine|
48176060|NCT00002716|DRUG|fluorouracil|
48517322|NCT05972174|BIOLOGICAL|mRNA-1018 for H7 Only|Sterile liquid for injection
48517323|NCT05972174|BIOLOGICAL|mRNA-1018 for H5 Only-CG|Sterile liquid for injection
48517324|NCT01990586|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
48517325|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
48517326|NCT00400842|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
48517327|NCT00400842|DRUG|Placebo|Placebo
48517328|NCT02508935|DRUG|XARTEMIS XR|XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets
48517329|NCT02676765|DRUG|allergen extract tablet|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
48376606|NCT01864746|DRUG|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
48376607|NCT01801306|DEVICE|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
48376608|NCT02763410|OTHER|PRBC transfusion|
48376609|NCT00509275|DRUG|W0027|capsule
48376610|NCT00509275|DRUG|Placebo|Placebo
48376611|NCT05309317|OTHER|Virtual Simulation Game for the Prevention of Catheter-Associated Urinary Tract Infections|"A training on Prevention of CAUTI will be held for the experimental and control groups. The experimental group will be able to play a seven-day virtual simulation game devised by the researcher to prevent CAUTI."
48376612|NCT05309317|OTHER|Ongoing education|"Only a course on Prevention of CAUTI will be given to the control group."
48376613|NCT01969331|DIETARY_SUPPLEMENT|Normia|One capsule twice a day/14 days
48376614|NCT01969331|DIETARY_SUPPLEMENT|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
48376615|NCT05723120|OTHER|Assessment Respiratory and Neuromuscular|Comparative Score
48376616|NCT04264806|DRUG|Azacitidine|Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
48376617|NCT04264806|DRUG|Cusatuzumab|Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
48376618|NCT04911569|DEVICE|Cryoneurolysis|Cryoneurolysis
48376619|NCT05110300|DEVICE|Body weight support system control group|Participants will complete the physical therapy exercises as described previously, without experiencing, therapist induced, balance perturbations.
48376620|NCT05110300|DEVICE|Body weight support system with balance perturbations|Participants will complete the physical therapy exercises as described previously, while experiencing intermittent, therapist induced, balance perturbations aimed at training the participant's balance-control and balance-reactions. With the ZeroG BWSS integrated TRiP module, therapist's are able to induce safe lateral, anterior, or posterior perturbations via a Wi-Fi-enabled handheld device. The force, or level, of perturbation can be adjusted from 1 (least amount of force) up to 10 (highest amount of force) using the same handheld device,
48376621|NCT04096716|DRUG|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
48517330|NCT02676765|DRUG|Placebo tablet|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
48018994|NCT04327284|DEVICE|Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)|"At the screening visit, potential subjects will be informed about the protocol and all questions related to the study will be answered. Medical and dental histories will be reviewed and physical evaluations will be performed in order to rule out local or systemic factors that would compromise the outcome of the study. A detailed extra and intra oral examination will be performed. Appropriate radiographic imaging studies will be obtained prior to the surgical visit (per the protocol of the University of Kentucky, College of Dentistry) including CBCT and intraoral scans for treatment planning implant through Straumann Guided Surgery workflow.~The duration of the present study is 1 year including the baseline or surgical visit, 2-weeks postoperative visit, 12-weeks baseline for control group and postoperative evaluations at 3, and 12 months."
48018995|NCT02629406|OTHER|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
48018996|NCT06573541|DEVICE|Use of ultrasound|Use of ultrasound in the initial management of patients in shock
48018997|NCT02648087|DEVICE|With and without SDB|Screening of sleep-disordered breathing (SDB)
48018998|NCT03760549|DRUG|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
48018999|NCT06368128|BEHAVIORAL|Indoor Rock Climbing Exercise Training Program|Training will occur 2-3 days per week for 60 minutes; ratings of perceived exertion between 3-7 on a scale of 0-10 will be targeted for the desired intensity throughout the program. Minutes of rock climbing will also be monitored to develop the progression strategy.
48019000|NCT05800288|DRUG|Propofol|Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
48019001|NCT03976440|OTHER|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
48019002|NCT01119261|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
48019003|NCT01119261|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
48019004|NCT06084585|DIETARY_SUPPLEMENT|Study Product A (High-dose 2X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
48176061|NCT00002716|DRUG|leucovorin calcium|
48176062|NCT00002716|PROCEDURE|laparotomy|
48376622|NCT00714025|DRUG|RAD001|RAD001 10mg, daily, PO
48376623|NCT05778682|PROCEDURE|Suctioning based protocol|cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.
48376624|NCT05778682|PROCEDURE|Usual Care|Usual care in our center is tolerance to a capping trial.
48376625|NCT06514508|DRUG|Motixafortide+G-CSF|Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
48376626|NCT06514508|DRUG|Placebo+G-CSF|Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.
48376627|NCT03866811|BEHAVIORAL|Dr. Erica|The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
48376628|NCT05483569|OTHER|Complex Decongestive Physiotherapy|Complete or complex decongestive physiotherapy (CDP) is a treatment for lymphedema, a condition in which excess fluid (lymph) collects in a part of the body. Damage to the lymph nodes or vessels, or a blockage leading to chronic swelling, usually causes lymphedema.
48376629|NCT05483569|OTHER|Multidimensional Diaphragmatic Breathing Exercises|Diaphragmatic breathing is an exercising technique to help strengthen your diaphragm and fill your lungs with air more efficiently.
48376630|NCT05483569|OTHER|Facial Release Technique|Fascial release is a manual therapy method that is applied holistically to the muscles and surrounding fascia through mechanical stimulation. It is a comprehensive approach to the evaluation and treatment of the muscular and fascia system in the body.
48376631|NCT01863160|DRUG|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream"
48376632|NCT01863160|DRUG|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
48376633|NCT00830310|BEHAVIORAL|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
48376634|NCT00830310|BEHAVIORAL|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
48517331|NCT01495078|PROCEDURE|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
48517332|NCT02914210|DEVICE|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
48517333|NCT02914210|OTHER|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
48019005|NCT06084585|DIETARY_SUPPLEMENT|Study Product B (Low-dose X)|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
48019006|NCT06084585|DIETARY_SUPPLEMENT|Placebo|participants in this arm will consume 1 sachet of this product with 200ml water per time, once a day after meal, for 3 months
48019007|NCT02350959|DRUG|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
48019008|NCT02350959|DRUG|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
48019009|NCT01025700|DRUG|Cesemat|1 mg capsule per day for 21 days
48019010|NCT04741659|DEVICE|Ventimask|The patients will be asked to breathe spontaneously using their actual low oxygen flow
48019011|NCT04741659|DEVICE|High Flow Nasal cannula (HFNC)|The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values \>/= 92%
48019012|NCT04741659|DEVICE|Helmet CPAP|The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values \>/= 92%
48019013|NCT04741659|DEVICE|Non Invasive Ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
48019014|NCT06318299|DIETARY_SUPPLEMENT|Ketone Ester|Commercially available ketone ester drink (KetoneAid, Virginia, USA)
48019015|NCT06318299|OTHER|Placebo|Taste and appearance matched noncaloric placebo drink
48019016|NCT05676242|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
48019017|NCT04231344|DEVICE|Laryngoscopy|Laryngoscopic examination of patients with GERD by two physicians
48019018|NCT03713489|PROCEDURE|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
48019019|NCT06658340|BEHAVIORAL|Positivity in Post-COVID|A training to support well-being and self-management in patients with post-COVID-19 syndrome
48019020|NCT05676385|DIETARY_SUPPLEMENT|First concept product (containing 50 grams of carbohydrates)|Fasted intake of First concept product (randomised)
48019021|NCT05676385|DIETARY_SUPPLEMENT|Second concept product (containing 50 grams of carbohydrates)|Fasted intake Second concept product (randomised)
48376635|NCT00830310|BEHAVIORAL|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
48376636|NCT00830310|BEHAVIORAL|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
48176063|NCT00002716|PROCEDURE|conventional surgery|
48376637|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
48376638|NCT01655810|DIETARY_SUPPLEMENT|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
48376639|NCT01655810|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg orally twice daily
48517334|NCT01656057|DRUG|Acetaminophen|Acetaminophen dissolved in 50 ml of water
48376640|NCT05595460|DRUG|RYZ101 Dose Level 1|Dose Level 1
48176064|NCT00001677|DRUG|Methotrexate|
48517335|NCT01656057|DRUG|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
48709236|NCT01710527|DRUG|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
48019022|NCT05676385|DIETARY_SUPPLEMENT|Reference product (containing 50 grams of carbohydrates)|Fasted intake of Reference product (randomised)
48376641|NCT05595460|DRUG|RYZ101 Dose Level 2|Dose Level 2
48376642|NCT05595460|DRUG|RYZ101 Dose Level 3|Dose Level 3
48709237|NCT01710527|DRUG|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
48709238|NCT04829474|OTHER|Survey|It is a survey that the patient and doctor must complete.
48176065|NCT00001677|DRUG|Fludarabine|
48176066|NCT04966065|DEVICE|Parietex Parastomal mesh|Laparoscopic Modified Sugarbaker technique for repair of parastomal hernias in end-colostomies
48176067|NCT06084676|DRUG|Immunotherapy|Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
48176068|NCT04195932|OTHER|Exercise training|
48176069|NCT04106570|OTHER|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
48176070|NCT01876615|DRUG|YH4808|experimental drug
48176071|NCT01876615|DRUG|Diclofenac|Depain tablet 25mg
48176072|NCT01876615|DRUG|YH4808+Diclofenac|
48709239|NCT04392908|OTHER|Communication memory|All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
48709240|NCT00771732|DEVICE|light therapy|6 minute light therapy
48709241|NCT00771732|DEVICE|light therapy|combination of wavelengths
48176073|NCT03367910|DRUG|Fecal microbiota transplant|150mL of FMT product RBX2660 delivered via enema
48176074|NCT02250534|OTHER|Very low nicotine content cigarettes|
48176075|NCT05046925|PROCEDURE|postoperatively transferral to PACU|patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.
48376643|NCT05595460|DRUG|RYZ101 Dose Level -1|Dose Level -1
48376644|NCT05595460|DRUG|Atezolizumab|Atezolizumab
48376645|NCT05595460|DRUG|Carboplatin|Carboplatin
48376646|NCT05595460|DRUG|Etoposide|Etoposide
48376647|NCT03864406|DRUG|Cobicistat|Each tablet of Tybost contains 150 mg of cobicistat.
48517336|NCT01656057|DRUG|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
48709242|NCT00267605|BEHAVIORAL|FHPADHD|Evidence-based psychological and behavioural distance intervention
48709243|NCT00267605|BEHAVIORAL|ADHD Standard Care|
48709244|NCT06352593|DRUG|Intraoperative Dexmedetomidine|Patients will be administered DEX 0.5 μg/kg for 10 min and then 0.4 μg/kg/h adjusted to 0.2-0.6 μg/kg/h.
48709245|NCT06352593|OTHER|Placebo|Patients will receive normal saline.
48376648|NCT03864406|DRUG|Darunavir/Cobicistat|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
48376649|NCT03864406|DRUG|Rivaroxaban|Each tablet of Xarelto contains 10 mg of rivaroxaban.
48376650|NCT00465322|DRUG|fluvastatin|
48517337|NCT01656057|OTHER|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
48517338|NCT01656057|OTHER|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
48517339|NCT00102752|DRUG|Glufosfamide|
48376651|NCT06038669|DEVICE|Dried blood spot device|Patients will be asked to provide a dried blood spot sample
48019023|NCT06131411|OTHER|Health promotion|Co-created culture-tailored intervention of health promotion aimed to increase healthy diet, physical activity and compliance with treatment protocols for diabetes.
48019024|NCT06131411|OTHER|Usual care|Health promotion activities routinely performed by Diabetes clinics at the recruiting centres.
48019025|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
48019026|NCT00513422|DIETARY_SUPPLEMENT|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
48019027|NCT00513422|DIETARY_SUPPLEMENT|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
48176076|NCT05046925|PROCEDURE|postoperatively transferral to ICU|patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
48176077|NCT04780984|DRUG|Tiotropium bromide inhalation solution|Tiotropium bromide inhalation solution
48376652|NCT06038669|OTHER|Healthcare professional interviews|Health care professionals only will be interviewed using the topic guide and asked about their experience of diabetes monitoring
48376653|NCT01878968|OTHER|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
48376654|NCT03131791|DEVICE|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
48376655|NCT03131791|DRUG|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
48376656|NCT04014556|DEVICE|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
48176078|NCT04780984|DRUG|Placebo|Placebo comparator
48176079|NCT02682004|OTHER|leptin, serotonin and adiponectin level|
48376657|NCT04014556|DRUG|Aflibercept|Aflibercept
48376658|NCT03348306|DEVICE|MRI|Brain and cardiac MRI in one time with gadolinium injection.
48376659|NCT03348306|BIOLOGICAL|Blood sample collection|A blood sampling is also collected for hematocrit measure.
48517340|NCT00102752|DRUG|Gemcitabine|
48376660|NCT03707106|BEHAVIORAL|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
48376661|NCT03707106|BEHAVIORAL|virtual reality based cue exposure|smoking cue exposure in virtual reality
48376662|NCT03707106|BEHAVIORAL|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
48376663|NCT04498260|DRUG|Local steroid - triamcinolone acetonide|(triamcinolone acetonide)
48376664|NCT04498260|DRUG|Oral steroid - predonisolone|(predonisolone)
48376665|NCT04436497|DRUG|Zilucoplan|"Drug: Zilucoplan Administration: Subcutaneous injection~Dosage: 0.3mg/kg administered daily"
48376666|NCT04436497|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Subcutaneous injection~Dosage: Daily subcutaneous injection"
48376667|NCT05829746|DEVICE|Tubridge|Intracranial stent for wide-necked aneurysms
48376668|NCT04868838|DRUG|Daratumumab|1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
48376669|NCT03090945|OTHER|This is an obsevational cohort study|no intervention
48376670|NCT04165850|DRUG|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
48376671|NCT04918186|DRUG|Durvalumab|1500mg IV, 60 min day 1 every 4 weeks
48376672|NCT04918186|DRUG|BA3011|IV
48376673|NCT04918186|DRUG|BA3021|IV
48376674|NCT04918186|DRUG|To be determined|To be determined
48376675|NCT06248866|OTHER|Extracorporeal Shock Wave Therapy|The affected hand or fingers will be positioned comfortably to ensure optimal access to the fibromatosis lesion. Gel or oil will be applied to the skin to enhance the transmission of shock waves. Shock wave therapy will be administered using the selected energy level and frequency settings. Energy level and frequency will be customized based on individual patient requirements. (1000-1500 shock/session, frequency between 5-12HZ, compression power of 1.5- 2.5 bars).and will receive traditional treatment
48376676|NCT06248866|OTHER|traditional treatment|the patients will receive traditional treatment in the form of laser (A low-level laser device with a wavelength of 830 nm and power output of 50 mW will be used as one Of the pain relief methods), ultrasound (An ultrasound device with a frequency of 1 MHz and an intensity of 1.5 W/cm² will be used), stretching and strengthening exercise and splinting.
48376677|NCT02764606|BIOLOGICAL|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
48376678|NCT05152498|DRUG|Fu Zheng Jie Du Hua Yu therapy|Fu Zheng Jie Du Hua Yu is a Chinese herbal compound
48376679|NCT04269161|DEVICE|Automatic control of inspired oxygen|A device will be used to automatically adjust the blend of oxygen and air with the ability to return to manual control as needed.
48376680|NCT05287165|DRUG|IM96 CAR-T cells|treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
48019028|NCT00513422|DIETARY_SUPPLEMENT|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
48019029|NCT04376996|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design - only a diagnostic testing|Only a diagnostic tests are planned: SARS-CoV-2 RNA in nasopharyngeal samples and anti-SARS-CoV-2 antibodies in blood
48019030|NCT03608800|BEHAVIORAL|Intermittent fasting|The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
48019031|NCT06572319|DRUG|Disitamab Vedotin(RC48) Plus Tratuzumab|Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.
48019032|NCT01132079|DRUG|cream treatment|
48376681|NCT06124716|OTHER|Enhanced COACH CDS Tool|CDS tool with features to promote high blood pressure management
48376682|NCT06124716|OTHER|Usual Care COACH CDS Tool|CDS tool with limited features to promote high blood pressure management
48376683|NCT05341427|DEVICE|electromagnetic device|electromagnetic waves for burn wound
48376684|NCT01395342|OTHER|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
48376685|NCT03772210|DEVICE|tDCS|Current will be administered to subject groups as specified in arm descriptions.
48376686|NCT03772210|OTHER|Sham|Apparent Stimulation administered
48376687|NCT04587362|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|High quality ultrasound scanners and high-resolution transducers, will be used to scan 16 joints sites for each subject. Ultrasound had excellent spatial resolution, making it an highly efficient, non-invasive tool for the assessment on enthesitis, which is an early feature of psoriatic arthritis. It is an affordable and accessible tool that is widely used in rheumatology practice.
48376688|NCT02022566|BEHAVIORAL|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
48376689|NCT02433522|DRUG|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
48376690|NCT02433522|DRUG|Placebo|
48376691|NCT04409327|DRUG|RTB101|Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
48376692|NCT04409327|DRUG|Placebo|Oral matching placebo once daily for 4 weeks
48376693|NCT01995656|DRUG|Placebo - Capsule|Administered orally
48376694|NCT01995656|DRUG|LY3108743 - Capsule|Administered orally
48376695|NCT01995656|DRUG|Placebo - Solution|Administered orally
48376696|NCT01995656|DRUG|LY3108743 - Solution|Administered orally
48376697|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
48176080|NCT02682004|OTHER|leptin,serotonin, adiponectin level|
48176081|NCT02820064|PROCEDURE|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
48176082|NCT01458925|DEVICE|The P1 Check-Cap capsule|The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
48176083|NCT00776659|OTHER|Aromasin|Non-Interventional study design.
48176084|NCT03993561|OTHER|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
48176085|NCT01391676|PROCEDURE|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
48176086|NCT05113797|DIAGNOSTIC_TEST|Lower Quarter Y-Balance Test|Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
48176087|NCT05113797|BEHAVIORAL|OPTIMAL motor learning theory|OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
48176088|NCT04378374|OTHER|Food-1|Baked food made of lentil flour
48176089|NCT04378374|OTHER|Food-2|Baked food made of lentil flour and wheat flour
48176090|NCT04378374|OTHER|Food-3|Baked food made of wheat flour
48176091|NCT04378374|OTHER|Food-4|Potable water (energy and carbohydrate-free control)
48176092|NCT02772718|DRUG|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
48176093|NCT02772718|DRUG|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
48176094|NCT02772718|DRUG|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
48019033|NCT05715645|PROCEDURE|Unilateral prosthetic knee surgery|Unilateral prosthetic knee surgery
48019034|NCT05715645|PROCEDURE|Analgesia|Analgesic management by adductor canal block
48019035|NCT06461104|BEHAVIORAL|Structured Physical Activity Programme|A somatic examination will also be conducted by a sports physician, which will include the assessment of muscle strength, cardiorespiratory fitness, walking gait, blood pressure, and body mass index (BMI). Based on this evaluation, the sports physician will design a personalised physical activity programme for the participants in the intervention group.
48176095|NCT02772718|DRUG|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
48376698|NCT01311531|PROCEDURE|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
48376699|NCT02721043|BIOLOGICAL|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
48176096|NCT00546247|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
48176097|NCT04334447|OTHER|Improved primary care HF diagnostics|Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
48376700|NCT02721043|DRUG|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
48376701|NCT02721043|DRUG|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
48176098|NCT04334447|OTHER|Heart Failure education|Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
48176099|NCT04334447|OTHER|Structured transitional protocol planning post-discharge care|Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
48176100|NCT06108453|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
48176101|NCT06108453|DRUG|Rifampicin|Co-administration of methotrexate and rifampicin
48176102|NCT01832454|OTHER|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
48176103|NCT00316498|DRUG|OGT918|
48176104|NCT02378298|DRUG|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
48176105|NCT02378298|DRUG|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
48376702|NCT03248557|DIAGNOSTIC_TEST|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
48376703|NCT04853953|OTHER|Incidence of bleeding complications in ARDS patients on veno-venous ECMO|All bleeding complications (especially cerebral bleedings) will be analyzed in the study groups. At the bleeding event, laboratory parameters of coagulation will be collected and the intensity of the ECMO treatment
48176106|NCT02378298|DRUG|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
48376704|NCT03471507|DRUG|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
48176107|NCT05035797|PROCEDURE|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation program which encompasses six evidence-based components according to literature review: 1) positioning; 2) passive range of motion (PROM) training; 3) neuromuscular electronic stimulation (NMES); 4) surface electrical phrenic nerve stimulation (SEPNS); 5) PNF techniques; and 6) airway clearance techniques; Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
48376705|NCT03471507|DRUG|Diclofenac sodium topical solution 1.5%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
48176108|NCT05035797|PROCEDURE|Usual care|Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
48176109|NCT04158271|DEVICE|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
48176110|NCT04158271|DEVICE|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
48176111|NCT04158271|DEVICE|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
48517341|NCT02508129|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
48176112|NCT01278615|OTHER|Laboratory Biomarker Analysis|Correlative studies
48176113|NCT01278615|DRUG|Selumetinib|Given PO
48176114|NCT05197114|OTHER|summerlunch+ At Home Food Skills Program|The summerlunch+ At Home program a virtual eight-week food skills program that teaches cooking, nutrition and environmental sustainability to children. The program has been adapted for those with Type 1 Diabetes to teach important food skills specific to diabetes management.
48517342|NCT02508129|BEHAVIORAL|Sleep Healthy Using the Internet|"SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure."
48709246|NCT02813668|BEHAVIORAL|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
48709247|NCT03062618|DRUG|PRCL-02|Oral tablet(s) administered with water
48709248|NCT03062618|DRUG|Placebo Oral Tablet|Administered with water
48709249|NCT04134130|DRUG|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
48517343|NCT02508129|BEHAVIORAL|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
48709250|NCT04134130|DRUG|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
48709251|NCT04134130|DRUG|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
48709252|NCT06607822|DEVICE|A patient-centered assistant system based on Large-Language Model (LLM)|Participants will engage in a 10-minute medical consultation using LLM model interface embedded in a tablet device before their regular face-to-face consulation with physicians. During the trials, participants could engage in free conversations covering aspects including risk factors, symptoms, diagnosis, examinations, treatment, advice and caution, etc. Participants who have completed the ophthalmic imaging examination will be asked to input results into the assistant model to generate structured reports.
48709253|NCT04495556|DIAGNOSTIC_TEST|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
48709254|NCT04522154|DIAGNOSTIC_TEST|Magnet resonance imaging|Patients will receive a cardiac magnet resonance tomography before and 3-month after the procedure
48517344|NCT03707210|BEHAVIORAL|VR training program|Use VR software to make a training education program.
48376706|NCT06042465|OTHER|acupuncture and Tui-na manipulations|"i. Patients in supine position with knee elevated 20-30 degrees bending using a pillow below.~ii. Acupuncture needle using 0.25 mm diameter and 1.5-inch length. iii. Choose 'A shi point' to inject the acupuncture needles. iv. Inject 4 acupuncture needles respectively at the upper, lower, lateral and medial edge of the patella, along the medial and lateral edge at the posterior surface of patella.~v. Connect the needles with electro-therapy, selecting high frequency and strength that the patients have sensation and acceptable. Time duration is 30 minutes each time. Infra-radiation is provided and warm above the treatment region.~vi. Tui-na manipulations using the method of 'Tui-na'. Time duration is 2-5 minutes. Patella is pushed up and elevated during treatment.~vii. No external herbal medicine for TCM group , other medication such as painkiller is required to record"
48709255|NCT05853055|PROCEDURE|Respiratory training|Respiratory training will be included in the rehabilitation program of a subgroup of post-COVID-19 patients. The intervention group will train twice daily for the length of their rehabilitation stay using an incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA). Subjects will be instructed to first completely exhale slowly. Then inspire slowly up to 70% of their vital capacity, producing a constant flow controlled via feedback from the device. This procedure will be repeated every 30 s (paced by a metronome) for 15 min. The training will be conducted twice a day, resulting in a total of 60 inspirations per day.
48517345|NCT06550817|OTHER|Growth mindset intervention|Online intervention is implemented and it lasts about 20 minutes each time, while face-to-face intervention lasts about 30 minutes each time, and they are carried out for a total of six weeks, face-to-face or telephone intervention is implemented once every two weeks for about 15 minutes each time
48517346|NCT06550817|OTHER|E-health Program|face-to-face e-health teaching in the first 6 weeks, and telephone follow-up were conducted once a week, for about 10 minutes each time in the last 6 weeks
48176115|NCT01309243|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
48176116|NCT01309243|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
48709256|NCT02275117|BIOLOGICAL|ALD403|
48709257|NCT02275117|BIOLOGICAL|Placebo|
48709258|NCT05773261|DEVICE|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
48709259|NCT05773261|DEVICE|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
48709260|NCT00842439|BEHAVIORAL|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
48709261|NCT00842439|DIETARY_SUPPLEMENT|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
48709262|NCT03756363|PROCEDURE|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
48376707|NCT06042465|OTHER|Physiotherapy|"i. Total 12 sessions of physiotherapy for 8 weeks training; ii. Treatment: Closed kinetic chain exercises program will be used when appropriate, which include:~1. Mini walk squat exercise~2. Forward step up~3. Lateral step up~4. Terminal knee extension~5. Knee taping~6. Unstable base training~7. Pain control~8. Manual Therapy Each session will approximately cost each patient 1 hours' time. There is no Chinese medicine is allowed for PT group , other medication such as painkiller is required to record."
48376708|NCT00509223|DEVICE|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
48376709|NCT00509223|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
48376710|NCT05861024|OTHER|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
48709263|NCT03756363|PROCEDURE|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
48709264|NCT05209308|DRUG|Zandelisib|Zandelisib taken orally for 7 days of each 28 day cycle
48709265|NCT05209308|DRUG|Rituximab|Rituximab IV for 6 cycles
48019036|NCT06461104|BEHAVIORAL|Psychoeducational Programme|The control group undergoes a 12-week psychoeducational programme on nutrition and PA, consisting of 8 sessions. Led by a dietitian and psychologist, topics include PA benefits, healthy eating, and sedentary lifestyle risks. The experimental group receives 3 sessions on dietary habits before starting PA intervention, ensuring differentiation. It's expected the experimental group directly benefits from exercise, while the control group benefits from PA education. At the trial's end, control group members can join the PA programme for free.
48019037|NCT02192450|DRUG|Insulin aspart/glargine|
48019038|NCT02192450|DRUG|Insulin aspart/degludec|
48376711|NCT04554563|OTHER|Core stability training|20 sessions of specific core stability exercise with no external loading.
48709266|NCT05209308|DRUG|Venetoclax|Orally - Ramp up weeks 1-5
48709267|NCT00091130|BIOLOGICAL|HspE7|Given SC
48709268|NCT00091130|OTHER|placebo|Given SC
48709269|NCT00091130|OTHER|laboratory biomarker analysis|Correlative studies
48709270|NCT06038526|PROCEDURE|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
48019039|NCT01978405|DRUG|Alpha lipoic acid|
48376712|NCT05431673|DRUG|Doxycycline|Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
48376713|NCT05431673|DRUG|Ciprofloxacin|Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma
48376714|NCT05431673|DRUG|Rifampin|Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
48709271|NCT06038526|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
48709272|NCT06038526|BIOLOGICAL|Canakinumab|Given SC
48709273|NCT06038526|PROCEDURE|Carbon Monoxide Measurement|Undergo CO testing
48709274|NCT06038526|OTHER|Survey Administration|Ancillary studies
48709275|NCT00336167|DRUG|bezafibrate (drug)|
48709276|NCT02763475|DRUG|cyclophosphamide|60mg/kg by vein on day -6
48709277|NCT02763475|DRUG|Fludarabine|25mg/m2 iv daily on day -5 to -1
48709278|NCT02763475|PROCEDURE|NK cell infusion|"* First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~* Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
48709279|NCT02763475|DRUG|IL-2|1x10\^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
48709280|NCT03591614|BIOLOGICAL|DKK1|The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
48709281|NCT03482284|OTHER|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
48709282|NCT03153644|BEHAVIORAL|Interview|1 hour semi-structured
48709283|NCT03153644|BEHAVIORAL|Observation|Field Observation
48709284|NCT00293709|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
48709285|NCT05694338|OTHER|Frailty survey|Frailty survey using the Clinical Risk Analysis Index (RAI-C).
48019040|NCT01999010|DEVICE|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
48709286|NCT06327633|OTHER|Olfactory Training|The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 5-min per time, with focus, until the completion of the study.
48376715|NCT05005468|DRUG|Camrelizumab|Camrelizumab is given on the first day of each cycle, intravenous drip.
48709287|NCT06345482|DRUG|MHB039A|a bispecific antibody
48709288|NCT00711347|DEVICE|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
48709289|NCT00711347|DEVICE|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
48709290|NCT02908685|DRUG|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
48709291|NCT02908685|DRUG|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
48019041|NCT01700816|DEVICE|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
48019042|NCT01700816|DEVICE|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
48019043|NCT04704245|DRUG|epidermal growth factor (EGF)-containing ointment|The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
48019044|NCT04704245|DRUG|Vehicle ointment|To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.
48019045|NCT04704245|PROCEDURE|Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser|"The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment.~The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency.~The end point of laser treatment for lentigines was immediate whitening."
48019046|NCT05923060|DRUG|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
48376716|NCT05005468|DRUG|Famitinib|Famitinib is administered orally, once a day.
48376717|NCT04307017|OTHER|StimaWell®EMS|The StimaWell®EMS device is a 12-channel medium-frequency device with modulated low frequency using a high-tech stimulation suit for the trunk and strap electrodes for the arms and legs allowing whole-body stimulation. The device has 70 preprogramed training programs based on goals (e.g., strengthening, endurance training, aerobic training).
48376718|NCT05508360|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
48709292|NCT03398265|BEHAVIORAL|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
48376719|NCT00294190|DRUG|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
48517347|NCT00269425|BEHAVIORAL|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
48517348|NCT00269425|BEHAVIORAL|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
48517349|NCT05457777|BEHAVIORAL|Motivational interview in digital game addiction|Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
48517350|NCT01708668|PROCEDURE|Epidural analgesia|
48709293|NCT03398265|OTHER|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
48517351|NCT01708668|PROCEDURE|Combined spinal-epidural analgesia|
48517352|NCT01708668|PROCEDURE|Continuous epidural infusion|
48709294|NCT04894643|RADIATION|Proton Ions|According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.
48709295|NCT04894643|DRUG|Nab-PACLitaxel|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes."
48019047|NCT05923060|PROCEDURE|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
48019048|NCT05923060|PROCEDURE|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
48019049|NCT02694991|OTHER|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
48019050|NCT02139852|DIETARY_SUPPLEMENT|Capsaicin|
48019051|NCT06573645|DRUG|Rituximab|Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).
48376720|NCT05279963|PROCEDURE|electroacupuncture|"The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks."
48709296|NCT04894643|DRUG|Gemcitabine|"Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel."
48376721|NCT05279963|DRUG|Amitriptyline|Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.
48376722|NCT05279963|PROCEDURE|sham electroacupuncture|"In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group."
48376723|NCT03773159|BIOLOGICAL|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
48376724|NCT03919669|DRUG|All Subjects|All subjects will be given the experimental tau PET radioligand \[18F\]MK-6240
48376725|NCT03950947|DEVICE|Amplatzer vascular plug|See above
48376726|NCT03950947|OTHER|Sham Controll|Angiography of the RIMA without occlusion
48376727|NCT05598502|DEVICE|REBOA, Resuscitative Endovascular Occlusion of the Aorta|The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
48376728|NCT05598502|OTHER|National guidelines|Standard management of postpartum hemorrhage according to Uganda national guidelines
48376729|NCT06484816|DRUG|TGRX-1942|At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
48376730|NCT03072576|DEVICE|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
48376731|NCT06426901|OTHER|Effects of Tan Tui Exercises on Strength and Performance of Football Players.|Tan Tui, Exercises Tan Tui, is a style of traditional Chinese martial art that emphasizes leg techniques, agility, and conditioning. Basic Kicking Drills. Stance Work. Forms (Taolu) Pattern Drills. Conditioning.Sparring (San Shou). This protocol will be implemented by District Physiotherapist who will visit the mentioned Football academies in group session.
48376732|NCT01439308|DRUG|Placebo|SB-705498 placebo
48376733|NCT01439308|DRUG|SB-705498|12mg intranasal SB-705498
48517353|NCT01708668|PROCEDURE|Intermittent epidural bolus|
48517354|NCT01470092|DRUG|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
48517355|NCT06400030|PROCEDURE|Root canal treatment with AH Plus sealer|- AH Plus sealer Group: the base and accelerator of AH Plus Sealer was mixed, then the walls of the canal were coated with the AH Plus sealer using K-File, then lateral condensation was performed through a number of gutta-percha cones.
48517356|NCT06400030|PROCEDURE|Root canal treatment with BioCeramic sealer|- BioCeramic Sealer Group: the canals in this group were filled using BioCeramic-based sealer and a single gutta-percha cone, and gently insert it into the root canal to the preselected working length without applying pressure.
48517357|NCT03506256|DRUG|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
48517358|NCT03498495|BEHAVIORAL|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
48517359|NCT01876225|BEHAVIORAL|Forced coughing during cervical punch biopsy|
48517360|NCT02531048|DEVICE|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
48709297|NCT04894643|DRUG|Capecitabine|Concomitant to proton-radiotherapy (on the same days, within week 14-19)
48517361|NCT02531048|DEVICE|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
48517362|NCT02531048|DEVICE|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
48709298|NCT04894643|PROCEDURE|Surgical resection of the pancreas (when feasible)|Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
48709299|NCT03122353|DRUG|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
48709300|NCT03122353|DRUG|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
48019052|NCT04948697|DRUG|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
48019053|NCT04948697|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
48709301|NCT03122353|DRUG|Placebo|vehicle used as placebo
48709302|NCT02115750|DRUG|Etanercept|Head-to-head comparison
48709303|NCT02115750|DRUG|CHS-0214|
48709304|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with carbohydrate counting|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the total grams of carbohydrates counted. This is the same as commercial hybrid closed-loop insulin therapy (standard treatment).
48709305|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with meal size estimation|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the qualitative amount of carbohydrates estimated (e.g., low-carb meal).
48019054|NCT04948697|DRUG|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
48019055|NCT05319418|BEHAVIORAL|Daily Blood Pressure Monitoring|Patients are provided standard off-the-shelf blood pressure monitors and take their BP vitals daily. Patients report their daily BP through phone or online. BP data is viewed online by physicians who use their independent medical judgement for any changes in medical management.
48019056|NCT05226104|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
48019057|NCT03397511|BEHAVIORAL|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
48709306|NCT06021158|COMBINATION_PRODUCT|Fully automated Lyumjev delivery system with meal detection|In this system, the patient does not initiate a Lyumjev insulin bolus at mealtime. An algorithm is used to detect a meal and administer a subsequent bolus, rather than requiring a carbohydrate count.
48709307|NCT04432493|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
48019058|NCT02783404|DRUG|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
48019059|NCT02783404|DRUG|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
48019060|NCT06367582|DEVICE|Vertebroplasty (VP)|Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
48019061|NCT06367582|DEVICE|Kyphoplasty (KP)|Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
48019062|NCT06367582|DEVICE|Pedicular Screw Augmentation (PSA)|Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
48019063|NCT06663137|DRUG|NDV01 intravesical controlled release formulation of gemcitabine and docetaxel|NDV01 is administered intravesically using a catheter.
48176117|NCT05005325|OTHER|Experimental group(Male)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
48019064|NCT00000571|DEVICE|ventilators, negative pressure|
48019065|NCT05280574|DEVICE|GE Portrait Monitor|All patients will be monitored
48019066|NCT05280574|DEVICE|GE Portrait Monitoring with intervened by clinician|Monitoring might be intervened if clinician believe that the alarm is clinically meaningful
48176118|NCT05005325|OTHER|Experimental group(Female)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
48019067|NCT05280574|DEVICE|GE Portrait Monitoring randomized to blinded or unblinded|Without intervention
48176119|NCT04438122|OTHER|Cabernet Sauvignon|Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
48176120|NCT04438122|OTHER|Tsipouro|Tsipouro is a greek spirit which contains 38% alcohol vol
48176121|NCT02627898|DRUG|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
48176122|NCT02627898|DRUG|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
48176134|NCT04724096|DIAGNOSTIC_TEST|Oxygen Enhanced MRI scan|Dynamic MRI scanning switching from breathing room air to high concentration oxygen part way through the scan.
48176135|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 20mg
48709308|NCT04432493|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
48176136|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 5 mg
48176137|NCT00600847|DRUG|placebo|single dose for 7 days, oral
48176138|NCT00358982|DRUG|MGCD0103|MGCD0103 administered orally three times per wek
48176139|NCT03209245|BIOLOGICAL|Purethal Mites|perennial allergren specific immunotherapy during 24 months
48176140|NCT03209245|OTHER|placebo injection|perrenial injection wich were administered in same protocol as Purethal
48176141|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
48376734|NCT00000549|DRUG|estrogen replacement therapy|
48176142|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
48176143|NCT01980602|PROCEDURE|Supervised Exercise program|
48176144|NCT02360813|BEHAVIORAL|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
48176145|NCT02360813|OTHER|Treatment as usual|Keep getting usual care.
48176146|NCT00456417|DRUG|123-I MNI-187 Injection and Imaging Procedures|
48376735|NCT00000549|DRUG|hormone replacement therapy|
48376736|NCT00000549|DRUG|estrogens|
48376737|NCT00000549|DRUG|progestins|
48709309|NCT05137457|OTHER|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
48709310|NCT05137457|OTHER|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
48709311|NCT01382121|BEHAVIORAL|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
48709312|NCT01382121|BEHAVIORAL|Control|watching a video unrelated to the fitness test and self-efficacy
48709313|NCT04897919|DRUG|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
48709314|NCT04897919|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
48709315|NCT05238012|DRUG|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
48709316|NCT05238012|DRUG|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
48709317|NCT05178030|OTHER|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
48709318|NCT00212199|DRUG|orlistat|
48709319|NCT00212199|BEHAVIORAL|Brief cognitive behavioral counseling|
48709320|NCT00145353|DRUG|Insulin NovoRapid versus Actrapid|
48709321|NCT04829305|DRUG|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
48709322|NCT05440006|DRUG|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
48709323|NCT04907149|DRUG|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
48709324|NCT04907149|DRUG|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
48709325|NCT04907149|DRUG|[14]GLPG3970 oral solution|Participants will receive a single oral dose \[14C\]GLPG3970.
48709326|NCT01238770|DRUG|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
48709327|NCT05709067|DIETARY_SUPPLEMENT|Probiotic|6 Billion CFU per day
48709328|NCT05709067|DIETARY_SUPPLEMENT|Placebo|0 CFU per day
48709329|NCT02111135|BIOLOGICAL|b-OPV|
48709330|NCT02111135|BIOLOGICAL|m-OPV2|
48709331|NCT02111135|BIOLOGICAL|m-IPV HD|
48709332|NCT02111135|BIOLOGICAL|t-IPV|
48709333|NCT05563883|OTHER|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
48376738|NCT02862743|OTHER|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
48376739|NCT02043626|OTHER|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
48517363|NCT02531048|DEVICE|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
48517364|NCT05696379|OTHER|Angiography derived index of micro-circulatory resistance (Angio-IMR)|Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.
48709334|NCT06079073|BEHAVIORAL|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
48709335|NCT01991223|DRUG|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
48517365|NCT00594373|DRUG|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
48709336|NCT01991223|DRUG|NS infusion|Normal saline will be infused during surgery
48176147|NCT00910260|PROCEDURE|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
48176148|NCT04759430|OTHER|Supervised Group|Individuals will apply ten different stabilization exercises in company with a physiotherapist.
48517366|NCT00594373|DRUG|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
48517367|NCT02756611|DRUG|Venetoclax|Tablets for oral administration
48517368|NCT00315796|DEVICE|Biophilic Nature Scene and Sound|
48176149|NCT04759430|OTHER|Telerehabilitation group|Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
48176150|NCT00226122|DRUG|Indomethacin|Indomethacin capsules 50 mg
48176151|NCT01579721|PROCEDURE|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
48517369|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
48517370|NCT01085760|DRUG|Vancomycin|Comparison of different doses of drug
48709337|NCT00444704|DRUG|PRA-027|
48376740|NCT02043626|OTHER|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
48376741|NCT02043626|OTHER|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
48176152|NCT05021445|COMBINATION_PRODUCT|plates based exercises|12 elderly participants receive intervention protocol of Plates- based exercises program total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
48376742|NCT02043626|OTHER|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
48176153|NCT05021445|COMBINATION_PRODUCT|conventional exercises|12 elderly participants,intervention protocol of Conventional balance training exercises,total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
48176154|NCT04410939|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction|PCR test is performed from the oropharyngeal and nasal swab samples taken before admission to each pregnant to prevent contamination from the pregnant women hospitalized in this clinic. In addition, the same test is done before each operation and before the operation. The aim of the study is to scan these tests retrospectively and to determine the rate of positive COVID-19 cases in asymptomatic pregnant women. The results will determine the importance of the measures to be taken in the pregnant and undergoing pregnant women.
48176155|NCT03257033|DRUG|Gemcitabine|Chemotherapy
48176156|NCT03257033|DRUG|nab-paclitaxel|Chemotherapy
48176157|NCT03257033|DEVICE|RenovoCath|Intra-arterial catheter
48176158|NCT04695652|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
48176159|NCT04695652|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
48176160|NCT04431245|DRUG|Entecavir|Study subjects will stop the antiviral therapy. Patients will be closely monitored every 6-8 weeks for virological flare and/or biochemical flare.
48376743|NCT06137794|OTHER|"Use of I-Anticoagulation to make the decision and manage patients"|I-Anticoagulation will offer a flexible and efficient communication platform for healthcare professionals and AF patients. The tool is composed of two modules: an anticoagulation decision support system and a full-process patient management system.
48376744|NCT00106717|PROCEDURE|Narrative medicine|
48376745|NCT01024894|DRUG|Interleukin-7|3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
48376746|NCT05227534|DEVICE|OverC multi-cancer detection blood test|Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
48709338|NCT01215617|BEHAVIORAL|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
48709339|NCT01215617|BEHAVIORAL|Control|Standard medical treatment
48709340|NCT06050668|COMBINATION_PRODUCT|Essential Amino Acid Supplementation|Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
48709341|NCT03647111|DRUG|Crizotinib|Crizotinib 250mg po bid
48709342|NCT03473964|DRUG|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
48709343|NCT02521233|DRUG|Candesartan + Chlorthalidone (8mg+12,5mg)|
48176161|NCT00934700|OTHER|Xenon gas|30% Xenon gas inhaled for 24 hours
48709344|NCT02521233|DRUG|Candesartan + Chlorthalidone (8 mg + 25 mg)|
48709345|NCT02521233|DRUG|losartan+hydrochlorothiazide|
48176162|NCT04324658|DEVICE|Lactiplus|capsules containing L. gasseri LA806
48176163|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
48176164|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
48176165|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
48709346|NCT01301521|DRUG|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
48176166|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
48176167|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
48176168|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
48176169|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
48376747|NCT00883831|PROCEDURE|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
48376748|NCT02050646|OTHER|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
48376749|NCT02050646|OTHER|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
48376750|NCT03628534|DEVICE|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
48176170|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
48709347|NCT05256420|DEVICE|Kinesiotape|Application of a kinesiotape bandage on the knee.
48176171|NCT06426147|DIETARY_SUPPLEMENT|L-citrulline|1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
48176172|NCT06426147|DIETARY_SUPPLEMENT|Placebo|1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
48709348|NCT05256420|DEVICE|Sham Bandage|Application of a sham bandage on the knee.
48176173|NCT04486313|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
48176174|NCT04486313|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
48176175|NCT04486313|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
48376751|NCT06126185|DIETARY_SUPPLEMENT|12-week course of synbiotic|A 12-week-course of synbiotic, which contains containing 5 billion colony-forming unit (CFU) of a combination of 4 probiotic species belonging to the genus of Lactobacillus, Bifidobacterium and Streptococcus, and 3 prebiotics, will be given to participants to take daily through oral route.
48376752|NCT04037826|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
48709349|NCT05910034|DRUG|Trilaciclib+Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
48376753|NCT04037826|DIETARY_SUPPLEMENT|Placebo|Placebo
48376754|NCT05811507|DIAGNOSTIC_TEST|serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate|Venous blood samples will be collected into sterile EDTA tubes around 10 am. Blood taken from controls will be collected at the same time. All samples will be delivered into the laboratory immediately after collection and centrifuged at 3000 × g, 4 °C for 10 min. Plasma samples were stored at -80 °C until the analysis using ELIZA
48376755|NCT05811507|DIAGNOSTIC_TEST|The Childhood Autism Rating Scale (CARS)|It is done by rating the child's behaviors from 1 to 4. 1 being normal for your child's age, 2 for mildly abnormal, 3 for moderately abnormal, and 4 as severely abnormal. Scores range from 15 to 60 with 30 being the cutoff rate for a diagnosis of mild autism. Scores 30-37 indicate mild to moderate autism, while scores between 38 and 60 are characterized as severe autism
48517371|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
48517372|NCT01085760|DRUG|Metronidazole|Comparison of different doses of drug
48709350|NCT05910034|DRUG|Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
48709351|NCT05910034|DRUG|Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
48709352|NCT05361499|BIOLOGICAL|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
48709353|NCT05361499|DRUG|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
48709354|NCT01309906|DEVICE|Investigational lens|Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
48176176|NCT03289702|DRUG|CORETOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
48517373|NCT01085760|DRUG|Vancomycin|Comparison of different drug doses
48709355|NCT01309906|DEVICE|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
48709356|NCT01610440|BIOLOGICAL|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
48709357|NCT05363761|COMBINATION_PRODUCT|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
48176177|NCT03289702|DRUG|BOTOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
48176178|NCT01379456|PROCEDURE|physiotherapy|exercises, 20 sessions over 10 weeks
48176179|NCT00846768|DRUG|BI 1744 CL|
48176180|NCT01682798|DIETARY_SUPPLEMENT|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
48176181|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
48176182|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
48176183|NCT04241809|DIAGNOSTIC_TEST|Bioaerosol Sampling|Cyclone collection of exhaled bioaerosol
48176184|NCT01316965|BEHAVIORAL|Multifaceted prevention program HELP(Hospital Elder Life Program)|"* A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~* B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~* C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
48376756|NCT05811507|DIAGNOSTIC_TEST|DSM-5 Diagnostic Criteria for ASD|Persistent deficits in social communication and social interaction across multiple contexts. Restricted, repetitive patterns of behavior, interests, or activities. Symptoms must be present in the early developmental period, Symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning.These disturbances are not better explained by intellectual disability or global developmental delay.
48376757|NCT05811507|DIAGNOSTIC_TEST|Assesment of IQ: The Stanford-Binet V (Stanford-Binet Intelligence Scales):|"IQ Score ranges for the Stanford-Binet:~Low average: 80-89 Average: 90-109 High average: 110-119 High achiever: 120-129 Moderately gifted: 130-144 Highly gifted: 145-160+"
48709358|NCT04732858|OTHER|Cross sectional e-Survey on surgeons exposed to any educational intervention|"Educational intervention was considered as any procedure or program to facilitate the acquisition of basic skills about the disease, its ramifications and treatment2,6,7:~* Education in infectious disease, including~  * pandemic training for health personnel~ * Personal protective equipment (PPE) and protection.~ * Specific speed-training focusing on environmental control (decontamination area, dressing...), personal protection, hand hygiene, sample management, risky gestures, control measures.~* Intensive care education:~  * mechanical ventilation~ * airways management~ * emergencies and cardiovascular drugs~ * Intensive care monitoring systems~* Basic nurse skills~* COVID-specific clinical management"
48709359|NCT01341691|OTHER|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
48709360|NCT00571636|DRUG|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
48376758|NCT01154530|OTHER|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
48376759|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (compact)|Circular cylindrical mirror modulated frame glasses (compact)
48376760|NCT05288335|DEVICE|Circular cylindrical mirror modulated frame glasses (strong defocus)|Circular cylindrical mirror modulated frame glasses (strong defocus)
48376761|NCT05288335|DEVICE|single vision frame glasses|single vision frame glasses
48376762|NCT01462409|DEVICE|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
48709361|NCT00571636|DRUG|5% glucose solution|ev continuous infusion
48709362|NCT04165187|OTHER|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
48709363|NCT04165187|OTHER|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
48709364|NCT01533467|DEVICE|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
48376763|NCT01462409|DEVICE|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
48376764|NCT01462409|DEVICE|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
48376765|NCT00592137|DIETARY_SUPPLEMENT|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
48376766|NCT00592137|DIETARY_SUPPLEMENT|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
48376767|NCT00592137|DIETARY_SUPPLEMENT|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
48376768|NCT03922048|DRUG|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
48176185|NCT05082181|BEHAVIORAL|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
48176186|NCT05082181|BEHAVIORAL|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
48176187|NCT03901443|OTHER|Survey on itch|self-administered patient questionnaire regarding the different aspects of itch
48176188|NCT00331708|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
48176189|NCT04709978|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study|Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
48176190|NCT04709978|DIAGNOSTIC_TEST|Nuclear medicine pulmonary aspiration study|Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
48376769|NCT03922048|DRUG|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) (total dose not to exceed 75 mg).
48517374|NCT02237586|BIOLOGICAL|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
48517375|NCT06432803|OTHER|PET-Scan analysis|Investigate and determine the clinical value of different cortex/striatal metabolic ratio patterns in each antibody-specific subtype of autoimmune encephalitis
48376770|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1.
48376771|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohorts 1 and 2.
48376772|NCT03922048|DRUG|HTX-011|Dose to be determined from Cohort 1 Part A.
48376773|NCT03922048|DEVICE|Luer Lock Applicator|Applicator for instillation.
48376774|NCT04108416|PROCEDURE|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
48517376|NCT04320043|PROCEDURE|Anterior cervical decompression|Any of the following anterior surgical techniques used to decompress the cervical nerve roots or spinal cord; corpectomy, Anterior Cervical Discectomy (ACD), Anterior Cervical Decompression and Fusion (ACDF) or ACDF with Plating
48517377|NCT03576664|DRUG|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
48517378|NCT03576664|DRUG|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
48517379|NCT04508738|OTHER|ERP|"The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture"
48517380|NCT04508738|OTHER|Placebo|"The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air"
48517381|NCT04457037|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells
48517382|NCT01562860|PROCEDURE|Pronator Teres Release|Surgical release of median nerve compression
48376775|NCT02945501|DEVICE|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
48376776|NCT02945501|DEVICE|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
48376777|NCT02341339|PROCEDURE|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
48376778|NCT01281475|DRUG|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
48176191|NCT04709978|DIAGNOSTIC_TEST|TOR-BSST and 3 oz Water Swallow|"The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed."
48176192|NCT04709978|DIAGNOSTIC_TEST|Sputum Culture|Patients will have sputum collected during stay (ED participants only)
48709365|NCT03279523|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
48709366|NCT06139562|BEHAVIORAL|Time-Restricted Feeding|Time-restricted feeding (TRF) is a dietary approach that includes a fasting protocol and a fasting period ranging from 3 to 21 hours during the day . Since there is no standard definition of TRF, fasting/feeding periods vary. In this study, 12-hour fasting and 12-hour feeding period defined by Pureza et al.(11) were taken as the TRF model. In the first 4-week arm of the study, applied a time-restricted feeding program from sunrise to sunset. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
48176193|NCT04709978|DIAGNOSTIC_TEST|MeMed BV®|A blood test to help determine if the infection is viral or bacterial (ED participants only)
48176194|NCT04709978|DIAGNOSTIC_TEST|Lung Ultrasound|To image the lungs (ED participants only)
48376779|NCT01281475|DRUG|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
48376780|NCT00718809|DRUG|saracatinib|Given orally
48376781|NCT05547516|DRUG|Standard infusion chemotherapy|standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery
48376782|NCT05547516|PROCEDURE|BL - 5 ala PDT|BL - 5 ala PDT - plan: 5ALA 1.5g (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd), dissolved in 50mL normal saline, was infused into the bladder for 2 hours before surgery and before each cystoscopy. Blue laser irradiation was performed under a flexible cystoscope at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
48376783|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
48376784|NCT00682006|OTHER|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
48376785|NCT00682006|DRUG|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
48376786|NCT04768881|DRUG|Selinexor|Dose and formulation: 80 mg (4 tablets of 20 mg)
48376787|NCT04768881|DRUG|Pembrolizumab|Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution
48376788|NCT00542165|DRUG|Alfuzosin|
48376789|NCT02903849|BEHAVIORAL|Drafting Motivational Messages|Write down three motivating messages
48376790|NCT02903849|BEHAVIORAL|Control Reminders|Receive standard reminders at three points during the challenge
48376791|NCT02903849|BEHAVIORAL|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
48376792|NCT05245461|OTHER|Assessments|Muscle Strength, Proprioception, Kinesiophobia
48376793|NCT04269317|DEVICE|Tixel C|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
48376794|NCT02315651|DIETARY_SUPPLEMENT|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
48376795|NCT02315651|DIETARY_SUPPLEMENT|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
48376796|NCT00625768|DRUG|AS1409|Study drug
48517383|NCT01562860|PROCEDURE|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
48517384|NCT01562860|PROCEDURE|dual compression release|both procedures will be done on the same day
48517385|NCT01562860|PROCEDURE|median nerve release only|only the carpal tunnel compression is released
48176195|NCT04709978|DIAGNOSTIC_TEST|Respiratory Function Tests|To measure respiratory pressures.
48176196|NCT03866447|DRUG|Vitamin D analog|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
48176197|NCT03866447|DRUG|Adapalene|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
48176198|NCT01135082|BIOLOGICAL|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
48176199|NCT02283021|OTHER|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
48376797|NCT01761565|DRUG|Single dose of SUF NT 15 mcg|
48376798|NCT01761565|DRUG|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
48709367|NCT06139562|BEHAVIORAL|Extended-Time Feeding|Extended-time feeding program was suggested that allows them to eat at any time of the day. During dietary interventions, a weight loss diet was applied to the participants. The daily energy requirements of the participants were calculated individually to lose 5% of their initial weight and the distributions of macronutrients were 45-60% of total energy from carbohydrates, 10-20% as protein and less than 35% from fat.
48709368|NCT00195520|DRUG|Totelle®|
48709369|NCT04659928|DEVICE|High volume evacuation (HVE)|Intra oral suction will be done and during the procedure,bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
48376799|NCT00814502|DRUG|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
48376800|NCT00814502|DRUG|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
48376801|NCT00242645|BEHAVIORAL|Health Information|
48376802|NCT00242645|BEHAVIORAL|Preventive Services|
48176200|NCT04687098|DRUG|Idarubicin|12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
48517386|NCT03464721|DEVICE|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
48517387|NCT04831814|DIAGNOSTIC_TEST|Near Focus NBI|Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.
48019068|NCT06663150|BEHAVIORAL|health intervention with a socio-community approach|"The intervention consists of five components, including education, cognitive stimulation, physical activity, nutrition, and socio-community aspects. The duration of the intervention will be 6 months and will be conducted in either in-person or virtual format, individually or in groups, depending on the nature of each component. Mode of Delivery:~The intervention will be offered in both in-person and synchronous virtual formats. Participants who are unable to attend in person or who face difficulties doing so on any occasion will have the option to join the sessions through a real-time videoconferencing platform. In both modalities, the professionals in charge will supervise and guide the activities, ensuring proper execution and adherence to the study's objectives. The research team will maintain a detailed record of attendance and participation using the RedCap platform for appropriate tracking."
48019069|NCT05338775|DRUG|Talquetamab|Talquetamab will be administered as a subcutaneous (SC) injection.
48517388|NCT04831814|DIAGNOSTIC_TEST|Standard Focus NBI|Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
48709370|NCT04659928|DEVICE|Extraoral vacuum aspirator (EVA)|Extraoral suction connected to dental suction will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
48176201|NCT04687098|DRUG|Ara-C|"200mg/m2/day, intravenous at induction phase; days 1-7.~- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5."
48019070|NCT05338775|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
48019071|NCT05338775|DRUG|PD-1 Inhibitor|The PD-1 inhibitor will be administered as an intravenous injection.
48019072|NCT00575588|DRUG|Metformin|open-label metformin
48019073|NCT00575588|DRUG|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
48019074|NCT00575588|DRUG|Saxagliptin|Saxagliptin 5 mg tablets
48019075|NCT05789082|DRUG|Divarasib|Participants will receive one of two doses of divarasib orally (PO), QD on days 1-21 of each 21-day cycle.
48019076|NCT05789082|DRUG|Pembrolizumab|Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle.
48019077|NCT05789082|DRUG|Carboplatin|Participants will receive IV carboplatin Q3W for four 21-day cycles.
48176202|NCT04687098|DRUG|G-CSF|"* Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~* Administration at consolidation phase day 7."
48176203|NCT04687098|PROCEDURE|Allogeneic matched or unrelated donor transplant.|To be performed in patients in the intermediate or adverse risk groups.
48176204|NCT04687098|PROCEDURE|Autologous peripheral blood stem cell transplant|To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
48376803|NCT00242645|BEHAVIORAL|Computer tailored information|
48376804|NCT03188250|BEHAVIORAL|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
48376805|NCT00852267|OTHER|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
48019078|NCT05789082|DRUG|Cisplatin|Participants will receive IV cisplatin Q3W for four 21-day cycles.
48019079|NCT05789082|DRUG|Pemetrexed|Participants will receive IV pemetrexed Q3W.
48019080|NCT05577052|RADIATION|Metastatic vertebrae treated with SBRT|High-dose SBRT treatment
48019081|NCT02896231|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
48019082|NCT03826329|OTHER|observational study|this is an observational study, there is no intervention in this study
48709371|NCT04659928|DEVICE|External evacuation device (EED)|Extraoral suction unit will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab.Patient will be given hydrogen peroxide rinse.
48709372|NCT04659928|DRUG|Hydrogen Peroxide|Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
48709373|NCT00694096|DRUG|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
48709374|NCT05961969|PROCEDURE|Robotic surgery|"1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
48709375|NCT02889679|PROCEDURE|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
48709376|NCT02889679|PROCEDURE|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
48709377|NCT02889679|PROCEDURE|Standard polypectomy|Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
48709378|NCT04793230|DIAGNOSTIC_TEST|biopsying|The procedure was carried out under general or local anesthesia. An otolaryngologist conducts the endoscopic intranasal operation, while an eye surgeon removes tissue from the sac and lacrimal tubes using lacrimal probes passed through the canaliculi.
48709379|NCT04185974|RADIATION|C12 re-irradiation|51 Gy(RBE) or 54 Gy
48709380|NCT04185974|RADIATION|Photon re-irradiation|54 Gy(RBE) or 60 Gy
48709381|NCT03279913|DEVICE|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
48709382|NCT05298995|BIOLOGICAL|GD2-CART01 (iC9-GD2-CAR T-cells)|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
48709383|NCT03670329|DEVICE|URGO2875|Dressing
48709384|NCT04720274|DEVICE|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
48709385|NCT01912157|BEHAVIORAL|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
48709386|NCT04986046|OTHER|Home Plate Lite|Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly.
48709387|NCT04986046|OTHER|Virtual Home Plate|Virtual Home Plate comprises two, 45-minute weekly sessions where parents work together with a study staff member to discuss the themes and prepare the components of a meal, including entrees, side dishes, and desserts.
48709388|NCT04986046|OTHER|Fruit and Vegetable prescription|All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
48019083|NCT04286347|PROCEDURE|HCV, HBV, HIV tests|HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
48019084|NCT03083288|DRUG|[18F]FluorThanatrace|\[18F\]FluorThanatrace is a radiotracer for PET/CT
48019085|NCT00403455|DRUG|Paroxetine|SSRI
48019086|NCT03878940|DIAGNOSTIC_TEST|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
48019087|NCT03903107|PROCEDURE|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
48019088|NCT03903107|PROCEDURE|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
48019089|NCT06410105|DEVICE|CLEAR ALIGNERS|The CA group included 13 patients treated with clear aligners Tree-dimensional images were captured using a CBCT scan (KaVo® Dental GmbH, Bismarckring, Germany). Te pre-treatment imaging parameters were 120 kV, 5 mA, 0.3 mm voxel size, and a feld of view of 230×170 mm
48019090|NCT05297994|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
48019091|NCT05297994|BIOLOGICAL|Inactivated influenza split vaccine|solution for intramuscular injection, 0.5 ml
48019092|NCT04055129|OTHER|No interventions|Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
48019093|NCT05063097|OTHER|urine test|The following illicit drugs will be evaluated for all consecutive patients by urine drug assay (NarcoCheck®, Kappa City Biotech SAS, Montluçon, France) within two hours of admission to the ICCU: i) cannabinoids (tetrahydrocannabinol \[THC\]), including cannabis and hashish; ii) cocaine and metabolites, including cocaine and crack; iii) amphetamines; iv) MDMA; and v) heroin and other opioids. In addition to the analysis of psychoactive drug use, the investigators will also use the NarcoCheck® urine drug assay to evaluate the associated use of the following psychostimulant drugs: barbiturates, benzodiazepines, tricyclic antidepressant drugs, methadone and buprenorphine.
48019094|NCT05063097|OTHER|Fagerström questionnaire|Tobacco consumption will also be evaluated for each patient using a Fagerström questionnaire.
48176205|NCT04687098|PROCEDURE|Measurable residual disease|To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
48176206|NCT03286309|DEVICE|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
48709389|NCT05132257|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
48709390|NCT02168972|DEVICE|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
48709391|NCT04994730|BEHAVIORAL|Quality of life according to the reconstruction technique|"For this retrospective analysis, 118 patients could be included, 17 of whom had undergone ante-brachial free flap reconstruction, 16 of whom had undergone this reconstruction within the last 2 years.~The primary endpoint: Analysis of the quality of life score according to the reconstruction technique (free ante-brachial flap versus others) will be performed by a Wilcoxon-Mann-Whitney test."
48709392|NCT04690907|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
48709393|NCT05352698|DIAGNOSTIC_TEST|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
48709394|NCT06408675|OTHER|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
48709395|NCT05028517|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
48709396|NCT05028517|OTHER|Coaching|A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
48709397|NCT03208114|OTHER|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
48709398|NCT00320749|DRUG|Capecitabine|Will be give on days 8-21
48709399|NCT00320749|DRUG|Docetaxel|Will be given on days 1 and 8,
48709400|NCT00320749|DRUG|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
48709401|NCT01701479|DRUG|ch14.18/CHO|
48709402|NCT01701479|DRUG|Aldesleukin|
48709403|NCT01701479|DRUG|Isotretinoin|
48709404|NCT00579241|PROCEDURE|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
48176207|NCT04387045|BEHAVIORAL|Guilty feelings|Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
48176208|NCT04570696|OTHER|NON INTERVENTIONAL|NON INTERVENTIONAL
48517389|NCT05668702|OTHER|crossover design|The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
48517390|NCT06552000|DEVICE|NovoTTF-200T System|Exposure/Frequency: 150 kHz Route: Transdermal through patented microarray system to the hemithorax affected with cancer, 2-4 week duration, target 18 hours/day (on average)
48517391|NCT02876718|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
48517392|NCT00114660|DRUG|Cocoa butter application|
48709405|NCT00005901|DRUG|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
48709406|NCT04344496|OTHER|PAM50|PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.
48709407|NCT01452139|GENETIC|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
48709408|NCT01452139|DRUG|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
48709409|NCT06350487|DRUG|SGLT2 inhibitor|Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
48709410|NCT00252460|DEVICE|Computed Tomography Scan and Magnetic Resonance Imaging|
48709411|NCT00785551|DRUG|quinine sulfate|2 x 324mg given in one dose to healthy subjects
48709412|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
48709413|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
48517393|NCT06552182|DRUG|HUC2-344|per oral
48517394|NCT06552182|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
48709414|NCT06413420|DRUG|Sunosi (solriamfetol)|Exposure to at least 1 dose of solriamfetol at any time during pregnancy.
48709415|NCT06413420|DRUG|Other prescription wake-promoting medications or stimulants|Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
48709416|NCT06413420|OTHER|No treatment|No treatment
48709417|NCT04854031|DEVICE|Cochlear Implants|Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
48709418|NCT05074888|DRUG|Prospekta|Oral administration.
48709419|NCT05074888|DRUG|Placebo|Oral administration.
48709420|NCT03197428|OTHER|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
48709421|NCT03197428|OTHER|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
48709422|NCT00005574|DRUG|Gentamicin|
48709423|NCT00617071|OTHER|medical chart review|
48709424|NCT00617071|OTHER|survey administration|
48019095|NCT05063097|OTHER|Exhaled carbon monoxide (CO) measurement|Active smoking will also be systematically investigated in all patients using a standardized exhaled carbon monoxide (CO) measurement with a CO-Check Pro device (Bedfont Scientific Ltd, Kent, UK) on arrival, with a measure of \> 3 parts per million (ppm) signifying active smoking.
48019096|NCT04379011|DRUG|Brivaracetam|Escalating brivaracetam dose to 150 mg twice daily for 3 months
48019097|NCT04379011|OTHER|Placebo|Placebo twice daily for 3 months
48019098|NCT02113020|DRUG|TAK-233|Oral administration of TAK-233
48019099|NCT02113020|DRUG|Placebo|Oral admininstration of Placebo
48019100|NCT05229224|OTHER|Osteo fluidic Sensitive méthod|Manual therapy, without manipulative treatment, based on rebalancing of the body with manual pressures on specific body areas.
48019101|NCT05229224|OTHER|Placebo method|Soft Manual pressures at specific points that are defined as non-effective and non-deleterious for patients.
48019102|NCT03642821|DEVICE|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
48019103|NCT00194012|DRUG|Aripiprazole|Addressed in arm description.
48019104|NCT00194012|DRUG|Placebo|Addressed in arm description.
48019105|NCT00826501|PROCEDURE|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
48019106|NCT00826501|PROCEDURE|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
48019107|NCT00592449|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
48019108|NCT00592449|BEHAVIORAL|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
48019109|NCT05988203|BIOLOGICAL|BNT166a|Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
48019110|NCT00471601|BEHAVIORAL|counseling intervention|
48019111|NCT00471601|BEHAVIORAL|questionnaire administration|
48019112|NCT00471601|BEHAVIORAL|psychosocial assessment and care|
48019113|NCT00471601|BEHAVIORAL|quality-of-life assessment|
48019114|NCT06052384|OTHER|Standard pain management combined with sleep disorder management|Standard pain management combined with sleep disorder management at M3, M6, and M12
48019115|NCT05002101|DIETARY_SUPPLEMENT|zinc|The zinc syrup was prepared with a concentration of 7 mg zinc in each 5 ml solution. Accordingly, children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
48019116|NCT05002101|DRUG|Placebo|Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
48019117|NCT06567808|DRUG|Cefazolin|administration as outlined
48019118|NCT06567808|DRUG|Vancomycin|administered as outlined
48019119|NCT01975844|OTHER|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
48376806|NCT00852267|OTHER|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
48376807|NCT00852267|OTHER|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
48709425|NCT00617071|PROCEDURE|fecal occult blood test|
48709426|NCT00617071|PROCEDURE|screening colonoscopy|
48709427|NCT05427539|DEVICE|TEST LENS|AO1DfA manufactured with PG hydration
48709428|NCT05427539|DEVICE|CONTROL LENS|AO1DfA manufactured with IPA hydration
48709429|NCT06487312|DEVICE|Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30|A clinical trial to evaluate the effectiveness and safety of a remote automated ultrasound diagnostic system for automated ultrasound examination using a remote automated ultrasound diagnostic system (model: CORUS-A30, Wuhan Cooper Technology Co., Ltd., China).
48709430|NCT04611425|DRUG|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
48709431|NCT00928278|DRUG|Treatment A|Inhaled, 300/150, single dose
48176209|NCT00656201|DRUG|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
48176210|NCT00656201|DRUG|Intramuscular Progesterone|Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
48176211|NCT03747614|DRUG|Fluorometholone|"Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452"
48176212|NCT03747614|DEVICE|Functional Slit-Lamp Biomicroscopy|A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
48176213|NCT01982786|RADIATION|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
48176214|NCT01982786|RADIATION|Brachytherapy|Brachytherapy boost
48176215|NCT02390661|DEVICE|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
48176216|NCT05327036|OTHER|collect information about all participants|collect information On age,pregnancy history,Height, weight,Gestational weeks of umbilical artery embolism,Gestational week of delivery, mode of delivery, newborn birth weight, birth height, Apgar score, umbilical cord length, umbilical cord placental insertion point, placental weight, pregnancy complications, coagulation function,after obtaining the consent of all participants.
48176217|NCT03932578|DRUG|Atropine sulfate|Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
48176218|NCT03932578|DRUG|Metoclopramide|Patients will receive IV metoclopramide 10 mg in 2 ml
48176219|NCT04589403|DRUG|OPT101|15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40
48176220|NCT01692145|DRUG|KCT-0809|
48176221|NCT01692145|DRUG|Placebo|
48176222|NCT03211585|DEVICE|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
48376808|NCT05508308|DEVICE|OxyMate|Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device
48376809|NCT05508308|OTHER|Manual oxygen control|Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
48376810|NCT05460195|DRUG|sintilimab combined with anlotinib|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab combined with anlotinib therapy repeats every 3 weeks until one year after surgery.
48376811|NCT05460195|DRUG|sintilimab monotherapy|Sintilimab (200mg/time, every 3 weeks) combined with anlotinib (12mg, once daily on day 1 to 14 per cycle) for 2 cycles (42 days). Radical surgery is performed within 4 - 6 weeks treatment. Sintilimab monotherapy repeats every 3 weeks until one year after surgery.
48376812|NCT03522285|OTHER|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
48709432|NCT00928278|DRUG|Treatment B|Inhaled, 300/150, single dose
48709433|NCT00928278|DRUG|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
48709434|NCT00928278|DRUG|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
48709435|NCT01135914|DRUG|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
48709436|NCT01135914|PROCEDURE|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
48709437|NCT02362204|BEHAVIORAL|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
48709438|NCT06461052|PROCEDURE|music therapy|The patient will benefit from viewing the video and the music therapy session in the waiting room of the operating room. The patient will be asked again for their anxiety score using an anxiety scale. This will define the main outcome of the study. Following this collection and in order not to influence the response, investigators will collect from the patient his compliance with the two proposed techniques as well as his appreciation of the tool.
48709439|NCT04124458|DEVICE|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
48376813|NCT04180956|OTHER|Bias-reduction Intervention|A training for doctors
48376814|NCT01934101|DRUG|CHR-5154|CHR-5154
48376815|NCT01934101|DRUG|Placebo|Placebo
48376816|NCT01662076|OTHER|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
48019120|NCT03795844|PROCEDURE|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
48019121|NCT03795844|PROCEDURE|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
48019122|NCT03795844|PROCEDURE|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
48376817|NCT02228148|DEVICE|NFS|Cochlear Nucleus Fitting Software
48376818|NCT02228148|DEVICE|CSS|Cochlear Nucleus Custom SoundTM Suite
48376819|NCT05385510|BIOLOGICAL|R21/Matrix-M™|Adjuvanted malaria vaccine
48376820|NCT02628197|DIETARY_SUPPLEMENT|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
48376821|NCT02628197|PROCEDURE|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
48376822|NCT00892710|DRUG|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
48376823|NCT00892710|DRUG|Bevacizumab|15 mg/kg IV every 21 days
48376824|NCT00892710|DRUG|Carboplatin|AUC=5 IV every 21 days
48376825|NCT03541408|OTHER|Control|Standard Of Care without Preventative Delirium Protocol
48709440|NCT01839240|DRUG|azacitidine|Given IV or SC
48709441|NCT01839240|DRUG|cytarabine|Given IV
48709442|NCT01839240|DRUG|mitoxantrone hydrochloride|Given IV
48709443|NCT01839240|OTHER|laboratory biomarker analysis|Correlative studies
48709444|NCT03328169|BEHAVIORAL|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
48019123|NCT03795844|PROCEDURE|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
48019124|NCT05423509|OTHER|Dynamic myofascial manipulation|Dynamic myofascial manipulation of the muscles in the back to improve the scoliosis appearance/flexibility/rotation
48376826|NCT03541408|OTHER|Preventative Delirium Protocol|Preventative Delirium Protocol
48376827|NCT01583699|PROCEDURE|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
48376828|NCT01583699|DEVICE|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
48376829|NCT03792880|BEHAVIORAL|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
48376830|NCT03792880|BEHAVIORAL|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
48376831|NCT02340117|GENETIC|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
48376832|NCT02340117|DRUG|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
48709445|NCT03328169|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
48019125|NCT05423509|OTHER|Standard AIS treatment with observation or bracing|Observation with radiographs and bracing of curves greater than 20 degrees
48019126|NCT01312961|DRUG|Dupilumab|Solution for injection, one subcutaneous injection.
48019127|NCT01312961|DRUG|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
48019128|NCT01312961|DRUG|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
48019129|NCT01312961|DRUG|Fluticasone monotherapy|Oral inhalation twice daily.
48019130|NCT01312961|DRUG|Albuterol|Oral inhalation as needed.
48019131|NCT01312961|DRUG|Levalbuterol|Oral inhalation as needed.
48019132|NCT02041429|DRUG|Ruxolitinib|
48376833|NCT02340117|DRUG|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
48709446|NCT02545660|OTHER|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
48709447|NCT02545660|OTHER|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
48019133|NCT02041429|DRUG|Paclitaxel|
48709448|NCT04904796|OTHER|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
48709449|NCT04904796|OTHER|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
48019134|NCT01648777|DEVICE|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
48709450|NCT06605794|DEVICE|FreeFlow percutaneous atrial septal shunt|The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
48709451|NCT00367744|DRUG|Rosiglitazone|Rosiglitazone 4mg BID
48019135|NCT01648777|DRUG|placebo|"* Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
48019136|NCT00355875|PROCEDURE|titration of oxygen during resuscitation|
48517395|NCT03869944|DRUG|Lamivudine Oral Solution|"During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART."
48517396|NCT05545189|DIAGNOSTIC_TEST|colonoscopy,polypectomy|polyp removal during colonoscopy
48019137|NCT06040697|DEVICE|Thermal Anisotropy|Usability assessment observation.
48019138|NCT02841644|PROCEDURE|Operatively treated traumatic arthrotomy|operatively treated traumatic arthrotomy.
48517397|NCT03196843|DRUG|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
48517398|NCT03196843|RADIATION|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
48709452|NCT00367744|DRUG|Placebo|Placebo for rosiglitazone
48709453|NCT03419273|PROCEDURE|bariatric surgery|We are recruiting only those going through bariatric surgery
48019139|NCT02841644|OTHER|Non-operatively treated traumatic arthrotomy|non-operatively treated traumatic arthrotomy.
48019140|NCT00727389|BEHAVIORAL|Physiotherapy|Exercise two days a week for six month
48019141|NCT03526224|DRUG|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
48019142|NCT03526224|DRUG|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
48019143|NCT03082339|OTHER|Cortisone|Observation of QTc-interval
48019144|NCT03590977|OTHER|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
48019145|NCT03590977|OTHER|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
48019146|NCT00003335|BIOLOGICAL|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
48019147|NCT00003335|DRUG|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
48019148|NCT00003335|DRUG|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
48376834|NCT04179929|DRUG|Pediatric-type of chemotherapy|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
48376835|NCT04179929|PROCEDURE|allogeneic HSCT|allogeneic HSCT
48019149|NCT00003335|DRUG|melphalan|melphalan IV for three days on days -4 to -2
48376836|NCT02160184|DEVICE|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
48376837|NCT05186116|PROCEDURE|Living donor liver transplant, Split liver transplant, RAPID, DDLT|Transplantation of part of the liver from a living donor, or entire cadaveric graft
48376838|NCT01660152|OTHER|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
48376839|NCT01660152|PROCEDURE|management of therapy complications|Receive VED
48019150|NCT00003335|DRUG|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
48019151|NCT00003335|PROCEDURE|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
48019152|NCT00003335|RADIATION|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
48019153|NCT06572904|DRUG|Tenoxicam Injectable Product|(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)
48019154|NCT06572904|DRUG|Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly|\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)
48019155|NCT03927157|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
48019156|NCT03927157|OTHER|Placebo|Placebo subcutaneous injection
48019157|NCT03265405|DRUG|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
48709454|NCT05731076|BEHAVIORAL|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
48376840|NCT01660152|PROCEDURE|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
48376841|NCT02401724|OTHER|Transcranial direct current stimulation|
48376842|NCT02401724|OTHER|Action Training|
48019158|NCT03265405|DRUG|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
48019159|NCT05460624|OTHER|Egg-containing breakfast|Involves participants eating six premade egg-containing breakfast meals per week for 12 weeks. Each meal contains 2 eggs to provide 12 eggs per week.
48376843|NCT00210366|DRUG|Idarubicin|
48376844|NCT03741816|DRUG|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
48709455|NCT03733028|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
48019160|NCT05460624|OTHER|Typical American-style breakfast excluding eggs|Involves participants eating six premade egg-excluding breakfast meals per week for 12 weeks. Breakfast meals are matched to the intervention egg-containing breakfast meals on total energy and saturated fat and to the 'What We Eat in America' on percent energy from macronutrients.
48376845|NCT04656249|DRUG|Lenvatinib|Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
48376846|NCT01195662|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
48376847|NCT01195662|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
48376848|NCT02602470|DRUG|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
48376849|NCT02602470|DRUG|Azelaic Acid Cream|Azelaic Acid Cream 20%
48376850|NCT02602470|DRUG|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
48376851|NCT02602470|DRUG|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
48517399|NCT05190939|DIAGNOSTIC_TEST|water as bladder distending media|water will be used for bladder dissension during cystoscopy
48709456|NCT03733028|BEHAVIORAL|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
48709457|NCT02319161|DRUG|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
48709458|NCT00177567|DRUG|lithium carbonate|
48019161|NCT02760238|OTHER|Observational|
48376852|NCT02602470|DRUG|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
48019162|NCT02691858|DRUG|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
48019163|NCT02691858|DRUG|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
48019164|NCT04754581|OTHER|Maximal ATP Production (ATPmax)|ATPmax will be measured in order to determine in vivo mitochondrial capacity. The magnetic resonance scans to measure mitochondrial energetics will also be performed.
48019165|NCT04754581|OTHER|Exercise Testing (VO2max)|Aerobic fitness level will be assessed while participant pedals on a stationary bicycle/walk on a treadmill. The volume of oxygen intake and carbon dioxide (CO2) production will be measured.
48019166|NCT04754581|PROCEDURE|Muscle Biopsy|Sample muscle cells from the left leg Vastus Lateralis (thigh) muscle.
48019167|NCT04754581|PROCEDURE|Adipose Tissue Biopsy|Sample fat tissue from the abdomen.
48019168|NCT04754581|OTHER|Hyperinsulinemic euglycemic clamp|Measurement of insulin sensitivity.
48019169|NCT04754581|OTHER|PET imaging|After an overnight fast, an intravenous catheter will be placed in each arm (one with arterial line for PET infusion, and the other for infusion of insulin, glucose, and 6,6 D2 glucose tracer. FDG-glucose will be injected followed by 90-minute PET scanning of the thigh.
48019170|NCT05390866|OTHER|HIIT|A single HIIT on a bicycle ergometer
48019171|NCT03412643|DRUG|Doxorubicin|60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
48376853|NCT02602470|DRUG|Metronidazole Lotion|Metronidazole Lotion 0,75%
48376854|NCT02602470|DRUG|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
48376855|NCT01724723|DRUG|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
48376856|NCT01722058|DRUG|Peptide application|
48376857|NCT02729597|OTHER|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
48376858|NCT02729597|OTHER|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
48376859|NCT02729597|OTHER|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
48376860|NCT02729597|OTHER|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
48517400|NCT05190939|DIAGNOSTIC_TEST|intravenous dye|intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
48376861|NCT01504074|BEHAVIORAL|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
48709459|NCT00177567|DRUG|Depakote-ER|
48709460|NCT00177567|DRUG|risperidone|
48709461|NCT00177567|DRUG|olanzapine|
48709462|NCT00177567|DRUG|paroxetine|
48376862|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10\^ 7 TCID50 administered intramuscularly
48709463|NCT00177567|DRUG|bupropion|
48709464|NCT00177567|DRUG|lamotrigine|
48019172|NCT03412643|DRUG|Cyclophosphamide|600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
48376863|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1|0.6 mg administered intramuscularly
48376864|NCT00011037|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
48376865|NCT00011037|BIOLOGICAL|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
48376866|NCT01339273|PROCEDURE|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
48376867|NCT01339273|PROCEDURE|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
48376868|NCT01283802|PROCEDURE|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~1. Direct ultrasound exploration without any contrast agents.~2. IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~3. IOCUS injection of an air bolus into the bile duct."
48376869|NCT06325969|DIAGNOSTIC_TEST|Detect the immune function of peripheral blood samples|Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.
48376870|NCT00674882|OTHER|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
48019173|NCT03412643|DRUG|Weekly Paclitaxel|80 mg/m2 IV weekly for 12 doses
48376871|NCT02777554|DRUG|Apremilast IR|Apremilast immediate release tablet
48019174|NCT03412643|DRUG|Trastuzumab|loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4
48019175|NCT03412643|DRUG|Pertuzumab|loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4
48019176|NCT03412643|DIAGNOSTIC_TEST|Celcuity CELx HSF|Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
48376872|NCT02777554|DRUG|Apremilast XL|Apremilast extended release formulation tablet
48376873|NCT02549612|DEVICE|Moniri Otovent|Please see arm description.
48376874|NCT02566629|OTHER|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
48376875|NCT03948321|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
48376876|NCT00701012|PROCEDURE|preservation of nerve fibers around IMA|low ligation
48376877|NCT00701012|PROCEDURE|resection of nerve fibers around IMA|high ligation
48376878|NCT02029729|DRUG|omaveloxolone|
48376879|NCT06409741|PROCEDURE|Biliary sphincterotomy|"ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up."
48376880|NCT05623189|DRUG|HTD1801|HTD1801,1250 mg, BID
48376881|NCT05623189|DRUG|Placebo|Placebo, BID
48376882|NCT05628337|OTHER|Motivational texting|Health related information relevant to a subject's diagnosis and ongoing treatment
48376883|NCT05628337|OTHER|Control|Non-motivational text messages containing no specific health information
48709465|NCT00177567|DRUG|venlafaxine|
48709466|NCT00177567|DRUG|tranylcypromine|
48709467|NCT00177567|DRUG|mirtazapine|
48709468|NCT04385641|OTHER|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
48709469|NCT04385641|OTHER|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
48709470|NCT02434354|DRUG|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
48709471|NCT04728152|OTHER|Blood and salivar test|"Saliva samples will be taken (concomitant with a visit carried out as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks).~Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks)."
48709472|NCT05290987|DEVICE|nasal spray|2 sprays in each nostril, 6 times a day
48709473|NCT03090386|OTHER|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
48709474|NCT04493684|DRUG|GSK3739937 (PIB)|GSK3739937 will be administered as oral suspension.
48709475|NCT04493684|DRUG|Placebo|Placebo will be given orally during each dosing day.
48709476|NCT04493684|DRUG|GSK3739937 (Tablet)|GSK3739937 Tablet will be administered via oral route.
48709477|NCT02198599|PROCEDURE|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
48709478|NCT03305419|DRUG|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
48709479|NCT03305419|DRUG|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
48709480|NCT05344352|DIETARY_SUPPLEMENT|Multistrain Probiotic|8-week daily administration
48709481|NCT05344352|OTHER|Placebo|8-week daily administration
48709482|NCT06305936|OTHER|Intervention with 100% plant-based diet|The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
48176223|NCT05999565|OTHER|Motor Imagery Exercises|"Lateralization Training: Individuals with cervical discogenic pain will receive lateralization training using a mobile application called Recognize Neck from the Neuro Orthopaedic Institute in Adelaide, Australia.~Kinesthetic Imagery: During this training, individuals will be asked to actively perform exercises and feel the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to imagine the positions of their bodies, the surface they are on, and the desired postures.~Visual Imagery: Individuals will be asked to actively perform exercises and visualize the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to mentally visualize their body positions, the surface they are on, and the exercises.~Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises in front of a mirror."
48709483|NCT06300723|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
48376884|NCT04344158|DRUG|AK105 Injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
48376885|NCT04344158|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
48376886|NCT04344158|DRUG|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
48376887|NCT02042807|DRUG|Placebo|
48709484|NCT04077866|DRUG|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
48709485|NCT04077866|BIOLOGICAL|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
48709486|NCT06606288|DEVICE|Conduction system pacing|Implant with a Medtronic dual-chamber transvenous pacemaker on or after the study data with lead type and placement data indicating conduction system pacing
48709487|NCT06606288|DEVICE|Bi-ventricular pacing|Implant with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study date
48709488|NCT01696617|DRUG|Aripiprazole 6-week group|
48709489|NCT01696617|DRUG|Aripiprazole 8-week group|
48709490|NCT01410669|BEHAVIORAL|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
48019177|NCT04261816|PROCEDURE|extubation in the operating room|Patients who underwent liver transplantation early extubation in the operating room immediately following liver transplantation
48019178|NCT04261816|PROCEDURE|extubation in the ICU|Patients who underwent liver transplantation extubation in the ICU following liver transplantation
48376888|NCT02042807|DRUG|MCS®|
48376889|NCT01035021|DRUG|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
48376890|NCT04689334|OTHER|Outcome|The number of surgeries
48019179|NCT02778529|DEVICE|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
48376891|NCT03808298|DRUG|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days
48376892|NCT03808298|DRUG|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
48376893|NCT03808298|DRUG|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
48376894|NCT03808298|DRUG|Active control [Moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
48376895|NCT03808298|DRUG|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
48376896|NCT03808298|DRUG|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
48709491|NCT05799989|PROCEDURE|Surgical fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with surgical fixation
48709492|NCT05799989|PROCEDURE|Atraumatic fixation|Pediatric patients with intravenous and/or intraarterial catheter in situ secured with atraumatic fixation
48709493|NCT01766492|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
48709494|NCT03128268|DEVICE|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
48376897|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
48376898|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
48709495|NCT01994863|DEVICE|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
48709496|NCT01994863|DEVICE|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
48709497|NCT01616940|BEHAVIORAL|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact."
48709498|NCT03457506|DIAGNOSTIC_TEST|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
48709499|NCT03773133|DRUG|Satoreotide tetraxetan|Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).
48709500|NCT03773133|DRUG|Satoreotide trizoxetan|Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
48709501|NCT01146652|DRUG|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48709502|NCT01456195|DRUG|Placebo|Fasiglifam placebo-matching tablets
48709503|NCT01456195|DRUG|Fasiglifam|Fasiglifam tablets
48709504|NCT01571128|OTHER|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
48709505|NCT01571128|OTHER|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
48709506|NCT01571128|DRUG|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
48709507|NCT01571128|BEHAVIORAL|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
48709508|NCT03651856|DRUG|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
48376899|NCT03808298|DRUG|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
48376900|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
48517401|NCT05190939|DIAGNOSTIC_TEST|No intervention|Saline only, no dye
48709509|NCT05596617|DRUG|Oral bedtime melatonin|Different doses of oral bedtime melatonin
48709510|NCT01869361|DRUG|Indomethacin|Study drug
48709511|NCT01869361|DRUG|Placebo|Control drug
48709512|NCT05192629|DRUG|Dexmedetomidine|Premedication by intranasal dexmedetomidine
48709513|NCT05192629|DRUG|Midazolam|Premedication by intranasal midazolam
48709514|NCT05362591|PROCEDURE|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
48709515|NCT05362591|PROCEDURE|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
48709516|NCT00183378|BEHAVIORAL|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
48376901|NCT03808298|DRUG|Placebo for Moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
48376902|NCT03808298|DRUG|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
48376903|NCT01714726|DRUG|MEDI2070|1 iv infusion on Week 0 and Week 4
48376904|NCT01714726|DRUG|placebo|1 iv infusion on Week 0 and Week 4
48709517|NCT00183378|BEHAVIORAL|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
48709518|NCT00183378|BEHAVIORAL|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
48176224|NCT05999565|OTHER|Motor Control Exercises|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
48176225|NCT04353206|BIOLOGICAL|Multiple Doses of Anti-SARS-CoV-2 convalescent plasma|Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.
48176226|NCT00165334|DRUG|Cetuximab|
48176227|NCT00165334|DRUG|Vinorelbine (Navelbine)|
48176228|NCT01775293|DEVICE|Non-absorbable polypropylene mesh|"2 step procedures~* first step is insertion of Non-absorbable polypropylene mesh under the facial skin~* second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
48176229|NCT05400252|BEHAVIORAL|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
48176230|NCT05400252|BEHAVIORAL|Health and Wellness|Health \& Wellness is an educational wellness intervention
48176231|NCT03700372|DEVICE|IOWA Approach Cardiac Ablation System|Epicardial ablation using the IOWA Approach Cardiac Ablation System
48176232|NCT00889967|DRUG|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
48176233|NCT00889967|DRUG|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
48376905|NCT03444129|BEHAVIORAL|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
48176234|NCT00889967|DRUG|Placebo|Placebo once daily by inhalation for 28 days
48176235|NCT05864118|DIAGNOSTIC_TEST|Respiratory pathogen panel PCR test|Respiratory pathogen panel PCR test and COVID-19 antibody test.
48176236|NCT05864118|DIAGNOSTIC_TEST|COVID-19 antibody test|COVID-19 antibody test
48176237|NCT02985047|OTHER|Brief Admission|Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
48176238|NCT03349411|DIAGNOSTIC_TEST|Confusion Assessment Method|This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.
48176239|NCT03349411|DIAGNOSTIC_TEST|Behavioral Inattention Test|This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
48176240|NCT03349411|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.
48176241|NCT03349411|DIAGNOSTIC_TEST|Florida Mental Status Examination|This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.
48376906|NCT03444129|BEHAVIORAL|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
48376907|NCT04131452|OTHER|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
48709519|NCT00183378|BEHAVIORAL|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
48709520|NCT01430507|DRUG|Revamilast|Tablet, Low dose, Once daily for 12 weeks
48709521|NCT01430507|DRUG|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
48709522|NCT01430507|DRUG|Revamilast|Tablet, High dose, Once daily for 12 weeks
48709523|NCT01430507|DRUG|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
48709524|NCT00221806|DEVICE|endothelialised prosthesis|
48709525|NCT00278902|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
48709526|NCT00427531|OTHER|physiologic testing|
48709527|NCT03723174|BEHAVIORAL|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
48709528|NCT05469789|OTHER|No Intervention|As it is an observational study, no intervention is administered in this study.
48376908|NCT04661865|OTHER|Health Information Package Program (HIP program )|"Fifteen minutes PowerPoint presentation will be introduced to women to increase women's educational experience and raise their level of engagement and commitment.~The principal investigator will narrate the video record with PowerPoint slides and it was recorded as a video and will include information regarding the introduction to pregnancy, causes and predisposing factors of iron deficiency anemia during pregnancy, signs and symptoms, prevention, management of iron deficiency anemia during pregnancy that includes iron therapy, iron supplementation, dietary management. Content validity for the information in the video will be done by sending it to three experts in maternity nursing. Iron supplementation will be given to all participants who will start by sixteen weeks of pregnancy and they will receive information regarding the proper usage of iron supplements."
48376909|NCT04163419|DRUG|Tanezumab|Tanezumab 10 mg SC
48376910|NCT04163419|DRUG|Placebo|Placebo 10 mg SC
48376911|NCT03414099|DRUG|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
48376912|NCT03414099|DRUG|Placebo|Placebo drink matched for taste and appereance
48709529|NCT06605131|DRUG|GP+Toripalimab+CCRT|"1. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
48517402|NCT06265194|BEHAVIORAL|EMDR|The fibromyalgia protocol applied to the patients in the study was developed specifically for fibromyalgia by Konuk, and colleagues (Konuk et al.). In addition to the article, the details of the protocol and the study sheet are presented supplementary. After a short introduction, the participants were informed about the protocol, their -consent was obtained for registration, and a visual, tactile and audio bilateral stimulus that will be used in the application was introduced.
48709530|NCT06605131|DRUG|GP+CCRT|"1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
48376913|NCT00457795|DRUG|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
48376914|NCT04984304|BEHAVIORAL|Lifestyle modifications and Antireflux diet|Patients in Arm 1 - mild cough only slightly worsening the quality of life (VAS 1-3) will undergo treatment using lifestyle modifications and an Antireflux diet for 3 months.
48376915|NCT04984304|DIAGNOSTIC_TEST|Extraesophageal reflux diagnostic|Patients in Arm 2 - moderate and severe cough that significantly worsen the quality of life (VAS 4-10) will undergo extraesophageal reflux diagnostics consisting of esophageal 24-hour pH/Impedance Reflux Monitoring and peptest study on fasting
48709531|NCT01291693|BEHAVIORAL|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
48709532|NCT01291693|BEHAVIORAL|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
48376916|NCT01297738|OTHER|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
48709533|NCT04509245|BEHAVIORAL|Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone|During the 12-week intervention participants were asked to adhere to a real food-based low-calorie diet supported by an app-guided digital education program as well as a low-calorie recipe book and received weekly coaching calls by nutritionists
48376917|NCT01297738|OTHER|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
48376918|NCT01297738|OTHER|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
48376919|NCT01297738|OTHER|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
48517403|NCT06265194|BEHAVIORAL|TAU|Treatment as Usual (TAU): Routine fibromyalgia treatments, referred to as Treatment as Usual (TAU) in this study, were initiated in the outpatient clinic conditions. TAU are treatments designed by rheumatologists in accordance with current rheumatology guidelines.
48176242|NCT03349411|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.
48709534|NCT04349748|BEHAVIORAL|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
48176243|NCT03349411|DIAGNOSTIC_TEST|Geriatric Depression Scale|Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.
48376920|NCT05729035|RADIATION|POCUS|Point of Care Ultrasound is complementary to a medical examination performed by primary care physicians
48376921|NCT04909879|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
48376922|NCT04909879|DRUG|Placebo|Excipient solution
48376923|NCT05897411|BEHAVIORAL|Unmasking previous conditioning procedure|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
48709535|NCT04349748|BEHAVIORAL|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
48709536|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Physics Forceps|Extraction of mandibular molars using physics forceps
48709537|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Conventional Forceps|Extraction of mandibular molars using conventional forceps
48709538|NCT01371253|OTHER|Nintendo wii balance training|
48709539|NCT01371253|OTHER|EVA-soles|
48709540|NCT02279849|OTHER|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
48709541|NCT02279849|OTHER|Pricing|The pricing incentives were used to help promote sales of healthier food items.
48709542|NCT02279849|OTHER|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
48709543|NCT01185964|BIOLOGICAL|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
48709544|NCT01185964|DRUG|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
48709545|NCT04666831|BEHAVIORAL|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
48709546|NCT03349424|DRUG|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
48709547|NCT03508193|OTHER|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
48709548|NCT01007071|DRUG|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
48709549|NCT01007071|DRUG|Placebo|Subjects randomized to placebo
48709550|NCT01323270|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
48709551|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
48709552|NCT01323270|BIOLOGICAL|Saline|0.5 mL dose, given at 0, 2 and 6 months.
48709553|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
48709554|NCT00597363|DEVICE|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
48709555|NCT00597363|OTHER|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
48709556|NCT03100812|BEHAVIORAL|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
48709557|NCT03100812|BEHAVIORAL|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
48709558|NCT05888961|BIOLOGICAL|Blood samples|"Fasting at the first session for hormonal measurements of leptin, insulin, acylated and non-acylated ghrelin, serotonin, albumin, protidemia and blood glucose.~Repeated at 6 and 12 months for follow-up"
48709559|NCT05888961|OTHER|Interviewing the subject and scales|"Collection of sociodemographic data, personal and family neurological history, treatments, MADRS depression scale and CDR autonomy scale.~Carried out at the 1st session"
48709560|NCT05888961|OTHER|Neurocognitive evaluation|cognitive complaint questionnaire (CCQ), taste, smell, MoCA and MMSE (if not performed in the previous 6 months) Carried out at the 1st session. Repeated at 6 and 12 months for follow-up.
48709561|NCT05888961|OTHER|Taste tests|"Sweet and salty flavors at the 1st session and acid and umami flavors at the 2nd session. Repeated at 6 and 12 months for follow-up.~Placement of electrodes on the scalp, recording of gustatory evoked potentials, subjective gustatory evaluation by means of visual analogue scales rated from 0 to 10, identification and naming of each of the primary flavors"
48709562|NCT05888961|OTHER|Computerized food preference questionnaires|Performed at the 1st session on a tactile tablet. Repeated at 6 and 12 months for follow-up.
48709563|NCT05888961|OTHER|Nutritional status - body composition|Measurement of anthropometric data, bioelectrical impedancemetry (measurement of fat mass, lean mass, water mass and bone mass in kg), measurement of blood pressure and heart rate Performed at the 2nd session Repeated at 6 and 12 months for follow-up.
48709564|NCT05235347|BIOLOGICAL|Sotrovimab|500mg IV
48709565|NCT00712530|BIOLOGICAL|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
48709566|NCT00712530|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
48176244|NCT03349411|DIAGNOSTIC_TEST|Kessler Foundation Neglect Assessment Process|This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
48709567|NCT05737420|DIAGNOSTIC_TEST|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
48709568|NCT05562180|BEHAVIORAL|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
48176245|NCT00983892|BEHAVIORAL|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
48176246|NCT04211311|OTHER|hybrid high-intensity training|FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
48709569|NCT03496350|BEHAVIORAL|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
48709570|NCT02282800|GENETIC|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
48176247|NCT01192776|PROCEDURE|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
48176248|NCT05467345|DEVICE|Contour Next and Contour Plus Elite BGMS testing of neonatal blood|The purpose of this study is to extend the intended use of two BGMSs to include testing of neonatal blood by Health Care Professionals in a clinical setting for the quantitative measurement of glucose levels in neonates.
48176249|NCT00083330|DRUG|VRC-HIVADV014-00-VP|
48176250|NCT00169845|DIETARY_SUPPLEMENT|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
48176251|NCT00169845|DIETARY_SUPPLEMENT|Placebo|Provided by Roche Vitamins Inc
48176252|NCT00002498|DRUG|CMF regimen|
48176253|NCT00002498|DRUG|cyclophosphamide|
48176254|NCT00002498|DRUG|fluorouracil|
48176255|NCT00002498|DRUG|methotrexate|
48176256|NCT00002498|DRUG|mitoxantrone hydrochloride|
48176257|NCT02335645|OTHER|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
48176258|NCT02660268|OTHER|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
48176259|NCT02759796|PROCEDURE|Tailoring the flap according to clinical assessment|After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
48176260|NCT02759796|PROCEDURE|Tailoring the flap according to ICG Angiography assessment|After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
48709571|NCT04111016|BEHAVIORAL|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
48176261|NCT02080377|DRUG|Glibenclamide|
48176262|NCT02080377|DRUG|Insulin|
48176263|NCT01518088|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to study foods
48176264|NCT05243615|BEHAVIORAL|Guided internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
48376924|NCT05897411|BEHAVIORAL|No unmasking of previous conditioning|An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
48376925|NCT01403636|DRUG|SAR245409|Pharmaceutical form:capsule Route of administration: oral
48176265|NCT05243615|BEHAVIORAL|Stroke rehabilitation mental health education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
48176266|NCT04016805|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion"
48176267|NCT04016805|DRUG|Umbralisib|"* Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis"
48376926|NCT05953610|DRUG|Acetazolamide 500 MG QHS|Acetazolamide
48376927|NCT05953610|DRUG|Eszopiclone 3 mg QHS|Eszopiclone
48376928|NCT00219349|BEHAVIORAL|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
48376929|NCT00219349|DRUG|escitalopram|10-20 mg per day for 12 weeks
48376930|NCT04411030|DRUG|ASTX660|Form: capsule; Route of administration: oral
48376931|NCT04411030|DRUG|Midazolam|Form: syrup; Route of administration: oral
48376932|NCT04411030|DRUG|Itraconazole|Form: capsule; Route of administration: oral
48376933|NCT04243811|DEVICE|Diode Laser|LLLT with dental needle for local anesthesia during dental treatment
48376934|NCT04243811|OTHER|topical anesthesia|topical anesthesia with dental needle for local anesthesia during dental treatment
48709572|NCT04216368|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
48709573|NCT04216368|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
48019180|NCT04155320|BEHAVIORAL|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
48019181|NCT04155320|BEHAVIORAL|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
48019182|NCT00997997|DRUG|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
48019183|NCT06381986|DRUG|SHJ002|Topical ophthalmic
48019184|NCT06381986|OTHER|Vehicle|Topical ophthalmic
48019185|NCT03169153|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
48019186|NCT03169153|DEVICE|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
48019187|NCT04079855|OTHER|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
48709574|NCT03764917|OTHER|Time|Different detecting time
48176268|NCT04016805|DRUG|Ibrutinib|"* Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis"
48176269|NCT04016805|DRUG|Venetoclax|"* BCL-2 inhibitor~* Tablet form, to be taken orally"
48176270|NCT04016805|DRUG|Acalabrutinib Oral Capsule|Kinase inhibitor, capsule form, to be taken orally
48176271|NCT01101061|DRUG|Romosozumab|Administered by subcutaneous injection
48176272|NCT01101061|DRUG|Placebo|Administered by subcutaneous injection
48176273|NCT04547621|DEVICE|Radiation|Intensity-modulated radiotherapy 20Gy/10fx
48176274|NCT04547621|DEVICE|Radiation|Hypofractionated Stereotactic Radiotherapy 30Gy/5fx
48176275|NCT04547621|DRUG|Temozolomide|Temozolomide 75 mg/m2 concurrently administered with RT.
48176276|NCT05051215|OTHER||
48376935|NCT03194594|DRUG|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
48376936|NCT03445325|BEHAVIORAL|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
48376937|NCT03077854|RADIATION|Functional Lung Avoidance Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
48176277|NCT03235362|DRUG|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
48176278|NCT03235362|DRUG|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
48176279|NCT03235362|DRUG|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
48176280|NCT00199160|DRUG|BAY 43-9006|
48176281|NCT05367206|DRUG|Albumin-Bound Paclitaxel|260mg/m2 q3w \*2 circles
48176282|NCT05367206|DRUG|Carboplatin|AUC 5-6 q3w \* 2 circles
48176283|NCT02928211|DEVICE|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
48176284|NCT02928211|DRUG|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
48176285|NCT02928211|RADIATION|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
48176286|NCT05887206|OTHER|Collection of datas|The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
48176287|NCT04733898|OTHER|SamenSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to elicit personal interaction.
48176288|NCT04733898|OTHER|FijnSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to not elicit personal interaction.
48709575|NCT04591548|DIAGNOSTIC_TEST|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
48709576|NCT03009708|OTHER|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
48176289|NCT01309477|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
48019188|NCT04079855|OTHER|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
48176290|NCT04067349|OTHER|Ergometry|"Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively."
48019189|NCT04079855|OTHER|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
48176291|NCT04492137|PROCEDURE|Cannulation technique|"Participants in the ultra early NKF group will be submitted to 2 standard cannulation attempts (2 contacts with the papilla) before starting NKF. If any of these 2 attemps is successful, NKF won't take place. If NKF is indeed performed and cannulation is not achieved within 8 minutes, the endoscopist is free to perform techniques other than NKF. On the other hand, participants in the standard cannulation group in which cannulation is not achieved within 8 minutes can cross-over to other advanced cannulation techniques (e.g. NKF). For ethical reasons we choose to exclude flat and intradiverticular/diverticular border papillas.~During ERCP all participants will be submitted to PEP prophylaxis with rectal indomethacin. A pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct.~For the purposes of the study, a dedicated form (attached) will be created with the various variables to be analyzed"
48176292|NCT02530398|DRUG|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
48176293|NCT01946555|DRUG|Morphine|
48709577|NCT02307292|DEVICE|POLARIS Peripheral Vascular Self Expanding Stent System|
48019190|NCT02685163|OTHER|Antioxidant ice-cream|Narutal Antioxidant ice-cream
48019191|NCT02685163|OTHER|Control Ice-cream|Natural Control Ice-cream
48019192|NCT01950143|DIETARY_SUPPLEMENT|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
48176294|NCT01946555|DRUG|Fentanyl|
48376938|NCT03077854|RADIATION|Standard Thoracic Radiotherapy|"* Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~* Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~* Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
48176295|NCT01946555|DRUG|Methadone|
48176296|NCT01946555|DRUG|Buprenorphine|
48176297|NCT01946555|DRUG|Oxycodone|
48176298|NCT01946555|DRUG|Hydromorphone|
48176299|NCT01946555|DRUG|Tapentadol|
48176300|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
48176301|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
48376939|NCT03096106|DEVICE||the investigators just observe the pressure time curve on the ventilation
48376940|NCT04555798|DRUG|Meropenem Injection|patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture
48376941|NCT04555798|DEVICE|A-V ECMO|Only patients of group B connected to A-V ECMO for two weeks
48376942|NCT06214429|DIAGNOSTIC_TEST|Vascular Ultrasound|Complete vascular ultrasound routine in B mode, color mode and Doppler.
48376943|NCT06214429|DIAGNOSTIC_TEST|Shear Wave Elastography|Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
48376944|NCT06214429|DIAGNOSTIC_TEST|Greyscale Median|Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
48376945|NCT06214429|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Assessment of the plaque and carotid residual lumen by magnetic resonance.
48376946|NCT06214429|DIAGNOSTIC_TEST|Histopathology|Histopathology findings for patients that undergo carotid endarterectomy.
48376947|NCT05467995|BIOLOGICAL|AK111|AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
48376948|NCT05467995|BIOLOGICAL|Placebo|Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
48176302|NCT03796208|BEHAVIORAL|Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)|Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).
48376949|NCT05116410|DRUG|HS-20094|Administrated SC
48376950|NCT05116410|DRUG|Placebo|Administrated SC
48376951|NCT03093129|DRUG|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
48376952|NCT03093129|OTHER|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
48376953|NCT01387958|DRUG|LCQ908|
48376954|NCT01387958|DRUG|Placebo|
48709578|NCT05526976|OTHER|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus \& Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
48019193|NCT01950143|DIETARY_SUPPLEMENT|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
48019194|NCT01950143|DIETARY_SUPPLEMENT|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
48019195|NCT02192684|DRUG|Pioglitazone|45 mg daily Insulin sensitizing
48019196|NCT02192684|DRUG|placebo|Compare with pioglitazone
48019197|NCT01194297|BIOLOGICAL|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
48019198|NCT01194297|BIOLOGICAL|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
48019199|NCT02629146|DRUG|Midazolam|
48019200|NCT02629146|DRUG|Fentanyl|
48019201|NCT02629146|DRUG|Isotonic saline|
48376955|NCT04177862|DRUG|Sublingual Sufentanil|30 mcg of sublingual sufentanil
48376956|NCT04177862|DRUG|IV Fentanyl|50 mcg of IV fentanyl
48376957|NCT00346970|DRUG|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
48376958|NCT00346970|DRUG|Placebo|Placebo tablets
48376959|NCT03156426|OTHER|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
48376960|NCT00993941|PROCEDURE|Autologous BMSCs transplantation|10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
48376961|NCT00993941|DRUG|Conserved therapy|Oral or intravenous administration
48376962|NCT01232764|OTHER|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
48376963|NCT02027831|DRUG|Indocyanine Green|
48376964|NCT02249546|DRUG|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
48376965|NCT02249546|DRUG|PPI-amoxicillin-clarithromycin|Triple therapy
48376966|NCT04787575|PROCEDURE|Oxygen-ozone therapy|"Oxygen-ozone therapy (group a) will be performed by:~i) Self-haemoinfusion of 200 cc. with concentrations of 40-50 μg/ml, to be performed two/three times a week, for a time of 6 weeks (for a maximum of 15 sessions); ii) Subcutaneous injections in the perilesional site at the dose of 5 cc. with concentrations of 4 μg,/ml, Cleanse wounds with 100 cc of 5-10 ug ozone gas"
48376967|NCT06135272|DRUG|Resin infiltration|Icon Resin Infiltration as minimally invasive technique
48376968|NCT06135272|DRUG|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish as minimally invasive technique
48376969|NCT06135272|DRUG|Light cured giomer varnish|Light cured giomer varnish as minimally invasive technique
48376970|NCT01317199|DRUG|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
48376971|NCT01317199|DRUG|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
48376972|NCT01317199|DRUG|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
48376973|NCT01317199|DRUG|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
48709579|NCT00693017|DRUG|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
48709580|NCT00693017|DRUG|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
48709581|NCT05502159|DRUG|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
48709582|NCT05502159|DRUG|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
48709583|NCT02334683|DEVICE|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
48709584|NCT02334683|DEVICE|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
48709585|NCT00867087|DRUG|inotuzumab ozogamicin (CMC-544)|1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
48019202|NCT06460623|OTHER|external mobilization|two 5-minute sessions of external manipulation per week over a 5-week period.
48709586|NCT00867087|DRUG|rituximab|375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
48709587|NCT06201793|DRUG|Mesalazine|Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
48709588|NCT06201793|DRUG|Minocycline|Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
48709589|NCT00898924|GENETIC|molecular diagnostic method|
48709590|NCT00898924|GENETIC|mutation analysis|
48709591|NCT05432388|DRUG|remibrutinib|oral tablets
48709592|NCT05432388|DRUG|placebo|oral tablets
48709593|NCT06287593|OTHER|ctDNA monitoring|Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
48019203|NCT06460623|OTHER|rectal coccygeal mobilization|consisted of two 5-minute sessions of external manipulation per week over a 5-week period.
48019204|NCT05244525|DRUG|Bupivacaine with Epinephrine|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Study patients will receive an injection containing a total volume of 20 mL of bupivacaine with epinephrine (0.3 mL epinephrine in 30 mL of 0.5% bupivacaine).The syringe will not be labeled, and the contents of the injection will not be disclosed to the surgeon to preserve blinding. The injection will be performed with an 18-gauge needle into the subacromial space via a posterior or lateral approach after positioning the patient in the beach chair position, but prior to prepping and draping.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale. Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
48376974|NCT02119858|DRUG|indocyanine green solution|Given transperineally
48376975|NCT02119858|OTHER|diffuse optical imaging|Undergo near infrared fluorescence imaging
48376976|NCT02119858|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
48376977|NCT02119858|PROCEDURE|therapeutic lymphadenectomy|Undergo lymphadenectomy
48376978|NCT01825421|OTHER|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
48376979|NCT01595399|DRUG|atropine|Atropine 0.02 mg/kg IV
48376980|NCT01595399|DRUG|Placebo|an equivalent volume of normal saline to atropine IV
48376981|NCT05053594|DRUG|Neostigmine 10 mcg/kg|Once the third response to TOF is obtained, neostigmine 10 mcg/kg will be administered
48376982|NCT05053594|DRUG|Neostigmine 20 mcg/kg|Once the third response to TOF is obtained, neostigmine 20 mcg/kg will be administered
48376983|NCT05053594|DRUG|Neostigmine 30 mcg/kg|Once the third response to TOF is obtained, neostigmine 30 mcg/kg will be administered
48376984|NCT05053594|OTHER|Placebo|Once the third response to TOF is obtained, saline will be administered
48376985|NCT02307695|DRUG|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
48376986|NCT02307695|DRUG|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
48376987|NCT05709392|PROCEDURE|Delayed cord clamping and early skin-to-skin contact|A new method for taking care of remature infants born in gestational weeks 30+0-34+6 will be introduced with delayed cord clamping and early skin-to-skin-contact with a parent. If the infant needs help with the breathing this can be given during the time when the cord is still intact.
48376988|NCT06363227|PROCEDURE|Standardized pain management|multimodal postoperative pain protocol
48709594|NCT01463930|BEHAVIORAL|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
48709595|NCT01463930|BEHAVIORAL|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
48376989|NCT03796572|DRUG|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
48376990|NCT03796572|OTHER|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
48376991|NCT03323021|OTHER|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
48376992|NCT03323021|OTHER|Standard of Care|Standard of Care
48376993|NCT03225950|OTHER|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
48376994|NCT03225950|DIAGNOSTIC_TEST|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
48376995|NCT03225950|GENETIC|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
48376996|NCT03225950|DIAGNOSTIC_TEST|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
48376997|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
48376998|NCT01551238|DIETARY_SUPPLEMENT|Differences in protein content of meals|Differences in protein content (energy percent) of meals
48376999|NCT02067728|BEHAVIORAL|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
48377000|NCT02067728|BEHAVIORAL|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
48377001|NCT03804554|OTHER|Non-Interventional|Non-Interventional
48709596|NCT01069861|DRUG|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
48019205|NCT05244525|DRUG|Bupivacaine alone|Randomization will be performed prior to surgery and group designation will be placed within an opaque envelope in the patient's chart.The circulating nurse will prepare the pre-operative injection. Control patients will receive an injection containing 20mL of 0.5% bupivacaine alone.Throughout the case, the mean arterial pressure of the patient will be monitored. At the conclusion of the surgical procedure, the surgeon will rate visual clarity on a visual analog scale.Changes in pump pressure from the initial pressure of 35mmHg during the surgical procedure will also be recorded.
48019206|NCT02885363|OTHER|Clinical examination|
48709597|NCT05027490|OTHER|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
48709598|NCT05027490|OTHER|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
48709599|NCT05027490|OTHER|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
48709600|NCT05027490|BEHAVIORAL|QVA Questionnaire|Food quality of life questionnaire
48019207|NCT02885363|OTHER|Blood sample|
48377002|NCT05912673|DEVICE|renal doppler|Toshiba Aplio ultrasound machine and renal resistive index will be measured (peak systolic velocity- end diastolic velocity/ peak systolic velocity
48377003|NCT01763125|OTHER|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
48377004|NCT06235034|OTHER|Diagnostic CT|radiotherapy will be designed on diagnostic CT. If plan is of sufficient quality, RT will be delivered to patient
48377005|NCT02249065|DRUG|Brimonidine|
48377006|NCT02226575|BEHAVIORAL|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
48377007|NCT03032939|PROCEDURE|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
48377008|NCT04899362|DEVICE|BB-RIC-D1/LAPUL Medical Devices Co, Ltd, China|The RIC consisted of 4 cycles of extremities ischemia (5-minute blood pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm. This intervention was undertaken twice a day for 7 days.
48377009|NCT04899362|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 3ml four times (at baseline and the first, seventh and eighth day of the study).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
48019208|NCT02885363|PROCEDURE|Echocardiography|
48377010|NCT04899362|DEVICE|dCA measurement|Serial measurements of dCA were performed at 10 days, baseline, 1st, 2ed, 4th, 7th, 8th, 10th, 14th, 21th and 35th of the study.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
48709601|NCT05027490|BEHAVIORAL|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
48709602|NCT05027490|BEHAVIORAL|Scratch & Snif Test|The Scratch \& Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
48709603|NCT05027490|BEHAVIORAL|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
48709604|NCT05027490|BEHAVIORAL|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
48709605|NCT05027490|BEHAVIORAL|Condiment questionnaire|This questionnaire used to assess condiments consumption
48709606|NCT05027490|BEHAVIORAL|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
48709607|NCT05027490|OTHER|Nutrition interview|This interview will be conducted by a dietician
48709608|NCT00493636|DRUG|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
48709609|NCT00493636|DRUG|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
48709610|NCT00493636|DRUG|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
48709611|NCT00493636|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
48709612|NCT05208086|DIAGNOSTIC_TEST|Detection of monoclonal component|Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
48709613|NCT06027333|BEHAVIORAL|inpatient rehabilitation|This is an uncontrolled observational study on patients undergoing usual care in pulmonary rehabilitation and care
48709614|NCT02425605|RADIATION|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
48019209|NCT03367533|DRUG|Ketamine|Intravenous ketamine
48019210|NCT03367533|DRUG|Perampanel|Oral perampanel (6 mg)
48377011|NCT03374709|DRUG|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
48709615|NCT02425605|DRUG|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
48709616|NCT05848700|DRUG|SEP-363856|SEP-363856 Tablet
48019211|NCT03367533|DRUG|Placebo|Oral placebo
48019212|NCT04243824|DRUG|Gallium 68 Macro-aggregated albumin|The radiotracer, Ga-68 MAA, will be administered prior to PET/MRI scan.
48019213|NCT02664038|BEHAVIORAL|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
48709617|NCT05848700|DRUG|Placebo|Placebo Tablet
48709618|NCT03638908|DRUG|Fluoxetine|
48019214|NCT02432365|DRUG|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
48709619|NCT00234481|DRUG|XL844|
48709620|NCT00585546|DRUG|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
48709621|NCT03589391|DEVICE|LOR measurement via device|The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
48019215|NCT02432365|DRUG|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
48019216|NCT02432365|PROCEDURE|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
48377012|NCT06439186|DRUG|Lidocain|Local anesthesia
48377013|NCT01590095|BEHAVIORAL|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age."
48019217|NCT06186388|DIAGNOSTIC_TEST|TEMPO iMOvifa|Screening test with 28 testing points
48019218|NCT03175042|DEVICE|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
48019219|NCT05535192|BEHAVIORAL|THRIVE|"The THRIVE Intervention will involve:~1) one in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study"
48019220|NCT05535192|BEHAVIORAL|Health Education Support Program|Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
48709622|NCT00058526|BIOLOGICAL|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
48709623|NCT00353431|DRUG|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
48709624|NCT05135858|DRUG|Glucarpidase|Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
48176303|NCT03796208|BEHAVIORAL|Treatment As Usual|Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
48709625|NCT05135858|DRUG|Methotrexate (MTX)|MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
48709626|NCT02839577|DRUG|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
48176304|NCT04732247|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
48709627|NCT02839577|DRUG|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
48176305|NCT04732247|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
48176306|NCT00927901|DRUG|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
48377014|NCT01590095|BEHAVIORAL|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
48019221|NCT01448759|OTHER|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
48176307|NCT00927901|DRUG|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
48176308|NCT00927901|DRUG|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
48709628|NCT00823992|DRUG|placebo|sc once weekly
48709629|NCT00823992|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
48019222|NCT00950638|DRUG|ARC1905|intravitreal injection
48176309|NCT00927901|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
48377015|NCT01590095|BEHAVIORAL|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
48709630|NCT02147223|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
48709631|NCT02147223|DIETARY_SUPPLEMENT|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
48709632|NCT06607393|DRUG|Pembrolizumab|
48019223|NCT04177524|DEVICE|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
48019224|NCT04177524|DEVICE|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
48709633|NCT06607393|DRUG|Pemetrexed|
48019225|NCT04177524|DEVICE|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
48019226|NCT04842240|PROCEDURE|Pre- or sub-pectoral implant based immediate breast reconstruction|All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.
48176310|NCT01586975|DRUG|Clopidogrel|Clopidogrel 75 mg QD
48176311|NCT01586975|DRUG|Aspirin 81 mg|Aspirin 81mg QD
48709634|NCT06607393|DRUG|Cisplatin|
48709635|NCT06607393|DRUG|Carboplatin|
48709636|NCT04704427|DEVICE|Non-invasive BCI training|In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
48709637|NCT04704427|OTHER|Traditional Physiotherapy protocol|In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
48176312|NCT01586975|DRUG|Aspirin >300 mg|Aspirin \>300 mg QD
48176313|NCT00890890|DRUG|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
48176314|NCT00890890|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
48176315|NCT01849445|PROCEDURE|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
48176316|NCT01849445|OTHER|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
48176317|NCT01284712|BIOLOGICAL|blood sample|blood sample coming from therapeutic bleeding in hospital
48176318|NCT04488861|OTHER|Non-interventional cohort study|Non-interventional cohort study
48176319|NCT00450398|DRUG|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
48709638|NCT03042377|OTHER|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
48709639|NCT03042377|DRUG|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
48709640|NCT03042377|DRUG|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.
48709641|NCT03042377|DRUG|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
48019227|NCT04488276|OTHER|In-depth interviews|In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
48019228|NCT06493370|DRUG|Intravenous ascorbic acid/vitamin C|A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
48019229|NCT04394351|DRUG|Dupilumab|Single-use, prefilled syringe
48019230|NCT04394351|DRUG|Matching Placebo|Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
48019231|NCT03676049|DRUG|Cannabidiol|CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
48019232|NCT05433883|PROCEDURE|sleep surgery|Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
48019233|NCT01014494|DEVICE|Adaprev|Class III Medical Device
48019234|NCT04972435|DIAGNOSTIC_TEST|Contrast sensitivity|All subjects performed the contrast sensitivity measurement preoperatively and one time at 2 months postoperatively.
48019235|NCT06662877|DRUG|Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib|Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W
48019236|NCT06662877|DRUG|Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)|Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
48019237|NCT04666649|DRUG|Venetoclax and pegcrisantaspase|Therapeutic
48019238|NCT06533306|PROCEDURE|Surgery for cryptorchidism.|Patients previously operated on for cryptorchidism.
48019239|NCT04989257|DRUG|Ticagrelor-based dual-antiplatelet therapy|Aspirin with ticagrelor
48019240|NCT04989257|DRUG|Clopidogrel-based dual-antiplatelet therapy|Aspirin with clopidogrel
48019241|NCT03992105|OTHER|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
48019242|NCT00400413|PROCEDURE|fMRI|
48019243|NCT04981119|OTHER|Apheresis|Apheresis procedure performed for collection of PBMCs.
48019244|NCT04981119|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
48019245|NCT04981119|DIAGNOSTIC_TEST|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
48517404|NCT03392350|BEHAVIORAL|Physician Body Scan Consultation with Behavioral Intervention|The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
48517405|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
48517406|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
48019250|NCT05272852|DEVICE|FARAPULSE™ Pulsed Field Ablation System Plus|Ablation using FARAPULSE™ Pulsed Field Ablation System Plus
48019251|NCT05495750|DRUG|Bupivacaine 0.25% Injectable Solution|ultrasound-guided bilateral suprazygomatic maxillary nerve block using 0.15 ml/kg.
48176320|NCT00450398|DRUG|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
48176321|NCT01449747|DRUG|Sitagliptin|Sitagliptin (100mg, per oral) once a day.
48176322|NCT01492621|DRUG|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
48176323|NCT05410119|BEHAVIORAL|8-week Resilience Group Psychotherapy|Resilience Group Psychotherapy was intervened by a psychotherapy developed by the researchers. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
48176324|NCT05410119|OTHER|Usual care|Usual care means treating as usual, such as regular home visit.
48176325|NCT03970499|PROCEDURE|brain tumor resection|Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
48176326|NCT02735590|DRUG|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
48176327|NCT02735590|DRUG|Rifapentine|Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
48377016|NCT01590095|BEHAVIORAL|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children \< 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
48517407|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
48709642|NCT00922155|DEVICE|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
48709643|NCT00864669|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
48709644|NCT00864669|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
48019252|NCT00774787|DRUG|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
48019253|NCT05505981|OTHER|Immediate PT|Patients will start PT immediately
48019254|NCT05505981|OTHER|Rest until pain resolves|Patients will wait to start PT until their pain resolves
48019255|NCT03915548|BEHAVIORAL|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
48019256|NCT03915548|BEHAVIORAL|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
48019257|NCT06570967|DRUG|Methimazole(MMI)|The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.
48019258|NCT02409615|OTHER|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
48019259|NCT02409615|OTHER|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
48019260|NCT05499676|DEVICE|SilverCloud Health Mobile Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs, including one for anorexia nervosa developed by our team. Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
48019261|NCT05499676|DEVICE|Social Networking Intervention: Facebook|Facebook is a social networking site that will offer participants the opportunity to interact with study team posts, post themselves, and connect with others in the study experiencing similar struggles in a private group
48019262|NCT02744846|DRUG|Antibiotics exposure|
48019263|NCT02894203|BEHAVIORAL|Mindfulness|
48019264|NCT02894203|BEHAVIORAL|Yoga|
48019265|NCT00927017|OTHER|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
48019266|NCT00927017|OTHER|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
48019267|NCT03125889|DEVICE|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
48019268|NCT02198547|DRUG|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
48019269|NCT02198547|DRUG|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
48019270|NCT00149708|DRUG|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
48019271|NCT06369740|OTHER|Case scenarios - questionnaire|Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
48176328|NCT05596747|DRUG|LY3209590|Administered SC.
48176329|NCT05596747|DRUG|Insulin Glargine|Administered SC.
48176330|NCT01473745|PROCEDURE|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
48176331|NCT01473745|PROCEDURE|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
48176332|NCT02444351|DRUG|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
48176333|NCT02444351|OTHER|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
48176334|NCT00749359|DRUG|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
48176335|NCT00389688|DRUG|cisplatin|
48176336|NCT00389688|DRUG|pemetrexed disodium|
48176337|NCT00389688|PROCEDURE|adjuvant therapy|
48176338|NCT00389688|PROCEDURE|conventional surgery|
48176339|NCT00389688|PROCEDURE|neoadjuvant therapy|
48176340|NCT04629443|DRUG|S 64315 (also referred as MIK665) and azacitidine|"The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days."
48176341|NCT04922645|DRUG|Ferric Citrate 1 gram Oral Tablet|Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
48176342|NCT04922645|DRUG|Standard of care phosphate-lowering therapy|Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
48176343|NCT04669379|BEHAVIORAL|EXPECT: Preoperative optimization of patient's expectations|Patients work through an online-tool (around 30 minutes). This preoperative intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the surgery-benefits and recovery process, giving information, and giving advice for coping resources.
48176344|NCT05098691|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
48176345|NCT05972798|OTHER|Omega-3 fatty acids|2.2 g/d omega-3 PUFAs (1.2g EPA and 1g DHA per day) in patients with LLD
48176346|NCT05972798|OTHER|Soybean oil|Soybean oil in patients with LLD
48176347|NCT03305887|DEVICE|"STRATAFIX™ Symmetric Knotless Tissue"|This devices will be used in deep and intermediate layers of barbed suture group.
48517408|NCT03846193|BIOLOGICAL|GT005|A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
48709645|NCT04744389|DEVICE|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
48019272|NCT06369740|OTHER|Case scenarios - Focus groups|Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
48019273|NCT06369740|OTHER|Use scenarios - Usability test|Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
48019274|NCT06369740|OTHER|Use scenarios - interview|The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
48019275|NCT01946061|DRUG|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
48517409|NCT03846193|DEVICE|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
48019276|NCT06387784|DIETARY_SUPPLEMENT|Beetroot juice|In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.
48176348|NCT03305887|DEVICE|VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
48176349|NCT03305887|DEVICE|"STRATAFIX Spiral sutures"|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
48176350|NCT03305887|DEVICE|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
48176351|NCT00549978|DRUG|Cilostazol|cilostazol, then cilostazol/probucol
48176352|NCT00549978|DRUG|Probucol|Probucol probucol/ cilostazol
48176353|NCT01973062|BIOLOGICAL|rituximab|Given IV
48176354|NCT01973062|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
48517410|NCT03846193|DEVICE|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
48709646|NCT04744389|DEVICE|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
48709647|NCT06186128|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
48709648|NCT01187446|RADIATION|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
48709649|NCT01187446|DRUG|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
48176355|NCT04692376|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.
48176356|NCT04692376|DRUG|Glucocorticoids|Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
48176357|NCT04692376|DRUG|cyclosporine|Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
48176358|NCT02525081|DRUG|Ramipril (ACE-inhibitor)|up to 10 mg
48176359|NCT02525081|DRUG|placebo|up to 10 mg
48377017|NCT01590095|BEHAVIORAL|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
48377018|NCT01590095|BEHAVIORAL|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation \& Hand washing (Combined WASH) Plus the intervention described above for nutrition.
48709650|NCT01381003|GENETIC|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
48709651|NCT00127283|DRUG|eptacog alfa (activated)|
48709652|NCT00824005|BIOLOGICAL|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
48709653|NCT00824005|BIOLOGICAL|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
48709654|NCT04357509|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
48709655|NCT02504112|OTHER|there is no intervention|
48709656|NCT00622089|DRUG|DIO-902|150mg DIO-902 + 10mg atorvastatin
48709657|NCT00622089|DRUG|DIO-902|300mg dose once per day for 24 weeks
48709658|NCT00622089|DRUG|DIO-902|450mg dose once per day for 24 weeks
48709659|NCT02653495|BIOLOGICAL|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
48709660|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
48709661|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
48709662|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
48709663|NCT04371822|DRUG|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
48709664|NCT04371822|OTHER|placebo|No Intervention
48709665|NCT02366117|BEHAVIORAL|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
48019277|NCT06387784|DIETARY_SUPPLEMENT|Placebo juice|In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.
48019278|NCT01243944|DRUG|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
48176360|NCT02977299|DRUG|Aripiprazole|Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
48176361|NCT02977299|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
48176362|NCT02977299|DRUG|Venlafaxine XR|Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
48176363|NCT04205656|BIOLOGICAL|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
48176364|NCT04205656|BIOLOGICAL|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
48176365|NCT04205656|OTHER|Control group (Placebo)|Participants will undergo ACLR surgery with no injection into their knee.
48709666|NCT02181101|DRUG|FEC-DocGemzar adjuvant chemotherapy|
48709667|NCT02181101|DRUG|FEC-Doc adjuvant chemotherapy|
48709668|NCT02181101|DRUG|Zoledronic acid i.v. 2 years|
48176366|NCT04875897|DEVICE|keepMED PAP device|The keepMED PAP device is an automatic, wearable positive airway pressure device indicated for treatment of obstructive sleep apnea. A therapeutic pressure is delivered to the patient upper airway through a nasal interface. It is similar to other marketed positive airway pressure devices with respect to its fundamental use of positive airway pressure for the treatment of sleep apnea as well as with regard to its functional components and accessories (e.g., a PAP unit, a mask/nasal interface, an air filter, tubing, etc.).
48176367|NCT00047541|DRUG|Alcon Investigational Agent|
48176368|NCT06192030|OTHER|Prediction model|We develop and validate clinical models to predict patient survival and gene signatures in ovarian metastases of colorectal cancer.
48176369|NCT05501782|OTHER|questionnaire|A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
48176370|NCT03643757|PROCEDURE|Thoracic epidural analgesia|Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
48176371|NCT03643757|DRUG|Bupivacaine|In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
48176372|NCT03600649|DRUG|Seclidemstat|Twice daily administration of seclidemstat
48176373|NCT03600649|DRUG|Cyclophosphamide|250 mg/m2/day on Days 1 thru 5 of a 21-day cycle
48176374|NCT03600649|DRUG|Topotecan|0.75 mg/m2/day on Days 1 thru 5 of a 21-day cycle
48176375|NCT03840109|BEHAVIORAL|Questionnaire 1a|Participants will be randomly shown two versions of messages in which the last 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48176376|NCT03840109|BEHAVIORAL|Questionnaire 1b|Participants will be randomly shown two versions of messages in which the first 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48176377|NCT03840109|BEHAVIORAL|Questionnaire 2a|Participants will be randomly shown two versions of messages in which the last 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48176378|NCT03840109|BEHAVIORAL|Questionnaire 2b|Participants will be randomly shown two versions of messages in which the first 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48176379|NCT03840109|BEHAVIORAL|Questionnaire 3a|Participants will be randomly shown two versions of messages in which the last 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48176380|NCT03840109|BEHAVIORAL|Questionnaire 3b|Participants will be randomly shown two versions of messages in which the first 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48176381|NCT03840109|BEHAVIORAL|Questionnaire 4a|Participants will be randomly shown two versions of messages in which the last 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48377019|NCT04961944|OTHER|Disease assessment|"A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.~The association between endotypes and disease progression will be tested."
48377020|NCT00292006|DEVICE|Computerized tomography|
48709669|NCT02181101|DRUG|Zoledronic acid i.v. 5 years|
48709670|NCT01151735|DRUG|C-1-esterase|1000 units of C-1-esterase inhibitor
48709671|NCT01151735|DRUG|C-1-esterase|1500 units of C-1-esterase inhibitor
48709672|NCT01151735|DRUG|placebo|placebo
48377021|NCT04186637|DRUG|ALPN-202|Multiple dose levels and dose regimens of ALPN-202 will be administered
48377022|NCT02753582|DIETARY_SUPPLEMENT|SOD+Gliadin Capsule|
48377023|NCT02753582|DIETARY_SUPPLEMENT|Placebo|
48709673|NCT05904028|DRUG|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule|Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
48709674|NCT05904028|DEVICE|Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule|Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
48709675|NCT00373165|DRUG|Ganciclovir|
48709676|NCT02159222|PROCEDURE|Additional physical therapy|
48709677|NCT03253172|DIETARY_SUPPLEMENT|Potassium Chloride|Two potassium supplements with varying anions.
48709678|NCT03253172|DIETARY_SUPPLEMENT|Potassium Citrate|Potassium Citrate
48709679|NCT03253172|DIETARY_SUPPLEMENT|Placebo|Placebo
48709680|NCT00499382|PROCEDURE|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
48709681|NCT00499382|PROCEDURE|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
48709682|NCT03171246|DIETARY_SUPPLEMENT|Solid food-based intervention|Individually tailored energy content according to age/activity
48176382|NCT03840109|BEHAVIORAL|Questionnaire 4b|Participants will be randomly shown two versions of messages in which the first 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
48019279|NCT01243944|OTHER|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
48176383|NCT00578578|DIETARY_SUPPLEMENT|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
48176384|NCT00414089|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|
48176385|NCT02520310|DEVICE|AVJ-514|Patients receiving AVJ-514 device
48019280|NCT01639209|PROCEDURE|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
48176386|NCT05379790|DRUG|Irinotecan|3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
48176387|NCT05379790|DRUG|CAPOX|Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
48176388|NCT03616860|DEVICE|Focused Ultrasound (FUS) BBB Disruption|FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
48709683|NCT01943838|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
48176389|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing every 2 weeks~* Intravenous injection"
48176390|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing weekly~* Intravenous injection"
48176391|NCT03647384|DRUG|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
48176392|NCT03647384|DRUG|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
48176393|NCT04267471|BEHAVIORAL|Tai Chi|Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
48709684|NCT04788797|DRUG|Prolyl Endopeptidase|Two capsules three times a day.
48176394|NCT04267471|BEHAVIORAL|Walking|Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
48176395|NCT02561806|DRUG|Ixekizumab|Administered SC
48176396|NCT02561806|DRUG|Ustekinumab|Administered SC
48709685|NCT04788797|OTHER|Placebo|Two capsules three times a day
48176397|NCT02561806|DRUG|Placebo|Administered SC
48176398|NCT02023749|DIETARY_SUPPLEMENT|Nut group|
48176399|NCT04429802|DRUG|Prucalopride|Orally administered
48019281|NCT01639209|PROCEDURE|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
48019282|NCT04771741|DRUG|Acetominophen|1,000 mg every 6 hours
48019283|NCT04771741|DRUG|Toradol|10 mg every 6 hours, days 0-3
48019284|NCT04771741|DRUG|Meloxicam|15 mg once daily, beginning post-op day 4
48176400|NCT04429802|DRUG|Placebo|Orally administered
48176401|NCT03993457|DRUG|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
48709686|NCT03018470|OTHER|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
48709687|NCT03871348|DRUG|SAR441000|"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"
48709688|NCT03871348|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
48019285|NCT04771741|DRUG|Cyclobenzaprine|10 mg every 8 hours
48019286|NCT04771741|DRUG|Lyrica|75 mg every 12 hours
48176402|NCT03993457|DRUG|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
48176403|NCT01419938|DEVICE|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
48176404|NCT01419938|DEVICE|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
48176405|NCT02438371|DRUG|Nifedipine|
48176406|NCT02438371|DRUG|Indomethacin|
48176407|NCT06456086|BIOLOGICAL|stimulation with EB virus|stimulation with EB virus
48176408|NCT02431455|DEVICE|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
48176409|NCT02431455|DEVICE|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
48176410|NCT03589300|DEVICE|Persona TM Tibia|Trabecular Metal tibia used in primary cementless total knee arthroplasty
48176411|NCT00002722|DRUG|cisplatin|
48176412|NCT00002722|DRUG|fluorouracil|
48176413|NCT00002722|DRUG|leucovorin calcium|
48709689|NCT00559468|DRUG|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
48709690|NCT00559468|DRUG|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
48709691|NCT00559468|DRUG|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
48377024|NCT05945368|DRUG|Eribulin mesylate injection、Pertuzumab、Trastuzumab|"* Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days"
48709692|NCT00559468|DRUG|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
48709693|NCT05296460|DRUG|Dapsone gel|The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
48709694|NCT01913665|OTHER|B.lactis|
48709695|NCT01913665|OTHER|Inulin|
48019287|NCT03311074|GENETIC|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
48377025|NCT03681912|BEHAVIORAL|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
48377026|NCT03681912|BEHAVIORAL|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
48709696|NCT01913665|OTHER|B.Lactis +Inulin|
48709697|NCT01913665|OTHER|Placebo|
48709698|NCT02408354|DRUG|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
48709699|NCT02408354|DRUG|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
48709700|NCT01156389|DRUG|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
48709701|NCT01156389|DRUG|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
48709702|NCT04205851|DRUG|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
48709703|NCT04205851|DRUG|Placebo|Saline
48019288|NCT05658926|BEHAVIORAL|Mindfulness|Patients will learn how to use diaphragmatic breathing with mindfulness
48019289|NCT05658926|OTHER|Education|Patients will be provided with education regarding the Gate Control Theory of Pain.
48019290|NCT02259608|BIOLOGICAL|BCG vaccine SSI|BCG vaccination
48709704|NCT03594149|DRUG|Levofloxacin|Levofloxacin 500 mg/d p.o.
48377027|NCT03681912|BEHAVIORAL|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
48377028|NCT01381068|DEVICE|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
48377029|NCT02223520|DRUG|Mupirocin and Chlorhexidine|
48377030|NCT02223520|DRUG|Placebo ointment and placebo cloths|
48377031|NCT01711424|DRUG|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
48377032|NCT04437732|DEVICE|Apioc-P and Apioc-PT Contact Lens Design|Novel soft contact lens design
48709705|NCT01063491|PROCEDURE|bypass graft angiography|
48709706|NCT05226364|PROCEDURE|Rubber tourniquet|The blood sample is taken with a rubber tourniquet
48709707|NCT05226364|PROCEDURE|Fabric tourniquet|The blood sample is taken with a fabric tourniquet
48709708|NCT05226364|PROCEDURE|Without tourniquet|The blood sample is taken without tourniquet
48019291|NCT05634616|DEVICE|Motor imagery and motor execution based BCI|We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed
48377033|NCT01048710|OTHER|No intervention|
48019292|NCT05634616|DEVICE|Sham BCI|The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
48019293|NCT04132349|DRUG|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
48019294|NCT06662669|DRUG|YL-13027|YL-13027 is a small molecule inhibitor of the TGF-βRI target.
48377034|NCT04383925|BIOLOGICAL|BCG-Japan|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).
48377035|NCT04383925|BIOLOGICAL|BCG-Russia|Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)
48377036|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma|Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
48377037|NCT04860531|DRUG|Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone|Lumbar Facet Joints intra-articular injection
48377038|NCT02349100|DEVICE|Nellix Endoprosthesis|Implantation of Nellix
48377039|NCT05041218|OTHER|Neural Interfaces Electroencephalogram measurement on Operators|Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
48517411|NCT03846193|DEVICE|GT005/ Device: Orbit™ Subretinal Delivery System|"A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor~Device: Orbit™ Subretinal Delivery System"
48517412|NCT04511585|BEHAVIORAL|Great Live and Move Challenge|Physical activity program for children
48709709|NCT00881153|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
48709710|NCT00881153|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
48709711|NCT06167005|PROCEDURE|Primary bariatric-metabolic surgery|Primary bariatric-metabolic surgery
48709712|NCT04599270|OTHER|PREVENTURE Program|Adolescents will be follow PREVENTURE program (2 session of 90 min).
48709713|NCT04599270|OTHER|Routine care|Adolescents will be follow routine care
48709714|NCT02404922|DRUG|CTP-730|
48709715|NCT02404922|DRUG|Placebo for CTP-730|
48709716|NCT00906139|DRUG|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
48709717|NCT00906139|DRUG|Midazolam|Midazolam dose: 0.1 mg/kg
48709718|NCT00906139|DRUG|Fentanyl|Fentanyl dose: 0.05 mg
48709719|NCT04546295|OTHER|Brushlink application|Brushlink application + Interproximal brush
48709720|NCT04546295|OTHER|Water-flosser|Water-flosser
48709721|NCT04546295|OTHER|Interproximal brush|Interproximal brush alone
48709722|NCT04863248|DRUG|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
48709723|NCT04863248|DRUG|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
48709724|NCT04863248|DRUG|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
48019295|NCT06662669|DRUG|HY-0102|HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
48019296|NCT06662669|DRUG|Gemcitabine|Gemcitabine is a pyrimidine antineoplastic chemotherapeutic agent.
48019297|NCT06662669|DRUG|Nab-paclitaxel|Paclitaxel for Injection (albumin bound) is a chemotherapeutic agent that acts as an antitumor agent by inhibiting tumor cell mitosis
48517413|NCT05114733|BEHAVIORAL|InVEST|Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months
48517414|NCT03399513|DRUG|Ibrutinib Oral Capsule [Imbruvica]|Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)
48709725|NCT03383757|DEVICE|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
48709726|NCT03095027|DEVICE|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
48709727|NCT03095027|DEVICE|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
48709728|NCT00119912|PROCEDURE|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
48709729|NCT00119912|PROCEDURE|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
48709730|NCT05349292|OTHER|ANH|one group will be managed with ANH and the other without (control group)
48709731|NCT03552211|DRUG|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
48709732|NCT03552211|OTHER|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
48377040|NCT01535209|RADIATION|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity \<2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity \>4cm in maximum diameter
48377041|NCT01535209|RADIATION|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
48709733|NCT02606435|PROCEDURE|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
48709734|NCT02606435|DEVICE|thrombus aspiration|thrombus aspiration with export catheter
48709735|NCT03103672|PROCEDURE|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
48019298|NCT03105050|OTHER|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
48019299|NCT02233231|DRUG|Varenicline|Varenicline 2 mg x 1 day 7 to week 12
48019300|NCT02233231|DRUG|Placebo|similar tabl
48176414|NCT00944229|DRUG|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
48176415|NCT00944229|DRUG|Placebo|4 capsules of placebo every 24 hours
48176416|NCT03447275|OTHER|Type 2 diabetes|Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
48377042|NCT02267343|DRUG|ONO-4538|
48377043|NCT02267343|DRUG|Placebo|
48377044|NCT01322061|DRUG|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
48377045|NCT06015061|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
48377046|NCT03846960|DEVICE|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
48377047|NCT03846960|DRUG|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
48377048|NCT06012357|DIAGNOSTIC_TEST|Nociception Coma Scale-Revised|Nociception Coma Scale-Revised Recorded after personalized painful stimulus
48377049|NCT05077033|DRUG|phIL12 GET|intratumoral phIL12 gene electrotransfer
48517415|NCT03399513|DRUG|R-CHOEP chemotherapy|Immunochemotherapy
48517416|NCT03732963|DRUG|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
48709736|NCT03999138|DIAGNOSTIC_TEST|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
48377050|NCT03156946|BEHAVIORAL|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
48377051|NCT03156946|BEHAVIORAL|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
48377052|NCT05888545|DEVICE|anti-adhesion diaphragm|Participants will be asked to place an anti-adhesion diaphragm in the uterus for 3-7 days after the abortion procedure.
48019301|NCT05850897|OTHER|Masaj|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
48019302|NCT03923127|OTHER|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
48176417|NCT01812798|OTHER|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
48377053|NCT03511391|DRUG|Nivolumab or Pembrolizumab or Atezolizumab|per national standard of care
48019303|NCT02137200|PROCEDURE|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
48176418|NCT02192723|DRUG|Typical antipsychotic|Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
48176419|NCT02192723|DRUG|Risperidone|2\~6mg/day, twice per day, 8 weeks
48176420|NCT02192723|DRUG|Olanzapine|Olanzapine, 400\~750mg/day, twice per day, 8 weeks
48377054|NCT03511391|RADIATION|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
48709737|NCT02139735|OTHER|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
48019304|NCT02137200|PROCEDURE|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
48377055|NCT03142230|OTHER|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
48377056|NCT03142230|OTHER|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
48517417|NCT03732963|DRUG|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
48019305|NCT05323383|BEHAVIORAL|Mindfulness Meditation|Participants in the mindfulness meditation condition will listen to a 20minute guided mindfulness meditation practice that holds the breath and body as the object of meditation.
48019306|NCT05323383|BEHAVIORAL|Self-hypnosis|Participants in self-hypnosis will listen to a 20-minute audio-guided hypnosis practice with an induction phase, followed by suggestions tailored towards shifts in affect and decentering, and then a re-alerting with post-hypnotic suggestions phase.
48019307|NCT05323383|OTHER|Attention Control|Control participants will listen to a 20-minute natural history recording which was chosen as past research has found that individuals who listen to it report this to be a neutral, but relaxing passage, and it has been used as an effective control condition in previous research.
48176421|NCT02192723|DRUG|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
48176422|NCT02192723|DEVICE|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
48176423|NCT02192723|DRUG|Ziprasidone|Ziprasidone 80\~160mg/day, twice per day, 8 weeks
48176424|NCT00456378|DEVICE|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
48377057|NCT00877526|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
48517418|NCT03027024|DEVICE|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
48517419|NCT01514461|DRUG|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
48517420|NCT01514461|DRUG|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
48517421|NCT01491451|DEVICE|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
48709738|NCT02139735|OTHER|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
48709739|NCT02139735|OTHER|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
48377058|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
48019308|NCT01816139|DRUG|Vehicle|Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
48377059|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
48377060|NCT04334356|BEHAVIORAL|Mobile Web App|App for preventing development of posttraumatic stress based on cognitive behavioral techniques.
48709740|NCT04490980|DRUG|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
48377061|NCT03401827|DRUG|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
48377062|NCT01639625|DRUG|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
48377063|NCT01667523|DIETARY_SUPPLEMENT|Capsaicin|1.5 mg capsaicin administered intraduodenally
48377064|NCT01667523|DIETARY_SUPPLEMENT|Cinnamaldehyde|70 mg per intervention administered intraduodenally
48377065|NCT01667523|DIETARY_SUPPLEMENT|Placebo|Physiological saline
48377066|NCT05190094|DRUG|Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)|A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
48517422|NCT01491451|DEVICE|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
48517423|NCT02933437|DRUG|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
48709741|NCT03705780|OTHER|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
48709742|NCT03705780|DIAGNOSTIC_TEST|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
48709743|NCT01738113|OTHER|Open Kinetic Chain exercise|"1. Hamstrings strengthening exercise~2. Quadriceps strengthening exercise~3. Hamstrings stretch~4. Hip extensors and abductors strengthening~5. Calf-muscles stretching~6. Strength exercise of ankle dorsiflexors \& plantar flexors"
48709744|NCT01738113|OTHER|Closed kinetic chain exercise|"1. Foot sliding from sitting~2. Seated Toe Raises~3. Hamstrings and quadriceps co-contraction from sitting~4. Bridging exercise~5. Sitting-to-standing~6. Side-to side, forward and backwards weight shifting~7. Lunge exercise~8. Squatting exercise~9. Standing Toe Raises~10. Standing Hamstrings Stretch"
48517424|NCT03854630|DRUG|Engerix-B|The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
48019309|NCT01816139|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
48019310|NCT04124549|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
48176425|NCT00456378|PROCEDURE|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
48176426|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
48176427|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
48176428|NCT01699464|DRUG|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
48176429|NCT02107742|PROCEDURE|Normal speed lidocaine injection|30 seconds
48176430|NCT02107742|PROCEDURE|Slow lidocaine injection|speed 45 seconds
48176431|NCT02107742|PROCEDURE|Fast lidocaine injection|speed 15 seconds
48377067|NCT02353273|DRUG|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
48517425|NCT05096910|PROCEDURE|Uterine Closure with monofilament or polyfilament suture materials|Postoperative 6th-month isthmocele rates
48709745|NCT04963530|PROCEDURE|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
48709746|NCT04963530|PROCEDURE|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
48176432|NCT06385613|BEHAVIORAL|Mobile-based stoma care education group|Individuals included in the intervention group will be given mobile-based stoma care trainings before surgery, on the 3rd postoperative day, on the day of discharge, and on the 1st and 3rd months after discharge, and their effectiveness will be measured using data collection forms.
48176433|NCT00907192|BEHAVIORAL|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
48377068|NCT03534934|DIAGNOSTIC_TEST|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
48377069|NCT03534934|DIAGNOSTIC_TEST|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
48377070|NCT03534934|OTHER|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
48377071|NCT03534934|DIAGNOSTIC_TEST|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
48377072|NCT03534934|DIAGNOSTIC_TEST|Duel-energy X-ray absorptiometry scan|Bone density measurement
48709747|NCT04963530|PROCEDURE|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
48709748|NCT04963530|PROCEDURE|No intervention|No intervention.
48709749|NCT00847665|OTHER|repositioning|Turning every 4 or 2 hours
48709750|NCT05564884|OTHER|no intervantion|no intervention
48709751|NCT00221715|DEVICE|femoropopliteal artery bypass|Bypass by autologous saphenous vein
48709752|NCT00221715|DEVICE|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
48709753|NCT02488291|DRUG|0.25 sufentanil|with different dosage
48709754|NCT02488291|DRUG|0.5µg/ml sufentanil|0.5µg/ml sufentanil
48709755|NCT02488291|DRUG|0.1% ropivacaine|0.1% ropivacaine
48709756|NCT03641248|DRUG|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
48709757|NCT03641248|DRUG|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
48377073|NCT03534934|DIAGNOSTIC_TEST|Multi-detector computed tomography|Hip and ankle CT scan
48377074|NCT03534934|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
48377075|NCT04114474|DIAGNOSTIC_TEST|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
48377076|NCT05097261|DRUG|Ketamine|Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
48709758|NCT06120361|DIAGNOSTIC_TEST|Plasma APS 2 score|APS 2 score (combination of ptau217/nptau217 and Ab42/Ab40). The cut off will be predefined. The samples will be analysed prospectively every two weeks.
48709759|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217/np-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
48709760|NCT06120361|DIAGNOSTIC_TEST|Plasma p-tau217|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
48709761|NCT06120361|DIAGNOSTIC_TEST|Plasma neurofilament light (NfL)|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
48709762|NCT06120361|DIAGNOSTIC_TEST|Plasma Ab42/Ab40|The cut off will be predefined. The samples will be analysed prospectively every two weeks.
48709763|NCT06120361|DIAGNOSTIC_TEST|MRI and CT of the brain|Structural brain imaging
48709764|NCT06120361|DIAGNOSTIC_TEST|Different cognitive tests|Both standard paper-and-pen tests as well as digital cognitive tests will be evaluated.
48709765|NCT00941369|DRUG|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
48709766|NCT05764473|OTHER|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
48709767|NCT05764473|OTHER|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
48709768|NCT05700292|OTHER|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
48709769|NCT05700292|OTHER|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
48709770|NCT06346366|DEVICE|Bihormonal artificial pancreas (BIHAP) / closed loop|"The investigational device is a dual-hormonal fully closed loop system (BIHAP; industrial name AP® 5, Inreda Diabetic B.V.) which aims at optimally controlling plasma glucose levels. This BIHAP contains of two pumps for subcutaneous infusion of either insulin (Humalog, 3 ml pre-fill cartridge, Eli Lilly) or glucagon (GlucaGen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) via an infusion set (Accu-Chek Insight Flex or AccuChek Flex Link, Roche), two subcutaneously placed glucose-sensors (Guardian, Medtronic) and an algorithm driving pump infusion rates based on the sensor input. Daily self-measurements of blood glucose (SMBGs; Accu-Chek Instant, Roche) are needed for calibration of the glucose sensors.~The BIHAP-system has to be worn continuously, except while showering."
48176434|NCT00907192|BEHAVIORAL|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
48176435|NCT02171130|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
48377077|NCT05097261|DRUG|Placebo|Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
48377078|NCT06192407|DIETARY_SUPPLEMENT|High Oleic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.
48377079|NCT06192407|DIETARY_SUPPLEMENT|High Palmitic Acid Diet|Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.
48377080|NCT05280886|PROCEDURE|therapeutic drug monitoring(TDM)|Based on this data, population pharmacokinetic models of antibiotics drugs that can be applicable to TDM will be developed.
48377081|NCT04780126|OTHER|Sarcopenia diagnosis|History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
48176436|NCT02414347|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
48709771|NCT00545220|BEHAVIORAL|problem-solving training|
48709772|NCT00545220|BEHAVIORAL|sham intervention|
48709773|NCT05273021|DIAGNOSTIC_TEST|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
48709774|NCT00541099|BIOLOGICAL|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
48709775|NCT00541099|DRUG|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
48709776|NCT02491034|BEHAVIORAL|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
48709777|NCT05420220|BIOLOGICAL|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
48709778|NCT05420220|COMBINATION_PRODUCT|Axitinib|5mg bid po
48709779|NCT05445908|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
48709780|NCT05445908|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
48709781|NCT06333743|PROCEDURE|laser ablation|Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.
48709782|NCT06333743|PROCEDURE|LEEP or Conization|The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
48176437|NCT02910843|DRUG|Regorafenib|"* Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~* Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
48176438|NCT02910843|DRUG|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
48176439|NCT02910843|RADIATION|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
48709783|NCT00006799|DRUG|megestrol acetate|
48709784|NCT00006799|PROCEDURE|quality-of-life assessment|
48709785|NCT00220493|DRUG|Ritalin|
48709786|NCT01636388|BIOLOGICAL|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
48709787|NCT00867776|BEHAVIORAL|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
48709788|NCT00006078|DIETARY_SUPPLEMENT|lycopene|
48709789|NCT00712621|BEHAVIORAL|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
48709790|NCT00712621|BEHAVIORAL|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
48709791|NCT00354107|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
48709792|NCT00354107|DRUG|therapeutic hydrocortisone|Given IT
48176440|NCT02910843|PROCEDURE|Surgery|6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
48176441|NCT03864341|BEHAVIORAL|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
48377082|NCT03429465|OTHER|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
48709793|NCT00354107|DRUG|ifosfamide|Given IV
48709794|NCT00354107|DRUG|carboplatin|Given IV
48709795|NCT00354107|DRUG|etoposide|Given IV
48709796|NCT00354107|DRUG|methotrexate|Given IT
48709797|NCT00354107|DRUG|cytarabine|Given IT
48709798|NCT00354107|OTHER|pharmacological study|Correlative studies
48709799|NCT00354107|OTHER|laboratory biomarker analysis|Correlative studies
48709800|NCT05544175|PROCEDURE|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
48377083|NCT00994123|DRUG|MM-121|MM-121 (SAR256212) = intravenous solution
48377084|NCT00994123|DRUG|Erlotinib|erlotinib = daily oral tablet
48377085|NCT02357017|DIETARY_SUPPLEMENT|NaCl tablets|
48709801|NCT00899717|PROCEDURE|Occlusal adjustment|modification of occlusal surfaces
48709802|NCT00899717|PROCEDURE|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
48709803|NCT02240849|DEVICE|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
48176442|NCT03864341|BEHAVIORAL|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
48176443|NCT03864341|BEHAVIORAL|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
48176444|NCT03598881|OTHER|Treatment|
48709804|NCT02240849|DEVICE|Placebo general pillow|
48709805|NCT04796688|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
48709806|NCT04615975|DIETARY_SUPPLEMENT|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
48709807|NCT00004446|DRUG|fluoxetine|
48709808|NCT06363578|DRUG|Dexmedetomidine 0.5 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
48176445|NCT02582398|OTHER|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
48176446|NCT02582398|OTHER|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
48176447|NCT00025662|DRUG|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
48176448|NCT00025662|DRUG|Isolex system|CD34 selection/ T cell depletion used this system
48176449|NCT03633864|BIOLOGICAL|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
48709809|NCT06363578|DRUG|Dexmedetomidine 1 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
48709810|NCT04262713|OTHER|Radiographs|Radiographs of the implanted hip with Meije duo size1 or 2 are performed in eligible patients ( Weigh\>60, Long neck stem, Varus; DEVANE score ≥ 4)
48709811|NCT01144260|DRUG|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
48709812|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
48709813|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
48709814|NCT05859373|COMBINATION_PRODUCT|TQB2450 injection, sequential or concurrent chemoradiation|TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
48709815|NCT01882517|DIETARY_SUPPLEMENT|Yogurt that contains plant stanol esters|
48709816|NCT01882517|DIETARY_SUPPLEMENT|Placebo yogurt|
48709817|NCT04755166|PROCEDURE|Lateral ridge augmentation|
48709818|NCT04943458|OTHER|Monitoring of cerebral autoregulation|Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.
48709819|NCT01188148|DRUG|Memantine|5 mg per day of memantine
48709820|NCT01188148|DRUG|Placebo|
48709821|NCT04244864|BEHAVIORAL|Cross-sectoral psychosocial intervention|The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
48019311|NCT04124549|OTHER|Intradialytic Combined Exercise|Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
48176455|NCT05331976|DIAGNOSTIC_TEST|Proof Lab Test System|Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
48176456|NCT03234998|DEVICE|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
48176457|NCT03234998|DEVICE|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
48176458|NCT02360800|PROCEDURE|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
48176459|NCT02360800|PROCEDURE|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
48019312|NCT03859232|OTHER|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
48019313|NCT03859232|OTHER|Cotton Padding|Cast with traditional cotton liner.
48019314|NCT04412902|DRUG|adjuvant therapy|Adjuvant chemotherapy and/or radiotherapy
48019315|NCT01940705|OTHER|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
48019316|NCT01940705|OTHER|Hearing-Aid DVD|Take-home DVD about hearing aids
48019317|NCT01940705|BEHAVIORAL|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
48019318|NCT01940705|OTHER|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
48019319|NCT06440772|DRUG|Ringer's Lactate Crystalloid Solutions|7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.
48019320|NCT00120042|DRUG|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
48019321|NCT00120042|DRUG|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
48019322|NCT05521893|OTHER|Telemedicine care|"In the telemedicine group, the appointments are performed online via scheduled videoconferences, on a monthly basis.~All women in the telemedicine group receive a smartphone with the installed application that enable transfer of the measured capillary glucose concentration."
48176460|NCT06038851|PROCEDURE|Para-Sartorial Compartments (PACS) Block|"This intervention was selected because it has the potential to optimize analgesia by skin coverage of the upper third of the surgical incision. The intervention will be performed as follows:~* The intermediate femoral cutaneous nerve will be visualized at the supralateral level of the sartorius muscle, in a duplicature of the fascia lata.~* The needle will be inserted at the same puncture site as for the femoral triangle block, with a latero-medial orientation in the plane (intracanalar compartment).~* In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed in addition, below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment)."
48176461|NCT06038851|PROCEDURE|Femoral Triangle Block (FTB)|"* The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~* The needle will be inserted with a latero-medial orientation in the plane.~* The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle."
48176462|NCT06038851|PROCEDURE|Infiltration between popliteal artery and capsule of the knee (IPACK) block|It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
48176463|NCT00983905|DRUG|Theophylline|single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
48019323|NCT05521893|OTHER|Standard care|In the standard care group, visits are scheduled at the diabetes clinic on a monthly basis.
48019324|NCT02996721|BIOLOGICAL|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
48176464|NCT00983905|DRUG|Colchicine|one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
48176465|NCT04243122|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|2.5mg twice per day for 6 months Then treated \& followed up as per standard of care
48176466|NCT04243122|DRUG|Aspirin 81 mg|81mg once per day for 6 months Then treated \& followed up as per standard of care
48176467|NCT03469492|DRUG|Insulin|Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
48176468|NCT03469492|BEHAVIORAL|exercise|Exercise in accordance to the guidelines established by the American Diabetes Association.
48176469|NCT03469492|DIETARY_SUPPLEMENT|Dietary counseling|Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
48176470|NCT02888236|DRUG|LEO 32731|
48176471|NCT02888236|DRUG|LEO 32731 Placebo|
48019325|NCT01360034|DRUG|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
48019326|NCT01360034|DRUG|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
48019327|NCT06023641|DRUG|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
48377086|NCT03844802|OTHER|Local Dry needling and exercise|"Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program."
48709822|NCT04244864|BEHAVIORAL|Treatment as usual (TAU)|"Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy."
48176472|NCT03927690|DRUG|LKA651|LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
48176473|NCT03927690|DRUG|Lucentis|Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
48176474|NCT03214536|PROCEDURE|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
48709823|NCT05374577|OTHER|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
48176475|NCT03214536|DRUG|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
48176476|NCT03214536|PROCEDURE|Spine surgery|Surgery of lumbar spine
48176477|NCT03214536|PROCEDURE|anesthesia|general anesthesia
48176478|NCT04142411|DRUG|Insulin|Ultrasound guided perineural injection therapy (PIT)
48176479|NCT04142411|DRUG|Sodium Hyaluronate|Ultrasound guided perineural injection therapy (PIT)
48176480|NCT04142411|DEVICE|Ultrasound|Philips Neuromuscular Ultrasound
48176481|NCT05632380|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection. If previously collected stem cells are available, no stem cell mobilization or collection is required, and patients will receive conditioning directly.
48176482|NCT05632380|BIOLOGICAL|C-CAR088|C-CAR088 is an BCMA targeted Chimeric Antigen Receptor-T cell product. Patients will receive C-CAR088 single dose infusion 3 days after ASCT. The dose level of C-CAR088 will be determined by the investigator.
48176483|NCT04206709|PROCEDURE|aerobic effort|Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
48176484|NCT04206709|OTHER|passive pedaling|20 minutes passive pedaling by upper limbs.
48176485|NCT01830062|OTHER|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
48176486|NCT01830062|OTHER|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
48176487|NCT02509312|DRUG|Ketorolac|Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
48176488|NCT02509312|DRUG|Placebo|Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
48176489|NCT04012086|OTHER|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
48176490|NCT06226298|DEVICE|Xiaxi postural hammock|Lie in the Xiaxi postural hammock for 10 minutes for 5 days.
48176491|NCT06226298|BEHAVIORAL|Yoga mat|Lie in the Yoga mat for 10 minutes for 5 days.
48176492|NCT05611541|BEHAVIORAL|Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group|The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
48176493|NCT05611541|BEHAVIORAL|The group who received diet therapy and practiced their daily activities.|The group who received diet therapy and practiced their daily activities.
48517426|NCT05729490|RADIATION|Coronary computed tomography angiography|"All patients will be subjected to:~Two CT scans (coronary calcium scoring and angiography) using 128 or 160-row scanners with a slice thickness of 0.5 mm (Revolution Evo 128, GE Health care, Chicago, Illinois, USA) or (Aquilion 160, Canon Medical Systems, Tochigi, Japan). Calcium scoring will be performed with the use of prospective electrocardiographic gating with 400-ms gantry rotation, 120-kV tube voltage, and 300-mA tube current. For CTA, retrospective electrocardiographic gating will be used, with heart rate adjusted gantry rotations of 350 ms to 500 ms to enable adaptive multisegmented reconstruction.~Iopromide (Ultravist 370, Bayer AG, Berlin, Germany) is the intravenous contrast medium that will be used for CTA. Beta-blockers will be given if the resting heart rate is 70 beats/min."
48709824|NCT05374577|OTHER|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
48709825|NCT02387164|DRUG|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
48709826|NCT02387164|DRUG|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
48709827|NCT00150228|DRUG|CP-526,555 (varenicline)|
48709828|NCT06180681|BEHAVIORAL|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
48709829|NCT06180681|BEHAVIORAL|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
48709830|NCT01895933|DEVICE|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
48709831|NCT00460954|DRUG|Sinemet® controlled release (Carbidopa/levodopa)|
48709832|NCT03622112|DRUG|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
48709833|NCT03622112|DRUG|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
48709834|NCT03622112|DRUG|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
48709835|NCT03622112|DRUG|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
48709836|NCT03622112|DRUG|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
48709837|NCT03622112|DRUG|Placebo for AZD7594 once daily.|Placebo for AZD7594
48709838|NCT03622112|DRUG|FF 100 µg once daily (open-label)|Fluticasone furoate
48709839|NCT01902563|OTHER|Osteopathic Manipulative Treatment|
48709840|NCT02003066|PROCEDURE|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
48176494|NCT04561167|OTHER|Cuspal reduction in MOD cavity in endodontically treated teeth|Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.
48176495|NCT04561167|OTHER|No cuspal reduction in MOD cavity in endodontically treated teeth|In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
48709841|NCT02003066|PROCEDURE|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
48709842|NCT03141788|DEVICE|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
48709843|NCT03627559|PROCEDURE|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
48709844|NCT03252093|DRUG|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
48709845|NCT03252093|DRUG|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
48709846|NCT02563860|DRUG|Lovastatin|dose escallating
48709847|NCT00853125|BIOLOGICAL|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
48709848|NCT00853125|DRUG|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
48709849|NCT03120858|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
48176496|NCT05032846|PROCEDURE|Ultrasound guided laparoscopic ovarian cystectomy|Laparoscopic ovarian cystectomy to be performed under intra-operative ultrasound guidance.
48176497|NCT05032846|OTHER|Laparoscopic Ovarian Cystectomy|Laparoscopic Ovarian Cystectomy will be performed as standard clinical practice.
48176498|NCT05416411|BEHAVIORAL|Inspiratory muscle training|Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.
48176499|NCT04571697|DRUG|Methotrexate|No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
48176500|NCT04571697|DRUG|Anti-TNF|No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
48176501|NCT04582747|DIAGNOSTIC_TEST|Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)|"Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively."
48517427|NCT04660279|DIAGNOSTIC_TEST|Dynamic Whole-Body parametric PET/CT|Dynamic whole-body PET/CT imaging protocol
48517428|NCT01943383|GENETIC|iPSC|Single blood draw for the production of induced pluripotent stem cells.
48517429|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
48517430|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
48709850|NCT03655327|OTHER|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
48709851|NCT02129478|DRUG|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
48709852|NCT02796872|DIETARY_SUPPLEMENT|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
48709853|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
48709854|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
48709855|NCT02796872|DIETARY_SUPPLEMENT|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
48709856|NCT01715350|DRUG|PM012|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
48709857|NCT01715350|DRUG|Placebo|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
48709858|NCT02109874|BIOLOGICAL|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
48019328|NCT06023641|DRUG|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
48709859|NCT02109874|BIOLOGICAL|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
48019329|NCT06023641|DRUG|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
48176502|NCT05932706|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
48377087|NCT03844802|OTHER|Distal Dry needling and exercise|"Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program."
48709860|NCT02051153|DRUG|Modafinil|Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).
48377088|NCT03844802|OTHER|Sham dry needling and exercise|"Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program."
48176503|NCT05932706|DEVICE|sham high definition transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.
48176504|NCT01018732|BIOLOGICAL|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
48176505|NCT02282306|BEHAVIORAL|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
48377089|NCT03844802|OTHER|Exercise|Patients will perform a home based therapeutic neck exercises program.
48019330|NCT06023641|PROCEDURE|Surgical Resection|Low, Intermediate and High-risk
48019331|NCT06023641|PROCEDURE|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
48019332|NCT06023641|DRUG|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
48377090|NCT01852669|PROCEDURE|Inversion|Patients inverted 30 degree head down in Trendelenburg position
48377091|NCT01852669|PROCEDURE|Shock Wave Lithotripsy|Shock wave lithotripsy
48377092|NCT01852669|DRUG|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
48377093|NCT05872113|COMBINATION_PRODUCT|Hs-hWE cream|The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.
48377094|NCT05872113|COMBINATION_PRODUCT|Placebo cream|The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
48377095|NCT03832426|DRUG|Narlaprevir|100 mg film-coated tablets
48377096|NCT03832426|DRUG|Ritonavir|100 mg film-coated tablets
48377097|NCT02058459|DEVICE|Holaira™ Lung Denervation System with energy delivery|
48377098|NCT02058459|DEVICE|Holaira™ Lung Denervation System without energy delivery|
48709861|NCT02051153|DRUG|Placebo|
48709862|NCT04864132|DIAGNOSTIC_TEST|6-minute walk test|This test assesses submaximal exercise capacity.
48709863|NCT04864132|DIAGNOSTIC_TEST|Incremental shuttle walk test|This test assesses maximal exercise capacity.
48709864|NCT05004038|BIOLOGICAL|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
48019333|NCT06023641|DRUG|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
48517431|NCT04413201|DRUG|Afatinib|Afatinib followed by osimertinib or ICT
48019334|NCT06023641|DRUG|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
48019335|NCT06023641|DRUG|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
48019336|NCT01503489|DRUG|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
48019338|NCT06068816|DIETARY_SUPPLEMENT|Nutrient-dense drink|a nutrient-dense drink developed by FrieslandCampina in line with the European Society for Clinical Nutrition and Metabolism guidelines for the dietary management of older malnourished patients
48019339|NCT00501891|DRUG|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
48019340|NCT00501891|DRUG|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
48019341|NCT05130567|DRUG|LP-128 capsules|Oral dosing with LP-128 capsules
48709865|NCT04736160|OTHER|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
48709866|NCT02337972|DRUG|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
48176506|NCT04038320|DRUG|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients \<75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
48176507|NCT04298099|DRUG|Ropivacaine|Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.
48176508|NCT00548847|BIOLOGICAL|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
48176509|NCT00548847|BIOLOGICAL|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
48176510|NCT02947841|OTHER|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
48176511|NCT02947841|OTHER|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
48176512|NCT05120154|OTHER|Online educational materials|The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
48176513|NCT05120154|BEHAVIORAL|Facilitated online webinars|Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
48709867|NCT02120170|PROCEDURE|Colon polypectomy|
48709868|NCT03078283|OTHER|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
48709869|NCT04956029|OTHER|There are no any interventions. This is to observe and test hospital cleanliness.|There are no any interventions. This is to observe and test hospital cleanliness.
48019342|NCT05130567|OTHER|Matching Placebo|Oral dosing with placebo capsules to match LP-128 capsules.
48019343|NCT00567788|DRUG|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
48176514|NCT03674762|DEVICE|Microgrooved dental implants|Dental Implant placement
48709870|NCT04070196|DIAGNOSTIC_TEST|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
48517432|NCT04413201|DRUG|Osimertinib|Osimertinib followed by ICT
48709871|NCT02362230|DRUG|Icotinib|Icotinib 125 mg BID
48176515|NCT03530462|DRUG|rituximab|375 mg/m2 weekly for 4 weeks
48176516|NCT03530462|DRUG|cyclophosphamide|750 mg/m2 monthly for 4-6 cycles depending on the response
48517433|NCT05355376|PROCEDURE|Bundle of measures to decreased SSI|
48019344|NCT00567788|DRUG|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
48019345|NCT04616144|DEVICE|Fresh Corneal Lenticule Implantation using Relex-Smile VisuMax Femtosecond Laser|Fresh Corneal Lenticule Implantation using ReLex-Smile
48019346|NCT00298038|DRUG|Rifaximin|Oral
48517434|NCT01323361|PROCEDURE|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
48709872|NCT04997265|OTHER|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
48709873|NCT04997265|OTHER|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
48176517|NCT03530462|DRUG|Steroids|500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
48176518|NCT03530462|DRUG|Intravenous immunoglobulin|intravenous immunoglobulin (IVIG) with or without plasmapheresis
48176519|NCT01947153|DRUG|Metformin|Free combination
48176520|NCT01947153|DRUG|Linagliptin|Fixed dose combination
48019347|NCT00298038|DRUG|Placebo|Oral
48019348|NCT05166005|DRUG|vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
48176521|NCT01947153|DRUG|Metformin|Combination
48176522|NCT01947153|DRUG|Linagliptin|Free combination
48019349|NCT03324165|OTHER|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
48019350|NCT05813054|DIETARY_SUPPLEMENT|HA matrix ingredient|1 capsule/day
48019351|NCT05813054|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
48019352|NCT02809976|DRUG|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
48019353|NCT06061211|OTHER|TREADMILL(PRECOR 964i treadmill) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: PRECOR 964i treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
48019354|NCT04140669|DEVICE|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
48019355|NCT01480115|OTHER|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
48019356|NCT02977949|DRUG|Raloxifene|
48019357|NCT04279444|DIETARY_SUPPLEMENT|BKR-017|BioKier, Inc. is developing colon-targeted, oral formulations of natural gut hormone secretagogues as non-prescription medical foods or supplements for nutritional use for improvement of insulin sensitivity.
48019358|NCT01412424|DRUG|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
48176523|NCT00001107|DRUG|Fluconazole|
48517435|NCT04343131|BEHAVIORAL|Dietary intervention|Crossover dietary manipulation using three different types of diet for 7 days each
48019359|NCT04620603|RADIATION|Low Dose Rate Brachytherapy (LDR)|LDR on treatment day 1
48176524|NCT00001107|DRUG|AmBisome|
48176525|NCT00765154|DRUG|darunavir|two 400mg tablets (800mg) once daily
48176526|NCT00765154|DRUG|ritonavir|one 100mg capsule once daily
48176527|NCT00251056|DRUG|mannitol|120mg BD
48176528|NCT00251056|DRUG|mannitol|40 mg BD
48176529|NCT00251056|DRUG|mannitol|240mg BD
48176530|NCT00251056|DRUG|mannitol|400mg BD
48176531|NCT05186896|OTHER|Risk perception questionnaire|A questionnaire for risk perception will be developed and administered
48176532|NCT00827775|DRUG|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
48176533|NCT03492710|BIOLOGICAL|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
48176534|NCT02901236|PROCEDURE|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
48709874|NCT05618730|DEVICE|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
48709875|NCT05618730|DRUG|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
48019360|NCT04620603|DRUG|Standard-of-Care Immunotherapy|Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
48377099|NCT01224600|OTHER|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
48709876|NCT03068416|BIOLOGICAL|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
48709877|NCT01716338|DRUG|Glyburide|
48709878|NCT01716338|DRUG|Placebo|
48709879|NCT06607276|DRUG|Adebrelimab and capecitabine|Adebrelimab：1200mg, iv, q3w capecitabine:1250mg/m2, po, bid,treat for 2 weeks and rest for 1 week
48709880|NCT06607276|DRUG|capecitabine|capecitabine:1250mg/m2, po, bid,treat for 2 weeks and rest for 1 week
48709881|NCT04152330|OTHER|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
48709882|NCT04740840|DRUG|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
48709883|NCT04740840|DRUG|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
48709884|NCT01749592|DEVICE|cochlear implant|Surgical implantation of a cochlear implant device
48709885|NCT05452369|DRUG|Rhomboid intercostal plane block|- 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
48709886|NCT03564405|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
48709887|NCT06076096|OTHER|Suprainguinal fascia iliaca block|The design of this study involved the retrospective analysis of data. Data was gathered from adult patients falling into the American Society of Anesthesiology (ASA) categories I to III, who were scheduled for elective lower limb surgical procedures. More specifically, patients who had undergone SIFIB either as the primary anesthesia approach or as part of their anesthesia regimen were included. Those who had received general anesthesia, neuraxial anesthesia, or infiltration anesthesia were excluded from the study. Importantly, all patients who participated in the study provided written informed consent for both their involvement in the study and the publication of their data.
48709888|NCT01817101|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
48709889|NCT04966728|DIAGNOSTIC_TEST|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
48709890|NCT00420810|DRUG|MK0928 / Duration of Treatment : 8 Weeks|
48019361|NCT01982916|DRUG|AGR tablet|
48377100|NCT01305694|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10\^5 MSCs per kg,qw,for 4 weeks
48019362|NCT01982916|DRUG|Placebo (for AGR tablet and/or Active Comparator)|
48019363|NCT01982916|DRUG|Active Comparator|
48019364|NCT05558410|DRUG|VX-548|Tablets for oral administration.
48019365|NCT05558410|DRUG|HB/APAP|Capsules for oral administration.
48019366|NCT05558410|DRUG|Placebo (matched to VX-548)|Placebo matched to VX-548 for oral administration.
48019367|NCT05558410|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
48019368|NCT05304559|DRUG|S-Ketamine|S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
48019369|NCT05304559|DEVICE|Continuous iliac fascia space block|After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
48019370|NCT05304559|DRUG|Normal saline|Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
48176535|NCT02901236|DRUG|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
48377101|NCT02583594|DRUG|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
48377102|NCT02583594|DRUG|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
48377103|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
48176536|NCT02901236|DRUG|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
48176537|NCT00004445|PROCEDURE|Surgery|
48176538|NCT00004445|DEVICE|IRS-8|
48176539|NCT02724293|DRUG|pregabaline 300 mg once.|patients received pregabaline 300 mg 2 hours pre-operatively.
48709891|NCT03285087|DRUG|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
48517436|NCT00778388|BIOLOGICAL|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
48709892|NCT00502723|PROCEDURE|Radical retropubic prostatectomy|Radical retropubic prostatectomy
48709893|NCT00502723|PROCEDURE|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
48709894|NCT06285747|OTHER|Non-Interventional Study|Non-Interventional Study
48709895|NCT03215706|BIOLOGICAL|Ipilimumab|Specified dose on specified day
48709896|NCT03215706|BIOLOGICAL|Nivolumab|Specified dose on specified day
48709897|NCT03215706|DRUG|Carboplatin|Specified dose on specified day
48709898|NCT03215706|DRUG|Paclitaxel|Specified dose on specified day
48709899|NCT03215706|DRUG|Pemetrexed|Specified dose on specified day
48709900|NCT03215706|DRUG|Cisplatin|Specified dose on specified day
48176540|NCT02724293|DRUG|pregabaline 300 mg twice.|patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
48176541|NCT02724293|DRUG|pregabaline 600 mg once.|patients received pregabaline 600 mg 2 hours pre-operatively.
48176542|NCT02724293|DRUG|placebo|patients received placebo
48176543|NCT02944396|DRUG|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
48176544|NCT02944396|DRUG|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
48176545|NCT02944396|DRUG|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
48176546|NCT02944396|DRUG|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
48176547|NCT02944396|DRUG|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
48176548|NCT06302725|PROCEDURE|Vaginal self sampling detecting HPV|IMIDs patients who are not up to date with CCS be included into the study to perform a vaginal self-screening (VSS) A positive VSS will be confirmed by a standard HPV test and management of the results of standard HPV test or VSS will be performed as planned following HAS guidelines. For women with a positive VSS, follow-up results (HPV test and cytology, biopsy, etc.) will be collected according to the usual procedures of the screening facility and in accordance with the recommendations of the Health authorities
48176549|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
48176550|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
48709901|NCT05423574|PROCEDURE|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
48709902|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
48709903|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
48709904|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
48709905|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
48709906|NCT06524557|DIAGNOSTIC_TEST|with chronic liver disease|patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
48019371|NCT03532516|DRUG|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
48377104|NCT02583594|DRUG|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
48377105|NCT02583594|DRUG|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
48377106|NCT02583594|DRUG|Loratadine|Pharmaceutical form:tablet Route of administration: oral
48377107|NCT02583594|DRUG|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
48377108|NCT02583594|DRUG|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
48709907|NCT02716701|BEHAVIORAL|Exercise Group|
48709908|NCT02716701|OTHER|Control Group|
48709909|NCT02716701|OTHER|wristband activity tracker|
48377109|NCT06249087|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48377110|NCT06249087|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48377111|NCT06249087|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48377112|NCT02675881|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
48377113|NCT02675881|DEVICE|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
48377114|NCT00069069|DRUG|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
48709910|NCT03981666|OTHER|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~* Ad hoc questionnaire for demographics and medical data;~* Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~* Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
48709911|NCT03946982|PROCEDURE|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
48709912|NCT03946982|PROCEDURE|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
48709913|NCT02238340|DRUG|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
48709914|NCT02238340|DRUG|Extended- release Oxycodone|
48709915|NCT02238340|DRUG|ketoprofen|
48709916|NCT02238340|DRUG|dipirone|
48709917|NCT02238340|DRUG|dexametasone|
48019372|NCT05769452|DEVICE|closed IV catheter system (BD Nexiva™)|There is a high-pressure extension set and a Q-syte split septum needle-free intervention device at the tip of the catheter. It creates a closed integrated system with this apparatus, reducing the risk of catheter-related bloodstream infection.
48019373|NCT05769452|DEVICE|open IV catheter (BD Insyte™ Autoguard™)|BD Instaflash™ needle technology improves initial entry success by confirming vascular access through the needle noch. It has flexible wings for secure cannula fixation.
48019374|NCT01339533|DEVICE|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
48709918|NCT02238340|DRUG|Morphine IV (rescue)|
48377115|NCT05818046|DIAGNOSTIC_TEST|transcutaneous oxygen pressure|External proxe fixed to the skin and ultrasound examination.
48709919|NCT01050374|DRUG|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
48019375|NCT06515548|DRUG|Vitamin D3 mouth wash|topical vitamin D oral mouth wash as every 10ml of the solution contains 3000 IU
48377116|NCT05818046|PROCEDURE|Supervised Exercise therapy|Supervised exercise therapy consists of three exercise sessions per week for 3 months, combining treadmill walking, lower limb muscle strengthening and stretching exercises. It is considered highly effective for people with leg pain related to peripheral arterial disease and has shown statistically significant improvements in maximum walking distance and quality of life parameters.
48019376|NCT01343706|DRUG|Placebo|Solution for oral administration
48377117|NCT05294133|BEHAVIORAL|physical activity|physical activity
48377118|NCT05278975|DRUG|RSO-021|A naturally-occurring, sulfur-rich, cyclic oligopeptide antibiotic of the thiopeptide class.
48709920|NCT01050374|DRUG|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
48377119|NCT03652129|PROCEDURE|Disinfection|Disinfection maneuver using LASER and nano irrigant
48377120|NCT00181051|DEVICE|Alaris AEP monitor|
48377121|NCT04624282|DIAGNOSTIC_TEST|different diseases|Patients will be divided into three groups, including chronic superficial gastritis ,chronic atrophic gastritis and gastric carcinoma.
48377122|NCT00483717|DRUG|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
48709921|NCT02474537|DRUG|INC280|Single 200 mg dose INC280
48709922|NCT04338724|DRUG|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
48019377|NCT01343706|DRUG|Placebo|Immediate release solid oral dosage (film-coated tablet)
48019378|NCT01343706|DRUG|BI 409306|Immediate release solid oral dosage (film-coated tablet)
48019379|NCT01343706|DRUG|BI 409306|solution for oral administration
48019380|NCT00733824|DRUG|AMD3100|
48019381|NCT00733824|DRUG|G-CSF|
48019382|NCT00733824|PROCEDURE|Apheresis|
48019383|NCT06033989|DRUG|Hyaluronic acid|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
48377123|NCT00483717|DRUG|Placebo|Intranasal (IN) placebo
48709923|NCT03726515|BIOLOGICAL|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
48709924|NCT03726515|BIOLOGICAL|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
48377124|NCT06540872|DRUG|[68Ga]Ga-FAPI-46|Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
48377125|NCT00845559|DRUG|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
48709925|NCT02307097|PROCEDURE|Cognitive-Behavioural Bibliotherapy|
48019384|NCT06033989|DRUG|sandblasted, and acid-etched|Delayed dental implant placement after application of surface treatment to enhance Osseointegration and healing .
48019385|NCT06033989|PROCEDURE|Delayed dental implant|Surgical procedure of delayed dental implant in posterior maxilla after application of surface treatment to enhance Osseointegration and healing .
48377126|NCT00003582|DRUG|amifostine trihydrate|
48377127|NCT00003582|DRUG|cisplatin|
48377128|NCT00003582|DRUG|fluorouracil|
48377129|NCT00003582|DRUG|paclitaxel|
48377130|NCT00003582|PROCEDURE|quality-of-life assessment|
48377131|NCT00003582|RADIATION|radiation therapy|
48709926|NCT02307097|PROCEDURE|Cognitive-Behavioural Therapy|
48709927|NCT02307097|OTHER|WAIT|
48709928|NCT01989702|OTHER|Fermented blueberry drink|
48019386|NCT04592705|DEVICE|Therapeutic plasma exchange|"TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP."
48019387|NCT00634413|DRUG|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
48019388|NCT00634413|DRUG|Placebo|Inhaled matching placebo administered twice daily for 28 days
48019389|NCT00634413|DRUG|Budesonide|Inhaled budesonide twice daily for 28 days
48019390|NCT02742103|BIOLOGICAL|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
48019391|NCT02742103|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
48019392|NCT02681926|PROCEDURE|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
48709929|NCT01989702|OTHER|Placebo drink|
48709930|NCT01989702|OTHER|Sachets with probiotic bacterial powder|
48709931|NCT01989702|OTHER|Sachets with placebo powder|
48019393|NCT04378075|DRUG|Vatiquinone|Vatiquinone will be administered per the treatment arm description.
48019394|NCT04378075|OTHER|Placebo|Vatiquinone-matching placebo will be administered per the treatment arm description
48019395|NCT03313596|DRUG|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
48019396|NCT03313596|PROCEDURE|LT|Orthotopic LT and subsequent immunosuppression therapy
48019397|NCT00982189|DRUG|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
48019398|NCT00982189|DRUG|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
48019399|NCT00377676|DRUG|Cycloset|Usual diabetes therapy plus Cycloset
48019400|NCT00377676|DRUG|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
48176551|NCT03837236|OTHER|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
48709932|NCT06606639|DIETARY_SUPPLEMENT|Caffeine|acute caffeine intake (3 mg/kg)
48019401|NCT06068205|DIAGNOSTIC_TEST|Blood test - atomic force microscopy in the force spectroscopy mode|A single blood test to be analysed through atomic force microscopy in the force spectroscopy mode
48377132|NCT01472666|DIETARY_SUPPLEMENT|High content of MC-SFA|12 weeks dietary intervention
48377133|NCT01472666|DIETARY_SUPPLEMENT|Whey|12 weeks dietary intervention
48709933|NCT06606639|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
48709934|NCT01304368|PROCEDURE|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
48709935|NCT04969965|DRUG|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
48709936|NCT00795834|DIETARY_SUPPLEMENT|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
48709937|NCT00795834|DIETARY_SUPPLEMENT|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
48377134|NCT01472666|DIETARY_SUPPLEMENT|Low content of MC-SFA|12 weeks dietary intervention
48019402|NCT03323268|DEVICE|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
48019403|NCT05030922|OTHER|Antiatherogenic diet|Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
48019404|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 1
48019405|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 2
48019406|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 dose from Dose Level 3
48019407|NCT06611436|DRUG|BE-101|IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
48019408|NCT03717337|PROCEDURE|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
48176552|NCT04665362|DRUG|Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib|"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
48176553|NCT01010087|DRUG|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
48377135|NCT01472666|DIETARY_SUPPLEMENT|Casein|12 weeks dietary intervention
48377136|NCT05765994|DIAGNOSTIC_TEST|Modified hydrogen breath test|A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
48709938|NCT05720364|DRUG|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
48019409|NCT03717337|PROCEDURE|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
48019410|NCT04317612|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
48019411|NCT04317612|OTHER|Reference product|Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
48019412|NCT03606161|OTHER|Questionnaire Administration|Ancillary studies
48019413|NCT03606161|PROCEDURE|Transcranial Magnetic Stimulation|Undergo nrTMS
48019414|NCT04424121|DIAGNOSTIC_TEST|CCTA|Coronary Computed Tomography Angiography
48709939|NCT05720364|DRUG|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
48709940|NCT05720364|DRUG|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
48709941|NCT04533542|OTHER|Measurement|Undergo sensory measurements
48709942|NCT04533542|OTHER|Questionnaire Administration|Ancillary studies
48709943|NCT03946124|DRUG|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
48709944|NCT05344339|PROCEDURE|Distal gastrectomy|Reconstruction after Distal Gastrectomy
48709945|NCT00067847|BEHAVIORAL|State-directed nutrition policy change|
48377137|NCT03294811|DEVICE|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
48709946|NCT01498627|BIOLOGICAL|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
48019415|NCT01895894|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 20\~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
48019416|NCT02304094|DRUG|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
48019417|NCT02304094|OTHER|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
48019418|NCT06573320|OTHER|physical exercise|physical exercise
48019419|NCT05102994|DIAGNOSTIC_TEST|mutation test|detect the tumor-related mutation in introcular fluid
48176554|NCT01625676|OTHER|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
48176555|NCT01625676|OTHER|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
48709947|NCT01498627|OTHER|Data collection|PGRx information system
48709948|NCT04410666|OTHER|Green Tea mouthwash|"an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute."
48019420|NCT05036187|BEHAVIORAL|Behavioral Weight Loss Intervention|Rx Weight Loss: PRIDE is a fully automated online behavioral obesity treatment that is tailored for sexual minority women and involves viewing 12 online video lessons delivered each week, self-monitoring body weight, calorie intake, and physical activity levels, and receiving personalized automated weekly feedback on progress toward goals.
48019421|NCT05036187|BEHAVIORAL|Minority Stress Intervention|The Minority Stress Intervention is designed to help sexual minority women cope with stress and stigma (e.g., due to weight, sexual orientation, gender). In this program, participants watch online video lessons that teach cognitive and behavioral strategies for coping with minority stress so that it may have less of an influence on participants' weight and well-being.
48019422|NCT05036187|BEHAVIORAL|Negative Body Image Intervention|The Negative Body Image Intervention is designed to help participants improve their body image. In this program, participants will watch online video lessons that provide education on queer women's body image and teach cognitive and behavioral strategies for improving your body image (regardless of your weight) to reduce its influence on your health.
48019423|NCT05036187|BEHAVIORAL|Social Support Intervention|The Social Support Intervention provides online opportunities for participants to receive more social support as they work toward their weight loss goals. Participants receive education on the importance of social support for weight management, they can earn badges for completing program milestones, and they gain access to a private online forum to get support and advice from other participants.
48019424|NCT01497379|PROCEDURE|surgical implantation of subretinal device|surgical implantation of subretinal device
48176556|NCT01993277|DEVICE|Nexalin Brain Stimulator|
48176557|NCT01993277|DEVICE|Fischer Wallace Stimulator|
48176558|NCT01993277|DEVICE|David Delight Stimulator|
48019425|NCT01497379|PROCEDURE|surgical implantation of subretinal device|intra-individual implant OFF
48176559|NCT01993277|BEHAVIORAL|Relaxation Therapy|
48176560|NCT06045663|PROCEDURE|laminectomy without lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
48176561|NCT06045663|PROCEDURE|laminectomy with lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
48176562|NCT01619462|BIOLOGICAL|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
48176563|NCT03497143|DRUG|Lamotrigine|Patients are tested for their normal prescription lamotrigine medication
48176564|NCT06055842|OTHER|over-denture|implant retained overdenture prosthesis.
48377138|NCT01261299|DRUG|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
48709949|NCT04410666|OTHER|Placebo Mouthwash|distilled water
48709950|NCT05571007|OTHER|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
48709951|NCT05571007|OTHER|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
48709952|NCT05997849|BEHAVIORAL|Mobile application|A mobile application for the management of anxiety and depressive symptoms through self-applied emotional regulation tools.
48709953|NCT04429581|OTHER|Anthropometry|
48377139|NCT06536478|OTHER|exercise|50 minutes of exercise twice a week, including stretching, core exercises, gross motor movements and balance exercises for 5 weeks
48377140|NCT06536478|OTHER|education|The patient will be given a one-time exercise education session and a 50-minute video that included stretching, core exercises, gross motor movements and balance exercises that could be practiced at home.
48377141|NCT02208466|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
48377142|NCT02208466|DRUG|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
48517437|NCT00778388|DRUG|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
48377143|NCT02208466|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
48377144|NCT02208466|DRUG|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
48517438|NCT03516656|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
48517439|NCT03516656|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
48709954|NCT05989568|BEHAVIORAL|BASIS-T|BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
48709955|NCT05989568|BEHAVIORAL|Attention Control (ACC)|Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
48709956|NCT01929720|BEHAVIORAL|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
48709957|NCT04536948|OTHER|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
48019426|NCT04510116|BEHAVIORAL|Adults in the Making program|The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
48709958|NCT04536948|OTHER|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
48709959|NCT05553964|DIAGNOSTIC_TEST|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
48176565|NCT06128213|DRUG|NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))|oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days
48709960|NCT00715364|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
48709961|NCT00715364|DRUG|Saline Placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
48709962|NCT03787810|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
48709963|NCT05084560|DRUG|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
48176566|NCT02836041|BEHAVIORAL|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
48176567|NCT02836041|DEVICE|actigraph|This device reliably measures sleep by monitoring the child's motion.
48377145|NCT03651440|OTHER|PNF|PNF
48709964|NCT05084560|DRUG|Placebo|Placebo
48377146|NCT03651440|OTHER|lumbar stabilization training|lumbar stabilization training
48377147|NCT03651440|OTHER|Physical Therapy|Physical Therapy
48377148|NCT03651440|OTHER|Control|Control group
48377149|NCT04209166|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
48377150|NCT04209166|DRUG|SSRIs/SNRIs+Mood Stabilizer|Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
48377151|NCT04209166|DRUG|SSRIs/SNRIs+Quetiapine|Patients will be treated with Quetiapine combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
48019427|NCT05875584|DIAGNOSTIC_TEST|rbcDNA test|fecal immunochemical test
48019428|NCT06105476|OTHER|Alcohol|Test drink with 12 g alcohol (30 g vodka 40%) in water
48019429|NCT06105476|OTHER|Alcohol+protein|Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water
48019430|NCT06105476|OTHER|Alcohol+retinol|Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water
48377152|NCT04209166|DRUG|Usual Treatment|Patients' treatment will be decided by the clinical doctor.
48517440|NCT03685344|DRUG|Loncastuximab Tesirine and Durvalumab|intravenous infusion
48709965|NCT02181478|DRUG|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
48709966|NCT02181478|DRUG|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
48709967|NCT02181478|RADIATION|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
48709968|NCT02181478|DRUG|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
48377153|NCT02665754|BIOLOGICAL|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
48709969|NCT02181478|DRUG|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
48377154|NCT02665754|BIOLOGICAL|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
48377155|NCT02665754|DRUG|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
48377156|NCT01741727|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion.
48377157|NCT05127109|COMBINATION_PRODUCT|Nutrition Ecosystem pathway|"1. parenteral nutrition initiated within 72 hours of operative intervention~   * Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~   * Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~  * BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~  * Philips Lumify L12-4 broadband linear array transducer ultrasound~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake"
48377158|NCT05127109|OTHER|Comparator|retrospective cohort of 300 historical matched control subjects
48377159|NCT02392377|DRUG|Paclitaxel|Given IV or IVPB
48377160|NCT02392377|DRUG|Carboplatin|Given IV or IVPB
48377161|NCT02392377|DRUG|Oxaliplatin|Given IV
48517441|NCT05088135|DEVICE|Bilateral Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as bilateral Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
48517442|NCT05088135|DEVICE|Unilateral-Right Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-right Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
48709970|NCT02181478|PROCEDURE|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
48019431|NCT06105476|OTHER|Retinol|Test drink with 1000 μg retinol in water
48019432|NCT02282449|DEVICE|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
48019433|NCT02282449|DEVICE|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
48019434|NCT06152276|OTHER|Diverting loop ileostomy|Diverting loop ileostomy following low anterior resection of colorectal cancer
48019435|NCT02403310|DRUG|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~* Dose Level 2: 80 mg twice weekly.~* Dose Level 1 (starting dose): 60 mg twice weekly.~* Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
48019436|NCT02403310|DRUG|Daunorubicin|"Induction: Daunorubicin 60 mg/m\^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m\^2/day (days 1-2)."
48176568|NCT02815059|DRUG|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
48377162|NCT02392377|DRUG|Leucovorin Calcium|Given IV
48377163|NCT02392377|DRUG|Fluorouracil|Given IV
48377164|NCT02392377|RADIATION|Radiation Therapy|Undergo radiation therapy
48377165|NCT02392377|PROCEDURE|Therapeutic Conventional Surgery|Undergo esophagectomy
48377166|NCT02392377|OTHER|Laboratory Biomarker Analysis|Correlative studies
48377167|NCT05718921|DRUG|YR001 Dose A on low body surface area|Part A: Single topical dose
48377168|NCT05718921|DRUG|YR001 Dose A on middle body surface area|Part A: Single topical dose
48377169|NCT05718921|DRUG|YR001 Dose A on high body surface area|Part A: Single topical dose
48709971|NCT02181478|PROCEDURE|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10\^6cells/kg (+/-20%).
48709972|NCT04790513|BIOLOGICAL|lerodalcibep|anti-PCSK9 small binding protein
48709973|NCT04790513|BIOLOGICAL|evolocumab|monoclonal antibody to PCSK9
48709974|NCT04790513|BIOLOGICAL|alirocumab|monoclonal antibody to PCSK9
48709975|NCT00301548|DRUG|perioperative chemotherapy|
48709976|NCT00393302|PROCEDURE|HIV screening in pregnancy|
48176569|NCT02815059|DRUG|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
48176570|NCT02815059|DRUG|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
48709977|NCT00693641|OTHER|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
48709978|NCT00693641|OTHER|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
48709979|NCT05827562|DIAGNOSTIC_TEST|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+"
48709980|NCT01453738|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
48709981|NCT01453738|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
48709982|NCT00442832|DRUG|TD-1792|TD-1792 2 mg/kg/day IV
48019437|NCT02403310|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m\^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m\^2/day (continuous infusion on days 1-5)."
48377170|NCT05718921|DRUG|YR001 Dose B on low body surface area|Part A: Single topical dose
48176571|NCT05101915|DRUG|RESP301|Inhaled IMP delivered via nebulisation
48377171|NCT05718921|DRUG|YR001 Dose B on middle body surface area|Part A: Single topical dose
48709983|NCT00442832|DRUG|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
48709984|NCT05989087|DIAGNOSTIC_TEST|CSF|Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
48176572|NCT04582669|DRUG|Intralesional Triamcinolone 10 mg/mL|Injection of 1 mL intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas.
48176573|NCT04582669|DRUG|Intralesional Triamcinolone 20 mg/mL|Injection of 1 mL intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas.
48377172|NCT05718921|DRUG|YR001 Dose B on high body surface area|Part A: Single topical dose
48709985|NCT06154941|PROCEDURE|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
48709986|NCT06154941|PROCEDURE|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
48709987|NCT02312219|DRUG|Folic Acid|1 mg folic acid once daily
48176574|NCT04582669|DRUG|Intralesional Triamcinolone 40 mg/mL|Injection of 1 mL intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas.
48176575|NCT04582669|DRUG|Placebo|Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
48176576|NCT02832284|DEVICE|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
48176577|NCT00243022|DRUG|Boswellia serrata extract|given orally
48176578|NCT00243022|DIETARY_SUPPLEMENT|cyanocobalamin|given orally
48176579|NCT00665132|DEVICE|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
48176580|NCT04721782|OTHER|smoking|to assess the effect of smoking of fetal liver circulation with prenatal Doppler Ultrasonography
48176581|NCT00451828|DRUG|Simvastatin|40mg/day
48176582|NCT03009019|DRUG|DFN-15 Active|
48377173|NCT05718921|DRUG|Placebo on low body surface area|Part A: Single topical dose
48377174|NCT05718921|DRUG|Placebo on middle body surface area|Part A: Single topical dose
48377175|NCT05718921|DRUG|Placebo on high body surface area|Part A: Single topical dose
48377176|NCT05718921|DRUG|YR001 Dose A on high body surface area twice daily|Part B: Multiple topical dose
48377177|NCT05718921|DRUG|YR001 Dose B on high body surface area twice daily|Part B: Multiple topical dose
48377178|NCT05718921|DRUG|Placebo on high body surface area twice daily|Part B: Multiple topical dose
48377179|NCT02544607|DRUG|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
48377180|NCT02544607|OTHER|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
48377181|NCT02158949|BEHAVIORAL|mROAD|
48709988|NCT02312219|DRUG|Placebo|placebo once weekly
48709989|NCT02312219|DRUG|Low Dose Methotrexate|An anti-inflammatory drug
48709990|NCT03984149|OTHER|Observational study|Observational study: There is no intervention.
48709991|NCT05302206|DIETARY_SUPPLEMENT|colonic infusion|colonic glucose or colonic saline infusion
48709992|NCT05102617|DEVICE|PicoSure Pro Device|This device will be used for up to 4 treatments over the designated areas.
48709993|NCT05102617|DEVICE|PicoSure Device|This device will be used for up to 4 treatments over the designated areas.
48709994|NCT05102617|DRUG|Topical Cosmeceuticals|Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
48176583|NCT03009019|OTHER|DFN-15 Placebo|
48176584|NCT00507806|DRUG|perflutren lipid microsphere|
48709995|NCT06235762|BEHAVIORAL|Nutritional Intervention|This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
48019438|NCT04453592|OTHER|No intervention assigned as part of this study.|"The intervention included in this study is part of routine medical care, and not assigned as a result of study participation. This study includes only the addition of a measurement; the bent knee fall out test. Therefore, we believe this study design is observational, and in line with the provided observation study design definition: Observational: studies in human beings in which biomedical and/or health outcomes are assessed in predefined groups of individuals. Participants in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the study participants. This includes when participants receive interventions as part of routine medical care, and a researcher studies the effect of the intervention.~See uploaded study protocol for further details."
48019439|NCT01274637|DRUG|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
48019440|NCT05654506|DRUG|Daratumumab|1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
48019441|NCT02717091|DRUG|FOLFIRINOX|
48019442|NCT02717091|DRUG|gemcitabine + nab-paclitaxel|
48019443|NCT00165282|BEHAVIORAL|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
48019444|NCT00165282|BEHAVIORAL|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
48019445|NCT06660550|PROCEDURE|laparoscopic inguinal hernia repair|traditional laparoscopic repair
48019446|NCT06660550|PROCEDURE|Needlescopic inguinal hernia repair|Needlescopic inguinal hernia repair
48019447|NCT06662682|OTHER|Whole-Body Vibration|The intervention (IC) will be specified as a five-minute Whole-Body Vibration session. The WBV take place on a side alternating vibration plate (Wellengang, Germany). The patients stand barefoot on the vibration plate on a prescribed position. In this position the amplitude will be 6-7mm. The WBV protocol contains mobilizing sequences with lower frequencies and activating sequences with higher frequencies
48176585|NCT01773876|DRUG|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
48176586|NCT01773876|DRUG|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
48176587|NCT05269927|DIAGNOSTIC_TEST|EEG|resting state EEG
48517443|NCT05088135|DEVICE|Unilateral-Left Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM.|It will be divided three groups as unilateral-left Auricular Vagus Nerve Stimulation (VSS). Auricular Vagus Nerve Stimulation will be performed with a device called VAGUSTIM. Auricular Vagus Nerve Stimulation will be performed for 20 minutes with a frequency of 10 Hz and a pulse width of 300 µs.
48709996|NCT04416607|DRUG|Corifollitropin Alfa|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
48709997|NCT04416607|DRUG|Menotropins|Primary outcome measure is ovarian response measured by FORT. Drugs are administrated for controlled ovarian stimulation prior in vitro fertilization.
48709998|NCT02408081|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
48709999|NCT05569538|DRUG|Bomedemstat|Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
48710000|NCT03080545|DRUG|Enstilar 0.005%-0.064% Topical Foam|Topical foam
48710001|NCT00875056|DRUG|Vorinostat|Two 100 mg oral capsules of vorinostat, twice daily (400 mg/day), on Days 1 through 14 of each 21 day cycle
48710002|NCT06349187|DIAGNOSTIC_TEST|Interview|Interviewing with using the Hall Emotional Intelligence test, the Maslach emotional burnout test, and the test for determining general and specialized digital competencies
48710003|NCT02142283|DEVICE|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
48710004|NCT02142283|OTHER|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
48019448|NCT06662682|OTHER|Control Condition|Non-intervention control condition
48176588|NCT05269927|DIAGNOSTIC_TEST|DNA samples|genotypings of twelve CNTNAP2 SNPs from DNA obtained by saliva samples
48176589|NCT05269927|DIAGNOSTIC_TEST|clinical data|"standardized scales measuring the infants' cognitive, motor and linguistic development administered at 6, 12 and 18. Measures available at 6 and 12 months: a) Bayley Scales of Infant and Toddler Development- Third Edition; b) Griffiths mental development scales (0-2) (GMDS-R); Measures available at 18 months: c) Language Development Survey (LDS); d) Il PRIMO VOCABOLARIO DEL BAMBINO (PVB); e) CHILD BEHAVIOR CHECKLIST (CBCL); (f) Modified Checklist for Autism in Toddlers (M-CHAT)."
48377182|NCT01171274|BEHAVIORAL|Hatha Yoga|"* 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day."
48710005|NCT00054951|DRUG|MTC-DOX for Injection|
48710006|NCT01524432|DRUG|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
48710007|NCT01524432|DRUG|Placebo|No drug loaded microcapsules socks
48710008|NCT03349645|BIOLOGICAL|4 mL injection of AMPION™|4 mL injection of AMPION™
48710009|NCT03455829|DRUG|G1T38|CDK 4/6 inhibitor
48710010|NCT03455829|DRUG|Osimertinib|EGFR TKI; 80 mg
48710011|NCT03172065|DRUG|Normal saline|intravenous flluid
48710012|NCT03172065|DRUG|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
48710013|NCT04066569|OTHER|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
48176590|NCT05269927|OTHER|environmental data|questionnaires administered to parents related to the following environmental factors: a) information about the presence of a clinical diagnosis of neurodevelopmental disorders within first-degree relatives; b) gestational age; c) birth weight; d) parental age and education; e) socio-economic status
48176591|NCT03656718|BIOLOGICAL|nivolumab|(Subcutaneous) Specified dose on specified days
48176592|NCT03656718|DRUG|rHuPH20|Specified dose on specified days Permeation enhancer
48710014|NCT04066569|OTHER|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
48176593|NCT03656718|BIOLOGICAL|nivolumab|(IV) Specified Dose on Specified Days
48176594|NCT04920747|DRUG|Taxane|docetaxel or paclitaxel
48176595|NCT04917263|DIAGNOSTIC_TEST|Immunohistochemistry, Flow citometry, Trascriptome analysis|we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
48710015|NCT06064877|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
48710016|NCT06064877|BIOLOGICAL|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
48176596|NCT02680197|DRUG|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
48176597|NCT04805957|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
48176598|NCT04001738|OTHER|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
48176599|NCT00197106|DRUG|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
48176600|NCT00197106|DRUG|fluticasone propionate 2 x 100 mcg|comparator
48377183|NCT01171274|BEHAVIORAL|Information regarding exercises and behaviour|"* 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
48377184|NCT04279873|DIAGNOSTIC_TEST|Microbiological diagnostics on pulmonary secretion|Culture, 16s, 18s, next generation sequencing
48377185|NCT02260570|DRUG|Tolcapone|COMT Inhibitor
48377186|NCT02260570|DRUG|Placebo|A pill that contains no active ingredient
48377187|NCT00766129|DEVICE|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
48377188|NCT00766129|DEVICE|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
48377189|NCT05334576|OTHER|Crizanlizumab|Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months
48377190|NCT06297642|DRUG|TQB2928 injection|Anti-CD47 monoclonal antibody
48377191|NCT06297642|DRUG|Penpulimab|Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
48377192|NCT01335620|DRUG|Raltegravir|400 mg twice daily
48710017|NCT06064877|OTHER|Placebo|Placebo for this study will be normal saline
48710018|NCT03856008|OTHER|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
48710019|NCT03856008|OTHER|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
48710020|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype AA|Hemodialysis
48710021|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype BB|Hemodialysis
48710022|NCT02377570|DEVICE|THERNOVA 400 dialyzer prototype CC|Hemodialysis
48710023|NCT02377570|DEVICE|FX CorDiax 80 dialyzer|Hemodialysis
48710024|NCT04046315|DIAGNOSTIC_TEST|CMR|GLS measurement with CMR
48710025|NCT01731730|DRUG|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
48710026|NCT01731730|DRUG|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
48710027|NCT01731730|DRUG|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
48710028|NCT01037049|OTHER|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
48710029|NCT04217967|DRUG|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
48710030|NCT04217967|DRUG|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
48377193|NCT01335620|DRUG|Tenofovir|245 mg once daily
48377194|NCT01335620|DRUG|Emtricitabine|200mg once daily
48710031|NCT00773786|DRUG|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
48377195|NCT01726426|DIETARY_SUPPLEMENT|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
48377196|NCT04852185|BIOLOGICAL|Vi-TT|Single-dose V-TT administered to children and adolescents between the ages of 9 months to 15 years.
48377197|NCT04852185|BIOLOGICAL|MCV-A vaccine|Single-dose of MCV-A vaccine (a meningococcal vaccine)
48710032|NCT00773786|DRUG|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
48710033|NCT00622947|PROCEDURE|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
48377198|NCT00207116|DRUG|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
48377199|NCT03433482|BIOLOGICAL|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
48377200|NCT03433482|BIOLOGICAL|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
48377201|NCT02064400|OTHER|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
48377202|NCT02064400|OTHER|Semi-structured patient interview|Semi-structured patient interview
48377203|NCT01901952|BEHAVIORAL|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
48377204|NCT01901952|BEHAVIORAL|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
48377205|NCT03054493|BEHAVIORAL|no intervention|no intervention
48710034|NCT00622947|PROCEDURE|Sham-rTMS|The coil is angled 90 degrees away from the scalp
48710035|NCT03885570|PROCEDURE|Mitral valve replacement|Blood transfusion
48710036|NCT03553498|DRUG|IV acetaminophen|acetaminophen given intravenously
48710037|NCT03553498|DRUG|IV placebo|given intravenously
48710038|NCT03553498|DRUG|hydromorphone|hydromorphone given intravenously
48710039|NCT01567501|DRUG|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
48710040|NCT01567501|DRUG|Levocetirizine Dihydrochloride|5 mg tablet once in a day
48710041|NCT06279793|DRUG|Long-chain n-3 fatty acids|"Omegaven® is a 10% fish oil emulsion supplement with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It is a lipid emulsion supplement that optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe:~Day -1: 0.20 g fish oil/kg BW/d; the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion.~Intraoperative Day: No dose~Post OP (Day 0): 0.20 g fish oil/kg BW/d~Post OP ( Day 1 to max Day 7): 0.20 g fish oil/kg BW/d"
48710042|NCT06279793|DRUG|Intravenous 0.9% Sodium Chloride|Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d)
48710043|NCT05939856|OTHER|Lymph node dissection before bladder resection|Lymph node dissection before bladder resection
48710044|NCT05939856|OTHER|Lymph node dissection after bladder resection|Lymph node dissection after bladder resection
48019449|NCT06572696|DIAGNOSTIC_TEST|Shulder Ultrasound|"Ultrasound Shoulder Pathology Rating Scale (USPRS) will be used in the evaluation. While the participants are in a sitting position; A total of 5 variables, including bicipital tendinopathy, supraspinatus tendinopathy, greater tuberculum cortical surface irregularity, supraspinatus dynamic and subscapularis dynamic examination, are evaluated and scored according to the level of pathology; The total USPRS score is obtained by adding the scores of all variables.~Another parameter evaluated by ultrasonography in this study is the acromiohumeral distance measurement. In AH distance measurement with MSK-US, two measurements will be made with all participants in a neutral resting position and their hands at the top of the circle with the elbow angle of 110 °. In both positions, the probe will be placed longitudinally at the lateral point of the acromion determined by palpation, the distance determined between the acromion and the humeral head will be displayed and measured."
48019450|NCT01856140|BIOLOGICAL|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
48019451|NCT04670679|DRUG|ERAS-601|Administered orally
48019452|NCT04670679|DRUG|Cetuximab|Administered via intravenous infusion
48019453|NCT04670679|DRUG|Pembrolizumab|Administered via intravenous infusion
48019454|NCT04283734|DEVICE|iFR pullback with Syncvision software (Volcano company)|iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
48710045|NCT03186391|OTHER|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
48710046|NCT05685732|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
48019455|NCT04981041|DRUG|Prasugrel or Ticagrelor|Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)
48019456|NCT04981041|DRUG|Clopidogrel|Clopidogrel and NOAC
48019457|NCT00985348|DRUG|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
48019458|NCT03808610|DRUG|Cyclophosphamide|Given IV
48019459|NCT03808610|DRUG|Cytarabine|Given IV
48019460|NCT03808610|DRUG|Dexamethasone|Given IV or PO
48019461|NCT03808610|DRUG|Methotrexate|Given IV
48019462|NCT03808610|DRUG|Nelarabine|Given IV
48019463|NCT03808610|DRUG|Pegaspargase|Given IV
48377206|NCT06042556|OTHER|IUD self-removal guide|We previously developed an online guide for IUD self-removal through an iterative process including advice from key expert informants, focus groups, interviews, and a pilot clinical study. It includes an online animation, step-by-step guide, troubleshooting tips, and information about pregnancy and contraception.
48710047|NCT05685732|OTHER|placebo|matching placebo
48019464|NCT03808610|DRUG|Prednisone|Given PO
48019465|NCT03808610|BIOLOGICAL|Rituximab|Given IV
48019466|NCT03808610|DRUG|Venetoclax|Given PO
48019467|NCT03808610|DRUG|Vincristine|Given IV
48019468|NCT03679260|OTHER|Carbohydrate restricted diet|20 grams total carbs/day
48019469|NCT03679260|OTHER|Non-restricted diet|Subject follows normal diet
48710048|NCT04963114|BEHAVIORAL|art therapy|guided art tour and workshop
48710049|NCT03302117|OTHER|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
48377207|NCT01484691|DRUG|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
48710050|NCT01620151|PROCEDURE|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
48710051|NCT00497328|DRUG|N-acetylcysteine|
48710052|NCT00497328|DRUG|Sodium Bicarbonate|
48710053|NCT00297973|PROCEDURE|Blood pressure measurements|
48710054|NCT00297973|PROCEDURE|Blood samples|
48019470|NCT03679260|OTHER|Phone counseling with dietitian|Weekly calls with dietitian
48019471|NCT03102476|DRUG|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
48377208|NCT02455960|DIETARY_SUPPLEMENT|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
48710055|NCT02362945|DRUG|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
48019472|NCT05686408|DRUG|TNX-601 ER|Patients will take 1 pill orally once daily for 6 weeks.
48019473|NCT05686408|DRUG|Placebo|Patients will take 1 pill orally once daily for 6 weeks.
48377209|NCT02455960|DIETARY_SUPPLEMENT|Placebo|
48377210|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Patients|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
48377211|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Caregiver|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
48377212|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
48377213|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
48377214|NCT00709449|DRUG|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
48377215|NCT03423004|PROCEDURE|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
48377216|NCT01520038|RADIATION|Proton therapy|
48377217|NCT01520038|RADIATION|IMRT|
48710056|NCT01767077|DIETARY_SUPPLEMENT|Butter oil|Daily intake of 40 g butter oil
48710057|NCT01767077|DIETARY_SUPPLEMENT|Cream|Daily intake of 100 g cream (40%)
48710058|NCT00394602|BEHAVIORAL|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
48710059|NCT00394602|OTHER|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
48710060|NCT05300685|DRUG|Standard Buccal Harvest|Our institutions current anesthetic regimen. Comparison group
48710061|NCT05300685|DRUG|Basic buccal procedure + Long acting local|Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
48710062|NCT05300685|DRUG|Basic buccal procedure + Buccal block|Addition of long-acting local anesthetic as a buccal block after oral graft harvest
48710063|NCT00000429|DRUG|Calcium carbonate|
48710064|NCT00002454|BIOLOGICAL|autologous tumor cell vaccine|
48710065|NCT02257177|DRUG|Inhaled TD139|DPI Galectin-3 inhibitor
48710066|NCT02257177|DRUG|Placebo|DPI placebo
48710067|NCT03622671|PROCEDURE|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
48710068|NCT03622671|PROCEDURE|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
48377218|NCT00835861|DRUG|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
48377219|NCT00835861|DRUG|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values \<90 and one hour post prandial values \<130.
48710069|NCT06606418|OTHER|Acupuncture group|The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.
48710070|NCT06606418|OTHER|Sham acupuncture group|The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
48377220|NCT05375942|DRUG|Inflectra|1. To describe the characteristics of patients newly initiated on Inflectra.
48377221|NCT05375942|DRUG|Inflectra|2. To describe 6-month outcomes after initiating Inflectra, among patients who have 6 months follow-up information in the CorEvitas' RA Registry.
48377222|NCT02900131|DRUG|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
48377223|NCT02900131|DRUG|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
48377224|NCT02066909|DRUG|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
48377225|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
48517444|NCT05258201|OTHER|Strain-counterstrain|Strain-counterstrain is also used for manual Trigger Point processing. This involves identifying active TRP and then applying pressure until a ridiculous reaction occurs. The area is then positioned to reduce tension in the injured muscle and later reduce tripod pain. When the pain subsides, the tissues that are most stressed feel relaxed and there is a local decrease in the ground
48710071|NCT00933244|DIETARY_SUPPLEMENT|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
48019474|NCT06527287|OTHER|Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)|The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.
48377226|NCT02066909|DRUG|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
48377227|NCT02066909|DRUG|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
48377228|NCT02066909|DRUG|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
48517445|NCT05258201|OTHER|Muscle Energy Technique|Muscle Energy Technique is a common way to achieve muscle tension release (stop) before stretching other's adductor muscles
48517446|NCT05803239|PROCEDURE|EBUS-TBNA|Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
48517447|NCT05803239|PROCEDURE|EBUS-TBMC via a tunnel|Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.
48019475|NCT06527287|OTHER|Evidence-Based|The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
48377229|NCT02066909|DRUG|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
48377230|NCT02066909|DRUG|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
48377231|NCT02066909|DRUG|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
48377232|NCT02066909|DRUG|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
48710072|NCT00933244|DIETARY_SUPPLEMENT|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
48710073|NCT00933244|DIETARY_SUPPLEMENT|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
48710074|NCT04267731|DIETARY_SUPPLEMENT|VMK223|Heat killed and purified Bifidobacterium breve polysaccharide-based extract
48710075|NCT04267731|DIETARY_SUPPLEMENT|Cellulose|Bulking agent in food production without probiotic properties
48019476|NCT06222255|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide (Lopmin®) involves administering Loperamide orally, with a daily dosage of 2 mg for males (2 tablets once daily) and 1 tablet for females (1 tablet once daily). This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate symptoms associated with LARS (Low Anterior Resection Syndrome).
48019477|NCT05609097|OTHER|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
48019478|NCT05609097|OTHER|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
48377233|NCT06231901|OTHER|CO-OP|With a task-specific and goal-focused CO-OP approach; it is aimed to increase one's skills, to teach to use self-generated cognitive strategies, and to encourage generalization and transfer to new situations and activities.
48377234|NCT06231901|OTHER|GDT|Goal-directed training included the active implementation of task-specific activities related to the child's functional goals. Focusing on motor learning, GDT is an activity-based approach to therapy that uses meaningful, self-selected goals to provide opportunities for problem solving and indirectly guide the movements necessary to successfully meet task demands
48377235|NCT06231901|OTHER|traditional occupational therapy|The program included functional one-handed and two-handed training and consisted of advice and treatment aimed at reducing spasticity, improving hand function and activities of daily living, and providing appropriate orthoses. It also includes techniques aimed at improving impairment (e.g., stretching, sensory stimulation) and strengthening activities (e.g., motor training, environmental modification, performing specific target activities) to help participants achieve their individual goals.
48377236|NCT05681221|OTHER|Nano silver particles and calcium hydroxide|Combination of two materials that can possibly eradicate the mixed odontogenic infection in the periapical area and dentinal tubules in necrotic primary second molars.
48377237|NCT05681221|OTHER|TAP|Triple antibiotic paste (TAP) is considered the gold standard in LSTR. It is a combination of ciprofloxacin, metronidazole and minocycline. Many anaerobic bacteria are resistant to ciprofloxacin. Hence, it is often used with metronidazole in treating mixed infections to compensate for its limited scope. Therefore, TAP can affect gram-negative, gram-positive, and anaerobic bacteria, and this combination can be effective against odontogenic microorganisms.
48377238|NCT04386798|OTHER|survey work|Bebeği Yenidoğan Yoğun Bakım Ünitesinde Yatan Annelerin Stres ve Anksiyete Düzeyleri anket yöntemi ile ölçülecektir.
48517448|NCT00770328|DRUG|Pentoxifylline|400mg PO TID x 8 weeks
48517449|NCT00770328|DRUG|Placebo|PO TID x 8 weeks
48710076|NCT04400084|OTHER|Placenta perfusion|Placenta perfusion in double closed circuit, during 3 hours
48517450|NCT06333704|BIOLOGICAL|SPIKEVAX Bivalent|No study drug will be administered during this study as this is an observational study.
48377239|NCT03130556|DRUG|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
48377240|NCT03130556|OTHER|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
48377241|NCT03130556|DRUG|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
48377242|NCT04803032|PROCEDURE|Superficial parotidectomy|The parotid gland was exposed with its capsule by subplatysmal and SMAS flaps. Dissection was performed from the tragal cartilage until the bony anterior wall of the external auditory canal; from there, the dissection was done using a blunt instrument. The styloid process's base is the upper point of the trident landmark; it is the superior portion of the trident landmark. Identification of the posterior belly of the digastric muscle till its origin was performed deep to the sternocleidomastoid muscle. ); it is the lower point of the landmark. The FNT is located in the region between these two structures. The dissection after identification of the main trunk of the facial nerve was similar to the routine parotidectomy. The surgical defect was closed over a removac suction drain using Vicryl materials; the skin was closed by 6-0 absorbable sutures. A dressing was applied to the surgical site. Then, a gauze was wrapped over the parotid area and secured around the forehead and neck.
48377243|NCT05188768|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
48517451|NCT06333704|BIOLOGICAL|SPIKEVAX X|No study drug will be administered during this study as this is an observational study.
48377244|NCT05188768|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
48019479|NCT03019497|BEHAVIORAL|Specific Modules|Educational session about a specific related problem
48377245|NCT01919437|DEVICE|Web-Enabled Cognitive Neuropsychological Evaluation System|
48019480|NCT03019497|BEHAVIORAL|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
48377246|NCT05298124|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
48377247|NCT05298124|OTHER|Medical therapy|Medical treatment in an intensive care unit
48517452|NCT06582173|OTHER|Face-to-face interviews assisted by a biographical grid|"Face-to-face interviews assisted by a biographical grid.~Healthcare event of the adolescent :~* medical specialist appointment~* general practitioner appointment~* emergency services use~* hospital admission~* diagnostic test~* medication use~* non-pharmacological treatment~* nursing or physical therapy~* alternative care~Biographical of the adolescent :~* Education event~  * Class/level~ * School~ * Attendance~ * Special arrangements~ * Grades~ * Off school education~* Family event~  * Separation/union~ * Birth/death~ * Leave/Arrival~ * Location/Moving~ * Disease/accident~* Peer events~  * Friendships~ * Love interests~ * Bullying~* Leisure \& interests events~  * Activity~ * Frequency"
48019481|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
48517453|NCT03637010|OTHER|Breakfast in the Classroom|For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
48377248|NCT02883400|DRUG|Spironolactone|spironolactone 25 mg up to 50 mg
48517454|NCT02841982|PROCEDURE|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
48517455|NCT02841982|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
48019482|NCT03639480|DRUG|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
48377249|NCT03904602|DEVICE|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
48377250|NCT03755856|OTHER|Questionnaire|Health-related quality of life
48377251|NCT00735748|DRUG|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
48377252|NCT00735748|DRUG|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
48517456|NCT02841982|DEVICE|PAJUNK StimuLong|
48019483|NCT03639480|DRUG|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
48019484|NCT05345483|DEVICE|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter
48019485|NCT02167035|DRUG|Combigan Two Times Daily (BID)|
48019486|NCT02167035|DRUG|Simbrinza Three Times Daily (TID)|
48019487|NCT03487913|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
48377253|NCT03770806|PROCEDURE|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
48517457|NCT02841982|DRUG|single dose ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified."
48517458|NCT02841982|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
48517459|NCT03216863|OTHER|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
48710077|NCT01669421|DRUG|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
48710078|NCT00144924|PROCEDURE|laparoscopy pyloromyotomy|laparoscopic pyloromyotomy
48710079|NCT00144924|PROCEDURE|open pyloromytomy|open pyloromyotomy
48710080|NCT03084913|OTHER|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
48710081|NCT03084913|OTHER|Prostate Cancer Foundation diet|followed for 8 weeks
48019488|NCT05634265|BEHAVIORAL|Vijana-SMART|The Vijana-SMART intervention is a facilitated peer group, delivered through WhatsApp. Intervention messages were developed based on findings from formative interviews and social support theory, which posits that individuals experience social support through informational, instrumental, companionship and emotional forms. Groups will have approximately 25 members and will be facilitated by a study team member, by sending weekly scheduled messages, answering participant questions, and encouraging group discussion. Intervention messages were designed based on guidance from formative interviews; topics include ART adherence, medication side effects, nutritional practices, depression, social support, HIV status disclosure, stigma, positive prevention, substance use, and contraception.
48019489|NCT04007952|PROCEDURE|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
48176601|NCT04373837|BEHAVIORAL|Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)|"The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
48377254|NCT03770806|PROCEDURE|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
48377255|NCT03770806|OTHER|No Block|routine iv and oral pain medication alone-observation only
48377256|NCT05493748|OTHER|Bladder training|Bladder training for overactive bladder syndrome.
48377257|NCT01353209|DRUG|Letrozole|2.5 mg daily for twelve months
48710082|NCT01757223|BIOLOGICAL|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
48377258|NCT01353209|DRUG|Placebo|placebo given daily for twelve months
48377259|NCT03370718|DRUG|Cabozantinib|Given PO
48377260|NCT03370718|OTHER|Pharmacogenomic Study|Correlative studies
48377261|NCT03370718|OTHER|Pharmacokinetic Study|Correlative studies
48377262|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
48377263|NCT03455842|BIOLOGICAL|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
48377264|NCT03455842|DRUG|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
48377265|NCT01994369|DRUG|EC17|
48377266|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
48377267|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
48377268|NCT00482664|DRUG|CP-866,087|Tablets for oral administration
48517460|NCT05610423|OTHER|no intervention|No intervention. Observational study only
48517461|NCT02547688|DEVICE|Nasal High Flow|
48710083|NCT01757223|BIOLOGICAL|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
48710084|NCT03741023|PROCEDURE|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
48710085|NCT05036382|BEHAVIORAL|Steps data observation|Sending more step data from the experimental group that received the incentive message
48176602|NCT04373837|OTHER|Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)|"The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
48176603|NCT05587452|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is performed to identify whether the patient has colorectal adenoma or cancer
48176604|NCT05587452|DIAGNOSTIC_TEST|Test of ctDNA methylation|A specified panel is used to detect the site of methylation of ctDNA in plasma
48176605|NCT05587452|DIAGNOSTIC_TEST|Test of characteristics of ctDNA fragment|Low pass whole genome sequencing is used to detect the characteristics of ctDNA fragment
48176606|NCT01380977|BEHAVIORAL|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
48176607|NCT01918371|DRUG|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
48710086|NCT05245630|PROCEDURE|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
48710087|NCT05245630|PROCEDURE|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
48710088|NCT05176002|DRUG|Camrelizumab|Neoadjuvant Camrelizumab combined with radiotherapy
48176608|NCT02754336|BEHAVIORAL|Cogmed Robomemo, working memory training|
48176609|NCT02754336|BEHAVIORAL|Othmer, neurofeedback|
48377269|NCT00482664|DRUG|Placebo|Tablets for oral administration
48377270|NCT00103389|DRUG|PI-88|PI-88+docetaxel
48377271|NCT00103389|DRUG|docetaxel|docetaxel only
48377272|NCT04800991|DEVICE|Rhexium Onco Nutrition|"The research devices in this study are classified into subject mobile application and investigator web portal with no invasive action on the human body"
48377273|NCT04085926|DEVICE|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
48377274|NCT04085926|DEVICE|Total contact cast|Custom-made total contact cast
48377275|NCT02145949|DRUG|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
48377276|NCT02145949|DRUG|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
48377277|NCT05942742|DEVICE|MRI Linac|External radiotherapy will be performed at Linac MRI, 25 fractions of radiation will be delivered for each patient.The MR-linac offers the ability to individualise and adapt daily treatment plans based on the position or anatomy of the day, following either a simple 'virtual couch shift' adapt-to-position (ATP) approach, or a more complex full reoptimisation adapt-to-shape (ATS) method based on the recontouring of relevant structures. During each radiation therapy, T2-weighted images and diffusion images will be purchased.Treatment plans can be produced and checked by appropriately trained Radiation Oncologists. Each radiation oncologist will decide based on the anatomy of the day the type of workflow to be used (ADP or ATS) for treatment.Patients will undergo accurate image acquisition, registration and interpretation to make sound clinical judgements and proceed to safe and accurate treatment delivery.
48710089|NCT03419949|DRUG|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
48710090|NCT03419949|DRUG|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
48710091|NCT02969096|PROCEDURE|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
48019490|NCT04739748|DIAGNOSTIC_TEST|complete blood picture|Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
48019491|NCT02690545|BIOLOGICAL|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10\^8 cells/m\^2 and 2x10\^8 cells/m\^2. Phase II patients will receive the dose level decided upon in Phase I.
48019492|NCT01642797|DEVICE|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
48019493|NCT01642797|DEVICE|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
48019494|NCT04339335|PROCEDURE|Pulsed radiofrequency of the occipital nerves|pulsed radiofrequency of the greater and lesser occipital nerves bilaterally
48019495|NCT01383681|OTHER|No treatment|There was no treatment in this study.
48710092|NCT05144880|OTHER|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
48710093|NCT03446053|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
48710094|NCT03446053|OTHER|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
48710095|NCT03122821|OTHER|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
48517462|NCT01737073|BEHAVIORAL|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
48710096|NCT03122821|OTHER|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
48710097|NCT05131776|DEVICE|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
48710098|NCT02510365|BIOLOGICAL|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
48710099|NCT02616497|DRUG|Aspirin|COX-1 inhibitor
48710100|NCT02616497|DRUG|Triflusal|COX-1 inhibitor
48710101|NCT03645694|DEVICE|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
48710102|NCT01359761|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
48710103|NCT06428565|DIAGNOSTIC_TEST|Low-level laser therapy (LLLT) or cold laser therapy|Low-level laser therapy (LLLT) or cold laser therapy
48377278|NCT05174208|OTHER|CTE examination|each patients should have undergone CTE examination
48517463|NCT01737073|BEHAVIORAL|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
48517464|NCT01737073|OTHER|Enhanced usual care|Weekly automated wellness tip and usual clinical care
48517465|NCT04488315|DRUG|Dexamethasone lipid microsphere plus ropivacaine|Local scalp infiltration solution will consist of 30ml miscible liquids containing 8 mg dexamethasone lipid microsphere, 150mg ropivacaine and normal saline.
48517466|NCT04488315|DRUG|Ropivacaine alone|Local scalp infiltration solution will consist of 30ml miscible liquids containing 150mg ropivacaine and normal saline
48517467|NCT06072573|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
48176610|NCT00070343|BIOLOGICAL|oblimersen sodium|
48710104|NCT04524559|OTHER|conventional physical therapy training|"The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity."
48176611|NCT00070343|DRUG|dacarbazine|
48710105|NCT04524559|OTHER|oral motor training.|"Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization"
48710106|NCT04579302|PROCEDURE|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
48710107|NCT04579302|PROCEDURE|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
48176612|NCT00510146|DRUG|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
48176613|NCT00510146|DRUG|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
48176614|NCT03284528|OTHER|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
48176615|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using blunt dissection technique|Renuvion/j-Plasma procedure using blunt dissection technique
48176616|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
48176617|NCT03470792|DEVICE|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
48176618|NCT01346462|BEHAVIORAL|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
48176619|NCT04358536|DEVICE|CovX|Convolutional neural network for classification of COVID-19 from chest X-rays
48710108|NCT04579302|DRUG|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
48710109|NCT04579302|DRUG|Bupivacaine|bupivacaine
48710110|NCT03809715|DEVICE|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
48710111|NCT04518852|COMBINATION_PRODUCT|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
48710112|NCT05819021|DEVICE|SAINT® Neuromodulation System (NMS)|The SAINT® NMS utilizes a type of accelerated iTBS delivered to a personalized treatment target derived from a functional MRI scan. SAINT® was designed to optimize the individual patient response to treatment. This novel approach to TMS is accomplished by focusing on three critical aspects of the treatment that drive effect. These aspects are personalized stimulation target, total course dose of stimulation, and neurophysiologically relevant stimulation pattern.
48176620|NCT00136682|DRUG|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
48176621|NCT00136682|DRUG|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
48176622|NCT03722498|DRUG|HAIC of FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48176623|NCT03722498|DRUG|Sorafenib|administration of Sorafenib
48176624|NCT03171935|DEVICE|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
48517468|NCT06072573|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
48710113|NCT05899231|BEHAVIORAL|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
48710114|NCT03075722|DEVICE|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
48710115|NCT00884910|DEVICE|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
48710116|NCT02115841|DEVICE|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
48710117|NCT01084278|DRUG|Colchicine|Colchicine tablets
48710118|NCT00670891|PROCEDURE|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease"
48710119|NCT06299982|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W (5 cycles)
48710120|NCT06299982|DRUG|608 Q4W|608 160 mg Q4W (3 cycles)
48710121|NCT02929901|DIETARY_SUPPLEMENT|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
48517469|NCT06372184|DRUG|Washed Microbiota Transplantation|Patients take four capsules containing washed microbiota once a day for five consecutive days
48517470|NCT06372184|DRUG|Placebo|Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
48517471|NCT01273896|DRUG|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
48517472|NCT00273897|DEVICE|Phoresor II|
48517473|NCT02836548|DRUG|Vorinostat|vorinostat 360 milligram once daily
48517474|NCT04422600|OTHER|There is no other intervention, only clinical treatment.|The investigators will then correlate that exposure with neurodevelopmental outcomes.
48517475|NCT04841577|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
48517476|NCT04841577|BIOLOGICAL|FLU-QIV|FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.
48517477|NCT03825224|PROCEDURE|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
48517478|NCT02771769|OTHER|blood draw|Participants will have a venous blood draw of \~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
48517479|NCT02315131|DRUG|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
48517480|NCT02315131|DRUG|Placebo|Placebo Comparator
48517481|NCT00098774|BIOLOGICAL|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC \> or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
48517482|NCT00098774|BIOLOGICAL|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, \& 24 of Cycle 1 nad Days 3 \& 10 of Cycle 2
48517483|NCT00098774|DRUG|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
48517484|NCT00098774|DRUG|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
48517485|NCT00098774|DRUG|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
48517486|NCT00098774|DRUG|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.
48517487|NCT00098774|DRUG|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
48517488|NCT01461915|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
48710122|NCT02929901|DIETARY_SUPPLEMENT|caffeine|caffeine plus placebo
48710123|NCT02929901|DIETARY_SUPPLEMENT|chlorogenic acid|chlorogenic acid plus placebo
48710124|NCT02929901|DIETARY_SUPPLEMENT|placebo|placebo plus placebo
48710125|NCT02970006|DEVICE|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
48710126|NCT05516784|DRUG|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
48710127|NCT05516784|DRUG|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
48710128|NCT00227318|DRUG|ATACAND|
48710129|NCT00346489|DRUG|5-fluorouracil|
48710130|NCT00346489|DRUG|Mitomycin C|
48710131|NCT05535738|DRUG|Squaric Acid Dibutyl Ester|Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
48710132|NCT05535738|OTHER|Known patch test allergens|Positive patch test allergens during the course of clinical patch testing will be re-applied on the back followed by skin sampling
48710133|NCT05535738|DRUG|Dupilumab|300mg
48710134|NCT05535738|DRUG|Adalimumab|40mg
48710135|NCT05535738|DRUG|Ustekinumab|45mg
48710136|NCT05535738|DRUG|Guselkumab|100mg
48710137|NCT05535738|DRUG|Canakinumab|150mg
48710138|NCT05535738|DRUG|Sarilumab|200mg
48710139|NCT05535738|DRUG|Triamcinolone Acetonide|0.1% ointment
48710140|NCT05535738|DRUG|Betamethasone Valerate|0.1% ointment
48710141|NCT05535738|DRUG|Fluticasone Propionate|0.005% ointment
48710142|NCT05535738|DEVICE|Microneedle|Painless and non-scarring skin sampling with a 7mm x 7mm patch of hydrogel-coated poly-l-lactide microneedles (\<2mm length) will be used to collect interstitial fluid
48710143|NCT05535738|DEVICE|Suction blistering|Suction blistering is a technique to induce and collect blister fluid using a negative pressure instrument (Electronic Diversities Finksburg, MD). It does not require local anesthetic, stitches or pain medication following the procedure. The blisters will be no greater than 1cm in diameter and no deeper than the epidermis (\<1mm deep). This process of inducing blisters is typically less than 1 hour. After the formation of blisters, the blister fluid will be extracted using a syringe. The blister roofs will be left attached to the skin and covered with petrolatum and a bandage.
48710144|NCT05535738|PROCEDURE|Skin punch biopsy|A skin biopsy is the removal of a small piece of tissue, under local anesthetic.
48710145|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666) IV|intravenous infusion
48710146|NCT05734521|BIOLOGICAL|avalglucosidase alfa-NGPT (GZ402666)|exposed via pregnancy and lactation
48710147|NCT00380029|DRUG|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
48710148|NCT00380029|PROCEDURE|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
48710149|NCT01068951|BIOLOGICAL|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
48710150|NCT04149223|OTHER|Evidence-based standardized Cirrhosis order set|Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
48710151|NCT02638389|DRUG|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
48710152|NCT03838991|OTHER|Blood sample|A study specific blood sample will be collected.
48710153|NCT03838991|OTHER|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
48710154|NCT05190029|DIAGNOSTIC_TEST|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
48710155|NCT05190029|OTHER|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
48710156|NCT05190029|PROCEDURE|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
48710157|NCT01620515|DRUG|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
48710158|NCT01620515|DRUG|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
48710159|NCT00383643|DRUG|zolpidem tartrate|
48710160|NCT00383643|DRUG|sodium oxybate|
48710161|NCT00383643|DRUG|Matching Placebos|
48710162|NCT03065101|DEVICE|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
48710163|NCT03065101|OTHER|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
48710164|NCT03065101|DEVICE|Sliding Hip Screw|Sliding Hip Screw
48710165|NCT02945553|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
48710166|NCT02945553|DEVICE|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
48710167|NCT00171925|DRUG|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
48710168|NCT00171925|DIETARY_SUPPLEMENT|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
48710169|NCT01766895|OTHER|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
48710170|NCT04126720|DIETARY_SUPPLEMENT|topical corticosteroids and vitamin E suplements|
48710171|NCT04126720|DRUG|Topical corticosteroid and placebo capsules|
48377279|NCT00736216|OTHER|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases \[STDs\], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
48710172|NCT03511625|DRUG|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
48019496|NCT01642394|BEHAVIORAL|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
48377280|NCT01343238|BEHAVIORAL|Diet|12 week diet behavior modification
48019497|NCT05050188|DRUG|H008|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.
48019498|NCT05050188|DRUG|H008 placebo|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
48019499|NCT05050188|DRUG|Lansoprazole|Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
48019500|NCT01141296|DRUG|fenofibrate|fenofibrate 200 mg PO daily for 1 year
48019501|NCT01141296|DRUG|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
48019502|NCT06100068|BEHAVIORAL|Mental Exercises and Temporal Alteration|Mental exercises during L-DIBH to distort the awareness of passage of time
48019503|NCT06460727|OTHER|task oriented exercise training on dynamic surface|Following exercises will be performed in this group: Make the child bounce on swiss ball, reaching the toy with both hand kept over the head on platform swing, high sitting on swiss ball throwing ball with both hands, reaching the toy with one hand shifting the wait towards reaching side.
48377281|NCT01343238|BEHAVIORAL|Exercise|12 week exercise behavioral intervention
48377282|NCT01343238|BEHAVIORAL|Diet and Exercise|12 week diet and exercise behavioral modification intervention
48710173|NCT03511625|DRUG|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
48019504|NCT06460727|OTHER|task oriented exercise training on static surface|The children in this group will receive following TOET: Sit to stand from various cjair heights , standing and reaching indifferent directions for an object, Stepping forwards, backwards, and sideways onto blocks of various heights, walking forward , backward and sideways, Walking up and down stairs
48019505|NCT04950335|PROCEDURE|AOPT|The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.
48377283|NCT00422058|DRUG|liraglutide|Injected s.c. (under the skin) once daily
48377284|NCT00422058|DRUG|orlistat|120 mg capsule. Administered thrice daily
48377285|NCT00422058|DRUG|placebo|Injected s.c. (under the skin) once daily
48176625|NCT03171935|DEVICE|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 \>92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 \>96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
48377286|NCT00564382|PROCEDURE|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
48019506|NCT04950335|PROCEDURE|AOCT|Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
48176626|NCT03171935|DEVICE|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
48176627|NCT01522690|OTHER|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
48176628|NCT03051997|BEHAVIORAL|Caregiver Contingency Management + Usual Drug Court Treatment|In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
48176629|NCT03051997|BEHAVIORAL|Usual Drug Court Treatment|Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
48176630|NCT01314599|DRUG|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
48019507|NCT00136708|PROCEDURE|Neonatal Resuscitation|
48019508|NCT00917059|DRUG|Escitalopram|Fixed dose of 10 mg per day
48176631|NCT04150185|PROCEDURE|Donor hepatectomy|
48176632|NCT02391077|OTHER|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
48176633|NCT02391077|OTHER|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
48176634|NCT02391077|OTHER|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
48176635|NCT03939481|DRUG|Chemotherapy|Given chemotherapy regimen
48377287|NCT04818866|DIAGNOSTIC_TEST|SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase|Biomarkers of inflammation
48710174|NCT05304143|OTHER|Virtual Immersive Reality Glasses|"The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored."
48710175|NCT05304143|OTHER|Conventional nurse support|Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
48019509|NCT00917059|DRUG|Bupropion XL|Fixed dose of 150 mg per day
48019510|NCT01116089|DRUG|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
48019511|NCT01116089|DRUG|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
48019512|NCT03976986|DEVICE|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
48176636|NCT03939481|OTHER|Functional Assessment|Functional and sensory clinician assessments
48019513|NCT03976986|DEVICE|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
48176637|NCT03939481|OTHER|Questionnaire Administration|Patient and physician reported responses
48377288|NCT01269528|OTHER|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
48377289|NCT01269528|OTHER|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
48710176|NCT02280824|PROCEDURE|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
48710177|NCT02280824|DEVICE|Amplatzer Duct Occluder|
48710178|NCT06325293|DRUG|Azithromycin Pfizer®|Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
48710179|NCT06325293|DRUG|Placebo|Control comparator arm: 5 days of placebo
48710180|NCT03834506|BIOLOGICAL|Pembrolizumab|IV infusion
48710181|NCT03834506|DRUG|Docetaxel|IV infusion
48710182|NCT03834506|DRUG|Prednisone|Oral tablets
48710183|NCT03834506|DRUG|Placebo|IV infusion
48710184|NCT03834506|DRUG|Dexamethasone|Oral tablets
48176638|NCT04869150|PROCEDURE|radial access coronary angiography|The right radial artery was cannulated with a 6-f radial sheath after local infiltration with 2% lidocaine.All patients received 5000 units of unfractionated heparin, 100 - 200 μg (depending on blood pressure) of nitroglycerin and 5 mg of diltiazem unless there was an absolute contraindication to diltiazem and anticoagulants.Coronary angiography was performed using the standard Judkins' technique via right radial access with a 5-f diagnostic catheter
48377290|NCT01269528|OTHER|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
48019514|NCT06454981|DEVICE|Hemodiafilter|"The enrolled patients were randomly divided into the experimental group and the control group, using the hemodiafilter (experimental device) produced by Shinva Medical Instrument Co.,Ltd."
48019515|NCT06454981|DEVICE|Fresenius Medical Care AG & Co.KGaA|The enrolled patients were randomly divided into the experimental group and the control group, using the FX 800HDF hollow fiber hemodialysis/filter (control device) produced by Fresenius Medical Care AG \& Co.KGaA (registered agent: Fresenius Medical Care (shanghai) Company Limted).
48019516|NCT02637934|DRUG|[18F]FluorThanatrace|
48377291|NCT01269528|OTHER|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
48019517|NCT02637934|RADIATION|PET/CT imaging sessions|
48019518|NCT06572722|DRUG|Atezolizumab|atezolizumab adjuvant therapy
48377292|NCT01269528|OTHER|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
48377293|NCT03233009|OTHER|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
48377294|NCT03233009|OTHER|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
48019519|NCT06572722|DRUG|Nivolumab|nivolumab neoadjuvant therapy
48019520|NCT06572722|DRUG|Pembrolizumab|pembrolizumab neoadjuvant+adjuvant therapy
48019521|NCT02839434|PROCEDURE|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
48019522|NCT06602921|DIETARY_SUPPLEMENT|TruBeet inorganic beetroot juice|400 mg nitrate-rich beetroot powder, mixed with 300 mL water.
48019523|NCT06602921|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg caffeine powder in capsule form.
48019524|NCT06602921|OTHER|Cold pressor test|3 min cold pressor test using the left foot in cold water (0-2 degree).
48176639|NCT05845840|DRUG|BRII-297|Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6
48176640|NCT05845840|DRUG|Placebo|Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
48176641|NCT04703868|DRUG|Rabeprazole Sodium 10mg|Part A: 1 tablet administered before the breakfast during 7 days
48176642|NCT04703868|DRUG|Rabeprazole Sodium 20mg|Part B: 1 tablet administered before the breakfast during 7 days
48377295|NCT03233009|OTHER|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
48377296|NCT03233009|OTHER|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
48710185|NCT01163773|OTHER|MILK|"Consumption of the 2 experimental diets~1. Milk diet~2. Control diet"
48710186|NCT03414255|BIOLOGICAL|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
48710187|NCT03414255|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
48710188|NCT03985982|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
48710189|NCT03985982|DRUG|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
48710190|NCT02836782|PROCEDURE|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
48710191|NCT01550341|DRUG|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
48710192|NCT01550341|DRUG|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
48710193|NCT06607926|DRUG|Thymosin Alpha 1|4.8 mg subcutaneous injection twice weekly over 12 weeks
48710194|NCT06607926|DRUG|Tislelizumab|200mg, IV, d1 of each 21-d cycle, four cycles
48176643|NCT03109652|DRUG|Tranexamic Acid|"On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)"
48176644|NCT00639314|PROCEDURE|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
48176645|NCT00639314|PROCEDURE|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
48377297|NCT03233009|OTHER|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
48517489|NCT01461915|DRUG|Gemcitabine|Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
48517490|NCT01461915|DRUG|Dociparstat|Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
48710195|NCT06607926|DRUG|Platinum-doublet chemotherapy|Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
48710196|NCT02947165|DRUG|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
48710197|NCT02947165|DRUG|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
48710198|NCT03345654|OTHER|Hearing Aids|The signal processing of newly fit hearing aids will be evaluated for acceptability based on the toolset, which takes additional patient information beyond hearing threshold (like cognition) to determine the optimal hearing aid signal processing strategies.
48710199|NCT06151951|OTHER|Cervical Stabilization|Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.
48176646|NCT02367105|DRUG|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
48377298|NCT00186082|DRUG|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
48176647|NCT02367105|OTHER|Lifestyle Therapy|Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week
48176648|NCT02367105|DRUG|Placebo|Placebo gel for testosterone
48176649|NCT04517942|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
48176650|NCT04517942|OTHER|Video + Expressive Writing|Brief video-based intervention (4 hours across two meetings)
48176651|NCT01409122|DRUG|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
48176652|NCT01409122|DRUG|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
48176653|NCT01409122|DRUG|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
48176654|NCT01409122|DRUG|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
48377299|NCT05059470|DRUG|Pembrolizumab|Given by IV
48377300|NCT00363935|DRUG|Dexmedetomidine|
48710200|NCT06151951|DEVICE|Pressure Biofeedback|"In this method patients in supine position. Sphygmomanometer is used and 100 mmHg pressure will be maintained before the treatment start then cuff will be placed under the occiopit of spine and patient will be asked to press the cuff against the occiopit until gauze show target pressure then hold this position for 6 second and release. Repeated this pressure to 10 times, 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
48176655|NCT01409122|DRUG|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
48176656|NCT01719588|DRUG|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
48176657|NCT04719715|DIAGNOSTIC_TEST|Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays|Measurement and evaluation of the ANCA testing
48176658|NCT04699097|DRUG|Azithromycin|250 mg tablet, 5 ml / 200 mg 30 ml suspension
48377301|NCT02620566|PROCEDURE|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
48377302|NCT02620566|PROCEDURE|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
48710201|NCT06151951|DEVICE|Visual Biofeedback|"In this method Led Head Band light will be used as a visual feedback. Patients in sitting or standing position with neck straight with the alignment of front wall marking followed by control movement training. Patient will be asked to follow the marking through head band light while performing motion control training. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
48710202|NCT04380103|DRUG|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
48710203|NCT00081315|DRUG|Amifostine|
48710204|NCT04623268|DIAGNOSTIC_TEST|Ultrasound and questionnaire|One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
48710205|NCT04685707|DEVICE|Visual feedback monitoring system (HFFS)|Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.
48710206|NCT04685707|OTHER|Control|Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
48710207|NCT01663324|DEVICE|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
48176659|NCT04400799|DRUG|Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml|daily incetion s.c. for 14 days
48176660|NCT03736278|OTHER|No intervention|We group the patients according to the outcome (survival vs mortality)
48176661|NCT05650541|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
48710208|NCT01663324|DEVICE|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
48710209|NCT04024332|DRUG|ACT-541468|ACT-541468 25 mg; administered orally
48377303|NCT03583840|BEHAVIORAL|ScreenMen website|An educational website that aims to improve evidence-based health screening uptake in men
48377304|NCT05969626|BIOLOGICAL|5-dose group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
48377305|NCT05969626|BIOLOGICAL|5-dose group of control vaccine|Subjects will be vaccinated on days 0, 3, 7, 14, and 28
48377306|NCT05969626|BIOLOGICAL|4-dose A group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 14
48377307|NCT05969626|BIOLOGICAL|4-dose B group of test vaccine|Subjects will be vaccinated on days 0, 3, 7, 28
48377308|NCT01454037|PROCEDURE|Prostate cryotherapy|cryoablate the prostate
48377309|NCT01454037|PROCEDURE|Radical prostatectomy|Remove prostate
48377310|NCT01454037|PROCEDURE|Radiation|Radiate prostate
48377311|NCT03377803|COMBINATION_PRODUCT|VP-102 - Cantharidin, Topical Film Forming Solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
48377312|NCT03377803|COMBINATION_PRODUCT|Placebo -Topical Film Forming Solution without VP-102|Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.
48710210|NCT02323841|PROCEDURE|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
48019525|NCT03865277|RADIATION|dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm.~Radiotherapy is always applied with 5 fractions per week."
48176662|NCT01151514|OTHER|Nephrologist referral|Nephrologist specialty, renal replacement therapy
48176663|NCT02802150|DIETARY_SUPPLEMENT|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
48176664|NCT02802150|DIETARY_SUPPLEMENT|Soy Bean Oil;placebo(4g/day)|parallel design
48710211|NCT04604197|OTHER|Angiography and Clinical Follow up|Angiography and Clinical Follow up
48176665|NCT05205564|OTHER|This is a cross-sectional research design.|No intervention will be involved in the study.
48176666|NCT00371995|DRUG|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
48176667|NCT05580497|DEVICE|Soft Wearable Robotic Knee System|Power assistance will be provided from the motor to the knee joint
48176668|NCT02743988|DRUG|Oxygen|Adapt inspired oxygen to achieve desired SpO2 target range
48377313|NCT01001286|BEHAVIORAL|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
48710212|NCT04604197|OTHER|Clinical Follow up|Clinical Follow up
48710213|NCT05925283|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
48710214|NCT05925283|DRUG|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
48710215|NCT05925283|DRUG|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
48710216|NCT03294096|DIETARY_SUPPLEMENT|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
48710217|NCT03294096|OTHER|Routine care|Routine post-op care
48710218|NCT04563728|BEHAVIORAL|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
48710219|NCT06496867|PROCEDURE|Early Internal Fixation|Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s). The implant number, design, diameter, thread type (fully-threaded or partially-threaded), sacral segment (S1, S2, S3, or any combination there of), length, trajectory including sacroiliac or transsacral-transiliac, application with or without a washer, and ingrowth or ongrowth surface designs will be at the discretion of the treating surgeon.
48710220|NCT06496867|OTHER|Nonoperative Care with Early Rehabilitation|Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization. Patients who are unable to ambulate with assistance after five or more days of attempted mobilization by rehabilitation providers may be considered for delayed internal fixation treatment at the discretion of the patient and the treating surgeon. Delayed internal fixation after five or more days of attempted mobilization by rehabilitation providers will not be considered a treatment crossover event.
48176669|NCT06551168|OTHER|Heat exposure|Participants will exercise at home while wearing a clothing ensemble over 19 one hour sessions. They will use validated perceptual scales to guide their effort and thermal sensation.
48176670|NCT06551168|OTHER|Control group|Participants will exercise at home over 19 one hour sessions. They will use heart rate to guide their effort. The exercise will take place in cool conditions
48176671|NCT00721032|PROCEDURE|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
48176672|NCT00721032|DRUG|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -\> new dose 100 once daily (QD) -\> 200 QD; 200 QD -\> 400 QD; 300 QD -\> 600 QD; 400 QD -\> 600 QD"
48176673|NCT05209724|BEHAVIORAL|Provider supervision/ feedback|Provider supervision/ feedback provided before and after walking sessions
48176674|NCT02121327|OTHER|disease management|disease management program include self management education
48710221|NCT01230515|OTHER|Individual patient interview, focus group and structured survey|
48710222|NCT01230515|OTHER|interview, focus group and structured survey|
48710223|NCT01230515|OTHER|interview, focus group and structured survey|
48710224|NCT01230515|OTHER|interview, focus group and structured survey|
48176675|NCT02121327|OTHER|usual care|usual care group receive regular outpatient treatment
48176676|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
48176677|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
48176678|NCT05678686|OTHER|Active Comparator: Routine Exercise Group|Exercises (tongue-palate exercises, tongue base exercises, Masako Maneuver, Mendelson Maneuver, Effortful Swallowing, Supraglottic exercises, thermal tactile stimulation) will be performed 2 days a week for 8 weeks, in total 16 sessions and these exercises applied by the physiotherapist.
48710225|NCT05693740|PROCEDURE|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
48710226|NCT06196424|OTHER|study questionnaire to investigate family history|Participants will be given a specific study questionnaire (paper-based) to fill at home, which was specifically designed to collect family history information
48710227|NCT01000922|DRUG|Regular Human Insulin|Individual dose of RHI administered subcutaneously
48710228|NCT01000922|DRUG|Lispro|Individual dose of lispro administered subcutaneously
48710229|NCT01000922|DRUG|VIAject|Individual dose of VIAject administered subcutaneously
48710230|NCT01000922|DRUG|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
48710231|NCT01000922|DRUG|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
48377314|NCT02384590|BEHAVIORAL|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
48377315|NCT01932541|DRUG|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
48710232|NCT01000922|DRUG|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
48377316|NCT02415907|DRUG|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
48710233|NCT03455868|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
48710234|NCT01564095|DRUG|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
48710235|NCT01564095|DRUG|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
48710236|NCT04687592|PROCEDURE|reduction and fixation|"* Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~* Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
48710237|NCT04612543|DEVICE|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
48710238|NCT04612543|DEVICE|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
48176679|NCT05678686|OTHER|Experimental: PNF Exercise|In addition to the practices in the control group, head-neck PNF(Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to both movement patterns by the physiotherapist using the combined isotonic contraction technique ), 2 days a week for 8 weeks, in total 16 sessions.
48377317|NCT02415907|DRUG|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
48710239|NCT06607237|DEVICE|DM-28|1 drop in each eye, 4 to 6 times per day
48377318|NCT02563366|OTHER|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
48377319|NCT02563366|OTHER|Saline|Saline is the placebo of MSCs in this study.
48377320|NCT05038085|BEHAVIORAL|progressive muscle relaxation exercise|"36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery."
48377321|NCT00591552|DEVICE|Harmonic ACE23P Scalpel|Lymph node dissection
48377322|NCT00591552|DEVICE|Electrocautery|
48710240|NCT04617886|OTHER|Sadness induction|"Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
48710241|NCT04617886|OTHER|Happiness induction|"Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
48710242|NCT02980146|OTHER|Non interventional study|
48710243|NCT04774900|PROCEDURE|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
48710244|NCT04774900|PROCEDURE|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
48710245|NCT04774900|PROCEDURE|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
48710246|NCT04774900|PROCEDURE|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
48710247|NCT04774900|PROCEDURE|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
48710248|NCT06605937|OTHER|Eustachian milking maneuver with routine postoperative treatment protocol|Eustachian milking maneuver will be applied by the patients parents 3 times a day for 7 days in the post-operative period.
48710249|NCT06605937|OTHER|Routine postoperative treatment protocol|The children adenoidectomy and/or adenotonsillectomy whose parents will not apply eustachian healing maneuvers in the post-operative period.
48710250|NCT02501720|PROCEDURE|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
48710251|NCT02501720|PROCEDURE|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
48710252|NCT02501720|PROCEDURE|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
48710253|NCT00085254|DRUG|cilengitide|Given IV
48710254|NCT00085254|DRUG|temozolomide|Given orally
48710255|NCT00085254|RADIATION|radiation therapy|Undergo radiotherapy
48377323|NCT03346109|RADIATION|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
48377324|NCT01388036|DRUG|esmolol|consecutive infusions of esmolol and normal saline (placebo)
48377325|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
48377326|NCT01298817|DIETARY_SUPPLEMENT|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
48710256|NCT00085254|OTHER|laboratory biomarker analysis|Correlative studies
48710257|NCT00085254|OTHER|pharmacological study|Correlative studies
48710258|NCT06127043|DRUG|Rosnilimab|PD-1 agonist antibody
48710259|NCT06127043|DRUG|Placebo|Administered via SC
48710260|NCT05256784|COMBINATION_PRODUCT|Natural probiotics|Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
48377327|NCT02300194|DRUG|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
48710261|NCT03619928|DEVICE|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
48710262|NCT03619928|DEVICE|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
48710263|NCT02131376|PROCEDURE|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
48710264|NCT02131376|PROCEDURE|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
48710265|NCT05798481|DRUG|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
48710266|NCT06180330|OTHER|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
48710267|NCT03557346|DEVICE|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
48710268|NCT05644145|BIOLOGICAL|Serological study after yellow fever vaccination|It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.
48710269|NCT05473351|OTHER|Questionnaire|Visual Analogic Scale
48710270|NCT01477463|DRUG|Vitamin D3|4,000 IU oral vitamin D3
48710271|NCT01477463|DRUG|placebo and vitamin D|
48710272|NCT01175200|DRUG|Clopidogrel|antiplatelet agent
48176680|NCT05678686|OTHER|Experimental: CTAR Exercise|In addition to the practices in the control group, CTAR exercises will be applied in the presence of a physiotherapist, 2 days a week for 8 weeks, a total of 16 sessions. In the CTAR exercise, the patient is asked to flexion and extension the neck by pressing a standard size and inflatable rubber ball placed under his chin against his sternum. Patients will be asked to do the exercise protocol, which consists of isometric and isotonic components.
48176681|NCT02880683|DEVICE|NeuroTronik CANS Therapy System|
48176682|NCT03585283|OTHER|Myofascial Group|Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)
48019526|NCT03865277|RADIATION|dose-escalated radiochemotherapy with carbon ion boost|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial.~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and treated in the study site Heidelberg, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases \> 2 cm using a carbon ion boost.~Radiotherapy is always applied with 5 fractions per week."
48176683|NCT03585283|OTHER|Sham Group|Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
48176684|NCT01985646|PROCEDURE|surgery treatment|one staged pull-through left-colectomy
48176685|NCT01985646|BEHAVIORAL|anal dilation|anal dilation
48176686|NCT01985646|BEHAVIORAL|colonic lavage|colonic lavage
48176687|NCT01985646|DRUG|oral probiotic|oral probiotic
48176688|NCT02240797|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
48710273|NCT01175200|DRUG|Prasugrel|antiplatelet agent
48710274|NCT01175200|DRUG|Lansoprazole|proton pum inhibitor
48710275|NCT01175200|DRUG|Placebo|placebo comparator similar to lansoprazole
48710276|NCT00665756|PROCEDURE|second Trabeculectomy|second trabeculectomy with mitomycin-c
48710277|NCT00665756|PROCEDURE|Ahmed Implant|Ahmed silicone drainage device
48710278|NCT06127355|DRUG|500 mg of ursodeoxycholic acid (UDCA)|Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
48176689|NCT00682227|BIOLOGICAL|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
48176690|NCT03855176|DRUG|Vaqta Injectable Product|Inactive vaccine against hepatitis A virus
48176691|NCT06164015|DIAGNOSTIC_TEST|3D Ultrasound scan with power Doppler angiography|The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.
48176692|NCT01951521|RADIATION|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
48176693|NCT06412536|OTHER|Blood work|Blood work on some participants to review eligibility for future clinical trials
48176694|NCT06547047|BEHAVIORAL|Speed, Agility, and Quickness (SAQ) Training|The SAQ training will include exercises designed to improve speed, agility, and quickness, such as ladder drills, cone drills, sprint drills, and reaction drills.
48176695|NCT06547047|BEHAVIORAL|Regular Training|Participants in the control group will follow a standard soccer training regimen, which includes general conditioning exercises, skill drills, and tactical training.
48377328|NCT02300194|DRUG|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
48377329|NCT01428388|DRUG|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
48710279|NCT06127355|OTHER|500 mg of Placebo|Administration of 500 mg of placebo /day
48710280|NCT04938999|BEHAVIORAL|Music-visual guided physical activity (MVgPA)|"The MVgPA adopts the information-motivation-strategy model to address the personal and environmental challenges in PA initiation and maintenance of adults with intellectual disability.~To support the staff of residential care facilities in implementing 24 sessions of MVgPA in 12 weeks, the first six sessions will be led by the RA1 and co-facilitated by the staff, while the subsequent sessions will be conducted by the staff only. At week 6, another set of MVgPA will be implemented to increase the participant's interest; two sessions will be co-facilitated by RA1. At weeks 6 and 9, the RN and RA1 will hold a meeting with the staff of the residential care facilities to acknowledge the achievement of the staff and adults with ID, as well as to address any of their concerns related to the implementation of MVgPA, and to identify the facilitators and tackle barriers to the implementation of the MVgPA."
48710281|NCT04938999|BEHAVIORAL|Usual care|As control group, residential care facilities will conduct their usual activities during the study period. A trained RA will record the activities conducted by the residential care facilities during the study period.
48710282|NCT03415698|DRUG|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
48710283|NCT03415698|DRUG|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
48710284|NCT02442453|DRUG|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
48710285|NCT02442453|DRUG|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
48710286|NCT06300918|OTHER|Time|Time point of injecting anti-VEGF drugs
48176696|NCT01168245|DEVICE|Sham-NICE-System|sham TMS and sham cognitive training
48176697|NCT01168245|DEVICE|NICE-System|TMS combined with cognitive training
48176698|NCT04240600|DIETARY_SUPPLEMENT|Experimental group|2 cans or bottles (200ml)per day, orally
48176699|NCT04240600|DIETARY_SUPPLEMENT|Control group|2 cans or bottles (200ml)per day, orally
48176700|NCT00005064|DRUG|bortezomib|Given IV
48176701|NCT02851849|DRUG|LGD-6972-5 mg|5 mg LGD-6972 QD
48176702|NCT02851849|DRUG|LGD-6972-10 mg|10 mg LGD-6972 QD
48176703|NCT02851849|DRUG|LGD-6972-15 mg|15 mg LGD-6972 QD
48176704|NCT02851849|OTHER|Placebo|Placebo QD
48176705|NCT00332826|DRUG|Technosphere Insulin|
48176706|NCT02894905|DRUG|AL-335|Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
48176707|NCT02321267|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
48176708|NCT02573545|DEVICE|Planning@IFE and Standard@IFE Software|
48176709|NCT02573545|DEVICE|MR Syngo (Numaris/4) software|
48710287|NCT05820698|OTHER|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
48710288|NCT05820698|OTHER|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
48710289|NCT05820698|OTHER|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
48710290|NCT06607198|DIAGNOSTIC_TEST|grading &amp; staging|To investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors
48710291|NCT06607198|DIAGNOSTIC_TEST|PitNET morphology analysis|Revision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion
48710292|NCT06607198|DIAGNOSTIC_TEST|Radiomics|To investigate radiomics features of PitNETs
48710293|NCT06607198|DIAGNOSTIC_TEST|Molecular test: proteomics|To investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]
48176710|NCT01448369|DEVICE|Blephasteam|10 minute treatment twice daily
48176711|NCT01448369|DEVICE|EyeGiene|10 minute treatment, twice daily
48176712|NCT01448369|DEVICE|Hot compresses|10 minute treatment, twice daily
48176713|NCT00875277|DRUG|LEO 29102 cream|
48176714|NCT00875277|DRUG|LEO 29102 Cream Vehicle|
48176715|NCT00875277|DRUG|Betamethasone Dipropionate Cream|
48176716|NCT00875277|DRUG|LEO 29102 Plus Calcipotriol Cream|
48176717|NCT00875277|DRUG|LEO 29102 Plus Betamethasone Dipropionate|
48176718|NCT00875277|DRUG|Daivobet® Ointment|
48176719|NCT00135577|DRUG|alvimopan|
48176720|NCT00135577|DRUG|placebo|
48176721|NCT00341471|PROCEDURE|Risk Behavior Prevention Intervention Program|
48176722|NCT00144846|DRUG|albuterol sulfate inhalation aerosol|
48176723|NCT02998398|OTHER|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
48176724|NCT00359047|BEHAVIORAL|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
48176725|NCT00359047|BEHAVIORAL|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
48176726|NCT02739776|DEVICE|Thermographic imaging|Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
48377330|NCT01428388|DRUG|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
48377331|NCT05208398|DRUG|Apixaban|5 mg twice daily, on top of standards of care.
48377332|NCT05208398|DRUG|Warfarin|Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations
48710294|NCT05326581|DEVICE|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
48377333|NCT00937859|DRUG|SER120|SER120
48710295|NCT02272751|BEHAVIORAL|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
48710296|NCT02272751|BEHAVIORAL|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
48710297|NCT01971463|OTHER|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
48019527|NCT03865277|RADIATION|standard radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region and 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes.~Radiotherapy is always applied with 5 fractions per week."
48019528|NCT01717573|PROCEDURE|Deferred stenting|
48019529|NCT01717573|PROCEDURE|Conventional treatment|
48019530|NCT05257265|DRUG|Centanafadine Hydrochloride|Capsule
48176727|NCT03269747|DRUG|Prednisone|2 tablets of Prednisone 20 Mg in the morning
48176728|NCT03269747|DRUG|Placebo|2 Placebo tablets in the morning
48710298|NCT00413920|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
48176729|NCT01628289|OTHER|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
48176730|NCT01628289|OTHER|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
48176731|NCT02833623|BEHAVIORAL|Short-message-based Re-education|
48710299|NCT00413920|DRUG|Prednisone|Oral tablets
48176732|NCT02833623|BEHAVIORAL|conventional education|
48176733|NCT06359496|OTHER|No intervention factor|No intervention factor
48176734|NCT01217619|DRUG|erlotinib|erlotinib 150mg/d continuously for 56 days
48377334|NCT00937859|DRUG|Placebo|Placebo
48377335|NCT00591916|DRUG|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
48377336|NCT00591916|PROCEDURE|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
48710300|NCT01048294|DEVICE|Original Energy Light,|9000 lux, 30 minutes in the morning
48710301|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 20 minutes in the morning
48176735|NCT02202109|BEHAVIORAL|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
48377337|NCT00591916|PROCEDURE|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
48019531|NCT05257265|OTHER|Placebo|Capsule
48019532|NCT06034080|OTHER|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
48019533|NCT06034080|OTHER|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
48377338|NCT00286936|DRUG|Zolpidem|
48377339|NCT04434534|DIETARY_SUPPLEMENT|Hipocaloric Diet with Açaí Juçara|Daily consumption of Açaí Juçara pulp (200g) and nutritional adequacy of meals in individualized diet plans calculated for each participant.
48377340|NCT04434534|OTHER|Hipocaloric Diet|Nutritional adequacy of meals in individualized diet plans calculated for each participant.
48377341|NCT03935282|OTHER|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
48377342|NCT04882514|BIOLOGICAL|p*17-K4S2|Administer p\*17-K4S2 25 μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
48377343|NCT04882514|BIOLOGICAL|J8-K4S2|Administer a vaccination schedule of J8-K4S2 50μg vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly
48019534|NCT06034080|OTHER|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
48377344|NCT04882514|BIOLOGICAL|Rabavert vaccine|Administer the standard Rabavert vaccine at 0, 3, and 6 weeks and evaluate the safety and antibody levels for a total of 6 months after the last injection. All vaccines will be administered intramuscularly. The Rabavert vaccine will be used as a control comparator as it has a similar approved dosing schedule to the investigational vaccines.
48377345|NCT05737394|PROCEDURE|Laparoscopic-guided TAP Block|Laparoscopically-assisted placement of block
48377346|NCT05737394|PROCEDURE|Ultrasound-guided TAP Block|Ultrasound-assisted placement of block
48176736|NCT02202109|BEHAVIORAL|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
48019535|NCT06034080|OTHER|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
48710302|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 30 minutes in the morning
48710303|NCT01846195|DEVICE|CM 1500|
48019536|NCT06034080|OTHER|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
48176737|NCT04314388|OTHER|Intervention: Outdoor Walking Rehabilitation Programme|Participants in the intervention group will take part in an instructor led outdoor walking rehabilitation programme which will last for 3 months. Alongside this participants will also be asked to complete a home exercise programme.
48176738|NCT04314388|OTHER|Control: The light Stretches Programme|Participants in the control group will be asked to keep to their normal activities of daily living, and given 10 targeted active stretches of the upper and lower body.
48176739|NCT04431219|BIOLOGICAL|LIS1|LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
48377347|NCT05298527|BEHAVIORAL|Back Massage|The woman lies face down and a pillow is placed under her forehead. Massage begins with effleurage. Petrissage is started from the sacrum and the hands are lifted up to the nape and repeated 4 times. After the petrissage movement is completed, effusion is applied to the area once. Friction is applied. After rubbing, tapotement is applied to the entire back.
48176740|NCT04764201|DRUG|HIP2001|Test drug
48176741|NCT04764201|DRUG|HGP2001|Reference drug
48377348|NCT00461591|DRUG|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
48377349|NCT00461591|DRUG|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
48377350|NCT00461591|PROCEDURE|TURBT|TransUrethral Resection of the Bladder Tumor
48377351|NCT00785252|DEVICE|Powered Intraosseous device (EZIO)|EZIO
48019537|NCT06331052|DEVICE|MR-guided Focused Ultrasound Ablation|3-D tractography Vim-FUSA -D tractography Vim-FUSA will be carried out as follows: (a) head shaving and placement of the stereotactic frame (Integra radionics frame, Integra Lifesciences, NJ, USA) secured to the skull with transcutaneous screws; (b) positioning on the procedure table and placement of the ultrasound transducer; (c) acquisition of conventional magnetic resonance (MR) imaging and co-registration with the CT head and 3-D tractography imaging acquired pre-surgically; (d) exploration of the target area with subtherapeutic sonications; (e) intraoperative monitoring with clinical testing of tremor and side effects with a standardized protocol. (f) Therapeutic sonications in the target area to deliver definitive ablation followed by clinical testing of tremor and side effects with a standardized protocol as described in section (e).
48019538|NCT00650533|DRUG|Glimepiride Tablets 1 mg|1mg, single dose fed
48019539|NCT00650533|DRUG|Amaryl® Tablets 1 mg|1mg, single dose fed
48176742|NCT04026399|OTHER|peripheral vibration stimulation|wearing a wristband that delivers imperceptible vibratory stimulation.
48176743|NCT04026399|BEHAVIORAL|therapy|practice of daily living tasks
48377352|NCT00785252|DEVICE|standard central line|placement of a central line
48019540|NCT00485108|DRUG|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
48176744|NCT03815383|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
48377353|NCT01172327|BEHAVIORAL|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
48710304|NCT02357862|PROCEDURE|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
48710305|NCT03467984|BIOLOGICAL|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
48710306|NCT03467984|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
48710307|NCT01090934|DEVICE|High Resolution EEG|High Resolution EEG
48710308|NCT01090934|DEVICE|Stereo-electroencephalography|SEEG
48710309|NCT06351319|DIAGNOSTIC_TEST|SVM model|Bronchoscopic ultrasound images were analyzed according to SVM mode
48019541|NCT00485108|DRUG|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
48019542|NCT00485108|DRUG|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
48019543|NCT01919385|DEVICE|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
48377354|NCT01172327|BEHAVIORAL|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
48710310|NCT03924583|DIAGNOSTIC_TEST|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
48710311|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 5|(Serving 1: 5 grams of creatine + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
48710312|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 3|(Serving 1: 3 grams of creatine + 5 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
48710313|NCT06606704|DIETARY_SUPPLEMENT|Creatine Intermittent 5|(Serving 1: 2.5 grams of creatine + 5.5 grams of placebo in the morning, Serving 2: 2.5 grams of creatine + 5.5 grams of placebo at least 6 hours after Serving 1).
48710314|NCT06606704|DIETARY_SUPPLEMENT|Placebo|(Serving: 8 grams of placebo in the morning; Servings 2: 8 grams of placebo at least 6 hours after Serving 1).
48710315|NCT00358332|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
48710316|NCT00358332|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
48710317|NCT03580642|DEVICE|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
48019544|NCT05691491|PROCEDURE|Biopsy|Undergo biopsy
48019545|NCT05691491|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48019546|NCT05691491|PROCEDURE|Computed Tomography|Undergo CT scan
48019547|NCT05691491|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48019548|NCT05691491|DRUG|Temozolomide|Given orally (PO)
48019549|NCT05691491|DRUG|Tuvusertib|Given PO
48019550|NCT06129292|BEHAVIORAL|EFT group|"Procedure 1: Preliminary tests will be carried out and then the 1st EFT session will be held.~2nd Procedure: After 10 days, the first final tests will be performed and then the second EFT session will be held."
48019551|NCT04689984|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
48019552|NCT04689984|DRUG|Astaxanthin|Astaxanthin 6 mg tablet once daily
48019553|NCT01248117|DRUG|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
48710318|NCT05799001|BEHAVIORAL|Dance therapy|"Patients will be randomized in 2 groups, experimental or control.~The experimental group will have 4 months of dance therapy with a professional dancer and will then resume there usual activities.~The control group will start with their usual activities in the nursing home for the first 4 months and then, they will have dance sessions with a nurse previously trained by the dancer."
48019554|NCT04067141|DEVICE|somofilcon A|Contact Lens
48019555|NCT04067141|DEVICE|nelfilcon A|Contact Lens
48710319|NCT01367704|BEHAVIORAL|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
48176745|NCT03336099|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall shower, penetrating shower~* Multiple local application cataplasm~* Single local application cataplasm~* Inhalation or collective steam bath~* Individual physiotherapy technique"
48710320|NCT03142724|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
48019556|NCT04090814|DEVICE|HeatTens (HV-F311-E)|(1) 2\~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
48710321|NCT05665673|OTHER|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
48176746|NCT05930808|DRUG|First Test Concor (Fasted)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
48176747|NCT05930808|DRUG|First Reference Concor (Fasted)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
48710322|NCT00990145|DRUG|EDP-322|
48176748|NCT05930808|DRUG|First Test Concor (Fed)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
48176749|NCT05930808|DRUG|First Reference Concor (Fed)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
48176750|NCT00867737|DRUG|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
48176751|NCT00867737|DRUG|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
48710323|NCT05997381|DEVICE|Arthroscopic rotator cuff repair with BioBrace® Implant augmentation.|An arthroscopic rotator cuff repair will be performed and augmented with the BioBrace® Implant. The BioBrace® Implant is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in rotator cuff repairs, it is placed on top of the tendons to augment and reinforce the underlying repair. The BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care rotator cuff repair techniques.
48710324|NCT05997381|PROCEDURE|Arthroscopic rotator cuff repair|An arthroscopic rotator cuff repair is performed using standard surgical procedure.
48019557|NCT02210299|OTHER|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
48176752|NCT00882076|DRUG|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
48377355|NCT04753931|OTHER|Sensory Training in addition to Bobath Training|Trunk-focused exercises will be applied for different senses (tactile, proprioceptive, etc.) in addition to Bobath exercises. Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
48019558|NCT03511482|DEVICE|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
48019559|NCT03511482|DEVICE|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
48176753|NCT00882076|DRUG|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
48377356|NCT04753931|OTHER|Bobath Training|Bobath exercises will be determined individually according to the evaluation results. In general, exercises aiming to muscle tone regulation, increase balance, walking, and functionality will be applied. Trunk-focused Bobath exercises will be selected.
48377357|NCT04535518|DRUG|IVIG|IVIG at a single dose of 2 g/kg
48019560|NCT04731129|DEVICE|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
48019561|NCT05090449|DRUG|Chlorthalidone (HIGROTON® 50)|Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
48019562|NCT05090449|DRUG|Losartan (COZZAR®)|Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
48019563|NCT05090449|DRUG|A1+ A2 Co-administration of Chlorthalidone and Losartan|50mg chlorthalidone + 100 mg losartan potassium
48019564|NCT05090449|DRUG|Chlorthalidone + Losartan Fixed-Dose combination|Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
48019565|NCT06261697|OTHER|A web based survey|An online based questionnaire includes three screens, the first includes the consent form, the second includes the demographic data , and the third page includes questionnaires
48176754|NCT00882076|DRUG|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
48176755|NCT00000104|PROCEDURE|ERP measures of attention and memory|
48019566|NCT05550129|DRUG|AMG 510|Oral tablet
48176756|NCT03954288|DIAGNOSTIC_TEST|serum for sclerostin ELISA test|Blood sample to measure serum sclerostin level
48176757|NCT04721288|OTHER|Active communication through Reboot application|Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.
48176758|NCT04721288|OTHER|Generic communication through Reboot application|Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.
48176759|NCT04266353|DIETARY_SUPPLEMENT|Resveratrol (RSV)|Participants will receive Resveratrol at 150 mg daily for 6 weeks.
48176760|NCT04811898|BIOLOGICAL|LNA-i-miR-221|LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
48176761|NCT02396446|OTHER|Abdominal acoustic measurement|Device meant to listen to the sounds of the gut to determine post op ileus.
48176762|NCT03020069|DEVICE|CGMS Device|
48176763|NCT03020069|OTHER|No Device|
48176764|NCT03378947|OTHER|clinical and pathological data EBV-related GZL and DLBCL|"Invesrigators will retrospectively collect clinical and pathological data of all EBV-related GZL and DLBCL in immunocompetent patients diagnosed in the pathology department Centre Hospitalier Lyon Sud.~Investigators will analyze their clinical feature and prognosis."
48176765|NCT02550912|DRUG|Vitamin D3|vitamin D drops for paediatrics
48176766|NCT02550912|OTHER|Placebo|glucose syrup with same taste and color to vitamin D3 drops
48176767|NCT06287086|DRUG|BRL-101 autologous hematopoietic stem and progenitor cells injection|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
48176768|NCT03055546|DRUG|Oxytocin|intranasal administration of oxytocin
48176769|NCT03055546|DRUG|Placebo|intranasal administration of placebo
48176770|NCT04800783|DIAGNOSTIC_TEST|Swallowing ultrasound|Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
48176771|NCT00507156|PROCEDURE|Standard primary PCI|Acute re-opening of the occluded coronary artery
48377358|NCT04535518|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 72 hours and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
48176772|NCT00507156|PROCEDURE|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
48377359|NCT04535518|DRUG|Infliximab|Intravenous infliximab at single dose of 5 mg/kg, given more than 2 hours.
48377360|NCT05583604|DRUG|secukinumab|The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
48377361|NCT03243552|DRUG|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
48176773|NCT06408688|DRUG|Immune checkpoint inhibitors plus Iscador® Qu.|Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.
48176774|NCT06408688|DRUG|Immune Checkpoint Inhibitors|Standard cancer treatment.
48176775|NCT03962322|OTHER|Weaning TDI|"Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation."
48176776|NCT02603705|DRUG|Oxycodone extended-release|
48176777|NCT03694262|DRUG|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
48176778|NCT03694262|DRUG|Bevacizumab|15mg/kg IV on day 1 of every cycle
48377362|NCT03243552|BEHAVIORAL|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
48377363|NCT03436940|OTHER|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
48176779|NCT03694262|DRUG|Atezolizumab|1,200mg IV on day 1 of every cycle
48176780|NCT04657562|DRUG|Tacrolimus|Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
48176781|NCT04657562|DIAGNOSTIC_TEST|Unbound tacrolimus measurement|Unbound tacrolimus measurement in plasma ultrafiltrate.
48176782|NCT04657562|DIAGNOSTIC_TEST|CYP3A4 and CYP3A5 genotyping|DNA purification and genotyping
48176783|NCT05700448|BIOLOGICAL|Sugemalimab|IV infusion
48176784|NCT05700448|DRUG|Placebo|IV infusion
48176785|NCT05700448|DRUG|Pegaspargase|Intramuscular injection
48377364|NCT03436940|OTHER|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
48176786|NCT05700448|DRUG|Gemcitabine|IV infusion
48176787|NCT05700448|DRUG|Oxaliplatin|IV infusion
48176788|NCT01711346|BIOLOGICAL|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
48176789|NCT01711346|BIOLOGICAL|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
48176790|NCT04147559|DEVICE|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
48176791|NCT00535938|OTHER|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
48176792|NCT03037047|DRUG|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
48176793|NCT03037047|DRUG|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
48176794|NCT00678483|DRUG|rimonabant (SR141716)|once daily
48517491|NCT06582836|BEHAVIORAL|The objective of the study was to investigate the effect of prior engagement of tooth with orthodontic appliance on post extraction pain among orthodontic patients|In this randomized clinical trial, 44 patients were recruited who needed bilateral extractions of first premolars in upper arches. Patients were divided into two groups based on the timing of extractions. Group A needed extractions before alignment while Group B needed extractions for retraction of anterior teeth. Group A was sent for extractions first while Group B went for orthodontic bonding and banding procedures for orthodontic treatment. After series of aligning wires (0.014, 0.016, 17x25, 19x25 Heat activated NiTi and 19x25 SS) patients from group B were sent for extractions. For pain assessment, an 11-point numerical rating scale (NRS) were given to record pain intensity at 2, 4, 8, 12 and then 24 hours after extraction for the next 7 days.
48710325|NCT00966849|OTHER|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
48710326|NCT00966849|OTHER|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
48710327|NCT00966849|OTHER|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
48710328|NCT00966849|OTHER|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
48176795|NCT01310712|DRUG|Oxybutynin|5 mg every 12 hours for 6 weeks
48517492|NCT01625988|DRUG|LY2951742|
48176796|NCT01310712|DRUG|placebo|placebo twice a day for 42 days.
48176797|NCT02579824|DRUG|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
48176798|NCT05076136|OTHER|Regional treatment|In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
48176799|NCT05076136|OTHER|Standard physiotherapy treatment|In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
48176800|NCT00639769|DRUG|cisplatin|Starting dose 30 mg/m2 Dose level -1 20 mg/m2
48517493|NCT01625988|DRUG|Placebo|
48019567|NCT05550129|DRUG|Metformin|Oral tablet
48176801|NCT00639769|DRUG|irinotecan hydrochloride|50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
48176802|NCT04749498|OTHER|White Bread|Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.
48710329|NCT04248920|BEHAVIORAL|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
48176803|NCT04749498|OTHER|Whole Wheat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
48019568|NCT01351740|DRUG|atazanavir|switch to unboosted atazanavir 400 mg daily
48019569|NCT01351740|DRUG|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
48710330|NCT02059759|DRUG|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
48710331|NCT02059759|DRUG|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
48019570|NCT03388073|OTHER|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
48176804|NCT04749498|OTHER|Barley Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
48176805|NCT04749498|OTHER|Oat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
48176806|NCT02028247|BEHAVIORAL|Personalized Cognitive-behavioral therapy|
48176807|NCT02028247|BEHAVIORAL|Standard Practice Cognitive-behavioral therapy|
48176808|NCT02028247|BEHAVIORAL|Treatment as Usual|
48377365|NCT04739202|DRUG|Atezolizumab + Ipatasertib|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
48377366|NCT04739202|DRUG|Atezolizumab + Bevacizumab|Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
48517494|NCT00556868|OTHER|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
48019571|NCT03388073|OTHER|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
48019572|NCT03388073|OTHER|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
48019573|NCT03388073|OTHER|Placebo|Placebo
48019574|NCT03310541|DRUG|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
48019575|NCT03310541|DRUG|Enzalutamide|Enzalutamide 160 mg PO once daily
48019576|NCT03310541|DRUG|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
48019577|NCT06422988|DIETARY_SUPPLEMENT|Probiotics|Any exposure to probiotics in first 14 days of life
48176809|NCT03927183|OTHER|person-centred practice|The structure and content of the intervention is constructed on principles for person-centredness. Each patients in the intervention are allocated a hospital-initiated nurse care manager during one year after surgery. Self-management support is primarily conducted between the patient and the nurse care manager. The primary goal of the support is to facilitate patients own resources in managing illness and health education on e.g. physical activity and diet. The support also comprises patient-held documentation and health plan. Other components of the intervention comprise accessibility and continuity which is secured by a structured clinical care pathway with planned care and defined care contacts. The patient has continuous access to the nurse care manager by telephone and face-to-face contact according to a structured follow-up plan. An interdisciplinary team as well as a patient education program constitutes distinct parts of the support during the year after surgery.
48176810|NCT05568368|OTHER|No intervention|no intervention
48176811|NCT05680324|PROCEDURE|Monsplasty|liposuction assisted monsplasty
48176812|NCT03638258|DRUG|Roflumilast Cream 0.3%|Applied once daily for 12 weeks
48176813|NCT03638258|DRUG|Roflumilast Cream 0.15%|Applied once daily for 12 weeks
48176814|NCT03638258|DRUG|Vehicle Cream|Applied once daily for 12 weeks
48176815|NCT01993771|PROCEDURE|Surgery with general anaesthesia.|
48710332|NCT02059759|DRUG|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
48710333|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
48710334|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
48710335|NCT03740542|PROCEDURE|Esophagectomy|Surgical removal of part of esophagus
48710336|NCT03740542|PROCEDURE|Pyloroplasty|pyloric drainage procedure
48710337|NCT03292939|DIAGNOSTIC_TEST|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
48019578|NCT06262087|BEHAVIORAL|Change of direction training|The experimental group is implemented FIFA 11+ program combined with COD training
48019579|NCT06262087|BEHAVIORAL|FIFA 11+ program|The experimental group is implemented FIFA 11+ program.
48019580|NCT01575561|DRUG|Lurasidone|Lurasidone 20-80 mg taken orally once daily
48176816|NCT01993771|PROCEDURE|Raw EEG|
48710338|NCT04736953|DRUG|Sirolimus|Sirolimus
48710339|NCT04736953|OTHER|Placebo|Placebo
48710340|NCT02370641|DIETARY_SUPPLEMENT|PomX|1000 mg POMx daily for 4 weeks
48710341|NCT02192762|BEHAVIORAL|Withdrawal regulation training|Withdrawal coping skills
48710342|NCT02192762|BEHAVIORAL|Relaxation training|Relaxation skills instruction
48710343|NCT01252550|DIETARY_SUPPLEMENT|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
48710344|NCT01252550|DIETARY_SUPPLEMENT|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
48710345|NCT05653882|BIOLOGICAL|AB248|Intravenous infusion of AB248: CD8+ T cell selective interleukin-2 investigational drug
48710346|NCT05653882|BIOLOGICAL|pembrolizumab|Intravenous infusion of pembrolizumab
48710347|NCT04841759|OTHER|Exercise|8 week exercise program, nutritional \& psychological consultation
48710348|NCT01296074|DRUG|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
48710349|NCT01643850|DRUG|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
48710350|NCT01643850|DRUG|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
48710351|NCT01994239|DRUG|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
48019581|NCT00844545|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
48176817|NCT05654805|DIETARY_SUPPLEMENT|Drinking powder supplement|Drinking powder supplement, to be taken twice daily over 12 weeks
48176818|NCT06485739|DRUG|Irinotecan liposomes combined with cisplatin/carboplatin|Irinotecan liposomes 70mg/m2，use on the first day of each cycle The dosage of cisplatin and carboplatin is determined by the researchers
48176819|NCT02737111|BEHAVIORAL|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
48377367|NCT01400191|DRUG|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
48710352|NCT01994239|RADIATION|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
48710353|NCT04268875|DEVICE|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
48710354|NCT02590562|OTHER|Routine clinical practice|
48710355|NCT05290454|OTHER|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
48710356|NCT05476432|PROCEDURE|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
48710357|NCT05476432|DRUG|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
48710358|NCT05476432|DRUG|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
48710359|NCT04526145|BEHAVIORAL|Stress and emotion management|Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
48019582|NCT06573710|DEVICE|sonic activator|Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
48710360|NCT02877654|PROCEDURE|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
48710361|NCT06194955|DRUG|GIP(1-42)|Infusion
48710362|NCT06194955|DRUG|GLP-1|Infusion
48710363|NCT06194955|DRUG|GLP-2|Infusion
48710364|NCT06194955|OTHER|Placebo|Saline
48710365|NCT05630222|DRUG|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
48710366|NCT05630222|DRUG|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
48710367|NCT05630222|DRUG|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
48517495|NCT04718454|DEVICE|dental attachment|This research aimed to evaluate the retentive power and wear of the smart box attachment use with tilted two implant assisted mandibular overdenture
48517496|NCT01917292|PROCEDURE|One-Stage Full-Mouth Disinfection|"1. Basic oral hygiene instructions~2. Dental extractions will be performed (only in cases of teeth that could not be saved)~3. Standard cycle of supragingival ultrasonic scaling and polishing~4. Scaling and root planning after the administration of local anesthesia, four quadrants in one session~5. Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
48710368|NCT06198101|OTHER|Myofascial Release Technique|The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.
48710369|NCT06198101|OTHER|Myofascial Release Technique along with segmental vibrator|this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
48710370|NCT03114124|DEVICE|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
48710371|NCT03114124|DEVICE|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
48710372|NCT05082350|DIETARY_SUPPLEMENT|black garlic|Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
48710373|NCT04326725|DRUG|Plaquenil 200Mg Tablet|health workers under risk who took this medications
48176820|NCT02737111|BEHAVIORAL|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
48176821|NCT02737111|BEHAVIORAL|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
48377368|NCT04103593|BEHAVIORAL|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
48377369|NCT06439134|DIAGNOSTIC_TEST|Pulmonary Ultrasound, Respiratory Function Test|Volunteers underwent pulmonary ultrasound and respiratory function test
48710374|NCT05433168|PROCEDURE|SHIATSU|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
48710375|NCT05433168|PROCEDURE|DUMMY SHIATSU|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
48710376|NCT00644618|DRUG|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
48710377|NCT00644618|OTHER|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
48710378|NCT02798991|DRUG|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
48176822|NCT02737111|BEHAVIORAL|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
48377370|NCT03079648|DIETARY_SUPPLEMENT|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
48377371|NCT03079648|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
48377372|NCT04575415|DRUG|Bevacizumab|Bevacizumab 15mg/kg or clinical routine dose by intravenous drip infusion on day 1 of a 21-day cycle
48517497|NCT01917292|PROCEDURE|Periodontal care|"1. Basic oral hygiene instructions~2. Standard cycle of supragingival ultrasonic scaling and polishing"
48517498|NCT03048227|DEVICE|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
48517499|NCT03248427|DRUG|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
48517500|NCT03248427|DRUG|Letrozole 2.5mg|Daily continuous
48517501|NCT03248427|DRUG|Doxorubicin|60 mg/m2 as a continuous IV perfusion
48517502|NCT03248427|DRUG|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
48517503|NCT03248427|DRUG|Paclitaxel|80 mg/m2, in one hour IV infusion
48517504|NCT00032786|DRUG|natalizumab|
48710379|NCT02798991|DRUG|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
48710380|NCT03488589|DIAGNOSTIC_TEST|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
48710381|NCT05489627|PROCEDURE|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
48710382|NCT01420172|OTHER|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
48710383|NCT03282110|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
48710384|NCT03282110|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
48710385|NCT03282110|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
48019583|NCT06573710|DEVICE|LASER activation|Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle
48019584|NCT06573710|DEVICE|Ultrasonic activation|ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA
48019585|NCT06573710|DEVICE|passive irrigation with Endodontic needle|Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA
48019586|NCT04480164|DRUG|NDMC|Repeated oral administration of ascending daily doses of NDMC (40mg, 60mg,120mg/day) vs placebo in 3 sequential cohorts
48176823|NCT02737111|BEHAVIORAL|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
48176824|NCT00945113|BEHAVIORAL|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
48710386|NCT04072679|DRUG|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
48019587|NCT06492304|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
48176825|NCT00177021|DRUG|Aldara Cream 5%|
48176826|NCT05181397|DRUG|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
48176827|NCT00429897|DRUG|Bendroflumethiazide 2.5mg - 5mg|
48377373|NCT04575415|DRUG|Erlotinib|Erlotinib 150mg, orally once a day
48377374|NCT04575415|DRUG|Gefitinib|Gefitinib 250mg, orally once a day
48710387|NCT01175642|BEHAVIORAL|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
48710388|NCT01175642|BEHAVIORAL|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
48176828|NCT00429897|DRUG|Amiloride 20-40mg|
48176829|NCT00429897|DRUG|Spironolactone 50-100mg|
48176830|NCT00429897|DRUG|Frusemide 20-40mg|
48176831|NCT00429897|DRUG|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
48377375|NCT04575415|DRUG|Icotinib|Icotinib 125mg three times a day
48377376|NCT04575415|DRUG|Afatinib|Afatinib 40 mg or clinical routine dose once daily
48377377|NCT04575415|DRUG|Dacomitinib|Dacomitinib 45mg or clinical routine dose once daily
48377378|NCT04575415|DRUG|Osimertinib|Osimertinib 80 mg once daily
48176832|NCT02050698|PROCEDURE|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
48377379|NCT03175068|BEHAVIORAL|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
48377380|NCT03175068|BEHAVIORAL|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
48377381|NCT01258010|DRUG|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
48377382|NCT01258010|DRUG|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
48377383|NCT01171794|DRUG|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
48019588|NCT04431102|OTHER|PILATES METHOD|"It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day."
48176833|NCT02050698|PROCEDURE|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
48176834|NCT03789812|DEVICE|Manual toothbrush|Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
48176835|NCT03789812|DEVICE|Electric Toothbrush|Electric toothbrush (Jetpik JP210) will be used to brush occlusal, buccal and lingual teeth surfaces.
48176836|NCT03789812|DEVICE|Superfloss|Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
48377384|NCT01171794|DRUG|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
48377385|NCT05295459|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
48377386|NCT05295459|DRUG|Sham procedure control|Sham procedure control
48377387|NCT05295459|OTHER|Background therapy|Daily Saline Irrigation
48377388|NCT04314115|OTHER|Mindfulness|Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.
48377389|NCT04314115|OTHER|Systemic therapy|Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.
48377390|NCT04314115|OTHER|Cognitive behavioral therapy and positive psychology|Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
48377391|NCT06096909|DRUG|Tafolecimab|The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.
48176837|NCT03789812|DEVICE|Dental Water Jet|Dental water jet (Jetpik JP210) will be used to clean interproximal teeth surfaces.
48377392|NCT06096909|DRUG|Cholesterol Absorption Inhibitor|Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.
48377393|NCT06096909|DRUG|Statin|Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.
48377394|NCT05483062|OTHER|galla chinensis|toothpaste
48377395|NCT05483062|OTHER|Stannous fluoride|Toothpaste
48377396|NCT00002329|DRUG|Celgosivir hydrochloride|
48377397|NCT00860756|OTHER|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
48710389|NCT04289077|OTHER|Questionnaires|- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
48710390|NCT00190138|DEVICE|Bi-ventricular pacing|
48710391|NCT01960127|BEHAVIORAL|Aerobic Exercise|Aerobic exercise
48710392|NCT01960127|BEHAVIORAL|No Intervention|No Intervention
48710393|NCT01355263|DRUG|iron and vitamin a|
48710394|NCT05607498|DRUG|EMB07|EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
48710395|NCT06037850|DEVICE|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
48710396|NCT06037850|DEVICE|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
48710397|NCT01579825|OTHER|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
48710398|NCT05801406|DEVICE|Tornado (Cook)|Fiducial marker endobronchial positioning under augmented fluoroscopy to mark ground glass opacities.
48710399|NCT01633515|PROCEDURE|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
48710400|NCT00492479|DRUG|Kinerase Pro+Therapy Line day repair, serum, night repair|
48710401|NCT00492479|DRUG|Kinerase Pro+Therapy Line Ultra rich day repair|
48710402|NCT00492479|DRUG|LubriDerm|
48710403|NCT03251040|DEVICE|Autologous activated fibrin sealant|Application of fibrin sealant
48710404|NCT01819558|BIOLOGICAL|recwt1-A10+AS01B|
48710405|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
48710406|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
48710407|NCT03789032|DRUG|Vadadustat|Vadadustat 300 mg
48710408|NCT03789032|DRUG|Rabeprazole|Oral Rabeprazole
48710409|NCT02729610|DEVICE|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
48710410|NCT02729610|DEVICE|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
48176838|NCT03629899|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
48377398|NCT04360213|DEVICE|Advanced multimodal wireless vital signs monitor|Investigators have developed a lightweight, stretchable 'skin-like' membranes, called skin sensors. These small, paper-thin monitors were created by matching the mechanical properties of skin, and can be applied to the skin's surface without skin disturbance. Each patch is encapsulated using medical grade materials and applied using single use medical grade skin adhesive integrated with eco-fused fabric (moisture wicking layer between adhesives). The adhesive may be changed between uses, and the device itself can be cleaned with Super Sani-Cloth®, commonly used in the hospital setting.
48710411|NCT04373499|BEHAVIORAL|Virtual Teach to Goal|Virtual Teach-to-Goal is an educational module that teaches children how to use their inhaler properly; this is done with an IPAD. In the module, the child will complete a series of questions as a pre-assessment, watch a video about how to use the inhaler properly, and then answer a series of questions as a post-assessment. If a child answers any questions incorrectly, they will watch the video again and have another chance to answer the incorrect questions. The child will receive instruction by video one or multiple times (up to 3 times), depending on how much they understand after each round of instruction, as demonstrated by their responses to questions.
48176839|NCT01808898|PROCEDURE|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
48176840|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
48176841|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
48176842|NCT02455999|DRUG|Placebo|Placebo eye drops administration for 10 consecutive days
48176843|NCT00032747|DRUG|Vasopressin V2 Receptor Antagonist|
48710412|NCT04373499|BEHAVIORAL|Brief Intervention|There is a handout that describes proper inhaler technique. The RA reads the handout to the child.
48710413|NCT01445522|DRUG|ABT-888|
48710414|NCT01445522|DRUG|Cyclophosphamide|
48710415|NCT06474091|OTHER|Non-Interventional Study|Non-Interventional Study
48710416|NCT05797038|DRUG|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
48710417|NCT00114023|DRUG|Imiquimod 5% cream|
48710418|NCT03783741|BEHAVIORAL|Questionnaire|Interview
48710419|NCT03897296|DIAGNOSTIC_TEST|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
48710420|NCT01620164|OTHER|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
48710421|NCT00536874|DRUG|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
48710422|NCT00536874|DRUG|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
48710423|NCT00536874|GENETIC|protein expression analysis|
48710424|NCT00536874|GENETIC|proteomic profiling|
48377399|NCT05890235|DRUG|Ningmitai Capsule|Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
48710425|NCT00536874|OTHER|diagnostic laboratory biomarker analysis|
48710426|NCT00536874|PROCEDURE|adjuvant therapy|
48176844|NCT05100810|OTHER|Natural History Study|Longitudinal assessment of disease progression of Angelman syndrome in patients
48710427|NCT00536874|PROCEDURE|neoadjuvant therapy|
48710428|NCT00536874|PROCEDURE|therapeutic conventional surgery|
48710429|NCT01161550|DRUG|Granulocyte colony-stimulating factor (G-CSF)|
48176845|NCT01168336|DRUG|Betahistine standard formulation|betahistine 24 mg tablets
48176846|NCT01168336|DRUG|Betahistine Extended Release formulation|betahistine 32 mg tablets
48176847|NCT01168336|DRUG|Placebo|matching placebo
48176848|NCT05376878|OTHER|Copper Cu 64-DOTA-Trastuzumab|Given IV
48176849|NCT05376878|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
48176850|NCT05376878|DEVICE|Positron Emission Tomography|Undergo PET/MRI
48176851|NCT05376878|BIOLOGICAL|Trastuzumab|Given IV
48710430|NCT01161550|DRUG|Cladribine|
48710431|NCT01161550|DRUG|Cytarabine|
48176852|NCT05376878|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
48176853|NCT01419977|DRUG|Placebo|Normal saline solution, administered by nursing staff once daily
48176854|NCT01419977|DRUG|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
48176855|NCT00089830|DRUG|MSI-1256F (Squalamine Lactate)|
48176856|NCT04145388|OTHER|online cancer risk assessment|Electronic surveys to collect family cancer history information.
48710432|NCT01161550|DRUG|All-Trans Retinoic Acid (ATRA)|
48710433|NCT01161550|DRUG|Midostaurin|
48710434|NCT01204229|BEHAVIORAL|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
48710435|NCT01204229|BEHAVIORAL|Brief Motivational Intervention (BMI)|Integrate drinking intervention
48710436|NCT02978105|OTHER|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
48710437|NCT02978105|OTHER|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
48019589|NCT04353297|OTHER|EEG-based BCI system for (hand) Motor Imagery training|The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).
48019590|NCT04353297|OTHER|Motor Imagery training|Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
48019591|NCT00374777|DRUG|zolpidem MR|oral
48019592|NCT00374777|DRUG|nitrazepam|oral
48019593|NCT00374777|DRUG|placebo|oral
48019594|NCT05053386|DRUG|Idarubicin Hydrochloride for Injection|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
48019595|NCT05053386|DRUG|Epirubicin|After an interventional treatment, CT and/or MRI, tumor-related markers, liver and kidney function and blood routine examinations will be reviewed every 4-6 weeks, based on the patient's response to the last treatment, changes in liver function and physical fitness, and CT And (or) dynamic enhanced MRI scan to evaluate the survival of liver tumors and determine the next TACE treatment. At least 2 cycles are applied and no more than 4 cycles are applied.
48019596|NCT04143347|OTHER|No Intervention|
48019597|NCT05841810|OTHER|mHealth Outreach|Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).
48019598|NCT05841810|OTHER|Care Coordination|Inclusive of standard of care coordination with added focus on completing outstanding preventive care practices. Care coordination will be focused on collaborative problem-solving and case management to help patients schedule and attend recommended annual preventive health care, including a routine physical exam, recommended preventive screenings and COVID-19 vaccination
48019599|NCT05750693|GENETIC|PIK3CA analysis|"PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations."
48019600|NCT03502603|DIAGNOSTIC_TEST|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
48019601|NCT03502603|DIAGNOSTIC_TEST|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
48019602|NCT03502603|DIAGNOSTIC_TEST|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
48019603|NCT03502603|DIAGNOSTIC_TEST|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
48019604|NCT03502603|DIAGNOSTIC_TEST|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
48710438|NCT06019247|OTHER|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
48019605|NCT03502603|DIAGNOSTIC_TEST|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
48176857|NCT04145388|OTHER|Usual care|Family cancer history captured by provider during a clinical encounter
48710439|NCT03089944|DRUG|Glecaprevir/Pibrentasvir|Tablet
48710440|NCT06309251|OTHER|ketogenic diet (as per clinical practice)|Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
48710441|NCT00914563|DEVICE|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
48019606|NCT03502603|DIAGNOSTIC_TEST|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
48019607|NCT03502603|DIAGNOSTIC_TEST|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
48710442|NCT00914563|OTHER|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
48019608|NCT03502603|DIAGNOSTIC_TEST|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
48019609|NCT03502603|DIAGNOSTIC_TEST|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
48019610|NCT03205085|RADIATION|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
48019611|NCT03205085|PROCEDURE|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
48019612|NCT03205085|OTHER|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
48019613|NCT05751135|DEVICE|Focal muscle vibration|Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
48710443|NCT03303859|DIAGNOSTIC_TEST|Bacterial vaginosis|
48710444|NCT02163720|DRUG|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
48710445|NCT00902018|DRUG|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
48710446|NCT00902018|DRUG|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
48176858|NCT06315114|BEHAVIORAL|Lighthouse MBT Parenting Program (LPP)|The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.
48176859|NCT06315114|BEHAVIORAL|Care as usual (CAU)|"1-2 next of kin sessions (called 'Familiesamtale') is considered the care as usual offered to parents in adult mental health service in the Capital Region of Denmark.~Parents are offered the possibility of bringing their spouse or offspring to one of the sessions."
48176860|NCT02510053|DRUG|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
48176861|NCT01089309|DRUG|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
48176862|NCT02895321|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
48176863|NCT02895321|OTHER|Colgate, Protection Caries|a fluorine-based toothpaste gels
48176864|NCT02895321|OTHER|Placebo gel|a glycerin and water gel
48176865|NCT02062645|DRUG|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
48176866|NCT04021225|DEVICE|Ectoin® Allergy Eye Drops 2%|A one-time application of 1-2 drops in the more affected eye will be investigated.
48710447|NCT00902018|OTHER|healthy controls|single blood draw for all measures included in the intervention arms
48019614|NCT05751135|PROCEDURE|Stretching|Stretching of shortened lower extremity muscle
48176867|NCT04021225|DEVICE|Ectoin® Eye Spray Colloidal|A one-time application of 1-2 drops in the more affected eye will be investigated.
48176868|NCT04021225|DEVICE|Tears Again® eye spray|A one-time application of 1-2 drops in the more affected eye will be investigated.
48377400|NCT05890235|DRUG|Tamsulosin Hydrochloride|Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
48710448|NCT00579046|DRUG|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
48710449|NCT00408096|PROCEDURE|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
48710450|NCT00951522|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
48019615|NCT05751135|PROCEDURE|Strengthening|Strengthening exercises for weak lower extremity muscles
48019616|NCT05751135|PROCEDURE|Positioning|Positioning of participant to maintain a good body posture
48019617|NCT05511714|DRUG|L-(11C) methionine|Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
48019618|NCT04526691|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle (starting datopotamab deruxtecan dose of 4.0 mg/kg)
48710451|NCT00951522|DRUG|Placebo|Inhaled placebo in sterile saline
48710452|NCT03494517|DRUG|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
48710453|NCT04706273|DEVICE|GORE® VIABAHN® Endoprosthesis|Participants receiving the GORE® VIABAHN® Endoprosthesis
48019619|NCT04526691|DRUG|KEYTRUDA®|Intravenous infusion Q3W on Day 1 of each 21-day cycle (fixed pembrolizumab dose 200 mg Q3W)
48710454|NCT03426475|PROCEDURE|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
48019620|NCT04526691|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (AUC 5)
48176869|NCT03579238|PROCEDURE|CV4|The occiput of a supine patient is held such that flexion motion is inhibited and extension motion is reinforced.
48176870|NCT03579238|PROCEDURE|touching|the clinician allows the participant's head to rest quietly upon his open palms on a table.
48176871|NCT05074771|DEVICE|ARC intellicare|ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
48176872|NCT05282836|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
48176873|NCT01748045|DRUG|inhaled nitric oxide|
48176874|NCT01748045|DRUG|Placebo Comparator - nitrogen gas|
48176875|NCT00736125|DEVICE|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
48176876|NCT00736125|DEVICE|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
48710455|NCT01028716|DRUG|Cyclophosphamide|Given IV
48710456|NCT01028716|BIOLOGICAL|Filgrastim|Given SQ
48710457|NCT01028716|DRUG|Fludarabine Phosphate|Given IV
48019621|NCT04526691|DRUG|Cisplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle (75 mg/m\^2)
48176877|NCT00034853|DRUG|meloxicam oral suspension|
48710458|NCT01028716|DRUG|Mycophenolate Mofetil|Given PO
48019622|NCT05790343|BEHAVIORAL|BAPHYC|Nine weekly peer led group meetings
48019623|NCT05484401|DRUG|Ibuprofen 200Mg Oral Cap|2 x 200mg Liquid Capsules once in 12 hours
48019624|NCT05484401|DRUG|Ibuprofen 200Mg Oral Tablet|2 x 200mg Tablets once in 12 hours
48019625|NCT05484401|OTHER|Placebo Liquid Capsule|2 x Liquid Capsules once in 12 hours
48019626|NCT05484401|OTHER|Placebo Tablets|2 x Tablets once in 12 hours
48019627|NCT04612491|BEHAVIORAL|Pre-operative Consultation|Pre-operative consultation will be given before Mohs surgery
48019628|NCT06663072|DRUG|Fulvestrant|"Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses."
48019629|NCT06663072|DRUG|177Lu-DOTATATE|"Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles."
48176878|NCT00034853|DRUG|naproxen oral suspension|
48710459|NCT01028716|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
48710460|NCT01028716|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
48710461|NCT01028716|DRUG|Tacrolimus|Given IV or PO
48710462|NCT01028716|RADIATION|Total-Body Irradiation|Undergo total-body irradiation (TBI)
48710463|NCT05536089|DIAGNOSTIC_TEST|a multi-locus blood-based assay|Colorectal tumor-specific plasma ctDNA methylation markers detection
48710464|NCT02036164|RADIATION|Pelvic radiation|"Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times"
48710465|NCT02036164|DRUG|Cisplatin|Cisplatin 40 mg/m2 i.v.
48710466|NCT02036164|DRUG|Paclitaxel|Paclitaxel 175 mg m2 i.v.
48710467|NCT02036164|DRUG|Carboplatin|Carboplatin AUC 5 i.v.
48710468|NCT05039671|BEHAVIORAL|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
48377401|NCT05383157|BEHAVIORAL|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
48517505|NCT02972892|DEVICE|Et Control Feature|Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.
48710469|NCT05030064|DRUG|Intestinal flora capsule|"This research group has independently researched and created a human intestinal flora capsule based on intestinal bacteria transplantation: Intestinal flora capsule, which has been declared a national invention patent (patent number: 2015103040414)."
48710470|NCT05030064|PROCEDURE|placebo capsule|Each placebo capsule is the two-layer empty capsule shell of the Intestinal flora capsule, which is made of titanium dioxide and iron oxide yellow. It is non-toxic and has the same appearance as the authentic Intestinal flora capsule.
48710471|NCT03445728|DRUG|Nicorandil|After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
48710472|NCT03445728|OTHER|Placebo|After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
48019630|NCT02124590|OTHER|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
48019631|NCT02124590|OTHER|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
48019632|NCT01416805|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
48019633|NCT01416805|BEHAVIORAL|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
48019634|NCT06280313|COMBINATION_PRODUCT|Splenectomy+Targeted therapy+ Immunotherapy|Eligible patients with unresectable hepatocellular carcinoma accompanied by cirrhotic portal hypertension were enrolled in the trial, and all participants underwent either open or laparoscopic splenectomy, with or without devascularization around the cardia. Starting two weeks post-surgery, patients began intravenous infusion of PD-1 monoclonal antibody, Tislelizumab, at a dosage of 200mg every three weeks. Three weeks post-surgery, patients commenced oral administration of the targeted therapy, Lenvatinib, with a dosage based on body weight: 8mg (≤60kg) or 12mg (\>60kg), once daily.
48019635|NCT04734353|DRUG|Prasugrel 5mg|Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months
48019636|NCT04734353|DRUG|Ticagrelor 60mg|Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months
48019637|NCT00820339|PROCEDURE|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
48019638|NCT00820339|PROCEDURE|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
48019639|NCT02266381|PROCEDURE|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
48019640|NCT02266381|PROCEDURE|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
48019641|NCT02266381|PROCEDURE|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
48019642|NCT06165705|DEVICE|CureSight|dichoptic therapy with anaglyph goggles and eye tracking
48019643|NCT00785226|DRUG|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
48710473|NCT06297850|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A CGM device placed on the posterior aspect of the upper arm in which a sensor placed in the skin registers glucose values. Via Bluetooth, these readings are sent to a receiver near the patient every 5 minutes. The CGM system can alert when deviating glucose levels, but will for this observational study be blinding to patients and clinical staff. Thus, the patients' diabetic care will rely on standard practice.
48710474|NCT00186212|BEHAVIORAL|workbook/journal on coping with breast cancer|
48710475|NCT00186212|BEHAVIORAL|standard educational materials on breast cancer|
48710476|NCT03255213|OTHER|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
48019644|NCT00785226|DRUG|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
48019645|NCT00204191|DRUG|tacrolimus|
48377402|NCT05383157|OTHER|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
48377403|NCT01756586|DRUG|Dexamethasone|
48377404|NCT01756586|DRUG|Bupivacaine|Control
48019646|NCT00129519|DRUG|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
48019647|NCT04428632|DRUG|Berotralstat|One 150mg capsule administered orally once daily
48019648|NCT02787356|DRUG|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
48019649|NCT02787356|DRUG|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
48019650|NCT00304070|DRUG|Cisplatin|Given IV
48019651|NCT00304070|PROCEDURE|Conventional Surgery|Patients undergo surgery
48019652|NCT00304070|DRUG|Doxorubicin Hydrochloride|Given IV
48019653|NCT00304070|DRUG|Etoposide|Given IV
48019654|NCT00304070|BIOLOGICAL|Filgrastim|Given subcutaneously
48019655|NCT00304070|DRUG|Mitotane|Given orally
48019656|NCT00304070|BIOLOGICAL|Pegfilgrastim|Given subcutaneously
48019657|NCT06664398|BEHAVIORAL|one HIIT|one HIIT high intensity interval training
48019658|NCT06664398|BEHAVIORAL|four HIIT|four HIIT high intensity interval training
48019659|NCT02360540|OTHER|Gestalt estimation|
48019660|NCT05676047|BEHAVIORAL|Cognitive Rehabilitation|A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
48019661|NCT05676047|OTHER|Education|The Education group will receive information about self-management of cognitive symptoms at the time of randomization, a common alternative for adults with Long COVID cognitive symptoms who do not receive Individual Therapy.
48019662|NCT02572271|PROCEDURE|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
48019663|NCT02572271|PROCEDURE|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
48019664|NCT02811198|OTHER|No intervention|
48019665|NCT06533397|PROCEDURE|Sinus floor elevation (SFE)|Patients rinse with 0.2% chlorhexidine solution for one minute before surgery. Under local anesthesia, a mucoperiosteal flap is raised from a midcrestal incision and two relieving incisions. Lateral window osteotomies are carried out using diamond burs. The Schneiderian membrane is carefully elevated and the synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) (2-3 cm3) is packed in the defect with light force. The buccal flap is then mobilized to allow tension-free primary closure. The margins are stabilized with single interrupted sutures. Antibiotics (1 g amoxicillin-clavulanate twice a day for 5 days, or in case of side effects or known allergy to penicillin, 300 mg clindamycin 4 times a day for 4 days), anti-inflammatory drugs (50 mg diclofenac 3 times a day for 3 days), and chlorhexidine mouthwash (twice a day for 21 days from the first day after surgery) are prescribed. Suture removal takes place after 10 days.
48019666|NCT06533397|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|A CBCT scan is performed before SFE surgery to evaluate the anatomy and pathologies of the maxillary sinus.
48019667|NCT06533397|DIAGNOSTIC_TEST|postoperative CBCT|A CBCT scan is performed following the 3- or 6-month-long healing period after SFE to evaluate the anatomy and healing of the augmented bone and the maxillary sinus.
48019668|NCT06533397|DIAGNOSTIC_TEST|bone core biopsy|At the time of dental implant placement, the first step of the implant bed preparation is performed using a trephine drill to harvest a bone core biopsy sample from the augmented bone. The biopsy sample is harvested from the implant bed, this way the patient is spared of excess surgical burden as this bone would be removed even if no biopsy sample was harvested during dental implant placement. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
48019669|NCT06533397|PROCEDURE|dental implant placement|Following the 3- or 6-month-long healing period following SFE, dental implants are placed non-submerged in the augmented bone under local anesthesia.
48019670|NCT06533397|PROCEDURE|fixed dental prosthesis (FDP) fabrication|3 months after dental implant placement, fixed dental prostheses are delivered on the dental implants.
48019671|NCT06533397|DEVICE|bone grafting|A synthetic bone graft material (Bond Apatite, Augma Biomaterials, Cesarea, Israel) is used during SFE.
48019672|NCT06040749|OTHER|Virtual group-based handcycling|Virtual group-based handcycling
48019673|NCT04313192|DEVICE|pulse rate of 2 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
48019674|NCT04313192|DEVICE|pulse rate of 10 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
48019675|NCT04313192|DEVICE|pulse rate of 150 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
48019676|NCT04363606|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
48019677|NCT04363606|BIOLOGICAL|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
48019678|NCT04363606|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
48377405|NCT06004518|OTHER|sexual counselling with PLISSIT model|sexual counselling with PLISSIT model
48377406|NCT00577382|DRUG|Sunitinib|
48377407|NCT02649127|BEHAVIORAL|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
48377408|NCT02649127|BEHAVIORAL|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity \[i. e., \>60% of oxygen uptake reserve (VO2R)\], and a time of 20-25 minutes each bout of training
48377409|NCT02649127|BEHAVIORAL|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
48377410|NCT03504501|DRUG|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
48377411|NCT03504501|DRUG|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
48019679|NCT04363606|DEVICE|actigraphy|assessment of sleep quality
48019680|NCT04363606|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging"
48176879|NCT01582373|BEHAVIORAL|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
48176880|NCT04293952|OTHER|Balance, Resistance, Aerobic, Cognition Exercises (BRACE)|BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.
48377412|NCT01225601|BEHAVIORAL|Tabacco discontinuation|Tabacco discontinuation
48377413|NCT05334992|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Individual therapy 12 to 16 weeks
48377414|NCT05334992|BEHAVIORAL|Behavior Activation|Individual therapy 12 to 16 weeks
48377415|NCT03116958|DEVICE|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
48377416|NCT03116958|DEVICE|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
48377417|NCT00118560|BEHAVIORAL|Physical exercise|treadmill walking
48377418|NCT00118560|BEHAVIORAL|Physical walking|calf muscle exercise
48377419|NCT01504126|DRUG|Chemotherapy|Undergo standard chemotherapy
48176881|NCT04293952|OTHER|Balance Resistance Exercise (BRE)|this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
48176882|NCT00037115|DRUG|interferon beta 1a|
48176883|NCT00037115|DRUG|methotrexate|
48377420|NCT01504126|DRUG|Propranolol Hydrochloride|Given PO
48377421|NCT01504126|OTHER|Quality-of-Life Assessment|Ancillary studies
48377422|NCT01504126|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48377423|NCT02475109|DRUG|PAN-90806 Ophthalmic Solution|
48377424|NCT03733665|OTHER|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
48377425|NCT02996838|DRUG|TQ-B3234|TQ-B3234 p.o. qd
48710477|NCT03368716|BEHAVIORAL|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
48377426|NCT06217562|DRUG|Vasopressin|Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
48377427|NCT06217562|OTHER|Recommendation to use a lower initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
48710478|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
48710479|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
48710480|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
48710481|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
48710482|NCT02839161|BIOLOGICAL|Na-GST-1/Alhydrogel|
48710483|NCT02839161|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
48710484|NCT02839161|BIOLOGICAL|Hepatitis B Vaccine|
48377428|NCT06217562|OTHER|Recommendation to use a higher initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
48710485|NCT00523705|DRUG|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
48710486|NCT00523705|OTHER|placebo|Placebo tablets matched to drug
48710487|NCT02562209|DIETARY_SUPPLEMENT|PACER Diet|Pacer diet to be followed for 8 weeks
48377429|NCT01798056|BIOLOGICAL|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
48377430|NCT01798056|DRUG|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
48710488|NCT02562209|OTHER|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
48377431|NCT05741762|OTHER|Retrospective chart review|The retrospective chart review will be done for patient admitted into ICU between 01/06/2017 to 01/06/2022
48377432|NCT01541644|DEVICE|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
48377433|NCT05375110|DEVICE|NoYA™ Radiofrequency Interatrial Shunt System|NoYA™ Radiofrequency Interatrial Shunt System include Adjustable Interatrial Shunt System and Radiofrequency Ablation Generator.
48377434|NCT03198819|DRUG|Local Rifampisin and İnrtravenous cefotaxime|
48377435|NCT04385719|DRUG|Remdesivir|Remdesivir (GS-5734) is a nucleoside analogue with in vitro activity against filoviruses EBOV, SUDV, BDBV and MARV, in addition to arenaviruses and coronaviruses
48710489|NCT05978076|OTHER|data collection|data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
48710490|NCT01449773|DIETARY_SUPPLEMENT|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
48710491|NCT01449773|DIETARY_SUPPLEMENT|Placebo|5 capsules/day containing corn and soybean oil
48019681|NCT04363606|OTHER|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
48710492|NCT02989051|OTHER|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
48710493|NCT02989051|OTHER|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of \>85% of normal fluid recommendations (for a healthy child).
48176884|NCT00037115|DRUG|methylprednisolone|
48176885|NCT05056727|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.~During Initiation Phase:~* S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.~* S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.~During Run-in and Maintenance Phases:~- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water."
48176886|NCT05056727|DRUG|Placebo|"Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water."
48176887|NCT05056727|DRUG|Lisinopril|Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
48176888|NCT05056727|DRUG|Valsartan|Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
48710494|NCT03190265|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
48176889|NCT05056727|DRUG|Irbesartan|"Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved."
48710495|NCT03190265|DRUG|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
48176890|NCT00470028|DEVICE|Transcranial Magnetic Stimulation|
48710496|NCT03190265|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
48710497|NCT03190265|DRUG|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
48710498|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
48710499|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
48710500|NCT00359333|DRUG|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
48710501|NCT03310008|BIOLOGICAL|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
48176891|NCT02725528|DRUG|collagenase injection|injection
48176892|NCT02725528|PROCEDURE|limited palmar fasciectomy|surgery
48176893|NCT00903071|BEHAVIORAL|Real PPL|See above arm description
48710502|NCT05048394|DEVICE|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
48710503|NCT05048394|DEVICE|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
48710504|NCT00990327|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
48710505|NCT00990327|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
48710506|NCT02728960|PROCEDURE|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
48710507|NCT06087263|DRUG|Regorafenib|Given by PO
48019682|NCT04363606|OTHER|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
48176894|NCT00903071|BEHAVIORAL|Sim PPL|See above arm description
48710508|NCT03704662|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48019683|NCT06131931|OTHER|CLP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Connecting Latinxs en Pareja (CLP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
48176895|NCT02884492|DRUG|18F-THK-5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
48377436|NCT01613066|PROCEDURE|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
48377437|NCT00040209|DRUG|JP 1730|
48377438|NCT00040209|DRUG|IV Levodopa|
48377439|NCT00040209|DRUG|IV Apomorphine|
48710509|NCT03704662|RADIATION|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
48710510|NCT04189653|OTHER|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
48710511|NCT04449939|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
48710512|NCT02705014|DRUG|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
48710513|NCT05530044|BEHAVIORAL|Social diffusion intervention|training in communication skills
48176896|NCT02884492|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
48176897|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
48176898|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
48176899|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
48176900|NCT01582503|DRUG|placebo|Subcutaneous repeating dose
48176901|NCT04150471|OTHER|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
48176902|NCT04866706|DEVICE|Visiol|VISIOL is a 2.0% (m/v) SH viscoelastic solution used for ocular surgery.
48176903|NCT01752764|OTHER|Test product: Salad with a high dosage fat|
48176904|NCT01752764|OTHER|Control product: Salad with low dosage fat|
48377440|NCT06515639|OTHER|Diet therapy for Classic IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants. The classic intermittent fasting diet was planned with a macronutrient distribution of 45-60% carbohydrates, 10-15% protein, and 25-30% fat. Additionally, total energy intake was reduced by 500-750 kcal.
48377441|NCT06515639|OTHER|Diet therapy for low carb-High fat IF diet group|The 16:8 intermittent fasting model was applied for six weeks. Time restrictions were tailored to fit the participants' lifestyles, with feeding times set between 10:00-12:00 and 18:00-20:00 for all participants.The low carb-high fat intermittent fasting diet included 10-30% carbohydrates and 50-65% fat.Additionally, total energy intake was reduced by 500-750 kcal.
48377442|NCT00403962|DRUG|vestipitant/paroxetine|
48377443|NCT02736331|DIETARY_SUPPLEMENT|Treatment 1|Treatment 1 Beverage
48377444|NCT02736331|DIETARY_SUPPLEMENT|Treatment 2|Treatment 2 Beverage
48377445|NCT04343508|OTHER|Fortified rice|100 g of rice was fortified with 150 µg vitamin A (Vitamin A palmitate), 0.5 mg vitamin B1 (thiamin mononitrate), 7 mg vitamin B3 (niacin amide), 0.6 mg vitamin B6 (pyrodoxine hydrochloride), 1 µg vitamin B12 (cyanocobalamin), 130 µg folic acid, 4 mg iron (ferric pyrosphosphate), and 6 mg zinc (zinc oxide).
48377446|NCT02818582|DRUG|GS-5734|Daily GS-5734 delivered intravenously (IV) for 5 days
48377447|NCT02818582|OTHER|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
48710514|NCT00113646|DRUG|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
48710515|NCT00113646|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
48710516|NCT01945645|BEHAVIORAL|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
48710517|NCT00776464|DEVICE|Noveon laser|Two wavelenghts of light
48710518|NCT02046174|BIOLOGICAL|RENCA macrobeads|
48176905|NCT03752242|DRUG|BMX-010 0.3%|Safety and efficacy of BMX-010 in topical treatment of acne.
48176906|NCT04134715|DRUG|PF-06826647|100 mg tablet
48176907|NCT04134715|DRUG|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
48377448|NCT03856502|DRUG|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
48377449|NCT03856502|DRUG|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
48377450|NCT06372262|OTHER|ergometer test|2000meter rowing ergometer test
48377451|NCT00536991|DIETARY_SUPPLEMENT|Calcitriol|Given PO
48710519|NCT04574856|RADIATION|Dose-Intensified Radiotherapy|Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.
48176908|NCT02933307|DEVICE|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
48176909|NCT02933307|DEVICE|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
48176910|NCT02281500|BIOLOGICAL|Human Plasma-Derived Fibrinogen Concentrate|A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20 mg/ml of active substance fibrinogen when reconstituted.
48176911|NCT03819751|PROCEDURE|MRI-targeted prostate biopsy|All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
48176912|NCT05914415|OTHER|Supportive care and education before surgery|we will give supportive and informative education before surgery in order to increase patient' recovery rates
48176913|NCT00632021|BEHAVIORAL|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
48176914|NCT00372346|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
48176915|NCT00005946|BIOLOGICAL|filgrastim|
48710520|NCT04574856|DRUG|Temozolomide|Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)
48710521|NCT04574856|DRUG|Adjuvant temozolomide|Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
48710522|NCT01192503|DRUG|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
48710523|NCT01192503|DRUG|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
48710524|NCT01442506|OTHER|biopsies|taking biopsies
48710525|NCT01442506|OTHER|biopsy|biopsy
48176916|NCT00005946|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48176917|NCT00005946|DRUG|cyclophosphamide|
48176918|NCT00005946|DRUG|etoposide|
48176919|NCT00907946|PROCEDURE|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
48176920|NCT00946205|PROCEDURE|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
48176921|NCT00946205|PROCEDURE|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
48710526|NCT03165214|DEVICE|coil|microcoils
48710527|NCT03165214|DEVICE|hystoacryl glue|hystoacryl mixed with lipidol
48710528|NCT05743075|DRUG|Ensifentrine|A dual PDE3/PDE 4 inhibitor
48710529|NCT05743075|DRUG|Placebo|Placebo solution
48710530|NCT02976480|PROCEDURE|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
48710531|NCT02976480|PROCEDURE|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
48710532|NCT04674501|PROCEDURE|Cardiac evaluation and blood sampling|"Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets."
48377452|NCT00536991|DRUG|Ketoconazole|Given PO
48710533|NCT02208453|DEVICE|InSpace Implantation|InSpace device Implantation
48710534|NCT02075047|DRUG|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
48710535|NCT02075047|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
48377453|NCT00536991|OTHER|Laboratory Biomarker Analysis|Correlative studies
48377454|NCT00536991|OTHER|Pharmacological Study|Correlative studies
48377455|NCT00536991|DRUG|Therapeutic Hydrocortisone|Given PO
48710536|NCT00902993|DRUG|AZD1446|Solution, oral single and multiple dose
48710537|NCT00902993|DRUG|Placebo|Placebo
48176922|NCT03717077|PROCEDURE|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
48710538|NCT03887065|DRUG|JM-4|Novel small human peptide derived from erythropoietin
48710539|NCT02624063|DRUG|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
48710540|NCT02624063|DRUG|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
48176923|NCT04169451|DRUG|Letrozole|Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
48377456|NCT01574976|BEHAVIORAL|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
48377457|NCT02409225|DEVICE|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
48377458|NCT02409225|DEVICE|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
48710541|NCT00454753|DRUG|Dasatinib|
48710542|NCT06209593|DIETARY_SUPPLEMENT|Compleat plant protein tube feed|Patients on a tube feed will act as their own control and switch to new tube feed.
48710543|NCT02727556|BEHAVIORAL|visual images|
48710544|NCT02980744|BEHAVIORAL|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
48710545|NCT04569136|OTHER|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
48176924|NCT00302926|PROCEDURE|energy restriction and maintenance|
48176925|NCT04777825|OTHER|Heart rate variability biofeedback training (Symbiocenter)|12 sessions of thirty minutes. Patients will participate through several serious game associated with HRV biofeedback training
48019684|NCT06131931|OTHER|WP Intervention|4 weekly sessions lasting approximately 60 minutes that will be audio recorded for quality assurance. Each couple will be assigned one RA who will serve as their facilitator and guide them through the Wellness Promotion (WP) sessions. The RA will deliver the appropriate intervention in either Spanish or English at the couple's preference. Sessions will be delivered via zoom (or comparable secure platform), using established procedures from the team's prior studies. Each participant will complete Qualtrics assessments at baseline, 3-, 6- and 9-months post randomization and biological (hair biomarkers for PrEP and ART adherence) and behavioral and psychosocial data collected.
48019685|NCT03173222|PROCEDURE|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
48019686|NCT00666367|DRUG|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
48019687|NCT00666367|DRUG|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
48019688|NCT05283291|BEHAVIORAL|Directed Imagery Technique|"The sound recording will include a soothing light background music for approximately 30 minutes.~Imagination will be practiced, starting with the patient's focusing his/her attention on his/her breath, relaxation, and relaxation with the suggestions given in the recording with the accompaniment of relaxing music."
48019689|NCT05245968|DRUG|Pimitespib|Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in the Dose Escalation Part. In Expansion Part-B, pimitespib will be administered with the starting dose of 160 mg daily.
48019690|NCT05245968|DRUG|Imatinib|Imatinib will be administered orally, after a meal and large glass of water QD. The doses in Dose Escalation Part will be 400 mg or 300 mg (De-escalation). The doses used in Expansion Part-A will be MTD or RD based on information, including the safety and PK data in the Dose Escalation Part. In Expansion Part-B, imatinib will be administered post after pimitespib discontinuation with the starting dose of 400 mg daily.
48019691|NCT05245968|DRUG|Sunitinib|Sunitinib will be administered orally QD with a starting dose of 50 mg, on a schedule of 4 weeks on treatment followed by 2 weeks off, and will be taken with or without a meal in Expansion Part-C.
48019692|NCT03120091|DEVICE|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
48019693|NCT06383364|BEHAVIORAL|Medication Coordinator|The Medication Coordinator calls the patient app seven days after discharge in the transition of care from hospital to home
48176926|NCT04777825|OTHER|psychoeducation session|Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).
48710546|NCT04569136|OTHER|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
48176927|NCT02345915|OTHER|Blood sample|
48176928|NCT02345915|OTHER|Electrocardiogram|
48710547|NCT04569136|OTHER|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
48710548|NCT04569136|OTHER|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
48710549|NCT04569136|OTHER|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
48176929|NCT01939951|DIETARY_SUPPLEMENT|Activation Energy Serum|7 drops or 21 drops twice daily
48176930|NCT03467698|DEVICE|Active tDCS|Real stimulation
48176931|NCT03467698|DEVICE|Sham tDCS|Sham stimulation
48176932|NCT01114672|DRUG|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
48710550|NCT01467115|RADIATION|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
48377459|NCT06149273|BEHAVIORAL|Sleep School|Sleep school is a structured method for the treatment of insomnia, which is based on cognitive behavioral therapy for insomnia (CBT-I). The central element of the method is a workbook for the patients. The essential parts of the method are strengthening the patient's self-efficacy, introducing the therapeutic exercises, and supporting the continued use of the exercises. The main themes of the Sleep school are information about sleep and the factors affecting it, behavioural components of CBT-I, like restricting the time spent in bed, cognitive components of CBT-I, like constructive worrying -exercise, and the exercises that aim to calm down mind and the autonomic nervous system. The Sleep School is held by an educated nurse.
48377460|NCT06149273|BEHAVIORAL|Treatment as usual|Oral and written information about improving sleep habits given by an educated nurse.
48710551|NCT01467115|DRUG|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
48710552|NCT01467115|BIOLOGICAL|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
48710553|NCT01467115|DRUG|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
48710554|NCT01467115|DRUG|Erythropoetin|Subcutaneous or intravenous
48710555|NCT01467115|DRUG|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
48710556|NCT01467115|DRUG|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
48710557|NCT01467115|DRUG|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
48710558|NCT05518773|OTHER|Observational|Observational
48710559|NCT00592540|PROCEDURE|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
48710560|NCT00309699|DRUG|Placebo|Daily for 3 weeks
48176933|NCT01114672|DRUG|Placebo|oral placebo once weekly
48176934|NCT00444262|PROCEDURE|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
48176935|NCT00444262|DRUG|VOLUVEN and others solute|VOLUVEN and others solute
48176936|NCT04820647|BEHAVIORAL|KF-STRIDE|KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
48176937|NCT01177995|BEHAVIORAL|Social Network Intervention|Social network leaders will communicate HIV prevention messages to members of their social networks.
48377461|NCT05849649|BEHAVIORAL|BumptUp|The app contains a number of evidence-based, expertly designed features to help women with healthier lifestyle habits during and after pregnancy.
48377462|NCT05849649|BEHAVIORAL|Educational Brochure|An evidence-based brochure on physical activity
48710561|NCT00309699|DRUG|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
48710562|NCT00309699|DRUG|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
48710563|NCT06281665|DRUG|Low-dose aspirin|The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
48710564|NCT06281665|DRUG|Placebo|The control group will receive similar appearing placebo daily for 6 months.
48176938|NCT03122847|DRUG|Methylprednisolone|Intravenous methylprednisolone
48710565|NCT03085511|BEHAVIORAL|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
48176939|NCT02163707|DRUG|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
48176940|NCT04053569|DIETARY_SUPPLEMENT|Table Grape supplement|5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
48176941|NCT03052712|BEHAVIORAL|social cognition|battery of tests of social cognition
48710566|NCT03085511|BEHAVIORAL|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
48710567|NCT03085511|BEHAVIORAL|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
48710568|NCT03085511|BEHAVIORAL|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
48176942|NCT00000349|DRUG|Flupenthixol|
48176943|NCT00220480|DRUG|escitalopram|10 to 30 mg / day
48176944|NCT03040830|DRUG|Progesterone 100 IM/day|Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
48176945|NCT05270369|BEHAVIORAL|digital CBTI|The app-based intervention will consists of 6 weekly sessions and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
48176946|NCT05270369|BEHAVIORAL|group CBTI|The group-based CBT-I intervention will consist of 6 weekly sessions (90-min, 5-8 adolescents in each group) and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
48176947|NCT04938622|OTHER|Sedentary Control|Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
48176948|NCT04938622|OTHER|Exercising control|Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
48517506|NCT02972892|DEVICE|Conventional Fresh Gas|"Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case."
48517507|NCT04877821|DRUG|Sintilimab|200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.
48517508|NCT04877821|DRUG|Anlotinib|12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
48710569|NCT01981200|OTHER|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
48176949|NCT04938622|OTHER|15 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
48176950|NCT04938622|OTHER|30 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
48176951|NCT04938622|OTHER|30 percent energy deficit (15/15)|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
48176952|NCT04938622|OTHER|60 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
48176953|NCT01907945|BEHAVIORAL|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
48176954|NCT01907945|BEHAVIORAL|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
48176955|NCT01377792|DRUG|Hypertonic saline|comparison of different dosages of drug
48377463|NCT03504956|DEVICE|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
48377464|NCT03504956|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
48377465|NCT03504956|DRUG|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
48377466|NCT01891227|DRUG|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
48019694|NCT04536844|DEVICE|Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)|An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
48019695|NCT04536844|OTHER|Conventional prescheduled follow-up|Patients will be followed in the outpatient clinic by prescheduled follow-up
48019696|NCT03284268|GENETIC|VCN-01|VCN-01 intravitreal injection
48019697|NCT05141682|DRUG|Oral Azacitidine|Given PO
48019698|NCT04010617|DEVICE|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
48517509|NCT04877821|DRUG|Nab paclitaxel|100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
48517510|NCT04877821|DRUG|Carboplatin|AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
48517511|NCT04877821|DRUG|Epirubicin|90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
48517512|NCT04877821|DRUG|Cyclophosphamide|600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
48517513|NCT03281018|BEHAVIORAL|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
48710570|NCT04401306|OTHER|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
48710571|NCT04401306|OTHER|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
48710572|NCT05842863|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a treatment program that helps teens reduce suicidal and self-harm behaviors by teaching them coping skills for managing negative emotions. DBT includes weekly individual therapy, weekly multifamily skills group, and 24/7 telephone-based skills coaching from the therapist.
48710573|NCT05842863|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBTI) is a type of counseling that helps people improve sleep by changing their sleep behaviors and thinking about sleep. In CBTI, people learn about sleep regulation, factors that influence quantity and quality of sleep, and specific techniques to optimize sleep. In this study, CBTI will be delivered using a self-guided online program called Firefly.
48710574|NCT03130660|DEVICE|Ultrasonography|Ultrasound guidance for central line
48710575|NCT01340937|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
48710576|NCT01340937|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
48710577|NCT01340937|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
48710578|NCT01340937|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
48710579|NCT01340937|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
48019699|NCT06055322|BEHAVIORAL|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
48019700|NCT03985319|DRUG|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
48710580|NCT00085982|DRUG|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
48710581|NCT05059223|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
48710582|NCT05059223|DRUG|Placebo|Placebo tablets, taken twice daily
48710583|NCT00481312|DRUG|Dexmedetomidine|Continuous Infusion
48710584|NCT00481312|DRUG|Midazolam|Continuous Infusion
48019701|NCT03985319|DRUG|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
48019702|NCT00948805|DRUG|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
48019703|NCT00948805|DRUG|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
48019704|NCT01903447|DRUG|SSRI|
48019705|NCT01903447|BEHAVIORAL|CBT|
48019706|NCT02833740|DEVICE|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
48517514|NCT00727012|DEVICE|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
48517515|NCT00860392|DRUG|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
48710585|NCT02523625|DEVICE|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
48710586|NCT01149486|DRUG|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
48710587|NCT01149486|DRUG|Hyzaar®|100/25 mg Tablets
48710588|NCT06339502|BEHAVIORAL|Jigsaw Technique|The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
48710589|NCT05285124|DRUG|Melatonin|Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
48710590|NCT05285124|OTHER|Placebo|Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS
48710591|NCT05285124|OTHER|HD-tDCS|Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes
48377467|NCT01891227|DRUG|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
48377468|NCT04494334|PROCEDURE|Bronchoscopy for Probable Idiopathic Pulmonary Fibrosis and Sarcoidosis|Blood samples and Nasosorption sampling
48377469|NCT03011385|BEHAVIORAL|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
48710592|NCT05940545|DRUG|Favipiravir|Small molecule antiviral
48710593|NCT05940545|DRUG|Ribavirin|Small molecule antiviral
48377470|NCT03011385|BEHAVIORAL|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
48710594|NCT02850263|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
48710595|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
48019707|NCT02659865|DRUG|Placebo|Administered orally
48019708|NCT02659865|DRUG|LY3039478 original formulation|Administered orally
48019709|NCT02659865|DRUG|LY3039478 new formulation|Administered orally
48377471|NCT03011385|BEHAVIORAL|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
48377472|NCT03011385|BEHAVIORAL|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
48517516|NCT03622424|DEVICE|Gelesis200|Gelesis200: Three (3)Gelesis200 capsules (2.10 g) three (3) times per day (i.e., breakfast, lunch, and dinner)
48517517|NCT03622424|DEVICE|Placebo|Placebo: Three (3)placebo capsules three (3) times per day (i.e., breakfast, lunch, and dinner)
48517518|NCT03622424|DEVICE|Gelesis200 and Placebo|Placebo and Gelesis200: Three (3) placebo capsules at breakfast,and three (3) Gelesis200 capsules (2.10 g)two (2) times per day (i.e., lunch and dinner)
48517519|NCT01748201|PROCEDURE|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
48517520|NCT02373449|OTHER|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
48517521|NCT02373449|DRUG|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
48710596|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
48019710|NCT04596852|DEVICE|Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch|"Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability."
48019711|NCT03541733|OTHER|mid-gut tubing|mid-gut tubing at different time
48019712|NCT01313572|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
48019713|NCT01313572|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
48019714|NCT01088516|DRUG|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
48377473|NCT04177901|DEVICE|Near infrared spectroscopy|It is used for detection of tissue oxygenation
48710597|NCT05425654|DRUG|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
48710598|NCT03876691|OTHER|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
48710599|NCT03876691|OTHER|Physician|The current emergency medical department departments within the preparation of the attending physician
48710600|NCT02905617|DEVICE|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
48517522|NCT03846583|DRUG|Tucatinib|Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
48710601|NCT01082510|DRUG|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
48517523|NCT03846583|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
48517524|NCT03846583|DRUG|Trastuzumab|"• Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system."
48517525|NCT03846583|DRUG|Aromatase Inhibitor|These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
48710602|NCT01082510|DRUG|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
48710603|NCT02937857|DRUG|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
48710604|NCT02937857|DRUG|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
48710605|NCT02508740|DRUG|bevenopran|Single oral dose
48019715|NCT04062305|BEHAVIORAL|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
48377474|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test|self-collected direct anterior nares swab samples
48517526|NCT01208805|BEHAVIORAL|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
48517527|NCT02687347|DRUG|oral methadone|Oral methadone is the study drug
48517528|NCT02687347|DRUG|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
48710606|NCT02312765|BEHAVIORAL|AirCare App|Tablet software to encourage adherence and support
48710607|NCT05985213|OTHER|data collection and follow-up|"Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection"
48019716|NCT04062305|PROCEDURE|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
48019717|NCT04062305|OTHER|Quality-of-Life Assessment|Ancillary studies
48019718|NCT04062305|OTHER|Questionnaire Administration|Ancillary studies
48019719|NCT00653224|DRUG|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
48019720|NCT00653224|DRUG|placebo|0 mg daily (matching oral tablet) for 14 days
48377475|NCT05732610|DIAGNOSTIC_TEST|MGC Health COVID-19 & Flu A+B Home Multi Test (2 to 13 y/o)|adult lay user collected anterior nares swab sample
48377476|NCT00323830|DRUG|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
48710608|NCT03454815|PROCEDURE|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
48019721|NCT05631639|DEVICE|PillSense System|The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.
48019722|NCT02220010|DEVICE|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
48019723|NCT05827302|DEVICE|Health Gauge AI-Based Wearable Device - Model: Phoenix|Wearable device
48377477|NCT04240782|BEHAVIORAL|Nutrition and hands on cooking classes for parents and their children|The adults and children will learn how to prepare the fresh produce during an age appropriate, evidence-based, family cooking school. The class will provide participants with a no-cost, low-risk incentive to try new vegetables, and will empower them to build healthier lives through nutrient-rich, locally sourced meals. Participants will also receive nutrition education and information on how they can integrate local produce into their food budget. One of the class sessions will focus solely on how to budget for healthy food, comparison shop, and make the most of their food dollars. Participants will learn how to use their SNAP benefits at local farmers markets.
48377478|NCT04240782|BEHAVIORAL|Produce allocations|Participants will also receive a produce allocation from a local farm during each session of the class.
48377479|NCT00003726|BIOLOGICAL|lepirudin|lepirudin
48377480|NCT03863925|DEVICE|Target controlled infusion, Schnider model|Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
48377481|NCT03863925|BEHAVIORAL|Bolus injection of Propofol|Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
48377482|NCT00859313|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
48377483|NCT04640168|DRUG|Baricitinib|Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
48377484|NCT04640168|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection, USP, is an adrenocortical steroid anti-inflammatory drug. It is a water-soluble inorganic ester of dexamethasone. Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant.
48710609|NCT04617418|BEHAVIORAL|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
48710610|NCT05929378|PROCEDURE|Lightweight mesh fixation|Lightweight mesh fixation in 3 points
48710611|NCT01893372|DRUG|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
48710612|NCT01893372|DRUG|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
48710613|NCT01574898|DRUG|V0474 - A mg|Single oral administration
48710614|NCT01574898|DRUG|V0474 - B mg|Single oral administration
48710615|NCT01574898|DRUG|V0474 - C mg|Single oral administration
48710616|NCT01574898|DRUG|V0018 - B mg|Single oral administration
48710617|NCT01574898|DRUG|Niquitin® Fresh Mint 4 mg|Single oral administration
48377485|NCT04640168|OTHER|Placebo|Placebo matching oral baricitinib or intravenous dexamethasone.
48517529|NCT02422797|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
48710618|NCT00681694|RADIATION|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
48710619|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
48377486|NCT04640168|DRUG|Remdesivir|Drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
48377487|NCT05493059|OTHER|Data collection|o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)
48710620|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
48710621|NCT05945134|OTHER|Visual and auditory feedback STS training|"30 minutes per session, 3 sessions per week, for a total of 3 weeks. The visual and auditory feedback signals will be given throughout the sit-to-stand movement. As the size of circle representing the weight bearing gets more even, and the mobile dot indicating the overall center of pressure moves forward and approaches the midline, the auditory cues will get louder to indicate proximity to the target. It allows the participants to adjust and relearn the correct weight shifting and symmetry.~The intensity will be adjusted based on different chair heights (e.g. 115%, 100%, 80% of lower leg length), various seat materials, and supported level of thigh (progressing from one-third of the length between the greater trochanter of the femur and the knee joint line to full support). The training program will be progressed according to the abilities of the participants."
48710622|NCT05945134|OTHER|Conventional STS training|30 minutes per session, 3 sessions per week, for a total of 3 weeks. All settings will be the same as the experimental group, except for the feedback. In the control group, the verbal cues will be given by the physical therapist and a mirror will be placed in front of the participant for visual feedback. During the sit-to-stand movement, participants will be asked to try to maintain the alignment in the midline.
48517530|NCT02422797|DRUG|RPV 25 mg|"Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV."
48019724|NCT03377335|DRUG|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
48019725|NCT03377335|DRUG|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: \>87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
48377488|NCT05493059|OTHER|Questionnaires|"o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)"
48377489|NCT04812886|OTHER|Epidemiological study|Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis
48377490|NCT00101140|DRUG|anti-thymocyte globulin|
48377491|NCT00101140|DRUG|fludarabine phosphate|
48377492|NCT00101140|DRUG|thiotepa|
48377493|NCT00101140|PROCEDURE|biological therapy|
48377494|NCT00101140|PROCEDURE|bone marrow ablation with stem cell support|
48710623|NCT05550623|DEVICE|Tourniquet|Tourniquet use in transfemoral amputation.
48710624|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
48710625|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
48710626|NCT00098722|DRUG|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
48377495|NCT00101140|PROCEDURE|chemotherapy|
48019726|NCT02630771|PROCEDURE|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
48019727|NCT03384667|DRUG|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
48019728|NCT03384667|DRUG|Placebo|The granules do not contain any active ingredients.
48710627|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
48710628|NCT00098722|DRUG|optimized background therapy|\[OBT (3-6 drugs based on treatment history and resistance testing)\]
48710629|NCT06605235|PROCEDURE|Local Anesthesia|In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
48710630|NCT05433038|DEVICE|skeletally anchored maxillary expander|used from day one and activated two times per day for two weeks
48710631|NCT05981079|DRUG|Piperacillin/tazobactam|Piperacillin Sodium and Tazobactam Sodium for Injection
48019729|NCT02569697|OTHER|HEC Placebo gel|
48019730|NCT02569697|OTHER|Placebo Intravaginal Ring|
48019731|NCT02569697|OTHER|Placebo Vaginal Film|
48019732|NCT02569697|OTHER|Placebo Vaginal Insert|
48019733|NCT01896895|DRUG|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
48377496|NCT00101140|PROCEDURE|non-specific immune-modulator therapy|
48377497|NCT00101140|PROCEDURE|peripheral blood stem cell transplantation|
48377498|NCT00101140|PROCEDURE|radiation therapy|
48377499|NCT01400659|PROCEDURE|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
48377500|NCT01400659|PROCEDURE|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
48377501|NCT02027246|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
48377502|NCT03740854|OTHER|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
48019734|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
48019735|NCT01896895|DRUG|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
48019736|NCT01896895|DRUG|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
48019737|NCT01224496|DRUG|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
48019738|NCT03645200|DRUG|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
48019739|NCT02879097|BIOLOGICAL|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
48019740|NCT02879097|BIOLOGICAL|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
48019741|NCT02879097|DRUG|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
48377503|NCT03740854|OTHER|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
48019742|NCT02879097|DRUG|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
48019743|NCT05395377|BEHAVIORAL|Registered Dietitian/Nutritionist|Participants received a FitBit Flex and Intensive Lifestyle Intervention coaching via telephone with Registered Dietitian/Nutritionist.
48019744|NCT05395377|BEHAVIORAL|Diabetes Prevention Program|Modified DPP group classes lead by a Registered Dietitian and Exercise Physiologist.
48377504|NCT01927159|BIOLOGICAL|ID93 + GLA-SE|
48377505|NCT01927159|OTHER|Placebo|
48377506|NCT01680757|DEVICE|LARIAT Suture Delivery Device and Accessories|
48377507|NCT02325739|DRUG|FGF401|FGF401 is a FGFR4 inhibitor.
48377508|NCT02325739|BIOLOGICAL|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
48377509|NCT04082416|BIOLOGICAL|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
48377510|NCT04082416|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
48377511|NCT00456027|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
48377512|NCT04895046|DRUG|Niraparib|300 mg taken orally (all cycles)
48377513|NCT04895046|DRUG|Dostarlimab|500 mg (cycles 1-4) intravenously
48377514|NCT04895046|DRUG|Dostarlimab|1000 mg (cycle 5+) intravenously
48377515|NCT03330340|PROCEDURE|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
48377516|NCT01536522|DIETARY_SUPPLEMENT|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
48377517|NCT01536522|DIETARY_SUPPLEMENT|Low Caloric Shake|participants will be provided a low caloric dietary shake
48710632|NCT04495868|DRUG|Bacteriostatic Normal Saline|A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
48710633|NCT04495868|DRUG|1% Lidocaine|A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
48377518|NCT01536522|BIOLOGICAL|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
48517531|NCT02422797|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
48176956|NCT03641456|DRUG|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
48710634|NCT02092051|DEVICE|Continuous glucose monitoring with DexCom G4 platina|
48710635|NCT00203112|DRUG|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
48176957|NCT03641456|DRUG|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
48710636|NCT00203112|DRUG|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
48710637|NCT00750529|DRUG|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
48176958|NCT03641456|DRUG|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
48377519|NCT03152058|DRUG|Certolizumab Pegol|"Certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter\] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
48377520|NCT00987506|DEVICE|XIENCE V®|Participants with placement of a XIENCE V® EESS
48377521|NCT03659032|PROCEDURE|Pediatric Manual Therapy|
48710638|NCT01468610|DRUG|desvenlafaxine|50-100 mg daily for 8 weeks
48710639|NCT01688921|BIOLOGICAL|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
48710640|NCT01688921|DEVICE|Needle-Syringe|
48710641|NCT01688921|DEVICE|Stratis needle-free injection device|
48710642|NCT00383734|DEVICE|Newfill|1 to 7 injections of drug
48710643|NCT00383734|DEVICE|Eutrophill|1 to 7 injections of drug
48710644|NCT01328041|DRUG|dolutegravir|50 mg twice daily
48710645|NCT06605196|BEHAVIORAL|Resources and guided facilitation|Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.
48710646|NCT06605196|BEHAVIORAL|Existing resources|Individuals will be referred to existing resources in the Learning Community.
48710647|NCT04126564|BEHAVIORAL|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
48377522|NCT03659032|PROCEDURE|Educational Physical Therapy|
48377523|NCT02064231|DEVICE|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
48176959|NCT02690337|DRUG|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
48377524|NCT02064231|DEVICE|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
48377525|NCT02064231|DEVICE|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
48176960|NCT04639986|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
48176961|NCT04639986|DRUG|Eribulin Mesylate Injection|Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
48176962|NCT04639986|DRUG|Capecitabine Oral Product|Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.
48176963|NCT04639986|DRUG|Gemcitabine Injection|Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
48176964|NCT04639986|DRUG|Vinorelbine injection|Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
48176965|NCT00498095|PROCEDURE|Renal biopsy|
48176966|NCT00621192|DRUG|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
48377526|NCT02064231|DEVICE|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
48377527|NCT02064231|DEVICE|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
48517532|NCT04913142|OTHER|Fecal and oral samples|oral and rectal swab from patients hospitalized at day 1, each 7 days and at the end of their ICU stay
48517533|NCT02368483|OTHER|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
48176967|NCT03897231|OTHER|questionnaire|Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH, AH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (TM) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
48176968|NCT01727206|DRUG|Tocilizumab|
48176969|NCT06547567|BEHAVIORAL|Motivational Interviewing|In addition to receiving the same health education intervention as the control group, the children and adolescents in the intervention group will undergo a group-based motivational interviewing intervention. This will be conducted by a professional team that has been trained and is qualified in motivational interviewing. The intervention will embody the spirit of motivational interviewing and the stages of group motivation development, primarily including: introductory tasks, exploratory tasks, expansion tasks, and action planning tasks.
48710648|NCT04126564|BEHAVIORAL|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
48710649|NCT06031142|DEVICE|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
48710650|NCT04695002|BEHAVIORAL|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
48377528|NCT05468866|GENETIC|Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR|detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
48377529|NCT04020822|DEVICE|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
48377530|NCT02319642|DRUG|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
48517534|NCT00871208|DRUG|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
48517535|NCT00871208|DRUG|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
48710651|NCT04695002|BEHAVIORAL|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
48710652|NCT05796115|PROCEDURE|Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
48710653|NCT05796115|PROCEDURE|Antibiotic prophylaxis for EOS|Infants will receive antibiotic prophylaxis for EOS.
48710654|NCT03719404|PROCEDURE|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
48710655|NCT03719404|PROCEDURE|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
48710656|NCT00413829|DRUG|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
48710657|NCT03353922|DRUG|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
48710658|NCT03353922|DRUG|Placebo Oral Tablet|sugar pill
48377531|NCT04060901|BEHAVIORAL|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
48377532|NCT01700894|BEHAVIORAL|Walking Program + Motivational Interviewing Calls|
48377533|NCT01700894|BEHAVIORAL|Walking Program + Automated Calls|
48377534|NCT01700894|BEHAVIORAL|Walking Program|
48377535|NCT05353920|OTHER|Cognitive training|cognitive related training bu virtual reality system
48710659|NCT01963013|DEVICE|Non-returning catheter valve|
48710660|NCT01963013|DEVICE|Conventional urine bag|
48710661|NCT06391281|OTHER|Education|The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
48710662|NCT00921414|DRUG|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
48710663|NCT00921414|OTHER|Watch and wait|No treatment patient follow-up every 2 months during 3 years
48710664|NCT05768204|DRUG|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
48710665|NCT05768204|OTHER|placebo|A placebo consistent in appearance with the prednisolone acetate.
48710666|NCT06321198|BIOLOGICAL|iMSC|Subjects will receive 4 or more times of iMSC injection
48019745|NCT05395377|BEHAVIORAL|Weight Watchers, Reimagined|Participants in this group were provided with an online access code to enroll in WW and could choose the format of their choice- group, online, and/or smartphone app.
48019746|NCT05395377|BEHAVIORAL|DPP or RDN Counseling + Medication|Participants met with a weight management specialist to receive weight loss medications, as well as, receiving either the DPP or Registered Dietitian coaching. Medications utilized in this study were Phentermine and Metformin. Metformin was prescribed if the participant could not tolerate Phentermine.
48019747|NCT05395377|OTHER|Bariatric Surgery Evaluation|Participants (BMI \> 40) were offered a consultation with the bariatric surgical program that requires lifestyle weight management during the first 6 months. Participants were also able to choose to receive one of the other 4 intervention options in the first six months prior to consideration for bariatric surgery.
48019748|NCT06569576|BEHAVIORAL|Wellness program|It combines seated yoga exercises, mindfulness, and social participation activities and discussions, and can be delivered in-person or via tele-health.
48019749|NCT06612086|DRUG|Dapagliflozin (Forxiga)|we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
48019750|NCT04840095|DRUG|Ketones|Sports supplement that is administered mid-scan.
48019751|NCT04840095|DRUG|Glucose|Supplement is administered mid-scan.
48019752|NCT06446492|OTHER|ViDEO explaining study|The research team will introduce themselves and ask the parents to watch an informational video explaining the ViDES study on an iPad while they stay in the room with the parents. After viewing the video, the team will answer any questions and provide written consent and enough time to decide whether to participate in the study. The research team will also provide a QR code that grants parents/guardians access to the video on their own device at any time. This allows them to pause, rewind, and revisit the information.
48019753|NCT06446492|OTHER|Usual Care|The research team will present a detailed explanation of the ViDES study, answer questions, provide written consent, and provide enough time to decide on participation or not in the study.
48019754|NCT05249725|DRUG|Irsogladine Maleate|Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
48377536|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
48377537|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
48377538|NCT00996073|BIOLOGICAL|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
48377539|NCT04698707|OTHER|Vascularized lymph node flap transfer|Patients who have received VLNT as their primary treatment but with minimal improvement
48176970|NCT04695886|OTHER|Community-delivered Integrated Malaria Elimination (CIME) intervention model|"Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management.~Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities.~Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral.~RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral."
48377540|NCT04698707|OTHER|Patients without prior lymphedema surgery|Patients without prior lymphedema surgery
48377541|NCT02130648|OTHER|A sampling of blood|A sampling of blood de 14 ml
48377542|NCT03821805|OTHER|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
48377543|NCT01683786|DRUG|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
48377544|NCT04962191|DIAGNOSTIC_TEST|Idylla EGFR Mutation Test|This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
48710667|NCT01206283|PROCEDURE|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
48019755|NCT05249725|DRUG|Hydrotalcite|Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
48377545|NCT00372658|DRUG|1% Lidocaine intracervical injection|
48176971|NCT03102866|OTHER|Best Practice|Receive usual care
48176972|NCT03102866|BEHAVIORAL|Exercise Intervention|Undergo aerobic and strength training exercise
48176973|NCT03102866|OTHER|Quality-of-Life Assessment|Ancillary studies
48377546|NCT02531958|OTHER|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
48377547|NCT04145739|OTHER|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
48377548|NCT03717220|PROCEDURE|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
48377549|NCT04088617|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
48377550|NCT04088617|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
48377551|NCT05938413|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
48377552|NCT05938413|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
48377553|NCT06261827|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
48377554|NCT06261827|DRUG|200-ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
48377555|NCT00627094|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
48377556|NCT00627094|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
48019756|NCT01566136|BEHAVIORAL|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
48176974|NCT03102866|OTHER|Questionnaire Administration|Ancillary studies
48176975|NCT03835962|DEVICE|NeuroCatch™ Platform|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
48019757|NCT03856216|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given IV
48019758|NCT03856216|DRUG|Bendamustine|Given IV
48019759|NCT03856216|BIOLOGICAL|Filgrastim-sndz|Given IV
48377557|NCT02184988|BIOLOGICAL|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
48377558|NCT06334627|BEHAVIORAL|Pre-Primary Intervention|School readiness intervention
48377559|NCT01165892|DRUG|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
48377560|NCT05228990|DEVICE|warm acupunctrue|"The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes."
48377561|NCT03094923|OTHER|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
48377562|NCT06286995|PROCEDURE|Chemomechanical preparation for root canals|After working length determination ,root canal preparation was made by two different NiTi File systems to both group ( the first group using Trunatomy file and the second one using edgeendo x7 file) and assessment of pain was made preoperatively and postoperatively and also apical fluid samples
48710668|NCT01206283|PROCEDURE|Cerebral perfusion pressure-targeted therapy|"* ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);"
48019760|NCT03856216|DRUG|Fludarabine|Given IV
48377563|NCT01153659|DRUG|E3810|RAB ER 50 mg capsule once per day on Days 1-5
48019761|NCT03856216|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
48019762|NCT03856216|DRUG|Melphalan|Given IV
48019763|NCT03856216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
48176976|NCT00578162|BEHAVIORAL|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
48176977|NCT04470843|DRUG|Acetazolamide|Being that adequate pain control is essential to recovery in the post-operative setting, efforts have been made to address this pain at its root. Prior studies have demonstrated that preoperative administration of acetazolamide decreased post-operative referred pain in the immediate post-surgical period.
48176978|NCT04470843|OTHER|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
48019764|NCT03856216|BIOLOGICAL|Rituximab|Given IV
48176979|NCT05431998|PROCEDURE|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement
48176980|NCT05431998|PROCEDURE|the use of autogenous bone graft in the jumping gap during immediate implant placement|the use of autogenous bone graft in the jumping gap during immediate implant placement
48176981|NCT04721964|DIETARY_SUPPLEMENT|Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)|Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
48377564|NCT01153659|DRUG|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
48377565|NCT01153659|DRUG|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
48377566|NCT05099744|BEHAVIORAL|Electrostimulation Therapy|During 20 minutes participants are connected to the handles and receive electrostimulation therapy.
48377567|NCT05099744|BEHAVIORAL|Relaxation|During 20 minutes participants receive a session of relaxation with guided imagination. These sessions will be implemented by a trained therapist who will follow a script. The relaxation sessions are based on Schultz's autogenic relaxation training, a relaxation technique based on autosuggestion.
48377568|NCT05099744|BEHAVIORAL|Placebo|During 20 minutes participants will be connected to the handles but will not receive any frequency.
48710669|NCT03401567|OTHER|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
48019765|NCT03856216|DRUG|Tacrolimus|Given IV and PO
48019766|NCT06663163|OTHER|Observation|This study was an observational study without intervention
48019767|NCT02708745|BEHAVIORAL|Intervention Survey|
48019768|NCT02708745|BEHAVIORAL|Placebo Survey|
48019769|NCT04901117|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
48019770|NCT04901117|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
48710670|NCT00900146|DRUG|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
48710671|NCT00900146|DRUG|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
48710672|NCT00900146|DRUG|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
48710673|NCT05472545|BEHAVIORAL|Neurofeedback|Real-time functional magnetic resonance imaging dyadic neurofeedback
48710674|NCT06344910|OTHER|Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies|"An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert."
48176982|NCT05100251|DRUG|WBC100|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage enroll 12 pancreatic patients with positive c-myc expression."
48176983|NCT04718233|DRUG|Sildenafil 25Mg Tablet|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
48176984|NCT04718233|DRUG|Placebo Oral Tablet|placebo will be administered orally in patients with recurrent pregnancy loss
48176985|NCT03385577|BEHAVIORAL|Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer|'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
48176986|NCT02790775|DRUG|Anti-VEGF in quadrant 1|
48176987|NCT02790775|DRUG|Anti-VEGF in quadrant 2|
48176988|NCT02790775|DRUG|Anti-VEGF in quadrant 3|
48176989|NCT02790775|DRUG|Anti-VEGF in quadrant 4|
48176990|NCT05585671|DRUG|Belimumab|Lupus patients without previous involvement of kidney are enrolled, and receive 2-year of 10mg/kg belimumab intravenously on the background of standard of care (SOC). During follow-up, we observe whether these patients will develop new-onset lupus nephritis.
48517536|NCT04841005|OTHER|The Square-Step Exercise Training|The Square-Step Exercise is instructed to walk according to the step pattern shown on a 100 \* 250 cm mat, divided into 40 squares of 25 cm each. It includes forward, backward, lateral and diagonal steps, and step patterns are progressively made more complex. Each pattern consists of two to 16 steps; Individuals are asked to repeat the step pattern until they reach the end of the mat. Each step pattern is repeated 4-10 times to ensure that individuals can complete the pattern. The individuals included in the study will exercise in easy-difficulty patterns for the first 2 weeks, medium-difficulty patterns in the 3rd and 4th weeks, medium and advanced patterns in the 5th and 6th weeks, and advanced patterns in the 7th and 8th weeks. The square-step exercise group will perform 15 minutes of warm-up exercise, 30 minutes of progressive square-step exercise, and 10 minutes of cool-down exercise accompanied by a physiotherapist, 3 days a week.
48710675|NCT05448313|BEHAVIORAL|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
48710676|NCT05448313|BEHAVIORAL|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
48710677|NCT02261129|DRUG|Telmisartan film-coated tablet|
48710678|NCT02261129|DRUG|Telmisartan uncoated tablet|
48710679|NCT02109523|BEHAVIORAL|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
48176991|NCT01507077|DRUG|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
48176992|NCT01507077|DRUG|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
48176993|NCT01181609|DRUG|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
48176994|NCT03043430|DRUG|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
48377569|NCT04524351|DRUG|Posiphen|Solid oral dosage form, capsule
48377570|NCT04524351|DRUG|Placebo|Solid oral dosage form, capsule
48377571|NCT04851704|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
48377572|NCT04583072|DIAGNOSTIC_TEST|The Stockholm3 test|Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
48377573|NCT04235725|OTHER|Harmonized Depression Outcome Measures|This is an observational study where retrospective data on previous disease status and patient characteristics will be collected and combined with longitudinal data from these data sources on outcomes during the study timeframe.
48377574|NCT04952610|DRUG|Etripamil NS 70 mg|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
48377575|NCT04952610|DEVICE|Aptar Pharma Nasal Spray Bidose System|Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
48377576|NCT03564977|BIOLOGICAL|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
48176995|NCT03043430|DRUG|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
48377577|NCT03010475|DRUG|Furosemide|Oral administration A total of three single doses.
48377578|NCT03010475|DRUG|Rosuvastatin|Oral administration. A total of three single doses.
48710680|NCT02109523|BEHAVIORAL|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
48710681|NCT02109523|BEHAVIORAL|Routine discharge counseling|
48710682|NCT04734821|PROCEDURE|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
48710683|NCT03913832|DEVICE|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions."
48710684|NCT03913832|DEVICE|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
48710685|NCT01919047|DRUG|Betanis|Oral
48019771|NCT04901117|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
48710686|NCT02885857|DRUG|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
48019772|NCT04901117|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
48176996|NCT01076998|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
48176997|NCT01076998|OTHER|Refresh PM Ointment|1 drop in each eye, one time
48176998|NCT04014790|DRUG|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
48019773|NCT04901117|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
48019774|NCT04901117|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
48019775|NCT04901117|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
48019776|NCT00131781|BEHAVIORAL|Cognitive Therapy|
48176999|NCT04014790|DRUG|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
48177000|NCT01285596|DRUG|Mirabegron|oral
48177001|NCT02674269|DRUG|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
48377579|NCT03010475|DRUG|SNAC|Oral administration. A total of five single doses.
48377580|NCT03010475|DRUG|Semaglutide|Oral administration. Once daily.
48377581|NCT06038370|BEHAVIORAL|Self-induced cognitive trance|The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
48377582|NCT00623441|DEVICE|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
48377583|NCT00707252|DRUG|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
48377584|NCT00707252|DRUG|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
48377585|NCT06428734|DIAGNOSTIC_TEST|hydrocephalus group|Diagnostic Test: high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
48377586|NCT06428734|OTHER|normal group|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS
48377587|NCT04441437|BEHAVIORAL|Task-oriented training with a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the splint group received 1-hour task-oriented training with wearing a customized dynamic hand splint, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
48177002|NCT02674269|DRUG|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
48177003|NCT02674269|DEVICE|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
48177004|NCT05921097|DIAGNOSTIC_TEST|Histamin-induced axon-reflex flare response|Histamin-induced axon-reflex flare response
48177005|NCT05921097|DIAGNOSTIC_TEST|Local heating-induced axon-reflex flare response|Local heating-induced axon-reflex flare response
48177006|NCT05921097|DIAGNOSTIC_TEST|2-point discrimination tasks|2-point discrimination tasks
48177007|NCT05921097|DIAGNOSTIC_TEST|NC-Stat DPNCheck|NC-Stat DPNCheck
48177008|NCT05921097|DIAGNOSTIC_TEST|QST|QST
48177009|NCT05921097|DIAGNOSTIC_TEST|Biothesiometry|Biothesiometry
48177010|NCT03989921|OTHER|no intervention. observational study|no intervention. observational study
48177011|NCT06489275|BEHAVIORAL|Building Financial Wellness|In addition to receiving services as usual, subjects attend financial literacy classes and booster sessions.
48177012|NCT06489275|OTHER|Services as Usual|Subjects continue to receive services as usual.
48177013|NCT05996978|OTHER|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
48177014|NCT03557606|PROCEDURE|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
48177015|NCT01337375|DRUG|peginterferon alfa 2a [Pegasys]|sc weekly
48177016|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv weekly
48177017|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|sc twice weekly
48177018|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv twice weekly
48377588|NCT04441437|BEHAVIORAL|Task-oriented training without a dynamic hand splint|In addition to conventional rehabilitation programs (therapy-as-usual), the subject in the no-splint group received 1-hour task-oriented training, totally 15 times in a duration of one month. The content of task-oriented training contained picking cubes from side to side with three-jaw grasp, lifting the cone to the shoulder height with the cylindrical grip and an extended elbow, picking up pegs and inserting it into the hole with palmar pinch, and grasping a soap to simulate wiping the body. Among the four tasks, two were chosen to train the subjects according to the abilities of subjects.
48377589|NCT00037908|PROCEDURE|Strength training|
48377590|NCT06452862|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both Diabetics and Healthy Volunteers will undergo MRI protocols including Blood Oxygen Level Dependence (BOLD), Intravoxel Incoherent Motion (IVIM), Arterial Spin Labeling (ASL), T1\&T2-mapping imaging and Magnetic Resonance Elastography (MRE). For Diabetics, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, Diabetics will undergo a renal biopsy to assess the extent of kidney damage.
48377591|NCT01207219|BEHAVIORAL|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
48377592|NCT01207219|BEHAVIORAL|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
48377593|NCT04290871|DRUG|Nitric Oxide Gas|Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
48377594|NCT04290871|OTHER|The delivery system will be set up anyway without study gas administration|The delivery system will be set up anyway without study gas administration
48177019|NCT01710800|DRUG|Esomeprazole|
48177020|NCT01710800|DRUG|placebo|
48177021|NCT02803099|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number-SR15-63-Z13-084).
48177022|NCT05347862|OTHER|Control group|At baseline, this group will receive only the usual standard advice to practice physical activity as an important measure to promote health benefits. During the intervention period, they will receive only telephone calls monthly to assess the physical activity practice, changes in medication, and adverse events. When appropriate, evaluations of 12 and 24 weeks will be scheduled.
48177023|NCT05347862|OTHER|Physical activity promotion|"The intervention will be based on a remote approach, for 24 weeks. The intervention will consist of telephone calls and sent messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants, plus short text messages promoting health behaviors related to self-care, nutrition, physical activity, and sedentary behavior.~Initially, this group will be followed weekly during the first 4 weeks. After this period this group can up to two weekly calls, according to their preference. The text messages will be weekly. During the telephone calls, the research team will verify the volume of PA achieved and help the participants to identify and overcome barriers to PA practice, and motivate and register any adverse events related or not to the study."
48177024|NCT00525278|DRUG|Levocetirizine dihydrochloride|
48177025|NCT03371745|PROCEDURE|Trophectoderm biopsy|Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
48177026|NCT03371745|PROCEDURE|Cryopreservation|Rapid freezing using vitrification
48177027|NCT03371745|PROCEDURE|Embryo Transfer|Transfer of embryo that has been cultured in vitro into the uterus
48177028|NCT00705562|OTHER|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
48377595|NCT02116309|DRUG|Rectal Indomethacin|
48377596|NCT02116309|DRUG|Epinephrine|
48710687|NCT01909882|OTHER|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
48710688|NCT05067920|DIAGNOSTIC_TEST|Levels of SARS-COV-2 antibodies|Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
48710689|NCT05067920|DIAGNOSTIC_TEST|rRT-PCR SARS-Cov-2|Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
48710690|NCT05067920|DIAGNOSTIC_TEST|Hematological and immunological biomarkers|Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
48710691|NCT05067920|DIAGNOSTIC_TEST|Mitochondrial DNA|One time quantification mitochondrial DNA haplogroup.
48710692|NCT05067920|DIAGNOSTIC_TEST|SARS-CoV-2 Viral Culturing|Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
48710693|NCT05067920|DIAGNOSTIC_TEST|Sequencing COVID-19|Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
48710694|NCT02615405|DIETARY_SUPPLEMENT|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.
48710695|NCT02615405|DIETARY_SUPPLEMENT|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.
48710696|NCT02615405|DIETARY_SUPPLEMENT|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
48377597|NCT01914107|PROCEDURE|real-time monitoring and instruction of cancer pain|as description in arm
48377598|NCT01914107|PROCEDURE|standard cancer pain care|as description in arm
48377599|NCT04575233|PROCEDURE|laparoscopic-assisted Transversus Abdominis Plane (TAP) block|"The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side."
48710697|NCT00410319|BEHAVIORAL|Fear-reducing Information|
48710698|NCT00410319|BEHAVIORAL|Symptom-based exercise|
48710699|NCT02845947|BEHAVIORAL|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
48377600|NCT04575233|PROCEDURE|ultrasound-assisted Transversus Abdominis Plane (TAP) block|Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
48377601|NCT04575233|DRUG|Ropivacaine|a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
48377602|NCT05957159|OTHER|Detoxification Program|Patients will begin inpatient or outpatient detoxification prior to completing imaging
48377603|NCT05957159|RADIATION|PKAB|90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
48710700|NCT03989973|DIAGNOSTIC_TEST|Gastroscopy|Gastroscopy
48710701|NCT05063188|OTHER|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
48710702|NCT05063188|OTHER|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
48710703|NCT06254872|BEHAVIORAL|Peer Mentors|Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
48710704|NCT00130143|DRUG|Ethyol (Amifostine)|
48710705|NCT06491290|OTHER|No intervention administered|NA (not applicable)
48377604|NCT05957159|RADIATION|CFN|90 Pet Imaging Scan using \[11C\]-Carfentanil
48019777|NCT00131781|BEHAVIORAL|Supportive Therapy|
48019778|NCT05053282|OTHER|endurance running exercise|regular competitive or non-competitive running of medium and/or high intensity with the duration at least 20 minutes per session
48019779|NCT05966831|BEHAVIORAL|Metacognitive Self-Control Training (MCT)|"Metacognitive Self-Control Training (MCT) was originally developed by the Michigan Skills Project for students in middle/high school. The MCT training intervention has been updated to be suitable for adults. MCT is a lecture style intervention that encompasses 13 modules (over the course of 4 weeks) on improving self-control that is to be delivered in a community setting. Across the training, participants will learn new tools for improving self-control."
48019780|NCT05966831|BEHAVIORAL|Virtual Reality Job Interview Training (VR-JIT)|VR-JIT provides trainees with an opportunity to repeatedly practice interviewing for a job at fictional company 'Wondersmart'. Prior to interviewing, trainees review self-guided e-learning materials on how to find, prepare for, succeed in, and follow-up on job interviews that includes the review of 10 job interview skills. Trainees also complete an online job application for one of 14 jobs (e.g., cashier, clerical, customer service, food services, inventory, janitorial, web developer) that informs the virtual interview experience.
48377605|NCT02586909|DRUG|RVT-101 35 mg tablets|once daily, oral tablets
48377606|NCT00076544|DRUG|Ziconotide|
48517537|NCT04841005|OTHER|Strengthening Exercise Training|Thera-Band brand elastic bands will be used to apply resistance in strengthening training. To determine the intensity of the exercise, the perceived difficulty level after 15 repetitions with the elastic band will be evaluated with the Borg scale. If the perceived difficulty level is at the level of 12-14 (slightly difficult), it will be considered as the starting difficulty level.In the strengthening exercise group will perform, shoulder abduction, shoulder press after elbow flexion, horizontal abduction, punching with an elastic band, triceps strengthening, external rotation of the shoulder, hip abduction with external rotation and sit-to-stand exercises for 8 weeks, 3 days / week , 3 sets / sessions, 8-12 repetitions. For each exercise, it will be applied as 8 repetitions in the initial workload. In the next exercise sessions, the number of repetitions will be increased until the patient can comfortably perform 12 repetitions with the same load.
48710706|NCT05526144|DRUG|Synthroid|Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
48710707|NCT05526144|DRUG|Placebo|Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
48710708|NCT01094353|PROCEDURE|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
48019781|NCT05669092|DRUG|Toripalimab|3mg/Kg iv d1q2w
48019782|NCT05669092|RADIATION|CRT|IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
48019783|NCT05669092|RADIATION|SCRT|25Gy/5fx
48019784|NCT05669092|DRUG|XELIRI|Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
48377607|NCT04029142|DIAGNOSTIC_TEST|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
48377608|NCT02329951|PROCEDURE|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
48377609|NCT02329951|PROCEDURE|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
48377610|NCT02329951|PROCEDURE|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
48377611|NCT00544778|BIOLOGICAL|filgrastim|
48710709|NCT01094353|PROCEDURE|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
48710710|NCT02299570|BIOLOGICAL|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
48710711|NCT02299570|OTHER|Placebo|A suspension of saline and cryoprotectant
48710712|NCT03859518|OTHER|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
48710713|NCT05220280|DRUG|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
48377612|NCT00544778|DRUG|dexrazoxane hydrochloride|
48377613|NCT00544778|DRUG|doxorubicin hydrochloride|
48377614|NCT00544778|DRUG|ifosfamide|
48377615|NCT00544778|DRUG|irinotecan hydrochloride|
48377616|NCT00544778|GENETIC|protein expression analysis|
48710714|NCT05220280|DRUG|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
48710715|NCT06389734|BEHAVIORAL|Manual soft tissue release|"The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
48710716|NCT06389734|BEHAVIORAL|Myofascial release|"The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
48710717|NCT06389734|BEHAVIORAL|Exercise training|The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
48710718|NCT04909892|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
48710719|NCT01286987|DRUG|Talazoparib|Oral capsule with multiple dosage forms given once daily
48710720|NCT05904522|DIAGNOSTIC_TEST|biopsy|biopsy for histopathological examination
48710721|NCT05297487|DEVICE|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
48710722|NCT03286946|PROCEDURE|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
48177029|NCT06484374|PROCEDURE|Robot-assisted minimally invasive treatment|An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.
48177030|NCT00592462|PROCEDURE|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
48710723|NCT03286946|PROCEDURE|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
48177031|NCT05691972|DEVICE|Restylane Contour|a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)
48177032|NCT04615598|BEHAVIORAL|Action observation|The idea is to show some videos with the aim of improving patients' tongue strength.
48177033|NCT04615598|BEHAVIORAL|Placebo group|The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
48710724|NCT02865889|PROCEDURE|Laparoscopy in Gynecologic Oncologic Indications|
48710725|NCT02865889|PROCEDURE|Conventional surgery (abdominal radical surgery)|
48710726|NCT01488214|OTHER|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
48710727|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
48710728|NCT05431920|DIETARY_SUPPLEMENT|Vitamin D₃ (25-hydroxy vitamin D)|Vitamin D3 oral supplementation
48710729|NCT03809091|DIAGNOSTIC_TEST|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
48710730|NCT01960543|DRUG|fentanyl 15 microg|
48710731|NCT01960543|DRUG|Bupivacaine 7 mg|
48710732|NCT01960543|DRUG|Bupivacaine 9 mg|
48019785|NCT05669092|DRUG|FOLFRINOX|Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
48710733|NCT01960543|DRUG|Levobupivacaine 7 mg|
48710734|NCT01960543|DRUG|Levobupivacaine 9 mg|
48710735|NCT02046850|DRUG|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
48019786|NCT01184352|DEVICE|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
48019787|NCT04536896|OTHER|Smartphone breastfeeding application|This intervention consists of a smartphone application which contains relevant information and topics regarding proper breastfeeding knowledge for medical students.
48019788|NCT04536896|OTHER|Traditional face-to-face breastfeeding lecture|This intervention consists of the impartition of a face-to-face breastfeeding course
48019789|NCT05027217|OTHER|No intervention|No intervention. Arms are subdivided based on patients' diagnostic status on admission to ICU.
48019790|NCT01993719|DRUG|Aldesleukin|720,000 IU/kg intravenous (IV) every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
48019791|NCT01993719|DRUG|Fludarabine|25 mg/m\^2/day intravenous piggy-back (IVPB) daily for 5 days
48019792|NCT01993719|DRUG|Fludarabine|30 mg/kg/day intravenous piggy-back (IVPB) daily for 3 days.
48019793|NCT01993719|DRUG|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV)
48019794|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
48019795|NCT01993719|DRUG|Cyclophosphamide|Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
48019796|NCT01993719|BIOLOGICAL|Young TIL|Day 0: Cells will be infused intravenously (IV)
48019797|NCT01993719|DRUG|Pembrolizumab|2 mg/kg intravenous (IV) on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
48019798|NCT02660359|BIOLOGICAL|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
48019799|NCT02660359|BIOLOGICAL|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
48019800|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
48019801|NCT02660359|DRUG|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
48019802|NCT00334659|DRUG|apricitabine|
48019803|NCT04790045|DRUG|Venetoclax|Core-needle biopsy to be performed before starting treatment in patients candidates to venetoclax-based regimens
48019804|NCT06250725|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|The intervention protocol will include CBTi principles like stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring. It will be done over 6 weeks with one session weekly via videoconference.
48019805|NCT01933334|DRUG|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
48019806|NCT02863354|DRUG|Aflibercept|Intravitreal injection
48710736|NCT02046850|DRUG|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
48710737|NCT02046850|DRUG|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
48710738|NCT02046850|DRUG|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
48710739|NCT05761366|DRUG|Al18F-PSMA-BCH PET/CT|Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
48710740|NCT00575432|RADIATION|diffusion MRI|diffusion MRI
48710741|NCT00575432|RADIATION|BOLD MRI|BOLD MRI
48710742|NCT00575432|OTHER|Clinical Outcome|Clinical outcome
48710743|NCT00554619|DRUG|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
48177034|NCT02591862|DRUG|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
48377617|NCT00544778|OTHER|immunoenzyme technique|
48377618|NCT00544778|PROCEDURE|adjuvant therapy|
48019807|NCT00009230|DRUG|Celecoxib|
48019808|NCT03104504|BEHAVIORAL|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
48377619|NCT00544778|PROCEDURE|conventional surgery|
48377620|NCT00544778|PROCEDURE|neoadjuvant therapy|
48710744|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
48019809|NCT03104504|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
48019810|NCT03104504|BEHAVIORAL|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
48019811|NCT03104504|BEHAVIORAL|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
48019812|NCT05042622|DEVICE|Cytokine adsorber filter|• Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
48019813|NCT05042622|DEVICE|Extracorporeal hemoperfusion cartridge|• Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
48019814|NCT04574622|DEVICE|radial Extracorporeal Shockwave Therapy|rESWT was given on gastrocnemius muscles with the subject lying on prone position. No anesthesia was required.
48019815|NCT02030691|DEVICE|Nasal continuous airway positive pressure (nCPAP)|
48377621|NCT00544778|RADIATION|radiation therapy|
48377622|NCT00856570|DRUG|warfarin|Oral
48377623|NCT00856570|DRUG|YM178|Oral
48377624|NCT00690846|DRUG|adalimumab|40 mg weekly adalimumab injection.
48377625|NCT00554268|DRUG|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
48710745|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
48710746|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
48710747|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
48710748|NCT05170750|OTHER|Foams|Every subject will perform 24 randomized trials on force platform.
48710749|NCT05170750|OTHER|Foam / Orthopedic insole|3/5 of the initial population will perform static and locomotion task, with randomized conditions.
48710750|NCT02279719|DRUG|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
48710751|NCT02279719|DRUG|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
48710752|NCT02279719|DRUG|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
48177035|NCT04597190|DRUG|Selective serotonin reuptake inhibitor|Prescribers and patients choose among three selective serotonin reuptake inhibitors (SSRI), sertraline, paroxetine, or fluoxetine based on patient's treatment history (i.e., failed SSRI trials due to side-effects or lack of efficacy) and preference. If a patient experiences problematic side effects after taking their choice of SSRI, the provider may switch them to another of the SSRI options during the first 8 weeks of follow-up. Patients on any antidepressant (including SSRIs) at enrollment will be cross-tapered over four weeks to either fluoxetine, sertraline or paroxetine (i.e., the old drug will be tapered down while the new drug is tapering up).
48177036|NCT04597190|DRUG|Serotonin-norepinephrine reuptake inhibitor|Prescribers will prescribe venlafaxine.
48377626|NCT01377207|PROCEDURE|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
48710753|NCT02516826|DRUG|Rosuvastatin|
48710754|NCT02516826|DRUG|Olmesartan|
48710755|NCT02516826|DRUG|Combination|Rosuvastatin/Olmesartan(Combination)
48710756|NCT02516826|DRUG|Placebo of Rosuvastatin|
48710757|NCT02516826|DRUG|Placebo of Olmesartan|
48710758|NCT02516826|DRUG|Placebo of Rosuvastatin/Olmesartan(Combination)|
48710759|NCT05523596|DRUG|ICM20|small molecules
48710760|NCT05523596|DRUG|Benznidazole|small molecule
48710761|NCT04367103|DRUG|Norepinephrine|prophylaxis for hypotension
48377627|NCT01717300|DRUG|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
48377628|NCT01717300|DRUG|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
48377629|NCT01717300|DRUG|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
48377630|NCT01717300|DRUG|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
48377631|NCT00700115|DRUG|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
48710762|NCT04367103|DRUG|Phenylephrine|standerd prophylaxis for hypotension
48710763|NCT04580745|DRUG|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
48710764|NCT04580745|DRUG|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
48710765|NCT03770494|DRUG|LY3405105|Administered orally.
48710766|NCT06394752|DEVICE|Visual Saline Infusion|Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
48710767|NCT06394752|DEVICE|Hydrosonography|Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
48377632|NCT00700115|DRUG|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
48377633|NCT01657591|DRUG|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
48710768|NCT05462977|BEHAVIORAL|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
48710769|NCT00195000|DRUG|Mylotarg|6 mg/m2 on day 1
48710770|NCT00195000|DRUG|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
48710771|NCT03350893|COMBINATION_PRODUCT|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)
48710772|NCT03350893|OTHER|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
48710773|NCT05737277|DRUG|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
48710774|NCT05737277|DRUG|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
48710775|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
48710776|NCT02757443|DRUG|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
48710777|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
48377634|NCT01657591|DRUG|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
48377635|NCT04148027|OTHER|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
48377636|NCT04148027|OTHER|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
48377637|NCT01713374|PROCEDURE|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
48377638|NCT01713374|OTHER|no intervention|control visit
48377639|NCT01713374|PROCEDURE|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
48517538|NCT06582394|COMBINATION_PRODUCT|Exp Group|Balance and coordination were targeted through virtual stepping tasks, where participants practiced stepping in various directions to improve postural control and lower limb function. Additionally, they performed virtual balance exercises by standing on simulated platforms of varying stability. For gait and mobility, participants practiced walking in a virtual environment with real-time feedback to correct gait abnormalities. They also encountered virtual obstacles, which required them to adapt their walking patterns and improve mobility. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
48019816|NCT02030691|DEVICE|Nasal high frequency percussive ventilation (nHFPV)|
48019817|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + placebo gel|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
48019818|NCT05028335|OTHER|Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%|Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
48019819|NCT01701466|OTHER|Aveeno cream|Twice a day
48019820|NCT01701466|OTHER|Flamazine cream|Twice a day, when there is dry desquamation
48019821|NCT01701466|OTHER|NeoVIDERM cream|Three times a day
48019822|NCT02109588|BEHAVIORAL|A supervised physical exercise program|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
48019823|NCT05775198|BIOLOGICAL|PBMC immunomodulated with IFNt|Autologous peripheral blood mononuclear cells (PBMC) isolated using a standard protocol will be cultured in the presence of interferon tau (IFNt) for 24 hours at 37 ˚C and administered in the uterine cavity of patients 1 day prior to embryo transfer.
48710778|NCT02757443|DRUG|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
48710779|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
48710780|NCT02757443|DRUG|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
48710781|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
48710782|NCT02757443|DRUG|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
48710783|NCT05837949|BEHAVIORAL|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
48019824|NCT01542866|OTHER|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
48177037|NCT04597190|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy will be delivered during six 30 minute sessions. The first session includes psychoeducation about symptoms of PTSD, provides a treatment rationale for approaching the trauma memory, and discusses the use of writing as a means of doing so. In sessions 2-6, patients will write about the memory of their worst traumatic event for 20 minutes, with a focus on details of the event and thoughts and feelings that occurred during the event. Patients are directed to write about the same trauma memory during each session. The session ends with the therapist instructing the patient to allow themselves to experience any trauma-related memories, images, thoughts, and feelings in the interval between sessions. The therapist reads the narrative between sessions to make sure instructions were followed. Feedback about the narrative is provided to the patient at the beginning of sessions 3-6. This feedback is used to prompt the patient for writing in the current session.
48177038|NCT03184506|OTHER|pre-warming|On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
48177039|NCT03184506|OTHER|no warming|patients were covered only with two layers of cotton blanket
48177040|NCT00809679|DRUG|T-62 Dose 1|Capsule dosage form 100 mg bid
48177041|NCT00809679|DRUG|T-62 Dose 2|Capsule dosage form 200 mg bid
48377640|NCT01713374|PROCEDURE|Cold pressure test|A hand will be placed in ice-cold water.
48377641|NCT01711736|BIOLOGICAL|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
48377642|NCT01711736|BIOLOGICAL|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
48377643|NCT02476058|DRUG|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
48710784|NCT00005764|DRUG|Lamivudine/Zidovudine|
48710785|NCT00005764|DRUG|Abacavir sulfate|
48710786|NCT00005764|DRUG|Lamivudine|
48710787|NCT05879770|OTHER|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
48019825|NCT01921972|DRUG|Galantamine CR|24 mg/day with dose-titration over twelve weeks
48019826|NCT01921972|DRUG|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
48019827|NCT01921972|DRUG|Placebo|Placebo will be similar in appearance to Memantine
48019828|NCT04978246|BEHAVIORAL|Neuropsychometric Test|Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI).
48019829|NCT06573151|DRUG|Selinexor, anti-PD-1 antibody and P-GemOx|Selinexor, 40mg, qw, po; Pegaspargase, 2500U/m2, IM, d1; Gemcitabine, 1000mg/m2, i.v., d1, d8; Oxaliplatin, 130mg/m2, i.v., d1; anti-PD1 antibody, 200mg, d2, i.v. (21d cycle);
48019830|NCT02157740|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
48019831|NCT06145828|DEVICE|Cytokine Adsorption|During treatment with cytokine adsorption cartridge, the patient's blood is passed through these cartridges, which contain substances that can adsorb specific cytokines. Excess cytokines are captured and removed by these substances, and then the cleansed blood is returned to the patient's body.
48019832|NCT04908813|DRUG|HLX22|IV Q3W D1
48019833|NCT04908813|DRUG|Placebo|IV Q3W D1
48019834|NCT04908813|DRUG|Trastuzumab|IV Q3W D1
48019835|NCT04908813|DRUG|Oxaliplatin|IV Q3W D1
48019836|NCT04908813|DRUG|Capecitabine|PO Q3W D1-D14
48710788|NCT04814368|BIOLOGICAL|canakinumab|intra-articular injection (into the knee)
48710789|NCT04814368|BIOLOGICAL|LNA043|intra-articular injection (into the knee)
48710790|NCT04814368|OTHER|Placebo to canakinumab|intra-articular injection (into the knee)
48710791|NCT04018560|BEHAVIORAL|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
48710792|NCT00001065|DRUG|Amphotericin B|
48710793|NCT04397913|DRUG|Paracetamol|15 mg/kg, q6h
48710794|NCT04397913|DRUG|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
48710795|NCT00573560|DEVICE|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
48710796|NCT05788705|DIETARY_SUPPLEMENT|"apigenin and glycyrrhizin"|"apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
48710797|NCT05788705|DIETARY_SUPPLEMENT|"glycyrrhizin and boswellic acid"|"boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months"
48710798|NCT05788705|DIETARY_SUPPLEMENT|"placebo"|"Placebo capsule will be administered two times daily for 6 months"
48710799|NCT04811105|PROCEDURE|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
48710800|NCT04140201|DRUG|Simvastatin 40mg|Drugs that lower lipid level
48710801|NCT04140201|DRUG|Fenofibrate 200mg|Drugs that lower lipid levels
48710802|NCT04140201|DRUG|Omega 3 fatty acid|Drugs that lower lipid levels
48710803|NCT01389401|DRUG|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
48710804|NCT00793572|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
48710805|NCT00793572|DRUG|Bortezomib|Given SC
48710806|NCT00793572|DRUG|Cyclosporine|Given IV
48710807|NCT00793572|DRUG|Cyclosporine|Given PO
48710808|NCT00793572|DRUG|Fludarabine Phosphate|Given IV
48710809|NCT00793572|OTHER|Laboratory Biomarker Analysis|Correlative studies
48710810|NCT00793572|DRUG|Melphalan|Given IV
48710811|NCT00793572|DRUG|Mycophenolate Mofetil|Given PO
48710812|NCT00793572|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
48710813|NCT00793572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
48710814|NCT00793572|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo transplantation
48177042|NCT00809679|OTHER|Placebo|Capsule dosage form placebo bid
48710815|NCT00793572|RADIATION|Total-Body Irradiation|Undergo radiotherapy
48710816|NCT06008769|BEHAVIORAL|12 Week Manualized Cognitive-Behavioral Therapy Intervention|The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
48710817|NCT00031746|DIETARY_SUPPLEMENT|soy protein isolate|25 mg daily
48710818|NCT00031746|DIETARY_SUPPLEMENT|casein proteins|25 mg daily
48177043|NCT01376297|DRUG|Netupitant and Palonosetron|
48177044|NCT01376297|DRUG|Aprepitant|
48710819|NCT01357876|OTHER|Metformin|withdrawral
48019837|NCT04962269|DIAGNOSTIC_TEST|MRI|monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model
48177045|NCT01376297|DRUG|Palonosetron|
48177046|NCT01376297|DRUG|Dexamethasone|
48177047|NCT03192969|DRUG|Abatacept|Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
48177048|NCT03192969|OTHER|Placebo|Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
48177049|NCT03192969|DRUG|Glucocorticoid Treatment|Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
48177050|NCT03354910|BEHAVIORAL|House Call|60 to 90 minute home based educational intervention which will be administered by a health educator.
48177051|NCT03354910|BEHAVIORAL|Peer Mentorship|A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
48177052|NCT01154062|DRUG|Pazopanib|Pazopanib tablet
48177053|NCT06124976|DRUG|ST-02|ST-02 drug instillation into the upper urinary tract (renal pelvis)
48177054|NCT02576327|DRUG|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
48177055|NCT02576327|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
48710820|NCT02351349|OTHER|multidisciplinary intervention|multidisciplinary intervention
48710821|NCT00868530|BIOLOGICAL|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
48710822|NCT05630651|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose level is 5.0×10\^12vg/kg.
48710823|NCT04261959|OTHER|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
48710824|NCT04261959|OTHER|Physiotherapy|Physiotherapy aims to reduce a patient's pain experience and increase their physical function through physical examination, diagnosis, prognosis, physical intervention, rehabilitation and education (including pain neurophysiology education).
48710825|NCT01243684|DEVICE|DTI - Diffusor Tensor Imaging|Radiology intervention
48710826|NCT03943680|DEVICE|PRGF|After tooth extraction, the socket will be grafted with PRGF-Endoret
48710827|NCT03943680|DEVICE|ABB|After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
48710828|NCT02912130|DIETARY_SUPPLEMENT|Protein Supplementation|1.2-1.5g/kg/body weight per day
48710829|NCT02912130|OTHER|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
48710830|NCT02912130|OTHER|Resistance Exercise|60 minutes per week of progressive resistance training
48710831|NCT05507632|COMBINATION_PRODUCT|Donafenib plus Sintilimab in combination with transarterial chemoembolisation|Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE)
48710832|NCT00199225|DRUG|Rupatadine|
48710833|NCT00199225|DRUG|moxifloxacin|
48710834|NCT00199225|PROCEDURE|Continous electrocardiographic register|
48710835|NCT00199225|PROCEDURE|Pharmacokinetic profile|
48710836|NCT00717587|DRUG|motexafin gadolinium|
48710837|NCT00717587|DRUG|sunitinib malate|
48710838|NCT00717587|GENETIC|comparative genomic hybridization|
48710839|NCT00717587|GENETIC|gene expression analysis|
48710840|NCT00717587|GENETIC|mutation analysis|
48710841|NCT00717587|GENETIC|polymorphism analysis|
48710842|NCT00717587|OTHER|immunohistochemistry staining method|
48710843|NCT00717587|OTHER|iodine I-124 girentuximab|
48710844|NCT00717587|OTHER|laboratory biomarker analysis|
48710845|NCT00717587|OTHER|pharmacological study|
48710846|NCT00717587|PROCEDURE|adjuvant therapy|
48710847|NCT00717587|PROCEDURE|neoadjuvant therapy|
48710848|NCT00717587|PROCEDURE|therapeutic conventional surgery|
48710849|NCT03593135|DIETARY_SUPPLEMENT|Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)|15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
48710850|NCT03593135|OTHER|Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)|Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
48710851|NCT00072891|BEHAVIORAL|telephone counseling|
48710852|NCT01065948|DEVICE|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
48710853|NCT05173610|RADIATION|Radiation: Stereotactic body radiotherapy (SBRT)|"Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~1. Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~2. Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~   i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision"
48710854|NCT06081413|PROCEDURE|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
48710855|NCT04612660|BEHAVIORAL|Education on cervical cancer prevetnion|Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
48710856|NCT04612660|BEHAVIORAL|Dynamic group interaction|Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
48710857|NCT04612660|BEHAVIORAL|Physician engagement|Engaging community bilingual physicians in cervical cancer screening and referral;
48177056|NCT02576327|DRUG|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
48177057|NCT05221138|DRUG|VV116|VV116 oral tablets, 400mg
48710858|NCT04612660|BEHAVIORAL|Patient Navigation|Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
48710859|NCT04612660|BEHAVIORAL|General Health Education|general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
48710860|NCT00650520|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
48710861|NCT00650520|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
48710862|NCT01575093|OTHER|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
48710863|NCT02845778|DRUG|Melatonin|Each sachet contains 0.5 g
48177058|NCT03739372|OTHER|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
48177059|NCT05479188|DEVICE|Cerebral oximetry|Cerebral oximetry monitoring with near-infrared spectroscopy.
48177060|NCT05479188|DEVICE|Peripheral oximetry|Tissue perfusion monitoring with somatic near-infrared spectroscopy.
48710864|NCT05126264|DRUG|Ibuprofen 400 mg|morning and afternoon
48710865|NCT05126264|DRUG|Ibuprofen 400 mg|morning, afternoon and night
48710866|NCT02443493|DEVICE|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
48710867|NCT02443493|DEVICE|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
48710868|NCT02443493|RADIATION|radiotherapy|
48710869|NCT02594098|DRUG|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
48710870|NCT02594098|DRUG|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
48710871|NCT02416986|BEHAVIORAL|6 hour smoking abstinence|
48710872|NCT02416986|BEHAVIORAL|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
48710873|NCT02416986|BEHAVIORAL|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
48710874|NCT00908648|PROCEDURE|Narrow Band Imaging|Narrow Band Imaging
48710875|NCT00496197|DRUG|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
48710876|NCT00496197|DRUG|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
48177061|NCT05479188|DEVICE|Cerebral autoregulation|Cerebral autoregulation monitoring with COx.
48177062|NCT05479188|DEVICE|Sublingual microscopy|Evaluation of microcirculation with sublingual microscopy.
48177063|NCT01103232|PROCEDURE|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
48177064|NCT01103232|PROCEDURE|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
48177065|NCT06356623|OTHER|1|this is not an intervention study
48177066|NCT05477303|OTHER|taking a picture of a painful facial expression|Immediately after surgery, the patient's facial expression and the NRS score and ANI score reported by the patient are checked together.
48177067|NCT01434680|BIOLOGICAL|MenC-CRM LIQ|One dose of MenC-CRM vaccine, liquid formulation
48177068|NCT01434680|BIOLOGICAL|MenC-CRM ROS|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.
48177069|NCT01434680|BIOLOGICAL|MenC-CRM EMV|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
48177070|NCT00119561|BEHAVIORAL|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
48177071|NCT02833298|BEHAVIORAL|Automated reminders|At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
48177072|NCT02833298|BEHAVIORAL|Patient navigation|The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
48177073|NCT00226993|DRUG|CPG 7909|
48177074|NCT00088647|DRUG|MST-997|
48377644|NCT02476058|DRUG|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
48377645|NCT02476058|DRUG|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
48517539|NCT06582394|OTHER|Control group|For gait training, participants practiced walking on flat surfaces, sometimes with the assistance of parallel bars or walking aids, to improve their walking speed, step length, and rhythm. They also performed sit-to-stand exercises to strengthen the lower limbs and improve mobility for daily activities. Additionally, manual therapy techniques, such as joint mobilizations and stretching, were applied to reduce spasticity and increase range of motion in the affected limbs. Both treatment groups progressed based on individual capabilities, with therapists adjusting exercises accordingly throughout the study. In this study, both the intervention and control groups underwent a 6-week treatment plan consisting of 5 sessions per week, with each session lasting 45 minutes.
48517540|NCT03511599|DRUG|Cycloserine|Cycloserine 100mg
48710877|NCT00496197|DRUG|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
48710878|NCT05154136|DRUG|Etrumadenant|Capsule
48377646|NCT05805072|DRUG|Selinexor|Selinexor 60 mg/day, orally on d1,4,8,11
48517541|NCT03511599|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
48377647|NCT05805072|DRUG|Homoharringtonine|Homoharringtonine 1 mg/day intravenously on days 3 to 9
48517542|NCT03511599|DRUG|Placebo Oral Tablet|Placebo tablet matched to cycloserine tab
48517543|NCT06427850|DRUG|Tranexamic acid|receive an injection of Tranexamic acid into the surgical site
48517544|NCT06427850|DRUG|Normal saline|receive an injection of Normal saline into the surgical site
48517545|NCT01764399|BEHAVIORAL|Care4U|
48710879|NCT05154136|DRUG|Itraconazole|Capsule
48710880|NCT05479435|BEHAVIORAL|Blue Prescription Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).
48710881|NCT05479435|BEHAVIORAL|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
48517546|NCT03200717|DRUG|Pazopanib|Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
48517547|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
48019841|NCT00388518|DRUG|Actos|45mg po daily
48019842|NCT00388518|DRUG|Placebo|po daily
48019843|NCT00388518|DRUG|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
48177075|NCT00438178|DRUG|Obatoclax mesylate (GX15-070MS)|
48177076|NCT05893914|PROCEDURE|Dry Needling and intramuscular electrical stimulation to trigger points|Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.
48177077|NCT02561247|DEVICE|Prismaflex HF20 CRRT Filter|
48377648|NCT05805072|DRUG|Cytarabine|cytarabine 10 mg/m2 q12h, intravenously on days 3 to 9
48377649|NCT05805072|DRUG|Aclacinomycin|aclacinomycin 10 mg/day intravenously on days 3 to 6
48377650|NCT05805072|DRUG|Granulocyte Colony-Stimulating Factor|granulocyte colony-stimulating factor 50-600 mcg/m2/day intravenously from days 2 to start, this dosage will be adjusted according to the hemogram,
48377651|NCT05805072|DRUG|Decitabine|Decitabine 20 mg/m2/day intravenously on days 1 to 5.
48377652|NCT05805072|DRUG|Azacitidine|Azacitidine 20 mg/m2/day subcutaneously on days 1 to 7
48377653|NCT05862870|BEHAVIORAL|painTRAINER|patient self-administered pain management web application
48377654|NCT06396806|PROCEDURE|indocyanine green fluorescence imaging lymphatic tracing|At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
48377655|NCT06294327|DEVICE|Reactive static air support surfaces|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge~* Repose® Foot Protectors"
48377656|NCT05252585|DRUG|Everolimus|"Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be:~* Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment)~* Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)"
48517548|NCT01638598|DRUG|Test drug|BI 1021958
48517549|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
48517550|NCT01638598|DRUG|Test drug|BI 1021958
48517551|NCT01638598|DRUG|Test drug|BI 1021958
48517552|NCT01638598|DRUG|Test drug|BI 1021958
48517553|NCT01638598|DRUG|Test drug|BI 1021958
48517554|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
48177078|NCT02561247|DEVICE|Prismaflex® System 7.10 and 7.20|
48019844|NCT04594512|OTHER|Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery|A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
48019845|NCT06137300|DRUG|Urinary kallidinogenase for injection|Urinary kallidinogenase 0.15PNA once daily for 7 days.
48019846|NCT06137300|OTHER|Guideline-prescribed medical therapy|Guideline-prescribed medical therapy
48019847|NCT02044081|DRUG|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
48019848|NCT02044081|DRUG|Placebo|Placebo is the vehicle without C16G2
48019849|NCT02044081|DRUG|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
48019850|NCT03494010|OTHER|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
48019851|NCT02877485|DRUG|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
48177079|NCT01363310|DRUG|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
48177080|NCT01363310|DRUG|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
48177081|NCT04528823|OTHER|Strategy 2: Symptom screen, Genexpert and TST|Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
48177082|NCT04528823|OTHER|Strategy 3:Symptom screen, CXR but NO TST|Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
48177083|NCT03793062|OTHER|No Interventions|Not applicable - No Interventions
48177084|NCT06499688|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
48177085|NCT06499688|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
48177086|NCT06499688|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
48177087|NCT02115919|DRUG|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
48177088|NCT02115919|DRUG|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
48019852|NCT02877485|DRUG|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
48177089|NCT00511836|DRUG|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
48177090|NCT00511836|DRUG|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
48177091|NCT02515006|OTHER|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
48177092|NCT02830009|OTHER|Urines samples|24-hour urines will be collected
48177093|NCT02830009|OTHER|Blood sample|
48177094|NCT03980197|OTHER|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
48177095|NCT03980197|OTHER|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
48177096|NCT00330356|BEHAVIORAL|Low Salt Diet versus High salt diet|
48377657|NCT02265991|PROCEDURE|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
48377658|NCT03704285|DRUG|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
48377659|NCT03704285|DEVICE|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
48377660|NCT00131001|PROCEDURE|contrast-enhanced magnetic resonance angiography|
48019853|NCT03977324|PROCEDURE|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
48019854|NCT03977324|PROCEDURE|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
48019855|NCT06142279|BIOLOGICAL|Sampling|At baseline, nasal, salivary and blood sampling will be taken for the participants.
48177097|NCT05029011|DEVICE|BRAEBON VTS|The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
48710882|NCT05479435|BEHAVIORAL|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
48710883|NCT05295823|DEVICE|Butterfly portable ultrasound device with bladder ultrasound images|Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images
48710884|NCT05295823|DEVICE|Butterfly portable ultrasound device with abstract bladder images|Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
48710885|NCT05140837|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
48710886|NCT05140837|DRUG|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
48710887|NCT01975337|DRUG|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
48710888|NCT03242772|DRUG|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
48710889|NCT03242772|BEHAVIORAL|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
48710890|NCT03242772|DRUG|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
48710891|NCT04231760|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
48710892|NCT04231760|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
48710893|NCT03871452|PROCEDURE|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
48710894|NCT04580706|OTHER|this is an observational study with none intervention|this is an observational study with none intervention
48710895|NCT05960305|OTHER|P1213416|Tobacco Flavor
48710896|NCT05960305|OTHER|P1213422|Tobacco Flavor
48710897|NCT05960305|OTHER|P1213716|Tobacco Flavor
48710898|NCT05960305|OTHER|P1213722|Tobacco Flavor
48377661|NCT06045910|DRUG|ALETA-001|ALETA-001 will be administered intravenously (IV) every two weeks.
48019856|NCT06142279|BIOLOGICAL|PCR (polymerase chain reaction) SARS-CoV-2|At baseline, this PCR SARS-CoV-2 will be taken for the participants.
48377662|NCT02681549|DRUG|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
48019857|NCT05239676|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells|The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient
48377663|NCT00705471|BIOLOGICAL|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
48377664|NCT00905437|DRUG|Placebo|Placebo as an adjunct to standard of care
48377665|NCT00905437|DRUG|Pregabalin|75 mg BD for 14 days
48377666|NCT01545401|OTHER|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~* Global CV Risks Self-Management Booklets~* CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
48377667|NCT03512704|OTHER|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
48517555|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
48710899|NCT05960305|OTHER|P1211216|Menthol Flavor
48710900|NCT05960305|OTHER|P1211222|Menthol Flavor
48710901|NCT05960305|OTHER|P1213616|Menthol Flavor
48710902|NCT05960305|OTHER|P1213622|Menthol Flavor
48710903|NCT05960305|OTHER|P1213816|NTNM Flavor
48710904|NCT05960305|OTHER|P1213822|NTNM Flavor
48710905|NCT05960305|OTHER|P1211916|NTNM Flavor
48710906|NCT05960305|OTHER|P1211922|NTNM Flavor
48710907|NCT00846040|OTHER|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
48710908|NCT00846040|OTHER|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
48710909|NCT00846040|DRUG|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
48710910|NCT00846040|DEVICE|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
48710911|NCT00846040|DEVICE|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
48177098|NCT02755129|OTHER|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
48177099|NCT02755129|OTHER|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
48177100|NCT02755129|OTHER|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
48177101|NCT02755129|OTHER|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
48377668|NCT04768283|OTHER|Additional balance and resistance training - 1|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises to improve static as well as dynamic balance ability, for 15-20 minutes.~The resistance training included exercises with weights (0,5, 1 or 2 kg), elastic resistance rubbers, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets."
48517556|NCT01638598|DRUG|matching placebo|matching placebo in each dose level
48710912|NCT04304170|DIETARY_SUPPLEMENT|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
48710913|NCT04304170|OTHER|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
48710914|NCT03226756|DRUG|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
48710915|NCT02978703|DRUG|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
48710916|NCT05883332|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
48710917|NCT05883332|OTHER|Oxygen|100% oxygen at 10 Liters/minute
48710918|NCT02539498|DEVICE|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
48177102|NCT02755129|OTHER|Reveal LINQ accelerometer|Walking exercises test
48177103|NCT02755129|OTHER|3D accelerometer|Walking exercises test
48177104|NCT04585100|DRUG|FM101 tablet|Bio-equivalent test (tablet vs oral solution)
48517557|NCT03817541|DEVICE|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
48517558|NCT06235489|OTHER|Palfique Bulk Flow|removal of caries in primary molars and placement of restorative materials
48517559|NCT04493671|DRUG|TBAJ-876 10mg|TBAJ-876 10mg tablets, oral suspension, orally administered
48517560|NCT04493671|DRUG|TBAJ-876 25mg|TBAJ-876 25mg tablets,oral suspension, orally administered
48710919|NCT02252549|DEVICE|SPIES+WLI assisted TURB|
48710920|NCT02252549|DEVICE|WLI assisted TURB|
48710921|NCT02699008|DRUG|Clopidogrel|Antiplatelet agent
48710922|NCT02699008|DRUG|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
48710923|NCT04022681|OTHER|BALLETS|Cohort were not exposed to any intervention. There information will be analysed from database searches.
48710924|NCT03928288|DRUG|Cabergoline 0.5 MG|Medication
48710925|NCT03928288|DRUG|Placebo - Cap|Placebo capsule
48710926|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
48710927|NCT01318070|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
48710928|NCT01318070|DRUG|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
48177105|NCT04585100|DRUG|FM101 oral solution|Bio-equivalent test (tablet vs oral solution)
48177106|NCT04585100|DRUG|Placebo|Placebo BID for 28 days
48377669|NCT04768283|OTHER|Additional balance and resistance training - 2|"Additional exercise program with balance and resistance training three times per week.~The balance training included exercises with static and dynamic balance training device Biodex Balance System TM SD, for 15-20 minutes. Exercises are performed with the following programs: Postural stability training, Limits of stability training, Weight shift training, Maze control training, Random control training, Percent weight-bearing training.~The resistance training included exercises with HUR strength training machines, intensity 30-50% 1-RM, 10 repetitions with 3 sets and 3 minute rest between sets. Strength training was performed with the following exercises: Leg press, leg extension, leg abduction, leg adduction."
48377670|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
48377671|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
48377672|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
48019858|NCT06219655|PROCEDURE|thoracoscopic sympathectomy|sympathectomy
48019859|NCT02261116|DRUG|Telmisartan|
48377673|NCT01277172|BIOLOGICAL|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
48377674|NCT05031559|BEHAVIORAL|Episodic Future Thinking|Participants are invited to imagine themselves in a positive situation after COVID-19 public health restrictions and guidelines are lifted. They are then reminded that their actions are able to change how soon this future can be achieved.
48377675|NCT05031559|BEHAVIORAL|Compassion Training|Participants are invited to imagine themselves in someone else's situation, who is in a bad situation due to COVID-19 (e.g., ER nurse, family of someone in ICU). They are then reminded that their decisions have an impact on the occurrence of these situations.
48377676|NCT05031559|BEHAVIORAL|Sham|Participants are invited to reflect on some COVID-19 related news, and reminded that their actions have bearing on the COVID-19 situation.
48377677|NCT03367676|DRUG|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
48377678|NCT03367676|DRUG|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w\*4
48377679|NCT02885831|DEVICE|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
48019860|NCT02261116|DRUG|Candesartan|
48019861|NCT02261116|DRUG|Placebo|
48019862|NCT04108039|DRUG|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles \>14mm or E2 levels \>400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
48377680|NCT02863588|BIOLOGICAL|seropositive for Toxoplasma gondii|blood sample
48377681|NCT05238922|DRUG|INCB0123667|25 mg tablets
48377682|NCT03172910|DRUG|Ciraparantag|Ciraparantag (administered over 10 minutes)
48517561|NCT04493671|DRUG|TBAJ-876 50mg|TBAJ-876 50mg tablets,oral suspension, orally administered
48517562|NCT04493671|DRUG|TBAJ-876 100mg|TBAJ-876 100mg tablets, oral suspension, orally administered
48517563|NCT04493671|DRUG|TBAJ-876 200mg|TBAJ-876 200mg tablets, oral suspension, orally administered
48517564|NCT04493671|DRUG|TBAJ-876 400mg|TBAJ-876 400mg tablets, oral suspension, orally administered
48517565|NCT04493671|DRUG|TBAJ-876 Dose XXXmg for Food cohort|Based on exposure levels from initial cohorts, a dose will be chosen for the food-effect cohort.
48517566|NCT04493671|DRUG|TBAJ-876 XXXmg for Part 2|Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.
48019863|NCT04108039|DRUG|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
48019864|NCT05009797|PROCEDURE|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
48019865|NCT02580526|PROCEDURE|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
48177107|NCT04585100|DRUG|FM101 150 mg|FM101 (150 mg) BID for 28 days
48177108|NCT04585100|DRUG|FM101 300 mg|FM101 (300 mg) BID for 28 days
48177109|NCT03119688|OTHER|Test Product|Micellar cleanser (0.09 ml)
48177110|NCT03119688|OTHER|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
48177111|NCT03119688|OTHER|Reference Product|Sterile Water (0.09 ml)
48177112|NCT03119688|OTHER|No Treatment|Unwashed area of the forearm
48177113|NCT03848884|BEHAVIORAL|Adherence monitoring and education|Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
48177114|NCT00277199|DRUG|Abatacept|
48177115|NCT02081937|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|
48710929|NCT04920006|BEHAVIORAL|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
48019866|NCT02580526|PROCEDURE|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
48019867|NCT03144726|DEVICE|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
48019868|NCT03144726|OTHER|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
48710930|NCT06430190|DRUG|Peginterferon α-2b injection|Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.
48019869|NCT03460340|DEVICE|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
48019870|NCT00821691|DRUG|Amantadin|Amantadin caps
48019871|NCT00821691|DRUG|Placebo|Placebo caps
48019872|NCT03735420|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
48019873|NCT03735420|DRUG|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
48019874|NCT04041505|BEHAVIORAL|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
48019875|NCT00618020|DEVICE|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
48019876|NCT02866617|DEVICE|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
48019877|NCT02203019|DRUG|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
48019878|NCT02203019|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
48710931|NCT06430190|DRUG|Peginterferon α-2b injection|Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.
48019879|NCT02203019|DRUG|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
48377683|NCT03172910|DRUG|Placebo|Saline for injection
48710932|NCT06430190|OTHER|CO2 laser|On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.
48710933|NCT00590824|DRUG|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
48710934|NCT00590824|DRUG|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
48710935|NCT01024582|PROCEDURE|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
48019880|NCT00927745|DEVICE|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
48019881|NCT00927745|DEVICE|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
48019882|NCT05195996|DRUG|Propranolol|intravenous propranolol for case patients
48019883|NCT05195996|DRUG|Saline|intravenous saline for placebo
48019884|NCT05990049|DRUG|Hyadent BG|Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)
48019885|NCT00927446|PROCEDURE|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
48019886|NCT03009071|PROCEDURE|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
48019887|NCT03009071|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
48019888|NCT01569334|BIOLOGICAL|blood samples|
48377684|NCT03172910|DRUG|Rivaroxaban|Rivaroxaban 20 mg given once per day (QD) in the morning
48377685|NCT05874921|DRUG|Jelmyto (mitomycin) for pyelocalyceal solution|"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
48377686|NCT01334502|BIOLOGICAL|rituximab|PO
48377687|NCT01334502|DRUG|cyclophosphamide|IV
48377688|NCT01334502|DRUG|doxorubicin hydrochloride|IV
48377689|NCT01334502|DRUG|everolimus|PO
48710936|NCT01024582|PROCEDURE|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
48710937|NCT01024582|RADIATION|accelerated partial breast irradiation|
48710938|NCT01024582|RADIATION|image-guided radiation therapy|
48710939|NCT03067493|BIOLOGICAL|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
48710940|NCT02960646|DRUG|Cyclophosphamide|Given IV
48710941|NCT02960646|BIOLOGICAL|Filgrastim|Given SC
48710942|NCT02960646|DRUG|Fludarabine Phosphate|Given IV
48710943|NCT02960646|OTHER|Laboratory Biomarker Analysis|Correlative studies
48710944|NCT02960646|DRUG|Melphalan|Given IV
48710945|NCT02960646|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
48710946|NCT02960646|BIOLOGICAL|Rituximab|Given IV
48710947|NCT02960646|DRUG|Tacrolimus|Given IV or PO
48710948|NCT02960646|RADIATION|Total-Body Irradiation|Undergo TBI
48710949|NCT02011620|OTHER|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
48377690|NCT01334502|DRUG|prednisone|PO
48710950|NCT02537262|DIETARY_SUPPLEMENT|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.
48710951|NCT02537262|DIETARY_SUPPLEMENT|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
48710952|NCT04093765|DIAGNOSTIC_TEST|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
48710953|NCT04093765|DRUG|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
48019889|NCT02340559|BEHAVIORAL|Meta-cognitive Training|
48377691|NCT01334502|DRUG|vincristine sulfate|IV
48377692|NCT04846010|COMBINATION_PRODUCT|PurWet|(1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
48377693|NCT04846010|COMBINATION_PRODUCT|FurFat|(2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
48517567|NCT04493671|DRUG|Matching Placebo for TBAJ-876 tablet|Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered
48710954|NCT03373032|OTHER|Stiper|"Stiper silicon tablets, for acupunture's stimulation of meridian points, the Stiper's chemical composition is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points, duration of 05 minutes."
48710955|NCT03373032|OTHER|Acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top,duration of 30 minutes.
48019890|NCT02340559|BEHAVIORAL|Psychoeducational group|
48019891|NCT04008134|BEHAVIORAL|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
48019892|NCT04008134|BEHAVIORAL|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
48019893|NCT04008134|BEHAVIORAL|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
48710956|NCT03373032|OTHER|Exercise|Will perform pre-defined kinesiotherapy based on the stretching of cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
48710957|NCT03373032|OTHER|Follow Up|Use of the therapeutic massager, in hands and feet, to stimulate region's sensitivity, women who were submitted to the chemotherapy treatment with Taxane and continued with changes in sensitivity. Once in each dermatome, adding time of 5 minutes of application on average.
48177116|NCT02718547|DRUG|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
48377694|NCT04846010|COMBINATION_PRODUCT|PurApo|(3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
48377695|NCT04846010|COMBINATION_PRODUCT|PurPhl|(4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
48377696|NCT04846010|COMBINATION_PRODUCT|PurClo|(2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
48710958|NCT03373032|OTHER|Observation|The waiting room (observation) group did not receive any intervention. Conduct evaluations of the research protocol as groups A, B and C.
48710959|NCT05708781|OTHER|Core strengthening exercise|"1. Isolated lumbar stabilization muscle training:~2. Bridge track:~3. Dead bug track:~4. Quadruped Track:~5. Supine Track:~6. Side-support Track:~7. Prone Track:~8. Standing Track:"
48710960|NCT05708781|OTHER|intensive dynamic back exercise|"1. Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~2. Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~3. Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
48710961|NCT05708781|OTHER|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
48710962|NCT06237920|DRUG|Nivolumab|Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
48710963|NCT06237920|DRUG|Relatlimab|Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
48019894|NCT05044741|PROCEDURE|Emergency surgical enterostomy|Emergency surgical enterostomy
48019895|NCT00451425|BEHAVIORAL|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
48019896|NCT02866578|PROCEDURE|Open lung protective ventilation strategy|
48377697|NCT04846010|COMBINATION_PRODUCT|PurInf|(1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
48377698|NCT04846010|COMBINATION_PRODUCT|Smoliv|(2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
48377699|NCT03061916|DIETARY_SUPPLEMENT|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
48019897|NCT00843791|DRUG|placebo|treatment with placebo for 3 months
48019898|NCT00843791|DRUG|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
48177117|NCT05575570|DEVICE|EVAR|EVAR stent graft and embolization material CE marked.
48377700|NCT03061916|DIETARY_SUPPLEMENT|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
48377701|NCT03061916|DRUG|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
48517568|NCT03910673|DRUG|Fosfomycin disodium|Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
48710964|NCT02002936|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
48710965|NCT01956045|OTHER|Patient's capacity|
48710966|NCT02588703|BEHAVIORAL|Cognitive Behavioral Therapy|Coping Skills Treatment
48710967|NCT02588703|BEHAVIORAL|Usual Care|Existing DUI program group counseling
48177118|NCT05722405|DRUG|Ixazomib plus low-dose lenalidomide|Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone
48177119|NCT05722405|DRUG|Ixazomib|Ixazomib alone
48177120|NCT02476747|OTHER|EMR|performing EMR for patients with small polyp
48177121|NCT02476747|OTHER|CSP|performing CSP for patients with small polyp
48177122|NCT00207818|DEVICE|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
48177123|NCT05144698|BIOLOGICAL|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
48710968|NCT02426190|OTHER|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
48019899|NCT03654677|BIOLOGICAL|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
48019900|NCT03654677|BIOLOGICAL|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
48019901|NCT02256046|DEVICE|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
48019902|NCT03891082|PROCEDURE|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
48710969|NCT02426190|OTHER|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
48019903|NCT03891082|PROCEDURE|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
48019904|NCT05181605|DRUG|Folfirinox and Stereotactic Body Radiotherapy|Neoadjuvant treatment is composed of folfirinox plus stereotactic body radiotherapy
48019905|NCT04978857|OTHER|autobiographic movie|viewing an autobiographic film through a virtual reality headset
48019906|NCT01108744|DRUG|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
48019907|NCT01108744|DRUG|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
48019908|NCT02978144|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
48019909|NCT02978144|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
48019910|NCT06663826|DIAGNOSTIC_TEST|oculomotor and pupillary function assessment|This is an exploratory open-label single-centre research project intended to collect data of PD patients in order to develop machine learning models for helping in the diagnosis and monitoring of PD. Each patient will have an initial visit and then a second visit after two weeks. The estimated duration of the study visit 1 is 3 hours, not taking into account the time for patient information and informed consent. The estimated duration of the study visit 2 is 2 hours. During these two visits, patients will undergo an MDS-UPDRS assessment, a neos examination, a standard manual ocular motor and pupil function examination, and gait assessment simultaneously with GaitQ senti and an IMU sensor placed on their back. In the two weeks separating the two visits, patient's gait will be monitored daily at home with GaitQ senti, where they will perform a daily TUG test comprising of 15 m walk, 5 sit to stand, and 5-minute walk. Healthy individuals data will be included from a previous study.
48019911|NCT00677339|DRUG|L-arginine|L-arginine 6g orally daily
48019912|NCT00677339|DRUG|Vitamin D|Cholecalciferol 50000 IU once monthly orally
48377702|NCT05872282|DEVICE|ZIPPER aortic arch stentgraft system|The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
48019913|NCT00677339|DRUG|Placebo L-arginine|placebo L-arginine once daily
48019914|NCT00677339|DRUG|Placebo Vitamin D|placebo vitamin D orally once monthly
48019915|NCT05831852|OTHER|no intervention|no intervention
48019916|NCT05506982|DRUG|Psilocybin|Given PO
48019917|NCT05506982|BEHAVIORAL|Psychotherapy|supportive care
48019918|NCT05506982|OTHER|Quality-of-Life Assessment|Ancillary studies
48019919|NCT05506982|OTHER|Questionnaire Administration|Ancillary studies
48019920|NCT03286140|PROCEDURE|Early endovenous ablation|
48019921|NCT03286140|PROCEDURE|Delayed endovenous intervention|
48019922|NCT01169389|PROCEDURE|Intraarticular injection|Durolane, one vial
48710970|NCT02426190|OTHER|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
48517569|NCT00706485|DEVICE|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
48710971|NCT02426190|OTHER|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
48710972|NCT05482815|DEVICE|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
48710973|NCT05302856|DIAGNOSTIC_TEST|Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)|Peripheric blood extraction
48710974|NCT04676308|OTHER|Artificial Intelligence|Artificial intelligence
48710975|NCT05756114|BEHAVIORAL|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
48710976|NCT05756114|OTHER|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
48710977|NCT00525824|DRUG|Rosuvastatin (Crestor)|10mg and 20 mg
48710978|NCT00525824|DRUG|Ezetimibe|10 mg
48710979|NCT00525824|DRUG|Simvastatin|40mg and 80 mg
48019923|NCT01169389|PROCEDURE|Intra-articular injection of 0.5% Bupivacaine|
48177124|NCT05144698|DRUG|Chemotherapy Prior to RAPA-201 Therapy|Carboplatin + Paclitaxel Regimen (CP Regimen)
48177125|NCT03840356|OTHER|Postoperative|No intervention is planned in the study. This study is simply evaluating the consistency with which patients report their pain levels to different members of the medical team.
48710980|NCT03872830|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
48710981|NCT03872830|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
48710982|NCT01161095|DEVICE|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
48710983|NCT05111106|DEVICE|Symfony IOL|Implantation of Intraocular lens with extended depth of focus.
48710984|NCT02635347|PROCEDURE|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
48710985|NCT02635347|DEVICE|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
48710986|NCT00202813|DEVICE|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
48710987|NCT06052111|DRUG|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
48019924|NCT05873387|DEVICE|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
48019925|NCT05286905|DEVICE|Osteosynthesis cephalomedullary nail|Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail
48517570|NCT01207895|DEVICE|PET imaging with [18F]-FLT|Up to three \[18F\]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
48517571|NCT01207895|DRUG|[18F]-fluorodeoxythymidine|\[18F\]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
48710988|NCT06052111|DRUG|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
48710989|NCT03514680|BEHAVIORAL|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
48710990|NCT02510651|PROCEDURE|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
48710991|NCT01778374|OTHER|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
48710992|NCT01778374|OTHER|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
48710993|NCT04912323|DEVICE|Percutaneous Implantation of the MAGNITUDE® Bioresorbable Arterial Scaffold|Placement of one or more MAGNITUDE® bioresorbable scaffolds using a percutaneous technique at one or more arterial stenoses.
48710994|NCT05411861|DRUG|Analgesic Non Narcotic|Injection of protocol-specified volume of local analgesic
48019926|NCT05286905|DEVICE|Osteosynthesis proximal femur locking plate|Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
48019927|NCT02621164|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
48377703|NCT02510131|BEHAVIORAL|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
48377704|NCT04864704|OTHER|dry needling|Physical therapy
48377705|NCT04667793|DRUG|Toripalimab + Chemotherapy|"Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel"
48377706|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
48377707|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
48377708|NCT02406066|DRUG|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone \& oxazepam) and 2 subjects will receive placebo.
48377709|NCT02406066|DRUG|Placebo|Each cohort will have 2 subjects receiving placebo
48377710|NCT01674010|DRUG|ELND005|
48377711|NCT01674010|DRUG|Lamotrigine|
48377712|NCT01674010|DRUG|Valproic acid|
48377713|NCT01674010|DRUG|Placebo|
48710995|NCT02125357|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
48517572|NCT05463640|BIOLOGICAL|ADGRE2 CAR-T|ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
48710996|NCT02125357|DRUG|Enzalutamide|160mg PO OD as per standard of care.
48710997|NCT04538274|BEHAVIORAL|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
48710998|NCT03417362|OTHER|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
48710999|NCT02456636|BEHAVIORAL|Fee-for-Service Model (FFS, In clinic individual visits)|To be performed by participant's doctor or other healthcare professional in their doctor's office.
48711000|NCT02456636|BEHAVIORAL|Patient Centered Medical Home (PCMH, In clinic group visits)|To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
48711001|NCT02456636|BEHAVIORAL|Disease Management (DM, Phone group visits)|To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
48711002|NCT01922063|BEHAVIORAL|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
48711003|NCT01922063|BEHAVIORAL|Sham neck massage|20x 30 minutes sessions of neck massage
48711004|NCT04376047|OTHER|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
48711005|NCT04376047|OTHER|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
48711006|NCT05751889|BEHAVIORAL|Serious Game|Serious Game embedded with healthcare information regarding HCV and safe sexual practice.
48711007|NCT05751889|BEHAVIORAL|Traditional Health Education|Reading materials regarding HCV and safe sexual practice.
48711008|NCT00832130|DEVICE|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
48711009|NCT00832130|DEVICE|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
48711010|NCT00088283|DRUG|pegaptanib sodium|
48711011|NCT05967546|OTHER|Observational|No interventions will be given to patients.
48177126|NCT03920098|OTHER|Nutrition and mental health during pregnancy|Altered metabolic milieu is defined as a fasting glucose level \>100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels \> 92 mg/dL and/or plasma glucose levels \> 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose \>100 mg/dL and/or \> 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
48517573|NCT00299130|DRUG|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
48711012|NCT05826730|OTHER|Eccentric Exercises|Eccentric Exercises for neck muscles.
48711013|NCT03264105|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
48711014|NCT03264105|OTHER|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
48711015|NCT02958202|DRUG|BMN 044 IV 6 mg/kg|
48711016|NCT02958202|DRUG|BMN 044 IV 9 mg/kg|
48711017|NCT02958202|DRUG|BMN 044 SC 6 mg/kg|
48711018|NCT06276582|DEVICE|Screening for neonatal jaundice with a mobile health device|Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
48711019|NCT00201591|BEHAVIORAL|Exercise training for 10 weeks|
48711020|NCT02838901|DRUG|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
48711021|NCT02838901|DRUG|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
48711022|NCT01556048|BEHAVIORAL|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
48019928|NCT02621164|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
48517574|NCT00299130|DRUG|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
48517575|NCT00299130|DRUG|Methylprednisolone|Intravenous infusion
48517576|NCT00299130|DRUG|Placebo|Placebo to rituximab intravenous infusion
48517577|NCT00299130|DRUG|Rituximab|Intravenous infusion
48711023|NCT04768959|BEHAVIORAL|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
48711024|NCT00664560|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
48711025|NCT00664560|DRUG|celebrex|200 mg celecoxib qd
48019929|NCT05874934|DEVICE|Intrahepatic biliary stent with retrieval string|Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
48019930|NCT06573567|DEVICE|Bioimpedance|Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
48019931|NCT06573567|DEVICE|Control|Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
48019932|NCT02418260|PROCEDURE|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
48177127|NCT00248534|BIOLOGICAL|rituximab|given IV days 1,8, 15 and 22
48177128|NCT00248534|DRUG|methylprednisolone|2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
48177129|NCT00248534|DRUG|temozolomide|Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
48177130|NCT01380288|DRUG|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
48177131|NCT02744170|DEVICE|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
48177132|NCT02744170|DEVICE|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
48177133|NCT02744170|DEVICE|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
48177134|NCT04847310|OTHER|Group brief transdiagnostic cognitive-behavioral therapy|An adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2015) and the IAPT programme (Clark, 2018). It has been developed by Cano-Vindel (González-Blanch et al., 2018) and consists in seven 90-minute sessions, provided by a non-assessor clinical psychologist in 12-16 weeks, with 8-10 participants per group. Sessions are weekly or biweekly, reducing their frequency as the intervention advances. The activities and homework proposed are supported with materials such as theory documents, a CD for progressive muscle relaxation, self-recording sheets, and a therapy web (www.desordenesemocionales.es).
48177135|NCT04847310|OTHER|Individual brief transdiagnostic cognitive-behavioral therapy|An adaption of the group therapy, with the same phases. However, since it is an individual intervention, it is more flexible than group one and its contents and duration can be personalized. This intervention consists of a minimum of 6 and a maximum of 8 sessions of 30-60 minutes, provided by a clinical psychologist not involved in the assessments.
48177136|NCT04847310|OTHER|Treatment as usual|Participants in this group will be provided the common primary care treatment by the GP, in a face-to-face consultation that seldom exceeds 10 minutes. TAU usually consists in pharmacological treatment prescribed by the GP, however, it might also consist in practical advice or even non-treatment (Watts et al., 2015). The first consultation will count as part of the recruitment process and, if the patient accepts to participate in the trial, no therapeutic help will be provided to them until they are allocated. Once in the TAU intervention, if the practitioner recommended any psychological treatment as part of it (e.g., referral to specialized care), the participant would be excluded to avoid contamination between clusters. TAU has not a specific amount of sessions; it will finish when the GP considers the patient is recovered.
48177137|NCT01936324|DRUG|Olumacostat Glasaretil Gel, 7.5%|Gel containing Olumacostat Glasaretil
48177138|NCT01936324|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
48177139|NCT01233999|DRUG|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
48177140|NCT05604807|OTHER|Dementia course with virtual reality|dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
48177141|NCT05604807|OTHER|Dementia course with no virtual reality|dementia course, intergenerational learning, world café teaching method and community practice
48177142|NCT06408363|BEHAVIORAL|Maneuver group|These maneuvers for Eustachian tube opening will be performed continuously during the compression phase of the hyperbaric chamber, every 30 minutes after reaching the desired pressurization level, and continuously during the decompression phase.
48177143|NCT05739539|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography angiography will be done postoperatively in both groups to assess the retinal microvascular changes
48177144|NCT05739539|DIAGNOSTIC_TEST|spectral domain optical coherence tomography|optical coherence tomography for ganglion cell complex (GCC) measurement and assessment of macular edema or epiretinal membrane formation will be done postoperatively in both groups
48177145|NCT02762305|OTHER|RSVP Bone Builders Group Exercise|
48177146|NCT00220909|DRUG|Lansoprazole|
48177147|NCT00663273|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
48711026|NCT00664560|DRUG|Placebo|sugar pill bid
48711027|NCT00664560|DRUG|Rescue Antacid|Antacid Tablets
48711028|NCT03351686|DRUG|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
48019933|NCT02418260|PROCEDURE|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
48019934|NCT02418260|PROCEDURE|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
48711029|NCT03846531|DEVICE|Nano-Pulse Stimulation (NPS)|The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
48019935|NCT00125554|DRUG|Metyrapone|
48019936|NCT04932265|DIETARY_SUPPLEMENT|HRG80™ Red Ginseng|Capsules containing red ginseng preparation HRG80 capsules, 200 mg - reference product
48019937|NCT04932265|COMBINATION_PRODUCT|HRG80™ Red Ginseng + gamma cyclodextrin|Chewable tablets containing red ginseng preparation HRG80 (100 mg) incorporated in gamma-cyclodextrin (GCD) - experimental modified product
48019938|NCT03766009|OTHER|Usual Care|Usual Care
48019939|NCT03766009|OTHER|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
48019940|NCT06364826|DRUG|Sintilimab, bevacizumab, gemcitabine|This is a prospective, single-center, single-arm, phase II clinical study. The study was intended to include patients with locoregionally advanced nasopharyngeal cancer identified by histology or cytology, who signed informed consent and met the screening criteria to enter the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
48517578|NCT05820126|BIOLOGICAL|Cold-stored platelet concentrate|Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for \>24 hours at 1-6˚C
48019941|NCT06364826|RADIATION|IMRT|IMRT
48019942|NCT01033747|DRUG|Deferasirox|10 mg/kg or 30 mg/kg orally daily
48019943|NCT01033747|DRUG|Deferasirox|5 mg/kg or 30 mg/kg orally daily
48019944|NCT05320653|DIETARY_SUPPLEMENT|Medical nutrition|Nutrition therapy of the critically ill patients
48377714|NCT01967810|DRUG|ANG1005|ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
48517579|NCT00006038|DRUG|cisplatin|
48517580|NCT00006038|DRUG|docetaxel|
48517581|NCT00006038|DRUG|floxuridine|
48517582|NCT00006038|DRUG|fluorouracil|
48517583|NCT00006038|DRUG|leucovorin calcium|
48517584|NCT00006038|PROCEDURE|conventional surgery|
48517585|NCT02258763|DRUG|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
48517586|NCT02258763|DRUG|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
48517587|NCT01654315|DEVICE|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
48517588|NCT01654315|BEHAVIORAL|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
48517589|NCT01957397|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
48517590|NCT01957397|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
48517591|NCT01957397|DEVICE|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
48517592|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
48711030|NCT00042432|DRUG|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
48711031|NCT05835232|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
48711032|NCT03144193|OTHER|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
48711033|NCT02084680|BEHAVIORAL|community health workers|community health workers offering individual prenatal education to pregnant women
48711034|NCT03694392|BIOLOGICAL|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
48019945|NCT06533709|DIAGNOSTIC_TEST|Radio-score|A score based on the LASSO regression model predicting the R0 resection of the primary debulking surgery of advanced ovarian cancer.
48517593|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
48019946|NCT02940470|OTHER|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
48019947|NCT02940470|OTHER|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
48517594|NCT06241625|DIAGNOSTIC_TEST|Virtual Reality (VR) Contrast Function Test|Patients perform a new Virtual Reality (VR) Contrast Function Test
48177148|NCT03061604|DEVICE|Hemospray|Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
48711035|NCT03694392|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
48177149|NCT03061604|DRUG|Octreotide|"Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour"
48711036|NCT03180437|PROCEDURE|IRE surgery|IRE surgery will be used in local tumor
48711037|NCT03180437|BIOLOGICAL|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
48711038|NCT00552630|DEVICE|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
48711039|NCT00552630|DRUG|placebo|placebo with same characteristics as drug
48711040|NCT02533765|DRUG|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
48711041|NCT06489704|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
48711042|NCT00041171|DRUG|Hypericum perforatum|
48711043|NCT00041171|DRUG|docetaxel|
48711044|NCT00041171|OTHER|placebo|
48711045|NCT01070563|OTHER|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
48711046|NCT04463628|BEHAVIORAL|Questionnaire|"The study questionnaire was constructed as follows:~* One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.~* The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown"
48019948|NCT05100862|DRUG|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
48019949|NCT05100862|DRUG|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
48177150|NCT03061604|BIOLOGICAL|Blood transfusion|Blood transfusion will be administered to all patients if needed
48177151|NCT03061604|DRUG|Ceftriaxone|Ceftriaxone will be administered to all patients on daily basis
48177152|NCT03667937|COMBINATION_PRODUCT|CUTIMED|Hydrophobic Dressing
48177153|NCT03667937|OTHER|AQUACEL silver|Silver Dressing
48711047|NCT04463628|BEHAVIORAL|Interview|Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.
48711048|NCT05639101|OTHER|Clinical Decission support system management & mobile App Intervention Group|"The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms."
48711049|NCT01655043|DRUG|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
48711050|NCT01655043|DRUG|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
48711051|NCT01937793|OTHER|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
48711052|NCT01937793|OTHER|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
48711053|NCT03627312|COMBINATION_PRODUCT|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
48711054|NCT03627312|COMBINATION_PRODUCT|Placebo|Fruit juice drink only
48177154|NCT02828345|OTHER|Specimen Collection|
48711055|NCT03627312|OTHER|Treatment as Usual|Young Offenders Intervention Programme
48711056|NCT00827281|DRUG|D-cycloserine|Single dosage prior to sessions 3, 4 \& 5
48711057|NCT00827281|DRUG|Placebo|Single dosage prior to sessions 3, 4 \& 5
48711058|NCT03145792|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
48711059|NCT03145792|BEHAVIORAL|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
48019950|NCT05100862|DRUG|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
48019951|NCT05100862|DRUG|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
48377715|NCT01967810|DRUG|Bevacizumab|For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
48377716|NCT05629260|DRUG|ATG|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT, with G-CSF/ATG based protocol.
48019952|NCT01714024|DEVICE|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
48177155|NCT01777126|OTHER|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
48517595|NCT02371434|BIOLOGICAL|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.
48711060|NCT05139199|BEHAVIORAL|Auricular Point Acupressure group|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
48711061|NCT02241330|DIETARY_SUPPLEMENT|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
48711062|NCT02241330|DIETARY_SUPPLEMENT|Fortification|Wheat flour is fortified before testmeal preparation
48711063|NCT02241330|DIETARY_SUPPLEMENT|Control|wheat flour is used as control comparator.
48711064|NCT05901363|PROCEDURE|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
48711065|NCT05901363|PROCEDURE|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
48711066|NCT03397888|DRUG|Betrixaban|80 mg capsule
48711067|NCT06066905|DRUG|chidamide and azacitidine|"chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally."
48711068|NCT01710943|BEHAVIORAL|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
48711069|NCT03153072|BIOLOGICAL|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
48711070|NCT02170363|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
48711071|NCT02153346|OTHER|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
48711072|NCT02153346|OTHER|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
48711073|NCT00777530|DRUG|Bosutinib (SKI-606)|
48711074|NCT02793830|OTHER|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
48711075|NCT02793830|OTHER|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
48019953|NCT01714024|DEVICE|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
48019954|NCT06152211|BEHAVIORAL|Choir|A choir for older adults is a musical/singing ensemble composed of individuals aged 65 and above. The choir rehearsals are weekly, 2 hours each and the length of the intervention is 16 weeks total.
48019955|NCT06152211|BEHAVIORAL|Group Music Listening|A weekly collective music listening, 2 hours each for 16 weeks.
48019956|NCT04260581|DRUG|Determination of drug effects through amantadine cessation|Patients will discontinue amantadine, which has been taken since beginning of diagnosis.
48019957|NCT03105843|DRUG|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
48019958|NCT03105843|DIAGNOSTIC_TEST|Eucapneic Voluntary Hyperventilation (EVH)|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
48711076|NCT05640206|PROCEDURE|i-PRF|Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly
48711077|NCT05640206|PROCEDURE|Arthrocentesis|Arthrocentesis performed with two-needle technique
48711078|NCT00535158|DRUG|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
48711079|NCT04889768|DRUG|HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
48711080|NCT04424992|OTHER|Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.|Describe the natural history and clinical evolution of hospitalized patients over time affected by SARS-COV-2 infection, understand the pathogenesis of the disease and improve the aids and therapeutic procedures.
48711081|NCT02794987|DEVICE|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
48711082|NCT00182767|DRUG|ixabepilone|Given IV
48711083|NCT00182767|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
48711084|NCT01810068|PROCEDURE|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
48711085|NCT01810068|PROCEDURE|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
48711086|NCT01810068|PROCEDURE|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
48711087|NCT01810068|PROCEDURE|Diagnostic cystoscopy|Cysto-urethroscopy
48711088|NCT04297189|BEHAVIORAL|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
48711089|NCT03742999|PROCEDURE|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
48711090|NCT03742999|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
48711091|NCT03742999|COMBINATION_PRODUCT|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
48711092|NCT04918953|DRUG|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
48711093|NCT04918953|DRUG|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
48377717|NCT05629260|DRUG|Post-transplantation cyclophosphamide|Patients with intermediate-high risk hematologic malignancy who are indicated for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and absence of HLA matched donors will be treated with haplo-HSCT with PT-Cy based protocol.
48711094|NCT02956850|OTHER|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
48711095|NCT02956850|DRUG|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
48711096|NCT00739180|OTHER|Control|Standard care control (no exercise)
48711097|NCT00739180|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
48517596|NCT04167111|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D
48517597|NCT05743010|DRUG|APL-1401|APL-1401 capsules orally once daily
48517598|NCT05743010|DRUG|Placebo|Placebo capsules orally once daily
48517599|NCT00067743|DRUG|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
48711098|NCT00739180|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
48019959|NCT03105843|DRUG|Mannitol Inhalation Kit|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
48377718|NCT01920269|PROCEDURE|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
48377719|NCT01920269|DRUG|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
48517600|NCT05652595|DRUG|GP40141|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
48517601|NCT05652595|DRUG|Nplate|Once, at a dose of 3 mcg/kg, Subcutaneously in the shoulder area
48711099|NCT00468676|BEHAVIORAL|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
48711100|NCT00468676|BEHAVIORAL|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
48711101|NCT01371643|DRUG|Octreotide LAR|
48711102|NCT01371643|PROCEDURE|transsphenoidal surgery|
48711103|NCT05145855|OTHER|Patient-tailored multimodal neglect rehabilitation|Patient-tailored neglect rehabilitation program which comprises 30-45 minutes of sessions, five times per week includes a combination of reading, copying, and representational drawing tasks with visual or verbal cueing, visual scanning, mirror therapy, and allocation of attention to the neglected side using multimodal stimulus in daily activities.
48711104|NCT05019612|PROCEDURE|Laparoscopy: A minimal invasive surgery|A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
48711105|NCT00828399|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine 30g/day
48711106|NCT00828399|DIETARY_SUPPLEMENT|Whole protein|Oral whole protein 30 g/day
48711107|NCT01663428|OTHER|Sup-ER Splint|
48019960|NCT00315094|BEHAVIORAL|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
48019961|NCT04295941|DRUG|TraZODone Hydrochloride 300 MG|Oral administration of Trazodone once-a-day.
48019962|NCT01788540|DRUG|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
48019963|NCT02720484|OTHER|Laboratory Biomarker Analysis|Correlative studies
48019964|NCT02720484|DRUG|Nivolumab|Given IV
48019965|NCT02127008|PROCEDURE|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
48019966|NCT02127008|PROCEDURE|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
48711108|NCT01663428|OTHER|Currently accepted treatment|
48711109|NCT03008902|PROCEDURE|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
48711110|NCT01994772|PROCEDURE|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
48711111|NCT01994772|PROCEDURE|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
48711112|NCT01173029|DRUG|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
48377720|NCT01920269|DEVICE|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
48377721|NCT04156438|DEVICE|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
48711113|NCT04143165|DRUG|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
48711114|NCT02969590|DRUG|Leuprolide acetate|Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
48711115|NCT02969590|DRUG|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
48711116|NCT02969590|DRUG|Progestin|Synthetic progestin to assess effects on cervical mucus.
48711117|NCT00953680|DRUG|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
48711118|NCT00953680|DRUG|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
48711119|NCT00953680|DRUG|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
48711120|NCT04972227|DRUG|CY6463|oral tablets
48711121|NCT04972227|DRUG|Placebo|oral tablets
48711122|NCT05923736|OTHER|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
48711123|NCT05923736|OTHER|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
48711124|NCT05923736|OTHER|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
48711125|NCT05923736|OTHER|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
48377722|NCT04156438|DEVICE|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
48177156|NCT01777126|OTHER|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
48377723|NCT02787148|BEHAVIORAL|Cognitive behavioral therapy|
48377724|NCT01460979|DRUG|Temsirolimus|25mg weekly intravenous until progression
48377725|NCT05649709|DRUG|L-VA dual therapy|1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
48377726|NCT05649709|DRUG|H-VA dual therapy|1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
48377727|NCT06127862|OTHER|Education group|Students in the experimental group were educated about environmental health and microplastica, and nursing interventions were made. The training was organized for twenty minutes in each session, with a total of four sessions at two-week intervals.
48711126|NCT02709187|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
48377728|NCT06127862|OTHER|No training was given|No training was given
48377729|NCT01985776|PROCEDURE|Exercise intervention|Functional stabilisation exercise for the trunk.
48177157|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
48177158|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
48177159|NCT01008163|DRUG|YY-351|comparison of different dosages of drug
48177160|NCT01008163|DRUG|Placebo|comparison of different dosages of drug
48177161|NCT00521859|DRUG|Cloretazine|800 mg/m\^2 by vein daily
48177162|NCT00521859|DRUG|Fludarabine|25 mg/m\^2 by vein daily x 5 Days
48177163|NCT00927524|DRUG|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
48177164|NCT00927524|DRUG|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
48177165|NCT02830048|DRUG|Glibenclamide|
48177166|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR and i-PRF|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
48177167|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
48177168|NCT00322686|DRUG|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
48177169|NCT00322686|DRUG|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
48177170|NCT04608136|BEHAVIORAL|Diet intervention|Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
48377730|NCT01985776|PROCEDURE|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
48377731|NCT03528265|DEVICE|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
48711127|NCT02709187|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
48711128|NCT02709187|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
48711129|NCT05393414|DRUG|Opioid based protocol|Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
48377732|NCT02989701|DRUG|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
48377733|NCT04851509|PROCEDURE|Dynamic Rotational Locking|Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.
48019967|NCT05801978|BIOLOGICAL|Live Attenuated Yellow Fever 17D Vaccine|The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial. The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative. Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
48177171|NCT00719043|BIOLOGICAL|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
48177172|NCT00719043|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
48177173|NCT00719043|BIOLOGICAL|Placebo|Administered as an intramuscular (IM) injection
48177174|NCT04522206|DRUG|Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone|"The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release"
48177175|NCT06546228|OTHER|No intervention. Only observational.|Only collection of data or parameters already required by the medical examination programmed.
48177176|NCT01540604|DRUG|CRD007|
48177177|NCT05471804|DIETARY_SUPPLEMENT|Sceletium tortuosum|Zembrin® is a proprietary low-alkaloid extract of Sceletium tortuosum, often consumed by healthy humans in order to decrease anxiety and stress and improve cognitive function under stressful situations
48377734|NCT04851509|PROCEDURE|Static Locking|Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.
48377735|NCT04061837|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
48711130|NCT05393414|DRUG|Opioid sparing protocol|Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
48377736|NCT01692990|DIETARY_SUPPLEMENT|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
48377737|NCT02442739|DRUG|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
48177178|NCT06397547|OTHER|Flipped Learning|Materials for students' pre-class studies and for use by the instructor during class will be created by the researchers. For students in the experimental group to come prepared for class according to the flipped learning model, digital materials will be prepared by the researchers. The experimental group will receive digital materials prior to the topic. The links to these materials will be sent to the students, who can access them via their mobile phones and watch the explanatory and demonstration videos as many times as they wish. Subsequently, the topic will be presented to the students. They will summarize the information learned from the videos and engage in question-answer sessions and discussions using prepared digital resources to address any points they do not understand. To reinforce the practices in the experimental group, online word clouds and quizzes will be sent.
48177179|NCT03616964|DRUG|Baricitinib|Administered orally.
48177180|NCT03616964|DRUG|Placebo|Administered orally
48177181|NCT06262178|BEHAVIORAL|Parenting-STAIR|10-15 week Parenting-STAIR
48377738|NCT02442739|OTHER|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
48377739|NCT04946669|DRUG|Abatacept|Abatacept is a CTLA-4 fusion protein that inhibits T cell activation by competitively binding to CD80/CD86 and blocking the second signal. To date, Abatacept has been approved by the FDA for the treatment of three types of rheumatoid immune diseases (refractory rheumatoid arthritis, juvenile idiopathic arthritis, and active psoriatic arthritis). The international consensus of experts recommends abacepil as a second-line regimen for the treatment of refractory dermatomyositis based on the evidence of case reports. However, to date, there is no relevant report or clinical study registration information of Abatacept in the treatment of dermatomyositis.
48377740|NCT00307775|DRUG|oestradiol|
48177182|NCT06262178|BEHAVIORAL|Treatment as Usual|Will include either Prolonged Exposure or Cognitive Processing Therapy
48177183|NCT01241006|DRUG|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
48177184|NCT01241006|DRUG|Prednisone|Prednisone 60mg PO q day for 5 days
48177185|NCT03913169|OTHER|Educational Implementation of Interprofessional Curriculum|The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
48177186|NCT05328310|DRUG|Nebivolol|Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
48377741|NCT03454191|PROCEDURE|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
48377742|NCT03454191|PROCEDURE|No injection|No injection
48377743|NCT06060912|DEVICE|Left Atrial Appendage Occlusion|Left Atrial Appendage Occlusion will be performed according to current international standards by experienced operators under TOE and angiographic guidance. Either a LAmbre occlusion device (group A) or an AMPLATZER Amulet occlusion device (group B) will be implanted depending on treatment allocation.
48377744|NCT03896802|PROCEDURE|Physiological assesment|"1. Arterial and mixed venous blood gas analysis.~2. Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~3. Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~4. Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~5. Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
48711131|NCT01560052|DRUG|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
48377745|NCT04017065|DEVICE|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
48517602|NCT06387134|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.
48517603|NCT06387134|DRUG|Conventional treatment with Western medicine|"Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021."
48517604|NCT02234102|DEVICE|Endoscopically guided laser ablation HeartLight system|
48517605|NCT00711035|BIOLOGICAL|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
48517606|NCT03638388|PROCEDURE|Dry needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
48177187|NCT04255745|BEHAVIORAL|progressive resistance training|Individual, tailored, progressive muscle strength and function intervention
48177188|NCT01636908|DRUG|Sunitinib|50 mg once daily, oral use, 14 days
48177189|NCT01636908|DRUG|Sorafenib|400 mg, twice daily, oral use, 14 days
48177190|NCT01636908|DRUG|Erlotinib|150 mg once daily, oral use, 14 days
48177191|NCT01636908|DRUG|Everolimus|10 mg once daily, oral use, 14 days
48177192|NCT01636908|DRUG|Lapatinib|1250 mg once daily, oral use, 14 days
48177193|NCT01636908|DRUG|Dasatinib|100 mg once daily, oral use, 14 days
48177194|NCT01636908|DRUG|Pazopanib|800 mg once daily, oral use, 14 days
48177195|NCT01636908|DRUG|Vemurafenib|960 mg twice daily, oral use, 15-21 days
48177196|NCT01636908|PROCEDURE|tumor biopsy|
48177197|NCT01636908|PROCEDURE|skin biopsy (optional)|
48177198|NCT00950196|DRUG|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
48019968|NCT05801978|BIOLOGICAL|Quadrivalent seasonal influenza vaccine|The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses. The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
48711132|NCT01560052|DRUG|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
48711133|NCT00792025|DRUG|sunitinib malate|
48019969|NCT05174975|BEHAVIORAL|App-based Positive Psychological Intervention|The PPI has included a 12-week PPI lessons. Each lesson has separated into 3 parts: introduction, activity, and feedback. Diabetes-related health education will include the basic knowledge of diabetes, diet, and exercise related videos. Physical records include record of daily blood sugar, blood pressure, HbA1c, diet, and exercise. In terms of dietary records, the amount of carbohydrates of each food will be calculate automatically after documented. Exercise records documents the burn of calories of each exercise (per 30 minutes). Both unit of dietary and exercise are based on Health Promotion Administration's criteria in Taiwan. Moreover, participants are available to have one-on-one instant online consultation with their diabetes educators via App.
48177199|NCT03893110|PROCEDURE|surgical stabilization of the spine due to primary and secondary spinal tumors|Posterior instrumentation with pedicle screw system
48177200|NCT00025909|PROCEDURE|Leukapheresis|
48377746|NCT04485871|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Triple Strength Omega-3 from Webber Naturals; 4 oral softgels (600 mg EPA and 300 mg DHA / softgel)
48377747|NCT03081130|PROCEDURE|Intravenous laser irradiation treatment|control group
48377748|NCT05628818|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Real anodal tDCS over the left dorsolateral prefrontal cortex in acute stroke patients to improve dysexecutive syndrome. Intensity: 2 mA. Stimulation period: 20 minutes.
48377749|NCT05628818|DEVICE|Sham Transcranial Direct current Stimulation|Sham anodal tDCS over the left dorsolateral prefrontal cortex: anodal tDCS. Intensity: 2 mA. Stimulation period: 1 minute. Afterwards, the device will automatically shut down but the sham stimulation period will last a total of 20 minutes.
48377750|NCT00636857|PROCEDURE|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
48711134|NCT03770728|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48711135|NCT03770728|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
48019970|NCT02230657|PROCEDURE|Same day discharge|
48711136|NCT03770728|DRUG|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
48711137|NCT02743780|DRUG|MGV354 ophthalmic suspension|
48019971|NCT02230657|PROCEDURE|Next day discharge|
48019972|NCT04401124|OTHER|no intervention|no intervention
48019973|NCT06202261|DRUG|TQB2930 for injection|TQB2930 for injection is a HER2 bispecific antibody.
48177201|NCT05889845|DRUG|Candin, Intradermal Solution|Injection at the base of the selected wart
48177202|NCT05889845|DRUG|Placebo|Injection at the base of the selected wart
48711138|NCT02743780|DRUG|MGV354 placebo|Inactive ingredients used as placebo comparator
48711139|NCT04449393|DEVICE|Emdogain® FL|Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
48711140|NCT04449393|OTHER|Scaling and root planing|Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
48019974|NCT06202261|DRUG|Paclitaxel for injection (albumin-bound)|It is an anti-microtubule chemotherapy drug
48019975|NCT06202261|DRUG|TQB3616 capsule|TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
48019976|NCT06202261|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
48377751|NCT00636857|PROCEDURE|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
48177203|NCT04230668|BEHAVIORAL|Cognitive Processing Therapy with Suicide Risk Management|CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
48377752|NCT01340794|OTHER|Laboratory Biomarker Analysis|Correlative studies
48377753|NCT01340794|DRUG|Pazopanib Hydrochloride|Given PO
48377754|NCT00003758|DRUG|cytarabine|
48377755|NCT00003758|DRUG|idarubicin|
48377756|NCT00003758|PROCEDURE|allogeneic bone marrow transplantation|
48377757|NCT00003758|PROCEDURE|autologous bone marrow transplantation|
48377758|NCT00003758|PROCEDURE|peripheral blood stem cell transplantation|
48377759|NCT05931601|DRUG|Noradrenaline|See arm description
48377760|NCT04847427|OTHER|Core exercises training|"Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM"
48377761|NCT04847427|OTHER|Structural exercises training|"Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
48377762|NCT04847427|OTHER|Accentuated eccentric exercises training|"Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Bulgarian squat jumps, 4 sets of 5 repetitions at 30% BM"
48377763|NCT04847427|OTHER|Control trial|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
48377764|NCT05101473|OTHER|Exercise Therapy|The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
48377765|NCT03740035|DEVICE|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
48711141|NCT02671539|GENETIC|rAAV2.REP1|single subretinal injection
48377766|NCT01077791|BEHAVIORAL|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
48377767|NCT03597126|DEVICE|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1\&2)
48377768|NCT03597126|DEVICE|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1\&2)
48517607|NCT03638388|PROCEDURE|Dry needling with intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
48517608|NCT01625091|DRUG|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
48019977|NCT06202261|DRUG|Capecitabine tablets|Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.
48517609|NCT01625091|DRUG|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
48517610|NCT02940496|DRUG|Elbasvir/Grazoprevir|Given PO
48019978|NCT06202261|DRUG|Vinorelbine tartrate injection|Vinorelbine is an anti-tumor drug of vinca alkaloids.
48019979|NCT06202261|DRUG|Eribulin mesylate injection|Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
48019980|NCT06202261|DRUG|gemcitabine hydrochloride for injection|Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
48019981|NCT05754086|BEHAVIORAL|Clear Speech|"This behavioral modification asks participants to speak more clearly, as if they were speaking to someone with a hearing loss."
48019982|NCT05754086|BEHAVIORAL|Less Clear Speech|"This behavioral modification asks participants to speak less clearly, as if they were in a room with many people and they were mumbling something to the person next to them that they didn't want other people in the room to hear."
48019983|NCT04424368|DEVICE|The remote monitoring system|Usage of remote monitoring system
48019984|NCT03394924|DRUG|EDP-305 1 mg|Two tablets daily for 12 weeks
48019985|NCT03394924|DRUG|EDP-305 2.5 mg|Two tablets daily for 12 weeks
48019986|NCT03394924|DRUG|Placebo|Two tablets daily for 12 weeks
48019987|NCT06396728|DIETARY_SUPPLEMENT|GI BIOTICS 100B UFC|Consumption of GI BIOTICS 100B UFC.
48019988|NCT06396728|DIETARY_SUPPLEMENT|Placebo Consumption|Consumption of a placebo capsule.
48711142|NCT02650128|DEVICE|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
48711143|NCT01158144|DRUG|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
48177204|NCT04230668|BEHAVIORAL|Treatment as Usual with Suicide Rick Management|In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
48711144|NCT01158144|DRUG|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
48711145|NCT00787930|DRUG|Valproic Acid|Tablets, 250mg-3000mg
48711146|NCT04393467|DEVICE|tSMS|tSMS delivered on bilateral motor cortex
48711147|NCT04393467|DEVICE|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
48711148|NCT05878756|OTHER|Functional Strength Training|In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
48711149|NCT01552785|DEVICE|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
48019989|NCT02791048|BEHAVIORAL|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
48019990|NCT04079933|OTHER|Oral tobacco-derived nicotine product (OTDN)|
48177205|NCT00805597|RADIATION|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
48177206|NCT00805597|RADIATION|no radiation|no radiotherapy
48177207|NCT02930252|DEVICE|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
48177208|NCT02930252|DEVICE|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
48711150|NCT02926092|DIAGNOSTIC_TEST|Observation|Observation of progression of disease over time
48177209|NCT01510353|DEVICE|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
48177210|NCT01045863|DRUG|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
48387998|NCT06322355|DIAGNOSTIC_TEST|Coronary angiography, Fractional Flow Reserve measurement, Intravascular ultrasound|Invasive CAG was conducted following standard clinical procedures, encompassing multiple projections of both the left and right coronary arteries. The FFR was precisely measured using either an intracoronary pressure wire (Pressure Wire X; Abbott Vascular, Santa Clara, USA) or a rapid-exchange pressure microcatheter (Insight Lifetech, Shanghai, China) during peak hyperemia. This state of maximal hyperemia was achieved through the intravenous infusion of adenosine triphosphate (ATP) at a concentration of 150 μg/kg/min, administered via the forearm vein. Upon completion of the FFR assessment, the pressure wire or microcatheter was carefully retracted to the tip of the guiding catheter for a routine drift check. IVUS imaging was meticulously conducted using the iLab™ IVUS system, coupled with a 40-MHz OptiCross IVUS catheter (Boston Scientific, Fremont, USA), at a steady pullback speed of 0.5 mm/s.
48177211|NCT01045863|DRUG|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
48517611|NCT02940496|OTHER|Laboratory Biomarker Analysis|Correlative studies
48517612|NCT02940496|BIOLOGICAL|Pembrolizumab|Given IV
48177212|NCT01045863|DRUG|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
48177213|NCT01045863|DRUG|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
48177214|NCT01045863|DRUG|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
48711151|NCT04103541|BEHAVIORAL|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
48377769|NCT03933709|DIETARY_SUPPLEMENT|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
48711152|NCT02891681|DEVICE|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
48711153|NCT05280327|OTHER|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
48711154|NCT00034164|DRUG|S-8184 Paclitaxel Injectable Emulsion|
48711155|NCT01218100|DRUG|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
48711156|NCT01218100|DRUG|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
48711157|NCT01218100|DRUG|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
48019991|NCT02259530|BEHAVIORAL|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
48019992|NCT01905982|PROCEDURE|reflectory breathing therapy|duration:2x60 minutes
48019993|NCT01905982|PROCEDURE|conventional breathing therapy|duration:4x30 minutes
48019994|NCT00099476|BEHAVIORAL|Effects of dark chocolate|
48019995|NCT02879461|PROCEDURE|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
48019996|NCT00557115|OTHER|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
48019997|NCT06570018|PROCEDURE|Post operative enhanced recovery elements|According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
48019998|NCT02710526|DRUG|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
48377770|NCT03933709|OTHER|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
48377771|NCT03933709|OTHER|recommended diet|WHO Diet
48517613|NCT02940496|DRUG|Ribavirin|Given PO
48711158|NCT01218100|DRUG|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
48711159|NCT02594800|DRUG|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
48711160|NCT03481803|DRUG|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
48711161|NCT00123097|COMBINATION_PRODUCT|Chlorinated polyethylene elastomer|Chlorinated polyethylene
48711162|NCT06385093|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
48711163|NCT06385093|DRUG|Alfacalcidol tablets|Oral Alfacalcidol 0.5μg daily
48711164|NCT06385093|DRUG|Calcium carbonate tablets|1.5g Calcium carbonate daily
48711165|NCT05973786|DRUG|Escitalopram|ATC code: N06AB10
48019999|NCT02002767|DRUG|Velpatasvir|Velpatasvir 100 mg (2 x 50 mg tablets) administered orally
48020000|NCT00000153|PROCEDURE|Blue-Green Argon Laser Treatment|
48020001|NCT00000153|PROCEDURE|Red Krypton Laser Treatment|
48020002|NCT06026566|DRUG|Dos of Afentanil 20|the dosage of Afentanil is 20 ng/ml for TCI
48711166|NCT05973786|DRUG|Sertraline|See arm description
48711167|NCT05973786|DRUG|Venlafaxine|See arm description
48711168|NCT05973786|DRUG|Lithium|See arm description
48711169|NCT05973786|DRUG|Valproate acid|See arm description
48711170|NCT05973786|DRUG|Quetiapine|See arm description
48711171|NCT00232388|PROCEDURE|Blood draw|
48177215|NCT04741737|PROCEDURE|reSLNB arm|Radioisotope, blue dye, dual mapping methods are all allowed for re-SLNB mapping. Positive finding in re-SLNB is defined according to AJCC 8th edition, as micrometastasis or macrometastasis. Isolated tumor cell is considered negative. When sentinel lymph node is not identified, axillary operation is via physician's choice. When re-SLNB finding is negative, no further axillary lymph node dissection is performed. If there is node metastasis from re-SLNB, axillary lymph node dissection or radiation therapy can be performed as in physician's choice.
48177216|NCT04008056|OTHER|Patient Reported Outcome questionnaire|34 question form to assess patient symptoms
48177217|NCT06190288|OTHER|Transitional care model|A newly developed care model to support frail older adults during their transition from hospital to home.
48711172|NCT04023357|OTHER|PEEK|New polyetheretherketones material
48711173|NCT04023357|OTHER|Emax|standard etchable glass ceramic used for Endocrowns
48711174|NCT04393688|COMBINATION_PRODUCT|Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter|"Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
48711175|NCT05870917|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
48711176|NCT05877040|DRUG|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
48711177|NCT02671149|DIETARY_SUPPLEMENT|Water|Participants will receive two cups of 150ml plain water
48711178|NCT05637489|BEHAVIORAL|PING|Brief survey of goals and preferences
48711179|NCT02141490|DRUG|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
48711180|NCT02141490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
48711181|NCT00462735|DRUG|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
48711182|NCT00462735|DRUG|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
48177218|NCT01536197|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
48177219|NCT01536197|PROCEDURE|Gastric banding|Laparoscopic adjustable gastric banding
48177220|NCT01536197|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy surgery
48177221|NCT03581669|DEVICE|Cerclage and total hip arthroplasty|acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
48711183|NCT00462735|DRUG|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
48711184|NCT00462735|PROCEDURE|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
48711185|NCT01982006|PROCEDURE|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
48177222|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
48177223|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
48177224|NCT04031573|DRUG|Placebo|Placebo will be administered via the enteral route, every 12 hours.
48177225|NCT00554645|BEHAVIORAL|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
48177226|NCT00554645|OTHER|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
48177227|NCT02288364|DRUG|1% Lidocaine|
48177228|NCT02288364|DRUG|1% Lidocaine plus sodium bicarbonate|
48177229|NCT05837299|DRUG|IMC008|allowing 10% dose error
48177230|NCT01280604|DRUG|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
48177231|NCT02670499|DEVICE|CPM|Used to aid in recovery from TKR
48177232|NCT02670499|DEVICE|GAPFLEX|Used to aid in the recovery of TKR
48177233|NCT02425241|BIOLOGICAL|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
48177234|NCT02425241|BIOLOGICAL|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.
48177235|NCT02425241|BIOLOGICAL|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10\^8 pfu at week 20
48177236|NCT02425241|DRUG|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
48177237|NCT02425241|OTHER|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
48177238|NCT03893006|DEVICE|Level of vehicle automation|From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
48177239|NCT02471482|OTHER|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
48177240|NCT03414047|DRUG|Prexasertib|Administered IV
48177241|NCT00523068|DRUG|Tolterodine|
48177242|NCT00523068|PROCEDURE|tension free vaginal tape|
48377772|NCT06516289|DRUG|HRS-1167|a highly selective PARP1 inhibitor
48711186|NCT01982006|DEVICE|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
48711187|NCT04790825|PROCEDURE|Full mouth scaling and root planing (FMSRP)|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
48711188|NCT04794647|OTHER|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
48020003|NCT06026566|DRUG|Dos of Afentanil 30|the dosage of Afentanil is 30 ng/ml for TCI
48020004|NCT06026566|DRUG|Dos of Afentanil 40|the dosage of Afentanil is 40 ng/ml for TCI
48020005|NCT06026566|DRUG|Dos of Afentanil 50|the dosage of Afentanil is 50 ng/ml for TCI
48177243|NCT01838486|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
48177244|NCT04188756|OTHER|Exercise|High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
48177245|NCT03613324|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
48377773|NCT06516289|DRUG|Famitinib|a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
48377774|NCT06516289|DRUG|Camrelizumab|a humanised anti-programmed death-1 (anti PD-1) antibody
48377775|NCT02048059|DRUG|ANG1005|
48377776|NCT01734109|DEVICE|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
48711189|NCT04794647|OTHER|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
48711190|NCT01236092|OTHER|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
48711191|NCT03430505|DEVICE|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
48711192|NCT03430505|DRUG|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
48711193|NCT01312389|BIOLOGICAL|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
48177246|NCT05293197|DEVICE|SonoCloud® (9 transducers)|SonoCloud®, sonication: dose escalation 6 cycles of sonication
48177247|NCT06282640|DRUG|Vitamin D|Vitamin D replacement therapy was administered at 50,000 IU weekly for 8 weeks.
48020006|NCT06026566|DRUG|Dos of Afentanil 60|the dosage of Afentanil is 60 ng/ml for TCI
48020007|NCT06026566|DRUG|Dos of Afentanil 70|the dosage of Afentanil is 70 ng/ml for TCI
48177248|NCT02878369|PROCEDURE|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
48177249|NCT05760911|BEHAVIORAL|Outdoor activities motivation with smartwatches|Wearing a smartwatch and receiving outdoor activity reminders and encouragement through a mini-program. The required outdoor time is at least 2 hours from Monday to Friday, and more than 2 hours on weekends.
48377777|NCT03521674|DEVICE|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
48377778|NCT02854202|OTHER|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
48377779|NCT02854202|OTHER|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
48377780|NCT02854202|OTHER|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
48377781|NCT05880069|OTHER|Pathogen resistant phenotype|Drug resistant phenotype of the target pathogen under study
48377782|NCT00937430|OTHER|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
48020008|NCT06026566|DRUG|Dos of Afentanil 80|the dosage of Afentanil is 80 ng/ml for TCI
48020009|NCT06026566|DRUG|Dos of Afentanil 90|the dosage of Afentanil is 90 ng/ml for TCI
48020010|NCT06026566|DRUG|Dos of Afentanil 100|the dosage of Afentanil is 100 ng/ml for TCI
48377783|NCT01070225|DRUG|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
48377784|NCT05993299|DRUG|Letetresgene autoleucel|Letetresgene autoleucel will be administered.
48377785|NCT05993299|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
48377786|NCT05993299|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
48387999|NCT02610842|OTHER|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
48388000|NCT04109768|BEHAVIORAL|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
48711194|NCT01312389|BIOLOGICAL|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
48711195|NCT01312389|BIOLOGICAL|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
48711196|NCT02917213|OTHER|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
48020011|NCT02476565|DEVICE|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
48020012|NCT02476565|DEVICE|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
48020013|NCT04679129|DRUG|ASC42|Oral tablets
48020014|NCT04679129|DRUG|Placebo|Oral tablets
48020015|NCT02486406|DRUG|Ombitasvir/paritaprevir/ritonavir|Film-coated tablet for oral use
48020016|NCT02486406|DRUG|Dasabuvir|Film-coated tablet for oral use
48020017|NCT02486406|DRUG|Ribavirin|Film-coated tablet for oral use
48020018|NCT02486406|DRUG|Ombitasvir mini tablet|Film-coated tablet for oral use
48020019|NCT02486406|DRUG|Paritaprevir mini tablet|Film-coated tablet for oral use
48020020|NCT02486406|DRUG|Ritonavir mini tablet|Film-coated tablet for oral use
48020021|NCT02486406|DRUG|Dasabuvir mini tablet|Film-coated tablet for oral use
48020022|NCT02486406|DRUG|Ribavirin solution|Oral solution
48020023|NCT00358267|PROCEDURE|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
48020024|NCT00358267|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
48020025|NCT02974361|DRUG|Ibuprofen|
48020026|NCT02974361|DRUG|Ibuprofen Lysine|
48020027|NCT02974361|DRUG|Ibuprofen-LDH|
48020028|NCT06142201|DRUG|JT001|oral administration
48020029|NCT01827904|DEVICE|Transcranial ExAblate|
48377787|NCT05417685|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
48377788|NCT05417685|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
48020030|NCT01827904|DEVICE|Sham Transcranial ExAblate|
48020031|NCT01842009|DEVICE|High Definition transcranial Direct Current Stimulation|
48020032|NCT06418971|BEHAVIORAL|CarePair|This study will pilot test the feasibility and acceptability of a digital self-assessment and referral tool using machine learning models to enhance service use and address unmet needs in ADRD caregivers.
48020035|NCT03063541|DRUG|Acetylsalicylic acid|100 mg daily as one tablet
48020036|NCT03063541|OTHER|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
48020037|NCT05734859|DEVICE|Electrolyzed Alkaline Ionizer|Patients will drink EHARW calculated by 20 mL/kg body weight/day which can be divided into several times a day for drinking. The patient is recommended to drink water in an empty stomach and to drink water generated from the device as soon as possible.
48020038|NCT00142909|DRUG|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
48020039|NCT00142909|DRUG|Placebo|Lofexidine Placebo
48020040|NCT05464628|DRUG|Atorvastatin|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
48020041|NCT05464628|DRUG|ASC42|Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
48020042|NCT04336579|BEHAVIORAL|Diaphragmatic Breathing|Simple diaphragmatic breathing exercise
48020043|NCT00515333|DRUG|TRx0014|Hard capsule; 60 milligrams; t.i.d.
48711197|NCT02917213|OTHER|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
48711198|NCT02917213|OTHER|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
48377789|NCT05417685|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
48377790|NCT03421873|OTHER|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
48377791|NCT02888782|OTHER|Pharmacist Consultation|
48377792|NCT03199924|DRUG|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
48377793|NCT03199924|DRUG|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
48377794|NCT03199924|DRUG|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
48020044|NCT00515333|DRUG|TRx0014|Hard capsule; 30 milligrams; t.i.d.
48377795|NCT03413618|DRUG|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
48020045|NCT00515333|DRUG|Placebo|Hard capsule; 0 milligrams; t.i.d.
48020046|NCT00515333|DRUG|TRx0014|Hard capsule, 100 milligrams, t.i.d.
48377796|NCT03413618|DRUG|Diosmin|600 mg q.d. for 12 month
48377797|NCT03413618|OTHER|compression stockings|above knee stocking for 12 month
48377798|NCT00978640|OTHER|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
48377799|NCT00978640|OTHER|exercise|exercise 1 h 50% VO2max
48388001|NCT02629627|DIETARY_SUPPLEMENT|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
48388002|NCT02629627|DRUG|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
48388003|NCT02629627|DIETARY_SUPPLEMENT|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
48388004|NCT02629627|OTHER|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
48388005|NCT04527549|DRUG|Dabrafenib mesylate|Given PO
48711199|NCT02917213|OTHER|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
48711200|NCT02917213|PROCEDURE|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
48711201|NCT02917213|OTHER|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
48020047|NCT04494919|DEVICE|Ultrafine Endoscope|The reversal of the normal colonoscope (CV-260SL; Olympus, Tokyo, Japan) along the guidewire to replace the UFE (GIF-XP260NS; Olympus, Tokyo, Japan).
48388006|NCT04527549|DRUG|Hydroxychloroquine|Given PO
48388007|NCT04527549|DRUG|Placebo Administration|Given PO
48388008|NCT04527549|DRUG|Trametinib dimethyl sulfoxide|Given PO
48388009|NCT06059547|DRUG|Nivolumab|Biological, monoclonal antibody
48711202|NCT02917213|OTHER|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
48711203|NCT02388594|DRUG|ZFN Modified CD4+ T Cells|
48177250|NCT04933799|DRUG|PF-06650833|"PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression."
48711204|NCT02388594|DRUG|Cyclophosphamide|
48177251|NCT04933799|DRUG|Matching Placebo|Placebo will match the study drug in dose, formulation, route and frequency.
48177252|NCT02927015|OTHER|Purple Majesty potato chips|Purple Majesty potato chips
48177253|NCT02927015|OTHER|Mountain Rose potato chips|Mountain Rose potato chips
48177254|NCT02927015|OTHER|White potato chips|White potato chips
48177255|NCT02927015|OTHER|Crackers|Crackers
48177256|NCT05080205|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
48177257|NCT00894998|BIOLOGICAL|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
48177258|NCT00894998|BIOLOGICAL|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
48177259|NCT06189989|BEHAVIORAL|The group to which a care package was applied in addition to the clinical routine care protocol)|"Intervention Group:~* Immediately after the newborn's admission to the intensive care unit, mechanical ventilation mode, physiological parameters, blood gas results and descriptive characteristics of the baby were recorded in the Data Collection and Daily Monitoring Form.~* In addition to the routine care practices of the clinic (every 3 hours / 8 times a day), the newborn's temporary tachypnea care package was applied. Postural drainage, percussion and vibration were applied 4 times a day for an average of 10-15 minutes.~* Mechanical ventilation mode and physiological parameters were recorded one hour after 4 daily maintenance applications.~* Blood gas parameters were evaluated immediately before and 1 hour after the newborn was separated from mechanical ventilation.~* Physiological parameters were recorded again 1 hour after the first routine nursing care after the newborn was separated from mechanical ventilation."
48388010|NCT06059547|DRUG|Visugromab (CTL-002)|Biological, monoclonal antibody
48388011|NCT06059547|DRUG|Placebo|Placebo for Visugromab (CTL-002)
48711205|NCT04937335|OTHER|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
48711206|NCT02089464|DEVICE|NBS-guided rTMS|
48711207|NCT02089464|DEVICE|Sham rTMS|
48711208|NCT02089464|PROCEDURE|Task oriented rehabilitation|
48711209|NCT00668018|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
48711210|NCT04070326|DRUG|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
48711211|NCT03504241|BIOLOGICAL|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
48711212|NCT03504241|DRUG|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
48711213|NCT03504241|DRUG|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
48711214|NCT03504241|DRUG|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
48711215|NCT03504241|DRUG|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
48020048|NCT06467318|DRUG|Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
48020049|NCT06467318|DRUG|NSAID, Paracetamol|Participants post mechanical pleurodesis on pneumothorax will be divided into two groups: Group A: patients taking classic pain management with NSAID. Group B: patients taking classic pain management without NSAID.
48020050|NCT02936076|OTHER|Exercise intervention|
48020051|NCT02936076|OTHER|Delayed exercise intervention|
48711216|NCT03504241|DRUG|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
48020052|NCT01734746|PROCEDURE|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
48020053|NCT03856229|DRUG|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
48020054|NCT03856229|DRUG|Shortened steroid regimen|"* Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~* Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
48177260|NCT01438762|BEHAVIORAL|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
48177261|NCT01438762|OTHER|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
48177262|NCT02760563|DRUG|BAY 987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application (Formulation number V26-160)
48177263|NCT04540562|OTHER|COPD app|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
48377800|NCT01118949|DRUG|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
48517614|NCT06582472|PROCEDURE|Ophthalmological examination including imaging assessments|Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)
48177264|NCT04340856|PROCEDURE|colon surgery|There are no guidelines to direct surgical therapy in patients with chronic megacolon. Historically, it is the surgeons individual choice to use one of the above mentioned surgical treatments. Therefore, the aim of this study is to analyze the success and downsides of the different surgical approaches.
48377801|NCT03791567|BIOLOGICAL|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
48377802|NCT01172860|DEVICE|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
48517615|NCT06582472|PROCEDURE|confocal analysis of cornea|Confocal analysis of cornea: a procedure to study and quantify possible corneal nerve degeneration as a marker of involvement of diabetic neuropathy
48517616|NCT06582472|PROCEDURE|Dynamic Vessel Analyzer (DVA)|Dynamic Vessel Analyzer (DVA), a device that measures the response of retinal arteries and veins to a standardized stimulus (flickering light) allowing direct quantification of the inflammatory status of the retinal vasculature
48711217|NCT03504241|DRUG|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
48711218|NCT04920721|OTHER|no intervention|no intervention descriptiv study
48711219|NCT06356779|PROCEDURE|Local ablative therapy (LAT)|Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions
48711220|NCT01777542|DRUG|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
48711221|NCT01777542|DRUG|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
48711222|NCT04920591|OTHER|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
48377803|NCT01286896|DRUG|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
48377804|NCT03950934|OTHER|no intervention, observational study, perioperative survey|no intervention
48177265|NCT04340856|DRUG|Laxatives|There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
48177266|NCT03913689|DEVICE|StimRouter Neuromodulation System|An implantable neuromodulation device that treats chronic peripheral nerve pain.
48177267|NCT03532269|DEVICE|Nightly App|The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
48177268|NCT00477464|DRUG|Lapatinib|1250mg once daily
48177269|NCT00477464|DRUG|capecitabine|2000mg/m\^2 twice daily (14 days out of 21 days)
48020055|NCT05569785|OTHER|Resistance Exercise Therapy|"4 weeks of Resistance Exercise Therapy. This is a 4 week resistance exercise training programme that can be completed at home. The programme is designed to be progressive. It was designed by a bariatric physiotherapist and an exercise physiologist. This exercise programme will be discussed at the screening visit, educational material will be provided to the participants who are randomised to the intervention RET group.~Safety advice will be given to each eligible participant to ensure that if they feel unwell, develop chest pain/tightness, then they must seek advice from GP/urgent care if necessary. The exercises will need to be performed at least three times a week. Compliance will be monitored with Fitbit downloads at each visit. Fitbits will be worn during exercise sessions only."
48177270|NCT05194670|DEVICE|enhanced depth of focus IOL|Acunex Vario AN6V, enhanced depth of focus IOL
48177271|NCT05194670|DEVICE|monofocal IOL|Acunex AN6, monofocal IOL
48177272|NCT02779348|DRUG|BIA 3-202|Nebicapone tablets 200 mg
48177273|NCT02779348|DRUG|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
48177274|NCT04245345|DEVICE|Accelerometer Sensing for Micra AV Study|Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
48177275|NCT01537185|OTHER|Placebo|3 cohorts of normal saline injection
48177276|NCT01537185|BIOLOGICAL|SPWCV+Alum 100 mcg|3 injections 28 days apart
48177277|NCT01537185|BIOLOGICAL|SPWCV+Alum 600 mcg|3 injections 28 days apart
48177278|NCT01537185|BIOLOGICAL|SPWCV+Alum 300 mcg|3 injections 28 days apart
48177279|NCT00739076|BEHAVIORAL|Virtual Reality|Using Virtual Reality for pain control
48177280|NCT03308578|DRUG|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
48177281|NCT03308578|DRUG|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
48177282|NCT05742048|DIAGNOSTIC_TEST|traumatic patient suspect to have long bone fracture between 18 - 65 years old|Number of patients diagnosed to have a long bone fracture by using ultrasound. Number of patients diagnosed to have a long bone fracture by using x-ray . Comparison between Ultrasound bone scan result and X-ray imaging accuracy and sensitivity.
48177283|NCT03845712|DRUG|doxecitine and doxribtimine|Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.
48177284|NCT01711398|DRUG|Drug|
48177285|NCT05799469|DRUG|Envafolimab|SC
48020056|NCT00144118|DRUG|sevoflurane or isoflurane|
48020057|NCT02823925|DRUG|Pamidronate or Zoledronate|
48020058|NCT00485537|PROCEDURE|oocyte retrieval and ICSI procedure|
48177286|NCT05799469|DRUG|Cisplatin|IV infusion
48177287|NCT05799469|RADIATION|External Beam Radiotherapy (EBRT)|45-50.4Gy
48177288|NCT05799469|RADIATION|Brachytherapy (BT)|Performed according to clinically required dose
48177289|NCT05783999|DEVICE|vibra plus|the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
48177290|NCT01907113|DRUG|BI 10773|oral administration
48177291|NCT01907113|DRUG|BI 10773|oral administration
48177292|NCT01907113|DRUG|BI 10773|oral administration
48177293|NCT01907113|DRUG|BI 10773|oral administration
48177294|NCT01907113|DRUG|BI 10773|oral administration
48177295|NCT01407276|DRUG|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
48020059|NCT04632667|BEHAVIORAL|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
48020060|NCT04632667|BEHAVIORAL|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
48377805|NCT03542175|DRUG|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
48020061|NCT01431508|DRUG|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
48020062|NCT01428323|DEVICE|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
48020063|NCT01639898|DRUG|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
48020064|NCT01639898|DRUG|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
48020065|NCT05233072|OTHER|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
48020066|NCT00000465|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
48020067|NCT00000465|PROCEDURE|coronary artery bypass|
48020068|NCT01103297|DEVICE|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
48020069|NCT01319734|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C supplementation 500mg
48020070|NCT01319734|DRUG|glyburide|this group receiving glyburide 5 mg alone
48020071|NCT03109834|DIETARY_SUPPLEMENT|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
48020072|NCT03109834|OTHER|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
48377806|NCT03542175|RADIATION|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
48020073|NCT03109834|DIETARY_SUPPLEMENT|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
48020074|NCT03109834|OTHER|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
48377807|NCT00995462|BEHAVIORAL|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
48377808|NCT04700592|OTHER|Gabapentin versus Ketamine|A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain
48020075|NCT00690547|OTHER|muscle activation|activation of the muscle quadriceps femoris
48020076|NCT02284997|DEVICE|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
48020077|NCT02610192|DEVICE|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
48020078|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
48517617|NCT06582472|PROCEDURE|tear sampling collection|Collect and analyze tear samples to identify biomarkers in tears and at the endothelium of the ocular surface through impression conjunctival cytology and the quantitative/qualitative analysis of pro-inflammatory cytokines
48177296|NCT02119949|BEHAVIORAL|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
48020079|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support (Wait-list)|Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
48377809|NCT02980666|DRUG|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
48377810|NCT02713724|BEHAVIORAL|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
48377811|NCT02713724|BEHAVIORAL|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
48377812|NCT03488537|DEVICE|AeonoseTM|Breath test
48517618|NCT06582472|PROCEDURE|blood sampling collection|collection and analysis of blood samples to identify diabetic retinopathy biomarkers and early abnormalities of the vascular retinal system.
48020080|NCT00968617|DRUG|MK2578|MK2578 1.0 mcg/kg/month
48020081|NCT00968617|DRUG|MK2578|MK2578 2.0 mcg/kg/month
48020082|NCT00968617|DRUG|MK2578|MK2578 3.6 mcg/kg/month
48020083|NCT00968617|DRUG|Comparator: darbepoetin alfa|darbepoetin alfa
48177297|NCT02119949|BEHAVIORAL|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
48177298|NCT05708300|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
48177299|NCT00375765|DRUG|Dutasteride|
48177300|NCT01654068|RADIATION|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
48177301|NCT04693910|OTHER|Multimedia-Based Hormone Therapy Information Program|The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
48177302|NCT06392893|COMBINATION_PRODUCT|Meat product without additives and allergens|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of meat products without additives and allergens (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
48177303|NCT06392893|COMBINATION_PRODUCT|Commercial meat product|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of commercial meat products (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
48177304|NCT04302493|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.
48177305|NCT04302493|BEHAVIORAL|Stroke Support Group (SSG)|As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
48177306|NCT00412880|DRUG|BI 2536|Intravenous Infusion
48177307|NCT03421639|DRUG|GnRH analog (11.25mg Leuprolide acetate)|11.25 Leuprolide acetate only one administration
48177308|NCT03421639|DRUG|Aromatase inhibitor and GnRH analog|1mg/day of Anastrazole for 3 months
48177309|NCT03421639|DRUG|Aromatase and GnRH analog (11.25mg Leuprolide acetate)|Leuprolide acetate 11.25mg only one
48177310|NCT03277352|DRUG|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
48177311|NCT03277352|DRUG|Epacadostat|Epacadostat will be self-administered orally at the protocol-defined dose.
48177312|NCT03277352|DRUG|Pembrolizumab|Pembrolizumab will be administered IV at the protocol-defined dose.
48177313|NCT00830687|DEVICE|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
48177314|NCT00684203|DRUG|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
48377813|NCT02706015|DRUG|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
48517619|NCT00283478|DRUG|Iscar Quercus|
48517620|NCT00283478|DRUG|Gemcitabine|
48517621|NCT02678208|DRUG|Tranexamic Acid|
48517622|NCT02678208|DRUG|5% glucose|
48517623|NCT01228019|DRUG|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
48517624|NCT03980652|PROCEDURE|Change of gloves and sterile instruments|Change of gloves and use of separate , sterile instruments before closing the abdominal wall
48377814|NCT02706015|DRUG|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
48711223|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 2-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
48020084|NCT00931905|DRUG|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
48020085|NCT00931905|OTHER|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
48020086|NCT04331080|DRUG|Granexin® gel 100 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
48020087|NCT04331080|DRUG|Granexin® gel 200 μM|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
48020088|NCT04331080|DRUG|Vehicle gel|Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
48020089|NCT02323464|PROCEDURE|Surgery for colorectal cancer|Includes open and minimally invasive surgery for colon- and rectal cancer
48020090|NCT02323464|OTHER|No Interventions|This is a control group from the population. They are not scheduled for surgery
48020091|NCT03708341|DRUG|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
48020092|NCT03708341|DRUG|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
48020093|NCT03732638|DRUG|Rimegepant|Rimegepant 75 mg tablet EOD
48020094|NCT03732638|DRUG|Placebo|Placebo tablet to match rimegepant tablet EOD
48020095|NCT06573801|DEVICE|Aktiia Bracelet|Wrist worn bracelet with an optical sensor that measures pulse wave characteristics at the wrist.
48020096|NCT06573801|DEVICE|Healthstats BPro Evo|Wrist worn watch that uses applanation tonometry to measure pulse wave characteristics at the wrist.
48020097|NCT06573801|DEVICE|Spacelabs OnTrak Ambulatory Blood Pressure monitor|Cuffed ambulatory BP monitor that will measure upper arm BP using oscillometry.
48020098|NCT03830502|PROCEDURE|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
48020099|NCT03060824|OTHER|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
48020100|NCT01003418|BIOLOGICAL|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
48020101|NCT01003418|BIOLOGICAL|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
48020102|NCT01003418|BIOLOGICAL|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
48020103|NCT00559897|OTHER|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
48020104|NCT00559897|PROCEDURE|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
48020105|NCT03755063|OTHER|Speech therapy apps|Speech therapy apps loaded on tablets
48020106|NCT06041477|DRUG|Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU|Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)
48020107|NCT06041477|DRUG|Concurrent Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the first cycle
48020108|NCT06041477|DRUG|Concurrent PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)
48020109|NCT06041477|DRUG|Sequential Lenvatinib|Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
48177315|NCT00684203|DRUG|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
48177316|NCT00684203|DRUG|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
48177317|NCT00684203|DRUG|Clopidogrel|100 mg two or three times daily for 60 days.
48177318|NCT06469567|OTHER|Patient Counselling|Doctor's counselling using Culturally-responsive pamphlet
48711224|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 1-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 24-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of the participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
48177319|NCT05629143|PROCEDURE|de-prescription of PPI via intermittent scheme|The patients will decrease their intake of PPIs via a de-prescription intermittent scheme. After one month, patients will stop their intake of PPI.
48711225|NCT06000631|BEHAVIORAL|Conventional Therapy with a 1-hour session|The other independent OT will be responsible for providing conventional therapy in the same location as the ROC-Stand training for a total of 24-week intervention based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general purpose of the training is to facilitate the developmental scales and improve mobility, socialization, and upper limb use in functional tasks.
48711226|NCT05922072|PROCEDURE|Nasogastric aspiration for measurement of Residual Gastric Volume|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric residual volume will be measured by taking Nasogastric tube aspirate.
48711227|NCT05922072|PROCEDURE|Nasogastric Aspiration for Measurement of Gastric pH|The patients enrolled in this study undergoing elective general anesthesia,their mean gastric gastric PH will be measured by taking Nasogastric tube aspirate.
48711228|NCT03162510|DRUG|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
48711229|NCT03162510|DRUG|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
48177320|NCT05629143|PROCEDURE|de-prescription of PPI via on-demand scheme|The patients will decrease their intake of PPIs via a de-prescription on-demand scheme. After one month, patients will stop their intake of PPI.
48377815|NCT05392465|OTHER|Fascial mobilization group|Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.
48177321|NCT05629143|DRUG|Alginate|The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
48177322|NCT04380428|OTHER|No Intervention. Observational study.|No Intervention. Observational study.
48388012|NCT04677894|DEVICE|Laryngoscopy|During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
48517625|NCT01849237|GENETIC|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).
48020110|NCT06041477|DRUG|Sequential PD-1 antibody|PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)
48177323|NCT04742062|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
48711230|NCT03162510|DRUG|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
48711231|NCT03162510|DRUG|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
48711232|NCT03855813|OTHER|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
48020111|NCT05457881|DIETARY_SUPPLEMENT|Scandi-Shake|Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
48177324|NCT04742062|OTHER|Placebo|100 mL 0.9% Sodium Chloride solution
48388013|NCT06566313|BEHAVIORAL|transcranial Direct Current Stimulation|On the basis of conventional anti-PD drugs, the left M1 region (based on the C3 coordinates of EEG 10-20 system and the surrounding FC1, FC5, CP1, CP5 coordinates) was treated with cathodic tDCS. The electrical stimulation intensity was 2.0mA, the treatment time was 20min, and the treatment lasted for 10 days.
48388014|NCT00002066|DRUG|Thymopentin|
48711233|NCT03855813|OTHER|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
48711234|NCT01480973|RADIATION|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
48711235|NCT03831945|BIOLOGICAL|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
48377816|NCT05392465|OTHER|Conventional physical therapy|Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
48020112|NCT05515432|DRUG|Single oral dose of BAY3283142 IR (immediate release) tablet|Single oral dose of BAY3283142 in participants with renal impairment compared to an age, gender and weight matched control group in an open-label study design
48020113|NCT02379598|DIETARY_SUPPLEMENT|Aminoacid based formula|Formula based on aminoacid
48020114|NCT02379598|DIETARY_SUPPLEMENT|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
48020115|NCT06531668|DIETARY_SUPPLEMENT|Beyond Hormone|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
48020116|NCT06531668|OTHER|Placebo|Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
48020117|NCT01813604|BIOLOGICAL|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
48020118|NCT01813604|BIOLOGICAL|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
48020119|NCT01813604|BIOLOGICAL|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
48020120|NCT01813604|BIOLOGICAL|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
48020121|NCT01813604|BIOLOGICAL|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
48177325|NCT02336256|PROCEDURE|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
48177326|NCT02931578|OTHER|Glucose100|
48177327|NCT02931578|OTHER|Glucose50|
48177328|NCT02931578|OTHER|Glucose42|
48177329|NCT02931578|OTHER|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
48177330|NCT01278147|BEHAVIORAL|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
48177331|NCT05972304|DEVICE|Nasal positive airway System by Vyaire Medical|Incidence of Hypercarbia and Hypoxia in interventional group and its monitoring using transcutaneous (SpO2) and (tCO2) Sensor
48177332|NCT00469456|DRUG|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
48177333|NCT00469456|DRUG|placebo|Placebo oral administration twice daily for 12 weeks
48177334|NCT04546022|DRUG|Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.|
48177335|NCT02957695|DEVICE|Placebo-Neurofeedback|The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
48177336|NCT02957695|DEVICE|Active-Neurofeedback|"The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH."
48177337|NCT02582385|OTHER|in-situ cytokine expression|
48177338|NCT02282423|BEHAVIORAL|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
48177339|NCT02282423|PROCEDURE|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
48177340|NCT02282423|PROCEDURE|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
48177341|NCT02282423|PROCEDURE|VO2max.|VO2max.
48377817|NCT02387723|BIOLOGICAL|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
48388015|NCT06106282|OTHER|Non-Interventional Study|Non-Interventional Study
48517626|NCT01849237|DRUG|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
48177342|NCT02282423|BEHAVIORAL|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
48377818|NCT04869618|DEVICE|Raman spectroscopy based device (SPECTRA IMDx)|The SPECTRA IMDx system is developed on the basis of Raman spectroscopy. It comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx system also comprises a SPECTRA IMDx probe that can be connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal, which is then parsed through an analysis algorithm for diagnosis.
48177343|NCT02282423|PROCEDURE|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
48377819|NCT05863780|OTHER|Carpal bone mobilization|"Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
48377820|NCT05863780|OTHER|Flexor retinaculum stretch|"Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
48377821|NCT05863780|OTHER|Carpal bone mobilization and flexor retinaculum stretch|"1. Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~2. Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins."
48377822|NCT04967599|BEHAVIORAL|Phenotype Feedback Intervention|Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
48377823|NCT04967599|BEHAVIORAL|Genotype Feedback Intervention|Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
48377824|NCT05036486|GENETIC|next-generation sequencing|Tumor tissue will be collected from advanced BTC patients for real-time next-generation sequencing analysis
48377825|NCT04383652|OTHER|Biological sample and clinical data collection|Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
48377826|NCT05584241|BEHAVIORAL|Diagnostic Disclosure Protocol|Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
48517627|NCT00704626|OTHER|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
48517628|NCT00704626|OTHER|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
48517629|NCT04859829|OTHER|Current Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.
48517630|NCT04859829|OTHER|No Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
48177344|NCT05064644|OTHER|Product that contains plant stanol ester|Product with active ingredient
48177345|NCT05064644|OTHER|Placebo product|Product without active ingredient
48177346|NCT05054569|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
48177347|NCT02755701|DRUG|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
48377827|NCT05584241|BEHAVIORAL|Biomarker Disclosure Protocol|Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
48377828|NCT01139138|DRUG|Panitumumab|Panitumumab 6mg/kg IV every 14 days
48377829|NCT01139138|DRUG|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
48377830|NCT01139138|DRUG|Everolimus|Everolimus daily po (dosage varies with cohort)
48517631|NCT02756208|BIOLOGICAL|300 ug FLSC vaccine|FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
48517632|NCT02756208|BIOLOGICAL|150 ug FLSC vaccine|FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
48517633|NCT02756208|BIOLOGICAL|75 ug FLSC vaccine|FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
48517634|NCT02756208|BIOLOGICAL|Placebo|Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
48517635|NCT05734651|DEVICE|PROMIS Stem|Primary Total Hip Arthroplasty with the PROMIS Stem (Fa. Falcon Medical, Mödling, Austria)
48517636|NCT05387187|DRUG|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
48517637|NCT05387187|DRUG|Pentoxifylline|Pentoxifylline 100mg TID
48711236|NCT03831945|BIOLOGICAL|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
48711237|NCT03831945|BIOLOGICAL|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is \> or = 200 copies/mL.
48377831|NCT06178276|DIAGNOSTIC_TEST|behavior|behavioral measurements will be performed during the oral comprehension testing
48377832|NCT06178276|DIAGNOSTIC_TEST|physiology|physiologic (autonomic) measurements will be performed during the oral comprehension testing
48711238|NCT06327893|OTHER|Submersion or immersion in liquid|The patient must have been submersed or immersed in liquid.
48377833|NCT06178276|DIAGNOSTIC_TEST|imaging|central (brain) measurements will be performed during the oral comprehension testing
48377834|NCT00058994|DRUG|anecortave acetate|
48711239|NCT00799045|DRUG|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
48377835|NCT05853081|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|The Fat-free mass index (FFMI) will be measured using bioelectrical impedance analysis. Exacerbations and mortality will be recorded during follow-up to evaluate the prognostic value of the FODE scale.
48711240|NCT02723006|DRUG|TAK-580|TAK-580 tablets
48177348|NCT02755701|DRUG|Placebo|Placebo will be administered in the same way
48377836|NCT02800317|PROCEDURE|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
48377837|NCT02820324|DRUG|Oliceridine|
48377838|NCT02820324|DRUG|Placebo|
48517638|NCT01094015|DRUG|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
48517639|NCT01094015|OTHER|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
48517640|NCT02354404|BIOLOGICAL|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
48020122|NCT02369497|DEVICE|HRA|Humeral head resurfacing with the HRA device
48177349|NCT00525928|DRUG|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
48177350|NCT03903835|DRUG|Enzalutamide Oral Capsule|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
48177351|NCT03903835|DRUG|Abiraterone Oral Tablet|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
48377839|NCT02820324|DRUG|Morphine|
48377840|NCT06205940|BEHAVIORAL|Audioguided Nature tour|Listening to audio instructions by an app while visiting nature. The instructions emphasize the connection between self and nature and direct attention to the present moment experience by guiding focus towards sensory experiences and specific natural elements.
48377841|NCT06205940|BEHAVIORAL|Non audio guided nature tour|Visiting nature without listening to audio instructions by an app
48377842|NCT00283517|DRUG|antipsychotics|as prescribed
48377843|NCT06033924|BEHAVIORAL|Walking Program: Internet-based|Internet pages allow participants to see step-count goals, progress over time and access to walking tips for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
48377844|NCT06033924|BEHAVIORAL|Walking Program: Telehealth-based|Telehealth sessions allow participants review step-count goals, progress over time and access to walking tips with the study coordinator for 12 weeks. Among participants who do not increase their step counts (\>15%), these non-responders will be rerandomized to received the combination of internet and telehealth or either along for an additional 12-weeks (total intervention time is 24-weeks). A follow-up phase of 12-weeks will be completed for a total participant duration of 36 weeks.
48377845|NCT00306800|PROCEDURE|Photodynamic therapy with methyl aminolevulinate cream|
48377846|NCT03512106|OTHER|Acupuncture|Chinese traditional acupuncture
48517641|NCT02354404|BIOLOGICAL|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each \[2x10(11) PU/mL total\].
48517642|NCT02354404|BIOLOGICAL|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
48517643|NCT02588963|OTHER|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
48711241|NCT02723006|DRUG|TAK-202|TAK-202 infusion
48711242|NCT02723006|DRUG|vedolizumab|vedolizumab infusion
48711243|NCT02723006|DRUG|nivolumab|nivolumab infusion
48711244|NCT02723006|DRUG|ipilimumab|ipilimumab infusion
48711245|NCT04014140|PROCEDURE|Coronary artery bypass grafting surgery (CABG)|Patients with MVCAD will undergo CABG as per standard of care.
48711246|NCT02818036|DRUG|Naltrexone|
48711247|NCT02818036|DRUG|Placebo|
48711248|NCT01740479|PROCEDURE|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
48711249|NCT00199316|DRUG|spinal morphine|
48177352|NCT03903835|DRUG|Carboplatin|Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].
48177353|NCT03903835|DRUG|Cabazitaxel 60 mg Solution for Injection|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
48377847|NCT02946515|BEHAVIORAL|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
48377848|NCT02946515|BEHAVIORAL|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
48377849|NCT04401462|PROCEDURE|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
48377850|NCT04401462|BEHAVIORAL|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
48377851|NCT01583465|DEVICE|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
48377852|NCT01583465|DEVICE|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
48377853|NCT01147432|DRUG|PF-04427429|Single dose IV infusion up to 300mg
48377854|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
48377855|NCT01147432|DRUG|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
48377856|NCT01147432|OTHER|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
48377857|NCT01147432|OTHER|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
48377858|NCT00594009|DEVICE|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
48377859|NCT05329012|DEVICE|DUL- Distal Ulna Locking PLate (I.T.S)|The patients are surgical treated with the Distal Ulna locking plate according to standard surgical procedures to treat the unstable distal ulna fractures.
48517644|NCT02588963|OTHER|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
48377860|NCT00564876|DRUG|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
48517645|NCT02588963|OTHER|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
48377861|NCT02092207|DRUG|KL7016 900mg|oral administration, 150mg 3tab, bid
48377862|NCT02092207|DRUG|KL7016 600mg|oral administration, 150mg 3tab, bid
48377863|NCT02092207|DRUG|Placebo|oral administration, 150mg 3tab, bid
48377864|NCT02424357|DRUG|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
48517646|NCT06452134|DRUG|Coenzyme Q10 100 MG Oral Tablet|Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
48177354|NCT03903835|DRUG|Docetaxel Injectable Solution|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
48177355|NCT03903835|DRUG|Radium Chloride Ra-223|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
48177356|NCT03903835|DRUG|Niraparib plus Abiraterone acetate plus Prednisone|Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
48377865|NCT02424357|DRUG|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
48517647|NCT06452134|DRUG|Placebo|Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
48517648|NCT01082497|BEHAVIORAL|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
48711250|NCT03466138|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
48711251|NCT01223898|DRUG|Tasigna|
48711252|NCT02710435|DEVICE|Reducer System|An aid in the management of chronic refractory angina pectoris
48177357|NCT03903835|DRUG|Capivasertib plus Docetaxel|Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
48177358|NCT03903835|DRUG|Apalutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
48377866|NCT02382107|OTHER|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
48517649|NCT02905188|GENETIC|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
48711253|NCT05685563|DIAGNOSTIC_TEST|DIERS formetic 4D|Assessment of mentioned tests and their comparison.
48711254|NCT01119833|DRUG|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
48711255|NCT01119833|DRUG|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
48377867|NCT05182840|DRUG|BI 690517|Film-coated tablets
48517650|NCT02905188|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
48517651|NCT02905188|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
48517652|NCT04861584|DRUG|Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin|4 cycle neoadjuvant therapy and radical cystectomy
48711256|NCT05172453|OTHER|comprehensive management algorithm for preventing mother-to-child transmission of HBV|"To standardize the clinical management of preventing MTCT of HBV and reduce incidences of MTCT, the Chinese Foundation for Hepatitis Prevention and Control (CFHPC) organized experts to compile the Management algorithm for prevention of mother-to-child transmission of hepatitis B virus based on the latest research progress and recently published guidelines, which includes 10 steps of pregnancy management and postpartum follow-up, among which screening, antiviral treatment, and infant immunization are its core contents."
48177359|NCT03903835|DRUG|Darolutamide|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
48377868|NCT05182840|DRUG|Placebo to BI 690517|Film-coated tablets
48377869|NCT05182840|DRUG|Empagliflozin|Empagliflozin
48377870|NCT05182840|DRUG|Placebo to empagliflozin|Placebo to empagliflozin
48377871|NCT00165191|DRUG|Doxorubicin|
48377872|NCT00165191|DRUG|Cisplatin|
48020123|NCT01187589|DEVICE|Pulsehaler|
48377873|NCT00165191|DRUG|5-fluorouracil|
48711257|NCT04303143|BEHAVIORAL|Self-Hypnosis|Self-Hypnosis
48711258|NCT04303143|BEHAVIORAL|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
48711259|NCT00712569|BEHAVIORAL|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
48711260|NCT00712569|BEHAVIORAL|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
48020124|NCT01187589|DRUG|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
48177360|NCT01924637|DRUG|Faster-acting insulin aspart|"A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
48177361|NCT01924637|DRUG|insulin aspart|"A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
48020125|NCT01344057|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
48177362|NCT03869736|DRUG|Nitrous Oxide|1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
48177363|NCT03869736|DRUG|Placebo|1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
48177364|NCT05597423|OTHER|Massage|The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
48177365|NCT05597423|OTHER|Placebo|The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
48177366|NCT04120142|OTHER|Pulmonary rehabilitation+IMT|The experimental group receives inspiratory muscle training and aerobic exercise.
48020126|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/1 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 1 hour later in the emergency department.
48020127|NCT05649384|DIAGNOSTIC_TEST|European Society of Cardiology hs-cTnT/I 0 h/3 h algorithm|High-sensitivity cardiac troponin (hs-cTn) blood tests are performed at admission (0 h) and 3 hours later in the emergency department.
48020128|NCT02855502|DRUG|Prednisolone|
48020129|NCT02855502|DRUG|Placebo|
48177367|NCT04120142|OTHER|Pulmonary rehabilitation|The Active Comparator group received only aerobic exercise.
48177368|NCT04847245|DRUG|Pregabalin 75mg tid + Duloxetine|Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
48177369|NCT04847245|DRUG|Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
48711261|NCT00712569|BEHAVIORAL|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
48711262|NCT05602675|DRUG|LY3871801|Administered orally.
48711263|NCT05602675|DRUG|Methotrexate|Administered orally.
48517653|NCT04682925|OTHER|skin care arm of where evidence-based practices in the implementation guide|"1. The nasal mucosa and nasal skin under the nasogastric tube will be cleaned and dried twice a day with a pH-compatible cleanser.~2. A water-based moisturizing cream will be applied to the nasal skin under the nasogastric tube twice a day, after care with a pH-compatible cleanser.~3. Spray skin barrier will be applied twice a day after applying water-based moisturizing cream to the nasal skin under the nasogastric tube.~4. The nasal mucosa and nasal skin under the nasogastric tube will be evaluated twice daily for signs of pressure-related injury. All these care interventions applied to the skin care arm will be applied together with the doctor and nurse responsible for the treatment and care of the patient."
48517654|NCT04682925|DEVICE|hydrocolloid (Convatec Granuflex-extra thin) dressing|The nasal skin of the patients and the surrounding skin will be cleaned with a pH-compatible cleaner, dried and a new hydrocolloid cover will be applied once a day. All these care interventions applied to the hydrocolloid dressing arm will be applied together with the physician and nurse responsible for the treatment and care of the patient.
48177370|NCT04847245|DRUG|Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
48377874|NCT04543747|DEVICE|HeartWare Ventricular Assist Device|The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
48377875|NCT03054675|DIAGNOSTIC_TEST|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
48517655|NCT04682925|OTHER|control|In routine care, the skin under the nasogastric tube is evaluated once a day for redness and wound formation by the nurse responsible for the patient's care and is cleaned and dried with appropriate cleaners.
48517656|NCT01382888|DRUG|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
48517657|NCT01382888|DRUG|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
48517658|NCT03757312|DIAGNOSTIC_TEST|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
48517659|NCT03637426|OTHER|Laser|GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
48711264|NCT05602675|DRUG|Warfarin|Administered orally.
48711265|NCT05602675|DRUG|Dextromethorphan|Administered orally.
48711266|NCT05602675|DRUG|Midazolam|Administered orally.
48711267|NCT05602675|DRUG|Repaglinide|Administered orally.
48711268|NCT04525924|DEVICE|bright light therapy|please see arm description
48711269|NCT00659100|DRUG|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
48711270|NCT03535662|DRUG|Orvepitant|Single oral dose
48177371|NCT04847245|DRUG|Intravenous administration of esketamine 0.50 mg/kg+Duloxetine|Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
48177372|NCT03638921|DRUG|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
48177373|NCT05132855|BIOLOGICAL|BNT162b2|BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
48177374|NCT05132855|BIOLOGICAL|mRNA-1273|mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
48177375|NCT05132855|BIOLOGICAL|MVC-COV1901|MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
48377876|NCT05756166|PROCEDURE|Biopsy|Undergo tumor biopsy
48711271|NCT03535662|DRUG|Itraconazole|Once daily dosing for 10 days
48711272|NCT06178016|OTHER|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
48020130|NCT02984501|RADIATION|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
48020131|NCT02984501|DRUG|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
48020132|NCT03243734|DEVICE|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
48020133|NCT04917198|PROCEDURE|median sternotomy|median sternotomy
48020134|NCT02697019|BEHAVIORAL|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
48020135|NCT01815671|PROCEDURE|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
48020136|NCT03913117|BIOLOGICAL|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
48020137|NCT03913117|BIOLOGICAL|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
48020138|NCT06441513|OTHER|Chinese traditional medicine nursing combined with case tracking management|First, we set up a team for the prevention of hand foot syndrome, including 1 head nurse of the tumor chemotherapy department, 2 doctors, 16 nurses (16 nurses were divided into 4 groups, each group designated a team leader) and the researchers of this experiment. Doctors are responsible for the diagnosis of HFS and the determination of traditional Chinese medicine prescriptions, head nurses and team leaders are responsible for quality control, and nurses are responsible for the assessment, intervention and evaluation of patients.
48020139|NCT06441513|OTHER|Health Education|elaborating the symptoms, mechanism and corresponding treatment measures of HFS for patients, reducing the fear of patients, helping them relax and adjust their mentality, and cooperating with observation.
48020140|NCT04380584|DIAGNOSTIC_TEST|plasma Apelin level|blood sample for detection of plasma Apelin level
48020141|NCT05658081|PROCEDURE|Kono-S group|patients in this arm will receive stapled Kono-S anastomosis after bowel resection
48020142|NCT05658081|PROCEDURE|Side-to-side group|patients in this arm will receive stapled antimesenteric isoperistaltic side-to-side anastomosis after bowel resection
48020143|NCT04362358|BEHAVIORAL|Online cognitive behavioral therapy (CBT)|7 sessions of Cognitive Behavioural Therapy (CBT) online + possibility to contact the psychological hotline
48020144|NCT04362358|BEHAVIORAL|Online bibliotherapy programme|online bibliotherapy programme on the Ma Santé website Also with explanatory sheets and tools to improve stress management and the possibility of contacting the Psychological Hotline
48020145|NCT02585739|GENETIC|blood sample|
48020146|NCT05423262|BIOLOGICAL|TRK-950|5 or 10 mg/kg administered intravenously over 60 minutes (weekly)
48020147|NCT05423262|BIOLOGICAL|TRK-950|10 mg/kg administered intravenously over 60 minutes (weekly)
48020148|NCT05423262|BIOLOGICAL|TRK-950|20 mg/kg administered intravenously over 60 minutes (bi-weekly)
48020149|NCT05423262|DRUG|Nivolumab|240 mg administered intravenously over 30 minutes (bi-weekly)
48177376|NCT02267564|PROCEDURE|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
48377877|NCT05756166|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48377878|NCT05756166|DRUG|Celecoxib|Given PO
48377879|NCT05756166|PROCEDURE|Computed Tomography|Undergo CT scan
48377880|NCT05756166|BIOLOGICAL|Interferon Alpha-2|Given IV
48377881|NCT05756166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48177377|NCT02267564|PROCEDURE|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
48177378|NCT01955759|DRUG|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
48177379|NCT01955759|DRUG|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
48177380|NCT01955759|DRUG|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
48377882|NCT05756166|BIOLOGICAL|Pembrolizumab|Given IV
48377883|NCT05756166|DRUG|Rintatolimod|Given IV
48377884|NCT00190476|DRUG|Weekly docetaxel alone|
48377885|NCT00190476|DRUG|Weekly docetaxel + cisplatin combination|
48377886|NCT00744029|BEHAVIORAL|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
48377887|NCT00681876|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
48377888|NCT00681876|DRUG|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
48377889|NCT00681876|DRUG|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
48377890|NCT02525575|BEHAVIORAL|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
48377891|NCT02950727|DEVICE|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
48377892|NCT02950727|DEVICE|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
48377893|NCT00650806|DRUG|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
48177381|NCT05254717|OTHER|counselling|intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
48177382|NCT00721812|DRUG|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
48377894|NCT00650806|DRUG|Placebo|One matching placebo capsule orally once daily for 12 weeks.
48177383|NCT04548297|OTHER|Assessment|Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
48177384|NCT02886598|DRUG|degarelix|
48177385|NCT00020761|DRUG|irinotecan hydrochloride|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."
48177386|NCT00020761|DRUG|paclitaxel|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
48177387|NCT01165606|PROCEDURE|Chest physiotherapy|
48377895|NCT02401217|OTHER|Phase 1- Arm 1 Infant Formula|Powder infant formula
48377896|NCT02401217|OTHER|Phase 2- Arm 2 Infant Formula|Powder infant formula
48377897|NCT02401217|OTHER|Phase 2- Arm 3 Infant Formula|Powder infant formula
48377898|NCT02054507|BEHAVIORAL|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
48377899|NCT05597930|DEVICE|Wrist and Thumb orthosis|Custom 3D printed thumb and wrist orthosis
48377900|NCT03019666|BIOLOGICAL|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"* Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)"
48377901|NCT06342791|DEVICE|laser acupuncture|laser use to stimulate acupuncture points
48377902|NCT04552223|DRUG|Nivolumab|Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
48377903|NCT04552223|DRUG|Relatlimab|Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
48377904|NCT02728141|OTHER|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
48377905|NCT02728141|OTHER|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
48377906|NCT03202329|OTHER|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
48377907|NCT03202329|OTHER|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
48377908|NCT03405545|BEHAVIORAL|High-intenstiy interval training|High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
48377909|NCT00390338|BIOLOGICAL|polarized dendritic cells|
48377910|NCT00390338|BIOLOGICAL|non-polarized dendritic cells|
48711273|NCT01551290|DRUG|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
48711274|NCT01551290|DRUG|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
48377911|NCT02396524|BEHAVIORAL|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
48711275|NCT04006301|DRUG|JNJ-74699157|Participants will receive JNJ-74699157 orally.
48711276|NCT03177811|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
48377912|NCT03737357|DEVICE|SLActive® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
48377913|NCT03737357|DEVICE|SLA® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
48377914|NCT02524366|DEVICE|Artificial Urinary Sphincter|
48377915|NCT05696691|DRUG|Ketamine Hydrochloride|100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
48377916|NCT05696691|BEHAVIORAL|Crisis Response Plan|"Crisis Response Plan is a brief, empirically-validated, Cognitive-Behavioral Therapy-based one-time therapy, and its administration typically takes 30-60 minutes. It begins with a narrative assessment (allowing patients to tell their story) and concludes with collaboratively constructed plan that outlines strategies for the patient's self-management of future acute suicidal crises. Patients who engage in CRP are given an index card to keep with them that summarizes the emotional management strategies that they collaboratively generate with the CRP provider."
48517660|NCT03637426|OTHER|nano-hydroxyapatite|The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
48517661|NCT03637426|OTHER|Laser + nano-hydroxyapatite|GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
48517662|NCT03637426|OTHER|PLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
48711277|NCT03177811|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
48711278|NCT01221025|DRUG|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
48711279|NCT00549185|DRUG|SAR3419|Intravenous infusion
48711280|NCT00912080|GENETIC|genomic signature|genomic signature analysis
48711281|NCT00642148|DRUG|GW856553|Active tablet
48377917|NCT02553291|BEHAVIORAL|SystemCHANGE|
48711282|NCT00642148|DRUG|Placebo|Placebo tablet and inhaler
48711283|NCT00642148|DRUG|Seretide|Active comparator inhaler
48711284|NCT01540409|DRUG|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
48711285|NCT00269503|PROCEDURE|Prone Distraction|
48711286|NCT00269503|PROCEDURE|Side-Posture Manipulation|
48711287|NCT00269503|PROCEDURE|Side-Posture Manipulation & Prone Distraction|
48711288|NCT00269503|PROCEDURE|Usual Care (Control Group)|
48377918|NCT02553291|BEHAVIORAL|Control|
48711289|NCT04363593|BIOLOGICAL|Serological test|Serological testing is performed for patients with confirmed COVID-19 infection by RT-PCR.
48711290|NCT04363593|BIOLOGICAL|Serum test|Use of the serum taken from patients consulted for suspicion of COVID-19 before the beginning of the trial
48711291|NCT05184465|PROCEDURE|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
48711292|NCT02306304|OTHER|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
48377919|NCT01305460|DRUG|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
48377920|NCT05173025|DRUG|Fimasartan|- Fimasartan group: fimasartan, 60 mg once a day, oral administration
48377921|NCT05814380|RADIATION|99mTc-DPD scintigraphy|99mTc-DPD scintigraphy
48377922|NCT05814380|DIAGNOSTIC_TEST|Collection of blood samples and echocardiography|Collection of blood samples from a peripheral vein and TTR sequencing. Transthoracic echocardiography.
48711293|NCT01752790|DRUG|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
48377923|NCT01135251|DRUG|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
48711294|NCT01752790|DRUG|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
48377924|NCT01135251|DRUG|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
48711295|NCT04391595|DRUG|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
48377925|NCT02341573|DRUG|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
48377926|NCT02341573|DRUG|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
48711296|NCT04391595|DRUG|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
48377927|NCT02113904|DRUG|Adalimumab|6 injections (one every 15 days during 3 months)
48377928|NCT02892916|DRUG|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
48377929|NCT02892916|DRUG|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
48377930|NCT01458535|DRUG|ABT-450|tablets
48377931|NCT01458535|DRUG|ABT-267|tablets
48377932|NCT01458535|DRUG|ribavirin|tablets
48377933|NCT01458535|DRUG|ritonavir|capsules
48377934|NCT05143489|DRUG|Preservative Free Lidocaine|The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
48517663|NCT06090201|OTHER|3-Tesla brain MRI and a comprehensive neuropsychological assessment|Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.
48517664|NCT04740450|DEVICE|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm _ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
48377935|NCT05143489|DRUG|Saline|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
48377936|NCT04657861|DRUG|APRIL CAR-T cells|Each subject receive APRIL CAR T-cells by intravenous infusion
48377937|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)|Huoxin Pill (concentrated pill) is composed of Radix Ginseng, Radix Aconiti Lateralis Preparata, Ganoderma, Flos Carthami, artificial Moschus, cultured calculus bovis in vitro, Fel Ursi, Margarita, Venenum Bufonis, and Borneolum Syntheticum. It has the effect of invigorating qi and promoting blood circulation. It has been marketed in China for more than 30 years. Clinical studies have shown that Huoxin Pill (concentrated pill) has significant clinical efficacy in improving the symptoms and prognosis of coronary heart disease and angina pectoris. Basic studies have also confirmed that Huoxin Pill (concentrated pill) can play a role in myocardial protection by dilating coronary arteries and promoting angiogenesis. It produced by Guangzhou yuekang biopharmaceuticals co., ltd.
48377938|NCT05489016|DRUG|Yuekang Huoxin Pills (concentrated pills)simulant|Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
48517665|NCT04740450|DEVICE|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
48377939|NCT00519909|OTHER|Dairy calcium|Diets with different content of calcium and fat
48377940|NCT04992780|RADIATION|Hypo-Fractionation|62.5 Gy in 25 fractions of 2.5 Gy/fraction
48177388|NCT04322812|DEVICE|Active PBMT|The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index \[WPI\] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.
48377941|NCT04992780|RADIATION|Standard-Fractionation|60 Gy in 30 fractions of 2 Gy/fraction
48377942|NCT04992091|OTHER|constructive debriefing|Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
48377943|NCT00589966|BEHAVIORAL|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
48377944|NCT00589966|BEHAVIORAL|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
48377945|NCT05033691|RADIATION|Stereotactic surgery|At two month (8 weeks) post Osimertinib start, patients will be randomized into one of the two study arms. Arm A patients will be treated with stereotactic surgery (SRS). In both arms Osimertinib treatment will continue.
48377946|NCT05959174|DEVICE|3D printed mitchigen appliance|the process of appliance construction done by intra-oral scanning of the arch and 3d printing
48517666|NCT01485822|PROCEDURE|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
48517667|NCT01485822|DRUG|Travoprost 0.004% ophthalmic solution|
48517668|NCT03649984|BEHAVIORAL|Symptom Navi© Program|Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.
48517669|NCT01386255|DRUG|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
48177389|NCT04322812|DEVICE|Placebo PBMT|The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to \>1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
48177390|NCT04331132|DRUG|Tolvaptan 15 MG|vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
48377947|NCT05959174|DEVICE|side chair appliance|the impresion will be taken to make a cast to reconstruct the appliance
48377948|NCT01301625|DEVICE|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
48517670|NCT01386255|DRUG|placebo|placebo. No other names
48517671|NCT02240615|DEVICE|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
48517672|NCT03714243|DEVICE|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
48517673|NCT02660905|DRUG|E/C/F/TAF;|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
48377949|NCT03811652|DRUG|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
48377950|NCT06143176|BEHAVIORAL|VR-based occupational therapy|All patients will undergo 20 sessions of virtual reality based occupational therapy for 30 minutes a day, 5 days a week for 4weeks
48377951|NCT00002037|DRUG|Trifluridine|
48377952|NCT02810210|OTHER|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
48377953|NCT02810210|OTHER|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
48517674|NCT02660905|DRUG|Ledipasvir-Sofosbuvir|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
48517675|NCT00369486|PROCEDURE|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
48517676|NCT00369486|DRUG|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
48517677|NCT00369486|DRUG|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
48517678|NCT00369486|DRUG|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
48517679|NCT00369486|DRUG|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
48377954|NCT03602976|DRUG|Ursodeoxycholic Acid|weight-based dosing
48377955|NCT01977703|OTHER|Ultra Conservative ICD Programming|
48377956|NCT01977703|OTHER|Traditional ICD Programming|
48377957|NCT00012766|BEHAVIORAL|Integrated team care|
48177391|NCT06542406|DEVICE|Endotracheal intubation|The first 40 successful and the first 40 unsuccessful ETE procedures were included in the study.
48177392|NCT01667549|OTHER|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
48177393|NCT00080860|GENETIC|microarray analysis|
48177394|NCT00080860|OTHER|immunohistochemistry staining method|
48177395|NCT00080860|PROCEDURE|conventional surgery|
48177396|NCT00080860|PROCEDURE|lymphangiography|
48177397|NCT00080860|PROCEDURE|radionuclide imaging|
48177398|NCT00080860|PROCEDURE|sentinel lymph node biopsy|
48177399|NCT00080860|RADIATION|technetium Tc 99m sulfur colloid|
48177400|NCT03016598|DRUG|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
48177401|NCT03016598|DRUG|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
48377958|NCT01001091|DRUG|AL-38583 ophthalmic solution|
48377959|NCT01001091|DRUG|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
48377960|NCT01001091|DRUG|Dexamethasone ophthalmic suspension, 0.1%|
48377961|NCT02313246|BEHAVIORAL|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
48377962|NCT03422276|OTHER|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
48517680|NCT02536846|DRUG|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
48177402|NCT01859611|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
48177403|NCT05330052|DEVICE|Agilik|The Agilik is a leg orthosis device supporting the knee joint, and is intended to be worn on one or both the legs. The device is customized for single patient use. It is composed of custom-fabricated polypropylene leg shells (thigh, calf and foot components) with joint supports, actuator, sensors, cabling and a battery waist pack. The Agilik is attached to the patient using straps - two on the thigh and two on the shank. A rotational linkage connects the thigh and calf portions of the device, is placed lateral to the knee joint, and is aligned with the knee center of rotation.
48177404|NCT03497715|DRUG|Ibuprofen lysine|Test 1
48377963|NCT03422276|OTHER|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
48377964|NCT05277987|DRUG|HEC-016(0.5×10^6 CAR-T Cells)|The initial dose is set to 0.5 × 10\^6 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group. DLT was observed within 28 days after cell infusion.
48377965|NCT05277987|DRUG|HEC-016(0.5×10^6.5 CAR-T Cells)|The Second dose is set 0.5 × 10\^6.5 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
48517681|NCT01133457|DRUG|Finasteride|Finasteride tablets 1 mg
48517682|NCT00985244|DRUG|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
48177405|NCT03497715|DRUG|Ibuprofen Sodium|Test 2
48177406|NCT03497715|DRUG|Ibuprofen|Test 3
48177407|NCT03497715|DRUG|Ibuprofen (Nurofen)|Reference 1
48177408|NCT03497715|DRUG|Ibuprofen (Wockhardt)|Reference 2
48517683|NCT00985244|DRUG|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
48711297|NCT05409859|OTHER|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
48177409|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
48177410|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
48377966|NCT05277987|DRUG|HEC-016(0.5×10^7 CAR-T Cells)|The Third dose is set 0.5 × 10\^7 car-t cells / kg, and 3 \~ 6 subjects are expected to be included in the dose group.
48377967|NCT05198414|OTHER|Focus group|Qualitative research methodology with healthcare workers
48711298|NCT02903758|OTHER|cross sectional|
48377968|NCT04675489|OTHER|Procedure: Vivity Toric IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
48711299|NCT00349687|BEHAVIORAL|self-control practice|
48711300|NCT04270058|DRUG|inotersen|TEGSEDI injection, for subcutaneous use
48711301|NCT01225965|DEVICE|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
48711302|NCT01225965|DEVICE|Placebo|Once daily inhalation of Placebo Inhalation Solution
48711303|NCT05826691|PROCEDURE|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
48020150|NCT02205619|DEVICE|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
48517684|NCT00655772|OTHER|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
48517685|NCT03744299|OTHER|Questionnaire|Patients and caregivers are asked to complete a questionnaire
48517686|NCT02903706|OTHER|Measure of Plasmodium prevalence (PCR)|
48517687|NCT05939765|DRUG|Antipsychotic|Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
48711304|NCT02444546|OTHER|Laboratory Biomarker Analysis|Correlative studies
48711305|NCT02444546|BIOLOGICAL|Sargramostim|Given SC
48711306|NCT02444546|BIOLOGICAL|Wild-type Reovirus|Given IV
48711307|NCT01540448|PROCEDURE|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
48711308|NCT01540448|PROCEDURE|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
48177411|NCT01085383|DRUG|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
48711309|NCT01540448|PROCEDURE|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
48711310|NCT04844203|DIAGNOSTIC_TEST|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
48711311|NCT03168243|DIETARY_SUPPLEMENT|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
48020151|NCT02205619|DEVICE|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
48177412|NCT00675792|DRUG|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
48177413|NCT00675792|DRUG|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
48177414|NCT00675792|DRUG|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
48177415|NCT03790904|OTHER|Co.|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
48177416|NCT03790904|OTHER|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
48177417|NCT03790904|OTHER|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
48177418|NCT04587986|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
48177419|NCT03060382|DEVICE|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
48177420|NCT03060382|BIOLOGICAL|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
48177421|NCT03535805|BEHAVIORAL|Mind My Mind (MMM)|"Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (\>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks."
48177422|NCT03535805|BEHAVIORAL|Treatment as Usual (TAU)|The parents in the TAU group are offered two sessions (week 2 and week 17) to support their attempts to seek help for the child in the municipality. This coordination is provided by psychologists (or other local professionals) who hold records of the currently available treatment options in the municipality. The TAU vary considerably from no intervention to counselling, talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. Some children are offered CBT interventions, but access to manualized treatment is generally very limited.
48177423|NCT03653247|BIOLOGICAL|Plerixafor|Plerixafor subcutaneous injection will be administered prior to apheresis.
48177424|NCT03653247|DRUG|Busulfan|Busulfan IV infusion will be administered as myeloablative conditioning therapy.
48177425|NCT03653247|GENETIC|BIVV003|BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.
48177426|NCT04325009|DRUG|Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab|"1. st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab"
48177427|NCT04325009|DRUG|Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab|"1. st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Lipitor 80mg Tab"
48177428|NCT01881152|OTHER|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
48177429|NCT01881152|OTHER|Usual care|Information on stroke usually delivered at the community level.
48177430|NCT00509405|DRUG|potassium citrate|6 times 10 mEq per day, oral for 24 months
48517688|NCT05949021|DRUG|Combination of liposomal doxorubicin|Combination of liposomal doxorubicin 30 milligrams per square meter and carboplatin (area under the curve 5), administered every 4 weeks for 4 cycles.
48711312|NCT03352583|DIETARY_SUPPLEMENT|Protein|40g calcium caseinate
48711313|NCT02496845|DRUG|VL#FIA3-30|Vasoactive dual treatment (MH30-01 \& IS045-01)
48711314|NCT01882010|DRUG|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
48377969|NCT01006031|DRUG|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
48177431|NCT00174447|DRUG|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
48377970|NCT05184491|DRUG|Naïve patients - ACO therapy|Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
48377971|NCT05184491|DRUG|Naïve patients - LNDL therapy|Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
48711315|NCT01882010|DRUG|placebo|saline solution daily subcutaneous injection 56 days
48177432|NCT05087836|DEVICE|Sensor at forehead area|NIRS sensor attached at forehead area.
48177433|NCT05087836|DEVICE|Sensor at temporal area|NIRS sensor attached at temporal area.
48177434|NCT04475237|OTHER|CT-scan evaluation and segmentation|CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.
48177435|NCT00761956|DEVICE|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
48177436|NCT00761956|DEVICE|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
48711316|NCT01882010|DIAGNOSTIC_TEST|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
48711317|NCT03887260|DRUG|Morphine PCA pump|Morphine given postoperatively.
48177437|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
48177438|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
48177439|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
48177440|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
48177441|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Cone Coil|The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.
48177442|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Sham Coil|The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
48177443|NCT04739410|DRUG|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well
48177444|NCT02906280|DEVICE|EBUS-TBNA needle|tissue sampling
48177445|NCT01805206|OTHER|Assessment of urinary iFABP|
48177446|NCT01805206|OTHER|Administration of enteral feedings|
48177447|NCT00941642|DRUG|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
48377972|NCT05184491|DRUG|Naïve patients - MNDL therapy|Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
48377973|NCT05184491|DRUG|Treatment-experienced patients- LNDL therapy|Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
48711318|NCT03887260|PROCEDURE|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
48711319|NCT03887260|DRUG|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
48711320|NCT02253823|DRUG|EFV|
48711321|NCT02253823|DRUG|TPV/RTV - low dose|
48711322|NCT02253823|DRUG|TPV/RTV - high dose|
48711323|NCT00136240|BEHAVIORAL|Computer Assisted Education for Behavior Change|
48711324|NCT00167102|DRUG|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
48711325|NCT03400657|PROCEDURE|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
48020152|NCT02205619|DEVICE|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
48020153|NCT03374124|DIAGNOSTIC_TEST|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
48020154|NCT01469676|DEVICE|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
48177448|NCT00941642|DRUG|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
48377974|NCT05184491|DRUG|Treatment-experienced patients- MNDL therapy|Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
48377975|NCT02866201|OTHER|Rectal swab|
48377976|NCT06165575|DEVICE|Press needle|Press needle is a very small needles (1-3 mm long) that are 'pressed' onto acupuncture point and are held in place with a small, sterile surgical adhesive patch.
48377977|NCT06165575|DEVICE|Sham press needle|Sham press needle is a surgical adhesive patch placed on acupuncture points
48377978|NCT05040295|DRUG|ritlecitinib|30 mg intact adult capsule
48377979|NCT05040295|DRUG|ritlecitinib|10 mg pediatric capsule
48377980|NCT05040295|DRUG|ritlecitinib|30 mg spray congealed beads
48377981|NCT05079711|DEVICE|SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)|The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
48377982|NCT04941014|BEHAVIORAL|Light Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Leisure Walk for 35 minutes
48377983|NCT04941014|BEHAVIORAL|Moderate Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform Brisk Walk for 30 minutes
48377984|NCT04941014|BEHAVIORAL|Vigourous Physical Activity|The guidelines from Rapid Assessment of Physical Activity (RAPA) participants were asked to perform jogging for 15 minutes
48377985|NCT06116357|DEVICE|External Ultrasonic Micro-bubble|The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
48517689|NCT01320891|BEHAVIORAL|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
48020155|NCT00801684|DRUG|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
48377986|NCT02503696|DEVICE|Stool Collection Kit|Stool Collection Kit.
48377987|NCT00917904|DRUG|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
48377988|NCT00917904|DRUG|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
48377989|NCT02222246|DRUG|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
48377990|NCT02222246|DRUG|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
48020156|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
48020157|NCT00801684|DRUG|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
48020158|NCT00801684|DRUG|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
48177449|NCT01965509|DRUG|PEX168 or placebo|injection has to administered subcutaneously weekly
48177450|NCT00740870|DEVICE|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
48711326|NCT03379987|DRUG|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
48711327|NCT03379987|DRUG|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
48711328|NCT00611468|DRUG|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
48177451|NCT03001622|BIOLOGICAL|IFX-1|chimeric, monoclonal antibody
48177452|NCT00038298|DRUG|Placebo|Placebo given 3 times weekly
48711329|NCT00611468|DRUG|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
48711330|NCT05207332|DIETARY_SUPPLEMENT|CHO+PRO|A vegan product containing carbohydrate and protein
48711331|NCT05207332|DIETARY_SUPPLEMENT|CHO|containing carbohydrate
48177453|NCT00038298|DRUG|AMG 719|50 mg 3 times weekly
48177454|NCT00038298|DRUG|AGM 719|200 mg 3 times weekly
48377991|NCT02222246|DRUG|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
48377992|NCT02222246|DRUG|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
48377993|NCT01312948|DEVICE|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
48711332|NCT00100230|DRUG|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
48711333|NCT02267330|PROCEDURE|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
48711334|NCT05933642|DRUG|Aminophylline|aminophylline 150mg
48711335|NCT05933642|DRUG|Frusemide|frusemide 120mg
48711336|NCT02885870|PROCEDURE|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
48711337|NCT00241514|DRUG|Esomeprazole|
48177455|NCT00038298|DRUG|AMG 719|400 mg 3 times weekly
48177456|NCT00038298|DRUG|placebo to AMG 719|Placebo dose given 3 times weekly
48177457|NCT01818609|BEHAVIORAL|Step reduction|taking less than 1500 steps/d
48177458|NCT01615172|PROCEDURE|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
48177459|NCT06407609|DIETARY_SUPPLEMENT|Curcuma and boswellia extracts plus low fodmap diet|Low Foodmap diet + Curcuma and boswellia extracts both formulated in sunflower lecithin (Phytosome™) and processed with a strong commitment to sustainability
48177460|NCT06407609|OTHER|Low Foodmap diet|such as lactose or gluten free diet in the last 6 months
48177461|NCT04961632|DRUG|Tamoxifen|Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of \>30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
48177462|NCT04961632|DRUG|Tamoxifen|Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
48177463|NCT04115852|BEHAVIORAL|fmri|functional magnetic resonance imaging
48177464|NCT04135508|DRUG|BAT1406|40mg/0.8ml
48177465|NCT04135508|DRUG|Humira|40mg/0.8ml
48177466|NCT03701633|DIAGNOSTIC_TEST|Postpartum ultrasound|Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
48177467|NCT01494545|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
48177468|NCT04429243|DEVICE|GORE® VIABAHN® Stent Graft|On Day 1, participants will receive the GORE® VIABAHN® Stent Graft.
48177469|NCT00480064|DRUG|Lomustine, intermediate dose cytarabine|
48177470|NCT05005299|DRUG|Venetoclax|Venetoclax is administered as an oral tablet once daily.
48177471|NCT05005299|DRUG|Fludarabine|Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
48177472|NCT05005299|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
48177473|NCT02400814|DRUG|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
48177474|NCT02400814|RADIATION|Stereotactic Body Radiation Therapy|Undergo SAR
48177475|NCT02311777|DRUG|Pregabalin|Pregabalin will be given orally during preoperative period
48177476|NCT02311777|DRUG|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
48177477|NCT02311777|DRUG|Placebo|Placebo will be given orally during preoperative period
48177478|NCT05256810|DRUG|ALN-XDH|ALN-XDH administered by SC injection
48177479|NCT05256810|DRUG|Placebo|Placebo administered by SC injection
48177480|NCT02187289|DEVICE|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
48177481|NCT02187289|DEVICE|Compression Sleeve, daytime wear|
48377994|NCT05649865|DIAGNOSTIC_TEST|Blood sample|Blood samples for analysis of circulating tumour HPVDNA
48711338|NCT05011214|DRUG|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
48711339|NCT05011214|DRUG|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
48711340|NCT03598205|COMBINATION_PRODUCT|DIABEC plus intravitreal dexamethazone|Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
48177482|NCT02187289|DEVICE|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
48177483|NCT03887247|BEHAVIORAL|E-mail Alert|Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.
48177484|NCT04221789|OTHER|TB treatment assistant|Cell phone app to support self administered treatment and monitor adherence
48177485|NCT01729468|DRUG|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
48177486|NCT01729468|DRUG|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
48177487|NCT03344016|OTHER|Contact by clinical center|Patients will be acitvely contacted by the clinical center for follow-up procedure
48177488|NCT02335333|OTHER|No treatment|
48177489|NCT00276666|DRUG|cisplatin|
48377995|NCT02988830|DEVICE|Subcutaneous Electric Lumbar Stimulation|
48377996|NCT03874507|OTHER|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
48177490|NCT00276666|DRUG|lomustine|
48177491|NCT00276666|DRUG|vincristine sulfate|
48177492|NCT00276666|PROCEDURE|adjuvant therapy|
48377997|NCT00226447|DRUG|Pegylated Interferon|
48377998|NCT00226447|DRUG|Lamivudine|
48711341|NCT01133626|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
48711342|NCT01133626|DRUG|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
48711343|NCT01133626|DRUG|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
48177493|NCT00276666|RADIATION|radiation therapy|
48177494|NCT00176059|DRUG|intravenous immunoglobulins (IVIG)|
48177495|NCT00176059|PROCEDURE|kidney transplantation|
48177496|NCT05549349|PROCEDURE|Cholecystectomy|Gallbladder removal
48177497|NCT00301483|DRUG|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
48177498|NCT00301483|OTHER|Standard of Care|Standard Therapy
48177499|NCT03031210|DRUG|Amoxicillin|(90 mg/kg/day) twice daily
48177500|NCT05907642|OTHER|Prune (dried plum)|Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
48177501|NCT02719756|DRUG|Metformin|Metformin tablets 1000 mg
48177502|NCT02719756|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets
48177503|NCT02719756|DRUG|Metformin up-titration|
48177504|NCT02775838|DRUG|Indocyanine green|perioperative application of Indocyanine green (ICG)
48177505|NCT00190099|DEVICE|Dexamethasone-Eluting Stent|
48177506|NCT02037776|DRUG|Rikkunshito|- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
48177507|NCT02037776|DRUG|Rikkunshito placebo|- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
48177508|NCT01640171|PROCEDURE|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
48177509|NCT01640171|DRUG|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
48517690|NCT01320891|BEHAVIORAL|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
48711344|NCT01133626|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
48711345|NCT01056003|OTHER|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
48177510|NCT01640171|DRUG|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
48177511|NCT01640171|DRUG|Acuvail|Anti-inflammatory drop given after treatment
48177512|NCT01640171|DRUG|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
48177513|NCT03039881|DEVICE|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
48177514|NCT02470923|DRUG|Nicotine replacement therapy|
48177515|NCT02470923|BEHAVIORAL|Intensive counseling|
48177516|NCT02470923|BEHAVIORAL|Medical advice|
48517691|NCT00004492|DRUG|clotrimazole|
48711346|NCT02120495|PROCEDURE|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
48711347|NCT00819377|DRUG|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
48711348|NCT00819377|DRUG|Normal saline|5 ml normal saline by inhalation over 15 min
48711349|NCT06411132|OTHER|observational study|observational study
48711350|NCT04401345|DRUG|Glycopyrrolate 0.2 MG/ML|In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
48177517|NCT03652350|PROCEDURE|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
48177518|NCT04268537|DRUG|PD-1 blocking antibody+standard treatment|After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
48177519|NCT04268537|DRUG|Thymosin+standard treatment|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
48177520|NCT04268537|OTHER|standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
48177521|NCT00047177|DRUG|Oxaliplatin|
48177522|NCT01832662|OTHER|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
48177523|NCT01832662|OTHER|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
48177524|NCT01832662|OTHER|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
48177525|NCT00460668|BEHAVIORAL|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
48177526|NCT02432963|OTHER|Laboratory Biomarker Analysis|Correlative studies
48177527|NCT02432963|BIOLOGICAL|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
48177528|NCT02432963|BIOLOGICAL|Pembrolizumab|Given IV
48517692|NCT00004492|DRUG|hydroxyurea|
48517693|NCT06581653|BEHAVIORAL|Phone-based PERT education intervention|Participants who allocate to the intervention group will receive regular phone-based PERT education intervention by professional team.
48517694|NCT03977142|DIAGNOSTIC_TEST|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
48711351|NCT04401345|DRUG|Normal saline|In this group, the patients will receive 1 ml of 0.9% normal saline
48711352|NCT02470754|DEVICE|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
48711353|NCT02470754|DEVICE|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
48020159|NCT00801684|DRUG|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
48020160|NCT06280352|DEVICE|Custom made Total Knee Arthroplasty|Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
48020161|NCT06280352|DEVICE|Functionally aligned robotically assisted total knee arthroplasty|Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
48177529|NCT04500613|PROCEDURE|Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.
48177530|NCT04500613|OTHER|No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)|Patients who are randomized to this group will not receive a bilateral erector spinae plane block
48177531|NCT02247843|BIOLOGICAL|βAS3-FB vector transduced peripheral blood CD34+ cells|CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
48177532|NCT00344032|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
48177533|NCT00344032|BIOLOGICAL|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
48177534|NCT01096576|DRUG|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
48177535|NCT01096576|DRUG|placebo|orally twice daily for 5 days
48177536|NCT01733589|DRUG|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
48177537|NCT01733589|DRUG|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
48177538|NCT01733589|DRUG|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
48177539|NCT01733589|OTHER|laboratory biomarker analysis|
48177540|NCT01733589|OTHER|CT perfusion imaging|
48177541|NCT05294718|PROCEDURE|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
48377999|NCT02002429|PROCEDURE|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
48177542|NCT05294718|PROCEDURE|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
48177543|NCT04477993|DRUG|Janus Kinase Inhibitor (ruxolitinib)|5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.
48177544|NCT04477993|OTHER|Placebo|Placebo tablets P.O. b.i.d. for 14 days.
48177545|NCT02893098|DRUG|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
48177546|NCT02893098|DRUG|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
48177547|NCT00910325|PROCEDURE|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
48378000|NCT02002429|PROCEDURE|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
48177548|NCT04698915|DRUG|Drug GC4711|15 Minute IV Infusion
48177549|NCT04698915|DRUG|Placebo|15 Minute IV Infusion
48177550|NCT01531101|BEHAVIORAL|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
48177551|NCT00479219|DRUG|GSI-953|
48177552|NCT00479219|OTHER|Placebo|
48177553|NCT02019641|OTHER|Aerobic Exercise Training (AET)|walking on a treadmill at vigorous intensity for up to 45 minutes
48177554|NCT02019641|OTHER|Education|Weekly education
48177555|NCT04690478|DEVICE|Electronic remote blood pressure monitor|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
48177556|NCT04690478|DEVICE|Ordinary household electronic sphygmomanometer|One group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
48177557|NCT04690478|DEVICE|Office electronic sphygmomanometer|One group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
48177558|NCT01209598|DRUG|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
48177559|NCT01209598|DRUG|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
48378001|NCT02002429|PROCEDURE|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
48177560|NCT02025855|DRUG|Methadone|
48177561|NCT02025855|DRUG|Placebo|
48177562|NCT04603833|DRUG|SHR3680+Docetaxel|Participants will receive SHR3680 combined with Docetaxel
48177563|NCT04603833|DRUG|SHR3680|Participants will receive SHR3680
48177564|NCT04603833|DRUG|Docetaxel|Participants will receive Docetaxel
48177565|NCT04632043|OTHER|Endotracheal intubation|Endotracheal intubation
48177566|NCT02209610|DEVICE|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
48177567|NCT02209610|DRUG|Intrathecal Fentanyl|Mu-opioid receptor agonist
48177568|NCT01003262|OTHER|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
48177569|NCT01003262|OTHER|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
48177570|NCT01270828|DRUG|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
48177571|NCT01270828|DRUG|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
48177572|NCT02246881|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
48378002|NCT02246244|DRUG|Escitalopram|
48177573|NCT06366503|PROCEDURE|Fractional Ablative CO2 Laser|A fractional ablative DEKA SmartXide Tetra CO2 laser treatment was performed after a 14-day washout period. Subjects were numbed for 1 hour prior to procedure with topical numbing cream (lidocaine 23%, tetracaine 7%). The global face was treated with a single pass. Treatment parameters include power 20 W, spacing 500 um (13% density), Dwell time 1200 us DEKA pulse mode, spray mode on.
48378003|NCT02246244|OTHER|Placebo|
48378004|NCT00674440|DRUG|F-DOPA|0.08-0.16 mCi/kg once
48378005|NCT00674440|RADIATION|PET scan|
48378006|NCT04423289|OTHER|Farmalarm|Monitoring after COVID-19 discharge from hospital via Farmalarm app
48378007|NCT00145795|DRUG|Kaletra + Current Dual NRTI Backbone|
48378008|NCT00145795|DRUG|Current Regimen|
48378009|NCT01530776|BEHAVIORAL|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
48517695|NCT00715624|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48378010|NCT04588740|DRUG|concentrated beet root juice|On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.
48378011|NCT04588740|DRUG|Placebo beet root juice|This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
48378012|NCT05141110|DRUG|NVP-1705|NVP-1705
48517696|NCT00715624|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48517697|NCT00715624|DRUG|Basal Insulin|Dose to be kept stable.
48177574|NCT06366503|OTHER|Facial Cleanser|Facial cleanser was to be used by subjects twice daily during the 14-day washout period and three times daily during the 14-day post-procedure timeline.
48177575|NCT06366503|OTHER|Facial Moisturizer|A bland facial moisturizer was to be used by subjects twice daily during the 14-day washout period and three times daily between day 3 and 14 post-procedure. Two pumps were to be applied to the face (avoiding the upper eyelid) after applying the active and comparator.
48177576|NCT06366503|OTHER|Sunscreen|During the 14-day washout period, a bland sunscreen was to be used by subjects in the morning after cleansing and facial moisturizer application with reapplications as needed throughout the day per FDA recommendations. For days 3-14 post-procedure, the bland sunscreen was to be used daily by subjects in the morning and afternoon after cleansing, split-face application of the active post-procedure cream and comparator anhydrous formulation, and facial moisturizer application.
48177577|NCT06366503|OTHER|Basic Ointment|The basic ointment was used only on the comparator side for three days (72 hours) post-procedure. This was a requirement of the comparator anhydrous formulation.
48177578|NCT06302595|DEVICE|MRI-guided prostate biopsy using the needle holder frame.|A needle holding frame will be used during a routine MRI-guided prostate biopsy procedure, where tissue samples are obtained from each suspected region found on MRI using an MRI-conditional core biopsy needle. In this routine procedure, tissue sampling is performed in an MRI gantry and intraprocedural MRI is used to localize the regions.
48177579|NCT00327353|DRUG|formoterol (TURBOHALER)|
48177580|NCT00327353|DRUG|Salmeterol (DISKUS)|
48378013|NCT05141110|DRUG|NVP-1705-R|NVP-1705-R
48711354|NCT02501317|BEHAVIORAL|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
48711355|NCT02501317|BEHAVIORAL|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
48177581|NCT03745586|DRUG|Tocilizumab|Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
48177582|NCT03745586|DRUG|Glucocorticoids|Day0-day2: methylprednisolone 500mg i.v.
48177583|NCT05475847|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection|C-TIL052A injection followed by injection of IL-2
48177584|NCT05605288|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Coronary angiography +/- percutaneous coronary intervention
48177585|NCT00908349|DRUG|Oxcarbazepine XR|Open Label Study
48177586|NCT05811884|DEVICE|Rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
48177587|NCT03548493|DRUG|Magnesium sulphate|Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
48177588|NCT03548493|DRUG|Fentanyl|Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
48177589|NCT03548493|DRUG|Propofol|In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
48177590|NCT03781245|OTHER|All the Right Moves for Subcontractors|"All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change."
48177591|NCT06060483|DEVICE|CGM|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR\>70%, TBR\<4%, TAR\<25%, and HbA1c\<7.0%. After the treatment reaches the standard, CGM is worn every six months.
48177592|NCT06141200|DRUG|NW Roselle|NW Roselle is a powdered extract from the flowers of Hibiscus Sabdariffa (300mg) and the leaves of Olea europaea (200 mg).
48378014|NCT03493477|OTHER|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
48378015|NCT02716415|DRUG|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
48177593|NCT06141200|DRUG|Captopril 25Mg Tab|Active Comparator
48177594|NCT03345147|OTHER|High Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
48177595|NCT03345147|OTHER|Normal Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
48517698|NCT00715624|DRUG|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
48517699|NCT00715624|DEVICE|Pen auto-injector|
48711356|NCT02488213|OTHER|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
48177596|NCT03553290|DEVICE|A.R.C. FOX Laser-FOX Q-810nm|805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
48517700|NCT01023035|DRUG|Boceprevir|800 mg given three times a day (TID), orally (PO)
48177597|NCT03553290|PROCEDURE|Control|Mechanical debridement alone
48517701|NCT01023035|DRUG|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
48517702|NCT01023035|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
48177598|NCT01601912|DRUG|Atomoxetine|40 mg, 1 application
48711357|NCT02488213|OTHER|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
48378016|NCT02716415|DRUG|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment"
48711358|NCT04773873|DEVICE|PFM Crowns on gold coping cast-on|Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck
48711359|NCT04773873|DEVICE|hybrid abutment lithium disilicate crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase
48711360|NCT04773873|DEVICE|hybrid abutment ceramic polymer infiltrated crown|Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
48177599|NCT01601912|DRUG|Citalopram|20 mg, 1 application
48711361|NCT06363318|PROCEDURE|Laparoscopic appendicectomy|In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
48711362|NCT05834491|DEVICE|minimal shoes and foot strengthening and flexibility exercises|Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
48711363|NCT05834491|DEVICE|Supportive Footwear, foot orthotic device and foot flexibility exercises|sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
48711364|NCT05162001|DRUG|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
48177600|NCT03887169|DRUG|Methionine|Administration of methionine from D1 to D60
48177601|NCT03887169|DRUG|Vitamin B12, B9, B6, C supplementation|In case of hyperhomocysteinemia
48177602|NCT03887169|DIAGNOSTIC_TEST|Methionine/homocysteine Dosage|Plasma concentration control of methionine and homocysteine from D0 to D75
48177603|NCT03887169|DIAGNOSTIC_TEST|Thoracic CT scan|At D60
48177604|NCT03887169|DIAGNOSTIC_TEST|Abdominal and liver ultrasound.|At D60
48378017|NCT05423639|DEVICE|palodent|innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.
48378018|NCT05423639|DEVICE|optracontact|The instrument is used to achieve large and tight proximal contacts in posterior teeth.
48388016|NCT04417127|OTHER|Integrated Community-Based (ICB) Care|The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.
48711365|NCT00148785|DRUG|Indinavir/Ritonavir/Fosamprenavir|
48711366|NCT02088502|DRUG|N-acetylcysteine|
48711367|NCT02088502|DRUG|Theophylline|
48177605|NCT03887169|DIAGNOSTIC_TEST|Brain MRI|In case of abnormal neurological examination
48177606|NCT03928392|BEHAVIORAL|SCUBA with Occupational Therapy (OT)|Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.
48177607|NCT03928392|BEHAVIORAL|Self-Contained Underwater Breathing Apparatus (SCUBA) without OT|Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
48177608|NCT05127018|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
48177609|NCT02493465|DRUG|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
48711368|NCT02088502|DRUG|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
48177610|NCT05397366|DIAGNOSTIC_TEST|Task Specific Training|"Group A will be given Task Specific protocol with routine physical therapy treatment for 45 mins on the upper limb for 3 days a week for a period of 12 weeks.~This Task Specific protocol will include different exercises like, do the polishing of the table top , can perform arm cradling, can supinate and pronate the cylindrical object with arm , while pushing the cylindrical object can extend the wrist , can reach forward to touch or to pick an object , can bend side ways to pick the object and place it on the table in front , can pour the 1/2cup of water to the wide jar that is held by the patient in other hand , patient can comb his hair , patient can drink and eat independently , can lift the jar and bring it close to lips , can pick up pen by using thumb and two fingers , can do the stacking checkers , can throw a ball into the basket , can push the ball on wall from front and side."
48177611|NCT05397366|DIAGNOSTIC_TEST|Neurodevelopmental Training|"Group B will receive the Neurodevelopmental protocol with the routine physical therapy for 45 mins on the upper limb 3 times a week for period of 12 weeks. The intervention will be performed by the trained physical therapist.~This Neurodevelopmental protocol will include different exercises like , patient should sit while bearing weight , patient can do self-overhead movements with hand clasped , while holding the gymnastic ball reach forward and overhead position while sitting , weight bearing while plantigrade or quadruped position , while sitting or standing can move the ball in forward , backward and sideways."
48177612|NCT02450890|DRUG|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
48388017|NCT04417127|OTHER|Microfinance|"Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning."
48517703|NCT01023035|DRUG|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
48517704|NCT00900419|OTHER|immunohistochemistry staining method|Laboratory test
48711369|NCT04104685|COMBINATION_PRODUCT|FCD105|Experimental combination
48711370|NCT04104685|DRUG|3% Minocycline Foam|Active Comparator
48711371|NCT04104685|DRUG|0.3% Adapalene Foam|Active Comparator
48711372|NCT04104685|OTHER|Vehicle Foam|Placebo
48711373|NCT00746915|DEVICE|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
48711374|NCT00205842|DRUG|alvimopan|
48711375|NCT02104271|PROCEDURE|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
48711376|NCT02104271|PROCEDURE|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
48177613|NCT02450890|DRUG|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
48177614|NCT02370901|DEVICE|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
48177615|NCT02370901|BEHAVIORAL|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
48177616|NCT05780216|DRUG|DMT + harmine|The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
48177617|NCT05780216|DRUG|Placebo|The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
48177618|NCT03297398|DRUG|Group-1 (15mg, OPK-88004)|15mg, OPK-88004
48177619|NCT03297398|DRUG|Group-2 (25 mg,OPK-88004)|25 mg,OPK-88004
48177620|NCT03297398|OTHER|Placebo|Placebo
48177621|NCT04745520|DEVICE|Rib fixation|"Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~* MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~* STRATOS™, MedXpert GmbH, Heitersheim, Germany~* NiTi Fixing PlatesTM, IAWAI, Yandzhou, China"
48177622|NCT04745520|DRUG|Analgesia|Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
48177623|NCT06054607|DIETARY_SUPPLEMENT|High-amylose maize starch+acetate/butyrate|High-amylose maize starch (HAMS), commercially available as Hylon VII (Ingredion, Inc.), to which the SCFA acetate or butyrate has been chemically added. Hylon VII is a HAMS containing \~70% amylose and used in a variety of food products. To produce SCFA-enriched HAMS, Hylon VII is chemically modified through esterification with the SCFA acetate or butyrate.
48177624|NCT06054607|OTHER|Low-amylose maize starch|Rapidly digestible low-amylose maize starch (0% amylose, 100% amylopectin) sold commercially as AMIOCA (Ingredion, Inc).
48177625|NCT01243411|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
48177626|NCT02140736|DRUG|Epoetin biosimilar|
48177627|NCT04271046|BEHAVIORAL|STAR-C-VTF|"1. One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~2. Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~3. secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months."
48378019|NCT05754359|BEHAVIORAL|I'm an Active Hero (IAAH) Intervention Program|"The I'm an Active Hero (IAAH) programme is a 10-week intervention aimed at increasing physical activity and decreasing sedentary behaviour in preschool-aged (aged 3-5 years) children. It is anticipated to begin in February 2023 to May 2023. Assessments will be conducted at baseline and immediately following the intervention. The IAAH-intervention will be implemented by the preschool teachers, who will have two teacher training sessions with the main researcher (myself). The IAAH-intervention involves environmental modifications (a classroom) to create areas with sufficient space for active play; classroom sessions these will be implemented for 10 weeks (a minimum of one hour per week); and parent involvement, such as the provision of parental-child interaction homework activities and written information (tip cards, posters, and newsletters). for parents on how to encourage their children to be active."
48378020|NCT01484717|BEHAVIORAL|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
48378021|NCT01484717|DRUG|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
48378022|NCT01484717|BEHAVIORAL|Telephone counseling|Participants receive brief twice weekly telephone counseling.
48378023|NCT02996604|OTHER|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
48378024|NCT02516462|DEVICE|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
48517705|NCT00900419|OTHER|laboratory biomarker analysis|Laboratory Test
48517706|NCT00900419|OTHER|sputum cytology|Laboratory Test
48517707|NCT00900419|PROCEDURE|biopsy|Laboratory Test
48378025|NCT02516462|DRUG|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
48517708|NCT05666076|PROCEDURE|Pericapsular nerve block|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
48711377|NCT04949568|BEHAVIORAL|Diabetes Self-Management Behaviors|The intervention is to be delivered by a diabetes educator.
48020162|NCT01019681|BIOLOGICAL|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
48711378|NCT02849782|DRUG|Fampridine|Oral intake of 10 mg twice daily
48020163|NCT02278497|OTHER|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
48020164|NCT01478789|DIETARY_SUPPLEMENT|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
48020165|NCT01478789|DIETARY_SUPPLEMENT|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
48378026|NCT03317691|DIAGNOSTIC_TEST|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
48378027|NCT00117013|DRUG|Fluorine-19-Fluoroded Xyglucose|
48378028|NCT00117013|DRUG|Topotecan|
48378029|NCT06008015|DRUG|BR1015|One tablet administered alone
48378030|NCT06008015|DRUG|BR1015-1|One tablet administered alone
48378031|NCT06008015|DRUG|BR1015-2|One tablet administered alone
48517709|NCT05666076|PROCEDURE|Suprascapular nerve block|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
48517710|NCT05666076|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
48517711|NCT05666076|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
48517712|NCT06397495|OTHER|Education|Cervical region manual therapy training will be given with flipped learning models.
48517713|NCT02732262|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
48517714|NCT02732262|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
48378032|NCT03735680|DRUG|ONM-100|A polymer micelle covalently conjugated to indocyanine green.
48378033|NCT02272569|DEVICE|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
48020166|NCT01478789|DIETARY_SUPPLEMENT|placebo|100g/d yogurt with no added plant sterol
48020167|NCT03115424|DRUG|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
48378034|NCT01561573|DEVICE|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
48517715|NCT02732262|DRUG|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
48517716|NCT04931121|DRUG|Viscosupplements|Synovial fluid is collected as part of a conventional injection of viscosupplement
48711379|NCT05448404|DRUG|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
48711380|NCT05448404|DRUG|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
48378035|NCT03878108|DIETARY_SUPPLEMENT|LCHF diet|low-carbohydrate, high-fat (LCHF)diet
48711381|NCT03564821|DRUG|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
48711382|NCT02228343|OTHER|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
48711383|NCT05254405|DRUG|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
48711384|NCT03788447|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
48711385|NCT03788447|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
48517717|NCT02166710|DEVICE|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
48517718|NCT02166710|DEVICE|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
48177628|NCT04271046|BEHAVIORAL|Control|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm."
48177629|NCT04786418|OTHER|Standard of care|Participants allocated to the control group will be given standard clinical information regarding healthy eating, physical activity and management of weight, in line with current NHS practise.
48177630|NCT04786418|DIETARY_SUPPLEMENT|Low-calorie diet|The LCD intervention group, will received a well validated, commercially available, intensive weight management protocol Counterweight-Plus.
48177631|NCT04467346|DRUG|Ped-TMZ|Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
48177632|NCT05663528|PROCEDURE|orotracheal intubation|Clinical and laboratory data will be collected from patients who are intubated after 48 hours of admission to the intensive care unit
48177633|NCT06183242|DRUG|Remaxa, enteric-coated tablets|enteric-coated tablets
48711386|NCT01276366|OTHER|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
48177634|NCT06183242|DRUG|Remaxol|solution for infusions
48177635|NCT06183242|DRUG|Placebo|enteric-coated tablets
48177636|NCT02782611|BEHAVIORAL|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
48177637|NCT04513977|OTHER|Geriatric Oncology Supportive Clinic|Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
48177638|NCT01983462|DRUG|Clonidine|
48711387|NCT01276366|OTHER|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
48177639|NCT01983462|DRUG|Hydrochlorothiazide|
48177640|NCT01983462|DRUG|Placebo|
48177641|NCT04966559|DRUG|Placebo treatment|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
48177642|NCT04966559|DRUG|Naldemedine 0.2 MG Oral Tablet|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
48177643|NCT03220997|DIETARY_SUPPLEMENT|Vitaflow Preload|Carbohydrate loading drink
48177644|NCT05196451|BEHAVIORAL|Rehabilitation based on CBT principles|Cf. arm description
48177645|NCT05047978|OTHER|Cow's milk protein infant formula|A routine cow's milk-based infant formula
48177646|NCT05047978|OTHER|Partially hydrolyzed protein infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
48177647|NCT00532246|DRUG|raloxifene|
48177648|NCT00532246|DRUG|Placebo|
48177649|NCT04962373|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
48177650|NCT06129032|PROCEDURE|Wound infiltration (LWI) + Intraperitoneal local anaesthetic (IPLA) instillation|"a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia.~A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision"
48177651|NCT06129032|PROCEDURE|Group QUADRATUS LUMBORUM BLOCK (QLB)|quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance
48177652|NCT01257399|DRUG|Asacol®|400 mg tablets
48177653|NCT01257399|DRUG|Mesalazine|400mg tablets
48177654|NCT03981718|PROCEDURE|Fat grafting|Lipoaspirates will be collected from the own subjects abdominal fat tissue, during the 2nd stage breast reconstruction and will be injected on each affected breast during the insertion of the permanent breast implant in the 2nd stage of breast reconstruction
48020168|NCT03115424|DRUG|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
48177655|NCT02868372|DRUG|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
48177656|NCT04128462|DRUG|MNK-6105|L-Ornithine Phenylacetate for IV infusion
48177657|NCT04128462|DRUG|Placebo|Matching placebo for IV infusion
48177658|NCT04128462|DRUG|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
48020169|NCT03115424|PROCEDURE|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
48020170|NCT01272167|BEHAVIORAL|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
48378036|NCT03878108|DIETARY_SUPPLEMENT|LFHC diet|low-fat, high-carbohydrate (LFHC) diet
48711388|NCT01276366|OTHER|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
48711389|NCT03065842|BEHAVIORAL|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
48711390|NCT03065842|BEHAVIORAL|Usual Standards|Usual standards according to the school curriculum in Kenya.
48711391|NCT01099657|BEHAVIORAL|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
48020171|NCT05894200|OTHER|Glass Ionomer cement pit and fissure sealant, Silver Diamine Fluoride|GC Fuji 7, e-SDF
48020172|NCT03969771|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
48020173|NCT00001100|DRUG|ganciclovir|
48177659|NCT01473615|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
48177660|NCT03635086|BIOLOGICAL|MV-CHIK lyophilised formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular \[IM\] injection): 5x10\^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.
48177661|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
48711392|NCT01099657|BEHAVIORAL|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
48020174|NCT04832555|RADIATION|Non elective radiotherapy|Simultaneous integrated boost on CTV volumes, delineated as per guidelines, with the exception of intermediate-low risk, where the CTVs are experimental.
48378037|NCT01254695|DEVICE|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
48378038|NCT03093558|BEHAVIORAL|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
48388018|NCT05167396|DEVICE|Retinaute (BioSerenity)|Wearable device in the form of a virtual reality headset for the recording of electrophysiological measurements such as electroretinogram (ERG) and electrocenphalogram (EEG), ISCEV standards
48388019|NCT05167396|DEVICE|EEG Headset 64 electrodes (BioSemi)|EEG headset with 64 electrodes for the recording of visual cortical electrophysiological signals
48388020|NCT05167396|DEVICE|MonPackOne (Metrovision)|"Standard device for the recording of electroretinography (ERG) measurements, ISCEV standards~WARNING : Device used only in 3 healthy controls to address the secondary objective"
48020175|NCT01465334|DRUG|Ofatumumab|
48020176|NCT01465334|DRUG|High-Dose Methylprednisolone|
48020177|NCT01465334|DRUG|Alemtuzumab|
48020178|NCT00285753|BEHAVIORAL|support groups|cognitive behavioral intervention with psychoeducation
48020179|NCT06481150|DRUG|Tenapanor|Each tablet 30 mg
48020180|NCT06481150|OTHER|Placebo|Placebo
48711393|NCT04072367|DEVICE|NeVa Stent Retrievers|thrombus removal
48711394|NCT04072367|DEVICE|Solitaire Stent Retrievers|thrombus removal
48711395|NCT01437176|DEVICE|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
48711396|NCT01437176|DEVICE|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
48177662|NCT03635086|BIOLOGICAL|MV-CHIK SPS® formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
48517719|NCT01962818|OTHER|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
48517720|NCT00795262|DRUG|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
48177663|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, high dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10\^6 ±0.5 log TCID50/dose.
48177664|NCT03635086|OTHER|Placebo|Sterile physiological saline solution (0.9% sodium chloride \[NaCl\]), administered by IM injection.
48517721|NCT00795262|DRUG|accupril, placebo|accupril 40 mg
48711397|NCT00712218|PROCEDURE|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
48711398|NCT00712218|PROCEDURE|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
48711399|NCT02119039|DEVICE|RGTA OTR 4120 (CACICOL20)|
48711400|NCT02119039|DEVICE|Genteal HA eye drops|
48711401|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose
48711402|NCT01098877|DRUG|PF-04634817|Oral solution, 1mg, single dose
48711403|NCT01098877|DRUG|PF-04634817|Oral solution, 3mg, single dose
48711404|NCT01098877|DRUG|PF-04634817|Oral solution, 10mg, single dose
48711405|NCT01098877|DRUG|PF-04634817|Oral solution, 30mg, single dose
48711406|NCT01098877|DRUG|PF-04634817|Oral solution, 100mg, single dose
48020181|NCT06574022|DRUG|Bupivacain|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 30 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
48020182|NCT06574022|DRUG|Exparel|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle of 20 cc of Exparel mixed with 10 cc of 0.5% bupivacaine after mastectomy completion and prior to reconstruction, if performed, or wound closure.
48020183|NCT06574022|PROCEDURE|Intraoperative Pecs II block (IOB) & superior AT (EX or BP)|Intraoperative direct visualization of the pectoralis nerves and injection using a 21-gauge needle with superior anesthetic as determined by stage I, after mastectomy completion and prior to reconstruction, if performed, or wound closure.
48020184|NCT06574022|PROCEDURE|Preoperative Pecs II block (POB) & superior AT (EX or BP)|Preoperative Pecs II block to be administered by 1 of 6 acute pain specialized anesthesiologists in same day surgery. Patient will be lightly sedated with midazolam, at the discretion of the anesthesiologist. The pecs II block will be performed under ultrasound guidance using a 21-gauge, 80 mm length needle to administer the superior anesthetic as determined in stage I.
48177665|NCT04543812|DRUG|Ferric citrate|Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
48177666|NCT04543812|DRUG|Placebo|Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
48177667|NCT02421536|OTHER|Vibrogent Smartphone Application|
48177668|NCT02740361|BEHAVIORAL|Deprexis, DeprexisPlus|Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
48177669|NCT02577588|BIOLOGICAL|re-activated T cells|autologous reactivated T cells against p53
48517722|NCT00795262|DRUG|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
48711407|NCT01098877|DRUG|PF-04634817|Oral solution, 300mg, single dose
48711408|NCT01098877|DRUG|PF-04634817|Oral solution, 600mg, single dose
48711409|NCT01098877|DRUG|PF-04634817|Oral solution, 900mg, single dose
48711410|NCT01098877|DRUG|PF-04634817|Oral solution, up to 900mg, single dose after food
48711411|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose after food
48711412|NCT04451824|DEVICE|CL-100|Red Light LED device for circumferential reduction
48711413|NCT04211987|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
48711414|NCT04211987|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
48711415|NCT03002623|DRUG|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
48711416|NCT02223611|DRUG|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)\<1.25 m2 40mg twice a day, 1.25 m2≤BSA\<1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
48711417|NCT02223611|DRUG|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
48711418|NCT05466500|PROCEDURE|Ultrasound guided axillary block with intravenous dexamethasone|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
48711419|NCT05466500|PROCEDURE|Ultrasound guided axillary block|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
48711420|NCT04833153|BEHAVIORAL|Person-First - Please (PFP)|PFP takes 10 weeks and consist of four modules: Information, Person, Autonomy and Dignity. Information module takes 1 hour contact on first week. The other modules will follow every third weeks, starting from week 2. So that on week 2, 5 and 8 researcher meet nurses in 4 hours education session. Between the modules, nurses can take contact online to the researcher.
48711421|NCT01047800|BEHAVIORAL|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
48711422|NCT06105086|OTHER|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
48711423|NCT01083498|DEVICE|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
48711424|NCT01680692|DRUG|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
48711425|NCT01680692|DEVICE|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
48711426|NCT01680692|DEVICE|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
48711427|NCT05787132|OTHER|Balance Board therapy|Balance board therapy will be performed. balance board therapy has been shown to improve the sitting balance in children with cerebral palsy
48711428|NCT05787132|OTHER|Perceptual Motor therapy|Perceptual motor therapy will be performed, it has been shown to improve dynamic sitting in children with cerebral palsy.
48711429|NCT02996799|OTHER|Umbilical cord milking|Milking of the umbilical cord at delivery
48711430|NCT05027932|OTHER|IN Placebo|The placebo will be normal saline in two syringes administered IN.
48378039|NCT05968469|DEVICE|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
48711431|NCT05027932|OTHER|IM Placebo|The placebo will be normal saline in a syringe administered IM.
48711432|NCT05027932|DRUG|BPL-1357|BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.
48711433|NCT03879044|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
48711434|NCT03776773|OTHER|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
48711435|NCT02526082|OTHER|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
48711436|NCT00088790|DRUG|AZD5438|
48177670|NCT01403649|BEHAVIORAL|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
48517723|NCT03252743|BEHAVIORAL|Exposure-based internet-delivered CBT|"The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises."
48177671|NCT01403649|OTHER|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
48177672|NCT02909309|DEVICE|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
48177673|NCT04867109|OTHER|Patients with Post menopausal bleeding|"Any patient presenting post-menopausal bleeding who is to undergo hysteroscopy or hysterectomy will have an additional blood tube taken during her pre-operative blood work-up for the determination of the serum markers HE4 and CA125, after having obtained her non-opposition to participate in the study.~The blood tube collected for the research will be sent to the biochemistry laboratory of the Nantes University Hospital for a centralized analysis.~This analysis will be done sequentially and the results will not be transmitted to the investigator.~At D0, the day of surgery, the operative report will be retrieved as well as the quality of life questionnaires SF12 and PGI-I and the acceptability questionnaire completed before surgery.~At 1 month after surgery, the anatomopathological results will be retrieved as well as the value of the tumour markers CA125 and HE4."
48177674|NCT04867109|DIAGNOSTIC_TEST|CA125 and HE4 assays|Blood was collected in a standard heparinized vial. Samples were sent to a central laboratory unit (biochemistry laboratory at the Nantes university hospital), centrifuged and plasmas were stored at -20°C until analysis. Plasma CA125 and HE4 concentrations were determined by run in single measurements using an electrochemiluminescence Elecsys immunoassay (ECLIA) on a Roche Diagnostics Cobas 8000® e602 analyser (Roche Diagnostics, Mannheim, Germany).
48378040|NCT05968469|OTHER|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
48711437|NCT05403892|DIAGNOSTIC_TEST|level laser lunge test|In order to perform the Level Laser Test, the operator 1 places a laser lever on the ground one metre aside and 50 cm forward the ankle to be examined. This laser (a 2-class laser not harmful to the eyes) maintains a linear laser light beam perpendicular to the floor. The examined leg is placed further forward to the other one, as it happens in the DLT. The teenage performs a forward lunge perpendicularly to the laser line, the heel positioning 50 cm from the laser line. Operator 1 has the subject perform a lunge while operator 2 measures the distance from the kneecap to the laser line. The measurement, deducted by 50 cm, leads to the heel-to-wall distance (value used to DLT).
48177675|NCT00311415|BIOLOGICAL|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
48711438|NCT05403892|DIAGNOSTIC_TEST|dorsiflexion Lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the teenage stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The teenage is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The teenage steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
48711439|NCT04384380|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
48711440|NCT05586958|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
48711441|NCT05586958|DRUG|Placebo|Matching placebo
48177676|NCT00373919|DRUG|intravenous (IV) administration of erythromycin|
48517724|NCT00904657|DRUG|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
48711442|NCT00002440|DRUG|Indinavir sulfate|
48711443|NCT00002440|DRUG|Ritonavir|
48711444|NCT00002440|DRUG|Abacavir sulfate|
48711445|NCT00002440|DRUG|Amprenavir|
48711446|NCT00002440|DRUG|Nelfinavir mesylate|
48711447|NCT00002440|DRUG|Saquinavir|
48177677|NCT04011293|BIOLOGICAL|CNCT19|0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.
48177678|NCT06316817|DEVICE|FloPatch|A novel, hands-free ultrasound patch for continuous monitoring of quantitative Doppler in the carotid artery.
48177679|NCT05314998|DRUG|Oxaliplatin|85 mg/m2 D1 over 2 hours every; 14 days, 12 cycles, 24 weeks
48177680|NCT05314998|DRUG|Irinotecan|150 mg/m2 D1 over 90 minutes to begin 30 min after the Folinic acid infusion is started; every 14 days, 12 cycles, 24 weeks
48177681|NCT05314998|DRUG|Folinic acid|400 mg/m2 (racemic mixture) (or 200 mg/m2 if L-folinic acid is used), IV infusion over 2 hours; every 14 days, 12 cycles, 24 weeks
48177682|NCT05314998|DRUG|5-fluorouracil|2.4 g/m2 IV continuous infusion over 46 hours (1200 mg/m2/ day); every 14 days, 12 cycles, 24 weeks
48177683|NCT05314998|DRUG|Gemcitabine|1000mg/m2 is given as an IV infusion over 30 minutes; on day 1, 8 and 15 out of 28 days (= 1 cycle); Repeated 6 times (i.e., 6 cycles) for 24 weeks
48177684|NCT05314998|DRUG|Capecitabine|1660mg/m2/day in two divided doses administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles i.e. 24 weeks
48177685|NCT02627768|DRUG|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
48177686|NCT04476836|OTHER|Animal-Assisted Therapy|Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
48177687|NCT03514381|DRUG|Patients starting a treatment with Doxorubicin and Ifosfamide|"9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)"
48177688|NCT05758987|BEHAVIORAL|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
48177689|NCT05758987|BEHAVIORAL|Prolonged exposure|A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
48711448|NCT02901925|DRUG|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
48177690|NCT03104283|DRUG|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
48177691|NCT00855725|OTHER|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
48177692|NCT00855725|OTHER|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
48177693|NCT00855725|OTHER|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
48177694|NCT00855725|OTHER|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
48177695|NCT02806505|DRUG|Peginterferon alfa-2a|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
48177696|NCT02542098|DRUG|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
48177697|NCT02194842|DRUG|Ra223|
48177698|NCT02194842|DRUG|Enzalutamide|
48177699|NCT02484664|DRUG|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
48177700|NCT01491906|BEHAVIORAL|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
48177701|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
48177702|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
48177703|NCT04467645|OTHER|reflexology|Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
48378041|NCT02430155|DEVICE|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
48378042|NCT02430155|DEVICE|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
48378043|NCT06650865|OTHER|Traditional Exercise Group|"It is important for the therapist to organize a exercise program to provide pain control. The exercise program should be specific and clear to the patient.~Exercises will be applied to this group. The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
48020185|NCT06401681|OTHER|Balance training|The balance exercises consist of single limb stances with eyes open and closed, single-leg hops with stabilization, and single-leg hops and reach. Thirty-second breaks will be provided between exercise sets. Progressions for single-leg stance exercises involve longer durations and introduction of unstable surfaces. Progressions for hopping exercises involve longer hopping distances. To progress to the next level, participants must complete a balance training session without any errors. Errors include 1) touching the floor or bracing with the opposite limb, 2) excessive lateral trunk flexion or hip abduction, 3) hands coming off hips (hop tasks) or shoulders (stance tasks), 4) missing the landing target, 5) using the reach leg for a substantial amount of weight bearing.
48517725|NCT06471374|BEHAVIORAL|Circadian rhythm assessment|Participants will arrive approximately 8 hours before participant's scheduled bedtime to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 66 hours (2.75 days). Upon awakening in the morning, participants will start a routine of up to 39 hours of wakefulness, under bedrest conditions. Saliva will be sampled frequently and blood will be drawn 3 times. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will be provided scheduled bathroom breaks when participants will use a commode next to the bed. Outside these scheduled bathroom breaks, participants will be provided a bedpan to use to go to the bathroom. At the end of the research procedures for Visit 4 participants will be given a recovery sleep opportunity and be discharged from the lab in the morning near participant's typical waketime.
48378044|NCT06650865|OTHER|Baduanjin Exercise Group|"In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
48378045|NCT06650865|OTHER|Telerehabilitation Group|"Baduanjin exercise will be applied simultaneously with the telerehabilitation method. In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
48378046|NCT06566638|DEVICE|NucleoCapture device|100ml NucleoCapture selective DNA adsorber.
48378047|NCT06160258|BEHAVIORAL|Ready to Eat (RTE)|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.
48378048|NCT06160258|BEHAVIORAL|Dried|Participants will be provided with dried whole grains for home preparation and consumption
48378049|NCT02557191|OTHER|Observational study|
48378050|NCT05531695|BEHAVIORAL|Exercise (either aerobic or flexibility)|
48517726|NCT06471374|BEHAVIORAL|Light sensitivity assessment|Participants will arrive in the afternoon to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 48 hours (2 days). Upon awakening in the morning, participants will be exposed to dim candlelight and then later in the day alternating intensities of dim and room light when we keep participants awake for up to 23 hours (We will ask participants to remain in bed seated for \~12.5 hours). Saliva will be sampled frequently. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will then have a second 9-hour sleep opportunity.
48711449|NCT05081947|BEHAVIORAL|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
48020186|NCT05078723|DIETARY_SUPPLEMENT|Limonene|The investigators will ask the participants to swish 5 times and swallow 1 oz water mixed with 500mg limonene (Jarrow Formula orange peel extract). The participant will be monitored for a total of 2 hours. Breath samples will be acquired at a total of 11 time points throughout the study. Measurements include 2 baseline measurements followed by the orange peel extract consumption.
48020187|NCT01711086|DEVICE|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
48020188|NCT01711086|DEVICE|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
48020189|NCT06202885|DRUG|Immunotherapy|Immunotherapy
48020190|NCT03000465|PROCEDURE|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
48378051|NCT06642441|DRUG|Chemotherapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive a 10 mg dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
48378052|NCT06642441|DRUG|Chemotherapy|Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
48378053|NCT02325206|DRUG|dapagliflozin|one administration in the morning
48378054|NCT02325206|DRUG|Placebo|one administration in the morning
48517727|NCT03946618|DEVICE|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
48177704|NCT04118283|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
48177705|NCT04118283|BEHAVIORAL|Health and Wellness|Health \& Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
48177706|NCT01430117|BIOLOGICAL|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
48517728|NCT05382234|DIAGNOSTIC_TEST|CBC, ESR ,CRP,Liver Function ,renal function ,ABG,Na,K,D-dimmer ,cardiac enzyme,ferritin ,blood and urine culture in negative cases|cllinical and laboratory evaluation of MIS-C,Effectivness of different therapeutic modalities,Outcome of cases (morbidity,mortality)
48177707|NCT04482153|DEVICE|fibroscan|The Controlled Attenuation Parameter (CAP) can using transient elastography (TE) (Fibroscan®) permits to efficiently separate different grades of severity of steatosis. CAP is based on the properties of ultrasonic signals acquired by the Fibroscan®. It allows to simultaneously measure liver stiffness and CAP in the same liver volume.
48378055|NCT04490772|DIAGNOSTIC_TEST|Laboratory tests|Laboratory tests such as CBC, Liver function and CRP
48378056|NCT06648603|BEHAVIORAL|Community-based larval source management|This project will foster active engagement with community stakeholders, including healthcare workers, community leaders, and other key informants, through participatory meetings aimed at co-creating and developing larval source reduction measures tailored to community's needs. This method emphasizes a participatory framework, ensuring that interventions are both community-informed and culturally relevant.
48517729|NCT01893515|DRUG|PRC-4016|
48711450|NCT03551977|BEHAVIORAL|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
48711451|NCT03551977|BEHAVIORAL|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
48020191|NCT06493890|OTHER|Validation PEQ-DLV|Validation of the Dutch Language version of the Prosthesis Evaluation Questionnaire
48517730|NCT01893515|DRUG|Placebo|
48517731|NCT00150956|PROCEDURE|Daily home hemodialysis|
48711452|NCT01172730|DEVICE|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
48711453|NCT03694873|DRUG|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
48711454|NCT03694873|DRUG|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
48020192|NCT03555669|OTHER|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
48020193|NCT05005611|DIETARY_SUPPLEMENT|Placebo|"A pack of powder without probiotics.~1 pack / day"
48020194|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus salivarius AP-32|"A pack of powder with probiotics Lactobacillus salivarius AP-32~1 pack / day"
48020195|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Bifidobacterium animalis subsp. lactis CP-9|"A pack of powder with probiotics Bifidobacterium animalis subsp. lactis CP-9~1 pack / day"
48020196|NCT05005611|DIETARY_SUPPLEMENT|Probiotics Lactobacillus rhamnosus LGG|"A pack of powder with probiotics Lactobacillus rhamnosus LGG~1 pack / day"
48020197|NCT01177501|DRUG|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
48378057|NCT06648603|DEVICE|Enhanced Aedes adults trapping (BG-GAT)|Furthermore, the project intends to determine whether the addition of cost-effective, gravid female mosquito-targeting traps, specifically two Biogents Gravid Aedes Traps (BG-GAT) per household, can improve the overall success of these community-based intervention.
48517732|NCT03066258|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
48517733|NCT05588414|PROCEDURE|Standardization of the sentinel node detection procedure|All patients included in the study underwent the same pre- and intra-operative procedure, consisting of a double systematic sentinel node detection, using sequential ICG and isotopic technique. The patient is his own control for the analysis of the performance of the ICG technique alone compared to the combined ICG and isotopic technique.
48517734|NCT00302289|DRUG|tyrosine, green tea, caffeine|
48711455|NCT00005636|DRUG|cisplatin|
48177708|NCT02548078|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
48177709|NCT02548078|BIOLOGICAL|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
48177710|NCT04137861|OTHER|Bioceramics|root repair material
48177711|NCT02787447|DRUG|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
48378058|NCT06648603|COMBINATION_PRODUCT|Community-based larval source management with Enhanced Aedes adults trapping (BG-GAT)|The community-based interventions and the BG-GAT deployment will be evaluated in combination to assess their individual and synergistic effects on vector control. This dual strategy combines local participation and practical, evidence-based solutions to address mosquito-borne illness transmission.
48378059|NCT01061346|OTHER|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
48711456|NCT00005636|DRUG|pemetrexed disodium|
48711457|NCT02526862|DEVICE|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
48711458|NCT02526862|DEVICE|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
48711459|NCT02526862|DEVICE|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
48711460|NCT04341545|OTHER|Placebos|Placebo 4 tablets a day for one week.
48711461|NCT04341545|DRUG|Letrozole tablets|Letrozole 10mg daily for one week.
48711462|NCT04304794|PROCEDURE|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
48711463|NCT04304794|DRUG|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
48711464|NCT04848714|DRUG|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL|Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
48378060|NCT01061346|OTHER|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
48378061|NCT01061346|OTHER|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
48517735|NCT01299012|DRUG|Liraglutide|Liraglutide s/c 0.6mg once daily.
48177712|NCT02787447|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
48177713|NCT02787447|DRUG|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
48177714|NCT02572115|BEHAVIORAL|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
48177715|NCT02572115|BEHAVIORAL|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
48177716|NCT01299311|BEHAVIORAL|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
48177717|NCT01299311|BEHAVIORAL|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
48177718|NCT02418962|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
48177719|NCT02418962|OTHER|Normal Saline|0.9% Sodium chloride solution for injection
48177720|NCT00542412|DRUG|Riluzole|
48711465|NCT01611051|DRUG|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
48711466|NCT01611051|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
48711467|NCT01611051|DRUG|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
48711468|NCT05226091|BEHAVIORAL|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
48711469|NCT05357963|PROCEDURE|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
48711470|NCT04690920|DRUG|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
48711471|NCT06455410|DRUG|GP|gemcitabine + cisplatin
48711472|NCT06455410|DRUG|Adebrelimab|a PD-L1 inhibitor
48711473|NCT06455410|DRUG|concurrent chemoradiotherapy (CCRT)|concurrent chemoradiotherapy (CCRT)
48711474|NCT00797238|OTHER||No intervention in this study
48711475|NCT02256410|DEVICE|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
48711476|NCT02256410|OTHER|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
48711477|NCT01093781|DRUG|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
48711478|NCT05947279|BEHAVIORAL|Comparing motor adaptation reaching performance|By comparing motor adaptation reaching performance between these three groups, the investigators can examine how stimulation to each specific area of the brain modulates different aspects of motor adaptation
48711479|NCT01952990|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
48711480|NCT03254914|PROCEDURE|Home Blood Pressure|Measure Home Blood Pressure
48711481|NCT05173428|BEHAVIORAL|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
48711482|NCT06176495|DIAGNOSTIC_TEST|Educational Text Messages|"The educational content will be targeted about Diabetes Education and will be guideline based with what complies to the standards of care instituted by the American Diabetes Association.~They text messages will comprise content related to general diabetes knowledge, diabetes management and control, coping with diabetes, and guidance on adopting a healthy lifestyle."
48711483|NCT02963987|OTHER|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
48711484|NCT05750810|OTHER|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
48711485|NCT00047619|PROCEDURE|Pulsatile Lavage|pulsatile lavage to wound bed
48711486|NCT00047619|OTHER|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
48378062|NCT00230113|DIETARY_SUPPLEMENT|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
48378063|NCT00230113|DIETARY_SUPPLEMENT|safflower oil|4 gm per day safflower oil
48378064|NCT02203773|DRUG|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
48711487|NCT03897946|BIOLOGICAL|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
48711488|NCT03381482|DIAGNOSTIC_TEST|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
48711489|NCT03381482|DIAGNOSTIC_TEST|Fasting blood sample|6x5 mL of fasting blood sample
48711490|NCT03381482|DIAGNOSTIC_TEST|Lumbar puncture|10 mL of CSF by lumbar puncture
48711491|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h."
48711492|NCT00357656|DRUG|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
48711493|NCT03663374|DRUG|Odelepan|Tablets, 125 mg
48020198|NCT05613634|DEVICE|Repetitive transcranial magnetic stimulation|A high frequency (10 Hz) rTMs on the dominant dorsolateral prefrontal cortex (DLPFC) was applied with the Magstim Rapid Magnetic Stimulator, Magstim Company. Patients were seated in a chair, arms and legs relaxed, head stable, and no movement was allowed during the procedure. Motor threshold (MT) was determined before each session and was defined as the percent intensity output of the stimulator that generated a 50µV motor evoked response in the abductor pollicis brevis (APB) muscle in five out of 10 trials. The DLPFC of dominant hemisphere was localized on the scalp 5.5 cm anterior to the hot spot for the contralateral APB muscle along the parasagittal plane. The average MT was 50 % (range, 45-55%) of the maximal output of the stimulator. The initial mapping procedure was completed with the coil oriented at 45° lateral diagonal orientation roughly perpendicular to the central sulcus and the center of the coil applied tangentially to the scalp.
48177721|NCT05162898|DRUG|toripalimab|240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
48517736|NCT06583213|PROCEDURE|Fractional Spinal Anaesthesia.|An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).
48517737|NCT06583213|PROCEDURE|Conventional Spinal Anaesthesia|"Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes."
48378065|NCT02203773|DRUG|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
48711494|NCT03663374|DRUG|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
48711495|NCT00295230|PROCEDURE|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
48177722|NCT05162898|DRUG|Lenvatinib|12mg (weight ≥60kg) or 8mg (weight \<60kg) orally, once a day
48177723|NCT05162898|DEVICE|Radiofrequency ablation|ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
48378066|NCT02203773|DRUG|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
48378067|NCT02203773|DRUG|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
48378068|NCT00124709|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
48378069|NCT00124709|DRUG|Corticosteroid|conventional corticosteroid-based treatment
48711496|NCT01303146|DRUG|rhARSA|intravenous infusion 100U/kg every other week for 18 months
48711497|NCT04151251|BEHAVIORAL|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
48711498|NCT04151251|OTHER|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
48711499|NCT03159689|OTHER|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
48711500|NCT03159689|OTHER|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
48378070|NCT01327066|DRUG|Droxidopa|600 mg, single oral dose
48378071|NCT01327066|DRUG|Droxidopa|2000 mg, single oral dose
48378072|NCT01327066|DRUG|Moxifloxacin|400 mg, single oral dose
48378073|NCT01327066|DRUG|Placebo|Placebo matching Droxidopa or Moxifloxacin
48378074|NCT06650085|PROCEDURE|Loop ileostomy|Patient undergoing anterior rectal resection will receive loop ileostomy
48378075|NCT06650085|PROCEDURE|Loop colostomy|Patient undergoing anterior rectal resection will receive loop colostomy
48378076|NCT03523676|DIAGNOSTIC_TEST|Red Cell Distribution Width|
48378077|NCT00593385|DEVICE|iCAST covered stent|Iliac stent implantation
48711501|NCT01189058|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
48378078|NCT03356470|OTHER|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
48378079|NCT02350114|PROCEDURE|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
48378080|NCT00814762|BIOLOGICAL|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
48378081|NCT00814762|BIOLOGICAL|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
48378082|NCT05437731|OTHER|Coated titanium mesh|patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
48177724|NCT03691545|BEHAVIORAL|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
48177725|NCT00196534|DRUG|Human Thrombin|
48177726|NCT00196534|DRUG|Bovine Thrombin|
48177727|NCT01007006|DEVICE|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
48177728|NCT02033473|DRUG|Apelin|An apelin clamp in which an apelin infusion will be administered
48177729|NCT02033473|DRUG|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
48177730|NCT00643318|RADIATION|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as \< 2 cm from carina and \< 2 cm from right and left mainstem bronchus and/or \< 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being \> 2 cms from the carina and \> 2 cms from the right and left mainstem bronchus and/or \> 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
48177731|NCT03587779|DRUG|Sevoflurane|Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.
48177732|NCT03587779|DRUG|Desflurane|Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
48177733|NCT00503607|DRUG|BLI-800|
48177734|NCT00503607|DRUG|Polyethylene glycol 3350 based bowel preparation|
48177735|NCT05256745|DRUG|TTP488|Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
48177736|NCT05256745|DRUG|ddAC/ddT|Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label
48177737|NCT05256745|DRUG|TC|Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
48177738|NCT05256745|DRUG|TCHP|Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
48177739|NCT05256745|DRUG|Chemotherapy regimen that includes ddAC|can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
48177740|NCT03014908|OTHER|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
48177741|NCT05975632|DEVICE|Device: Self testing Potassium device|"Calibration Phase (1 visit) (Hemodialysis patients and subjects not on dialysis) Each patient will have one venous blood collection. Among them, one 30 patients one capillary sample is collected. In this phase, the HCP is the user of the device.~Comparison Phase~For subject not on dialysis (total 2 visits):~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test~For Hemodialysis patients (total 1 visit) :~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test"
48177742|NCT05649189|DIAGNOSTIC_TEST|telomere length measure|length of telomere between two groups
48177743|NCT02139462|OTHER|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
48177744|NCT02139462|OTHER|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
48378083|NCT05437731|OTHER|Uncoated titanium mesh|patients will undergo reconstruction using the conventional uncoated titanium mesh.
48378084|NCT05478356|DRUG|low-dose atropine eye drops|low-dose atropine eye drops
48378085|NCT05478356|DEVICE|orthokeratology|orthokeratology, ortho-K lenses
48378086|NCT04472910|DRUG|Modified Folforinox (mFFX)|Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
48378087|NCT02684370|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
48177745|NCT04021082|DRUG|Cerdulatinib|Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
48711502|NCT01189058|PROCEDURE|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for \>90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
48378088|NCT02684370|DRUG|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
48378089|NCT02684370|DRUG|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
48711503|NCT00546260|DRUG|placebo|administration of iv bolus prior to angiography
48378090|NCT02684370|DRUG|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
48378091|NCT02556112|BEHAVIORAL|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
48378092|NCT02556112|BEHAVIORAL|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
48378093|NCT02556112|BEHAVIORAL|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
48378094|NCT01758991|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
48378095|NCT00824993|DRUG|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
48378096|NCT00824993|DRUG|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
48711504|NCT00546260|DRUG|PRT060128 Potassium|administration of iv bolus prior to angiography
48711505|NCT01071005|DRUG|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
48711506|NCT01071005|DRUG|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
48711507|NCT04766385|DRUG|KHK7791|oral administration
48711508|NCT02792491|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
48711509|NCT01596335|DRUG|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
48711510|NCT01596335|DRUG|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
48711511|NCT01151605|DRUG|insulin infusion|insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
48711512|NCT01151605|DRUG|Dextrose infusion|Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
48711513|NCT01151605|DRUG|Saline Infusion|Saline will be infused at 100ml/hr
48711514|NCT04326036|PROCEDURE|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
48711515|NCT04326036|DEVICE|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
48020199|NCT05613634|OTHER|Cawthorne Cooksey exercises|Cawthorne Cooksey exercises were carried in the following sequence: First, bed exercises; eye movements (up and down, side to side, focusing on a finger that is one feet distance); head movements (bending up and down, side to side first with eye opened then closed). Second, sitting exercises involved same eye and head movements, shoulder shrugging, turning head and trunk alternately to the right and left, bending head and trunk forward, and pick an object from the ground. Third, standing exercises involved same eye, head, and shoulder movements, changing position from sitting to standing with eye open then closed, throw a ball from hand to hand above eye level, throw a ball from hand to hand beneath knee, changing position from sitting to standing and turn around in between. Fourth, moving around exercises where the patient revolved around a person sitting in the center who throw him a ball and to whom it was returned.
48020200|NCT04298255|OTHER|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
48020201|NCT04298255|OTHER|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
48020202|NCT06075628|OTHER|Left Atrial Appendage Occlusion|Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.
48020203|NCT04736459|PROCEDURE|Pre-washed catheter vs. Unwashed catheter in the intrauterine insemination|The pre-washed catheter will be washed with culture medium before intrauterine insemination The unwashed catheter will not be washed with culture medium as a standard intrauterine insemination procedure
48020204|NCT03499652|DIAGNOSTIC_TEST|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
48020205|NCT01970332|PROCEDURE|Revascularization Surgery|
48378097|NCT03036540|DEVICE|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
48378098|NCT06187207|DIAGNOSTIC_TEST|Hand acceleration time (HAT) measurement|Hand Duplex Ultrasound to measure the Hand Acceleration Time (HAT)
48378099|NCT04380493|DIAGNOSTIC_TEST|hepatic transient elastography using S probe and M probe|
48378100|NCT04717323|DEVICE|mPAD (or TPAD) Pelvic Assist Device|Gait retraining device that applies pelvic forces and measures response
48378101|NCT04717323|DEVICE|No Intervention|Gait with no pelvic assistance
48378102|NCT02936466|BEHAVIORAL|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
48378103|NCT06440044|OTHER|Data collection|A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.
48378104|NCT03431688|DRUG|PAM|treatment with PPI, metonidazole, amoxicillin
48378105|NCT03431688|DRUG|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
48378106|NCT01869959|DRUG|LY2405319|Administered SC
48020206|NCT01970332|OTHER|Supervised exercise therapy|
48020207|NCT06457958|DRUG|Sevoflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
48378107|NCT01869959|DRUG|Placebo|Administered SC
48378108|NCT03205839|BEHAVIORAL|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
48378109|NCT00740129|DRUG|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
48711516|NCT04326036|PROCEDURE|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
48711517|NCT04326036|DRUG|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
48711518|NCT04326036|DRUG|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
48711519|NCT00463983|DRUG|octreotide|
48388021|NCT06111794|OTHER|REACH TBI|Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) is a six-session, telephone intervention for Caregivers of Veterans and Services Members with TBI. The intervention focuses on problem solving training, stress management, and psychoeducation. Trained Program Coaches will deliver the REACH TBI intervention by meeting one-on-one via telephone with participants.
48020208|NCT06457958|DRUG|Desflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
48020209|NCT05889624|BEHAVIORAL|CBT|"During an 8-week active treatment, participants will receive 6 telehealth CBT sessions, followed by a maintenance phase (16 weeks) when participants will receive 3 booster CBT sessions. The sessions will be conducted by teletherapists from the Clinical Coordinating Center at Cincinnati Children's using a standardized treatment manual. A parent/legal guardian will be included in 2 sessions teaching ways to be active coaches, encouraging use of effective coping skills and refraining from reinforcement of maladaptive coping. Each session will be about 45 minutes."
48020210|NCT05889624|DRUG|Amitriptyline|During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
48020211|NCT00678600|OTHER|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
48020212|NCT00678600|OTHER|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
48020213|NCT02535195|DIETARY_SUPPLEMENT|Ginger supplement|
48020214|NCT02535195|DIETARY_SUPPLEMENT|Placebo (starch)|
48020215|NCT03348267|DIETARY_SUPPLEMENT|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
48020216|NCT03348267|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
48020217|NCT05209191|BEHAVIORAL|Student Athlete Wellness Portal|A web-based design that illustrates various opioid misuse and diversion resistance strategies.
48020218|NCT00030797|DRUG|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
48020219|NCT00030797|DRUG|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
48020220|NCT06259344|BEHAVIORAL|Fractioned Pain Science Education (FPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 2 sessions of 45 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
48020221|NCT06259344|BEHAVIORAL|Full Dosage Mode Pain Science Education (FDPSE)|Pain Science Education (PSE) will be administered in workshop sessions with interactive presentations, using different resources as metaphors and videos. It will be held in 6 sessions of 15 minutes each, covering 6 topics of Explain Pain and Explain Pain Supercharged books.
48020222|NCT06259344|OTHER|Manual Therapy|Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
48177746|NCT02832349|OTHER|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
48177747|NCT00489528|DRUG|Somatropin; Recombinant human growth hormone (r hGH)|
48177748|NCT00932295|OTHER|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
48020223|NCT06259344|OTHER|Orofacial and Neck Exercises (ONE)|"Orofacial Exercises: Mandibular body-condylar cross-pressure chewing technique; Post-isometric relaxation stretches-laterotrusion and opening (10 times/session; 10 seconds).~Neck Motor Control Exercises: Bracing exercises (6 hierarchical levels - HL). Extreme range of motion exercises (stable spine). Cervical isometric exercises (5 HL) directly forward, obliquely, toward right and left, and directly backward (stable spine - elastic resistive bands). Functional training with elastic resistance and exercise balls on unstable surfaces (8 HJ). The progress in each exercise domain will happen when sustaining the contraction for 10 seconds, 10 times."
48378110|NCT01151501|DEVICE|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) \>92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2\>92%.
48020224|NCT03006328|BEHAVIORAL|GEM|Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.
48020225|NCT03006328|BEHAVIORAL|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
48177749|NCT00932295|OTHER|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
48177750|NCT00932295|OTHER|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
48177751|NCT00932295|OTHER|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
48517738|NCT05082740|OTHER|Notification of a revised breast cancer risk estimate|These women will be given the opportunity to learn of their revised breast cancer risk estimate which has been re-calculated with the inclusion of new strong independent risk factors. These women will be offered a clinical consultation to discuss their risk and will a subset will be asked to take part in a qualitative interview about their experiences.
48177752|NCT01982175|BIOLOGICAL|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3\~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~--------------------------------------------------------------------------------"
48177753|NCT00983112|DRUG|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
48177754|NCT00983112|DRUG|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
48020226|NCT06146322|OTHER|WR|Unsweetened preload condition: 240 mL white glutinous rice, 250 kcal, 0 g β-glucan
48020227|NCT06146322|OTHER|LB|Unsweetened preload condition: 240 mL low β-glucan barley, 250 kcal, \~4 g β-glucan
48020228|NCT06146322|OTHER|MB|Unsweetened preload condition: 240 mL medium β-glucan barley, 250 kcal, \~5 g β-glucan
48177755|NCT02830828|OTHER|Investigation of precision pinch grip control|
48177756|NCT05553093|DRUG|Tirzepatide|Tirzepatide ih qw
48177757|NCT05553093|DRUG|Insulin Glargine|6 IU ih qd
48711520|NCT01739933|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
48711521|NCT01739933|DRUG|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
48711522|NCT02855723|OTHER|Surgery: GS strategy|sentinel node biopsy
48020229|NCT06146322|OTHER|HB|Unsweetened preload condition: 240 mL high β-glucan barley, 250 kcal, \~6 g β-glucan
48020230|NCT06146322|OTHER|WR+50g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL white glutinous rice + 50g HFCS, 391 kcal, 0 g β-glucan
48020231|NCT06146322|OTHER|LB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL low β-glucan barley + 50 g HFCS, 391 kcal, \~4 g β-glucan
48020232|NCT06146322|OTHER|MB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL medium β-glucan barley + 50 g HFCS, 391 kcal, \~5 g β-glucan
48020233|NCT06146322|OTHER|HB + 50 g HFCS|Sweetened condition with high fructose corn syrup (HFCS): 240 mL high β-glucan barley + 50 g HFCS, 391 kcal, \~6 g β-glucan
48020234|NCT00491686|DRUG|AZD6765|intravenous infusion
48020235|NCT06431763|DRUG|Inclisiran sodium|300 mg s.c. administered at day 1 and day 90
48177758|NCT00636662|OTHER|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
48177759|NCT03630406|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal Tactile Imaging
48177760|NCT01427049|DEVICE|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
48177761|NCT04871347|DRUG|TWP-101|IV infusion
48517739|NCT04418102|DIETARY_SUPPLEMENT|Palmitic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period
48020236|NCT06431763|DRUG|BPA|180 mg daily per oral
48020237|NCT06043414|DEVICE|triclosan-coated barbed suture|STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.
48020238|NCT06043414|DEVICE|triclosan-coated non-barbed suture|PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.
48177762|NCT03975842|OTHER|Sinonasal and otologic evaluation|"At onset, each participant had:~* sinonasal evaluation (several nasal signs and symptoms were evaluated, bilateral endoscopic nasal examination, computed tomography (CT) of the sinuses when sinus surgery became necessary).~* otologic evaluation (evaluation of middle ear status, documentations of personal history of otologic disease, otoscopic examination, pure-tone audiometry and tympanometry)"
48177763|NCT04191876|OTHER|Wellth - Financial Incentives|Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
48177764|NCT05865171|DRUG|IXP|Tablets for oral administration.
48177765|NCT06317038|DEVICE|Total 30 Contact Lens|Patients will be give a contact lens for 1 month
48177766|NCT02762903|PROCEDURE|TSA with tenotomy technique|Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
48177767|NCT02762903|PROCEDURE|TSA with lesser tuberosity osteotomy technique|Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
48177768|NCT02762903|DEVICE|Shoulder prosthesis|"Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device."
48177769|NCT03512197|DRUG|Midostaurin|Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.
48177770|NCT03512197|DRUG|Placebo|Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
48177771|NCT03512197|DRUG|Chemotherapy|Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
48517740|NCT04418102|DIETARY_SUPPLEMENT|Stearic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
48711523|NCT02855723|OTHER|Surgery: Classic strategy|systematic lymphadenectomy
48177772|NCT03630263|OTHER|Raw Corn Starch|Raw corn starch (30 g) will be added to 200 g of applesauce and served to participants, gastric emptying rate, and postprandial glucose will be measured.
48177773|NCT03630263|OTHER|No Raw Corn Starch|200 g of applesauce will be consumed and gastric emptying rate, and postprandial glucose will be measured.
48517741|NCT01301729|DRUG|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
48517742|NCT01301729|DRUG|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
48711524|NCT02962596|OTHER|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
48378111|NCT03237000|DRUG|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
48517743|NCT01301729|DRUG|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
48517744|NCT01228799|PROCEDURE|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
48517745|NCT01228799|PROCEDURE|Canaloplasty|Canaloplasty with implant of suture
48711525|NCT03237130|PROCEDURE|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
48711526|NCT00794365|DRUG|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
48711527|NCT02182908|OTHER|PET-Scan|PET-Scan
48020239|NCT06043414|DEVICE|Non-coated non-barbed suture|PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
48020240|NCT04819685|DRUG|KANG FU PEN|FU PEN: anti-radiation spray (liquid dressing) treatment which is a protective irrigation solution against rays
48020241|NCT04177355|BIOLOGICAL|BG505 SOSIP.664 gp140|Administered by IM injection
48020242|NCT04177355|BIOLOGICAL|Placebo|Administered by IM injection
48020243|NCT04177355|BIOLOGICAL|3M-052-AF|Administered by IM injection
48020244|NCT04177355|BIOLOGICAL|CpG 1018|Administered by IM injection
48020245|NCT04177355|BIOLOGICAL|GLA-LSQ|Administered by IM injection
48020246|NCT04177355|BIOLOGICAL|Alum (Aluminum Hydroxide Suspension)|Administered by IM injection
48020247|NCT04177355|BIOLOGICAL|Trimer 4571|Administered by IM injection
48020248|NCT03395535|PROCEDURE|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
48020249|NCT03395535|DRUG|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
48020250|NCT05501509|PROCEDURE|Coracoclavicular fixation with acromioclavicular stabilization for the management of an unstable acromiclavicular luxation|Using a 3-hole third plate and high resistance sutures across the acromioclavicular joint to achieve horizontal and vertical stability of the joint
48020251|NCT05501509|PROCEDURE|Coracoclavicular fixation for the management of an unstable acromiclavicular luxation|Isolated coracoclavicular repair using a 3 hole third plate.
48020252|NCT03864614|DRUG|SAGE-217|SAGE-217
48020253|NCT01339650|DRUG|ABT-767|ABT-767 once or twice daily for a 28 day cycle
48020254|NCT02786615|BEHAVIORAL|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
48177774|NCT04198948|DRUG|Omeprazole|Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.
48177775|NCT04198948|DRUG|Placebo oral tablet|Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
48177776|NCT04198948|DRUG|Gliclazide|Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
48378112|NCT00649714|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fed
48378113|NCT00649714|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fed
48378114|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA-compatible Related|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
48711528|NCT03151798|BEHAVIORAL|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
48711529|NCT03151798|BEHAVIORAL|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
48711530|NCT03151798|OTHER|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
48711531|NCT01847105|OTHER|RevitaLens|Multi-purpose disinfecting solution
48711532|NCT01847105|OTHER|OptiFree PureMoist|Multi-purpose disinfecting solution
48177777|NCT00687245|DRUG|esomeprazole magnesium|capsules, oral, qd, one day
48177778|NCT05803642|DRUG|Olanzapine|intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
48177779|NCT05803642|DRUG|Haloperidol|intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
48177780|NCT03953456|DRUG|elafibranor 120mg|elafibranor 120mg is a coated tablet for oral administration, once daily
48177781|NCT03953456|DRUG|Placebo|Placebo is a coated tablet for oral administration, once daily
48177782|NCT05353660|OTHER|No intervention|No intervention
48177783|NCT03182998|OTHER|Internet-Based Intervention|"Receive Knowing your Options decision aid"
48177784|NCT03182998|OTHER|Internet-Based Intervention|"Receive Prostate Choice decision aid"
48177785|NCT03182998|OTHER|Best Practice|Undergo usual care
48177786|NCT03182998|OTHER|Quality-of-Life Assessment|Ancillary studies
48177787|NCT03182998|OTHER|Questionnaire Administration|Ancillary studies
48177788|NCT03182998|OTHER|Survey Administration|Ancillary studies
48177789|NCT03182998|OTHER|Laboratory Biomarker Analysis|Correlative studies
48177790|NCT05425225|OTHER|Low level LASER therapy|Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds. Two sessions will be given per week for total of 6 weeks.(20)
48177791|NCT05425225|OTHER|Conventional physical therapy|Hot pack for 15 to 20 minutes followed by 10 repetitions of sustained stretching (10 seconds hold), for 3 days a week for 6 week
48177792|NCT01079247|OTHER|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
48177793|NCT01079247|OTHER|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
48177794|NCT04289259|OTHER|TMB assessment|Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
48711533|NCT01920763|OTHER|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
48711534|NCT06145516|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Hybrid CBT-I (self-guided digital format focusing on sleep restriction therapy and stimulus control + telehealth video-consultations with psychologist)
48711535|NCT06145516|BEHAVIORAL|Sleep education therapy (SET)|Self-guided digital sleep education (sleep hygiene, sleep physiology, sleep disturbances etc) + telehealth video-consultations with research nurse
48711536|NCT06463704|OTHER|There is no intervention|There is no intervention
48711537|NCT04589351|DRUG|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
48711538|NCT04589351|DRUG|Placebo|Matching placebo
48711539|NCT02249494|OTHER|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
48711540|NCT02249494|OTHER|nutritional counseling|Performing routine nutritional counseling in their clinical practice
48177795|NCT00995384|PROCEDURE|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
48177796|NCT06202911|DRUG|oral n-acetyl cysteine|the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance
48177797|NCT06202911|OTHER|placebo|the control group will receive placebo
48177798|NCT04290611|DRUG|Enzalutamide|Enzalutamide for the treatment of prostate cancer or other solid tumors
48177799|NCT03177681|OTHER|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
48177800|NCT03177681|OTHER|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
48177801|NCT03177681|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
48177802|NCT03177681|DEVICE|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
48177803|NCT03177681|OTHER|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
48177804|NCT01522703|DRUG|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
48177805|NCT01522703|DRUG|Placebo|Alfalfa Sprouts
48177806|NCT00758823|DEVICE|Paranix|pediculicide product
48177807|NCT00288223|DRUG|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
48177808|NCT01903083|DRUG|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
48177809|NCT01903083|DRUG|Gemcitabine|Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
48177810|NCT01903083|RADIATION|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
48177811|NCT01903083|PROCEDURE|Pancreaticoduodenectomy|Surgical resection.
48177812|NCT01193998|OTHER|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
48711541|NCT02249494|DEVICE|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
48177813|NCT01193998|OTHER|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
48020255|NCT06532838|PROCEDURE|Optimized treatment strategies|The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.
48177814|NCT04805450|PROCEDURE|ES before fully covered SEMS placement|
48020256|NCT06532838|PROCEDURE|Traditional treatment strategies|Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
48177815|NCT04805450|PROCEDURE|no ES before fully covered SEMS placement|
48177816|NCT03563313|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months at home.
48177817|NCT03563313|DEVICE|Sensor-augmented pump (SAP)|Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
48177818|NCT01646528|PROCEDURE|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
48177819|NCT04338906|DRUG|Camostat Mesilate|400 mg tid, d1-d7
48020257|NCT00002312|DRUG|Delavirdine mesylate|
48020258|NCT00002312|DRUG|Zidovudine|
48020259|NCT02954913|PROCEDURE|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
48177820|NCT04338906|DRUG|Placebo|Instead of Camostat Mesilate, tid, d1-d7
48177821|NCT04338906|DRUG|Hydroxychloroquine|400 mg bid on day 1, 200 mg bid d2-d7
48517746|NCT05810428|PROCEDURE|GKRS-VR training|One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.
48020260|NCT05393310|OTHER|post isometric relaxation|The therapist will apply Post isometric relaxation ensure that foot will not actually move and only a static muscle contraction apply and held for 20 seconds. This will be followed by 2-3 second of relaxation, and then the foot passively stretched to dorsiflexion up to the palpated barrier and/or tolerance to stretch. This will continue until no further gains achieved 2 sets of 5 repetitions a day for 3 days a week for 4 weeks
48020261|NCT05393310|OTHER|MWM group|MWM group will receive inferior tibiofibular, talocrural, or cubometatarsal MWM 2-8 treatment sessions over 4 weeks.
48177822|NCT03596398|GENETIC|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
48177823|NCT03501810|DEVICE|Distractor use for vertebrae separation|Distractor use where separation of vertebrae is required, including corpectomy, insertion of disc prosthesis, insertion of an anterior lumbar interbody fusion (ALIF) cage, and tumor surgery
48177824|NCT05317559|BEHAVIORAL|room light|The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
48177825|NCT05451797|DEVICE|Implant of WiSE-CRT with intracardiac pacemaker|Implant of two cardiac devices
48177826|NCT05455372|DRUG|PPI quadruple therapy|PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
48177827|NCT02621554|DIETARY_SUPPLEMENT|resveratrol supplementation|6 months of resveratrol supplementation
48177828|NCT02621554|DIETARY_SUPPLEMENT|Placebo|6 months of placebo intake
48378115|NCT04684979|BIOLOGICAL|Hematopoietic Stem Cells from HLA Unrelated|NMA PBSCT (Non-Myeloablative peripheral blood stem cell transplantation) incorporating rituximab and utilizing PBSC (Peripheral blood stem cells) to increase graft cell dose in patients with selected B lymphoid malignancies.
48378116|NCT06542809|OTHER|Questionnaire|Recruitment will take place through routine paediatric endocrinology consultations with physicians registered with BELSPEED. These doctors will take the time to explain the questionnaire. And allow the patient to complete it.
48378117|NCT01133912|DRUG|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
48378118|NCT04034329|PROCEDURE|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
48378119|NCT04034329|PROCEDURE|EVLA|Endovenous Laser Ablation
48378120|NCT04103268|OTHER|sepsis|patients in the ICU with infection called sepsis
48711542|NCT04159363|OTHER|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
48711543|NCT00645879|DRUG|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
48020262|NCT02527720|BEHAVIORAL|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at \~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
48020263|NCT06078397|DEVICE|remote programming|Remote programming (RP) is a new type of patient management method after DBS surgery, which allows physicians to understand the patient's movement symptoms and adjust parameters through video conferencing. At the same time, the RP system also includes device checks, medication adjustments, psychological counseling, and other contents. Compared to standard programming that requires going to the hospital, the application of RP can save the burden on patients and their caregivers.
48020264|NCT06078397|DEVICE|standard programming|Programming refers to a series of methods that set the parameters of the IPG after the implantation of DBS, and adjust the device parameters based on the patient's symptoms during subsequent follow-up to maintain the efficacy of electrical stimulation.
48020265|NCT03221257|DRUG|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
48020266|NCT03221257|DRUG|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
48711544|NCT00645879|DRUG|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
48711545|NCT00645879|DRUG|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
48711546|NCT00525629|DIETARY_SUPPLEMENT|Walnuts|48 Grams of Walnuts Daily
48711547|NCT00525629|DIETARY_SUPPLEMENT|Control|Control Diet with No Walnuts
48711548|NCT05766904|BIOLOGICAL|4CMenB vaccine|Four-component MenB vaccine
48711549|NCT05766904|OTHER|Placebo|0.9% Sodium Chloride Inj. B.P.
48711550|NCT03184363|DRUG|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
48020267|NCT03221257|DRUG|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
48177829|NCT03968068|PROCEDURE|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
48378121|NCT03585166|PROCEDURE|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
48711551|NCT01410292|OTHER|GI and fiber meals|meals with different fiber content and glycemic index
48711552|NCT01410292|OTHER|meals|four different meal regarding GI and fiber content
48378122|NCT03585166|PROCEDURE|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
48378123|NCT06442111|DRUG|The intravenous ferritin group|Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
48378124|NCT06442111|DRUG|The placebo group|Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
48378125|NCT03893279|BEHAVIORAL|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
48517747|NCT05810428|PROCEDURE|Control Group|Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.
48711553|NCT01053559|DRUG|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
48711554|NCT02282371|DRUG|Cetuximab|
48711555|NCT02282371|DRUG|BYL719|
48177830|NCT03968068|PROCEDURE|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
48177831|NCT00431613|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
48177832|NCT00431613|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
48177833|NCT00431613|DRUG|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
48177834|NCT00431613|RADIATION|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
48177835|NCT00431613|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
48177836|NCT01850823|DRUG|placebo|
48177837|NCT01850823|DRUG|Mometasone Nasal Spray|
48177838|NCT01850823|DRUG|Mometasone nasal spray|
48177839|NCT06083610|OTHER|miRNA levels analysis from saliva samples|Each participant will be given two 50-mL Falcon tubes and will be asked to expectorate a small amount (about 1 mL) of saliva before and immediately after the end of exercise. Part of each saliva sample will be mixed with an equal volume of denaturing solution included in the mirVanaTM PARISTM kit from Ambion, Foster City, CA, in order to inactivate ribonucleases. Serum samples will be separated by centrifugation at 4000 rpm from the saliva samples taken into the biochemistry tubes of the participants and controls and will be raised to -80 centigrade degrees until the study day. Micro RNA will be isolated from serum samples on the working day. Determination of microRNA expression levels (micro RNA-1 and micro RNA-133a) will be determined by reverse transcriptase polymerase chain reaction (RT-PCR) (Applied Biosystems 7500 Fast Real-Time PCR).
48177840|NCT04388696|BEHAVIORAL|Sisterhood 2.0|The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
48177841|NCT05870228|BEHAVIORAL|Strathclyde Sleep Intervention|Manual-based CBT-I
48711556|NCT02282371|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
48177842|NCT02781311|DRUG|Setipiprant|Setipiprant tablets, orally, BID for 24 weeks.
48177843|NCT02781311|DRUG|Placebo|Placebo tablets, orally, BID for 24 weeks.
48378126|NCT05075551|DEVICE|Acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL23 is in the sacral region, in the second posterior sacral foramen; BL54 is in the fourth posterior sacral foramen, 3 cun beside the median sacral crest; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
48388022|NCT03457727|DRUG|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
48711557|NCT03990207|DEVICE|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
48711558|NCT06605703|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
48177844|NCT02781311|DRUG|Finasteride|Finasteride tablet, orally, once daily for 24 weeks.
48177845|NCT06301347|BEHAVIORAL|Learning through Play Plus|Combination of two interventions: Learning through Play and Cognitive Behaviour Therapy
48177846|NCT02802358|PROCEDURE|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
48177847|NCT00051623|DRUG|Infliximab|
48177848|NCT05553223|BEHAVIORAL|Microdoses of activity|Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
48177849|NCT00801411|DRUG|cyclophosphamide|Given IV
48177850|NCT00801411|DRUG|docetaxel|Given IV
48177851|NCT00801411|DRUG|doxorubicin hydrochloride|Given IV
48177852|NCT00988533|DRUG|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
48177853|NCT00813098|DRUG|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
48177854|NCT00813098|DRUG|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
48177855|NCT00813098|DRUG|Placebo|Matching placebo dosing with daily oral intake
48177856|NCT03182296|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
48177857|NCT01159522|DRUG|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
48177858|NCT00394420|BEHAVIORAL|Telephone Quitline|
48711559|NCT06605703|DRUG|Bupropion-Naltrexone|Bupropion-Naltrexone
48711560|NCT06605703|DRUG|Bupropion-Naltrexone-Metformin|Bupropion-Naltrexone-Metformin
48711561|NCT03037099|BEHAVIORAL|Enhanced GI Concept Education|
48711562|NCT00733772|DIETARY_SUPPLEMENT|flaxseed|30 grams/day of flaxseed for 12 weeks
48711563|NCT00733772|BEHAVIORAL|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
48711564|NCT03624426|DEVICE|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
48711565|NCT03619226|OTHER|test patch|the test patch consists of an adhesive patch
48378127|NCT05075551|DEVICE|Sham acupuncture|Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used.These volunteers will receive relatively shallow needling at bilateral sham SP6, BL54, BL23 and BL35. This treatment gets involved in the same duration and frequency of sessions, but the treatment was delivered superficially at non-acupuncture points 10 mm to the lateral of corresponding acupuncture and not above a meridian line (10mm to SP6, BL54, BL23 and BL35).The same equipment of fMRI scanner will be used.
48378128|NCT05075551|OTHER|fMRI scan|Both two group will get fMRI scan week 0 (before treatment), week 12 (after treatment) and week 36 (following up). The resting-state fMRI data will be obtained by using a 3.0T GE MR 750 MRI scanner with an eight-channel phase array head coil at the Huashan Hospital, Shanghai. The high resolution T1-weighted magnetic resonance images will be collected by a three-dimensional fast spoiled gradient-echo dual-echo sequence \[repetition time (TR) = 8100 ms; echo time (TE) = 3.1 ms; FA = 8 deg; matrix=256 × 256; field of view (FOV)=25.6× 25.6 cm2; slice thickness=1 mm; no gap and 156 slices\]. The whole resting state fMRI data will be acquired by using a gradient-recalled echo-planar imaging pulse sequence (TR/TE = 2,000/30 ms; FA = 90°; acquisition matrix = 64×64; FOV = 22×22 cm2; slice thickness= 4 mm; 43 slices and total 240 time points; no gap).
48020268|NCT05236790|DIAGNOSTIC_TEST|Detection and classification and size measurement of polyp by Artificial Intelligence (Cad eye) and the Scale Eye|Detection and classification and size measurement of polyp by Artificial Intelligence (CADeye) and Scale Eye This study will be conducted in multiple phases: phase 1 (pilot phase, n=40 polyps, about 60 patients) to evaluate the feasibility of applying Scale Eye in real-time practice, training endoscopists to work with CADe and CADx and determining the sample size and reference standard to evaluate SCALE-EYE during the second phase of the study (randomized controlled trial), phase 2 will evaluate the performance of SCALE-EYE and CAD-eye in real-time practice. The sample size for phase 2 (RCT comparing visual with scasle eye) will be based on the pilot data allowing to compare relative accuracy of size measurement with scale eye versus visual size estimation. After completion of phase 2 later phases will use instruments such as snare and/or forceps as reference measurement devices compared to relative accuracy of measurement when using scale eye.
48020269|NCT06457152|OTHER|EHR-Emedded Alert|For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
48020270|NCT01662869|DRUG|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
48177859|NCT01550523|DRUG|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
48177860|NCT01550523|DEVICE|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
48378129|NCT01046175|PROCEDURE|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
48177861|NCT00296010|DRUG|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
48378130|NCT01046175|PROCEDURE|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
48378131|NCT05735860|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Four VRET sessions of approx. one hour each session taking place in an individual setting accompanied by a therapist. The participants wear a head-mounted display showing different musical performance scenarios (i.e. audition in a concert hall/ recording studio/ in front of a professional jury/ an audience/ a class of music students) that are selected individually by a previously standardized, graded exposure procedure.
48020271|NCT01662869|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
48020272|NCT01662869|DRUG|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
48020273|NCT01662869|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
48020274|NCT01662869|DRUG|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
48020275|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 1|The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
48177862|NCT00296010|DRUG|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
48378132|NCT05735860|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Four PMR sessions of approx. 45min each session taking place in an individual setting accompanied by a therapist. The sessions follow a previously standardized procedure.
48378133|NCT00683670|DRUG|cyclophosphamide|
48378134|NCT00683670|BIOLOGICAL|Mature dendritic cell vaccine|
48378135|NCT01340807|OTHER|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
48378136|NCT03602846|DIETARY_SUPPLEMENT|Medical Nutrition Therapy|Only given medical nutrition therapy.
48378137|NCT03602846|DRUG|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
48020276|NCT04448860|BEHAVIORAL|performance of behavioral locomotion tasks phase 2|The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
48020277|NCT05008055|DRUG|Capivasertib|Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
48020278|NCT06440668|BEHAVIORAL|Chronic Pain Management Workshop with Non-Pharmacological Therapies|"1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient."
48020279|NCT03099382|BIOLOGICAL|camrelizumab|Subjects receive camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks
48020280|NCT03099382|DRUG|Docetaxel|Subjects receive Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks
48020281|NCT03099382|DRUG|Irinotecan|Subjects receive Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks
48020282|NCT00014144|DRUG|gefitinib|
48020283|NCT02209324|DRUG|ASP2151|
48020284|NCT00861341|DRUG|Aspirin|81 mg
48177863|NCT00296010|DRUG|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
48177864|NCT00296010|PROCEDURE|adjuvant therapy|
48177865|NCT00296010|RADIATION|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
48177866|NCT04131764|DIAGNOSTIC_TEST|Reflex (Brightlamp Inc., Purdue University)|The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
48177867|NCT04423172|DEVICE|the new tissue containment system|Using the new tissue containment system during Laparoscopic hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
48177868|NCT04201145|DRUG|Pembrolizumab|IV, predetermined dosage, twice per cycle
48020285|NCT00861341|DRUG|Pioglitazone|30mg Pioglitazone x1
48378138|NCT03602846|DRUG|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
48378139|NCT00795886|DRUG|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
48378140|NCT00104858|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
48020286|NCT04840745|DRUG|CKD-841 A-1 3.75mg|Single injection, subcutaneous injection
48020287|NCT04840745|DRUG|CKD-841 A-1 1.88mg|Single injection, subcutaneous injection
48020288|NCT04840745|DRUG|CKD-841 D 2.92mg|Single injection, subcutaneous injection
48020289|NCT04840745|DRUG|Leuplin Inj. 3.75 mg|Single injection, subcutaneous injection
48020290|NCT00812812|DRUG|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
48020291|NCT00812812|DRUG|paroxetine 20mg tablet|1 tablet once a day
48177869|NCT04201145|DRUG|Defactinib|Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort
48177870|NCT04216485|BEHAVIORAL|Intensive Lifestyle Intervention|Dietary intervention combined with healthy lifestyle counseling
48177871|NCT04216485|BEHAVIORAL|Standard Care|Standard prenatal care on diet, nutrition and physical activity
48177872|NCT04729842|PROCEDURE|Axillary Brachial plexus block|Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R
48177873|NCT04458220|OTHER|photo and voice obtained|The 3D face scanner and camera is used to obtain 3D or 2-dimensional portrait images of patients in different positions and from different angles.The Hi-Fi Recorder is used to obtain sound samples of patients in different word.
48177874|NCT01355978|DEVICE|Noninvasive Open Ventilation System|Noninvasive ventilation system
48378141|NCT00104858|DRUG|Cyclosporine|Given PO
48378142|NCT00104858|DRUG|Fludarabine Phosphate|Given IV
48378143|NCT00104858|OTHER|Laboratory Biomarker Analysis|Correlative studies
48378144|NCT00104858|DRUG|Mycophenolate Mofetil|Given PO
48378145|NCT00104858|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
48378146|NCT00104858|OTHER|Pharmacological Study|Correlative studies
48378147|NCT00104858|BIOLOGICAL|Rituximab|Given IV
48378148|NCT00104858|RADIATION|Total-Body Irradiation|Undergo TBI
48020292|NCT00812812|DRUG|matched placebo to paroxetine 10mg|2 tablets once a day
48020293|NCT00812812|DRUG|matched placebo to paroxetine 20mg|1 tablet once a day
48020294|NCT01706952|DRUG|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
48020295|NCT01706952|DRUG|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
48020296|NCT05206968|RADIATION|pelvic radiograph|Patients with hip involvement underwent a pelvic radiograph
48020297|NCT04504227|DIETARY_SUPPLEMENT|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
48020298|NCT04504227|DIETARY_SUPPLEMENT|Slightly thickened liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
48020299|NCT04504227|DIETARY_SUPPLEMENT|Mildly thickened liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
48020300|NCT04504227|DIETARY_SUPPLEMENT|Moderately thickened liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
48020301|NCT04306224|BIOLOGICAL|IMC-002|IMC-002 blocks the interaction between CD47 and SIRPα.
48020302|NCT01070810|DRUG|D5W|Dextrose 5%
48020303|NCT01070810|DRUG|Thiamine|Thiamine 200mg in 50ml D5W
48020304|NCT00597805|BEHAVIORAL|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
48020305|NCT04800185|DRUG|Crisaborole 2% Top Oint|To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
48020306|NCT04800185|GENETIC|Skin Microbiome Swabs|At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
48020307|NCT05723523|OTHER|CI-CDS|The CI-CDS system is a clinical decision support tool that assists clinicians in the diagnosis and management of cognitive impairment.
48177875|NCT01672398|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
48177876|NCT00033943|DRUG|deligoparin|
48177877|NCT03362541|BEHAVIORAL|MS INFoRm|MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.
48378149|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
48177878|NCT03362541|BEHAVIORAL|Usual Care Control Group|The usual care webpage will contain content from widely available resources about MS fatigue.
48378150|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
48378151|NCT01399619|DRUG|BI201335|BI201335 for 12w
48711566|NCT04808206|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
48177879|NCT01303315|DEVICE|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
48177880|NCT05006222|DRUG|Enzyme Replacement Agent|Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
48378152|NCT01399619|DRUG|BI201335 24W|BI201335 for 24w
48378153|NCT01399619|DRUG|PegIFN/RBV|PegIFN/RBV for 24 or 48w
48378154|NCT01399619|DRUG|Bi 201335|BI 201335 for 24 w
48378155|NCT03881748|OTHER|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
48378156|NCT03881748|OTHER|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
48388023|NCT03457727|DRUG|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
48388024|NCT01419405|DRUG|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
48388025|NCT01419405|DRUG|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
48711567|NCT04436471|BIOLOGICAL|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
48711568|NCT02448979|PROCEDURE|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
48711569|NCT02448979|PROCEDURE|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
48020308|NCT06569342|PROCEDURE|Intradetrusor BoNT-A|For intravesical injections, BoNT-A (Allergan, Irvine, CA, USA) was diluted in 0.9% saline to 10 93 international units/ml. Multiple injections were distributed throughout the detrusor, using a 94 transurethral 23-gauge injection needle under rigid cystoscopic guidance (9.8 Fr paediatric 95 cystoscope) at 10 units/kg to a maximum of 300 units. All injections were performed under general 96 anaesthesia with antibiotic prophylaxis given intra-operative as single dose intravenously.
48020309|NCT00058240|DRUG|alvocidib|Given IV
48020310|NCT04866394|RADIATION|SBRT|Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
48020311|NCT00477711|DRUG|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
48020312|NCT02116322|PROCEDURE|EUS-FNA with Corkscrew technique|
48020313|NCT02116322|DEVICE|Expect 19 G Flex needle|
48020314|NCT00638547|DRUG|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
48020315|NCT05337501|OTHER|Collecting data|Anamnesis, clinical examination, Quantitative Sensory Testing (following DFNS, German Research Network on Neuropathic Pain, protocol), visual TOJ (Temporal Order Judgement) task
48020316|NCT02784314|PROCEDURE|Robotic-Assisted Radical Prostatectomy|
48378157|NCT06539845|BEHAVIORAL|Outbreak Preparedness Intervention for the Orang Asli|"The chosen villages will be given the intervention package, which includes a workshop, simulation exercises, and a card game, in addition to educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This entire package will be delivered once, during the workshop, after they have answered the survey at T0."
48378158|NCT06539845|BEHAVIORAL|Educational Brochures for the Orang Asli|"The chosen villages will be given educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This will be given once during the first encounter with the participant, after they have answered the survey at T0."
48378159|NCT04150107|DRUG|ORMD-0801 Treatment A|Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
48020317|NCT02784314|PROCEDURE|Laparoscopic Radical Prostatectomy|
48020318|NCT04354831|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|"* SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion"
48020319|NCT04352933|DRUG|Hydroxychloroquine - Daily dosing|"Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
48020320|NCT04352933|DRUG|Hydroxychloroquine - Weekly Dosing|"Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months)"
48020321|NCT04352933|OTHER|Matched Placebo Hydroxychloroquine|"Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)"
48020322|NCT05979805|OTHER|Conventional Educational interventions|Conventional educational methods can be verbal, written or visual and can be combined for greater understanding and effectiveness in oral health and dietary routines. The education are imparted in the first appointment of the appliances cementation by a video and oral health instruction booklet and each patient receive an oral hygiene kit. This education is repeated in month 1 and 3 after appliances cementation.
48177881|NCT02341586|OTHER|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
48378160|NCT04150107|DRUG|ORMD-0801 Treatment B|Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
48378161|NCT04150107|OTHER|Placebo|Fish oil capsule
48378162|NCT05200975|DIAGNOSTIC_TEST|Venapunction|Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total.
48711570|NCT02378194|DRUG|Placebo|24 weeks, once daily oral administration
48378163|NCT04943523|DIETARY_SUPPLEMENT|Krill Oil|Krill oil supplements 4g/day
48711571|NCT02378194|DRUG|HD-003 (800mg/day)|24 weeks, once daily oral administration
48711572|NCT02378194|DRUG|HD-003 (1600mg/day)|24 weeks, once daily oral administration
48378164|NCT04943523|DIETARY_SUPPLEMENT|Vegetable Oil|vegetable oil supplements 4g/day
48378165|NCT04876482|PROCEDURE|transoral robotic surgery|transoral robotic surgery (TORS) which remove the extra soft tissue of the base of the tongue and soft palate in this study
48711573|NCT01667146|OTHER|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH \> 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
48711574|NCT01667146|OTHER|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
48177882|NCT02341586|DIETARY_SUPPLEMENT|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
48378166|NCT04876482|DEVICE|oral appliance|It is a kind of treatment for the participants who refuse surgeries and choose to use other kinds of conservative treatment. The conservative treatments included oral appliance, losing weights and using continuous positive airway pressure. The oral appliance would be wore only at night and it would press the soft palate and protrude the jaw.
48177883|NCT02341586|OTHER|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
48177884|NCT05174598|DRUG|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Topical spray formulation containing Calcipotriol 50 μg/g. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
48378167|NCT04876482|DEVICE|using continuous positive airway pressure|The participants only used CPAP at night. The device composed of a main machine, pipe and mask. The participants would instruct to wore the mask. The main machine would give positive airway pressure to open the airway and avoid collapsing.
48177885|NCT05174598|DRUG|Calcipotriol Ointment 50 micrograms/g|Topical Ointment formulation containing Calcipotriol 50 micrograms/g. Twice daily treatment by applying on a psoriasis affected area for 8 weeks.
48177886|NCT05174598|OTHER|Placebo|Topical spray formulation containing Vehicle of test formulation. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
48378168|NCT04876482|BEHAVIORAL|losing weights|The participants would ask to lose weight by changing their diets and exercising, without using drugs and surgeries.
48378169|NCT04876482|COMBINATION_PRODUCT|oropharyngeal rehabilitation|OPR included exercise for soft palate, tongue and oropharynx. There are 13 movements in OPR. The movements would be teach by a physical therapist.
48378170|NCT06336629|DRUG|Winlevi (clascoterone) 1% & Duac gel|Participants will use Winlevi (clascoterone) 1% and Duac gel as per label
48378171|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
48711575|NCT01974752|DRUG|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
48711576|NCT01974752|DRUG|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
48177887|NCT04843410|OTHER|Hand-foot exercise|The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.
48177888|NCT04843410|OTHER|The routine care|Education about chemotherapy-associated peripheral neuropathy risk factors, why it develops and its management
48177889|NCT00960609|PROCEDURE|Ultrasound guided liver resection|
48177890|NCT00796393|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
48177891|NCT00796393|DIETARY_SUPPLEMENT|Starch of potato|1 pill per day for 12 weeks
48177892|NCT01547221|DRUG|clotrimazole|single application of 1%clotrimazole ear drop
48177893|NCT01547221|DRUG|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
48177894|NCT00746109|PROCEDURE|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
48177895|NCT00746109|PROCEDURE|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
48177896|NCT05980962|PROCEDURE|Inferior oblique anteriorization|symmterical anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion
48177897|NCT05980962|PROCEDURE|Inferior oblique anteriorization together with unliateral resction|asymmterical surgery, anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion in one eye, and an additional 3-5 mm resction of the inferior oblique in the eye with the larger devation
48711577|NCT01974752|DRUG|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
48711578|NCT03606447|DRUG|Uproleselan|\[14C\]-Uproleselan
48711579|NCT06140797|COMBINATION_PRODUCT|Multimodal prehabilitation combined with perioperative ERAS care（PREERAS）|Pre-admission risk assessment and targeted intervention provided by multidisciplinary team
48711580|NCT00000558|DRUG|angiotensin-converting enzyme inhibitors|
48711581|NCT00497237|DRUG|Beclomethasone plus formoterol fixed combination|100+6 pMDI
48711582|NCT00497237|DRUG|Fluticasone plus salmeterol fixed combination|diskus 250/50
48711583|NCT03197974|BEHAVIORAL|Mindfulness for Bipolar|Brief online self-management program with email coaching support
48177898|NCT03121209|PROCEDURE|Revascularization|Patients in this arm are randomized to CEA/CAS plus IMM
48177899|NCT03121209|OTHER|Intensive Medical Management (IMM) alone|Patients in this arm are randomized to intensive medical management (IMM) alone
48177900|NCT01375114|DRUG|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
48177901|NCT01375114|DIETARY_SUPPLEMENT|Placebo|Placebo by mouth twice daily for 4 weeks.
48177902|NCT01375114|BEHAVIORAL|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
48177903|NCT01137747|DRUG|Carfilzomib|
48177904|NCT03593330|OTHER|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
48177905|NCT02874573|DRUG|Tocilizumab|Investigational agent
48177906|NCT02874573|DRUG|Normal saline|Placebo
48177907|NCT03041298|PROCEDURE|MR mammography with Dotarem|
48177908|NCT05634798|OTHER|no intervention|There is no intervention in this study.
48177909|NCT01893853|OTHER|Exercise Intervention|Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
48177910|NCT01834586|DRUG|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
48177911|NCT04286763|DIAGNOSTIC_TEST|Biliary RMI and CT scan.|"For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients."
48378172|NCT00151775|DRUG|placebo|Cohorts A, B, C: placebo, once daily
48711584|NCT03197974|BEHAVIORAL|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
48711585|NCT02542891|OTHER|Blended CBT|
48711586|NCT02542891|OTHER|Treatment as Usual (TAU)|
48711587|NCT05388773|PROCEDURE|therapeutic conventional surgery|Transoral surgical resection of tumor(s).
48711588|NCT05388773|OTHER|laboratory biomarker analysis|Correlative studies
48711589|NCT05388773|OTHER|quality-of-life assessment|Ancillary studies.
48711590|NCT05388773|RADIATION|intensity-modulated radiation therapy|Low-dose IMRT
48711591|NCT05388773|DRUG|Cisplatin|Given IV.
48711592|NCT05388773|DRUG|Carboplatin|Given IV
48177912|NCT02760485|DRUG|itacitinib|Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
48177913|NCT02760485|DRUG|ibrutinib|
48177914|NCT05638737|DRUG|AZD4831|AZD4831
48177915|NCT05638737|OTHER|Placebo|Placebo
48177916|NCT05998330|BEHAVIORAL|LiverPAL|The intervention include integrating early palliative care with usual hepatology care to evaluate and treat patients' symptoms, enhance their illness and prognostic understanding, support their coping, and coordinate their serious illness, transitional, and end-of-life care.
48177917|NCT00656032|OTHER|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
48177918|NCT00656032|OTHER|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
48177919|NCT04915131|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes."
48177920|NCT00503503|DRUG|Enbrel (etanercept)|
48177921|NCT00969969|DEVICE|Arthrodesis|arthrodesis using screws and/or a plate
48177922|NCT00969969|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
48177923|NCT05239715|DIAGNOSTIC_TEST|Ocular biometry|Biometry using swept-source OCT Argos, swept-source OCT IOLMaster 700, swept-source OCT Anterion, PCI Pentacam AXL, OcuScan RxP and Itrace measurement
48177924|NCT03774875|DRUG|Apremilast|Apremilast 30 mg tablets taken orally twice a day.
48711593|NCT02168738|DRUG|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
48177925|NCT03774875|DRUG|Placebo|Placebo tablets taken orally twice a day
48177926|NCT04502992|BEHAVIORAL|Acceptance and Committment Therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles \& McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
48711594|NCT02168738|DRUG|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
48177927|NCT03088098|DEVICE|LAAO|Left atrial appendage occlusion for stroke prevention
48177928|NCT03884712|DEVICE|CalmiGo|The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
48177929|NCT05111743|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
48177930|NCT04400968|PROCEDURE|Auricular therapy|The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen \[FT2\], uterus \[FT5\], sympathetic \[HI4\], kidney \[CS6\], heart \[CI4\], endocrine \[IT2\] and thalamus \[PC2\].
48177931|NCT04400968|PROCEDURE|kinesio tape|Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.
48177932|NCT04400968|PROCEDURE|Auricular therapy Placebo group|Sham auricular therapy
48177933|NCT04400968|PROCEDURE|kinesio tape Placebo group|Sham kinesio tape
48177934|NCT02274077|DRUG|EXPAREL|
48177935|NCT02274077|DRUG|Normal Saline|
48177936|NCT01896453|PROCEDURE|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
48177937|NCT01896453|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
48177938|NCT00030823|BIOLOGICAL|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
48711595|NCT02168738|DRUG|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
48711596|NCT04081961|DEVICE|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
48177939|NCT00030823|BIOLOGICAL|QS21|
48177940|NCT05479461|OTHER|Digital Hypertension Management System|Mobile health technology using physician- directed, semi-automated management of hypertension
48177941|NCT05479461|OTHER|Usual Care|The participants will receive usual care
48177942|NCT05419310|OTHER|Rehabilitation - core strengthening|Physical rehabilitation based on core strengthening
48711597|NCT04664530|DRUG|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
48177943|NCT05419310|OTHER|Rehabilitation - rehabilitation pilates|Physical rehabilitation based on rehabilitation pilates
48177944|NCT05419310|OTHER|Elastic taping application|Application of elastic taping
48177945|NCT03258671|DRUG|EGFR-TK Inhibitor|·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
48177946|NCT03258671|RADIATION|Intensity Modulated Radiation Therapy|"High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"
48378173|NCT00151775|DRUG|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
48711598|NCT04664530|DRUG|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
48020323|NCT05979805|BEHAVIORAL|Motivational intervention|In addition to the conventional educational method, a motivational interviewing (MI) by Miller and Rollnick of 30 minutes will be used, with an initial script according to the stage of change in each patient in T0. The reinforcements of motivational interviewing are in month one and three after the installation of the braces, they will have the same methodology but will be focused on the aspects that in the previous session or in the clinical assessment were detected as the most important deficiencies or risk factors for the patient.
48020324|NCT05573516|PROCEDURE|Open reduction and internal fixation|unicortical fully threaded 4mm screws will be used as positional screws after completely reducing the fracture
48020325|NCT05638360|DRUG|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
48020326|NCT05638360|DRUG|Placebo|Each patch contains 13g starch and 10c.c. water.
48020327|NCT00191321|DRUG|Teriparatide|
48020328|NCT04849975|OTHER|Pelvimetric measurements|The patients in this group are pregnant women after failure of external manual version (EMV) in case of breech fetal presentation. The participants will successively perform MRI pelvimetry (conventional management) and EOS imaging.
48020329|NCT01713777|DRUG|"Lamotrigine Generic A"|
48020330|NCT01713777|DRUG|"Lamotrigine generic B"|
48020331|NCT03156231|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
48020332|NCT03156231|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
48020333|NCT04886167|DRUG|AbobotulinumtoxinA|Injection of platysmal bands.
48177947|NCT05105568|BEHAVIORAL|Process-based therapy|Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
48177948|NCT04248907|OTHER|0 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
48388026|NCT01419405|DRUG|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
48711599|NCT03089879|BIOLOGICAL|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
48711600|NCT00136968|DRUG|Voriconazole|
48711601|NCT00064766|DRUG|doxycycline|
48711602|NCT04840563|DEVICE|Kalifon A|Commercially available kalifilcon A lenses
48711603|NCT04840563|DEVICE|Dailies Total1|Dailies Total1
48711604|NCT04840563|DEVICE|Precision1|Precision1
48711605|NCT01390324|DRUG|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
48711606|NCT01390324|DRUG|Naratriptan|Tablets containing naratriptan 2,5 mg
48711607|NCT01390324|DRUG|Naproxen|Tablets containing naproxen 500 mg
48711608|NCT00494377|DRUG|duloxetine|
48711609|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention with Reflection|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.
48711610|NCT05267132|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
48711611|NCT05267132|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
48711612|NCT03698786|BEHAVIORAL|Exercise|Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
48177949|NCT04248907|OTHER|2 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
48177950|NCT04248907|OTHER|4 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
48177951|NCT03763149|BIOLOGICAL|IBI188|"The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days."
48177952|NCT02725567|DRUG|IVA|Granules in sachet for oral administration.
48177953|NCT04008147|DIETARY_SUPPLEMENT|100mg iron fumarate|100mg iron fumarate b.i.d. for 4 consecutive days
48177954|NCT04008147|DIETARY_SUPPLEMENT|Burgerstein Schwangerschaft & Stillzeit|contains 30 mg iron fumarate, given on 14 consecutive days
48177955|NCT06382389|DRUG|EMONO|Exposure of Emono via facial mask
48177956|NCT06382389|DRUG|Medical air|exposure to Medical Air
48020334|NCT04521010|OTHER|COVID-19 pandemic|The aim of the study was to evaluate the staff absenteeism in the initial period of the COVID-19 pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań Poznań as well as to assess the level of performance of medical services that were assigned to the Hospital under contract with National Health Fund, the payer of public health services in Poland.
48020335|NCT06535256|DRUG|bupivacaine with dexamethasone|intra-peritoneal instillation of bupivacaine with dexamethasone (received 40 mL of 0.25% bupivacaine + 16 mg dexamethasone with 5 ml normal saline).
48177957|NCT01789840|DEVICE|Embosphere Microspheres|
48177958|NCT01789840|PROCEDURE|TURP|
48177959|NCT01028612|RADIATION|thermal ablation with external beam radiation|thermal ablation with external beam radiation
48177960|NCT02149706|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
48177961|NCT02149706|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
48177962|NCT01043198|GENETIC|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)~* Standardized screening with :~* radiological (hands, feet, spine ; and renal ultrasonography)~* biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
48177963|NCT01828866|BEHAVIORAL|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
48020336|NCT06535256|DRUG|bupivacaine with dexmedetomidine|intra-peritoneal instillation of bupivacaine with dexmedetomidine (received 40 mL of 0.25% bupivacaine + dexmedetomidine 1 μg/kg with normal saline 5 ml).
48020337|NCT03073616|DEVICE|Lung ultrasound|Lung ultrasound and chest RX
48020338|NCT06513624|DRUG|ETC-159|ETC-159 will be administered orally.
48020339|NCT06513624|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously.
48378174|NCT03911557|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
48378175|NCT00008034|DRUG|capecitabine|
48711613|NCT01969500|BEHAVIORAL|Mobile Application|
48020340|NCT06513624|DRUG|Denosumab / Zoledronic Acid|Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.
48020341|NCT05075876|DRUG|SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)|Single application for 6 days
48177964|NCT01828866|BEHAVIORAL|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring"
48177965|NCT00623363|DRUG|piclozotan|piclozotan, intravenous (IV) infusion
48378176|NCT00008034|DRUG|cyclophosphamide|
48378177|NCT00008034|DRUG|epirubicin hydrochloride|
48378178|NCT00236730|DRUG|topiramate|
48378179|NCT02848859|BEHAVIORAL|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
48711614|NCT01969500|BEHAVIORAL|Treatment as Usual (TAU)|
48711615|NCT05257148|DRUG|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
48711616|NCT05257148|DRUG|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
48020342|NCT05075876|DRUG|SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)|Single application for 6 days
48177966|NCT00623363|DRUG|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline) intravenous (IV) infusion
48177967|NCT01013545|BEHAVIORAL|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
48378180|NCT02848859|BEHAVIORAL|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
48378181|NCT05558735|OTHER|urine collection|urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
48020343|NCT02579291|OTHER|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
48020344|NCT02579291|OTHER|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
48177968|NCT03970057|BEHAVIORAL|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
48177969|NCT03970057|OTHER|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
48177970|NCT03715868|OTHER|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
48177971|NCT05660330|BEHAVIORAL|Holistic semi-tailormade well-being intervention|The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
48177972|NCT06545578|OTHER|low-level laser therapy|The Low-level laser (LLL) pain-relief instrument RG-300IB (code E22), manufactured in China, was utilized for low-level laser therapy (LLLT) in Group A . The therapy employed a wavelength of 830 nm (near infrared) and involved careful skin contact hygiene at specified positions, 2.5 and 3.5 cm laterally from the spinous process (L4, L5, or S1) and one distal level segment. The laser operated at a repetition rate of 5,000, with a power density of 300 mW/cm2 and a power output of 10 mW. Each point received 3 J of energy, resulting in a density of 3 J/cm2, with four points. The spot size was 1 cm, and each point received a 30-second treatment. The energy was administered three times per week for four weeks
48378182|NCT05558735|OTHER|canine detection|urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
48517748|NCT06582550|PROCEDURE|Minor Hand Procedure|Unilateral minor hand procedure (carpal tunnel release, trigger finger A1 pulley release, lesion excision)
48517749|NCT04190758|OTHER|Care as usual|No intervention will be given. The study will follow the effects of care as usual.
48020345|NCT02070159|DRUG|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
48020346|NCT02070159|DRUG|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
48020347|NCT02070159|DRUG|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
48020348|NCT04933435|OTHER|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
48378183|NCT02095834|DRUG|Bendamustine Hydrochloride|Given IV
48378184|NCT02095834|DRUG|Carfilzomib|Given IV
48378185|NCT02095834|DRUG|Dexamethasone|Given PO or IV
48378186|NCT02095834|OTHER|Laboratory Biomarker Analysis|Correlative studies
48378187|NCT05234073|BEHAVIORAL|SEE Learning Online Training|This intervention includes classes about socioemotional learning theory and practice, topics related to ethics and well-being practices
48378188|NCT05234073|BEHAVIORAL|Waiting list|This group will wait for one month to receive SEE Learning Online Training
48378189|NCT04296331|DIAGNOSTIC_TEST|POC|DC DOC's current testing practice offers opt-out POC testing with the INSTI® finger stick test at entry
48517750|NCT03723356|DIAGNOSTIC_TEST|Siemens Biograph mMR (molecular MR)|5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
48517751|NCT03723356|DIAGNOSTIC_TEST|fMRI|High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
48378190|NCT04296331|DIAGNOSTIC_TEST|Ag/Ab|The DC DOC will transition from offering their current POC testing upon entry to offering opt-out HIV testing with Ag/Ab: ARCHITECT® laboratory-based test.
48378191|NCT04296331|DIAGNOSTIC_TEST|POC + Ag/Ab|As the DC DOC transitions to utilizing the Ag/Ab: ARCHITECT® laboratory-based test from their current POC testing, jail nurses will offer new entrants op-out testing with the two methods
48378192|NCT05355506|DEVICE|Application|Knowledge \& record
48378193|NCT00564473|BEHAVIORAL|questionnaire|"* questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~* Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
48378194|NCT00978120|BIOLOGICAL|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
48378195|NCT00978120|BIOLOGICAL|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
48378196|NCT04698018|DRUG|Faster Aspart|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
48378197|NCT04698018|DRUG|Novo Rapid|Administered s.c. (subcutaneously, under the skin) of the lower abdomen using a pen-injector.
48378198|NCT01683565|DRUG|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
48378199|NCT01683565|OTHER|Canola Oil Placebo|2.5mL per day for 90 days
48378200|NCT00329225|DRUG|rosiglitazone|
48020349|NCT06536010|DRUG|Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；|VAG in the induction phase of the ND-AML treatment protocol
48020350|NCT00852397|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
48020351|NCT00852397|DRUG|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
48020352|NCT00852397|OTHER|Placebo|Placebo tablet for 24 weeks
48020353|NCT04632940|DRUG|Pamrevlumab|Pamrevlumab will be administered per dose and schedule specified in the arm description.
48378201|NCT01664260|DRUG|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
48378202|NCT01664260|DRUG|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
48378203|NCT03818334|DRUG|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
48378204|NCT03818334|DRUG|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
48378205|NCT03302221|DRUG|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
48177973|NCT06545578|OTHER|TENS|TENS Intelect Advanced device (Chattanooga, Mouguerre, France). The parameters for TENS stimulation included a frequency range of 60-80 Hz, a pulse width of 50-80 ms, and an intensity of 10-30 mA. Before commencing therapy, patients were provided information regarding the therapeutic approach and any potential adverse effects. During the procedure, two channels (four electrodes) were employed, with one set placed on the right and one on the left paraspinal muscles at the level of L2-L4. Active electrodes from the other channels were affixed 1.5 cm laterally to the spine, while passive electrodes were positioned 3 cm away. TENS therapy was utilized for 30 minutes in Group B, and the intensity of the pain and discomfort was adjusted to the patient's tolerance level.
48177974|NCT06545578|OTHER|motor control exercises|Training in coordinated trunk muscle action, including decreasing overactive superficial muscles and independent activation of deep muscles (such as transversus abdominis and multifidus). Exercises for the pelvic floor muscles, controlling respiration, and regulating the position and movement of the spine were added to these exercises.
48177975|NCT02411617|DEVICE|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
48177976|NCT06061380|OTHER|no intervation taken|
48177977|NCT00001359|DRUG|Penicillin or Placebo|
48177978|NCT00265720|OTHER|Control|Written materials only
48378206|NCT03302221|DRUG|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
48378207|NCT03302221|DRUG|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
48378208|NCT04629209|DRUG|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
48177979|NCT00265720|OTHER|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
48177980|NCT00265720|BEHAVIORAL|one on one education|one on one education with a health educator
48177981|NCT00265720|BEHAVIORAL|Group education|Education in a small group
48378209|NCT06519539|BEHAVIORAL|PORTIONS-4 behaviour change strategies|The intervention includes 4 components, including: a portion control tool set previously developed and tested in our laboratory; a supporting guide (physical book) with dietary, activity and behavioural recommendations; a mobile application aligned with the guide; and biweekly telephone calls from the psychologist and/or dietitian.
48378210|NCT00314275|DEVICE|Coronary Artery Stenting|Drug eluting stent
48177982|NCT06254755|DEVICE|mechanical thrombectomy|mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.
48177983|NCT01057251|DRUG|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
48378211|NCT00314275|DEVICE|Endeavor|Drug eluting stent
48378212|NCT06050382|OTHER|PROGRESSIVE RELAXATION TRAINING|"Both intervention groups were instructed and trained by a physiotherapist 2times a week for 30 minutes each over 6 weeks, The sessions were held in a well-lit, clean and comfortable room with a temperature of 22-24 degrees. Women were asked to stop eating and wear comfortable clothes at least two hours before the sessions. Before the training, relaxation exercises and breathing techniques explained to the women.~The women lied in the supine position firstly. Then the therapist instructed them to contract and release different muscle groups. They practiced tensing a muscle group until they felt the slight contraction and then released it, simultaneously relaxing other muscle groups. During the session, women were instructed to contract the muscles for 10-20 seconds during deep diaphragmatic breathing and to relax for 30-40 seconds while exhaling."
48177984|NCT01057251|DRUG|Placebo|5 mg or 20 mg once daily, oral administration
48177985|NCT04654962|PROCEDURE|Anesthetic nerve block|iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
48378213|NCT05570734|BEHAVIORAL|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
48378214|NCT05570734|BEHAVIORAL|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
48378215|NCT05570734|BEHAVIORAL|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
48378216|NCT05570734|BEHAVIORAL|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
48378217|NCT06126107|BEHAVIORAL|Brief Normative Feedback|Once a participant has completed the assessment of their drinking during the baseline battery, the participant will receive brief normative feedback about how their drinking compares to their peers.
48378218|NCT06126107|BEHAVIORAL|Loss-framed Text-messaging|Daily text-messages on the consequence of hazardous drinking.
48378219|NCT06126107|BEHAVIORAL|Gain-framed Text-messaging|Daily text messages on the benefits of reducing drinking to safe guidelines.
48378220|NCT00000518|PROCEDURE|electrophysiology|
48378221|NCT00000518|PROCEDURE|electrocardiography, ambulatory|
48378222|NCT00000518|DRUG|imipramine|
48378223|NCT00000518|DRUG|mexiletine|
48378224|NCT00000518|DRUG|procainamide|
48020354|NCT04632940|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
48020355|NCT04632940|DRUG|Corticosteroids|Systemic deflazacort or equivalent potency of corticosteroids administered orally
48020356|NCT01816620|DRUG|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
48378225|NCT00000518|DRUG|quinidine|
48378226|NCT00000518|DRUG|sotalol|
48378227|NCT06132711|OTHER|APRIL-BAFF-Bicephali CAR-T cells|Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.
48378228|NCT02046720|DRUG|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
48378229|NCT02451631|OTHER|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
48378230|NCT02451631|DEVICE|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
48020357|NCT06183229|DRUG|Cycloferon|Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
48388027|NCT01578018|OTHER|Measure DCAM levels in blood|Measure DCAM levels in blood
48388028|NCT01578018|OTHER|DCAM levels in blood|DCAM levels in blood
48020358|NCT06183229|DRUG|Placebo|Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
48020359|NCT01578551|DRUG|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
48020360|NCT01578551|DRUG|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
48020361|NCT01578551|DRUG|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
48020362|NCT01578551|DRUG|Metformin|1000 mg twice daily with food.
48378231|NCT02616107|OTHER|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~1. Becoming a Cancer Caregiver \[role, changes, challenges, adjusting, self-care\]~2. Basics of Cancer Caregiving \[physical, functional, emotional, social, \& spiritual support; treatment timeline worksheet\]~3. Caregiver's Role in Managing Patient Care \[who/what is involved; health care professionals worksheet\]~4. Managing Cancer Symptoms and Side Effects \[common symptoms/side effects; maintaining health; nutrition \& exercise; medication management worksheet\]~5. Care Options: \[information on curative, palliative and hospice care\]~6. Talking About Goals of Care \[information on goals of care conversations\]~7. Managing Transitions \[defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet\]"
48378232|NCT02616107|OTHER|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
48378233|NCT00302068|BEHAVIORAL|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
48020363|NCT02109055|OTHER|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
48020364|NCT02109055|OTHER|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
48020365|NCT04158401|DEVICE|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
48378234|NCT00302068|DRUG|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
48378235|NCT00302068|DRUG|Placebo Pill.|Placebo pill, daily, for 16 weeks.
48378236|NCT01725217|BIOLOGICAL|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
48177986|NCT02844530|DRUG|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
48378237|NCT06128109|DEVICE|Thioderm Strong|Test Device
48378238|NCT06128109|DEVICE|Juvéderm VOLUMA Lidocaine|Comparator Device
48020366|NCT00234884|BIOLOGICAL|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
48378239|NCT00182208|DEVICE|Veno-device (Venowave)|
48378240|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 Dose Level 1
48378241|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 Dose Level 2
48378242|NCT05629559|BIOLOGICAL|4D-310|Single IV administration of 4D-310 at the selected dose
48378243|NCT03480243|DRUG|Padsevonil (UCB0942)|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
48177987|NCT02844530|DRUG|chemotherapy/ immunotherapy|
48177988|NCT00156923|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
48020367|NCT02523833|DRUG|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
48020368|NCT04077008|PROCEDURE|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
48378244|NCT03480243|DRUG|Erythromycin|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
48177989|NCT00156923|DRUG|Medisorb naltrexone 190 mg|Administered via IM injection once every 4 weeks for up to 3.5 years.
48177990|NCT03062085|OTHER|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
48177991|NCT00778921|DRUG|Amlodipine 10 mg|Amlodipine 10 mg
48177992|NCT00778921|DRUG|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
48177993|NCT00778921|DRUG|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
48378245|NCT03358017|DRUG|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
48020369|NCT04077008|PROCEDURE|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
48020370|NCT06222996|BEHAVIORAL|vaccine hesitation training|Training will be given to primiparous expectant mothers on vaccine hesitation with the support of the web page created by the researcher
48177994|NCT03174782|DRUG|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
48378246|NCT03358017|DRUG|Atorvastatin 80mg|80mg /die os for 6 months
48378247|NCT03358017|DRUG|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
48378248|NCT00762073|DRUG|budesonide|oral suspension
48378249|NCT00762073|DRUG|placebo|oral suspension matching budesonide
48177995|NCT03174782|DRUG|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
48378250|NCT01997060|BEHAVIORAL|Intensive Lifestyle Intervention|
48378251|NCT03245359|DEVICE|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
48378252|NCT03245359|DEVICE|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
48378253|NCT03245359|DRUG|Short-term ON-Q|Bupivacaine 0.125%
48378254|NCT03245359|DEVICE|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
48020371|NCT05059392|BEHAVIORAL|Training for Awareness, Resilience and Action (TARA)|See arm description
48020372|NCT02507102|DEVICE|Voyager|Non-invasive RFE therapy
48020373|NCT05565612|DIETARY_SUPPLEMENT|Normodigest Classic|Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
48020374|NCT05565612|DIETARY_SUPPLEMENT|Placebo|Compound based on maltodextrin and other excipients
48177996|NCT00022607|BIOLOGICAL|bevacizumab|
48177997|NCT00022607|DRUG|thalidomide|
48177998|NCT03542162|BIOLOGICAL|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
48177999|NCT06545812|DRUG|Epidural steroid injection (ESI)|Minimally invasive methods such as epidural steroid injection (ESI) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution. They reduce inflammation by inhibiting pro-inflammatory mediators and causing a reversible local anesthetic effect.
48020375|NCT05194176|DEVICE|Virtual Reality|For all VR exercises a head mounted display (HMD), the PICO G2 4K (Barcelona, Spain) will be used. Together with SyncVRMedical (Utrecht, Netherlands) a VR dashboard has been created from which patients can chose the different exercises.
48178000|NCT06545812|DEVICE|Physical therapy for disc herniation|BTL Laser therapy, BTL ultrasound therapy and BTL Transcutaneous electrical nerve stimulation - TENS
48178001|NCT00103636|PROCEDURE|Extending peripheral intravenous (IV) cannula dwell times|
48178002|NCT04022577|BEHAVIORAL|Adherence Therapy|Motivational interviewing-based AT in this study was based on Chien et al., (2016) and Gray et al., (2010) eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
48020376|NCT01018849|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
48020377|NCT01018849|DIETARY_SUPPLEMENT|Placebo|placebo by mouth every 2 months for 1 year
48020378|NCT02447991|DRUG|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
48020379|NCT02447991|DRUG|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
48020380|NCT03888313|OTHER|Pretreatment group consultation|A consultation in group with several patients and one surgeon
48020381|NCT03120104|OTHER|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just one month before the stoma closure
48020382|NCT03120104|OTHER|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2\~3 times a week, for 4 weeks) just two weeks after the stoma closure
48178003|NCT04022577|BEHAVIORAL|control group|The control group received routine care
48178004|NCT05069298|DIETARY_SUPPLEMENT|Silibinin A|The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
48378255|NCT03245359|DEVICE|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
48378256|NCT03245359|DRUG|Long-term ON-Q|Bupivacaine 0.125%
48378257|NCT04734366|PROCEDURE|"Uterine closure with Baseball suture technique"|"A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision."
48378258|NCT04734366|PROCEDURE|Single Layer Continuous Locked|Suturing is continued by passing through the previous stitch.
48378259|NCT06182410|DRUG|Defibrotide|Given intravenously (IV)
48378260|NCT05277909|OTHER|The expert assessment of shoulder impairments and individualised treatment plan|The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.
48178005|NCT05603897|OTHER|Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)|Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.
48178006|NCT05603897|OTHER|Non-standardized clinical swallow evaluation|Participants will receive current standard of care for dysphagia screening and treatment.
48178007|NCT00134771|DRUG|Nutrient enriched infant formula|
48378261|NCT05277909|OTHER|A minimal physiotherapeutic rehabilitation program delivered in a pamphlet|This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.
48378262|NCT04711642|DRUG|The study will include three arms, one non interventional and 2 interventions. The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)|All groups will receive a topical steroid-antibiotic for 3 weeks. The study groups will be also prescribed eye drops containing sodium hyaluronate 0.1% from the postoperative day 7 for 4 weeks.
48378263|NCT05319509|DEVICE|gameChange|Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
48711617|NCT05257148|DRUG|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
48378264|NCT03476395|OTHER|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
48378265|NCT01429142|BEHAVIORAL|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
48378266|NCT01429142|BEHAVIORAL|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
48378267|NCT02070367|OTHER|Somatosensory rehabilitation|
48378268|NCT02070367|OTHER|Usual treatment: physiotherapy|
48378269|NCT00122954|DRUG|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
48711618|NCT01059253|OTHER|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
48711619|NCT00042068|DRUG|Meloxicam|
48711620|NCT04636177|BEHAVIORAL|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
48711621|NCT06185842|BEHAVIORAL|breathing exercise, walking exercise and vaccination counseling|"Participants will perform diaphragmatic breathing exercises and pursed lip breathing exercises two days a week for eight weeks.~Participants will be asked to walk for 20-30 minutes every day for eight weeks. Monitoring will be done weekly.~Participants will be counseled about infectious diseases, modes of transmission and the importance of vaccination, and will be advised to receive influenza and pneumococcal vaccines recommended for this age group.~The 5A model guide will be used regarding behavioral change towards physical activity and vaccination."
48178008|NCT00771095|BEHAVIORAL|podcasting|
48178009|NCT00499928|DRUG|SB-751689|
48178010|NCT06239259|OTHER|Questionare As described in Secondary Outcomes|All patients will recieve Questionare As described in Secondary Outcomes, and will be interviewd by a well-trained reaserch assistanced
48178011|NCT05394090|DIAGNOSTIC_TEST|saliva stimulation|In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
48178012|NCT00803777|DEVICE|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
48178013|NCT06486727|DEVICE|Redtouch|675-nm laser
48178014|NCT02759237|DEVICE|CoreValve System Family|"Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK \& EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System \& EnVeo R Loading System - Used to load the TAV onto the delivery system"
48178015|NCT03669198|DIAGNOSTIC_TEST|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
48178016|NCT03777852|DIAGNOSTIC_TEST|First Questionnaire application|Women with breast cancer will respond to the First Breast Q questionnaire before treatment with breast cancer reconstruction surgery.
48711622|NCT01766349|BEHAVIORAL|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
48711623|NCT05622266|PROCEDURE|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
48178017|NCT03777852|DIAGNOSTIC_TEST|Second Questionnaire application|Women with breast cancer will respond to the Second Breast Q questionnaire after treatment with breast cancer reconstruction surgery.
48178018|NCT01210378|DRUG|Nitroglycerin patch|Nitroglycerin patch
48178019|NCT01454388|OTHER|breakfast|
48178020|NCT03000348|DRUG|Cysteamine|Oral Cysteamine Capsule
48178021|NCT03000348|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
48178022|NCT01861977|BEHAVIORAL|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
48178023|NCT01861977|BEHAVIORAL|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
48178024|NCT03569605|BEHAVIORAL|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
48178025|NCT03569605|BEHAVIORAL|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
48178026|NCT01527162|DEVICE|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
48178027|NCT01527162|OTHER|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
48178028|NCT02682940|DEVICE|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
48378270|NCT00122954|DRUG|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
48378271|NCT02614352|DRUG|Atorvastatin + Candesartan|
48378272|NCT02614352|DRUG|AG1502|
48378273|NCT03699722|BEHAVIORAL|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
48711624|NCT05622266|PROCEDURE|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
48378274|NCT03699722|BEHAVIORAL|Information|Format: Information handouts
48378275|NCT01477775|DRUG|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
48378276|NCT01477775|DRUG|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
48378277|NCT04867980|DRUG|ACP-196|Participants will receive a single oral dose of 100 mg ACP-196 (1 x 100 mg capsule) on Day 1 (Treatment A) and 400 mg ACP-196 (4 x 100 mg capsules) on Day 1 (Treatment B) according to the randomization scheme.
48378278|NCT04867980|DRUG|Moxifloxacin 400 mg|Participants will receive a single oral dose of 400 mg moxifloxacin (1 x 400 mg tablet) on Day 1 (Treatment C) according to the randomization scheme.
48378279|NCT04867980|DRUG|Placebo|Participants will receive a single oral dose of ACP-196 matching placebo (4 x 100 mg matching placebo capsules) and moxifloxacin matching placebo (1 x 400 mg matching placebo tablet) on Day 1 (Treatment D) according to the randomization scheme.
48711625|NCT04401956|OTHER|bread|Different types of bread
48020383|NCT05696197|BEHAVIORAL|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
48020384|NCT02442700|DRUG|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
48020385|NCT02442700|DRUG|placebo|Treatment B = administration placebo for 12 weeks
48020386|NCT05303805|DRUG|Sevoflurane|Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.
48020387|NCT05303805|COMBINATION_PRODUCT|Cyteal|Rinsing and cleaning of ulcer.
48020388|NCT05268796|BEHAVIORAL|Behavior therapy|Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.
48020389|NCT05268796|OTHER|Psychoeducation|Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
48020390|NCT05981651|OTHER|non-intervention|non-intervention
48020391|NCT05060224|DEVICE|EasyLaser: Low Level Laser therapy|
48020392|NCT00028834|DRUG|gemcitabine hydrochloride|Given IV
48020393|NCT00028834|BIOLOGICAL|bevacizumab|Given IV
48378280|NCT04122339|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
48020394|NCT00028834|OTHER|laboratory biomarker analysis|Correlative studies
48020395|NCT02537080|DRUG|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
48020396|NCT02537080|DRUG|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
48020397|NCT04898010|DEVICE|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
48020398|NCT00530023|DEVICE|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
48020399|NCT02710630|DRUG|Dabigatran etexilate tablet E1|
48020400|NCT02710630|DRUG|Dabigatran etexilate tablet D1|
48020401|NCT02710630|DRUG|Dabigatran etexilate tablet C1|
48020402|NCT02710630|DRUG|Dabigatran etexilate tablet B1|
48020403|NCT02710630|DRUG|Dabigatran etexilate tablet A1|
48020404|NCT02710630|DRUG|Dabigatran etexilate capsule|
48020405|NCT02602288|BEHAVIORAL|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
48020406|NCT02602288|BEHAVIORAL|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
48020407|NCT02602288|BEHAVIORAL|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
48178029|NCT05476510|DRUG|Postoperative management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
48378281|NCT04447963|DEVICE|Non-invasive treatment of facial wrinkles|Application of radiofrequency field which provides controlled heating to the skin.Therapeutic effect is observed when the tissue temperature reaches 40-45 degrees Celsius.
48378282|NCT03891602|BEHAVIORAL|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
48711626|NCT06136286|DEVICE|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
48711627|NCT00035360|DRUG|PEG-Intron|
48711628|NCT05747482|OTHER|Surgery procedure|Omentectomy vs omental preservations during gastric surgery
48020408|NCT02602288|DEVICE|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
48020409|NCT02602288|DEVICE|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
48020410|NCT02602288|DRUG|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
48020411|NCT03383588|DRUG|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
48020412|NCT03383588|DRUG|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
48020413|NCT03383588|DRUG|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
48020414|NCT03383588|DRUG|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
48711629|NCT01371240|DRUG|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
48711630|NCT04699292|PROCEDURE|Surgery|Surgery
48020415|NCT03383588|OTHER|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
48020416|NCT01798446|DRUG|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
48020417|NCT04590547|DRUG|GLS-1027|GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.
48020418|NCT04590547|DRUG|Placebo|Placebo looks like GLS-1027
48020419|NCT00244244|DRUG|arimoclomol|
48020420|NCT03264157|DRUG|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
48711631|NCT04699292|RADIATION|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
48711632|NCT04699292|RADIATION|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
48020421|NCT03264157|DRUG|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
48020422|NCT03264157|BIOLOGICAL|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
48020423|NCT04006158|DEVICE|LED bed|Low risk FDA cleared full body LED bed
48020424|NCT01464918|DEVICE|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
48020425|NCT01259986|PROCEDURE|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm\^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
48178030|NCT00016445|DRUG|growth hormone|
48178031|NCT04470869|OTHER|Phone call|The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
48378283|NCT03891602|BEHAVIORAL|Patient Trust in the Medical|"Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbachs alpha of 0.84."
48378284|NCT03891602|BEHAVIORAL|Decision Conflict Scale (DCS) - Lung Cancer Screening|"The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by OConnor,74-75 and validated in many health decisions including breast cancer screening with Cronbachs alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict."
48378285|NCT03891602|BEHAVIORAL|Shared Decision Making Questionnaire (SDM-Q)- Patient|"Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbachs alpha of 0.94."
48711633|NCT04699292|RADIATION|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
48711634|NCT04699292|RADIATION|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
48711635|NCT02823132|BIOLOGICAL|blood sample|
48711636|NCT03453255|DRUG|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
48711637|NCT03263468|PROCEDURE|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
48711638|NCT03263468|PROCEDURE|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI
48711639|NCT02516293|BEHAVIORAL|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
48711640|NCT03816280|PROCEDURE|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
48378286|NCT03891602|BEHAVIORAL|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
48378287|NCT03891602|BEHAVIORAL|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
48378288|NCT03496597|PROCEDURE|Retinal imaging assessment|"* OCT-angiography~* Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~* Eye fundus photography: macular image~* Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
48711641|NCT03816280|PROCEDURE|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
48711642|NCT03816280|PROCEDURE|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
48711643|NCT00159575|DRUG|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
48020426|NCT06573528|DRUG|CS060380|Tablets administered orally
48020427|NCT01775137|DRUG|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
48378289|NCT03496597|PROCEDURE|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
48378290|NCT03321773|DRUG|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
48378291|NCT03321773|DRUG|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
48378292|NCT02524262|DIETARY_SUPPLEMENT|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
48378293|NCT01285180|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
48378294|NCT05079984|BEHAVIORAL|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
48378295|NCT03730623|BEHAVIORAL|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
48711644|NCT00531297|PROCEDURE|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
48711645|NCT03720665|COMBINATION_PRODUCT|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
48378296|NCT04619758|OTHER|Emollient (sunflower oil)|In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
48378297|NCT01987570|DRUG|Allopurinol|
48378298|NCT01987570|DRUG|Placebo|
48378299|NCT01998165|DRUG|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
48020428|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on Planned Behavior Theory|On the basis of Planned Behavior Theory, an training intervention is planned in three stages for medical nutrition, physical activity and gestational diabetes follow-up.
48517752|NCT03723356|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging (DSI)|DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
48020429|NCT04874922|BEHAVIORAL|Gestational Diabetes Training Intervention based on standart|Standard training for gestational diabetes will be given once at 28 weeks of gestation.
48020430|NCT03223558|BEHAVIORAL|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
48020431|NCT06025721|BEHAVIORAL|Cardiovascular Risk Homeless Support|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking\>medication\>sleep\>physical activity\>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
48020432|NCT03028376|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
48517753|NCT00469664|DRUG|Guanfacine/Tenex|
48020433|NCT01170897|DRUG|PEGPH20|PEGylated Recombinant Human Hyaluronidase
48020434|NCT00226434|PROCEDURE|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
48020435|NCT00226434|PROCEDURE|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
48020436|NCT00161928|BIOLOGICAL|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
48020437|NCT06131918|DRUG|Resveratrol, Alpha lipoic acid, Super oxide dismutase|Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
48020438|NCT06131918|DRUG|Resveratrol|Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
48517754|NCT03153033|BEHAVIORAL|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
48020439|NCT06131918|DRUG|Alpha lipoic acid|Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
48020440|NCT06131918|DRUG|Super Oxide Dismutase|Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
48020441|NCT01736852|DEVICE|CRB|Labor induction using the CRB
48517755|NCT00595309|BIOLOGICAL|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
48517756|NCT03632915|DRUG|Levetiracetam|Standard of care
48517757|NCT03632915|DRUG|Lacosamide|Standard of care
48517758|NCT03632915|DRUG|Phenytoin|Standard of care
48517759|NCT03632915|DRUG|Phenobarbital|Standard of care
48517760|NCT03632915|DRUG|Ketamine|Standard of care
48020442|NCT01736852|DRUG|Pitocin|Labor induction using Pitocin
48020443|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
48020444|NCT00887341|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
48020445|NCT04249843|DRUG|BGB-3245|administered orally (PO)
48178032|NCT03787420|OTHER|communication system|"We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale."
48178033|NCT05436210|OTHER|foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test|Patients will be evaluated only observationally without intervention by foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test
48378300|NCT04420559|OTHER|Intramuscular Injection|Intramuscular Benzathine Penicillin Injection Procedure
48378301|NCT02189538|DIETARY_SUPPLEMENT|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
48517761|NCT03632915|DRUG|Valproic Acid|Standard of care
48517762|NCT05915260|DIAGNOSTIC_TEST|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
48178034|NCT00320398|DRUG|Fondaparinux|
48517763|NCT03794050|OTHER|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
48378302|NCT02189538|DIETARY_SUPPLEMENT|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
48378303|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 10µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen
48378304|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 40µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen
48378305|NCT05208710|BIOLOGICAL|Vaccination with PANHPVAX 100µg|Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
48378306|NCT05100706|DRUG|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
48378307|NCT05100706|DRUG|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
48378308|NCT04536480|BEHAVIORAL|Time Limited Eating|The TLE intervention arm will involve instructing participants to consume their usual kind and amount of food and beverages (all calories) within a pre-specified 8-hour period, fasting for the remaining 16-hours. They will be free to divide their food and beverage intake into as many meals or snacks as desired during the 8-hour period. Participants will be allowed to consume non-caloric beverages (water, tea, coffee) during the fasting period. No energy restriction will be required.
48378309|NCT04536480|BEHAVIORAL|Components Common to All Study Arms.|All participants will receive two hours of standard nutrition counseling recommended for adolescents living with T2D. No specific caloric restriction will be recommended. All participants will maintain their usual lifestyle, including physical activity and sleep patterns. Physical activity and sleep recommendations consistent with the American Academy of Pediatrics guidelines for adolescents will be encouraged but not formally prescribed.
48378310|NCT04536480|BEHAVIORAL|Control|Participants assigned to the control arm will be instructed to consume food over a 12-h or more eating window. No energy restriction will be required.
48378311|NCT04536480|DEVICE|Continuous Glucose Monitor|All participants will be trained to wear a blinded continuous glucose monitor sensor using manufacturer educational materials under the supervision of research staff. Participants will be asked to wear the CGM for the duration of the study. During each study visit, the CGM reader will be connected to the site database to create an individual participant report. Participants will be provided enough sensors to replace the sensor every 14 days. The participants and guardians will be educated on how to use the CGM and receive 1:1 coaching on how to change the sensor, which will be completed either independently or under study team guidance. At each weekly phone meeting, study staff will monitor any challenges related to CGM wear, including participant discomfort, skin adherence, and other issues.
48378312|NCT05557409|DRUG|AXS-05|AXS-05 tablets, taken twice daily
48378313|NCT05557409|DRUG|Placebo|Placebo tablets, taken twice daily
48378314|NCT00621309|DRUG|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
48378315|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (\~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
48378316|NCT00621309|DIETARY_SUPPLEMENT|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
48378317|NCT03503565|PROCEDURE|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
48517764|NCT03794050|OTHER|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
48517765|NCT04778475|OTHER|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
48020446|NCT04472351|BEHAVIORAL|ASCEND-I|"The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties."
48517766|NCT04778475|OTHER|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
48517767|NCT01225250|DEVICE|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
48020447|NCT01732835|DEVICE|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
48178035|NCT05480462|BIOLOGICAL|Clodivac|A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.
48378318|NCT02596009|DEVICE|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
48178036|NCT05480462|BIOLOGICAL|Td-Impfstoff Merieux|One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
48178037|NCT01827098|PROCEDURE|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
48378319|NCT02596009|DEVICE|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
48020448|NCT06317805|DRUG|Generic treprostinil sodium + Standard of Care (Double Oral)|Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
48178038|NCT04574232|DRUG|knee intra-articular infiltration with Triamcinolone acetonide|knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
48178039|NCT04544865|DEVICE|Staple Line Reinforcement|ENDOPATH ECHELON Staple Line Reinforcement is used for reinforcement of staple lines during lung resection and bariatric surgical procedures, according to instructions for use.
48178040|NCT02077205|BEHAVIORAL|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
48378320|NCT02596009|DEVICE|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
48378321|NCT01473537|DRUG|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
48378322|NCT00131937|DRUG|sorafenib tosylate|Given orally
48378323|NCT04354740|PROCEDURE|with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)|"II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:"
48378324|NCT00071006|DRUG|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
48378325|NCT04493255|DRUG|[14C]E7090|\[14C\]E7090, oral capsule.
48378326|NCT05828030|PROCEDURE|high flow nasal cannula|the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
48378327|NCT05828030|PROCEDURE|Oxygen mask|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
48378328|NCT04113746|BEHAVIORAL|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
48378329|NCT04113746|BEHAVIORAL|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
48378330|NCT00006049|DRUG|carboplatin|
48378331|NCT00006049|DRUG|gefitinib|
48378332|NCT00006049|DRUG|paclitaxel|
48378333|NCT04335760|COMBINATION_PRODUCT|Modified Bruce protocol on treadmill|"Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available."
48020449|NCT06317805|DRUG|Standard of Care - Double Oral|All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
48178041|NCT03666195|COMBINATION_PRODUCT|Titanium Dioxide Nanoparticles|incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
48178042|NCT00461643|DRUG|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
48178043|NCT01304628|DRUG|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
48378334|NCT05137431|OTHER|HFNO and NIV|"Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV.~Parameters to record~* Respiratory parameters (respiratory rate)~* SpO2~* Ventilator settings~* Patient's tolerance (VAS; between 0-100)~* Arterial blood gas (HFNO and NIV at 1 hour)~* Clinical parameters (D dimer, CRP, ROX index)~Intubation criteria~* Loss of consciousness~* Agitation~* Persistent hypotension~* Need for fluid resuscitation~* Need for vasopressor~* Respiration rate ≥40/min~* SpO2 \<92~* pH\<7.30"
48378335|NCT02714413|DIETARY_SUPPLEMENT|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
48378336|NCT02714413|DIETARY_SUPPLEMENT|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
48711646|NCT04306289|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
48711647|NCT03649373|PROCEDURE|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
48711648|NCT04299919|PROCEDURE|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
48711649|NCT04299919|PROCEDURE|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
48378337|NCT02714413|OTHER|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
48711650|NCT02156817|OTHER|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
48711651|NCT04197063|BEHAVIORAL|Sweetened beverage portion size limit|
48378338|NCT00498004|DRUG|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
48378339|NCT01863394|OTHER|Screening by mothers|
48711652|NCT02904122|OTHER|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
48711653|NCT02024022|DRUG|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
48378340|NCT01863394|OTHER|Active comparator: Screening by community health workers|
48517768|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
48711654|NCT02024022|DRUG|Individualized approach|
48711655|NCT01390779|DEVICE|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
48711656|NCT04931290|PROCEDURE|Supracapsular Ahmed Glaucoma Valve plate delivery technique|incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
48178044|NCT00723385|DIETARY_SUPPLEMENT|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
48178045|NCT00723385|OTHER|Placebo|Administration of placebo for 12 weeks with repeated D measurements
48178046|NCT01211444|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
48178047|NCT01440413|BIOLOGICAL|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.~Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
48178048|NCT02991586|BEHAVIORAL|Dialectical Behaviour Therapy|Group of families
48178049|NCT05333822|DIETARY_SUPPLEMENT|Bashan|a vegetable plant based compound drink add after three meals for 14 days
48378341|NCT01363531|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
48378342|NCT02783976|DRUG|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
48378343|NCT02168569|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
48378344|NCT02168569|DRUG|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
48378345|NCT02986048|OTHER|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
48378346|NCT04283513|DRUG|Virazole|Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
48378347|NCT03497000|PROCEDURE|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
48517769|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
48517770|NCT03123068|DRUG|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
48711657|NCT02445937|BEHAVIORAL|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
48178050|NCT05333822|OTHER|water|water as placebo
48711658|NCT02880514|DEVICE|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
48178051|NCT05125081|DRUG|Liuwei Dihuang Pill (marketed product in China)|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
48178052|NCT05125081|DRUG|Liuwei Dihuang Pill（placebo ）|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
48178053|NCT04486976|DEVICE|Cornea/Anterior Segment OCT CASIA2|Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.
48178054|NCT04486976|DEVICE|Optovue RTVue XR Avanti|Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
48178055|NCT02686099|DEVICE|SternaLock 360|Sternal closure with SternaLock 360
48378348|NCT03497000|PROCEDURE|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
48378349|NCT04166188|PROCEDURE|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
48378350|NCT01016366|DRUG|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
48378351|NCT01016366|DRUG|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
48517771|NCT03123068|OTHER|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
48517772|NCT04663971|PROCEDURE|Any surgery|Any surgical procedures performed for inflammatory bowel diseases
48711659|NCT02880514|PROCEDURE|Balloon Sinus Dilation Alone|
48711660|NCT00200538|DRUG|memantine|
48711661|NCT03671408|OTHER|clinical measurements|only clinical parameters were recorded
48711662|NCT06099470|OTHER|Real-time synchronized telerehabilitation program (STP).|patient education, core stabilization exercises, strengthening exercises, stretching exercises
48378352|NCT03730025|OTHER|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
48378353|NCT03730025|OTHER|Auscultation without NeoTapAS|Auscultation without NeoTapAS
48378354|NCT03964142|OTHER|Cardiac rehabilitation|"Integrated cardiac rehabilitation program that includes supervised exercise training\*.~\* Due to the COVID-19 pandemic, supervised physical exercise training had to be conducted telematically (through live guided training sessions conducted online, with the same design, frequency, and dosage of exercise)."
48711663|NCT06099470|OTHER|Pre-recording non-synchronized telerehabilitation program (NSTP)|Pre-recording non-synchronized telerehabilitation program (NSTP)
48378355|NCT03611452|PROCEDURE|Episiotomy|repair of perineal muscles and skin
48378356|NCT04158466|DEVICE|Kalifilcon A Daily Disposable Contact Lenses|Contact lens
48378357|NCT04158466|DEVICE|Biotrue ONEday Daily Disposable Contact Lenses|Contact lens
48378358|NCT03417245|DRUG|fitusiran|by SC injection
48378359|NCT03417245|DRUG|factor concentrates|by intravenous (IV) injection
48711664|NCT06099470|OTHER|Home non-supervised control group (HCG)|Home non-supervised control group (HCG)
48711665|NCT02605811|DRUG|temozolomide|
48711666|NCT02605811|RADIATION|prophylaxis cranial radiotherapy|2
48020450|NCT05372198|DRUG|Chohort 1: Surufatinib|Surufatinib 300mg, qd, every 3 weeks as a cycle
48178056|NCT02686099|DEVICE|Wire Cerclage|Sternal closure with standard wire cerclage
48378360|NCT02513095|DRUG|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
48378361|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP)|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
48517773|NCT04663971|PROCEDURE|Any medical treatment|Any treatment (including non-surgical) performed for inflammatory bowel diseases
48517774|NCT05708430|DRUG|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
48020451|NCT05372198|DRUG|Chohort 2: Immunotherapy|Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
48178057|NCT00264563|BEHAVIORAL|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
48178058|NCT00264563|BEHAVIORAL|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
48178059|NCT00784745|DRUG|Dexamethasone|2mg morning and night for 5 days.
48178060|NCT05749861|DRUG|CKD-348(5)|QD, PO
48178061|NCT05749861|DRUG|CKD-828, D097, D337|QD, PO
48378362|NCT02396849|DEVICE|Continuous Positive Airway Pressure (CPAP) Sham|Subjects assigned to this group will be asked to use the CPAP Sham machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
48378363|NCT01715675|DIETARY_SUPPLEMENT|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
48378364|NCT01715675|DIETARY_SUPPLEMENT|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
48378365|NCT02279472|PROCEDURE|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
48378366|NCT06455930|DEVICE|Stand-on ride-on power mobility device|Children will receive the adapted toy car (individually-adapted stand-on PMD) to take home and use for three months. PMD will be used at their house and familiar environments to the family (e.g., neighborhood, parks, schools).
48378367|NCT03058159|OTHER|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
48378368|NCT05891795|DRUG|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
48378369|NCT05891795|DRUG|Vehicle|Apply a thin layer to the affected area twice daily.
48517775|NCT00420732|BIOLOGICAL|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
48711667|NCT00495521|DRUG|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
48711668|NCT03425721|OTHER|No Intervention|No Intervention is administered in this study.
48711669|NCT05058105|DRUG|FL058 500mg and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48711670|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48711671|NCT05058105|DRUG|FL058 1000mg（ IV 120min）|D1 qd;
48711672|NCT05058105|DRUG|FL058 Placebo （ IV 120min）|D1 qd;
48711673|NCT05058105|DRUG|Meropenem 1000 mg （ IV 120min）|D4 qd;
48711674|NCT05058105|DRUG|Meropenem Placebo （ IV 120min）|D4 qd;
48711675|NCT05058105|DRUG|FL058 1000mg and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
48711676|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
48711677|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48711678|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48711679|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48378370|NCT05897931|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by starting from the lumbosacral region, continuing from the lower thoracic region, and finishing by applying it to the scapular region, interscapular region, and cervico-occipital region.
48378371|NCT05897931|OTHER|Kinesio Tape Application|"Taping will be applied to the levator scapula and upper trapezius muscles in a Y shape, with 25% tension and while the participants were in an upright position. Again in the same position, this time the C shaped taping technique will be adhered with 50% tension from the middle fibers of the trapezium to the last rib."
48378372|NCT02259426|DRUG|Dihydroartemisinin-piperaquine combination (Artekin)|
48378373|NCT02259426|DRUG|Primaquine|Single-dose 0.25mg/kg
48522747|NCT04768192|PROCEDURE|Physical Rehabilitation without lokomat|"Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~1. strengthening exercises had to involve all the lower limb joints (no segmental intervention)~2. during each session, at least 4 out of the 7 categories above had to be delivered~3. the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings."
48711680|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48711681|NCT05058105|DRUG|FL058 2000mg and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48711682|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
48711683|NCT02612701|OTHER|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
48711684|NCT02612701|OTHER|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
48711685|NCT02612701|OTHER|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
48711686|NCT02612701|OTHER|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
48378374|NCT05181501|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|"CT103A is a customized, BCMA-targeted genetically modified autologous T cell immunotherapy, which can identify and eliminate malignant and normal cells expressing BCMA. CAR specifically recognizes BCMA with single chain fragment variable (ScFv), and promotes the activation, proliferation, cytokine secretion and target cell killing of CAR-T through the CD3ζ domain. And 4-1BB enhances the expansion and persistence of CT103A.~CT103A will be infused at 1.0×10\^6 /kg via intravenous drip within 24h to 72h after chemotherapy conditioning regimen at the recommended infusion rate of 3-5 mL/min."
48711687|NCT05211921|DEVICE|Multi-Gyn ActiGel Plus|vaginal gel
48378375|NCT04780360|PROCEDURE|Cayanoacrylate tissue adhesives|Cyanoacrylates are a family of strong fast-acting adhesives with industrial, medical, and household uses. They are various esters of cyanoacrylic acid. The acryl groups in the resin rapidly polymerize in the presence of water to form long, strong chains
48378376|NCT04780360|PROCEDURE|Silk suture|Non Absorbalble suture materiel used to fixed the edges of the incision in place until healing
48020452|NCT05372198|DRUG|Chohort 2: Surufatinib|Surufatinib 250mg, qd, every 3 weeks as a cycle
48711688|NCT02750384|DRUG|DSM265 50% SDD granules|Single oral dose 400 mg
48711689|NCT02750384|DRUG|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
48711690|NCT00387738|BIOLOGICAL|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
48711691|NCT00387738|BIOLOGICAL|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
48020453|NCT05852444|DEVICE|Passive Ultrasonic Activation|Agitation of root canal irrigation solution with an ultrasonic activation device (Ultra X).
48020454|NCT05852444|DEVICE|Manual Dynamic Agitation|Agitation of root canal irrigation solution with master gutta percha cone
48020455|NCT04645212|BIOLOGICAL|ADVM-022|Long term follow-up of subjects that received ADVM-022
48020456|NCT01060384|DRUG|Lenalidomide|"Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I"
48020457|NCT01060384|DRUG|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
48020458|NCT03899116|OTHER|deflation of pneumatic tourniquet|gradual deflation with variable degrees
48020459|NCT01170780|DRUG|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
48020460|NCT01170780|DRUG|Saline|2 ml IV
48378377|NCT00344968|DRUG|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
48378378|NCT00344968|DRUG|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
48378379|NCT00344968|PROCEDURE|Standard of care laser photocoagulation|Laser photocoagulation
48711692|NCT04535713|DRUG|Gemcitabine|600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
48711693|NCT04535713|DRUG|Doxorubicin|18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
48020461|NCT02270060|OTHER|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
48020462|NCT02270060|OTHER|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
48711694|NCT04535713|DRUG|Docetaxel|25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
48711695|NCT04535713|DRUG|Nivolumab|240 mg i.v. on Day 1 beginnning Cycle 2+
48711696|NCT00554398|DRUG|MK-0518 400mg twice a day|Raltegravir, MK-0518
48711697|NCT03234556|PROCEDURE|Biopsy of Prostate|Undergo SR-Bx
48711698|NCT03234556|OTHER|Laboratory Biomarker Analysis|Correlative studies
48711699|NCT03234556|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Undergo MRI
48711700|NCT03234556|DIAGNOSTIC_TEST|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
48711701|NCT00580125|DRUG|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
48711702|NCT00580125|OTHER|Placebo|Placebo, oral capsule, once daily for 21 days
48378380|NCT02938819|OTHER|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
48378381|NCT02938819|OTHER|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
48378382|NCT01977131|OTHER|Cells|
48517776|NCT03708302|PROCEDURE|Unilateral serratus plane block|Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
48711703|NCT00580125|DRUG|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
48711704|NCT00580125|DRUG|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
48711705|NCT00580125|DRUG|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
48711706|NCT00376805|DRUG|Fludarabine|administered intravenously 25 mg/m\^2 times 5 doses
48711707|NCT00376805|DRUG|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
48711708|NCT00376805|RADIATION|Total body irradiation|200 cGy (gray) on day -1
48711709|NCT00376805|OTHER|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
48711710|NCT00376805|BIOLOGICAL|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
48711711|NCT03515551|DRUG|IMCnyeso|Weekly IV infusions of IMCnyeso
48020463|NCT03704545|OTHER|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
48178062|NCT01772823|BEHAVIORAL|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
48378383|NCT00240331|DRUG|10mg Rosuvastatin|
48378384|NCT00240331|DRUG|Placebo|
48711712|NCT01480609|DRUG|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
48711713|NCT03538444|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
48711714|NCT03538444|DEVICE|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
48378385|NCT06567444|OTHER|Working memory intervention|During the intervention, the participants in the ADHD group received five computerized working memory training sessions per week over five weeks, and each session lasted 20 minutes. This training paradigm is based on previous studies which show improvements in working memory capacities after a 5-week training period.
48378386|NCT01135147|BEHAVIORAL|Diet|Dietary therapy and physical education
48378387|NCT01135147|PROCEDURE|Surgery|Adenotonsillectomy along with diet and physical therapy
48378388|NCT04888780|OTHER|The web-based Watson's Human Care Theory oriented training|Video calls were held every 15 days via the skype program with complete adherence to the schedule. In these interviews, the clinical picture of diabetes and the psychosocial status of adolescents were discussed. A total of 14 interviews with 15-day intervals were made with each adolescent. All video interviews were carried out by the first researcher and they were all recorded.
48711715|NCT04900337|DRUG|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
48711716|NCT04900337|DRUG|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
48711717|NCT02078102|DRUG|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
48711718|NCT02078102|DRUG|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
48711719|NCT00168103|BIOLOGICAL|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
48020464|NCT03704545|OTHER|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
48378389|NCT05598762|GENETIC|Tape strips|Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.
48378390|NCT00859352|DRUG|AZD1981|oral tablets during 14 consecutive days.
48711720|NCT00168103|BIOLOGICAL|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
48020465|NCT03704545|OTHER|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
48378391|NCT00859352|DRUG|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
48378392|NCT03962751|BEHAVIORAL|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
48378393|NCT03962751|BEHAVIORAL|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
48378394|NCT03962751|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
48378395|NCT05079204|OTHER|Intra oral scan|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions Intervention consists in an 3D intra oral representation of the oral cavity.
48378396|NCT05079204|OTHER|No intervention|No intervention
48378397|NCT03754595|PROCEDURE|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
48378398|NCT03754595|PROCEDURE|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
48378399|NCT04681859|DEVICE|High Flow Nasal Oxygen (HFNO) treatment|Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
48378400|NCT04681859|DEVICE|Continuous Positive Airway Pressure (CPAP) therapy using OxyJet|Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.
48020466|NCT04578314|BEHAVIORAL|Relating Therapy|Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.
48711721|NCT00344734|DRUG|Ng-monomethyl-L-arginine (drug)|
48711722|NCT05154617|DIAGNOSTIC_TEST|Standard surgical monitoring, along with the Flo Trac® system monitoring.|Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
48020467|NCT04578314|OTHER|Treatment as usual|TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
48378401|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
48020468|NCT00765245|DRUG|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
48020469|NCT00765245|DRUG|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
48378402|NCT01800500|BEHAVIORAL|smoking cessation intervention|Purchase ST products using escalating product prices
48378403|NCT01800500|OTHER|questionnaire administration|Ancillary studies
48378404|NCT01800500|OTHER|quality-of-life assessment|Ancillary studies
48378405|NCT01800500|OTHER|laboratory biomarker analysis|Correlative studies
48378406|NCT01800500|OTHER|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
48378407|NCT01800500|OTHER|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
48378408|NCT00919932|BEHAVIORAL|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
48378409|NCT00919932|DEVICE|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
48378410|NCT05289921|BIOLOGICAL|HU-014 Inj|HU-014 Inj was given an injection to 5 Upper limb muscle
48378411|NCT03022526|PROCEDURE|CSE|
48378412|NCT03022526|PROCEDURE|Epidural|
48378413|NCT03022526|DRUG|Bupivacaine / fentaNYL|
48378414|NCT02973282|OTHER|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
48388029|NCT02866409|PROCEDURE|scalp block|"In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves"
48711723|NCT01247532|BEHAVIORAL|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
48711724|NCT01143051|DRUG|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
48711725|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
48711726|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
48711727|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
48020470|NCT00765245|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
48020471|NCT00260052|DRUG|Erythropoietin administration|
48020472|NCT04596163|PROCEDURE|Transversus thoracis muscle plane block|After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
48020473|NCT01163682|DEVICE|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
48020474|NCT01163682|DEVICE|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The electro-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
48711728|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
48020475|NCT05691075|PROCEDURE|Arthrodesis of the metatarsophalangeal joint|Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
48020476|NCT03639155|DRUG|vadadustat reference tablets|oral tablet
48020477|NCT03639155|DRUG|vadadustat test tablets|oral tablet
48020478|NCT00710502|PROCEDURE|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
48020479|NCT00710502|PROCEDURE|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
48178063|NCT01772823|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
48178064|NCT01772823|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
48378415|NCT01148875|BEHAVIORAL|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
48711729|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
48711730|NCT04102553|DRUG|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
48711731|NCT04102553|DRUG|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
48711732|NCT02529748|OTHER|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
48711733|NCT02529748|OTHER|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
48178065|NCT05000632|BEHAVIORAL|Smoke Free SafeCare|SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.
48178066|NCT05000632|BEHAVIORAL|Standard SafeCare|SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
48178067|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
48178068|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
48178069|NCT01320878|DRUG|distilled water|distilled water 2 ml per session
48178070|NCT04351945|PROCEDURE|Blood test|Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
48178071|NCT04066517|PROCEDURE|SBRT|Multimodal-imaging guided SBRT for VT ablation.
48178072|NCT04460729|DRUG|Capmatinib|400 mg administered orally twice daily
48178073|NCT06172114|PROCEDURE|Alveolar ridge preservation using sticky bone|In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
48178074|NCT00105105|DRUG|Mifepristone|
48178075|NCT04865055|OTHER|cyclic merocyanine|long-UVA absorber
48178076|NCT04865055|OTHER|placebo|placebo
48517777|NCT03708302|PROCEDURE|Unilateral parasternal infrapectoral block|"Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration.~Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration."
48178077|NCT01686490|BEHAVIORAL|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
48178078|NCT01686490|BEHAVIORAL|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
48711734|NCT02529748|OTHER|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
48178079|NCT02294097|PROCEDURE|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
48178080|NCT02394522|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
48178081|NCT02394522|DEVICE|Active Ingredient|Transfluthrin (Active ingredient)
48178082|NCT02394522|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
48378416|NCT02743182|DRUG|Pegylated interferon alfa-2a|
48378417|NCT03801863|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
48378418|NCT03801863|DRUG|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
48378419|NCT00005658|DRUG|Glycine|
48378420|NCT05429749|DRUG|Ferinject|Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
48378421|NCT05429749|DRUG|Normal saline|Normal saline 250ml is administered between the admission day and the surgery day.
48020480|NCT03261557|BEHAVIORAL|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
48711735|NCT02071420|BEHAVIORAL|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
48178083|NCT01169636|DRUG|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
48178084|NCT01169636|DRUG|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
48178085|NCT01169636|DRUG|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
48178086|NCT01169636|DRUG|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
48178087|NCT01169636|DRUG|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
48178088|NCT01169636|DRUG|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
48178089|NCT04553445|BEHAVIORAL|Chronotype|Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.
48178090|NCT04553445|BEHAVIORAL|Green exercise|Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
48178091|NCT04850235|DRUG|Nab paclitaxel|Nab paclitaxel plus cisplatin and capecitabine as neoadjuvant chemotherapy
48178092|NCT05336617|PROCEDURE|colonoscopy|A colonoscopy is an exam used to examine the colon and rectum. During a colonoscopy, a long, flexible tube is inserted into the rectum. A tiny video camera at the tip of the tube allows the doctor to view the inside of the entire colon.
48178093|NCT02838784|OTHER|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
48178094|NCT02838784|PROCEDURE|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
48178095|NCT03097406|PROCEDURE|Global Unite hemiarthroplasty|A hemiarthroplasty used for complex fractures of the proximal humerus.
48178096|NCT03097406|PROCEDURE|Global Advantage|A total shoulder prosthesis used for osteoarthritis
48178097|NCT03097406|PROCEDURE|Global FX|A hemiarthroplasty used for complex fractures of the proximal humerus.
48178098|NCT03097406|PROCEDURE|Global Unite total shoulder arthroplasty|A total shoulder prosthesis used for osteoarthritis
48178099|NCT04328103|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Following established procedures at the DES at NYSPI, 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
48178100|NCT04328103|BEHAVIORAL|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
48178101|NCT02424019|DRUG|ILUVIEN 0.19 MG|
48178102|NCT05938101|BEHAVIORAL|Behavioral therapy|Behavioral therapy and psychotherapy
48178103|NCT02457442|DRUG|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
48178104|NCT02457442|DRUG|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
48178105|NCT02457442|DRUG|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
48178106|NCT02457442|DRUG|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
48388030|NCT02866409|PROCEDURE|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
48388031|NCT02866409|DRUG|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
48388032|NCT02866409|DRUG|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
48020481|NCT03261557|BEHAVIORAL|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
48178107|NCT02457442|DRUG|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision."
48178108|NCT02457442|DRUG|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision."
48178109|NCT03984175|PROCEDURE|Implementation of Processes|Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
48178110|NCT02619526|DRUG|Nebivolol|Nebivolol 10mg, once a day
48178111|NCT02619526|DRUG|Carvedilol|Carvedilol 25mg, twice a day
48178112|NCT00889837|DRUG|Inhaled Loxapine|Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
48178113|NCT00889837|DRUG|Inhaled Placebo|Staccato Placebo, inhalations x 2 , 10 hours apart
48178114|NCT05241132|DRUG|Tislelizumab plus chemotherapy|"1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
48178115|NCT06544447|DEVICE|taVNS|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
48178116|NCT06544447|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
48178117|NCT01728623|DRUG|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
48178118|NCT04453163|PROCEDURE|Vertebroplasty|Patient will undergo a surgery in percutaneous vertebroplasty
48178119|NCT00315679|DRUG|Pentoxifylline (also known as oxpentifylline)|
48020482|NCT00944775|BEHAVIORAL|Exercise training|10-month exercise training program during hemodialysis sessions
48178120|NCT01122563|DRUG|Solifenacin|oral
48178121|NCT00760344|DRUG|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
48178122|NCT00760344|DRUG|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
48178123|NCT00760344|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
48178124|NCT00760344|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
48178125|NCT00760344|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
48178126|NCT00760344|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
48178127|NCT06110065|DRUG|CT-guided Pudendal Nerve Cryoneurolysis|CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.
48178128|NCT06110065|DRUG|Percutaneous image-guided cryoneurolysis|Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
48178129|NCT06456606|PROCEDURE|before prone position|It was evaluated with transesophageal echocardiography
48517778|NCT04234971|DRUG|Intervention group (DBM/BMP)|All patients will undergo a standard procedure for exposure of the cleft alveolar defect and closure of all oronasal fistulae. After induction of general anesthesia, the patient will be intubated with an oral ray tube and prepped and draped in sterile fashion. Pre-operative antibiotics will be given to cover oral flora (i.e. Unasyn or clindamycin if penicillin allergy exists). The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed. For the treatment group, 10cc of crushed DBM will be mixed with the micro-sized sponge of rh-BMP-2 (Infuse Bone Graft, Medronic, Minneapolis, MN). The sponge and DBM will then be packed into the defect to completely fill the bony space (FIGURE 3). The anterior mucosa will then be closed.
48711736|NCT02071420|BEHAVIORAL|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
48178130|NCT06456606|PROCEDURE|the first hour of prone position|It was evaluated with transesophageal echocardiography
48178131|NCT06456606|PROCEDURE|the first hour of returning to the supine position|It was evaluated with transesophageal echocardiography
48020483|NCT06331208|DIAGNOSTIC_TEST|non-contrast chest CT|patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
48178132|NCT02658175|DRUG|Volanesorsen|300 mg volanesorsen administered via SC injection.
48178133|NCT01240889|DRUG|Fluticasone|nasal spray
48178134|NCT01240889|DRUG|Fluticason|2 sprays per day in each nostril
48178135|NCT05846438|OTHER|Showering 48 hours after surgery|The main intervention is allowing patients to shower 48 hours after surgery
48178136|NCT01700283|BEHAVIORAL|exercise education and walking program|12-week moderate intensity walking program
48178137|NCT01391429|BEHAVIORAL|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
48378422|NCT04393987|BEHAVIORAL|Treatment Compliance Training|Treatment Compliance Training consist of: Introduction of Treatment Compliance Program and Information about the Disease, Therapies for Bipolar Disorder and Importance of Treatment Compliance, Drugs Used for Bipolar Disorder, Effects and Side effects, Strategies to Solve Treatment-Related Problems and Cope with Stress, Beliefs, Attitudes, and Stigmatization Towards Patient/Disease in Bipolar Disorder. The sessions were held in the form of PowerPoint presentations. In the Treatment Compliance Training, lecture, question-answer, homework, sharing experiences, video presentation, summarization were used.The day before each session, patients were phoned and reminded of the time of the session.
48378423|NCT03140813|DRUG|AZD7325 (High-Dose)|15mg PO BID
48378424|NCT03140813|DRUG|AZD7325 (Low-Dose)|5mg PO BID
48020484|NCT06331208|DIAGNOSTIC_TEST|spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
48020485|NCT06331208|DIAGNOSTIC_TEST|Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood|patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
48020486|NCT06331208|DIAGNOSTIC_TEST|supine bike exercise during right heart catheterisation|subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC
48020487|NCT06331208|DIAGNOSTIC_TEST|Lung ventilation/perfusion SPECT|subgroup of HF subjects will undergo ventilation/perfusion SPECT
48020488|NCT03864497|PROCEDURE|Myocardial perfusion imaging|
48020489|NCT01771276|DEVICE|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
48020490|NCT05429476|DRUG|Tissue Plasminogen Activator (Alteplase)|"Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour~Other Names:~Actilyse Activase tPA r-tPA"
48020491|NCT03176394|DEVICE|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
48020492|NCT03176394|DEVICE|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
48020493|NCT03146702|OTHER|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
48378425|NCT03140813|DRUG|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
48378426|NCT03418025|BEHAVIORAL|Exercise Intervention|Undergo Exercise Together intervention
48378427|NCT03418025|OTHER|Questionnaire Administration|Ancillary studies
48378428|NCT03418025|OTHER|Survey Administration|Ancillary studies
48378429|NCT03143075|DIETARY_SUPPLEMENT|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
48378430|NCT01882166|DRUG|fostimon|
48378431|NCT01882166|DRUG|puregon|
48378432|NCT00054639|BIOLOGICAL|oblimersen sodium|Given IV
48378433|NCT00054639|BIOLOGICAL|rituximab|Given IV
48378434|NCT00054639|OTHER|laboratory biomarker analysis|Correlative studies
48517779|NCT04234971|DRUG|Control group(autologous ICBG)|The patient will be induced with anesthesia, prepped, and draped. The intra-oral space will be exposed and the nasal floor and palatal mucosa will be primarily closed to create a water-tight space for the graft. The integrity of the nasal floor mucosa will be tested using methylene blue dye. Following closure of the fistula, the alveolar bone graft will be performed.In the control group, the ICBG will be harvested percutaneously using the Accumed bone graft harvesting system. Briefly, an incision will be made in iliac crest and drill bit inserted. Multiple passes of the drill be used to harvest as much autograft bone as possible from the cancellous region of the iliac crest.Following harvest, fibrin glue will be instilled for hemostasis and a Ropivicaine On-Q pain pump inserted for post-operative pain control. The harvest bone graft will be packed into the alveolar defect in a similar fashion and the mucosa closed anteriorly.
48517780|NCT05806840|BEHAVIORAL|Rapid Adaptation to Prevent Drug Use (RAPD)|RAPD will include a novel bundle of implementation strategies to support rapid responses to urgent drug use events. The strategies deployed will be based on the first step of the After Action Review: critical analysis and reflection.
48378435|NCT01398540|BIOLOGICAL|IXIARO|2 immunizations (0,5ml) with a 28 day interval
48020494|NCT04982029|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|600mg
48020495|NCT04982029|DRUG|Placebo|Matching placebo
48020496|NCT05973487|BIOLOGICAL|TSC-204-A0201|Escalating doses of TSC-204-A0201 as a monotherapy
48020497|NCT05973487|BIOLOGICAL|TSC-204-C0702|Escalating doses of TSC-204-C0702 as a monotherapy
48020498|NCT05973487|BIOLOGICAL|TSC-200-A0201|Escalating doses of TSC-200-A0201 as a monotherapy
48020499|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-C0702|Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
48020500|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-200-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
48020501|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-200-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
48020502|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-203-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
48020503|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-203-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
48020504|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-203-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
48378436|NCT00308555|DRUG|Cannabis|
48378437|NCT04045041|BEHAVIORAL|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
48378438|NCT01719263|DEVICE|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
48178138|NCT04183010|BEHAVIORAL|Physical activity coaching|"Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~1. A low intensity activity from one of the categories they selected upon start of coaching~2. A moderate-to-vigorous endurance activity~3. The participant will be linked to video content with exercise tutorials/video coaching~4. Option to skip exercise that day~5. Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~1. Yes~2. No~3. Give me a different exercise"
48178139|NCT01438840|DRUG|Avatrombopag|
48178140|NCT01438840|DRUG|Placebo|
48178141|NCT01438840|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
48178142|NCT04285047|OTHER|Advancing Patient Experience (APEX) in COPD|Involves both EMR and PRIO data
48378439|NCT01719263|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
48378440|NCT02983357|RADIATION|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
48517781|NCT05806840|BEHAVIORAL|Standard Implementation|Standard implementation of the Michigan Model for Health (MMH) includes curriculum materials and as-needed technical assistance provided by a school health coordinator.
48517782|NCT05669235|DIAGNOSTIC_TEST|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
48517783|NCT04187170|OTHER|Strength physical training|progressive high-load strength training over 6 months, consisting in repeated physical exercises to increase the muscular mass and force by altering concentric and eccentric muscle contractions against high resistance.
48517784|NCT05190705|DRUG|Loncastuximab Tesirine|Administered by intravenous infusion
48517785|NCT05190705|DRUG|Dexamethasone|Taken orally or administered by intravenous infusion
48517786|NCT01675648|DRUG|Lofexidine|
48020505|NCT05973487|BIOLOGICAL|TSC-203-A0201|Escalating doses of TSC-203-A0201 as a monotherapy
48020506|NCT05973487|BIOLOGICAL|TSC-204-A0101|Escalating doses of TSC-204-A0101 as a monotherapy
48020507|NCT05973487|BIOLOGICAL|TSC-201-B0702|Escalating doses of TSC-201-B0702 as a monotherapy
48020508|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-A0101|Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101
48020509|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-201-B0702|Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702
48020510|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-204-A0101|Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101
48020511|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-201-B0702|Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702
48020512|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-204-A0101|Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101
48020513|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-201-B0702|Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702
48020514|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-204-A0101|Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101
48020515|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-201-B0702|Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702
48020516|NCT03553745|BEHAVIORAL|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
48020517|NCT03553745|BEHAVIORAL|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
48020518|NCT03553745|BEHAVIORAL|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
48378441|NCT02983357|OTHER|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
48378442|NCT02983357|OTHER|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
48378443|NCT03351348|DRUG|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
48020519|NCT06572202|BEHAVIORAL|Positive Psychology Intervention|The 14-session intervention program is designed to enhance various internal resiliency factors. It begins with an orientation to positive psychology and setting group guidelines. Cognitive resilience is developed through identifying personal and signature strengths, reappraising memories, and learning savoring techniques. Emotional resilience is strengthened by focusing on forgiveness, managing decision fatigue, and fostering positive communication. Spiritual resilience is cultivated through gratitude practices and exploring hope and optimism. Behavioral resilience is addressed by recognizing strengths in others and engaging in altruism. The final session integrates all these elements to promote lasting positive changes in engagement, relationships, meaning, and accomplishments. Mid-session feedback ensures the program's effectiveness and responsiveness to participants' needs.
48020520|NCT01867684|OTHER|Psychotherapy|
48020521|NCT01260610|DRUG|Tenofovir|300 mg of Tenofovir daily
48020522|NCT01260610|DRUG|Telbivudine|600 mg of Telbivudine daily
48378444|NCT03351348|BEHAVIORAL|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).
48378445|NCT03351348|OTHER|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
48711737|NCT02071420|BEHAVIORAL|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
48020523|NCT01260610|DRUG|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
48020524|NCT02358486|DEVICE|Acupuncture|"1. Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~2. Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 \~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
48178143|NCT05953831|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
48020525|NCT02358486|DEVICE|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
48020526|NCT02317640|DRUG|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
48711738|NCT02071420|DEVICE|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
48711739|NCT00869050|DRUG|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
48711740|NCT00869050|DRUG|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
48020527|NCT02317640|OTHER|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
48020528|NCT02317640|DEVICE|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
48020529|NCT00013897|DRUG|Atazanavir|
48178144|NCT05953831|DRUG|Placebo|Placebo to CDR132L
48020530|NCT00013897|DRUG|Lamivudine/Zidovudine|
48020531|NCT00013897|DRUG|Efavirenz|
48020532|NCT04749264|BEHAVIORAL|Mindfulness meditation retreat|6 to 7-days mindfulness retreat (Vipassana/insight meditation). The retreats are held in silence and led by senior teachers with many years of experience in teaching meditation. The focus of the retreat is the practice of mindfulness meditation while sitting and walking. Retreats include focused attention and open monitoring mindfulness meditation practices. Each retreat has a similar practice schedule thus the amount and nature of formal practice is mostly the same.
48020533|NCT03454594|DEVICE|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
48020534|NCT03963518|DRUG|Immune checkpoint inhibitor|Immune checkpoint inhibitor
48020535|NCT03919175|DRUG|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
48020536|NCT03919175|DRUG|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
48178145|NCT06054919|DRUG|Cholecalciferol|vitamin D3
48517787|NCT01675648|DRUG|Diazepam|
48517788|NCT01675648|DRUG|Placebo for Lofexidine|
48378446|NCT05198739|OTHER|Video Interaction Project (VIP) program|Video Interaction Project (VIP) is a strengths-based, family-centered intervention designed to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines. In VIP's core component, a VIP coach video-records the parent / child for 3-5 minutes playing/reading with a provided toy and/or book, then reviews the video with the parent to facilitate self-reflection on the interaction and identifies and reinforces strengths. In the US, VIP is delivered in the context of pediatric primary care visits, with a COVID-19 remote adaptation (see Section 6 for details). Research staff will delivery VIP through video calls with subjects in Brazil.
48378447|NCT05781204|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
48378448|NCT01754012|DIETARY_SUPPLEMENT|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
48378449|NCT01592526|OTHER|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
48378450|NCT01592526|OTHER|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
48378451|NCT02613559|BIOLOGICAL|TK001|Intravitreal Injection
48378452|NCT02088866|DRUG|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
48378453|NCT02464176|DRUG|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
48378454|NCT02464176|DRUG|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
48378455|NCT02464176|DRUG|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
48378456|NCT02464176|PROCEDURE|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
48378457|NCT02464176|DRUG|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
48378458|NCT06522360|DRUG|Brigatinib|Given by mouth
48378459|NCT06522360|DRUG|Carboplatin|Given by mouth
48178146|NCT02801864|DEVICE|Real tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
48378460|NCT06522360|DRUG|Pemetrexed|Given by vein
48378461|NCT05138510|BEHAVIORAL|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
48378462|NCT03620669|DRUG|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
48378463|NCT02222168|DRUG|BI 409306|film-coated tablet
48378464|NCT01471600|PROCEDURE|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
48020537|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
48020538|NCT02795286|DEVICE|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
48020539|NCT02795286|DEVICE|Artis Haemodialysis Machine w/o ASIST Software|
48178147|NCT02801864|DEVICE|Sham tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
48378465|NCT06448169|DRUG|PD-1 inhibitor|PD-1 inhibitor combined with neoadjuvant chemotherapy
48378466|NCT01973699|OTHER|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
48378467|NCT01260064|PROCEDURE|Open appendectomy|The subjects will have traditional open appendectomy procedure.
48378468|NCT01260064|PROCEDURE|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
48378469|NCT01260064|PROCEDURE|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
48378470|NCT01701180|DRUG|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
48378471|NCT01701180|DRUG|Placebo|
48378472|NCT03609970|DIETARY_SUPPLEMENT|Vitamin D|Daily 4X 1000IU cholecalciferol
48178148|NCT02801864|OTHER|Intensive Speech Therapy|Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
48178149|NCT06538467|OTHER|Hip extension exercise with inertial load|Hip extension exercise with inertial load
48178150|NCT06538467|OTHER|Hip extension exercise with gravitational load|Hip extension exercise with gravitational load
48178151|NCT00060437|DRUG|perifosine|
48178152|NCT03946098|BEHAVIORAL|iCBT|A newly developed iCBT protocol targeting problem gambling.
48178153|NCT06480435|OTHER|Chest physical Therapy|Chest Percussion is a conventional method to clear airway and mobilize the thick mucus from the chest wall. Percussion can be applied by both manually and mechanically, but the mechanical percussion is more useful
48178154|NCT06480435|OTHER|Lungs squeezing technique|"It improves the oxygen saturation and lung volumes better than percussion.~This technique has two phases:~1. Squeezing phase~2. Release phase"
48178155|NCT04142099|BEHAVIORAL|skin to skin contact 60 min group|Newborns are exposed to maternal and child skin within five minutes of birth for 60 min.
48178156|NCT04142099|BEHAVIORAL|skin to skin contact 20min group|Newborns are exposed to maternal and child skin within five minutes of birth for 20 min.
48178157|NCT05037253|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
48178158|NCT00628277|BEHAVIORAL|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
48178159|NCT00628277|BEHAVIORAL|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
48178160|NCT01263054|DEVICE|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
48178161|NCT01263054|OTHER|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
48178162|NCT03202485|DEVICE|Toric Implantable Collamer Lens|uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
48178163|NCT03202485|DEVICE|ICL + Astigmatic keratotomy|uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
48178164|NCT02575950|DRUG|LEO43204|
48178165|NCT02575950|DRUG|Placebo|
48178166|NCT04634370|BIOLOGICAL|Natural Killer Cells infusion|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
48178167|NCT03096756|DRUG|GC4702 dry powder|5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
48178168|NCT03096756|DRUG|GC4702 lipid suspension|112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
48178169|NCT03096756|OTHER|GC4419 IV|infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.
48178170|NCT03096756|OTHER|Placebo Dry Powder|Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
48178171|NCT03096756|OTHER|Placebo lipid suspension|Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
48378473|NCT03609970|RADIATION|UVR (Solar simulated radiation)|1.25 SED Solar simulated radiation twice weekly
48517789|NCT01675648|DRUG|Placebo for Diazepam|
48378474|NCT05920057|BEHAVIORAL|constructive emotional management interventions|The Constructive emotional management interventions sessions were conducted in the activity rooms of the elderly clubs where the researchers met the participants. Participants completed a baseline evaluation of the outcome measures of the researched variables after being found to be eligible for the current study and indicating their willingness to participate willingly. After explaining the study's objectives to participants, the researchers themselves delivered the Constructive Emotional Management Interventions program, which had been vetted by experts in the field.
48378475|NCT03514823|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
48378476|NCT03514823|OTHER|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
48378477|NCT00338377|BIOLOGICAL|Dendritic Cell Immunization|1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
48378478|NCT00338377|DRUG|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
48020540|NCT03333746|OTHER|Laboratory Biomarker Analysis|Correlative studies
48178172|NCT03096756|OTHER|Fed Condition|with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.
48178173|NCT03096756|OTHER|Fasting Condition|For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
48178174|NCT03096756|DRUG|GC4702 lipid suspension - Part 2|Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
48178175|NCT03716765|DIETARY_SUPPLEMENT|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
48178176|NCT00464945|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
48378479|NCT00338377|DRUG|Fludarabine|25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
48378480|NCT00338377|BIOLOGICAL|T-Cells|On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.
48378481|NCT00338377|BIOLOGICAL|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
48378482|NCT00338377|DRUG|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
48378483|NCT00338377|BIOLOGICAL|Intrathecal T-Cells|5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
48178177|NCT04226937|OTHER|Not Applicable as this is a translational, sample collection study.|"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."
48178178|NCT03144297|OTHER|Lumbar puncture|diagnostic lumbar puncture
48020541|NCT03333746|DRUG|Lenalidomide|Given PO
48178179|NCT03144297|OTHER|BOD POD (air-displacement plethysmography)|Assessment of body fat
48178180|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
48378484|NCT00338377|BIOLOGICAL|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
48020542|NCT03333746|BIOLOGICAL|Nivolumab|Given IV
48020543|NCT03333746|OTHER|Pharmacological Study|Correlative studies
48020544|NCT06271096|DRUG|Intra muscular Midazolam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
48020545|NCT06271096|DRUG|Intravascular Diazepam|ROUTE OF ADMINISTRATION AND DRUG EFFICACY COMPARED
48020546|NCT02573987|DRUG|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
48020547|NCT02573987|DRUG|Lidocaine|standard strategy by local injection anesthesia of lidocaine
48178181|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
48178182|NCT01183442|DRUG|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
48178183|NCT03497156|DRUG|Lercanidipine|Patients are tested for their normal prescription lercanidipine medication
48178184|NCT00949793|DEVICE|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
48178185|NCT00724386|DRUG|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
48178186|NCT00724386|DRUG|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
48178187|NCT00724386|DRUG|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
48178188|NCT00724386|RADIATION|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
48378489|NCT04029766|DRUG|HSK3486|
48378490|NCT02000466|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires
48378491|NCT01737203|DRUG|Viagra|50 mg tablet on Day 1 of each period
48378492|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
48378493|NCT01737203|DRUG|sildenafil ODT|50 mg tablet on Day 1 of each period
48378494|NCT01767649|OTHER|Caesarean|Collection of tissues and blood
48378495|NCT01767649|OTHER|Vaginal delivery|Collection of tissues and blood
48020548|NCT01522859|DEVICE|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
48020549|NCT04233814|DRUG|Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)|LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
48020550|NCT04233814|DRUG|Placebo|Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
48020551|NCT03545126|OTHER|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
48178189|NCT04751240|BEHAVIORAL|SIT and resistance training|Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
48178190|NCT02077725|OTHER|interdisciplinary polypharmacy clinic visit|
48178191|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet|Investigational Medicinal Product
48178192|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet|Climodien (Bayer plc.)
48178193|NCT02324777|DRUG|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
48178194|NCT02324777|DEVICE|Volcano® Medic Vapourizer|"Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique."
48378496|NCT04465591|DIAGNOSTIC_TEST|troponin T fragmentation test|laboratory test from blood sample
48378497|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
48378498|NCT01796769|DEVICE|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
48378499|NCT01177865|OTHER|informational intervention|
48378500|NCT01177865|OTHER|questionnaire administration|
48517790|NCT06357585|OTHER|Web based education|Web-based training will be provided to the parents in the experimental group regarding care practices for children diagnosed with leukemia.
48378501|NCT02478216|PROCEDURE|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
48378502|NCT04281147|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Follow clinical administration
48517791|NCT06357585|OTHER|inactive group|Parents in the control group will continue to receive routine care and treatment.
48517792|NCT05892744|DRUG|Sertraline|50-200mg/day
48711741|NCT01180816|DRUG|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
48711742|NCT06138444|DIETARY_SUPPLEMENT|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
48178195|NCT06401837|BEHAVIORAL|Circadian based acupressure application|Acupoints include three points in hand: PC6 Neiguan, LI4 Hegu, HT7 Shenmen; two points in leg: SP6 Sanyinjiao \& ST36 Zusanli; and one point in back: DU14 Dazhui will be selected. The nurse will also teach patients and their caregiver how to apply acupressure on these acupoints. Self-administered acupressure application on the above acupoints will be performed and followed in the second week. A rehabilitation program and routine care will be scheduled as usual except for acupressure.
48178196|NCT02800447|DRUG|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1\~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1\~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1\~14
48178197|NCT02800447|DRUG|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
48178198|NCT03232710|DRUG|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
48178199|NCT03232710|DRUG|abilify|Aripiprazol orodispersible tablets 10mg
48711743|NCT06138444|OTHER|Fruit juice|Fruit juice is used as a placebo.
48178200|NCT04219280|DRUG|Quillivant XR|Long-lasting liquid solution of Quillivant XR.
48178201|NCT04219280|DRUG|Placebo|Liquid solution to mimic the color and taste of Quillivant XR.
48178202|NCT05538247|DRUG|Indomethacin|Immediate release oral capsules 50 mg, 3 times a day for 6 days
48178203|NCT05538247|DIETARY_SUPPLEMENT|S. boulardii CNCM I-745|Two 250 mg capsules orally twice daily for 14 days
48178204|NCT05538247|DRUG|Placebo|Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days
48178205|NCT02447718|BIOLOGICAL|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
48178206|NCT02447718|BIOLOGICAL|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
48711744|NCT01339715|PROCEDURE|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
48711745|NCT04075422|DRUG|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
48711746|NCT03649529|BIOLOGICAL|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
48711747|NCT03934970|DIAGNOSTIC_TEST|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
48711748|NCT02699450|DRUG|Faricimab|Faricimab will be administered by IVT injection in the study eye.
48711749|NCT02699450|DRUG|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
48178207|NCT02447718|BIOLOGICAL|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
48178208|NCT06145425|OTHER|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based mindfulness training (audio files).
48178209|NCT03703726|DIETARY_SUPPLEMENT|Reference meal|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
48178210|NCT03703726|DIETARY_SUPPLEMENT|Test meal A|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
48178211|NCT03703726|DIETARY_SUPPLEMENT|Test meal B|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Warm temperature extruding process (60-70 C°) was used to produce the extruded rice"
48178212|NCT03703726|DIETARY_SUPPLEMENT|Test meal C|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 °C) was used to produce the extruded rice."
48178213|NCT03703726|DIETARY_SUPPLEMENT|Test meal D|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
48178214|NCT03703726|DIETARY_SUPPLEMENT|Test meal E|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~warm temperature extruding process (60-70 C°) was used to produce the extruded rice."
48711750|NCT04316741|BEHAVIORAL|Snapcoach|A brief motivational interviewing-based intervention combined with health coaching via social media for 4 weeks
48711751|NCT04437719|OTHER|Obvio-19 app|"As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months."
48711752|NCT05315427|OTHER|one music therapy session|Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
48711753|NCT01889134|DRUG|Sedron (alendronate)|
48711754|NCT01889134|PROCEDURE|Parathyroidectomy|
48178215|NCT03703726|DIETARY_SUPPLEMENT|Test meal F|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 C°) was used to produce the extruded rice."
48178216|NCT00273208|BEHAVIORAL|10 week behavioral intervention program|
48178217|NCT00508274|DRUG|lapatinib|Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
48178218|NCT00508274|DRUG|capecitabine|Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
48178219|NCT00066846|BIOLOGICAL|bevacizumab|
48178220|NCT00066846|DRUG|fluorouracil|
48178221|NCT00066846|DRUG|leucovorin calcium|
48178222|NCT04156399|OTHER|Acupuncture|All subjects will receive a standardized 18 needle acupuncture protocol.
48178223|NCT04367077|BIOLOGICAL|MultiStem|intravenous infusion
48178224|NCT04367077|BIOLOGICAL|Placebo|intravenous infusion
48178225|NCT03238807|DRUG|Human Chorionic Gonadotropin|500 IU of human Chorionic Gonadotropin
48178226|NCT04886817|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families|"A 6-month intervention based on the use of 4 components: an educational video, provision of a water-promotion toolkit, a mobile phone application (app), and a series of 14 computerized interactive voice response (IVR) phone calls to parents to compare families' SSB's consumption behaviors"
48178227|NCT00244647|DRUG|RESTEN-MP|
48178228|NCT00899977|DRUG|Placebo|Matching placebo
48178229|NCT00899977|DRUG|TC-5214|
48178230|NCT04171947|DEVICE|Matuzalem ovule|vaginal ovule with 2 mg tea extract
48178231|NCT04171947|DEVICE|Vehicle ovule|polyethylene glycol vaginal ovule
48178232|NCT05928663|OTHER|double surgical gloves|In the intervention group, the surgical team members wore brown colored ENCORE® Latex Micro as the inner glove, while white MEDI-GRIP® Latex Standard was used as the outer glove
48178233|NCT05928663|OTHER|single surgical gloves|MEDI-GRIP® Latex Standard surgical gloves were included in the study as a single layer sterile surgical glove in the control group
48378503|NCT01102166|OTHER|Acapella with nebulization|"1. st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~   The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~2. nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
48378504|NCT02351050|DEVICE|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
48178234|NCT03732976|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
48178235|NCT03732976|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
48178236|NCT02462343|OTHER|walk tests|
48178237|NCT05648396|OTHER|FFRangio|Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
48178238|NCT00293345|DRUG|gemcitabine hydrochloride|
48178239|NCT00293345|DRUG|triapine|
48178240|NCT03569592|BEHAVIORAL|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
48178241|NCT06489249|DRUG|Placebo|Oral placebo tablet
48178242|NCT06489249|DRUG|Salsalate 750 MG Oral Tablet [DISALCID]|Oral salsalate tablet
48178243|NCT03617068|DRUG|Cocos Nucifera Whole|Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance
48178244|NCT03617068|DRUG|Cocos Nucifera Whole|For dermatopharmacokinetic evaluation using tape/ skin stripping
48178245|NCT03936959|DRUG|LY3434172|Administered IV
48178246|NCT01472614|DRUG|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
48178247|NCT01560195|DRUG|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
48178248|NCT01560195|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
48178249|NCT01560195|DRUG|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
48178250|NCT04178811|DEVICE|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in management of Benign Prostatic Hyperplasia patients
48178251|NCT01674803|DEVICE|Orsiro|biodegradable polymer sirolimus eluting stent
48178252|NCT01674803|DEVICE|Synergy|biodegradable polymer everolimus eluting stent
48178253|NCT01674803|DEVICE|Resolute Integrity|durable polymer zotarolimus-eluting stent
48178254|NCT00000454|DRUG|nicotine replacement patch|
48178255|NCT02842983|DRUG|Esmolol|conventional management plus esmolol infusion
48178256|NCT00155532|PROCEDURE|3 mm-punch biopsies of the skin|
48178257|NCT03465943|DRUG|Ringer|1L of Ringer's solution as a preload in one group.
48178258|NCT03465943|DRUG|Voluven|500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
48378505|NCT02351050|OTHER|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
48378506|NCT03876795|BIOLOGICAL|Bone Marrow Concentrate|Bone Marrow Concentrate injection
48378507|NCT06465160|BIOLOGICAL|MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)|"The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.~On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.~MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.~Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant."
48517793|NCT06340997|DEVICE|Transesophageal echocardiography|"* D.Echocardiography(Transthoracic and transesophageal):~* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).~The following conventional parameters were measured :~* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.~* Transesophageal echocardiogram (TEE) (to detect LAA function) .~* LAA flow velocity patterns by pulsed-wave Doppler~* Early diastolic emptying velocity~* Late diastolic emptying velocity or LAA contraction flow~* LAA filling velocity~* Systolic reflection waves~* Two-Dimensional- LAA fractional area change (LAAAC%)"
48517794|NCT03077139|DEVICE|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
48517795|NCT00699998|DRUG|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
48711755|NCT04638842|BEHAVIORAL|Online Intervention Grief COVID-19|The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
48711756|NCT06352528|DRUG|Repotrectinib|Specified dose on specified days
48711757|NCT01773343|PROCEDURE|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
48711758|NCT05391425|OTHER|no intervention|no intervention planned, since it is an observational study
48711759|NCT01873729|DRUG|Naltrexone|Adults with ADHD
48711760|NCT00418275|GENETIC|Recombinant Human Plasminogen Activator (HTUPA)|
48711761|NCT04177420|DEVICE|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
48711762|NCT04177420|DEVICE|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
48517796|NCT00699998|DRUG|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
48517797|NCT00699998|DRUG|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
48711763|NCT04177420|DEVICE|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
48711764|NCT04177420|DEVICE|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
48711765|NCT01229943|BIOLOGICAL|Bevacizumab|Given IV
48020552|NCT06420635|BEHAVIORAL|Interdisciplinary intervention program on maternal self-efficacy and the motor development of premature children|The experimental group will receive an intervention about maternal self-efficacy and motor stimulation strategies for premature children applied by mothers. There will be two face-to-face meetings: the first with a theoretical session on motor development, a practical workshop on stimulation skills using a baby simulator and strengthening of maternal self-efficacy. The second meeting seeks for mothers to reflect on self-efficacy and carry out practical simulation of strategies with their children. At home (for four weeks), self-efficacy will be strengthened through 4 strategies twice a week, for 8 sessions. Mothers will put into practice with the baby the 10 stimulation strategies explained in the face-to-face sessions, must complete 14 sessions per week, 2 times a day, for a total of 56 sessions. The initial measurement will be carried out before the intervention, the second at 4 weeks and the third at 8 weeks after the intervention began.
48020553|NCT06420635|BEHAVIORAL|Traditional kangaroo program|The control group will receive the conventional family-centered care plan, including kangaroo position, exclusive breastfeeding, and outpatient follow-up. The traditional intervention for the control group is based on the Kangaroo Mother Method (KMC) program, proposed according to technical guidelines, which promotes skin-to-skin contact between mother and premature baby. In periodic outpatient consultations, clinical assessments are carried out focused on optimal growth (goal 15-20g/kg/day), neurological and psychomotor development, and timely detection of pathologies that require specialized care according to findings. Compliance with the vaccination schedule and medical indications, and assurance of breastfeeding, are monitored. The frequency of check-ups is daily initially, then weekly until 40 weeks and then monthly. The approach includes early stimulation and follow-up until 12 months of corrected age.
48020554|NCT01142258|DRUG|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
48020555|NCT01142258|DRUG|Placebo|Inactive or inert pill which will be used as a comparator
48020556|NCT01202838|DEVICE|Composite Implant|Subjects receiving composite implants
48020557|NCT01136837|OTHER|primary pcı|
48020558|NCT02443298|DRUG|placebo|Matching placebo for risankizumab
48020559|NCT02443298|DRUG|risankizumab|Monoclonal IgG antibody
48020560|NCT06121882|DEVICE|Microfragmented Adipose Tissue derived using the Lipogems® System|Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.
48020561|NCT06121882|DRUG|Saline Injection|Intra-articular knee injection of saline
48020562|NCT02461589|DRUG|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
48020563|NCT02461589|DRUG|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
48020564|NCT02461589|DRUG|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
48020566|NCT03766646|DEVICE|Optiflow|45l.min oxygen
48020567|NCT06105489|PROCEDURE|Lateral Sinus Lift using tunnel flap technique|"The surgical procedure will involve the following steps:~* A single vertical anterior incision will be made, at least 10 mm mesially to the expected outline of the bony window.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
48020568|NCT06105489|PROCEDURE|Lateral Sinus Lift using crestal incision flap|"The surgical procedure will involve the following steps:~* A horizontal incision is made on the top of the alveolar ridge, along with two additional releasing incisions in the mesial and distal regions.~* A full-thickness flap will be carefully elevated to expose the lateral wall of the maxillary sinus.~* A trap door will be created in the lateral wall of the maxillary sinus using either a dedicated piezosurgical insert or a straight handpiece with a 3mm round diamond bur.~* The door will be removed.~* The sinus membrane will be gently elevated using various-shaped curettes until it becomes completely detached from the lateral, inferior, and medial walls of the sinus.~* The maxillary sinus will be filled with a heterologous bone graft with a well-documented efficacy.~* The flaps will be meticulously sutured."
48020569|NCT03009110|DEVICE|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
48517798|NCT00791544|DRUG|AVE1642|intravenous infusion
48517799|NCT00791544|DRUG|sorafenib|oral intake
48711766|NCT01229943|DRUG|Everolimus|Given PO
48711767|NCT01229943|DRUG|Octreotide Acetate|Given IM
48517800|NCT00791544|DRUG|erlotinib|oral intake
48711768|NCT03505489|PROCEDURE|Deep inhalation technique|Use of deep inhalations for administration of inhalant
48711769|NCT03505489|PROCEDURE|Tidal breathing technique|Use of tidal breathing for administration of inhalant
48711770|NCT03505489|DRUG|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
48711771|NCT03505489|DRUG|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
48711772|NCT00970450|DRUG|Paracetamol|Paracetamol 1 g i.v. once
48178259|NCT04903899|COMBINATION_PRODUCT|177Lu-DOTATATE|A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
48378508|NCT05321342|BEHAVIORAL|Bullying Classroom Check-Up (BCCU)|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida \[UCF\]; Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
48378509|NCT01743495|BEHAVIORAL|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
48378510|NCT05361200|BEHAVIORAL|Dynamic high-cadence cycling|Resistance settings will be changed based on entropy of cadence every 3 sessions. Cadence will be set at 80RPM for both groups
48378511|NCT05287581|BEHAVIORAL|MOVES|The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
48378512|NCT04782973|OTHER|AMAZE (TM) Disease Management Platform|Providing patients with smartphone app that will integrate with provider facing dashboard within electronic medical record.
48378513|NCT05376657|DIETARY_SUPPLEMENT|Cherry collagen drink|consume 1 sachet per day
48378514|NCT05376657|DIETARY_SUPPLEMENT|Placebo drink|consume 1 sachet per day
48378515|NCT00314847|DEVICE|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
48378516|NCT04176068|COMBINATION_PRODUCT|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
48378517|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
48711773|NCT00970450|DRUG|Tropisetron|Tropisetron 5 mg i.v. once
48711774|NCT00970450|DRUG|Placebo|Saline
48711775|NCT02851407|DRUG|Defibrotide|
48711776|NCT02851407|OTHER|Best Supportive Care|
48711777|NCT00023686|PROCEDURE|surgery|
48020570|NCT03009110|DEVICE|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
48020571|NCT02039531|BIOLOGICAL|Plasma rich in growth factors|
48020572|NCT02039531|DRUG|Hyaluronic Acid|
48020573|NCT01795001|OTHER|No intervention|
48020574|NCT00928317|DRUG|ART621|3.0mg/kg s.c.
48020575|NCT00928317|DRUG|ART621|1.5mg/kg s.c.
48020576|NCT00928317|DRUG|ART621|0.75mg/kg s.c.
48020577|NCT00928317|DRUG|Placebo|Placebo s.c.
48020578|NCT03957174|DRUG|Reboxetine|Single dose used to increase central norepinepherine
48020579|NCT03957174|DRUG|Rivastigmine|Single dose to increase central acetylcholine
48178260|NCT05635175|OTHER|hip abductors physiotherapy self training|hip abductors self training program during 7 to 10 weeks associate with a PFMT
48178261|NCT05635175|OTHER|Standard pelvic floor muscle training|Standard pelvic floor muscle training
48020580|NCT03957174|DRUG|Placebo oral tablet|Single dose as control condition
48020581|NCT04868201|DEVICE|0-anxiety|0-anxiety is a self-guided app-based utilizing virtual reality establish in cognitive behavior therapy treatment.
48020582|NCT06573047|OTHER|kinesotape|a- Kinesio-tape: cure tape (made in Korea) made from 100% gentle cotton fibre and 100% medical grade acrylic adhesive. its Hypoallergenic, water-resistant and does not limit range of motion (ROM), it is come with different colours and sizes. Kinesio Tape is safe enough for a baby's sensitive skin, and gentle enough for aging individuals, flexible enough for rehabilitation, durable enough to support working muscle, joint or ligament and strong enough for athletes at any level.
48178262|NCT05635175|OTHER|Standard pelvic floor muscle training self training|Standard pelvic floor muscle training self training
48178263|NCT03764995|OTHER|Standard bowel management|Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
48178264|NCT03764995|OTHER|Abdominal massage|Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.
48378518|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
48378519|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
48378520|NCT04481087|DEVICE|Clearfil SE Bond|Adhesive systems
48711778|NCT00023686|RADIATION|radiation|
48711779|NCT01549535|DEVICE|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
48378521|NCT04481087|DEVICE|Tetric N-Bond|Adhesive systems
48020583|NCT06573047|BEHAVIORAL|Chest physiotherapy exercises|selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
48178265|NCT03764995|OTHER|Placebo Ultrasound|Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
48178266|NCT00557661|DRUG|CD-NP|24 hr intravenous infusion
48178267|NCT00501956|DRUG|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
48178268|NCT03498586|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
48178269|NCT03498586|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
48178270|NCT04297072|DRUG|Rivaroxaban (Xarelto, BAY-597939)|Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
48178271|NCT04297072|DRUG|VKAs|Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
48178272|NCT03132662|DIETARY_SUPPLEMENT|Omega-3|3 gr/day of Omega-3
48178273|NCT03132662|DIETARY_SUPPLEMENT|Very Low Calorie Diet|4 servings/day Optifast
48178274|NCT03666806|BIOLOGICAL|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
48378522|NCT02262572|DRUG|Telmisartan /HCTZ - compression tablet (DC)|
48378523|NCT02262572|DRUG|Telmisartan /HCTZ - dry granulation tablet (DG)|
48378524|NCT02262572|DRUG|Telmisartan /HCTZ - present commercial formulation|
48020584|NCT02717793|OTHER|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
48020585|NCT05416619|DEVICE|REMO®|The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles. REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation. The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment.
48020589|NCT05019586|DRUG|levofloxacin, amoxicillin, clarithromycin|Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days
48020590|NCT02864017|PROCEDURE|Enteral nutrition|
48020591|NCT02864017|DIETARY_SUPPLEMENT|L-Citrulline|
48020592|NCT02864017|DIETARY_SUPPLEMENT|Placebo|
48020593|NCT00780572|BEHAVIORAL|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
48020594|NCT02284828|DRUG|BIA 2-093|
48178275|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
48711780|NCT06153433|DRUG|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
48711781|NCT06153433|DRUG|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
48711782|NCT05086757|BEHAVIORAL|TRRP|Receive TRRP services
48020595|NCT06572280|DEVICE|PNS group|non-invasive phrenic nerve stimulation
48020596|NCT01040871|DRUG|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
48178276|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
48378525|NCT05957939|DRUG|Alkaline Glucosodiene Molecules|Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
48378526|NCT01477541|OTHER|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
48378527|NCT00685074|BEHAVIORAL|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
48378528|NCT00685074|BEHAVIORAL|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
48711783|NCT05086757|BEHAVIORAL|Enhanced Usual Care|Participants will receive an educational flyer with service referrals
48020597|NCT01040871|DRUG|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
48020598|NCT01040871|DRUG|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
48020599|NCT01040871|DRUG|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
48020600|NCT01040871|DRUG|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
48020601|NCT01040871|DRUG|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
48178277|NCT05563649|BEHAVIORAL|Online Guided Self-Help-Family-based Treatment|GSH-FBT consists of 10 20-minute sessions for parents only over 9 months. Sessions follow an online curriculum of 65 short videos: 62 with an expert clinician instructing parents on the principles of FBT, and 3 reflections from an adolescent who recovered from AN and completed FBT. Each lecture series contains an introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual Help Your Teenager Beat an Eating Disorder. Three lectures include additional resources for parents (e.g., Academy of Eating Disorder (AED) Medical Management Guidelines). Homework assignments are included with some lectures (e.g., strategies to help the child eat during meals, practice making calorically dense meals). In line with GSH approaches, coach-therapists direct parents, to watch or re-watch specific video content contained in the online learning material related to their questions rather than direct behavioral change.
48178278|NCT05563649|BEHAVIORAL|FBT via Videoconferencing|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
48178279|NCT01793077|DRUG|Depo-Eligard®|Subcutaneous
48378529|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
48020602|NCT02388321|DRUG|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
48378530|NCT01204606|PROCEDURE|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* 43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
48378531|NCT01961765|DRUG|cabozantinib|
48378532|NCT01133366|DRUG|warfarin sodium|25 mg of warfarin oral (single dose)
48378533|NCT01133366|DRUG|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
48378534|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
48378535|NCT01407965|PROCEDURE|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
48378536|NCT04530422|DRUG|Sofosbuvir plus Ledipasvir|"Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days."
48020603|NCT02388321|DRUG|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
48020604|NCT04049994|DRUG|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
48020605|NCT04049994|DRUG|Placebo oral tablet|Placebo oral tablet
48020606|NCT02880852|DRUG|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
48020607|NCT06435026|DRUG|FTC/TDF 200mg/300mg|Standard Dose
48020608|NCT06435026|DRUG|FTC/TDF 300mg/450mg|150% Standard Dose
48020609|NCT06435026|DRUG|FTC/TDF 400mg/600mg|200% Standard Dose
48020610|NCT02939105|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform treatments.
48020611|NCT05430386|DRUG|HS-10241|"Dose escalation: HS-10241 and Almonertinib will be administered in combination. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.~Dose expansion: HS-10241 and Almonertinib will be administered in the dose identified in Part 1 to further investigate the safety, tolerability, pharmacokinetics, and efficacy of this combination therapy."
48020612|NCT05368805|DRUG|Fruquintinib|Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5
48020613|NCT05368805|DRUG|Dabigatran Etexilate|Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5
48178280|NCT03094962|OTHER|Motion capture|Capture kinematics of finger movements
48178281|NCT03094962|DIAGNOSTIC_TEST|MR scan|Capture MR images of hand and fingers in three postures
48178282|NCT03094962|DIAGNOSTIC_TEST|CT scan|Capture CT images of hand and fingers in three postures
48178283|NCT04089072|DRUG|Methylene Blue|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin), they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
48178284|NCT04089072|DRUG|Phenylephrine|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin) already , they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
48178285|NCT01445990|DEVICE|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
48178286|NCT03462043|COMBINATION_PRODUCT|ND0612|s.c. infused
48378537|NCT02715843|DRUG|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
48378538|NCT02223624|OTHER|walking and light weights|
48378539|NCT02223624|OTHER|eccentric aerobic exercise|
48378540|NCT02223624|OTHER|concentric aerobic exercise|
48378541|NCT04494191|DRUG|Flibanserin 100Mg Tab|One tablet contains 100 mg Flibanserin
48378542|NCT04494191|DRUG|Flibanserin 100 MG [Addyi]|One tablet contains 100 mg Flibanserin
48711784|NCT06480175|PROCEDURE|cervical plexus block|patients will receive cervical radiofrequency ablation on both sides then after 2 weeks they will be readmitted and will receive superficial cervical plexus block on one side only
48711785|NCT06444217|PROCEDURE|skin biopsy|skin biopsy
48711786|NCT01294462|DRUG|Ticagrelor|90 mg, oral dose twice daily
48020614|NCT05368805|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
48378543|NCT00100282|DRUG|PPI-1019 (APAN)|
48020615|NCT00293540|PROCEDURE|oophorectomy|Excision of an ovary
48020616|NCT00293540|DRUG|Tamoxifen|20 mg orally every day
48020617|NCT05132335|OTHER|Imaging Biomarkers|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections \[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"
48020618|NCT06325995|RADIATION|Conventional radiation therapy|66-74 Gy in 33-37 daily fractions of 2 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
48020619|NCT06325995|RADIATION|Hypofractionated radiation therapy|57.5-65 Gy in 23-26 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
48020620|NCT00900991|BIOLOGICAL|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
48378544|NCT03961932|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
48378545|NCT00478218|DRUG|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
48378546|NCT00478218|DRUG|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22
48378547|NCT00478218|DRUG|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
48178287|NCT03462043|COMBINATION_PRODUCT|CLES|Carbidopa-Levodopa Enteral Suspension.
48378548|NCT03591666|DRUG|Anlotinib|Anlotinib p.o. qd
48378549|NCT06402825|BEHAVIORAL|Fit-for-Fertility program|Women in the intervention group had to delay fertility treatments for 6 months and were offered the interdisciplinary lifestyle intervention, which was provided for a maximum of 18 months or until the end of a pregnancy that occurred. The lifestyle intervention consisted of individual meetings with a dietitian and a kinesiologist trained in motivational interviewing, combined with 12 educational group sessions during the first 6 months. Details of the lifestyle intervention are presented in the previously published protocol (Duval et al., 2015).
48378550|NCT04208061|DRUG|Dabigatran Etexilate|Participants will receive single dose of dabigatran etexilate orally.
48378551|NCT04208061|DRUG|DRV/COBI|Participants will receive oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI).
48378552|NCT04208061|DRUG|Ritonavir|Participants will receive ritonavir orally.
48378553|NCT04208061|DRUG|Darunavir|Participants will receive Darunavir orally.
48378554|NCT04233372|DRUG|Delstrigo|"Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir disoproxil.~1 covered tablet for day .( will be administered 28 days maximum)"
48378555|NCT05076812|DIAGNOSTIC_TEST|measure plasma level of interleukin 38 by ELISA kit|draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
48711787|NCT01294462|DRUG|Clopidogrel|75 mg, oral dose once daily
48711788|NCT01294462|DRUG|Acetylsalicylic acid ASA|Low Dose ASA
48711789|NCT03221608|PROCEDURE|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
48711790|NCT03221608|PROCEDURE|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
48378556|NCT06186466|OTHER|Observational Survey and Analysis|This study does not involve a clinical or medical intervention. Instead, it employs an observational survey method to gather data from family members of patients who visited the Health Sciences University Van Training and Research Hospital's emergency department between December 1, 2023, and June 1, 2024. The study aims to use logistic regression analysis to identify factors influencing the intent of violence against healthcare professionals. The survey includes structured questionnaires and scales developed based on theoretical frameworks and previous research. The gathered data will be statistically analyzed using the G\*Power software to assess the significance and impact of various factors on the propensity for violence.
48378557|NCT03638479|OTHER|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
48378558|NCT02798302|OTHER|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
48378559|NCT05878496|PROCEDURE|fixation by plate and screws|reduction and fixation of pediatric fracture neck femur by plate and screws
48378560|NCT05761171|PROCEDURE|Biospecimen Collection|Undergo collection of blood and CSF samples
48378561|NCT05761171|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
48378562|NCT05761171|DRUG|Calaspargase Pegol|Given IV
48378563|NCT05761171|DRUG|Cytarabine|Given IV and IT
48378564|NCT05761171|PROCEDURE|Echocardiography|Undergo ECHO
48378565|NCT05761171|DRUG|Fludarabine Phosphate|Given IV
48378566|NCT05761171|DRUG|Hydrocortisone Sodium Succinate|Given IT
48517801|NCT06551415|DRUG|Dabigatran Etexilate 150mg|100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
48378567|NCT05761171|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48378568|NCT05761171|DRUG|Methotrexate|Given IT
48378569|NCT05761171|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
48378570|NCT05761171|DRUG|Prednisolone|Given PO or via NG, NJ, ND or G-tube
48378571|NCT05761171|DRUG|Prednisone|Given PO or via NG, NJ, ND or G-tube
48517802|NCT06551415|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
48517803|NCT05175235|DEVICE|CURATE.AI|Efficacy and toxicity measurements at the end of each two-/three- week dosing cycle, together with an information on given drugs and their doses, and other patient data, will be used by CURATE.AI to recommend the dose of nivolumab/pembrolizumab for the next cycle. The clinical investigators will decide whether or not to administer or prescribe the dose recommendation from CURATE.AI.
48517804|NCT05175235|DRUG|Nivolumab, Pembrolizumab|Treatment with the selected regimen will take up to a maximum duration of 12 months, in two-/three- week cycles. CURATE.AI dose recommendations will be generated before each chemotherapy cycle; fixed throughout the cycle; Maximum total cumulative dose per cycle of nNivolumab/pembrolizumab in the predetermined safety range is set at 100% of standard starting dose (i.e. , 240 mg/m2 once every 2 weeks for single agent Nivolumab and 200 mg/m2 once every 3 weeks for single agent Pembrolizumab). Minimum total cumulative dose per cycle of nivolumab/pembrolizumab in the predetermined safety range is set at 30% of the standard starting dose (i.e. 8072 mg/m2 once every 2 weeks for single agent Nivolumab and 60 mg/m2 once every 3 weeks for single agent Pembrolizumab). Subject-specific dosing range may alter those numbers to suit the specific circumstances of the subject, thus giving the subject specific safe dosing range.
48517805|NCT05884502|DRUG|combination of high-dose rosuvastatin and ezetimibe|combination of rosuvastatin 20mg and ezetimibe 10mg
48378572|NCT05761171|DRUG|Revumenib|Given PO or via NG, NJ, ND or G-tube
48378573|NCT05761171|DRUG|Vincristine Sulfate|Given IV
48378574|NCT03690375|DEVICE|Broad Band Light (BBL)|Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
48378575|NCT03962426|DEVICE|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~* Recognition: a speeded face matching task~* Face to Face: a speeded facial emotion matching task~* Gaze Match: a speeded gaze matching task~* Face Poke: a continuous performance task with facial expressions"
48378576|NCT01735136|DIETARY_SUPPLEMENT|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
48378577|NCT01735136|DIETARY_SUPPLEMENT|Placebo|Placebo (10g/day)
48378578|NCT03764241|DRUG|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
48378579|NCT03764241|DRUG|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
48378580|NCT06111976|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
48517806|NCT05884502|DRUG|high-dose rosuvastatin single administration|rosuvastatin 20mg monotherapy
48517807|NCT02766335|DRUG|Docetaxel|Given IV
48517808|NCT02766335|BIOLOGICAL|Durvalumab|Given IV
48711791|NCT05446792|OTHER|PFMT|The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
48711792|NCT05446792|OTHER|PE|"The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups."
48020621|NCT06197139|DRUG|[177Lu]Lu-XT117|\[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
48020622|NCT01176591|DRUG|Placebo session 1, Aprepitant session 2|placebo in session 1, Aprepitant 80 mg in session 2, oral administration.
48266866|NCT03986255|PROCEDURE|Lumbar Puncture|"The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point."
48020623|NCT01176591|DRUG|Placebo session 1, Placebo session 2|Placebo, one per session, oral administration
48020624|NCT01478698|DRUG|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
48378581|NCT06111976|PROCEDURE|Placebo|"sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions.~A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions."
48378582|NCT01113073|OTHER|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
48378583|NCT01113073|OTHER|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
48378584|NCT01113073|OTHER|passive leg raising test|performing the passive leg raising test
48378585|NCT04689126|PROCEDURE|surgical or nonsurgical endodontic treatment|Change in diagnosis and treatment plans between the two imaging - periapical radiography and cone beam computed tomography
48378586|NCT00924820|DRUG|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
48378587|NCT03825887|DRUG|Nalbuphine|"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
48517809|NCT02766335|OTHER|Laboratory Biomarker Analysis|Correlative studies
48517810|NCT01531088|BEHAVIORAL|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
48020625|NCT01478698|DRUG|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
48020626|NCT02760186|PROCEDURE|Altitude Exposure|Altitude Exposure
48020627|NCT06402500|DRUG|Icon Infiltrant|White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
48020628|NCT06402500|DRUG|Bioactive infiltrant|White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
48020629|NCT03533400|DEVICE|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
48020630|NCT03533400|DEVICE|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
48020631|NCT01717417|DEVICE|miniscrew|
48020632|NCT01717417|DEVICE|TPA|
48020633|NCT01311830|BEHAVIORAL|Telephone Counseling|
48020634|NCT01311830|BEHAVIORAL|Written Materials|
48020635|NCT04227483|DRUG|Deflazacort|Deflazacort for 4 months
48378588|NCT03825887|DRUG|Morphine|"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
48178288|NCT04394312|OTHER|Parent PLAYSHOP|"The Parent PLAYSHOP includes:~1. Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~2. Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~3. Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support."
48378589|NCT02469402|DIETARY_SUPPLEMENT|Standard infant formula|
48378590|NCT02469402|DIETARY_SUPPLEMENT|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
48378591|NCT06367751|DIAGNOSTIC_TEST|ctDNA measurement|Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.
48378592|NCT00886977|DRUG|YAM80|Oral administration, 2 to 6 mg, once a day.
48378593|NCT02431507|DEVICE|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
48711793|NCT00536016|DRUG|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
48711794|NCT03289832|DIETARY_SUPPLEMENT|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
48517811|NCT01679990|BIOLOGICAL|PLX-PAD Low dose|
48711795|NCT03289832|DIETARY_SUPPLEMENT|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
48711796|NCT06022081|DIAGNOSTIC_TEST|Lung ultrasound to detect pneumothorax.|Within a maximum of two hours after chest tube removal, the sonographic exam will be performed with an ultrasound device to assess residual PNX using a portable ultrasound device. The examination will require patients to lie face upward and will be performed at three different sites on both sides of the patient's chest. Each chest site will be imaged for approximately 10-20 seconds, allowing a complete examination of each side in approximately 30-60 seconds. The total study time for the LUS exam is approximately 2 minutes. The results of this assessment will be compared to the standard chest x-ray performed by a radiologist who is unaware of the study.
48378594|NCT02742415|BEHAVIORAL|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
48378595|NCT05180682|OTHER|Gait Training|"the physical therapist will provide different protocol at different weeks in the following way.~first week: first fitting and initial Gait training second week: Specific Gait Training third week: Advance Gait Training fourth week: Functional Training"
48020636|NCT04227483|DRUG|Prednisolone|Prednisolone for 4 months
48020637|NCT04345146|COMBINATION_PRODUCT|FSRT combined with Bevacizumab|"Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT.~Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases."
48378596|NCT05543226|DRUG|PHGG-rich enteral nutrtiion|PHGG-rich enteral nutrition
48378597|NCT01469416|DRUG|Rosuvastatin|Rosuvastatin 20 mg PO x 1
48378598|NCT01469416|DRUG|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
48378599|NCT06041100|DEVICE|Exoskeleton|Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.
48378600|NCT00959075|DIETARY_SUPPLEMENT|Vitamin B1|100 mg Twice a day
48178289|NCT00664183|DRUG|Vitreosolve|Intravitreal injection
48378601|NCT00959075|DIETARY_SUPPLEMENT|Placebo|Sugar pill
48517812|NCT01679990|BIOLOGICAL|PLX-PAD high doses|
48517813|NCT01679990|BIOLOGICAL|Double Placebo|
48517814|NCT01679990|BIOLOGICAL|high dose +Placebo|
48517815|NCT06228001|DEVICE|Actimyo|Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
48178290|NCT02626442|OTHER|Exercise|6 month group exercise class
48178291|NCT00495092|DRUG|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
48378602|NCT04121832|DEVICE|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
48378603|NCT04121832|OTHER|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
48378604|NCT05635929|COMBINATION_PRODUCT|Composition comprising olive oil, xylitol and betaine|Topical composition in the form of a gel.
48378605|NCT04943536|DRUG|bicalutamide|localized anti-androgen therapy
48711797|NCT03777709|BEHAVIORAL|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
48711798|NCT03058666|DRUG|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
48711799|NCT03058666|DEVICE|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
48378606|NCT04943536|RADIATION|Stereotactic body radiation therapy|localized radiation therapy
48378607|NCT02137070|PROCEDURE|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
48378608|NCT02137070|OTHER|Non surgical/Community volunteers|Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss
48378609|NCT05428306|DRUG|A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)|Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
48517816|NCT02755649|DRUG|Dupilumab|
48517817|NCT02755649|DRUG|Matching Placebo|
48517818|NCT01674218|DRUG|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
48711800|NCT04663061|BEHAVIORAL|Medical weight loss|Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
48711801|NCT04663061|BEHAVIORAL|Diabetes education|Participants will receive standard of care diabetes education
48711802|NCT04663061|BEHAVIORAL|Continuous glucose monitoring|Participants will use CGM devices to track blood glucose levels in near real time
48711803|NCT04657640|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
48020638|NCT02385955|PROCEDURE|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
48711804|NCT04657640|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)|"Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS."
48711805|NCT04094233|DIETARY_SUPPLEMENT|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
48711806|NCT04094233|OTHER|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
48711807|NCT04774471|DIAGNOSTIC_TEST|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
48020639|NCT05371210|OTHER|SAIF|Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
48020640|NCT06662604|BIOLOGICAL|Bone marrow stem cells concentrate , platelet rich fibrin , bone graft|All participants will be treated with Bone marrow stem cells concentrate , platelet rich fibrin , bone graft.
48020641|NCT06662604|BIOLOGICAL|platelet rich fibrin and bone graft|All participants will treated with platelet rich fibrin PRF , bone graft.
48020642|NCT01016834|DEVICE|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
48020643|NCT01016834|DRUG|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
48020644|NCT01802411|DRUG|EXPAREL 266 mg|
48020645|NCT01802411|DRUG|Placebo|
48020646|NCT04654689|DIETARY_SUPPLEMENT|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
48178292|NCT00495092|DRUG|Biperiden|Biperiden 2-4 mg/d p.o.
48178293|NCT00495092|DRUG|Placebo|Placebo + Placebo
48178294|NCT03587337|OTHER|POEM|Pt. are going to submit a POEM procedure.
48178295|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
48178296|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
48178297|NCT03042299|DRUG|TAK-536|TAK-536 granules.
48178298|NCT03042299|DRUG|TAK-536|TAK-536 tablet.
48266867|NCT05130307|BEHAVIORAL|virtual reality game|participants interact with a computer generated world
48266868|NCT04853628|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).
48020647|NCT04654689|OTHER|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
48178299|NCT05301998|OTHER|Skin and thickness measurement/breast MRI|"Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital"
48178300|NCT04799847|DRUG|Catumaxomab|This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
48178301|NCT05940831|BEHAVIORAL|Support-Moms|Scheduled SMS-audio messages from the final messaging prototype (SM), plus social supporter engagement through SMS (SS).
48178302|NCT05940831|BEHAVIORAL|Control|Routine care/ information giving
48178303|NCT06336512|DIAGNOSTIC_TEST|ELISA|Estimation of Zonulin by ELISA from the Blood samples which were obtained at time of pregnancy .
48178304|NCT01398462|DRUG|CWP232291|IV Infusion
48178305|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
48178306|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
48178307|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
48178308|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
48178309|NCT00965120|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
48178310|NCT00965120|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
48178311|NCT00965120|DRUG|Placebo (saline)|Systemic infusion of placebo (saline).
48178312|NCT05669976|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).
48178313|NCT05669976|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
48711808|NCT02986243|OTHER|Exercise|6 months worth of exercise regimen
48020648|NCT04654689|DIETARY_SUPPLEMENT|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
48178314|NCT00522717|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
48178315|NCT00522717|BEHAVIORAL|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
48378610|NCT05428306|DRUG|A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)|A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
48378611|NCT05428306|DRUG|A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)|A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
48378612|NCT02713100|BEHAVIORAL|level of agitation|psychological pain
48378613|NCT02223637|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
48378614|NCT03148912|DIAGNOSTIC_TEST|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
48378615|NCT03790475|OTHER|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
48378616|NCT03790475|OTHER|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
48378617|NCT06276647|BEHAVIORAL|HOME|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum patients. The patient navigator will explain this pamphlet at postpartum discharge, then will follow-up with the patients up to 30 days in the postpartum period.
48378618|NCT00734318|DRUG|Flutiform 250/10 micrograms|
48378619|NCT00734318|DRUG|Flutiform 50/5 micrograms|
48378620|NCT00734318|DRUG|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
48020649|NCT04654689|DRUG|G04CB02|G04CB02, in a single daily dose for 4 months
48020650|NCT04654689|OTHER|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
48378621|NCT00734318|DRUG|Flixotide pMDI 250 micrograms|
48378622|NCT01884909|DRUG|Metoprolol Succinate ER Tablet 200 mg|1 \* 200 mg tablet per day
48711809|NCT02986243|DIETARY_SUPPLEMENT|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
48711810|NCT01556776|DRUG|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
48711811|NCT01556776|DRUG|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
48711812|NCT05529355|DRUG|Envafolimab plus Endostar and S-1|Immunotherapy combined with chemotherapy and anti VEGFR therapy
48711813|NCT05529355|DRUG|Envafolimab plus Endostar|Immunotherapy combined with anti VEGFR therapy
48711814|NCT05529355|DRUG|Envafolimab plus S-1|Immunotherapy combined with chemotherapy
48711815|NCT02421913|DRUG|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
48517819|NCT01674218|DRUG|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
48711816|NCT05349838|DRUG|Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy|Daily oral tablet
48711817|NCT04364607|DRUG|Neostigmine|Participants will receive 0.5 mg IM neostigmine
48711818|NCT04364607|DRUG|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
48711819|NCT03538184|PROCEDURE|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
48711820|NCT03538184|PROCEDURE|Drill|Preparation of implant beds entirely with conventional implant drills
48711821|NCT00681564|PROCEDURE|One-Stage Full-Mouth Disinfection|"* Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
48711822|NCT00681564|PROCEDURE|Periodontal care|"* Basic oral hygiene instructions~* Supragingival plaque removal"
48711823|NCT01945736|DRUG|Methadone|To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.
48711824|NCT00016744|DRUG|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
48711825|NCT00016744|DRUG|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
48711826|NCT00016744|DRUG|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
48020651|NCT04674059|OTHER|patient survey|A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.
48020652|NCT05940285|DIAGNOSTIC_TEST|Dynamic 99mTc-Tetrofosmin CZT-SPECT|Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
48020653|NCT03862118|OTHER|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
48378623|NCT01884909|DRUG|'TOPROL-XL®' ER Tablets 200 mg|1 \* 200 mg tablet per day
48378624|NCT05335161|DEVICE|Home-based leg heat therapy|The Aquilo system consists of a garment that contains an inner water-circulating pad that is compressed by air bladders. The volume of air inflating the air bladders is pressure-controlled so the garment automatically adjusts to the shape and size of all legs. The touch screen console contains pre-programmed settings for ease of use. After baseline characteristics are established, patients will be provided with the Aquilo device and will be instructed on how to operate the equipment and how to rapidly remove the system if the alarm sounds or if they have any unusual feeling. Patients in both groups will also receive a logbook to record their sessions. Patients will undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. Water at 42ºC will be perfused through the water-circulating garment for 90 min, with the goal of increasing skin temperature in the calf to \~37ºC.
48378625|NCT04216134|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
48378626|NCT04216134|PROCEDURE|Positron Emission Tomography|Undergo 68GA-PSMA-11 PET
48378627|NCT04056650|DRUG|L-theanine|up to 250 mg
48711827|NCT02630017|DRUG|ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
48711828|NCT02630017|DRUG|ADHD placebo first, methylphenidate second|double-blind, counter-balanced administration
48711829|NCT02630017|DRUG|Non-ADHD methylphenidate first, placebo second|double-blind, counter-balanced administration
48711830|NCT02630017|DRUG|Non-ADHD placebo first, methylphenidate second|
48711831|NCT05753566|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
48711832|NCT05753566|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
48711833|NCT05753566|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
48711834|NCT03497091|OTHER|Enteral Formula|Enteral Feeding with an amino acid-based formula
48711835|NCT02825420|DRUG|trabectedin|
48711836|NCT02217371|OTHER|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
48711837|NCT05744375|DRUG|Trastuzumab deruxtecan|"All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met."
48178316|NCT05258409|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
48178317|NCT05258409|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
48178318|NCT01741389|DRUG|"Melatonin (Circadin)"|
48178319|NCT06351462|OTHER|Spermogram|Spermogram will be proposed to men
48178320|NCT06351462|OTHER|Hospital Anxiety and Depression Scale (HADS)|Anxiety and depression will be evaluated 10 years after HSCT
48178321|NCT06351462|OTHER|SF36 Quality of life questionnaire|Quality of life will be evaluated 10 years after HSCT
48178322|NCT06351462|OTHER|Psychologist interview|During a follow-up visit
48178323|NCT06351462|OTHER|Optional sera banking|One in the study
48020654|NCT03400397|OTHER|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
48020655|NCT06208527|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of 2000 mg NR is administered daily for 1 year.
48178324|NCT06351462|OTHER|Optional DNA banking|Once in the study
48178325|NCT05156515|DIAGNOSTIC_TEST|68Ga-THP-APN09|APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan.
48711838|NCT05489653|BEHAVIORAL|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
48711839|NCT03628638|OTHER|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
48711840|NCT00188851|DRUG|therapeutic management strategy|
48711841|NCT04773561|DEVICE|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
48711842|NCT03797118|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
48711843|NCT04039607|DRUG|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
48711844|NCT04039607|DRUG|Ipilimumab|Participants will receive ipilimumab as IV infusion.
48020656|NCT06208527|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
48020657|NCT05910775|BEHAVIORAL|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
48020658|NCT05211024|DRUG|Penicillin G Benzathine|Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care
48020659|NCT00863538|DRUG|KPS-0373|
48020660|NCT06487039|DRUG|EB-203|Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
48020661|NCT03512340|DRUG|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
48711845|NCT04039607|DRUG|Sorafenib|Participants will receive sorafenib as oral tablets.
48020662|NCT06123767|PROCEDURE|CAS + Intravascular measuring the pressure gradient|"Measurements taken during the procedure during CAS~* placement of a FFR- micro catheter on the neuroprotection wire and taking a measurement before the stenosis and in the internal carotid artery above the stenosis~* reading the pressure gradient after obtaining a stable value (a minimum of 5 cardiac cycles)~  * the study of intravascular pressure measurements will be performed using a special micro catheter"
48020663|NCT06123767|PROCEDURE|CAS (standard)|"Animation of blood pressure measurements on the FFR console without actual measurement in carotid artery (blinding of the study to the patient) during CAS procedure."
48020664|NCT06123767|DIAGNOSTIC_TEST|Doppler ultrasonound of cephalic arteries|non-invasive assessment of carotid stenosis before surgery and assessment of results after CAS (3 and 12 months after CAS)
48020665|NCT06123767|RADIATION|Angio-CT of the neck and head|Non-invasive pre-operative assessment and post-CAS result (3 months after)
48517820|NCT01674218|OTHER|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
48517821|NCT00781807|OTHER|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~1. Nutrition management~2. Home-based ergometer training program~3. Psychosocial support"
48020666|NCT06123767|OTHER|Otolaryngological examination|Hearing and balance tests (before and after CAS) - prospective follow-up
48020667|NCT06123767|OTHER|Psychological examination|psychological examination with questionnaires (before and after CAS) - prospective follow-up
48020668|NCT06123767|OTHER|Neurological examination|neurological examination with questionnaires (before and after CAS) - prospective follow-up
48020669|NCT06123767|DIAGNOSTIC_TEST|MR cerebral perfusion|"Assessment of the cerebral perfusion alterations using DSC (dynamic susceptibility contrast) MR perfusion, before and after CAS (after 3 months):~Parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), time to peak (TTP), and mean transit time (MTT) will be generated and used for the qualitative and quantitative analyses of the following perfusion parameters:~* cerebral blood volume (CBV) value in ml/100ml;~* cerebral blood flow (CBF) value in ml/100ml/min;~* mean transit time (MTT) value in seconds~* time to peak (TTP) value in seconds"
48020670|NCT06532331|DRUG|ONO-7475|Specified dose on specified days
48020671|NCT06532331|DRUG|ONO-4538|Specified dose on specified days
48020672|NCT06532331|DRUG|Nab-paclitaxel|Specified dose on specified days
48020673|NCT06532331|DRUG|Gemcitabine|Specified dose on specified days
48178326|NCT03371368|PROCEDURE|Roux-en-Y Gastric Bypass (RYGBP)|This is a standard RYGBP procedure that would be performed clinically and is not research-specific.
48178327|NCT03371368|PROCEDURE|Sleeve Gastrectomy (SG)|This is a standard SG procedure that would be performed clinically and is not research-specific.
48178328|NCT03371368|BEHAVIORAL|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
48178329|NCT01196819|DEVICE|Firehawk|Implantation of Firehawk drug eluting stent
48178330|NCT01196819|DEVICE|Xience V|Implantation of Xience V drug eluting stent
48178331|NCT00693433|DRUG|dexamethasone|Given orally
48178332|NCT00693433|DRUG|temsirolimus|Given IV
48178333|NCT00693433|OTHER|laboratory biomarker analysis|Correlative studies
48178334|NCT00186459|BEHAVIORAL|Hypocaloric diet of varying macronutrient composition|
48178335|NCT06428877|OTHER|analyzed on the post-operative scanner|analyzed on the post-operative scanner
48178336|NCT00966979|DEVICE|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
48178337|NCT03833362|DRUG|Narlaprevir|yellow film-coated 100 mg. tablets
48020674|NCT02170727|DRUG|DCV/ASV/BMS-791325|
48020675|NCT04614259|DRUG|Bupivacain|"The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis"
48178338|NCT03833362|DRUG|Ritonavir|100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
48178339|NCT03833362|DRUG|Placebo Narlaprevir|yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
48378628|NCT04056650|DIETARY_SUPPLEMENT|Caffeine supplement|50-400mg
48378629|NCT04056650|DEVICE|N1 app|N1 App on mobile device
48711846|NCT04039607|DRUG|lenvatinib|Participants will receive lenvatinib as oral capsules.
48711847|NCT03023696|PROCEDURE|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
48711848|NCT03023696|PROCEDURE|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
48711849|NCT02088593|DEVICE|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
48020676|NCT04614259|COMBINATION_PRODUCT|i.v. analgesia|"Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes"
48178340|NCT03833362|DRUG|Placebo Ritonavir|100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
48178341|NCT03833362|DRUG|Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b|180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
48178342|NCT03833362|DRUG|Ribavirin|"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b"
48178343|NCT03943017|OTHER|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
48178344|NCT05834023|DRUG|Bupivacaine-Lidocaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml
48178345|NCT05834023|DRUG|Bupivacaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
48178346|NCT00827736|PROCEDURE|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
48178347|NCT00827736|DRUG|ISDN ointment|application of ISDN 1% ointment 6 times a day
48178348|NCT00827736|DRUG|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
48178349|NCT03420898|OTHER|Quality Improvement Intervention, prescription reduction|The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
48178350|NCT05833659|PROCEDURE|The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy|Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
48178351|NCT04919070|BEHAVIORAL|Connect for Caregivers|The intervention being studied is a single session guided behavioral intervention to improve social connectedness in caregivers of individuals with ADRD. The intervention, Connect for Caregivers, provides psychoeducation on the importance of social connectedness for health and well-being, includes a card-sort process to identify and prioritize barriers to connectedness, and provides personalized resources and strategies for caregivers to use to increase their social connectedness.
48178352|NCT02444728|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
48178353|NCT02444728|DRUG|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
48178354|NCT02444728|DRUG|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
48178355|NCT02444728|DRUG|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
48178356|NCT00952848|OTHER|questionnaire administration|Pain Rating Score
48178357|NCT00952848|OTHER|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
48178358|NCT00952848|OTHER|Quality of Life instrument|Uniscale 0-100 scale global quality of life
48178359|NCT00952848|DEVICE|MC5-A Scrambler device|Electrical stimulation for 60 minutes
48178360|NCT01743976|DRUG|Donepezil|donepezil 5 mg once daily for 6 weeks
48178361|NCT01743976|DRUG|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
48178362|NCT04212754|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
48178363|NCT03287778|DIETARY_SUPPLEMENT|Pyridoxine|Max dose of 400 mg QD PO
48178364|NCT03287778|DIETARY_SUPPLEMENT|Placebo|Matching placebos will be administered.
48178365|NCT02639806|DRUG|Sevoflurane|
48178366|NCT02639806|DRUG|Lidocaine|
48178367|NCT04762303|OTHER|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
48178368|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with a general anger trigger and 10 anger management strategies
48178369|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with 10 specific anger triggers and 10 anger management strategies
48178370|NCT04400344|OTHER|No intervention|No intervention
48178371|NCT06183983|DIAGNOSTIC_TEST|Extended MRI|The MRI-protocol before radiotherapy is extended with 20 minutes.
48178372|NCT01958242|OTHER|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
48178373|NCT00348868|BEHAVIORAL|enhanced behavioral motivation counseling|
48178374|NCT00348868|BEHAVIORAL|Motivational counseling|
48178375|NCT00348868|BEHAVIORAL|Standard counseling|
48178376|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D
48178377|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
48178378|NCT00433797|DIETARY_SUPPLEMENT|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
48178379|NCT05549947|DRUG|SHR1819|Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，
48178380|NCT05549947|DRUG|Placebo|Treatment group D：placebo
48517822|NCT03775486|DRUG|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
48711850|NCT02088593|BEHAVIORAL|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
48711851|NCT00539513|DRUG|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
48711852|NCT00539513|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
48020677|NCT05814341|DRUG|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
48020678|NCT00005787|BIOLOGICAL|epoetin alfa|
48378630|NCT01111968|BIOLOGICAL|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
48378631|NCT01111968|BIOLOGICAL|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
48020679|NCT00005787|BIOLOGICAL|filgrastim|
48020680|NCT00005787|BIOLOGICAL|recombinant flt3 ligand|
48020681|NCT00005787|BIOLOGICAL|recombinant interleukin-3|
48020682|NCT00005787|BIOLOGICAL|sargramostim|
48020683|NCT00005787|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
48020684|NCT03991195|DIETARY_SUPPLEMENT|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
48178381|NCT00377988|DRUG|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
48178382|NCT00377988|DRUG|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
48178383|NCT04969809|DIAGNOSTIC_TEST|Ultrasound of the jugular veins|Ultrasound of the jugular veins to assess the thickness of the carotid intima media
48020685|NCT03991195|DIETARY_SUPPLEMENT|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
48020686|NCT02760394|DEVICE|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
48178384|NCT04969809|DIETARY_SUPPLEMENT|addition of phenylalanine-free protein substitutes|addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
48178385|NCT00745771|DRUG|Diractin|
48178386|NCT00745771|DRUG|Diractin|
48378632|NCT01111968|BIOLOGICAL|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
48711853|NCT03112967|OTHER|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
48711854|NCT03112967|OTHER|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
48711855|NCT05753930|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
48020687|NCT01125423|DRUG|Milnacipran|Subject with Fibromyalgia will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
48020688|NCT01125423|PROCEDURE|Skin biopsy|Subjects with Fibromyalgia will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
48020689|NCT01125423|PROCEDURE|Skin Biopsy|Control Subjects will have 3 mm skin biopsies obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
48020690|NCT04275648|DIAGNOSTIC_TEST|AsthmaTuner exercise field test|AsthmaTuner consist of a a bluetooth spirometer and smartphone app with protocol for measuring lung function (FEV1) and perform 8 min exercise challenge test and a healthcare web interface.
48178387|NCT00302523|DRUG|Tacrolimus|FK506,0.1mg/kg/d
48178388|NCT03471377|OTHER|standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.
48378633|NCT01111968|BIOLOGICAL|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
48378634|NCT01111968|BIOLOGICAL|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
48378635|NCT01111968|BIOLOGICAL|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
48517823|NCT03775486|DRUG|Placebo for Olaparib|Matching tablet
48517824|NCT03775486|DRUG|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
48517825|NCT03775486|DRUG|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
48517826|NCT03775486|DRUG|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
48020691|NCT05378867|BIOLOGICAL|TRS003|"* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle followed by switch to:~* TRS003, 5 mg/kg IV every 14 days with mFOLFOX6 until end of treatment due to PD, intolerability or other cause for stopping treatment. Intensive PK sampling will be performed after 7 cycles of this TRS003 switch period"
48711856|NCT06356012|DRUG|Imiquimod|Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
48711857|NCT06356012|PROCEDURE|Loop Electrosurgical Excision Procedure|Active comparator group will be treated with LEEP.
48020692|NCT05378867|BIOLOGICAL|China-approved Bevacizumab|• Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle
48020693|NCT05378867|DRUG|mFOLFOX6|"The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus."
48020694|NCT06326372|PROCEDURE|control|Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation
48020695|NCT06326372|PROCEDURE|ORi+SpO2|"Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg"
48020696|NCT02158039|DRUG|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
48020697|NCT02158039|DRUG|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
48020698|NCT04894474|DRUG|BI 767551 intravenous|BI 767551 intravenous
48020699|NCT04894474|DRUG|BI 767551 inhalation|BI 767551 inhalation
48020700|NCT04894474|DRUG|Placebo intravenous|Placebo intravenous
48020701|NCT04894474|DRUG|Placebo inhalation|Placebo inhalation
48178389|NCT03471377|OTHER|assigned a planned case duration value from predictive model|"Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model."
48178390|NCT05421156|PROCEDURE|Subtotal Laparoscopic Hysterectomy|Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.
48178391|NCT05421156|PROCEDURE|Total Laparoscopic Hysterectomy|Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
48178392|NCT03446638|DRUG|FDA-approved drug or combination of drugs|Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
48178393|NCT03446638|DRUG|FLAG induction|Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count \> 500/ microliter for 3 days.
48178394|NCT03446638|DRUG|7 + 3 induction|Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
48178395|NCT03446638|DRUG|Low-dose cytarabine|Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
48711858|NCT05873179|OTHER|role-playing for learning the clinical interview|role-playing for learning the clinical interview
48711859|NCT06061289|DIETARY_SUPPLEMENT|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
48020702|NCT01611259|DRUG|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
48020703|NCT04250324|BIOLOGICAL|BZ019|A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
48020704|NCT06573749|DIETARY_SUPPLEMENT|Bioactive whey protein concentrate|Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.
48020705|NCT06573749|DIETARY_SUPPLEMENT|Pea-based protein supplement|Every day for 12 weeks, participants will mix 1 pre-packaged sachet with \~350ml of water and consume the resultant drink alongside their breakfast.
48178396|NCT03446638|OTHER|Supportive care alone|Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
48378636|NCT01111968|BIOLOGICAL|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
48378637|NCT01111968|BIOLOGICAL|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
48378638|NCT01111968|BIOLOGICAL|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
48020706|NCT00176098|PROCEDURE|Hypnoanalgesia; Hypnotic shielding|
48020707|NCT00003326|DRUG|paclitaxel|
48378639|NCT01111968|BIOLOGICAL|placebo group 14|All elements of the vaccine but antigen and adjuvant
48378640|NCT05396326|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
48020708|NCT00753324|DRUG|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
48178397|NCT03446638|DEVICE|Computational biology simulations software|Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
48711860|NCT04202146|BEHAVIORAL|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
48711861|NCT02868450|BIOLOGICAL|Blood Sample|
48711862|NCT00763906|DEVICE|norepinephrine infused at the clinician's discretion|
48178398|NCT05234775|DRUG|lerodalcibep|300 mg of each drug given SC as single dose
48378641|NCT05396326|DRUG|Teysuno|Oral S-1, 40mg-60mg bid, day 1-14 for four 21-day cycles.
48378642|NCT05396326|PROCEDURE|Transarterial arterial chemoinfusion and embolism (TACiE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1, if applicable.
48378643|NCT00750373|PROCEDURE|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
48378644|NCT02163525|PROCEDURE|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
48378645|NCT02163525|PROCEDURE|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
48378646|NCT02163525|PROCEDURE|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
48711863|NCT00763906|DEVICE|norepinephrine infused under computerized fuzzy logic control|
48378647|NCT01896518|DRUG|Nicotine polacrilex|
48378648|NCT01896518|DRUG|Tobacco lozenge|
48378649|NCT04999904|OTHER|Uneven Treadmill Intervention|Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.
48378650|NCT04999904|OTHER|Standard of Care Physical Therapy|Standard of Care Physical Therapy
48378651|NCT05487859|DRUG|Acarbose Tablets|Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
48378652|NCT00219024|DRUG|aliskiren|
48378653|NCT04510558|DEVICE|Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson \& Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
48517827|NCT03775486|DRUG|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
48517828|NCT03775486|DRUG|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
48517829|NCT03775486|DRUG|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
48711864|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
48711865|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
48711866|NCT01283906|DEVICE|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
48711867|NCT01283906|DEVICE|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
48711868|NCT05596487|OTHER|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
48711869|NCT02273635|DRUG|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
48378654|NCT04510558|PROCEDURE|Stoma closure without mesh|"* Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing"
48378655|NCT01161212|OTHER|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
48378656|NCT01161212|OTHER|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
48711870|NCT02273635|DRUG|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
48711871|NCT05857033|OTHER|Buccal and direct palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection
48020709|NCT05632952|DEVICE|Intraperitoneal Onlay Mesh positioning Plus|"Intraperitoneal Onlay Mesh (IPOM) Plus with closure of the hernia defect will be performed according to the common recommendations.~The closure of the wall defect will be decided according to the surgeon evaluations: hernia size and choice of technique will be recorded in the database. The mesh will have an overlap of at least 5 cm on all sides of the defect. Dimension of the mesh will be sized to overlap the hernia orifice by at least five centimetres and placed in the intraperitoneal position. Using non-articulating laparoscopic fixation devices, 5.1-mm non-absorbable or absorbable tacks will be then positioned around the circumference of the prosthesis in a 3-row manner or 2-row manner based on the intraoperative findings, the patient's specific situation and the operating surgeon's decision."
48178399|NCT03298529|OTHER|glucose solution|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
48711872|NCT05857033|OTHER|Buccal and indirect palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection
48378657|NCT01587352|OTHER|Laboratory Biomarker Analysis|Correlative studies
48378658|NCT01587352|DRUG|Vorinostat|Given PO
48711873|NCT05857033|OTHER|Buccal and direct palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection
48378659|NCT02009111|BEHAVIORAL|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
48378660|NCT04589793|BEHAVIORAL|Life Style|Life Style intervention including physical activity, diet, sleep and stress
48517830|NCT05561725|DRUG|Dexamethasone postoperative|"Patients randomized to the dexamethasone cohort will be administered 8 mg of dexamethasone with 3 additional (8mg doses) administered at 8-hour intervals following surgery for a total of 4 doses.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
48711874|NCT05857033|OTHER|Buccal and indirect palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
48711875|NCT03998748|OTHER|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
48711876|NCT01391598|DRUG|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
48711877|NCT01391598|DRUG|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
48711878|NCT03614416|DEVICE|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
48711879|NCT03614416|DEVICE|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
48517831|NCT05561725|DRUG|Standard of Care|"Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014."
48711880|NCT03614416|PROCEDURE|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
48711881|NCT04789161|PROCEDURE|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
48711882|NCT04789161|PROCEDURE|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
48711883|NCT01745523|PROCEDURE|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
48711884|NCT01745523|PROCEDURE|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
48178400|NCT03298529|OTHER|Traditional egg pasta|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
48178401|NCT03298529|OTHER|Pasta with eight egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
48378661|NCT00744068|BEHAVIORAL|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
48517832|NCT04218734|DRUG|DBPR108|DBPR108: 100 mg, once daily for 24 weeks.
48517833|NCT04218734|DRUG|metformin hydrochloride|metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.
48517834|NCT04218734|DRUG|placepo|placebo:100 mg, once daily for 24 weeks.
48711885|NCT06102356|OTHER|Questionnaire|DLQI TSQM v.II PHQ-9 DS14
48711886|NCT01587638|DRUG|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
48711887|NCT01587638|DRUG|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
48711888|NCT01471418|DRUG|PET/CT with 18-FDG|FDG uptake
48711889|NCT02601092|PROCEDURE|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
48711890|NCT02601092|PROCEDURE|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
48020710|NCT02112786|DEVICE|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
48020711|NCT06269614|DIETARY_SUPPLEMENT|Probiotic|Consumption of probiotic with parent- as tolerated for 4 weeks.
48020712|NCT06098755|BEHAVIORAL|Transcendence Research: Holistic Education|With informed consent the participant act as a partner to their health and acknowledges responsibility for self-help or self-care directed activities in a non-clinical setting. Transcendence in research involves actively exploring the best possible options or resources for a resolution or self-determination or hypotheses. To reinforce healthy activities, periodic forecast consist of one or more of the following variables: lectures, group discussions, team building exercises, faith-based initiatives, respite, support group, supportive care, natural food remedies, critical thinking questioning and tests.
48711891|NCT04225442|OTHER|Fatty meal to challenge the physiological chronobiome in healthy young and old|The intervention consists of a fatty meal
48711892|NCT02116114|OTHER|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
48020713|NCT00249145|DRUG|risperidone|
48020714|NCT04468048|OTHER|"Music: Nada Himalaya performed by S. G. Sachchidananda"|"Music: Nada Himalaya performed by S. G. Sachchidananda"
48020715|NCT03808285|OTHER|mandibular osteomylitis|
48020716|NCT06572618|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48020717|NCT06572618|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48020718|NCT06572618|DRUG|Nemtabrutinib|Given PO
48020719|NCT06572618|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT scan
48020720|NCT06572618|BIOLOGICAL|Rituximab|Given IV
48020721|NCT05080582|BEHAVIORAL|Mother-Scented Simulated Hand|Preterm neonates wrapped with a warm Mother-Scented Simulated Hand during the invasive procedures
48020722|NCT05080582|BEHAVIORAL|NICU Standard Care|Neonates were placed in a side-lying position, while their extremities were flexed close to the body and wrapped with rolled sheets or towels to simulate the intrauterine posture.
48020723|NCT03516916|OTHER|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
48517835|NCT05845983|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
48020724|NCT02329405|DRUG|Rifampicin|
48020725|NCT02329405|DRUG|Placebo|
48020726|NCT04856163|BEHAVIORAL|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
48020727|NCT03529630|OTHER|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
48020728|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
48020729|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
48020730|NCT01694706|DRUG|omeprazole|medium dose of omeprazole
48020731|NCT01694706|DRUG|faldaprevir|medium dose of faldaprevir
48020732|NCT06161363|OTHER|The Morisky Medication Adherence Scale|The Morisky Medication Adherence Scale will be completed bu the patients
48178402|NCT03298529|OTHER|Pasta with four eggs/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
48020733|NCT04489095|DIAGNOSTIC_TEST|Electrophysiology Study|After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
48020734|NCT03827798|DRUG|CFZ533|s.c.
48020735|NCT03827798|DRUG|Placebo to CFZ533|s.c.
48020736|NCT03827798|DRUG|LYS006|p.o.
48020737|NCT03827798|DRUG|Placebo to LYS006|p.o.
48020738|NCT03827798|DRUG|MAS825|s.c.
48020739|NCT03827798|DRUG|Placebo to MAS825|s.c.
48020740|NCT03827798|DRUG|LOU064 25mg|p.o.
48020741|NCT03827798|DRUG|LOU064 100mg|p.o.
48020742|NCT03827798|DRUG|Placebo to LOU064|p.o.
48020743|NCT03827798|DRUG|VAY736|s.c.
48020744|NCT03827798|DRUG|Placebo to VAY736|s.c.
48378662|NCT02980484|PROCEDURE|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
48378663|NCT02980484|PROCEDURE|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
48378664|NCT01970423|DEVICE|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
48378665|NCT01970423|DEVICE|conventional right ventricular stimulation|
48020745|NCT01151241|PROCEDURE|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
48378666|NCT00373282|DRUG|Triamcinolone acetonide|
48711893|NCT03165123|DRUG|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
48378667|NCT05669612|DIETARY_SUPPLEMENT|Dairy based protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
48378668|NCT05669612|DIETARY_SUPPLEMENT|Mixed protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
48378669|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 1|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
48378670|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 2|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
48378671|NCT05246631|DRUG|Dexamethasone injection|Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
48378672|NCT05246631|DRUG|Haloperidol Injection|Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
48378673|NCT01652040|DEVICE|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
48711894|NCT03165123|DRUG|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
48378674|NCT01652040|DRUG|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
48378675|NCT03264573|BIOLOGICAL|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
48378676|NCT03264573|DEVICE|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
48378677|NCT00359866|RADIATION|IMRT with tomotherapy|
48711895|NCT01442064|DRUG|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
48711896|NCT01332838|PROCEDURE|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
48711897|NCT01332838|DEVICE|compression stockings (Sigvaris )|Specialized monoleg compression
48711898|NCT04133896|DIAGNOSTIC_TEST|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
48378678|NCT05935449|DEVICE|Formaderm Lidocaine|Dermal filler injection to facial areas
48378679|NCT05935449|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
48378680|NCT02551874|DRUG|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
48378681|NCT02551874|DRUG|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
48378682|NCT02551874|DRUG|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
48378683|NCT02551874|DRUG|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
48378684|NCT00998166|DRUG|Pemetrexed|"1. Pre-hydration for 1-1/2 hours at 250 ml/hour~2. Pemetrexed 500 mg/m2 IV over 10 minutes~3. Return to hydration for 30 minutes at 250 ml/hour"
48378685|NCT00998166|DRUG|Cisplatin|4. Cisplatin 75mg/m2 IV over 60-120 minutes
48378686|NCT00998166|DRUG|Bevacizumab|5. Bevacizumab 15mg/kg IV over 90 minutes
48378687|NCT00186875|DRUG|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
48378688|NCT00186875|DRUG|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
48378689|NCT00186875|DRUG|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
48378690|NCT00186875|DRUG|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
48378691|NCT00186875|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
48378692|NCT00186875|PROCEDURE|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
48711899|NCT05594069|OTHER|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
48711900|NCT05594069|OTHER|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
48711901|NCT03076086|OTHER|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
48178403|NCT03298529|OTHER|Hyperproteic pasta (with added gluten and albumin)|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
48178404|NCT03298529|OTHER|Pasta with only four egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
48178405|NCT00677768|OTHER|No intervention|Sample collection
48178406|NCT00997711|DEVICE|Cypher|Sirolimus-eluting stents
48178407|NCT04673045|DEVICE|Active Electrical stimulation|The intensity of stimulation will be set within the subject's tolerance level. The amplitude was adjusted to produce muscle contraction without affecting the patient's comfort. The cathode electrode will be placed over the common peroneal nerve as it passes over the head of the fibula and the anode will be placed on mid-muscle belly on one third of the line between fibular head and medial malleolus on paretic limb.
48178408|NCT04673045|DEVICE|Sham Electrical Stimulation|For sham group, the current intensity will gradually decreased after few seconds to 0. Therefore, the participant will experience a passage of current on the muscle at the beginning but received no current for the rest of the stimulation period. The participants will be informed that the stimulation below the sensory level.
48178409|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (apical position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
48378693|NCT00186875|PROCEDURE|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
48711902|NCT03790358|DRUG|Lysergic Acid Diethylamide|Drug will be administered in solution form.
48711903|NCT05936502|OTHER|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
48711904|NCT01165320|DRUG|Caspofungin|
48711905|NCT01657136|DRUG|Ivabradine|comparison of different drugs
48711906|NCT01657136|DRUG|Beta blocker|comparison of different drugs
48711907|NCT04982497|BEHAVIORAL|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
48711908|NCT04982497|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
48711909|NCT03395301|DEVICE|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
48711910|NCT03760159|DEVICE|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
48711911|NCT02485652|DRUG|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
48711912|NCT04477629|DRUG|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
48178410|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (crestal position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
48178411|NCT02486419|OTHER|Outdoor weather|Seasonal changes in temperature
48178412|NCT02934945|DRUG|budesonide 160μg/formoterol 4.5μg|SMART regimen
48378694|NCT02784028|OTHER|SGM-101|Administration of SGM-101 prior surgery
48378695|NCT06496984|OTHER|Nutritional intervention|Diet changes with different dietary therapies, such as oral nutritional supports (ONS), extra nutritional cares, diet changes without supplements and artificial nutrition.
48378696|NCT00548340|DRUG|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
48517836|NCT05845983|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
48517837|NCT00002422|DRUG|HE2000|
48020746|NCT01151241|OTHER|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
48378697|NCT00548340|DRUG|Placebo|Placebo capsules, PO daily for five weeks
48378698|NCT00548340|DRUG|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
48378699|NCT06311981|RADIATION|carbon ion radiotherapy|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
48711913|NCT04477629|DRUG|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
48711914|NCT04477629|DRUG|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
48711915|NCT04477629|DRUG|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
48711916|NCT04551001|PROCEDURE|Cold forcep polypectomy|Removal of appropriate polyps using cold forceps until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
48378700|NCT06311981|OTHER|targeted therapy|targeted therapy
48711917|NCT04551001|PROCEDURE|Cold snare polypectomy|Removal of appropriate polyps using cold snare until no polyp visible under white light. Two additional biopsies performed at margins of polypectomy site.
48711918|NCT00722202|DRUG|ERB-257|
48711919|NCT00722202|OTHER|placebo|
48711920|NCT04094649|DEVICE|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
48711921|NCT05079750|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
48711922|NCT00139763|PROCEDURE|Educational Materials|
48711923|NCT05006209|OTHER|One visit root canal treatment|
48378701|NCT06311981|OTHER|single regimen chemotherapy in sequence with radiotherapy|single regimen chemotherapy in sequence with radiotherapy
48711924|NCT05006209|OTHER|Two visit root canal treatment|
48711925|NCT00262678|DRUG|EN3267|
48711926|NCT02081638|DRUG|Aspirin|Daily Asprin daily
48378702|NCT01310725|PROCEDURE|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
48711927|NCT02081638|DRUG|Atorvastatin|Daily Atorvastatin Daily
48711928|NCT03668054|DRUG|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
48020747|NCT01151241|OTHER|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
48020748|NCT02294292|DRUG|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
48020749|NCT02294292|DRUG|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
48020750|NCT02294292|PROCEDURE|Endoscopic Variceal Ligation|
48711929|NCT00868218|BIOLOGICAL|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
48711930|NCT01022515|OTHER|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
48378703|NCT04469712|PROCEDURE|SASI Bipartition|SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
48378704|NCT04469712|PROCEDURE|Gastric bypass|A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
48711931|NCT01022515|OTHER|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
48711932|NCT03683654|OTHER|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
48711933|NCT02526823|DRUG|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
48178413|NCT05820113|DEVICE|Deep learning based reconstruction of T2-TSE sequence|A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
48178414|NCT04114097|DRUG|Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Explore the systemic effects of Betnovate
48178415|NCT04114097|DRUG|Protopic, tacrolimus ointment 0.1%|Compare the systemic effects of Betnovate to Protopic
48178416|NCT04088929|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
48178417|NCT03418493|DRUG|LY3316531 - IV|Administered IV.
48178418|NCT03418493|DRUG|LY3316531 - SC|Administered SC.
48178419|NCT03418493|DRUG|Placebo - IV|Administered IV.
48178420|NCT04052945|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4) within first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6 )."
48178421|NCT04052945|PROCEDURE|sham acupuncture|"For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4) with first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6)."
48178422|NCT00702598|BEHAVIORAL|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
48711934|NCT02526823|DRUG|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
48178423|NCT00702598|BEHAVIORAL|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
48178424|NCT03853252|OTHER|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
48178425|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|20 μg
48378705|NCT04054934|BEHAVIORAL|Reversed Circadian Rhythm|Revered day/ night sleep cycle
48517838|NCT03657186|DIETARY_SUPPLEMENT|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
48517839|NCT03657186|OTHER|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
48178426|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|100 μg
48178427|NCT03547245|BIOLOGICAL|DPBS Sucrose|Placebo
48178428|NCT04363619|DIAGNOSTIC_TEST|OCT and OCTA|Fundoscopy, OCT and OCTA will be performed 4 times in patients
48178429|NCT03171532|PROCEDURE|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
48178430|NCT01003145|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
48178431|NCT03981497|PROCEDURE|Microwave ablation (MWA)|Thermal ablation
48178432|NCT00133055|BEHAVIORAL|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
48178433|NCT00133055|BEHAVIORAL|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
48378706|NCT04054934|BEHAVIORAL|Normal Circadian Rhythm|Normal day/ night sleep cycle
48378707|NCT04233606|OTHER|Hypertonic Saline|Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
48378708|NCT04233606|OTHER|Normal Saline|Infusion of normal saline to inhibit the secretion of the hormone vasopressin
48378709|NCT05978375|PROCEDURE|Posterior intra-articular distraction and fusion|Using reduction using posterior intra-articular distraction and fusion technique.
48178434|NCT06348264|DRUG|Rezvilutamide|Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
48711935|NCT02956304|OTHER|PMv stimulation (iTBS)|PMv stimulation (iTBS)
48711936|NCT02956304|OTHER|PMv inhibition (cTBS)|PMv inhibition (cTBS)
48711937|NCT02956304|OTHER|Control (SHAM)|Control (SHAM)
48178435|NCT06348264|DRUG|Leuprolide Acetate|The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
48178436|NCT02803671|DEVICE|TFU-NIRS|
48178437|NCT02803671|DEVICE|NIRS|
48178438|NCT02803671|DEVICE|EEG|
48711938|NCT03590132|BEHAVIORAL|Strong African American Families Program|SAAF is a 7 session family skills training program
48711939|NCT03590132|BEHAVIORAL|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
48711940|NCT03372551|DEVICE|somofilcon A 1 day test lens|Contact lens
48711941|NCT03372551|DEVICE|somofilcon A 1 day control lens|Contact lens
48711942|NCT06218381|OTHER|Very Brief Exposure to Combat Images|In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
48711943|NCT04599868|DRUG|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
48711944|NCT00000729|DRUG|Foscarnet sodium|
48711945|NCT06233864|DRUG|Disitamab Vedotin|Disitamab Vedotin
48711946|NCT06233864|DRUG|Gemcitabine|Gemcitabine
48711947|NCT01244789|DRUG|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
48711948|NCT01244789|OTHER|observation|active observation
48711949|NCT04415879|DEVICE|N-95 Respirator|N-95 mask will be worn as personal protective equipment during a graded exercise test
48711950|NCT04415879|DEVICE|Cloth Face Mask|A cloth mask will be worn as personal protective equipment during a graded exercise test
48711951|NCT04415879|DIAGNOSTIC_TEST|Graded exercise test|No personal protective equipment during a graded exercise test
48711952|NCT00058149|DRUG|gemcitabine hydrochloride|
48711953|NCT00058149|DRUG|oxaliplatin|
48711954|NCT01804712|DRUG|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
48711955|NCT02350387|PROCEDURE|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
48178439|NCT05327101|OTHER|Patient Preference Survey|Patient preference survey on implantable cardiac pacemaker systems
48178440|NCT01179412|DRUG|2% povidone-iodine|apply 4 times a day for one week
48711956|NCT02350387|PROCEDURE|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
48711957|NCT02744612|DRUG|Brentuximab Vedotin|Given IV
48711958|NCT02744612|DRUG|Ibrutinib|Given PO
48711959|NCT04699812|DEVICE|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
48711960|NCT03990103|DRUG|S1|80-120 mg/day, PO, D1-14, every 21 days
48711961|NCT03990103|DRUG|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
48711962|NCT03990103|DRUG|Bevacizumab|200 mg, IP, D1, every 21 days
48711963|NCT03990103|DRUG|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
48711964|NCT01666119|DRUG|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
48711965|NCT00303446|DRUG|Dutasteride|Dutasteride 0.5 mg/day
48711966|NCT00303446|DRUG|Placebo|Matched placebo
48711967|NCT05244460|DRUG|Droperidol Injectable Product|Treatment
48711968|NCT05244460|DRUG|Diphenhydramine|Treatment
48020751|NCT01110291|DRUG|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
48020752|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
48020753|NCT03378596|DIETARY_SUPPLEMENT|L-arginine|L-arginine - sachet dissolved in water
48020754|NCT03378596|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline - sachet dissolved in water
48020755|NCT03378596|DIETARY_SUPPLEMENT|Placebo|Placebo (corn starch) - sachet dissolved in water
48178441|NCT01179412|DRUG|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
48178442|NCT06546358|DRUG|Trazodone|Participants will be randomized to receive either quetiapine or trazodone.
48711969|NCT03001700|DEVICE|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
48711970|NCT06219733|DRUG|Vactosertib|200 mg PO BID 5 days on / 2 days off
48711971|NCT06219733|DRUG|Imatinib|Imatinib 400 mg PO QD daily
48178443|NCT06546358|DRUG|Quetiapine|Participants will be randomized to receive either quetiapine or trazodone.
48711972|NCT01113489|DRUG|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
48711973|NCT01113489|DRUG|placebo|1 ml b.i.d.
48178444|NCT03297476|DIAGNOSTIC_TEST|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
48178445|NCT01605656|BEHAVIORAL|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
48178446|NCT01605656|BEHAVIORAL|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
48178447|NCT01605656|BEHAVIORAL|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
48711974|NCT03184610|DEVICE|OCT-scanning|All participants will be scanned with a OCT-device
48711975|NCT04206553|DRUG|dupilumab|Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
48178448|NCT06171022|OTHER|Cherry seed pillow|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of heated cherry seed pillow will be applied to the participant's back area.
48711976|NCT04206553|DRUG|Matching Placebo|Matching dupilumab without active substance
48711977|NCT04206553|DRUG|Oral corticosteroids (OCS)|Prednisone or prednisolone per standard of care to obtain control of disease activity.
48020756|NCT06341244|DEVICE|Air Stacking Technique|To perform the air stacking technique, an air manual breathing unit (AMBU) was used, attached to a unidirectional valve and nasal/oral mask. For each AMBU manual compression (three in the total), the patient was instructed to breathe in deeply and hold the air inside the lungs.
48020757|NCT05269524|BEHAVIORAL|Internet-delivered tailored cognitive behavior therapy|Therapists-supported tailored 10-week treatment for depression in older adults.
48020758|NCT00452504|DRUG|SRA-444|
48020759|NCT01253616|DEVICE|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
48711978|NCT01504633|DIETARY_SUPPLEMENT|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
48711979|NCT03359057|DRUG|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
48378710|NCT05978375|PROCEDURE|Anterior transoral release and posterior cantilever reduction and fusion|Using anterior transoral release and posterior cantilever reduction and fusion technique.
48378711|NCT05978375|PROCEDURE|TARP|Using TARP technique.
48020760|NCT01858194|DEVICE|Renal sympathetic denervation|"* The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~* After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
48020761|NCT01858194|DEVICE|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
48020762|NCT04777461|OTHER|Survey on patient's perspectives on the development of an structured education programme for PCOS|The outcome of this survey will help with developing curriculum for the structured education programme.
48020763|NCT04777461|OTHER|Pre-pilot questionnaire|The questionnaire is aimed to capture the knowledge and expectations of the participants from taking part in the educational sessions.
48020764|NCT04777461|OTHER|Piloting the structured education programme for PCOS|Piloting the education program through 2 educational group sessions
48020765|NCT04777461|OTHER|Post-pilot questionnaire|The questionnaire aimed to capture participant's satisfactions and knowledge gained by taking part in the pilot study
48178449|NCT06171022|OTHER|Control|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of hotpack will be applied to the participant's back area.
48178450|NCT04253119|DRUG|Antiretroviral/Anti HIV|NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
48178451|NCT00157898|DRUG|MK0826; ertapenem sodium|
48178452|NCT00157898|DRUG|Comparator: ceftriaxone + metronidazole|
48711980|NCT03359057|DRUG|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
48711981|NCT04332471|PROCEDURE|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
48711982|NCT04332471|PROCEDURE|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
48711983|NCT04332471|DEVICE|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
48378712|NCT04272411|DEVICE|Sham SCS stimulation|Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
48711984|NCT04332471|OTHER|Home therapy|Stretching and ice massage
48378713|NCT04272411|DEVICE|Tonic SCS stimulation|Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
48378714|NCT04272411|DEVICE|Burst SCS Stimulation|Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
48378715|NCT05874544|DRUG|Vonoprazan|Proton pump inhibitor
48378716|NCT05874544|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
48378717|NCT05874544|DRUG|Tetracycline|Antibiotics for H. pylori eradication
48378718|NCT05874544|DRUG|Metronidazole|Antibiotics for H. pylori eradication
48020766|NCT04777461|OTHER|cognitive outcomes outcome evaluation form|This aimed to capture skills developed, knowledge gained and changes in participants behaviour and perceptions by taking part in the pilot study.
48020767|NCT01318564|DRUG|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
48178453|NCT01339624|DRUG|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
48378719|NCT05874544|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
48378720|NCT05874544|DRUG|Rifabutin|Antibiotics for H. pylori eradication
48378721|NCT01826201|DRUG|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
48378722|NCT01826201|DRUG|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
48378723|NCT02181075|DRUG|ThermoDox® (LTLD)|ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
48378724|NCT02181075|DEVICE|Focused Ultrasound of Target Liver Tumour|Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
48178454|NCT01339624|DRUG|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
48178455|NCT03032107|DRUG|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
48178456|NCT03032107|DRUG|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
48178457|NCT03004586|DEVICE|25-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
48178458|NCT03004586|DEVICE|22-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
48378725|NCT02181075|DIAGNOSTIC_TEST|Pre-LTLD Biopsy of Target Liver Tumour|
48378726|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD Biopsy of Target Liver Tumour|
48711985|NCT04831528|DRUG|Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others|After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
48711986|NCT05533463|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
48711987|NCT01007123|DRUG|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
48711988|NCT04976218|BIOLOGICAL|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
48711989|NCT00070681|PROCEDURE|Polysomnography|
48711990|NCT04086797|DIETARY_SUPPLEMENT|IQP-AE-103|1980 mg
48711991|NCT04086797|DIETARY_SUPPLEMENT|Placebo|Placebo
48711992|NCT00145691|DRUG|Oxcarbazepine|
48711993|NCT06426368|DIAGNOSTIC_TEST|ST2|ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
48711994|NCT04871802|DIETARY_SUPPLEMENT|Taxifolin Aqua|Dietary supplement
48711995|NCT00205543|PROCEDURE|uvulopalatopharyngoplasty with or without sutures|standard UPPP
48711996|NCT00450671|PROCEDURE|Collagen Plug Placement|
48711997|NCT00450671|PROCEDURE|Seton placement|
48711998|NCT01816906|DEVICE|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
48711999|NCT01816906|DEVICE|Footwear: MCP|One group of patients will receive footwear with MCP insoles
48712000|NCT03383783|DRUG|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
48178459|NCT03004586|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
48178460|NCT06201637|OTHER|Performance Test|Performance Test
48178461|NCT02080546|PROCEDURE|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
48178462|NCT02080546|PROCEDURE|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
48378727|NCT02181075|DIAGNOSTIC_TEST|Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour|
48712001|NCT03383783|DRUG|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
48712002|NCT03383783|DRUG|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
48712003|NCT03383783|DRUG|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
48712004|NCT01703117|DRUG|Riluzole|20-22 subjects between the ages of 60-85 will receive study drug.
48712005|NCT01703117|DRUG|Placebo|20-22 subjects between the ages of 60-85 will receive placebo
48712006|NCT04412733|DEVICE|Therapeutic Pulsed Ultrasound|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
48712007|NCT04412733|DEVICE|Sham Ultrasound|Control group received sham ultrasound treatment
48712008|NCT04900610|DIETARY_SUPPLEMENT|MenaQ7 ®, Nattopharma, ASA, Hovik, Norway|daily per os supplementation of 1mg MK-7
48712009|NCT04224272|DRUG|ZW25 (Zanidatamab)|Administered intravenously
48178463|NCT02080546|DEVICE|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
48178464|NCT04715685|BEHAVIORAL|40 minute session|The 40 minute session will include all of the content contained in the 20 minute session, but will include a greater explanation of each of the mind and body skills, followed by in vivo practice of each skill with the nurse. Sessions will also include review of home practice for each group.
48178465|NCT04715685|BEHAVIORAL|20 minute session|For participants randomized to the 20 minute session, content will include pain education, followed by brief explanations of each of the mind and body skills, in vivo diaphragmatic breathing practice and demonstration of use of biofeedback card. Sessions will also include review of home practice for each group.
48178466|NCT04715685|BEHAVIORAL|home practice e-health|Participants will be provided and instructed on access to a migraine-specific interactive web portal, Migraine e-Health. This web-based tool actively guides participants in practicing evidence-based mind and body skills. Use of the Migraine -e-Health application for the high dose capitalizes on teaching participants mind and body skills while increasing accessibility due to implementation on mobile devices.
48178467|NCT04715685|BEHAVIORAL|home practice handout|Participants will be given a handout of commercially available free apps relevant to the mind body skills introduced.
48178468|NCT04715685|BEHAVIORAL|phone call|The dose of phone call will occur about 4 weeks following the face-to-face mind and body introduction session and will last approximately 5-10 minutes. The phone call will be used to promote adherence to home-practice and answer questions related to skill use/home practice completion.
48178469|NCT00631345|BEHAVIORAL|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
48178470|NCT00631345|OTHER|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
48378728|NCT02181075|DEVICE|Thermometry of Target Tumour|A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
48378729|NCT06567600|DRUG|Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody|"Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met."
48020768|NCT01318564|BEHAVIORAL|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
48020769|NCT03943368|DEVICE|Ceevra Reveal|3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
48378730|NCT05199714|DRUG|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
48712010|NCT04224272|DRUG|Palbociclib|Administered orally
48712011|NCT04224272|DRUG|Fulvestrant|Administered as an intramuscular injection
48020770|NCT00781326|DRUG|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
48020771|NCT00781326|DRUG|Placebo|Placebo will be given in doses matching those of nimodipine.
48020772|NCT02762591|DRUG|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
48020773|NCT00215293|DEVICE|Cervical I/F Cage|
48020774|NCT00215293|DEVICE|Autograft or allograft with a plate, or autograft alone.|
48712012|NCT04421872|OTHER|receiving general anesthesia|patients receiving surgery under general anesthesia
48712013|NCT06367907|OTHER|schema therapy|In this study, we aim to investigate the mode of action of the core therapeutic techniques implemented in schema therapy (ST), a psychotherapy that particularly addresses deficits of emotion regulation and of social interaction in personality disorders.
48712014|NCT05950061|DRUG|Sertraline|Sertraline (200 mg/day) capsule
48712015|NCT05950061|DRUG|Escitalopram|Escitalopram (10 mg/day) capsule
48712016|NCT01977443|DRUG|APD-209 Eye drops|
48712017|NCT01977443|DRUG|APD-209 Placebo Eye drops|
48712018|NCT02014480|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
48712019|NCT02014480|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
48712020|NCT02014480|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
48712021|NCT05785260|BEHAVIORAL|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
48178471|NCT00631345|BEHAVIORAL|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
48178472|NCT00631345|BEHAVIORAL|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
48178473|NCT04674254|DRUG|Bevacizumab Injection|Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.
48712022|NCT00600041|DRUG|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
48712023|NCT00600041|DRUG|Placebo|Identical infusion manner like experimental arm
48712024|NCT04126265|DEVICE|Artificial intelligence assisted colonoscopy|The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
48178474|NCT04674254|PROCEDURE|Targeted retinal photocoagulation|Targeted retinal photocoagulation will be administered to nonperfused areas detected on fundus fluorescein angiography at baseline and repeated every 3 months as needed for 12 months.
48178475|NCT04674254|PROCEDURE|Standard pan-retinal photocoagulation|Standard pan-retinal photocoagulation will be applied to perfused and nonperfused areas of the retinal periphery at baseline and every 3 months as needed for 12 months.
48178476|NCT00561717|DRUG|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
48178477|NCT00561717|DRUG|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
48178478|NCT00561717|DRUG|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
48178479|NCT00561717|DRUG|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
48712025|NCT04348045|DRUG|Arm A - Olaparib|"300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued."
48712026|NCT04348045|DRUG|ARM B - durvalumab plus selumetinib|"Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily"
48378731|NCT05199714|DEVICE|Artificial Pancreas|Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.
48712027|NCT04348045|DRUG|ARM C FOLFIRI|FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
48712028|NCT04686760|DRUG|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
48712029|NCT06508710|DRUG|Ketamine|Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
48712030|NCT06508710|DRUG|Placebo|Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
48712031|NCT00146185|DRUG|ALGRX 3268|
48178480|NCT00179257|DRUG|sertraline (Zoloft)|
48178481|NCT01187745|OTHER|CT Scan followed by ultrasound|A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
48378732|NCT05199714|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
48378733|NCT05199714|DRUG|Aspart|Aspart insulin delivered in a basal-bolus manner.
48712032|NCT03918226|PROCEDURE|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
48712033|NCT00964340|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
48712034|NCT00964340|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
48712035|NCT05553977|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
48178482|NCT06307067|DIAGNOSTIC_TEST|Urine dipstick|Urine dipstick is a point of care test that can be performed on the urine in the public health center.
48178483|NCT01610960|DEVICE|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
48178484|NCT01610960|DEVICE|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
48178485|NCT06140394|OTHER|diode laser|low level diode therapy
48712036|NCT05553977|PROCEDURE|Colonoscopy|Colonoscopy will be performed to every patient included in the study
48020775|NCT01002599|DEVICE|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
48020776|NCT01002599|DEVICE|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
48020777|NCT03120650|OTHER|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
48020778|NCT03120650|OTHER|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
48712037|NCT03691350|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
48712038|NCT03691350|DRUG|Cigarette|Smoke usual brand
48712039|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC with nicotine
48712040|NCT03691350|OTHER|Electronic Cigarette|Smoke SREC without nictoine
48712041|NCT03691350|OTHER|Laboratory Biomarker Analysis|Correlative studies
48712042|NCT03691350|DRUG|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
48712043|NCT03691350|OTHER|Questionnaire Administration|Ancillary studies
48712044|NCT00662376|DIETARY_SUPPLEMENT|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
48712045|NCT04481802|DEVICE|RadiaAce gel|Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
48020779|NCT02341196|PROCEDURE|CEA|Patients in both groups received an intra-operative angiography
48178486|NCT06140394|OTHER|non surgical scaling|non surgical scaling using ultrasonic
48178487|NCT01270698|DRUG|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
48178488|NCT01006616|DRUG|Navarixin|Navarixin 10 mg and 30 mg capsules
48712046|NCT04481802|DEVICE|Biafine|Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
48712047|NCT04956094|DIAGNOSTIC_TEST|GGT/Uric Acid|Standard laboratory blood testing for GGT and uric acid levels.
48712048|NCT00919867|DRUG|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
48020780|NCT05549674|OTHER|The COPAIN study is observational. There is no intervention.|The COPAIN study is observational. There is no intervention.
48020781|NCT06204159|DEVICE|TACE Catheters|"End Hole and TriNav catheters are FDA approved. This study is comparing the two for chemotherapy delivery during the TACE procedure.~This study will randomize which catheter is used for the first TACE procedure and the other catheter will be used for the second TACE procedure"
48178489|NCT01006616|DRUG|Placebo|Placebo to navarixin capsules
48178490|NCT01006616|DRUG|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
48178491|NCT03201900|DRUG|E2007|Oral tablet
48178492|NCT03434028|DRUG|Early Vasopressors|"Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met."
48178493|NCT03434028|OTHER|Early Fluids|"Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted."
48178494|NCT01099579|DRUG|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
48378734|NCT05250739|OTHER|Strength training|Strength training was performed with resistance bands. The band was fastened to the unaffected ankle, while the participant was told to perform front and back pulls, as well as adduction and abduction movements with the affected ankle. They were told to control the ankle movement and to make it slow. Since the first day, they were told to perform the exercise pulling the band as if they wanted to make the resistance of 5 on a scale from 0 to 10.
48712049|NCT00919867|DRUG|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
48712050|NCT00919867|DRUG|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
48712051|NCT04619446|DEVICE|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
48712052|NCT04619446|DEVICE|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
48712053|NCT01449110|DIETARY_SUPPLEMENT|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
48712054|NCT01449110|DIETARY_SUPPLEMENT|Placebo in secondary prevention|"12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
48178495|NCT01099579|DRUG|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
48378735|NCT05250739|OTHER|Neuromuscular training|consisted in a multi-station training with 6 exercises, increasing the difficulty progressively as the participants controlled the execution. The exercises were all performed barefoot and with the injured foot. These were a combination of standing and jumping exercises involving the injured ankle. The participants did not start the next progression until they perform a complete circuit in the level before.
48378736|NCT02188927|OTHER|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
48378737|NCT02188927|BEHAVIORAL|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
48712055|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in primary prevention (PP)|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
48712056|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in SP|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
48020782|NCT00472914|DEVICE|portable surface electromyography|
48178496|NCT01099579|DRUG|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
48178497|NCT01099579|DRUG|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
48178498|NCT00435955|PROCEDURE|High dose chemotherapy with autologous transplantation|
48178499|NCT00435955|DRUG|Rituximab|
48178500|NCT05810805|OTHER|gas component of digestive tract|Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
48178501|NCT03875781|DRUG|Chemotherapy|"Arm A : Experimental~* Intervention Type : Drug~* Intervention Name : Modified FOLFIRINOX (experimental arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
48178502|NCT03875781|DRUG|Radiochemotherapy|"Arm B: Active comparator~* Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor."
48178503|NCT04344665|OTHER|Virtual Care and Remote Automated Monitoring|Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.
48178504|NCT05484232|PROCEDURE|Laparoscopic Cholecystectomy|Early laparoscopic cholecystectomy in patients with acute calcular cholecystitis
48178505|NCT03852108|OTHER|Comfort Care|Face, Hand and body care for 15 to 45 minutes
48178506|NCT04354168|BEHAVIORAL|mHealth Application|Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
48178507|NCT04622098|PROCEDURE|Endoscopic ultrasound|"this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~1. the tumor location,~2. layer of origin,~3. maximal diameter,~4. regularity of extraluminal border,~5. echopattern,~6. presence of cystic spaces or echogenic foci."
48178508|NCT01758744|DRUG|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
48178509|NCT01853189|OTHER|OMT + Usual Care|patients from this group received 6 sessions of OMT
48178510|NCT01853189|OTHER|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
48178511|NCT05779917|BIOLOGICAL|CAR-T cells|Transfer CAR-T cells into patients for anti-ancer therapy.
48178512|NCT01152476|DRUG|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
48178513|NCT01152476|DRUG|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
48178514|NCT04422093|DEVICE|OrthoKontrol|Fixing OrthoKontrol Sensor on multibracket appliance to measure cooperation
48178515|NCT04247269|OTHER|Enteral Tube Feeding|Enteral tube feeding
48517840|NCT05907239|DEVICE|Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 1.5cm in depth, frequency of 8Hz and intensity of 0.048mJ/mm² as long as it is tolerable to the patient (it can be reduced to a tolerable intensity of at least 0.018mJ/mm²) starting with a density of energy flow between 0.12 to 0.15 mJ/mm2, starting from an adaptation dose of 0.10 mJ/mm2 in the first 500 impulses. The non-stationary technique will be used, slowly moving the applicator. Shockwave therapy will be weekly, totaling five consecutive weeks.
48378738|NCT06363552|DRUG|SC0191|The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.
48378739|NCT06363552|DRUG|SC0191 + Bevacizumab|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle."
48178516|NCT00394589|DRUG|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
48178517|NCT00394589|DRUG|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
48178518|NCT00394589|DRUG|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
48020783|NCT02409485|BEHAVIORAL|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
48020784|NCT01675180|OTHER|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
48020785|NCT01675180|OTHER|Control|No intervention
48020786|NCT00113516|DRUG|carboplatin|AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
48378740|NCT06363552|DRUG|SC0191 + 5-FU/LV|"1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days."
48378741|NCT03917654|BIOLOGICAL|Pfs230D1M-EPA/AS01|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2X dilution of the high dose (160 (Micro)g/mL in 0.5 mL volume) in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by GSK
48378742|NCT03917654|BIOLOGICAL|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
48378743|NCT03917654|BIOLOGICAL|TYPHIM Vi (Salmonella typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
48020787|NCT00113516|DRUG|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
48020788|NCT00113516|DRUG|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
48020789|NCT06573892|DIETARY_SUPPLEMENT|Probiotic|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
48020790|NCT06573892|DIETARY_SUPPLEMENT|Placebo|Patients will receive the product twice a day, a single dose of the product is packaged in sachets. The product can be hired in the form of a powder or diluted with a small amount of water. The general course is 90 days.
48020791|NCT04959084|OTHER|Laser acupuncture therapy and pelvic floor training|The laser will be applied directly to the skin over acupuncture points and each point receive a shoot of 65 seconds followed by Pelvic floor exercises for 15 min.
48517841|NCT05907239|DEVICE|Placebo Focused Extracorporeal Shockwave Therapy|We will apply 2000 focal shock wave impulses starting in each region of the affected masticatory muscles and looking for compromised muscles in the masticatory muscles such as: masseter, temporal, pterygoid (medial and lateral and digastric through a piezoelectric generator F7, G3 with a focus of 0cm depth, frequency of 8Hz and intensity of 0.048mJ/mm² with a fake gel pad applicator.
48378744|NCT03917654|BIOLOGICAL|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
48378745|NCT03917654|BIOLOGICAL|AVAXIM|AVAXIM - Pediatric \[Hepatitis A Vaccine Inactivated\] is a sterile, whitish, cloudy suspension. The active ingredient is a purified and formaldehyde-inactivated hepatitis A virus (HAV) obtained from the GBM strain, cultured on MRC-5 human diploid cells. HAV is adsorbed onto aluminum.
48020792|NCT00004926|DIETARY_SUPPLEMENT|vitamin D3 analogue ILX23-7553|
48020793|NCT04274517|OTHER|Sterile Water|1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
48020794|NCT04274517|OTHER|3.5% Betadine|1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
48020795|NCT04274517|OTHER|0.05% Chlorhexidine Gluconate|1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
48020796|NCT02182544|DRUG|WAL801CL dry syrup|
48378746|NCT04144140|DRUG|E7766|E7766, solution, intratumorally
48020797|NCT02182544|DRUG|Ketotifen fumarate dry syrup|
48020798|NCT02182544|DRUG|Ketotifen fumarate dry syrup placebo|
48020799|NCT02182544|DRUG|WAL 801 CL dry syrup placebo|
48020800|NCT03267238|BIOLOGICAL|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
48378747|NCT00702975|DRUG|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
48378748|NCT06470126|PROCEDURE|2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)
48378749|NCT06470126|PROCEDURE|0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.
48378750|NCT06470126|PROCEDURE|2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.|The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
48378751|NCT00131027|DRUG|Cyclophosphamide|
48378752|NCT00131027|DRUG|Daunorubicin|
48378753|NCT00131027|DRUG|Vincristine|
48378754|NCT00131027|DRUG|Prednisolone|
48378755|NCT00131027|DRUG|L-asparaginase|
48378756|NCT00131027|DRUG|Cytarabine|
48378757|NCT00131027|DRUG|Etoposide|
48378758|NCT00131027|DRUG|Dexamethasone|
48378759|NCT00131027|DRUG|Methotrexate|3 g/sqm (high dose)
48378760|NCT00131027|DRUG|Mercaptopurine|
48378761|NCT00131027|DRUG|Doxorubicin|
48378762|NCT00131027|DRUG|Methotrexate|0.5 g/sqm (intermediate dose)
48378763|NCT00931866|DRUG|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
48378764|NCT00931866|DRUG|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
48378765|NCT00838175|PROCEDURE|suture mediated closure|Suture mediated closure of femoral venous access
48378766|NCT00065169|DRUG|Celecoxib|
48378767|NCT05710367|DRUG|Dapagliflozin 10mg Tab|Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.
48378768|NCT05710367|DRUG|Placebo|matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
48378769|NCT05463978|DEVICE|Sculptra Aesthetic|Sculptra Aesthetic in non-facial areas
48378770|NCT00004646|DRUG|prednisone|
48712057|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
48378771|NCT04928924|PROCEDURE|Total Hip Arthroplasty|We will be observing patients who have undergone surgical replacement of arthritic hip with an implant.
48378772|NCT00925795|OTHER|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
48378773|NCT00925795|OTHER|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
48378774|NCT05254691|PROCEDURE|Sprinting|"The ventilator mode is switched to PS ventilation. The level of PS is set to meet the level of PS set when the patient is ventilated in the SIMV-PS mode. The patient will be in the PS mode until he or she clinically shows increased work-of-breathing (tachypnoea and the presence of nasal flaring and intercostal and/or interjugular retractions indicate increased work of breathing). This sprinting is performed on the theory that the respiratory muscles can be slowly trained to sustain complete spontaneous breathing. Also, theoretically this sprinting allows a better global and regional distribution of the tidal volume in the lung."
48378775|NCT04025697|OTHER|Complete Denture|A conventional CD will be constructed
48378776|NCT04025697|OTHER|Rapid prototyped denture|A 3d printed complete denture will be constructed
48378777|NCT00062075|DRUG|romidepsin|Given IV
48378778|NCT01065246|DRUG|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
48712058|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
48378779|NCT05542173|DRUG|BALI association|BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
48378780|NCT05542173|DRUG|Placebo|Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
48378781|NCT04353115|DEVICE|Training with Serious game|training the gaze stability with a serious game, 20 minutes a day, 2 days a week for 5 weeks in the presence of a doctor or physiotherapist, at the hospital to avoid addiction at home.
48378782|NCT05969275|BIOLOGICAL|Allogeneic umbilical cord-derived human mesenchymal stromal cells|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
48378783|NCT05969275|OTHER|Placebo|Intravenous infusion of placebo, with excipients
48378784|NCT00062829|BEHAVIORAL|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
48378785|NCT02616458|OTHER|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
48378786|NCT02616458|OTHER|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
48378787|NCT02844829|OTHER|Prostate MRI|MRI of the prostate prior to prostate biobsy
48378788|NCT06181552|DIAGNOSTIC_TEST|fundus photograpgy|All the participants will undergo fundus photography.
48378789|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography|All the participants will undergo OCT examination.
48712059|NCT06108648|DRUG|Lavender essential oil 10%, diluted in 90% olive oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth.~Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest.~Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
48712060|NCT06108648|OTHER|Control|Standard care according to national standards.
48712061|NCT03109808|OTHER|e-health strategy|"* First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~* Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
48712062|NCT03109808|OTHER|Traditional Oral Hygiene Education|traditional oral hygiene education
48712063|NCT03829943|DIAGNOSTIC_TEST|Vitamin D|Blood will be drawn for Vitamin D level
48712064|NCT04377802|DIAGNOSTIC_TEST|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
48712065|NCT06078111|BEHAVIORAL|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
48712066|NCT06078111|BEHAVIORAL|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
48712067|NCT00858897|OTHER|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-\[3,3-2H2\]cysteine
48712068|NCT00858897|DRUG|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
48712069|NCT00628589|DRUG|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
48712070|NCT00628589|DRUG|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
48712071|NCT00628589|DRUG|Inhaled placebo|Inhaled placebo
48712072|NCT01707589|DEVICE|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
48378790|NCT06181552|DIAGNOSTIC_TEST|optical coherence tomography angiography|All the participants will undergo OCT-A examination.
48712073|NCT00591149|DRUG|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
48712074|NCT00591149|DRUG|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
48712075|NCT00591149|DRUG|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
48378791|NCT00908362|DRUG|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
48378792|NCT00908362|DRUG|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
48378793|NCT00908362|DRUG|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
48712076|NCT01510184|DRUG|Zevalin|Zevalin administered intravenous infusion.
48712077|NCT01510184|DRUG|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
48712078|NCT01510184|DRUG|Rituximab|Rituximab administered by intravenous infusion.
48712079|NCT01510184|DRUG|In-111 Zevalin|In-111-Zevalin administered by intravenously.
48712080|NCT00002955|DRUG|fluorouracil|
48712081|NCT00002955|DRUG|leucovorin calcium|
48712082|NCT00002955|DRUG|trimetrexate glucuronate|
48020801|NCT05539950|OTHER|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).
48020802|NCT05539950|OTHER|Health education|Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
48178519|NCT06330987|DEVICE|electrocardiograph|Ten standard derivation electrodes were used to acquired FANTE registrations. The peripheral electrodes (Left (L), Right (R) and Foot (F)) were placed on the maternal abdomen in a triangle around the navel (orange) with lower apex, while the precordial ones (C1, C2, C3, C4, C5, C6) were put on an external circle. The Neutral electrode was on the right side of the patient abdomen. The software was configured so that the system acquired and wrote on disk 8 signals (2 bipolar and 6 referenced to the centroid of the three L, R and F leads) at 1000 sps with a resolution of 0.763uV. This high resolution is needed to resolve the very small voltage changes related to fetal cardiac activity.
48178520|NCT01206699|DRUG|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
48178521|NCT01206699|DRUG|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
48020803|NCT01166984|DRUG|AB103|Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes
48020804|NCT01166984|DRUG|Placebo|Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
48178522|NCT04981353|PROCEDURE|bilateral erector spinae plane block at T11|A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal directio
48178523|NCT03082755|DRUG|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
48178524|NCT03082755|DRUG|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
48178525|NCT00413855|PROCEDURE|laparoscopic appendectomy or not (surgery)|
48178526|NCT02126462|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|
48178527|NCT02126462|BIOLOGICAL|Na-GST-1/Alhydrogel®|
48178528|NCT02126462|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
48178529|NCT04457817|DEVICE|CRI|Monitoring via CRI
48178530|NCT00026182|BIOLOGICAL|rituximab|Given IV
48178531|NCT00026182|BIOLOGICAL|recombinant interleukin-12|Given SC
48178532|NCT00026182|OTHER|laboratory biomarker analysis|Correlative studies
48178533|NCT00026182|OTHER|questionnaire administration|Ancillary studies
48178534|NCT00026182|PROCEDURE|quality-of-life assessment|Ancillary studies
48178535|NCT04310332|DRUG|1L-PEG|"The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
48178536|NCT04310332|DRUG|4L-PEG|"The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
48178537|NCT01043445|DIETARY_SUPPLEMENT|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
48178538|NCT01043445|DIETARY_SUPPLEMENT|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
48178539|NCT01043445|DIETARY_SUPPLEMENT|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
48378794|NCT03077581|DRUG|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
48378795|NCT03077581|DRUG|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
48020805|NCT05482347|OTHER|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
48020806|NCT06060405|DRUG|Durvalumab|Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.
48178540|NCT03288077|OTHER|Tryptophan|Beverage including tryptophan
48178541|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
48178542|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
48178543|NCT03448705|BIOLOGICAL|3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
48712083|NCT02536066|BEHAVIORAL|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
48712084|NCT02502513|BEHAVIORAL|Brief computerized intervention|"Computer game Tetris"
48712085|NCT01219036|DRUG|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
48712086|NCT00904618|PROCEDURE|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
48712087|NCT00904618|PROCEDURE|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
48712088|NCT00904618|DRUG|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
48712089|NCT01342965|DRUG|Erlotinib|Erlotinib was supplied as tablets.
48178544|NCT03448536|DRUG|Naproxen Sodium, (Aleve, BAY117031)|220 mg \*2 tablets, orally, single dose
48178545|NCT03448536|DRUG|Acetaminophen (Tylenol Extra Strength)|500 mg \*2 caplets, orally, single dose
48712090|NCT01342965|DRUG|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
48712091|NCT05203978|PROCEDURE|colonoscopy|Colonoscopy
48712092|NCT06023628|OTHER|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
48712093|NCT05908708|DEVICE|Medtronic 780G® hybrid closed loop|"Medtronic 780G® hybrid closed loop system uses the commercial auto-mode with an insulin pump and continuous glucose monitoring."
48712094|NCT00197145|DRUG|GW873140|400 mg twice daily
48712095|NCT04264650|BEHAVIORAL|an mHealth intervention|The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
48712096|NCT00569309|BIOLOGICAL|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
48712097|NCT00569309|OTHER|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
48178546|NCT05205109|DRUG|ATG-037|"Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1."
48178547|NCT05205109|DRUG|KEYTRUDA ®( Pembrolizumab)|"Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1."
48378796|NCT03077581|DRUG|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
48378797|NCT00739830|DRUG|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
48712098|NCT00569309|OTHER|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
48378798|NCT00739830|DRUG|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
48712099|NCT04253990|PROCEDURE|Precut EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
48712100|NCT04253990|PROCEDURE|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
48712101|NCT04183855|DIETARY_SUPPLEMENT|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
48712102|NCT04183855|DIETARY_SUPPLEMENT|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
48020807|NCT06060405|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.
48378799|NCT00739830|DRUG|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
48378800|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane|Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
48378801|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST) + collagen membrane|Minimally Invasive Surgery Technique (MIST) + collagen membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
48712103|NCT04183855|BEHAVIORAL|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
48712104|NCT00101764|DRUG|Triamcinolone Acetonide|
48712105|NCT03355560|DRUG|Nivolumab|Nivolumab 480 mg IV infusion
48712106|NCT02719119|PROCEDURE|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
48712107|NCT02719119|PROCEDURE|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
48712108|NCT02393846|DRUG|Ketoprofen gel|Topical ketoprofen as used in gel form.
48178548|NCT05714423|PROCEDURE|Mini-PCNL|Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.
48178549|NCT05714423|PROCEDURE|RIRS|RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
48378802|NCT06371027|PROCEDURE|Minimally Invasive Surgery Technique (MIST)|Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
48378803|NCT00280839|DRUG|Topiramate|
48378804|NCT00280839|DRUG|Placebo|
48378805|NCT01275170|DRUG|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
48378806|NCT01275170|DRUG|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
48378807|NCT01275170|DRUG|Caffeine|Caffeine caplet, single 200 mg dose, orally
48378808|NCT01275170|DRUG|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
48378809|NCT01275170|DRUG|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
48378810|NCT02619565|OTHER|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
48378811|NCT06133465|PROCEDURE|Surgical wide local excision|Surgical excision of breast carcinoma
48378812|NCT06133465|PROCEDURE|Cavity shaving|Cavity shaving of resection margins to guarantee oncological safety
48378813|NCT06133465|PROCEDURE|Excision margin surgical clearance|Surgical clearance of involved and/or closed excision margins
48378814|NCT06133465|RADIATION|Adjuvant Radiotherapy|Adjuvant radiotherapy
48378815|NCT06133465|BIOLOGICAL|Adjuvant Hormone Therapy|Adjuvant hormone therapy
48378816|NCT00773201|DRUG|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
48378817|NCT06084442|PROCEDURE|Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia|"Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."
48378818|NCT04869475|DRUG|Arsenic trioxide|This is a single-arm study with all patients receiving arsenci trioxide.
48378819|NCT03118401|OTHER|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
48378820|NCT03118401|OTHER|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
48378821|NCT01040624|RADIATION|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
48378822|NCT01040624|RADIATION|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
48378823|NCT01298362|DRUG|Aromatase Inhibitors|
48378824|NCT01298362|DRUG|Chemotherapy|
48378825|NCT04547829|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
48378826|NCT01377857|BEHAVIORAL|Monetary Incentive|$1, $5, or $10 incentive
48378827|NCT01377857|BEHAVIORAL|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
48378828|NCT01377857|BEHAVIORAL|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
48378829|NCT00990366|DEVICE|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
48378830|NCT05243472|DIETARY_SUPPLEMENT|Protein nutritional supplement|Participants in the intervention group will receive protein-enriched soups (24-30g of protein). Protein may come from either soy, bean or milk products.
48378831|NCT02992782|BEHAVIORAL|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
48378832|NCT02992782|BEHAVIORAL|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
48378833|NCT02992782|BEHAVIORAL|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
48378834|NCT06520488|DRUG|HRS-4642|Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
48378835|NCT00138866|DRUG|Risedronate|
48378836|NCT00347776|DRUG|azithromycin|oral antibiotic
48378837|NCT00347776|DRUG|topical tetracycline|
48378838|NCT02871869|DRUG|vindesine|3 mg/㎡ (maximum dosage: \<4mg), d1, 21 d as a cycle, for 4～6 cycles
48378839|NCT02871869|DRUG|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
48378840|NCT02871869|DRUG|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
48378841|NCT02871869|DRUG|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
48378842|NCT02871869|DRUG|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
48378843|NCT02871869|DRUG|Rituximab|375mg/㎡,one day before CHOP protocol
48378844|NCT01678391|PROCEDURE|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
48378845|NCT04179188|PROCEDURE|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
48378846|NCT00252668|DRUG|Etanercept|
48378847|NCT00252668|DRUG|Methotrexate|
48378848|NCT04634565|DRUG|PF-06651600|oral PF-06651600 tablet 200 mg once daily
48378849|NCT04746001|DIAGNOSTIC_TEST|Genomic sequencing|Sequencing data
48378850|NCT04746001|DIAGNOSTIC_TEST|Histological examination|Images for deep learning
48378851|NCT02060526|DRUG|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase \[rhHNS\]
48378852|NCT01201122|DRUG|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- \<30 kg, 30-40kg, \>40kg.~For body wt. 15- \<20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- \<30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- \<40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
48378853|NCT01609608|PROCEDURE|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
48378854|NCT01826929|OTHER|Therapeutic education|
48712109|NCT02393846|DRUG|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
48378855|NCT05329441|BEHAVIORAL|Trier Social Stress Test (TSST)|In this mechanistic study, all participants will undergo a modified version of the Trier Social Stress Test (TSST), which is a well-validated psychosocial stress paradigm, adapted for adolescents that involves no deception and is considered a very mild stressor. The TSST comprises of two stress tests: a 5-minute arithmetic task and a 5-minute speech task. Due to repeated testing of the TSST, participants will be randomized to one task at T1 and complete the second task at T2 (counterbalanced design). Every 5 minutes, participants will provide ratings of their mood using a visual analogue scale (1-10) of eight mood states (Afraid, Confused, Sad, Angry, Energetic, Tired, Happy, and Tense) that will be used as potential behavioral responses to social stress. Glutamate and inflammation outcomes will be examined acutely and from T1 and T2.
48378856|NCT04890691|DEVICE|Feel Bright Light|During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
48378857|NCT04595617|BIOLOGICAL|Antibodies screening|All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.
48378858|NCT01166126|DRUG|temsirolimus|Given IV
48378859|NCT01166126|DRUG|selumetinib|Given orally
48378860|NCT01166126|OTHER|laboratory biomarker analysis|Correlative studies
48378861|NCT05630768|DRUG|Risedronate Sodium 35 MG [Actonel]|Risendronate Sodium Tab. 35mg, orally, once weekly
48378862|NCT05630768|DRUG|Calcium Vitamin D combination|orally, once daily for concomitant drug
48378863|NCT04592666|DRUG|Almonertinib|the standard therapy of single agent almonertinib
48378864|NCT04592666|DRUG|Pemetrexed|standard dose
48712110|NCT05544942|DIETARY_SUPPLEMENT|Lactobacillus plantarum|1 capsule once a day
48712111|NCT05544942|OTHER|maltodextrin|1 capsule once a day
48378865|NCT04592666|DRUG|Carboplatin|AUC=5
48378866|NCT02279082|DRUG|DFN-02|Active Experimental Drug
48378867|NCT02797951|DRUG|Galcanezumab|Administered SC
48378868|NCT03804060|DEVICE|Thermogard XP3|Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
48378869|NCT03804060|PROCEDURE|Recanalization only|Standard of Care for recanalization
48378870|NCT05794126|DEVICE|Lens 1|Soft multifocal hydrogel contact lens for 15 minutes
48378871|NCT05794126|DEVICE|Lens 2|Soft multifocal silicone hydrogel contact lens for 15 minutes.
48378872|NCT00975000|DRUG|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
48378873|NCT00975000|DRUG|Placebo|Administered orally following the same dosing regimen as the experimental arm.
48378874|NCT00186173|BEHAVIORAL|After school sports program|After school team sports intervention designed specifically for overweight and obese children
48378875|NCT00186173|BEHAVIORAL|After school health education|After school health and nutrition education program
48378876|NCT01280760|OTHER|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
48712112|NCT03800589|PROCEDURE|phacoemulsification with implantation of the Ex-Press|The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
48020808|NCT00435123|DIETARY_SUPPLEMENT|Nutritional Supplement ProStat 64 twice a day|
48020809|NCT00435123|DIETARY_SUPPLEMENT|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
48020810|NCT00007800|BEHAVIORAL|Behavioral Group Weight Loss Intervention|
48378877|NCT04105465|DEVICE|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
48712113|NCT03800589|PROCEDURE|deep sclerectomy, phacoemulsification, ExPress implantation|The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
48020811|NCT00007800|BEHAVIORAL|Motivational Interviewing|
48020812|NCT00367263|DRUG|Alvesco (Ciclesonide) 160 ug/day|
48020813|NCT01358981|DRUG|LY2881835|Administered orally
48020814|NCT01358981|DRUG|Placebo|Administered orally
48020815|NCT04426058|DRUG|CMP|Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
48020816|NCT04426058|DRUG|Fascia Illica|Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
48020817|NCT01835782|DRUG|L-Serine|
48020818|NCT00821626|DEVICE|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
48020819|NCT00821626|OTHER|Control|No rapid flu test
48712114|NCT00871117|BIOLOGICAL|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
48178550|NCT01126697|DRUG|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
48712115|NCT00871117|BIOLOGICAL|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
48712116|NCT00871117|BIOLOGICAL|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
48712117|NCT03297489|PROCEDURE|Diagnostic Microscopy|Undergo observation via intravital microscopy
48712118|NCT03297489|DRUG|Fluorescein Sodium Injection|Given IV
48712119|NCT03297489|OTHER|Laboratory Biomarker Analysis|Correlative studies
48712120|NCT05240768|DIAGNOSTIC_TEST|Fractional flow reserve, instantaneous wave-free Ratio|Clinical outcomes observed for patients with moderate coronary lesions in whom coronary revascularization was deferred due to a negative physiologic study.
48712121|NCT04465877|DRUG|JTT-662|Active drug tablets containing JTT-662
48712122|NCT04465877|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
48020820|NCT01459796|DRUG|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
48178551|NCT03783689|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
48378878|NCT03199989|DRUG|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
48712123|NCT02523131|DEVICE|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
48712124|NCT02523131|DEVICE|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
48712125|NCT01811303|OTHER|D-fagomine|Measure the changes produced on the postprandial Glycaemic response
48712126|NCT03994315|OTHER|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
48712127|NCT03994315|OTHER|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
48712128|NCT03359707|OTHER|survey|no intervention just survey
48712129|NCT06055465|DRUG|Sacituzumab Govitecan|"* 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion"
48712130|NCT06055465|DRUG|Pembrolizumab|"* 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion"
48712131|NCT01081301|BEHAVIORAL|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
48712132|NCT03861572|OTHER|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
48020821|NCT01459796|DRUG|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
48020822|NCT01459796|DRUG|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
48020823|NCT06146244|PROCEDURE|sinus lift|Implant placement on grafted sinus vs antral autogenous bone
48020824|NCT06146244|DEVICE|resonance frequency analysis|analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
48020825|NCT02279810|BEHAVIORAL|survey|Survey
48020826|NCT04296617|OTHER|Medical Chart Review|Review of medical chart
48020827|NCT04293887|DRUG|Recombinant human interferon α1β|Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
48020828|NCT06112210|OTHER|HBOT group|The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
48378879|NCT03199989|OTHER|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
48712133|NCT03861572|OTHER|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
48712134|NCT05173415|DEVICE|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
48712135|NCT05173415|DEVICE|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
48712136|NCT00832247|GENETIC|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
48712137|NCT04539522|BEHAVIORAL|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
48712138|NCT04539522|BEHAVIORAL|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
48712139|NCT02583100|BEHAVIORAL|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
48712140|NCT02583100|BEHAVIORAL|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
48712141|NCT05761678|OTHER|Questionnaire quality of life|"Quantitative - Validated online self-questionnaires scientifically to assess quality of life and support perceived social. Items created for the study concerning socio-demographic characteristics and satisfaction of health services concerning the accompaniment of the transidentity.~Qualitative - Semi-structured interviews based on a guide maintenance."
48712142|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 1|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
48712143|NCT06465264|DRUG|Amlodipine group 1|"One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
48712144|NCT06465264|DRUG|Allisartan Isoproxil/Amlodipine group 2|"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
48712145|NCT06465264|DRUG|Allisartan Isoproxil group 2|"One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."
48712146|NCT04492709|DRUG|Midazolam|The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
48712147|NCT04492709|DRUG|AZD5718|The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
48712148|NCT03745183|OTHER|Senna alata leaf decoction|"Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
48020829|NCT06112210|OTHER|CON group|The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
48020830|NCT00466193|DRUG|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
48378880|NCT03362411|DRUG|BMS-986205|Single 100 mg dose on Day 1 and Day 15
48378881|NCT03686085|DRUG|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
48378882|NCT03686085|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
48020831|NCT00466193|DRUG|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
48020832|NCT01183091|PROCEDURE|Ablation of atrial fibrillation|Ablation of atrial fibrillation
48020833|NCT01307501|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
48378883|NCT06540937|DRUG|Leflunomide Pill|This is a single-arm, single-center, phase II clinical study. Primarily evaluated in advanced MEN-1 neuroendocrine tumors. The initial efficacy of leflunomide tablets in second-line treatment provided evidence for phase III clinical trials.
48020834|NCT05252026|BEHAVIORAL|PROCARE-I (UP-A for indicated purposes)|This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
48020835|NCT05252026|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
48020836|NCT06337929|OTHER|CAPOEIRA TRAINING|The protocol of the capoeira training program and the movements (blows, dodges and flourishes) will be based on the Capoeira Abadá method.
48020837|NCT06337929|OTHER|CONTROL GROUP|The protocol of the control group will be based on an intervention with capoeira movements, however, without important cardiovascular, neuromuscular and metabolic demands, being an activity with stretching movements from positions of the capoeira modality itself.
48020838|NCT05036642|DEVICE|Compliant Passive Arm Support|The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
48020839|NCT04878705|DRUG|TWP-201|a single subcutaneous injection
48020840|NCT04878705|DRUG|placebo|a single subcutaneous injection
48178552|NCT03189147|PROCEDURE|Biceps Tenodesis|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
48712149|NCT02621177|BIOLOGICAL|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
48712150|NCT02621177|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
48712151|NCT00787137|DRUG|PG102|A single intravenous infusion
48712152|NCT00787137|DRUG|Placebo comparator|Phosphate-buffered saline
48712153|NCT03257163|DRUG|Capecitabine|Given PO
48020841|NCT03351894|PROCEDURE|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
48020842|NCT03351894|PROCEDURE|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
48020843|NCT02129686|PROCEDURE|Immediate Acupuncture Group|
48020844|NCT02129686|PROCEDURE|Delayed Acupuncture Group|
48178553|NCT03189147|PROCEDURE|Debridement|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
48378884|NCT00943826|DRUG|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
48712154|NCT03257163|OTHER|Laboratory Biomarker Analysis|Correlative studies
48712155|NCT03257163|BIOLOGICAL|Pembrolizumab|Given IV
48712156|NCT03257163|RADIATION|Radiation Therapy|Undergo radiation therapy
48712157|NCT06149117|DRUG|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|Take one capsule orally every cycle(T or R)
48712158|NCT00002598|BIOLOGICAL|recombinant interferon alfa|
48712159|NCT00002598|BIOLOGICAL|sargramostim|
48712160|NCT00002598|DRUG|cyclophosphamide|
48020845|NCT02421991|BEHAVIORAL|Telephone Delivered Intervention|
48020846|NCT00185133|DRUG|Olmesartan medoxomil|
48020847|NCT00185133|DRUG|Amlodipine|
48378885|NCT00943826|DRUG|Temozolomide|75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
48378886|NCT00943826|RADIATION|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
48712161|NCT00002598|DRUG|cytarabine|
48712162|NCT00002598|DRUG|etoposide|
48712163|NCT00002598|DRUG|methotrexate|
48712164|NCT00002598|DRUG|mitoxantrone hydrochloride|
48712165|NCT00002598|PROCEDURE|bone marrow ablation with stem cell support|
48712166|NCT00002598|RADIATION|radiation therapy|
48712167|NCT03589365|OTHER|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
48712168|NCT04685629|DIAGNOSTIC_TEST|25 post ICU-patients|patients who were hospitalized in an intensive care unit
48712169|NCT04685629|OTHER|25 post non-ICU patients|patients who were not hospitalized in an intensive care unit
48712170|NCT02066506|OTHER|asymptomatic group|2 visits with MRI
48712171|NCT02066506|OTHER|symptomatic group|2 visits with MRI
48712172|NCT05969717|DRUG|GD-iExo-001|One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
48378887|NCT00943826|DRUG|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
48378888|NCT03042338|BEHAVIORAL|CET: Central Executive Training|CET: Central Executive Training
48378889|NCT03042338|BEHAVIORAL|CET: Comparison Executive Training|CET: Comparison Executive Training
48378890|NCT00779142|DRUG|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
48378891|NCT02900508|OTHER|Exergaming training|
48712173|NCT05969717|OTHER|normal saline|One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
48020848|NCT03356002|DEVICE|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
48020849|NCT06294314|PROCEDURE|Fertilized ACL|Fertilized ACL is an acl reconstruction with Bone marrow aspirate, demineralized bone matrix, and an internal brace.
48020850|NCT02424916|BIOLOGICAL|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
48020851|NCT04337567|PROCEDURE|radiofrequency ablation|ablative treatment as allocated to radiofrequency ablation
48178554|NCT04906265|OTHER|Intervention|The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed, sideway deviation during walking)
48178555|NCT04906265|OTHER|Control|Standard rehabiliation
48178556|NCT04970719|DRUG|Baricitinib|4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
48378892|NCT02900508|OTHER|Physical therapy intervention|
48378893|NCT04490109|BIOLOGICAL|B244|B244 suspension
48178557|NCT04970719|DRUG|Dexamethasone|and 6 mg\* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
48178558|NCT04970719|DRUG|Remdesivir|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
48378894|NCT04490109|BIOLOGICAL|Vehicle|Vehicle suspension
48378895|NCT06032026|DRUG|11C-HY-2-15 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-HY-2-15
48712174|NCT00873535|DRUG|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
48378896|NCT06032026|DIAGNOSTIC_TEST|brain MRI|brain MRI scan
48378897|NCT06032026|DIAGNOSTIC_TEST|Amyloid PET scan|PET scan with Florbetaben F18 or 11C-PiB
48378898|NCT06032026|BEHAVIORAL|Neurological assessments|Neurological assessments, including video interview
48378899|NCT03187639|DIAGNOSTIC_TEST|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or \> 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
48378900|NCT03187639|DIAGNOSTIC_TEST|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites... (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
48378901|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
48378902|NCT05602480|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL, Intramuscular
48378903|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
48020852|NCT04337567|PROCEDURE|ballon cryoablation|ablative treatment as allocated to ballon cryoablation
48020853|NCT00097591|DRUG|Prasugrel|Administered orally
48712175|NCT00873535|DRUG|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
48020854|NCT00097591|DRUG|Clopidogrel|Administered orally
48020855|NCT03266445|DRUG|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
48020856|NCT05838222|BEHAVIORAL|Solution Focused Intervention|A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
48020857|NCT05838222|OTHER|Treatment as Usual|The patient receives standardized care from primary care team without the SFBT intervention
48020858|NCT05233891|PROCEDURE|Breast reconstruction|Breast reconstruction after breast cancer.
48020859|NCT05233891|PROCEDURE|Breast reduction|Breast reduction due to breast hypertrophy.
48517842|NCT06449612|DEVICE|TeleRehaStroke: Training programme using the 'Blended Clinic' mobile application|Primary end users (patients after stroke) will be familiarised with the application and the 'TeleRehaStroke' programme in two to three sessions during their last two to three weeks prior to discharge from the inpatient rehabilitation centre. This includes performing daily exercises, wearing an activity tracker and measuring blood pressure daily. Following discharge from rehabilitation, they will continue to use the application for 12 weeks.
48517843|NCT05052112|OTHER|E-PR-01|Active arm
48178559|NCT01362647|PROCEDURE|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
48178560|NCT01362647|PROCEDURE|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
48378904|NCT03039829|DIETARY_SUPPLEMENT|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
48712176|NCT05942378|DRUG|HRXG-K-1939|HRXG-K-1939
48712177|NCT05942378|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody
48712178|NCT06252896|OTHER|INSTRUMENTAL-ASSISTED SOFT TISSUE MOBILIZATION TECHNIQUE|After all evaluations were made, IASTM was applied to the individuals in the intervention group for five minutes each, for a total of 20 minutes, on the quadriceps and hamstring muscles of both extremities, respectively.
48712179|NCT06252896|OTHER|NO INTERVENTION|The control group waited for 30 minutes after the initial measurements and all measurements were repeated.
48712180|NCT05725460|PROCEDURE|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
48020860|NCT01057212|DRUG|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
48020861|NCT01057212|DRUG|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
48020862|NCT00541762|DIETARY_SUPPLEMENT|Fat perfusion to the small intestine|"1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~2. Orlistat perfused to the small intestine~3. DEXLOX as CCK-1 receptor antagonist"
48020863|NCT03905759|DRUG|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
48020864|NCT03905759|DRUG|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
48020865|NCT03905759|DRUG|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
48020866|NCT06387472|DEVICE|AI algorithm to evaluate photographs of skin test patch regions|Interpretation of skin test patch regions via artificial intelligence (AI)
48020867|NCT06387472|DEVICE|Allergen Patch|Contains dime-sized disks which have different substance to which a person may be allergic.
48020868|NCT02453789|DRUG|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
48020869|NCT02453789|DRUG|Placebo|
48020870|NCT06657547|OTHER|Normal conditions|Participants are administered salmeterol, after which they perform various performance tests in normal conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
48378905|NCT03039829|DIETARY_SUPPLEMENT|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
48378906|NCT01112969|BEHAVIORAL|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
48517844|NCT05052112|OTHER|E- PR-02|Placebo arm
48517845|NCT05861297|DRUG|Dexamethasone|Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months
48378907|NCT01112969|OTHER|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
48378908|NCT05007938|DRUG|Icotinib|Icotinib is a EGFR ihibitior.
48020871|NCT06657547|OTHER|Heated conditions|Participants are administered salmeterol, after which they perform various performance tests in heated conditions. Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
48378909|NCT05007938|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
48378910|NCT05131152|DRUG|Cyclosporine|0.05% cyclosporine Eye Drops; Sodium Hyaluronate Eye Drops, 0.02% Fluoromethalone Eye Drops.
48378911|NCT05131152|DEVICE|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy|oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
48517846|NCT05861297|DRUG|Prednisolone and Azathioprine|the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.
48517847|NCT05861297|DRUG|Rituximab|The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month
48517848|NCT05861297|DRUG|Eltrombopag|The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months
48517849|NCT05861297|DRUG|Romiplostim|The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months
48517850|NCT05584111|DRUG|STC-15|STC-15 oral capsules various dosing regimen in 3-week cycles
48020872|NCT06657547|DRUG|Salmeterol inhalation and urine samples|After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period. Two hours after inhalation, the participants collect spot urine samples at home
48020873|NCT05585333|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
48378912|NCT01824095|DIETARY_SUPPLEMENT|Dietary supplement|
48378913|NCT06060717|DEVICE|F&P Caramel|Nasal mask
48517851|NCT02713009|DIETARY_SUPPLEMENT|Pregnancy multi-vitamin (including 10μg vitamin D3)|
48517852|NCT02713009|DIETARY_SUPPLEMENT|10μg vitamin D3|
48517853|NCT02713009|DIETARY_SUPPLEMENT|0μg vitamin D (placebo)|
48517854|NCT00391560|DRUG|perifosine|Identical intervention in both arms.
48020874|NCT00685815|DRUG|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
48020875|NCT00685815|DRUG|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
48020876|NCT06573177|OTHER|Referral to the gender identity service.|Referral to the national gender identity service consisting of the Sexological Clinic, Child and Adolescent Mental Health Center, and Department of Growth and Reproduction in the Capital Region of Denmark.
48020877|NCT06071039|COMBINATION_PRODUCT|3D spacer Fabric Based Mattress|For the patients in the intervention group, the 3D spacer fabric-based mattress was used instead of the operating room theater mattress. The pressure level of the patients was monitored throughout the surgery.
48020878|NCT00509197|DRUG|Placebo (sham inhaler)|
48020879|NCT00509197|DRUG|Fluticasone|Fluticasone 250mcg bid for one month
48378914|NCT00026156|DRUG|docetaxel|
48378915|NCT00026156|DRUG|vinorelbine tartrate|
48378916|NCT03957161|OTHER|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
48378917|NCT01821131|OTHER|muffin|
48378918|NCT04614480|GENETIC|Exome analysis|Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
48378919|NCT05918211|DRUG|Udenafil|Active drug
48378920|NCT05918211|DRUG|Placebo|Matching Placebo
48378921|NCT02513680|DEVICE|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
48378922|NCT02513680|DEVICE|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
48378923|NCT04259398|DRUG|Propofol|propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
48378924|NCT04259398|DRUG|Sevoflurane|sevoflurane is administered for induction and maintenance of anesthesia
48378925|NCT05333861|DRUG|hetrombopag|According to prescription
48378926|NCT04638218|DEVICE|Rehabilitation Training System|The system can capture useful biomechanical data accurately, such as the location of body centre of mass (COM), the body joint angles, and the body posture. These useful data are stored in a database and can be conveniently accessed by the therapists, which facilitate the follow-up of the patients' therapeutic progress.
48378927|NCT04520633|OTHER|biologic initiation|introduction or modification of biotherapy at M0
48378928|NCT01193478|DRUG|GS-5885|tablet, oral, 3 mg once daily for 3 days
48378929|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
48378930|NCT01193478|DRUG|GS-5885|tablet, oral, 10 mg once daily for 3 days
48517855|NCT03594760|DIAGNOSTIC_TEST|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
48517856|NCT03511092|DIETARY_SUPPLEMENT|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
48378931|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
48378932|NCT01193478|DRUG|GS-5885|tablet, oral, 30 mg once daily for 3 days
48378933|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
48020880|NCT04262258|DIETARY_SUPPLEMENT|Blueberry enriched diet|The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
48020881|NCT03213093|OTHER|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
48020882|NCT03525834|DRUG|Everolimus|Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
48378934|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
48020883|NCT02081794|OTHER|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
48020884|NCT02081794|OTHER|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
48517857|NCT03511092|DIETARY_SUPPLEMENT|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
48517858|NCT03511092|DIETARY_SUPPLEMENT|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
48517859|NCT03511092|OTHER|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
48178561|NCT04618380|DIAGNOSTIC_TEST|bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity|"The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test."
48378935|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
48378936|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
48378937|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
48378938|NCT01193478|DRUG|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
48378939|NCT01193478|DRUG|Placebo|tablet, oral, once daily for 3 days
48517860|NCT04352725|PROCEDURE|End-expiratory lung volume measurement and incremental PEEP titration|"* End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o~* incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o"
48712181|NCT06260137|PROCEDURE|Rhomboid intercostal block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle before surgery.
48712182|NCT06260137|PROCEDURE|Rhomboid intercostal and subserratus plane block|Patients will be injected with a local anesthetic drug under the rhomboid intercostal muscle and the serrates anterior muscle before surgery.
48178562|NCT03234712|DRUG|ABBV-321|Intravenous infusion
48178563|NCT01477736|DRUG|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
48178564|NCT01477736|DRUG|Botulinum toxin A|300 U intradetrusor injection
48178565|NCT05663164|DRUG|Vitamin B|vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
48178566|NCT05663164|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
48178567|NCT03091582|BEHAVIORAL|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
48178568|NCT03091582|BEHAVIORAL|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
48178569|NCT03091582|BEHAVIORAL|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
48378940|NCT04566965|DIAGNOSTIC_TEST|SARS-CoV-2|"1. Testing weekly samples from nasal swabs to promptly diagnose acute COVID-19 infection.~2. Testing monthly serum samples to document post-viral infection."
48378941|NCT06343922|BEHAVIORAL|oral motor facilitation technique group|oral motor facilitation technique
48378942|NCT06343922|OTHER|traditional oral motor exercises group|traditional oral motor exercises
48378943|NCT05837884|DIAGNOSTIC_TEST|blood sampling|Participants will provide a blood sample that will be used to determine whether they have a monoclonal protein
48378944|NCT05677412|BEHAVIORAL|suggestive relaxation|suggestive story before sleep onset
48378945|NCT05677412|BEHAVIORAL|Neutral story|neutral story before sleep
48378946|NCT06246630|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
48378947|NCT00883129|DRUG|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
48378948|NCT00883129|DRUG|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
48020885|NCT06160024|BEHAVIORAL|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
48020886|NCT04089644|DEVICE|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
48020887|NCT04089644|DEVICE|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
48020888|NCT00434720|DEVICE|GlideScope Specific Stylet|
48020889|NCT06535633|OTHER|Intervention arm: Exercise class|The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
48020890|NCT06572917|DRUG|Indomethacin|Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
48020891|NCT06572917|DRUG|Placebo|Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
48020892|NCT03435094|DRUG|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
48020893|NCT03435094|DRUG|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
48020894|NCT01458171|BIOLOGICAL|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
48178570|NCT04456712|DRUG|Ciprofloxacin 400 MG/200 ML Intravenous Solution|antibiotic
48178571|NCT04456712|DRUG|Levofloxacin 750 MG|antibiotic
48178572|NCT05414383|DEVICE|CADx|A novel CADx system for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy.
48178573|NCT04728139|DIAGNOSTIC_TEST|glypican 3|Assessment of glypican 3 presence in colorectal cancer patients using ELISA
48178574|NCT04967183|DIAGNOSTIC_TEST|Annual FIT|"Patients will be offered an annual FIT and colonoscopy will be performed if fecal hemoglobin concentration is ≥10µg / g of feces. After performing a colonoscopy the FIT will be sent to the patient:~* After one year if the unscheduled colonoscopy has been incomplete or a lesion requiring endoscopic surveillance has been completely resected.~* After five years if the colonoscopy has evaluated the entire mucosa, it is normal or with lesions that do not require endoscopic surveillance (1-2 non-advanced adenomas)."
48178575|NCT04967183|PROCEDURE|Endoscopic surveillance.|First surveillance colonoscopy will be performed in three-year time. If an advanced adenoma or at least three non-advanced adenomas are detected, colonoscopy will be repeated after 3 years. In contrast, if colonoscopy is normal or 1-2 non-advanced adenomas are detected, colonoscopy will be repeated after 5 years.
48712183|NCT00623662|OTHER|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
48020895|NCT06571123|OTHER|İnteractive floor|Interactive floor The interactive floor system includes a computer, camera and projection. With the projection, videos that are ready on the computer are projected on the floor, image processing is done with the camera and it detects whether there is an object on the floor or not and creates effects on the video. For example, on the floor containing colored balloons, the balloons burst with the movement of the child. With this visual mobility, it is aimed to draw the child's attention to another direction.
48020896|NCT02181868|OTHER|Biodegradable and titanium fixation used in mandibular fractures.|
48020897|NCT01692197|DRUG|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
48020898|NCT01692197|DRUG|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
48020899|NCT01692197|DRUG|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).
48020900|NCT01692197|DRUG|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
48020901|NCT04944823|OTHER|Clinical follow-up for 24 months|Sampling and clinical follow-up for 24 months
48020902|NCT03347994|DRUG|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
48020903|NCT05776108|DRUG|Cabotegravir IR Formulation (reference)|Cabotegravir IR Formulation (reference) will be administered.
48020904|NCT05776108|DRUG|Cabotegravir DT Formulation (test 1)|Cabotegravir DT Formulation (test 1) will be administered.
48020905|NCT05776108|DRUG|Cabotegravir DT Formulation (test 2)|Cabotegravir DT Formulation (test 2) will be administered.
48020906|NCT04901559|PROCEDURE|Graft type at ACLR|The choice of graft at primary ACL Reconstruction
48020907|NCT06573138|DRUG|Selinexor, anti-PD-1 antibody plus Golidocitinib|Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.
48020908|NCT06171152|DRUG|Liraglutide Pen Injector [Saxenda]|A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
48020909|NCT06171152|OTHER|Medication Diary|Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
48020910|NCT00129415|PROCEDURE|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
48020911|NCT00129415|PROCEDURE|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
48517861|NCT03900455|DEVICE|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
48020912|NCT02305940|DRUG|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
48020913|NCT02305940|DRUG|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
48378949|NCT00883129|DRUG|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
48020914|NCT06531733|DEVICE|Sleep Promoting (pink noise)|Participants will be provided with comfortable headphones to wear throughout their daytime sleep opportunity. The headphones will deliver a continuous pink noise sound no greater than 50 decibels. Participants will be allowed to turn down the sound of the pink noise if they find it too loud. Participants will wear the headphones with no noise during the placebo condition.
48020915|NCT06531733|DEVICE|Wake Promoting (blue enriched light plus a nap)|Participants randomized to the blue-enriched light and nap condition will have the blue-enriched light turned on during their nighttime stay in the lab. The light will be turned off for up to one hour during the nap. During the placebo condition, participants will have an overhead room light of \~150 lux illuminated throughout their nighttime stay in the lab. This light level reflects an older NASA standard which was used in the design of some Artemis vehicles. During the placebo condition, participants will be asked to engage in quiet activities such as reading for one hour.
48020916|NCT00291382|DRUG|Salmeterol/fluticasone propionate combination|
48020917|NCT05344105|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
48020918|NCT06574334|PROCEDURE|Proprioceptive exercise|"* The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test."
48020919|NCT01070927|DRUG|RO4929097|80mg po daily, 3 days on 4 days off schedule
48020920|NCT01070927|DRUG|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
48178576|NCT06544564|DEVICE|Membrane-Wrap Lite™|Membrane- Wrap Lite™
48178577|NCT06544564|DEVICE|CT-Shield™|CT-Shield™
48178578|NCT06544564|DEVICE|Membrane Wrap™|Membrane Wrap™
48178579|NCT06544564|DEVICE|Membrane Wrap - Hydro™|Membrane Wrap - Hydro™
48178580|NCT06544564|OTHER|Standard of Care|SOC treatment will be defined as: 1) debridement of non-viable, necrotic tissue, 2) application of Biologic as the primary, wound covering, 3) application of a dressing over Biologic that maintains moisture balance, 4) application of a Class 3 high compression system, and 5) wrapping with a covering dressing
48178581|NCT01813305|DRUG|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
48712184|NCT00623662|OTHER|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
48178582|NCT01813305|DRUG|CSTC1 Matched vehicle|
48178583|NCT01542346|PROCEDURE|subcutaneous adaption|
48178584|NCT04334616|DEVICE|Video Laryngocope|VDL used for VDL arm
48178585|NCT04334616|DEVICE|Macintosh Conventional Laryngocope|Used for Conventional laryngocope arm
48178586|NCT01061190|DRUG|Propranolol|oral application of 160 mg Propranolol for 30 days
48178587|NCT00853372|DRUG|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.
48178588|NCT00853372|DRUG|Trebananib|Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
48178589|NCT03176901|BEHAVIORAL|Mindfulness-Based Stress Reduction|This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
48178590|NCT03176901|BEHAVIORAL|Health Enhancement Program|This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
48712185|NCT00004437|DEVICE|Multichannel Auditory Brain Stem Implant|
48712186|NCT04348019|BEHAVIORAL|Fasting|Fasting was defined as no foods or caloric beverages.
48020921|NCT04589559|BEHAVIORAL|Heart Rate Variability Biofeedback Training|First, participants are taught how to do relaxed, abdominal breathing. Second, they are taught how to breathe at a slow rate of 0.1 Hz (i.e., one completed breath cycle every 10 seconds). Third, they are taught how to monitor their heart rate variability (HRV) in real time using the smartphone app, which receives data wirelessly via Bluetooth from the heart rate monitor. Participants are instructed that their goal is to increase their HRV during the three weeks of at-home practice.
48020922|NCT06567639|PROCEDURE|Catheter ablation|"Hybrid epicardial right ventricular (RVOT-EPI) mapping and Brugada syndrome substrate ablation technique.~The procedure is performed in the hybrid operating room. The Advisor™ HD-Grid Mapping Catheter is delivered inside the chest through a working port and positioned under thoracoscopic view over the pulmonary artery that is consequently labeled on EAM. As a standard protocol the mapping catheter is positioned over the pulmonary artery and moved down progressively over the RVOT-EPI under continuous thoracoscopic view and at least three consecutive beats are required for each recording location point with a stable catheter position."
48020923|NCT06227780|OTHER|Alpha Auditory Entrainment|"Alpha Brainwave Entrainment (AAE) stimulus: starts at high theta range (7-Hz) through high alpha (13-Hz) in 2 Hz steps on a 500 Hz sine carrier tone~Target frequency: 10 Hz~Delivery: headphones/speakers"
48020924|NCT06227780|OTHER|Sham|"Sham stimulus: carrier tone alone~Target frequency: N/A~Delivery: headphones/speakers"
48020925|NCT00515476|BEHAVIORAL|physical exercise|8 weeks of regular exercise training
48020926|NCT06347185|PROCEDURE|Early palliative care, integrated with the standard oncologic care (proactive approach)|Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.
48020927|NCT06347185|PROCEDURE|Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)|The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
48020928|NCT06573086|OTHER|Resistance Training|12-week resistance training
48020929|NCT06358924|OTHER|Potassium nitrate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of the desensitizing agent recommended by the manufacturer (After Whitening Mousse), once for 10 minutes.
48020930|NCT06358924|OTHER|Casein phosphopeptide-amorphous calcium phosphate with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Mi Paste Plus once for 3 minutes.
48378950|NCT02920866|BEHAVIORAL|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
48388033|NCT02843529|OTHER|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
48178591|NCT06074692|COMBINATION_PRODUCT|Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)|Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
48178592|NCT01430637|GENETIC|DNA analysis|
48178593|NCT01430637|GENETIC|RNA analysis|
48178594|NCT01430637|GENETIC|gene expression analysis|
48178595|NCT01430637|GENETIC|mutation analysis|
48178596|NCT01430637|GENETIC|nucleic acid sequencing|
48178597|NCT01430637|GENETIC|polymerase chain reaction|
48178598|NCT01430637|OTHER|laboratory biomarker analysis|
48178599|NCT01430637|OTHER|pharmacogenomic studies|
48178600|NCT01576198|GENETIC|DNA analysis|
48178601|NCT01576198|GENETIC|nucleic acid amplification|
48178602|NCT01576198|OTHER|diagnostic laboratory biomarker analysis|
48178603|NCT01576198|OTHER|medical chart review|
48178604|NCT03598699|DRUG|AXR-159|AXR-159 Ophthalmic Solution
48178605|NCT03598699|DRUG|Vehicle|AXR-159 Ophthalmic Solution Vehicle
48712187|NCT02133664|DRUG|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
48712188|NCT02133664|DRUG|Placebo|placebo lipoic acid and placebo oil
48712189|NCT01778322|PROCEDURE|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
48712190|NCT03710239|DEVICE|Dilapan-S|Synthetic osmotic dilator
48712191|NCT03710239|DEVICE|Laminaria|Seaweed-based osmotic dilator
48178606|NCT02244138|BEHAVIORAL|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
48712192|NCT02954419|OTHER|No intervention|No intervention
48712193|NCT01709942|DRUG|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
48712194|NCT01709942|DRUG|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were \>300pg/ml
48712195|NCT04741191|OTHER|Cycle ergometer training|Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
48712196|NCT04741191|OTHER|Conventional therapy|In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
48712197|NCT02720601|DRUG|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
48712198|NCT01344538|DRUG|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
48712199|NCT01344538|DIETARY_SUPPLEMENT|Placebo Capsule|2.0 g per day
48712200|NCT03327376|DEVICE|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
48020931|NCT06358924|OTHER|Hydroxyapatite with fluoride|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of Hydroxyapatite and Fluoride (ReminPro) once for 3 minutes.
48020932|NCT06358924|OTHER|PAMAM-carboxylic acid dendrimer|Bleaching of teeth using in-Office chemically-activated bleaching agent (Power Whitening YF) was performed followed by the application of PAMAM once for 30 minutes.
48712201|NCT05615194|DRUG|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
48712202|NCT05615194|DRUG|Placebo|Volume equivalent in infusion over 10 minutes
48712203|NCT05945771|DIETARY_SUPPLEMENT|Grape seed extract|Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
48712204|NCT00902421|DRUG|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
48712205|NCT00902421|DRUG|Antimuscarinics|Antimuscarinics for 3 months
48712206|NCT05332249|PROCEDURE|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
48712207|NCT04358705|OTHER|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
48712208|NCT04358705|BEHAVIORAL|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office in Columbus, Ohio where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (e.g., tobacco product images) are viewed (n=30) for 10 seconds per image. Following each image, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image.
48712209|NCT04358705|OTHER|Eye tracking survey|Other Names: Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
48712210|NCT04358705|BEHAVIORAL|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
48712211|NCT04358705|OTHER|Aim 3 survey|"Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences"
48378951|NCT02920866|BEHAVIORAL|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
48378952|NCT03542864|DIETARY_SUPPLEMENT|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
48378953|NCT03542864|OTHER|Control|Progress registration of body composition values
48378954|NCT03542864|OTHER|Data analysis|Statistical analysis of all data
48378955|NCT00233675|DRUG|GABITRIL (tiagabine hydrochloride; CEP-6671)|
48378956|NCT01785251|DEVICE|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
48378957|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"1. st line:~   * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * Bevacizumab until PD or unacceptable toxicity~  * At PD patients will go to the 2nd treatment line.~2. nd line:~   * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~  * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
48378958|NCT01935492|DRUG|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~1. st line~   * Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~  * Bevacizumab until PD or unacceptable toxicity~  * At PD \< 3 months after last paclitaxel start 2nd treatment line.~  * At PD ≥ 3 months after last paclitaxel, start another 4 cycles~  * Bevacizumab until the next PD or unacceptable toxicity~  * At the next PD start the 2nd treatment line.~2. nd line:~   * Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~  * At PD \< 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~  * At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~  * At the next PD start 3rd treatment line."
48378959|NCT02514434|RADIATION|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
48378960|NCT02514434|RADIATION|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
48378961|NCT02393404|OTHER|PT-FMT|Physiotherapeutic functional movement-power training
48378962|NCT02393404|OTHER|FMT alone|Physiotherapeutic power training
48378963|NCT03448562|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
48378964|NCT03448562|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
48378965|NCT05571397|DEVICE|Dexcom G6|Continuous Glucose Monitor
48378966|NCT01629121|BEHAVIORAL|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
48378967|NCT00150137|DRUG|Methimazole|
48712212|NCT04358705|OTHER|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
48178607|NCT06168253|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
48020933|NCT02515019|DEVICE|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
48178608|NCT06168253|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
48178609|NCT01296009|DRUG|Traditional Chinese medicine(Zhuyun Recipe)|The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
48178610|NCT04816123|DRUG|[14C]Donafenib|Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
48388034|NCT05230160|OTHER|Intermittent Fasting|"Intermittent Fasting (IF) is a dietary intervention that involves periodic intervals of no or very limited energy intake. Fasting and feeding intervals vary and the practice of IF commonly consists of either a daily fast for 16 hours, a 24-hour fast on alternate days, or a fast two days per week on non-consecutive days.~For the study, the IF group will be asked to fast for 16 consecutive hours, 6 days per week. This means they will have an 8-hour eating window (e.g., eat from 10 a.m. to 6 p.m.) each day. They will be asked to eat the same types of food and the same amounts as usual, but only during the 8-hour eating window."
48388035|NCT06326112|DRUG|Furosemide Injection|o.5 mg/kg bid or tid IV
48388036|NCT06326112|DRUG|Metolazone Tablets|Diuretic as needed
48020934|NCT02516059|DRUG|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
48020935|NCT02516059|DRUG|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
48020936|NCT02516059|DRUG|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
48517862|NCT03900455|PROCEDURE|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
48020937|NCT02516059|DEVICE|epidural catheter|
48020938|NCT01223079|DRUG|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
48020939|NCT01223079|DRUG|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
48020940|NCT00991302|BEHAVIORAL|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
48020941|NCT05095480|DRUG|Red Yeast Rice Pill|Taking Lesstat
48020942|NCT05095480|DRUG|Placebo|Placebo receiving group
48020943|NCT00991601|PROCEDURE|FNAC (fine needle aspiration cytology)|UL guided biopsy
48020944|NCT03737461|DRUG|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
48020945|NCT03737461|OTHER|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
48020946|NCT05133648|PROCEDURE|Hip Fracture Surgery|Hip fracture surgery
48020947|NCT05133648|OTHER|COVID-19 infection|COVID-19 infection
48020948|NCT03370328|OTHER|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
48020949|NCT03370328|OTHER|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
48020950|NCT03713567|BEHAVIORAL|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
48020951|NCT00903838|DRUG|pardoprunox|1.5 to 12 mg/day
48020952|NCT00903838|DRUG|pramipexole|0.75-4.5 mg/day
48178611|NCT01423708|DRUG|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of \>5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels \<5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
48178612|NCT03941899|OTHER|Levobupivacaine in QLB II|Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
48178613|NCT02858128|OTHER|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
48178614|NCT03685682|BIOLOGICAL|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
48178615|NCT05428111|DIAGNOSTIC_TEST|flow cytometric immunophynotyping|Expression of programmed death-1 (PD-1) \& programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping
48178616|NCT05121389|DRUG|normal saline|Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
48178617|NCT04692467|DRUG|Amlodipine 5mg|Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.
48178618|NCT01470599|DRUG|CP-690,550|ORAL TABLET, TWICE DAILY
48178619|NCT01470599|DRUG|CP-690,550|ORAL TABLETS, TWICE DAILY
48178620|NCT01756144|DEVICE|rhBMP-2|
48178621|NCT05155943|DEVICE|KALPA X™|Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
48178622|NCT01840449|DRUG|Somatuline Autogel® 60, 90 or 120 mg|
48178623|NCT03660397|PROCEDURE|Selective endovascular chemical ablation of adrenal gland|Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
48178624|NCT03660397|DRUG|Traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
48517863|NCT00616512|PROCEDURE|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
48378968|NCT05151991|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS."
48517864|NCT00711880|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
48517865|NCT00711880|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
48178625|NCT04509674|DRUG|Empagliflozin|Empagliflozin
48517866|NCT05821335|OTHER|Leap motion assisted rehabilitation|Hand Therapy via leap motion sensor
48517867|NCT05821335|OTHER|Traditional program|Hand Therapy by physiotherapist via traditional methods
48712213|NCT04358705|OTHER|Supplemental Aim 1 Interviews|Participants from the preceding online survey (who identify as women from Aim 1/supplemental aim 1 survey) who agreed to be contacted for future study will be emailed an invitation to the eligibility screener. Individuals interested will complete a screener to ensure participants identify as women and to verify that they have ever used cigarillos. Eligible participants will be contacted to schedule a 60- to 90-minute Zoom interview about their tobacco, nicotine, and cannabis product use experiences, with particular focus on flavored cigarillo usage initiation, current use, and responses to potential flavor restrictions.
48712214|NCT01628614|OTHER|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
48178626|NCT04509674|DRUG|Placebo|Placebo
48178627|NCT02994784|DRUG|Propylene Glycol-Free Melphalan Hydrochloride|Intravenous Propylene Glycol-Free Melphalan Hydrochloride
48178628|NCT04468230|DRUG|Nicotine Transdermal Patch|Nicotine Treatment Condition
48178629|NCT02164019|PROCEDURE|long-stem cemented hemiarthroplasty (LSCH)|
48178630|NCT02164019|PROCEDURE|intramedullary nailing (IMN)|
48178631|NCT02164019|BEHAVIORAL|questionnaires|
48178632|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
48178633|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
48178634|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
48178635|NCT02185898|OTHER|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
48178636|NCT02185898|OTHER|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
48178637|NCT02185898|OTHER|Electronic cigarette #1|Electronic cigarette
48178638|NCT02185898|OTHER|Electronic cigarette #2|Electronic cigarette
48178639|NCT02185898|OTHER|Electronic cigarette #3|Electronic cigarette
48178640|NCT02185898|OTHER|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
48178641|NCT00364390|DRUG|Anginera, a human tissue replacement therapy|
48178642|NCT06400615|DRUG|AD109|Oral administration at bedtime
48178643|NCT04553588|OTHER|Disposal pouch|Medication Disposal Pouch
48178644|NCT01249508|OTHER|nutrition label|
48178645|NCT04477356|PROCEDURE|SU|Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
48178646|NCT04477356|PROCEDURE|DG|Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
48178647|NCT04398368|DRUG|Gemcitabine Hydrochloride|Given intravesically
48178648|NCT01440010|RADIATION|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
48178649|NCT00975676|OTHER|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
48378969|NCT05151991|OTHER|Fixed orthodontic treatment with ceramic brackets|"Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS"
48378970|NCT02867748|PROCEDURE|TVT-Abbrevo|
48378971|NCT02867748|PROCEDURE|Serasis|
48378972|NCT03379038|OTHER|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
48712215|NCT04220112|PROCEDURE|Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)|RT-fMRI neurofeedback targeting down-regulation of the amygdala
48712216|NCT04220112|PROCEDURE|Sham Procedure|RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
48378973|NCT03379038|OTHER|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
48378974|NCT01961778|DEVICE|Radio-Frequency Ablation|
48378975|NCT01961778|DEVICE|Cryotherapy|
48378976|NCT03704194|BEHAVIORAL|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
48378977|NCT03704194|BEHAVIORAL|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
48517868|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
48517869|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
48517870|NCT04500717|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
48517871|NCT04500717|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
48517872|NCT05223140|BEHAVIORAL|Birth within 7 minutes of rumping|Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus
48517873|NCT05223140|BEHAVIORAL|Premature cord clamping|Umbilical cord clamping \<1 minute following birth
48517874|NCT02557763|DEVICE|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
48712217|NCT04902521|DEVICE|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
48712218|NCT04902521|DEVICE|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
48020953|NCT03219333|DRUG|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
48020954|NCT04788992|OTHER|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
48020955|NCT04788992|OTHER|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
48020956|NCT03449303|OTHER|EOI|Topically-applied oil
48020957|NCT03449303|OTHER|Placebo|Topically-applied oil
48020958|NCT05491733|DRUG|APX001|Low-load oral tablet
48020959|NCT05491733|DRUG|APX001A|High-load oral tablet
48020960|NCT02438241|PROCEDURE|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
48020961|NCT02438241|PROCEDURE|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
48178650|NCT01869140|DEVICE|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
48178651|NCT05657756|DEVICE|Randomize clinical trial using hand dynamometer|Our research article involves 100 patients aged over 18 years old with ASAI\&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
48178652|NCT00002668|BEHAVIORAL|Observation|
48020962|NCT02438241|PROCEDURE|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
48020963|NCT03570736|PROCEDURE|Minimal invasive surgical technique|Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.
48378978|NCT06208670|BEHAVIORAL|Progressive muscle relaxation exercises|PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
48712219|NCT04441164|OTHER|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
48178653|NCT00002668|BEHAVIORAL|Educational Intervention and Behavioral Skills Training|
48178654|NCT00130845|DRUG|Octreotide Acetate in Microspheres|
48378979|NCT06208670|BEHAVIORAL|Violent tendency Scale|Violent tendency Scale
48712220|NCT04441164|OTHER|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
48712221|NCT04441164|OTHER|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
48712222|NCT04441164|OTHER|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
48712223|NCT04441164|OTHER|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
48020964|NCT03570736|PROCEDURE|Open Flap Debridement|Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
48020965|NCT05693922|DEVICE|Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
48020966|NCT05693922|BEHAVIORAL|Single-session behavioral activation|"Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities"
48020967|NCT05693922|DEVICE|Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
48020968|NCT03769441|DRUG|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
48020969|NCT03769441|DRUG|Sodium chloride|Four intravenous dosages of sodiumchloride
48020970|NCT03527992|DEVICE|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
48020971|NCT03527992|DEVICE|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
48020972|NCT03127124|DRUG|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
48178655|NCT00130845|DRUG|Placebo|
48178656|NCT00550446|DRUG|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
48178657|NCT00550446|DRUG|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
48178658|NCT00550446|DRUG|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
48020973|NCT03127124|DRUG|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
48020974|NCT03127124|DRUG|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
48378980|NCT02122874|DEVICE|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
48378981|NCT02122874|OTHER|1200 Kcal diet|
48378982|NCT05860452|OTHER|ropivacaine|single shot bilateral TAP block
48178659|NCT00550446|DRUG|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
48178660|NCT00550446|DRUG|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
48178661|NCT00550446|DRUG|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
48178662|NCT00550446|DRUG|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
48178663|NCT04860856|DRUG|0.5% ropivacaine|The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
48178664|NCT04860856|DRUG|Normal Saline|20ml of normal saline
48178665|NCT02716298|DEVICE|fanfilcon A|contact lens
48178666|NCT02716298|DEVICE|lotrafilcon B|contact lens
48378983|NCT05860452|OTHER|normal saline|single shot bilateral TAP block
48378984|NCT04892875|DRUG|Zimberelimab|Zimberelimab will be administered at a dose of 360 mg IV on Day 1 of each 21-day cycle for up to 11 cycles.
48378985|NCT04892875|DRUG|Etrumadenant|Etrumadenant will be administered at a dose of 150 mg by mouth once daily on days 1-21 of each 21-day cycle for up to 11 cycles.
48378986|NCT04892875|DRUG|Cisplatin|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
48020975|NCT03127124|DRUG|Leucovorin Calcium Injection|Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).
48178667|NCT01765738|DEVICE|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
48178668|NCT01200498|DRUG|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
48178669|NCT01776359|DIETARY_SUPPLEMENT|High Protein|2.4g/kg of protein
48178670|NCT01776359|DIETARY_SUPPLEMENT|Low Protein|1.2g/kg of protein
48378987|NCT04892875|RADIATION|Radiation|Concurrent weekly cisplatin and radiation will be administered as part of the subject's standard of care. Cisplatin and radiation will be initiated on the same day and continue for up to 7.5 weeks.
48378988|NCT01529697|BEHAVIORAL|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
48378989|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening.
48378990|NCT05724615|BEHAVIORAL|Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance|Participants will be sent an order for their lab screening and the recourse of the labs where they can schedule the screening. They will also receive text messages to remind them to have their lab completed as well as a link to schedule the lab and inform them of walk-in hours.
48378991|NCT04116307|DIETARY_SUPPLEMENT|Polymethylsiloxane|
48378992|NCT04116307|DIETARY_SUPPLEMENT|Lactobacillus reuteri|
48712224|NCT04441164|OTHER|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
48020976|NCT03127124|DRUG|Eloxatin Injectable Product|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
48020977|NCT03345459|OTHER|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
48020978|NCT05457270|DRUG|AZD4831|Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
48178671|NCT06019065|DRUG|AJA001|AJA001
48178672|NCT06019065|OTHER|Placebo|Placebo
48178673|NCT00503724|DRUG|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
48178674|NCT03496376|OTHER|Kinesio Taping|The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
48178675|NCT03496376|OTHER|Deep Breathing Exercises|Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
48178676|NCT04839055|DRUG|Coenzyme A Combined With Abiraterone|Abiraterone 4 pieces per day. Coenzyme A 200U
48178677|NCT04839055|DRUG|Abiraterone|Abiraterone
48020979|NCT00956150|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
48020980|NCT00956150|DRUG|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
48020981|NCT00956150|DRUG|Placebo|Placebo TID PO x 10 days
48020982|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules (CALM)|CALM is a cognitive-behavioral intervention for childhood anxiety. CALM consists of five modules. The primary components include psychoeducation, relaxation training (C), behavioral exposure (A), cognitive restructuring (L), and relapse prevention (M). There is also an optional parent psychoeducation module. Students randomized to the CALM condition will receive the 5 modules over 8 weeks.
48178678|NCT01809899|BEHAVIORAL|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
48712225|NCT04441164|OTHER|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
48020983|NCT04693858|BEHAVIORAL|Child Anxiety Learning Modules--Relaxation (CALM-R)|CALM-R serves as an active comparison condition to CALM and consists of 5 modules of relaxation skills. The key components of CALM-R include psychoeducation, deep breathing, progressive muscle relaxation, guided imagery, and relapse prevention. Students randomized to the CALM-R condition will receive the 5 modules over 8 weeks.
48178679|NCT01809899|BEHAVIORAL|Consent as Usual|Routine informed consent procedures
48178680|NCT01408810|DRUG|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
48178681|NCT01296763|DRUG|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
48178682|NCT01296763|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
48178683|NCT01296763|DRUG|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
48178684|NCT01296763|DRUG|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
48517875|NCT03892603|OTHER|Strengthening exercises program|Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
48020984|NCT02835014|BEHAVIORAL|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
48020985|NCT02835014|BEHAVIORAL|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
48178685|NCT01296763|DRUG|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
48178686|NCT04370535|DEVICE|cellulose|The subjects of group A and group C receive boxes containing placebo for supplementation for a total of 12 weeks.
48178687|NCT04370535|DEVICE|PMA-zeolite|The subjects of group B and group D receive boxes containing PMA-zeolite for supplementation for a total of 12 weeks.
48178688|NCT02697838|DRUG|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
48178689|NCT02697838|DRUG|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~4. other paclitaxel-based regimens"
48178690|NCT06401278|DEVICE|Transcutaneous electrical acupoint stimulation|"It will be performed by using the TENS device on acupoint (TEAS) as the following:~The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)"
48178691|NCT06401278|DEVICE|Transcutaneous electrical nerve stimulation (group b):|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
48178692|NCT05805839|DRUG|C-11 ER176 Radiotracer|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
48178693|NCT05805839|DRUG|C11 Pittsburgh Compound B|Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
48178694|NCT05805839|DIAGNOSTIC_TEST|PET/CT scan|Imaging of entire brain
48712226|NCT01012921|DEVICE|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
48178695|NCT05805839|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging of the Brain
48178696|NCT03634839|DRUG|Flavoring Agents|Flavor of e-liquid - sweet or tobacco
48178697|NCT03634839|DRUG|Nicotine|Nicotine level (36 mg/ml)
48712227|NCT01012921|DEVICE|MembraGel|Device application at surgery
48712228|NCT01012921|OTHER|Bio-Gide® membrane|Device application at surgery
48712229|NCT00100295|DRUG|Hypericum perforatum|300 mg capsule taken three times a day
48712230|NCT00100295|OTHER|Placebo|300 mg given three times a day, containing rice protein powder
48712231|NCT05081063|COMBINATION_PRODUCT|Routine labs|Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
48712232|NCT02839902|DRUG|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
48712233|NCT02839902|OTHER|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
48020986|NCT02835014|BEHAVIORAL|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
48378993|NCT04828551|DEVICE|Ultrasound based shear wave speed and fat quantification methods|Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system
48378994|NCT04828551|DIAGNOSTIC_TEST|Blood collection|"Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes.~Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed"
48020987|NCT00102791|DRUG|ICA-17043|
48378995|NCT04828551|OTHER|Physical measurements|Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.
48378996|NCT04828551|OTHER|Clinical history and medication reviews|"The following questionnaires will be administered at Screening:~Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire~The following questionnaires will be administered at Visit 1 and Visit 2:~Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire"
48378997|NCT04219046|DRUG|Naloxégol oxalate|Oral administration once daily
48378998|NCT04219046|DRUG|Placebo oral tablet|Oral administration once daily
48378999|NCT05036876|DRUG|Degludec|Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
48379000|NCT05036876|DRUG|Glargine U300|Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.
48379001|NCT04472273|PROCEDURE|high-flow nasal cannula / classic nasal cannula|The oxygen given with nasal cannula cannot be humidified, causing drying in mucous membranes at high flow rates of more than 4L/min and problems in patient compliance.This situation prevents us to increase the oxygen FiO2 rate applied to the patient above 40%.According to the nasal cannula high-flow nasal cannula where heated and humidified oxygen can be delivered, oxygen therapy can be applied at a flow rate of 25L/min.It provides high flows easily, prevents the airway epithelium from drying out and improves mucus cleansing, causing a decrease in anatomical dead space.It provides discharge of expired air in the upper airways.It increases alveolar ventilation.It offers a stream adjusted to all children.Flow and titration can be adjusted according to the child's weight and effect.
48379002|NCT05090046|OTHER|Trauma exposure|Exposure to the Canterbury earthquake sequence and other relevant psychological trauma
48517876|NCT03892603|OTHER|Motor control exercises program|Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
48020988|NCT00786916|DRUG|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
48020989|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
48178698|NCT02150395|OTHER|music therapy|
48020990|NCT00786916|DRUG|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
48379003|NCT01528839|DRUG|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
48379004|NCT01528839|DRUG|Placebo|
48379005|NCT05406466|DRUG|Tislelizumab|a PD-1 immune check inhibitor
48020991|NCT04382118|OTHER|Data collection from routine medical records|Data collection from routine medical records (clinical and radiological data)
48379006|NCT05406466|DRUG|Lenvatinib|multitargeted receptor tyrosine kinase inhibitor
48020992|NCT06502457|DRUG|painkiller|The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
48020993|NCT06502457|OTHER|hypnosis group|"The hypnosis group will receive a hypnosis session after the fetal heart rate has been recorded. Automated measurement of blood pressure and maternal heart rate will take place during the session in order to objectively assess the impact of the session on the mother.~Patients in the hypnosis group will then have access to the virtual reality headset on request throughout the latency or maturation phase, and will also be able to benefit from a painkiller in accordance with the service protocol if they so request."
48379007|NCT05406466|DRUG|Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
48379008|NCT00160719|PROCEDURE|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
48379009|NCT03317925|PROCEDURE|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
48379010|NCT02689505|DRUG|BI 836880|
48020994|NCT02425631|DEVICE|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
48020995|NCT03264625|DRUG|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
48379012|NCT02074982|DRUG|AIN457 300 mg|
48379013|NCT02074982|DRUG|ustekinumab 45/90 mg|
48379014|NCT02074982|DRUG|placebo secukinumab|Placebo
48020996|NCT03264625|OTHER|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
48020997|NCT00636454|BEHAVIORAL|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
48020998|NCT00636454|OTHER|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
48020999|NCT01312545|DEVICE|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
48021000|NCT01312545|DEVICE|Medpor|commercial porous polyethylene
48379015|NCT01610726|PROCEDURE|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
48379016|NCT00798902|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
48021001|NCT03250962|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
48021002|NCT03250962|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
48021003|NCT05290129|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
48379017|NCT00798902|OTHER|Iliac crest autograft|autograft
48379018|NCT04998669|DRUG|Loncastuximab tesirine|"Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle."
48379019|NCT04998669|DRUG|Rituximab|"Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician."
48379020|NCT06650982|OTHER|Pecha Kucha presentation on MDPRI|Students in the experimental arm will be given training on MDRPI.
48379021|NCT02876185|OTHER|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
48712234|NCT05202665|PROCEDURE|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
48712235|NCT05202665|PROCEDURE|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
48021004|NCT01003249|DRUG|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
48021005|NCT01003249|DRUG|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
48178699|NCT02957955|BEHAVIORAL|High-Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
48178700|NCT02379962|OTHER|no intervention|
48178701|NCT00078143|BEHAVIORAL|Behavior Therapy|
48178702|NCT03242668|PROCEDURE|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
48178703|NCT03242668|PROCEDURE|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
48178704|NCT03242668|DRUG|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
48178705|NCT01266161|DRUG|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
48517877|NCT03892603|OTHER|Education and advice|Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
48712236|NCT05423938|DIETARY_SUPPLEMENT|Diabetic|It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA
48712237|NCT05423938|DIETARY_SUPPLEMENT|Control|It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
48712238|NCT04596332|OTHER|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
48712239|NCT02443194|DRUG|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
48712240|NCT02443194|DRUG|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
48712241|NCT02118597|DRUG|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
48712242|NCT02118597|DRUG|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
48712243|NCT02118597|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
48712244|NCT02118597|DRUG|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
48712245|NCT03204552|OTHER|No intervention (observational study)|No intervention (observational study)
48712246|NCT02664051|DRUG|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
48712247|NCT02664051|DRUG|placebo|100mg 4x2 daily mannitol
48712248|NCT04828291|BEHAVIORAL|Benign Behavioral Interventions|This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
48712249|NCT06496438|DIETARY_SUPPLEMENT|Psychobiotics|Dietary Supplement: A four probiotic regime, containing Lactobacillus rhamnosus, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and Bifidobacterium longum at a concentration of 1, 000,000,000 CFU.
48712250|NCT06496438|OTHER|Placebo|The placebo regime, containing powdered glucose polymer, will be identical in packaging, appearance, consistency, and solubility in drinking water, thus making it impossible to recognize which are placebo and which the therapeutic formulation. Both will be identically standardized by the same pharmaceutical company \[Uni-Pharma, Greece\].
48712251|NCT00933920|DRUG|Aliskiren|
48517878|NCT00098605|DRUG|lapatinib ditosylate|Given orally
48021006|NCT05904600|DEVICE|Respiratory muscle training|The training of the intervention group will have an initial workload of 30% of maximal inspiratory and expiratory pressures, which will be increased weekly by 10% according to tolerance, if not tolerated by 5%. In addition, patients will be instructed to maintain a normal respiratory rate (12-16 breaths per minute). Moreover, they will continue their usual treatment.
48021007|NCT05904600|DEVICE|Control group|In the control group, the respiratory muscle training will be simulated by using the device without load throughout the study period using an opaque adhesive tape surrounding the device to mask the valve position.
48712252|NCT00933920|DRUG|Aliskiren|
48021008|NCT04574362|DRUG|Rimegepant|One 75mg orally disintegrating tablet
48178706|NCT01266161|DRUG|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
48178707|NCT00985270|DRUG|Rifampicin|
48712253|NCT01767493|DRUG|[18F]Florbetapir PET imaging|\[18F\]Florbetapir and PET imaging
48178708|NCT00985270|DRUG|Placebo|
48517879|NCT00098605|OTHER|laboratory biomarker analysis|Correlative studies
48517880|NCT00098605|PROCEDURE|quality-of-life assessment|Ancillary studies
48712254|NCT04862897|OTHER|Patient-controlled admissions|Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
48712255|NCT02761694|DRUG|Vevorisertib|Administered as an oral dose every day or every other day.
48712256|NCT02761694|DRUG|Fulvestrant|Administered as an intramuscular (IM) injection.
48712257|NCT02761694|DRUG|Paclitaxel|Administered as an intravenous (IV) infusion.
48712258|NCT03470129|DEVICE|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
48712259|NCT04909502|DRUG|EHP-101 25 mg OD|25 mg OD during the first 28 Days of the trial
48712260|NCT04909502|DRUG|EHP-101 25 mg BID|25 mg BID during the first 28 Days of the trial
48712261|NCT04909502|DRUG|EHP-101 50 mg OD|After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
48712262|NCT04909502|DRUG|EHP-101 50 mg BID|After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
48712263|NCT04294316|DIAGNOSTIC_TEST|Sonovue|Twice dose of 2.4ml of Sulphur hexafluoride microbubbles contrast Sonovue administration to evaluate brain microcirculation
48712264|NCT05910125|DRUG|Aspirin|See arm/group descriptions.
48021009|NCT04574362|DRUG|Placebo|Matching placebo
48021010|NCT00633035|DRUG|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
48178709|NCT03708705|OTHER|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
48178710|NCT00299598|DEVICE|alkylated polyethylenimine nanoparticles antibacterial evaluation|
48178711|NCT03206268|DEVICE|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
48178712|NCT03331926|DRUG|Xiapex|Follow-up of effect of treatment
48178713|NCT05994976|PROCEDURE|Blood samples collection|biomarkers and optional genetic analysis
48021011|NCT00633035|DRUG|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
48517881|NCT00098605|OTHER|questionnaire administration|Ancillary studies
48712265|NCT05910125|DRUG|Clopidogrel|See arm/group descriptions.
48021012|NCT03030612|DRUG|ARGX-110|ARGX-110 will be administered intravenously.
48021013|NCT03030612|DRUG|AZA|AZA will be administered subcutaneously/intravenously.
48021014|NCT03599427|DRUG|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
48021015|NCT03599427|DRUG|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
48021016|NCT04808609|DEVICE|Lumme mobile phone application|Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
48021017|NCT04808609|BEHAVIORAL|Standard of Care|Smoking cessation counseling and nicotine replacement therapy
48379022|NCT05852106|OTHER|"Surgical Simulation with 3D Heart Model and Parental Education with Congenital Heart Disease Parent Education Booklet and tailored 3D Heart Modeling"|The first step in the modeling process is masking. For this study, the average minimum value for masking ventricles and large vessels was set between 80 and 200 HU (Brüning et al., 2022). Threshold values of min 216 HU - max 1502 HU are used. At these HU values, the blood in the heart and great vessels is masked and the outline of the heart is revealed. Lowering the minimum HU value is necessary to make the heart walls more visible. However, this results in masking unwanted soft tissues other than the heart, such as muscle and fat. The masked unnecessary surrounding tissues are removed first with the cropping mask and then manually by marking along the contours of the heart and great vessels. Thus, a model containing only the heart and the desired large vessels will be created and cleaned from the surrounding tissues. With this mask, 3D reconstruction will be performed, and the model will be ready for printing.
48379023|NCT03117972|DRUG|FOLFOXIRI|12 cycles
48379024|NCT03117972|DRUG|FOLFOX|12 cycles
48379025|NCT03117972|DRUG|FOLFIRI|12 cycles
48379026|NCT03117972|DRUG|Bevacizumab|12 cycles
48379027|NCT03117972|DRUG|LV5FU2|Maintenance chemotherapy
48712266|NCT05910125|DRUG|Alteplase|See arm/group descriptions.
48712267|NCT03661736|OTHER|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
48712268|NCT04988282|DRUG|Methylprednisolone Tablet|Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
48712269|NCT00685646|DRUG|antiandrogen therapy|Up to 24 courses of therapy
48712270|NCT00685646|DRUG|zoledronic acid|Up to 24 courses of therapy
48712271|NCT02263456|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
48712272|NCT01018095|DRUG|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
48712273|NCT02810938|DEVICE|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
48021018|NCT03352115|DRUG|Prednisolone|5 day course of oral prednisolone
48021019|NCT03352115|DRUG|Placebos|Placebo syrup
48021020|NCT04237298|DEVICE|Modified vacuum-formed retainer covering the palete|The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
48021021|NCT04237298|DEVICE|Hawley retainer|Standard retention regime for patients with arch expansion. Patients will be instructed to wear the retainer 24 hours during the study period.
48021022|NCT06572878|OTHER|Cognitive training|Cognitive training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The cognitive training task components will specifically focus on attention, learning and memory, executive function, perceptual-motor skills, and language.
48021023|NCT06572878|OTHER|Physical training|Physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The physical training task components will specifically focus on strength, balance, agility, gait, low-volume aerobic, and flexibility.
48021024|NCT06572878|OTHER|Combined cognitive and physical training|Combined cognitive and physical training will follow a group format, with each group consisting of 4-16 participants. Each group will be in a private, independent room for their training sessions and will not interact with participants from other groups. The combined cognitive and physical training components will specifically focus on a single cognitive task and simultaneously handle a single physical task.
48178714|NCT05994976|PROCEDURE|Oral samples collection|biomarkers analysis
48379028|NCT03117972|DRUG|Capecitabine|Maintenance chemotherapy
48379029|NCT00270400|DRUG|nesiritide|
48379030|NCT06040099|DRUG|Durvalumab|Durvalumab IV (intravenous)
48379031|NCT06040099|DRUG|Bevacizumab|Bevacizumab IV (intravenous)
48517882|NCT01673230|PROCEDURE|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
48517883|NCT03440125|DRUG|Cayenne Pepper topical|20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
48517884|NCT03440125|DEVICE|Electrical stimulation|Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
48517885|NCT03440125|PROCEDURE|Massage|10 minutes of classical massage of low back pain area.
48712274|NCT00044187|DRUG|Sibutramine|
48178715|NCT05994976|PROCEDURE|Hair samples collection|biomarkers analysis
48178716|NCT05994976|PROCEDURE|Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)|biomarkers analysis
48379032|NCT06040099|PROCEDURE|Transarterial Radioembolization (TARE)|Yttrium 90 glass microspheres will be administered
48379033|NCT06604806|PROCEDURE|PENG Block|With the patient in the supine position, the ultrasound probe is placed transversely over the anterior superior iliac spine (ASIS). After identifying the ASIS, the transducer is aligned with the pubic ramus and rotated approximately 45 degrees to become parallel to the inguinal crease. The transducer is moved medially until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and psoas tendon are clearly visualized as anatomical landmarks. After confirming the correct location with saline injection, 50 mg of 0.25% bupivacaine will be administered.
48379034|NCT06604806|PROCEDURE|Quadro-Iliac plane block|With the patient in the prone position, a low-frequency convex transducer (2-6 MHz) and a 22G x 100 mm peripheral nerve block needle (Stimuplex® Ultra 360®, B-Braun) will be used. The transducer will be placed transversely at the L3 level to identify the spinal processes, followed by lateral movement to visualize the transverse process within the erector spinae muscle. The transducer will then be rotated parasagittally and moved caudally to locate where the Quadratus Lumborum muscle (QLM) attaches to the iliac crest. After confirming the location with saline, 50 mg of 0.25% bupivacaine will be administered under the fascia of the QLM.
48379035|NCT03985293|DRUG|Placebo|4 matching placebo tablets taken twice a day (BID)
48379036|NCT03985293|DRUG|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
48379037|NCT05537259|OTHER|Observation Group|No intervention; this is an observational study.
48379038|NCT05359861|DRUG|SRF388|SRF388 will be administered by intravenous injection (IV)
48379039|NCT05359861|DRUG|Atezolizumab|Azezolizumab will be administered by IV
48379040|NCT05359861|DRUG|Bevacizumab|Bevacizumab will be administered by IV
48379041|NCT05359861|DRUG|Placebo|Placebo will be administered by IV
48379042|NCT05320926|DRUG|Clopidogrel monotherapy|Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.
48178717|NCT05994976|PROCEDURE|Skin surface material samples|biomarkers analysis
48379043|NCT05320926|DRUG|Aspirin monotherapy|Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.
48379044|NCT05320926|DEVICE|zotarolimus-eluting stent (Resolute Onyx ®)|zotarolimus-eluting stent (Resolute Onyx ®)
48178718|NCT05994976|PROCEDURE|Drainage fluid samples collection|biomarkers analysis
48178719|NCT05994976|PROCEDURE|Stool samples collection|biomarkers analysis
48178720|NCT01845805|DRUG|oral azacitidine|
48178721|NCT01845805|OTHER|Observation|
48178722|NCT01810276|OTHER|Saline|400 mL of Saline will be given intravenously over 2 hours once
48379045|NCT04567680|BEHAVIORAL|Acceptance and Commitment Therapy to Improve Social Support for Veterans with PTSD|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
48517886|NCT02289703|DRUG|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
48517887|NCT00512577|OTHER|Red blood cell transfusion|Pre-operative red blood cell transfusion
48021025|NCT06572878|OTHER|Passive information activities|In passive informational activities, which include a variety of puzzles, audiobooks, and diverse reading materials such as newspapers or listening to news content.
48021026|NCT05747846|PROCEDURE|Carpal tunnel release, WALANT technique|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.
48021027|NCT05747846|PROCEDURE|Carpal tunnel release using a tourniquet|Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
48021028|NCT05211219|DIETARY_SUPPLEMENT|Probiotics|According to the groups, they were involved simultaneously with the treatment, kefir group was advised to consume kefir as a liquid once a day in 14 days; the probiotics group was advised to consume as a chewable tablet once a day in 14 days; the control group was advised without additional food supplements.
48021029|NCT05211219|DIETARY_SUPPLEMENT|AOÇ Kefir|AOÇ Kefir
48021030|NCT05211219|OTHER|Food without additional food supplements|Food without additional food supplements
48379046|NCT04567680|BEHAVIORAL|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
48379047|NCT02305069|DRUG|Pioglitazone|Described elsewhere
48379048|NCT02305069|DRUG|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
48021031|NCT02736162|OTHER|No treatment (intervention) was administered|
48021032|NCT04274738|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
48021033|NCT04274738|DRUG|Ibrutinib|Ibrutinib capsules will be administered per dose and schedule specified in the arm.
48021034|NCT03705754|DEVICE|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
48021035|NCT03054844|DRUG|Lidocaine|Lidocaine will be administered before administration of midazolam.
48021036|NCT03054844|DRUG|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
48021037|NCT03054844|DRUG|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
48021038|NCT01973829|OTHER|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
48021039|NCT01061060|DRUG|Prostaglandin I2|oral
48021040|NCT01061060|DRUG|Placebo|oral
48021041|NCT02044887|OTHER|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
48021042|NCT05812482|PROCEDURE|Drug balloon dilatation|The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated
48021043|NCT05812482|PROCEDURE|Direct vision internal urethrotomy (DVIU)|A control subject will choose DVIU surgery until the desired effect is achieved
48021044|NCT01049555|OTHER|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
48021045|NCT00807781|BIOLOGICAL|Mammaglobin-A DNA vaccine|
48379049|NCT02305069|DRUG|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
48379050|NCT02305069|DRUG|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
48517888|NCT02977819|OTHER|Meditation practice|18 months
48021046|NCT05884437|PROCEDURE|Chiropractic adjustment|Participants will receive 6 weeks of chiropractic care. The frequency of care will be determined by the field clinician. Participants will have their spine assessed for the presence of vertebral subluxations per their clinician's normal and customary procedures. The adjustment technique(s) utilized by the field clinician will be at their discretion.
48178723|NCT01810276|OTHER|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
48178724|NCT00381797|BIOLOGICAL|Bevacizumab|Given IV
48178725|NCT00381797|RADIATION|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
48178726|NCT00381797|DRUG|Irinotecan Hydrochloride|Given IV
48178727|NCT00635401|DRUG|Varenicline|0.5 mg BID for 7 weeks
48178728|NCT00909129|DRUG|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
48178729|NCT00909129|DRUG|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
48178730|NCT04042077|DRUG|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
48178731|NCT04042077|DRUG|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
48178732|NCT04042077|DRUG|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
48178733|NCT04042077|DRUG|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
48178734|NCT04042077|DRUG|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
48712275|NCT04424056|DRUG|Anakinra +/- Ruxolitinib (stages 2b/3)|administration of Anakinra +/- ruxolitinib, depending of evolution
48712276|NCT04424056|DRUG|Anakinra and Ruxolitinib (Advanced stage 3)|administration of Anakinra and ruxolitinib
48712277|NCT04424056|DRUG|Tocilizumab +/- ruxolitinib (stages 2b/3)|administration of Tocilizumab +/- ruxolitinib, depending of evolution
48712278|NCT04424056|DRUG|Tocilizumab and Ruxolitinib (Advanced stage 3)|administration of Tocilizumab and Ruxolitinib
48712279|NCT04424056|OTHER|Standard of care|Treatment with drugs or procedures in routine clinical practice
48178735|NCT05840562|DRUG|Capsaicin|Application of capsaicin patches 179 mg
48178736|NCT05840562|DRUG|Duloxetine|Administration of duloxetine
48178737|NCT03958006|DEVICE|Cochlear implant|Tumor resection with cochlear implant
48178738|NCT01095133|DRUG|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
48379051|NCT02305069|DRUG|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
48712280|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
48178739|NCT01095133|DRUG|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
48178740|NCT01979263|OTHER|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
48178741|NCT01979263|OTHER|Placebo Computer Task|Computer task that does not actively modify attention bias
48178742|NCT06153030|OTHER|no intervention|No intervention
48178743|NCT00887029|DRUG|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
48178744|NCT00887029|DRUG|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
48178745|NCT04999605|DRUG|AK112 low dose|AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor
48178746|NCT04999605|DRUG|AK112 medium dose|AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
48379052|NCT02305069|OTHER|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
48379053|NCT02305069|OTHER|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
48712281|NCT03958591|DRUG|CSII and thereafter combination therapy, followed up in traditional ways|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
48712282|NCT03958591|DRUG|Traditionally upgrading therapy, followed up in traditional ways|The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
48712283|NCT00885638|DRUG|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
48712284|NCT00885638|DRUG|placebo|A placebo tablet is given before ingestion of macronutrients
48712285|NCT00168077|DRUG|Prothrombin Complex Concentrate|
48712286|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Oral Solution
48712287|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 125 mg|Oral Solution
48712288|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 250 mg|Oral Solution
48712289|NCT03554772|DRUG|Placebo|Oral Solution
48712290|NCT02668861|DRUG|Vitamin D|Vitamin D 4000IU/day for 8 weeks
48712291|NCT02668861|DRUG|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
48712292|NCT02668861|OTHER|placebo|placebo for 8 weeks
48712293|NCT05744726|BIOLOGICAL|A-PRF|0.5 to 1g of Advance Platelet-Rich Fibrin (A-PRF) clot for each dental socket.
48379054|NCT04129645|DEVICE|URS|"URS is a permanent ureteral stent made of nitinol and covered by a polymer, that is indicated to open strictures in the ureter.~Study patients who has strictures in the ureter, will be implanted with the URS for long term opening of the stricture."
48712294|NCT05744726|COMBINATION_PRODUCT|Bone-wax|0.5 to 1g of Bone-wax for each dental socket
48712295|NCT00997425|DEVICE|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
48712296|NCT03224871|DRUG|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
48712297|NCT03224871|DRUG|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
48712298|NCT03224871|DRUG|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
48021047|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+CS + PO)|The enucleation procedures, which were meticulously carried out in order to remove the odontogenic keratocyst in one piece without breaking its lining or leaving any epithelial remnants.The peripheral ostectomy treatment will be carried out with a large spherical bur and plenty of irrigation.After filling the bone cavity with more sterile gauze, the Carnoy's solution was slowly injected into it with a plastic syringe. The gauze was continuously injected with CS until it was fully saturated without leaking too much into the surrounding tissues. The CS was held in place for 3 minutes.
48021048|NCT06133764|PROCEDURE|Decompression/ marsupialization (D/M)|A surgical window will be created in the cyst wall to drain the contents while retaining continuity between the cyst and the oral cavity
48021049|NCT06133764|PROCEDURE|Enucleation (E)|The enucleation will be accomplished in the same manner that it will be performed in the group of Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
48021050|NCT06133764|PROCEDURE|Enucleation+Carnoy's solution (E+CS)|Both enucleation and Carnoy's solution will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+Carnoy's solution chemical cauterization (E+ PO+ CS).
48021051|NCT06133764|PROCEDURE|Enucleation+ Peripheral Ostectomy (E+ PO)|Both enucleation and peripheral ostectomy will be carried out as planned in the group Enucleation+ Peripheral Ostectomy+ Carnoy's solution chemical cauterization (E+ PO+ CS).
48021052|NCT04127032|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
48021053|NCT06211582|DEVICE|Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)|The Alkasite-Based Tooth-Colored Material
48021054|NCT06211582|DEVICE|Equia Forte HT ( GC, Tokyo, Japan)|Glass Hybrid Restorative Material
48021055|NCT06211582|DEVICE|Gradia Direct Posterior ( GC, Tokyo, Japan)|Conventional Composite Resin
48021056|NCT05859347|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive neuromodulatory technique that applies alternating magnetic fields to the scalp to induce electric currents in localized cortical tissue. The intervention (LF or HF rTMS) will be administered daily 5 days/week for 4 weeks, using the MagVenture MMC-140 circular coil, with the brain regions targeted as the bilateral prefrontal cortex and the insula.
48021057|NCT05171569|DEVICE|Virtual care with remote automated monitoring (RAM)|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
48021058|NCT02772016|DRUG|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
48021059|NCT05600400|RADIATION|Stereotactic Ablative Body Radiation|2 Fraction
48379055|NCT00112086|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
48379056|NCT05259059|OTHER|No intervention is involved|No intervention is involved
48379057|NCT04328168|PROCEDURE|ROM exercises, stretching, positioning, gait training|
48379058|NCT04328168|PROCEDURE|by two physiotherapist under the supervision of a doctor|
48379059|NCT05069376|DEVICE|Ureteral Stent of 5-16 or 5-18|Boston Scientific Polaris™ Ultra Ureteral Stent
48712299|NCT03224871|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
48021060|NCT02634658|OTHER|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
48021061|NCT02634658|OTHER|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
48379060|NCT05069376|DEVICE|Ureteral Stent of 5-22 or 5-24|Boston Scientific Polaris™ Ultra Ureteral Stent
48379061|NCT03297593|DRUG|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
48379062|NCT03297593|DRUG|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
48379063|NCT03359499|DRUG|Bacillus clausii|Oral suspension administered BID
48517889|NCT02977819|OTHER|Learning English as a foreign language|18 months
48712300|NCT00505037|DRUG|ASP1585|Oral
48712301|NCT00505037|DRUG|Placebo|Oral
48021062|NCT02634658|OTHER|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
48712302|NCT00505037|DRUG|Sevelamer hydrochloride|Oral
48712303|NCT01361074|BEHAVIORAL|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
48021063|NCT00192725|OTHER|rapid tryptophan depletion|Amino-acid mixture without tryptophan
48021064|NCT03604718|BIOLOGICAL|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
48021065|NCT02252081|DRUG|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
48021066|NCT02252081|DRUG|Placebo|placebo pill(s) orally per day for 16 weeks
48021067|NCT00734838|DEVICE|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
48021068|NCT04487977|OTHER|Survey|Answering a survey on airway management in COVID-19 patients
48021069|NCT00546143|DRUG|Omalizumab|
48021070|NCT00546143|DRUG|Omalizumab|
48021071|NCT00546143|DRUG|Omalizumab|
48379064|NCT03359499|DRUG|Trimebutine|One tablet of 200 mg of trimebutine administered BID
48379065|NCT02255045|DRUG|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
48379066|NCT02255045|DRUG|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
48379067|NCT02255045|DRUG|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
48379068|NCT02255045|DRUG|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
48517890|NCT03383523|DRUG|Emodepside (BAY 44-4400)|2 tablets compared to the liquid formulation
48517891|NCT04912232|DEVICE|Detection of Occult Hemorrhage in Trauma Patients|Non-invasive monitoring of trauma patients
48517892|NCT01778634|DRUG|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
48517893|NCT01778634|DRUG|Placebo|D5W
48517894|NCT05115695|OTHER|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
48517895|NCT05115695|OTHER|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
48517896|NCT01284361|DEVICE|30 cm Intermittent Catheter|Randomized cross-over
48379069|NCT03733379|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
48178747|NCT04999605|DRUG|AK112 high dose|AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
48178748|NCT00002406|DRUG|Indinavir sulfate|
48178749|NCT01580683|DRUG|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
48379070|NCT03733379|DRUG|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
48379071|NCT03733379|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
48379072|NCT03733379|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
48021072|NCT04297046|DEVICE|PCA (patient controlled analgesia)|Intravenous Patient-Controlled Analgesia was used for postoperative pain control with a bolus dose of 25 mg Tramadol and a lockout interval of 20 min. The pain was evaluated at different times after the operation, both at rest and movement (Dynamic VAS) at the 0., 2., 6., 12. hours and 24h later. All patients received 1 g iv paracetamol 8 hourly intervals regularly. 75 mg im diclofenac sodium was given as rescue analgesic.
48178750|NCT01580683|OTHER|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
48178751|NCT03166046|DEVICE|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
48178752|NCT03166046|DEVICE|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
48178753|NCT02219399|DIETARY_SUPPLEMENT|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
48178754|NCT02219399|DIETARY_SUPPLEMENT|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
48178755|NCT02219399|DIETARY_SUPPLEMENT|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
48379073|NCT03733379|DIETARY_SUPPLEMENT|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
48379074|NCT03733379|DIETARY_SUPPLEMENT|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
48178756|NCT05196880|DEVICE|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
48379075|NCT03174457|DRUG|Micafungin|Intravenous
48517897|NCT01284361|DEVICE|40 cm Intermittent Catheter|randomized cross-over
48517898|NCT02494661|BEHAVIORAL|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
48517899|NCT02494661|BEHAVIORAL|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
48021073|NCT06346977|DRUG|Pemetrexed|Intrathecal injection of pemetrexed
48021074|NCT06037889|DRUG|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
48021075|NCT06037889|DRUG|Aspirin tablet|Aspirin. Oral administration.
48021076|NCT06037889|DRUG|Clopidogrel tablet|Clopidogrel. Oral administration.
48178757|NCT05115045|DIAGNOSTIC_TEST|plasmatic SARS-CoV-2 RNA quantification|plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR
48178758|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
48021077|NCT00646958|DRUG|Radezolid|450mg PO QD
48021078|NCT00646958|DRUG|Radezolid|450mg PO BID
48178759|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
48178760|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 0
48178761|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
48178762|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
48379076|NCT01881711|DEVICE|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
48379077|NCT01881711|DEVICE|Imaging|Imaging of ventricle size
48712304|NCT01361074|BEHAVIORAL|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
48712305|NCT01884493|DEVICE|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
48712306|NCT01884493|DEVICE|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
48712307|NCT00002427|DRUG|Hydroxyurea|
48712308|NCT00002427|DRUG|Stavudine|
48712309|NCT00002427|DRUG|Didanosine|
48712310|NCT02596373|DRUG|Mitoxantrone Hydrochloride Liposome Injection|
48712311|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
48712312|NCT00509743|DRUG|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
48712313|NCT05732584|OTHER|structured family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
48178763|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 4
48178764|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
48178765|NCT01264445|BIOLOGICAL|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
48178766|NCT05920863|PROCEDURE|TACE|TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
48178767|NCT05920863|DRUG|Tislelizumab, Lenvatinib|Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day.
48178768|NCT05995093|OTHER|no intervention|no intervention
48712314|NCT05732584|OTHER|unstructured family voice stimulation|The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
48712315|NCT02276118|DEVICE|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
48021079|NCT00646958|DRUG|Linezolid|600mg PO BID
48021080|NCT01353339|DRUG|Levofloxacin|500mg, PO, once daily for 3 months
48021081|NCT05740930|OTHER|Partition defocus myopia management spectacle lens|Participants in the intervention group will receive the partition defocus myopia management spectacles lens and receive follow-up checks.
48021082|NCT05740930|OTHER|Spectacle lenses with aspherical lenslets|Participants in the control group will receive the spectacle lenses with aspherical lenslets and receive follow-up checks.
48021083|NCT01030224|DRUG|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
48021084|NCT01030224|DRUG|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
48021085|NCT05944263|BEHAVIORAL|weRISE; The gratitude, kindness and hope (GKH) program|weRISE is an arts based train the trainer intervention that promotes positive mental health through cultivating gratitude, kindness and hope among youth in schools and informal settlements in India and Kenya
48178769|NCT06031961|DRUG|melatonin|We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
48178770|NCT02134366|DRUG|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
48379078|NCT00061269|PROCEDURE|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
48379079|NCT03076710|DRUG|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
48379080|NCT03076710|DRUG|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
48379081|NCT02616341|BEHAVIORAL|Team ERP (T-ERP) Intervention|
48379082|NCT02616341|BEHAVIORAL|Treatment as Usual (TAU)|
48379083|NCT00620191|DRUG|Metformin|Metformin 1000 mg twice a day titrated from 500 mg once a day
48021086|NCT05944263|BEHAVIORAL|The [adapted] Stan Kutcher Teen Mental Health (TMH) program|The 'Teen Mental Health' curriculum developed by Dr. Stan Kutcher, aims to increase mental health literacy among young people ;will be used in the control group (active comparator group). The control intervention consists of eight sessions (45 minutes each) delivered by older groups of young people (ages 18-24) in schools and community settings through a didactic approach.
48021087|NCT03272191|PROCEDURE|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
48021088|NCT00151645|DRUG|activated lymphocytes|
48021089|NCT01959581|DEVICE|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
48021090|NCT06464055|DRUG|Dose Escalation|GQ1010
48021091|NCT06464055|DRUG|Dose Expansion1|GQ1010 dose1
48379084|NCT00620191|DRUG|Placebo|Placebo identical to metformin 2 tablets twice a day titrated from one table once a day
48379085|NCT01757795|DRUG|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
48379086|NCT01757795|DRUG|Placebo|Placebo will be intravenously administered
48379087|NCT05518058|OTHER|device and exercises|device and exercises
48379088|NCT04836832|DRUG|Acalabrutinib|Given PO
48379089|NCT04836832|DRUG|Duvelisib|Given PO
48712316|NCT02276118|DEVICE|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
48712317|NCT05713903|PROCEDURE|Laparoscopic right colectomy|Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
48712318|NCT05713903|PROCEDURE|Open right colectomy|Resection of the ascending colon via an open approach, adhering to the CME principles
48712319|NCT05804630|DRUG|Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)|As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
48517900|NCT00005811|DRUG|topotecan hydrochloride|Given IT
48712320|NCT03366103|BIOLOGICAL|Navitoclax|Given PO
48712321|NCT03366103|DRUG|Vistusertib|Given PO
48712322|NCT00149994|DRUG|Cyclosporine A|
48712323|NCT00149994|DRUG|Tacrolimus|
48712324|NCT00149994|DRUG|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
48712325|NCT00149994|DRUG|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
48712326|NCT00149994|DRUG|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
48712327|NCT02574013|DEVICE|Endoractor®|Endoscopic sponge for retraction of small intestine
48712328|NCT00751309|OTHER|Non-interventional|Post-transplantation observational study
48712329|NCT00989521|DRUG|PUR003|PUR003 for inhalation
48712330|NCT00989521|DRUG|Placebo|Normal saline for inhalation
48021092|NCT06464055|DRUG|Dose Expansion2|Drug: GQ1010 dose2
48021093|NCT06464055|DRUG|phase II|Drug: GQ1010 RP2D
48021094|NCT03783559|DRUG|TACE|TACE
48021095|NCT03783559|DRUG|chemotherapy±target therapy|chemotherapy±target therapy
48021096|NCT06431620|DRUG|Recombinant Human Thyroid Stimulating Hormone|recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
48021097|NCT01075321|DRUG|everolimus|Given orally
48021098|NCT01075321|DRUG|lenalidomide|Given orally
48021099|NCT01075321|OTHER|laboratory biomarker analysis|Correlative studies
48021100|NCT01075321|GENETIC|polymorphism analysis|Correlative studies
48021101|NCT01075321|OTHER|immunohistochemistry staining method|Optional correlative studies
48021102|NCT01075321|GENETIC|microarray analysis|Optional correlative studies
48021103|NCT01075321|GENETIC|fluorescence in situ hybridization|Optional correlative studies
48021104|NCT06569043|OTHER|Breakfast Bar|Packaged breakfast bar product available in retail stores
48021105|NCT06463535|DRUG|Omega 3|SRP + OMEGA 3
48021106|NCT06463535|PROCEDURE|SRP alone|Scaling and root planning
48021107|NCT03327480|OTHER|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
48021108|NCT05789875|OTHER|aDOT-CEI|For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
48021109|NCT00228449|DRUG|peginesatide|
48021110|NCT03767491|DEVICE|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
48178771|NCT02134366|DRUG|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
48178772|NCT02134366|DRUG|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
48379090|NCT04887922|DEVICE|MIR Spirobank G|FDA-approved, Bluetooth digital spirometer
48517901|NCT00005811|OTHER|laboratory biomarker analysis|Correlative studies
48517902|NCT02970487|DEVICE|Intraocular implant of the Precisight|Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
48021111|NCT04167397|OTHER|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
48021112|NCT03991741|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
48021113|NCT03991741|BIOLOGICAL|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
48379091|NCT04887922|DEVICE|ZEPHYRx®|ZEPHYRx® has developed a 1) digital Bluetooth-enabled IS that allows for the continuous and objective remote monitoring of patient compliance with pre- and postoperative IS via a smartphone app and online provider dashboard.
48379092|NCT04887922|DEVICE|Conventional spirometer|Will be provided to participants
48379093|NCT06538376|DIAGNOSTIC_TEST|Portable Dynamic Digital Radiography (DDR)|"(DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team).~If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication."
48379094|NCT05242900|PROCEDURE|Complete decongestive therapy|The investigators will identify participants undergoing clinically-indicated interventions that they are already receiving for their routine clinical management (complete decongestive physical therapy). They will make no evaluation of the efficacy of these procedures, but rather will test fundamental hypotheses regarding lymphatic clearance of tissue sodium.
48379095|NCT05242900|OTHER|Standard imaging protocol|The standard imaging protocol entails noninvasive magnetic resonance imaging techniques including sodium and lymphatic angiography.
48517903|NCT06093893|DRUG|Dexmedetomidine|1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
48517904|NCT06093893|DRUG|Nicardipine|1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or
48517905|NCT06093893|DRUG|Labetalol|20 - 80 mg will be administered intravenously at 10-minute intervals to maximum of 300 mg;
48712331|NCT04585711|DRUG|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
48712332|NCT00385398|DRUG|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
48712333|NCT00385398|DRUG|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
48712334|NCT00385398|RADIATION|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
48712335|NCT01684644|BEHAVIORAL|New Forest Parenting Programme|
48712336|NCT01684644|BEHAVIORAL|Treatment as usual|
48712337|NCT05324020|BEHAVIORAL|Medication adherence eHealth intervention|"The eHealth intervention consists a Medication Event Monitoring Systems (MEMS®) Helping Hand and MEMS Adherence Software application. The eHealth intervention will support BCS to adhere to their OHT (i) by alerting them to take their OHT, and (ii) by allowing patient-physician communication.~The eHealth intervention comprises a questionnaire that should be filled-out weekly and that informs about the presence and severity of side effects. These data are collected in real-time and monitored on a weekly basis by the clinical research nurse (CRN) in charge of the study. In case of an alert, meaning recurrent non-adherence and/or reporting of side-effects, the CRN will contact the breast cancer nurse (BCN) in charge of the patient. Thus the BCN will contact the patient by phone to check on their health status and together define the future procedures (behavioral strategies)."
48021114|NCT06535269|PROCEDURE|Monopolar Hemorroidecotmy|Hemorrhoidectomy with monopolar diathermy
48712338|NCT00511433|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
48712339|NCT00511433|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
48712340|NCT01669018|PROCEDURE|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
48021115|NCT06535269|PROCEDURE|Caiman Hemorroidectomy|Hemorrhoidectomy with Caiman® bipolar energy
48021116|NCT02588118|DRUG|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
48178773|NCT01670071|DRUG|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
48021117|NCT02588118|DRUG|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
48021118|NCT04980638|BIOLOGICAL|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
48021119|NCT00506935|DRUG|GVG|5 grams GVG
48178774|NCT01670071|DRUG|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
48712341|NCT01669018|PROCEDURE|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
48178775|NCT01262547|DEVICE|Dermabrasion-Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
48379096|NCT06355180|DRUG|Subanesthetic dose intravenous esketamine|"The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Esketamine (0.2mg/kg) is given intravenously three times a week for two weeks. Dosage and sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments."
48379097|NCT06355180|DEVICE|Modified electroconvulsive therapy|"The study, lasting 12 weeks, includes a 2-week intervention and 10-week follow-up. Modified electroconvulsive therapy (MECT) is given three times a week for two weeks. Sessions may adjust for safety and efficacy, with study treatments limited during follow-up.~Efficacy is evaluated via scales measuring suicidal ideation, depression, cognition, and social function. Adverse effects are tracked through vital signs, exams, events, and tests.~Biological samples (blood, urine, feces) are collected from some participants at baseline, post-first, and sixth treatments for omics analyses.~Brain imaging from some participants at baseline and post-sixth treatment aims to obtain high-resolution T1, T2 FLAIR, resting fMRI, and DTI images.~Electrophysiological data, including resting state EEG signals and task paradigms, are collected from some participants at baseline, after the first, and sixth treatments."
48379098|NCT01808508|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
48379099|NCT01808508|DEVICE|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
48379100|NCT02059681|OTHER|Autologous bone marrow derived-CD133+ cells|Cell therapy
48379101|NCT05764629|DIAGNOSTIC_TEST|blood test|Testing the peripheral blood for PPDM-C, including blood glucose, glycated hemoglobin A1c, fasting insulin and C-peptide, etc.
48712342|NCT01976897|OTHER|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
48379102|NCT05764629|DRUG|pharmacologic approaches to glycemic treatment|documenting the change of glycemic treatment during the follow-up period
48379103|NCT04536818|PROCEDURE|Laparotomy|Exploratory laparotomy.
48517906|NCT02145715|DRUG|Velcade|
48517907|NCT02145715|DRUG|Thalidomide|
48517908|NCT02145715|DRUG|Dexamethasone|
48517909|NCT02145715|DRUG|Panobinostat|
48712343|NCT01976897|OTHER|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
48021120|NCT00506935|DRUG|placebo|placebo
48021121|NCT03208972|DRUG|low dose hCG|
48021122|NCT03208972|DRUG|hp-FSH|
48021123|NCT03208972|DRUG|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG"
48021124|NCT05673694|DRUG|EG017|According to the dosage group of the program, once a day.
48021125|NCT03955484|DIAGNOSTIC_TEST|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
48178776|NCT01262547|PROCEDURE|Dermabrasion|Only dermabrasion (removal of epidermis) alone will be done at baseline.
48178777|NCT05276778|DIAGNOSTIC_TEST|Diabetic Retinopathy Screening|Screenings are performed in the diabetes consultation in general practice
48178778|NCT02171884|OTHER|Sample of cord blood|
48178779|NCT02171884|OTHER|Sample of placenta|
48178780|NCT04564521|DRUG|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.
48178781|NCT04564521|DRUG|Normal saline|Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
48178782|NCT01902186|DRUG|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
48021126|NCT01700946|DRUG|dexamethasone|given intravenously or orally
48021127|NCT01700946|DRUG|vincristine sulfate|given intravenously
48021128|NCT01700946|BIOLOGICAL|rituximab|given intravenously
48178783|NCT01902186|DRUG|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
48178784|NCT05750589|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
48178785|NCT05750589|DRUG|Providone-Iodine|5% Providone-Iodine
48178786|NCT05917132|OTHER|Nutritionnal intervention|Participants will be provided with meals corresponding to each diet during the week. Participants will be required to eat only the meals provided.
48178787|NCT00905034|DRUG|Methotrexate|200 mg/m\^2 by vein on days 1 and 15.
48178788|NCT00905034|DRUG|Vincristine|1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
48178789|NCT00905034|DRUG|PEG-l-asparaginase|2500 International units/m\^2 by vein on days 2 and 16
48178790|NCT00905034|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
48178791|NCT00905034|DRUG|Rituximab|Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
48178792|NCT02825186|DRUG|Loteprendol etabonate 0.5%|Steroid eye drops used after strabismus surgery.
48178793|NCT02825186|DRUG|Dexamethasone 0.1%|
48178794|NCT03003598|OTHER|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
48379104|NCT06487390|BEHAVIORAL|PrEP Pro training intervention|Training intervention adapted from evidence-based HIV epidemiology, sexual history taking, and PrEP prescription curricula.
48021129|NCT01700946|DRUG|clofarabine|given intravenously
48021130|NCT01700946|DRUG|cyclophosphamide|given intravenously
48178795|NCT03003598|OTHER|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
48178796|NCT00184379|BEHAVIORAL|Psychoeducation|Structured disorder-related educational program for relatives
48178797|NCT05495698|DRUG|single-inhaler triple therapy (Trimbow)|Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
48379105|NCT06108973|DEVICE|Capnography|To know the Co2 graph in COPD and Normal patients under General Anesthesia
48379106|NCT02230332|DRUG|Alendronate|
48517910|NCT03872973|OTHER|Neuromuscular Training|"The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses."
48021131|NCT01700946|DRUG|etoposide|given intravenously
48021132|NCT01700946|BIOLOGICAL|aldesleukin|given subcutaneously
48021133|NCT01700946|DRUG|pegaspargase|given intravenously
48021134|NCT01700946|DRUG|methotrexate|given intrathecally or intravenously
48021135|NCT01700946|DRUG|mercaptopurine|given orally
48021136|NCT01700946|DRUG|cytarabine|given intrathecally or intravenously
48021137|NCT01700946|DRUG|mitoxantrone|given intravenously
48021138|NCT01700946|DRUG|teniposide|given intravenously
48021139|NCT01700946|DRUG|vinblastine|given intravenously
48021140|NCT01700946|BIOLOGICAL|natural killer cell infusion|undergo allogeneic natural killer cell infusion
48021141|NCT01700946|OTHER|laboratory biomarker analysis|correlative studies
48021142|NCT01700946|DRUG|therapeutic hydrocortisone|given intrathecally
48021143|NCT01700946|PROCEDURE|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
48021144|NCT01700946|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
48021145|NCT01953484|OTHER|Change in extracorporeal carbon dioxide removal|
48021146|NCT03185624|DRUG|Rifaximin|Antibiotics
48021147|NCT02838017|DEVICE|Tissue Adhesive|
48178798|NCT05495698|DEVICE|E-health application: Curavista app & FindAir e-device|Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir
48178799|NCT05495698|DRUG|multi-inhaler triple therapy (Qvar + Bevespi)|Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
48178800|NCT04016272|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
48178801|NCT04016272|DEVICE|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
48178802|NCT04064294|DRUG|Intravenous Infusion|Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
48178803|NCT00227123|DRUG|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
48178804|NCT00839332|DRUG|LY2603618|
48379107|NCT02230332|DRUG|Placebo|
48379108|NCT05809440|OTHER|20-minute mindful breathing session|A 20-minute mindful breathing session guided by a trained medical doctor. The session consisted of four 5-minute breathing exercises done consecutively. Participants were instructed to close their eyes and bring their attention to their breathing, and re-direct their attention back to their breathing once they were distracted.
48379109|NCT02407483|DEVICE|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
48379110|NCT02407483|DEVICE|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
48379111|NCT01898390|PROCEDURE|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
48178805|NCT00839332|DRUG|Gemcitabine|
48178806|NCT00573651|OTHER|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
48178807|NCT01437423|BIOLOGICAL|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
48178808|NCT05040945|PROCEDURE|Traditional corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with traditional corticotomy will be applied.
48178809|NCT05040945|PROCEDURE|Flapless corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with flapless corticotomy will be applied.
48178810|NCT03437135|DIAGNOSTIC_TEST|Glasgow Hearing Status Inventory questionnaire|"This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no."
48178811|NCT04519593|PROCEDURE|Laparoscopic myomectomy with prior temporary uterine blood supply occlusion|Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
48178812|NCT04519593|PROCEDURE|Conventional laparoscopic myomectomy|Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
48379112|NCT00632866|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
48379113|NCT00632866|DRUG|Placebo|Placebo : 2cp/ day since 24 weeks
48712344|NCT01976897|OTHER|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
48712345|NCT05728151|DRUG|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
48178813|NCT04517383|PROCEDURE|post-operative sedation|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
48178814|NCT04517383|PROCEDURE|routine recovery|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
48178815|NCT05442346|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
48178816|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
48178817|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
48178818|NCT01288209|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
48178819|NCT01288209|DRUG|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
48178820|NCT01288209|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
48178821|NCT05352945|DEVICE|HyPNOS self-hypnosis mask from DREAMINZZ|"The use of the HyPNOS self-hypnosis mask from DREAMINZZ allows patients to immerse themselves in a state of self-hypnosis.~A Hypnos session is a narrative accompanied by spatialized sounds (3D) and ambiance for an immersive experience.~We aim to evaluate the use of the HyPNOS mask in the management of pain and anxiety in botulinum toxin injections"
48178822|NCT03045809|DIAGNOSTIC_TEST|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
48178823|NCT00698347|DEVICE|M2a-Magnum™ Hip System|
48379114|NCT00421746|DRUG|Piboserod|
48712346|NCT05728151|DRUG|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
48379115|NCT02495974|DRUG|enzalutamide|oral
48379116|NCT02765906|OTHER|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
48712347|NCT05728151|DRUG|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
48712348|NCT05976022|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
48379117|NCT02765906|OTHER|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
48379118|NCT00209560|DRUG|fospropofol disodium|
48517911|NCT03872973|OTHER|Strobe Glasses|Stroboscopic glasses, which is characterized by intermittent vision obstruction, is a clinical tool that allows clinicians to examine sensory feedback in a progressive manner without fully seeing visual information.
48021148|NCT02838017|DEVICE|Sterile strips|
48178824|NCT05874778|DRUG|6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy|All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
48178825|NCT05874778|RADIATION|Radiotherapy beyond standard R-CHOP Chemotherapy|Radiotherapy: after completion of the standard R-CHOP treatment, enrolled patients will be divided into radiotherapy group and non-radiotherapy group. In radiotherapy group, further consolidation radiotherapy targeting patients' pre-treatment large masses or extranodal affected areas will be given, with routine segmentation of 30-36Gy/15-18f.
48178826|NCT01452737|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Golytely the day prior to procedure.
48178827|NCT01452737|DRUG|2L Golytely/bisacodyl|Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
48178828|NCT04797598|OTHER|Virtual reality group|This will receive Virtual reality sessions and both group will receive conventional physical therapy as base line treatment
48178829|NCT04797598|OTHER|Cyclic training group|This will receive cyclic training session. both group will receive conventional physical therapy as base line treatment
48178830|NCT02871583|PROCEDURE|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
48178831|NCT02871583|PROCEDURE|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
48178832|NCT03374293|RADIATION|Radiation|RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .
48178833|NCT03374293|DRUG|Anti-PD-1 Antibody|Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
48178834|NCT03253068|DRUG|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
48178835|NCT03984877|DIAGNOSTIC_TEST|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
48178836|NCT00848510|BIOLOGICAL|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease \[SD\], complete response \[CR\], or partial response \[PR\]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
48178837|NCT03672487|DRUG|Benznidazole|Benznidazole tablet
48178838|NCT03672487|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic Benznidazole
48178839|NCT06149845|PROCEDURE|Full Pulpotomy|Pulpotomy is a more conservative pulp treatment option where only the coronal pulp is removed and a medicament placement over the remnant radicular pulp after haemostasis is achieved.
48178840|NCT02656550|PROCEDURE|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
48178841|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
48178842|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
48266869|NCT04853628|BEHAVIORAL|Alerta Alcohol 2.0|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
48712349|NCT01666639|BEHAVIORAL|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
48712350|NCT01666639|BEHAVIORAL|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
48712351|NCT01997814|DRUG|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
48712352|NCT01997814|DRUG|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
48712353|NCT04143217|DRUG|SPN-812|SPN-812 200 to 600 mg/day
48712354|NCT02390674|DRUG|Ciclosporin|Comparison between ciclosporin and placebo
48712355|NCT02390674|DRUG|Saline|
48712356|NCT04312607|DIAGNOSTIC_TEST|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
48379119|NCT06192069|OTHER|Sustainable Heat Strain Prevention Program for Agricultural Elderly Workers (SHiP-AEW)|The SHiP-AEW is a 4-week multifaceted intervention program focused on evidence-based heat strain prevention strategies for agricultural workers over 60 years old. Delivered through weekly 1-hour sessions, the program incorporates the following primary components:
48379120|NCT00910000|DRUG|Vorinostat|
48712357|NCT05993780|OTHER|No drugs or biologial agents were used in our trial|Before the measurement, a recruitment maneuver was performed for 30-40 s at a PEEP level of 20 cmH2O. At four different PEEP levels of 15, 10, 5, and 0 cmH2O, a decreasing PEEP trial was performed, and the measurement results were recorded.The measurement time at each PEEP level was chosen as 10 minutes. At the end of the measurement, static compliance was measured by applying an end-inspiratory pause. Respiratory system elastance,static strain volume gain was calculated.The estimated lung volume recovered was calculated using the formula ∆EELV - (∆PEEP x Compliance PEEPlow) and compared with the volume gain.
48712358|NCT00991328|PROCEDURE|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
48712359|NCT04175522|DRUG|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
48379121|NCT00910000|DRUG|Carboplatin|
48379122|NCT00910000|DRUG|Gemcitabine|
48379123|NCT06246656|PROCEDURE|Maxillary Expansion|Palatal Expansion using a CAD/CAM appliance
48379124|NCT06636019|DEVICE|Myopia control contact lens|Myopia control contact lens is placed on the study eye.
48379125|NCT00003104|RADIATION|radiation therapy|
48379126|NCT00007332|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
48266870|NCT01960322|BEHAVIORAL|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
48379127|NCT00007332|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
48379128|NCT02632448|DRUG|LY2880070|Capsules
48379129|NCT02632448|DRUG|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
48379130|NCT01905631|DRUG|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
48379131|NCT00011999|DRUG|cisplatin|
48021149|NCT03204942|DEVICE|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
48021150|NCT03204942|DEVICE|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
48021151|NCT03204942|DRUG|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
48379132|NCT00011999|DRUG|paclitaxel|
48021152|NCT00945516|DEVICE|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
48021153|NCT00945516|DEVICE|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
48021154|NCT00096941|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
48021155|NCT05163860|OTHER|Survey|Participants will complete an online survey.
48021156|NCT02316236|DRUG|dexmedetomidine|an alpha-2 receptor agonist
48021157|NCT02316236|OTHER|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
48021158|NCT02316236|OTHER|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
48021159|NCT05187455|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
48021160|NCT06075511|DIAGNOSTIC_TEST|6 minutes walk distance|Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
48021161|NCT06075511|BEHAVIORAL|Activity Monitor|Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
48379133|NCT00011999|PROCEDURE|conventional surgery|
48379134|NCT00011999|RADIATION|radiation therapy|
48178843|NCT05713162|BEHAVIORAL|Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).|The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
48021162|NCT06075511|BEHAVIORAL|Continuous Glucose Monitor|Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
48517912|NCT02307773|DRUG|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
48379135|NCT00900276|OTHER|immunologic technique|
48379136|NCT00900276|OTHER|laboratory biomarker analysis|
48379137|NCT00900276|OTHER|mass spectrometry|
48379138|NCT01366846|OTHER|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
48021163|NCT06075511|BEHAVIORAL|Blood Pressure Monitoring|Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
48379139|NCT03676816|PROCEDURE|vaginal self sampling|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
48379140|NCT03676816|PROCEDURE|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
48517913|NCT01223391|OTHER|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
48021164|NCT06075511|DIAGNOSTIC_TEST|Blood Pressure Monitoring|24-hour ambulatory blood pressure monitoring
48021165|NCT06075511|DIAGNOSTIC_TEST|Body Composition Scan|Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.
48021166|NCT06075511|DIAGNOSTIC_TEST|Mixed meal testing|Subjects will consume 6 ml/kg body weight of Boost, up to maximum of 360 ml, within 5 min
48021167|NCT06075511|DIAGNOSTIC_TEST|Quality of Life|Subject will complete Quality of Life Questionnaire
48021168|NCT00259753|DRUG|Bevasiranib|
48021169|NCT03421613|DRUG|3VM1001|Self treatment 3 times daily for 10 days
48021170|NCT03421613|OTHER|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
48021171|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
48021172|NCT00824590|DRUG|Dimebon|a single oral dose of 20 mg Dimebon
48178844|NCT05846698|DRUG|Luo-Bu-Fu-Ke-Bi-RI Pill|10 pills twice daily
48178845|NCT05846698|DRUG|tibolone|2.5 mg once daily
48178846|NCT03391856|DRUG|N-acetyl-L-cysteine (NAC)|NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
48178847|NCT03391856|OTHER|supportive therapy|prophylactic platelet transfusion was given when platelet count \<20000/ul
48178848|NCT06463236|OTHER|Guiding treatment|Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process
48178849|NCT06463236|OTHER|empirical therapy|Experiential treatment by grassroots doctors
48178850|NCT02365103|OTHER|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
48178851|NCT02365103|OTHER|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
48178852|NCT02365103|OTHER|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
48517914|NCT01223391|OTHER|No abdominal binder|Standing without abdominal binder for 3 minutes
48021173|NCT00491244|DRUG|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
48021174|NCT00491244|DRUG|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
48021175|NCT02610140|DRUG|Anetumab ravtansine (BAY94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
48021176|NCT02610140|DRUG|Vinorelbine|Starting dose: 30mg/m\^2 administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
48178853|NCT02365103|OTHER|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
48178854|NCT03470545|DRUG|mavacamten|mavacamten capsules
48178855|NCT03470545|DRUG|Placebo|placebo oral capsule
48178856|NCT06228820|DRUG|Aspirin 81Mg Ec Tab|Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
48178857|NCT01674920|BEHAVIORAL|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
48178858|NCT05915533|OTHER|Dance therapy|Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
48517915|NCT04505566|DRUG|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
48517916|NCT04505566|DRUG|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
48712360|NCT05123521|DIAGNOSTIC_TEST|urine analysis|Urine was then tested for evidence of substance abuse using the multi-drug screen panel dip steak ABONtm (Abon Biopharm (Hangzhou) CO., Ltd) which is a lateral flow chromatographic immunoassay . It allowed for qualitative detection of multiple drugs in a single run. This kit was chosen for its ability to detect the most commonly abused substances in Egypt, namely: opioids, benzodiazepines, hashish, and tramadol. A single coloured line at region C for of a specific drug indicated a positive result, whilst two coloured lines at both regions C and T indicated a negative result. The absence of coloured lines was an indication of the invalidity of the particular kit, and the kit was discarded.
48178859|NCT00311246|DRUG|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
48178860|NCT05109936|DRUG|Adenuric|Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), hypo-uricemic treatment, for a period of 2 x 6 weeks
48712361|NCT04646161|DRUG|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
48178861|NCT06039722|DEVICE|Pulse ablation catheter|Pulse ablation catheter is used to ablate the junction of left atrium and pulmonary vein, removing pulmonary vein potential
48178862|NCT00120809|DRUG|Sulfadoxine-pyrimethamine|
48178863|NCT00003626|DRUG|dolastatin 10|
48178864|NCT01192789|DRUG|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
48021177|NCT03430466|DRUG|Durvalmab&Tremelimumab&Fulvestrant|Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks
48712362|NCT00723346|BIOLOGICAL|GRASPA|50 UI/Kg
48021178|NCT04332744|DRUG|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
48021179|NCT04332744|DRUG|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
48021180|NCT02248584|DIETARY_SUPPLEMENT|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
48021181|NCT00217906|BEHAVIORAL|A+ Asthma early intervention program|
48021182|NCT02671123|PROCEDURE|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
48379141|NCT01723371|DRUG|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
48379142|NCT03596476|PROCEDURE|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
48712363|NCT00723346|BIOLOGICAL|GRASPA|100 UI/Kg
48021183|NCT02671123|PROCEDURE|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
48021184|NCT05919238|COMBINATION_PRODUCT|Padeliporfin Vascular Targeted Photodynamic (VTP) therapy|The laser light fiber with inflatable balloon to dam SMA blood flow during light illumination will be placed by an Interventional Radiologist in the SMA via a transfemoral artery approach. The balloon will be inflated to impede blood flow for total of 10 minutes during light illumination
48021185|NCT02031276|DRUG|risankizumab IV|risankizumab administered by IV infusion
48021186|NCT02031276|DRUG|risankizumab SC|risankizumab administered by SC injection
48021187|NCT02031276|DRUG|Placebo|Placebo for risankizumab administered by IV infusion
48178865|NCT01192789|OTHER|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
48178866|NCT04185298|BEHAVIORAL|mSIM intervention plus activity monitoring|Participants will receive the full mSIM intervention and be monitored (via Fitbit)
48379143|NCT03596476|PROCEDURE|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
48517917|NCT04505566|OTHER|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
48712364|NCT00723346|BIOLOGICAL|GRASPA|150 UI/Kg
48712365|NCT00723346|DRUG|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
48021188|NCT05341921|BEHAVIORAL|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
48021189|NCT05341921|BEHAVIORAL|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
48021190|NCT05341921|BEHAVIORAL|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
48021191|NCT02262429|OTHER|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
48712366|NCT03211793|DRUG|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
48021192|NCT02262429|OTHER|ONS Standard Feeding|Standard of care
48178867|NCT04185298|BEHAVIORAL|Activity monitoring|Participants will have activity monitored (via Fitbit)
48178868|NCT01542554|OTHER|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
48712367|NCT03211793|OTHER|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
48712368|NCT01981863|DRUG|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
48712369|NCT01981863|DRUG|Placebo|Placebo administered in same volume as in experimental arm.
48712370|NCT02227173|DRUG|BMS-986020|
48712371|NCT02227173|DRUG|Montelukast|
48712372|NCT02227173|DRUG|Flurbiprofen|
48712373|NCT02227173|DRUG|Digoxin|
48021193|NCT01826149|DRUG|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
48021194|NCT01826149|DRUG|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
48021195|NCT01826149|DRUG|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
48712374|NCT01170598|OTHER|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
48712375|NCT02670798|PROCEDURE|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
48712376|NCT04233658|DRUG|Placebo|3x2 capsules / day
48712377|NCT04233658|DRUG|Cynara Scolymus|3x2 capsules / day
48021196|NCT04575779|DRUG|Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h|To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.
48021197|NCT01390558|PROCEDURE|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
48021198|NCT01067079|OTHER|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
48021199|NCT01340989|PROCEDURE|alteration of the insufflation gas|addition of 4% oxygen
48021200|NCT01340989|PROCEDURE|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~* humidification~* set temperature of 32°C"
48178869|NCT01542554|OTHER|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
48178870|NCT00479843|BEHAVIORAL|Nutritional programme|
48712378|NCT01649544|DEVICE|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
48712379|NCT01649544|DRUG|Amiodarone|
48712380|NCT03275688|DIAGNOSTIC_TEST|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
48712381|NCT01672099|DIETARY_SUPPLEMENT|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
48712382|NCT01672099|DIETARY_SUPPLEMENT|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
48712383|NCT01765426|BIOLOGICAL|TDV|TDV suspension for intradermal administration
48712384|NCT01765426|DRUG|Placebo|Phosphate buffered saline (PBS)
48021201|NCT01340989|PROCEDURE|standard pneumoperitoneum|no intervention besides the use of CO2
48021202|NCT03551652|DRUG|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years
48021203|NCT05117827|DEVICE|Power Wheelchair Standing Device|A power wheelchair standing device is a power wheelchair that allows a child to electronically move between sitting and standing. It can be driven in either position. The Permobil F5 Corpus VS is the specific power wheelchair standing device to be used in this study.
48021204|NCT05247944|PROCEDURE|Fenestrated and branched endovascular aortic repair (F-BEVAR)|Fenestrated and branched endovascular aortic repair (F-BEVAR)
48021205|NCT05247944|PROCEDURE|Open repair|Open surgery for complex abdominal aortic aneurysm
48178871|NCT00385099|DRUG|GW876008|
48178872|NCT01555398|DIETARY_SUPPLEMENT|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
48178873|NCT03229486|DRUG|Sugammadex Injection [Bridion]|Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
48178874|NCT03229486|DRUG|Neostigmine+Glycopyrronium|Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
48712385|NCT03927313|DRUG|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
48712386|NCT03927313|DRUG|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
48712387|NCT03927313|DRUG|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
48712388|NCT03927313|DRUG|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
48712389|NCT03927313|DRUG|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
48712390|NCT02753621|BEHAVIORAL|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
48021206|NCT04798300|PROCEDURE|Newly Introduced Gradient Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Newly Introduced Gradient Monolithic Zirconia to measure wear
48021207|NCT04798300|PROCEDURE|Full Strength Monolithic Zirconia|Fabrication of full-coverage crowns over posterior teeth using Full Strength Monolithic Zirconia to measure wear
48021208|NCT04111341|DRUG|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
48021209|NCT04111341|DRUG|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
48021210|NCT05898087|DRUG|Marcaine 0.25 % Injectable Solution|Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia
48021211|NCT05898087|DRUG|Saline|Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
48021212|NCT05868798|DRUG|Ammonia Inhalant|For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
48021213|NCT05068765|OTHER|Communication skills psychoeducation|Intervention explanations are explained in the groups section.
48021214|NCT05068765|OTHER|General psychoeducation|İntervention descriptions are explained in the intervention groups section.
48379144|NCT03596476|PROCEDURE|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
48712391|NCT02753621|BEHAVIORAL|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
48712392|NCT02523768|DRUG|ATG-F|
48021215|NCT01713803|DRUG|Buprenorphine and naloxone|
48021216|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position
48021217|NCT06572501|PROCEDURE|Robot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position|This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position
48021218|NCT05323305|PROCEDURE|ultrasound guided regional block|Bupivacaine injection by the use of ultrasound in the pectointercostal fascial plane in one group and in the trasversus thoracic plane in the other group.
48021219|NCT02182284|DRUG|low dose BI 201335 NA soft gelatine capsule (SGC)|
48178875|NCT04546802|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir / Grazoprevir
48178876|NCT00737828|OTHER|Perioperative care pathway guided by CPX results|"* AT \> 11ml/min/kg no myocardial ischaemia or Ve/VO2 \<35 - Level 1 Ward Care~* AT \> 11ml/min/kg with myocardial ischaemia or Ve/VO2 \>35 - Level 2/3 (ITU) Critical Care Unit~* AT \<11mls/min/kg - Level 2/3 Critical Care Unit~* AT \<8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
48379145|NCT03596476|PROCEDURE|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
48379146|NCT03194295|BEHAVIORAL|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
48517918|NCT02905032|BEHAVIORAL|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
48517919|NCT01050465|OTHER|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
48712393|NCT02523768|DRUG|Simulect|
48712394|NCT01129882|DRUG|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
48021220|NCT02182284|DRUG|high dose BI 201335 NA soft gelatine capsule (SGC)|
48021221|NCT02182284|DRUG|low dose BI 201335 NA powder in bottle (PIB)|
48021222|NCT02182284|DRUG|high dose BI 201335 NA powder in bottle (PIB)|
48712395|NCT00096525|DRUG|lenalidomide|
48712396|NCT05879367|DRUG|Eflornithine (Dose Level 1)|Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
48712397|NCT05879367|DRUG|Eflornithine (Dose Level 2)|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
48712398|NCT05879367|DRUG|Eflornithine (Dose Level -1)|Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
48021223|NCT03948074|DRUG|Cannabis|Medicinal Cannabis Oil
48021224|NCT00253526|DRUG|bevacizumab|
48712399|NCT05879367|DRUG|Temozolomide|Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
48712400|NCT01011933|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48712401|NCT01011933|DRUG|Selumetinib|Given PO
48021225|NCT00253526|DRUG|gemcitabine hydrochloride|
48266871|NCT03175341|DRUG|Ascorbic Acid|1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
48266872|NCT03175341|DRUG|Placebos|100 ml normal saline 0.9%
48379147|NCT03194295|BEHAVIORAL|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
48021226|NCT00253526|PROCEDURE|adjuvant therapy|
48021227|NCT00253526|PROCEDURE|anti-cytokine therapy|
48379148|NCT04189224|DEVICE|JJV Investigational Multifocal Contact Lens|TEST
48379149|NCT04189224|DEVICE|1-Day Acuvue® Moist Brand Multifocal Contact Lens|CONTROL
48379150|NCT03250611|PROCEDURE|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
48379151|NCT06540690|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
48517920|NCT05296174|OTHER|cognitive-oriented intervention program|The experimental group was offered six 40-minute courses once a week.
48021228|NCT00253526|PROCEDURE|antiangiogenesis therapy|
48021229|NCT00253526|PROCEDURE|antibody therapy|
48021230|NCT00253526|PROCEDURE|biological therapy|
48021231|NCT00253526|PROCEDURE|chemotherapy|
48021232|NCT00253526|PROCEDURE|conventional surgery|
48021233|NCT00253526|PROCEDURE|growth factor antagonist therapy|
48021234|NCT00253526|PROCEDURE|monoclonal antibody therapy|
48021235|NCT00253526|PROCEDURE|surgery|
48021236|NCT05005546|BEHAVIORAL|Yoga|Yoga will be applied to mothers in the yoga group
48021237|NCT05005546|BEHAVIORAL|Laughter Yoga|Laughter Yoga will be applied to mothers in the yoga group
48021238|NCT00224159|BEHAVIORAL|Drug and Dietary behavior|
48021239|NCT01668095|OTHER|Laboratory Biomarker Analysis|Correlative studies
48021240|NCT00127790|BEHAVIORAL|CBT for Insomnia (CBT-I)|
48021241|NCT00127790|BEHAVIORAL|CBT for Pain (CBT-P)|
48021242|NCT03823651|BEHAVIORAL|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
48021243|NCT03823651|BEHAVIORAL|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
48021244|NCT03823651|BEHAVIORAL|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
48021245|NCT03823651|BEHAVIORAL|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
48021246|NCT05580575|DEVICE|Daily disposable toric soft contact lens|Daily disposable toric soft contact lens
48021247|NCT05580575|DEVICE|Monthly replacement toric daily wear soft contact lens|Monthly replacement toric daily wear soft contact lens
48021248|NCT00130884|DRUG|levosimendan|
48021249|NCT06383182|PROCEDURE|endovascular treatment|all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
48021250|NCT05739500|OTHER||no intervention, just observation
48021251|NCT00088218|DRUG|Clofarabine|1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
48021252|NCT00088218|DRUG|Ara-C|20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
48021253|NCT05937035|PROCEDURE|Customized allogenic bone block surgery|After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
48021254|NCT04479891|DRUG|pyrotinib tablet|single oral dose of SHR6390 or co-administered with itraconazole
48021255|NCT04479891|DRUG|Itraconazole capsule|200 mg itraconazole QD
48021256|NCT01131481|DEVICE|Intraocular lens|
48021257|NCT00403546|DRUG|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
48021258|NCT00403546|DRUG|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
48517921|NCT05296174|OTHER|health education activities program|The control group was offered health education activities once a week.
48517922|NCT00313989|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants
48379152|NCT04111939|OTHER|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
48379153|NCT04111939|OTHER|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
48712402|NCT05182580|DIAGNOSTIC_TEST|Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema|If patients receive a negative result they do not see the retina specialist
48021259|NCT00403546|DRUG|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
48021260|NCT04830826|PROCEDURE|Surgeries|Surgeries
48021261|NCT01804959|DIETARY_SUPPLEMENT|Vivomixx probiotics|
48021262|NCT04486859|DRUG|LMWH/Rivaroxaban|combined prevention
48021263|NCT04486859|DEVICE|IPC|mechanical prevention
48021264|NCT01626976|DRUG|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
48021265|NCT01626976|DRUG|Placebo|Solution, single dose
48021266|NCT01626976|DRUG|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
48021267|NCT01626976|DRUG|Placebo|suspension, single dose
48021268|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
48021269|NCT01626976|DRUG|Placebo|suspension, single dose
48021270|NCT01626976|DRUG|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
48021271|NCT01626976|DRUG|Placebo|suspension, single dose
48021272|NCT01626976|DRUG|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
48178877|NCT00664105|DRUG|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
48379154|NCT01440075|OTHER|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
48517923|NCT05966415|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily.
48021273|NCT01626976|DRUG|Placebo|suspension, single dose
48021274|NCT02732847|OTHER|A delayed prescription dated 2 days after clinical office visit|
48021275|NCT02732847|DRUG|Usual Dated|
48021276|NCT01650389|BIOLOGICAL|MVA85A|
48021277|NCT01650389|BIOLOGICAL|Candin|
48021278|NCT01650389|BIOLOGICAL|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
48021279|NCT00995449|BIOLOGICAL|KB003|KB003 IV x5 doses
48021280|NCT00995449|OTHER|Placebo Comparator|Placebo IV x5 doses
48021281|NCT01100177|DRUG|Sunitinib|Sunitinib 37.5mg/m2/d
48517924|NCT05966415|OTHER|placebo|4 capsules once daily OR 2 capsules twice daily
48712403|NCT00000627|DRUG|Fluconazole|
48712404|NCT04091984|DIAGNOSTIC_TEST|Prospera|No Interventions, this is an observational study.
48712405|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
48021282|NCT01100177|RADIATION|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
48021283|NCT05349669|DRUG|Jafron use during CPB|Use of filter Jafron during CPB
48021284|NCT00664144|DRUG|Rasburicase (SR29142)|
48021285|NCT02658851|DEVICE|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
48021286|NCT01010984|DEVICE|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
48021287|NCT01840592|DRUG|Sorafenib|
48021288|NCT01840592|DRUG|Doxorubicin|
48021289|NCT00634647|DRUG|Satraplatin|80 mg/m\^2 days 1-5 of every 35 day cycle
48021290|NCT00634647|DRUG|prednisone|5 mg twice daily every 35 days
48021291|NCT02873104|DEVICE|truSculpt rf device|radiofrequency device
48021292|NCT04900974|DRUG|Doravirine|100mg
48021293|NCT05826821|DRUG|Pirfenidone|Intervention drug
48021294|NCT02530619|DRUG|Alisertib|Given PO
48021295|NCT02530619|OTHER|Laboratory Biomarker Analysis|Correlative studies
48021296|NCT02530619|OTHER|Pharmacological Study|Correlative studies
48021297|NCT03650426|PROCEDURE|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
48021298|NCT03650426|PROCEDURE|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
48021299|NCT04629664|DRUG|FX-322|Active Comparator
48021300|NCT04629664|OTHER|Placebo|Placebo
48021301|NCT01072487|PROCEDURE|Capnography|Monitoring of the capnography curve for early detection of apnea
48178878|NCT00664105|DRUG|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
48712406|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
48712407|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
48379155|NCT04216992|DEVICE|Cone beam computed tomography|The contrast agent (Omnipaque, GE Healthcare, Ireland) was instilled to conﬁrm the epidural space. With use of a calibrated angiographic C-arm system and a postprocessing workstation, we acquired volume data sets from two dimensional digital projection images obtained to reconstruct the 3D-RE during a C-arm rotation around the patient axis.
48021302|NCT00335244|DRUG|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
48021303|NCT00335244|DRUG|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
48021304|NCT04849234|BEHAVIORAL|newborn cries|"Their cries will be longitudinally registered from the age of birth until the first 15 minutes of birth using an automatic record device: Recorder ZOOM H4N.~The wav-sized files obtained from each recording will then be analyzed indiscriminately via an acoustic processing script created for the PRAAT software® by the post-doctoral fellows of the ENES laboratory (Sensory NeuroEthology Team) on the site of the Faculty of Sciences of Saint-Etienne."
48021305|NCT03809845|DEVICE|High-density surface electromyography|High-density surface electromyography
48021306|NCT02805842|DRUG|Tacrolimus BID|Administration of Tacrolimus BID
48021307|NCT02805842|DRUG|Advagraf QD|administration of Advagraf QD
48021308|NCT01727531|DRUG|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
48021309|NCT05205603|DRUG|Infliximab|Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
48021310|NCT05205603|DRUG|Vedolizumab|Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
48178879|NCT00664105|RADIATION|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
48178880|NCT05337488|OTHER|questionnaire with interview|They will be invited to complete a questionnaire and an individual semi-structured interviews.
48178881|NCT04306146|DRUG|CAD-9303|Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
48379156|NCT06361368|DIETARY_SUPPLEMENT|PS150|Participants took one capsule with PS150 after dinner for 30 days.
48178882|NCT04306146|DRUG|Placebos|Capsules
48178883|NCT00370643|DRUG|human regular insulin|
48178884|NCT06118242|OTHER|Use of oral care solutions|Oral care solutions to be used: Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid
48178885|NCT03635736|OTHER|multiple-spectral-sonography as acustocerebrography (ACG)|After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
48379157|NCT06361368|DIETARY_SUPPLEMENT|Placebo|Participants took one capsule with placebo after dinner for 30 days.
48379158|NCT05344417|PROCEDURE|Pneumoperitoneum Pressure|"Low Pneumoperitoneum Pressure: defined as an intrabdominal pressure between 8-12 mmHg during the laparoscopic procedure.~High Pneumoperitoneum pressure: defined as an intrabdominal pressure of 15 mmHg or more during the laparoscopic procedure.~Note: surgeons will set the pneumoperitoneum at the lowest value they are comfortable with based on their surgical criteria"
48379159|NCT05344417|PROCEDURE|Neuromuscular blockade|"Moderate neuromuscular blockade: defined as the presence of 1 or 2 responses after train-of-four stimulation.~Deep neuromuscular blockade: defined as no response to train-of-four stimulation and 1 or less responses after post-tetanic count stimulation."
48379160|NCT05344417|DEVICE|Pneumoperitoneum insufflation device|"AirSeal® device or Olympus standard of care insufflation device. Both devices are approved for use in laparoscopic gastrointestinal surgeries."
48021311|NCT05205603|DRUG|Mesalazine|Mesalazine, 4-6g/d, systemic and/or topical administration
48021312|NCT02703844|DEVICE|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
48021313|NCT02703844|DEVICE|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
48021314|NCT04725994|DRUG|IDX-1197+XELOX|The dose levels will be escalated following a 3+3 dose escalation scheme.
48021315|NCT04725994|DRUG|IDX-1197+Irinotecan|The dose levels will be escalated following a 3+3 dose escalation scheme.
48021316|NCT02509741|BEHAVIORAL|Education|
48021317|NCT02509741|DIETARY_SUPPLEMENT|Food replacement|
48021318|NCT02509741|BEHAVIORAL|IOT monitoring|
48021319|NCT06275100|OTHER|Prehabilitation|"Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support."
48021320|NCT05935826|DRUG|Essential Amino Acid Supplement by Amino Co|2 months of twice daily consumption of Purity (EAA), followed by 10 months open label extension of EAA
48021321|NCT05935826|OTHER|Placebo|2 months of twice daily consumption of Placebo, followed by 10 months open label extension of EAA
48021322|NCT00875394|DRUG|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
48021323|NCT00875394|DRUG|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
48021324|NCT00875394|DRUG|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
48021325|NCT00875394|DRUG|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
48021326|NCT05410912|PROCEDURE|Great saphenous vein stripping and ambulatory phlebectomy|All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
48021327|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
48178886|NCT00899145|OTHER|Laboratory Biomarker Analysis|Correlative studies
48178887|NCT00612352|DRUG|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
48178888|NCT03118167|DIETARY_SUPPLEMENT|Tea polyphenols|Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
48178889|NCT03118167|DIETARY_SUPPLEMENT|AOB-w|Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
48178890|NCT03118167|OTHER|Placebo|Edible starches 0.35g, edible capsule
48178891|NCT03118167|OTHER|Acrylamide (Potato Chips)|Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
48379161|NCT05344417|DRUG|Neuromuscular blockade reversal|"Neostigmine: for Arm 1 only (standard use).~Sugammadex: will be used for the other arms in the study.~All drugs used in our randomized trial (neuromuscular blockade with rocuronium and reversal with neostigmine or sugammadex) are standard of care and approved for use by our institutional Institutional Review Board (IRB) Ethics Committee for this trial."
48379162|NCT03223506|DRUG|Paracetamol|
48379163|NCT01556490|DEVICE|TheraSphere|Yttrium 90 microspheres
48379164|NCT02844231|OTHER|Single-photon emission computed tomography|
48021328|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
48021329|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.075%)|QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
48021330|NCT06016972|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
48021331|NCT03860389|OTHER|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
48178892|NCT02230462|OTHER|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
48379165|NCT01891669|DRUG|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
48712408|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
48178893|NCT04444219|OTHER|Breakfast meals|Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.
48178894|NCT01309698|DRUG|Vildagliptin (LAF237)|
48178895|NCT01309698|DRUG|Voglibose|
48178896|NCT01309698|DRUG|Vildagliptin and Voglibose|
48178897|NCT02833961|DEVICE|Magnetic resonance imaging|
48178898|NCT05395923|PROCEDURE|Suture|The pressure application will be applied before the incision on the palate.
48178899|NCT05395923|PROCEDURE|No Suture CTG -Control|A graft will be taken from the palate before the procedure is applied.
48178900|NCT01466790|DRUG|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
48178901|NCT01466790|DRUG|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
48178902|NCT01466790|DRUG|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
48021332|NCT00003863|GENETIC|comparative genomic hybridization|
48021333|NCT00003863|GENETIC|cytogenetic analysis|
48021334|NCT00003863|GENETIC|fluorescence in situ hybridization|
48021335|NCT00003863|GENETIC|gene rearrangement analysis|
48021336|NCT04183400|BEHAVIORAL|Safety Awareness For Empowerment (SAFE)|SAFE is a mindfulness-based cognitive-behavioral intervention that aims to build risk-related attention skills.
48021337|NCT01334931|RADIATION|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
48178903|NCT02188394|DRUG|Anesthetic blockades with bupivacaine|
48178904|NCT02188394|DRUG|Isotonic saline injection|
48178905|NCT00219245|DRUG|Rivastigmine|
48379166|NCT01891669|DRUG|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
48379167|NCT04928625|DRUG|SHR-A1904|SHR-A1904
48379168|NCT02978729|OTHER|Two-way videoconference remote genetic counseling|
48712409|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
48712410|NCT00979368|DRUG|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
48712411|NCT02076360|BEHAVIORAL|Preoperative Video|Patients will watch preoperative instructional video
48712412|NCT00016367|BIOLOGICAL|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
48712413|NCT00016367|DRUG|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
48712414|NCT00016367|DRUG|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
48712415|NCT00659217|BIOLOGICAL|mesenchymal stem cell|Autologous MSC transplantation
48712416|NCT05981937|DRUG|ICG solution|ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
48712417|NCT06416176|OTHER|Mindfulness-Based Stress Reduction (MBSR) Program|Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
48712418|NCT02549352|DRUG|LEO43204 gel|
48021338|NCT01334931|RADIATION|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
48178906|NCT04196543|OTHER|écho-doppler with ultrasonar Sonovue® injection|"During this unique visit they will benefit from 2 imaging exams performed by two different operators:~* Echo-doppler without standard method contrast injection (common practice)~* An echo-doppler with Sonovue® ultrasound injection Ultra_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later."
48178907|NCT03988998|DRUG|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
48178908|NCT03988998|DRUG|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
48178909|NCT04461769|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
48379169|NCT02978729|OTHER|Telephone remote genetic counseling|
48712419|NCT02549352|DRUG|Vehicle gel|
48712420|NCT01724567|OTHER|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
48712421|NCT01724567|OTHER|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
48712422|NCT00681980|DRUG|Valproic acid|15 mg/kg/day
48712423|NCT00681980|DRUG|costicosteroids|metypredsolone 1 g/day
48712424|NCT00681980|DRUG|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
48712425|NCT06239246|OTHER|Behavioral|"Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);"
48712426|NCT02836873|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
48712427|NCT02836873|DRUG|Placebo|Placebo (inactive) tablet to match the active comparator
48379170|NCT01628159|DEVICE|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
48712428|NCT06337474|DRUG|anti-CD19 CAR NK cells (KN5501)|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
48712429|NCT04965961|DRUG|EPO|Please refer to the arm description
48712430|NCT04965961|OTHER|Control group - saline injection|Please refer to the arm description
48712431|NCT04947631|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
48021339|NCT05890027|DRUG|Phenylephrine Ophthalmic|One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.
48021340|NCT05890027|OTHER|Eyelid Tape|Participants will have the affected eye with ptosis manually lifted using tape.
48021341|NCT03142074|OTHER|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
48021342|NCT03142074|RADIATION|ECG-gated CT|Image analysis of ECG-gated CT.
48712432|NCT04947631|DRUG|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
48712433|NCT04947631|DRUG|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
48712434|NCT04947631|DRUG|DKF-313 placebo|Once daily for 48 weeks
48712435|NCT04947631|DRUG|Dutasteride placebo|Once daily for 48 weeks
48712436|NCT04947631|DRUG|Tadalafil placebo|Once daily for 48 weeks
48712437|NCT03263312|BEHAVIORAL|Exercise|Exercise training all patients enrolled.
48712438|NCT05433740|DEVICE|Proseal Laryngeal mask fixation|fixation with Proseal Laryngeal mask adjustable ligament
48712439|NCT02975414|PROCEDURE|rTARUP technique|obot-assisted rTARUP technique
48712440|NCT00600691|DRUG|Finasteride|one tablet (5mg) of finasteride
48712441|NCT06482320|DIAGNOSTIC_TEST|Recording EKG traces on the smartwatch|Upon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it.
48712442|NCT00801476|PROCEDURE|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
48712443|NCT02854124|PROCEDURE|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
48712444|NCT02295007|BEHAVIORAL|text message|
48021343|NCT04223856|DRUG|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
48178910|NCT01682746|DRUG|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
48178911|NCT02646735|DRUG|Fulvestrant 500 mg|Fulvestrant 500mg will be given monthly.
48178912|NCT02646735|DRUG|Exemestane 25 mg|Exemestane 25mg will be given once daily.
48178913|NCT01898715|DRUG|ATR-101|
48021344|NCT04223856|DRUG|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
48178914|NCT04476940|BEHAVIORAL|COVID-19 Breastfeeding Support|Intervention will be implemented by trained prenatal care providers to provide comprehensive exclusive breastfeeding and COVID-19 breastfeeding guideline education and support to study participants.
48712445|NCT00458042|DRUG|treprostinil sodium|
48021345|NCT04223856|DRUG|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
48021346|NCT04223856|DRUG|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
48021347|NCT04223856|DRUG|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
48379171|NCT01012609|OTHER|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
48379172|NCT04237831|DRUG|BMS-986259|Specified Dose on Specified Days
48379173|NCT06426316|BIOLOGICAL|Blood test|1 blood test of maximum 40 millilitres per patient
48021348|NCT01429545|DRUG|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
48021349|NCT01429545|DRUG|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
48021350|NCT03741959|PROCEDURE|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
48178915|NCT05092698|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
48178916|NCT05092698|DIETARY_SUPPLEMENT|Herbal oil|Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
48178917|NCT04896788|BIOLOGICAL|Monitoring of the immune response|Blood sample at 3,6,12,18 and 24 months in order to assess the blood level of anti-S1 / RBD anticoprs
48178918|NCT01377168|DRUG|oral naltrexone|
48178919|NCT01377168|DRUG|Placebo pill|
48178920|NCT04127903|OTHER|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
48379174|NCT05557526|OTHER|Expectation optimization|A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
48178921|NCT02549417|DRUG|KHK7580|Oral administration
48178922|NCT00087945|DRUG|Abacavir sulfate|
48178923|NCT00087945|DRUG|Abacavir sulfate, lamivudine, and zidovudine|
48178924|NCT02432170|DEVICE|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
48178925|NCT06090162|DIAGNOSTIC_TEST|ctDNA detection|ctDNA detection on CSF and blood
48178926|NCT00299806|DRUG|Aliskiren|
48178927|NCT05815537|OTHER|Low-Reverberation|The exposure to low-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., small classroom.
48379175|NCT04833816|DRUG|Administration of drug|Administration of ketamin during the 48h after trauma
48021351|NCT03741959|PROCEDURE|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
48021354|NCT00971971|PROCEDURE|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
48021355|NCT00971971|PROCEDURE|Standard SLED|
48021356|NCT05450289|DRUG|Nigella Sativa Oil|In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
48021357|NCT05450289|DRUG|Allergen Specific Immunotherapy|In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
48021358|NCT05450289|DRUG|Standard pharmacotherapy|Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
48021359|NCT05383677|DRUG|Anifrolumab|Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
48021360|NCT05383677|DRUG|Placebo|Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
48021361|NCT01196871|DRUG|Migalastat HCl|Oral capsules, single dose
48712446|NCT03671707|BEHAVIORAL|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
48712447|NCT03671707|DRUG|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
48021362|NCT01196871|BIOLOGICAL|Agalsidase Beta|IV infusion, single dose
48021363|NCT01196871|BIOLOGICAL|Agalsidase Alfa|IV infusion, single dose
48712448|NCT03671707|BEHAVIORAL|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
48021364|NCT03646422|OTHER|Registry of patients (exposure is Cutaneous Lymphoma)|
48021365|NCT05660109|DRUG|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
48021366|NCT05660109|OTHER|Placebo|Placebo
48021367|NCT04755660|BEHAVIORAL|Exercise behavior change for resistance exercise|The intervention includes motivational interviews and self-efficacy theory-based exercise behavior and home-based resistance exercise intervention (by Elastic Band or non- Elastic Band ), and 3 follow-up telephone calls. The usual care group will receive exercise counseling.
48021368|NCT01807585|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
48021369|NCT01807585|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
48178928|NCT05815537|OTHER|High-Reverberation|The exposure to high-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., large lecture hall/auditorium.
48379176|NCT01211158|DRUG|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
48712449|NCT03671707|BEHAVIORAL|Very brief advice|Subjects will receive general advice to quit
48712450|NCT03671707|BEHAVIORAL|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
48712451|NCT03148145|BEHAVIORAL|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
48712452|NCT03148145|BEHAVIORAL|Message Delivery by Smartphone|Message Delivery by Smartphone
48712453|NCT05675267|OTHER|data collection|HEART score calculation
48712454|NCT00263640|BIOLOGICAL|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
48712455|NCT00263640|DRUG|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
48021370|NCT01807585|DEVICE|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
48178929|NCT00263497|DEVICE|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
48712456|NCT00579995|DRUG|Oral N-Acetylcysteine|600 milligrams (mg)
48712457|NCT00579995|DRUG|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
48712458|NCT06477471|OTHER|MetProrenes|Take one slow-release capsule twice a day, after meal.
48712459|NCT03283098|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
48712460|NCT03283098|DRUG|Placebo|Placebo supplied to match active intervention.
48712461|NCT02607540|OTHER|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
48712462|NCT02607540|OTHER|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
48712463|NCT02607540|RADIATION|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
48712464|NCT02844335|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
48712465|NCT02844335|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
48712466|NCT06247228|BEHAVIORAL|Click2Move|One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
48712467|NCT03177447|BEHAVIORAL|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
48712468|NCT00440856|BEHAVIORAL|Presentation of excised intervertebral disc fragments|
48712469|NCT04029389|DEVICE|Injection|Local corticosteroid injection
48712470|NCT04029389|DEVICE|Tibial nerve block|Tibial nerve block
48712471|NCT04029389|OTHER|Conservational therapy|Only exercise and foot insoles
48712472|NCT03251586|DIAGNOSTIC_TEST|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
48178930|NCT03069144|DRUG|HAT1 topical solution|HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
48712473|NCT03251586|DIAGNOSTIC_TEST|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
48021371|NCT02972580|GENETIC|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
48021372|NCT00004026|DRUG|CT-2584|
48021373|NCT00004026|DRUG|chemotherapy|
48021374|NCT04166318|DRUG|Capecitabine|Given PO
48021375|NCT04166318|DRUG|Fluorouracil|Given IV
48021376|NCT04166318|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48021377|NCT04166318|DRUG|Mitomycin|Given IV
48021378|NCT04166318|OTHER|Quality-of-Life Assessment|Ancillary studies
48021379|NCT04166318|OTHER|Questionnaire Administration|Ancillary studies
48021380|NCT05520216|DEVICE|Spinal mouse (idiag m360)|A noninvasive Spinal Mouse device will be used to measure the thoracic kyphosis and lumbar lordosis angle of the spinal column in the sagittal plane. It will be displayed on the computer aided software screen where the thoracic and lumbar region angles are calculated by swiping over the spinal processes from top to bottom with the Spinal Mouse (IDIAG m360) device. Measurements will be taken while standing on a flat surface. The volunteer will take off his upper clothes and shoes during the examination. Relax your arms and torso will be positioned next to you. The distance between the feet will be approximately waist width and parallel to each other, the knees will be straight and face motionless. He will stand where he feels comfortable. A Spinal Mouse examination will be performed and data will be recorded.
48021381|NCT05520216|BEHAVIORAL|chest circumference measurement|Measurements will be taken from the axillary (4th rib level - two fingers below the axilla), epigastric (xiphoid process level) and subcostal (9th rib level) regions at the time of normal, maximal inspiration, and maximal expiration using a tape measure while the patient is in a sitting position. The tape measure will be placed in the area to be measured. Care will be taken that there is no folding or horizontal level difference in the tape measure and that the fingers are not under the tape measure. Normal respiration will be measured first and recorded in centimeters (cm). The patient will then be asked to take a deep, long breath towards the bottom of the tape measure. The value obtained will be recorded as the deep inspiration value. Immediately after deep inspiration, the patient will be asked to make a deep and long expiration. The obtained value will be recorded as deep expiration.
48021382|NCT05520216|BEHAVIORAL|Maximum Breath Hold Test|During the breath-hold measurement, the subject will sit in a chair with a backrest. He will take a deep breath through his nose. We do not want maneuvers (Valsalva and Müller) and diaphragm contractions that will affect the breath-hold time, so volunteers will be observed throughout the test. The test will be terminated as soon as involuntary diaphragm contractions are seen. This test will be applied 3 times by resting the volunteer with breaks for 5 minutes. The average of 3 test results will be taken (Lin, Y. C.: Effect of O2 and CO2 on breath hold breaking point. In The Physiology of Breath Hold Diving. (eds): CEG Lundgren, M Ferringo, Undersea and Hyperbaric Medical Society Inc, Bethesda, Maryland, p: 75-87 1987.).
48178931|NCT03069144|DRUG|Calcipotriol|Calcipotriol ointment (0.005%) will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
48178932|NCT05359055|DRUG|SPH3127 tablet|100mg once daily on Day 1 and Day 8
48712474|NCT03051984|DEVICE|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
48178933|NCT05359055|DRUG|Itraconazole|200mg once daily from Day 3 to Day10.
48712475|NCT02860624|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
48712476|NCT02860624|DRUG|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
48712477|NCT05622435|DEVICE|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
48712478|NCT00572611|DRUG|[14C]-bilastine|Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
48712479|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
48712480|NCT00334581|DRUG|Irbesartan|Administration throughout the study period
48178934|NCT05359055|DRUG|SPH3127 tablet|200mg once daily on Day 1 and Day 12.
48178935|NCT05359055|DRUG|Rifampin|600mg once daily from Day 3 to Day13.
48178936|NCT00559377|OTHER|18F-fluoromisonidazole|Undergo \^18F FMISO PET scan
48178937|NCT00559377|RADIATION|fluorodeoxyglucose F 18|Undergo \^18F FDG PET scan
48178938|NCT00559377|PROCEDURE|positron emission tomography|Undergo \^18F-FMISO and \^18F FDG PET scan
48517925|NCT06550583|DIAGNOSTIC_TEST|Pap smear /Test|"Patients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina.~• A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination"
48517926|NCT00277693|DRUG|Spironolactone (drug)|
48712481|NCT04024904|DEVICE|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
48712482|NCT01167010|DRUG|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
48712483|NCT01167010|DRUG|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
48712484|NCT01167010|DRUG|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
48712485|NCT06293638|DRUG|Alcohol|Alcohol consumption is shown to reduce tremor in individuals with essential tremor. The alcoholic beverage will be dispensed by the a clinician study investigator, and the participant will be administered the alcoholic beverage until their tremor is decreased, as determined by the clinician. Individual sensitivity to the tremor-mitigating effects of alcohol varies, but it is anticipated that only light (1-2 40% ABV drinks, containing 1-2 units of absolute alcohol (10 mL. or 8 g of pure ethanol)) consumption will be necessary. Participants will then repeat motor task and data collection while the alcohol is effective at controlling tremor, beginning approximately 15-20 minutes after consumption.
48712486|NCT06293638|DRUG|Alprazolam|Alprazolam is shown to reduce tremor in individuals with essential tremor. The primary investigator will select the appropriate dose for the patient (0.5mg for patients with a body weight of up to 75kg, and 0.75mg for participants with a body weight of 75kg and higher). Participants will swallow the drug with a glass of water in the presence of the research team. If participants have not reached a sufficient level of tremor improvement, a subsequent dose of up to a total of 1.0mg of alprazolam per participant will be requested. Participants will then repeat motor task and data collection.
48712487|NCT06293638|DEVICE|Cold Therapy|One or both of the participant's upper limbs will be wrapped with pre-chilled ice packs or a cold water circulating device such as a cryomanchet (e.g., the Breg PolarCare Glacier), and the skin temperature monitored until it lowers to 15-25°C. Participants will then repeat motor task and data collection while the limb is cool.
48712488|NCT06293638|PROCEDURE|Peripheral Nerve Stimulation|Electrical stimulation will be applied using techniques similar to those applied during standard somatosensory evoked potential testing. Specifically, adhesive surface electrodes will be placed above the median and radial nerves at the wrist. Stimulation paradigms will be tailored to each participant based on the frequency characteristics of their tremor. Participants will receive between 20-60 minutes of stimulation, then will repeat motor task and data collection. Transcutaneous peripheral nerve stimulation may help mitigate tremor, with effects lasting beyond cessation of stimulation1-3.
48712489|NCT05499793|DIETARY_SUPPLEMENT|Zingiber Officinale powder|Ginger powder
48712490|NCT05499793|DIETARY_SUPPLEMENT|Placebo|Starch powder
48712491|NCT01239888|DRUG|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
48712492|NCT01239888|DRUG|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
48712493|NCT01239888|DRUG|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
48712494|NCT05318612|PROCEDURE|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
48712495|NCT05318612|PROCEDURE|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
48712496|NCT04594265|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
48712497|NCT04594265|DIETARY_SUPPLEMENT|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
48712498|NCT03396679|OTHER|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
48712499|NCT02435290|BEHAVIORAL|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
48712500|NCT06351098|BEHAVIORAL|nap|Children are nap promoted
48712501|NCT01742910|PROCEDURE|intraocular lens implantation|
48712502|NCT02426775|DRUG|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
48712503|NCT02010736|OTHER|Single treadmill gait training with additional loading|
48712504|NCT00034229|DRUG|Felbamate|
48712505|NCT01515475|PROCEDURE|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
48712506|NCT00961792|DRUG|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
48712507|NCT00961792|DRUG|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
48517927|NCT05002088|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
48712508|NCT00961792|DRUG|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
48712509|NCT00961792|DRUG|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
48712510|NCT01068782|DRUG|XL184|given orally as capsules
48712511|NCT03738501|OTHER|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
48712512|NCT03738501|OTHER|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
48178939|NCT00559377|OTHER|tissue oxygen measurement|Undergo \^18 F FMISO PET and \^18F FDG PET
48178940|NCT00000677|DRUG|SCH 39304|
48712513|NCT02580383|PROCEDURE|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
48712514|NCT06473974|DRUG|Test cosmetic product|"Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out."
48712515|NCT04511117|OTHER|Control group|ProTaper Next rotary system and iRoot SP sealer with composite restorations.
48712516|NCT04511117|OTHER|Endocrown group|ProTaper Next rotary system and iRoot SP sealer with endocrown restorations.
48712517|NCT05273216|DIAGNOSTIC_TEST|Transcranial Duplex Sonography|Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.
48178941|NCT06137976|PROCEDURE|Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)|Placement of tube through the nose or mouth into the stomach for gastric decompression
48178942|NCT02722811|DRUG|Etanercept|etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
48178943|NCT02722811|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 8 weeks
48178944|NCT05501756|DRUG|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
48178945|NCT02344017|DRUG|ODM-204|co-administered with prednisone, orally daily
48178946|NCT02344017|DRUG|Prednisone|ODM-204 is co-administered with oral prednisone
48178947|NCT03602586|DRUG|Epacadostat|Given PO
48379177|NCT01211158|DRUG|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS\<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
48379178|NCT04271241|OTHER|Passive stretching (PS) training|PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
48517928|NCT05300750|OTHER|Oral fluids|Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.
48712518|NCT05273216|DIAGNOSTIC_TEST|Brain MRI|The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
48178948|NCT03602586|BIOLOGICAL|Pembrolizumab|Given IV
48178949|NCT00912223|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~* Rituxan 375 mg/m\^2 on Day -13~* Rituxan 1000 mg/m\^2 on Days -6, +1, and +8~* Fludarabine 30 mg/m\^2 on Days -5 to -3~* Cyclophosphamide 750 mg/m\^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~* Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~* Methotrexate 5 mg/m\^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
48178950|NCT04181489|DRUG|Sintilimab|Sintilimab 200mg d0
48178951|NCT04181489|DRUG|Rituximab|Rituximab 375 mg/m2 d0
48178952|NCT04181489|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
48178953|NCT04181489|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
48178954|NCT04181489|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
48178955|NCT04181489|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
48379179|NCT04761926|DEVICE|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
48379180|NCT06364007|DRUG|HAIC+STRIDE+Len|patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
48379181|NCT00084188|BEHAVIORAL|Behavior Therapy|
48379182|NCT03495752|OTHER|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
48379183|NCT04392791|OTHER|balneotherapy|Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
48379184|NCT05704946|OTHER|THE EFFECT OF LAVENDER INHALATION ON SLEEP QUALITY IN INDIVIDUALS WITH CORONARY HEART DISEASE|The index includes 24 questions that evaluate the quality of sleep and the type and severity of sleep disorders experienced in the last 1 month period. The total score in the index takes a value between 0-21. If the total score is higher than 5, it is interpreted as poor sleep quality.
48379185|NCT01991756|DEVICE|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
48379186|NCT03575806|COMBINATION_PRODUCT|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
48379187|NCT03575806|PROCEDURE|TACE|TACE:transcatheter arterial chemoembolization.
48178956|NCT04361812|DRUG|HS632|Subcutaneous injection of HS632
48178957|NCT04361812|DRUG|Omalizumab (Xolair®)|Subcutaneous injection of Omalizumab Xolair®)
48178958|NCT05707884|OTHER|critical care management|The different sedation methods result in considerable differences in terms of set-up costs and the management of the patient, which will be examined in a direct comparison.
48379188|NCT02332044|DRUG|Erdos|capsule, 300mg
48379189|NCT02332044|DRUG|Talion|tablet, 10mg
48379190|NCT02332044|DRUG|Erdos, Talion|capsule 300mg and tablet 10mg
48379191|NCT02471794|BEHAVIORAL|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
48379192|NCT04714710|DRUG|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
48379193|NCT04714710|DRUG|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
48379194|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 1 initial treatment (W1\~W6). Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
48379195|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
48379196|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine+Mercaptopurine|Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
48379197|NCT04773366|DRUG|Prednisone+Cytarabine+vincristine|Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)
48379198|NCT04773366|DRUG|Prednisone+vincristine+Mercaptopurine|Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
48379199|NCT04773366|DRUG|Prednisone+vincristine|Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6
48379200|NCT04773366|DRUG|Prednisone+vincristine|. Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w
48379201|NCT04773366|OTHER|Local therapy|Local therapy/wait and see. Group 4
48517929|NCT05300750|OTHER|Chewing gum|Chewed free sugar gum for 15 minutes
48178959|NCT00895726|DRUG|APD209|Oral tablets twice per day for 56 days
48379202|NCT06116903|GENETIC|Blood sampling|Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors
48379203|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 7 days
48379204|NCT01205139|DRUG|TDF|300 mg tablet once daily for 7 days
48379205|NCT01205139|DRUG|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
48379206|NCT01205139|DRUG|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
48379207|NCT01205139|DRUG|TMC278|25 mg tablet once daily for 11 days
48379208|NCT01205139|DRUG|TMC435|150 mg capsule once daily for 11 days
48379209|NCT03304132|OTHER|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
48379210|NCT03304132|OTHER|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
48379211|NCT03028077|DIETARY_SUPPLEMENT|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
48379212|NCT03028077|DIETARY_SUPPLEMENT|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
48379213|NCT03028077|DIETARY_SUPPLEMENT|Placebo|Placebo 1 g/day
48379214|NCT03669627|BIOLOGICAL|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
48379215|NCT03669627|BIOLOGICAL|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
48379216|NCT03669627|BIOLOGICAL|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
48379217|NCT03669627|BIOLOGICAL|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
48379218|NCT02973789|DEVICE|NovoTTF-200T|"Patients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.~Other Name: TTFields~Drug: Immune checkpoint inhibitors or docetaxel Patients receive standard of care with Immune checkpoint inhibitors or docetaxel"
48379219|NCT02973789|DRUG|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
48379220|NCT00944528|RADIATION|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
48379221|NCT02996942|BIOLOGICAL|Factor VIII replacement|Patients receive their usual treatment
48379222|NCT04065997|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
48379223|NCT04778319|OTHER|occlusion of tubes|to occlude the fallopian tubes
48379224|NCT04778319|OTHER|non occlusion of tubes|not to occlude the tubes
48379225|NCT06651216|OTHER|Stool analysis|Analysis of infant fecal microbiota
48379226|NCT06651216|OTHER|breast milk analysis|Analysis of the effect of breast milk miRNAs on infant fecal microbiota
48379227|NCT04604353|DIAGNOSTIC_TEST|Polygenic Risk Score|Risk description to patient based on PRS
48379228|NCT04604353|DIAGNOSTIC_TEST|Coronary Calcium Score|Risk description to patient based on CCS
48379229|NCT05912192|DRUG|Elonide Nasal Spray|50mcg/dose One puff for each nostrils twice daily
48379230|NCT05912192|DRUG|Nasonex Nasal Spray|50mcg/dose One puff for each nostrils twice daily
48379231|NCT05912192|DRUG|Normal saline|50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
48379232|NCT05638438|PROCEDURE|transarterial therapies|transarterial therapies combine with donafenib and Anti-PD-1 Antibody
48379233|NCT00877799|DRUG|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
48379234|NCT00877799|DRUG|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
48379235|NCT00877799|DRUG|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
48379236|NCT00877799|DRUG|Placebo|Matched placebo administered the day after surgery (Day 1)
48379237|NCT00877799|DRUG|Placebo|Matched placebo administered immediately after surgery (Day 0)
48379238|NCT03204006|DRUG|Dexmedetomidine|Dexmedetomidine preinduction
48379239|NCT03204006|DRUG|sterile saline|normal saline preinduction
48379240|NCT01740297|DRUG|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
48379241|NCT01740297|DRUG|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
48379242|NCT01572610|DRUG|RTA 402|once a day, oral administration
48379243|NCT04966702|DRUG|Albendazole Pill|Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
48379244|NCT04966702|DRUG|Ivermectin Pill|Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
48379245|NCT04966702|DRUG|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
48379246|NCT02372786|DRUG|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
48379247|NCT02372786|DRUG|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
48379248|NCT02372786|DEVICE|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
48379249|NCT02372786|DEVICE|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
48379250|NCT03910309|DEVICE|TLIF with Titan TT/TO interbody cage|fusion surgery
48379251|NCT06234683|OTHER|Web-based educational video on pneumococcal vaccination|Participants will receive a link to view a short video on pneumococcal vaccination.
48379252|NCT06234683|OTHER|Reminder email to be vaccinated|Participants will receive a reminder email to be vaccinated.
48379253|NCT03456986|BEHAVIORAL|PATH neurotraining|Tunes up the center of the motion discrimination (dorsal stream) working range
48379254|NCT03456986|BEHAVIORAL|Orientation Discrimination|Tunes up the ventral stream most sensitive to high contrast and colored patterns.
48379255|NCT04984694|BEHAVIORAL|Computerized virtual reality training programs group (Hot-Plus group)|"In this study, the investigators utilised interactive-video games called Xavix Hot Plus(Hot-plus, Shinsedai\[SSD\] Co. Ltd, Shiga Japan), which was designed specifically for rehabilitation and reported high participant motivation and enjoyment while playing."
48379256|NCT04984694|BEHAVIORAL|Social interaction group|The social interaction group will get together as a group for social interaction one hour weekly for 12 weeks.
48712519|NCT05273216|DIAGNOSTIC_TEST|Blood biomarkers|"Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz."
48712520|NCT03365141|DRUG|Triamcinolone acetonide 0.4mg/cc|"* Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~* Once weekly, for a total of 12 weeks"
48712521|NCT03365141|DEVICE|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
48379257|NCT03752424|DRUG|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
48379258|NCT03752424|DRUG|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
48712522|NCT03365141|DRUG|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
48379259|NCT05843539|GENETIC|Biological and epigenetic measures|This study also includes an exploratory biological ancillary study that aims to identify the gene expression variations that are determinant in terms of vulnerability/protection (cytogenetic and transcriptome), through the measurement of the level of biological chronic stress and epigenetic methylations of the NR3C1 and FKBP5 genes, in relation to adversity in childhood And to show the convergence between self-reported measures related to the presence of ACEs and attachment disorders with assays of chronic stress and epigenetic biomarkers.
48379260|NCT05283109|BIOLOGICAL|Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine|Vaccine that includes 3 peptides (EphA2 linked to P30 peptide, pp65 linked to P30 peptide, and Survivin linked to P30 peptide)
48379261|NCT05283109|DRUG|Hiltonol|Hiltonol® is made up of synthetic (manmade) RNA (ribonucleic acid) and is used as an adjuvant to the vaccine, meaning it is used with the vaccine to stimulate or enhance the activation of your immune system.
48712523|NCT03824275|DRUG|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
48712524|NCT02442791|DRUG|Byetta (Lilly, Exenatide)|See description of Arms
48712525|NCT02442791|OTHER|20% Human Albumin|See description of Arms
48712526|NCT04546373|DRUG|Niraparib|Patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria. The study comprises a single study visit, in which the patient will give her informed consent to participate (when the patient is alive) and the physician will extract the study data from the patient's medical charts. All eligible deceased and consenting living patients at the participating centers will be included. Data will be directly retrieved from hospital medical records and reported in the electronic Case Report Form (eCRF).
48021383|NCT05520216|BEHAVIORAL|Sit and Reach|While the participant is sitting on the floor with his back to the wall and his legs are fully extended in front of him, his knees should be in full contact with the floor. The box will be placed on the sole of the participant's feet (without shoes) in full contact with the volunteer's feet. The participant will be instructed to lean forward as slowly as possible, keeping their fingertips level with each other and their legs straight on the floor. He will be asked to slowly lie down along the ruler three times, and on the third attempt the volunteer will be instructed to reach out as far as possible and hold for 2 seconds. This value will be saved
48021384|NCT01306552|BEHAVIORAL|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
48021385|NCT01306552|BEHAVIORAL|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
48021386|NCT01306552|BEHAVIORAL|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
48379262|NCT02494882|DRUG|Ruxolitinib|
48712527|NCT06374576|BEHAVIORAL|Lecture on eHealth literacy|There will be a lecture on eHealth literacy. The lecture will be delivered by one well-trained lecturer. , the lecture will be held for old adults in small groups, including a structured curriculum consisting of 4 parts: 5 minutes for the introduction, 40 minutes for the lecture and demonstration, and 40 minutes for hands-on session, 5 minutes for wrapping up. The contents covered in the 40-minute lecture were as follows: 1) smartphone internet basics; 2) introduction of the website prepared for this study; 3) evaluation of the credibility of online health information.
48712528|NCT06374576|BEHAVIORAL|Digital intervention on eHealth literacy|1-week digital intervention, which are multiple messages about the lecture topic will be provided
48379263|NCT02494882|DRUG|Dasatinib|
48379264|NCT02494882|DRUG|Dexamethasone|
48379265|NCT03403010|OTHER|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
48379266|NCT03209973|DRUG|Tislelizumab|Administered as specified in the treatment arm
48712529|NCT06374576|BEHAVIORAL|Lecture on general health|A lecture session that focus on the general health but not eHealth literacy will be provided
48712530|NCT06374576|BEHAVIORAL|Digital intervention on general health|1-week digital intervention, which are multiple messages about the lecture topic will be provided
48712531|NCT02034175|DEVICE|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
48712532|NCT02034175|DEVICE|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
48712533|NCT05114122|PROCEDURE|Vonlay Ceramic restorations|vonlay is a hybrid of an onlay with an extended buccal veneer surface for use in bicuspid regions where there is mostly enamel to bond to. The vonlay is less invasive, more readily repairable, less technique-sensitive to attain adequate bonding, and will leave sounder tooth structure remaining if further treatment is required in the future
48712534|NCT05114122|PROCEDURE|Onlay Ceramic restorations|Onlays are used to restore large areas of decay and also used to replace old restorations, whether they are defective amalgam fillings, old cast-gold onlays, or fabricated from some other material
48712535|NCT00791557|DRUG|Infliximab|IV drug given at weeks 1,2,14,22
48712536|NCT03369899|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
48712537|NCT05911438|DRUG|Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)|Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
48021387|NCT06057415|PROCEDURE|HAPTOS (Handling Adapted to Postnatal age with Tactile-kinaesthetic and Oral sensorimotor Stimulation|Tactile-kinaesthetic and Oral sensorimotor Stimulation
48021388|NCT06521502|OTHER|Blood collection|"Blood will be collected from a catheter (IV) that is already in place or using a needle stick into a vein.~Blood will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort)."
48021389|NCT06521502|OTHER|Urine Collection|"Urine will be collected through a urinary catheter that is already in place or by urinating into a cup.~Urine will be collected in hospital only (Cohorts A, B)"
48021390|NCT06521502|OTHER|Nasal, oral, and rectal swabs|"Nasal, oral, and rectal swabs inserted into the nose, mouth, and rectum, respectively. The swabs will be rubbed inside the cavity and then removed the swab.~Oral and nasal swabs will also be collected in hospital (Cohort A, B) and at visits 3, 6, and 12 months following hospitalization for (Long-term Outcomes Cohort). Rectal swabs will be collected in hospital only (Cohorts A, B)."
48021391|NCT06521502|OTHER|Stool collection|"Stool will be collected either in a cup after defecation or by collecting it from a tube or bag that may already be in place that is catching stool.~Stool will be collected in hospital (Cohorts A, B) and at visits 3, 6, and 12 months following hospitalization (Long Term Outcomes Cohort)."
48021392|NCT06521502|OTHER|Heat Moisture Exchange Filter collection|"An HME filter is a sponge that is placed in the tubing between a patient and breathing machine. It reduces the amount of heat and moisture a patient loses when on a breathing machine. Moisture from breath is collected in this filter. The filter is changed every few hours. When the filter is changed, it will be saved to collect the moisture that it contains and run tests on it.~HME filters will be collected in hospital on intubated patients only (Cohorts A, B)."
48021393|NCT06521502|OTHER|Tracheal Aspirate sample collection|"Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.~Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)"
48021394|NCT06521502|PROCEDURE|Non-bronchoscopic bronchoalveolar lavage (NBBAL)|"The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.~NBBAL will be performed in hospital on intubated patients only (Cohort A)"
48021395|NCT06521502|OTHER|Surveys|Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
48021396|NCT06521502|OTHER|Short physical performance battery|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)~Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.~Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.~4-meter walk: For this test the participant will walk 4 meters as quickly as possible."
48178960|NCT03421405|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
48178961|NCT05009199|DRUG|[18F]MNI-444|Subjects will undergo PET imaging using \[18F\]MNI-444.
48178962|NCT01151423|BIOLOGICAL|Caplacizumab|"* Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received caplacizumab up to 30 days after the last PE session."
48178963|NCT01151423|BIOLOGICAL|Placebo|"* Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received placebo up to 30 days after the last PE session."
48021397|NCT06521502|OTHER|Hand grip strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength."
48178964|NCT02219698|DRUG|Ibuprofen|
48178965|NCT02219698|DRUG|Paracetamol|
48178966|NCT05194163|DRUG|MW150|oral-delivered capsule of study drug
48178967|NCT05194163|DRUG|Placebo|oral delivered capsule matched to study drug capsule
48178968|NCT00333255|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|
48178969|NCT00460902|DEVICE|Transcranial Magnetic Stimulation (TMS)|
48178970|NCT02950051|DRUG|Fludarabine|Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
48178971|NCT02950051|DRUG|Cyclophosphamide|Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
48712538|NCT05911438|OTHER|Basic Treatment|Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
48712539|NCT04461574|DEVICE|Orcellex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
48712540|NCT04461574|DEVICE|Cervex Brush|Subjects will receive vaginal vault smear using both Orcellex Brush and Cervex Brush at the same follow-up visit, with order of smear taking decided by randomization.
48712541|NCT01125969|BEHAVIORAL|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
48712542|NCT01125969|BEHAVIORAL|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
48712543|NCT01125969|BEHAVIORAL|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
48712544|NCT01073540|DRUG|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
48712545|NCT01073540|DRUG|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
48712546|NCT01281098|PROCEDURE|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
48712547|NCT01281098|DRUG|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
48712548|NCT01544452|PROCEDURE|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
48021398|NCT06521502|OTHER|CNS Vital Signs|"At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):~The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes."
48021399|NCT06521502|OTHER|Muscle Ultrasound|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body."
48021400|NCT06521502|OTHER|Muscle Strength|"At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~A dynamometer will be used to measure muscle strength in the dominant leg."
48021401|NCT06521502|OTHER|Spirometry|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can."
48021402|NCT06521502|OTHER|Lung Diffusion Testing (DLCO)|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out."
48712549|NCT01544452|PROCEDURE|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
48178972|NCT02950051|BIOLOGICAL|Rituximab|Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
48178973|NCT02950051|DRUG|Bendamustine|Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
48178974|NCT02950051|DRUG|Venetoclax|"Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d"
48712550|NCT00701298|BIOLOGICAL|peginterferon alfa-2b|Given SC
48379267|NCT05700526|DEVICE|Planning of multiplanar and/or multifocal osteotomies in children by using VSP, PSIs and customized structural bone allograft|Preoperative VSP is performed starting from 3D digital models obtained from DICOM data of CT-scan with a segmentation process. If applicable, a model of the contralateral limb is obtained and used as reference for the correction. The surgeon and the engineer together define the surgical strategy, establishing the correction, the design of Patient-Specific Instruments (PSIs) and the hardware to implant. Then, through VSP, an ideal model of the bone graft is designed.
48712551|NCT00701298|DRUG|decitabine|Given IV
48712552|NCT00701298|OTHER|laboratory biomarker analysis|Correlative studies
48379268|NCT05700526|DEVICE|Routine preparation of bone graft according to standard protocols|The size dimensions obtained through VSP are used by the tissue bank to manually cut a structural bone graft according to the standard protocols.
48712553|NCT06036381|DIAGNOSTIC_TEST|Radiomic analysis of imaging - MRI, PET, CT|Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.
48712554|NCT02738476|PROCEDURE|Patellofemoral arthroplasty|
48712555|NCT04947878|OTHER|Prompt list|The patients in the intervention group will review a prompt list before their visit.
48379269|NCT05700526|DEVICE|Preparation of bone graft with virtual bone-matching and GSIs|The best donor bone is identified by matching the 3D models provided by bone bank with the planned graft, considering not only the size but also the most suitable configuration of cortical and medullary bone. Then GSIs are designed and 3D printed to perform the exact cut on the donor bone according to the experimental protocol.
48712556|NCT04371640|DRUG|Sirolimus 1 MG/ML|Oral solution
48021403|NCT06521502|RADIATION|Chest CT Scan|"At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs."
48021404|NCT05984394|DIAGNOSTIC_TEST|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT|BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
48021405|NCT00399438|DRUG|Placebo|Tablets, Oral, once daily, 2 weeks
48712557|NCT04371640|DRUG|Placebo|Oral solution
48712558|NCT03780959|DRUG|Etanercept|Administered twice weekly by subcutaneous injection
48021406|NCT00399438|DRUG|BMS-562086|Tablets, Oral, once daily, 2 weeks
48712559|NCT03780959|DRUG|Placebo|Administered twice weekly by subcutaneous injection
48712560|NCT05003661|BEHAVIORAL|Parents' Voice|the intervention is recording of parents voice of reading children's book.
48712561|NCT02840786|DEVICE|plaque excision system|
48712562|NCT02840786|DEVICE|balloon and Stent|
48712563|NCT01214304|OTHER|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
48178975|NCT02950051|BIOLOGICAL|Obinutuzumab|"Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d"
48379270|NCT05700526|PROCEDURE|Corrective osteotomy|The acute surgical correction is performed according to VSP using PSI and the customized bone graft. Preoperative variables (age, sex, disease, deformity), intraoperative variables (operation time, intraoperative complications, use of fluoroscopy, intraoperative bleeding) are registered.
48712564|NCT01214304|OTHER|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
48712565|NCT04710407|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
48712566|NCT00301535|DRUG|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
48712567|NCT02460913|PROCEDURE|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
48712568|NCT02460913|DRUG|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
48712569|NCT03995056|BEHAVIORAL|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
48021407|NCT06528301|GENETIC|UB-VV111|UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
48021408|NCT06528301|DRUG|rapamycin|Rapamycin is an FDA-approved drug.
48712570|NCT05346146|DRUG|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
48021409|NCT01609556|DRUG|Mirvetuximab soravtansine|Mirvetuximab soravtansine IV infusion will be administered as per dose and schedule specified in the respective arms.
48021410|NCT00159523|DIETARY_SUPPLEMENT|Probiotic|
48021411|NCT00159523|BIOLOGICAL|placebo|
48712571|NCT01403545|DRUG|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
48712572|NCT01403545|OTHER|Placebo|5% glucose infusion over 120 minutes
48712573|NCT01683513|DRUG|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
48021412|NCT03483623|OTHER|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
48021413|NCT03483623|OTHER|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
48021414|NCT03483623|OTHER|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
48021415|NCT03483623|OTHER|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
48021416|NCT04856319|PROCEDURE|Dental implant placement|Insertion of not more than two dental implants at the same area
48021417|NCT04856319|DRUG|Antibiotic prophylaxis|Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
48021418|NCT04856319|OTHER|Placebo|Per-os placebo (inert polysaccharide) will be administered one hour prior to the surgery
48178976|NCT02950051|DRUG|Ibrutinib|"Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d"
48712574|NCT04540458|OTHER|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
48178977|NCT00251888|DRUG|campto (irinotecan)|
48379271|NCT02872584|DRUG|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
48712575|NCT04540458|OTHER|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
48021419|NCT04136106|DRUG|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
48021420|NCT05580913|BEHAVIORAL|Resistance training|12 weeks of resistance-training performed two times per week
48712576|NCT03452826|DEVICE|Antibiotic therapy according to the result of mPCR (device)|"* Phone call at D28 and D90, unless the patient is still hospitalized;~* Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~* Collection of an additional respiratory tract sample for biological banking in both arms."
48021421|NCT05947539|BEHAVIORAL|"Kisoboka Mukwano (It is possible, my love!) Intervention"|The intervention consists of 5 bi-weekly sessions each lasting 60 to 90 minutes. It uses motivational interviewing, peer navigation, and behavioral economics to promote strategies for economic strengthening, reductions in male partner alcohol use, coping with relationship conflict and stress, changing norms that reduce intimate partner violence and support engagement in HIV care and antiretroviral therapy (ART) adherence among adolescent girls and young women living with HIV, and, thereby, enhances future sustained viral suppression and benefits of treatment as prevention.
48178978|NCT00251888|DRUG|cisplatin (cisplatyl)|
48178979|NCT03038269|BEHAVIORAL|Upper Extremity Robotics, tDCS|Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
48712577|NCT04192968|OTHER|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
48712578|NCT04192968|OTHER|Additional exams|"* Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
48712579|NCT03413098|DEVICE|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
48712580|NCT00050973|DRUG|bexarotene|
48712581|NCT03000543|BIOLOGICAL|Vaccine|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
48712582|NCT02867618|DRUG|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
48712583|NCT02867618|DRUG|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
48712584|NCT01646619|DRUG|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
48712585|NCT01646619|DRUG|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
48178980|NCT04396847|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
48178981|NCT04396847|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
48178982|NCT00220623|DRUG|antidepressant medications, flexible drug choice|
48712586|NCT02966795|DRUG|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
48712587|NCT00434759|BEHAVIORAL|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
48712588|NCT00434759|BEHAVIORAL|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
48712589|NCT04290468|DEVICE|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
48712590|NCT02691403|DRUG|levo-bupivacaine|
48712591|NCT02691403|DRUG|normal saline|
48712592|NCT03897894|BEHAVIORAL|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
48712593|NCT05677503|DIAGNOSTIC_TEST|CBC|measurement of CBC will be performed at the time of admission and by the time of discharge
48712594|NCT05677503|DIAGNOSTIC_TEST|(NT-proBNP)|measurement of serum NT-proBNP levels will be performed at the time of admission and by the time of discharge
48712595|NCT05677503|DIAGNOSTIC_TEST|(cTnT)|measurement of cTnT levels will be performed at the time of admission and by the time of discharge
48712596|NCT02255565|DRUG|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
48712597|NCT02255565|DRUG|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
48712598|NCT02255565|DRUG|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
48021422|NCT05947539|BEHAVIORAL|Screening and Referral|Intimate partner violence screening, alcohol screening, and referral
48178983|NCT00220623|BEHAVIORAL|CBT, Psychodynamic or Supportive Psychotherapy|
48712599|NCT05610306|OTHER|Qualitative interview|Qualitative interviews to gain insight into the impact of ichthyosis on the biological, psychological, and social quality of life in adult and elderly patients.
48712600|NCT03687957|DRUG|rhIL-7-hyFc|-Given by intramuscular injection
48712601|NCT03687957|DRUG|Placebo|-Given by intramuscular injection
48712602|NCT03687957|DRUG|Temozolomide|-Standard of care
48712603|NCT03687957|RADIATION|Radiation therapy|-Standard of care
48379272|NCT01905891|PROCEDURE|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
48379273|NCT05214339|DRUG|Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab|The patient will receive Hepatic Arterial Infusion(mFOLFOX7) on the first day, and intravenous infusion of Bevacizumab on the 4th day, and intravenous infusion of Sintilimab on the 25th day. The intervention is repeated every 3 weeks.
48379274|NCT04698668|DEVICE|fusion imaging|To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
48379275|NCT01114126|DRUG|Neu-P11|comparison of different dosages of drug
48712604|NCT03687957|PROCEDURE|Blood sample|"* Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression"
48712605|NCT00701636|DRUG|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
48712606|NCT05773365|OTHER|PENG block with or without local anaesthetic infiltration|As mentioned.
48712607|NCT01763320|PROCEDURE|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
48712608|NCT01763320|DRUG|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
48379276|NCT01114126|DRUG|Neu-P11 placebo|comparison of different dosages
48712609|NCT02513823|DIETARY_SUPPLEMENT|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
48712610|NCT01667562|DRUG|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
48178984|NCT02516865|DEVICE|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
48178985|NCT02516865|DEVICE|Ankle weights|Worn during typical daily activities.
48379277|NCT04891445|BEHAVIORAL|Nursing monitoring program|A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.
48379278|NCT04891445|BEHAVIORAL|As usual|Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
48712611|NCT00170196|DRUG|prednisone|
48178986|NCT05417347|OTHER|Low-fat dairy products|Milk: low fat (less than 2% M.F.) Yogurt: less than 2% M.F. Cheese: less than 20% M.F.
48178987|NCT05417347|OTHER|Full-fat dairy products|Milk: full-fat milk Yogurt: 2% and more M.F. Cheese: Regular cheese products
48712612|NCT05023616|OTHER|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
48712613|NCT05023616|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
48712614|NCT05985278|DRUG|[ Lu-177]-Catalase|\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
48712615|NCT02578433|BEHAVIORAL|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
48712616|NCT02578433|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
48712617|NCT00000262|DRUG|30% Nitrous oxide|
48712618|NCT00000262|DRUG|0.4% Sevoflurane|
48712619|NCT00000262|DRUG|0.2% sevoflurane|
48712620|NCT00000262|OTHER|Placebo|
48712621|NCT02174523|DRUG|40mg lurasidone|
48379279|NCT02288949|OTHER|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
48379280|NCT00623688|DEVICE|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
48712622|NCT02174523|DRUG|placebo|
48379281|NCT00623688|DEVICE|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
48712623|NCT01363180|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
48178988|NCT00552864|DRUG|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
48178989|NCT00552864|DRUG|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
48178990|NCT03534583|OTHER|Sudarshan Kriya Yoga|Participants in the SKY group will undergo an oline 12-week training course conducted by certified teachers of the Art of Living Foundation
48178991|NCT03534583|OTHER|Health Enhancement Program|Participants in the online HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
48379282|NCT04034875|OTHER|Questionnaire|questionnaire
48379283|NCT00991146|DRUG|canakinumab|canakinumab
48379284|NCT03091478|DRUG|Pembrolizumab|200mg every 3 weeks
48379285|NCT00470249|DRUG|Carboplatin|At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
48379286|NCT00470249|DRUG|Gemcitabine Hydrochloride|1500 mg/m2 on day 2 of every 2-week cycle
48379287|NCT05201898|OTHER|control:usual medical management|with regular doctor visits every 3 months
48379288|NCT05201898|BEHAVIORAL|intervention 1:usual medical management+individual dieting consultation|with regular doctor visits every 3 months and dietitian visits every 3 months
48379289|NCT05201898|BEHAVIORAL|intervention 2:usual medical management+individual dieting consultation+ daily tea drinking|with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
48712624|NCT01363180|OTHER|No stress condition|
48712625|NCT01930552|DRUG|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
48712626|NCT01930552|DRUG|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
48712627|NCT01930552|DRUG|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
48712628|NCT01930552|DRUG|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
48712629|NCT05577832|PROCEDURE|Helfer Skin Tap Technique|In a single-group design, 3 technique injections will be administered to the patients, to be randomized. The HST technique will be applied to patients in any one of 1days in a randomized fashion.
48712630|NCT05577832|PROCEDURE|ShotBlocker Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 1 weeks(3 days) in a randomized manner.
48712631|NCT05577832|PROCEDURE|Standard Technique|Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per days, to be randomized. The standard technique will be applied to patients in any one of 1 weeks in a randomized fashion.
48712632|NCT02429713|PROCEDURE|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
48379290|NCT01092286|OTHER|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
48379291|NCT03696537|DRUG|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
48379292|NCT03696537|RADIATION|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
48379293|NCT01857011|DRUG|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
48178992|NCT01356563|BEHAVIORAL|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
48178993|NCT00883636|OTHER|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
48178994|NCT00883636|OTHER|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
48178995|NCT00883636|OTHER|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
48178996|NCT03562390|DRUG|Irinotecan|The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
48379294|NCT01857011|DRUG|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
48712633|NCT02429713|PROCEDURE|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
48712634|NCT04420962|DIAGNOSTIC_TEST|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
48712635|NCT00374894|DRUG|2,3-dimercaptosuccinic acid|
48712636|NCT03414112|BIOLOGICAL|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
48712637|NCT04962230|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
48712638|NCT04962230|DRUG|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
48712639|NCT04962230|DRUG|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
48379295|NCT00295919|DRUG|fenretinide lipid matrix|
48379296|NCT00295919|DRUG|ketoconazole|
48379297|NCT00295919|OTHER|laboratory biomarker analysis|
48379298|NCT00295919|OTHER|pharmacological study|
48379299|NCT04209426|DEVICE|THA with SYMBOL CUP DMR HA|
48379300|NCT04209426|DEVICE|THA with SYMBOL CUP DM CEM|
48379301|NCT06298916|COMBINATION_PRODUCT|64Cu-LNTH-1363S|64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,
48379302|NCT05154487|DRUG|Alpelisib Pill|Kinase inhibitor
48379303|NCT05154487|DRUG|Fulvestrant injection|estrogen receptor agonist
48178997|NCT05075512|DRUG|anlotinib, fulvestrant|anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
48178998|NCT06121804|DRUG|Immunosuppressive Agents|Prescribing immunosuppressive agents
48178999|NCT03632083|DEVICE|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
48179000|NCT03632083|DEVICE|Lite Contact Lens Solution|Lite Contact Lens Solution
48179001|NCT03632083|DEVICE|fanfilcon A soft contact lens|fanfilcon A soft contact lens
48179002|NCT03632083|DEVICE|comfilcon A soft contact lens|comfilcon A soft contact lens
48179003|NCT03137706|PROCEDURE|Biospecimen Collection|Undergo fresh tumor tissue collection
48179004|NCT03137706|OTHER|Laboratory Biomarker Analysis|Correlative studies
48179005|NCT03137706|OTHER|Laboratory Procedure|Tissue stiffness and cell viability analysis
48712640|NCT00769717|BEHAVIORAL|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
48712641|NCT00769717|BEHAVIORAL|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
48712642|NCT00490139|DRUG|Lapatinib|Small molecule inhibitor
48712643|NCT00490139|BIOLOGICAL|Trastuzumab|Antibody
48712644|NCT01605318|DRUG|Labetuzumab Govitecan (LG)|Administered as a slow intravenous (IV) infusion.
48712645|NCT02157792|DRUG|M6620|
48712646|NCT02157792|DRUG|Gemcitabine|
48712647|NCT02157792|DRUG|Cisplatin|
48712648|NCT02157792|DRUG|Etoposide|
48179006|NCT02997332|DRUG|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
48179007|NCT02997332|DRUG|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
48179008|NCT02997332|DRUG|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
48179009|NCT02997332|DRUG|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
48179010|NCT03108976|OTHER|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
48179011|NCT03108976|OTHER|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
48179012|NCT03108976|OTHER|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
48179013|NCT02689947|DEVICE|Restylane Silk|
48712649|NCT02157792|DRUG|Carboplatin|
48179014|NCT02314104|DRUG|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
48179015|NCT05272709|DRUG|TT-702|TT-702 will be administered orally, once daily, for up to 12 months.
48179016|NCT05272709|DRUG|Darolutamide|Darolutamide will be administered orally, twice daily, for up to 12 months.
48021423|NCT03881462|PROCEDURE|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
48179017|NCT04889027|DIAGNOSTIC_TEST|Standardized Infant NeuroDevelopmental Assessment|The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome (Hadder-Algra et al., 2018).
48179018|NCT05046106|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
48179019|NCT05046106|OTHER|Placebo|Caramel, chocolate brown, flavor (E_1982648), dextrin
48179020|NCT00114296|DIETARY_SUPPLEMENT|omega-3 fatty acid|
48179021|NCT04481646|DIAGNOSTIC_TEST|Face mask sampling|Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.
48179022|NCT00861822|OTHER|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
48179023|NCT04784455|DRUG|nomacopan (rVA576)|The study population will consist of paediatric patients who have undergone allogeneic or autologous HSCT and develop HSCT-TMA within a year of HSCT
48712650|NCT02157792|DRUG|Irinotecan|
48712651|NCT01276444|DEVICE|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
48179024|NCT04699968|DRUG|SHR-1701，Famitinib|SHR -1701, Intravenous ；Famitinib, oral
48179025|NCT04699968|DRUG|SHR-1701|SHR -1701, Intravenous
48179026|NCT00347399|DRUG|bevacizumab intravitreal injection|
48179027|NCT00347399|PROCEDURE|verteporfin photodynamic therapy|
48179028|NCT03293836|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
48179029|NCT03293836|PROCEDURE|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
48179030|NCT02113410|BEHAVIORAL|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
48379304|NCT06153758|DRUG|Danuglipron|Danuglipron oral tablets
48712652|NCT01276444|DEVICE|transpulmonary thermodilution + central venous saturation|Described in details above
48712653|NCT01878110|BEHAVIORAL|COMB|
48712654|NCT02370095|DRUG|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
48712655|NCT02370095|DRUG|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
48712656|NCT02897531|PROCEDURE|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
48712657|NCT02897531|PROCEDURE|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
48712658|NCT04026269|DRUG|MOAP|the new chemotherapy regimen for r/r cHL
48712659|NCT04274153|BIOLOGICAL|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
48712660|NCT03117946|OTHER|Biological samples|blood and tumor tissue sample
48712661|NCT03344640|DRUG|secukinumab|AIN457 300 mg subcutaneously for 12 weeks
48712662|NCT03344640|OTHER|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
48021424|NCT01168934|DRUG|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
48179031|NCT02113410|BEHAVIORAL|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
48021425|NCT01168934|DRUG|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
48179032|NCT06255925|BEHAVIORAL|KF-STRIDE® Into Work!|Treatment group will receive 10 web based sessions of a strength-based training tool(once or twice a week). Sessions are approximately 60 minutes long.
48179033|NCT01628692|DRUG|Daclatasvir|Tablets, oral, 30 mg, once daily
48379305|NCT00696826|DRUG|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
48712663|NCT03849690|DRUG|TAK-906|TAK-906 capsules.
48379306|NCT02402556|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
48379307|NCT05457829|DRUG|Doxorubicin Hydrochloride Liposome+Irinotecan|Q3W, 2 cycles.
48712664|NCT03849690|DRUG|Esomeprazole|Esomeprazole capsules.
48712665|NCT03150069|OTHER|Interview|In-person or telephone in-depth interview
48021426|NCT03503968|DRUG|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
48179034|NCT01628692|DRUG|Simeprevir|Capsule, oral, 150 mg, once daily
48179035|NCT01628692|DRUG|Ribavirin|Tablets, oral, 500-600 mg, twice daily
48179036|NCT05438134|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
48179037|NCT04909138|DEVICE|DRG stimulation 20 Hz 30/90|Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF
48179038|NCT04909138|DEVICE|DRG stimulation 5 Hz 30/90|Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
48179039|NCT03625453|DRUG|ABX-1431|Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
48179040|NCT03625453|DRUG|Placebo|Part 1: 8 weeks with daily administration
48379308|NCT05457829|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 2 cycles.
48379309|NCT00619658|OTHER|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
48379310|NCT06542393|DRUG|Erythropoietin|"* Treatment regimen for hospitalized patients awaiting non-urgent surgeries: Administer EPO 600 IU/kg/week via subcutaneous (SC) or intravenous (IV) route, followed by 300 IU/kg/day via SC or IV 10 days before surgery. If ferritin \< 100 ng/dL, supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 1000 mg/week).~* Treatment regimen for hospitalized patients awaiting non-urgent surgeries with less than 5 days until surgery: Administer 40000 UI of EPO intravenous (IV) attack and supplement with IV iron (Iron hydroxide up to 600 mg/week or Ferric carboxymaltose up to 2000 mg/week), then 300UI/Kg/day IV or SC of EPO until day of surgery."
48712666|NCT01962987|DRUG|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
48021427|NCT03503968|OTHER|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
48021428|NCT03186898|RADIATION|Proton Therapy (Radiation Therapy)|Undergo proton therapy
48021429|NCT03186898|RADIATION|Photon Therapy (Radiation Therapy)|Undergo photon therapy
48021430|NCT03930745|OTHER|Placebo|Placebo vaginal inserts.
48021431|NCT03930745|DRUG|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
48379311|NCT06542393|PROCEDURE|blood transfusion|"After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb \> 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC."
48712667|NCT01962987|OTHER|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
48712668|NCT04879849|DRUG|Pembrolizumab|IV infusion.
48712669|NCT04879849|DRUG|TAK-676|IV infusion.
48712670|NCT04879849|RADIATION|Image-guided radiation therapy|Radiation therapy.
48021432|NCT04550962|DRUG|Dupilumab SAR231893|"Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:"
48021433|NCT03229551|DRUG|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
48179041|NCT04863820|DIAGNOSTIC_TEST|cutaneous silent period|form of Nerve conduction studies
48179042|NCT02132871|DEVICE|Impedance cardiography Physioflow ®|
48179046|NCT05784922|OTHER|Educational Lung Cancer Screening (LCS) Video|An educational video on lung cancer screening tailored to Hispanic current and former smokers.
48712671|NCT06472869|OTHER|NJOY ACE e-cigarette|Patients will be provided with NJOY ACE electronic cigarettes and 5% nicotine e-liquid cartridges in tobacco flavor for 4 weeks and asked to use the electronic cigarette as a substitute for smoking combustible cigarettes during the 4 weeks
48712672|NCT00273754|DRUG|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
48712673|NCT00273754|DRUG|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
48179047|NCT04683341|DRUG|Tenofovir Alafenamide Tablets|Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA \< 20 IU/mL) will be enrolled.
48179048|NCT04749355|DRUG|BST-236|BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
48179049|NCT05739110|BEHAVIORAL|tumor micronecrosis|whether HCC patients have tumor micronecrosis or not
48021434|NCT03229551|DRUG|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
48179050|NCT05675319|DRUG|Allogeneic Stem Cells|Allogeneic Stem Cell Transplantation
48179051|NCT05675319|DRUG|carfilzomib/lenalidomide/dexamethasone (KRD)|triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version
48379312|NCT04680390|BEHAVIORAL|Standard of care engagement practices|The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
48712674|NCT04698135|OTHER|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
48712675|NCT04698135|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
48712676|NCT04698135|OTHER|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
48712677|NCT03162484|BEHAVIORAL|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
48712678|NCT05385445|BEHAVIORAL|Audit and Feedback|The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
48712679|NCT01810848|DEVICE|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
48712680|NCT01810848|OTHER|Control|Control is puncture of the skin at the site of the knee.
48712681|NCT00115999|DRUG|alfimeprase|
48712682|NCT05477537|OTHER|Adapted physical activity program|subjects with Anorexia Nervosa (AN) involved in a day hospital or an inpatient program following HAS guidelines for anorexia nervosa treatment (treatment as usual) who will receive in addition an adapted physical activity program (one lesson per week, during 8 weeks) Adapted Physical Activity program, including psychoeducation on both problematic physical activity and consequences in terms of physical activity good practice leads to a better outcome among persons suffering from anorexia nervosa.
48712683|NCT05477537|OTHER|Treatment as usual group|Subjects with Anorexia Nervosa involved in a day hospital or an inpatient program following HAS guidelines for AN treatment (treatment as usual)
48379313|NCT04680390|BEHAVIORAL|Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women|kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
48712684|NCT04109131|OTHER|Samples collection: Plasma|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"
48021435|NCT03025620|DIETARY_SUPPLEMENT|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
48021436|NCT03025620|DIETARY_SUPPLEMENT|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
48021437|NCT00499369|DRUG|irinotecan hydrochloride|Given IV
48021438|NCT00499369|DRUG|leucovorin calcium|Given IV
48021439|NCT00499369|DRUG|fluorouracil|Given IV
48021440|NCT00499369|BIOLOGICAL|cetuximab|Given IV
48179052|NCT05675319|DRUG|elotuzumab/lenalidomide/dexamethasone (ERD)|triple regimen for first relapse should be applied according to latest SmPC version
48179053|NCT05675319|DRUG|daratumumab/bortezomib/dexamethasone (DVD)|triple regimen for first relapse should be applied according to latest SmPC version
48179054|NCT05675319|DRUG|daratumumab/lenalidomide/dexamethasone (DRD)|triple regimen for first relapse should be applied according to latest SmPC version
48179055|NCT05675319|DRUG|ixazomib/lenalidomide/dexamethasone (IRD)|triple regimen for first relapse should be applied according to latest SmPC version
48179056|NCT05675319|DRUG|pomalidomide/bortezomib/dexamethasone (PVD)|triple regimen for first relapse should be applied according to latest SmPC version
48179057|NCT05675319|DRUG|carfilzomib/daratumumab/dexamethasone (KDD)|triple regimen for first relapse should be applied according to latest SmPC version
48712685|NCT04109131|OTHER|Samples collection: CSF|Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
48712686|NCT04109131|OTHER|Samples collection: Non-CNS Metastatic Tumour Tissue|Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
48712687|NCT04109131|OTHER|Brain MRI|"Part A:~* Brain MRI at inclusion is allowed within 45 days before enrolment~* Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"
48712688|NCT04109131|OTHER|Samples collection: Serum|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5."
48021441|NCT00499369|BIOLOGICAL|bevacizumab|Given IV
48021442|NCT00753441|PROCEDURE|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
48021443|NCT00753441|PROCEDURE|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
48021444|NCT06330441|PROCEDURE|endoscopic ultrasonography|endoscopic ultrasonography - frequency defined by arm
48021445|NCT06330441|PROCEDURE|magnetic resonance|magnetic resonance - frequency defined by arm
48379315|NCT06425822|DIAGNOSTIC_TEST|Left atrial electroanatomical mapping|Left atrial electroanatomical mapping (substrate and functional mapping)
48379316|NCT03331952|OTHER|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
48379317|NCT03331952|OTHER|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
48021446|NCT06330441|DIAGNOSTIC_TEST|laboratory examination|hematology, biochemistry, Na+, K+, Cl-, Ca2+, bilirubin, ALT, AST, GGT, ALP, lactate dehydrogenase, creatinine, urea, fasting glycemia, HbA1c, alpha-amylase, LPS, albumin, total protein, CA19-9, CEA
48712689|NCT01920893|DRUG|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
48712690|NCT01920893|DRUG|Dupilumab|Solution for injection; Subcutaneous injection.
48712691|NCT01920893|DRUG|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
48712692|NCT02956759|PROCEDURE|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
48712693|NCT01448824|DRUG|LY2484595|Administered orally
48712694|NCT01448824|DRUG|Placebo|Administered orally
48712695|NCT01448824|DRUG|Ketoconazole|Administered orally
48712696|NCT00089986|DRUG|Intravenous GR270773- Phospholipid Emulsion|
48021447|NCT00036166|DRUG|FK463|
48021448|NCT04382326|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
48021449|NCT04382326|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
48021450|NCT02200042|RADIATION|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
48021451|NCT02293005|DRUG|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
48712697|NCT00089986|OTHER|Placebo|
48712698|NCT01902888|DEVICE|GORE® VIABAHN® Endoprosthesis|
48379318|NCT03331952|OTHER|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
48712699|NCT02638207|DRUG|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
48712700|NCT05819307|DEVICE|OCT/FLIM|OCT/FLIM imaging of the retina
48021452|NCT01683591|PROCEDURE|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
48021453|NCT02588040|BIOLOGICAL|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
48021454|NCT01849341|DRUG|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
48021455|NCT01849341|DRUG|Roflumilast 500 mcg per day|
48021456|NCT06573255|OTHER|Healthy group|Cardiopulmonary exercise test, respiratory function tests, respiratory muscle strength and physical activity assessment will be performed in this group.
48021457|NCT03294434|OTHER|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
48021458|NCT05087940|DRUG|Add-on therapy|Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker
48021459|NCT01326780|DRUG|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
48021460|NCT01326780|DRUG|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
48021461|NCT01326780|DRUG|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
48021462|NCT01326780|OTHER|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
48021463|NCT01975389|DRUG|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
48021464|NCT01975389|DRUG|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
48179058|NCT05675319|DRUG|Autologous Stem Cells|Autologous Stem Cell Transplantation
48179059|NCT05675319|DRUG|daratumumab/pomalidomide/dexamethasone (DPD)|triple regimen for first relapse should be applied according to latest SmPC version
48179060|NCT05675319|DRUG|isatuximab/carfilzomib/dexamethasone (Isa-KD)|triple regimen for first relapse should be applied according to latest SmPC version
48179061|NCT05675319|DRUG|selinexor/bortezomib/dexamethasone (SVD)|triple regimen for first relapse should be applied according to latest SmPC version
48179062|NCT05806151|DIAGNOSTIC_TEST|Genetic and immunologic assessments|Definitive Local Therapies including surgery, radiotherapy, radio-frequency ablation of metastases.
48179063|NCT05975047|DRUG|LIV001|Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;
48179064|NCT05975047|DRUG|Placebo|Participants will receive matching placebo across Part A and B of the study
48179065|NCT05969678|BEHAVIORAL|breathing training|receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete
48179066|NCT00160797|DEVICE|MIS™ Minimally Invasive Solutions™ TKA System|
48179067|NCT05557071|BEHAVIORAL|Digital Health Behaviour Change Platform|"Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect."
48179068|NCT04531306|OTHER|Kinesio® Tape|Fascial taping technique for myofascial trigger points on the iliotibial band
48179069|NCT04074343|DRUG|TAS-102|Given PO
48179070|NCT04074343|DRUG|Irinotecan|Given IV
48179071|NCT00478283|OTHER|survey administration|
48179072|NCT03040245|BEHAVIORAL|Whiplash book|
48179073|NCT02706249|DRUG|Enoxaparin|
48179074|NCT02671214|OTHER|Control|100 g high fibre flour
48179075|NCT02671214|OTHER|Active 2|98 g high fibre flour + 2 g guar gum
48179076|NCT02671214|OTHER|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
48179077|NCT02671214|OTHER|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
48179078|NCT02671214|OTHER|Active 5|96 g high fibre flour + 4 g guar gum
48179079|NCT02671214|OTHER|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
48379319|NCT05316376|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
48379320|NCT05316376|DRUG|paclitaxel|paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
48712701|NCT04932603|OTHER|Standard of care, with intervention of the multidisciplinary team|Patients with AF, aged of 75 years or more, with evaluation of their antithrombotic treatment by the multidisciplinary team. The review of patient's file by the multidisciplinary team is based on physician decision. These patients are hospitalized in one of the 6 geriatrics units participating in the study and / or are hospitalized in another ward but their clinical file is reviewed by the multidisciplinary team.
48712702|NCT05122923|DEVICE|Serious Game S'TIM|Video Game S'tim : the patient is inside a bedroom and he has to find a friend outside. this game will study the orientation, the memory of the patient
48712703|NCT04982406|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
48712704|NCT05959629|DEVICE|Waterlase Express™, BIOLASE®|Er,Cr:YSGG laser 2780nm (Waterlase Express™, BIOLASE®) with 300μm tip (EdgePro #3) will be placed into the mid-root of the canal. The tip will be activated and slowly withdrawn to the orifice (1-2mm/sec) following the manufacturer settings (energy 15 Millijoule (mJ), repetition rate 50 Hertz (Hz), 0% air, 0% water).
48712705|NCT05959629|OTHER|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using 1.5cc of 3% NaOCl in between files.
48712706|NCT00526110|DRUG|5-Fluorouracil|2.2 Gm/m\^2 IV over 48 hours on Day 1.
48712707|NCT00526110|DRUG|Docetaxel|20 mg/m\^2 IV over 60 minutes
48712708|NCT00526110|DRUG|Oxaliplatin|85 mg/m\^2 IV over 120 minutes on Day 1.
48179080|NCT02671214|OTHER|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
48179081|NCT02671214|OTHER|Active 8|94 g high fibre flour + 6 g guar gum
48179082|NCT02671214|OTHER|Active 9|98 g high fibre flour + 2 g konjac mannan
48179083|NCT02671214|OTHER|Active 10|96 g high fibre flour + 4 g konjac mannan
48179084|NCT02671214|OTHER|Active 11|100 g low fibre flour
48179085|NCT02671214|OTHER|Active 1|85 g high fibre flour + 15 g legume flour
48179086|NCT04044703|DRUG|Vancomycin - model-based dosing regimen|A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
48179087|NCT01335906|OTHER|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
48179088|NCT00499278|BEHAVIORAL|Rehabilitation after joint replacement surgery|
48179089|NCT04330378|OTHER|Hospital-at-home|As per experimental arm
48179090|NCT04330378|OTHER|Usual in-hospital care|As per control arm
48179091|NCT04718311|DRUG|Oral lichen clinical Healing evaluation|Treatments were topically applied for 5 days
48379321|NCT02333175|OTHER|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
48379322|NCT03803371|DRUG|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
48379323|NCT03803371|DRUG|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
48379324|NCT00103376|DRUG|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
48379325|NCT00103376|DRUG|LH-RH Agonist|given as a 3 month depo-injection
48379326|NCT00103376|DRUG|Androgen Receptor Antagonists|given orally daily for 3 months
48379327|NCT05046145|BEHAVIORAL|speech therapy for chewing + real tDCS|participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
48379328|NCT00563706|DRUG|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
48021465|NCT02481687|OTHER|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
48712709|NCT05922410|RADIATION|cone beam computed tomography|cone beam computed tomography
48712710|NCT02057094|DIETARY_SUPPLEMENT|Protein, High-Protein, and Control|
48712711|NCT03267173|DRUG|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
48712712|NCT01371149|OTHER|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
48712713|NCT04350021|DRUG|Capecitabine, Cyclophosphamide|Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
48712714|NCT01298102|BIOLOGICAL|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
48712715|NCT03110653|DRUG|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
48712716|NCT03110653|DRUG|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
48021466|NCT03832192|BEHAVIORAL|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
48021467|NCT04273100|COMBINATION_PRODUCT|PD-1 mAb combined with TACE and lenvatinib|the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib)
48021468|NCT01427712|DRUG|Pancrelipase|
48021469|NCT00099697|DRUG|DHEA|
48021470|NCT05368597|PROCEDURE|PCI in native vessel or in bypass graft|Native vessel PCI,which choose native coronary artery as the target vessel, while the bypass graft PCI choose graft vessel as the target vessel.
48021471|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
48021472|NCT00537524|BIOLOGICAL|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
48021473|NCT04849949|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
48021474|NCT04849949|OTHER|Black walnut|Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
48021475|NCT04849949|OTHER|English walnut|Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
48021476|NCT05155735|PROCEDURE|Replantation|Surgical reattachment of a severed body part
48021477|NCT05155735|PROCEDURE|Primary wound closure|Primary wound closure with removal of exposed bone
48179092|NCT03754790|DRUG|Fitusiran|Pharmaceutical form:solution for injection Route of administration: subcutaneous
48179093|NCT00672282|DRUG|Bicalutamide|150mg p.o. daily
48179094|NCT00672282|DRUG|Placebo|
48179095|NCT03128671|BEHAVIORAL|FAVoR Intervention|The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
48179096|NCT03544645|OTHER|"Audiovisual material video"|an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.
48379329|NCT00563706|DRUG|risperidone|
48712717|NCT00826358|DRUG|ABT-143|Once, please see Arm Description for more details.
48712718|NCT00826358|DRUG|ABT-335|Once, see Arm Description for more detail
48712719|NCT00826358|DRUG|rosuvastatin|once, see Arm Description for more detail
48712720|NCT05126160|DIAGNOSTIC_TEST|Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
48712721|NCT04940897|OTHER|Use of CareSens ketone meter|Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
48712722|NCT02813642|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
48712723|NCT02813642|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
48712724|NCT02813642|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
48712725|NCT02648022|BEHAVIORAL|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
48712726|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
48712727|NCT03192033|DEVICE|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
48712728|NCT03192033|DEVICE|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
48021478|NCT01264861|DRUG|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
48712729|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
48179097|NCT03544645|OTHER|"Printed material brochure"|an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
48379330|NCT00563706|OTHER|placebo|
48712730|NCT03208530|BEHAVIORAL|Brief motivational interview intervention|A brief (\<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
48712731|NCT03503292|DRUG|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
48379331|NCT05283655|BEHAVIORAL|Gut-directed hypnotherapy|hypnotherapy
48379332|NCT04939337|DRUG|TH-SC01|Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)
48379333|NCT06471023|DIETARY_SUPPLEMENT|TP1|Vitamin C formulation 1, 1000 mg
48379334|NCT06471023|DIETARY_SUPPLEMENT|TP2|Vitamin C formulation 2, 1000 mg
48712732|NCT03503292|DRUG|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
48712733|NCT05044104|DEVICE|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
48712734|NCT04763486|DRUG|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
48712735|NCT04517786|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
48712736|NCT01218451|BIOLOGICAL|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
48712737|NCT01218451|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
48712738|NCT01218451|BIOLOGICAL|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
48712739|NCT05210868|DRUG|CM355|"1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug"
48712740|NCT02130336|BEHAVIORAL|Aerobic interval training|
48712741|NCT02130336|BEHAVIORAL|Continuous moderate-intensity exercise|
48179098|NCT03411993|DIAGNOSTIC_TEST|Focused cardiac echography|All pregnant women attending antenatal care will be eligible to undergo focused cardiac echo to identify underlying cardiac disease
48021479|NCT01470027|DRUG|N-acetylcysteine|900mg NAC effervescent tablets
48021480|NCT01470027|DRUG|Placebo|effervescent tablets
48179099|NCT04793750|DIAGNOSTIC_TEST|Cepheid GeneXpert HIV-1 Qual POC HIV VL test|POC Nucleic acid-based test for HIV RNA.
48179100|NCT04793750|DIAGNOSTIC_TEST|DPP HIV-Syphilis test system|POC Tests for antibodies to HIV 1/2 and Treponema pallidum.
48379335|NCT06471023|DIETARY_SUPPLEMENT|TP3|Vitamin C formulation 3, 1000 mg
48379336|NCT06471023|DIETARY_SUPPLEMENT|TP4|regular Vitamin C, 3000 mg
48379337|NCT06471023|DIETARY_SUPPLEMENT|CP|Vitamin C formulation 4, 1000 mg
48379338|NCT06471023|DIETARY_SUPPLEMENT|RP|regular Vitamin C, 1000 mg
48379339|NCT01912469|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
48379340|NCT01912469|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
48712742|NCT04276688|DRUG|Lopinavir/ritonavir|400mg/100mg twice daily for 14 days
48712743|NCT04276688|DRUG|Ribavirin|400mg twice daily for 14 days
48712744|NCT04276688|DRUG|Interferon Beta-1B|0.25mg subcutaneous injection alternate day for 3 days
48179101|NCT04793750|DIAGNOSTIC_TEST|OraQuick|POC oral fluid swab test for HIV 1/2 antibodies.
48179102|NCT04696783|DRUG|Esomeprazole Magnesium Enteric-coated Tablets|Nexium taken once every 2 days plus lifestyle adjustment
48179103|NCT04696783|BEHAVIORAL|Lifestyle adjustment|Lifestyle adjustment
48712745|NCT03950687|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
48712746|NCT03950687|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
48712747|NCT04364061|OTHER|Moderate Intensity Continuous Exercise|Participant completed a moderate intensity continuous cycling exercise (MICE) during 35 min at 60-65% thPHRmax
48179104|NCT01748305|BEHAVIORAL|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
48179105|NCT05886946|OTHER|ABG|ABG
48179106|NCT00368641|DRUG|Extraneal|Periotneal Dialysis
48712748|NCT04364061|OTHER|High-Intensity Interval Exercise (1)|Participant completed a high-intensity interval cycling exercise (HIIE 1) during 20min with 60 cycles of speeding up for 8s and pedaling slowly for 12s at 80-90% thPHRmax
48712749|NCT04364061|OTHER|High-Intensity Interval Exercise (2)|Participant completed a high-intensity interval cycling exercise (HIIE 2) during 20min with 10 x 1-min bouts at 80-90% thPHRmax, separated by 1-min recovery bouts
48021481|NCT06532227|OTHER|No intervention|No intervention excepted data collection
48021482|NCT06327126|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
48021483|NCT06327126|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
48179107|NCT04813497|DIAGNOSTIC_TEST|Serology to determine SARS-CoV-2 infection|Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
48179108|NCT01547598|DRUG|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
48179109|NCT01547598|DRUG|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
48179110|NCT01547598|DRUG|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
48179111|NCT05161793|DEVICE|Tele-Monitor DM|Remote monitoring of CGM data to identify, contact, and provide diabetes management for patients who are having episodes of hypoglycemia, hyperglycemia and/or difficulty using their CGM device.
48179112|NCT00791375|BEHAVIORAL|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
48179113|NCT00810342|BEHAVIORAL|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
48179114|NCT00810342|BEHAVIORAL|physical activity standard|standard print and website information on how to become more active
48179115|NCT01927107|DIETARY_SUPPLEMENT|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
48179116|NCT03061058|DRUG|Docetaxel|intraperitoneal and/or intravenous
48179117|NCT03061058|DRUG|Oxaliplatin|intravenous
48179118|NCT03061058|DRUG|Cisplatin|intraperitoneal
48712750|NCT03905317|DRUG|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
48712751|NCT03905317|RADIATION|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
48712752|NCT03905317|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
48179119|NCT03061058|DRUG|Irinotecan|intraperitoneal and/or intravenous
48179120|NCT03061058|DRUG|Pemetrexed|intraperitoneal and/or intravenous
48179121|NCT03061058|DRUG|S1|oral
48021484|NCT04632446|OTHER|Early diagnosis|Early diagnosis. Upgrade program implementation.
48712753|NCT05179083|OTHER|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
48712754|NCT05179083|OTHER|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
48179122|NCT03099408|DRUG|Metronidazole Oral|Oral metronidazole 400 mg BID for 7 days at first month.
48179123|NCT03099408|DRUG|"Metronidazole and Lactobacillus"|Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
48712755|NCT00533065|DRUG|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
48712756|NCT01537146|DRUG|Ropivacaine|Bolus infusion via catheter/6H for 24H
48712757|NCT01537146|DRUG|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
48021485|NCT05071755|PROCEDURE|Gastrectomy|Radical Total Gastrectomy, Radical Partial gastrectomy (Proximal / Subtotal)
48021486|NCT04407663|OTHER|Telemedicine to remote outpatient visit in bariatric patient|Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
48021487|NCT02091167|DEVICE|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
48021488|NCT06533774|DEVICE|Phonak Audéo Lumity 90-R|This study will be using the Audeo L90-R devices, which are programmed by the hearing care professional (HCP) using Target fitting software version 8.1.
48021489|NCT04713748|DEVICE|Tasso-SST on Demand|Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection. Both blood samples will be spun and processed for serum. Serum will be frozen and shipped to the lab at Duke for antibody testing. Antibody results will be compared between the two methods.
48021490|NCT04713748|OTHER|Regular Phlebotomy|Participants will have a small blood sample collected via regular venipuncture.
48021491|NCT01455883|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
48021492|NCT01455883|DRUG|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
48021493|NCT06532825|DIAGNOSTIC_TEST|heart monitoring|individual comparison of heart rate variability at admission with a repeated measurement before discharge
48021494|NCT05927402|OTHER|Laughter Therapy Based on Kolcaba Comfort Theory|The laughter yoga will be applied to experimanetal group. Every laughter yoga practice is 45 minutes long and is planned 3 times a week for a total of 6 sessions. Control group patients will take only routine nursing care.
48179124|NCT00332969|DRUG|Octreotide|
48179125|NCT03049345|PROCEDURE|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
48179126|NCT03049345|DRUG|Radioactive Tracers|see above
48179127|NCT03049345|DRUG|Methylene Blue 20 MG/ML|see above
48712758|NCT02144545|PROCEDURE|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
48712759|NCT02144545|PROCEDURE|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
48712760|NCT02144545|PROCEDURE|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
48712761|NCT02144545|PROCEDURE|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
48712762|NCT03385265|BEHAVIORAL|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
48712763|NCT03385265|OTHER|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
48712764|NCT01079013|DRUG|treosulfan|12 g/m2 x 3 days
48712765|NCT02822131|DIETARY_SUPPLEMENT|sodium phosphate|
48712766|NCT02822131|DRUG|sevelamer, sodium bicarbonate, sodium chloride|
48179128|NCT03871621|DRUG|Diabetes Medicines|Anti-diabetic medications except SGLT2 inhibitors
48179129|NCT03871621|DRUG|Dapagliflozin|Dapagliflozin tablet (10 mg)
48179130|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored protonated e-liquid
48179131|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unflavored protonated e-liquid
48179132|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored unprotonated cigarette
48179133|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unfavored unprotonated cigarette
48712767|NCT03489967|OTHER|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
48712768|NCT03627065|DRUG|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
48712769|NCT01269385|BIOLOGICAL|alemtuzumab|Given subcutaneously
48179134|NCT05455086|PROCEDURE|Computed Tomography|Undergo PET/CT
48712770|NCT01269385|BIOLOGICAL|rituximab|Given IV
48712771|NCT01269385|DRUG|PGG beta-glucan|Given IV
48712772|NCT01269385|OTHER|flow cytometry|Correlative studies
48712773|NCT01269385|OTHER|laboratory biomarker analysis|Correlative studies
48712774|NCT01269385|GENETIC|DNA analysis|Correlative studies
48712775|NCT01269385|GENETIC|fluorescence in situ hybridization|Correlative studies
48712776|NCT01269385|GENETIC|polymerase chain reaction|Correlative studies
48712777|NCT01269385|GENETIC|polymorphism analysis|Correlative studies
48179135|NCT05455086|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48179136|NCT05455086|OTHER|Questionnaire Administration|Ancillary studies
48179137|NCT00387699|BIOLOGICAL|bevacizumab|
48179138|NCT00387699|DRUG|cisplatin|
48179139|NCT00387699|DRUG|etoposide|
48179140|NCT00387699|RADIATION|radiation therapy|
48179141|NCT02489409|DRUG|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
48179142|NCT02489409|DRUG|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
48712778|NCT01269385|GENETIC|mutation analysis|Correlative studies
48712779|NCT01357824|PROCEDURE|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
48712780|NCT06358560|OTHER|Therapeutic exercises|Rehabilitation exercises designed to achieve the treatment goal
48179143|NCT02489409|DRUG|Navelbine|40 mg/d, iv, d1, 8
48179144|NCT02489409|DRUG|Platinum|30 mg/m2, iv 3h, d1-3
48179145|NCT02489409|DRUG|Xeloda Tablets:|2 000 mg/m2, po, d1-14
48179146|NCT06546345|DEVICE|KeriFlex®|The KeriFlex® finger joint prothesis MCP is designed to replace a damaged metacarpophalangeal (MCP) joint and the KeriFlex® finger joint prothesis PIP is designed to replace a damaged proximal interphalangeal (PIP) joint.
48179147|NCT05939999|OTHER|Experimental: Elastic tape (ET)|The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
48179148|NCT05939999|OTHER|Sham Comparator: Sham (SH)|The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
48179149|NCT00283777|DRUG|Chromium Picolinate|
48179150|NCT01190644|DRUG|Sotatercept|single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85
48179151|NCT00828893|DEVICE|navigation station|navigation station for gestures (carried out under CT) guidance
48179152|NCT03783676|DRUG|Remifentanil|Receive remifentanil bolus and infusion guided by an algorithm.
48179153|NCT03783676|DRUG|Normal saline|Receive normal saline bolus and infusion guided by the remifentanil algorithm.
48179154|NCT04354246|DRUG|Dose escalation: COM902 monotherapy.|COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
48179155|NCT04354246|COMBINATION_PRODUCT|Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)|Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
48179156|NCT04354246|DRUG|Cohort expansion: COM902 (RDFE) monotherapy.|COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
48712781|NCT00661024|PROCEDURE|intraoperative RLN visualization|intraoperative RLN visualization
48712782|NCT00661024|PROCEDURE|intraoperative neuromonitoring of the RLN|IONM
48712783|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
48712784|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
48712785|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
48712786|NCT00953524|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
48712787|NCT05739695|DIAGNOSTIC_TEST|Virtual bronchoscopy navigation|It is planned to use VBN as the only navigation technique to compare it with rEBUS
48712788|NCT05739695|DIAGNOSTIC_TEST|radial EBUS|It is planned to use rEBUS as the only navigation technique to compare it with VBN
48712789|NCT02209402|BEHAVIORAL|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
48712790|NCT02146703|DRUG|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14"
48179157|NCT04354246|DRUG|Cohort expansion: COM902 in combination with COM701 (both at the RDFE).|COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
48179158|NCT04354246|COMBINATION_PRODUCT|Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.|Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
48179159|NCT01854736|DRUG|Grazax|GRAZAX
48179160|NCT01854736|OTHER|Placebo|Placebo
48179161|NCT03188653|OTHER|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
48179162|NCT03188653|OTHER|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
48179163|NCT03188653|OTHER|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
48179164|NCT03188653|OTHER|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
48179165|NCT03188653|OTHER|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
48179166|NCT03188653|OTHER|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
48712791|NCT02262078|DRUG|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
48179167|NCT03188653|OTHER|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free \& Clear Liquid Cleanser
48712792|NCT02262078|OTHER|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
48179168|NCT06486584|BEHAVIORAL|Contingency Management|Contingency management payment for no disruptive behaviors each week.
48712793|NCT02106247|DRUG|BI 1181181 high dose|two tablet
48712794|NCT02106247|DRUG|BI 1181181 low dose|one tablet
48712795|NCT02106247|DRUG|Placebo|tablet
48712796|NCT03230812|DRUG|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
48712797|NCT00283972|DEVICE|LAP-BAND System|
48712798|NCT00106691|DRUG|Toremifene 20 mg|The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
48712799|NCT00106691|DRUG|Placebo|The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
48712800|NCT03093974|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d dosing).~The 1 MIU/mL CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (\~10 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d (morning and evening) over a period of 12 months.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g., salbutamol /albuterol), supplied by the Sponsor, could be taken to improve tolerability."
48712801|NCT03093974|OTHER|Placebo|1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
48179169|NCT00813982|DEVICE|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
48179170|NCT00813982|DEVICE|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
48179171|NCT02371772|OTHER|Training|Patients were trained to monitor INR and dose warfarin
48179172|NCT03371823|OTHER|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
48179173|NCT03371823|DRUG|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
48179174|NCT00850486|DEVICE|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
48179175|NCT05026489|GENETIC|G6PD gene deficiency|we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.
48712802|NCT06268327|DRUG|Cisplatin injection and gemcitabine|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
48712803|NCT06268327|DRUG|Capecitabine tablets|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
48712804|NCT05388838|BIOLOGICAL|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
48712805|NCT05270226|BEHAVIORAL|The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)|"The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists)."
48712806|NCT01431937|DRUG|GSK2018682|Active Drug
48712807|NCT01431937|DRUG|Placebo|Placebo
48712808|NCT04542668|OTHER|Cycling then running|Ergometer cycling Treadmill running
48712809|NCT04542668|OTHER|Running then cycling|Treadmill running Ergometer cycling
48712810|NCT04542668|OTHER|Inotropy|Adrenaline induced inotropy
48712811|NCT04542668|OTHER|Resting|Subjects must be minimally physically active
48712812|NCT02658747|OTHER|No intervention|No intervention administered in this study
48712813|NCT04488744|DRUG|Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s|Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
48179176|NCT06242938|PROCEDURE|Early intensive antihypertensive treatment|"1. Treatment starts within 1 hour after randomization~2. SBP target:130-140 mmHg within 1 hour after treatment~3. The researchers can independently select oral + intravenous antihypertensive medications. Any type of antihypertensive drugs can be selected (eg. β-blokers, α-blockers, CCBs, ARBs/ACEIs, diuretic, etc.)."
48179177|NCT02594046|OTHER|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
48179178|NCT05364580|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
48179179|NCT05364580|BIOLOGICAL|Botox®|Botulinum toxin Type A
48179180|NCT03416413|PROCEDURE|Ambulatory phlebectomy|Minor surgery to remove varicose vein tributaries
48179181|NCT03416413|DRUG|Foam sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
48379341|NCT04883892|PROCEDURE|BMAC|"patients will be injected with BMAC into the ankle joint, after treatment patients will be followed up to 24 months. In particular patients will be assessed after treatment at 1, 3, 6, 12 and 24 months.~During the injection, samples of BMAC will be collected for the characterization of the phenotype markers and clonogenic capability"
48712814|NCT01678352|BIOLOGICAL|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
48712815|NCT01678352|DRUG|Imiquimod|Cohort 1 Cohort 2 Cohort 3
48712816|NCT00266838|DRUG|Maxidex; Lacrystat|6 times daily, for 20 weeks.
48712817|NCT03825692|DRUG|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
48712818|NCT03825692|DRUG|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
48712819|NCT00022724|DRUG|temsirolimus|
48712820|NCT05010941|DEVICE|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
48021495|NCT03632356|BEHAVIORAL|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
48021496|NCT03632356|DIAGNOSTIC_TEST|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
48021497|NCT02678611|DIETARY_SUPPLEMENT|Basis 250|
48712821|NCT02648451|DIETARY_SUPPLEMENT|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
48021498|NCT02678611|DIETARY_SUPPLEMENT|Basis 500|
48712822|NCT02291848|BIOLOGICAL|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
48712823|NCT02291848|BIOLOGICAL|TAA-specific CTLs- fixed dose|"Fixed dose of 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
48021499|NCT02678611|DIETARY_SUPPLEMENT|Placebo|
48021500|NCT01546493|RADIATION|MRI|MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
48179182|NCT04086238|DRUG|Decitabine|Capsules containing a combination of decitabine and THU
48021501|NCT01546493|RADIATION|qCT|Quantitative computed tomography(QCT) scans using a CT phantom
48179183|NCT00034554|BIOLOGICAL|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5\* patient safely completing the 2nd vaccination at the lower dose level.
48179184|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
48379342|NCT04883892|PROCEDURE|HA|patients will be treated with two injection of HA, one every 15 days, into the ankle joint. After treatment these patients will be followed up to 24 months. At 12 months patients can decide to cross.over in the BMAC arm treatment. After cross-over patients will be assessed for further 12 months.
48379343|NCT00826878|DRUG|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
48379344|NCT01103908|DEVICE|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
48379345|NCT06652022|RADIATION|Systematic therapy combined with radiotherapy|Systematic medical therapy is same as the systematic treatment group. SBRT radiotherapy or conventional fractionated radiotherapy can be used according to the extent and size of the metastatic foci. SBRT radiotherapy is preferred, and a higher dose should be given as far as possible when the normal tissues permit, with a preferred single dose of ≥5Gy.
48712824|NCT04688918|PROCEDURE|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
48021502|NCT01546493|OTHER|Motion Analysis|3D motion analysis to assess hip function.
48021503|NCT01546493|RADIATION|PET-MRI|Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
48021504|NCT06222476|DRUG|Dorzagliatin|Dorzagliatin will be initiated and maintained at 75mg twice a day
48021505|NCT06222476|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg once a day
48021506|NCT02595684|DRUG|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
48021507|NCT02595684|DRUG|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
48021508|NCT00103649|DRUG|xaliproden (SR57746A)|
48021509|NCT02595567|DEVICE|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
48021510|NCT06574087|DIAGNOSTIC_TEST|hrHPV test and cytology|Perfomance of hrHPV test and cytology
48379346|NCT06652022|DRUG|Systematic drug treatment|The choice of first-line treatment is based on the guidelines, and may include chemotherapy or immune checkpoint inhibitors, or a combination of therapies. For patients who can tolerate cisplatin, chemotherapy is given with the gemcitabine-cisplatin regimen, as follows: gemcitabine 1000mg/m2 d1,8; cisplatin 70 mg/m2, avoiding light, intravenous drip d2; 3 weeks for 1 cycle. For intolerant patients, the gemcitabine-carboplatin regimen is given as follows: gemcitabine 1000 mg/m2 d1,8, IV, carboplatin (4.5×\[GFR+25\]) mg, IV, d1; 3 weeks as 1 cycle. Immune checkpoint inhibitors and targeted agents may be administered if the patient does not tolerate chemotherapy; either in combination with chemotherapy or directly as first line.
48379347|NCT04968873|PROCEDURE|Cholecystectomy and common bile duct exploration|During elective open cholecystectomy, a basal commcn dile duct (CBD) manometry was obtained immediately after cholecystectomy, with a 10 Fr. silicone T tube introduced into the cystic duct and connected to a glass manometer.
48379348|NCT00604760|DRUG|MEM 3454|Capsule 5 mg once a day
48379349|NCT00604760|DRUG|MEM 3454|Capsule 15 mg once a day
48712825|NCT04688918|PROCEDURE|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
48712826|NCT06138405|BEHAVIORAL|Immediate intervention Group|The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
48379350|NCT00604760|DRUG|MEM 3454|Capsule 50 mg once a day
48379351|NCT00604760|DRUG|Placebo for MEM 3454|Capsule once a day
48712827|NCT06138405|BEHAVIORAL|Delayed intervention (control) Group|The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
48712828|NCT01822535|DRUG|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
48712829|NCT03971604|DRUG|Vitamin A|treated with Vitamin A
48712830|NCT03971604|DRUG|Vitamin E|treated with Vitamin E
48712831|NCT05239221|DRUG|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
48712832|NCT05239221|DRUG|Placebo|Saline solution visually matching active medication
48021511|NCT05404438|OTHER|Oral Appliances|A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
48021512|NCT02360917|OTHER|Emerging from the Haze|A 6 week psycho-educational class
48021513|NCT06227494|BEHAVIORAL|Fiber Intervention|Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.
48021514|NCT06227494|BEHAVIORAL|Standard Weight Loss Education|Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
48021515|NCT05897359|BEHAVIORAL|bCBTMI|This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.
48021516|NCT05897359|BEHAVIORAL|Control|The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
48021517|NCT04163276|DIAGNOSTIC_TEST|18F FDG PET exam|All patients have received 18F-FDG PET/CT in nuclear medicine
48021518|NCT06573957|DRUG|Dexmedetomidine|Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
48021519|NCT06573957|DRUG|Lidocain|Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
48379352|NCT01095458|BEHAVIORAL|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
48379353|NCT03839693|BIOLOGICAL|botulinum toxin, Type A|topical liniment
48379354|NCT03839693|BIOLOGICAL|Vehicle|Vehicle Formulation
48379355|NCT06344650|PROCEDURE|Blood sample|Collection of blood serum for molecular and biochemical tests
48379356|NCT06344650|DIAGNOSTIC_TEST|Radiological tests|Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
48712833|NCT00151034|DRUG|Trastuzumab|
48021520|NCT05929014|DEVICE|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
48021521|NCT05929014|DEVICE|Cathodal-Transcranial direct current stimulation (cathodal-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal electrode will be attached over the left primary motor area while the anodal will be applied over the right supraorbital.
48021522|NCT05929014|DEVICE|Sham bilateral-tDCS|Sham bilateral-tDCS
48021523|NCT05929014|DEVICE|Sham cathodal-tDCS|Sham cathodal-tDCS
48379357|NCT06344650|OTHER|Questionnaires|Compilation of questionnaires (AcroQol, SF-36)
48712834|NCT00151034|DRUG|Paclitaxel|
48712835|NCT00151034|DRUG|Carboplatin|
48379358|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
48379359|NCT00718146|BIOLOGICAL|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
48379360|NCT01256086|DRUG|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
48379361|NCT01256086|DRUG|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
48379362|NCT01256086|DRUG|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
48379363|NCT01256086|DRUG|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
48712836|NCT00151034|DRUG|Gemcitabine|
48712837|NCT01545232|BIOLOGICAL|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
48179185|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
48179186|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
48179187|NCT05500781|BEHAVIORAL|Coaching HER|The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in \[the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches\]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
48179188|NCT04355936|DRUG|Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.|Control arm will receive standard care.
48179189|NCT05531071|DEVICE|Biofeedback electrical stimulation|treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
48179190|NCT05531071|PROCEDURE|Acupuncture|acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
48179191|NCT05531071|COMBINATION_PRODUCT|Acupuncture combined with biofeedback electrical stimulation|treated with acupuncture combined with biofeedback electrical stimulation.
48179192|NCT03911362|BEHAVIORAL|Lumbopelvic Stabilisation Exercises Group|Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
48379364|NCT00939861|PROCEDURE|laparoscopy|colorectal resection
48379365|NCT00939861|PROCEDURE|laparotomy|colorectal resection
48379366|NCT01187511|DRUG|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
48379367|NCT01187511|DRUG|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
48712838|NCT01545232|BIOLOGICAL|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
48712839|NCT04031274|DEVICE|TAVI|Trascatheter aortic valve implantation
48712840|NCT04031274|DEVICE|TMVR/r|Transcatheter mitral valve replacement/repair
48712841|NCT03198195|PROCEDURE|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
48712842|NCT01852825|BIOLOGICAL|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
48712843|NCT01852825|OTHER|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
48712844|NCT01852825|BIOLOGICAL|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
48712845|NCT01688947|DRUG|V116517 50-mg tablets|Taken orally twice daily
48021524|NCT04212507|DIAGNOSTIC_TEST|The serum level of Claudin-3 and intestinal Fatty acid binding protein|The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.
48021525|NCT01963624|DEVICE|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
48379368|NCT03080207|PROCEDURE|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).
48028764|NCT03980470|DEVICE|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
48379369|NCT03080207|PROCEDURE|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise)."
48712846|NCT01688947|DRUG|V116517 30-mg tablets|Taken orally twice daily
48712847|NCT01688947|DRUG|Pregabalin capsules|1-2 capsules taken orally twice daily
48712848|NCT01688947|DRUG|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
48712849|NCT04316078|OTHER|patient engagement platform|"1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
48028765|NCT00499187|PROCEDURE|Blood Draws|A single whole blood sample was collected for genomic analysis.
48379370|NCT03080207|PROCEDURE|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
48379371|NCT03166969|PROCEDURE|Holter 21 days|
48712850|NCT04298866|OTHER|Experimental Arm|"* 3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~* 7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~* Neuropsychological battery including chronometric measures obtained through a computer interface"
48712851|NCT00445939|BIOLOGICAL|adalimumab|160 mg at Week 0, 80 mg at Week 2
48712852|NCT00445939|BIOLOGICAL|adalimumab|80 mg at Week 0, 40 mg at Week 2
48712853|NCT00445939|BIOLOGICAL|placebo|Placebo at Week 0 and Week 2
48712854|NCT00274560|DRUG|Tiotropium|
48712855|NCT00274560|DRUG|Salmeterol|
48712856|NCT00438854|DRUG|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
48028766|NCT00298428|PROCEDURE|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
48028767|NCT06047769|OTHER|Board Games|Participants will receive cognitive training in board games including Ludo, Chutes \& Ladder and Chess with both single and multiplayer modes. After 1 week of training, participants will receive intervention of 1 hour per day, three days a week for 8 weeks completing a total of 1440 minutes. With this technique, we will target the cognitive process of information processing, speed and executive function of the patient.
48028768|NCT03879018|BEHAVIORAL|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
48028769|NCT02186951|DRUG|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
48028770|NCT02186951|DRUG|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
48028771|NCT00845910|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
48028772|NCT00845910|DRUG|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
48028773|NCT00845910|DRUG|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
48028774|NCT05412862|BEHAVIORAL|Positive Psychology + Motivational Interviewing|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in physical activity.
48028775|NCT00567242|BEHAVIORAL|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
48028776|NCT00567242|BEHAVIORAL|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
48028777|NCT00502125|PROCEDURE|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
48028778|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
48028779|NCT02817451|BIOLOGICAL|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
48028780|NCT02455986|BEHAVIORAL|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
48028781|NCT00174993|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
48028782|NCT00174993|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
48028783|NCT06491121|OTHER|Technology supported High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home, supported by a smartphone application
48028784|NCT06491121|OTHER|Moderate Intensity Training|patients will perform a 12-week MIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory continuous load, general resistance and core muscle training, all at moderate intensity. Phase 2 is a similar 12-week MIT program at home with an exercise program on paper.
48712857|NCT00297102|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
48712858|NCT00297102|DRUG|Placebo|once daily
48712859|NCT04965922|BEHAVIORAL|Multimodal intervention|"The intervention consists of identifying the individual needs of each caregiver and patient and identifying sources of improvement in the management of daily life, including the optimization of social support. This optimization requires the involvement of people in the environment (family, friends, neighbours) who can provide help, support of any kind, recurrent or punctual, minimizing negative family interactions and maximizing positive contributions by each in supporting and supporting the individual.~The intervention is personalized in the sense that the content of each session seeks to adapt itself to the specificities of the couple situation and its surroundings.~interviews/meetings involving a psychologist social worker."
48712860|NCT02775110|OTHER|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
48021526|NCT05087043|DEVICE|Oral motor stimulation (OMS) and The supplemental nursing system (SNS)|OMS and an SNS were applied to preterm infants in the experimental group. Oral stimulation intervention provides assisted movement to activate muscle contraction and provides movement against resistance to build strength. The cheeks (internal and external), lips, gums, tongue, and palate were stimulated by finger-stroking following the protocol. OMS consisted of intra (oral region) and peri-oral stimulation (around the oral region). The OMS was administered three times a day by a nurse, from the day of initiation of oral feeding to the day of independent oral feeding 15 minutes before the feeding schedule. A bottle/container was filled with breast milk before the process and given to the baby via SNS while the baby was holding the mother's breast. The SNS consists of a syringe/container and a feeding catheter. One end of the feeding probe is inside the syringe/container, while the other end of it is fixed to the mother's nipple using plaster.
48179193|NCT03911362|BEHAVIORAL|Pelvic Floor Exercises Group|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
48179194|NCT05827770|DRUG|Toripalimab combined with Temozolomide|Toripalimab combined with Temozolomide
48179195|NCT00640744|DRUG|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
48179196|NCT01408745|DEVICE|Sternumfix|sternotomy closure with Sternumfix
48179197|NCT01408745|PROCEDURE|steel wire|sternotomy closure with steel wire
48379372|NCT06556576|DEVICE|IMPROVA Platform|"Adolescents, teachers, school staff, and parents will have access to a variety of content aimed at promoting the mental health and well-being of adolescents that can be accessed through the IMPROVA platform, an innovative eHealth solution that can be accessed via app and website.~Students: around 20 modules that can be grouped in five categories: Me and My Emotions, Me and My Body, Me and My Relationships, School and Free time, and Finding my Strengths.~Teachers and other school staff: 1) pedagogical and health-related modules to support their students and teaching practices; 2) modules to manage their own health; 3) tutoring sessions: resources (lessons plans) for tutors (teachers or other school staff) for carrying out a discussion with students in topics related to the students' health and wellbeing.~Parents: contents on promoting positive relationships, emotional and social skills, positive behaviour, behaviours to support wellbeing, and family-school collaboration."
48379373|NCT03775694|DEVICE|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
48379374|NCT06329765|BEHAVIORAL|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.|Exercise with CUped - a motor-assisted, split crank pedaling device and undergo 50 m of gait training.
48712861|NCT03000504|DEVICE|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
48712862|NCT03812926|DEVICE|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
48021527|NCT06061458|DIAGNOSTIC_TEST|speech auditory brainstem response|A diagnostic objective test to evaluate the speech process in hearing impaired children
48712863|NCT00040807|DRUG|docetaxel|
48712864|NCT00040807|DRUG|irinotecan hydrochloride|
48712865|NCT06034067|PROCEDURE|Osseodensification osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
48021528|NCT01384539|DRUG|Cholecalciferol|
48021529|NCT01384539|DRUG|Calcitriol|
48021530|NCT04964934|DRUG|AZD9833|Dosage formulation: AZD9833 tablets will be administered orally
48179198|NCT01130311|DRUG|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
48179199|NCT01130311|DRUG|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
48179200|NCT05889949|DRUG|Sorafenib|oral sorafenib
48179201|NCT05889949|DRUG|Lenvatinib|oral lenvatinib
48179202|NCT01898780|PROCEDURE|pancreaticojejunostomy with horizontal mattress suture|
48179203|NCT01898780|PROCEDURE|pancreaticojejunostomy with interrupted suture|
48179204|NCT04246853|DEVICE|Transcranial direct current stimulation (tDCS) of the resting state motor network|Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
48021531|NCT04964934|DRUG|AZD9833 Placebo|Dosage formulation: AZD9833 placebo tablets will be administrated orally.
48021532|NCT04964934|DRUG|Anastrozole|Dosage formulation: anastrozole tablets will be administered orally.
48712866|NCT06034067|PROCEDURE|Standardized osteotomy preparation|The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
48179205|NCT00992719|BIOLOGICAL|Inactivated H1N1 Vaccine|H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
48179206|NCT00708851|OTHER|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week"
48021533|NCT04964934|DRUG|Anastrozole placebo|Dosage formulation: anastrozole placebo tablets will be administrated orally.
48179207|NCT00708851|DEVICE|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
48179208|NCT04751136|DRUG|cerebrolysin|Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
48379375|NCT01225029|OTHER|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
48379376|NCT05455294|DRUG|Navitoclax|See Arm Description
48379377|NCT05455294|DRUG|Venetoclax|See Arm Description
48379378|NCT05455294|DRUG|Decitabine|See Arm Description
48712867|NCT02044601|DRUG|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
48021534|NCT04964934|DRUG|Letrozole|Dosage formulation: letrozole tablets will be administered orally.
48021535|NCT04964934|DRUG|Letrozole placebo|Dosage formulation: letrozole placebo tablets will be administered orally.
48712868|NCT02044601|DRUG|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
48712869|NCT02044601|DRUG|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
48712870|NCT02044601|DRUG|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
48712871|NCT02044601|RADIATION|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
48712872|NCT00330044|DRUG|Premetrexed (Alimta)|
48712873|NCT00330044|DRUG|Carboplatin|
48021536|NCT04964934|DRUG|Palbociclib|Dosage formulation: palbociclib tablets/capsules will be administered orally
48379379|NCT03746249|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48021537|NCT04964934|DRUG|Abemaciclib|Dosage formulation: abemaciclib tablets will be administered orally
48021538|NCT04964934|DRUG|Luteinizing hormone-releasing hormone (LHRH) agonist|Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
48021539|NCT04964934|DRUG|Ribociclib|Dosage formulation: ribociclib tablets will be administered orally
48021540|NCT05758025|PROCEDURE|"Resection based on thymus-vascular-inferior parathyroid complex"|"Before clearing the central lymph nodes, looking for the thyro-thymic ligament first, looking for the inferior parathyroid along the thyro-thymic ligament. Dissect and leave the thymus-vascular-inferior parathyroid complex laterally; the inner side of this layer is the tissue of the central area. Then remove the central lymph nodes. Check for parathyroids in the removed specimen, transplant the parathyroids which are removed by accident."
48021541|NCT04162704|DEVICE|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
48021542|NCT05611528|DRUG|Evinacumab|Evinacumab 15 mg/kg administered intravenously every 4 weeks
48379380|NCT03746249|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
48712874|NCT02073357|PROCEDURE|Light general anaesthesia (BIS = 50)|
48712875|NCT02073357|PROCEDURE|deep general anaesthesia (BIS = 35)|
48712876|NCT03251859|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
48712877|NCT03251859|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg daily
48712878|NCT00144768|DRUG|laronidase|dose of 0.58mg/kg body weight IV every week
48712879|NCT03035253|DRUG|OMP-305B83|
48712880|NCT03035253|DRUG|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
48712881|NCT03035253|DRUG|FOLFOX|Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
48712882|NCT00657371|DEVICE|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
48712883|NCT03026478|DRUG|Betamethasone Dipropionate|
48379381|NCT05170217|DRUG|THC|Inhaled cannabis containing 10mg THC
48379382|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 10mg CBD
48712884|NCT03026478|DRUG|Clobetasol Propionate|
48379383|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 20mg CBD
48379384|NCT05170217|DRUG|Cannabidiol|Inhaled cannabis containing 30mg CBD
48379385|NCT03624049|OTHER|Exercise|Community based exercise programs held 2-3 times per week
48712885|NCT03404804|DRUG|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
48712886|NCT03630302|DEVICE|DBS|Deep Brain Stimulation
48712887|NCT01335750|OTHER|Multipurpose Solution #1|B\&L Renu Fresh Multipurpose Solution
48379386|NCT03624049|OTHER|Health Class|Community based health class held 1 time per week
48379387|NCT03684018|BIOLOGICAL|IgPro10|Normal human immunoglobulin G administered intravenously
48712888|NCT01335750|OTHER|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
48712889|NCT01335750|OTHER|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
48712890|NCT01335750|OTHER|Multipurpose Solution #4|Saline Solution
48712891|NCT06200922|OTHER|Pelvic physiotherapy|All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
48712892|NCT02372552|DEVICE|CROMA|Microwave coagulation of small blood vessels
48712893|NCT01696344|PROCEDURE|PVAI|
48712894|NCT01696344|PROCEDURE|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
48712895|NCT01483534|DEVICE|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
48712896|NCT04662073|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
48712897|NCT04662073|DRUG|Placebo|Placebo to match camostat administered orally four times daily
48712898|NCT03727087|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
48379388|NCT00006292|DRUG|Infliximab|
48379389|NCT04551612|RADIATION|Multislice computed tomography temporal bone|Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
48379390|NCT05732025|DEVICE|Electrohydraulic shock wave lithotripsy|Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
48379391|NCT05732025|DEVICE|Rotary atherectomy|Pre-treatment of severe calcified coronary lesions with rotary atherectomy
48379392|NCT04016909|PROCEDURE|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
48379393|NCT05163249|DRUG|Osimertinib|osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
48379394|NCT05163249|DRUG|Savolitinib|savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met
48379395|NCT05562596|DIAGNOSTIC_TEST|Measurement of oxysterol profile, including 20 molecules, in liquor before and after surgery|Samples are quantitated by deuterium-labeled mass-spectrometry amalysis.
48712899|NCT01470690|DRUG|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
48712900|NCT01470690|DRUG|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
48712901|NCT05242666|DIAGNOSTIC_TEST|3T MR Imaging of the cervical spinal cord|Patients will undergo either Magnetic Resonance Imaging of the Spinal Cord
48712902|NCT05242666|OTHER|Positron Emission Tomography using [11C]PIB|Patients will undergo combination MRI/PET using a \[11C\]PIB radiotracer
48712903|NCT05242666|OTHER|3T MR Imaging of the Brain|3T MR Imaging of the Brain
48712904|NCT05242666|OTHER|7T MR Imaging of the Spinal Cord|7T MR Imaging of the Spinal Cord
48712905|NCT01234805|PROCEDURE|yoga therapy|Participates in yoga classes and yoga at home
48712906|NCT01234805|OTHER|questionnaire administration|Ancillary studies
48379396|NCT00718627|BIOLOGICAL|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
48379397|NCT05144724|PROCEDURE|Volume targeted ventilation|Positive pressure ventilation will be provided using a set tidal volume
48712907|NCT01234805|PROCEDURE|quality-of-life assessment|Ancillary studies
48712908|NCT04433559|DRUG|Tadalafil 1,5 mg oral tablets|Use of tadalafil in the treatment of FSIAD
48712909|NCT04433559|DRUG|Placebo oral tablets|Use of placebo in control group
48712910|NCT03433820|OTHER|Observation of wound healing|Observation of wound healing after skin biopsy
48712911|NCT03410797|DEVICE|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
48712912|NCT02251132|DRUG|TPV low 1|
48712913|NCT02251132|DRUG|TPV low 2|
48712914|NCT02251132|DRUG|TPV medium|
48712915|NCT02251132|DRUG|TPV high 1|
48712916|NCT02251132|DRUG|TPV high 2|
48712917|NCT02251132|DRUG|RTV low|
48712918|NCT02251132|DRUG|Ritonavir high|
48712919|NCT02251132|DRUG|Radiolabelled erythromycin|
48179209|NCT04224454|OTHER|Questionnaire|"Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data."
48712920|NCT02333149|DIETARY_SUPPLEMENT|Melatonin|"Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
48179210|NCT05730998|DIETARY_SUPPLEMENT|ANTHOCRAN FITOSOMA|The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
48179211|NCT05730998|DIETARY_SUPPLEMENT|PLACEBO|Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
48712921|NCT02333149|DRUG|Placebo|Placebo frequency and volume are identical to the experimental arm
48179212|NCT05015725|DIAGNOSTIC_TEST|Quality of life assessment, biochemical measures|"Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to \~50 items including demographic variables.~Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels."
48379398|NCT05144724|PROCEDURE|Pressure targeted ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
48712922|NCT00839865|DRUG|herb ointment|a kind of ointment made from herb
48712923|NCT03724981|DRUG|Dulaglutide Pen|Injected on a practice pad.
48179213|NCT01486368|DRUG|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
48379399|NCT03146819|DEVICE|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
48379400|NCT03146819|DEVICE|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
48379401|NCT03598075|OTHER|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 120 micrograms over 20 minutes .
48379402|NCT03598075|OTHER|CGRP|CGRP It will be given intravenously at the rate of 30 microgram over 20 minutes.
48379403|NCT00638950|DIETARY_SUPPLEMENT|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
48712924|NCT03724981|DRUG|Semaglutide Pen|Injected on a practice pad.
48712925|NCT03213574|OTHER|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
48179214|NCT00224029|DRUG|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
48179215|NCT04640818|DRUG|Cladribine Oral Tablet|Treatment according to the label and medical prescription
48179216|NCT04640818|DRUG|Rituximab|Treatment according to the label and medical prescription
48179217|NCT04640818|DRUG|Ocrelizumab|Treatment according to the label and medical prescription
48179218|NCT02536495|DRUG|Docetaxel|Given IV
48179219|NCT02536495|OTHER|Laboratory Biomarker Analysis|Correlative studies
48179220|NCT02536495|OTHER|Pharmacological Study|Correlative studies
48179221|NCT02536495|DRUG|Selinexor|Given PO
48179222|NCT01389414|DRUG|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
48712926|NCT03213574|OTHER|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
48712927|NCT02961790|DRUG|Oxybutynin Chloride|Given PO
48712928|NCT02961790|OTHER|Placebo|Given PO
48712929|NCT02961790|OTHER|Quality-of-Life Assessment|Ancillary studies
48712930|NCT02961790|OTHER|Questionnaire Administration|Ancillary studies
48712931|NCT01561755|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
48712932|NCT01561755|DRUG|Placebo|Placebo - 2gr/kg over 2 days of saline
48712933|NCT03964532|DRUG|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
48712934|NCT03964532|DRUG|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
48712935|NCT05445206|DEVICE|CardioPulmonary Management Device (CPM)|CPM device is used in tangent with reference capnography device.
48379404|NCT00638950|DIETARY_SUPPLEMENT|Placebo|The placebo products were commercial dairy products with comparable fat contents.
48379405|NCT01329562|DRUG|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
48021543|NCT03548610|OTHER|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (\>1.5cm) involving the lower limbs
48021544|NCT05821010|COMBINATION_PRODUCT|Lyophilized fecal microbiota transplantation capsules|Oral administration (capsule)
48021545|NCT05821010|COMBINATION_PRODUCT|Placebo capsules|Oral administration (capsule)
48179223|NCT01389414|DRUG|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
48379406|NCT01329562|DRUG|Placebo|A placebo tablet matching Treximet for oral administration.
48379407|NCT00795210|DRUG|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
48379408|NCT00795210|DRUG|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
48379409|NCT03131466|DEVICE|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
48379410|NCT03131466|DRUG|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
48379411|NCT06519201|DEVICE|SRT with SpineCare|Korean medicine doctors performed the treatment regimens.The TG underwent SRT with SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
48712936|NCT02446418|DRUG|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
48712937|NCT02446418|DRUG|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
48712938|NCT02446418|DRUG|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
48712939|NCT02446418|DRUG|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
48712940|NCT02446418|DRUG|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
48712941|NCT02446418|DRUG|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
48712942|NCT01933126|DRUG|HCG injection|
48712943|NCT01933126|DRUG|Placebo|
48021546|NCT05821010|DIETARY_SUPPLEMENT|A. soehngenii|Oral administration (capsule)
48021547|NCT05821010|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Oral administration (capsule)
48021548|NCT05821010|DIETARY_SUPPLEMENT|B. animalis subsp. lactis|Oral administration (capsule)
48021549|NCT05821010|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Oral administration (dissolved in water)
48021550|NCT01467323|DRUG|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
48021551|NCT01467323|DRUG|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
48712944|NCT02703870|DEVICE|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
48712945|NCT02703870|DEVICE|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
48712946|NCT02703870|BEHAVIORAL|VRT|Vision restoration training, 10 sessions, 20 minutes
48712947|NCT03884192|DRUG|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
48712948|NCT00266929|PROCEDURE|surgical|surgical treatment of odontoid fractures
48712949|NCT00266929|PROCEDURE|conservative treatment|conservative stabilization of fractures
48712950|NCT01025362|BEHAVIORAL|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
48179224|NCT01930214|DEVICE|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
48379412|NCT06519201|DEVICE|SRT without SpineCare|Korean medicine doctors performed the treatment regimens. The CG underwent SRT without SpineCare. Treat-ment was administered for six consecutive weeks, with sessions held twice per week dur-ing the first four weeks and once per week during the final two weeks. No additional treatments (e.g., procedures or surgeries) were allowed during the six-week period. To an-alyze pain according to the number of treatment sessions, a counselor assessed patients using the NRS after each of the ten treatment sessions. To compare the differences in Cobb's angle between the groups, X-rays were performed after the first and tenth treatment sessions. Detailed records of adverse events were maintained before and after each treat-ment session.
48379413|NCT05128552|DEVICE|Lung volume recruitment technique|A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
48379414|NCT05128552|OTHER|Traditional chest physiotherapy|Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
48712951|NCT01025362|BEHAVIORAL|Standard care|Child Health Services offered standard care
48712952|NCT03164083|BIOLOGICAL|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
48712953|NCT03164083|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
48712954|NCT01376479|BIOLOGICAL|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
48712955|NCT01376479|BIOLOGICAL|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
48712956|NCT01376479|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
48712957|NCT04592172|BEHAVIORAL|Bedtime Routine Education|The intervention aims to promote healthy sleep and improved developmental outcomes in infants. Individualized bedtime routine education, including such activities as a bath, teeth-brushing, reading stories, singing songs, and cuddling will be implemented by research assistants at the 12-month well-child visit. Reinforcement of the bedtime routine education will be implemented at the 15-month visit. Each individualized bedtime routine will incorporate 3-5 steps and a bedtime routine chart depicting those steps will be created and provided to the families. Families will receive materials for their bedtime routines, including a CuddleBright kit, 1-2 additional bedtime books, toothbrush/toothpaste , and the created bedtime chart. On top of that, families will also receive a children's book provided by Reach Out and Read through the study period.
48712958|NCT05945459|DIETARY_SUPPLEMENT|High-calorie density formula (1 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
48712959|NCT05945459|DIETARY_SUPPLEMENT|Standard formula (0.67 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
48712960|NCT05138068|DRUG|MDMA|Two 8-hour experimental sessions will occur within the 11-session intervention in which participants will take a dose of MDMA. In the first Experimental Session, the initial dose will be 80 mg MDMA, with a supplemental dose of 40 mg 1.5 to 2 hours later unless contraindicated. In the second Experimental Session, the initial dose may be increased to 120 mg MDMA unless contraindicated with an additional dose of 40 mg 1.5 to 2 hours after the initial dose is given unless contraindicated.
48712961|NCT05138068|BEHAVIORAL|Psychotherapy|Adjunctive, manualized psychotherapy will be provided by a team of two therapists during the MDMA-assisted therapy sessions
48712962|NCT06044805|DRUG|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
48712963|NCT06044805|DRUG|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
48712964|NCT05295147|OTHER|Palmar Grasp Reflex Stimulation|The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
48712965|NCT06508307|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors|The maximum number of lesions that each participant is allowed to inject at one time is two.
48712966|NCT06072092|DEVICE|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
48712967|NCT05891028|DRUG|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
48712968|NCT05891028|DRUG|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
48179225|NCT04776902|BEHAVIORAL|Survey|Patients will fill a questionary with 8 questions.
48179226|NCT01411098|RADIATION|3-dimensional conformal radiation therapy|Undergo 3D-CRT
48179227|NCT01411098|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
48179228|NCT01411098|DRUG|cisplatin|Given IV
48179229|NCT01411098|DRUG|etoposide|Given IV
48712969|NCT06168851|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
48179230|NCT02804451|DEVICE|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
48179231|NCT02804451|DEVICE|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
48179232|NCT02804451|DEVICE|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
48179233|NCT02804451|DEVICE|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
48179234|NCT02788071|DIETARY_SUPPLEMENT|FMT capsules|25 capsules per day for 12 days
48712970|NCT05752227|PROCEDURE|Transthoracic biopsy|Us guided transthoracic biopsy
48712971|NCT05752227|RADIATION|CT chest|Computed tomography
48712972|NCT03908190|BEHAVIORAL|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
48179235|NCT02788071|DIETARY_SUPPLEMENT|FMT placebo|25 capsules per day for 12 days
48712973|NCT03798054|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48712974|NCT03798054|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48712975|NCT03798054|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
48021552|NCT01751568|DRUG|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
48021553|NCT01312116|BEHAVIORAL|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
48021554|NCT01312116|BEHAVIORAL|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
48021555|NCT02376426|BIOLOGICAL|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29, 57.
48021556|NCT02376426|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29, 57.
48021557|NCT02376426|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
48021558|NCT00338351|BIOLOGICAL|Pneumococcal (vaccine)|
48021559|NCT02984176|DRUG|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
48021560|NCT02984176|DRUG|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
48021561|NCT02556008|DRUG|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
48021562|NCT00718718|DRUG|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
48021563|NCT00718718|DRUG|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
48021564|NCT00718718|DRUG|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
48021565|NCT00718718|DRUG|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
48021566|NCT00718718|DRUG|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
48021567|NCT05924828|OTHER|no intervention|no intervention
48021568|NCT03887481|DEVICE|"High-definition active tDCS (HD-tDCS) + Repeat After Me (RAM) Treatment"|"Device: Active HD-tDCS \& Repeat After Me (RAM) Treatment~Stimulation will be delivered by a battery-driven constant current stimulator. Electrical current will be administered to left supramarginal gyrus (L_SMG). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
48179236|NCT03839810|OTHER|stochastic resonance electrical stimulation|"stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training"
48179237|NCT00404885|DRUG|Placebo|PO BID
48179238|NCT00404885|DRUG|LX211|0.2 mg/kg, twice a day (BID)
48179239|NCT00404885|DRUG|LX211|0.4 mg/kg, twice a day (BID)
48179240|NCT00404885|DRUG|LX211|0.6 mg/kg, twice a day (BID)
48179241|NCT00817245|DRUG|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
48179242|NCT04965753|DRUG|FHD-609|FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
48179243|NCT01937026|DRUG|Baricitinib|Administered orally
48712976|NCT03798054|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
48712977|NCT03798054|DRUG|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
48712978|NCT03250039|DRUG|PF-04965842|14C labeled PF-04965842
48712979|NCT03250039|DRUG|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
48179244|NCT01937026|DRUG|Probenecid|Administered orally
48179245|NCT05359692|BIOLOGICAL|INCAGN01876|INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.
48179246|NCT05359692|BIOLOGICAL|retifanlimab|retifanlimab will be administered via IV Q4W
48179247|NCT03508947|DRUG|WVE-210201|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
48179248|NCT03508947|DRUG|Placebo|Sodium Chloride
48179249|NCT04771364|OTHER|ASAP care's protocol|Early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic patient's therapy (in particular with regard to sedative, anticholinergic and psychotropic drugs).
48712980|NCT04580277|DRUG|Tofacitinib 10 mg|Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
48712981|NCT01825278|DEVICE|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
48021569|NCT03887481|DEVICE|"Sham + Repeat After Me (RAM) Treatment"|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Participants will receive RAM consisting of word span repetition span (increasing length, with/without response delay). Span tasks will be manipulated in terms of list length (single words, pair, triplets) and response delay (1 sec, 5 sec). Each list will consist of 10 spans. During each trial, participants will be asked to repeat words in the span after a response delay."
48021570|NCT03189914|DRUG|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
48021571|NCT00647855|DRUG|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
48021572|NCT00647855|DRUG|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
48028785|NCT06491121|OTHER|High Intensity Training|patients will perform a 12-week HIT program comprising of 1,5h exercise therapy sessions twice a week. The program is a combination of cardiorespiratory interval, general resistance, and core muscle strength training, all at high intensity. phase 2 is a similar 12-week HIT program at home with an exercise program on paper.
48028786|NCT04393883|DRUG|A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;|(A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
48179250|NCT01287728|DRUG|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
48179251|NCT05323045|DRUG|BYON3521|BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
48179252|NCT00004922|DRUG|irinotecan hydrochloride|
48179253|NCT04182347|OTHER|Health Research ToolKit Development|"The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning."
48179254|NCT04515056|DRUG|Papain 10 µg|The area will be exposed to 10 µg of papain.
48179255|NCT04515056|DRUG|Papain 50 µg|The area will be exposed to 50 µg of papain.
48179256|NCT04515056|DRUG|Papain 100 µg|The area will be exposed to 100 µg of papain.
48179257|NCT04515056|OTHER|Vehicle|The area will be exposed to vehicle
48179258|NCT04515056|DRUG|Papain 1 SPT|Papain will be applied by 1 SPT prick thought the skin
48379415|NCT06650735|PROCEDURE|BMR resection|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose medial rectus muscle. Area that will be resected will be marked using calipers. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle.~The muscle then excised anterior to the sutures and the stump cut flush to the sclera.~The muscle will be sutured again to the original insertion by scleral sutures which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
48517930|NCT04671693|OTHER|PASCA intervention|"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."
48517931|NCT02673814|BIOLOGICAL|durvalumab|
48712982|NCT03159364|BIOLOGICAL|pathogen-specific CTLs|Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
48712983|NCT04927767|DEVICE|denture adhesive|Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
48712984|NCT00043823|DRUG|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
48712985|NCT00043823|DRUG|Tarceva|100 mg By Mouth Daily for 3 Weeks
48517932|NCT02673814|BIOLOGICAL|bavituximab|
48517933|NCT03349346|DRUG|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
48517934|NCT03349346|DRUG|Rituximab|375 mg/m\^2 administered intravenously
48712986|NCT03035773|BEHAVIORAL|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
48712987|NCT03035773|BEHAVIORAL|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
48179259|NCT04515056|DRUG|Papain 5 SPT|Papain will be applied by 5 SPT pricks thought the skin
48517935|NCT03349346|DRUG|Ifosfamide|3 mg/m\^2 administered intravenously
48517936|NCT03349346|DRUG|Carboplatin|635 mg/m\^2 administered intravenously
48517937|NCT03349346|DRUG|Etoposide|100 mg/m\^2 administered intravenously
48517938|NCT02910011|DRUG|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
48517939|NCT01024257|RADIATION|beta-irradiation|
48517940|NCT01024257|PROCEDURE|conjunctival autograft|
48517941|NCT01022697|OTHER|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
48379416|NCT06650735|PROCEDURE|BLR recession|"Lid speculum will be applied. Fornix conjunctival incision will be used to expose lateral rectus muscle. Double-armed polyglactin 910 suture (6/0 Vicryl) will be used in securing the muscle close to the insertion.~The muscle will then be cut anterior to the sutures flush with the sclera. Calipers will used to mark the new insertion on sclera measured from the stump. The muscle will be sutured again to the new insertion by scleral sutures, which will be tied together.~Conjunctiva will be closed using polyglactin 910 suture (6/0 Vicryl)."
48379417|NCT02209272|DRUG|bacteriostatic saline|
48021573|NCT06573580|OTHER|The essential public health service（EPHS）for COPD|"Each group plans to recruit 3,000 participants. For the intervention group, the community-based management includes adding COPD management-related content to the primary public health service. This includes: Providing at least four follow-ups during the project at the 3rd, 6th, 9th, and 12th months. During each follow-up, patients must complete the COPD Patient Follow-up Questionnaire and receive oral health education and targeted clinical advice from the general practitioner (GP). In addition, the GPs must also distribute educational booklets and materials, record symptom assessment results and acute exacerbation situations, and provide targeted clinical advice and clinical decisions to the COPD patients according to the checklist of Chinese guideline for management of COPD in primary care. At the baseline and the last follow-up, patients need to undergo a routine physical examination, pulmonary function test, and bronchodilator test at their community health centers"
48021574|NCT04418206|OTHER|patients COVID 19|Exposure to SARS-Cov2 but no symptoms (patient's family, medical staff) and General population (volunteers not exposed to SARS-Cov2)
48021575|NCT05222568|BEHAVIORAL|Lateral positioning|After the DLT intubation, the patient is placed in lateral decubitus position
48379418|NCT02209272|DRUG|buffered lidocaine|
48379419|NCT04125498|OTHER|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
48517942|NCT01649986|BEHAVIORAL|Non-pharmacologic intervention|Diet and physical exercise
48517943|NCT01649986|DRUG|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
48517944|NCT06551337|DRUG|Vitamin D3|The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
48021576|NCT05222568|DEVICE|Cuff pressure measurement|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning
48021577|NCT00922610|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
48021578|NCT03556319|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
48021579|NCT03556319|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator
48021580|NCT00660010|DRUG|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
48021581|NCT03591692|PROCEDURE|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
48021582|NCT03591692|PROCEDURE|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
48021583|NCT02174094|DRUG|Clobazam|
48021584|NCT02174094|DRUG|Placebo|
48021585|NCT01326520|DIETARY_SUPPLEMENT|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
48021586|NCT01326520|DIETARY_SUPPLEMENT|diary product|The patients will consume daily 250 mL of a common dairy product.
48021587|NCT00672880|BEHAVIORAL|Self-System Therapy|12 sessions of structured Self-System Therapy
48021588|NCT00672880|BEHAVIORAL|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
48021589|NCT00672880|OTHER|Standard Care|Study participants continue with their usual medical care, no changes.
48028787|NCT04393883|DRUG|B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;|(B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
48028788|NCT06635343|OTHER|CPRP|In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.
48028789|NCT06635343|OTHER|Experimental Inspiratuar Muscle Training|In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia
48379420|NCT04125498|OTHER|Placebo treatment|Similar to OMT without pressure
48379421|NCT04125498|OTHER|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
48379422|NCT04260594|DRUG|Arbidol|Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
48379423|NCT04260594|OTHER|basic treatment|basic treatment
48379424|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
48379425|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
48712988|NCT03035773|BEHAVIORAL|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
48379426|NCT01465048|BIOLOGICAL|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
48712989|NCT02798770|OTHER|No Intervention Foreseen|
48712990|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
48712991|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
48712992|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
48712993|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
48021590|NCT04372615|DRUG|Inebilizumab|"RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care)."
48021591|NCT04372615|DRUG|Placebo|The placebo group will receive IV matching placebo on Day 1 and Day 15,
48021592|NCT02527057|DEVICE|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
48028790|NCT04797858|BEHAVIORAL|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
48028791|NCT04797858|BEHAVIORAL|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
48028792|NCT03326999|DRUG|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
48028793|NCT03326999|DRUG|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
48028794|NCT03326999|DRUG|Saline|Saline as placebo comparator
48028795|NCT05153837|OTHER|saline intravenous administration|Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
48028796|NCT05153837|OTHER|oral water|500 ml oral water
48028797|NCT01721018|BIOLOGICAL|HSV1716 Intra-pleural delivery|
48028798|NCT00349089|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
48028799|NCT00349089|DRUG|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
48028800|NCT00349089|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
48028801|NCT04223453|DIAGNOSTIC_TEST|BIA and DXA|Patients with acute pneumonia measured simultaneously with DXA-scan and BIA-impedance
48028802|NCT01031147|OTHER|Examination|3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
48028803|NCT06050460|DRUG|SA55 Injection|Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
48028804|NCT06050460|OTHER|Placebo for SA55 injection|Placebo for Novel coronavirus broad-spectrum neutralizing antibody SA55 injection
48028805|NCT04492046|OTHER|Manual Lymph Drainage|Manual lymph drainage is an effective therapeutic method used in the conservative treatment of lipedema. The application was performed on both lower extremities for 45 minutes.
48028806|NCT04492046|OTHER|Bandaging|Multilayered compression bandaging techniques have an assisting role in the further reduction of the volume of the limb and enhance the continuous pump mechanism via the active involvement of muscle pumps. All patients received bandages following Manual lymph drainage application.
48028807|NCT01260246|DRUG|sitagliptin|pill, 100mg/daily for 6 months
48028808|NCT01260246|DRUG|placebo|placebo match for 6 months
48028809|NCT00358046|DRUG|ILY101|
48028810|NCT02133846|DRUG|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
48028811|NCT02133846|DRUG|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
48028812|NCT02133846|DRUG|Placebo|500mL 0.9% sodium chloride
48712994|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
48179260|NCT04515056|DRUG|Papain 25 SPT|Papain will be applied by 25 SPT pricks thought the skin
48179261|NCT04515056|OTHER|Cowhage|The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
48179262|NCT05061199|PROCEDURE|approach of anastomosis|The approach of anastomosis
48179263|NCT03712592|OTHER|Pre and post running evaluations|"Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage."
48179264|NCT05566392|DIAGNOSTIC_TEST|Brain MRI|Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
48179265|NCT02080390|PROCEDURE|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
48179266|NCT00370110|DRUG|Itopride 100 mg|100 mg three times daily
48379427|NCT05623826|OTHER|Cognitive- behavioral imagery-based training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and a repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
48712995|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
48712996|NCT01261130|BIOLOGICAL|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
48712997|NCT04542460|PROCEDURE|PCI|"A loop recorder is implanted i all patients in both study groups to investigate:~* Prevalence and severity of cardiac arrhythmias.~* Effect on detected arrhythmia, in particular ventricular tachyarrhythmia, of optimal medical therapy vs. coronary revascularization by PCI.~* Prevalence and severity of cardiac arrhythmias in CTO-patients with failed PCI.~* Indication for prophylactic ICD implantation in CTO-patients treated conservatively or by PCI and after failed PCI.~* Relation of arrhythmias to angina pectoris symptoms (CCS class), Quality of life questionnaire results and presence of myocardial reversible perfusion defects by CMRI."
48712998|NCT04983836|PROCEDURE|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
48712999|NCT04983836|PROCEDURE|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
48713000|NCT02387125|BIOLOGICAL|CMB305|
48713001|NCT02387125|BIOLOGICAL|G100|
48713002|NCT02387125|DRUG|Metronomic CPA|
48379428|NCT00066417|DRUG|cyclophosphamide|
48713003|NCT00640640|DEVICE|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
48713004|NCT00640640|DRUG|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
48713005|NCT00640640|DRUG|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
48713006|NCT05270902|DEVICE|CytoSorb Adsorber|Polymer based adsorber system for the elimination of cytokines
48713007|NCT05093543|BEHAVIORAL|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
48179267|NCT00370110|OTHER|Placebo|
48713008|NCT01628367|PROCEDURE|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
48713009|NCT01628367|DEVICE|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
48179268|NCT00370110|DRUG|Itopride 200 mg|200 mg three times daily
48179269|NCT00004039|BIOLOGICAL|recombinant interferon alfa|
48179270|NCT00004039|BIOLOGICAL|rituximab|
48179271|NCT00004039|DRUG|cyclophosphamide|
48179272|NCT00004039|DRUG|doxorubicin hydrochloride|
48179273|NCT00004039|DRUG|prednisone|
48179274|NCT00004039|DRUG|vincristine sulfate|
48379429|NCT00066417|DRUG|cyclosporine|
48379430|NCT00066417|DRUG|fludarabine phosphate|
48379431|NCT00066417|DRUG|methylprednisolone|
48713010|NCT01628367|BIOLOGICAL|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
48713011|NCT01628367|BIOLOGICAL|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
48713012|NCT01628367|BIOLOGICAL|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
48379432|NCT00066417|DRUG|therapeutic allogeneic lymphocytes|
48379433|NCT00066417|DRUG|thiotepa|
48713013|NCT01628367|DRUG|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
48379434|NCT00066417|PROCEDURE|allogeneic bone marrow transplantation|
48379435|NCT00066417|PROCEDURE|biological therapy|
48379436|NCT00066417|PROCEDURE|bone marrow ablation with stem cell support|
48028813|NCT02133846|DRUG|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
48028814|NCT01365000|DRUG|NKTR118 Formulation 1|Oral dose, 25 mg
48028815|NCT01365000|DRUG|NKTR118 Formulation 2|Oral dose, 25 mg
48028816|NCT01365000|DRUG|NKTR118 Formulation 3|Oral dose, 25 mg
48028817|NCT01365000|DRUG|NKTR118 Formulation 1a|Oral dose, 25 mg
48028818|NCT01365000|DRUG|NKTR118 Formulation 3a|Oral dose, 25 mg
48379437|NCT00066417|PROCEDURE|bone marrow transplantation|
48379438|NCT00066417|PROCEDURE|chemotherapy|
48379439|NCT00066417|PROCEDURE|leukocyte therapy|
48379440|NCT00066417|PROCEDURE|non-specific immune-modulator therapy|
48379441|NCT00066417|PROCEDURE|peripheral blood lymphocyte therapy|
48379442|NCT00066417|PROCEDURE|peripheral blood stem cell transplantation|
48713014|NCT01618617|DIETARY_SUPPLEMENT|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
48713015|NCT01618617|DIETARY_SUPPLEMENT|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
48379443|NCT00066417|PROCEDURE|radiation therapy|
48379444|NCT06650657|BEHAVIORAL|touchpoint method|Touchpoint is a quality approach that can be applied to increase the sense of personal connection with the instructor, ensure that students are making satisfactory progress, increase instructor-student and student-instructor interactions, and increase student satisfaction, unlike traditional learning models.
48021593|NCT03042312|DRUG|177Lu-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
48021594|NCT01984723|DRUG|Experimental: EVP-6124|
48021595|NCT03853707|DRUG|Atezolizumab|Given IV
48021596|NCT03853707|DRUG|Capecitabine|Given PO
48021597|NCT03853707|DRUG|Carboplatin|Given IV
48021598|NCT03853707|DRUG|Ipatasertib|Given PO
48021599|NCT03853707|DRUG|Paclitaxel|Given IV
48021600|NCT03853707|OTHER|Quality-of-Life Assessment|Ancillary studies
48021601|NCT03853707|OTHER|Questionnaire Administration|Ancillary studies
48021602|NCT00829621|OTHER|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
48021603|NCT00829621|OTHER|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
48028819|NCT02813226|OTHER|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
48028820|NCT04834323|PROCEDURE|distal mesogastric fixation after sleeve gastrectomy|Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum \& mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum \& mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
48028821|NCT02008383|BIOLOGICAL|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
48028822|NCT02008383|DRUG|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
48028823|NCT04671862|DEVICE|Photobiomodulation|"Parameters: combined 633nm and 870 nm @1000mW~* 1 Treatment 4J continuous prior to RT. (Within 14 days of RT start)~* 3 treatments weekly during RT (6 J at 12 Hz, 80% duty cycle)"
48028824|NCT06533982|OTHER|High intensity interval exercise session|Physical activity session supervised and adapted on ergometer
48028825|NCT06533982|OTHER|Isometric neuromuscular exercise session|Physical activity session supervised and adapted with a handgrip
48028826|NCT03856346|DIAGNOSTIC_TEST|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
48028827|NCT04887870|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
48028828|NCT04887870|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
48028829|NCT04887870|DRUG|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
48028830|NCT04887870|DRUG|Enfortumab Vedotin-Ejfv|Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
48028831|NCT04887870|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
48028832|NCT01663493|PROCEDURE|FNB|
48028833|NCT04258020|DEVICE|BiPAP|Bilevel Positive Airway Pressure (BiPAP) oxygen administration
48028834|NCT04258020|DEVICE|HFNC|Heated High Flow Nasal Cannula oxygen administration
48028835|NCT00720954|PROCEDURE|Ct-guided pleural needle biopsy|Biopsy of pleura
48028836|NCT00720954|PROCEDURE|Thoracoscopy|Biopsy of pleura
48028837|NCT02966067|DEVICE|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
48028838|NCT02966067|DEVICE|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
48028839|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
48179275|NCT03051425|DIETARY_SUPPLEMENT|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
48179276|NCT03051425|DIETARY_SUPPLEMENT|Placebo|120 mL of low-fat milk
48179277|NCT02173145|DRUG|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
48179278|NCT02173145|DRUG|placebo|Placebo will be given 3 times a wek over a period of 3 months.
48179279|NCT02872311|BIOLOGICAL|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
48179280|NCT02872311|BIOLOGICAL|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
48179281|NCT02872311|BIOLOGICAL|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
48517945|NCT03835702|OTHER|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
48713016|NCT06462534|BEHAVIORAL|Band-Frail Program|"Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information."
48713017|NCT01718249|OTHER|Implantable neurostimulation system|
48021604|NCT06534138|BEHAVIORAL|Physical exercise|The CP-exercise group was categorized based on patients' self-reported daily exercise time into four levels: 15 minutes/day, 30 minutes/day, 45 minutes/day, and ≥60 minutes/day. Additionally, resistance exercise and endurance exercise were distinguished based on patients' self-reported exercise modalities, including swimming, jogging, brisk walking, practicing Tai Chi, and dumbbell training.
48021605|NCT06214455|OTHER|Low sugar diet and 10-12 hour eating window|Low sugar diet and 10-12 hour eating window for four weeks
48021606|NCT06214455|OTHER|Low sugar diet, 8 hour eating window and fasting|Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
48179282|NCT02872311|BIOLOGICAL|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
48179283|NCT04631588|DRUG|Botox|Intradermal (ID) injection
48179284|NCT04631588|DRUG|Placebo|Intradermal (ID) injection
48179285|NCT03449862|OTHER|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
48179286|NCT03499262|BEHAVIORAL|Group Social ABCs|Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
48179287|NCT00002647|DRUG|verteporfin|
48179288|NCT00002647|PROCEDURE|conventional surgery|
48179289|NCT05281289|OTHER|kinesio-tape|KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.
48713018|NCT01640418|DEVICE|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
48713019|NCT02209948|DRUG|Temozolomide|
48021607|NCT01540227|DRUG|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
48021608|NCT03154697|OTHER|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
48021609|NCT00129259|BIOLOGICAL|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
48021610|NCT00129259|OTHER|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
48713020|NCT00461994|BEHAVIORAL|diet|
48379445|NCT02080624|DRUG|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
48379446|NCT06567210|BEHAVIORAL|CBCTi|The program is composed of weekly online modules that include written information and interactive components such as schematics, images, videos, and questions. The content of the modules follows traditional and validated cognitive-behavioural therapy for insomnia protocols including sleep education, behavioural strategies (e.g., stimulus control, bedtime retraining, sleep hygiene), cognitive restructuration approaches (e.g., thought reappraisal, imagery, mindfulness), and relaxation practices (progressive muscle relaxation and autogenic training). In addition, further content aims to stabilize and amplify circadian rhythmicity through light exposure in the morning, daytime moderate physical activity, and evening time warm baths. Participants complete daily sleep diaries throughout the intervention.
48379447|NCT06567210|BEHAVIORAL|General sleep information|General sleep health information and access to daily sleep diaries during 8 weeks
48379448|NCT02793258|DEVICE|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
48021611|NCT00129259|DIETARY_SUPPLEMENT|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
48021612|NCT00439140|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
48021613|NCT00439140|DRUG|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
48021614|NCT04641468|PROCEDURE|DCB|OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
48021615|NCT02722694|DRUG|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
48021616|NCT02722694|OTHER|Placebo|Subjects received weekly SC placebo injections for 24 weeks
48379449|NCT03716830|DEVICE|verum acupuncture|Participants will receive real acupuncture treatment.
48713021|NCT00461994|BEHAVIORAL|exercise|
48713022|NCT00461994|BEHAVIORAL|diet and exercise|
48713023|NCT05236985|DRUG|Oxytocin bolus or oxytocin infusion|"On the day of surgery, the patients will be randomized to either bolus or infusion administration of oxytocin.~On the day of the procedure, periprocedural data and patient satisfaction (single question) will be recorded."
48713024|NCT05764668|DRUG|Zihua Wenfei Zhisou Granule|14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
48713025|NCT05764668|DRUG|Placebo|14 daily- doses of placebo，one bag at a time (15 g/bag), three times/day
48713026|NCT06100094|OTHER|semi-structured qualitative interviews|"During the interview, a list of semi-open questions will be asked :~* What were your expectations/state of mind before the group?~* How would you describe your experience overall?~* If you had to describe the group how would you do it?~* Between two group sessions, how did it go for you?~* What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file"
48713027|NCT05129514|OTHER|Manual Lymphatic Drainage (MLD)|The participant will be placed in a supine position and manual lymphatic drainage will be performed for 50 minutes. During the three intervening days, daily 50 minute sessions of manual lymphatic drainage will be provided.
48713028|NCT01638208|DRUG|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
48713029|NCT02126566|DEVICE|Administration of light therapy - measurement of results before and after therapy|
48713030|NCT02492360|PROCEDURE|Blood sample collection|Six tubes of blood will be collected during one blood draw.
48713031|NCT02492360|BEHAVIORAL|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
48021617|NCT02722694|DRUG|Methotrexate|All Subjects received backup Methotrexate treatment.
48021618|NCT04202159|DRUG|Perampanel|Perampanel tablets.
48021619|NCT04202159|DRUG|Perampanel|Perampanel oral suspension.
48713032|NCT01901965|BEHAVIORAL|Neuromuscular electrical stimulation|
48713033|NCT01901965|BEHAVIORAL|eccentric training|
48713034|NCT02124512|DRUG|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
48021620|NCT06270121|BEHAVIORAL|Living-lab digital intervention group|Older adults will receive individualized daily health feedback via the mobile applications, which will be shared with caregivers. They will also receive support for health emergency by the platform sending automatic emergency push alarm to community and family caregivers.
48379450|NCT03716830|DEVICE|sham acupuncture|Participants will receive sham acupuncture treatment.
48713035|NCT02124512|OTHER|Placebo|80 mg placebo once daily
48713036|NCT01150201|DRUG|Aliskiren|For CKD treatment
48713037|NCT01150201|DRUG|Losartan|Control
48713038|NCT02327936|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
48713039|NCT02327936|DRUG|Oxybutynin XL|Administer medication to patients with overactive bladder
48713040|NCT03641846|OTHER|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
48021621|NCT00268125|DEVICE|Acupression's bracelet|
48021622|NCT00268125|BEHAVIORAL|Hygiene and dietetic advices|
48379451|NCT03716830|DEVICE|real tDCS|Participants will receive real transcranial direct current stimulation.
48379452|NCT03716830|DEVICE|sham tDCS|Participants will receive sham transcranial direct current stimulation.
48379453|NCT05252273|OTHER|Observational, No intervention|Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
48379454|NCT04518527|DEVICE|Tape|The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
48713041|NCT03641846|OTHER|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
48713042|NCT03843944|DRUG|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
48713043|NCT05166382|BEHAVIORAL|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
48021623|NCT04335877|OTHER|Private sector component + modified BCC|Intervention group will be exposed to the private sector component + modified BCC and will receive current standard care
48021624|NCT06155045|PROCEDURE|Modified Carbo-dissection Technique|This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
48021625|NCT06155045|PROCEDURE|Conventional Arm|This technique uses only the electrocautery as conventional model
48021626|NCT01066559|PROCEDURE|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
48379455|NCT05952570|DIETARY_SUPPLEMENT|oral protein nutritional supplement (Fresubin protein powder)|50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
48021627|NCT01066559|PROCEDURE|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
48021628|NCT01066559|BIOLOGICAL|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
48021629|NCT01066559|BIOLOGICAL|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
48021630|NCT02805192|DEVICE|Size Measurement by a Smart phone App|
48021631|NCT00393445|DRUG|GLP-1 control|intravenous infusion of GLP-1
48021632|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
48021633|NCT00393445|DRUG|saline control|intravenous infusion of saline
48379456|NCT05952570|OTHER|routine nutrition regimen|50 patients will receive a routine nutrition regimen for 3 months. (control group)
48379457|NCT04898946|BIOLOGICAL|CoronaVac Vaccine|CoronaVac Vaccine
48379458|NCT04898946|BIOLOGICAL|BNT162b2 Vaccine|Covid-19 BNT162b2 Vaccine
48379459|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
48713044|NCT05166382|BEHAVIORAL|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
48713045|NCT05518370|OTHER|Hippotherapy simulator training|Hippotherapy simulator training will be designed for the individual basis.
48713046|NCT05518370|OTHER|Traditional physiotherapy|Traditional physiotherapy within a specific program
48713047|NCT02568449|DRUG|Nintedanib|Given PO
48713048|NCT02898961|DRUG|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
48713049|NCT06343038|DRUG|Injection, 161Tb-SibuDAB,1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
48713050|NCT06343038|DRUG|Injection, 177Lu-PSMA-I&T, 1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
48713051|NCT06343038|DRUG|Injection, 161Tb-SibuDAB, Dose Escalation|"Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed."
48713052|NCT02220023|DRUG|INOmax Inhalation|
48713053|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy|The experimenter gives the subject psychoeducation about emotional regulation and distraction strategy with the help of a conversation and a presentation.
48713054|NCT06197464|DEVICE|Using the FLOAT app on a virtual reality device|The subject should wear the VR device, and use the FLOAT application.
48179290|NCT05281289|OTHER|stretching exercise|15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest
48713055|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy + Application|psychoeducation on emotional regulation and distraction strategy + Application
48713056|NCT04919460|OTHER|clinical observation combined with pathological biopsy|Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
48713057|NCT04919460|OTHER|Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy|(2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
48713058|NCT01768156|OTHER|Experimental arm|"Serum samples are collected:~* at time of diagnosis of recurrence (before 1st chemotherapy)~* during each cycle of chemotherapy~* after the end of chemotherapy~* every 3 month until treatment failure (3-6 samples)~* stop at the progression or after 18 months post chemotherapy"
48179291|NCT05281289|OTHER|instructions about dealing with calf cramps|instructions about dealing with calf cramps by self low sustained stretch of calf muscle
48179292|NCT06511492|OTHER|No intervention in this study|No intervention in this study
48179293|NCT02196805|DRUG|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
48379460|NCT00864604|DRUG|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
48379461|NCT02175927|DRUG|Lansoprazole|antisecretory drug of each quadruple therapy
48713059|NCT03529097|DRUG|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
48713060|NCT03529097|DRUG|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
48021634|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
48021635|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
48179294|NCT02196805|DRUG|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
48179295|NCT03596242|OTHER|SMS System|Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence
48179296|NCT03596242|BEHAVIORAL|blood pressure control education|standard blood pressure control education given during visits
48179297|NCT06546540|DRUG|Telitacicept|160mg，once weekly
48179298|NCT04454099|DIAGNOSTIC_TEST|4 kind of FOBT and colonoscopy with pathological examination|Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.
48179299|NCT01214421|DRUG|Tolvaptan|Tablets of 15 or 30 mg
48179300|NCT00480675|PROCEDURE|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
48179301|NCT00480675|PROCEDURE|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
48713061|NCT03529097|DRUG|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
48713062|NCT05554978|DRUG|Landiolol|patient receives landiolol in addition to standard-of-care
48713063|NCT05554978|DRUG|Sodium Chloride (NaCl) 0.9%|Placebo
48021636|NCT00393445|DRUG|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
48379462|NCT02175927|DRUG|Bismuth Potassium Citrate|one component of each quadruple therapy
48379463|NCT02175927|DRUG|Metronidazole|antibiotic of each quadruple therapy
48713064|NCT02976025|OTHER|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
48713065|NCT02976025|OTHER|Collaborative Care|Standard collaborative care implementation training and support.
48021637|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in Sodium chloride|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride
48021638|NCT06534697|DRUG|Naropin, 0.2% Injectable Solution in dextrose 5%|Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%
48021639|NCT06534697|DRUG|Dextrose 10 % in Water|Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
48021640|NCT03455283|DRUG|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
48379464|NCT02175927|DRUG|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
48379465|NCT02175927|DRUG|Tetracycline|antibiotic of classical quadruple therapy
48379466|NCT04759352|OTHER|Post-test genetic counseling delivered by telephone|Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.
48379467|NCT06337344|BEHAVIORAL|Baduanjin|The treatment group will individually perform single-session Baduanjin by following a video broadcasted the standardised BDJ protocol, which lasted for 12 minutes including 6 times of BDJ movements. Breathing rhythm is emphasised to be followed by participants.
48379468|NCT06337344|BEHAVIORAL|Exercise|The active control group will individually perform 8-sets of aerobic exercise movement by following a video selected by registered physiotherapist.
48379469|NCT06337344|BEHAVIORAL|Video Viewing|The control group will individually watch a 12-minute video with 6-minute introducing BDJ practice and 6 minute introducing aerobic exercise. This control group is used for controlling the effect of behavioural movement and brain activity generated by passive video viewing.
48713066|NCT00225589|DRUG|Rosuvastatin calcium|
48713067|NCT03079401|BIOLOGICAL|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
48713068|NCT04912895|DEVICE|PneumoniaCheck|Participants are asked to do 5 sets of 10 coughs, with at least 15 minutes between sets, into the PneumoniaCheck device.
48713069|NCT02356094|PROCEDURE|Pentacam|Corneal topography using Scheimpflug Pentacam examination
48713070|NCT00926133|OTHER|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
48713071|NCT02494089|OTHER|distress analysis|
48713072|NCT01617135|DRUG|CVT-301|
48713073|NCT01617135|DRUG|Placebo|
48713074|NCT01617135|DRUG|Sinemet (carbidopa/levodopa)|
48713075|NCT01617135|DRUG|CVT-301|
48713076|NCT05545202|OTHER|Pentaisomaltose|Each subject will receive 1 or 2 bags with cryopreserved cells according to randomization group.
48713077|NCT02581462|DRUG|FLOT alone|"Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43"
48713078|NCT02581462|BIOLOGICAL|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43."
48713079|NCT01262170|DIETARY_SUPPLEMENT|CigRx Lozenge|lozenge made of dietary supplements
48713080|NCT01262170|OTHER|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
48713081|NCT04008992|DRUG|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
48713082|NCT04008992|OTHER|Placebo|Placebo matching BMS-986259
48021641|NCT03455283|OTHER|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
48379470|NCT02698319|BEHAVIORAL|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
48713083|NCT04008992|DIAGNOSTIC_TEST|P-Aminohippurate|Diagnostic Agent
48713084|NCT04008992|DIAGNOSTIC_TEST|Iohexol|Diagnostic Agent
48713085|NCT02568098|DRUG|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
48713086|NCT02568098|DRUG|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
48713087|NCT02568098|DRUG|DHA-PQP|Regimen 6: DHA-PQP
48713088|NCT00938977|DEVICE|CPAP|Before and after effect of treatment with CPAP
48713089|NCT00938977|DEVICE|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
48713090|NCT05223062|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
48713091|NCT05223062|OTHER|Compliance-Questionnaire-Rheumatology (CQR)|"The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking \<80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100."
48021642|NCT05051644|BEHAVIORAL|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
48021643|NCT05051644|BEHAVIORAL|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
48713092|NCT05223062|OTHER|The Brief Illness Perception Questionnaire (BIPQ)|The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.
48713093|NCT05223062|OTHER|The Beliefs About Medicines Questionnaire (BMQ)|The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.
48713094|NCT05223062|OTHER|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
48713095|NCT05223062|OTHER|The Psoriatic Arthritis Quality of Life (PsAQoL)|The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
48713096|NCT02770976|DEVICE|Increasing and decreasing NAVA levels with 10-min intervals|
48713097|NCT01512680|BEHAVIORAL|Education to Functional Insulin Therapy|"* Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
48713098|NCT03180398|DEVICE|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
48028840|NCT00613951|DRUG|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
48379471|NCT01370291|OTHER|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
48379472|NCT01370291|OTHER|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
48379473|NCT01370291|OTHER|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
48713099|NCT02609048|DRUG|Placebo Comparator|Placebo Capsule (2 taken once daily)
48713100|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
48713101|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
48713102|NCT00738764|BIOLOGICAL|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
48713103|NCT00162461|DRUG|Phenytoin single dose (300 mg)|
48713104|NCT04401670|OTHER|HPV screening and triage tests|The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.
48713105|NCT04401670|BEHAVIORAL|HPV self-sampling|"The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\]."
48021644|NCT04988165|DRUG|Traditional Chinese Medicine|It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
48021645|NCT03865121|DRUG|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
48021646|NCT03221413|DEVICE|transcranial alternating current stimulation (tACS)|
48021647|NCT01112085|DRUG|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
48021648|NCT01112085|DRUG|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
48379474|NCT05847309|OTHER|Delayed extubation|Patients randomized to delayed extubation, will be extubated 6-12 hours after endovascular treatment under general anesthesia.
48021649|NCT00296101|BEHAVIORAL|Physical Activity|
48021650|NCT03212586|DRUG|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
48021651|NCT03212586|DRUG|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
48021652|NCT06570096|DRUG|Lidocaine 2% then bupivacaine 0.5%|Patients will receive 10 ml of lidocaine 2% then 10 ml of bupivacaine 0.5% with a delay of 120s between injections.
48021653|NCT06570096|DRUG|Lidocaine 2% and bupivacaine 0.5%|Patients will receive 20 ml of freshly prepared mixtures of 10 ml of lidocaine 2% and 10 ml of bupivacaine 0.5%.
48021654|NCT05856292|OTHER|Teach Back|Standard cancer pain educational intervention enhanced with teach-back method
48021655|NCT05856292|OTHER|Placebo|Standard cancer pain educational intervention without enhancement
48021656|NCT02048761|DRUG|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
48021657|NCT02048761|DRUG|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
48021658|NCT05191706|DRUG|Dexamethasone|single anterior chamber injection
48379475|NCT05847309|OTHER|Early extubation|Patients randomized to early extubation, will be extubated \< 6 hours after endovascular treatment under general anesthesia.
48379476|NCT04470856|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|An occlusion manoeuvre during the end of expiration for 20 seconds
48379477|NCT01556659|DRUG|Absence of vitamin K antagonist|Dual anti-platelet therapy
48021659|NCT05191706|DRUG|Prednisolone Acetate Ophthalmic|topical administration four times a day for 28 days, followed by treatment taper
48021660|NCT02015377|OTHER|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
48021661|NCT03127397|BEHAVIORAL|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
48379478|NCT00661791|BEHAVIORAL|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
48379479|NCT00661791|BEHAVIORAL|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
48379480|NCT04130477|DEVICE|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
48379481|NCT04130477|DEVICE|Clear Aligner therapy|Clear Aligner therapy
48021662|NCT02804165|GENETIC|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
48021663|NCT00803023|DRUG|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
48021664|NCT00803023|DRUG|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
48021665|NCT00803023|DRUG|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
48021666|NCT00803023|DRUG|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
48021667|NCT01429896|OTHER|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
48021668|NCT06573658|BEHAVIORAL|Perturbation-based balance training (PBT)|It will be a two-session training with each session lasting for approximately half an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.
48021669|NCT06573658|BEHAVIORAL|Active control (control)|It will be a two-session training with each session lasting for approximately half an hour. The same training duration and format will be used as the PBT group, except no perturbations will be induced during the treadmill walking.
48379482|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
48379483|NCT00661037|DEVICE|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
48379484|NCT02452775|BIOLOGICAL|OC-L|
48379485|NCT02452775|OTHER|Montanide|
48379486|NCT02452775|OTHER|poly-ICLC (Hiltonol),|
48379487|NCT03563716|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
48379488|NCT03563716|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
48379489|NCT03563716|DRUG|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
48379490|NCT06176417|PROCEDURE|horizontal ridge augmentation by decompression technique.|Instead of a cover screw, a 2-mm healing abutment was used after implant insertion
48021670|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
48379491|NCT06176417|PROCEDURE|horizontal ridge augmentation by ridge splitting technique using piezosurgery.|horizontal ridge augmentation was done using piezosurgery tips and bone expanders
48713106|NCT01603797|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
48021671|NCT00752505|DRUG|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
48021672|NCT00883571|PROCEDURE|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
48379492|NCT05356546|OTHER|Study-required procedures include: tissue collection from device capsule, questionnaire collection, and photo collection|Enrolled participants will have already received the TYRX™ Absorbable Antibacterial Envelope and will be clinically indicated to have a replacement with any market-released, commercially available (in the geographies they are used) CIED and lead(s) with or without the use TYRX™ Absorbable Antibacterial Envelope, as prescribed by and used on-label by their physician.
48379493|NCT00731640|DEVICE|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
48379494|NCT06374693|DEVICE|Transcutaneous Vagus Nerve Stimulation|"* Pulse width - 25ms~* Frequency - device default (20 or 25Hz)~* Intensity - below pain threshold.~* Frequency - 45 minutes twice daily. On the basis of similarity to other studies, practicalities on the ward and clinical scenario~We have chosen a duration of 5 days based on the usual clinical pathway of inpatient management at the Royal Hallamshire Hospital, and have chosen to deliver the treatment twice daily to optimise the dose. This is a pilot study with feasibility outcomes and as such we will be exploring the feasibility of this treatment regimen.~The Parasym Device will be applied to the left tragus (figure 1) as this is the most common site for tVNS delivery in neurological studies and is associated with few afferents to the heart."
48379495|NCT06374693|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation|The active intervention will be compared to sham tVNS where the vagal nerve stimulator will be attached to the earlobe instead of the tragus, in keeping with evidence that this does not cause vagus nerve stimulation and is in line with sham methods used in other studies. We do not anticipate that patients will have the intervention long enough to become familiar with the common sensations associated with true tVNS intervention. At the end of the intervention period, participants will be asked if they thought they had received true of sham tVNS to understand the blinding ability of the sham.
48379496|NCT00775827|DRUG|fenofibrate 160 mg tablets|
48713107|NCT01236872|DIETARY_SUPPLEMENT|Beetroot juice|250ml once of beetroot juice
48713108|NCT01236872|DIETARY_SUPPLEMENT|Water|250ml once of low-nitrate mineral water
48713109|NCT05551975|OTHER|Control Product|Fed from Study Day 1
48713110|NCT05551975|OTHER|Experimental Product 1|Fed from Study Day 1
48713111|NCT05551975|OTHER|Experimental Product 2|Fed from Study Day 1
48713112|NCT02680574|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
48713113|NCT02680574|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
48713114|NCT01335529|DRUG|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"* Screen period from Week-8~* Standard treatment from day 0 to week 4 (W4)~* Three-drug-regimen (Boceprevir introduction) from W4 to W8~* HCV RNA determination at W8 determines treatment group and participation duration:~  * If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~ * If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
48713115|NCT01754298|PROCEDURE|Retro-articular drilling|"* Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~* Use a 0.045 K-wire for drilling.~* Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
48713116|NCT01754298|PROCEDURE|Trans-articular drilling|"* Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~* Use a 0.045 K-wire for drilling~* A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
48713117|NCT00084019|DRUG|Atazanavir|
48713118|NCT00084019|DRUG|Ritonavir|
48713119|NCT05712304|DIAGNOSTIC_TEST|second examination of the proximal colon|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
48713120|NCT04027270|OTHER|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
48713121|NCT01134406|DEVICE|Hydros Joint Therapy|Single intra-articular injection.
48713122|NCT01134406|DEVICE|Hydros-TA Joint Therapy|Single intra-articular injection
48028841|NCT00613951|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
48379497|NCT05538039|OTHER|Distract with play dough|Distract with play dough
48379498|NCT05538039|OTHER|Distract with play kaleidoscope|Distract with play kaleidoscope
48179302|NCT04381923|DEVICE|Helmet Continuous Positive Airway Pressure (CPAP)|Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (Sp02) remains \< 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
48179303|NCT04381923|DEVICE|High Flow Nasal Oxygen (HFNO)|HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (SpO2) remains \< 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
48179304|NCT05574777|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation to the gastric mucosa and preventing thermal damage to the muscle layer.
48179305|NCT02926924|DEVICE|Wound Vac|a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.
48179306|NCT02926924|OTHER|Standard Dressing|standard dressing with drain tube and bandage
48179307|NCT03379558|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:as per routine practice Route of administration: subcutaneous
48179308|NCT06276400|OTHER|Emotion valence|Positive vs. Negative (temporally extended sequence)
48179309|NCT06276400|OTHER|Time|∆ Temporal evidence (i.e. relative time difference of stimulus-type exposure across a sequence: 1200 vs. 1800)
48179310|NCT06276400|DEVICE|TMS Stimulation|FPl vs. mid-LPFC vs. non-PFC Control (S1); Specific LPFC region (vs. non-PFC active Control) function is manipulated with an inhibitory TMS protocol (cTBS).
48379499|NCT05538039|OTHER|Control group|Routine nursing care
48379500|NCT00710008|OTHER|exercise training|3 bouts of exercise at 90%RCP during one week
48379501|NCT00036556|DRUG|Atrasentan|
48713123|NCT01134406|DEVICE|Synvisc-One|Single intra-articular injection.
48379502|NCT03818542|DRUG|ABBV-181|intravenous infusion
48379503|NCT03818542|DRUG|ABBV-368|intravenous infusion
48379504|NCT03818542|DRUG|ABBV-927|intravenous infusion
48713124|NCT04275609|OTHER|AI generated report|After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
48713125|NCT04275609|OTHER|physicians writing report|After the endoscopic procedure, the physicians writing the report in computer according the procedure.
48379505|NCT03818542|DRUG|ABBV-927|intratumoral injection
48713126|NCT04024215|DEVICE|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
48379506|NCT04381793|DIETARY_SUPPLEMENT|Recovery Factors|Porcine serum amino acid/peptide
48379507|NCT03508076|DEVICE|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
48379508|NCT03508076|DEVICE|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
48028842|NCT00613951|DRUG|metformin|Tablets, 1500-2000 mg/daily
48028843|NCT04771169|OTHER|vestibular Training Group|this Group will receive vestibular Adaptation \& Balance exercises
48028844|NCT04771169|OTHER|Virtual Reality Group|This Group will receive Virtual Reality Training by using exergaming.
48028845|NCT02721238|BIOLOGICAL|20% Albumin|
48028846|NCT02721238|OTHER|Plasmalyte|
48028847|NCT03943095|OTHER|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
48028848|NCT03943095|OTHER|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
48028849|NCT01579123|PROCEDURE|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
48379509|NCT04452994|DRUG|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0\*10\^6 CAR-positive viable T cells/kg).
48379510|NCT03500029|RADIATION|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
48713127|NCT04634708|OTHER|No intervention|No intervention due to observational design
48713128|NCT05675761|DRUG|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
48713129|NCT02572232|DEVICE|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
48713130|NCT03481920|DRUG|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
48713131|NCT03481920|DRUG|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
48379511|NCT03500029|DRUG|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
48379512|NCT01292291|OTHER|biologic sample preservation procedure|
48379513|NCT01292291|OTHER|laboratory biomarker analysis|
48379514|NCT01292291|OTHER|study of socioeconomic and demographic variables|
48379515|NCT01292291|PROCEDURE|diffusion-weighted magnetic resonance imaging|
48379516|NCT01292291|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
48379517|NCT01292291|PROCEDURE|multiparametric magnetic resonance imaging|
48713132|NCT03985007|DRUG|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
48379518|NCT01292291|PROCEDURE|quality-of-life assessment|
48379519|NCT01292291|PROCEDURE|transperineal prostate biopsy|
48379520|NCT01292291|PROCEDURE|transrectal prostate biopsy|
48379521|NCT01292291|PROCEDURE|ultrasound-guided prostate biopsy|
48379522|NCT02861404|GENETIC|skin flakes collection|viral status assessment of skin flakes
48379523|NCT02774577|OTHER|whole body vibration training in vibrating platform in young|
48379524|NCT02774577|OTHER|whole body vibration training in vibrating platform in elderly|
48379525|NCT03605758|DRUG|Ivermectin|Ivermectin is an anti-parasitic
48379526|NCT04712058|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]|Biktarvy will be administered on the same day of diagnosis. The daily dosing will be continued for 48 weeks.
48713133|NCT06087900|OTHER|Moderate continuous training (MICT)|The participants received a moderate continuous training (MICT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 50 minutes of exercise at 65-70% of maximal heart rate, and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise increases to 70-75% of maximal heart rate at week 7-12.
48713134|NCT06087900|OTHER|High intensity interval training (HIIT)|The participants received a 7x2 high intensity interval training (HIIT) program of walking or running a treadmill 3 days/week, 12 weeks. This training comprises training comprises 5 minutes of warm up at 50-55% of maximal heart rate, following by 28 minutes of exercise (2 minutes of high intensity at 85-90% of maximal heart rate interval with 2 minutes of low intensity at 50-55% of maximal heart rate 7 times), and 5 minutes of cool down at 50-55% of maximal heart rate. The intensity of exercise at high intensity increases to 90-95% of maximal heart rate at week 7-12.
48713135|NCT06087900|OTHER|Inspiratory muscle training (IMT)|The participants received Powerbreathe ® ClassicLight in this training program. The IMT group demonstrated the training 8 cycles of 30 breath, 5 days/week with progressive load 50% of maximal inspiratory pressure (MIP) at week 1-3, 60% of MIP at week 4-6, 70% of MIP at week 7-9, and 80% of MIP at week 10-12. Every first day of the week participants had to undergoing load adjustment at laboratory
48713136|NCT06087900|OTHER|Control|The CON group did not have any intervention but usual care.
48713137|NCT01437527|BEHAVIORAL|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
48713138|NCT01437527|BEHAVIORAL|therapy as usual|Body image therapy as usual
48713139|NCT00428220|DRUG|sunitinib|sunitinib
48713140|NCT03182595|DRUG|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
48713141|NCT00364533|DRUG|Tapentadol IR (CG5503)|Fixed Dose 50, 75, \& 100 mg BID for 3 days
48713142|NCT00364533|DRUG|Placebo|Fixed Dose Matching placebo for 3 days
48713143|NCT00364533|DRUG|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
48713144|NCT00364533|DRUG|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days
48713145|NCT04342689|DRUG|Dietary Supplement containing resistant starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
48713146|NCT04342689|DIETARY_SUPPLEMENT|Placebo Starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
48713147|NCT00767234|PROCEDURE|Observation|Standard of Care
48713148|NCT02764528|BEHAVIORAL|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
48713149|NCT02764528|BEHAVIORAL|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
48021673|NCT00883571|PROCEDURE|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
48021674|NCT00883571|PROCEDURE|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
48021675|NCT00490425|DRUG|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
48021676|NCT04358926|DEVICE|Hyperbaric oxygen therapy|8 sessions in 4 days of breathing 100% oxygen in 2.2 ATA. Each session is 60 minutes. 1 meter/minute compression/decompression
48021677|NCT06215638|DRUG|Bortezomib|Bortezomib 2 mg per week subcutaneously, for twelve weeks in total
48379527|NCT03292731|DRUG|17-Hydroxyprogesterone caproate 250mg or 500 mg.|For the pharmacodynamic study, subjects receiving either 250mg or 500 mg dose will be studied to relate the plasma concentration at 26-30 to the rate of sPTB. For the safety study, subjects will be randomized to either the 250mg or 500 mg dose.
48021678|NCT04527263|DIAGNOSTIC_TEST|measurement of urinary 5-HIAA|urinary assessment of 5-HIAA
48021679|NCT06414291|OTHER|Plain Water|Plain water without calories, sweetener, or electolytes
48713150|NCT02764528|BEHAVIORAL|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
48021680|NCT06414291|OTHER|Liquid IV Hydration Multiplier|Drink with 22 grams of carbohydrate, 1020 milligrams of sodium, and 760 milligrams of potassium per liter. Hydration multiplier liquid IV
48021681|NCT06414291|OTHER|Liquid IV Sugar Free|10 grams of carbohydrate, 1060 milligrams of sodium, and 760 milligrams of potassium per liter. Sugar free Liquid IV
48021682|NCT06377553|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
48021683|NCT06377553|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the pelvis and abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired when necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
48713151|NCT05097508|DRUG|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
48021684|NCT06377553|OTHER|Rectal Ultrasound Gel Injection|About 50ml of ultrasound gel will be placed into the vagina using the blunt end of the ultrasound gel tube or a Foley catheter or a syringe with a blunt Christmas tree end. No ultrasound probe will be inserted into the vagina, no external ultrasound probe will be used. No ultrasound study will be performed. The ultrasound gel will only be used to distend the vagina and improve the quality of MRI images; this is standard of practice in MRI for endometriosis and for several other gynecological diseases.
48021685|NCT00258986|PROCEDURE|Living donornephrectomy|
48021686|NCT06391827|DRUG|DA-7503 Single dose|Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
48021687|NCT06391827|DRUG|DA-7503 Multiple dose|Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
48021688|NCT06391827|DRUG|Placebo Single dose|Oral administraion for once.
48021689|NCT06391827|DRUG|Placebo Multiple dose|Oral administration once daily for 7 days
48021690|NCT04899063|DEVICE|ELIOS Procedure|Treatment with the ELIOS System
48021691|NCT05605366|DRUG|Minocycline|Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
48021692|NCT05605366|DRUG|Placebo|This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
48021693|NCT03495960|DRUG|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 \& 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
48021694|NCT03495960|DRUG|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
48021695|NCT03495960|DRUG|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
48021696|NCT03495960|DRUG|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
48021697|NCT03495960|RADIATION|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
48021698|NCT03495960|DRUG|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
48021699|NCT03246009|DRUG|rHSA/GCSF|single injection-1.8mg
48021700|NCT03246009|DRUG|rHSA/GCSF|single injection-2.1mg
48021701|NCT03246009|DRUG|rHSA/GCSF|single injection-2.4mg
48021702|NCT03246009|DRUG|rHSA/GCSF|multiple injection-1.8mg
48713152|NCT05097508|DRUG|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
48021703|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.1mg
48021704|NCT03246009|DRUG|rHSA/GCSF|multiple injection-2.4mg
48713153|NCT05097508|DEVICE|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
48021705|NCT00389818|BIOLOGICAL|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
48021706|NCT00389818|BIOLOGICAL|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
48713154|NCT05097508|DEVICE|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
48179311|NCT02635178|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
48379528|NCT03292731|DRUG|Safety study of 500 mg dose.|Subjects randomized to 250 mg or 500 mg dose
48379529|NCT06301126|OTHER|Virtual reality|The system included an Xbox 360® console, a sensor that detects motion (Kinect®), and a projector device with loudspeakers. The console, which was mounted on a table, reached 1 m tall. The Kinect® motion sensor was attached to the projector, which showed images onto a wall 2.5 metres distant from the playing field. The playing field was at least 1.8 m wide and 1.8 m long, with the Kinect® sensor situated 1.2 m away. The device was calibrated before each training session to accurately follow the motions of each subject.
48713155|NCT03250078|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
48021707|NCT00389818|BIOLOGICAL|rituximab|375 mg/m2 IV Day 1 of each cycle
48021708|NCT00389818|BIOLOGICAL|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
48021709|NCT00389818|DRUG|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
48021710|NCT00389818|DRUG|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
48021711|NCT00389818|DRUG|prednisone|100 mg PO Days 1-5 of each cycle
48021712|NCT00389818|DRUG|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
48021713|NCT00389818|OTHER|immunohistochemistry staining method|tissue specimen collected at baseline
48021714|NCT00389818|OTHER|laboratory biomarker analysis|tissue specimen collected at baseline
48379530|NCT06301126|OTHER|conventional physical therapy exercise program|Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
48021715|NCT01920295|DEVICE|Cryoballoon ablation|
48021716|NCT01438632|DEVICE|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
48021717|NCT01876121|DRUG|Celecoxib|oral
48021718|NCT03269591|DEVICE|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
48021719|NCT03269591|DRUG|diclofenac tablets|drugs
48021720|NCT03269591|DIAGNOSTIC_TEST|Visual analogue scale|a graphic rating scale
48021721|NCT03269591|DIAGNOSTIC_TEST|Progesterone blood level|blood test
48713156|NCT04459806|PROCEDURE|intracranial pressure monitoring|Invasive monitoring of intracranial pressure by using CereLink monitor.
48713157|NCT00287937|DRUG|vorinostat|Given orally
48517946|NCT05333705|BIOLOGICAL|infusion of natural killer cells|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured. NK cell production will be infused after chemotherapy
48713158|NCT00287937|DRUG|paclitaxel|Given IV
48713159|NCT00287937|DRUG|carboplatin|Given IV
48713160|NCT00287937|OTHER|laboratory biomarker analysis|Correlative studies
48713161|NCT00287937|OTHER|pharmacological study|Correlative studies
48713162|NCT01041443|DRUG|5-fluoro-2-deoxycytidine|Given IV
48713163|NCT01041443|DRUG|tetrahydrouridine|Given IV
48713164|NCT01041443|OTHER|laboratory biomarker analysis|Correlative studies
48713165|NCT01041443|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
48713166|NCT01041443|GENETIC|DNA methylation analysis|Correlative studies
48517947|NCT04387942|DRUG|IL-2|For all patients,rhIL-2 infusions seven days;recurrent patients was applied again for 7 days;patients who were diagnosed HSPN were treated on a routine basis for 7 consecutive days, and then once every two week for 3months.
48517948|NCT05017246|DRUG|Bupivacaine|-Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP
48517949|NCT05017246|DRUG|Morphine|-Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)
48713167|NCT03342352|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
48713168|NCT03342352|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
48713169|NCT03342352|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
48713170|NCT03342352|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
48517950|NCT05017246|DRUG|Lidocaine|-Lidocaine infusion 1 mg/kg ideal body weight (IBW)
48517951|NCT01794455|DRUG|Sertraline|50mg - 200mg daily
48517952|NCT01794455|DRUG|Candesartan|4mg - 32mg daily
48713171|NCT03342352|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
48713172|NCT03342352|DRUG|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
48713173|NCT03342352|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
48713174|NCT03378089|BEHAVIORAL|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
48713175|NCT03378089|BEHAVIORAL|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
48713176|NCT05528900|DIAGNOSTIC_TEST|allergy test|allergy test are oral food challenge , prick test and IgE blood rate
48713177|NCT06366542|OTHER|Vestibular Rehabilitation Therapy (VRT)|The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
48713178|NCT06366542|OTHER|Virtual reality exercises|The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.
48713179|NCT06366542|OTHER|Optokinetic Stimulation exercises|Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
48713180|NCT04904809|DEVICE|Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System|The Perclose ProGlide SMC and Perclose ProStyle SMCR in this study will be used for multiple access site closures in a single vein in the ablation procedure.
48713181|NCT02494843|OTHER|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
48713182|NCT02494843|OTHER|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
48713183|NCT00293904|BIOLOGICAL|CYT005-AllQbG10|
48713184|NCT05577364|DRUG|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
48713185|NCT05577364|DRUG|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
48713186|NCT02270762|OTHER|Rest in bed|
48713187|NCT02270762|OTHER|Passive verticalization|
48713188|NCT02270762|OTHER|Rest in bed|
48517953|NCT04192461|PROCEDURE|Tooth guided immediate implant placement|The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
48713189|NCT06012279|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
48713190|NCT03900923|DRUG|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
48517954|NCT04780178|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
48713191|NCT04414124|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
48713192|NCT04414124|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
48713193|NCT03815994|DEVICE|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
48713194|NCT03781219|DRUG|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
48713195|NCT03781219|DRUG|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
48713196|NCT00871546|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
48713197|NCT00871546|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
48713198|NCT00871546|BIOLOGICAL|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
48713199|NCT06309511|DIAGNOSTIC_TEST|Arterial tonometry|Arterial transcutaneous tonometry
48713200|NCT03747900|DRUG|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
48713201|NCT03747900|COMBINATION_PRODUCT|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
48713202|NCT04642924|DRUG|SGM-101|Fluorescence-guided surgery
48021722|NCT03269591|DIAGNOSTIC_TEST|Menstrual symptom questionnaire|questionnaire
48517955|NCT03849157|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
48517956|NCT05796076|DEVICE|Virtual reality|Participants in the intervention group will be received VR during the suturing procedure. Virtual reality is a three dimensions of width, height and depth that is generated digitally in a computer-generated environment that allows a user to interact with it 16.
48517957|NCT05900778|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
48517958|NCT05900778|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
48713203|NCT03693313|BEHAVIORAL|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
48713204|NCT02418312|DRUG|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
48713205|NCT02418312|DRUG|Placebo|placebo plus thienopyridine
48021723|NCT00399152|DRUG|Perifosine|Perifosine Oral Dose
48021724|NCT00399152|DRUG|Sunitinib Malate|Sunitinib oral dose
48021725|NCT01040611|BEHAVIORAL|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
48713206|NCT01911312|DEVICE|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
48713207|NCT01911312|DEVICE|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
48713208|NCT05302258|DIAGNOSTIC_TEST|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
48713209|NCT04750980|OTHER|food allergy|food allergy
48713210|NCT04750980|OTHER|respiratory allergy|respiratory allergy
48713211|NCT04750980|OTHER|healthy controls|healthy controls
48713212|NCT01420627|BIOLOGICAL|EZN-2279|Weekly administration of EZN-2279 via IM injection
48713213|NCT01420627|BIOLOGICAL|Adagen|
48713214|NCT00313768|DRUG|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
48713215|NCT00313768|DRUG|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
48713216|NCT03927352|BIOLOGICAL|SCT630|Administered by subcutaneous injection
48713217|NCT03927352|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
48713218|NCT02410824|DEVICE|stenfilcon A toric lens|toric contact lens
48713219|NCT02410824|DEVICE|etafilcon A toric lens|toric contact lens
48713220|NCT06519461|BEHAVIORAL|Family-centered teaching model|The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
48021726|NCT04987918|DIAGNOSTIC_TEST|Applied Biosystems TaqPath COVID- 19 Combo Kit|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
48021727|NCT04623801|PROCEDURE|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
48021728|NCT03323099|BEHAVIORAL|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
48021729|NCT03323099|BEHAVIORAL|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
48713221|NCT05993273|PROCEDURE|Epidural|The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.
48021730|NCT05663489|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|A concentrated and exposure-based psychological treatment over four consecutive days
48021731|NCT01677195|DRUG|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
48021732|NCT01677195|DRUG|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
48021733|NCT05058274|DEVICE|Implant of the AT-TORBI 709 lens|Implant of the AT-TORBI 709 lens
48021734|NCT03750136|DRUG|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
48021735|NCT03750136|DRUG|Furosemide Injection|high dose furosemide
48021736|NCT01347021|PROCEDURE|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
48021737|NCT00354926|BIOLOGICAL|AME-133v (LY2469298)|IV 4X weekly X 4
48021738|NCT05622773|OTHER|Mat use application|In the research, repeated measurements will be made by using mats and foot baths in a single group and the data will be recorded.
48021739|NCT00013793|BEHAVIORAL|Motivational enhancement and ultrasound|
48021740|NCT02972099|DEVICE|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
48021741|NCT02972099|DEVICE|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
48021742|NCT04159831|DRUG|LTI-01|single-chain urokinase plasminogen activator, scuPA
48021743|NCT04159831|DRUG|Placebo|normal saline
48021744|NCT05360095|BEHAVIORAL|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
48021745|NCT05360095|BEHAVIORAL|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
48028850|NCT01579123|PROCEDURE|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
48028851|NCT03060941|BEHAVIORAL|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
48028852|NCT03060941|BEHAVIORAL|Facility access|Participants will receive at 6 month membership to a local fitness facility.
48028853|NCT03060941|BEHAVIORAL|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
48028854|NCT03060941|BEHAVIORAL|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
48028855|NCT03060941|BEHAVIORAL|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
48713222|NCT05993273|PROCEDURE|ESP block|Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.
48713223|NCT05993273|PROCEDURE|Cryoanalgesia|Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
48713224|NCT03752268|BEHAVIORAL|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
48713225|NCT03351556|BEHAVIORAL|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
48713226|NCT03351556|BEHAVIORAL|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
48713227|NCT03509493|DIAGNOSTIC_TEST|FibriCheck|Digital health application
48021746|NCT05360095|BEHAVIORAL|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
48021747|NCT04313153|DRUG|Vadadustat|oral tablets
48021748|NCT04313153|DRUG|Darbepoetin alfa|intravenous or subcutaneous solution
48021749|NCT00098215|BEHAVIORAL|Pediatric residency training on tobacco|
48179312|NCT02635178|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
48021750|NCT05520476|DEVICE|Neuroliten MVP system|The Neuroliten MVP system will be an App that gets uploaded to the patients iPhone from the App Store.
48021751|NCT05407545|DEVICE|Current prosthesis|A unilateral transfemoral amputee will conduct experiments with the current prosthesis
48021752|NCT05407545|DEVICE|Active Prosthesis (PowerKnee)|A unilateral transfemoral amputee will conduct experiments with the Power Knee. The PowerKnee is an active prosthesis developed by Össur.
48021753|NCT05932316|DIAGNOSTIC_TEST|spirometry|participants will undertake spirometry testing before and after bronchodilators and placebo
48021754|NCT05932316|DRUG|Salbutamol|Salbutamol inhalation to determine bronchodilator response
48021755|NCT05932316|DRUG|placebo|placebo inhalation prior to repeating spirometry
48713228|NCT06373770|DIAGNOSTIC_TEST|Ayres sensory integration therapy|"A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior."
48713229|NCT06373770|DIAGNOSTIC_TEST|Behaviour Therapy|The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
48713230|NCT06484920|DRUG|ATRA|150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)
48713231|NCT06484920|DRUG|Pembrolizumab|200mg Q3W pembrolizumab
48713232|NCT00044889|DRUG|clofarabine (IV formulation)|
48713233|NCT05709925|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|The Graston Technique which is the Instrument Assisted Soft Tissue Mobilization is the use of a firm instrument to break tissue adhesions and mobilize scar tissue thus improving pain, range of motion and disability.
48021756|NCT03788889|DRUG|Ketamine|Ketamine infusion
48021757|NCT03788889|DRUG|Phenobarbital|Phenobarbital intravenous injection
48179313|NCT03763045|DRUG|Sildenafil|Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily
48179314|NCT03763045|DRUG|Sildenafil|Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily
48713234|NCT05709925|PROCEDURE|myofascial release|myofascial release through stripping technique to the lumbar region.
48713235|NCT05529979|DEVICE|EPIONE® CT-Guided Percutaneous procedures|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
48713236|NCT04994873|BEHAVIORAL|STEP|Behavioral intervention to increase positive affect
48713237|NCT04994873|BEHAVIORAL|Enhanced TAU|Standard care plus a phone app with a personalized safety plan
48179315|NCT03763045|OTHER|Placebo|Placebo tablet.
48179316|NCT01189422|DRUG|teplizumab or placebo|infusion or injection
48713238|NCT03801746|DRUG|vadadustat|Oral dose 300 mg
48713239|NCT03801746|DRUG|Rifampin|IV Rifampin
48021758|NCT03788889|DRUG|Lorazepam|Standard of Care
48021759|NCT03788889|DRUG|Placebo A|Placebo injection
48021760|NCT03788889|DRUG|Placebo B|Placebo infusion
48021761|NCT01198184|DRUG|temsirolimus|Given IV or PO
48021762|NCT01198184|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
48021763|NCT01198184|OTHER|laboratory biomarker analysis|Correlative studies
48021764|NCT01198184|OTHER|pharmacological study|Correlative studies
48028856|NCT04977167|DRUG|HG146|HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
48028857|NCT04977167|DRUG|PD-(L)1 antibody|PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
48028858|NCT02075593|DRUG|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
48713240|NCT03801746|DRUG|Probenecid|Oral Probenecid
48713241|NCT03801746|DRUG|Cyclosporins|Oral Cyclosporine
48713242|NCT01839019|DRUG|ODM-102|Single dose escalation
48713243|NCT01839019|DRUG|Placebo for ODM-102|Single dose escalation
48713244|NCT03160469|DEVICE|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) \& class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
48713245|NCT05593614|DRUG|ATX01 10%|A 100 mL bottle of hydrogel formulation containing 10% amitriptyline hydrochloride w/w
48713246|NCT05593614|DRUG|ATX01 15%|A 100 mL bottle of hydrogel formulation containing 15% amitriptyline hydrochloride w/w
48713247|NCT05593614|DRUG|Placebo|A 100 mL bottle of hydrogel formulation containing no active substance
48713248|NCT01247935|OTHER|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
48713249|NCT01247935|OTHER|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
48713250|NCT01247935|OTHER|Control|Patients are monitored for pain and discomfort
48713251|NCT05066646|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
48713252|NCT05528367|DRUG|Nab-PTX,S-1,Tirelizumab|"S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
48713253|NCT05528367|RADIATION|Chemoradiation|45-50Gy/25F
48713254|NCT00353873|DRUG|Fluticasone propionate|200μg twice daily
48713255|NCT00353873|DRUG|Fluticasone propionate/salmeterol|50/100μg twice daily
48713256|NCT00051467|GENETIC|TNFerade|
48713257|NCT04053751|PROCEDURE|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
48713258|NCT06076928|DEVICE|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
48713259|NCT06076928|DEVICE|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
48713260|NCT06076928|OTHER|Standard Treatment of Care|Standard Conventional Occupational Therapy
48713261|NCT03404908|PROCEDURE|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
48713262|NCT03404908|PROCEDURE|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
48713263|NCT03404908|DRUG|Ropivacaine|In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
48713264|NCT03404908|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
48713265|NCT03404908|DRUG|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
48713266|NCT03404908|DRUG|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
48713267|NCT03404908|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
48713268|NCT03404908|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
48713269|NCT01958021|DRUG|LEE011|Ribociclib was administered orally at a dose of 600 mg once daily (three 200 mg capsules).
48713270|NCT01958021|DRUG|Letrozole|Letrozole 2.5 mg tablets taken orally.
48713271|NCT01958021|DRUG|LEE011 Placebo|Matching ribociclib placebo was the control drug and was administered orally once daily.
48713272|NCT02075632|DRUG|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
48713273|NCT06196398|DRUG|Standard Medical Treatment on the basis of anti-platelet therapy|"1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.~2. Intensive statin therapy: Statins with high doses~3. Blood pressure: below 140/90mmHg~4. LDL: less than 1.81mmol/L(70mg/dl)~5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%~6. Cigarette and alcohol quitting~7. Oral anticoagulants for atrial fibrillation"
48713274|NCT05628051|PROCEDURE|ultrasonographic measurement of carotid artery corrected flow time (FTc)|Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
48713275|NCT02251717|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
48713276|NCT00279097|DEVICE|High Frequency Chest Wall Oscillation|
48713277|NCT03523273|DRUG|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
48713278|NCT03523273|DRUG|Placebo|Placebo administration will match the study drug.
48713279|NCT02252809|DRUG|adalimumab|
48713280|NCT02252809|DRUG|methylprednisolone|
48713281|NCT01229748|BEHAVIORAL|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
48713282|NCT01229748|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
48713283|NCT01229748|BEHAVIORAL|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
48713284|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
48713285|NCT01836796|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
48713286|NCT00504790|DRUG|GSK923295|anti-mitotic compound
48517959|NCT04175288|OTHER|Ultrasound, manual therapy and exercise|The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
48713287|NCT02740543|DRUG|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
48713288|NCT01016314|DEVICE|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
48713289|NCT01016314|DEVICE|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
48713290|NCT04906967|PROCEDURE|flaps|coverage of soft tissue defect around ankle
48713291|NCT00334906|DRUG|memantine HCl|
48713292|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
48713293|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
48713294|NCT01903395|BEHAVIORAL|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
48713295|NCT05016167|PROCEDURE|Replacement every 24 hours|"Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded."
48713296|NCT05016167|PROCEDURE|Replacement every 12 hours|"Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded."
48021765|NCT05169294|OTHER|Telerehabilitation Program|Telerehabilitation program: Intervention will be applied by video interview for eight weeks, 3 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on fine motor skills, handwriting skills and activities of daily life of the individuals.
48179317|NCT01106365|DEVICE|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
48517960|NCT05159024|DIAGNOSTIC_TEST|CRP, PCT, and WBCs trajectories|the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
48713297|NCT02805400|OTHER|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
48713298|NCT03675425|OTHER|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
48713299|NCT03675425|OTHER|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
48713300|NCT03694743|DEVICE|2Shape rotary system|root canal preparation
48021766|NCT05169294|OTHER|Written Home Program|Home program: After the evaluations, the activities towards the determined goals will be communicated to the parents as a home program in written and electronic format. Instructions and key points for the correct implementation of the activities will be presented to the parent, both in writing and verbally; The parent will be able to send questions and receive feedback to the therapists over the phone at any stage of the eight-week home program intervention process. No intervention will be applied to the child through direct video calls.
48021767|NCT02741947|DRUG|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
48021768|NCT02741947|DRUG|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
48021769|NCT02445235|OTHER|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
48713301|NCT05379114|OTHER|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
48713302|NCT05379114|OTHER|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
48021770|NCT03054909|BIOLOGICAL|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
48021771|NCT03054909|BIOLOGICAL|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
48021772|NCT04965779|DEVICE|Abdominal Binder|Women in the intervention group use an abdominal binder from postpartum hour 1 to 48, and will be checked every 6 hours. The abdominal circumference of the women is measured at the anterior superior iliac spine and umbilicus level with a tape measure before the application, and the binder size is adjusted to be 5% smaller (approximately 0.5-1 cm) than the measurement obtained.
48021773|NCT04965779|OTHER|Postpartum nursing care|Postpartum nursing care the follow-up protocol includes the evaluation and record between postpartum 1. and 48. hours of pain level, analgesic administration, follow-up of the puerperal bleeding, and uterine tone, measure of hemodynamic parameters measuring, hemoglobin level and hematocrit ratio, and assessment breastfeeding.
48021774|NCT01624545|OTHER|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
48713303|NCT00803413|BEHAVIORAL|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
48021775|NCT03985813|BEHAVIORAL|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
48713304|NCT00803413|BEHAVIORAL|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
48021776|NCT05315388|OTHER|Immersion therapy in nature - Vitamin N|"Usual therapy group The first saliva sample will be taken upon awakening to determine cortisol concentration. At their workplace, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~Group 2A and Group 2B In the natural environment, a saliva sample will be taken upon awakening to determine cortisol concentration. After arrival at the site, they will be asked to remain seated and silent for 3 minutes, the following will be taken: blood pressure, heart rate, psychological instruments (stress-anxiety), blood sample.~The first phase is a session of observation of the site for 15 minutes. A slow, unhurried walk will be performed for 1 hour and 45 minutes. The order of activities (sitting and walking) will be established to ensure reliability of physiological measurements."
48021777|NCT06364566|RADIATION|Neoadjuvant chemradiotherapy|Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage
48021778|NCT06364566|PROCEDURE|Minimally invasive esophagectomy|The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes
48021779|NCT01111500|DEVICE|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
48021780|NCT01111500|DEVICE|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
48021781|NCT00789217|PROCEDURE|Immediate skin test|Intradermal test with immediate reading
48021782|NCT05251233|DRUG|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
48021783|NCT05251233|DRUG|Pantoprazole|The study will use commercial supply.
48021784|NCT06532747|BEHAVIORAL|Integrated Lifestyle Intervention (ILI)|ILI participants will receive training in empirically supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with BWL content adapted to meet the needs of EAs.
48021785|NCT06532747|BEHAVIORAL|Monitoring with digital tools|All participants will receive digital tools to facilitate self-monitoring-the initial 4-month program will consist of group sessions via Zoom (8 weekly, 4 bi-weekly) with weekly tailored e-coaching, followed by monthly boosters through 12 months.
48021786|NCT05239026|BEHAVIORAL|Advanced treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
48021787|NCT05239026|BEHAVIORAL|Traditional treadmill walking|Participants will walking on a treadmill for 6 5-minute Blocks. Participants will walk at self-selected cadence during Blocks 1-3. Speed will progressively increase during Blocks 4-6.
48021788|NCT03728582|DEVICE|Active tDCS plus Speech-Language Therapy|1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
48713305|NCT00803413|BEHAVIORAL|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
48713306|NCT00803413|BEHAVIORAL|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
48713307|NCT02753127|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
48713308|NCT02753127|DRUG|Fluorouracil|
48713309|NCT02753127|DRUG|Leucovorin|
48713310|NCT02753127|DRUG|Irinotecan|
48713311|NCT02753127|DRUG|Bevacizumab|
48713312|NCT00121394|PROCEDURE|Chlorhexidine vaginal and infant wash|
48713313|NCT00623545|DRUG|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
48713314|NCT05794711|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
48021789|NCT03728582|DEVICE|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
48517961|NCT00513136|BEHAVIORAL|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
48713315|NCT04813172|BEHAVIORAL|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
48517962|NCT00513136|BEHAVIORAL|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
48517963|NCT02206360|PROCEDURE|Endoscopic Ultrasound|
48713316|NCT03223467|PROCEDURE|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
48713317|NCT05026372|BEHAVIORAL|Mindfulness Compassion (MC)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
48713318|NCT05026372|BEHAVIORAL|Mindfulness Gratitude (MG)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
48713319|NCT05026372|BEHAVIORAL|Mindfulness Value-Based Living (MV)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
48713320|NCT05088993|OTHER|Antigravity treadmill training|This group received antigravity treadmill training 100% weight bearing
48713321|NCT05088993|OTHER|Conventional exercise program|This group received the conventional exercise program only.
48713322|NCT03032653|OTHER|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
48713323|NCT03032653|OTHER|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
48713324|NCT04175574|OTHER|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
48713325|NCT03663530|BEHAVIORAL|Meal times|Meal times vary based on the arm: aligned or misaligned
48713326|NCT04465318|OTHER|E-cigarette (EC)|NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.
48713327|NCT04465318|OTHER|Nicotine Replacement Therapy (NRT)|Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD \>= 20) or 14 mg nicotine patch (for those with CPD \< 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.
48713328|NCT04465318|BEHAVIORAL|Smoking Harm Reduction Counseling Sessions|Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
48713329|NCT00099229|DRUG|Licarbazepine|
48713330|NCT03504813|OTHER|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
48713331|NCT03504813|OTHER|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
48713332|NCT03504813|OTHER|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
48179318|NCT01651533|BEHAVIORAL|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
48179319|NCT01651533|BEHAVIORAL|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
48179320|NCT04467398|PROCEDURE|trigeminal nerve block|Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.
48179321|NCT04643093|DRUG|Pitavastatin|Pitavastatin, QD
48179322|NCT04643093|DRUG|Ezetimibe|Ezetimibe, QD
48517964|NCT02206360|PROCEDURE|Magnetic Resonance Imaging (MRI)|
48517965|NCT04247100|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Active Transcutaneous Auricular Microstimulation delivered by TENS device
48517966|NCT04247100|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
48713333|NCT03504813|BEHAVIORAL|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
48713334|NCT01154283|DEVICE|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
48379531|NCT06481397|DEVICE|ONCObind (Onco-Seraph) 100 Filter|"The ONCObind (Onco-Seraph) 100 Microbind® Affinity Blood Filter (Onco-Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Onco-Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins.~Literature search yielded over 45 publications and 370 treated patients with Seraph platform technology for pathogen removals without significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of Onco-Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Onco-Seraph 100, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use."
48713335|NCT06247774|BEHAVIORAL|Cardiac Rehabilitation|Participation in a 12-week cardiac rehabilitation program
48713336|NCT06247774|BEHAVIORAL|Attention Control|Participants will receive regular phone calls in place of cardiac rehabilitation visits
48713337|NCT04676867|DRUG|Dalcetrapib|Dalcetrapib 300 mg Film-Coated Tablets
48713338|NCT04676867|OTHER|Placebo|Placebo Tablets
48713339|NCT03386747|BEHAVIORAL|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
48713340|NCT03386747|BEHAVIORAL|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
48713341|NCT02120963|BEHAVIORAL|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
48713342|NCT05363865|BEHAVIORAL|Virtual Community Intervention|Modules of community building, HIV/HCV prevention, drug and service stigma, identification of mental health problems
48713343|NCT05363865|BEHAVIORAL|Standard of Care|health websites and county information provided to participants
48713344|NCT04711941|BEHAVIORAL|Rehabilitation training|Rehabilitation with behavioural stimuli
48713345|NCT04026360|OTHER|no intervention|
48713346|NCT00457977|BIOLOGICAL|Pneumovax (PPSV23)|Injection
48713347|NCT00457977|BIOLOGICAL|Prevnar (PCV7)|Injection
48713348|NCT01224821|BIOLOGICAL|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
48713349|NCT03732365|COMBINATION_PRODUCT|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
48713350|NCT03732365|DRUG|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
48713351|NCT00975065|DRUG|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
48021790|NCT02550613|DEVICE|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
48713352|NCT00975065|DRUG|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
48021791|NCT01709058|DRUG|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
48021792|NCT01709058|OTHER|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
48379532|NCT05841862|DEVICE|2C-QD|Quantum Dot
48179323|NCT04643093|DRUG|1PC111|1PC111, QD
48517967|NCT00425763|DRUG|AQAS|AQAS dosed by body weight, on days 0, 1, 2
48517968|NCT05021432|OTHER|Virtual reality training group|This group will receive video based games
48713353|NCT05109221|DEVICE|ultrasound|using of ultrasound in prediction of difficult intubation in obese surgical patients
48713354|NCT03943550|DRUG|RO7049665|Multiple ascending doses of RO7049665 will be administered SC.
48713355|NCT03943550|DRUG|Placebo|Matching placebo will be administered SC.
48713356|NCT04859244|DRUG|GS-441524|750 mg administered as a solution
48713357|NCT02466074|DRUG|Acetazolamide|see arm description
48713358|NCT02466074|DRUG|Placebo|Placebo arm
48713359|NCT03117608|BIOLOGICAL|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
48713360|NCT03117608|BIOLOGICAL|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
48713361|NCT05857449|DRUG|LPM3480392|Intravenous infusion
48713362|NCT05736705|PROCEDURE|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
48713363|NCT05736705|DEVICE|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
48713364|NCT03813004|DIAGNOSTIC_TEST|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~1. left treadmill belt deceleration for right leg toe off~2. right treadmill belt deceleration for left leg toe off~3. left treadmill belt acceleration for right leg heel strike~4. right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
48179324|NCT01991145|PROCEDURE|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
48379533|NCT05841862|DEVICE|Sham 2C-QD|Sham Intravitreal Injection
48379534|NCT01856348|DRUG|Vitamin D|
48379535|NCT04951895|DIAGNOSTIC_TEST|MRI|MRI of TMJ
48379536|NCT06308523|DRUG|AP303 150 μg|AP303 Tablet 150 μg QD
48517969|NCT05021432|OTHER|Circuit Training group|They will receive Task-oriented Circuit training exercise program
48517970|NCT02773602|DRUG|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
48713365|NCT00534378|DRUG|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
48713366|NCT00987896|DEVICE|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
48713367|NCT05187754|OTHER|Mindfulness-based breathing therapy program|Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.
48713368|NCT01329614|BEHAVIORAL|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
48713369|NCT01329614|DRUG|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
48713370|NCT01329614|BEHAVIORAL|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
48713371|NCT01329614|BEHAVIORAL|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
48713372|NCT05863923|BEHAVIORAL|mHealth Messaging to Motivate Quitline use and Quitting among Persons Living With HIV (PLWH) in Vietnam (M2Q2-HIV)|Participants in the intervention group will be exposed to the texting intervention through a series of culturally tailored assessments and motivational text messages from the text messaging system sent throughout the 6 months of duration of the study.
48713373|NCT05863923|BEHAVIORAL|M2Q2-HIV Comparison|Participants in the comparison group will be exposed to a brief set of five texts with facts about smoking risks and assessment messages that are not culturally tailored from the text messaging system.
48713374|NCT05008484|DEVICE|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
48713375|NCT05008484|DRUG|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
48713376|NCT05008484|PROCEDURE|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
48713377|NCT05694910|OTHER|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
48713378|NCT03019978|OTHER|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
48713379|NCT04883528|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
48713380|NCT04883528|DRUG|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
48713381|NCT05289583|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
48713382|NCT04702906|OTHER|standard treatment|Standard treatment if indicated.
48713383|NCT04702906|DRUG|"trimetazidine hydrochloride metacardia ® 20 mg tablet"|"trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)"
48713384|NCT03701997|DEVICE|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
48713385|NCT05516030|OTHER|HIFT for people with MRD|12-wk, 3x/week HIFT participation for individuals with MRD
48713386|NCT06099106|DEVICE|SEPIOLA System|Implantation of the SEPIOLA device into the left atrial appendage.
48713387|NCT02262442|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
48713388|NCT02262442|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
48713389|NCT04014543|OTHER|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
48713390|NCT01898104|RADIATION|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
48713391|NCT01898104|DRUG|Valproic Acid|
48713392|NCT01898104|DRUG|Capecitabine|
48713393|NCT02110888|DEVICE|Subcutaneous peripheral nerve stimulation|
48713394|NCT02110888|OTHER|SCS Only|
48713395|NCT00066469|BIOLOGICAL|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
48713396|NCT00066469|DRUG|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
48713397|NCT00066469|DRUG|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
48713398|NCT00066469|DRUG|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
48713399|NCT03476876|COMBINATION_PRODUCT|Dermacell|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
48713400|NCT03476876|COMBINATION_PRODUCT|Integra|Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
48713401|NCT04609930|DRUG|Anti-PD-1 or anti-PD-L1|Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
48713402|NCT00183963|DRUG|Tamoxifen|20mg
48713403|NCT00183963|DRUG|Fulvestrant|250mg
48179325|NCT01991145|BIOLOGICAL|Erythropoietin alfa|
48179326|NCT01991145|OTHER|Rehabilitation|Active rehabilitation
48179327|NCT01991145|PROCEDURE|Placebo UCB|
48179328|NCT01991145|BIOLOGICAL|Placebo EPO|
48179329|NCT04457596|BIOLOGICAL|Trastuzumab Emtansine|Given IV
48179330|NCT04457596|DRUG|Placebo Administration|Given PO
48179331|NCT04457596|DRUG|Tucatinib|Given PO
48179332|NCT04457596|OTHER|Questionnaire Administration|Ancillary studies
48179333|NCT04457596|OTHER|Quality-of-Life Assessment|Ancillary studies
48179334|NCT01144390|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
48179335|NCT01144390|DRUG|methadone maintenance treatment|methadone maintenance treatment
48179336|NCT01190722|DRUG|etoricoxib|120 mg once daily for the 1st 6 postoperative days
48179337|NCT01190722|DRUG|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
48179338|NCT04231162|DIETARY_SUPPLEMENT|Active product|Bifidobacterium lactis HN019 (probiotic powder). One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
48179339|NCT04231162|DIETARY_SUPPLEMENT|Control product|Placebo. One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
48179340|NCT00673127|DRUG|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
48179341|NCT01339962|OTHER|Non-interventional|Non-interventional (retrospective chart reviews)
48179342|NCT05432284|DRUG|Placebo|Placebo (ambient air)
48179343|NCT05432284|DRUG|THC|Pure THC vapor
48179344|NCT05432284|DRUG|Beta-Myrcene|Pure beta-myrcene vapor
48179345|NCT01512550|PROCEDURE|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
48179346|NCT01512550|PROCEDURE|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
48713404|NCT00183963|DRUG|Fulvestrant|500 mg IM
48713405|NCT04557475|DRUG|Aspirin|Two tablets daily with dinner
48713406|NCT01544413|PROCEDURE|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
48179347|NCT01512550|DEVICE|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
48179348|NCT03139305|DRUG|Glucagon|Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
48179349|NCT03139305|DRUG|Glucagon|High dose intravenous infusion for 72 hours at 25 ng/kg/min
48713407|NCT05920044|OTHER|balance and proprioception training program.|"The program will include exercises focused on improving ankle stability and joint position sense, such as single-leg stance, wobble board, and resistance band exercises.~Participants will attend two supervised sessions per week and perform home-based exercises 3-4 times per week.~Progression of exercises will be individualized based on participant performance and tolerance."
48713408|NCT05920044|OTHER|Usual care|"Participants will continue their usual care, including general strength and flexibility exercises.~No specific balance and proprioception training will be provided."
48179350|NCT03139305|DRUG|Placebo|Intravenous infusion of saline for 72 hours
48713409|NCT01592617|DRUG|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
48713410|NCT05484817|DIAGNOSTIC_TEST|Assessment of cardiovascular risk factor, endocrine hormones and related biomarker|Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
48713411|NCT05767580|OTHER|evaluation|The Timed Get Up and Go test to assess dual-tasking, the 4m Walk Test to assess gait, and the Footprint Method to assess cadence
48713412|NCT03824405|DRUG|BTX 1204|BTX 1204 liquid formulation
48713413|NCT03824405|DRUG|Vehicle|Vehicle liquid formulation
48713414|NCT00642369|DRUG|quetiapine fumarate|600-750mg/day
48379537|NCT06308523|DRUG|Placebo 150 μg|Placebo Tablet 150 μg QD
48713415|NCT00642369|DRUG|haloperidol|6-40mg/day
48713416|NCT00174174|DRUG|Modafinil|
48713417|NCT00823745|DRUG|[14C]-PF-00868554|solution, single dose
48713418|NCT04333056|OTHER|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
48713419|NCT02194920|PROCEDURE|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
48021793|NCT02277626|DEVICE|Electro Flo 5000|Airway clearance device
48179351|NCT04472845|RADIATION|1 week RT|RT will be delivered over 1 week
48179352|NCT04472845|RADIATION|2 week RT|RT will be delivered over 2 week
48179353|NCT05172986|BEHAVIORAL|Follow-up patient program|An additional paramedical visit will be carried out before the surgery. The interview is carried out by the healthcare team. An organization within the service has been set up so that a nurse can be totally seconded for the RAAC mission. The consultation lasts 30 to 45 minutes.
48179354|NCT05768399|DIAGNOSTIC_TEST|The level of biomarkers in Peripheral blood|All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.
48379538|NCT06308523|DRUG|AP303 300 μg|AP303 Tablet 300 μg QD
48379539|NCT06308523|DRUG|Placebo 300 μg|Placebo Tablet 300 μg QD
48379540|NCT05769348|DEVICE|HD-tDCS Active Protocol|non-invasive brain stimulation (active protocol)
48379541|NCT05769348|DEVICE|HD-tDCS Sham Protocol|non-invasive brain stimulation (sham protocol)
48379542|NCT02822729|DRUG|DE-117 ophthalmic solution|
48379543|NCT02822729|DRUG|Timolol ophthalmic solution|
48379544|NCT05821023|OTHER|messages|Different messages describing either the benefits of breast cancer screening aimed at supporting continued screening or messages describing the harms of over-screening and making recommendations to stop screening
48379545|NCT00398476|DRUG|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
48713420|NCT03209648|DRUG|Debio 1450|Debio 1450, 40 mg capsule.
48713421|NCT03209648|DRUG|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
48179355|NCT03200652|DIETARY_SUPPLEMENT|Metabolic availability of lysine in wheat|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
48713422|NCT01827813|PROCEDURE|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
48713423|NCT01827813|PROCEDURE|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
48713424|NCT01827813|PROCEDURE|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
48713425|NCT03692481|RADIATION|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
48713426|NCT00046163|DRUG|midodrine hydrochloride (ProAmatine®)|
48713427|NCT05563116|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
48179356|NCT01055236|DRUG|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
48179357|NCT01306006|BIOLOGICAL|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
48179358|NCT01335412|BIOLOGICAL|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
48179359|NCT06137612|DIAGNOSTIC_TEST|MRI|axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.
48179360|NCT00025506|OTHER|Laboratory Biomarker Analysis|Correlative studies
48379546|NCT00398476|DRUG|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
48713428|NCT00140699|BEHAVIORAL|Balance|
48713429|NCT03212417|OTHER|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
48713430|NCT04545437|OTHER|Admission to ICU|Exposure is admission to an Intensive Care Unit
48713431|NCT03243578|OTHER|None as this is an observational study|
48179361|NCT00025506|DRUG|Thalidomide|Given orally
48179362|NCT04911478|GENETIC|ADI-001|No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy
48179363|NCT03471364|DRUG|Ketoconazole|Applied topically
48179364|NCT03471364|OTHER|Laboratory Biomarker Analysis|Correlative studies
48179365|NCT03471364|OTHER|Placebo Administration|Applied topically
48179366|NCT03471364|OTHER|Quality-of-Life Assessment|Ancillary studies
48179367|NCT03471364|OTHER|Questionnaire Administration|Ancillary studies
48179368|NCT03956693|BEHAVIORAL|HEADS: UP|"HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories."
48713432|NCT00594542|DRUG|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
48179369|NCT03423368|DEVICE|Libramed|Policaptil Gel Retard
48179370|NCT03423368|DEVICE|Placebo|Placebo-comparator
48379547|NCT00313482|DRUG|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
48379548|NCT00313482|DRUG|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
48713433|NCT00300482|DRUG|ABT-335|135 mg, daily, 12 weeks
48713434|NCT00300482|DRUG|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
48021794|NCT02277626|DEVICE|Incourage Vest System|Airway Clearance Device
48021795|NCT02067013|DRUG|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
48379549|NCT00313482|DRUG|Prednisone|5 mg orally BID on Day 1 continuously
48379550|NCT00726440|DEVICE|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
48517971|NCT02773602|DRUG|Clonidine|2 μg/kg of clonidine in 1 ml saline
48517972|NCT02773602|DRUG|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
48713435|NCT00300482|DRUG|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
48179371|NCT05575817|BEHAVIORAL|Web Based Patient Tutorial on Prolonged Grief Disorder Therapy|"The patient tutorial will contain 9 modules, each designed to be used flexibly in conjunction with Prolonged Grief Disorder Therapy (PGDT) telehealth sessions with the therapist. Each module takes about 15-30 minutes to complete. The patient tutorial consists of information about grief and adaptation to loss, including a description of seven healing milestones that are the focus of PGDT and an explanation of prolonged grief and how to understand it. In addition, the tutorial has descriptions of the procedure, goals and rationale for a series of in-session therapeutic exercises to be undertaken with the therapist, as well as descriptions and encouragement to participate in interim therapeutic activities (i.e., homework) assigned by the therapist after each treatment session. The tutorial also contains a self-assessment component for each module that can be completed by the patient and shared with the therapist."
48179372|NCT06030960|DEVICE|Virtual Reality (VR)|Virtual Reality (VR) Stabilization Exercises
48713436|NCT02649855|BIOLOGICAL|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
48379551|NCT00726440|DEVICE|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
48379552|NCT00726440|DEVICE|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
48713437|NCT02649855|BIOLOGICAL|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
48713438|NCT02649855|DRUG|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
48713439|NCT03728491|DEVICE|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
48713440|NCT03728491|DEVICE|Healthy figurants|Medical students or volunteers without any pathology in thorax
48713441|NCT04688541|DEVICE|Optitip Catheter (LinC Medical)|The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.
48713442|NCT04688541|DEVICE|Foley catheter|Foley catheter
48713443|NCT05133869|DEVICE|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
48713444|NCT00431951|DRUG|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
48713445|NCT00431951|DRUG|Placebo|Capsules to match experimental drug
48713446|NCT00212186|DRUG|Selenium Supplements (essential nutrient)|
48713447|NCT00517439|DRUG|Copegus|1000/1200mg po daily for 24 weeks
48021796|NCT02067013|OTHER|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
48021797|NCT00124150|DRUG|Intravenous magnesium sulfate infusion|80mg per day
48179373|NCT06030960|OTHER|Regular Exercises|Regular Stabilization Exercises
48379553|NCT06045377|DIETARY_SUPPLEMENT|Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia|A prospective single center cohort study
48379554|NCT04366115|DRUG|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
48379555|NCT04366115|DRUG|Placebo|Single IV infusion in normal saline over 1 hour to patients.
48379556|NCT06651892|DRUG|Enema Phosphates Sodium|oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
48379557|NCT06651892|DRUG|Glycophos Injectable Product|intravenous sodium glycerophosphate as the standard of care or active control
48379558|NCT00657176|DRUG|OPB-31121|"* 100mg tablet~* oral administration, Qd"
48713448|NCT00517439|DRUG|Pegasys|180 micrograms sc weekly for 24 weeks
48713449|NCT00517439|DRUG|Pegasys|90 micrograms sc weekly for 24 weeks
48713450|NCT00517439|DRUG|RO4588161|1000mg po bid for 24 weeks
48713451|NCT00517439|DRUG|RO4588161|500mg po bid for 24 weeks
48713452|NCT00517439|DRUG|RO4588161|1500mg po bid for 24 weeks
48713453|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
48713454|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
48713455|NCT05579249|DRUG|Semaglutide|Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
48713456|NCT05579249|DRUG|Orlistat|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
48021798|NCT00809289|DRUG|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
48021799|NCT00809289|DRUG|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
48179374|NCT06030960|OTHER|patient instructions and education|a unified form of patient instructions and education in regards of LBP
48179375|NCT01972945|PROCEDURE|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
48179376|NCT01972945|PROCEDURE|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
48179377|NCT04088045|DEVICE|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
48179378|NCT00107523|DRUG|cytarabine|
48379559|NCT05867511|BEHAVIORAL|iPAL App|"The intervention will have a duration of eight weeks. It is theory-based, will be delivered to participants' smartphones via the study app (except components 5 and 6), and comprises the following components:~1. Theory-based individualized feedback.~2. Self-generated motivational messages.~3. Motivation for habit formation through push messages.~4. Motivational images and videos that participants handed in or selected will be sent to them through the app.~5. Study-specific social media groups. Participants will be offered the option to participate in study-specific social media groups.~6. Posting motivational stories. A story of a person, who successfully changed his or her lifestyle to be more physically active and/or less sedentary, will be posted once a week in the study-specific social media groups."
48379560|NCT06330467|DIAGNOSTIC_TEST|psychometric assessment|Psychometric testing to assess trauma and dissociative disorders, and in particular dissociative identity disorder.
48713457|NCT05579249|DRUG|Phentermine/Topiramate|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
48713458|NCT05579249|DRUG|Naltrexone/Bupropion|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
48713459|NCT05579249|DRUG|Liraglutide|Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
48713460|NCT01925911|DRUG|IPI-145|25 mg BID Oral Capsule
48021800|NCT00809289|DRUG|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
48021801|NCT04555746|BEHAVIORAL|Physical activity|Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
48179379|NCT00107523|DRUG|idarubicin|
48179380|NCT00107523|DRUG|pravastatin|
48179381|NCT06371469|BEHAVIORAL|PHeBAC|Multi-interventions to health behaviour against cancer in mothers of Intellectual Disabled Children
48179382|NCT06371469|BEHAVIORAL|Control Group|Providing brochures from the Ministry of Health, answering questions and providing the researcher's phone number
48179383|NCT01630005|BEHAVIORAL|talk therapy|Psychotherapy
48179384|NCT02361398|OTHER|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
48179385|NCT04731350|DEVICE|radial extracorporeal shock wave|Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
48179386|NCT04731350|DEVICE|iontophoresis|Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
48179387|NCT04731350|OTHER|Exercise|strengthening exercise
48379561|NCT06330467|DIAGNOSTIC_TEST|semi-structured clinical interview|Semi-structured interview for the assessment of dissociative disorders (SCID-D : Semi-structured Clinical Interview for diagnosing DSM-5 and ICD-11 Dissociative Disorders)
48379562|NCT00004454|GENETIC|lymphocyte gene therapy|
48379563|NCT04379232|BIOLOGICAL|Screening test for covid ( RT PCR and CT Chest)|Each patient was screened before surgery with RT PCR and CT Chest. Post operatively, if symptoms, patients are tested with RT PCR and CT Chest
48713461|NCT01925911|DRUG|Midazolam|2 mg midazolam syrup
48713462|NCT01459991|OTHER|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
48713463|NCT01459991|OTHER|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
48713464|NCT03875807|PROCEDURE|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
48713465|NCT03875807|PROCEDURE|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
48713466|NCT02892721|OTHER|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
48713467|NCT06046469|DIAGNOSTIC_TEST|CT with contrast|CT abdomen and pelvis with IV contrast
48713468|NCT06046469|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis with contrast
48713469|NCT06046469|PROCEDURE|TURBT|transurethral resection of bladder tumor
48713470|NCT06484010|OTHER|SNAPPS Model of case presentation|"The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified."
48713471|NCT06395402|DRUG|Lutetium Lu 177 dotatate therapy|LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
48021802|NCT05024812|DRUG|fruquintinib＋toripalimab + SOX|phase Ib: fruquintinib (dose finding): L1: 3 mg/d，L2: 4 mg/d，L3: 5 mg/d, qd po, D1-14, Q3W toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W. phase II: fruquintinib: RP2D toripalimab: 240mg, I.V., D1, Q3W; S-1: 40-60mg bid, D1-14, Q3W; Oxaliplatin: 130mg/m\^2, ivgtt 2h, D1,Q3W.
48713472|NCT03234439|BEHAVIORAL|myStrength|myStrength is a digital self-care behavioral and wellness platform
48713473|NCT00996801|DRUG|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
48713474|NCT00996801|DRUG|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
48713475|NCT00996801|DRUG|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
48713476|NCT00996801|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
48713477|NCT00996801|DRUG|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
48713478|NCT00996801|DRUG|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
48713479|NCT03812185|DEVICE|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
48713480|NCT00627536|DRUG|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
48713481|NCT00627536|DRUG|Placebo|Matched to avotermin dosage strength
48713482|NCT06456125|DEVICE|amber SEL-P Peripheral Liquid Embolic System|Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.
48021803|NCT03526523|BEHAVIORAL|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
48021804|NCT01175655|OTHER|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
48021805|NCT04175262|DRUG|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
48021806|NCT05086458|DIETARY_SUPPLEMENT|probiotics|probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
48713483|NCT03854292|PROCEDURE|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
48713484|NCT01041300|DEVICE|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
48713485|NCT01041300|DEVICE|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
48021807|NCT06573489|DRUG|Fospropofol|Use fospropofol for general anesthesia maintenance
48021808|NCT06573489|DRUG|Propofol|Use propofol for general anesthesia maintenance
48517973|NCT06568510|PROCEDURE|Continuous peripheral nerve block|A perineurial catheter is placed to a nerve structure through a Touchy needle
48179388|NCT04715022|DRUG|Ascorbic acid solution (American Regent Laboratories Inc.)|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
48179389|NCT04715022|DRUG|Saline|Placebo (saline) will be administered
48179390|NCT06333977|DRUG|LC542019|oral dose, once daily
48179391|NCT06333977|DRUG|Placebo|matching placebo
48179392|NCT04865692|OTHER|BFRT|Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
48179393|NCT04865692|OTHER|Routine Physical Therapy|knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
48179394|NCT05550571|DEVICE|Nautilus Intrasaccular Bridging System|Patients will be treated with the Nautilus, then followed-up for 12 months
48179395|NCT02339545|DEVICE|Coronary Orbital Atherectomy plus Stenting|
48179396|NCT05057247|DRUG|Duvelisib|"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."
48179397|NCT05057247|DRUG|Docetaxel|Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
48179398|NCT02121912|DEVICE|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
48179399|NCT02121912|DEVICE|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
48713486|NCT05819073|OTHER|Plain water|Subjects will use plain water as an oral rinse twice a day for 3 days.
48713487|NCT05819073|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
48713488|NCT02111655|DEVICE|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
48179400|NCT03316807|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
48179401|NCT03316807|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
48179402|NCT01228877|OTHER|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
48179403|NCT00594698|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
48179404|NCT03231969|DRUG|Bilastine 0.2%|1 drop in each eye at 3 separate times during a 25 day period.
48179405|NCT03231969|DRUG|Bilastine 0.4%|1 drop in each eye at 3 separate times during a 25 day period.
48179406|NCT03231969|DRUG|Bilastine 0.6%|1 drop in each eye at 3 separate times during a 25 day period.
48179407|NCT03231969|DRUG|Bilastine 0%|1 drop in each eye at 3 separate times during a 25 day period.
48179408|NCT00003072|DRUG|amifostine trihydrate|
48179409|NCT00003072|DRUG|carboplatin|
48179410|NCT00003072|DRUG|paclitaxel|
48379564|NCT05580432|BEHAVIORAL|Parenting with Positive Behavior Interventions|"Parenting with Positive Behavior Interventions is a 5 month packaged intervention. The curriculum and each element of the training and coaching program is described in detail below.~Each month, participants will participate in the following five activities:~1. Didactic Training: Participants will view a presentation~2. Workbook/Homework: Participants will complete a guided worksheet~3. Coaching Meeting - Planning: Participants will meet with a coach who is an expert in autism and behavior~4. Coaching - Observation/ Feedback: The coach will observe parent implementing the strategy, then provide feedback and direction regarding use of technique~5. Virtual Parent Community of Support Meeting: Attend parent led community support meeting to network, share experiences and information, and exchange ideas"
48379565|NCT05425550|DEVICE|medidux™ app|Use of the regular medidux™ application for 12 (maximum 16) weeks
48713489|NCT02111655|PROCEDURE|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
48713490|NCT02111655|PROCEDURE|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
48713491|NCT02111655|PROCEDURE|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
48713492|NCT02111655|PROCEDURE|urea method|Quarterly recirculation with urea method.
48713493|NCT02419131|BEHAVIORAL|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
48713494|NCT02419131|BEHAVIORAL|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
48713495|NCT02419131|BEHAVIORAL|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
48713496|NCT02161276|DRUG|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
48713497|NCT02161276|DRUG|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
48379566|NCT00066586|DRUG|exemestane|exemestane 25 mg once daily x 1 year
48021809|NCT06534294|OTHER|reflexology|Reflex therapy was done for each patient for 30 minutes, first for the right foot and then for the left foot (15 minutes each) and breathing exercises in 3 stages
48021810|NCT06534294|OTHER|breathing exercise|breathing exercise done as 3 stages,stage one for 5 minutes, stage two for 10 minutes end stage ; Close eyes and focus your present feelings, Then Relax the whole body for 5 minutes.
48021811|NCT06534294|OTHER|standard care|standard medical care no other treatment
48021812|NCT06304740|DRUG|IMG-007|Subcutaneous injection of IMG-007
48021813|NCT06304740|DRUG|Placebo|Subcutaneous Injection of Placebo
48021814|NCT02319239|RADIATION|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
48021815|NCT02319239|RADIATION|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
48021816|NCT02319239|RADIATION|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
48021817|NCT01623440|COMBINATION_PRODUCT|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
48517974|NCT00546663|DRUG|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
48021818|NCT01623440|COMBINATION_PRODUCT|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
48021819|NCT03727893|BEHAVIORAL|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
48021820|NCT03727893|BEHAVIORAL|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
48021821|NCT05580900|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment.
48021822|NCT05580900|OTHER|Live Modality (control)|For this evaluation, the live or in-person modality is considered the control group.
48021823|NCT05708079|PROCEDURE|Endovascular thrombectomy|An endovascular thrombectomy is the removal of a thrombus (blood clot) under image guidance. A thrombectomy is most commonly performed for an arterial embolism, which is an arterial blockage often caused by atrial fibrillation, a heart rhythm disorder.
48179411|NCT03170843|DEVICE|use of plastic ring wound retractor|the experimental arm will use the plastic ring wound retractor for wound protection.
48179412|NCT02980523|DRUG|PRO-157|PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
48179413|NCT02980523|DRUG|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
48179414|NCT02980523|DRUG|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
48179415|NCT02980523|DRUG|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
48179416|NCT01382498|DRUG|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
48179417|NCT01382498|DRUG|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
48179418|NCT00079339|RADIATION|radiation therapy|Undergo radiotherapy
48021824|NCT06428201|DIAGNOSTIC_TEST|Control Group|The control group receives standard care, which includes routine medical management and general physical rehabilitation exercises. This involves regular consultations with healthcare providers and exercises aimed at maintaining mobility and physical function. The control group also follows a schedule of three 45-minute sessions per week for 12 weeks, ensuring a consistent comparison with the experimental group.
48179419|NCT00079339|DRUG|tipifarnib|Given orally
48179420|NCT03253432|OTHER|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
48179421|NCT02024659|DRUG|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
48179422|NCT02024659|OTHER|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
48179423|NCT06198699|DIETARY_SUPPLEMENT|Jing Si Herbal Tea|Consuming Jing Si Herbal Tea for three months; twice per day with each time 14 g of Jing Si Herbal in 600 ml water
48379567|NCT00066586|DRUG|Placebo|placebo once daily x 1 year
48517975|NCT00799058|DRUG|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
48179424|NCT06198699|DIETARY_SUPPLEMENT|Barley Tea|Consuming Barley Tea for three months; twice per day with each time 600 ml barley tea consumption
48179425|NCT04682132|DIAGNOSTIC_TEST|COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.
48713498|NCT04076345|DIAGNOSTIC_TEST|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
48179426|NCT04415645|DRUG|[14C]-VVZ-149|A single IV infusion of radio-labeled VVZ-149
48179427|NCT04817605|OTHER|Therapeutic Exercise|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
48713499|NCT04656106|DRUG|Ryzodeg®|All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.
48713500|NCT00221624|DRUG|Peginterferon alfa-2a|
48713501|NCT00221624|DRUG|ribavirin|
48713502|NCT00221624|DRUG|amantadine|
48021825|NCT06428201|COMBINATION_PRODUCT|Experimental Group|The experimental intervention involves tele-rehabilitation-based task-specific training to enhance cognitive functions in multiple sclerosis (MS) patients. This program includes cognitive exercises targeting memory, attention, executive function, and processing speed, conducted remotely via a tele-rehabilitation platform. Patients participate in three 45-minute sessions per week for 12 weeks. Each session is guided by a trained therapist, ensuring personalized support and real-time feedback.
48021826|NCT01423513|OTHER|Fibular Taping|Tape with be applied with tension.
48179428|NCT00705601|PROCEDURE|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
48379568|NCT06095089|DRUG|JNJ-78278343|JNJ-78278343 will be administered.
48379569|NCT06095089|DRUG|JNJ-87189401|JNJ-87189401 will be administered.
48379570|NCT00803582|PROCEDURE|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
48021827|NCT01423513|OTHER|Sham Taping|Tape will be applied without tension
48021828|NCT03474159|DEVICE|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
48021829|NCT03474159|DEVICE|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
48021830|NCT03474159|DEVICE|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
48021831|NCT00865527|OTHER|Fecal occult blood test|FOBT
48021832|NCT00865527|PROCEDURE|Virtual colonoscopy|computed tomographic colonography
48021833|NCT00865527|PROCEDURE|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
48021834|NCT05296616|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|Mindfulness Based Stress Reduction intervention is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 90 minute sessions, once per week for eight weeks.
48021835|NCT06486545|DRUG|Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)|"Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first)."
48021836|NCT01587183|BEHAVIORAL|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
48179429|NCT02602483|DRUG|Ibuprofen|
48379571|NCT00803582|PROCEDURE|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
48379572|NCT01412411|BEHAVIORAL|Nutritionl Education|to assess the change in behaviour
48379573|NCT01412411|DIETARY_SUPPLEMENT|Oral Iron Supplementation along with Nturition Eductaion|
48713503|NCT03147313|DEVICE|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
48713504|NCT03147313|DEVICE|Sham|Extracorporeal shock wave treatment will be faked.
48713505|NCT01414205|DRUG|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
48713506|NCT01414205|DRUG|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
48713507|NCT01988545|OTHER|1,5 nmol/kg,GLP-1 sc injection|
48713508|NCT01988545|OTHER|1,5 nmol/kg GLP-1 9-36amide, sc injection|
48713509|NCT01988545|OTHER|Exendin-4 ;10 ug,sc injection|
48713510|NCT01988545|OTHER|saline|
48713511|NCT04677426|DRUG|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
48179430|NCT02602483|DRUG|Magnesium|
48179431|NCT02602483|DRUG|Ascorbic Acid|
48179432|NCT02602483|DRUG|Placebo|
48379574|NCT01412411|DIETARY_SUPPLEMENT|Multiple micronutrient fortification plus Nutrition Education|
48379575|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
48379576|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
48379577|NCT05893524|DIAGNOSTIC_TEST|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
48379578|NCT02863874|DEVICE|VicrylPlus®|Suture
48379579|NCT02863874|DEVICE|Vicryl®|Suture
48379580|NCT04125082|DRUG|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
48379581|NCT03122327|OTHER|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
48379582|NCT05260528|DRUG|Cytarabine and Idarubicin|"Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3"
48379583|NCT05260528|DRUG|CPX-315|"Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3"
48713512|NCT02775331|OTHER|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
48713513|NCT02775331|OTHER|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
48021837|NCT01587183|BEHAVIORAL|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
48021838|NCT01587183|BEHAVIORAL|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
48021839|NCT06123039|DIAGNOSTIC_TEST|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
48021840|NCT06123039|PROCEDURE|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
48021841|NCT02490813|DIETARY_SUPPLEMENT|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
48021842|NCT02490813|DIETARY_SUPPLEMENT|Placebo|Placebo will be starch with colorings
48021843|NCT02239458|DRUG|Saxagliptin|
48021844|NCT03775005|RADIATION|standard treatment|3000 cGy in 10 daily fractions
48021845|NCT03775005|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
48021846|NCT05787769|DRUG|P shot arm ( Autologous Platelet Rich Plasma)|Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
48021847|NCT05787769|DRUG|PDE5i arm|Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
48021848|NCT03370341|DEVICE|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
48021849|NCT03370341|DEVICE|sham tDCS|sham tDCS with behavioral tasks to assess IA
48021850|NCT05720832|OTHER|WINGS-IP1 Smartphone Application|"The technology-based SSIP (WINGS) offers disease-related information and builds up social inner circles between patients, their friends, and family members while facilitating to organize, perform, and enjoy activities and content."
48021851|NCT00750945|OTHER|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
48021852|NCT00750945|OTHER|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
48021853|NCT00750945|OTHER|Home program|Home walking program 6 days/wk x 4 weeks
48179433|NCT00872001|DRUG|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
48379584|NCT06653582|OTHER|Postural reeducation|The program will include postural awareness, stretching, McKenzie's method, and manual therapy for 12 weeks.
48379585|NCT06653582|OTHER|Pelvic floor exercises|The program will include pelvic floor exercises for 12 weeks. Three sets of 10 long contractions will be performed, each sustained for 6-8 seconds, three times a day. After each contraction, participants will be asked to rest for the same period. Two series of 10 fast contractions will be recommended, consisting of short, quick exercises of 1- to 2-second contractions, followed by long, sustained exercises lasting 5-10 seconds.
48379586|NCT03309072|DEVICE|tDCS|active tDCS
48379587|NCT03309072|DEVICE|sham tDCS|sham tDCS
48379588|NCT04595825|BIOLOGICAL|Anti-human CCL24 monoclonal antibody (CM-101)|Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
48379589|NCT04595825|OTHER|Placebo|Placebo - intravenous infusion
48021854|NCT05916755|DIAGNOSTIC_TEST|Whole Genome Sequencing|Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.
48021855|NCT05916755|DIAGNOSTIC_TEST|RNA-Sequencing|RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).
48021856|NCT05916755|DIAGNOSTIC_TEST|Microbiome analysis|Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.
48379590|NCT04387812|DEVICE|Xtrodes home PSG system|Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
48379591|NCT02344212|BEHAVIORAL|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
48379592|NCT05284227|OTHER|Electronic Clinical Decision Support Application|Preoperative anaesthesiological assessment and risk evaluation using a clinical decision support application, that calculates perioperative risks for the patient and informs the anaesthesiologist on indicated diagnostics and procedures according to clinical guidelines in real-time.
48021857|NCT05916755|DIAGNOSTIC_TEST|ctDNA analysis|ctDNA analysis will be performed in plasma before and during NACT.
48021858|NCT05916755|DIAGNOSTIC_TEST|TCR-β repertoire sequencing|TCR-β repertoire sequencing will be performed in plasma before and during NACT.
48021859|NCT05916755|DIAGNOSTIC_TEST|PBMCs phenotyping|PBMCs phenotyping will be performed in plasma before and during NACT.
48379593|NCT05284227|OTHER|Standard procedures of the hospital and Sham Clinical Decision Support Application|Preoperative anaesthesiological assessment using standard procedures of the hospital. In addition a sham clinical decision support application will be used. Information on perioperative risks and indicated diagnostic procedures according to clinical guidelines is not given to the physician.
48379594|NCT01584050|DIETARY_SUPPLEMENT|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
48379595|NCT01584050|DIETARY_SUPPLEMENT|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
48379596|NCT01584050|DIETARY_SUPPLEMENT|Placebo|frequency: once daily, duration: 12 weeks
48379597|NCT04281030|BEHAVIORAL|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
48379598|NCT04281030|BEHAVIORAL|Monitored Usual Care (MUC)|Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
48379599|NCT05820880|DRUG|Fixed [Per/Ind/Aml]|Fixed Dose combination of Perindopril/Indapamide/Amlodipine
48379600|NCT05820880|DRUG|Free [Per/Ind + Aml]|Free dose combination of Perindopril/Indapamide and Amlodipine
48379601|NCT00721513|BIOLOGICAL|cetuximab|
48379602|NCT00721513|DRUG|cisplatin|
48021860|NCT05916755|DRUG|Pembrolizumab|Pembrolizumab will be given in combination with standard NACT.
48021861|NCT05916755|DRUG|Chemotherapy|Standard NACT will be given.
48379603|NCT00721513|DRUG|docetaxel|
48379604|NCT00721513|DRUG|fluorouracil|
48379605|NCT00721513|PROCEDURE|computed tomography|
48379606|NCT00721513|PROCEDURE|positron emission tomography|
48379607|NCT00721513|PROCEDURE|quality-of-life assessment|
48379608|NCT00721513|RADIATION|3-dimensional conformal radiation therapy|
48379609|NCT00721513|RADIATION|intensity-modulated radiation therapy|
48379610|NCT03504839|DEVICE|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
48021862|NCT01383941|DRUG|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
48021863|NCT01034917|DRUG|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
48021864|NCT01034917|DRUG|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
48021865|NCT05946668|PROCEDURE|Biospecimen Collection|Undergo vaginal specimen self-collection via vaginal swab collection kit
48021866|NCT05946668|OTHER|Electronic Health Record Review|Medical records reviewed
48379611|NCT02702375|OTHER|Fructose-containing Sugars|
48379612|NCT03066011|DRUG|Isavuconazonium sulfate|Oral and Intravenous
48379613|NCT03066011|DRUG|Voriconazole|Oral and Intravenous
48379614|NCT03066011|DRUG|Posaconazole|Oral and intravenous
48379615|NCT03586427|DRUG|AGN-241751|AGN-241751 administered orally as a single tablet
48379616|NCT03586427|DRUG|Placebo|Placebo administered orally as a single tablet
48379617|NCT04435431|DRUG|Mesdopetam|Oral use
48021867|NCT05946668|OTHER|Questionnaire Administration|Complete questionnaires
48021868|NCT03653429|DRUG|Tranexamic Acid|administered prior to surgical incision
48179434|NCT00872001|DRUG|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
48179435|NCT00723125|DRUG|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
48179436|NCT00723125|DRUG|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
48179437|NCT00723125|DRUG|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
48179438|NCT00406900|PROCEDURE|Treatment of metastatic disease|
48179439|NCT05801445|BEHAVIORAL|Occupation-based activity|Painting large-scale canvas
48179440|NCT05801445|BEHAVIORAL|Body-Weight Exercise|Body-weight exercises designed for older adults
48179441|NCT06385106|DEVICE|Real repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session.
48179442|NCT06385106|DEVICE|Sham repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session. The patients were applied with the coil angled away from the head to reproduce the noise of the stimulation as well as some local sensation
48179443|NCT02270307|DRUG|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
48179444|NCT02270307|BIOLOGICAL|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
48179445|NCT06499389|PROCEDURE|Systematic and early intensive instrumental respiratory physiotherapy for patients undergoing difficult ventilatory weaning|Patients randomized to this group will receive 3 sessions per day of intensive early respiratory physiotherapy with instrumental techniques from randomization to day 7, before and after any extubation. The strategy will be applied until day 7 of randomization, regardless of the patient's status (intubated or not).
48379618|NCT04435431|DRUG|Placebo|Oral use
48379619|NCT05026424|OTHER|Balance oral nutritional drink - control|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.
48379620|NCT05026424|OTHER|Balance oral nutritional drink - test|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
48021869|NCT03653429|DRUG|Normal saline|administered prior to surgical incision
48379621|NCT01441622|DEVICE|AL539 (SRETT)|recording data with AL539 (SRETT)
48379622|NCT04756466|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
48517976|NCT00799058|DRUG|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
48517977|NCT00799058|DRUG|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
48517978|NCT03475992|DEVICE|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
48517979|NCT02281422|DRUG|BIA 2-093|
48021870|NCT05343312|DRUG|AL (Coartem)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
48179446|NCT06499389|PROCEDURE|Protocolized standard-of-care respiratory physiotherapy|Patients in this group will receive standardized and protocolized respiratory physiotherapy to reproduce the usual practices of non-expert centers,1 to 2 sessions of manual respiratory physiotherapy (not assisted by an instrumental technique) per day until the day of successful extubation, or until day 7 if necessary
48517980|NCT03252067|DRUG|azithromycin eyedrop|Tear samples will be collected using the strips.
48179447|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
48179448|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
48179449|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
48179450|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
48379623|NCT04756466|DIETARY_SUPPLEMENT|Lactobacillus|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
48517981|NCT03635476|OTHER|Qualitative interview study|The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.
48517982|NCT02904863|BIOLOGICAL|Extra blood draw samples|
48517983|NCT03182426|DRUG|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
48517984|NCT03182426|DRUG|Alemtuzumab|T-cell depletion
48517985|NCT03182426|DRUG|Anakinra|Anti-inflammatory
48517986|NCT03182426|DRUG|Etanercept|Anti-inflammatory
48517987|NCT03182426|DRUG|Liraglutide|Beta-cell regeneration
48517988|NCT04714073|DRUG|BI 706321|BI 706321
48517989|NCT04714073|DRUG|Itraconazole|Itraconazole
48379624|NCT05252507|BEHAVIORAL|Paint Night|There will be 8 Sessions (4 paint nights and 4 educational sessions alternating weeks). For the painting sessions, participants will paint for 45 minutes and then participate in a combined presentation/discussion session (45 minutes). For the educational sessions, they will attend a 30-minute presentation presented by a researcher on heart health and then have the opportunity to discuss with the researcher and other members of the group (60 minutes).
48379625|NCT04532827|BEHAVIORAL|Case formulation with web-program|"The first meeting includes an interview to establish understanding on the participant´s symptomatology and current life situation, a case formulation (CF) will be build based on it. The CF is presented in the second session and modifications can be made to ensure acceptability for the participant. Goals for web program (WB) are set based on the CF and understanding of the factors contributing to the participant´s wellbeing.~WB modules are instructed to complete during the week. Modules include psychoeducation, experiential exercises and training aimed at improving wellbeing and psychological flexibility. Web-therapist will offer written feedback. The participants can contact the therapist via the WB and al messages will be replied within one week. Automatic reminders will be sent if a participant has not been active in the WB, the therapists will call participants who have discontinued using the WB."
48379626|NCT02778269|DEVICE|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
48379627|NCT02778269|DEVICE|Dexcom G4-System|Continuous Glucose Monitoring
48379628|NCT03542825|DRUG|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
48379629|NCT03542825|DRUG|Iron Supplement|Iron Sulphate 150 mg once daily
48379630|NCT03542825|DRUG|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
48379631|NCT02736669|BEHAVIORAL|Energy Reduction|
48379632|NCT03890133|BEHAVIORAL|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
48379633|NCT03890133|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
48379634|NCT00135811|DRUG|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
48379635|NCT00135811|DRUG|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
48379636|NCT05552898|DIETARY_SUPPLEMENT|Sleep Study Product Usage|Participants will use their Radicle Sleep study product as directed for a period of 4 weeks.
48379637|NCT01042288|DRUG|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
48379638|NCT01042288|DRUG|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
48179451|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
48517990|NCT06306261|OTHER|questionnaire|UC patients will be subjected to a questionnaire each month about their habits.
48713514|NCT04092192|DEVICE|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
48179452|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
48179453|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
48179454|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
48713515|NCT05786339|DRUG|Tested Irbesartan Tablet|T
48713516|NCT05786339|DRUG|Reference Irbesartan Tablet|R
48713517|NCT03512431|DIAGNOSTIC_TEST|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
48179455|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
48713518|NCT02085525|OTHER|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
48713519|NCT00872378|DRUG|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
48713520|NCT00872378|DRUG|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
48713521|NCT03276052|DRUG|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
48713522|NCT04606433|DRUG|GNC-038|Administration by intravenous infusion.
48713523|NCT05562349|DRUG|Clavulanic Acid Only Product|Drug will be given in 250mg capsules
48179456|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
48179457|NCT01310699|DEVICE|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
48179458|NCT00160550|DRUG|Levetiracetam|
48179459|NCT03617289|DRUG|Magnesium Sulfate|
48713524|NCT05562349|DRUG|Placebo|Capsule with no active medication - identical to drug capsule
48713525|NCT00247442|BEHAVIORAL|Decision aid|
48021871|NCT05343312|DRUG|AS-AQ (Carsucam)|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, and 28 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
48379639|NCT01042288|DRUG|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
48379640|NCT05292248|BEHAVIORAL|Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving|Multicomponent psychoeducational intervention focused on financial wellbeing
48713526|NCT06115694|DEVICE|TCI Articulating Introducer|use
48713527|NCT06115694|DEVICE|GlideRite® Rigid Stylet|use
48179460|NCT03617289|DRUG|D5W|
48179461|NCT00718471|DRUG|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
48179462|NCT00718471|DRUG|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
48179463|NCT04703400|OTHER|anonymous survey|anonymous survey with 25 mandatory questions
48517991|NCT05694689|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
48517992|NCT05694689|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/ day are provided as part of usual care. At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
48713528|NCT00363727|DRUG|ropinirole controlled-release (REQUIP CR) for RLS|
48713529|NCT03758313|OTHER|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
48179464|NCT04058470|DRUG|Toripalimab, Rituximab|Toripalimab in combination with Rituximab will be administered every 3 weeks up to 4 cycles.
48179465|NCT04058470|DRUG|R-CHOP Protocol|After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
48179466|NCT01388062|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
48379641|NCT04375566|OTHER|Patient Decision Aid|More than 20 IT specialists, 15 doctors and 15 patients
48379642|NCT01301248|OTHER|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
48379643|NCT01301248|OTHER|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
48713530|NCT00900185|GENETIC|mutation analysis|
48713531|NCT00900185|GENETIC|polymerase chain reaction|
48713532|NCT00900185|GENETIC|polymorphism analysis|
48713533|NCT01651832|BEHAVIORAL|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
48713534|NCT05148416|RADIATION|High intensity laser treatment|20 patients received high power laser therapy . Zimmer High power laser applied by laser probe perpendicular to and in slight contact with the skin around knee joint , the total energy was delivered to the patient during one session was 1060 j in 3 phases of treatment.
48713535|NCT05148416|DEVICE|sham HILT.|"20 patients received placebo laser  sham laser . The same treatment protocol of HILT was given to the sham group, but the laser instrument was switched off during applications. All laser applications were performed by the same physiotherapist."
48379644|NCT03160092|OTHER|Intervention|"The intervention aims to:~* Support the participant to explore their unusual experiences~* Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~  * Helping them to recognise how common these unusual experience~ * Supporting them to make sense of their unusual experiences~ * Supporting them to understand why they may be experiencing these symptoms~ * Challenging any unhelpful beliefs they hold about their symptoms~* Help the participant to recognise the triggers to their unusual experiences~* Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
48379645|NCT01568255|DRUG|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
48379646|NCT01568255|DRUG|Placebo|placebo at 50,000IU for 8 weeks
48379647|NCT05774080|OTHER|Observational|Observational
48379648|NCT00323362|DRUG|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
48379649|NCT00323362|DRUG|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
48379650|NCT04681001|DEVICE|nasal spray|application of nasal spray into nostrils and mouth
48379651|NCT02378870|DRUG|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
48379652|NCT02378870|DRUG|Placebo|
48379653|NCT02647632|DRUG|Grazoprevir/Elbasvir|
48379654|NCT02647632|DRUG|Sofosbuvir|
48379655|NCT02647632|DRUG|Ribavirin|
48379656|NCT00833391|DRUG|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
48379657|NCT00453336|DRUG|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
48713536|NCT05148416|OTHER|knee osteoarthritis conventional exercises program|"knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
48713537|NCT05250050|DRUG|Esomeprazole|20mg bid
48713538|NCT05250050|DRUG|Bismuth potassium citrate|0.6g bid
48713539|NCT05250050|DRUG|Metronidazole|0.4g qid
48713540|NCT05250050|DRUG|Clarithromycin|0.5g bid
48713541|NCT05250050|DRUG|Levofloxacin|0.5g qd
48713542|NCT05250050|DRUG|Amoxicillin|1g bid
48379658|NCT00453336|PROCEDURE|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
48379659|NCT06507059|DRUG|cabotegravir/rilpivirine (600mg/ 900mg)|Immediate switch from oral antiretroviral to long-acting injectables
48379660|NCT06507059|DRUG|Antiretroviral Combinations|Standard all-oral antiretroviral combinations
48379661|NCT04299126|DEVICE|high absorption pad for blood and pus|High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
48379662|NCT04299126|DEVICE|commercial wound dressing|Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
48379663|NCT03300804|DRUG|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
48379664|NCT03300804|DRUG|Placebo|Placebo herb formulation
48379665|NCT06037148|BIOLOGICAL|DM-101PX|subcutaneous injection of DM-101PX
48713543|NCT05250050|DRUG|Tetracycline|0.5g qid
48713544|NCT04623515|OTHER|REDCap Questionnaires|Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
48713545|NCT00235391|DRUG|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
48179467|NCT00750451|DRUG|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
48179468|NCT00750451|DRUG|crinone 8% gel|routine luteal phase support with progesterone gel
48379666|NCT06037148|BIOLOGICAL|Placebo to Match DM-101PX|Placebo to match DM-101PX administered subcutaneously
48379667|NCT00552422|DRUG|domperidone|10mg orally four times per day
48379668|NCT05278624|DRUG|Roflumilast Cream|Topical Cream
48379669|NCT04901182|DIAGNOSTIC_TEST|the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)|the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
48379670|NCT03384576|OTHER|Music intervention|Classical music to be played in the Emergency waiting room
48379671|NCT03384576|OTHER|No music|No music played in emergency waiting room
48379672|NCT02048527|OTHER|Global|Single medium for the culture of embryos from Day1 to Day 5
48379673|NCT02048527|OTHER|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
48379674|NCT02823782|OTHER|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
48379675|NCT02823782|OTHER|neuropsychological assessment|
48379676|NCT04926857|OTHER|Non-Interventional|Non-Interventional
48379677|NCT02364882|DRUG|Sildenafil|
48379678|NCT06539611|OTHER|Observational|This study is observationnal: Questionnaires to assess the endpoint
48379679|NCT05970848|DEVICE|Washing Pipe With a Spray Nozzle|Administration of topical airway anesthesia via a washing pipe with a spray nozzle using the spray-as-you-go technique
48379680|NCT05252169|OTHER|Proprioceptive training|"Proprioceptive Training will include some active exercises such as stair climbing up and down,one leg standing,Walking heel to toes,rising from a standard chair.~And swiss ball training will be applied passively by therapist in which child will sit on the ball and ball will be rolled from side to side,Extension rotation and flexion rotation will be performed to facilitate trunk rotation,Trunk rotation will be performed with stabilized pelvis and hip."
48379681|NCT05252169|OTHER|Routine Physical therapy|"Group A will be given routine physical therapy which will be of 60 minutes each session. The routine physical therapy will include~* Passive stretching exercises~* Weight bearing exercises~* Functional strength training Duration of the treatment will be 3 days a week for 12 weeks i.e., 36 sessions. Each session will be of 60 minutes."
48713546|NCT01615601|DRUG|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
48021872|NCT05343312|DRUG|DHP|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
48021873|NCT05343312|DRUG|PA|"Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure.~Follow-up visits will take place on days 1, 2, 3, 7, 14,21, 28, 35 and 42 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication.~Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. The Molecular markers associated with suboptimal response to ACTs will be investigated."
48021874|NCT03238001|DEVICE|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
48021875|NCT00320216|DRUG|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
48379682|NCT04688034|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724.
48379683|NCT00296192|DRUG|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
48379684|NCT00296192|OTHER|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
48713547|NCT01615601|DRUG|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
48713548|NCT01615601|DRUG|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
48713549|NCT01615601|DRUG|Other antiretroviral medications|Given as per Canadian Product Monograph
48713550|NCT06136572|DIAGNOSTIC_TEST|Rathus Assertiveness scale|Questionnaire completion
48379685|NCT05731973|PROCEDURE|Intercostal nerve cryoablation|Intercostal nerve cryoablation is applied during Nuss procedure.
48713551|NCT03023826|DRUG|LY3202626 (R-Fasting)|Administered orally
48379686|NCT05731973|DRUG|Thoracic epidural analgesia (continuous infusion with sufentanyl (1 µg/ml) and bupivacaine (1.25 mg/ml))|Thoracic epidural is placed prior to Nuss procedure
48379687|NCT05731973|DRUG|Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))|Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
48379688|NCT05731973|DRUG|Opioids (oxycodone with prolonged discharge 10 mg PO every 12 hours and oxycodone 5 mg every 6 hours, as needed)|Opioids
48379689|NCT00658086|DRUG|ALN-RSV01|administered by nebulization once daily for 3 days
48379690|NCT00658086|DRUG|normal saline|administered by nebulization once daily for 3 days
48379691|NCT05534698|PROCEDURE|PCI|Revascularization by PCI
48379692|NCT05534698|PROCEDURE|CABG|Revascularization by CABG
48713552|NCT03023826|DRUG|LY3202626 (T1-Fasting)|Administered orally
48713553|NCT03023826|DRUG|LY3202626 (T1-Fed)|Administered orally
48713554|NCT02266277|OTHER|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
48713555|NCT02266277|OTHER|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
48713556|NCT02266277|OTHER|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
48713557|NCT02266277|OTHER|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
48713558|NCT00002368|DRUG|Nevirapine|
48713559|NCT00002368|DRUG|Lamivudine|
48179469|NCT01945398|OTHER|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
48021876|NCT00320216|DRUG|Placebo|Patients in the placebo group will receive placebo medication.
48021877|NCT02805257|DRUG|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
48021878|NCT02805257|OTHER|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
48021879|NCT02805257|PROCEDURE|Ahmed Glaucoma Valve Implant|Implantation of Ahmed Valve in study eye
48021880|NCT04748380|OTHER|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
48021881|NCT04748380|OTHER|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
48021882|NCT02589119|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
48021883|NCT05077254|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
48021884|NCT05077254|BIOLOGICAL|Moderna COVID-19 Vaccine 2023-2024|Administration: One dose administered intramuscularly.
48021885|NCT05077254|DRUG|SOC IS Regimen|Participants will continue to take their prescribed immunosuppression (IS) medications without alterations in schedule and dosing, per protocol instruction.
48021886|NCT05077254|DRUG|SOC IS Reduction|Participants will reduce their standard of care immunosuppression medications (IS) before and after the COVID-19 vaccine booster (1 dose), per protocol instruction.
48021887|NCT05896592|DIAGNOSTIC_TEST|Invasive electrophysiological study|Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
48021888|NCT05896592|DIAGNOSTIC_TEST|Extracardiac vagal stimulation|"Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia."
48021889|NCT05896592|PROCEDURE|Cardioneuroablation|CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
48021890|NCT05896592|PROCEDURE|Redo cardioneuroablation|It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
48021891|NCT05896592|PROCEDURE|Implantation of the implantable loop recorder|Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
48021892|NCT05896592|DIAGNOSTIC_TEST|Pacemaker check|It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
48179470|NCT01945398|OTHER|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
48179471|NCT00229762|BEHAVIORAL|phone call from nurses - informational only|
48179472|NCT05917860|DRUG|Degarelix|Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
48379693|NCT00622752|DRUG|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
48379694|NCT00622752|DRUG|placebo|2 X placebo tablets to match EVT 302 5 mg
48379695|NCT00622752|DRUG|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
48379696|NCT00622752|DEVICE|NRT placebo|Medically inert plaster cut to match the NRT plaster
48379697|NCT00608075|DRUG|lithium|600 mg - 1800 mg per day
48379698|NCT00608075|DRUG|Lithium|600 - 1800 mg
48713560|NCT01414764|OTHER|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
48713561|NCT01414764|DRUG|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
48713562|NCT01798641|DEVICE|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
48379699|NCT00698009|DRUG|Fludarabine|25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
48021893|NCT05896592|DIAGNOSTIC_TEST|Implantable loop recorder check|Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
48021894|NCT05896592|DIAGNOSTIC_TEST|Holter ECG|24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
48021895|NCT05896592|DIAGNOSTIC_TEST|Anamnesis|Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
48021896|NCT05166122|DIAGNOSTIC_TEST|Artificial Intelligence|Introduction of digitized system with an AI tool to detect and intrepret the severity of diabetic retinopathy and presence of diabetic macular edema in screening for diabetes patients
48021897|NCT04120896|BEHAVIORAL|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
48379700|NCT00698009|DRUG|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
48379701|NCT00698009|BIOLOGICAL|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
48379702|NCT00698009|DRUG|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
48517993|NCT05694689|OTHER|Usual Care|Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices
48713563|NCT04181580|DEVICE|Made-to-measure compression garment|Made-to-measure compression garment
48517994|NCT06124729|DRUG|Bevacizumab Combined With PD-1 Monoclonal Antibody|Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS colorectal cancer with liver metastases
48713564|NCT06053957|PROCEDURE|early mobilization|early mobilization program
48713565|NCT06174389|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.
48713566|NCT05774184|BIOLOGICAL|barzolvolimab|subcutaneous administration
48713567|NCT05774184|DRUG|Matching Placebo|subcutaneous administration
48021898|NCT04120896|BEHAVIORAL|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
48021899|NCT03603964|DRUG|Guadecitabine|Guadecitabine
48021900|NCT06498050|DRUG|intravitreal injection of Brolucizumab 6 mg in study eye|After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.
48517995|NCT03427515|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10\^9 CFU/day
48713568|NCT03333395|DRUG|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
48713569|NCT03333395|DRUG|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
48021901|NCT04279925|DEVICE|ORIF (Open reduction internal fixation): locally-made miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using locally-made miniplate and screw produced by the Faculty of Engineering Universitas Indonesia. The plate used in the study is a straight plate with 4 and 5 holes with the dimension of 17mm long, 4 mm wide and 0.56 mm thick.
48021902|NCT04279925|DEVICE|ORIF: Imported miniplate and screw|Fracture lines in this group underwent open reduction internal fixation (ORIF) procedure which consists of realignment of the bone achieved from surgical mean and stabilization of the bone fragments by using Biomet® miniplate 1.5 produced by Biomet, included in the Lorenz® Plating System Midface. The particular plate used in the study is a straight plate with 4 holes, 17mm length and 0.6mm thick, coded 01-7047 in the catalog. Biomet® screw 1.5 utilized in this study is also produced by Biomet, included in the Lorenz® Plating System Midface. The dimension of the screw is 4mm length, 1.5 mm diameter, and coded 91-6104 1.5 mm X-Drive Self drilling screws.
48517996|NCT03427515|DIETARY_SUPPLEMENT|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10\^9 CFU/day
48021903|NCT01892475|BEHAVIORAL|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~1. Accurately predicting step target attainment the following months (SGD10)~2. Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
48021904|NCT01892475|BEHAVIORAL|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
48517997|NCT03427515|DIETARY_SUPPLEMENT|Placebo|30 days of supplementation
48517998|NCT00411411|DRUG|Januvia|200 mg t.i.d
48021905|NCT01192594|BEHAVIORAL|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
48517999|NCT00411411|DRUG|Placebo|Placebo
48518000|NCT00943748|DRUG|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
48021906|NCT01192594|BEHAVIORAL|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
48021907|NCT02375412|PROCEDURE|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
48021908|NCT04854200|DEVICE|Medtronic HeartWare ™ HVAD™ System|The Medtronic HeartWare™ HVAD™ System includes a ventricular assist device (VAD) that helps the heart pump and increases the amount of blood that flows through the body in patients with advanced heart failure.
48021909|NCT01369628|DRUG|Atacicept|"1. Regimen 1: Atacicept 25 mg weekly for 12 weeks~2. Regimen 2: Atacicept 75 mg weekly for 12 weeks~3. Regimen 3: Atacicept 150 mg weekly for 12 weeks"
48021910|NCT01306136|BEHAVIORAL|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
48021911|NCT01306136|BEHAVIORAL|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
48518001|NCT00943748|DRUG|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
48518002|NCT05107271|DIAGNOSTIC_TEST|COVID-19 serosurvey|COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity
48518003|NCT01666769|DRUG|Micafungin|4 mg/kg/day
48713570|NCT04225091|DIETARY_SUPPLEMENT|Testing product|consume 1 bottle (50 mL) per day for 28 days
48713571|NCT04225091|DIETARY_SUPPLEMENT|Blank|consume 1 bottle (50 mL) per day for 28 days
48713572|NCT05999526|OTHER|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
48713573|NCT05999526|OTHER|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
48713574|NCT04926090|BEHAVIORAL|Emotional Support Plan - Clinician Guided (ESP-C)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-C is delivered by a clinician in 2 sessions.
48713575|NCT04926090|BEHAVIORAL|Emotional Support Plan - Self Guided (ESP-S)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-S is created by the participant on their own, with the support of self-guided materials.
48713576|NCT01256281|PROCEDURE|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
48713577|NCT00966719|OTHER|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
48713578|NCT04643639|DEVICE|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
48713579|NCT04333953|OTHER|No intervention|No intervention, observational study
48379703|NCT00698009|DRUG|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
48379704|NCT05275556|DEVICE|Computer-Assisted Detection (CADe) Device|The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
48518004|NCT01666769|DRUG|Micafungin|8 mg/kg/day
48021912|NCT05134376|OTHER|During Episiotomy Repair, Women Will Be Watching Virtual Reality Glasses Accompanied by Music|Unlike the experimental group, only video and music application will not be applied to the pregnant women included in the control group. Other applications will be done exactly.
48518005|NCT01666769|DRUG|Micafungin|Standard of care Dosing
48713580|NCT00795912|DRUG|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
48713581|NCT05944562|DRUG|Tulmimetostat|Patients should take CPI-0209 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following CPI-0209 dosing). Each dose of CPI-0209 should be taken with a glass of water and consumed over as short a time as possible.
48713582|NCT04836390|DRUG|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
48713583|NCT03700450|DRUG|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
48713584|NCT04890587|DRUG|AL8326 tablets|Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
48713585|NCT03009838|DRUG|Letrozole|oral tablets 2.5 mg
48713586|NCT03009838|PROCEDURE|ovarian drilling|laparoscopic electrocauterization
48713587|NCT06179160|DRUG|INCB161734|INCB161734 will be administered at protocol defined dose.
48713588|NCT06179160|DRUG|Cetuximab|Cetuximab will be administered at protocol defined dose.
48713589|NCT06179160|DRUG|Retifanlimab|Retifanlimab will be administered at protocol defined dose.
48713590|NCT06507501|OTHER|Low Load Blood Flow Restriction Exercise Training (LL-BFRE)|Blood Flow Restriction exercise training, also known as occlusion training or KAATSU training, is a contemporary exercise training method based on partially restricting arterial and venous blood flow for short periods.
48713591|NCT06507501|OTHER|High Load Resistive Exercise Training (HL-RE)|HL-RE is a conventional, well known exercise method to enhance muscle strength and improve physical performance. It's performed by using resistance bands or weights applying on the extremity.
48713592|NCT00051220|BEHAVIORAL|One-Session Treatment for Specific Phobias|
48713593|NCT02751034|DEVICE|Neuramis® Deep Lidocaine|HA filler
48713594|NCT02751034|DEVICE|Restylane® PERLANE-L|HA filler
48713595|NCT01537081|DRUG|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
48713596|NCT01537081|DRUG|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
48713597|NCT01537081|DRUG|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
48713598|NCT02584387|BEHAVIORAL|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
48713599|NCT01359605|DRUG|varespladib methyl|500 mg oral suspension
48713600|NCT03838016|BEHAVIORAL|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
48713601|NCT06276218|DEVICE|Clavicular brace|Clavicular brace for conservative treatment of closed midshaft clavicular fractures
48713602|NCT05018806|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
48179473|NCT05917860|DEVICE|MRI-guided transurethral ultrasound ablation (TULSA)|MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
48179474|NCT01979289|OTHER|computerized cognitive remediation|
48713603|NCT05018806|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
48713604|NCT00002824|BIOLOGICAL|gene therapy|
48021913|NCT04150575|DRUG|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
48179475|NCT01979289|OTHER|computerized cognitive remediation:Control|
48179476|NCT04256369|COMBINATION_PRODUCT|Parenteral Nutrition (PN) Premixed Olimel N9E|Parenteral nutrition
48179477|NCT02184299|DRUG|Nevirapine|
48713605|NCT00002824|DRUG|chemotherapy|
48713606|NCT00002824|DRUG|ganciclovir|
48713607|NCT00002824|PROCEDURE|conventional surgery|
48713608|NCT04811443|DRUG|Empegfilgrastim|Extimia®
48713609|NCT00837876|DRUG|Sorafenib|400 mg taken by mouth 1 time per day.
48713610|NCT00837876|DRUG|Erlotinb|150 mg taken by mouth 1 time per day.
48713611|NCT05110560|BEHAVIORAL|"Stay at Home Take a Step Program (SHTSP)"|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
48713612|NCT00520013|DRUG|bevacizumab|
48713613|NCT00520013|DRUG|erlotinib|
48713614|NCT00520013|DRUG|paclitaxel|
48713615|NCT00520013|DRUG|carboplatin|
48713616|NCT02621398|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
48713617|NCT02621398|DRUG|Carboplatin|Given IV
48713618|NCT02621398|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
48713619|NCT02621398|OTHER|Laboratory Biomarker Analysis|Correlative studies
48713620|NCT02621398|DRUG|Paclitaxel|Given IV
48713621|NCT02621398|BIOLOGICAL|Pembrolizumab|Given IV
48379705|NCT03029754|PROCEDURE|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
48379706|NCT03526549|BIOLOGICAL|CCH-aaes|Administered to participants who qualified for, and opted for, retreatment.
48379707|NCT03526549|OTHER|Observation|No treatment administered during 180 days of observation.
48379708|NCT06493110|PROCEDURE|Gastric ultrasound|To compare gastric volumes in standard fasting state before surgery in diabetic and non-diabetic pregnant women by evaluating the gastric antrum with ultrasound.
48179478|NCT02184299|DRUG|Prednisone|
48179479|NCT03116282|BEHAVIORAL|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
48379709|NCT06103162|DEVICE|flexible feeding plate|One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
48021914|NCT03440632|DEVICE|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
48021915|NCT02647359|DRUG|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
48379710|NCT06538194|PROCEDURE|Mesotherapy|For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
48379711|NCT05880758|BEHAVIORAL|Intermittent Short Sleep (ISS)|Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
48021916|NCT02647359|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
48379712|NCT05880758|BEHAVIORAL|Social Jetlag (SJL)|2-hour delayed sleep timing.
48379713|NCT05880758|BEHAVIORAL|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
48021917|NCT00452634|DRUG|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
48379714|NCT03383302|RADIATION|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
48713622|NCT00650455|DRUG|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
48021918|NCT00452634|DRUG|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
48021919|NCT00452634|DRUG|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
48021920|NCT06196723|PROCEDURE|transjugular intrahepatic portal shunt|TIPS was performed by experienced clinicians in the Gastroenterology/Hepatology Department according to standard operating procedures, utilizing 8 mm or 10 mm expanded polytetrafluoroethylene-covered stents at the discretion of the local physician.
48021921|NCT04561362|DRUG|BT8009|Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive a 60-minute IV infusion of BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
48179480|NCT00527150|DRUG|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
48179481|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
48379715|NCT03383302|DRUG|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
48379716|NCT02826239|DEVICE|multiple breath washout test (MBW)|measured in upright and supine position
48379717|NCT04240665|BEHAVIORAL|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
48713623|NCT00650455|DRUG|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
48713624|NCT00650455|DRUG|placebo|placebo tablet every morning and capsule every evening for 12 weeks
48713625|NCT05510882|OTHER|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
48713626|NCT05118984|DRUG|Azithromycin capsule (Zithromax, Pfizer) (250 mg)|Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
48713627|NCT05118984|DRUG|Placebo|A treatment that has no active properties
48713628|NCT03653572|DEVICE|Ultrasound exam|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
48021922|NCT04561362|DRUG|Pembrolizumab|Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.
48021923|NCT02798848|DEVICE|Tablet computer|iPad
48021924|NCT03192891|DIAGNOSTIC_TEST|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
48021925|NCT05500976|OTHER|Semi-controlled dietary intervention - Western|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Western diet foods (eg, beef, potatoes, bread, sour cream) provided during each intervention and will be repeated twice.
48021926|NCT05500976|OTHER|Semi-controlled dietary intervention - MiniMed|Participants will complete a 2-week washout prior to a 16-week randomized, crossover semi-controlled feeding study of mini-MED vs Western diet. Each diet intervention will last four weeks, with 500 kcal/day of target Mediterranean foods (eg, oatmeal, salmon, nuts, basil, olive oil, fruits) provided during each intervention and will be repeated twice.
48021927|NCT04932174|OTHER|High-intensity Interval Training|"Consisting of the following program:~* Warming up period for 10 minutes at 60-70% of HR max.~* Training phase 4x4 min intervals at 85-90% of HRmax with a 3 min active recovery at 70% of HRmax between each interval.~* Duration of HIIT 4 minute~* Number of interval per session 4~* Duration of rest interval 3 minute 3-10 min cool-down period, giving a total of 60 min."
48379718|NCT06649981|DIETARY_SUPPLEMENT|FMT capsule|"A lyophilized gut microbiota capsule derived from a rigorously screened, healthy, and physically active donor, free of gastrointestinal diseases, antibiotic use, and chronic conditions. The donor\&#39;s diverse microbiome is supported by a nutrient-rich diet and active lifestyle. The lyophilization process preserves microbial integrity, offering a high-potency dose aimed at restoring and optimizing the gut microbiome of older adults.~This intervention is specifically designed for older adults to enhance resilience to stress, cognitive function, muscular strength, and metabolic health. It is part of a controlled clinical study with follow-up assessments at weeks 1, 4, 8, and 20 post-intervention. This targeted approach distinguishes it from other microbiome-based therapies by focusing on comprehensive health benefits for an aging population."
48379719|NCT06649981|DIETARY_SUPPLEMENT|Placebo Capsule(s)|"A placebo capsule will be used in this study to serve as a control, allowing us to objectively assess the true effects of the lyophilized gut microbiota intervention. The use of a placebo is essential to eliminate bias and ensure that any observed outcomes can be confidently attributed to the actual intervention rather than to psychological or other non-specific effects.~The placebo capsule will be identical in appearance, size, shape, and color to the interventional capsule to maintain blinding for both participants and researchers. This ensures that neither group knows which capsule is being administered, thereby preserving the study's integrity and validity by preventing any expectations or beliefs from influencing the results."
48379720|NCT03583931|PROCEDURE|VATS Decortication|Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
48379721|NCT03583931|DRUG|Fibrinolytic Therapy|Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
48518006|NCT00700362|PROCEDURE|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
48179482|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
48179483|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
48179484|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
48713629|NCT06107439|BIOLOGICAL|Bood and urine sampling|Bood and urine sampling
48713630|NCT03282773|DEVICE|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
48021928|NCT04932174|OTHER|Low-intensity Continuous Training|"Consisting of the following program:~* Warming up period for 10 minutes.~* Training phase for 60-minute walking on a treadmill at intensity 40-50% HRR (1- 6) weeks then 60-70% HRR (7-12) weeks.~* cooling down period for 10 minutes."
48179485|NCT05570305|DRUG|Zibotentan|Zibotentan 1.5 mg once per day as a hard capsule.
48179486|NCT05570305|DRUG|Dapagliflozin|Dapagliflozin 10 mg once per day as a tablet.
48179487|NCT05570305|DRUG|Placebo|Matching placebo.
48179488|NCT05570305|DRUG|Dapagliflozin and Zibotentan|Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
48179489|NCT03153813|DRUG|capsaicin 8% patches (Qutenza)|
48021929|NCT06393361|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
48179490|NCT03153813|OTHER|Placebo patches|
48713631|NCT03282773|DEVICE|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
48713632|NCT00474864|DRUG|GW856553|
48713633|NCT01061047|DRUG|Ertapeneme|
48179491|NCT01078922|DRUG|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
48379722|NCT02585375|DRUG|Preservative-free latanoprost 50µg/ml|
48021930|NCT06393361|DRUG|Brentuximab Vedotin, anti-PD-1 antibody.|Brentuximab Vedotin 1.8mg/kg d1, anti-PD-1 antibody d1. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
48021931|NCT04701268|OTHER|Device: Hemiverse|Implantation of the hemiverse shoulder prothesis
48021932|NCT03334500|DEVICE|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
48021933|NCT03334500|DRUG|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
48021934|NCT02543541|BEHAVIORAL|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
48021935|NCT02543541|BEHAVIORAL|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
48021936|NCT04535037|BIOLOGICAL|DTPa-HBV-IPV/Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTPa-HBV-IPV/Hib vaccine administered by intramuscular injection into the right thigh
48021937|NCT04535037|BIOLOGICAL|DTaP5-HBV-IPV-Hib|3 doses (1 each at 2, 4 and 12 months of age) of DTaP5-HBV-IPV-Hib vaccine administered by intramuscular injection into the right thigh
48021938|NCT04535037|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|3 doses (1 each at 2, 4 and 12 months of age) of pneumococcal 13-valent conjugate vaccine administered by intramuscular injection into the left thigh
48021939|NCT04715594|DEVICE|1st-generation drug-eluting stent|Implantation of 1st-generation drug-eluting stent
48021940|NCT04715594|DEVICE|2nd-generation drug-eluting stents|Implantation of 2nd-generation drug-eluting stent
48179492|NCT01966198|OTHER|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
48021941|NCT06535581|PROCEDURE|surgery patient|patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
48021942|NCT00969852|DRUG|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
48021943|NCT05052359|DIAGNOSTIC_TEST|Lectin-histochemistry retrospectively performed|Lectin-histochemistry was performed on 37 archival paraffin wax-embedded specimens of various follicular thyroid tumours (10 follicular adenomas (FA), 10 minimally invasive follicular carcinomas (miFTC), 13 widely invasive follicular cancers (wiFTC) and 4 metastatic follicular thyroid cancers (metFTC)).
48179493|NCT01667406|DRUG|Kisspeptin 1.6nmol/kg|single kisspeptin dose 1.6 nmol/kg subcutaneously
48179494|NCT01667406|DRUG|Kisspeptin 3.2nmol/kg|single kisspeptin dose 3.2 nmol/kg subcutaneously
48179495|NCT01667406|DRUG|Kisspeptin 6.4nmol/kg|single kisspeptin dose 6.4 nmol/kg subcutaneously
48179496|NCT01667406|DRUG|Kisspeptin 9.6nmol/kg|single kisspeptin dose 9.6 nmol/kg subcutaneously
48179497|NCT01667406|DRUG|Kisspeptin 12.8nmol/kg|single kisspeptin dose 12.8 nmol/kg subcutaneously
48379723|NCT02585375|DRUG|Preserved latanoprost 0.005%|
48179498|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg double|kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
48379724|NCT04993937|OTHER|Intervention|Interventional group will receive 6 weeks of plyometric training and receive training for week and three sessions in a week.
48379725|NCT04993937|OTHER|Control Group|Control group will follow their daily routine activities and may involve in any other exercise program rather than plyometric exercises.
48379726|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
48179499|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg + saline|kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
48179500|NCT05267795|BEHAVIORAL|Experimentally-induced pain|Specific pain levels were applied on the participants' fingernails in each of 40 experimental trials using pressure algometry.
48179501|NCT02397343|DRUG|Hyperbaric oxygen|
48179502|NCT02449057|OTHER|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
48179503|NCT04243642|DEVICE|IntelliSpace Cognition|Philips IntelliSpace Cognition (ISC) is a digital assessment platform that supports Healthcare Professionals (HCP) in assessing the cognition of individuals. It consists of two interfaces connected to the DCDx-module in the cloud. ISC is hosted on the Philips Health Suite Digital Platform (HSDP). The first interface is the patient's interface and is presented via a tablet to collect data on how the patient performs a series of tests. The second interface is the clinician's interface and can be used on any PC or tablet. It allows for assessments to be selected and administered, observations made, data analytics performed and the generation of a report.
48179504|NCT00005871|DRUG|fluorouracil|
48179505|NCT00005871|DRUG|rubitecan|
48379727|NCT03145038|DRUG|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
48021944|NCT06014658|DRUG|Antibody-Drug Conjugate|MBRC-101: AN ANTI-EPHA5 MONOMETHYL AURISTATIN E (MMAE) ANTIBODY DRUG CONJUGATE
48021945|NCT03223103|DRUG|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
48379728|NCT03145038|DRUG|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
48379729|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
48021946|NCT03223103|DEVICE|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
48021947|NCT03223103|BIOLOGICAL|Peptides|synthetic long peptides (SLP) as vaccine substrate
48021948|NCT02705131|DEVICE|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
48021949|NCT02705131|DEVICE|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
48021950|NCT00030589|DRUG|bexarotene|
48021951|NCT00030589|DRUG|methoxsalen|
48021952|NCT00030589|PROCEDURE|UV light therapy|
48021953|NCT06097052|DEVICE|Hypotension Predictive Index|Introduction of Hypotension Predictive index and transition from a reactive to a proactive approach of intraoperative hypotension treatment.
48021954|NCT00338026|DRUG|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
48021955|NCT00982319|DRUG|Broccoli sprout extract|100 µmols of sulforaphane (dissolvable)
48021956|NCT00982319|DRUG|Mango juice|150 mL of mango juice
48021957|NCT05401123|DEVICE|milking pump|"n the study, all mothers who come to the Lactation/Relactation outpatient clinic will be informed about the study, and mothers who accept the study will have to fill out the Conformity to Criteria Form created by the researcher. Between the ages of 20-35, postpartum 1-5. Participants who gave birth after the 37th week of pregnancy, did not have literacy problems, mental disabilities and communication problems, did not have chronic diseases, did not use any medication, and volunteered to participate in the study will be included in the study. by milking, 2 ml of first milk will be taken from the participants in the control group (via the milking pump). The collected milk will be taken to the laboratory for analysis by the researcher."
48021958|NCT03095300|PROCEDURE|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
48021959|NCT01696435|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
48021960|NCT01696435|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
48021961|NCT01696435|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
48021962|NCT01696435|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
48021963|NCT03799575|BEHAVIORAL|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
48021964|NCT00151801|DRUG|estroprogestins|
48021965|NCT00151801|DRUG|interferon-beta 1a|
48021966|NCT04950608|DRUG|Psilocybin|Oral, single administration, dosage 25 mg orally
48021967|NCT04950608|BEHAVIORAL|Psychotherapy|The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
48021968|NCT04475003|OTHER|Teaching|Teaching session about anaphylaxis
48021969|NCT02733497|PROCEDURE|Sympathectomy|Resection of ganglia at T3 level
48021970|NCT02733497|PROCEDURE|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
48179506|NCT03320395|DEVICE|Small bowel RFA treatment|"The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites."
48179507|NCT03664206|DIAGNOSTIC_TEST|MRS, conventional TMS and treshold tracking TMS|"Using~* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~* SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
48179508|NCT04063046|DRUG|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
48179509|NCT04063046|DRUG|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
48179510|NCT02638688|OTHER|ultrasound|
48021971|NCT00000838|DRUG|Lamivudine|
48021972|NCT00000838|DRUG|Stavudine|
48021973|NCT00000838|DRUG|Zidovudine|
48021974|NCT00000838|DRUG|Didanosine|
48021975|NCT03282084|DIAGNOSTIC_TEST|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
48021976|NCT03282084|DIAGNOSTIC_TEST|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
48021977|NCT03882619|BEHAVIORAL|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
48179511|NCT03937713|DRUG|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
48179512|NCT03937713|BEHAVIORAL|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
48179513|NCT03922022|BEHAVIORAL|EIM exercise classes and intervention|This is a complex intervention. On recruitment, they will be seen by a nurse and counselled using motivational technique. They will then undergo a 12-week class. The exercise levels will be regularly feedback to the patients by use of mobile devices and trackers. Peer support is formed during the 12-week class. Resources to continue exercise will be provided to patients. Regular monitoring of physical improvement will be feedback to patients to encourage continued exercise.
48179514|NCT02632812|DRUG|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
48179515|NCT02632812|DRUG|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
48379730|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
48379731|NCT03145038|DRUG|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
48379732|NCT02984904|OTHER|survey|survey
48379733|NCT06303024|OTHER|personalized combined physical and cognitive intervention|The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
48379734|NCT03938454|DRUG|crizanlizumab|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
48379735|NCT05814224|DIAGNOSTIC_TEST|Liquid biopsy and CT scan|"CT scan and liquid biopsy blood sample are performed at baseline, after 8 weeks from baseline and, then, every 12 weeks.~Between two subsequent CT scan another liquid biopsy blood sample is performed.~CEA and CA 15.3 will be performed at baseline and then concomitantly to the radiological evaluation"
48379736|NCT06129500|BEHAVIORAL|Cognitive Behavioural Therapy for Problematic Impulsive Behaviours|Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.
48379737|NCT02384031|DEVICE|Traumatic needle|Lumbar puncture is performed with a traumatic needle
48379738|NCT02384031|DEVICE|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
48379739|NCT03830073|GENETIC|Measurement of VDR genetic polymorphism|VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
48379740|NCT03337373|DRUG|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
48379741|NCT04791410|PROCEDURE|microvascular decompression|Microvascular decompression of rostral ventrolateral medulla
48379742|NCT02689973|BEHAVIORAL|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
48379743|NCT02689973|BEHAVIORAL|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
48379744|NCT02689973|BEHAVIORAL|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
48379745|NCT03371095|DRUG|Infliximab|Use of infliximab instead of cyclophosphamide
48379746|NCT03371095|DRUG|Cyclophosphamide|Use of cyclophosphamide
48179516|NCT02632812|DRUG|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
48379747|NCT01424631|PROCEDURE|single incision laparoscopic appendectomy|
48179517|NCT04980079|PROCEDURE|Primary ureterscopy URS|Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy
48179518|NCT04980079|PROCEDURE|deferred ureteroscopy URS|insertion of a double -J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done .
48379748|NCT01424631|PROCEDURE|conventional laparoscopic appendectomy|
48379749|NCT01716546|DRUG|Pazopanib|
48379750|NCT01890876|OTHER|Walking uphill|ascending about 500 m
48179519|NCT02757820|DEVICE|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
48021978|NCT03705039|OTHER|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
48021979|NCT03705039|OTHER|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
48021980|NCT02268591|DEVICE|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
48021981|NCT03108534|DRUG|CHF1535 NEXThaler|Rescue treatment
48021982|NCT03108534|DRUG|CHF1535 pMDI|Rescue treatment
48179520|NCT02757820|DEVICE|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
48379751|NCT01890876|OTHER|Walking downhill|descending about 500 m
48713634|NCT02156557|BIOLOGICAL|Colon KCC Heptapeptide|"* Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports."
48179521|NCT02757820|DEVICE|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
48179522|NCT00932971|DRUG|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
48179523|NCT00932971|DRUG|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
48179524|NCT02394652|DRUG|Metformin|Metformin is an antidiabetic agent given orally.
48179525|NCT02394652|DRUG|Cisplatin|Cisplatin is an antineoplastic agent given intravenously.
48179526|NCT02394652|DRUG|FAZA|FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
48179527|NCT03860090|DEVICE|Pacemaker implant|Implantation of endovenous cardiac stimulation device.
48379755|NCT01998659|DRUG|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
48379756|NCT01998659|DRUG|Placebo|Oral drinking solution
48379757|NCT01269346|DRUG|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
48379758|NCT04979325|OTHER||
48379759|NCT02835664|DIETARY_SUPPLEMENT|Nicotinamide Riboside (Niagen)|
48379760|NCT02835664|DIETARY_SUPPLEMENT|Placebo|
48379761|NCT05624515|DEVICE|dry needling|Active trigger point puncture of the angularis scapulae muscle
48379762|NCT05624515|OTHER|Ischaemic compression|Ischaemic compression at the active trigger point of the angularis scapulae muscle
48379763|NCT06466967|DEVICE|Advanced hybrid closed-loop CamAPS FX|Treatment with a strict programmed glucose target (80-99 mg/dL).
48713635|NCT05801055|DRUG|Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone|The combination drink containing N-acetyl cysteine and simethicone help to disperse bubbles and mucus present in the stomach. During routine upper gastrointestinal endoscopy mucus and bubbles sometimes may hinder mucosal visibility, so small submucosal lesions, ulcers, erosions, and even flat pre-malignant lesions can be missed during endoscopy. The Japanese guidelines also recommend the use of this combination drink to detect early gastric cancers. So we plan to evaluate the role of this drink in improving gastric mucosal visibility in patients undergoing upper gastrointestinal endoscopy.
48713636|NCT04341987|BEHAVIORAL|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
48713637|NCT04341987|OTHER|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
48713638|NCT00533858|DRUG|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
48713639|NCT03655223|DIAGNOSTIC_TEST|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
48713640|NCT05562362|DRUG|RE-021, sparsentan|RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
48713641|NCT00137696|BIOLOGICAL|Vaccination with inactivated polio vaccine|
48713642|NCT00137696|PROCEDURE|Collection of serum|
48379764|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^6 cells/m2"
48379765|NCT00703222|BIOLOGICAL|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP|"SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^7 cells/m2"
48021983|NCT03108534|DRUG|Placebo|Rescue treatment
48179528|NCT03860090|DEVICE|Defibrillator implant|Implantation of endovenous cardiac defibrillation device.
48379766|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
48379767|NCT01569074|DRUG|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
48713643|NCT03739957|DEVICE|BPCO Media Kit|Telemonitoring system for patients with COPD
48713644|NCT02737644|OTHER|observation|This is an observational study
48713645|NCT05825924|DEVICE|E-Cigarette|E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes
48021984|NCT04788732|DEVICE|ECG and EEG monitoring|the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
48713646|NCT05825924|DRUG|Nicotine patch|The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
48713647|NCT03294135|BIOLOGICAL|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
48021985|NCT00767000|DRUG|MK-0941|MK-0941 tablets three times daily
48021986|NCT00767000|DRUG|Comparator: Placebo|Matching placebo to MK-0941 three times daily
48713648|NCT02815436|OTHER|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
48713649|NCT02815436|OTHER|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
48713650|NCT04129905|BIOLOGICAL|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
48713651|NCT04129905|DIAGNOSTIC_TEST|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
48379768|NCT01569074|DRUG|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
48379769|NCT01569074|DRUG|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
48379770|NCT01569074|DRUG|Placebo|Placebo twice daily for 12 weeks
48379771|NCT06002425|OTHER|Clinician-Directed Treatment Plan|In this approach, clinicians do not employ any technological assistance and rely solely on their professional expertise and experience to formulate treatment plans for participants.
48713652|NCT04129905|DIAGNOSTIC_TEST|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
48713653|NCT04129905|DIAGNOSTIC_TEST|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
48713654|NCT04129905|DIAGNOSTIC_TEST|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
48713655|NCT04129905|DIAGNOSTIC_TEST|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
48713656|NCT04129905|BIOLOGICAL|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
48713657|NCT04626089|DRUG|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
48713658|NCT04626089|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
48713659|NCT04423588|DIAGNOSTIC_TEST|dexlansoprazole serum concentration|6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.
48713660|NCT04423588|DIAGNOSTIC_TEST|upper endoscopy|6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.
48713661|NCT03094286|DRUG|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
48713662|NCT04944368|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
48021987|NCT00767000|BIOLOGICAL|Lantus|Lantus injection once daily
48021988|NCT00767000|DRUG|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
48021989|NCT02782481|DRUG|ND0612|
48021990|NCT02782481|DRUG|Placebo|
48021991|NCT02591394|BEHAVIORAL|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
48021992|NCT02591394|BEHAVIORAL|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
48179529|NCT03860090|PROCEDURE|AXILLARY VEIN ACCESS|Fluoroscopy-guided axillary puncture to get vein access
48179530|NCT03860090|PROCEDURE|CEPHALIC VEIN ACCESS|Optimized cephalic vein cutdown to get vein access
48179531|NCT01585298|DRUG|FTY720|
48713663|NCT04944368|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
48021993|NCT06508554|OTHER|Haptonomy|5. With the energy work, we will move on to the stage of harmonizing the intuitive and heart energy fields. It will be ensured that the mother's communication with her baby has a spiritual dimension as well as a physical one. 6. Then the stage of touching and communicating with the baby will begin. The hands of the researcher and the pregnant woman will be placed on the pregnant woman's uterus. Then, the pregnant woman will be the first to call her baby. This call to the baby will be repeated 2-3 times. 7. The pregnant woman and her uterus will be touched and exercises will be performed to adapt to the fetus. The aim is to increase the emotional awareness of the pregnant woman and to enable her to play intrauterine games with her baby (such as calling the baby, shaking her belly, moving the baby to the touched area with the mother's voice). Haptonomy will be completed with a deep relaxation exercise that will support the heart-uterus connection accompanied by breathing exercises.
48021994|NCT04620317|DIETARY_SUPPLEMENT|Synbiotic|10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
48518007|NCT00700362|PROCEDURE|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
48713664|NCT00871039|DRUG|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
48713665|NCT00871039|DRUG|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
48713666|NCT03958656|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
48713667|NCT03958656|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
48713668|NCT03958656|DRUG|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
48713669|NCT03958656|BIOLOGICAL|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
48713670|NCT03109028|BEHAVIORAL|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
48713671|NCT03109028|BEHAVIORAL|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
48021995|NCT04620317|DIETARY_SUPPLEMENT|Placebo|Non-active ingredients - Maltodextrins
48021996|NCT05071261|DIAGNOSTIC_TEST|Hepatitis C Virus Screening|1-2 Blood Screenings for Hepatitis C Virus
48021997|NCT00085410|DRUG|bortezomib|Given IV
48379772|NCT06002425|OTHER|ChatGPT-Assisted Treatment Plan|In this approach, clinicians utilize the ChatGPT technological tool, formulating treatment plans for participants based on its suggestions and their own professional expertise.
48518008|NCT05089669|OTHER|Interactive e-book|The nasogastric tube feeding interactive e-book has a lot of elements such as text content, videos, pictures, links, and other interactive content with which the students can interact. The participants can use the interactive e-book to learn nasogastric tube feeding.
48518009|NCT05089669|OTHER|paper textbook|The paper textbook has text content and pictures. The participants can use the paper textbook to learn nasogastric tube feeding.
48713672|NCT03109028|BEHAVIORAL|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
48713673|NCT03109028|BEHAVIORAL|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
48713674|NCT03109028|BEHAVIORAL|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
48713675|NCT03109028|OTHER|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
48713676|NCT01563289|DRUG|Ibuprofen|3 times a day
48713677|NCT01563289|DRUG|Placebo|3 times a day
48021998|NCT05658692|DEVICE|protective ventilation|Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
48713678|NCT04442321|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
48021999|NCT05658692|BEHAVIORAL|prone position ventilation|patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
48022000|NCT05658692|DRUG|glucocorticoid therapy|"Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours)."
48022001|NCT05658692|OTHER|restrictive fluid resuscitation|"1. without other organ dysfunction patients: Minimize fluid was given;~2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance."
48022002|NCT05658692|BIOLOGICAL|Thymosin Alpha|People received thymosin Alpha subcutaneous injections, twice a week.
48022003|NCT05658692|DRUG|Muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
48022004|NCT05658692|OTHER|Integrated Chinese and Western Medicine Treatment|"1. ventilation;~2. conventional western medicine treatment；~3. Chinese herbal medicine（Determining medication based on syndrome differentiation）"
48379773|NCT05785273|DEVICE|Pupillometer|1st pupil evaluation between induction of general anesthesia and onset of surgery. After incision, at least 3 pupil evaluations are performed. Measurements are spaced 15 minutes apart and also taken at least 10 minutes after any variation in drugs dosage
48379774|NCT06265376|BEHAVIORAL|Educational Video|A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
48379775|NCT04381117|DRUG|Previously Treated with EN3835|No treatment to be administered - Observational only
48379776|NCT02570217|DEVICE|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
48379777|NCT02570217|DEVICE|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
48379778|NCT03056456|DRUG|LY900014|Administered subcutaneously (SC)
48379779|NCT03056456|DRUG|Insulin Lispro (Humalog)|Administered SC
48713679|NCT04442321|OTHER|Sham PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe~The electrical current will not be working, and the needles will be placed during 30 minutes:~- Administration - One per week~Self-management loaded exercises prescribed by a physical therapist, two times per week."
48713680|NCT04615260|DEVICE|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
48713681|NCT00270660|BEHAVIORAL|biopsy, audiometry, ET function test, ear swab culture, DNE|
48713682|NCT00549029|GENETIC|DNA|withdraw 5\~10mL blood from vein only once during the whole design
48713683|NCT04266470|DEVICE|Lara Scan|"Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan."
48713684|NCT04266470|DIAGNOSTIC_TEST|PET/CT Scan - Pre-treatment and Post-treatment|The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.
48713685|NCT00257595|DRUG|Cetirizine Dry Syrup|
48713686|NCT00000765|DRUG|Zidovudine|
48713687|NCT01444027|BEHAVIORAL|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
48713688|NCT04867941|DRUG|ACP-196|All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
48713689|NCT01300819|OTHER|Placebo|"Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
48022005|NCT05658692|DRUG|statin therapy|"1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died."
48022006|NCT05658692|COMBINATION_PRODUCT|anti-infective treatment|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
48022007|NCT05658692|DEVICE|Extracorporeal Membrane Oxygenation（ECMO）|"1. For severe ARDS patients with refractory hypoxemia within 7 days of onset;~2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O;~3. V-V Model."
48022008|NCT05658692|GENETIC|stem cell therapy|A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.
48022009|NCT05658692|DRUG|Sedative analgesia/muscle relaxant therapy|Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
48713690|NCT01300819|DRUG|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
48179532|NCT02595606|DRUG|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
48713691|NCT06185634|OTHER|Dietary intervention - Pasta at dinner|"The pasta at dinner nutritional intervention will consist, as the name suggests, in eating pasta at dinner for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
48713692|NCT06185634|OTHER|Dietary intervention - Pasta at lunch|"The pasta at lunch nutritional intervention will consist, as the name suggests, in eating pasta at lunch for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
48179533|NCT05765747|DRUG|Yunnan Baiyao|Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
48179534|NCT05765747|DRUG|Celecoxib 200mg|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
48713693|NCT05499338|PROCEDURE|Stretching program|The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
48713694|NCT04007289|DRUG|Apixaban|Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events
48179535|NCT01772563|DRUG|volasertib|Solution for infusion
48179536|NCT01772563|DRUG|itraconazole|capsules
48179537|NCT00487032|DRUG|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
48179538|NCT00487032|DRUG|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
48179539|NCT00487032|DRUG|Prazosin hydrochloride|Prazosin 1mg one dose only
48179540|NCT00487032|DRUG|Placebo to Prazosin|Placebo 1 tablet one dose only
48713695|NCT04007289|DRUG|Placebo|Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
48713696|NCT03132103|DIETARY_SUPPLEMENT|Oral Vitamin D3|
48179541|NCT04403906|DIAGNOSTIC_TEST|PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)|The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
48179542|NCT02720211|DEVICE|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
48179543|NCT02720211|DEVICE|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
48179544|NCT05143112|BIOLOGICAL|Allogeneic CD19 CR-T cell|Allogeneic CD19 CR-T cell infusion
48518010|NCT01624025|OTHER|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
48713697|NCT03132103|DIETARY_SUPPLEMENT|Placebo Oral Vitamin D3|
48179545|NCT01977027|OTHER|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
48179546|NCT03304756|DRUG|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
48713698|NCT03132103|RADIATION|Solar simulated radiation (SSR)|
48179547|NCT03324971|OTHER|Medications review|"Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines."
48713699|NCT03132103|RADIATION|Placebo SSR|
48713700|NCT04526717|DRUG|MPT0B640|Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
48179548|NCT00912145|DRUG|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
48179549|NCT02376647|OTHER|Driving pressure limited ventilation|"Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.~Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment."
48179550|NCT02376647|OTHER|Conventional ventilation|Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
48179551|NCT00996502|DRUG|Docetaxel|"Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
48179552|NCT00996502|DRUG|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
48713701|NCT00836459|BEHAVIORAL|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
48713702|NCT00836459|BEHAVIORAL|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
48713703|NCT05881720|DRUG|Sacubitril / Valsartan Oral Tablet|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
48713704|NCT05881720|DRUG|Valsartan 80 mg|group 2 received valsartan (N=40, target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.
48713705|NCT03461406|BIOLOGICAL|Fibrin Sealant Grifols|The FE Grifols solution was applied topically via drip or spray application.
48713706|NCT03461406|BIOLOGICAL|EVICEL|The EVICEL solution was applied topically via drip or spray application.
48179553|NCT00996502|DRUG|Erlotinib|200 mg of Erlotinib PO daily days 2-16
48179554|NCT00996502|DRUG|Prednisone|5 mg of Prednisone PO bid
48179555|NCT02880839|DEVICE|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
48713707|NCT05680155|DRUG|Ecnoglutide|Subcutaneous Injection
48713708|NCT05680155|DRUG|Placebo|Subcutaneous Injection with matched volume
48713709|NCT01797848|DRUG|Peginterferon alfa 2a|
48713710|NCT01797848|DRUG|Ribavirin|
48713711|NCT01797848|DRUG|Placebo matching Daclatasvir|
48713712|NCT01797848|DRUG|Daclatasvir|
48713713|NCT02436408|DRUG|Vismodegib|
48179556|NCT02880839|DEVICE|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
48179557|NCT02880839|DEVICE|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
48179558|NCT03713320|DRUG|Cobomarsen|At least weekly doses of cobomarsen (282 mg) throughout study treatment period
48179559|NCT03713320|DRUG|Vorinostat|Daily doses of vorinostat throughout study treatment period
48713714|NCT04054492|BIOLOGICAL|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
48713715|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
48713716|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
48713717|NCT00583791|DEVICE|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
48713718|NCT02688088|DRUG|Drug Cocktail|Administered orally
48713719|NCT02688088|DRUG|Abemaciclib|Administered orally
48713720|NCT01479595|DRUG|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
48713721|NCT01479595|DRUG|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
48179560|NCT02751749|BEHAVIORAL|Unified Protocol|
48379780|NCT06455670|DRUG|Sanhan Huayin recipe, Qingre Huatan recipe or Zaoshi Huatan recipe|On the basis of conventional treatment of western medicine,the experimental group will be given Sanhan Huayin granule , Qingre Huatan granule or Zaoshi Huatan granule based on CM syndrome differentiation.Take 1 dose daily for 10 days.
48022010|NCT05658692|DRUG|inotropes therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
48022011|NCT05658692|DRUG|Vasoactive drug therapy|"According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021."
48022012|NCT01866436|OTHER|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
48022013|NCT01866436|OTHER|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
48022014|NCT03488381|DEVICE|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
48022015|NCT01697306|DRUG|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
48022016|NCT01697306|DRUG|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
48179561|NCT03339271|BEHAVIORAL|Technology-Enhanced Support|The study nurse will meet with the caregiver daily until patient is discharged from the hospital. The caregiver will take home an iPad upon discharge, and will have an initial video chat with the study nurse within 24-48 hours of hospital discharge and weekly for 8 weeks after that.
48379781|NCT06455670|DRUG|Sanhan Huayin recipe placebo, Qingre Huatan recipe placebo or Zaoshi Huatan recipe placebo|On the basis of conventional treatment of western medicine, in the experimental group 5% of the placebo drug, color, smell, taste, appearance, weight, similar to the experimental drug, drug packaging and test group. One dose was given daily for 10 days.
48379782|NCT03515681|BEHAVIORAL|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
48379783|NCT03908840|BIOLOGICAL|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
48713722|NCT04104022|BEHAVIORAL|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
48022017|NCT03821428|PROCEDURE|Acupuncture|Needling of P6 and CV24 points
48022018|NCT03821428|PROCEDURE|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
48022019|NCT00614939|DRUG|Saxagliptin|2.5 mg once daily oral dose
48179562|NCT03339271|BEHAVIORAL|Usual Care Support|The patient's doctor and nurses with input from the Palliative Care service will help the caregiver make a plan for discharge of the patient, and for taking care of the patient upon discharge. Someone from the study team will call the caregiver once a month for the duration of the study after the patient discharges from the hospital.
48179563|NCT06326879|OTHER|No intervention|Questionnaires compilation and sample collection
48379784|NCT06369077|DRUG|dorzolamide/timolol|Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost
48518011|NCT03064724|BEHAVIORAL|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
48022020|NCT00614939|DRUG|Placebo|Placebo
48022021|NCT04704414|DEVICE|Exophthalmos measurement|Exophthalmos measurement with iPhone 11 vs Artec Space Spider 3D Scanner vs Hertel Exophthalmometer.
48022022|NCT03755765|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
48022023|NCT03755765|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
48179564|NCT04545528|BEHAVIORAL|Dietary recommendations|The test group will be seen by a nutritionist and will receive specific dietary recommendations according to their specific comorbidities and drugs
48179565|NCT05679999|DIAGNOSTIC_TEST|CIMT (Carotid artery intima media thickness measurement)|Carotid artery intima media thickness measurement with ultrasound
48379785|NCT03986216|DEVICE|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
48379786|NCT02507531|DEVICE|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
48518012|NCT06007235|DEVICE|CACIPLIQ20|CACIPLIQ20 contains RGTA heparan sulphate mimetics
48518013|NCT06007235|DRUG|Placebo|Saline solution in identical spray bottles
48713723|NCT04104022|BEHAVIORAL|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
48022024|NCT03755765|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
48379787|NCT01124500|DRUG|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
48379788|NCT03952377|DRUG|SX600|Transforaminal Epidural Injection
48379789|NCT03952377|DRUG|Placebo|Transforaminal Epidural Injection
48379790|NCT02843490|DRUG|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
48379791|NCT02290652|OTHER|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
48379792|NCT02290652|OTHER|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty \& Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
48379793|NCT03546270|BEHAVIORAL|Swimming|This group completed 20-weeks of swimming
48379795|NCT04491474|DRUG|Lidocaine Hydrochloride|While performing these procedures, 1 ml of 2% lidocaine hydrochloride and 1 ml of %0.9 saline will be used for creating a solution of 2 ml of 1% lidocaine for nerve block. Also 2 ml of saline will be used for placebo effect. For blocking the GON region 0.75 ml of 1% lidocaine will be applied and 0.75 ml of saline for placebo effect(8). During applying to the SON region 0.25 ml of 1% lidocaine for blockage and 0.25 ml of saline for placebo effect will be used(8). The GON injection site was planned to be 2 cm lateral and 2 cm below the occipital protrusion and the SON injection site was planned as the area with frontal incisor in the orbital arch
48379796|NCT04491474|DRUG|Placebo|There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
48518014|NCT03816475|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
48022025|NCT00710333|DRUG|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
48022026|NCT00710333|DRUG|placebo|placebo
48179566|NCT05019170|BEHAVIORAL|Smartphone-based Financial Incentives|Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
48179567|NCT05019170|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
48518015|NCT04283422|DIAGNOSTIC_TEST|Biofire filmarray|"Identification of microorganisms including:~1. Isolation of microorganisms:~   The sample will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates,~2. Identification of the organism by Vitek2~3. Antibiotic sensitivity test of the organism by Vitek2~4. Identification of the organism by Biofire filmarray"
48518016|NCT04639284|DRUG|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
48518017|NCT03187535|DEVICE|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
48518018|NCT03187535|OTHER|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
48179568|NCT04164862|DEVICE|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
48518019|NCT03434522|DEVICE|vBloc Maestro Rechargeable System|vBloc therapy consists of a neuromodulation device that delivers intermittent, controllable electrical blocking algorithms, to the intra-abdominal vagus nerve for the treatment of obesity.
48713724|NCT05481424|OTHER|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
48179569|NCT05298397|OTHER|EAT-PTSD adapted for youth for anxiety|"This is an eight session (90 minute sessions) weekly experiential group treatment. The first session includes psychoeducation, orientation to treatment, a barn tour, and ends with meeting the horses. Subsequent sessions involve increasingly complex encounters and interactions with horses accompanied by feedback and direction from the treatment. Early phase treatment exercises acquaint patients with the horse, with grooming exercises, leading with a rope or a wand, and directing the horse. The middle phase furthers patients' mastery and comfort with the horse in individual and teamwork exercises. The final session includes a graduation ceremony. All intervention sessions begin with Opening Circle and end with Closing Circle. Opening Circle incorporates a grounding exercise and is orients participants to the session to check in regarding thoughts and feelings. Closing Circle reviews lessons learned during the session, eliciting participant feedback and facilitating discussion."
48179570|NCT02648542|OTHER|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
48179571|NCT02648542|DEVICE|transcranial direct current stimulation|Low-current electrical brain stimulation
48379797|NCT02204709|OTHER|2N Trout|Diploid/2N trout source
48518020|NCT05119257|BIOLOGICAL|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
48179572|NCT02648542|OTHER|Combined CAS and tDCS|Combined auditory and electrical stimulation
48379798|NCT02204709|OTHER|3N Trout|Triploid/3N trout source
48379799|NCT02204709|OTHER|Tilapia|Tilapia/control fish source
48379800|NCT05797948|DRUG|Obinutuzumab|Obinutuzumab Injection 1000mg ivgtt C1-C4 d1；
48379801|NCT05797948|DRUG|Zanubrutinib|Zanubrutinib 160mg (2 capsules) oral bid；
48379802|NCT05797948|DRUG|Lenalidomide|Lenalidomide 25mg (1 capsule) oral C1-C4 d1-d10.
48518021|NCT05667376|OTHER|Local drug delivery|Local application of curcumin gel into the periodontal pocket
48518022|NCT05667376|DRUG|curcumin gel|curcumin gel
48518023|NCT05481619|DRUG|Vedolizumab|"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."
48713725|NCT05481424|OTHER|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
48713726|NCT05396729|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
48713727|NCT03749096|DRUG|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
48713728|NCT03749096|DRUG|Placebos|Normal Saline
48713729|NCT01522144|BEHAVIORAL|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
48022027|NCT01911533|PROCEDURE|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
48022028|NCT01911533|PROCEDURE|No extracorporeal CO2-removal|Patients are their own control group.
48022029|NCT04463901|PROCEDURE|Pterygium excision|Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
48022030|NCT04463901|PROCEDURE|Intraoperative mitomycin C|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
48022031|NCT04463901|PROCEDURE|Conjunctival autograft|A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
48022032|NCT04463901|PROCEDURE|Limbal conjunctival autograft|A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
48379803|NCT05797948|DRUG|CD19/CD22 CAR-T|Targets of CAR-T cells are tandem CD19/CD22. 1 \* 10 \^ 7/kg dual-target CAR-T cells were reinfused with 10%, 30% and 60% of the total dose on d1, d2, d3 respectively.
48379804|NCT05797948|DRUG|Azacitidine For Injection|Azacitidine For Injection 100mg i.h. d1-d5;
48379805|NCT05797948|DRUG|Fludarabine|Fludarabine 300mg/m2 ivgtt d3-d5;
48379806|NCT05797948|DRUG|Cyclophosphamide|Cyclophosphamide 300mg/m2 ivgtt d3-d5.
48713730|NCT05000268|OTHER|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
48713731|NCT00000630|BIOLOGICAL|HIVAC-1e|
48379807|NCT00562874|DIETARY_SUPPLEMENT|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
48713732|NCT00000630|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
48713733|NCT02606227|BEHAVIORAL|Financial incentive|Vouchers
48713734|NCT02606227|OTHER|No financial incentive|No financial intervention
48713735|NCT04720768|DRUG|Binimetinib|MEK inhibitor
48713736|NCT04720768|DRUG|Encorafenib|BRAF inhibitor
48713737|NCT04720768|DRUG|Palbociclib|CDK4/6 inhibitor
48713738|NCT02787590|DRUG|Simvastatin|
48713739|NCT02787590|DRUG|Matched Placebo (for Simvastatin)|
48713740|NCT01945775|DRUG|talazoparib|Until progression or unacceptable toxicity develops
48713741|NCT01945775|DRUG|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
48713742|NCT01826266|DRUG|PER977, Placebo|
48713743|NCT05133713|DEVICE|Catheter directed therapy|Thrombectomy
48713744|NCT05133713|DRUG|Systemic anticoagulation|Conservative therapy
48713745|NCT05913102|DRUG|PDLLA|Administer PDLLA/saline every 2 weeks for 2.5 months
48713746|NCT04660721|COMBINATION_PRODUCT|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
48713747|NCT04660721|COMBINATION_PRODUCT|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
48713748|NCT05185895|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
48713749|NCT05185895|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
48713750|NCT02361424|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
48713751|NCT02361424|DRUG|placebo|
48713752|NCT04552548|OTHER|regional nerve block|Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
48713753|NCT04526873|BEHAVIORAL|Postcard|Mailed
48713754|NCT04526873|BEHAVIORAL|Phone call|May be automated or by human
48713755|NCT04526873|BEHAVIORAL|Humor/Salience|Funny cartoon + health risk examples
48713756|NCT04526873|BEHAVIORAL|Telehealth|Information about video visit
48713757|NCT06594796|BEHAVIORAL|Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)|One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
48713758|NCT06446908|BEHAVIORAL|Telehealth coaching for liver disease|"This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor."
48713759|NCT00033709|DRUG|temozolomide|
48713760|NCT00033709|DRUG|thalidomide|
48713761|NCT03397134|DRUG|Placebo Oral Tablet|Placebo administered as a single dose once daily
48713762|NCT03397134|DRUG|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
48518024|NCT03928301|BEHAVIORAL|Wholetones Music|Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
48518025|NCT03928301|BEHAVIORAL|Classical Music|Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
48713763|NCT03397134|DRUG|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
48713764|NCT05945056|OTHER|Frog Leg Exercise|The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.
48713765|NCT05945056|OTHER|Electrotherapy(Transcutaneous Electrical Nerve Stimulator)|TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
48713766|NCT05945056|OTHER|Exercise Therapy|Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
48713767|NCT02635334|DRUG|Montelukast 10 mg orally|
48713768|NCT02635334|OTHER|Placebo|
48713769|NCT03808363|OTHER|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
48713770|NCT03970174|OTHER|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
48713771|NCT00773240|DRUG|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
48713772|NCT00773240|DRUG|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
48713773|NCT05767502|DIAGNOSTIC_TEST|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~* Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~* Patients with an M+E score of 7 are assigned a verbal score of +2~* Patients with an M+E score of 8-9 are assigned a verbal score of +4~* Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~* 0 points if both pupils react to light,~* 1 point if a pupil does not react to light and has anisocoria,~* 2 points if both pupils do not react to light"
48713774|NCT00315770|PROCEDURE|weight loss diets for young adults|
48713775|NCT02983591|DRUG|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
48713776|NCT02983591|DRUG|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
48713777|NCT02983591|DRUG|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
48713778|NCT00806442|DRUG|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
48713779|NCT00806442|DIETARY_SUPPLEMENT|Corn Oil|9 g/day of corn oil
48713780|NCT04843098|DRUG|TL117|TL117 capsules orally once daily
48022033|NCT04798586|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
48022034|NCT06536166|DRUG|Ruxolitinib|IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.
48022035|NCT06536166|DRUG|Placebo|IBM patients treated by placebo, twice a day, during 12 months.
48022036|NCT05885347|OTHER|360 videos|Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.
48179573|NCT02648542|OTHER|Sham stimulation|Sham stimulation
48179574|NCT02305745|OTHER|Observational|
48179575|NCT00476112|DRUG|Vernakalant Injection 20 mg/mL|
48179576|NCT02895360|DRUG|BAL101553|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)
48179577|NCT02895360|DRUG|BAL101553 at MTD|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
48179578|NCT03516097|BEHAVIORAL|Structured school based intervention|Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
48713781|NCT04843098|DRUG|Paclitaxel|Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 28-day treatment cycle.
48022037|NCT05885347|OTHER|VR|Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.
48022038|NCT05885347|OTHER|AR|Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
48022039|NCT05885347|OTHER|Control group|Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
48022040|NCT01055392|DRUG|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
48022041|NCT01055392|DRUG|Placebo|Identical placebo tablets were administered twice-a-day for two years.
48022042|NCT00363714|DRUG|AGN211745|100microgram single intravitreal injection
48022043|NCT00363714|DRUG|AGN211745|200microgram single intravitreal injection
48022044|NCT00363714|DRUG|AGN211745|400microgram single intravitreal injection
48179579|NCT03516097|DEVICE|mobile app usage|The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
48179580|NCT05282251|DRUG|Intrapleural bupivacine nebulization|Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo
48179581|NCT05282251|DRUG|Intravenous paracetamol and ketorolac|Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
48713782|NCT01451229|DRUG|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
48713783|NCT02699151|DRUG|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
48713784|NCT02699151|PROCEDURE|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
48713785|NCT02699151|OTHER|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
48379808|NCT00562874|DIETARY_SUPPLEMENT|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
48379809|NCT00562874|DIETARY_SUPPLEMENT|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
48379810|NCT03323034|DRUG|Irinotecan|Given IV
48379811|NCT03323034|DRUG|Pevonedistat|Given IV
48379812|NCT03323034|DRUG|Temozolomide|Given PO
48379813|NCT04139642|DEVICE|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
48713786|NCT05890378|OTHER|Testing water|Using existing secondary data available on the research communities as well as qualitative inquiry, we will purposefully select 40 water sources for the water analysis across from the communities selected for the implementation research (up to 30 communities with a maximum of 5 water sources per community). The selection of water sources will be stratified by type of water sourceand near the route for long-term animal migration. For each water source, we will aim to have a water sample collected at all water sources twice a day (morning and later afternoon) once a week for four weeks, varying the day of the week. Thus, we will collect a total of 320 water samples in the course of four weeks at the end of the dry season before the rains start.
48713787|NCT01344629|DRUG|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
48713788|NCT01344629|DRUG|Telmisartan|Telmisartan 80 mg tablet
48713789|NCT01344629|DRUG|Amlodipin|Amlodipin 5mg tablet
48713790|NCT06437886|OTHER|opioid-sparing protocol|Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
48713791|NCT01609335|DRUG|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
48713792|NCT01609335|DRUG|C-11 PiB|One time intravenous administration of 10-20 mCi
48713793|NCT05556629|OTHER|No Intervention|This is a non-interventional study.
48713794|NCT02876497|OTHER|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
48713795|NCT01561547|BEHAVIORAL|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
48022045|NCT00363714|DRUG|AGN211745|800microgram single intravitreal injection
48022046|NCT00363714|DRUG|AGN211745|1200microgram single intravitreal injection
48022047|NCT00363714|DRUG|AGN211745|1600microgram single intravitreal injection
48022048|NCT01183793|RADIATION|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
48022049|NCT03626181|DEVICE|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
48022050|NCT00141440|PROCEDURE|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
48179582|NCT02599922|BIOLOGICAL|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
48179583|NCT04921579|PROCEDURE|En masse retraction|Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.
48379814|NCT06549439|RADIATION|Electron FLASH radiotherapy|A nominal electron energy of 9 MeV will be used for both Flash-RT and Conv-RT, which guarantees ≥ 90% dose coverage up to a depth of 2.8 cm. Shallower lesions will be treated with the same electron energy and with a bolus. In order to treat these patients, field sizes between 2x2cm2 and 10x10cm2 will be used, which can be delivered with sufficient flatness (\<5%) and symmetry (\<2%) by the FlashTrueBeam v2.7.5.
48379815|NCT04136522|PROCEDURE|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
48713796|NCT01561547|DIETARY_SUPPLEMENT|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
48713797|NCT02252601|OTHER|HFDT test|
48713798|NCT02252601|OTHER|Pure tone Audiogram|
48713799|NCT02031224|BEHAVIORAL|Conventional low protein diet|
48713800|NCT02031224|DIETARY_SUPPLEMENT|Very low protein diet supplemented with Ketosteril|
48713801|NCT02152514|DRUG|Intrathecal Morphine/Sufentanil|
48179584|NCT04921579|PROCEDURE|Two-Step retraction|Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
48713802|NCT02152514|DEVICE|PCA|
48713803|NCT02695368|DEVICE|Novaerus NV800 on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
48713804|NCT02695368|DEVICE|Novaerus NV800 off|The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
48179585|NCT03339947|OTHER|Questionnaire|
48518026|NCT02716545|DEVICE|balloon assisted enteroscopy|Patients with recurrent bleeding (\>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
48518027|NCT02559180|DRUG|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
48179586|NCT00113269|DRUG|basiliximab|IV
48518028|NCT00141089|DRUG|Tegaserod|
48179587|NCT00113269|DRUG|rabbit anti-thymocyte globulin|IV
48179588|NCT00113269|DRUG|tacrolimus|oral
48179589|NCT00113269|DRUG|alemtuzumab|Intravenous (IV)
48179590|NCT00113269|DRUG|mycophenolate mofetil|oral
48179591|NCT00113269|DRUG|steroids|IV and/or oral
48179592|NCT00321685|BIOLOGICAL|Bevacizumab|Given IV
48179593|NCT00321685|DRUG|Capecitabine|Given PO
48179594|NCT00321685|DRUG|Fluorouracil|Given IV
48179595|NCT00321685|DRUG|Leucovorin Calcium|Given IV
48179596|NCT00321685|DRUG|Oxaliplatin|Given IV
48179597|NCT00321685|RADIATION|Radiation Therapy|Undergo radiotherapy
48179598|NCT00321685|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
48379816|NCT04136522|PROCEDURE|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
48518029|NCT01445704|DIETARY_SUPPLEMENT|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
48518030|NCT01445704|DIETARY_SUPPLEMENT|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
48518031|NCT02172807|DRUG|Tiotropium low|Tiotropium 18 µg inhalation capsule
48518032|NCT02172807|DRUG|Tiotropium high|Tiotropium 36 µg inhalation capsule
48713805|NCT02695368|DEVICE|Novaerus NV800 on or off|Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
48713806|NCT02248207|DRUG|Pramipexole|
48713807|NCT00240110|DRUG|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
48713808|NCT00240110|DRUG|Placebo|Control arm
48713809|NCT00240110|DRUG|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
48713810|NCT04214431|BEHAVIORAL|Mindfulness-Based Childbirth Education|8-week mindfulness-based childbirth education
48713811|NCT05482659|BEHAVIORAL|Health education on healthy nutrition and regular physical activity based on the transtheoretic model|An announcement was made by visiting all the faculties at Nuh Naci Yazgan University, stating the content of the research and the duration of the research. Among the volunteer students, students who met the inclusion criteria were included in the study. Afterwards, the students were assigned to the groups by the statistician using a simple randomization method. As a result of the pre-test, it was determined which change stage each student was in according to the Transtheoretic model (TTM). The students were not given information about which group they were in and what stage they were in according to TTM. Health education was given to university students once a week by online education method and it took 4 weeks-30 days to complete the research. The average duration of the health education given to each student is 30-45 minutes. When the training process was over, the post-test questions were sent to the students by the online survey method.
48713812|NCT00671372|DRUG|FOLFIRI regimen|Intravenous repeating dose
48713813|NCT00671372|DRUG|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
48713814|NCT00671372|DRUG|cetuximab|Intravenous repeating dose
48379817|NCT00566397|DRUG|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
48379818|NCT00566397|DRUG|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
48379819|NCT00566397|DRUG|Placebo|Placebo
48379820|NCT00336531|DRUG|itraconazole|2.5 mg/kg twice daily for the first two days --\> once daily
48379821|NCT03722459|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
48379822|NCT05688527|OTHER|Cleansing Balm|DermResults Cleansing Balm w/ Avocado Oil twice daily
48379823|NCT05688527|OTHER|Toning Essence|DermResults Advanced Toning Essence w/ Mineral Booster twice daily
48379824|NCT05688527|OTHER|Facial Serum|DermResults Advanced Serum w/ Hyaluronic Acid twice daily
48379825|NCT05688527|OTHER|Moisturizer|DermResults Advanced Moisturizer w/ Hyaluronic Acid twice daily
48379826|NCT05688527|OTHER|Eye Cream|DermResults Advanced Eye Cream w/ Hyaluronic Acid twice daily
48379827|NCT06622083|OTHER|Education|Students in both groups will be given 40 minutes of both theoretical and practical training on the anatomy of the pelvic floor, its contraction mechanism, function and dysfunctions, evaluation and physiotherapy and rehabilitation. Theoretical training will be given through presentation and question-answer techniques containing this information, and practical training will be given through a pelvic model and gynecological examination simulator.
48379828|NCT06622083|OTHER|Education and Aerobic exercise|Participants in the exercise group will undergo an aerobic exercise program using the Monark 938E Nova Ergometer and software before the training session. The bike operates with its computer software integrated with the ECG system. The aerobic exercise program will consist of 3-5 minutes of warm-up, 20 minutes of exercise, and 3-5 minutes of cool-down, performed at a moderate intensity. During the exercise session, heart rate will be recorded every 5 minutes using a Polar ECG sensor connected via Bluetooth to the 938E Nova Ergometer, while perceived exertion will be measured using Borg's 6-20 rating scale
48379829|NCT06313697|BIOLOGICAL|GR2102 injection|single dose
48379830|NCT06313697|BIOLOGICAL|placebo|single dose
48379831|NCT02611076|BEHAVIORAL|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
48379832|NCT02611076|BEHAVIORAL|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
48379833|NCT02865616|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
48379834|NCT02865616|DRUG|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
48379835|NCT01092676|DRUG|Ibuprofen Regular Dosing|Regular dosing
48379836|NCT01092676|DRUG|PRN dosing Ibuprofen|PRN dosing Ibupofen
48379837|NCT02592070|BEHAVIORAL|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
48379838|NCT06652477|DIAGNOSTIC_TEST|ELISA|ElISA kit to detect autoantibodies against desmoglein 3 in tissues of oral lichen planus lesions
48379839|NCT02599298|DEVICE|Continuous Positive Airway Therapy|
48379840|NCT02599298|BEHAVIORAL|Sleep-Study Guided Multidisciplinary Therapy|
48379841|NCT01640964|DRUG|Terlipressin acetate|IV bolus injection
48379842|NCT01640964|DRUG|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
48379843|NCT02860026|OTHER|Marketed cow's milk-based infant formula|
48379844|NCT02860026|OTHER|Cow's milk-based infant formula with added nutrients|
48379845|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
48379846|NCT04755088|DRUG|Surufatinib|Subjects to receive Surufatinib 300mg on Day 1
48379847|NCT02668445|OTHER|Standard meal containing low or high carbohydrate content|
48379848|NCT04615338|OTHER|no intervension|no intervention needed just observation and description
48379849|NCT03605277|DRUG|Asciminib|40 mg single dose
48379850|NCT04529941|DEVICE|Device Implant with Active Treatment|ScNS at 3.5mA output for 2 weeks
48379851|NCT04529941|DEVICE|Device Implant without Active Treatment|No device output for 2 weeks
48379852|NCT02224794|DEVICE|Ovation® Abdominal Stent Graft Platform|
48518033|NCT02172807|DRUG|Placebo MDI|Placebo metered dose inhaler (MDI)
48379853|NCT04960137|DEVICE|button plates fixation system|The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
48518034|NCT02172807|DRUG|Placebo inhalation capsule|
48518035|NCT02172807|DRUG|Oxitropium|Oxitropium MDI (100 µg/puff)
48713815|NCT00671372|DRUG|dulanermin|Intravenous repeating dose
48179599|NCT05213442|DIAGNOSTIC_TEST|To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.|"Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires)."
48179600|NCT04811326|RADIATION|NB-UVB|radiation
48179601|NCT04811326|DRUG|Latanoprost|eye drops
48379854|NCT04960137|DEVICE|Non-absorbable Suture Anchor|A conventional device used in surgery for shoulder dislocation.
48379855|NCT02057549|DRUG|Haloperidol|Intravenous dose of haloperidol 5 mg.
48379856|NCT02057549|DRUG|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
48379857|NCT02530801|DRUG|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
48379858|NCT02530801|DRUG|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
48379859|NCT01511562|DRUG|carmustine|Given IV
48379860|NCT01511562|DRUG|cytarabine|Given IV
48379861|NCT01511562|DRUG|etoposide|Given IV
48713816|NCT00671372|DRUG|irinotecan|Intravenous repeating dose
48713817|NCT06375785|OTHER|Otago-based (slow rhythmic) exercise group|"Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position"
48022051|NCT04401228|OTHER|predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables?|"patients were questioned about their usual medication (Sartan, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drug, immunosuppressive drugs), their health condition (diabetes, hypertension, tobacco use, mental status). The Body mass index was computed.~Age, gender, caucasian/african, weight, body mass index, number of days with symptoms before hospitalization, asthenia, pyrexia, dyspnea, chest pain, digestive sign, anosmia, ageusia, confusion, Travel or contact \< one month, cigarette consumption ,hypertension, diabetes, mental status, angiotensin-converting-enzyme inhibitors, Sartan, non-steroidal anti-inflammatory drugs, immunosuppressive drugs, SpO2,Thoracic Computerized Tomography : % of lung injury, Thoracic Computerized Tomography : density of lung injury, blood type, white blood cells, neutrophils, lymphocytes, blood platelets, fibrinogen, ferritin, triglycerides, LDH, troponin, CRP. The dates of admission to ICU and death were recorded"
48022052|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
48022053|NCT00917592|DRUG|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
48179602|NCT02875145|PROCEDURE|Cataract surgery|
48179603|NCT06367634|DEVICE|injection in NLF|TEOSYAL® PureSense ULTRA DEEP is a sterile, transparent, non-pyrogenic, viscoelastic gel made of HA of non-animal origin
48179604|NCT05382039|DEVICE|Transcutaneous Electrical Nerve Stimulation|High frequency sensory transcutaneous electrical nerve stimulation
48179605|NCT04036045|OTHER|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
48379862|NCT01511562|DRUG|thiotepa|Given IV
48379863|NCT01511562|PROCEDURE|stem cell transplant|
48379864|NCT01511562|DRUG|G-CSF|
48518036|NCT01659957|BEHAVIORAL|Group Couples Counseling|
48518037|NCT01659957|BEHAVIORAL|One-on-One Couples Counseling|
48518038|NCT06138691|COMBINATION_PRODUCT|Ketamine Infusion plus RO DBT|The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
48713818|NCT06375785|OTHER|LSVT BIG-based (large amplitude) exercise group|"Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking"
48713819|NCT01921413|DEVICE|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
48713820|NCT00420173|PROCEDURE|Laboratory analysis|blood withdrawal
48713821|NCT05094479|BEHAVIORAL|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
48713822|NCT06008496|PROCEDURE|Day case surgery|Operation, surgical group, magnitude of surgery, anaesthetic type.
48713823|NCT04333940|PROCEDURE|periapical surgery|clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
48713824|NCT03283969|OTHER|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
48713825|NCT03283969|OTHER|Isocaloric powder|Isocaloric powder
48713826|NCT01871155|DIETARY_SUPPLEMENT|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
48379865|NCT02618148|DRUG|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
48713827|NCT00320255|DRUG|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
48179606|NCT04036045|OTHER|Echocardiogram|Patients will have an echocardiogram at four time points during the study
48379866|NCT02618148|DRUG|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
48379867|NCT04796259|DIETARY_SUPPLEMENT|Malt ingredient|Solution with malt-derived ingredient
48379868|NCT04796259|DIETARY_SUPPLEMENT|Non-alcoholic beer solids|Solution with non-alcoholic beer solids
48518039|NCT01694225|OTHER|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
48713828|NCT00320255|DRUG|Placebo|Oral tablets administered once daily
48713829|NCT03833570|DIETARY_SUPPLEMENT|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
48713830|NCT03833570|DRUG|Miconaz oral gel|Antifungal agent
48713831|NCT03833570|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
48179607|NCT04036045|OTHER|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
48179608|NCT01081275|BEHAVIORAL|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
48379869|NCT02365701|DRUG|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
48379870|NCT02365701|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
48713832|NCT03833570|DRUG|Oracure gel|Topical analgesic gel
48713833|NCT03833570|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
48713834|NCT02189499|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
48713835|NCT01173549|DRUG|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
48713836|NCT01173549|OTHER|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
48713837|NCT04333602|DIAGNOSTIC_TEST|Urinary culture and treatment if asymptomatic bacteriuria is detected|Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
48713838|NCT06467669|OTHER|Wrist denervation procedure|To summarize, a Wagner incision is made starting over the junction of the glabrous and non-glabrous skin overlying the thumb CMC joint extending toward the distal wrist crease. The branches of the superficial radial nerve are identified as lying perpendicular to the plane overlying the fascia of the thenar muscles. The branches of the lateral antebrachial cutaneous nerve are identified and resected within the anatomic snuffbox deep to the first compartment. Finally, the thenar muscle fibers are divided at their proximal origin to identify the articular branches of the posterior cutaneous branch of the median nerve.
48713839|NCT03270267|OTHER|Questionnaires|
48713840|NCT06256354|OTHER|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
48713841|NCT06256354|OTHER|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8℃."
48713842|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the reception area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the treatment room after meeting the child in the reception area while wearing the friendly attire.
48713843|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in the treatment area in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the treatment room after meeting the child in the reception area while wearing the conventional attire.
48713844|NCT06122883|BEHAVIORAL|Evaluation the effectiveness of distraction in both reception and treatment areas in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing friendly attire in the reception area and treatment room.
48379871|NCT03611595|DRUG|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
48379872|NCT03611595|DRUG|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
48713845|NCT06122883|BEHAVIORAL|Evaluation of the effectiveness of basic behavior guidance techniques without using any type of distraction aids in the management of anxious pediatric patients during dental local anesthesia|Buccal and palatal infiltration will be administrated with basic behavior guidance techniques while the dentist wearing conventional attire in the reception area and treatment room.
48379873|NCT01042379|DRUG|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
48713846|NCT00000504|DRUG|encainide|
48713847|NCT00000504|DRUG|moricizine|
48713848|NCT00000504|DRUG|flecainide|
48713849|NCT00000504|DRUG|imipramine|
48713850|NCT01670565|DRUG|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
48713851|NCT01670565|DRUG|Mycophenolate Mofetil|Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
48713852|NCT01670565|OTHER|Placebo Infusion|Infusion of normal saline
48379874|NCT01042379|DRUG|AMG 386 with or without Trastuzumab|Arm is closed.
48713853|NCT01228994|DRUG|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
48713854|NCT01228994|DRUG|placebo pill|placebo pill
48379875|NCT01042379|DRUG|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
48379876|NCT01042379|DRUG|MK-2206 with or without Trastuzumab|Arm is closed.
48379877|NCT01042379|DRUG|AMG 386 and Trastuzumab|Arm is closed.
48179609|NCT01081275|BEHAVIORAL|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
48179610|NCT02834936|DRUG|pyrotinib|
48179611|NCT00040495|DRUG|Pantoprazole|
48379878|NCT01042379|DRUG|T-DM1 and Pertuzumab|Arm is closed.
48379879|NCT01042379|DRUG|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
48518040|NCT03640494|DEVICE|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
48518041|NCT02681510|DRUG|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
48518042|NCT02681510|DRUG|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
48713855|NCT01228994|DRUG|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
48518043|NCT02681510|DRUG|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
48518044|NCT01223378|DRUG|BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
48518045|NCT01223378|DRUG|Latanoprost|0.005% ophthalmic solution, QD 28 days
48518046|NCT02411825|DRUG|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48518047|NCT02411825|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
48518048|NCT02411825|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
48518049|NCT03431714|DRUG|Artesunate amodiaquine|Drugs were administered under observation of the study nurse for three days
48518050|NCT01169792|DRUG|tamoxifen|
48713856|NCT05501613|DIAGNOSTIC_TEST|Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring
48713857|NCT02680210|OTHER|Questionnaires and cognitive measures|
48713858|NCT06128980|DRUG|GDMT|Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
48713859|NCT02823184|BIOLOGICAL|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
48713860|NCT05270291|PROCEDURE|rectal swab|rectal swab
48713861|NCT03622034|OTHER|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
48713862|NCT05593276|BEHAVIORAL|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
48713863|NCT02804308|BEHAVIORAL|Combined Training|
48713864|NCT06521437|DEVICE|TMS targeting the hippocampus indirectly via its network|Subjects will receive high-frequency repetitive TMS to a parieto-occipital location defined in each subject based on high resting-state fMRI connectivity with the hippocampus at baseline
48713865|NCT05569876|OTHER|Controlled hypoglycemic state|Voice sampling is performed in different glycemic states (euglycemia and hypoglycemia).
48713866|NCT01503996|BEHAVIORAL|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
48379880|NCT01042379|DRUG|Ganetespib|Arm is closed.
48713867|NCT01067599|OTHER|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
48379881|NCT01042379|DRUG|ABT-888|Arm is closed.
48379882|NCT01042379|DRUG|Neratinib|Arm is closed.
48518051|NCT02237703|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
48518052|NCT05761899|COMBINATION_PRODUCT|Gene-Corrected Macrophages administered by bronchoscopic instillation|This study will evaluate administration of autologous bone marrow CD34+ cell-derived, CSF2RA lentiviral vector-transduced macrophages (CSF2RA gene-corrected macrophages) by bronchoscopic instillation into individual lung segments on three occasions at 2-month intervals in patients with hPAP. The target (maximum) number of cells to be administered is 778 million gene-corrected macrophages per 70 kg patient, which is equal to 11.1 million cells/kg of ideal body weight.
48518053|NCT02163265|PROCEDURE|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
48518054|NCT00100308|DRUG|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
48518055|NCT00100308|DRUG|saline|Saline placebo
48518056|NCT01948115|DRUG|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
48518057|NCT00006286|DRUG|Fluoxetine|
48518058|NCT00006286|BEHAVIORAL|Psychotherapy|
48713868|NCT01067599|OTHER|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
48379883|NCT01042379|DRUG|PLX3397|Arm is closed.
48713869|NCT01067599|OTHER|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
48713870|NCT02193087|DRUG|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
48713871|NCT02193087|DRUG|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
48713872|NCT02193087|DRUG|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
48713873|NCT02193087|DRUG|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
48713874|NCT02165293|DRUG|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
48713875|NCT02358044|DRUG|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
48713876|NCT02358044|BIOLOGICAL|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
48713877|NCT02358044|DRUG|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
48713878|NCT02358044|DRUG|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
48379884|NCT01042379|DRUG|Pembrolizumab - 4 cycle|Arm is closed.
48379885|NCT01042379|DRUG|Talazoparib plus Irinotecan|Arm is closed.
48379886|NCT01042379|DRUG|Patritumab and Trastuzumab|Arm is closed.
48379887|NCT01042379|DRUG|Pembrolizumab - 8 cycle|Arm is closed.
48379888|NCT01042379|DRUG|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
48379889|NCT01042379|DRUG|Durvalumab plus Olaparib|Arm is closed.
48379890|NCT01042379|DRUG|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
48379891|NCT01042379|DRUG|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
48379892|NCT01042379|DRUG|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
48379893|NCT01042379|DRUG|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
48379894|NCT01042379|DRUG|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
48379895|NCT01042379|DRUG|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
48379896|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
48713879|NCT03069287|BEHAVIORAL|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
48713880|NCT01376375|PROCEDURE|Acupuncture|
48713881|NCT00775112|DEVICE|pillow|use of pillow for lumbar punctures
48179612|NCT00085566|DRUG|everolimus|
48179613|NCT00085566|DRUG|gefitinib|
48713882|NCT05455580|BEHAVIORAL|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
48713883|NCT01711281|DEVICE|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
48713884|NCT03283436|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
48713885|NCT02608450|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
48713886|NCT02608450|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
48713887|NCT04907435|PROCEDURE|simultaneous operations|simultaneous operations
48713888|NCT05818761|DEVICE|virtual reality|wearing virtual reality glasses
48713889|NCT05818761|BEHAVIORAL|stress ball|squeezing the stress ball during the attempt
48713890|NCT03194191|DEVICE|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
48713891|NCT06360081|DRUG|Zongertinib|Zongertinib
48713892|NCT03236168|DRUG|Ivermectin|A single weight based dose of ivermectin
48713893|NCT03236168|DRUG|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
48713894|NCT03236168|DRUG|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
48713895|NCT03159507|DIETARY_SUPPLEMENT|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
48713896|NCT00989235|DRUG|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
48713897|NCT00989235|DRUG|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
48713898|NCT01389349|OTHER|Acupuncture|Battlefield acupuncture protocol
48179614|NCT00097838|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
48379897|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
48713899|NCT01389349|OTHER|Sham Control|Sham control acupuncture
48713900|NCT05581095|BEHAVIORAL|Mindful Eating Self-Help Program|10-week exposure to mindful eating principles and practices outlined in the Eat What You Love, Love What You Eat for Binge Eating book
48713901|NCT05581095|BEHAVIORAL|Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)|10-week exposure to using a mindful eating mobile phone application daily.
48713902|NCT04922931|PROCEDURE|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
48713903|NCT03080883|DRUG|Apixaban|Given PO
48379898|NCT01042379|DRUG|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
48379899|NCT01042379|DRUG|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
48379900|NCT01042379|DRUG|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
48379901|NCT01042379|DRUG|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
48379902|NCT01042379|DRUG|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
48379903|NCT01042379|DRUG|VV1 + Cemiplimab|VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
48379904|NCT01042379|DRUG|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
48379905|NCT01042379|DRUG|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
48379906|NCT01042379|DRUG|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
48379907|NCT01042379|DRUG|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
48379908|NCT01042379|DRUG|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
48379909|NCT01042379|DRUG|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
48713904|NCT05650138|OTHER|Jacobson's progressive muscular relaxation technique|subjects will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks.
48713905|NCT05650138|OTHER|30 min walk|30 minutes walk twice a week for 4 weeks
48379910|NCT01042379|DRUG|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
48379911|NCT01042379|DRUG|ARV-471 + Abemaciclib|ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
48379912|NCT01042379|DRUG|Endoxifen + Abemaciclib|Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
48379913|NCT01042379|DRUG|Rilvegostomig + TDXd|Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
48379914|NCT01042379|DRUG|Dan222 + Niraparib|DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
48379915|NCT01042379|DRUG|Sarilumab + Cemiplimab + Paclitaxel|Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
48379916|NCT02736006|OTHER|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
48379917|NCT03396601|DRUG|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
48379918|NCT03396601|DRUG|Placebo|Normal Saline placebo will be infused IV over 40 minutes
48379919|NCT02244385|OTHER|no intervention|
48379920|NCT00168766|DRUG|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
48379921|NCT03291249|DRUG|Foralumab|Anti CD3 mAb
48713906|NCT04720716|DRUG|IBI310|IBI310 IV d1, Q6W
48713907|NCT04720716|DRUG|Sintilimab|sintilimab IV d1, Q3W
48713908|NCT04720716|DRUG|Sorafenib|Sorafenib 400mg po
48713909|NCT04139681|DRUG|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
48713910|NCT05606419|DIETARY_SUPPLEMENT|CDED+PEN|Dietary intervention (Liquid food replacement intervention and specific exclusion diet). Focus on 24 hour diet recalls to asses adherence.
48713911|NCT05606419|DIETARY_SUPPLEMENT|PEN+usual care|Liquid food replacement intervention and regular diet. Focus on 24 hour diet recalls and FFQ to asses dietary habits.
48379922|NCT03291249|OTHER|placebo|Placebo oral solution
48713912|NCT05606419|DIETARY_SUPPLEMENT|CDED+dairy|Dietary intervention (Specific exclusion diet plus early dairy introduction). Focus on 24 hour diet recalls to asses adherence.
48713913|NCT01437644|DRUG|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
48713914|NCT04942665|DRUG|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
48713915|NCT04942665|DEVICE|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
48379923|NCT03291249|DRUG|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
48379924|NCT03743571|DEVICE|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
48713916|NCT06453603|DRUG|PRP injection|Receive pes anserinus PRP injection
48518059|NCT06581276|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is an evidence-based behavioral pain treatment intervention for Chronic Pain, anxiety and depression, and substance use disorders, being studied as a group-based therapy delivered by substance use counselors in an opioid treatment program.
48379925|NCT03743571|BEHAVIORAL|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
48713917|NCT06453603|DRUG|corticosteroid injection|Receive pes anserinus corticosteroid injection
48379929|NCT02615652|OTHER|no intervention|no intervention, observational study
48379930|NCT03486015|DRUG|Sterile water|2 ml of sterile water
48379931|NCT03486015|DRUG|30% glucose|2 ml of 30% glucose
48713918|NCT04783649|DIAGNOSTIC_TEST|Papanicolaou cytological test|Cervical smear stained using conventional Papanicolaou technique.
48379932|NCT00259311|DRUG|LY2422347|
48379933|NCT00259311|DRUG|placebo|
48379934|NCT03240809|BIOLOGICAL|Brodalumab|140 mg SC dose
48379935|NCT03240809|BIOLOGICAL|Brodalumab|70 mg SC dose
48379936|NCT03076307|BEHAVIORAL|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
48518061|NCT02737774|DRUG|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
48379937|NCT03572049|DRUG|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
48379938|NCT03572049|DRUG|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
48379939|NCT02921607|OTHER|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
48379940|NCT01717729|PROCEDURE|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
48713919|NCT04783649|DIAGNOSTIC_TEST|Local cytological test (H&E stain)|Cervical smear stained using conventional hematoxylin and eosin staining techniques
48713920|NCT04783649|DIAGNOSTIC_TEST|Validated HPV DNA Test|Digene HC2 HPV DNA Test
48713921|NCT04783649|DIAGNOSTIC_TEST|Local HPV test|RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)
48713922|NCT04783649|DIAGNOSTIC_TEST|Colposcopy|Women with positive cytology results are referred to colposcopy and biopsy
48713923|NCT04348175|DRUG|Setmelanotide|Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
48713924|NCT04272008|DRUG|Segesterone Acetate and Ethinyl Estradiol|Annovera taken alone
48713925|NCT04272008|OTHER|Tampon|Annovera with tampon use
48713926|NCT01637389|OTHER|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
48379941|NCT01717729|RADIATION|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
48379942|NCT04375527|DRUG|Binimetinib|Given PO
48518062|NCT02737774|DRUG|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
48713927|NCT01637389|OTHER|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
48713928|NCT01731834|OTHER|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
48713929|NCT05458089|DIAGNOSTIC_TEST|18F-FDG|18F-FDG intravenous injection
48713930|NCT06348914|BEHAVIORAL|Knowledge assessment|survey on knowledge of a group of dental students regarding vital pulp therapy
48713931|NCT06348914|OTHER|Educational Material|An awareness lecture on vital pulp therapy will be given to a group of the students right after they answer the questionnaire for the first time.
48518063|NCT03068728|DEVICE|Arista|
48713932|NCT01656226|DEVICE|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
48379943|NCT04375527|BIOLOGICAL|Nivolumab|Given IV
48379944|NCT04375527|OTHER|Questionnaire Administration|Ancillary studies
48379945|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
48379946|NCT00938015|OTHER|Questionnaire|This is a non-interventional study
48379947|NCT04144309|PROCEDURE|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: Ten points will be used, including GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), CV12 (Zhongwan), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), SP6 (Sanyinjiao), KI3 (Taixi).~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
48518064|NCT03068728|DEVICE|Nexfoam|
48518065|NCT03068728|DEVICE|Nasopore|
48379948|NCT04144309|PROCEDURE|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
48379949|NCT03176576|BEHAVIORAL|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
48379950|NCT03176576|OTHER|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
48713933|NCT01656226|OTHER|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
48713934|NCT01688843|DEVICE|INGEVITY lead|
48713935|NCT00737594|DRUG|Placebo|Matching placebo capsules for oral administration
48713936|NCT00737594|DRUG|Cobiprostone|Cobiprostone capsules for oral administration
48713937|NCT01887119|DRUG|Eplerenone|
48713938|NCT01887119|OTHER|Placebo|Eplerenone-matched placebo
48713939|NCT06096974|DRUG|YL-17231|YL-17231 will be administered orally once daily in a continuous regimen
48713940|NCT00276094|DRUG|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
48713941|NCT00276094|DRUG|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
48713942|NCT00276094|DRUG|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
48713943|NCT00276094|DRUG|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
48713944|NCT02582281|DEVICE|intrauterine device TCu 380A|
48379951|NCT03176576|OTHER|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
48379952|NCT03176576|OTHER|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
48379953|NCT04800510|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
48379954|NCT06116799|DEVICE|Orthotic|Arch support orthotic
48379956|NCT00018343|DRUG|estrogen|
48379957|NCT04985825|DRUG|Imgatuzumab|Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
48379958|NCT06538311|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
48713945|NCT05203367|DRUG|BAR502|"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."
48713946|NCT05203367|DRUG|Placebo|Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
48713947|NCT01283490|DEVICE|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
48518066|NCT01395927|DRUG|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
48379959|NCT06538311|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
48379960|NCT06566469|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
48379961|NCT06566469|DRUG|Esketamine|Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
48379962|NCT06566469|DRUG|Normal saline|Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
48518067|NCT01395927|DRUG|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
48518068|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block|
48518069|NCT03228797|PROCEDURE|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
48518070|NCT03228797|PROCEDURE|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
48713948|NCT01283490|DEVICE|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
48713949|NCT02154048|DRUG|Ropivacaine|
48713950|NCT02154048|DRUG|Dexamethasone|
48713951|NCT02154048|OTHER|Placebo|
48713952|NCT04412213|OTHER|Stuttering severity instrument for school-age children (SSI-3 Arabic version)|Stuttering severity instrument for school-age children (SSI-3 Arabic version) for measuring stuttering severity Stanford Binet test version 4 to evaluate the mentality (IQ)
48713953|NCT05703620|DEVICE|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
48713954|NCT03452904|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
48713955|NCT03452904|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
48022054|NCT05363891|DRUG|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
48022055|NCT05363891|DRUG|Placebo|Placebo
48022056|NCT02259621|DRUG|Nivolumab|Anti-PD-1 Therapy
48379963|NCT05712603|DIAGNOSTIC_TEST|FIB4-score|A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
48379964|NCT05712603|DIAGNOSTIC_TEST|Vibration controlled transient elastography|VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
48379965|NCT05712603|DIAGNOSTIC_TEST|Enhanced Liver Fibrosis test|The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
48379966|NCT00369798|PROCEDURE|PET scan|
48713956|NCT03070197|OTHER|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
48713957|NCT03070197|OTHER|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
48379967|NCT00369798|DRUG|Rolipram|
48379968|NCT00370929|BEHAVIORAL|Meditation|
48379969|NCT06566833|DRUG|self assmbling peptide p11-4 combined with 0.05% fluoride|biomimetic remineralizing agent
48379970|NCT06566833|DRUG|Casein phosphopeptide amorphous calcium phosphate|remineralizing agents that acts as a fluoride booster
48379971|NCT06566833|DRUG|5% sodium fluoride varnish|remineralizing agent that is used as a gold standard for remineralization
48518071|NCT01822717|BEHAVIORAL|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
48518072|NCT01822717|BEHAVIORAL|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
48713958|NCT01568372|OTHER|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
48713959|NCT05639322|DRUG|Ketamine Hydrochloride|Ketamine-HCL IV 1mg/kg (up to 100 mg) over 2 hours, on weeks 2, 7, and 12.
48713960|NCT05639322|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioural Therapy/ Mindfulness Based Meditation therapy (CBT/MM) remotely for 16 hours between weeks 1 to 16 inclusive + in-person sessions on weeks 2, 7 and 12
48713961|NCT05639322|OTHER|Ketamine + Cognitive Behavioral Therapy|Ketamine-HCL + CBT/MM according to the same directions specified in Arm 1 and Arm 2.
48713962|NCT00236418|DRUG|topiramate|
48713963|NCT02675192|OTHER|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
48713964|NCT05765149|OTHER|No intervention|This is an observational study, no intervention will be implemented.
48713965|NCT01209663|OTHER|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
48713966|NCT04104074|RADIATION|Radiotherapy|"Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.~Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy."
48713967|NCT04104074|DRUG|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
48518073|NCT03031418|DIAGNOSTIC_TEST|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
48179615|NCT00097838|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
48179616|NCT04418661|DRUG|SAR442720|Pharmaceutical form: Varies Route of administration: Varies
48179617|NCT04418661|DRUG|Pembrolizumab|Pharmaceutical form:Sterile Lyophilized powder for reconstitution Route of administration: Infusion
48179618|NCT04418661|DRUG|Adagrasib|Pharmaceutical form:Sterile Tablet Route of administration: Oral
48179619|NCT01488955|DRUG|Ibuprofen|400 mg oral once a day from day 0 for 3 days
48179620|NCT01488955|DRUG|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
48179621|NCT02854371|DRUG|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
48179622|NCT02854371|DRUG|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
48179623|NCT02291822|DRUG|Gadobenate Dimeglumine|gadolinium contrast agent
48179624|NCT05052502|OTHER|Case Management and Follow-up|"Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions."
48179625|NCT05052502|OTHER|Reactive focal mass drug administration (rfMDA)|"Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials.~For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants."
48179626|NCT04731974|DRUG|Melatonin 3 MG|Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
48518074|NCT04966871|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
48713968|NCT01416441|DRUG|Aripiprazole|Aripiprazole tablets orally once daily.
48179627|NCT04731974|OTHER|Placebo|Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
48713969|NCT03047018|BEHAVIORAL|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
48713970|NCT02998047|DRUG|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
48713971|NCT04806490|DIAGNOSTIC_TEST|the diagnosis for Yin Deficiency Syndrome|The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
48713972|NCT01878669|DRUG|N-acetyl cysteine|
48022057|NCT02259621|DRUG|Carboplatin|Anti-PD-1 Therapy
48022058|NCT02259621|DRUG|Paclitaxel|Anti-PD-1 Therapy
48518075|NCT04966871|BIOLOGICAL|PfSPZ Challenge (7G8) for CHMI|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
48518076|NCT04966871|OTHER|Normal Saline|normal saline placebo control
48518077|NCT03493412|DRUG|Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)|5 mg/kg will be used as the dose of BH4
48713973|NCT01878669|DRUG|Saline|
48518078|NCT03493412|DRUG|Placebo|Placebo
48518079|NCT06456242|BEHAVIORAL|CounsCM+MedCM (Health Rewards)|Small financial incentives for completing quitline calls (CounsCM) plus small financial incentives for taking varenicline (MedCM).
48713974|NCT05976451|COMBINATION_PRODUCT|melatonin with collagen matrix|(CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
48713975|NCT05976451|COMBINATION_PRODUCT|connective tissue graft (CTG)|control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
48713976|NCT04159272|BEHAVIORAL|Mindfulness Training|"The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (\>3 years of experience). During the trial they will receive regular supervision."
48713977|NCT03674099|DRUG|Imatinib Mesylate|Tablets 400 mg
48713978|NCT03674099|DRUG|Methylprednisolone|1 g tablets or infusion
48713979|NCT04154319|BEHAVIORAL|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
48713980|NCT04154319|BEHAVIORAL|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
48713981|NCT06521073|BEHAVIORAL|education|"Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17)."
48022059|NCT02259621|DRUG|Ipilimumab|Anti-PD-1 Therapy
48022060|NCT06419127|DIAGNOSTIC_TEST|Timelapse incubation and PGT|Patients will have their embryos cultured in a timelapse incubator and their PGT results will be compared to the data collected during timelapse incubation.
48022061|NCT04387162|BEHAVIORAL|Prism Adaptation Treatment|Spatial retraining treatment
48022062|NCT03195413|PROCEDURE|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
48022063|NCT03195413|DRUG|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
48022064|NCT03195413|DEVICE|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
48022065|NCT01709227|DRUG|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output \<1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output \>1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
48022066|NCT01709227|PROCEDURE|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
48022067|NCT02041455|DRUG|Melatonin and Placebo|
48713982|NCT04798742|PROCEDURE|Gluteus maximus transfer|Gait analysis study of 15 patients with gluteus medius disruption
48179628|NCT01275768|PROCEDURE|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
48179629|NCT05170269|DRUG|BT097|Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
48379972|NCT05136482|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will exert a constant pressure of 25 mmHg throughout each test session. The device will pump temperature-controlled cold water through the cuff in order to reduce the skin temperature around the knee (and intra-articular temperature). Depending on the condition, the temperature of the water being pumped through the device will be either 6, 8, 10, or 12℃. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
48379973|NCT03638648|DRUG|Capecitabine|Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
48713983|NCT06013280|OTHER|Progresive Muscle Relaxation and Breathing Exercise|"Intervention protocol contains 40 minuntes sessions, which involved tensing and relaxing the body along with deep breathing.~Protocol consisted with; Warm-up (5 minutes breathing exercise) Progressive Muscle Relaxation Exercises (The participants performed PMR for each body part in a particular order, beginning with the face muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet. This muscle tensing and relaxing procedures were performed in accompaniment with deep breathing.) Cool-down (5 minutes breathing exercise)"
48713984|NCT05561465|PROCEDURE|Pterygomaxillary disjunction with interposition Y-shape plate|All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
48713985|NCT04841161|BEHAVIORAL|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
48022068|NCT02041455|DRUG|Amitriptyline and Placebo|
48022069|NCT02041455|DRUG|Melatonin and Amitriptylin|
48022070|NCT04480645|DEVICE|CivaDerm|radioactive bandage
48022071|NCT00541047|DRUG|bicalutamide|
48022072|NCT00541047|DRUG|goserelin acetate|
48022073|NCT00541047|DRUG|leuprolide acetate|
48022074|NCT00541047|PROCEDURE|adjuvant therapy|
48022075|NCT00541047|PROCEDURE|quality-of-life assessment|
48022076|NCT00541047|RADIATION|radiation therapy|
48022077|NCT06237426|DRUG|Methylone|"A course of methylone treatment includes weekly oral methylone administrations for up to 4 weeks.~Participants may be eligible to receive up to two courses of methylone treatment in this study. After a course of methylone treatment is complete, participants will return to observational study visits."
48022078|NCT02791139|OTHER|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
48022079|NCT02791139|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
48022080|NCT02791139|OTHER|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
48022081|NCT02791139|OTHER|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
48022082|NCT02791139|OTHER|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
48022083|NCT02791139|OTHER|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
48022084|NCT01826825|BEHAVIORAL|Cognitive Screen|Cognitive Screen
48022085|NCT01826825|BEHAVIORAL|Mini-Cog|Cognitive Screen
48022086|NCT06338995|DRUG|LY3650150|Administered SC.
48022087|NCT06338995|DRUG|Placebo|Administered SC.
48022088|NCT06338995|DRUG|Standard therapy for INCS|Administered as intranasal spray.
48022089|NCT05873192|DRUG|ADT|Given by PO
48022090|NCT05873192|DRUG|Enzalutamide|Given by PO
48022091|NCT05873192|DRUG|Talazoparib|Given by PO
48022092|NCT05873192|DRUG|Degarelix|Given PO or given INJ
48022093|NCT05873192|DRUG|Luprolide|Given PO or given INJ
48022094|NCT06494735|BEHAVIORAL|MyMCT|Using the french version of the metagognitive bibliotherapy MyMCT
48022095|NCT05351216|OTHER||No intervention
48022096|NCT04795505|BEHAVIORAL|Intervention|The subsequent visit was through WeChat-based online consultations. Follow-up, assessments and feedback were done at each visit. After follow-up, medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided.
48713986|NCT04841161|BEHAVIORAL|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
48713987|NCT01036529|DEVICE|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
48713988|NCT01036529|PROCEDURE|Back Surgery|Different types of back surgery may be performed
48713989|NCT01256463|BEHAVIORAL|HIV prevention intervention|
48713990|NCT02767479|DRUG|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
48713991|NCT02767479|DRUG|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
48713992|NCT03291262|OTHER|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
48713993|NCT04421859|OTHER|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
48713994|NCT00706329|DEVICE|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
48179630|NCT02745639|RADIATION|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
48179631|NCT02745639|DRUG|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
48179632|NCT05142800|DEVICE|Perometer|The perometer uses light sensors to calculate the length and volume of your arms
48179633|NCT05142800|DEVICE|SOZO device|The machine measures the amount of fluid on the arm(s)
48179634|NCT05471440|DRUG|Direct boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
48179635|NCT05471440|DRUG|Direct boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
48713995|NCT04079062|BIOLOGICAL|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
48713996|NCT04079062|BIOLOGICAL|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
48022097|NCT04795505|BEHAVIORAL|Control|The subsequent visit was through an offline outpatient clinic at 4 different community hospitals. Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention
48022098|NCT00175136|DEVICE|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
48022099|NCT03886038|BIOLOGICAL|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
48022100|NCT05212636|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|A total of 12 sessions of rTMS (5 sessions per week for 2 weeks, follow by 1 session per week for next 2 weeks) .
48022101|NCT01266239|PROCEDURE|kissing balloon inflation|Kissing balloon inflation following the MV stenting
48022102|NCT01266239|DEVICE|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
48179636|NCT05471440|DRUG|Post-poned boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
48179637|NCT05471440|DRUG|Post-poned boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
48379974|NCT03741335|OTHER|Resistance Training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
48379975|NCT03741335|OTHER|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session
48379976|NCT03741335|OTHER|Tai Chi|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
48379977|NCT04538716|PROCEDURE|transconjunctival lower blepharoplasty|transconjunctival lower blepharoplasty associated with stromal vascular fraction gel (SVF-gel)
48713997|NCT04079062|BIOLOGICAL|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
48713998|NCT04079062|BIOLOGICAL|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
48518080|NCT02681835|DEVICE|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
48713999|NCT04079062|BIOLOGICAL|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
48714000|NCT03597607|BEHAVIORAL|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
48179638|NCT05142579|OTHER|ENDOTRAKEAL TUBE HOLDER|During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
48179639|NCT05142579|OTHER|BANDAGE|On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
48179640|NCT06090175|OTHER|Projector colleyscope group|Projector kaleidoscope will be used in children aged 3-6 who are administered inhaler medication.
48518081|NCT02681835|DEVICE|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
48714001|NCT03597607|BEHAVIORAL|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
48714002|NCT02372708|DRUG|dinitrophenyl(DNP)|
48714003|NCT02372708|RADIATION|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
48714004|NCT00970983|PROCEDURE|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
48179641|NCT06090175|OTHER|Matching card group|Matching card will be used in children aged 3-6 who are administered inhaler medication.
48179642|NCT02888223|BIOLOGICAL|SCT800|
48179643|NCT02888223|BIOLOGICAL|Xyntha|
48518082|NCT04748107|DIAGNOSTIC_TEST|Impendence Cardiography|ICG is a noninvasive method of determining the amount of blood flow using the Non-Invasive Cardiac System - Cardiac Surveyor (NICaS) system, which provides an assessment of the cardiovascular system, respiratory system, and fluid retention.
48518083|NCT01772875|PROCEDURE|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
48518084|NCT02982291|PROCEDURE|Williams flexion protocol|The Williams flexion protocol group will participate in 15 treatment sessions.
48714005|NCT00970983|PROCEDURE|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
48714006|NCT05482581|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
48714007|NCT02654392|DIETARY_SUPPLEMENT|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
48714008|NCT02654392|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
48714009|NCT00162240|DRUG|Muraglitazar|
48714010|NCT01892761|DRUG|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
48714011|NCT00390481|PROCEDURE|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
48714012|NCT04216940|DEVICE|mechanical preparation of root canal system|Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
48714013|NCT05331703|OTHER|designed physical therapy program in addition to program of virtual reality.|physical therapy program in addition to program of virtual reality.
48714014|NCT05331703|OTHER|designed physical therapy program in addition to program of mirror therapy.|physical therapy program in addition to program of mirror therapy.
48714015|NCT05326360|DRUG|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
48714016|NCT05324423|DRUG|Colchicine|Colchicine0.5 mg Oral Tablet Day-7\~Day25 qd；Febuxostat 40 mg Oral Tablet Day1 and Day14 qd；XNW3009 0.5 mg Oral Tablet Day8 and Day21 qd
48179644|NCT01515722|BEHAVIORAL|Health education intervention (HEI)|"* \<Part 1\> Understanding OAB~* \<Part 2\> Behavioral/lifestyle modification~* \<Part 3\> Bladder training~* \<Part 4\> Understanding antimuscarinics"
48179645|NCT02131727|BEHAVIORAL|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
48518085|NCT02982291|PROCEDURE|Focused spinal stenosis rehabilitation|The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
48518086|NCT02301390|DRUG|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
48518087|NCT02301390|DEVICE|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
48518088|NCT00033007|BEHAVIORAL|Behavior Therapy|
48518089|NCT06582017|BIOLOGICAL|QXL138AM Injection every 2 weeks by IV Infusion|masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a
48518090|NCT04841837|BEHAVIORAL|Time-restricted feeding|limit daily food intake to a period of 10 hours
48179646|NCT02131727|BEHAVIORAL|Ask Me 3|"Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers."
48714017|NCT00815191|DEVICE|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
48022103|NCT05760092|COMBINATION_PRODUCT|Institutional standard treatment for xerostomia and Long Covid|(Medical follow-up at the general outpatient clinic for prescription and control of medications, underlying diseases, clinical status and routine short, medium and long-term care follow-up, standard guidelines for the use of aerobic physical activity in those who do not have contraindications, stretching exercises, ergonomics, home adaptation to maximize functionality and energy savings, emotional cognitive support psychotherapy, socio-educational measures, sleep hygiene, Nutritional follow-up and monitoring, dentistry follow-up at the University's odontological team, guidance on proper oral hygiene, use of low-sugar diets, daily topical use of fluoride and antimicrobial mouthwash to prevent dental caries, oral hydration, guidance on avoiding cigarette use or intake of caffeine-containing beverages . When necessary, measures such as oral lubricants, artificial saliva, measures to prevent aspirations, as well as the careful use of liquids during meals, can be instituted ) +
48379978|NCT03681925|DIAGNOSTIC_TEST|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
48518091|NCT04522726|DRUG|Weiyang Yuping Fang|Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
48714018|NCT00815191|DEVICE|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
48022104|NCT05760092|RADIATION|Photobiomodulation Therapy|Application of Red LED in the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, for 36 seconds, twice a week for 06 weeks.
48022105|NCT05760092|RADIATION|Placebo Photobiomodulation Therapy|All parameters as the number of points, dose and place of application of the PBM will be the same as described in the item PBM therapy Intervention Group, however in the placebo PBM equipment will be turned off. The device activation noise will be recorded and used to mimic the irradiation.
48179647|NCT02569632|BIOLOGICAL|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
48179648|NCT04276298|DRUG|Metronidazole cream|10% metronidazole applied rectally
48179649|NCT04276298|DRUG|Metronidazole and Diltiazem cream|Combination Metronidazole and Diltiazem applied rectally
48179650|NCT04276298|DRUG|Metronidazole and Lidocaine cream|Combination metronidazole and lignocaine applied rectally
48179651|NCT04276298|DRUG|Metronidazole, Diltiazem and Lidocaine cream|Combination of all active agents tested applied rectally
48179652|NCT06119347|DRUG|AntiVEGF|anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
48179653|NCT06119347|DRUG|ICIs|immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
48379979|NCT03472391|BEHAVIORAL|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
48379980|NCT06335394|OTHER|NVD003|Autologous osteogenic implant NVD-003 for bone reconstruction
48179654|NCT05286463|COMBINATION_PRODUCT|bee venom gel phonophoresis|a noncontact low-frequency pulsed ultrasound delivered through Bee Venom previously prepared gel as topical application using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
48379981|NCT05045339|PROCEDURE|Ball Exercises|Different ball exercises which include stability ball roll, stability ball hug, catching, throwing was performed. Along with these exercises, ball tapping exercise was also performed. Exercises were performed with 55 and 65 inch gym ball and a small regular plastic ball.
48379982|NCT04359888|OTHER|Multi-Modality Balance Intervention|Three one-hour training sessions 2-3x per week for six weeks in Multi-Modality Balance Intervention (MMBI). (See Study Design)
48714019|NCT05985876|BEHAVIORAL|KULEA-NET application|African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.
48379983|NCT04359888|OTHER|Balanced Reach Training (BRT)|One-hour training sessions 2-3x per week for six weeks in the Balanced Reach Training Protocol (BRTP) (See Study Design).
48179655|NCT05286463|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
48179656|NCT00459797|DEVICE|Conventional (reusable) Glidescope|
48714020|NCT05985876|BEHAVIORAL|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
48179657|NCT00459797|DEVICE|Single-use Glidescope videolaryngoscope|
48179658|NCT05574868|DEVICE|Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis|Treatment: Erectile dysfunction
48379984|NCT04478994|BIOLOGICAL|TEPEZZA|TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
48379985|NCT04478994|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
48379986|NCT05819411|BEHAVIORAL|Project iSTRIVE|This intervention includes 6 face-to-face therapy sessions with a trained clinician to develop skills to counter internalized stigma and shame as barriers to HIV self-care. Both the intervention group and the active control group will also receive a mobile app-based iDOT intervention.
48379987|NCT05819411|BEHAVIORAL|incentivized Directly Observed Therapy (iDOT)|Both the intervention group and the active control group will receive a mobile app-based iDOT intervention.
48379988|NCT06650033|RADIATION|Adaptive radiotherapy +/- margin reduction|Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
48379989|NCT06650033|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
48379990|NCT05925036|DRUG|Mesenchymal stem cells|Autologous bone marrow derived MSCs
48379991|NCT05925036|OTHER|Placebo|Controls
48379992|NCT03729830|DEVICE|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
48714021|NCT01046227|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
48022106|NCT00698958|PROCEDURE|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
48022107|NCT00698958|PROCEDURE|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
48022108|NCT05227079|DEVICE|MultCROC multibite forcep|Alligator style 2.4 mm diameter jaws that can hold up to six samples in one pass through endoscope.
48022109|NCT05227079|DEVICE|Conventional double bite forcep|Use of conventional double bite forceps that can store up to two specimens in one pass through endoscope
48022110|NCT02715765|DEVICE|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
48022111|NCT02715765|DEVICE|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
48379993|NCT02468167|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
48379994|NCT02468167|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
48379995|NCT02468167|DRUG|N-butyl-2-cyanoacrylate|
48379996|NCT02468167|DRUG|Lauromacrogol|
48714022|NCT00704561|DEVICE|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
48714023|NCT00704561|DEVICE|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
48518092|NCT04530955|DEVICE|Prometra II Programmable Pump - Flowonix Medical|The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
48179659|NCT06194812|OTHER|Pain Catastrophizing scale|"Participants' fear and avoidance behaviors will be evaluated with the Fear Avoidance Beliefs Questionnaire (KKBS) (Appendix 2).~Participants' fear of movement will be evaluated with the Tampa Kinesiophobia Scale (TKS) (Appendix 3).~Pain Catastrophizing Scale (PAS) (Appendix 4) will be used to evaluate the participants' pain-related thoughts and feelings.~The amount of improvement in symptoms perceived by the participants will be evaluated at the end of the treatment with the Global Perceived Impact Scale (GAES) (Appendix 5). Participants were asked How would you describe your current situation compared to the beginning of treatment? question will be asked."
48179660|NCT01354249|DIETARY_SUPPLEMENT|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
48179661|NCT02780895|DRUG|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
48518093|NCT00317694|DRUG|Fermagate|Film coated tablet 500mg
48518094|NCT00317694|DRUG|Placebo|Oral administration, film coated tablet, 0mg
48179662|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary somatosensory cortex|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
48379997|NCT00728273|DIETARY_SUPPLEMENT|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
48379998|NCT00985127|DRUG|placebo|administered daily for 21 days
48379999|NCT00985127|DRUG|BCX4208|Administered daily for 21 days.
48380000|NCT06390280|PROCEDURE|intraoperative Fraction of Inspired Oxygen|Group I intraoperative Fraction of Inspired Oxygen 30%, Group II intraoperative Fraction of Inspired Oxygen 80% applied group.
48380001|NCT01060007|RADIATION|External beam radiation|
48380002|NCT01060007|DRUG|Oxaliplatin|
48380003|NCT01060007|DRUG|Leucovorin|
48380004|NCT01060007|DRUG|5-FU|
48380005|NCT01060007|DRUG|Capecitabine|
48380006|NCT00290511|DRUG|Fludarabine|25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
48022112|NCT02715765|DEVICE|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
48380007|NCT00290511|DRUG|Mitoxantrone|10 mg/m\^2 IV over 5-30 minutes on Day 2.
48380008|NCT00290511|DRUG|Rituximab|375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
48380009|NCT00290511|DRUG|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
48380010|NCT00290511|DRUG|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
48380011|NCT02237066|DEVICE|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
48380012|NCT02237066|DEVICE|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
48022113|NCT04955938|DRUG|Ivosidenib|A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
48022114|NCT04955938|DRUG|Enasidenib|A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
48518095|NCT01668914|PROCEDURE|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
48518096|NCT01668914|RADIATION|99mTc-SC|Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
48022115|NCT04955938|DRUG|Fedratinib|This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
48022116|NCT00054899|BIOLOGICAL|EP2101|
48518097|NCT01668914|DEVICE|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
48518098|NCT01668914|DEVICE|LSG|lymphoscintigraphy was performed 0.5\~1.0 hour before surgery
48518099|NCT01668914|DRUG|Methylthioninium|Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
48179663|NCT06262425|DEVICE|repetitive Transcranial Magnetic Stimulation over primary motor cortex|It will be applyed a magnetic field over the primary motor cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
48179664|NCT06262425|DEVICE|sham repetitive Transcranial Magnetic Stimulation|It will be applied a sham stimulation with the same protocol that pretends to create the illusion of being stimulated
48179665|NCT03758794|OTHER|interactive lecture|an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
48179666|NCT03758794|OTHER|online education|an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
48179667|NCT00415701|DRUG|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
48179668|NCT00415701|DRUG|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
48179669|NCT00415701|DRUG|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
48179670|NCT00415701|DRUG|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
48179671|NCT00415701|OTHER|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
48179672|NCT01322009|DRUG|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
48380013|NCT04232761|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug administration as determined by treating physician
48380014|NCT04342130|DRUG|Morphine|30 mg oral tablet
48380015|NCT04753606|DRUG|Obicetrapib|tablets
48179673|NCT01322009|DRUG|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
48179674|NCT03451409|OTHER|Tasked based functional MRI (fMRI)|2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.
48179675|NCT03451409|OTHER|Eye Tracking Device|Camera aimed at eyes to record eye movements during tasks
48179676|NCT06355323|OTHER|Blood test|Blood test
48714024|NCT00704561|DEVICE|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
48179677|NCT06355323|OTHER|chest CT scan|chest CT scan
48179678|NCT00458393|DRUG|daily TDF/FTC|daily oral medication
48179679|NCT00458393|DRUG|Placebo|daily oral medication
48179680|NCT01740154|PROCEDURE|transcranial magnetic stimulation|Undergo TMS
48179681|NCT01740154|PROCEDURE|electromyography|Undergo EMG
48179682|NCT01740154|OTHER|survey administration|Ancillary studies
48380016|NCT05727865|BEHAVIORAL|Online CBT following cardiac surgery|It will include psychoeducation, behavioral activation to address post-operative fatigue and depression, interoceptive exposure to reduce fear of cardiac-related symptoms and in-vivo exposure to reduce avoided situations, and activities to enhance physical activity and wellbeing. Labeling (i.e., describing post-operative and/or cardiac-related symptoms, thoughts, and feelings) will be used continuously during treatment to enhance the effect of exposure and pain management
48380017|NCT02299661|DRUG|DS-1093a|DS-1093a, single oral doses up to 50 mg
48714025|NCT00704561|DEVICE|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
48179683|NCT01740154|DRUG|sunitinib malate|Given PO
48380018|NCT00807040|PROCEDURE|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
48380019|NCT00807040|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
48518100|NCT02372279|OTHER|Embryo observation|In EO group, conventional observations will be made.
48518101|NCT04808973|DRUG|Dolutegravir plus lamivudine in a FDC|All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
48518102|NCT00269139|BEHAVIORAL|Crisis resolution|
48518103|NCT00367978|DRUG|Amlodipine/benazepril|
48714026|NCT02265419|DEVICE|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
48179684|NCT04174209|BEHAVIORAL|Cylinder|Patients who receive the Jackson Cross Cylinder Method
48179685|NCT04174209|BEHAVIORAL|Dial|Patients who receive the Astigmatic Dial Technique Method.
48179686|NCT04174209|BEHAVIORAL|Slit|Patients who receive the Stenopeic slit Method.
48179687|NCT05651113|OTHER|SCID Screening|The addition of newborn bloodspot screening for severe combined immunodeficiency
48179688|NCT04157036|DRUG|Ibuprofen|Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
48179689|NCT04157036|DRUG|Methylprednisolone|Subject will take 40mg Methylprednisolone 45 minutes prior to anesthetic delivery
48179690|NCT00569010|DRUG|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days
48179691|NCT00569010|DRUG|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)"
48179692|NCT04952701|DEVICE|Control lenses|Control Multifocal lenses
48179693|NCT04952701|DEVICE|Test lenses|Test Multifocal lenses
48714027|NCT00162279|DRUG|Abatacept|
48714028|NCT03579446|DRUG|Hydrocodone|Given by PO
48179694|NCT02874105|OTHER|Group C: physiotherapy protocol with Conventional physiotherapy.|
48179695|NCT02874105|OTHER|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
48179696|NCT03952507|DRUG|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
48179697|NCT03952507|DRUG|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
48179698|NCT00859976|DEVICE|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
48179699|NCT00859976|DEVICE|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
48179700|NCT00428337|BIOLOGICAL|EP-1233|DNA-HIV-recombinant vaccine
48179701|NCT00428337|BIOLOGICAL|MVA-mBN32|HIV-recombinant viral vaccine
48714029|NCT03579446|DRUG|Hydromorphone|Given by PO
48714030|NCT03579446|DRUG|Levorphanol|Given PO
48714031|NCT03579446|DRUG|Morphine|Given by PO
48179702|NCT00940862|BIOLOGICAL|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
48179703|NCT00940862|DEVICE|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
48179704|NCT00940862|OTHER|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
48179705|NCT00301561|PROCEDURE|Simplified follow-up approach of ARV treatment|"Simplify treatment follow-up :~* some clinical consultations will be performed by nurses under the physicians' responsibility ;~* the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~* the biologic assessment for tolerability will be limited"
48179706|NCT00301561|PROCEDURE|Standard follow-up approach of ARV treatment|"Standard treatment follow-up :~* all clinical consultations will be performed by physicians ;~* the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~* the biologic assessment for tolerability will be available as needed"
48179707|NCT00002430|DRUG|Indinavir sulfate|
48179708|NCT00002430|DRUG|Nelfinavir mesylate|
48179709|NCT00002430|DRUG|Lamivudine|
48179710|NCT00002430|DRUG|Stavudine|
48714032|NCT03579446|DRUG|Oxycodone|Given by PO
48714033|NCT03579446|DRUG|Oxymorphone|Given by PO
48179711|NCT01844726|DRUG|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
48518105|NCT04465981|DIAGNOSTIC_TEST|Sampling|Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
48714034|NCT03579446|OTHER|Questionnaire Administration|Ancillary studies
48714035|NCT00074373|OTHER|No intervention; observational|
48179712|NCT01844726|DRUG|Placebo|Single injection of placebo (saline)
48179713|NCT00870532|DRUG|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
48179714|NCT00870532|DRUG|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
48179715|NCT02386553|DRUG|Nusinersen|Solution for intrathecal injection
48179716|NCT00347698|DRUG|intravitreal injection of bevacizumab|
48179717|NCT00347698|PROCEDURE|panretinal photocoagulation|
48179718|NCT05513183|PROCEDURE|Intraoperative blood and peritoneal fluid samplings during HIPEC|"- Intraoperative samplings of blood and peritoneal fluids during HIPEC :~* Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~* Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)"
48179719|NCT02612506|DRUG|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
48179720|NCT02612506|DRUG|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
48179721|NCT01954433|PROCEDURE|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
48518106|NCT05726786|DRUG|Immunonutrition|"Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag"
48179722|NCT01954433|PROCEDURE|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
48714036|NCT03208920|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
48714037|NCT03208920|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
48714038|NCT03515174|OTHER|Supportive Care Program|This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.
48714039|NCT03515174|OTHER|Usual Care|Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
48714040|NCT02360644|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
48380020|NCT02769182|DEVICE|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
48380021|NCT02769182|BEHAVIORAL|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
48179723|NCT01954433|PROCEDURE|Resection interposition suspension arthroplasty (RISA)|"One of five surgical techniques can be used in this study, as routinely performed by each surgeon:~1. RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping~2. RISA with FCR-Ligament modified according to Weilby~3. RISA with APL-Ligament (abductor pollicis longus ligament)~4. RISA with Graftjacket modified according to Weilby~5. Resection arthroplasty"
48380022|NCT02448212|DRUG|TS-121|Oral
48380023|NCT02448212|DRUG|[11C]TASP0410699|Intravenous radiotracer
48380024|NCT02448212|RADIATION|Positron Emission Tomography (PET)|Imaging scanning procedure
48380025|NCT00262483|DRUG|VX-950|
48380026|NCT00262483|DRUG|ribavirin|
48380027|NCT00262483|DRUG|peginterferon alfa-2a|
48714041|NCT00272688|DRUG|Levodopa (drug), intraduodenal administration|
48714042|NCT03002688|OTHER|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
48714043|NCT04405544|DIAGNOSTIC_TEST|CT-scan|chest CT-scan
48714044|NCT04405544|DIAGNOSTIC_TEST|EEG|Electroencephalography
48179724|NCT01805245|BEHAVIORAL|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
48179725|NCT01939561|DRUG|Lamotrigine|
48380028|NCT00708656|DRUG|mesalazine (Asacol®)|800 mg tablets
48380029|NCT00648739|DRUG|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
48179726|NCT01939561|DRUG|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
48179727|NCT00307164|DRUG|NucleomaxX|36 g sachet taken orally three times daily
48380030|NCT01042691|DRUG|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
48380031|NCT06479148|DEVICE|enVista® Aspire™|Eyes will receive enVista® Aspire™ lenses
48380032|NCT06479148|DEVICE|An IOL with a slightly extended depth of focus|Eyes will receive lenses with a slightly extended depth of focus
48380033|NCT06479148|DEVICE|MX60E|Eyes will receive MX60E lenses
48714045|NCT04405544|DIAGNOSTIC_TEST|EP|Evoked potential
48380034|NCT01725204|DRUG|Dasatinib + PegIFN|
48380035|NCT04555772|OTHER|factors evaluation|They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
48380036|NCT01058707|DRUG|MLN0128|MLN0128 capsules
48714046|NCT04405544|DIAGNOSTIC_TEST|Pulse oximetry|Pulse oximetry
48714047|NCT04405544|DIAGNOSTIC_TEST|Blood tests|Blood tests
48714048|NCT00714766|PROCEDURE|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
48714049|NCT03110445|BIOLOGICAL|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
48714050|NCT00468936|DRUG|Myfortic|enteric coated Cellcept pills in applicable dose for patient
48714051|NCT03697993|DRUG|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
48380037|NCT06411431|PROCEDURE|Early Chest Tube Removal|"Subjects within the Early Removal group will have their chest tube removed if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
48714052|NCT03697993|DRUG|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
48714053|NCT00918268|BIOLOGICAL|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
48714054|NCT03234348|DEVICE|Percutaneous coronary intervention|PCI + stent implantation
48714055|NCT02916407|DRUG|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
48518107|NCT05565430|OTHER|Acute Hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
48179728|NCT00307164|DRUG|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
48179729|NCT06120868|OTHER|Surefil one®|For Surefil one® restorations, the capsule will be activated by pressing it against a stable surface, then mixed in a capsule mixer for 10 s. The capsule tip will be inserted into the proximal box, and the material is extruded as the tip is gradually moved in a coronal direction, ensuring that the material adapts to the cavity bottom and walls.
48179730|NCT06120868|OTHER|Filtek One|Scotchbond™ Universal (SBU) will be used as an adhesive system in self-etch mode for FiltekTM One restoration. SBU will be applied actively for 20 seconds with a disposable brush tip, air-dried gently for 5 seconds to create a consistent bond thickness, then light-cured for 10 seconds. The FiltekTM One will be packed in increments up to 4 mm thick. A second layer of FiltekTM One will be applied on top of the first 4-mm layer if 4 mm is not adequate to properly restore the tooth. Each increment will be light cured for 20 seconds.
48179731|NCT04234945|DRUG|Doxycycline Capsule|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
48179732|NCT04234945|DRUG|Multivitamins W/Iron Tab|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
48179733|NCT00511186|DRUG|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
48179734|NCT00511186|DRUG|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
48518108|NCT05565430|OTHER|Chronic hyperventilation|Laryngoscopy to assess vocal cord function during acute hyperventilation in normal subjects and asthmatics.
48518109|NCT05565430|DRUG|Effects of anticholinergic medication|Laryngoscopy to assess vocal cord function after administration of anticholinergic medication.
48518110|NCT00626457|BEHAVIORAL|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
48518111|NCT06353698|DIETARY_SUPPLEMENT|fasting mimicking diet|Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
48518112|NCT03347201|DEVICE|HMS Plus|Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
48518113|NCT00978874|RADIATION|fludeoxyglucose F 18|
48714056|NCT02916407|DRUG|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
48179735|NCT01906983|OTHER|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
48179736|NCT02676609|DEVICE|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
48179737|NCT00151398|DRUG|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
48179738|NCT00151398|DRUG|Donepezil|10 mg donepezil QD dosed up to 40 weeks
48179739|NCT01017263|DRUG|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
48179740|NCT01500993|DRUG|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
48179741|NCT01500993|DRUG|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
48179742|NCT04302129|PROCEDURE|Erector spinae plane block|20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
48179743|NCT04302129|DRUG|Multimodal analgesia|Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
48518114|NCT00978874|RADIATION|fluorine F 18 EF5|
48179744|NCT02522988|BEHAVIORAL|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
48179745|NCT00072605|DRUG|VRC-EBODNA012-00-VP|
48179746|NCT03569475|DRUG|Levomilnacipran ER|Levomilnacipran extended-release oral capsules
48179747|NCT03569475|DRUG|Fluoxetine|Fluoxetine oral capsules
48179748|NCT03569475|DRUG|Placebo|Matching placebo oral capsules
48179749|NCT02132715|BEHAVIORAL|Resistance Exercise|
48179750|NCT02132715|BEHAVIORAL|KAATSU exercise|
48518115|NCT01526057|BIOLOGICAL|PF-05280586|1000 mg, IV on days 1 and 15
48179751|NCT02056002|OTHER|Usual Care|- Standard CPAP educational training
48518116|NCT01526057|BIOLOGICAL|MabThera|1000 mg, IV on days 1 and 15
48518117|NCT01526057|BIOLOGICAL|Rituxan|1000 mg, IV on days 1 and 15
48714057|NCT03422692|BIOLOGICAL|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
48714058|NCT03422692|BIOLOGICAL|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
48714059|NCT06213142|OTHER|CBToolkit|CB Toolkit Mindful Awareness module to increase awareness and tolerance of physical sensations and emotional experiences using mindfulness practices. The module involves videos with motion graphics, video demos, voiceover, music, and sound effects intermixed throughout with a variety of interactive exercises tailored to specific core components. The module aims to establish understanding of the intervention concept (psychoeducation), increase self-efficacy in mindfulness skills via active practice and personalized feedback, and facilitate self-reflection and understanding of strengths and improvement areas related to mindfulness. CBToolkit Flexible Problem Solving module to promote cognitive flexibility, applying problem-solving strategies in difficult scenarios, and learning to modify behavioral action tendencies. Videos and activities will be tailored to provide examples of effective problem-solving techniques and provide personalized reinforcing and/or scaffolded feedback.
48179752|NCT02056002|OTHER|Peer-Buddy System|"* Two 30-minute in person sessions with Peer Buddy~* Standard CPAP educational training~* Eight phone conversations with Peer Buddy over 3 months~* Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~- Home visit to collect CPAP information~Three Month Visit:~* Questionnaires~* Psycho Motor Vigilance Test (PVT) Video Game~* Collect CPAP information~* Measure weight~* Measure blood pressure~Six Month Visit:~* Questionnaires~* PVT (Video game)~* Collect CPAP information~* Measure Weight~* Measure Blood Pressure~* Evaluate the program and Peer Buddy"
48179753|NCT02056002|OTHER|Usual Care|- Educational Brochures
48179754|NCT02056002|OTHER|Usual Care|- Educational DVD videos mailed to participant
48179755|NCT06319183|DRUG|Salbutamol|We will recruit at least 15 male and 15 female volunteers, dividing study participants into two groups based on sex. Before administration, the temperature of the brown adipose tissue area in the scapular region of participants will be recorded using an infrared thermometer. Subsequently, participants will inhale the asthma medication salbutamol according to the safe dosage requirements (100ug). Eight hours later, the temperature changes in the brown adipose tissue area in the scapular region will be detected using an infrared thermometer. During the 8-hour waiting period, the participants' heart rate and blood pressure will be monitored; finally, we will draw 1 milliliter of venous blood from the arm of the participants for blood component analysis. The single trial process will last up to 8 hours, with no follow-up required.
48179756|NCT00568841|DRUG|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
48179757|NCT00568841|PROCEDURE|FDG-/FLT-PET|
48179758|NCT06062199|PROCEDURE|Training in the A-DIVA scale and its failure prediction score|Nurses are trained in the A-DIVA scale and its predictive failure score. This score enables them to adapt their approach to peripheral venous line insertion.
48179759|NCT01242371|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
48518118|NCT06261424|PROCEDURE|IMPACT - rehabIlitation prograM for sPAstiC aTaxias|The rehabilitation program will last 12 weeks and consists of three training sessions of 60 minutes per week (2 sessions in a therapy room and 1 session in an adapted pool with multiple levels of water) for a total of 36 sessions. Participants will be divided into 7 subgroups of 6 participants and each sub-group will be supervised by one physiotherapist (PT) and one physiotherapy technologist for safety considerations. It will focus on these three domains: 1) postural control; balance, trunk-limbs and multi-joints control and coordination and 3) functional mobility. Each domain contains a standardized list of exercises with different difficulty levels and specific times allocation. All exercises will be executed by the participants at each session at the appropriate difficulty level. The initial level of difficulty for each exercise will be determined by the PT based on individual results of the pre-intervention assessment and on individual performance, fatigue level and safety.
48518119|NCT05854524|PROCEDURE|Aerobic exercise|The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).
48518120|NCT03382587|DRUG|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
48518121|NCT06266611|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
48518122|NCT06266611|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
48518123|NCT06266611|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
48518124|NCT02605915|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
48714060|NCT06246019|DIAGNOSTIC_TEST|Early adoption of blood-based biomarkers for Alzheimer's disease|A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
48179760|NCT01242371|DIETARY_SUPPLEMENT|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
48179761|NCT01687868|DRUG|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
48179762|NCT06156917|DIAGNOSTIC_TEST|diagnostic accuracy|Aims of the present project are: to investigate the relationship between incident PD dementia and multimodal parameters as cardiovascular autonomic dysfunction, altered cerebral glucose metabolism, and genetic biomarkers; development of an algorithm predictive for PD-related dementia, combining the rele- vant multidimensional parameters under study; longitudinal follow-up of clinical and cognitive status in PD patients with and without dementia along four years.
48518125|NCT02605915|DRUG|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter\*min (mg/mL\*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
48518126|NCT02605915|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
48518127|NCT02605915|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
48714061|NCT00322946|BIOLOGICAL|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
48714062|NCT00322946|BIOLOGICAL|Placebo|Placebo for rDEN4delta30-4995
48179763|NCT01642147|DEVICE|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI-DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
48179764|NCT01642147|PROCEDURE|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
48179765|NCT01642147|PROCEDURE|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
48179766|NCT01642147|PROCEDURE|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
48714063|NCT04418336|PROCEDURE|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique|Endoscopic Pilonidal sinus treatment (EPSIT) versus Sinus Laser Closure (SiLaC) versus lay open technique in sacrococcygeal Pilonidal sinus treatment
48179767|NCT01642147|PROCEDURE|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
48179768|NCT01186731|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
48179769|NCT05910892|DRUG|Aromatherapy packet|5 deep breaths from packet prior to treatment
48179770|NCT05910892|DRUG|Placebo packet|5 deep breaths from packet prior to treatment
48179771|NCT04827589|DRUG|Tirabrutinib|Tablets administered orally
48179772|NCT04827589|DRUG|Placebo|Tablets administered orally
48714064|NCT03303898|PROCEDURE|Blood sampling|sampling of 7 blood tubes
48714065|NCT03143673|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
48714066|NCT02441348|BEHAVIORAL|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
48714067|NCT00123773|PROCEDURE|Positron Emission Tomography|
48714068|NCT00003825|DRUG|pentosan polysulfate sodium|
48714069|NCT00003825|PROCEDURE|quality-of-life assessment|
48714070|NCT00503334|DIETARY_SUPPLEMENT|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
48179773|NCT05611853|DRUG|BN301|BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
48179774|NCT05563090|OTHER|Questionnaires+Tongue diagnosis+Pulse diagnosis|Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools
48380038|NCT06411431|PROCEDURE|Standard Chest Tube Removal|"Subjects within the Standard Removal group will have their chest tube removal on POD#2 if the following criteria are met on the morning of POD#1:~* ≤1 cm of apical pleural separation and no other areas of pleural separation~* No air leak~* No bloody output or concern for bleeding~* \< 400cc of drainage"
48518128|NCT02605915|DRUG|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
48518129|NCT02605915|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
48714071|NCT06051747|PROCEDURE|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
48714072|NCT03239782|BEHAVIORAL|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
48179775|NCT02656849|DRUG|BAY 1000394|
48380039|NCT06411431|DEVICE|Apical Chest Tube|A single apical chest tube will be placed and connected to a suction device at least -20 mmHg suction.
48714073|NCT05104619|PROCEDURE|tongue surgery|In squamous cell carcinoma of the tongue, complete surgical resection of the tumor
48714074|NCT05869422|DIETARY_SUPPLEMENT|Iron|90 ± 5 days of daily oral iron supplementation.
48714075|NCT05869422|OTHER|Placebo|90 ± 5 days of daily oral placebo intake.
48714076|NCT01255007|OTHER|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
48714077|NCT01174017|RADIATION|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
48380040|NCT06650358|DEVICE|Light Adjustable Lens+|The Light Adjustable Lens+ (LAL+) is a posterior chamber, UV absorbing, three-piece, foldable, photo reactive silicone intraocular lens with a squared-posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure to the implanted LAL+ using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change postoperatively. A subsequent lock-in exposure is delivered to the implanted LAL+ to stabilize the lens power. The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus.
48380041|NCT00023426|DRUG|rifapentine|
48714078|NCT01174017|RADIATION|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
48179776|NCT04009629|BEHAVIORAL|Moderate Intensity Aerobic Exercise|Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
48518130|NCT02605915|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
48714079|NCT00238784|DRUG|Budesonide/formoterol Turbuhaler|
48179777|NCT02958241|OTHER|MRI|Supine and weight bearing MRI
48179778|NCT02599688|OTHER|Observation only|No intervention in this study.
48518131|NCT02605915|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
48714080|NCT01155466|DRUG|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
48714081|NCT01155466|DRUG|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
48518132|NCT00295425|DRUG|Cyclosporine A versus mycophenolate mofetil for psoriasis|
48518133|NCT01937078|DRUG|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
48714082|NCT01155466|DRUG|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
48714083|NCT01155466|DRUG|Placebo to Preladenant Tablet|one tablet orally twice daily
48714084|NCT01155466|DRUG|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
48714085|NCT01155466|DRUG|Placebo to Rasagiline capsule|one capsule orally in AM
48179779|NCT01530737|DRUG|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
48179780|NCT01530737|OTHER|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
48380042|NCT00285012|DRUG|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
48380043|NCT00285012|DRUG|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
48380044|NCT06519422|DRUG|Tranexamic Acid 500 MG|Tablets
48380045|NCT06519422|OTHER|Matched placebo|Matched placebo tablets (inactive ingredients only, including microcrystalline cellulose, magnesium stearate BP and lactose)
48380046|NCT00792142|DRUG|bortezomib|Given IV
48380047|NCT00792142|DRUG|dexamethasone|Given orally
48380048|NCT00792142|DRUG|melphalan|Given IV
48714086|NCT05693142|GENETIC|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
48714087|NCT02242981|DRUG|LY2623091|Administered orally
48714088|NCT05026892|OTHER|no intervention|no intervention, only collection of data
48714089|NCT00612742|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
48380049|NCT00792142|DRUG|thalidomide|Given orally
48380050|NCT00792142|GENETIC|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
48380051|NCT00792142|GENETIC|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
48714090|NCT00612742|DRUG|placebo gel|once daily transdermal placebo gel
48714091|NCT03313284|PROCEDURE|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
48714092|NCT03313284|PROCEDURE|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
48714093|NCT03313284|PROCEDURE|Control|No intervention
48714094|NCT01659281|DRUG|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
48714095|NCT01659281|DRUG|Artesunate|4 mg/kg/day for 3 days
48714096|NCT01659281|DRUG|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
48714097|NCT01659281|DRUG|Mefloquine|8 mg/kg daily for 3 days
48714098|NCT01898949|OTHER|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
48714099|NCT00917072|BEHAVIORAL|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
48380052|NCT00792142|OTHER|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
48714100|NCT00917072|BEHAVIORAL|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
48380053|NCT00792142|OTHER|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
48714101|NCT00917072|BEHAVIORAL|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
48714102|NCT04819230|BEHAVIORAL|Cognitive Bias Modification|A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)
48714103|NCT04819230|BEHAVIORAL|Cognitive Bias Control|A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
48714104|NCT03811847|DRUG|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
48179781|NCT03807609|OTHER|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48179782|NCT03807609|OTHER|EX -30. Condition with an acute exercise set 30 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48179783|NCT03807609|OTHER|EX-180. condition with an acute exercise set 180 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48179784|NCT00002740|BIOLOGICAL|filgrastim|
48179785|NCT00002740|DRUG|carboplatin|
48179786|NCT00002740|DRUG|cyclophosphamide|
48179787|NCT00002740|DRUG|doxorubicin hydrochloride|
48179788|NCT00002740|DRUG|etoposide|
48380054|NCT00792142|PROCEDURE|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
48380055|NCT00792142|PROCEDURE|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
48714105|NCT03811847|OTHER|Placebo|Placebo comparator MPH Matched Placebo Tablet
48714106|NCT03444766|DRUG|Nivolumab|specified dose on specified days
48714107|NCT03597178|DEVICE|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
48179789|NCT00002740|DRUG|mesna|
48179790|NCT00002740|DRUG|vincristine sulfate|
48179791|NCT00002740|PROCEDURE|conventional surgery|
48179792|NCT00002740|PROCEDURE|peripheral blood stem cell transplantation|
48179793|NCT00002740|RADIATION|low-LET cobalt-60 gamma ray therapy|
48179794|NCT00002740|RADIATION|low-LET photon therapy|
48179795|NCT01236352|DRUG|BMS-911543|
48179796|NCT01447576|DRUG|ADT|Once daily dosing during the duration of the study.
48179797|NCT01447576|DRUG|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
48179798|NCT04283227|GENETIC|OTL-200|All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
48179799|NCT06157528|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients were treated with abarelix prior to the examination
48179800|NCT05208346|DIETARY_SUPPLEMENT|Mixed meals|Mixed meals enriched with either 25 or 50 g of canola or coconut oil
48179801|NCT06008223|DRUG|vitamin B6|The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.
48179802|NCT06008223|DRUG|0.9% sodium chloride solution|That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
48179803|NCT03830762|DRUG|Xanamem|Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
48179804|NCT03830762|DRUG|Matching Placebo|Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
48380056|NCT00029159|DRUG|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
48380057|NCT00029159|DRUG|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
48380058|NCT00029159|OTHER|placebo|an inactive substance
48714108|NCT00003671|DRUG|asparaginase|
48714109|NCT00003671|DRUG|cyclophosphamide|
48714110|NCT00003671|DRUG|cytarabine|
48714111|NCT00003671|DRUG|daunorubicin hydrochloride|
48714112|NCT00003671|DRUG|dexamethasone|
48714113|NCT00003671|DRUG|leucovorin calcium|
48714114|NCT00003671|DRUG|mercaptopurine|
48714115|NCT00003671|DRUG|methotrexate|
48714116|NCT00003671|DRUG|thioguanine|
48714117|NCT00003671|DRUG|vincristine sulfate|
48714118|NCT01246479|PROCEDURE|Blood draw|blood draw at Month 12, Month 24 and Month 36.
48714119|NCT01246479|BIOLOGICAL|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
48714120|NCT02914548|DRUG|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
48380059|NCT04129866|BEHAVIORAL|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
48380060|NCT04129866|BEHAVIORAL|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
48380061|NCT05991622|DRUG|Combined LAI Treatment: Cabenuva and Sublocade|A preliminary test of the combined LAI treatment will be conducted with a total of 40 individuals diagnosed with HIV and OUD that meet all other study inclusion criteria. Treatment will take place primarily at TMH IC (n=30), however, about one-quarter of participants will undergo the pilot test at the RIDOC (n=10). Participants will complete a baseline interview, receive the combined LAI treatment (described below), and complete follow-up assessments at 1-, 3-, and 6-months following initiation of injectable medication. Of the 40 participants, 25 will be purposefully selected to engage in qualitative interviews to assess the strengths and limitations of the clinical protocol and combined treatment as well as describe their reasons for LAI uptake or discontinuation. We will also elicit feedback from clinic staff and other key stakeholders regarding the delivery of the clinical protocol and other implementation factors
48380062|NCT04241081|BEHAVIORAL|Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia|This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.
48380063|NCT02592369|DEVICE|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
48714121|NCT02914548|DRUG|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
48714122|NCT05315375|DEVICE|corpectomy|vertebral corpectomy using expandable cage
48714123|NCT03377738|DIAGNOSTIC_TEST|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
48714124|NCT00666497|DRUG|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
48714125|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
48714126|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
48714127|NCT02166645|OTHER|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
48714128|NCT02166645|OTHER|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
48714129|NCT00603070|OTHER|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
48179805|NCT06499662|OTHER|Vagus Nerve Neurodynamics|This intervention involves passive cervical movements designed to enhance vagus nerve functionality.
48714130|NCT00603070|OTHER|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
48179806|NCT06499662|OTHER|Guided Breathing|This intervention consists of diaphragmatic breathing guided by a recording to maintain a rate of 6 breaths per minute.
48179807|NCT06499662|OTHER|Manual Therapy|This intervention includes suboccipital inhibition techniques applied during the session.
48714131|NCT01530841|DEVICE|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
48714132|NCT01066780|DEVICE|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
48714133|NCT00321997|DRUG|Pegaptanib sodium|
48714134|NCT02677636|DRUG|MSRD-100|MSRD-100 is a topical gel.
48179808|NCT02530788|DRUG|Selenium Supplement (sodium selenite)|"On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
48179809|NCT02530788|DRUG|Placebo|"On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
48179810|NCT05995847|BEHAVIORAL|Harmonica playing program plus basic PR care with routine follow-up|The intervention will last for a total of six months. During this period, patients are expected to play the harmonica daily for 30 minutes, five days a week. Additionally, patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months.
48518134|NCT04327011|BIOLOGICAL|Toca 511 vector|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
48518135|NCT04327011|DRUG|Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine|Toca FC is an extended-release formulation of flucytosine.
48518136|NCT01173120|DEVICE|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
48179811|NCT05995847|BEHAVIORAL|Basic PR care with routine follow-up|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months
48518137|NCT02287714|PROCEDURE|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
48518138|NCT02287714|PROCEDURE|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
48518139|NCT03203200|BEHAVIORAL|ZETRA cognitive behavioral structural|ZETRA cognitive behavioral structural
48518140|NCT00823810|OTHER|PET/CT|18F-FDG PET/CT
48714135|NCT02677636|DRUG|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
48714136|NCT01361932|OTHER|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
48714137|NCT06258057|OTHER|Not applicable / database analysis|Not applicable / database analysis
48714138|NCT01845584|DRUG|NPB-01|
48714139|NCT06200974|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
48714140|NCT02177019|OTHER|Personalized health plan|
48714141|NCT04739397|DEVICE|Glare Testing|Vision in Cataract patients were tested with and without the EpiGlare Tester
48714142|NCT01020162|DRUG|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
48714143|NCT01020162|PROCEDURE|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
48714144|NCT04291794|DRUG|Propofol|2mg/kg single bolus
48714145|NCT04291794|DRUG|Propofol Injection [Diprivan]|Tritiated Target-Controlled Infusion
48179812|NCT02528851|PROCEDURE|Extubation from endotracheal mechanical ventilation to CPAP|"Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation."
48179813|NCT04505475|PROCEDURE|Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)|single and multiple teeth extraction, surgical tooth extraction, third molar surgery, gingivectomy, soft-tissue biopsy
48179814|NCT00793247|DRUG|PRU-PLA-PRU-PLA|
48179815|NCT00793247|DRUG|PLA-PRU-PLA-PRU|
48179816|NCT00793247|DRUG|PLA-PRU-PRU-PLA|
48179817|NCT00793247|DRUG|PRU-PLA-PLA-PRU|
48179818|NCT01375751|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
48179819|NCT01375751|BIOLOGICAL|Placebo|d by subcutaneous injection
48179820|NCT05802771|PROCEDURE|surgical resection|surgical resection of the lung cancer
48179821|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
48179822|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
48179823|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
48179824|NCT02209181|DRUG|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
48179825|NCT06168162|OTHER|titated PEEP to best static compliance|the Intraoperative PEEP will be titrated to best static compliance for each patient
48179826|NCT04576845|OTHER|Survey|The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
48179827|NCT01035541|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
48179828|NCT02309671|DRUG|FE 999049|
48179829|NCT02309671|DRUG|follitropin beta|
48179830|NCT00590226|DRUG|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
48714146|NCT05121025|DIAGNOSTIC_TEST|Analysis of gut microbiome and immune signatures|The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
48714147|NCT04349241|DRUG|favipiravir|pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor
48179831|NCT00590226|DRUG|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
48179832|NCT06377956|OTHER|Observation without intervention|Observation of gut length, food intake, fecal and urine calories, body composition, microbiota, metabolic rate, metabolomics.
48179833|NCT01347671|DRUG|GRT6005|25µg/day once daily
48179834|NCT01347671|DRUG|GRT6005|75 µg/day once daily
48179835|NCT01347671|DRUG|GRT6005|200 µg/day once daily
48179836|NCT01347671|DRUG|Matching Placebo|Once daily
48179837|NCT03155854|PROCEDURE|Pretendinous cord excision|The cord/palmar fascia will be excised during surgery.
48179838|NCT03155854|PROCEDURE|Division/manipulation of the cord|The pretendinous cord will be divided and incised during surgery.
48179839|NCT01547117|RADIATION|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
48179840|NCT01547117|RADIATION|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
48179841|NCT01547117|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
48179842|NCT01547117|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
48714148|NCT04349241|DRUG|Standard of care therapy|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
48714149|NCT02128243|DRUG|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
48714150|NCT02128243|DRUG|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
48714151|NCT03546504|BEHAVIORAL|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
48179843|NCT02650466|DEVICE|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
48179844|NCT00216047|DRUG|PTK787|PTK787 daily
48179845|NCT00216047|DRUG|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle\*
48179846|NCT04711083|DIAGNOSTIC_TEST|overnight pulse oximetry|"Wrist worn Overnight oximetry was performed using portable Nonin 2500 (Nonin Medical Inc., USA) pulse oximeters. The test was explained to the subjects and their caregiver by experienced health-care staff from the sleep unit. The recording was done at home and started just before going to bed and ended on awakening; the recommended duration was a minimum of 5 h and a maximum of 7 h. The awake SpO2, mean SpO2. The data were analysed to calculate the overnight minimum SpO2, mean SpO2, dip frequency (defined as a fall in SpO2 of \> 4%), the percentage of oximetry sleep time spent with a SpO2 of \< 90%, and the total oximetry time. Recordings were classified as normal (\< 4.9 desaturation events an hour), equivocal (5 to 14.9 desaturation events an hour), or abnormal (\> 15 desaturation events an hour) according to the severity and pattern of nocturnal desaturation observed ."
48179847|NCT02311088|DRUG|Caffeine|
48179848|NCT02311088|DRUG|Placebo|
48714152|NCT02863523|BEHAVIORAL|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
48714153|NCT04502121|BEHAVIORAL|EXPECT: Preoperative optimization of cardiac valve patient's expectations|The psychological, preoperative intervention follows a treatment manual. Patients get a personal intervention one day before surgery (30-40 minutes). It includes the development of an individual, subjectively perceived disease model, the treatment outcome expectations and the personalized outcome expectancy. Additionally they get two booster telephone calls 4 and 8 weeks after the surgery to recall the discussed topics and to talk about their recovery process (10-15 minutes).
48179849|NCT06237777|GENETIC|SKG0106 intravitreal injection dose level 1, 2 or 3|SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
48179850|NCT06293339|BIOLOGICAL|CHMI with 3D7 malaria|Controlled human malaria infection with 3D7 malaria through mosquito bites
48380065|NCT06647446|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software of digital physiotherapy and telerehabilitation TRAK. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
48714154|NCT02221518|BEHAVIORAL|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
48714155|NCT05705752|OTHER|Balance training|12 sessions of balance training en 4 weeks, with a duration of 40-45 min each.
48714156|NCT05705752|OTHER|Pilates training|12 sessions of Pilates training en 4 weeks, with a duration of 40-45 min each.
48179851|NCT05271344|DIETARY_SUPPLEMENT|Nutritional Products|Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
48179852|NCT04264975|PROCEDURE|fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
48179853|NCT05492968|DRUG|Epinephrin|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
48179854|NCT05492968|DRUG|Norepinephrine|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
48714157|NCT00964847|BEHAVIORAL|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
48714158|NCT00964847|BEHAVIORAL|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
48714159|NCT04467476|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
48380066|NCT06647446|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
48380067|NCT00808769|DRUG|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
48380068|NCT00808769|DRUG|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
48380069|NCT05666765|DRUG|Isotretinoin ,silymarin|20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
48380070|NCT04666935|OTHER|The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program|Sport Injury Prevention Program.
48380071|NCT04666935|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
48380072|NCT04115800|DRUG|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
48380073|NCT02705534|DRUG|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
48179855|NCT05492968|DRUG|Phenylephrine|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
48380074|NCT02705534|DRUG|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
48714160|NCT03627169|DEVICE|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
48714161|NCT05473013|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Standard behavioral therapy for eating disorders aimed at changing behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
48179856|NCT00000598|BEHAVIORAL|diet, fat-restricted|
48179857|NCT00000598|BEHAVIORAL|exercise|
48380075|NCT02705534|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
48380076|NCT02245997|RADIATION|External beam radiotherapy|
48380077|NCT02245997|RADIATION|proton beam RT|
48380078|NCT02099929|OTHER|Coffee with Sugar|300mL of Coffee with 30g of Sugar
48380079|NCT02099929|OTHER|Coffee without Sugar|300mL of Coffee without Sugar
48380080|NCT02099929|OTHER|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
48380081|NCT02099929|OTHER|Water with Sugar|300mL of Water with 30g of Sugar
48179858|NCT00823836|DRUG|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
48179859|NCT00823836|DRUG|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
48179860|NCT00014287|DRUG|gemcitabine hydrochloride|
48518141|NCT03416829|BEHAVIORAL|Ambulatory voice biofeedback|Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
48714162|NCT05473013|BEHAVIORAL|Skills Monitoring On|Integrates behavioral treatment for eating disorders with a more complex self-monitoring than the self-monitoring protocol with traditional behavioral treatment. Via a smartphone application, participants will be asked to self-monitor skill usage of the skills provided during treatment sessions on top of monitoring their eating patterns, binging, and (if applicable) compensatory behaviors.
48714163|NCT05473013|BEHAVIORAL|Automated Reminder Messages|Integrates behavioral treatment for eating disorders with two randomly time automated push notifications from a smartphone application each week to remind participants about skills they have learned in session to encourage skill use.
48518142|NCT03086486|DRUG|Pretomanid|200mg tablets
48518143|NCT03086486|DRUG|Linezolid|Scored 600mg tablets
48179861|NCT04802304|OTHER|Beyond Bias Treatment|The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
48518144|NCT03086486|DRUG|Bedaquiline|100mg tablets
48518145|NCT03086486|DRUG|Placebo Linezolid|Scored 600 mg tablets
48518146|NCT00614640|BIOLOGICAL|DermaVir patch|DNA Vaccine
48518147|NCT00614640|BIOLOGICAL|Placebo patch|10% dextrose (D-glucose) solution
48714164|NCT05473013|BEHAVIORAL|JITAIs|Integrates behavioral treatment for eating disorders with push notifications each week from a smartphone application to remind participants about skills they have learned in session to encourage skill use during app-identified moments of need (i.e., JITAIs, just-in-time adaptive interventions).
48380082|NCT02099929|OTHER|Water without Sugar|300mL of Water without Sugar
48380083|NCT04330677|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
48380084|NCT04330677|DRUG|Placebo nasal spray|The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
48380085|NCT04330677|DRUG|Estrogen Gel|Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
48380086|NCT04330677|DRUG|Placebo Gel|Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
48380087|NCT06427382|DEVICE|Perfusion index|Perfusion index determination using non-invasive pulse oximetry
48380088|NCT04945226|DRUG|Finasteride 1mg Tablet|Propecia Tablet 1mg
48380089|NCT04945226|DRUG|IVL3001|Finasteride long acting injection
48380090|NCT04973670|DRUG|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h for 1-7 days
48380091|NCT04973670|DRUG|Placebo|The same amount of NS containing only sivelestat sodium excipients
48518148|NCT04771559|OTHER|COVID-19 antibody test|5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples
48518149|NCT01994850|DRUG|brentuximab vedotin|Trade name: Adcetris
48518150|NCT03844256|COMBINATION_PRODUCT|nivolumab 480mg|Immuno-chemoradiotherapy
48022117|NCT06572176|BEHAVIORAL|With fluorescent concretization group|"Nurses were given the fluorescent lotion and asked to apply it all over their hands. The CE-certified test lotion is in gel form and is safety-approved. The lotion disperses particles the same size as bacteria on the skin. These particles settle on the skin, similar to the behavior of microorganisms, but disappear with hand washing under the influence of fluorescent light. They were then asked to wash their hands with 4 ml of soap. Two researchers marked the hand washing steps independently using the Hand Washing Skill Checklist. The duration of hand washing was recorded with a mobile stopwatch for each participant. Hand washing efficiency was evaluated using the Derma Litecheck device. UV rays were used after using the test lotion and drying the hands. Since any fluorescent material left on the hands would shine under UV light, it was possible to judge how well the hands were cleansed. The dirty spots were shown to the participants, and the reason for this was discussed."
48022118|NCT00039767|DRUG|Lepirudin|
48022119|NCT06198439|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Therapy System
48022120|NCT02554773|DRUG|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
48022121|NCT02758236|OTHER|No Intervention|No Intervention
48022122|NCT06562595|BEHAVIORAL|Education Intervention|Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.
48022123|NCT05438953|BIOLOGICAL|Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)|Participant of these arm will receive 2 doses of MVA vaccine spaced 28 days apart
48380092|NCT02020421|DEVICE|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
48518151|NCT03844256|COMBINATION_PRODUCT|nivolumab 3mg/kg, ipilimumab 1mg/kg|Immuno-chemoradiotherapy
48518152|NCT03844256|COMBINATION_PRODUCT|nivolumab 1mg/kg, ipilimumab 3mg/kg|Immuno-chemoradiotherapy
48518153|NCT05429892|BEHAVIORAL|Smoking cessation counseling and food delivery|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Smokers enrolled in the TRTsocialmot1 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
48518154|NCT05429892|BEHAVIORAL|Smoking cessation counseling|"The community health workers will delivery five 30-minute sessions during intervention months 1 through 5 to provide interpersonal level support for smoking cessation. The community health workers will conduct real-time video motivational counseling to clients. The community health workers will implement the 5As (Ask, Advise, Assess, Assist, Arrange) and support smokers in quitting, if ready, and build confidence toward quitting if they are uncertain about change.~Participants will receive educational materials."
48714165|NCT02847858|BEHAVIORAL|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
48714166|NCT00527020|DRUG|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
48380093|NCT02020421|DEVICE|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
48179862|NCT03613636|DIAGNOSTIC_TEST|Enzyme-linked immunospot (ELISpot) assay [Blood]|The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].
48179863|NCT04952363|DEVICE|A vertical vibration platform PowerVibe Zen Pro 5900|Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
48380094|NCT02020421|DEVICE|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
48518155|NCT05429892|BEHAVIORAL|Food delivery|"Smokers enrolled in the TRTsocial2 arm will be provided with monthly delivery of food boxes in accordance with the number of persons in the household and caloric intake needed to support one week's worth of family meals. Healthy meal preparation instructions will be included and delivery by project staff will reduce transportation barriers to food access rural counties.~Participants will receive educational materials."
48518156|NCT02403258|OTHER|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
48714167|NCT00527020|DRUG|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
48714168|NCT00527020|DRUG|Placebo|Placebo tablets will be given to the subjects.
48714169|NCT04927104|DEVICE|PEEK Knee Prosthesis|After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
48714170|NCT00716378|BEHAVIORAL|Teen Passenger Presence|
48714171|NCT05734274|OTHER|Probiotics|Probiotics lozenge containing at least 200 million active Limosilactobacillus reuteri.
48714172|NCT05734274|OTHER|Negative control|Sugar-free negative control lozenges.
48714173|NCT05162742|DRUG|Colchicine|ATC: M04AC01
48714174|NCT05162742|DRUG|Placebo|Placebo tablets
48714175|NCT01476280|DRUG|palonosetron|0.075mg immediately before induction of anesthesia
48714176|NCT01476280|DRUG|Ramosetron|0.3mg immediately before induction of anesthesia
48714177|NCT05586672|DEVICE|EEG-HR|Passation EEG-HR
48714178|NCT05586672|DIAGNOSTIC_TEST|ADI-R|Passation of ADI-R scale
48714179|NCT05586672|DIAGNOSTIC_TEST|ADOS-2|Passation of ADOS-2 scale
48714180|NCT05586672|DIAGNOSTIC_TEST|IDE|Passation of IDE scale
48714181|NCT05586672|DIAGNOSTIC_TEST|MSEL|Passation of MSEL scale
48022124|NCT01778192|DRUG|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
48022125|NCT01778192|DRUG|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
48022126|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
48714182|NCT05586672|DIAGNOSTIC_TEST|Dunn|Passation of Dunn scale
48714183|NCT01335841|DEVICE|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
48714184|NCT06518642|DEVICE|Sooma tDCS portable device - active stimulation|"The Sooma tDCS has been certified to comply with the EU Medical Device Regulation (MDR certification), and has been approved for both clinic and at-home use, specially customized for our study, such that it allows for doubleblinding: participant, investigator and assessor.~For the tDCS stimulation, saline-soaked, 25cm2 diameter sponge electrodes will be used."
48714185|NCT06518642|DEVICE|Sooma tDCS portable device - sham stimulation|"The Sooma tDCS has been certified to comply with the EU Medical Device Regulation (MDR certification), and has been approved for both clinic and at-home use, specially customized for our study, such that it allows for doubleblinding: participant, investigator and assessor.~For the tDCS stimulation, saline-soaked, 25cm2 diameter sponge electrodes will be used."
48714186|NCT04713618|PROCEDURE|Pelvic Examination|Undergo pelvic exam
48714187|NCT04713618|OTHER|Survey|Complete surveys
48714188|NCT02311569|DRUG|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
48714189|NCT01183819|BEHAVIORAL|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
48714190|NCT01183819|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
48714191|NCT01183819|BEHAVIORAL|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
48714192|NCT01183819|BEHAVIORAL|Control Games|Control games session 3 times a week for 12 weeks
48714193|NCT04881851|DIETARY_SUPPLEMENT|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
48714194|NCT04881851|DIETARY_SUPPLEMENT|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
48022127|NCT01778192|DRUG|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
48022128|NCT03898245|DEVICE|apply tDCS|Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
48179864|NCT04952363|DEVICE|HFCWO|Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
48022129|NCT03898245|DEVICE|Sham tDCS|Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
48380095|NCT02020421|DEVICE|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
48380096|NCT05479734|BEHAVIORAL|mHealth Intervention|A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
48380097|NCT03147209|BEHAVIORAL|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
48380098|NCT00939367|DRUG|Zolpidem Tartrate Tablets 10 mg|
48380099|NCT00939367|DRUG|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
48380100|NCT03257800|DRUG|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
48380101|NCT03257800|DRUG|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
48380102|NCT05071846|BIOLOGICAL|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
48380103|NCT02399410|DRUG|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
48518157|NCT02403258|BEHAVIORAL|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
48714195|NCT04881851|DIETARY_SUPPLEMENT|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
48714196|NCT01100567|DEVICE|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
48022130|NCT00126048|DRUG|Atorvastatin|40mg tablet
48022131|NCT00126048|DRUG|Placebo|Placebo tablet
48179865|NCT04374786|DEVICE|Calm Meditation App|"Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
48518158|NCT01286753|DRUG|Vemurafenib|Vemurafenib 960 mg orally twice daily.
48518159|NCT05611554|BEHAVIORAL|ACT|Psychological intervention focused on (a) values clarification, (b) defusion strategies, (c) training in flexible attention to the present moment (mindfulness), and (d) committed action and psychological acceptance through metaphors and experiential exercises.
48714197|NCT02768025|OTHER|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
48518160|NCT02498392|DRUG|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
48714198|NCT02768025|OTHER|NRT, counselling|Nicotine Replacement Therapy, counselling
48714199|NCT01688739|DRUG|Erenumab|Administered by subcutaneous injection or intravenous injection
48714200|NCT01688739|DRUG|Placebo|Administered by subcutaneous injection or intravenous injection
48179866|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 1, for 12 days
48179867|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 2, for 12 days
48179868|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 3, for 12 days
48179869|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 4, for 12 days
48179870|NCT05203705|DRUG|Enoxaparin|Enoxaparin, for 12 days
48380104|NCT02399410|PROCEDURE|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
48380105|NCT02399410|DRUG|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
48714201|NCT04883840|DRUG|Rosuvastatin 10mg|Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
48714202|NCT05778773|PROCEDURE|TAVR (Transcatheter Aortic Valve Replacement)|Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
48714203|NCT05778773|PROCEDURE|AVR (Aortic Valve Replacement)|Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
48179871|NCT02165826|DRUG|Roflumilast|Roflumilast tablets
48380106|NCT02894541|DRUG|CKD-519 100mg|
48380107|NCT02894541|DRUG|CKD-519 200mg|
48380108|NCT02894541|DRUG|CKD-519 100mg|
48380109|NCT02894541|DRUG|CKD-519 200mg|
48714204|NCT03920267|DRUG|BMS-986165|Specified dose on specified days
48380110|NCT01028274|DIETARY_SUPPLEMENT|Placebo|Two capsules, twice daily with meals for 12 weeks.
48380111|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
48380112|NCT01028274|DIETARY_SUPPLEMENT|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
48380113|NCT03130634|DRUG|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
48380114|NCT05232929|DRUG|Risdiplam|Participants will receive risdiplam orally.
48380115|NCT06580041|DRUG|Pramipexole|CAU plan modified to include a trial of pramipexole.
48380116|NCT06580041|DRUG|Methylphenidate|CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine).
48380117|NCT06580041|DRUG|Phenelzine|CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole).
48380118|NCT06580041|BEHAVIORAL|Mindfulness-based Stress Sensitivity Therapy (MBSST)|CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
48380119|NCT06580041|BEHAVIORAL|Complicated Grief Treatment (CGT)|CAU plan modified to include a trial of CGT.
48380120|NCT06580041|OTHER|Care as usual (CAU) plan|Unmodified CAU plan.
48380121|NCT02151565|DEVICE|HTEMS|
48714205|NCT06027411|DEVICE|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
48714206|NCT04600336|DRUG|Oxybutynin Chloride|Given PO
48714207|NCT04600336|DRUG|Placebo Administration|Given PO
48714208|NCT04600336|OTHER|Quality-of-Life Assessment|Ancillary studies
48380122|NCT02151565|DEVICE|TENS|
48380123|NCT05552157|DRUG|Remternetug (SC)|Administered subcutaneously every 12 weeks
48179872|NCT02165826|DRUG|Roflumilast Placebo|Roflumilast placebo-matching tablets
48380124|NCT05552157|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
48714209|NCT04600336|OTHER|Questionnaire Administration|Ancillary studies
48714210|NCT02982018|DEVICE|senofilcon A with new UV blocker|Investigational Contact Lens
48714211|NCT02982018|DEVICE|senofilcon A|J\&J Marketed Contact Lens
48714212|NCT05013658|BEHAVIORAL|pressure measurement|pressure measurement with pilot balloon palpation
48714213|NCT01219933|DRUG|methylprednisolone|starting dose \>/= 1 mg and \</= 20 mg orally daily, according to dose-reduction schedule
48179873|NCT02165826|DRUG|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
48179874|NCT02505893|BIOLOGICAL|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
48380125|NCT00783939|DRUG|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
48380126|NCT06566144|OTHER|Standard treatment|The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].
48380127|NCT06566144|OTHER|Osteopathy treatment|The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions
48380128|NCT06257459|PROCEDURE|subinguinal varicocelectomy|exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
48380129|NCT02504060|DRUG|Starch Placebo|
48380130|NCT02504060|DRUG|N-acetyl-D-glucosamine|
48380131|NCT05359146|DRUG|161Tb-DOTA-LM3|"161Tb-DOTA-LM3 is a therapeutic medicinal product with three main components, namely (a) Terbium-161 (161Tb), a beta minus-, gamma- and Auger-/conversion electron-emitting radionuclide with a half-life of 6.96 days; (b) DOTA, a chelator that allows stable complexation of 161Tb; and (c) LM3, an antagonistic SST analogue which binds to SST2 receptors (SST2 receptor antagonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
48518161|NCT02498392|OTHER|Placebo|Matching Placebo will be administered orally.
48714214|NCT01219933|DRUG|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
48714215|NCT04213144|DEVICE|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
48714216|NCT04213144|DEVICE|Sham MED|Sham MED is intended to be used for soft tissue healing
48714217|NCT00731965|BIOLOGICAL|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
48714218|NCT02922842|DEVICE|Transcutaneous Electrical Nerve Stimulation|
48714219|NCT04701580|DIAGNOSTIC_TEST|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
48714220|NCT04701580|DIAGNOSTIC_TEST|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
48179875|NCT02505893|DRUG|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
48179876|NCT02505893|DRUG|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
48179877|NCT02505893|DRUG|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
48179878|NCT01937195|DEVICE|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
48179879|NCT03562429|DRUG|TGF|TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
48179880|NCT03562429|DRUG|TGFP|TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
48179881|NCT04849689|BEHAVIORAL|Whole-food, plant-based lifestyle|"The WFPB lifestyle program included:~1. Nutrition/plant-based food (energy intake: at least 90% of whole-food, plant-based diet and ≤ 10% of energy intake from plant-based meal replacements (PBMR) and dietary supplements (e.g., vitamin B12, D, and EPA and DHA omega-3 fatty acids).~2. Physical activity (habitual; organized and other).~3. Support system (lectures, workshops and individual nutrition counselling, grocery shopping assistance, cooking classes, regular measurements body composition, food logging, regular medical monitoring)."
48179882|NCT01067287|DRUG|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
48518162|NCT03081780|BIOLOGICAL|FATE-NK100|"Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
48518163|NCT00580892|DEVICE|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
48518164|NCT04370834|BIOLOGICAL|Tocilizumab|Given IV
48518165|NCT05107401|BEHAVIORAL|Digital Crowdsourced Intervention to Reduce HIV Stigma among Adolescents and Young Adults|Adolescents and young adults will participate in a crowdsourcing contest to create digital materials to reduce HIV stigma in order to increase HIV testing. Entries will be judged by a community judging panel and expert judging panel. Winning entries will be selected for the digital intervention and presented to participants in the intervention arm.
48714221|NCT06162091|OTHER|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
48179883|NCT01067287|BIOLOGICAL|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
48179884|NCT01764308|DIETARY_SUPPLEMENT|Omega-3|1200mg twice a day for 24 weeks
48179885|NCT01764308|DIETARY_SUPPLEMENT|Placebo|4 tablets twice a day for 24 weeks
48714222|NCT00732355|DEVICE|Syph-Check POC|Rapid membrane test for syphilis antibodies
48714223|NCT05221112|OTHER|diagonal pattern training|patients will receive proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.
48714224|NCT05221112|OTHER|single plane training|patients will receive single plane training of proprioceptive neuromuscular facilitation in control group
48714225|NCT03100721|BEHAVIORAL|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
48714226|NCT03100721|PROCEDURE|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
48714227|NCT04403594|OTHER|dry needling|dry needling followed by functional electrical stimulation and treadmill training
48179886|NCT05264701|OTHER|Physiotherapist supervised exercise training|Exercise training for 12 weeks will be given by video talk accompanied by a physiotherapist.
48179887|NCT05264701|OTHER|Exercise training via phone app|Exercise training for 12 weeks will be given over the developed phone application.
48179888|NCT05264701|OTHER|Physical activity recommendations|The program will be consist of 12 weeks of physical activity recommendations.
48179889|NCT01124097|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
48179890|NCT01124097|DRUG|Placebo|Tablets will be used.
48380132|NCT05359146|DRUG|177Lu-DOTATOC|"177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a half-life of 6.65 days; (b) DOTA, a chemical chelator that allows stable complexation of 177Lu; and (c) TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to SST2 and much less to SST5 receptors (SST2 receptor agonist).~All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection."
48380133|NCT02302118|PROCEDURE|Esophagogastrectomy|Esophagogastrectomy
48380134|NCT02959398|DEVICE|Standard mammography|Standard mammography
48380135|NCT02959398|DEVICE|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
48380136|NCT00408135|DRUG|telithromycin (HMR3647)|
48380137|NCT00774774|DEVICE|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
48714228|NCT01074333|DRUG|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
48380138|NCT00774774|DEVICE|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~* during the night,~* when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
48380139|NCT05388760|DRUG|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.
48022132|NCT04863950|DRUG|Lomustine|"For surgical cohort patients, lomustine will be initiated (C1D1) within 6 weeks of surgery as soon as patient is deemed by the investigator (or designee) to be recovered enough for chemotherapy. Initiation of lomustine must be initiated within 6 weeks. If patient cannot be safely initiated on lomustine within this timeframe then they will be replaced.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), lomustine will be initiated on C1D1.~For both cohorts, lomustine will be administered as 110 mg/m2 PO once every 6 weeks."
48022133|NCT04863950|DRUG|Imipramine Hydrochloride|"For the surgical cohort, imipramine hydrochloride will be initiated within a minimum of 16 days to a maximum of 3 weeks prior to surgery. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day to attain a maximum dose of 200mg/day in 16 days.~For non-surgical cohort patients (the decision for surgery is made independent of study participation), imipramine hydrochloride will be initiated on Cycle 1 Day 1. Imipramine hydrochloride will be administered as 50mg PO (oral) QHS (at bedtime) for 4 days followed by a dose increase (taper-up) of 50mg/day every fourth day, if tolerated, to attain a maximum dose of 200mg/day in 16 days."
48380140|NCT03106701|PROCEDURE|Ablation|Epicardial Radiofrequency ablation
48380141|NCT02413723|DEVICE|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
48380142|NCT02413723|DEVICE|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
48380143|NCT05078359|DIAGNOSTIC_TEST|Prostate Magnetic resonance Imaging|Magnetic resonance imaging (MRI) uses a magnetic field, radiofrequency pulses, and a computer to produce detailed pictures of the organ. Prostate MRI evaluate the presence and extent of prostate cancer and determine whether it has spread around the organ
48380144|NCT02021019|PROCEDURE|Renal Denervation|Renal Denervation
48380145|NCT05546515|DRUG|Suvorexant (dual orexin receptor antagonist)|Participants will be prescribed up to 30 days of SUVO.
48380146|NCT05546515|DRUG|Placebo|Participants will be prescribed up to 30 days of placebo medication.
48380147|NCT03148834|PROCEDURE|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
48518166|NCT06575465|BEHAVIORAL|Healthy lifestyle nutrition, culture and physical activity workshops|The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.
48518167|NCT06575465|OTHER|Usual care|Usual care patients receive in their primary health care
48714229|NCT00747344|DRUG|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
48714230|NCT00747344|DRUG|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
48714231|NCT00747344|DRUG|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
48022134|NCT01190241|DRUG|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
48022135|NCT00652457|DRUG|Memantine|10 mg BID x 3 months
48022136|NCT02773979|DRUG|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
48022137|NCT02773979|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
48022138|NCT02773979|OTHER|Placebo|Placebo
48022139|NCT00974428|DIETARY_SUPPLEMENT|Wobenzym® N|4 tablets TID, 6 weeks
48022140|NCT00974428|DIETARY_SUPPLEMENT|Placebo|4 tablets TID
48022141|NCT04986618|OTHER|One-way Nordic Exercise|Participants in this group will be given the standard Nordic Hamstring exercise.
48022142|NCT04986618|OTHER|Two-way Nordic Exercise|In addition to the standard Nordic Hamstring exercise, participants in this group will do the same exercise backwards for the quadriceps.
48022143|NCT00849342|DRUG|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
48380148|NCT02231606|OTHER|Free Glasses|Provide free glasses
48518168|NCT04944706|DRUG|Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time|Take 3 times a day after meals,24 weeks
48714232|NCT00747344|DRUG|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
48179891|NCT04661943|DRUG|Tucidinostat|Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
48179892|NCT05995652|PROCEDURE|elastography|elastography
48179893|NCT01964846|DIETARY_SUPPLEMENT|Resveratrol, curcumin|
48179894|NCT01964846|DIETARY_SUPPLEMENT|Placebo|
48380149|NCT02231606|OTHER|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
48380150|NCT02231606|OTHER|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
48380151|NCT03673111|DRUG|Y14|Gut hormone analogue
48179895|NCT04231045|DEVICE|PiCCO device cardiac monitoring|"PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated"
48179896|NCT04502797|BEHAVIORAL|Electronic Patient Visit Assessment (ePVA)|The ePVA is an mHealth clinical support tool. The ePVA consists of a patient-reported measure that focuses on symptoms common to HNC (i.e. pain, eye, ear, nasal, mouth, voice, fibrosis, edema, skin, gastrointestinal, fatigue, limitation in movement, sleep, breathing, difficulty eating or drinking, swallowing, communication, social activities, anxiety, depression, and daily activities). PROMIS® questionnaires (pain intensity 3a, fatigue 6a, sleep disturbance 6a, anxiety 6a, depression 6a) are embedded within the ePVA.
48179897|NCT06080360|OTHER|Patient-Reported Outcome Measures|Functional Independence Measurement-FIM, Barthel Index and European Quality of Life-5 Dimensions Questionnaire-EQ-5D, which are self-report based evaluation methods, were applied to patients who received routine treatment and met the inclusion criteria.To determine the patients' level of participation in the treatment, Hopkins was scored by the physiotherapist applying the treatment.
48380152|NCT03673111|DRUG|Placebo|0.9% saline
48380153|NCT04707612|OTHER|No intervention.|No intervention.
48518169|NCT04944706|DRUG|Qishen Yiqi dripping pills 4 bags/time|Take 3 times a day after meals,24 weeks
48179898|NCT02460055|DEVICE|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
48179899|NCT02460055|DRUG|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
48179900|NCT02460055|DRUG|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
48179901|NCT02460055|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
48179902|NCT02460055|DRUG|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
48179903|NCT02460055|DRUG|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
48179904|NCT02058836|DRUG|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
48179905|NCT02058836|PROCEDURE|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
48179906|NCT04077385|BEHAVIORAL|Retrieval-extinction (R-E) Training|The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip.
48380154|NCT05328999|DIETARY_SUPPLEMENT|Probiotics (Omnibiotic (R))|As intervention in the randomized placebo controlled double blind trial, 30 males will receive either probiotics or placebo once daily for 3 months. Sperm count and microbiome analysis before and after intervention will be performed.
48380155|NCT00221416|DRUG|Aripiprazole|5-20 mg/day
48380156|NCT04111666|BIOLOGICAL|AL101|Active dose of AL101
48380157|NCT04111666|OTHER|Placebo|Saline solution administered as a single and multiple infusion as placebo.
48380158|NCT06102070|OTHER|Blood samples drawing|10 ml of periferal blood
48380159|NCT06102070|OTHER|Skin biopsy|Skin biopsy only in some index cases depending of the pathology at the recruitment
48380160|NCT00582634|DRUG|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
48518170|NCT04944706|DRUG|Qishen Yiqi dripping pills placebo 4 bags/time|Take 3 times a day after meals,24 weeks
48714233|NCT04355858|DRUG|SHR7390|MEK1/2 inhibitor
48714234|NCT04355858|DRUG|Famitinib|Multi-target tyrosine kinase inhibitor
48714235|NCT04355858|DRUG|SHR3162|PARP inhibitor
48714236|NCT04355858|DRUG|Pyrotinib|HER1 / HER2 receptor tyrosine kinase inhibitor
48714237|NCT04355858|DRUG|Capecitabine|In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
48714238|NCT04355858|DRUG|SHR1210|PD-1 antibody
48714239|NCT04355858|DRUG|Everolimus|mTOR inhibitor
48714240|NCT04355858|DRUG|Nab paclitaxel|Albumin bound paclitaxel
48714241|NCT04355858|DRUG|SHR2554|EZH2 inhibitor
48714242|NCT04355858|DRUG|SHR3680|AR inhibitor
48179907|NCT04077385|BEHAVIORAL|Extinction Training|The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
48714243|NCT04355858|DRUG|SHR6390|CDK4/6 inhibitor
48714244|NCT04355858|DRUG|SHR1701|anti-PD-L1/TGF-βRII bifunctional fusion protein
48714245|NCT04355858|DRUG|SERD|Fulvestrant
48714246|NCT04355858|DRUG|AI|aromatase inhibitor
48714247|NCT04355858|DRUG|VEGFi|Bevacizumab
48714248|NCT00711113|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
48714249|NCT05863234|DRUG|PPMX-T003|The therapeutic agent is administered continuously intravenously
48714250|NCT06013956|DEVICE|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
48714251|NCT06013956|DRUG|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
48714252|NCT00229580|BEHAVIORAL|3 session brief intervention with health behavior feedback|
48714253|NCT00229580|OTHER|treatment as usual|
48179908|NCT02271022|OTHER|Non-Interventional Study|Non-Interventional Study
48179909|NCT02927912|RADIATION|Electron Beam Therapy|Undergo IOERT boost
48380161|NCT04912973|PROCEDURE|Robotically Assisted Total Knee Arthroplasty - Knee Replacement|Robotically Assisted Total Knee Arthroplasty with a particular alignment strategy
48518171|NCT00390208|DRUG|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
48179910|NCT02927912|PROCEDURE|Lumpectomy|Undergo lumpectomy
48179911|NCT02927912|OTHER|Quality-of-Life Assessment|Ancillary studies
48518172|NCT00390208|DRUG|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
48714254|NCT02737995|DRUG|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
48714255|NCT00189943|BIOLOGICAL|MVA-BN|
48714256|NCT03066362|OTHER|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
48179912|NCT02927912|OTHER|Questionnaire Administration|Ancillary studies
48714257|NCT00252226|DRUG|Quetiapine|
48714258|NCT06162533|BIOLOGICAL|Vaccination against SARS-CoV-2|Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2
48714259|NCT03343080|DRUG|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
48714260|NCT03343080|OTHER|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
48714261|NCT06270251|BEHAVIORAL|CBIT|"8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics."
48714262|NCT01812356|DEVICE|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
48714263|NCT01812356|DEVICE|Cryomaze procedure using Argon|Cryomaze procedure using Argon
48714264|NCT00378937|DRUG|acetaminophen|
48179913|NCT02927912|RADIATION|Radiation Therapy|Undergo whole breast radiation therapy
48179914|NCT02927912|PROCEDURE|Reconstructive Surgery|Undergo oncoplastic reconstruction
48179915|NCT03468179|DIETARY_SUPPLEMENT|Oatmeal|Subjects will be fed a calculated serving of oatmeal.
48380162|NCT02395393|DEVICE|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
48380163|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
48380164|NCT00692601|DIETARY_SUPPLEMENT|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
48714265|NCT00378937|DRUG|codeine phosphate|
48714266|NCT00378937|DRUG|dextropropoxyphene hydrochloride|
48714267|NCT00378937|DRUG|morphine sulfate|
48714268|NCT00378937|DRUG|oxycodone hydrochloride|
48714269|NCT00378937|PROCEDURE|management of therapy complications|
48714270|NCT00378937|PROCEDURE|quality-of-life assessment|
48714271|NCT00570934|DIETARY_SUPPLEMENT|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
48714272|NCT00570934|DIETARY_SUPPLEMENT|Calcium|1 gm calcium as calcium carbonate
48714273|NCT00570934|DIETARY_SUPPLEMENT|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
48714274|NCT00570934|DRUG|Placebo|Placebo
48714275|NCT01382004|DRUG|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
48714276|NCT01382004|DRUG|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
48179916|NCT01392703|DRUG|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
48179917|NCT01392703|DRUG|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
48179918|NCT01392703|DRUG|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
48179919|NCT03306004|OTHER|Questionare|
48179920|NCT04962698|BEHAVIORAL|Visual motor imagery (MI)|Subjects will relax their muscles and perform conventional visual motor imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
48179921|NCT04962698|BEHAVIORAL|Kinesthetic MI|The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
48179922|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction with MI|Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
48179923|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction without MI|Subjects will perform the Robot-Hand Interaction without MI.
48179924|NCT04962698|BEHAVIORAL|Virtual-Hand Interaction|Subjects will interact with visual feedback of virtual robot actions on a monitor.
48179925|NCT04962698|BEHAVIORAL|Robotic Action Observation|Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic hand.
48179926|NCT04962698|BEHAVIORAL|Rest|Subjects will rest without a task.
48179927|NCT02519946|OTHER|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
48380165|NCT00692601|DIETARY_SUPPLEMENT|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
48380166|NCT04047316|DEVICE|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
48380167|NCT04122677|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw.
48518173|NCT04875351|DIAGNOSTIC_TEST|Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test|The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (\>5 year) endocrine therapy.
48714277|NCT03620357|DEVICE|CGM|CGM Group: Dexcom G6 CGM
48380168|NCT06653192|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
48380169|NCT06653192|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~Size: 10x40mm or 10x60mm or 10x80mm."
48714278|NCT03620357|DEVICE|SMBG|SMBG Group: Blood Glucose Meter
48022144|NCT03565718|BEHAVIORAL|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
48022145|NCT03565718|BEHAVIORAL|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
48022146|NCT02029924|DRUG|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
48022147|NCT02029924|DRUG|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
48022148|NCT01825551|DRUG|Granulocyte Colony Stimulating Factor|
48022149|NCT01825551|DRUG|Placebo|
48022150|NCT06563089|OTHER|blood sampling|Albumin level in blood
48022151|NCT05264805|DRUG|0.25% Bupivacaine|20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
48022152|NCT05040412|DEVICE|difficult laryngoscopy|Patients will be intubated with the direct laryngoscope.
48022153|NCT04960813|BEHAVIORAL|Structured games|"Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home."
48380170|NCT06653192|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm."
48380171|NCT03740126|DIAGNOSTIC_TEST|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
48022154|NCT04960813|BEHAVIORAL|Playgroup|"Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions."
48380172|NCT00002074|DRUG|Fluconazole|
48518174|NCT01494116|OTHER|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
48518175|NCT06171399|BEHAVIORAL|"All Natural descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48518176|NCT06171399|BEHAVIORAL|"Gluten-free descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48380173|NCT00002074|DRUG|Amphotericin B|
48518177|NCT06171399|BEHAVIORAL|"Vegan descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48518178|NCT06171399|BEHAVIORAL|"100% Organic descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48714279|NCT01897545|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
48022155|NCT05237765|OTHER|controlled (automatic) massage|Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
48380174|NCT00353392|DEVICE|Laser Therapy|
48380175|NCT01338909|DRUG|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
48380176|NCT01338909|DRUG|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
48380177|NCT02484209|DRUG|Metformin|Metformin 1500 mg daily for 16 weeks
48380178|NCT02484209|DRUG|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
48380179|NCT02484209|DRUG|Metformin|metformin 1500 mg daily for 16 weeks
48380180|NCT02738606|DRUG|Chemotherapy|
48518179|NCT06171399|BEHAVIORAL|"Handcrafted descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48518180|NCT06171399|BEHAVIORAL|"Made with live resin descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48518181|NCT06171399|BEHAVIORAL|"Fast-acting descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48714280|NCT01897545|PROCEDURE|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
48714281|NCT01278784|DEVICE|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
48714282|NCT01278784|DEVICE|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
48518182|NCT06171399|BEHAVIORAL|"Relax descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48518183|NCT06171399|BEHAVIORAL|"Energy Boost descriptor"|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48518184|NCT06171399|BEHAVIORAL|No descriptor (control)|Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
48714283|NCT03980821|DRUG|AZD4635|AZD4635 taken orally
48714284|NCT00554099|DRUG|Mesalamine|6 - 400 mg tablets once daily
48714285|NCT00554099|DRUG|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
48714286|NCT00554099|DRUG|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
48714287|NCT00554099|OTHER|Dietary Advice|Dietary advice
48714288|NCT00554099|DRUG|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
48714289|NCT01182974|DRUG|paracetamol|1 gr of paracetamol PO/PZ/PR
48714290|NCT01182974|DRUG|dypirone|1 gr PO/PZ/PR/IM
48714291|NCT03278431|DRUG|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
48714292|NCT03278431|DRUG|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
48714293|NCT03278431|DRUG|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
48714294|NCT03278431|DRUG|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
48714295|NCT03578484|DIAGNOSTIC_TEST|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
48714296|NCT02639338|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
48714297|NCT02639338|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
48714298|NCT00609791|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
48714299|NCT00609791|OTHER|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
48714300|NCT00609791|OTHER|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
48714301|NCT00609791|OTHER|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
48518185|NCT00620386|DEVICE|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
48714302|NCT00609791|OTHER|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
48714303|NCT00609791|PROCEDURE|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
48714304|NCT00609791|PROCEDURE|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
48714305|NCT00533650|DRUG|MK0429|
48714306|NCT00289198|DRUG|FF|fluticasone furoate 110 μg nasal spray
48714307|NCT00289198|DRUG|Placebo|placebo nasal spray
48518186|NCT00620386|DEVICE|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
48714308|NCT01811602|OTHER|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
48714309|NCT01811602|OTHER|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
48714310|NCT05304429|BEHAVIORAL|nutrition education|Educational sessions with topics that will address the management and prevention of frailty syndrome focusing on protein intake and physical activity
48022156|NCT01529645|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
48022157|NCT01529645|BIOLOGICAL|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
48022158|NCT01529645|BIOLOGICAL|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
48714311|NCT05304429|BEHAVIORAL|nutritional counseling|nutritional counseling system based on the com-b model through three strategies: goal setting, self-monitoring and social support
48714312|NCT05215015|BIOLOGICAL|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
48714313|NCT00453947|DEVICE|CPAP and Non Invasive Ventilation|
48179928|NCT05064579|OTHER|Questionnaires|Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.
48179929|NCT01237847|BEHAVIORAL|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
48179930|NCT01237847|BEHAVIORAL|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
48179931|NCT01237847|BEHAVIORAL|Wait list comparison group|Wait list comparison group to receive intervention at later point.
48179932|NCT04912310|DEVICE|Argon laser peripheral iridoplasty|Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication
48179933|NCT03302390|PROCEDURE|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than \<3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
48179934|NCT02148510|DEVICE|Monobloc|Construction fitted to upper and lower jaw
48179935|NCT02148510|DEVICE|Bibloc|Biblock construction
48179936|NCT02813993|OTHER|Health educational video|
48179937|NCT01435707|OTHER|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
48179938|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
48179939|NCT01435707|OTHER|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
48179940|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
48179941|NCT00405938|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
48179942|NCT00405938|DRUG|Anastrozole|anastrozole (1 mg orally daily)
48179943|NCT00405938|DRUG|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
48518187|NCT03396003|DEVICE|GALILEI G6 Lens Professional|Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
48518188|NCT03396003|DEVICE|Oculus Pentacam AXL|A single measurement of the eye will be taken using the Oculus Pentacam AXL
48518189|NCT02439216|DRUG|Edasalonexent|
48714314|NCT02606760|DRUG|P-3073|
48022159|NCT01529645|BIOLOGICAL|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
48179944|NCT02271230|DRUG|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
48179945|NCT02271230|DIETARY_SUPPLEMENT|Fish oil (EPA/DHA) alone|1 g/d fish oil
48179946|NCT02271230|DRUG|Vitamin D alone|2000 IU vitamin D
48179947|NCT02271230|OTHER|Placebo|Vitamin D placebo and fish oil placebo
48179948|NCT05841589|PROCEDURE|Green tea extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
48179949|NCT05841589|PROCEDURE|Garlic with lime extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
48179950|NCT05841589|PROCEDURE|Pomegranate extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
48179951|NCT05841589|PROCEDURE|Chlorhexidine mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
48179952|NCT02911194|DIETARY_SUPPLEMENT|a2 milk|replace all milk with a2 milk
48179953|NCT02911194|DIETARY_SUPPLEMENT|a1 containing milk|use a1 containing milk
48179954|NCT01642095|OTHER|Laboratory Biomarker Analysis|Correlative studies
48179955|NCT03443414|DRUG|RPL554 suspension|A dual PDE3/PDE 4 inhibitor
48179956|NCT03443414|DRUG|Placebo|Placebo solution
48380181|NCT02738606|OTHER|Laboratory Biomarker Analysis|Correlative studies
48380182|NCT02738606|PROCEDURE|Metastasectomy|Undergo lung metastasectomy
48380183|NCT02738606|OTHER|Quality-of-Life Assessment|Ancillary studies
48380184|NCT02738606|PROCEDURE|Therapeutic Conventional Surgery|Undergo hepatectomy
48380185|NCT04300049|DRUG|Glucagon Infusion|Study participants will receive glucagon infusion (6ug/kg/min for 12 hours) 12 hours.
48380186|NCT04300049|OTHER|Saline|Study participants will receive saline infusion for 12 hours.
48518190|NCT02439216|DRUG|Placebo|
48518191|NCT01581125|BEHAVIORAL|Sleep:wake 1|Sleep and Wake durations for arm 1
48518192|NCT01581125|BEHAVIORAL|Sleep:wake 2|Sleep and Wake durations for arm2
48714315|NCT02606760|DRUG|Vehicle of P-3073|
48714316|NCT00700102|DRUG|Chemotherapy|As prescribed
48714317|NCT00700102|DRUG|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
48179957|NCT01021371|BEHAVIORAL|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
48022160|NCT01529645|OTHER|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
48022161|NCT02242786|RADIATION|External beam radiation therapy|
48179958|NCT00706771|DRUG|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
48179959|NCT00706771|DRUG|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
48179960|NCT03831854|DRUG|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P\<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P\<.05).
48179961|NCT03831854|DRUG|Placebo|300 mg of oral Placebo
48179962|NCT03831854|DRUG|Ketamine|1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
48179963|NCT04366362|PROCEDURE|Individualised ACL reconstruction|ACL reconstruction based on anatomical and functional distinctiveness of each patient separately
48714318|NCT04959812|DRUG|Sufentanil|Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
48179964|NCT04366362|PROCEDURE|Conventional ACL reconstruction|ACL reconstruction based on surgeons experience without taking into account any other patients characteristics
48714319|NCT04959812|OTHER|Placebo|Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.
48179965|NCT04885348|BEHAVIORAL|Intervention Group (Dental Home Visits + Dental Home Education Leaflets)|No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.
48714320|NCT06450860|OTHER|Nutrition Interventions|Individualized food provision and/or supplemental referral based on participant's unique needs/responses to assessment (NSAT). Food provision interventions include medically tailored meals, home delivered prepared meals, grocery boxes, grocery delivery services, food pantries, and soup kitchens/meal sites. Supplemental interventions include SNAP benefit enrollment support, nutrition education, and cooking education.
48179966|NCT04885348|BEHAVIORAL|Control Group (Dental Home Education Leaflets)|Only Dental Home Education Leaflets were provided every six months for 2 years.
48179967|NCT03735953|DIAGNOSTIC_TEST|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
48179968|NCT05693909|DRUG|SP-420|Capsules for oral intake
48179969|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 75 mg/capsule|Take 2 capsules per day at any time.
48179970|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 50 mg/capsule|Take 2 capsules per day at any time.
48179971|NCT05803083|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
48179972|NCT00592189|PROCEDURE|blood draw|blood collection
48179973|NCT04457258|PROCEDURE|Computed Tomography|Undergo PET/CT
48179974|NCT04457258|DRUG|Gallium Ga 68 FAPi-46|Given IV
48714321|NCT04104919|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
48714322|NCT04104919|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
48714323|NCT04128982|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
48179975|NCT04457258|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48179976|NCT04457258|RADIATION|18F-FDG|Given IV
48179977|NCT00603811|BIOLOGICAL|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
48714324|NCT00983736|DRUG|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
48714325|NCT00983736|DRUG|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
48714326|NCT05493189|OTHER|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
48179978|NCT00603811|BIOLOGICAL|Placebo|Placebo
48179979|NCT04752800|DEVICE|Direct Current Transcranial Stimulation - tDCS|Intervenção Ativa
48179980|NCT04752800|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham Intervention
48179981|NCT05140083|DRUG|68Ga-NOTA Evans Blue|Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
48179982|NCT05888610|BEHAVIORAL|Digital Outpost|A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
48380187|NCT04114591|PROCEDURE|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
48380188|NCT04672369|BIOLOGICAL|IBI939|IBI939 injection
48380189|NCT04672369|BIOLOGICAL|Sintilimab|Sintilimab injection
48518193|NCT06583057|PROCEDURE|Thermal ablation|Patients who underwent thermal ablation were performed in the outpatient clinic's operating room under local anesthesia. Thermal ablation was performed under real-time ultrasound-guided. The 18-G bipolar radiofrequency applicator with a 0.9 cm active tip (CelonProSurge micro 100-T09, Olympus Surgical Technologies Europe) , or a 16-G/17-G cooled microwave antenna with a 0.3 cm tip (ECO-100A1, YIGAO MWA system Co., Ltd; KY-2000, Kangyou Medical, Nanjing, China) was used during ablation.
48714327|NCT04504890|DEVICE|EYE-SYNC|Nystagmograph used to measure eye movement
48022162|NCT02376413|PROCEDURE|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
48022163|NCT02376413|DRUG|Chemotherapy or endocrine therapy or Trastuzumab therapy|
48022164|NCT02376413|RADIATION|Radiation therapy|
48022165|NCT00893490|DEVICE|Ahmed Glaucoma Valve (AGV)|AGV implantation
48714328|NCT01457677|DRUG|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
48714329|NCT01457677|DRUG|RO4995819|5 mg oral once daily for 6 weeks
48714330|NCT01457677|DRUG|RO4995819|15 mg oral once daily for 6 weeks
48714331|NCT01457677|DRUG|RO4995819|30 mg oral once daily for 6 weeks
48714332|NCT01828138|DIETARY_SUPPLEMENT|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
48714333|NCT01828138|DIETARY_SUPPLEMENT|Placebo|Placebo are given in 5 days
48022166|NCT00893490|DRUG|Mitomycin C (MMC)|3 minute MMC application
48022167|NCT00893490|PROCEDURE|amniotic membrane coverage|single layer coverage of amniotic membrane
48380190|NCT03994991|DEVICE|active TMS|Transcranial magnetic stimulation
48714334|NCT01708447|DRUG|L.M.X.4.® cream|A lidocaine topical anesthetic cream
48714335|NCT01708447|OTHER|A placebo cream|Placebo cream containing no anesthetic properties.
48714336|NCT01708447|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48022168|NCT04628429|DRUG|Erenumab|anti-CGRP-receptor monoclonal anti-body
48022169|NCT04628429|DRUG|Galcanezumab|anti-CGRP-ligand monoclonal anti-body
48022170|NCT04628429|DRUG|Fremanezumab|anti-CGRP-ligand monoclonal anti-body
48022171|NCT04280211|OTHER|Respiratory Assessment|Spirometric measurement
48022172|NCT04280211|OTHER|Vestibular Assessment|Assessment of peripheral vestibular dysfunction, angular vestibule ocular reflex, vestibular dysfunction
48022173|NCT04280211|OTHER|Balance Assessment|Postural stability
48022174|NCT03615651|DIETARY_SUPPLEMENT|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
48022175|NCT03615651|OTHER|Placebo|Placebo intervention.
48022176|NCT00779246|OTHER|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
48022177|NCT00779246|DRUG|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
48022178|NCT00779246|OTHER|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
48022179|NCT06434532|OTHER|v-Care Online Game|A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval
48380191|NCT03994991|DEVICE|sham TMS|Sham transcranial magnetic stimulation
48380192|NCT00052507|DRUG|bortezomib|
48380193|NCT02264886|RADIATION|MRI-guided stereotactive body radiation therapy|
48380194|NCT03799445|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
48380195|NCT03799445|BIOLOGICAL|Ipilimumab|Given IV
48380196|NCT03799445|BIOLOGICAL|Nivolumab|Given IV
48380197|NCT03799445|OTHER|Quality-of-Life Assessment|Ancillary studies
48380198|NCT03799445|OTHER|Questionnaire Administration|Ancillary studies
48380199|NCT05011357|DRUG|Phenylephrine|Phenylephrine will be administered as an infusion
48380200|NCT05011357|DRUG|Saline Control|Saline infusion
48380201|NCT04334122|OTHER|Instrument-assisted soft tisue mobilization|"All patients in the experimental group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.~In addition to the traditional physiotherapy program, the patients in the experimental group were subjected to tool-assisted soft tissue mobilization 3 times a week (12 sessions with 1 day interval).~All evaluations were repeated to all patients in the experimental and control groups after four weeks."
48380202|NCT04334122|OTHER|Traditional physiotherapy|All patients in the control group were given a traditional physiotherapy program applied in lumbar disc herniation for 4 weeks (20 sessions) and 5 days a week.
48380203|NCT02965027|DRUG|Prazosin|
48380204|NCT02965027|DRUG|Placebo|
48380205|NCT01953523|PROCEDURE|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
48380206|NCT06653491|OTHER|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure|high-speed, low-amplitude talocrural decompression technique and changes at the level of mobility and plantar pressure in a supine position
48380207|NCT06653491|OTHER|simulated ankle technique|simulated ankle technique in a supine position
48380208|NCT01412294|DRUG|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
48380209|NCT01971099|DRUG|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
48380210|NCT01971099|OTHER|Placebo|patients will take one pill a day (the same shape of the drug)
48380211|NCT00333437|DRUG|Mycophenolate mofetil|
48714337|NCT02649192|BIOLOGICAL|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
48714338|NCT02649192|DIETARY_SUPPLEMENT|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
48714339|NCT02649192|OTHER|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
48714340|NCT02608580|OTHER|Survey|
48022180|NCT06434532|OTHER|Case-based online discussion|A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
48022181|NCT03532789|DRUG|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
48179983|NCT06314139|DEVICE|continuous theta-burst stimulation (cTBS)|Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
48714341|NCT04412122|OTHER|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
48714342|NCT04412122|OTHER|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
48714343|NCT04412122|OTHER|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
48714344|NCT04412122|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
48714345|NCT02933567|OTHER|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
48022182|NCT03532789|DRUG|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
48022183|NCT06280300|OTHER|health services intervention|Health services intervention
48022184|NCT02488044|DRUG|AEB1102|modified human arginase I
48022185|NCT06572371|PROCEDURE|Laparoscopic pyeloplasty|The first trocar was inserted under vision through the same supraumbilical incision and the intraperitoneal cavity was inspected The second 5 mm trocar was placed in the midclavicular line 2 inches below the costal margin. The third 10 mm trocar was placed lateral to the rectus muscle at the level of the anterior superior iliac spine. In right-sided pyeloplasty, a fourth trocar was inserted below the xiphistemum for liver retraction. Incision of the line of Toldt and mobilization of the colon was the first step of the transperitoneal approach. A 4/0 polysorbe stay suture was taken in the lateral aspect of the ureter distal to uretero-pelvic junction obstruction to identify the correct orientation after dismembering the ureter. A full thickness anastomosis was started from the angle of V shape spatulation to the lower pole of the renal pelvis.
48022186|NCT06572371|PROCEDURE|Open pyeloplasty|"A flank incision with the patient in lateral position was undertaken in open pyeloplasty. After accessing the retro- peritoneum, the ureter was identified and traced cranially till the PUJ segment.~Traction sutures was placed on the renal pelvis followed by excision of the narrowing segment. The ureter was spatulated by approximately 2 cm and a reduction pyeloplasty was performed, where necessary. Anastomosis was undertaken using vicryl 4-0 sutures. The primary anastomotic site was sutured in interrupted fashion followed by a continuous running suture of the posterior wall. Next, antegrade DJ stenting was performed and the anterior wall was anastomosed. After haemostatic control a 22 Fr drain was placed in the surgical bed."
48022187|NCT05548075|DRUG|Psilocybin|Up to 25mg of Psilocybin on 2 occasions.
48179984|NCT02827032|DEVICE|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
48179985|NCT05450536|OTHER|Video Model and Role Play|Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
48714346|NCT05491421|DRUG|ZT002|"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
48022188|NCT05548075|BEHAVIORAL|Therapeutic support|Psychological and physical therapeutic support
48179986|NCT00480142|DRUG|Oxycodone 10 mg|
48179987|NCT05511337|OTHER|Caloric restriction and control oxalate and citrate foods|Restriction of 500 kilocalories from the usual diet plus a decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) for 28 days. The treatment will be given through an individualized meal plan.
48179988|NCT05511337|OTHER|Caloric restriction|Restriction of 500 kilocalories from the usual diet for 28 days. The treatment will be given through an individualized meal plan
48179989|NCT05511337|OTHER|Real-life intervention with control oxalate and citrate foods|Decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) without restriction in kilocalories from the usual diet for 28 days. Treatment will be given only through dietary counseling.
48179990|NCT00992992|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
48179991|NCT01999777|DRUG|USL261|
48714347|NCT05491421|OTHER|Placebo|"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"
48179992|NCT01999777|DRUG|Placebo|
48179993|NCT01458522|DRUG|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
48179994|NCT01458522|DRUG|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
48179995|NCT02701998|BEHAVIORAL|mHealth-Enhance Physical Activity Intervention|
48179996|NCT02701998|OTHER|Physical Activity Intervention|
48179997|NCT04421339|DIETARY_SUPPLEMENT|Melatonin|Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
48380212|NCT04220723|OTHER|Frailty Assessment|"Liver Frailty Index measurements:~1. Grip strength: the average of three trials, measured in the subject's dominant hand using a hand dynamometer~2. Timed chair stands: measured as the number of seconds it takes to do five chair stands with the subject's arms folded across the chest~3. Balance testing: measured as the number of seconds that the subject can balance in three positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each."
48380213|NCT04220723|OTHER|Functional Capacity Assessment|Shuttle Walk Test: The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases. The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends. The number of shuttles is recorded. Each shuttle represents a distance of ten metres (i.e each time the patient reaches a cone is 1 shuttle).
48714348|NCT00057434|DRUG|multivitamin|
48022189|NCT02430077|DRUG|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
48022190|NCT02430077|DRUG|Placebo|Identical to Obeticholic Acid - placebo drug
48022191|NCT01962974|BIOLOGICAL|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
48179998|NCT04421339|OTHER|Placebo|Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
48179999|NCT02581059|DRUG|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
48180000|NCT02581059|DIETARY_SUPPLEMENT|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
48180001|NCT03025932|PROCEDURE|repair of giant hiatal hernia with mesh and anterior fundoplication|
48180002|NCT02369861|DRUG|ST266|Topical ocular application 4 times per day
48180003|NCT02369861|DRUG|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
48180004|NCT03293069|DRUG|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
48714349|NCT05347940|OTHER|mirror therapy|A Mirror box will be used to easily create illusion. It' is a box with one mirror in the center where on each side of it, the hands are placed in a manner that the affected limb is kept covered always and the unaffected limb is kept on the other side whose reflection can be seen on the mirror.
48714350|NCT05347940|OTHER|traditional physiotherapy protocol for flexor tendon repair|include stretching exercises and active ROM exercises
48714351|NCT01604655|PROCEDURE|Coronary CT Angiography|CCTA
48714352|NCT01604655|PROCEDURE|Stress Test|Stress Test
48714353|NCT00584571|PROCEDURE|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
48714354|NCT00584571|DRUG|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
48714355|NCT06287619|DRUG|Monoferric Injectable Product|Ferric derisomaltose will be prepared by an unblinded research pharmacist as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
48714356|NCT06287619|OTHER|0.9% sodium chloride solution|Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
48714357|NCT05132517|DIAGNOSTIC_TEST|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
48714358|NCT05566457|DRUG|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
48714359|NCT02011490|DRUG|sugammadex|sugammadex 4 mg/kg IV bolus
48714360|NCT05947630|DEVICE|Ankle Foot Orthosis (AFO)|3D treatment (AFO will be printed) versus traditional made AFO
48518194|NCT06583057|PROCEDURE|Thyroid lobectomy|Patients who underwent thyroid lobectomy were performed in the operating theater under general anesthesia. Lobectomy (or lobectomy plus isthmusectomy) with prophylactic central neck dissection were performed.
48714361|NCT05947630|DEVICE|Knee Ankle Foot Orthosis (KAFO)|3D treatment (KAFO will be printed) versus traditional made KAFO
48714362|NCT00413374|DRUG|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
48714363|NCT00319657|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
48714364|NCT00319657|RADIATION|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
48714365|NCT04723225|OTHER|Cat-Cow Yoga|Cat-Cow is one of the essential postures in yoga for its beneficial reasons. It is an alternate shift of posture from flexion of the back (rounded) to the extension of the back (arched). During each set of movement, inhalation and exhalation will be guided
48714366|NCT00902148|DEVICE|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
48714367|NCT00266344|DRUG|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
48714368|NCT00266344|DRUG|Placebo / Duration of Treatment 3 Weeks|
48022192|NCT05628740|DRUG|3 mg NOC-100 (via nebulizer)|Participants determined to be eligible for Part 1 of the study will be enrolled and will be assigned to receive a single dose of the reference nebulizer treatment of NOC 100 at 3 mg (Treatment A) in Period 1
48518195|NCT05178498|PROCEDURE|Follow-Up|Undergo follow up
48714369|NCT04503590|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
48714370|NCT00550433|DEVICE|Bazedoxifene/Conjugated Estrogens|
48714371|NCT00690807|DRUG|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
48022193|NCT05628740|DRUG|1 mg NOC-110 (via DPI) [1x 1 mg capsule]|Participants will be randomized to receive single doses of 1 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
48022194|NCT05628740|DRUG|3 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 3 mg NOC-110 (via DPI) in a crossover fashion according to a prespecified randomization schedule
48180005|NCT03293069|DRUG|Placebo Oral Tablet|the placebo twice daily morning and evening.
48180006|NCT00541151|DEVICE|MiniArc|sling system
48518196|NCT05178498|PROCEDURE|Physical Examination|Complete physical measurements
48518197|NCT05178498|OTHER|Questionnaire Administration|Complete questionnaires
48518198|NCT04542057|DRUG|Ensifentrine|"Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks"
48518199|NCT04542057|DRUG|Placebo|"Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks"
48518200|NCT02698111|DRUG|Donafenib|donafenib 200mg，bid
48518201|NCT02934464|DRUG|RAMUCIRUMAB|
48518202|NCT02934464|DRUG|Paclitaxel|Paclitaxel
48518203|NCT02934464|DRUG|FOLFOX 4|
48518204|NCT02934464|DRUG|mFOLFOX 6|
48518205|NCT02934464|DRUG|XELOX|
48180007|NCT06177899|PROCEDURE|Splitting of bone and fixation of bone laminae differ between the 3 groups.|In split-box technique, all osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. In reverse split box technique, differs from the split-box technique as follows: it involves reversing the separated corticocancellous bone block before fixation. In sliding split box technique, differs from the split-box technique as follows: horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone.
48022195|NCT05628740|DRUG|Placebo (via DPI)|Participants will be randomized to receive single doses of placebo via capsule in a crossover fashion according to a prespecified randomization schedule
48022196|NCT05628740|DRUG|6 mg NOC-110 (via DPI)|Participants will be randomized to receive single doses of 6 mg NOC-110 via DPI in a parallel fashion according to a prespecified randomization schedule
48022197|NCT05628740|DRUG|Placebo (via DPI) [2x Placebo capsules]|Participants will be randomized to receive single doses of Placebo (via DPI) \[2x Placebo capsules\] in a parallel fashion according to a prespecified randomization schedule
48022198|NCT02192268|OTHER|PEP|
48022199|NCT02192268|OTHER|HFOO|
48022200|NCT02192268|OTHER|Assisted Coughing|
48022201|NCT06560268|DRUG|Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.|Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
48022202|NCT00022776|PROCEDURE|Surgical decompression|Simple decompression not requiring fusion.
48022203|NCT00022776|PROCEDURE|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
48180008|NCT00930956|DIETARY_SUPPLEMENT|Resistant Starch|30 g of carbohydrate per Arm
48380214|NCT06283056|DEVICE|Device treatment|InMode RF system with Morpheus8 Body (up to 7mm depth) Eligible subjects will undergo two treatments with the Morpheus8 device using the 3, 5 7 mm depths or sequential (Burst) mode, based on the treating physician's discretion..each subject is approximately 9 months (including screening, two treatments (2 months apart) and 3 follow-up visits at 1 month, 3 months, and 6 months post treatment.
48380215|NCT04717934|DEVICE|GAL1906|hyaluronic acid dermal filler gel
48380216|NCT03563729|DRUG|Pembrolizumab Injection [Keytruda]|Alone
48380217|NCT03563729|DRUG|Ipilimumab Injection [Yervoy]|In combination with nivolumab.
48714372|NCT03781791|DRUG|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
48714373|NCT03781791|DRUG|Placebo Treatment|Placebo will be administered in tablet form, once daily.
48714374|NCT04299763|DIETARY_SUPPLEMENT|Oat Beta-glucan as a Supplement in Type 2 Diabetics|44 subjects were randomized into two groups, placebo (PL) and β-glucan (BG). Each person received a package with a supplement sufficient for 12 weeks, adding 5 g of supplement to breakfast, which could contain beta-glucan or not. Blood and stool samples were requested at the beginning and at the end of the intervention.
48714375|NCT04147598|OTHER|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
48022204|NCT00608829|DEVICE|GORE TAG® Thoracic Endoprosthesis|Implant
48022205|NCT00503841|DRUG|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
48022206|NCT00503841|OTHER|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
48022207|NCT00503841|OTHER|laboratory biomarker analysis|Correlative studies
48022208|NCT00503841|PROCEDURE|biopsy|14 days prior to surgery
48022209|NCT00503841|PROCEDURE|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
48022210|NCT00503841|PROCEDURE|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
48022211|NCT05169879|PROCEDURE|coronal flaring|early coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone
48022212|NCT05169879|PROCEDURE|Non coronal flaring|No coronal flaring will be performed
48022213|NCT06574256|OTHER|Chemotherapy symptom Management Online Education|"Randomization was achieved and data collection began. Patients were given the Chemotherapy Symptom Management Education Booklet and were informed that they would be contacted by phone.~In the second and third stages of data collection, they were called by phone on the 7th day after receiving chemotherapy treatment. The symptoms experienced by the patient were evaluated with the N-SDS and the quality of life was evaluated with the EORTC QLQ-C30. Online nursing education videos were sent to the women in the intervention group regarding the symptoms they experienced. The practices they performed from the suggestions in the education videos and education booklets sent were recorded on the nurse follow-up form.~In the fourth stage, the practices specified in the third stage were repeated on the 7th day after the third chemotherapy course, and at this stage, the satisfaction of the women in the intervention group with the online education was evaluated."
48022214|NCT04371276|OTHER|No intervention|Blood samples will be collected from recruited subjects from invited households for testing for hepatitis B (HBsAg, anti-HBs and anti-HBc) and hepatitis A (anti-HAV)
48022215|NCT05083767|OTHER|Experimental|The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.
48022216|NCT05083767|OTHER|Control|The control group was advised to their normal physical activity level, diet, and medication.
48380218|NCT03563729|DRUG|Nivolumab Injection [Opdivo]|In combination with ipilimumab.
48714376|NCT04147598|OTHER|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
48714377|NCT04082910|DRUG|Metoprolol|Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
48714378|NCT04082910|DRUG|metoprolol, infliximab, etanercept, tocilizumab and/or other agents|During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
48714379|NCT00693004|DRUG|PRX-03140|
48714380|NCT00693004|DRUG|Donepezil|
48714381|NCT00693004|DRUG|Placebo|
48714382|NCT00276627|BEHAVIORAL|communication lecture|lecture on communication skills with oncology patients
48022217|NCT05442411|DRUG|Ropivacaine 0.75% Injectable Solution|comparison of scalp block vs conventional post operative parecoxib
48180009|NCT05950100|DEVICE|Virtual reality group|"It is composed of the physiotherapeutic procedures usually used in the hospital applied by the institution's physiotherapist, and the immersive virtual reality therapy that will be conducted by a third researcher (blind to the sampling and evaluations). Physiotherapeutic consultations will have the conventional duration offered by the Institution and therapy with virtual reality will last 10 minutes, using the game Aviãozinho. Both interventions will have a frequency of 2x a day (morning and afternoon shifts), during the period of 4 days."
48380219|NCT03563729|DRUG|Encorafenib|In combination with binimetinib
48380220|NCT03563729|DRUG|Binimetinib|In combination with encorafenib
48380221|NCT03563729|DRUG|Dabrafenib|In combination with dabrafenib
48518206|NCT05848791|OTHER|Exercise exposure|Participants are exposed to three different air quality environments in central London, chosen to maximise differences in nontailpipe air pollution. Participants will cycle at 60% of estimated maximum vo2 on static bikes for six 15 minute bouts with 15 minutes rest between bouts.
48518207|NCT06012851|BEHAVIORAL|Mobile behavioral parent training (mBPT) and prompts|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access. In-the-moment feedback will include parenting feedback and parenting strategies.
48714383|NCT00276627|BEHAVIORAL|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
48714384|NCT01519050|BEHAVIORAL|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
48714385|NCT00539617|DRUG|Erlotinib|Tarceva single agent therapy: 150 mg/day PO
48380222|NCT03563729|DRUG|Trametinib|In combination with trametinib
48380223|NCT06518057|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
48714386|NCT00539617|DRUG|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
48714387|NCT00539617|DRUG|Leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
48380224|NCT06518057|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
48714388|NCT00539617|DRUG|Oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
48380225|NCT06518057|OTHER|Electronic Health Record Review|Ancillary studies
48380226|NCT06518057|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48380227|NCT06518057|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48380228|NCT06518057|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48380229|NCT06518057|RADIATION|Proton Beam Craniospinal Irradiation|Undergo proton CSI
48380230|NCT06518057|OTHER|Survey Administration|Ancillary studies
48380231|NCT06518057|RADIATION|Volume Modulated Arc Therapy|Undergo photon VMAT CSI
48714389|NCT01344044|DEVICE|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
48714390|NCT06351709|OTHER|Stretching|Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
48022218|NCT01351129|DRUG|Formulation 1|150-mg immediate release tablet (single dose)
48180010|NCT02276534|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention.
48180011|NCT02276534|BEHAVIORAL|Delayed Intervention|
48180012|NCT03157908|DEVICE|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
48180013|NCT05550753|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies.4 BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
48180014|NCT05550753|BEHAVIORAL|No intervention - placebo control|No intervention - placebo control
48180015|NCT04584892|DRUG|Turoctocog alfa|Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
48180016|NCT03546816|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
48180017|NCT03546816|DRUG|Placebo Tablets|Placebo Tablets
48180018|NCT02914899|BEHAVIORAL|Surveys|"Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography \[LDCT\] scan), had barriers, felt satisfied, etc."
48180019|NCT02914899|BEHAVIORAL|Navigation|CHWs facilitated SDM and LCS for drivers, providing navigation ( finding a PCP, scheduling appointments, assisting with insurance, etc.), following up on results and next steps.
48180020|NCT02914899|BEHAVIORAL|Focus groups|Gained drivers' perspectives on adapting the community health worker (CHW) model to facilitate lung cancer screening (LCS).
48180021|NCT02914899|BEHAVIORAL|In-depth interviews|"Interviews with Chinese livery bases elicited perspectives on adapting the CWH model for the drivers' occupational environment.~Interviews with PCPs, clinic directors, etc. serving Chinese communities provided insight into adapting the CHW model within the health care context."
48180022|NCT03422445|DRUG|Apatinib|Apatinib：500mg/d，qd，po，d1-28
48180023|NCT03422445|DRUG|Temozolomide|Temozolomide：300mg/d，qd，po，d1-5
48180024|NCT03119883|OTHER|5-Carbon C 13-labeled Glutamine|Given IV
48380232|NCT04833569|BIOLOGICAL|ICG-PDT|An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients
48714391|NCT06351709|OTHER|Hot pack application|Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
48180025|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of blood
48180026|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate samples
48180027|NCT03119883|OTHER|Uniformly-labeled [13C]glucose|Given IV
48380233|NCT04833569|DEVICE|peri-implant mechanical debridement|The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
48380234|NCT02424851|DRUG|Bortezomib|"1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
48380235|NCT02424851|DRUG|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
48380236|NCT02424851|DRUG|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
48380237|NCT02424851|DRUG|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
48022219|NCT01351129|DRUG|Formulation 2|150-mg modified release capsule, short duration (single dose)
48022220|NCT01351129|DRUG|Formulation 3|150-mg modified release capsule, long duration (single dose)
48022221|NCT03957122|DEVICE|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~* 2000 pulses~* intensity of 110% resting motor threshold~* 10 sessions (daily from Monday to Friday)~* positioning of coil according to EEG position CP5/CP6"
48022222|NCT02286882|DRUG|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
48022223|NCT04726865|OTHER|Naser Al-Husban|voluntary completion of an online questionnaire
48714392|NCT06351709|OTHER|Cold pack application|For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
48022224|NCT03791398|DRUG|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
48714393|NCT03993223|BEHAVIORAL|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
48714394|NCT00000357|DRUG|Buprenorphine|
48714395|NCT04382625|DRUG|Hydroxychloroquine|Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
48714396|NCT01891344|DRUG|Oral rucaparib|600 mg BID
48714397|NCT00598078|DRUG|Sodium Oxybate|Dose 1
48022225|NCT03791398|DRUG|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
48714398|NCT00598078|DRUG|Sodium Oxybate|Dose 2
48714399|NCT00598078|OTHER|Placebo|Dose 3
48714400|NCT03097575|DRUG|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
48714401|NCT03097575|DEVICE|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
48022226|NCT03791398|DRUG|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
48022227|NCT01739322|BIOLOGICAL|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
48518208|NCT05714878|BEHAVIORAL|aerobic exercise; resistance exercise; nutritional support; psychological support|Patient with gastric cancer received two weeks of prehabilitation intervention. An individualized exercise program was established according to the FITT (Frequency, Intensity, Time and Type) principle. Aerobic exercise: 3-5 times/week, 30-60 min jogging or brisk walking per time, intensity based on heart rate and modified Borg-scale. Resistance exercise: 2-3 times/week, 10-12 RM per sets, 2-3 sets with 2 min interval rest, seated knee up, knee extension, etc. Nutritional support: 30kcal/kg/d, 1.5mg/kg/d protein, oral nutritional supplement with suggested recipes. Psychological support: provided with guidance on gastric cancer, regular online chat through Wechat, alcohol quitting, smoking cessation and light music.
48380238|NCT05564507|DIAGNOSTIC_TEST|TEE simulation-based training|"All participants of the TEE simulation-based training group received:~1. a traditional didactic training using e-learning with a national free-access online course;~2. two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator."
48380239|NCT02928562|OTHER|exercise|cyclic exercise, aerobic exercise and resistant training exercise
48714402|NCT04139720|BEHAVIORAL|e-book|sexual harassment prevention via education e-book
48022228|NCT05158062|BIOLOGICAL|pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
48022229|NCT05158062|DRUG|olaparib|olaparib 300 mg twice daily (BID) during maintenance period
48380240|NCT05965232|DIAGNOSTIC_TEST|Fibroscan|"Performing FibroScan :~The patient is positioned supine, with the right arm in maximum abduction to clear the intercostal spaces.The measurement itself is performed on the right lobe of the liver via the intercostal (intersection of the mid-axillary line and the xiphoid process) using a dedicated probe (3.5 MHz) after application of a conduction gel to the skin. FibroScan® examinations are carried out by personnel trained in the use of the device.This training is specific and validated by the device's manufacturer manufacturer, EchosensTM (Paris). Ten valid measurements at the same measurement point in the right liver must be be performed, with an interquartile range/median ratio ≤ 30 (required only if the elastometry value is \> 7.1 KPa."
48380241|NCT04859959|DIAGNOSTIC_TEST|Gallium-68 Pentixafor PET/CT|Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
48714403|NCT03221790|OTHER|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
48714404|NCT01107119|OTHER|integrated care pathway|communication and follow-up program for integrated care
48714405|NCT01107119|OTHER|usual care|
48714406|NCT03411109|DRUG|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
48022230|NCT05158062|BIOLOGICAL|bevacizumab|bevacizumab 15 mg/kg Q3W
48022231|NCT05158062|DRUG|carboplatin|carboplatin AUC=5 or 6 Q3W during treatment period
48022232|NCT05158062|DRUG|paclitaxel|paclitaxel 175 mg/m2 Q3W during treatment period
48022233|NCT05158062|DRUG|docetaxel|docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
48022234|NCT06377839|BIOLOGICAL|Advanced platelet-rich fibrin in the ekstraction socket|Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
48022235|NCT02155439|DRUG|5-fluorouracil|antimitotic drug
48022236|NCT02155439|DRUG|Triamcinolone|
48380242|NCT05500729|OTHER|Hamstrings maximal voluntary isometric contraction.|Hamstrings maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
48518209|NCT03242525|DIAGNOSTIC_TEST|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
48518210|NCT04827498|DIAGNOSTIC_TEST|Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment|Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire
48518211|NCT03147430|OTHER|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
48714407|NCT05857904|DEVICE|CT-FFR|CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
48714408|NCT05857904|DEVICE|QFR|Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
48714409|NCT02159118|DEVICE|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
48714410|NCT02159118|DEVICE|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
48714411|NCT04956055|OTHER|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
48714412|NCT00004174|BIOLOGICAL|filgrastim|
48714413|NCT00004174|DRUG|cyclophosphamide|
48380243|NCT05500729|OTHER|Quadriceps maximal voluntary isometric contraction|Quadriceps maximal voluntary isometric contraction (MVIC) will be measured with an isometric dynamometer (3 reps x 5 sec work x 10 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum.
48714414|NCT00004174|DRUG|paclitaxel|
48714415|NCT00004174|DRUG|thiotepa|
48714416|NCT00004174|PROCEDURE|peripheral blood stem cell transplantation|
48714417|NCT00004174|RADIATION|radiation therapy|
48714418|NCT01342549|DRUG|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
48714419|NCT01342549|DRUG|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
48714420|NCT03730012|DRUG|gilteritinib|Oral tablet
48380244|NCT06653231|DRUG|local delivery of Curcumin gel|The test site will be completely undiluted curcumin gel through a 2 mL disposable syringe was placed in the test site and isolated with cotton rolls (not to contaminate the medication with saliva) Patients were recalled after a week for refrained from using any other oral hygiene measures in the observation period, recalled after a month for follow-up.
48380245|NCT00278473|BEHAVIORAL|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
48518212|NCT01096797|DRUG|Sevoflurane|"* Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~* Anaesthesia maintenance: sevoflurane 2-3 %~* Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~* Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
48714421|NCT03730012|DRUG|atezolizumab|Intravenous infusion
48714422|NCT04376957|BEHAVIORAL|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
48714423|NCT04376957|BEHAVIORAL|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
48714424|NCT05597644|PROCEDURE|Trans-arterial uterine artery embolization|transarterial angioembolization of uterine artery
48714425|NCT00047333|DRUG|erlotinib hydrochloride|Given PO
48714426|NCT00047333|OTHER|laboratory biomarker analysis|Correlative studies
48714427|NCT00047333|OTHER|pharmacological study|Correlative studies
48714428|NCT01742572|BEHAVIORAL|Diet|Change in dietary intake
48714429|NCT02791412|PROCEDURE|percutaneous coronary intervention or coronary-artery bypass graft|
48714430|NCT04000334|OTHER|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
48714431|NCT04000334|OTHER|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
48714432|NCT05840692|DRUG|Escitalopram 20 mg|Antidepressant
48714433|NCT05840692|DRUG|Placebo|
48714434|NCT04868487|OTHER|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
48714435|NCT02386215|BEHAVIORAL|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
48714436|NCT03816839|DRUG|Amcenestrant (SAR439859)|"Pharmaceutical form: Capsules~Route of administration: Oral"
48714437|NCT02267954|OTHER|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
48714438|NCT03084042|DEVICE|fMRI|
48714439|NCT06157320|DRUG|Shen-Fu|Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
48380246|NCT00278473|BEHAVIORAL|Supportive Therapy|Social Support Problem-Solving Group Treatment
48380247|NCT05081115|DIAGNOSTIC_TEST|ABCDE-Stress Echo|Each laboratory will adopt the preferred Echo stress among physical pharmacologic or pacing stress according to guidelines recommendations. Pharmacologic testing will be with dobutamine or vasodilators (dipyridamole, adenosine or regadenoson) according to physician preferences, patients' contraindications, local availability and cost. Pacing stress can be performed with transesophageal or with external permanent pacemaker. A standardized format with the ABCDE protocol will be followedl. Step D is easy with vasodilator, less easy with dobutamine, not easy and less feasible - impossible with (peak or post) treadmill exercise. Our recommendation is to use semi-supine exercise, capturing coronary flow signal in early or intermediate stages when most flow increases and feasibility is still high. When treadmill is used, step D is skipped; if information is deemed important, a vasodilator test can be performed at 30' after the end of exercise focused on CFVR and heart rate response.
48380248|NCT05081115|DIAGNOSTIC_TEST|SE diastolic assessment|The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation, at intermediate load of exercise and/or 1- 2 min after the end of the exercise. We will also assess, at baseline, intermediate load (50 watts) and peak-post stress: end-diastolic left ventricular volume index; end-systolic left ventricular volume index; ejection fraction and both stroke volume and cardiac output (to assess conventional contractile reserve); mitral regurgitation and left ventricular outflow tract obstruction; pulmonary artery systolic pressure; B-lines; right ventricular free wall strain to assess the presence of right ventricular dysfunction; left atrial volume index; peak atrial longitudinal strain; and mitral inflow E velocity and mitral annulus e' tissue Doppler velocity; global longitudinal strain (GLS).
48714440|NCT06157320|DRUG|Norepinephrine (NE)，antibiotics，fluid resuscitation|empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
48714441|NCT00331227|DRUG|Isotonix OPC-3 (flavonoid supplement)|
48714442|NCT00689000|DRUG|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
48714443|NCT04575818|DRUG|GLPG4059 oral suspension|GLPG4059 for oral administration
48714444|NCT04575818|DRUG|Placebo|Placebo oral suspension
48714445|NCT04575818|DRUG|GLPG4059 tablet|GLPG4059 for oral administration
48714446|NCT06414421|OTHER|Transcuten Electriacal Nerve Stimulation|In TENS group patients, 4 electrodes of the TENS device were placed 3-5 minutes before the biopsy procedure, and the application was started and TENS was applied throughout the procedure. continued. TENS was applied again for 30 minutes 2 hours after the procedure.
48714447|NCT03688698|RADIATION|PET/MRI|PET/MRI scans
48714448|NCT05958823|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block
48714449|NCT05958823|PROCEDURE|PECS I-II|PECS I-II
48714450|NCT00003772|PROCEDURE|quality-of-life assessment|
48714451|NCT01460407|DRUG|LY2216684|Administered orally
48714452|NCT01460407|DRUG|Clarithromycin|Administered orally
48714453|NCT04483115|DRUG|TPN171H|Tablets; Oral; Single dose
48380249|NCT05081115|DIAGNOSTIC_TEST|SE Right ventricular function assessment|Right ventricular function will be assessed at baseline and peak stress with variations of tricuspid annular plane systolic excursion, an index of right ventricular longitudinal function, and right ventricular fractional area change (a load-dependent index of right ventricular inlet function). To distinguish between genuine right ventricular dysfunction and/or pathological increases in pulmonary vascular load, we will combine systolic pulmonary artery pressure and right ventricular end-systolic area to calculate right ventricular end-systolic pressure-area relation. Peak systolic tricuspid annulus velocity and conventional indices of left ventricular systolic and diastolic function will also be measured at baseline and peak stress according to the standard ABCDE-FGLPR protocol. Right ventricular free wall strain combined with interventricular septum strain will be assessed. Left ventricular function, wall motion score index and E/e' at baseline and peak stress.
48518213|NCT04327323|DEVICE|CCM device implantation|CCM implantation involves the introduction of two active fixation stimulation leads, fixed on the interventricular septum, and connected to the CCM generator (Optimizer Smart IV, Impulse Dynamic, and any subsequent versions of the same device) inserted in the subcutaneous or submuscular pocket. The implantation is ususally performed using vascular access via right or left cephalic or subclavian vein. The CCM signal consists of 2-3 biphasic pulses lasting 10 msec (total duration of about 20 ms) with an amplitude between 4.0 and 7.5 V, delivered during the absolute refractory period of the ventricle, at a distance of 40 msec from ventricular sensing. The CCM device is compatible with other pacing and defibrillation devices already implanted in the patient; at the time of the implantation, the devices are checked in order to confirm the absence of interference between the devices. The patient is instructed to charge the device battery weekly.
48518214|NCT03146104|DRUG|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
48518215|NCT03146104|DRUG|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
48518216|NCT03631316|DRUG|Generic Valganciclovir|900 mg daily during 4 days
48518217|NCT03631316|DRUG|Innovative Valganciclovir|900 mg daily during 4 days
48714454|NCT04483115|DRUG|Placebo|Tablets; Oral; Single dose
48714455|NCT04483115|DRUG|Tadalafil|Tablets; Oral; Single dose
48714456|NCT04598126|OTHER|Traditional physical therapy|Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
48714457|NCT04598126|OTHER|patient education manual +traditional physical therapy|"Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/"
48714458|NCT03854890|DRUG|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
48022237|NCT00591812|DEVICE|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
48714459|NCT00407004|DEVICE|MARS (Molecular Adsorbents Recirculating System)|
48714460|NCT00407004|DEVICE|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
48714461|NCT06229665|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
48714462|NCT04793997|BIOLOGICAL|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
48714463|NCT04793997|BIOLOGICAL|Placebo spray|Throat spray
48714464|NCT03084354|OTHER|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
48714465|NCT01482897|DRUG|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
48714466|NCT01482897|DRUG|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
48714467|NCT01482897|DRUG|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
48714468|NCT06323798|DIAGNOSTIC_TEST|MRI|Standard paranasal sinus MRI
48714469|NCT00385723|DIETARY_SUPPLEMENT|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
48022238|NCT02250885|DRUG|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
48022239|NCT06572709|DIAGNOSTIC_TEST|Parasternal intercostal muscle thickness with ultrasonography|Ultrasonographic measurements were performed of the bilateral parasternal intercostal muscle thickness in the supine position in the stroke patient group. Ultrasonographic measurements were performed of dominant side parasternal intercostal muscle thickness in the supine position in healthy individuals group. Spirometry evaluation was performed in both groups.
48022240|NCT03542227|OTHER|First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
48714470|NCT00385723|DIETARY_SUPPLEMENT|Placebo|matching placebo capsule daily for 4 months
48714471|NCT01341301|RADIATION|Total Body Irradiation|Undergo TBI
48714472|NCT01341301|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
48714473|NCT01341301|DRUG|Cyclophosphamide|Given IV
48714474|NCT01341301|DRUG|Tacrolimus|Given IV or PO
48714475|NCT01341301|DRUG|Mycophenolate mofetil|Given IV or PO
48714476|NCT01341301|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
48022241|NCT03542227|OTHER|Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
48022242|NCT02815111|DRUG|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
48022243|NCT02815111|DRUG|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
48022244|NCT02815111|DRUG|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
48022245|NCT02815111|DRUG|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
48022246|NCT06460194|DRUG|Botuinum toxin|Injection of botulinum toxin in the palm of the hand
48022247|NCT00501449|BEHAVIORAL|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
48714477|NCT01341301|OTHER|Laboratory biomarker analysis|Correlative studies
48714478|NCT01869413|DRUG|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
48714479|NCT01869413|DRUG|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
48714480|NCT01863134|DRUG|Eptifibatide|
48714481|NCT01863134|DRUG|Placebo|
48714482|NCT04999865|OTHER|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
48180028|NCT01642953|DIETARY_SUPPLEMENT|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
48714483|NCT06289088|OTHER|First Intervention|Firstly, For individuals with low back pain, all measurements will be evaluated without wearing any orthosis. The waist circumference of individuals with low back pain will be measured and the orthosis was adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the measurements will be repeated. Then, the person will be asked to wear the orthosis without any intervention.
48714484|NCT06289088|OTHER|Second Intervention|Firstly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be repeated. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis.
48022248|NCT00426478|DRUG|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
48022249|NCT00426478|DRUG|Amlodipine (5mg)|
48180029|NCT05317507|DRUG|CBD oil|50 mg
48180030|NCT05317507|DRUG|CBD oil|100 mg CBD
48380250|NCT05081115|DIAGNOSTIC_TEST|SE in heart donors|The examination of the heart starts with a resting transthoracic echocardiography. Exclusion criteria are: resting wall motion score index\>1.0; ejection fraction \<45%; diastolic dysfunction of grade 2 or more; hemodynamically significant (moderate or higher) valve regurgitation or stenosis; severe left ventricular hypertrophy (left ventricular mass index \>175 g/m2). A pharmacological SE with dipyridamole (0.84 mg/kg over 6 minutes) is recommended. The diagnostic end-points are stress-induced RWMA and abnormalities in global LVCR. All images will be analyzed as per guidelines similarly to the other projects, with emphasis on wall motion score index and LVCR based on ejection fraction and force. The hearts excluded from donation for RWMA or abnormal LVCR could however be collected for heart valve preparation and evaluated by coronary angiography and by pathological examination according to local facilities.
48380251|NCT04189666|DRUG|Rivastigmine Transdermal System [Exelon]|compare the ability of the drug in preventing postoperative delirium
48380252|NCT04189666|DRUG|Melatonin|compare the ability of the drug in preventing postoperative delirium
48380253|NCT02206984|DRUG|Tamoxifen|
48380254|NCT02206984|DRUG|Anastrozole|
48380255|NCT02206984|DRUG|Fulvestrant|
48380256|NCT00958659|OTHER|laboratory biomarker analysis|Correlative studies
48022250|NCT05989399|DIAGNOSTIC_TEST|circulating neutrophils|evaluation of circulating neutrophils level
48022251|NCT04819360|DRUG|VESIcare 10Mg Tablet|"Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks"
48022252|NCT04819360|DRUG|Botox 100 UNT Injection|1 injection of Botox® 100 UNT
48022253|NCT02885233|BEHAVIORAL|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
48380257|NCT03857308|BEHAVIORAL|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
48380258|NCT03857308|BEHAVIORAL|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
48022254|NCT02885233|BEHAVIORAL|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
48022255|NCT03732248|DRUG|Rapamycin|Immunosuppressive drug
48022256|NCT03732248|DRUG|Placebo|Inert drug
48022257|NCT03938701|DRUG|Adalimumab-800CW|Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
48180031|NCT05317507|DRUG|Placebo|Placebo
48180032|NCT02953509|DRUG|Magrolimab|Administered intravenously
48180033|NCT02953509|DRUG|Rituximab|Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13
48180034|NCT02953509|DRUG|Gemcitabine|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
48714485|NCT06289088|OTHER|Third Intervention|Firstly, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be done. The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis. Lastly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotis. After waiting with the orthosis for half an hour, all measurements will be evaluated.
48714486|NCT00682136|PROCEDURE|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
48180035|NCT02953509|DRUG|Oxaliplatin|Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4
48714487|NCT05013268|DRUG|Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin|"* Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none"
48380259|NCT04639570|OTHER|KneuroKnits|The KneuroKnits program will be based upon current knitting education practices and leading practices in facilitation of social participation for individuals with neurodevelopmental disorders, physical disabilities, and acquired brain injuries. The program will consist of 4 weekly sessions in which participants will learn knitting fundamentals and have opportunities to socialize over a shared occupation. The 4 weekly sessions of the KneuroKnits curriculum will include related knitting and social skills themes of the week. Each session will begin with a structured lesson on the knitting topic of the day, and will then continue into knitting practice and social interaction. Participants will be encouraged to practice their new skills (knitting and social) between sessions, and will be allowed to keep all materials that they use or create.
48714488|NCT00993109|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
48714489|NCT00993109|DRUG|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
48714490|NCT05309213|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level:5 x 10\^4 CAR+ T cells/kg,1x 10\^5 CAR+ T cells/kg,3 x 10\^5 CAR+ T cells/kg,1 x 10\^6 CAR+ T cells/kg
48714491|NCT03783104|DIETARY_SUPPLEMENT|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
48714492|NCT01794741|DRUG|Dymista Nasal Spray|
48380260|NCT00406497|DRUG|Difluprednate Ophthalmic Emulsion|
48180036|NCT01782768|DEVICE|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
48714493|NCT01794741|DRUG|Fluticasone propionate nasal spray|
48180037|NCT02087215|DRUG|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
48180038|NCT02087215|DRUG|Placebo|
48180039|NCT00302159|PROCEDURE|adjuvant therapy|
48714494|NCT02495064|DRUG|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
48714495|NCT00219037|DRUG|aliskiren|
48180040|NCT00302159|DRUG|Temozolomide|Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.
48714496|NCT03345524|OTHER|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
48714497|NCT03345524|OTHER|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
48380261|NCT01988194|PROCEDURE|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
48380262|NCT00738140|BEHAVIORAL|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
48380263|NCT02840019|DEVICE|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
48380264|NCT02840019|PROCEDURE|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
48380265|NCT02008487|OTHER|Wound powder application|Powder application to wound per protocol.
48714498|NCT03000491|OTHER|No intervention|Variations in clinical practice as assessed by data relating to asthma extracted from patient electronic health records.
48022258|NCT03938701|DEVICE|Fluorescence Imaging|"Fluorescence Imaging Rheumatoid Arthritis (RA):~Open-air camera - a camera that enables detection of fluorescent signals.~Fluorescence Imaging inflammatory bowel disease (IBD):~Molecular Fluorescence Endoscopy - a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
48022259|NCT04922593|DRUG|LY03010; paliperidone palmitate|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
48022260|NCT04922593|DRUG|INVEGA SUSTENNA|INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.
48022261|NCT05067075|DEVICE|Blinded CGM|CGM that records blood glucose but is not visible to patient or provider in real-time
48022262|NCT00580905|DRUG|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
48022263|NCT00580905|DRUG|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
48180041|NCT00302159|DRUG|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
48714499|NCT03968159|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
48714500|NCT03968159|DRUG|Placebo|Placebo (2×placebo tablets \[size- and color-matched to pimavanserin\]) administered orally as a single dose once daily
48714501|NCT00740714|DRUG|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
48180042|NCT00302159|RADIATION|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
48714502|NCT00740714|DRUG|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
48714503|NCT03024645|BEHAVIORAL|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
48714504|NCT03024645|OTHER|Treatment as usually (TAU)|performed in primary care settings
48714505|NCT04673916|DRUG|Healing evaluation|Treatments were topically applied for 5 days
48714506|NCT02741570|BIOLOGICAL|Nivolumab|
48714507|NCT02741570|BIOLOGICAL|Ipilimumab|
48380266|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
48380267|NCT00633217|DRUG|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
48380268|NCT03680209|OTHER|Simulation|pre-training observation training post training observation
48714508|NCT02741570|DRUG|Cetuximab/Erbitux|
48714509|NCT02741570|DRUG|Cisplatin/Platinol|
48714510|NCT02741570|DRUG|Carboplatin/Paraplatin|
48714511|NCT02741570|DRUG|Fluorouracil/Adrucil|
48714512|NCT01741532|DRUG|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
48714513|NCT01741532|DRUG|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
48714514|NCT04370990|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
48714515|NCT05053841|DRUG|Metformin|
48714516|NCT03952117|DEVICE|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
48714517|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
48714518|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
48714519|NCT01095653|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
48714520|NCT01095653|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
48518218|NCT01964079|DRUG|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
48714521|NCT03302455|BEHAVIORAL|eCBTI|The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
48714522|NCT00894478|PROCEDURE|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
48714523|NCT00894478|PROCEDURE|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
48714524|NCT01811576|DRUG|TV-1106|
48714525|NCT01811576|DRUG|Recombinant human growth hormone|Subcutaneous once daily
48180043|NCT04087564|OTHER|music intervention|"The music intervention (Unwind), developed by the investigators collaborators at the Sync Project, is a machine learning protocol that generates specific sounds and phrases of music that are stitched into a music track in response to user-reported pain, anxiety and catastrophizing scales. Unwind is delivered via a web application on a smart phone.~Participants will also listen to white noise and their favorite music throughout the study session"
48180044|NCT00298688|DRUG|Gefitinib|
48180045|NCT02306590|DIETARY_SUPPLEMENT|Calogen|
48180046|NCT02306590|DIETARY_SUPPLEMENT|Placebo|
48180047|NCT00280865|DRUG|Tesaglitazar|
48180048|NCT00280865|DRUG|Pioglitazone|
48180049|NCT00280865|BEHAVIORAL|Dietary and Lifestyle Modification Counseling|
48180050|NCT06319157|DEVICE|minimal access breast reconstruction with a latissimus dorsi muscle flap|minimal access breast reconstruction with a latissimus dorsi muscle flap
48180051|NCT06319157|DEVICE|conventional breast reconstruction with a latissimus dorsi muscle flap|conventional breast reconstruction with a latissimus dorsi muscle flap
48180052|NCT00607464|DEVICE|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
48180053|NCT01606319|DRUG|Acetaminophen|15 mg/kg every 6 hours as needed
48380269|NCT04507282|DRUG|LMWH|COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
48380270|NCT06449352|DRUG|Netarsudil|netarsudil 0.02%
48180054|NCT01606319|DRUG|Ibuprofen|9.4 mg/kg every 6 hours as needed
48180055|NCT01339299|DRUG|recombinant luteinizing hormone (r-LH)|administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
48380271|NCT06449352|DRUG|Brimonidine|brimonidine 0.1%
48380272|NCT06329375|OTHER|Nutrition program|Nutrition program with twice daily meal delivery up to 90 days post-discharge and food and diet education at discharge.
48180056|NCT01339299|DRUG|recombinant human chorionic gonadotropin (r-hCG)|administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
48180057|NCT06079268|OTHER|the initial gastric ultrasound|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
48180058|NCT06079268|OTHER|the gastric ultrasound last 3 minutes|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
48180059|NCT02671110|BEHAVIORAL|Transforming Your Life|See Transforming Your Life Arm
48180060|NCT02671110|BEHAVIORAL|Diabetes Prevention Program|See Diabetes Prevention Program Arm
48380273|NCT02400697|OTHER|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
48380274|NCT03441620|DIETARY_SUPPLEMENT|strawberries|Freeze-dried strawberry powder
48380275|NCT03441620|OTHER|Control powder|Control powder matched for fiber and strawberries
48380276|NCT06578078|DRUG|Sodium Zirconium Cyclosilicate|Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
48714526|NCT06375642|DRUG|Adebrelimab|Adebrelimab, Surufatinib and HAIC
48714527|NCT03417596|OTHER|Control|Routine treatment
48022264|NCT00580905|DRUG|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
48022265|NCT02211989|DRUG|BI 14332 CL|
48022266|NCT02211989|DRUG|Placebo|
48022267|NCT03598998|BIOLOGICAL|Pembrolizumab|Given IV
48380277|NCT06578078|DRUG|Standard of care treatment (RAASi therapy)|Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
48380278|NCT03217474|PROCEDURE|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
48380279|NCT03217474|DRUG|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
48380280|NCT03217474|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
48380281|NCT06538493|BEHAVIORAL|JUMPSTART-ANAI|"Patient questionnaire about experiences, preferences, and concerns regarding ACP followed by feedback form with tips for initiating ACP conversation with provider at next clinical visit."
48380282|NCT06001736|PROCEDURE|Contralateral C7 root transfer for the treatment of spastic hemiparesis.|Performing surgery to transfer the C7 nerve to treat stroke patients experiencing spastic hemiparesis.
48380283|NCT00578448|DRUG|Belatacept|IV infusion
48380284|NCT06342661|DIAGNOSTIC_TEST|Neuropsychological testing|The primary outcomes were Mini-Mental State Examination and Montreal Cognitive Assessment scores for screening of cognitive decline, which are recommended by NINDS-AIREN. The secondary outcomes included the performance in five cognition domains: (1) verbal memory, Hopkins Verbal Learning Test ; (2) visual-spatial ability, Clock Drawing test; (3) executive function, Trail Making test (TMT) (B time); (4) attention, TMT (A time); and (5) language tests, Boston Naming test2 (BNT-2)
48714528|NCT03417596|BEHAVIORAL|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
48022268|NCT03598998|DRUG|Pralatrexate|Given IV
48714529|NCT01034618|DIETARY_SUPPLEMENT|Protein hydrolyzation|
48714530|NCT02818439|OTHER|evaluation of frailty|
48028859|NCT04197947|DEVICE|Neuro Omega|"A neurophysiological navigation system NeuroOmegaTM (Alpha Omega. Israel) was implemented in our group and the operation of this system for aDBS experiment is proved to be successful (Fig 9, 10). This system was proved by both FDA and tFDA. The aDBS stimulation algorithm will be integrated with NeuroOmegaTM. The aDBS stimulation control will achieve through self-developed algorithms or built-in scripting of the system. We introduce NeuroOmega system to conduct the designed aDBS experiment for its multifunction and safety. Our group has established collaboration with Department of Eelectronic Engineering in Chang Gung University (Co-PI HL Chan) and BERTEC in National Ciao Tung University (Co-PI MD Ker). Three postdoctor fellows and one senior engineer have been working on the operation of this aDBS system.~All hardware and software problems could be sorted out in time."
48028860|NCT00758953|DRUG|Danazol Once Weekly|semi-solid
48028861|NCT00758953|DRUG|Danazol Twice Weekly|semi-solid
48380285|NCT06561620|DRUG|Befotertinib|Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
48380286|NCT00014300|DRUG|glufosfamide|
48518219|NCT01964079|DRUG|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (\>140 mmHg) or diastolic (\>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
48714531|NCT05655143|BEHAVIORAL|Balance training|"Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task."
48714532|NCT05214989|BEHAVIORAL|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
48714533|NCT02726191|BEHAVIORAL|Spatial Match Exercise|
48028862|NCT00758953|DRUG|Placebo Once Weekly|semi-solid
48028863|NCT00758953|DRUG|Placebo Twice Weekly|semi-solid
48028864|NCT06410066|OTHER|no intervention|
48518220|NCT01696760|DRUG|acetylsalicylic acid|325 mg twice a day
48518221|NCT01696760|DRUG|enoxaparin|40 mg once daily
48022269|NCT03524391|BEHAVIORAL|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
48022270|NCT03524391|DRUG|Chemotherapy|Usual Care group had standard chemotherapy regimens
48022271|NCT04245735|DIAGNOSTIC_TEST|perfusion index|To test the objective role of perfusion index in assessing the success of the peripheral nerve block in children under sedation.
48022272|NCT01361087|OTHER|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
48022273|NCT03128749|BEHAVIORAL|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
48022274|NCT03128749|DRUG|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
48022275|NCT05825287|OTHER|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
48022276|NCT05825287|OTHER|Management training|Management training
48022277|NCT02279303|BEHAVIORAL|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
48022278|NCT02279303|BEHAVIORAL|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
48022279|NCT04779957|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
48022280|NCT06312098|OTHER|remote ischemic preconditioning (RIPC)|After induction of anesthesia, the paired RIPC group took the RIPC intervention on the upper arm in the lateral position. The RIPC intervention was applied using a manual cuff inflator, which consisted of three cycles of 5-min inflation of the blood pressure cuff (to 250 mmHg, or to 50 mmHg higher than the preoperative SBP), followed by 5-min deflation of the cuff. In the no-RIPC group, a blood pressure cuff was also applied on the upper arm but was not inflated.
48022281|NCT04696159|PROCEDURE|Pyloromyotomy|Endoscopic Per-Oral Pyloromyotomy (POP)
48022282|NCT02769143|OTHER|Whole-Body Vibration|Will be performed six months of WBV exercises
48022283|NCT02769143|OTHER|Pilates|Will be performed six months of Pilates exercises
48022284|NCT04523129|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
48022285|NCT04523129|DRUG|Vehicle topical ocular, eye drops|Vehicle
48022286|NCT02160873|OTHER|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
48022287|NCT02160873|OTHER|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
48022288|NCT00206674|DRUG|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
48022289|NCT00206674|DRUG|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
48022290|NCT03283670|DRUG|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
48022291|NCT03283670|DRUG|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
48518222|NCT01696760|DEVICE|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
48518223|NCT06248125|BEHAVIORAL|Singing intervention|The goal of this intervention is to improve the frequency and quality of active parent-infant interaction via infant-directed singing.
48022292|NCT03283670|DRUG|Placebo Gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
48022293|NCT03319927|BEHAVIORAL|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
48022294|NCT01390246|DRUG|Bupropion SR|Bupropion SR 150 mg tablet
48022295|NCT01390246|BEHAVIORAL|Smoking Cessation Counseling|35-min counseling by trained research nurse
48022296|NCT01390246|DRUG|Placebo|Matching Bupropion SR placebo tablet
48022297|NCT06572527|BEHAVIORAL|Physical Activity Program|"Nurse-Led Coordinated Physical Activity Program for Child Health, developed as part of the Coordinated Approach to Child Health program for preschool children."
48022298|NCT04636892|OTHER|MindMics earbud|Novel noninvasive wearable infrasound sensor
48028865|NCT02287103|OTHER|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
48180061|NCT00003477|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
48180062|NCT06495593|DRUG|Ocrelizumab|Standard ocrelizumab dosing
48180063|NCT02881047|DEVICE|CO2 Laser|Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
48518224|NCT06248125|BEHAVIORAL|Music listening intervention|This intervention follows the same structure as the singing intervention but focuses on the use of passive music listening rather than live singing.
48714534|NCT02726191|BEHAVIORAL|Temporal Sequence Reconstruction Exercise|
48714535|NCT02726191|BEHAVIORAL|Token Task Exercise|
48180064|NCT02881047|RADIATION|Ultrasound|Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
48380287|NCT05129527|DEVICE|InspirerMundi app|"Patients in the experimental group, in addition to usual care, will be invited to use the InspirerMundi app for 4 months to support adherence to preventive inhaled medication and their asthma self-management. The purpose of the InspirerMundi app is to transform the adherence process into a positive experience through immediate and pleasant rewards. The InspirerMundi app integrates 3 main components: monitoring (symptoms, control, adherence), gaming and social/peer support.~Participants will be able to include their action plan in the app. Within the action plan, the application can lead to changes in the medication effectively taken, which means that the therapeutic level can be adjusted according to the action plan.~Participants in the experimental arm will be able to share with their physician, through the app, their medication adherence and asthma control data in the 3 months visit, and whenever patients wish during the study period."
48380288|NCT05129527|OTHER|Usual care|Usual care will consist of pharmacological treatment and medical monitoring through routine medical visits.
48518225|NCT06248125|BEHAVIORAL|Book reading intervention|This intervention follows the same structure as the singing intervention, but without the musical elements, while emphasizing enriched parent- infant interaction in non-musical (or less-musical) contexts.
48714536|NCT02726191|BEHAVIORAL|Story Recall Exercise|
48380289|NCT00609115|DEVICE|AMES device (test)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
48380290|NCT00609115|DEVICE|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
48380291|NCT00609115|DEVICE|AMES device (crossover)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
48380292|NCT06096246|PROCEDURE|Pulmonary vein isolation|The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
48380293|NCT06096246|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
48518226|NCT00919295|DRUG|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
48518227|NCT00919295|DRUG|placebo|placebo
48518228|NCT01042769|DRUG|Aleglitazar|aleglitazar 150 micrograms po daily
48518229|NCT01042769|DRUG|Placebo|placebo control po daily
48518230|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk|Patients in Arm 1, after the surgical procedure, will receive radiotherapy to the at-risk mucosa.
48518231|NCT06578871|PROCEDURE|Surgical Intervention|These patients will undergo Neck dissection, TORS tonsillectomy (unilateral vs bilateral tonsillectomy at the discretion of the treating physician) + ipsilateral tongue base mucosectomy.
48714537|NCT02726191|BEHAVIORAL|Sample-Match (Within Modality) Exercise|
48714538|NCT02726191|BEHAVIORAL|Pair-Match (Across-Modality) Exercise|
48714539|NCT02726191|BEHAVIORAL|Triad-FiguresExercise|
48714540|NCT02726191|BEHAVIORAL|Monster Garden Exercise|
48714541|NCT02726191|BEHAVIORAL|Memory Match Exercise|
48714542|NCT02726191|BEHAVIORAL|Memory Matrix Exercise|
48714543|NCT02726191|BEHAVIORAL|Familiar Faces Exercises|
48714544|NCT02726191|BEHAVIORAL|Lost in Migration Exercise|
48714545|NCT02726191|BEHAVIORAL|Playing Koi Exercise|
48028866|NCT02287103|OTHER|Eating Breakfast|YesB: will eat all three meals
48028867|NCT05260710|BEHAVIORAL|Telemedicine Intervention|"Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases."
48028868|NCT01903655|OTHER|telomere length|
48028869|NCT06531954|DEVICE|Vagus nerve stimulation|Vagus nerve stimulation group: Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain.
48518232|NCT06578871|RADIATION|Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck|For Arm1, after the surgical procedure, the patients will receive radiotherapy to the ipsilateral neck. For Arm2, the patients will only receive IMRT to neck, if multiple ipsilateral nodes or single ipsilateral node \>3 cm is observed
48180065|NCT02881047|DIAGNOSTIC_TEST|Skin Biopsy|standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
48180066|NCT06523543|PROCEDURE|Inclusion (Visit 1 - Week 7-16)|Extraction of cervico-vaginal sampling
48380294|NCT06096246|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
48380295|NCT06096246|PROCEDURE|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
48380296|NCT02127021|DRUG|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
48380297|NCT02127021|DRUG|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
48380298|NCT03826446|PROCEDURE|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
48518233|NCT02268877|OTHER|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
48518234|NCT02268877|DEVICE|Ultrasound|An ultrasound will be performed by a radiology department technician
48518235|NCT03337399|OTHER|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
48180067|NCT06523543|DIAGNOSTIC_TEST|Second semester of pregnancy (Visit 2 - Week 20-24)|Ultrasound examination (determination of chromosomal sex)
48180068|NCT06523543|DIAGNOSTIC_TEST|Third semester of pregnancy (Visit 3- Week 34)|Ultrasound examination (determination of chromosomal sex) if this has not be done during the Visit 2 or if a new determination correcting the previous one is provided.
48180069|NCT06263439|DIAGNOSTIC_TEST|Throat/buccal swab sample|The study involves the genome detection of enteroviruses in throat or mouth swabs taken from children with a diagnosis of HFMD or herpangina. If positive, the precise type of enterovirus responsible will be identified by sequencing a viral genomic region.
48180070|NCT03513744|DIETARY_SUPPLEMENT|human milk oligosaccharides|mixture of five different human milk oligosaccharides
48180071|NCT03509246|DRUG|Pegylated liposomal doxorubicin plus Bortezomib|Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
48180072|NCT01755546|DRUG|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
48180073|NCT02719314|DRUG|Glucocorticoid treatment|Glucocorticoid treatment
48380299|NCT01353586|DEVICE|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
48380300|NCT03229902|BEHAVIORAL|mantra meditation|see study description
48380301|NCT05049902|DRUG|Amoxicillin|Use according to the drug combination options selected by each center.
48380302|NCT05049902|DRUG|Clarithromycin|Use according to the drug combination options selected by each center.
48380303|NCT05049902|DRUG|Tetracycline|Use according to the drug combination options selected by each center.
48380304|NCT05049902|DRUG|Metronidazole|Use according to the drug combination options selected by each center.
48380305|NCT05049902|DRUG|Bismuth Potassium Citrate|Use according to the drug combination options selected by each center.
48380306|NCT05049902|DRUG|Colloidal Bismuth Pectin|Use according to the drug combination options selected by each center.
48380307|NCT05049902|DRUG|Vonoprazan fumarate|Use according to the drug combination options selected by each center.
48380308|NCT02900157|BIOLOGICAL|MEDI9090|MEDI9090 will be administered by IV infusion
48380309|NCT02900157|BIOLOGICAL|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
48380310|NCT03562923|DRUG|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
48380311|NCT03562923|DRUG|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
48380312|NCT03562923|DRUG|Placebo|Placebo Product
48380313|NCT00584831|DEVICE|senofilcon A|toric contact lens
48380314|NCT00584831|DEVICE|balafilcon A|toric contact lens
48380315|NCT00584831|DEVICE|omafilcon A|toric contact lens
48518236|NCT03337399|OTHER|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
48714546|NCT03994016|BEHAVIORAL|WiseGuyz|"The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement."
48714547|NCT03423290|DEVICE|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
48714548|NCT02571660|DRUG|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
48380316|NCT00584831|DEVICE|lotrafilcon B|toric contact lens
48380317|NCT03163823|OTHER|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
48380318|NCT03163823|OTHER|Standard of Care|Standard of Care communication methods
48380319|NCT06381115|BEHAVIORAL|SleepWell24 Application|The SleepWell24 application will use connections with a Shelly smart plug and a Fitbit Charge 4 along with weekly questionnaires to monitor CPAP usage.
48380320|NCT00605969|PROCEDURE|Motion analysis|Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
48380321|NCT00605969|DIAGNOSTIC_TEST|Computed Tomography|Participants will undergo computed tomography (CT) scan of their hip.
48380322|NCT05285553|DEVICE|MiSight 1 Day|Part 1 of the study - subjects will be randomized to wear MiSight 1 Day for three years.
48380323|NCT05285553|DEVICE|Proclear 1 day|"Part 1 of the study - subjects will be randomized to wear Proclear 1 day for three years.~Part 2 of the study - All the subjects will wear Proclear 1 day lenses for one year."
48380324|NCT02012751|DEVICE|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
48380325|NCT05409300|BIOLOGICAL|BBIBP-CorV|Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide
48380326|NCT02530086|PROCEDURE|Nasogastric tube placement|Placement of a Nasogastric tube
48380327|NCT02530086|PROCEDURE|No Nasogastric tube use|No placement of a Nasogastric tube
48380328|NCT06515847|OTHER|End of Life Nursing Care Plan|the patients of experimental group were cared according to the nursing care plan based on Kolcaba's comfort theory,
48380329|NCT01284413|DRUG|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
48518237|NCT02742883|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
48518238|NCT06416514|OTHER|Personalized intervention|Personalized intervention means implementing multi-component non-pharmacological interventions based on different health profiles，such as art therapy, exercise therapy, cognitive therapy and other monotherapies. Usual care means care as routine.
48518239|NCT02649569|DEVICE|Monitoring Device|Wear activity monitor
48022299|NCT05882851|BEHAVIORAL|determination of the current nutritional status of patients|No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
48022300|NCT03156465|DEVICE|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
48180074|NCT04107597|OTHER|Core stabilization exercises|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes
48518240|NCT02649569|OTHER|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
48022301|NCT06572189|GENETIC|Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)|Receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days (the dosing interval will be adjusted based on the tolerability, safety, and therapeutic effect of the subjects), for one treatment cycle. Treatment will continue until the occurrence of disease progression, death, intolerable toxicity, voluntary withdrawal of informed consent, loss to follow-up, initiation of new antitumor treatment, or termination of the study by the investigator (whichever comes first), and completion of the final follow-up and assessment 14 days after the last administration.
48022302|NCT05038488|DRUG|MIB-626|Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
48022303|NCT05038488|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
48022304|NCT05038488|OTHER|Home Treatment|Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
48022305|NCT00153101|DRUG|Telmisartan|
48518241|NCT04782076|DRUG|Dabigatran|Administered orally.
48518242|NCT04782076|DRUG|Selpercatinib|Administered orally.
48518243|NCT04110210|DRUG|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
48022306|NCT00153101|DRUG|Combination of Telmisartan and Ramipril|
48022307|NCT00153101|DRUG|Ramipril|
48180075|NCT04107597|OTHER|Core stabilization exercises and paced breathing training|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
48180076|NCT04107597|OTHER|Myofascial trigger point release|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes
48714549|NCT02571660|DRUG|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
48714550|NCT05281770|DRUG|Erenumab|treatment with erenumab as chosen by treating physician
48714551|NCT05281770|DRUG|Fremanezumab|treatment with fremanezumab as chosen by treating physician
48714552|NCT05281770|DRUG|Galcanezumab|treatment with galcanezumab as chosen by treating physician
48714553|NCT02483130|DIETARY_SUPPLEMENT|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
48714554|NCT02483130|OTHER|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
48714555|NCT02827500|DRUG|ivabradine|Active Comparator: ivabradine
48714556|NCT02827500|OTHER|Usual Care|Placebo Comparator: usual care
48714557|NCT00456066|DEVICE|Export Aspiration System|Patients scheduled for emergency angioplasty
48022308|NCT00887172|DRUG|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
48022309|NCT00887172|DRUG|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
48518244|NCT04110210|DRUG|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
48518245|NCT03935698|OTHER|Physiotherapy|
48518246|NCT03052751|DRUG|UCB7665|UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
48518247|NCT03052751|OTHER|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
48518248|NCT01313377|DRUG|gemcitabine hydrochloride|
48518249|NCT01313377|DRUG|oxaliplatin|
48518250|NCT01313377|OTHER|clinical observation|
48518251|NCT01313377|PROCEDURE|adjuvant therapy|
48022310|NCT00887172|DRUG|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
48022311|NCT05014100|DRUG|Orelabrutinib tablet|Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
48518252|NCT01313377|PROCEDURE|quality-of-life assessment|
48022312|NCT05014100|DRUG|Lenalidomide|"Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up"
48022313|NCT04408963|BIOLOGICAL|VRC-HIVMAB0102-00-AB|The VRC-HIVMAB0102-00-AB (CAP256V2LS) broadly neutralizing monoclonal antibody (bNAb) targets the V1V2 region of the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
48022314|NCT04734379|DRUG|Fasudil|Oral fasudil 180 mg/day
48380330|NCT03075215|DEVICE|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
48380331|NCT03361839|DIAGNOSTIC_TEST|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
48380332|NCT00798161|DRUG|BI 1356|BI 1356 high dose tablet, once daily
48380333|NCT00798161|DRUG|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
48380334|NCT00798161|DRUG|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
48518253|NCT00003392|BIOLOGICAL|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
48518254|NCT00003392|DRUG|carboplatin|18 AUC IV, approximately days 21, 42
48518255|NCT00003392|DRUG|cyclophosphamide|4 gm/m2 IV, day 1
48518256|NCT00003392|DRUG|melphalan|140 mg/m2 IV , approximately day 63
48518257|NCT00003392|DRUG|paclitaxel|170 mg/m2 IV day 1
48518258|NCT00003392|PROCEDURE|bone marrow ablation with stem cell support|
48518259|NCT00003392|PROCEDURE|peripheral blood stem cell transplantation|
48518260|NCT04080739|DRUG|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
48518261|NCT05697523|OTHER|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test|Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
48380335|NCT00798161|DRUG|Metformin|Metformin 500 mg tablet, twice daily
48380336|NCT00798161|DRUG|metformin|metformin 1000 mg tablet, twice daily
48380337|NCT00798161|DRUG|matching placebo|matching placebo
48380338|NCT06598800|DRUG|Drug: BG-T187|Intravenous administration
48380339|NCT00644527|OTHER|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
48022315|NCT02793492|DEVICE|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
48380340|NCT00644527|OTHER|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
48380341|NCT02769832|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
48380342|NCT02769832|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
48380343|NCT03664388|DRUG|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
48380344|NCT00611780|RADIATION|tube voltage|standard 120 kV
48380345|NCT00611780|RADIATION|tube voltage|reduced voltage of 100 kV
48380346|NCT04130997|BIOLOGICAL|Ublituximab|Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
48022316|NCT00345579|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
48022317|NCT00345579|BIOLOGICAL|ActHIB|3-dose intramuscular injection
48022318|NCT00345579|BIOLOGICAL|Pediarix/Infanrix Penta|3-dose intramuscular injection
48022319|NCT03697785|DEVICE|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
48022320|NCT05273892|BEHAVIORAL|Diet + Activity + Sleep|Personalized lifestyle behavior change counselling
48022321|NCT05273892|BEHAVIORAL|Diet + Activity|Personalized lifestyle behavior change counselling
48022322|NCT00612066|DRUG|rosiglitazone maleate|
48022323|NCT04252235|DEVICE|Air purifier|The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
48022324|NCT04252235|DEVICE|Sham air purifier|The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
48022325|NCT01787604|PROCEDURE|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
48022326|NCT01787604|PROCEDURE|Aortic Valve Reimplantation Procedure|David I
48022327|NCT00164801|DRUG|Baclofen, Diltiazem|
48022328|NCT03160430|DRUG|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
48022329|NCT03160430|DRUG|Placebos|matching placebo capsule
48022330|NCT02256111|DRUG|Enzalutamide|
48022331|NCT02256111|DRUG|Androgen deprivation therapy|
48022332|NCT02256111|BEHAVIORAL|Supervised exercise training|
48022333|NCT03136601|OTHER|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
48022334|NCT06532448|DIAGNOSTIC_TEST|Single dose low-risk penicillin challenge|Initial screening to establish low risk allergy status followed by a single dose challenge using a standard penicillin dose. All challenges will be oral, conducted in a hospital setting and will be followed by a 1 hour monitoring period.
48180077|NCT04107597|OTHER|Myofascial trigger point release and paced breathing training|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
48380347|NCT04562766|DRUG|Rilzabrutinib|400mg Caplet
48380348|NCT04562766|DRUG|Placebo|400mg Caplet
48380349|NCT03908229|PROCEDURE|Trainee colonoscopy|Colonoscopy performed by trainee
48380350|NCT03908229|PROCEDURE|Experienced physician colonoscopy|Experienced physician colonoscopy
48380351|NCT00005607|DRUG|FOLFIRI regimen|
48380352|NCT00005607|DRUG|fluorouracil|
48380353|NCT00005607|DRUG|irinotecan hydrochloride|
48380354|NCT00005607|DRUG|leucovorin calcium|
48380355|NCT06652984|OTHER|Exercise 1|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
48380356|NCT06652984|OTHER|Exercise 2|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
48380357|NCT00956813|DIETARY_SUPPLEMENT|flaxseed|Given orally
48380358|NCT00956813|OTHER|placebo|Given orally
48380359|NCT05859464|DRUG|ZL-1218|ZL-1218 dose escalation
48380360|NCT05859464|DRUG|Pembrolizumab|Combination treatment with ZL-1218
48380361|NCT01928810|BEHAVIORAL|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
48380362|NCT03958045|COMBINATION_PRODUCT|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
48380363|NCT05044910|DIETARY_SUPPLEMENT|Ready to Use supplementary food (RUSF)|Children with malnutrition will be given RUSF
48380364|NCT04938102|DRUG|Botulinum Toxin Type A Injection [Botox]|Injection of 100 units of botulinum toxin into the lower esophageal sphincter (25 units in each quadrant).
48714558|NCT04346979|OTHER|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
48714559|NCT04346979|OTHER|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
48022335|NCT02466945|DEVICE|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
48022336|NCT04726709|BEHAVIORAL|Poised for Parkinson's|Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
48022337|NCT01231711|BEHAVIORAL|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
48022338|NCT03609801|BEHAVIORAL|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
48022339|NCT03609801|BEHAVIORAL|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
48022340|NCT04660981|BEHAVIORAL|Antenatal education|Training Program on Fear of Childbirth Based on Motivational Interview Method
48022341|NCT03505658|BEHAVIORAL|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
48714560|NCT02385916|OTHER|EstroSense®/MD|A natural product already approved by Health Canada
48022342|NCT01701375|DRUG|PD 0332991|• PD 0332991 will be given orally days 1,2,3
48380365|NCT04481399|BEHAVIORAL|Family Strengthening Intervention for Early Childhood Development|The Family Strengthening Intervention for Early Childhood Development (FSI-ECD) is an evidence-based home-visiting behavioral intervention for vulnerable families with children aged 6-36 months. The FSI-ECD targets improving parental emotion regulation and parent-child interactions to improve parental mental health and child development outcomes and reduce family violence. FSI-ECD compromises five core components delivered in 12 modules delivered in weekly sessions via active coaching by community health workers. Core components include coaching on: a) nutrition, health and hygiene; b) early stimulation and playful parenting; c) building resilience and coping skills; d) building problem-solving skills; and d) building emotion regulation and conflict resolution skills.
48022343|NCT06573034|BEHAVIORAL|Daoist Zhanzhuang|Each session of practice will last 30 minutes, and participants are expected to participate every day for 3 months. During the initial 3 weeks, participants will engage in in-person sessions 3 times a week. On non-session days, they can choose to either attend a Zoom practice session with the coach or submit a recording of their individual practice for fidelity check. In Week 4, participants will attend an in-person session for both practice and assessment. Over the subsequent 8 weeks, participants will either attend in-person or Zoom sessions, with a total of 3 check-in sessions.
48022344|NCT06573034|BEHAVIORAL|Sham Wall Squat|Same as the Zhanzhuang group.
48022345|NCT05335356|BIOLOGICAL|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40; Before dosing at Week 16, patients in the Stelara group were randomly assigned in a 1:1 ratio to receive either Bmab 1200 or Stelara
48022346|NCT05335356|BIOLOGICAL|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
48022347|NCT06567509|OTHER|Core stability exercises and Short foot exercises|Core stabilty exercises are the exercises where subjects will be trained to perform exercises like: Curl ups, bridging, side bridges, Planks, and Quadripedal stance exercises in a phased manner, each phase lasting 2 weeks. Complexities and duration of exercises will be increased in each phase. Short foot exercises for control group will include traditional treatment of stretching and strengthening of foot musculature.
48022348|NCT06567509|OTHER|Conventional foot exercises and short foot exercises|Ankle dorsiflexion, Plantar flexion, Inversion and Eversion range of motion exercises
48022349|NCT04557722|PROCEDURE|0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
48714561|NCT02385916|OTHER|Placebo|Placebo
48714562|NCT05100823|PROCEDURE|Nasal cells sampling|Nasal epithelium brushing in intermediate turbinate using a specific curette following a local anesthesia with Xylocaine 5% nebulizer.
48714563|NCT05100823|PROCEDURE|Rectal biopsy sampling|Forceps Biopsy Procedure (Servidoni et al., 2013) Only for volunteer patients included in the Montpellier center.
48022350|NCT04557722|PROCEDURE|New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy|after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
48380366|NCT04481399|OTHER|Community Health Worker Routine|Standard CHW care involves three home visiting sessions delivered to families following childbirth with weekly supervision via phone or face-to-face. Topics of home visiting sessions include: skilled post-natal care for mothers, early initiation of breastfeeding and exclusive breastfeeding practices, adequate nutrition, immunization services and timely use of these services, hand washing and hygiene practices (including waste disposal and food hygiene), building the capacity of family members to appropriately take care of newborns and children under age 5, and building the capacity of family members to recognize and act on postnatal danger signs for newborns, mothers, and children under 5. CHWs also conduct screenings for acute malnutrition and growth monitoring to identify early referrals, and they can provide family planning methods, deworming tablets and other vitamins for acute malnutrition, dehydration, and anti-malaria treatment. Each home-visiting session lasts about 60 minutes.
48380367|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections
48380368|NCT00968539|BIOLOGICAL|GSK investigational vaccine GSK2340269A|Two intramuscular injections
48380369|NCT03207607|OTHER|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
48380370|NCT03207607|OTHER|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
48380371|NCT03207607|OTHER|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
48380372|NCT03207607|OTHER|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
48380373|NCT03207607|OTHER|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
48380374|NCT03207607|OTHER|Snack skipping|no snack
48380375|NCT00198588|DRUG|argatroban|beginning dose: 0.7microgram/kg/H
48380376|NCT00306124|DRUG|Levodopa|
48380377|NCT04054323|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
48380378|NCT05513807|DRUG|Nicotinamide treatment|3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
48380379|NCT05513807|DRUG|Placebo treatment|3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
48380380|NCT05225324|DRUG|Equfina 50 mg|Equfina 50 mg tablets.
48714564|NCT01004016|DRUG|KPS-0373|
48022351|NCT03649126|BEHAVIORAL|Implementation tools|Implementation tools developed by experts in order to increase the use of SSR in pathology
48380381|NCT02908191|DRUG|ABI-H0731|
48380382|NCT02908191|DRUG|Placebo for ABI-H0731|
48380383|NCT02908191|DRUG|Entecavir|Used to treat adults with chronic hepatitis B virus
48380384|NCT02908191|DRUG|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
48380385|NCT02908191|DRUG|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
48380386|NCT02908191|DRUG|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
48380387|NCT01700686|OTHER|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
48022352|NCT02416323|OTHER|AIM HI Training|
48380388|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: Placebo|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
48380389|NCT06650670|DIETARY_SUPPLEMENT|Dietary Supplement: EPP|Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
48380390|NCT00886626|DRUG|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
48380391|NCT02328170|OTHER|EUROIMMUN Allergy|Immunoblot assay
48380392|NCT02328170|OTHER|ImmunoCap|Fluoroallergosorbent test
48380393|NCT05054088|DEVICE|T-Detect COVID test|• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.
48380394|NCT01010724|DRUG|bIAP|
48714565|NCT01004016|DRUG|Placebo|
48714566|NCT05057715|BIOLOGICAL|VCN-01|Intravenous administration of VCN-01
48714567|NCT05057715|BIOLOGICAL|huCART-meso Cells|Intravenous administration of huCART-meso cells
48714568|NCT02657564|DRUG|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
48380395|NCT01010724|DRUG|Placebo|
48714569|NCT06073639|PROCEDURE|Autogenous dentin graft|Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
48180078|NCT03024463|PROCEDURE|IM-SLNB and IMLN dissection|Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection
48714570|NCT05400902|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W"
48180079|NCT03225976|DEVICE|Light-Emitting Diode Device|"The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
48180080|NCT03225976|DEVICE|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
48180081|NCT01705405|DEVICE|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
48518262|NCT06365528|PROCEDURE|Subcutaneous tunnelling|The Subcutaneous tunnelling group will undergo PICC placement under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe and place with additional subcutaneous tunnelling. After vein puncture with the access needle, a Nitinol guidewire will be placed as usual. We will make a tunnel distal to the initial venepuncture site using an additional 14-gauge needle. After resolution of the loop over the venepuncture site, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction plus the subcutaneous tunnel before being inserted in the usual manner.
48714571|NCT02896036|PROCEDURE|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
48180082|NCT03697694|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
48180083|NCT03697694|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
48180084|NCT02706951|DRUG|Methotrexate|Capsule; Oral
48180085|NCT02706951|DRUG|Upadacitinib|Tablet; Oral
48180086|NCT02706951|DRUG|Placebo Upadacitinib|Tablet; Oral
48180087|NCT02706951|DRUG|Placebo Methotrexate|Capsule; Oral
48180088|NCT01424462|DRUG|A|Single dose treatment IR formulation
48180089|NCT01424462|DRUG|B|Low Extended release single dose
48180090|NCT01424462|DRUG|C|Medium extended release formulation
48180091|NCT01424462|DRUG|D|High extended release rate single dose
48180092|NCT01283022|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
48180093|NCT03834389|BEHAVIORAL|Case- based Learning|critical thinking, self efficacy, focus group interview
48180094|NCT00954005|DRUG|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
48180095|NCT05780905|DRUG|Semaglutide Auto-Injector|"Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration."
48180096|NCT05780905|OTHER|Placebo|Placebo
48180097|NCT06032507|PROCEDURE|Bone lavage previous to cementation|Bone lavage previous to cementation in total knee arthroplasty
48180098|NCT03230045|DEVICE|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
48180099|NCT03230045|DEVICE|no treatment|electrodes are attached, but no stimulation is given
48180100|NCT03065933|DRUG|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
48380396|NCT06063980|PROCEDURE|Conventional sinus lift surgery|After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
48518263|NCT06365528|PROCEDURE|Non-tunnelling|The Non-tunnelling group will have PICC placement with the traditional method under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe. After vein puncture with the access needle, a Nitinol guidewire will be placed. After, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction.
48518264|NCT05895201|DRUG|Sitagliptin|600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.
48518265|NCT05895201|DRUG|Bortezomib|1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.
48518266|NCT05895201|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on days +3 and +4
48022353|NCT01097226|OTHER|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
48380397|NCT06063980|PROCEDURE|Two-stage-sinus-lift procedure|Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
48380398|NCT05018533|DRUG|TAKC-02|Inhalation Solution
48714572|NCT02896036|PROCEDURE|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
48518267|NCT01753180|BIOLOGICAL|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
48518268|NCT01753180|DRUG|saline|Local intra-coronary administration of saline at or into the CTO
48522997|NCT04254848|OTHER|oral stereognostic test|Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
48714573|NCT04970160|PROCEDURE|TSARP|We make four different surgical operations for female patients with rectovestibular fistula
48714574|NCT04970160|PROCEDURE|PSARP|Posterior sagittal anorectoplasty
48380399|NCT05018533|DRUG|Placebo|Inhalation Solution
48380400|NCT03466060|DEVICE|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48380401|NCT03466060|DEVICE|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48380402|NCT03466060|DEVICE|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48380403|NCT03466060|DEVICE|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48380404|NCT03466060|DEVICE|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48380405|NCT03466060|DEVICE|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48714575|NCT04970160|PROCEDURE|Classic ASARP|Anterior Sagittal anorectoplasty
48022354|NCT01097226|OTHER|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
48022355|NCT01097226|OTHER|Apple granules delivering 70 mg epicatechin|Delivered as a puree
48022356|NCT01097226|OTHER|Water delivering no epicatechin|Delivered as flavoured water
48714576|NCT04970160|PROCEDURE|Modified ASARP|External anal sphincter preservation
48714577|NCT01261169|DRUG|Myfortic|Myfortic in uveitis
48022357|NCT03176108|BEHAVIORAL|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
48022358|NCT03176108|BEHAVIORAL|Body mediation|Body mediation (theatre)
48022359|NCT03021759|BEHAVIORAL|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
48022360|NCT03021759|BEHAVIORAL|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
48022361|NCT06038682|DRUG|Argatroban Injection|Argatroban will be administered to the study subjects in this group in order to achieve anticoagulation.
48380406|NCT03466060|DEVICE|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48022362|NCT06038682|DRUG|Heparin|Heparin will be administered to the study subjects in this group in order to achieve anticoagulation.
48022363|NCT04876027|DRUG|GLP-1 RAs|GLP-1 receptor agonist is a glucagon-like peptide 1 analog, which is related to improving blood sugar control, weight loss and appetite suppression, and reducing cardiovascular risk.
48022364|NCT04876027|OTHER|calorie restricted diet|Calorie restricted diet can improve insulin sensitivity, liver fat in patients with visceral obesity, and metabolism and hormone levels in obese women with PCOS.
48180101|NCT03716388|BIOLOGICAL|Fecal Microbiota Transplantation|Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
48380407|NCT03466060|DEVICE|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
48518269|NCT06577922|OTHER|Establishment of a simulation lab and provision of simulation based trainings|In each hospital, the investigators will perform an initial need assessment to identify the existing skills labs' space, equipment and trained human resources. Then, maternal and neonatal health simulation labs will be established in each hospital. One simulation lab will have 5 rooms- one auditorium hall, one debrief room, two simulation rooms, and one high fidelity simulation room. Equipment and manikins required for practicing maternal and neonatal health related skills will be installed in the simulation lab, along with guidance/ checklists for skills practice. After completion of lab set-up, trainings will be provided to trainers/ MNH staff of each hospital on simulation based methodology, especially focusing on Essential Care for Labor and Birth (ECLB), Bleeding after Birth (BAB), and Helping Babies Breathe (HBB) modules. Similarly, the investigators will also provide training for simulation lab operation and maintenance.
48518270|NCT05748587|DIAGNOSTIC_TEST|Serum Iron|Serum iron levels in study groups
48518271|NCT05748587|DIAGNOSTIC_TEST|RBCs Alpha-synuclein|α-syn levels in RBCs
48714578|NCT04820634|OTHER|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.
48714579|NCT04820634|OTHER|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
48022365|NCT04777344|BEHAVIORAL|Tobacco Treatment Specialist (TTS) intervention|A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
48022366|NCT01842828|OTHER|Standard care plus electronic cigarettes|
48180102|NCT03716388|DRUG|Mesalamine Granules|Mesalamine granules 4 grams a day
48380408|NCT04045405|DRUG|CDR132L|i.v. administration
48022367|NCT01842828|BEHAVIORAL|Standard care|
48022368|NCT04666441|DRUG|REGN10933+REGN10987 combination therapy|Administered IV or SC single dose
48380409|NCT05140473|BEHAVIORAL|perceived workload|Perceived workload takes into account the acts and care performed but also the pressure felt of having been efficient in its task, the efforts made and the level of frustration felt.
48380410|NCT04389294|DIAGNOSTIC_TEST|SARS-CoV2 serum antibody testing|Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.
48380411|NCT06230705|OTHER|Guided management|Guided Management
48380412|NCT06230705|OTHER|Self management|Self management
48022369|NCT04666441|DRUG|Placebo|Administered IV or SC single dose to match
48380413|NCT06385509|DRUG|Jatenzo|237 mg JATENZO twice daily
48518272|NCT05748587|DIAGNOSTIC_TEST|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
48518273|NCT05748587|RADIATION|Brain computed tomography|Brain CT of patients after admission
48518274|NCT05748587|DIAGNOSTIC_TEST|Brain Iron|Iron in brain homogenate of rats
48518275|NCT05748587|DIAGNOSTIC_TEST|Brain Alpha-synuclein|α-syn expression in rat's brain
48518276|NCT05748587|DIAGNOSTIC_TEST|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
48522998|NCT01660425|BEHAVIORAL|Enhancement with psychosocial intervention|
48714580|NCT05214391|DRUG|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
48180103|NCT03716388|OTHER|Placebo infusion|Water with food grade colour to resemble fecal slurry
48180104|NCT03716388|OTHER|Placebo granules|Granules resembling mesalamine granules, 4 grams a day
48180105|NCT06428864|DEVICE|Plaster cast|Wearing a Garchois brace produced after a plaster cast
48714581|NCT04764734|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
48518277|NCT05748587|DRUG|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
48714582|NCT04254016|DIETARY_SUPPLEMENT|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
48714583|NCT03254277|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
48714584|NCT03254277|DRUG|Placebo|Placebo
48380414|NCT02720796|OTHER|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
48380415|NCT06653556|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
48022370|NCT06572254|OTHER|Early Childhood Development Newborn Parenting Education Program|Investigators will be adapting the model used here at the tertiary care of newborn parenting which investogators have developed based on the nurturing care framework and keys to the caregiving framework. Both models have shown reliable evidence of their effectiveness.
48022371|NCT06573515|DEVICE|high tone power therapy|female patients will receive high-tone power therapy using a device (HiTop 191 Medizintechnik, Rimbach, Germany) duration 30 minutes at 2 sessions per week for 6 weeks
48022372|NCT06573515|DEVICE|interferential current therapy|female patients will receive interferential current therapy using Enraf-Nonius (ENDOMED 484, Germany)The electrode pairs will placed at a distance of at least 2.5 cm from each other. The utilized parameters will have a base frequency of 4,000 Hz, a modulation frequency range of 10 Hz-20 Hz, spectrum mode triangular, and slope 1/1 in a quadripolar manner with a beat frequency of 80 Hz. duration of treatment session 20 minutes 2 sessions per week for 6 weeks
48022373|NCT06573515|DEVICE|conventional physical therapy|female patients will receive conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
48022374|NCT04537091|PROCEDURE|rESWT|rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
48022375|NCT04537091|PROCEDURE|PRP injection|PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
48022376|NCT04828759|BEHAVIORAL|VR-treatment|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
48380416|NCT02152631|DRUG|Abemaciclib|Administered orally
48380417|NCT02152631|DRUG|Erlotinib|Administered orally
48380418|NCT05773924|DEVICE|triLift system|To evaluate the efficacy of the triLift™ treatment
48380419|NCT01761123|BIOLOGICAL|VXA-A1.1|
48380420|NCT06514365|DRUG|IPACK block with Bupivacaine 0.25% with adrenaline|The iPACK in performed in the popliteal fossa about 1 finger breath above the patella, ecoguided. That aims to anesthetize the articular branches to the posterior aspect of the knee in the popliteal region.
48518278|NCT04190121|DIETARY_SUPPLEMENT|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
48518279|NCT05472246|DEVICE|Wearing a virtual reality headset|VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure
48518280|NCT04983134|BEHAVIORAL|Enhanced CHW Intervention|community-based intervention
48522999|NCT05369754|BIOLOGICAL|YBSW015 injection|Prepared YBSW015 injection is intravenously injected by an infusion pump or gravity infusion with intravenous infusion of 250 mL for 60 min±10 min.
48714585|NCT00024310|DIETARY_SUPPLEMENT|folic acid|
48714586|NCT00024310|DRUG|lometrexol|
48714587|NCT00024310|DRUG|paclitaxel|
48714588|NCT03527628|DRUG|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
48714589|NCT03527628|DRUG|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
48714590|NCT03527628|DRUG|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
48714591|NCT03527628|DRUG|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
48714592|NCT03527628|DRUG|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
48022377|NCT04828759|BEHAVIORAL|Treatment as usual|The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
48022378|NCT03036514|DEVICE|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
48180106|NCT06428864|DEVICE|3D Scanning|Wearing a Garchois brace produced after assessment of the thoracic volume with the 3D scan
48180107|NCT03051893|DRUG|Chronocort|Modified formulation of hydrocortisone
48180108|NCT00175747|DRUG|Inhaled Budesonide 800 µg twice daily|
48180109|NCT01012245|OTHER|no intervention|
48180110|NCT04533009|PROCEDURE|spine surgery|Tramadol-paracetamol 325mg/37,5mg two tablets twice daily
48380421|NCT04275375|OTHER|observation study about the autonomic response after spinal anesthesia|ECG waveforms were continuously recorded using a multichannel polygraphic system (Embla N7000, Natus, Pleasanton, CA). The data were saved at a rate of 1024 Hz directly to a memory card within the device for offline analysis of heart rate variability (HRV) and PPG. All data included in the analysis were obtained from continuous artifact-free ECG recordings for analysis of the immediate effects of spinal anesthesia.
48380422|NCT01687127|DIETARY_SUPPLEMENT|Folic acid|Supplement
48380423|NCT01687127|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate, calcium salt|Supplement
48380424|NCT02585193|BEHAVIORAL|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
48180111|NCT00002796|DRUG|fluorouracil|Given IV
48180112|NCT00002796|DRUG|sodium phenylbutyrate|Given IV
48180113|NCT00002796|DRUG|indomethacin|Given orally
48380425|NCT05946096|OTHER|Dynamic surface exercise training|Dynamic surface exercise training involves a set of exercises that are performed on various dynamic surfaces like gym ball and vestibular swing. All these exercise provide optimal arousal as they provide proprioceptive and vestibular stimulus. This group received a set of exercises on various dynamic surfaces.These exercises were implemented for 60 minutes for four days a week for two months.And it was observed how these exercises impacted gross motor function and trunk control of children with diplegic cerebral palsy of GMFCS level 3 and 4
48518281|NCT06338579|OTHER|Questionnaire|"A questionnaire is distributed and self-administered 4 weeks before the start of an embarked mission on a surface ship at the Toulon naval base, during an embarked mission of at least 4 weeks.~The questionnaire consists of 2 parts:~* A section on socio-demographic characteristics~* A section on self-medication practices during this deployment"
48022379|NCT03036514|DRUG|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
48380426|NCT05946096|OTHER|conventional physical therapy|conventional physical therapy based on NDT involves a set of exercises that mostly include positioning exercises such as quadruped, side sitting, reaching sideways and overhead in sitting and catch and throw activities.
48380427|NCT04587635|DIETARY_SUPPLEMENT|PHGG|PHGG
48380428|NCT04587635|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48380429|NCT01897480|BIOLOGICAL|LY2875358|Administered IV
48380430|NCT01897480|DRUG|Erlotinib|Administered Orally
48518282|NCT05532033|DEVICE|High flow nasal cannula|A device able to delivery high flow oxygen therapy
48518283|NCT05532033|DEVICE|Facial mask|standard oxygen therapy
48022380|NCT03188640|PROCEDURE|Laparoscopic gastric-bypass surgery|Female participants with BMI \>30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
48022381|NCT04522947|OTHER|Milkshake fMRI|While in the MRI scanner, the participant is shown a cue indicating the impending delivery of either milkshake or tasteless solution, followed by a brief blank screen, then delivery of the sip, and then a swallow cue. This procedure is repeated throughout the task.
48180114|NCT00002796|BIOLOGICAL|recombinant interferon gamma|Given subcutaneously
48180115|NCT05194033|DIETARY_SUPPLEMENT|Probiotics daily|Probiotics 1 time/day for 7 consecutive days
48180116|NCT05194033|DIETARY_SUPPLEMENT|Placebo daily|Placebo 1 time/day for 7 consecutive days
48180117|NCT04075786|OTHER|Survey|Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
48180118|NCT05478382|DRUG|Pregabalin 25 MG|Patients are given 0 to 3 capsules per administration according to their allocated group.
48180119|NCT05478382|DRUG|Placebo|Patients are given 0 to 3 capsules per administration according to their allocated group.
48180120|NCT02994771|DRUG|Lymfactin® [1 x 10E10 vp]|Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
48180121|NCT02994771|DRUG|Lymfactin® [1 x 10E11 vp]|Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
48180122|NCT03226301|DRUG|Ibrutinib + Venetoclax 15 cycles|"Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28"
48180123|NCT03226301|DRUG|Ibrutinib until progression/relapse|420mg ibrutinib daily until progression/relapse
48180124|NCT03226301|DRUG|Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles|"Cycle 1: 420 mg ibrutinib \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28"
48180125|NCT06051071|DEVICE|Transcranial Direct Current Stimulation (tDCS)|In tDCS, surface electrodes (anode and cathode) inject low-intensity direct current through the skull to modulate brain activity and cortical excitability
48180126|NCT05784766|DIAGNOSTIC_TEST|30-second ECG using the Kardia Mobile|30-second ECG using the Kardia Mobile
48714593|NCT03527628|DRUG|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
48518284|NCT06017050|BEHAVIORAL|BullyDown|BullyDown is an 8 week, text messaging-based prevention program aimed to prevent bullying behaviors among middle school-aged youth. Message content is based upon the social-emotional learning model.
48518285|NCT06017050|BEHAVIORAL|Attention-matched control|The attention-matched control will receive the messages for the same number of days as the intervention. Content will talk about 'healthy lifestyle' topics, such as fitness and healthy social media use.
48518286|NCT02934399|OTHER|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
48714594|NCT02897752|DEVICE|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
48714595|NCT02897752|OTHER|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
48714596|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
48714597|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
48714598|NCT01576328|DRUG|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
48714599|NCT05281536|OTHER|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
48714600|NCT01985490|PROCEDURE|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
48380431|NCT02346071|BEHAVIORAL|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
48380432|NCT02346071|OTHER|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
48380433|NCT03296904|DEVICE|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
48380434|NCT04706065|GENETIC|SHMT1 polymorphism|It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
48380435|NCT06340750|BIOLOGICAL|LMY-920|CAR T Therapy
48380436|NCT06353217|OTHER|Patient Group (Hypoglycemia Prevention Program)|"The Hypoglycemia Prevention Program:~The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit."
48380437|NCT06353217|OTHER|Primary Care Physician Group|The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.
48380438|NCT06353217|OTHER|Clinic Staff Group|Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.
48380439|NCT05831475|BEHAVIORAL|Intergenerational Virtual Paired Exercise|Participants will be paired with someone older/ younger and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
48518287|NCT03744247|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48518288|NCT03744247|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
48518289|NCT03744247|DRUG|Placebo|Intravenously every 2 weeks
48518290|NCT06581588|DEVICE|THRIVE|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen
48714601|NCT05730647|OTHER|None intervention (observational study)|None intervention (observational study)
48714602|NCT03720600|BEHAVIORAL|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
48714603|NCT03825250|DRUG|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
48714604|NCT03340896|DRUG|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
48518291|NCT06581588|DEVICE|THRIVE combine nasopharyngeal airway|Device: Optiflow and THRIVE technique Nasal high flow humidified oxygen and nasopharyngeal airway
48714605|NCT03340896|DRUG|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
48380440|NCT05831475|BEHAVIORAL|Peer Virtual Paired Exercise|Participants will be paired with someone of the same age group and will engage in exercise videos with the ability to simultaneously video chat with their partner while exercising. Participants will log on with their partner twice a week for 8 weeks.
48380441|NCT04773314|OTHER|PROPESS Cohort|Non-intervention
48380442|NCT03252236|BEHAVIORAL|Tai Chi|Modified 12-form Yang style Tai Chi.
48380443|NCT03252236|BEHAVIORAL|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
48380444|NCT00241059|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
48380445|NCT03252665|DRUG|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
48380446|NCT03252665|DRUG|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
48380447|NCT03252665|DRUG|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
48380448|NCT02780817|OTHER|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
48380449|NCT02780817|OTHER|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
48380450|NCT00389168|DRUG|Irbesartan|Titrated to 300 mg od, 48 weeks.
48380451|NCT00389168|DRUG|Atenolol|Titrated to 100 mg od, 48 weeks.
48380452|NCT03451474|PROCEDURE|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
48380453|NCT01018680|DRUG|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
48380454|NCT01018680|DRUG|Placebo|Taken by mouth, once daily for 10 weeks
48380455|NCT04301401|OTHER|Vaginal swabs|On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
48380456|NCT04301401|OTHER|Stool samples|Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
48380457|NCT04301401|OTHER|Urine samples|Urine samples will also be taken before surgery and 6 weeks after surgery.
48380458|NCT02047929|OTHER|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
48380459|NCT03892902|DRUG|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
48380460|NCT03892902|DRUG|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
48380461|NCT03892902|OTHER|Placebo|Matching to maintain blinding.
48714606|NCT03340896|DRUG|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
48022382|NCT05706558|PROCEDURE|Esophagectomy|Esophagectomy
48380462|NCT04885842|OTHER|injection I-PRF|injection I-PRF with brackets
48714607|NCT03340896|RADIATION|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
48714608|NCT02165462|OTHER|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
48714609|NCT05418153|DEVICE|Tecnis Synergy IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
48714610|NCT04304183|PROCEDURE|total colectomy, ileorectal anastomosis|all patients underwent total colectomy and ileorectal anastomosis.The anastomosis was stapled in all patients.
48714611|NCT00410826|DRUG|erlotinib hydrochloride|Given orally
48022383|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays
48022384|NCT05168319|DEVICE|Repetitive transcranial magnetic stimulation|Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays
48022385|NCT05168319|DEVICE|Sham stimulation|Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
48022386|NCT06535308|DRUG|BnH-015B 5 mg|Korean / 3 on BnH-015B, 1 on placebo
48022387|NCT06535308|DRUG|BnH-015B 10 mg|Korean / 6 on BnH-015B, 2 on placebo
48022388|NCT06535308|DRUG|BnH-015B 20 mg|Korean / 6 on BnH-015B, 2 on placebo
48022389|NCT06535308|DRUG|BnH-015B 40 mg (Dietary impact)|Korean / 6 on BnH-015B, 2 on placebo
48022390|NCT06535308|DRUG|BnH-015B 40 mg|Caucasian / 6 on BnH-015B, 2 on placebo
48022391|NCT06535308|DRUG|BnH-015B 80 mg|Korean / 6 on BnH-015B, 2 on placebo
48714612|NCT00410826|DRUG|cisplatin|Given IV
48714613|NCT00410826|RADIATION|3-dimensional conformal radiation therapy|35 fractions
48714614|NCT00410826|RADIATION|intensity-modulated radiation therapy|35 fractions
48714615|NCT00410826|PROCEDURE|quality-of-life assessment|Ancillary studies
48714616|NCT02288013|PROCEDURE|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
48714617|NCT00545532|DRUG|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
48714618|NCT00545532|OTHER|placebo|Placebo matched to oseltamivir po twice daily for 10 days
48714619|NCT01986387|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
48380463|NCT03930615|DRUG|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
48380464|NCT03930615|DRUG|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
48714620|NCT01741337|PROCEDURE|Adaptive servo-ventilation post-operative treatment for 6 months|
48714621|NCT02821377|DRUG|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
48714622|NCT02821377|DRUG|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
48714623|NCT02821377|PROCEDURE|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
48714624|NCT00377559|DRUG|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
48380465|NCT01976325|OTHER|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
48714625|NCT00612859|DRUG|levetiracetam|
48714626|NCT04388046|DEVICE|Herbst fixed functional appliance|Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
48714627|NCT06511297|DIAGNOSTIC_TEST|comprehensive metabolic phenotyping|The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.
48714628|NCT02679625|DEVICE|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
48714629|NCT01248754|PROCEDURE|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
48380466|NCT04308356|BEHAVIORAL|Dedicated Discussions on Anticipating preferences of care in the event of Aggravation (DDA)|interview 2
48380467|NCT04308356|OTHER|Autonomy Preference Index (API ) questionnaire - Information|part of interview 1
48380468|NCT04308356|OTHER|anxiety and depression (HADS) questionnaire|part of interview 1
48714630|NCT06155734|DRUG|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
48714631|NCT05551676|PROCEDURE|transforaminal group|Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.
48180127|NCT05784766|OTHER|routine care|medical review
48180128|NCT06146192|DRUG|Colchicine|colchicine 1-2 mg/day
48714632|NCT05551676|PROCEDURE|Lateral parasagittal group|Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
48714633|NCT01603381|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
48714634|NCT02262819|DRUG|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
48714635|NCT05341999|OTHER|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
48714636|NCT05341999|DRUG|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
48380469|NCT00106613|DRUG|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
48380470|NCT06465459|PROCEDURE|LAMBRE device implantation|LAMBRE device implantation
48380471|NCT00326118|BIOLOGICAL|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
48022392|NCT06535308|DRUG|BnH-015B 160 mg|Korean / 6 on BnH-015B, 2 on placebo
48022393|NCT06535308|DRUG|BnH-015B 40 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
48022394|NCT06535308|DRUG|BnH-015B 80 mg (MAD)|Korean / 6 on BnH-015B, 2 on placebo
48022395|NCT06535308|DRUG|BnH-015B 40 mg (Part II)|Korean / 9 subjects
48022396|NCT06535308|DRUG|BnH-015B 80 mg (Part II)|Korean / 9 subjects
48022397|NCT06535308|DRUG|BnH-015B Placebo (Part II)|Korean / 6 subjects
48022398|NCT04192097|OTHER|Professionalism curriculum|"One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues"
48180129|NCT02736279|DRUG|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
48180130|NCT02028286|DRUG|CLS001|
48380472|NCT00326118|BIOLOGICAL|Priorix™|One subcutaneous dose at 12-18 months of age
48380473|NCT00326118|BIOLOGICAL|Hiberix™|One intramuscular dose at 12-18 months of age.
48380474|NCT00326118|BIOLOGICAL|Meningitec™|One intramuscular dose at 12-18 months of age
48380475|NCT02183948|DRUG|Oxytocin|
48380476|NCT02183948|DRUG|Placebo|
48380477|NCT03165253|DRUG|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
48380478|NCT03165253|DRUG|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
48380479|NCT03165253|DRUG|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
48380480|NCT03165253|DRUG|Omeprazole|1 mg/kg/day
48714637|NCT05341999|OTHER|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
48380481|NCT00514501|DRUG|Iodofiltic acid I 123|
48518292|NCT02514902|DEVICE|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
48380482|NCT05248919|DRUG|Epclusa (nucleotide HCV NS5B polymerase inhibitors).|Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
48380483|NCT06442774|OTHER|Mobile application|"The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS)."
48380484|NCT06442774|OTHER|Monitoring via wearable|Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
48380485|NCT04940091|DRUG|Epidural analgesia|Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
48380486|NCT05901376|DIAGNOSTIC_TEST|MicroRNA|MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
48380487|NCT04387227|DRUG|Carboplatin|Given IV
48518293|NCT03883035|OTHER|automatic quality-control system|Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.
48518294|NCT00972296|DEVICE|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
48518295|NCT03151174|DRUG|Vitamin D 10000 UNT|10000 IU Vitamin D per day
48518296|NCT03151174|DRUG|Vitamin D 5000 UNT|5000 IU Vitamin D per day
48518297|NCT02358902|DEVICE|tDCS|tDCS - DC stimulator, Neurocom, Germany
48518298|NCT02358902|PROCEDURE|active intervention of aerobic exercise|different types of aerobic exercise
48518299|NCT02358902|DEVICE|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
48518300|NCT02358902|PROCEDURE|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
48518301|NCT04269473|PROCEDURE|Telehealth Gait Retraining|Telehealth gait retraining is a novel approach to train participants to adopt a non-rearfoot foot strike pattern during running via telecommunications. During telehealth gait retraining, video of a participant's running form are sent to clinicians over a mobile device app and running form feedback is given. This process is repeated once a week for four weeks and then every other week until week 8.
48518302|NCT04269473|PROCEDURE|Standard Physical Therapy Treatment|Participants receiving standard Physical Therapy will visit the Physical Therapy Clinic every 2 to 3 weeks to be treated by a Physical Therapist.
48180131|NCT01509443|OTHER|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
48180132|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A' ) in fluid responsive position
48380488|NCT04387227|BIOLOGICAL|Pembrolizumab|Given IV
48380489|NCT04387227|PROCEDURE|Computed Tomography|Undergo CT
48380490|NCT04387227|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48380491|NCT04387227|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48518303|NCT04269473|PROCEDURE|Return to Running Protocol|The Return to Running protocol is a six-phase running volume progression to re-introduce running slowly and safely after experiencing a running-related injury.
48518304|NCT04269473|PROCEDURE|At Home Exercise Program|The At Home Exercise Program consists of 4 lower leg and foot exercises that participants can perform on their own time.
48518305|NCT05547997|OTHER|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
48518306|NCT05547997|OTHER|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
48518307|NCT02680236|OTHER|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
48518308|NCT04784611|BEHAVIORAL|Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention|Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
48380492|NCT00139802|DEVICE|Coronary Stent Implantation|
48380493|NCT04221100|DEVICE|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
48380494|NCT00448110|DRUG|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
48380495|NCT00448110|DRUG|Intravenous Ketorolac|Intravenous Ketorolac
48380496|NCT00448110|DRUG|placebo|placebo
48028870|NCT06531954|BEHAVIORAL|Breathing exercise|Breathing exercise group: The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
48028871|NCT04701021|BIOLOGICAL|TENDU|The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.
48028872|NCT00153738|DRUG|phytosterol|
48028873|NCT00000129|PROCEDURE|Radial Keratotomy|
48028874|NCT00023829|DRUG|bicalutamide|
48028875|NCT00023829|DRUG|flutamide|
48380497|NCT01140815|DEVICE|Total Knee Replacement|Smith and Nephew Total Knee Replacement
48380498|NCT01140815|DEVICE|Deuce|Smith and Nephew Bicompartmental Knee Replacement
48380499|NCT02423564|DIETARY_SUPPLEMENT|Digesta Lac|
48380500|NCT02423564|OTHER|Placebo|
48380501|NCT04716816|PROCEDURE|Stripping massage|Stripping massage for rhomboid myofascial trigger points
48518309|NCT01117974|PROCEDURE|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
48518310|NCT03105518|DRUG|Fentanyl|0.5, 1 mcg/kg
48022399|NCT01643473|BEHAVIORAL|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
48022400|NCT01643473|OTHER|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
48022401|NCT05711550|DEVICE|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
48022402|NCT05711550|DEVICE|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
48380502|NCT05432466|DRUG|ACER-002 (celiprolol) 200 mg BID|ACER-002 (celiprolol) 200 mg BID
48380503|NCT05432466|DRUG|Placebo BID|placebo for ACER-002
48022403|NCT04768647|DEVICE|TNM|TNM is a small portable head set that can be used by the participants at home to stimulate the vestibular system
48022404|NCT01542528|BEHAVIORAL|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
48022405|NCT00793910|DRUG|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
48180133|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A') in non-fluid responsive position
48180134|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in fluid responsive position
48180135|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in non-fluid responsive position
48180136|NCT04171245|OTHER|Laughie laughter prescription|Creation of a Laughie; laughing with their Laughie 3x a day
48180137|NCT04171245|DEVICE|Sleep tracking equipment|Tracking sleep using equipment
48380504|NCT06021873|PROCEDURE|SADI-S|Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy
48380505|NCT00902265|DRUG|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
48380506|NCT01017965|DEVICE|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
48380507|NCT01465594|PROCEDURE|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
48380508|NCT01465594|PROCEDURE|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
48380509|NCT06542822|DRUG|Ferric derisomaltose|See group descriptions
48380510|NCT06362707|DRUG|Fasudil|A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.
48380511|NCT06362707|DRUG|Placebo|Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
48380512|NCT05270772|BIOLOGICAL|CAR-T-19 Cells|T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
48380513|NCT03253809|DEVICE|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
48518311|NCT03105518|DRUG|Acetaminophen|Single + Oxycodone
48714638|NCT00378599|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
48714639|NCT00886119|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
48714640|NCT00886119|DEVICE|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
48714641|NCT03385278|OTHER|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
48022406|NCT00793910|DRUG|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
48022407|NCT01320163|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
48022408|NCT01320163|DEVICE|Laryngeal Mask Airway|supra-glottic airway device
48180138|NCT01463228|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
48180139|NCT01463228|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
48180140|NCT06076408|OTHER|SNAGS with Pilates|Patients will Receive Sustained Natural Apophyseal glides and Pilates Technique. Pilates Exercises focusses on five main areas (breath control, pelvic lumbar region, chest, shoulder positioning, head and neck positioning) a special session was organized for each patient
48022409|NCT06133491|BIOLOGICAL|Daxibotulinumtonix A|SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.
48180141|NCT06076408|OTHER|SNAGS|Patients will Receive Sustained Natural Apophyseal glides
48380514|NCT02381366|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
48380515|NCT05732103|DRUG|CTX-712|CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 weekly, depending on their dose level assignment, during each 28-day cycle.
48714642|NCT03920059|DRUG|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
48022410|NCT02863016|DEVICE|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
48180142|NCT05168098|OTHER|board game comparison|The group used 24 board games popular among the elderly population in Taiwan, including Noah's Ark, Splash Attack, Pengoloo, Speedy, and Zingo. Because some games were too complicated for the participants to play, some game rules were modified into more simple and directive thinking.
48380516|NCT06212609|OTHER|transcranial electrical stimulation therapy|new procedure of non-invasive, individualized and optimized transcranial electrical stimulation therapy in the management of pharmaco-resistant focal epilepsies
48380517|NCT06650176|BEHAVIORAL|Lifestyle Management|The Metrikamind intervention features a unique digital ecosystem designed to manage mental health specifically in workplace contexts, with a focus on aiding recovery and facilitating the return to work for employees on sick leave. This innovative tool employs bifactor models to enhance the accuracy of self-reported data, effectively countering potential faking behaviors. Through continuous, real-time data collection on a user-friendly platform, Metrikamind tracks and assesses various mental health conditions, including stress, anxiety, and depression. The intervention\&amp;#39;s advanced analytics enable personalized feedback and targeted interventions, improving the detection, management, and ultimately, the mitigation of mental health issues. By focusing on individuals currently unable to work due to mental health challenges, Metrikamind aims to support their recovery and accelerate their readiness to return to work, thus addressing both immediate and long-term recovery trajectories.
48380518|NCT04846907|OTHER|Web-based survey|Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
48714643|NCT01444586|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
48714644|NCT00004142|DRUG|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
48714645|NCT00004142|DRUG|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
48022411|NCT06421233|OTHER|massage|Endorphin massage will be given for 15 minutes every 2 hours.
48022412|NCT00684580|OTHER|Data Collection|Continuing review of outcomes and late toxicities
48022413|NCT01793857|OTHER|Data collection|Paper questionnaire
48022414|NCT00260923|DRUG|aliskiren|
48022415|NCT01286818|BIOLOGICAL|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
48022416|NCT01286818|DRUG|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
48022417|NCT01286818|DRUG|levofolinate|IV infusion, 200 mg/m² every 2 weeks
48022418|NCT01286818|DRUG|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
48028876|NCT00023829|DRUG|releasing hormone agonist therapy|
48028877|NCT00023829|PROCEDURE|adjuvant therapy|
48380519|NCT03279120|DRUG|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
48714646|NCT00004142|PROCEDURE|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
48714647|NCT00004142|PROCEDURE|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
48714648|NCT05867290|BEHAVIORAL|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
48714649|NCT00020462|BIOLOGICAL|aldesleukin|
48714650|NCT00020462|BIOLOGICAL|autologous tumor cell vaccine|
48714651|NCT00596115|DRUG|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
48714652|NCT01928823|BEHAVIORAL|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
48714653|NCT01928823|DRUG|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
48022419|NCT04788147|DEVICE|RMRS IDE Device|Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
48380520|NCT03279120|DRUG|Placebo|Used for 90 days (Continuous or Interrupted)
48380521|NCT01652807|BEHAVIORAL|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
48518312|NCT03105518|DRUG|Oxycodone|With Acetaminophen
48714654|NCT01046604|DRUG|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
48714655|NCT00094718|BIOLOGICAL|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
48714656|NCT00094718|BIOLOGICAL|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
48714657|NCT01397682|OTHER|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
48714658|NCT06120595|DRUG|REBECCA-assisted intervention 1|The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
48714659|NCT06120595|BEHAVIORAL|REBECCA-assisted intervention 2|The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
48714660|NCT06120595|OTHER|Standard follow-up|Standard follow-up
48714661|NCT02060994|OTHER|No intervention|No intervention
48518313|NCT00946920|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
48714662|NCT02576665|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
48714663|NCT02576665|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
48714664|NCT00003963|BIOLOGICAL|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
48714665|NCT00003963|DRUG|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
48714666|NCT01376570|BEHAVIORAL|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
48022420|NCT05522036|COMBINATION_PRODUCT|Metvix + Dermaris|Photodynamic Therapy
48022421|NCT04471259|OTHER|Classification statistics|We classified patients by gender, age, recovery time,etc
48028878|NCT00023829|RADIATION|radiation therapy|
48380522|NCT01443676|DRUG|Bevacizumab|Bevacizumab will be added to radiotherapy
48380523|NCT01443676|RADIATION|Radiation therapy|Radiation therapy
48028879|NCT03220191|DRUG|Palbociclib|palbociclib tablet formulation
48028880|NCT03220191|DRUG|Rabeprazole|rabeprazole as PPI
48380524|NCT03890380|DEVICE|Magneto Wire|Patients will be treated with Magneto Wire
48380525|NCT06653543|OTHER|Mulligan mobilization with arm movement|mulligan mobilization applied on cervical spine with arm movement
48380526|NCT06653543|OTHER|conventional therapy of cevical radiculopathy|hot pack for 10 minutes, active ranges of motion (AROMs) with 3 sets of 10 repetitions and isometrics for each movement repeated 20 times with the hold of 6 to 10 seconds in each repetition
48518314|NCT00946920|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
48518315|NCT00361647|PROCEDURE|Diagnostic screening for occult malignancy|
48518316|NCT04881786|DEVICE|Orthodontic forces|56g force and 224g force
48518317|NCT02749500|OTHER|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
48180143|NCT05168098|OTHER|olfactory stimulation intervention|The group used 15 flavors of essential oil (i.e., lavender, rosemary, sweet orange, lemongrass, mint, and hinoki) and essence (i.e., lemon, coffee, peach, magnolia, chocolate, jasmine, strawberry, pomelo, and passion fruit), purposefully selecting two to three flavors for each session. Because some flavors are familiar to the participants and some are not, the familiar flavors were initially used to trigger memory. The unfamiliar flavors (i.e., lavender, rosemary, sweet orange, and lemon) were used in later sessions because those were recognized as having potential effects on cognitive function
48380527|NCT04612465|BIOLOGICAL|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10\^7 cells of ASC per 1cm\^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
48180144|NCT00959010|DIETARY_SUPPLEMENT|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
48380528|NCT04612465|DRUG|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
48380529|NCT06370884|DRUG|IMT|a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
48380530|NCT00659945|DRUG|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
48518318|NCT02749500|DEVICE|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
48518319|NCT06582797|OTHER|discontinuation of ART|patient will discontinue their standard of care HIV treatment with ART while being closely monitored
48714667|NCT01376570|BEHAVIORAL|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
48714668|NCT05845944|OTHER|Video-supported education group|Providing training on nutrition with a nasogastric tube in pediatric patients with a video-supported education method
48714669|NCT03173911|DEVICE|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
48714670|NCT00167180|PROCEDURE|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
48714671|NCT00167180|DRUG|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
48714672|NCT01655381|DRUG|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
48714673|NCT00360932|DEVICE|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
48714674|NCT06131944|BEHAVIORAL|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
48180145|NCT00959010|DIETARY_SUPPLEMENT|Placebo|capsules containing middle chain triglycerides
48180146|NCT06258954|OTHER|3D reconstruction|3D reconstruction based on CT data and It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size of the DLT for lung isolation.
48180147|NCT06258954|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and height.
48180148|NCT05479474|BIOLOGICAL|Platelet rich plasma|"Patients will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.~* On the third month after the testicular PRP procedure, a TESE will be performed~* If the procedure is successful a new IVF cycle using the sperm procured from the procedure will be done."
48380531|NCT00659945|DRUG|Ondansetron plus placebo|Ondansetron plus placebo
48380532|NCT05511155|OTHER|Oxygen therapy|Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.
48380533|NCT00741026|DRUG|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
48518320|NCT01444261|DIETARY_SUPPLEMENT|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
48518321|NCT01444261|OTHER|control|No dietary supplements
48380534|NCT00741026|DRUG|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
48380535|NCT04069208|DRUG|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
48380536|NCT04629534|DRUG|High dose Cholecalciferol|Mothers in experimental group will receive 6,000 IU of vitamin D in addition to their prenatal vitamin, daily for 3 months. Infants in this group will receive placebo vitamin D drops
48518322|NCT01750190|DRUG|Roxadustat|Oral tablets
48714675|NCT00302016|DRUG|AMN107|
48714676|NCT04178993|DRUG|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
48714677|NCT04178993|DRUG|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
48380537|NCT04629534|DRUG|Cholecalciferol|Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D. Infants of the mothers in this group will receive standard 400 IU of vitamin D
48380538|NCT05879315|OTHER|Fall risk prevention in hospital|All patients (hip and knee) upon admission to the Orthopedic Department of the DRS (Rizzoli Sicily Department), throughin the pre-operative setting will undergo an assessment of mobility level, dynamic stability and co-ordination: Test UP and GO, Il Four Square Step Test, Stabilometric Analysis. After admission to the DRS Rehabilitation Medicine Department, hip and knee will receive an evaluation, which is currently used, consisting of: History of fall risk through multidimensional assessment, Compilation of ICF(International Classification of Functioning, Disability and Health) and Barthel Index. The following ratings will also be added: Compiling the Morse scale, Pharmacological history, CIRS (Cumulative Illness Rating Scale)
48714678|NCT04178993|DRUG|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
48022422|NCT02744924|BEHAVIORAL|Physical activity intervention|"The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
48380539|NCT01301157|DRUG|M518101|Proper quantity twice a day
48380540|NCT01301157|DRUG|placebo|Proper quantity twice a day
48380541|NCT01301157|DRUG|Dovonex|Proper quantity twice a day
48380542|NCT00585468|DRUG|Myfortic|Myfortic 720 mg orally twice daily
48380551|NCT01852786|OTHER|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
48380552|NCT01852786|OTHER|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
48380553|NCT05263804|OTHER|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
48380554|NCT05263804|OTHER|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
48380555|NCT02569502|DRUG|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
48380556|NCT02435875|OTHER|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
48714679|NCT04178993|DRUG|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
48380557|NCT05333458|BIOLOGICAL|Atezolizumab|Given IV
48380558|NCT05333458|PROCEDURE|Biopsy|Undergo biopsy
48380559|NCT05333458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48714680|NCT05961176|DEVICE|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
48714681|NCT00376701|DRUG|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
48714682|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
48714683|NCT00376701|DRUG|Bevacizumab|Intravitreal 1.25 mg
48714684|NCT00376701|DRUG|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
48022423|NCT05718908|DIETARY_SUPPLEMENT|Food supplement|FibrofixPlus® is an authorized food supplement.
48022424|NCT02787616|GENETIC|buccal swab|cheek swab for DNA sampling
48380560|NCT05333458|PROCEDURE|Computed Tomography|Undergo CT
48380561|NCT05333458|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48380562|NCT05333458|DRUG|Selinexor|Given PO
48380563|NCT02454699|DRUG|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
48518323|NCT01750190|DRUG|Placebo|Oral tablets
48518324|NCT03817190|DRUG|DS107|DS107 Capsule
48180149|NCT04950062|OTHER|High Intensity Interval Training|"1. Warming up period for 5 min at an intensity corresponding to 65-75% of heart rate maximum (HRmax).~2. Training phase for 30 min divided into four sets of 4-min length each at intensity equals 80-90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.~3. Cooling down period for 5 min of at 50-60% of the HRmax. All subjects will be trained at the lower intensity limit for the first 2 weeks of the program before increasing the intensity levels toward the upper limit."
48380564|NCT02454699|OTHER|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
48380565|NCT01250691|OTHER|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
48380566|NCT06017362|DRUG|Insulin|Topical insulin 1UI/ml 4 times a day
48022425|NCT04871139|PROCEDURE|Biopsy|Undergo biopsy
48180150|NCT04950062|OTHER|Intermittent Fasting 16/8 Protocol|Every subject will be instructed to fast a fixed 16 hours followed by 8 hours of eating every day through the whole study period based on their life and sleeping style. During fasting, zero-calorie coffee, tea and water intake will be permitted. Beverages containing calories were consumed during the feeding hours each day. All subjects will be instructed about their optimum caloric requirement based on their basal metabolic rate that will be calculated in advance to avoid over consumption of food on severe caloric restriction as we like to investigate the effect of this way of fasting on reducing weight and improving functional capacity.
48380567|NCT06017362|DRUG|Artificial tear|Artificial tears 4 times a day
48380568|NCT05749549|DRUG|BR1733|Subjects will receive oral administration of BR1733.
48380569|NCT01959217|BEHAVIORAL|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
48380570|NCT05242406|OTHER|Expiratory muscle trainig|This exercise will be used to strengthen forced expiratory muscles.
48380571|NCT00251680|DRUG|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
48380572|NCT00251680|DRUG|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
48380573|NCT01778309|DIETARY_SUPPLEMENT|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
48518325|NCT03817190|DRUG|Placebo|Placebo capsule
48518326|NCT00173511|DEVICE|24 hr Holter monitor|
48180151|NCT03995342|DIETARY_SUPPLEMENT|Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
48714685|NCT01293643|DRUG|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
48714686|NCT01293643|DRUG|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
48180152|NCT03995342|DIETARY_SUPPLEMENT|Maltodextrin|Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
48714687|NCT04879394|OTHER|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
48714688|NCT00037674|DRUG|Topiramate|
48714689|NCT00272116|DRUG|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
48180153|NCT02716363|DEVICE|Rotational Atherectomy by Rotablator|
48180154|NCT04333732|DRUG|MR or M-M-R II ® vaccine|Education and surveillance plus MR or M-M-R II ® vaccine
48518327|NCT01126242|DEVICE|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
48714690|NCT00272116|DRUG|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
48714691|NCT03405935|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
48022426|NCT04871139|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
48022427|NCT04871139|OTHER|Questionnaire Administration|Ancillary studies
48022428|NCT04871139|OTHER|Radioactive Iodine|Given IV
48022429|NCT06228092|DRUG|neostigmine/glycopyrrolate|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
48022430|NCT06228092|DRUG|Sugammadex|Anesthesia personnel will administer the drug as a bolus over 5 seconds in an intravenous catheter upon conclusion of anaesthesia with a TOF within the range from TOF count of 2 to a TOF ratio \< 0.60
48180155|NCT04333732|DRUG|Placebo|Placebo injection
48180156|NCT01265043|OTHER|Oral hygiene intervention|Oral health promotion intervention
48380574|NCT05952154|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular end-diastolic volume and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries.
48380575|NCT03718559|DRUG|Edoxaban Monotherapy|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
48380576|NCT03718559|DRUG|Edoxaban plus Single Antiplatelet Agent|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
48518328|NCT01126242|DEVICE|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
48518329|NCT01126242|DEVICE|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
48518330|NCT01823367|BEHAVIORAL|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
48518331|NCT04970628|OTHER|Medical records collection|Patient's medical records before and after surgery.
48518332|NCT05593809|RADIATION|SPECT with pentavalent 99mTc DMSA|"A dose of 555-740 MBq 99mTc (V) DMSA is injected into a peripheral vein. Delayed brain SPECT/CT images will be obtained at 2-3 h after injection. Imaging will be performed on a hybrid dual head SPECT/CT machine (Symbia T, Siemens, Erlangen, Germany) fitted with a low energy high-resolution collimator, using 15% energy window set at 140 keV.~SPECT images are acquired in a noncircular 360° arc for a total of 64 frames, 25-s/frame, using a 128 × 128 matrix size. Following SPECT acquisition, low-dose CT is acquired for anatomical localization and attenuation correction. The used CT parameters are: tube voltage 130 kV, tube current 80 mA, and slice thickness 1 mm. Images will be reconstructed using manufacturer's iterative protocol (four iterations, four subsets, and Gaussian filter 8 mm). The reconstructed images will be reviewed on a viewing workstation running OsiriX MD version 6.5.2 (Pixmeo, Bernex, Switzerland)."
48714692|NCT00984815|DRUG|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
48714693|NCT02351687|DIETARY_SUPPLEMENT|Lipid Nutrient Supplement|
48022431|NCT03065387|DRUG|Everolimus|Given PO
48380577|NCT00137306|PROCEDURE|Facilitate evidence-based treatment for depression|
48380578|NCT02376582|BIOLOGICAL|DNA|DNA co-administered with protein at month 0, 1 and 6
48518333|NCT00309855|DRUG|Placebo|im and orally
48518334|NCT00309855|DRUG|Testosterone|injections
48518335|NCT00309855|DRUG|Anastrazole|orally x 21 days
48518336|NCT00309855|DRUG|Dutasteride|orally x 21 days
48518337|NCT05179109|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery for severe deep endometriosis
48518338|NCT02404480|DRUG|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
48714694|NCT02351687|DRUG|Sulfadoxine-pyrimethamine|
48714695|NCT02351687|DRUG|Albendazole|
48714696|NCT02351687|DRUG|Zinc|
48714697|NCT02351687|OTHER|Insecticide-treated bednet|
48714698|NCT05524610|BEHAVIORAL|Sexual Function Screening Approach|"The screening approach will consist of:~1. Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~2. An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site."
48022432|NCT03065387|DRUG|Neratinib|Given PO
48022433|NCT03065387|DRUG|Palbociclib|Given PO
48022434|NCT03065387|DRUG|Trametinib|Given PO
48022435|NCT05508334|DRUG|RC88|Every 2 weeks for a maximum of 2 years
48380579|NCT02376582|BIOLOGICAL|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
48380580|NCT04772456|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
48380581|NCT00467051|DRUG|Carboplatin|Given IV
48380582|NCT00467051|BIOLOGICAL|Filgrastim|Given IV or subcutaneously
48380583|NCT00467051|DRUG|Ifosfamide|Given IV
48380584|NCT00467051|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48380585|NCT00467051|DRUG|Paclitaxel|Given IV
48022436|NCT01038921|DRUG|Melatonin|8 mg dose of Melatonin
48022437|NCT01038921|DRUG|Placebo|Placebo
48022438|NCT01584284|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
48022439|NCT05971212|BEHAVIORAL|Behavioural sleep clinic access|Access to behavioural Sleep Clinic
48022440|NCT04204421|OTHER|Experience Sampling Method (ESM)|Experience Sampling Method (ESM) is a method for real time complaints assessment where people are asked to fill out a questionnaire 10 times per day at random moments. This will be done via a mobile phone application.
48022441|NCT00734526|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
48022442|NCT00734526|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
48180157|NCT06371586|DRUG|Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy|Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
48022443|NCT00734526|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
48022444|NCT01172938|DRUG|Apremilast 20mg|Apremilast 20 mg twice daily, orally
48022445|NCT01172938|DRUG|Apremilast 30mg|Apremilast 30 mg twice daily, orally
48180158|NCT01783158|PROCEDURE|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
48180159|NCT04695704|DRUG|Montelukast|10 mg oral montelukast once daily for 28 days
48180160|NCT04695704|OTHER|placebo|10 mg oral placebo once daily for 28 days
48518339|NCT04146012|DEVICE|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
48518340|NCT03027960|DRUG|Empagliflozin|10mg empagliflozin for a 2-week period
48714699|NCT05378932|OTHER|Actigraphy|Sleep efficiency recording at home by means of actigraphy during 10 consecutive days.
48180161|NCT05472103|BEHAVIORAL|ergonomics surgical workshop|ergonomics surgical workshop
48714700|NCT05378932|OTHER|Recording of proximal and distal skin temperature and temperature of the bedroom|"Recording of proximal and distal skin temperature at home by data loggers placed on the skin during 10 consecutive days.~Recording of temperature of the bedroom by a data logger during 10 consecutive days."
48714701|NCT05378932|OTHER|Questionnaires assessing subjective sleep quality|"One-off questionnaires assessing subjective sleep quality. The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality with questions about sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction during the last month.~The Epworth Sleepiness Scale evaluates daytime sleepiness and comprises 8 items (situations) during which individuals assess how likely they would fall asleep."
48714702|NCT05378932|OTHER|Sweat test|One-off measurement of sweating by a sweat test at the hospital.
48714703|NCT05378932|OTHER|Urine melatonin assay|Two urine melatonin at home during 24 hours, one during a week day and one during the weekend
48714704|NCT05378932|OTHER|Polysomnography|Sleep architecture assessed by a polysomnography during one night at home.
48714705|NCT05378932|OTHER|Standardized psychological and neuropsychological assessment|One-off psychological and neuropsychological assessment of patients with HED during a hospital visit
48714706|NCT01500369|OTHER|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
48714707|NCT01500369|OTHER|standard of care|Placebo Comparator
48714708|NCT05642143|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
48714709|NCT05642143|DIAGNOSTIC_TEST|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
48714710|NCT05642143|DIAGNOSTIC_TEST|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
48714711|NCT05642143|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
48714712|NCT05642143|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
48714713|NCT05642143|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
48714714|NCT05642143|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
48714715|NCT05642143|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
48714716|NCT05642143|DIAGNOSTIC_TEST|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
48714717|NCT05642143|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
48714718|NCT05642143|DIAGNOSTIC_TEST|Force plate platform|Evaluation of balance while standing still
48714719|NCT05642143|DIAGNOSTIC_TEST|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
48714720|NCT05642143|DIAGNOSTIC_TEST|Isometric leg extension strength|Evaluation of muscle strength
48380586|NCT00855634|PROCEDURE|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
48380587|NCT00855634|PROCEDURE|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
48714721|NCT05642143|DIAGNOSTIC_TEST|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
48714722|NCT06355115|DRUG|Cefazolin 1000 MG Injection|Cefazolin 1000 mg given intravenously
48714723|NCT05590000|DEVICE|Gemini SCS neuromodulation system|This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
48714724|NCT04888143|OTHER|questionnaires|evaluation of hearing performance and quality of life questionnaires
48380588|NCT01800812|BIOLOGICAL|Injections of OM-174|
48714725|NCT04888143|OTHER|Evolutionary algorithm|application of the evolutionary algorithm and customized frequency allocation on a separate program.
48518341|NCT03027960|DRUG|Placebo Oral Capsule|10 mg placebo for a 2-week period
48518342|NCT02812563|OTHER|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
48518343|NCT05217576|DEVICE|NBM-200|Finger Prick and Venipuncture
48518344|NCT00584454|BIOLOGICAL|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
48518345|NCT04810715|OTHER|Patients with Ankylosing Spondylitis|Observational study, not applicable
48518346|NCT04708223|DEVICE|Direct restorative treatment with fast-curing composites (Tetric PowerFill/ Tetric PowerFlow)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric PowerFill/ Tetric PowerFlow (test group) was cured for 3 s.
48714726|NCT05352269|BIOLOGICAL|XBI-302|Fecal Microbiota Transplantation Capsules
48714727|NCT05352269|BIOLOGICAL|XBI-302 Placebo|XBI-302 Placebo
48380589|NCT05917080|OTHER|Manual Therapy|"Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time."
48714728|NCT00755534|DRUG|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
48714729|NCT00755534|DRUG|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
48714730|NCT00755534|DRUG|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
48714731|NCT00755534|DRUG|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
48714732|NCT00571207|DEVICE|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
48022446|NCT01172938|DRUG|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
48022447|NCT01172938|DRUG|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
48022448|NCT04188041|OTHER|TB Infection ECHO|A six-month virtual telementoring course regarding TB infection testing and treatment that incorporates didactics, case presentation, and discussion
48180162|NCT02734186|DRUG|Praziquantel|Anthelminthic
48180163|NCT00126139|DRUG|Abciximab|
48714733|NCT00571207|BEHAVIORAL|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
48714734|NCT06126367|DIAGNOSTIC_TEST|Thrombotic assessment|"The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
48714735|NCT06126367|DIAGNOSTIC_TEST|Measurement of Lp(a)|"Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
48714736|NCT03283150|DRUG|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.
48714737|NCT03283150|DRUG|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
48714738|NCT03283150|DRUG|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
48714739|NCT03397992|OTHER|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
48380590|NCT02201732|PROCEDURE|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
48380591|NCT02201732|PROCEDURE|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
48380592|NCT04899219|DRUG|ACT-1014-6470 40 mg|ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
48714740|NCT05516849|DRUG|Oxandrolone|Oxandrolone is a synthetic anabolic androgenic steroid that induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis and efficient utilisation of amino acids. Oxandrolone was first synthesized in 1962 through 17alpha-alkylation of testosterone resulting in a formal composition of (4bS,7S,9aS,9bR,11aS)-tetradecahydro-7-hydroxy-4aS,6aS,7-trimethyl- cyclopentanaphthopyran-2(1H)-one and molecular formula of C19H30O3.
48714741|NCT05516849|OTHER|Placebo|As there is currently no approved medication to aid in soft-tissue regeneration, we will be using a placebo control.
48714742|NCT04462991|DIAGNOSTIC_TEST|corneal topography|In all patients, TCT will be measured first by WaveLight® Oculyzer™II Pentacam HR and second by The Optovue AS-OCT .
48714743|NCT02138240|BEHAVIORAL|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
48714744|NCT00137826|DRUG|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
48714745|NCT00137826|DRUG|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
48714746|NCT03041142|BEHAVIORAL|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
48714747|NCT03041142|OTHER|Routine|The participants continued to maintain their routine
48028881|NCT06246877|BEHAVIORAL|virtual reality applied group|"Before the K-wire is removed and dressed, the three-dimensional video that the child likes and wants to watch will be placed on virtual reality glasses and attached to the child.~During the procedure, the child will be allowed to watch videos through virtual reality glasses."
48380593|NCT06318494|OTHER|jumping performance|"Patients suffering from chronic ankle instability symptomatic of recurrent subjective and objective instability will be considered. Patients will be compared to a control group of healthy volunteer subjects.~T0 Explanation of the study and written informed consent.~* Verification of inclusion/exclusion criteria and verification of previous or ongoing treatments.~* AOFAS Rating Scales,~* Tegner activity level~* Vertical Jump Test (CMJ) by foot pedal"
48380594|NCT02220621|DEVICE|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
48380595|NCT02220621|DEVICE|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
48380596|NCT03334227|DEVICE|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 \> 92% and with, at least, 30 liters of total flow.
48380597|NCT04544748|BIOLOGICAL|GNR-051|Anti-PD1 monoclonal antibody
48380598|NCT02760849|OTHER|Laboratory Biomarker Analysis|Correlative studies
48380599|NCT02760849|PROCEDURE|Oophorectomy|Undergo ISDO
48380600|NCT02760849|OTHER|Quality-of-Life Assessment|Ancillary studies
48380601|NCT02760849|PROCEDURE|Salpingectomy|Undergo ISDO
48380602|NCT02760849|PROCEDURE|Salpingo-Oophorectomy|Undergo RRSO
48380603|NCT05966155|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
48380604|NCT05966155|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
48380605|NCT05542212|DEVICE|Transcranial Magenetic Stimulation|Intermittent Theta Burst Stimulation (iTBS) treatment plan: iTBS treatment for the left dlPFC were used for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
48380606|NCT05542212|DEVICE|Sham Transcranial Magenetic Stimulation|Sham stimulation: The coil angle is set at 90° to the scalp for Sham stimulation of the left dlPFC for a total of 20 treatments (one time each Monday to Friday, continuous treatment for 4 weeks).
48380607|NCT02284880|DRUG|BIA 2-093|MF - Marketed formulation
48380608|NCT02284880|DRUG|BIA 2-093|TBM - to-be-marketed
48380609|NCT05159713|BEHAVIORAL|dCBI|"The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation."
48518347|NCT04708223|DEVICE|Direct restorative treatment with conventionally applied composites (Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill)|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored. Adhese Universal in self-etch mode, was used to prepare the surfaces for the composite fillings. Tetric EvoCeram Bulk Fill/ Tetric EvoFlow Bulk Fill (control group) were conventionally cured for 10 s per increment.
48714748|NCT01504581|BIOLOGICAL|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
48714749|NCT01504581|BIOLOGICAL|HM10660A placebo|Single dose of HM10660A Placebo
48714750|NCT01504581|BIOLOGICAL|Pegasys|Single dose of Pegasys 180ug
48714751|NCT01862341|DIETARY_SUPPLEMENT|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
48714752|NCT01702740|DRUG|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
48714753|NCT01702740|DRUG|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
48714754|NCT01702740|DRUG|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
48714755|NCT01702740|DRUG|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
48028882|NCT00254982|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
48714756|NCT01697150|DEVICE|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
48380610|NCT05159713|BEHAVIORAL|Treatment as Usual|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
48380611|NCT00561600|DEVICE|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
48714757|NCT04126889|OTHER|questionnaire survey|questionnaire survey
48714758|NCT02144155|DRUG|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
48714759|NCT02144155|DRUG|Placebo|placebo drug
48180164|NCT01083199|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
48380612|NCT00561600|DEVICE|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
48380613|NCT06651034|OTHER|Platelet Rich Plasma|Under aseptic measures, a phlebotomist obtained the blood in vacutainers. Vacutainers was centrifuged and middle zone containing platelet rich plasma was aspirated in a 5 ml disposable syringe. The patient received intralesional injection
48380614|NCT06650631|DEVICE|Knee Heatwraps|To treat the painful knee joint in patients with osteoarthritis without acute flares or inflammation. The investigational device will be used in accordance with the Instructions for Use.
48380617|NCT01819012|DRUG|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
48380618|NCT01819012|DRUG|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
48380619|NCT01819012|DRUG|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
48380620|NCT02103985|DRUG|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
48380621|NCT05725642|OTHER|Polysomnography|Polysomnography
48380622|NCT06491433|DEVICE|H2-BP|"The patient will have the test device applied to one wrist to measure blood pressure and the control device applied to the upper arm of the same arm to measure blood pressure.~1. H2-BP: The test device is placed on the wrist and presses a button to start pressurising. When the measurement is complete, the systolic and diastolic blood pressure is displayed on the screen.~2. big ben® Sphygmomanometer: The cuff is placed on the upper arm and the pump is pressed manually to inflate. 2 measurers will measure systolic and diastolic blood pressure by connecting 2 stethoscopes separately to one cuff.~Due to the external nature of the study medical device, it is not possible to blind subjects and investigators, so that subjects and measurers are aware of the allocation. Therefore, blinding of subjects and measurers will not be used in this study."
48380623|NCT02288234|DRUG|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
48380624|NCT03733301|DRUG|Baricitinib|Administered orally.
48714760|NCT06169800|DEVICE|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
48714761|NCT00866671|DRUG|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
48714762|NCT03605069|DRUG|QR-313|QR-313 will be applied topically once daily for 8 weeks of treatment.
48714763|NCT03605069|DRUG|Placebo|Placebo will be applied topically once daily for 8 weeks of treatment.
48380625|NCT03733301|DRUG|Topical corticosteroid|Administered as standard-of-care.
48380626|NCT03733301|DRUG|Placebo|Administered orally.
48380627|NCT03330275|DEVICE|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
48380628|NCT03330275|DEVICE|Commercial ACUVUE OASYS|senofilcon A
48180165|NCT02375451|OTHER|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
48380629|NCT03330275|DEVICE|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
48380630|NCT05813730|OTHER|urinary creatinine excretion measurement|Urine samples will be collected up to 6 times a day from birth until discharge from the maternity hospital, to analyze the kinetics of creatinuria.
48380631|NCT01146340|RADIATION|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
48714764|NCT06234436|BIOLOGICAL|Plasma exchenge|Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
48022449|NCT04689386|OTHER|"Group I (GE-I) - Stimulation of reflex rolling from the Vojta method"|"This manoeuvre does not require the newborn to be moved, but only a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface.~A digital pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. A one minute stimulus will be performed on each side. The intervention will be repeated twice a day, ensuring that the period between one intervention and another is at least two hours."
48022450|NCT04689386|OTHER|Group II (GE-II) - expiratory flow increase technique|The technique adapted to the premature infant will be performed. This maneuver consists of slowly applying light pressure to the infant's chest with one hand, obliquely, starting from the end of the inspiratory plateau until the end of expiration, which is prolonged. The hand should be placed between the sternal notch and the xiphoid process of the newborn's sternum. The therapist's other hand is placed on the last ribs (without applying pressure) as a bridge, of which the columns are the thumb and forefinger (or middle finger). Therefore, contact with the infant's abdomen is avoided and the expansion of the lower rib is limited, allowing a better displacement of the diaphragm and avoiding an increase in intra-abdominal pressure. The maneuver will be repeated three times, respecting the infant's responses and their physiological constants. The intervention will be repeated twice a day, trying to ensure that the period between one intervention and another is at least 2 hours.
48380632|NCT06145399|DIAGNOSTIC_TEST|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
48380633|NCT06145399|DIAGNOSTIC_TEST|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
48518348|NCT04051346|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
48518349|NCT04051346|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
48518350|NCT06551883|PROCEDURE|different bowel preparation regime|Patients in Group B receive the 3L of PEG in a single dose
48518351|NCT06551883|PROCEDURE|traditional bowel preparation regime|Patients in Group A receive the 3L of PEG in a split dose
48518352|NCT01574690|DEVICE|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
48518353|NCT01574690|PROCEDURE|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
48518354|NCT01574690|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
48518355|NCT03908437|DRUG|buprenorphine/naloxone|"A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs"
48518356|NCT02191293|DRUG|Viramune® tablets|
48714765|NCT00810901|BEHAVIORAL|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
48714766|NCT00810901|BEHAVIORAL|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
48714767|NCT05740917|DRUG|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
48714768|NCT00699218|DEVICE|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
48714769|NCT05075395|DEVICE|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
48714770|NCT04378400|PROCEDURE|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
48380634|NCT06145399|DRUG|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
48714771|NCT05497258|DEVICE|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
48714772|NCT02772796|DRUG|SENS-218|Oral Administration
48380635|NCT05686928|DRUG|Cetaphil Healing Ointment|Topical ointment application twice daily
48518357|NCT03676218|OTHER|Elderly cancer patients|No intervention: consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
48518358|NCT02006732|DRUG|olodaterol|fixed dose combination
48518359|NCT02006732|DRUG|tiotropium|fixed dose combination
48518360|NCT02006732|DRUG|placebo|
48714773|NCT05666232|DIAGNOSTIC_TEST|renal resistive index and myocardial performance index|"Transthoracic echocardiography and transabdominal ultrasonography will be performed before induction of anesthesia, after termination of operation and before transmission to ICU and then daily for the early seven postoperative days.~RRI = (peak systolic velocity - end diastolic velocity) ∕ peak systolic velocity: Then, we will obtain the mean RRI from the above three measurements.~We will consider RRI ≥0.7 as abnormal and define it as subclinical AKI.~Myocardial performance index (using tissue doppler) =~(isovolumetric contraction time + isovolumetric relaxation time) / ejection time. We will consider MPI ≥0.4 as abnormal and define it as subclinical LV dysfunction."
48714774|NCT03354832|OTHER|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
48714775|NCT03354832|OTHER|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
48022451|NCT05279261|PROCEDURE|The axillary approach|The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
48714776|NCT03354832|OTHER|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
48022452|NCT04049526|BEHAVIORAL|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
48022453|NCT03103529|OTHER|Active Rehabilitation|
48022454|NCT01764334|DEVICE|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
48022455|NCT01394861|DEVICE|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
48022456|NCT03173196|DEVICE|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
48022457|NCT00803894|DRUG|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
48380636|NCT01406327|DRUG|Ambrisentan|Ambrisentan
48714777|NCT03354832|OTHER|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
48714778|NCT01591863|DRUG|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
48714779|NCT02958306|BIOLOGICAL|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
48714780|NCT04494724|DRUG|Clazakizumab|Infusion
48714781|NCT04494724|DRUG|Placebo|Infusion
48714782|NCT06508138|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus|"About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization"
48714783|NCT00084175|BEHAVIORAL|Behavior Therapy|
48022458|NCT00803894|DRUG|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
48022459|NCT00803894|DRUG|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
48022460|NCT00519805|DRUG|dalteparin|
48714784|NCT00973102|DRUG|Premarin IV|One time dose of Premarin IV
48714785|NCT00973102|DRUG|Placebo|One time dose of placebo.
48380637|NCT06641245|DIETARY_SUPPLEMENT|Folic Acid|folic acid (0.6 mg)
48022461|NCT00519805|PROCEDURE|quality-of-life assessment|
48022462|NCT03268811|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
48022463|NCT04334603|OTHER|Exercise Training Program|The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
48022464|NCT04292301|DEVICE|STrategically Acquired Gradient Echo (STAGE)|The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
48022465|NCT05905965|DRUG|Empagliflozin 20 mg|Patients receiving empagliflozin 20 mg daily - experimental arm
48028883|NCT00905580|DRUG|Pregabalin|Pregabalin 150 mg orally
48380638|NCT06641245|DIETARY_SUPPLEMENT|5-MTHF (5-methyltetrahydrofolate)|0.625 mg/d (6S)-5-MTHF
48380639|NCT03632057|DEVICE|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
48714786|NCT04118569|BEHAVIORAL|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
48022466|NCT05905965|DRUG|Empagliflozin 10 mg|Patients receiving empagliflozin 10 mg daily - control arm
48022467|NCT01418300|DRUG|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
48518361|NCT05880511|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
48518362|NCT05880511|DEVICE|Augmented Reality Sensorimotor Training|Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
48518363|NCT05880511|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
48518364|NCT06046898|DEVICE|non-invasive ventilation with or without resistance|non-invasive ventilation with or without resistance.
48518365|NCT06221826|DRUG|Mexidol|Neurocytoprotector
48518366|NCT00550459|DRUG|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
48518367|NCT00550459|DRUG|Placebo|Placebo tablet given once daily for 21 days
48518368|NCT01340131|DRUG|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
48518369|NCT01340131|DRUG|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
48518370|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with ALL plasty|ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).
48518371|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with modified Lemaire's LET|ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
48518372|NCT02054052|DRUG|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
48518373|NCT01424007|BEHAVIORAL|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
48714787|NCT01573637|DRUG|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
48714788|NCT01573637|DRUG|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
48714789|NCT00700583|DRUG|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
48714790|NCT02990195|OTHER|Chyme reinfusion|
48022468|NCT01229228|DRUG|Naproxen Test|200-mg single dose
48022469|NCT01229228|DRUG|Naproxen Test|400-mg (2 x 200-mg)
48022470|NCT01229228|DRUG|Naprosyn|single dose
48022471|NCT01229228|DRUG|Naprosyn|single dose
48022472|NCT01229228|DRUG|Placebo|single dose
48022473|NCT03737214|DRUG|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
48022474|NCT00208208|DRUG|Ziprasidone|
48380640|NCT03632057|DEVICE|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
48518374|NCT03209843|PROCEDURE|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
48714791|NCT01995955|PROCEDURE|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
48714792|NCT00601913|DRUG|erlotinib hydrochloride|
48714793|NCT00601913|GENETIC|protein analysis|
48714794|NCT00601913|GENETIC|western blotting|
48022475|NCT05093452|BEHAVIORAL|Motivational Interviewing|Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a midwife. The midwife will have first received a standardized 3 days training session on the content and techniques of MI. The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
48022476|NCT05093452|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the midwife.
48028884|NCT00905580|DRUG|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
48380641|NCT06649786|PROCEDURE|Endoscopic superior rectal mucosal ligation|The patient takes the left side decubitus position, the endoscope is connected with 6 serial ligators, the cup of the sleeve is pointed at the upper edge of the straight anal line and the rectal mucosa is continuously aspirated under negative pressure. The mucosa enters the sleeve and sees a full-screen red sign. The sensing loop is successfully triggered, indicating that the loop is complete.
48518375|NCT04648787|BEHAVIORAL|family-integrated care|One week after admission, the parents of premature infants were informed by telephone one day in advance to enter the ward for family participation nursing, and the guidance of daily life nursing for premature infants was given on the same day, including hand hygiene, breast feeding, pacification, changing diapers, bathing and establishment of parent-child relationship. Before discharge, theparents of premature infants should be informed by telephone one day in advance to enter the ward again for family participation nursing, and half a day's guidance was given, including observation and treatment of common symptoms and signs, guidance of home safety prevention and learning to write diary of premature infants.
48518376|NCT04648787|BEHAVIORAL|traditional nursing|In hospital education: the health education manual for premature infants will be issued at the time of discharge; the patient's condition will be answered by telephone from 14:00 to 16:00 every day.
48714795|NCT00601913|OTHER|immunohistochemistry staining method|
48714796|NCT00601913|OTHER|laboratory biomarker analysis|
48714797|NCT00601913|OTHER|liquid chromatography|
48714798|NCT00601913|OTHER|mass spectrometry|
48028885|NCT06334770|DEVICE|Roxolid implants|four Straumann BLX® roxolid implant 15% zirconium and 85% titanium), 3.7 mm in diameter, and 10 mm in length.implants were selected with the following criteria: tapered, self-tapping, aggressively threaded,were inserted with novalock attachments.
48714799|NCT00601913|PROCEDURE|neoadjuvant therapy|
48714800|NCT00601913|PROCEDURE|therapeutic conventional surgery|
48714801|NCT03286777|DIETARY_SUPPLEMENT|Placebo|Mannitol and silicon dioxide capsules
48714802|NCT03286777|DIETARY_SUPPLEMENT|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
48714803|NCT03286777|DIETARY_SUPPLEMENT|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
48714804|NCT05286372|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
48714805|NCT02020772|OTHER|coordinating primary health care|
48714806|NCT02020772|OTHER|usual primary health care|
48714807|NCT05825144|DEVICE|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
48714808|NCT05825144|OTHER|Conventional rehabilitation|Regular post-stroke rehabilitation
48714809|NCT01615055|DRUG|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
48714810|NCT01615055|OTHER|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
48028886|NCT06334770|DEVICE|Titanium implants|four conventional acid etched pure implants tapered, self-tapping, threaded, two-piece, with the 10 mm length and 3.7 mm diameter were inserted with Sphero flex attachments.
48028887|NCT00214877|DRUG|Methylene Blue|
48028888|NCT04365946|PROCEDURE|Gastroscopy|Upper GI endoscopy and biopsy
48380642|NCT06649786|PROCEDURE|Endoscopic hemorrhoid ligation|The patient takes the left side decubitus position,the endoscope is connected with 6 serial ligators,the cup the sleeve is aligned with the base of the hemorrhoid (above the dentate line) for continuous negative pressure suction.The hemorrhoid enters the sleeve and sees a full-screen red sign. Turn the handle of the sleeve clockwise and feel that the loop is successfully triggered, the ligature is completed.
48714811|NCT05492760|DEVICE|cryoballoon ablation|Patients with AF will accept cryoballoon ablation.
48518377|NCT04198194|DIAGNOSTIC_TEST|Predictors of events|Apple Heart \& Movement Study in Apple Research app
48518378|NCT02012270|PROCEDURE|PRINCIPLES technique|"Principles technique for closure of midline laparotomy incisions~* closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~* the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~* the SL/WL ratio should be at least 4/1~* SL/WL = (150cm x number of sutures used) - (the suture remnants)~* the mean stitch length should be less than 4 cm (suture length / number of stitches placed)"
48518379|NCT02012270|PROCEDURE|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
48380643|NCT04461912|DEVICE|Eye Scan Ultrasound System (ESUS)|"• For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved."
48380644|NCT06354127|DRUG|DWP450|The test drug or control drug is injected on the day of administration.
48380645|NCT06354127|DRUG|Botox®|The test drug or control drug is injected on the day of administration.
48380646|NCT00998231|BIOLOGICAL|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
48380647|NCT03448380|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
48380648|NCT01457690|DRUG|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
48380649|NCT01457690|DRUG|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
48380650|NCT01457690|DRUG|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
48380651|NCT05458791|DEVICE|Intra-arterial Perfusion|All patients will undergo standard of care locoregional intra-arterial (IA) treatment for HCC. The procedure will take place utilizing fluoroscopic and CT guidance. Following catheterization of the femoral or radial artery, CT angiography of the hepatic circulation will be performed to define the hepatic vascular anatomy. Intra-arterial CT perfusion will be performed prior to IA treatment by the interventional radiologist to understand the dynamics of hepatic circulation or to manage the IA treatment strategy.
48518380|NCT03495375|DIETARY_SUPPLEMENT|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
48518381|NCT03495375|OTHER|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
48518382|NCT01195610|BEHAVIORAL|Dietary intervention|Instruction to diet for 6 month
48380652|NCT03545568|OTHER|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
48380653|NCT04626635|DRUG|REGN7075|Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
48380654|NCT04626635|DRUG|cemiplimab|administered concomitantly Q3W by IV infusion or SC injection
48518383|NCT01907230|DRUG|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
48518384|NCT05810103|DRUG|DP303c|DP303c injection, 3.0 mg/kg, every 3 weeks.
48518385|NCT05974852|OTHER|Ocrelizumab|Non-interventional
48380655|NCT04626635|DRUG|Platinum-based doublet chemotherapy|administered IV Q3W
48380656|NCT05692570|DRUG|PBI-200 Tablet|PBI-200 is a TRK inhibitor
48380657|NCT05692570|DRUG|Ritonavir Oral Tablet|Ritonavir is a potent CYP3A inhibitor
48380658|NCT05692570|DRUG|Cobicistat Oral Tablet|Cobicistat is a potent CYP3A inhibitor
48380659|NCT06649370|DRUG|Hypotensive Drugs and/or Vasoactive Drugs|If the patients' mean arterial pressure falls below 60 mmHg or 20% below the preoperative value, ephedrine will be administered.
48380660|NCT04401995|DRUG|Vidutolimod (CMP-001)|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
48380661|NCT04401995|BIOLOGICAL|Nivolumab|a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
48380662|NCT04401995|OTHER|[18F]F-AraG PET/CT|\[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
48380663|NCT03209154|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
48380664|NCT03209154|DEVICE|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
48380665|NCT02261558|OTHER|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
48380666|NCT02261558|OTHER|Clinical Vocal Improvisation|\* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
48380667|NCT05002738|DRUG|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
48380668|NCT02253849|DRUG|Carbamazepine|
48380669|NCT02253849|DRUG|Tipranavir|
48380670|NCT02253849|DRUG|Ritonavir|
48518386|NCT06170216|DRUG|immunochemotherapies|Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
48518387|NCT02952586|DRUG|Avelumab|Avelumab + SOC Chemoradiation
48518388|NCT02952586|OTHER|Chemoradiation|Cisplatin + Radiation Therapy
48380671|NCT03762642|PROCEDURE|Mastectomy|Removal of the whole breast
48380672|NCT03762642|PROCEDURE|Breast-Conserving Surgery|Removal of the cancerous tissue only
48380673|NCT03514446|DRUG|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
48380674|NCT01605539|DRUG|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
48380675|NCT01605539|DRUG|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
48380676|NCT01605539|DRUG|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
48380677|NCT06649916|BEHAVIORAL|Parentese Speech|Novel words are introduced in parentese, a type of speech that is typically characterized by greater pitch variation, longer duration, and louder volume
48380678|NCT06649916|BEHAVIORAL|Adult Registered Speech|Novel words are introduced in standard adult register.
48380679|NCT01686607|DRUG|Parenteral micafungin application|Parenteral
48380680|NCT01686607|DRUG|Other parenteral antifungal drugs|Parenteral
48380681|NCT06650904|OTHER|simulation based training|Simulation practice enables the acquisition of realistic skills. Semi-structured scenarios used in the training allow nurses to demonstrate their real communication skills.
48518389|NCT00843661|DRUG|ezetimibe|10 mg ezetimibe/day
48380682|NCT05798325|OTHER|2MWT|Two minutes walk tests.
48380683|NCT05798325|OTHER|MFM32|Motor Function Measurement (MFM) is a quantitative scale created to measure global motor functional abilities in a person with neuromuscular disease.
48380684|NCT05798325|OTHER|MyoGrip|The MyoGrip is a dynamometer for measuring grip strength.
48518390|NCT00843661|DRUG|fenofibrate|200 mg fenofibrate/day
48518391|NCT00843661|DRUG|pravastatin|40 mg pravastatin/day
48518392|NCT06022068|DRUG|Sirolimus|7 mg taken once per week during 26 weeks.
48518393|NCT04099004|OTHER|Neural Imaging|During the acquisition of magnetic resonance (MR) images, the study participants will lie on the scanner table. For most portions of MR acquisition, the study participants will be instructed to lie still. For other parts of the acquisition, study participants will be asked to complete a combined knee and hip flexion/extension movement and a quadriceps contraction task in which they will be asked to 'squeeze' their quadriceps while keeping the rest of their body still. For the last 15 minutes of MR acquisition, the researcher will place one hand above the participants' knee and apply intermittent pressure to their quadriceps and medial aspect of the patella. Pain scales will be administered after every fMRI task to assess subjective perceptions of pain. Peripheral pulse oximetry and respiration waveforms will be collected for data analysis in order to minimize the potential confounding effect from the physiological changes.
48518394|NCT01757275|DRUG|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
48518395|NCT01757275|DRUG|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
48518396|NCT01757275|DRUG|Esomeprazole Mg|40 mg tablet once daily for 27 days
48714812|NCT02144987|BIOLOGICAL|Bone Marrow CD133+ Stem Cell Transplantation|"1. Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~2. BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~   The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~3. CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~4. Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~5. Hysteroscopy will be performed 2-3 months after stem cell transplantation~6. Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
48714813|NCT00307567|BIOLOGICAL|Pneumococcal (vaccine)|
48714814|NCT00619346|DRUG|Placebo|Placebo tablets, BID X 14 days
48714815|NCT00619346|DRUG|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
48714816|NCT01831440|BEHAVIORAL|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
48714817|NCT01831440|DRUG|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
48714818|NCT03361904|PROCEDURE|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
48380685|NCT05798325|OTHER|QOL-gNMD|"The Quality of Life in genetic Neuromuscular Disease questionnaire (QoL-gNMD) is a patient reported outcome measure (PROM) tool specifically designed for patients with a lowly progressive neuromuscular disease with genetically predominant muscular damage"
48518397|NCT02797171|BIOLOGICAL|VRC01|Administered by intravenous (IV) infusion
48518398|NCT02797171|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
48714819|NCT04545047|BIOLOGICAL|COVID-19 convalescent plasma|Convalescent plasma collected from individuals who have recovered from COVID-19
48714820|NCT02330523|DEVICE|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
48380686|NCT05798325|DIAGNOSTIC_TEST|Spirometry|Forced vital capacity (FVC), peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV1) will be measured in the hospital with the local hospital device (e.g. Vitalograph) under the supervision of the clinical evaluator, and at home with a portable device.
48518399|NCT02309307|DEVICE|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
48380687|NCT05798325|DEVICE|Acceleromerty|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
48518400|NCT06068556|BIOLOGICAL|GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition|Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.
48028889|NCT00620308|DRUG|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
48714821|NCT02330523|DEVICE|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
48714822|NCT03634371|DRUG|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
48714823|NCT03634371|DRUG|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
48714824|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
48714825|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
48714826|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
48714827|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
48714828|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
48714829|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
48714830|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
48714831|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
48714832|NCT04095689|DRUG|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
48022477|NCT03360500|OTHER|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
48380688|NCT05798325|OTHER|10mWT|10 meters walking Test.
48380689|NCT05798325|OTHER|PUL|The Performance of the Upper Limb (PUL) is a functional scale specifically designed for assessing upper limb function in Duchenne muscular dystrophy.
48518401|NCT06582966|DRUG|Doxycyclin|Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.
48028890|NCT00620308|DRUG|Placebo|Dextrose 5% in water (the vehicle)
48380690|NCT05798325|OTHER|NSAA|The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy.
48380691|NCT05798325|OTHER|NSAD|The NSAD was developed to measure motor performance in ambulant and non-ambulant subjects as part of the clinical outcome study of dysferlinopathy.
48518402|NCT02252354|DRUG|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
48518403|NCT02252354|DRUG|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
48028891|NCT03906370|DIAGNOSTIC_TEST|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
48518404|NCT02252354|DRUG|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
48714833|NCT04095689|DRUG|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
48714834|NCT04095689|DRUG|IL-12 gene therapy|Adenoviral-mediated IL-12
48714835|NCT01023386|DRUG|YM155|I.V.
48714836|NCT01463111|DRUG|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
48714837|NCT01463111|DRUG|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
48714838|NCT01463111|DRUG|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
48714839|NCT05853315|PROCEDURE|Surgery|Surgical Excision
48714840|NCT00764257|DEVICE|PREVELLE Shape|
48380692|NCT05798325|OTHER|TANS|This scale is derived from the North Star Ambulatory Assessment and several items from the Egan Klassifikation Scale (EK2).
48380693|NCT05798325|OTHER|MyoPinch|The MyoPinch is a high-precision dynamometer that allows the evaluation of key pinch strength.
48380694|NCT05798325|OTHER|MyoQuad|The MyoQuad is a high-precision dynamometer that allows the evaluation of knee extension strength.
48518405|NCT03551821|DRUG|ATI-50002|Topical Solution
48518406|NCT03156504|DRUG|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
48518407|NCT04594824|OTHER|No Intervention|no intervention
48714841|NCT00764257|DEVICE|Restylane|
48714842|NCT06520631|OTHER|Ice packs (cryotherapy)|"One group of patients receives ice pack applied on the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis.~The second group of patients receives ice pack applied on contralateral to the site of the cannulation, for 20 sessions (3 sessions per week) it introduced for 5-10 minutes before the beginning of the dialysis."
48714843|NCT01063842|DRUG|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
48714844|NCT01063842|DRUG|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
48714845|NCT03205852|OTHER|questionnaire|fulfillment of questionnaire
48714846|NCT02830607|DEVICE|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
48714847|NCT02211118|DRUG|Intranasal dexemdetomidine (IN-DEX)|
48714848|NCT00442091|DRUG|dandelion juice|10 ml bid for 20-30 days
48714849|NCT02485925|DEVICE|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
48380695|NCT05798325|OTHER|ACTIVLIM|Activity limitations, as measured by ACTIVLIM, is defined as the difficulties a patient may have in executing daily activities, whatever the strategies involved.
48380696|NCT05798325|OTHER|PREM|This questionnaire is made up of simple questions relating to the assessments and assessment tools that were used during the study.
48380697|NCT05798325|OTHER|SF-MPQ|The main component of the SF-MPQ consists of 15 descriptors (11 sensories; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe.
48380698|NCT05798325|OTHER|FSS|The Fatigue Severity Scale is used to assess the severity of fatigue and its impact on daily living. The patient responds on a Likert-type scale ranging from 1 to 7.
48380699|NCT05798325|OTHER|IPAQ|This questionnaire assesses overall physical activity and the level of sedentary lifestyle during the last seven days.
48380700|NCT05798325|OTHER|Rang of motion|The EasyAngle® is a digital goniometer improving long established goniometric functionality with rotation, inclination, and scoliosis measurement capabilities.
48380701|NCT05798325|DEVICE|Goniometry|The Links sensor system is a measuring device and consists of the Links Pods and the Links Hub. The Links pods contain an accelerometer, gyroscope and magnetometer to measure position relative to a global reference frame.
48380702|NCT05798325|OTHER|Video captured monitoring|"Once every four weeks, while wearing the Yumen electronic goniometers (Links Sensor System), the patients will be asked to record on video three tasks related to:~1. Upper limbs: hands to head~2. Lower limbs: Sit to stand with or without the help of a person~3. Self-defined important task: A task of the patient's choice, from a list of tasks, representative of his/her motor difficulties or hindrance to autonomy."
48380703|NCT05798325|DEVICE|Activity monitoring|Wearable devices (connected watch) will collect health-related data on a 24/7 basis remotely as patients go through their daily routines at home and work.
48380704|NCT06650007|DRUG|HRS9531 Injection|HRS9531 Injection
48380705|NCT06650007|DRUG|HRS9531 Placebo Injection|HRS9531 Placebo Injection
48380706|NCT04756167|OTHER|Conventional Treatment|Hotpack, TENS, ultrasound and exercise
48380707|NCT04756167|OTHER|Myofascial Release Treatment|Hotpack, TENS, ultrasound, exercise and myofascial release therapy for subscapularis and serratus anterior muscles
48380708|NCT00727675|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
48380709|NCT01300741|DEVICE|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
48714850|NCT01509677|DRUG|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
48714851|NCT01509677|DRUG|Placebo|tablet, once daily, oral administration in the morning after breakfast
48714852|NCT05748704|OTHER|Short-term modified fasting|STMF regimen consists of a low-calorie diet aimed at providing 800-1,000 kcal/day, lasting five days and with the following composition: 10% carbohydrates, 15% proteins, 75% lipids. During the days of STMF, patients will be required to write down the foods consumed in a food diary in order to calculate calorie and nutrients intake. The STMF regimen will be administered tentatively on a monthly basis (depending on the therapeutic regimen the patient undergoes) and in any case no more frequently than once every three weeks.
48022478|NCT03360500|OTHER|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
48028892|NCT00274534|DRUG|Tiotropium|
48380710|NCT01300741|DEVICE|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
48380711|NCT01300741|DEVICE|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
48380712|NCT06207045|PROCEDURE|limb elevation|limb elevation more than 45 degrees
48380713|NCT01587807|DRUG|GSK1995057|inhaled dose (volume based on cohort)
48380714|NCT01587807|PROCEDURE|bronchoalveolar lavage|BAL
48380715|NCT01587807|DRUG|LPS|50 μg
48380716|NCT01587807|DRUG|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
48380717|NCT05245292|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30 mg/kg
48714853|NCT02242175|DEVICE|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
48714854|NCT00534508|DRUG|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
48380718|NCT05245292|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 10 mg/kg
48380719|NCT05245292|DRUG|N803|Subcutaneous injections of N803 at 6 mcg/kg
48380720|NCT03599882|DEVICE|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
48380721|NCT03155269|DIETARY_SUPPLEMENT|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
48518408|NCT05146830|OTHER|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
48028893|NCT00274534|DRUG|Salmeterol|
48028894|NCT03049046|DRUG|CC100|synthetic caffeic acid phenethylester
48518409|NCT03525886|DRUG|NBI-74788|Capsule, administered daily.
48518410|NCT00314210|DRUG|Quetiapine SR|
48518411|NCT04063215|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
48714855|NCT03378648|DRUG|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
48714856|NCT03378648|DRUG|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
48714857|NCT03378648|DRUG|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
48714858|NCT02674282|PROCEDURE|ACL reconstruction|ACL reconstruction with hamstrings autograft.
48714859|NCT02262104|BEHAVIORAL|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
48028895|NCT03049046|DRUG|Placebos|Diluent
48028896|NCT06259968|DEVICE|Neuromuscular electrical stimulation|Patients in the neuromuscular electrical stimulation group will receive neuromuscular electrical stimulation without the concomitant execution of voluntary quadriceps contraction
48028897|NCT06259968|DEVICE|Neuromuscular electrical stimulation with superimposed voluntary contraction|Patients will be instructed to perform maximum voluntary contractions superimposed on neuromuscular electrical stimulation
48028898|NCT02837744|DEVICE|Axiostat®|Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
48028899|NCT01934218|DEVICE|Gel-One|
48028900|NCT01934218|DEVICE|PBS|
48028901|NCT01244152|BEHAVIORAL|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
48028902|NCT01244152|BEHAVIORAL|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
48714860|NCT02262104|BEHAVIORAL|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
48714861|NCT05840107|BIOLOGICAL|GC012F injection|GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously
48714862|NCT02403895|DRUG|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
48714863|NCT02403895|DRUG|paclitaxel|Taxane
48022479|NCT03360500|OTHER|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
48022480|NCT01807130|OTHER|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
48380722|NCT03155269|DIETARY_SUPPLEMENT|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
48380723|NCT06647862|DRUG|IMM01|IV infusion
48380724|NCT06647862|DRUG|Azacitidine|subcutaneous injection
48380725|NCT06647862|DRUG|Placebo|IV infusion
48714864|NCT05154760|OTHER|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
48714865|NCT05281094|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
48714866|NCT05281094|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
48714867|NCT05661305|OTHER|Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.|Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
48714868|NCT02773771|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive \>3g of HMB/ day.
48180166|NCT02264262|OTHER|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
48180167|NCT00375622|DRUG|Tamoxifen|
48180168|NCT05979428|DRUG|NNC0491-6075|NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
48380726|NCT05694026|DEVICE|Intense pulsed light|IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
48380727|NCT05694026|DRUG|Diquafosol tetrasodium|3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in dry eye signs and symptoms
48380728|NCT05213065|OTHER|Sphenopalatine ganglion block with 0.5% bupivacaine|Repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device.
48380729|NCT05213065|OTHER|Sphenopalatine ganglion block with saline|Repetitive SPG blockade using saline delivered with the Tx360® device.
48380730|NCT04692974|DEVICE|Mobile phone application and smart watch|Mobile phone application prompts
48714869|NCT02773771|DIETARY_SUPPLEMENT|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
48714870|NCT02773771|DIETARY_SUPPLEMENT|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
48714871|NCT04523350|DEVICE|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
48714872|NCT04523350|OTHER|TAE or cTACE|Bland TAE or cTACE
48714873|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of normal protein liquid diet supplementation|group 1 (control group) who will get a hospital formula of normal protein liquid diet supplementation (40 grams per 1000 mL)
48714874|NCT04911712|DIETARY_SUPPLEMENT|a hospital formula of high protein liquid food supplementation|group 2 (intervention group) will get a hospital formula of high protein liquid food supplementation (60 grams per 1000 mL) as much as 2 bottles (each bottle contains 200 mL)
48714875|NCT00002055|DRUG|Pentamidine isethionate|
48380731|NCT06382324|BEHAVIORAL|mindfulness practice of body scan|Mindfulness intervention is one kind of psychological intervention. The founder of Mindfulness-Based Stress Reduction (MBSR), Jon Kabat-Zinn, described mindfulness as \&#34;awareness that arises through paying attention, on purpose, in the present moment, non-judgmentally\&#34; (Kabat-Zinn, 2003). Moreover, these attitudes can be nurtured through various practices such as body scan, meditation, yoga, mindful eating, and mindful walking. Mindfulness practices are recognized for their ability to alleviate stress among athletes and enhance their recovery capabilities (Li et al., 2019). Mindfulness practice has been shown to enhance athletes\&#39; performance (Chen et al., 2018)、 improve sleep quality (Rusch et al., 2019)，which in turn promotes emotional stability and physical recovery.
48380732|NCT06382324|BEHAVIORAL|listening to light music|listening to light music asa control
48380733|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
48380734|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
48380735|NCT03950817|DRUG|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
48380736|NCT04649151|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
48380737|NCT04649151|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
48380738|NCT04649151|BIOLOGICAL|mRNA-1273.222|Sterile solution for injection
48380739|NCT02303977|DRUG|Abraxane|
48380740|NCT02303977|DRUG|Gemcitabine|
48380741|NCT01284842|OTHER|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
48380742|NCT00357734|DRUG|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
48380743|NCT05100277|GENETIC|Oncotype DX® Assay|After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
48380744|NCT05100277|OTHER|Cost|Changes in treatment costs were estimated from Pérola Byington Hospital.
48380745|NCT03504527|DRUG|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
48380746|NCT03504527|DRUG|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
48518412|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 1|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
48518413|NCT06557499|DEVICE|Polyurethane (PU) male condom-Test condom 2|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
48518414|NCT06557499|DEVICE|Natural Rubber Latex (NRL) male condom- Control condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a maximum 5-week period (assessment period). Couples will repeat the assessment period for each of the 3 condom types.
48518415|NCT04588389|DRUG|Ropivacaine injection Location 1|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1
48518416|NCT04588389|DRUG|Ropivacaine injection Location 2|Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2
48518417|NCT04588389|DRUG|Multimodal Pharmacological Management|standard of care multimodal pharmacological management
48518418|NCT00931645|PROCEDURE|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
48518419|NCT00931645|PROCEDURE|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
48714876|NCT05107973|OTHER|Baduajin|The intervention will consist in a 1 hour supervised Baduajin sessions conducted once a week a certified instructor with more than 10 years of experience. Each session will start with 5 min of warm up, 50 minutes of Baduajin and 5 min of cool down. In the main part the participants exercise the wholes set of Baduajin that consist of eigth forms.
48714877|NCT02900638|BEHAVIORAL|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
48714878|NCT01460719|BIOLOGICAL|V212|V212 viral antigen for HZ
48714879|NCT02876874|DRUG|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
48380747|NCT05288621|DEVICE|electroacupuncture|"For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment."
48380748|NCT04024527|DRUG|Esomeprazole|Proton pump inhibitor
48380749|NCT04024527|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
48380750|NCT04024527|DRUG|Metronidazole|Antibiotic for H. pylori eradication
48380751|NCT06000007|DEVICE|2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app|2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.
48380752|NCT06000007|OTHER|Treatment as usual|Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.
48380753|NCT00002738|DRUG|leucovorin calcium|
48380754|NCT00002738|DRUG|trimetrexate glucuronate|
48022481|NCT01807130|OTHER|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
48022482|NCT01665235|DRUG|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
48022483|NCT01665235|DRUG|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
48022484|NCT01665235|DRUG|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
48022485|NCT01665235|DRUG|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
48022486|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Norway|
48022487|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
48022488|NCT02897947|PROCEDURE|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
48022489|NCT06425172|DEVICE|Cranial Remolding Orthosis|A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
48022490|NCT03934268|GENETIC|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
48022491|NCT00621439|DRUG|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
48022492|NCT00621439|DRUG|Placebo|Patients will receive placebo.
48022493|NCT00874744|DRUG|Bevacizumab|1.25mg bevacizumab (0.05ml)
48022494|NCT00874744|DRUG|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
48022495|NCT03726359|RADIATION|Fractionated Stereotactic Radiation Therapy|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
48022496|NCT02972697|RADIATION|11C-acetate ligand|
48022497|NCT02972697|RADIATION|FDG ligand|
48022498|NCT01669343|DRUG|Letrozole|Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
48022499|NCT05961293|DEVICE|NeuroGlove|NeuroGlove is a non-invasive device that provides peripheral somatosensory stimulation to the hand of a stroke victim during acute, subacute, or chronic phases of a stroke. NeuroGlove provides sensory stimulation in the forms of pneumatic puffs of air. There is some early evidence that early peripheral sensory stimulation may improve neurological outcomes following an ischemic stroke.
48518420|NCT00931645|PROCEDURE|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) \& cyclophosphamide (300 mg/sqm)
48518421|NCT03578393|DEVICE|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
48022500|NCT01336465|DRUG|placebo|Repeating subcutaneous injection
48022501|NCT01336465|DRUG|rhuMAb Beta7|Repeating subcutaneous injection
48022502|NCT04280198|BEHAVIORAL|Triple P Parenting Videos|Four video clips from the online Triple P Parenting program will be used to promote specific positive parenting practices.
48022503|NCT04280198|BEHAVIORAL|Activity Boxes|There will be about 4 planned activities per week within activity boxes provided to families. The activities will be a context in which the positive parenting behaviors can be practiced. Each activity will take about 15 minutes. Families can pick each week whether they'd like their parenting practice to be embedded in reading activities, nature walks/active games, or arts and crafts. Instructions will be included with each activity, including prompts to allow the parent to apply learnings from that week's parenting video and to allow interactions to be child-led.
48022504|NCT02731092|DIETARY_SUPPLEMENT|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
48022505|NCT01148810|DRUG|BAF312|
48022506|NCT01148810|DRUG|Placebo|
48022507|NCT02515162|PROCEDURE|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
48022508|NCT02515162|PROCEDURE|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
48022509|NCT03540901|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
48022510|NCT03540901|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
48022511|NCT06024447|PROCEDURE|Subgingival Instrumentation|Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.
48022512|NCT01877421|DRUG|2 mg KSL-W|
48022513|NCT01877421|DRUG|4 mg KSL-W|
48022514|NCT01877421|DRUG|6 mg KSL-W|
48022515|NCT01877421|DRUG|10 mg KSL-W|
48022516|NCT01877421|DRUG|20 mg KSL-W|
48518422|NCT01602393|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
48518423|NCT01602393|DRUG|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
48518424|NCT01602393|DRUG|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
48022517|NCT01877421|DRUG|30 mg KSL-W|
48022518|NCT01877421|DRUG|50 mg KSL-W|
48022519|NCT01877421|DRUG|75 mg KSL-W|
48022520|NCT01877421|DRUG|100 mg KSL-W|
48022521|NCT01877421|OTHER|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
48022522|NCT03015077|DIETARY_SUPPLEMENT|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
48022523|NCT03015077|DIETARY_SUPPLEMENT|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
48022524|NCT03015077|RADIATION|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
48022525|NCT01690403|DRUG|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
48022526|NCT01690403|DRUG|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
48380755|NCT06649890|DEVICE|Xperience™ Advanced Surgical Irrigation|Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.
48380756|NCT06649890|DEVICE|Dilute Povidone-Iodine|5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
48380757|NCT00026312|BIOLOGICAL|Aldesleukin|Given IV
48380758|NCT00026312|BIOLOGICAL|Dinutuximab|Given IV
48380759|NCT00026312|DRUG|Isotretinoin|Given PO
48518425|NCT04536376|BEHAVIORAL|Resilience Program|Subjects receive program devices, and will be asked to wear during rest and sleep on a nightly basis along with active use during daytime. Notifications are sent daily, individualized approach developed and sent to participants to participate on.
48518426|NCT03280264|DRUG|KHK7580|oral administration
48022527|NCT01210768|DRUG|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
48518427|NCT03461601|PROCEDURE|HCG Uterine flushing|HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.
48180169|NCT05979428|DRUG|Placebo|Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
48518428|NCT03461601|PROCEDURE|IUI|Intrauterine insemination (IUI)
48022528|NCT01210768|DRUG|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
48022529|NCT06171867|DEVICE|PNEUMACRIT|Monitoring of breathing
48380760|NCT00026312|OTHER|Laboratory Biomarker Analysis|Correlative studies
48380761|NCT00026312|OTHER|Pharmacological Study|Correlative studies
48380762|NCT00026312|OTHER|Quality-of-Life Assessment|Ancillary studies
48380763|NCT00026312|BIOLOGICAL|Sargramostim|Given IV or SC
48022530|NCT02977377|OTHER|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
48028903|NCT02488434|DEVICE|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
48380764|NCT05728359|OTHER|Observational study|Blood sampling and clinical data collection
48518429|NCT03461601|PROCEDURE|Vaginal flushing with 10 ml normal saline|Flushing of the vagina with 10 ml of saline
48518430|NCT00226096|DRUG|Labetalol Hydrochloride|
48518431|NCT00226096|DRUG|Metoprolol tartrate|
48518432|NCT00226096|DRUG|Hydralazine Hydrochloride|
48028904|NCT00053833|DRUG|irinotecan|
48180170|NCT03672942|BEHAVIORAL|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
48180171|NCT03672942|BEHAVIORAL|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
48180172|NCT03672942|BEHAVIORAL|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
48518433|NCT00226096|DRUG|Glycerol Trinitrate|
48518434|NCT00226096|DRUG|Phentolamine mesylate|
48518435|NCT00226096|DRUG|Nicardipine|
48518436|NCT00226096|DRUG|Urapidil|
48518437|NCT00226096|DRUG|Esmolol|
48518438|NCT00226096|DRUG|Clonidine|
48518439|NCT00226096|DRUG|Enalaprilat|
48714880|NCT00136006|BEHAVIORAL|Study to determine the burden of disease|
48714881|NCT02749942|DEVICE|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
48714882|NCT02749942|DEVICE|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
48714883|NCT00866346|BIOLOGICAL|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
48022531|NCT02977377|OTHER|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
48022532|NCT06272916|DRUG|Aminophylline , magnesium sulphate and placebo|Comparison of the Effect of Aminophylline, Magnesium Sulphate and Placebo in Prevention of Post Dural Puncture Headache in Parturient Undergoing Caesarean Section
48022533|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.
48022534|NCT02428036|BIOLOGICAL|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.
48022535|NCT02356016|BEHAVIORAL|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
48022536|NCT02356016|BEHAVIORAL|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
48380765|NCT03669874|DEVICE|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
48714884|NCT05648149|BEHAVIORAL|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
48714885|NCT00849602|DRUG|Placebo|Placebo bid for three days
48714886|NCT00849602|DRUG|Chloroquine|Chloroquine bid for three days
48714887|NCT03412097|OTHER|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
48714888|NCT06545266|PROCEDURE|micro-fragmented adipose tissue injection|Micro-fragmented adipose tissue was obtained through the Lipogems kit and intraarticularly injected after an arthroscopic debridement.
48022537|NCT02356016|OTHER|control (dietary counseling)|Monthly dietary counseling only
48714889|NCT00769028|DRUG|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
48022538|NCT02934139|DRUG|Cavosonstat|CFTR modulator that stabilizes CFTR
48022539|NCT02934139|OTHER|Placebo|Matched placebo
48022540|NCT05626361|OTHER|Dysphagia training|Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided
48022541|NCT05626361|OTHER|Reading material|Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
48518440|NCT00226096|DRUG|Nitroprusside|
48518441|NCT05975593|OTHER|Tumor collection via biopsy|"Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence."
48714890|NCT00769028|DRUG|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
48714891|NCT00151788|DRUG|Pactimibe sulfate|
48714892|NCT04993729|DRUG|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
48714893|NCT04993729|DRUG|Placebo capsule|Placebo capsules, p.o. TID.
48714894|NCT04861246|DEVICE|Laser|The device will be used to do Laser treatment. To compare the therapeutic effect to laser treatment before and post treatment for 14 and 60 days.
48714895|NCT04861246|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain OCT images before and after laser treatment of skin.
48714896|NCT04861246|DEVICE|VISIA®|The device is skin analysis system and will be used to obtain before and after images of laser treatment.
48714897|NCT05014503|OTHER|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
48380766|NCT05607056|DIETARY_SUPPLEMENT|Sinquanon|"This probiotic food supplement includes fourteen probiotic bacterial strains of Lactobacillus Spp, Bifidobacterium Spp., Bacillus coagulans, Saccharomyces boulardii, three prebiotics and Vitamin-B complex - B1, B2, B3, B6, B7, B9 in an enterosolvent cellulose capsule. The product includes supplementary substances: maltodextrin and magnesium stearate.~2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing."
48380767|NCT05607056|DIETARY_SUPPLEMENT|Placebo|The placebo product will have the same appearance as the active product and the same composition but without the live bacteria, prebiotics, and vitamin-B complex. 2 capsules once a day during the antibiotic dosing. 1 capsule a day for 14 days following completion of antibiotic dosing.
48022542|NCT01083550|OTHER|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
48022543|NCT01401530|BIOLOGICAL|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
48380768|NCT00207025|DRUG|BMS-275183|
48380769|NCT05468034|BEHAVIORAL|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
48380770|NCT02783300|DRUG|GSK3326595|GSK3326595 will be administered with and without food, in tablet and capsule formulation.
48380771|NCT02783300|DRUG|Pembrolizumab|Pembrolizumab will be administered.
48022544|NCT05356559|DIETARY_SUPPLEMENT|Intervention|12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 8 weeks
48022545|NCT05356559|OTHER|Control|Isocalorific Maltodextrin Citrus Flavoured Powder for 8 weeks
48714898|NCT05014503|OTHER|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
48714899|NCT00650026|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
48022546|NCT02406144|DRUG|MLN9708|
48022547|NCT02406144|DRUG|Lenalidomide|
48022548|NCT02406144|DRUG|Dexamethasone|
48028905|NCT03609827|DRUG|Melphalan|
48022549|NCT02889081|OTHER|maternal biological folate level|supplementation status and serum level
48022550|NCT02889081|OTHER|maternal biological Vitamin D level|supplementation status and serum level
48022551|NCT02188823|BEHAVIORAL|Low carbohydrate diet|
48022552|NCT06039332|PROCEDURE|Fitting of the audioprocessor with the auditory implant BCI602|to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
48022553|NCT05835726|DRUG|Daratumumab|NDMM (newly diagnosed multiple myeloma) who fulfill the inclusion criteria, candidate to stem cell mobilization, collection, and autologous stem cell transplant who receive a Daratumumab-containing induction regimen.
48022554|NCT06254144|BEHAVIORAL|functional magnetic resonance imaging (fMRI)|The investigators will utilize standard BOLD fMRI in blocked-design tasks and resting state (participant is given no overt task) in the study. Anatomical scans with T1-weighted contrast, quantitative measurement of spin relaxation times, and diffusion tensor imaging (DTI) are also used as an anatomical reference for functional activation as well as to investigate a brain structural relationship with the participants' task performance, including successful emotion regulation.
48022555|NCT04824846|BEHAVIORAL|Integrated back pain module (IBPM)|All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.
48022556|NCT04824846|OTHER|Health Educational Pamphlet.|In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
48022557|NCT00902200|DRUG|AR-12286|See arms
48022558|NCT00902200|DRUG|AR-12286 vehicle|See arms
48022559|NCT02019719|DRUG|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
48022560|NCT02019719|DRUG|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
48022561|NCT04592692|DRUG|PEGylated Liposome (PEGLip)|Intravenous co-administration of PEGLip with Simoctocog alfa
48022562|NCT03674424|DRUG|Avelumab|Chemotherapy with or without avelumab followed by surgery
48022563|NCT03674424|PROCEDURE|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
48022564|NCT03674424|COMBINATION_PRODUCT|CG|Chemotherapy 4 cycles of 3 weeks
48022565|NCT03674424|COMBINATION_PRODUCT|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
48022566|NCT03674424|COMBINATION_PRODUCT|PG|Chemotherapy 2 cycles of 4 weeks
48022567|NCT04795271|OTHER|Orthopedic intervention|"In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite."
48380772|NCT02457780|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
48518442|NCT05975593|OTHER|Blood collection|"Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence"
48518443|NCT05975593|DEVICE|Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)|"Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.~The imaging will be performed when possible."
48518444|NCT03560128|DEVICE|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
48714900|NCT05466695|DRUG|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
48022568|NCT03686774|DRUG|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
48380773|NCT02457780|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
48380774|NCT05981131|DRUG|N803 plus Bacillus Calmette-Guerin (BCG)|QUILT-2.005 phase 1b (NCT02138734) was an open-label, dose-escalation, multicenter study of intravesical Bacillus Calmette-Guerin (BCG) plus N-803 in BCG-naïve non muscle invasive bladder cancer (NMIBC). A modified 3 + 3 design was used. Three subjects were enrolled at each dose level starting at 100 μg/instillation of N-803 and subsequently increasing to 200 μg/instillation and 400 μg/instillation. A standard dose of BCG, 50 mg, was employed. The primary endpoints of the study were: determination of the maximum tolerated dose (MTD) and designation of the recommended dose (RD) of N-803 in combination with BCG in subjects who have BCG-naïve NMIBC; safety profile of N-803 plus BCG in treated subjects; and disease response rate in treated subjects. A total of 9 subjects with high-risk, high-grade, BCG-naïve, NMIBC were enrolled into 3 cohorts and treated by intravesical administration of N-803 plus BCG.
48380775|NCT02889627|DRUG|Fecal microbiota suspension|The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.
48714901|NCT01044316|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
48714902|NCT06055816|DRUG|Endostar and Envafolimab|Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
48714903|NCT03908645|DEVICE|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
48714904|NCT03908645|DEVICE|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
48022569|NCT03686774|OTHER|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
48022570|NCT02323724|GENETIC|BRAF V600E mutation by pyrosequencing technique|
48022571|NCT05387759|DRUG|Aticaprant Supratherapeutic Dose|Aticaprant supratherapeutic dose capsule will be administered orally.
48022572|NCT05387759|DRUG|Aticaprant Therapeutic Dose|Aticaprant therapeutic dose capsule will be administered orally.
48022573|NCT05387759|DRUG|Placebo|Placebo will be administered orally.
48022574|NCT05387759|DRUG|Moxifloxacin|Moxifloxacin capsule will be administered orally.
48714905|NCT01484834|BEHAVIORAL|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
48022575|NCT00054535|BIOLOGICAL|aldesleukin|
48714906|NCT01484834|BEHAVIORAL|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
48022576|NCT00054535|BIOLOGICAL|recombinant fowlpox-tyrosinase vaccine|
48714907|NCT01484834|BEHAVIORAL|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
48022577|NCT00054535|BIOLOGICAL|vaccinia-tyrosinase vaccine|
48022578|NCT02376049|DRUG|Pimecrolimus cream|
48380776|NCT04871451|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
48380777|NCT06650995|OTHER|Exercise training|exercise intervention will consist of supervised, home-based, combined training with elements of endurance, resistance and respiratory training
48022579|NCT02376049|DRUG|Betamethasone dipropionate cream|
48380778|NCT05696457|BEHAVIORAL|Passive music therapy|Patients included in the experimental group receive a 25 min passive music therapy session on a daily basis, which changes depending on their emotion.
48380779|NCT03153319|DRUG|Adalimumab Injection [Humira]|Investigational Drug
48380780|NCT03153319|DRUG|Saline Solution for Injection|Placebo Comparator
48714908|NCT01484834|OTHER|Control Company|No intervention was applied for the participants of this group
48714909|NCT04656795|DRUG|MT-7117|MT-7117
48714910|NCT02428920|BEHAVIORAL|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
48714911|NCT01497821|DRUG|AMG 172|AMG 172 is an antibody drug conjugate
48714912|NCT05781958|DRUG|Cadonilimab+Gem/Cis|Cadonilimab (500mg, iv, Q3W, Day1) with gemcitabine(1000mg/m\^2, iv, Q3W, Day1and Day8) plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8) up to 8 cycles followed by cadonilimab (500mg, iv, Q3W, Day1) plus capecitabine（1000 mg/m\^2 orally according to Body Surface Area (BSA)，BID，Q3W，on Days 1-14）as maintenance therapy until disease progression or other discontinuation criteria, up to 24months.
48714913|NCT05256797|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
48714914|NCT05256797|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
48714915|NCT01198457|DRUG|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
48714916|NCT01012206|BEHAVIORAL|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
48022580|NCT02376049|DRUG|Clobetasol propionate cream|
48022581|NCT02376049|DRUG|Glaxal Base cream vehicle|
48022582|NCT00667784|BEHAVIORAL|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
48022583|NCT03598504|DEVICE|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
48022584|NCT04833257|DRUG|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
48022585|NCT02573324|DRUG|Temozolomide|Oral Capsule
48022586|NCT02573324|DRUG|Depatuxizumab mafodotin|Intravenous (IV) Infusion
48022587|NCT02573324|RADIATION|Radiation|
48022588|NCT02573324|DRUG|Placebo for ABT-414|IV Infusion (IV)
48022589|NCT00004867|PROCEDURE|conventional surgery|
48022590|NCT00004867|PROCEDURE|positron emission tomography|
48022591|NCT00004867|PROCEDURE|radionuclide imaging|
48022592|NCT00004867|RADIATION|fludeoxyglucose F 18|
48022593|NCT00004867|DRUG|chemotherapy|
48022594|NCT00004867|RADIATION|Radiotherapy|
48022595|NCT00765167|DRUG|Fluoride|Brush half mouth twice daily for four days
48022596|NCT00765167|DRUG|Triclosan|Brush half mouth daily for four days
48022597|NCT00765167|DRUG|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
48022598|NCT00765167|DRUG|Fluoride|Brush half mouth daily for four days
48380781|NCT01965600|DRUG|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
48380782|NCT01965600|DRUG|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
48380783|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
48380784|NCT01965600|DRUG|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
48380785|NCT01965600|DRUG|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
48380786|NCT01965600|OTHER|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
48380787|NCT04514224|OTHER|Gabby implementation|Iimplement an evidence-based preconception care intervention, Gabby, into community-based health settings
48380788|NCT04514224|OTHER|Evaluate the Gabby implementation|Assess implementation outcomes using the Proctor Implementation Outcomes Framework
48714917|NCT00025168|DRUG|gemcitabine hydrochloride|
48714918|NCT00025168|DRUG|irinotecan hydrochloride|
48714919|NCT00025168|RADIATION|radiation therapy|
48022599|NCT03396744|DEVICE|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
48022600|NCT00574860|DRUG|EN3285|Oral rinse
48022601|NCT00574860|DRUG|Placebo|Oral rinse
48022602|NCT00574860|OTHER|Standard of care|This will be the therapy most commonly used the the institution treating the patient
48022603|NCT06534866|OTHER|Traditional Physical Therapy|"1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch"
48022604|NCT06534866|OTHER|Kinesiotaping|In the first step, after the metatarsophalangeal joints is dorsiflexed, the first strap will be adhered firmly to the posterior heel at its proximal end. The other end of the strap is cut into four slices of equal width. Each slice is applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap is applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot
48022605|NCT02510157|DRUG|Dexamethasone|active comparator
48022606|NCT02510157|DRUG|Normal Saline|placebo controlled intervention
48022607|NCT02510157|DRUG|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
48022608|NCT01366833|RADIATION|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
48022609|NCT01366833|PROCEDURE|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
48380789|NCT04649437|DIAGNOSTIC_TEST|Quantitative sensory testing|Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
48380790|NCT06180993|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
48022610|NCT03702465|OTHER|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
48022611|NCT03702465|OTHER|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
48022612|NCT03702465|OTHER|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
48022613|NCT00529932|OTHER|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
48022614|NCT00529932|OTHER|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
48022615|NCT05333445|BEHAVIORAL|educational program|"Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient"
48022616|NCT05333445|BEHAVIORAL|risk factors management|identify risk factors and offer guidance based on management strategies for the specific risk factor in each case
48380791|NCT02923557|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
48022617|NCT05333445|BEHAVIORAL|telephone and e-mail contact|patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.
48022618|NCT05333445|OTHER|usual care|standard care
48022619|NCT06111092|OTHER|Design Thinking|Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
48714920|NCT03116542|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
48714921|NCT03844113|DRUG|Carnosine|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
48022620|NCT06111092|OTHER|Focus Groups|Participants attend the FG that includes the introduction. discussion, and reflection.
48022621|NCT02841423|PROCEDURE|neuropsychological test battery|
48022622|NCT03224468|DRUG|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
48714922|NCT03844113|DRUG|Placebo|Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
48022623|NCT03290716|OTHER|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
48714923|NCT03008135|OTHER|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
48714924|NCT03008135|OTHER|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
48714925|NCT05669586|DRUG|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
48714926|NCT04337736|OTHER|Physical exercise|
48022624|NCT03290716|OTHER|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
48022625|NCT01348529|BEHAVIORAL|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
48022626|NCT00287911|DRUG|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
48714927|NCT03734068|DEVICE|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
48022627|NCT00287911|DRUG|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
48022628|NCT00287911|RADIATION|brachytherapy|Some patients may also undergo brachytherapy
48022629|NCT00287911|RADIATION|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
48714928|NCT03734068|DRUG|Doxorubicin|Doxorubicin is loaded to LIfePearl
48714929|NCT00821249|DRUG|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
48022630|NCT02973451|DRUG|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
48022631|NCT02973451|DRUG|local Bupivacaine|Bupivacaine Trocar Site Infiltration
48022632|NCT01330940|DIETARY_SUPPLEMENT|Orange soda|32 ounces per day
48022633|NCT05908240|OTHER|Care Coordinator Model|A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
48714930|NCT00821249|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
48714931|NCT00821249|DRUG|Dexamethasone, steroid; oral|Part 3: standard of care.
48022634|NCT04600648|DIAGNOSTIC_TEST|Serum insulin level|Measure levels before and after weight loss related to bariatric surgery
48022635|NCT04600648|DIAGNOSTIC_TEST|Serum Leptin test|Measure levels before and after weight loss related to lifestyle change weight loss
48180173|NCT00763594|BEHAVIORAL|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
48180174|NCT00763594|BEHAVIORAL|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
48380792|NCT01564810|DRUG|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
48380793|NCT01564810|DRUG|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
48714932|NCT03929289|BEHAVIORAL|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
48714933|NCT06398964|DIETARY_SUPPLEMENT|3-hydroxybutyrat|The intervention is administered as a drink.
48714934|NCT06398964|DIETARY_SUPPLEMENT|Isocaloric placebo drink|The intervention is administered as a drink.
48714935|NCT01630551|DIETARY_SUPPLEMENT|Fishoil supplement|1 capsule per day
48714936|NCT01630551|DIETARY_SUPPLEMENT|Olive Oil|1 capsule per day
48022636|NCT03096548|BEHAVIORAL|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
48028906|NCT02458105|BEHAVIORAL|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
48180175|NCT05115708|PROCEDURE|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group
48180176|NCT05115708|PROCEDURE|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
48180177|NCT04197167|PROCEDURE|Hysteroscopy|Diagnostic procedure
48714937|NCT02008513|BIOLOGICAL|AFFITOPE® AD02|
48714938|NCT02008513|BIOLOGICAL|Placebo|
48714939|NCT04053595|DIAGNOSTIC_TEST|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume \>10% after fluid administration.
48180178|NCT04197167|DEVICE|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis
48714940|NCT04053595|DIAGNOSTIC_TEST|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
48714941|NCT05841199|DIAGNOSTIC_TEST|Pressure and flow measurement during simulated VT|Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
48180179|NCT00936598|DRUG|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women = or \> 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
48180180|NCT00936598|DRUG|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
48180181|NCT00523952|DRUG|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
48180182|NCT00160082|DRUG|Xepol|
48180183|NCT03662646|OTHER|no intervention performed- observational only|no intervention performed- observational only
48180184|NCT00000983|DRUG|Zidovudine|
48380794|NCT04408625|BIOLOGICAL|LY3884963|Participants will receive a single dose of LY3884963, administered intra cisterna magna
48380795|NCT04408625|DRUG|Methylprednisolone|IV pulses every 2 weeks in the first 3 months.
48380796|NCT04408625|DRUG|Optional Sirolimus|At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
48714942|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.|Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
48714943|NCT05547529|PROCEDURE|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy|Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
48714944|NCT06112652|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48518445|NCT03560128|DEVICE|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
48518446|NCT03322644|BEHAVIORAL|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
48714945|NCT06112652|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48380797|NCT04408625|DRUG|Optional Prednisone|If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
48518447|NCT00003274|BIOLOGICAL|gp100 antigen|
48714946|NCT06112652|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48714947|NCT06112652|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
48714948|NCT06112652|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
48714949|NCT02012088|DRUG|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
48714950|NCT02012088|DRUG|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
48714951|NCT04866875|BEHAVIORAL|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
48714952|NCT00128713|PROCEDURE|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10\^11 platelets per m\^2 BSA
48714953|NCT00128713|PROCEDURE|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10\^11 platelets per m\^2 BSA
48714954|NCT00128713|PROCEDURE|Higher Dose Prophylactic Platelet Transfusions|4.4 \* 10\^11 platelets per m\^2 BSA
48714955|NCT00040508|DRUG|Sirolimus|
48518448|NCT00003274|BIOLOGICAL|incomplete Freund's adjuvant|
48518449|NCT00003274|BIOLOGICAL|sargramostim|
48518450|NCT00003274|BIOLOGICAL|tyrosinase peptide|
48022637|NCT03096548|BEHAVIORAL|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
48022638|NCT03890302|DRUG|FB704A|Administered by IV infusion
48022639|NCT03890302|DRUG|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
48022640|NCT03272100|PROCEDURE|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
48518451|NCT02201784|DRUG|Levobupivacaine|Comparison of Equipotent doses
48518452|NCT02201784|DRUG|Ropivacaine|Comparison of equipotent doses
48518453|NCT03381170|BIOLOGICAL|Ublituximab|Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
48714956|NCT01735708|BEHAVIORAL|HIVPASS|
48714957|NCT01735708|OTHER|Health Education|
48714958|NCT05066945|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
48714959|NCT05070910|BEHAVIORAL|Therapy|The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
48714960|NCT03225261|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
48714961|NCT03225261|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
48714962|NCT02433873|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
48714963|NCT04542096|DEVICE|Lung electrical impedance tomography monitoring|A belt for recording changes in electrical impedance in the skin will be fastened for the purpose of this study with no other additional procedures
48714964|NCT00134732|BIOLOGICAL|Live attenuated human rotavirus vaccine|
48714965|NCT01776671|DRUG|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
48022641|NCT05107986|PROCEDURE|laparoscopic repair|All patients of cohort underwent laparoscopic repair.
48714966|NCT00319475|PROCEDURE|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
48714967|NCT03094858|DEVICE|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
48714968|NCT03094858|DEVICE|Wristband|Wristband will monitor activity of all participants
48714969|NCT03094858|DEVICE|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
48714970|NCT00029757|DRUG|Estrogen|
48714971|NCT03873961|DEVICE|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
48714972|NCT03873961|DEVICE|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
48714973|NCT04500236|OTHER|General anesthesia|Surgery under general anesthesia with the use of propofol
48714974|NCT04500236|OTHER|Hypno-analgesia|Surgery under Hypnosis session and analgesics
48714975|NCT04810936|DIETARY_SUPPLEMENT|oral nutritional supplements|Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
48714976|NCT05525754|PROCEDURE|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
48714977|NCT02061397|DRUG|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
48714978|NCT02061397|DRUG|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
48714979|NCT02061397|DRUG|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
48022642|NCT06114797|OTHER|Chamomile|"* Chamomile was topically applied to the oral mucosa as oral rinse.~* Based on this protocol, patients had oral rinses 3 times per day.~* Patients were instructed to perform chamomile rinses in the oral mucosa.~* Patients were instructed not to swallow the chamomile oral rinse."
48022643|NCT06114797|OTHER|Saline mouthwash|Saline mouthwash was used by elderly patients in the control arm.
48022644|NCT06148597|PROCEDURE|Modified thoracoabdominal nerves block through perichondrial approach (M-TAPA)|application local anesthetic between internal oblique and transversus abdominis muscle at the level of 10th costal cartilage
48022645|NCT06574282|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(1-4 weeks after the 1st measurement)
48022646|NCT01702792|BIOLOGICAL|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
48022647|NCT00005619|GENETIC|polymerase chain reaction|
48022648|NCT00005619|OTHER|flow cytometry|
48022649|NCT00005619|OTHER|immunohistochemistry staining method|
48022650|NCT04285606|BEHAVIORAL|Patient-led rehab with short immobilization|Short immobilization followed by patient-led shoulder rehab
48022651|NCT01166932|DRUG|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
48022652|NCT01166932|DRUG|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
48022653|NCT00064805|BEHAVIORAL|Cognitive Therapy to Improve Reading|
48028907|NCT02458105|BEHAVIORAL|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
48180185|NCT03969576|PROCEDURE|DEB-TACE|"Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response."
48180186|NCT03969576|PROCEDURE|cTACE|"Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response."
48180187|NCT02543099|DRUG|policosanol|Patients will receive policosanol 20mg Qd
48180188|NCT02543099|DRUG|placebo|Patients will receive placebo 20mg Qd;
48180189|NCT04641117|OTHER|Exercise|Walking and Power Training
48180190|NCT01582698|BIOLOGICAL|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
48380798|NCT06396208|DRUG|Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)|Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
48380799|NCT06396208|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
48380800|NCT05660135|DRUG|Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca|Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
48380801|NCT05848518|OTHER|Rehabilitation program|The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)
48380802|NCT04491773|DRUG|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
48380803|NCT04637815|BEHAVIORAL|Motivational Network Intervention|Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.
48714980|NCT04214912|COMBINATION_PRODUCT|Personalized Survivor Care Plan (PSCP)|Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
48180191|NCT03360110|DEVICE|Phoebe test lens|Daily disposable contact lens
48180192|NCT03360110|DEVICE|stenfilcon A lens (control)|Daily disposable contact lens
48180193|NCT02695147|PROCEDURE|TAVI|
48180194|NCT00391339|DRUG|Bryophyllum p.|
48180195|NCT05730114|DRUG|Antiplatelet Drug|anti-P2Y12 oral agent administered during primary percutaneous coronary intervention.
48180196|NCT02562898|DRUG|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
48180197|NCT02562898|DRUG|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
48380804|NCT04637815|OTHER|Usual Care|Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
48380805|NCT04186234|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
48380806|NCT00375024|PROCEDURE|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
48380807|NCT00375024|PROCEDURE|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
48714981|NCT04504942|DRUG|Leronlimab|Drug: Leronlimab 525mg
48180198|NCT02562898|DRUG|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
48380808|NCT03185949|DEVICE|Endobar Infusion Catheter System|Bariatric embolization with microspheres using Endobar Infusion Catheter System
48380809|NCT03185949|BEHAVIORAL|Behavioral therapy|Healthy diet and exercise
48380810|NCT04931875|DEVICE|Total body PET/CT (uExplorer)|A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
48380811|NCT03442894|PROCEDURE|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
48380812|NCT03442894|PROCEDURE|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
48380813|NCT03442894|PROCEDURE|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
48380814|NCT04655365|DRUG|Enzalutamide capsule|160 mg po id
48380815|NCT02806700|BEHAVIORAL|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
48380816|NCT05214976|DRUG|Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound)|Firstly Dose Escalation of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) should be conducted. According to the DLT data in the dose escalation period, dosage of Famitinib malate capsule or Paclitaxel For Injection(Albumin Bound) would be adjusted. After dose escalation period, in order to evaluate the tolerance, study would choose the dosage regimen to complete the Dose Expansion period. The indication expansion would be conducted after that. The study would select specific indications based on the previous efficacy data with the RP2D of the combination therapy.
48380817|NCT06338280|OTHER|Sonara|Sonara virtual dosing window and engagement platform
48380818|NCT06107465|DRUG|Nitroglycerin|high dose Nitroglycerin
48380819|NCT04527159|DRUG|Fluoraphat Pro / VivaSens|desensitizing agents for treatment of dentinal hypersensitivity
48714982|NCT00686842|DRUG|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
48380820|NCT01002417|DRUG|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
48380821|NCT01002417|DRUG|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
48380822|NCT01002417|DRUG|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
48714983|NCT00686842|GENETIC|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
48714984|NCT00686842|GENETIC|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
48714985|NCT00686842|GENETIC|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
48714986|NCT00686842|OTHER|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
48714987|NCT00686842|OTHER|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
48714988|NCT00686842|OTHER|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
48714989|NCT00686842|PROCEDURE|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
48180199|NCT03554031|DRUG|Recombinant Human Growth Hormone (rhGH) Injection|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
48180200|NCT05143164|DEVICE|hydrocolloid dressing|Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.
48180201|NCT05143164|DRUG|Gentamicin Sulfate, Topical|Application of gentamicin to exit site daily
48714990|NCT01998893|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
48714991|NCT01421316|RADIATION|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
48714992|NCT00359567|DRUG|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
48714993|NCT00359567|DRUG|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
48714994|NCT03697278|DEVICE|Smith medical CADDsolis|This group will be monitoring from a network.
48180202|NCT04666363|OTHER|Lavender oil|the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
48380823|NCT03115320|DRUG|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
48714995|NCT02033590|DEVICE|Biodegradable (purified) surgical silk scaffold|
48380824|NCT03115320|OTHER|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
48714996|NCT03794869|OTHER|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
48714997|NCT03794869|OTHER|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
48714998|NCT05436587|GENETIC|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
48714999|NCT06108843|OTHER|Myofascial Arm Pull and Active Release Technique|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
48715000|NCT06108843|OTHER|Myofacial Arm Pull|Six weekly sessions of the treatment will be given over the course of four weeks. Baseline treatment includes Ultrasound for 10 minutes.
48715001|NCT02830204|DEVICE|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
48715002|NCT01920152|BIOLOGICAL|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
48022654|NCT04691479|BEHAVIORAL|Motivational Interview (MI) & Adherence Follow-Up|"1. MEntA: Educational \& Training Program~2. Stratification: Identification of Personal Variables (Age, Level of study, Work status, preference of care attention, digital behaviour)~3. Adherence evaluation: Evaluation of Perceived Competence, Quality of Life, Mood, Activities, Social relations and Social Support~4. Identification of Care plan and Schedule next visits~5. Follow-up D30-D60-D90-D180 depending of the care plan, through the channel that belong for each care plan"
48715003|NCT01920152|DEVICE|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
48715004|NCT03220607|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
48715005|NCT00214474|BEHAVIORAL|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
48715006|NCT00214474|BEHAVIORAL|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
48715007|NCT00868673|DIETARY_SUPPLEMENT|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
48022655|NCT04691479|BEHAVIORAL|Adherence Follow-Up|The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
48380825|NCT04094402|OTHER|None. It is an observational study|None. It is an observational study
48380826|NCT03801200|DRUG|Apatinib|radiotherapy with Apatinib
48380827|NCT05272267|OTHER|AI-assisted models providing diagnosis and prognostic information|AI-assisted models providing diagnosis and prognostic information in the ED, including triage, ICD coding, chest x ray alerts, critical event alerts, readmission prediction, and post-cardiac arrest prognostication.
48380828|NCT05272267|PROCEDURE|Critical treatment|Critical treatment of the emergency room
48518454|NCT06161753|BEHAVIORAL|Cognitive Functional Therapy|"CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management."
48715008|NCT00868673|DIETARY_SUPPLEMENT|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
48022656|NCT01266772|DRUG|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
48022657|NCT01266772|DRUG|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
48022658|NCT00585897|BEHAVIORAL|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
48022659|NCT04819997|OTHER|Educational Intervention|Participate in videoconference session
48028908|NCT01329601|BEHAVIORAL|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
48028909|NCT01329601|BEHAVIORAL|booklet based training|Home based training of episodic memory using paper-pencil exercizes
48180203|NCT02264782|OTHER|Computer-Assisted Intervention|Complete PreView
48380829|NCT05736549|DRUG|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
48380830|NCT05736549|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
48380831|NCT00407966|DRUG|alvocidib|Given IV
48380832|NCT00407966|DRUG|cytarabine|Given IV
48715009|NCT04184128|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
48518455|NCT02386124|OTHER|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
48715010|NCT05213208|DRUG|Propofol|Using \> 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
48715011|NCT03054597|DEVICE|Circular light motion|Exercise with circular light motion
48715012|NCT03054597|DEVICE|Diagonal light motion|Exercise with diagonal light motion
48715013|NCT03054597|DEVICE|Peripheral light motion|Exercise with peripheral light motion
48715014|NCT03054597|PROCEDURE|Exercise|
48715015|NCT01813838|DRUG|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
48715016|NCT01813838|DRUG|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
48715017|NCT01813838|DRUG|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
48715018|NCT06378645|DRUG|General Anesthesia: Propofol|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Propofol will be administered intravenously using the target-controlled infusion algorithm with effect site concentrations between 1.5-4.0 µg/ml necessary."
48715019|NCT06378645|DRUG|General Anesthesia: Sevoflurane|"Transurethral surgery at the Department of Urology (University Hospital Zurich) performed under study arm-specific anesthesia.~Sevoflurane will be given in gaseous form via the endotracheal tube in concentrations between 1.5-2.5% Vol."
48715020|NCT01434329|GENETIC|DNA methylation analysis|
48715021|NCT01434329|GENETIC|gene expression analysis|
48715022|NCT01434329|GENETIC|microarray analysis|
48715023|NCT01434329|OTHER|laboratory biomarker analysis|
48715024|NCT01434329|OTHER|medical chart review|
48715025|NCT04174651|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
48380833|NCT00407966|DRUG|mitoxantrone hydrochloride|Given IV
48380834|NCT01696266|OTHER|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
48518456|NCT05606406|OTHER|Nocturnal Oxygen|Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
48180204|NCT02264782|OTHER|Computer-Assisted Intervention|Watch an educational video
48380835|NCT04782258|DRUG|Tolvaptan Suspension|Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
48518457|NCT02656069|DRUG|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
48518458|NCT02656069|DRUG|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
48380836|NCT04782258|DRUG|Tolvaptan Tablets|Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
48380837|NCT02314130|DIETARY_SUPPLEMENT|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
48380838|NCT03148873|DEVICE|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
48380839|NCT05776407|DRUG|ThisCART19A|Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
48518459|NCT01372748|OTHER|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
48518460|NCT01372748|OTHER|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
48518461|NCT03426189|PROCEDURE|Leukapheresis|Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
48518462|NCT03426189|PROCEDURE|Lymph node biopsy|Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
48518463|NCT03112473|BEHAVIORAL|Task-orientated training|Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
48518464|NCT03112473|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
48518465|NCT03112473|DEVICE|Sham electrical nerve stimulation|A identical-looking TENS devices that electrical circuit has been disconnected.
48518466|NCT01495702|DRUG|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
48022660|NCT06192511|BEHAVIORAL|Educational Website and Video|The website offers users the opportunity to choose to watch a 4-minute video or read relevant information about Newborn Screening and the Michigan BioTrust. If they choose to read, the website is designed to present information in an engaging manner, while providing optional voiceover. The video uses a mixture of live action shots and animation, all with voiceover. All materials are available in English, Spanish and Arabic.
48380840|NCT05776407|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
48518467|NCT01495702|DRUG|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
48022661|NCT03892889|COMBINATION_PRODUCT|Abilify MyCite®|Combination product of aripiprazole tablet embedded with sensor and wearable patch.
48380841|NCT05776407|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
48380842|NCT05776407|DRUG|Etoposide|Etoposide is used for lymphodepletion.
48022662|NCT01679119|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
48022663|NCT01679119|DRUG|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
48022664|NCT01679119|DRUG|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
48022665|NCT01679119|DRUG|Rituximab|Rituximab 375mg/m2 IV given day 1
48180205|NCT02264782|OTHER|Questionnaire Administration|Ancillary studies
48518468|NCT01495702|DRUG|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
48518469|NCT01068548|OTHER|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
48518470|NCT06551233|DRUG|9MW2821|Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
48518471|NCT02552901|DRUG|0.1 mg/kg ICG Dose|least efficacious dose
48380843|NCT00326625|DRUG|40 mg glatiramer acetate|parenteral drug
48022666|NCT01679119|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
48022667|NCT01679119|DRUG|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
48180206|NCT00246935|DRUG|Roflumilast|
48180207|NCT02882997|BEHAVIORAL|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
48380844|NCT00326625|DRUG|Placebo|
48518472|NCT02552901|DRUG|0.5 mg/kg ICG dose|per package insert
48715026|NCT04174651|BEHAVIORAL|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
48715027|NCT01842581|DRUG|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
48715028|NCT01842581|DRUG|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
48180208|NCT02882997|BEHAVIORAL|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
48380845|NCT06541314|DRUG|Fluzoparib|Fluzoparib (50mg per capsule) 150mg po bid. Take Fluzoparib for 3 weeks, then stop for 1 week, constituting a 28-day cycle. Administer 2 cycles in total.
48380846|NCT01038076|BEHAVIORAL|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
48380847|NCT04720976|DRUG|JAB-3312|JAB-3312 will be administered orally, variable dose.
48715029|NCT05988320|PROCEDURE|Pranayama breathing exercise|"Pranayama is an important step in yoga, way of life, and is translated as the science of breathing, breath control, willful breathing. This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through"
48380848|NCT04720976|DRUG|Binimetinib|Binimetinib will be administered orally.
48380849|NCT04720976|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous infusion.
48380850|NCT04720976|DRUG|Sotorasib|Sotorasib will be administered orally.
48380851|NCT04720976|DRUG|Osimertinib|Osimertinib will be administered orally.
48380852|NCT03933046|DIAGNOSTIC_TEST|PSG|polysomnography and urine analaysis for protein levels
48380853|NCT02880709|DIETARY_SUPPLEMENT|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
48380854|NCT02325193|DEVICE|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
48380855|NCT05471375|OTHER|Database Entry|Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
48380856|NCT03621566|OTHER|No intervention|Routine care (registry)
48380857|NCT03296397|BIOLOGICAL|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
48380858|NCT03296397|BIOLOGICAL|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
48380859|NCT06269042|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances,
48380860|NCT00201266|PROCEDURE|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
48715030|NCT04448015|OTHER|Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care|University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
48715031|NCT00711802|DRUG|Daptomycin|
48028910|NCT05303987|DRUG|Propofol sedation|"After induction with sevoflurane then Propofol will be initiated.~If adequate sedation cannot be attained then a ketamine rescue can be given."
48028911|NCT05303987|DRUG|Dexmedetomidine sedation|"After induction with sevoflurane then Dexmedetomidine will be given.~If adequate sedation cannot be attained then a ketamine rescue can be given."
48028912|NCT05053087|DRUG|Ropivacaine Continuous Infusion|0.2% continuous infusion 6mL/hr
48028913|NCT05053087|DRUG|Ropivacaine Intermittent Bolus|0.2% intermittent bolus infusion 8mL every 2 hours
48028914|NCT05053087|DRUG|Placebo|Saline filled catheter
48028915|NCT05525624|DEVICE|TRAMPRE|discharge interventions Transition Model is discharge interventions in parents of preterm infants.
48028916|NCT05525624|OTHER|Control Group|routine neonatal clinic discharge training of the hospital
48028917|NCT05031910|OTHER|Medical Device Usage and Evaluation|Undergo virtual reality imaging via VR/3D-CEPs
48028918|NCT05031910|OTHER|Best Practice|Receive standard of care
48028919|NCT05031910|PROCEDURE|Resection|Undergo surgical resection
48028920|NCT05648591|DRUG|Iloperidone|oral tablet
48028921|NCT01637753|DRUG|Carmustine(BCNU)|Carmustine Sustained Release Implant
48380861|NCT05434949|DIAGNOSTIC_TEST|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
48380862|NCT05434949|OTHER|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
48380863|NCT00039429|DRUG|atrasentan hydrochloride|
48028922|NCT01637753|PROCEDURE|Surgery|Routine tumor resection surgery
48380864|NCT05377541|PROCEDURE|Surgical treatment of femur fracture|Definitive surgical treatment of femur fracture.
48380865|NCT02847078|DEVICE|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
48380866|NCT02847078|DEVICE|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
48380867|NCT06239207|BIOLOGICAL|Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)|Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution
48715032|NCT00711802|DRUG|Standard of Care (SOC)|
48380868|NCT06239207|BIOLOGICAL|Platelet Rich Plasma|PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
48380869|NCT02086734|OTHER|Perfusion-CT|"1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
48715033|NCT05995223|OTHER|Submaximal exercise protocol|Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
48028923|NCT05382416|BEHAVIORAL|SHARE! Peer Toolkit Training|The SHARE! Peer Toolkit training is designed to improve the performance of peer workers in their provision of peer support. The training covers each of the 12 tools in the Peer Toolkit, which are taught through brief presentations followed by group discussions and interactive exercises to help people competently use each of the tools. Training sessions are typically two hours each, three times per week for 10 weeks.
48028924|NCT04972500|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
48028925|NCT00059683|PROCEDURE|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
48180209|NCT04157933|DRUG|009-A1|Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
48518473|NCT02134652|OTHER|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
48715034|NCT01744717|OTHER|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~* TURNING / POSITIONING (moving side to side or up or down in bed)~* ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~* NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
48715035|NCT00244348|DRUG|Oxaliplatin (via HAI)|
48715036|NCT00244348|DRUG|5 Fluorouracil (systemic)|
48715037|NCT00652899|BIOLOGICAL|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
48715038|NCT00652899|DRUG|Cyclophosphamide|60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
48715039|NCT00652899|DRUG|Fludarabine phosphate|25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.
48715040|NCT00652899|RADIATION|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
48715041|NCT00652899|BIOLOGICAL|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 \* 10\^7/kg
48715042|NCT00652899|BIOLOGICAL|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
48715043|NCT02182609|DRUG|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
48715044|NCT00450736|DRUG|celecoxib|
48715045|NCT00450736|PROCEDURE|adjuvant therapy|
48715046|NCT00450736|RADIATION|radiation therapy|
48715047|NCT01873053|DRUG|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
48715048|NCT01873053|DRUG|Placebo|
48715049|NCT06329882|DRUG|Sitagliptin 100mg|Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
48715050|NCT06329882|DRUG|Doxycyclin|Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
48715051|NCT02316210|DEVICE|electrical stimulation|
48715052|NCT05008757|OTHER|no drug|no intervention
48715053|NCT02009293|OTHER|Cough monitor|questionnaires about cough and quality of life
48715054|NCT05271825|DEVICE|Broadband amplification from hearing aids|Amplification from 125 Hz to 10 kHz
48715055|NCT05271825|DEVICE|Band-limited amplification from hearing aids|Amplification from 25 Hz to 3-4 kHz
48715056|NCT00390117|DRUG|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
48715057|NCT00390117|OTHER|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
48180210|NCT04157933|DRUG|009-A2|Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6
48180211|NCT04157933|DRUG|009-A3|Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
48715058|NCT05716893|BEHAVIORAL|Adaptive Aerobic Training/AT Dosing|o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
48715059|NCT05716893|BEHAVIORAL|Standard (fixed) Aerobic Training/AT dosing|In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
48715060|NCT05050396|PROCEDURE|Cooled versus thermocoagulant Radiofrequency Ablation in pain relief of knee osteoarthritis|Radiofrequency (RF) ablation, or modulation of the sensory innervation surrounding the knee, specifically the genicular nerves (GNs), has emerged as a therapeutic option to treat chronic knee OA pain for patients who are unresponsive to conservative treatments or are unsuitable candidates for total knee arthroplasty (TKA). \[16, 17\] Similar to conventional RFA, water-cooled radiofrequency (CRF) ablation is a novel technology that utilizes thermal ablative mechanisms; however, CRF gives the ability to create a greater local neuronal lesion to increase the changes of effective denervation \[20\]
48180212|NCT04157933|DRUG|009-A0|Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
48715061|NCT00086502|DRUG|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
48028926|NCT04625803|DRUG|Camrelizumab , apatinib and chemotherapy|"Camrelizumab 200 mg, IV infusion on Days 1 each 14-day cycle~Apatinib 250mg oral administration once a day, for two months~mFOLFOX6 oxaliplatin 85 mg/m\^2 IV infusion on Day 1 of each14-day cycle. Fluorouracil: 400 mg/m2 as a bolus injection given after a two-hour leucovorin infusion at a dose of 400 mg/m2. The loading dose is then followed by a 46-hour 5-fluorouracil infusion of 2,400 mg/m2 via a pump programmed to provide a constant drug infusion rate."
48180213|NCT04157933|DRUG|009-B1 (active --> placebo) crossover|Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2
48180214|NCT04157933|DRUG|009-B2 (placebo --> active) crossover|Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
48380870|NCT04087486|DIAGNOSTIC_TEST|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~* The Patient Competency Rating Scale (PCRS)~* TEM (Multiple errands test)~* GREFEX~* 5 POINTS TEST~* TAP 2.3~* Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
48380871|NCT06242262|OTHER|Deep neuromuscular block|Patients will receive deep neuromuscular block by using cis-atracurium. After tracheal intubation for 15 min, a cis-atracurium pump will be started, and its rate will be adjusted to maintain a post-tetanic count (PTC) in the 1-2 range.
48380872|NCT06242262|OTHER|Moderate neuromuscular block|Patients will receive moderate neuromuscular block by using cis-atracurium. Pump delivery of cis-atracurium will be started when the TOF count returned to 2. The TOF count is maintained between 1 and 3 by adjusting the pump rate
48380873|NCT06538389|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48380874|NCT06538389|DRUG|BRC-001|Given PO
48180215|NCT02531867|BIOLOGICAL|Asfotase Alfa|
48380875|NCT06538389|DRUG|Placebo Administration|Given PO
48380876|NCT06538389|OTHER|Questionnaire Administration|Ancillary studies
48380877|NCT02183168|DRUG|Meloxicam suppository|
48715062|NCT00086502|DRUG|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
48180216|NCT04624945|DIAGNOSTIC_TEST|APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)|"Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6)."
48380878|NCT02183168|DRUG|Meloxicam tablet|
48715063|NCT00086502|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
48380879|NCT02183168|DRUG|Indomethacin|
48380880|NCT00442572|DRUG|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
48380881|NCT03781817|DRUG|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
48715064|NCT00086502|DRUG|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
48715065|NCT04637919|BIOLOGICAL|IN-B001 EV71 A dose|Inactivated vaccine against EV71, three doses, 28 days interval
48715066|NCT04637919|BIOLOGICAL|IN-B001 CVA16 B dose|Inactivated vaccine against CVA16, three doses, 28 days interval
48715067|NCT04637919|BIOLOGICAL|IN-B001 Bivalent C dose|Inactivated vaccine against EV71/CVA16, three doses, 28 days interval
48715068|NCT04637919|BIOLOGICAL|Placebo|Placebo, three doses, 28 days interval
48715069|NCT01680627|BEHAVIORAL|CASI|
48715070|NCT05864131|BEHAVIORAL|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
48715071|NCT05864131|BEHAVIORAL|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
48715072|NCT04533399|BIOLOGICAL|SARS-CoV-2 rS/Matrix-M1 Adjuvant|Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
48715073|NCT04533399|OTHER|Placebo|Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
48715074|NCT04218162|DRUG|Lasmiditan 50mg|Lasmiditan 50mg
48715075|NCT04218162|DRUG|Lasmiditan 100mg|Lasmiditan 100mg
48715076|NCT04218162|DRUG|Placebo|Placebo
48715077|NCT03983772|DIETARY_SUPPLEMENT|RS blend|The intervention is a proprietary resistant starch blend.
48022668|NCT06535724|PROCEDURE|Chronic plantar fasciitis endoscopic debridement coupled with heel spur resection|"1. Preoperative Preparation: popliteal nerve block, patient positioning supine with the operated limb fully externally rotated, spinal anesthesia, tourniquet application.~2. Surgical Procedure:~   * Initial Marking from the heel bone arch to the calcaneal bone to locate the entry point.~  * First Incision and Portal Creation: an initial incision at the palpated site using a size 11 blade; blunt dissection to reveal the plantar fascia; arthroscope entry.~  * Secondary Entry: 3 cm distally from the initial incision; positioning of the arthroscope; additional blunt dissection and obturator insertion.~  * Operative Technique: continuous irrigation with sterile saline; 3.5-mm shaver introduced through the distal portal; meticulous debridement of inflamed and pathological tissue; removal of calcaneal spurs; thinning of the plantar fascia~3. Postoperative Care • Careful monitoring and guided rehabilitation to support optimal healing and recovery."
48022669|NCT05781035|PROCEDURE|dexmedetomidine|patients will recieve moderate sedation by dexmedetomidine as study group
48022670|NCT05781035|PROCEDURE|general anesthesia|general anesthesia with neuromuscular blockade under controlled ventilation as control group.
48022671|NCT04998240|BIOLOGICAL|BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)|"The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~Mode of Administration:~Intramuscular~Storage Conditions: 2°C to 8°C"
48180217|NCT04923945|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
48715078|NCT03983772|OTHER|Placebo|The placebo is starch.
48715079|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
48715080|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
48715081|NCT01386242|OTHER|Saline Injection|Saline Injection, 1mL, im,three times per week
48715082|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
48715083|NCT01162174|DIETARY_SUPPLEMENT|Oligonol|
48715084|NCT04338633|DRUG|Conventional calcium hydroxide paste|Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
48715085|NCT04338633|DRUG|Calcium hydroxide nanoparticle|Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
48715086|NCT04338633|DRUG|Combined Calcium hydroxide with silver nanoparticle|Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
48715087|NCT01495468|BIOLOGICAL|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
48715088|NCT02878668|PROCEDURE|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
48715089|NCT01340508|RADIATION|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
48715090|NCT02362126|DEVICE|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
48518474|NCT06052046|DEVICE|TOTAL30 for Astigmatism Contact Lenses|Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
48715091|NCT04900948|DRUG|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
48022672|NCT04998240|BIOLOGICAL|Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),|"Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein), manufactured by Johnson and Johnson in the United States of America.~Dose formulation: One dose (0.5 ml) contains contains 5 x 10 10 virus particles~Mode of administration: Intramuscular~Storage Conditions: 2°C to 8°C"
48180218|NCT02485899|BIOLOGICAL|BMN 190|300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
48518475|NCT04324021|BIOLOGICAL|Emapalumab|I.v. infusion every third day
48180219|NCT02485899|DEVICE|Intracerebroventricular (ICV) access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
48715092|NCT04900948|DRUG|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
48715093|NCT03763344|BEHAVIORAL|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery \& cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
48180220|NCT02250690|DEVICE|experimental group - tDCS|
48380882|NCT03781817|DRUG|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
48715094|NCT05502666|BEHAVIORAL|¡Salud! Por la Vida|Lay health worker (LHW) delivered educational intervention for colorectal cancer screening (CRCS). The intervention consisted in having the participant complete a tailored interactive multimedia intervention (TIMI). TIMI consisted of a series of educational videos that addressed common barriers to colorectal cancer screening as well as provided information about colorectal cancer (CRC) and CRCS tests. Participants were able to tailor the TIMI for sex (male/female) and CRC family history. After TIMI completion, the LHW provided participant with a copy of the SPLV newsletter and printed infographics on CRC, CRCS, and an action plan tailored by type of CRCS (FOBT/FIT or colonoscopy). The Intervention Group subject participation took approx. up to 2 hours and Control Group up to 1 hour (half hour for each: baseline and follow-up interview). Follow-up data was collected 6 months post education session (intervention group) or post-baseline survey (control group).
48180221|NCT02250690|DEVICE|Control group (tDCS sham)|
48180222|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
48180223|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
48180224|NCT01333111|DRUG|nonacog beta pegol|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
48022673|NCT04998240|BIOLOGICAL|Placebo - Normal saline (0.9% sodium chloride solution)|"Placebo - Normal saline (0.9% sodium chloride solution)~Dose formulation: Not Applicable~Mode of administration: Intramuscular~Storage conditions: 15°C to 30°C"
48022674|NCT01076595|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
48022675|NCT05625204|BEHAVIORAL|Center based attention control|Center based attention control
48180225|NCT04944498|PROCEDURE|Modified Tarsorrhaphy|A combination of levator recess, lateral tarsorrhaphy of 10 mm, and lateral canthopexy/lateral tarsal strip
48180226|NCT04944498|PROCEDURE|Gold Weight Implant|Installation of 1,5 gram gold weight implant above tarsal plate and underneath levator recess
48380883|NCT05181553|OTHER|Canada's Food Guide principles (CFG diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
48518476|NCT04324021|BIOLOGICAL|Anakinra|Daily i.v. infusion
48518477|NCT06582589|DEVICE|Healsea Children|Subjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out
48518478|NCT02185079|BEHAVIORAL|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
48715095|NCT01231321|DRUG|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
48715096|NCT03423108|BEHAVIORAL|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
48715097|NCT03423108|BEHAVIORAL|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
48715098|NCT05231200|BEHAVIORAL|QI Team Building|Each NICU will create a core QI team composed of 6-8 multidisciplinary members including a parent advisor, when feasible. This team will lead the QI activities and education, and champion the culture and practice change in the unit.
48715099|NCT05231200|BEHAVIORAL|QI education|Each NICU QI team will receive standardized QI education using the 6-hour EPIQ Workshop which involves hands-on approach to enable teams to successfully implement QI projects together. EPIQ 10 Steps and QI Tools will be used to build the team's understanding of QI using realistic improvement opportunities based on the standardized care bundles identified in the trial.
48715100|NCT05231200|OTHER|Standardized care bundle- respiratory care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for stabilization and respiratory care in moderate and late preterm infants (MLPIs) including~1. establishing effective ventilation in the delivery room~2. prevention of hypothermia~3. early diagnosis and management of respiratory distress with continuous positive airway pressure (CPAP)~4. standardized approach for surfactant indications and administration~5. standardized approach for early extubation."
48715101|NCT05231200|OTHER|Standardized care bundle- nutritional care|"A care bundle is a small, simple set (3-5 elements) of evidence-based practices that, when performed collectively and reliably, will result in improved patient outcomes. This bundle will aim to implement best practices for nutritional support in MLPIs including~1. early initiation of enteral or parenteral nutrition;~2. standardized tables for feeding initiation and progression~3. optimizing breastfeeding and use of mother's own milk~4. standardized approach for a transition from enteral nutrition via tube feeds to oral feeds."
48715102|NCT05231200|BEHAVIORAL|QI mentoring|Each NICU in the intervention arm will have one or more assigned members of the study team who are experienced in collaborative QI and EPIQ methods. The mentors will help local QI teams to engage frontline staff in QI and navigate the unit-specific challenges.
48715103|NCT05231200|BEHAVIORAL|Collaborative networking|The study team will conduct virtual meetings every 2 months for the NICUs in intervention arm allowing local QI teams to discuss progress, and share data. The investigators will arrange annual in-person or virtual meetings for the NICUs in the intervention arm to present projects, successes, and lessons learned. These NICUs will have continuing access to the data and will receive quarterly reports using statistical process control charts outlining the unit's performance compared to other units and to the group average.
48715104|NCT05231200|OTHER|Current practice- standard of care|All participating NICUs will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. NICUs in the control arm can continue conducting QI activities relevant to current practice, but without receiving the interventions outlined above until they transition to the intervention arm. The investigators will capture these activities and account for them in the analysis.
48715105|NCT05665400|DEVICE|Bloomlife Lovelace FT|Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
48380884|NCT05181553|OTHER|Standard North American diet (NAD diet)|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the eating habits of Canadians.
48715106|NCT04584346|DIETARY_SUPPLEMENT|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
48715107|NCT04584346|OTHER|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
48715108|NCT03542916|DRUG|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
48022676|NCT05625204|BEHAVIORAL|Center based HIIT|Center based HIIT
48715109|NCT03542916|DRUG|NESP 60ug|NESP 60ug SC, IV injection
48715110|NCT03417817|DEVICE|Bravo|wireless pH monitoring over 96 hours
48715111|NCT00563095|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|
48715112|NCT00563095|PROCEDURE|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
48715113|NCT00099294|DRUG|Glufosfamide|
48715114|NCT04217161|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
48022677|NCT05625204|BEHAVIORAL|Home based HIIT|Home based HIIT
48715115|NCT00260065|DRUG|Decitabine|20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
48715116|NCT03135925|OTHER|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
48022678|NCT00529945|DEVICE|PFx Closure System|
48022679|NCT02341248|OTHER|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
48022680|NCT00358241|PROCEDURE|Nerve block|
48380885|NCT01789476|DRUG|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
48380886|NCT01789476|DRUG|Placebo|Matching placebo administered using same dosing algorithm as the active arm
48380887|NCT04539106|DRUG|intravitreal injection of Ranibizumab|intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus
48380888|NCT06652971|DRUG|CKD-379|QD, PO
48518479|NCT02185079|BEHAVIORAL|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
48022681|NCT06439758|DRUG|Metformin|Metformin 1000 mg/day for 6 months
48022682|NCT06439758|BEHAVIORAL|Lifestyle|Dietary lifestyle modifications
48022683|NCT05969353|OTHER|accupunture|BFA
48715117|NCT04690192|BIOLOGICAL|CNCT19|2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
48715118|NCT04690192|DRUG|Gemcitabine Injection|600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
48715119|NCT04690192|DRUG|busulfan|105mg/m2, day -7 until -5,
48715120|NCT04690192|DRUG|Melphalan Injection|60mg/m2, day -3, -2
48715121|NCT00491660|BEHAVIORAL|supine positioning|
48715122|NCT00491660|BEHAVIORAL|lateral positioning|
48715123|NCT03777124|DRUG|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
48715124|NCT03777124|DRUG|Apatinib|Subjects receive Apatinib orally every day
48715125|NCT03777124|DRUG|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
48715126|NCT03777124|DRUG|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
48715127|NCT03753100|OTHER|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
48715128|NCT03067285|DRUG|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
48715129|NCT03067285|DRUG|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
48715130|NCT03188835|DIETARY_SUPPLEMENT|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
48715131|NCT03188835|OTHER|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
48715132|NCT03188835|RADIATION|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
48715133|NCT03188835|RADIATION|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
48715134|NCT03188835|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
48715135|NCT03188835|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
48715136|NCT03188835|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
48715137|NCT03188835|DEVICE|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
48715138|NCT03188835|DEVICE|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
48715139|NCT03188835|DEVICE|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
48715140|NCT03188835|DEVICE|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
48715141|NCT00349258|DRUG|Leuprolide acetate|
48715142|NCT03156959|BEHAVIORAL|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
48715143|NCT03156959|BEHAVIORAL|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
48715144|NCT05364736|DIETARY_SUPPLEMENT|Highland barley β-glucan dietary supplement|100 mL oral liquid mainly containing highland barley β-glucan once daily for 12 weeks
48715145|NCT05364736|OTHER|Placebo controls|Placebo with a similar appearance and taste to highland barley β-glucan supplement
48380889|NCT05416346|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-i) has been showed to be effective in reducing insomnia symptoms and insomnia-related symptoms, including sleepiness, dysfunctional beliefs and attitudes about sleep, anxiety and depressive symptoms
48518480|NCT04486365|PROCEDURE|Bifocal bone transport.|The bifocal approach is a single osteotomy to create one transported bone segment between the osteotomy and the defect.
48380890|NCT05416346|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE group received sleep hygiene education delivered in text form, and the same intervention as the dCBT-i group did after four weeks.
48380891|NCT02322866|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
48380892|NCT02322866|DRUG|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
48380893|NCT01832896|DRUG|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
48380894|NCT06220916|BEHAVIORAL|Dance training in Classical Ballet and Contemporary Dance|Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
48380895|NCT06522828|DRUG|SSGJ-707|SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
48380896|NCT06522828|DRUG|carboplatin|chemotherapy
48380897|NCT06522828|DRUG|paclitaxel|chemotherapy
48380898|NCT04801069|DEVICE|Nocturnal Ventilation|AirCurve 10CS PaceWave (Resmed)
48518481|NCT04486365|PROCEDURE|Trifocal bone transport|The trifocal approach is two osteotomies creating two separate transported bone segments.
48518482|NCT03354715|DEVICE|Rapid prototyping Denture base|The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
48518483|NCT03354715|DEVICE|Heat Cured Conventional Complete Denture|it is the main treatment for most of completely edentoulous Cases
48518484|NCT04683224|BIOLOGICAL|UB-612|100 µg \[microgram\] of an experimental study vaccine
48518485|NCT04683224|OTHER|Placebo|Placebo is a 0.9% sodium chloride (normal saline) injection
48518486|NCT02291640|DEVICE|MIL|direct laryngoscopy
48380899|NCT05400590|PROCEDURE|Peripheral venous blood sample|2.5% of body weight
48380900|NCT05400590|PROCEDURE|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
48380901|NCT03712462|BEHAVIORAL|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
48380902|NCT03712462|BEHAVIORAL|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
48518487|NCT02291640|DEVICE|CoPilot|video laryngoscopy
48380903|NCT00790972|DRUG|Sinofresh|two sprays in each nostril three times daily for one week
48380904|NCT00790972|DRUG|Placebo|two sprays in each nostril three times daily for one week
48518488|NCT05215132|RADIATION|MRI|1.5T or 3T MRI scanner (Siemens Medical Systems)
48380905|NCT02384980|DEVICE|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
48380906|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - Walking|30 minutes of walking or light jogging a day at a moderate intensity for 30 minutes a day, 5 days a week for 12 weeks
48380907|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - HIIT Cycling|Four, 4 minute high intensity intervals of exercise, separated by 3 minutes of lower intensity exercise + a 10 minute warm up and 5 minute cool down for 40 minutes a day, 3 days a week for 12 weeks
48380908|NCT02936349|OTHER|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
48380909|NCT02189928|DEVICE|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
48380910|NCT02189928|OTHER|Usual care|
48380911|NCT03976674|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
48518489|NCT05215132|DRUG|Gadavist 2Ml Solution for Injection|Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
48518490|NCT02176265|DEVICE|Qvanteq bioactive coronary stent|PCI
48518491|NCT04912089|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
48518492|NCT03958292|DEVICE|IODIM|Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
48518493|NCT00050245|DRUG|Rituximab|
48518494|NCT04199052|BEHAVIORAL|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
48715146|NCT03022500|DRUG|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
48715147|NCT06110455|OTHER|Neuromuscular Training exercises|The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.
48715148|NCT06110455|OTHER|Hip and Knee Muscular Strength exercises|The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
48715149|NCT05152706|OTHER|Aerobic training|Cycling at the aerobic intensity
48715150|NCT05152706|OTHER|Photobiomodulation|Photons therapy
48715151|NCT02000011|OTHER|comprehensive geriatric assessment (CGA)|
48715152|NCT02000011|OTHER|Geriatric intervention plan (GIP)|
48715153|NCT04159532|DIETARY_SUPPLEMENT|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
48715154|NCT04159532|DIETARY_SUPPLEMENT|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
48715155|NCT04159532|DIETARY_SUPPLEMENT|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
48715156|NCT03322423|DEVICE|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
48715157|NCT03322423|DEVICE|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
48715158|NCT03322423|DEVICE|Spherical Contact Lens 2|BioTrue ONEDay Spherical
48715159|NCT03043677|BIOLOGICAL|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
48380912|NCT04246411|BEHAVIORAL|Ultrasound-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field.~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
48022684|NCT00020410|BIOLOGICAL|filgrastim|
48518495|NCT06194461|BIOLOGICAL|AZD5851|Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884.
48518496|NCT06194461|BIOLOGICAL|AZD0754|Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729.
48518497|NCT00006509|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
48715160|NCT04101617|BEHAVIORAL|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
48715161|NCT00334360|DRUG|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
48715162|NCT00334360|DRUG|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
48715163|NCT00334360|DRUG|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
48715164|NCT00334360|DRUG|Control|No drugs given during controlled hypothermia
48715165|NCT02993042|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
48715166|NCT04412694|DRUG|Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).|Preoperative oral dexamathasone supplementation in a single dose of 8mg.
48715167|NCT04412694|DRUG|Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).|Preoperative oral supplementation of sweetener in a single dose.
48715168|NCT04412694|DIAGNOSTIC_TEST|Preoparative blood laboratory tests|Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
48715169|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 6 hour|At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
48715170|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory blood tests at 24 hour|At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
48715171|NCT04412694|DIAGNOSTIC_TEST|Postoperative laboratory drainage fluid tests at 24 hour|At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
48715172|NCT04412694|PROCEDURE|Total thyroidectomy|Patients will undergo total thyroidectomy under general anesthesia.
48715173|NCT04412694|OTHER|Symptomatic hypocalcaemia at 6 hour|At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
48715174|NCT04412694|OTHER|Symptomatic hypocalcaemia at 24 hour|At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
48715175|NCT04412694|OTHER|Postoperative pain at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
48715176|NCT04412694|OTHER|Postoperative pain at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
48518498|NCT00006509|BIOLOGICAL|gp160 MN/LAI-2|
48715177|NCT04412694|OTHER|Postoperative nausea and vomiting at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
48715178|NCT04412694|OTHER|Postoperative nausea and vomiting at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
48715179|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 6 hour|At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
48715180|NCT04412694|OTHER|Postoperative sore throat and hoarseness at 24 hour|At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
48715181|NCT00005013|DRUG|Sertraline|
48715182|NCT00005013|DRUG|Hypericum perforatum (St. John's wort)|
48715183|NCT01812369|DRUG|GEMCITABINE CISPLATINE|
48715184|NCT01812369|DRUG|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
48715185|NCT06035744|DRUG|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
48380913|NCT04246411|BEHAVIORAL|Auscultation-guided determination of cuffless RAE tube depth|"1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA~2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field~3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning"
48380914|NCT06649656|DRUG|TQB2252 injection|TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
48715186|NCT06035744|DRUG|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
48715187|NCT03358641|OTHER|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
48715188|NCT04231214|DRUG|Olodaterol-Tiotropium|5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
48715189|NCT04173195|OTHER|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
48022685|NCT00020410|PROCEDURE|peripheral blood stem cell transplantation|
48380915|NCT02248428|DRUG|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
48518499|NCT01493921|DRUG|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
48715190|NCT06216314|OTHER|Heart rate (HR)|Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.
48715191|NCT06216314|OTHER|Race pace based approach (RP)|"Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace"
48715192|NCT06216314|OTHER|Heart rate + heart rate variability (HRV)|Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
48715193|NCT00951249|BEHAVIORAL|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
48715194|NCT00951249|BEHAVIORAL|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
48715195|NCT00951249|BEHAVIORAL|Peer health care system navigators|HIV/STI treatment and other medical and social services
48715196|NCT00951249|BEHAVIORAL|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
48715197|NCT05858957|DRUG|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
48715198|NCT05858957|DRUG|Saline|100 ml saline infusion apply to the Group S
48715199|NCT02402686|DRUG|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
48715200|NCT04393272|DEVICE|Three dimensional sensor system designed for fall detection (Fearless)|Detection of falls in nursing home residents and acute geriatric hospital patiients
48715201|NCT02688582|OTHER|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
48715202|NCT00005647|DRUG|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
48715203|NCT00005647|DRUG|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
48715204|NCT00892606|DRUG|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
48715205|NCT00892606|DRUG|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
48715206|NCT03381313|BEHAVIORAL|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
48715207|NCT06105294|BEHAVIORAL|time-restricted eating|Restrict eating to a 10-hour window.
48715208|NCT05512702|DRUG|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
48380916|NCT02248428|DRUG|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
48715209|NCT05512702|DRUG|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
48715210|NCT02652416|DRUG|BI 1026706|oral administration
48715211|NCT02652416|DRUG|Placebo|placebo
48715212|NCT05389501|BEHAVIORAL|Social policy intervention to support women of reproductive years|"The project team will attempt to address this challenge by delivering the following interventions through social workers in underdeveloped primary healthcare settings to promote maternal and child health:~1. Developing a database on a digital app of participants in the study and use the data for development of an Index for Maternal Health and Wellbeing~2. Conducting a Community Assessment Needs~3. Conduct a psychosocial needs assessment~4. Develop interprofessional health workforce collaboration~5. Measure basic clinical health indicators~6. Provide health awareness and literacy training to participants"
48715213|NCT04041206|DEVICE|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
48715214|NCT01741714|OTHER|Sham chiropractic manipulative therapy|Sham manipulation
48380917|NCT02248428|DRUG|Cyclophosphamide|300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
48380918|NCT02248428|DRUG|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
48715215|NCT01741714|OTHER|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
48715216|NCT04902664|BEHAVIORAL|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
48715217|NCT04902664|BEHAVIORAL|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
48715218|NCT04902664|BEHAVIORAL|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
48715219|NCT04902664|BEHAVIORAL|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
48715220|NCT05892367|OTHER|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
48022686|NCT00020410|RADIATION|yttrium Y 90 monoclonal antibody B3|
48022687|NCT00346034|DRUG|Pregabalin|150 to 600mg/day
48022688|NCT01853150|DEVICE|rTMS Motor cortex|
48022689|NCT01853150|DEVICE|rTMS Supplementary motor area|
48380919|NCT05980637|DRUG|Shaoyao Gancao Decoction with Addition|11g twice daily for 4 weeks
48380920|NCT05980637|OTHER|Placebo|11g twice daily for 4 weeks
48518500|NCT01493921|DRUG|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
48518501|NCT00492440|BIOLOGICAL|recombinant interleukin-7|
48518502|NCT00492440|GENETIC|gene expression analysis|
48715221|NCT02552251|BIOLOGICAL|Hormonal balance measurements|
48715222|NCT02552251|BIOLOGICAL|metabolic balance measurements|
48380921|NCT03487146|DEVICE|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
48715223|NCT02552251|BIOLOGICAL|bone balance measurements|
48715224|NCT02552251|BEHAVIORAL|quality of life assessment|
48715225|NCT01964599|DIETARY_SUPPLEMENT|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
48715226|NCT01964599|DIETARY_SUPPLEMENT|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
48715227|NCT01964599|DIETARY_SUPPLEMENT|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
48715228|NCT01964599|DIETARY_SUPPLEMENT|Control|
48715229|NCT01533090|DRUG|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
48380922|NCT00828009|BIOLOGICAL|bevacizumab|IV
48380923|NCT00828009|BIOLOGICAL|Tecemotide|
48022690|NCT00210652|DRUG|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
48380924|NCT00828009|DRUG|carboplatin|IV
48380925|NCT00828009|DRUG|cyclophosphamide|IV
48380926|NCT00828009|DRUG|paclitaxel|IV
48380927|NCT00828009|RADIATION|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
48380928|NCT05117307|DRUG|Bupivacaine 0.25% Injectable Solution|Ultrasound-guided block with 20 ml %0.25 bupivacaine, per side
48380929|NCT06251765|OTHER|Clinical scores|Clinical scores will be administered to patients
48715230|NCT01533090|DRUG|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
48715231|NCT03561701|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
48715232|NCT03561701|DRUG|Placebo|matching placebo capsule
48715233|NCT03090074|BEHAVIORAL|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
48715234|NCT03090074|BEHAVIORAL|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
48715235|NCT05118815|OTHER|Slim abutment|Use a narrower abutment to see if they present a better biological seal.
48715236|NCT05118815|OTHER|Standard abutment|Use a standard abutment
48380930|NCT06251765|OTHER|Range of Motion|Evalutation of knee mobility
48380931|NCT06018363|BIOLOGICAL|Allogenic B7H3 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^7 cells) , dose 2 (3 × 10\^7 cells), dose 3 (1× 10\^8 cells); Phase 2 : dose of RP2D.
48380932|NCT04131439|DIAGNOSTIC_TEST|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
48715237|NCT02893826|DRUG|EG-1962 (nimodipine microparticles)|
48715238|NCT02893826|DRUG|Enteral Nimodipine|
48715239|NCT00018382|DRUG|rosiglitazone|
48715240|NCT05471102|PROCEDURE|Study group: lower segment resection with ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection with ligation ((suturing)) of the anterior division of the internal iliac artery (4 cm distal to the bifurcation of the common iliac artery); in addition to the bilateral uterine artery ligation at 2 levels; bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision.
48715241|NCT05471102|PROCEDURE|Control group: lower segment resection without ligation of the anterior division of the internal iliac artery|Cases managed by uterine lower segment resection without ligation of the anterior division of the internal iliac artery. (i.e., only bilateral ligation at a level below the lower most placental part followed by bilateral uterine artery ligation at the level of the hysterotomy incision).
48715242|NCT05909774|DEVICE|"Test with Atalante exoskeleton in continuous walk type"|"The continuous walk is smoother and more physiologic than the push and swing walk"
48715243|NCT00892359|DRUG|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
48715244|NCT00002342|DRUG|Tecogalan sodium|
48715245|NCT00493428|DRUG|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
48715246|NCT00733135|DEVICE|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
48022691|NCT06105307|BEHAVIORAL|RN-SLEEP|RN-SLEEP is a training program delivered via mobile application and designed to help improve the sleep of nurses who engage in shift work. RN-SLEEP aims to include training on strategies for sleeping while working shift work, basics of sleep science and physiology, behavior change components (i.e., goal setting), and components of cognitive behavioral therapy for insomnia (i.e., relaxation).
48022692|NCT06105307|BEHAVIORAL|Healthy Habit - Educational Control|Healthy habit app (i.e., exercise tracking) to act as a control arm for the RN-SLEEP intervention
48380933|NCT05297604|RADIATION|Vascular photobiomodulation (VPBM)|The participants received a 20-minute single session of VPBM. This noninvasive method involves the use of low-power laser coupled to a bracelet designed to transport the light beam transcutaneously over the radial artery. The laser device (DMC Therapy Ec) delivered irradiation with a power of 100 ± 20 mW, wavelength of 660 ± 10 nm (red light) and energy of 120 J applied continuously, with irradiance of 35 W/cm².
48380934|NCT05297604|RADIATION|Sham group (simulated vascular photobiomodulation)|Simulated radiation. The participants received a single session.
48715247|NCT01120314|DRUG|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
48380935|NCT05144971|DIAGNOSTIC_TEST|Glucose, Creatinine|Compare diagnostic tests to reference methods
48380936|NCT02320734|DRUG|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
48380937|NCT01771627|DRUG|varenicline|Given PO
48380938|NCT01771627|DRUG|nicotine patch|
48380939|NCT05672277|OTHER|TENS 1|Parasacral TENS will be applied for 30 minutes 3 days a week during 6 weeks.
48715248|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
48715249|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
48380940|NCT05672277|OTHER|TENS 2|Parasacral TENS will be applied for 30 minutes one day a week during 6 weeks.
48518503|NCT00492440|GENETIC|polymerase chain reaction|
48518504|NCT00492440|GENETIC|protein expression analysis|
48518505|NCT00492440|OTHER|flow cytometry|
48518506|NCT00492440|OTHER|immunoenzyme technique|
48518507|NCT00492440|OTHER|immunologic technique|
48518508|NCT00492440|OTHER|laboratory biomarker analysis|
48518509|NCT00492440|OTHER|pharmacological study|
48715250|NCT03930550|PROCEDURE|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
48715251|NCT05953116|DIETARY_SUPPLEMENT|Nutrition supplementation|Blinded researchers will provide the randomly assigned supplement product to the trial participants for a period of 90 days. Used packaging will be collected at the end of every week from each trial participant to monitor compliance.
48715252|NCT05953116|OTHER|Exercise|Trained researchers will facilitate resistance-based exercises two to three times a week in an enclosed venue (gym). Trial participants will be assessed at baseline for one repetition maximum (1RM) which will serve as a basis for load progression. A target of 3 sets and 6-15 repetitions with at least 30 seconds rest in between sets will be performed by the trial participants under supervision of a trained researcher.
48715253|NCT01169688|OTHER|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
48715254|NCT02004145|BEHAVIORAL|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
48715255|NCT02004145|BEHAVIORAL|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
48715256|NCT04035564|DRUG|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
48715257|NCT04035564|DRUG|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
48715258|NCT01610596|DRUG|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
48715259|NCT01610596|DRUG|Placebo|
48715260|NCT02080325|OTHER|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
48715261|NCT02080325|OTHER|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
48715262|NCT03906656|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
48180227|NCT05350488|OTHER|Informational Interview|Interview topics will fall in the broad categories of assessing medical knowledge and understanding of stroke, knowledge of medical and community resources, understanding and experience of post-stroke rehabilitation barriers faced upon reintegrating back home and ability to continue management of stroke diagnosis and suggestions for improvement.
48380941|NCT00692198|DRUG|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
48715263|NCT03906656|DEVICE|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
48715264|NCT00246506|PROCEDURE|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
48380942|NCT05646342|OTHER|Measure of CO by ECHocardiac Machine|we will realise ETT before and after PLR in all women that eligible of crieria inclusion , in obstetric consultation
48715265|NCT00246506|PROCEDURE|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
48715266|NCT02617940|OTHER|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
48715267|NCT02617940|OTHER|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
48715268|NCT04562597|DRUG|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
48715269|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
48715270|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
48380943|NCT00778193|DRUG|Naproxen|1 tablet 500mg BID for 8 days
48380944|NCT00778193|DRUG|Aspirin|1 tablet 81mg QD for 8 days
48380945|NCT00778193|DRUG|Celecoxib|1 capsule 200mg QD for 8 days
48715271|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
48380946|NCT00778193|DRUG|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
48380947|NCT00778193|DRUG|Placebo|1 capsule BID for 8 days
48380948|NCT01249625|DEVICE|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
48380949|NCT01249625|DEVICE|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
48380950|NCT06520839|DRUG|Tadalafil 5mg|We will include in the study 90 patients with diabetes and erectile dysfunction. We will use the IIEF-5 questionnaire to confirm the diagnosis of erectile dysfunction. Patients between the ages of 40 and 65 who score 21 points or less on the IIEF-5 scale will be included in the study. Each patient will receive drug tadalafil 5 mg every day for three months.
48380951|NCT05825417|DRUG|Selexipag|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
48380952|NCT05825417|DRUG|Riociguat|If Arm A - Up-titration to maximum tolerated dose followed by de-escalation If Arm B - Up-titration to maximum tolerated dose followed by observation, modification or transition at discretion of responsible care team where necessary.
48380953|NCT05825417|DEVICE|CardioMEMS pulmonary artery pressure monitor|Implantation and remote monitoring established with patient initiated daily readings
48380954|NCT05825417|DEVICE|Confirm Rx|Implantation and remote monitoring established with automated daily readings / downloads
48380955|NCT04327869|DEVICE|Magnetically controlled capsule endoscopy|The subjects swallowed the capsule with water in the left lateral position. When capsule enter stomach cavity, subject was asked to sit up and ingested 4 g aerogenic powder with 5 ml water to distend the stomach, and performed gastric baseline examinations to identify the lesions. After baseline examination, subjects ingested dyed sucralfate gel and performed the first-time examination. The examination was repeated at 30 min intervals, until dyed sucralfate gel disappeared completely.
48380956|NCT05670912|DRUG|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
48380957|NCT05670912|DRUG|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
48380958|NCT01982539|DRUG|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
48380959|NCT04114461|DRUG|HL-TOF tab. 5mg|HL-TOF
48380960|NCT04114461|DRUG|Xeljanz tab. 5mg|Xeljanz
48380961|NCT01432600|DRUG|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
48380962|NCT01432600|DRUG|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
48380963|NCT01432600|DRUG|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
48380964|NCT03184467|DRUG|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
48380965|NCT03184467|DRUG|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
48715272|NCT04562597|DRUG|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
48715273|NCT04562597|DRUG|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
48715274|NCT05536856|DRUG|a new effervescent mixture 5-florouracil formula|30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
48715275|NCT05536856|DRUG|5-Fluorouracil plain powder|30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
48380966|NCT03184467|DRUG|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
48380967|NCT05392920|OTHER|assessment study|there is no intervention in this study
48380968|NCT03053102|DRUG|Danicopan|Danicopan was administered as multiple oral doses over a period of at least 28 days.
48715276|NCT00046150|DRUG|Insulin glulisine (HMR1964)|
48715277|NCT04286672|DIAGNOSTIC_TEST|Metadherin|study alterations of MTDH gene expression in the serum of bladder cancer patients
48715278|NCT01328262|OTHER|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
48715279|NCT01328262|OTHER|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
48715280|NCT03671629|OTHER|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
48715281|NCT02750865|BEHAVIORAL|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
48518510|NCT03907371|DRUG|Donepezil Hydrochloride|Donepezil will be used with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24).
48518511|NCT03907371|OTHER|Placebo|Placebo will be used with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24).
48518512|NCT01408602|DRUG|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
48518513|NCT01408602|DRUG|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
48518514|NCT01408602|DRUG|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
48518515|NCT03906110|BEHAVIORAL|Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials|Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.
48518516|NCT03906110|BEHAVIORAL|Contact Message|Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
48715282|NCT04287803|DRUG|Methoxyflurane|Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
48715283|NCT02513758|OTHER|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
48715284|NCT06157944|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
48715285|NCT06294938|OTHER|Cacao fruit pulp|Cacao pulp puree
48715286|NCT06294938|OTHER|Dextrose|Dextrose beverage
48715287|NCT01442792|DRUG|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
48715288|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
48715289|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
48715290|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
48715291|NCT02345356|GENETIC|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
48715292|NCT02345356|OTHER|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
48715293|NCT00030771|DRUG|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
48715294|NCT00030771|RADIATION|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
48715295|NCT00030771|PROCEDURE|Surgery|3-4 weeks after termination of radiotherapy
48715296|NCT06434129|DIAGNOSTIC_TEST|DTI|Diffusion MRI imaging
48715297|NCT03202108|DIETARY_SUPPLEMENT|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
48715298|NCT03859739|DRUG|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
48715299|NCT03986047|DEVICE|Thermal care|Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
48715300|NCT03986047|OTHER|Exercises|In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
48715301|NCT03986047|DEVICE|Sham|The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
48715302|NCT03986047|BEHAVIORAL|Education for the management of acute low back pain|Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
48715303|NCT01478841|DRUG|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
48715304|NCT01478841|DRUG|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
48715305|NCT01209871|BIOLOGICAL|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
48715306|NCT01209871|OTHER|Laboratory Biomarker Analysis|Correlative studies
48715307|NCT00539422|GENETIC|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
48715308|NCT00241098|DRUG|valsartan|
48715309|NCT02510183|DEVICE|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
48380969|NCT06375577|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
48715310|NCT02510183|DEVICE|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
48715311|NCT04409717|PROCEDURE|Type II endoleak treatment|Type II endoleak endovascular treatment
48380970|NCT06375577|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) SIS Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
48715312|NCT04668924|PROCEDURE|Epi-on PiXL in high oxygen|After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for \> 50D 15 J/cm\^2 will be used.
48715313|NCT02369666|DIETARY_SUPPLEMENT|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
48715314|NCT02369666|DIETARY_SUPPLEMENT|Placebo|Contains MCT oil.
48715315|NCT05027620|OTHER|Motor-cognitive exercise therapy in the home|"Participants engage in a progressive 10-week exercise program targeted at improving motor and cognitive function. Motor exercises target functional strength, gait and physical activity level. Training sessions occur 3 times weekly and supported by a digital application which has been adapted for people with Parkinson's disease. Weeks 1-2 focus solely on motor exercises. Dual-task (Motor-cognitive) exercises are introduced at week 3 and progressed until week 10. Participants are also encouraged to increase the physical activity levels during the 10 week period.~Weekly contact is made using the video function/ telephone with clinical specialists/ researchers. Two home visits will occur, the first one week prior to the intervention and at the 5-week period. Participants receive motivational messaging and reminders via the app during the intervention period."
48715316|NCT04079543|OTHER|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
48715317|NCT04079543|OTHER|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
48715318|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 10 mg/d|L-Ergothioneine 10 mg/d
48715319|NCT04556032|DIETARY_SUPPLEMENT|L-Ergothioneine 25 mg/d|L-Ergothioneine 25 mg/d
48715320|NCT04556032|OTHER|Placebo|0 mg/d L-Ergothioneine
48715321|NCT01579487|DEVICE|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
48715322|NCT03205904|DIETARY_SUPPLEMENT|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
48715323|NCT01632241|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
48715324|NCT01632241|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
48715325|NCT01632241|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
48715326|NCT04058704|DRUG|Icotinib|125mg Tid/375mg per day
48715327|NCT04058704|RADIATION|SRS/WBRT/HA-WBRT/SMART|\>3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
48715328|NCT03483870|DRUG|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
48715329|NCT03483870|DRUG|Placebo|2 mL of normal saline 0.9% IV injection
48715330|NCT03483870|DRUG|Granisetron|2 mL of 2 mg granisetron IV injection
48715331|NCT05359133|DRUG|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
48715332|NCT05359133|DRUG|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
48715333|NCT03819608|DEVICE|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
48715334|NCT03819608|BEHAVIORAL|real APT|APT-III is an attention processing training program
48715335|NCT03819608|BEHAVIORAL|placebo APT|computerized cognitive training
48715336|NCT03819608|DEVICE|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
48715337|NCT01555554|DRUG|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
48715338|NCT01555554|OTHER|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
48180228|NCT05350488|OTHER|Focus Group|Focus group topics will fall into the same broad categories as the informational interviews, however will be asked from a caregiver's perspective
48715339|NCT06400732|DEVICE|Fitbone Transport and Lengthening System|Implantation of the intramedullary Fitbone Transport Nail and subsequent bone segment transport and, optionally, lengthening.
48715340|NCT02241187|DRUG|PEGPH20|
48715341|NCT02241187|DRUG|Cetuximab|
48715342|NCT02241187|DEVICE|DW & DCE-MRI|
48715343|NCT02241187|OTHER|blood draws|Blood samples will be drawn at various time points.
48715344|NCT04147975|DIAGNOSTIC_TEST|RaPID/BSI Test|RaPID/BSI Test
48715345|NCT02630368|DRUG|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
48715346|NCT02630368|DRUG|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
48715347|NCT02630368|DRUG|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
48715348|NCT02630368|DRUG|Avelumab and JX-594 and Cyclophosphamide|"Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections ."
48715349|NCT01268917|DRUG|aspirin|aspirin 100mg daily until the surgery day
48715350|NCT01268917|DRUG|aspirin|aspirin is stopped 5-7 days before operation
48715351|NCT03356977|DRUG|Crisaborole ointment 2%|Applied BID
48715352|NCT03346551|BEHAVIORAL|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
48715353|NCT03346551|BEHAVIORAL|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
48380971|NCT06375577|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and insulin sampled throughout a 1-hour modified oral glucose tolerance test. Gas exchange will also be monitored throughout the 1-hour study visit.
48518517|NCT03906110|BEHAVIORAL|Personalized One on One Education|"* Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~* Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~* For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~* Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided."
48715354|NCT01452295|DRUG|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
48715355|NCT03582904|PROCEDURE|tDCS|real or sham tDCS delivered to primary motor cortex
48715356|NCT05206071|BIOLOGICAL|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
48715357|NCT00702455|BEHAVIORAL|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
48715358|NCT00702455|BEHAVIORAL|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
48380972|NCT05980013|DEVICE|Whole blood donation supine|Subjects will undergo a 1-unit whole blood donation in a supine position
48380973|NCT05980013|DEVICE|Whole blood donation reclined|Subjects will undergo a 1-unit whole blood donation in a reclined position
48518518|NCT03906110|DIAGNOSTIC_TEST|Fecal Immunochemical Test (FIT)|The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
48518519|NCT06582628|DRUG|Enzalutamide capsule|Enzalutamide capsules 160 mg orally daily
48518520|NCT06582628|DRUG|Enzalutamide capsule and Talazoparib capsule|Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
48715359|NCT01900977|OTHER|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
48715360|NCT01900977|OTHER|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
48715361|NCT01900977|OTHER|Standard of Care|
48715362|NCT02018874|DRUG|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D."
48518521|NCT04520126|DIETARY_SUPPLEMENT|Olivomed (capsules containing hydroxytyrosol)|patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.
48518522|NCT04520126|DIETARY_SUPPLEMENT|OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).|patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.
48715363|NCT02018874|DRUG|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
48715364|NCT03923582|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, LGBT and sexual violence, clinical skills training, ethics and policy writing, and community resources and cultural considerations."
48715365|NCT02775942|BIOLOGICAL|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
48715366|NCT02775942|BIOLOGICAL|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
48715367|NCT02775942|BIOLOGICAL|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
48715368|NCT02775942|BIOLOGICAL|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
48715369|NCT05927545|PROCEDURE|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
48715370|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
48715371|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
48715372|NCT05291936|DEVICE|PRECISION1® for Astigmatism Contact Lenses|TEST
48715373|NCT05291936|DEVICE|MyDay® Toric Soft Contact Lenses|CONTROL
48715374|NCT01007422|BEHAVIORAL|telephone-based intervention|
48715375|NCT01007422|OTHER|communication intervention|
48715376|NCT01007422|OTHER|intervention by caregiver|
48518523|NCT05256186|OTHER|Basketball Pre-injury Attack program|The intervention had a total duration of 24 weeks, with 3 sessions per week (before starting training) with a total duration of 12 to 15 minutes per session. Each session consisted of 8 exercises with a load of 2 to 3 series between 6 and 12 repetitions; and with a rest at the end of each series of \<60 seconds.
48518524|NCT01060072|DRUG|Loteprednol etabonate|Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
48518525|NCT01060072|DRUG|Vehicle of Loteprednol Etabonate|Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
48518526|NCT02255799|DRUG|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
48715377|NCT01007422|OTHER|medical chart review|
48715378|NCT01007422|OTHER|survey administration|
48715379|NCT01007422|PROCEDURE|end-of-life treatment/management|
48715380|NCT01007422|PROCEDURE|pain therapy|
48715381|NCT01007422|PROCEDURE|psychosocial assessment and care|
48715382|NCT03895177|DIAGNOSTIC_TEST|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
48715383|NCT06010381|OTHER|Muscle energy technique|It was applied on the shoulder flexion and the external rotation. An isometric contraction of the agonist muscle (the muscle which requires stretching) for 7 seconds with gentle muscle contraction to avoid the risk of increasing the muscle tone. This contraction started just short of the restrictive barrier. After that, the patient is asked to relax for 2-3 seconds and then the therapist stretches the contracted muscle in the opposite direction for 30 seconds. This is repeated three repetitions for each muscle.
48022693|NCT05254379|DEVICE|tDCS|"tDCS is a painless brain stimulation treatment that uses direct electrical currents (at a constant, low-intensity level) to stimulate specific parts of the brain and help modulate neuronal activity. Participants will receive a series of tDCS treatments during the Intensive Outpatient Program (IOP) coupled with blood and saliva collections.~Participants will administer a stimulation session via the Soterix 1x1 tDCS mini-CT Stimulator, after being provided a single-use code to unlock the device by the research staff once proper contact quality is achieved. After the participant enters the unlock code, the screen on the device will show a timer that counts down the minutes until the end of the session. After 20 min, the device will turn off automatically and the study staff will instruct the participant to remove the headset and discard the sponges and to store safely all materials for the next session."
48022694|NCT00721994|DEVICE|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
48022695|NCT04341922|BEHAVIORAL|Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic|The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes \[e.g. becoming unemployed\]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).
48518527|NCT02255799|DRUG|Placebo|Placebo capsule once daily for 70 days.
48518528|NCT00365703|PROCEDURE|Feeding tube insertion|"1. Orogastric feeding tube~2. Nasogastric feeding tube"
48518529|NCT00417170|DRUG|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
48715384|NCT06010381|OTHER|Maitland mobilization|At the start of each session, the physical therapist examined the patient's ROM in all directions to obtain information about the end-range position and the end feel of the glenohumeral joint. Start with rhythmic mid-range mobilization with the patient in a supine position. The therapist's hands are placed close to the glenohumeral joint, and the humerus is brought into a position of maximal flexion in the sagittal plane. After 10 to 15 repetitions of intensive mobilization techniques in this end-range position, the direction of mobilization will be altered by varying the plane of elevation or by varying the degree of rotation. When alternating the direction of mobilization, other movements such as gliding techniques and distraction in that joint position were (inferior gliding, anterior gliding, and posterior gliding).
48715385|NCT06010381|OTHER|Traditional shoulder exercise|Traditional shoulder exercises in the form of shoulder range of motion exercises, stretching exercises and, scapular stabilization.
48715386|NCT04149860|DRUG|Lu AF87908|Lu AF87908 concentrate for solution for intravenous (IV) infusion
48715387|NCT04149860|DRUG|Placebo|Concentrate for solution for IV infusion
48715388|NCT01470833|PROCEDURE|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
48715389|NCT04591743|DEVICE|Active TCS|TCS active at 1 Hz on the right DLPFC for 6 weeks
48715390|NCT04591743|DEVICE|Placebo TCS|Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
48715391|NCT04591743|DRUG|nicotine treatment|at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
48715392|NCT04591743|OTHER|Questionnaires|"EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART"
48715393|NCT02948907|OTHER|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
48715394|NCT02188498|PROCEDURE|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
48715395|NCT03149952|OTHER|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
48715396|NCT05977348|BEHAVIORAL|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
48715397|NCT05977348|BEHAVIORAL|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
48022696|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
48715398|NCT05977348|BEHAVIORAL|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
48715399|NCT05977348|BEHAVIORAL|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
48518530|NCT00417170|DRUG|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
48715400|NCT04588155|DEVICE|Functional assessment|Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution
48715401|NCT04588155|OTHER|Clinical assessment|"Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution"
48518531|NCT00417170|DRUG|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
48022697|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
48022698|NCT01040130|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
48022699|NCT01040130|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose
48715402|NCT03371953|DRUG|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
48715403|NCT03371953|DRUG|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
48715404|NCT03371953|DRUG|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
48715405|NCT02995226|OTHER|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
48715406|NCT02995226|OTHER|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
48380974|NCT06142448|DEVICE|Cueing app|"All participants that are included come to the movement lab for the baseline measurement. The baseline measurement consists out of extensive clinimetrics (for example MDS-UPDRS) to identify patient characteristics. With the use of an objective gait assessment, the effectiveness of both internal and external cueing is determined. This will divide the participants in three groups; responders, non-responders and in between. Participants who clearly respond to either internal or external cueing (determined as the responders) are asked to apply the working form of cueing in daily life during the six-month follow-up. During this period the participants will use a mobile application that can provide them with a rhythmic auditory stimulus and records the use of this application.~After 6 months, both the responders and non-responders are asked to return to the lab for the follow up measurement in which the baseline measurement is repeated to evaluate the effect of long-term cueing."
48380975|NCT00111007|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
48380976|NCT00111007|DRUG|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m\^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
48518532|NCT00417170|DRUG|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
48715407|NCT04069247|BEHAVIORAL|ECBT-I|The eCBT-I will be delivered through a mobile application (eSleep) with a personal password.
48380977|NCT00111007|DRUG|Placebo|Placebo, 2 tablets bid Study Days 2-19
48518533|NCT02224989|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
48518534|NCT00797589|DRUG|HES|20ml/kg as prime fluid
48518535|NCT00797589|DRUG|Ringer lactate|
48518536|NCT02556957|BEHAVIORAL|HealthScouts|
48518537|NCT02556957|OTHER|Standard of Care|
48518538|NCT04563507|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
48518539|NCT04563507|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
48715408|NCT04069247|BEHAVIORAL|HE|The HE will be delivered in control though a mobile application (eSleep) with a personal password.
48715409|NCT02425800|OTHER|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
48715410|NCT02425800|OTHER|Laboratory Biomarker Analysis|Correlative studies
48380978|NCT06526585|BEHAVIORAL|Cyclic Sighing Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing practice during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the cyclic sighing during the 2 MRI assessments.~The cyclic sighing protocol consists of a breathing pattern that involves inhaling deeply, starting abdominally, inhaling through the nose until lungs feel comfortably filled, immediately followed by a second shorter inhale, also through the nose, to maximally inflate the lungs. Then participants are instructed to slowly exhale through the mouth until their lungs feel empty. This cycle is repeated for 10 minutes."
48380979|NCT06526585|BEHAVIORAL|Box Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the box breathing during the 2 MRI assessments.~The CO2 tolerance test is done at baseline to determine their comfort level with the duration of each side of the box during box breathing.~The box breathing protocol consists of a four-part breathing technique. The practice involves breathing through the nose in four equally timed parts: inhale, hold, exhale, and hold again, forming a 'box' of breaths (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold).This cycle is repeated for 10 minutes."
48380980|NCT06526585|BEHAVIORAL|Hypnosis|Participants are instructed to sit comfortably or lie down during the 28 day at home practice (Participants will be lying down in the scanner during the 2 MRIs). Then participants are asked to look up, slowly close their eyes, take a deep breath, slowly exhale, and let their body float, and then to imagine floating in a bath, a lake, a hot tub, or floating in space. Participants are then asked to picture an imaginary screen and visualize a place where it would naturally feel comfortable and relaxed. The participants then divide the screen in half and picture on the left side one thing that is causing them stress, with the rule that no matter what the participant picture, to keep their body comfortable and relaxed. Then on the right side of the screen the participants are asked to picture one thing that can be done about the problem on the left. At the end the participant will be guided to come out of the state of hypnosis. This exercise will take 10 minutes.
48380981|NCT06526585|BEHAVIORAL|Audiobook|Participants are instructed to be seated or lying down, and can keep eyes open or closed throughout the 10 minutes of listening to the audiobook during the 28 days. Participants are instructed to keep their eyes closed during the 2 MRI assessments.
48380982|NCT04882085|DRUG|Zavicefta, Ceftazidime-Avibactam|CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
48518540|NCT04563507|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
48518541|NCT06581718|DEVICE|Eye Gaze Control|Eye Gaze Control - UGI and LGI endoscopy
48715411|NCT01804569|OTHER|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
48715412|NCT01735669|DRUG|Remifentanil|
48715413|NCT01735669|DRUG|Nitrous Oxide|
48380983|NCT04882085|DRUG|Best Available Treatment|main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
48380984|NCT04463992|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
48380985|NCT04463992|OTHER|Usual Care|Usual care as provided by local oncologists
48518542|NCT00171951|DRUG|Pasireotide|Pasireotide 600 μg or 900 μg was administered as an SC injection.
48518543|NCT05161338|DIAGNOSTIC_TEST|MICROBIOME GENETIC ANALYSIS|Vaginal samples will be taken. A floxed nylon swab will be rotated against the posterior vaginal wall, Nucleic acid extraction and genetic analisys will be performed
48518544|NCT05161338|DIAGNOSTIC_TEST|VAGINAL PH VALUE|Intravaginal Ph value meassurement.
48518545|NCT05161338|DIAGNOSTIC_TEST|SERUM PROGESTERONE LEVELS|Determination of serum P4 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day-.
48518546|NCT05161338|DIAGNOSTIC_TEST|SERUM OESTRADIOL LEVELS|Determination of serum E2 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day.
48518547|NCT01016327|DRUG|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
48518548|NCT03157479|DRUG|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
48715414|NCT06031545|OTHER|Long peripheral venous catheters for use|Long peripheral venous catheters for use during the perioperative period in obese patients
48715415|NCT06031545|OTHER|Midline catheter|Midline catheters for use during the perioperative period in obese patients
48715416|NCT02192229|DRUG|50.000 IU vitamin D3 (Biodal 50,000 IU)|
48715417|NCT02192229|DRUG|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
48715418|NCT01357954|OTHER|Regular physiotherapy|The child's regular physiotherapy
48715419|NCT01357954|OTHER|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
48715420|NCT02857192|BIOLOGICAL|Blood samples|
48715421|NCT03480789|DRUG|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
48715422|NCT03480789|DEVICE|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
48715423|NCT03308045|BIOLOGICAL|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
48715424|NCT02226198|DRUG|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
48715425|NCT02226198|DRUG|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
48715426|NCT04911764|DIAGNOSTIC_TEST|Three-min Step Test and Exercise desaturation detection in COPD|For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
48022700|NCT01040130|DRUG|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
48022701|NCT06057012|DRUG|BRII-296|2 intramuscular injections 300 mg each of BRII-296 admixed with Depo Medrol 40 mg/mL per injection, will be administered in participants with PPD.
48022702|NCT00501605|DRUG|AZD2171|
48022703|NCT04338815|OTHER|Exoskeleton optimization|Participants will walk 10 times of 1 minute duration while an optimization algorithm changes the assistance profile of an exoskeleton.
48022704|NCT04338815|OTHER|Endurance evaluation|Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.
48022705|NCT05811377|DRUG|Ferumoxytol|After fully emptying the bladder with a catheter,1.5mg of Ferumoxytol combined with Gadobutrol 302 mg will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to an MRI scan of the bladder. After the MRI is completed, the Ferumoxytol will be drained through the catheter and the catheter will be removed.
48022706|NCT05811377|DRUG|Gadobutrol|After fully emptying the bladder with a catheter, 302 mg of Gadobutrol (combined with Ferumoxytol) will be instilled into the bladder through the catheter. The catheter will be plugged, and the patient will submit to a MRI scan of the bladder. After the MRI is completed, the Gadobutrol will be drained through the catheter and the catheter will be removed.
48022707|NCT02377986|BEHAVIORAL|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
48022708|NCT02377986|BEHAVIORAL|In-Home Decluttering|In-home decluttering practice
48022709|NCT01260922|DRUG|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
48022710|NCT01260922|DRUG|Aricept®|10 mg Orally Disintegrating Tablet
48715427|NCT04484623|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
48715428|NCT04484623|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
48022711|NCT01368458|OTHER|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
48022712|NCT03526913|PROCEDURE|PRP|PRP: autologous platelet-rich plasma
48022713|NCT03526913|PROCEDURE|STSG|skin graft: Split Thickness Skin Grafting (STSG)
48022714|NCT01789944|BEHAVIORAL|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
48022715|NCT03663114|DRUG|Lenvatinib|Lenvatinib capsule
48715429|NCT04484623|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
48715430|NCT04484623|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
48715431|NCT04175925|DRUG|BMS-986322|Specified Dose on Specified Days
48715432|NCT04175925|OTHER|BMS-986322 Placebo|Specified Dose on Specified Days
48715433|NCT04175925|DRUG|famotidine|Specified Dose on Specified Days
48715434|NCT00524589|DIETARY_SUPPLEMENT|calcitriol|IV
48715435|NCT00524589|DRUG|dexamethasone|Oral
48715436|NCT00524589|GENETIC|protein expression analysis|Correlative Study
48022716|NCT04107090|OTHER|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
48022717|NCT04107090|OTHER|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
48022718|NCT04107090|OTHER|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
48022719|NCT05027191|DIAGNOSTIC_TEST|Neutrophil Gelatinase-Associated Lipocalin (NGAL)|The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.
48022720|NCT05027191|DRUG|Desflurane|Desflurane
48022721|NCT05027191|DRUG|Sevoflurane|Sevoflurane
48022722|NCT04478097|DRUG|CKD-330 Tab. and D086 Tab.|1T
48022723|NCT04478097|DRUG|CKD-333 Tab.|1T
48715437|NCT00524589|OTHER|laboratory biomarker analysis|Correlative Study
48715438|NCT00670176|BEHAVIORAL|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
48715439|NCT05828420|OTHER|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
48715440|NCT05828420|OTHER|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
48715441|NCT05828420|OTHER|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
48715442|NCT03000777|DIETARY_SUPPLEMENT|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
48715443|NCT03000777|OTHER|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
48518549|NCT03157479|DRUG|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
48380986|NCT03014570|BEHAVIORAL|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
48715444|NCT04785625|COMBINATION_PRODUCT|Bupivacaine Hydrochloride|INL-001 (bupivacaine hydrochloride) implant
48715445|NCT04785625|COMBINATION_PRODUCT|Placebo collagen-matrix implant|Placebo collagen-matrix implant
48715446|NCT01332188|DRUG|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
48715447|NCT01332188|DRUG|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
48715448|NCT01332188|DRUG|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
48715449|NCT01332188|DRUG|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
48715450|NCT03703310|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
48715451|NCT03703310|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
48715452|NCT03301064|BEHAVIORAL|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
48715453|NCT03301064|OTHER|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
48380987|NCT03014570|BEHAVIORAL|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
48518550|NCT03157479|DIAGNOSTIC_TEST|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
48715454|NCT01479946|DRUG|Electrochemotherapy|bleomycin together with electroporation
48715455|NCT05609344|BEHAVIORAL|SBIRT|Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
48715456|NCT00758121|DEVICE|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
48380988|NCT04100369|DIAGNOSTIC_TEST|laboratory|Arm
48380989|NCT06652581|PROCEDURE|Modified Thorachoabdominal Nerve Block Perichondrial Approach(M-TAPA|USG Guided Bilateral Modified Thorachoabdominal Nerve Block Perichondrial Approach (M-TAPA) using 20 ml Bupivacaine 0,25%.
48715457|NCT01842594|DRUG|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
48715458|NCT06113705|DIAGNOSTIC_TEST|18F-GE-180 PET|PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
48715459|NCT06113705|DIAGNOSTIC_TEST|Advanced MRI|MRI examination using advanced sequences to characterize tumor microstructure and function
48715460|NCT06113705|OTHER|Collection of hematopoietic stem cells|Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
48715461|NCT06113705|OTHER|Blood withdrawal|blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
48022724|NCT05900947|OTHER|analysis of carotid atherosclerotic plaque|To assess the presence of air pollutants (benzene, toluene, xylene, and ethylbenzene) or of microplastics within tissues from atherosclerotic plaques by Chromatographic analyses.
48022725|NCT01984398|DRUG|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
48022726|NCT01984398|DRUG|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
48380990|NCT06652581|DEVICE|Opioid Intravena|Opioid Intravenous post Surgery without M-TAPA Block delivered with PCA Machine
48380991|NCT05158972|DRUG|Dymista|1 spray per nostril twice daily up to four weeks
48518551|NCT03157479|DIAGNOSTIC_TEST|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
48518552|NCT00673439|DRUG|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
48380992|NCT06219148|BEHAVIORAL|Music Therapy Telehealth|Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.
48715462|NCT06113705|OTHER|Collection of Cancer Stem Cells|Glioblastoma stem cells (GSCs) will be isolated from the tumor
48715463|NCT00633230|DRUG|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
48715464|NCT00633230|OTHER|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
48715465|NCT00226863|BEHAVIORAL|meditation plus education|
48715466|NCT00226863|BEHAVIORAL|group psychotherapy with hypnosis plus education|
48715467|NCT00226863|BEHAVIORAL|education|
48715468|NCT04478032|DEVICE|deep transcranial magnetic stimulation with H7 coil|low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
48715469|NCT02111291|BIOLOGICAL|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
48715470|NCT02111291|BIOLOGICAL|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
48715471|NCT03288194|BEHAVIORAL|Problem-Solving Treatment|
48715472|NCT03288194|BEHAVIORAL|Time Management|
48715473|NCT02023021|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48715474|NCT02023021|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
48022727|NCT01984398|DRUG|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
48518553|NCT00673439|DRUG|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
48518554|NCT03158922|GENETIC|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
48518555|NCT03158922|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
48715475|NCT03558074|DRUG|ALK4290|ALK4290 400 mg tablet twice a day
48715476|NCT02585648|DEVICE|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
48715477|NCT02585648|DEVICE|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
48715478|NCT00755469|PROCEDURE|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
48715479|NCT02103374|DRUG|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
48715480|NCT02103374|DRUG|Placebo|1 capsule lactose during 48 weeks
48715481|NCT01025570|DRUG|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
48715482|NCT00620152|BEHAVIORAL|1|Low glycemic load diet by telephone counseling
48715483|NCT00620152|BEHAVIORAL|2|Low fat diet by telephone counseling
48715484|NCT06385535|BEHAVIORAL|Habit Reversal Training (HRT)|Habit Reversal Training (HRT) is a multicomponent treatment package developed to treat a repetitive behaviors. HRT includes (1) increasing awareness of discrete occurrences of tics and associated premonitory urges (PMUs; i.e., awareness training), (2) teaching the patient to suppress tics by engaging in behaviors that are physically incompatible with target tics (i.e., competing response \[CR\] training), and (3) prompting and reinforcing between-session patient engagement with therapeutic techniques and homework (i.e., providing social support).
48715485|NCT04220437|OTHER|no interventin|Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
48715486|NCT00300677|DRUG|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
48715487|NCT06358586|DRUG|Tachipirina® 120 mg/5 mL oral suspension, new flavour|A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
48715488|NCT05434013|BEHAVIORAL|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
48715489|NCT05434013|BEHAVIORAL|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
48518556|NCT03158922|PROCEDURE|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
48518557|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
48022728|NCT01984398|DRUG|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
48022729|NCT01963689|OTHER|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
48022730|NCT01963689|OTHER|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
48022731|NCT01963689|OTHER|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
48022732|NCT05036083|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
48022733|NCT05036083|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
48022734|NCT05036083|OTHER|Electronic Health Record Review|Medical records reviewed
48022735|NCT05036083|DRUG|Iodinated Contrast Agent|Given IV
48022736|NCT03223389|DIETARY_SUPPLEMENT|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
48022737|NCT03223389|DIETARY_SUPPLEMENT|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
48022738|NCT03223389|DIETARY_SUPPLEMENT|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
48022739|NCT05872230|DEVICE|Massage Percussion Therapy device|Using massage percussion postoperatively.
48022740|NCT05257993|DRUG|JPI-547|"* Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split."
48022741|NCT05257993|DRUG|modified FOLFIRINOX|"* After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle"
48022742|NCT05257993|DRUG|Gemcitabine-nab-paclitaxel|"* After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle"
48022743|NCT04695691|DEVICE|Cutera Laser System|Subjects will receive laser treatments
48022744|NCT02664428|DIETARY_SUPPLEMENT|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
48022745|NCT02664428|DIETARY_SUPPLEMENT|Control|A daily dose of about 90 gram will be given for 8 weeks
48022746|NCT03112772|OTHER|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
48022747|NCT03112772|OTHER|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
48022748|NCT06464835|DEVICE|Transcranial magnetic stimulation|The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
48022749|NCT04894435|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine|Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
48022750|NCT04894435|BIOLOGICAL|BNT162b2|A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
48022751|NCT04894435|BIOLOGICAL|ChAdOx1-S [recombinant]|A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
48715490|NCT05434013|BEHAVIORAL|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
48715491|NCT03679637|BEHAVIORAL|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
48715492|NCT04794764|DEVICE|McGrath Mac|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
48715493|NCT04794764|DEVICE|Macintosh Laryngoscope|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
48715494|NCT02838615|PROCEDURE|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
48715495|NCT01196494|PROCEDURE|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
48715496|NCT02534662|DEVICE|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
48022752|NCT04894435|OTHER|0, 28 day schedule|Second injection administered 28 days post first injection
48715497|NCT04333342|DEVICE|heart rate monitoring using wearable devices|Using Fitbit (TM) wearable devices, heart rate, activity data are collected. Based on these data, resting heart rate is monitored daily basis. If resting heart rate increase beyond set range, users are notified to visit the hospital.
48715498|NCT06508645|DRUG|DWP14012 injection|"1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)"
48715499|NCT01658137|OTHER|Prudent Diet|This intervention lasts 2 weeks (14 days).
48715500|NCT01658137|OTHER|Typical Western Diet|This intervention lasts 2 weeks (14 days).
48022753|NCT04894435|OTHER|0, 112 day schedule|Second injection administered 112 days post first injection
48180229|NCT04423419|PROCEDURE|PENG block|The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
48518558|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
48518559|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
48518560|NCT03558438|OTHER|No interventions|No interventions
48518561|NCT05177185|RADIATION|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
48715501|NCT01406496|DRUG|insulin|Three different timings of insulin delivered by a pump
48715502|NCT00857948|DRUG|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
48715503|NCT00857948|DRUG|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
48715504|NCT03797092|BIOLOGICAL|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
48715505|NCT03797092|OTHER|Control group|No treatment
48715506|NCT00569088|DRUG|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
48715507|NCT00569088|DRUG|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
48022754|NCT04894435|BIOLOGICAL|Covifenz|COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
48518562|NCT05177185|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
48518563|NCT00694200|DRUG|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
48715508|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
48022755|NCT02621905|DRUG|Sporanox|At least 2 capsules twice a day for 3 weeks
48022756|NCT02621905|DRUG|Lozanoc|At least 2 capsules twice a day for 3 weeks
48715509|NCT00966290|DRUG|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
48715510|NCT03454867|DEVICE|Hemofiltration|
48715511|NCT03454867|PROCEDURE|Standard acute ischemic stroke treatment|
48715512|NCT01547312|DRUG|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
48715513|NCT01547312|PROCEDURE|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
48715514|NCT01547312|PROCEDURE|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
48715515|NCT01547312|PROCEDURE|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
48715516|NCT01547312|DRUG|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
48715517|NCT01547312|DRUG|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
48715518|NCT01547312|DRUG|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
48715519|NCT01547312|PROCEDURE|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
48715520|NCT01403376|DRUG|teriflunomide|"Film-coated tablet~Oral administration"
48715521|NCT01403376|DRUG|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
48715522|NCT01403376|BIOLOGICAL|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
48715523|NCT05544032|DRUG|axatilimab|Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
48715524|NCT04161378|DIAGNOSTIC_TEST|Cardiac imaging|"* Transthoracic echocardiography~* Late gadolinium enhancement CMR"
48180230|NCT04423419|PROCEDURE|fascia iliaca block|ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
48180231|NCT04423419|OTHER|IV analgesia|IV analgesia
48180232|NCT05258591|DEVICE|Axem Home|Rehabilitation system comprised of functional near-infrared spectroscopy headband (measuring from the motor cortex), as well as tablet-based software application (guiding stroke survivors through rehabilitation exercises for their hands/arms).
48180233|NCT03570151|OTHER|no intervention|no intervention will be done
48180234|NCT05500079|DEVICE|Wrist splint|A wrist splint is a It stabilizes your wrist. Wearing a wrist splint minimizes pressure on the median nerve.
48715525|NCT04161378|DIAGNOSTIC_TEST|Laboratory analysis|"* complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP"
48715526|NCT03399357|BIOLOGICAL|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
48715527|NCT04969848|OTHER|Wearable sensor|IMU sensor (as part of eMSGait device) worn at the hip during T25FW
48715528|NCT02322294|DIETARY_SUPPLEMENT|Glucodia™|
48715529|NCT02322294|OTHER|Placebo|
48180235|NCT05500079|OTHER|Pulsed radiofrequency current|Pulsed rf current is delivered to the median nerve trace via transcutaneous pads. Pain expression is suppressed in the dorsal horn of the spinal cord.
48180236|NCT01546506|DRUG|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
48518564|NCT00694200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
48715530|NCT05229796|DRUG|Empagliflozin 10 mg Tab|The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
48180237|NCT05875454|DIAGNOSTIC_TEST|Histopathological examination of tru-cut needle biopsy|Renal biopsies fixed in formalin from patients with suspected medical renal disease will be processed and examined for histopathological diagnosis.
48180238|NCT04853498|DRUG|TQB3720|This is an androgen receptor antagonists.
48380993|NCT06219148|BEHAVIORAL|Non-Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.
48380994|NCT06219148|BEHAVIORAL|Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
48380995|NCT05391607|DRUG|Hyperoncotic Albumin 20%|Intravenous administration during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
48518565|NCT02995863|DEVICE|Rigid Rocker Sole Footwear|
48518566|NCT02995863|DEVICE|Therapeutic Footwear|
48518567|NCT03284723|DRUG|PF-06804103|Dose Escalation Part - 1A Dose Expansion Part - 2A
48518568|NCT03284723|DRUG|PF-06804103 + Palbociclib +Letrozole|Dose Escalation - Part 1B Dose Expansion - Part 2B
48518569|NCT00464789|DRUG|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
48518570|NCT00494962|DRUG|lecozotan SR|
48518571|NCT03616587|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
48518572|NCT03616587|DRUG|AZD9833|Part B: AZD9833 monotherapy expansion.
48518573|NCT03616587|DRUG|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation
48518574|NCT03616587|DRUG|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
48715531|NCT03622437|BEHAVIORAL|Patient-led follow-up|"1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses"
48715532|NCT03622437|OTHER|Standard follow-up|"Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
48715533|NCT03922256|OTHER|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
48715534|NCT01605942|DRUG|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
48180239|NCT06155110|DRUG|cardiomyopeptidin|cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
48180240|NCT03640247|DRUG|Non-narcotic group regimen|Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
48380996|NCT05391607|DRUG|Isooncotic Albumin 5%|Intravenous administration of Albumin 5% 12ml/kg (ideal body weight) completed by a Ringer-lactate crystalloid ratio 1:1 to total amount of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
48380997|NCT05391607|DRUG|Ringer's Lactate Crystalloid Solutions (control group)|Intravenous administration of Ringer-lactate ratio 3:1 of total of blood loss during removal of the bladder (i.e. the bleeding part) of cystectomy procedures.
48380998|NCT06026969|OTHER|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
48518575|NCT03616587|DRUG|AZD9833 with everolimus|Part E: AZD9833 in combination with everolimus dose escalation
48715535|NCT01605942|DRUG|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
48715536|NCT00801060|DRUG|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
48518576|NCT03616587|DRUG|AZD9833 with everolimus|Part F: AZD9833 in combination with everolimus dose expansion
48518577|NCT03616587|DRUG|AZD9833 with abemaciclib|Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation
48518578|NCT03616587|DRUG|AZD9833 with abemaciclib|Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion
48518579|NCT03616587|DRUG|AZD9833 with capivasertib|Part I: AZD9833 in combination with capivasertib dose escalation
48518580|NCT03616587|DRUG|AZD9833 with capivasertib|Part J: AZD9833 in combination with capivasertib dose expansion
48518581|NCT03616587|DRUG|AZD9833 with ribociclib|Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation
48518582|NCT03616587|DRUG|AZD9833 with ribociclib|Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion
48518583|NCT03616587|DRUG|AZD9833 with anastrozole|Part M: AZD9833 in combination with anastrozole dose escalation
48518584|NCT03616587|DRUG|AZD9833 with anastrozole|Part N: AZD9833 in combination with anastrozole dose expansion
48518585|NCT06568224|DRUG|Mesalazine|oral mesalazine 1g qid
48518586|NCT00273689|DRUG|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
48715537|NCT00801060|DRUG|FCR|Dosage, schedule, and duration in the protocol
48022757|NCT02270346|DEVICE|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
48180241|NCT03640247|DRUG|Narcotic group regimen|Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
48380999|NCT05726110|DRUG|Selinexor|Given PO
48381000|NCT05726110|DRUG|Homoharringtonine|Given per standard of care
48381001|NCT05726110|DRUG|Daunorubicin|Given per standard of care
48381002|NCT05726110|DRUG|Cytarabine|Given per standard of care
48381003|NCT05726110|DRUG|Granulocyte Colony-Stimulating Factor|Given per standard of care
48381004|NCT05726110|DRUG|Aclacinomycin|Given per standard of care
48381005|NCT05259748|BEHAVIORAL|Psychoeducation Based on the Transtheoretical Model on Healthy Lifestyle Behaviors|Healthy lifestyle behaviours psychoeducation programme, based on the Transtheoretical Model, with 6 sessions (healthcare responsibility, nutrition, physical activity, spiritual development, interpersonal relationships, stress management) was applied to the intervention group for 6 weeks as three days in the weekdays and two sessions in a day. Psychoeducation was carried out by the researcher on the same day but within different time zones. Each psychoeducation session took 90-120 minutes with the breaks taken considering the participants' mood. After completing six sessions, the behavioural change identification form and Healthy Lifestyle Behaviors Scale II were applied to the intervention group again.
48381006|NCT04025866|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
48518587|NCT00273689|DRUG|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
48715538|NCT04855071|DEVICE|Non-ablative radiofrequency application|Non-ablative radiofrequency application will be applied with MJS intracavitary probe, in monopolar application, reaching a temperature between 42-45ºC in the tissues (according to the patient's tolerance), and with a power of 50% until the desired temperature is reached. It will be applied with a frequency that will be individualized according to the maximum level of energy absorption by the patient's tissues (between 0.8-1.2MHz) and with a dose of approximately between 3-4 KJ depending on the application time (20 minutes / session). In addition, they will be applied 1 session per week. The treatment will last 8 weeks.
48381007|NCT04025866|OTHER|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
48381008|NCT01283009|DRUG|Inactive Substance|Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
48381009|NCT01283009|DRUG|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
48381010|NCT02505841|OTHER|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
48381011|NCT02505841|DRUG|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
48381012|NCT03667781|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
48518588|NCT02176954|DEVICE|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
48022758|NCT02270346|DEVICE|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
48180242|NCT01692093|DIETARY_SUPPLEMENT|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
48180243|NCT01692093|DIETARY_SUPPLEMENT|Placebo|Placebo
48180244|NCT01493037|DEVICE|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
48381013|NCT05100628|DRUG|NOX66|"NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
48381014|NCT05100628|DRUG|NOX66|"NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
48381015|NCT05100628|DRUG|NOX66|"NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
48381016|NCT05100628|DRUG|NOX66|MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
48381017|NCT05100628|DRUG|Doxorubicin|Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
48518589|NCT02176954|DEVICE|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
48022759|NCT04760470|OTHER|Technology-assisted upper extremity rehabilitation|Subjects get 6 weeks of technology-assisted upper extremity rehabilitation
48022760|NCT01200121|DRUG|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
48381018|NCT03930524|BEHAVIORAL|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on prevalence of drinking, consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. Students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
48381019|NCT03930524|BEHAVIORAL|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
48518590|NCT02176954|DEVICE|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
48022761|NCT01200121|OTHER|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
48022762|NCT06497517|DRUG|GSK5464714- Camlipixant|GSK5464714- Camlipixant will be administered
48381020|NCT03930524|BEHAVIORAL|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for online use in studies conducted by Drs. Larimer and Lee (e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
48381021|NCT03930524|BEHAVIORAL|Health Promotion Consultation|A health promotion consultation via a campus clinic is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
48381022|NCT03930524|BEHAVIORAL|M-Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
48381023|NCT03479619|DEVICE|Lancing device A|Glucoject Dual Plus lancing device
48381024|NCT03479619|DEVICE|Lancing device B|Droplet lancing device
48381025|NCT03479619|DEVICE|Lancing device C|Commercially available lancing device
48381026|NCT03479619|DEVICE|28 G lancet|Droplet 28 G
48381027|NCT03479619|DEVICE|30 G lancet|Droplet personal lancet 30 G
48381028|NCT03479619|DEVICE|33 G lancet|Droplet personal lancet 33 G
48381029|NCT03479619|OTHER|Lancing depth setting (1)|The lowest depth setting (1)
48381030|NCT03479619|OTHER|Lancing depth setting (5)|The highest depth setting (5)
48518591|NCT01667328|PROCEDURE|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
48518592|NCT01667328|PROCEDURE|Standard of care|Control group will receive standard of care with no massage therapy
48518593|NCT04304989|OTHER|mHealth program|mobile health applications
48518594|NCT04304989|OTHER|usual care|usual care
48022763|NCT05988216|BIOLOGICAL|BRL-301|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
48022764|NCT02779218|PROCEDURE|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
48022765|NCT02779218|PROCEDURE|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
48022766|NCT02779218|PROCEDURE|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
48022767|NCT01672151|DRUG|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
48022768|NCT01176903|DRUG|Glycopyrrolate|pressurized metered dose inhaler
48022769|NCT01176903|DRUG|Tiotropium|inhalation powder, hard capsule
48022770|NCT01176903|DRUG|placebo|pressurized metered dose inhaler
48022771|NCT03025165|OTHER|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
48022772|NCT03025165|OTHER|Home-Based ART Delivery|Provision of ART care to an individual at their home
48518595|NCT00850811|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
48518596|NCT01134302|PROCEDURE|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
48381031|NCT06567496|OTHER|First Resort|First Resort is an 8-week, self-guided, at-home, virtual reality program designed to be used as an intervention to help manage stress, worry, and sadness. It is grounded on evidence-based cognitive behavioral therapy and acceptance and commitment therapy techniques, including psychoeducation, mindfulness, behavioral activation through values clarification and goal setting, and cognitive reframing to identify and reframe cognitive distortions.
48518597|NCT01134302|PROCEDURE|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
48518598|NCT06256614|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive three doses of WMT for T1DM.
48518599|NCT04031625|OTHER|Metastatic Colorectal Cancer Database|Metastatic Colorectal Cancer Database
48518600|NCT02295501|BIOLOGICAL|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
48518601|NCT05211635|DIETARY_SUPPLEMENT|Vitamin D|One capsule daily for 84 days
48518602|NCT05211635|OTHER|Placebo|One capsule daily for 84 days
48518603|NCT04417413|DEVICE|Fotona ProlapLase|Non-ablative SMOOTH mode intravaginal Er:YAG teratment for pelvic organ prolapse
48715539|NCT04855071|OTHER|Usual intervention|The usual intervention will consist of supervised individualized sessions that will include application of exercises to balance the pelvis and their muscles, treatment of trigger points, teaching activation of the transverse abdominis with ultrasound biofeedback and teaching reflex activation exercises of the transverse abdominis and pelvic floor muscles in different body positions. In addition, standards of water, urination, food, defecation, postural hygiene and physical activity will be provided. It is also recommended different life habit advices related to tobacco use, constipation, etc.
48715540|NCT01411358|BIOLOGICAL|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
48715541|NCT01411358|BIOLOGICAL|elderly aged over 60|one dose of 0.5mL AdimFlu-S
48715542|NCT02739321|DEVICE|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
48715543|NCT03164850|DEVICE|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
48022773|NCT03025165|OTHER|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
48022774|NCT01719965|OTHER|Interviews and Focus Group Discussions|
48022775|NCT01784705|DEVICE|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
48022776|NCT01784705|DEVICE|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
48381032|NCT03495765|DRUG|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
48381033|NCT02262507|DEVICE|Device Wearing|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins. Each subject will undergo repeat oto-acoustic measures both wearing the device and not wearing the device
48381034|NCT05185791|OTHER|Pre-ERAS® phase (current clinical practice)|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
48381035|NCT05185791|OTHER|Post-ERAS® implementation phase|Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
48518604|NCT05771389|DIAGNOSTIC_TEST|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
48518605|NCT06583070|RADIATION|Radiation therapy|Administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions in conjunction with targeted and immunotherapy
48518606|NCT00611546|OTHER|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
48518607|NCT00611546|OTHER|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
48518608|NCT02574182|RADIATION|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
48518609|NCT00621270|DRUG|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
48518610|NCT05137587|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
48518611|NCT05137587|DRUG|propofol|propofol
48518612|NCT05137587|DRUG|ketamine|ketamine
48518613|NCT01910428|DRUG|L-asparaginase encapsulated in RBC|"* 50 IU/kg IV~* 100 IU/kg IV~* 150 IU/kg IV~* 200 IU/kg IV"
48715544|NCT00605553|DRUG|Placebo|"Placebo oral capsules~Placebo for 7 days"
48715545|NCT00605553|DRUG|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
48381036|NCT04476576|BEHAVIORAL|Aerobic exercise (experimental)|3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.
48381037|NCT04476576|BEHAVIORAL|Flexibility exercise (active comparator)|Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.
48518614|NCT05807204|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
48518615|NCT05807204|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
48518616|NCT00327366|PROCEDURE|Light therapy|
48518617|NCT04580407|BIOLOGICAL|TAK-672|B-Domain Deleted Recombinant Porcine Factor VIII
48518618|NCT04944186|OTHER|Structured Pressure Injury Patient Education (mySPIPE)|It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing
48518619|NCT04944186|OTHER|Standard Patient Education|No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
48518620|NCT06423339|PROCEDURE|Ultrasound guided Genicular nerve block|Ultrasound guided genicular nerve block
48715546|NCT05157347|OTHER|Robot-assisted Training|The gait training in this study uses an exoskeletal wearable robot (Product name: ANGEL LEGS M20, Angel robotics, Co., Ltd.) consisting of a wearable part, a hip or knee joint gear providing the auxiliary force, and a controller backpack. This product is a powered orthopedic device for gait rehabilitation and treatment such as the lower limb muscle reconstruction and joint motion recovery in patients or handicapped individuals. The product consists of a power part, a controller part and a gear part, while the device is powered by an electric motor and the device motion induces the gait posture to support the lower limbs and allow the gait training to be performed.
48715547|NCT05157347|OTHER|Conventional Therapy|The conventional gait rehabilitation has been performed as a 1:1 training session between the therapist and a stroke patient.
48715548|NCT02576860|DRUG|CLS001 (Omiganan)|Topical gel
48381038|NCT02046655|DRUG|Corifollitropin alfa|
48381039|NCT02046655|DRUG|rFSH|
48381040|NCT03289182|DRUG|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
48381041|NCT04424732|RADIATION|Stereotactic Body Radiotherapy|This is a prospective study of breast bone only oligometastases (up to three sites). Following systemic treatment and primary tumor control, patients will receive SBRT to all metastatic sites. Data on toxicities and oncological outcomes will be collected for future analysis. There will be no change in the standard systemic therapy nor the local therapy of the primary tumor.
48518621|NCT06423339|PROCEDURE|Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee|Ultrasound guided Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee
48518622|NCT06423339|PROCEDURE|Adductor canal block|Ultrasound guided sub-sartorial Adductor canal block
48518623|NCT06423339|DRUG|Bupivacaine Hydrochloride|Pupivacaine 0.5% in 20 ml vial
48518624|NCT01436630|OTHER|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
48518625|NCT05713565|DEVICE|A digital care solution for patients with Coronary Artery Disease|A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
48518626|NCT05713565|OTHER|Standard of care for patients with Coronary Artery Disease|Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
48715549|NCT02576860|DRUG|Vehicle|Vehicle gel
48715550|NCT03897218|DIETARY_SUPPLEMENT|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
48715551|NCT03897218|DIETARY_SUPPLEMENT|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
48381042|NCT03577665|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
48022777|NCT05041166|DRUG|Hyperpolarized [13C] Pyruvate|Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
48180245|NCT03990636|DRUG|Metil 5-aminolevulinate|Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
48381043|NCT00078273|BEHAVIORAL|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
48381044|NCT00078273|BEHAVIORAL|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
48381045|NCT04281849|BEHAVIORAL|BAMS-HF Program|"BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully."
48022778|NCT01083381|DRUG|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
48022779|NCT01083381|DRUG|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
48022780|NCT01747759|OTHER|Kruskal-Wallis and qualitative parameters|
48022781|NCT04685577|DRUG|Nefopam|Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
48381046|NCT06558682|DRUG|Disitamab Vedotin and Cisplatin|Disitamab Vedotin: 2mg/Kg,ivdrip, 3 weeks/cycle,3 cycles. Cisplatin: 75-80mg/m2, ivdrip, 3 weeks/cycle,3 cycles.
48381047|NCT02753777|OTHER|Questionnaires|
48381048|NCT03953391|OTHER|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
48381049|NCT03953391|OTHER|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
48518627|NCT01659125|BEHAVIORAL|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
48022782|NCT04685577|OTHER|Placebo (Vehicle)|Participants will receive vehicle with out the investigational product
48022783|NCT04631666|BIOLOGICAL|DZIF-10c|SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion
48022784|NCT04631666|OTHER|Placebo|Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
48022785|NCT05635747|DEVICE|Relizorb Enzyme Cartridge|Tube feeds run across device to digest fats.
48022786|NCT03839667|BEHAVIORAL|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
48180246|NCT02023359|DRUG|Everolimus and exemestane|
48180247|NCT02574962|DRUG|H.P. Acthar® Gel|
48518628|NCT06069167|OTHER|Collection of data related to bowel urgency|Data will be extracted from the patient's medical record and patients will be interviewed to collect data specific to the research
48518629|NCT04006002|OTHER|Metabolic and Hormonal profile|To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
48180248|NCT00490945|DRUG|VEC-162|
48180249|NCT06464952|DIETARY_SUPPLEMENT|Resistant potato starch|Prebiotic
48180250|NCT06464952|DIETARY_SUPPLEMENT|Powdered cellulose|Active comparator
48180251|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
48180252|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
48180253|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
48180254|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
48715552|NCT04839848|DEVICE|Lichtenstein mesh repair|A groin hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures
48022787|NCT03839667|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
48180255|NCT05223972|OTHER|Schroth Treatment|Schroth exercises consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. The ultimate goal of the Schroth method is to enable the patient to consciously maintain correct posture in their daily living activities. To achieve this requires repeating corrective movements performed to improve postural motor control. Schroth exercises also include strength and endurance training of postural muscles in order to improve the curve, raise the patient's self-image, and reduce pain. In this study, the Schroth exercises progressed from more to less passive support, from more to less feedback, and from lying to sitting or standing positions, according to the patient's ability to perform the specific exercise
48180256|NCT03785106|DRUG|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
48518630|NCT02211196|BEHAVIORAL|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
48022788|NCT03839667|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
48180257|NCT03785106|DRUG|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
48180258|NCT01939301|DRUG|Inhaled Nitric Oxide|Nitric Oxide + oxygen
48180259|NCT01939301|DRUG|Sham|Nitrogen + Oxygen
48180260|NCT00476528|BEHAVIORAL|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
48180261|NCT00476528|BEHAVIORAL|Reality Orientation|A quasiexperimental study
48022789|NCT03798691|BIOLOGICAL|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
48022790|NCT04203719|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
48022791|NCT04203719|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
48022792|NCT03789526|PROCEDURE|ultrasound guidance|ultrasound guidance of tendon injection
48022793|NCT01870700|DRUG|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
48022794|NCT01870700|DRUG|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
48180262|NCT00620269|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
48180263|NCT00620269|DRUG|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
48180264|NCT00620269|DRUG|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 \& 8 every 3 weeks X 2 cycles
48180265|NCT00620269|RADIATION|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
48180266|NCT03126110|DRUG|INCAGN01876|In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().
48180267|NCT03126110|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
48715553|NCT02789410|DRUG|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
48180268|NCT03126110|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
48180269|NCT06050759|DIAGNOSTIC_TEST|CRP and Albumin level in blood sample|CRP and Albumin levels will be measured from blood samples of the patients to determine CRP/Albumin Ratio
48180270|NCT00370370|DRUG|bevacizumab|Injection of intravitreal bevacizumab
48180271|NCT00370370|DRUG|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
48381051|NCT02641691|RADIATION|Radiation|
48381052|NCT02641691|DRUG|Oxaliplatin|
48518631|NCT02211196|OTHER|survey administration|Ancillary studies
48518632|NCT02211196|OTHER|questionnaire administration|Ancillary studies
48715554|NCT02789410|DRUG|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
48715555|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for MIP-1 alpha
48715556|NCT05314192|DIAGNOSTIC_TEST|salivary test|saliva was assessed for IL-6
48022795|NCT06098599|DRUG|Doxorubicin hydrochloride liposome injection|Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
48022796|NCT02947347|DRUG|ibrutinib|ibrutinib 560mg administered orally
48180272|NCT01497106|BEHAVIORAL|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
48180273|NCT01497106|BEHAVIORAL|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
48180274|NCT00336817|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
48180275|NCT00336817|DRUG|CellCept|CellCept 500mg or 1000mg BID for 90 days
48381053|NCT02641691|DRUG|Leucovorin|
48518633|NCT05305066|DRUG|TNFi|TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
48518634|NCT05305066|DRUG|Anti-IL6|Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
48518635|NCT05305066|DRUG|JAKi|JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
48518636|NCT02617797|DEVICE|Radiofrequency|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
48518637|NCT02617797|DEVICE|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
48518638|NCT00425321|DRUG|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
48518639|NCT00425321|DRUG|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
48518640|NCT00425321|DRUG|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
48180276|NCT01993849|DRUG|N-Acetylcysteine (NAC)|This is the medication N-acetylcysteine (NAC)
48180277|NCT01993849|OTHER|Placebo|Placebo, designed to match in appearance to NAC
48180278|NCT04292080|DRUG|Dimethyl Fumarate (TECFIDERA™)|Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
48180279|NCT04292080|OTHER|No active : no treatment|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
48381054|NCT02641691|DRUG|Fluorouracil|
48518641|NCT00425321|DRUG|Placebo|Placebo once daily for up to 12 weeks
48518642|NCT00947921|PROCEDURE|Plasty|Restrictive Annuloplasty
48518643|NCT00947921|PROCEDURE|Prosthesis|Valve replacement
48518644|NCT05224609|DRUG|Lorlatinib|Single 100mg oral dose anti-cancer agent
48180280|NCT04678908|DRUG|HB0025|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
48180281|NCT03409731|DEVICE|ABSORB GT1 BVS|Patients receiving Absorb GT1 BVS
48180282|NCT01142167|PROCEDURE|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
48180283|NCT01142167|PROCEDURE|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
48180284|NCT00780455|DRUG|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
48381055|NCT02494804|DRUG|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
48381056|NCT02494804|BIOLOGICAL|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
48381057|NCT04453475|BEHAVIORAL|Training session adressing information and health literacy|The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
48518645|NCT00218387|DRUG|Modafinil|200mg Modafinil
48518646|NCT00218387|DRUG|Modafinil|400mg Modafinil
48518647|NCT00218387|DRUG|Matching Placebo|Matching Placebo
48518648|NCT04678050|DRUG|Ketamine/ propofol|ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
48518649|NCT04678050|DRUG|Dexmedetomidine|Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
48518650|NCT06338722|OTHER|Making it Work Systemic Sclerosis|One 2 hour virtual meeting per week for 5 weeks, plus an individual meeting with an occupational therapist and a vocational counselor
48518651|NCT00779831|DRUG|120 mg Pseudoephedrine hydrochloride extended release tablets|
48518652|NCT00004338|DRUG|zinc acetate|
48518653|NCT01027598|DRUG|Pazopanib|Pazopanib: 600 mg orally daily
48518654|NCT01027598|DRUG|Erlotinib|Erlotinib: 150 mg orally daily
48518655|NCT06142474|DRUG|SGLT2 inhibitor|Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
48518656|NCT04292444|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.
48518657|NCT04292444|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
48518658|NCT04173325|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
48381058|NCT03217500|PROCEDURE|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
48381059|NCT03217500|PROCEDURE|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
48715557|NCT01300351|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
48715558|NCT01300351|DRUG|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
48381060|NCT03217500|PROCEDURE|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
48381061|NCT03217500|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
48518659|NCT04173325|DRUG|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
48715559|NCT03696082|BEHAVIORAL|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
48381062|NCT03217500|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
48381063|NCT05901194|DRUG|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
48381064|NCT03813966|DIAGNOSTIC_TEST|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
48381065|NCT03901339|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
48381066|NCT03901339|DRUG|Eribulin|Administered intravenously per NCCN guidelines
48381067|NCT03901339|DRUG|Capecitabine|Administered orally per NCCN guidelines
48381068|NCT03901339|DRUG|Gemcitabine|Administered intravenously per NCCN guidelines
48381069|NCT03901339|DRUG|Vinorelbine|Administered intravenously per NCCN guidelines
48381070|NCT03296592|DIAGNOSTIC_TEST|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
48381071|NCT04897724|OTHER|dental composite|clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
48518660|NCT03616457|DEVICE|Automated Breast Ultrasound (ABUS)|Participants will undergo imaging with ABUS.
48715560|NCT03696082|BEHAVIORAL|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
48180285|NCT00780455|DRUG|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
48180286|NCT02684123|DRUG|Apremilast|Subjects will get drug or placebo
48180287|NCT02684123|DRUG|Placebo|
48180288|NCT04692545|DIETARY_SUPPLEMENT|Immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
48180289|NCT01065467|DRUG|LBH589|Taken orally three times per week.
48180290|NCT04967898|OTHER|bowen technique|Bowen technique is a soft tissue mobilization technique. This medical care involves short mild rolling moves over the muscles, nerves, ligaments, and tendons of flesh utilizing the hands, fingers and thumb. Sequence of receiving bilateral rolling moves over segments of the erector spinae from the lumber toward cervical spine, latissimus dorsi, the gluteal, the hamstring muscles proximally and distally, tensor facia Lata and a medial hip striated muscle move.
48180291|NCT04967898|OTHER|sustained stretching|static stretching is one of the most common and safest technique used for hamstring tightness. A static stretch is performed by inserting muscles at their greatest attainable length and holding that position for an amount of your time.
48180292|NCT02204098|BIOLOGICAL|Mammaglobin-A DNA Vaccine|
48180293|NCT02204098|PROCEDURE|Optional biopsy|
48180294|NCT04416932|PROCEDURE|Ultasound|Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.
48180295|NCT00617929|BIOLOGICAL|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
48180296|NCT00617929|BIOLOGICAL|rituximab|administered 375 mg/m\^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
48180297|NCT00617929|DRUG|clofarabine|administered 30 mg/m\^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
48381072|NCT01510587|BEHAVIORAL|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
48381073|NCT01510587|BEHAVIORAL|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
48715561|NCT03696082|BEHAVIORAL|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
48715562|NCT03696082|BEHAVIORAL|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
48381074|NCT00094900|DRUG|IL-1 Trap|
48180298|NCT00617929|PROCEDURE|stem cell transplantation|administered on Day 0 per institutional guidelines.
48180299|NCT00002463|DRUG|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
48180300|NCT00002463|DRUG|Leucovorin Calcium|
48180301|NCT00002463|DRUG|Mechlorethamine Hydrochloride|
48180302|NCT00002463|DRUG|Methotrexate|
48180303|NCT00002463|DRUG|Prednisone|
48180304|NCT00002463|DRUG|Procarbazine Hydrochloride|
48180305|NCT00002463|DRUG|Vincristine Sulfate|
48180306|NCT00002463|PROCEDURE|Conventional Surgery|
48180307|NCT01183247|DRUG|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
48180308|NCT01183247|DRUG|Everolimus|Add everolimus de novo to tacrolimus and MMF
48180309|NCT01183247|DRUG|Prednisone|Add prednisone de novo to tacrolimus and MMF
48180310|NCT03482752|DRUG|Molgramostim|300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
48381075|NCT04003103|DRUG|Islatravir|Islatravir 30 mg capsules taken by mouth.
48381076|NCT04003103|DRUG|Placebo|Placebo capsules taken by mouth.
48518661|NCT02490644|PROCEDURE|Blood sampling|Blood sampling 5ml
48715563|NCT00494715|DRUG|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
48715564|NCT00494715|DRUG|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
48022797|NCT02947347|DRUG|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
48022798|NCT02947347|DRUG|rituximab|rituximab 375mg/m\^2 IV
48022799|NCT04018872|DRUG|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
48022800|NCT05476003|PROCEDURE|Ultrasound-guided Bilateral superficial cervical plexus block|"This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus."
48022801|NCT05476003|DRUG|Midazolam|All patients will be premedicated with Midazolam (0.02mg/Kg).
48180311|NCT03191071|DIAGNOSTIC_TEST|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
48180312|NCT03191071|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
48180313|NCT03191071|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
48180314|NCT03191071|DIAGNOSTIC_TEST|Naso-pharyngeal swab and sputum culture|A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
48180315|NCT03648528|DRUG|cholecalciferol|
48180316|NCT03648528|DRUG|placebo|
48180317|NCT01150045|DRUG|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
48180318|NCT01150045|DRUG|5-fluorouracil|Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.
48180319|NCT01150045|OTHER|placebo|Patients receive placebo administered by mouth, once daily.
48022802|NCT01259193|DRUG|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
48022803|NCT00648479|DEVICE|The Guiding Star|
48022804|NCT00648479|DEVICE|fluoroscopy (OEC 9800 - General Electric)|
48022805|NCT02206802|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
48022806|NCT04020731|BEHAVIORAL|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
48180320|NCT01150045|DRUG|oxaliplatin|Patients receive 85 mg/m\^2 intravenous over two hours.
48180321|NCT01150045|DRUG|leucovorin|Patients receive 400 mg/m\^2 intravenous over two hours.
48180322|NCT01289210|DRUG|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
48022807|NCT04635046|PROCEDURE|Transfer or extirpation of the peroneus longs tendon|Tendon transfer or extirpation of peroneus longus or brevis tendon, ligamental reconstruction +/- calcaneal osteotomy
48022808|NCT02839291|OTHER|quality of life questionaries|
48022809|NCT02839291|DRUG|intravenous or oral bone antiresorptive treatments|
48022810|NCT02578524|OTHER|Survey|
48022811|NCT06416488|BEHAVIORAL|HIIT intervention|Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.
48022812|NCT06416488|BEHAVIORAL|General health education|General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
48022813|NCT04674345|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity (dose range, 200-800 mg daily).
48022814|NCT04411290|PROCEDURE|Total thyroidectomy (TT)|Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)
48715565|NCT00494715|DRUG|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
48715566|NCT00366028|BEHAVIORAL|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
48715567|NCT00366028|BEHAVIORAL|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
48022815|NCT05148494|DRUG|Fleet Enema|standard pre-op application, see arm description
48180323|NCT03062449|DRUG|L-Serine|Gummy containing L serine dose
48180324|NCT03062449|OTHER|Placebo Gummy|Gummy with no dosing of L Serine
48022816|NCT05148494|DRUG|Pico-Salax|standard pre-op application, see arm description
48022817|NCT03293342|BEHAVIORAL|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~* Psychoeducation about anxiety~* Exploration of the individual anxiety~* Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
48022818|NCT03293342|COMBINATION_PRODUCT|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
48180325|NCT04427176|DEVICE|ARFC mask|Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.
48381077|NCT02297438|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
48180326|NCT01729845|DRUG|Cytarabine|Given IV
48180327|NCT01729845|DRUG|Decitabine|Given IV
48180328|NCT01729845|DRUG|Etoposide|Given IV
48180329|NCT01729845|OTHER|Laboratory Biomarker Analysis|Correlative studies
48180330|NCT01729845|DRUG|Mitoxantrone Hydrochloride|Given IV
48180331|NCT04092452|DRUG|PF-06650833|400 mg QD
48180332|NCT04092452|DRUG|PF-06700841|45 mg QD
48381078|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
48381079|NCT02297438|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
48381080|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
48715568|NCT00287794|DRUG|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
48715569|NCT01747200|PROCEDURE|Sham rTMS|
48715570|NCT01747200|PROCEDURE|Bilateral rTMS at same frequency and in phase|
48715571|NCT01747200|PROCEDURE|Bilateral rTMS at different frequencies|
48180333|NCT04092452|DRUG|PF-06826647|400 mg QD
48180334|NCT04092452|DRUG|Placebo|placebo
48381081|NCT03544697|PROCEDURE|Skin expansion and repair with flaps|
48022819|NCT00585065|DEVICE|CRT device implant|The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
48022820|NCT00143858|DEVICE|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
48180335|NCT03694977|DRUG|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
48518662|NCT02271932|OTHER|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
48518663|NCT05442801|DRUG|Cyclopentolate|Well known eye drop used for cycloplegic refraction among children.
48715572|NCT01747200|PROCEDURE|Bilateral rTMSat same frequency and out of phase|
48715573|NCT01747200|PROCEDURE|rTMS over TP8|
48715574|NCT01747200|PROCEDURE|rTMS over TP7|
48180336|NCT00832468|OTHER|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
48180337|NCT00832468|OTHER|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
48180338|NCT03082898|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
48180339|NCT01477580|BIOLOGICAL|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48180340|NCT01477580|BIOLOGICAL|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48180341|NCT01477580|BIOLOGICAL|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
48180342|NCT01477580|BIOLOGICAL|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48381082|NCT06542666|OTHER|Cognitive Functional Therapy|"The intervention focuses on addressing the maladaptive cognitive, physical, and lifestyle behaviors related to the disorder.~Cognitive functional therapy will focus on factors considered to contribute to the pain disorder, addressing the following topics:~1. The multidimensional nature of persistent pain, beliefs, emotions, and behaviors (movement and lifestyle) that can reinforce a vicious cycle of pain sensitization and disability.~2. Specific functional training designed to normalize maladaptive and provocative postural and movement behaviors as directed by the individual's presentation.~3. Targeted functional integration into daily activities that are avoided and/or provocative for the patient.~4. Counseling on physical activity and lifestyle, which will include promoting a gradual increase in physical activity based on the individual's preference and availability, advice on sleep hygiene, stress management strategies, and social re-engagement"
48518664|NCT05442801|DRUG|Tropicamide|Well known eye drop used for cycloplegic refraction among children.
48518665|NCT01073085|BEHAVIORAL|"Web-based automated coaching by e-mails"|
48518666|NCT01073085|BEHAVIORAL|Self-help guide|
48715575|NCT05713084|OTHER|mandibular setback using BSSRO|mandibular setback using BSSRO
48715576|NCT02822378|DIETARY_SUPPLEMENT|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
48715577|NCT02822378|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
48715578|NCT02822378|DIETARY_SUPPLEMENT|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
48715579|NCT04149574|DRUG|nivolumab|Specified Dose on Specified Days
48715580|NCT04149574|OTHER|Placebo|Specified Dose on Specified Days
48715581|NCT04149574|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
48022821|NCT00993720|DRUG|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
48022822|NCT00993720|DRUG|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
48180343|NCT01477580|BIOLOGICAL|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48180344|NCT01477580|BIOLOGICAL|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
48180345|NCT01477580|BIOLOGICAL|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
48715582|NCT02053662|PROCEDURE|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
48715583|NCT06098664|DIAGNOSTIC_TEST|AI-enabled ECG score for Atrial Fibrillation (DNN score)|"A 12-lead ECG, performed within 24 hours before the Pulmonary Vein Isolation (PVI) procedure, will be used to calculate the DNN score.~(DNN score details: https://doi.org/10.1016/j.jacep.2023.04.008)"
48715584|NCT06098664|DIAGNOSTIC_TEST|Atrial voltage map in sinus rhythm|An atrial voltage map will be constructed prior to the PVI procedure.
48180346|NCT01477580|BIOLOGICAL|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48381083|NCT06542666|OTHER|Exercises|"Individuals allocated to this group will perform stretching and strengthening exercises. The self-stretching exercises will target the upper trapezius and posterior shoulder region. Each stretching exercise will be performed for 3 repetitions of 30 seconds, with an interval of 10 seconds between repetitions.~The strengthening exercises will be performed using resistance elastic bands. Three sets of 10 repetitions will be performed for each strengthening exercise, with 1 minute of rest between sets. The strengthening exercises will target the lower and middle trapezius, anterior serratus, and the external and internal rotators of the shoulder."
48715585|NCT05158985|OTHER|phonophoresis|treatment
48180347|NCT01477580|BIOLOGICAL|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48180348|NCT01477580|BIOLOGICAL|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48180349|NCT01477580|BIOLOGICAL|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48022823|NCT00993720|OTHER|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
48022824|NCT04409756|OTHER|shoulder rating questionnaire|to investigate reliability of turkish version of shoulder rating questionnaire
48022825|NCT06534333|OTHER|Ultrasonography|musculoskeletal ultrasonography
48180350|NCT01477580|BIOLOGICAL|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
48022826|NCT04572347|OTHER|Observational|It is an observational study, and no intervention will be provided.
48180351|NCT01477580|BIOLOGICAL|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
48180352|NCT00206856|DEVICE|Triage® B-Type Natriuretic Peptide (BNP) Test|
48180353|NCT01792388|DIETARY_SUPPLEMENT|Vitamin D|Capsule Form
48180354|NCT01792388|DIETARY_SUPPLEMENT|Soya Bean oil|Capsule form
48180355|NCT04563299|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
48180356|NCT04563299|DRUG|Prednisolone Acetate|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
48180357|NCT05809336|DRUG|Inosine 0.2g orally 3 times/day|inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
48180358|NCT05809336|DRUG|PD-1/PD-L1 inhibitor ,chemotherapy/targeting|PD-1/PD-L1 inhibitor ± chemotherapy/targeting
48381084|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake|6g protein per day for 8wk
48381085|NCT01894542|DIETARY_SUPPLEMENT|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
48715586|NCT05158985|OTHER|exercises|treatment
48715587|NCT05371041|DEVICE|Medtronic Percept Neurostimulator|This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
48381086|NCT01894542|DIETARY_SUPPLEMENT|Control|
48518667|NCT00356525|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
48022827|NCT03455075|DRUG|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
48022828|NCT03455075|DRUG|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
48022829|NCT03455075|DRUG|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
48022830|NCT06173791|DEVICE|DFDBA fibers|Bone Allograft fibers used in dental sinus reconstruction surgery
48022831|NCT06173791|DEVICE|DFDBA particles|Bone Allograft particles used in dental sinus reconstruction surgery
48381087|NCT04985032|RADIATION|stereotactic body radiation therapy|Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less
48381088|NCT04888377|DRUG|Aspirin|Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
48381089|NCT04888377|DRUG|Placebo|Participant's mothers were administered placebo throughout their pregnancy with the participant.
48022832|NCT06173791|DEVICE|DBBM|DBBM is routinely used in sinus augmentation to support dental implant placement and restoration of missing teeth.
48381090|NCT01058226|BIOLOGICAL|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
48518668|NCT00356525|DRUG|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
48022833|NCT01958918|DRUG|Ranibizumab|0.5 mg intravitreal injection
48022834|NCT01958918|DRUG|Aflibercept|2 mg intravitreal injection
48022835|NCT03017508|DRUG|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
48022836|NCT03017508|DRUG|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
48022837|NCT01889589|OTHER|Surveillance|
48022838|NCT00000123|DEVICE|Polymethyl Methacrylate-Silicone Contact Lenses|
48022839|NCT00000123|DEVICE|Polymethyl Methacrylate Contact Lenses|
48022840|NCT03965260|BIOLOGICAL|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
48381091|NCT05378568|OTHER|the selection scheme of peripheral venous access devices|"Based on the Facilitator Toolkit of the promoting action on research implementation in health services integrated framework(i-PARIHS), the implementation plan of peripheral intravenous infusion device selection in hospitalized children was formulated and applied, so as to change the practice behavior of nurses in the intervention group. The specific process mainly includes: tailoring evidence; baseline review; situational analysis; promotion and implementation strategy like lectures, group discussions, operation demonstrations, and scenario simulations."
48518669|NCT00356525|DRUG|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
48518670|NCT00356525|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
48518671|NCT00599053|DRUG|Azithromycin|10 mg/kg IV per dose given for 10 days
48518672|NCT00828165|DRUG|ARRY-300, MEK inhibitor; oral|single dose, escalating
48518673|NCT00828165|DRUG|Placebo|matching placebo
48715588|NCT01024491|DRUG|paroxetine|daily dose of paroxetine 15mg for 12 weeks
48022841|NCT04966104|BEHAVIORAL|ODYSSEE-vCHAT|Automated digital counselling program with social network support
48022842|NCT01699399|PROCEDURE|water immersion|
48022843|NCT01699399|PROCEDURE|water exchange|
48022844|NCT01699399|PROCEDURE|air insufflation|
48022845|NCT06398704|OTHER|Standart of care|No additional intervention was made. An evaluation was made.
48022846|NCT04021680|OTHER|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
48022847|NCT03404024|BIOLOGICAL|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
48022848|NCT03404024|BIOLOGICAL|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
48022849|NCT03404024|BIOLOGICAL|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
48022850|NCT03404024|DRUG|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
48022851|NCT03404024|BIOLOGICAL|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
48381092|NCT05378568|OTHER|the existing nursing routine|To choose infusion device according to nurse's working experience. First, nurse placed a peripheral intravenous catheter. The patients and family decide whether to place the central intravenous infusion device according to the recommendation of the medical staff.
48715589|NCT01024491|DRUG|paroxetine|active daily treatment with paroxetine 20 mg
48715590|NCT01024491|DRUG|placebo|active daily treatment with placebo
48381093|NCT05779059|DRUG|De-escalation to ticagrelor 60 mg at day 30|Change of P2Y12 receptor antagonist regimen to ticagrelor 60 mg bid at day 30.
48381094|NCT05779059|DRUG|De-escalation to prasugrel 5 mg at day 30|Change of P2Y12 receptor antagonist regimen to prasugrel 5 mg qd at day 30.
48381095|NCT05779059|DRUG|Switch to ticagrelor 60 mg at day 45|Switch to ticagrelor 60 mg bid at day 45.
48381096|NCT05779059|DRUG|Switch to prasugrel 5 mg at day 45|Switch to prasugrel 5 mg qd at day 45.
48022852|NCT03404024|BIOLOGICAL|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
48381097|NCT00383929|DRUG|Candesartan cilexetil|32mg oral
48381098|NCT00383929|DRUG|Hydrochlorothiazide|12.5 mg oral
48381099|NCT00383929|DRUG|Hydrochlorothiazide|25 mg oral
48381100|NCT03288428|DRUG|Nalbuphine|patient controlled analgesia with Nalbuphine
48381101|NCT03288428|DRUG|Morphine|patient controlled analgesia with Morphine
48381102|NCT04517630|DIAGNOSTIC_TEST|urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic|Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment
48715591|NCT06275750|DEVICE|Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
48715592|NCT04792333|DRUG|firibastat|Single oral dose of 500 mg administration on Day 1
48715593|NCT03421743|DRUG|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
48381103|NCT06005077|OTHER|Perineal Massage Group|While the pregnant woman was in the lithotomy position, massage was applied with two fingers and rhythmic U-shaped movements starting from the side walls 3-4 cm inside the vagina and towards the rectum. This implementation was done for 10 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
48381104|NCT06005077|OTHER|Perineal Warm Compress Application Group|Sterile compresses kept in hot water of 40 C were placed on the perineum. Compresses that cooled down and became dirty were changed every 5-8 minutes. This implementation was done for 30 minutes in three stages according to cervical dilatation. It was applied when the cervical dilatation was 3-4 cm, 5-7 cm, and 8-10 cm.
48381105|NCT06005077|OTHER|Perineal Massage and Perineal Warm Compress Application Group|When the cervical dilatation was 3-4 cm, 30 minutes of warm compress and 10 minutes of perineal massage were performed. These two methods were applied when the cervical dilatation was 5-7 cm and 8-10 cm as well .
48381106|NCT06650449|OTHER|Mobile App-Based Mental Health Support|This intervention uses a mobile application designed to deliver Cognitive Behavioral Therapy (CBT) techniques. The app provides 12 weekly tasks aimed at reducing emotional distress and depressive symptoms in healthcare workers. Tasks include exercises on emotional regulation, coping strategies, and mindfulness. Participants receive notifications to encourage task completion, and the app tracks progress over the 3-month period. At the start and end of the study, participants will complete the PHQ-9 and GHQ-12 questionnaires to assess their mental health status.
48715594|NCT03421743|DRUG|Antimycobacterial regimen|Multidrug NTM guideline-based antimycobacterial regimen
48381107|NCT04635956|DRUG|Drug therapy|6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
48381108|NCT04552158|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet (MedDiet) is a nutritional model inspired by the traditional dietary pattern of some of the countries of the Mediterranean basin. Mediterranean dietary pattern (MDP) gather the following characteristics: abundant consumption of olive oil and high consumption of fruits, vegetables, cereals (preferably as whole grain), legumes, nuts and seeds. The MDP also includes moderate consumption of fish and shellfish, white meat, eggs, and fermented dairy products (cheese and yogurt), as well as relatively small amounts of red meat, processed meats, and foods rich in sugars. Frequent but moderate intake of wine, especially red wine with meals is also recommended
48518674|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
48518675|NCT01056289|DRUG|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
48715595|NCT01768104|PROCEDURE|ESTD|"1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors... Endoscopy 2012; 44: 231-235)"
48381109|NCT02355366|BEHAVIORAL|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
48381110|NCT02355366|BEHAVIORAL|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
48381111|NCT00928629|PROCEDURE|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
48381112|NCT06457659|BEHAVIORAL|Early Rehab Group|The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation. The basic theme was to check the physical psychological and QOL in early prostheic-fitted patients through WHO_QOL.
48381113|NCT06457659|OTHER|Delayed Rehab Group|The 2nd group of 25 patients was fitted with Prosthesis after 6 months after amputation. No physical rehab was done during this period including physiotherapy and prosthetic treatment. The main aim was to check the significant impact of delayed rehabilitation.
48518676|NCT01056289|DRUG|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
48518677|NCT03811691|DIAGNOSTIC_TEST|MRI exam|Pacing system safety and stability under MRI scan environment
48715596|NCT01768104|PROCEDURE|VATS|"1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
48715597|NCT02788201|DRUG|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
48715598|NCT02788201|OTHER|COXEN|The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
48715599|NCT01352637|DRUG|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
48715600|NCT01352637|DRUG|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
48715601|NCT01352637|DRUG|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
48715602|NCT01352637|DRUG|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
48715603|NCT03216486|DRUG|BPS804|IV administration of BPS804 in 5% Dextrose solution
48715604|NCT03490604|DEVICE|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
48715605|NCT03490604|OTHER|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
48715606|NCT03778320|DRUG|CTP-692|Single oral dose
48715607|NCT03778320|DRUG|D-Serine|Single oral dose
48715608|NCT04373447|PROCEDURE|lap fundus-calot cholecystectomy|use laparoscopic fundus-calot approach
48715609|NCT04373447|PROCEDURE|open cholecystectomy|use open approach
48715610|NCT05510661|DEVICE|Export Catheter|Manual thrombus aspiration with the use of export catheter during primary PCI
48715611|NCT05510661|DEVICE|Balloon catheter|Predilatation with balloon catheter
48715612|NCT04251780|PROCEDURE|Surgical Treatment of Hyperaldosteronism|Surgery of an Aldosterone-producing adenoma
48518678|NCT04756661|DRUG|Carbetocin|100 mcg of Carbetocin intravenous injection
48518679|NCT04756661|DRUG|Oxytocin|10 IU oxytocin IV drip
48518680|NCT04756661|DRUG|Misoprostol|400 mcg rectal
48518681|NCT06582485|DRUG|iCM012 solution 2 mg/mL|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
48715613|NCT04251780|DRUG|Drug treatment of Hyperaldosteronism|Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
48715614|NCT01336751|DRUG|Insulin glargine|solution for subcutaneous injection
48715615|NCT01336751|DRUG|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
48715616|NCT00711490|DRUG|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
48715617|NCT03910166|PROCEDURE|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
48715618|NCT03910166|PROCEDURE|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
48715619|NCT03545711|DRUG|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
48518682|NCT06582485|DRUG|Placebo|200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
48518683|NCT03505086|DIAGNOSTIC_TEST|Blood withdrawal|"* Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~* Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~* Urine sampling will be for a maximum of 5 times per admission.~* Urine can be sampled from a catheter when present, or collected regular."
48715620|NCT04279145|DEVICE|swan ganze catheter /echocardiography|"Right heart catheterization and mixed venous blood samples will be obtained for ABG, biomarkers (troponin , uric acid and micro RNA).~Each subject will have echocardiography, 6 MWD, clinical functional class and blood sample at the day of right heart catheterization or at least less than week of right heart catheterization"
48715621|NCT02467920|DRUG|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
48715622|NCT02467920|DRUG|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
48715623|NCT02148432|DRUG|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
48715624|NCT02148432|DRUG|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
48715625|NCT02246192|PROCEDURE|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
48715626|NCT02246192|PROCEDURE|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
48715627|NCT02707211|BIOLOGICAL|Anti-oxLDL IgM antibody|Immunization
48715628|NCT01969877|DRUG|cetuximab|
48715629|NCT01969877|DRUG|cisplatin|
48715630|NCT03855800|DIAGNOSTIC_TEST|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
48715631|NCT03855800|PROCEDURE|Pancreatic Surgery|Surgical resection of pancreatic cyst
48715632|NCT03855800|PROCEDURE|Endoscopy Exam|Clinically indicated endoscopic ultrasound
48715633|NCT04527523|DIAGNOSTIC_TEST|Optical Coherence Tomography|OCT is an imaging method that uses light waves to create images of the retina.
48715634|NCT04816383|OTHER|"Breastfeeding at AU Apple-Based Smartphone Application"|This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
48715635|NCT04651010|OTHER|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
48715636|NCT02067325|OTHER|Thai massage|
48715637|NCT03582813|BEHAVIORAL|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
48715638|NCT03582813|BEHAVIORAL|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
48715639|NCT01399632|BEHAVIORAL|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
48715640|NCT01399632|BEHAVIORAL|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
48715641|NCT02922166|DRUG|SRX246|oral capsule
48715642|NCT02922166|DRUG|Placebo|oral capsule
48518684|NCT03505086|OTHER|Questionnaire for former bleeding events|Questionnaire to investigate a bleeding tendency before diagnosis.
48715643|NCT03227068|OTHER|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
48022853|NCT03404024|DEVICE|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
48022854|NCT04011475|DRUG|Tiotropium + Olodaterol|Spiolto®
48022855|NCT04011475|DRUG|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
48022856|NCT04011475|DRUG|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
48715644|NCT03227068|OTHER|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
48715645|NCT04075409|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
48715646|NCT02317809|DRUG|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
48381114|NCT06497595|BEHAVIORAL|Wegovy (2.4 Mg Dose) + exercise & nutrition|Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.
48381115|NCT06497595|OTHER|Wegovy (2.4 Mg Dose) + usual care|Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
48715647|NCT02317809|DRUG|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
48715648|NCT02395055|DRUG|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
48715649|NCT02395055|DRUG|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
48715650|NCT01287377|BEHAVIORAL|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
48715651|NCT01287377|DRUG|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
48715652|NCT04721522|DIAGNOSTIC_TEST|blood sampling & ultrasound|"Blood sampling:~Serum P4 \& estradiol will be performed on the day of triggering and on the day of embryo transfer. Progesterone/ Estradiol (P4/E2) ratio will be calculated Ultrasound: On triggering day, at time of ovum pick up and on ET day, we will measure~1. Endometrial thickness~2. Endometrial pattern~3. Endometrial compaction: the difference in measurement of endometrial thickness between the day of embryo transfer and the day of triggering.~4. Junctional zone thickness~5. Uterine contraction (peristalsis).~6. Blood flow of uterine vessels: PI of the uterine arteries will be calculated also Endometrial - sub endometrial blood flow"
48715653|NCT02183129|DRUG|Diclofenac|
48028927|NCT03985423|DRUG|Emapalumab-Lzsg|Patients were administered Emapalumab-Lzsg by intravenous (i.v.) infusion over a period of 1 to 2 hours, at an initial dose of 6 mg/kg and continued at 3 mg/kg, every 3 days for the first 2 weeks (Study Day \[SD\] 15), and then twice-a-week. If the treating physician deemed appropriate, the dose of emapalumab could be increased (up to 10 mg/kg), guided by clinical and laboratory response.
48381116|NCT04895904|OTHER|No intervention|Our study is an observational study and the main purpose of our study is to observe the efficacy of endoscopic hemostasis and drug therapy
48381117|NCT05514327|RADIATION|ultra-fraction radiotherapy|the R/R DLBCL patients would receive ultra-fraction radiotherapy as bridging therapy before the CD19 CART cell infusion
48715654|NCT02183129|DRUG|Meloxicam|
48715655|NCT04117763|DRUG|Empagliflozin 25 MG|Empagliflozin once daily, for three months
48715656|NCT02476110|DIETARY_SUPPLEMENT|Oral nutritive supplements|
48715657|NCT00004705|DRUG|amiloride|
48715658|NCT00004705|DRUG|uridine|
48715659|NCT00254683|DEVICE|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
48715660|NCT03698175|BEHAVIORAL|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
48715661|NCT03698175|BEHAVIORAL|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
48715662|NCT00005632|BIOLOGICAL|MUC1-KLH vaccine/QS21|
48715663|NCT03515941|DRUG|Oxaliplatin|130 mg/m2 by IV (Arm 1)
48715664|NCT03515941|DRUG|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
48715665|NCT03515941|DRUG|Leucovorin|400 mg/m2 by IV (Arm 1 \& Arm 2)
48715666|NCT03515941|DRUG|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
48028928|NCT05157646|BEHAVIORAL|Fitness tracker|Participants will be asked to wear a Fitbit fitness tracker and report their fitness activity to the study team
48028929|NCT04307823|OTHER|Treadmill training|"3 days per week, starting at shorter duration 5-20min and progressed to 30- 40mins.~Training% or Intensity was kept 40-70%,~Training Heart Rate (HR) was calculated through formula:~HR max HR rest\*Ex intensity + HR rest Rate of Perceived Exertion (RPE) 9-14 ON 6 -20 RPE scale The session was terminated if sustained ventricular arrhythmia, symptomatic drop in blood pressure, ST elevation, or development of severe symptoms"
48715667|NCT03515941|RADIATION|radiation|45 Gy in 1.8 Gy/fraction
48381118|NCT02317796|DRUG|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
48381119|NCT00517868|DRUG|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
48381120|NCT00517868|DRUG|Placebo|Liquid formulation without active URG101 drug components
48715668|NCT03071991|PROCEDURE|study group|local anesthetic drug will be used
48715669|NCT03071991|PROCEDURE|control group|no local anesthetic drug will be used
48381121|NCT00615927|DRUG|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant \& must be taken in sitting position; mini of 2hrs should be allowed between last drug intake \& going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/\> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 \& continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
48381122|NCT04402580|DRUG|Rituximab Biosimilar|for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
48381123|NCT04402580|DRUG|Mycophenolate Mofetil|1,200 mg/1,73 sqm orally divided in 2 daily doses
48381124|NCT02175472|DEVICE|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
48381125|NCT02175472|DEVICE|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
48381126|NCT01019746|DRUG|propofol|propofol administration
48381127|NCT04649931|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
48381128|NCT02942537|DEVICE|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
48381129|NCT02942537|PROCEDURE|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
48381130|NCT04340739|OTHER|online patient education teach mindfulness based stress reduction|This is an online self management chronic pain curriculum that presents adapted Mindfulness Based Stress Reduction through videos, audios, and written materials
48381131|NCT05802147|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact
48381132|NCT02006901|PROCEDURE|microdecompression|a minimal invasive surgical technique
48381133|NCT02006901|PROCEDURE|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
48381134|NCT06172569|DEVICE|Spartan Stem, World Acetabular Cup and World Liner|"The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating.~The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner"
48381135|NCT00952432|DRUG|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
48381136|NCT00952432|PROCEDURE|Acupuncture|Acupuncture
48381137|NCT02098434|BEHAVIORAL|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
48715670|NCT04835376|DEVICE|Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis|Patients/guardians/caregivers will be given 3 percussor palm cups to use over the course of 6 days. Each cup will be trialed for 2 days, allowing for equal time dedicated to each.
48715671|NCT03514498|PROCEDURE|Dental surgery|All types of dental surgery
48381138|NCT00944125|DEVICE|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
48381139|NCT00944125|DEVICE|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
48381140|NCT02612649|DRUG|Ramosetron|Oral
48381141|NCT03294382|DRUG|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
48381142|NCT03294382|DRUG|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
48381143|NCT02084329|DEVICE|Weighted Compression Vest|
48715672|NCT02317952|OTHER|Experimental Extensively Hydrolyzed Formula|
48715673|NCT02317952|OTHER|Active Comparator Formula|
48715674|NCT00487370|PROCEDURE|Implantation of gold beads around a knee through needles|
48715675|NCT00487370|PROCEDURE|Sham implantation: Insertion of needles around a knee|
48715676|NCT01592019|DRUG|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
48715677|NCT01592019|DEVICE|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
48715678|NCT01592019|DRUG|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
48715679|NCT01592019|DEVICE|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
48715680|NCT05656833|DEVICE|Fractional 1927nm Low-Powered Diode Laser|Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser
48715681|NCT05656833|OTHER|Topical Cysteamine|Topical Cysteamine cream will be used on the entire face.
48715682|NCT06243055|OTHER|questionnare|laval questionnare
48022857|NCT05063201|DRUG|Cariprazine 1.5 MG|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
48022858|NCT05063201|DRUG|Placebo|Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
48381144|NCT05636618|DRUG|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered every 8 weeks for a maximum of four doses
48381145|NCT05636618|DRUG|[212Pb]VMT-α-NET|Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
48381146|NCT06651632|DEVICE|Aquablation Therapy|The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.
48381147|NCT06651632|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.
48381148|NCT06651138|RADIATION|Fluoroscopy|Pulsed or Continuous fluoroscopy during MILD procedure
48381149|NCT03780101|DIAGNOSTIC_TEST|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
48381150|NCT05069129|BIOLOGICAL|Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
48381151|NCT05069129|BIOLOGICAL|Inactivated COVID-19 vaccine (Vero cells)|Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
48381152|NCT05069129|BIOLOGICAL|3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)|Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
48381153|NCT02768935|PROCEDURE|blood sample|blodd sample at 12 months
48381154|NCT03520582|DEVICE|Tube placement|Placement of enteral feeding tubes
48381155|NCT00004123|DRUG|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
48381156|NCT00004123|PROCEDURE|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
48381157|NCT00004123|RADIATION|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
48518685|NCT03857815|RADIATION|anti-PD-1 antibody|"In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks."
48518686|NCT00960219|DRUG|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
48022859|NCT03762226|DRUG|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
48022860|NCT02673697|DEVICE|Perceval valve|Sutureless Aortic Biological Valve
48381158|NCT00004123|RADIATION|Radiation Therapy (RT)|5 days a week for 4 weeks
48381159|NCT05901636|BIOLOGICAL|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
48518687|NCT00960219|DRUG|placebo|1# BID, oral, for 6 weeks
48022861|NCT02673697|DEVICE|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
48381160|NCT05901636|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly.
48381161|NCT05901636|BIOLOGICAL|Al(OH)3|Al(OH)3 will be administered intramuscularly.
48381162|NCT06533410|DIAGNOSTIC_TEST|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that|The FM Diagnosis and Assessment Scale will be filled out, and there will be no other interventions beyond that
48381163|NCT00034593|DRUG|ALIMTA|
48381164|NCT00034593|DRUG|gemcitabine|
48381165|NCT06302075|OTHER|One Day Rehabilitation|Patient discharged at home the day after the operation and carrying out outpatient rehabilitation according to the clinical standard
48381166|NCT06302075|OTHER|Fast Rehabilitation|Patient discharged to the rehabilitation department of the Institute 48 hours after surgery which carries out rehabilitation during the hospital stay according to the clinical standard
48381167|NCT04162301|DRUG|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
48381168|NCT06417853|BIOLOGICAL|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) Injection
48518688|NCT00149474|BEHAVIORAL|Peak Flow Monitoring|
48518689|NCT04808674|BEHAVIORAL|Cognitive remediation program|Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer
48022862|NCT01626365|PROCEDURE|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
48381169|NCT06417853|COMBINATION_PRODUCT|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)|12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
48381170|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)|25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
48715683|NCT06243055|OTHER|questionnare|Obese-Specific Quality of Life
48715684|NCT06243055|OTHER|questionnare|SF-12 Quality of Life scale
48022863|NCT01626365|PROCEDURE|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
48022864|NCT00263692|BIOLOGICAL|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
48381171|NCT06417853|BIOLOGICAL|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) with MF59® Injection
48381172|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)|12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
48381173|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)|12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
48381174|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)|20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
48381175|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)|20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
48381176|NCT06417853|DEVICE|Microarray Patch Delivery System|Vaccine free Microarray Patch Delivery System (VXS-1219U)
48381177|NCT06327204|DEVICE|940-nm diode laser / one session|laser therapy using a 940-nm diode laser / one session per week
48381178|NCT06327204|DEVICE|940-nm diode laser / two session|laser therapy using a 940-nm diode laser / two session per week
48381179|NCT06327204|DEVICE|940-nm diode laser/ three session|laser therapy using a 940-nm diode laser / three session per week
48381180|NCT05411848|DIETARY_SUPPLEMENT|2kcal HP PlantBased|Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
48381181|NCT00924313|DRUG|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
48518690|NCT01935830|RADIATION|[11c] LAAM|intravenous administration of 15-20 mCi of \[11c\] LAAM.
48518691|NCT01935830|DRUG|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
48518692|NCT01935830|DRUG|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
48022865|NCT00206063|DRUG|EXANTA|
48022866|NCT02202135|DRUG|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
48381182|NCT01728935|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
48381183|NCT05372211|OTHER|not use of any intervention|not use of any intervention
48381184|NCT06148077|OTHER|Manual Therapy|3 times a week, for 6 weeks.
48381185|NCT06148077|OTHER|Motor control exercises|3 times a week, for 6 weeks.
48381186|NCT01736982|BEHAVIORAL|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
48381187|NCT01736982|OTHER|Standard of Care|Standard smoking cessation counseling
48381188|NCT01736982|OTHER|Standard of Care|transdermal nicotine replacement \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\]
48381189|NCT01736982|OTHER|Standard of Care|Breath sample monitoring
48381190|NCT02160054|DRUG|Graceptor®|oral
48381191|NCT02016027|DRUG|Carica folia|
48381192|NCT02676232|BEHAVIORAL|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
48381193|NCT04753879|DRUG|Nab-paclitaxel|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane"
48381194|NCT04753879|DRUG|Gemcitabine|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar"
48381195|NCT04753879|DRUG|Cisplatin|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
48381196|NCT04753879|DRUG|Irinotecan|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
48715685|NCT04500340|BEHAVIORAL|Group CBT for test anxiety|The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
48715686|NCT01705158|DRUG|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
48715687|NCT02564861|DRUG|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
48715688|NCT02564861|DRUG|Placebo|Placebo matching DS-1971a suspension
48381197|NCT04753879|DRUG|Capecitabine|"1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda"
48381198|NCT04753879|DRUG|Pembrolizumab|"1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda"
48381199|NCT04753879|DRUG|Olaparib|"1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza"
48518693|NCT06199284|DEVICE|Atalante exoskeleton|The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities.
48518694|NCT04825912|BEHAVIORAL|Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience|The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
48518695|NCT04904250|DEVICE|Emboshield|a distall occlusion Emboshield NAV6 will be used as the embolism protection device during CAS
48518696|NCT04904250|DEVICE|Spider|a distal SpiderFX will be used as the embolism protection device during CAS
48715689|NCT04467970|PROCEDURE|Unicompartmental Knee Replacement|Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.
48022867|NCT02202135|DRUG|Vancomycin|IV vancomycin 15mg/kg every 12 hours
48022868|NCT02202135|DRUG|Aztreonam|IV aztreonam 1 g every 8 hours
48381200|NCT02017782|DEVICE|Dust|Dust (250-300µg/m3),
48381201|NCT02017782|DEVICE|Ozone|(0,1ppm ozone),
48381202|NCT02017782|DEVICE|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
48518697|NCT00789035|DRUG|BI 10773|
48022869|NCT04870567|RADIATION|Stereotactic ablative radiotherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
48022870|NCT04870567|RADIATION|High dose rate brachytherapy|Patients were randomly assigned (1:1) to conventionally high dose rate brachytherapy or stereotactic body radiotherapy. Randomisation was done Chief researcher blinded to patient data by telephone stratification by risk group (low or intermediate).
48518698|NCT00789035|DRUG|placebo|
48022871|NCT02662712|DRUG|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
48022872|NCT02662712|DRUG|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
48022873|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
48022874|NCT02199691|BIOLOGICAL|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, IM
48381203|NCT02017782|DEVICE|Placebo (Filtered air)|Placebo treatment (Filtered air \<20 ug/m3)
48518699|NCT00789035|DRUG|metformin|
48518700|NCT05085444|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
48518701|NCT04257539|BEHAVIORAL|Intervention to Reduce Sedentary Time|Chronic low back pain participants in the intervention group will be provided with a wrist-worn activity device that vibrates after prolonged sedentariness and meet with a health coach trained in motivational interviewing to discuss individual sedentary levels and provide education surrounding sitting habits and strategies for new habit development. Participants will meet with the health coach initially and at 4 weeks during the 8 week intervention period.
48518702|NCT03404674|BIOLOGICAL|CssBA|Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B
48518703|NCT03404674|BIOLOGICAL|dmLT|Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211
48715690|NCT04467970|PROCEDURE|High Tibial Osteotomy|High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
48715691|NCT02623075|BIOLOGICAL|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
48715692|NCT00002514|BIOLOGICAL|sargramostim|
48715693|NCT00002514|DRUG|asparaginase|
48381204|NCT02673827|OTHER|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
48381205|NCT03713515|BEHAVIORAL|ALTA|The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
48381206|NCT06651489|DRUG|Guselkumab|Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
48381207|NCT05486975|BIOLOGICAL|CT0591CP Cells|CT0591CP cells
48381208|NCT04723667|BEHAVIORAL|13-week multimodal intervention|The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.
48381209|NCT04723667|BEHAVIORAL|5-week health education programme|The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up
48518704|NCT04105010|DRUG|AZD4205|AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
48715694|NCT00002514|DRUG|cyclophosphamide|
48381210|NCT00625313|DEVICE|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
48381211|NCT06507709|PROCEDURE|Low volume CBCT|3-D imaging used during dental practice
48381212|NCT04723329|BEHAVIORAL|Web-based exercise training based on the transtheoretic model|Motivating interviews will be provided to the patients to receive training on the website by contacting them one-on-one. In the following 1st and 3rd months, patients will be contacted individually again to confirm whether they follow the website, and they will be asked to fill in the scales on the website by providing consultancy on the issues they need. In the 6th month, the final test data will be obtained from the website using the same data collection forms.
48381213|NCT05668377|DEVICE|PulseAI ECG Platform|Cloud-based AI-enabled ECG analysis platform
48381214|NCT06468449|OTHER|Lower limb power output training|"Lower limb power output training content:~Half squat up squat: 70%1R (6 repetitions × 5sets) + 5 knees jumps × 5 sets with an interval of 90 seconds；"
48381215|NCT06468449|OTHER|Force Combined Speed training|"Lower limb Force Combined Speed training content:~Rapid half squat : Optimal load (6 sets × 7 repetitions). Rest intervals between sets range from 2 to 5 minutes."
48381216|NCT01504152|BEHAVIORAL|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
48381217|NCT01467518|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
48518705|NCT03366207|DRUG|Ciprofloxacin|Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
48518706|NCT04656600|DRUG|Cerezyme® / Imiglucerase|Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
48715695|NCT00002514|DRUG|cytarabine|
48715696|NCT00002514|DRUG|daunorubicin hydrochloride|
48715697|NCT00002514|DRUG|dexamethasone|
48715698|NCT00002514|DRUG|etoposide|
48715699|NCT00002514|DRUG|imatinib mesylate|
48715700|NCT00002514|DRUG|leucovorin calcium|
48715701|NCT00002514|DRUG|mercaptopurine|
48715702|NCT00002514|DRUG|methotrexate|
48715703|NCT00002514|DRUG|prednisone|
48715704|NCT00002514|DRUG|thioguanine|
48715705|NCT00002514|DRUG|vincristine sulfate|
48715706|NCT00002514|PROCEDURE|allogeneic bone marrow transplantation|
48715707|NCT00002514|PROCEDURE|autologous bone marrow transplantation|
48715708|NCT00002514|PROCEDURE|peripheral blood stem cell transplantation|
48715709|NCT00002514|RADIATION|radiation therapy|
48715710|NCT00143533|DRUG|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
48715711|NCT04945967|PROCEDURE|New Method|Physiological flexion in therapeutic positioning, oral stimulation, stimulation of synergistic movements, and stimulation for non-nutritive sucking by using special designed pacifier for premature infant.
48715712|NCT04945967|PROCEDURE|Conventional Method|Oral stimulation and non-nutritive sucking stimulation using usual pacifier.
48715713|NCT04579094|OTHER|Feces sampling at inclusion (J0)|Feces sampling at inclusion (J0)
48022875|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
48022876|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
48022877|NCT02199691|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
48180359|NCT02134509|BEHAVIORAL|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
48180360|NCT02134509|BEHAVIORAL|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
48180361|NCT05435911|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia
48180362|NCT05435911|DRUG|Flumazenil|Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
48180363|NCT05435911|DRUG|Propofol|Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
48180364|NCT01296555|DRUG|Fulvestrant|Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics \[SmPC\]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
48381218|NCT01467518|DRUG|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
48381219|NCT00066859|DRUG|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
48381220|NCT00066859|DIETARY_SUPPLEMENT|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
48381221|NCT03055273|BEHAVIORAL|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
48715714|NCT03973463|BEHAVIORAL|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
48715715|NCT05275946|DRUG|Targeted alpha therapy|Single intravenous administration
48715716|NCT03624088|BEHAVIORAL|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
48715717|NCT03093636|DEVICE|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
48715718|NCT03093636|OTHER|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
48715719|NCT00975819|DRUG|sirolimus|liquid dosing based on trough levels
48715720|NCT03873506|DRUG|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
48715721|NCT05529342|BIOLOGICAL|Gene modified therapy|No investigational cell product will be administered
48715722|NCT05536622|DIAGNOSTIC_TEST|High resolution infrared imaging|High resolution infrared imaging of limb of concern and unaffected limb (control).
48715723|NCT04239794|DRUG|Propofol|General anesthesia during the laparoscopic colorectal surgery is achieved by using a target-controlled intravenous infusion of propofol.
48022878|NCT02199691|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
48022879|NCT02199691|BIOLOGICAL|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
48022880|NCT03981406|BEHAVIORAL|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
48022881|NCT03981406|BEHAVIORAL|Standard of Care|Control group will receive standard of care treatment for IPF.
48381222|NCT05592704|DEVICE|Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises|Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
48381223|NCT03797378|OTHER|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
48381224|NCT01360021|DRUG|Symbicort|Breath actuated metered dose inhaler
48381225|NCT01360021|DRUG|Symbicort|Actuation counter pressured metered dose inhaler
48715724|NCT04239794|DRUG|Sevoflurane|General anesthesia during the laparoscopic colorectal surgery is achieved by using an inhalation agent (Sevoflurane).
48715725|NCT00000916|DRUG|Indinavir sulfate|
48715726|NCT00000916|DRUG|Lamivudine/Zidovudine|
48715727|NCT00000916|DRUG|Hydroxyurea|
48715728|NCT00000916|DRUG|Lamivudine|
48715729|NCT00000916|DRUG|Stavudine|
48715730|NCT00000916|DRUG|Zidovudine|
48715731|NCT00000916|DRUG|Didanosine|
48715732|NCT02042313|OTHER|continuous epidural infusion|
48715733|NCT02042313|OTHER|combined paravertebral infusion and single shot of TAP block|
48715734|NCT02156544|DRUG|CKD-519|
48715735|NCT02156544|DRUG|placebo|
48715736|NCT01241760|DRUG|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
48715737|NCT01241760|DRUG|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
48715738|NCT01241760|DRUG|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
48715739|NCT01241760|DRUG|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
48715740|NCT05990699|BEHAVIORAL|Mindfulness-Based Relapse Prevention program|"This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
48715741|NCT00687609|DRUG|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
48715742|NCT03324425|DRUG|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
48715743|NCT04579172|PROCEDURE|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
48715744|NCT04579172|PROCEDURE|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
48715745|NCT01971216|BEHAVIORAL|Relaxation|
48715746|NCT06441292|PROCEDURE|AI-assisted|utilize advanced deep learning models that integrate multi-modal image fusion from multi-parameter ultrasound and MRI to guide the biopsy process
48715747|NCT06441292|PROCEDURE|Non-AI-assisted|undergo standard prostate biopsy procedures without additional technological assistance
48715748|NCT01582737|DRUG|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
48715749|NCT03855202|BIOLOGICAL|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
48715750|NCT03855202|BIOLOGICAL|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
48715751|NCT03855202|BIOLOGICAL|PS|PS,dose is 70mg/kg
48715752|NCT03855202|OTHER|Placeo|0.9% sodium chloride installation after 24 hours
48715753|NCT03554980|DRUG|Silver Diamine Fluoride|SDF will be applied with a brush.
48715754|NCT03554980|DRUG|Sodium Fluoride varnish|NaF will be applied with a brush
48715755|NCT01057056|OTHER|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
48715756|NCT00914550|OTHER|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
48715757|NCT01305603|DRUG|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
48715758|NCT01305603|PROCEDURE|Injection|Injection under ultrasound-guidance
48715759|NCT03167489|BEHAVIORAL|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
48180365|NCT01296555|DRUG|GDC-0032|Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
48180366|NCT01296555|DRUG|Letrozole|Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
48180367|NCT01296555|DRUG|Midazolam|Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.
48180368|NCT01476605|PROCEDURE|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
48022882|NCT05991141|OTHER|Apnea|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The experimental group (EG) added throughout the 6 minutes intervention the following breathing pattern cyclically: 5 seconds breathing normally followed by 10 seconds of low volume apnoea, performing a total of 24 cycles of normal breathing continued by apnoea.
48180369|NCT01476605|PROCEDURE|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
48180370|NCT01476605|PROCEDURE|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
48381226|NCT01360021|DRUG|Budesonide|Actuation counter pressured metered dose inhaler
48022883|NCT05991141|OTHER|Control Intervention|In both experimental and control groups participants walked on a treadmill at 5.5 km/h with 5º inclination for 6 minutes. The Control group (CG) performed this protocol breathing normally.
48022884|NCT01972061|DEVICE|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
48022885|NCT06449911|PROCEDURE|HIFU|300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
48022886|NCT02506998|BIOLOGICAL|DLE|Adjuvant treatment
48180371|NCT02698306|DRUG|Dexamethasone|Dexamethasone
48180372|NCT02698306|DRUG|Diclofenac Sodium|Diclofenac Sodium
48180373|NCT01289132|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
48180374|NCT01289132|DRUG|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
48180375|NCT01289132|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
48180376|NCT01289132|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
48518707|NCT03267212|DEVICE|Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
48715760|NCT02428621|DEVICE|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
48715761|NCT02428621|DEVICE|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
48022887|NCT02506998|OTHER|Second generation anti histamines + Nasal corticosteroids|Standard treatment
48715762|NCT05117619|BEHAVIORAL|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
48715763|NCT05117619|BEHAVIORAL|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
48715764|NCT03913845|DRUG|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
48180377|NCT01289132|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
48180378|NCT01289132|DRUG|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
48715765|NCT03913845|DRUG|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
48715766|NCT03095586|OTHER|News items with spin|Interpretation of news items with spin
48180379|NCT01289132|DRUG|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
48715767|NCT03095586|OTHER|News items without spin|Interpretation of news items without spin
48180380|NCT04214353|DIAGNOSTIC_TEST|68Ga-PSMA-PET/CT|All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
48715768|NCT05788315|OTHER|Cultural Formulation Interview|The Cultural Formulation Interview will be used at the start of treatment in the intervention group against a standard practice intake in the control group.
48715769|NCT05278364|DRUG|SY-5007|a RET selective Inhibitor
48715770|NCT00581828|DRUG|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
48715771|NCT00567918|DRUG|FK506|Ophthalmic suspension
48715772|NCT04534101|BEHAVIORAL|Virtual Reality Mindfulness|This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
48715773|NCT04564248|OTHER|Website access|website access will be provide to families
48715774|NCT05254561|BIOLOGICAL|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
48715775|NCT01430676|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
48022888|NCT00913159|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
48022889|NCT04387253|DIAGNOSTIC_TEST|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus|Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus Presence of SARS-COV-2 virus in samples taken from mother and father. Circulating anti-SARS-COV-2 antibodies in the mother.
48022890|NCT06572566|OTHER|Non-invasive examination and assessment.|1) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
48022891|NCT06311500|BEHAVIORAL|Sleep health enhancement intervention|4 weekly visits of education and strategies to enhance sleep health
48180381|NCT04214353|DIAGNOSTIC_TEST|18FDG-PET/CT|All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
48180382|NCT02204553|DRUG|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
48180383|NCT04207645|DIAGNOSTIC_TEST|Modified RIPASA score|Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
48180384|NCT01298882|DRUG|Diacerein|
48180385|NCT01298882|OTHER|Placebo|
48180386|NCT05874310|GENETIC|FT-002|Comparison of different dosages of FT-002
48180387|NCT05750836|OTHER|Specific nursing support|"* 3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~* interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver"
48381227|NCT03635021|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
48381228|NCT03635021|DRUG|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
48381229|NCT03635021|DRUG|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
48715776|NCT05823844|DRUG|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
48715777|NCT05823844|DRUG|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
48715778|NCT05595018|OTHER|End user|Participants will provide their opinions in two rounds to reach consensus
48715779|NCT05595018|OTHER|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
48715780|NCT05595018|OTHER|Supply side|Participants will provide their opinions in two rounds to reach consensus
48715781|NCT05595018|OTHER|Funder|Participants will provide their opinions in two rounds to reach consensus
48715782|NCT05595018|OTHER|Academia|Participants will provide their opinions in two rounds to reach consensus
48715783|NCT00859339|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
48715784|NCT00859339|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
48715785|NCT00859339|DRUG|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
48715786|NCT00859339|PROCEDURE|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
48381230|NCT03635021|DRUG|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
48381231|NCT02027766|OTHER|Calf muscle stretching|
48381232|NCT03542929|DEVICE|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
48381233|NCT02139969|DEVICE|GreenLight XPS Laser System|
48381234|NCT03225339|DIETARY_SUPPLEMENT|Low Energy Diet|Low Energy Diet
48381235|NCT05762588|DEVICE|Juggerknot with Broadband tape|The JuggerKnot system is comprised of a coreless sleeve structure and suture. The anchors are intended for use in soft tissue to bone fixation by bunching against the bone when deployed. The anchor sleeve material is polyester. Suture materials are ultra-high molecular weight polyethylene. The device has 510K FDA clearance.
48715787|NCT04234087|OTHER|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
48715788|NCT00049777|DRUG|Drotrecogin Alfa (Activated)|
48715789|NCT00049777|DRUG|Unfractionated heparin|
48715790|NCT00049777|DRUG|Low molecular weight heparin|
48715791|NCT02044666|DEVICE|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
48715792|NCT03455439|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
48715793|NCT06228638|OTHER|CognivAID (Sailuotong)|CognivAiD is 27.27 mg of panax ginseng standard extract, 27.27 mg of gingo biloba standard extract and 5.46 mg of crocus sativus standard extract which is equal to 60mg /capsule .CognivAiD is available at 60 mg /cap 2 caps twice a day.
48715794|NCT01388751|PROCEDURE|night splinting|splint finger at night for 4 weeks
48715795|NCT02544256|PROCEDURE|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
48715796|NCT05764031|OTHER|Clinical pilates exercise|Clinical pilates is an exercise modality in which postural muscles are worked out with various body movements, and involves multi-muscle synergies that improve spinal stabilization, flexibility and endurance.
48715797|NCT05764031|OTHER|Aerobic exercise|Aerobic exercise (also known as endurance activities, cardio or cardio-respiratory exercise) is physical exercise of low to high intensity that depends primarily on the aerobic energy-generating process.
48180388|NCT05750836|OTHER|Non-specific nursing support|Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
48180389|NCT00943722|BIOLOGICAL|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
48180390|NCT01383447|DRUG|entinostat|Given PO
48518708|NCT03267212|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
48022892|NCT04946513|OTHER|Muscle volumes were measured on pre- and postoperative MRI scans.|Muscle volumes were measured on pre- and postoperative MRI scans.
48022893|NCT02488512|DRUG|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
48022894|NCT05372484|DEVICE|Multimodal optical imaging|Women referred for colposcopy due to abnormal cervical screening will be recruited into the experimental group of the study. Imaging of study participants will take place during the colposcopy examination.
48022895|NCT02563041|DRUG|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
48022896|NCT02563041|DRUG|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
48022897|NCT00614029|DEVICE|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
48022898|NCT00002526|BIOLOGICAL|filgrastim|
48022899|NCT00002526|DRUG|doxorubicin hydrochloride|
48022900|NCT00002526|DRUG|ifosfamide|
48022901|NCT06271551|DRUG|Transdermal estrogen|Participants (n=155) receiving transdermal estradiol for 12 months.
48022902|NCT06271551|DRUG|Active Comparator: Androgen deprivation therapy|Participants (n=155) receiving solely androgen deprivation therapy for 12 months.
48022903|NCT06271551|BEHAVIORAL|Resistance training|Participants (n=30 in each arm) performing supervised resistance training for six months.
48022904|NCT06126562|DRUG|Lanifibranor|Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
48022905|NCT06017284|DRUG|Thalidomide|Thalidomide 100 mg/day, once a day, orally intake at night.
48022906|NCT06017284|DRUG|Nab paclitaxel|nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
48022907|NCT06017284|DRUG|Gemcitabine|gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
48022908|NCT06017284|DRUG|Placebo|Placebo, 100 mg/day, once a day, orally intake at night.
48022909|NCT04318210|DRUG|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|
48022910|NCT02338362|DRUG|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
48022911|NCT02338362|DRUG|Saline placebo inhaler|saline metered dose inhaler
48180391|NCT01383447|DRUG|imatinib mesylate|Given PO
48180392|NCT01383447|OTHER|laboratory biomarker analysis|Correlative studies
48180393|NCT01383447|OTHER|pharmacological study|Correlative studies
48180394|NCT01383447|GENETIC|western blotting|Correlative studies
48518709|NCT03267212|OTHER|Functional Electrical Stimulation Row Training (FESRT)|FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
48518710|NCT05295576|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
48518711|NCT01654692|DRUG|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
48381236|NCT04765501|OTHER|Survey study|Headache Impact Questionnaire (HIQ) will be applied.
48381237|NCT04647448|DIAGNOSTIC_TEST|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
48518712|NCT02562066|DRUG|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
48518713|NCT02562066|DRUG|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
48715798|NCT01557881|DEVICE|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center \[SCC\] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
48715799|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with the digital method
48715800|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with a speculum
48715801|NCT05682989|PROCEDURE|Urodynamic investigations before and after a mesh surgery protocol.|Urodynamic investigations (The urodynamic study included free uroflowmetry, postvoid residual, filling and voiding cystometry, and a urethral pressure profile. The filling cystometry and urethral pressure profile were performed with 37 degrees C normal saline similar to body temperature at an infusion rate of 80 ml/min.
48715802|NCT05682989|PROCEDURE|Urodynamic investigations before and after a robotic-assisted sacrocolpopexy protocol.|All surgeries were performed using a DaVinci robotic system (Intuitive® Surgical Inc., Sunnyvale, California,US) with standardized technique and materials. Patients were positioned in dorsal lithotomy and steep Trendelenburg position. Trocars were placed bilaterally, and an assistant port was placed laterally. The peritoneum was opened medial to the ureter to develop an avascular space. The mesh was placed on the posterior and anterior vaginal wall and fixed at the level of anterior longitudinal ligaments S1/S2 by sutures. An intraoperative clinical examination was performed to ensure the mesh was in a tension-free position.
48715803|NCT05682989|PROCEDURE|Urodynamic investigations before and after a hysterectomy with trans-vaginal mesh repair|In summary, a vertical incision was made in the anterior vaginal wall to access the vesicovaginal space. The sacrospinous ligament was dissected, and an applicator was inserted and positioned over the SSL. The anchor was fixed to the SSL and the thread was attached to the mesh. The mesh was then adjusted in a tension-free manner, excess mesh was cut, and the incision was closed with suture.
48022912|NCT03614026|BEHAVIORAL|Teachers and Parents as Partners|Family-school partnership intervention
48381238|NCT03619512|GENETIC|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
48518714|NCT02720848|DEVICE|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
48518715|NCT02720848|DEVICE|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
48518716|NCT02964312|DEVICE|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
48715804|NCT01107561|OTHER|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
48715805|NCT01107561|DEVICE|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
48381239|NCT03619512|GENETIC|RNA sequencing|Characterization of tumor transcriptomic profile.
48381240|NCT03619512|OTHER|Mass spectrometry|Characterization of tumor proteomic profiles.
48381241|NCT00626067|DEVICE|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
48518717|NCT01951924|DRUG|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
48518718|NCT01951924|DRUG|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
48518719|NCT06287398|DRUG|Epcoritamab|"Epcoritamab (Epcor) is a bispecific antibody recognizing the T-cell antigen CD3 and the B-cell antigen CD20. Epcor is a supplied as a concentrate for solution for intended subcutaneous injection. The dose must be prepared by a qualified pharmacist using aseptic technique.~Epcoritamab-Salvage treatment phase:~2-3 cycles of R-DHAOx therapy (rituximab, dexamethasone, cytarabine, oxaliplatin), given every 21 days combined with Epcoritamab subcutaneous weekly dosing (priming 0.16mg Cycle 1 Day 1, intermediate 0.8mg cycle 1 day 8, full dose 48mg from cycle 1 day 15 onwards)~Epcoritamab Consolidation phase:~6 cycles (28 days each) of subcutaneous Epcoritamab, commencing between 6-12 weeks post ASCT.~Epcoritamab dosing and timing for consolidation:~* Cycle 1 Day 1: Priming (0.16mg) dose~* Cycle 1 Day 8: intermediate (0.8mg) dose~* Cycle 1 Day 15: full dose 48mg~* Cycle 1 Day 22, Cycle 2-3 Days 1, 8, 15 and 22: 48mg~* Cycles 4 to 6 - Days 1 and 15 (fortnightly dosing): 48mg"
48715806|NCT05351723|OTHER|Exercise + cognitive training + education|"The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention."
48715807|NCT03209076|PROCEDURE|Robotic|Robotic low anterior resection
48180395|NCT01383447|OTHER|immunohistochemistry staining method|Correlative studies
48381242|NCT00626067|DEVICE|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
48381243|NCT00626067|DEVICE|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
48381244|NCT03707145|BEHAVIORAL|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
48381245|NCT03707145|BEHAVIORAL|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
48381246|NCT03707145|BEHAVIORAL|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
48381247|NCT06558799|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields exert electric forces intended to disrupt cancer cell division and induce immunogenic cell death.
48381248|NCT06558799|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
48715808|NCT03209076|PROCEDURE|Laparoscopic|Laparoscopic low anterior resection
48180396|NCT01383447|OTHER|flow cytometry|Correlative studies
48180397|NCT01383447|GENETIC|polymerase chain reaction|Correlative studies
48180398|NCT01383447|OTHER|high performance liquid chromatography|Correlative studies
48381249|NCT00260949|PROCEDURE|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
48381250|NCT02912507|DEVICE|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
48381251|NCT02912507|DEVICE|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
48715809|NCT00736775|DRUG|anti-Abeta|Intravenous single and multiple doses
48715810|NCT00736775|DRUG|placebo|Intravenous single and multiple doses
48715811|NCT02441140|PROCEDURE|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
48180399|NCT01383447|OTHER|mass spectrometry|Correlative studies
48180400|NCT02102412|BIOLOGICAL|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
48381252|NCT01466907|OTHER|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
48381253|NCT01466907|OTHER|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
48381254|NCT01679691|OTHER|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
48381255|NCT03635970|PROCEDURE|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
48715812|NCT02441140|PROCEDURE|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
48715813|NCT02441140|PROCEDURE|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
48715814|NCT02441140|PROCEDURE|Blood collection|Intravenous blood collection will be drawn from an IV
48381256|NCT05774782|DEVICE|Cerebral flow diverter|The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.
48381257|NCT03140527|DRUG|PTI-801|Active
48381258|NCT03140527|DRUG|Placebo|Placebo
48381259|NCT03140527|DRUG|PTI-808|Active
48022913|NCT06316804|BEHAVIORAL|Video Intervention 1|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
48180401|NCT01178307|BEHAVIORAL|Questionnaires|10 minutes to complete 3 questionnaires for development of MDASI-GIST
48381260|NCT03140527|DRUG|Placebo|Placebo
48381261|NCT06225674|DEVICE|Episealer Talus implant|This is an observational study, no intervention will be done. The aim for the clinical investigation is to collect data from approximately 25 adult subjects who were treated for focal osteochondral defect with Episealer Talus implant in 6 clinics (Sweden and Germany) since January 2020.
48381262|NCT02544126|DEVICE|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
48381263|NCT02544126|BEHAVIORAL|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
48381264|NCT02981628|DRUG|Asparaginase Erwinia chrysanthemi|Given Asparaginase Erwinia chrysanthemi
48381265|NCT02981628|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48381266|NCT02981628|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and biopsy
48381267|NCT02981628|DRUG|Calaspargase Pegol|Given IV
48381268|NCT02981628|DRUG|Cyclophosphamide|Given IV
48381269|NCT02981628|DRUG|Cytarabine|Given IV or SC
48381270|NCT02981628|PROCEDURE|Diagnostic Imaging|Undergo imaging
48381271|NCT02981628|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
48715815|NCT02441140|PROCEDURE|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
48715816|NCT03024138|RADIATION|Repeat CT scan|
48381272|NCT02981628|DRUG|Leucovorin Calcium|Given PO or IV
48715817|NCT03447093|DRUG|Methimazole Pill|Patients who developed GD received methimazole treatment
48715818|NCT03447093|DRUG|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
48381273|NCT02981628|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
48381274|NCT02981628|DRUG|Methotrexate|Given IT
48381275|NCT02981628|DRUG|Pegaspargase|Given IV or IM
48381276|NCT02981628|DRUG|Vincristine|Given IV
48381277|NCT03979339|PROCEDURE|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
48381278|NCT00245258|DRUG|Sildenafil Citrate|
48715819|NCT02833792|DRUG|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
48022914|NCT06316804|BEHAVIORAL|Video Intervention 2|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
48022915|NCT06316804|BEHAVIORAL|Video Intervention 3|An experimental self-administered video-based mobile app with narratives on mental illness after the waitlist period has been completed. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
48022916|NCT02566837|PROCEDURE|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
48381279|NCT03693235|PROCEDURE|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
48381280|NCT04518449|PROCEDURE|medial border along the left side of SMA|to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
48381281|NCT04518449|PROCEDURE|medial border along the left side of SMV|to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
48715820|NCT02833792|OTHER|Placebo|Intravenous administration
48715821|NCT00029458|DRUG|Clozapine|
48715822|NCT01301105|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
48715823|NCT01301105|BEHAVIORAL|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
48715824|NCT03289169|DRUG|MEDITOXIN®|20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
48715825|NCT02610491|DIETARY_SUPPLEMENT|Hesperidin|Citrus peel extract
48715826|NCT02610491|DIETARY_SUPPLEMENT|Placebo|Cellulose
48715827|NCT00499408|DIETARY_SUPPLEMENT|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
48715828|NCT00499408|DIETARY_SUPPLEMENT|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
48715829|NCT05079633|BIOLOGICAL|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
48518720|NCT03772717|DEVICE|Non-invasive vagus nerve stimulation (nVNS)|The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week. The two electrodes for the device will be placed on the subjects left cervical (neck) region. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.
48518721|NCT03772717|OTHER|Standard of care treatment|Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
48518722|NCT02877225|DRUG|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
48715830|NCT05079633|BIOLOGICAL|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
48715831|NCT04229212|DEVICE|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
48715832|NCT00070252|DRUG|Capecitabine|Given PO
48381282|NCT00941681|DRUG|CK-1827452|50 mg MR CK-1827452 BID for 10 days
48381283|NCT00941681|DRUG|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
48381284|NCT00941681|DRUG|CK-1827452|100 mg MR CK-1827452 BID for 10 days
48381285|NCT02513732|DEVICE|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
48022917|NCT02566837|PROCEDURE|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
48022918|NCT05987267|OTHER|multidisciplinary precision care|The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
48381286|NCT01036594|DRUG|Ketoconazole|200mg during first week of study (run-in phase), then 400mg po tid
48715833|NCT00070252|DRUG|Docetaxel|Given IV
48381287|NCT01036594|DRUG|Hydrocortisone|"Hydrocortisone 20mg po qam and 10mg po qpm~If participant has ≥30% PSA decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by PSAWG criteria) is documented. After that, drug will be discontinued. If participant has \<30% PSA decline, patient goes off study."
48381288|NCT01036594|DRUG|Dexamethasone|"Dexamethasone 0.5mg po bid~If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
48715834|NCT00070252|OTHER|Laboratory Biomarker Analysis|Correlative studies
48381289|NCT03325569|DIAGNOSTIC_TEST|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
48381290|NCT01013402|DRUG|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
48381291|NCT01013402|DRUG|Human Insulin|0.1U/kg IV pulse.
48381292|NCT03589729|DRUG|Cladribine|Given IV
48180402|NCT01178307|BEHAVIORAL|Interview|Each interview will take approximately 30 minutes.
48180403|NCT01178307|BEHAVIORAL|MDASI-GIST Questionnaire|Every 4 weeks for one year
48381293|NCT03589729|DRUG|Cytarabine|Given IV
48518723|NCT02877225|DRUG|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
48518724|NCT03998267|DEVICE|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
48518725|NCT03998267|OTHER|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
48518726|NCT03376919|DEVICE|CLs++ gait training|CLs++ gait training
48381294|NCT03589729|DRUG|Dexrazoxane Hydrochloride|Given IV
48381295|NCT03589729|DRUG|Gemtuzumab Ozogamicin|Given IV
48381296|NCT03589729|DRUG|Idarubicin|Given IV
48381297|NCT03668613|DRUG|secukinumab low dose|dose depends on the weight group
48381298|NCT03668613|DRUG|secukinumab high dose|dose depends on the weight group
48381299|NCT00616889|DRUG|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
48518727|NCT02627690|OTHER|islet transplanted|islet transplantation
48518728|NCT02627690|OTHER|non islet transplanted|no islet transplantation (for a non nephrologic reason)
48715835|NCT00070252|OTHER|Pharmacological Study|Correlative studies
48715836|NCT00070252|DRUG|Tipifarnib|Given orally (PO)
48715837|NCT00430001|DRUG|docetaxel|
48715838|NCT00430001|DRUG|vinorelbine|
48715839|NCT00430001|DRUG|trastuzumab|
48715840|NCT05709522|BEHAVIORAL|Neurocognitive tools|Neurocognitve and psychological tools
48715841|NCT05181202|OTHER|Blood sampling|Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
48715842|NCT01724424|DRUG|Melatonin|20 mg oral single dose
48022919|NCT03052985|PROCEDURE|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
48381300|NCT06215872|OTHER|Therapeutic Exercises|Participants who have inclusion criterias after DRF reconstrontion pos-op 4. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize or structered exercises pragram with telerehabilition during 4 weeks and 16 sessions. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
48715843|NCT01724424|DRUG|Melatonin|30 mg oral single dose
48381301|NCT01654211|DRUG|danoprevir|single iv infusion
48381302|NCT01654211|DRUG|danoprevir|single oral dose
48715844|NCT01724424|DRUG|Melatonin|50mg oral single dose
48715845|NCT01724424|DRUG|Melatonin|100mg oral single dose
48715846|NCT06090032|DEVICE|Ultrasound|We will use ultrasongraphy as a part of assessment in respiratory intensive care unit patients with ventilator associated pneumonia
48715847|NCT02864173|GENETIC|Whole genome small nucleotide polymorphism genotyping|
48715848|NCT03730766|DRUG|Esomeprazole|Proton pump inhibitor
48715849|NCT03730766|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
48715850|NCT03730766|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
48022920|NCT04632992|DRUG|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
48022921|NCT04632992|DRUG|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
48180404|NCT04485299|DRUG|Bifluorid 10 ,VOCO|NaF and CaF 10 %
48180405|NCT04485299|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
48381303|NCT01654211|DRUG|placebo|single iv infusion
48381304|NCT01654211|DRUG|ritonavir|oral doses
48381306|NCT03087448|DRUG|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
48381307|NCT03087448|DRUG|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
48381308|NCT01357382|OTHER|Low carbohydrate diet|restrict carbohydrate consumption to \< 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
48715851|NCT02834923|BEHAVIORAL|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
48715852|NCT02834923|BEHAVIORAL|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
48715853|NCT04135859|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
48715854|NCT04135859|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
48715855|NCT04595877|DRUG|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
48715856|NCT04595877|BEHAVIORAL|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
48715857|NCT04595877|BIOLOGICAL|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
48715858|NCT04595877|OTHER|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
48715859|NCT05692310|OTHER|placing a standard central venous line|Patients will benefit from the technique of central venous line placement by conventional ultrasound.
48381309|NCT02684526|PROCEDURE|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
48022922|NCT04632992|DRUG|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
48381310|NCT02684526|PROCEDURE|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
48381311|NCT04070157|DRUG|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
48715860|NCT05692310|OTHER|placement of a central venous line using an ultraportable ultrasound device|Patients will have a central venous line placed using an ultraportable ultrasound device
48715861|NCT01752400|DRUG|AUY922|
48715862|NCT02001896|DRUG|gemcitabine; cisplatin or carboplatin; erlotinib|
48715863|NCT02001896|DRUG|erlotinib|
48715864|NCT04671082|DRUG|Tolperisone Hydrochloride|TID
48715865|NCT04671082|DRUG|Placebo|TID
48715866|NCT02736513|DRUG|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
48715867|NCT05183269|DEVICE|Oncomfort virtual reality monitor (Oncomfort SA, Wavre, Belgium)|Use of the Oncomfort virtual reality monitor
48715868|NCT05092165|DRUG|Methylene Blue|1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
48022923|NCT04632992|DRUG|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
48022924|NCT04632992|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
48022925|NCT04632992|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
48022926|NCT04632992|DRUG|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
48022927|NCT04632992|DRUG|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
48022928|NCT04632992|DRUG|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
48022929|NCT04632992|DRUG|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
48022930|NCT04632992|DRUG|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
48022931|NCT04632992|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
48022932|NCT06572462|DRUG|individualized ATG dosing strategy|Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
48022933|NCT04547959|DEVICE|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
48022934|NCT06283758|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
48022935|NCT06283758|DEVICE|Sham-control group|Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
48022936|NCT01615445|DRUG|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
48022937|NCT01615445|DRUG|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
48022938|NCT05913297|DIAGNOSTIC_TEST|Magnetic Resonance|Magnetic Resonance
48022939|NCT05913297|DIAGNOSTIC_TEST|Polysomnographic evaluation|Polysomnographic evaluation
48180406|NCT01434745|DRUG|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
48180407|NCT01434745|DIETARY_SUPPLEMENT|Lactose|Lactose will be administered in a capsule formula.
48180408|NCT01336205|DRUG|NKTR-118|25 mg oral tablet once daily
48715869|NCT05092165|OTHER|Control|Usual care during renal replacement therapy
48180409|NCT01336205|DRUG|Usual care|As prescribed by the investigator
48180410|NCT01838954|DEVICE|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
48180411|NCT03772093|DEVICE|Trabert current|Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.
48381312|NCT04070157|DRUG|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
48381313|NCT04755426|BEHAVIORAL|AVITA--Aortic Valve Improved Treatment Approaches|AVITA is an interactive shared decision making tool that helps patients clarify their treatment goals and preferences and communicate those preferences to their valve specialist.
48381314|NCT04905589|DIETARY_SUPPLEMENT|BetaQuik™|MCT (Medium chain triglycerides)
48381315|NCT04905589|DIETARY_SUPPLEMENT|WheyBasics|Whey Protein Isolate
48518729|NCT05794698|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
48518730|NCT04742829|DIETARY_SUPPLEMENT|INTRAVIT ®|2 tablets per day morning and evening before meals
48518731|NCT02435732|DRUG|Placebo saline solution|saline solution
48518732|NCT02435732|DRUG|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
48518733|NCT02435732|DRUG|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
48715870|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
48022940|NCT06097039|DEVICE|abdominal U/S|A convex transducer with a frequency range of 2-5 MHz was used for ultrasound. Based on a visual study of the intensity of the echogenicity and under the assumption that the gain setting is optimal, various (0-3) degrees of steatosis have been proposed. Grade I occurs when the echogenicity is simply increased; grade II occurs when the echogenic liver obscures the echogenic walls of the portal vein branches; and grade III occurs when the echogenic liver obscures the diaphragmatic contour.
48022941|NCT06097039|DEVICE|Fibroscan with Controlled Attenuated Parameter (CAP scan):|"Using FibroScan502 (Echosens, Paris, France), liver stiffness measurement (LSM) and CAP were acquired. Before the treatment, all subjects will be instructed to fast for at least 8 hours.~The median of 10 measurements served as the LSM score, which was only deemed credible if at least 10 successful acquisitions were made and the IQR-to-median ratio of the 10 acquisitions was below 30%. If 10 successful acquisitions are made, CAP measures were deemed trustworthy and taken into account in the final analysis.~CAP graded the degree of hepatic steatosis using the M probe in accordance with standard cut-off values (S1=222-232; S2= 233-289; and S3 290 dB/m)."
48022942|NCT02005341|DEVICE|nanOSS|
48022943|NCT02005341|DEVICE|Autograft|
48022944|NCT01936961|DRUG|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
48022945|NCT01936961|RADIATION|Hypofractionated Radiotherapy|
48022946|NCT04943926|OTHER|Energy restricted diet|Nutritional complete formula diet followed by an energy restricted diet
48022947|NCT04943926|OTHER|Low carbohydrate high fat diet|Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
48022948|NCT03073603|DRUG|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
48022949|NCT03073603|DRUG|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
48022950|NCT03221036|DRUG|Vedolizumab IV|Vedolizumab IV infusion
48022951|NCT03221036|DRUG|Placebo|Matching-placebo IV infusion
48022952|NCT01629082|DRUG|Clofarabine|
48022953|NCT01629082|DRUG|Lenalidomide|
48022954|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose1|Tablet,dose1,QD
48022955|NCT04180982|DRUG|SHR4640 dose1 plus Febuxostat dose2|Tablet,dose1, dose2 QD
48022956|NCT04180982|DRUG|SHR4640 dose2 plus Febuxostat dose3|Tablet,dose2, dose3 QD
48022957|NCT02174536|BIOLOGICAL|Decidual stromal cells|Decidual stromal cells (approximately 1x10\^6 cells/kg) will be infused intravenously.
48022958|NCT02174536|BIOLOGICAL|Placebo|
48022959|NCT04736784|OTHER|Food-based - beetroot juice|Beetroot juice containing approximately 340 mg nitrate daily
48022960|NCT04736784|OTHER|Food-based - leafy green vegetable juice|Leafy green vegetable juice containing approximately 340 mg nitrate daily
48022961|NCT00642304|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
48022962|NCT00766415|DRUG|AZD1981|Oral tablet, twice daily, 4 weeks treatment
48022963|NCT00766415|DRUG|Placebo|Placebo
48022964|NCT00025350|DRUG|gefitinib|
48022965|NCT03049059|DEVICE|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
48022966|NCT03049059|DRUG|4% hydroquinone cream|
48022967|NCT04652193|PROCEDURE|Recovery profile from general anesthesia|It includes the phases during recovery from general anesthesia: Time to spontaneous ventilation, Laryngeal Mask Airway (LMA) removal time, open eyes, and Post-Anesthesia Care Unit (PACU) discharge.
48381316|NCT04905589|OTHER|Iso-voluminous water|Iso-voluminous Water as comparitor to Betaquik or WheyBasics
48381317|NCT05074459|DRUG|Eptinezumab Mammalian Cell Line|Concentrate for solution for IV infusion
48715871|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
48022968|NCT03892941|DEVICE|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
48180412|NCT03772093|OTHER|Manual massage|Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
48715872|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
48715873|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
48715874|NCT01605487|DRUG|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
48715875|NCT01605487|DRUG|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
48715876|NCT01199276|DRUG|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
48715877|NCT01199276|DRUG|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
48715878|NCT04716075|DRUG|Acalabrutinib 2x100 MG Oral Capsule + alloSCT|Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
48715879|NCT01237262|DRUG|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
48022969|NCT06573476|BEHAVIORAL|PRC supported text + AI driven CSDH-enhanced text|"In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text check-ins to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges."
48022970|NCT06573476|BEHAVIORAL|AI driven CSDH-enhanced text only|In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.
48022971|NCT06573476|BEHAVIORAL|Treatment as Usual (TAU)|In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.
48022972|NCT00262834|DRUG|vorinostat|Given orally, conventional surgery to follow.
48022973|NCT00262834|OTHER|conventional surgery|Undergo conventional surgery
48180413|NCT04715555|DEVICE|Electrocardiogram monitoring|Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
48180414|NCT04715555|DEVICE|Electrocardiogram recording|Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
48180415|NCT04715555|DEVICE|Photoplethysmogram monitoring|Photoplethysmogram monitoring using a wearable device on the wrist.
48180416|NCT04715555|OTHER|Feedback questionnaire|A questionnaire to collect feedback on participants' experiences of wearing the devices.
48381318|NCT05074459|DRUG|Eptinezumab Yeast Cell Line|Concentrate for solution for IV infusion
48381319|NCT04505592|DRUG|Tenecteplase|First 20 patients randomized to treatment arm will receive 0.25 mg/kg of tenecteplase. Next 20 patients randomized to treatment arm will receive 0.50 mg/kg of tenecteplase. Both will receive concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
48022974|NCT06573554|OTHER|Total Contact Cast|TCC will be applied to the Charcot patients
48381320|NCT04505592|DRUG|Placebo|Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
48715880|NCT02688868|DEVICE|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
48022975|NCT06573554|OTHER|Posterior Slab|Posterior Slab will be applied to the Charcot patients
48022976|NCT00185029|PROCEDURE|Ferumoxtran-10 enhanced MRI (MRL)|
48180417|NCT00424567|PROCEDURE|Fracture surgery|
48180418|NCT00424567|DRUG|Cultured Bone Marrow Tissue|
48518734|NCT05706103|BEHAVIORAL|Specific skilled motor training|Participants allocated to the skilled motor training group will receive sensorimotor training of the intrinsic muscles of the lumbopelvic region, namely the multifidus, transversus abdominis, and pelvic floor muscles.
48518735|NCT05706103|BEHAVIORAL|General extension training|Participants allocated to the general extension training group will receive general training exercises using the David Back equipment from the Back Unit at Ghent University Hospital
48381321|NCT04300478|BEHAVIORAL|REx Condition First|REx condition: Participants will complete a whole-body REx workout consisting of 1-set to failure (e.g. RPE of 9-10 on 10-point scale on final reps) on 12 exercises in the Exercise Research Laboratory (located in the CTRC), with a 3-minute rest between exercises. Participants will complete the following exercises: leg press; leg extension; leg curl; hip abduction; hip adduction; chest press; overhead press; seated row; overheard pulldowns and assisted triceps dips on Cybex resistance equipment; barbell calf raises on a Smith machine; and dumbbell biceps curls. Resistance for the REx trial will be determined based on the exercise familiarization session. Specifically, we will target a resistance level needed for each participant to complete \~12-15 repetitions per exercise, using proper form, with an RPE of 9-10 on a 10-point scale on final reps. This protocol eliminates the need for max testing in order to set an exercise protocol off of a specific intensity based on % of 1RM.
48381322|NCT04300478|BEHAVIORAL|Sedentary Control Condition First|Sedentary control condition: Participants will sit quietly in a seated position for the entire duration of this condition.
48715881|NCT03625232|DEVICE|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
48180419|NCT04773925|BEHAVIORAL|Mindfulness counseling|Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
48715882|NCT04218357|DRUG|Probenecid|safety
48022977|NCT01023126|BEHAVIORAL|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
48022978|NCT01821781|DRUG|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
48022979|NCT04934670|DRUG|T-Guard|T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
48180420|NCT06411509|OTHER|TC plus active rTMS|The rTMS intervention is performed using a MagPro X100 by MagVenture with a water-cooled figure-of-eight coil. Before the treatment session, the resting motor threshold of the left abductor pollicis brevis is determined. The rMT is defined as the minimum intensity which produces five motor evoked potential responses of at least 50 μV in 10 trials at rest. A protocol of 1 Hz rTMS at 80% of RMT is applied over the frontal area of the right DLPFC. The coil position is localized using a frameless stereotactic neuronavigation system (TMS-Navigator, Localite GmbH, Bonn, Germany). Participants receive only three sessions of TC per week without rTMS during in the week 1 and 2, and the TC potocol is same as the TC-alone group. Participants receive daily rTMS (30 minutes) for 5 days a week combined with three sessions of TC in the last 2 weeks. Active rTMS deliveres at 1 Hz for 30 min (1800 pulses per session) with the intensity of 80% rMT.
48180421|NCT06411509|OTHER|Tai Chi plus sham rTMS|Sham rTMS is administrated the same procedures as the active rTMS but with low intensity of 20% rMT to elicit similar skin sensations and sounds. The TC protocol in this group is the same as the TC-alone group.
48381323|NCT01764776|DRUG|LDE225|LDE225
48381324|NCT03842202|DRUG|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous \[s.c.\], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
48381325|NCT03842202|DRUG|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
48022980|NCT04934670|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
48022981|NCT02447731|DEVICE|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
48022982|NCT00002684|DRUG|cisplatin|
48022983|NCT00002684|DRUG|ifosfamide|
48022984|NCT00002684|DRUG|paclitaxel|
48022985|NCT03219528|DRUG|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
48022986|NCT03219528|OTHER|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
48022987|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
48022988|NCT01917045|DRUG|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
48022989|NCT01917045|DRUG|Morphine|morphine 0. 5mg/ml
48381326|NCT02418338|OTHER|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
48381327|NCT00211575|BEHAVIORAL|Disease Management Assessment|
48715883|NCT04218357|DRUG|Matching placebo|Placebo
48715884|NCT01356342|BIOLOGICAL|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections"
48715885|NCT01167868|DRUG|FosD|oral tablet
48715886|NCT01167868|DRUG|Placebo|oral tablet
48715887|NCT00023751|DRUG|fluorouracil|
48715888|NCT00023751|DRUG|leucovorin calcium|
48715889|NCT00023751|PROCEDURE|conventional surgery|
48715890|NCT00023751|RADIATION|radiation therapy|
48715891|NCT05625373|DRUG|Vancomycin|The powder will be placed within the surgical wound prior to skin closure.
48381328|NCT00620776|BEHAVIORAL|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
48381329|NCT00620776|DRUG|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
48715892|NCT03927287|DIAGNOSTIC_TEST|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
48715893|NCT06113224|PROCEDURE|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
48715894|NCT06113224|PROCEDURE|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
48715895|NCT05754060|OTHER|Saint-Louis Lille Battery (SSLIB)|"Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)"
48715896|NCT00103519|DRUG|DITPA (3,5-diiodothyropropionic acid)|
48715897|NCT00103519|DRUG|Placebo|Placebo
48715898|NCT04804735|DEVICE|REV : local anesthesia and virtual reality|REV : local anesthesia and virtual reality in Implanted Venous Access Device (IVAD) procedure under local anesthesia
48715899|NCT04804735|DEVICE|MUS : local anesthesia and music therapy|MUS : local anesthesia and music therapy in Implanted Venous Access Device (IVAD) procedure under local anesthesia
48715900|NCT06299722|OTHER|STEEL|Relatively heavy strength training
48715901|NCT06299722|OTHER|Circuit training|Circuit training
48715902|NCT04857645|DRUG|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
48180422|NCT06411509|BEHAVIORAL|TC-alone|Participants in the TC-alone group attend a simplified Yang style 8-Form Easy TC training program in a group format. Each session lasts for 60 minutes and are conducted three times per week over a period of four weeks. In the first session, the certified TC instructor explains the exercise theory and procedures. The remaining sessions includes 5 to 10 minutes warm-up and a review of TC principles, 45 minutes meditative movements, and 5 to 10 minutes cool-down
48381330|NCT04104152|OTHER|CSD1902-11|A 2.4% nicotine ENDS product
48518736|NCT06094881|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
48715903|NCT04857645|OTHER|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
48715904|NCT05598723|DRUG|IncobotulinumtoxinA (XEOMIN®)|IncobotulinumtoxinA (XEOMIN®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
48715905|NCT05598723|DRUG|OnabotulinumtoxinA (BOTOX®)|OnabotulinumtoxinA (BOTOX®) is injected into specific targets at two different time points. Changes in chronic migraine frequency and duration are recorded and compared.
48022990|NCT03857438|DRUG|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
48381331|NCT04104152|OTHER|CSD1902-12|A 2.4% nicotine ENDS product
48715906|NCT06396715|DEVICE|Transcranial direct current stimulation|tDCS is a type of non-invasive brain stimulation that in a standard paradigm, low intensity current (1-2 mA) is applied continuously through a battery connected to two 20 to 35 cm2 surface electrodes located on the scalp: an anode and a cathode. In the interhemispheric competition model, tDCS can serve as a means to increase ipsilesional cortical excitability through anodal stimulation, to decrease contralesional cortical excitability through cathodal stimulation, or to do both through a montage of bi-hemispheric electrodes.
48715907|NCT03074266|DIAGNOSTIC_TEST|GEM Hemochron 100 ACT|Activated Clotting Time
48715908|NCT02291393|DEVICE|80 lead ECG|
48715909|NCT05002842|BEHAVIORAL|LovingKindess Meditation|Participants will have access to a recording of a script to guide them through meditation
48022991|NCT03857438|DIAGNOSTIC_TEST|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
48022992|NCT00411307|DRUG|OROS hydromorphone HCI|
48022993|NCT01696032|DRUG|SGI-110|
48022994|NCT01696032|DRUG|Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)|Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
48022995|NCT01696032|DRUG|Carboplatin|
48022996|NCT04951310|BEHAVIORAL|Philly Vax Sweepstakes|"The Philly Vax Sweepstakes is a citywide sweepstakes designed to motivate Philadelphians to get vaccinated against COVID-19. A total of 36 vaccinated Philadelphians will win among three cash prize packages, distributed from the total cash pool. These 36 will be chosen over three drawings, with 12 residents chosen in each drawing."
48022997|NCT01376752|PROCEDURE|Maximal cytoreductive surgery|Maximal cytoreductive surgery
48715910|NCT04695028|OTHER|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
48715911|NCT05962034|DRUG|Aspirin|650 mg aspirin (Acetylsalicylic acid)
48715912|NCT05962034|OTHER|Placebo|placebo capsule
48715913|NCT04668235|DRUG|AZVUDINE|5 tablets QD + standard treatment for up to 14 days
48715914|NCT04668235|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment for up to 14 days
48715915|NCT02469714|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
48715916|NCT01295736|DRUG|Sildenafil|Sildenafil 20 mg TID per os during 90 days
48715917|NCT01295736|DRUG|placebo|Placebo pills TID per os during 90 days
48715918|NCT03978780|PROCEDURE|Erector spinae plane block|80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
48715919|NCT03978780|PROCEDURE|Placebo Block|Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
48715920|NCT02514668|DRUG|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
48715921|NCT00123266|DRUG|Microplasmin|2 mg/kg, IA over 75 mins
48715922|NCT02989844|DRUG|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
48715923|NCT00908115|BIOLOGICAL|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
48022998|NCT01376752|DRUG|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
48381332|NCT04104152|OTHER|CSD1902-13|A 2.4% nicotine ENDS product
48381333|NCT04104152|OTHER|CSD1902-14|A 2.4% nicotine ENDS product
48381334|NCT04104152|OTHER|CSD1902-21|A 5.0% nicotine ENDS product
48381335|NCT04104152|OTHER|CSD1902-22|A 5.0% nicotine ENDS product
48715924|NCT06146868|OTHER|Doing questionnaire|Participants will provide their opinions in a questionnaire
48715925|NCT05451680|DEVICE|Negative pressure device|Negative-pressure therapy postoperatively on the full-thickness skin graft
48715926|NCT05451680|PROCEDURE|Conventional care|Conventional dressing postoperatively on the full-thickness skin graft
48715927|NCT01342744|DRUG|Metformin|Metformin(850 mg) 1tab oral twice aday
48715928|NCT01342744|DRUG|Placebo|Placebo 1 tab oral twice a day
48715929|NCT01983280|OTHER|Healing Touch|
48715930|NCT03224403|DRUG|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
48715931|NCT03224403|DRUG|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
48715932|NCT03224403|DRUG|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
48715933|NCT03224403|DRUG|Placebo|2 placebo caplets
48715934|NCT00153829|BEHAVIORAL|Multifaceted outreach facilitation for chronic illness care|
48022999|NCT00969891|OTHER|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
48023000|NCT06030193|DRUG|QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
48381336|NCT04104152|OTHER|CSD1902-23|A 5.0% nicotine ENDS product
48381337|NCT04104152|OTHER|CSD1902-24|A 5.0% nicotine ENDS product
48381338|NCT02014194|BEHAVIORAL|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
48381339|NCT04548336|BEHAVIORAL|Motor Imagery|Motor imagery group will have to imagine motor gestures of static and dynamic balance
48381340|NCT04548336|BEHAVIORAL|Action observation|Action observation group will have to observe static and dynamic equilibrium motor gestures
48381341|NCT04548336|BEHAVIORAL|Placebo group|This group will watch a video of nature without a human component.
48381342|NCT02989922|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
48715935|NCT04194723|PROCEDURE|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
48715936|NCT01969617|DRUG|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
48715937|NCT01969617|DRUG|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
48715938|NCT01905722|OTHER|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
48023001|NCT06030193|DRUG|QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
48715939|NCT01905722|OTHER|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
48023002|NCT06030193|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
48023003|NCT03634761|BEHAVIORAL|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
48715940|NCT02646839|DEVICE|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
48715941|NCT02667782|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
48715942|NCT02667782|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
48023004|NCT03634761|BEHAVIORAL|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
48023005|NCT02238301|OTHER|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
48023006|NCT02238301|OTHER|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
48023007|NCT03022357|OTHER|Patient assessment|Clinical examination, Examination, Questionnaires
48023008|NCT03022357|RADIATION|DATScan|In small subgroup
48023009|NCT03022357|RADIATION|Orbital X-Ray|If foreign body in eye needs exclusion
48023010|NCT03022357|OTHER|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
48381343|NCT06179186|DEVICE|Intense Pulsed Light|The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
48381344|NCT06179186|DEVICE|Diode Laser|The axilla will be treated with diode laser, being right or left, depending upon randomization.
48518737|NCT01145469|GENETIC|DNA analysis|
48381345|NCT06330480|OTHER|Intervention group|Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)
48381346|NCT04480502|BIOLOGICAL|Envafolimab|PD-L1 single domain antibody for subcutaneous injection.
48518738|NCT01145469|GENETIC|gene expression analysis|
48518739|NCT01145469|GENETIC|polymorphism analysis|
48518740|NCT01145469|OTHER|laboratory biomarker analysis|
48518741|NCT01145469|OTHER|medical chart review|
48518742|NCT06208540|DRUG|Cerebrolysin|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.
48518743|NCT06208540|OTHER|olfactory and gustatory trainings|olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
48518744|NCT06008184|OTHER|24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva)|"24 hours sampling of 4 biological fluids:~* blood: sampling every 20 minutes (through a venous catheter)~* ISF: automated sampling every 20 minutes (microdialysis technique connected to U-Rhythm device)~* Sweat : collection of 1 to 3 samples at 4 differents timepoints~* Saliva : sampling every hour (except during the night)"
48518745|NCT06008184|OTHER|24 hours sampling of ISF or sweat (after validating the correlation with blood)|24 hours sampling in an ambulatory setting
48715943|NCT05017129|BEHAVIORAL|Inmates Care|The single intervention is a computer-based learning program.
48715944|NCT01340781|PROCEDURE|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
48381347|NCT04480502|DRUG|Ipilimumab|CTLA-4 monoclonal antibody
48381348|NCT06005974|DRUG|REC-4881|REC-4881 4mg capsules
48381349|NCT05643807|DEVICE|Flexible cystoscopy|Urinary cytology will be collected through the flexible cystoscope itself at the end the cystoscopy. Before starting the urinary collection, the cystoscope will either be placed in front of a suspected intravesical lesion (if present) or at the bladder neck (if no lesion present).
48381350|NCT05643807|DEVICE|Urinary catheter|Urinary cytology will be collected through a Ch14 urinary catheter after the cystoscopy
48518746|NCT03189992|DRUG|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
48518747|NCT03189992|DRUG|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
48518748|NCT04659642|DRUG|Dexmedetomidine Injection [Precedex]|the drug is given 15 minutes before the estimated end of surgery
48518749|NCT04659642|DRUG|Fentanyl Citrate Injection|the drug is given 15 minutes before the estimated end of surgery
48518750|NCT04659642|COMBINATION_PRODUCT|dexmedetomidine and fentanyl|the combination of the two drugs with the same used doses is given 15 minutes before the estimated end of surgery
48715945|NCT02463032|DRUG|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
48023011|NCT02912351|OTHER|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
48381351|NCT06174922|DRUG|Prednisolone|Prednisolone for 4 months
48381352|NCT06174922|DRUG|Itraconazole|SUBA-itraconazole for 4 months
48518751|NCT00714194|PROCEDURE|Normal continuous sedation|Normal continuous sedation.
48518752|NCT00714194|OTHER|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
48518753|NCT00801502|DIETARY_SUPPLEMENT|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
48518754|NCT00801502|OTHER|Control|No change to habitual diet from week 20 of pregnancy until giving birth
48518755|NCT04107909|PROCEDURE|laparoscopic cholecystectomy|"Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor."
48518756|NCT00866021|DRUG|Lopinavir/ritonavir|NRTI sparing-regimen
48518757|NCT00866021|DRUG|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
48715946|NCT00906724|PROCEDURE|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
48180423|NCT06411509|BEHAVIORAL|Low intensity physical exercise|To achieve the same exercise volume with TC-alone group, participants in the low-intensity physical exercise control group attend a four-week exercise training in group format. Exercise sessions are 60 minutes with three times per week. Each exercise session consists of 5 to 10 minutes warm-up, 45 minutes of aerobic training, and a 5 to 10 minutes cool-down.
48715947|NCT03467490|BEHAVIORAL|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
48715948|NCT01786460|OTHER|Blood draw at Days 0, 7, 14, and 21|
48715949|NCT00768404|DRUG|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
48715950|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Medtronic 4th gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Medtronic 4th gen balloon
48715951|NCT06183879|DEVICE|cryoballoon pulmonary vein isolation (Boston 2nd gen balloon)|Standard of care cryoballoon pulmonary vein isolation with Boston 2nd gen balloon
48715952|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
48715953|NCT01565941|DRUG|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
48715954|NCT00707746|DRUG|mipomersen|
48715955|NCT00707746|DRUG|placebo|
48715956|NCT03149003|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
48023012|NCT06267482|PROCEDURE|ROSA PSA Parapatellar Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be the same as the standard of care (medial parapatellar approach).
48381353|NCT00437294|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease
48381354|NCT00437294|DRUG|placebo|oral, daily, 21-day cycles until progressive disease
48381355|NCT00437294|DRUG|capecitabine|1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
48381356|NCT02902107|DEVICE|CivaSheet|
48023013|NCT06267482|PROCEDURE|ROSA PSA Subvastus Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be an alternative, quad-sparring, subvastus approach.
48381357|NCT02902107|RADIATION|Brachytherapy|
48023014|NCT06321705|DRUG|CS1|CS1 delayed release capsules will be supplied with 160 mg active pharmaceutical ingredient (API) per capsule. Three dose levels will be administered in this expanded access study at the same dose the patient received in the parent study (CS1-003) of 480 mg, 960 mg, or 1920 mg. All patients will later have the option to be titrated to the most efficacious and safe dose determined from the ongoing CS1-003 study when completed.
48381358|NCT02902107|PROCEDURE|surgical resection|
48023015|NCT00661063|DRUG|ketamine|ketamine 150 mcg/g bid
48023016|NCT00661063|DRUG|vehicle gel|bid - 12 weeks
48381359|NCT06455163|OTHER|Eerder Erbij|The intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group for persons in the early stage of dementia and their main informal caregiver (e.g. spouse, relative), who receive little or no formal care. The intervention will discuss the effects of dementia, and how to cope and adjust to those effects. It will take place in small group sessions led by a health care professional (e.g. casemanager) and is intended for both the person with dementia and the caregiver. The intervention will be personalised to meet needs, interests and strengths of the dyad by discussing the sessions content at the start of the intervention.
48381360|NCT00363272|DRUG|ispinesib|Given IV
48715957|NCT03149003|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
48715958|NCT00288457|DEVICE|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
48715959|NCT03287570|DEVICE|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
48715960|NCT03287570|PROCEDURE|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
48715961|NCT03287570|OTHER|Usual care|The patients in this group maintain the usual treatment and self-care.
48023017|NCT00661063|DRUG|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
48381361|NCT00363272|OTHER|laboratory biomarker analysis|Correlative studies
48381362|NCT00363272|OTHER|pharmacological study|Correlative studies
48381363|NCT00417820|DRUG|BCT194|
48518758|NCT06581679|DRUG|Triptorelin|GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
48518759|NCT06581679|DEVICE|levonorgestrel-releasing intrauterine system|The levonorgestrel-releasing intrauterine system releasing 20 levonorgestrel daily.
48518760|NCT06581679|PROCEDURE|frozen embryo transfer|"Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.~The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur."
48518761|NCT00142025|DRUG|Oxcarbazepine|
48518762|NCT04061239|DRUG|CPX-351|CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
48518763|NCT04061239|DRUG|Daunorubicin|Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
48518764|NCT04061239|DRUG|Cytarabine|Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
48518765|NCT04061239|DRUG|Azacitidine|Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
48518766|NCT05424679|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention is a brief intervention that directly targets suicide risk with demonstrated efficacy and is a recommended best practice for suicide prevention. The intervention aims to provide participants with an individualized set of steps that can be used progressively to both reduce risk and maintain safety when under particular stress. It also includes a series of brief telephone calls to revise the safety plan and facilitate connections to care. The study team will adapt the intervention to target a larger range of mental health distress.
48715962|NCT00596141|DEVICE|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
48023018|NCT00661063|DRUG|clonidine gel 1%|bid 12 weeks
48023019|NCT05277467|OTHER|no intervention|no intervention
48023020|NCT04166305|GENETIC|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
48023021|NCT02410681|DEVICE|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~1. 3 recordings after the baseline visit~2. 3 recordings 6 weeks after the baseline visit~3. 3 recordings one year after the baseline visit"
48023022|NCT02410681|RADIATION|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
48023023|NCT02410681|OTHER|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~1. At the baseline visit~2. Three months after the baseline visit~3. One year after the baseline visit"
48023024|NCT03554122|PROCEDURE|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
48023025|NCT03554122|PROCEDURE|Placebo|Patients spinal injections were performed without Shotblocker
48180424|NCT06485648|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Treatment: G(glucocorticoid) + i.v. uc-MSC (1×106 cells/Kg)
48381364|NCT02384239|DRUG|Palbociclib|Given orally (PO)
48381365|NCT02384239|DRUG|Tamoxifen|Given orally (PO)
48381366|NCT02384239|DRUG|Fulvestrant|Given by intramuscular (IM) injection.
48381367|NCT05368376|DRUG|Labetalol Hydrochloride Oral Tablet|Labetalol 200 mg
48381368|NCT05368376|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol 100 mg
48381369|NCT00352664|DRUG|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
48381370|NCT00352664|DRUG|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
48180425|NCT06485648|DRUG|Normal saline|Control: G(glucocorticoid) + i.v. Normal saline
48180426|NCT03876106|DRUG|LUT014|Topical
48381371|NCT01246102|DRUG|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
48381372|NCT05459012|OTHER|follow-up|Questionnaire of Quality of life
48715963|NCT03368014|BEHAVIORAL|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
48715964|NCT00327574|BEHAVIORAL|Home heath education +/_ GP training|
48715965|NCT05682300|PROCEDURE|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
48715966|NCT01527383|BIOLOGICAL|V212|V212 viral antigen for HZ
48715967|NCT01527383|BIOLOGICAL|Placebo|Placebo comparator to V212 vaccine
48715968|NCT04896203|PROCEDURE|rotational thromboelastometry|Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
48715969|NCT06326749|OTHER|Modified Graded Motor Imagery and Conventional Treatment Group|A modified form of graded motor imagery training and conventional rehabilitation will be applied.
48715970|NCT06326749|OTHER|Graded Motor Imagery and Conventional Treatment Group|Graded motor imagery training and conventional rehabilitation will be applied.
48715971|NCT06326749|OTHER|Conventional Treatment Group|conventional rehabilitation will be applied.
48715972|NCT06370234|RADIATION|Whole body 18F-FDG Positron Emission Tomography|The subjects enrolling and participating this study will have done PET/MR during pre-operation chemotherapy. But, in normal procedure, they will not have done.
48715973|NCT03481712|DIAGNOSTIC_TEST|Diagnostic tests|"Head-to-head comparison between:~* CADScor and Diamond-Foster score~* Rb PET and 3T CMRI~* QFR and ICA-FFR"
48715974|NCT03281551|DRUG|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
48715975|NCT05014113|DEVICE|DELTA-ST cup in combination with MINIMA stem|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
48715976|NCT00840580|DRUG|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
48715977|NCT00840580|DRUG|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
48381373|NCT02879552|PROCEDURE|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
48023026|NCT02063646|DIETARY_SUPPLEMENT|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
48023027|NCT02063646|DIETARY_SUPPLEMENT|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
48381374|NCT02879552|PROCEDURE|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
48381375|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
48381376|NCT01489306|DRUG|MDT-637|Inhaled doses of MDT-637 over a 10 day period
48715978|NCT03112304|BEHAVIORAL|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
48715979|NCT03112304|OTHER|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
48715980|NCT04928209|OTHER|Speech-Language Teletherapy|Access to speech-language teletherapy will be provided as a supplement to Usual Care for subjects randomized to this group. Access is provided by way of 1) direct referral by the clinical team to a teletherapist; 2) availability of a teletherapy slot. All teletherapy providers will be licensed speech-language pathologists (SLPs) and/or credentialed teachers of the deaf (TODs) with specialized training to work with children who are D/HH using an LSL approach. Fluent English and Spanish speaking providers will be matched to the child's home, native language. Teletherapy itself is within routine clinical care and is not considered a research activity. Children who randomize to the Low TT study arm will receive access to an 18-month course of weekly teletherapy, in accordance with the centers' standard of care. The exact details of the therapy course and frequency will be determined based on individual family needs.
48381377|NCT00556166|DEVICE|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
48715981|NCT06000306|DIAGNOSTIC_TEST|Digital Droplet PCR|Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
48715982|NCT00944736|DIETARY_SUPPLEMENT|VSL#3|1 packet BID
48715983|NCT00944736|DIETARY_SUPPLEMENT|Placebo|1 inactive packet BID
48715984|NCT02146677|OTHER|Osteopathic manipulative treatment|
48715985|NCT02146677|OTHER|Sham therapy|
48023028|NCT06308913|DRUG|INCB081776|INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
48381378|NCT03949634|DRUG|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
48023029|NCT06308913|DRUG|Pembrolizumab|Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
48023030|NCT06308913|RADIATION|Palliative RT|Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
48381379|NCT03949634|DRUG|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
48381380|NCT03949634|DRUG|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
48381381|NCT03949634|DRUG|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
48381382|NCT03949634|DRUG|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
48381383|NCT03055286|DRUG|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
48023031|NCT00277017|DRUG|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
48023032|NCT04136938|OTHER|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
48715986|NCT02146677|OTHER|Usual care|
48715987|NCT00913393|DRUG|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
48715988|NCT00913393|DRUG|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
48715989|NCT00913393|DRUG|Placebo|Placebo IV every 2 weeks for 22 weeks
48715990|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of low dose casein (5 gram)
48715991|NCT01509469|DIETARY_SUPPLEMENT|Casein|Ileal infusion of high dose casein (15 gram)
48715992|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
48715993|NCT01509469|DIETARY_SUPPLEMENT|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
48715994|NCT01509469|OTHER|Saline|Ileal infusion with saline (180mL in total)
48715995|NCT01509469|DIETARY_SUPPLEMENT|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
48715996|NCT06245239|DEVICE|perfusion index|measurement of perfusion index
48381384|NCT04715880|PROCEDURE|Paravertebral block/Intercostal Block (PVB/ICB) group|A paravertebral catheter will be placed by surgeon into pleural cavity and will not be loaded with bolus dose. At the end of surgery the (consultant anaesthesiologist) will perform intrathoracic unilateral intercostal nerve block two level above and two level below and at site of incision with 4 ml per level of 0.25 % bupivacaine followed by continuous infusion with 0.25 % bupivacaine at 6-8 ml/hour through catheter placed in paravertebral space.
48381385|NCT04715880|PROCEDURE|Paravertebral Block (PVB) group|A paravertebral catheter will be placed by the surgeon before closure of thoracotomy wound. The catheter will be introduced percutaneously through 18 gauge needle into the pleural cavity. The tip of catheter will be loaded by anaesthesiologist with 0.25 % isobaric bupivacaine with 20 ml followed by continuous infusion with bupivacaine 0.25 % at 6-8 ml per hour
48518767|NCT05424679|BEHAVIORAL|Caring Contacts|Caring contacts is a cost and time effective suicide prevention intervention. It traditionally utilizes letters and postcards that are sent to an individual to remind them that they are cared about and that they matter. Research suggests that this intervention significantly reduces the likelihood of dying by suicide and suicide attempt over a person's lifetime. This intervention has the potential to reach more individuals at risk in the community. In this study, the research team will allow participants to receive these messages by postcard/MMS and will adapt the intervention to align with cultural values.
48518768|NCT04044872|DIAGNOSTIC_TEST|[1-13C]pyruvate along with MRI imaging|\[1-13C\]pyruvate: 0.1 mmol/kg dose will be injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s at the time of imaging performed at baseline (prior to radiation therapy), and 1 month after completion of radiation therapy.
48518769|NCT05215951|DRUG|osimertinib|Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
48518770|NCT05913544|OTHER|SINTYA|10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
48518771|NCT05999383|DRUG|Cannabis|Participants will vape marijuana in varying doses from the PAX device
48518772|NCT05999383|DRUG|Nicotine|Participants will vape regular and Very Low Nicotine content cigarettes from the PAX device
48518773|NCT05999383|DEVICE|Pax Loose Leaf Vaporizer|In all arms, participants will be using the PAX Loose Leave Vaporizer.
48518774|NCT03251001|PROCEDURE|Control|Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
48518775|NCT03251001|DEVICE|Acellular Dermal Matrix|Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
48518776|NCT04729816|OTHER|Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.|"Phase 1: Participants will be provided with a high fat/low fiber diet in the form of packed out meals and snacks for 10 days in total (days 2-11 and days 54-63)~Phase 2: Participants will be provided with the high fat/low fiber diet, plus 1 daily fiber-blend snack serving from days 12-25~Phase 3: Participants will receive 2 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 26-39.~Phase 4: Participants will receive 3 daily fiber-blend snack servings to supplement the high fat/low-fiber diet from days 40-53.~Phase 5: Participants will return to the unsupplemented high fat/low fiber diet for days 54-63"
48518777|NCT03389347|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
48518778|NCT03389347|DEVICE|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
48518779|NCT03389347|OTHER|Laboratory Biomarker Analysis|Correlative studies
48715997|NCT05789186|DRUG|CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic|CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
48381386|NCT05180994|DRUG|Topical infliximab|Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.
48381387|NCT05180994|OTHER|No topical infliximab|No treatment with infliximab.
48381388|NCT01082601|PROCEDURE|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
48381389|NCT01638416|OTHER|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
48381390|NCT06649760|BEHAVIORAL|Gain and loss framed mobile text messages|To assess the effect of message framing on enhancing oral health practices in a group of refugees
48381391|NCT02205281|BEHAVIORAL|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
48381392|NCT03529539|DRUG|PSV|
48381393|NCT04189536|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
48381394|NCT05891288|OTHER|BioCoat® by Premier®|Bioactive pits and fissure sealant
48715998|NCT05789186|DRUG|Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration|Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
48715999|NCT05789186|DRUG|Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration|Placebo without drug treatment effect
48381395|NCT05891288|OTHER|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
48716000|NCT00290875|BEHAVIORAL|Use of Xrays for diagnosis|
48716001|NCT05549310|DEVICE|CPAP|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
48716002|NCT05549310|DEVICE|high-flow nasal canula oxygen therapy|At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
48023036|NCT00226941|DRUG|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
48518780|NCT02620436|OTHER|Core Mother Shelter Model|"1. Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~2. Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~3. Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
48518781|NCT05001646|DEVICE|In-home resonance-based electromagnetic field protection device|Participants will have an in-home EMF protection device
48518782|NCT01228617|DRUG|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
48381396|NCT01554917|DRUG|Iguratimod|taken orally, 2 tablets/day (bid)
48716003|NCT00994591|DRUG|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
48716004|NCT00612625|DRUG|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
48518783|NCT01228617|DRUG|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
48518784|NCT04927845|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivers content via independent modules. Principles covered in content modules: Psychoeducation; Self-monitoring; Values-based goal-setting; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Relaxation strategies; Maintenance planning. Modules get released week-by-week, and participants are self-guided through content. To facilitate skills practice, every module is accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displays user progress, including self-rating graphs and a history log of skills practice. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity."
48518785|NCT03081832|DRUG|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
48518786|NCT03081832|OTHER|Control|Not treated.
48518787|NCT01916044|OTHER|Ultrasound|Measure of Uterine Segment by Ultrasound
48518788|NCT02272257|BEHAVIORAL|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
48716005|NCT00612625|DRUG|Saline|continuous infusion of saline
48716006|NCT02914288|OTHER|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
48518789|NCT02272257|BEHAVIORAL|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
48518790|NCT05546437|DEVICE|Ion Endoluminal System|Ion Endoluminal dye marking procedure for pulmonary nodule
48518791|NCT04580264|BEHAVIORAL|REINTERVENTION|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
48518792|NCT00129571|DRUG|XL820|
48716007|NCT05308498|DIAGNOSTIC_TEST|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
48716008|NCT05308498|DIAGNOSTIC_TEST|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
48381397|NCT03537625|DIETARY_SUPPLEMENT|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
48518793|NCT02796053|DRUG|TAB08|The TAB08 will be administered intravenously, by infusion.
48518794|NCT02796053|OTHER|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
48518795|NCT00698711|BIOLOGICAL|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
48518796|NCT00002376|DRUG|Indinavir sulfate|
48518797|NCT00002376|DRUG|Lamivudine|
48518798|NCT00002376|DRUG|Stavudine|
48716009|NCT05305547|DRUG|S-217622|Administered as a round tablet.
48716010|NCT05305547|DRUG|Placebo|Administered as a round tablet.
48716011|NCT01292083|DRUG|azacitidine|Given IV
48716012|NCT01292083|OTHER|laboratory biomarker analysis|Correlative studies
48716013|NCT01292083|OTHER|immunohistochemistry staining method|Correlative studies
48381398|NCT01081431|DRUG|Lenalidomide|10 mg d1-d21 of a 28-day cycle
48716014|NCT01292083|GENETIC|polymerase chain reaction|Correlative studies
48716015|NCT01292083|GENETIC|western blotting|Correlative studies
48716016|NCT01292083|GENETIC|nucleic acid sequencing|Correlative studies
48716017|NCT01292083|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
48023037|NCT00226941|DRUG|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
48023038|NCT00226941|DRUG|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
48381399|NCT02743598|DRUG|Liraglutide|
48381400|NCT04013373|DEVICE|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
48381401|NCT00539006|DRUG|FPNS|fluticasone propionate nasal spray
48381402|NCT00539006|DRUG|FFNS|fluticasone furoate nasal spray
48716018|NCT03396055|OTHER|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
48716019|NCT03759041|DRUG|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
48716020|NCT03759041|DRUG|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
48381403|NCT00539006|DRUG|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
48381404|NCT00539006|DRUG|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
48381405|NCT05903092|DRUG|Durvalumab|1500mg IV on Day 1 of every Cycle
48381406|NCT05903092|DRUG|Monalizumab|1500mg IV on Day 1 of every Cycle
48381407|NCT05903092|DRUG|Carboplatin or Cisplatin|"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2"
48381408|NCT05903092|DRUG|Etoposide|80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
48381409|NCT02434029|DRUG|Budesonide 1mg orodispersible tablet twice daily|
48023039|NCT00226941|RADIATION|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
48023040|NCT00226941|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
48023041|NCT04892654|DRUG|Doravirine|Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor
48381410|NCT02434029|DRUG|Placebo orodispersible tablet twice daily|
48381411|NCT06016231|DEVICE|Light Adjustable Lens|The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
48381412|NCT00805857|DRUG|Tipranavir|
48381413|NCT06652568|DEVICE|ThinkSono System|The ThinkSono Guidance System is a guidance software expected to help non-radiology specialist healthcare professionals produce compression ultrasound image data that meet or exceed the minimal image quality criteria for a remote diagnosis by an expert (e.g. radiologist).
48381414|NCT02604849|DRUG|Neomycin|
48381415|NCT02604849|DRUG|Streptomycin|
48381416|NCT02604849|DRUG|Gentamicins|
48381417|NCT04745572|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
48381418|NCT04745572|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
48381419|NCT03182972|OTHER|Medication reconciliation|Pre-post intervention
48381420|NCT03372265|DRUG|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
48381421|NCT05417477|DEVICE|use of an e-health application|Use of the e-health application throughout the duration of the study combined with the usual management of the disease and 20 physiotherapy sessions.
48518799|NCT00002376|DRUG|Zidovudine|
48518800|NCT00002376|DRUG|Didanosine|
48716021|NCT03759041|DRUG|SER-287|Once-daily dosing of SER-287
48716022|NCT03759041|DRUG|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
48716023|NCT05021692|BEHAVIORAL|Web-based support program for pregnant women with preeclampsia based on the Health Promotion Model|support program
48023042|NCT04892654|DRUG|Dolutegravir|Antiretroviral, Integrase strand transfer inhibitors
48023043|NCT04892654|OTHER|Triple cART regimen|Participant standard triple cART regimen
48028930|NCT04307823|OTHER|Treadmill protocol and Respiratory training|"Treadmill protocol~Spirometry:~Volumetric exercises, using incentive Spirometer 10-15 repetitions~Slow breathing training:~5 minutes: spontaneous breathing, 4 minutes: controlled breathing (15 breaths/min) 4 minutes of controlled breathing (6 breaths/min) Treatment provided for 3 days in a week for a period of 4 weeks"
48381422|NCT06234969|DEVICE|Continuous Theta Burst Stimulation to the Intraparietal Sulcus|Continuous Theta Burst Stimulation delivered to the Intraparietal Sulcus
48381423|NCT06234969|DEVICE|Sham Continuous Theta Burst Stimulation|Sham Continuous Theta Burst Stimulation
48381424|NCT06019611|DEVICE|Percutaneous epidural stimulation|"Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
48381425|NCT06201676|DRUG|Ketorolac Injection|Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
48381426|NCT06201676|OTHER|Normal Saline|0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).
48518801|NCT05084482|OTHER|Prediction models|The prediction scores are validated by the CAM-ICU scores up to 14 days after ICU admission.
48716024|NCT04841603|DEVICE|Mindshift CBT|A tablet with the Mindshift CBT app installed. Mindshift CBT is a free, evidence based app developed by Anxiety Canada, designed to help users reduce symptoms of anxiety and distress.
48716025|NCT04841603|DEVICE|Treatment as Usual|Treatment as usual. A tablet identical to the intervention group, but without the Mindshift CBT app is available for patients to use during their inpatient stay.
48716026|NCT00048750|DRUG|Micafungin|IV
48716027|NCT00048750|DRUG|Placebo|IV
48716028|NCT02819960|DRUG|Probio-Tec® BG-VCap-6.5|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
48716029|NCT02819960|DRUG|Placebo|Maltodextrin
48716030|NCT04921085|OTHER|Cross-sectional obeservational survey|Cross-sectional obeservational survey
48716031|NCT02398695|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
48180427|NCT05907317|DEVICE|Cerebral oximetry monitoring device|Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.
48180428|NCT05907317|OTHER|Usual care|Treatment as usual
48180429|NCT03795857|BEHAVIORAL|Semi-structured interviews|The purpose of this study is to describe the experience of pregnancy by parents who have chosen to carry to term despite a lethal fetal diagnosis. Therefore, semi-structured interviews will be conducted to explore the links between context, feeling, involvement, decision and actions during pregnancy, whether within the couple or in its environment.
48180430|NCT03376035|OTHER|Temperature measurement of breast|Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
48180431|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
48180432|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
48381427|NCT04836637|DIETARY_SUPPLEMENT|Maltodextrin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
48381428|NCT04836637|DIETARY_SUPPLEMENT|Calcium-carbonate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
48381429|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
48381430|NCT04836637|DIETARY_SUPPLEMENT|Calcium-enriched permeate with Inulin|Three capsules are to be consumed with one sachet dissolved in 200 ml. of water for breakfast and later for dinner resulting in a total of six capsules and two sachets via oral consumption daily.
48518802|NCT05930379|OTHER|LSVT-Loud delivered by telerehabilitation|LSVT-Loud treatment delivered by telerehabilitation
48518803|NCT05930379|OTHER|LSVT-Loud in the clinic|LSVT-Loud delivered face-to-face in the clinic
48518804|NCT03092219|DEVICE|TEOSYAL RHA Redensity|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
48518805|NCT03736031|BEHAVIORAL|Intervention (Promotora)|If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
48716032|NCT06008899|PROCEDURE|US assisted caudal epidural pulsed radiofrequency|patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
48716033|NCT04524650|DIAGNOSTIC_TEST|the level of vWF|the peripheral level of vWF
48716034|NCT04590690|OTHER|Special diet|The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
48716035|NCT04051554|OTHER|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
48716036|NCT04051554|OTHER|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
48716037|NCT06183372|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
48716038|NCT06183372|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
48716039|NCT02557113|PROCEDURE|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
48716040|NCT02557113|PROCEDURE|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
48716041|NCT04665115|DRUG|Ibrutinib|Given PO
48716042|NCT04665115|OTHER|Quality-of-Life Assessment|Ancillary studies
48716043|NCT04090034|PROCEDURE|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
48716044|NCT06305195|DIAGNOSTIC_TEST|heart rate variability test|"First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed."
48381431|NCT03752866|DEVICE|Portico™ Valve, Portico Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
48381432|NCT03752866|DEVICE|Portico™ Valve, FlexNav Delivery System(s) and Loading System(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
48381433|NCT00660855|DRUG|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
48518806|NCT05999214|DIAGNOSTIC_TEST|99mTc-H7ND SPECT/CT imaging performed|99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
48518807|NCT01275729|DRUG|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
48518808|NCT04973566|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
48518809|NCT04973566|DRUG|Etanercept|Etanercept will be administered subcutaneously.
48518810|NCT04973566|DRUG|Hydroxychloroquine|HCQ will be administered orally.
48518811|NCT03038386|OTHER|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
48518812|NCT04584411|DIAGNOSTIC_TEST|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~* Cine imaging using SSFP sequence for cardiac structure and function.~* Tissue characterization imaging, T1 and T2.~* Myocardial perfusion imaging.~* Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities\[5\]"
48518813|NCT03659929|DRUG|Amphetamine Sulfate|active experimental AR19
48518814|NCT03659929|DRUG|Placebo|Matching placebo
48716045|NCT03542851|DRUG|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
48716046|NCT03542851|DRUG|Placebo oral capsule|Placebo will be presented as oral capsule.
48518815|NCT02396719|DEVICE|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
48518816|NCT04435249|OTHER|BPF-001|Expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold
48518817|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
48518818|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
48518819|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
48518820|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
48518821|NCT05081986|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
48518822|NCT05081986|DRUG|Cycloserine|Cycloserine 100mg
48518823|NCT05081986|DRUG|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
48518824|NCT06264063|BEHAVIORAL|control group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
48716047|NCT06103487|GENETIC|No Intervention|Observational study
48716048|NCT02236416|BEHAVIORAL|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
48716049|NCT02236416|BEHAVIORAL|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
48716050|NCT05961449|BEHAVIORAL|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
48518825|NCT06264063|BEHAVIORAL|experimental group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
48716051|NCT05961449|BEHAVIORAL|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline.
48716052|NCT00825396|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
48716053|NCT05455008|BEHAVIORAL|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
48381434|NCT06648213|OTHER|Physiotherapy|Therapy group: In addition to routine care, they will be arranged according to the needs of the baby in the form of positioning, hand contacts, passive and active movement of the arms and legs for the development of movement, sensory stimuli around the mouth for oral motor organisation. Neurodevelopmental-based application will be applied three days a week, once a day for 10-15 minutes, from the 34th week until 36th week when vital signs are stable.
48518826|NCT06264063|DIAGNOSTIC_TEST|EEG power in alpha band|partecipants were submitted to registration of electrical activity with EEG to study the EEG power in alpha band
48518827|NCT04535687|DRUG|Fluzoparib|Fluzoparib
48518828|NCT05467787|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
48716054|NCT01377948|BEHAVIORAL|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
48381435|NCT02037594|BEHAVIORAL|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
48381436|NCT02037594|BEHAVIORAL|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
48381437|NCT02037594|BEHAVIORAL|PrEP Information (Active Control)|Standard of Care Information about PrEP
48381438|NCT02037594|BEHAVIORAL|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
48381439|NCT06653049|DEVICE|Reinforcement Learning (RL) Personalised Exercise Prescription via i80 BPM App|This intervention involved the use of a smartphone app, i80 BPM, which delivered personalised exercise prescriptions using a reinforcement learning (RL) model. The RL algorithm tailored the exercise sessions by adapting variables such as intensity, duration, and exercise type based on individual user preferences, real-time feedback, and performance data. This dynamic personalisation was designed to enhance user satisfaction and engagement over the 12-week study period. Participants completed three exercise sessions per week.
48381440|NCT06653049|DEVICE|Generic Non-Personalised Exercise Prescription via i80 BPM App|This intervention used the same i80 BPM smartphone app to deliver generic, pre-designed exercise sessions that did not adapt based on user preferences or feedback. The exercise sessions were standardised for all participants, with no customisation. The control arm served as a comparator to evaluate the impact of personalised, RL-driven exercise prescriptions. Participants completed three exercise sessions per week.
48381441|NCT02603341|RADIATION|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
48381442|NCT02603341|RADIATION|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
48381443|NCT01873131|DRUG|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
48381444|NCT01873131|DEVICE|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
48381445|NCT00957840|PROCEDURE|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
48381446|NCT03868917|PROCEDURE|thoracic paravertebral block using pressure measurement technique|The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
48381447|NCT01238861|BIOLOGICAL|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
48381448|NCT01238861|BIOLOGICAL|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
48381449|NCT01238861|BIOLOGICAL|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
48381450|NCT01238861|OTHER|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
48716055|NCT02335632|DRUG|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
48716056|NCT02335632|DRUG|Placebo|For probiotics
48716057|NCT01968577|DRUG|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
48716058|NCT03294070|COMBINATION_PRODUCT|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
48716059|NCT03490149|DEVICE|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
48028931|NCT04901611|BEHAVIORAL|Parental touch|Parental touch in the form of stroking at 3cm/s for 10 seconds on the posterior lower limb where the heel lance will be/has been administered
48028932|NCT03797534|OTHER|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
48716060|NCT03490149|DRUG|Medication - Treatment as usual|Medication only sample - Treatment as usual
48716061|NCT05229263|DIAGNOSTIC_TEST|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
48716062|NCT04423458|DEVICE|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
48716063|NCT00283816|DRUG|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
48716064|NCT00283816|DRUG|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
48716065|NCT00283816|BEHAVIORAL|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
48716066|NCT00283816|BEHAVIORAL|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
48716067|NCT00283816|PROCEDURE|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
48716068|NCT00283816|PROCEDURE|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
48716069|NCT00283816|PROCEDURE|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
48716070|NCT00283816|PROCEDURE|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
48716071|NCT00283816|DRUG|placebo|placebo capsules, two capsules BID
48716072|NCT00915668|DRUG|JNJ-31001074|
48716073|NCT02744807|OTHER|Chronic endometritis|with or without Chronic endometritis
48716074|NCT05343234|DRUG|Placebo|tree different placebo drugs with tree different names and scheduled will be given
48716075|NCT05258084|BEHAVIORAL|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
48716076|NCT00542737|BEHAVIORAL|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
48381451|NCT05360017|DEVICE|litestepper single lower limb rehabilitation training robot|The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
48381452|NCT03041818|BEHAVIORAL|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
48381453|NCT03525769|DIAGNOSTIC_TEST|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
48518829|NCT05467787|BEHAVIORAL|Video-chat Psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
48518830|NCT02431364|DRUG|Verdinexor|Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
48518831|NCT02431364|OTHER|Placebo|Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
48180433|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
48180434|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
48180435|NCT03452865|DRUG|Esomeprazole|"160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml."
48381454|NCT04045054|BEHAVIORAL|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
48716077|NCT03285958|BEHAVIORAL|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
48023044|NCT01496651|PROCEDURE|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
48023045|NCT01496651|PROCEDURE|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
48023046|NCT01785589|PROCEDURE|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
48023047|NCT05748639|OTHER|Mobile health application|Participants randomized to receive the QG-A (Experimental) intervention will receive monthly appointments with a medical provider, access to naltrexone, and weekly and bi-weekly appointments with a licensed clinical counselor through an integrated digital health application.
48381455|NCT04020614|OTHER|Survey|A survey with 13 questions will be applied to the patients
48381456|NCT06653881|OTHER|ARCHWIRE|Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
48518832|NCT00972595|DRUG|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
48518833|NCT00972595|DRUG|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
48716078|NCT00265070|DRUG|Gefitinib|250 mg tablet oral daily dose
48180436|NCT03452865|DRUG|Placebo|0.9% sodium chloride (same ml of the study drug)
48180437|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + OTf|OTf (apo ovotransferrin) + FeSO4
48180438|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + Lf|Lf (lactoferrin) + FeSO4
48180439|NCT05233709|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate
48180440|NCT03843398|PROCEDURE|Colorectal cancer resection via minilaparotomy|According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.
48180441|NCT03843398|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
48180442|NCT00164268|BEHAVIORAL|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
48180443|NCT03904940|DEVICE|Total Contact Insole|Ethyl vinyl acetate insole shaped in the cast of the patient's foot.
48381457|NCT05393570|BEHAVIORAL|Healthy Lifestyle Behavioral Intervention (MBS -supported intervention)|After patient/parent consent is completed, participants will begin the pre-MBS intervention phase. A minimum of 6 1- hour sessions will occur pre-MBS, and 26 will occur post-MBS.Dr. Klement, MBS coordinator and a diabetes educator will manage session delivery to adolescents/parents. All content will follow the Diabetes Prevention Program (DPP)-adapted curriculum flow. After that the research assistant will perform outreach, reminder calls, and follow-up for missed appointments. Pre-and post-MBS intervention delivery (based on adapted curriculum/model) may consist of a combination of 1-on-1 and group sessions (in-person or virtually), and online support tools, dependent upon adolescent/parent qualitative feedback on delivery method preference.
48716079|NCT04512638|DRUG|Antibiotics|"Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed."
48716080|NCT04512638|DRUG|Chlorhexidine mouthwash|Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
48716081|NCT04512638|PROCEDURE|Minimally invasive surgery with LPRF|Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
48716082|NCT04512638|PROCEDURE|Surgical resection|Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
48716083|NCT06508684|DRUG|BTK inhibitor|BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
48716084|NCT00784732|DRUG|QAV680|
48716085|NCT00784732|DRUG|QAV680|
48023048|NCT05748639|OTHER|Medical Management|Participants randomized to receive the MM (Control) intervention will receive monthly appointments with a medical provider and access to naltrexone.
48381458|NCT04596618|DEVICE|Forearm cooling|forearm cooling will be performed for active cooling assessment.
48381459|NCT01975129|DRUG|Vagitocin|
48381460|NCT03585894|OTHER|Sumatriptan|Receive intravenous infusion of sumatriptan
48381461|NCT03585894|OTHER|Ketorolac|Receive intravenous infusion of ketorolac
48381462|NCT04212624|OTHER|Human retinal pigment epithelial (HuRPE) cell injection|Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
48716086|NCT00784732|DRUG|Mometasone Furoate|
48716087|NCT05942118|PROCEDURE|Breast conservative surgery|Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization
48716088|NCT03919513|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
48716089|NCT02953236|PROCEDURE|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
48716090|NCT02953236|PROCEDURE|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
48716091|NCT02127034|DRUG|Mirabegron|oral
48716092|NCT02127034|DRUG|Solifenacin|oral
48716093|NCT02127034|DRUG|Digoxin|oral
48716094|NCT03340194|RADIATION|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
48716095|NCT03340194|PROCEDURE|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
48180444|NCT03904940|DEVICE|Ethyl vinyl acetate flat insole|Flat insole made of the same material ethyl vinyl acetate
48381463|NCT04217239|PROCEDURE|MIE Ivor- Lewis|minimally invasive esophagectomy (MIE) with intrathoracic anastomosis
48381464|NCT04217239|PROCEDURE|MIE McKeown|minimally invasive esophagectomy (MIE) with cervical anastomosis
48716096|NCT05154604|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
48716097|NCT02994693|DEVICE|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
48716098|NCT03883334|DRUG|Metisoprinol|Immunodulator
48716099|NCT03757130|DRUG|AMG 598|AMG 598 administered by subcutaneous injection
48716100|NCT03757130|DRUG|Placebo|Placebo matching to AMG 598 administered by subcutaneous injection
48716101|NCT03757130|DRUG|Liraglutide|Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
48381465|NCT02259166|OTHER|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
48023049|NCT05298605|BEHAVIORAL|Faith in Action! Church-based Navigation Model|Cancer screening education and navigation by identified trained navigators in faith based settings + American Cancer Society Screening Guidelines pamphlet
48381466|NCT00683891|DRUG|FazaClo (clozapine, USP) ODT|
48381467|NCT06425718|PROCEDURE|Postoperative Pain Management Technique|Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
48381468|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
48381469|NCT04677907|DEVICE|Persona (Zimmer) posterior stabilised cemented Trabecular Metal™ (Tibia and Femur) prosthesis|Persona (Zimmer) posterior stabilised uncemented Trabecular Metal™ (Tibia and Femur) prosthesis vs a Persona (Zimmer) posterior stabilised cemented prosthesis
48716102|NCT03353766|DEVICE|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
48716103|NCT01231815|RADIATION|15O-H2O PET -|Assessment of coronary reserve using PET
48716104|NCT01231815|RADIATION|MRI|Assessment of coronary reserve using MRI
48716105|NCT00405379|DEVICE|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
48716106|NCT00279838|PROCEDURE|Computer Assisted Navigation Knee Replacement|
48023050|NCT05298605|OTHER|Control|Presentation on healthy behaviors (physical activity, nutrition) + American Cancer Society Screening Guidelines pamphlet
48023051|NCT04777279|BEHAVIORAL|individual physical exercise group|The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
48023052|NCT04777279|DIETARY_SUPPLEMENT|individual Branched-Chain Amino Acids supplements group|The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
48381470|NCT06418932|DEVICE|UrgoK2 / UrgoK2 Lite|Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.
48381471|NCT06418932|OTHER|Controll|Administration of parenteral diuretics only
48023053|NCT04777279|OTHER|combination of physical exercise and nutrition supplements group|The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
48180445|NCT00691600|DRUG|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
48381472|NCT04865536|DRUG|1800 mg TBI-223|3 x 600 mg SR1 tablets
48716107|NCT01829282|BEHAVIORAL|Risk Reduction|
48716108|NCT05429645|PROCEDURE|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
48716109|NCT05523505|DEVICE|Sham intervention|Use of the non-invasive brain stimulation device to simulate peripheral experience of stimulation without actually stimulating the brain.
48716110|NCT05523505|DEVICE|RLN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left angular gyrus and left temporal pole using transcranial alternating current stimulation (tACS).
48716111|NCT05523505|DEVICE|CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex using transcranial alternating current stimulation (tACS).
48180446|NCT00691600|DRUG|Placebo|Placebo caps or suspension every 12 hours for 10 days
48180447|NCT01613963|DRUG|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
48180448|NCT05289219|BEHAVIORAL|EXPOBAR|Each session will start with 5 minutes of warm-up and finalization with 10 minutes of a cool-down, with work of flexibility and proprioception. The maintenance of balance and postural stability may be compromised in obese individuals, depending on the degree of obesity, although the support base provided by the position of the foot is proportional to the structural morphology of each subject. Flexibility is also gradually impaired in obese individuals and of course, these changes may be related to postural changes aggravated by a sedentary lifestyle and biological aging itself alongside all metabolic alterations inherent to the pathology of obesity (Benetti et al., 2016). And the warm-up and the cool-down will be developed as the component of training with the evolution by phases, both in time and in intensity. The first phase will include 20 minutes of interval training, encompassing circuit strength training. Each phase will have an increment of 10 minutes in the central block.
48180449|NCT04338412|DEVICE|ProSeal-LMA™|It is a second generation LMA that is commonly used among all other LMAs
48180450|NCT06442696|OTHER|Health Education: Healthy Choices Program|Six session for students and school personel
48180451|NCT06514573|DIETARY_SUPPLEMENT|Sodium Butyrate|Daily supplementation with 1 sachet per day for 16 weeks
48180452|NCT06514573|DIETARY_SUPPLEMENT|Placebo (cornstarch)|Daily supplementation with 1 sachet per day for 16 weeks
48180453|NCT04200222|DIAGNOSTIC_TEST|cadmium, lead and vanadium measurements and compare|"The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363."
48180454|NCT05822128|OTHER|Test of an alternative Epworth Sleepiness Scale ESS-ALT in French|Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
48180455|NCT01224522|PROCEDURE|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
48381473|NCT04865536|DRUG|2400mg TBI-223|3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
48381474|NCT04865536|DRUG|3000mg TBI-223|4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
48381475|NCT04865536|DRUG|TBI-223 Placebo|3 x Placebo tablets
48716112|NCT05523505|DEVICE|RLN and CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the bilateral dorsolateral prefrontal cortex and left angular gyrus using transcranial alternating current stimulation (tACS).
48180456|NCT01224522|PROCEDURE|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
48180457|NCT06487143|DRUG|Triptorelin pamoate（15mg）|Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.
48180458|NCT06487143|DRUG|Triptorelin acetate （3.75mg）|Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
48180459|NCT03506347|DRUG|Vancomycin|Antibiotic
48180460|NCT00979186|DEVICE|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
48381476|NCT04865536|DRUG|TBI-223 Placebo|4 x Placebo tablets
48381477|NCT04865536|DRUG|TBI-223 Placebo|5 x Placebo tablets
48381478|NCT06650501|DRUG|Dabigatran|Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.
48381479|NCT06650501|DRUG|Apixaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
48381480|NCT06650501|DRUG|edoxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
48381481|NCT06650501|DRUG|Rivaroxaban|Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
48381482|NCT06487182|OTHER|reiki|reiki
48716113|NCT05021549|DEVICE|nasal prong|apneic preoxygenation group (30 patients), will receive 10 L/ min of O2 via nasal prong during preintubation apnia
48180461|NCT01991847|BEHAVIORAL|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
48381483|NCT06487182|OTHER|placebo reiki|placebo reiki
48381484|NCT00138801|DRUG|Ceftriaxone|
48381485|NCT00138801|DRUG|Doxycycline|
48381486|NCT04165824|DRUG|MT-1186|"* An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
48381487|NCT05263024|DEVICE|atrial appendage clip|During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
48381488|NCT06405152|OTHER|Chart review|Retrospective Chart Review
48381489|NCT06566092|BIOLOGICAL|LN-145/LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
48381490|NCT04478773|PROCEDURE|MRI|MRI with or without contrast
48518834|NCT02006602|DRUG|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
48716114|NCT01341626|BEHAVIORAL|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
48180462|NCT00754598|DEVICE|Tomosynthesis digital mammography imaging system|a full-field digital mammography system where multiple images are acquired at various angles near the normal to the detector. Breast compression is performed in a standard geometry. The acquired images are reconstructed using mathematical algorithms, not unlike CT reconstructions, to generate a set of thin slices parallel to the breast platform. The reconstructed slices can be viewed individually or in a movie format.
48180463|NCT04539067|DRUG|HHMG|Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
48180464|NCT04732871|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
48180465|NCT02132117|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
48180466|NCT02132117|DRUG|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
48180467|NCT03085199|PROCEDURE|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, LARS commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
48180468|NCT04264546|BIOLOGICAL|sIPV|The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
48381491|NCT02057224|PROCEDURE|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
48381492|NCT00270205|BIOLOGICAL|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
48381493|NCT00270205|BIOLOGICAL|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
48381494|NCT00270205|BIOLOGICAL|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
48381495|NCT05507671|BIOLOGICAL|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
48381496|NCT05507671|OTHER|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
48180469|NCT04810468|OTHER|Anthropometric measurment|Anthropometric measurment used to asses the wheight in kelogram and asses height in cetemeter and also asses BMI
48180470|NCT00590564|DRUG|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
48381497|NCT05990608|OTHER|Peabody Developmental Motor Scales-2, PDMS|"The Peabody Developmental Engine Scales-2, PDMS, is a standardized norm-referenced test used to determine the motor skill level of children aged 0 to 6, identify delays in engine development, and determine individual needs and challenges. The 2 scalar, which allows children to evaluate rough and thin motor skills, consists of 6 sub-tests and 249 articles. The rough motor scale contains 4 sub-tests and 151 items, including reflex, equilibrium, locomotion and object manipulation. The slim motor scale consists of 2 sub-tests and 98 items, including cognition and visual-motor integration. Using the age-appropriate normal value ranges in the test manual to determine developmental stress risk and level, the coarse motor skills, slim motor skills, and general motor development are categorized as very low, low, below average, above average, high, very high."
48381498|NCT01682681|DRUG|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
48381499|NCT06565897|DRUG|Test regimen|toothpaste \& manual toothbrush
48381500|NCT06565897|DRUG|Control regimen|toothpaste \& manual toothbrush
48023054|NCT04012398|DIAGNOSTIC_TEST|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
48381501|NCT05794555|BEHAVIORAL|Enhanced Usual Care|Patients will be provided and counseled on two methods which will enhance care. The first is a handout on nutrition recommendations and protein supplementation. This will include the recommendation of both high protein snacks during the daytime (e.g., protein bars) and a high-protein night-time snack (e.g., peanut butter and crackers). The second will be to counsel participants on falls prevention methods that can be enacted in day-to-day life. All participants will be provided with a standard hand-out of Centers for Disease Control and Prevention (CDC)-endorsed fall-risk reduction measures.
48381502|NCT05794555|DRUG|Lactulose|"Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2."
48716115|NCT01341626|BEHAVIORAL|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
48381503|NCT05794555|BEHAVIORAL|Investigator recommended exercise|Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.
48023055|NCT01794949|DEVICE|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
48023056|NCT03191344|BEHAVIORAL|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
48023057|NCT04930029|OTHER|Ten year evaluation|Clinical, biological and endoscopic evaluation
48023058|NCT03663413|DEVICE|non-invasive monitor|cutaneous EEG monitor
48023059|NCT01841749|PROCEDURE|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
48023060|NCT01444534|DEVICE|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
48023061|NCT01444534|DEVICE|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
48023062|NCT03773744|DRUG|Ad-MAGEA3|Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
48023063|NCT03773744|DRUG|MG1-MAGEA3|MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
48023064|NCT03773744|DRUG|Pembrolizumab|monoclonal antibody; checkpoint inhibitor of PD1
48023065|NCT03773744|DRUG|Cyclophosphamide|low-dose chemotherapy
48381504|NCT05794555|BEHAVIORAL|TeleTai-Chi (virtual)|TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
48716116|NCT03723538|DRUG|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
48716117|NCT04952038|BEHAVIORAL|sleep disorder|ALS patients with or without sleep disorder
48716118|NCT01430325|DRUG|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
48716119|NCT01430325|DRUG|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
48716120|NCT01307202|DRUG|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
48716121|NCT01307202|DRUG|Placebo|Placebo will match the the gabapentin pill and will be given orally.
48716122|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
48716123|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
48716124|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
48716125|NCT00787202|DRUG|CP- 690 550|Administration via oral route twice daily for the duration of treatment
48716126|NCT00787202|OTHER|placebo|Administration via oral route twice daily for the duration of treatment
48381505|NCT01269671|DRUG|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
48381506|NCT01269671|OTHER|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
48381507|NCT01153971|DRUG|rituximab|1
48381508|NCT00403611|DRUG|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
48716127|NCT04519047|BIOLOGICAL|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
48381509|NCT00403611|DRUG|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
48381510|NCT00474994|DRUG|sunitinib malate|
48381511|NCT06574386|DIAGNOSTIC_TEST|Neurodevelopmental assessment|Neurodevelopmental assessment
48381512|NCT04341727|DRUG|Hydroxychloroquine Sulfate|anti-rheumatic drug (DMARD)
48381513|NCT04341727|DRUG|Azithromycin|Antibiotic
48381514|NCT04341727|DRUG|Chloroquine Sulfate|Antimalarial
48381515|NCT02674568|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
48381516|NCT05993481|DIAGNOSTIC_TEST|Blood Pressure Measurement|"NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program."
48381517|NCT01584804|DRUG|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
48716128|NCT02977845|BEHAVIORAL|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
48381518|NCT01584804|DRUG|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
48180471|NCT04176289|DIAGNOSTIC_TEST|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI\> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
48381519|NCT06411756|BEHAVIORAL|Narrative videos|Culturally targeted narrative videos will be sent via email.
48381520|NCT06411756|BEHAVIORAL|A Fitbit activity tracker|A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
48381521|NCT06411756|OTHER|Daily text message|A daily adaptive step goal that will be sent via text message with a short positive message.
48518835|NCT02006602|DRUG|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
48518836|NCT04235244|OTHER|Thermo mechanical device|The thermomechanical-analgesia device will be placed and operated 30 seconds before the injection into the abdominal area,and injection will be applied by sliding the device to the side of the selected region during the injection,
48180472|NCT00891046|DRUG|Canakinumab|Canakinumab
48180473|NCT06066151|DIETARY_SUPPLEMENT|Minayo Yeast Drink Product|Participants need to drink one piece of the products each day, for 4 consecutive weeks.
48381522|NCT06411756|OTHER|Monthly Zoom meeting|Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
48381523|NCT06411756|OTHER|Website access|Access to Physical Activity Centers Empowerment (PACE) website.
48381524|NCT06411756|OTHER|Printed materials|"Printed materials from the American College of Sport's Medicine's Moving through Cancer campaign."
48381525|NCT06411756|BEHAVIORAL|Printed materials|"Printed materials from the American College of Sports Medicine's Moving through Cancer campaign."
48381526|NCT06450509|BEHAVIORAL|Babble Boot Camp|Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
48381527|NCT06089590|OTHER|Non-interventional|This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
48518837|NCT04235244|OTHER|local coolant spray|Coolant spray will be applied to the abdominal area for 5 seconds at a distance of 15 cm.
48518838|NCT04235244|OTHER|ıce battery|abdominal bölgeye uygulamadan önce ve sonra 5 dk. lokal soğuk uygulama
48518839|NCT03855982|DRUG|Drug inducing myocarditis|Drugs susceptible to induce myocarditis
48381528|NCT05493683|DRUG|Disitamab vedotin|2.0mg/kg，q2w
48381529|NCT05493683|DRUG|Tislelizumab|400mg，q6w
48518840|NCT00743418|DEVICE|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
48518841|NCT03166098|DIAGNOSTIC_TEST|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
48518842|NCT05596656|DIAGNOSTIC_TEST|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
48381530|NCT00925509|PROCEDURE|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
48381531|NCT06167759|OTHER|Opioid Use Agreement|This was previously developed specifically for surgical patients using a modified Delphi method with a group of experts (including surgeons, nurses, advanced practices providers, quality improvement experts, and patients).
48518843|NCT05717660|COMBINATION_PRODUCT|SBRT on all sites of metastatic disease+Apalutamide|oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
48023066|NCT05163145|OTHER|TPN|early detection of comlications of prolonged TPN on neonatal liver
48023067|NCT01010581|DRUG|SC12267 (4SC-101)|oral administration
48518844|NCT03956940|DEVICE|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
48023068|NCT01010581|DRUG|Placebo|oral administration
48023069|NCT01010581|DRUG|Methotrexate|oral administration
48180474|NCT01095159|DEVICE|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
48518845|NCT01868347|OTHER|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
48518846|NCT01868347|OTHER|control|PEEP after pneumoperitoneum and trendelenburg
48518847|NCT01443728|DRUG|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month
48518848|NCT01443728|DRUG|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month
48518849|NCT03414216|PROCEDURE|Group 1 early offloading surgery|As above.
48518850|NCT03414216|PROCEDURE|Group 2 - off-loading in fiberglass cast|As above.
48518851|NCT04298632|BEHAVIORAL|Safety Education Program|this is a pesticide safety education program
48023070|NCT01010581|DRUG|Folic Acid|oral administration
48023071|NCT02092948|RADIATION|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
48023072|NCT05153018|OTHER|Blood collection|a 4-mL blood sample collected in a dry tube
48023073|NCT01438411|DRUG|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
48180475|NCT01095159|DEVICE|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
48023074|NCT01474135|DRUG|0.25% AR-12286 / 0.004% travoprost|
48023075|NCT01474135|DRUG|0.5% AR-12286, 0.004% travoprost|
48023076|NCT01474135|DRUG|0.004% Travoprost|
48023077|NCT00616967|DRUG|carboplatin|Given IV
48023078|NCT00616967|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
48023079|NCT00616967|DRUG|vorinostat|Given orally
48023080|NCT00616967|OTHER|placebo|Given orally
48023081|NCT04151862|DEVICE|tight eye bandage|sterile eye pad made of 100% cotton
48023082|NCT04151862|DEVICE|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
48023083|NCT00875953|PROCEDURE|standard neck dissection|standard surgical technique
48023084|NCT00875953|PROCEDURE|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
48023085|NCT04407897|RADIATION|Stereotactic radiotherapy|Three different dose fractionation schemes will be available: 45 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 8 fractions.
48023086|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum|The therapist will coach parents in the context of clinic-based play activities and help parents identify contexts and activities at home where the parents could follow up on the program at home. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
48180476|NCT06125899|BEHAVIORAL|emhGAP-Age|"* Adapted emhGAP-IG;~* Adapted Problem-Solving Therapy (PST-PC)~* Support/supervision of lay providers~* Links to social support resources."
48180477|NCT02333266|OTHER|Candidemia|
48180478|NCT03004404|DRUG|Placebo|Placebo
48716129|NCT04402294|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will create individualized TMS targets using deep learning methods on task and resting fMRI data to target working memory augmentation. The individualized target will be stimulated in a subsequent fMRI scan involving working memory task performance interleaved with repetitive TMS (rTMS) delivered at a variety of stimulation frequencies. Based on activation readouts in response to rTMS, an optimal and sub-optimal brain state frequency to impact working memory performance will be selected for each participant. Participants will receive rTMS at each frequency separately for three days (six days total), with the order of frequency randomly assigned and counterbalanced. Following each three day protocol, another fMRI working memory readout will be conducted to support the targeting and frequency selection algorithms.
48716130|NCT02579694|DEVICE|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
48716131|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
48716132|NCT02980094|DIETARY_SUPPLEMENT|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
48716133|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
48716134|NCT02980094|DIETARY_SUPPLEMENT|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
48716135|NCT02961192|BEHAVIORAL|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
48716136|NCT02961192|BEHAVIORAL|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
48716137|NCT02961192|BEHAVIORAL|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
48716138|NCT00990912|DRUG|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
48716139|NCT00990912|DRUG|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
48716140|NCT00990912|DRUG|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
48381532|NCT01612988|DRUG|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
48381533|NCT06121986|BEHAVIORAL|Modified Mediterranean Ketogenic Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet in addition to titrating into a ketogenic macronutrient ratio across the first 5 weeks, starting at 50% fats/25% protein/25% net carbohydrates up to 70% fats/25% protein/5% net carbohydrates).
48381534|NCT06121986|BEHAVIORAL|Mediterranean Nutrition Adherence Program|Participants will be provided with education, support, and resources for following a Mediterranean diet.
48381535|NCT04355767|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
48381536|NCT04355767|BIOLOGICAL|Saline|Saline with multivitamin administered via intravenous (IV) infusion..
48023087|NCT05792449|BEHAVIORAL|Foundational Skills Curriculum - Telerehabilitation|Parent-child interactions during activities at home will be observed through video conferencing. Parents will be encouraged to interact with their child using strategies aimed at increasing their child's attention and motivation, turn-taking routines, initiating and responding to joint attention, communication, etc. Intervention sessions empower and equip parents with skills and strategies to engage with their child at home. Since the program involves behavioural intervention and parent coaching, active participation of parent and child are key to each session.
48518852|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
48518853|NCT06496048|DRUG|Irinotecan|Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk
48518854|NCT06496048|DRUG|Lurbinectedin|Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)
48518855|NCT06496048|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk
48716141|NCT06184841|DRUG|HAIC combined with intravenous PD-1|Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
48716142|NCT00206284|DRUG|AZD0865|
48716143|NCT00532571|DRUG|CoQ10|
48518856|NCT03345680|OTHER|Referred to a specific hospital for treatment|To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
48518857|NCT00015886|DRUG|docetaxel|75 milligrams per meter squared intraveneously
48518858|NCT00015886|DRUG|fluorouracil|350 milligrams intraveneously
48518859|NCT05309018|OTHER|Interviews|Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
48518860|NCT02965417|DRUG|Sym004|Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
48716144|NCT03745352|DRUG|Azacitidine|Given IV or SC
48381537|NCT06652906|DRUG|Sodium phosphate powder|After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
48518861|NCT02566889|DRUG|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
48716145|NCT03745352|DRUG|Pevonedistat|Given IV
48716146|NCT02096666|DRUG|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
48518862|NCT04296591|DIAGNOSTIC_TEST|fetal heart doppler findings|Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
48716147|NCT02253056|OTHER|Fasting / Caloric Restriction|
48716148|NCT02253056|OTHER|Healthy Diet|
48023088|NCT00423436|BEHAVIORAL|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
48716149|NCT02446873|OTHER|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
48716150|NCT05729698|DEVICE|Baby warmer swaddle|Baby Swaddle with Heating System
48716151|NCT05729698|OTHER|polyethylene bag|polyethylene food bag
48716152|NCT05655273|DRUG|Prograf|Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
48716153|NCT05655273|DRUG|Envarsus|Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
48716154|NCT02032641|DEVICE|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
48716155|NCT00284713|PROCEDURE|intracoronary infusion of BMC|catheter delivery of stem cells
48023089|NCT00423436|BEHAVIORAL|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
48716156|NCT04453813|DRUG|Toripalimab plus concurrent chemo-radiotherapy|"1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
48716157|NCT04453813|DRUG|Concurrent chemo-radiotherapy|"1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy"
48716158|NCT01124877|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
48716159|NCT05956808|DEVICE|Phonak Naida BTE hearing aid|Newest generation of ultra-power Phonak BTE hearing aids
48716160|NCT05956808|DEVICE|Phonak Naida legacy BTE hearing aid|Previous model/generation of the Naida BTE hearing aid
48716161|NCT02452853|PROCEDURE|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
48716162|NCT02452853|DRUG|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
48716163|NCT06508268|BEHAVIORAL|GAITRite walkway system OR 4-meter walking speed test|Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test
48716164|NCT06508268|BEHAVIORAL|Jamar hand dynamometer|Hand grip strength will be assessed by a Jamar hand dynamometer
48716165|NCT06508268|BEHAVIORAL|Picture description task|Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)
48716166|NCT06508268|BEHAVIORAL|Autobiographical semi-structured conversation|Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation
48716167|NCT06508268|BEHAVIORAL|Verbal fluency|The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
48716168|NCT04902651|DEVICE|HM242-Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
48716169|NCT04902651|DEVICE|Intrasite Gel|HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
48716170|NCT03972319|DIETARY_SUPPLEMENT|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
48716171|NCT05828875|OTHER|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
48023090|NCT00423436|BEHAVIORAL|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
48023091|NCT02770391|DRUG|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
48023092|NCT02770391|DRUG|Apalutamide|Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.
48023093|NCT02770391|PROCEDURE|Radical prostatectomy|
48716172|NCT01369082|DRUG|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
48716173|NCT05254496|BEHAVIORAL|Dietary Intervention Classes|Participants will attend classes once per week for 6 months and then bi-weekly for 6 months.
48716174|NCT05991765|OTHER|Digit Tip Wound|Digit Tip Wound Exudate Sample Collected while Dressing Change
48180479|NCT03004404|DRUG|BI 730357|powder for reconstitution of an oral solution (PfoS)
48180480|NCT03004404|DRUG|BI 730357|BI 730357 film-coated tablet
48180481|NCT04296747|DRUG|induction chemotherapy|Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
48180482|NCT04296747|PROCEDURE|surgery|After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
48518863|NCT04177446|DIETARY_SUPPLEMENT|a production consist of various oligopeptides and the whey protein|patients will be given extra protein intake except the basic energy intake
48716175|NCT05991765|OTHER|Split Skin Donor Site Wound|Split Skin Donor Site Wound Exudate Sample while Dressing Change
48518864|NCT04177446|DIETARY_SUPPLEMENT|basic energy intake|supplement as basic energy intake
48716176|NCT00751283|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
48716177|NCT04175067|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
48716178|NCT04175067|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
48716179|NCT02753686|DRUG|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
48716180|NCT02753686|DRUG|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
48716181|NCT02332772|OTHER|Data Collection|Data collected from endoscopy procedures.
48518865|NCT04177446|DIETARY_SUPPLEMENT|maltodextrin|used as placebo in the control group
48716182|NCT00817648|DRUG|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
48716183|NCT00817648|DRUG|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
48716184|NCT05618782|DRUG|LEVI-04|Intravenous infusion
48716185|NCT05618782|OTHER|Placebo:|Placebo dose intravenous infusion
48716186|NCT05785507|OTHER|PriskA tool|PriskA tool is an algorithm that generates a risk score of having PCOS.
48716187|NCT03622021|DRUG|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
48716188|NCT03141463|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
48518866|NCT00530205|OTHER|physiologic testing|
48518867|NCT00530205|OTHER|questionnaire administration|
48716189|NCT04104659|DRUG|MK 6240|"PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
48518868|NCT00530205|PROCEDURE|management of therapy complications|
48716190|NCT03118999|DIETARY_SUPPLEMENT|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
48716191|NCT03118999|DIETARY_SUPPLEMENT|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
48716192|NCT03118999|DIETARY_SUPPLEMENT|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
48716193|NCT00259298|DRUG|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
48716194|NCT00830713|PROCEDURE|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
48518869|NCT00530205|RADIATION|radiation therapy|
48518870|NCT00002817|BIOLOGICAL|sargramostim|
48518871|NCT00002817|BIOLOGICAL|vaccinia-GM-CSF vaccine|
48518872|NCT00719186|DRUG|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
48518873|NCT00719186|DRUG|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
48518874|NCT02961998|DRUG|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
48518875|NCT02961998|DRUG|Sorafenib|Each group will receive sorafenib as basic treatment.
48518876|NCT02920671|OTHER|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
48518877|NCT02920671|OTHER|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
48716195|NCT04588506|PROCEDURE|Lower Trapezius Tendon Transfer Technique|Lower Trapezius tendon used in repairing cuff tear
48716196|NCT04588506|PROCEDURE|Latissimus Dorsi Tendon Transfer Technique|Latissimus Dorsi tendon used in repairing cuff tear
48716197|NCT04588506|PROCEDURE|Pectoralis Tendon Transfer Technique|Pectoralis tendon used in repairing cuff tear
48381538|NCT06652906|DRUG|Polyethylene glycol electrolyte dispersion|After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
48381539|NCT06008470|OTHER|observational tests|"Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity"
48716198|NCT03765151|DEVICE|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
48716199|NCT03765151|OTHER|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
48716200|NCT05394480|DIAGNOSTIC_TEST|Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.|Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
48716201|NCT02634606|DRUG|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
48716202|NCT02634606|DRUG|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
48716203|NCT02634606|DRUG|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
48716204|NCT03476616|DRUG|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
48180483|NCT04296747|RADIATION|chemoradiotherapy|After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
48381540|NCT04760639|DIAGNOSTIC_TEST|Breath test|Participants provide a breath sample
48381541|NCT04054011|DRUG|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
48518878|NCT02920671|OTHER|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
48518879|NCT02920671|OTHER|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
48716205|NCT03476616|DRUG|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
48716206|NCT01787318|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
48716207|NCT01787318|DEVICE|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
48716208|NCT00003358|DRUG|chemotherapy|
48716209|NCT00003358|DRUG|cisplatin|
48716210|NCT00003358|DRUG|gemcitabine hydrochloride|
48716211|NCT03458858|OTHER|Mixed Berry Diet|Mixed Berry Treatment
48716212|NCT03458858|OTHER|Carbohydrate Control Jello|Carbohydrate Control
48716213|NCT03458858|OTHER|Fiber Enriched Jello|Fiber Control
48716214|NCT03458858|OTHER|Low Fiber Mixed Berry Juice|Anthocyanin Control
48381542|NCT01530152|PROCEDURE|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
48716215|NCT00219882|DRUG|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
48716216|NCT05832112|PROCEDURE|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
48716217|NCT00860015|DRUG|Alimta|"500 mg/m2 via IV over 10 minutes~A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer."
48716218|NCT00860015|DRUG|Gemcitabine|"1000 mg/m2 via IV over 90 minutes~A nucleoside analog used as chemotherapy."
48716219|NCT03356509|BEHAVIORAL|Exercise|Exercise will be performed on a stationary bicycle ergometer.
48716220|NCT04119622|DRUG|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
48716221|NCT04119622|DRUG|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
48716222|NCT04119622|DRUG|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
48716223|NCT02278614|DRUG|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
48716224|NCT02278614|DRUG|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
48023094|NCT06520748|OTHER|Hand rehabilitation program using the computerized glove|The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software
48023095|NCT06520748|OTHER|Selected hand program|Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
48023096|NCT05718622|DEVICE|real EECP|Real EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 150 millimeters of mercury.
48023097|NCT05718622|DEVICE|sham EECP|Sham EECP treatment is delivered 45min per day for 14 sessions continuously. The treatment pressure sets at 75 millimeters of mercury.
48381543|NCT05311111|PROCEDURE|distal radial artery approach|Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
48716225|NCT02726880|BEHAVIORAL|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
48716226|NCT02726880|BEHAVIORAL|Referral for care|Referral for mental health issues and family support services
48716227|NCT01283308|BEHAVIORAL|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
48716228|NCT01283308|BEHAVIORAL|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
48716229|NCT00808535|PROCEDURE|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
48716230|NCT04021173|DRUG|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
48716231|NCT04021173|DRUG|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
48716232|NCT02448888|OTHER|Adapted exercise|2 months, 3 times/week
48023098|NCT02184468|OTHER|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
48023099|NCT03217136|DRUG|Ceftolozane/Tazobactam|Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
48716233|NCT02448888|OTHER|General exercise recommendations|2 months, 3 times/week
48716234|NCT05255042|OTHER|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
48716235|NCT05928611|PROCEDURE|Inferior alveolar nerve block with dexamethasone|Using articaine for inferior alveolar block with intraligmentary dexamethasone
48716236|NCT05928611|PROCEDURE|Buccal infiltratation with dexamethasone|Using articaine for buccal infiltratation with intraligmentary dexamethasone
48716237|NCT05928611|PROCEDURE|Inferior alveolar nerve block|Using articaine for injection
48716238|NCT00576030|OTHER|hab cof with water|habitual coffee drinker provided with water
48716239|NCT00576030|OTHER|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
48716240|NCT00576030|OTHER|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
48716241|NCT00576030|OTHER|non-hab cof with water|non-habitual coffee drinkers given water
48716242|NCT00576030|OTHER|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
48716243|NCT00576030|OTHER|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
48716244|NCT01440517|DRUG|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
48716245|NCT03808753|DIAGNOSTIC_TEST|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
48716246|NCT03808753|OTHER|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
48716247|NCT03889236|OTHER|Fasting mimicking diet Prolon|5-day fasting mimicking diet
48716248|NCT03889236|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Food supplement
48716249|NCT03889236|DIETARY_SUPPLEMENT|Placebo|Placebo
48716250|NCT00837018|OTHER|physical exercise program|45 min, 3times a week
48716251|NCT03207945|DRUG|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
48716252|NCT03207945|OTHER|Placebo|Placebo
48716253|NCT05586698|PROCEDURE|Auricular acupressure|We conducted auricular acupressure at zero acupoints on the left ear with Vaccaria ear seed (Group A) or removed seed (Group B) in 20 minutes, with 2 times of auricular acupressure. The stimulation was performed for 30 seconds each time, with two pressure movements per second, resulting in a total of 60 pressure movements per stimulation.
48716254|NCT00973882|DRUG|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
48716255|NCT00973882|DRUG|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
48716256|NCT02609685|OTHER|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
48716257|NCT00001812|DRUG|Nystatin|
48716258|NCT06508931|DRUG|zamtocabtagene autoleucel (MB-CART2019.1)|Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
48716259|NCT03078738|DRUG|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
48716260|NCT03078738|OTHER|Matching Placebo|Microcrystalline cellulose
48716261|NCT05617300|BEHAVIORAL|Mindfulness-Based Dementia Caregiving|Mindfulness Based Stress Reduction (MBSR) is a standardized program that is both psychoeducation and skills-based, which uses mindfulness meditation practices to help people better cope with their emotions. This study uses a version of MBSR designed specifically for care partners of people living with dementia (PLWD) called Mindfulness Based Dementia Caregiving. Mindfulness Based Dementia Caregiving (MBDC) is a program with 8 weekly 2 hour sessions (plus one extended practice 4 hour retreat) including both formal and informal mindfulness practices, role play, and lectures combined with some dementia-specific education. Participants learn how to incorporate mindfulness practices into day-to-day life to help cope with the challenges and stresses of dementia care.
48716262|NCT01628861|DEVICE|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
48716263|NCT01628861|BEHAVIORAL|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
48716264|NCT06357468|OTHER|midwife-led births in low risk women in pregnancy|Pregnant women in the low-risk collective are cared for in a midwife-led delivery room if they wish to have a natural birth
48716265|NCT02259140|PROCEDURE|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
48716266|NCT02259140|PROCEDURE|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
48716267|NCT02762747|PROCEDURE|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
48716268|NCT00247832|BEHAVIORAL|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
48716269|NCT00247832|BEHAVIORAL|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
48716270|NCT04268277|DRUG|Rituximab|100 mg concentrate for solution for infusion
48381544|NCT05311111|PROCEDURE|conventional radial artery approach|Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
48716271|NCT04268277|DRUG|Pembrolizumab|100 mg/ 4mL concentrate for solution for infusion
48716272|NCT04643119|DEVICE|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
48716273|NCT04643119|DEVICE|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
48716274|NCT01801176|OTHER|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
48716275|NCT00885768|PROCEDURE|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
48716276|NCT04301180|DEVICE|Education food|The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
48716277|NCT00136825|DRUG|N-Acetylcysteine|
48716278|NCT00136825|DRUG|Placebo|
48716279|NCT04194918|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
48716280|NCT04194918|OTHER|Text Message|Receive text messages
48716281|NCT04194918|OTHER|Handout|Receive handouts via email
48716282|NCT04194918|OTHER|Questionnaire Administration|Ancillary studies
48716283|NCT04194918|OTHER|Quality-of-Life Assessment|Ancillary studies
48381545|NCT04700813|DIAGNOSTIC_TEST|search for rare pathogenic mutations|search for rare pathogenic mutations causing diabetes type 2
48716284|NCT04194918|OTHER|Survey Administration|Ancillary studies
48716285|NCT00028431|BIOLOGICAL|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
48716286|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intracoronary)
48716287|NCT00927615|DRUG|abciximab|0.25 mg/kg body weight (intravenous)
48381546|NCT02974270|DRUG|Leuprolide|
48381547|NCT06466369|DRUG|Tadalafil|tadalafil 2.5 mg, 5 mg
48716288|NCT05697666|OTHER|Modulation of the depth of the neuromuscular blockade|"Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade"
48716289|NCT04851821|DRUG|Quercetin|Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
48716290|NCT04108715|PROCEDURE|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
48381548|NCT01876927|OTHER|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
48381549|NCT01876927|OTHER|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
48381550|NCT03184402|DRUG|DWJ1252|tablet
48381551|NCT03184402|DRUG|Gasmotin|tablet
48381552|NCT03184402|DRUG|Placebo of Gasmotin|tablet
48381553|NCT03184402|DRUG|Placebo of DWJ1252|tablet
48381554|NCT05551936|DRUG|Bendamustine|90 mg/m\^2 IV Days 1-2, Cycles 1-3
48381555|NCT05551936|DRUG|Rituximab|375 mg/m\^2 IV Day 1 Cycles 1-6
48381556|NCT05551936|DRUG|Tazemetostat|RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
48381557|NCT04158739|DRUG|Cytarabine|Given IT
48381558|NCT04158739|BIOLOGICAL|Flotetuzumab|Given IV
48180484|NCT05994469|BEHAVIORAL|Copenhagen Adduction Exercise|The CAE is performed by side-lying on the floor with the dominant lower limb supported in the air by a teammate, the hip is adducted until the body forms a straight line from the ankles to the shoulders (concentric phase), then the player is instructed to lower the body slowly (eccentric phase) until reaching the floor to start the next repetition.
48180485|NCT02660515|PROCEDURE|Additional wrist arthroscopy|
48180486|NCT02660515|PROCEDURE|ORIF|
48180487|NCT01026298|OTHER|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
48716291|NCT04108715|PROCEDURE|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
48716292|NCT02320851|BEHAVIORAL|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
48716293|NCT02320851|BEHAVIORAL|Self-help group (SHG)|(see description of corresponding study arm)
48716294|NCT03395730|DRUG|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
48716295|NCT03395730|PROCEDURE|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
48716296|NCT03395730|PROCEDURE|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
48716297|NCT05259644|DEVICE|laparoscopic sleeve gastrectomy|Surgical procedure - laparoscopic sleeve gastrectomy.
48716298|NCT05259644|OTHER|conservative treatment of obesity|Diet and exercise
48716299|NCT05259644|DEVICE|endoscopic gastric plication|Endoscopic procedure - endoscopic gastric plication
48716300|NCT03036436|BEHAVIORAL|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
48716301|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 1
48180488|NCT04749407|GENETIC|biomarker detection|PBMC and ctDNA analysis
48180489|NCT01913899|OTHER|Occupational/ physical therapy|
48180490|NCT01913899|OTHER|Mirror therapy|- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
48381559|NCT05498545|BIOLOGICAL|LUCAR-B68 cells product|Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen
48180491|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
48180492|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using standard care bougie|After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
48180493|NCT04410809|BIOLOGICAL|TA-46|Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
48180494|NCT04410809|OTHER|Placebo|The same composition as the active medication but without the active substance TA-46
48180495|NCT01198483|PROCEDURE|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
48180496|NCT01198483|PROCEDURE|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
48180497|NCT01266746|PROCEDURE|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
48180498|NCT06538298|OTHER|Multimodal Exercise Program with Gamification|A comprehensive exercise program for 3 days a week for 6 weeks that utilizes non-contact boxing and gamification at moderate to vigorous intensity.
48180499|NCT06120647|DIETARY_SUPPLEMENT|Essential amino acids (EAA)|intake of 240 mg EAA per kg lean body mass after a resistance exercise session
48381560|NCT04683874|DEVICE|3D printed tray|3D printed tray
48381561|NCT03215602|OTHER|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
48381562|NCT03215602|OTHER|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
48381563|NCT01729546|DEVICE|7 Blood glucose monitoring systems|
48381564|NCT06565975|DRUG|Oral azacitidine|As per product label, prescribed by treating physician
48381565|NCT06081894|DRUG|Aficamten|Oral Tablet
48381566|NCT06081894|DRUG|Placebo|Oral Tablet
48381567|NCT03299439|OTHER|acupuncture|a stimulation of the body or auricular points
48180500|NCT05932147|OTHER|Pilates exercise|"1. Shoulder Abduction with External Rotation exercise~2. Shoulder bridge exercise~3. Mermaid sitting exercise.~4. Standing Pilates mermaid exercise with towel~5. Rocking exercise~6. Saw Pilates exercise.~7. Bird-dog Pilates exercise.~8. Roll up exercise.~9. Cobra pose exercise.~10. Child pose exercise."
48180501|NCT05932147|OTHER|Manual lymphatic massage|"procedures of Manual lymphatic drainage program Things to know about MLD Massage~* Use only gentle pressure, just enough to see your skin move.~* Massage should not be painful.~* Do not rub your skin red.~* Do massage each day.~* Repeat each step 5 to 10 times.~* The massage should take about 15 to 30 minutes."
48381568|NCT03628781|OTHER|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
48381569|NCT03628781|OTHER|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
48381570|NCT04670510|OTHER|On-site AE|"Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18.~All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session"
48381571|NCT04670510|OTHER|At-home AE|Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session.
48381572|NCT04670510|OTHER|Social Engagement (SE)|To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period.
48381573|NCT02487459|BIOLOGICAL|BPX-501|T cells transduced with CaspaCIDe suicide gene
48381574|NCT02487459|DRUG|AP1903|dimerizer drug administered to treat GVHD
48716302|NCT06506994|DRUG|HRS-9057|HRS-9057 injection dose 2
48716303|NCT06506994|DRUG|Tolvaptan|Tolvaptan tablets
48381575|NCT06651073|OTHER|Observational|There is no intervention involved in the study. It is purely observational.
48381576|NCT03592680|DIETARY_SUPPLEMENT|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
48716304|NCT00581867|DRUG|Insulin Aspart|40IU insulin aspart applied intranasally
48716305|NCT00581867|DRUG|Placebo|Placebo
48716306|NCT01586104|RADIATION|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
48716307|NCT05854953|DEVICE|Hawley retainers in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
48716308|NCT05854953|DEVICE|Hawley retainers in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
48716309|NCT05854953|DEVICE|VFRs in dry storage condition|Three months later, an exchange of storage methods from dry to wet conditions will take place.
48180502|NCT02938897|BEHAVIORAL|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
48180503|NCT02938897|BEHAVIORAL|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
48180504|NCT02938897|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
48180505|NCT03796000|PROCEDURE|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
48180506|NCT05425407|DIETARY_SUPPLEMENT|whey protein|Daily 45g of whey protein supplementation during a three week eccentric training period
48180507|NCT05425407|DIETARY_SUPPLEMENT|whey protein + collagen peptide|Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
48381577|NCT03592680|OTHER|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
48381578|NCT00163371|DRUG|Ciclesonide|
48716310|NCT05854953|DEVICE|VFRs in wet storage condition|Three months later, an exchange of storage methods from wet to dry conditions will take place.
48716311|NCT05854953|DEVICE|Baseline characteristics|Hawley retainers and VFRs that are newly constructed will be used as baseline samples. The samples will be taken for microbial, physical and mechanical tests.
48180508|NCT05881239|DEVICE|AROMHA Brain Health Test|The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
48180509|NCT06385847|DRUG|Zoladex|Patients received 3.6 mg subcutaneous Zoladex
48180510|NCT06385847|DRUG|LY01005|Patients received 3.6 mg intramuscular LY01005
48381579|NCT04380662|OTHER|Risk factors|"The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain...~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA...)"
48381580|NCT06046404|PROCEDURE|closed reduction|the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
48381581|NCT06046404|PROCEDURE|no closed reduction|no reduction will be performed
48716312|NCT03507959|OTHER|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
48716313|NCT03507959|OTHER|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
48716314|NCT03507959|OTHER|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
48716315|NCT03507959|OTHER|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
48716316|NCT01987219|DRUG|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
48716317|NCT01987219|DRUG|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
48716318|NCT01987219|OTHER|placebo|Saline solution 3 cc NA
48180511|NCT05379153|DEVICE|Laser Therapy|Undergo vaginal fractional CO2 laser therapy
48180512|NCT05379153|DEVICE|Sham Intervention|Undergo placebo procedure
48180513|NCT05379153|OTHER|Questionnaire Administration|Ancillary studies
48180514|NCT05379153|OTHER|Quality of Life Assessment|Ancillary studies
48180515|NCT06545279|PROCEDURE|Hall Crown Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation.
48180516|NCT06545279|PROCEDURE|Modified Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation but with interproximal slicing.
48180517|NCT00146198|DRUG|ALGRX 4975|
48180518|NCT04287140|OTHER|Bolus fluid administration|1000 ml of 0.9% normal saline bolus over one hour
48381582|NCT05950204|DIETARY_SUPPLEMENT|ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)|Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.
48381583|NCT05614102|DRUG|BAY2965501|Daily oral application
48381584|NCT05614102|DRUG|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
48180519|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
48381585|NCT03573843|OTHER|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
48381586|NCT03573843|OTHER|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
48381587|NCT03716440|OTHER|Nature exposure|Participants will view images of nature.
48381588|NCT03716440|OTHER|Non-nature exposure|Participants will view non-nature images.
48381589|NCT04404192|DRUG|PH94B|Intranasal administration of 100 microliters to each nostril 4 times a day
48716319|NCT03306641|DEVICE|Test Contact Lens|Daily disposable contact lens
48716320|NCT03306641|DEVICE|Nelfilcon A|Focus Dailies All Day Comfort contact lens (nelfilcon A)
48716321|NCT05162053|DRUG|vicagrel Capsules|Oral administration for 7 days under fasting
48716322|NCT05162053|DRUG|Clopidogrel Tablets|Oral administration for 7 days under fasting
48716323|NCT02525939|DRUG|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
48716324|NCT02525939|DRUG|Placebo|matching placebo tablets
48716325|NCT02225912|OTHER|PrevinC|
48180520|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
48180521|NCT02706847|DRUG|Placebo|Tablet; Oral
48716326|NCT02225912|DRUG|placebo|
48180522|NCT02706847|DRUG|Upadacitinib|Tablet; Oral
48180523|NCT05879003|DEVICE|novel brace with neuromuscular electrical stimulation|The symptomatic rotator cuff tear subjects had NMES on scapular muscles and adductor muscle
48180524|NCT05879003|BEHAVIORAL|scapular and adductor exercise|The symptomatic rotator cuff tear subjects conduct scapular and adductor exercise
48180525|NCT05284955|DEVICE|CardioMEMS HF System|The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.
48716327|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
48716328|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
48180526|NCT05284955|DRUG|Standard heart failure medical therapy|Standard heart failure medical therapy as recommended by guidelines.
48180527|NCT01846403|DEVICE|Semi-quantitative urine pregnancy test|
48180528|NCT01041989|BEHAVIORAL|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
48180529|NCT01041989|BEHAVIORAL|Exercise|Guided muscle strength training and aerobic exercise.
48180530|NCT01041989|BEHAVIORAL|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
48180531|NCT01041989|OTHER|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
48180532|NCT02835027|PROCEDURE|Open versus endovascular surgery|Treatment for acute ischemia
48180533|NCT01550432|DIETARY_SUPPLEMENT|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
48180534|NCT01550432|DIETARY_SUPPLEMENT|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
48180535|NCT01550432|OTHER|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
48180536|NCT04073797|DRUG|Inclisiran|Inclisiran 284 mg, one injection
48180537|NCT04073797|DIAGNOSTIC_TEST|68Ga-DOTATATE PET-MRI|68Ga-DOTATATE PET-MRI at baseline and 12 weeks
48180538|NCT04073797|DRUG|Colchicine|Colchicine 500 mcg tablet once daily
48180539|NCT06289647|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
48180540|NCT05716529|OTHER|rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
48180541|NCT01210651|BEHAVIORAL|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
48180542|NCT01210651|BEHAVIORAL|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
48180543|NCT00835185|BIOLOGICAL|IMC-11F8 (necitumumab)|IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
48716329|NCT02986100|DRUG|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
48716330|NCT02986100|DRUG|Rucaparib|200 \& 300 mg tablet
48180544|NCT00835185|DRUG|Oxaliplatin|Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
48180545|NCT00835185|DRUG|Folinic acid (FA)|FA 400 mg/m² IV infusion bolus injection
48180546|NCT00835185|DRUG|5-FU|5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
48180547|NCT02573649|DEVICE|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
48180548|NCT02573649|DEVICE|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
48381590|NCT04404192|DRUG|Placebo|Intranasal administration of 100 microliters to each nostril 4 times a day.
48716331|NCT05793606|PROCEDURE|Deltoid ligament repair|Surgical repair for the deltoid ligament
48716332|NCT05052437|DRUG|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
48716333|NCT05052437|DRUG|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
48523000|NCT03022370|BEHAVIORAL|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
48716334|NCT01555515|PROCEDURE|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
48716335|NCT01555515|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
48716336|NCT00624416|DRUG|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
48716337|NCT04705415|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
48716338|NCT04705415|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
48716339|NCT02536300|DRUG|Idelalisib|Idelalisib tablet administered orally
48716340|NCT02624193|BEHAVIORAL|MBSR Program|Mindfulness-based stress reduction, as described previously.
48716341|NCT02624193|BEHAVIORAL|HT Program|Health education curriculum, as described previously
48381591|NCT05206279|DRUG|Ureteral injection of Indocyanine Green Powder (diluted)|The intervention we study is the intraureteral injection of ICG during a laparoscopic deep infiltrative endometriosis resection procedure. Cystoscopy with intraureteral administration of ICG will be performed, after which intervention the ureters will be examined by laparoscopy. ICG is injected cystoscopy-guided into the ureters (cystoscopy-guided) in a dosage of 5 or 10ml (25mg ICG in 5 or 10ml NaCl) per ureter as a bolus injection.
48381592|NCT03984994|OTHER|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
48716342|NCT00424190|DRUG|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
48716343|NCT00424190|DRUG|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
48716344|NCT03346265|OTHER|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
48716345|NCT03346265|OTHER|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
48023100|NCT03217136|DRUG|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.
48023101|NCT03217136|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
48180549|NCT06454305|OTHER|Active cycle of breathing technique|Breathing control, thoracic expansion and forced expiratory training are the three components of ACBT. The purpose of the thoracic expansion phase is to facilitate the release of secretions, enhance ventilation, and supply the necessary volume for forced expiratory breathing. Secretions are moved into the central airways during the forceful expiratory exercise that follows The three stages of ACBT
48381593|NCT03984994|OTHER|Strength training|3 months of center-based, supervise strength training
48716346|NCT04878744|BEHAVIORAL|Shmapped|Novel app-based intervention to improve wellbeing in patients with common mental health problems.
48716347|NCT02002468|OTHER|Test result sent by letter|
48716348|NCT02002468|OTHER|Test result conveyed by general practitioners|
48716349|NCT01253265|DRUG|LY2439821|Administered subcutaneously
48716350|NCT01253265|DRUG|Placebo|Administered subcutaneously
48716351|NCT04247126|DRUG|SY-5609|An oral CDK7 Inhibitor
48023102|NCT03217136|DRUG|Placebo for Metronidazole|Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
48023103|NCT00357305|DRUG|vorinostat|Given orally
48023104|NCT00357305|DRUG|cytarabine|Given IV
48023105|NCT00357305|DRUG|etoposide|Given IV
48023106|NCT00357305|OTHER|pharmacological study|Correlative studies
48023107|NCT00357305|OTHER|laboratory biomarker analysis|Correlative studies
48381594|NCT01495104|DRUG|RO4917838|Multiple doses
48381595|NCT01495104|DRUG|valproate|Multiple doses
48381596|NCT06286397|DRUG|1% Clascoterone|Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
48381597|NCT06286397|DRUG|Vehicle Cream|Application of a vehicle cream to the natal cleft twice daily for 12 weeks
48381598|NCT04324814|DRUG|SHR-1701|Anti-PD-L1/TGFβ fusion protein
48716352|NCT04247126|DRUG|Fulvestrant|Estrogen receptor antagonist
48716353|NCT04247126|DRUG|Gemcitabine|Nucleoside metabolic inhibitor
48716354|NCT04247126|DRUG|Nab-paclitaxel|Taxane-type chemotherapy
48716355|NCT06225947|DRUG|Lemborexant 5 MG|The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
48716356|NCT05189249|OTHER|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
48716357|NCT04842474|OTHER|Gaze stability exercises and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
48716358|NCT01690351|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
48381599|NCT06650696|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task online designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
48381600|NCT06650696|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
48381601|NCT06650696|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training online on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
48381602|NCT04466371|OTHER|Questionnaire|A questionnaire to assess satisfaction with online learning and knowledge about COVID-19
48381603|NCT03136978|DIAGNOSTIC_TEST|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
48381604|NCT00390091|DRUG|abetimus sodium (LJP 394)|
48381605|NCT04516356|OTHER|Korean hand acupressure|According to the working principle of Korean hand acupressure; There are active points and areas in the hands and feet that fit the whole body. The active points on the hands and feet are properly matched to reflect the anatomy of the whole organism. Areas in the body and systems suitable for them are in constant contact. In the patient, the signal wave moves from the damaged point or area and reaches the appropriate point immediately. Thus, changes such as severe pain, skin discoloration, hardening, thickening and thinning in some parts of the skin occur at that point. With the stimulation of the effective point, a treatment wave occurs that heals the sick organ.
48381606|NCT06456827|OTHER|Bite force and Gcf|"change in bite force will be measured by bite force measuring device at, T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval.~Changes in the following parameters - changes in change in levels of bone turnover markers CTX and BALP using ELISA at T0(at the time of retainer delivery), T1(1 month of retainer delivery), T2(3 months of retainer delivery) and T3 (6 months of retainer delivery) ,T4 (12 months of retainer delivery) time interval"
48381607|NCT04701957|BEHAVIORAL|Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
48381608|NCT04273763|DRUG|Bromhexine Hydrochloride Tablets|Bromhexine Hydrochloride Tablets
48381609|NCT04273763|DRUG|Arbidol Hydrochloride Granules|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.
48381610|NCT04273763|DRUG|Recombinant Human Interferon α2b Spray|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.
48381611|NCT00717808|DRUG|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
48381612|NCT00717808|DRUG|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
48381613|NCT01950052|DIETARY_SUPPLEMENT|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
48381614|NCT05025904|BEHAVIORAL|Real-time fMRI neurofeedback (rt-fMRI NFB)|Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
48523001|NCT04132687|PROCEDURE|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
48716359|NCT01690351|DRUG|PF-05089771|Capsules TS formulation- fasted
48716360|NCT01428336|PROCEDURE|1 ug ACTH stimulation test|1 ug cortrosyn dose
48716361|NCT01428336|PROCEDURE|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
48716362|NCT01428336|PROCEDURE|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
48716363|NCT01428336|PROCEDURE|Insulin tolerance test|subjects will undergo an insulin tolerance test
48716364|NCT04603222|DEVICE|SUMMIT BRUSH|SUMMIT BRUSH used for the treatment of blepharitis
48716365|NCT04603222|OTHER|Ocusoft Lid Scrub Original Foaming Eyelid Cleanser|treating blepharitis with Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
48716366|NCT03997643|RADIATION|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
48716367|NCT03997643|RADIATION|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
48716368|NCT04713033|DIAGNOSTIC_TEST|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
48716369|NCT04713033|DIAGNOSTIC_TEST|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
48716370|NCT02258555|DRUG|GS-9901|GS-9901 tablets administered orally
48381615|NCT05025904|BEHAVIORAL|Сognitive behavioral therapy (CBT)|A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.
48381616|NCT05025904|BEHAVIORAL|EEG neurofeedback (EEG NFB)|EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
48716371|NCT04127799|OTHER|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
48716372|NCT04127799|OTHER|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
48381617|NCT02439593|OTHER|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
48381618|NCT02439593|OTHER|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
48381619|NCT02073591|OTHER|Ceradan Cream|
48381620|NCT02073591|OTHER|Ceradan Wash|
48381621|NCT03251443|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
48381622|NCT04358822|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after specific time intervals
48381623|NCT05068700|DEVICE|Integrated Pulmonary Index|Medtronic Capnostream 35p monitoring parameter
48716373|NCT03840525|BEHAVIORAL|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
48716374|NCT03840525|BEHAVIORAL|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
48023108|NCT06068894|DIETARY_SUPPLEMENT|"Humanized galacto-oligosaccharides (hGOS)"|10-15 g/day of hGOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage
48023109|NCT06068894|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|10-15 g/day of GOS, which will be provided to participants as a powder that can be added to any non-alcoholic beverage.
48023110|NCT06068894|OTHER|Matching Placebo|10-15 g/day powdered corn syrup comprised of fructose, glucose, and an inert cellulose material that matches the consistency, color sweetness, and taste of the prebiotics, that can be added to any non-alcoholic beverage.
48023111|NCT00054002|PROCEDURE|adjuvant therapy|Lung surgery
48023112|NCT00054002|PROCEDURE|conventional surgery|Lung surgery
48023113|NCT00054002|DRUG|porfimer sodium|iv
48023114|NCT03175640|BEHAVIORAL|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
48023115|NCT04363905|DIETARY_SUPPLEMENT|Placebo|100 mg lactose per day for 6 weeks
48023116|NCT04363905|DIETARY_SUPPLEMENT|Ferrous sulfate|20 mg per day of elemental iron for 6 weeks
48381624|NCT05068700|DEVICE|Standard capnography monitoring|Medtronic Capnostream 35p monitoring parameter
48381625|NCT06296901|OTHER|Perineal Wipe|use of perineal wipe
48381626|NCT01051076|DRUG|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
48381627|NCT00457249|BIOLOGICAL|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
48381628|NCT00457249|BIOLOGICAL|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
48381629|NCT05006313|DEVICE|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
48381630|NCT05549986|OTHER|Observational|Observational
48381631|NCT04148469|PROCEDURE|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
48523002|NCT00181714|DRUG|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
48518880|NCT04588493|DIAGNOSTIC_TEST|Lower extremity Lymphoscintigraphy|Study of lymphoscintigraphy (LCG) abnormalities in a group of patients with history of infiltration of modeling substances in buttocks and hips and complain about lower extremities edema. LCG was performed and evaluated by a single nuclear medicine specialist through injection of the sulfur nanocolloid Technetium 99m, injected intradermal and interdigital in bilateral toes. Dynamic studies were requested for all patients. Standardized acquisition times at 15, 30, 60 and 120 minutes after injection were taken. The following parameters were considered to obtain the transport index in each pelvic limb: transport kinematics, distribution pattern, index time for the appearance of regional lymph nodes, number and collection of colloids in lymph nodes and presence and quality of the colloid uptake by the lymphatic vessels. Summation of these five components resulted in the transport index, which could range from 0 to 45 points
48518881|NCT05593744|OTHER|no intervention|This is an observational study so not involved intervention
48518882|NCT01707056|OTHER|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
48518883|NCT01707056|OTHER|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
48518884|NCT01707056|OTHER|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
48716375|NCT03950713|BEHAVIORAL|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
48716376|NCT04317157|DIETARY_SUPPLEMENT|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
48716377|NCT04317157|OTHER|Placebo|Placebo pill.
48716378|NCT00613080|DRUG|capecitabine|1650 mg/m\^2/day orally 5 days/week during radiotherapy.
48716379|NCT00613080|DRUG|oxaliplatin|
48381632|NCT04148469|PROCEDURE|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
48381633|NCT04148469|PROCEDURE|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
48381634|NCT03047512|BEHAVIORAL|Experimental: Internet-based program|"* Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
48381635|NCT01752608|BEHAVIORAL|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
48381636|NCT04076982|DIETARY_SUPPLEMENT|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
48381637|NCT04076982|OTHER|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
48381638|NCT06650462|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
48381639|NCT00152594|DRUG|voriconazole|
48381640|NCT03974607|BEHAVIORAL|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
48381641|NCT01891136|DRUG|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
48381642|NCT05340049|DIAGNOSTIC_TEST|Online questionnaire of children's backgrounds|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children.
48518885|NCT01707056|OTHER|Water|Taking Synthroid with water for a period of 6 weeks.
48518886|NCT03917927|DEVICE|Eztetic dental implant|narrow diameter dental implant
48518887|NCT02380326|PROCEDURE|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
48716380|NCT00613080|PROCEDURE|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
48716381|NCT00613080|RADIATION|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
48023117|NCT05330663|DIETARY_SUPPLEMENT|Low protein diet with Fresubin® renal|Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
48716382|NCT00613080|DRUG|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1."
48716383|NCT04035096|DRUG|Ascorbic Acid|"1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
48716384|NCT04035096|OTHER|Control group|"1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care"
48023118|NCT05330663|OTHER|Low protein diet with normal food|All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
48023119|NCT02344186|DRUG|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
48023120|NCT03698955|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
48381643|NCT05340049|OTHER|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
48381644|NCT05340049|PROCEDURE|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (placebo, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the therapies were expressed as percentages of satisfaction with the classifications of 25% (apparent changes less than half of the sample in each therapy group), 50% (apparent changes in half of the sample plus one in each therapy group) and 75-100% (apparent changes in all or almost all of the sample in each therapy group)."
48381645|NCT03971422|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
48381646|NCT03971422|OTHER|Placebo|Subjects will receive placebo at pre-specified time points.
48381647|NCT05190562|DRUG|Zinc Sulfate 110 MG (Zinc 25 MG) Oral Tablet|Zinc sulfate is an inorganic compound. It is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk
48381648|NCT05186974|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
48381649|NCT05186974|DRUG|Pembrolizumab|Administered intravenously
48716385|NCT03322501|BEHAVIORAL|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
48716386|NCT01656629|DRUG|Teriparatide|20 mcg subq daily for 3 months
48023121|NCT03698955|OTHER|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
48023122|NCT06560541|OTHER|UKMRC9|UKMRC9 is a low glycemic index and polyphenol-rich red pigmented rice
48023123|NCT06560541|OTHER|White rice|White rice refers to a local polished rice
48023124|NCT03322306|GENETIC|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
48023125|NCT06235749|DRUG|Calcium Gluconate 10%|Administration of Calcium Gluconate 10% IV following umbilical cord clamping
48023126|NCT06235749|DRUG|sodium chloride 0.9%|Administration of sodium chloride 0.9% IV following umbilical cord clamping
48023127|NCT00000463|DRUG|lovastatin|
48381650|NCT05186974|DRUG|Carboplatin|Administered intravenously
48381651|NCT05186974|DRUG|Cisplatin|Administered intravenously
48518888|NCT03854760|BEHAVIORAL|anesthesiologist with limited experiment|Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
48716387|NCT01656629|DRUG|Alendronate|70 mg weekly for 3 months
48716388|NCT01656629|DIETARY_SUPPLEMENT|calcium and vitamin D|
48716389|NCT02321891|DEVICE|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
48716390|NCT00343915|BIOLOGICAL|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, \& 6)
48716391|NCT00343915|BIOLOGICAL|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)
48381652|NCT03654495|OTHER|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (\~1 min) for game change."
48518889|NCT04118491|DEVICE|hyperbaric oxygen and sham hyperbaric oxygen|see arm descriptions
48518890|NCT01331993|DRUG|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
48716392|NCT00343915|BIOLOGICAL|placebo|In the primary study: 1 deep intramuscular injection (month 1)
48716393|NCT03964753|DRUG|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
48716394|NCT03964753|PROCEDURE|surgery|surgery
48716395|NCT05410262|OTHER|Evaluation of CT images|A helicoidal CT scanner will be used (Aquilion CXL, Toshiba, Japan), with AIDR 3D technique (Adaptive Iterative Dose Reduction 3D) in order to minimize exposure to X-rays. Two complete thorax CT scans will be performed, one of them in expiratory pause (PEEP) and the other in inspiratory pause (PPlat). Esophageal pressure shall be measured (FluxMed GrT, Argentina) and transpulmonary pressure will be calculated at the end of inspiration (Ppl-insp) and expiration (Ppl-exp).
48716396|NCT04266509|DRUG|PF-06651600|50 milligram (mg) tablet
48716397|NCT04266509|DRUG|Rifampin|600 mg provided as two 300 mg capsules.
48518891|NCT01331993|DRUG|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
48523003|NCT03879785|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
48716398|NCT00152568|BEHAVIORAL|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
48716399|NCT00467675|DEVICE|CGM System for Type 1 and Type 2 Diabetes Mellitus|
48716400|NCT02187315|DEVICE|Chrono-chemotherapy pump:Melodie|
48716401|NCT02187315|DEVICE|Routine intravenous drip|
48716402|NCT02187315|DRUG|induction chemotherapy|
48716403|NCT02187315|DRUG|cisplatin chrono-chemotherapy|
48716404|NCT02187315|RADIATION|intensity-modulated radiation therapy|
48716405|NCT02187315|DRUG|cisplatin routine-chemotherapy|
48716406|NCT02227823|DRUG|Pyridostigmine Bromide|
48716407|NCT03036462|DRUG|Iron|i.v. iron administration
48716408|NCT03036462|DRUG|Saline|i.v. NaCl administration
48716409|NCT01217320|DIETARY_SUPPLEMENT|creatine|5g/d throughout 12 weeks
48023128|NCT00000463|DRUG|cholestyramine|
48023129|NCT00000463|DRUG|warfarin|
48023130|NCT05797779|PROCEDURE|Skin biopsy|Punch biopsy of the skin
48023131|NCT01813526|OTHER|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
48023132|NCT05352074|PROCEDURE|subtotal colectomy with cecal-rectal anastomosis|The intervention involves, after a complete mobilization of the colon, a resection 2-3 cm distal to the ileocecal junction and at the upper part of the rectal ampulla; the cecum is then lowered into the pelvis, without any rotation, and an antiperistaltic cecorectal anastomosis is performed between the cecal fundus (after appendectomy) and the rectum, after introduction of a stapler through the cecal resection line. In the laparoscopic approach we use 5 trocars (trocar 1 periumbilical, trocars 2-3-4-5 drawing a 15-cm side square around trocar 1), using a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The cecal-rectal anastomosis is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
48023133|NCT05352074|PROCEDURE|total colectomy with ileorectal anastomosis|After a complete mobilization of the colon, a resection 2-3 cm proximal to the ileocecal junction is conducted. Use a Pfannestiel incision to perform the anastomosis and to remove the resected colon. The ileorectal anastomosis (end to end) is performed by introducing the stapler via the anus, with the intention of carrying out a ''cleaner,'' ''tensionless'' procedure.
48023134|NCT00351780|DEVICE|FFR measurement, side branch angioplasty|
48023135|NCT01105533|DRUG|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
48023136|NCT01105533|DRUG|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
48023137|NCT01105533|DRUG|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
48023138|NCT01105533|DRUG|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
48023139|NCT01105533|DRUG|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
48023140|NCT01105533|DRUG|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
48023141|NCT01105533|DRUG|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
48716410|NCT01217320|DIETARY_SUPPLEMENT|placebo (dextrose)|5g/d throughout 12 weeks
48716411|NCT05128006|OTHER|New patient teledermatology visit|new patient teledermatology visits
48716412|NCT04594460|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.
48716413|NCT04594460|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
48518892|NCT01331993|DRUG|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
48518893|NCT06364059|PROCEDURE|Decompressive craniectomy with evacuation of subdural hematoma|Adult patients who underwent decompressive craniectomy with evacuation of subdural hematoma.
48023142|NCT01105533|DRUG|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
48023143|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
48023144|NCT01105533|DRUG|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
48023145|NCT03793101|PROCEDURE|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
48023146|NCT05806762|DEVICE|BioIntellisense|Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
48023147|NCT05747677|DRUG|HH-120 Nasal Spray|HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
48023148|NCT06431750|OTHER|Secukinumab|This is an observational study, there is no treatment allocation.
48023149|NCT02680691|OTHER|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
48023150|NCT02680691|OTHER|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
48023151|NCT01384344|OTHER|observational|Observation during a physical exercise
48023152|NCT05570695|BEHAVIORAL|attention right training, ARTNF|In a first verum neurofeedback condition, participants will be instructed to focus attention on their right hand and the up-regulation of alpha oscillations in the right hemisphere relative to alpha oscillations in the left hemisphere will be incentivized through neurofeedback.
48023153|NCT05570695|BEHAVIORAL|attention left training, ALTNF|In a second verum neurofeedback condition, participants will be instructed to focus attention on their left hand and the down-regulation of right relative to left alpha oscillations will be incentivized.
48023154|NCT05570695|BEHAVIORAL|sham attention right training, ARTsham|During the first sham neurofeedback condition, participants will be instructed to focus attention on their right hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ARTNF for ARTsham, will be replayed (yoked feedback).
48023155|NCT05570695|BEHAVIORAL|sham attention left training, ALTsham|During the second sham neurofeedback condition, participants will be instructed to focus attention on their left hand. However, the feedback signal will not mirror their brain activity. Instead, the feedback signal and the corresponding reward of the last matching verum condition completed by a previous participant, i.e., ALTNF for ALTsham, will be replayed (yoked feedback).
48023156|NCT00857194|PROCEDURE|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
48023157|NCT00857194|PROCEDURE|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
48023158|NCT04791358|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
48023159|NCT04931849|DRUG|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
48023160|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
48023161|NCT01259544|DRUG|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
48023162|NCT00188097|BEHAVIORAL|Diagnosis of variceal bleeding and dits control in cirrhosis|
48023163|NCT05802745|OTHER|Reintubation|Patients requiring re-intubation for acute respiratory failure.
48023164|NCT00273611|BEHAVIORAL|Pharmacist Education about Vitamin D|
48023165|NCT06294002|OTHER|Dynamic neuromuscular stabilisation group|DNS group protocol involved 5 min a moderate intensity warm-up, 40 minutes of DNS movements according to the DNS approach, different diaphragmatic breathing, mobility and controlled movement exercises and 5 minutes of cool-down. Exercises gradually increased in complexity and difﬁculty level regarding DNS training principles. The participants were instructed to refrain from engaging in high-intensity anaerobic or anaerobic resistance training throughout the study period to prevent potential disruptions in the study results.
48023166|NCT06294002|OTHER|Whole body vibration group|WBV was performed on the Power Plate Next Generation vibration platform (Power Plate North America, Chicago, IL). All training routines were approximately 50 minutes long, commencing with 5 minutes of moderate-intensity warm-up and concluding with a cool-down period. The program consisted of 8-10 static and dynamic exercises for PS that progressively increased in difficulty and complexity. During the training process, the frequency increased from 20 to 35 Hz in the last week of the experiment; the exercise duration was from 20 - 60 seconds (in the previous week), followed by 1-minute seated rest. Moreover, the complexity and difficulty of exercise increased over the experimental period. The resting period between sets was constant from the start to the end of the training process. During the experiment, the WBV intervention group performed three weekly training sessions.
48381653|NCT03654495|OTHER|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
48381654|NCT05109169|COMBINATION_PRODUCT|FINGER 2.0 multidomain lifestyle-based intervention|"Multimodal lifestyle-based precision prevention intervention, including:~* Optimized FINGER multidomain lifestyle intervention (diet, physical activity, cognitive training and cardiovascular/metabolic risk monitoring and social interaction)~* Metformin (Glucophage® XR)"
48381655|NCT05109169|OTHER|Self-guided multidomain lifestyle intervention|Participants build their own healthy lifestyle program based on standard healthy lifestyle advice on diet, physical activity, cognitive training and cardiovascular/metabolic risk
48381656|NCT03313388|DIETARY_SUPPLEMENT|Drink|Beverage to be consumed
48381657|NCT02801734|OTHER|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
48381661|NCT03459066|DIAGNOSTIC_TEST|Institution-Group|"The study includes three measurement times:~* Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~* Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~* Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
48381662|NCT00472004|DRUG|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
48381663|NCT00472004|DRUG|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
48381664|NCT05879341|OTHER|High intensitiy interval training|The participants will perform HIIT at 85% of their heart rate reserve. There will be 8 cycles of high intensity with four minutes of rest intervals in between.
48716414|NCT04782947|DEVICE|Exoskeletal assisted walking|Exoskeletal assisted walking includes the use of robotic suit to train participant to walk with different level of assistance.
48716415|NCT04782947|DEVICE|Epidural Stimulation|lumbo-sacral epidural simulation at the beginning of the study.
48716416|NCT04782947|PROCEDURE|Resistance Training|Using two forms of resistance training to increase muscle size. The first form includes seated leg extension exercise for 12 weeks followed by a second form that includes sit-to-stand exercise using participant's body weight.
48716417|NCT04782947|DEVICE|delayed-ES|lumbo-sacral epidural simulation starting 6 months after the beginning of the study.
48716418|NCT04782947|PROCEDURE|no-Resistance training|The participants will perform 24 weeks of passive movement or passive stretching from seated position.
48180550|NCT06454305|OTHER|Blow Bottle Technique|A 1-liter plastic bottle was filled with water to a height of 10 centimeters for this intervention. The water in the bottle was filled using a 30-cm-long tube that was placed 8 cm down. The participants were instructed to sit on a bed with comfortable position, Hold the bottle with one hand and the tube with the other Blowing Technique, Put the tube in mouth by holding lips firmly, Breath in through nose and out through mouth, Blowing enough water is bubbled, Short Breaks for 2 to 3 mints, When mucus rises up get out of it by coughing or huffing
48180551|NCT01486381|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
48180552|NCT00522743|DRUG|growth hormone and gonadotropin-releasing hormone agonist|GH \& GNRHa treatment
48180553|NCT00522743|DRUG|growth hormone|GH treatment
48180554|NCT05124288|OTHER|Observations on Relapsed AML Allogeneic Transplanted patients|This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
48180555|NCT04670770|DRUG|Drug - SHR1459|Oral Tablets taken once daily for 52 weeks
48180556|NCT03373851|DEVICE|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
48518894|NCT02683421|DRUG|Tilmanocept|
48716419|NCT05873036|DIAGNOSTIC_TEST|Aerobic Training|Aerobic Training to Improve Functional Ability After Breast Cancer Surgery
48716420|NCT05873036|DIAGNOSTIC_TEST|Progressive Resistance Training|Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery
48716421|NCT03653468|BEHAVIORAL|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
48180557|NCT02580175|PROCEDURE|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
48716422|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
48716423|NCT06138925|OTHER|Analysis of running|analysis of running on flat ground at different speeds (comfortable and fast)
48716424|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
48518895|NCT00321191|DRUG|No nitrous oxide|
48518896|NCT00321191|DRUG|Administration of N2O|
48518897|NCT05061589|PROCEDURE|permanent colostomy|An operation that creates an opening for the colon through the abdomen
48381665|NCT06653829|DEVICE|SPARK|A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
48716425|NCT01565564|BEHAVIORAL|Shared glycaemic control care within the local three-tier's antenatal care network|"* Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;"
48180558|NCT02580175|PROCEDURE|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
48716426|NCT04438876|OTHER|Functional Power Training|The exercise intervention encompassed high-velocity movement, balance, and mobility exercises with the use of body weight and resistance bands as resistance. Participants were instructed to move rapidly during the concentric phase and slowly during the eccentric phase when performing the dynamic exercises.
48716427|NCT04438876|OTHER|Usual care|Participants either continued the usual exercise program provided by their respective community senior activity centers or their personal exercise routine.
48180559|NCT03654768|DRUG|Bosutinib|Given PO
48180560|NCT03654768|DRUG|Dasatinib|Given PO
48381666|NCT04143477|DRUG|peficitinib|Oral
48381667|NCT06649877|BIOLOGICAL|MK-6194|single injected dose
48518898|NCT05220644|PROCEDURE|Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection
48518899|NCT06581458|DRUG|tDCS|The immediate intervention group will continue to receive five tDCS treatments per week for 6 months. The late intervention group will receive five sham treatments per week for 3 months and then begin receiving five weekly tDCS treatments for an additional 3 months.
48518900|NCT06581367|DRUG|Tailoring the course duration to the patient's needs.|Patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment including vital signs (temperature, blood pressure, respiratory rate, pulse, and oxygen saturation) and C-reactive protein rapid testing after completing two full days of antibiotic.
48716428|NCT05118802|OTHER|Interview|Attends Interviews
48716429|NCT05118802|OTHER|Survey Administration|Complete Survey
48716430|NCT05736003|PROCEDURE|Laparoscopic cholecystectomy|Removal of gallbladder laparoscopically
48180561|NCT03654768|OTHER|Laboratory Biomarker Analysis|Correlative studies
48180562|NCT03654768|DRUG|Nilotinib|Given PO
48180563|NCT03654768|DRUG|Ruxolitinib|Given PO
48180564|NCT03654768|DRUG|Imatinib|Given PO
48381668|NCT03755960|PROCEDURE|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
48381669|NCT03755960|DRUG|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
48381670|NCT05232318|OTHER|Leveling and alignment|Root resorption comparison through the use of CBCT
48381671|NCT02137031|DEVICE|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
48518901|NCT06581367|DRUG|Complete a 7-day course|The antibiotic course must be completed (7 days at least).
48518902|NCT02819089|DRUG|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
48518903|NCT02819089|OTHER|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
48716431|NCT05545865|OTHER|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
48180565|NCT02296892|DRUG|Remimazolam|For induction and maintenance of sedation
48180566|NCT02296892|DRUG|Placebo|Inactive control arm
48180567|NCT02296892|DRUG|Midazolam|For induction and maintenance of sedation
48716432|NCT05545865|OTHER|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
48716433|NCT05545865|OTHER|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
48716434|NCT05545865|OTHER|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
48716435|NCT05545865|OTHER|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
48716436|NCT06243120|DRUG|Lidocaine IV|The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
48716437|NCT00139256|DRUG|Betamethasone|Betamethasone injection
48023167|NCT06294002|OTHER|Dynamic neuromuscular stabilisation with whole body vibration group|The MIX group underwent a two-month training program consisting of three weekly sessions, including a 50-minute exercise program with a 5-minute warm-up and cool-down period. The training included 20 minutes of WBV and 20 minutes of DNS training, following previous research and training recommendations. VIBRO exercises were performed on the Power Plate Next Generation vibration platform, with 6-8 exercises for balance and PS. Participants were advised not to engage in high-intensity anaerobic or anaerobic resistance training. The training protocol was adapted from previous research.
48023168|NCT05341089|DRUG|LY3502970|Administered orally.
48023169|NCT03684798|OTHER|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
48023170|NCT03684798|OTHER|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
48180568|NCT01806935|DEVICE|DC086|
48180569|NCT01806935|DEVICE|Placebo|
48716438|NCT00563862|PROCEDURE|Conventional RT|
48716439|NCT00563862|PROCEDURE|Accelerated RT|
48180570|NCT03828188|DIETARY_SUPPLEMENT|Red Ginseng Concentrated Powder|Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
48180571|NCT03828188|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
48180572|NCT04291209|DRUG|N-Acetyl Cysteine|One ear will be randomly chosen for the experimental treatment of intratympanic NAC. The other ear will serve as the control ear which will not receive any injection.
48716440|NCT00563862|DRUG|Cisplatin|
48716441|NCT00563862|DRUG|5-fluorouracil|
48716442|NCT03817294|OTHER|Comparison of exercise training modalities|As above
48716443|NCT01694277|DRUG|Masitinib|12 mg/kg/day
48716444|NCT01694277|DRUG|Sunitinib|50 mg/day
48716445|NCT05009602|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
48023171|NCT02464501|OTHER|Paclitaxel administration using the OPC|
48023172|NCT04242316|BEHAVIORAL|Mirror Therapy|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.
48023173|NCT04242316|BEHAVIORAL|Bilateral arm training|Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks, but without a mirror. The patients can take a direct view of their paretic hand.
48180573|NCT03965780|OTHER|SPIN-SSLED Program|"The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups."
48180574|NCT03757871|DEVICE|Laser stimulation|an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
48716446|NCT05009602|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery.
48716447|NCT05009602|DIAGNOSTIC_TEST|Exercise Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery, following the participant completing 50 consecutive repetitions of active dorsiflexion whilst standing.
48716448|NCT05009602|DIAGNOSTIC_TEST|Audible handheld Doppler|Audible CW Doppler interrogation of the dorsalis pedis and posterior tibial artery.
48716449|NCT05009602|DIAGNOSTIC_TEST|Visual handheld Doppler|Visual CW interrogation of the dorsalis pedis and posterior tibial artery was performed using the handheld Huntleigh Digital Dopplex device.
48381672|NCT06327048|OTHER|Individual cognitive rehabilitation training based on Remind strategy was given|This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function
48381673|NCT05707806|DEVICE|MRI|Enables the use of custom pulse sequence
48381674|NCT06323265|DRUG|Adebrelimab + chemotherapy|Adebrelimab: 1200mg, d1, iv (30-60min), Q3W ,up to progressive disease or toxicity intolerable Chemotherapy: etoposide 100mg/m2，d1-3，iv；carboplatin AUC=5-6，d1，iv；or cisplatin 75mg/m2，d1，iv，Q3W，4 cycles；
48381675|NCT06323265|RADIATION|±chest radiotherapy|Chest radiotherapy: 3Gy/15f-18f or 2Gy/20f-25f
48180575|NCT04561778|DEVICE|HOT-CRT|Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.
48180576|NCT04561778|DEVICE|Biventricular Pacing|Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
48381676|NCT02918318|DRUG|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
48381677|NCT02918318|DRUG|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
48381678|NCT02918318|DRUG|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
48381679|NCT02918318|DRUG|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
48381680|NCT02185027|OTHER|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
48381681|NCT05631756|OTHER|Lung Ultrasound|Evaluation of the Lung Ultrasound Score in patients presenting an interstitial syndrom on the lung ultrasound and to compare it with PaO2/FiO2
48716450|NCT05009602|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|"Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.~To be used in 3 participating centers only."
48381682|NCT02796365|OTHER|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
48716451|NCT02084238|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
48716452|NCT02220751|DRUG|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
48716453|NCT02220751|PROCEDURE|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
48180577|NCT03118245|DEVICE|AuraGain|After anesthetic induction, AuraGain is inserted in children
48180578|NCT03118245|DEVICE|I-gel|After anesthetic induction, I-gel is inserted in children
48381683|NCT05123807|OTHER|Cytoreductive surgery|(an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy
48381684|NCT03239340|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
48381685|NCT00759369|OTHER|Water prescription|Water prescription in 12 to 16 equally divided doses
48381686|NCT00490399|DRUG|gemcitabine|
48381687|NCT00490399|DRUG|cisplatin|
48381688|NCT00981565|PROCEDURE|open carpal tunnel release|surgery to release the carpal tunnel
48381689|NCT00981565|OTHER|Night-cast|individual night time splinting
48381690|NCT04575987|OTHER|Questionnaire|"Questionnaires will be sent by email or by post, in which questions about PFD, obstetrical history or dietetic follow-up will be asked.~Some obstetrical issues will be get from women medical files."
48381691|NCT04998396|BIOLOGICAL|AAV9 BBP-812|Sterile solution for injection for 1-time use via volumetric infusion pump
48381692|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
48381693|NCT00681447|PROCEDURE|Lumbar Interlaminar Epidural injection|"1. Lumbar interlaminar epidural injections under fluoroscopy~2. Epidural tray and needle~3. Drugs:~0.5% Xylocaine and non-particulate Celestone"
48381694|NCT03305926|OTHER|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
48523004|NCT04537884|DRUG|UBX1325|Investigational drug intravitreal injection
48023174|NCT03701477|BEHAVIORAL|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
48023175|NCT03701477|BEHAVIORAL|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
48180579|NCT04443959|BEHAVIORAL|PUMAS|Treatment consists of 6 weekly telemedicine sessions during pregnancy.
48023176|NCT05595798|DIAGNOSTIC_TEST|Airmod breathing sound monitoring|Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
48180580|NCT02287233|DRUG|Venetoclax|Venetoclax will be taken orally once daily.
48518904|NCT01938495|DEVICE|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
48716454|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48716455|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48716456|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48716457|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
48716458|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
48716459|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
48716460|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
48716461|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
48716462|NCT03899064|DRUG|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
48716463|NCT04110470|DIAGNOSTIC_TEST|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
48716464|NCT04110470|DIAGNOSTIC_TEST|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
48716465|NCT01009346|DRUG|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001"
48716466|NCT01009346|DRUG|Cetuximab|250mg/m2/week
48716467|NCT01009346|DRUG|Cisplatin|40mg/m2 Day 1, 8 every 28 days
48716468|NCT01009346|DRUG|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
48716469|NCT00930969|DEVICE|ICD|Subjects implanted with an ICD.
48716470|NCT02080260|DRUG|regorafenib|Single agent drug therapy with regorafenib
48716471|NCT06036953|DEVICE|electrical muscle stimulation|The electric muscle stimulator (EMS) used in this study was from Funcare (Funcare Co., Ltd, Taichung, Taiwan). EMS electrodes were attached to the biceps of both hands, the abdomen, and the quadriceps of both legs sequentially. Each part was stimulated once a day for 30 minutes.
48023177|NCT06531759|DRUG|Fentanyl|Fentanyl soaked nasal packs.
48023178|NCT05418621|DRUG|Enamel Matrix Derivative application|in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
48023179|NCT05418621|OTHER|Saline application|in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
48180581|NCT02287233|DRUG|Cytarabine|Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
48716472|NCT01582048|DRUG|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
48180582|NCT02227797|DRUG|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
48180583|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate.|Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate in patients with hydrosalpinx prior to IVF
48523005|NCT00020631|DRUG|pirfenidone|
48716473|NCT01837667|DRUG|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
48716474|NCT01837667|DRUG|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
48716475|NCT01048866|DRUG|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
48716476|NCT01048866|DRUG|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
48518905|NCT02661217|DRUG|LCZ696|"LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient."
48716477|NCT01048866|DRUG|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
48716478|NCT02673320|PROCEDURE|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
48716479|NCT02673320|PROCEDURE|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
48716480|NCT04641949|PROCEDURE|Lower body negative pressure (LBNP)|LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
48716481|NCT05238259|DEVICE|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
48716482|NCT05238259|DEVICE|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
48716483|NCT04400578|DEVICE|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
48180584|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)
48023180|NCT03117335|DRUG|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
48180585|NCT06378697|DRUG|AK111|Drug: AK111 subcutaneous injection at week 0,1, 4 and 4-weekly thereafter until week 48.
48716484|NCT03211026|OTHER|No intervention|No intervention
48023181|NCT03117335|DRUG|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
48180586|NCT06378697|DRUG|Placebo+AK111|Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.
48180587|NCT03245177|BIOLOGICAL|Pembrolizumab|Anti-PD-1 antibody
48381695|NCT03305926|OTHER|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
48381696|NCT03305926|OTHER|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
48023182|NCT06538532|OTHER|Zamzam water|Zamzam water
48180588|NCT03245177|RADIATION|Radiotherapy|60-66 Gy in 30-33 fractions, 2 Gy per fraction
48180589|NCT01426347|DRUG|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
48180590|NCT01426347|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
48381697|NCT03305926|OTHER|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
48381698|NCT04234516|DRUG|Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film|3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
48381699|NCT04234516|DRUG|Morphine Sulfate 30 mg|oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
48381700|NCT05156060|DRUG|Gabapentin|Taken by mouth 3 times per day
48381701|NCT05156060|DRUG|Ketamine|Administered intranasally 3 times per day
48381702|NCT05948826|DRUG|TORL-3-600|antibody drug conjugate
48381703|NCT06332924|BEHAVIORAL|motivational discussion group|There will be 3 interviews with the motivational interview group, one week apart.
48381704|NCT01267227|DRUG|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
48023183|NCT00548782|OTHER|Paleolithic diet|diet
48023184|NCT00548782|OTHER|ADA ( American Diabetes Association) recommended diet|diet
48023185|NCT03402243|OTHER|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
48023186|NCT03402243|OTHER|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
48023187|NCT03402243|OTHER|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
48023188|NCT02555410|DEVICE|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
48023189|NCT02956629|DRUG|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
48023190|NCT02956629|DRUG|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
48023191|NCT02956629|DRUG|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
48023192|NCT05977595|OTHER|Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries|Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
48023193|NCT04333277|OTHER|Probiotic|Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
48023194|NCT04333277|OTHER|Maltodextrin|Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
48023195|NCT05855629|DIETARY_SUPPLEMENT|Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule|Lactobacillus Rhamnosus 1,5 х 10\*9, Inulin 25mg, D-chiro-inositol 250mg
48023196|NCT05855629|DRUG|Topical Adapalene, Benzoyl Peroxide Gel|Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
48023197|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
48023198|NCT01146938|DRUG|fimasartan|single administration of fimasartan 120mg
48023199|NCT03041610|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
48023200|NCT02097875|DRUG|BLZ-100|
48023201|NCT04260191|DRUG|AMG 910|IV Infusion
48023202|NCT02262845|DEVICE|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
48023203|NCT06398353|OTHER|Real acupuncture|Real acupuncture twice a week for two weeks
48023204|NCT06398353|OTHER|Sham acupuncture|Sham acupuncture twice a week for two weeks
48023205|NCT04112849|DIAGNOSTIC_TEST|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
48023206|NCT03843502|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
48023207|NCT05031624|DRUG|CDX-0159|Single subcutaneous dose of one of four dosages of CDX-0159
48023208|NCT05031624|DRUG|Normal saline|Single subcutaneous dose of normal saline
48023209|NCT05871164|PROCEDURE|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
48023210|NCT06003595|OTHER|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
48023211|NCT04183933|OTHER|Pilates Exercise|Pilates exercises will be given for 6 weeks, 3 days in a week.
48023212|NCT04183933|OTHER|Combined Exercise|Combined exercise will be given for 6 weeks, 3 days in a week.
48023213|NCT04351152|BIOLOGICAL|Lenzilumab|Administered as an intravenous (IV) infusion
48023214|NCT04351152|DRUG|Standard of Care|Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
48023215|NCT04552873|DRUG|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
48023216|NCT04552873|OTHER|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
48023217|NCT02098343|DRUG|APR-246|Intravenous infusion.
48023218|NCT02098343|DRUG|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
48023219|NCT05243108|DIETARY_SUPPLEMENT|dietary nucleotides|1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
48023220|NCT05243108|DIETARY_SUPPLEMENT|placebo|placebo
48518906|NCT03980535|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48518907|NCT03980535|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
48518908|NCT03545542|DIAGNOSTIC_TEST|Initial fecal microbiome|Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
48518909|NCT03545542|DIAGNOSTIC_TEST|Initial fecal volatile organic compounds|Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
48518910|NCT03545542|DIAGNOSTIC_TEST|Initial breath volatile organic compounds|Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
48518911|NCT03545542|DIAGNOSTIC_TEST|Microbiome under chemotherapy|Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to Société Internationale d´Onclogie Pediatrique Neuroblastoma Group (SIOPEN) guidelines
48716485|NCT01032317|DEVICE|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
48716486|NCT05957029|DEVICE|NuEra Tight RF system|monopolar radiofrequency device
48716487|NCT06279702|OTHER|SERIOUS GAME|Students will play serious game that about first aid.
48716488|NCT06279702|OTHER|COMICS|students will learn comics that about first aid.
48180591|NCT02780505|DRUG|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
48180592|NCT02780505|DRUG|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
48180593|NCT05079594|OTHER|Mother voice|"Five minutes before the procedure, the mother's voice recording will be played to the baby and the speaker will be placed 30 cm away from the baby. The baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins. Physiological values of the baby will be noted by the researcher 1 minute before the procedure.As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher. After the procedure, the recording will continue to be played until the baby's mother's voice returns to the basal values. Physiological values and comfort levels of the baby will be noted by the researcher 1 minute and 2 minute after the procedure. 2 minutes after the procedure, the baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale."
48180594|NCT05079594|OTHER|White noise|"Before Operation The decibel meter will be set to an average of 50-60 dB and the speakers will be played at a distance of 30 cm.~Intervention in this group will be made at the elevation. White noise will be played five minutes before the procedure.The baby's comfort level and physiological values will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins.~Order of Operation As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher.~Post-Processing After the procedure, white noise will continue to be listened to until the baby's physiological values return to basal values. Physiological values and baby's comfort level of the baby will be noted by the researcher 1 minute and 2 minute after the heel blood collection is completed."
48180595|NCT05090267|DIETARY_SUPPLEMENT|Probiotic Supplement|Participants will take a probiotic supplement or placebo for 90 days.
48180596|NCT05090267|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
48381705|NCT01267227|DRUG|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
48716489|NCT00475215|DRUG|Sugammadex|Sugammadex solution for injection.
48716490|NCT00475215|DRUG|Rocuronium|Rocuronium bromide solution for injection.
48716491|NCT02439567|DEVICE|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
48716492|NCT03791853|DIAGNOSTIC_TEST|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
48716493|NCT04679844|DEVICE|MagnetOs Putty|MagnetOs Putty use in instrumented posterolateral fusion, 5cc-10cc mixed with autograft bone in a 1:1 ratio per spine level at the randomized assigned side.
48381706|NCT01267227|DRUG|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
48518912|NCT03545542|DIAGNOSTIC_TEST|Fecal volatile organic compounds under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
48716494|NCT04679844|DEVICE|Demineralized Bone Matrix mixed with Autograft Bone|Demineralized Bone Matrix mixed with Autologous bone graft used in instrumented posterolateral fusion, 5cc-10cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side.
48716495|NCT00069524|DRUG|oyster mushroom|
48180597|NCT05423483|BEHAVIORAL|Safe Home Text Message Reminders|Text messages sent 2x a week with reminders to keep lethal means restricted and surveys of lethal means practices that serve as a prompt to adhere to suggested restriction measures.
48381707|NCT01267227|DRUG|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
48381708|NCT05319652|BEHAVIORAL|Pain self-management program|Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
48381709|NCT05571618|DRUG|ADC|Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
48381710|NCT06103617|DRUG|Penicillamine|Participants in this group are treated with Penicillamine (250mg each time, 4 times per day) during reradiation.
48381711|NCT03857425|DRUG|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3\*420mg,twice daily for 8 weeks
48381712|NCT03857425|DRUG|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
48381713|NCT03857425|DRUG|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3\*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3\*350mg, three times daily for 8 weeks
48381714|NCT05643859|DIETARY_SUPPLEMENT|Dietary Fiber|Given PO
48381715|NCT05643859|PROCEDURE|Proctoscopy or anoscopy with Biopsy|Undergo proctoscopy or anoscopy
48180598|NCT05732805|BIOLOGICAL|BCD-217|Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
48180599|NCT05732805|BIOLOGICAL|BCD-100|Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
48381716|NCT05643859|PROCEDURE|Colonoscopy|Undergo Colonoscopy
48381717|NCT05643859|OTHER|Questionnaire Administration|Ancillary studies
48518913|NCT03545542|DIAGNOSTIC_TEST|Breath volatile organic compounds under chemotherapy|"Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
48518914|NCT03545542|DIAGNOSTIC_TEST|Final microbiome|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
48180600|NCT05732805|BIOLOGICAL|Placebo|Placebo
48180601|NCT04592497|PROCEDURE|AF ablation|Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
48381718|NCT00840762|OTHER|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
48381719|NCT00840762|OTHER|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
48381720|NCT00940446|DEVICE|Insorb staples|absorbable staples required for wound closure
48381721|NCT00940446|DEVICE|metal staples (Ethicon metal stapler)|wound closure with metal staples
48381722|NCT05847621|BEHAVIORAL|Peer recovery coaching with linkage to recovery resources|Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.
48381723|NCT05847621|BEHAVIORAL|Usual Care|Participants will be provided with a list of community recovery resources.
48381724|NCT05003752|RADIATION|External beam radiation therapy, High-dose-rate brachytherapy|Combined hypofractionated external beam radiation therapy (EBRT) plus high dose-rate brachytherapy (HDR-BT) schedule (total dose of EBRT 36 Gy/ in 12 fractions of 3 Gy plus HDR-BT with a total physical dose of 14 Gy in a single fraction)
48381725|NCT05003752|DRUG|Goserelin 10.8 mg|Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
48381726|NCT03290131|DRUG|Arbaclofen|Arbaclofen Extended Release Tablet
48381727|NCT03290131|DRUG|Placebo|Placebo comparator
48381728|NCT00703261|DRUG|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
48381729|NCT00703261|DRUG|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
48381730|NCT05934305|BEHAVIORAL|Matter Intervention|This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.
48180602|NCT01677299|DRUG|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
48180603|NCT01677299|DRUG|EFB0026 (metformin immediate-release)|Active comparator
48180604|NCT02402322|BEHAVIORAL|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
48180605|NCT02402322|BEHAVIORAL|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
48180606|NCT02466243|DRUG|JBT-101|"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
48381731|NCT05934305|BEHAVIORAL|Control Condition|The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
48518915|NCT03545542|DIAGNOSTIC_TEST|Final fecal volatile organic compounds|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
48716496|NCT05995977|BEHAVIORAL|Nursing interventions based on protection motivation theory in patients with hypertension|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
48716497|NCT04754685|DRUG|Intra-articular injection of platelet-rich plasma|The patient was put in 20 degree flexion in supine position with the knee. Under aseptic conditions, a 21-gage needle was used to inject 5 mL of PRP into the suprapatellar knee joint pouch, using a superolateral method. Local anesthetics were not used. Patients were instructed after the injection to refrain from physical exercise for at least 24 hours but no restriction was specified regarding activities of daily living. Three IA-PRP injections were administered at 2-week intervals. The same physician who was engaged in selecting and testing participants did the injections
48716498|NCT04528459|DEVICE|Stryker© ADAPT™ platform|The ADAPT system is a software platform that utilizes augmented reality to assist surgeons with implant alignment, lag screw length and positioning, and distal interlocking screw placement for cephalomedullary fixation of peritrochanteric femur fractures.
48716499|NCT04528459|RADIATION|Traditional fluoroscopy|For patients in the control group, traditional fluoroscopy will be utilized for placement of the cephalomedullary nail.
48180607|NCT02466243|DRUG|Placebo|"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
48180608|NCT02125071|OTHER|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
48180609|NCT02358447|PROCEDURE|TKR|non-navigated versus computer-navigated total knee replacement
48180610|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
48716500|NCT00002762|BEHAVIORAL|patient interviewing to obtain menstrual history|
48716501|NCT00002762|PROCEDURE|blood sampling|
48716502|NCT00002465|DRUG|megestrol acetate|
48716503|NCT02179255|DRUG|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
48716504|NCT02179255|DRUG|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
48716505|NCT03571672|DRUG|DEFINITY|All subjects will receive a single dose of DEFINITY®
48381732|NCT02892435|DEVICE|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
48381733|NCT02892435|DEVICE|conventional dressing|positioning conventional dressing
48716506|NCT03755232|DIETARY_SUPPLEMENT|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
48716507|NCT03755232|OTHER|Control|water or dextrose or white bread
48180611|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
48180612|NCT00981539|PROCEDURE|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
48180613|NCT02900898|OTHER|Dynamic exercise and Mediterranean diet|DE, MD
48180614|NCT02900898|OTHER|Dynamic exercise|DE
48180615|NCT02900898|OTHER|Mediterranean diet|MD
48180616|NCT02900898|OTHER|Control|Control
48180617|NCT02830529|BEHAVIORAL|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
48180618|NCT02830529|BEHAVIORAL|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
48180619|NCT03372590|OTHER|NICU-based rehabilitation bundle|Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
48180620|NCT03372590|OTHER|Standard of care|Standard NICU care
48180621|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
48180622|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
48180623|NCT03034590|OTHER|questionnaire|
48381734|NCT00312650|DRUG|liposomal doxorubicin and gemcitabine|
48381735|NCT06032260|OTHER|Enriched panettone|Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
48381736|NCT06032260|OTHER|Panettone standard|Volunteers consumed 100 grams of panettone standard
48381737|NCT05568875|OTHER|e-self-management intervention (Happy Hands app)|"The 12-week intervention consists of 30 short informational videos addressing the themes prioritized by the patient research partners. These themes are further operationalized into the following categories: Information on hand OA, Hand exercises, Use of assistive devices and orthoses, Medication and surgical alternatives, and Self-management of the disease. Additionally, the intervention includes a hand exercise program consisting of 8 videos providing instructions on warm up, exercises to improve mobility, strength and coordination, and a stretching exercise. The intervention group will additionally receive treatment as usual."
48381738|NCT05568875|OTHER|Treatment as usual|Treatment as usual may vary from no treatment at all to referral to a patient education group program, or occupational therapy.
48381739|NCT04639050|DRUG|RO7126209|RO7126209 will be administered intravenously as specified in each treatment arm.
48716508|NCT02079935|BEHAVIORAL|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
48716509|NCT02079935|BEHAVIORAL|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
48716510|NCT01275092|DEVICE|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
48716511|NCT03924999|COMBINATION_PRODUCT|Combined decongestive treatment (CDT) & Combined exercise|Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
48716512|NCT03924999|COMBINATION_PRODUCT|Intermittent pneumatic compression & Combined exercise|Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
48716513|NCT03924999|COMBINATION_PRODUCT|Combined exercise|30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
48716514|NCT00002652|DRUG|suramin|
48023221|NCT04459416|OTHER|Acupuncture|Acupuncture treatments will be scheduled to cover the period of high symptom burden. Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. Electrical stimulation (e-acupuncture) may be applied to the ST36 and SP6 points when appropriate as per standard acupuncture practice.
48023222|NCT04459416|DRUG|opioid|All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
48023223|NCT04459416|OTHER|Assessments|Participants will be asked to complete patient reported outcomes assessments online using REDCap or, If they prefer, via pencil and paper or over the phone. Assessments at baseline (within 4 weeks before HiChemo) and on or about days 7, 15, 30, and 90 after the first dose of HiChemo.
48023224|NCT00694460|BIOLOGICAL|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
48023225|NCT00694460|BIOLOGICAL|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
48023226|NCT00694460|BIOLOGICAL|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
48023227|NCT00694460|BIOLOGICAL|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
48023228|NCT00694460|BIOLOGICAL|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
48023229|NCT05101252|DEVICE|senofilcon A C3|TEST Lens
48023230|NCT05101252|DEVICE|Dailies Total 1 Multifocal Contact Lenses|CONTROL Lens
48023231|NCT02229097|DRUG|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
48023232|NCT02229097|DRUG|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
48023233|NCT05531214|BEHAVIORAL|Multidisciplinary Care Coordination Team|The intervention group will be patients whose primary care clinicians will be receiving guidance and recommendations from the multidisciplinary team consisting of cardiologists, nephrologists, and specialty pharmacists.
48023234|NCT04064697|DRUG|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
48180624|NCT03379545|DIAGNOSTIC_TEST|3-dimensional (3D) magnetic resonance (MR) imaging|MRI is performed using 3T scanners with a dedicated 16-channel shoulder array coils. The MRI sequences include 3-mm slice thickness and 0.5-mm gap width with a field of view of 14 or 15 cm. There were 6 diagnostic sequences with axial, coronal, and sagittal proton density weighting as well as coronal T2 with frequency selective fat suppression and sagittal T1 images.
48180625|NCT03379545|DIAGNOSTIC_TEST|3D computed tomography (CT) imaging|The CT protocol consists of 3-mm axial images of the glenoid reconstructed into 1-mm sagittal and coronal 2D reconstructions using the following parameters: 120 kV, 280 mA, and pitch of 0.9. The CT data were also used to produce a 3D reconstruction of each glenoid.
48180626|NCT04430803|DIETARY_SUPPLEMENT|Hydrogen-rich water|A tablet that produces hydrogen dissolved in a glass of water
48180627|NCT04430803|OTHER|Control Water|A glass of tap water
48180628|NCT01436305|DRUG|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
48381740|NCT04639050|DRUG|Placebo|RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
48381741|NCT02010346|PROCEDURE|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
48381742|NCT03375346|DEVICE|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
48716515|NCT02048215|DRUG|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
48716516|NCT02048215|DRUG|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
48716517|NCT02048215|DRUG|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
48716518|NCT02048215|OTHER|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of \~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
48180629|NCT01436305|DRUG|MMF|"All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.~Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily."
48381743|NCT03375346|OTHER|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
48381744|NCT04440761|OTHER|Observation only|Observation only
48716519|NCT00993499|DRUG|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
48716520|NCT00993499|DRUG|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
48716521|NCT02426151|DRUG|BEPO-A|BEPO-A (Bioreactor manufacturing process)
48716522|NCT02426151|DRUG|REPO-A|REPO-A (Roller bottle manufacturing process)
48180630|NCT01436305|BIOLOGICAL|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication\[s\])
48180631|NCT01436305|DRUG|Short-term Tac|Short-term (3 months)
48180632|NCT01436305|DRUG|tacrolimus|maintenance
48180633|NCT01436305|BIOLOGICAL|Belatacept|maintenance
48180634|NCT01436305|DRUG|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
48381745|NCT02944344|BEHAVIORAL|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
48180635|NCT03190512|OTHER|Psychological measurements|Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
48180636|NCT02617979|OTHER|SAFECARE at Home customized lessons|
48180637|NCT00284193|DRUG|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
48180638|NCT00284193|DRUG|FEIBA- Activated Prothrombin Complexes|
48180639|NCT05584605|BEHAVIORAL|Aerobic treadmill training|The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.
48180640|NCT05584605|BEHAVIORAL|Stretching exercise|Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR
48180641|NCT02719743|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
48180642|NCT05191147|DIETARY_SUPPLEMENT|Dietary supplement|We will study dietary supplement consumption among pregnant women
48180643|NCT02008071|BEHAVIORAL|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
48180644|NCT02008071|BEHAVIORAL|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
48180645|NCT03545412|DEVICE|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
48180646|NCT03197025|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.
48180647|NCT03197025|BIOLOGICAL|E6 T Cell Receptor (TCR)|On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
48180648|NCT06334341|BEHAVIORAL|Computer-based simulation training for providers|"A Computer-Based Simulation training for providers, based on the Centers for Disease Control and Prevention Guide for Healthcare Professional: Discussing Sexual Health with Your Patients, current PrEP information, and the Social Cognitive Theory. This is a single-session, 30-minute training module contains educational information with animated narration about PrEP, how to take a sexual health history, understanding internal bias, potential patient barriers to PrEP as well as recorded video-simulated encounters, in which providers view different types of patient/provider interactions."
48180649|NCT06334341|BEHAVIORAL|Best Practice Alert|A Best Practice Alert will alert providers to patients who are part of the Centers for Disease Control and Prevention PrEP priority populations.
48180650|NCT06334341|BEHAVIORAL|HIV Risk Assessment|A risk assessment tool that considers the behaviors - i.e., types of sexual activities, protective behaviors (condoms, PrEP, ART), and other factors (HIV status, sexually transmitted infections) of the respondent.
48180651|NCT06334341|BEHAVIORAL|PrEP Informational Video|A short informational video, tailored to the local Detroit context with themes that will focus on introducing PrEP, stigma surrounding taking PrEP, and potential barriers and how to overcome them.
48180652|NCT02039648|OTHER|Rumex acetosa L. extract|
48180653|NCT02039648|OTHER|Placebo|
48180654|NCT04049981|DEVICE|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
48180655|NCT04810897|OTHER|Exercise|Exercise programme is reported in the clinical trial registration number is NCT03473834.
48023235|NCT06574321|BEHAVIORAL|Teen Talk High School Refresher (TTHSR)|"TTHSR is designed to equip 11th and 12th grade students with the knowledge and skills necessary to make informed sexual health decisions as they transition from high school into adulthood, in order to prevent behavioral risk factors that contribute to unintended pregnancy and sexually transmitted infections.~As a result of the California Healthy Youth Act, which mandates sexual health education (SHE) in public schools, most students this age will have received prior SHE. TTHSR is a 5-hour booster intervention, delivered in five 1-hour sessions during late high school, intended to enhance the effectiveness of previous SHE."
48023236|NCT05584449|OTHER|Counseling|Attend online group facilitated by two oncology social workers
48023237|NCT05584449|PROCEDURE|Discussion|Discuss survivorship issues/concerns
48023238|NCT05584449|OTHER|Informational Intervention|Receive young adult cancer survivorship information
48180656|NCT00627354|DRUG|etoposide|
48180657|NCT00627354|DRUG|mitoxantrone hydrochloride|
48180658|NCT00627354|DRUG|prednisone|
48180659|NCT00627354|DRUG|vinorelbine tartrate|
48180660|NCT02778672|OTHER|Thermal imaging of infant's chest with a mobile phone|
48180661|NCT06195462|OTHER|Laying on of hands with intention health (LHHI)|The participants will receive systemic acupuncture. The no healers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
48180662|NCT06195462|OTHER|Laying on of hands by spiritist passe|The participants will receive systemic acupuncture. The healers will prepare before the start with prayer for connection with Good Spirits and will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
48180663|NCT06195462|OTHER|Control|The participants will receive systemic acupuncture and they not receive the laying on of hands.
48180664|NCT00423566|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
48180665|NCT01350232|DRUG|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
48180666|NCT01350232|DRUG|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
48716523|NCT05558462|DRUG|XC8|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
48716524|NCT05015790|DEVICE|virtual reality Bliss Solution|use virtual reality Bliss Solution
48716525|NCT02223416|DRUG|RGB-10|
48023239|NCT05584449|OTHER|Medical Chart Review|Ancillary studies
48381746|NCT00684645|DRUG|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
48381747|NCT05843253|DRUG|Ribociclib|Ribociclib PO qd on days 1-21
48716526|NCT02223416|DRUG|Teriparatide|
48716527|NCT05506488|DRUG|Dasatinib 100 MG + Quercetin (1000 MG)|The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
48716528|NCT05506488|OTHER|Placebo|The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
48716529|NCT01538940|BIOLOGICAL|Intradermal vaccine|15ug
48716530|NCT01538940|BIOLOGICAL|Intramuscular vaccine|15ug
48716531|NCT03050515|BIOLOGICAL|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
48180667|NCT01350232|DEVICE|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
48716532|NCT03393507|DRUG|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
48716533|NCT03393507|DRUG|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time\> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
48716534|NCT03198806|OTHER|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
48716535|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
48716536|NCT03198806|OTHER|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
48716537|NCT03198806|OTHER|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
48716538|NCT02017145|DRUG|Chloraprep|
48023240|NCT05584449|OTHER|Quality-of-Life Assessment|Ancillary studies
48716539|NCT00993733|PROCEDURE|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
48716540|NCT01676519|PROCEDURE|PCI|percutaneous coronary intervention
48716541|NCT03730077|DRUG|18F-FMISO|18F-FMISO PET/CT
48716542|NCT00849875|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
48023241|NCT05584449|OTHER|Questionnaire Administration|Ancillary studies
48023242|NCT01543256|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|"Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)"
48023243|NCT01543256|DEVICE|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
48023244|NCT02669186|DRUG|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
48023245|NCT02669186|DRUG|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
48023246|NCT05073536|DEVICE|mini-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
48023247|NCT05073536|DEVICE|normal-sized MCE|Enrolled participants were randomly allocated into the normal-sized MCE group or mini-sized MCE group in a 1:1 ratio.
48023248|NCT01820130|DEVICE|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
48023249|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (INMUT-KB) (exp. group)|Interaction-focused music therapy with children with cancer and their significant others, delivered by trained music therapists.
48023250|NCT05534282|BEHAVIORAL|Music Therapy with Children (MUT-K) (exp. group)|Interaction-focused music therapy with children with cancer without the involvement of significant others, delivered by trained music therapists.
48180668|NCT01350232|RADIATION|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
48180669|NCT01350232|DRUG|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
48180670|NCT01350232|DRUG|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
48180671|NCT01350232|DRUG|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
48716543|NCT00849875|DRUG|Dacarbazine|Intravenous administration Chemotherapy
48716544|NCT00174538|DRUG|Codeine (30 mg)|
48381748|NCT05843253|DRUG|Everolimus|Everolimus PO qd on days 1-28
48381749|NCT02587117|DRUG|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
48381750|NCT02587117|DRUG|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
48381751|NCT01389856|DRUG|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
48381752|NCT01389856|DRUG|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
48381753|NCT03449277|DRUG|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
48381754|NCT00163527|DRUG|Roflumilast|
48381755|NCT00351611|DRUG|Lyrica (pregabalin)|150 mg twice a day, oral administration
48518916|NCT03545542|DIAGNOSTIC_TEST|Final breath volatile organic compounds|Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
48518917|NCT03806010|PROCEDURE|Quantitative sensory testing|Quantitative sensory testing
48716545|NCT03121170|OTHER|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
48716546|NCT03121170|OTHER|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
48716547|NCT02043119|BEHAVIORAL|Breastfeeding Clinic|
48716548|NCT05458453|DRUG|Esketamine|Self-controlled intravenous analgesia pump was used for continuous injection, and it was prepared according to sufentanil 1.5ug/ml+ esketamine 0.75ug/ml+16mg ondansetron. After the operation, the analgesic pump was connected, and sufentanil 0.1ug/kg/h+ esketamine 0.05mg/kg/h was pumped continuously for 24 hours. The continuous infusion of analgesia pump is (kg body weight/15) ml/h. (e.g. 60kg, pump speed 4ml/h, total amount 96ml).
48023251|NCT05534282|BEHAVIORAL|Interaction-focused Music Therapy with Children and Significant Others (WG-KB) (control group)|Study participants randomized to this group receive the intervention INMUT 10 weeks after the experimental groups.
48023252|NCT00812929|DRUG|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
48381756|NCT00351611|DRUG|placebo|Twice a day, oral administration
48381757|NCT03940898|DEVICE|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
48381758|NCT03508466|BEHAVIORAL|hypersensitivity reaction|Previous hypersensitivity reaction
48381759|NCT00401414|DRUG|Warfarin|2 mg tablets take as directed by study staff (based on INR)
48518918|NCT01960309|OTHER|Minimal invasive cardiac imaging|"* Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography"
48518919|NCT05027152|OTHER|Resistance training|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise. The repetitive task training group will carry out exercises involving upper and lower limbs.
48518920|NCT05027152|OTHER|Repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
48518921|NCT00687830|DRUG|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
48518922|NCT00687830|DRUG|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
48518923|NCT01570478|DRUG|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
48180672|NCT01350232|PROCEDURE|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
48180673|NCT03040947|OTHER|Cardiovascular Magnetic Resonance|
48180674|NCT01342432|OTHER|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
48180675|NCT01342432|OTHER|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
48180676|NCT02398032|DEVICE|CPAP nasal|During the night
48180677|NCT02398032|DEVICE|sham CPAP nasal|During the night
48180678|NCT00855413|DRUG|Darunavir|800 mg orally once daily
48180679|NCT00855413|DRUG|Ritonavir|100 mg orally once daily
48180680|NCT00855413|DRUG|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
48716549|NCT05866120|OTHER|Physiotherapy on the ground|Physical therapy will be performed on the ground, in 12 weeks, twice a week. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
48716550|NCT05866120|OTHER|Aquatic physiotherapy|Aquatic physiotherapy will be performed in 12 weeks, twice a week, in shallow water. The exercises will be based on a protocol developed by the researchers. This protocol has 15 exercises, aimed at muscle function and extensor musculature. All exercises can be adapted according to the severity of the individual, as well as the progression of these exercises will be made according to the adaptation and ease of individuals throughout the intervention.
48180681|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for severity of sleep disorders|Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).
48180682|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for distress caused by sleep disorders|Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
48180683|NCT02276638|DEVICE|Specular Microscope Nidek CEM-530|Nidek CEM-530
48180684|NCT02276638|DEVICE|Specular Microscope Konan CELLCHEK XL|Konan CELLCHEK XL
48180685|NCT01971281|DEVICE|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
48180686|NCT01971281|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
48180687|NCT01971281|DRUG|nab-Paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
48180688|NCT04629456|OTHER|neuromuscular electric stimulation|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
48716551|NCT02909855|OTHER|No intervention|Participants in this study will not receive any interventions as part of the study.
48716552|NCT00841399|BIOLOGICAL|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
48180689|NCT04629456|OTHER|Exercises|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
48180690|NCT03672799|BEHAVIORAL|Rehabilitation Planning Consult (RPC)|"Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC."
48180691|NCT03672799|OTHER|Wait list control (WLC)|"Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC."
48180692|NCT01495910|DRUG|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
48180693|NCT05861765|DRUG|Papaverine Hydrochloride|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
48381760|NCT05396833|DRUG|Tuvusertib|Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
48381761|NCT05396833|DRUG|Lartesertib|Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
48716553|NCT00678535|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
48716554|NCT00678535|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
48381762|NCT05396833|DRUG|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
48518924|NCT01570478|DRUG|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
48716555|NCT00678535|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
48716556|NCT02558400|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
48716557|NCT02558400|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
48716558|NCT02558400|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
48716559|NCT01216943|DRUG|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
48716560|NCT03454516|OTHER|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
48716561|NCT01971268|DEVICE|Dental Implant|place dental implants according to manufacturer guidelines
48716562|NCT01971268|DEVICE|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
48716563|NCT01971268|DEVICE|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
48716564|NCT04382521|BEHAVIORAL|Text Message Intervention|Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
48716565|NCT01483209|DRUG|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
48716566|NCT01556061|DEVICE|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
48716567|NCT01556061|DEVICE|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
48518925|NCT02322905|BEHAVIORAL|Emotion Regulation Therapy|8 sessions of ERT
48518926|NCT06553352|DRUG|Zanubrutinib combined with Obinutuzumab|Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
48518927|NCT05083026|DIAGNOSTIC_TEST|COVID-19 neutralizing antibody|"This study enrolled persons already who received COVID-19 vaccination under government policy.~1. We collect 5mL blood at 2, 4, 6, 9, 12 months after COVID-19 vaccination~2. isolate serum and store in -80 degree deep freezer~3. measure neutralizing Antibody"
48716568|NCT05920473|DEVICE|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
48023253|NCT00812929|DRUG|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
48023254|NCT03147105|BEHAVIORAL|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
48023255|NCT06024954|OTHER|aromatherapy|"Patients in the aromatherapy group use 5% lavender oil with a diffuser for 15-20 minutes in accordance with the Aromatherapy-Clinical Guideline For Midwives. NHS.~Trust 1-15) has been applied. The diffuser was placed 30 cm from the participants and five (5) drops of essential lavender oil were placed on the filter paper. Within 10-15 minutes after the completion of the inhalation, data collection forms were applied again, and pain, anxiety, blood pressure, pulse and respiratory rate were evaluated."
48180694|NCT05861765|DRUG|normal saline|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, then continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
48381763|NCT01721941|DRUG|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
48381764|NCT01721941|DRUG|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
48716569|NCT05920473|DEVICE|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
48716570|NCT01956370|DEVICE|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
48716571|NCT01956370|PROCEDURE|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
48023256|NCT06024954|OTHER|music therapy|"The relaxing music group listened to specially composed MusiCure® compositions in soft rhythm, including melodies with harp, cello, strings and sound elements from nature (eg rain, bird, forest sound). Listened with headphones for 20 minutes."
48023257|NCT06024954|OTHER|aromatherapy and music therapy|Inpatients will be given music with a loudspeaker with the effect of aromatherapy inhaler for three consecutive days. Within 10-15 minutes after the completion of the inhalation, data collection forms will be applied again, pain, anxiety, blood pressure, pulse, respiratory rate were evaluated.
48023258|NCT00583492|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10\^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
48180695|NCT03636373|DRUG|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
48023259|NCT00583492|RADIATION|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
48180696|NCT03636373|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
48180697|NCT02627378|OTHER|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
48381765|NCT01721941|DRUG|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
48381766|NCT01721941|DRUG|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
48381767|NCT02916056|DRUG|Azeliragon 5mg|
48381768|NCT03962114|DIETARY_SUPPLEMENT|Vitamin B3|capsules with niagen
48381769|NCT05703009|DRUG|Sacrosidase Oral Solution|Study drug
48523006|NCT05881434|OTHER|Emergency Department Visit Expectations Questionnaire|Patients presented with novel questionnaire designed to illicit patient's self-reported expectations across four domains (overall purpose of visit, medication intervention, imaging intervention and disposition) during check-in when arriving at the emergency department. Patients instructed to present the completed questionnaire to the treating provider.
48716572|NCT05135611|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
48023260|NCT02270580|BEHAVIORAL|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
48023261|NCT02270580|BEHAVIORAL|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
48023262|NCT03658720|DRUG|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
48381770|NCT05703009|DRUG|Placebo|Placebo
48381771|NCT06199518|PROCEDURE|transperitoneal laparoscopic ureterolithotomy (T-LUL)/ retrograde flexible ureteroscopy (R-URS) /Antegrade mini-percutaneous flexible ureteroscopy (A-URS)|extraction or fragmentation of large proximal ureteral stones via different minimally invasive procedures
48381772|NCT04513665|DRUG|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
48716573|NCT02528357|DRUG|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
48716574|NCT02528357|DRUG|Pembrolizumab|Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
48716575|NCT06320548|DIETARY_SUPPLEMENT|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
48180698|NCT02627378|OTHER|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
48180699|NCT03736889|DRUG|Tislelizumab (BGB-A317)|Anti-PD-1 Antibody
48180700|NCT01729715|BEHAVIORAL|Internet|
48381773|NCT02300272|DEVICE|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
48381774|NCT02300272|DEVICE|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
48716576|NCT06320548|DIETARY_SUPPLEMENT|Free diet|Patients had free diet.
48716577|NCT00097890|DRUG|Replagal (Agalsidase Alfa)|
48381775|NCT05254041|OTHER|Menstrual Cup Removal|Participants will be asked to remove Menstrual cup by breaking the seal.
48381776|NCT04561973|BEHAVIORAL|numerical rating scale|Patients seen for routine planned visits complete a self-administered retrospective questionnaire about pain during the last 3 months, and a prospective diary during the two weeks following the visit.
48381777|NCT06168084|DRUG|Vonoprazan|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
48716578|NCT00097890|DRUG|Replagal|
48716579|NCT00456976|DRUG|Selegiline|
48716580|NCT01274611|DRUG|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
48716581|NCT01274611|DEVICE|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
48716582|NCT04320511|DEVICE|CT-V|CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
48716583|NCT04148508|BEHAVIORAL|Tailored Emotional Competence Self-help|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
48381778|NCT06168084|DRUG|amoxicillin|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
48716584|NCT04148508|BEHAVIORAL|Cognitive-behavioural Approach|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
48716585|NCT04148508|BEHAVIORAL|Self-monitoring|Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
48381779|NCT06168084|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
48381780|NCT06168084|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
48716586|NCT01562405|DRUG|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
48716587|NCT01562405|DRUG|Lenalidomide|15 to 25 mg days 1-21, given orally
48716588|NCT01562405|DRUG|Dexamethasone|40 mg days 1,8,15,22; given orally
48023263|NCT05746338|DEVICE|Ring-type wearable device|The ring-type wearable device is a slim, lightweight smart ring that continuously tracks blood oxygen saturation and heart rate throughout the day.
48023264|NCT05746338|DEVICE|Overnight polysomnography|Overnight polysomnography is the gold standard for diagnosing OSAS.
48023265|NCT00242034|PROCEDURE|CT and MRI with contrast|
48180701|NCT01729715|BEHAVIORAL|DVD|
48716589|NCT01562405|DRUG|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
48716590|NCT03233022|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
48716591|NCT04710914|DRUG|Prolonged sedation with isoflurane|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
48716592|NCT04710914|DRUG|Prolonged sedation with midazolam|"Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam"
48028933|NCT04570826|OTHER|Meditation.|The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.
48028934|NCT04570826|OTHER|Scientific descriptions about meditation.|The control group received scientific descriptions about meditation.
48381781|NCT06168084|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
48381782|NCT06168084|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
48716593|NCT02466113|OTHER|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
48716594|NCT02466113|OTHER|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
48716595|NCT00343382|DRUG|pilocarpine hydrochloride|Given orally
48716596|NCT00343382|OTHER|placebo|Given orally
48716597|NCT04103463|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
48716598|NCT04103463|OTHER|Home exercise|Home exercise
48716599|NCT02196415|DEVICE|Biplanar Radiography|standard biplanar radiography of the foot
48716600|NCT04032080|COMBINATION_PRODUCT|Drug 1: LY3023414; Drug 2: Prexasertib|"Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry.~Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses."
48381783|NCT06254131|DRUG|Ondansetron lozenge (Ondalenz ©)|Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
48381784|NCT06254131|DRUG|Ondansetron IV|Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.
48381785|NCT03330977|DEVICE|Compression garments|"Patients will wear the compression garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the compression garments at inclusion."
48716601|NCT04798040|OTHER|cold application|To reduce pain, cold application is applied around the drain before the drain is removed.
48716602|NCT04798040|OTHER|lavender oil inhalation|To reduce pain, lavender oil is inhaled prior to drain removal.
48716603|NCT04798040|OTHER|oxygen administration|To reduce pain, oxygen is inhaled prior to drain removal.
48716604|NCT05693051|OTHER|Prone position ventilation|Turning the patient prone for 16 hours
48716605|NCT02099201|DRUG|ACT-389949 40 mg|
48716606|NCT02099201|DRUG|ACT-389949 200 mg|Predicted dose
48716607|NCT02099201|DRUG|ACT-389949 800 mg|Predicted dose
48716608|NCT02099201|DRUG|ACT-389949 (Group C1 dose to be selected)|
48716609|NCT02099201|DRUG|ACT-389949 (Group C2 dose to be selected)|
48716610|NCT02099201|DRUG|Placebo|
48716611|NCT03510871|DRUG|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
48716612|NCT00276614|DRUG|bortezomib|
48716613|NCT04086446|DEVICE|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
48716614|NCT04086446|DEVICE|Sham tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
48716615|NCT01852383|DRUG|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
48716616|NCT05837858|OTHER|whole grain-wheat flour food+standardized meals|whole grain food made by 50 g whole grain wheat flour
48716617|NCT05837858|OTHER|refined wheat flour food+standardized meals|refined grain food made by 50 g refined wheat flour
48716618|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
48716619|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
48716620|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
48716621|NCT01690624|DRUG|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
48716622|NCT03140982|DIAGNOSTIC_TEST|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
48180702|NCT04786613|OTHER|Intra-articular 20 mg, 1.0% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
48381786|NCT03945929|BEHAVIORAL|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
48716623|NCT01846559|BIOLOGICAL|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
48716624|NCT01846559|DRUG|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
48716625|NCT01846559|DRUG|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
48716626|NCT02650271|DRUG|Entecavir|Patients will be received entecavir (10 mg/d) before liver resection.
48716627|NCT02650271|DRUG|Tenofovir|Patients will be received tenofovir before liver resection.
48716628|NCT05654688|OTHER|graston and muscle energy technique|"Graston technique (Gt) is a technique of mobilization of soft tissue using instruments which consider myofascial release instrument that has been reported to relieve pain, improve overall function, and increase range of motion.~Muscle energy technique (MET) is a term composed of various types of active muscular relaxation and stretching procedures. The two cornerstone forms of MET are reciprocal inhibition and post isometric relaxation. In theory, reciprocal inhibition takes advantage of the neurological phenomena of muscular contraction, which results in an inhibitory effect on the antagonistic muscles."
48716629|NCT01650714|OTHER|Full thickness gastric biopsy|
48716630|NCT01650714|PROCEDURE|Full thickness gastric biopsy|
48716631|NCT01289223|DRUG|Bendamustine IV|
48381787|NCT00096317|DRUG|ixabepilone|
48381788|NCT00096317|DRUG|ketoconazole|
48381789|NCT06173882|BEHAVIORAL|Ordinary moxibustion volume group|Moxibustion for 10 minutes per acupoint
48716632|NCT01289223|OTHER|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
48716633|NCT05246826|OTHER|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
48716634|NCT05246826|OTHER|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
48716635|NCT03691779|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet orally once daily in the morning.
48716636|NCT03691779|DRUG|IVA|IVA tablet orally once daily in the evening.
48716637|NCT01064687|DRUG|LY2189265|
48716638|NCT01064687|DRUG|Exenatide|
48716639|NCT01064687|DRUG|Placebo|
48716640|NCT01064687|DRUG|Metformin|
48716641|NCT01064687|DRUG|Pioglitazone|
48716642|NCT04731207|DEVICE|Optovue®|Optical coherence tomography and optical coherece tomography angiography
48716643|NCT03541187|BIOLOGICAL|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
48716644|NCT03541187|BIOLOGICAL|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
48716645|NCT00755547|OTHER|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
48716646|NCT05874492|OTHER|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
48716647|NCT03166579|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
48716648|NCT00586443|DRUG|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~* 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~* 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~* 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~  1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~ 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\*~     * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
48716649|NCT03403985|DRUG|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
48716650|NCT03403985|DRUG|Mineral Trioxide Aggregate|MTA will be used in this group
48381790|NCT06173882|BEHAVIORAL|First group of heavy moxibustion|Moxibustion for 20 minutes per acupoint
48381791|NCT06173882|BEHAVIORAL|Second groups of heavy moxibustion|Moxibustion for 30 minutes per acupoint
48381792|NCT06525506|BIOLOGICAL|IBI311 (20 mg)|Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.
48381793|NCT06525506|BIOLOGICAL|IBI311 (3-20 mg)|Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.
48381794|NCT06525506|BIOLOGICAL|IBI311 (10 mg)|Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.
48716651|NCT02462408|PROCEDURE|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
48381795|NCT06525506|BIOLOGICAL|IBI311 (3-10mg/kg)|Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.
48518928|NCT05850364|BIOLOGICAL|Sabin Strain Inactivated Poliovirus Vaccine|Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i.e., co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered administration group 2 (group S2). Participants in group C1 and C2 will receive sIPV at 6,10, 14 weeks old, administered concomitantly with routine infant vaccine (may include DTP-HepB-Hib vaccine, PCV10 or rotavirus vaccine in accordance with the local routine vaccination schedule). Participants in group S1 will receive sIPV at 6,10,14 weeks old, and receive routine infant vaccines at 8,12,16 weeks old. Participant s in group S2 will receive routine infant vaccines at 6,10,14 weeks old, and receive sIPV at 8,12, 16 weeks old.
48518929|NCT00136253|BEHAVIORAL|Help dietitians and patients address specific nutritional barriers|
48716652|NCT02462408|PROCEDURE|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
48716653|NCT02714270|PROCEDURE|modified partograph|
48716654|NCT02714270|PROCEDURE|paperless partograph|
48381796|NCT00622622|BIOLOGICAL|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
48381797|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
48716655|NCT02270723|DRUG|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
48716656|NCT02270723|DRUG|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
48716657|NCT02782325|BIOLOGICAL|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
48381798|NCT01418365|DRUG|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
48381799|NCT06372392|DEVICE|Universal meal coefficient utilization|Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
48381800|NCT01256229|DEVICE|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
48381801|NCT01256229|DEVICE|hearing aids|This is the conventional therapy for deaf children with developmental delays.
48381802|NCT00000459|BEHAVIORAL|diet, fat-restricted|
48381803|NCT05924009|PROCEDURE|Transcranial Magnetic Stimulation, TMS|"The best location for evoking an electromyographic (EMG) response of the first dorsal interosseus (FDI) muscle in the dominant hand and the minimum stimulation intensity required to evoke a certain EMG response amplitude (Motor Threshold, MT) are used as reference to determine the best location and stimulation parameters to evoke GEPs.~After identification of the GEP hot-spot, a water load test is administered to determine whether satiety shapes GEP responses.~In subsequent study visits, the water load test is preceded by application of neuromodulatory repetitive TMS (rTMS), targeted to the GEP hotspot."
48518930|NCT05145426|DEVICE|Low Intensity Focused Ultrasound|Application of LIFU
48716658|NCT02782325|BIOLOGICAL|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
48716659|NCT05424263|DRUG|Calcium Acetate Oral Solution|Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
48716660|NCT05424263|DRUG|Calcium Carbonate Oral Suspension|Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
48716661|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
48180703|NCT04786613|OTHER|Intra-articular 32 mg, 1.6% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
48180704|NCT04786613|OTHER|Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection|"Intra-articular 2,4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in single session will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
48180705|NCT02106364|DRUG|Insulin Peglispro|Administered SQ
48518931|NCT06020144|DRUG|TLL-018|Oral tablets administered 2pieces BID for 52 weeks.
48180706|NCT02106364|DRUG|Insulin Glargine|Administered SQ
48518932|NCT06020144|DRUG|Tofacitinib|Oral tablets administered 1pieces BID for 52 weeks.
48518933|NCT00037583|DRUG|Gemtuzumab Ozogamicin|
48518934|NCT03080870|OTHER|Art|Multicomponent art intervention
48381804|NCT06650046|PROCEDURE|Topping-off Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
48381805|NCT06650046|PROCEDURE|Fusion Group|"Topping-off group Patients who have undergone the Topping-off system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.~Fusion group Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University."
48518935|NCT04449211|DEVICE|Implantation|Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
48518936|NCT03225001|DEVICE|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
48518937|NCT01284452|DRUG|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
48518938|NCT01284452|DRUG|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
48518939|NCT03073824|DEVICE|vSculpt|Pelvic Floor Toning and Vaginal Rejuvenation Device
48518940|NCT02925403|BIOLOGICAL|R21/Matrix-M1|
48518941|NCT02925403|OTHER|Saline|
48518942|NCT00637494|DRUG|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
48518943|NCT00637494|DRUG|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
48518944|NCT02245607|BEHAVIORAL|Compensatory Cognitive Training|
48518945|NCT02245607|BEHAVIORAL|Recreational Therapy|
48518946|NCT02289443|OTHER|complete denture|Comparison of different procedures
48518947|NCT04886661|OTHER|CHRONIC NECK PAIN|Demographic information will be collected. Neck Disability Index will be filled. Physical examination will be performed.
48518948|NCT02848209|PROCEDURE|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
48716662|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
48716663|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
48518949|NCT02848209|PROCEDURE|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
48518950|NCT02848209|PROCEDURE|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
48716664|NCT06083532|BEHAVIORAL|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity \& repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity \& Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
48180707|NCT06077903|BIOLOGICAL|GT101|Autologous tumor infiltrating lymphocyte injection
48518951|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
48518952|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
48518953|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
48518954|NCT01088958|DIETARY_SUPPLEMENT|Micronutrient powders (Sprinkles)|"Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg"
48518955|NCT06166524|PROCEDURE|Catheter ablation for atrial fibrillation using pulsed-field energy|Patients will undergo pulmonary vein isolation using pulsed-field energy
48518956|NCT06166524|PROCEDURE|Conservative arm|Patients will undergo electrical cardioversion with consequent treatment with antiarrhythmic drugs
48518957|NCT02633592|OTHER|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
48381806|NCT01534390|DEVICE|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
48381807|NCT03911700|DEVICE|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
48518958|NCT02633592|OTHER|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
48518959|NCT03481010|PROCEDURE|PAO with hip arthroscopy|Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
48518960|NCT03481010|PROCEDURE|PAO without hip arthroscopy|"Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia."
48518961|NCT03972761|DEVICE|Magnetic Resonance Imaging (MRI) 3 tesla|Functional neuroimaging objectifies the activation of specific areas of the brain
48518962|NCT05606783|BEHAVIORAL|Telehealth Follow-up Visits|"• Follow-up with patients once per week for six (6) weeks via scheduled 20-minute telehealth appointment with each patient via the HIPAA secure and compliant platform, VSee~o During this telehealth appointment, the study pharmacists will counsel the patients on their blood pressure readings for that week and provide lifestyle education focusing on patient-specific diet and exercise recommendations"
48518963|NCT05606783|BEHAVIORAL|Surveys|"A pre- and post-survey will be given at the initial and final in-person appointments, respectively~• These surveys will collect basic patient demographics, knowledge of blood pressure, comfort with checking blood pressure at home, and previous experience working with a pharmacist"
48518964|NCT05606783|DEVICE|Devices|"Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~• The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily"
48518965|NCT00251511|DRUG|Arsenic Trioxide|
48518966|NCT06042543|DIAGNOSTIC_TEST|Screening with HPV test|Women aged 25-49 yrs will be screened with a validated HPV test. They will also provide urine samples for HPV test. Women HPV positive in either sample will be referred to colposcopy for disease ascertainment.
48518967|NCT02325076|DEVICE|Spirodoc|A device to detect the physical condition of the lungs
48518968|NCT02952469|DRUG|(68Ga)PSMA-HBED-CC|Experimental radiotracer for imaging prostate cancer
48518969|NCT00641628|PROCEDURE|mastectomy|
48518970|NCT01822626|BEHAVIORAL|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
48518971|NCT04097340|DEVICE|Attentional Bias Retraining (ABR)|Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
48518972|NCT04097340|DEVICE|Control Training|Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
48518973|NCT02734407|PROCEDURE|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
48518974|NCT02734407|DRUG|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
48518975|NCT00461942|DRUG|Green Tea Polyphenols (EGCG/ECG)|
48518976|NCT06054035|DRUG|Dapagliflozin (Forxiga®)|Dapagliflozin 10 mg once daily for 2 years. Route of administration: oral.
48518977|NCT06054035|DRUG|Placebo matching Dapaglifolzin|Placebo matching Dapaglifolzin once daily for 2 years. Route of administration: oral.
48180708|NCT03575676|DRUG|SOM3355 100mg BID|Oral
48518978|NCT06054035|BEHAVIORAL|Lifestyle Intervention|Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).
48518979|NCT00290550|DRUG|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
48518980|NCT02045901|DRUG|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
48518981|NCT02045901|DRUG|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
48180709|NCT03575676|DRUG|SOM3355 200mg BID|Oral
48381808|NCT06421662|BEHAVIORAL|Attachment Training|"The study group was trained online by a psychologist on attachment in two sessions. In order to measure the level of attachment knowledge before and after the training, a test form prepared by the researcher based on the literature and expert opinion was used as pre-test and post-test. In the 8th week after delivery, Maternal Attachment Inventory  developed by Mary Muller in 1994 and Turkish validity and reliability study was conducted by Şirin and Kavlak."
48381809|NCT06651463|OTHER|Videorecording|Two cameras will be used to make the recordings: a classic camera placed on a stand 1 meter from your head, outside the sterile area and the color camera of the microscope used for the surgery.
48180710|NCT03575676|DRUG|Placebo BID|Oral
48180711|NCT03506659|DEVICE|SUDO-SCAN Device|Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
48180712|NCT04467892|DRUG|methylprednisolone|received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
48180713|NCT04467892|DRUG|Methyl Prednisolonate|received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
48180714|NCT04467892|DEVICE|ventilators|all patients in both groups will be ventilated with CMV for 2 weeks
48180715|NCT01495676|OTHER|Radiation + cisplatin|"RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.~A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.~* In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.~* In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study."
48180716|NCT01495676|OTHER|Radiation + cisplatin + gemcitabine|"Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.~Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection."
48180717|NCT06546059|DEVICE|narrow band ultraviolet-B|vitiligo patients will recevie twice sessions per week
48180718|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
48180719|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
48381810|NCT06537336|DEVICE|QoL|QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).
48381811|NCT06537336|DEVICE|lung function|lung function tests using spirometry
48381812|NCT06326476|DRUG|Siplizumab|40 mg doses
48381813|NCT02164084|DRUG|SB204|SB204 Gel with hydrogel
48381814|NCT02164084|DRUG|Vehicle Gel|Vehicle Gel with hydrogel
48518982|NCT03348163|DRUG|B/FTC/TAF|B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)
48716665|NCT04932291|DRUG|vafidemstat|1.2mg capsule
48716666|NCT04932291|DRUG|Placebo|placebo capsule
48716667|NCT05162261|DEVICE|Tixel C|Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
48381815|NCT04340570|BEHAVIORAL|Medication management via televisit to home|Pharmacist led home based televisit for medication management
48381816|NCT03727113|PROCEDURE|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
48518983|NCT03348163|DRUG|Current ART|Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
48381817|NCT03727113|PROCEDURE|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
48518984|NCT02964247|DRUG|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
48381818|NCT04205864|DRUG|Thrombi-Gel|Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy
48381819|NCT04205864|PROCEDURE|Conventional Pelvic lymphadenectomy|Conventional Pelvic lymphadenectomy
48381820|NCT06650839|DEVICE|NIUT|Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft
48381821|NCT01797809|DRUG|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
48381822|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 5mg/day for one year
48381823|NCT01203982|DRUG|Rosuvastatin|Rosuvastatin 40mg/day for one year
48381824|NCT02804659|OTHER|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
48381825|NCT02992808|DRUG|recombinant gonadotropins|
48381826|NCT02992808|DRUG|HP-HMG|
48381827|NCT03582657|DEVICE|dental implant (KONTACT N)|Implant-supported prosthetic restoration
48518985|NCT02964247|DRUG|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
48716668|NCT05162261|DEVICE|LipiFlow|Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.
48716669|NCT02338934|DRUG|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
48716670|NCT05443282|DIAGNOSTIC_TEST|Prolidase Level|Measurement of venous blood serum level of prolidase enzyme level by ELISA method.
48716671|NCT05443282|DIAGNOSTIC_TEST|Follicle Stimulating Hormone Level|Measurement of venous blood serum level of follicle stimulating hormone level.
48716672|NCT05443282|DIAGNOSTIC_TEST|Estradiol Level|Measurement of venous blood serum level of estradiol hormone level.
48716673|NCT05443282|DIAGNOSTIC_TEST|Proline Level|Measurement of venous blood serum level of proline level.
48716674|NCT05443282|DIAGNOSTIC_TEST|Hydroxyproline Level|Measurement of venous blood serum level of hydroxyproline level.
48716675|NCT05443282|DIAGNOSTIC_TEST|Anti-mullerian Hormone Level|Measurement of venous blood serum level of anti-mullerian hormone level.
48716676|NCT05443282|DIAGNOSTIC_TEST|Antral Follicle Count|Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.
48716677|NCT05443282|DIAGNOSTIC_TEST|Prolactine Level|Measurement of venous blood serum prolactine hormone level.
48716678|NCT05443282|DIAGNOSTIC_TEST|Thyroid Stimulating Hormone Level|Measurement of venous blood serum thyroid stimulating hormone level.
48023266|NCT01316627|BEHAVIORAL|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
48023267|NCT01316627|BEHAVIORAL|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
48023268|NCT04397081|OTHER|HPV test results|The human papillomavirus (HPV) test detects the presence of the human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The procedure includes taking samples of your cervical cells using a soft brush and a flat scraping device called a spatula. This doesn't hurt, and you may not even feel the sample being taken.
48023269|NCT01595516|DRUG|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
48023270|NCT01595516|DRUG|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
48023271|NCT01595516|DRUG|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
48023272|NCT01595516|OTHER|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
48180720|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
48180721|NCT05399368|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
48180722|NCT05399368|OTHER|Placebo|Nonactive placebo tablet
48716679|NCT04682990|DEVICE|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
48716680|NCT04682990|OTHER|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
48716681|NCT04682990|DIAGNOSTIC_TEST|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
48716682|NCT04682990|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
48716683|NCT04682990|OTHER|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
48716684|NCT04682990|OTHER|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
48180723|NCT03008109|DRUG|EGFR-TK Inhibitor|
48180724|NCT00557531|DEVICE|BL-1040|2 mL of BL-1040
48381828|NCT00464308|DRUG|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
48716685|NCT04682990|OTHER|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
48716686|NCT04682990|OTHER|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
48716687|NCT06344572|DEVICE|SAT-001|Device: SAT-001(a Software as Medical Device) Using SAT-001 application for 48 weeks and wearing single vision spectacles
48716688|NCT06344572|OTHER|Single vision spectacles|Wearing single vision spectacles
48716689|NCT00568477|DRUG|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over \>=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
48716690|NCT04596865|PROCEDURE|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
48381829|NCT00464308|DRUG|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
48381830|NCT00464308|DRUG|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
48716691|NCT03271047|DRUG|binimetinib|Orally, twice daily.
48716692|NCT03271047|DRUG|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
48716693|NCT03271047|DRUG|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
48716694|NCT02212171|OTHER|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
48716695|NCT01309022|DRUG|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
48716696|NCT01309022|DRUG|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
48716697|NCT01309022|DRUG|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
48716698|NCT01309022|DRUG|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
48716699|NCT06179420|OTHER|total cumulative gonadotrophin usage|total dosage in IU
48180725|NCT02653209|DRUG|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
48180726|NCT02653209|DRUG|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
48381831|NCT02648646|OTHER|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
48381832|NCT03382691|DEVICE|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
48381833|NCT00001080|BIOLOGICAL|Influenza Virus Vaccine|
48381834|NCT00001080|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
48381835|NCT00001080|DRUG|Lamivudine|
48381836|NCT06244134|PROCEDURE|ultrasound guided autologous blood injection|guided
48381837|NCT06244134|PROCEDURE|non guided autologous blood injection|non guided
48716700|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
48716701|NCT03302286|DIAGNOSTIC_TEST|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
48716702|NCT04438499|DEVICE|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
48716703|NCT03112746|BEHAVIORAL|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
48716704|NCT04097496|BEHAVIORAL|Act Out! Intervention|Data included in the description of the intervention arm.
48716705|NCT02944565|BIOLOGICAL|Daratumumab|Given IV
48716706|NCT03157583|OTHER|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
48381838|NCT05552183|DRUG|oral dose of 200 mg pacritinib twice daily (BID)|Subjects will receive 200 mg BID pacritinib for 14 days.
48381839|NCT06493188|OTHER|High-fidelity interprofessional simulation|Students will participate in realistic (high-fidelity) interprofessional simulation scenarios to practice and interpret ABG procedures
48518986|NCT04902014|BEHAVIORAL|Motivational Interviewing|The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
48518987|NCT04902014|BEHAVIORAL|Education|These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
48716707|NCT03157583|OTHER|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
48023273|NCT01595516|OTHER|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
48023274|NCT01595516|OTHER|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (\~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
48023275|NCT04620434|DEVICE|Video laryngoscopic view|The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
48023276|NCT04620434|DEVICE|Direct laryngoscopic view|The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
48023277|NCT06572761|DRUG|Combination of antibiotics|Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
48023278|NCT06572761|DEVICE|Emergency cerclage|Emergency cerclage
48180727|NCT02653209|DRUG|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
48381840|NCT06493188|OTHER|Low-fidelity interprofessional simulation|Students will take part in low-fidelity interprofessional simulation scenarios. Cases will be discussed, and reflection on ABG execution and interpretation will be guided using paper descriptions and clinical files
48381841|NCT00247416|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.
48381842|NCT00247416|DRUG|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
48381843|NCT00247416|DRUG|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
48381844|NCT01412307|DRUG|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
48023279|NCT06572761|DRUG|Vaginal progesterone|Vaginal progesterone
48023280|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence A|Starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.
48381845|NCT01412307|DRUG|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
48180728|NCT05132881|OTHER|Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS)|The intervention administered is the TaVNS program and the fMRI scans to evaluate changes in the brain. The TaVNS program consists of placing ear buds from the device into each ear. They are initially sprayed once with a small amount of saline that is also provided as part of the TaVNS materials. Once the ear buds are placed in each ear, the test subject will start a preprogramed session of vibrations that will stimulate the vagus nerve. The session will last for 15 minutes and then the subject will take the ear buds out and clean them. They will use the TaVNS program once a day for 3 months.
48180729|NCT05132881|OTHER|Waitlist Control|Baseline imaging and follow up imaging for comparison to the TaVNS health device group at approximately 3 months. The TaVNS intervention is offered after completion of the imaging.
48180730|NCT05132881|OTHER|Healthy Controls: Substudy Group III|fMRI Imaging to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
48180731|NCT05132881|OTHER|Distressed Workers: Subgroup II|Subgroup II of 10 subjects with distress(all receiving TaVNS) will undergo fMRI scans with the TaVNS system being turned on and off while in the scanner to observe for any immediate effects and to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
48180732|NCT01441583|DEVICE|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
48180733|NCT01441583|DEVICE|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
48180734|NCT00197223|BIOLOGICAL|Influenza vaccine|
48180735|NCT06131775|BIOLOGICAL|Blood sampling|One blood sample of 10mL is realized before initiation of immunotherapy
48180736|NCT06131775|BIOLOGICAL|Blood sampling|Three blood samples of 10mL are realized at distinct steps of patients disease management : one before the curative surgery, one after three months and one after six months.
48180737|NCT02022111|BEHAVIORAL|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
48180738|NCT02022111|BEHAVIORAL|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
48180739|NCT02022111|OTHER|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients and their usual care providers.
48180740|NCT02022111|OTHER|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
48180741|NCT02022111|OTHER|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
48180742|NCT02547441|DRUG|CLS001 (Omiganan)|Topical gel
48180743|NCT02547441|DRUG|Vehicle|Vehicle Gel
48180744|NCT03282136|DRUG|Incretin Effect|The patients will receive incretins therapy.
48180745|NCT03282136|DEVICE|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
48180746|NCT06001866|BEHAVIORAL|Retrieval-based verb learning|"Learning sessions: Novel verbs are practiced on Day 1. In one condition, the words are learned using repeated spaced retrieval practice - retrieval trials are initially immediate, then occur after 3 intervening words. In the other condition, the words and video are presented without retrieval trials. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word in the context of a sentence twice with actors and objects viewed during learning and twice with new actors and objects. One week after Day 1, this recall test is completed again. At this time, the child's ability to generalize the verb to a new sentence frame will be assessed. Finally, the child will complete a recognition test: viewing pairs of video clips, the child will hear each novel verb and point to the video clip that depicts that action."
48716708|NCT03157583|OTHER|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
48716709|NCT03157583|OTHER|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
48716710|NCT03157583|OTHER|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
48716711|NCT03157583|OTHER|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
48518988|NCT04902014|BEHAVIORAL|Wearable Fitness Trackers|Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
48716712|NCT03157583|OTHER|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
48716713|NCT06423391|OTHER|NeuOst|As above
48716714|NCT06423391|OTHER|Control Intervention|As above
48716715|NCT06423391|OTHER|Usual Care|As above
48716716|NCT05766033|OTHER|Enamel conditioning with a novel etchant paste|The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
48716717|NCT04248894|OTHER|Exercise training of High Intensity|High intensity
48716718|NCT04248894|OTHER|Exercise training of Moderate Intensity|Moderate intensity
48716719|NCT04248894|OTHER|Untraining|Sedentary
48716720|NCT03963089|PROCEDURE|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
48716721|NCT03963089|PROCEDURE|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
48716722|NCT03963089|PROCEDURE|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
48716723|NCT03963089|PROCEDURE|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
48716724|NCT03395561|DIETARY_SUPPLEMENT|green coffee|2 capsuls
48716725|NCT03395561|OTHER|control|2 capsuls
48716726|NCT02302183|DEVICE|FreeO2 v2.0 automatic adjustment|
48716727|NCT02302183|DEVICE|FreeO2 v2.0 data collecting|
48716728|NCT04188652|OTHER|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
48716729|NCT00138047|DRUG|zinc supplementation|
48716730|NCT02642965|DRUG|Cytarabine|Given IT or IV
48716731|NCT02642965|BIOLOGICAL|Filgrastim|Given SC or IV
48716732|NCT02642965|DRUG|Fludarabine Phosphate|Given IV
48716733|NCT02642965|OTHER|Laboratory Biomarker Analysis|Correlative studies
48381846|NCT01412307|OTHER|Bio-specimen Retention|Samples with DNA and without DNA
48716734|NCT02642965|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48716735|NCT02642965|OTHER|Pharmacological Study|Correlative studies
48716736|NCT04660227|PROCEDURE|Exercise Trainning|Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
48716737|NCT04660227|OTHER|Control Group|Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
48716738|NCT05481099|BEHAVIORAL|Intervention|Cognitive-behavioural-based intervention combined with mindfulness (attention focus), psychoeducation, and relaxation techniques (short version of Jacobson's progressive relaxation, breathing exercises)
48180747|NCT00004072|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
48180748|NCT00004072|DRUG|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
48180749|NCT04650698|DRUG|Tranexamic acid (TXA) injection|IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)
48180750|NCT00516139|DRUG|Lamotrigine|Open-label
48180751|NCT00583947|DRUG|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
48180752|NCT00583947|DRUG|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
48180753|NCT04454788|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
48381847|NCT05276934|DIAGNOSTIC_TEST|Brain computed tomography|This study will use an established local protocol for DCI and intracranial arterial vasospastic stenosis screening, and follow-up to make sure that all patients have the same protocol and don't lose any chance of improvement and good outcome : CT perfusion at different time intervals
48381848|NCT05925478|PROCEDURE|Ptergyopalatine Fossa Block|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
48381849|NCT05925478|DRUG|Bupivacaine 0.25% Injectable Solution|Injection of local anesthetic (e.g. Bupivacaine) into the pterygopalatine fossa to treat headache related to aneurysmal subarachnoid hemorrhage
48716739|NCT05497856|OTHER|Integrated neuromuscular inhibition technique|Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks
48716740|NCT05497856|OTHER|Myofascial Release|Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
48716741|NCT02811783|DRUG|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
48716742|NCT02811783|DRUG|Placebo Lotion|Topical TID for 2 weeks
48716743|NCT01806064|DRUG|TRC105 and Axitinib|
48716744|NCT01806064|DRUG|Axitinib|
48716745|NCT06187025|OTHER|Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
48381850|NCT02415634|OTHER|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~* Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~* Part 2: A rehabilitation goal setting care plan~* Part 3: A patient communication forum~* Part 4: Useful supports and contact information~* Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
48716746|NCT06187025|OTHER|Ecological Momentary Assessment (EMA)|Daily EMA evaluations during 12 weeks
48716747|NCT00746733|DRUG|Lisdexamfetamine Dimesylate|50mg capsule
48716748|NCT00746733|DRUG|Adderall XR (mixed salts amphetamine)|20mg capsule
48716749|NCT00129610|BEHAVIORAL|Virtual Reality Therapy|
48180754|NCT04454788|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
48180755|NCT05671497|DRUG|Cilostazol 100 MG|An antiplatelet agent used for intermittent claudication , it has an anti-inflammatory effect which will help control patients with Rheumatoid arthritis
48180756|NCT05671497|DRUG|conventional synthetic antirheumatic drugs|methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
48180757|NCT00696488|DRUG|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
48180758|NCT02342145|DRUG|Basiliximab,|Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
48716750|NCT00129610|BEHAVIORAL|Cognitive Behavior Therapy|
48716751|NCT00647660|DRUG|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
48716752|NCT00647660|DRUG|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
48716753|NCT00946725|DRUG|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
48716754|NCT00946725|DRUG|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
48716755|NCT02231762|DRUG|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
48716756|NCT02231762|DRUG|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
48180759|NCT02342145|DRUG|cyclosporine A|Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
48180760|NCT02342145|DRUG|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
48180761|NCT02342145|DRUG|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
48180762|NCT02967276|DRUG|Metformin XR|500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
48518989|NCT04902014|BEHAVIORAL|Wearable Fitness Tracker+|These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
48716757|NCT06190327|BEHAVIORAL|Blended indoor and outdoor multicomponent structured exercise|Participants will receive a 16-week blended indoor and outdoor multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Session 1/week will conduct in indoor setting, while session 2/week will conducted in outdoor setting (park). Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
48716758|NCT06190327|BEHAVIORAL|Indoor-only multicomponent structured exercise|Participants will receive a 16-week indoor-only multicomponent structured exercise program, with 2 sessions per week (90 mins/session). Both two sessions will conducted in indoor setting. Each session will comprise 10-min warm-up, 30-min aerobic training, 20-min muscle strength, 20-min postural balance training, and 10-min cool-down.
48716759|NCT02046070|DRUG|Cyclophosphamide|Cyclophosphamide tablets
48716760|NCT02046070|DRUG|Ixazomib|Ixazomib capsules
48180763|NCT02967276|DRUG|Dexamethasone|4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
48180764|NCT04028817|DEVICE|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
48180765|NCT04028817|DEVICE|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
48381851|NCT02415634|OTHER|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
48381852|NCT02416505|BEHAVIORAL|Verbal+Anatomic Model|
48381853|NCT02416505|BEHAVIORAL|Verbal+Video|
48381854|NCT00960648|DEVICE|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
48381855|NCT00960648|DEVICE|Cypher|Retrospective historical controls that received sirolimus-eluting stent
48381856|NCT05317923|OTHER|Flow Controlled Ventilation|Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
48716761|NCT02046070|DRUG|Dexamethasone|Dexamethasone tablets
48023281|NCT04231656|DEVICE|CLEARSIGHT and NICCOMO measurements in sequence B|Starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position and collect the last group of figures.
48023282|NCT02908568|DEVICE|Spring device|Brisk dilatation of fhe mouth.
48023283|NCT02908568|DEVICE|Mandible stimulator|Stimulation of fhe mouth.
48381857|NCT01905176|OTHER|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
48518990|NCT04174625|DIETARY_SUPPLEMENT|Dietary Supplement: Omega3-FA|Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
48716762|NCT01881022|BEHAVIORAL|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
48023284|NCT06112236|OTHER|no intervention|no intervention
48023285|NCT05582863|OTHER|Virtual reality exercise intervention|The experimental group performed a 75-90-minute VR exercise routine twice a week for 12 weeks.
48023286|NCT05038059|DRUG|ethanolic extract of sapindus mukorossi|ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
48023287|NCT05038059|DRUG|ethylene diamine tetra acetic acid|used as final endodontic irrigant in root canal therapy
48023288|NCT03893227|OTHER|Questionnaire|Patients and healthy controls will fill out a questionnaire
48023289|NCT04879238|BEHAVIORAL|BEING|60 minute yoga session that blends mindfulness techniques
48023290|NCT01884350|DRUG|Apixaban|
48023291|NCT06531499|DRUG|AAA617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
48180766|NCT01928693|DRUG|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
48180767|NCT01928693|DRUG|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
48180768|NCT01928693|DRUG|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
48716763|NCT05976464|DRUG|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
48180769|NCT02016209|DRUG|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
48180770|NCT00518856|OTHER|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
48180771|NCT00518856|OTHER|Standard of care|continued with current standard of care for birth attendants
48180772|NCT01790295|DRUG|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
48716764|NCT02907749|DRUG|Spironolactone and carvedilol|Patients are treated with carvedilol in combination with spironolactone.
48180773|NCT04594733|DRUG|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
48180774|NCT04594733|DRUG|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
48180775|NCT03364777|OTHER|emotional state|anxiety or depression state evaluated by emotional scale
48180776|NCT05573100|DRUG|CU06-1004|CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
48180777|NCT05878912|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
48180778|NCT06189209|DRUG|Tenalisib|Tenalisib will be administered 800mg BID, orally
48180779|NCT04855942|DEVICE|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
48180780|NCT04855942|DEVICE|physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
48381858|NCT01905176|OTHER|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
48716765|NCT02907749|DRUG|Carvedilol|Patients are treated with carvedilol only.
48716766|NCT00000652|DRUG|Zidovudine|
48716767|NCT00000652|DRUG|Didanosine|
48716768|NCT05513313|BIOLOGICAL|JYNNEOS|smallpox vaccine
48716769|NCT02360293|BEHAVIORAL|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
48180781|NCT04411186|PROCEDURE|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Subjects receive standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
48381859|NCT01905176|OTHER|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 \& 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 \& 2
48381860|NCT04080362|DEVICE|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
48381861|NCT05903781|DIAGNOSTIC_TEST|Prostate MRI|MRI of the prostate
48381862|NCT05849129|DRUG|Ascorbic acid|High dose ascorbic acid delivered intravenously
48381863|NCT05849129|OTHER|Normal Saline|0.9% NaCl solution
48381864|NCT02660489|DRUG|OC459|
48381865|NCT02660489|DRUG|Placebo|
48381866|NCT02660489|OTHER|Rhinovirus|Inoculation with rhinovirus serotype 16
48518991|NCT02186002|DRUG|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
48381867|NCT04359758|BEHAVIORAL|Proactive Streamlined Genetic Education and Testing|This intervention consists of the proactive delivery of genetic education print materials followed by streamlined and facilitated access to genetic testing.
48381868|NCT04359758|BEHAVIORAL|Usual Care|This intervention consists of a standard genetic referral letter that notified the participant that he qualified for genetic referral, recommends the scheduling of a genetic counseling session and provides a telephone number for scheduling.
48381869|NCT01282879|DRUG|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
48381870|NCT05966142|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
48381871|NCT05966142|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
48381872|NCT04781309|DRUG|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
48023292|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
48023293|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) antagonists|Degarelix, Relugolix
48023294|NCT04365322|OTHER|Additional biological samples|Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
48023295|NCT03624361|DEVICE|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
48023296|NCT02745626|DEVICE|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
48023297|NCT05848739|DRUG|ST316|IV
48023298|NCT05848739|DRUG|FOLFIRI regimen & bevacizumab|"FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg."
48023299|NCT05848739|DRUG|Fruquintinib|5 mg once a day for the first 21 days of a 28-day cycle
48023300|NCT05848739|DRUG|Lonsurf & bevacizumab|Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
48023301|NCT03934229|DIETARY_SUPPLEMENT|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
48023302|NCT04198623|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast(Singulair) 10mg to be taken at least 2 hours prior to initiation of monoclonal antibody infusion addition to institutional protocol premedication regiment
48023303|NCT05071417|DRUG|Semaglutide|Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
48023304|NCT03207750|BIOLOGICAL|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
48023305|NCT03207750|BIOLOGICAL|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
48023306|NCT03207750|BIOLOGICAL|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
48023307|NCT03207750|BIOLOGICAL|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
48023308|NCT02497326|DRUG|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
48381873|NCT01198327|DRUG|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
48381874|NCT01198327|OTHER|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
48381875|NCT00817427|OTHER|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
48381876|NCT00817427|OTHER|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
48381877|NCT02901184|DRUG|Spironolactone|Treatment with Spironolactone tablets on top of standard care
48716770|NCT02360293|BEHAVIORAL|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
48716771|NCT02177513|DRUG|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
48716772|NCT02177513|DRUG|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
48381878|NCT02901184|OTHER|Standard care|Standard care does not involve Spironolactone
48381879|NCT05146999|BIOLOGICAL|QM1114-DP|QM1114-DP
48381880|NCT05146999|BIOLOGICAL|Placebo|Placebo
48381881|NCT06336603|DRUG|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)
48381882|NCT02399046|DEVICE|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
48381883|NCT02399046|DEVICE|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
48381884|NCT02243709|DRUG|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
48381885|NCT02953873|DRUG|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
48381886|NCT02953873|DRUG|Mycophenolate mofetil|≥500mg twice a day
48381887|NCT02953873|DRUG|Prednisone|goal dose 5mg daily
48381888|NCT02953873|DRUG|Mycophenolate Sodium|≥360mg twice a day
48381889|NCT00271037|PROCEDURE|Colpocleisis prolapse repair surgery|
48381890|NCT00271037|PROCEDURE|sling or other to treat or prevent stress incontinence|
48381891|NCT01164280|OTHER|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
48381892|NCT04557293|DEVICE|Continuous Positive Airway Pressure (CPAP) treatment|Treatment of Obstructive sleep apnoea syndrome with CPAP
48381893|NCT03810027|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
48381894|NCT04540172|BEHAVIORAL|Music Therapy|"Mahur tune, one of the nonverbal instruments of the Traditional Turkish Music Authorities, was selected for the study with the opinion of a music therapy specialist."
48716773|NCT02177513|DRUG|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
48716774|NCT02177513|DRUG|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
48716775|NCT02177513|DRUG|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
48381895|NCT04540172|BEHAVIORAL|Progressive Muscle Relaxation Exercise|"In this study, the steps of applying progressive muscle relaxation exercise were created with the guidance of the Relaxation Exercises  materials of the Turkish Psychological Association."
48381896|NCT01744275|DIETARY_SUPPLEMENT|Omega 3 fatty acids|
48381897|NCT01744275|DIETARY_SUPPLEMENT|corn oil|Placebo
48381898|NCT05124912|PROCEDURE|Radiation Therapy|Post-op hypofractionated therapy or no radiation therapy
48381899|NCT05124912|DRUG|Steroid Therapy|Best medical management with steroid therapy
48381900|NCT05124912|PROCEDURE|Laser Interstitial Thermal Therapy|Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
48381901|NCT02003248|DEVICE|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
48381902|NCT05749900|DRUG|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
48381903|NCT04785846|DEVICE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
48381904|NCT05922540|OTHER|Intravenous thrombolysis|Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients
48180782|NCT04411186|PROCEDURE|ERAS and 5 Lung Protective Interventions|"Subjects will receive the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height) Positive end-expiratory pressure (PEEP) 7cm H2O5 Immediately post intubation recruitment breath (30cm water for 30 seconds) Every 1 hour recruitment breath (30cm water for 30 seconds) 40% FIO2 initially - titrate up as necessary to maintain SPO2 \>94%"
48381905|NCT01079000|BEHAVIORAL|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
48381906|NCT01079000|BEHAVIORAL|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
48381907|NCT01079000|BEHAVIORAL|Usual care|Usual care provided to asthma patients when discharged from the ED
48381908|NCT03058081|DEVICE|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
48381909|NCT04520087|PROCEDURE|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
48381910|NCT00540735|PROCEDURE|photodynamic therapy|
48023309|NCT02497326|DRUG|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
48023310|NCT02497326|DRUG|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score \>4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
48381911|NCT00335816|DRUG|fluorouracil|Given IV
48381912|NCT00335816|DRUG|leucovorin calcium|Given IV
48381913|NCT00335816|DRUG|oxaliplatin|Given IV
48381914|NCT00335816|PROCEDURE|conventional surgery|Patients undergo surgery
48381915|NCT00335816|RADIATION|radiation therapy|Patients undergo radiotherapy
48381916|NCT00335816|OTHER|laboratory biomarker analysis|Correlative studies
48381917|NCT00335816|GENETIC|DNA analysis|Correlative studies
48381918|NCT00335816|GENETIC|polymerase chain reaction|Correlative studies
48381919|NCT00335816|OTHER|immunohistochemistry staining method|Correlative studies
48381920|NCT04151316|PROCEDURE|crown preparation|includes tooth preparation
48381921|NCT04151316|PROCEDURE|vertical preparation|type of vertical preparation on the tooth that accepts the crown
48716776|NCT04042272|DIAGNOSTIC_TEST|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
48381922|NCT04151316|PROCEDURE|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
48381923|NCT03183739|DRUG|ASP8062|ASP8062 will be administered orally.
48381924|NCT03183739|DRUG|Placebo|Placebo will be administered orally.
48381925|NCT01738282|DRUG|Baclofen|
48381926|NCT01738282|DRUG|Placebo (for baclofen)|
48381927|NCT00075101|DRUG|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
48381928|NCT01040468|PROCEDURE|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
48381929|NCT01040468|PROCEDURE|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
48381930|NCT01040468|BEHAVIORAL|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
48381931|NCT00139243|DRUG|Taxotere|
48716777|NCT05610046|DEVICE|Infrared sauna heating|Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
48381932|NCT00139243|DRUG|Cisplatin|
48381933|NCT00139243|DRUG|5-Fluorouracil|
48381934|NCT00139243|DRUG|Leucovorin|
48023311|NCT05861115|DEVICE|"Chang Gung Ventricular Systolic Dysfunction Screening Software"|This software is suitable for 12-lead ECG signals of adults over 20 years old, and assists doctors in screening patients for left ventricular systolic dysfunction.
48023312|NCT00380640|DRUG|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
48716778|NCT05610046|DEVICE|Sham sauna|Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.
48716779|NCT04239300|BEHAVIORAL|Delivery in water|Participants delivery in water
48716780|NCT03917069|DRUG|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
48716781|NCT03917069|DRUG|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
48023313|NCT00380640|DRUG|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
48381935|NCT03590691|OTHER|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
48518992|NCT02186002|DRUG|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
48023314|NCT05702957|DRUG|letrozole 2.5mg-7.5mg|Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
48180783|NCT00728299|DRUG|PomWonderful Juice|8 oz per day each day for 78 weeks
48180784|NCT00728299|DRUG|Placebo juice|8 oz per day for 78 weeks
48180785|NCT03432390|DEVICE|Continuous Positive Airway Pressure|A continuous positive airway pressure will be delivered to the patients during the induction of general anesthesia through the anesthesia work station
48180786|NCT03432390|DEVICE|Open system ventilation|Facemask ventilation adapted to the anesthesia work station
48180787|NCT01558323|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
48716782|NCT00330928|DEVICE|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
48716783|NCT00330928|DEVICE|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
48716784|NCT01653899|DRUG|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
48180788|NCT01066715|DRUG|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
48180789|NCT01066715|DRUG|Placebo|Sterile solution subcutaneously administered monthly for 6 months
48180790|NCT00011934|BIOLOGICAL|recombinant interferon alfa|
48716785|NCT02570243|DRUG|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
48716786|NCT02570243|DRUG|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
48023315|NCT05702957|DRUG|Clomiphene Citrate 50mg-150mg|Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
48023316|NCT02450994|DRUG|Dexamethasone|
48023317|NCT02450994|DRUG|Placebo|
48023318|NCT02172209|DRUG|BI 10773|
48023319|NCT04813341|OTHER|Pilates training|Bridging, roll up, one leg circle (both ways); single straight leg stretches; double leg stretches; side kick up and down; side kick circles. The participant will be instructed to perform 3-5 repetitions of these movements at the start, and to add two more repetitions for each movement every week until the end of the intervention.
48023320|NCT04813341|OTHER|Aerobic Training|"WALKING: 10 mint brisk walk excluding warm up and cool down in 5 days/ week STATIONARY CYCLE: for 10 mints, 5 days/ week~SITTING EERCISES:~Chest stretch: ask to hold for 5 seconds and perform 5 repetitions Upper body twist: ask to cross the arms against chest and hold for 5 seconds, perform 5 repetitions Hip marching: Ask the client to sit on chair with arm rest and lift each of her leg 5 times~BALANCE EXERCISES:~Sideways walking: ask to perform 10 steps on each way (side to side), 5 days/week.~Heel to Toe walk: perform at least 5 steps and increase gradually in each repetition, 5days/ week Step up and down: Ask to step up and down on given surface, 5 repetitions on each leg, 5 days/ week."
48180791|NCT00011934|BIOLOGICAL|sargramostim|
48180792|NCT00011934|PROCEDURE|autologous bone marrow transplantation|
48180793|NCT00687947|DRUG|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
48180794|NCT02149524|DRUG|Herceptin (trastuzuamb)|Intravenous administration
48180795|NCT02149524|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
48180796|NCT03723577|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
48518993|NCT02186002|DRUG|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
48518994|NCT02186002|DRUG|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
48716787|NCT00556179|DRUG|Lactoserum (Dermacyd Femina®)|Once a day during three months
48716788|NCT02855944|DRUG|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
48716789|NCT02855944|DRUG|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice a day
48716790|NCT02724735|DRUG|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
48716791|NCT02325063|DRUG|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
48716792|NCT02325063|DRUG|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
48716793|NCT02325063|DRUG|Corticoid injection|Patients will be treated with an injection of Corticoids.
48716794|NCT04821323|DRUG|Indomethacin|Indomethacin capsules will be administered orally.
48716795|NCT04821323|DIAGNOSTIC_TEST|Lactulose-mannitol|Lactulose-mannitol solution will be administered orally.
48180797|NCT03482362|DRUG|Vinorelbine Tartrate|Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
48180798|NCT02280512|DEVICE|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
48180799|NCT04947514|DRUG|Tranexamic acid|Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
48518995|NCT02186002|DRUG|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
48180800|NCT04947514|OTHER|Placebo (topical saline)|The untreated breast will receive topical saline.
48180801|NCT03498469|BEHAVIORAL|Standardized reintegration package|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. Home visitation will begin during the family assessment and preparation stages and continue throughout the 15-month post-reunification follow-up period. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
48180802|NCT03498469|BEHAVIORAL|Enhanced reintegration package|Participants assigned to this arm will receive an enhanced reintegration package that consists of the parenting program, individualized case management, and the reunification grant. will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months. The individualized case management and the reunification grant will be similar to those in the comparison arm.
48180803|NCT02643628|PROCEDURE|Microneedling|
48180804|NCT02643628|DEVICE|Microneedling followed by Bellafill treatment|
48518996|NCT02186002|DRUG|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
48180805|NCT03396068|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
48180806|NCT03396068|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
48180807|NCT01798342|DIETARY_SUPPLEMENT|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
48180808|NCT01798342|DIETARY_SUPPLEMENT|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
48180809|NCT04902183|DRUG|CovenD24|The drug will be administrated once daily for 5 days
48180810|NCT01377298|DRUG|Pazopanib|200mg/tablet, 800mg/day PO.
48180811|NCT02168322|DEVICE|collagen membrane|bovine collagen membrane used for selective tissue regeneration
48180812|NCT02168322|DEVICE|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
48180813|NCT00164710|DRUG|sulfadoxine-pyrimethamine|
48180814|NCT00164710|DRUG|amodiaquine plus sulfadoxine-pyrimethamine|
48180815|NCT00164710|DRUG|amodiaquine plus artesunate|
48180816|NCT00164710|DRUG|chlorproguanil-dapsone plus artesunate|
48180817|NCT00164710|DRUG|lumefantrine-artemether|
48180818|NCT02413814|BEHAVIORAL|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
48180819|NCT02413814|BEHAVIORAL|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
48180820|NCT02652195|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
48180821|NCT02652195|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
48180822|NCT06324045|OTHER|Deprescribing|"1. The clinical pharmacist will review the patient's medications using validated screening tools, draft a deprescribing plan of the potential problematic medications, consult with the physician (MDT-CKD nephrologist), make the needed amendments, and document in the medical records.~2. The plan will be implemented and monitored during the patient's appointments for 1- 2 weeks at the center by the nephrologist.~3. The medication plan will be reconciled before discharge from dialysis or a planned appointment, and patients will be given a deprescribing card containing medication information. A note will be posted on CERNER as well. The primary care physician might also be contacted by the MDT-CKD team for consultation or any inquiries regarding the patient's condition or medications.~4. The MDT-CKD specialist nurse will conduct 3 post-appointment follow-up phone calls on day 2, day 7, and day 28 to enquire about any withdrawal symptoms or any concerns of the patient."
48180823|NCT04189055|DRUG|Cetuximab|Cetuximab 500mg/m² IV, day 1
48518997|NCT02186002|DRUG|Placebo|
48518998|NCT00360984|DRUG|insulin glargine|
48180824|NCT04189055|DRUG|Irinotecan|Irinotecan 180mg/m² IV, day 1
48180825|NCT02839785|DRUG|Ibuprofen|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
48518999|NCT00360984|DEVICE|continuous subcutaneous insulin infusion|
48519000|NCT03296501|BIOLOGICAL|Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients|3 injections of ADRC: 1 intraspinal and 2 intrathecal
48519001|NCT02561325|DRUG|Sodium Bicarbonate and Sodium chloride|
48519002|NCT02033538|DRUG|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
48519003|NCT06137469|DRUG|Acetaminophen/SHR20004|SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
48519004|NCT06137469|DRUG|Acetaminophen/Placebo|Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
48519005|NCT00132860|DRUG|azithromycin|
48023321|NCT04279574|DEVICE|Lithium disilicate onlays (IPS emaxCAD/Ivoclar)|Restoration of posterior teeth
48023322|NCT04279574|DEVICE|Chairside zirconia crowns (3M)|Restoration of posterior teeth
48023323|NCT02881281|OTHER|educational program for Development of problem-solving skills|
48023324|NCT02881281|OTHER|no education program|no education program
48023325|NCT06572553|DRUG|Faricimab|Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.
48023326|NCT01169857|DRUG|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
48023327|NCT00289796|BIOLOGICAL|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
48023328|NCT05861544|DIETARY_SUPPLEMENT|Pomegranate juice|The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
48023329|NCT01769794|DRUG|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
48023330|NCT01769794|DRUG|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
48023331|NCT01769794|DRUG|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
48023332|NCT06443190|OTHER|Indigenous Patient Navigator Support|See Arm Description
48023333|NCT02533882|BEHAVIORAL|Movement to Music|
48023334|NCT02533882|BEHAVIORAL|Adapted Yoga|
48023335|NCT02783586|PROCEDURE|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
48023336|NCT02783586|PROCEDURE|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
48023337|NCT02783586|DRUG|Bupivacaine|20 ml of bupivacaine with adrenaline
48180826|NCT02839785|DRUG|Placebo|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
48180827|NCT00178854|DRUG|Risperidone|
48180828|NCT02673411|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
48381936|NCT03590691|OTHER|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
48519006|NCT06551480|DEVICE|Biometry|Only one eye from each patient will be included in the study. All subjects and patients included in the study will undergo biometric measurements with both devices (IOL master 500 and VCSEL based swept source optical biometry).
48023338|NCT02783586|DEVICE|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
48716796|NCT02519868|DEVICE|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
48381937|NCT03590691|BEHAVIORAL|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
48381938|NCT03590691|BEHAVIORAL|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
48381939|NCT05299359|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
48180829|NCT02354547|GENETIC|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
48381940|NCT04780776|DEVICE|UVB treatment|5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention
48716797|NCT02519868|DEVICE|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
48716798|NCT04326660|OTHER|SCOPE-Chinese Women|SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
48716799|NCT04485689|DRUG|Capsaicin Topical - alone|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
48716800|NCT04485689|DRUG|Placebo - alone|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
48180830|NCT02354547|DRUG|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
48180831|NCT02354547|DRUG|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
48180832|NCT02949245|PROCEDURE|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
48716801|NCT04485689|DRUG|Capsaicin Topical - ice|5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
48180833|NCT04197479|DRUG|Placebo|Matching tablets
48180834|NCT04197479|DRUG|Resmetirom|Tablet
48180835|NCT00074295|BIOLOGICAL|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
48381941|NCT04780776|DEVICE|Sham comparator|5+16 weeks of visible light exposure
48381942|NCT05199649|DRUG|SintilimabCombined With Chemotherapy|Sintilimab and chemotherapy are carried out at the same time for every 3 weeks
48381943|NCT00734188|DRUG|PTI-6D2|monoclonal antibody
48381944|NCT03648073|DRUG|[68Ga]DOTATATE-PET/MRI|\[68Ga\]DOTATATE-PET/MRI
48381945|NCT02594254|DRUG|C16G2 Gel|Antimicrobial peptide
48381946|NCT02594254|OTHER|Placebo|Placebo
48381947|NCT06325722|OTHER|Low-carbohydrate Diet|Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate
48716802|NCT04485689|DRUG|Placebo - ice|5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
48716803|NCT05896852|BEHAVIORAL|physical activity|Participants will increase their physical activity through walking.
48381948|NCT06325722|OTHER|Low-fat Diet|Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
48381949|NCT03879759|DRUG|NAC 2400mg/day|2400mg/day 2 x 600mg b.d
48381950|NCT03879759|DRUG|Placebo|4 matched placebo tablets/day
48381951|NCT03323944|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
48023339|NCT05567991|BEHAVIORAL|Comprehensive Mindulness-Based Intervention (C-MBI)|C-MBI, was administer online via Zoom and included: 10 Integral Meditation classes lasting approximately 35 minutes each, given twice a week (Monday and Wednesday); 10 minutes of yoga exercises focused on breathing and posture before each IM class; and dietary advice. Regarding this latter, the participants received via email a document which entailed non-mandatory dietary suggestions to promote healthy nutrition, sleep and stress-relief. An online lecture held by the nutritionist with a question-and-answer format was also organized. The degree to which to follow this advice was left to the discretion of each participant. The core of our intervention was represented by the IM training, that is a MBI intervention, that simultaneously uses breathing, focusing attention, releasing of physical tensions, thoughts and feeling sensations through internal senses and imagery, allowing a quick relaxation and more deeply a physical, energetic, and spiritual well-being.
48180836|NCT02036437|DRUG|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
48180837|NCT02036437|DRUG|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
48180838|NCT05876169|PROCEDURE|Orthognathic surgery|Surgical corrections of the maxilla and/or the mandible. Integrated jaw-neck movement patterns, muscle activity, bite force and occlusal contact area will be registered and mapped with quantitative objective functional variables. The state-of-the-art core equipment to evaluate jaw-neck motor function in detail is located in the Movement Lab (Department of Odontology, Umeå University).
48023340|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
48180839|NCT00009906|DRUG|Imatinib Mesylate|Given orally
48180840|NCT02993536|OTHER|Biospecimen Collection|
48180841|NCT03927898|DRUG|Toripalimab|Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT
48180842|NCT03927898|RADIATION|Stereotactic Body Radiotherapy|Participants receive SBRT (BED\>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
48180843|NCT03552562|DEVICE|Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)|Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
48180844|NCT01347372|BEHAVIORAL|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
48180845|NCT00938405|DRUG|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
48519007|NCT02706444|DEVICE|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
48519008|NCT02706444|DEVICE|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
48519009|NCT04480684|DIAGNOSTIC_TEST|Three-dimensional Endoanal Ultrasound|"Three-dimensional endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. The anorectal transducer is inserted directly into the anal canal which allows assessment of the anal sphincter complex.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
48716804|NCT06096506|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($30 per class = $150 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions
48716805|NCT03662659|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
48716806|NCT03662659|BIOLOGICAL|Nivolumab|Specified dose on specified days
48716807|NCT03662659|DRUG|XELOX|Oxaliplatin + capecitabine
48716808|NCT03662659|DRUG|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
48716809|NCT03662659|DRUG|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
48716810|NCT03190694|DRUG|Dapagliflozin 10mg|Tablet
48716811|NCT03817073|DEVICE|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
48716812|NCT04547114|DIAGNOSTIC_TEST|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
48381952|NCT06649175|OTHER|Exercise|"Close kinetic chain (CKC) exercises :~1. Supine wall push exercise: Start position: supine with the both leg against wall, other limb straight. Exercise action: push against wall for thirty seconds.~2. Wall push against Swiss ball exercise: Start position: Supine with a Swiss ball between patient's legs and the wall. Exercise action: push against the wall for thirty seconds.~3. Supine half bridging exercise: Start position: Lying on back, knees bent Exercise action: keeping spine neutral and hinging up from the hips, move into a bridge."
48381953|NCT06649175|OTHER|Exercise|"Control Group (A): will receive the traditional physical therapy (PT) , the traditional physical therapy program will include the following:~* Stretching exercise for shortening muscle of lower limbs (LL) mainly (hip flexors, adductors, knee flexors and ankle planter flexors).~* Balance training from standing while giving perturbations.~* Balance board training.~* Step ups: repeated stepping anteriorly and laterally onto a step with both legs alternatively, progressing to higher step and decreasing upper extremity support.~* Forward and backward walking (with or without handheld mobility devices).~* Side walking (with or without handheld mobility devices).~* Walking in astride line (with or without handheld mobility devices)."
48519010|NCT04480684|DIAGNOSTIC_TEST|Transperineal Ultrasound(multiplanar)|"If endoanal ultrasound is declined or not tolerated, the anal sphincter will also be assessed using three-/four-dimensional (3D/4D) transperineal ultrasound with the probe placed externally on the area of the fourchette.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
48519011|NCT04480684|DIAGNOSTIC_TEST|The MolecuLight i:X: Bacterial autofluorescence camera|"The bacterial load of the perineal wound will be measured every week using the MolecuLight i:X. This is a system, which uses fluorescent illumination to capture and document the presence of bacteria.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed.~These findings will be supported by microbiological analysis of the wound fluid with swab culture and sensitivity."
48519012|NCT04480684|DEVICE|Silhouette® 3D camera: Three-dimensional wound measuring camera|For wound that have superficially dehisced, the wound surface area, depth, volume and healing progress will be precisely measured using the Silhouette® 3D camera. This is a system that uses 3D laser technology to track wound healing progression.
48519013|NCT04393714|PROCEDURE|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
48519014|NCT02574598|DRUG|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
48519015|NCT02574598|DRUG|Docetaxel|Use on both arms as standard of care.
48519016|NCT04756115|PROCEDURE|Vascular Surgery.|Open Vascular, endovascular or hybrid procedures.
48519017|NCT06582537|PROCEDURE|Participants sample collection|A skeletal muscle biopsy and a venous blood sample will be collected. The skin biopsy will be obtained during the incision needed for the muscle biopsy.
48519018|NCT01434914|DRUG|octenisept®|Cutaneous solution
48519019|NCT01434914|DRUG|Placebo|Cutaneous use
48519020|NCT03610152|BEHAVIORAL|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
48519021|NCT05264181|DEVICE|Percutaneous pulmonary valve implantation|Percutaneous pulmonary valve implantation using SAPIEN 3 valve in the context of routine care of patients with congenital heart diseases
48519022|NCT02521649|DRUG|G17DT|
48519023|NCT01795417|DEVICE|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
48519024|NCT01795417|DEVICE|XP200 RF device|4 RF treatments of periorbital region on one side of the face
48519025|NCT01103492|DEVICE|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
48023341|NCT00967187|DRUG|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
48023342|NCT05706259|DIETARY_SUPPLEMENT|Soft gelatin 200000 IU vitamin D3 capsule|Weekly single dose for 3-weeks
48381954|NCT04973917|PROCEDURE|respiratory support|respirators for invasive mechanical ventilation
48716813|NCT05588037|PROCEDURE|FLACS +PPV+IOL + air|The procedures are combined the FLACS +PPV+IOL + air.
48716814|NCT05588037|PROCEDURE|FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex|The procedures are combined the FLACS +PPV+IOL + epiretinal membrane peeling + Ozurdex.
48716815|NCT05588037|PROCEDURE|FLACS + PPV+IOL + internal limiting membrane peeling + air|The procedures are combined the FLACS + PPV+IOL + internal limiting membrane peeling + air.
48716816|NCT05588037|PROCEDURE|FLACS + PPV+IOL|The procedures are combined the FLACS + PPV+IOL.
48023343|NCT05706259|DIETARY_SUPPLEMENT|Orodispersible (sachet) 200000 IU vitamin D3|Weekly single dose for 3-weeks
48023344|NCT03046680|OTHER|Health Coaching|
48023345|NCT03046680|OTHER|Multiprofessional Team|
48023346|NCT05390489|DRUG|Cascara pulp arabica gayo coffee cream|extract of cascara pulp arabica gayo coffee
48381955|NCT00206037|DEVICE|COLLOSS E|
48381956|NCT00206037|DEVICE|TomoFix Plate|
48519026|NCT01824381|PROCEDURE|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times."
48716817|NCT04836416|OTHER|Observational|Observational
48716818|NCT00512018|DEVICE|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
48381957|NCT06330506|OTHER|Pressure ulcer prevention pack|The pressure ulcer prevention package to be prepared by the researchers will be applied
48381958|NCT03126175|DEVICE|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
48381959|NCT03126175|DEVICE|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
48381960|NCT02469558|DIETARY_SUPPLEMENT|Winclove 851 and 110|prebiotic and probiotic mixture
48381961|NCT02469558|DIETARY_SUPPLEMENT|Placebo|white powder without pro/probiotic
48381962|NCT03741543|OTHER|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
48381963|NCT06106217|OTHER|bapne|An exercise program was created in the form of a movement sequence consisting of nine movement combinations.
48381964|NCT06106217|OTHER|qi gong|The exercise program, which was prepared in a 40-minute sequence, was arranged as 10 minutes of warm-up, 20 minutes of Qi Gong exercises, and 10 minutes of cool-down.
48381965|NCT02325414|DRUG|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
48381966|NCT02325414|DRUG|Placebo|Placebo (saline) infusion to match zoledronic acid
48716819|NCT00512018|OTHER|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
48716820|NCT00493519|PROCEDURE|chocolate cake|
48716821|NCT00882908|DRUG|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
48716822|NCT00882908|DRUG|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
48023347|NCT05640934|DRUG|Melatonin|The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.
48023348|NCT05640934|DRUG|Placebo|The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
48381967|NCT01407627|DIETARY_SUPPLEMENT|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
48381968|NCT03843775|DRUG|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
48381969|NCT03843775|DRUG|Encorafenib|encorafenib 450 mg oral QD
48716823|NCT00882908|DRUG|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
48716824|NCT00882908|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
48716825|NCT01789528|DRUG|CAZ-AVI|IV infusion
48716826|NCT01789528|DRUG|CXL|IV infusion
48716827|NCT05990023|OTHER|Traditional vestibule rehabilitation training|"* Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements."
48023349|NCT03292757|DRUG|Indocyanine Green|Fluorescent dye - indocyanine green
48023350|NCT06296342|BEHAVIORAL|Exposure to information framing message|The information framing message presents the objective of the front-of-package labeling policy as providing nutritional information.
48023351|NCT06296342|BEHAVIORAL|Exposure to healthier choices framing message|The healthier choices framing message presents the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
48023352|NCT06296342|BEHAVIORAL|Exposure to industry framing message|The industry framing message presents the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
48023353|NCT05946018|OTHER|Educational video on ergonomics|A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.
48023354|NCT05946018|OTHER|Verbal physical therapy coaching sessions|Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
48023355|NCT01686087|BEHAVIORAL|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
48023356|NCT01686087|PROCEDURE|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
48023357|NCT00486343|DRUG|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
48023358|NCT00486343|DRUG|Placebo|Placebo tablets 2x600mg BID for 24 weeks
48023359|NCT01037309|DRUG|PRO044 SC|Subcutaneous injection, once a week, for five weeks
48023360|NCT01037309|DRUG|PRO044 IV|Intravenous injection, once a week, for five weeks
48023361|NCT00094380|DRUG|CTLA4-IgG4m (RG2077)|
48023362|NCT00094380|DRUG|Cyclophosphamide|
48381970|NCT00660101|BIOLOGICAL|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
48519027|NCT01824381|PROCEDURE|Obtaining and Cryopreservation of amniotic membrane|
48519028|NCT01824381|DRUG|amniotic membrane|
48519029|NCT05237323|DRUG|mycophenolate mofetil 2 g per day|mycophenolate mofetil 2 g per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
48519030|NCT05237323|DRUG|azathioprine of 150 [75; 150] mg per day|azathioprine at an average dose of 150 \[75; 150\] mg per day and methylprednisolone in an average starting dose 24 \[24; 32\] mg per day and standard drug therapy for heart failure.
48519031|NCT04980989|DEVICE|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
48519032|NCT03905694|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
48519033|NCT00316927|DRUG|acetylsalicylic acid|
48519034|NCT00316927|DRUG|dexamethasone|
48519035|NCT00316927|DRUG|diethylstilbestrol|
48519036|NCT04997863|DEVICE|Sericin hydrogel sheet impregnated with EBN extract|Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
48519037|NCT04997863|DEVICE|Placebo hydrogel sheet|Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
48519038|NCT02413229|DRUG|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
48519039|NCT02413229|DRUG|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
48519040|NCT06582667|PROCEDURE|PENG block|US guided PENG block in hip fracture without anti thrombotic therapy
48519041|NCT04040556|OTHER|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
48519042|NCT00428233|PROCEDURE|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
48519043|NCT00000929|DRUG|Nonoxynol-9|
48519044|NCT03950154|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab injection
48519045|NCT03950154|DRUG|Oxaliplatin|Oxaliplatin injection
48519046|NCT03950154|DRUG|Capecitabine|Capecitabine oral agent
48519047|NCT03950154|BIOLOGICAL|PD1-T cells|PD1-T cells injection
48716828|NCT05990023|OTHER|Dual-task vestibule rehabilitation training|"* Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements."
48716829|NCT06002984|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
48716830|NCT02449018|DRUG|QBW251|QBW251 capsule(s) taken orally twice per day
48716831|NCT02449018|DRUG|Placebo|Matching placebo capsule(s) taken orally twice per day
48716832|NCT03382067|DIETARY_SUPPLEMENT|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
48716833|NCT03382067|OTHER|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
48716834|NCT04141189|PROCEDURE|weekly|fetal surveillance frequency
48716835|NCT04141189|PROCEDURE|bi-weekly|fetal surveillance frequency
48716836|NCT05268744|DRUG|Micronutrient|Subject will take micronutrient supplement daily for 8 weeks
48716837|NCT04132492|OTHER|no intervention|there is no intervention
48716838|NCT04304911|BEHAVIORAL|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
48716839|NCT04304911|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
48716840|NCT03305380|OTHER|No interventions|As this is a patient registry, there are no interventions.
48716841|NCT00913614|DRUG|Eplivanserin (SR46349)|Oral administration
48023363|NCT00055328|BEHAVIORAL|Problem-Solving Treatment for Primary Care|
48023364|NCT05134805|PROCEDURE|Bipolar hemiarthroplasty , proximal femoral nail|"* Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail)."
48023365|NCT04842695|DEVICE|electroacupuncture group|compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
48519048|NCT02072343|DEVICE|No-DCCM|
48519049|NCT02072343|DEVICE|DCCM|
48519050|NCT02072343|OTHER|Water 5ml in tracheal tube|
48519051|NCT02072343|OTHER|Water 10ml in tracheal tube|
48716842|NCT02215928|GENETIC|mutation analysis|Correlative studies
48023366|NCT02692989|PROCEDURE|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
48023367|NCT00145834|BEHAVIORAL|community based trial|
48716843|NCT02215928|OTHER|cytology specimen collection procedure|Correlative studies
48716844|NCT02215928|OTHER|laboratory biomarker analysis|Correlative studies
48716845|NCT03047291|DRUG|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
48716846|NCT03047291|DEVICE|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
48716847|NCT00371969|BEHAVIORAL|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
48716848|NCT00371969|BEHAVIORAL|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
48716849|NCT00111540|DRUG|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
48716850|NCT01312649|BEHAVIORAL|Experimental psychology methods (computer tests)|
48180846|NCT00938405|DRUG|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
48180847|NCT03667118|DIETARY_SUPPLEMENT|Food Supplement|A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
48381971|NCT06324968|DIAGNOSTIC_TEST|Positive serology for anti-SSA|Blood sample which detect serology for anti-SSA.
48381972|NCT06643975|OTHER|One-piece zirconia dental implants|One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
48381973|NCT06643975|OTHER|One-piece titanium dental implants|One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
48381974|NCT04666870|OTHER|myopia or not myopia|visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
48381975|NCT00733642|BIOLOGICAL|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
48381976|NCT00733642|BIOLOGICAL|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
48519052|NCT00805467|DRUG|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
48519053|NCT05682612|OTHER|outcome|hospital survivors and nonsurvivors
48519054|NCT05682612|OTHER|Subtype of COVID-19|Different subtype of COVID-19
48716851|NCT01304329|DRUG|BI 10773|Medium dose oral administration
48716852|NCT01304329|DRUG|simvastatin|Medium dose oral administration
48716853|NCT01304329|DRUG|simvastatin|Medium dose oral administration
48716854|NCT01304329|DRUG|BI 10773|Medium dose oral administration
48716855|NCT02745717|DRUG|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
48716856|NCT02745717|PROCEDURE|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
48716857|NCT02745717|DRUG|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
48716858|NCT03426631|DRUG|Placebo oral capsule|Placebo capsule 30 minutes before sleep
48716859|NCT03426631|DRUG|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
48716860|NCT00901511|PROCEDURE|Baseline WLL|Scheduled bilateral WLL
48716861|NCT00901511|DRUG|Sargramostim|Inhaled GM-CSF
48180848|NCT05176691|DRUG|HMPL-760|Administered orally QD for 28-day cycles
48180849|NCT06547788|OTHER|Mitral valve repair with creation of an 8 mm inter-atrial shunt|Mitral valve repair with creation of an 8 mm inter-atrial shunt
48381977|NCT00733642|BIOLOGICAL|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
48381978|NCT00733642|BIOLOGICAL|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
48381979|NCT03855930|DIAGNOSTIC_TEST|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
48381980|NCT06650813|OTHER|Drépa-FACETS Program|Drépa-FACETS Program for Sickle Cell Disease
48381981|NCT02701660|DEVICE|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
48381982|NCT04812548|DRUG|sabatolimab|Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days
48381983|NCT04812548|DRUG|azacitidine|A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).
48381984|NCT04812548|DRUG|venetoclax|Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
48381985|NCT01959984|OTHER|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
48381986|NCT01959984|OTHER|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
48381987|NCT06036914|DRUG|Bumetanide|Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
48519055|NCT02208830|OTHER|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
48519056|NCT02208830|OTHER|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
48716862|NCT00901511|PROCEDURE|Rescue WLL|Unscheduled bilateral WLL
48716863|NCT02087202|DRUG|Magnesium Sulfate|magnesium sulfate is added to the patients
48716864|NCT02087202|DRUG|ketamine|ketamine is added to the patients.
48716865|NCT01550393|GENETIC|proteomic profiling|
48716866|NCT01550393|OTHER|enzyme-linked immunosorbent assay|
48716867|NCT01550393|OTHER|laboratory biomarker analysis|
48716868|NCT01550393|OTHER|medical chart review|
48180850|NCT05367505|DEVICE|iFuse-3D implant|The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.
48180851|NCT00385307|DRUG|amibegron (SR58611A)|
48180852|NCT02447653|DEVICE|G7 HA Acetabular Component|G7 HA Acetabular Component
48180853|NCT02447653|DEVICE|G7 PPS Acetabular Component|G7 PPS Acetabular Component
48180854|NCT01715207|DRUG|Aliskiren|
48716869|NCT04933760|DIAGNOSTIC_TEST|Cytovale IntellipSep test|The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.
48180855|NCT01715207|DRUG|Atenolol|
48180856|NCT03702387|PROCEDURE|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
48180857|NCT02850042|BEHAVIORAL|Occupation-based practice (OBP)|
48180858|NCT02850042|BEHAVIORAL|Modified-constraint induced therapy (m-CIT)|
48180859|NCT05671354|DEVICE|the auto-wrapping commode chair|The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
48180860|NCT02874599|PROCEDURE|Dental restoration|Damaged teeth will be restored
48716870|NCT02686476|DRUG|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
48716871|NCT06518707|OTHER|Phrenic nerve stimulation|A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.
48716872|NCT02333981|DEVICE|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
48716873|NCT01028066|OTHER|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
48180861|NCT04211025|OTHER|Modest|The modest intervention consists of a 30-minute appointment (by phone or in-person) with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, the designated staff follows-up with a phone call or email.
48180862|NCT04211025|OTHER|Intensive|The intensive intervention consists of a 30-minute appointment with the designated staff using the Benefits Screening Tool , and a plan is developed. At 4 weeks, a follow-up appointment is booked for 30 minutes, and progress on the plan is assessed. At 12 weeks after the initial meeting, the designated staff follows-up with a phone call or email.
48180863|NCT01267240|DRUG|Capecitabine|Given PO
48180864|NCT01267240|DRUG|Vorinostat|Given PO
48180865|NCT01906697|PROCEDURE|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
48180866|NCT01906697|PROCEDURE|middle turbinate resection|middle turbinate resection
48180867|NCT01906697|PROCEDURE|middle turbinate medialization|middle turbinate medialization
48180868|NCT02866396|DRUG|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
48381988|NCT06036914|DRUG|Furosemide|"Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID."
48180869|NCT02866396|OTHER|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
48381989|NCT00288782|DRUG|Mirtazapine|
48381990|NCT03083457|DRUG|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
48381991|NCT03083457|DRUG|General anesthetic|Total intravenous anesthesia with a standard protocol
48381992|NCT03083457|DRUG|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
48381993|NCT03083457|PROCEDURE|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
48381994|NCT03083457|PROCEDURE|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
48519057|NCT06550947|GENETIC|Immunohistochemistry|Immunohistochemical expression of ALDOA in bladder urothelial carcinoma
48519058|NCT03817827|OTHER|Acupuncture|this group will receive Acupuncture for 30 minutes three times per week
48023368|NCT05582538|DRUG|Ceralasertib|240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
48381995|NCT04273659|DIETARY_SUPPLEMENT|Pulses and cereals|Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
48180870|NCT04738643|OTHER|Tobacco Use Treatment Service and Varenicline Management|The VM intervention builds upon the established TUT Service process. In addition to connecting the patient to TUT Service via electronic referral, it activates a medication management protocol that: 1) actively confirms no evidence of renal failure or pregnancy with oncology provider, 2) automates a referral to prescribing providers within the TUT Service team, prompting a call-back to patient within 24 hours, 3) provides written AVS instructions to contact TUT Service for initiation instructions and clinic appointment, and 4) pends a varenicline prescription to the medication list, ready for reconciliation by TUT Service prescribing clinicians. The protocol formalizes standard management principles for varenicline, including follow-up evaluation, pre-quit period duration, and side effect amelioration.
48180871|NCT00514800|BEHAVIORAL|Intervention - a validated home BP monitor and support from the specialist nurse|
48381996|NCT03372018|BEHAVIORAL|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
48381997|NCT03372018|BEHAVIORAL|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
48716874|NCT01028066|BEHAVIORAL|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
48716875|NCT04077294|OTHER|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
48023369|NCT05582538|DRUG|Durvalumab|1500 mg i.v. day 1 (q28)
48381998|NCT04048616|DIETARY_SUPPLEMENT|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
48023370|NCT05582538|DRUG|Nab-paclitaxel|100mg/m2 i.v. day 1,8,15 (q28)
48023371|NCT04544826|DRUG|JNJ-77474462|JNJ-77474462 will be administered as SC injection.
48023372|NCT04544826|DRUG|Placebo|Matching placebo to JNJ-77474462 will be administered as SC injection.
48381999|NCT04048616|DIETARY_SUPPLEMENT|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
48382000|NCT04048616|OTHER|microcrystalline cellulose|identical placebo capsule
48023373|NCT03952884|BEHAVIORAL|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
48023374|NCT03952884|BEHAVIORAL|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
48519059|NCT03817827|DIETARY_SUPPLEMENT|Diet supplementary|Diet supplementary with soy product
48519060|NCT02898376|OTHER|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa"
48519061|NCT02898376|DRUG|Pentoxifylline|400 mg bid during at least 6 months
48519062|NCT02898376|DRUG|Tocopherol acetate|500 mg bid during at least 6 months
48519063|NCT05368493|OTHER|MRI task|Task fMRI (Simon) \[ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. \] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
48023375|NCT03952884|DIETARY_SUPPLEMENT|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
48382001|NCT04048616|OTHER|maltodextrin powder|isocaloric placebo powder
48382002|NCT05156866|DRUG|TORL-2-307-ADC|antibody drug conjugate
48382003|NCT03815227|OTHER|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
48382004|NCT04160273|DIAGNOSTIC_TEST|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
48023376|NCT03952884|DIETARY_SUPPLEMENT|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
48023377|NCT05025293|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|100ml Zoledronic acid (5mg/100ml) administered intravenously
48023378|NCT05025293|DRUG|sodium chloride|100ml NaCl 9mg/ml administered intravenously
48023379|NCT05912946|DRUG|Interferon|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.
48023380|NCT05912946|DRUG|Sodium Hyaluronate|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.
48023381|NCT05912946|DRUG|Sodium Chloride Injection|The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
48023382|NCT05906407|OTHER|Genomic Profiling / Sequencing|Procedure: genomic profiling (Whole-Genome- / Exome-Sequencing + RNA-Sequencing) in high-risk early breast cancer patients pre- and post neoadjuvant therapy
48023383|NCT06535009|DRUG|ONO-7914|Specified dose on specified days
48716876|NCT04077294|OTHER|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
48716877|NCT00025116|DRUG|gefitinib|
48180872|NCT00514800|BEHAVIORAL|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
48382005|NCT06651333|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
48716878|NCT04907968|DRUG|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
48716879|NCT04907968|DRUG|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
48716880|NCT00456599|DRUG|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
48716881|NCT00456599|DRUG|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
48716882|NCT00456599|PROCEDURE|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
48023384|NCT06535009|DRUG|ONO-4538|Specified dose on specified days
48023385|NCT00053131|BIOLOGICAL|filgrastim|
48023386|NCT00053131|BIOLOGICAL|sargramostim|
48023387|NCT00053131|DRUG|cytarabine|
48023388|NCT00053131|DRUG|mitoxantrone hydrochloride|
48023389|NCT02820987|DRUG|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
48023390|NCT02820987|DRUG|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
48023391|NCT02820987|DRUG|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
48023392|NCT06315491|DRUG|CBX-12|CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
48023393|NCT01847508|DEVICE|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
48023394|NCT01847508|DEVICE|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
48519064|NCT04447560|PROCEDURE|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
48716883|NCT03043495|PROCEDURE|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
48716884|NCT03043495|DRUG|Dexamethasone|Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
48716885|NCT03381417|DRUG|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
48716886|NCT03381417|DRUG|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
48023395|NCT06535113|OTHER|Clinical Practice|"All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.~There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures."
48023396|NCT02782819|DRUG|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
48180873|NCT04319146|PROCEDURE|robot-assisted radical prostatectomy|robot-assisted radical prostatectomy as first-line treatment
48180874|NCT01390350|DRUG|Canakinumab|150mg subcutaneous injections on day 0
48180875|NCT01390350|DRUG|Placebo|150mg subcutaneous injections on day 0
48716887|NCT05393739|DEVICE|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
48716888|NCT05691023|DEVICE|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
48716889|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
48716890|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
48716891|NCT02382848|DRUG|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
48716892|NCT02382848|DRUG|Placebo|Prazosin-matched placebo pill
48382006|NCT06653673|BEHAVIORAL|ChatGPT supported Online Guided Self-Help Program (GSHP)|"Guided Self-Help Program (GSHP)~The Guided Self-Help Program (GSHP) was developed by Fairburn and Carter for patients with binge eating disorder and later adapted to address various eating behaviors, forming an intervention protocol. GSHP modules consist of:~Starting self-monitoring, Establishing regular eating patterns, Applying the mindful eating rule and developing alternatives to emotional eating, Practicing problem-solving exercises, Addressing diet-related issues and body image, and Termination modules.~Session Structure:~Session 1 focuses on tracking eating patterns and raising self-awareness about eating habits. Individuals are asked to maintain a daily record via a shared Google Forms link. This food diary is later processed through ChatGPT, and personalized feedback is provided.~Session 2 provides psychoeducation on developing regular eating patterns. It emphasizes recognizing hunger and satiety cycles and reducing triggers. Participants are asked to log their meals daily"
48519065|NCT02444910|DRUG|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
48519066|NCT00271232|DEVICE|Cardiac resynchronization therapy|
48519067|NCT01159730|DRUG|VB-201 or Placebo|
48023397|NCT02782819|DRUG|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
48023398|NCT05230329|PROCEDURE|right sided hemicolectomy, laparoscopy|Comparison of CME
48023399|NCT05145231|OTHER|observational|The scales will be filled by asking the family.
48023400|NCT00840970|DEVICE|non-coated Intranasal Splint|placement of non-coated intranasal splint following FESS
48023401|NCT00840970|DEVICE|Sinexus Intranasal Splint|placement of Sinexus Intranasal Splint placed following FESS
48023402|NCT02439086|DEVICE|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
48023403|NCT02567422|DRUG|Berzosertib|Given IV
48382007|NCT00250965|DRUG|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
48180876|NCT04182113|DEVICE|1 Hz rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
48180877|NCT04182113|DEVICE|Sham rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
48180878|NCT02363998|DRUG|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
48382008|NCT02294565|DRUG|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
48716893|NCT03294629|DEVICE|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
48716894|NCT02916225|BEHAVIORAL|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
48716895|NCT02916225|BEHAVIORAL|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
48716896|NCT02358655|OTHER|Retrospective review of OAC prescription|
48180879|NCT03903497|DEVICE|NBI|optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
48180880|NCT03457974|OTHER|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
48519068|NCT03583476|DRUG|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
48180881|NCT01485107|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
48180882|NCT01076764|DRUG|Otamixaban|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
48180883|NCT01076764|DRUG|Placebo (for Otamixaban)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
48023404|NCT02567422|DRUG|Cisplatin|Given IV
48023405|NCT02567422|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48023406|NCT02567422|OTHER|Laboratory Biomarker Analysis|Correlative studies
48023407|NCT02567422|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48023408|NCT02567422|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48023409|NCT02567422|RADIATION|Radiation Therapy|Undergo radiation therapy
48023410|NCT02449824|OTHER|magnetic resonance imaging|early MRI
48023411|NCT05109910|PROCEDURE|Pelvic lymph node dissection|Bilateral extended pelvic lymph node dissection
48023412|NCT01506245|BEHAVIORAL|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
48180884|NCT01076764|DRUG|UFH|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
48180885|NCT01076764|DRUG|Placebo (for UFH)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
48180886|NCT01076764|DRUG|Eptifibatide|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
48023413|NCT05166252|BEHAVIORAL|Time out from smartphone use during meal time|"One parent will be instructed to install a study app. Further, he/she press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and the parent needs to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the parent is instructed to take a picture with their smartphone from the smartphone-free family meal table . The time-out is over as soon as the parent presses the stop button."
48023414|NCT05166252|BEHAVIORAL|Control condition|The same as the experimental condition but without a timeout from smartphone use.
48023415|NCT06573333|PROCEDURE|Umblical Cord Clamping|Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate
48023416|NCT04964089|DRUG|KSI-301|Intravitreal Injection
48023417|NCT04964089|DRUG|Aflibercept|Intravitreal Injection
48023418|NCT04964089|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
48023419|NCT06535698|DIETARY_SUPPLEMENT|Perelel Health Hormonal Balance Support|The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine.
48382009|NCT02294565|DRUG|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
48382010|NCT04156009|OTHER|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
48382011|NCT04156009|OTHER|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
48023420|NCT00759967|PROCEDURE|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
48180887|NCT01076764|DRUG|Placebo (for Eptifibatide)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
48023421|NCT00759967|PROCEDURE|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
48023422|NCT02144675|DRUG|choline magnesium trisalicylate|Given PO
48023423|NCT02144675|DRUG|idarubicin|Given IV
48180888|NCT05146115|OTHER|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
48180889|NCT05889962|PROCEDURE|Pudendal nerve block|Patients who are randomized in the pudendal block group will receive bilateral pudendal nerve block with ropivacaine.
48180890|NCT05889962|PROCEDURE|Placebo block|Patients who are randomized in the placebo group will receive bilateral pudendal block with normal saline.
48382012|NCT03179462|DIETARY_SUPPLEMENT|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
48382013|NCT03179462|DIETARY_SUPPLEMENT|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
48023424|NCT02144675|DRUG|cytarabine|Given IV
48023425|NCT02144675|OTHER|laboratory biomarker analysis|Correlative studies
48023426|NCT00248222|BEHAVIORAL|Supervised aerobic training|
48180891|NCT02578498|DIETARY_SUPPLEMENT|High carbohydrate intake|Carbohydrate intake \< 50 gram
48180892|NCT02578498|DIETARY_SUPPLEMENT|Low carbohydrate intake|Carbohydrate intake \> 250 gram
48180893|NCT03008304|DRUG|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
48180894|NCT00585078|DRUG|Capecitabine|
48023427|NCT02709070|PROCEDURE|resection|hepatectomy for HCC
48023428|NCT02709070|PROCEDURE|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
48023429|NCT05958992|OTHER|E-cigarette|Participants will self-administer experimenter-provided e-cigarettes
48023430|NCT01218724|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
48180895|NCT00585078|DRUG|Oxaliplatin|
48180896|NCT01398696|PROCEDURE|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
48180897|NCT01398696|PROCEDURE|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
48180898|NCT05616598|DRUG|Sofosbuvir +daclatasvir+ simeprevir+Ribavirin|Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
48382014|NCT03179462|DIETARY_SUPPLEMENT|Tofu intake|Each participant will consume 2 ounces of tofu.
48382015|NCT06391047|OTHER|Mulligan's Squeeze Technique - manual therapy|This technique was introduced by Brian R. Mulligan. In this technique the therapist places thumb along the tender joint margin and applies force centrally. The patient actively flexes knee and therapist progressively enhances force and at end applies overpressure. This force is decreased as knee moves towards extension. This method helps to maintain the meniscus in its normal position and corrects the derangement of meniscus.
48382016|NCT06391047|OTHER|Conventional Physiotherapy|It includes stretching and strengthening exercises of muscles of the knee joint.
48382017|NCT05246982|DRUG|HLX07+HLX10+oxaliplatin+capecitabine|HLX07 1500mg+HLX10 300mg+oxaliplatin 130mg/m2+capecitabine 1000mg/m2 q3w
48716897|NCT02358655|OTHER|Prescription of OAC in ED|
48716898|NCT02358655|OTHER|Community AF clinic|
48023431|NCT01163734|DRUG|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
48023432|NCT01163734|OTHER|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
48023433|NCT04170127|PROCEDURE|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
48023434|NCT05091034|BEHAVIORAL|Controlling Asthma Program for Adolescents (CAMP Air)|Controlling Asthma Program for Adolescents (CAMP Air) is an e-health intervention grounded in social cognitive theory and motivational interviewing to guide teens through asthma self-care and how to navigate the health care system. It makes use of various interactive and personalized approaches.
48023435|NCT05091034|BEHAVIORAL|Attention Control Asthma Education Intervention|Using Asthma Plus, an asthma education program, teens learn about asthma and other conditions relevant to asthma and adolescents.
48023436|NCT01911052|OTHER|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
48180899|NCT05717218|DEVICE|Ultra-protective mechanical ventilation monitored by electrical impedance tomography|"A silicone EIT belt will be placed around the patient's thorax (sixth intercostal parasternal space). EIT data will be generated by application of a small alternating electrical current (5 mA at 50 kHz). Introduction of ultraprotective mechanical ventilation will be monitored."
48180900|NCT02409446|DIETARY_SUPPLEMENT|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
48382018|NCT05246982|DRUG|HLX07|HLX07 1500mg q3w
48382019|NCT03273257|DRUG|Riociguat|"Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
48382020|NCT03273257|DRUG|Placebo|Placebo will be given analogue to riociguat with matching tablets.
48382021|NCT03273257|PROCEDURE|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
48382022|NCT03286530|DRUG|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
48023437|NCT01911052|OTHER|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
48023438|NCT03475641|DRUG|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
48023439|NCT03475641|PROCEDURE|The current standard treatment|Tumescent anesthesia.
48023440|NCT03956602|OTHER|Pretzels|To examine postprandial responses of pretzel consumption
48023441|NCT03956602|OTHER|Brazil nuts|To examine postprandial responses of Brazil nut consumption
48023442|NCT03956602|OTHER|Potato chips|To examine postprandial responses of potato chip consumption
48023443|NCT03956602|OTHER|Mixed nuts|To examine postprandial responses of mixed nut consumption
48023444|NCT03956602|OTHER|White bread|To examine postprandial responses of white bread consumption
48023445|NCT03956602|OTHER|Dried mango|To examine postprandial responses of dried mango consumption
48180901|NCT06547216|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
48519069|NCT05616793|BIOLOGICAL|AAV8.hLCA5|Adeno-associated virus vector expressing human LCA5 gene
48519070|NCT02267018|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
48716899|NCT05210634|DIETARY_SUPPLEMENT|THCv|THCv in MCT oil
48716900|NCT01727011|RADIATION|IPAS|
48716901|NCT05667805|DRUG|Platelet Concentrate|Liberal use (standard treatment)
48716902|NCT05667805|DRUG|Prothrombin Complex Concentrate|Liberal use (standard treatment)
48716903|NCT05667805|OTHER|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
48716904|NCT06486272|OTHER|Financial Navigator|"Intervention: Access to a Financial Navigator We anticipate the Financial Navigator will meet at least 2 times and up to 2 additional visits, at a time convenient for the family. Examples of financial services that will likely be offered by the Financial Navigator are tax filing, applying for benefits and financial counseling. The program will be flexible and family centered. Families can choose if they would like to meet the Financial Navigator in person at the NNFU appointment, during another medical appointment, or at another time during a virtual visit. The Financial Navigator will be integrated into the existing SickKids Resource Navigation Service. At the 18-month NNFU visit the study will be completed."
48023446|NCT03956602|OTHER|Mango fruit|To examine postprandial responses of fresh mango consumption
48023447|NCT03055234|DRUG|Oral Treprostinil|Extended-release oral tablet for TID administration
48023448|NCT03055234|DRUG|Placebo|Matching placebo for TID administration
48023449|NCT06173154|OTHER|Care system to prevent ID|The caregivers of this unit receive training about iatrogenic dependency and how prevent it. They set up this prevention and the research compare evolution of dependence hospitalized patients.
48180902|NCT04961242|DEVICE|Together for Wellness digital mental health website|The intervention is a digital mental health resources website that includes multiple, free resources for broad public use. Different categories of resources include information on COVID-19 from CDC, multi-language versions of the UCLA Mindfulness App and other meditation programs, resources for families and social connection, including addressing discrimination or equity, and resource links.
48716905|NCT03442517|BEHAVIORAL|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
48716906|NCT03442517|OTHER|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
48716907|NCT01243567|DRUG|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
48716908|NCT01243567|DRUG|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
48023450|NCT06173154|OTHER|Routine care|standard care without any specific system in place
48023451|NCT05927441|DEVICE|DragonFly Transcatheter Mitral Valve Repair System|Edge-to-edge repair with DragonFly System
48023452|NCT05987891|DIAGNOSTIC_TEST|Treadmill exercise stress test|Ellestad protocol will be applied in all subjects up to fatigue and recovery will be monitored.
48023453|NCT04724811|PROCEDURE|Open reduction and internal fixation (ORIF)|"Approaches used:~* Intrapelvic approach +/- iliac window~* Kocher-Langenbeck approach"
48180903|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
48180904|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
48519071|NCT03305250|DEVICE|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
48716909|NCT01565395|DRUG|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
48716910|NCT01565395|DRUG|placebo|Sterile preservative free 0.9% saline
48023454|NCT02131298|DRUG|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
48023455|NCT02131298|DRUG|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
48023456|NCT05257538|OTHER|FMT|Fecal microbiota transfer from a healthy and tested volunteer
48180905|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
48180906|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
48716911|NCT01706042|OTHER|legume meal|
48716912|NCT01706042|OTHER|white bread|
48716913|NCT02459275|OTHER|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.
48382023|NCT06035328|OTHER|Wheat (Four times per week)|Case wheat allergy that on four times/week dose during one year maintenance phase of wheat OIT
48716914|NCT02459275|DRUG|Metoclopramide|Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
48716915|NCT00823212|DEVICE|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
48716916|NCT00823212|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
48716917|NCT00823212|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
48382024|NCT06540430|BEHAVIORAL|The Use of a Mobile Application for Stoma Self-Care|The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care. The app provides patients with information on diet, physical activity, stoma care, emotional support, and daily living needs.
48382025|NCT05543629|BIOLOGICAL|BMS-986442|Specified dose on specified days
48382026|NCT05543629|BIOLOGICAL|Nivolumab|Specified dose on specified days
48519072|NCT04092140|DEVICE|ultrasound|easy new non invasive tool
48023457|NCT05257538|OTHER|placebo enema|colored water enema
48023458|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
48382027|NCT05543629|DRUG|Docetaxel|Specified dose on specified days
48023459|NCT02117570|BIOLOGICAL|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
48023460|NCT02117570|BIOLOGICAL|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
48023461|NCT04455100|DRUG|SHR1459/Itraconazole|SHR1459 will be administered on Day 1 and Day 7. Itraconazole will be administered on Day 4 to Day 8
48023462|NCT00721526|DRUG|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
48382028|NCT05543629|DRUG|Carboplatin|Specified dose on specified days
48382029|NCT05543629|DRUG|Pemexetred|Specified dose on specified days
48382030|NCT05543629|DRUG|Paclitaxel|Specified dose on specified days
48382031|NCT05562232|DIETARY_SUPPLEMENT|Creatine Monohydrate|Follows
48519073|NCT05136807|OTHER|Quality-of-Life Assessment|Complete questionnaires
48180907|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
48180908|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
48180909|NCT03947008|OTHER|Intuitive Eating Program|"A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions."
48382032|NCT03969160|BEHAVIORAL|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
48382033|NCT06649630|DRUG|NNC0442-0344 A|"SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally."
48382034|NCT06649630|DRUG|Placebo|"SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally."
48382035|NCT02724215|DEVICE|Sleep Apnea Screening (Out of Center Polysomnography Device)|
48382036|NCT00882804|DRUG|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
48382037|NCT00882804|DRUG|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
48382038|NCT01797068|BEHAVIORAL|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
48023463|NCT05242614|BEHAVIORAL|The Hybrid Mindfulness-based Dementia caregiving program (MBDCP)|The hybrid MBDCP includes 6 weekly 90-minute group-based sessions delivered through a face-to-face (1st, 2nd, and 6th sessions) and online approach (3rd, 4th, and 5th sessions). The online session is designed for self-directed learning. The MBDCP includes different mindfulness practices (e.g., mindful eating, body scanning, and mindful walking), psychoeducation on caregiving, and group sharing, aimed at helping caregivers to develop mindfulness skills through the formal and informal practice of mindfulness, and to integrate these skills into their everyday life. The duration of each session is 90 minutes. Th MBDCP will be delivered by a qualified mindfulness therapist. In the MBDCP's online sessions, the caregivers will watch a teaching video (e.g., a video demonstrating mindfulness practices) through a website.
48023464|NCT05242614|BEHAVIORAL|Psychoeducation educational program|This program serves as a control for the social effects of the MBDCP. The brief education program consists of 6 weekly 90-minutes group sessions in which the sessions (1st, 2nd, and 6th) and (3rd 4th 5th) will be delivered through the face-to-face and online approach respectively, with the similar group size of the MBDCP. The education contents include caregiving skills, education on mood, and group sharing. The program will be led by a nurse.
48023465|NCT04488731|BEHAVIORAL|Normal BMI and moderate coffee consumption|Normal BMI and moderate coffee consumption
48023466|NCT04488731|BEHAVIORAL|Normal BMI and heavy coffee consumption|Normal BMI and heavy coffee consumption
48023467|NCT04488731|BEHAVIORAL|overweight and moderate coffee consumption|overweight and moderate coffee consumption
48382039|NCT01797068|OTHER|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
48382040|NCT02006810|BEHAVIORAL|Induction of endothelial function variations|
48382041|NCT01934062|PROCEDURE|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 \& 7/31/2013.~--------------------------------------------------------------------------------"
48382042|NCT05488067|DRUG|atorvastatin|Oral atorvastatin treatment for ALGS children with xanthoma
48382043|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
48382044|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
48382045|NCT02928991|OTHER|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
48382046|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
48382047|NCT03225313|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound \& locally surrounding the hernia
48382048|NCT03225313|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
48382049|NCT02922231|BIOLOGICAL|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
48382050|NCT02189200|DIETARY_SUPPLEMENT|oat bran - 40g|oat bran - 40g per day
48382051|NCT02189200|DIETARY_SUPPLEMENT|refined rice flour- 40g|refined rice flour - 40g per day
48023468|NCT04488731|BEHAVIORAL|overweight and heavy coffee consumption|overweight and heavy coffee consumption
48382052|NCT03205046|DRUG|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
48382053|NCT03205046|DRUG|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
48180910|NCT03667664|BEHAVIORAL|Physical exercises et nutritional counseling in elderly people at risks of loss of autonomy|"* Pre-program : eligibility criteria, nutritional status (MNA score, BMI, recent loss of weight), previous history, comorbidities, clinical examination, number of loss in the previous year, Rapid Assessment of Physical Activity score, activities of daily living and Instrumental activities of daily living, Medical Outcome Study Short Form 36 score, physical tests (Hand grip, Short Physical Performance Battery, Knee extension, Neurocom platform physical tests, Dual X-Ray Absorptiometry and Bio-impedance for Body Mass measurement, Muscular echography.~* Implementation of a one year multimodal program based on physical exercises and nutrition counseling as a way of preventing dependence and loss of autonomy in elderly people."
48180911|NCT04606147|PROCEDURE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions.in lateral position \&arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
48382054|NCT03062878|OTHER|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
48716918|NCT00823212|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
48716919|NCT04251975|DEVICE|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
48023469|NCT03891212|BEHAVIORAL|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
48023470|NCT03872050|DIAGNOSTIC_TEST|No intervention apart from tests, including interview|No interventions
48023471|NCT03062891|PROCEDURE|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
48023472|NCT00235534|BEHAVIORAL|Immediate initiation of OCPs|
48023473|NCT00235534|BEHAVIORAL|Delayed initiation of OCPs|
48023474|NCT02829034|DRUG|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
48023475|NCT02829034|DRUG|Placebo|Placebo by mouth twice per day for a total of 26 weeks
48023476|NCT02503280|DRUG|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10\^8 (200 million) hMSCs.
48023477|NCT02503280|DRUG|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10\^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
48023478|NCT02503280|DRUG|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
48023479|NCT02503280|DEVICE|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
48023480|NCT03274700|DRUG|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
48023481|NCT03274700|DRUG|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
48023482|NCT01979926|DRUG|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
48023483|NCT00359762|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
48023484|NCT00359762|DRUG|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
48023485|NCT05517343|OTHER|Real-time endoscopic optical diagnosis|The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
48023486|NCT06535282|OTHER|surgery|Surgical treatment of conductive hearing loss with tinnitus
48023487|NCT00560833|DRUG|esmirtazapine|
48023488|NCT00560833|DRUG|Placebo|
48023489|NCT06065696|PROCEDURE|Early mobilization|Patients who received early mobilization in postoperative period
48023490|NCT06065696|PROCEDURE|No early mobilization|Patients who did not receive early mobilization in postoperative period
48023491|NCT05313243|DRUG|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.
48023492|NCT05313243|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
48023493|NCT00539526|DRUG|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
48023494|NCT00539526|DRUG|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
48023495|NCT00539526|DRUG|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
48382055|NCT03062878|OTHER|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
48716920|NCT04459975|OTHER|Non interventional study|"Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis"
48716921|NCT03464422|BEHAVIORAL|ESTEEM conneCT|"The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
48180912|NCT04606147|PROCEDURE|Erector spinae plane block|The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
48382056|NCT03062878|OTHER|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
48382057|NCT03062878|OTHER|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
48382058|NCT06532162|DRUG|1% Lidocaine Paracervical Block|"A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm)."
48716922|NCT02654236|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
48716923|NCT02654236|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
48716924|NCT02421601|DRUG|Condoliase|1.25 U, intradiscal injection, one time
48716925|NCT03109262|PROCEDURE|Computed Tomography (CT)|As part of PET/CT and SPECT/CT scans.
48716926|NCT03109262|PROCEDURE|Positron Emission Tomography (PET)|As part of PET/CT scan
48023496|NCT05804058|PROCEDURE|Revision surgery|Patients due to undergo prosthetic revision surgery for any reason (infection or aseptic)
48023497|NCT05557279|DRUG|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
48023498|NCT02917109|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
48382059|NCT06532162|DRUG|Normal Saline Paracervical Injection|A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 4 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
48382060|NCT00572910|BIOLOGICAL|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
48382061|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
48382062|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
48382063|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
48382064|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
48382065|NCT00572910|BIOLOGICAL|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
48382066|NCT05489952|DRUG|iron sucrose and ferrous lactate|The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.
48382067|NCT03158857|DRUG|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
48519074|NCT05136807|OTHER|Questionnaire Administration|Complete questionnaires
48519075|NCT00659243|DRUG|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
48519076|NCT00659243|DRUG|Placebo|One week treatment
48716927|NCT03109262|DEVICE|90-Yttrium (Y-90) Glass Microspheres|Radiolabel for PET/CT scan
48716928|NCT03109262|DIAGNOSTIC_TEST|Technetium 99mTc albumin aggregated (99mTc-MAA)|Radiolabel for 99mTc-MAA SPECT/CT Scan
48716929|NCT03109262|PROCEDURE|Single-photon emission computerized tomography (SPECT) scan|As part of SPECT/CT scan
48716930|NCT04047420|DRUG|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
48716931|NCT02012686|DEVICE|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
48716932|NCT01316952|DRUG|Carvedilol immediate release only|All dosages of carvedilol immediate release
48716933|NCT01316952|DRUG|Carvedilol extended release only|All dosages of carvedilol extended release
48716934|NCT01316952|DRUG|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
48716935|NCT01316952|DRUG|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
48382068|NCT02492009|BEHAVIORAL|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
48382069|NCT02492009|BEHAVIORAL|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
48382070|NCT05647395|BEHAVIORAL|Tracheal tube cuffs differ in deflation|When removing the endotracheal tube, the gas in the cuff is drawn at a uniform and slow pace
48382071|NCT02217397|DEVICE|OA, CPAP, combination therapy|
48382072|NCT06068088|BEHAVIORAL|Self-administered survey at hospital|Self-administered survey on the food practices of the patient Completion before the beginning of chemoradiotherapy
48382073|NCT06068088|BIOLOGICAL|Blood sample for nutritional assessment|15 ml of blood sampled during nutritional examination before the beginning and during the month following the end of chemoradiotherapy
48382074|NCT06068088|OTHER|Consultation with nutritionist doctor and dietician|Before the beginning and during the month following the end of chemoradiotherapy Consultation of approximatively one hour
48382075|NCT04000958|DRUG|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
48382076|NCT04000958|DRUG|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
48023499|NCT02310438|OTHER|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
48382077|NCT06002828|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48716936|NCT01316952|DRUG|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
48716937|NCT01316952|OTHER|No β-blocker|No β-blocker within the month prior to the index date
48716938|NCT00343863|DRUG|palonosetron hydrochloride|Given IV
48716939|NCT00343863|DRUG|cyclophosphamide|Given orally
48716940|NCT00343863|DRUG|dexamethasone|Given orally or IV
48716941|NCT00343863|DRUG|doxorubicin hydrochloride|Given IV
48716942|NCT00343863|PROCEDURE|quality-of-life assessment|Ancillary studies
48382078|NCT06002828|OTHER|Quality-of-Life Assessment|Complete questionnaires
48716943|NCT00343863|PROCEDURE|nausea and vomiting therapy|Given IV
48716944|NCT00343863|PROCEDURE|management of therapy complications|Given IV
48716945|NCT00343863|DRUG|ondansetron hydrochloride|Given IV
48023500|NCT02033889|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
48023501|NCT02033889|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
48023502|NCT02033889|DRUG|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
48382079|NCT06002828|OTHER|Questionnaire Administration|Complete questionnaires
48382080|NCT05681299|DRUG|growth hormone and lirglutide|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
48382081|NCT05681299|DRUG|growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
48716946|NCT00343863|OTHER|survey administration|Ancillary studies
48716947|NCT05758285|OTHER|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
48716948|NCT00901797|PROCEDURE|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
48519077|NCT05639582|OTHER|fractal analysis|fractal analysis is a method that numerically expresses bone changes.
48716949|NCT00901797|PROCEDURE|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
48180913|NCT00741832|DEVICE|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
48180914|NCT00741832|OTHER|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
48180915|NCT02999243|BEHAVIORAL|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
48180916|NCT02999243|BEHAVIORAL|Harm reduction education|Both arms will receive harm reduction education
48180917|NCT04745936|OTHER|Style curve similar to natural curvature of endotracheal tube|Stylet curvature is made similar to the natural curvature of endotracheal tube for intubation using C-MAC videolaryngoscope.
48180918|NCT04745936|OTHER|Style curve similar to hockey stick shape|Stylet curvature is made similar to hockey stick shape for intubation using C-MAC videolaryngoscope.
48180919|NCT05200325|OTHER|Educational materials for TissueCypher|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
48382082|NCT05681299|DRUG|liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
48382083|NCT05681299|DRUG|Placebo|Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
48382084|NCT02871921|BEHAVIORAL|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated
48382085|NCT06411002|DRUG|DAXXIFY|Intramuscular injection of daxibotulintoxinA-lanm
48382086|NCT06653868|PROCEDURE|dental implant with bone augmentation|gap distance augmentation with bone graft
48382087|NCT04917406|DRUG|Application of lidocaine together with dexamethasone|Lidocaine 2% is applied on the positive pole while dexamethasone 4 mg/ml is applied on the negative pole. Through the use of current the drugs penetrate the fascia.
48382088|NCT04917406|DEVICE|Application of ultrasound as physical therapy|The application dose will be 0.65 Watt for 7 minutes in the area of most painful affectation by means of a circular movement and a 1MZ head.
48382089|NCT05371236|OTHER|Questionnaire|Phase I will use a descriptive qualitative approach to understand pediatric cancer patients' opinions related with spiritual issues and experience. The results of the qualitative study will be used to compare with the items of the original scale, and emerging themes will be used to generate new items. Phase Ⅱ will translates the original scale and validates the psychological properties of scale adapted for pediatric cancer patients.
48519078|NCT03153163|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
48519079|NCT00000967|DRUG|Interferon alfa-2a|
48519080|NCT00000967|DRUG|Zidovudine|
48519081|NCT02575833|DRUG|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
48519082|NCT02575833|DRUG|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
48519083|NCT02841501|GENETIC|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
48023503|NCT02033889|OTHER|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
48716950|NCT04577079|DEVICE|Evaluation of the need of emergency medical services|The main aim of this study is to validate the use of IPFM in a hospital setting by evaluating the association of IPFM output with 1) clinical urgency and severity of the conditions (using Emergency Severity Index \[ESI\], an international triaging protocol for emergency units, and an assessment by triage nurse); and 2) actual diagnoses made by the hospital doctors. The objective is also to assess the correlation of IPFM output with redirection or referral to various specialties
48716951|NCT02352636|OTHER|magnetotherapy|The magnetic pellets will contain an average of \~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
48023504|NCT02033889|DRUG|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
48023505|NCT02033889|BIOLOGICAL|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
48382090|NCT06515925|BEHAVIORAL|Our Whole Lives (OWL)|"OWL is a nine-session, web-accessible, self-paced mindfulness curriculum that has interactive components of self-monitoring and social support (online community). Our Whole Lives (OWL) online curriculum of self-management topics such as mindfulness, mind-body practices, education about chronic pain therapies, stress reduction, sleep, and nutrition.~Once a week for 9 weeks participants will attend a 1.5 -2-hour online group session via Zoom or Google Meets, accessing it through GEMINI platform."
48382091|NCT06515925|BEHAVIORAL|Low Dose Mindfulness Training|The GEMINI platform will facilitate the delivery of a low-dose version of Our Whole Lives program. OWL in this arm is a nine-session, web-accessible, self-paced curriculum, self-monitoring. Participants will interface with the GEMINI platform's static content.
48382092|NCT02837666|DIETARY_SUPPLEMENT|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
48382093|NCT02837666|OTHER|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
48382094|NCT02837666|OTHER|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
48382095|NCT02837666|OTHER|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
48519084|NCT03126435|DRUG|EndoTAG-1|twice weekly
48716952|NCT02352636|DEVICE|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
48716953|NCT02352636|OTHER|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
48023506|NCT02033889|DRUG|Metformin|Metformin \>=1500 mg/day, orally, once a day
48023507|NCT00062244|BIOLOGICAL|oblimersen sodium|Given IV
48023508|NCT03678181|BEHAVIORAL|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
48023509|NCT03678181|BEHAVIORAL|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
48023510|NCT03678181|BEHAVIORAL|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
48023511|NCT06458010|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
48023512|NCT01969838|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
48023513|NCT01969838|DRUG|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
48023514|NCT01969838|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
48023515|NCT01969838|DRUG|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
48023516|NCT04315311|DRUG|CREON|Capsule: Oral
48023517|NCT05158946|BEHAVIORAL|Future Oriented Group Training|This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
48023518|NCT02211300|DEVICE|The OptiScanner|treatment of blood glucose per standard of care
48180920|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
48180921|NCT01038453|OTHER|placebo tablet|placebo 2 tablet, once a day,
48180922|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
48519085|NCT03126435|DRUG|Gemcitabine|once weekly
48519086|NCT03240029|OTHER|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
48519087|NCT02848001|DRUG|CC-90009|CC-90009
48716954|NCT03741803|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
48023519|NCT02211300|DEVICE|YSI 2300 STAT Plus™|
48519088|NCT00528047|DRUG|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
48716955|NCT03741803|PROCEDURE|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
48716956|NCT02389205|OTHER|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
48716957|NCT00031980|DRUG|cyclosporine|
48716958|NCT03823872|OTHER|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
48716959|NCT03823872|OTHER|Normal feeding|Normal feeding= consume food per normal schedule
48716960|NCT03618940|BEHAVIORAL|Knowledge and Attitude on burn prevention|"1.Introduction to Home Safety~2 Fire Safety \& Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust \&First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical \& Appliances \& Outlets)~4 Firecrackers Safety (Safety around Firecrackers \& Open Flames)~5. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop \& Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke"
48180923|NCT02386878|BEHAVIORAL|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
48382096|NCT02837666|OTHER|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
48519089|NCT02436226|DRUG|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
48716961|NCT02036736|DRUG|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
48716962|NCT02036736|DRUG|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
48716963|NCT04728594|BEHAVIORAL|Social Proof|Email
48716964|NCT04728594|BEHAVIORAL|Reframing|Email
48716965|NCT04728594|BEHAVIORAL|Scarcity Message|Email
48382097|NCT06474780|DEVICE|Weight: 414g Size: 19.5cm x 14cm x 11cm Compatibility: Android and iOS VR Box 3.0 3D Virtual Reality Glasses Has the Feature of Fixation with Headband It has a lens mechanism tha|Patients in the experimental group were fitted with virtual reality glasses for 3 cycles and were allowed to watch videos of city tours, walks in the forest, and nature walks for 15 minutes, depending on their choice.
48382098|NCT01463631|DRUG|LY3007113|Administered orally
48382099|NCT04980599|DIETARY_SUPPLEMENT|probiotic drink with Lactobacillus paracasei K56|Probiotic drink (K56 10\^11CFU) 350ml/d for 60days
48382100|NCT04980599|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin ,for 60days
48382101|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E3|Probiotic powder 3.0g/d (K56 10\^10cfu) 60days;
48716966|NCT02723370|BEHAVIORAL|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
48716967|NCT03189654|DEVICE|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
48716968|NCT05491746|DEVICE|Eye4|Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.
48716969|NCT05491746|OTHER|Placebo|This is the patient's best corrected vision with or without glasses/contact lenses
48716970|NCT00432744|DRUG|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
48716971|NCT00432744|DRUG|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
48716972|NCT00979355|DEVICE|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
48716973|NCT05186441|OTHER|DMPFC iTBS|The intermittent theta-burst stimulation (iTBS) (i.e. two excitatory intervention paradigm) to target DMFPC can improve out-of-control behavior and decision-making model.
48180924|NCT02386878|BEHAVIORAL|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
48716974|NCT05186441|OTHER|DLPFC iTBS|The intermittent theta-burst stimulation (iTBS) to target DLFPC (i.e. region within the executive control network) can effectively reduce craving, which is probably associated with enhancement of executive function.
48716975|NCT05120947|RADIATION|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
48716976|NCT05120947|RADIATION|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
48382102|NCT04980599|DIETARY_SUPPLEMENT|Probiotic powder E5|probiotic powder 8g/day for 60days
48716977|NCT05120947|RADIATION|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
48382103|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E7|probiotic k56 capsule, 2capsules/d (10\^7cfu) for 60days
48382104|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E9|probiotic k56 capsule, 2capsules/d (10\^9cfu) for 60days
48382105|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E10|probiotic k56 capsule, 2capsules/d (10\^10cfu) for 60days
48382106|NCT04980599|DIETARY_SUPPLEMENT|probiotic capsule E11|probiotic k56 capsule, 4capsules/d (10\^11cfu) for 60days
48382107|NCT00474370|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
48382108|NCT00474370|DRUG|Placebo|One tablet of placebo once daily.
48382109|NCT02111265|DRUG|Remifentanil|"1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure"
48382110|NCT02111265|DRUG|Cisatracurium|"1. Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~2. Cisatracurium is stopped before skin closure."
48382111|NCT02111265|DRUG|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
48382112|NCT02111265|DEVICE|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
48382113|NCT03679234|OTHER|Routine infant formula|Routine infant formula with probiotic
48382114|NCT05888818|OTHER|Cold application|A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
48382115|NCT03361709|DRUG|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
48023520|NCT02349711|DIETARY_SUPPLEMENT|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
48023521|NCT02349711|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
48023522|NCT03701659|PROCEDURE|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
48716978|NCT03412149|PROCEDURE|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
48023523|NCT03701659|DRUG|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
48023524|NCT02148094|DRUG|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
48180925|NCT02284009|BIOLOGICAL|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
48716979|NCT03412149|PROCEDURE|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
48716980|NCT03099148|DRUG|Reference Formulation (R)|Administered PO
48519090|NCT02436226|DRUG|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
48519091|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
48519092|NCT01085071|DRUG|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
48716981|NCT03099148|DRUG|LY3337641 (T1)|20 mg PO
48519093|NCT03845192|DEVICE|ORI measurement by Radical 97|"ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®."
48716982|NCT03099148|DRUG|LY3337641 (T2)|20 mg PO
48023525|NCT03280277|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
48023526|NCT03280277|DRUG|Ferumoxytol|Given IV
48716983|NCT03299543|DEVICE|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
48023527|NCT05953194|BEHAVIORAL|Exposure to counter-marketing messages|Counter-marketing messages about sugary drinks that incorporate principles of effective counter-marketing campaigns, including describing industry manipulation of consumers, appealing to emotions (especially anger), describing health consequences, and criticizing the industry for demographic targeting. Messages include text adapted from prior counter-marketing campaigns. Participants will view a total of 4 messages developed for this arm.
48716984|NCT01754194|PROCEDURE|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
48716985|NCT01754194|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
48716986|NCT05458661|DEVICE|Clinical Prototype BioBase (SN 07 and SN 08)|Scheimpflug- or OCT based corneal tomographers with the ability to measure anterior and posterior corneal curvature maps \>6mm diameter and corneal pachymetry maps \>6mm.
48716987|NCT01053013|BIOLOGICAL|RENCA macrobeads|
48716988|NCT05471180|OTHER|protective spray film|Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film.
48716989|NCT05471180|DEVICE|photobiomodulation therapy|application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days.
48716990|NCT01668641|DRUG|GLPG0634|
48716991|NCT01668641|DRUG|Placebo|
48716992|NCT03508323|DRUG|Teneligliptin|20mg/qd
48716993|NCT03508323|DRUG|Placebo|1T/qd
48382116|NCT03361709|DRUG|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
48023528|NCT05953194|BEHAVIORAL|Exposure to traditional health messages|Traditional health messages focused on the health consequences of sugar-sweetened beverage consumption, using text adapted from prior sugary drink campaigns. Participants will view a total of 4 messages developed for this arm.
48023529|NCT05953194|BEHAVIORAL|Exposure to control (neutral) messages|Control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
48180926|NCT02284009|BIOLOGICAL|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
48519094|NCT05492643|BIOLOGICAL|one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
48023530|NCT02784418|PROCEDURE|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
48180927|NCT02284009|BIOLOGICAL|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
48382117|NCT03233191|PROCEDURE|Digital Mammography|Undergo DM
48382118|NCT03233191|PROCEDURE|Digital Tomosynthesis Mammography|Undergo TM
48382119|NCT03233191|OTHER|Laboratory Biomarker Analysis|Correlative studies
48382120|NCT05039931|DRUG|GNC-035|Administration by intravenous infusion.
48382121|NCT06013462|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK (Descemet Membrane Endothelial Keratoplasty) is a surgical technique used to treat primary or secondary corneal endothelial decompensation.
48382122|NCT06226571|DRUG|SNDX-5613|Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
48382123|NCT06226571|DRUG|Chemotherapy Regimen|Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
48382124|NCT06226571|DRUG|HiDAC|Consolidation: Participants will receive HiDAC IV.
48716994|NCT05838014|OTHER|Sleep deprivation|Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise
48716995|NCT05838014|OTHER|Normal sleep|Participants will undertake \~8 hours of normal sleep prior to completing exercise
48716996|NCT02725112|DRUG|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
48716997|NCT02725112|DRUG|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
48023531|NCT02784418|PROCEDURE|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
48023532|NCT03270761|OTHER||
48023533|NCT06561113|OTHER|Caffeine intake|One cup of Turkish coffee contains 60 mg/65 ml (1 Turkish coffee cup) of caffeine. Participants will be instructed to sit for 10 minutes before drinking coffee. To prepare the Turkish coffee, 5 g of ground dry coffee will be mixed in 100 mL of tap water and left to boil in a coffee machine. When the first boil starts, it will be removed from the machine and poured into the cup. Then, 65 ml of Turkish coffee will be given to the subjects to ensure oral caffeine intake.
48023534|NCT05761691|PROCEDURE|Dental treatment|Children treated for ECC under general (DGA) and local anesthesia (LA).
48180928|NCT00466713|DRUG|Rosiglitazone therapy|
48382125|NCT01569594|DEVICE|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
48382126|NCT06491264|DEVICE|Transcranial electrical stimulation|We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
48382127|NCT05964400|BEHAVIORAL|duoABLE|Stroke participant-caregiver duos (dyads) will meet with an occupational therapist 12 times (2x/week for 6 weeks, approximately 30 minutes/session) to apply activity monitoring, activity scheduling, collaborative problem solving, self-assessment, and social interdependence to self-selected activities that aim to increase both dyad members' physical activity levels
48382128|NCT02575807|BIOLOGICAL|CRS-207|via IV infusion
48382129|NCT02575807|DRUG|Epacadostat|PO BID
48382130|NCT02575807|BIOLOGICAL|Pembrolizumab|via IV infusion
48382131|NCT06138041|DRUG|intravenous lidocaine infusion|Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.
48716998|NCT02725112|DRUG|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
48716999|NCT02725112|DRUG|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
48717000|NCT02725112|DRUG|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
48717001|NCT02725112|DRUG|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
48717002|NCT03299231|DEVICE|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
48382132|NCT06138041|DRUG|Saline|Same volume of normal saline in bolus and continuous infusion as lidocaine group.
48382133|NCT01440608|DRUG|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
48382134|NCT01440608|DRUG|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
48519095|NCT05492643|OTHER|Cellular Immunity|the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
48519096|NCT05492643|OTHER|Humoral Immunity|the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
48519097|NCT05492643|OTHER|Safety|all the 500 participants enrolled will undergo safety observation
48519098|NCT03953612|DRUG|Pregnenolone (PREG)|2 doses of PREG (300 or 500 mg/day)
48519099|NCT03953612|DRUG|Placebos|placebo
48180929|NCT00080990|DRUG|alvocidib|Given IV
48519100|NCT05161910|OTHER|Biomarkers|Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).
48519101|NCT00709995|DRUG|Enzastaurin|Administered orally
48717003|NCT03299231|DEVICE|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
48519102|NCT00709995|DRUG|Sunitinib|Administered orally
48180930|NCT00080990|DRUG|fluorouracil|Given IV
48180931|NCT00080990|DRUG|oxaliplatin|Given IV
48382135|NCT01440608|DIETARY_SUPPLEMENT|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
48382136|NCT03531684|DIETARY_SUPPLEMENT|MMFS-205-SR|Twice daily, oral, 500 mg tablets
48519103|NCT00709995|DRUG|Placebo|Administered orally
48519104|NCT03839537|OTHER|Exposure measurement|"* 2 measurements per subject (in warm season and in cold season)~* Devices placed inside taxi vehicles on the passenger seat in a sampling bag"
48717004|NCT02190305|DEVICE|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
48519105|NCT03839537|OTHER|Spirometry test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will inhale and exhale in the device"
48519106|NCT03839537|DIAGNOSTIC_TEST|Exhaled carbon monoxide test|"* 2 measurements per subject - before and after the work shift - in warm and cold seasons~* Subject will exhale in the device"
48519107|NCT03839537|DIAGNOSTIC_TEST|Skin allergy test|- Performed by a physician during the inclusion clinical examination
48519108|NCT03839537|DIAGNOSTIC_TEST|Spirometry test|- Performed by a physician during the inclusion clinical examination
48717005|NCT06466993|BEHAVIORAL|Intervention of standardized relaxing breathing|Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
48180932|NCT00080990|DRUG|leucovorin calcium|Given IV
48180933|NCT04460833|DEVICE|Feedback modalities given through an augmented reality headset|All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
48180934|NCT06102564|BEHAVIORAL|Group schematherapy|Brief group schematherapy for mothers with young children (age 0-5) focused on attachment relations between mother and child
48180935|NCT01449786|DRUG|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
48717006|NCT02794389|DRUG|N-acetyl cysteine|
48180936|NCT01449786|DRUG|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
48382137|NCT03531684|DIETARY_SUPPLEMENT|Placebo|Twice daily, oral
48717007|NCT02794389|DRUG|Placebo|
48717008|NCT02827383|BEHAVIORAL|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
48382138|NCT03960268|DRUG|Brodalumab|interleukin 17 receptor A antagonist
48382139|NCT05919771|OTHER|rock climbing|Vertical ascent of a surface specifically designed to elicit the skills that might be required to scale a naturally occurring rock formation
48382140|NCT00319488|DRUG|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
48382141|NCT00319488|DRUG|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
48382142|NCT00319488|DRUG|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
48023535|NCT05257889|DIAGNOSTIC_TEST|blood and CSF studies + neuroimaging studies|blood and CSF studies + neuroimaging studies
48023536|NCT03464682|DRUG|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
48717009|NCT04069377|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
48717010|NCT04069377|OTHER|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
48717011|NCT00404170|DRUG|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
48023537|NCT03464682|DRUG|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
48023538|NCT03464682|DRUG|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
48382143|NCT00929552|DIETARY_SUPPLEMENT|Dietary oils (fish, vegetable oil)|6g pr day.
48717012|NCT01632644|OTHER|Survey/Interview|Each group will be surveyed and interviewed.
48717013|NCT04832139|DRUG|Marstacimab PFP|300 milligrams (mg) subcutaneous injection marstacimab PFP
48717014|NCT04832139|DRUG|Marstacimab PFS|300 mg subcutaneous injection of marstacimab PFS
48717015|NCT04284566|BEHAVIORAL|TAU + multicomponent treatment FIBROWALK|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
48717016|NCT04284566|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
48717017|NCT03610139|DIETARY_SUPPLEMENT|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
48717018|NCT00033540|DRUG|capecitabine|650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
48717019|NCT00033540|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
48717020|NCT02131519|PROCEDURE|internal jugular vein catheter placement|
48717021|NCT00661388|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
48717022|NCT02178046|DEVICE|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
48023539|NCT03464682|DRUG|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
48023540|NCT03464682|DRUG|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
48180937|NCT01449786|OTHER|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
48180938|NCT05762952|DRUG|Dapagliflozin 10mg Tab|Once daily oral dapagliflozin 10mg
48382144|NCT06651424|DIETARY_SUPPLEMENT|Combination of Lactobacillus probiotics (no comercial)|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
48382145|NCT06651424|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
48023541|NCT03464682|DRUG|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
48023542|NCT02998294|DEVICE|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
48023543|NCT02998294|DEVICE|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
48023544|NCT05634681|RADIATION|Plan of the day|Several treatment plans are prepared and the appropriate plan is used at each treatment session.
48023545|NCT05634681|RADIATION|Standard plan|One treatment plan
48180939|NCT05762952|DRUG|Placebo|Placebo capsules formulated by pharmacy to be indistinguishable from active drug
48180940|NCT00585871|DRUG|clonidine|0.1 mg tid
48180941|NCT00585871|DRUG|metoprolol|25 mg tid
48180942|NCT02978677|RADIATION|Radiotherapy 68 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton
48180943|NCT02978677|RADIATION|Radiotherapy 72 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton
48180944|NCT02978677|RADIATION|Radiotherapy 60 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton
48180945|NCT00926575|DRUG|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
48382146|NCT01015118|DRUG|Placebo|comparator to BIBF 1120
48382147|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
48382148|NCT01015118|DRUG|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
48382149|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
48717023|NCT01180608|OTHER|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)"
48180946|NCT00926575|DRUG|Placebo|Two tablets QID for 50 days
48180947|NCT04783103|DEVICE|a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil|3 weeks home use
48180948|NCT00609401|DRUG|Nexavar (Sorafenib)|400 mg bid
48180949|NCT00609401|DRUG|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
48180950|NCT05489562|DEVICE|Intraoral Suction|stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
48519109|NCT03839537|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide Testing|- Performed by a physician during the inclusion clinical examination
48519110|NCT00047112|DRUG|cisplatin|
48717024|NCT03759964|DRUG|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
48717025|NCT03759964|DRUG|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
48180951|NCT01475422|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
48717026|NCT06105658|BIOLOGICAL|Unrelated umbilical cord blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
48180952|NCT01475422|BEHAVIORAL|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
48717027|NCT06105658|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
48180953|NCT04627415|BEHAVIORAL|Promoting Engagement with ADHD Pre-Kindergarteners|Optimism Training includes the following strategies: 1) Identifying situations and associations 2) Determining consequences of beliefs 3) Use distractions to interrupt negative thinking 4) dispute current thinking 5) substitute positive, productive thoughts 6) practice skills to recognize/modify self-talk 7) Maintain positive changes in self-talk
48180954|NCT04419805|DEVICE|Single Palatal TAD|A single mini-screw inserted in the mid-palate
48180955|NCT04419805|DEVICE|Two buccal TADs|Two buccal TADs inserted in the upper jaw
48519111|NCT00047112|DRUG|fluorouracil|
48519112|NCT00047112|PROCEDURE|conventional surgery|
48519113|NCT00047112|PROCEDURE|neoadjuvant therapy|
48519114|NCT00047112|RADIATION|radiation therapy|
48180956|NCT03259399|GENETIC|detection of genotype|detection of genotype by next generation sequencing
48180957|NCT06485336|DRUG|Atorvastatin 40mg|Each tablet will be taken once daily for 84 days.
48519115|NCT06407739|OTHER|Three-Phase Physical Therapy Intervention|Phase 1: It include subtalar and talocrural joint mobilization in the supine position along with stretching and home education Stage 2: It include subtalar and talocrural joint mobilization in the supine position along with Kinesiotaping and functional exercises Phase 3: this phase include balance and propioceptive training aling with along with strengthening exercises of peroneal and tibialis anterior
48519116|NCT04071405|OTHER|Non-intervention|Non-intervention observational study
48717028|NCT06105658|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
48717029|NCT06105658|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
48717030|NCT01195688|DRUG|BI 638683 or placebo|oral doses given to 6 subjects per dose group
48180958|NCT06485336|DRUG|Placebo|Each tablet will be taken once daily for 84 days.
48180959|NCT04054414|DRUG|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
48180960|NCT04054414|DRUG|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
48180961|NCT01636622|DRUG|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
48382150|NCT01015118|DRUG|Paclitaxel|Paclitaxel (standard chemo-therapy)
48519117|NCT05765500|DRUG|Relugolix|Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
48519118|NCT05765500|DRUG|Leuprolide|Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
48519119|NCT04458285|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.
48519120|NCT04458285|DRUG|Valsartan 80mg Tablet|Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
48519121|NCT06581900|OTHER|Vitamin B12|Quantification of Vitamin B12
48717031|NCT01195688|DRUG|Placebo solution|oral doses given to 2 subjects per dose group
48717032|NCT06458231|DEVICE|Blood Catheters|Central line as a predisposing factor for Blood stream infection
48717033|NCT05060380|OTHER|Exercise training|Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.
48717034|NCT04566653|DRUG|Calcium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
48717035|NCT04566653|DRUG|Lokelma® 5 g/45mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
48717036|NCT04566653|DRUG|Lokelma® 10 g/45 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
48717037|NCT04566653|DRUG|Veltassa® 8,4 g/80mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
48717038|NCT04566653|DRUG|Sodium Polystyrene Sulphonate 15g/60 mL water|K+ binder, not for treatment but for tasting (sip-and-spit taste test)
48717039|NCT02535416|DRUG|ARC-520|
48717040|NCT02535416|DRUG|cetirizine|
48717041|NCT02535416|DRUG|diphenhydramine|
48180962|NCT01636622|DRUG|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
48180963|NCT01636622|DRUG|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
48382151|NCT01015118|DRUG|Carboplatin|Carboplatin (standard chemo-therapy)
48382152|NCT02943369|DRUG|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
48382153|NCT02943369|DRUG|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
48382154|NCT06651645|OTHER|COVID-19 Surge|Impact of COVID-19 pandemic on hospital care delivery
48382155|NCT05132543|DEVICE|High density micro-electrocorticography for neural speech prothesis|ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
48382156|NCT04130555|DEVICE|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
48382157|NCT01261962|DIETARY_SUPPLEMENT|zinc|zinc sulfate, 35 mg twice daily for 4 months
48382158|NCT01261962|OTHER|Placebo|Placebo, One capsule, twice daily for 4 months
48519122|NCT03697824|DRUG|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
48519123|NCT03697824|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
48180964|NCT00513201|DRUG|lyspro|
48519124|NCT03697824|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
48717042|NCT04838704|DRUG|Ruxolitinib+Calcineurin +Methotrexate|low-dose ruxolitinib combine with calcineurin and short course of methotrexate.
48717043|NCT04838704|DRUG|Calcineurin +Methotrexate+Mycophenolate mofetil|calcineurin and short course of methotrexate and mycophenolate mofetil
48717044|NCT03926962|DRUG|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
48717045|NCT03926962|DRUG|Placebo Oral Tablet|Visually matching placebo
48717046|NCT02745847|RADIATION|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
48717047|NCT04761744|DRUG|Nivolumab|Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
48717048|NCT06339138|OTHER|Non-Interventional Study|Non-interventional study
48717049|NCT01077180|DEVICE|Implantation of the Rheos System|Open label
48717050|NCT01077180|OTHER|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
48717051|NCT00346840|DRUG|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
48717052|NCT00346840|DRUG|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
48180965|NCT00513201|DRUG|regular insulin|
48180966|NCT00166881|DRUG|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
48180967|NCT04797390|DEVICE|Advanced Pneumatic Compression Device (APCD)|Once daily treatment with Flexitouch Plus.
48382159|NCT00678652|BIOLOGICAL|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
48382160|NCT00678652|BIOLOGICAL|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
48382161|NCT00678652|BIOLOGICAL|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
48382162|NCT00678652|BIOLOGICAL|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
48382163|NCT01320826|PROCEDURE|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
48519125|NCT03697824|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
48519126|NCT00398866|DRUG|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
48717053|NCT00346840|DRUG|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
48717054|NCT00346840|DRUG|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
48717055|NCT05792267|DEVICE|artificial intelligence system|Patients will undergo EUS examination with the assistance of artificial intelligence(AI) system.
48717056|NCT05042609|DRUG|TRS01|TRS01 eye drops Dosed four times a day (QID)
48717057|NCT05042609|DRUG|FDA approved steroid eye drop (masked)|FDA approved steroid eye drop Dosed four times a day (QID)
48717058|NCT03916016|BEHAVIORAL|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
48717059|NCT03916016|BEHAVIORAL|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
48717060|NCT02593708|DRUG|Neratinib|
48717061|NCT02593708|DRUG|Paclitaxel|
48180968|NCT04797390|OTHER|Usual Care|Usual care consists of a two-phase CDT. Phase 1 includes consultation with a lymphedema therapist, patient education, MLD, compression garments or bandages, skin care techniques, and a program of exercises and postural recommendations. Phase 2 consists of ongoing self-care, where patients conduct a life-long program of disease management that mimics the program in phase 1.
48180969|NCT03780010|DRUG|TRC105|Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
48180970|NCT06031636|DRUG|Oncolytic Adenovirus H101|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
48717062|NCT02593708|DRUG|Pertuzumab|
48180971|NCT06031636|DRUG|Programmed death receptor-1 inhibitor|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
48180972|NCT03050190|GENETIC|Therapeutic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
48180973|NCT01062269|DRUG|Cholestyramine|Cholestyramine 4 grams one time dose
48180974|NCT01062269|DRUG|Cholestyramine|Cholestyramine 12 grams one dose, one day
48180975|NCT01062269|DRUG|Tang|Tang one dose one day
48382164|NCT03503201|DIETARY_SUPPLEMENT|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
48382165|NCT04936568|OTHER|Palliative Care Referral System - PCRS|Implementation of a system to help oncologists to identify criteria for referring patients to specialized outpatient palliative care (Palliative Care Referral System - PCRS)
48382166|NCT03854799|DRUG|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
48519127|NCT00398866|DRUG|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
48717063|NCT02593708|DRUG|Trastuzumab|
48717064|NCT00693654|DRUG|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (\&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
48180976|NCT04127071|PROCEDURE|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
48180977|NCT04127071|PROCEDURE|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
48180978|NCT02518815|DEVICE|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
48180979|NCT06395922|DEVICE|Blockbuster LMA|The LMA was inserted using the recommended technique, with the patient's head in the sniffing position. The appropriate size was selected based on body weight (size 3 for 30-50 kg, size 4 for 50-70 kg)
48180980|NCT06395922|DEVICE|Baska Mask|The BM was inserted by opening the mouth, avoiding the tongue, and negotiating the palatopharyngeal curve using the hand-tab.
48180981|NCT04346810|OTHER|Patient management suffering of coronavirus infection|Welle-being and stress of the caregivers
48180982|NCT02552017|DEVICE|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
48180983|NCT00443209|DRUG|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
48717065|NCT00693654|DRUG|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
48717066|NCT00764907|DRUG|asparaginase|Given IV during reinduction
48717067|NCT00764907|DRUG|cyclophosphamide|Given IV during reinduction
48717068|NCT00764907|DRUG|cytarabine|Given IV during reinduction
48180984|NCT00443209|DRUG|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
48180985|NCT00443209|DRUG|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
48180986|NCT00443209|DRUG|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
48180987|NCT00443209|DRUG|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
48180988|NCT00443209|DRUG|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
48180989|NCT01258647|DIETARY_SUPPLEMENT|caterpillar cereal|A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
48180990|NCT01410864|DEVICE|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
48717069|NCT00764907|DRUG|daunorubicin hydrochloride|Given IV during reinduction
48717070|NCT00764907|DRUG|dexamethasone|Given IV or orally during reinduction
48717071|NCT00764907|DRUG|doxorubicin hydrochloride|Given IV during reinduction
48717072|NCT00764907|DRUG|etoposide|Given IV during reinduction
48519128|NCT00398866|DRUG|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
48717073|NCT00764907|DRUG|ifosfamide|Given IV during reinduction
48717074|NCT00764907|DRUG|leucovorin calcium|Given IV during reinduction
48180991|NCT01410864|OTHER|Control|Devices or drugs used to seal the dura (other than DuraSeal)
48180992|NCT02466347|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
48180993|NCT02466347|DRUG|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
48382167|NCT03854799|DRUG|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
48382168|NCT03854799|RADIATION|EXTERNAL---BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
48519129|NCT05238610|PROCEDURE|PFO closure|PFO-closure will be performed after 3-6 month of observation and monitoring for paroxysmal atrial fibrillation
48717075|NCT00764907|DRUG|mercaptopurine|Given orally during reinduction
48519130|NCT04101409|OTHER|Decision aids|Shared decision making with decision aids
48519131|NCT03263676|DEVICE|Icon resuable underwear|Reusable incontinence underwear
48717076|NCT00764907|DRUG|methotrexate|Given orally during reinduction
48180994|NCT02097186|PROCEDURE|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
48180995|NCT00513747|BIOLOGICAL|rituximab|Given IV over 4 hours
48180996|NCT00513747|DRUG|fludarabine phosphate|Given IV over 30 minutes
48382169|NCT01810575|DRUG|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
48382170|NCT01810575|DRUG|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
48382171|NCT01810575|DRUG|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
48519132|NCT03263676|DEVICE|Disposable pad|Standard market disposable pad
48180997|NCT00001509|DRUG|IFN-alpha with retinoic acid|
48180998|NCT03292445|PROCEDURE|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
48717077|NCT00764907|DRUG|prednisone|Given intrathecally during reinduction
48717078|NCT00764907|DRUG|thioguanine|Given orally during reinduction
48717079|NCT00764907|DRUG|vincristine sulfate|Given IV during reinduction
48717080|NCT00764907|DRUG|vindesine|Given IV during reinduction
48717081|NCT01116427|BIOLOGICAL|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
48717082|NCT01116427|DRUG|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
48717083|NCT04469231|DEVICE|Anterior Cervical Discectomy & Fusion|ACDF
48717084|NCT01516567|DRUG|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
48717085|NCT04050267|DRUG|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
48717086|NCT04050267|OTHER|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
48717087|NCT02559661|OTHER|Training on a virtual simulator in eye surgery|
48519133|NCT01184430|DEVICE|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
48519134|NCT01139229|OTHER|hybrid everted esophagogastric anastomosis|
48519135|NCT01139229|OTHER|the conventional hand-sewn anastomosis|
48519136|NCT01139229|OTHER|a stapled anastomosis|
48382172|NCT04092608|PROCEDURE|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
48519137|NCT05279911|RADIATION|low-level laser therapy (LLLT)|low-level laser therapy (LLLT) with dental implants has been suggested to improve bone quality during osseointegration. Low-level laser (Gallium Aluminum Arsenide Diode \[Ga-Al-As\]) (wavelength: 808 nm, average power density: 50 mW, circular spot diameter:0.71 cm, spot area: 0.4cm2) in continuous mode was applied in six points in contact with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before and immediately after suturing. The application points were divided into two points in the labial region where the implant would be placed (apical and cervical); two points in the lingual region (apical and cervical); and two points in the occlusal direction. After suturing the laser protocol was repeated in the same points following the same protocol, resulting in a total dose of 66 J for each application moment (before and after implant placement).
48519138|NCT04156581|DRUG|Bupivacaine|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
48519139|NCT04156581|DRUG|Dexamethasone|Dexamethasone is a corticosteroid that reduces inflammation.
48519140|NCT04156581|OTHER|Saline|Saline is a mixture of NaCl and water that can be used as a placebo.
48519141|NCT01972399|PROCEDURE|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
48519142|NCT01972399|PROCEDURE|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
48717088|NCT03946865|OTHER|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
48717089|NCT03885050|OTHER|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
48717090|NCT06326684|DRUG|Alcohol|The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
48519143|NCT04742374|BIOLOGICAL|Blood sampling|Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
48717091|NCT06326684|DRUG|Placebo|The effects of placebo will be determined.
48382173|NCT04092608|PROCEDURE|LOW CVP (restrictive group)|Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
48382174|NCT01296269|DRUG|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
48519144|NCT01051362|DRUG|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
48519145|NCT04138381|DRUG|Selinexor|oral selinexor given once weekly (Cohort A), oral selinexor given BIW (Cohort B)
48519146|NCT04138381|DRUG|Imatinib|imatinib 400 mg, once daily (Cohort A)
48519147|NCT00264901|DRUG|insulin detemir|
48519148|NCT03942601|DRUG|Temsirolimus|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
48519149|NCT03942601|DRUG|Temsirolimus and dexamethasone sodium phosphate|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
48519150|NCT03165812|PROCEDURE|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
48717092|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 1 will be determined.
48717093|NCT06326684|DRUG|Suvorexant|The effects of suvorexant dose 2 will be determined.
48717094|NCT00342706|PROCEDURE|Community based intervention|
48717095|NCT00332865|BEHAVIORAL|Swallowing Exercises|Daily exercises
48717096|NCT01930760|BEHAVIORAL|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
48382175|NCT01296269|DRUG|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
48382176|NCT01296269|DRUG|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
48382177|NCT03949764|DRUG|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
48717097|NCT01930760|BEHAVIORAL|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
48382178|NCT05809999|PROCEDURE|Standard colonoscopy with targeted biopsies|Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
48382179|NCT01554696|DRUG|peficitinib|oral
48382180|NCT01554696|DRUG|Placebo|oral
48382181|NCT01554696|DRUG|methotrexate|oral
48382182|NCT03359278|PROCEDURE|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
48382183|NCT03913429|PROCEDURE|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
48382184|NCT03913429|PROCEDURE|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
48382185|NCT06177626|BEHAVIORAL|Aerobic Training|Aerobic training on stationary bike 5x a week for 30 minutes a day
48382186|NCT06177626|BEHAVIORAL|Balance Training|Training 5x a week for 30 minutes. Standard of care.
48382187|NCT06651086|BEHAVIORAL|Unstuck and On Target|Unstuck and on Target (Unstuck; Cannon et al., 2021) is a cognitive-behavioral, intervention designed to be feasibly delivered by teachers and school staff in the elementary school setting. It was adapted for and pilot-tested in outpatient mental health. Unstuck targets key executive functions, including flexibility, goal-setting, planning, and coping. Sessions include prescribed content and activities to facilitate guided practice and home extension activities to aid generalization beyond the therapeutic session. It includes both child- and caregiver-directed strategies. It has been shown effective for youth with autism and attention-deficit/hyperactivity disorder.
48717098|NCT04172168|DIAGNOSTIC_TEST|Heart rupture|Left ventricular free-wall ruptrue after AMI
48382188|NCT06651086|BEHAVIORAL|Unified Protocol for Children|Unified Protocol for Children is a transdiagnostic, cognitive-behaviorally based treatment targeting shared core dysfunctions underlying emotional disorders, including distress intolerance and emotional dysregulation. It was developed by integrating cognitive-behavioral and mindfulness strategies and includes prescribed activities, in-vivo experiments, and home-extension components to promote generalization. It includes both child- and caregiver-directed strategies. In addition to its effectiveness for youth with emotional disorders, recent work supports its efficacy for youth with additional non-emotional disorders (e.g., externalizing challenges, irritability).
48519151|NCT03165812|PROCEDURE|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
48519152|NCT03096158|OTHER|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
48519153|NCT03096158|OTHER|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
48382189|NCT03361540|DRUG|ASP8302|ASP8302 will be administered orally.
48382190|NCT03361540|DRUG|Placebo|Placebo will be administered orally.
48382191|NCT04708834|DRUG|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily for following 46 weeks
48717099|NCT04738253|DIAGNOSTIC_TEST|Ultrasonography|The ultrasound measurement s of the axillary recess capsule thickness.
48717100|NCT04423601|DRUG|SHR6390 tablet|single oral dose of SHR6390 or co-administered with itraconazole.
48519154|NCT03096158|OTHER|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
48180999|NCT03292445|DRUG|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover \>10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
48181000|NCT05952947|BIOLOGICAL|HRYZ-T101 Injection|On day 1, the TCR-T cells will be administered intravenously.
48181001|NCT05952947|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
48181002|NCT02460562|DEVICE|S-PRG filler|"Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567."
48382192|NCT06282250|BEHAVIORAL|Bright light therapy + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: BLT will be administered for 30 minutes on five consecutive days, starting on Monday of the work week, between 7:30 AM and 10:00. The effect of the light therapy is evaluated by means of the Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). Further treatment strategy is determined on the basis of these results:~* If the patient has achieved remission (QIDS-SR \< 6), BLT has been successful and the patient can continue with PE and IMCT.~* If there is insufficient or no response (QIDS-SR of 6 or higher), BLT is extended with five more sessions the following week.~* If necessary, a third week is optional.~Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
48382193|NCT06282250|BEHAVIORAL|Blue-light blocking glasses + Psycho-education + Imagery focused Cognitive Therapy|"Week 1-3: blue-light blocking glasses will be administered. Week 2-4: Psycho Education will follow, 1 session.~Week 3/4-9/10: ImCT will follow, 6 sessions."
48382194|NCT06282250|BEHAVIORAL|Psycho-education + Imagery focused Cognitive Therapy|"Week 1: Psycho Education, 1 session.~Week 2-7: ImCT will follow, 6 sessions."
48382195|NCT02696837|DEVICE|ETT|
48382196|NCT02696837|DEVICE|Proseal LMA|
48382197|NCT02696837|DRUG|Rocuronium|
48382198|NCT02696837|OTHER|No Muscle Relaxant|
48382199|NCT02696837|DRUG|Rocuronium|
48382200|NCT05741788|DEVICE|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
48717101|NCT04423601|DRUG|Itraconazole capsule|200 mg itraconazole was administered in the morning.
48717102|NCT00002447|DRUG|Ritonavir|
48717103|NCT00002447|DRUG|Efavirenz|
48717104|NCT00002447|DRUG|Saquinavir|
48717105|NCT01689350|GENETIC|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
48717106|NCT02366767|DEVICE|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
48717107|NCT02366767|DEVICE|Control|Threshold suspend
48382201|NCT02633462|PROCEDURE|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
48382202|NCT02633462|DRUG|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
48382203|NCT00673868|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
48382204|NCT00194116|DRUG|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
48717108|NCT06182696|BIOLOGICAL|OriCAR-017|GPCRC5D-directed chimeric antigen receptor modified T cells
48717109|NCT03386734|PROCEDURE|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
48717110|NCT03386734|PROCEDURE|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
48717111|NCT04410744|DIAGNOSTIC_TEST|Ultrasonographic examination|All clinical examinations (physical exam) and ultrasounds are performed by a single surgeon and a single radiology resident supervised by the same abdominal radiology consultant, respectively.
48717112|NCT00599456|DIETARY_SUPPLEMENT|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
48717113|NCT00599456|DIETARY_SUPPLEMENT|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
48717114|NCT05479045|BIOLOGICAL|NY-ESO-1 Peptide vaccine|300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks.
48717115|NCT05479045|DRUG|Toripalimab-tpzi|240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine
48382205|NCT00194116|DRUG|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
48382206|NCT00545493|DRUG|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
48382207|NCT00545493|DRUG|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
48382208|NCT02423746|BEHAVIORAL|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
48382209|NCT02423746|BEHAVIORAL|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
48382210|NCT04749173|DRUG|DWRX2003, 96mg|Drug: Placebo Intramuscularly injection at predefined injection sites
48382211|NCT04749173|DRUG|DWRX2003, 432mg|Drug: Placebo Intramuscularly injection at predefined injection sites
48382212|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
48382213|NCT04749173|DRUG|DWRX2003, 144mg|Drug: Placebo Intramuscularly injection at predefined injection sites
48382214|NCT02786810|DRUG|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
48382215|NCT06592924|DRUG|Abiraterone|Assigned prior to enrollment
48382216|NCT06592924|DRUG|Enzalutamide|Assigned prior to enrollment
48519155|NCT03956394|DIAGNOSTIC_TEST|UltraFast ultrasound|The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
48519156|NCT06042244|OTHER|Multimodal Exercise Group|Listed in arm/ group descriptions
48519157|NCT06042244|OTHER|Waitlist|listed in arm/group description
48519158|NCT03106428|DRUG|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
48519159|NCT06566690|DEVICE|Addition of ORi monitoring to SpO2 monitoring|Integration of Oxygen Reserve Index (ORi) monitoring into standard SpO2 monitoring
48717116|NCT01366612|DRUG|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
48717117|NCT01366612|DRUG|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
48181003|NCT02460562|DEVICE|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
48382217|NCT06592924|DRUG|Apalutamide|Assigned prior to enrollment
48382218|NCT06592924|DRUG|Darolutamide (BAY 1841788)|Assigned prior to enrollment
48382219|NCT06592924|DRUG|Docetaxel|Assigned at enrollment
48717118|NCT03384914|BIOLOGICAL|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
48382220|NCT06592924|DRUG|ADT|Physician's choice. Assigned prior to enrollment
48382221|NCT05476809|BEHAVIORAL|smart-cloth assisted home nursing|The upgraded smart-cloth assisted home nursing integrate smart-cloth monitoring system, home nursing, and family caregiver feedback app. The persons living with dementia will be asked to wear a smart cloth 24 hours a day and will be monitored on abnormal activity level, going out alone, abnormal number of getting-up at night, fall risks. In addition, monitoring for medication, abnormal life pattern, quality of hired help will also be included. The warning signals, along with weekly summary and related information will be sent to the family caregiver interactive App after the assessment of the home care nurses to provide guidance for family care.
48382222|NCT03581500|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
48382223|NCT03581500|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
48382224|NCT05882656|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
48519160|NCT01918566|DIETARY_SUPPLEMENT|tap water|
48519161|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
48519162|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
48519163|NCT01918566|DIETARY_SUPPLEMENT|25g Fructose in 300ml tap water|
48519164|NCT01918566|DIETARY_SUPPLEMENT|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
48519165|NCT01918566|DIETARY_SUPPLEMENT|300ml tap water with 450ppm lactisole|
48181004|NCT05161741|DRUG|Insulin|Human rDNA Insulin (Insuget, local brand of Getz Pharma)
48181005|NCT01021709|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 \& 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
48181006|NCT03251612|DRUG|Based on sensitivity analysis|"* 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin"
48181007|NCT04466410|BIOLOGICAL|XT-150|Single bolus intrathecal injection
48181008|NCT04466410|BIOLOGICAL|Placebo|Placebo is a sterile phosphate-buffered saline
48181009|NCT03600415|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
48181010|NCT03600415|OTHER|Säntis; 2500m above sea level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
48181011|NCT05160571|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
48181012|NCT01530893|DIETARY_SUPPLEMENT|Flavanone - supplement|acute single optimal dose
48181013|NCT01530893|OTHER|Flavanone - food|acute single dose
48181014|NCT01530893|OTHER|Flavanone - placebo|acute single dose (flavanone free)
48181015|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - supplement|acute single optimal dose
48181016|NCT01530893|OTHER|Isoflavone - food|acute single optimal dose
48181017|NCT01530893|OTHER|Isoflavone - placebo|acute single dose (isoflavone free)
48181018|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
48181019|NCT01530893|DIETARY_SUPPLEMENT|Flavan-3-ol - supplement|acute single optimal dose
48181020|NCT01530893|OTHER|Flavan-3-ol - food|acute single optimal dose
48181021|NCT01530893|OTHER|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
48181022|NCT01530893|DIETARY_SUPPLEMENT|Anthocyanin - supplement|acute single optimal dose
48181023|NCT01530893|OTHER|Anthocyanin - food|acute single optimal dose
48181024|NCT01530893|OTHER|Anthocyanin - placebo|acute single dose (anthocyanin free)
48181025|NCT02630407|BIOLOGICAL|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
48181026|NCT02630407|OTHER|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
48181027|NCT00424788|PROCEDURE|Plasma exchange|
48181028|NCT00424788|DRUG|natalizumab treatment|
48181029|NCT02676843|DRUG|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
48181030|NCT00902798|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
48181031|NCT00902798|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
48181032|NCT05901155|DEVICE|MedAL-mentor|MedAL-mentor is a near real-time monitoring and benchmarking dashboard based on data collected through ePOCT+, providing direct feedback on several clinical indicators (antibiotic prescription, performance of key measurements, signs, and diagnostic tests).
48181033|NCT02846493|DRUG|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
48181034|NCT02846493|DRUG|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
48181035|NCT00296738|DEVICE|SPECT/CT|GE INFINIA HAWKEYE
48181036|NCT02905409|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
48181037|NCT01929876|DRUG|Cobimetinib|10 milligram (mg) (2\* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
48181038|NCT01929876|DRUG|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
48519166|NCT05105997|DRUG|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
48717119|NCT03384914|BIOLOGICAL|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
48181039|NCT05869045|OTHER|Diaphragm shortening fraction measurement by point-of-care ultrasound.|A noninvasive and feasible method to assess diaphragmatic function and predict the prognosis of patients with respiratory failure presenting to the emergency department. The method consists of measuring the diaphragmatic thickness at the end of inspiration and expiration using a linear probe placed in the subcostal region and calculating the percentage of change using the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100. A value lower than 10% indicates diaphragmatic dysfunction and a higher risk of adverse outcomes.
48181040|NCT05838690|OTHER|Personalized Intubation Safety (PINS) Bundle|The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan
48181041|NCT05015543|OTHER|Personal Training Program|One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
48181042|NCT02538315|DRUG|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by \[18F\]FDOPA PET/CT imaging
48181043|NCT06191081|PROCEDURE|lymphaticovenous anastomosis|lymphaticovenous anastomosis
48181044|NCT00830609|DRUG|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)
48181045|NCT00830609|DRUG|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb\>12g/dl over 4 or 24 weeks
48181046|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 24 weeks
48181047|NCT00830609|DRUG|ribavirin|ribavirin 800 mg/day for 24 weeks
48181048|NCT00830609|DRUG|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
48181049|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
48181050|NCT05336175|DRUG|Angiotensin 1-7|"A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days."
48181051|NCT05336175|DRUG|Saline solution|Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
48382225|NCT04066127|DEVICE|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
48382226|NCT04066127|DEVICE|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
48382227|NCT03390010|DRUG|Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergine|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
48519167|NCT05105997|DRUG|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
48519168|NCT00356226|DRUG|clonidine|
48717120|NCT00693472|DRUG|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
48181052|NCT04246398|OTHER|FMT|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
48181053|NCT04246398|OTHER|FMT - placebo|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
48382228|NCT03390010|DRUG|Syntocinon and using extra uterotonic drugs when needed ; methergine carboprost|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
48519169|NCT00032383|BEHAVIORAL|Tai Chi|
48717121|NCT00693472|DRUG|Placebo|Matching placebo capsule administered orally every 12 hours
48717122|NCT00693472|DRUG|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
48181054|NCT01688817|OTHER|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
48519170|NCT05204992|PROCEDURE|ultrasound guided hydrodissection|Injection of steroids, saline and bupivicaine ultrasound guided
48717123|NCT00693472|DRUG|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
48717124|NCT00831701|DRUG|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
48717125|NCT00831701|DRUG|Placebo|One placebo pill per day for 21 days or until stone expulsion
48717126|NCT01960088|DRUG|HPV vaccine|
48181055|NCT01688817|OTHER|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
48181056|NCT03451708|DEVICE|OKS|Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
48717127|NCT00138112|DRUG|Empirical Vancomycin|
48717128|NCT00138112|DRUG|Prophylactic Vancomycin|
48717129|NCT02744989|DEVICE|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
48717130|NCT02744989|DEVICE|Sham tDCS|The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
48717131|NCT04791059|DRUG|S-ketamine|S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.
48717132|NCT04791059|DRUG|Dexmedetomidine|Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.
48717133|NCT04791059|DRUG|Sufentanil|Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
48181057|NCT04669145|DRUG|Ropivacaine|Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
48181058|NCT00784147|DRUG|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
48181059|NCT00784147|DRUG|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
48382229|NCT05769465|DRUG|disease modifying treatments|Patients will be enrolled if exposed to nusinersen, risdiplam, onasemnogene abeparvovec
48519171|NCT05560607|DRUG|AZD7503 Intervention|"Part A: Participants will be screened for histologic evidence of NAFLD or NASH and all eligibility criteria in part A prior to enrollment in part B.~Part B: Participants consented to part B will be administered the study drug over the course of 31 days. At the end of the study a liver biopsy will be collected to measure for endpoints."
48519172|NCT00290004|DRUG|motexafin gadolinium|
48717134|NCT00806923|DRUG|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
48717135|NCT00806923|DRUG|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
48717136|NCT00806923|DRUG|Placebo|iv on day 1 of each 3 week cycle until disease progression
48717137|NCT00806923|DRUG|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
48717138|NCT00806923|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
48717139|NCT03667846|DRUG|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
48717140|NCT03667846|OTHER|Placebo|Placebo tablets will be encapsulated in identical capsules.
48717141|NCT01100528|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
48717142|NCT01100528|DRUG|dacarbazine|Given IV on days 1 and 29
48717143|NCT01100528|OTHER|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
48717144|NCT03303118|OTHER|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
48717145|NCT06020846|OTHER|Soleus Pushup Exercise|"Patient will be seated on a chair, his legs at 90 degrees to the floor, keep the toes, and feet flat on the ground, and move his heels up and down continuously.~4 sets of 15 minutes each,1hour total intervention time"
48717146|NCT06020846|OTHER|treadmill walk group 2|The patient will do treadmill walk at normal walking speed, 4 sets of treadmill walk for 15 minutes each, 1hour total intervention time
48717147|NCT03618914|BIOLOGICAL|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
48023546|NCT04590755|BEHAVIORAL|Interactive father-child sessions and website|The Run Daddy Run intervention will consist of 5 (inter)active sessions for fathers and their children + 1 follow-up session, each session lasting 90 minutes. These sessions will be given to 8 groups of +- 13 families (fathers and their children), guided by 2 facilitators and will take place every 2 weeks, at a location in the neighborhood of fathers and children (e.g. school of the children). Additionally, a website will be available for the fathers and their children, with additional information about the project, tips and information about being active together (e.g. movement breaks, fundamental movement skills, etc.) and limiting screen time. In addition, fathers and their children will also log their goals on this website, and between two sessions (= a period of 2 weeks) they will be asked to keep track of their co-PA on this website, aiming to reach their goal.
48717148|NCT05323123|BEHAVIORAL|PrEP Romania|Enrolled participants will receive PrEP education and adherence counseling from trained counselors, and have a medical evaluation from a physician, who will prescribe PrEP.
48023547|NCT03588572|DRUG|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
48181060|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
48181061|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
48181062|NCT01605786|OTHER|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
48181063|NCT02398045|OTHER|Computerised CBT for OCD|Computerised CBT for OCD
48181064|NCT01803334|OTHER|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
48181065|NCT00459914|DEVICE|cpap treatment during sleep|CPAP
48181066|NCT04797117|DIAGNOSTIC_TEST|blood sample|"The blood samples for the study for each patient will be collected in the form of additional tubes.~* either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~* either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization."
48181067|NCT01783340|DRUG|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
48181068|NCT01783340|DRUG|Placebo|Placebo capsules will be administered at each immunization
48181069|NCT01783340|BIOLOGICAL|Immunization with falciparum|three inoculations with 5 infected mosquito bites
48181070|NCT02727257|PROCEDURE|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
48181071|NCT02281162|OTHER|Blood Draw|Blood Draw
48181072|NCT05068921|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
48717149|NCT02983422|DRUG|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
48717150|NCT02983422|DRUG|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
48717151|NCT02983422|DRUG|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
48181073|NCT01266018|DRUG|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
48519173|NCT02779166|DRUG|Celecoxib|Received 400mg celecoxib prior to surgery
48023548|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：abdomen. Second period. upper arm. Third period: thigh).
48023549|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：upper arm. Second period: thigh. Third period: abdomen).
48023550|NCT06086912|DRUG|HR17031|Receive a single dose of HR17031 at every period (First period：thigh. Second period: abdomen. Third period: upper arm).
48519174|NCT02779166|DRUG|placebo|
48717152|NCT03730545|DIETARY_SUPPLEMENT|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
48717153|NCT00369694|DRUG|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
48717154|NCT00369694|DRUG|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
48717155|NCT00636012|PROCEDURE|verum acupuncture|acupuncture at St36 and Pe6
48717156|NCT00636012|PROCEDURE|sham acupuncture|superficial needling at sham points
48717157|NCT02266875|DRUG|hypertonic saline|
48717158|NCT02266875|DRUG|standard saline|
48717159|NCT00823277|OTHER|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after \~ 1 Year.
48717160|NCT04534348|DEVICE|70% isopropyl alcohol-impregnated catheter caps|Implementation of 70% isopropyl alcohol-impregnated catheter caps in order to assess the number of CLABSI diagnosed during 1 Year
48717161|NCT04825990|DRUG|Pembrolizumab|200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.
48717162|NCT02331979|DEVICE|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
48717163|NCT04602026|OTHER|Best Practice|Receive standard of care
48717164|NCT04602026|BEHAVIORAL|Exercise Intervention|Complete home exercise intervention
48717165|NCT04602026|PROCEDURE|Physical Therapy|Undergo physical therapy
48717166|NCT04602026|OTHER|Questionnaire Administration|Ancillary studies
48717167|NCT02520921|DRUG|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
48717168|NCT02520921|DRUG|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
48717169|NCT04886947|PROCEDURE|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
48717170|NCT03974204|PROCEDURE|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
48717171|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* When suspected metastatic meningitis symptoms arise and~* at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
48717172|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* 1 month after the beginning of the specific treatment,~* 3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
48717173|NCT04292990|DRUG|Fentanyl|Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
48717174|NCT04292990|DRUG|Morphine|Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
48023551|NCT04642105|DEVICE|Sensor-Dot and Plug 'n Patch system|We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
48023552|NCT03129347|DRUG|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
48023553|NCT00907270|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
48023554|NCT01491477|DEVICE|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
48023555|NCT01491477|DEVICE|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
48023556|NCT00520416|PROCEDURE|Carbon dioxide angiogram|see description of procedure
48717175|NCT04142151|DRUG|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
48717176|NCT04142151|DRUG|Aspirin|Aspirin produced by Bayer Co., Ltd.
48717177|NCT04142151|DRUG|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
48717178|NCT04142151|DRUG|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
48023557|NCT03779529|DIETARY_SUPPLEMENT|Olive oil|Intervention includes dosage and amount of biophenols administered daily
48023558|NCT05234099|DIAGNOSTIC_TEST|18F-FDG Positron emission tomography - MRI|All the examinations will be performed in the supine position on the same integrated 3T PET-MRI scanner
48023559|NCT05234099|DIAGNOSTIC_TEST|Multiparametric ultrasound imaging|Acquisitions of respiratory muscles (diaphragm, intercostal muscles) will be performed using two 6 MHz central frequency linear transducer (SL 10-2) driven by two identical ultrafast ultrasound devices.
48181074|NCT04237285|OTHER|Inhalation aromatherapy|Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
48181075|NCT05401383|DEVICE|Lumevis (IIa class)|intake of Lumevis 30 minutes before EGDS
48181076|NCT04665609|DRUG|Anlotinib and TQB2450 solution|Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
48181077|NCT04665609|DRUG|TQB2450 solution|TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
48181078|NCT00372736|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
48181079|NCT00372736|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
48181080|NCT00372736|GENETIC|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs \> 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs \> 5 x ULN1
48181081|NCT00372736|GENETIC|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
48181082|NCT00372736|OTHER|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
48181083|NCT00372736|OTHER|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
48181084|NCT00372736|OTHER|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
48181085|NCT00372736|OTHER|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
48181086|NCT02825251|DRUG|Faster-acting insulin aspart|Injected s.c. /subcutaneously (under the skin)
48181087|NCT02825251|DRUG|insulin aspart|Injected s.c. /subcutaneously (under the skin)
48181088|NCT01928667|OTHER|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
48181089|NCT00092326|DRUG|MK0966, rofecoxib|
48181090|NCT00092326|DRUG|Comparator: oxycodone with acetaminophen, placebo|
48023560|NCT05234099|DIAGNOSTIC_TEST|Surface electromyography|sEMG recordings will be performed in the left side on the sternocleidomastoid muscle, the intercostal parasternal muscle, and the external oblique muscle using pairs of 20-mm-diameter silver chloride surface electrodes.
48023561|NCT05234099|DIAGNOSTIC_TEST|Transdiaphragmatic preasure measurmement|Esophageal and gastric pressures will be measured using 8-cm balloon-catheters.
48023562|NCT05234099|DIAGNOSTIC_TEST|Magnetic stimulation of the phrenic nerves|In order to quantify the contractile fatigue in diaphragm induced by the ventilatory task (described below), we will use bilateral anterior magnetic stimulation of the phrenic nerves using two Magstim 200 stimulator.
48023563|NCT05234099|DIAGNOSTIC_TEST|Ventilation against inspiratory loading|A POWERbreathe KH2 device (POWERbreathe International Ltd) will be connected on the inspiratory side of the two-way valve. Level of inspiratory loading will be randomized in order to produce different amounts of muscle work in each subject.
48717179|NCT05722041|PROCEDURE|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
48717180|NCT03242252|DRUG|Placebo|"Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily.~Route of administration: Oral"
48717181|NCT03242252|DRUG|Sotagliflozin|"Sotagliflozin 200 mg, tablet, orally once daily.~Route of administration: Oral"
48717182|NCT05479149|OTHER|Training protocol with the cervical device for treatment (CDAT).|Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.
48717183|NCT05479149|OTHER|Conventional training protocol|Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
48717184|NCT00967161|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
48023564|NCT05494398|DRUG|N-acetylcysteine|12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
48181091|NCT04382235|DEVICE|Non-invasive ventilatory support|All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
48717185|NCT00967161|PROCEDURE|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
48717186|NCT03331783|OTHER|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
48717187|NCT03331783|OTHER|LT-2|This patch is made of a new adhesive
48717188|NCT03331783|OTHER|LT-21|This patch is made of a new adhesive
48717189|NCT03331783|OTHER|33-20|This patch is made of a new adhesive
48181092|NCT03326362|OTHER|Resistance training|Comparison between high and low intensities trainings described in arms
48181093|NCT03225898|OTHER|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
48717190|NCT02989805|BEHAVIORAL|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
48717191|NCT00139217|DRUG|iNO|
48717192|NCT00139217|PROCEDURE|Non-invasive nitric oxide|
48717193|NCT04093336|BIOLOGICAL|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
48717194|NCT04093336|BIOLOGICAL|Placebo|Placebo
48717195|NCT04093336|OTHER|standardized treatment|standardized treatment
48717196|NCT00552448|DEVICE|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
48717197|NCT00509093|DRUG|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
48717198|NCT00509093|GENETIC|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
48023565|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
48717199|NCT00509093|GENETIC|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
48717200|NCT00509093|GENETIC|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
48717201|NCT00509093|OTHER|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
48382230|NCT04066101|GENETIC|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
48382231|NCT04066101|OTHER|caries activity|"Dental caries lesions of all patient scored as initial, moderate or advanced caries~Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed"
48382232|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
48382233|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
48181094|NCT03225898|OTHER|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
48519175|NCT05528978|BEHAVIORAL|Shambhavi Kriya|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
48717202|NCT00509093|PROCEDURE|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
48717203|NCT03311984|DIAGNOSTIC_TEST|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
48717204|NCT04264143|DRUG|Infusate with MTX110 and gadolinium|Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
48717205|NCT04264143|DEVICE|Convection-Enhanced Delivery (CED)|CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
48717206|NCT05517902|BIOLOGICAL|StrataGraft|StrataGraft® Construct
48717207|NCT00779961|PROCEDURE|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
48382234|NCT03660059|DRUG|Peficitinib|Oral
48382235|NCT03660059|DRUG|Plaebo|Oral
48382236|NCT03660059|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
48717208|NCT00779961|PROCEDURE|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
48717209|NCT02776033|DRUG|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
48717210|NCT02776033|DRUG|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
48717211|NCT05997576|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
48382237|NCT05921370|DRUG|Silodosin 8 mg|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"
48717212|NCT05997576|DRUG|Placebo|Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
48382238|NCT05921370|DRUG|Placebo|"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."
48382239|NCT02072707|PROCEDURE|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
48382240|NCT02072707|PROCEDURE|Endocardial VT Ablation|Endocardial Only VT ablation
48519176|NCT01231776|OTHER|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
48717213|NCT05052060|OTHER|Group A|19 patients will be treated with pelvic tilt exercises
48717214|NCT05052060|OTHER|Group B|19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
48023566|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
48023567|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
48023568|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
48023569|NCT02322606|DRUG|TAK-137 5 mg tablet, TAK-137 placebo tablet|
48023570|NCT02322606|DRUG|TAK-137 5mg tablet, TAK-137 placebo tablet|
48382241|NCT04011891|PROCEDURE|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
48181095|NCT03003806|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
48382242|NCT04011891|PROCEDURE|Open Partial Nephrectomy|Standard open partial nephrectomy
48382243|NCT04495296|DRUG|TST001|TST001 will be administered by specified doses on specified day
48382244|NCT04495296|DRUG|Oxaliplatin|Oxaliplatin will be administered by specified doses on specified day
48382245|NCT04495296|DRUG|Capecitabine|Capecitabine will be administered by specified doses on specified day
48382246|NCT04495296|DRUG|Paclitaxel|Paclitaxel will be administered by specified doses on specified day
48382247|NCT04495296|DRUG|Gemcitabine|Gemcitabine will be administered by specified doses on specified day
48382248|NCT04495296|DRUG|Cisplatin|Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
48382249|NCT04495296|DRUG|Nivolumab|Nivolumab will be administered by specified doses on specified day
48382250|NCT06647043|DIETARY_SUPPLEMENT|SMT04 Pro|Consists of a blend of food-grade Bifidobacterium as active probiotics
48382251|NCT01165424|DRUG|mometasone furoate|"MFNS 50 μg spray device~* 3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
48382252|NCT03176628|DIETARY_SUPPLEMENT|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
48382253|NCT03176628|DIETARY_SUPPLEMENT|Placebo|Placebo capsule(s)
48382254|NCT05248854|OTHER|Sensorimotor exercise training|The program included side stepping, tandem walking, perturbation exercise, overcoming mini obstacles, walking different surfaces and traditional hip and knee exercise. Participants applied these exercise as home program between postoperative second weeks and 8th weeks, 3-5 day /week , 20 25 min every session.
48382255|NCT05248854|OTHER|Core stabilization exercise training|Core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research.core stabilization exercise program was also prepared parallel to the sensorimotor training group intensity; the program contained traditional hip and knee exercise combining the core stabilization as mat activities depending on previous research
48382256|NCT06650241|OTHER|Behavioral therapy|
48382257|NCT06650241|OTHER|Lip Bumper Therapy|
48717215|NCT06254664|DRUG|Tiotropium 18 µg inhalation powder, hard capsule|Tiotropium 18 µg administered using Zephir inhaler
48717216|NCT06254664|DEVICE|Zephir inhaler|Tiotropium 18 µg administered using Zephir inhaler
48717217|NCT03889548|OTHER|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
48717218|NCT00494559|DRUG|Pioglitazone|Actos 15mg once a day before breakfast
48717219|NCT00494559|DRUG|Placebo|Placebo drug with the same appearance as actos
48382258|NCT06650241|OTHER|Modified Twin-Block Therapy|
48382259|NCT01932515|BEHAVIORAL|A revised screening instrument for use in Deaf children|
48382260|NCT05393635|BIOLOGICAL|ITIL-168|"ITIL-168 is a cell therapy product derived from a participant's own TILs. A portion of tumor is resected to make a personalized ITIL-168 product. If appropriate, participants may receive bridging therapy after recovering from the tumor resection during ITIL-168 manufacturing. Once ITIL-168 has been made, the participant is treated with up to 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.~Drug: Pembrolizumab Participants will receive 1 dose of pembrolizumab following tumor resection prior to receiving ITIL-168, and additional doses for up to a year after ITIL-168 infusion."
48382261|NCT00912327|BIOLOGICAL|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
48382262|NCT03381807|BIOLOGICAL|hAESCs|5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
48382263|NCT06611085|OTHER|cold application group|The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.
48382264|NCT06611085|OTHER|vibration group|The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.
48717220|NCT02869412|OTHER|Computer-Assisted Intervention|Use BCG website
48717221|NCT02869412|OTHER|Computer-Assisted Intervention|Use passive website
48717222|NCT02869412|OTHER|Quality-of-Life Assessment|Ancillary studies
48717223|NCT02869412|OTHER|Questionnaire Administration|Ancillary studies
48717224|NCT02395211|BEHAVIORAL|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
48717225|NCT02395211|DEVICE|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
48181096|NCT03003806|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
48181097|NCT01712269|PROCEDURE|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
48181098|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
48181099|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
48181100|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
48181101|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
48181102|NCT02912754|DRUG|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
48181103|NCT02912754|DRUG|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
48382265|NCT06611085|OTHER|vibration and ice group|In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
48382266|NCT04598815|DRUG|Sirolimus|"Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g."
48382267|NCT00381667|DRUG|GW642444M|M salt
48382268|NCT00381667|DRUG|GW642444H|H salt
48382269|NCT00381667|OTHER|placebo|placebo
48382270|NCT05990946|DEVICE|ePRO based Remote Symptom Management provide by a mobile phone app|"Alerts are triggered if any of 5 core symptoms scored ≥4, prompting remote clinician feedback and guidance on symptom management. This is facilitated through the Shuyu mobile application, which serves as the platform for monitoring symptoms and communication."
48023571|NCT05229679|DIAGNOSTIC_TEST|HPV testing|All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
48717226|NCT00002363|DRUG|Peptide Construction 3, Synthetic|
48717227|NCT03729193|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
48023572|NCT01324024|DRUG|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
48023573|NCT01324024|DRUG|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
48023574|NCT01455649|DRUG|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
48023575|NCT01455649|DRUG|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
48181104|NCT02781649|DRUG|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
48181105|NCT02781649|DRUG|Ribavirin|Ribavirin 1200 mg/d (\> 75 kg) or 1000 mg/d (\< 75 kg) by mouth daily in two divided doses
48181106|NCT02781649|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily
48181107|NCT06416332|OTHER|group A: in face to face live therapeutic exercise|"In group A: in face to face live therapeutic exercise the program and its progressivity will be determined and performed for life according to the progress of the patient, with a frequency of sessions twice a week, session duration 45 minutes, following the recommended dosage of exercise according to clinical guidelines, while the total duration of the intervention will be eight weeks. You will be instructed to perform the program at home, 3 times a week. The standardized exercise program to be followed by this group will include :~1. Exercises to strengthen the hip and knee muscles through isometric contractions and resistance exercises using elastic bands.~2. Balance and neuromuscular coordination exercises."
48382271|NCT04485026|RADIATION|Local consolidative radiation therapy|All local consolidative radiation therapy should be delivered using hypofractionated local consolidative radiation therapy (\>2 Gy per fraction). Exceptions may be approved on a case by case basis by the trial principal investigator. Three-dimensional conformal radiotherapy (3D-CRT), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and proton beam therapy (PBT) are all acceptable.
48023576|NCT02740348|BEHAVIORAL|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
48717228|NCT05995041|BIOLOGICAL|CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells|Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
48717229|NCT03724656|DEVICE|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
48717230|NCT03724656|DEVICE|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
48717231|NCT00869830|OTHER|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
48023577|NCT02740348|BEHAVIORAL|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
48181108|NCT06416332|OTHER|group B: telerehabilitation program|In group B: telerehabilitation program, the therapeutic exercise program will follow the same structure, which was mentioned above. The differentiation in the intervention of this group will be that the explanation of the exercises, their presentation, monitoring and information of the participants will be done through the telerehabilitation platform and special data processing software. The intervention time remains the same, with the physical therapist during these 45 minutes of the session , to evaluate the data on the patients progress by receiving the information through the software and to inform the patient of any changes in the progressivity of the exercise program. The other parameters of the intervention remain the same, as in person exercise.
48181109|NCT00484601|DRUG|Ifosfamide|
48181110|NCT00484601|DRUG|Doxorubicin|
48181111|NCT05578430|DRUG|Cadonilimab|10mg/kg by intravenous infusions every 3 weeks
48181112|NCT05578430|PROCEDURE|TACE|TACE will be performed per institutional standard of care.
48181113|NCT05578430|PROCEDURE|Surgery|Surgery will be performed per institutional standard of care.
48181114|NCT02897089|DEVICE|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
48181115|NCT02665585|PROCEDURE|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
48181116|NCT03866369|DRUG|Moxifloxacin|Single oral dose at D-8
48181117|NCT03866369|DRUG|Placebo|Single oral dose at D-1
48519177|NCT05778812|BEHAVIORAL|Full Sleep|"Daily lessons about sleep and skills that can help with sleep. Participants also record information about each night's sleep in their sleep log. Every seven nights, they also complete the Sleep Needs Questionnaire. At the beginning, middle, and end of the study, they complete the Insomnia Severity Inventory in the app. At the end of every week, a sleep schedule and weekly summary are calculated via automated formulas. The app also contains access to messaging a coach, for participants to ask questions about their daily lessons and application of the skills and to feel supported and accountable.~The REST device in the Full Sleep program uses radar to passively track sleep patterns and nighttime awakenings. It also offers white noise options and audio guidance for relaxation techniques and stimulus control."
48717232|NCT06263049|PROCEDURE|transurethral resection of prostate|resection of prostate by using bipolar cautarization
48717233|NCT01146288|DRUG|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
48023578|NCT04135131|OTHER|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
48181118|NCT03866369|DRUG|Lanifibranor|Single daily oral dose during 14 days
48181119|NCT03866369|DRUG|Placebo|Single daily oral dose during 14 days
48181120|NCT01667809|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
48181121|NCT01667809|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
48023579|NCT01151553|DEVICE|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
48181122|NCT03163706|BEHAVIORAL|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
48181123|NCT01804010|DRUG|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
48717234|NCT01146288|DRUG|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
48181124|NCT04864366|DRUG|Tenofovir Alafenamide 25 MG [Vemlidy]|TAF is administered as a 25mg/tablet, taken orally with food once daily, for 48 weeks.
48717235|NCT04832945|DRUG|Ivermectin 6 Mg Oral Tablet|Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
48717236|NCT05096754|DEVICE|OCS Liver|Transplant with an OCS preserved liver.
48717237|NCT02659553|PROCEDURE|steatosis|Liver Transplantation with graft steatosis
48717238|NCT03677479|PROCEDURE|socket preservation procedure|socket preservation of post extraction site using bone xenografts
48717239|NCT04708132|PROCEDURE|Screw retained restoration|Hybrid prosthesis
48717240|NCT04708132|PROCEDURE|implant-retained ball overdentures|Removable prosthesis
48717241|NCT02411786|BIOLOGICAL|pTVG-AR|Given ID
48717242|NCT02411786|BIOLOGICAL|gm-csf|Given ID
48023580|NCT06535867|DIAGNOSTIC_TEST|mHealth|The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
48023581|NCT03969810|BEHAVIORAL|Rounding Summary|Written summary of rounds
48023582|NCT04787666|PROCEDURE|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet|Using of non-invasive mask ventilation, high-flow oxygen therapy through a nasal cannula (high-flow nasal oxygenation) and non-invasive ventilation with a helmet for tackling the problem of respiratory failure
48023583|NCT02802553|DEVICE|Smart Goggle|Smart Goggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The Smart Goggles is a non-invasive imaging system that does not require contact with patients.
48181125|NCT04430166|DRUG|PD-1 monoclonal antibody|200mg / intravenous drip, once every three weeks
48181126|NCT03177109|DRUG|5% fluoride varnish|Applied topically as a coating at single point in time
48181127|NCT03177109|DRUG|8% arginine containing paste|Applied topically as a coating at single point in time
48181128|NCT03177109|DRUG|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
48181129|NCT04482478|DIETARY_SUPPLEMENT|Extract of Dolichos lablab Linne (EDL)|Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day)
48181130|NCT04482478|OTHER|Placebo oral tablet|Placebo: consumed in the same way as the investigational product
48717243|NCT04985539|DEVICE|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
48717244|NCT01394614|BIOLOGICAL|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
48717245|NCT04616209|BIOLOGICAL|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
48717246|NCT05301738|OTHER|Plyometric Exercises|The plyometric exercise group received a 12-week plyometric training program. Each session lasted 45 minutes and was repeated two times a week. The training was conducted in conformity with the National Strength and Conditioning Association guidelines and American Academy of Pediatrics safety standards. The plyometric exercise program consisted of ten unilateral and bilateral lower limb plyometrics in the form of hopping/bounding/jumping activities. The Iplyometric workout was proceeded by a 5-minute warm-up and ended up with a 5-minute cool-down
48717247|NCT05301738|OTHER|Standard Physical Therapy|The control group received their usual physical rehabilitation program for 45 minutes, twice/week for 12 consecutive weeks. The program comprised advanced balance training, and gait training exercises, postural and flexibility exercises, strength training exercises.
48181131|NCT01938313|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~7. Epidural patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~10. Perioperative High content Oxygen therapy~11. No drain insertion~12. No Levin tube~13. Patients will be discharged at POD#4 if there's no problem."
48181132|NCT01938313|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Routine drain insertion~12. Levin tube insertion if needed"
48181133|NCT02518347|DIETARY_SUPPLEMENT|FDS-Strawberry|Natural frozen and dried strawberries
48181134|NCT02518347|DIETARY_SUPPLEMENT|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
48181135|NCT02089139|DEVICE|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
48181136|NCT02089139|OTHER|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks"
48181137|NCT01011699|DRUG|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
48717248|NCT04316156|DEVICE|Uincare Homeplus|Interactive digital healthcare system
48717249|NCT04316156|OTHER|Brochure|Brochure
48717250|NCT03935555|DRUG|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
48023584|NCT02802553|OTHER|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
48023585|NCT02802553|DEVICE|SPY Elite Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
48023586|NCT02802553|DEVICE|Quest near-infrared (NIR) Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
48023587|NCT02802553|DEVICE|PDE Imaging system|Previously validated fluorescence detection system. Will be used to look at the same regions as the Smart Goggles to confirm sensitivity
48023588|NCT02802553|DEVICE|Gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
48023589|NCT02802553|OTHER|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
48717251|NCT02226549|DRUG|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
48717252|NCT02226549|DRUG|VDV|VDV 80 mg tablet administered orally once daily
48023590|NCT01421810|DRUG|Dexamethasone|1 mg PO
48023591|NCT01421810|DRUG|rhCG|25 mcg IV
48717253|NCT02226549|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48717254|NCT01646203|BIOLOGICAL|IMC-TR1|Administered intravenously
48717255|NCT02120365|DRUG|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
48717256|NCT02120365|DRUG|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
48717257|NCT00180297|DEVICE|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
48717258|NCT05810285|DEVICE|GKS Prime Flex Mobile knee|Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
48717259|NCT00186537|DRUG|Rosiglitazone|
48023592|NCT06159894|OTHER|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
48023593|NCT06159894|OTHER|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
48717260|NCT00186537|DRUG|Fenofibrate|
48717261|NCT00186537|BEHAVIORAL|Weight Loss|
48717262|NCT05543018|DIAGNOSTIC_TEST|Electroretinogram|Retinal function assessment using electroretinogram
48717263|NCT05543018|PROCEDURE|Vitrectomy operation|Vitrectomy operation to treat retinal detachment
48717264|NCT02601547|DEVICE|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
48717265|NCT06177470|DEVICE|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
48717266|NCT06177470|DEVICE|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
48717267|NCT04670393|DIETARY_SUPPLEMENT|FertyBiotic Woman Plus|4g Myo-Inositol, 421 mg D-Chiro-Inositol, 400 mcg folic acid, 55 mcg selenium, 15 mcg vitamin D, 1,8 mg melatonin,2x109 Lactobacillus rhamnosus, 2x109 Lactobacillus crispatus and 2x109 Lactobacillus plantarum
48717268|NCT04670393|OTHER|Placebo|400 mcg folic acid
48717269|NCT04767165|DIAGNOSTIC_TEST|MRI|Dynamics of Bone marrow fat fraction by mDixon-quant (%)
48717270|NCT00487643|PROCEDURE|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
48717271|NCT00690287|DRUG|AZD6370|Oral single doses a+b+c, o.d., suspension
48717272|NCT00690287|DRUG|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
48717273|NCT00690287|DRUG|Placebo|Placebo
48717274|NCT03912701|DIAGNOSTIC_TEST|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
48717275|NCT01573481|OTHER|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
48717276|NCT01573481|OTHER|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min).
48382272|NCT04485026|DRUG|Standard of care radiation therapy|Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
48382273|NCT04492488|DRUG|MRG002|Administrated intravenously
48717277|NCT04822246|PROCEDURE|Control: Hand instrumentation for caries excavation|"An enamel hatchet will be used to create access to the carious lesion and then removal of soft carious tissue will be undertaken with excavators. Excavation will be stopped when some resistance to excavation will be felt and the cavity will be then conditioned with polyacrylic acid for 20 s, washed and dried with cotton pellets. A high-viscosity glass-ionomer cement will be used to restore the cavity. Moisture control will be achieved with the use of cotton wool rolls. A chair-side assistant will hand-mix the glass-ionomer according to manufacturers' instructions and it will be placed in the cavity using the press-finger technique whenever the type of cavity allows it. In the case of root restorations, a glove coated with petroleum jelly will be used similarly to the press-finger technique to better condense the material into the cavity. Excess material will be removed; the restoration will be coated with petroleum jelly. No local anaesthetic will be used to provide ART treatment."
48717278|NCT04822246|PROCEDURE|Intervention 1: EMS Airflow device for caries excavation|An enamel hatchet will first be used to gain access into the cavity. Then the powder-water prophylaxis device will be used for the removal of soft carious tissue with the sodium bicarbonate powder-water jet. Excavation will be stopped when the colour of the lesion begins to darken and all the soft deposits are evacuated. The excavation will be done intermittently allowing sufficient time to check with hand instrument the surface hardness of the lesion. If the lesion is still soft excavation will be continued until the surface is hard suitable for restoring. The cavity will be then rinsed with copious water spray to evacuate all the powder-water material. The restoration procedure with a glass-ionomer cement will be done following the same procedures as in the control group.
48382274|NCT06539078|OTHER|Maximal exercise test|Participants will undertake an incremental ramp test on a cycle ergometer to determine maximal oxygen uptake (V̇O2max) and the gas exchange threshold (GET). Throughout the exercise test, muscle oxygenation and deoxygenation will be monitored by NIRS.
48717279|NCT04822246|PROCEDURE|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|The participants allocated to this group will have the caries excavated as described for the control group. Then prior to filling the excavated cavity, the procedure of sodium bicarbonate powder-water jet irrigation as described for the intervention group #1 will be performed to condition the prepared excavated cavity. Then the restorative procedure will be completed with the restorative material and procedures as described for the previous groups.
48023594|NCT02908438|DRUG|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
48023595|NCT01114646|DEVICE|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
48023596|NCT01114646|DEVICE|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
48023597|NCT06128135|OTHER|Technology acceptance questionnaire for prostheses users.|One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.
48023598|NCT06128135|OTHER|Technology acceptance questionnaire for relatives of prostheses users.|One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
48023599|NCT06128135|OTHER|Technology acceptance questionnaire for therapists|One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
48023600|NCT04199247|BEHAVIORAL|Sub symptom aerobic exercise|Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
48023601|NCT03949725|BEHAVIORAL|Hans Kai Program|In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
48023602|NCT03386617|DRUG|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
48023603|NCT01702129|DRUG|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
48023604|NCT06298643|PROCEDURE|Red blood cell transfusion|≥2 units of red blood cell transfusion
48023605|NCT06298643|PROCEDURE|Red blood cell transfusion|0 units or \<2 units of red blood cell transfusion
48023606|NCT05290259|OTHER|Ballroom Dance|The Ballroom Basics for Balance Program is a dance focused exercise program developed by a Physical Therapist in the Madison area.
48382275|NCT06539078|OTHER|3D Ultrasound|Muscle volume and morphological characteristics will be assessed via 3D ultrasound imaging.
48382276|NCT06539078|OTHER|Dynamometry|To determine the contractile properties of the knee extensors, participants will perform maximal isometric and isoinertial contractions of the knee extensors on a dynamometer.
48382277|NCT06539078|OTHER|Exercise test and occlusions|Participants will perform a series of moderate-intensity constant power output exercise bouts on a cycle ergometer following which the recovery rates of muscle V̇O2 will be determined via a series of intermittent arterial occlusions. Throughout all tests, pulmonary gas exchange and ventilation will be determined and muscle oxygenation and deoxygenation will be monitored by NIRS.
48382278|NCT06539078|OTHER|Exercise test in MRI|Exercise will be performed on a custom-built magnetic resonance-compatible cycle ergometer in supine position for determination of muscle phosphocreatine recovery kinetics using 31phosphorous magnetic resonance spectroscopy \[31P-MRS\].
48382279|NCT06539078|PROCEDURE|Muscle biopsy|A muscle biopsy will be obtained from the vastus lateralis using a modified Bergström needle technique with suction.
48382280|NCT02097966|DRUG|Daclatasvir|
48382281|NCT02097966|DRUG|Sofosbuvir|
48382282|NCT02097966|DRUG|Ribavirin|
48382283|NCT03478813|BEHAVIORAL|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
48382284|NCT03644927|BEHAVIORAL|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
48382285|NCT03644927|BEHAVIORAL|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
48382286|NCT05863325|DRUG|HB1801|HB1801 will be administered by intravenous (IV) injections on the first day of each cycle.
48382287|NCT05863325|DRUG|Taxotere|Taxotere will be administered by intravenous (IV) injections on the first day of each cycle.
48382288|NCT02866370|DRUG|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
48382289|NCT02866370|DRUG|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
48382290|NCT02866370|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
48382291|NCT02866370|DRUG|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
48382292|NCT02866370|DRUG|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
48382293|NCT02866370|DRUG|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
48382294|NCT06651242|OTHER|Decision-making information aids|Provide a decision-making information aids to assist patients and their parents in treatment decision making.
48023607|NCT03611803|DEVICE|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
48023608|NCT03611803|OTHER|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
48023609|NCT05018845|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48382295|NCT06651242|OTHER|Routine care|Routine care
48717280|NCT00573807|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
48717281|NCT03186014|DEVICE|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
48717282|NCT04973345|DRUG|Terbutaline|management of asthma symptoms
48717283|NCT01808885|DRUG|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
48717284|NCT01808885|DRUG|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
48717285|NCT04447599|OTHER|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
48717286|NCT04109846|OTHER|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be at discretion of treating provider
48717287|NCT04109846|OTHER|Euploid Transfer|Standard of Care Protocol
48717288|NCT03550404|BEHAVIORAL|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
48717289|NCT01439074|DEVICE|Mepilex Ag|Dressing
48717290|NCT01439074|DRUG|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
48717291|NCT05895903|DEVICE|Screw expander|threadform screw expanders with special condensing burs for lateralization and compaction of bone
48023610|NCT03617809|PROCEDURE|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
48023611|NCT01754714|DRUG|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
48023612|NCT01754714|DRUG|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
48023613|NCT01754714|DRUG|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
48717292|NCT05895903|DEVICE|Osseodensification drills|special drills to expand narrow alveolar ridges.
48717293|NCT03597477|DRUG|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
48717294|NCT01056120|DEVICE|Pro Kinetic Energy bare metal stent|PCI
48717295|NCT04138719|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
48717296|NCT04138719|DRUG|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
48023614|NCT03505476|DEVICE|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
48023615|NCT03505476|OTHER|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
48023616|NCT03505476|OTHER|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
48023617|NCT05331742|DRUG|Vaccine|patients who have received vaccine against coronavirus disease infection
48023618|NCT03424746|DRUG|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
48023619|NCT02121145|BIOLOGICAL|Vivotif|3 oral doses
48023620|NCT02121145|BIOLOGICAL|Typherix|one intramuscular dose
48023621|NCT01422759|DRUG|Spironolactone|50-100 mg PO BID (X 12 weeks)
48023622|NCT03313362|DEVICE|SPEAC System|Seizure Monitoring and Alerting System
48382296|NCT04394572|BIOLOGICAL|Blood sample|All patients included in the study will have blood sample
48717297|NCT06316973|DRUG|CS-1103|CS-1103 for infusion
48717298|NCT06316973|DRUG|Sterile Saline|Sterile Saline for Injection
48717299|NCT01532544|DRUG|Ilomedin and Integrilin|Continuous infusion
48717300|NCT01532544|DRUG|low molecular weight heparin.|
48717301|NCT05665699|DRUG|D-0120|increasing dose of D-0120
48717302|NCT05665699|DRUG|Allopurinol|standard dosing
48717303|NCT05792644|DRUG|crizotinib for rearrangement-negative, high phosphorylated ALK patients|Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.
48717304|NCT06464094|OTHER|User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
48717305|NCT02702531|DEVICE|FloShield Defogging and Cleaning System|
48717306|NCT00844805|DRUG|Infliximab|
48717307|NCT00844805|DRUG|Placebo|
48717308|NCT00844805|DRUG|Naproxen|
48717309|NCT01049802|DEVICE|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
48717310|NCT02595697|BEHAVIORAL|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
48717311|NCT04226976|DEVICE|Otoband|Participants with AUV will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
48519178|NCT05778812|BEHAVIORAL|Path to Better Sleep|Path to Better Sleep is a self-management tool for insomnia. It is available as a web-based program at https://www.veterantraining.va.gov/apps/insomnia/index.html#dashboard. Path to Better Sleep is intended to be completed over six weeks, and includes weekly educational lessons about sleep which include videos, visual depictions, and interactive activities, in addition to sleep check-ins (e.g., knowledge checks, self reflections about sleep). It also includes sleep logging. Participants in this condition will be asked to share their sleep log weekly via email, as Stanford and Koko Labs do not receive access to the data.
48717312|NCT04226976|DEVICE|Placebo Device|Participants with AUV will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
48717313|NCT04973462|DRUG|standard treatment COVID-19 + Triazavirin|to evaluate the efficacy and safety (side effects and / or adverse effects) of Triazavirin and Oseltamivir as treatment of Coronavirus Disease 2019
48717314|NCT02495688|PROCEDURE|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
48717315|NCT02495688|PROCEDURE|General anesthesia|Standard procedure.
48717316|NCT03926312|DEVICE|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
48717317|NCT05348746|OTHER|Advanced Analysis of Polymorphism|Assessment of Plasmodium falciparum drug resistance. Target P. falciparum drug resistance genes: Pfk13 propeller, Pfdhfr and Pfdhps. The polymorphisms analysis of the propeller domain of the Pfk13 gene will be performed by PCR amplifications and subsequent sequencing. Analysis of Pfdhfr gene at codons 51, 59, 108 and Pfdhps gene at codon positions 436, 437, 540, 581, 613 will be done by means of amplifications and subsequent Sanger sequencing. Molecular studies will be performed only for research purposes and will have no impact on the clinical management of study patients.
48717318|NCT02574741|BEHAVIORAL|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
48717319|NCT02574741|DRUG|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
48717320|NCT02574741|DRUG|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
48717321|NCT03919227|PROCEDURE|empty bladder before inserting UAS|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.
48023623|NCT03313362|DEVICE|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
48717322|NCT03919227|PROCEDURE|do not interfere with the filling degree of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
48717323|NCT00003787|BEHAVIORAL|educational/counseling intervention|
48717324|NCT00003787|BEHAVIORAL|therapeutic dietary intervention|
48717325|NCT05479123|DRUG|Propranolol three times a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit."
48023624|NCT00963664|DRUG|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
48023625|NCT00963664|DRUG|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
48023626|NCT00111943|DRUG|1% tenofovir gel|
48382297|NCT05661903|OTHER|Spinal Cord Stimulator Set to Minimal/No Stimulation Setting|Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
48382298|NCT05661903|OTHER|Usual Care|Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
48382299|NCT05324254|DEVICE|Weighted blanket|A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
48382300|NCT02525380|PROCEDURE|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
48023627|NCT02671669|BEHAVIORAL|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
48181138|NCT01011699|DRUG|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
48382301|NCT05808699|DEVICE|handheld fundus camera|Fundus camera
48382302|NCT04527406|PROCEDURE|posterior hemivertebra resection|The subjects in early surgical group are arranged to be admitted to for surgical treatment very soon. The operation choice is posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
48717326|NCT05479123|DRUG|Propranolol twice a day|"Patients with larger (\>2cm) or multiple (\>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit."
48717327|NCT05479123|DRUG|Timolol|Patients with a small (\<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
48519179|NCT03296527|DRUG|Follitropin alfa|GONAL-F dose was fixed for the first 5 stimulation days.
48519180|NCT03296527|DRUG|Follitropin delta|REKOVELLE (FE 999049) was fixed throughout the stimulation period.
48519181|NCT05760248|DRUG|10XB-101 Solution for Injection, 6.0%|The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
48519182|NCT05760248|DRUG|Placebo Solution for Injection (no active ingredient)|Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
48717328|NCT04401839|DRUG|Oxytocin IV shot|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
48717329|NCT04401839|DRUG|Oxytocin IV drip|administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
48717330|NCT04401839|PROCEDURE|Amr maneuver|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
48717331|NCT04557787|DEVICE|SpeediCath® Standard female|Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard female.
48717332|NCT04557787|DEVICE|New intermittent Variant 1 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 1 catheter.
48717333|NCT04557787|DEVICE|New intermittent Variant 2 catheter for females|Intermittent catheterization through the urethra draining the bladder, using the new Variant 2 catheter.
48717334|NCT01529736|PROCEDURE|High torque insertion|Osseotite implant placed with high insertion torque forces
48717335|NCT01529736|PROCEDURE|Low torque insertion|Osseotite implant placed with low insertion torque forces
48023628|NCT02671669|BEHAVIORAL|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~* Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~* Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
48023629|NCT04832204|DRUG|Apatinib and Camrelizumab for Injection|Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
48023630|NCT00617149|BEHAVIORAL|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
48023631|NCT05495503|DEVICE|Prototype (814A-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
48023632|NCT05495503|DEVICE|Prototype (814B-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
48023633|NCT05495503|DEVICE|Prototype (814C-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
48519183|NCT05257226|BEHAVIORAL|frailty|questionaire
48519184|NCT03505970|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
48717336|NCT00379977|BIOLOGICAL|diphtheria, tetanus, pertussis & Hib vaccine|
48717337|NCT01001546|BEHAVIORAL|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
48717338|NCT01001546|BEHAVIORAL|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
48717339|NCT00771121|DRUG|urea/lactic acid|new emulsion type
48717340|NCT00771121|DRUG|Placebo|only emulsion base
48717341|NCT03839992|DIAGNOSTIC_TEST|spirometry|measure spirometry and lung CT
48717342|NCT05900570|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
48717343|NCT01115335|PROCEDURE|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
48717344|NCT01013779|DRUG|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
48023634|NCT05495503|DEVICE|Prototype (814D-v1)|Application on PIH located on the dorsal area (2 treatments during the study).
48717345|NCT01013779|DRUG|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
48717346|NCT01013779|RADIATION|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
48717347|NCT05544630|DEVICE|computerized dynamic posturography (sensory orgnization test)|assess of an individual's ability to maintain static and dynamic stance. The assessment is composed of a battery of tests that are similar to everyday conditions of daily living. There are four main components to CDP that are used clinically: the Sensory Organization Test (SOT),
48717348|NCT02275728|OTHER|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
48717349|NCT02275728|OTHER|Eletromyography Biofeedback|
48717350|NCT03430271|OTHER|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
48717351|NCT03430271|OTHER|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
48717352|NCT00461305|DRUG|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
48717353|NCT00461305|DRUG|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
48717354|NCT05942794|DEVICE|Screening examination|"After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module."
48717355|NCT04350060|OTHER|Retro-fitted room with technological enhancements|Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
48717356|NCT01164332|OTHER|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
48717357|NCT01790555|DRUG|Namisol|
48717358|NCT01790555|DRUG|Diazepam/placebo|
48717359|NCT03894384|DIAGNOSTIC_TEST|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
48717360|NCT04164641|DEVICE|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
48717361|NCT02644902|OTHER|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
48717362|NCT02644902|OTHER|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
48717363|NCT05079399|OTHER|Blood draw|Blood samples will be collected via venipuncture
48717364|NCT02754583|BEHAVIORAL|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
48717365|NCT02754583|BEHAVIORAL|Standard of care WASH intervention|Stand of care WASH arm
48717366|NCT02754583|DRUG|Azithromycin|20mg/kg
48717367|NCT02754583|DRUG|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
48023635|NCT01319006|DRUG|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
48519185|NCT03505970|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
48519186|NCT01651793|OTHER|Caffeinated cocoa|70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
48717368|NCT02754583|OTHER|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
48023636|NCT01319006|DRUG|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
48519187|NCT01651793|OTHER|Cocoa|21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
48023637|NCT01319006|DRUG|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
48023638|NCT05148000|BIOLOGICAL|QM1114-DP|QM1114-DP
48023639|NCT01327534|DRUG|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
48023640|NCT01327534|DRUG|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
48023641|NCT06200805|BEHAVIORAL|tai ji quan|24-Style Taijiquan as an Intervention for College Students with Insomnia
48023642|NCT03578900|DRUG|Xeros|
48023643|NCT03578900|DRUG|Citric Acid based Mouthwash|
48382303|NCT04527406|PROCEDURE|conservative treatment+ delayed posterior hemivertebra resection|In traditional surgical group, subjects received conservative treatment firstly with custom-made braces to delay the progression of scoliosis. It is planned to use the classic posterior hemivertebrae resection + posterior pedicle screw placement + scoliosis correction to complete the correction around the age of 5. The operation choice is identical with early surgical group. During operation pedicle screws are placed in the adjacent vertebrae of the head and tail of the Hemivertebra. Wedge resection of the hemivertebrae is performed afterward. Finally, two rods are placed between the pedicle screws. Intraoperative fluoroscopy confirms that the internal fixation position is good.
48382304|NCT03888651|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
48519188|NCT01651793|OTHER|Caffeine|473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
48023644|NCT05014009|BEHAVIORAL|FIFA11+ and multidirectional training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time."
48382305|NCT03888651|OTHER|Questionnaire Administration|Complete questionnaire
48382306|NCT01607580|DRUG|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
48181139|NCT01011699|DRUG|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH \> 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
48181140|NCT00760747|DRUG|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
48181141|NCT00004254|DRUG|raltitrexed|
48519189|NCT01651793|OTHER|Placebo|473 ml of brewed water, caramel coloring and one packet Truvia sweetener
48181142|NCT01390441|BIOLOGICAL|MK-8808|MK-8808 500 mg/m\^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
48181143|NCT01390441|BIOLOGICAL|MabThera® (rituximab)|MabThera® 500 mg/m\^2 or 1000 mg administered by IV on Day 1 and Day 15
48181144|NCT01390441|DRUG|Methotrexate|Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
48181145|NCT01390441|BIOLOGICAL|Rituxan® (rituximab)|Rituxan® 1000 mg administered by IV on Day 1 and Day 15
48519190|NCT04394039|OTHER|Public space exposure|landscapes with nature and/or classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to noncontemplative ones.
48519191|NCT02351661|OTHER|There was no intervention|observational study, no intervention
48717369|NCT04100434|DRUG|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
48717370|NCT04798469|DRUG|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
48717371|NCT04798469|DRUG|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
48181146|NCT01390441|DRUG|Methylprednisolone|Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
48181147|NCT01390441|DRUG|Acetaminophen|Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
48181148|NCT01390441|DRUG|Loratadine|Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
48181149|NCT01376154|DRUG|Lamivudine|
48717372|NCT00892203|DRUG|BGG492|
48717373|NCT00892203|DRUG|Sumatriptan|
48717374|NCT00892203|DRUG|Placebo|
48717375|NCT00463463|DRUG|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
48717376|NCT01459913|DRUG|Telaprevir|Tablet
48717377|NCT01459913|DRUG|Pegylated Interferon Alfa-2a|Subcutaneous Injection
48717378|NCT01459913|DRUG|Ribavirin|Tablet
48717379|NCT01101698|DRUG|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
48717380|NCT01101698|DRUG|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
48717381|NCT03974672|PROCEDURE|Re-laparotomy|
48382307|NCT06621511|BEHAVIORAL|OurSleepKit|OurSleepKit is developed as an app including a patient version and a partner version, to be downloaded on the patient's or partner's mobile devices at home. The goal of OurSleepKit is to coach mutual engagement and model positive partner involvement in CPAP treatment, thus motivating greater CPAP adherence. Using OurSleepKit, both the patient and partner will complete periodic assessments tracking various aspects of their sleep and CPAP use. The assessment data are then processed by OurSleepKit to provide customized and dynamically updated support content consisting of brief story-telling videos featuring real-life couples' experiences emphasizing positive dyadic coping and problem-solving strategies. OurSleepKit delivers timely tailored prompts through push notifications on the users' mobile devices' screens, linked to relevant support content, to facilitate positive conversation in the dyad and offer in-the-moment support for CPAP use.
48023645|NCT05014009|BEHAVIORAL|FIFA11+ and linear sprint training (MD)|"This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time."
48023646|NCT05494112|DIETARY_SUPPLEMENT|Celastrol|same dose of Celastrol will be given every day for a period of 90-days to all participants.
48023647|NCT01260441|OTHER|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
48023648|NCT00461903|DRUG|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
48023649|NCT03765957|BIOLOGICAL|Mesenchymal Stem Cells|After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
48023650|NCT01731171|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
48181150|NCT03541681|PROCEDURE|Glucocorticoid Injections|1 ml Dexamethasone + 0,5 ml Bupivacain
48181151|NCT03541681|PROCEDURE|Anesthetic Injections|0,5 ml Bupivacain
48181152|NCT02772562|BIOLOGICAL|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
48382308|NCT00596973|PROCEDURE|Surgical Treatment|Ileal transposition with sleeve gastrectomy
48717382|NCT04319744|OTHER|other|Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
48717383|NCT01634529|DRUG|V158866|Single ascending oral doses of V158866 and Placebo
48717384|NCT01634529|DRUG|V158866|Multiple ascending oral doses of V158866 and Placebo
48717385|NCT01157208|OTHER|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
48717386|NCT01157208|OTHER|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
48181153|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)
48382309|NCT05288452|BEHAVIORAL|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
48382310|NCT05288452|DIETARY_SUPPLEMENT|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
48717387|NCT06497335|DIAGNOSTIC_TEST|non invasive hemoglobin measure|non invasive hemoglobin measure
48717388|NCT00630227|BIOLOGICAL|Biologic Lung Volume Reduction|20 mL Hydrogel
48382311|NCT05288452|BEHAVIORAL|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
48382312|NCT05288452|BEHAVIORAL|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
48382313|NCT00421486|PROCEDURE|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
48382314|NCT00075465|DRUG|docetaxel|
48382315|NCT00075465|DRUG|epirubicin hydrochloride|
48382316|NCT01905813|DRUG|INCB040093|Escalating doses starting at 100 mg every day (QD)
48382317|NCT01905813|DRUG|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
48382318|NCT06651996|DEVICE|one session of face-to-face telerehabilitation tutorial (OST)|The first group participated in a face-to-face tele-rehabilitation session in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
48382319|NCT06651996|DEVICE|Three session of face-to-face telerehabilitation tutorials (TST)|The second group participated in three face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
48382320|NCT06651996|DEVICE|Six session of face-to-face telerehabilitation tutorials (SST)|The third group participated in six face-to-face tele-rehabilitation sessions in the hospital on the use of sensors and rehabilitation software before the home-rehabilitation session. Thereafter, the tele-rehabilitation program included muscle strengthening, flexibility stretching, and movement quality training every Tuesday, Thursday, and Saturday.
48382321|NCT06641271|DEVICE|Closed Loop Trans-Auricular Vagus Nerve Stimulation System|A closed loop system that delivers stimulation to the vagus nerve via the ear non-invasively following a trigger event.
48382322|NCT06641271|DEVICE|Placebo|A closed-loop vagus nerve stimulation device that can deliver sham stimulation to the ear to simulate stimulation of the vagus nerve.
48382323|NCT06653270|OTHER|Virtual reality simulator|A in-house developed immersive virtual simulation of a normal vaginal delivery developed using a Unity Engine and installed in Oculus® Quest 2 head-mounted device
48717389|NCT02971241|BEHAVIORAL|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
48023651|NCT01731171|DIETARY_SUPPLEMENT|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
48023652|NCT05712226|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 35 minutes.
48023653|NCT01313559|DRUG|Pasireotide|Given IM
48023654|NCT01313559|DRUG|Everolimus|Given PO
48023655|NCT01313559|OTHER|Laboratory biomarker analysis|Correlative studies
48023656|NCT01785745|OTHER|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
48717390|NCT02696408|DEVICE|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
48717391|NCT02696408|DEVICE|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
48717392|NCT00099060|DRUG|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~* Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~* Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
48717393|NCT03081676|DRUG|Glimepiride 1Mg Tablet|Glimepiride
48717394|NCT03081676|DRUG|Glucagon-like Peptide-1|GLP-1 infusion
48717395|NCT03081676|DRUG|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
48717396|NCT03081676|DRUG|Placebo Oral Tablet|Placebo
48717397|NCT03081676|DRUG|Placebo infusion|Placebo (saline)
48717398|NCT03796754|BEHAVIORAL|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
48717399|NCT01247363|DRUG|LY2608204|Administered orally.
48717400|NCT04142190|DRUG|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
48717401|NCT04142190|DRUG|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
48717402|NCT06161285|OTHER|Sampling|Single-time sampling of respiratory virus-infected children
48382324|NCT06653270|OTHER|Mannequin-based simulator|Legacy PROMPT Flex® mannequin
48382325|NCT00183170|DRUG|Alcohol|Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
48382326|NCT00183170|OTHER|Placebo|Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.
48382327|NCT06257511|BEHAVIORAL|Simulation-Based Mastery Learning of the Non-technical skills|Participants will participate in a simulation-based mastery learning of the non-technical skills.
48382328|NCT03397576|BEHAVIORAL|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
48382329|NCT02539472|OTHER|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
48382330|NCT00608127|DEVICE|LupusorbTM|Single treatment
48717403|NCT02634021|DRUG|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
48382331|NCT04679233|OTHER|Prescription aerobic exercise|high intensity interval training, 5 weeks, 2 sessions/week - supervised by a clinician.
48717404|NCT02634021|DRUG|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
48717405|NCT02072187|DIETARY_SUPPLEMENT|Active|
48717406|NCT02072187|DIETARY_SUPPLEMENT|Placebo|
48717407|NCT00027586|DRUG|Imatinib mesylate (STI571)|400 mg twice a day orally
48382332|NCT03253666|OTHER|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
48382333|NCT00953017|DRUG|Miralax (PEG 3350)|Miralax 255gm bottle
48181154|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
48181155|NCT04228198|PROCEDURE|Radical cystectomy|Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
48181156|NCT02414009|DRUG|Capecitabine|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
48382334|NCT00953017|DRUG|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
48382335|NCT00953017|DRUG|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
48519192|NCT06058624|BEHAVIORAL|Veteran ACT for Chronic Pain (VACT-CP)|"Participants receive 7 online modules, provided as weekly sessions that feature Coach Anne as a virtual, animated treatment guide. All content is presented interactively, through text-based conversations with Coach Anne. Veterans will hear what Coach Anne says and respond to her using text-based dialogue options that will trigger different responses from Coach Anne as the conversation progresses, to allow the system to responsively interact in a personalized manner with the Veteran. Veterans will also be presented with videos (e.g., Veteran narratives, metaphors), in-module assessments (e.g., values assessments), and interactive opportunities for goal setting."
48519193|NCT06058624|BEHAVIORAL|Online Pain School|"Participants will receive 7 modules (15 to 20 minutes each) of content based on a common non-ACT based VA treatment option, Pain School. The adaptation used for this study, Online Pain School, will support Veterans' self-management of their chronic pain by providing informational videos on chronic pain and its health impacts, short behavioral exercises to help with pain management, and psychoeducation on different wellness techniques for their pain management toolbox."
48519194|NCT05584384|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
48519195|NCT05584384|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
48519196|NCT02304393|DRUG|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
48519197|NCT02304393|DRUG|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
48519198|NCT04999657|DEVICE|Non-invasive low-frequency tibial nerve stimulator (TNS-01)|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
48519199|NCT04290455|DEVICE|Microblepharoexfoliative procedure with BlephEx™|The device will be used to clean both upper and lower eyelid in the office visit.
48717408|NCT06195995|DEVICE|Transcranial alternating current stimulation-true stimulus|Three conductive electrodes are placed overhead. In the 10/20 international placement system, a 4.45 9.53 cm electrode is placed on the forehead corresponding to Fpz, Fp1 and Fp2. Two 3.18 3.81 cm electrodes are placed on the mastoid region of each side. The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. The frequency of stimulation is 77.5Hz, and the current is 15mA.
48717409|NCT02068118|DEVICE|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
48717410|NCT05053412|DIAGNOSTIC_TEST|Helio Liver Test|A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.
48717411|NCT04347980|DRUG|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
48717412|NCT04347980|DRUG|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
48717413|NCT02089152|OTHER|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
48717414|NCT04336371|DIAGNOSTIC_TEST|Self-administered questionnaires|Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
48519200|NCT04290455|PROCEDURE|Eyelid cleansing with eyelid wipes (Optase)|Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
48519201|NCT04290455|PROCEDURE|Daily eyelid cleansing with eyelid wipes (Optase)|Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
48519202|NCT06387355|DIAGNOSTIC_TEST|Coronary computed topography (CT) angiography with FFR-CT|The investigational treatment strategy will have a coronary CT angiography diagnostic imaging with computational analysis FFR-CT (Fractional Flow Reserve from the coronary CTA)
48382336|NCT00953017|DRUG|Golytely (polyethylene glycol)|Golytely 1 gallon
48717415|NCT03217032|BIOLOGICAL|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
48519203|NCT01669291|DRUG|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
48519204|NCT01669291|DRUG|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
48181157|NCT02414009|DRUG|Temozolomide|Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.
48382337|NCT06420726|BEHAVIORAL|Resistance Exercise|Supervised resistance exercise
48519205|NCT01669291|DRUG|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
48717416|NCT04316806|DIETARY_SUPPLEMENT|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
48717417|NCT04316806|DRUG|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
48717418|NCT04332614|BEHAVIORAL|Less-is-better|Email
48717419|NCT04332614|BEHAVIORAL|Social proof|Email
48717420|NCT04332614|BEHAVIORAL|Endowment / decision staging|Email
48181158|NCT02414009|DRUG|Irinotecan|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
48382340|NCT04406363|OTHER|non interventional|non interventional
48382341|NCT04457323|DRUG|Metoprolol|S-Metoprolol XR 25 mg and 50 mg Film Coated Tablets
48382342|NCT04457323|DRUG|Metoprolol|Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets
48519206|NCT06176729|DRUG|Polatuzumab Vedotin, Rituximab, Lenalidomide|polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days
48519207|NCT03594071|DEVICE|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
48519208|NCT03314909|PROCEDURE|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
48519209|NCT03314909|PROCEDURE|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
48717421|NCT04332614|BEHAVIORAL|Standard email|Email
48717422|NCT03888677|DRUG|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
48382343|NCT00997269|DIETARY_SUPPLEMENT|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
48382344|NCT00997269|DIETARY_SUPPLEMENT|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
48717423|NCT02061046|DEVICE|CPAP therapy|8 weeks of CPAP therapy
48717424|NCT04654871|DIETARY_SUPPLEMENT|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
48382345|NCT04456998|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
48382346|NCT04456998|DRUG|Placebo|Matching capsule containing placebo
48382347|NCT04456998|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
48382348|NCT01847625|OTHER|simulator|
48382349|NCT04401709|DRUG|Gemcitabine/Capecitabine|gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 \~ 21 days for 4 weeks
48717425|NCT04654871|PROCEDURE|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
48717426|NCT04654871|PROCEDURE|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
48717427|NCT04654871|PROCEDURE|THE therapy|Interferential and Heating for 20 min
48717428|NCT03951909|BEHAVIORAL|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
48717429|NCT03951909|BEHAVIORAL|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
48382350|NCT04401709|DRUG|Capecitabine|total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 \~ 14 days for 3 weeks
48519210|NCT03314909|PROCEDURE|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
48717430|NCT05479929|OTHER|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
48717431|NCT02303782|DRUG|OTX015|
48717432|NCT02303782|DRUG|Vidaza (azacitidine)|
48717433|NCT04884542|DEVICE|Revision Total Knee Arthroplasty|Total Knee Arthroplasty in case of failure of a previous operation.
48519211|NCT00180999|DRUG|Erythropoiétine|
48519212|NCT03845686|DIAGNOSTIC_TEST|Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)|The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
48519213|NCT05392868|DEVICE|SDF|38% silver diamine fluoride solution
48519214|NCT05392868|DEVICE|KNO3|5% potassium nitrate solution
48717434|NCT02852941|DEVICE|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
48519215|NCT03667638|COMBINATION_PRODUCT|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
48519216|NCT04545840|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
48717435|NCT02852941|DEVICE|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
48717436|NCT03323606|BEHAVIORAL|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
48717437|NCT03323606|BEHAVIORAL|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
48717438|NCT05616884|PROCEDURE|Cementless fixation|Three dimensional printed porous metal, a biomaterial with morphological and mechanical properties that resemble those of native trabecular bone, is now being used for fixation of the tibial component in unicondylar knee arthroplasty. This can reliably achieve osseointegration into the tibia and could lead to a lower risk of aseptic loosening which is the leading cause of revision in partial knee replacements.
48717439|NCT04021524|DRUG|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
48717440|NCT04021524|DRUG|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
48717441|NCT03262207|OTHER|Extraction genomic DNA|
48717442|NCT03262207|OTHER|Analysis of methylation profiles of numerous GSI and TE|
48717443|NCT03262207|OTHER|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
48717444|NCT03262207|OTHER|Method of protein detection by immunostaining and flow cytometry|
48717445|NCT03077698|DRUG|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
48717446|NCT03077698|DRUG|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
48717447|NCT04243395|OTHER|Pork|1 oz lean pork
48717448|NCT04243395|OTHER|Egg|1 large whole egg
48717449|NCT04243395|OTHER|Black beans|0.5 cups cooked black beans
48717450|NCT04243395|OTHER|Almonds|0.5 oz almonds
48717451|NCT00316888|BIOLOGICAL|cetuximab|Given IV
48519217|NCT02063750|OTHER|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
48717452|NCT00316888|DRUG|cisplatin|Given IV
48717453|NCT00316888|DRUG|fluorouracil|Given IV
48717454|NCT00316888|RADIATION|radiotherapy|Given once daily 5 days a week for 5 weeks
48717455|NCT05932121|PROCEDURE|Thyroid lobectomy via trans-axillary approach|Patient with PTC underwent thyroid lobectomy via trans-axillary approach
48717456|NCT05932121|PROCEDURE|Thyroid lobectomy via open approach|Patient with PTC underwent thyroid lobectomy via open approach
48717457|NCT00473603|DRUG|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
48717458|NCT00566865|DRUG|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
48717459|NCT00566865|DRUG|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
48717460|NCT03546218|DEVICE|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
48181159|NCT02414009|DRUG|Fluorouracil|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
48519218|NCT02063750|OTHER|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
48717461|NCT03546218|DEVICE|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
48717462|NCT00487448|DRUG|Fludarabine|
48717463|NCT00487448|DRUG|Cytarabine|
48717464|NCT00487448|DRUG|G-CSF|
48717465|NCT00487448|DRUG|Idarubicin|
48717466|NCT00487448|PROCEDURE|Peripheral blood stem cell transplantation|
48717467|NCT00487448|PROCEDURE|Bone marrow transplantation|
48717468|NCT02087813|DRUG|Alpha1-antitrypsin|
48717469|NCT02087813|DRUG|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
48717470|NCT04276155|DRUG|non-systematic prescription of anticoagulant therapy|the prescription of anticoagulant is managed by an implantable device follow up
48717471|NCT05886530|OTHER|No intervention|Observational data collection only.
48717472|NCT02482857|DRUG|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
48717473|NCT04174300|PROCEDURE|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
48717474|NCT02614482|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
48717475|NCT00382915|DEVICE|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
48717476|NCT02955680|PROCEDURE|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
48717477|NCT02955680|PROCEDURE|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. "
48181160|NCT02414009|DRUG|Leucovorin|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
48181161|NCT02578888|OTHER|Palliative Therapy|Palliative Therapy
48181162|NCT02578888|OTHER|Palliative Therapy + idiographic|Ancillary studies
48181163|NCT04588675|DIAGNOSTIC_TEST|MRI|the patients will underwent dobutamine stress cardiac MRI
48181164|NCT00003428|DRUG|arzoxifene hydrochloride|
48181165|NCT00568698|DRUG|Hydroxyurea|
48181166|NCT00568698|DRUG|Placebo to match hydroxyurea|
48181167|NCT06541639|BIOLOGICAL|EVM16|cancer vaccine
48181168|NCT06541639|DRUG|Tislelizumab|Anti-PD1 antibody
48181169|NCT01107899|DRUG|clopidogrel|taken orally, day one, single dose
48181170|NCT01107899|DRUG|prasugrel|taken orally, day one, single dose
48181171|NCT04735783|DIETARY_SUPPLEMENT|Placebo breakfast|Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
48181172|NCT04735783|DIETARY_SUPPLEMENT|Typical whole-food breakfast|Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
48181173|NCT04735783|DIETARY_SUPPLEMENT|Water-only control|Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
48181174|NCT01020214|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
48181175|NCT01020214|DRUG|Benicar HCT® Tablets 40 mg/25 mg|
48181176|NCT00480155|BIOLOGICAL|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
48717478|NCT01171586|BEHAVIORAL|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
48717479|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
48717480|NCT02683668|COMBINATION_PRODUCT|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
48717481|NCT02683668|COMBINATION_PRODUCT|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
48717482|NCT00221975|DRUG|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
48717483|NCT00221975|DRUG|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
48717484|NCT00221975|DRUG|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (\<2 months versus ≥2 months).
48717485|NCT00329927|BIOLOGICAL|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
48717486|NCT06427070|OTHER|Irrigating solution|Saline, sodium hypochlorite, chlorohexidine
48717487|NCT02047201|RADIATION|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
48717488|NCT02047201|RADIATION|PET/CT|Assessing tumor response using FDG-PET/CT.
48717489|NCT02047201|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
48181177|NCT00480155|OTHER|Placebo|
48181178|NCT02731911|DRUG|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
48181179|NCT02989090|OTHER|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
48181180|NCT02989090|OTHER|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
48181181|NCT02417649|BIOLOGICAL|Placebo|"1. The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
48181182|NCT02417649|BIOLOGICAL|Ismigen|"1. The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
48181183|NCT03212768|PROCEDURE|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
48181184|NCT00497666|DRUG|Rosiglitasone (retrospective observation)|
48519219|NCT06583005|DEVICE|Vibrotactile Coordinated Reset|The Stanford CR glove is designed to administer vibrotactile coordinated reset stimulation, which consists of vibratory stimulation of the fingertips delivered in a specific pattern which is design to disrupt and normalize abnormal brain synchrony.
48519220|NCT06581354|PROCEDURE|PROVISIONALIZATION|glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
48519221|NCT05349708|DEVICE|THE-FACS|Telehealth home-monitoring tablet and blood pressure cuff
48519222|NCT04459741|DIETARY_SUPPLEMENT|Dietary salt (Sodium chloride)|Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
48519223|NCT01936350|DRUG|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
48519224|NCT01936350|DRUG|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
48519225|NCT02091856|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
48519226|NCT06133361|BIOLOGICAL|PRP injection|The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.
48519227|NCT06133361|PROCEDURE|En-masse retraction of upper anterior teeth|The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
48519228|NCT04154631|BEHAVIORAL|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
48382351|NCT03073291|BEHAVIORAL|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
48382352|NCT01952873|OTHER|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
48382353|NCT01952873|OTHER|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
48382354|NCT04942561|DEVICE|Samsung Gear VR|Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
48519229|NCT04154631|BEHAVIORAL|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
48519230|NCT04154631|OTHER|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
48519231|NCT00533286|DRUG|benzodiacepine|diazepam (2 x 5 mg/ die)
48519232|NCT03024788|DEVICE|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
48519233|NCT04835857|DEVICE|ViTrack|ViTrack is a continuous non-invasive wearable blood pressure cuff.
48519234|NCT04835857|DEVICE|Oscillometric BP Device|Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
48519235|NCT04835857|DEVICE|Auscultatory cuff|The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
48519236|NCT04384094|DEVICE|Esthesiometer measurement|Measuring the corneal sensitivity using rebound technology.
48717490|NCT02047201|DRUG|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
48717491|NCT02047201|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
48717492|NCT01821456|DRUG|Antiinfectives|To analyze to efficacy of (novel) drug therapies
48717493|NCT02654418|PROCEDURE|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
48717494|NCT01638559|DRUG|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
48382355|NCT04942561|DEVICE|Merge VR|Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
48382356|NCT04009681|DRUG|THOR-707|Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration
48382357|NCT04009681|DRUG|Checkpoint inhibitor|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
48382358|NCT04009681|DRUG|anti-EGFR antibody|Pharmaceutical form: solution for IV administration; Route of administration: IV administration
48717495|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
48717496|NCT04404270|BEHAVIORAL|Questionnaire|"Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3).~The questionnaire includes:~* medical data (height, weight, smoking, history of intense stress);~* socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.);~* clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19;~* use of care, hospitalization, work stoppage in the last 3 months;~* contact with people who are symptomatic or proven COVID-19."
48717497|NCT04404270|DIAGNOSTIC_TEST|Anti-SARS-CoV2 serological controls and serum neutralization|Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
48717498|NCT00475865|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
48717499|NCT00475865|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
48382359|NCT04303065|DRUG|Dexamethasone Oral|It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
48382360|NCT04303065|DRUG|Placebo oral tablet|The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
48519237|NCT01121250|BEHAVIORAL|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
48717500|NCT00475865|DRUG|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
48382361|NCT04071925|PROCEDURE|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
48717501|NCT02017561|BEHAVIORAL|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
48717502|NCT02017561|DRUG|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
48717503|NCT05143866|BEHAVIORAL|Cognitive behavioral therapy guided self help (CBTgsh)|Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide
48717504|NCT06508372|DRUG|Topical thymoquinone Ointment|One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
48717505|NCT06508372|DRUG|topical placebo ointment|In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
48717506|NCT03452033|DRUG|H-1337 Placebo|H-1337 Placebo Vehicle
48717507|NCT03452033|DRUG|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
48717508|NCT03452033|DRUG|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
48717509|NCT03452033|DRUG|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
48717510|NCT02051023|DRUG|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
48519238|NCT01121250|BEHAVIORAL|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
48717511|NCT02051023|DRUG|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
48717512|NCT05828472|DRUG|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
48519239|NCT05324124|DRUG|Selpercatinib|Administered orally.
48717513|NCT05828472|DRUG|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
48717514|NCT01890395|OTHER|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
48717515|NCT00725244|DEVICE|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
48382362|NCT06650891|DRUG|Quercetin|oral quercetin prior to surgery
48717516|NCT00725244|DEVICE|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
48717517|NCT05750433|DIETARY_SUPPLEMENT|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
48717518|NCT05750433|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is rice based powder which was used as placebo.
48717519|NCT05750433|DIETARY_SUPPLEMENT|B. subtilis DE111|Bacillus subtilis probiotics.
48717520|NCT03078933|DEVICE|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
48717521|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
48717522|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
48717523|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
48717524|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
48519240|NCT05736861|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
48519241|NCT05736861|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
48519242|NCT01102101|DRUG|Remifentanil|Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
48382363|NCT06650891|OTHER|Placebo|capsule identical looking to quercetin
48717525|NCT00744666|DRUG|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
48382364|NCT04999137|DRUG|Vitamin C|Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
48382365|NCT04999137|DRUG|Vitamin B1|Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
48382366|NCT05855967|DRUG|Ixekizumab|Administered SC
48382367|NCT01302288|PROCEDURE|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
48519243|NCT00451204|DRUG|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
48717526|NCT01272791|BIOLOGICAL|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
48382368|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
48382369|NCT04166851|BEHAVIORAL|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
48382370|NCT00923299|DRUG|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
48519244|NCT00451204|DRUG|Placebo|Placebo capsule, once a day, treatment duration is 2 years
48519245|NCT00451204|DRUG|Copaxone|Injection, once a day, all subjects
48519246|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
48717527|NCT01272791|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
48717528|NCT05045677|OTHER|digital DBT skills intervention|The digital intervention consists of 6 modules that will be delivered over 6 to 10 days. The modules cover mindfulness skills, emotion regulation skills and distress tolerance skills.
48717529|NCT05045677|OTHER|Standard Care|Standard inpatient care includes a multi-disciplinary team approach including daily psychiatric review, medication management and in-person psychosocial interventions (social work, nursing).
48717530|NCT00769249|OTHER|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
48717531|NCT00769249|OTHER|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
48717532|NCT00769249|PROCEDURE|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
48717533|NCT05027685|DEVICE|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
48717534|NCT02532712|DRUG|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
48717535|NCT02532712|DRUG|Placebo|Placebo with same shape and size
48717536|NCT05472077|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
48717537|NCT01958892|PROCEDURE|TURP, TUERP|
48717538|NCT03826680|PROCEDURE|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
48181185|NCT04517968|OTHER|immediate implant with customized healing abutment|"* All patients will be operated under local anesthesia.~* Atraumatic extraction of the remaining root or tooth will be achieved.~* A careful curettage of the socket will be performed if any granulation tissue is present.~* Sequential drilling of the osteotomy site with copious irrigation will be done~* The Implant is secured in place using a torque wrench.~* Fabrication of the customized abutment with flowable composite by first placing a rubber dam between the abutment and the implant to prevent leakage of composite into the socket then start adding the composite in a manner to seal the socket.~* Finishing the composite outside the patient's mouth will be done to ensure the borders are smooth with no sharp ends.~* The abutment will be attached to the implant."
48181186|NCT00003058|DRUG|troglitazone|
48181187|NCT01450293|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|1x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
48519247|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
48181188|NCT01450293|BIOLOGICAL|AdCH63 ME-TRAP, MVA ME-TRAP|5x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
48181189|NCT05172492|DEVICE|Endocare|Endocare will be administred through a virtual reality headseat used one to twice a day.
48181190|NCT05172492|DEVICE|Digital control|Digital control will be administred through a virtual reality headseat used one to twice a day.
48717539|NCT03826680|PROCEDURE|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
48519248|NCT00462917|BEHAVIORAL|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."
48519249|NCT00462917|BEHAVIORAL|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
48519250|NCT00462917|BEHAVIORAL|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."
48519251|NCT00462917|BEHAVIORAL|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
48023657|NCT01785745|OTHER|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
48519252|NCT03658395|PROCEDURE|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
48519253|NCT03658395|PROCEDURE|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
48519254|NCT05703087|BEHAVIORAL|Positive cueing in the information video before a primary TKA|Two weeks before the surgery, in the outpatient clinic (during their preoperative appointment), the pre-surgery information video was shown to the patients. Patients were randomly allocated to either the positive cueing group (intervention) or the standard care group (control) with Castor EDC (14) using a variable block randomization model. Patients did not know whether they watched the adapted video or the standard video.
48519255|NCT05709379|BEHAVIORAL|Sedentary behavior|Interrupting sitting with walking/jogging at either high -or low physical activity intensity.
48519256|NCT01254773|DRUG|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
48519257|NCT03904290|OTHER|PFO Closure|Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
48519258|NCT00767403|BEHAVIORAL|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
48519259|NCT00767403|BEHAVIORAL|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
48717540|NCT01005212|DRUG|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
48023658|NCT02711657|OTHER|Fibrocyte measurement and lung function test.|
48023659|NCT04530799|OTHER|Identification of biomarkers for IAPA via patient sampling|Blood, BAL, microbiome
48023660|NCT01070290|DRUG|ARQ 197|120 mg capsule administered twice daily
48023661|NCT01070290|DRUG|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
48023662|NCT03357042|OTHER|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
48023663|NCT03357042|OTHER|Standard of care|Normal concussion treatment; physical and cognitive rest
48717541|NCT01473095|DRUG|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
48023664|NCT03751904|DEVICE|AcoustiCare|Electronic stethoscope
48023665|NCT01071395|DRUG|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
48181191|NCT03235206|OTHER|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
48181192|NCT02906020|DRUG|venglustat GZ/SAR402671|Pharmaceutical form: capsule Route of administration: oral
48181193|NCT02906020|DRUG|Placebo|Pharmaceutical form: capsule Route of administration: oral
48717542|NCT02689076|OTHER|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
48717543|NCT02689076|OTHER|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
48717544|NCT02124954|DRUG|TA-8995|
48717545|NCT02124954|DRUG|Midazolam|
48717546|NCT02124954|DRUG|Digoxin|
48717547|NCT00459537|DRUG|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
48717548|NCT00459537|DRUG|amorolfine nail lacquer|5 % amorolfine nail lacquer
48717549|NCT06252818|DEVICE|ReHub|ReHub provides support to rehabilitation professionals by offering information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation.
48717550|NCT03560466|DRUG|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
48023666|NCT01071395|DRUG|Placebo|Sugar pill given 3 times daily
48023667|NCT05729074|DRUG|IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
48023668|NCT05729074|DRUG|IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
48023669|NCT05729074|DRUG|IN-A002 Ointment 1% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
48023670|NCT05729074|DRUG|IN-A002 Ointment 3% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
48023671|NCT05729074|DRUG|IN-A002 Ointment 5% or IN-A002 Placebo Ointment|Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
48023672|NCT05729074|DRUG|IN-A002 Ointment 1%|Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
48023673|NCT05729074|DRUG|IN-A002 Ointment 3%|Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
48023674|NCT05729074|DRUG|Elidel Cream 1% (pimecrolimus)|Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
48519260|NCT00767403|BEHAVIORAL|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
48717551|NCT03560466|DRUG|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
48717552|NCT03560466|DRUG|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
48717553|NCT04862728|OTHER|- Strong kids screening tool - Stamp screening tool - PYMS screening tool|Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP) evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk (low, medium or high).Screening Tool for Impaired Nutritional Status and Growth (STRONG kids). It consists of four items: subjective clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. Patients classified at high nutritional risk have a longer hospitalization and a negative standard deviation score (SDS) for weight-for-height (WFH), which indicated a state of acute malnutrition.The Pediatric Yorkhill Malnutrition Score (PYMS) is adopted among medical and surgical patients between 1 and 16 years of age. The PYMS assesses four items: BMI, history of recent weight loss,
48717554|NCT05036200|DEVICE|pulsed dye laser|four pulsed dye laser sessions were administered every eight weeks in the 21 patients
48717555|NCT01451190|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
48717556|NCT05919641|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging.
48717557|NCT02899923|OTHER|Data collection|
48717558|NCT03785587|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
48717559|NCT06298981|DEVICE|noninvasive and investigational NuraLogix AMC-SDK|The NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.
48717560|NCT00506597|DRUG|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
48023675|NCT02048956|OTHER|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
48717561|NCT04240093|BEHAVIORAL|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
48717562|NCT04240093|BEHAVIORAL|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
48717563|NCT04240093|OTHER|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
48717564|NCT03829345|DRUG|Olaparib|Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
48717565|NCT00002460|DRUG|goserelin acetate|
48519261|NCT04586270|DRUG|TAS0612|oral tablets
48717566|NCT00002460|DRUG|tamoxifen citrate|
48717567|NCT00002460|PROCEDURE|ablative endocrine surgery|
48023676|NCT02048956|OTHER|Control group|Standard exercises of hydrotherapy
48023677|NCT05176327|DEVICE|Exoskeleton training with Ekso NR|Walking exercise with Ekso NR
48023678|NCT01523691|BEHAVIORAL|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
48023679|NCT01523691|BEHAVIORAL|Control sleep|Regular amounts of sleep across study protocol
48023680|NCT02528201|DRUG|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
48023681|NCT02528201|DRUG|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
48023682|NCT02528201|DRUG|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
48717568|NCT00002460|PROCEDURE|oophorectomy|
48717569|NCT01433302|PROCEDURE|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
48717570|NCT04534413|DEVICE|composite optical fiberscope (COF)|Fiber Technology
48717571|NCT06390787|DRUG|Metoclopramide and Vitamin B6|We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
48717572|NCT06390787|DRUG|Vitamin B6|We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
48023683|NCT03937167|OTHER|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
48181194|NCT05554783|DIAGNOSTIC_TEST|Trendelenburg position|Positioning the patient with head 15 degrees down
48023684|NCT01159418|DRUG|Panobinostat (LBH589), Carboplatin and Paclitaxel|"1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
48023685|NCT06479174|BEHAVIORAL|CHAMPS-TR|Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).
48023686|NCT05486949|DRUG|AZD4205 and carbamazepine|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
48717573|NCT06390787|DRUG|Ondansetron|We gave only Zofran as a treatment for managing nausea and vomiting.
48717574|NCT06390787|DRUG|Metoclopramide|We gave only Metoclopramide as a treatment for managing nausea and vomiting.
48717575|NCT03580824|BIOLOGICAL|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
48717576|NCT05960084|OTHER|screening|screening for colistin resistant E. coli
48717577|NCT04866355|OTHER|Lumbar spine manipulation|Lumbar spine manipulation
48717578|NCT04866355|DRUG|Hyoscine and Ibuprofen|hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
48717579|NCT02583321|DEVICE|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
48717580|NCT02583321|DEVICE|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
48717581|NCT01295684|OTHER|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
48023687|NCT05486949|DRUG|AZD4205 and itraconazole|All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
48023688|NCT02677545|DRUG|Ticagrelor|
48519262|NCT05180448|BEHAVIORAL|Coach Share On|If an index participant is randomized to have Coach Share ON, the coach will have continuous access to objective, real-time, detailed device data, and address data directly in all individual interactions with index participants (groups, individual weigh-ins, phone calls, texts), conveying that they are closely monitoring progress.
48717582|NCT01295684|OTHER|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
48717583|NCT03503058|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
48023689|NCT02677545|DRUG|Clopidogrel|
48023690|NCT02677545|DRUG|Aspirin|
48023691|NCT05457335|PROCEDURE|undergoing PGT|Preimplantation genetic testing for aneuploidy
48023692|NCT02308202|DRUG|doxazosin|
48023693|NCT02308202|DRUG|Perindopril|
48023694|NCT02308202|DRUG|Placebo|
48023695|NCT04790149|OTHER|Conventional Rehabilitation|Motor Imagery Training combined with Active functional exercises
48023696|NCT04790149|OTHER|NEUROM + tDCS|NEUROM combined to tDCS
48023697|NCT04790149|OTHER|NEUROM|protocol to induce motor recovery
48181195|NCT00085397|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
48181196|NCT00085397|BIOLOGICAL|gp100 antigen|Given IV
48717584|NCT03503058|BIOLOGICAL|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
48717585|NCT03503058|OTHER|Normal Saline|0.9% Sodium chloride
48717586|NCT03503058|DRUG|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
48023698|NCT01475526|OTHER|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
48023699|NCT06532045|DEVICE|Transcutaneous electrical nerve stimulation|TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.
48382371|NCT00923299|DRUG|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~* Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~* Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
48382372|NCT05755399|DEVICE|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
48519263|NCT05180448|BEHAVIORAL|Group Share On|If Group Share is ON, participants in a given LM group will view and respond to aspects of each other's self-monitoring device data in their small-group text messages. Each small group participant's data will be highlighted one day of the month, and content from the Group Share Off message library also will be sent.
48717587|NCT01762254|PROCEDURE|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
48717588|NCT01762254|PROCEDURE|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
48717589|NCT03605290|DIAGNOSTIC_TEST|REHAGAIT ANYLIZER|Gait analysis instrumentation
48717590|NCT00724412|OTHER|Systane|Dry Eye relief eye drops
48717591|NCT00724412|OTHER|Optive|Dry Eye relief eye drops
48717592|NCT04023123|OTHER|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
48717593|NCT02636946|DRUG|Bimatoprost SR|Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
48717594|NCT02636946|DRUG|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
48717595|NCT02636946|PROCEDURE|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
48023700|NCT01851005|DRUG|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
48717596|NCT02636946|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
48717597|NCT05902481|OTHER|Education|education about breastfeeding with mixed reality technology.
48717598|NCT02374658|BEHAVIORAL|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
48717599|NCT00110487|DRUG|ERB-041|
48717600|NCT05644795|DIETARY_SUPPLEMENT|Wheat/milk free diet (W/MFD) group|Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
48717601|NCT05644795|DIETARY_SUPPLEMENT|Rice/turkey free diet (R/TFD) group|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
48023701|NCT01851005|DRUG|Sevoflurane|Control Vol% to maintain BIS 40\~45
48023702|NCT01851005|DRUG|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
48023703|NCT01851005|DRUG|Normal saline|Use as placebo
48023704|NCT01851005|DRUG|Rocuronium|0.8 mg/kg for induction
48181197|NCT00085397|BIOLOGICAL|therapeutic autologous dendritic cells|Given IV
48382373|NCT06289010|BEHAVIORAL|Family-Focused Treatment for Childhood-Depression (FFT-CD)|"This intervention includes 12 one-hour, in-person sessions. FFT-CD was designed to help families gain skills to combat depression and create ways of interacting that protect the child from the negative sequelae of stress. Within a broad psychoeducational framework, interpersonal factors impacting youth depression and the interplay of mood and interpersonal interactions are emphasized. Participants are taught to identify Upward Spirals - positive interactions fueling positive moods leading further upward - and Downward Spirals - negative interactions fueling negative moods leading further downward. The treatment rationale is to stop downward spirals and to start upward spirals; this idea provides a foundation for skills building to help the child and family better navigate stress. Handouts, role-playing, behavioral rehearsal, and homework assignments are all used to help shape behaviors."
48382374|NCT06650306|OTHER|This study does not involve any interventions|This study does not involve any interventions
48382375|NCT04566666|DRUG|Placebo|Placebo of SCD-044 product
48382376|NCT04566666|DRUG|SCD-044_Dose 1|SCD-044 tablets in Dose 1.
48382377|NCT04566666|DRUG|SCD-044_Dose 2|SCD-044 tablets in Dose 2
48382378|NCT04566666|DRUG|SCD-044_Dose 3|SCD-044 in Dose 3
48717602|NCT05019989|BEHAVIORAL|Intervention group on diet and physical activity|"The intervention wanted to increase physical activity, controlling weight, promoting healthy diet.~1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week~2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables~3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)"
48717603|NCT05019989|BEHAVIORAL|Control group: only public recommendation an lifestyle|"1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid.~2. Dissemination of the information on the study by media~3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang"
48717604|NCT04041427|DRUG|Albendazole Pill|Albendazole 400mg po
48717605|NCT04041427|OTHER|High fat content diet|High fat content diet
48717606|NCT04041427|OTHER|Moderate fat content die|Moderate fat content die
48717607|NCT00581451|DRUG|bifeprunox|oral tablet once daily
48717608|NCT05007977|DRUG|ZT-01 low dose|Single subcutaneous (SC) injection of ZT-01 3 mg during hypoglycemic clamp
48717609|NCT05007977|DRUG|ZT-01 high dose|Single SC injection of ZT-01 20 mg during hypoglycemic clamp
48717610|NCT05007977|DRUG|Placebo|Single SC injection of placebo during hypoglycemic clamp
48717611|NCT01143896|OTHER|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
48717612|NCT01333670|DEVICE|Prontosan wound irrigation solution|"* cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution"
48181198|NCT01874509|BEHAVIORAL|Check Your Drinking|
48382379|NCT02495636|DRUG|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
48382380|NCT02495636|DRUG|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
48382381|NCT06651164|DIAGNOSTIC_TEST|psychosocial risk screening|"* combined tablet-based screening questionnaire for psychosomatic screening and social service screening~* in case of positive psychosomatic or social service screening subsequent psychosomatic and / or social service consultation"
48382382|NCT02355314|OTHER|Doppler-based renal|Doppler-based renal : day 0 and day 3
48382383|NCT02355314|BIOLOGICAL|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
48382384|NCT05424939|PROCEDURE|Colectomy|Colon resection
48382385|NCT05424939|PROCEDURE|Stoma procedures|Any type of colostomy or ileostomy with or without bowel resection
48382386|NCT05424939|PROCEDURE|By-pass/laparotomy/laparoscopy/biopsy|Any palliative surgery without bowel resection
48382387|NCT00679094|DRUG|Bowman-Birk inhibitor concentrate|Given orally
48382388|NCT00679094|OTHER|placebo|Given orally
48023705|NCT01639001|DRUG|Crizotinib|250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
48023706|NCT01639001|DRUG|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
48181199|NCT01874509|BEHAVIORAL|Alcohol Help Centre|
48181200|NCT00360477|PROCEDURE|Floseal|Bioglue that seals the kidney
48181201|NCT00360477|PROCEDURE|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
48181202|NCT00360477|PROCEDURE|Fascial Stitch|Stitch that closes the kidney
48519264|NCT05180448|BEHAVIORAL|Friend/Family Share On|Index participants who are randomized to have Friend/Family Share ON will give their friend or family member access to their self-monitoring data. Text messages sent by the program bot, which includes the index participant and friend/family member, will use a similar format as described in Group Share ON. The friend or family member will be trained to respond to data in ways that enhance the participant's motivation and self-regulation.
48717613|NCT01333670|DRUG|Isotonic solution (saline or lactated ringer)|"* cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution"
48717614|NCT05040906|DRUG|H02+CHOP|"Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
48717615|NCT05040906|DRUG|Rituxan +CHOP|"Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
48717616|NCT02805231|OTHER|Vitamin D receptor polymorphic analysis|
48717617|NCT05269225|OTHER|Organic diet|Organically produced foods.
48717618|NCT05269225|OTHER|Conventional diet|Conventionally produced foods.
48717619|NCT02071186|DEVICE|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
48717620|NCT02071186|OTHER|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
48181203|NCT01855347|DEVICE|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
48181204|NCT05656794|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
48181205|NCT06164808|DEVICE|HeartWatch|The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.
48181206|NCT01969045|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
48181207|NCT01969045|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
48181208|NCT03247738|DRUG|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
48181209|NCT03247738|OTHER|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
48181210|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
48181211|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
48181212|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
48181213|NCT02573272|DRUG|eslicarbacepine|
48181214|NCT02840864|DEVICE|Sonography assisted breast surgery|
48181215|NCT06152679|OTHER|None - qualitative interviews|Qualitative interviews with patients asking about their experience of day-case endourology.
48181216|NCT00624910|DRUG|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
48181217|NCT00624910|DRUG|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
48382389|NCT00679094|OTHER|pharmacological study|Correlative studies
48382390|NCT00679094|OTHER|laboratory biomarker analysis|Correlative studies
48717621|NCT02071186|OTHER|Standard of care|
48717622|NCT04214886|DRUG|Fludarabine|Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
48717623|NCT04214886|DRUG|Cyclophosphamide|Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
48717624|NCT04214886|BIOLOGICAL|CD19-CD34 CAR transduced T cells|CD19-CD34 CAR transduced T cells are the subject's own immune cells that target B cell markers on cancer cells.
48717625|NCT01304810|BIOLOGICAL|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
48717626|NCT01304810|BIOLOGICAL|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
48717627|NCT05001841|PROCEDURE|Lung Transplantation|Double lung transplant
48717628|NCT04806360|PROCEDURE|ACRF surgery|A new surgical procedure that previously proposed by our team.
48717629|NCT04806360|PROCEDURE|conventional anterior surgery|Anterior cervical discectomy and fusion surgery or anterior cervical corpectomy and fusion surgery.
48717630|NCT04806360|PROCEDURE|conventional posterior surgery|Laminectomy and fusion surgery or laminoplasty surgery.
48717631|NCT02212158|BEHAVIORAL|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
48717632|NCT01271257|DRUG|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
48181218|NCT04730674|DRUG|tetracycline mixed with xylocaine|10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
48181219|NCT03865953|DRUG|LAT8881|LAT8881 oral capsule
48181220|NCT03865953|DRUG|Placebo|Placebo oral capsule
48181221|NCT03257098|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
48181222|NCT04834492|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty in Crowe type 4 developmental dysplasia of the hip.
48181223|NCT02520700|DEVICE|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
48181224|NCT02484989|OTHER|Surviellance card|
48181225|NCT01947712|DIETARY_SUPPLEMENT|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
48181226|NCT01947712|DIETARY_SUPPLEMENT|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
48181227|NCT01856517|DRUG|Clonidine|
48382391|NCT03026894|RADIATION|Panoramic Radiograph|Measurement of bone resorption
48181228|NCT01856517|DRUG|Placebo|
48181229|NCT04250779|DEVICE|CapMedic smart inhaler device|The CapMedic device provides active coaching to promote correct and regular use of MDI.
48181230|NCT04250779|BEHAVIORAL|Video-based guidance|Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
48181231|NCT02626247|DIETARY_SUPPLEMENT|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
48181232|NCT02626247|OTHER|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
48181233|NCT00167232|DRUG|Naltrexone|
48181234|NCT01883284|OTHER|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
48181235|NCT06022445|OTHER|CARPET prognostic model|For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
48382392|NCT03026894|DEVICE|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
48382393|NCT04207359|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
48717633|NCT02303899|DRUG|Gemcitabine|infusion drug
48717634|NCT02303899|DRUG|Imatinib mesylate|oral drug
48717635|NCT06296641|BEHAVIORAL|Needs navigation intervention|The investigator anticipates that this will include a baseline financial, education and vocational assessment, likely using a virtual platform. Participants who screen positive will be connected to community resources and for consultation. There will be a 1-month, 3-month and 6-month check-in to address any financial concerns through additional counseling/navigation.
48717636|NCT04221191|DRUG|Dimethyl Fumarate|DMF as prescribed as standard of care.
48717637|NCT04221191|OTHER|PSP|PSPs is to support patient care.
48717638|NCT02783378|DRUG|Gaviscon Syrup|
48717639|NCT03449433|DRUG|LY900014|Administered SC
48717640|NCT03449433|DRUG|Insulin Lispro|Administered SC
48717641|NCT03449433|DRUG|Insulin Aspart|Administered SC
48717642|NCT03449433|DRUG|Insulin Aspart|Administered SC
48717643|NCT02359214|DIETARY_SUPPLEMENT|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
48519265|NCT05180448|BEHAVIORAL|Coach Share Off|Among index participants who are randomized to have Coach Share OFF, the coach will have no access to their device data. Index participants will be explicitly told their coach does not have data access. During groups and phone calls, the participant will self-report progress, and goal setting will be based on that self-report. Text messages from the coach will be personalized in the OFF condition, as they are when coach data sharing is ON, though these messages will not be informed by device data. Instead, text messages will provide a reminder of key goals and strategies discussed in the previous phone call and provide encouragement for participant efforts.
48717644|NCT02359214|OTHER|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
48717645|NCT04988997|DRUG|Vurolenatide 50mg/PBO|Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks
48717646|NCT04988997|DRUG|Vurolenatide 100mg/PBO|Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks
48717647|NCT04988997|DRUG|Vurolenatide 50/50 mg|Vurolenatide - 50 mg weekly SC administration
48717648|NCT04988997|DRUG|Placebo|PBO - weekly SC administration
48717649|NCT04046172|PROCEDURE|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
48717650|NCT04046172|PROCEDURE|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
48717651|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
48023707|NCT01639001|DRUG|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
48023708|NCT03231371|DRUG|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
48023709|NCT06573203|DEVICE|Non-contact heart rate and respiratory rate monitoring system|Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.
48023710|NCT06573203|DEVICE|Mindray ECG monitor|Heart rate and respiratory rate of each enrolled child were monitored after admission.
48717652|NCT02968914|BIOLOGICAL|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
48717653|NCT01113034|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
48717654|NCT01113034|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
48717655|NCT02538133|BIOLOGICAL|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
48717656|NCT00298493|PROCEDURE|Sedation management strategy|
48717657|NCT04399954|DIETARY_SUPPLEMENT|Ketoflo|Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
48717658|NCT03374202|GENETIC|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
48717659|NCT00514228|DRUG|sunitinib malate|"* Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule"
48717660|NCT02907853|BEHAVIORAL|Contingency Management|as described above
48717661|NCT01176955|BEHAVIORAL|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
48717662|NCT01176955|DRUG|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
48181236|NCT01893047|BEHAVIORAL|live music|live harp music
48181237|NCT01893047|BEHAVIORAL|recorded music|recorded harp music
48717663|NCT03364972|DEVICE|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
48717664|NCT05231447|OTHER|Environmental survey|"Exposure to environmental factors, drugs or individual toxicity during the periconceptional period and at the beginning of the pregnancy will be investigated by means of a questionnaire administered to the parents. This questionnaire, drawn up by the Aquitaine Reproduction Enfance Maternité et Impact Santé-environnement (ARTEMIS) centre and completed by both members of the couple, will constitute an initial assessment that will make it possible to collect environmental exposures for the parents of cases identified by the register."
48717665|NCT03059771|BEHAVIORAL|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
48717666|NCT03059771|BEHAVIORAL|Control|The control group will only engage in a goal-setting session.
48717667|NCT03761394|DEVICE|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
48717668|NCT03761394|DEVICE|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
48717669|NCT03761394|DEVICE|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
48717670|NCT03474081|DRUG|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
48717671|NCT03474081|DRUG|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
48382394|NCT02772341|DEVICE|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
48717672|NCT03474081|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
48717673|NCT03474081|DRUG|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
48717674|NCT03474081|DRUG|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
48717675|NCT03474081|DEVICE|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
48717676|NCT03474081|DEVICE|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
48717677|NCT03474081|DEVICE|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
48717678|NCT05759468|DRUG|Investigational Product - MIB 626|The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
48717679|NCT05759468|DRUG|Placebo|Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
48717680|NCT03559699|DRUG|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
48717681|NCT00739466|DRUG|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
48717682|NCT00739466|DRUG|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
48717683|NCT00739466|DRUG|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
48717684|NCT01350115|DRUG|LDE225|supplied as 100 mg capsules
48023711|NCT06573203|DEVICE|aEEG|Each enrolled child underwent a 6-hour sleep-wake cycle, quiet sleep, and active sleep monitoring after admission.
48717685|NCT01350115|DRUG|Placebo|supplied in capsules
48717686|NCT02082106|OTHER|Alpine skiing|
48717687|NCT02082106|OTHER|cross country skiing|
48717688|NCT02082106|OTHER|Indoor training (cycling)|
48717689|NCT04384107|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.
48717690|NCT04384107|BIOLOGICAL|PCV13|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
48717691|NCT05928832|OTHER|Follow-up by a case-manager and access to the internet platform|Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
48023712|NCT06573203|OTHER|Neonatal Sleep-Wake Assessment Tool (NSWAT) included four dimensions: eye movement, respiratory rate, facial expression and muscle activity.|The study nurses observed and scored the children's sleep-wake status 10 minutes after two meals during the mattress test period, each time for 5 minutes.
48023713|NCT05085457|DIAGNOSTIC_TEST|ExPreS Protocol|Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
48023714|NCT02677805|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
48023715|NCT02677805|DRUG|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
48023716|NCT02677805|DRUG|Botulinum Toxin A - Open Label|Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
48023717|NCT02143622|BIOLOGICAL|LJM716|antibody
48023718|NCT02143622|BIOLOGICAL|cetuximab|antibody
48181238|NCT06171035|OTHER|3D-printed high-fidelity craniofacial manikin model education|Slide-based presention plus 3D printed model
48181239|NCT06171035|OTHER|Traditional model education|Slide-based presention plus traditional model
48382395|NCT02772341|OTHER|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
48382396|NCT06551506|BIOLOGICAL|Abrysvo|A maternal RSV vaccine based on the prefusion F protein administered during pregnancy
48382397|NCT06551506|BIOLOGICAL|Beyfortus|A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants
48382398|NCT03456401|DRUG|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
48382399|NCT01995604|OTHER|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
48382400|NCT01995604|OTHER|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
48519266|NCT05180448|BEHAVIORAL|Group Share Off|Among index participants randomized to have Group Share OFF, supportive accountability will not be the target of participant interactions and no data will be shared with LM program peers. Instead, once weekly prompts for small group text exchanges will encourage index participants to provide social support (primarily of the informational type) to each other. Index participants will be explicitly told that they should not include information on goal progress such as weight change or minutes of PA.
48519267|NCT05180448|BEHAVIORAL|Friend/Family Share Off|If an index participant is randomized to Friend/Family Share OFF, the text messages from the bot will prompt the participant and friend/family member to communicate about the LM program; those messages will be standardized, except for names, and will not be tailored to index participant progress. Index participants will be instructed to refrain from sharing any device data with friends or family members.
48717692|NCT03244319|DRUG|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).
48717693|NCT03244319|DRUG|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
48023719|NCT05854290|BEHAVIORAL|CRT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
48023720|NCT05854290|BEHAVIORAL|CBT|Participants will complete an 8-week intervention, 2 sessions per week. Co-INTEGRATE sessions take 30-50 minutes to complete. Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking.
48519268|NCT05180448|BEHAVIORAL|Behavioral Weight Loss Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
48519269|NCT04943133|DEVICE|Blood pressure measurement and collection of the oscillometric curve for later SFATI analysis|Brachial systolic arterial blood pressure will be systematically taken with acquisition of the oscillometric curve for analysis and measurement with the SFATI system and simultaneous electronic recording of the Korotkoff sound (auscultatory method) and a search for SFATI arterial stiffness markers for all patients. Brachial systolic arterial blood pressure will be measured with the help of a cuff equipped with a Biopac SS30L electronic stethoscope and a MA-300 phonocardiographic microphone, placed side-by-side immediately downstream from the brachial occlusion cuff. The various signals (pneumatic cuff, oscillometric signal and Korotkoff sounds) will be digitalized by an MP35 system.
48717694|NCT03244319|DRUG|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
48717695|NCT01689545|BEHAVIORAL|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
48717696|NCT01689545|BEHAVIORAL|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
48023721|NCT05854290|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications for the persons with MCI, such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
48023722|NCT05854290|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15-minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval).~Weekly on the day of the last therapy session, before or after the session, all patients, regardless of the group assigned to, will be asked to complete an electronic brief questionnaire to provide information, on sleep, recreational habits, alcohol intake, exercise, and smoking."
48023723|NCT01032694|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
48717697|NCT01689545|BEHAVIORAL|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
48023724|NCT01032694|DRUG|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
48023725|NCT01224041|DRUG|Tacrolimus|oral
48181240|NCT03518242|DRUG|Cyclophosphamide|Given PO
48181241|NCT03518242|DRUG|Methotrexate|Given PO
48181242|NCT03518242|DRUG|Capecitabine|Given PO
48181243|NCT03518242|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
48023726|NCT05431855|BEHAVIORAL|eWrapper-Engagement strategies to facilitate alcohol biosensor wearing|We will conduct a 30-day micro-randomized trial (MRT)--a clinical trial design for developing and optimizing mHealth interventions to test which engagement strategy works better, for who, and under what condition. A subset of the participants will be micro-randomized in the morning and in the evening, to either a prompt delivering non-contingent small reward (reciprocity); or a prompt containing feedback on self-monitoring progress based on dynamic self-regulation theories (personalized feedback); or no prompt.
48181244|NCT01013688|PROCEDURE|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
48717698|NCT01689545|BEHAVIORAL|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
48717699|NCT01485380|DRUG|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
48717700|NCT02132273|OTHER|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
48181245|NCT05731505|BEHAVIORAL|theory-based education-consulting|Parents in the study groups were provided with training and support in line with their needs in the educational issues specified in the Family Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, Needs Determination Form, Relaxed Behavior Checklist (KDKL), Quality of Life for Children Parent Form (PIDQ) and Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before the education, 1 month and 3 months after the education.
48519270|NCT04943133|DEVICE|Blood pressure measurement with the usual equipment used in the department|Brachial systolic blood pressure will be taken via the conventional oscillometric method, only for hospitalized women. Blood pressure will be measured on the same arm with the help of a conventional Dinamap-type automat (GE), with at least 2 minutes between the end of the first measurement and the start of the second inflation.
48023727|NCT05036148|OTHER|Data analysis|MH registry data will be screened for MH positive diagnosis
48023728|NCT02886845|GENETIC|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
48023729|NCT01702233|DRUG|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
48023730|NCT01702233|DRUG|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
48023731|NCT01702233|DRUG|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
48023732|NCT02799433|BEHAVIORAL|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
48023733|NCT02799433|BEHAVIORAL|Usual services|Control condition
48181246|NCT02142634|DRUG|Budesonide granules 9 mg|per day
48717701|NCT04352257|RADIATION|pelvic Ultrasound|pelvic and transrectal ultrasound
48717702|NCT06284616|BEHAVIORAL|JASP-1|patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
48717703|NCT01390207|OTHER|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
48717704|NCT01672866|BIOLOGICAL|Placebo|Placebo to match SIM via subcutaneous injection every week
48717705|NCT01672866|BIOLOGICAL|SIM|Subcutaneous injection every week
48181247|NCT02142634|DRUG|Placebo granules|per day
48717706|NCT04268433|OTHER|N/A - Non-interventional study|"Stages:~1. Patient information and written informed consent (3 Copies. To be carried out \>24 hours after receiving the patient information sheet)~2. Physiological recording set up (ECG, BP, sensor and respiratory band)~3. Control period - no music played~4. Series of pieces of music without tempo control~5. Repeat series of pieces of music with tempo control~6. Participant leaves the study"
48717707|NCT05835921|DEVICE|Virtual Reality|Both groups will receive a Virtual Reality Park experience, which is an empty park with no avatars. Only the experimental group will have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
48717708|NCT00391001|DRUG|Taurine|double-blind, placebo-controlled, adjunctive medication
48717709|NCT01399892|DIETARY_SUPPLEMENT|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
48717710|NCT00543296|DRUG|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
48717711|NCT05336825|DEVICE|CO2 laser|Mona Lisa CO2 laser
48717712|NCT05336825|DRUG|Lidocaine patch 5%|lidocaine
48717713|NCT04581343|DRUG|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
48717714|NCT05358431|OTHER|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
48717715|NCT00164398|BEHAVIORAL|HIP: HIV Intervention for Providers|
48717716|NCT02102126|PROCEDURE|Renal denervation|
48519271|NCT04943133|DEVICE|systematic measurement of pulse wave velocity (aortic and brachial)|"Carotid to femoral and carotid to radial pulse wave velocity (Complior) will be systematically determined for hospitalized women and offered to all women seen for consultation.~Pulse wave velocity will be measured with the help of a Complior tonometric system (Alam Medical, Vincennes, France), with which the aorta and the arterial axes of the upper limb used to measure blood pressure can also be measured."
48717717|NCT02511600|OTHER|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
48717718|NCT02511600|OTHER|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
48717719|NCT02511600|BEHAVIORAL|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
48717720|NCT03107923|DIAGNOSTIC_TEST|Dobutamine stress test|Test of myocardial reserve
48717721|NCT02761577|DRUG|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
48717722|NCT02761577|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
48717723|NCT02981524|DRUG|CY|CY is administered intravenously at 200 mg/m2
48717724|NCT02981524|BIOLOGICAL|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
48519272|NCT05450419|DIETARY_SUPPLEMENT|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 \& week 4.
48717725|NCT02981524|DRUG|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
48717726|NCT03318224|OTHER|none (observational study)|only assessments via questionnaires, no interventions
48717727|NCT01740544|OTHER|Cathodal tDCS|Cathodal tDCS applied over the right PPC
48519273|NCT05450419|DIETARY_SUPPLEMENT|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 \& week 4.
48717728|NCT01740544|OTHER|Sham tDCS|Sham tDCS applied over the right PPC
48717729|NCT00003252|DRUG|amifostine trihydrate|
48717730|NCT06257836|OTHER|MPFL-reconstruction|Children with patella dislocations are operated from 2016-2022 with a quadriceps knee cap stabilization technique.
48717731|NCT05093920|DRUG|Doxorubicin-Eluting Beads|"* The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
48717732|NCT00392808|BIOLOGICAL|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
48717733|NCT06103227|DRUG|Prednisone 5Mg|Prednisone administered for three weeks. If pregnant women weighs less than 90 kg , she will receive prednisone on altering days instead of every morning for pregnant women weighing more than 90 kg.
48717734|NCT03738319|GENETIC|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
48717735|NCT04139278|OTHER|Observational|Observational retrospective study
48023734|NCT04440111|OTHER|One year training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice."
48023735|NCT04440111|OTHER|Two years training|"At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process."
48023736|NCT03513029|DEVICE|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
48023737|NCT01420406|OTHER|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
48023738|NCT01420406|OTHER|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
48023739|NCT01420406|OTHER|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
48023740|NCT01420406|OTHER|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
48181248|NCT05385237|DIAGNOSTIC_TEST|4D-MRI|Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.
48181249|NCT01694888|OTHER|lecture|Teaching documentation skill using lecture method
48181250|NCT06311747|BEHAVIORAL|Oculo-motor exercises|Oculo-motor exercises will be applied as an intervention. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
48181251|NCT03866096|OTHER|Experimental|The player will perform exercises of balance, stability, and strengthening of the abdomen, back and gluteus. All these exercises will be carried out in first instance on flat surfaces and later on unstable surfaces to increase the difficulty of it. The training will be done in different levels of difficulty, once the participant managed to master the initial level, advance to the next level to complete the three levels of difficulty during the 6 weeks of training. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of the intervention of the experimental group will last 20 minutes
48382401|NCT00462241|PROCEDURE|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
48519274|NCT03405025|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.
48519275|NCT03405025|DEVICE|ultrasound|ultrasound
48023741|NCT04823845|DRUG|Topical Adapalene Gel 0.1%|applying Adapalene Gel 0.1% to plantar warts topically
48023742|NCT05282004|DRUG|SOK583A1|SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
48023743|NCT05319314|DRUG|GCC19CART|Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
48519276|NCT03541928|DRUG|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
48717736|NCT02066415|BIOLOGICAL|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
48717737|NCT02066415|DRUG|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
48717738|NCT00741702|OTHER|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP \>=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP\>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP\>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP\>=13/80 mm Hg, increase verapamil to 240 mg/d
48717739|NCT04913701|OTHER|Observation group 1|Subjects will be followed with 3 swabs and serological test
48023744|NCT05668494|OTHER|immediate loading of implants|This is a randomized control clinical trial including 24 implants, immediately loaded with definitive abutment protocol and 24 implants immediately loaded with with temporary abutment protocol
48023745|NCT04823338|BEHAVIORAL|Conectar Jugando Online Program|Online play sessions with modern board and card games guided by the study researchers
48023746|NCT03550963|OTHER|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
48023747|NCT03550963|OTHER|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
48023748|NCT00131794|BIOLOGICAL|BCG|
48717740|NCT05308524|DIAGNOSTIC_TEST|ICU scoring system in covid 19|The intensive care unit (ICU) at Assiut University Hospital, which is supervised by the staff members of the Chest Diseases Department and designated to deal with critically ill Covid 19 patients.
48717741|NCT01313819|DRUG|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
48717742|NCT04413903|PROCEDURE|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
48717743|NCT00449449|DRUG|Pertubation with Lidocain Solution|
48717744|NCT02315508|DRUG|AUT00063|800 mg orally, once a day, for 4 weeks
48717745|NCT02315508|DRUG|Placebo|orally, once a day, for 4 weeks
48717746|NCT00106600|DRUG|Pixantrone IV infusion|
48717747|NCT03096873|BEHAVIORAL|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
48717748|NCT02492074|DRUG|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
48717749|NCT02492074|DRUG|Cannabidiol|oral administration of cannabidiol
48717750|NCT02492074|DRUG|Placebo|oral administration of placebo
48717751|NCT03315169|OTHER|External dressing|Application of external dressing whilst perianal abscess cavity heals.
48717752|NCT03315169|OTHER|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
48717753|NCT01669408|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
48717754|NCT04593459|DIETARY_SUPPLEMENT|Probiotic|See Arm description
48717755|NCT04593459|DRUG|Metformin Hydrochloride|See Arm description
48717756|NCT04593459|DIETARY_SUPPLEMENT|Probiotic Placebo|See Arm description
48717757|NCT05782192|DRUG|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
48717758|NCT05782192|DRUG|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
48717759|NCT05782192|DRUG|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
48717760|NCT01349062|DRUG|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
48717761|NCT01993316|DEVICE|Mitsar 201 neurofeedback|
48717762|NCT04386499|DIETARY_SUPPLEMENT|Resveratrol|mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6
48519277|NCT03541928|DRUG|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
48717763|NCT04386499|DIETARY_SUPPLEMENT|Folic acid|400 mcg of folic acid
48717764|NCT04132635|DEVICE|artificial dermis|artificial dermis will be used after fully debridement of the wound
48717765|NCT04132635|OTHER|growth factor|growth factor
48717766|NCT02154685|BEHAVIORAL|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
48717767|NCT02154685|BEHAVIORAL|Non-Retrieval Extinction|Neutral cue exposure.
48717768|NCT03722654|BEHAVIORAL|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
48717769|NCT04672525|DRUG|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
48717770|NCT04672525|DRUG|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
48717771|NCT05117021|DRUG|Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg|Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
48717772|NCT04858685|OTHER|early mobilization|early mobilization was defined, on the basis of the ERAS protocol, as mobilization of a few steps or a few meters from the bed within the first 24 hours after surgery with another person's support/control and/or a walking aid.
48717773|NCT03129594|DIAGNOSTIC_TEST|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
48717774|NCT04911491|DEVICE|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
48717775|NCT04911491|DEVICE|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
48181252|NCT03866096|OTHER|Control|Neuromuscular training will be applied through balance and stability exercises on both flat and unstable surfaces. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of each session of the control group is 10 minutes.
48181253|NCT01416935|OTHER|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
48181254|NCT04311047|DIAGNOSTIC_TEST|USPIO-enhanced MRI|Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
48181255|NCT04679155|BEHAVIORAL|Eating Time Restriction|early vs late time of day restriction
48181256|NCT00353886|PROCEDURE|TONI-3|
48181257|NCT00353886|PROCEDURE|WRAT-3|
48181258|NCT00353886|PROCEDURE|Connor's Rating Scales PRS & TRS|
48717776|NCT01595581|DRUG|Testosterone|8 weeks of testosterone administration beginning 2 weeks before ACL surgery
48717777|NCT01595581|DRUG|Placebo|8 weeks of saline administration beginning 2 weeks before ACL surgery
48519278|NCT03541928|DRUG|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
48181259|NCT00353886|PROCEDURE|Peabody Picture Vocabulary Test|
48181260|NCT00353886|PROCEDURE|Children's Memory Scale|
48181261|NCT00353886|PROCEDURE|WISC-3|
48181262|NCT00353886|PROCEDURE|Behavioral Assessment System for Children PRS & TRS|
48181263|NCT05311722|DRUG|Dexmedetomidine|Inj dexmedetomidine, will be given in infusion over 10 mins and their effect on post spinal shivering will be assessed.
48181264|NCT05311722|DRUG|Ketamine|Ketamine
48519279|NCT03541928|DRUG|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
48519280|NCT03541928|RADIATION|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
48519281|NCT03541928|PROCEDURE|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
48181265|NCT05311722|DRUG|Tramadol|Tramadol
48181266|NCT04537871|PROCEDURE|Bioelectric Impedance Analysis|Undergo bioelectric impedance analysis
48519282|NCT04513392|PROCEDURE|Laser treatment|A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
48717778|NCT06105359|BEHAVIORAL|Dignity therapy|"Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session."
48717779|NCT06105359|OTHER|standardize care|Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
48717780|NCT01502150|OTHER|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
48717781|NCT01502150|OTHER|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
48181267|NCT04537871|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48181268|NCT04537871|PROCEDURE|Cardiopulmonary Exercise Testing|Undergo cardiopulmonary exercise test
48181269|NCT04537871|PROCEDURE|Echocardiography|Undergo echocardiogram
48181270|NCT04537871|PROCEDURE|Physical Performance Testing|Undergo physical function tests
48181271|NCT04537871|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
48181272|NCT04537871|OTHER|Questionnaire Administration|Ancillary studies
48181273|NCT04537871|PROCEDURE|Ultrasound|Undergo musculoskeletal ultrasound
48181274|NCT00178451|DRUG|Abciximab|
48181275|NCT04792398|DRUG|Incobotulinumtoxin A (BTX A) Xeomin®|Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)
48181276|NCT04563598|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
48181277|NCT04563598|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
48181278|NCT03874936|DRUG|Dexamethasone 24mg Solution for Injection|Administrated i.v.
48181279|NCT03874936|DRUG|Saline Solution for Injection|administrated i.v.
48181280|NCT00312585|PROCEDURE|Acupuncture|
48181281|NCT00312585|PROCEDURE|Sham comparator|
48181282|NCT01124071|BEHAVIORAL|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
48519283|NCT00606632|DRUG|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
48519284|NCT00606632|PROCEDURE|CT|contrast enhanced CT scan
48181283|NCT01124071|BEHAVIORAL|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
48181284|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on conventional coronary angiography|Revascularized coronary arteries are decided based on conventional coronary angiography (quantitative coronary angiography)
48181285|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.|Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.
48181286|NCT00254969|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
48181287|NCT04686292|DIAGNOSTIC_TEST|urine flow cytometry|Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
48181288|NCT05099289|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
48181289|NCT02182232|DRUG|BIBF 1120|
48181290|NCT02182232|DRUG|Paclitaxel|
48181291|NCT02182232|DRUG|Carboplatin|
48181292|NCT05834920|DEVICE|Transcranial pulse stimulation (TPS)|Participants will be treated with the TPS device NEUROLITH (Storz Medical AG). Treatments will be administered for up to 12 sessions within 4 weeks, each session consisting of 6000 TPS pulses of 0.2 mJ/mm².
48181293|NCT05834920|DEVICE|Neurofeedback|Participants will engage in a neurofeedback game designed to increase the ratio of theta/beta frequency bands in electroencephalography measurement. This intervention will be delivered for up to 12 sessions within 4 weeks.
48181294|NCT01022411|DIETARY_SUPPLEMENT|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
48181295|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
48181296|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
48519285|NCT01295320|PROCEDURE|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
48519286|NCT00836784|OTHER|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
48519287|NCT00836784|OTHER|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
48717782|NCT05714943|BEHAVIORAL|DigiKnowIt News: Teen|Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
48717783|NCT04700956|PROCEDURE|primary abdominal closure|The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
48717784|NCT04700956|DEVICE|abdominal closure with prophylactic mesh|After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
48181297|NCT00755417|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
48181298|NCT02962414|DRUG|everolimus|everolimus, 2mg dispersible tablets
48181299|NCT04456647|OTHER|Parenteral nutrition|Parenteral nutrition treatment in palliative care
48181300|NCT04374747|BEHAVIORAL|Dietary Counseling|The counseling approach will employ strategies shown to be successful in previous and ongoing dietary modification studies including supportive and motivational interviewing techniques. Each woman in the diet intervention group will be assigned a trained nutrition coach/counselor. Counselors will focus on helping participants identify and address barriers to achieving the goal of consuming at least 8 to 10 servings of nutrient dense fruits and vegetables each day (e.g., modifying recipes and food preparation). Participants will also receive weekly boxes of fruits and vegetables .
48181301|NCT02446613|OTHER|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
48181302|NCT01015677|DRUG|MK-6913|
48181303|NCT01015677|DRUG|17-β estradiol|
48181304|NCT01015677|DRUG|Placebo to MK-6913|
48181305|NCT01015677|DRUG|Placebo to 17-β estradiol|
48519288|NCT00625820|DRUG|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
48181306|NCT01015677|DRUG|MK-6913 25 mg|
48519289|NCT00625820|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
48519290|NCT00404287|DRUG|Fluvastatin|
48519291|NCT06112860|DEVICE|Over the counter hearing aid|An over the counter hearing aid is a device that provides amplification appropriate for individuals with mild to moderate hearing loss. Participants will receive the devices with typical directions and have one scheduled remote visit one week after receiving devices with an audiologist.
48717785|NCT06255067|DRUG|Minocycline hydrochloride with noisome carrier|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
48717786|NCT06255067|DRUG|Minocycline Hydrochloride only|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
48717787|NCT05615857|DEVICE|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
48717788|NCT03587753|OTHER|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
48717789|NCT02496169|DEVICE|eucaLimus|Percutaneous Coronary Intervention (PCI)
48717790|NCT05690750|OTHER|No intervention|No intervention as this is an observational study.
48717791|NCT00334282|DRUG|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
48717792|NCT00334282|DRUG|placebo|matching placebo (800 mg tablet) once daily
48717793|NCT02267304|DRUG|50 mL of sodium chloride (0,9%)|
48717794|NCT02267304|DRUG|Morphine 0,05mg/kg|
48717795|NCT02267304|DRUG|Naloxone 10mg|
48717796|NCT05792592|DIAGNOSTIC_TEST|IOS (Impulse Oscillometry)|Small Airways Disease Assessment
48717797|NCT06516263|PROCEDURE|Leukocyte and platelet rich fibrin|Formation of an Leukocyte and platelet rich fibrin clot and placement into the osteotomy site prior to implant placement
48717798|NCT06516263|PROCEDURE|Standard implant placement|Standard implant placement without Leukocyte and platelet rich fibrin
48717799|NCT05929339|DRUG|Oxytocin|Intravenous oxytocin
48717800|NCT02437409|DEVICE|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
48023749|NCT04712318|PROCEDURE|Relex Smile|Procedure/Surgery: Relex Smile The residual myopic refraction on Pseudophakic patients after 6 months using Relex-Smile surgery by VisuMax femtosecond laser. The residual refractive power was min -0.75D.The optical zone (lenticule diameter) and cap diameter were 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule was extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker(ViscotMedster).
48717801|NCT04346030|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
48717802|NCT04346030|DRUG|lidocaine hydrochloride|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
48717803|NCT04346030|DRUG|normal saline|ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
48717804|NCT02673567|DRUG|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
48023750|NCT04712318|PROCEDURE|Relex smile with fresh corneal lenticule implantation|"VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule.~The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision.~In pseudophakic patients with hyperopic astigmatism residual refraction, corneal topography-guided intrastromal fresh lenticular implantation should be performed according to the low K values."
48181307|NCT04358692|DEVICE|Aixplorer Mach30|To measure myocardial stiffness by ShearWave elastography on not beating heart
48717805|NCT02673567|DRUG|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
48717806|NCT02673567|DRUG|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
48717807|NCT02673567|DRUG|Placebo|Matching Placebo
48717808|NCT01636713|DRUG|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
48717809|NCT01636713|DRUG|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
48717810|NCT01636713|DRUG|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
48717811|NCT04527419|PROCEDURE|Systematically mediastinal lymph node dissection|Systematically mediastinal lymph node dissection will be performed.
48717812|NCT04527419|PROCEDURE|No mediastinal lymph node dissection|No mediastinal lymph node dissection will be performed.
48717813|NCT01038726|OTHER|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
48717814|NCT01038726|OTHER|Cognitive Training|Based on cognitive training program Brain Fitness®
48717815|NCT01038726|OTHER|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
48717816|NCT01038726|OTHER|Educational Sessions|DVD-based educational programs on history, art, and literature
48717817|NCT03984630|BEHAVIORAL|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
48717818|NCT04757948|PROCEDURE|Acupuncture|Acupuncture of acupoints P-6 and St-36
48717819|NCT04757948|DEVICE|TENS|TENS of acupoints P-6 and St-36
48717820|NCT04757948|DEVICE|Sham-TENS|Sham-TENS of acupoints P-6 and St-36
48717821|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.
48717822|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.
48717823|NCT02254785|DRUG|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
48717824|NCT02254785|DRUG|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
48717825|NCT02254785|DRUG|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
48717826|NCT03146780|PROCEDURE|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
48717827|NCT03146780|PROCEDURE|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
48717828|NCT03146780|PROCEDURE|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
48717829|NCT03146780|PROCEDURE|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
48717830|NCT04172961|DRUG|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
48717831|NCT04172961|DRUG|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
48717832|NCT02994368|OTHER|Observation|
48717833|NCT02728414|DIETARY_SUPPLEMENT|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
48717834|NCT02728414|DIETARY_SUPPLEMENT|placebo|the patients in this arm will receive placebo intervention
48717835|NCT00137189|PROCEDURE|Resource-oriented music therapy|
48717836|NCT00137189|PROCEDURE|Standard care|
48717837|NCT01863251|DRUG|Atomoxetine|
48717838|NCT02973191|DRUG|JCAR015|
48717839|NCT05579873|PROCEDURE|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
48717840|NCT01052961|DRUG|Oseltamivir|oseltamivir 150 mg bd for 5 days
48717841|NCT06450613|DEVICE|radiofrequency ablation|HCC Radiofrequency ablation
48717842|NCT06450613|OTHER|percutaneous ethanol injection|HCC percutaneous ethanol injection
48717843|NCT05718193|DIAGNOSTIC_TEST|DeFrame|The DeFrame system is applicated during colonoscopy. The DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, notifying the endoscopists of the presence of the lesion.
48717844|NCT05718193|DIAGNOSTIC_TEST|Classified DeFrame|The Classified DeFrame system is applicated during colonoscopy. The Classified DeFrame system superimposes a rectangular box on the polyp lesion area in the colonoscopy field of view, the color of the rectangle box will turn blue when the polyp is considered as an adenoma, notifying the endoscopists of the presence of the lesion.
48717845|NCT05718193|DIAGNOSTIC_TEST|conventional colonoscopy|conventional colonoscopy
48717846|NCT00633789|DRUG|brivanib|Tablets, Oral, 800 mg, once daily, until progression
48717847|NCT00633789|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, until progression
48023751|NCT03650881|DRUG|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
48382402|NCT00462241|OTHER|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
48717848|NCT01910870|DRUG|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
48717849|NCT01910870|DRUG|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
48717850|NCT04367597|DEVICE|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
48717851|NCT02714361|DIETARY_SUPPLEMENT|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
48717852|NCT02714361|OTHER|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
48181308|NCT05283356|DRUG|Ticagrelor 60mg|Ticagrelor 60mg BID after TAVI
48382403|NCT03363724|OTHER|HaGuide version 1.0 software module|
48717853|NCT02365285|DRUG|Galantamine|16 mg po prior to the infusion of intralipid
48717854|NCT02365285|DRUG|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
48717855|NCT02365285|DRUG|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
48717856|NCT02365285|DRUG|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
48717857|NCT06508606|DRUG|AK117|AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred
48717858|NCT06508606|DRUG|anti-EGFR|anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
48717859|NCT05090514|BEHAVIORAL|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
48717860|NCT05090514|BEHAVIORAL|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
48717861|NCT05407961|DRUG|LY3532226|Administered SC.
48717862|NCT05407961|DRUG|Placebo|Administered SC.
48717863|NCT05407961|DRUG|Dulaglutide|Administered SC.
48717864|NCT05105893|OTHER|Dates group|Seven dates to be provided to patients
48717865|NCT06384690|DIETARY_SUPPLEMENT|Micro-vegetable blend|The intervention in this study is 6 weeks with a daily proprietary blend micro-vegetables that has been freeze-dried
48717866|NCT06384690|DIETARY_SUPPLEMENT|Placebo|The intervention in this study is 6 weeks with a placebo supplement
48717867|NCT00791401|DRUG|ER OROS Paliperidone|
48717868|NCT03493789|DRUG|Fludeoxyglucose F-18|Given IV
48717869|NCT03493789|PROCEDURE|Positron Emission Tomography (PET)|Undergo FDG-PET
48519292|NCT06112860|BEHAVIORAL|Communication Strategies Information/Counseling|Communication Strategies provide information meant to help an individual compensate for hearing loss. The information provides tips both for the individual with hearing loss and for those communicating. People who choose not to pursue hearing aids will typically be given communication strategies information to help them manage their hearing loss. Participants will receive the counseling information in the mail and then have a 1 week follow-up appointment with an audiologist.
48717870|NCT03493789|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
48717871|NCT00369226|DRUG|Bortezomib (Velcade)|Infusion for a total of 3 doses
48717872|NCT00369226|DRUG|Tacrolimus|Taken until Doctor determines it is not necessary any more
48717873|NCT00369226|DRUG|Methotrexate|Infusion for a total of 4 doses
48717874|NCT00369226|PROCEDURE|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
48717875|NCT00012090|DRUG|bicalutamide|
48717876|NCT00012090|DRUG|goserelin acetate|
48717877|NCT01359462|DRUG|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
48717878|NCT00386477|PROCEDURE|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
48382404|NCT06609252|OTHER|Breast milk odour|On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.
48382405|NCT06609252|OTHER|Mother voice|Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound.
48382406|NCT03415412|DEVICE|Clearfil Univesal Bond|Adhesive systems
48382407|NCT03415412|DEVICE|IBond Universal|Adhesive systems
48382408|NCT03415412|DEVICE|G-Premio Bond|Adhesive systems
48382409|NCT01068093|DRUG|Ezetimibe|10mg daily
48382410|NCT02609932|DRUG|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
48382411|NCT03128801|PROCEDURE|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
48382412|NCT03128801|PROCEDURE|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
48382413|NCT06648486|DEVICE|With the assistance of wearable isokinetic training robot|A child with SMA will use a wearable isokinetic training robot to train the knee joint for 20 sessions.
48382414|NCT05866614|DRUG|Remsima IV|Patient will be treated with Remsima IV as per the SmPC or
48382415|NCT05866614|DRUG|Remsima SC|Patient will be treated with Remsima SC as per the SmPC
48382416|NCT05497219|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
48382418|NCT00000254|DRUG|40% Nitrous oxide|Used as pain assay positive control
48717879|NCT06027346|BIOLOGICAL|Bio-008|The subjects in each dose group received the corresponding dose of BIO-008 monotherapy, administered intravenously (ivd) for a duration of 0.5 to 3 hours (the researchers can adjust the administration time according to the patient's tolerance). If there is an infusion reaction, the infusion can be suspended and completed within 12 hours. Administer on the first day of each cycle, once every 3 weeks (1 cycle, i.e. 21 days) (Q3W) until the criteria for termination of treatment or withdrawal from the study are met, whichever occurs first.
48717880|NCT00495924|PROCEDURE|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
48717881|NCT06244836|OTHER|Implementation of a bundle of care|
48717882|NCT03453866|PROCEDURE|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
48717883|NCT03453866|PROCEDURE|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
48717884|NCT01557959|DRUG|cisplatin|Given IV
48382419|NCT00000254|OTHER|Sham comparator|0% isoflurane in oxygen
48382420|NCT00000254|DRUG|0.2% isoflurane|
48181309|NCT05891652|PROCEDURE|modified thoracoabdominal nerve block through perichondrial approach|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
48181310|NCT04218474|PROCEDURE|Evaluation Of Cross Mental Nerve Transfer In Restoration Of Chin &Lip Sensation Post Inferior Alveolar Nerve Injury|-sural nerve harvest ,and use it as conduit between injured mental nerve and the normal one
48181311|NCT00483353|PROCEDURE|Intra-nasal allergen challenge with Phleum pratense.|
48181312|NCT00483353|PROCEDURE|Collection of nasal effluent using filter paper.|
48181313|NCT00483353|PROCEDURE|Measurement of nasal congestion using acoustic rhinometry.|
48181314|NCT00919945|OTHER|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
48181315|NCT00919945|OTHER|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
48181316|NCT02313389|DRUG|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
48181317|NCT05790525|DRUG|Standard bismuth quadruple|Use the standard bismuth quadruple regimen recommended by the latest Chinese guidelines
48181318|NCT01617499|BEHAVIORAL|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
48181319|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
48181320|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
48181321|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
48181322|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
48181323|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
48181324|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
48717885|NCT01557959|BIOLOGICAL|pegfilgrastim|Given SC
48717886|NCT01557959|DRUG|erlotinib hydrochloride|Given PO
48717887|NCT01557959|OTHER|laboratory biomarker analysis|Optional correlative study
48717888|NCT01557959|GENETIC|polymorphism analysis|Correlative study
48181325|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
48181326|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
48181327|NCT05355168|PROCEDURE|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery|neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
48181328|NCT05290012|OTHER|Dark Chocolate|A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
48181329|NCT00541905|DRUG|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
48181330|NCT03922152|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
48181331|NCT00920647|OTHER|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
48181332|NCT00920647|DRUG|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
48181333|NCT00920647|DRUG|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
48181334|NCT00920647|DRUG|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
48181335|NCT01774305|DRUG|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
48181336|NCT01774305|DRUG|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
48382421|NCT00000254|DRUG|0.4% isoflurane|
48717889|NCT01557959|OTHER|pharmacogenomic studies|Correlative study
48717890|NCT01557959|GENETIC|genetic linkage analysis|Correlative study
48717891|NCT01557959|DRUG|docetaxel|Given IV
48717892|NCT05532267|DRUG|Ciprofloxacin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
48717893|NCT05532267|DRUG|Ciproxin 750 mg|an immediate release film-coated tablet containing 750 mg Ciprofloxacin
48181337|NCT03253120|OTHER|Water|Patient/ Healthy volunteer will drink 5dl of Water
48519293|NCT03181412|DIAGNOSTIC_TEST|Questionnaire|"Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist."
48519294|NCT04365803|PROCEDURE|vacuum-assisted breast biopsy|patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
48519295|NCT00373763|PROCEDURE|Fetoscopic tracheal balloon occlusion|
48717894|NCT03468972|DRUG|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
48519296|NCT00712790|DRUG|Sorafenib|Tablet, 400mg orally, twice daily
48717895|NCT03468972|OTHER|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
48717896|NCT03889210|OTHER|HVMN Ketone|Water-based, flavoured sport beverage
48717897|NCT03889210|OTHER|Placebo|Water, stevia, malic acid, and thickening agent
48717898|NCT05810714|OTHER|Best Practice|Receive usual care
48717899|NCT05810714|OTHER|Fecal Immunochemical Test|Receive FIT kit
48717900|NCT05810714|BEHAVIORAL|Health Education|Receive audio brochure
48717901|NCT05810714|BEHAVIORAL|Health Education|Receive video brochure
48717902|NCT05810714|OTHER|Scheduled Notification|Receive scheduled reminder
48717903|NCT05810714|OTHER|Survey Administration|Ancillary studies
48717904|NCT05805748|BEHAVIORAL|serious game rehabilitation|The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
48717905|NCT00248430|BIOLOGICAL|aldesleukin|
48717906|NCT00248430|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48717907|NCT00248430|DRUG|melphalan|
48717908|NCT00248430|PROCEDURE|bone marrow ablation with stem cell support|
48717909|NCT00248430|PROCEDURE|peripheral blood stem cell transplantation|
48181338|NCT00148252|DRUG|Mycophenolate mofetil withdrawal|
48181339|NCT00148252|DRUG|Cyclosporione A withdrawal|
48519297|NCT00712790|RADIATION|SIR-Spheres|one time treatment and capped at 3.0 Gbq
48519298|NCT03209895|DIETARY_SUPPLEMENT|Joint Health Product|Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
48519299|NCT03209895|DIETARY_SUPPLEMENT|Placebo|Palm oil Softgel capsule
48717910|NCT01155921|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
48717911|NCT02486991|PROCEDURE|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
48181340|NCT03750526|BEHAVIORAL|rTMS and AR|rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
48519300|NCT03209895|DIETARY_SUPPLEMENT|Glucosamine / Chondroitin|Glucosamine 1500 mg, Chondroitin 1200 mg per day
48717912|NCT02486991|PROCEDURE|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
48717913|NCT02871687|DRUG|Simvastatin|Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure
48717914|NCT02871687|DRUG|Pravastatin|Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure
48717915|NCT02871687|OTHER|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
48382422|NCT00000254|DRUG|0.6% isoflurane|
48382423|NCT00381186|BEHAVIORAL|diet- and exercise intervention|
48717916|NCT00979849|DRUG|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
48181341|NCT03750526|BEHAVIORAL|Sham rTMS and AR|Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
48181342|NCT03750526|BEHAVIORAL|AR|AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
48181343|NCT03750526|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
48181344|NCT02394665|RADIATION|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
48181345|NCT02394665|DRUG|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle."
48181346|NCT02394665|BEHAVIORAL|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
48181347|NCT02394665|RADIATION|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
48181348|NCT02394665|RADIATION|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
48717917|NCT00979849|DRUG|Placebo|Solution for nebulisation, inhaled
48181349|NCT02394665|DEVICE|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
48717918|NCT05568030|BEHAVIORAL|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
48717919|NCT05568030|BEHAVIORAL|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
48717920|NCT00408590|BIOLOGICAL|carcinoembryonic antigen-expressing measles virus|
48519301|NCT02060812|PROCEDURE|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
48519302|NCT02060812|PROCEDURE|Group II, SSNB alone|This is same as the Group I, SSNB \& ANB, but ANB was performed with placebo(10mL normal saline).
48717921|NCT00408590|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|
48717922|NCT00408590|GENETIC|reverse transcriptase-polymerase chain reaction|
48717923|NCT00408590|OTHER|laboratory biomarker analysis|
48717924|NCT03602885|BEHAVIORAL|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
48717925|NCT03602885|BEHAVIORAL|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
48717926|NCT03329963|BEHAVIORAL|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
48181350|NCT05444036|DRUG|Ketamine|compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties
48717927|NCT03329963|BEHAVIORAL|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last \~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of \~90 min duration (\~15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
48717928|NCT05640609|COMBINATION_PRODUCT|Capeox regimen combined with Sintilimab and Bevacizumab|Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
48717929|NCT00143780|BIOLOGICAL|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
48717930|NCT00143780|BIOLOGICAL|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
48519303|NCT04975711|DRUG|HIP2105|Test drug
48519304|NCT04975711|DRUG|RLD2104|Reference drug
48717931|NCT02792998|DRUG|IW-1701|IW-1701 Tablet
48717932|NCT02792998|DRUG|Placebo|Matching Placebo Tablet
48717933|NCT02809053|BIOLOGICAL|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
48382424|NCT00669110|DRUG|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"* tablet~* subjects randomly assigned to 10-200 mg/day by age group~* 6 month treatment period(\~182 days)"
48382425|NCT05365776|BEHAVIORAL|Graded Exposure Therapy|Graded exposure therapy is delivered by a psychologist over 12 individual (1:1) secure videoconference sessions. The core active ingredient is graded situational exposure to foster habituation and challenge beliefs that the avoided activities are dangerous. Homework exercises involve planned exposure exercises in the home and community to support generalization.
48717934|NCT02809053|BIOLOGICAL|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
48519305|NCT01313052|BEHAVIORAL|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
48717935|NCT03502304|BEHAVIORAL|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
48717936|NCT03715192|BIOLOGICAL|LY3462817 IV|Administered IV
48519306|NCT01313052|BEHAVIORAL|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
48717937|NCT03715192|BIOLOGICAL|LY3462817 SC|Administered SC
48717938|NCT03715192|DRUG|Placebo|Administered IV
48717939|NCT04808271|DIETARY_SUPPLEMENT|Bifidobacterium breve Bif195|1 capsule daily for 8 weeks
48382426|NCT05365776|BEHAVIORAL|Prescribed aerobic exercise|Participants will be asked to complete 30 minutes of aerobic exercise on 5 days/week for a 12-week period. Participants select the mode (e.g., swimming, jogging, bicycling) and location of exercise (e.g., outdoors, a gym or community centre, at home). The initial exercise intensity target will be based on the Buffalo Concussion Bike Test. The target progression will be 3-5 beats per minute every two weeks.
48023752|NCT03650881|DRUG|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
48023753|NCT03753958|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
48023754|NCT03753958|RADIATION|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
48023755|NCT01081587|PROCEDURE|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
48023756|NCT01081587|BEHAVIORAL|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
48023757|NCT01081587|OTHER|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
48382427|NCT05365776|OTHER|Enhanced usual care|Usual care (education about concussion from the website: concussion.vch.ca/) will be enhanced through email message support.
48519307|NCT01679652|DRUG|Nebivolol|Tablet i blinded in capsula
48717940|NCT04808271|DIETARY_SUPPLEMENT|Placebo|1 capsule daily for 8 weeks
48717941|NCT00437450|DRUG|Epoetin/Atra|
48717942|NCT04326764|DRUG|Panobinostat|"Panobinostat should be taken orally once on each scheduled day at about the same time, either with or without food. Each dose of panobinostat should be taken with a cup of water.~The capsules should be swallowed as whole. If vomiting occurs during the course of treatment, no re-dosing is allowed before the next scheduled dose. If one dose is forgotten during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next schedule treatment day. The patient should then continue treatment with the original dosing schedule.~Panobinostat will be administered at a dose of 20 mg three times weekly (TIW) every second week and will be dosed on a flat scale of mg/day and not by weight or body surface area.~Panobinostat will be dispensed as a 20 mg capsule or as two 10 mg capsules."
48519308|NCT01679652|DRUG|placebo|
48519309|NCT05782673|DEVICE|wearable MAIJU for motor assessment|The novel multisensor wearable MAIJU will be used to measure infants' motor performance at home. The recordings are repeated at 2 months intervals betveen 6 and 18 months of age.
48717943|NCT05455177|OTHER|Digital first-line intervention for osteoarthritis including exercise and education|The digital OA management programme was delivered by a smartphone application, including education and exercises based on a face-to-face osteoarthritis self-management programme provided nationwide in Sweden and designed according to national and international guidelines. Over 12 weeks, which is the recommended minimum duration of a self-management intervention for OA, a total of 163 exercise sessions and 31 educational sessions are provided.
48717944|NCT03484364|BEHAVIORAL|ENACTS|Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
48717945|NCT05259761|OTHER|Unmanned ariel vehicle|Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
48717946|NCT04077372|BEHAVIORAL|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
48717947|NCT04077372|BEHAVIORAL|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
48717948|NCT02535299|DRUG|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
48717949|NCT02535299|DRUG|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
48717950|NCT04836676|DEVICE|C-REX Device|"The investigational devices are C-REX LapAid Cath or C-REX RectoAid Cath. C-REX LapAid Cath consists of an invasive surgical part, i.e. anastomotic ring comprised of two LapAn coupled by DMC/DM, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX RectoAid Cath consists of an invasive surgical part, i.e. an anastomotic ring comprised of RectoAn and LapAn, intended for short-term use, and surgical instruments for assisting the placement of the anastomotic ring to intestine.~C-REX LapAid Cath and C-REX RectoAid Cath are easy to use, with unique possibility to control and validate the integrity of the anastomosis during and after surgery."
48717951|NCT01519739|DEVICE|MediGuide™|MediGuide™ system will be used to guide CRT implants
48717952|NCT00780481|DRUG|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
48519310|NCT04795895|DIAGNOSTIC_TEST|ultrasonography (US)|US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.
48717953|NCT02547493|BIOLOGICAL|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
48717954|NCT02547493|BIOLOGICAL|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
48382428|NCT06065631|DEVICE|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
48023758|NCT02318329|DRUG|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
48023759|NCT02766608|DRUG|BFF MDI 320/9.6 μg|Blinded Treatment
48023760|NCT02766608|DRUG|BFF MDI 160/9.6 μg|Blinded Treatment
48023761|NCT02766608|DRUG|FF MDI 9.6 μg|Blinded Treatment
48023762|NCT02766608|DRUG|BD MDI 320 μg|Blinded Treatment
48023763|NCT02766608|DRUG|Symbicort® TBH 400/12 μg BID|Open Label
48382429|NCT06065631|OTHER|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
48382430|NCT03465982|PROCEDURE|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
48519311|NCT04795895|DIAGNOSTIC_TEST|Standard routine (SR)|Standard routine (SR)
48717955|NCT02547493|DRUG|Abatacept|Abatacept started on frst day
48717956|NCT00281190|PROCEDURE|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
48023764|NCT02533843|PROCEDURE|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
48023765|NCT04276272|OTHER|Imaging scan|PET/CT scan
48717957|NCT00281190|PROCEDURE|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
48023766|NCT06346561|DRUG|Dexmedetomidine|the reduction of controlled hypotension and the control of hemodynamic responses of the body
48717958|NCT04479683|OTHER|FTH then DH support|"FTH output and DH relay one day a week until the minimum healthy weight. This treatment combines over one day a medical evaluation by a senior psychiatrist, family work (parents group and multi-family therapy session), a therapeutic education group, a cognitive remediation group and a dietary follow-up with therapeutic meals.~During this phase, all children are evaluated once a week on a somatic level."
48717959|NCT04479683|OTHER|standard care|continuation of full-time hospitalization until the minimum healthy weight is reached, defined as the weight corresponding to the return to the previous BMI corridor (previous BMI +/- 1 BMI corridor, e.g. change from 25th to 10th percentile). This management combines bi-weekly medical follow-up by a senior psychiatrist, weekly family work, weekly therapeutic education group, weekly cognitive remediation group and bi-weekly dietary follow-up with therapeutic meals.
48717960|NCT03504566|DRUG|Linagliptin|Linagliptin
48717961|NCT03504566|DRUG|Empagliflozin|Empagliflozin
48717962|NCT03504566|DRUG|Telmisartan|Telmisartan
48717963|NCT03504566|DRUG|Sulodexide|Sulodexide
48717964|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
48717965|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
48717966|NCT00532792|BIOLOGICAL|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
48717967|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
48023767|NCT06346561|DRUG|Labetalol|the reduction of controlled hypotension and the control of hemodynamic responses of the body
48519312|NCT06285292|DEVICE|EMY|"Patients in the intervention group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study"
48023768|NCT02657850|OTHER|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
48023769|NCT02657850|OTHER|head neck self reporting|head and neck patient self reports dysphagia symptoms
48382431|NCT03465982|PROCEDURE|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
48519313|NCT05076357|BEHAVIORAL|Caloric Restriction|-30% of participants total energy requirements
48717968|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
48717969|NCT00532792|BIOLOGICAL|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
48717970|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
48519314|NCT05076357|OTHER|Cold intervention|Sessions of 90min each every 2nd day involving cold exposure
48519315|NCT00003126|DRUG|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
48519316|NCT01722630|DRUG|Dopamine|
48717971|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
48717972|NCT00532792|BIOLOGICAL|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
48717973|NCT00532792|BIOLOGICAL|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
48023770|NCT02657850|OTHER|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
48023771|NCT03036566|DEVICE|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
48382432|NCT06650202|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
48717974|NCT04932213|DRUG|Tropicamide Ophthalmic|Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
48717975|NCT03635034|DEVICE|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
48717976|NCT03635034|DEVICE|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
48717977|NCT06308250|OTHER|MIME THERAPY|"Mime therapy consist of:~Self massage: patients will be taught to massage their face and neck daily for about 10 minutes which includes effleurage and kneading of both sides of face.~Breathing exercises: patient will be taught to recognize tension and feel the difference between tension and relaxation in facial musculature for 5 minutes. Expiration exercises will be used to induce relaxation.~Articulation: vowels such as a,e,i,o,u and consonants such as p and b will be used to teach position of the lips for 5 minutes.~Facial expression exercises: forehead wrinkle, smiling, eye closure, frowning, disgust, surprise, anger, sadness will be performed for 10 minutes"
48717978|NCT06308250|OTHER|ACTION OBSERVATION THERAPY|"Function of each of the muscle is observed for 3 minutes and then executed for 2 minutes.~Frontalis (Raising eyebrows and forehead wrinkling). Corrugator Supercili (Moving the eyebrow down and inward toward the nose and inner eye).~Orbicularis oculi (Closing the eyelids). Buccinator (Blowing air in and out of the mouth). Zygomaticus major (Smiling). Orbicularis oris (Lip pursing or puckering)."
48717979|NCT03100214|OTHER|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
48717980|NCT03100214|OTHER|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
48717981|NCT04979403|OTHER|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
48717982|NCT06034756|OTHER|TMJ dysfunction|Fonseca's Anamnestic Questionnaire (FAQ) was used for TMJ dysfunction. The diagnostic accuracy of the FAQ was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
48717983|NCT06034756|OTHER|Maximum pain-free mouth opening (MMO)|The maximum pain-free mouth opening was recorded using a 15 cm ruler
48181351|NCT03021551|DEVICE|Rainbow sensor|Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
48717984|NCT06034756|OTHER|Forward head posture|Forward head posture was evaluated by CVA using a goniometer. CVA was measured in degrees as the angle between the horizontal plane, the seventh cervical vertebra and the ear hole
48382433|NCT04429633|DRUG|Candesartan|If GLS decreased less than 18% or LVEF decreased to 45-50% during the treatment of adjuvant trastuzumab, start candesartan medication.
48717985|NCT06034756|OTHER|Tongue strength and endurance|Tongue strength and endurance were evaluated with IOPI (Medical LLC, Redmond, WA), which has been clinically validated and reliable
48023772|NCT04598282|DEVICE|Prokera Slim|Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.
48023773|NCT04598282|OTHER|Standard of Care|Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
48181352|NCT00825305|BIOLOGICAL|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
48382434|NCT06550440|BEHAVIORAL|family integrated care|Trained NICU nurses give effective education to parents of children, and regard parents as a part of NICU team, so that they can actively provide positive care for babies instead of passive caregivers. Parents mainly participate in nursing care such as bottle feeding, changing diapers, skin contact and so on.
48023774|NCT06024746|DRUG|Finerenone|Oral finerenone.
48023775|NCT06024746|DRUG|Empagliflozin|Oral empagliflozin.
48023776|NCT00889421|DRUG|Apremilast|oral dose of 30 mg BID for 6 months
48181353|NCT00825305|BIOLOGICAL|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
48181354|NCT05331469|DRUG|NPH basal insulin titration|Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
48181355|NCT04513743|DIAGNOSTIC_TEST|24/7 EEG™ SubQ|24/7 EEG™ SubQ device will be worn by each subject for 365 nights
48519317|NCT04366947|DEVICE|NIO® (Intraosseous access)|obtaining intravascular access using a ready intravenous NIO needle set
48382435|NCT06650137|DIAGNOSTIC_TEST|diaphragmatic ultrasound|"The examination is performed with a phased array probe, also known as a cardiac probe. The technique used will be that described and validated in anterior studies: the patient is in the Fowler position: half-seated, at an angle of around 45 degrees. The patient is ventilating spontaneously, and no participation is required. The probe is positioned in the sub-costal region between the mid-clavicular and anterior axillary line on the right, and between the anterior and middle axillary line in the sub- or intercostal region on the left. The liver is used as an acoustic window for the right hemi-diaphragm. The probe is oriented medially, cranially and dorsally.~The operator switches to time-motion (TM) mode when an angle of over 70° is achieved between the upper part of the diaphragm and the analysis axis in the most cephalic part of the diaphragm. The image is frozen when 6 respiratory cycles have been measured."
48382436|NCT01829490|BIOLOGICAL|ChAdOx1 85A|Intramuscular injection
48382437|NCT01829490|BIOLOGICAL|MVA85A|Intramuscular injection
48717986|NCT06034756|OTHER|Static endurance evaluation of the trunk muscles|The Trunk Flexors Endurance Test and the Biering Sorenson Test were used. These static tests are measurements targeting the local core muscles.
48717987|NCT06034756|OTHER|Dynamic endurance evaluation of the core muscles|The Sit-ups and the Modified Push-ups Tests were used. These dynamic tests are measurements targeting the global core muscles.
48717988|NCT02844283|DRUG|Ad-HGF|
48717989|NCT02844283|OTHER|0.9% NaCl|
48717990|NCT00886249|DEVICE|Acrysof IQ|Intraocular lens
48717991|NCT00886249|DEVICE|Acrysof Natural IOL|Intraocular Lens
48717992|NCT00165542|OTHER|A PROTEIN level|
48717993|NCT00093886|DRUG|clevidipine|
48717994|NCT00093886|DRUG|nitroglycerin|
48023777|NCT03699306|PROCEDURE|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
48023778|NCT01842789|DEVICE|Acessa Procedure|Acessa Procedure
48382438|NCT01262391|DRUG|Solifenacin succinate suspension 2.5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
48382439|NCT01262391|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
48717995|NCT03242018|DRUG|Placebo|Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
48023779|NCT01068431|OTHER|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
48023780|NCT00066092|DRUG|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
48023781|NCT00066092|DRUG|filgrastim|Filgrastim given daily for PBPC mobilization
48023782|NCT00066092|DRUG|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
48023783|NCT06515860|DIAGNOSTIC_TEST|Liquid biopsy for MPNST development|Participants will be asked to complete a blood sample (liquid biopsy) at baseline (15 mL, approximately 1 tablespoon) and every 6 months (10 mL) for the five-year follow-up period.
48023784|NCT06531525|DRUG|Enoxaparin|Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
48181356|NCT01690468|DRUG|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
48717996|NCT03242018|DRUG|Sotagliflozin|Sotagliflozin 200 mg, tablet, orally, once daily.
48717997|NCT05252221|OTHER|ATC Intervention|The ATC intervention offers convenient access to specialty consultation for PCPs and offers patients direct access to addiction treatment in a non-stigmatized primary care setting
48717998|NCT01735071|DRUG|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
48717999|NCT01735071|DRUG|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
48718000|NCT04560894|DRUG|SCT-I10A|Participants receive SCT-I10A intravenously，200mg，d1，Q3w
48718001|NCT04560894|DRUG|SCT510|Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
48718002|NCT04560894|DRUG|Sorafenib 200mg|Participants receive sorafenib orally，400mg bid
48718003|NCT00617955|DRUG|Aprotinin|compare outcomes of Aprotinin versus Amicar
48718004|NCT00617955|DRUG|Amicar|compare outcomes of Aprotinin versus Amicar
48718005|NCT00000120|DRUG|Erythromycin Ointment|
48718006|NCT00000120|DRUG|Silver Nitrate Drops|
48718007|NCT04625868|OTHER|Educational video|Patients will watch a preoperative educational video on proper opioid use and disposal.
48718008|NCT03071484|DEVICE|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
48718009|NCT03792152|DRUG|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
48718010|NCT03792152|DRUG|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
48718011|NCT00841932|PROCEDURE|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
48718012|NCT04202198|BIOLOGICAL|A-PRF|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla.previously prepared PRF membranes are placed through the access hole and the flap is advanced. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
48181357|NCT01690468|DRUG|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
48181358|NCT03167853|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
48181359|NCT03659331|DIETARY_SUPPLEMENT|Zinc|blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
48181360|NCT02330276|DRUG|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
48181361|NCT06300983|BEHAVIORAL|Psychoeducative|The intervention consiste of 5 sessions (Table 1), with each lasting 100 minutes and delivered on a weekly basis. Individual meetings will be conducted with each participant prior to starting the group work. These were considered pre-intervention sessions, during which patients provided informed consent to participate in the study and the first assessment tests were administered.
48718013|NCT04202198|PROCEDURE|pinhole surgical technique only|local anesthesia was administered followed by placement of a hole in the alveolar mucosa adjacent to mesial most recession tooth. tunneling instruments are used to elevate a full thickness tunnel upto the CEJ sparing the tip of the papilla followed by advancement of the flap. 5-0 polyglycolic acid sutures is used to secure the advanced flap.
48718014|NCT00320138|PROCEDURE|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
48718015|NCT06147921|DRUG|Verasone|Administered by sinonasal irrigation.
48718016|NCT00096018|DRUG|fludarabine phosphate|Given IV
48718017|NCT00096018|DRUG|thalidomide|Orally
48718018|NCT01685983|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
48718019|NCT01685983|DRUG|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
48718020|NCT02525913|DEVICE|RFA Applicator|
48718021|NCT03132519|DRUG|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
48718022|NCT04235569|DRUG|Warfarin Sodium 5 MG|warfarin sodium 5mg tablets
48718023|NCT04235569|DRUG|Warfarin Sodium 3 MG|warfarin sodium 3mg tablets
48718024|NCT04235569|DRUG|Enoxaparin Sodium 100 MG/ML Prefilled Syringe|"Clexane® Syringes 2,000 IU (20 mg)/0.2 ml solution for injection in pre-filled syringes.~Clexane® Syringes 4,000 IU (40 mg)/0.4 ml solution for injection in pre-filled syringes.~Clexane® Syringes 6,000 IU (60 mg)/0.6 ml solution for injection in pre-filled syringes.~Clexane® Syringes 8,000 IU (80 mg)/0.8 ml solution for injection in pre-filled syringes.~Dose was determined individually for each patient as 1mg/kg every 12 hours."
48718025|NCT04356794|OTHER|Acupuncture needle with electrical stimulation|EA is treated for 4 weeks, 3 times per week.
48718026|NCT04356794|OTHER|Sham electroacupuncture|Sham EA is treated for 4 weeks, 3 times per week.
48718027|NCT02308488|RADIATION|Intensity-modulated radiation therapy (IMRT)|Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
48181362|NCT06300983|BEHAVIORAL|Placebo|The control group, which do not receive any psychoeducative intervention
48181363|NCT00759642|DRUG|lapatinib|lapatinib 1500 mg PO daily
48181364|NCT04996940|DEVICE|E-cigarette product|"Participants will be randomized 1:1 to e-cigarette flavor order either:~1. tobacco e-cigarette~2. menthol e-cigarette"
48718028|NCT06222489|DRUG|89Zr-Patritumab deruxtecan|Day 1, day 3, day 6, day 11 and day 26 of first course
48718029|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: OPD-Scan|Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.
48718030|NCT04602923|DIAGNOSTIC_TEST|Corneal topography: Pentacam|Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.
48718031|NCT04008511|DRUG|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
48718032|NCT04008511|DRUG|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
48718033|NCT04008511|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
48718034|NCT04008511|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
48718035|NCT02194322|DRUG|BIBN 4096 BS - in single rising doses|
48718036|NCT02194322|DRUG|Placebo|
48718037|NCT02876328|BIOLOGICAL|Ad26.ZEBOV|0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
48718038|NCT02876328|BIOLOGICAL|MVA-BN-Filo|0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
48718039|NCT02876328|BIOLOGICAL|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
48718040|NCT02876328|BIOLOGICAL|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
48718041|NCT02876328|BIOLOGICAL|rVSV boost|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
48519318|NCT04366947|DEVICE|Standard of Care (Intravenous access)|obtaining intravascular access using a standard intravenous cannula
48718042|NCT00762996|DEVICE|etafilcon A|contact lens
48023785|NCT06531525|DRUG|Aspirin|Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
48023786|NCT06531525|DRUG|Enoxaparin|Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
48023787|NCT03770572|GENETIC|Low dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose
48519319|NCT00682474|BEHAVIORAL|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
48519320|NCT00682474|BEHAVIORAL|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
48519321|NCT01163864|BEHAVIORAL|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
48023788|NCT03770572|GENETIC|High dose AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at high dose
48718043|NCT00762996|DEVICE|omafilcon A|contact lens
48023789|NCT02726815|OTHER|Questionnaire|Questionnaire based study using a symptom assessment tool
48181365|NCT00336336|DRUG|n-3 PUFA|1 g die per os
48181366|NCT00336336|DRUG|Rosuvastatin|10 mg die per os
48181367|NCT00336336|DRUG|Placebo|1 gram c. per os
48181368|NCT00336336|DRUG|Placebo|10 mg c. per os
48181369|NCT06394609|OTHER|double loaded knotted suture anchor|arthroscopic bankart repair by using double loaded knotted suture anchor
48718044|NCT05208775|PROCEDURE|PDT|"Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.~Laser irradiation:~48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts."
48718045|NCT05208775|PROCEDURE|ESD|The patients received standard endoscopic submucosal dissection after enrollment.
48181370|NCT06394609|OTHER|double grand knot|arthroscopic bankart repair by using double grand knot
48718046|NCT04356482|BIOLOGICAL|convalescent plasma|"In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case.~In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated."
48718047|NCT02982499|DEVICE|magnetic resonance image (MRI)|Radiographic imaging that takes about 30-45 minutes
48718048|NCT02982499|DEVICE|Optical Coherence Tomography (OCT)|Images taken from the back of the eye (retina)
48718049|NCT04095130|DIAGNOSTIC_TEST|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
48718050|NCT02334488|DRUG|Everolimus|Active Comparator
48718051|NCT02334488|DRUG|Tacrolimus|Active Comparator
48023790|NCT03492307|OTHER|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
48023791|NCT03492307|OTHER|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
48023792|NCT04882501|OTHER|QUEASEEase aromatherapy quick tab|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
48023793|NCT04882501|OTHER|Placebo product|Once patient complains of nausea above intervention will be administered for 5 minutes and nausea level reassessed.
48181371|NCT05472584|OTHER|Electrophysiology assessment - corticospinal tract|Kinematics and cortical spinal motor excitability
48181372|NCT05472584|OTHER|Electrophysiology assessment - reticulospinal tract|Kinematics and reticular spinal motor excitability
48181373|NCT05472584|OTHER|Electrophysiology assessment - spinal motoneuron|Kinematics and spinal motoneuron excitability
48181374|NCT05472584|OTHER|Activity-based training|Motor task
48181375|NCT05472584|OTHER|Transcutaneous spinal cord stimulation|Non-invasive spinal cord stimulation
48181376|NCT02488083|DEVICE|Ultrashape|circumference reduction
48181377|NCT06270277|DIAGNOSTIC_TEST|Pediatric Quality of Life Inventory (PedsQL)|Questionnaire
48181378|NCT06270277|DIAGNOSTIC_TEST|Strengths and Difficulties Questionnaire (SDQ)|Questionnaire
48181379|NCT06097962|DRUG|NK510|Intravenous infusion
48181380|NCT06097962|DRUG|Tislelizumab，atezolizumab or sugemalimab|Administer according to the instructions
48181381|NCT05037747|BEHAVIORAL|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
48181382|NCT01130168|DRUG|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
48181383|NCT01130168|DRUG|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
48181384|NCT01130168|DRUG|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
48181385|NCT03672175|DRUG|SAGE-217|SAGE-217 hard gelatin capsules.
48181386|NCT03672175|DRUG|Placebo|SAGE-217 matched placebo hard gelatin capsules.
48382440|NCT01262391|DRUG|Solifenacin succinate suspension 10 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
48382441|NCT02930538|OTHER|Survey|Completing a survey on RedCap
48718052|NCT02334488|DRUG|Mycophenolate sodium|Experimental Arm
48718053|NCT01152515|DRUG|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
48718054|NCT03463395|DEVICE|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
48718055|NCT04830124|DRUG|Nemvaleukin Alfa Subcutaneous|Subcutaneous injection of nemvaleukin every 7 days
48718056|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
48718057|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous Less Frequent Dosing|Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)
48718058|NCT04830124|DRUG|Pembrolizumab|Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
48718059|NCT01347255|DRUG|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
48718060|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
48718061|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
48718062|NCT01347255|DRUG|Daivobet® ointment|once daily application, 4 weeks
48718063|NCT01180517|PROCEDURE|Percutaneous coronary intervention (PCI)|balloon angioplasty
48718064|NCT01180517|PROCEDURE|PCI|balloon angioplasty
48718065|NCT00142623|BEHAVIORAL|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
48718066|NCT05506839|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
48718067|NCT04218071|DRUG|Ruxolitinib|Ruxolitinib at protocol-specified doses for given platelet count
48718068|NCT04218071|DRUG|9-ING-41|9-
48718069|NCT02038660|DEVICE|Balloon angioplasty|
48718070|NCT00215865|DRUG|PEGIntron plus ribavirin|
48718071|NCT01743404|DIETARY_SUPPLEMENT|Inflaminat|
48382442|NCT05637515|BIOLOGICAL|Humira 40 MG in Prefilled Syringe|Humira (40 mg every other week)
48382443|NCT05637515|BIOLOGICAL|Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe|"• Subjects will receive Humira (initial dose of 80 mg \[2 × 40 mg\]; Day 1 administered subcutaneously (SC), followed by 40 mg SC given every other week starting 1 week after the initial dose (last dose at Week 10).~Hulio (40 mg every other week) at Week 12 and Week 14~* Humira (40 mg every other week) at Week 16 and Week 18, and~* Hulio (40 mg every other week) at Week 20, Week 22, Week 24 and Week 26."
48382444|NCT00709904|DRUG|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
48382445|NCT00709904|DRUG|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
48382446|NCT00709904|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
48382447|NCT01065545|DRUG|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
48382448|NCT05963022|DRUG|Tirzepatide|Administered SC
48382449|NCT05963022|DRUG|Placebo|Administered SC
48382450|NCT02459470|PROCEDURE|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
48382451|NCT05885711|OTHER|self-management|self-managing a pessary: removing, cleaning and inserting
48519322|NCT01163864|BEHAVIORAL|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
48519323|NCT00368797|DRUG|XRP0038 (NV1FGF)|
48519324|NCT03482973|DRUG|Bupivacaine Group|20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
48718072|NCT01743404|DRUG|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
48718073|NCT03033953|DIETARY_SUPPLEMENT|Native whey|
48519325|NCT03482973|OTHER|Placebo|20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
48718074|NCT03033953|DIETARY_SUPPLEMENT|Milk|
48718075|NCT03033953|OTHER|Strength training|
48718076|NCT02003937|BEHAVIORAL|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
48718077|NCT03276949|DEVICE|Blood glucose measurement|Device used to measure blood glucose levels
48718078|NCT00513396|DRUG|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
48382452|NCT06641687|OTHER|24% Sucrose|Participants will be given either sugar water (24% sucrose) randomly
48382453|NCT06641687|OTHER|Sterile water|Participants will be given sterile water randomly
48382454|NCT01254357|OTHER|Questionnaire self report|Burn specific outcome measurement and global health measurement
48382455|NCT01966185|OTHER|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
48382456|NCT05014139|DRUG|Enfortumab vedotin|Given into the bladder (intravesically)
48382457|NCT05997316|BEHAVIORAL|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
48519326|NCT03687840|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
48519327|NCT06382532|DIAGNOSTIC_TEST|Niacin skin reaction test|Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.
48519328|NCT03740581|DRUG|Insulin|Basal Bolus regimen (Participant to receive, Insulin \>= 3 times per day)
48519329|NCT04774016|OTHER|Test formula A without added pre- and pro-biotic|An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
48519330|NCT04774016|OTHER|Test formula B with synbiotic|Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
48382458|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.|"* An interactive mobile based application will be developed with the following features to assist in monitoring and preventing relapse.~* Purpose of the Mobile based application: The mobile application will be an interactive tool designed to assist in monitoring and preventing relapse of alcohol use disorder. It will provide various features to support users in their journey to sobriety, including personalized recovery plans, goal setting, progress tracking, stress and craving management tools, educational resources, daily reflection prompts, emergency assistance, personalized reminders, progress reports, and psychoeducational videos.~* The Target population: 40 Male patients selected through randomized sampling, aged between 18 and 59 years, who have participated in Nurse-Conducted Brief Intervention (NCBI) for AUD in the Gastroenterology ward with diagnosis of alcohol dependence use disorder based on ICD-10 who have access to smartphone application and have the ability to use it."
48519331|NCT04774016|OTHER|Test formula C with HMOs|Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
48718079|NCT00513396|DRUG|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
48718080|NCT01521299|DRUG|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
48718081|NCT00403780|DRUG|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
48718082|NCT00403780|DRUG|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
48718083|NCT06391853|DRUG|Insulin|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
48718084|NCT06391853|DRUG|Placebo|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
48718085|NCT06508463|PROCEDURE|Biopsy|Undergo tumor biopsy
48718086|NCT06508463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48718087|NCT06508463|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
48718088|NCT06508463|PROCEDURE|Computed Tomography|Undergo SPECT/CT
48718089|NCT06508463|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48718090|NCT06508463|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
48718091|NCT06508463|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
48718092|NCT06508463|BIOLOGICAL|Cemiplimab|Given IV
48718093|NCT06508463|BIOLOGICAL|Ipilimumab|Given IV
48718094|NCT02259985|DRUG|Itasetron tablet|
48718095|NCT02259985|DRUG|Itasetron infusion|
48718096|NCT02259985|OTHER|high fat breakfast|
48718097|NCT01710735|PROCEDURE|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
48718098|NCT05525949|DEVICE|VIVID Brain|Participants receive visual perceptual training using the VIVID Brain software.
48718099|NCT05525949|OTHER|No-treatment Control|No-treatment is administered during control period.
48718100|NCT04581382|BIOLOGICAL|Nivolumab|Given IV
48718101|NCT04581382|BIOLOGICAL|Pembrolizumab|Given IV
48718102|NCT04581382|RADIATION|Radiation Therapy|Undergo radiation therapy
48718103|NCT04581382|BIOLOGICAL|Therapeutic Exchange Plasma|Undergo therapeutic plasma exchange
48718104|NCT04581382|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48718105|NCT04581382|PROCEDURE|Computed Tomography|Undergo CT
48718106|NCT04581382|PROCEDURE|Positron Emission Tomography|Undergo PET
48718107|NCT04581382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48718108|NCT04652674|BEHAVIORAL|Telemedicine visit|A postoperative visit with the patient's surgeon conducted remotely via audio/video smartphone app
48718109|NCT04652674|BEHAVIORAL|In-person postoperative visit|A standard-of-care in-person postoperatively visit with the patient's surgeon
48718110|NCT04366375|DIAGNOSTIC_TEST|PTX-3|Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.
48718111|NCT00607854|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
48718112|NCT02064972|OTHER|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
48181387|NCT01087515|OTHER|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
48519332|NCT05298917|DEVICE|silicone hydrogel contact lens|silicone hydrogel contact lens
48718113|NCT02846246|OTHER|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
48718114|NCT02846246|OTHER|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
48181388|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
48181389|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
48718115|NCT02584361|PROCEDURE|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
48718116|NCT02584361|PROCEDURE|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
48718117|NCT00841048|DRUG|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
48718118|NCT00841048|DRUG|Placebo|
48181390|NCT01026129|DRUG|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
48181391|NCT05923346|OTHER|GLUTLEARN|"The group will be made up of users of the social network Instagram who have celiac disease or are close to a celiac patient (parent/guardian of celiac children or cohabitants).~The intervention will be carried out through the social network Instagram. Participants will be recruited through the same social network. Participants must agree to take part in the study.~The educational intervention will be carried out for one month, where each day a post will be uploaded with specific, truthful and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management."
48718119|NCT03980717|DEVICE|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
48718120|NCT04465565|PROCEDURE|9% Sodium Chloride (NaCl) IV|9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
48718121|NCT02609945|DRUG|zolmitriptan|Oral Tablet and Nasal Spray
48718122|NCT02609945|DRUG|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
48718123|NCT00199667|DRUG|Mycophenolate Mofetil|
48718124|NCT00199888|DRUG|124-Iodine-cG250 (124I-cG250)|
48718125|NCT00350467|DRUG|ER OROS paliperidone and Olanzapine|
48181392|NCT03903718|DRUG|Oseltamivir|75 mg capsules orally twice a day from Day 2 to Day 7
48181393|NCT03903718|BIOLOGICAL|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
48718126|NCT00226135|DRUG|lithium or lamotrigine|
48718127|NCT04943562|DIAGNOSTIC_TEST|ACT+EEG|Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
48023794|NCT01336127|BEHAVIORAL|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
48181394|NCT03903718|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
48382459|NCT06652802|BEHAVIORAL|Nurse-Conducted Brief Intervention (NCBI)|"* Nurse-Conducted Brief Intervention (NCBI) is a feasible and acceptable model of care for males diagnosed with Alcohol Use Disorders (AUDs) in gastroenterology settings. The study found that the Nurse-Conducted Brief Intervention (NCBI) had a positive impact on promoting abstinence in patients with AUDs, and the preliminary findings demonstrate probable good outcomes. \[21\].~* It consists of a trained Nurse delivering three individual sessions with the patient over a span of two to three days (15 to 20 mins each) during their period of admission in the ward and one session with the family members."
48382460|NCT06652204|OTHER|questionnaire|Caregivers must reply to the French version of the QASCI questionnaire, the ZBI (Zarit Burden Interview) questionnaire, HADS (Hospital Anxiety and Depression Scale), and WHOQOL-Bref (World Health Organization Quality of Life Instrument - Short Form). After 15 days, they wil reply to the French version of the QASCI questionnaire (to asse the reliability).
48519333|NCT04333485|OTHER|Home-based Active Case Finding (HACF)|Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.
48519334|NCT04333485|OTHER|Telephonic Active Case Finding (TACF)|Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
48519335|NCT06487793|BEHAVIORAL|Enhanced Insomnia Coach|The intervention combines the Insomnia Coach app with additional brief alcohol intervention to facilitate behavior change for both drinking behavior and insomnia symptoms. Insomnia Coach contains multiple components of CBT-I (e.g., stimulus control, cognitive restructuring, relaxation training, sleep hygiene/psychoeducation, monitoring of sleep via journals). The brief alcohol intervention content added to the CBT-I app is based on CBT skills for moderate drinking, delivered in a motivational enhancement style, and has demonstrated efficacy among young adults and veterans (e.g., correcting perceived norms, use of protective behavioral strategies, challenging expectancies).
48718128|NCT03474198|DRUG|Rifampicin|10mg/kg
48718129|NCT03474198|DRUG|Isoniazid|5mg/kg
48718130|NCT03474198|DRUG|Pyrazinamide|25mg/kg
48718131|NCT03474198|DRUG|Ethambutol|15mg/kg
48718132|NCT03474198|DRUG|Linezolid|600mg
48718133|NCT03474198|DRUG|Clofazimine|200mg
48718134|NCT03474198|DRUG|Rifapentine|1200mg
48718135|NCT03474198|DRUG|Levofloxacin|1000mg
48718136|NCT03474198|DRUG|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
48023795|NCT01620463|DRUG|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
48023796|NCT01620463|DRUG|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
48718137|NCT03474198|DRUG|Rifampicin|35mg/kg
48718138|NCT04407065|DRUG|Double trigger|Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
48718139|NCT04407065|DRUG|HCG trigger|Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
48023797|NCT00883389|DEVICE|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
48023798|NCT00422539|DRUG|70% trichloroacetic acid|
48023799|NCT05361473|DEVICE|The NeoHilda Point of care method|This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
48023800|NCT05361473|PROCEDURE|Traditional evaluation|Traditional way of evaluation
48023801|NCT04596072|COMBINATION_PRODUCT|Chinese traditional rehabilitation|Chinese traditional rehabilitation including acupuncture and herbs
48023802|NCT03540342|PROCEDURE|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
48023803|NCT04614428|BEHAVIORAL|RESILIENCE Program|"In addition to the standard care participants would normally receive (including exposure to any standard hospital avoidance programs), the 150 participants assigned to the RESILIENCE Program group will receive a combination of strategies designed to promote seasonal resilience.~This includes profiling of seasonal vulnerability; a 60-80 minute home visit by the RESILIENCE Nurse to assess physiological status, behavioural adaptations, environment, and modulating factors; a dedicated RESILIENCE Clinic with a dedicated RESILIENCE physician to develop a long-term plan to help promote/maintain seasonal resilience and; a structured follow-up over the next 12 months to monitor and adjust the participant's status and management from a seasonal perspective."
48181395|NCT05074199|PROCEDURE|W-plasty/Linear closure|"The patient's wound will be labeled A if it is on the left or superior side of the investigator and B if it is on the right or inferior side. A predetermined, concealed randomization number will be obtained from the RedCap randomization module, which will specify how side A is to be treated. Side B will be treated the opposite way as A. Side A will always be closed first. The side assigned to be closed in a traditional straight line (SL) will have the standing cutaneous deformity (dog ear) excised in the standard manner using Burrow's triangles, resulting in an elliptical defect amenable to linear closure. The side assigned to be closed with W-plasty will have the dog ear excised in a zig-zag fashion consistent with the W plasty flap design. Both sides of the wound will receive subcuticular closure with interrupted subdermal sutures as is the standard of care, followed by a standard running cuticular closure with absorbable suture material."
48181396|NCT03234946|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
48181397|NCT04650399|BIOLOGICAL|Active|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
48181398|NCT04650399|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
48181399|NCT00915577|DRUG|Interferon beta-1a|30mcg, IM once-a-week
48181400|NCT00915577|DEVICE|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
48181401|NCT00232219|DRUG|Fish oil|
48181402|NCT05592977|DEVICE|Intra-Oral Distalizing Device|The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
48382461|NCT00679042|BIOLOGICAL|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
48382462|NCT01068418|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
48718140|NCT05952401|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (patient smoking cessation handout and brief advice).
48718141|NCT05952401|BEHAVIORAL|"Nudges"|"Patients in the experimental arm will receive practice guidelines (patient smoking cessation handout and brief advice) and Nudges to Quit, guideline-informed messages immediately following patient tobacco treatment needs assessment."
48718142|NCT03256747|DEVICE|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
48718143|NCT03256747|DEVICE|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
48718144|NCT02804750|DRUG|CORT125134|
48718145|NCT03304067|BEHAVIORAL|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
48718146|NCT06266104|PROCEDURE|Image Enhanced Endoscopy Filters|Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).
48023804|NCT03930017|BIOLOGICAL|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
48023805|NCT04051892|DEVICE|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
48023806|NCT06536075|RADIATION|Sialoscintigraphy|Sialoscintigraphy
48382463|NCT03047889|DRUG|standard therapy|standard therapy for advanced/metastatic breast cancer
48382464|NCT03690206|DRUG|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
48382465|NCT03690206|DRUG|Placebo|Placebo for glepaglutide
48718147|NCT04621500|DRUG|cholecalciferol|Enrolled subjects will supplement with vitamin D3 at 4,000 IU daily for one year
48023807|NCT04602520|BEHAVIORAL|3 Wishes Project|Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
48718148|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq|RNA-seq analysis will be used to (a) identify changes in transcriptional profiles and biological pathways in the prostate between African American and Caucasian men and (b) compare Allostatic Load results to determine stress response and (c) identify changes in the molecular signature in relation to vitamin D levels
48718149|NCT04621500|PROCEDURE|Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation|Pathology results of the prostate biopsies will be analyzed for changes in the (a) Gleason Score (b) the number of positive cores (0 to 12) and (c) the highest percentage of positive core involvement (0 to 100%).
48718150|NCT04621500|DIAGNOSTIC_TEST|Allostatic Load Measurements at baseline and after one year vitamin D3 supplementation|Allostatic Load measurements to determine body stress compared at baseline and after one year of vitamin D3 supplementation. Also compared with RNA-seq results to determine stress response.
48718151|NCT03779503|DEVICE|midafilcon A|midafilcon A 1 day daily disposable contact lens
48718152|NCT03779503|DEVICE|somofilcon A|somofilcon A 1 day daily disposable contact lens
48718153|NCT04836988|OTHER|Three months of digitally delivered osteoarthritis treatment|Digitally delivered osteoarthritis management including education and exercise and weight control if needed
48718154|NCT04836988|OTHER|Three months of face-to-face delivered osteoarthritis treatment|Face-toface delivered osteoarthritis management including education and exercise and weight control if needed
48718155|NCT04863196|OTHER|Laser therapy Treatment Group|laser in gastric mucosa lesion
48718156|NCT04863196|OTHER|Barrier Dust Treatment Group|barrier powder in gastric mucosa lesion
48718157|NCT03406416|DEVICE|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
48718158|NCT06203067|BEHAVIORAL|Standard of Care|Quarterly clinic visits with endocrinology provider.
48718159|NCT06203067|BEHAVIORAL|Type 1 Together|In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.
48718160|NCT06516744|DIETARY_SUPPLEMENT|Bye Bye Bloat Capsules|Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
48718161|NCT03042260|DRUG|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
48382466|NCT06563661|OTHER|The 21-style specific dance exercises|The 21 dance styles (dance in a group), chosen and modified from seven dance styles, including cha-cha, jive, rumba, salsa, waltz, tango, and macarena, were developed by a group of experienced dance and rehabilitation experts and have been previously practised by a group of older adults in our pilot work, demonstrating good feasibility and positive participants' feedback.
48023808|NCT03383432|DEVICE|Intrauterine device|Copper T 380 A
48382467|NCT06650111|OTHER|Rereading of biopsies|Rereading of biopsies, blinded to the final diagnosis, by a pathologist specializing in nephropathology. This review includes: an optical microscopy study on a fragment fixed with routine staining, an optical microscopy study on a frozen fragment, an immunohistochemical study on a frozen fragment if available.
48718162|NCT03042260|DRUG|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
48718163|NCT00085332|DRUG|docetaxel|
48023809|NCT03383432|RADIATION|Ultrasound|Transabdominal ultrasound
48023810|NCT03383432|PROCEDURE|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
48023811|NCT05745857|DRUG|Avastin|Orally administered
48023812|NCT05745857|DRUG|Erbitux|Orally administered
48023813|NCT05745857|DEVICE|Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy|Fluorescent endoscope fiber and spectroscopy probe will be inserted through the working channel of the normal clinical therapeutic endoscope
48718164|NCT03023163|OTHER|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
48718165|NCT02501564|DRUG|Naproxen Sodium Codeine|One tablet twice a day
48718166|NCT02501564|DRUG|Placebo|One tablet twice a day
48718167|NCT05901805|OTHER|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
48519336|NCT06487793|BEHAVIORAL|Sleep hygiene comparator|Content is based on sleep hygiene practices, but without additional CBT-I content featured in the experimental condition. There is also not brief alcohol intervention content in the control condition.
48718168|NCT05867537|DIETARY_SUPPLEMENT|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
48718169|NCT05996809|DEVICE|Coseal|Adhesion reduction
48718170|NCT03529110|DRUG|Trastuzumab deruxtecan (T-DXd)|T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.
48382468|NCT06650111|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The clinical data of the care of patients at whom the biopsies belong will be analyzed until the date of the patient's last follow-up (before 12/31/2021).
48382469|NCT01607866|PROCEDURE|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
48382470|NCT01607866|PROCEDURE|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
48718171|NCT03529110|DRUG|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label.
48718172|NCT03734029|DRUG|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
48718173|NCT03734029|DRUG|Capecitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
48718174|NCT03734029|DRUG|Eribulin|Administered according to label, as one option for Physician's Choice (determined before randomization)
48718175|NCT03734029|DRUG|Gemcitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
48718176|NCT03734029|DRUG|Paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
48718177|NCT03734029|DRUG|Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
48718178|NCT02285530|DRUG|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle.
48382471|NCT01977924|DIETARY_SUPPLEMENT|one month polyphenols supplementation (600mg)|
48382472|NCT01977924|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|
48382473|NCT05775341|OTHER|No Intervention|This is purely an observational study.
48382474|NCT04410627|OTHER|HoPE Website|Educational website focused on hospice care
48382475|NCT01607398|DRUG|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
48382476|NCT01607398|DRUG|Placebo|Placebo inhalation, twice daily, from week0 -12.
48181403|NCT03708237|DRUG|Ropinirole|ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
48382477|NCT05354999|DIETARY_SUPPLEMENT|Sodium bicarbonate and caffeine|On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
48718179|NCT02285530|PROCEDURE|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
48718180|NCT02285530|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
48718181|NCT02857101|OTHER|dosage of calprotectin|
48718182|NCT06461728|DEVICE|a new prototye device that heat and activate sodium hyochlorite (Aseptico)|endoactivator : it is a sonic activator device
48718183|NCT01407523|DRUG|Levetiracetam|"* Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily"
48718184|NCT05390541|BEHAVIORAL|Empowered to Test Yourself|There will be 5 sessions of the intervention, all of which will follow the same format. Participants will be sent push notifications for each session. Each session will begin with using relevant constructs from sIMB (i.e., information and behavioral skills). Next, participants will choose positive outcomes resulting from the behavior, barriers to performing the behavior (mental contrasting), select situational cues and action plans to overcome selected barriers (implementation intentions), and practice typing in implementation intentions and positive outcomes from memory (memory practice). To ensure participants retain the implementation intentions, the investigators will use memory practice. Participants will be asked to self-code if the participant is correct or incorrect. Lastly, participants will learn behavioral skills to engage in each of the 5 actions to increase self-efficacy.
48718185|NCT05390541|OTHER|Educational Control|Participants will receive the HIV/STI home testing kit, instructions to mail in the kit, notification when results are ready to check online, treatment from a provider at Kind Clinic for positive results, and referral to Kind Clinic for PrEP. Each session and assessment will occur every 3 days. Session 1: Basic information about STIs. Session 2: HIV and stigma, basic information about HIV, and HIV transmission facts and myths. Session 3: Four stories about different people who are HIV-positive, how HIV was contracted, and one story about a woman who contracted herpes and how to all cope and live healthy lives. Session 4: How to disclose positive STI status. Session 5: Basic information about PrEP, and information on how to correctly use a male condom, female condom, and dental dam.
48718186|NCT00031018|DRUG|Aricept|
48718187|NCT00031018|DRUG|IFN-alpha2A|
48718188|NCT04639817|DRUG|Levofloxacin|Levofloxacin administration
48718189|NCT04639817|DRUG|trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole administration
48718190|NCT00948948|DEVICE|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~* Gel-filled device which is available in smooth surface and textured surface (Siltex®)~* Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
48718191|NCT04790487|DRUG|CPM|one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day
48718192|NCT04790487|DRUG|Placebo|Saline
48718193|NCT01471912|PROCEDURE|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
48718194|NCT03597282|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
48718195|NCT03597282|BIOLOGICAL|Nivolumab|monoclonal antibody against PD-1
48718196|NCT03597282|OTHER|Adjuvant|immune adjuvant
48718197|NCT03597282|BIOLOGICAL|APX005M|monoclonal agonist antibody against CD40
48382478|NCT00967707|DRUG|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
48181404|NCT03708237|DRUG|Gabapentin|GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
48382479|NCT00967707|DRUG|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
48519337|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
48519338|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
48718198|NCT03597282|BIOLOGICAL|ipilimumab|monoclonal antibody against CTLA4
48181405|NCT03708237|DRUG|Placebos|Opaque gel capsules filled with methylcellulose 1500 filler
48181406|NCT04444843|DRUG|Mycophenolate Mofetil Capsules|Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
48181407|NCT02106195|DRUG|Belumosudil|
48181408|NCT00959777|DRUG|DA-3031|
48181409|NCT00959777|DRUG|Filgrastim|
48181410|NCT00915083|DRUG|Amrubicin|40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
48023814|NCT05454293|OTHER|One Talk at a Time: Race|This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
48382480|NCT06545019|BEHAVIORAL|Informative Video on Perioperative Anxiety and Maternal Satisfaction|An informative video designed to address potential sources of perioperative anxiety and dissatisfaction during elective lower segment caesarean section under spinal anaesthesia. The video provides details about the procedure, expected sensations, and management of discomfort to enhance patient understanding and reduce anxiety. It is administered to the intervention group of patients scheduled for elective caesarean section, allowing them to view it on their personal devices before the surgery.
48382481|NCT03170271|DRUG|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
48382482|NCT03170271|DRUG|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
48181411|NCT05194475|OTHER|Thermogenic Ready-to-drink Beverage|Thermogenic ready-to-drink beverage, which will be ingested by the participant.
48382483|NCT06226064|DRUG|VES001|VES001 is an oral, blood brain barrier penetrating ligand of sortilin.
48382484|NCT06226064|DRUG|Placebo|A matching dosage form, indistinguishable from the active treatment will be used as the placebo treatment.
48382485|NCT06650436|DIAGNOSTIC_TEST|EEG|The phase lag index will be used to assess functional connectivity between time series based on the consistency with which one signal is leading or lagging with respect to another signal.The PLI characterizes the asymmetry in the distribution of instantaneous phase differences between signals. If such an asymmetry is present, a phase coupling is assumed between signals, reflecting synchronized activity. Importantly, zero-phase coupling is discarded in the PLI as this may represent activity from common sources picked up at different electrodes. Based on the MST, network measures can be calculated. It is a measure of network efficiency. Leaf fraction quantifies the fraction of nodes in the whole network that have only one connecting edge, which is a measure of network integration.
48519339|NCT04208100|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. The 595nm and 660nm wavelengths of the Lutronic PicoPlus Laser system are used for the treatment of benign pigmented lesions.
48023815|NCT05454293|OTHER|One Talk at a Time: General|This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
48023816|NCT03984266|DIAGNOSTIC_TEST|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
48023817|NCT01264302|DRUG|Finasteride|Finasteride Tablets 5 mg
48023818|NCT02540239|DRUG|2L PEG|
48023819|NCT02540239|DRUG|2L PEG+simethicone|
48023820|NCT05492318|DRUG|ITF2357 Givinostat 10mg/mL|Dose: 10 mg/mL; Dosage form: oral suspension
48023821|NCT05492318|DRUG|Midazolam 1Mg/Ml (Pf) Inj Syringe 5Ml|Dose: 1 mg/ml; Dosage form: solution for injection/infusion or rectal administration
48023822|NCT05492318|DRUG|Midazolam Oral Liquid Product|Dose: 2.5 mg; Dosage form: oromucosal solution
48023823|NCT05492318|DRUG|Dabigatran Etexilate 75 MG [Pradaxa]|Dose: 75 mg; Dosage form: hard capsules
48023824|NCT05492318|DRUG|Clarithromycin 500Mg Tab|Dose: 500 mg; Dosage form: immediate-release film-coated tablets
48023825|NCT01754558|PROCEDURE|Ajust system|The use of Ajust system for stress incontinence
48023826|NCT01754558|PROCEDURE|TVT/TVT-O|sling surgery
48718199|NCT04981028|OTHER|Questionnaires (including PHQ-9, TYM and SF-36)|For the acute group, a questionnaire is completed on neurological symptoms at presentation plus specific questions to include brain imaging performed, treatments received and whether they survived the hospital admission (AQ1). There will be a healthcare practitioner led questionnaire (AQ2) and 3 patient led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (AQ3) completed at 1 week, 1 month, 3 months, 6 months and 12 months following diagnosis. For the chronic TTP group, participants will have a questionnaire completed (CQ1) and 3 patient-led questionnaires (PHQ-9, TYM and SF-36) plus a supplementary questionnaire (CQ2). Where neurological symptoms are present, questionnaires will be completed 6 monthly; where there are no neurological symptoms questionnaires are completed every 12 months. The healthy volunteers will complete participant led questionnaires (namely PHQ-9, TYM, SF-36) plus a supplementary baseline questionnaire at two time points 12 months apart.
48023827|NCT01034124|DRUG|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
48023828|NCT00165724|DRUG|Donepezil Hydrochloride|
48382486|NCT06650436|DIAGNOSTIC_TEST|MRI|"Manual segmentation of the acute ischemic lesion will be performed on MRI of the brain. Support vector regression-based lesion symptom mapping (SVR-LSM) will be performed to determine the association between AIL location and PSD. We will also perform an assumption-free region of interest (ROI)-based analysis by using support vector regression. The ROIs will be determined by the AAL atlas and ICBM-DTI-81 white matter tract atlas in MNI-152 space.~The MRI's will be performed within 72 hours of the stroke onset with a follow-up of 12 months."
48718200|NCT04887389|DRUG|Nano Silver Fluoride varnish|Nano Silver Fluoride(5%) is a new experimental formulation containing silver nanoparticles, chitosan and fluoride combines preventive and antimicrobial properties. It is a yellow solution and safe to be used in humans
48718201|NCT04887389|DRUG|nano-hydroxyapatite varnish|nano-hydroxyapatite (10%) has antibacterial effect, higher solubility, surface energy and bioactivity and its structure is similar to dental apatite.
48718202|NCT04887389|DRUG|sodium Fluoride Varnish|Fluoride varnish (5%) applied every six months is effective in preventing caries in the primary and permanent dentition of children and adolescents
48718203|NCT05883358|DRUG|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
48718204|NCT01110798|OTHER|intraoperative complication management/prevention|
48718205|NCT01110798|PROCEDURE|assessment of therapy complications|
48023829|NCT02604589|DRUG|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
48023830|NCT02604589|PROCEDURE|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
48023831|NCT02604589|DRUG|bupivicaine 0.25%|Low Dose analgesia
48023832|NCT02604589|DRUG|bupivicaine 0.5%|High dose analgesia
48023833|NCT02073045|OTHER|educational intervention|Receive educational handouts
48023834|NCT02073045|OTHER|lymphedema survey|Ancillary studies
48023835|NCT05144191|DEVICE|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
48023836|NCT04442594|PROCEDURE|virtual reality session|"The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation."
48023837|NCT03042806|BEHAVIORAL|questionnaire|all the COPD patients will be ask to complete the questionnaire
48023838|NCT01204892|PROCEDURE|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
48023839|NCT01204892|PROCEDURE|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
48023840|NCT01658683|BEHAVIORAL|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
48023841|NCT02746692|OTHER|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
48023842|NCT02746692|OTHER|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
48382487|NCT06650436|DIAGNOSTIC_TEST|Depression screening and neuropsychological tests|"Screening post-stroke delirium (during first 72hours after stroke symptom onset):~4AT test score: 0-12 (\>/= 4: diagnosis of (post-stroke) delirium) RASS score: from -5 until +4 Screening post-stroke cognitive impairment (3months, 12 months): MOCA score: 0-30~Screening post-stroke depression:~Patient Health Questionnaire-2: score 0-6 Hospital Anxiety and Depression Scale: score 0-21Anxiety and 0-21Depression"
48718206|NCT01110798|PROCEDURE|gastrointestinal complications management/prevention|
48718207|NCT01110798|PROCEDURE|quality-of-life assessment|
48718208|NCT01110798|PROCEDURE|therapeutic conventional surgery|
48718209|NCT01243528|OTHER|Laboratory values|Laboratory values which represent nutritional status
48718210|NCT05760846|DEVICE|REAplan®|motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms
48718211|NCT05760846|DEVICE|Dextrain Manipulandum®|motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
48023843|NCT03574454|OTHER|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
48023844|NCT01465490|BEHAVIORAL|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
48023845|NCT02939222|DEVICE|Implant placement|Routine implant placement in the ideal three dimensional implant position
48718212|NCT06374186|BEHAVIORAL|Behavioral Intervention with financial rewards and coaching|Participants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual.
48023846|NCT01287442|PROCEDURE|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
48382488|NCT05793060|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine 50 Mcg
48382489|NCT05793060|DRUG|Dexamethasone Phosphate|Dexamethasone 4 mg
48382490|NCT00000868|BIOLOGICAL|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
48718213|NCT06374186|BEHAVIORAL|Control|Participants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual.
48718214|NCT04037150|DIAGNOSTIC_TEST|Circulating tumor DNA|Circulating tumor DNA
48023847|NCT04273958|DEVICE|Virtual reality helmet|During a painful procedure, the patient will watch a virtual world in a virtual reality helmet, while wearing a noise-canceling headset with soothing music.
48023848|NCT04273958|DEVICE|Computer screen|During a painful procedure, the patient will watch the same virtual world, while wearing a noise-canceling headset with the same soothing music.
48181412|NCT05194475|OTHER|Placebo Ready-to-drink Beverage|Placebo ready-to-drink beverage, which will be ingested by the participant.
48181413|NCT03533205|DIAGNOSTIC_TEST|Hypotension Probability Indicator|The accurary of the Hypotension Probability Indicator (HPI) is tested in the created offline database. This means data was prospectively collected but the HPI algorithm was not tested prospectively but after collection in the offline database.
48181414|NCT03105063|DIAGNOSTIC_TEST|ultrasound scan of the hip|validation of Ultrasound test as a tool for diagosing AIIS morphology
48382491|NCT00000868|BIOLOGICAL|Aluminum hydroxide|
48382492|NCT00000868|BIOLOGICAL|MF59|
48382493|NCT00000868|BIOLOGICAL|rgp120/HIV-1MN|
48382494|NCT06271109|PROCEDURE|Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically based on surgical anatomical segmentation of the liver
48382495|NCT06271109|PROCEDURE|Non-Anatomical laparoscopic liver resection for liver neoplasms|resection of liver tumors laparoscopically not based on surgical anatomical segmentation of the liver
48382496|NCT03623217|BEHAVIORAL|Qualitative interviews with participants|For the development and validation of a questionnaire.
48718215|NCT03125811|OTHER|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
48718216|NCT03125811|DRUG|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
48718217|NCT03632603|RADIATION|No intervention|No intervention during study period.
48718218|NCT01650415|DRUG|Erythropoietin|twice a week for 1 month
48718219|NCT01650415|DRUG|Placebo erythropoietin|twice a week for 1 month
48718220|NCT05786365|DRUG|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
48718221|NCT00329615|DRUG|Insulatard, flexpen|
48718222|NCT04315636|DRUG|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
48718223|NCT01797380|DRUG|Placebo|Placebo daily for duration of double-blind portion of trial
48718224|NCT01797380|DRUG|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
48718225|NCT02230371|DRUG|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
48718226|NCT02230371|DRUG|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
48718227|NCT01635764|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
48718228|NCT05696574|DRUG|Vaginal Misoprostol|Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
48718229|NCT05696574|DRUG|Oral Misoprostol|Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
48718230|NCT04258995|BIOLOGICAL|Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)|2 formulations at 1 dose level
48519340|NCT06115525|OTHER|mNUTRIC score|The mNUTRIC score is a useful means of gauging the nutritional risk of patients in intensive care. Originally designed for IC unit patients, the score is calculated even when patient cooperation is unfeasible, making it applicable for intubated patients. Information necessary for calculation can be obtained from the patient's kin. The mNUTRIC score (without IL-6) classifies patients according to predefined metrics. The following information is necessary: (1) the patient's age, (2) their APACHE II score, (3) their SOFA score, (4) their comorbidities, and (5) the number of days they were hospitalized before being admitted to ICU.
48023849|NCT06364046|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
48181415|NCT02491710|DEVICE|Training on low-cost box trainer|
48718231|NCT00011011|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
48718232|NCT02406443|DRUG|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
48718233|NCT02406443|OTHER|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
48718234|NCT03795090|COMBINATION_PRODUCT|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
48718235|NCT03795090|COMBINATION_PRODUCT|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
48718236|NCT01978626|BEHAVIORAL|App modules|
48718237|NCT01978626|BEHAVIORAL|Traditional CBT-I|
48718238|NCT03785951|DIETARY_SUPPLEMENT|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
48718239|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
48718240|NCT03785951|DIETARY_SUPPLEMENT|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
48718241|NCT03266913|DRUG|Probiotic|Probiotics drop
48718242|NCT02137187|PROCEDURE|AV junction ablation|AV junction ablation
48718243|NCT02137187|DEVICE|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
48718244|NCT02137187|DRUG|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
48718245|NCT02137187|DEVICE|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
48718246|NCT01929538|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography
48718247|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 12mm in diameter|
48718248|NCT01929538|DEVICE|covered self-expanding biliary metal stent, 10mm in diameter|
48718249|NCT02706028|DEVICE|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
48718250|NCT02706028|DEVICE|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
48718251|NCT05736939|OTHER|Out-patient Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.
48718252|NCT02525094|BIOLOGICAL|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
48718253|NCT02525094|BIOLOGICAL|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
48718254|NCT02706561|BEHAVIORAL|questionnaires|
48718255|NCT02706561|BEHAVIORAL|three in-person sessions|
48718256|NCT02706561|BEHAVIORAL|monthly phone calls|
48718257|NCT02706561|BEHAVIORAL|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
48718258|NCT02706561|BEHAVIORAL|Enhanced Monitoring and Education (EME)|
48718259|NCT03432416|DRUG|NES-E2 CVR|NES-E2 CVR
48718260|NCT02525991|DEVICE|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
48718261|NCT04860622|DIAGNOSTIC_TEST|Serum thyroid function tests|At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
48718262|NCT02162212|OTHER|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
48718263|NCT02162212|OTHER|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c \< 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is \<130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
48718264|NCT05793034|DIAGNOSTIC_TEST|Biological biomarker assessment|IHC, PCR, NGS, methylome
48718265|NCT01048450|RADIATION|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
48718266|NCT01048450|PROCEDURE|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
48718267|NCT01048450|PROCEDURE|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
48718268|NCT00005079|PROCEDURE|conventional surgery|
48718269|NCT02642146|DRUG|Calcium Channel Blockers|
48718270|NCT02642146|DRUG|Phosphodiesterase Inhibitors|
48718271|NCT02642146|DRUG|Endothelin receptor blocker|
48718272|NCT02642146|DRUG|Prostanoids|
48718273|NCT02642146|DRUG|Other vasodilator|
48181416|NCT02491710|DEVICE|Training on standard box trainer|
48718274|NCT05069207|OTHER|POWER breathe K5|Maximum inspiratory pressure (MIP) and volume (Volume (V)) parameters will be evaluated with the POWER breathe K5 to evaluate
48718275|NCT02995044|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
48718276|NCT02995044|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
48718277|NCT06239090|DEVICE|Rehacor-T|During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
48718278|NCT06239090|BEHAVIORAL|Sham Intervention|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
48382497|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
48718279|NCT03234296|DRUG|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
48519341|NCT06115525|OTHER|NRS-2002|The NRS-2002 score is a tool utilised to measure the nutritional risk of patients in intensive care units. This tool was specifically developed for the purpose of evaluating intensive care unit patients and can be calculated without requiring the patient's active involvement. Additionally, it can be applied to patients who have been intubated and the required information can be sourced from their family members or relatives. The Nutritional Risk Screening (NRS)-2002 assesses a patient's nutritional risk based on five variables: (1) recent unexplained weight loss, (2) appetite, (3) BMI, (4) disease-related stress factors (comorbidities), and (5) age over 70 years which is an additional risk factor.
48519342|NCT06582329|DRUG|Alfa1 Antitrypsin|Participants will be treated intravenously with A1AT 120 mg/kg bodyweight once a week for 4 weeks (4 total infusions).
48718280|NCT03234296|OTHER|Placebo|Intravenous placebo followed by per oral placebo
48718281|NCT04407104|DIAGNOSTIC_TEST|skin prick-test|retrospective study on data already collected
48382498|NCT00446134|DRUG|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
48718282|NCT00113750|BIOLOGICAL|TreeMATA MPL|
48718283|NCT00641342|DEVICE|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
48718284|NCT00984607|PROCEDURE|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
48718285|NCT02534116|PROCEDURE|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
48718286|NCT02534116|PROCEDURE|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
48718287|NCT03693339|DRUG|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
48718288|NCT04905355|DEVICE|Virtual reality|The VR used during the ambulatory orthopedic surgery allows immersive experience in HD-2D virtual environment. Patient can choose among movies, cartoons, entertainments offered for visualization during the surgery
48718289|NCT02119156|DRUG|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
48718290|NCT05302141|BEHAVIORAL|Wear 3D printing assistive device|"Wear 3D printing aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
48718291|NCT05302141|BEHAVIORAL|Wear universal cuff device|"Wear universal cuff aids and engage in functional tasks, including eating, typing, and writing.~At home: use daily, 30 minutes each time; Treatment room: 30 minutes twice a week"
48718292|NCT03577392|DRUG|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
48718293|NCT03577392|DRUG|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
48718294|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
48718295|NCT04801888|BIOLOGICAL|Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.|The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
48718296|NCT03345719|DIAGNOSTIC_TEST|3D Cone-Beam Imaging|
48718297|NCT02127294|DEVICE|transcatheter patent foreman ovale closure|
48718298|NCT03371173|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
48718299|NCT04036994|DEVICE|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions three times a week for the total duration of 12 weeks starting at their last CT administration.
48718300|NCT01972685|PROCEDURE|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
48718301|NCT01972685|PROCEDURE|Transbronchial Biopsy|
48718302|NCT01972685|PROCEDURE|VATS biopsy|
48718303|NCT01288612|DEVICE|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
48718304|NCT01288612|DEVICE|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
48718305|NCT03839836|OTHER|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
48718306|NCT03384823|DRUG|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
48718307|NCT03384823|DRUG|Placebo|placebo to match EDP-938
48718308|NCT06328452|DEVICE|FibroScan|All the study population will be submitted to Fibroscan examination with CAP (Echosens FibroScan® Compact 530). To evaluate steatosis and fibrosis, participants will be asked to fast for at least 3 hours before the test. To capture a controlled attenuation parameter (CAP) score and liver stiffness measurement (LSM), 10 valid scans per subject will be needed.
48718309|NCT05216055|COMBINATION_PRODUCT|Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline|Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL
48718310|NCT05216055|DRUG|Liposomal bupivacaine|Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
48718311|NCT02333890|DRUG|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
48718312|NCT02333890|DRUG|Placebo|
48718313|NCT01058135|OTHER|Hi-maize starch (Low dose)|resistant starch
48718314|NCT01058135|OTHER|Hi-maize starch (High-dose)|resistant starch
48718315|NCT01058135|OTHER|Control (starch)|rapidly digestible starch
48718316|NCT00690170|DRUG|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
48718317|NCT00690170|DRUG|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
48718318|NCT00690170|DRUG|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
48718319|NCT00690170|DRUG|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
48382499|NCT00446134|DRUG|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
48382500|NCT00446134|DRUG|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
48382501|NCT06506669|PROCEDURE|Oral sedation|Oral medication for anxiolysis administered in the preoperative setting
48382502|NCT06506669|PROCEDURE|Placebo|A placebo pill with no active ingredients administered in the preoperative setting
48382503|NCT05744388|DEVICE|Gliderite® shape modification|The stylet will be more obtuse angle than the standard shape. The stylet will be lubricated also before being fitted inside the endotracheal tube. The blade will be introduced inside the mouth midline, the tube will be held from the upper third and introduced in the midline also sliding over the blade and introduced inside the glottis.
48382504|NCT01356290|DRUG|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
48382505|NCT01356290|DRUG|Thalidomide|3mg/kg, oral, daily, 1 year
48382506|NCT01356290|DRUG|Celecoxib|50-400mg, oral bid, daily, 1 year
48382507|NCT01356290|DRUG|Fenofibric acid|90mg/m2, oral, daily, 1 year
48382508|NCT01356290|DRUG|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
48382509|NCT01356290|DRUG|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
48382510|NCT01356290|DRUG|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
48382511|NCT01356290|DRUG|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
48382512|NCT04837586|OTHER|Standard Care|Individuals will receive standard care for their obesity through the Pediatric Weight Management Clinic.
48382513|NCT04837586|DEVICE|Simple Scale|Individuals will be encouraged to perform daily weighing at home on a simple scale.
48382514|NCT04837586|DEVICE|EHR-Connected Scale|Individuals will be encouraged to perform daily weighing at home on a Smart scale that connects to the EHR. Clinic staff will review weight entries in the EHR and provide feedback.
48382515|NCT04607772|DRUG|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
48718320|NCT01046240|DRUG|Palonosetron|Palonosetron 3 mg administered SC or IV
48718321|NCT04947306|DEVICE|Tetragraph® (Senzime, Uppsala, Sweden)|The Tetragraph® is a recently marketed electromyographic neuromuscular monitor that uses a disposable electrode array (TetraSens) that combines stimulating and recording electrodes
48718322|NCT04947306|DEVICE|TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)|The TOF Watch® SX is a common used neuromuscular monitor
48382516|NCT04607772|DRUG|Rituximab|Dose: 375 mg/m\^2
48382517|NCT04607772|DRUG|Bendamustine|Dose: 90 mg/m\^2
48382518|NCT04607772|DRUG|Polatuzumab Vedotin|Dose: 1.8 mg/kg
48382519|NCT04607772|DRUG|Ibrutinib|Dose: 420, 560 mg
48382520|NCT04607772|DRUG|Lenalidomide|Dose: 20, 25 mg
48382521|NCT04607772|DRUG|Tafasitamab|Dose: 12 mg/kg
48382522|NCT04607772|DRUG|Venetoclax|Dose: 200, 400, 600, 800 mg
48382523|NCT04607772|DRUG|Gemcitabine|Dose: 1000 mg/m\^2
48382524|NCT04607772|DRUG|Oxaliplatin|Dose: 100 mg/m\^2
48382525|NCT00359073|DRUG|montelukast|10 mg everyday
48382526|NCT00359073|DRUG|placebo|like placebo
48382527|NCT03779282|DRUG|Dexmedetomidine|see descriptions
48382528|NCT06007378|OTHER|Bupivacaine and ketamine|Bilateral erector spinae plane block (bupivacaine and ketamine)
48382529|NCT06007378|OTHER|Bupivacaine and transdermal fentanyl patch|Bilateral erector spinae plane block (bupivacaine) and transdermal fentanyl patch
48382530|NCT06007378|OTHER|Bupivacain|Bilateral erector spinae plane block (bupivacaine)
48382531|NCT06467305|DEVICE|continuous theta-burst stimulation (cTBS)|Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
48181417|NCT02484547|DRUG|Aducanumab (BIIB037)|Low dose
48181418|NCT02484547|DRUG|Aducanumab (BIIB037)|High dose
48382532|NCT06467305|BEHAVIORAL|Adaptation|Auditory adaptation in speech
48382533|NCT02002949|PROCEDURE|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
48718323|NCT04515953|DRUG|ND-340|ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.
48718324|NCT04515953|DRUG|IV-PCA|IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
48718325|NCT02813395|DEVICE|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
48718326|NCT02813395|DEVICE|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
48718327|NCT00657150|DRUG|Enoxaparin|40 mg once daily
48718328|NCT00657150|DRUG|Dabigatran etexilate|220 mg once daily
48718329|NCT00236392|DRUG|rabeprazole|
48718330|NCT03123614|DRUG|Loteprednol Etabonate 0.5% Oph Gel|
48718331|NCT03123614|DRUG|Prednisolone Acetate 1% Oph Susp|
48718332|NCT04570683|DRUG|Nivolumab 10 MG/ML|Se previously
48718333|NCT04570683|DEVICE|Ablative fractionated laser|Se previously
48718334|NCT00624780|DRUG|Pregabalin|Pregabalin 150-300 mg given twice a day
48718335|NCT00624780|DRUG|Lorazepam|Lorazepam 3-4 mg given twice a day
48718336|NCT00624780|DRUG|Pregabalin|Pregabalin 450-600 mg given twice a day
48718337|NCT00624780|DRUG|Placebo|Placebo
48718338|NCT04788771|PROCEDURE|Tracheal intubation in laparoscopic extraperitoneal hernia repair|laryngeal mask airway in laparoscopic extraperitoneal hernia repair
48718339|NCT04485195|DRUG|Vernakalant|an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
48718340|NCT04485195|DRUG|Procainamide|15 mg/kg in 500 mL of normal saline given over 60 minutes
48718341|NCT05453162|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
48718342|NCT05123404|DIAGNOSTIC_TEST|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
48718343|NCT05123404|PROCEDURE|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
48718344|NCT02046694|DRUG|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
48718345|NCT00242333|DRUG|AD 237|
48718346|NCT06175351|DRUG|9MW1911|Participants will receive IV 9MW1911 every 4 weeks.
48718347|NCT06175351|DRUG|Placebo|Participants will receive IV placebo every 4 weeks.
48718348|NCT03323736|COMBINATION_PRODUCT|Iontophoresis & tube placement|Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.
48718349|NCT03323736|DEVICE|Tube placement|Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
48718350|NCT04528615|BEHAVIORAL|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
48718351|NCT04528615|BEHAVIORAL|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
48718352|NCT06463353|OTHER|trilinolein cream group|Apply trilinolein cream evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
48181419|NCT02484547|DRUG|Placebo|Placebo
48181420|NCT04962451|DRUG|ticagrelor + ASA|On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
48382534|NCT02002949|PROCEDURE|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
48181421|NCT04962451|DRUG|Placebo+ASA|Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
48181422|NCT01176461|BIOLOGICAL|MART-1|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
48181423|NCT01176461|BIOLOGICAL|NY-ESO-1|NY-ESO-1 peptide vaccine
48181424|NCT01176461|BIOLOGICAL|gp100:209-217(210M)|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
48181425|NCT01176461|BIOLOGICAL|gp100:280-288(288V)|gp100:280-288(288V) peptide vaccine
48718353|NCT06463353|OTHER|cream base group|Apply cream base evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
48718354|NCT02677844|DRUG|Abemaciclib|Administered orally
48023850|NCT06364046|DRUG|Serplulimab|Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
48023851|NCT06364046|PROCEDURE|Intravenous chemotherapy|Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
48023852|NCT05759091|BEHAVIORAL|cognitive defusion techniques|"Defusing from your delusions helps to lessen their negative impact on your behaviour. So defusion is a vital step towards being able to act flexibly, in accordance with core values, instead of being dictated to by inflexible rules, reasons, judgments etc. There are numerous exercises in ACT Companion with a focus on identifying unhelpful thoughts which would benefit from defusion, or building defusion skills, most of which are found in the open up section of the app. Some of these are reading and writing exercises, and some are guided meditation audio recordings.~ACT Companion defusion exercises~1. Letting go~2. Not good enough~3. Thought defusion~4. Observing your thoughts~5. Labelling thoughts and feelings~6. I am having the thought that.....~7. milk.milk.milk exercise~8. silly voice exercise, passenger on the bus, tug of war with a monster"
48718355|NCT02677844|DRUG|Placebo|Administered orally
48718356|NCT02677844|DRUG|Loperamide|Administered orally
48023853|NCT04499157|DRUG|MEMOPTIC|Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
48023854|NCT04499157|DRUG|usual treatment of glaucoma|Patients will receive only their usual treatment of glaucoma.
48023855|NCT00322062|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
48718357|NCT01011972|DRUG|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
48718358|NCT03462186|OTHER|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
48023856|NCT00322062|DRUG|Sodium Phosphate Solution|1 x 45ml solution, BID
48181426|NCT01176461|DRUG|Montanide ISA 51 VG|Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
48718359|NCT04353219|DEVICE|compression stocking|participants will continue their training program as prepared by their coach with compression stocking
48718360|NCT04353219|OTHER|control|participants will continue their training program as prepared by their coach without compression stocking
48718361|NCT00771797|DIETARY_SUPPLEMENT|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
48718362|NCT00771797|DIETARY_SUPPLEMENT|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
48718363|NCT02159677|DEVICE|EIM Measurements|
48519343|NCT03220854|RADIATION|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
48718364|NCT02042534|DRUG|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
48718365|NCT02042534|DRUG|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
48718366|NCT03458702|BEHAVIORAL|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)\], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
48718367|NCT03458702|BEHAVIORAL|Quiet Rest|Participants completed 30 min of quiet rest
48718368|NCT02250664|OTHER|Very low nicotine content cigarettes|Very low nicotine content cigarettes
48718369|NCT02631733|DRUG|Ferumoxytol|Given IV
48718370|NCT02631733|DRUG|Irinotecan Sucrosofate|Given IV
48718371|NCT02631733|OTHER|Laboratory Biomarker Analysis|Correlative studies
48718372|NCT02631733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48718373|NCT02631733|DRUG|Veliparib|Given PO
48718374|NCT06349135|PROCEDURE|Open Reduction & Internal Fixation|Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
48718375|NCT01075971|DRUG|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
48718376|NCT01075971|DRUG|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
48718377|NCT06376071|DIAGNOSTIC_TEST|functional endoscopic sinus surgery|functional endoscopic sinus surgery for diagnosis the disease
48718378|NCT01169584|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
48718379|NCT01656369|PROCEDURE|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
48718380|NCT01656369|PROCEDURE|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
48718381|NCT01362452|GENETIC|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
48181427|NCT01176461|BIOLOGICAL|BMS-936558|BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
48382535|NCT06034301|DEVICE|Medication Reminder App|"If the participant is randomized to the intervention group, they will:~1. receive a brief education session and be handed a flyer about the importance of medication adherence.~2. get training on how to use the medication reminder app and participant will be given a user guide on how to use the app~3. demonstrate their understanding on an iPad using the teach back method~4. install and set up the medication reminder app on their phone~5. receive a MEMS cap and be given instructions on how to use it with their blood pressure medication. Study team members will use a participant ID to log into the MEMS cap application; no identifiable information will be entered."
48382536|NCT00502749|BEHAVIORAL|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
48718382|NCT01362452|PROCEDURE|Cord Blood Infusion|Cord blood infusion on Day 0.
48181428|NCT01562106|PROCEDURE|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
48382537|NCT00502749|BEHAVIORAL|Questionnaires|Questionnaires taking 15 minutes to complete.
48382538|NCT02181127|DEVICE|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
48382539|NCT00249327|BEHAVIORAL|education|
48181429|NCT00198003|BEHAVIORAL|Educational program to address patients' expectations|
48382540|NCT05233397|DRUG|Tocilizumab|For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
48382541|NCT02466776|DEVICE|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean delivery (CD).
48382542|NCT02466776|DEVICE|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean delivery (CD).
48382543|NCT01431807|DRUG|SYR-472|oral, for up to 52 weeks.
48382544|NCT04800159|DRUG|THC Cannabis|Vaporization of cannabis
48382545|NCT04800159|DRUG|CBD Cannabis|Vaporization of cannabis
48382546|NCT04800159|DRUG|Placebo|Vaporization of placebo
48382547|NCT06566053|OTHER|Observation|Observation
48382548|NCT01600755|BIOLOGICAL|Iltamiocel|Single intrasphincteric injection of iltamiocel at a dose of 250 x 10\^6 cells
48382549|NCT04928599|OTHER|Electronic Health Record Review|Review of medical records
48382550|NCT04928599|OTHER|Interview|Complete interview
48382551|NCT04928599|OTHER|Survey Administration|Complete survey
48718383|NCT05665049|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
48718384|NCT04129710|DRUG|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
48718385|NCT04129710|DRUG|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
48718386|NCT04129710|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
48718387|NCT04129710|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
48718388|NCT04129710|DRUG|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
48181430|NCT01158989|DEVICE|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
48382552|NCT06617546|DRUG|FTX-101|Lyophilized powder for subcutaneous or intravenous injection
48382553|NCT06617546|DRUG|Placebo|Lyophilized powder for subcutaneous or intravenous injection
48382554|NCT06652841|DEVICE|transShield Embolic Protection System|Patient undergoing TAVR procedure will receive the transShield EPS with the intent to capture and remove debris dislodged during the interventional procedure.
48718389|NCT04129710|DRUG|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
48382555|NCT06634420|BIOLOGICAL|NTLA-2002|CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration
48382556|NCT06634420|BIOLOGICAL|Normal Saline IV Administration|The administration of intravenous (IV) normal saline
48382557|NCT03007615|OTHER|Intimate Lubricant Gel|
48382558|NCT00663039|DRUG|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
48382559|NCT00663039|DRUG|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
48718390|NCT05977452|DIAGNOSTIC_TEST|Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale|Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
48181431|NCT04662437|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing|From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
48181432|NCT00636480|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
48181433|NCT00636480|DRUG|ChloraPrep One Step|Administer topically
48181434|NCT00636480|DRUG|Sterile saline|0.9% NaCl solution
48181435|NCT05323630|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
48181436|NCT01928238|DEVICE|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
48181437|NCT01928238|DEVICE|Noninvasive pressure support ventilation (NPSV)|
48181438|NCT04539483|DRUG|HDIT101 (blinded therapy)|Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
48181439|NCT04539483|DRUG|Placebo (blinded therapy)|Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
48181440|NCT04539483|BEHAVIORAL|Photo documentation of orolabial herpes lesions|Patients will be asked to document their orolabial lesions with photos by using their smart phone
48181441|NCT04539483|BEHAVIORAL|Completion of questionnaires (patient-reported outcomes)|Patients will be asked to document their health status in questionnaires by using their smart phone
48718391|NCT00403533|DRUG|20 mg of atorvastatin daily|
48718392|NCT03869333|BIOLOGICAL|Invaplex[AR-DETOX]|Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex\[AR-Detox\]) Vaccine
48718393|NCT03869333|OTHER|Placebo|Saline
48718394|NCT02499692|DEVICE|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
48718395|NCT03505736|BIOLOGICAL|Adenosine|Given IV
48718396|NCT03505736|PROCEDURE|Magnetic Resonance Imaging|Undergo CMR imaging
48718397|NCT03505736|DRUG|Regadenoson|Given IV
48718398|NCT03505736|PROCEDURE|Stress Management Therapy|Undergo stress test
48718399|NCT05957614|PROCEDURE|Traditional rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture, including immobilization, early weightbearing ankle motion exercise and isolated early ankle motion exercises.
48181442|NCT04539483|PROCEDURE|28-day swabbing of orolabial region|Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
48181443|NCT04539483|PROCEDURE|Blood drawings|Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
48181444|NCT01657799|DRUG|Veliparib|Veliparib capsules for oral administration
48181445|NCT01657799|DRUG|Placebo|Placebo to veliparib capsules for oral administration
48181446|NCT01657799|RADIATION|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
48181447|NCT01179503|DIETARY_SUPPLEMENT|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
48181448|NCT01179503|DIETARY_SUPPLEMENT|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
48181449|NCT01511497|BIOLOGICAL|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
48181450|NCT01511497|OTHER|Normal saline|Intravenous, normal saline
48181451|NCT02016378|BEHAVIORAL|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
48382560|NCT06567886|DEVICE|Light Therapy|"Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy."
48181452|NCT02016378|BEHAVIORAL|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
48382561|NCT06567886|BEHAVIORAL|Sleep Stabilization|All participants will be asked to follow a fixed sleep schedule.
48382562|NCT04895748|DRUG|DFF332|Hif2alpha inhibitor
48382563|NCT04895748|DRUG|RAD001|mTOR inhibitor
48718400|NCT05957614|PROCEDURE|Acupuncture-assisted Rehabilitation Protocol|Add acupuncture treatment on the basis of traditional rehabilitation protocol.The acupuncture procedure is as follows, acupuncture treatment is carried out for half an hour every day in two weeks after surgery. The acupoints on the affected side are ST36(ZuSanLi), GB34(YangLingQuan) and SP9(YinLingQuan), and the acupoints on the healthy side are Ki3(TaiXi), bl60(KunLun) and PC7(DaLing).
48718401|NCT04787068|BEHAVIORAL|Occupational Therapy support|Intervention include (a) didactic education about diseases; (b) the use of errorless techniques to improve assistance for CR's Activities of Daily Living (ADL), Instrumental ADL, and communication tasks; (c) the use of incentives (e.g., providing a favorite scented shampoo); (e) use of a schedule/calendar on a computer, cell phone and/or blackboard in CR's home to coordinate caregiving tasks for family members; (f) suggesting more frequent PACE daycare visits or use of a nearby PACE, having a snack or short game to prevent going to bed right after dinner); (d) use of the Buffalo Functional Exercise for strengthening ( a home-based exercise developed for PACE by the PI and shown to be effective in preventing falls)
48718402|NCT01751776|DRUG|Placebo matching BI 655064|Placebo matching BI 655064 injected subcutaneous.
48718403|NCT01751776|DRUG|BI 655064|BI 655064 injected subcutaneous
48718404|NCT04340440|PROCEDURE|D1 lymphadenectomy|Radical gastrectomy with D1 lymphadenectomy
48718405|NCT04340440|PROCEDURE|D2 lymphadenectomy|Radical gastrectomy with D2 lymphadenectomy
48718406|NCT04846530|DEVICE|RHA® 1, RHA® 2, RHA® 3, and RHA® 4|For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
48181453|NCT01752010|OTHER|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
48181454|NCT01752010|DEVICE|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
48181455|NCT01752010|DEVICE|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
48382564|NCT04895748|DRUG|PDR001|anti-PD-1
48718407|NCT05860491|OTHER|dietary fiber|Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
48718408|NCT02723890|DEVICE|Tyto Device|
48718409|NCT02606266|DRUG|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
48718410|NCT02406352|DEVICE|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
48718411|NCT05440136|DRUG|LY3462817 (SC)|Administered SC.
48718412|NCT05440136|DRUG|Placebo (SC)|Administered SC.
48519344|NCT03220854|OTHER|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
48718413|NCT05440136|DRUG|LY3462817 (IV)|Administered IV.
48718414|NCT05440136|DRUG|Placebo (IV)|Administered IV.
48718415|NCT05480449|BIOLOGICAL|Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)|The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
48718416|NCT00215215|DEVICE|Vagus Nerve Stimulation Therapy|
48718417|NCT01282294|DEVICE|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
48382565|NCT04895748|DRUG|NIR178|Adenosine A2A antagonist receptor
48718418|NCT02554214|DEVICE|Glafkos drainage device|
48718419|NCT01071356|BEHAVIORAL|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
48718420|NCT01071356|BEHAVIORAL|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
48023857|NCT04509531|BEHAVIORAL|Wise Intervention (SA, ITP and resilience)|The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
48023858|NCT04509531|BEHAVIORAL|Standard preventive intervention|The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
48023859|NCT03153332|OTHER|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
48023860|NCT04574895|OTHER|Hematology Review|VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
48023861|NCT02473952|DRUG|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
48023862|NCT02473952|DRUG|Placebo|
48181456|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from animal sources.|Diet was prescribed to the participant and menus and recipes were also provided.
48181457|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from plant sources.|Diet was prescribed to the participant and menus and recipes were also provided.
48181458|NCT03564197|OTHER|18F-PD-L1|18F-PD-L1 PET/CT scan
48718421|NCT02130986|OTHER|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
48382566|NCT03878056|DEVICE|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
48382567|NCT03176927|DIAGNOSTIC_TEST|magnetogastrogram|
48382568|NCT03505606|DIAGNOSTIC_TEST|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
48382569|NCT05188274|DIETARY_SUPPLEMENT|T92|T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
48382570|NCT05188274|DIETARY_SUPPLEMENT|Placebo|The placebo matched to T92 granules will be taken BID for 8 weeks.
48519345|NCT03220854|OTHER|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
48519346|NCT03270969|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
48718422|NCT02130986|OTHER|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.
48718423|NCT02130986|OTHER|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~\> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~\> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (\> 0.25-0.5 ug/L:3 days; \> 0.5-1.0 ug/L:5 days; \>1.0 ug/L:7 days). Physician follow-up is recommended."
48718424|NCT02130986|OTHER|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
48718425|NCT05694715|DRUG|Niraparib|Given orally
48718426|NCT05694715|DRUG|Irinotecan|Given intravenously (IV)
48718427|NCT05338203|OTHER|tandem breastfeedıng|mother mılk wıll collected from mothers and they wıll be analyzed in laboratuar.
48181459|NCT02531854|DRUG|ADXS11-001|ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.
48181460|NCT02531854|DRUG|Pemetrexed|Chemotherapy
48718428|NCT00001724|DRUG|Flurbiprofen|
48181461|NCT05559632|PROCEDURE|osteotomy for implant placement|preparing the bone for implant placement
48718429|NCT03132025|DRUG|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
48718430|NCT03132025|DRUG|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
48181462|NCT01013142|DRUG|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
48718431|NCT00989391|DRUG|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
48718432|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
48718433|NCT00989391|DRUG|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
48718434|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
48718435|NCT00989391|DRUG|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
48718436|NCT00989391|DRUG|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
48718437|NCT03419390|DEVICE|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
48718438|NCT03187834|DRUG|Azithromycin|Children in this arm will receive Azithromycin once a day.
48718439|NCT03187834|DRUG|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
48718440|NCT03187834|DRUG|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
48718441|NCT03187834|DRUG|Placebo|Children in this arm will receive Placebo once a day.
48718442|NCT01902459|BIOLOGICAL|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
48718443|NCT01902459|OTHER|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
48181463|NCT01013142|DRUG|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
48181464|NCT01013142|DRUG|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
48718444|NCT04340193|DRUG|nivolumab|Specified dose on specified days
48718445|NCT04340193|DRUG|ipilimumab|Specified dose on specified days
48181465|NCT05050526|BEHAVIORAL|Real-time videoconference-based Exercise program|12-week exercise program consisting of two weekly 45 minute group-based sessions, remotely supervised by a professional via real-time videoconference. Each session will consist of a warm-up (5-10 min), general strengthening (30 min) and cool-down (5-10 min). Warm-up will include general joint mobility and exercises focused on increasing heart rate. General strengthening will include 4 series of 6 exercises (2 for lower limb, 2 for upper limb and 2 for the trunk) performed with minimal equipment, combining body-weight and elastic-band exercises. Three difficulty levels will be set for each of the exercises, and progression will be made at weeks 5 and 9. Participants will be asked to work in a given rate of perceived exertion (between 3 and 5 in Borg's CR10 scale) and not to reach failure in any of the exercises. Cool-down will include stretching and breathing/relaxing exercises.
48181466|NCT04236232|DIAGNOSTIC_TEST|Thyroid function|Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
48023863|NCT01501318|BEHAVIORAL|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
48023864|NCT01501318|BEHAVIORAL|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
48023865|NCT03923634|DEVICE|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
48023866|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate|Zinc Picolinate (50 mg PO TID x 5 days)
48023867|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2 grams po BID x 5 days
48023868|NCT04542993|DIETARY_SUPPLEMENT|Zinc Picolinate Placebo|Zinc Picolinate Matched Placebo PO TID x 5 days
48718446|NCT04340193|PROCEDURE|TACE|TACE (Trans-arterial ChemoEmbolization)
48718447|NCT04272333|DRUG|Motolimod|Intratumoral microdose injection by the CIVO device.
48718448|NCT04272333|BIOLOGICAL|Nivolumab|Intratumoral microdose injection by the CIVO device.
48718449|NCT04272333|COMBINATION_PRODUCT|Motolimod + Nivolumab|Intratumoral microdose injection by the CIVO device.
48718450|NCT03974737|DEVICE|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
48718451|NCT06286826|PROCEDURE|Postero-lateral thoracotomy|this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture
48718452|NCT06286826|PROCEDURE|Minithoracotomy|Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)
48718453|NCT02624336|OTHER|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
48718454|NCT02624336|OTHER|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
48718455|NCT02624336|OTHER|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
48718456|NCT00663286|DRUG|IDP-110|Topical application for 12 weeks
48718457|NCT00663286|DRUG|Clindamycin|Topical application for 12 weeks
48718458|NCT00663286|DRUG|Benzoyl peroxide|Topical application for 12 weeks
48181467|NCT04596605|OTHER|T2309|Food for Special Medical Purpose / 4 capsules daily for 12 weeks
48023869|NCT04542993|DIETARY_SUPPLEMENT|Resveratrol Placebo|Resveratrol Matched Placebo PO BID x 5 days
48023870|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type A mouldable adhesive|
48023871|NCT01782196|DEVICE|Enhanced one piece drainable pouch with Type B mouldable adhesive|
48023872|NCT02390804|DEVICE|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
48023873|NCT02390804|DEVICE|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
48023874|NCT02723617|OTHER|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
48519347|NCT04817618|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
48519348|NCT04817618|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
48718459|NCT00663286|DRUG|Vehicle|Topical application for 12 weeks
48023875|NCT02723617|OTHER|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
48023876|NCT02723617|OTHER|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
48023877|NCT02723617|OTHER|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
48023878|NCT03846024|DEVICE|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
48023879|NCT00510029|DRUG|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
48023880|NCT05820750|DEVICE|photodynamic therapy|root canal treatment of primary molars using photodynamic therapy
48023881|NCT05820750|PROCEDURE|pulpectomy with metapex|root canal treatment using standard technique
48023882|NCT04103229|PROCEDURE|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
48718460|NCT03166072|OTHER|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
48181468|NCT04596605|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules daily for 12 weeks
48181469|NCT00974389|BIOLOGICAL|bevacizumab|
48181470|NCT00974389|DRUG|tegafur-gimeracil-oteracil potassium|
48718461|NCT03166072|OTHER|No Intervention|Participants will continue to receive treatment as usual
48718462|NCT05207163|BEHAVIORAL|Continuing medical education|Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
48718463|NCT04721340|OTHER|Test Group|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
48718464|NCT04721340|OTHER|Control Grup|Individuals who meet the inclusion criteria will be evaluated for manual dexterity, performance, muscle strength and fatigue, respectively, on a predetermined day.
48718465|NCT02515201|DRUG|Taurolidine|taurolidine in central catheter lumen
48718466|NCT02515201|DRUG|Heparin|heparin in central venous catheter lumen
48181471|NCT05217355|DRUG|MBA-P01 (Botulinum toxin A)|MBA-P01 will be injected into the Glabellar line
48181472|NCT05217355|DRUG|Placebo|Placebo will be injected into the Glabellar line
48718467|NCT04123223|BEHAVIORAL|Cognitive Remediation|Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
48718468|NCT04123223|BEHAVIORAL|Computer Games|Sham placebo treatment
48718469|NCT04284813|BEHAVIORAL|CRAFT-FT|CRAFT-FT will be delivered via telemedicine. Topics include building motivation, self-care, communication, understanding patterns of behavior, positive reinforcement, and negative consequences. The intervention will be tailored to families of individuals experiencing psychosis and substance use who are enrolled in first episode psychosis outpatient services. Participants will be asked to completed assessments at pre-treatment, mid-treatment (approximately week 3), post-treatment, and a follow-up assessment approximately 3 month post-treatment.
48718470|NCT03762967|BIOLOGICAL|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
48718471|NCT03762967|DRUG|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
48718472|NCT03542435|DRUG|SXC-2023|Oral capsule
48718473|NCT03542435|DRUG|Placebo|Placebo
48718474|NCT00004751|PROCEDURE|Surgery|
48718475|NCT00004751|PROCEDURE|Physical therapy|
48718476|NCT04371341|PROCEDURE|erector spinae block by 0.25% bupivacaine|A mark will be applied on the required level (T8), the midline (spinous processes) and the injection points 3 cm from midline.While the patient is in a sitting position with support from a member of staff, Preparation of the field with iodine will be made. Using ultrasound guidance with a 6-10 MHz linear probe anatomical landmarks will be identified including the transverse process at T8 level and the three layers of muscles from posterior to anterior: trapezius-rhomboid-erector spinae. After subcutaneous lidocaine 2% injection a 22-G spinal needle will be inserted under ultrasound guidance in plane, aiming towards the transverse process. After a Gentle contact with the transverse process, 0.25% bupivacaine is injected in increments with careful repetitive aspiration to avoid intravascular injection.
48718477|NCT05394532|OTHER|Education|Common Education
48718478|NCT00348114|PROCEDURE|Transplantation of cultivated limbal epithelium|
48718479|NCT05918627|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
48718480|NCT05918627|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
48181473|NCT01227616|DRUG|Ferumoxytol|IV Ferumoxytol
48718481|NCT00801047|DRUG|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
48718482|NCT00801047|DRUG|Remifentanil|40-50 mic per 1-2 min via PCA
48718483|NCT01564524|PROCEDURE|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
48718484|NCT05042960|OTHER|Brightness|Changing the colors or brightness on the device (computer screen) for one month
48718485|NCT05260333|DEVICE|Butterfly iQ transperineal ultrasound exam|Transperineal ultrasound
48718486|NCT04533074|BIOLOGICAL|Single-visit regeneration protocol|In a single visit, access opening, minimal instrumentation and irrigation will be done. After irrigation and drying, the apical tissue will be irritated to evoke bleeding in the canal, using a precurved K-file 2mm past the apical foramen, with the goal of having the entire canal filled with blood to the level of the cemento-enamel junction. The bleeding will be stopped at a level that allows for 3-4 mm of restorative material. Three millimeters of Biodentine will then be placed directly over the blood clot of each tooth. A 3-4 mm layer of glass ionomer is flowed gently over the capping material. Each access cavity will be restored using composite resin.
48023883|NCT06535178|BEHAVIORAL|Sleep Regularity Group|Maintained consistent sleep onset time (±30 min self-selected sleep time) for 12-weeks.
48023884|NCT04870151|PROCEDURE|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
48023885|NCT04870151|PROCEDURE|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
48023886|NCT03084328|DIETARY_SUPPLEMENT|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
48023887|NCT00271336|DRUG|Pentoxifylline|
48023888|NCT04621305|OTHER|normal saline|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered
48519349|NCT01584817|OTHER|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
48519350|NCT02535793|OTHER|blood test (four dry tubes 7ml) and prick tests|
48023889|NCT04621305|DRUG|Bolus Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.
48519351|NCT00697151|DRUG|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
48181474|NCT01227616|DRUG|Iron Sucrose|IV Iron Sucrose
48718487|NCT04533074|BIOLOGICAL|Multiple-visits regeneration protocol|In the first visit, access opening, minimal instrumentation and irrigation will be done. The root canal will be then dried and filled with calcium hydroxide paste. The tooth will be sealed with an intermediate restorative material (IRM), and the patient will be dismissed for 1-4weeks. In the second appointment, response to initial treatment will be assessed and the steps will be repeated if symptoms are persistent. If there are no symptoms, evoking bleeding to the level of the cemento-enamel junction will be done followed by Biodentine application over the blood clot with final glass ionomer and composite restorations.
48718488|NCT04313322|BIOLOGICAL|WJ-MSCs|"WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.~WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
48718489|NCT03821272|BIOLOGICAL|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
48718490|NCT03821272|BIOLOGICAL|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
48718491|NCT01611220|BEHAVIORAL|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
48718492|NCT05908968|DIETARY_SUPPLEMENT|ELO water|Drinking 1.5 litres daily of ELO water for 12 weeks
48718493|NCT02287753|OTHER|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
48181475|NCT04758052|OTHER|Timing of placement|Simultaneous placement of tracheostomy and gastrostomy
48181476|NCT06231537|DIAGNOSTIC_TEST|Visual oral examination|"Oral preventive examinations in the three groups will be conducted over a one-year period. Individuals with oral injuries will be referred to stomatology, aligning with the existing protocol. Histopathological examinations of the biopsied lesions will be performed at the Oral Pathology Laboratory of the Faculty of Dentistry at the Federal University of Rio de Janeiro, following the established procedures.~Users diagnosed with malignancy will be directed to receive treatment at the reference hospital, with monitoring carried out by the Basic Health Unit responsible for coordinating care, in accordance with the current protocol.~In addition to histopathological examinations, the Faculty of Dentistry will be available to conduct a physical examination and biopsy if the user is not attended to by the Municipal Health Department. This additional resource ensures comprehensive care for individuals who may not have immediate access to municipal health services."
48181477|NCT01089296|OTHER|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
48181478|NCT03659383|COMBINATION_PRODUCT|Optimal hypoglycemic treatment|Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
48181479|NCT04883060|DEVICE|midline localizer|a midline localizer device with a laser pointer is used to localize where the midline is likely to be located on the patient head prior to the surgery.
48181480|NCT04727359|OTHER|FIT64b model project|FIT64b model project: The SHI funds AOK Baden-Württemberg and SVLFG (as an agricultural health insurance fund) have established a contract (duration = at least eight year) with the model hospital for an alternative remuneration / financing of patients treated in the model hospital (FIT64b hospital, UKT). This contract encourages the model hospital an alternative treatment of their patients (with the above mentioned SHI fund), for example fewer inpatient and more outpatient treatment.
48181481|NCT00440388|DRUG|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
48519352|NCT00697151|DRUG|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
48519353|NCT05387343|DIAGNOSTIC_TEST|Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Test|Boosters will be given after month 3 after transplant, and the 2nd booster will be given 3 months after the first.
48519354|NCT00079950|DRUG|Pegamotecan|
48519355|NCT05018377|PROCEDURE|Racz adhesolysis|adhesiolysis in failed back surgery
48519356|NCT05018377|DEVICE|NAVI adhesolysis|adhesiolysis in failed back surgery
48519357|NCT01431365|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
48519358|NCT01431365|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
48519359|NCT04304092|OTHER|Exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
48519360|NCT05208489|OTHER|there is no intervention involved in this study|there is no intervention involved in this study.
48718494|NCT05953948|OTHER|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
48519361|NCT06582420|DRUG|Fibrinogen concentrate|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
48718495|NCT00099281|DRUG|YMB 1002|
48718496|NCT05266560|DRUG|ciprofol|A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
48718497|NCT05266560|DRUG|Propofol|Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
48718498|NCT03847857|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
48718499|NCT03847857|PROCEDURE|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
48718500|NCT05826223|OTHER|Implementation and evaluation of a sepsis sub-phenotyping algorithm|The algorithm will run silently in the background and continuously compute the subphenotypes of patients who are presenting to the emergency department (ED) with suspected infection.
48718501|NCT01206686|BEHAVIORAL|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
48718502|NCT01206686|BEHAVIORAL|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
48718503|NCT01206686|BEHAVIORAL|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
48718504|NCT02968381|BEHAVIORAL|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
48718505|NCT02968381|BEHAVIORAL|Control Condition|Telephone coaching using standard cognitive behavioral methods
48718506|NCT06226168|OTHER|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
48718507|NCT06226168|OTHER|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
48718508|NCT06187168|PROCEDURE|exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.|This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
48718509|NCT01260025|DRUG|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
48718510|NCT00457444|DRUG|Pollen|
48718511|NCT03298841|DEVICE|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
48718512|NCT06373783|PROCEDURE|subepithelial connective tissue graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of the canine and the mesial of the first molar in the palate. Connective tissue dimensions were approximately 10x5x2 mm. The graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and an electronic caliper during surgery.
48718513|NCT06373783|PROCEDURE|de- epithelize gingival graft|The area where the gingival recession occurred was prepared with the modified coronally positioned flap technique developed by Zuchelli. A shallow horizontal incision was made at ≈3 mm apical from the gingival margin of the maxillary molar teeth using a number 15 scalpel blade. Subsequently, a parallel horizontal incision, at ≈ 4 mm apical from the first horizontal incision, was traced in conjunction with two vertical releasing incisions to delineate a rectangular area. Then, the uppermost epithelial layer was scraped off using a size 11 scalpel tip. The connective tissue graft to be taken from the palate area was 10x5x2 mm in size, and the graft thickness was measured with an endodontic spreader from 3 points (mesial, buccal, and distal) and electronic caliper during surgery.
48181482|NCT00440388|DRUG|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
48718514|NCT06373783|DIAGNOSTIC_TEST|ultrasonography|"Clinical parameter measurements (probing depth (PD), clinical attachment level (CAL), gingival recession depth and width, keratinized tissue width and height) were taken on the day of surgery, the 3rd days, the 14th days, the 1st month, the 3rd months and the 6th months.~Ultrasonography measurements A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the receiver site in the buccal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit pulsatility index (PI) = (Vmax-Vmin) (Vmean) (Vmax is peak systolic flow velocity. Vmin is diastolic flow velocity and Vmean is mean flow velocity.) The mean PI values of each patient were measured."
48718515|NCT01193166|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
48718516|NCT01193166|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 12 months
48718517|NCT01193166|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
48718518|NCT01193166|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
48718519|NCT01193166|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
48718520|NCT01193166|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
48718521|NCT01193166|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
48718522|NCT01193166|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
48718523|NCT06218706|DEVICE|Low Intensity Focussed Ultrasound|The major objective of this study is to further test safety, tolerability, and feasibility of LIFU in this population as well as investigate the impact of LIFU on opioid and other substance use. The primary endpoint is 90 days (Post-LIFU Week 12) following Active/Sham LIFU. After the primary endpoint is reached, the blind will be broken and the group who received Sham LIFU will cross-over and receive Active LIFU
48382571|NCT05158907|OTHER|Patient reported Adverse event scale|Participants will be given a patient reported AE scale with numbers from 0 to 10 before start of each chemotherapy cycle. The PRAE scale will be like a Visual Analogue Scale and the patients will be given instructions how to record AEs that they experience after each chemotherapy cycle, until the first radiological assessment is done (palliative settings) or after 4 cycles of chemotherapy in adjuvant settings. Participants will take scale home to record the adverse effects and give it a number. Only the most severe will be analyzed. When patient reports for the next cycle of chemotherapy they will be asked to deposit the scale before meeting the physician. The physician will ask patient about the AEs experienced with the chemotherapy and record them using CTCAE grade. The study participants, at the start of chemotherapy cycle, will be informed, as a standard practice, to report to the emergency or contact nearest local clinic/hospital if the AE is severe or can't be managed at home.
48382572|NCT05279807|DRUG|Zofenopril|Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
48382573|NCT05279807|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
48382574|NCT06422949|DEVICE|Hilotherm® Cooling treatment|Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
48382575|NCT06379984|DRUG|Buprenorphine|Sublingual buprenorphine
48718524|NCT00384982|PROCEDURE|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
48718525|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
48718526|NCT05742204|OTHER|Plasma protein biomarker analysis|Plasma samples of control subjects were collected.
48718527|NCT03118830|DRUG|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
48718528|NCT03118830|DRUG|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
48718529|NCT03118830|DRUG|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
48718530|NCT00313547|DRUG|Quinapril 40 mg|
48718531|NCT00313547|DRUG|Quinapril 10 mg and amlodipine 5 mg|
48718532|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
48718533|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
48718534|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
48718535|NCT01545050|BIOLOGICAL|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
48718536|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
48023890|NCT04621305|DRUG|Continuous Infusion Remimazolam|Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
48023891|NCT02755935|DEVICE|Cochlear Nucleus CI532|cochlear implantation
48023892|NCT01398605|OTHER|Exercise training|Different dose of exercise training
48023893|NCT03319043|DRUG|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
48023894|NCT05191498|DEVICE|QuiremSpheres®|Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
48023895|NCT05427149|DRUG|25 mg MgSO4 (Magnezyum Sulfat %15, Biofarma, Istanbul, Turkey)|It will be evaluated whether there is postpinal shivering in the cases.
48023896|NCT03072901|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
48023897|NCT05040217|GENETIC|AAV2-BDNF Gene Therapy|AAV2-BDNF is a genetically engineered adeno-associated virus serotype 2 (AAV-2) that expresses the human BDNF cDNA.
48023898|NCT05040217|BIOLOGICAL|AAV2-BDNF Gene Therapy|Gene therapy is a biological therapy delivering the BDNF gene to the brain
48023899|NCT01745263|DRUG|Vitamin D3|2000 IU/d
48023900|NCT01745263|DRUG|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
48023901|NCT01745263|PROCEDURE|Strength Home Exercise|
48181483|NCT05987098|DIAGNOSTIC_TEST|BBPA PET examination|A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.
48181484|NCT05812586|BIOLOGICAL|SCB-2019/Clover|SCB-2019/Clover Vaccine
48023902|NCT01745263|PROCEDURE|Flexibility Home Exercise|
48181485|NCT05812586|BIOLOGICAL|AstraZeneca/Fiocruz|AstraZeneca/Fiocruz Vaccine
48181486|NCT05812586|BIOLOGICAL|Pfizer/Wyeth|Pfizer/Wyeth Vaccine
48181487|NCT04692805|DEVICE|coils|EUS-guided injection of coils
48181488|NCT04692805|DRUG|cyanoacrylate glue|EUS-guided injection of cyanoacrylate glue
48718537|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
48023903|NCT00797784|DRUG|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
48181489|NCT04329546|OTHER|NA (no intervention)|NA (no intervention)
48181490|NCT02646709|DRUG|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
48181491|NCT02646709|DRUG|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
48023904|NCT00187798|DRUG|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
48023905|NCT00090012|DRUG|Olanzapine|
48023906|NCT00090012|DRUG|Quetiapine|
48023907|NCT01235910|DRUG|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
48023908|NCT04297878|DIETARY_SUPPLEMENT|probiotic supplement Streptococcus salivarius K12 (Bactoblis®)|Probiotic food supplement
48023909|NCT02264834|DRUG|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
48023910|NCT02264834|DRUG|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
48023911|NCT02264834|PROCEDURE|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
48023912|NCT00617240|DRUG|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
48023913|NCT00617240|DRUG|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
48023914|NCT03111225|DIAGNOSTIC_TEST|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
48023915|NCT04229719|DRUG|N-acetyl-5-methoxytryptamine|1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
48023916|NCT01923181|DRUG|semaglutide|Once-daily oral administration as tablets.
48181492|NCT02646709|DRUG|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
48181493|NCT02646709|DRUG|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
48181494|NCT01636583|DEVICE|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
48181495|NCT01636583|DEVICE|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
48718538|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
48718539|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
48718540|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
48718541|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
48718542|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
48718543|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
48718544|NCT01545050|BIOLOGICAL|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
48718545|NCT03324919|BEHAVIORAL|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
48718546|NCT04278937|DRUG|Azithromycin Tablets|one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
48718547|NCT02698904|BEHAVIORAL|Guided Relaxation Technique|
48718548|NCT02698904|OTHER|Documentary Movie|
48718549|NCT02323152|BEHAVIORAL|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
48023917|NCT01923181|DRUG|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
48023918|NCT01923181|DRUG|oral placebo|Once-daily oral administration as tablets.
48023919|NCT05339685|DRUG|BL-M02D1|Administration by intravenous infusion
48023920|NCT05660525|DRUG|4 weeks of Nicotine lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
48023921|NCT05660525|DRUG|8 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch. Some will also be randomized to receive an additional 4 weeks of the NRT Patch
48023922|NCT05660525|BEHAVIORAL|QuitAid|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the QuitAid intervention, based on a medication adherence intervention, addresses perceptions (e.g., motivation, self-efficacy, beliefs) and practicalities of using NRT (e.g., monitoring NRT use, establishing a reminder system). QuitAid includes 1 in-person session and 5 follow-up telephonic sessions with the participant's local pharmacist/technician.
48718550|NCT02323152|OTHER|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
48718551|NCT04944732|DIAGNOSTIC_TEST|laboratory examination, auxiliary examination, pathological results|Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
48718552|NCT04179513|BIOLOGICAL|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
48718553|NCT04179513|BIOLOGICAL|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses."
48718554|NCT01400243|DRUG|Nicotine|Nicotine patch 7mg
48718555|NCT01400243|DRUG|Placebo Patch|Placebo patch
48718556|NCT01188616|BEHAVIORAL|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
48718557|NCT00721721|BEHAVIORAL|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
48718558|NCT00721721|BEHAVIORAL|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
48023923|NCT05660525|BEHAVIORAL|Smokefree TXT|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive the SmokefreeTXT is a text-messaging program offered through the National Cancer Institute's Smokefree.gov initiative, which sends pre-programmed messages timed around a quit date. Participants will receive 3-5 messages a day for 7 weeks. The first week of messages focus on preparation and the remaining 6 weeks of messages focus on post-cessation strategies (e.g., relapse prevention), all timed relative to the quit date set at enrollment.
48023924|NCT05660525|BEHAVIORAL|Tobacco Quitline|All participants will receive at least 4 weeks of the NRT Patch. Some participants will also be randomized to receive a 4-session proactive tobacco quitline, with each session lasting 20-30 minutes and occurring on days 7, 14, 21 and 28.The quitline intervention incorporates 3 phases: (1) preparing to quit, (2) quitting process, and (3) relapse prevention.
48023925|NCT05660525|DRUG|4 weeks of Nicotine Replacement Therapy Patch|All participants will receive at least 4 weeks of the NRT Patch.
48181496|NCT01636583|OTHER|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
48181497|NCT02161406|DRUG|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
48181498|NCT02161406|DRUG|Placebo|125 mg of Placebo
48718559|NCT00721721|DIETARY_SUPPLEMENT|Potassium Supplementation|60 mmol potassium supplement
48718560|NCT04297969|DIAGNOSTIC_TEST|"objective pediatric vision screen GCK glow fixation"|2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
48718561|NCT02257723|DRUG|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
48718562|NCT02257723|PROCEDURE|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
48718563|NCT02257723|PROCEDURE|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48718564|NCT02257723|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
48023926|NCT05660525|DRUG|8 Weeks Nicotine Lozenge|All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 8 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
48023927|NCT03632161|DRUG|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
48023928|NCT03632161|DRUG|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
48023929|NCT01085318|DRUG|Rebif|44 mcg tiw
48023930|NCT00119444|PROCEDURE|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
48023931|NCT02393313|PROCEDURE|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
48023932|NCT02393313|DEVICE|Rayner T-flex Toric IOLs|
48023933|NCT02297152|DEVICE|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
48023934|NCT03868904|DEVICE|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
48023935|NCT03095989|BEHAVIORAL|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
48023936|NCT05684484|DRUG|Roflumilast 500 Ug ORAL TABLET [Daliresp]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
48023937|NCT05684484|DRUG|corticosteroids +immune suppressive +amino salicylic acid|conventional treatment
48023938|NCT05743166|PROCEDURE|Bariatric surgery|JDF11 JDF41 JDF97
48023939|NCT00023452|DRUG|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
48023940|NCT00023452|DRUG|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
48023941|NCT01851057|BEHAVIORAL|STAR|Problem-solving and education intervention (8 total sessions)
48023942|NCT01851057|BEHAVIORAL|Education Only|Education around epilepsy (8 total sessions)
48023943|NCT01557660|DRUG|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
48023944|NCT00406029|DRUG|Preladenant|1 mg BID capsules
48519362|NCT06582420|DRUG|Standard trauma care|Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of FC. The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.
48023945|NCT00406029|DRUG|Preladenant|2 mg BID capsules
48023946|NCT00406029|DRUG|Preladenant|5 mg BID capsules
48023947|NCT00406029|DRUG|Preladenant|10 mg BID capsules
48181499|NCT03253263|DRUG|OHB-607|Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
48181500|NCT02031536|DRUG|everolimus|Given PO
48181501|NCT02031536|OTHER|placebo|Given PO
48181502|NCT01586481|DEVICE|SANIDIAB|off-loading shoe
48181503|NCT01586481|DEVICE|BAROUK|old shoe
48023948|NCT00406029|DRUG|Placebo|BID capsules
48023949|NCT00406029|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
48023950|NCT00406029|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
48023951|NCT01538875|DRUG|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
48181504|NCT00728000|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
48181505|NCT00728000|DRUG|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
48181506|NCT00728000|DRUG|Erlotinib|100mg/day PO on days 1-14 and 15-28
48382576|NCT01830712|DRUG|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
48382577|NCT00030849|BIOLOGICAL|recombinant interferon alfa|
48382578|NCT00030849|DRUG|bexarotene|
48382579|NCT04758715|OTHER|Food provided from a commercial meal service provider for a week|Meals from a commercial meal service provider provide for a week to participant
48382580|NCT06623006|BEHAVIORAL|mobile health (mhealth)|The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
48382581|NCT03409328|BEHAVIORAL|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
48718565|NCT02257723|PROCEDURE|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
48718566|NCT01950585|DRUG|Hydroxyurea|
48718567|NCT04534907|COMBINATION_PRODUCT|The combination of exposure and response prevention (ERP) and VR|The combination of exposure and response prevention (ERP) and VR aimed to investigate the combination of an immersive virtual reality environment (VRE) alongside therapist delivered CBT to reduce anxiety when the OCD patients were induced by virtual scene.Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get VR+ERP session twice a week. From the fourth week to the seventh week, patients weill get VR+ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
48718568|NCT04534907|BEHAVIORAL|Traditional ERP|Patients will achieve the exposure based CBT for total 10 times excluding 8 sessions of ERP. Structured protocol described by Foa et al., 2012. Specially, patients will get the first CBT session in the first week for 90 minutes in order to gather detailed information of individual's symptom. Then the next 2 weeks, patients will get ERP session twice a week. From the fourth week to the seventh week, patients weill get ERP session once a week. In the end of the eighth week, patients will get the last session of the exposure-based CBT for relapse prevention.
48718569|NCT03684304|DEVICE|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
48718570|NCT02921009|DEVICE|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
48718571|NCT03675516|OTHER|No specific intervention|Usual care
48718572|NCT06133296|OTHER|Conventional fixed treatment|Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment
48718573|NCT06133296|OTHER|Clear aligner treatment|After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
48718574|NCT01904656|BEHAVIORAL|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
48382582|NCT01299428|DEVICE|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
48382583|NCT01350609|DRUG|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
48382584|NCT01350609|DRUG|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
48382585|NCT05268003|DRUG|Ponatinib|Given by PO
48382586|NCT05268003|DRUG|Venetoclax|Given by PO
48023952|NCT01538875|DRUG|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
48382587|NCT05268003|DRUG|Mini-hyper CVD|Given by IV (vein)
48382588|NCT04929834|OTHER|Hydrating emollient + body lotion for immunotherapy-related side effects|Hydrating, hypo-allergenic, and anti- itching emollient and body lotion for immunotherapy-related skin reactions
48023953|NCT01323439|DEVICE|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
48023954|NCT04672434|DRUG|Sym021|Sym021 is a humanized anti-PD-1 antibody.
48023955|NCT04672434|DRUG|Sym024|Sym024 is an anti-CD73 antibody.
48023956|NCT06572813|DRUG|Bortezomib Injection|Bortezomib Injection, a kind of chemotherapy drug
48382589|NCT05679193|DRUG|Propranolol|"Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily"
48382590|NCT04216953|DRUG|Cobimetinib|"Adults: 20mg film coated tablet~Paediatrics:~i) powder for oral suspension containing 250mg of cobimetinib~ii) for pediatric patients ≥12 years-old and with a BW ≥60kg : 20mg film coated tablet same as adults"
48382591|NCT04216953|DRUG|Atezolizumab|20-mL glass vial containing 1200 mg of atezolizumab.
48382592|NCT03682211|DRUG|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
48718575|NCT01904656|BEHAVIORAL|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
48718576|NCT04783857|DRUG|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
48718577|NCT03201692|DEVICE|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
48718578|NCT03201692|DEVICE|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
48718579|NCT00955149|DRUG|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
48718580|NCT05063266|OTHER|Deep Breathing Exercise|control groups received deep breathing exercise 6 days a week for two weeks. Deep breathing exercises includes diaphragmatic breathing and pursed lip breathing.
48718581|NCT05063266|OTHER|Inspiratory muscle Training|Treatment group received inspiratory muscle training 20 minutes 6 days a week for two weeks.IMT was done by using pressure threshold device.
48023957|NCT06572813|DRUG|Sintilimab|PD-1 antibody
48023958|NCT06572813|DRUG|mFOLFIRINOX|Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
48023959|NCT02455908|DRUG|Proleukin®|
48023960|NCT05057676|BEHAVIORAL|Immediate Autoimmune Intervention Mastery Course (AIM)|Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
48023961|NCT05057676|BEHAVIORAL|Immediate Question and Answer sessions. (AIM Q and A sessions)|Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
48023962|NCT05057676|BEHAVIORAL|Delayed Autoimmune Intervention Mastery Course (delayed AIM course)|Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care
48023963|NCT05057676|BEHAVIORAL|Delayed AIM Question and Answer sessions|Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.
48023964|NCT04457648|DEVICE|manuka honey 16% eye drops ( Optimel )|16% manuka honey eye drops, australian FDA approved
48023965|NCT04457648|DEVICE|systane eye drops|systane lubricant eye drops
48023966|NCT00665119|DRUG|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
48023967|NCT00665119|DRUG|placebo|NaCl 0.9 %
48023968|NCT00672477|DRUG|Methylnaltrexone|
48023969|NCT00672477|DRUG|Placebo|
48023970|NCT04170192|PROCEDURE|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
48023971|NCT04939259|DEVICE|New Music Program|A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.
48023972|NCT04939259|DEVICE|Standard Listening Program|A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
48023973|NCT04368936|GENETIC|Isolated DNA, Real Time PCR|"We are isolated DNA from the blood sample. To determine the genotypes of the analyzed polymorphisms use real-time PCR using TaqMan essays.~When analyzing the KCC2 polymorphisms, the VIC dye gene corresponded to the C allele, and the FAM dye corresponded to the T allele, while at the TRPV1 gene polymorphism, the VIC dye corresponded to the C allele and the FAM dye to the G allele."
48023974|NCT00630877|DRUG|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
48023975|NCT00630877|DRUG|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
48023976|NCT00630877|DRUG|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
48023977|NCT00630877|DRUG|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
48382593|NCT03682211|DRUG|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
48382594|NCT04374136|DRUG|AL001|Administered via intravenous (IV) infusion
48382595|NCT04374136|DRUG|Placebo|Administered via intravenous (IV) infusion
48382596|NCT04374136|DRUG|Open label - AL001|Administered via intravenous (IV) infusion
48718582|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram \[mcg\]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
48718583|NCT02546960|BIOLOGICAL|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
48718584|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
48718585|NCT02546960|BIOLOGICAL|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
48718586|NCT02546960|BIOLOGICAL|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups \>=18 to \<50 years and \>=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
48718587|NCT02546960|DRUG|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
48181507|NCT05013515|DRUG|Surufatinib|"Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator."
48181508|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
48181509|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
48181510|NCT02643147|DRUG|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
48181511|NCT01006525|DRUG|zolpidem|placebo or zolpidem (10mg)daily for one year
48181512|NCT00561899|DRUG|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
48718588|NCT02391376|OTHER|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
48718589|NCT02391376|OTHER|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
48718590|NCT02391376|OTHER|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
48718591|NCT00780286|DEVICE|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
48718592|NCT00780286|DEVICE|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
48718593|NCT00788580|DRUG|pazopanib hydrochloride|
48718594|NCT00788580|DRUG|temsirolimus|
48718595|NCT00788580|PROCEDURE|immunoenzyme technique|
48718596|NCT00788580|PROCEDURE|laboratory biomarker analysis|
48718597|NCT00788580|PROCEDURE|pharmacological study|
48718598|NCT06406803|BEHAVIORAL|Dietary energy restriction|Patients enrolled in the dietary energy restriction group will reach an energy deficit of 40% only through reduced dietary intake.
48718599|NCT06406803|BEHAVIORAL|Daily exercise|Patients in the daily exercise group will reach an energy deficit of 40% through reduced dietary intake and increased physical activity (exercise).
48718600|NCT03556098|DRUG|glucose-dependent insulinotropic peptide|Infusion of GIP
48718601|NCT03556098|DRUG|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP\[3-30\]
48718602|NCT03556098|DRUG|Saline Solution|Infusion of Saline
48718603|NCT02337699|DEVICE|Implantation with the commercially available Axium neurostimulator|
48718604|NCT02337699|PROCEDURE|QST Testing|
48718605|NCT00469963|PROCEDURE|quality-of-life assessment|quality-of-life assessment
48718606|NCT00469963|RADIATION|yttrium Y 90 resin microspheres|radiation therapy
48718607|NCT06280534|DRUG|Test drug XT1061 capsules and placebo,Single dose group|Eight people took capsules of the test drug XT1061 and two people took a placebo.
48718608|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Multiple dosing group|D1-D7 were administered under fasting conditions for 7 consecutive days, of which D1-D6 were administered BID and D7 was administered once in the morning under fasting conditions only.Eight people took capsules of the test drug XT1061 and two people took a placebo.
48718609|NCT06280534|DRUG|Test drug XT1061 capsules and placebo，Food Impact Group|Eight people in group A took the test drug XT1061 capsules and two people took placebo, and all eight people in group B took the test drug XT1061 capsules.
48718610|NCT02839239|DIETARY_SUPPLEMENT|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
48718611|NCT02839239|DIETARY_SUPPLEMENT|Drops with vitamin D3|Oil suspension with vitamin D3
48718612|NCT02506660|DRUG|Bupivacaine|
48718613|NCT02506660|DRUG|Perineural dexamethasone|Dexamethasone in nerve block
48718614|NCT02506660|DRUG|Intravenous dexamethasone|
48718615|NCT02506660|DRUG|Intravenous saline|
48718616|NCT02506660|DRUG|Perineural saline|Saline in nerve block
48718617|NCT01760811|DRUG|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
48718618|NCT00518674|PROCEDURE|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
48718619|NCT03987932|BEHAVIORAL|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
48718620|NCT03987932|BEHAVIORAL|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
48718621|NCT03987932|BEHAVIORAL|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
48718622|NCT04327635|DRUG|PEP|A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.
48718623|NCT05478668|OTHER|visual analog scale|In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
48718624|NCT01310959|OTHER|Database|Database
48718625|NCT03622177|PROCEDURE|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
48718626|NCT03622177|BIOLOGICAL|blood drawn|Additional blood drawn by venepuncture
48718627|NCT05932264|DRUG|Apatinib + Fluzoparib|Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
48718628|NCT05932264|DRUG|Apatinib + Fluzoparib + Adebrelimab|Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
48718629|NCT02616393|DRUG|Tesevatinib|
48718630|NCT02332733|BIOLOGICAL|TV003|10\^3 plaque forming units (PFU) of rDEN1 delta 30, 10\^3 PFU of rDEN2/4 delta 30(ME), 10\^3 PFU of rDEN3 delta 30/31-7164, and 10\^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
48718631|NCT02332733|BIOLOGICAL|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
48718632|NCT03845972|PROCEDURE|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
48718633|NCT04602767|DRUG|Vasopressin|Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg
48718634|NCT04602767|DRUG|Phenylephrine|Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
48718635|NCT00907296|BIOLOGICAL|Romosozumab|Administered by subcutaneous injection
48718636|NCT00907296|DRUG|Placebo|Administered by subcutaneous injection
48718637|NCT00625612|DRUG|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
48718638|NCT00625612|DRUG|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
48382597|NCT06531343|PROCEDURE|LDCT scan and simultaneous [18F]FDG PET/CT on new-generation long axial field of view scanner|"18F\]FDG will be injected intravenously, and PET/CT images will be acquired after 60 minutes (± 10 minutes). PET/CT images will be first analysed with the lung window to detect any findings suggestive of a lung tumour.~Whole-body PET/CT images will be then analysed to detect any incidental finding in the chest as well as other anatomical areas included in the field of view. PET/CT images will be considered positive if there is at least one non-calcified lung nodule or any suspicious finding on CT scan characterised by focal \[18F\]FDG uptake deviating from physiological distribution or above physiological background activity."
48382598|NCT06531343|PROCEDURE|LDTC only|The LDCT scan will be performed in single deep inspiratory breath hold. No intravenous contrast will be administered.
48382599|NCT06652711|BEHAVIORAL|2-month access to mental health app|Participants will have access to the well-being app for two months.
48382600|NCT06652711|BEHAVIORAL|Direct incentive|A $10 gift card are given to participants at the end of the study if they used the app sufficiently.
48718639|NCT05045170|DRUG|Influence of propofol sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to propofol sedation (stage 1), 5-10 minutes after the start of propofol sedation (stage 2), 10 minutes after propofol sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
48382601|NCT06652711|BEHAVIORAL|4-month access to mental health app|Participants will have access to the well-being app for four months.
48382602|NCT06652711|BEHAVIORAL|Lottery incentive|Participants can participate in a draw of $150 gift cards at the end of the study if they used the app sufficiently.
48382603|NCT04253028|DEVICE|NERv's Inline Device|NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
48382604|NCT05123040|DRUG|Ruxolitinib 10 MG Oral Tablet|By mouth twice daily through day 56, then tapered
48382605|NCT05123040|DRUG|hCG|2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
48718640|NCT05045170|DRUG|Influence of dexmedetomidine sedation on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to dexmedetomidine sedation (stage 1), 5-10 minutes after the start of dexmedetomidine sedation (stage 2), 10 minutes after dexmedetomidine sedation is finished and consciousness is restored (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
48023978|NCT04915469|OTHER|Standardized enhanced adherence counseling package|A standardized package was developed to support the adherence counsellor and other cadres to ensure provision of quality EAC sessions for children, adolescents and their caregivers. The package included; 1) Orientation and on job mentorship on EAC processes to clinicians, nurses, peer educators and mentor mothers. 2) Using a communication's training curriculum, providers were trained on psychosocial support and communication skills for children and their caregivers. 3) Appointment management was done using appointment dairies or a digital platform that sends patients short message services (SMS) reminders 3 days and 1 day before a scheduled clinic day. 4)Home visits. - All home visits were done according to the EGPAF standard operation procedures (SOPs) drawn from the Kenya National guidelines. 5) Individualized case management -Each EAC client was allocated a case manager who ensured that the barriers to adherence were identified and tackled both at individual and community level.
48382606|NCT05123040|DRUG|Corticosteroids|"Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg"
48023979|NCT05148715|DRUG|Tacrolimus|Single dose intravenous tacrolimus over 4 hour infusion at a dose of 0.02 mg/kg ideal body weight diluted with 0.9% sodium chloride starting 4-8 hours before scheduled organ recovery.
48023980|NCT05148715|DRUG|Placebo|Single dose of intravenous 0.9% sodium chloride over 4 hour infusion, starting 4-8 hours before scheduled organ recovery.
48023981|NCT03644979|OTHER|Skydiving|Tandem skydiving (with an experienced instructor)
48023982|NCT06532539|DRUG|Paclitaxel and Cisplatin|"Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used."
48023983|NCT06532539|DRUG|Cadonilimab|Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.
48519363|NCT04521894|DEVICE|Positron emission tomography/computerized tomography (PET/CT)|"1. Genetic factors and age:~   Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~2. Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~3. Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~4. Infection:~5. Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~6. Daily diet: The corrective mechanism of diet in PCa is not very clear.~7. Drinking history:"
48519364|NCT03731442|RADIATION|Involved field irradiation|Involved field irradiation; intensity-modulated radiation therapy
48519365|NCT03731442|RADIATION|Elective field irradiation|Elective field irradiation; intensity-modulated radiation therapy
48519366|NCT03731442|DRUG|Paclitaxel|Paclitaxel 135-150mg/m2, d1, every 3 weeks
48519367|NCT03731442|DRUG|Platinum|for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;
48519368|NCT03731442|DRUG|PEG-rhG-CSF|PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
48023984|NCT06532539|RADIATION|Radiotherapy|"Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases.~Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases.~Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 2-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions.~echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy."
48023985|NCT05464147|DEVICE|DynamX Drug-Eluting Coronary Bioadaptor System|DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
48023986|NCT00289341|BIOLOGICAL|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
48023987|NCT00289341|BIOLOGICAL|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
48023988|NCT00326508|DRUG|Daclizumab|
48023989|NCT05090072|BEHAVIORAL|Advance Directives|The palliative care physician engaged patients and their caregivers in an open discussion about patients' answers to the Advance Directives document, to explore and clarify all doubts and questions prompted by the document
48023990|NCT05090072|BEHAVIORAL|Control|The palliative care physician undergone a conference with both patients and caregivers and evaluated patients' symptoms using the the Edmonton Frail Scale (Bruera, 1991), adapted to the Portuguese population. The Advance Directives theme wasn't approached during this conference.
48023991|NCT01272934|DRUG|Diclofenac Sodium|Topical gel 1%-4 times daily
48023992|NCT01272934|OTHER|Placebo|Topical gel-4 times daily
48023993|NCT05177809|OTHER|Clinical rating scale to measure ataxia disease severity and progression|SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.
48023994|NCT00844441|OTHER|medical chart review|
48023995|NCT00844441|OTHER|questionnaire administration|
48023996|NCT00844441|PROCEDURE|quality-of-life assessment|
48023997|NCT05944900|PROCEDURE|Cyanoacrylate glue application|"The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.~Cyanoacrylate glue should be applied in accordance with the instructions for use.~Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly."
48023998|NCT03499158|OTHER|nerve conduction study|nerve conduction study
48023999|NCT01597206|DEVICE|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
48024000|NCT01597206|OTHER|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
48024001|NCT02094989|OTHER|posture dependence of VCG-ECG-transformation|
48024002|NCT06532006|DRUG|HLX22|HLX22 15mg/kg Q3w
48024003|NCT06532006|DRUG|Pembrolizumab|Pembrolizumab 200mg q3w
48024004|NCT06532006|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
48024005|NCT06532006|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 ,Q3W
48024006|NCT06532006|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
48024007|NCT05106868|DEVICE|acupuncture|Acupuncture is a form of alternative medicine and a component of traditional Chinese medicine (TCM) in which thin needles are inserted into the acupoints on body to treat diseases.
48024008|NCT00173667|DRUG|Nifedipine 30 mg GITS|
48024009|NCT00819182|BEHAVIORAL|Paced respiration|Breathing exercise
48024010|NCT00819182|BEHAVIORAL|Sham comparator: fast shallow breathing|sham breathing exercise
48024011|NCT05561127|COMBINATION_PRODUCT|GIE Medical ProTractX3 TTS DCB|"The ProTractX3 Drug-coated balloon is a 0.035 guidewire compatible over-the-wire catheter."
48024012|NCT05561127|OTHER|Control|Standard of Care Endoscopic Dilation
48024013|NCT03510481|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
48024014|NCT03510481|DRUG|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
48024015|NCT03510481|DRUG|artemether 20mg/lumefantrine 120mg (AL)|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
48024016|NCT03348904|DRUG|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
48024017|NCT03348904|DRUG|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
48024018|NCT03348904|DRUG|Placebo|Matching placebo for epacadostat administered orally twice daily.
48024019|NCT03348904|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
48718641|NCT05045170|DRUG|Influence of spinal anesthesia on memory consolidation and 'working memory'|Spinal anesthesia is performed by anesthesiologist. Memory testing is conducted immediately prior to operation (stage 1), 5-10 minutes after the start of operation (stage 2), 10 minutes before the end of operation (stage 3). Five emotionally neutral words are heard by the patients twice at each stage to assess the impact of sedation on memory consolidation. The patients repeat the memorized words after each audition. To assess the effect of sedation on the 'working memory', anesthesiologist asked the patient to remember and reproduce the memorized words five minutes after learning in the second stage. Approximately, 24 hours after the end of anesthesia, recall and recognition of the experimental words are tested. The number of words in recall and recognition testing is recorded by researcher.
48718642|NCT01228292|DRUG|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
48024020|NCT03348904|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
48718643|NCT01228292|DRUG|Citrasate|Citrasate is infused as a dialysate
48718644|NCT00841750|PROCEDURE|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
48718645|NCT00841750|PROCEDURE|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
48718646|NCT03939078|RADIATION|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sessions, with one month interval between them.
48024021|NCT03348904|DRUG|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
48024022|NCT03348904|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
48024023|NCT03348904|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
48024024|NCT05248893|DRUG|AGN-151586|Intramuscular Injection
48024025|NCT01335711|DRUG|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)"
48024026|NCT01335711|DRUG|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
48024027|NCT00003878|DRUG|polifeprosan 20 with carmustine implant|
48024028|NCT00003878|PROCEDURE|conventional surgery|
48024029|NCT00853450|DRUG|AZD6482|Single intravenous infusion during a maximum of 5 hours
48181513|NCT00561899|DRUG|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
48181514|NCT00561899|DRUG|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
48718647|NCT06486688|BEHAVIORAL|Centralized Virtual SBIRT|Brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician
48718648|NCT00488124|DRUG|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
48718649|NCT04034940|OTHER|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
48718650|NCT04976933|BEHAVIORAL|mHealth adherence app|The mHealth app is designed to remind caregivers to give medication in the outpatient setting, track adherence, and capture real time barriers to adherence if medication is missed.
48718651|NCT00350428|PROCEDURE|Laser Preipheral Iridotomy and phacoemulsification|
48718652|NCT04080323|DRUG|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
48718653|NCT04080323|DRUG|placebo|1 vaginal tablet of placebo 60 minutes before surgery
48718654|NCT00228046|DRUG|Divalproex Sodium|
48024030|NCT00853450|DRUG|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
48024031|NCT00853450|DRUG|ASA|75 mg orally once daily during 7 days in each treatment arm
48024032|NCT03448549|DRUG|Oxaliplatin|adjuvant chemotherapy
48024033|NCT03448549|DRUG|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
48024034|NCT03448549|DRUG|Xeloda|adjuvant chemotherapy
48024035|NCT05008510|DRUG|Sabizabulin|Sabizabulin (Veru-111)
48024036|NCT05008510|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan-hziy
48024037|NCT05008510|DRUG|Sabizabulin/Sacituzumab govitecan-hziy Combo|Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
48181515|NCT04238533|OTHER|eADAPT training|eADAPT training for myoelectric prosthesis users is the comparator training.
48718655|NCT00228046|DRUG|Methylphenidate|
48718656|NCT00228046|DRUG|Dextroamphetamine|
48718657|NCT00228046|DRUG|Mixed Amphetamine Salts|
48718658|NCT00228046|BEHAVIORAL|Family Counseling|
48718659|NCT00228046|BEHAVIORAL|Behavior Management Training with Parents|
48718660|NCT00109356|DRUG|AQ4N (Chemotherapy)|
48718661|NCT01702168|OTHER|Provider training: Cognitive Processing Therapy (CPT)|
48181516|NCT04238533|OTHER|Conventional training|Conventional training with Myoboy has been the only training available to users.
48024038|NCT05205772|DEVICE|transcranial magnetic stimulation|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. This device is FDA approved for treatment of depression and other neuropsychiatric disorders, and is regularly used in neurologic and psychiatric research.~iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes."
48024039|NCT05623709|DEVICE|Positive airway pressure with continuous positive airway pressure or noninvasive ventilation|CPAP or NIV prescribed by the treating respirologist for long-term use at home
48024040|NCT04153409|DRUG|LAT8881|Two 30 mg capsules of LAT8881
48024041|NCT04153409|DRUG|Placebo|Two capsules of placebo
48024042|NCT00466323|BEHAVIORAL|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
48024043|NCT00466323|BEHAVIORAL|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
48024044|NCT00475826|DRUG|Statins and Ezetimibe|
48024045|NCT01910844|DRUG|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
48024046|NCT01910844|DRUG|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
48024047|NCT04359836|OTHER|There is no intervention in this study|There is no intervention in this study
48024048|NCT05626192|OTHER|Anatomical dissection and Immunohistochemical techniques|Anatomical dissection and description
48024049|NCT02014961|PROCEDURE|Dermal biopsy|Skin biopsy
48024050|NCT02014961|BEHAVIORAL|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
48024051|NCT02014961|GENETIC|Whole-exome sequencing|Whole-exome sequencing (WES)
48024052|NCT02684591|DRUG|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
48024053|NCT02684591|DRUG|Placebo|Placebo
48718662|NCT03362697|DIETARY_SUPPLEMENT|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
48024054|NCT04455386|DIAGNOSTIC_TEST|Stress radiography,Anterior drawer test,Stress ultrasound,Computed tomography, Magnetic resonance imaging,Arthroscopy|All patients suspected chronic ankle instability, will perform an anterior drawer test, stress ultrasound, computed tomography, magnetic resonance imaging of ankle. Patients with chronic ankle instability will be recommended to perform an arthroscopic repair if non-operative treatment failed.
48024055|NCT06213597|OTHER|routine swallowing rehabilitation|Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
48519369|NCT03851029|OTHER|Tai chi|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
48024056|NCT06213597|DEVICE|real repetitive transcranial magnetic stimulation|In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.
48024057|NCT06213597|DEVICE|sham repetitive transcranial magnetic stimulation|The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
48181517|NCT04721899|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
48024058|NCT05796752|DRUG|Memantine|Cognition-enhancing medication
48181518|NCT01398098|DRUG|Sodium phosphate|32 tablets
48181519|NCT01854307|PROCEDURE|Pneumoperitoneum and SVV/PPV|
48181520|NCT00003495|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48181521|NCT00420784|DRUG|Telaprevir|tablet
48024059|NCT05796752|BEHAVIORAL|ComB Behavioral Therapy|Therapy for BFRBs
48181522|NCT00420784|DRUG|Ribavirin|tablet
48181523|NCT00420784|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
48181524|NCT00420784|DRUG|Matching Placebo|Tablet
48181525|NCT00531726|DEVICE|DBS of Cg25|
48024060|NCT02323594|DRUG|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
48024061|NCT02323594|DRUG|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
48181526|NCT02383992|DRUG|3% H2O2 solution|
48024062|NCT02323594|DRUG|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
48181527|NCT02383992|DRUG|0.9% normal saline|
48181528|NCT02444468|DEVICE|Flowtron ACS800|Flowtron ACS800 and bandage
48181529|NCT02444468|OTHER|Bandage|Bandage only
48181530|NCT05702541|DEVICE|Lehfilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses
48181531|NCT05702541|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses
48181532|NCT05702541|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
48181533|NCT05739136|DRUG|Relugolix + Estradiol + Norethindrone Acetate|Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
48181534|NCT04119843|DRUG|Mangoral|800 mg manganese chloride \[II\] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3
48181535|NCT00590525|PROCEDURE|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
48181536|NCT01018108|PROCEDURE|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
48181537|NCT01018108|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
48181538|NCT01018108|OTHER|Questionnaire Administration|Ancillary study
48181539|NCT01018108|OTHER|Laboratory Biomarker Analysis|Correlative Study
48181540|NCT00047723|DRUG|minocycline|
48718663|NCT03362697|DRUG|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
48718664|NCT05610956|DRUG|Empagliflozin|Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
48718665|NCT05610956|DRUG|conventional treatment|conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
48718666|NCT00539929|DRUG|E6201 0.005%|
48024063|NCT02323594|DRUG|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
48024064|NCT00517920|DRUG|ABT-869|0.25 mg/kg QD
48181541|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
48181542|NCT00676845|DRUG|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
48181543|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
48181544|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
48181545|NCT02504749|PROCEDURE|general anasthesia,spinal anasthesia|"Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated ."
48181546|NCT04382846|DRUG|Nitazoxanide|Nitazoxanide
48181547|NCT04331483|OTHER|Physical activity program|"Supervised sessions of at least 15 minutes 4 times a Week combined with unsupervised sessions.~The supervised activities include moderate-intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient can also do unsupervised sessions, autonomously, on the bike thanks to a smartphone application developed by the Kiplin company, with challenges to be carried out by teams of 2 to 5 people (team including several patients, possibility to include relatives) over periods of 1 to 3 weeks per challenge."
48718667|NCT00539929|DRUG|E6201 0.01%|
48024065|NCT01487330|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
48024066|NCT00265057|DRUG|ADH -1 (Exherin™)|
48024067|NCT01978119|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
48024068|NCT01978119|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
48024069|NCT02731001|RADIATION|Proton therapy|
48024070|NCT02731001|RADIATION|Photon therapy|
48024071|NCT05629026|PROCEDURE|Micro-biopsies|Two micro-biopsies of limb tissue will be carried out, one on the lymphedema and one in the upper limb not affected.
48181548|NCT02630706|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
48024072|NCT01621360|PROCEDURE|Arthroscopic hip surgery|Hip arthroscopy
48024073|NCT01621360|OTHER|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
48181549|NCT02630706|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
48181550|NCT02630706|DRUG|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
48718668|NCT00539929|DRUG|E6201 0.03%|
48718669|NCT00539929|DRUG|Placebo|
48718670|NCT06421402|OTHER|Air quality monitoring at patient's home|"Indoor Air Quality:~- MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3)~Outdoor Air Quality:~- Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3"
48024074|NCT06243913|PROCEDURE|IUI with vitrified sperm from donor:|"After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol."
48024075|NCT05841745|DEVICE|Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
48024076|NCT02621762|DEVICE|Magnesium|Magnesium in dialysate increased
48024077|NCT02621762|DEVICE|Bicarbonate|Bicarbonate in dialysate increased
48024078|NCT02893722|DRUG|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
48024079|NCT02893722|DRUG|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
48024080|NCT01491243|DRUG|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
48024081|NCT01491243|DRUG|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
48718671|NCT06421402|OTHER|Questionnaires: Baseline & every six months|"General surveys:~* PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires.~* PREMs: Patient-Reported Indicator Survey (PaRIS)~Disease specific questionaires:~* COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale.~* Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22)."
48718672|NCT06421402|DIAGNOSTIC_TEST|Lung function Testing: Baseline & every six months & during exacerbations|"* Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1)~* Forced Oscillation Technique: Impedance, resistance and reactance.~Ancillary measurements: Systemic arterial pressure and pulse oximetry."
48024082|NCT04442516|OTHER|Questionnaire, sampling of blood, urine and saliva|We are following patients who are receiving Cisplatin as part of their cancer therapy.
48024083|NCT05806697|PROCEDURE|Electroencephalogram (EEG)|The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
48024084|NCT05806697|PROCEDURE|Oculomotor tests|All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
48024085|NCT05806697|PROCEDURE|MRI|All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
48024086|NCT05806697|RADIATION|18-F amyloid PET Scan|The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
48181551|NCT02630706|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
48181552|NCT02630706|DRUG|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
48181553|NCT02166476|DRUG|Meropenem-Vaborbactam|Meropenem-vaborbactam
48181554|NCT02166476|DRUG|Piperacillin-Tazobactam|Piperacillin-tazobactam
48181555|NCT02166476|DRUG|Levofloxacin|Levofloxacin
48181556|NCT02166476|DRUG|Saline|Saline
48181557|NCT01520337|DEVICE|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
48181558|NCT03024996|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
48181559|NCT03024996|OTHER|Placebo|Placebo matching to atezolizumab q3w
48181560|NCT00846508|DRUG|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
48181561|NCT04417569|DRUG|hCG|human chorionic gonadotropin
48181562|NCT04417569|DIAGNOSTIC_TEST|Ultrasound|Endometrial thickness monitoring
48181563|NCT04417569|OTHER|Blood test|Progesterone, Luteinizing Hormone, Estradiol
48181564|NCT06311643|OTHER|Postpartum back massage in study group|Effleurage massage from shoulders toward lower back
48181565|NCT04045847|BIOLOGICAL|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
48181566|NCT00167154|DRUG|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
48181567|NCT04215315|OTHER|Retrospective observation|Case note and imaging review
48181568|NCT03985436|BEHAVIORAL|Trek for Surgical Success|Cognitive behavioral therapy for pain
48024087|NCT05806697|RADIATION|18F-fluorodeoxyglucose (FDG) PET Scan|Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
48519370|NCT03851029|OTHER|Aerobic Training|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
48519371|NCT06384833|DRUG|Ascorbic acid|Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days
48181569|NCT06266598|DRUG|Metformin|Only obese children with insulin resistance were treated with metformin.
48181570|NCT04242992|BEHAVIORAL|CETA|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.
48181571|NCT04242992|OTHER|Short Message Service (SMS) text reminders|Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
48181572|NCT01383330|DRUG|megace|800mg
48181573|NCT01383330|DRUG|DW-ES(A)|625mg
48181574|NCT01383330|DRUG|DW-ES(B)|625mg
48519372|NCT06384833|DRUG|N-acetyl cysteine|NAC (effervescent) 600mg 1 tab PO OD for 45 days
48519373|NCT06384833|OTHER|placebo|pharmacologically inactive substance
48181575|NCT00639899|PROCEDURE|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
48181576|NCT00926081|BEHAVIORAL|Supervised exercise training|A standardized supervised exercise training program
48181577|NCT01075477|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
48181578|NCT02412449|DRUG|AKB-6548 tablet, reference formulation given in the fasted state|
48181579|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fasted state.|
48181580|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fed state|
48181581|NCT03480113|BEHAVIORAL|Mindfulness-based Intervention|mindful breath, body scan, sitting meditation and walking meditation and so on.
48181582|NCT03480113|BEHAVIORAL|Physical fitness intervention|giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.
48181583|NCT03272503|DRUG|Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Pimozide 2mg tablets will be taken once daily.
48181584|NCT03272503|DRUG|Placebo Oral Tablet|Identical matching placebo lactose tablets
48519374|NCT04405297|DEVICE|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
48519375|NCT00000542|DRUG|Inhibitors, ACE|
48519376|NCT00000542|DRUG|amlodipine|
48519377|NCT00000542|DRUG|lisinopril|
48519378|NCT00000542|DRUG|doxazosin|
48519379|NCT00000542|DRUG|chlorthalidone|
48519380|NCT00000542|DRUG|pravastatin|
48519381|NCT00000542|BEHAVIORAL|diet, fat-restricted|
48519382|NCT02969421|OTHER|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
48519383|NCT02969421|OTHER|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
48718673|NCT06421402|OTHER|EMR & registry data|"Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases.~Registry data: from the Catalan Health Surveillance System (CHSS)."
48181585|NCT04601597|DEVICE|Shu Bei Kang (China) Midline Catheters|The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
48718674|NCT06421402|DEVICE|Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)|Health Circuit: chat, short questionnaires (Likert scale). As needed.
48519384|NCT02740192|PROCEDURE|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
48181586|NCT00856245|DRUG|Rituximab|375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
48181587|NCT03432468|DRUG|Valsartan 1|the high dose of valsartan
48181588|NCT03432468|DRUG|Valsartan 80 mg|a single dose of valsartan
48181589|NCT00356759|DRUG|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
48181590|NCT04375267|DRUG|177Lu-DOTA-TATE + olaparib|177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
48181591|NCT01536171|OTHER|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
48718675|NCT06421402|DEVICE|Physiological data - Beat One Watch|Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))
48718676|NCT06421402|DEVICE|Patient Empowerment|Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor
48718677|NCT06421402|OTHER|Characteristics of exacerbations|Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.
48718678|NCT00066547|BIOLOGICAL|monoclonal antibody HuHMFG1|
48718679|NCT06217419|DEVICE|Radio Frequency IDentification (RFID) device|"RFID devices monitor breathing patterns by means of temperature measurements of the respiratory airflow. The temperature gradient of the air flow in and out of the airways can be correlated to the flow-based respiratory patterns. Accordingly, a temperature-based breath monitoring can be achieved by means of on-skin RFID sensors attached below the nose. Finally, a bilateral measurement of nostrils respiratory flow can provide more information since nasal cavities do not behave in the same way during a respiratory cycle.~In this project we will evaluate the possibility to perform domestic breath flow analysis by exploiting thin, lightweight and battery-less sensing plasters directly attached under the nose. The system includes a proper external reader interrogating the face sensors that is capable to directly communicate with smartphone/pc/tablet/cloud environment."
48718680|NCT00955604|DRUG|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
48718681|NCT00955604|DRUG|Group R Rasagiline|At least 2 months of rasagiline
48181592|NCT02312206|DRUG|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
48181593|NCT02312206|OTHER|Placebo|Placebo
48181594|NCT04434118|DRUG|Traditional antirheumatic drugs|Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
48181595|NCT05473936|BEHAVIORAL|Community Health Worker led curriculum|The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
48181596|NCT02111863|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
48181597|NCT02111863|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
48181598|NCT02111863|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
48181599|NCT02111863|BIOLOGICAL|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
48181600|NCT04927364|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil|The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
48519385|NCT02740192|PROCEDURE|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
48519386|NCT02740192|DRUG|Ropivacaine|Ropivacaine was used for the periarticular injection
48519387|NCT02740192|DRUG|Bupivacaine|Bupivacaine was used for the periarticular injection
48519388|NCT01342601|DEVICE|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
48718682|NCT00955604|DRUG|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
48718683|NCT02784015|DRUG|Cisplatin|
48718684|NCT02784015|DRUG|Etoposide|
48718685|NCT02784015|DRUG|Doxorubicin|
48718686|NCT02784015|DRUG|Cyclophosphamide|
48718687|NCT02784015|DRUG|Ifosfamide|
48718688|NCT02784015|DRUG|Carboplatin|
48718689|NCT02784015|RADIATION|Radiotherapy|
48181601|NCT06140342|BEHAVIORAL|Feasibility study of music-based mobile app|To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.
48181602|NCT04434001|DRUG|Fibrinogen Concentrate Human|Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
48181603|NCT04434001|DRUG|Prothrombin Complex Concentrate|Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
48181604|NCT04434001|BIOLOGICAL|Fresh Frozen Plasma|Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
48181605|NCT01793636|DRUG|AZD2014|AZD2014 vs Everolimus
48181606|NCT01793636|DRUG|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
48181607|NCT01073319|OTHER|Placebo|Administration of placebo pill
48181608|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
48181609|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
48181610|NCT01052363|DRUG|Bevacizumab, CA4P|
48181611|NCT02923505|PROCEDURE|polygraphy or polysomnography|
48181612|NCT03450668|DEVICE|mOm incubator|24 hour usage of test incubator
48181613|NCT03450668|DEVICE|standard incubator|standard incubator
48181614|NCT02970097|DRUG|20ml bolus of 0.5% ropivicaine|local anesthetic
48181615|NCT02970097|DRUG|10 ml of 0.5% ropivicaine|local anesthetic
48181616|NCT02970097|DRUG|Midazolam|1-2 mg of medication given intravenously before nerve block
48181617|NCT02970097|DRUG|Fentanyl|50-100 mcg of medication given intravenously before nerve block
48181618|NCT04001335|DIAGNOSTIC_TEST|Dental Broach|Dental broach, RDT and PCR
48181619|NCT01177956|BIOLOGICAL|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
48519389|NCT01342601|DEVICE|Placebo products|Nasal Spray and Eye drops without Ectoin
48718690|NCT02784015|DRUG|Thiotepa|
48718691|NCT02784015|DRUG|Melphalan|
48181620|NCT01177956|DRUG|Cisplatin|Subjects will receive 75 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
48181621|NCT01177956|DRUG|5-Fluorouracil|Subjects will receive 750 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
48181622|NCT00611169|DRUG|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
48181623|NCT01612247|DRUG|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
48181624|NCT01816347|PROCEDURE|Routine PCI|
48181625|NCT03236610|DRUG|tenofovir monotherapy|switching to tenofovir monotherapy
48181626|NCT03236610|DRUG|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
48181627|NCT02719041|OTHER|Immunohistochemistry staining method|
48181628|NCT02992847|OTHER|Unenhanced MRI|
48181629|NCT04636645|OTHER|Normal treadmill|Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.
48181630|NCT04636645|OTHER|Anti-gravity treadmill with lower limb positive pressure|Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
48181631|NCT04636645|OTHER|Anti-gravity treadmill with without lower limb positive pressure|Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
48181632|NCT01949636|OTHER|Functional Magnetic Resonance Imaging|
48519390|NCT06037863|OTHER|Best Practice|Undergo bladder filling prior to CT
48181633|NCT00607581|DRUG|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
48181634|NCT00607581|DRUG|lenalidomide|lenalidomide: 15 mg orally on days 1-21
48181635|NCT00607581|DRUG|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
48181636|NCT01025505|DRUG|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
48181637|NCT01025505|DRUG|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
48181638|NCT01459146|DRUG|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
48519391|NCT06037863|PROCEDURE|Computed Tomography|Undergo CT
48519392|NCT06037863|OTHER|Electronic Health Record Review|Ancillary studies
48181639|NCT01459146|DRUG|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
48181640|NCT01459146|DRUG|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
48181641|NCT05097937|OTHER|Sham intervention|The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
48024088|NCT05806697|BIOLOGICAL|Blood sampling|A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
48024089|NCT05806697|BIOLOGICAL|Lumbar puncture|A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
48181642|NCT05097937|OTHER|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
48181643|NCT05097937|OTHER|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
48181644|NCT00832000|DRUG|Mexiletine|200 mg three times a day; in pill form
48181645|NCT00832000|DRUG|Placebo|Placebo three times a day; in pill form
48181646|NCT06547268|DEVICE|Wireless sensor and platform|Skin-mounted sensor that pairs with tablet platform
48181647|NCT05236647|DRUG|Morphine|Intravenous morphine infusion compared to subcutaneous morphine infusion
48181648|NCT05586412|DEVICE|vagus nerve stimulation|Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
48181649|NCT01565317|OTHER|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
48181650|NCT05726266|OTHER|Music|Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
48718692|NCT02611141|PROCEDURE|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
48718693|NCT01354704|DRUG|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
48024090|NCT02859194|PROCEDURE|Veno-veno-arterial ECMO|
48024091|NCT04118218|OTHER|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% \[1, 2, 3, 4\]."
48181651|NCT05726266|OTHER|Audiobook|Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
48181652|NCT02267265|OTHER|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
48718694|NCT01897649|DIETARY_SUPPLEMENT|NUTRIOSE FB06|15g/day NUTRIOSE FB06
48181653|NCT02267265|OTHER|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
48519393|NCT06037863|PROCEDURE|Imaging Technique|Undergo bladder emptying prior to CT
48519394|NCT06037863|OTHER|Questionnaire Administration|Ancillary studies
48718695|NCT01897649|DIETARY_SUPPLEMENT|GLUCIDEX 21|15g/day GLUCIDEX 21
48718696|NCT04789694|OTHER|Physiological intervention|"* Rehabilitation specialist consultation (3x)~* Individualized home-based exercise plan~* Functional capacity measuring"
48519395|NCT06037863|RADIATION|Radiation Therapy|Undergo radiation therapy
48718697|NCT04789694|BEHAVIORAL|Psychological intervention|"* Clinical psychologist consultation (3x)~* Anxiety and depression scoring~* Psychological support"
48718698|NCT04789694|DIETARY_SUPPLEMENT|Nutritional intervention|"* Nutritional specialist consultation (3x)~* Malnutrition scoring~* Dietary supplementation"
48024092|NCT01887431|OTHER|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
48024093|NCT01887431|OTHER|Conventional therapy|3-month routine clinic visits
48024094|NCT00711685|PROCEDURE|coronary artery bypass grafting via midline sternotomy|
48382607|NCT06649617|OTHER|Control Group (Standard Procedure)|Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied. .
48519396|NCT06249061|DIETARY_SUPPLEMENT|oral sodium bicarbonate|Those in the oral sodium bicarbonate intervention group will be encouraged to sip a solution of 1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved into 250ml of water throughout labour with other drinks. If the first solution is fully consumed, a second solution will be prepared and offered. Thus, each participant can receive a maximum dose of 2 imperial teaspoons (\~10g) of sodium bicarbonate.
48519397|NCT02333084|DIETARY_SUPPLEMENT|PRN Joint Health Formula|
48519398|NCT02333084|DIETARY_SUPPLEMENT|placebo|
48519399|NCT02333084|DIETARY_SUPPLEMENT|PRN Flex Omega Benefits® combination|
48519400|NCT06265259|DRUG|Initiation of vasopressine as a first vasoconstrictive drug|The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.
48718699|NCT03612843|OTHER|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
48718700|NCT03821623|DRUG|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
48718701|NCT03821623|OTHER|Placebo|Subjects will take placebo pills twice a day for 3 months
48718702|NCT04254874|DRUG|Abidol hydrochloride|0.2g once, 3 times a day,two weeks
48718703|NCT04254874|DRUG|Abidol Hydrochloride combined with Interferon atomization|Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
48718704|NCT00469326|DRUG|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
48718705|NCT04152434|DRUG|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
48718706|NCT01299571|DRUG|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
48718707|NCT03287674|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
48718708|NCT03287674|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
48718709|NCT03287674|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
48718710|NCT03287674|DRUG|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
48718711|NCT03287674|DRUG|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
48718712|NCT03287674|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
48024095|NCT04265079|OTHER|Additional weight at hand|Added weight of an inactive hand orthosis (300 gram)
48024096|NCT03593083|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
48024097|NCT03593083|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
48024098|NCT01682291|BEHAVIORAL|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
48024099|NCT01682291|DIETARY_SUPPLEMENT|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
48024100|NCT00836641|BIOLOGICAL|prevenar|7-valent pneumococcal conjugate vaccine
48024101|NCT00836641|BIOLOGICAL|pneumovax|23 valent pneumococcal polysaccharide vaccine
48024102|NCT01411189|DRUG|Menthol|20 mL NPO-11 in prefilled syringe
48024103|NCT01994486|DRUG|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
48024104|NCT03946332|BEHAVIORAL|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
48718713|NCT04460586|DRUG|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
48266873|NCT03787589|BEHAVIORAL|Exercise Prescription|"Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription and monitor adherence."
48382608|NCT06649617|OTHER|Music Therapy Group|Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
48382609|NCT06649617|OTHER|Virtual Reality Group|Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
48382610|NCT03733418|DRUG|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
48382611|NCT03733418|DRUG|Placebo|Placebo that matched the vitamin D3 color was provided.
48382612|NCT00869700|DRUG|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
48718714|NCT04460586|DRUG|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
48718715|NCT03552588|DIAGNOSTIC_TEST|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
48718716|NCT05116605|OTHER|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
48024105|NCT03946332|BEHAVIORAL|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
48024106|NCT02688634|DRUG|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
48266874|NCT06272344|OTHER|Teleconsultation|Teleconsultation at 6 months
48266875|NCT05187832|DRUG|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
48718717|NCT05453994|DRUG|H. pylori eradication|PPIs-based Antimicrobial agents for H. pylori eradication
48718718|NCT06176508|DRUG|HS-10374|Administered orally QD for 16 weeks
48718719|NCT06176508|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 16 weeks
48024107|NCT05316857|DRUG|Orelabrutinib + Rifampin|Orelabrutinib + Rifampin
48024108|NCT05316857|DRUG|Orelabrutinib + Itraconazole|Orelabrutinib + Itraconazole
48024109|NCT05487924|OTHER|SVV-GDHT|GDHT guided by SVV using Flotra/Vigileo monitor
48024110|NCT05487924|OTHER|O2ER-GDHT|GDHT guided by O2ER
48024111|NCT05487924|OTHER|conventional care|conventional fluid therapy without GDHT
48519401|NCT06265259|DRUG|Initiation of noradrenaline as a first vasoconstrictive drug|ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
48382613|NCT05782907|DRUG|Upadacitinib|Oral Solution/ Tablets
48519402|NCT05280301|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
48181654|NCT04487353|OTHER|Labor mechanism application developed with virtual reality technology (VRT-LMA)|"In phase I: VRT-LMA application was developed. (Female in lithotomy position, bony pelvis, flexion of the coccyx back about 2 cm and the Hodge plane were modeled as lines. The theory training to be given to the control group was prepared in accordance with the curriculum.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~III. In the second stage: the post-test and analyzes were performed after 5 weeks in both groups."
48181655|NCT00739115|OTHER|Heliox gas|Heliox gas used in conjunction with nasal CPAP
48181656|NCT00048503|DRUG|ZARNESTRA, tipifarnib, R115777|
48181657|NCT02265666|DRUG|BIIL 284 BS Tablet FF|
48181658|NCT02265666|DRUG|BIIL 284 BS tablet C|
48181659|NCT02265666|OTHER|standard breakfast|
48181660|NCT04806594|DEVICE|Papix acne scar|PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration
48382614|NCT04243655|DEVICE|HA 330-II|One unit for 2-4 hours treatment, for 3 consecutive days
48382615|NCT04243655|DRUG|Standard medical treatment (SMT)|SMT as per patients requirement- Management of cerebral edema/intracranial hypertension: prophylactic antibiotics, administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure, volume replacement and pressor support (noradrenaline, doubutamine, dopamine) as needed, NAC and correction of metabolic parameters.
48382616|NCT01754805|DRUG|peficitinib|oral
48382617|NCT01754805|DRUG|methotrexate|oral
48519403|NCT03514290|RADIATION|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
48382618|NCT06382766|DIAGNOSTIC_TEST|Skeletal Muscle Ultrasonography|Skeletal Muscle Ultrasonography in Detection of Malnutrition and Prediction of The Outcome among critically ill children
48382619|NCT05662319|DRUG|Fitusiran|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
48382620|NCT05662319|DRUG|Clotting factor concentrates (CFC) or bypassing agents (BPA)|"* Coagulation factor VIII (ATC code: B02BD02)~* Coagulation factor IX (ATC code: B02BD04)~* Coagulation factor VIIa (ATC code: B02BD08)~* Factor VIII inhibitor bypassing activity (ATC code: B02BD03)~Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)"
48382621|NCT05662319|DRUG|Antithrombin concentrate (ATIIIC)|Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
48382622|NCT05772104|DRUG|Shugan Jieyu Capsules|Oral, 4 Capsules, BID
48519404|NCT03514290|OTHER|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
48519405|NCT03514290|OTHER|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
48718720|NCT06176508|DRUG|Tofacitinib 5Mg Tab,Oral|Administered orally BID for 16 weeks
48718721|NCT01853072|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
48718722|NCT01853072|OTHER|Nepafenac vehicle|Inactive ingredients used as placebo comparator
48718723|NCT01853072|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
48718724|NCT05504668|DIETARY_SUPPLEMENT|Turmeric Brainwave|A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.
48382623|NCT05772104|DRUG|Shugan Jieyu Capsules+Placebo|"Drug: Shugan Jieyu Capsules, Oral，3 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID"
48718725|NCT04526470|DRUG|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
48718726|NCT04526470|DRUG|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
48382624|NCT05772104|DRUG|Placebo|Oral，4 capsules，BID
48382625|NCT05257109|OTHER|Water Concentration 1|E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.
48718727|NCT04094961|DRUG|Ixazomib|Oral, administered four times per cycle
48718728|NCT04094961|DRUG|Pomalidomide|Oral, administered 14 times per cycle
48266876|NCT00003490|BIOLOGICAL|sargramostim|
48266877|NCT00003490|DRUG|cyclophosphamide|
48266878|NCT00003490|DRUG|prednisone|
48266879|NCT00003490|DRUG|vincristine sulfate|
48181661|NCT05747612|OTHER|Counseling and Coaching|"Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives."
48181662|NCT05692219|BEHAVIORAL|Lifestyle medicine|6 weeks booklet-delivered multicomponent lifestyle medicine intervention
48181663|NCT05692219|BEHAVIORAL|Cognitive behavioral therapy|6 weeks booklet-delivered self-help cognitive behavioral therapy
48181664|NCT01519778|DRUG|TR701 FA|1 tablet 200 mg once daily
48181665|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine
48181666|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with normal saline
48181667|NCT05280197|DRUG|liposomal bupivacaine plus free bupivacaine|TAP block using liposomal bupivacaine plus free bupivacaine
48382626|NCT05257109|OTHER|Water Concentration 2|E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
48382627|NCT05257109|OTHER|Water Concentration 3|E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.
48718729|NCT04094961|DRUG|Dexamethasone|Oral, fixed dose administered 8 times per cycle
48382628|NCT05257109|OTHER|Water Concentration 4|E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
48382629|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W0, W4, W8 and W20|
48382630|NCT00219362|BIOLOGICAL|one injection of vCP1452 at W4, W8 and W20|
48382631|NCT00219362|BIOLOGICAL|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
48519406|NCT02106234|OTHER|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
48718730|NCT00314301|DEVICE|loaded sit-to-stand training|
48181668|NCT05280197|DRUG|normal saline|TAP block using normal saline
48181669|NCT01536587|DRUG|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
48181670|NCT04867447|DIAGNOSTIC_TEST|Psychological trauma evaluation|"Psychological trauma exposure is assessed by validated scales:~* Childhood Trauma Questionnaire (CTQ)~* Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~* Cumulative Trauma Scale.~* The Holmes and Rahe Stress Scale.~Other clinical scales used:~* Positive and Negative Syndrome Scale (PANSS).~* Dissociative Experiences Scale (DES)~* Mini-Mental State Examination (MMSE)."
48181671|NCT02607787|BEHAVIORAL|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
48181672|NCT02607787|OTHER|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
48519407|NCT00192803|DRUG|candesartan|
48718731|NCT02988999|DIETARY_SUPPLEMENT|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
48718732|NCT02988999|DIETARY_SUPPLEMENT|erythritol|non-calorie sweetener
48718733|NCT05740319|OTHER|FMT|FMT refers to transplanting healthy donor-derived microbiota to participants via oral capsule or injection of fecal suspension via nasojejunal tube.
48718734|NCT01035346|DRUG|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
48718735|NCT01035346|DRUG|Placebo|Single dose of a placebo
48181673|NCT03679897|DRUG|Ropivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
48181674|NCT03679897|DRUG|Levobupivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
48382632|NCT06243510|OTHER|apixaban|Participants will be randomized to receive a prescription for prophylactic apixaban
48382633|NCT06243510|OTHER|enoxaparin|Participants will be randomized to receive a prescription for prophylactic enoxaparin
48519408|NCT04071834|DIAGNOSTIC_TEST|ELISA|Detection of blood orphanin and norepinephrine in patients
48519409|NCT05949697|DIETARY_SUPPLEMENT|Dry Eye Drink|Dry Eye Drink is a dietary supplement containing electrolytes, vitamins and natural anti-inflammatories.
48181675|NCT03095170|BEHAVIORAL|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
48718736|NCT00606398|PROCEDURE|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
48718737|NCT03693547|DRUG|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
48519410|NCT05963815|OTHER|Spine surgery|Patients operated with laminectomy, microscopic discectomy, percutaneous transforaminal endoscopic discectomy, and spondylodesis.
48718738|NCT03622320|OTHER|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
48718739|NCT03613467|PROCEDURE|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
48718740|NCT03613467|PROCEDURE|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
48718741|NCT02301481|RADIATION|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
48181676|NCT03095170|BEHAVIORAL|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
48181677|NCT03095170|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
48181678|NCT03095170|BEHAVIORAL|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
48181679|NCT03095170|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
48181680|NCT03815253|OTHER|acupuncture|"Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
48382634|NCT01170767|DRUG|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
48718742|NCT02301481|DRUG|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
48718743|NCT02301481|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
48382635|NCT01170767|DRUG|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
48382636|NCT05591404|BEHAVIORAL|Trier Social Stress Test (TSST)|Participants randomized to the TSST arm will experience the Trier Social Stress Test.
48382637|NCT05635643|DRUG|CHS-114|CHS-114
48382638|NCT05635643|DRUG|toripaliamab|toripalimab-tpzi
48718744|NCT02301481|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
48718745|NCT04292457|DRUG|Propofol|Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
48718746|NCT04292457|DRUG|Sevoflurane|Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
48718747|NCT06129929|BEHAVIORAL|Hospital Jujutsu Group, HJJ Group|The aim of this study, procedures, methodology, and the subject's rights were well explained to the eligible nursing staff according to the informed consent form. Written informed consent was obtained from each participant before data collection.
48024112|NCT05547932|PROCEDURE|RIB+SAP blocks|RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
48382639|NCT05393765|BEHAVIORAL|Yönetebilirim|"Yönetebilirim is an interactive web-based program developed to improve the self-management skills of individuals with MS by supporting self-regulation under the leadership of nurses."
48382640|NCT04964960|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy that can help fight certain cancers.
48382641|NCT04964960|DRUG|Nab paclitaxel|Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.
48024113|NCT02559986|OTHER|telephone interview|telephone interview about their care received during the first year of life and associated events
48382642|NCT04964960|DRUG|Paclitaxel|Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.
48382643|NCT04964960|DRUG|Pemetrexed|Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.
48382644|NCT04964960|DRUG|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.
48382645|NCT06567275|PROCEDURE|block|ultrasound guided nerve block
48382646|NCT05887752|OTHER|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation."
48382647|NCT05887752|DEVICE|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
48382648|NCT01901939|OTHER|exercise|daily tailored low level pedaling exercise at bedside
48382649|NCT00822237|BIOLOGICAL|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart
48382650|NCT00822237|BIOLOGICAL|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart
48718748|NCT01314560|OTHER|Blood sample|Blood sample
48718749|NCT06507397|DRUG|hyperbaric bupivacaine and fentanyl|Patients received 3ml hyperbaric bupivacaine 0.5% combined with 25 microg of fentanyl.
48181681|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
48382651|NCT00822237|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection \~6 weeks apart
48382652|NCT00835133|OTHER|biologic sample preservation procedure|one blood sample
48382653|NCT00835133|OTHER|medical chart review|confirmation of cancer diagnosis
48382654|NCT00835133|OTHER|survey administration|at baseline enrollment and 12 months post-enrollment
48382655|NCT04384887|BEHAVIORAL|covid-19 positive pregnant women|"It is planned to receive pregnant women who are admitted to the clinic or outpatient clinic and who are offered inpatient follow-up and treatment with the diagnosis of COVID-19.~Pregnant women who do not have covid-19 disease as a control group and who do not have a comorbid disease at similar gestational week will be included in the study. As a control group, covid-19 pcr negative patients will be admitted to our clinic in the same period."
48382656|NCT04612712|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
48382657|NCT04612712|BIOLOGICAL|KN046 Injection|5mg/kg Q3W
48382658|NCT03914209|OTHER|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
48519411|NCT00001021|BIOLOGICAL|rgp120/HIV-1IIIB|
48024114|NCT00647231|DRUG|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
48024115|NCT00647231|OTHER|Placebo Patch|Treatment with placebo patch
48519412|NCT00001021|BIOLOGICAL|rgp120/HIV-1MN|
48519413|NCT04197778|DRUG|DDO-3055 tablet|DDO-3055 tablet, 2 single doses separated by 6 days.
48718750|NCT06507397|DRUG|plain bupivacaine and fentanyl|Patients received 15 mL mixture of (0.25% plain bupivacaine and 50 µg fentanyl) over 5 minutes, injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
48718751|NCT03056963|BEHAVIORAL|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
48718752|NCT03056963|BEHAVIORAL|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
48382659|NCT03759509|BEHAVIORAL|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
48382660|NCT04571164|DRUG|LY03003(Rotigotine,extended-release microspheres)|During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
48382661|NCT04571164|DRUG|Placebo,extended-release microspheres|During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
48718753|NCT01166061|BIOLOGICAL|Placebo|Solution resembling active solution but without peptides
48382662|NCT00142961|DRUG|Atomoxetine|atomoxetine
48382663|NCT00142961|OTHER|placebo|
48382664|NCT05816304|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
48718754|NCT01166061|BIOLOGICAL|ToleroMune Grass|1 x4 administrations 4 weeks apart
48718755|NCT02933840|DEVICE|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
48718756|NCT02410265|BEHAVIORAL|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
48718757|NCT02410265|BEHAVIORAL|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
48718758|NCT04432805|DEVICE|Performing of lung ultrasound|Performing of lung ultrasound at bedside in labor ward or in COVID unit
48718759|NCT06506006|BIOLOGICAL|Covid infection|outcome with and without covid infection
48181682|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
48181683|NCT04785768|DRUG|Morphine Sulfate Sustained-release Tablets|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for day 1; 2）the total equianalgesic of the previous 24 hours/2 for day 2 ; 3）Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；4) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours;"
48181684|NCT06492772|OTHER|experimental group|The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
48181685|NCT04451837|DRUG|Semaglutide|Ozempic s.c. once weekly for 6 months
48181686|NCT04451837|DRUG|Dapagliflozin|Forxiga 10 mg p.o. once daily for 6 months
48181687|NCT02619214|DRUG|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
48718760|NCT00225342|DRUG|Rosiglitazone|
48718761|NCT00225342|DRUG|Gliclazide (Comparison drug)|
48718762|NCT03323671|DRUG|preemptive mefenamic acid|preemptive analgesia before menstrual pain
48181688|NCT02619214|DRUG|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
48382665|NCT06384170|DEVICE|Spinal Cord Stimulation- Closed loop|This is a percutaneously placed epidural electrode that is connected to a battery-powered impulse generator for power. The electrical delivery is monitored in real-time with the measurement of evoked compound action potentials and adjusted to provide titration of therapeutic stimulation delivery.
48718763|NCT03323671|DRUG|mefenamic acid|mefenamic acid given only during menstruation
48181689|NCT00364364|DRUG|Radiolabeled humanized PAM4 IgG|
48519414|NCT02666729|PROCEDURE|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
48718764|NCT04015869|DRUG|Allopregnanolone|neurosteroid
48718765|NCT04015869|DRUG|Placebos|placebo
48718766|NCT05473286|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
48718767|NCT02499042|DRUG|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
48718768|NCT02302235|OTHER|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.
48718769|NCT02302235|OTHER|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
48718770|NCT03163368|RADIATION|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
48718771|NCT03163368|PROCEDURE|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
48718772|NCT04059107|DEVICE|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
48718773|NCT04419480|DEVICE|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
48718774|NCT00026377|DRUG|bicalutamide|50 mg daily for 1 month
48718775|NCT00026377|DRUG|flutamide|250 mg 3 times daily for 1 month
48718776|NCT00026377|DRUG|goserelin acetate|3.6 mg once a month for 4 months
48181690|NCT02109666|DRUG|Abatacept|
48181691|NCT02772237|BIOLOGICAL|Riboflavin|Riboflavin 400mg daily
48181692|NCT02772237|BIOLOGICAL|Placebo|
48181693|NCT02162017|OTHER|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
48181694|NCT02162017|OTHER|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
48181695|NCT02201901|DRUG|SOF/VEL|400/100 mg tablets administered orally once daily
48181696|NCT02201901|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
48181697|NCT00534053|OTHER|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
48181698|NCT02868671|OTHER|acupuncture|
48718777|NCT00026377|DRUG|leuprolide acetate|7.5 mg once a month for 4 months
48718778|NCT00026377|DRUG|SU5416|IV infusion at assigned dose
48718779|NCT00026377|RADIATION|radiation therapy|daily for 5 days each week
48718780|NCT00001307|DRUG|Oxygen-15 Water|
48718781|NCT00001307|DRUG|Capsaicin|
48718782|NCT05004974|DRUG|Sintilimab|Sintilimab is administered every 3 weeks (200mg, IV).
48718783|NCT05004974|DRUG|Pemigatinib|Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
48718784|NCT03697044|PROCEDURE|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
48718785|NCT01303302|DEVICE|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
48382666|NCT04633434|BEHAVIORAL|The Talk Parenting Skill for Alexa|In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
48382667|NCT02252172|DRUG|Daratumumab IV|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
48382668|NCT02252172|DRUG|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
48382669|NCT02252172|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenously once in a week.
48382670|NCT02252172|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
48718786|NCT01303302|DEVICE|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
48718787|NCT02383433|DRUG|Regorafenib|Given PO
48718788|NCT02383433|DRUG|Gemcitabine Hydrochloride|Given IV
48718789|NCT00068510|BIOLOGICAL|therapeutic autologous dendritic cells|
48718790|NCT04515329|DRUG|Cyclosporine|Eye drops taken twice daily.
48718791|NCT04515329|DRUG|Artificial tear|Preservative-free artificial tear drops 4 times a day.
48718792|NCT02767739|BEHAVIORAL|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
48181699|NCT02868671|OTHER|sham acupuncture|
48382671|NCT04679649|OTHER|Manual spinal mobilisation physiotherapy|Manual spinal mobilisation is a physiotherapy technique to improve spinal mobility by gently applying pressure manually on the each segmental vertebrae by hands-on treatment of a physiotherapist.
48718793|NCT00871923|DRUG|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
48718794|NCT00871923|RADIATION|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
48718795|NCT02972541|DEVICE|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
48718796|NCT02972541|DEVICE|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
48718797|NCT03345576|DEVICE|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
48382672|NCT04881448|DIAGNOSTIC_TEST|collection of serum/capillary creatinine values|collection of serum/capillary creatinine values
48382673|NCT01600612|DRUG|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
48382674|NCT01600612|DRUG|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
48382675|NCT01600612|DRUG|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
48382676|NCT06651801|BEHAVIORAL|Group Medical Visits|Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
48382677|NCT05134740|BIOLOGICAL|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10\^7/m2"
48519415|NCT02666729|PROCEDURE|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
48519416|NCT04736745|BIOLOGICAL|IPN59011|Powder and solvent for solution for injection
48718798|NCT03345576|DRUG|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
48718799|NCT04326855|OTHER|Incremental shuttle walking protocol (ISWT)|Patients will perform an incremental shuttle walk test to the limit of tolerance to establish peak walking speed. The test will be developed in a 10-m course corridor, and it will be externally-paced via a recorded metronome that gives a signal for each stride. The walking pace will be increased every minute and the test will be terminated when the individual is no longer able to keep up the pace. Pulmonary variables will be recorded breath-by-breath. Cardiac output will be assessed every min. Arterial oxygen saturation will be measured by a pulse oximeter. Patients will score the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every minute.
48718800|NCT04326855|OTHER|Endurance shuttle walking (ESW) protocol|Subsequently, during the second visit all patients will perform the continuous endurance shuttle walk (ESW) protocol to the limit of tolerance at a walking speed corresponding to 85% of VO2 peak derived by the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions to walk for as long as possible although there will be a predetermined 6 minute maximum point. No further encouragement will be provided during the exercise performance. The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
48718801|NCT04326855|OTHER|First Intermittent shuttle walking protocol|All patients will perform an intermittent shuttle walking protocols to the limit of tolerance (visit 3) by alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak (equivalent to the continuous ESW protocol) with 1-min rest periods.The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point.Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
48718802|NCT04326855|OTHER|Second Intermittent shuttle walking protocol|To obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses this intermittent shuttle walking protocol will be repeated on a different day (visit 4). The test will be terminated when the individual is no longer able to keep up the pace or stops due to intolerable exertional symptoms although there will be a predetermined 20 minute maximum point. Gas exchange and cardiorespiratory variables will be assessed as per visit 1.
48382678|NCT00940329|DRUG|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
48382679|NCT00940329|DRUG|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
48382680|NCT02985515|BEHAVIORAL|Smell training|Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
48382681|NCT02190968|BEHAVIORAL|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
48382682|NCT02190968|BEHAVIORAL|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
48382683|NCT06385821|BIOLOGICAL|Grippol Quadrivalent|Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
48519417|NCT04736745|BIOLOGICAL|Azzalure|Powder for solution for injection
48519418|NCT04736745|DRUG|Placebo|Powder for solution for injection
48519419|NCT02846571|BIOLOGICAL|Human Pancreatic Islet Transplantation|Human pancreatic islet transplantation in the eye anterior chamber of legally blind patients with insulin-dependent type 1 or type 2 diabetes
48181700|NCT02080403|DRUG|2.5 mg Chlorhexidine gluconate chip|Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
48382684|NCT06385821|BIOLOGICAL|Grippol Plus|Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
48382685|NCT06134687|PROCEDURE|Endoscopic Submucosal Dissection|Removal of study eligible lesions per endoscopic submucosal dissection
48382686|NCT06134687|DEVICE|Novel Rigidizing Overtube|Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
48718803|NCT04326855|OTHER|Focus group study|Semi-structured interviews to explore patients' preferences of undertaking the intermittent or continuous ESW protocols and healthcare professionals' perceived factors affecting the implementation of these protocols in the PR setting. These semi-structured interviews consist of questions in some degree predetermined order but still ensures flexibility in the way issues are addressed to the patients. Conversation is sustained in an informal tone and lasts for about an hour. Participants are allowed for an open response in their own words.
48718804|NCT03623178|OTHER|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
48718805|NCT03623178|OTHER|Treatment As Usual|The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
48718806|NCT01237782|DRUG|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
48718807|NCT01237782|DRUG|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
48718808|NCT05011721|DEVICE|Activity tracker|"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."
48718809|NCT02416700|PROCEDURE|immediate implant surgery|Surgery of dental implants in one side of the mouth.
48718810|NCT02416700|DEVICE|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
48718811|NCT03273660|DEVICE|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
48382687|NCT03731117|DRUG|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
48718812|NCT02952560|OTHER|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
48718813|NCT01029444|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
48718814|NCT04622904|DRUG|lidocaine-magnesium infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of ketamine of 0.35 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 0.2 mg/kg/h of ketamine will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
48382688|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 1|5.0 e5/ kg CD19-BCMA CAR-T positive T cells
48382689|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|1.5 e6/ kg CD19-BCMA CAR-T positive T cells
48382690|NCT06371040|DRUG|CD19-BCMA Targeted CAR-T Dose 2|5 e6/ kg CD19-BCMA CAR-T positive T cells
48718815|NCT04622904|DRUG|lidocaine-ketamine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of magnesium of 50 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Followingly, 10 mg/kg/h of magnesium will be administered intraoperatively diluted in a 60 mL syringe and administered at a rate of 20 mL/h
48718816|NCT04622904|DRUG|lidocaine infusion|A bolus dose of lidocaine of 1.5 mg/kg will be administered within 10 minutes preoperatively diluted in 100 mL of saline. Then, 3 mg/kg/h of lidocaine will be administered intraoperatively. A bolus dose of normal saline 100 mL will be administered preoperatively within 10 minutes. Followingly, normal saline will be administered intraoperatively at a rate of 20 mL/h
48718817|NCT03990805|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection
48718818|NCT03990805|DRUG|saline|saline, 1 time injection
48382691|NCT01030055|DRUG|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
48718819|NCT03409510|RADIATION|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
48382692|NCT05056740|BIOLOGICAL|Data analysis|Analysis of the data from routine care at the end of the diagnostic work-up
48382693|NCT05632055|OTHER|blood draw|Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
48382694|NCT04130594|BIOLOGICAL|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
48382695|NCT04130594|OTHER|placebo|placebo
48718820|NCT01534949|BIOLOGICAL|rituximab|375 mg/m2 by intravenous \[IV\] infusion
48718821|NCT03331822|OTHER|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
48024116|NCT05801601|BEHAVIORAL|Many Ways of Being, an innovative sexual health promotion program focused on addressing rigid gender norms and promoting healthy relationships|The Many Ways of Being program is a gender-synchronous program informed by Equimundo's existing single-gender Manhood 2.0 and Sisterhood 2.0 programs. The curriculum is designed to shift unequal gender attitudes and behaviors and provide skill-building on maintaining healthy relationships, making healthy and informed decisions around sex, and avoiding risky sexual behaviors.
48382696|NCT02493023|DEVICE|navigated bronchoscopy|
48382702|NCT03305159|DRUG|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
48382703|NCT03305159|DRUG|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
48382704|NCT02064374|DRUG|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
48382705|NCT02064374|DRUG|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
48382706|NCT02064374|DRUG|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
48382707|NCT04983628|OTHER|Tumor molecular profiling|targeted DNA NGS
48181701|NCT05018897|BEHAVIORAL|To Share or Not to Share|Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.
48181702|NCT05018897|BEHAVIORAL|Peer Support|Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
48181703|NCT05498922|PROCEDURE|Peak pressure when mechanical ventilation was switched around a reasonable range|The research protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and written informed consents were obtained from all patients. After induction of anesthesia, Rb patients were transorally intubated and mechanically ventilated. The inspiratory time, ventilation rate, positive end-expiratory pressure, and oxygen concentration were set consistently among patients. When anesthesiologist switch the peak pressure around a reasonable range, indices including tidal volume, lung compliance, mean airway pressure on ventilator screen changed and were recorded when stable. All the ventilator setting parameters followed the guidance of mechanical ventilation in neonates and children (https://doi.org/10.1007/978-3-030-83738-9_8). All the anesthesia and ventilation performance were conducted by a fully qualified senior anesthesiologist to assure standardized and safe anesthesia, ventilation and operation procedure.
48181704|NCT04056793|OTHER|Optimized birthing position|The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
48181705|NCT05383105|PROCEDURE|Virtual bronchoscopic navigation|Virtual bronchoscopy navigation (VBN) calculates the access to a solitary pulmonary nodule via a trans-parenchymal route. In contrast to the gold Standard transthoracic approach, with this technique also very small lesions (7 mm diameter), and lesions which cannot be reached via the transthoracic route - located in the inner two thirds of the lung - can be approached.
48181706|NCT03712449|DEVICE|JUVÉDERM®|Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).
48181707|NCT03712449|DRUG|BOTOX Cosmetic®|BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
48718822|NCT05500300|DEVICE|Neo-Russian|"Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
48718823|NCT05500300|DEVICE|Aussie|"Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
48718824|NCT05500300|DEVICE|RBS|"Subjects will receive RBS electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
48382708|NCT06616753|BIOLOGICAL|vaccination status|knowledge of own vaccination status
48181708|NCT03712449|DRUG|BELKYRA®|BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).
48718825|NCT05500300|DEVICE|RBS-IPI|"Subjects will receive RBS-IPI electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
48024117|NCT05801601|BEHAVIORAL|A career readiness program|Youth enrolled in the control condition will receive a career readiness curriculum, either International Youth Foundation's Passport to Success, LAYC's Next Generation program or LAYC's Career Readiness Curriculum, depending on the site and implementation period. These programs equip young people with a range of professional, employment readiness, and practical skills that will help them stay in school and acquire the education, professional skills, employment
48024118|NCT01316848|DRUG|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
48382709|NCT02801149|PROCEDURE|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
48024119|NCT04083989|OTHER|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
48382710|NCT05558007|DRUG|Tadalafil 5mg|Daily oral administration of tadalafil 5mg
48382711|NCT05558007|DRUG|BZ371A|Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
48024120|NCT03749226|DRUG|Aztreonam lysine|nebulization
48382712|NCT05558007|DRUG|Oral Placebo|Oral administration of a placebo pill
48382713|NCT05558007|DRUG|Topical Placebo|Topical application of 1.5 mL of placebo
48382714|NCT05866159|OTHER|Kinesiotape using Rocktape®|Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
48382715|NCT05866159|OTHER|Sham taping|sham taping with Rocktape®, with no tension.
48382716|NCT05858515|DRUG|Baricitinib 4 MG|Nonproprietary name: Baricitinib
48718826|NCT05500300|DEVICE|HIFEM|"Subjects will receive HIFEM electrical stimulation with three reps (5 sec work x 60 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.~They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction."
48024121|NCT03749226|DEVICE|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
48024122|NCT03749226|DEVICE|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
48024123|NCT05996887|OTHER|standard care protcol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to standard care protocol.
48024124|NCT05996887|OTHER|enhanced recovery protocol|All patients will receive antiemetics as haloperidol 2 mg and dexamethasone 8 mg and ondansetron 8 mg in addition to following the recommendation of ERAS society guidelines.
48024125|NCT06573099|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
48181709|NCT03712449|OTHER|SkinMedica|SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
48181710|NCT04287283|OTHER|Hyperbaric Oxygen|40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
48382717|NCT05858515|DRUG|Placebo|Placebo
48519420|NCT05029219|DEVICE|Arm I (Virtual reality group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The test group receives about 60 minutes of training using a virtual reality program."
48718827|NCT01092962|DRUG|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
48718828|NCT01092962|DRUG|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
48718829|NCT05641987|BEHAVIORAL|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
48718830|NCT03198364|BEHAVIORAL|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
48718831|NCT03198364|BEHAVIORAL|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
48718832|NCT05135481|PROCEDURE|phrenectomy|The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
48024126|NCT03032692|DEVICE|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
48024127|NCT03032692|OTHER|Exercise with biofeedback|
48024128|NCT03032692|OTHER|exercise without biofeedback|
48024129|NCT03771729|DRUG|LCZ 696|LCZ696 200mg twice daily
48024130|NCT00766376|DEVICE|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
48718833|NCT05135481|OTHER|Increased lactation support|Management in group 2 will include increased lactation care both during hospital stay and post discharge.
48024131|NCT01332305|DRUG|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
48718834|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
48718835|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
48718836|NCT00454649|DRUG|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
48718837|NCT00454649|DRUG|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
48024132|NCT01332305|DRUG|Placebo|Placebo orally once daily
48024133|NCT02352493|DRUG|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
48024134|NCT02352493|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
48024135|NCT04612270|OTHER|Venous blood collection|Two venous blood collections in within one week. No drug-related intervention in-vivo.
48024136|NCT03681301|OTHER|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
48024137|NCT01252251|DRUG|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
48024138|NCT03007316|PROCEDURE|VIP graft|surgical soft tissue grafting concomitant to implant placement
48024139|NCT00320346|BIOLOGICAL|Pandemic Influenza Vaccine|
48024140|NCT05710068|DEVICE|RF Microneedle|Pulsed-type RF device in bipolar mode with 25 non-insulated microneedles every 2 weeks for 6 month
48519421|NCT05029219|DEVICE|Arm II (Self study group)|"In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The control group have provided with video materials and books provided during audiovisual education and have given time for self-study for 60 minutes. Subsequently, a second test is performed with a fluroscopy-guided lumbar transforaminal epidural block with a human-shaped phantom."
48024141|NCT05710068|DRUG|Combination cream|5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months
48024142|NCT03884283|DEVICE|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)
48024143|NCT01428492|DRUG|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
48024144|NCT01428492|DRUG|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
48024145|NCT01428492|DRUG|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
48024146|NCT03748498|DEVICE|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
48024147|NCT00000597|DRUG|antilymphocyte serum|
48024148|NCT00000597|DRUG|nandrolone|
48024149|NCT04861649|BIOLOGICAL|fecal microbiota transplantation|"The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)"
48024150|NCT00148343|DEVICE|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation \& use for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
48181711|NCT01688310|PROCEDURE|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has ...an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
48181712|NCT01688310|PROCEDURE|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
48382718|NCT05040386|BEHAVIORAL|EPIC|Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.
48382719|NCT05040386|OTHER|Usual COPD Care|Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.
48382720|NCT06650345|OTHER|supervised aerobic exercise|In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
48382721|NCT02526017|BIOLOGICAL|Cabiralizumab|Solution for IV administration
48024151|NCT00148343|OTHER|Conventional Standard of Care|Conventional standard of care (which may include implementation \& use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for \~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
48024152|NCT00148343|PROCEDURE|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
48024153|NCT00985218|DEVICE|SMART System|microfluidic embryo culture system
48181713|NCT00808145|DRUG|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
48181714|NCT00329563|DRUG|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
48181715|NCT02435576|RADIATION|Radiotherapy (primary or postoperative)|
48181716|NCT00692458|DRUG|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
48181717|NCT00692458|DRUG|Comparator: placebo|placebo; oral, once daily for approximately 60 months
48181718|NCT01547624|OTHER|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
48181719|NCT00907764|DRUG|regadenoson|400 ug, IV
48181720|NCT00637468|DRUG|Intravenous injection of heparin|
48181721|NCT00637468|DRUG|Intravenous injection of acetazolamide|
48382722|NCT02526017|BIOLOGICAL|Nivolumab|Solution for IV administration
48382723|NCT03287908|DRUG|AMG 701|Subjects will receive IV infusions of AMG 701.
48181722|NCT00637468|PROCEDURE|Local intra-arterial fibrinolysis|
48181723|NCT00637468|PROCEDURE|Globe massage|
48181724|NCT00637468|DRUG|Topical use of beta-blocker|
48181725|NCT00637468|DRUG|Isovolaemic haemodilution|
48181726|NCT00637468|DRUG|Acetylsalicylic acid|
48181727|NCT02339597|PROCEDURE|Automatic Positive Airway Pressure (APAP) initiation|
48718838|NCT00454649|DRUG|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
48718839|NCT00454649|DRUG|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
48718840|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
48718841|NCT00454649|DRUG|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
48519422|NCT01456806|OTHER|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
48718842|NCT00454649|DRUG|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.
48718843|NCT00454649|DRUG|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.
48718844|NCT05287048|DIAGNOSTIC_TEST|MCM5 ELISA|ADXGYNAE is a non-invasive ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the detection of endometrial cancer in women with postmenopausal bleeding who are suspected of having endometrial cancer. Participants will be asked to provide a urine specimen, which will be centrifuged before the sediment is lysed. The lysed sample will then be tested with the MCM5 ELISA.
48718845|NCT00005976|DRUG|carboplatin|
48718846|NCT00005976|DRUG|pyrazoloacridine|
48718847|NCT00710242|DRUG|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
48718848|NCT00710242|DRUG|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
48181728|NCT02478645|DRUG|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
48382724|NCT03287908|DRUG|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
48382725|NCT03287908|DRUG|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
48382726|NCT06269705|DRUG|ZILRETTA|IA injection of 32 mg ZILRETTA
48382727|NCT06269705|DRUG|TCA-IR|IA injection of 40 mg TCA-IR
48382728|NCT06269705|OTHER|Placebo|IA injection of placebo (normal saline)
48718849|NCT02488642|DRUG|Isosorbide Dinitrate|
48718850|NCT02488642|DRUG|Misoprostol|
48718851|NCT02488642|DRUG|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
48718852|NCT01981889|DRUG|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
48718853|NCT04208087|DRUG|SI-722|SI-722 will be intravesically instilled.
48718854|NCT04208087|DRUG|Placebo|Placebo will be intravesically instilled.
48718855|NCT05901324|RADIATION|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
48718856|NCT04941404|DRUG|TQ05105 tablets|Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
48718857|NCT05995197|OTHER|action observation|cartoon observation
48718858|NCT06282601|OTHER|Audiogram|Tonal and vocal free-field without lip-reading
48718859|NCT06282601|OTHER|Musical priming for the syntax test|Listening to music with a regular or irregular rhythm, then judging the grammaticality of 2x6 blocks of French sentences interrupted by a pause, each block presenting 4 sentences including 2 grammatically correct sentences and 2 grammatically incorrect sentences. The sentences are pronounced by a French female voice at a natural rhythm and comfortable volume.
48181729|NCT02478645|DRUG|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
48181730|NCT02478645|DRUG|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
48181731|NCT03626831|DRUG|Evolocumab Prefilled Syringe|Injection of study drug
48181732|NCT03626831|DRUG|Placebos|Injection of placebo
48519423|NCT04211116|DEVICE|Central venous line insertion|Pediatric patients indicated to central venous line insertion
48519424|NCT03888066|DRUG|Patiromer|The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
48181733|NCT02053883|DRUG|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
48718860|NCT06282601|OTHER|Test MMSE|test to assess a person's cognitive functions and memory capacity.
48382729|NCT06456749|COMBINATION_PRODUCT|Integrated Disease Management|For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
48382730|NCT04914234|DRUG|Atenolol Succinate Oral Tablet|Atenolol 50 mg
48382731|NCT04914234|DRUG|Metoprolol Succinate Oral Tablet|Metoprolol 100 mg
48382732|NCT05375487|OTHER|Carbonated Natural Mineral Water|750 mL/day of carbonated natural mineral water, with high content of bicarbonate, calcium, and magnesium, in three portions of 250 mL (one portion 30 minutes prior to lunch, one during the afternoon and the last portion minutes before dinner), during 4 weeks.
48382733|NCT05375487|OTHER|Low Mineral Water|750 mL/day of low mineral water (one third prior to lunch, one third during the afternoon and the last third 30 minutes before dinner), during 4 weeks.
48382734|NCT03949946|PROCEDURE|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
48382735|NCT03814824|DIAGNOSTIC_TEST|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
48382736|NCT03814824|DIAGNOSTIC_TEST|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
48382737|NCT03125239|DRUG|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
48718861|NCT06282601|OTHER|Barcelona Music Reward Questionnaire|"20 questions exploring 5 main facets of the musical reward experience, with 4 items for each of the 5 facets, for which participants indicate the level of agreement using a 5-level scale, ranging from strongly disagree to strongly agree."
48024154|NCT00985218|DEVICE|Culture dish|Standard IVF culture dish
48024155|NCT01061294|PROCEDURE|Advanced CustomVue™ iLASIK procedure|
48024156|NCT01061294|DEVICE|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
48024157|NCT04913857|BEHAVIORAL|24-week SUDOKU Training Programme|12-week face-to-face training session and a 12-week facilitated self-practice
48024158|NCT04913857|OTHER|Control Arm (wait-list)|wait-list comparison group will receive the same program upon completion of the 6-month posttest evaluation on study outcomes
48024159|NCT04757012|DEVICE|calinange|calinange
48024160|NCT01799174|PROCEDURE|UVA-1 Phototherapy|
48024161|NCT01799174|PROCEDURE|Placebo|
48024162|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
48024163|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
48024164|NCT00828646|DRUG|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
48024165|NCT00828646|DRUG|Placebo|Capsules, Oral, once daily, 14 days
48024166|NCT05039268|DRUG|3K3A-APC Protein|3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
48024167|NCT02905526|BEHAVIORAL|Contraceptive instant messages|Contraceptive Instant messages
48024168|NCT02905526|OTHER|Mobile phone app|Mobile phone app
48024169|NCT00038493|DRUG|Temozolomide and SCH66336|
48024170|NCT05013892|RADIATION|NTS-WBRT (normal tissue sparing whole brain radiation therapy)|Radiation
48024171|NCT05013892|DRUG|Memantine|Capsule, taken orally
48024172|NCT03056846|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
48024173|NCT03056846|DIETARY_SUPPLEMENT|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
48024174|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
48382738|NCT03125239|DRUG|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
48382739|NCT04293562|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
48382740|NCT04293562|DRUG|Asparaginase|Given IM or IV
48718862|NCT03256435|BEHAVIORAL|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
48718863|NCT03396510|OTHER|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
48718864|NCT05147103|DEVICE|Low-Intensity Focused Ultrasound|LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
48382741|NCT04293562|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
48382742|NCT04293562|PROCEDURE|Biospecimen Collection|Correlative studies
48382743|NCT04293562|PROCEDURE|Bone Marrow Aspiration|Undergo BM aspiration
48382744|NCT04293562|PROCEDURE|Bone Marrow Biopsy|BM biopsy
48382745|NCT04293562|BEHAVIORAL|Cogstate Assessment Battery|Ancillary studies
48382746|NCT04293562|PROCEDURE|Computed Tomography|Undergo CT
48382747|NCT04293562|DRUG|Cytarabine|Given IV or IT
48382748|NCT04293562|DRUG|Daunorubicin Hydrochloride|Given IV
48382749|NCT04293562|DRUG|Dexrazoxane Hydrochloride|Given IV
48382750|NCT04293562|DRUG|Etoposide|Given IV
48382751|NCT04293562|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
48382752|NCT04293562|DRUG|Gemtuzumab Ozogamicin|Given IV
48382753|NCT04293562|DRUG|Gilteritinib Fumarate|Given PO/NG/G-tube
48382754|NCT04293562|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48382755|NCT04293562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48181734|NCT02053883|DRUG|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
48382756|NCT04293562|DRUG|Methotrexate|Given IT
48382757|NCT04293562|DRUG|Mitoxantrone Hydrochloride|Given IV
48382758|NCT04293562|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
48382759|NCT04293562|DRUG|Therapeutic Hydrocortisone|Given IT
48382760|NCT02181673|DRUG|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
48382761|NCT02181673|DRUG|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
48382762|NCT00088400|DRUG|TransMID|
48382763|NCT05940558|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
48382764|NCT01212432|DRUG|Daptomycin|Daptomycin kinetics in CRRT
48718865|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on M1 and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The participants will be positioned in ventral decubitus position. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on C3 to stimulate the left primary motor cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
48024175|NCT03056846|DIETARY_SUPPLEMENT|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
48024176|NCT02343341|BEHAVIORAL|Preschool Health Promotion Education Program|
48024177|NCT05743985|OTHER|Cannabigerol|Hemp-derived full spectrum cannabigerol oil carried in an organic coconut (MCT) oil within hydroxypropyl methylcellulose capsules.
48024178|NCT01854554|RADIATION|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
48024179|NCT01854554|RADIATION|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
48181735|NCT00711308|DRUG|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
48181736|NCT00711308|DRUG|acenocoumarol|acenocoumarol for 6 months
48382765|NCT04279002|OTHER|Brief 15-question questionnaire|Questionnaire is mailed retrospectively to the respiratory rehabilitation program and aimed at targeting 17 psycho-social traits. Response time is estimated at 10 minutes
48382766|NCT04912804|OTHER|Questionnaires|SF-12, GHQ-12 and HAQ
48024180|NCT01854554|BEHAVIORAL|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
48024181|NCT01854554|BEHAVIORAL|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
48024182|NCT04419636|DRUG|Lu AG06466|capsules, orally
48024183|NCT01706510|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
48024184|NCT01706510|DRUG|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
48024185|NCT04989998|DEVICE|Hip7 Software on Kick/ CORI platforms|Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
48024186|NCT04989998|DEVICE|Conventional surgical procedures|THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
48024187|NCT05170698|PROCEDURE|Coaltion excision and arthroereisis|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
48024188|NCT05170698|PROCEDURE|Coalition excision and corrective osteotomies|Both done to treat rigid flat foot with talocalcaneal coalition. Talocalcaneal coalition excision and management of rigid pes planovalgus in adolescent
48024189|NCT03498534|DRUG|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
48181737|NCT01515852|PROCEDURE|general anesthesia in stereotactic biopsy|stereotactic biopsy
48181738|NCT01515852|PROCEDURE|local anesthesia in stereotactic biopsy|stereotactic biopsy
48181739|NCT01722747|BEHAVIORAL|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)|A 7-month intervention was conducted over one academic year \& included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
48181740|NCT01952847|OTHER|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
48024190|NCT03498534|DRUG|Isoniazid 300 MG|+ TST test will receive isoniazid 300MG Tab for 6 months
48181741|NCT01952847|DRUG|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
48181742|NCT01952847|BEHAVIORAL|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
48718866|NCT04496661|DEVICE|Transcranial Direct Current Stimulation on DLPFC and Peripheral Electrical Stimulation|Patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes, paired to the same PES protocol. The direct current (2 mA) will be transferred through a neuro-stimulator (TransCranial Technologies, Hong Kong, China), with the use of electrodes and 4x4 cm sponges moistened with 0.9% saline solution. The anodic electrode will be placed on F3 to stimulate the left dorsolateral cortex according to the international 10-20 EEG system. The reference electrode will be positioned in the supra orbital contralateral region. For the PES, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed).
48024191|NCT03498534|DRUG|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
48024192|NCT05699863|BEHAVIORAL|Lifestyle intervention|"Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months."
48024193|NCT03465540|DRUG|AMG 397|AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
48024194|NCT03465540|DRUG|Dexamethasone|Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
48718867|NCT04496661|DEVICE|Sham tDCS and PES|For sham tDCS and PES stimulation, patients will be submitted to 10 treatment sessions, five days a week, for 30 minutes. The anodic electrode will be positioned on the left primary motor cortex, but the current will be turned off automatically after 30 seconds. The reference electrode will be positioned in the supra orbital contralateral region. For sham PES stimulations, four self-adhesive electrodes with dimensions of 5 x 5 cm will be placed at the height between the T12 and S1 vertebrae in order to cover the entire lumbar area. A 20Hz frequency and pulse duration of 330ms will be provided by means of two channels from an electro-stimulator (Neurodyn, Ibramed), but the current will be turned off automatically after 30 seconds.
48718868|NCT00777699|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
48718869|NCT00777699|DRUG|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
48718870|NCT01073124|PROCEDURE|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
48718871|NCT00531583|DRUG|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
48718872|NCT01496105|DRUG|Lidocaine|
48718873|NCT01496105|DRUG|saline|
48181743|NCT04413422|DRUG|type of hypnotic used for induction of general anesthesia|
48382767|NCT02570399|RADIATION|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
48382768|NCT00838760|DRUG|TMC558445; TMC310911; Darunavir; Placebo|
48718874|NCT04615325|DRUG|RO7303359|RO730359 will be administered as a single intravitreal injection.
48718875|NCT03876600|PROCEDURE|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
48718876|NCT00444977|BEHAVIORAL|Case-management linkage intervention|dental care
48024195|NCT03465540|DRUG|Azacitidine|Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
48024196|NCT01902017|DRUG|Ketotifen|5 mg PO bid
48024197|NCT01902017|DRUG|Placebo|5 mg placebo PO bid
48024198|NCT00487201|PROCEDURE|endoscopic balloon dilatation|
48024199|NCT00487201|PROCEDURE|plastic stent placement|
48024200|NCT00659165|DRUG|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
48181744|NCT00136370|DRUG|Chlorhexidine|
48181745|NCT00136370|PROCEDURE|Birth canal wipe|
48181746|NCT00136370|PROCEDURE|sterile water external genital wipe|
48181747|NCT05326698|PROCEDURE|Medtronic NIM Eclipse for evoked potentials recording|Recording of somesthetic and motor evoked potentials during endoscopic posterior cervical foraminotomy.
48181748|NCT03838523|OTHER|Open Label Placebo|See group description
48181749|NCT02169557|DRUG|Fexinidazole|
48382769|NCT01102881|DIETARY_SUPPLEMENT|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
48382770|NCT01102881|DIETARY_SUPPLEMENT|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
48718877|NCT01939132|DRUG|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
48718878|NCT01439126|DRUG|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
48718879|NCT01439126|DRUG|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
48718880|NCT04311398|DIAGNOSTIC_TEST|New QIAstat-Dx fully automatic multiple PCR detection platform|We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients
48718881|NCT02713529|BIOLOGICAL|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
48382771|NCT01102881|DIETARY_SUPPLEMENT|placebo|low fiber breakfast cereal and muffin
48382772|NCT00554788|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
48382773|NCT00554788|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
48718882|NCT04170387|OTHER|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
48382774|NCT00554788|DRUG|Carboplatin|Given IV
48382775|NCT00554788|DRUG|Cisplatin|Given IV
48382776|NCT00554788|DRUG|Cyclophosphamide|Given IV
48382777|NCT00554788|DRUG|Etoposide|Given IV
48382778|NCT00554788|BIOLOGICAL|Filgrastim|Given SC
48382779|NCT00554788|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
48024201|NCT00659165|DRUG|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
48024202|NCT06164912|OTHER|Transcranial Magnetic Simulation with Pseudofeedback|Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
48024203|NCT06164912|OTHER|Transcranial Magnetic Simulation with Neurofeedback|Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
48718883|NCT05212844|PROCEDURE|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
48718884|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
48024204|NCT03663075|BEHAVIORAL|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
48024205|NCT03663075|BEHAVIORAL|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
48024206|NCT01231698|DRUG|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
48024207|NCT01231698|OTHER|control|standard treatment without strict heart rate control
48382780|NCT00554788|RADIATION|Radiation Therapy|Undergo radiotherapy
48718885|NCT00313976|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
48718886|NCT05978635|BEHAVIORAL|Group A Standard 4 deep breaths measured in milliliters from the ventilator.|Tidal volume breath measured in milliliters
48718887|NCT05978635|BEHAVIORAL|Group B Coached 4 deep breaths measured in milliliters from the ventilator|Coached tidal volume breath measured in milliliters
48718888|NCT01401699|DEVICE|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
48718889|NCT00261508|DRUG|risperidone|
48718890|NCT03296631|OTHER|collection of diapers with fresh stools|collection of diapers with fresh stools
48718891|NCT03551665|BEHAVIORAL|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
48718892|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection|9MW1411 injection
48024208|NCT06161909|DRUG|sintilimab|200mg fixed dose Q3W,1 year
48024209|NCT04498884|DRUG|Rinsulin® mix 30/70|one subcutaneous injection at a dose of 0.4 IU/kg
48181750|NCT00746629|BEHAVIORAL|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
48181751|NCT02339623|DEVICE|Ultrasound imaging|"1. - Fetal adrenal gland volume calculation using 3D ultrasound~2. - Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~3. - CL measurement using 2D ultrasound"
48181752|NCT02557126|DRUG|URC102|
48181753|NCT02557126|DRUG|Placebo|
48181754|NCT05225207|OTHER|Non-interventional|No intervention will be administered.
48382781|NCT00554788|DRUG|Thiotepa|Given IV
48382782|NCT00554788|DRUG|Vincristine Sulfate|Given IV
48382783|NCT05735717|DRUG|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
48382784|NCT05735717|DRUG|Busulfan|Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
48382785|NCT05735717|DRUG|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
48382786|NCT05735717|DRUG|Rituximab|200 mg/m2 intravenous given once on day-1
48382787|NCT05735717|DRUG|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
48382788|NCT06144645|DEVICE|tVNS, intermittent stimulation|transcutaneous vagus nerve stimulation, intermittent stimulation
48382789|NCT06144645|DEVICE|tVNS, continuous stimulation|transcutaneous vagus nerve stimulation, continuous stimulation
48382790|NCT06067191|DRUG|RV299|Oral Suspension
48382791|NCT06067191|DRUG|Placebo|matching placebo
48382792|NCT05635682|OTHER|Observational and anthropometric assesments|Plantar sensation, foot reaction time, head and trunk proprioceptions, posture, balance and gait assesments
48382793|NCT06650943|BEHAVIORAL|Nursing Consultation in Weight Management and Metabolic syndrome|Based on the Carbohydrate-insulin Theory
48382794|NCT00179101|PROCEDURE|Deep Brain Stimulation|
48382795|NCT00003652|DRUG|cisplatin|
48382796|NCT00003652|DRUG|fluorouracil|
48382797|NCT00003652|PROCEDURE|neoadjuvant therapy|
48382798|NCT00003652|RADIATION|radiation therapy|
48382799|NCT00916773|DEVICE|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
48382800|NCT05456321|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS)
48382801|NCT05456321|BEHAVIORAL|Cognitive Training|Computerized Cognitive Training
48382802|NCT05456321|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS)
48382803|NCT06652737|BIOLOGICAL|PfSPZ-LARC2 Vaccine|The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double genetic deletion, of the Mei2 and LINUP genes, and undergo developmental arrest in the late liver stages without releasing merozoites into the blood stream (no blood stage parasites are produced)
48382804|NCT06652737|BIOLOGICAL|Normal Saline (Placebo)|Normal Saline Placebo
48718893|NCT04784312|COMBINATION_PRODUCT|9MW1411 injection placebo|9MW1411 injection placebo
48181755|NCT00807105|DEVICE|H-coil dTMS|treatment with deep TMS stimulation.
48382805|NCT06653699|DRUG|2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID|In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
48382806|NCT06653699|DRUG|1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID|In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
48382807|NCT03916055|BEHAVIORAL|Exposure and response prevention (ERP)|"The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist."
48382808|NCT03916055|BEHAVIORAL|Education on tics|"The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist."
48382809|NCT03948646|DRUG|Sofpironium Bromide, 15%|Active
48382810|NCT03948646|DRUG|Vehicle|Vehicle gel
48718894|NCT03928626|BEHAVIORAL|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
48718895|NCT03928626|BEHAVIORAL|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
48718896|NCT01612650|DEVICE|tomosynthesis|2 incidences 3D numeric mammography
48718897|NCT01612650|DEVICE|2D mammography|2 incidences 2D analogic mammography
48718898|NCT05920772|BEHAVIORAL|KickAsh! intervention|The general aim of the KickAsh! intervention is to prevent smoking initiation in adolescents living in vulnerable socioeconomic situations. The intervention exists of different components concerning smoking prevention. Most components have a direct influence on smoking initiation by affecting several determinants of the adolescents. These components include smoke-free games, mood boards, a smoke-free camp, the Kick some Ash!-challenge and exercises concerning self-efficacy and skills. Yet, some of the components target adolescents by influencing their environment, i.e. smoking policy in the organisation and youth workers as role models. All components are developed using a combination of theoretical methods to change or influence these determinants or environmental factors.
48718899|NCT01386268|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
48718900|NCT03917550|BEHAVIORAL|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
48718901|NCT03917550|BEHAVIORAL|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
48382811|NCT03014427|OTHER|Biological Database|Biological Database
48519425|NCT03888066|DRUG|Placebos|The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
48519426|NCT00082277|DRUG|Anastrozole|1mg/Day Oral
48382812|NCT03955016|OTHER|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~1. Interval training on a cyclo-ergometer~2. Strength training of the upper and lower extremities~3. Guided walks"
48382813|NCT03642158|DEVICE|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
48382814|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
48718902|NCT05616585|OTHER|Pharmacokinetic (PK)- Controlled Feeding Diet|Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
48382815|NCT01320176|BIOLOGICAL|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
48382816|NCT02975882|DRUG|Irinotecan Hydrochloride|Given PO
48382817|NCT02975882|OTHER|Laboratory Biomarker Analysis|Correlative studies
48718903|NCT05616585|OTHER|Dose Response (DR)- Controlled Feeding Diet|Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.
48718904|NCT03027232|OTHER|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
48718905|NCT01008969|OTHER|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
48718906|NCT01915823|DRUG|azelastine hydrochloride and fluticasone propionate|
48519427|NCT00082277|DRUG|Risedronate Sodium|35mg/week, oral
48382818|NCT02975882|OTHER|Pharmacological Study|Correlative studies
48382819|NCT02975882|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
48382820|NCT02975882|DRUG|Temozolomide|Given PO
48519428|NCT04113018|DRUG|Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab|Experimental
48519429|NCT02770482|BIOLOGICAL|spinal fluid collection|
48718907|NCT01915823|DRUG|Dymista vehicle|
48718908|NCT00140959|DRUG|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
48024210|NCT04498884|DRUG|Humulin® M3|one subcutaneous injection at a dose of 0.4 IU/kg
48718909|NCT00140959|DRUG|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
48718910|NCT02974894|DIETARY_SUPPLEMENT|Probiotic (Lactobacillus Plantarum)|
48718911|NCT02974894|DIETARY_SUPPLEMENT|Placebo|
48718912|NCT00421642|DRUG|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
48718913|NCT05105113|PROCEDURE|Zirconia dental implant installation surgery|Dental implant installation surgery using zirconia one-piece implant (Tav-dental)
48718914|NCT03109691|DRUG|bupivacaine|group 1
48718915|NCT03109691|DRUG|Dexamethasone|group 2
48718916|NCT03109691|DEVICE|ultrasound|in all groups
48718917|NCT02371200|DEVICE|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
48519430|NCT00543881|DEVICE|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
48519431|NCT00543881|DEVICE|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
48024211|NCT06573827|DIAGNOSTIC_TEST|Blood and urine sample evaluation|Blood and urine sample evaluation will be performed in healthy female volunteers.
48519432|NCT03437408|DEVICE|Mapping and ablation|High density substrate map. Data collection during ablation
48181756|NCT06016699|OTHER|blood draws|Blood draws to collect PBMCs at baseline (week 0), during (chemo)radiation treatment (end of week 3 and/or before delivery of cycle 4 of cisplatin) and after conclusion of (chemo)radiation (week 9, week 12, week 20, week 34 and week 60, respectively 1 week, 5 weeks, 3 months, 6 months and 12 months after completion of (chemo)radiation) in order to compare immunological function upon treatment with either protons or photons
48519433|NCT05665725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48519434|NCT05665725|PROCEDURE|Computed Tomography|Undergo CT scan
48519435|NCT05665725|PROCEDURE|Positron Emission Tomography|Undergo PET scan
48519436|NCT05665725|BIOLOGICAL|Siltuximab|Given IV
48519437|NCT06128408|DRUG|risperidone, olanzapine, aripiprazole|Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.
48519438|NCT02256423|DRUG|REFERENCE 1: Nurofen® 200 mg tablet|
48024212|NCT00743353|DRUG|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
48024213|NCT02929810|BEHAVIORAL|sleep extension|
48024214|NCT02929810|BEHAVIORAL|sleep maintenance|
48181757|NCT00543062|DRUG|Inhaled placebo|Inhaled Staccato placebo (0 mg)
48519439|NCT02256423|DRUG|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
48519440|NCT02256423|DRUG|ibuprofen 200 mg soft gel capsule|
48519441|NCT01911897|DEVICE|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
48519442|NCT00074308|DRUG|imatinib mesylate|Given orally
48519443|NCT00074308|BIOLOGICAL|bevacizumab|Given IV
48519444|NCT00074308|OTHER|pharmacological study|Correlative studies
48024215|NCT02423382|PROCEDURE|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
48024216|NCT01246726|PROCEDURE|CT SCAN|Prior to radiotherapy + after radiotherapy completion
48024217|NCT01246726|PROCEDURE|MRI scan|Prior to radiotherapy + after completion of radiotherapy
48024218|NCT01246726|PROCEDURE|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
48024219|NCT04689828|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
48024220|NCT04689828|DRUG|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
48024221|NCT04689828|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
48024222|NCT04689828|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
48024223|NCT02928692|DRUG|Minocycline|
48024224|NCT02928692|DRUG|Placebo|
48181758|NCT00543062|DRUG|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
48181759|NCT00543062|DRUG|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
48181760|NCT00543062|DRUG|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
48181761|NCT00543062|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
48382821|NCT01076140|DRUG|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
48382822|NCT01076140|DRUG|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
48519445|NCT00074308|OTHER|laboratory biomarker analysis|Correlative studies
48519446|NCT00362336|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
48519447|NCT00362336|BIOLOGICAL|CombAct-HIB®|0.5 mL, IM
48519448|NCT00362336|BIOLOGICAL|Engerix B® Pediatric|0.5 mL, IM
48519449|NCT04635917|OTHER|Personalized diet|Participants in this group will receive tailored nutrition counseling from a dietitian. To facilitate meeting these dietary goals, participants will be provided with nuts, fruits, and vegetables.
48519450|NCT04635917|OTHER|Conventional dietary advice|Participants in the CD group will receive non-personalized, conventional dietary advice by a dietitian based on the MyPlate guidelines.
48519451|NCT05361863|DEVICE|Orthodontic brackets|Interventions involving orthodontic brackets of different slot sizes
48519452|NCT00711243|DRUG|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
48519453|NCT00711243|DRUG|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
48382823|NCT06650059|OTHER|Questionnaire|Self-questionnaire intended to each patient with sickle cell disease seen in consultation in one of the three reference centers participating in the study. Patients will complete the questionnaire once, on site.
48718918|NCT04112979|BEHAVIORAL|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
48024225|NCT03291444|BIOLOGICAL|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
48382824|NCT05238701|DRUG|LPM3770164 sustained release tablet|LPM3770164 sustained release tablet will be administrated orally single-dose on day 1
48718919|NCT04112979|BEHAVIORAL|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
48718920|NCT04112979|BEHAVIORAL|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
48718921|NCT05614284|DEVICE|Virtuos|Use of autograft or Virtuous Lyograft as an adjunct to spinal fusion in TLIF.
48718922|NCT04454645|BEHAVIORAL|mABC|Intervention targets parenting sensitivity and nurturance.
48718923|NCT04454645|BEHAVIORAL|mDEF|Intervention targets parenting enhancing infant cognitive development
48718924|NCT03361189|DEVICE|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
48718925|NCT03361189|DEVICE|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
48718926|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
48718927|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
48718928|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
48718929|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
48718930|NCT00832052|DRUG|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
48718931|NCT00117689|BIOLOGICAL|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
48718932|NCT00117689|DRUG|Corticosteroid|For a minimum of 3 months
48718933|NCT00117689|DRUG|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
48718934|NCT00117689|DRUG|Mycophenolate Mofetil|for at least 1 month posttransplant
48718935|NCT06507670|DIAGNOSTIC_TEST|Point of care ultrasound|"Point of care medical ultrasound machines will be used to sonographically visualize the esophagus and following sonographic data will be collected:~* Presence/absence of suspected foreign body~* Sonographic esophageal measurements (diameters, area)~* Other relevant secondary sonographic findings"
48718936|NCT03135210|OTHER|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
48718937|NCT03135210|DEVICE|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
48718938|NCT05205369|BEHAVIORAL|10-week home-based Yi Jin Bang exercise program|Each participant in this group will do a home-based Yi Jin Bang exercise program four times a week for ten consecutive weeks, which consists of ten minutes of warm-up, 18 minutes of Yi Jin Bang exercise (ten exercises), and ten minutes of cool-down. To learn how to conduct the home-based exercise session, each participant will be invited to one introductory session before starting the prescribed exercise program. Two experienced Yi Jin Bang instructors will lead the introductory session. Besides, in order to monitor participants' adherence and help them to conduct self-training, we will use the Zoom Meeting application. Zoom can capture and record participants' movements through the webcam. During the introduction sessions, we will teach participants how to use Zoom. Furthermore, we will provide support for adherence to the home exercise sessions through telephone calls or e-mail every two weeks.
48024226|NCT03291444|BIOLOGICAL|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
48024227|NCT02015234|DRUG|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
48024228|NCT00022516|DRUG|Cyclophosphamide|50 mg/day orally continuously for 1 year
48024229|NCT00022516|DRUG|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
48024230|NCT00171587|DRUG|PTK787/ZK 222584 (vatalanib)|
48382825|NCT05238701|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
48519454|NCT00711243|DRUG|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
48519455|NCT00001725|DRUG|Dextromethorphan|
48519456|NCT05236192|BEHAVIORAL|Take Root Home Visitation (TRHV)|TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.
48519457|NCT05236192|BEHAVIORAL|Services as Usual (SAU)|SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
48718939|NCT05205369|BEHAVIORAL|10-week home-based usual exercise therapy program|Among exercise therapy in the treatment of SAPS, stretching and strengthening protocols are often used . Therefore, participants in this group will do a standardized home-based stretching and strengthening exercise program four times per week for ten weeks, which is set up according to a previous study. This program has been demonstrated that can be effective in reducing pain and improving function in patients with SAPS. For strengthening exercises, elastic bands will be used. To learn how to conduct the self-training program, each participant in this group will also be invited to one introductory session before starting the prescribed exercise training. Two certificated physiotherapists will lead the introductory session. In addition, a video demonstration clip will be given to each participant to provide a home reference, and the Zoom Meeting application will be used to help monitor the exercise.
48718940|NCT01556321|DIETARY_SUPPLEMENT|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
48181762|NCT05260593|DEVICE|Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
48519458|NCT05470608|DRUG|SL-1002|SL-1002 injectable solution
48718941|NCT01556321|DIETARY_SUPPLEMENT|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule \[84.5 mg EGCG + 2.1 mg caffeine \], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
48718942|NCT01468636|DRUG|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
48718943|NCT01468636|DRUG|Placebo|200mg BID x 8 weeks
48718944|NCT03463954|DEVICE|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
48519459|NCT05470608|DRUG|Placebo|Matching placebo injectable solution
48718945|NCT06529848|OTHER|Exercise training|"The training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised .~Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels.~Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment."
48718946|NCT04439994|OTHER|hypertonic saline|The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution
48718947|NCT04439994|OTHER|Saline injection|The participant will be given i.d. in 0.1 mL volumes of a saline solution
48718948|NCT04439994|PROCEDURE|Blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
48718949|NCT05365737|OTHER|Oral rinse|Participants use mouthwasher for a given time.
48718950|NCT05365737|OTHER|Saliva harvest|Non-stimulated saliva harvesting
48718951|NCT06476158|DEVICE|Kaiku Health|Digital follow-up with Kaiku Health as medical device
48718952|NCT00876785|OTHER|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
48718953|NCT00876785|OTHER|wheat bread based breakfast|Reference wheat bread breakfast
48718954|NCT04361890|DIAGNOSTIC_TEST|perineal ultrasound|all women will have ultrasound measurements of the bladder neck descent, of the movement of the ano-rectal angle during a Valsalva maneuver and elastographic measurement before and after PFMT. All measurement will be conducted by perineal route, with is a non invasive ultrasound route
48519460|NCT00055367|DRUG|natalizumab|
48519461|NCT00559533|DRUG|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
48519462|NCT00619060|DRUG|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
48519463|NCT00619060|DRUG|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
48519464|NCT03215927|DRUG|Abatacept|Abatacept 125mg subcutaneous weekly
48519465|NCT03215927|OTHER|Placebo|Placebo
48519466|NCT02712723|DRUG|Letrozole|Nonsteroidal aromatase inhibitor
48519467|NCT02712723|DRUG|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
48519468|NCT02712723|DRUG|Placebo|Placebo for ribociclib
48519469|NCT04141774|DEVICE|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
48382826|NCT05838352|OTHER|telerehabilitation exercise|The telerehabilitation program is as follows; Respiratory exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities, using medium-hardness resistance exercise band. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. Exercises 1st-3rd weeks with 10 repetitions; 15 repetitions in weeks 4-6; In the 7th and 8th weeks, it will be done as 2 sets of 10 repetitions.Posture exercises: Basic posture exercises will be explained. Tabletop movements will be taught in clear, various positions that concern the spine, scapula and pelvis.Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking).
48382827|NCT05838352|OTHER|Control Group|The surveys in the outcome measures section will be applied once as a pre-test. Children in both groups will receive conventional institutional rehabilitation in the rehabilitation center. Children in the conventional rehabilitation group, which is the control group, will only be included in the supervised program. This group will not receive a telerehabilitation program.
48382828|NCT05939401|OTHER|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
48382829|NCT05965323|BEHAVIORAL|Health Education|Health education with comic books and videos
48718955|NCT06225271|BEHAVIORAL|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
48718956|NCT05226611|OTHER|Counterstrain|Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
48718957|NCT04994418|DIETARY_SUPPLEMENT|Recommended sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily recommended sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
48382830|NCT04855201|DRUG|Bocidelpar|Oral
48382831|NCT04855201|DRUG|Placebo|Oral
48382832|NCT05935930|DRUG|Propofol 10 MG/ML Injection|Propofol infusion
48382833|NCT05935930|DRUG|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
48382834|NCT06652880|DEVICE|Digital technology|The digital app is a customized comprehensive self-management platform designed to provide recovery and parenting support for individuals with substance use disorders.
48382835|NCT06652880|OTHER|Bibliotherapy|Bibliotherapy control group will receive parenting book what to expect the first year.
48382836|NCT00682097|DRUG|RO4998452|Escalating oral doses
48382837|NCT00682097|DRUG|placebo|Oral doses
48382838|NCT06147856|DRUG|mRNA-3210|IV infusion
48718958|NCT04994418|DIETARY_SUPPLEMENT|High sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily high sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
48382839|NCT06132087|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
48382840|NCT06132087|PROCEDURE|Computed Tomography|Undergo CT
48382841|NCT06132087|PROCEDURE|Distal Pancreatectomy|Undergo distal pancreatectomy
48382842|NCT06132087|PROCEDURE|Laparoscopy|Undergo laparoscopy
48382843|NCT06132087|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48382844|NCT06132087|PROCEDURE|Pancreaticoduodenectomy|Undergo pancreaticoduodenectomy
48382845|NCT06132087|OTHER|Questionnaire Administration|Ancillary studies
48382846|NCT06132087|PROCEDURE|Surgical Procedure|Undergo surgical resection
48382847|NCT06132087|PROCEDURE|Total Pancreatectomy|Undergo total pancreatectomy
48382848|NCT02303275|BEHAVIORAL|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
48382849|NCT02303275|BEHAVIORAL|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
48519470|NCT04141774|BEHAVIORAL|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
48519471|NCT04141774|OTHER|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
48519472|NCT04141774|OTHER|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
48382850|NCT05558709|OTHER|REALSOCOG|Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB N°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.
48519473|NCT03014843|DRUG|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
48519474|NCT03014843|DRUG|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
48382851|NCT05558709|OTHER|BCS|Social-cognitive tasks from the BCS (Ehrlé et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.
48382852|NCT05558709|OTHER|Hetero-questionnaires|Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \& le GREFEX, 2008; Gury and Ehrlé, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.
48382853|NCT06415669|DRUG|Paclitaxel for injection (albumin-bound)|100 mg/m2, day 1, day 8, every 21 days for a cycle.
48519475|NCT03014843|OTHER|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
48519476|NCT06582381|OTHER|Meal set A|morning meal: low carbohydrate, low protein, low fat afternoon meal: high carbohydrate, high protein, high fat
48519477|NCT06582381|OTHER|Meal set B|morning meal: low carbohydrate, high protien, low fat meal afternoon meal: high carbohydrate, low protein, high fat meal
48519478|NCT06582381|OTHER|Meal set C|morning meal: low carbohydrate, low protien, low fat meal afternoon meal: high carbohydrate, high protein, low fat meal
48519479|NCT06582381|OTHER|Meal set D|morning meal: high carbohydrate, low protien, low fat meal afternoon meal: low carbohydrate, high protein, high fat meal
48519480|NCT01937871|DRUG|5 mg Tadalafil|Administered orally
48519481|NCT01937871|DRUG|Placebo|Administered orally
48519482|NCT01937871|DRUG|0.2 mg Tamsulosin|Administered orally
48718959|NCT04994418|DIETARY_SUPPLEMENT|High sodium and high fructose diet|Upon completion of a 7 day dietary intervention of consuming the high sodium and high fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
48382854|NCT06415669|DRUG|Adebrelimab|20mg/kg or 1200mg, the first day, every 21 days as a cycle.
48024231|NCT03818217|DEVICE|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
48382855|NCT06415669|DRUG|Apatinib mesylate|250mg once a day for 5 consecutive days and discontinue for 2 days
48382856|NCT04748549|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
48519483|NCT04566055|DEVICE|AlloSure|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause.
48519484|NCT03564158|DRUG|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
48519485|NCT03564158|DRUG|Placebo|Placebo
48024232|NCT03818217|DEVICE|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
48024233|NCT00698529|BEHAVIORAL|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
48024234|NCT00698529|BEHAVIORAL|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
48024235|NCT00698529|BEHAVIORAL|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
48024236|NCT01929356|PROCEDURE|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
48519486|NCT03564158|DRUG|Moxifloxacin|Active Comparator
48519487|NCT00805324|DRUG|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
48519488|NCT04860674|DRUG|PD-1 inhibitor +ICE|PD-1 inhibitor (tirelizumab) combined with ifosfamide, carboplatin and etoposide (ICE) regimen
48519489|NCT06200506|DEVICE|Transabdominal radiofrecuency application|"A transabdominal radiofrequency application will be performed, with a suprapubic active plate and a passive plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks.~Frequency: 3 times a week sessions will be held three times a week for three weeks"
48519490|NCT06200506|DEVICE|Intracavitary radiofrequency application|"An intracavitary vaginal radiofrequency application will be performed, with an active intracavitary head and with a fixed plate at the sacral level.~Patient position: Supine position. Sessions:9 Duration: 20 minutes Total intervention: 3 weeks. Frequency: 3 times a week sessions will be held three times a week for three weeks."
48519491|NCT03930537|DEVICE|Hip replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
48519492|NCT03288818|DRUG|Mechlorethamine Hydrochloride Gel|Given topically
48519493|NCT03288818|PROCEDURE|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
48519494|NCT02538822|DEVICE|dynamic imaging|In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
48718960|NCT01541917|BEHAVIORAL|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
48519495|NCT02538822|DEVICE|mechanical testing|In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
48718961|NCT01541917|BEHAVIORAL|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
48718962|NCT04172467|OTHER|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
48718963|NCT04064645|DEVICE|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
48382857|NCT04748549|OTHER|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
48382858|NCT04748549|OTHER|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
48519496|NCT01982955|DRUG|Tepotinib|Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
48519497|NCT01982955|DRUG|Gefitinib|Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
48718964|NCT03009643|DRUG|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
48718965|NCT03009643|DEVICE|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
48718966|NCT03009643|DEVICE|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
48718967|NCT04392921|DRUG|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~* If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
48382859|NCT06650917|BEHAVIORAL|the experiment group were treated acupoint massage combined with ear point pressing beans|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~Patients in the experiment group were treated with auricular point pressing on basis if the treatment of the control group. Selecting 10 acupoints including Tanzhong, Tiantu, Dingchuan(both sides), Feishu(both sides), Yuji(both sides), and Lieque(both sides), and massage each acupoint for about 3 minutes. Acupoint massage once a day from Monday to Friday, lasting for 30 minutes each time. Selecting the Fengxi(both sides), Lung(both sides), Bronchial(both sides), and Shenmen(both sides) acupoints on the ear for ear point pressing beans. The operator rubs the above acupoints with their hands for about 5 minutes, and then performs ear point pressing beans on these 4 acupoints. The ear point pressing beans is performed once a day from Monday to Friday."
48519498|NCT01982955|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
48519499|NCT01982955|DRUG|Cisplatin|Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
48024237|NCT04321460|DRUG|LRG-002|Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
48024238|NCT04321460|DRUG|Placebo|Capsules containing placebo
48024239|NCT01089140|DRUG|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
48024240|NCT01089140|DRUG|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
48024241|NCT01089140|DRUG|Saline solution|Saline placebo
48519500|NCT01982955|DRUG|Carboplatin|Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
48181763|NCT05260593|DEVICE|Placebo Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
48382860|NCT06650917|BEHAVIORAL|the control group were treated with acupoint massage|"Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage."
48382861|NCT06163898|DRUG|Alnuctamab|Specified dose on specified days
48519501|NCT00795327|DEVICE|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
48519502|NCT01728844|DEVICE|beta-tricalcium phosphate alone|
48519503|NCT01728844|DEVICE|GFeBGS 0.1%|
48519504|NCT01728844|DEVICE|GFeBGS 0.3%|
48519505|NCT01728844|DEVICE|GFeBGS 0.4%|
48519506|NCT06054321|DRUG|stepwise pharmacotherapy|In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
48519507|NCT06054321|DRUG|antidepressant monotherapy group|In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
48519508|NCT01171261|BEHAVIORAL|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
48519509|NCT06372574|DRUG|RO7617991|RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
48519510|NCT06372574|DRUG|Tocilizumab|Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.
48519511|NCT02825771|BEHAVIORAL|Caring Contacts Messages|Text messages expressing care and support are sent following initial meeting on the following schedule: next day, 6 weekly, 9 bi-weekly, 7 monthly; one each on birthday, holiday, and seasonal (total of 25)
48519512|NCT02825771|BEHAVIORAL|Usual Care|Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
48519513|NCT04128189|BIOLOGICAL|Shingrix|Both arms receive standard 2 doses of Shingrix. Transplanted subjects may receive 3rd dose.
48519514|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using Gow-Gates anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using Gow-Gates anesthesia technique. Patients were monitored for TCR during the procedure.
48382862|NCT06163898|DRUG|Mezigdomide|Specified dose on specified days
48382863|NCT06163898|DRUG|Dexamethasone|Specified dose on specified days
48382864|NCT02140801|DRUG|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
48382865|NCT02140801|DRUG|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
48382866|NCT02591173|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
48382867|NCT02591173|DRUG|Saline|Normal saline will be used as the placebo comparator.
48382868|NCT06561048|DRUG|Soquelitinib|Soquelitinib 200 mg tablets will be taken by mouth two times a day
48519515|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using inferior alveolar nerve block anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using inferior alveolar nerve block anesthesia technique and supplemental anesthesia (buccal- mylohyoid). Patients were monitored for TCR during the procedure.
48718968|NCT04392921|DRUG|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
48718969|NCT05227599|OTHER|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
48718970|NCT03048838|BEHAVIORAL|Risk reduction behavioral intervention|
48718971|NCT03048838|BEHAVIORAL|Wellness Promotion Intervention|
48718972|NCT05207969|PROCEDURE|Instruction to urinate|Cystoscopy procedure will be done based on cystoscopy protocol. During scope procedure, patient will be ask to urinate and this will lead to contraction of urinary bladder and relaxation of external urethral sphincter. Scope will then pass through external urethral sphinter and go to the urinary bladder
48718973|NCT02295241|OTHER|No intervention|This is an observational trial, no interventions are being used.
48718974|NCT00393341|PROCEDURE|Blood Draw|Blood sample will be drawn from a vein in the arm.
48718975|NCT02533726|OTHER|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
48718976|NCT02533726|OTHER|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
48718977|NCT02533726|OTHER|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
48718978|NCT03008382|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
48718979|NCT03008382|DRUG|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
48718980|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
48718981|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
48718982|NCT04018313|BIOLOGICAL|CT-P39|150 mg/mL, Solution for injection in PFS
48519516|NCT05464979|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation.
48718983|NCT04018313|BIOLOGICAL|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
48181764|NCT05260593|DEVICE|Wrist splint|Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
48181765|NCT05260593|OTHER|tendon and nerve gliding exercises|During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
48519517|NCT05464979|DRUG|midazolam, fentanyl|Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score.
48718984|NCT04018313|BIOLOGICAL|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
48718985|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
48718986|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
48718987|NCT02772978|DRUG|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
48718988|NCT02772978|DRUG|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
48718989|NCT01878994|BEHAVIORAL|Counselling group|
48718990|NCT01878994|BEHAVIORAL|Nereu group|
48382869|NCT06561048|DRUG|Belinostat|Belinostat (1000 mg/m2) will be administered by intravenous infusion once daily on Days 1 through 5 of each 21-day cycle
48382870|NCT06561048|DRUG|Pralatrexate|Pralatrexate (30 mg/m2) will be administered intravenously over 3 to 5 minutes once weekly for 6 weeks in each 7-week cycle
48382871|NCT01148628|DRUG|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
48382872|NCT02998372|PROCEDURE|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
48382873|NCT05459077|BEHAVIORAL|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
48718991|NCT00843544|BEHAVIORAL|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~1. Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~2. Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~3. Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
48718992|NCT04118790|OTHER|Clinical Assessment|"1. Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~2. Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
48718993|NCT04118790|PROCEDURE|MRI scan|1. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
48718994|NCT01972698|OTHER|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~* A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~* Participant will have access to an ultrasound simulator.~* Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
48718995|NCT01972698|OTHER|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~* Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~* Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
48718996|NCT00915148|OTHER|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
48718997|NCT01479582|DRUG|Access to unlicensed cord blood units|
48718998|NCT03375372|PROCEDURE|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
48718999|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
48719000|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
48719001|NCT01289106|BIOLOGICAL|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
48181766|NCT04451811|DRUG|OPL-002|Spray dried dispersion and tablet formulation
48382874|NCT06119737|OTHER|Exercise|Effects of exercises on TSH levels
48382875|NCT06537921|DRUG|Minocycline 200mg|Dosage: 2x100mg/daily for 8 weeks
48382876|NCT06489197|DRUG|Ivonescimab combined with albumin paclitaxel and cisplatin|Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
48181767|NCT03330613|DIAGNOSTIC_TEST|PAEDS|pediatric emergency delirium scale
48719002|NCT05732636|OTHER|Validation study|"The whole protocol is divided into two stages: Urdu Translation and validation. Following steps were involved.~1. First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1)~2. Second Version: Three experts compared the original FADI with urdu version of FADI.~3. Backward translation: Version 2 was translated Back in English by an independent translator.~4. Third Version: was finalized after tracking differences in forward and backward translation.~5. Final Version: of Urdu FADI was used on Chronic Ankle Instability patients.~Foot and Ankle Disability Index(FADI) Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability."
48719003|NCT02679365|PROCEDURE|lower segment cesarean section and double lock closure of rectus sheath|
48719004|NCT02679365|PROCEDURE|lower segment cesarean section and continuous non-locking closure of rectus sheath|
48181768|NCT03330613|PROCEDURE|TIVA|Total intravenous anesthesia with propofol
48181769|NCT03330613|PROCEDURE|Inhalational anesthesia|Inhalational (volatile) anesthesia with sevoflurane
48719005|NCT02498574|DEVICE|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
48719006|NCT02498574|BEHAVIORAL|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
48181770|NCT02668627|PROCEDURE|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
48181771|NCT05021471|OTHER|biofeedback|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
48181772|NCT05021471|OTHER|hamstrings stretching|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
48181773|NCT01313169|OTHER|EMR Reminder|EMR reminders displayed
48181774|NCT01313169|OTHER|EMR Reminder + Panel management|EMR Reminder + Panel management
48719007|NCT06507033|DEVICE|Mobile application and an arm volume measurement device|The intervention consists mainly of two steps; (a) development of a mobile application with an arm volume measurement device (b) evaluation of the effectiveness of the products. Five components will be involved in the development of the mobile application. These components are; (I) exercise, (II) education, (III) coping mechanisms, (IV) arm volume measurement/recording and (V) appointment, exercise and measurement reminder panel. Exercise videos will include stretching exercises for the shoulder and arm as recommended in the guidelines
48719008|NCT06036329|DEVICE|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
48719009|NCT06036329|DEVICE|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
48719010|NCT01895244|DRUG|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
48719011|NCT00969436|BIOLOGICAL|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
48719012|NCT00969436|BIOLOGICAL|Priorix™|Subcutaneous injection
48719013|NCT00969436|BIOLOGICAL|Varilrix™|Subcutaneous injection
48719014|NCT04042376|DRUG|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg\*3 capsules taken together at one time).
48719015|NCT06237803|OTHER|storage of biological samples|collect and store biological samples
48719016|NCT01617447|DRUG|Placebo of Aripiprazole|administered orally once daily
48719017|NCT01617447|DRUG|Aripiprazole|Flexibly dose administered orally once daily
48719018|NCT05735522|DEVICE|Extracorporeal magnetic stimulation|Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
48719019|NCT05735522|OTHER|Sham|The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
48719020|NCT01571869|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
48719021|NCT01571869|OTHER|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
48719022|NCT03700619|OTHER|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
48719023|NCT03283397|DRUG|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
48719024|NCT03283397|DRUG|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
48719025|NCT03631212|BEHAVIORAL|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
48382877|NCT04980066|PROCEDURE|Sticky bone and EDTA|treatment using Sticky bone after EDTA root surface biomodification
48382878|NCT04980066|PROCEDURE|Sticky bone|treatment using Sticky bone
48519518|NCT02490631|DRUG|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
48382879|NCT02188667|OTHER|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
48382880|NCT02188667|OTHER|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
48382881|NCT02359409|DEVICE|goggle balloon|Colonoscopy will be performed using the water immersion technique.
48382882|NCT02359409|OTHER|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
48382883|NCT06652516|PROCEDURE|plasma exchange|"comparison between the 2 methods of plasma exchange as regards efficacy, performance and adverse events.~Procedure of therapeutic plasma exchange (TPE) :~mTPE will be done by bellco hemodialysis machine (Formula 2000), while cTPE will be done by Nigale Plasma Collector (XJC 2000). The vascular access used for both types of plasma exchange will be central venous catheter inserted into the internal jugular vein, subclavian or femoral vein.~Prescription of TPE The amount of plasma to be treated is usually equivalent to the patient's estimated plasma volume (EPV).~Estimated plasma volume will be calculated using the following formula (Kaplan formula) in litres:~* EPV = 0.07 x wt (kg) x (1 - hematocrit) in males.~* EPV = 0.065 x wt (kg) x (1 - hematocrit) in females."
48382884|NCT06282029|BEHAVIORAL|Group Therapy|Acceptance and Commitment Therapy based group therapy
48519519|NCT01059461|DRUG|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
48519520|NCT02816606|PROCEDURE|Flexible reamers|These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
48519521|NCT02816606|PROCEDURE|70-degree arthroscope|Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
48519522|NCT05148221|OTHER|Questionnaires|Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
48519523|NCT05148221|OTHER|Actigraph and activPAL devices|Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
48519524|NCT04860180|PROCEDURE|adrenalectomy|
48519525|NCT02966977|OTHER|Conventional microbiological identification by culture plate|Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
48519526|NCT02966977|OTHER|Direct mass spectrometry identification from urine sample|The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
48719026|NCT05749354|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through."
48719027|NCT03211013|DRUG|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
48382885|NCT06075927|BIOLOGICAL|Virus specific T cells|"Subjects will receive partial HLA-matched viral-specific T cells (VSTs) against both CMV and EBV on one of the following dose levels:~Level One: 1 x 10\^7 cells/m2 Level Two: 2 x 10\^7cells/m2 Level Three: 5x 10\^7 cellss/m2"
48719028|NCT03211013|DRUG|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
48382886|NCT02676518|OTHER|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
48519527|NCT00929851|DRUG|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
48519528|NCT00929851|DRUG|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
48519529|NCT00425204|DRUG|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
48519530|NCT00544635|DEVICE|no intervention|no intervention
48519531|NCT00544635|DEVICE|light|scars will be treated with light
48519532|NCT04470648|DIAGNOSTIC_TEST|blood test for SARS-COV2 serology|each person who will accept to participate will have a bood test for a SARS-COV2 serology
48382887|NCT04518800|DRUG|Jin Youli(PEG-rhG-CSF)|Jin Youli(PEG-rhG-CSF) was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight \<45 kg. Inject once every chemotherapy cycle
48382888|NCT02473107|OTHER|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
48382889|NCT02473107|OTHER|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
48719029|NCT00600769|DRUG|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
48719030|NCT05620784|DRUG|Furosemide|20mg of IV furosemide injection during the morcellation phase of HoLEP
48719031|NCT05053607|BEHAVIORAL|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
48719032|NCT05053607|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
48719033|NCT02437786|DRUG|GRAZAX|GRAZAX
48719034|NCT01756118|DRUG|BEZ235|A minimum of 3 dose levels
48719035|NCT00964301|OTHER|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
48719036|NCT00964301|OTHER|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
48719037|NCT03612323|DRUG|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
48719038|NCT03612323|DRUG|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
48519533|NCT00727103|DRUG|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
48382890|NCT03352804|OTHER|Screening of MDR Bacteriae|questionnaire will be filled by every patient
48382891|NCT04238494|DIAGNOSTIC_TEST|Nuclear magnetic resonance (NMR)|Muscle architecture, lipid and active tissue muscle content should be measured. Proton NMR imaging (MRI)
48519534|NCT00727103|DRUG|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
48519535|NCT03188224|OTHER|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
48719039|NCT06119438|OTHER|Aromatherapy|Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
48181775|NCT02442193|OTHER|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
48181776|NCT00565071|DEVICE|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
48382892|NCT04711135|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
48382893|NCT03378310|DRUG|BMS-986205 reference tablet|Single, 100 mg oral dose.
48519536|NCT04468451|BEHAVIORAL|A 48-hour ROC training program with a standing posture|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
48382894|NCT03378310|DRUG|BMS-986205 tablet with free base|Single, 100 mg oral dose.
48519537|NCT04468451|BEHAVIORAL|A 24-hour ROC training program with a standing posture|The 1-hour training session is composed of a 30-to-35-minute car play and a 25-minute natural play. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
48719040|NCT04810611|DRUG|MBG453|Anti-TIM3 monoclonal antibody
48382895|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
48382896|NCT00380861|DEVICE|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
48382897|NCT06650189|OTHER|Music intervention|Recorded music created by a certified music therapist
48382898|NCT06653127|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients. Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence.
48382899|NCT05413395|OTHER|topical colloidal oatmeal formulation with a modified plant oil|"Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties."
48382900|NCT05413395|OTHER|topical colloidal oatmeal formulation|Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation
48382901|NCT05215509|BEHAVIORAL|Exercise|Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
48382902|NCT05215509|BEHAVIORAL|No exercise|Control group, therefore no supervised exercise regime
48382903|NCT05665816|DEVICE|Stent PULSAR® -18 T3,|"Post-authorization, prospective and multicenter registry to evaluate the clinical results of the PULSAR® -18 T3 stent, in the treatment of de novo or restenotic lesions of the superficial femoral and/or popliteal artery, primarily as salvage, in a population of patients residing in Spain and in real life conditions."
48719041|NCT04810611|DRUG|NIS793|Anti-TGF-β monoclonal antibody
48719042|NCT04810611|DRUG|canakinumab|Anti-IL-1β monoclonal antibody
48719043|NCT02033213|OTHER|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
48719044|NCT02033213|OTHER|Liberal group|"A group of patients who received \> 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
48719045|NCT01521910|DIETARY_SUPPLEMENT|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses \>= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
48719046|NCT01521910|DIETARY_SUPPLEMENT|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
48719047|NCT00412074|DRUG|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
48719048|NCT00412074|DRUG|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
48719049|NCT00412074|DRUG|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
48719050|NCT03369431|DIETARY_SUPPLEMENT|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
48382904|NCT04839835|OTHER|waiting room enriched with music, paintings and artificial plants|waiting room enriched with music, paintings and artificial plants
48382905|NCT03128931|DEVICE|Pediatric SedLine forehead EEG sensor|Pediatric EEG sensor.
48382906|NCT03107715|BEHAVIORAL|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
48382907|NCT03107715|BEHAVIORAL|Positive Messaging|iPad based behavioral intervention facilitated by researcher
48719051|NCT03369431|DIETARY_SUPPLEMENT|Placebo|4.4 grams of maltose and silicon dioxide per sachet
48719052|NCT02170766|DRUG|BIBR 1048 low1|
48719053|NCT02170766|DRUG|BIBR 1048 low2|
48719054|NCT02170766|DRUG|BIBR 1048 medium|
48719055|NCT02170766|DRUG|BIBR 1048 high|
48181777|NCT04342312|PROCEDURE|Pulmonary vein isolation|Participation in this study does not influence the choice of ablation technique. Usually, cryoballoon ablation is chosen for patients with paroxysmal AF and no previous ablations. Radiofrequency ablation is often used for redo procedures or for patients with persistent AF. Hybrid ablations are most applied in persistent AF patients. However, physicians may deviate from these standard approaches for a variety of reasons, including personal experience or preference.
48719056|NCT02170766|DRUG|Pantoprazole|
48719057|NCT02725281|OTHER|Stress ball|The patients in this group were given stress ball into their both palms 5 min before the lithotripsy and told to squeeze the ball whenever they would like until end of the process. This ball was medium hard and has been made of high quality silicon.
48719058|NCT02725281|OTHER|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
48719059|NCT00924404|DRUG|Xylitol|5% solution for sinus rinse
48719060|NCT00924404|DRUG|Saline|saline for sinus rinse
48719061|NCT03802539|DEVICE|Glass Liner|restoration of root caries according to two different protocols
48719062|NCT01943019|DRUG|Linagliptin|
48719063|NCT05490589|OTHER|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
48719064|NCT06519383|PROCEDURE|guided implant surgery|Surgical guide is fabricated and fitted onto the patient's arch and implant is placed with guide in place.
48719065|NCT01862835|DRUG|Degarelix|
48181778|NCT01386723|DRUG|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
48382908|NCT05936788|OTHER|Active cycle of breathing technique|Group A will receive ACBTs with 1 session a day for total 2 days in a week.
48382909|NCT05936788|OTHER|diaphragmatic breathing|Group B will receive diaphragmatic breathing for 1 session a day for total 2 days in a week.
48719066|NCT01862835|DRUG|Testosterone|
48719067|NCT01862835|DRUG|Anastrozole|
48719068|NCT01862835|DRUG|Estrogen patch|
48181779|NCT00343993|DEVICE|noninvasive positive pressure ventilation|
48181780|NCT02020746|DRUG|EscharEx|
48181781|NCT02020746|DRUG|Gel Vehicle|
48181782|NCT05141396|OTHER|Telehealth- enabled support for SAT/SBT adherence|Telehealth-enabled support over and above usual audit and feedback includes identifying candidates for spontaneous awakening and breathing trials, prompting bedside providers and guiding execution of the coordinated spontaneous awakening and breathing trials as needed.
48181783|NCT05141396|OTHER|Usual audit and feedback for SAT/SBT adherence|Usual audit and feedback
48181784|NCT03113383|DEVICE|Thoracoabdominal Aortic Aneurysm Repair|Thoracoabdominal aortic aneurysm repair
48181785|NCT05247697|DRUG|Mirtazapine 7.5 MG Oral Tablet once daily at bedtime|Mirtazapine 7,5 mg capsule
48719069|NCT00419315|BEHAVIORAL|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
48719070|NCT00419315|BEHAVIORAL|Usual Care|Usual care included a referral to a specialty addiction treatment program.
48719071|NCT04798209|DRUG|ACT-777991 (SAD)|ACT-777991 administered as hard capsules for oral use.
48719072|NCT04798209|DRUG|ACT-777991 (MAD)|ACT-777991 administered as hard capsules for oral use, once daily.
48719073|NCT04798209|DRUG|Placebo (SAD)|ACT-777991 matching placebo administered as hard capsules for oral use.
48719074|NCT04798209|DRUG|Placebo (MAD)|Matching placebo administered as hard capsules for oral use, once daily.
48719075|NCT04798209|DRUG|14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer, administered intravenously.
48719076|NCT04798209|DRUG|Microtracer matching placebo (SAD - Absolute Bioavailability)|Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
48719077|NCT04798209|DRUG|14C-ACT-777991 microtracer (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer, oral solution..
48719078|NCT04798209|DRUG|Microtracer matching placebo (MAD - ADME)|Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
48719079|NCT03329716|OTHER|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
48719080|NCT01441011|BEHAVIORAL|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
48519538|NCT04468451|BEHAVIORAL|A regular therapy program without receiving any ROC training|The regular therapy group will be an active control group without receiving any additional training. The training dosage will be their own therapy, including occupational, physical and speech therapy. They will continue their regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks.
48519539|NCT03099109|DRUG|LY3321367|Administered IV
48519540|NCT03099109|DRUG|LY3300054|Administered IV
48519541|NCT00199394|DRUG|Istradefylline (KW-6002)|
48519542|NCT06132061|OTHER|universal prevention|Health education related to depression to strengthen the participants' self-care skills to reduce sub-health risk factors.
48519543|NCT06132061|OTHER|selective prevention|Psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) aimed at risk factors to prevent more severe depressive symptoms.
48382910|NCT03052374|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
48382911|NCT00683046|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
48382912|NCT00683046|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
48382913|NCT00683046|DRUG|Stem cells|Stem cell infusion on day 0.
48382914|NCT00683046|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
48382915|NCT06566443|DRUG|Honokiol|Honokiol will be given orally at a starting dose of 1 capsule (250 mg/ capsule) per day for 2 weeks. Dose levels will escalate based on dose-limiting toxicity occurrence. We will start at one capsule (250 mg) once daily, dose 0 would be one capsule (250 mg) twice daily, dose +1 would be 500mg in the AM and 250mg in the evening, and +2 would be 500 mg twice daily.
48519544|NCT06132061|OTHER|targeted prevention|Therapeutic psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) to reduce patients' depressive symptoms.
48519545|NCT06132061|OTHER|Waiting treatment.|Waiting treatment.
48519546|NCT00271193|BEHAVIORAL|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
48519547|NCT00916643|DEVICE|HELP Secura (apheresis treatment)|Process is described in Arm (above).
48519548|NCT04852029|OTHER|Low dose hCG|Patients will either maintain the current dose of have an increased dose prescribed based on randomization
48519549|NCT05016739|DEVICE|CADISS|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~2. Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
48519550|NCT02122029|BEHAVIORAL|Lifestyle counselling|Behavioral techniques for weight management
48519551|NCT02122029|PROCEDURE|Bariatric Surgery|Vertical Banding Gastroplasty
48719081|NCT01441011|BEHAVIORAL|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
48719082|NCT03654287|OTHER|Treatment|The CELS way to intervene severe sepsis and refractory shock
48719083|NCT06282965|DRUG|Angiotensin (1-7)|The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.
48719084|NCT06282965|DRUG|Sterile saline|Sterile solution of 0.9% NaCl in water.
48719085|NCT03075995|OTHER|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
48719086|NCT05999110|OTHER|Physical Exercise|The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
48719087|NCT01531972|DRUG|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
48719088|NCT01531972|DRUG|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
48719089|NCT00468845|DRUG|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
48719090|NCT00468845|DRUG|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
48719091|NCT00468845|DRUG|matched placebo|matched placebo
48719092|NCT05484570|OTHER|Interval History|"The study coordinator or another team member will review standard health questions relevant to DNA repair disorders. The control group will not undergo an interval history. These questions will include:~1. How the participant's appetite and general weight trajectory has been since the last assessment~2. Any episodes of unexplained bleeding or bruising~3. Any jaundice~4. General level of alertness and interaction with family and others~5. Any changes in cognitive function such as speech, following commands, comprehension~6. Any changes in motor function, including the development of tremors and stiffness in movements"
48719093|NCT05484570|OTHER|Physical Examination|A board-certified neurologist (the principal investigator) will perform a general physical examination and a neurological examination and complete a standard CRF to document relevant findings. The control group will not undergo a physical examination.
48719094|NCT05484570|OTHER|ECAB Assessment|"An Early Clinical Assessment of Balance (ECAB) will be performed by the physical therapist. Part I can be assessed in all affected individuals, and Part II requires ambulation. For non-ambulatory individuals, only Part I will be applied. The items in the ECAB are summarized as follows:~Part I. Head and trunk postural control (maximum 36 points) Head righting - lateral (right and left) Head righting - extension Head righting - flexion Rotation in trunk (right and left) Equilibrium reactions in sitting (right and left) Protective extension - side Protection extension - backward Part II. Sitting and standing postural control (maximum 64 points) Sitting with back unsupported but feet supported on floor or on a stool Sitting to standing Standing unsupported with eyes closed Standing unsupported with feet together Turns 360 degrees Placing alternate foot on the step while standing unsupported"
48519552|NCT00839397|DRUG|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
48519553|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP|Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
48382918|NCT05784311|DRUG|Cefuroxime|1500mg IV cefuroxime thrice daily during five days.
48382919|NCT05784311|DRUG|Metronidazole|500mg IV metronidazole thrice daily during five days.
48382920|NCT06653725|DIETARY_SUPPLEMENT|1,3-butanediol|1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily
48382921|NCT06653725|DIETARY_SUPPLEMENT|Placebo|Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
48024242|NCT04117828|DIETARY_SUPPLEMENT|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
48181786|NCT05247697|DRUG|Placebo oral tablet once daily at bedtime|Matching placebo
48382922|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 1|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
48719095|NCT05484570|OTHER|Gait Assessment|"For ambulatory participants, the physical therapist will also assess standardized gait outcome measures, including:~1. Gait Speed: may be measured over a 10 meter distance, assessing both comfortable walking speed and fast walking speed~2. 10-meter walk/run: timed assessment at fastest gait attainable. This assessment would be omitted for those participants who are determined to have a high fall risk.~3. Timed Up and Go (TUG): time to stand from a chair, walk 3 meters, go around a cone, and return to the chair (with or without an assistive device)~4. Dynamic Gait Index (DGI): assesses 8 balance challenges while walking"
48719096|NCT05484570|OTHER|Specimen Sample Collection|"Total blood volumes collected at each visit will be limited to 5mL/kg body weight, with a maximum of 18mL.~Saliva samples may be obtained if research is taking place where blood samples cannot be drawn or transferred."
48719097|NCT00239954|DRUG|Escitalopram|
48024243|NCT05446415|OTHER|Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.|Preoperative and postoperative
48024244|NCT01747681|PROCEDURE|Microfracture|
48024245|NCT05906693|OTHER|Quality of life|Parkinson's Disease Quality of Life Questionnaire (PDQ-39)
48024246|NCT05906693|OTHER|Upper limb functionality|Nine-Hole Peg Test
48024247|NCT05906693|OTHER|Grip and pinch strength|Dynamometer
48024248|NCT05906693|OTHER|Tremor amplitude|Electromyography
48024249|NCT05906693|OTHER|Depression and anxiety levels|Hospital Anxiety and Depression Scale
48024250|NCT05906693|OTHER|Clinical manifestations|The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
48382923|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 2|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
48382924|NCT04798027|BIOLOGICAL|SARS-CoV-2 mRNA vaccine formulation 3|Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
48024251|NCT03132116|DRUG|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
48024252|NCT03132116|DRUG|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
48181787|NCT00283283|BIOLOGICAL|Fluzone® (Aventis Pasteur inactivated influenza vaccine)|A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
48719098|NCT02679820|DEVICE|Copper T intrauterine device|
48719099|NCT04376827|DRUG|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 via IV administration.
48719100|NCT04376827|DRUG|Placebo|Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
48719101|NCT04376827|DRUG|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 via SC route.
48024253|NCT02545712|OTHER|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
48024254|NCT02545712|OTHER|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
48024255|NCT02545712|OTHER|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
48024256|NCT02545712|OTHER|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
48024257|NCT02545712|OTHER|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
48024258|NCT02545712|OTHER|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
48024259|NCT02545712|OTHER|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
48024260|NCT02545712|OTHER|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
48024261|NCT02545712|OTHER|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
48181788|NCT05395364|BEHAVIORAL|Intervention program BeE-school|The intervention program will be co-developed and directed to school professionals. It will be based on the promotion of health literacy and lifestyles.
48382925|NCT04798027|BIOLOGICAL|Placebo (0.9% normal saline)|Pharmaceutical form: Liquid Route of administration: Intramuscular injection
48382926|NCT03025360|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
48024262|NCT02545712|OTHER|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
48719102|NCT04376827|DRUG|Standard-of-care treatment|Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
48719103|NCT05115747|OTHER|weight off-loading aerobic exercise training.|"Mild to moderate intensity weight off-loading aerobic exercise training on the anti-gravity Alter-G treadmill. (speed 8-12 mph, 50%-70% heart rate reserve HRR, 12-16 score on the Borg's scale)"
48719104|NCT00766246|DRUG|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
48719105|NCT00766246|DRUG|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
48719106|NCT00766246|DRUG|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
48719107|NCT03833713|BEHAVIORAL|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
48719108|NCT03833713|BEHAVIORAL|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
48719109|NCT01560299|DRUG|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
48719110|NCT01560299|DRUG|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
48719111|NCT01560299|DRUG|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
48024263|NCT04779645|DRUG|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
48024264|NCT04779645|DRUG|Placebo|12-Week, once weekly subcutaneous injection with placebo
48024265|NCT01358526|DRUG|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
48024266|NCT01358526|DRUG|Placebo|Placebo tablets to match OXN taken orally every 12 hours
48024267|NCT01220908|DEVICE|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
48024268|NCT01220908|DEVICE|Coils|Lung Volume Reduction Coil(s)
48024269|NCT00938925|PROCEDURE|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
48719112|NCT02447094|DRUG|Alteplase|Intravenous (i.v.) tPA per the standard of care
48719113|NCT00299780|DRUG|Stem cell mobilization|
48719114|NCT01356732|DRUG|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
48024270|NCT00938925|PROCEDURE|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
48382927|NCT05168943|DEVICE|Nylon (Polyamide) Epidural Catheter|Nylon (Polyamide) Epidural Catheter
48024271|NCT02948985|OTHER|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
48719115|NCT02712424|BIOLOGICAL|DAR-901|
48719116|NCT02712424|BIOLOGICAL|Sterile saline placebo|
48024272|NCT06260657|OTHER|Histological analysis on fetal ethmoids|Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
48024273|NCT05035082|DRUG|semaglutide|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
48024274|NCT05035082|DRUG|oral glucose-lowering medications (commercially available)|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
48024275|NCT04574544|DRUG|Zinc Supplementation|The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
48024276|NCT04574544|BEHAVIORAL|Nutrition education of mothers|Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
48024277|NCT03047616|OTHER|Blood and Urine Collection|
48024278|NCT01471535|DRUG|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
48382928|NCT05168943|DEVICE|Polyurethane Epidural Catheter|Polyurethane Epidural Catheter
48382929|NCT06014008|OTHER|Test product consumption group|Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
48719117|NCT03927079|BIOLOGICAL|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
48719118|NCT03927079|PROCEDURE|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
48719119|NCT03927079|BIOLOGICAL|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
48719120|NCT01367392|DEVICE|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
48719121|NCT06172920|DRUG|Tramadol hydrochloride|Patients are receiving tramadol hydrochloride under thoracic surgery
48719122|NCT06172920|DRUG|Aldolan|Patients are receiving meperidine under thoracic surgery
48719123|NCT06172920|DRUG|Morphine hydrochloride|Patients are receiving Morphine hydrochloride under thoracic surgery
48719124|NCT02117349|DRUG|Raplixa|Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
48719125|NCT02117349|DEVICE|Gelfoam|Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.
48719126|NCT02117349|DRUG|Rescue treatment|Thrombin-containing hemostats included in standard care at the site
48719127|NCT06515314|BIOLOGICAL|AFP Specific T Cell Receptor T Cells|"AFP Specific T Cell Receptor T Cells On day 1, the TCR-T cells will be administered intravenously.~Drug: Fludarabine + Cyclophosphamide Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days"
48719128|NCT02185989|OTHER|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
48719129|NCT04114799|PROCEDURE|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
48719130|NCT04114799|PROCEDURE|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
48719131|NCT02062983|DRUG|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
48719132|NCT00780273|DEVICE|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
48719133|NCT00780273|DEVICE|Biomet 3i Prevail Implants|
48719134|NCT01824706|PROCEDURE|craniectomy|craniectomy
48719135|NCT05601362|DEVICE|Gamified Attention Bias Modification|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
48719136|NCT05601362|DEVICE|Gamified Placebo Training|Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
48719137|NCT05716243|DEVICE|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
48719138|NCT05716243|DEVICE|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
48719139|NCT03657147|BEHAVIORAL|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
48719140|NCT02916459|DEVICE|21G EBUS-TBNA needle|
48719141|NCT02916459|DEVICE|Flexible 19G EBUS-TBNA needle|
48719142|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
48719143|NCT00645463|DRUG|CP-945,598|20 mg CP-945,598 alone
48719144|NCT06141837|OTHER|Observation|No intervention: observational study
48719145|NCT01519999|BEHAVIORAL|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
48719146|NCT03191877|DIETARY_SUPPLEMENT|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
48719147|NCT00424268|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
48719148|NCT00424268|DRUG|Placebo|once daily
48719149|NCT02446470|PROCEDURE|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
48719150|NCT02446470|PROCEDURE|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
48382930|NCT00258310|DRUG|capecitabine|Capecitabine 1000mg/day for one year
48382931|NCT00258310|PROCEDURE|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
48382932|NCT01554059|DRUG|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
48382933|NCT01554059|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly \* 6 doses 3-4 weeks after radical resection
48382934|NCT01554059|DRUG|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly\*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
48519554|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP + Coaching|"Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
48519555|NCT03541317|BEHAVIORAL|Stage 2 Strategy: Augment with Facilitation|In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
48519556|NCT03541317|BEHAVIORAL|Stage 2 Strategy: No augmentation|Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
48519557|NCT06581952|BEHAVIORAL|Poem writing|"The poem themes will focus on accomplishment moments, joyful moments, and gratitude. Participants will be motivated to write at least one poem in each session. The instructor will lead the participants to improve the poem after the participants complete the first draft. The participants will be encouraged to perform in reading their completed poem, sharing their feelings and expressing the meaning of the poems during the session.~In the second session, participants will be invited to do a poem reading performance using one of their newly written poems."
48519558|NCT06044142|DRUG|Curcumin|Curcumin and low laser therapy will be used on patients undergoing chemotherapy
48519559|NCT06044142|DEVICE|Laser|Low level laser therapy
48519560|NCT05122169|DRUG|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
48719151|NCT01373320|BEHAVIORAL|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
48719152|NCT05004506|DRUG|Adductor Canal Block|The anesthesia provider will identify the adductor canal using ultrasound guidance and inject 15ccs of 0.5% marcaine with epinephrine around the saphenous nerve.
48024279|NCT02063503|OTHER|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
48382935|NCT01554059|RADIATION|Radiotherapy|2GY daily \*20次
48382936|NCT06123624|DRUG|Desflurane Inhalation Solution|Keeping the anesthesia using desflurane inhalation solution as 1 minimal alveolar concentration
48519561|NCT05122169|DRUG|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
48519562|NCT05446558|PROCEDURE|Intracorporeal anastomosis|"Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis."
48519563|NCT05446558|PROCEDURE|Extracorporeal anastomosis|"A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis."
48719153|NCT05004506|DRUG|Intra-articular Injection|receive 20ccs of 2% lidocaine with epinephrine as an intra-articular injection
48024280|NCT05877729|OTHER|Standard of Care|The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
48382937|NCT06123624|DRUG|Sevoflurane Inhalation Solution|Keeping the anesthesia using sevoflurane inhalation solution as 1 minimal alveolar concentration
48382938|NCT06249438|BIOLOGICAL|CD20/BCMA-directed CAR-T cells|Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
48382939|NCT06576479|DIETARY_SUPPLEMENT|Nutritious Shake|Powder 70 g/d diluted in 237 ml natural water
48382940|NCT06576479|BEHAVIORAL|Nutritional counseling|Specialized nutritional recommendations for CKD
48382941|NCT05795361|DRUG|Idursulfase-IT|Participants will continue to receive the same dose of idursulfase-IT, once monthly, that was administered during the HGT-HIT-046 \[NCT01506141\] or SHP609-302 \[NCT02412787\] study \[10mg or 30mg\] along with intravenous (IV) infusions of standard-of-care therapy Elaprase via intrathecal drug delivery device (IDDD) or lumbar punctures.
48382942|NCT05164562|OTHER|Data collection|Description: musculoskeletal disorders of upper limb evaluation
48382943|NCT00305331|DRUG|Domperidone (drug)|
48382944|NCT05037968|DEVICE|MagnetOs Flex Matrix|Procedure: Instrumented Posterolateral Lumbar Fusion
48519564|NCT03338530|BEHAVIORAL|Comprehensive School-Based Intervention|School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
48024281|NCT05877729|BEHAVIORAL|Video-counseling+app|"The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier)."
48519565|NCT00504751|DRUG|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
48519566|NCT00504751|DRUG|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:~* Dexamethasone 40 mg IV days 1-4~* Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~* Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~* Cisplatin 25 mg IV days 1-4~* Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~* Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~* VELCADE 1.5 mg/m2 on days 2 and 5"
48519567|NCT05722561|BEHAVIORAL|Telehealth Motivational Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.
48519568|NCT05722561|DRUG|Nicotine Replacement Product|Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
48519569|NCT05722561|DEVICE|National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).|Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
48519570|NCT03748446|DRUG|Xenon|The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
48719154|NCT00905086|OTHER|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
48024282|NCT05054023|DRUG|Soulagel®|topic gel
48519571|NCT03748446|DRUG|Nitrogen gas|nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
48519572|NCT01458353|PROCEDURE|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
48719155|NCT00905086|PROCEDURE|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
48719156|NCT00905086|PROCEDURE|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
48024283|NCT05054023|DRUG|Arthrosyl®|topic gel
48024284|NCT04671511|PROCEDURE|Targeted Axillary Dissection|Sentinel Node Biopsy (SNB; using Tc99 +/- Blue dye) + Radioactive Seed Localisation (RSL) of clipped node using I125 seed = Targeted Axillary Dissection (TAD)
48024285|NCT04671511|DIAGNOSTIC_TEST|Ultrasound of the axilla|Prospectively recorded preoperative ultrasound of the axilla. Number of suspicious nodes recorded. Biopsy and clipping of the positive node.
48181789|NCT06148402|DRUG|Fruquintinib plus camrelizumab and capecitabine|fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
48181790|NCT03569215|BEHAVIORAL|Questionnaire|All included patients will be exposed to questionnaires and psychiatric diagnostic tests
48181791|NCT02464605|BIOLOGICAL|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
48519573|NCT01458353|PROCEDURE|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
48519574|NCT06579625|OTHER|Cancer education|Participants in the experimental group will receive cancer education.
48519575|NCT03135002|OTHER|Other|
48519576|NCT03073876|DRUG|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
48519577|NCT03073876|DRUG|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
48519578|NCT05334641|OTHER|Listening Music|The patients in the experimental group were listened to music.
48519579|NCT05334641|OTHER|Not Listening Music|The control group was not listened to music.
48519580|NCT00185588|DRUG|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
48519581|NCT00185588|DRUG|Gemcitabine|850 mg/m2
48719157|NCT00905086|PROCEDURE|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
48719158|NCT00997399|DRUG|panobinostat (LBH589)|
48519582|NCT02908971|BEHAVIORAL|soy based formula at infancy|The intervention is only past history of soy consumption
48382945|NCT03880955|DEVICE|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
48382946|NCT00337155|DRUG|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
48382947|NCT05966129|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
48519583|NCT02392585|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
48519584|NCT02392585|PROCEDURE|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
48719159|NCT00143377|DRUG|tolterodine SR, overactive bladder|
48719160|NCT01627444|PROCEDURE|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
48719161|NCT04997525|DRUG|Estradiol Tablets|Combined with progesterone
48024286|NCT04741425|OTHER|REST intervention|"The breastfeeding talk will be conducted by Zoom at the third trimester about breastfeeding benefits and other practical advices. There is also a sharing session by a successful breastfeeding mother and a group discussion with different breastfeeding scenarios.~Once the mothers return home after delivery, individualized breastfeeding coaching will be provided by PI through a daily Zoom videoconference within 24 hours upon hospital discharge till Day 7 after delivery.~During the last breastfeeding videoconference, mothers will be reminded to have weekly telephone follow-ups by PI from week 2 to 2 months postpartum.~Women who are randomised into the intervention group will receive REST in addition to the standard antenatal and postnatal care (described at below) by the Obstetrics Department of their delivery hospitals."
48719162|NCT04997525|DRUG|Progesterone|Combined with estradiol
48719163|NCT04997525|DRUG|Follitropin Alfa|Combined with hCG
48024287|NCT01954017|BIOLOGICAL|STP206|Live Biotherapeutic
48024288|NCT01954017|OTHER|Control|Sterile Water
48024289|NCT05778214|DEVICE|Interventional Robotic System|Cerebral angiography was performed by using the interventional robotic system
48024290|NCT05036122|DEVICE|LabClasp|Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.
48024291|NCT01849367|DEVICE|Eldith Neuroconn tDCS device|
48024292|NCT01494285|DRUG|ARK-E021 5%|Topically applied once daily at bedtime
48024293|NCT01494285|DRUG|ARK-E021 10%|Topically applied once daily at bedtime
48024294|NCT01494285|DRUG|Placebo|Topically applied once daily at bedtime
48024295|NCT04984642|OTHER|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
48024296|NCT06532591|DRUG|cadonilimab+paclitaxel+carboplatin|PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 ivgtt d1, q3w, carboplatin AUC 5 ivgtt d1, q3w
48024297|NCT06336135|OTHER|autologous hair follicle derived secretome|aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.
48024298|NCT04071873|DIAGNOSTIC_TEST|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
48024299|NCT04071873|BEHAVIORAL|HIV testing education|Participants will be provided with education on community based HIV resources.
48719164|NCT04997525|DRUG|Chorionic Gonadotropin, Alpha|In either natural cycle or combined with Follitropin Alfa
48719165|NCT02822300|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74_R84-086)
48719166|NCT02633553|RADIATION|adjuvant radiotherapy|50Gy/25Fx
48519585|NCT01689883|DEVICE|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
48719167|NCT05334420|BEHAVIORAL|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
48719168|NCT05334420|OTHER|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
48719169|NCT00202033|BEHAVIORAL|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
48719170|NCT00635089|DRUG|reslizumab|
48719171|NCT02182674|DRUG|Placebo Combivent HFA|
48719172|NCT02182674|DRUG|Combivent HFA|
48719173|NCT02182674|DRUG|Combivent (CFC)|
48024300|NCT05897645|OTHER|Registration|collect clinical date, assess the morphologic characteristics of plaque
48024301|NCT00182689|DRUG|sorafenib tosylate|Given orally
48382948|NCT05966129|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
48382949|NCT00421369|DRUG|sertraline|
48382950|NCT00421369|DRUG|triiodothyronine (T3)|
48382951|NCT00421369|DRUG|reboxetine|
48382952|NCT05789316|OTHER|Ototoxicity Screening Protocol|The ototoxicity screening protocol contains a functional and objective component. The functional component is the Hearing Handicap Inventory for the Elderly - Screening Version (HHIE-S). The objective component will be pure tone audiometry. A 2 kHz tone at 40 dB will play through over-the-ear headphones and subjects will indicate whether they heard it.
48382953|NCT01736527|DRUG|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
48382954|NCT04993287|OTHER|Non-invasive continuous remote monitoring with structured escalation pathway|Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
48382955|NCT04993287|OTHER|Affective Analysis of Participant Response to Continuous Remote Patient Monitoring|Surveys and interviews with enrolled participants
48382956|NCT03856632|DRUG|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
48519586|NCT01207180|OTHER|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
48519587|NCT01207180|OTHER|Satisfaction survey|Patients will be given a satisfaction survey.
48519588|NCT01207180|OTHER|Control group --- no intervention|Control group
48519589|NCT00233948|DRUG|nelfinavir mesylate|Given orally
48719174|NCT02182674|DRUG|Placebo Combivent (CFC)|
48719175|NCT02699268|OTHER|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
48719176|NCT01333995|BEHAVIORAL|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
48719177|NCT00775333|PROCEDURE|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
48719178|NCT05915624|OTHER|telephone counseiling|One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
48719179|NCT03362229|PROCEDURE|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
48719180|NCT03362229|PROCEDURE|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
48719181|NCT03930875|OTHER|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
48024302|NCT00651989|OTHER|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
48024303|NCT06239116|DRUG|Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)|Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
48024304|NCT06239116|DRUG|Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)|Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
48024305|NCT06239116|DRUG|Part C: RM-718|Multiple ascending doses of RM-718 (specific to Part C dose cohorts)
48024306|NCT01687517|DRUG|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
48519590|NCT00233948|PROCEDURE|biopsy|Correlative studies
48519591|NCT00233948|OTHER|laboratory biomarker analysis|Correlative studies
48519592|NCT00233948|OTHER|pharmacological study|Correlative studies
48519593|NCT00233948|GENETIC|gene expression analysis|Correlative studies
48519594|NCT00233948|GENETIC|western blotting|Correlative studies
48719182|NCT01127841|DRUG|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
48719183|NCT03275948|OTHER|whole grain|whole grain rye
48719184|NCT03275948|OTHER|reference|white wheat bread
48719185|NCT02714881|DRUG|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
48719186|NCT02714881|RADIATION|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
48719187|NCT04040842|DIAGNOSTIC_TEST|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
48719188|NCT06427694|DRUG|Aldesleukin|IL2 antagonist
48719189|NCT06427694|DRUG|Dextrose 5% in water|matched placebo to active
48719190|NCT02142881|OTHER|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of \<130 mmHg.
48519595|NCT00233948|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
48519596|NCT00233948|OTHER|immunoenzyme technique|Correlative studies
48719191|NCT02142881|OTHER|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
48719192|NCT00002039|DRUG|Foscarnet sodium|
48719193|NCT03161860|BEHAVIORAL|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
48719194|NCT01838785|DRUG|18F-DTBZ AV-133|
48024307|NCT02693444|DRUG|Lidocaine|
48024308|NCT02693444|DRUG|Saline|
48024309|NCT00879294|DEVICE|Motion sickness wristband|No drugs are involved.
48024310|NCT00879294|DIETARY_SUPPLEMENT|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
48024311|NCT01317953|DIETARY_SUPPLEMENT|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
48024312|NCT04405024|DIAGNOSTIC_TEST|Hepatitis C testing|Hepatitis C Screening
48024313|NCT01099995|OTHER|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
48024314|NCT01099995|OTHER|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
48719195|NCT05937594|GENETIC|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
48719196|NCT05246930|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
48719197|NCT01363583|DRUG|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
48719198|NCT01363583|DRUG|normal saline|0.5-1.5 ml/hour during 4 days
48719199|NCT03823950|DRUG|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
48719200|NCT01767272|DRUG|fexofenadine|fexofenadine brand name
48719201|NCT03772418|DRUG|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
48719202|NCT03772418|DRUG|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
48719203|NCT03659058|DRUG|silymarin|silymarin 140 three times daily
48719204|NCT03659058|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
48719205|NCT03659058|DRUG|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
48719206|NCT03659058|DRUG|Colchicine|Colchicine 0.6
48719207|NCT03659058|OTHER|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
48719208|NCT05620953|DIAGNOSTIC_TEST|respiratory specimen|nasopharyngeal swab or nasal aspiration or broncho-alveolar lavage
48719209|NCT05607329|PROCEDURE|Secondary cytoreduction|Open surgery is conducted by senior clinicians in gynecological oncology. Operation time，location and number of relapsed lesions, location and number of excised lesions, Whether achieved R0 or not, and other information are recorded.
48519597|NCT03028116|BIOLOGICAL|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
48519598|NCT03028116|BIOLOGICAL|Placebo|water for injection
48519599|NCT04179318|DIAGNOSTIC_TEST|Geneswell BCT|Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
48519600|NCT03090646|OTHER|Financial Incentive|Up to three gift cards to a major online retailer.
48719210|NCT05607329|DRUG|Chemotherapy|chemotherapy
48719211|NCT04543240|DEVICE|Integra™ dermal regeneration template|Integra a biologic dressing for deep wounds or large soft tissue defects that penetrate to the level of bone
48719212|NCT01549795|PROCEDURE|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
48719213|NCT01549795|RADIATION|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
48719214|NCT01549795|RADIATION|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
48719215|NCT01549795|DRUG|Capecitabine|Capecitabine - administered till liver transplantation
48719216|NCT01549795|PROCEDURE|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
48719217|NCT04738591|DEVICE|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
48719218|NCT02221154|DIETARY_SUPPLEMENT|Inofolic®|
48719219|NCT02221154|OTHER|Gonadotropins; Folic Acid|standard ovarian stimulation
48519601|NCT05211648|DEVICE|Aktiia Bracelet|Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The optical signals at the wrist are recorded non-invasively by means by the Aktiia bracelet. The Blood Pressure measurements are further determined from these optical signals and are compared to weekly and monthly Blood Pressure averages measured manually by traditional Home Blood Pressure Monitoring.
48519602|NCT00444587|DRUG|Second line chemotherapy|As prescribed
48519603|NCT00444587|DRUG|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
48519604|NCT02850731|DEVICE|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
48519605|NCT02392949|BEHAVIORAL|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
48519606|NCT02392949|OTHER|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
48519607|NCT06550414|DRUG|Dexmedetomidine|Active comparator: dexmedetomidine group
48519608|NCT06550414|DRUG|Bupivacain|Placebo comparator: bupivacaine group
48519609|NCT05352750|BIOLOGICAL|SON-1010|SON-1010 multiple ascending dose
48519610|NCT04607135|DEVICE|Acoustic radiation force impulse (ARFI)|"Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system"
48519611|NCT04607135|DEVICE|Ultrasound|Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
48519612|NCT06581094|DIETARY_SUPPLEMENT|UCII, glucosamine and curcumin|The dosage was 42 mg UCII, 460 mg glucosamine and 380 mg curcumin per day, and placebo (only 42 mg UCII).
48519613|NCT02304029|DEVICE|MRI|
48519614|NCT02000791|OTHER|Comparison of fibreoptic view|
48519615|NCT00890617|PROCEDURE|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
48519616|NCT00890617|DRUG|Prednisone|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
48519617|NCT02386137|DEVICE|Contrast-enhancement ultrasound with Sonovue|
48519618|NCT00000525|DRUG|hydrochlorothiazide|
48519619|NCT00000525|BEHAVIORAL|diet, potassium supplementation|
48519620|NCT00000525|BEHAVIORAL|diet, magnesium supplementation|
48719220|NCT05027984|DEVICE|Optical coherence tomography|OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.
48719221|NCT05027984|DEVICE|iFR/FFR/RFR|The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
48519621|NCT00000525|DRUG|triamterene|
48719222|NCT01134926|DRUG|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
48719223|NCT06507839|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
48519622|NCT00000525|DRUG|chlorthalidone|
48519623|NCT03352687|PROCEDURE|anterior SSAX|block of the suprascapular nerve block for shoulder surgery by anterior way
48519624|NCT03352687|PROCEDURE|posterior SSAX|block of the suprascapular nerve block for shoulder surgery by posterior way
48519625|NCT04858932|DEVICE|Continuous Glucose Monitor|a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
48519626|NCT04858932|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
48519627|NCT04858932|DEVICE|Food Weight Scale|a scale to measure food weight
48519628|NCT04858932|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
48519629|NCT02135614|DRUG|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
48519630|NCT02135614|DRUG|Presatovir placebo|Presatovir placebo tablets administered orally
48719224|NCT06507839|OTHER|Placebo|Matching placebo
48519631|NCT01644240|DRUG|TD-8954|Intravenous infusion
48519632|NCT01644240|DRUG|Placebo - saline|Intravenous infusion
48519633|NCT04183621|DIAGNOSTIC_TEST|high resolution impedance manometry|Two detailed swallow assessments to be carried out at between 2-4 months and 8-10 months of age
48519634|NCT01555216|DRUG|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
48519635|NCT01555216|DRUG|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
48519636|NCT05024747|DRUG|NicoDerm CQ patch (GSK Dungarvan)|A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.
48519637|NCT05024747|DRUG|NicoDerm CQ (Alza)|A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
48519638|NCT06058104|DEVICE|Charades based mobile digital therapeutic|The mobile app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parents are asked to play with their child 15 minutes 3-4 times per week for 8 weeks.
48519639|NCT05156671|BIOLOGICAL|Adrecizumab (HAM 8101)|Drip infusion over 60 minutes.
48519640|NCT05156671|DRUG|Placebo|Drip infusion over 60 minutes
48519641|NCT02881502|OTHER|severe asthma group|No intervention
48519642|NCT02577991|DRUG|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
48519643|NCT02577991|DRUG|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
48519644|NCT00191607|DRUG|Gemcitabine|
48519645|NCT00191607|DRUG|liposomal doxorubicin|
48519646|NCT06583161|BEHAVIORAL|Moderate drinking|Drink up to 16 grams of alcohol daily or almost daily \[repeated assessment center visit\] or 8-16 grams of alcohol 4 or more times per week \[web-based mental health questionnaire\]
48519647|NCT06583161|BEHAVIORAL|Quitting|No alcohol consumption
48519648|NCT06583161|BEHAVIORAL|Social drinking|Drink up to 16 grams of alcohol 1-2 days per week or drink 1-3 times per month or only on special occasions \[repeated assessment center visit\], or drink 8-16 grams of alcohol 2-3 times per week or drink 4 times per month or less \[web-based mental health questionnaire\]
48519649|NCT06583161|BEHAVIORAL|Heavy/binge drinking|Drink more than 16 grams of alcohol daily or almost daily or more than 40 grams of alcohol 1-2 days per week \[repeated assessment center visit\], or 24 grams of alcohol or more 4 or more times per week or 40 grams of alcohol or more 2-3 times per week \[web-based mental health questionnaire\]
48719225|NCT05592496|PROCEDURE|Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.|After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
48181792|NCT01233661|OTHER|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
48519650|NCT04214197|DRUG|Crisaborole 2% Top Oint|Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
48719226|NCT05592496|DEVICE|Catheter insertion technique by using special tube t|By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
48181793|NCT01390142|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
48181794|NCT01390142|PROCEDURE|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
48181795|NCT01390142|PROCEDURE|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
48181796|NCT00121121|BIOLOGICAL|Lipopeptides LIPO-4|
48181797|NCT01335945|PROCEDURE|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
48181798|NCT02001909|DRUG|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
48181799|NCT02001909|DRUG|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
48181800|NCT04751682|BIOLOGICAL|BBV154 Vaccine|Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.
48181801|NCT04751682|BIOLOGICAL|Placebo|Placebo
48181802|NCT03990142|DIAGNOSTIC_TEST|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
48519651|NCT05831371|DIAGNOSTIC_TEST|TEP FDG|FDG TEP peformed in clinical routine
48519652|NCT04095039|PROCEDURE|Hemodialysis|Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl
48181803|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
48181804|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
48181805|NCT00196391|DRUG|DR-2021a|1 capsule daily for 10 days
48519653|NCT00989482|BEHAVIORAL|Computer kiosk Education|computerized patient education; guidelines for physicians
48519654|NCT00866359|DRUG|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
48181806|NCT00196391|DRUG|DR-2021b|1 capsule daily for 10 days
48181807|NCT00196391|DRUG|DR-2021c|1 capsule daily for 10 days
48181808|NCT00196391|DRUG|DR-2021d|1 capsule daily for 10 days
48181809|NCT00196391|DRUG|DR-2021e|1 capsule daily for 10 days
48181810|NCT00196391|OTHER|Placebo|1 matching placebo capsule for 10 days
48181811|NCT02484378|DRUG|CER-001|Engineered pre-beta HDL particle
48181812|NCT02484378|DRUG|Placebo|Normal saline
48181813|NCT01852188|OTHER|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
48181814|NCT00013611|DRUG|Proleukin|Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
48181815|NCT04950036|DIAGNOSTIC_TEST|Diagnostic Test|The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.
48181816|NCT03045913|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
48181817|NCT03840265|PROCEDURE|carotid endarterectomy|In this project the following parameters will be assessed both in asymptomatic and symptomatic patients underwent carotid endarterectomy: 1) hemodynamic modeling of effect of the supraaortic arteries anatomic variations and pathologies 2, preoperative stroke risk prediction based on comparative analysis of CTA results of plaque morphology and ultrasound-based plaque elastography analysis, 3) cerebral flow measurement by transcranial Doppler sonography(TCD), 4) presence recent of silent brain ischemia on DWI-MRI, 5) OCT angiography could be a useful non-invasive method for evaluation of the outcome of carotid interventions
48181818|NCT04699045|OTHER|No active intervention|
48519655|NCT00866359|DRUG|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
48519656|NCT04124445|PROCEDURE|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
48519657|NCT03925675|DRUG|PET/CT with F-Fluciclovine (Axumin)|Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
48181819|NCT01097499|DEVICE|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
48181820|NCT04897204|PROCEDURE|Catheter ablation and left atrial appendage occlusion|The patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion.
48181821|NCT04897204|PROCEDURE|Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion|These patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion, combined with additional left atrial appendage occlusion.
48181822|NCT02145169|DRUG|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
48181823|NCT03238222|BEHAVIORAL|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 \& 2) and 2 x 20-minute follow-up telephone calls (weeks 6 \& 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
48181824|NCT04484584|OTHER|complex decongestive therapy|Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
48181825|NCT02418715|OTHER|Water Aerobics Training|
48181826|NCT00723749|DRUG|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine \& 0.5 mg naloxone and 8 mg buprenorphine \& 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
48181827|NCT00414258|PROCEDURE|breastfeeding|See detailed description.
48519658|NCT04053127|DEVICE|RAVANS|Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
48519659|NCT01074944|DRUG|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
48181828|NCT03639753|BEHAVIORAL|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules
48519660|NCT06571773|PROCEDURE|intraoperative implantation of Capsular Tension Ring|The Capsular Tension Ring(ACPi-11; Bausch + Lomb, Rochester, New York, USA) is a device made of PMMA with blunt-tipped eyelets at its ends. It can be inserted at any point during cataract surgery, following the creation of a strong anterior capsulotomy via capsulorhexis
48519661|NCT06571773|PROCEDURE|none intraoperative implantation of CTR|the surgeon did a surgery without the intraoperative implantation of CTR
48519662|NCT03732430|DRUG|IBI308|A humanized anti-PD-1 monoclonal antibody
48519663|NCT01433367|DEVICE|CerPass® Total Disc Replacement|Single level cervical disc disease
48719227|NCT05592496|PROCEDURE|"Connection of catheters bilateraly to easy pump system,"|"Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. Easy pump system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour"
48719228|NCT05592496|DIAGNOSTIC_TEST|VAS scale for pain control|By using Visual Analog scale of pains, the pain score is fixed
48719229|NCT03230292|DRUG|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
48519664|NCT06460805|DIETARY_SUPPLEMENT|Partial enteral nutrition|70% caloric intake from enteral nutrition formula and 30% caloric intake from a limited range of solid foods
48519665|NCT01926574|BEHAVIORAL|long rehabilitation program|
48519666|NCT01926574|BEHAVIORAL|short rehabilitation program|
48519667|NCT01926574|BEHAVIORAL|Acceptance and commitment therapy (ACT)|
48519668|NCT01842529|BIOLOGICAL|botulinum toxin injection|
48719230|NCT01840358|OTHER|Observation of hypoglycemias frequency 3 days before and after pump initiation|
48719231|NCT04022018|RADIATION|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
48719232|NCT04022018|RADIATION|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
48719233|NCT02421263|DRUG|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
48024315|NCT00961974|BEHAVIORAL|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
48024316|NCT00961974|BEHAVIORAL|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
48024317|NCT02303964|BIOLOGICAL|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
48024318|NCT02303964|DRUG|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
48024319|NCT05355389|BEHAVIORAL|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
48382957|NCT03856632|OTHER|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
48382958|NCT03856632|DRUG|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
48382959|NCT03856632|PROCEDURE|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
48382960|NCT04707014|BEHAVIORAL|Hypnosis|Rapid conversational hypnosis
48382961|NCT04707014|BEHAVIORAL|Attention-distracting techniques|i-pad with movies, games and music
48382962|NCT05258500|OTHER|Ghostly app|For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
48382963|NCT05258500|OTHER|Blood flow restriction|Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
48382964|NCT05258500|OTHER|Leaflet|This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
48719234|NCT00044824|DRUG|Fexofenadine|
48719235|NCT05505188|OTHER|Questionnaire|"Self-questionnaires are completed by the patient at the time of this consultation:~* Neuropathic pain: NPSI in screening~* Anxiety/depression: HADS in screening~* Quality of life: EORTC (QLQC30 and H\&N43)~* Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification.~Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain.~Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression.~Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report"
48719236|NCT06443346|OTHER|Eosinophilic Esophagitis|Eosinophilic Esophagitis patients with a proper diagnosis
48719237|NCT01973608|DRUG|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
48181829|NCT03639753|OTHER|Usual Practice|Standard care for teens who get licensed in the state of PA
48181830|NCT00044746|DRUG|Piperacillin/Tazobactam|
48382965|NCT06103656|DRUG|Drug: Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT.
48382966|NCT06103656|DRUG|Drug: Placebo|Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
48519669|NCT01842529|BIOLOGICAL|0.9% normal saline injection|
48719238|NCT01973608|DRUG|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
48181831|NCT04584671|DIAGNOSTIC_TEST|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
48181832|NCT04584671|DIAGNOSTIC_TEST|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
48181833|NCT04584671|DIAGNOSTIC_TEST|Pulmonary Function Tests (PFT)|Participants will have their lung function evaluated using PFT
48181834|NCT04584671|DIAGNOSTIC_TEST|Six Minute Walk Test (6MWT)|Participants will perform the six minute walk test as a measure of exercise capacity
48382967|NCT06103656|DRUG|Drug: Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
48382968|NCT04637217|DIAGNOSTIC_TEST|Optical Coherence Tomography|Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
48382969|NCT03673137|DEVICE|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
48382970|NCT03673137|DRUG|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
48382971|NCT03872908|DEVICE|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
48382972|NCT03872908|DEVICE|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
48382973|NCT02439801|PROCEDURE|PEEP 0|0 cmH2O positive end expiratory pressure
48719239|NCT01973608|DRUG|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
48719240|NCT01973608|DRUG|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
48719241|NCT01973608|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
48719242|NCT05440448|DEVICE|Patch-free occlusion therapy|Use of filters in glasses to provide occlusion therapy
48382974|NCT02439801|PROCEDURE|PEEP 5|5 cmH2O positive end expiratory pressure
48382975|NCT02439801|PROCEDURE|PEEP 8|8 cmH2O positive end expiratory pressure
48382976|NCT01210625|DIETARY_SUPPLEMENT|Nutrabiotix|Fiber supplement: 9mg or 12mg
48382977|NCT01210625|DIETARY_SUPPLEMENT|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
48382978|NCT03423914|BEHAVIORAL|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
48382979|NCT03423914|OTHER|Only Writing|Participants write about knowledge related to infant care during four days
48382980|NCT06647940|DRUG|Orelabrutinib Oral Tablet|Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen
48382981|NCT06647940|DRUG|R-CHOP Protocol|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
48719243|NCT05440448|DEVICE|Adhesive patch|Standard-of-care occlusion therapy with an adhesive patch
48181835|NCT04584671|DIAGNOSTIC_TEST|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
48181836|NCT04584671|DIAGNOSTIC_TEST|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
48181837|NCT04584671|OTHER|Questionnaires|Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
48181838|NCT02542410|DRUG|Cabergoline|
48181839|NCT02542410|DRUG|Norethindrone acetate|
48382982|NCT03232775|OTHER|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
48382983|NCT03232775|OTHER|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
48519670|NCT01842529|DEVICE|Implantable loop recorder|
48719244|NCT05577546|OTHER|Moor S brace treatment|The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
48181840|NCT00943046|DEVICE|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
48181841|NCT05794243|DRUG|LY3493269|Administered orally.
48181842|NCT02864823|PROCEDURE|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
48181843|NCT05928949|OTHER|pilates exercises|Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.
48181844|NCT03815864|DIAGNOSTIC_TEST|Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation|Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)
48181845|NCT02922283|DEVICE|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
48181846|NCT02922283|PROCEDURE|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
48181847|NCT02922283|DEVICE|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
48181848|NCT02922283|PROCEDURE|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
48519671|NCT04060056|OTHER|Standardized breakfast|Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
48519672|NCT04060056|OTHER|Standardized snack|Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
48519673|NCT04060056|OTHER|Standardized lunch|Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
48519674|NCT05688917|DIETARY_SUPPLEMENT|Green coffee been extract|supportive treatment
48519675|NCT05688917|OTHER|Placebo|Placebo capsule
48519676|NCT06316011|DEVICE|Magnetocardiography|Magnetocardiography
48181849|NCT02419768|OTHER|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
48181850|NCT05895708|OTHER|Specific strengthening and stretching exercise|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
48382984|NCT04174443|PROCEDURE|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
48382985|NCT04174443|PROCEDURE|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
48519677|NCT01531660|BEHAVIORAL|step-up jogging program|
48519678|NCT03817645|OTHER|Zeolite|The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
48519679|NCT05775887|BIOLOGICAL|UQSC2 Vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
48181851|NCT05895708|OTHER|General Exercise|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
48181852|NCT05302297|DRUG|Cemiplimab|Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
48181853|NCT00462111|DRUG|Indometacin|
48181854|NCT05736419|DRUG|Fludarabine|PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
48181855|NCT05736419|DRUG|Cyclophosphamide|Cyclophosphamide will be administered Post-Transplant
48181856|NCT05736419|DRUG|Tacrolimus|Tacrolimus will be administered beginning on day +5
48181857|NCT05736419|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
48382986|NCT06145451|BEHAVIORAL|Family Success Network|The Family Success Network (FSN) is a community-based maltreatment prevention program that is being piloted to serve caregivers of children aged between 0-18 in the Trumbull, Mahoning, and Columbiana Counties in Ohio. FSN is a comprehensive multi-tier program providing information and referrals to community resources at Tier I (i.e., the initial contact stage), caregiver education, and financial literacy program along with concrete support at Tier II (i.e., enrollment in family coaching services in FSN), and a life skills program and monthly home visits for families with more intensive needs at tier III (most intensive level of FSN services).
48519680|NCT05775887|BIOLOGICAL|NVX-CoV2373 vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
48719245|NCT05577546|OTHER|Schroth Three-Dimensional Scoliosis Exercise Treatment|Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
48519681|NCT03303235|DRUG|Methylergonovine|IV vs IM
48719246|NCT01760473|DRUG|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
48719247|NCT00012363|DRUG|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
48719248|NCT00012363|DRUG|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
48719249|NCT04485260|DRUG|KRT-232|administered by mouth
48181858|NCT05736419|BIOLOGICAL|Rabbit ATG|The dose and schedule of ATG will be determined according to the nomogram in Appendix A
48181859|NCT05736419|DRUG|Dexamethasone|Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
48181860|NCT05736419|DRUG|Bortezomib|Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
48181861|NCT05736419|DRUG|Rituximab|Rituximab on days -71, -58, -43, and -30.
48382987|NCT03099655|DEVICE|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
48382988|NCT02339246|DRUG|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
48382989|NCT02339246|DRUG|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
48382990|NCT01853969|OTHER|Typing assessment|
48181862|NCT03827447|DRUG|Vancomycin Oral Capsule|125 mg capsules every 6 hours for 14 days.
48181863|NCT03827447|DRUG|Placebo Oral Capsule|Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
48181864|NCT03363347|DRUG|Redifferentiation with retinoid acid|In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
48181865|NCT03441100|DRUG|IMA202 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
48181866|NCT03441100|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
48181867|NCT06544369|BIOLOGICAL|COVID-19 vaccin|injection
48181868|NCT02751047|OTHER|manual ventilation|Facemask ventilation is performed by manual bagging with reservoir bag.
48382991|NCT06504407|BEHAVIORAL|Bingo Educational Game|The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
48719250|NCT04485260|DRUG|Ruxolitinib|administered by mouth
48719251|NCT00832494|DRUG|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
48719252|NCT06385717|RADIATION|chemo-radiation|different Chemo-radiotherapy regimen
48719253|NCT06508723|PROCEDURE|Dental implant placement|The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.
48519682|NCT06582823|OTHER|Health belief model-based community educational program|"The 5-week intervention includes two weekly 60-minute face-to-face sessions for 8-10 participants, two weekly telephone follow-ups, and a booster session.~Week 1: Focuses on increasing knowledge about atrial fibrillation (AF), its risks, complications, and treatment benefits. The principal investigator (PI) provides education using interactive methods and colored visuals.~Week 2: Emphasizes skill building for pulse palpation to detect irregular pulses. Participants learn through demonstrations and practice using a simulated arm.~Weeks 3-4:Telephone follow-ups monitor adherence to pulse checking and address barriers. Support and advice are provided by the PI.~Week 5: A booster session reinforces knowledge and skills with scenario-based practice and use of a simulated arm."
48519683|NCT06582823|OTHER|Control|The control group will receive an information leaflet presenting information about AF, health risks and complications associated with AF, common methods to screen for AF, and follow-up actions if positive screening results are suspected.
48519684|NCT00141050|DRUG|Focalin XR|
48382992|NCT05390086|OTHER|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
48382993|NCT00825669|DRUG|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
48382994|NCT00825669|PROCEDURE|Laser ablation|Laser ablation is given to the PVTT.
48382995|NCT01828164|DEVICE|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
48382996|NCT01828164|DEVICE|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
48382997|NCT03408327|DEVICE|Wearable technology|Fitness wristband \& APP
48719254|NCT01189292|DRUG|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
48382998|NCT03408327|BEHAVIORAL|LINE group|Promote social interaction
48519685|NCT00561119|DRUG|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 \& 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
48519686|NCT05626205|DEVICE|PARO robot|PARO is an advanced interactive robot. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties. PARO has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment. PARO can learn to behave in a way that the user prefers, and to respond to its new name.
48519687|NCT01889147|BIOLOGICAL|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
48719255|NCT01189292|OTHER|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
48719256|NCT01487993|DRUG|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
48719257|NCT01487993|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
48719258|NCT04592900|OTHER|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
48719259|NCT04149678|DRUG|Ozanimod|Ozanimod
48719260|NCT04149678|DRUG|Cyclosporine|Cyclosporine
48719261|NCT06495866|RADIATION|ultrasound|Ultrasound finding of entheseal sites of upper \& lower limbs of all groups and scoring according to enthesitis scoring system
48382999|NCT03408327|BEHAVIORAL|Group activities|Which was developed by applying social cognitive theory
48383000|NCT03408327|DEVICE|Health promotion manual|Which was about general physical activity promotion content
48383001|NCT01959282|DRUG|Placebo|Participants will receive placebo once daily
48383002|NCT01959282|DRUG|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
48383003|NCT01959282|DRUG|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
48383004|NCT01959282|DRUG|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
48383005|NCT01959282|DRUG|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
48383006|NCT01285388|DRUG|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
48719262|NCT04213170|DRUG|sintilimab|Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d
48719263|NCT03333148|DRUG|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
48719264|NCT03333148|OTHER|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
48719265|NCT02995551|PROCEDURE|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
48719266|NCT02995551|BEHAVIORAL|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
48181869|NCT02751047|OTHER|Pressure controlled mechanical ventilation|Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
48181870|NCT04340765|DRUG|18F-fluorocholine|Dual phase 18F-fluorocholine PET/CT
48181871|NCT05569213|DIAGNOSTIC_TEST|motor evoked potentials|see previous descriptions
48181872|NCT05783713|OTHER|Influenza Vaccination|Describe and measure any differences in total influenza vaccination coverage, in different categories of professionals and in different operational units.
48181873|NCT02961478|DRUG|IOHEXOL|Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
48181874|NCT06278337|GENETIC|genetic restrospective study|it is not an interventional study but observational
48383007|NCT06652373|BEHAVIORAL|Behavioural change through education|The content of the perinatal grief counselling training to be used in the study will be created in 8 modules and will be applied to midwives. The planned perinatal grief counselling training for midwives will be carried out online and it is aimed that midwives gain perinatal grief counselling skills and competence and increase their competence to cope with the problems they may encounter in the counselling process.
48383008|NCT01656850|OTHER|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
48383009|NCT01656850|OTHER|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
48719267|NCT06046690|DEVICE|Mechanical Ventilation Device|"During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
48181875|NCT04657042|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Four-dimensional MRI of torso
48181876|NCT00781937|DRUG|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
48181877|NCT00781937|DRUG|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
48181878|NCT00537121|DRUG|fluorouracil|Given IV
48181879|NCT00537121|DRUG|irinotecan hydrochloride|Given IV
48181880|NCT00537121|DRUG|leucovorin calcium|Given IV
48181881|NCT00537121|DRUG|vorinostat|Taken Orally
48181882|NCT00537121|OTHER|pharmacological study|Correlative Study
48519688|NCT01889147|BIOLOGICAL|Placebo|
48519689|NCT02194361|DRUG|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
48519690|NCT02194361|DRUG|Placebo|
48519691|NCT02094417|DRUG|AMG531|Subcutaneous, weekly injection
48181883|NCT03329300|BEHAVIORAL|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
48719268|NCT06046690|DEVICE|External Device|"The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
48181884|NCT05698732|DEVICE|Coroflex® ISAR NEO coronary stent system|Patients in whom treatment with Coroflex® ISAR NEO coronary stent system has been attempted
48383010|NCT03804372|DRUG|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
48383011|NCT03804372|DRUG|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
48719269|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
48719270|NCT01651390|DEVICE|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
48719271|NCT05849818|DEVICE|full-immersive VRapeutic software gaming technology|"* Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~* Viblio VRapeutic fully immersive game will be used.~* Manual instructions of the game will be followed and features of the game will be customized.~* The child instructed to put back a pile of books on the floor into their shelves.~* Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~* Level III distracting tasks during book ordering~* The complexity of the game depend on task duration, number of books and the nature of distractors"
48719272|NCT01995552|DEVICE|External Loop Recorder|
48181885|NCT01699737|DRUG|JTT-851|
48383012|NCT03804372|DRUG|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
48383013|NCT03731325|BEHAVIORAL|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
48383014|NCT06651762|PROCEDURE|unilateral Radiofrequency|unilateral genicular nerve cooled radio frequency ablation pre-operative
48181886|NCT01699737|DRUG|Glimepiride|Encapsulated Glimepiride tablets
48181887|NCT01699737|DRUG|Placebo for Active|
48383015|NCT06651762|PROCEDURE|bilateral Radiofrequency|bilateral genicular nerve cooled radio frequency ablation pre-operative
48181888|NCT01699737|DRUG|Placebo for comparator|
48181889|NCT01921907|DRUG|AD17137 topical treatment|
48181890|NCT01921907|DRUG|Placebo|
48383016|NCT06651762|PROCEDURE|Epidural|Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
48383017|NCT01079572|OTHER|in-person|Follow-up appointments will be completed in-person as per usual
48181891|NCT02561208|OTHER|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
48181892|NCT00455897|DRUG|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
48181893|NCT00455897|DRUG|CHOP|Administered as part of standard care
48719273|NCT06025734|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) treatment|Spina Bifida pediatric patients with neurogenic bladder will be in Transcutaneous Tibial Nerve Stimulation (TTNS) treatment. Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session)
48719274|NCT03246490|OTHER|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
48719275|NCT02279498|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
48719276|NCT02279498|DRUG|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
48383018|NCT01079572|OTHER|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
48181894|NCT00455897|DRUG|Rituximab|Administered as part of standard treatment
48181895|NCT06212089|DRUG|TR-012001|A single dose of TR-012001 will be administered.
48181896|NCT06212089|OTHER|Placebo|A single dose of placebo will be administered.
48383019|NCT05119556|BEHAVIORAL|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
48383020|NCT04896697|DRUG|vilastobart (XTX101)|vilastobart (XTX101) monotherapy
48383021|NCT04896697|DRUG|Atezolizumab|1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
48719277|NCT01711866|DRUG|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
48719278|NCT02177409|DRUG|Telmisartan|
48719279|NCT02177409|DEVICE|Amlodipine|
48719280|NCT02177409|DRUG|Placebo|
48181897|NCT03159351|DEVICE|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
48181898|NCT03159351|DEVICE|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
48719281|NCT05140551|DEVICE|COMPASS: digital CBT|COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
48719282|NCT02641522|DRUG|Siltuximab|Single infusion of siltuximab (11 mg/kg)
48181899|NCT00564148|DRUG|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
48181900|NCT03531554|DIETARY_SUPPLEMENT|ketone ester drink|395 mg of ketone ester/kg
48181901|NCT03531554|BEHAVIORAL|exercise|35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.
48181902|NCT03531554|PROCEDURE|muscle biopsy|biopsy from the quadriceps muscle prior to and immediately after upright bicycling
48181903|NCT03531554|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
48181904|NCT02130245|PROCEDURE|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
48181905|NCT02130245|PROCEDURE|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
48719283|NCT05221775|DRUG|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
48719284|NCT01866033|DRUG|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
48719285|NCT01866033|DRUG|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
48719286|NCT01866033|DRUG|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
48719287|NCT01866033|DRUG|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
48719288|NCT02644356|BEHAVIORAL|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
48719289|NCT02089113|DRUG|Dexamethasone|
48383022|NCT04896697|DRUG|vilastobart (XTX101)|In combination with Atezolizumab
48383023|NCT05958238|DEVICE|AR/VR oral care training system|Students simulated the treatment of the elderly with different physical and oral conditions using virtual situations and employed suitable oral care methods depending on each situation through VR. They learned the Bass brushing technique, the interdental brush cleaning method, and the soft tissue cleaning method through AR.
48383024|NCT05958238|OTHER|Traditional classroom teaching|The well-trained oral hygienist provided traditional oral care instruction with the same teaching content in the AR/VR-based training system.
48383025|NCT01448070|DRUG|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
48383026|NCT06338176|OTHER|OPTIMUS-SAB clinical care pathway|Activation of SAB clinical care pathway within EMR system.
48719290|NCT02089113|PROCEDURE|Placebo Vehicle|
48719291|NCT01815632|OTHER|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
48719292|NCT01815632|OTHER|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
48383027|NCT05643118|GENETIC|OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)|Clear colorless solution dissolved in 1X PBS and injected intravitreally
48024320|NCT05355389|BEHAVIORAL|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
48383028|NCT02658578|PROCEDURE|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
48383029|NCT06631235|OTHER|orthopedic appliance|appliances are used to correct skeletal class II due to mandibular deficiency
48719293|NCT04809974|DRUG|Niagen|The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
48383030|NCT06631235|OTHER|aesthetic orthopedic appliance|aesthetic appliances are used to correct skeletal class II due to mandibular deficiency
48383031|NCT02326337|DEVICE|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
48383032|NCT02326337|DEVICE|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
48383033|NCT02150889|BEHAVIORAL|Running Program|16 week supervised running program
48383034|NCT02150889|BEHAVIORAL|Yoga Program|once weekly supervised yoga
48383035|NCT04667507|DRUG|Dexamethasone Ophthalmic implant|Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
48383036|NCT04757896|PROCEDURE|Lateral costoclavicular approach|USG guided lateral costoclavicular approach for brachial plexus block
48383037|NCT04757896|PROCEDURE|Medial costoclavicular approach|USG guided medial costoclavicular approach for brachial plexus block
48719294|NCT00810940|DRUG|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
48719295|NCT00810940|DRUG|mannitol|mannitol plus standard treatment
48719296|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
48719297|NCT01519674|DRUG|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
48719298|NCT01519674|DRUG|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
48719299|NCT01519674|DRUG|metformin|Subjects will continue on their pre-trial metformin treatment.
48719300|NCT02032342|DEVICE|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
48719301|NCT02032342|DEVICE|Arndt® blocker|Arndt® blocker for selective lobar deflation
48181906|NCT03567876|DRUG|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
48181907|NCT00129142|DRUG|Toremifene Citrate|
48383038|NCT00538473|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
48181908|NCT00976690|DRUG|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
48383039|NCT00538473|BIOLOGICAL|Fluarix™|Single dose, intramuscular injection
48719302|NCT02032342|DEVICE|Cohen blocker|Cohen blocker for selective lobar deflation
48181909|NCT02153905|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
48383040|NCT00526929|DRUG|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
48383041|NCT00359359|DRUG|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
48383042|NCT00359359|DRUG|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
48383043|NCT01912391|DRUG|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
48383044|NCT01912391|DRUG|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
48383045|NCT02677337|OTHER|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
48719303|NCT02032342|DEVICE|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
48181910|NCT02153905|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
48383046|NCT02677337|OTHER|Educational Program|
48383047|NCT04909177|OTHER|Smartphone application (app) in combination with headset|The intervention oVRcome is self-help VRET for specific phobia, that is delivered through a smartphone application (app) in combination with headset that holds the smartphone and uses 360º video. oVRcome includes 6 modules of psychoeducation, relaxation, mindfulness, cognitive techniques, exposure through VR, and a relapse prevention module which are aimed to be completed weekly.
48383048|NCT00104962|DRUG|lenalidomide|Given orally
48383049|NCT03172715|PROCEDURE|Locking plate|Osteosynthesis
48383050|NCT03172715|PROCEDURE|TKR|Total knee arthroplasty
48719304|NCT01888419|OTHER|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
48181911|NCT02153905|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
48181912|NCT02153905|BIOLOGICAL|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
48383051|NCT00322530|PROCEDURE|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
48719305|NCT02120703|DRUG|Pregabalin|Pregablin 75 mg per oral two times a day
48719306|NCT02120703|DRUG|Gabapentin|Gabapentin 200 mg twice daily per oral
48719307|NCT04411537|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
48719308|NCT04411537|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
48719309|NCT04411537|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
48719310|NCT04411537|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
48719311|NCT05898230|DEVICE|Mitral Valve Replacement|Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
48719312|NCT05933629|BEHAVIORAL|Online EmReg|A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
48719313|NCT05933629|BEHAVIORAL|Consultation Sessions|3 months of bi-weekly consultation sessions
48719314|NCT01827332|DRUG|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
48719315|NCT01827332|DRUG|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
48719316|NCT04744012|PROCEDURE|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
48719317|NCT00181610|DRUG|Recombinant Human Prolactin|60 mcg/kg every 12 hours
48719318|NCT00181610|BIOLOGICAL|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
48181913|NCT00269932|DRUG|levofloxacin|
48719319|NCT00181610|BIOLOGICAL|Normal Saline|twice per day
48719320|NCT04610736|DRUG|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
48719321|NCT01883011|DRUG|Piracetam|
48719322|NCT01883011|OTHER|Placebo|
48719323|NCT06158230|DRUG|Pizotifen|Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
48719324|NCT06158230|DRUG|Amitriptyline-propranolol|"Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses"
48024321|NCT04897048|PROCEDURE|Incremental exercise test (IET)|Incremental cardio pulmonary exercise test until exhaustion
48024322|NCT04897048|PROCEDURE|Constant work rate exercise test (CWRET)|constant (on 75% Wmax) cardio pulmonary exercise test until exhaustion
48024323|NCT01614210|DRUG|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
48024324|NCT01614210|PROCEDURE|Breast cancer surgery|Breast cancer surgery
48024325|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
48181914|NCT04803747|DRUG|Tranexamic acid (TXA)|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
48181915|NCT04803747|DRUG|Placebo (0.9 % Saline)|Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
48719325|NCT03050762|OTHER|Data Collection|Participant information collected from either source document or direct participant response.
48719326|NCT03050762|BEHAVIORAL|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
48719327|NCT04014621|DEVICE|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
48719328|NCT04624334|OTHER|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
48719329|NCT04624334|OTHER|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
48719330|NCT04624334|OTHER|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
48719331|NCT01741831|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
48024326|NCT00437489|DRUG|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
48024327|NCT02792582|RADIATION|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
48719332|NCT00316693|BIOLOGICAL|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
48719333|NCT00316693|BIOLOGICAL|Aimmugen™|Intramuscular injection, 3 doses
48719334|NCT06008483|DRUG|153-Sm-DOTMP (Samarium-153-DOTMP)|This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.
48719335|NCT05367141|OTHER|"CDSS (MedicBK)"|"Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care."
48719336|NCT06213337|OTHER|Foot care training with virtual classroom|Providing foot care training once every two weeks in virtual classes created via the Google meet application.
48719337|NCT06213337|OTHER|Foot care training with SMS support|Total of 60 SMS messages containing foot care information will be sent, one every day.
48024328|NCT02792582|PROCEDURE|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
48024329|NCT02999308|OTHER|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
48024330|NCT02497664|OTHER|Active Breathing Control|
48024331|NCT03584594|DIAGNOSTIC_TEST|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
48024332|NCT03196921|DRUG|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
48024333|NCT02325882|DRUG|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
48719338|NCT06213337|OTHER|Foot care training with virtual classroom and SMS support|Providing foot care training once every two weeks in virtual classes created via the Google meet application. Furthermore, total of 60 SMS messages containing foot care information will be sent, one every day.
48719339|NCT06289816|PROCEDURE|Minimally Invasive Surgery|Minimally Invasive Surgery : Laparoscopic partial splenectomy, cystectomy, and cyst deroofing.
48024334|NCT02325882|DRUG|Fentanyl 1|conventional fentanyl-based epidural PCA
48024335|NCT02325882|DRUG|Fentanyl 2|conventional fentanyl based intravenous PCA
48024336|NCT06534307|BEHAVIORAL|Questionnaire Child Behaviour Checklist|The Child Behavior Checklist comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of problems.
48024337|NCT06534307|BEHAVIORAL|Questionnaire Young Self Report|The Questionnaire Young Self Report comprises items assigned to 8 subscales describing various behavioral areas. These subscales can be summed up to scores for internalizing and externalizing problems as well as a total score.
48024338|NCT06534307|DIAGNOSTIC_TEST|physical examination|physical development examination including height (in cm), weight (in g) and tanner states
48024339|NCT06534307|DIAGNOSTIC_TEST|metabolic examination|metabolic development using blood analysis including blood components, metabolic parameters (Glucose, HbA1c, cholestrol)
48181916|NCT02453984|OTHER|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
48181917|NCT01681615|DRUG|Acetylsalicylate|1-2 drops
48181918|NCT01681615|DRUG|Isotonic NaCl|1 drop
48719340|NCT01805544|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
48719341|NCT00689754|PROCEDURE|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
48719342|NCT01203358|DRUG|Exosurf|Infants received up to four intratracheal doses of the surfactant.
48719343|NCT01203358|DRUG|Survanta|Infants received up to four intratracheal doses of the surfactant.
48719344|NCT00182897|BEHAVIORAL|Skills Building for Caregiver Health and Care-recipient|
48719345|NCT06113575|DEVICE|NeuroStar TMS|NeuroStar TMS treatment - 90-120% of Observed MT, 3 pulses/burst, 5 bursts/sec, 2 sec stimulation, 20 msec interval, 20 trains, 600 total pulses/session for 36 treatments in 5 days. 6 treatments on day 1, 8 treatments on days 2, 3, and 4, 6 treatments on day 5.
48719346|NCT01561963|DRUG|Apremilast|Tablets for oral administration
48719347|NCT01561963|DRUG|Rifampin Oral Capsules|Capsules for oral administration
48719348|NCT01561963|DRUG|Rifampin IV Solution|Intravenous (IV) solution
48719349|NCT05832736|PROCEDURE|Robotic hemi-prostatectomy with urethral preservation|Robotic hemi-prostatectomy with urethral preservation
48719350|NCT03241004|OTHER|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
48719351|NCT05136898|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
48719352|NCT02227836|DEVICE|Allergy Patch Testing|
48719353|NCT04787380|DEVICE|Heartfelt device|"The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition."
48719354|NCT02953665|DRUG|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
48719355|NCT02953665|DRUG|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
48719356|NCT03517995|DRUG|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
48719357|NCT03517995|OTHER|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
48719358|NCT03517995|PROCEDURE|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
48719359|NCT05122117|DEVICE|Methylene blue mediated Photodynamic therapy|Methylene blue (MB) with a concentration of 10 mg/mL was delivered inside the periodontal pocket. MB was injected inside in the selected periodontal pockets 4 - 6 mm with the help of a blunt needle and left for 1 min. Later, the periodontal pockets were flushed with distilled water for 3 min to remove the excess MB. The diode laser HELBO® TheraLite - Bredent Medical, Germany) of diameter 200 µm was used to deliver the light to initiate the disinfection process. Each participant underwent single session of laser exposure. The laser parameters such as wavelength, spot area, power output and laser energy were set at 660 nm, 0.028 cm2, 60 mW/cm2, and 150 mW, respectively. The laser was subjected for a period of 30 s in each pocket.
48719360|NCT05122117|PROCEDURE|Non-surgical periodontal therapy|A single session of full-mouth ultrasonic scaling using a sterilized scaler was rendered to the control group. Deep pockets were additionally approached and cleaned by using manual 'After Fives' Gracey curette for root planning (Hu Friedy Gracey After Five Vision curette; HuFriedy, Chicago, USA). This session was followed by a polishing session. A motivational session was conducted where the patients were educated on the importance of maintaining a good oral hygiene by brushing their teeth twice daily followed by the regular use of dental floss and chlorhexidine mouth wash twice daily, respectively.
48719361|NCT00668590|BEHAVIORAL|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
48719362|NCT00668590|BEHAVIORAL|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
48024340|NCT06534307|BEHAVIORAL|Questionnaire Reynolds Intellectual Assessment Scales and Screening|"The RIAS is standardized intelligence test. The RIAS provides an Total Intelligence Index (GIX, estimate of the general intelligence/g-factor), Verbal Intelligence Index (VIX) and the Nonverbal Intelligence Index (NIX). Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better cognitive performance."
48024341|NCT06534307|DIAGNOSTIC_TEST|electroencephalogram|neurocognitive development
48181919|NCT02461862|BEHAVIORAL|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
48181920|NCT02461862|PROCEDURE|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
48024342|NCT06534307|OTHER|Questionnaire Movement Assessment Battery for Children|"The M-ABC-2 is an standardized test to assess the motoric development. Adding up subscores addressing manual dexterity, aiming and catching, and balance delivers a total score of the motoric performance.~Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better performance."
48181921|NCT02461862|PROCEDURE|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
48181922|NCT02187367|BIOLOGICAL|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
48181923|NCT01864460|BEHAVIORAL|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
48719363|NCT03002454|DRUG|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
48719364|NCT03675542|DRUG|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
48719365|NCT01522404|DRUG|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
48719366|NCT01522404|DRUG|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
48719367|NCT03984487|BEHAVIORAL|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
48719368|NCT03984487|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
48719369|NCT04234958|OTHER|Osteopathic manipulative treatment|Specific protocol including 4 osteopathic techniques targeting the pericardium
48719370|NCT04234958|OTHER|Sham therapy|Sham therapy mimicking the osteopathic techniques applied to experimental group
48719371|NCT00489736|DRUG|dronedarone (SR33589)|oral administration
48719372|NCT00489736|DRUG|amiodarone|oral administration
48719373|NCT00004864|DRUG|GEM 231|
48719374|NCT00004864|DRUG|docetaxel|
48719375|NCT02456857|BIOLOGICAL|Bevacizumab|Given IV
48719376|NCT02456857|DRUG|Everolimus|Given PO
48719377|NCT02456857|OTHER|Laboratory Biomarker Analysis|Correlative studies
48024343|NCT06534307|OTHER|Questionnaire Continuous Performance Test|The CPT measures selective attention, sustained attention as well as impulsive behavior. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean worse performance.
48181924|NCT01174264|OTHER|Pharmacological Study|Correlative studies
48719378|NCT02456857|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
48719379|NCT01709201|BEHAVIORAL|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
48719380|NCT00148447|DRUG|escitalopram|
48719381|NCT01109771|DEVICE|permanent mesh fixation|Permanent mesh fixation will be used.
48719382|NCT01109771|DEVICE|absorbable mesh fixation|Absorbable mesh fixation will be used.
48719383|NCT01883752|PROCEDURE|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
48719384|NCT05197582|OTHER|tele-monitoring|The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
48719385|NCT01703065|DRUG|Cabozantinib|Given orally once a day
48719386|NCT04108728|DIAGNOSTIC_TEST|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
48719387|NCT03204890|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
48181925|NCT01174264|DRUG|Vismodegib|Given PO
48719388|NCT00078065|DRUG|Xcellerated T Cells|
48719389|NCT03783611|BEHAVIORAL|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
48383052|NCT04984499|DEVICE|Dental implant|"The procedure used to accomplish its intended use is as follows :~The recipient implant site is prepared using a drilling sequence, then the implant is placed at the crestal level with a cover screw to allow the tissues healing. After this healing phase, the final prosthesis will be loaded on the implant."
48719390|NCT03255759|DIAGNOSTIC_TEST|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
48024344|NCT06534307|OTHER|Questionnaire Diagnostic System for Mental Disorders|The FBB-ADHS assesses a total score for ADHD-like behavior and subscores for the symptom trias of ADHD (attention deficit, motoric hyperactivity as well as impulsive behavior, Questionnaire scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of symptoms.
48024345|NCT06534307|DIAGNOSTIC_TEST|kidney function tests|urine examination (proteomics, cytokines, lipidomics)
48024346|NCT06534307|OTHER|Questionnaire Five to Fifteen|The FTF 5-15R is a questionnaire to evaluate the child's developmental outcome in different areas of everyday life (cognition, language, and motor impairment as well as social, emotional, and behavioral problems). Individual item scores are added up per area and divided by the number of items. This results in a common scale value. Range of Percentile scores from 0 to 100 (0-90: no developmental problem; 90 and higher: hint for developmental problem). Higher scores mean worse developmental outcome.
48024347|NCT06534307|DIAGNOSTIC_TEST|cardiovacular examination|measurement of pulse wave velocity
48024348|NCT05507710|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Imaging with ICG near-infrared fluorescence is performed besides clinical judgement of the DIEP flap for perfusion evaluation. Based on fluorescence imaging, additional malperfused area(s) are resected.
48024349|NCT05324475|DIETARY_SUPPLEMENT|BCAA|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1
48024350|NCT05324475|DIETARY_SUPPLEMENT|Micronutriments|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g
48024351|NCT05324475|DIETARY_SUPPLEMENT|standard treatment + placebo|daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo
48024352|NCT00460512|DRUG|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
48383053|NCT00329758|DRUG|rosuvastatin|20 mg oral, during 10 days
48383054|NCT00329758|DRUG|Placebo|
48383055|NCT00988039|DRUG|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
48383056|NCT00988039|DRUG|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
48181926|NCT04034849|RADIATION|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
48383057|NCT00988039|DRUG|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
48383058|NCT04308759|OTHER|Experimental Smoking Cessation Program|Participate in Quitbot experimental cessation program
48519692|NCT05382403|DEVICE|Jada® System|This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
48719391|NCT00685373|DRUG|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
48719392|NCT05449275|OTHER|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
48719393|NCT05449275|OTHER|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
48719394|NCT02300597|OTHER|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
48719395|NCT00203021|DRUG|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
48719396|NCT04878536|DIETARY_SUPPLEMENT|Collagen drink|Testing product
48719397|NCT04878536|DIETARY_SUPPLEMENT|Blank|Placebo drink
48719398|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
48024353|NCT00093145|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
48181927|NCT04034849|RADIATION|Placebo|Device turned off
48181928|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic RFA assisted TE|
48719399|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
48719400|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
48719401|NCT00391391|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
48719402|NCT01860898|OTHER|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
48719403|NCT03690180|DIAGNOSTIC_TEST|serum magnesium|assessment of serum magnesium in all patients
48719404|NCT04966000|BEHAVIORAL|Prism Adaptation Therapy|Participants wear goggles with built-in prisms (a 20-diopter lens) that shift the visual scene to the right. While wearing the googles they reach to and cross out 60 lines/circles, requiring them to learn to reach more leftward than the visual targets appear. Participants can only see the end of their movements.
48719405|NCT01762267|OTHER|nutrition intervention|DASH diet control diet
48719406|NCT00311116|DRUG|Vitamin E|
48719407|NCT05874349|BEHAVIORAL|General variables|Variables evaluated: age, sex, location, extent, and phenotype of IBD according to the Montreal classification, smoking habit, therapeutic requirements (immunosuppressants, biologics, steroids, salicylates, drugs that cause enteropathy such as olmesartan, valsartan, non-steroidal anti-inflammatory drugs, etc, ...).
48719408|NCT05874349|BEHAVIORAL|Clinical activity|Clinical activity was evaluated using the Harvey-Bradshaw index (HBI) (cut-off values: \<5, remission; 5-7, mild activity; 8-16, moderate activity; and \>16, severe activity).
48383059|NCT04308759|OTHER|Control Smoking Cessation Program|Participate in Quitbot control cessation program
48719409|NCT05874349|PROCEDURE|Laboratory data|Laboratory data: blood count, renal function and C-reactive protein, anti-transglutaminase antibodies, genetic study of celiac disease DQ2.5, DQ8, and DQ2.2, study of parasites, fecal calprotectin.
48024354|NCT00093145|DRUG|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
48024355|NCT00093145|DRUG|Herceptin®|Administered by IV infusion
48024356|NCT05786677|OTHER|Physiotherapy protocol|"the physiotherapy protocol which will include: 4. Exercise in the form of: d. Breathing exercise e. Aerobic exercise (walking on treadmill with a speed of 3 miles per hour and 0% inclination) f. Bridging exercise 5. Manual techniques in the form of:~1. Suboccipital release~2. Diaphragm release~3. Clavi-pectoral myofascial release 6. Home Routine~c. Hot tub bath for 30 minutes d. Breathing exercise"
48024357|NCT05786677|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRIs)
48024358|NCT00000435|DRUG|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
48024359|NCT00000435|DRUG|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
48719410|NCT05874349|PROCEDURE|Endoscopic and histology data|"Endoscopic signs suggestive of CD in UDT (presence of canker sores, ulcers, ...) and colon inflammatory activity was evaluated when available in patients with active disease using the Simple Endoscopic Score for CD (SES-CD: 0-2, remission; 3-6, mild endoscopic activity; 7-15, moderate endoscopic activity; and \>15, severe endoscopic activity).~Duodenal biopsies were assessed by 2 pathologists and were evaluated according to Marsh classification modified by Ensari \[Marsh 0, 1, 2 or 3\], the limit of normality for intraepithelial lymphocytes (IELs) per 100 enterocytes is set at 25, gastric biopsies (determination of H. Pylori by immunohistochemistry) and esophageal biopsies was recorded too.~Percentage of lymphocyte subpopulations are assessed by flow cytometry."
48719411|NCT02421926|DRUG|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
48719412|NCT05630638|DRUG|Doravirine|Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil
48719413|NCT05630638|DRUG|Dolutegravir|Fixed dose combination of dolutegravir, lamivudine and tenofovir disoproxil
48719414|NCT01020708|DRUG|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
48719415|NCT01020708|DRUG|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
48719416|NCT01020708|DRUG|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
48719417|NCT05896787|DRUG|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
48024360|NCT02348138|OTHER|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
48383060|NCT06638866|DIAGNOSTIC_TEST|Pancreatic imaging AI model|Subjects identified with pancreatic lesions by the AI model, which include PDAC and non-PDAC subtypes, will be required to undergo questionnaire, blood tests (including CA19-9, CA125, CEA, etc.) and further imaging examinations (including contrast CT, MRI, EUS, etc.) to confirm the final status of the pancreatic lesion.
48519693|NCT05382403|OTHER|Standard care|Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
48719418|NCT02476123|BIOLOGICAL|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
48719419|NCT01726673|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
48024361|NCT00795600|DRUG|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
48024362|NCT00795600|DRUG|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
48719420|NCT01726673|DEVICE|Placebo sham|
48719421|NCT00273845|BEHAVIORAL|Motivational interviewing|One session
48719422|NCT00273845|BEHAVIORAL|Strengths-Based Case Management|5 sessions
48719423|NCT01660100|PROCEDURE|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
48024363|NCT02288429|DRUG|colistimethate sodium|
48024364|NCT00511862|DEVICE|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
48024365|NCT03860194|DIETARY_SUPPLEMENT|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
48024366|NCT06531447|DRUG|Cisplatin|Every 21 days 6 cycles
48181929|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic partial nephrectomy|
48383061|NCT00027573|BIOLOGICAL|filgrastim|
48383062|NCT00027573|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48024367|NCT06531447|DRUG|Gemcitabine|Every 21 days (First and 8th days) 6 cycles
48024368|NCT06531447|DRUG|Doxorubicin|Every 21 days 4 cycles
48024369|NCT06531447|DRUG|Cyclophosphamide|Every 21 days 4 cycles
48024370|NCT06531447|DRUG|Paclitaxel|Every 21 days 4 cycles or once a week for 12 weeks
48024371|NCT00744536|DRUG|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
48024372|NCT00965523|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m\^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
48024373|NCT03430154|OTHER|No treatment given|No treatment given
48024374|NCT05477823|RADIATION|External beam radiation therapy|Standard of care EBRT
48024375|NCT05477823|RADIATION|Prostate brachytherapy boost|Standard of care BTX
48024376|NCT05477823|DRUG|Androgen deprivation therapy|Standard of care ADT
48383063|NCT00027573|DRUG|cyclophosphamide|
48383064|NCT00027573|DRUG|fludarabine phosphate|
48383065|NCT00027573|DRUG|methotrexate|
48719424|NCT01660100|PROCEDURE|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
48719425|NCT01584635|PROCEDURE|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
48024377|NCT05477823|DIAGNOSTIC_TEST|Positron emission tomography (PET)/magnetic resonance imaging (MRI)|Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
48024378|NCT05840653|OTHER|psychotherapeutic intervention|The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
48024379|NCT04193202|DRUG|Gefapixant|Administered twice daily as an oral tablet of 45 mg
48024380|NCT04193202|DRUG|Placebo|Administered twice daily as a placebo oral tablet matching gefapixant
48024381|NCT05377320|OTHER|Clinical Decision Aid|The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
48024382|NCT05377320|OTHER|Standard Care|Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
48024383|NCT01055639|BEHAVIORAL|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
48024384|NCT01055639|BEHAVIORAL|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
48024385|NCT02804919|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
48024386|NCT01168050|DRUG|Nilotinib|Nilotinib 400 mg twice per day
48024387|NCT02261818|BEHAVIORAL|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
48024388|NCT03947645|DEVICE|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
48024389|NCT03947645|DEVICE|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
48024390|NCT03787667|DIAGNOSTIC_TEST|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
48024391|NCT02227160|BEHAVIORAL|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
48024392|NCT02227160|BEHAVIORAL|Outpatient counseling and support groups|Usual mental health care
48024393|NCT05029648|OTHER|Cohort|Cohort
48024394|NCT03384758|DEVICE|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
48024395|NCT04191759|DIAGNOSTIC_TEST|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
48024396|NCT01778465|BEHAVIORAL|Low salicylate diet|Participants followed a 7 days period under a Low salicylate diet
48024397|NCT01778465|BEHAVIORAL|Normal Diet|Participants followed a 7 days period under a Normal Diet
48024398|NCT04091841|DRUG|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
48024399|NCT04091841|OTHER|Carbo Mass|Three sachet of Carbo Mass supplement to be mixed in with water used daily.
48181930|NCT01907932|DEVICE|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
48181931|NCT01749852|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
48719426|NCT02884375|OTHER|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence"
48181932|NCT01749852|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
48383066|NCT00027573|DRUG|tacrolimus|
48383067|NCT00027573|PROCEDURE|peripheral blood stem cell transplantation|
48383068|NCT05032183|DRUG|Cyclophosphamide|Given IV
48383069|NCT05032183|DRUG|Cytarabine|Given IT
48383070|NCT05032183|DRUG|Dexamethasone|Given IV or PO
48383071|NCT05032183|BIOLOGICAL|Filgrastim-sndz|Given SC
48383072|NCT05032183|DRUG|Leucovorin|Given IV
48383073|NCT05032183|DRUG|Mercaptopurine|Given PO
48383074|NCT05032183|DRUG|Mesna|Give IV
48383075|NCT05032183|DRUG|Methotrexate|Given IT
48383076|NCT05032183|BIOLOGICAL|Pegfilgrastim|Given SC
48383077|NCT05032183|DRUG|Prednisone|Given PO
48383078|NCT05032183|BIOLOGICAL|Rituximab|Given IV
48719427|NCT00411190|DRUG|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
48719428|NCT00411190|DRUG|Acetaminophen|Acetaminophen will be administered orally
48719429|NCT00411190|DRUG|Ibuprofen|Ibuprofen will be administered orally
48383079|NCT05032183|BIOLOGICAL|Tagraxofusp-erzs|Given IV
48383080|NCT05032183|DRUG|Vincristine|Given IV
48383081|NCT03285152|OTHER|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
48383082|NCT03285152|OTHER|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
48383083|NCT02437175|DIETARY_SUPPLEMENT|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
48383084|NCT02437175|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
48383085|NCT05340309|BIOLOGICAL|Atezolizumab and Recombinant Human Hyaluronidase|Given SC
48719430|NCT00411190|DRUG|Atorvastatin|Atorvastatin will be administered orally
48181933|NCT02869256|OTHER|Practices evaluation|Practices evaluation
48181934|NCT05811299|OTHER|Kinesio taping|Total of 8 sessions for 4 weeks 2 sessions in a week.
48181935|NCT05811299|OTHER|Abominal exercises|Total of 8 sessions for 4 weeks 2 sessions in a week.
48181936|NCT00778245|DRUG|cefprozil 500mg tablets|
48383086|NCT05340309|OTHER|Survey Administration|Ancillary studies
48383087|NCT01903213|DRUG|bixalomer|Oral
48383091|NCT02705664|DRUG|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
48383092|NCT02705664|DRUG|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
48383093|NCT02705664|DRUG|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
48383094|NCT01338701|PROCEDURE|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
48383095|NCT01338701|PROCEDURE|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
48383096|NCT01338701|OTHER|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
48383097|NCT06649734|OTHER|Delphi Study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
48383098|NCT04335292|DRUG|Osimertinib First-Line|Osimertinib, 80 mg, oral, daily
48719431|NCT03658070|DRUG|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
48181937|NCT03405077|BEHAVIORAL|IPT Online Training|"First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training."
48181938|NCT04692090|OTHER|Yoga|"Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks."
48024400|NCT01389219|OTHER|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
48181939|NCT02885792|OTHER|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
48181940|NCT02885792|OTHER|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
48181941|NCT02885792|OTHER|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
48383099|NCT04335292|DRUG|Platinum + Pemetrexed Chemotherapy Second-Line|Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
48024401|NCT00268749|DRUG|glycine|0.8 g/kg/day
48024402|NCT01266759|DRUG|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
48024403|NCT01266759|DRUG|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
48181942|NCT02885792|PROCEDURE|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
48181943|NCT04258657|DRUG|paclitaxel-albumin and S-1|neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
48181944|NCT03837483|GENETIC|OTL-103|Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
48181945|NCT00916305|OTHER|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
48181946|NCT00916305|OTHER|Unmodified audio video|An audio video with unaltered music
48383100|NCT04335292|DRUG|Osimertinib Third-Line|Rechallenge with osimertinib, 80 mg, oral, daily
48181947|NCT04826276|OTHER|smoking abstinence|participants will be asked to not smoke for at least 12 hours
48181948|NCT04826276|OTHER|smoking satiety|participants will be asked to smoke as usual
48181949|NCT05426993|OTHER|Complex decongestive physiotherapy|CDT is a treatment approach consisting of manual lymph drainage, skin care, compression bandage and exercises.
48181950|NCT00187499|DRUG|Inhaled fluticasone 500 ug BID for 8 weeks|
48181951|NCT06277180|PROCEDURE|Surgery|Surgery is performed based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, and all 68Ga-TCR-FAPI-avid lesions are resected.
48519694|NCT06263933|OTHER|Insight Scale|Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group
48519695|NCT06263933|OTHER|Semi-directional interviews|"In the end of the intervention. In the end of DIPEM Or in the end of control group.~This intervention will be held after one month of hospitalization."
48024404|NCT00443547|DEVICE|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
48024405|NCT01679535|BEHAVIORAL|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
48024406|NCT05889936|BEHAVIORAL|Lev|Lev includes three sessions using psychoeducation, motivational interviewing, and applied behavioral analyses. Lev also include two homework assignments. The second session can be repeated if needed. Lev-s and Lev are described in two manuals.
48181952|NCT06277180|PROCEDURE|Surgery|68Ga-TCR-FAPI PET/CT identified distant metastasis or unresectable lesions, but the patient is still recommended to undergo surgery for debulking or reduce symptoms.
48519696|NCT06263933|OTHER|routine care|routine care
48519697|NCT06263933|OTHER|session of mutual assistance with a mediator psychologist|session of mutual assistance with a mediator psychologist
48519698|NCT06582030|BEHAVIORAL|Assessment|Ancillary studies
48181953|NCT05963009|DRUG|baxdrostat (formerly CIN-107) oral solution|5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study
48181954|NCT03210649|DRUG|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14
48181955|NCT03210649|DRUG|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14
48181956|NCT06471712|DRUG|18F-LNC1007 Injection|Healthy volunteers will receive 1 MBq/kg and cancer patients will receive 3.7 MBq/kg. The injection will be carried out on the scan bed via an IV indwelling catheter. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
48181957|NCT02677077|DRUG|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
48181958|NCT04211389|DRUG|ARQ-151 0.3% cream|ARQ-151 0.3% cream
48181959|NCT04211389|DRUG|ARQ-151 vehicle cream|ARQ-151 vehicle cream
48181960|NCT04031196|PROCEDURE|QLB|QLB type 2 approach
48181961|NCT04031196|PROCEDURE|TAP block|classic TAP block approach
48181962|NCT01660256|DRUG|OPC-12759|Instillation, 4 times/day for 4 weeks
48181963|NCT01660256|DRUG|Placebo|
48181964|NCT04083924|OTHER|Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound|Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
48181965|NCT02046512|DIETARY_SUPPLEMENT|Probiotic|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
48181966|NCT02046512|OTHER|Placebo|Sugar pill
48181967|NCT01224470|DRUG|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
48181968|NCT01857726|DRUG|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
48181969|NCT01857726|DRUG|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
48181970|NCT02497846|DEVICE|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity \[I\]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
48181971|NCT00785954|DRUG|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
48181972|NCT01181791|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
48181973|NCT01181791|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
48181974|NCT00131105|BEHAVIORAL|The Stanford Active Choices program|
48181975|NCT01399762|DEVICE|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
48181976|NCT05760521|OTHER|Provider Educational Intervention|Following the informed consent (10 min) and sociodemographic survey (5 minutes), the providers in Arm A will be offered education of two days, six hours each day, with support and follow-up. They will also be asked to complete brief knowledge and confidence surveys pre-post-intervention (30 minutes total).
48024407|NCT01469689|OTHER|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
48024408|NCT01469689|OTHER|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
48024409|NCT06240026|DEVICE|taVNS|transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.
48181977|NCT05182307|DEVICE|DurAVR™ THV System|Transcatheter Aortic Valve Implantation (TAVI) Procedure
48181978|NCT01746147|OTHER|No intervention and study treatment|
48181979|NCT02119897|DEVICE|Low Level Light Therapy|
48719432|NCT01328340|OTHER|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
48024410|NCT06240026|DEVICE|Earlobe Stimulation|Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.5cm and 1cm rounds, attached to a digitimer.
48024411|NCT04225845|BEHAVIORAL|Phone therapy|Weekly phone calls by lay trained personnel to deliver problem solving therapy.
48024412|NCT04225845|BEHAVIORAL|Cash transfer|One-time cash transfer of Rs.1000.
48024413|NCT01916018|OTHER|Clinical and radiologic exams and blood samples|
48024414|NCT00917345|DRUG|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
48024415|NCT04485403|DRUG|Ibuprofen|800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
48181980|NCT03181659|PROCEDURE|Manual Therapy, Therapeutic Education, Therapeutic Exercice|They will receive 8 sessions (2 sessions per week) of joint and neural manual therapy, and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation. The therapeutic exercise program is based on stabilization of the lumbopelvic region.
48181981|NCT03181659|PROCEDURE|Therapeutic Education, Therapeutic Exercice|They will receive a total of 8 sessions (2 sessions per week) of therapeutic exercise based on the stabilization of the lumbopelvic region and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation.
48181982|NCT05897047|COMBINATION_PRODUCT|Additional interventional telemedical management|Predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
48024416|NCT05520957|PROCEDURE|Tracheostomy|We collected data from all tracheotomised patients including age, sex, existing comorbidities, duration indicators (length of endotracheal intubation, day of tracheotomy, length of stay in the intensive care unit (ICU), and total length of hospital stay), respirator weaning marked with YES / NO. From the laboratory parameters, we analyzed: lactate, urea, creatinine, potassium and D-dimer. They were collected at two time intervals, before tracheotomy and after tracheotomy.
48024417|NCT02983578|DRUG|Danvatirsen|Given IV
48024418|NCT02983578|BIOLOGICAL|Durvalumab|Given IV
48383108|NCT01913769|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
48383109|NCT03367741|PROCEDURE|Biopsy|Undergo tumor biopsy
48383110|NCT03367741|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48383111|NCT03367741|DRUG|Cabozantinib S-malate|Given PO
48383112|NCT03367741|PROCEDURE|Computed Tomography|Undergo CT scan
48719433|NCT01328340|OTHER|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
48719434|NCT05300841|DRUG|dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
48181983|NCT02472054|DRUG|Alemtuzumab|
48383113|NCT03367741|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48383114|NCT03367741|BIOLOGICAL|Nivolumab|Given IV
48383115|NCT06653660|OTHER|Clinical examination|For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.
48719435|NCT05300841|DRUG|estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
48719436|NCT02920957|DEVICE|comfilcon A|contact lens
48181984|NCT02472054|DRUG|Methyl Prednisolone (MP)|
48383116|NCT00646282|DRUG|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH\>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH \<300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
48383117|NCT06039293|BEHAVIORAL|Cognitive behavioral therapy and physical activity sessions|The intervention group will receive 10 sessions of cognitive behavioral therapy (CBT) and 6 physical activity sessions over the 12-week period. All Program AACTIVE CBT sessions and exercise sessions will run concurrently and take place virtually using Master of Social Work (MSW) trainees and Movement Science Master of Science students from the University of Michigan.
48719437|NCT02920957|DEVICE|senofilcon C|contact lens
48719438|NCT04317326|PROCEDURE|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
48719439|NCT04317326|PROCEDURE|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
48719440|NCT04317326|PROCEDURE|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
48383118|NCT06039293|BEHAVIORAL|Enhanced Usual Care + Diabetes Basics Web Series|"Participants will receive the American Diabetes Association Diabetes Basics web series (one video per week for 10 weeks) or Diabetes Basics handouts sent via mail."
48719441|NCT04317326|PROCEDURE|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
48719442|NCT01730404|DRUG|CHF6001 DPI|
48719443|NCT01730404|DRUG|Roflumilast|
48719444|NCT01730404|DRUG|Placebo|
48719445|NCT05769166|OTHER|thired domain of nordic orofcial test-screen|its a questionnaire which the parent will answer
48719446|NCT05477199|OTHER|Cognitive behavioral principles-based treatment program|The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.
48719447|NCT05477199|OTHER|Control intervention|Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
48024419|NCT04585334|DRUG|Tricortin 1000|Tricortin 1000 \[2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)\] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
48383119|NCT05477368|DIETARY_SUPPLEMENT|D-β-hydroxybutyric acid with R-1,3-butanediol|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
48383120|NCT05477368|OTHER|Inert placebo|Pre-intervention (baseline) and post-intervention measurements will be obtained before and after the 90-day period respectively.
48383121|NCT06649604|DEVICE|Vibration Anesthesia Device|The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device
48719448|NCT02191605|BEHAVIORAL|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
48383122|NCT06649604|PROCEDURE|Panretinal Photocoagulation|Laser treatment for diabetic retinopathy done in a standard fashion
48719449|NCT02191605|BEHAVIORAL|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
48719450|NCT02458547|DRUG|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0
48383123|NCT04450316|DRUG|Naltrexone|4.5mg tab (low-dose) nightly
48383124|NCT04450316|DRUG|Placebo|1 tab nightly
48719451|NCT02458547|DRUG|Propofol|Total intravenous anesthesia with propofol target controlled infusion
48719452|NCT02458547|DRUG|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
48719453|NCT06397508|DRUG|AGMB-129|Each participant will receive 3 study interventions, 1 in each intervention period
48719454|NCT02984059|GENETIC|Genomic DNA|blood draw
48719455|NCT02984059|GENETIC|RNA analysis|Mucosal Biopsy via colonoscopy
48719456|NCT02984059|GENETIC|Microbiome|Stool microbiome
48719457|NCT02984059|OTHER|Calprotectin|stool or blood analysis for calprotectin
48024420|NCT04585334|DRUG|Itami|Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).
48181985|NCT02472054|DRUG|Cyclosporin A (CSA)|
48383125|NCT04244162|DIAGNOSTIC_TEST|Brain Imaging|Magnetic resonance imaging (MRI) using diffusion tensor imaging (DTI)-based mean diffusivity (MD) measures.
48719458|NCT02984059|OTHER|Pain questionnaires|PSDS PCS-C/P PBI APPT
48719459|NCT02984059|OTHER|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
48719460|NCT03945019|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
48719461|NCT03945019|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
48719462|NCT04313491|OTHER|Yoga|Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
48719463|NCT00504140|DRUG|Etoposide|100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
48181986|NCT02906722|DRUG|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
48383126|NCT04244162|DIAGNOSTIC_TEST|Cognitive testing|Wide Range Assessment of Memory and Learning (WRAML2), Montreal Cognitive Assessment (MoCA), and Confusion Assessment Method for the ICU -severity (CAM-ICU S) tests.
48383127|NCT04244162|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory markers
48719464|NCT00504140|DRUG|Interferon Alpha|5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
48383128|NCT04800822|DRUG|PF-07284892|PF-07284892
48383129|NCT04800822|DRUG|lorlatinib|lorlatinib
48719465|NCT00233012|DRUG|Topiramate|
48719466|NCT00680758|DRUG|cisplatin|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients"
48719467|NCT00680758|DRUG|everolimus|"* Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients"
48024421|NCT04585334|DRUG|Placebo|Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
48024422|NCT05063734|DRUG|THR-687 dose level 1|3 intravitreal injections of THR-687 dose level 1, 1 month apart
48024423|NCT05063734|DRUG|THR-687 dose level 2|3 intravitreal injections of THR-687 dose level 2, 1 month apart
48024424|NCT05063734|DRUG|THR-687 selected dose level|3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
48024425|NCT05063734|DRUG|Aflibercept|3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
48024426|NCT01661660|OTHER|observationnal|Observation during a physical exercise
48024427|NCT02453113|OTHER|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
48181987|NCT02906722|DRUG|Intravenous placebo|administration once, twice or 3 times per day according to renal function
48181988|NCT02906722|DRUG|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
48181989|NCT02906722|DRUG|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
48383130|NCT04800822|DRUG|binimetinib|binimetinib
48719468|NCT00680758|DRUG|paclitaxel|"* Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients"
48383131|NCT04800822|BIOLOGICAL|cetuximab|cetuximab
48383132|NCT04800822|DRUG|encorafenib|encorafenib
48383133|NCT06649812|PROCEDURE|Biopsy|Undergo optional tumor biopsy
48181990|NCT00953316|OTHER|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
48181991|NCT01301599|DRUG|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
48181992|NCT01301599|DRUG|alpha blocker monotherapy|alpha blocker monotherapy group
48181993|NCT01301599|DRUG|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
48181994|NCT04992754|BEHAVIORAL|psychotherapy, lifestyle counseling|psychotherapy, lifestyle counseling
48181995|NCT03928223|OTHER|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
48181996|NCT02272361|OTHER|laparoscopic sacrocolpopexy|
48181997|NCT02272361|OTHER|vaginal mesh surgery|
48181998|NCT02600078|DEVICE|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
48181999|NCT02600078|OTHER|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
48182000|NCT02600078|OTHER|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
48383134|NCT06649812|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48383135|NCT06649812|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
48383136|NCT06649812|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
48383137|NCT06649812|PROCEDURE|Computed Tomography|Undergo CT
48383138|NCT06649812|DRUG|Ibrutinib|Given PO
48383139|NCT06649812|DRUG|Lenalidomide|Given PO
48383140|NCT06649812|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48383141|NCT06649812|BIOLOGICAL|Obinutuzumab|Given IV
48383142|NCT06649812|PROCEDURE|Positron Emission Tomography|Undergo PET
48383143|NCT06649812|DRUG|Prednisone|Given PO
48383144|NCT06649812|DRUG|Venetoclax|Given PO
48383145|NCT05168657|DEVICE|Bionic Pancreas|14 days using the insulin-only configuration of the iLet Bionic Pancreas (Beta Bionics, Inc.), which automates insulin delivery, as the only intended mode of insulin delivery.
48383146|NCT05168657|OTHER|Usual Care|14 days of the participant's usual care of their type 1 diabetes
48383147|NCT05041868|OTHER|Treatment|After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after treatment). The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment.
48383148|NCT05743244|DRUG|Abrocitinib 200 MG Oral Tablet|Abrocitinib
48383149|NCT05743244|DRUG|Ritlecitinib|Ritlecitinib
48383150|NCT05743244|DRUG|Placebo|Placebo for Abrocitinib or Ritlecitinib
48383151|NCT06551987|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|6 weekly, 50-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
48383152|NCT06551987|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|4 weekly, 30-minute sessions delivered individually using in-person or telehealth format by a trained behavioral health provider.
48383153|NCT02195271|DEVICE|Transcranial Direct Current Stimulation (tDCS)|
48383154|NCT02195271|DRUG|Melatonin|
48383155|NCT06542653|PROCEDURE|PCI|successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients
48383156|NCT06542653|DRUG|OMT|optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
48383157|NCT01482442|DRUG|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
48719469|NCT00231231|DEVICE|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
48719470|NCT00231231|DEVICE|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
48719471|NCT06346249|OTHER|Electrical Stimulation Therapy|Ten Electrical Stimulation Therapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
48024428|NCT03937375|BEHAVIORAL|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
48024429|NCT03937375|BEHAVIORAL|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
48024430|NCT01853449|DRUG|Fentanyl Citrate|
48024431|NCT01853449|OTHER|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
48024432|NCT01853449|DRUG|Placebo|0.9% saline
48024433|NCT04414644|BEHAVIORAL|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
48024434|NCT02762409|OTHER|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
48024435|NCT02762409|OTHER|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
48024436|NCT06535087|DRUG|Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis|"1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation."
48024437|NCT06059703|PROCEDURE|Blood punction|Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
48024438|NCT06059703|PROCEDURE|Central blood sampling|Central blood sampling (2 ml) at inclusion and 3 months after treatment
48024439|NCT06059703|PROCEDURE|Intracranial pressure measurement|Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
48024440|NCT02574923|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
48024441|NCT01621373|DRUG|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
48024442|NCT05724199|DRUG|Rocatinlimab|Subcutaneous (SC) injection
48024443|NCT05724199|OTHER|Placebo|SC injection
48024444|NCT06535789|DRUG|Inhaled Technosphere Insulin|Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
48024445|NCT05590091|OTHER|Parenteral nutrition;Enteral nutrition|The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation
48383158|NCT01482442|DRUG|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
48383159|NCT02590146|BEHAVIORAL|Non-pharmacologic pain control adjuncts|
48383160|NCT05101057|DEVICE|SpinalogicTM Bone Graft Stimulator|The SpinalogicTM is a portable, battery-powered, microprocessor-controlled, non-invasive bone growth stimulator. The device is currently approved and commercially indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels.
48383161|NCT01199510|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
48383162|NCT01199510|OTHER|Standard of Care|Post Cataract Surgery Standard of Care
48383163|NCT06630858|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.
48383164|NCT06630858|PROCEDURE|Intrathecal Morphine|Intrathecal morphine will be performed (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric bupivacaine).
48383165|NCT06630858|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
48383166|NCT04024254|DRUG|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
48519699|NCT06582030|OTHER|Educational Activity|View the chronically relapsing brain disease vignette
48024446|NCT02479425|PROCEDURE|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
48024447|NCT02973659|DRUG|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
48024448|NCT02973659|DRUG|Placebos|
48024449|NCT00934193|DRUG|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
48024450|NCT00934193|DRUG|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
48024451|NCT01143259|DRUG|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
48024452|NCT01143259|DRUG|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
48024453|NCT02569047|PROCEDURE|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
48024454|NCT02569047|PROCEDURE|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
48024455|NCT01699997|DRUG|Oxytocin|Intranasal spray with 40 IU of OXT
48024456|NCT01699997|DRUG|Placebo|Intranasal spray with placebo solution
48024457|NCT03864900|BEHAVIORAL|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
48024458|NCT04533841|DRUG|Misoprostol|Pt will receive misoprostol for labor induction then after 30 minutes will receive ether propranolol or misoprostol
48024459|NCT04533841|DRUG|Placebo|placebo
48024460|NCT04533841|DRUG|Propranolol|Propranolol
48024461|NCT03893448|BIOLOGICAL|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
48024462|NCT03893448|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
48024463|NCT03893448|BIOLOGICAL|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at \~2, \~4, and \~6 months of age.
48024464|NCT03893448|BIOLOGICAL|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
48024465|NCT03893448|BIOLOGICAL|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at \~2, \~4, and \~6 months of age.
48024466|NCT03893448|BIOLOGICAL|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
48024467|NCT03893448|BIOLOGICAL|MMR II™|One MMR II™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
48024468|NCT03893448|BIOLOGICAL|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
48024469|NCT03893448|BIOLOGICAL|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
48024470|NCT04681521|OTHER|Hot and Cold compress, nursing interventions|using thermal compress at 38-39 °C (hot) and 15-16 °C (cold) on the distal regions of both lower extremities of the patients
48719472|NCT06346249|OTHER|Manual Therapy|Manual Therapy consistin of soft tissue mobilization and release techniques over the neck and craniocervical regions. Ten sessions.
48182001|NCT02600078|OTHER|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
48182002|NCT05390177|BEHAVIORAL|Video type|One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
48182003|NCT05252936|OTHER|COVID-19 vaccine social media campaign exposure|A series of animated video clips will be promoted through Facebook Ads and randomized at the individual level across Facebook users throughout the entire country. To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish, 2) K'iche', and 3) Kaqchikel languages. The videos are visually identical and follow the same audio script, translated into the three focal language. Local voiceover artists were used to record the scripts in the three languages. A control group that is not exposed to any of the social media campaign content will serve as active comparator to allow for comparison of outcomes with treatment arms.
48182004|NCT06222242|BEHAVIORAL|mychoiceTM|mychoiceTM is an online, educational tool designed to help prepare patients for a conversation with their provider about clinical trials as a treatment option. It consists of text, animations, and videos of real cancer patients sharing their experience with clinical trials. It is not meant to be a recruitment tool, but rather a preparatory tool to promote shared decision making between patients and providers.
48383167|NCT00586677|BEHAVIORAL|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
48182005|NCT05114369|PROCEDURE|Curative surgery|
48182006|NCT04115189|DRUG|Sunitinib|Patients to receive Sunitinib as first line therapy for mRCC
48182007|NCT00447590|DEVICE|LAP-BAND System|Restriction of food intake
48182008|NCT05329168|DRUG|Tonabacase (LSVT-1701)|4.5 or 6.0 mg/kg IV once daily for 4 days
48182009|NCT01907698|BEHAVIORAL|Vaginal intercourse|vaginal intercourse at least twice a week
48182010|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
48182011|NCT00636740|DRUG|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
48182012|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
48182013|NCT03639727|DIAGNOSTIC_TEST|Citric acid aerosol bronchial challenge|Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
48383168|NCT00586677|BEHAVIORAL|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
48383169|NCT00586677|BEHAVIORAL|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
48383170|NCT00592007|DRUG|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
48383171|NCT01788969|DRUG|Lexapro|Agent + training vs Placebo + training
48719473|NCT06346249|OTHER|Exercise Therapeutic|The exercise therapeutic program consisting of neck movement control and stretching exercise. Ten sessions.
48719474|NCT00487123|DRUG|Valsartan+/- Hydrochlorothiazide|
48182014|NCT03639727|DIAGNOSTIC_TEST|Mannitol aerosol bronchial challenge|Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
48182015|NCT05372107|DRUG|AG-80308|AG-80308 Eye Drop Solution
48182016|NCT00530582|DRUG|progesterone|300mg progesterone /placebo each for 21 days
48719475|NCT05956509|BIOLOGICAL|ABBV-950|Intramuscular (IM) Injection
48182017|NCT00729638|DRUG|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
48182018|NCT00729638|DRUG|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
48182019|NCT01973140|DRUG|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
48182020|NCT01973140|DRUG|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
48182021|NCT06225440|DIETARY_SUPPLEMENT|Levagen+® Palmitoylethanolamide (PEA)|Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
48182022|NCT06225440|DIETARY_SUPPLEMENT|Placebo|Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
48182023|NCT04912713|OTHER|Stress group|This group will perform the MAST stress protocol
48182024|NCT04912713|OTHER|Control group|This group will perform the MAST control protocol
48182025|NCT01982409|BIOLOGICAL|Live Attenuated Varicella Vaccine|
48182026|NCT05692583|DIAGNOSTIC_TEST|ultrasound examination of wrist|musculoskeletal ultrasound examination of affected wrist
48182027|NCT01727661|BEHAVIORAL|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
48182028|NCT01727661|BEHAVIORAL|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
48182029|NCT01727661|BEHAVIORAL|quality of life|assessing quality of life using short-forum 36 (questionnaire)
48182030|NCT00012662|BEHAVIORAL|Diabetes Self Management Education|
48182031|NCT00610727|DRUG|Prochlorperazine 0.5 mg IV over 5 sec|IV Prochlorperazine for bioavailability
48182032|NCT00610727|DRUG|Inhaled prochlorperazine 0.625 mg|Inhaled Staccato Prochlorperazine 0.625 mg
48182033|NCT00610727|DRUG|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato Prochlorperazine 1.25 mg
48383172|NCT01788969|DRUG|Placebo|Agent + training vs Placebo + training
48383173|NCT05562713|BEHAVIORAL|Present Bias without Loss Aversion|Small prize for each step completed; large prize for independent CIC
48383174|NCT05562713|BEHAVIORAL|Present Bias with Loss Aversion|Prizes only if fully independent CIC demonstrated
48383175|NCT03936946|BEHAVIORAL|Audio Content 1|\~30 minute daily audio recordings of content 1 for 28 days
48383176|NCT03936946|BEHAVIORAL|Audio Content 2|\~30 minute daily audio recordings of content 2 for 28 days
48383177|NCT04365127|DRUG|Progesterone 100 MG|Subcutaneous administration twice daily
48383178|NCT06651125|OTHER|Adapted Physical Activity|Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
48383179|NCT04771273|DRUG|BI 456906|BI 456906
48383180|NCT04771273|DRUG|Placebo|Placebo
48182034|NCT00610727|DRUG|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato Prochlorperazine 2.5 mg
48182035|NCT00610727|DRUG|Inhaled prochlorperazine 5 mg|InhaledStaccato Prochlorperazine 5 mg
48383181|NCT04401046|OTHER|Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later|The first survey will include questions relative to sociodemographic characteristics, existence of psychological troubles; living conditions in the Covid19 pandemic context; IES-R, Stait Trait Anxiety, and the fear of a cancer recurrence scales, satisfaction with cancer care and medical status of patients (diagnosis, ongoing treatment, follow-up of the disease).
48519700|NCT06582030|OTHER|Educational Activity|View the brain disease vignette
48182036|NCT00610727|DRUG|Inhaled prochlorperazine 10 mg|InhaledStaccato Prochlorperazine 10 mg
48182037|NCT00610727|DRUG|Inhaled placebo|Inhaled Staccato Placebo (0 mg)
48182038|NCT00610727|DRUG|Prochlorperazine 10 mg IV over 5 sec|Prochlorperazine 10 mg IV over 5 sec for patient qualification
48182039|NCT02617953|DEVICE|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
48519701|NCT06582030|OTHER|Educational Activity|View the disease vignette
48519702|NCT06582030|OTHER|Educational Activity|View the illness vignette
48024471|NCT05186324|OTHER|Interview|"During each interview, patients will be asked questions to collect demographic and clinical information, and asked a set of open-ended questions with probes to describe their experiences with Fabry disease (symptomology and impacts on patient's lives \[i.e., activities of daily living, school/work, ability to take holidays/vacation\]), and pegunigalsidase alfa treatment (experience of infusions and schedule) and their experience of change in symptoms and impacts over the BRIGHT-F51 clinical study.~A semi-structured discussion guide will be used to conduct the approximately 60-minute interviews. The use of open-ended questions avoids bias and questions will not be read verbatim to allow for a free-flowing discussion."
48024472|NCT01702883|OTHER|Internet Survey|prompt to complete internet survey
48024473|NCT05252559|PROCEDURE|ultrafiltration|In cardiac surgery patients, ultrafiltration is usually applied to reduce free water and concentrate all blood components before weaning from cardiopulmonary bypass
48024474|NCT05252559|DIAGNOSTIC_TEST|maximal clot firmness in EXTEM assay of ROTEM test|before and after applying ultrafiltration, arterial blood sample underwent EXTEM and FIBTEM assays of rotational thromboelastometry
48024475|NCT02348164|OTHER|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
48024476|NCT02348164|OTHER|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
48024477|NCT01858454|PROCEDURE|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
48024478|NCT01858454|PROCEDURE|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere \[Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.\].
48024479|NCT06534606|PROCEDURE|Electrotherapy and physical agents|"Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks."
48024480|NCT06534606|PROCEDURE|Headache SNAGs|"Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total."
48024481|NCT06534606|PROCEDURE|Sternocleidomastoid Release|Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.Frequency: 3 times a week for 2 weeks. 6 sessions in total.
48024482|NCT04096092|OTHER|No intervention|No intervention
48024483|NCT06536218|BEHAVIORAL|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION|CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
48024484|NCT01513772|DRUG|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
48024485|NCT01513772|DRUG|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
48519703|NCT06582030|OTHER|Educational Activity|View the disorder vignette
48519704|NCT06582030|OTHER|Educational Activity|View the problem vignette
48519705|NCT06582030|OTHER|Training|Attend a SAS workshop
48719476|NCT05956509|BIOLOGICAL|BOTOX|Intramuscular (IM) Injection
48024486|NCT04663815|BEHAVIORAL|Animal-assisted activity|The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
48024487|NCT04663815|OTHER|Control intervention|The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
48024488|NCT03062826|DRUG|dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)|Patients who met the inclusion criteria will be treated with dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel).
48383182|NCT02976389|OTHER|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
48719477|NCT05956509|DRUG|Placebo for ABBV-950|Intramuscular (IM) Injection
48383183|NCT02976389|OTHER|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
48719478|NCT04180787|DIETARY_SUPPLEMENT|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
48719479|NCT02074072|DEVICE|15 degree left-lateral tilt wedges|The wedges are made of aluminium
48719480|NCT02074072|DEVICE|30 degree left-lateral tilt wedges|The wedges are made of aluminium
48024489|NCT02024334|DRUG|Leflunomide|
48024490|NCT01446848|DIETARY_SUPPLEMENT|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
48024491|NCT00771680|DRUG|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
48024492|NCT00771680|DRUG|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
48024493|NCT00771680|DRUG|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
48024494|NCT05394623|DIAGNOSTIC_TEST|HDV-Ab (IgG), HDV-RNA, RNA genotype|Anti-HDV was evaluated semiquantitatively by means of end-point dilutions. Quantitative HDV-RNA was performed by means of LightCycler 2.0. Genotyping of HDV was performed by direct sequencing of the delta antigen region.
48024495|NCT00319423|PROCEDURE|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
48024496|NCT05015153|OTHER|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
48024497|NCT02278276|DRUG|sodium polysulthionate|Bioavailable composition of α-sulfur
48383184|NCT02976389|OTHER|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
48383185|NCT00054275|DRUG|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
48719481|NCT04835168|DRUG|BT-11 low|Oral
48719482|NCT04835168|DRUG|BT-11 high|Oral
48719483|NCT04835168|DRUG|Placebo|Oral
48719484|NCT04946617|DRUG|undefined|Rinsing with mouthwashes
48719485|NCT04507165|PROCEDURE|Paravertebral block+Anterior serratus plane block|"Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure."
48719486|NCT04507165|DRUG|opioid free anesthesia|"Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h)."
48719487|NCT04507165|DRUG|opioid based anesthesia|"Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively."
48719488|NCT03766269|DRUG|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
48024498|NCT02278276|DRUG|Placebo|400 mg capsules containing placebo
48024499|NCT01942382|DRUG|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
48024500|NCT02009618|DRUG|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
48024501|NCT02009618|DRUG|placebo|
48024502|NCT00558285|DRUG|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
48024503|NCT00558285|DRUG|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
48182040|NCT02617953|DEVICE|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
48024504|NCT00558285|DRUG|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
48024505|NCT00558285|DRUG|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
48024506|NCT03110159|DRUG|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
48024507|NCT03110159|DRUG|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
48024508|NCT04462796|DIETARY_SUPPLEMENT|Magnesium Citrate|Magnesium Citrate 200 mg daily
48182041|NCT02617953|DEVICE|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
48182042|NCT04533048|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
48182043|NCT04533048|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
48383186|NCT00054275|DRUG|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
48383187|NCT03412448|OTHER|observation|Observation,
48383188|NCT00513578|BIOLOGICAL|PR1 leukemia peptide vaccine|
48383189|NCT00513578|BIOLOGICAL|incomplete Freund's adjuvant|
48383190|NCT00513578|BIOLOGICAL|sargramostim|
48383191|NCT06650280|OTHER|Hyaluronic Acid (HA)|hyaluronic acid coated implants will be placed in posterior maxilla to evaluate rapid osseointegration
48383192|NCT06650280|OTHER|nano-hydroxyapatite|nano-hydroxyapatite coated implants will be placed in posterior maxilla to assess rapid osseointegration
48383193|NCT06650280|OTHER|sandblasted acid etched|SLA coated implants will be placed in posterior maxilla and implant stability will be evaluated
48719489|NCT02747212|DEVICE|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
48719490|NCT02930408|PROCEDURE|electrocardiogram|
48719491|NCT02930408|PROCEDURE|Echocardiography|
48719492|NCT02818114|BEHAVIORAL|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
48719493|NCT00553007|PROCEDURE|Periodontal therapy|Normal periodontal therapy is performed.
48383194|NCT05087576|BEHAVIORAL|Expressive Helping|Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.
48719494|NCT02064608|DRUG|AZD2014|mTOR inhibitor
48024509|NCT05658861|OTHER|Milk containing A1 and A2 beta-casein|Single dose of commercial milk
48024510|NCT05658861|OTHER|Milk containing only A2 beta-casein|Single dose of A2 milk
48024511|NCT03453333|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
48024512|NCT03453333|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
48024513|NCT02040597|DRUG|Beclometasone/Formoterol/Glycopyrrolate|
48024514|NCT00578370|DRUG|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
48024515|NCT00578370|DRUG|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
48024516|NCT00578370|DRUG|0.1% betamethasone|Solution 200µl once a day (26 days)
48024517|NCT00578370|DRUG|0.005% calcipotriol|Solution 200µl once a day (26 days)
48024518|NCT00578370|DRUG|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
48519706|NCT06191029|BEHAVIORAL|Urdu translated cognitive failure questionnaire|Urdu Translated version of cognitive failure questionnaire will be given to adults to fill it accordingly and then it's reliability and validity will be checked
48519707|NCT04998656|DEVICE|Werewolf FLOW 50|Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.
48519708|NCT04998656|OTHER|Control|Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
48383195|NCT05087576|BEHAVIORAL|Caregiving Fact writing|Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
48383196|NCT05601414|DEVICE|BIO-Z|a novel cuffless continuous BP wrist monitor
48383197|NCT05601414|DEVICE|Finapres Nova|a cuffless continuous BP monitor
48383198|NCT00794222|DEVICE|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
48383199|NCT06108297|DIETARY_SUPPLEMENT|Lithium|Elemental lithium as lithium aspartate.
48383200|NCT06105697|OTHER|Blood flow restriction Running on Treadmill|Soccer players included in experimental group I will carry out this program for 6 weeks, setting the blood pressure to \~ 60% of limb occlusion pressure (AOP). They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
48383201|NCT06105697|OTHER|Running on Treadmill|Soccer players included in experimental group II will carry out the program for 6 weeks without occlude the blood pressure. They will run for 4 sets of 5 minutes, separated by 1 minute of rest, at 50-60% of their maximum Aerobic Speed.
48383202|NCT02730039|BEHAVIORAL|workshop|
48383203|NCT02730039|BEHAVIORAL|follow-up calls & webinars|
48383204|NCT02730039|BEHAVIORAL|assessments|
48383205|NCT04792073|DRUG|Avelumab|Avelumab 800 mg given intravenously over 60 minutes (+20 minutes / -10 minutes) every 2 weeks (+/- 3 days)
48383206|NCT04792073|RADIATION|Comprehensive Ablative Radiation Therapy|Comprehensive ablative radiation therapy 24 Gy in 3 fractions every 2-3 days
48383207|NCT03861689|DIAGNOSTIC_TEST|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
48383208|NCT05181176|DIETARY_SUPPLEMENT|Coffee|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
48519709|NCT00207519|BEHAVIORAL|weekly behavioral modification group|
48519710|NCT00207519|BEHAVIORAL|liquid meal replacements|
48519711|NCT02905604|DEVICE|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
48519712|NCT02905604|DEVICE|dmPFC Sham iTBS|Sham iTBS
48182044|NCT02932553|DEVICE|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
48519713|NCT03989492|OTHER|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
48519714|NCT01917214|OTHER|Sutent: Observational Study|Sutent oral therapy
48519715|NCT04553159|BIOLOGICAL|Autologous adipose derived stem cells|Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
48519716|NCT05088850|OTHER|no intervention|no intervention
48519717|NCT04510532|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment
48519718|NCT01245283|OTHER|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
48182045|NCT01306123|DRUG|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
48383209|NCT05181176|DIETARY_SUPPLEMENT|Green tea|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
48383210|NCT05181176|DIETARY_SUPPLEMENT|Herbal tea (placebo)|3 weight-loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).
48383211|NCT00632138|BEHAVIORAL|exercise intervention|
48383212|NCT00632138|OTHER|questionnaire administration|
48383213|NCT00632138|PROCEDURE|biofeedback|
48383214|NCT00632138|PROCEDURE|management of therapy complications|
48383215|NCT00632138|PROCEDURE|psychosocial assessment and care|
48383216|NCT00632138|PROCEDURE|quality-of-life assessment|
48383217|NCT04942964|DRUG|Bocidelpar|Oral
48383218|NCT04703647|OTHER|Administration of questionnaires for prospective group|Questionnaires: administration at T0, T1,T2,T3 and T4 of Short Form Health Survey (SF-36),Brief Pain Inventory (BPI),Disabilities of the Arm, Shoulder and Hand (DASH) for upper limb,Foot and Ankle Ability Measure (FAAM) for lower limb,Hospital Anxiety And Depression Scale (HADS),Tampa Scale of Kinesiophobia (TSK),Pain Catastrophizing Scale (PCS),Pattern Of Activity Measure - Pain (POAM-P) .
48719495|NCT05142345|OTHER|CONTINUUM Intervention|The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology nurse practitioner within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
48719496|NCT05142345|OTHER|Usual Care|Patients assigned to the usual care group will have their post-discharge follow-up scheduled per hospital, outpatient oncology team, and patient preference.
48719497|NCT01472211|DEVICE|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
48383219|NCT04703647|OTHER|Blood samples for prospective group|Blood samples at T0,T1,T2 and T3.
48719498|NCT01472211|DEVICE|placebo filter|filter purifies water
48719499|NCT01472211|OTHER|disinfection tablets|government promoted tablets disinfect water
48719500|NCT03568955|DIAGNOSTIC_TEST|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
48383220|NCT04703647|OTHER|Blood samples for control group|Blood samples just one time
48383221|NCT04943510|OTHER|Physical exercices|"surface EMG: surface electrodes will be positioned on the muscles to evaluate the level of muscle activation~non invasive muscular neurostimulations : application of a percutaneous electrical stimulation of the motor nerve of the considered muscle and a direct electrical stimulation of the muscle"
48383222|NCT03387423|DRUG|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
48719501|NCT04082780|DRUG|Rifamycin SV MMX|Intervention arm
48719502|NCT04082780|OTHER|Placebo|Placebo arm
48719503|NCT03678831|PROCEDURE|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
48719504|NCT04207918|RADIATION|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
48719505|NCT04207918|DRUG|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
48719506|NCT04207918|DRUG|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
48383223|NCT00056537|DRUG|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
48383224|NCT00564486|DRUG|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
48383225|NCT00564486|DRUG|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
48383226|NCT00564486|DRUG|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
48383227|NCT00564486|DRUG|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
48383228|NCT06063954|OTHER|electroacupuncture|Electroacupuncture (EA) is a form of acupuncture in which a weak electric current is passed through the acupuncture needles into acupoints in the skin.
48719507|NCT06119295|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants. Depending on the condition participants are in, they will be served either a portion size which consists of the amount of food they consumed in the first test session, or a reduced portion size. Within these two reduced portion size conditions, one group of participants will be made aware that their portion size has been reduced, the other will not and instead will be told that this portion size is the same as the amount of food they consumed in the previous session.
48383229|NCT06650852|BIOLOGICAL|BRII-179|BRII-179 will be given via intramuscular injection
48182046|NCT01306123|DRUG|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
48182047|NCT05703152|OTHER|Combined Exercise|Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
48383230|NCT06650852|DRUG|BRII-835 (VIR-2218)|BRII-835 will be given via subcutaneous injection
48383231|NCT06650852|BIOLOGICAL|PEG-IFNα|PEG-IFNα will be given via subcutaneous injection
48383232|NCT06650852|DRUG|Placebo of BRII-179|Placebo of BRII-179 will be given via intramuscular injection
48383233|NCT06650852|DRUG|Placebo of BRII-835|Placebo of BRII-835 will be given via subcutaneous injection
48383234|NCT05444114|BEHAVIORAL|Mental Exercise|Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story
48383235|NCT00683462|DRUG|Placebo|
48383236|NCT00683462|DRUG|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
48519719|NCT01245283|OTHER|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
48519720|NCT01245283|OTHER|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
48519721|NCT02326636|BIOLOGICAL|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
48182048|NCT03209869|BIOLOGICAL|Ex vivo Expanded and Activated Haploidentical Donor NK Cells|Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.
48182049|NCT03209869|BIOLOGICAL|Hu14.18-IL2|The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
48519722|NCT02078700|OTHER|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
48383237|NCT00683462|DRUG|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
48383238|NCT06412380|PROCEDURE|Implant insertion|All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.
48383239|NCT03576794|DRUG|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
48383240|NCT03576794|DRUG|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
48383241|NCT05196802|COMBINATION_PRODUCT|mHeart.4u|The mHeart.4U is a multiple-components intervention entailing the adoption and use of technological devices and self-management recommendations tailored to behavioural modifications (e.g. physical exercise and dietary patterns)
48383242|NCT04223622|BIOLOGICAL|ASC secretome|The osteochondral explants isolated from arthroplasty patients will be induced to an OA phenotype and treated with ASC secretome (either complete conditioned medium or extracellular vesicles) in order to investigate its therapeutic potential.
48519723|NCT03860324|PROCEDURE|Single-shot erector spinae plane block|Single-shot Erector Spinae Plane block with 30ml of ropivacaine 0,5% + adrenaline 150mcg.
48719508|NCT00947414|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
48719509|NCT00947414|DEVICE|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
48719510|NCT02662114|OTHER|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
48024519|NCT04876508|OTHER|Accupressure|Patients in the experimental group will be given acupressure once a day for 7 consecutive days. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the patients are in supine position, pressure will be applied to each acupressure point around the navel, respectively, Zhongwan (CV12), Guanyuan (CV4) and Tianshu (ST25) for 2 minutes for a total of 6 minutes.
48024520|NCT00194922|DIETARY_SUPPLEMENT|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
48383243|NCT04389008|OTHER|no interventions|no interventions
48719511|NCT02927262|DRUG|Gilteritinib|Oral tablet
48719512|NCT02927262|DRUG|Placebo|Oral tablet
48719513|NCT02008422|DRUG|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
48719514|NCT02008422|DRUG|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
48719515|NCT02008422|DRUG|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
48383244|NCT01901393|DRUG|IV ibuprofen|
48519724|NCT03860324|PROCEDURE|Single-shot fascia iliaca block|Single-shot Fascia Iliaca block with 40ml of ropivacaine 0,2%
48519725|NCT06575543|RADIATION|CT|3D CT scan have been used to evaluate the tunnels location after ACL reconstruction, as they can provide excellent perspective of the tunnel aperture, good visualization of bony structure and shape of the intercondylar notch, that preclude the use of a conventional 2-dimensional CT scan for measurement of the ACL tunnels location
48383245|NCT01901393|DRUG|Ketorolac|
48519726|NCT04849871|RADIATION|External Beam Accelerated Partial Breast Irradiation|APBI simulation must take place no more than 8 weeks from final definitive breast surgery.
48519727|NCT03987997|DEVICE|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
48519728|NCT03473184|DRUG|Diacerein 1% ointment|Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
48719516|NCT05236712|BEHAVIORAL|Mobile app|The app sends reminder 'push' notifications to complete weekly surveys. The survey is a series of questions about foods and drinks participants had in the last week. Once the weekly survey is completed the app generates a personalized weekly report showing foods we encourage participants to eat more of, eat less of, or keep eating the same amount of. The app will also show menu recommendations for breakfast, lunch, dinner, and snacks that will help participants to eat healthier. Finally, the app also has a feature that allows chatting with the research team by sending and receiving in-app texts.
48719517|NCT02273570|DRUG|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
48719518|NCT02273570|DRUG|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
48719519|NCT05054543|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
48719520|NCT05054543|DRUG|Placebo|0.9% Sodium Chloride
48719521|NCT03435562|OTHER|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
48719522|NCT03435562|OTHER|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
48024521|NCT02799082|DRUG|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
48719523|NCT03435562|OTHER|Own Brand cigarette|Effects of own brand cigarette use.
48719524|NCT01737294|DRUG|Qutenza exposure|Cutaneous patch
48024522|NCT02799082|DRUG|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
48024523|NCT00951067|OTHER|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~* exercise~* elevate arm~* wear an arm compression garment"
48383246|NCT06283485|DEVICE|ultrasound examination|"Phase 1 1: Taking ultrasound images from healthy volunteers (150 volunteers) to produce artificial intelligence - How to take PENG and Suprainguinal Fascia Iliaca Block sonoanatomical images is as follows.~Phase 2: In the second phase of the study, Smart Alfa Teknoloji San. and Tic. Inc. Artificial intelligence technology called Nerveblox, which was developed with the data received in the first stage with the support of the company, will be used. It is the validation and accuracy study of the artificial intelligence technology developed in the first stage. The accuracy study will be conducted on 40 healthy volunteers. 20 men and 20 women will be included in the study."
48383247|NCT00256841|DRUG|Chemotherapy|
48383248|NCT00256841|PROCEDURE|Radiation Therapy|
48383249|NCT05651373|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
48383250|NCT05651373|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
48719525|NCT06383104|OTHER|Intervention|Three myofascial release techniques will be performed with low load and long duration stretching to the myofascial complex to restore optimal length, decrease pain and improve function. In the development of the deep myofascial techniques, respiratory synchronisation with the patient will be performed. Proprioceptive neuromuscular facilitation techniques will be performed by executing diagonal spiral movements against resistance, several times, through a full range of motion. Three sets of three repetitions with 6-second contractions and a 30-second rest between sets shall be performed.
48719526|NCT03567018|DEVICE|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
48719527|NCT05755555|BEHAVIORAL|Visit a doctor|Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)
48719528|NCT00054691|DRUG|Iressa|250 mg by mouth daily
48719529|NCT00003447|DRUG|gemcitabine hydrochloride|
48024524|NCT00951067|DEVICE|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
48024525|NCT00951067|DEVICE|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
48024526|NCT00951067|DEVICE|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
48024527|NCT00951067|DEVICE|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
48024528|NCT04133844|BIOLOGICAL|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
48719530|NCT00003447|DRUG|vinorelbine tartrate|
48719531|NCT01522430|PROCEDURE|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
48719532|NCT01522430|PROCEDURE|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
48024529|NCT04526808|OTHER|FODMAP diet|low FODMAP diet
48024530|NCT02798198|OTHER|T2DM|T2DM without DKD
48024531|NCT02429063|OTHER|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
48024532|NCT02429063|OTHER|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
48024533|NCT03594994|BEHAVIORAL|Sleep extension|Extend time-in-bed by one hour
48024534|NCT02911402|OTHER|sea sickness questionnaires|
48024535|NCT03335657|OTHER|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
48024536|NCT03335657|OTHER|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
48024537|NCT02682654|DEVICE|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
48024538|NCT02682654|DEVICE|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
48383251|NCT05651373|DRUG|CertolizumabPegol injection|200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
48383252|NCT00297063|DRUG|Rosiglitazone|
48519729|NCT04321681|OTHER|no intervention|no intervention
48719533|NCT03445910|DRUG|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
48719534|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
48719535|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
48719536|NCT02817347|DRUG|piperacillin 2% + tazobactam 0.25%|
48719537|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5%|
48719538|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0%|
48519730|NCT06281444|DEVICE|ESWT|"All patients in both groups will be applied with a home-based exercise program around for 30-minutes per day for four weeks. The exercises that mentioned in the research content are knee range of motion and strengthening exercises for the knee. It will be checked by phone on a weekly basis. Also, each patient in group 1 will receive shockwaves of continuous frequency and intensity (1000 shocks, 2.0 to 3.0 bar,10 Hz and 0.08-0.25mJ/mm2 energy range), while the second group of patients will receive sham-ESWT.~ESWT application will be applied to the medial part of the knee area on the side where the pain is described, or at the patellofemoral and tibiofemoral borders of the affected knee, and will be given in four sessions in total once a week."
48182050|NCT01792531|BEHAVIORAL|Parent training group|The More \& Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More \& Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
48383255|NCT06651307|DEVICE|Lifting with elbow sleeves|Lifting with elbow sleeves
48519731|NCT06281444|DEVICE|Sham-ESWT|Sham ESWT application will be set to 1000 pulses, 2-3 bar pressure, 10 Hz frequency and 0 mJ/mm2 energy to be sham.
48519732|NCT04343157|RADIATION|Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)|In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
48519733|NCT03410056|DRUG|Efavaleukin alfa|Efavaleukin alfa administered as a subcutaneous injection.
48519734|NCT03410056|DRUG|Placebo|Placebo administered as a subcutaneous injection.
48519735|NCT00690066|DRUG|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
48719539|NCT01643876|BEHAVIORAL|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
48719540|NCT03037541|DRUG|Carac Cream|Carac Cream will be used once daily for seven consecutive days
48719541|NCT03037541|DRUG|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
48719542|NCT04649047|BEHAVIORAL|Goal-oriented episodic future thinking|All participants will receive a 3-week web-based intervention plus individual health coaching. The intervention topics include stress management, healthy eating, and physical activity
48719543|NCT05749653|DRUG|Bi-annual CDTI|Bi-annual CDTI
48719544|NCT02002572|OTHER|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
48719545|NCT01232153|DEVICE|Non invasive ventilation|Non invasive ventilation
48024539|NCT05937022|DEVICE|Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
48024540|NCT05937022|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
48719546|NCT02940782|PROCEDURE|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
48024541|NCT02480621|DRUG|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
48182051|NCT01792531|BEHAVIORAL|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
48383256|NCT03467373|DRUG|Glofitamab|Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
48383257|NCT03467373|DRUG|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
48383258|NCT03467373|DRUG|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m\^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
48383259|NCT03467373|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
48383260|NCT03467373|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle
48383261|NCT03467373|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
48383262|NCT03467373|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
48719547|NCT02940782|PROCEDURE|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
48719548|NCT02940782|DEVICE|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
48383263|NCT03467373|DRUG|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
48383264|NCT03467373|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
48182052|NCT01792531|BEHAVIORAL|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
48182053|NCT06423651|BEHAVIORAL|Cognitive Remediation (REHACOP)|REHACOP is a structured neuropsychological rehabilitation program that covers most of the cognitive deficits present in psychotic disorder: attention, learning and memory, executive functions, language, social cognition, daily life activities, social skills and psychoeducation. The modules of language, social cognition and psychoeducation will not be used in the present clinical trial. Each module includes a hierarchy of exercises based on the cognitive subarea to be worked on and the grade of difficulty demanded for the performance of each task.The format of the sessions will be the same as MCT, that is, groups of 6-10 patients who will receive weekly sessions of 45-60 minutes in length. In this case, the duration of the intervention will be 12 sessions.
48383265|NCT02461147|PROCEDURE|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
48719549|NCT04170829|BIOLOGICAL|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
48719550|NCT00402493|DRUG|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
48024542|NCT02842567|DRUG|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
48024543|NCT02842567|DRUG|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
48024544|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) Low Dose|BLB201 10\^6 PFU
48383266|NCT04242901|DIAGNOSTIC_TEST|Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo|Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
48383267|NCT03024359|DIETARY_SUPPLEMENT|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
48383268|NCT06652126|OTHER|Microbiological examinations.|"* BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient."
48719551|NCT00402493|DRUG|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
48719552|NCT00402493|DRUG|Ibuprofen|ibuprofen 200mg
48024545|NCT05655182|BIOLOGICAL|PIV5-vectored RSV Vaccine (BLB-201) High Dose|BLB201 10\^7 PFU
48024546|NCT05655182|DRUG|Placebo|The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
48024547|NCT04139811|OTHER|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
48024548|NCT01391377|DRUG|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
48024549|NCT01391377|DRUG|Sugar pill|Placebo
48024550|NCT00770016|DRUG|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
48024551|NCT02932631|OTHER|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
48024552|NCT00127673|DRUG|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
48024553|NCT00127673|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
48024554|NCT05685485|PROCEDURE|Standard Implantation|Traditional Ahmed plantation without vicryl ligature
48024555|NCT05685485|PROCEDURE|Tied off Tube|Ahmed implantation with vicryl ligature
48024556|NCT06071000|BEHAVIORAL|Neuro-developmental stimulation (Neuro-vývojová stimulace).|Neuro-developmental stimulation is exercise based intervention program that is focused on repeating reflex movements and thus inhibiting reflexive response.
48383269|NCT06567834|DEVICE|Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (Models ZXR00V/ZXW150)|Multifocal IOL with violet light filtration and high-resolution lathing
48383270|NCT06567834|DEVICE|Tecnis Symfony/Tecnis Symfony Toric (Models ZXR00/ZXT150)|Multifocal IOL with ultraviolet filtration
48383271|NCT05649787|BEHAVIORAL|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
48383272|NCT05649787|BEHAVIORAL|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
48719553|NCT05531721|OTHER|Observation|Observation and retrospective data collection
48719554|NCT00944463|DRUG|Gemcitabine+simvastatin|Gemcitabine and simvastatin
48719555|NCT00944463|DRUG|Gemcitabine+Placebo|Gemcitabine plus Placebo
48719556|NCT04827797|DEVICE|balls|Birth balls to exercise
48719557|NCT00980304|DRUG|Rituximab|
48719558|NCT02816203|DEVICE|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
48719559|NCT01922375|DRUG|Naftopidil|
48719560|NCT00000572|PROCEDURE|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
48719561|NCT00000572|PROCEDURE|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
48383273|NCT05649787|BEHAVIORAL|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
48383274|NCT04431960|DRUG|blackcurrant (BC) extract|A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
48383275|NCT03554759|DRUG|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
48383276|NCT05326412|DRUG|Itepekimab SAR440340|Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
48383277|NCT05103683|DRUG|TORL-1-23|antibody drug conjugate (ADC)
48383278|NCT02273349|DEVICE|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
48383279|NCT01190202|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick
48383280|NCT01190202|PROCEDURE|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
48383281|NCT05677763|DRUG|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
48383282|NCT05677763|DRUG|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
48383286|NCT02724176|DRUG|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
48383287|NCT06652217|DEVICE|Digitally manufactured occlusal splint.|digitally manfactured occlusal splint using intra oral scanner and jaw traccking device for data acqusition and 3d printing for manfacturing of the device
48383288|NCT06652217|DEVICE|conventionally manufactured occlusal splint|the occlusal device will be manufactured conventionally using impression and and anterior deprogramer with bite registeration material for data aquesition and usual construction method using clear acrylic.
48024557|NCT00110240|DRUG|vildagliptin|
48024558|NCT04286035|DRUG|Bupivacaine Injection|Femoral nerve block with 20 ml %0.375 bupivacaine
48024559|NCT04286035|DRUG|Bupivacaine Injection|Adductor canal block with 20 ml %0.375 bupivacaine
48024560|NCT03197493|DRUG|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
48024561|NCT04879472|PROCEDURE|Osteosynthesis|The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
48024562|NCT02243787|DRUG|COVA322|
48024563|NCT02243787|OTHER|Placebo|
48383289|NCT04935866|OTHER|Near-infrared spectroscopy (NIRS)|Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
48383290|NCT01699100|OTHER|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure \> 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
48383291|NCT04469465|DRUG|Danicopan|Oral tablet
48383292|NCT04469465|DRUG|Placebo|Oral tablet
48383293|NCT04469465|DRUG|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
48383294|NCT05348785|DRUG|BIIB122|Administered as specified in the treatment arm
48024564|NCT00982020|DRUG|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
48024565|NCT00982020|BEHAVIORAL|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
48024566|NCT00982020|BEHAVIORAL|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
48383295|NCT05348785|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm
48383296|NCT03273816|BEHAVIORAL|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
48383297|NCT01803464|DEVICE|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
48383298|NCT01803464|DRUG|Botox|Children who are candidates to receive Botox as part of their standard of care.
48383299|NCT06061328|BEHAVIORAL|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
48519736|NCT00690066|DRUG|Placebo|Intravenous infusion of excipients of PROCHYMAL®
48383300|NCT06061328|BEHAVIORAL|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
48383301|NCT06509542|BEHAVIORAL|Objective assessment of upper limb use during activities in ecological situation|Twenty-five patients will be recorded performing three activities during their rehabilitation: getting dressed, preparing a meal, and eating a meal. The movements of their upper limbs will be tracked using wrist-worn accelerometers and video cameras.
48519737|NCT01030302|DRUG|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
48719562|NCT06025799|BEHAVIORAL|Mindfulness-based stress reduction intervention|The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
48719563|NCT01839656|DRUG|nusinersen|Administered by intrathecal (IT) injection
48383302|NCT03683719|DRUG|Delgocitinib cream|Cream for topical application.
48383303|NCT03683719|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
48719564|NCT04405271|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks
48719565|NCT04405271|DRUG|Placebo|A dose of 1 tablet per day will be administered for a total of 12 weeks.
48719566|NCT06182605|DEVICE|multifunctional instruments|Ophthalmic retractors can be used to lift the lens during surgery to assist in lens sucking or resection; Intraoperative injection of reagent, which has the advantage of retractable, micro-incision. Ophthalmic hooks can be used to secure support capsular bags; auxiliary cleavage; polishing capsule; Viscoelastic agent is injected as needed. The front end of the membranous cataract scissor is a capsular tearing forceps, and the capsule tearing and capsule scissors can be flexibly switched. All three instruments have the functions of two or three traditional instruments, which can be designed to reduce the number of times the instruments enter and exit the incision during surgery, improve surgical efficiency,
48719567|NCT06182605|DEVICE|traditional instruments|traditional Cataract-assisted instruments for cataract operation.Puncture knives, microscissors, microscopic forceps, nucleus hooks, lens graft forceps, are used to cut the cornea, assist in removing the cloudy lens, suturing wounds.
48519738|NCT01547390|DRUG|Aspirin|
48383304|NCT05582655|BEHAVIORAL|ONLINE|The ONLINE intervention applies the JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation: Kasari et al., 2021) social communication intervention for young children with autism. The JASPER approach has been tested in a caregiver-mediated format where caregivers are taught to use the JASPER strategies with their children during play and home routine (e.g., Kasari et al., 2010; Kasari et al., 2014). The JASPER intervention is being adapted in this study to include online web based materials.
48383305|NCT05582655|BEHAVIORAL|COACH|COACH includes live synchronous caregiver coaching in the JASPER intervention model. Coaching follows prior published JASPER caregiver coaching protocols (e.g., Shire, Shih, Barriault, \& Kasari, 2022). This implementation strategy has been tested in a pilot study when applied by community early intervention providers (Shire, Baker Worthman, \& Arbuckle, 2021).
48519739|NCT01547390|DRUG|placebo|
48519740|NCT00005603|DRUG|asparaginase|
48519741|NCT00005603|DRUG|cyclophosphamide|
48519742|NCT00005603|DRUG|cytarabine|
48519743|NCT00005603|DRUG|daunorubicin hydrochloride|
48519744|NCT00005603|DRUG|dexamethasone|
48519745|NCT00005603|DRUG|doxorubicin hydrochloride|
48519746|NCT00005603|DRUG|mercaptopurine|
48519747|NCT00005603|DRUG|methotrexate|
48519748|NCT00005603|DRUG|prednisone|
48519749|NCT00005603|DRUG|thioguanine|
48519750|NCT00005603|DRUG|vincristine sulfate|
48519751|NCT04028557|OTHER|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
48519752|NCT06530797|DRUG|First-line Adebrelimab regiment for advanced stage ES-SCLC|First-line Adebrelimab in any regiment for advanced stage ES-SCLC
48519753|NCT06530797|DRUG|Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC|Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
48519754|NCT02463773|DEVICE|Ultrasound|Diaphragmatic excursion ultrasound assessment
48719568|NCT06233994|BIOLOGICAL|ZG005 Powder for Injection|ZG005 will be administered at a dose of 10 mg/kg by intravenous (IV) infusion, once every 3 weeks (Q3W).
48719569|NCT06233994|DRUG|Donafenib Tosilate Tablets|Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
48719570|NCT06233994|BIOLOGICAL|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion, once every 3 weeks (Q3W).
48719571|NCT05149131|DRUG|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
48719572|NCT00974285|DRUG|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
48719573|NCT00974285|DRUG|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
48719574|NCT00748709|DRUG|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
48383306|NCT06582680|OTHER|Ambient Heat|Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
48383307|NCT03151707|DRUG|Nicotinamide Riboside|Nicotinamide riboside 2g/day for a 2 week duration
48383308|NCT00031096|DRUG|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
48383309|NCT00031096|DRUG|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
48383310|NCT00989365|OTHER|Aerobic training|Treadmill training
48383311|NCT05744635|DRUG|Tacrolimus|Tacrolimus received as part of routine clinical care
48383312|NCT03728257|BEHAVIORAL|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, Versatile and Integrated System for Tele-Rehabilitation (VISYTER)/two-way video communication system. Interactive intervention sessions will be delivered to the home via real time video conferencing (up to 12 sessions and a behavioral contract plan to prepare for phase 2); and Phase 2. Transition to self-management. Three telephone sessions (3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
48383313|NCT03728257|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
48383314|NCT05884866|DRUG|Dapagliflozin 10mg Tab|see arms
48383315|NCT05884866|DRUG|Balcinrenone 50mg Capsule|see arms
48383316|NCT05884866|DRUG|Balcinrenone 100mg Capsule|see arms
48383317|NCT05884866|DRUG|Dapagliflozin matching Placebo|see arms
48383318|NCT05884866|DRUG|Balcinrenone 50mg matching Placebo|see arms
48383319|NCT05884866|DRUG|Balcinrenone 100mg matching Placebo|see arms
48383320|NCT04984161|OTHER|education|The aim of this project is to examine the effect of stoma care education on the knowledge and skill levels of pediatric surgery nurses about stoma care.
48383321|NCT06397001|DRUG|nL-SAA1-01|Personalized antisense oligonucleotide
48383322|NCT04969263|BIOLOGICAL|BNT162b2 vaccine (Pfizer/BioNTech)|30 microgram dose
48383323|NCT04969263|BIOLOGICAL|mRNA-1273 vaccine (Moderna)|100 microgram dose
48719575|NCT03494218|DIAGNOSTIC_TEST|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
48383324|NCT04074109|COMBINATION_PRODUCT|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
48383325|NCT04074109|BEHAVIORAL|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
48383326|NCT01321970|PROCEDURE|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
48383327|NCT01321970|PROCEDURE|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
48383328|NCT01321970|PROCEDURE|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~* Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~* Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~* Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
48383329|NCT00670527|PROCEDURE|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the \[18F\]Fluorocholine PET/CT scan. \[18F\]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
48383330|NCT01728376|DRUG|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
48383331|NCT01728376|DRUG|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
48383332|NCT00088504|DRUG|Merimepodib|
48383333|NCT00088504|DRUG|PEG-Interferon-alpha 2a (Pegasys®)|
48383334|NCT00088504|DRUG|Ribavirin (Copegus®)|
48519755|NCT06268288|DEVICE|GammaCore intervention|Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day
48719576|NCT03233295|DRUG|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
48719577|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
48719578|NCT01187459|DIETARY_SUPPLEMENT|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
48719579|NCT02771626|DRUG|CB-839|Glutaminase inhibitor
48719580|NCT02771626|DRUG|Nivolumab|PD-1 inhibitor
48719581|NCT01305655|DRUG|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is \>250 µM, 36 hour levels \>30 µM or 42 hours levels \>10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
48024567|NCT04244474|DRUG|A single one ml injection|All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
48024568|NCT01055743|PROCEDURE|Radical resection|Radical resection of hepatocellular carcinoma
48383335|NCT02577094|DRUG|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
48383336|NCT02577094|DRUG|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
48383337|NCT02577094|BIOLOGICAL|allogeneic stem cell transplantation.|At Day 0
48383338|NCT02577094|DRUG|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
48383339|NCT02577094|BIOLOGICAL|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
48383340|NCT03686488|DRUG|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
48383341|NCT03686488|DRUG|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
48383342|NCT05564533|BEHAVIORAL|Heart-Smile Training Intensive Introduction Program (HST-IIP)|"Heart-Smile Training (HST) is an interoceptive compassion program designed to develop the qualities of compassion, empathy, and kindness for oneself and others with a focus on interoceptive awareness. It is unique from other compassion trainings in its focus on 1) embodiment of warmth and tenderness of compassionate feeling with a compassionate body scan meditation, 2) development of an authentic presence, characterized by a warm feeling of loosened attachment to ego-based self, and 3) cultivation of joy triggered by genuine smile to oneself. HST-IIP is a 3-day/4-week/1-day interoceptive compassion program that shares the same core elements and practices as HST 3-day intensive program. Unlike HST, the format of the HST-IIP has an extended duration to develop self-regulation through the cultivation of emotional and behavioral regulation."
48383343|NCT01421524|DRUG|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are \> 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
48519756|NCT06268288|OTHER|STEPS management protocol|STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals
48519757|NCT00775619|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
48719582|NCT02678884|DRUG|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
48024569|NCT01055743|DRUG|Fluorouracil Implants|Implanted during the surgical treatment
48024570|NCT00910481|DEVICE|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
48519758|NCT05225779|DIAGNOSTIC_TEST|12- derivation Electrocardiography|6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
48519759|NCT04601766|DRUG|APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
48719583|NCT02964832|DEVICE|Grasp method|
48719584|NCT02964832|DEVICE|Armband-in-hand method|
48719585|NCT02964832|DEVICE|Armband-on-arm method|
48024571|NCT01607905|DRUG|Selinexor|Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
48024572|NCT01607905|DRUG|Acetaminophen|Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
48719586|NCT00601861|DRUG|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
48719587|NCT04363047|OTHER|40ml blood sample|We'll be collecting cells, DNA and serum.
48719588|NCT03897036|DRUG|CX-4945|API powder-in-capsule in 200 mg strength
48024573|NCT00964691|DRUG|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
48024574|NCT00964691|DRUG|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
48024575|NCT05850533|BEHAVIORAL|Virtual Tai Chi Easy|Unique to other mind-body therapies, Tai Chi Easy (TCE) is multi-component mind-body therapy including: 1) Gentle movement, 2) Breath practice, 3) Self-massage, and 4) Meditation.
48024576|NCT02942160|BIOLOGICAL|Collagenase Clostridium Histolyticum|
48024577|NCT02639884|DEVICE|SedLine EEG|
48024578|NCT02639884|DEVICE|RRa monitoring|
48182054|NCT06423651|BEHAVIORAL|Metacognitive Training (MCT)|The MCT consists in 8 weekly sessions of 45-60 minutes in length. Each group of patients should be made up of 6-10 patients. The material of the training program is available online at: http://www.uke.de/mkt. The material contains 16 powerpoint presentations (2 per each module), one manual and 6 pamphlets of tasks to do at home. The modules are as follows: Module 1: Attribution; Module 2: Jumping to conclusions (1st part); Module 3: Changing beliefs; Module 4: To emphatise (1st part); Module 5: Memory; Module 6: To emphatise (2nd part); Module 7: Jumping to conclusions (2nd part); and Module 8: Self-esteem and mood.
48383344|NCT01421524|DRUG|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
48719589|NCT00324441|DEVICE|Iratherm® 1000|
48024579|NCT01513304|PROCEDURE|Manual therapy|
48024580|NCT06214546|OTHER|Regular walking|Participants perform 6 overground walking trials (12.5 m) without support system. Participants perform all measurements (regular walking, Myosuit, ZeroG) on one single measurement day.
48024581|NCT06214546|DEVICE|Myosuit|Participants perform 6 overground walking trials (12.5 m) while wearing the Myosuit. ZeroG and Myosuit intervention will be performed in random order.
48182055|NCT03040609|BEHAVIORAL|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
48182056|NCT03040609|BEHAVIORAL|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
48024582|NCT06214546|DEVICE|ZeroG|Participants perform 6 overground walking trials (12.5 m) while walking in the ZeroG. ZeroG and Myosuit intervention will be performed in random order.
48024583|NCT00815126|PROCEDURE|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
48024584|NCT02596724|OTHER|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
48024585|NCT00001631|PROCEDURE|Magnetic resonance imaging|
48024586|NCT02736539|DRUG|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
48182057|NCT03040609|BEHAVIORAL|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
48182058|NCT02718261|DRUG|Pantoprazole|
48383345|NCT01421524|DRUG|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
48383346|NCT01421524|DRUG|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
48383347|NCT06642662|DIAGNOSTIC_TEST|Somascan 5.0|This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.
48519760|NCT04601766|DRUG|APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
48719590|NCT05782114|OTHER|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
48024587|NCT02736539|DRUG|Placebo|Placebo treatment
48182059|NCT02718261|DRUG|Saline 0.9% (matching placebo)|
48024588|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
48024589|NCT01577134|BEHAVIORAL|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
48024590|NCT01577134|BEHAVIORAL|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
48024591|NCT06497257|OTHER|Evaluating wrist flexor and extensor peak torque|Evaluation of wrist flexor and extensor peak torque
48024592|NCT06497257|OTHER|Evaluating functional disability|Evaluation of functional disability
48182060|NCT00146445|BEHAVIORAL|Peer Mentoring Intervention|
48182061|NCT03329729|OTHER|Rosuvastatin|Hyperlipidemic patients treated with rosuvastatin
48182062|NCT00383123|BIOLOGICAL|Fluarix™|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
48182063|NCT00383123|BIOLOGICAL|Fluzone|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
48024593|NCT06497257|OTHER|Evaluating hand grip strength|Evaluation of hand grip strength
48719591|NCT05782114|OTHER|Traditional physical therapy program|"1. Instruction to wear Thumb Spica splint:~   The Thumb Spica splint will be used for 4 weeks for both groups of patients.~2. Ultrasound Therapy:~   Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~3. Stretching exercise:~1. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4) Strengthening exercise:~1. Resisted exercise for thumb extension:~2. Resisted exercise for thumb abduction:~3. Resisted exercise for thumb opposition:~4. Wrist radial deviation strengthening:~5. Grip strengthening:~6. Finger spring:"
48024594|NCT05820022|OTHER|Research Barriers Scale|This scale was prepared after a detailed literature review and sent to five physiatrists for review and feedback. It consists of 21 items with Likert-type responses and two open-ended questions. It is designed to measure the barriers that individuals or groups face in conducting research. The scale includes a list of potential barriers and asks respondents to rate the extent to which they experience each barrier. Examples of barriers that may be included in such a scale could include lack of funding, limited access to resources or equipment, time constraints, difficulty finding participants or accessing data, institutional or administrative hurdles, and so on.
48719592|NCT06302894|BEHAVIORAL|Self-sufficiency|Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
48024595|NCT03300388|DIETARY_SUPPLEMENT|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
48024596|NCT03300388|DIETARY_SUPPLEMENT|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
48719593|NCT04536038|BEHAVIORAL|Opt-out|A study coordinator will call the patient unless they opt-out. See arm description for more details.
48719594|NCT02124772|DRUG|Trametinib|Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
48024597|NCT03300388|OTHER|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
48383348|NCT06415032|PROCEDURE|Mastectomy with Quilting sutures without drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After the mastectomy, the skin flaps are sutured onto the pectoral muscle using polyfilament absorbable sutures (e.g. Stratafix PDS® 1 CT needle) placed at 4- to 5-cm intervals in two or three rows depending on the extent of the skin flaps. Care is taken to prevent dimpling of the skin. The axillary region is also approximated. Care is taken to prevent damage to nerves and blood vessels. No suction drains are placed. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference.
48719595|NCT02124772|DRUG|Dabrafenib|Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
48719596|NCT03738007|DEVICE|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
48024598|NCT05404022|OTHER|Tailored nutrition and physical activity programme|"Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required"
48024599|NCT05395624|DRUG|18F-OP-801|18F Hydroxyl Dendrimer
48519761|NCT02449980|PROCEDURE|Primary Surgery Group|Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
48719597|NCT03738007|DEVICE|Perlane|Treatment with Perlane
48719598|NCT01242566|DRUG|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
48719599|NCT03601559|DIETARY_SUPPLEMENT|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
48719600|NCT03601559|DIETARY_SUPPLEMENT|Placebo|Inert placebo matched for taste and appearance
48719601|NCT05732961|DRUG|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
48719602|NCT03101007|DEVICE|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
48024600|NCT02120924|DRUG|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
48519762|NCT02449980|PROCEDURE|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
48024601|NCT02120924|DRUG|Vehicle|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
48383349|NCT06415032|PROCEDURE|Mastectomy with Conventional sutures with drain placement|The nipple-areola complex is removed, and dissection of skin flaps is performed using electrocautery. The breast tissue, including the prepectoral fascia is removed from the pectoral muscle. After mastectomy no flap fixation is performed. The skin is closed in a conventional manner using an absorbable skin suture. One or two suction drains are placed before skin closure. The drains are placed in the mastectomy gutter lateral to the pectoral muscle and/or in the prepectoral area. For skin closure, the edges are sutured using absorbable monofilament sutures (e.g. Biosyn l® 3-0, Monocryl® 3-0) depending on the surgeon's preference. Drain output is recorded daily. Drain removal policy varies among participating centres. In some centres drain removal is based on volume of drained fluids while in other centres it depends on the postoperative time
48383350|NCT06504290|DRUG|VV119 Placebo （in healthy adult subjects）|"VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days.~VV119 2 mg Group:2 subjects will receive VV119 Placebo 2 mg, orally once daily for 14 days.~VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally once daily for 14 days."
48383351|NCT06504290|DRUG|VV119 （in healthy adult subjects）|"VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days.~VV119 2 mg Group:6 subjects will receive VV119 2 mg, orally once daily for 14 days.~VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally once daily for 14 days."
48383352|NCT06504290|DRUG|VV119(in adult patients with schizophrenia)|VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
48383353|NCT06504290|DRUG|VV119 Placebo （in adult patients with schizophrenia）|VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
48383354|NCT03718221|OTHER|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
48519763|NCT00580502|DEVICE|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m\^2
48519764|NCT02794727|DEVICE|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
48519765|NCT02794727|DEVICE|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
48519766|NCT03552510|PROCEDURE|Oro-pharyngeal Administration of Mother's Milk|Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
48519767|NCT04118023|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging Test|MAGNETOM Terra - 7T MRI Scanner by Siemens Healthineers. Each patient enrolled will undergo the study imaging test prior to planned diagnostic knee arthroscopy.
48719603|NCT03101007|DEVICE|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
48719604|NCT00069992|RADIATION|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
48719605|NCT00069992|DRUG|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
48719606|NCT00069992|DRUG|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
48719607|NCT03576105|COMBINATION_PRODUCT|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
48719608|NCT03576105|COMBINATION_PRODUCT|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
48719609|NCT03576105|COMBINATION_PRODUCT|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
48024602|NCT02120924|DRUG|Finacea|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
48024603|NCT01921348|DEVICE|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
48719610|NCT03576105|COMBINATION_PRODUCT|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
48719611|NCT04498377|BIOLOGICAL|F-652|IL-22 fusion protein administered intravenously
48719612|NCT04498377|BIOLOGICAL|Placebo|Placebo administered intravenously
48719613|NCT03689244|DRUG|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 to 8 tablets at each administration
48719614|NCT03689244|DRUG|Placebo|Oral tablets without active compound
48719615|NCT05559125|DRUG|STSA-1002 Injection|Intravenous injection
48719616|NCT05559125|DRUG|STSA-1005 Injection|Intravenous injection
48383355|NCT03718221|OTHER|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
48383356|NCT06650332|DRUG|cadonilimab|Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
48719617|NCT03159104|DRUG|Tenoten for children|Tablet for oral use.
48719618|NCT03159104|DRUG|Placebo|Tablet for oral use.
48719619|NCT04869033|OTHER|Farinelli's Breathing Exercise|after 1 minute of normal breathing, follow this instruction; inhale 2 seconds, suspend 2 seconds, exhale 2 seconds. inhale 3 seconds, suspend 3 seconds, exhale 3 seconds. inhale 4 seconds, suspend 4 seconds, exhale 4 seconds. inhale 5 seconds, suspend 5 seconds, exhale 5 seconds. inhale 6 seconds, suspend 6 seconds, exhale 6 seconds. This cycle lasted 1 minute (60 seconds), called Farinelli's breathing (FB). When participants finished these cycle, repeated it again 4 times. 1 minute of NB + 4 minutes of FB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
48719620|NCT04869033|OTHER|Diaphragmatic Breathing Exercise|after 1 minute of normal breathing, inhale 2 seconds and exhale 2 seconds with nasal airway. Continued breathing this pattern until 4 minutes, then back to normal breathing 1 minute . 1 minute of NB + 4 minute of DB called 1 set. The participants were asked to practice 6 sets/day, 5 days/week (Monday-Friday) for week 1-4, and increased duration to 8 sets/day, 5 days/week for week 5-8.
48719621|NCT02471768|PROCEDURE|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
48719622|NCT04941937|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
48719623|NCT04941937|DRUG|Thalidomide|100mg/d, Po. on day1-28
48719624|NCT04941937|DRUG|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
48719625|NCT04941937|DRUG|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
48719626|NCT04941937|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
48719627|NCT03344263|DIAGNOSTIC_TEST|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
48719628|NCT03530085|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -9 to -7.
48719629|NCT03530085|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
48719630|NCT03530085|DRUG|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -6 to -3.
48719631|NCT05250791|DRUG|Lidocaine hydrochloride 2% for injection|An intravenous bolus of 2% lidocaine will be administered following the induction of anaesthesia at 1.5mg/kg ideal body weight over 20 minutes followed by intravenous infusion of 1.5 mg/kg/hour ideal body weight with a maximum rate of 120mg/hour for 24 hours.
48719632|NCT05250791|DRUG|0.9% sterile Sodium Chloride solution for injection|Administered as lidocaine
48719633|NCT02461316|OTHER|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
48719634|NCT00582738|DRUG|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
48182064|NCT04724915|PROCEDURE|Conventional Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with manual instrumentarium (jig-based).
48182065|NCT04724915|PROCEDURE|Robot-Assisted Total Knee Arthroplasty|People will undergo surgery to replace the knee joint with a prosthesis in case of osteoarthritis. This will be performed with the help of a surgical robot.
48383357|NCT06650332|DRUG|Trastuzumab|loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
48182066|NCT01268124|DRUG|HTC-867|
48182067|NCT03784781|BIOLOGICAL|Biopsy|Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
48383358|NCT06650332|DRUG|XELOX|Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
48383359|NCT06650332|DRUG|Disitamab Vedotin|1.5、2.0、2.5mg/kg，IV，D1，Q2W
48383360|NCT06650332|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
48383361|NCT06565741|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
48719635|NCT00582738|DRUG|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
48719636|NCT03130426|DRUG|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
48719637|NCT03130426|DRUG|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
48719638|NCT03130426|DRUG|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
48719639|NCT03130426|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
48719640|NCT02091284|DEVICE|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
48719641|NCT00418431|DRUG|Intravitreal injection of Bevacizumab|
48719642|NCT04644913|BEHAVIORAL|Quality of life questionnaire|Sending of 2 questionnaires (SF 36 and TESS)
48719643|NCT04148612|DIAGNOSTIC_TEST|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
48519768|NCT00247676|DRUG|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
48519769|NCT03583307|DRUG|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
48519770|NCT02553772|DRUG|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
48519771|NCT02553772|DRUG|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
48719644|NCT01872442|DRUG|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
48719645|NCT01872442|DRUG|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
48719646|NCT03619135|DEVICE|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
48719647|NCT03619135|OTHER|Placebo|No use of the Buzzy (standard IV access techniques)
48719648|NCT00697437|DRUG|Docetaxel|70mg q3wx 1 dose
48719649|NCT00697437|DRUG|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
48719650|NCT04433013|DRUG|Lianhua Qingwen|The LHQW capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
48383362|NCT06565741|PROCEDURE|ThuFLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
48383363|NCT06170632|DEVICE|Biliary drainage|Biliary drainage with FC-SEMS Niti-S FLARE TYPE
48383364|NCT01410747|DRUG|Tacrolimus|oral
48519772|NCT05623501|DRUG|Dihydromyricetin|Dose-escalation and lysine preparation
48519773|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
48719651|NCT04433013|DRUG|Placebo|The placebo capsules will be administered to trial participants 4 capsules, 3 times a day, after meal
48719652|NCT01243489|OTHER|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
48719653|NCT00957333|OTHER|ketamine|
48719654|NCT00457223|PROCEDURE|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
48719655|NCT03689712|DRUG|GC4419 90mg|60 minute IV infusion
48719656|NCT03689712|DRUG|Placebo|60 minute IV infusion
48719657|NCT01999075|DEVICE|Lung Volume Recruitment (LVR)|LVR will be used twice per day
48719658|NCT01999075|OTHER|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
48719659|NCT02279836|DEVICE|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
48719660|NCT03349866|DRUG|apatinib|apatinib：250mg qd po
48719661|NCT03349866|DRUG|Capecitabine|1000mg/m2 bid d1-14
48719662|NCT03349866|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
48719663|NCT03349866|RADIATION|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
48719664|NCT03957941|BEHAVIORAL|FamilyLink Pumping|Viewing baby via FamilyLink while pumping
48719665|NCT03957941|BEHAVIORAL|Standard Pumping|Not viewing baby via FamilyLink while pumping
48719666|NCT03168100|DRUG|Elotuzumab|administered via IV infusion
48719667|NCT03168100|DRUG|Lenalidomide|taken by mouth
48719668|NCT03168100|DRUG|Dexamethasone|taken by mouth
48383365|NCT06043102|DEVICE|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
48383366|NCT04762212|PROCEDURE|Mobilization with movement and stretching, stretching or control|The participants will receive a therapist performed mobilization with movement and then instructed in a stretching program to be followed for one week or only receive instruction in a stretching program to be followed for one week on the hip with the greatest limitation in motion. The hip with the least amount of limitation will not receive an intervention.
48383367|NCT04733807|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Hospital employers vaccinated with BNT162b2 mRNA against Sars-Cov2 are studied for serum antibody response.
48383368|NCT06510114|DRUG|methylprednisolone(daily scheme)|0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.
48519774|NCT03649997|DRUG|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
48519775|NCT03649997|DRUG|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
48719669|NCT03168100|DRUG|Bortezomib|administered as a subcutaneous injection
48719670|NCT03444454|BEHAVIORAL|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
48719671|NCT03444454|BEHAVIORAL|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
48719672|NCT03444454|BEHAVIORAL|VRRS Khymeia plus active tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
48519776|NCT00477880|BIOLOGICAL|Cetuximab|
48519777|NCT05725551|DEVICE|ShotBlocker|"Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer."
48519778|NCT05725551|OTHER|Finger Puppet group|"During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
48383369|NCT06510114|DRUG|methylprednisolone(weekly scheme)|0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
48383370|NCT00946556|DRUG|Valacyclovir|1g po od for 2 months
48024604|NCT01921348|DEVICE|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
48024605|NCT05915065|DEVICE|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
48024606|NCT02578485|DEVICE|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
48182068|NCT03784781|BIOLOGICAL|Blood collection|Blood collection (+15mL/ current care)
48383371|NCT00946556|DRUG|Placebo|Placebo po od for 2 months
48519779|NCT05725551|OTHER|Balloon group|"An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale."
48519780|NCT02654028|PROCEDURE|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
48519781|NCT02654028|OTHER|Control group|These group of patients will not receive autotransfusion before liver resection.
48719673|NCT03444454|BEHAVIORAL|VRRS Khymeia plus placebo tDCS|"Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.~The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
48719674|NCT02049619|DEVICE|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
48719675|NCT02126072|DIETARY_SUPPLEMENT|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
48719676|NCT02126072|DIETARY_SUPPLEMENT|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
48719677|NCT03851419|DIAGNOSTIC_TEST|Diagnosis of (Neuro)cysticercosis|"* Serological tests for cysticercosis~* Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~* Stool testing for T. solium"
48719678|NCT05077358|PROCEDURE|Intracorporeal anastomosis|In this group, the anastomosis is performed inside the abdominal cavity with a laparoscopic technique. Specimen extraction will be done through Pfannenstiel incision or similar incision in lower abdomen.
48719679|NCT05077358|PROCEDURE|Extracorporeal anastomosis|In this group, the anastomosis is performed by pulling out the bowel through a laparotomy.
48182069|NCT03784781|BIOLOGICAL|Bronchoalveolar lavage|Bronchoalveolar lavage fluid (3mL/Kg)
48383372|NCT00529165|PROCEDURE|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
48383373|NCT04769830|OTHER|Bowel sound|The characteristic data of bowel sounds, such as 24-hour average intestinal rate, duration of gastrointestinal sounds, amplitude, maximum frequency and average frequency, were collected to observe the differences of intestinal sounds among different AGI grades.
48383374|NCT06633757|DRUG|RCT1100|mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
48383375|NCT01054209|DEVICE|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm"
48383376|NCT06652061|DIAGNOSTIC_TEST|Dual Energy X-Ray Absorptiometry Scan (DEXA Scan)|"A DEXA scan, or Dual-Energy X-ray Absorptiometry, is a specialized imaging technique used to measure Bone Mineral Density (BMD). It is commonly employed to diagnose osteoporosis and assess the risk of fractures, especially in areas prone to bone density loss, such as the spine, hip, and forearm. The scan works by using two low-energy X-ray beams that pass through the bone, allowing it to differentiate between bone and soft tissue and calculate the bone's density. DEXA is considered the gold standard for osteoporosis diagnosis due to its high accuracy and precision.~The DEXA scan is a non-invasive, out-patient and painless procedure. Patients lie on an examination table while the scanner passes over the targeted area, typically the hip and spine. The entire procedure is straightforward, taking around 10 to 30 minutes depending on the areas being scanned."
48719680|NCT04102722|DEVICE|MUST device|Imaging with MUST device
48719681|NCT01968057|DRUG|Baricitinib|Administered orally
48719682|NCT01968057|DRUG|Ciclosporin|Administered orally
48719683|NCT02604758|BEHAVIORAL|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
48719684|NCT02795312|BEHAVIORAL|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
48719685|NCT05077462|DRUG|C52R1M Tab. and C52R2 Tab.|Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
48719686|NCT05077462|DRUG|AJU-C52H|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
48719687|NCT02144831|DRUG|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
48719688|NCT02989129|BEHAVIORAL|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
48719689|NCT02989129|DRUG|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
48182070|NCT04443478|PROCEDURE|Radical gastrectomy with dissection of lower mediastinal lymph node|Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.
48719690|NCT01694719|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|
48719691|NCT01694719|BEHAVIORAL|Cognitive Control Training|
48719692|NCT04287088|DIAGNOSTIC_TEST|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
48182071|NCT05668299|DEVICE|TrachFlush|See detailed description previously entered.
48182072|NCT02546947|OTHER|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
48182073|NCT00234897|DRUG|adalimumab|
48024607|NCT02578485|DEVICE|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
48383377|NCT06652061|DIAGNOSTIC_TEST|X-Ray (Hip and Spine)|Hip and spine X-rays are specific types of radiographic imaging used primarily to evaluate bone health, joint integrity, and alignment in these crucial areas. In the context of osteoporosis assessment, hip and spine X-rays can reveal signs of bone thinning or fractures, serving as an initial screening tool before more detailed imaging like a DEXA scan. During a hip X-ray, the patient typically lies on an examination table with the hip positioned for a clear view of the pelvis and femur. In a spine X-ray, the patient's posture may vary, often lying on the table in either a supine or lateral position to capture views of the vertebrae in the lower back (lumbar spine). Patients may be asked to remain very still, or even hold their breath momentarily, to prevent motion blur, which can obscure important details. Both hip and spine X-rays are quick and painless, generally taking only a few minutes, with the X-ray exposure itself lasting less than a second.
48383378|NCT05032573|DIETARY_SUPPLEMENT|Olive oil and Dietary Guideline recommendations|60 mL of olive oil and healthy diet recommendations
48383379|NCT05032573|OTHER|Dietary Guideline recommendations|healthy diet recommendations
48383380|NCT06652321|PROCEDURE|Endothelial Side Up Femtosecond Laser Assisted DSAEK|"The Femto LDV Z8 laser system will be set to create a 100 μm thick graft with a 7.5 mm diameter.~The graft will be inverted, placed endothelial side up in the anterior chamber, and coated with Viscoat. A fixation ring will center the graft by holding the scleral rim with forceps.~After cutting, the cornea should remain endothelium-up, stained with Trypan Blue, and dissected using a blunt spatula. The graft will be placed on a Busin glide and coated with Viscoat.~A 3-4 mm corneal incision will be made, and Descemet's membrane will be marked and stripped. The graft will be inserted using the Busin glide, spreading automatically. A small air bubble will fill the anterior chamber to compress the graft for 10 minutes."
48182074|NCT05338697|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation (TMS)|No intervention used. This study is using TMS to obtain motor evoked potential (MEP), a prognostic biomarker. The TMS procedure is being conducted during the first week of hospitalization, which required registration under an IDE. Only TMS devices that have received 510(k) clearance from the FDA are used in this study, consisting of MEGA-TMS and MagStim 200-2.
48182075|NCT03019081|DRUG|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
48182076|NCT03019081|OTHER|placebo|placebo
48182077|NCT05987020|OTHER|Aromatherapy|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil."
48182078|NCT05223868|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
48182079|NCT05223868|DRUG|Placebo|Placebo tablet will be administered orally.
48182080|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use supplementary food (RUSF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf
48182081|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
48182082|NCT01457274|OTHER|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80)."
48182083|NCT01663038|DRUG|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
48182084|NCT01663038|DRUG|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
48182085|NCT01663038|DRUG|Aspirin|
48182086|NCT00281320|DRUG|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
48182087|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
48383381|NCT00136565|DRUG|Velcade|1.5 mg/m², D1, D5, 4 cycles
48383382|NCT00136565|DRUG|Doxorubicin|75 mg/m², D1, 4 cycles
48024608|NCT02578485|DEVICE|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
48024609|NCT02578485|DEVICE|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
48182088|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
48182089|NCT04003194|OTHER|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
48024610|NCT02578485|DEVICE|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
48719693|NCT01009190|DRUG|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
48719694|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
48024611|NCT03178734|DEVICE|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
48024612|NCT01218646|BIOLOGICAL|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
48024613|NCT01218646|BIOLOGICAL|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
48383383|NCT00136565|DRUG|Prednisone|60 mg/m², D1-D5, 4 cycles
48383384|NCT00136565|DRUG|Cyclophosphamide|1200 mg/m², D1, 4 cycles
48383385|NCT00136565|DRUG|Vindesine|2 mg/m², D1, D5, 4 cycles
48383386|NCT00136565|DRUG|Bleomycin|10 mg, D1, D5, 4 cycles
48383387|NCT04511975|DRUG|IBI188|IBI188: 100 mg/mL, intravenous infusion once a week
48383388|NCT04511975|DRUG|Azacitidine|Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle
48383389|NCT01907516|DEVICE|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
48719695|NCT01009190|DRUG|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
48024614|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
48024615|NCT01218646|BIOLOGICAL|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
48182090|NCT04003194|OTHER|Green Beans - control|The control was 1/2 cup of green beans each day.
48182091|NCT00475644|DRUG|Enzastaurin|Administered orally
48182092|NCT02043743|BIOLOGICAL|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
48383390|NCT01907516|BEHAVIORAL|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
48383391|NCT04027634|OTHER|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
48383392|NCT05879796|DRUG|cis-platinum|chemotherapeutics
48024616|NCT01722591|DEVICE|Cardiapex device|Cardiapex percutaneous transapical access and closure system
48024617|NCT02591693|BEHAVIORAL|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
48024618|NCT00930358|DRUG|MEOPA|anaesthetic gaz inhalation
48024619|NCT00930358|DRUG|general anaesthesia|Anaesthetic intravenous route
48719696|NCT01009190|DRUG|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
48719697|NCT06182241|BEHAVIORAL|Retention in cervical cancer care intervention|Aim 1 data will inform this intervention, however the participant intervention will likely be one or two sessions, conducted in-person, coupled with text- or phone-based client navigation with women who received abnormal high-risk Pap smear results. We anticipate that the intervention may integrate (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) motivational interviewing to assess pros and cons of attending a follow-up appointment and completing treatment; (3) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (4) problem-solving to increase social support, and (5) patient navigation tools to mitigate clinic-level challenges.
48719698|NCT05173961|OTHER|Internet-Based Intervention|Use oncpatient mobile application
48719699|NCT05173961|OTHER|Survey Administration|Complete survey
48719700|NCT05261581|PROCEDURE|Erector Spinae Plane Block|Erector spinae block (ESB) is an ultrasound-guided interfascial plane block. The local anesthetic is injected using ultrasound guidance superficial to transverse process and deep to erector spinae muscle group
48719701|NCT05261581|DRUG|NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
48719702|NCT05261581|BEHAVIORAL|Home Exercise Programme|Home exercise programme will include some stretches that aid in pain relief by helping take stress off the low back and hips, core stabilization exercises and postural exercises.
48024620|NCT03556761|DRUG|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
48024621|NCT03556761|DRUG|Placebo Oral Tablet|Placebo, PO, daily
48024622|NCT01903278|DRUG|PEG-IFN-SA /RBV|
48024623|NCT01903278|DRUG|Pegasys /RBV|
48024624|NCT00217789|PROCEDURE|Bronchoalveolar Lavage and Venipuncture|
48024625|NCT01115439|DRUG|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
48024626|NCT02418546|BEHAVIORAL|In-Person Nutritional Counseling by a Registered Dietitian|
48024627|NCT02418546|BEHAVIORAL|Nutritional counseling using an e-Health Application|
48719703|NCT00034879|DRUG|ZD1839 (Gefitinib)|
48719704|NCT04667416|BIOLOGICAL|PalinGen Flow Amniotic Tissue Allograft|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
48719705|NCT00002807|RADIATION|radiation therapy|45 Gy in 25 fractions over 5 weeks
48182093|NCT04833478|BEHAVIORAL|Anxiety|Techniques used to reduce anxiety in paediatric patients.
48719706|NCT02428413|DEVICE|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
48719707|NCT02428413|DEVICE|Standard oxygen mask|Provide supplemental oxygen
48719708|NCT05996042|BEHAVIORAL|Time-restricted diet|"On Tuesdays, Thursdays and Saturdays, only eating is allowed between 7am and 3pm. The rest of the time, only drinking pure water is allowed, which is an eight-hour eating window and a 16-hour fasting period.~On Mondays, Wednesdays and Fridays, under the unified guidance of the physical education teachers of the Health Science Department from 6:00 PM to 7:00 PM, the venue is the gymnasium and sports field of Peking University Health Science Center. The exercise items include aerobics, yoga and comprehensive physical training."
48719709|NCT02675335|DRUG|Sitagliptin|
48719710|NCT02675335|DRUG|Placebo|
48519782|NCT05204706|OTHER|MyManis app|The women will receive a brochure outlining the app features and step guide on how to download the app which will be available in both Bahasa Melayu and English languages. A link to download the app via text message will also be sent to participants for convenience. Once the app has been downloaded, participants will be invited to set up an account. Once completed this will give them full access to the MyManis app. The key component of MyManis app content presented under six main tabs which are homepage, information, diet, exercise, wellbeing and GDM monitoring. The women will be invited to join group peer support through WhatsApp facilitated by a dietitian trained in motivational interviewing. The women will be notified via text message if an update of the app is required. If there's women who have not accessed the app for over a two-week period will be flagged and a notification will be sent via the app to motivate app engagement.
48719711|NCT03864393|OTHER|Multimodal overground locomotor training|Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
48719712|NCT02017522|DEVICE|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
48719713|NCT02096263|BIOLOGICAL|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
48719714|NCT02096263|BIOLOGICAL|Pediarix|3 doses administered intramuscularly in the right thigh
48024628|NCT04696796|PROCEDURE|Mediolateral Episiotomy with BasIQ-4 Surgical Knife|Mediolateral episiotomy will be performed with BasIQ-4 Surgical Knife which cuts from distal to the center with inner knife.
48024629|NCT04696796|PROCEDURE|Mediolateral Episiotomy with Episiotomy Scissors|Mediolateral episiotomy will be made from the central to the distal with episiotomy scissors
48024630|NCT05219201|DEVICE|partial-body cryotherapy chamber session|"The cryotherapy procedure consisted of a 2-3 min stay in the cryotherapy chamber:~* at -30°C for sham cryotherapy session~* at -120°C for cryotherapy intervention session. For Inpatients, cryotherapy session will be performed daily, late in the afternoon, excluding saturdays and sundays, during 3 weeks. (15 sessions) For outpatient, cryotherapy session will occured late in the afternoon each day care (15 sessions)."
48024631|NCT02709967|OTHER|Material support|Writing materials
48182094|NCT04262206|DRUG|Atorvastatin 40 Mg Oral Tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
48182095|NCT04262206|DRUG|Placebo oral tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
48719715|NCT02096263|BIOLOGICAL|ActHIB|4 doses administered intramuscularly in the upper left thigh
48719716|NCT02096263|BIOLOGICAL|Pentacel|4 doses administered intramuscularly in the right thigh
48719717|NCT02096263|BIOLOGICAL|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
48719718|NCT02096263|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the right thigh
48182096|NCT02552147|DRUG|Transdermal nicotine|
48182097|NCT02552147|OTHER|Transdermal placebo|
48519783|NCT02509169|DRUG|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
48719719|NCT02096263|BIOLOGICAL|Hiberix|1 dose administered intramuscularly in the left thigh
48719720|NCT02096263|BIOLOGICAL|Prevnar13|3 doses administered intramuscularly in the lower left thigh
48024632|NCT02709967|OTHER|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
48024633|NCT02709967|BEHAVIORAL|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
48024634|NCT06129058|DEVICE|At-home transcranial direct current stimulation (tDCS)|30 minutes session 5 days/week for 3 weeks.
48024635|NCT06129058|DEVICE|Sham at-home tDCS|30 minutes session 5 days/week for 3 weeks.
48719721|NCT02096263|BIOLOGICAL|Rotarix|2 doses administered orally
48719722|NCT02049138|DRUG|Upadacitinib|Tablet taken orally
48719723|NCT02049138|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine (PCV-13)|Administered by intramuscular injection
48719724|NCT05360329|PROCEDURE|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
48182098|NCT02239744|BEHAVIORAL|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
48182099|NCT03550469|DEVICE|Computer-assisted Oxygen Weaning|Oxygen therapy weaning will be guided by a model-based computer algorithm. The computer will detect patients' oxygen saturation and made recommendations for oxygen weaning. A clinical at the bedside will make the adjustments in oxygen therapy if appropriate.
48182100|NCT05588583|DEVICE|Mepilex Up|"Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~* a soft silicone wound contact layer (Safetac)~* a flexible absorbent pad of compressed polyurethane foam~* an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane"
48719725|NCT04689971|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
48519784|NCT02509169|OTHER|TAE|Trans-catheter embolization
48719726|NCT04689971|DRUG|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
48719727|NCT00460590|BIOLOGICAL|MVA 85A|ID vaccine
48719728|NCT01167907|DEVICE|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
48024636|NCT03870230|DEVICE|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
48182101|NCT04268056|DIAGNOSTIC_TEST|Collection of skin culture samples|Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
48182102|NCT00550212|DRUG|neratinib|HKI-272, Single-dose capsule and solution
48719729|NCT01167907|DRUG|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
48719730|NCT05330858|DRUG|ESK-001|Oral tablet or liquid
48719731|NCT05330858|DRUG|Rabeprazole|Oral Tablet
48719732|NCT05451355|BEHAVIORAL|Family Safety Check-In|Prototype decision aid to support within-family communication and decision making about firearm storage.
48519785|NCT05977023|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of bipolar depression
48519786|NCT05977023|DRUG|Placebo Cap|Use of placebo as a comparator.
48519787|NCT05934227|DRUG|Amoxicillin 500 milligrams capsules plus metronidazole 400 milligrams|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of amoxicillin (500 milligrams) + metronidazole (400 milligrams) three times a day for 7 days after SRP
48519788|NCT05934227|OTHER|placebo|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of placebo containing corn starch capsules three times a day for 7 days after SRP
48519789|NCT00795652|BEHAVIORAL|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
48519790|NCT04760717|DRUG|Spironolactone Pill|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
48024637|NCT03870230|DEVICE|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
48024638|NCT03870230|DEVICE|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
48024639|NCT03870230|DEVICE|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
48719733|NCT05451355|BEHAVIORAL|AAP Firearm Storage Web Page|Educational web page that discusses safe firearm storage practices.
48719734|NCT05291559|DIETARY_SUPPLEMENT|Enterade|Enterade is a glucose-free, amino acid-based medical food containing specific amino acids (aspartic acid, valine, serine, threonine and tyrosine) in addition to electrolytes and a non-sugar sweetener.
48719735|NCT05291559|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical product to Enterade except without added amino acids.
48719736|NCT06365138|BEHAVIORAL|Bahaviour at the time of an aortic aneurysm rupture|Questionnaire and patient interview, diary for day of rupture and the three previous days
48719737|NCT06403878|DRUG|Carboplatin|neoadjuvant chemotherapy，2cycles.
48719738|NCT06403878|DRUG|Nab paclitaxel|neoadjuvant chemotherapy，2cycles.
48719739|NCT06403878|DRUG|Sintilimab|neoadjuvant immunotherapy，2cycles.
48719740|NCT04069923|OTHER|Magnesium-based Bone Void Filler|Given intraoperatively
48024640|NCT03870230|DEVICE|Laser Speckle Flowgraphy (LSFG)|to assess retinal blood flow, LSFG will be performed
48719741|NCT01022359|DEVICE|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
48719742|NCT01022359|DEVICE|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
48719743|NCT05113667|OTHER|Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program|Clinical pharmacist provided medication reconciliation and medication review during the hospital stay.
48719744|NCT05119140|DRUG|Hydroxychloroquine|400mg of hydroxychloroquine per oral daily
48719745|NCT05119140|DRUG|Mesalamine|the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
48719746|NCT02117635|BIOLOGICAL|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
48719747|NCT05792566|OTHER|Atomic app|Using the Atomic app to improve physical activity
48719748|NCT04597671|DRUG|Durvalumab|Durvalumab is used as standard of care
48719749|NCT04597671|RADIATION|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
48519791|NCT04012567|DEVICE|Investigational device: Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.
48519792|NCT04012567|DEVICE|Control device: BIOSURE HA Interference Screw|BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
48519793|NCT04960592|DEVICE|Spinal Cord Stimulation|Temporary implantation of a clinical available neurostimulator.
48719750|NCT00381875|BIOLOGICAL|E1M184V peptide vaccine|
48719751|NCT00381875|BIOLOGICAL|incomplete Freund's adjuvant|
48719752|NCT00381875|BIOLOGICAL|sargramostim|
48719753|NCT00381875|OTHER|immunoenzyme technique|
48719754|NCT01453517|BEHAVIORAL|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
48719755|NCT01883648|DRUG|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
48719756|NCT01883648|OTHER|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
48719757|NCT05829863|BEHAVIORAL|educational message exposure|Exposing African American young adult vapers to persuasive anti-vaping public service announcements (PSAs) with the goal of reducing their subsequent e-cigarette use.
48719758|NCT01528748|BEHAVIORAL|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
48719759|NCT00238459|DRUG|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
48719760|NCT00238459|DRUG|multiple licensed drugs not randomized|
48719761|NCT00238459|DRUG|multiple licensed antiretroviral drugs; not randomized|
48719762|NCT00238459|OTHER|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
48719763|NCT04689152|BIOLOGICAL|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
48719764|NCT01965223|RADIATION|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
48024641|NCT05346510|PROCEDURE|ALND Group|ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
48024642|NCT01544244|PROCEDURE|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
48024643|NCT01544244|PROCEDURE|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
48024644|NCT03462667|BEHAVIORAL|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
48719765|NCT01965223|RADIATION|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
48719766|NCT03123042|PROCEDURE|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
48719767|NCT00491374|DRUG|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
48719768|NCT00491374|DRUG|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
48024645|NCT03462667|OTHER|Standard of Care|Patients receive normal pre-surgery standard of care.
48024646|NCT03000894|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
48719769|NCT03842683|OTHER|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
48024647|NCT05616130|OTHER|Data Collection|Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
48024648|NCT05616130|PROCEDURE|Bone marrow collection and blood collection|At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
48024649|NCT05616130|OTHER|Serial interviews to complete surveys and questionnaires|Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
48024650|NCT05616130|OTHER|Telephone follow up call|The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
48024651|NCT01187238|DRUG|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
48024652|NCT06168643|OTHER|Core stability|Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.
48024653|NCT06168643|OTHER|Core stability with pregnancy support belt|Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
48024654|NCT04547972|OTHER|Higher-load resistance training|This intervention will have one arm and one leg of each participant training with \~80% of their one repetition maximum
48024655|NCT04547972|OTHER|Lower-load resistance training|This intervention will have one arm and one leg of each participant training with \~30% of their one repetition maximum
48024656|NCT01200381|OTHER|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
48024657|NCT01200381|OTHER|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
48024658|NCT01200381|OTHER|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
48024659|NCT01863017|DEVICE|tDCS|
48024660|NCT01924936|BEHAVIORAL|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
48024661|NCT05360238|BIOLOGICAL|MB-106|T-cells derived from autologous leukapheresis that are genetically modified.
48024662|NCT06119659|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
48024663|NCT06119659|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
48024664|NCT06119659|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
48024665|NCT03891524|DRUG|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
48519794|NCT02829645|OTHER|Clinical assessment|Clinical assessment with questionnaires
48519795|NCT02766270|DRUG|Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
48519796|NCT02766270|RADIATION|Radiotherapy|
48719770|NCT00003847|DRUG|biricodar dicitrate|
48719771|NCT00003847|DRUG|doxorubicin hydrochloride|
48719772|NCT00003847|DRUG|vincristine sulfate|
48719773|NCT01012752|BIOLOGICAL|modified allergen extract|subcutaneous injections
48719774|NCT01012752|BIOLOGICAL|Placebo|subcutaneous injections
48024666|NCT03891524|DRUG|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
48719775|NCT02338375|BIOLOGICAL|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
48719776|NCT02230683|DRUG|IDN-6556|25 mg BID
48719777|NCT02713516|OTHER|Virtual Reality|Use of virtual reality to deliver exposure therapy
48024667|NCT03891524|DRUG|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
48024668|NCT03891524|DRUG|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
48024669|NCT03891524|DRUG|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
48024670|NCT03891524|DRUG|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
48024671|NCT04911543|DRUG|[18F]-JNJ-70099731|\[18F\]JNJ-70099731 injection will be administered intravenously.
48024672|NCT04420299|DRUG|Bemiparin|Bemiparin at therapeutic dose for 10 days
48024673|NCT04420299|DRUG|Bemiparin|Bemiparin at prophylactic dose for 10 days
48182103|NCT02083601|BEHAVIORAL|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
48182104|NCT02083601|BEHAVIORAL|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
48024674|NCT02765945|OTHER|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
48024675|NCT02919852|PROCEDURE|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
48024676|NCT05194410|BEHAVIORAL|First 3 months of virtual, team-based exercise|Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
48024677|NCT05194410|BEHAVIORAL|Second 3 months of virtual, team-based exercise|Same as above
48024678|NCT01653431|DEVICE|Transcranial direct current stimulation|
48519797|NCT00814476|OTHER|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
48519798|NCT00814476|OTHER|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
48024679|NCT01722331|DRUG|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
48719778|NCT05569694|OTHER|Movement-based pelvic health education|A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
48719779|NCT03947970|DRUG|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
48719780|NCT05501314|OTHER|Early discharge with remote home monitoring.|After at least 48 hours of hospital admission, patients are discharged early with the use of remote home monitoring. During home monitoring, heartrate, respiratory rate, posture and movement are monitored every 5 minutes for at least 4 days, using a wearable sensor. Core temperature is monitored using an ear thermometer. Patients are contacted once per day by a nurse from the Virtual Monitoring Centre (VMC) to assess pancreatitis related complaints, intake of fluids and food, pain and the use of analgesics. Patients are asked to provide information to the hospital using a smartphone app.
48719781|NCT01510171|DRUG|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
48719782|NCT01510171|DRUG|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
48719783|NCT00758589|DRUG|AZD1981|Oral tablet, 50 mg twice daily
48719784|NCT00758589|DRUG|AZD1981|Oral tablet, 400 mg twice daily
48719785|NCT00758589|DRUG|AZD1981|Oral tablet, 1000 mg twice daily
48719786|NCT00758589|DRUG|Placebo|
48719787|NCT04754230|DRUG|Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)|Medication administered 15 minutes prior to end of surgery.
48719788|NCT01278316|BEHAVIORAL|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
48719789|NCT01278316|BEHAVIORAL|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
48719790|NCT00783913|OTHER|Visumotor Upper Extremity Training|Control
48719791|NCT00783913|OTHER|Anodal/Sham tDCS|Condition
48719792|NCT02022241|DRUG|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
48719793|NCT01369680|DRUG|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
48024680|NCT01722331|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
48024681|NCT01722331|DRUG|Matching Placebo|Matching placebo to tildrakizumab PFS
48024682|NCT05242679|OTHER|Myofascial release technique along with conventional physiotherapy exercises|Myofascial release technique was performed using a tennis ball along with conventional physiotherapy exercises.
48719794|NCT03770247|PROCEDURE|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
48024683|NCT05242679|OTHER|Conventional physiotherapy exercises|Conventional physiotherapy exercises were performed including the range of motion/flexibility exercises, strength training, postural control, functional exercises, and gait training.
48024684|NCT03529526|DRUG|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
48024685|NCT05189574|PROCEDURE|Endoscopic negative pressure therapy|Endoscopic placement of a sponge in/at staple line leaks under negative pressure.
48024686|NCT03111498|OTHER|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
48383393|NCT05879796|RADIATION|radiation|"External beam radiotherapy was performed using IMRT/VMAT radiotherapy with pelvic and/or extended field irradiation at a total dose of 45-50.4 Gy;1.8-2.0 Gy/f,25 -28 f. In patients with pelvic lymph node metastasis, para-aortic lymph node metastasis, and retroperitoneal lymph node metastasis, local lesions were simultaneously boosted to 60 Gy. In FIGO stage IIIB, simultaneous or late course boost to 60 Gy was given parametrially.~Brachytherapy: High dose rate (HDR) afterloading brachytherapy was used, with a total dose of 30-40 Gy and a cumulative dose of 80-85 Gy at point A/HRCTV D90; if the tumor diameter was ≥ 4 cm, the cumulative dose of ≥ 87 Gy at point A/HRCTV D90. Brachytherapy combined with external beam radiation therapy was completed within 8 weeks."
48383394|NCT05879796|DRUG|Envafolimab Injection|PD-L1 antibody
48719795|NCT03770247|PROCEDURE|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
48719796|NCT01256021|DRUG|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
48719797|NCT04065633|DRUG|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
48719798|NCT04065633|DRUG|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
48383395|NCT05879796|DRUG|Recombinant Human Endostatin Injection|angiogenesis inhibitors
48383396|NCT05857501|DEVICE|abdominopelvic computerized tomography (CT) without contrast|scan combines a series of X-ray images taken from different angles around your body and uses computer processing to create cross-sectional images (slices) of the bones, blood vessels and soft tissues inside your body. CT scan images provide more-detailed information than plain X-rays do.
48383397|NCT06653738|DRUG|Empagliflozin 25 MG|Once daily per os for 3 years
48519799|NCT00196326|DRUG|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
48024687|NCT03111498|OTHER|theory-based training programme|theory-based training programme for conducting VAD
48024688|NCT00147147|PROCEDURE|Gastrectomy with D2 or greater lymph node dissection|
48719799|NCT04065633|DRUG|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
48719800|NCT04065633|DRUG|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
48024689|NCT00147147|DRUG|Gastrectomy+ chemotherapy|
48024690|NCT03486041|BEHAVIORAL|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
48024691|NCT03486041|BEHAVIORAL|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
48024692|NCT04718246|OTHER|Dental Implants Placed In hyperlipidemia patients|"A preoperative cone beam CT (CBCT) will be performed for each patient prior to the surgery.~Surgical phase (T0):~After local anesthetics, all osteotomies will be prepared by the same operator, using a drilling speed of 1200 rpm, under copious irrigation with normal saline.~* Penetration of cortical bone will be achieved with no. 6 round burs.~* The osteotomies will be widened, using a drill 1 mm larger than the final drill provided by the manufacturer. The final size of the control osteotomies were same diameter of the implant.~* Periotest® will measure initial implant stability. Implant site exposure will take place 6 months following the implant placement. Insertion of the healing collars in order to obtain adequate soft tissue form for 1-2 weeks"
48383398|NCT06653738|DRUG|Placebo|Once daily per os for 3 years
48383399|NCT06653738|BEHAVIORAL|Personalized dietary counseling|Personalized dietary counseling based on repeat 24-hr urine collections and dietary assessments for 3 years
48383400|NCT06653738|BEHAVIORAL|Generic dietary counseling|Generic dietary counseling based on current guidelines without 24-hr urine collection results and without specific dietary assessments for 3 years
48383401|NCT00301873|DRUG|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
48383402|NCT05263869|DRUG|MRG002|Administrated intravenously
48519800|NCT02574832|DRUG|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
48519801|NCT02480517|DEVICE|Ultrasound|
48519802|NCT02480517|DEVICE|Sham Ultrasound|
48719801|NCT00068094|DRUG|Probiotic-containing powder|
48719802|NCT02482402|DRUG|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
48719803|NCT02482402|DRUG|Placebo|inhalation solution placebo
48719804|NCT02704689|DEVICE|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
48719805|NCT02274259|DRUG|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
48719806|NCT02274259|DRUG|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
48182105|NCT04707950|DRUG|Tranexamic Acid 100 milligram/Milliliter|"Participants will be divided into two groups: a study group \& a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~* Bleeding continues after 30 minutes~* Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
48383403|NCT03162276|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
48383404|NCT03162276|BEHAVIORAL|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
48519803|NCT02207634|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
48519804|NCT02207634|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
48719807|NCT02478450|BIOLOGICAL|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
48719808|NCT03569839|DRUG|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
48719809|NCT04378296|OTHER|Teledermatology|The experimental group will be made up of dermatological patients monitored asynchronously.
48719810|NCT03328858|OTHER|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
48024693|NCT04751253|DEVICE|High Intensity Laser Therapy|different doses of energies of high-intensity LASER on pain and functional activity in patients with chronic knee OA.
48024694|NCT05630716|DEVICE|NICOM|non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
48024695|NCT02125058|PROCEDURE|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
48182106|NCT04707950|DRUG|Oxytocin|both groups will be given oxytocin as a standard management
48182107|NCT05257447|DRUG|Baclofen 20 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
48719811|NCT05323071|OTHER|Sucrose 24%|"According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL"
48719812|NCT01781351|OTHER|Taping the ankle|
48719813|NCT04150692|BIOLOGICAL|Dara-SC|-Subcutaneous daratumumab and hyaluronidase-fihj
48719814|NCT04150692|PROCEDURE|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
48719815|NCT04150692|PROCEDURE|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
48719816|NCT03960723|OTHER|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
48719817|NCT03624452|OTHER|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
48719818|NCT03624452|OTHER|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
48024696|NCT02125058|PROCEDURE|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
48182108|NCT05257447|DRUG|Chlorzoxazone 500 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
48182109|NCT05257447|DRUG|Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet|Concurrent single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
48182110|NCT00730015|DRUG|Matching Placebo|Oral, once daily
48024697|NCT05919810|OTHER|Probiotic|Oral probiotic
48024698|NCT05919810|DIETARY_SUPPLEMENT|Oral herbal powder supplement|oral herbal powder
48024699|NCT02376452|DRUG|Raltitrexed|2mg/m2 iv gtt, d1
48024700|NCT02376452|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
48024701|NCT02376452|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
48024702|NCT02376452|DRUG|Leucovorin|400mg/m2 iv gtt,d1
48024703|NCT06223945|DIAGNOSTIC_TEST|Prevention algorithm|Development of an algorithm for the prevention of thrombohemorrhagic complications
48182111|NCT00730015|DRUG|Linaclotide|Oral, once daily
48182112|NCT01071837|DRUG|APG101|400mg weekly as intravenous infusion
48383405|NCT04324957|OTHER|Neonatal cardio-pulmonary outcome measure used to assess cardio-pulmonary status|Neonatal cardio-pulmonary outcome measure will be used to assess overall status of pulmonaryand cardio-vascular system
48519805|NCT02207634|DRUG|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
48519806|NCT04057729|DRUG|IMP4297|10mg/capsule.
48519807|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
48182113|NCT01071837|PROCEDURE|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
48182114|NCT02808247|DRUG|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
48383406|NCT06648226|BEHAVIORAL|Health swaps|"Participants will view health grade labels on all products in the online grocery store indicating their healthfulness as estimated by United Kingdom Ofcom Nutrient Profiling Model scores. The health score labels will mimic Nutri-Score labels, a labeling system used in some European countries, showing a color-coded grade of A (green) through F (red) on each product. Products with A and B labels will meet the United Kingdom's cutoff for products that can be marketed to children and C, D and F labels products are less healthy than this cutoff (based on tertiles of Ofcom scores within each food group). When participants attempt to add a less healthy product to their cart (e.g., C, D or F health label), the store will automatically suggest a healthier product from the same category (e.g., with a A or B health label)."
48383407|NCT06648226|BEHAVIORAL|Environment swaps|"Participants will view climate grade labels on all products indicating their climate impact. The climate impact is calculated as the greenhouse gas emissions associated with producing the product in carbon dioxide equivalents (CO2-eq) per 100g (i.e., carbon footprint). Labels will be applied based on quintiles of carbon footprints in each food group. When participants attempt to add a high-climate-impact product to their cart (e.g., with a C, D, or F climate label), the store will automatically offer them swaps to more environmentally sustainable products (e.g., with a A or B climate label)."
48383408|NCT06648226|BEHAVIORAL|Combined health and environment swaps|"Participants will view both the health and climate grade labels on all products in the online grocery store. When participants attempt to select a product with a C, D, or F label on either dimension to their cart, the store will automatically offer them swaps to products that offer improvement over the original food on at least 1 dimension (health or environmental sustainability) and were at least as good or better on the other dimension, with the additional guardrail that the store never suggests products with a C, D or F label on either dimension."
48383409|NCT06648226|BEHAVIORAL|Control|Participants will not view any extra labels or be offered any swaps in the online grocery store.
48383410|NCT02317523|BEHAVIORAL|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
48719819|NCT01270152|DRUG|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
48024704|NCT05269264|DIAGNOSTIC_TEST|Assessor A (first measurement): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
48182115|NCT02808247|DRUG|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
48182116|NCT00004060|DRUG|exatecan mesylate|
48182117|NCT06028490|BIOLOGICAL|GR1802 injection-1|subcutaneous，dose\*1
48182118|NCT06028490|BIOLOGICAL|GR1802 injection-2|subcutaneous，dose\*2
48182119|NCT06028490|BIOLOGICAL|Placebo|subcutaneous，dose\*2
48182120|NCT02981927|OTHER|Physical inactivity|
48182121|NCT02373540|DEVICE|Algovita Spinal Cord Stimulation system|
48719820|NCT00629473|DRUG|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
48719821|NCT00629473|DRUG|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
48182122|NCT04592094|DEVICE|Blueback® Physio|Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
48182123|NCT01831037|OTHER|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (\>50% of cases).
48719822|NCT00629473|DRUG|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
48719823|NCT00554762|DRUG|GW842166X|Administer
48719824|NCT06387199|DRUG|Semaglutide with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
48719825|NCT06387199|DRUG|Placebo with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
48719826|NCT04273022|OTHER|Exercise|A single bout of standardized, moderate exercise
48024705|NCT05269264|DIAGNOSTIC_TEST|Assessor B: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
48519808|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
48719827|NCT04093804|DEVICE|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
48024706|NCT05269264|DIAGNOSTIC_TEST|Assessor A (second measurement: measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist
48719828|NCT03203733|DEVICE|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
48719829|NCT03203733|OTHER|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
48719830|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
48024707|NCT05269264|DIAGNOSTIC_TEST|Assessor A (2 weeks later): measurement methods and questionnaires for the assessment of LLL|pitting test at the level of the foot, leg and midline region; skinfold test at the level of the foot, leg and midline region; skin hardness test at the level of the foot, leg and midline region; measurement with MoistureMeterD at the level of the foot, leg and midline region; measurement with SkinFibroMeter at the level of the foot, leg and midline region; circumference measurements at the level of the leg and midline region; perometry at the level of the leg; water displacement measurement at the level of the foot; measurements with bio-impedance spectroscopy/analysis devices at the level of the lower limbs and a questionnaire regarding skin integrity (ICC compression questionnaire) that should be completed by the therapist and a self-reported disease-specific quality of life questionnaire (Lymph-ICF-LL) that is completed by the patient at the end of this evaluation
48024708|NCT00447863|DRUG|Levonorgestrel/Ethinyl Estradiol|
48182124|NCT01831037|OTHER|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
48383411|NCT02317523|BEHAVIORAL|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
48383412|NCT05917938|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
48383413|NCT00331929|DEVICE|Minato A 500 AS spirometer|Spirometry at rest
48383414|NCT00506558|PROCEDURE|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
48719831|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
48719832|NCT01459367|DRUG|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
48719833|NCT06508736|BEHAVIORAL|Storytelling|It is aimed that adolescents gain behavioral change through stories.
48519809|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
48719834|NCT06508736|BEHAVIORAL|Training|Participants will be trained on cyberbullying in 4 sessions.
48719835|NCT00885482|DRUG|Lamiduvine (Epivir)|Epivir 300 mg
48719836|NCT00885482|DRUG|Atazanavir (Reyataz)|Reyataz 300 mg
48719837|NCT00885482|DRUG|Ritonavir (Norvir)|Norvir 100 mg
48719838|NCT04375176|DIAGNOSTIC_TEST|Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2|Phenotypic and functional analysis of monocytes and NK cells
48719839|NCT04147533|DRUG|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
48383415|NCT00506558|PROCEDURE|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
48519810|NCT03889886|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
48519811|NCT01427699|DRUG|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
48519812|NCT04328701|BEHAVIORAL|Mindfulness-based Cognitive Behavioral Therapy|Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
48519813|NCT00261443|DRUG|Lithium or Valproate with placebo (PBO)|"Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily"
48519814|NCT00261443|DRUG|Lithium or Valproate with Aripiprazole|"Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day"
48519815|NCT03993379|DRUG|CX-072|CX-072 in combination with ipilimumab
48519816|NCT03993379|DRUG|Ipilimumab|CX-072 in combination with ipilimumab
48519817|NCT02103855|DRUG|Belatacept|
48519818|NCT05012020|DEVICE|mHealth Remote Monitoring platform|Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
48519819|NCT05294250|DRUG|XC8|XC8 10 mg film-coated tablets, 3 discrete doses of 20 mg each separated by 7-day wash-out periods
48719840|NCT04147533|DRUG|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
48719841|NCT04147533|DRUG|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
48719842|NCT02037490|BEHAVIORAL|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
48719843|NCT05037084|OTHER|no intervention|no intervention
48383416|NCT04695210|BEHAVIORAL|Virtual peer-to-peer support|See arm description
48383417|NCT05344391|OTHER|BFR cycling|Cycling with BFR followed by shoulder exercises
48383418|NCT05344391|OTHER|Cycling without BFR|Cycling without BFR followed by shoulder exercises
48383419|NCT05419687|BEHAVIORAL|Training in de-escalating violence|"* Individual educational component through a de-escalating violence training for health care workers (verbal and non-verbal de-escalating techniques)~* Refreshment training in the form of collaborative learning"
48383420|NCT05419687|BEHAVIORAL|Code of conduct delivered via a warning board|A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
48383421|NCT01819467|DEVICE|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
48383422|NCT05417009|DEVICE|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
48383423|NCT03373825|BEHAVIORAL|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
48383424|NCT06649214|DRUG|Olanzapine-samidorphan；|orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.
48383425|NCT06649214|DRUG|Olanzapine|orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
48383426|NCT04905238|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure
48383427|NCT05243810|DEVICE|EPC Silver Wound Gel|Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application.
48383428|NCT05167994|DRUG|Anlotinib hydrochloride|Anlotinib 12mgQD, from D1 of pre-operative IMRT to 1 month after end of IMRT
48383429|NCT04034524|DRUG|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
48383430|NCT04034524|DRUG|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
48383431|NCT00973167|DEVICE|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
48383432|NCT05978817|DEVICE|Damon Ultima bracket|It is metal twin bracket with their recommended arch wire
48024709|NCT01478945|DEVICE|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
48024710|NCT02162810|DRUG|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
48024711|NCT02162810|DRUG|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
48024712|NCT01772953|DRUG|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
48024713|NCT00439777|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
48024714|NCT00439777|DRUG|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
48024715|NCT02431975|DRUG|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
48024716|NCT02431975|DRUG|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
48182125|NCT06161337|DIETARY_SUPPLEMENT|Meals|"Each subject will participate in 4 visits with a 1-week washout period in between visits.~Each visit will be either a morning or evening consumption of either a standardized mixed meal of containing 600 calories (standard control) or 2400 calories (overeating meal) - meals will have the same nutrient composition."
48182126|NCT02185547|DRUG|Zoloft|Sertraline treatment 25 mg
48519820|NCT06376058|DRUG|Chloroprocaine 1% Injectable Solution|• in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
48519821|NCT06376058|DRUG|Ropivacaine 0.75% Injectable Solution|• in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
48519822|NCT06388005|OTHER|emotional freedom technique (EFT)|The emotional freedom technique (EFT), founded by American scholar Gary Craig, is based on the methods of meridian science in traditional Chinese medicine (TCM) and Western psychology. Guided by the TCM theory of meridians, it quickly releases negative emotions by combining acupoint stimulation with neuro-linguistic programming, and its effectiveness has been confirmed by multiple studies.
48519823|NCT05808322|DRUG|Ropeginterferon alfa-2b|A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.
48719844|NCT05339282|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
48719845|NCT05330793|DIETARY_SUPPLEMENT|Oral probiotic|an oral probiotic intervention with or without a novel ADP1 toothpaste
48719846|NCT05330793|DIETARY_SUPPLEMENT|Placebo|placebo without Oral probiotic or toothpaste
48719847|NCT04825067|DEVICE|Respiratory Sensor measurements|The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
48719848|NCT05686096|DRUG|MYK-224|Specified dose on specified days
48719849|NCT00447473|DRUG|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
48719850|NCT00447473|DRUG|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
48719851|NCT00447473|DRUG|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
48182127|NCT02185547|BEHAVIORAL|ICBT|Internet behavioral cognitive therapy only
48182128|NCT05865522|OTHER|Trapezius Massage|The patients in Trapezius Massage Group will be given classical massage to the trapezius muscle for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
48383433|NCT00761735|BIOLOGICAL|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
48383434|NCT00761735|DRUG|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
48383435|NCT01829659|DRUG|Ticagrelor|
48719852|NCT02318290|DRUG|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
48719853|NCT06464861|BIOLOGICAL|CD19-CAR-NK/T|Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
48719854|NCT06256146|OTHER|Food allergy desensitization / Oral Immunotherapy|"Participants consume increasing doses of allergenic food daily until they reach a maintenance dose. In the case of the High Dose Arm, participants will progress to a daily dose of either 1200 mg, 300 mg or 200 ml of egg, peanut or milk respectively.~Participants randomized to the Low Dose Arm also begin by consuming small amounts of the allergenic food, gradually increasing the daily dose. However, participants in this group only progress to 300 ml, 30 mg or 50 ml daily dose of egg, peanut or milk respectively.~The Cooked/Transformed Allergen Arm begins the desensitization with a cooked or transformed form of the allergen - muffins in the case of egg or milk, Bamba puffs in the case of peanut. Participants take increasing amounts of these products (one muffin for egg and milk and four Bamba puffs for peanut) then transition to egg, milk or peanut. Participants then continue their dose progression, getting to 1200 mg, 200 ml or 300 mg for egg, milk and peanut respectively."
48719855|NCT05274360|BEHAVIORAL|Mobile evidence-based aphasia therapy|Use of mobile application to practice language for 2 weeks with a recommendation of 2 sessions per day of 20 minutes. The Android application, which is a Unity-based 2D game, will be installed on the patient's own phone, and they will play individually with the support of a family member if needed. The patients are free to start and stop using the application at any time. The application is safe to use, and it consists of therapeutic training methods such as object-matching, word search, writing, and manual voice recordings.
48719856|NCT05274360|BEHAVIORAL|Conventional aphasia rehabilitation|Control Group (conventional aphasia rehabilitation). No therapy as patients are in the chronic stage, where they do not receive healthcare rehabilitation training.
48719857|NCT03921333|DIETARY_SUPPLEMENT|Low dose response efficacy of plant extracts|300mg
48719858|NCT03921333|DIETARY_SUPPLEMENT|Middle dose response efficacy of plant extracts|500mg
48719859|NCT03921333|DIETARY_SUPPLEMENT|High Dose response efficacy of plant extracts|700mg
48719860|NCT03921333|DIETARY_SUPPLEMENT|Placebo|Cellulose microcrystalline
48719861|NCT01293981|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
48719862|NCT05639881|BEHAVIORAL|Enhancing Your Immune Health|In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
48182129|NCT05865522|OTHER|Foot Massage|The patients in Foot Massage Group will be given foot massage for 6 weeks, 2 sessions per week (12 sessions in total) by the researcher in the physical therapy unit.
48182130|NCT03538782|PROCEDURE|Percutaneous biliary drainage|The initial puncture of the bile duct with an access needle is performed by ultrasound guidance or by fluoroscopic guidance. After injection of the radiopaque contrast media into the bile duct system the rest of the examination is performed by fluoroscopic guidance. All different PTBD procedures are analyzed: insertion, exchange or removal of a plastic catheter, metal stent implantation, PTBD with cholangioscopy, PTBD with ballon dilatation, PTBD with lithotrypsy or diagnostic percutaneous transhepatic cholangiography.
48182131|NCT00298675|DRUG|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
48182132|NCT00298675|DRUG|irinotecan|Irinotecan administered weekly, IV.
48383436|NCT05668962|DRUG|Selpercatinib|Selpercatinib Oral, twice daily during initial treatment period (28 Days). A second course of selpercatinib if the participant is demonstrating clinical benefit to the initial course selpercatinib and deemed clinically appropriate by the treating investigator
48719863|NCT05107583|BEHAVIORAL|Low-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (\<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
48383437|NCT05668962|DRUG|Sodium Iodine I-131|I-131 NaI, oral, is a standard treatment for all types of follicular-derived thyroid cancers, except anaplastic thyroid cancer
48383438|NCT05668962|DRUG|rhTSH|"RhTSH injection, dosage per protocol, timing per protocol during the initial treatment period per standard of care.~Participants may receive a second course of rhTSH if the participant is demonstrating clinical benefit to the initial course rhTSH and deemed clinically appropriate by the treating investigator."
48719864|NCT05107583|BEHAVIORAL|High-Carbohydrate Pre-Exercise Meal|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (\~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.
48383439|NCT06568289|DRUG|Lignocaine|A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
48719865|NCT05107583|BEHAVIORAL|Fasted Exercise|Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
48719866|NCT00050674|DRUG|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
48719867|NCT05463068|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
48719868|NCT01638104|DRUG|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
48719869|NCT01638104|DRUG|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
48024717|NCT02431975|DRUG|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
48719870|NCT01742065|OTHER|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
48719871|NCT03547934|DEVICE|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
48719872|NCT03559894|DIAGNOSTIC_TEST|Trans-thoracic echocardiography|Trans-thoracic echocardiography
48719873|NCT02581930|DRUG|Ibrutinib|Given PO
48719874|NCT02581930|OTHER|Laboratory Biomarker Analysis|Correlative studies
48719875|NCT02581930|OTHER|Pharmacogenomic Study|Correlative studies
48719876|NCT02581930|OTHER|Pharmacological Study|Correlative studies
48719877|NCT05570071|DEVICE|physical therapy|medical treatment of pelvic floor
48719878|NCT00319241|BEHAVIORAL|Parenting Intervention|
48719879|NCT05020964|DRUG|Trastuzumab and Pyrotinib|"Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs."
48519824|NCT05808322|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
48519825|NCT02678078|PROCEDURE|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
48719880|NCT00368121|DRUG|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
48719881|NCT00364052|DRUG|oral Valganciclovir vs oral Ganciclovir|
48024718|NCT02431975|DRUG|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
48024719|NCT00909259|DEVICE|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
48719882|NCT00478790|DEVICE|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
48024720|NCT03806738|OTHER|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
48024721|NCT03806738|OTHER|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
48024722|NCT05104398|DEVICE|Efferon CT|extracorporeal adsorbers containing mesoporous styrene-divinylbenzene copolymer to remove pro-inflammatory 6-60 kD molecules
48024723|NCT02965560|DIAGNOSTIC_TEST|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
48024724|NCT02774109|DIETARY_SUPPLEMENT|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
48024725|NCT02774109|DIETARY_SUPPLEMENT|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
48024726|NCT02774109|PROCEDURE|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
48024727|NCT02774109|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
48024728|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 1|Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
48024729|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 2|Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
48024730|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 3|Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
48024731|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 4|Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
48024732|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 6|Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
48024733|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 7|Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
48024734|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 8|Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
48024735|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 9|Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
48024736|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 10|Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
48024737|NCT05446740|BIOLOGICAL|GSK4382276A Dose level 11|Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
48024738|NCT05446740|COMBINATION_PRODUCT|FDQ21A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
48024739|NCT05446740|COMBINATION_PRODUCT|FDQ22A-NH|Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
48024740|NCT01284400|OTHER|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
48024741|NCT01557946|DRUG|citalopram|citalopram 20-40 mg daily
48024742|NCT04168749|COMBINATION_PRODUCT|Numeta G13|10 days
48024743|NCT01640301|BIOLOGICAL|Aldesleukin|Given SC
48024744|NCT01640301|DRUG|Cyclophosphamide|Given IV
48182133|NCT04928807|COMBINATION_PRODUCT|Short course radiotherapy sequential camrelizumab and chemotherapy|Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
48024745|NCT01640301|DRUG|Fludarabine Phosphate|Given IV
48024746|NCT01640301|OTHER|Laboratory Biomarker Analysis|Correlative studies
48024747|NCT01640301|BIOLOGICAL|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
48024748|NCT00013312|PROCEDURE|Determine colonic tone|
48024749|NCT02065466|DRUG|nab-paclitaxel|
48024750|NCT02065466|DRUG|Temozolomide|
48024751|NCT02065466|DRUG|Bevacizumab|
48024752|NCT01337245|DRUG|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
48024753|NCT02806986|BIOLOGICAL|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
48024754|NCT04141293|PROCEDURE|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
48719883|NCT02054793|DRUG|Itraconazole|100 mg 200 mg 300 mg
48519826|NCT00038025|DRUG|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
48519827|NCT01525017|BIOLOGICAL|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
48519828|NCT04996979|DRUG|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
48519829|NCT04996979|DRUG|Placebo|Standard care
48519830|NCT05152862|PROCEDURE|Laser|Retinal laser photocoagulation
48519831|NCT05152862|PROCEDURE|Anti VEGF|Anti-VEGF intravitreous injection
48719884|NCT02054793|DRUG|Orteronel|300 mg
48719885|NCT03443232|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
48383440|NCT06568289|DRUG|Bupivacaine|A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
48719886|NCT03443232|PROCEDURE|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
48024755|NCT05505708|DRUG|hydroxyethyl starch in sodium chloride injection Brand Name: Voluven|"(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5."
48719887|NCT01146964|PROCEDURE|MSSICS|Manual super small incision cataract surgery
48719888|NCT01146964|PROCEDURE|Phacoemulsification|cataract surgery with Phacoemulsification
48024756|NCT05505708|DRUG|saline solution|Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
48182134|NCT02548676|DEVICE|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
48182135|NCT02024295|DRUG|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
48182136|NCT02024295|DRUG|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
48182137|NCT02024295|DRUG|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
48182138|NCT04042753|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks,
48182139|NCT04042753|DRUG|Nivolumab|Nivolumab 1 mg/kg every 3 weeks for 4 cycles
48383441|NCT01278381|PROCEDURE|Pancreaticoduodenectomy|Resection of pancreatic lesion
48519832|NCT00055731|DRUG|bicalutamide|
48519833|NCT00055731|DRUG|Goserelin Acetate|
48719889|NCT00969072|DRUG|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
48719890|NCT00969072|DRUG|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
48719891|NCT00969072|DRUG|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
48519834|NCT00055731|DRUG|docetaxel|
48519835|NCT00055731|DRUG|Estramustine phosphate sodium|
48519836|NCT00055731|DRUG|acetylsalicylic acid|
48519837|NCT00055731|PROCEDURE|conventional surgery|
48519838|NCT00055731|RADIATION|radiation therapy|
48519839|NCT04967326|DRUG|Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)|
48519840|NCT04109144|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin during the 2nd of 3 total paracentesis being monitored
48519841|NCT04109144|BIOLOGICAL|Albumin|Albumin will be used during the 1st and 3rd paracentesis
48519842|NCT04109144|PROCEDURE|Large Volume Paracentesis (LVP)|All participants who have this procedure, meet eligibility criteria and who consent
48519843|NCT02827955|DEVICE|Gamma Knife® radiosurgery bilateral|
48383442|NCT04966117|BEHAVIORAL|Risk-Guided DMP|"Patients will be assigned a cardiac nurse to help manage their heart condition who will:~1. develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~2. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~3. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~4. invite participation to a supervised 6-week group exercise program which will require using our on-site gym."
48383443|NCT04966117|BEHAVIORAL|Usual Care|Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
48182140|NCT04042753|DRUG|Nivolumab|Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
48182141|NCT03017937|DEVICE|Q-collar|capture ultrasound images at each pressure point
48519844|NCT05475197|DEVICE|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
48519845|NCT06488144|BEHAVIORAL|Health coach|Health Coaching
48519846|NCT06488144|BEHAVIORAL|Remote Incentive Program|Behavioral incentive program including gamification, social incentivization, and monitoring.
48519847|NCT01892956|OTHER|Nutritional intervention|"2 dietary interventions~1. personalized diet based on algorithm predictions of glucose response to foods~2. Mediterranean-style diet"
48519848|NCT04666454|DRUG|Adenosine|Adenosine infusion 70 µg/kg/min for 3 hours.
48519849|NCT04666454|DRUG|Dipyridamole 200 mg|200 mg b.i.d
48519850|NCT04666454|DRUG|Apixaban 5 mg Oral Tablet|5mg b.i.d
48519851|NCT04666454|OTHER|Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome|This treatment will vary depending on local routines and the degree of adherence to the recommendations.
48519852|NCT04402411|PROCEDURE|Quadratus lumborum block|The patient will be placed in a lateral position with the side to be blocked facing upwards. The ultrasound probe will be properly sterilized and with sterile covers. An 18-20 gauge blunt tipped block needle or a Tuohy needle is advanced under ultrasound guidance on the posterior aspect of the Quadratus Lumborum. The QL muscle is identified with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the QL muscle adherent to the apex of the transverse process, a well recognisable pattern of a shamrock with three leaves can be seen.
48719892|NCT02541136|BEHAVIORAL|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
48719893|NCT06089941|OTHER|circulating tumoral DNA detection|blood samples taken at diagnosis, mid-treatment, end of treatment and in the event of relapse
48719894|NCT04591249|BEHAVIORAL|Physical activity intervention|Participants will 1) receive Fitbit, 2) be enrolled in a secure electronic platform to access Fitbit data, 3) receive 8-week remote counseling by a physical therapist that will include motivational interviewing and creating SMART goals (1 session per week) through a web-based teleconference platform, and 4) receive usual postoperative care directed by their surgeon. The first session will be 45 minutes and sessions 2-8 will be 30 minutes each. During the sessions, participant's confidence in meeting daily step goals will be assessed using a 0-10 scale. If self-reported confidence to meet their goal is \<8, the physical therapist will help participants modify their goal using techniques such as problem-solving, positive statements and affirmations. Progression will be made only if daily steps goals are met for at least 4 out of 7 days a week. If this weekly step goal is not met, a physical therapist will help the participant identify solutions for realistic progression.
48182142|NCT05976776|BEHAVIORAL|The Childbirth and Parenthood Preparation Education|"The Childbirth and Parenthood Preparation Education program will be applied to the experimental group for a period of 1 month (each week, once a week in total four sessions)."
48182143|NCT03745547|OTHER|Adherence to wearing a Spire wearable health monitor|Participants will wear a Spire health monitor every day for 9 months and receive weekly emails with a short survey about the participant's condition and symptoms. If participants fail to respond to this email or Spire detects that a participant is not wearing the monitor, participants will be contacted by a nurse. While participants are wearing the monitor, Spire will make sure the sensors are collecting data but will not review the data in real time. If a participant's monitor stops sending data to Spire for more than 24 hours, the participant will be contacted. If the participant is unreachable for 10 days the participant's emergency contact will be contacted. If neither the participant nor the emergency contact is reachable over 24 days the participant will be removed from the study.
48719895|NCT04591249|OTHER|Usual care|Participants will receive postoperative care as determined by their treating surgeon. This includes lifting restrictions, advice to stay active, and oral analgesics as needed. Physical therapy referral will be at the discretion of the surgeon. However, physical therapy is not typically started until 12 weeks after surgery.
48519853|NCT04402411|PROCEDURE|Transversus abdominis plane block|"The patient will be supine while performing the block and sterilization of the site of the ultrasound and needle entry will be performed.~The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest.~The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles."
48719896|NCT04190004|DRUG|Vasopressins|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
48719897|NCT04190004|DRUG|Placebo|40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
48719898|NCT05517798|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
48719899|NCT02248740|PROCEDURE|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
48024757|NCT00358735|DEVICE|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
48024758|NCT00358735|DRUG|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
48024759|NCT00907569|RADIATION|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
48024760|NCT03196765|DRUG|Sobetirome (NV1205)|Once a day oral dose of the study drug
48024761|NCT04170647|DRUG|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
48024762|NCT06573788|BEHAVIORAL|Internet + wearble device multimodal prehabilitation|Use the Prehabilitation Learning Platform to learn what to do and follow along with the videos for follow up exercises
48024763|NCT06573788|BEHAVIORAL|traditional multimodal prehabilitation|The researchers used a prehabilitation manual to explain to subjects what they needed to do, and the patients went home and practiced on their own, recording the exercises daily
48182144|NCT01821937|DRUG|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
48519854|NCT04402411|DRUG|Intravenous opioid|Patients will receive morphine 0.1 mg/kg
48719900|NCT06135363|DRUG|SC1011|SC1011 tablet
48719901|NCT06135363|DRUG|Placebo tablet|SC1011-matching placebo tablet
48719902|NCT01030185|DEVICE|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
48024764|NCT02264223|DIETARY_SUPPLEMENT|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
48024765|NCT02264223|DIETARY_SUPPLEMENT|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
48024766|NCT01025713|DRUG|GS-9411|Inhaled GS-9411
48519855|NCT01618565|PROCEDURE|Hands-On Training|one-time, 30 minute hands-on training
48519856|NCT01618565|PROCEDURE|Demonstration|30 minutes passive training
48719903|NCT00846989|DRUG|RKI983A|RKI983 0.05 % twice daily
48024767|NCT01025713|DRUG|Placebo|Inhaled Placebo
48024768|NCT03637998|BEHAVIORAL|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
48182145|NCT01821937|DRUG|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
48519857|NCT02875990|BIOLOGICAL|Blood sample|
48519858|NCT06582121|OTHER|Polysomnography|An overnight sleep study
48519859|NCT00925704|DRUG|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
48719904|NCT00846989|DRUG|RKI983A|RKI983 0.1 % twice daily
48719905|NCT00846989|DRUG|Latanoprost|Latanoprost 0.005 % once a day
48182146|NCT04432792|OTHER|Questionnaire|Study survey participants will be administered 3 online surveys.
48182147|NCT03510767|DRUG|TQ-B3525|TQ-B3525 p.o. qd
48182148|NCT03026647|PROCEDURE|Suture|To examine different types of suture material used for hysterotomy closure in cesarean section and determine if one is preferred above other types due to a complications profile.
48182149|NCT01672138|PROCEDURE|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
48182150|NCT01672138|PROCEDURE|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
48182151|NCT01672138|PROCEDURE|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
48182152|NCT04816864|DIAGNOSTIC_TEST|extracardiac vagal nerve stimulation (ECANS) + EPS|"The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~1. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~2. ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~3. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing."
48182153|NCT03218566|DEVICE|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
48182154|NCT03622255|PROCEDURE|MINST|Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.
48182155|NCT03622255|PROCEDURE|MINST with EMD|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
48182156|NCT02872389|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
48182157|NCT02872389|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
48182158|NCT02314351|DRUG|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
48182159|NCT02314351|DRUG|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
48182160|NCT02314351|DRUG|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
48182161|NCT00490698|DRUG|Zoledronate|4 mg IV Once Every 4 Weeks
48182162|NCT00490698|DRUG|Atorvastatin|20 mg PO Daily
48182163|NCT03135106|DRUG|Erdafitinib|A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.
48182164|NCT03135106|DRUG|Fluconazole|A 400-mg fluconazole orally (4\*100 mg capsules) will be administered from Day 1 to Day 11.
48182165|NCT03135106|DRUG|Itraconazole|A 200-mg itraconazole orally (2\*100 mg capsules) will be administered from Day 1 to Day 11.
48182166|NCT05205070|BIOLOGICAL|Rosnilimab|humanized monoclonal antibody
48182167|NCT05205070|BIOLOGICAL|Placebo|Placebo solution
48182168|NCT03267810|DEVICE|TENS|TENS: TENS 7000 - : TENS applies low-level electrical current via four pads, 2 pads affixed paraspinally, at the level of the spinal cord injury, and 2 affixed on the ventral side to areas within the dermatome corresponding to the level of injury. 15 minutes of high frequency followed by 15 minutes of low frequency will be applied at each session
48182169|NCT03267810|OTHER|Sham TENS|Inactive electrodes - for two 15 minute trials, neither high nor low frequency.
48182170|NCT04292470|DRUG|Amitriptyline|Amitriptyline tablet
48182171|NCT03178045|OTHER|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
48383444|NCT01100398|PROCEDURE|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
48719906|NCT05553275|PROCEDURE|Usual Care|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely managed with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor. Blood sugars of more than 110 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour. If blood sugar 111-140, insulin drip at 1 unit/hour will be given and continued if blood sugar is 111-140.If blood sugar is 141-180, then drip will be changed to to 1.5 unit/hour and if blood sugar is 181-220, drip will be changed to 2.0 units/hour and MD will be called if blood sugar is more than 221 mg/dl"
48519860|NCT00925704|DRUG|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
48519861|NCT00925704|DRUG|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
48719907|NCT05553275|PROCEDURE|Permissive intrapartum glucose control|"Blood sugar evaluation (accuchecks) every four hours in latent labor and every 2 hours in active labor.Participants will be routinely management with maintenance fluids of lactated ringers during latent labor and lactated ringers with dextrose 5% in active labor.Blood sugars of more than 180 mg/dl at any time point in labor will be treated with an insulin drip as follows:~Regular insulin (100 units) in 100cc of normal saline, with Lactated Ringers with 5% dextrose at 125cc/hour.If blood sugar is 181-200, insulin drip at 1 unit/hour will be given. If blood sugar is 201-220, then drip will be changed to 1.5 units/hour. If blood sugar is 221 - 250, then drip will be changed to 2.0 units/hour and if blood sugar is more than 251 MD will be called."
48719908|NCT04073160|DRUG|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
48519862|NCT04658914|BIOLOGICAL|Rotarix|Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10\^6 CCID50(median cell culture infective doses) of G1P\[8\] rotavirus, RIX4414 strain produced in Vero cells. This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
48719909|NCT04073160|DRUG|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
48719910|NCT04073160|RADIATION|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
48383445|NCT05612971|BEHAVIORAL|iAmHealthy Parents First|iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.
48383446|NCT05612971|BEHAVIORAL|iAmHealthy|The iAmHealthy group will receive newsletters for three months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
48719911|NCT04073160|DRUG|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
48719912|NCT04473365|OTHER|Intestinal parasite|Pre-existing intestinal parasite infection present or absent at time of admission
48719913|NCT00897390|DRUG|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
48719914|NCT00897390|DRUG|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
48719915|NCT00897390|DRUG|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
48719916|NCT00117793|DEVICE|Total Surface Bearing Suction Socket|Current clinical practice
48719917|NCT00117793|DEVICE|Vacuum assisted socket system|Novel socket system
48182172|NCT03178045|OTHER|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
48383447|NCT06188923|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
48383448|NCT06188923|DRUG|Placebo|Same as active comparator, except placebo dispensed
48519863|NCT04658914|BIOLOGICAL|Trivalent P2-VP8|Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P\[4\] (DS-1), P\[6\] (1076), and P\[8\] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide. A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
48519864|NCT03171012|OTHER|Lower limbs CRT|cycle ergometer for lower limbs
48719918|NCT02035956|BIOLOGICAL|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
48719919|NCT01747252|DIETARY_SUPPLEMENT|RGC|
48719920|NCT01747252|DIETARY_SUPPLEMENT|RGC|
48519865|NCT03171012|OTHER|Upper limbs CRT|cycle ergometer for upper limbs
48719921|NCT01747252|DIETARY_SUPPLEMENT|Resveratrol|The equivalent of 150 mg resveratrol
48719922|NCT01107938|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
48719923|NCT01107938|DRUG|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
48719924|NCT01107938|DRUG|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
48719925|NCT04334213|DRUG|CKD-501|QD, PO
48519866|NCT03171012|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
48519867|NCT03171012|OTHER|respiration|respiration
48024769|NCT01541657|OTHER|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
48182173|NCT00531622|DRUG|saredutant (SR48968)|oral administration, capsules
48182174|NCT00531622|DRUG|escitalopram|oral administration, capsules
48519868|NCT02280200|DEVICE|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
48182175|NCT00531622|DRUG|placebo|oral administration, capsules
48182176|NCT05678283|DRUG|[14C]CC-90010|Specified dose on specified days
48182177|NCT05678283|DRUG|CC-90010|Specified dose on specified days
48719926|NCT04334213|DRUG|D745, D150|QD, PO
48182178|NCT02712970|PROCEDURE|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of \<1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
48182179|NCT02712970|PROCEDURE|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
48182180|NCT02712970|PROCEDURE|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
48182181|NCT02712970|PROCEDURE|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
48182182|NCT05673733|OTHER|scapular stabilization exercises with exergaming training|Group A will receive scapular stabilization exercises with exergaming training
48182183|NCT05673733|OTHER|exergaming training|Group B will receive only exergaming training
48182184|NCT03234361|DIETARY_SUPPLEMENT|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
48182185|NCT03234361|DIETARY_SUPPLEMENT|Low Phosphate Phase|2 capsules of sodium chloride.
48182186|NCT02389322|BIOLOGICAL|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
48182187|NCT02389322|BIOLOGICAL|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
48182188|NCT02389322|BIOLOGICAL|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
48182189|NCT02389322|BIOLOGICAL|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
48182190|NCT02593123|DRUG|mycophenolate mofetil|Given PO, by mouth, orally or IV, intravenous medication administration.
48519869|NCT04563936|DRUG|LY01005 3.6 mg|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
48182191|NCT02593123|BIOLOGICAL|Sargramostim|"GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF."
48519870|NCT04563936|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
48519871|NCT01197911|DRUG|aleglitazar|single oral dose
48519872|NCT05436730|DEVICE|Ambulatory blood pressure measurement device|Assessment of the 24-h blood pressure profile
48519873|NCT05436730|DEVICE|Sphygmocor|Assessment of the arterial stiffness
48519874|NCT05436730|DEVICE|VaSera-VS|Assessment of the arterial stiffness
48719927|NCT04334213|DRUG|CKD-501, D745, D150|QD, PO
48719928|NCT05630976|DRUG|Isavuconazole|This is a single arm study, all enrolled participants will receive the study intervention.
48024770|NCT01541657|OTHER|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
48024771|NCT01541657|OTHER|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
48024772|NCT01381055|DRUG|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
48182192|NCT02593123|BIOLOGICAL|Filgrastim|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
48519875|NCT05436730|DEVICE|Somnocheck|Assessment of the sleep breath disturbances
48519876|NCT06581926|OTHER|Behavioral assessment|nutrition knowledge reward-related eating body awareness
48519877|NCT02801123|BEHAVIORAL|Mindfulness Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
48519878|NCT02801123|BEHAVIORAL|Tai Chi/Qigong (TCQ) for Cancer Patients|"TCQ involves a series of slow specific movements or forms done in a meditative fashion. It is purported that focusing the mind solely on the movements of the form helps to bring about a state of mental calm and clarity. The practice itself has been separated from its martial arts roots and is widely taught as a health behavior practice and exercise. Qigong exercises generally have three components: a posture (whether moving or stationary), breathing techniques, and mental focus on guiding qi through the body. Our program, developed specifically for a cancer patient population, incorporates simple Tai Chi elements within a healing framework stemming from Qigong principles."
48719929|NCT03801330|OTHER|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
48024773|NCT01381055|DRUG|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
48024774|NCT03634592|PROCEDURE|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
48024775|NCT04705077|DRUG|SR419|2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
48024776|NCT01785524|DRUG|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
48719930|NCT03801330|OTHER|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
48719931|NCT02546089|OTHER|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
48719932|NCT02546089|OTHER|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
48719933|NCT02546089|OTHER|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
48719934|NCT05314933|DRUG|2-Deoxyglucose|Intranasal administration
48719935|NCT05314933|OTHER|Placebo|Intranasal administration
48024777|NCT01785524|OTHER|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
48024778|NCT02825394|OTHER|anti-Xa activity point-of-care testing (aXa-POCT)|
48024779|NCT02825394|OTHER|ecarin clotting time point-of-care testing (ECT-POCT)|
48024780|NCT02371369|DRUG|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
48024781|NCT02371369|DRUG|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
48182193|NCT02466698|PROCEDURE|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
48024782|NCT03074006|DRUG|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
48024783|NCT06534463|OTHER|All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.|The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
48024784|NCT04938037|PROCEDURE|US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine|nerve block
48024785|NCT02823145|DRUG|ZX008 (Fenfluramine Hydrochloride)|
48024786|NCT01602315|DRUG|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
48024787|NCT01602315|DRUG|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
48182194|NCT02466698|DRUG|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
48182195|NCT02466698|DRUG|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
48383449|NCT06653920|OTHER|Chiropractic|SM used by the practitioner was the chiropractic side posture pisiform contact push move with a P-A thrust isolated to the lumbosacral joints and applied to the side of primary back and/or leg pain. Patients presenting with spondylolisthesis received a side posture distraction type maneuver instead of a P-A thrust. As pain began to subside during subsequent visits patients were transitioned to bilateral application of SM, rather than continuing treatment only on the side of back pain or radiculopathy.
48383450|NCT06653920|OTHER|Exercise|Core spine stretch and strength training throughout the course of care.
48383451|NCT06653920|OTHER|Cryotherapy|Therefore, during each treatment session when patients reported pain they received pretreatment with cryotherapy using a reusable ice pack (Polar Ice, Pelton/Shepherd Industries, Stockton, California) wrapped in 2 layers of headrest paper, but otherwise applied directly to the skin vertically along the lumbosacral spine, for 5 minutes.
48383452|NCT06653920|DEVICE|Spinalator|When patients no longer reported leg pain, spinalator intersegmental traction at \~10 lb/F, while the patient was lying supine with an ice pack between the traction table and the lumbar spine, was permitted as a pretreatment to side posture lumbar manipulation.
48383453|NCT06651970|DRUG|Acalabrutinib|Acalabrutinib Monotherapy
48024788|NCT01602315|BIOLOGICAL|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
48024789|NCT01602315|DRUG|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
48024790|NCT04695093|OTHER|Ultra Low Emission Zone (ULEZ)|"The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area."
48024791|NCT05415228|DRUG|68Ga-PSMA-11|68Ga-PSMA-11 is a radiopharmaceutical for the detection of prostate cancer using PET/CT imaging
48024792|NCT05760066|OTHER|Resistance Training Preconditioning|Resistance training prior to disuse-induced atrophy followed by another period of resistance training
48024793|NCT05760066|OTHER|Control|Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
48024794|NCT03013647|DRUG|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face"
48719936|NCT01965899|DEVICE|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
48719937|NCT03130452|DRUG|Lansoprazole 30mg|lansoprazole 30 mg tablet
48182196|NCT02466698|DRUG|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
48719938|NCT03130452|DRUG|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
48719939|NCT03130452|DRUG|Clarithromycin 500mg|Clarithromycin 500mg tablet
48719940|NCT03130452|DRUG|Metronidazole 500 mg|Metronidazole 500 mg tablet
48719941|NCT03931915|DRUG|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
48719942|NCT03931915|DRUG|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
48719943|NCT01073878|DEVICE|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
48719944|NCT01469403|BEHAVIORAL|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
48719945|NCT03530332|DIAGNOSTIC_TEST|PreTRM test|Blood test to determine risk of preterm birth
48719946|NCT03255538|OTHER|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
48719947|NCT03255538|OTHER|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
48719948|NCT03255538|OTHER|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
48719949|NCT01497613|BEHAVIORAL|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
48719950|NCT01497613|BEHAVIORAL|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
48719951|NCT00005053|DRUG|glufosfamide|
48182197|NCT06420050|BEHAVIORAL|Instagram Intervention|The intervention consists of a study Instagram page, which will post intervention content every day for 42 days.
48719952|NCT02575118|DEVICE|Restoration of dental caries with dental composite|
48719953|NCT00618605|BIOLOGICAL|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
48719954|NCT01122108|DRUG|Cholestyramine|Cholestyramine 12 grams, one time dose
48719955|NCT01122108|DRUG|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
48719956|NCT00599690|PROCEDURE|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
48719957|NCT01903889|OTHER|clinic based intervention|counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
48182198|NCT01755676|DRUG|Orlistat 60 mg|1 tablet 3 times a day
48182199|NCT01755676|OTHER|Placebo|1 tablet 3 times a day
48519879|NCT06291194|DRUG|AJU-S56 5%|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
48719958|NCT01903889|OTHER|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
48719959|NCT04118907|DEVICE|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
48719960|NCT03867019|DIAGNOSTIC_TEST|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)"
48719961|NCT04187742|BEHAVIORAL|Social Comparison Email vs. Standard Email|Evaluate whether emails with social comparison incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
48182200|NCT00005997|DRUG|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
48383454|NCT06651970|OTHER|Investigator's choice of treatment|control arm treatment type will be defined by the PI prior to randomisation
48719962|NCT04187742|BEHAVIORAL|Maintenance Certification Email vs. Standard Email|Evaluate whether emails with maintenance certification incentives will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without social comparison incentives
48024795|NCT01797146|PROCEDURE|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter _________~  * Type and duration of central venous catheter use~  * Indication of urinary catheter _________~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
48024796|NCT01990443|DRUG|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
48024797|NCT01990443|DRUG|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
48024798|NCT04702074|DRUG|Traditional Chinese medicine granules|"Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months."
48024799|NCT04702074|DRUG|Traditional Chinese medicine granules placebo|"Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules ."
48024800|NCT04700423|DRUG|moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
48024801|NCT04700423|DRUG|ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
48024802|NCT04700423|DRUG|ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]|Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
48024803|NCT04700423|DRUG|ivermectin (200 µg/kg)|Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
48024804|NCT04700423|DRUG|moxidectin (8 mg)|Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
48024805|NCT05941650|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
48024806|NCT05941650|OTHER|Corn Starch|This group will receive 12 g of corn starch as a control group.
48719963|NCT04187742|BEHAVIORAL|Report Opening Status Email vs. Standard Email (among previous report openers and non-openers)|Evaluate whether emails informing physicians of their report opening status (among those who have previously opened at least one report and those who have never opened a report) will encourage greater report opening by physicians leading to greater reductions in antibiotic use, than a standard email without report opening status information
48719964|NCT04596085|DIETARY_SUPPLEMENT|Investigational Product - ViraCide|Viracide
48024807|NCT01022034|PROCEDURE|sacral rectopexy with sutures or meshes|
48024808|NCT01022034|PROCEDURE|full rectal mobilization from the sacrum without sacral rectopexy|
48024809|NCT05184413|OTHER|Multimodal treatment|A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
48024810|NCT05184413|OTHER|Unimodal treatment|An unimodal telerehabilitation intervention will be performed through Whatsapp video calls. The treatment will include only a therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
48182201|NCT01010204|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
48383455|NCT04842448|DRUG|Hyperbaric oxygen|Hyperbaric oxygen 240 kPa for 90 minutes (with 10 min compression time, 2 air bakes and 10 minutes decompression time).
48519880|NCT06291194|DRUG|Placebo Group(Vehicle)|After Randomization(Week 0), Participants will be administered with the durg, QID(4 times in a day, and 1 drop per each times) until end of trial(Week 24).
48519881|NCT00665782|OTHER|laboratory biomarker analysis|
48519882|NCT00665782|OTHER|questionnaire administration|
48719965|NCT04596085|OTHER|Placebo - Starch Powder Soft gels|Starch Powder Soft gels
48719966|NCT03819452|DIAGNOSTIC_TEST|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
48719967|NCT01329913|DRUG|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
48719968|NCT01329913|DRUG|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
48719969|NCT01329913|DRUG|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
48719970|NCT01329913|DRUG|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
48719971|NCT01329913|DRUG|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
48024811|NCT02167022|OTHER|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
48024812|NCT03789539|BIOLOGICAL|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
48024813|NCT03789539|BIOLOGICAL|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
48024814|NCT03789539|BIOLOGICAL|Placebo|Placebo saline
48024815|NCT01698060|BIOLOGICAL|ND1.1|
48024816|NCT06038877|OTHER|Interviews|Individual semi-structured interviews
48024817|NCT06038877|OTHER|Qualitative analysis|Thematic analysis of the content of responses
48024818|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
48024819|NCT00384085|DRUG|Insulin Glargine|Subcutaneous injection once-a-day
48024820|NCT00384085|DRUG|Premixed Insulin|Subcutaneous injection twice-a-day.
48024821|NCT00384085|DRUG|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
48024822|NCT02412267|DRUG|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
48182202|NCT01010204|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
48182203|NCT00047255|BIOLOGICAL|trastuzumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
48519883|NCT00665782|OTHER|study of socioeconomic and demographic variables|
48719972|NCT01329913|DRUG|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
48719973|NCT04109976|DRUG|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
48719974|NCT01518504|OTHER|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
48383456|NCT04842448|PROCEDURE|Sham treatment|Sham treatment 134-120 kPa Air (with 5 min compression time, and 5 min decompression to 120 kPa, two air brakes will be reported to the subjects)
48519884|NCT00665782|PROCEDURE|assessment of therapy complications|
48519885|NCT00665782|PROCEDURE|psychosocial assessment and care|
48519886|NCT00665782|PROCEDURE|therapeutic conventional surgery|
48024823|NCT04962971|DIETARY_SUPPLEMENT|X|exocyan
48024824|NCT04962971|DIETARY_SUPPLEMENT|Y|exocyan
48024825|NCT04962971|DIETARY_SUPPLEMENT|Z|exocyan
48024826|NCT04396886|DRUG|Bintrafusp Alfa|Bintrafusp alfa will be administered intravenously every 2 weeks
48024827|NCT00047463|DEVICE|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
48024828|NCT00047463|DEVICE|Placebo-CPAP|Placebo-CPAP
48024829|NCT06377735|PROCEDURE|BAI-BACE|Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
48024830|NCT02526134|DEVICE|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
48024831|NCT05881941|DEVICE|using a soundproof nebulizer with a music and a funny mask added|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
48024832|NCT05881941|DEVICE|using a silent nebulizer with no extra attachments|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
48024833|NCT05881941|DEVICE|using a routinely employed nebulizer|There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
48024834|NCT00501384|DRUG|satavaptan (SR121463B)|
48024835|NCT02448303|DRUG|Pembrolizumab|
48024836|NCT02448303|DRUG|Acalabrutinib|
48024837|NCT05758662|DIAGNOSTIC_TEST|18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)|Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
48024838|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
48383457|NCT02425358|OTHER|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
48519887|NCT05712239|OTHER|Advices|The advices will include patient's reassurance and description of possible causes of neck pain such as poor working ergonomics, common bad postures especially while using electronic devices for long periods and not adjustable sleeping pillows. Also, patient will be educated how to modify these different causes and asked to apply gentle neck range of motion exercises
48719975|NCT01518504|OTHER|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
48024839|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
48719976|NCT03510351|DRUG|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
48719977|NCT01194622|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
48719978|NCT01194622|DRUG|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
48719979|NCT01194622|DRUG|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
48719980|NCT03139799|BEHAVIORAL|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
48719981|NCT03139799|BEHAVIORAL|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
48024840|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
48719982|NCT05251532|OTHER|Kinesio Taping|In addition to Kinesio Tex tape distortion taping, conventional rehabilitation is applied.
48024841|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
48024842|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
48024843|NCT00844194|DRUG|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
48024844|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
48024845|NCT00844194|DRUG|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
48024846|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
48024847|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
48024848|NCT00844194|DRUG|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
48024849|NCT00844194|DRUG|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
48024850|NCT03095417|BEHAVIORAL|Physical Exercise Intervention|In home exercise intervention.
48024851|NCT03095417|BEHAVIORAL|Cognitive Training Intervention|Online cognitive training modules.
48024852|NCT03095417|BEHAVIORAL|Stretching Control|In home stretching.
48024853|NCT03095417|BEHAVIORAL|Cognitive Control|Online control puzzles and games.
48024854|NCT04884126|PROCEDURE|dental implant placement|The time of dental implant surgery
48024855|NCT02656446|DEVICE|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
48383458|NCT02425358|OTHER|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
48719983|NCT05251532|OTHER|Conventional Rehabilitation|Conventional rehabilitation practices are carried out
48719984|NCT04072107|DRUG|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
48719985|NCT04072107|DRUG|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
48719986|NCT04663334|OTHER|inverse myocardial remodeling|a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
48024856|NCT02656446|DEVICE|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
48024857|NCT05906121|DRUG|lidocaine-ketamine infusions|Lidocaine and ketamine are infused over a period of 30 minutes. The dosage of lidocaine is 4mg/kg is maintained throughout the infusions, and the dosage of ketamine is increased within the first three infusions from 0.15mg/kg at the first, to 0.25mg/kg at the second and 0.5mg/kg at the third infusion. In case patients already experiencing sufficient analgesic effect and/or improvement in quality of life after the 1st or 2nd infusion or if side effects do not allow a further dose increase, no further step up of ketamine dosage is made. As a part of this study, at the end of the first, second and third infusion, side effects will be screened using customized questionnaires (SF - MPQ, BDI-II)
48024858|NCT01546415|DRUG|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
48024859|NCT02731131|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
48024860|NCT02731131|DRUG|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
48024861|NCT00746603|DRUG|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
48024862|NCT03391648|OTHER|Observation|Observation only
48024863|NCT06054646|BIOLOGICAL|Amnion collagen|A collagen extract sourced from the human amniotic membrane
48024864|NCT06054646|BIOLOGICAL|Platelet-rich plasma|Autologous preparation of PRP
48024865|NCT05175352|DRUG|Cendakimab|Specified dose on specified days
48024866|NCT05175352|DRUG|CYP substrates|Specified dose on specified days
48024867|NCT05223543|DIAGNOSTIC_TEST|Blood sample|extraction of blood samples from women undergoing ovarian cystectomy or oophorectomy due to suspected Dermoid cyst and analysing plasma for antibodies
48024868|NCT05497843|DRUG|Chiauranib|50mg, orally once daily
48024869|NCT00058305|DRUG|bryostatin 1|Given IV
48024870|NCT00058305|DRUG|vincristine sulfate|Given IV
48024871|NCT00058305|OTHER|laboratory biomarker analysis|Correlative studies
48024872|NCT05456295|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
48024873|NCT05746039|DRUG|Semaglutide Pen Injector|Once weekly subcutaneous injection
48024874|NCT02283528|DEVICE|Stryker Hybrid|Place Hybrid arch bars
48024875|NCT02283528|DEVICE|Erich|Control group is Erich arch bars
48024876|NCT06434961|DRUG|SHR6508 plus oral placebo tablets|SHR6508 plus oral placebo tablets
48024877|NCT06434961|DRUG|Cinacalcet plus intravenous placebo|Cinacalcet plus intravenous placebo
48024878|NCT00338338|DRUG|Lacidipine 4 or 6 mg (oral)|
48024879|NCT00338338|DRUG|Amlodipine 5 or 10 mg(oral)|
48024880|NCT05812027|DIAGNOSTIC_TEST|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain TAA and LOH.
48024881|NCT00310687|PROCEDURE|BLOOD DRAW|
48024882|NCT00364481|DRUG|omeprazole|
48024883|NCT00364481|BEHAVIORAL|Tongue exercises|
48024884|NCT05311033|OTHER|Exacyl|Healthy males with at risk of post-inflammatory hyperpigmentation have a skin samples for evaluate the activity of tranexamic acid.
48024885|NCT03029208|DRUG|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
48024886|NCT03029208|DRUG|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
48024887|NCT03029208|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
48024888|NCT02560129|OTHER|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
48024889|NCT06283849|BEHAVIORAL|strategies to break up SB|Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
48383459|NCT02425358|OTHER|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
48383460|NCT02425358|OTHER|PCI only|The saline was intracoronary infusion with the use of microtubular.
48383461|NCT01902992|DRUG|Depiquick Birch (DPG103)|
48383462|NCT01902992|DRUG|Placebo|
48182204|NCT00047255|DRUG|carboplatin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
48719987|NCT06301295|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject suspected of early-stage, resectable lung cancer will undergo bronchooscopic procedure. Ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Subsequently, intratumoral washing is performed. After undergoing surgery for suspected early-stage lung cancer, the analysis of next generation sequencing is conducted on intratumoral washing, tissue from surgical specimen, and blood.
48719988|NCT06103994|DIETARY_SUPPLEMENT|Multistrain probiotic|Multistrain Probiotic
48719989|NCT06103994|OTHER|Placebo|Placebo
48719990|NCT05105867|BIOLOGICAL|Anti-CD19 Universal CAR-T Cells injection|Anti-CD19 Universal CAR-T Cells injection will be administered by vein after lymphodepletion.
48182205|NCT00047255|DRUG|docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
48182206|NCT00047255|BIOLOGICAL|trastuxumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
48519888|NCT05712239|OTHER|Cervical and Scapular Stabilization Exercises|"Deep neck flexor training will be performed in neurodevelopment stages (supine at first week using pressure biofeedback unit , prone at second week, quadrupedal at third week, bipedal at fourth week).~Scapular stabilization exercises will include modified prone cobra, trapezius muscle exercise progression (3 stages), wall press and extension of the thoracic spine using foam roller. The modified prone cobra and the first stage of trapezius muscle exercise progression will be applied during the first two weeks. The second and third stages of trapezius muscle exercise will be applied during the last two weeks of our rehabilitation program. All exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets with 20 sec rest between each set. While wall press and thoracic extension exercises will be applied throughout the 4 weeks for 3 sets of 10 repetitions with 20 sec rest between each set."
48519889|NCT05712239|OTHER|Lumber Core Stability Program|"The program will be performed in three stages: activation, dynamic stabilization, and advanced core strengthening stages. Each stage will be applied for 4 sessions.~The activation stage will be based on the learning to activate transversus abdominis muscle from crock lying position using pressure biofeedback unit. In the dynamic stabilization stage, the patient will be instructed to slowly raise both arms in the scapular plan then return to the sides while maintaining the transversus abdominis muscle activation. Also, the patient will apply bridging exercise in this stage. The advanced core strengthening stage will include prone plank and side plank (right and left sides). All the exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets. The rest of 20 sec will be taken between each set."
48519890|NCT02245009|PROCEDURE|Cardioversion|
48719991|NCT03510325|DRUG|Olanzapine|Commonly used oral antipsychotics intervention therapy.
48719992|NCT03510325|DRUG|Risperidone|Commonly used oral antipsychotics intervention therapy.
48719993|NCT03510325|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
48719994|NCT03510325|DRUG|Amisulpride|Commonly used oral antipsychotics intervention therapy.
48719995|NCT03510325|DRUG|Paliperidone long-acting injection|long-acting injection
48719996|NCT03119389|BEHAVIORAL|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
48719997|NCT02476474|PROCEDURE|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
48719998|NCT02476474|PROCEDURE|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
48719999|NCT01566578|DRUG|Human recombinant epidermal growth factor|topical
48720000|NCT01566578|OTHER|Placebo cream|Dermal cream without EGF
48720001|NCT02391961|DRUG|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
48720002|NCT02391961|DRUG|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
48720003|NCT02204852|DRUG|Iloprost+eptifibatide|
48720004|NCT02204852|DRUG|Placebo|
48720005|NCT05735756|DRUG|Citalopram 20mg|Citalopram 20mg once a day for 12 weeks
48720006|NCT05735756|DRUG|Placebo|Placebo once a day for 12 weeks
48720007|NCT04326686|OTHER|Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet|30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
48720008|NCT03933176|PROCEDURE|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
48024890|NCT00286143|DRUG|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
48024891|NCT01301963|DRUG|plerixafor|Given SC
48024892|NCT01301963|BIOLOGICAL|filgrastim|Given SC
48024893|NCT03735966|DRUG|Pyrotinib plus trastuzumab and docetaxel and carboplatin|pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
48024894|NCT05872139|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
48024895|NCT05872139|DIETARY_SUPPLEMENT|Mitoquinone Mesylate|MitoQ was given once (single dose, 80 mg)
48024896|NCT06534060|BIOLOGICAL|Genetic: MB-105|MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
48720009|NCT00882739|DRUG|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
48720010|NCT00882739|DRUG|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
48720011|NCT00882739|DRUG|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
48720012|NCT02247180|BEHAVIORAL|cognitive rehabilitation|
48720013|NCT02247180|BEHAVIORAL|standardized cognitive training|
48024897|NCT00046345|DRUG|Atazanavir (BMS-232632)|
48024898|NCT02706353|DRUG|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
48182207|NCT00047255|DRUG|Docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
48720014|NCT00673881|DRUG|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
48720015|NCT03924921|OTHER|autogenic training|autogenic training
48720016|NCT00766974|DEVICE|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
48720017|NCT00766974|DEVICE|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
48720018|NCT05728073|PROCEDURE|ERCP|Patients separated to two groups according to having a ERCP history before the operation
48720019|NCT05577949|OTHER|Structured aerobics exercise|A 12 week structured aerobics exercise program will be offered. The patient has to perform exercise five times a week , 30 minutes a day
48720020|NCT03463668|DEVICE|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
48720021|NCT01394887|DRUG|Metformin|850 mg of metformin twice daily over 12 weeks
48720022|NCT01394887|DRUG|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
48720023|NCT00349830|PROCEDURE|blood draw|
48720024|NCT00286221|DRUG|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
48519891|NCT04652778|DEVICE|Pulsed Field Ablation (PFA) using the Centauri System|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation; cavo-tricuspid isthmus (CTI) line ablation may be performed as needed
48519892|NCT03520257|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
48720025|NCT00286221|DRUG|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
48024899|NCT02706353|DRUG|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
48024900|NCT00905333|DRUG|Candesartan (test)|16 mg oral tablet, single dose
48720026|NCT00299247|DRUG|sulfadoxine/pyrimethamine|
48720027|NCT02434328|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
48720028|NCT02434328|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
48720029|NCT03554135|OTHER|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with \< 6 months prognostic score attendance
48720030|NCT01877889|DRUG|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
48720031|NCT01877889|DRUG|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
48720032|NCT00858663|RADIATION|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
48720033|NCT00858663|DRUG|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
48720034|NCT00031564|BIOLOGICAL|Interleukin-2|
48720035|NCT00031564|BIOLOGICAL|B7-1|
48024901|NCT00905333|DRUG|Felodipine (test)|5 mg oral extended release tablet, single dose
48024902|NCT00905333|DRUG|Candesartan Cilexetil|16 mg oral tablet, single dose
48024903|NCT00905333|DRUG|Felodipine|5 mg oral extended release tablet, single dose
48024904|NCT06502314|BEHAVIORAL|Stress management training|"It is a psychoeducational program that includes seven modules (1. Stress and its components, 2. Stress Management, 3. Crisis and its components, 4. Crisis Management, 5. Anger and its components, 6. Anger Management, 7. Psychological resilience)~."
48182208|NCT01479270|DRUG|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
48383463|NCT05621317|BIOLOGICAL|PVX-108|PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
48519893|NCT03520257|DEVICE|Radiotherapy|Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
48519894|NCT02831426|DEVICE|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
48519895|NCT02831426|DEVICE|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
48182209|NCT00947323|DRUG|Simvastatin|simvastatin 20 daily for six months.
48182210|NCT00947323|DRUG|Placebo|
48182211|NCT01727869|DRUG|REGN1400|
48182212|NCT01727869|DRUG|Erlotinib|
48383464|NCT05621317|BIOLOGICAL|Placebo|Matching placebo comprises the formulation vehicle without peptides
48383465|NCT04515940|DIETARY_SUPPLEMENT|acceptability, tolerance and palatability study|prospective acceptability study
48383466|NCT06049355|OTHER|Exercise Intervention|Undergo Exercise Together exercise program
48383467|NCT06049355|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48383468|NCT06049355|OTHER|Educational Intervention|Receive educational materials
48383469|NCT05629741|DRUG|CMTX-101|Administered as specified in the treatment arm
48383470|NCT05629741|DRUG|Placebo|Administered as specified in the treatment arm
48383471|NCT02025400|OTHER|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
48383472|NCT02025400|OTHER|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
48383473|NCT03677973|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
48383474|NCT03677973|OTHER|Placebo|Matching Placebo
48383475|NCT03965507|OTHER|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
48383476|NCT04116359|DRUG|Cisplatin|Given IV
48383477|NCT04116359|DRUG|Etoposide|Given IV
48383478|NCT04116359|DRUG|Etoposide Phosphate|Given IV
48383479|NCT04116359|DRUG|Molibresib|Given PO
48519896|NCT00150280|DRUG|celecoxib and ibuprofen SR|
48519897|NCT02685735|DRUG|Gabapentin|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
48720036|NCT00663299|DEVICE|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
48182213|NCT01727869|DRUG|Cetuximab|
48182214|NCT03124693|DEVICE|Rainbow DCI pulse oximeter sensor|
48182215|NCT01468077|DRUG|Tocilizumab|8 mg/kg infusion
48182216|NCT03700905|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
48182217|NCT03700905|RADIATION|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
48182218|NCT03700905|DRUG|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
48182219|NCT03700905|DRUG|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
48182220|NCT03700905|DRUG|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
48182221|NCT01568385|DRUG|TAK-438|
48182222|NCT01337206|DEVICE|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
48182223|NCT01337206|PROCEDURE|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
48383480|NCT04116359|DRUG|Molibresib Besylate|Given PO
48383481|NCT06653712|DIAGNOSTIC_TEST|Diagnostic Test|"The following clinical data sources are used:~* Personal interview (anamnesis)~* Physical examination~* Questionnaires~* Functional assessment~* Imaging techniques~The following biological materials are used:~• Max. 30 ml of blood"
48024905|NCT03103867|DEVICE|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
48024906|NCT03103867|DEVICE|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
48024907|NCT05417711|DEVICE|Transcutaneous Vagus Nerve Stimulation Paired with Tailor-Made Notched Music Therapy|The pulse frequency of vagus nerve stimulation is 25 Hz, the pulse width is 200 US, and the intensity is 1-10 mA. Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. The tVNS and TMNM begin at the same time during treatment.
48024908|NCT05417711|DEVICE|Tailor-made Notched Music Training|Tailor-made notched music is produced by filtering a frequency band of 1/2 octave width centered at the individual tinnitus frequency. When two sides of tinnitus frequencies are different, each side of music are filtered respectively, according to the different tinnitus frequency. When only have unilateral tinnitus or bilateral tinnitus in the same central frequency, both sides of music are filtered with the same tinnitus frequency. At the beginning of TMNMT, 10 seconds sham vagus nerve stimulation is output, whose parameters are as same as experimental group.
48024909|NCT00172510|PROCEDURE|blood drawing|
48024910|NCT03407352|BEHAVIORAL|Active Video Game Play|60 minutes of active video game play at a moderate intensity
48024911|NCT03407352|BEHAVIORAL|Passive Video Game Play|60 minutes of passive video game play
48182224|NCT03115398|BEHAVIORAL|Pedometer-based Walking Program|Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
48182225|NCT05421468|OTHER|L-Thyroxine time B (5-15 minutes Before dawn)|Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
48383482|NCT04145804|DEVICE|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
48383483|NCT03922984|PROCEDURE|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
48519898|NCT02685735|DRUG|Placebo|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
48024912|NCT06544408|DEVICE|Cool B70 AP Coil - Active (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
48024913|NCT06544408|DEVICE|Cool B70 AP Coil- Sham (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
48182226|NCT05526365|OTHER|Reduced Idea Density|Question idea density reduced (ratio of propositions to total words used).
48182227|NCT00373451|DRUG|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute \[maximum of 10 µg/minute\] infusion for 12 hours)
48182228|NCT00373451|DRUG|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
48024914|NCT06544408|DEVICE|Cool D-B80 AP Coil - Active (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
48024915|NCT06544408|DEVICE|Cool D-B80 AP Coil - Sham (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
48519899|NCT00080145|DRUG|Risperidone|
48024916|NCT06544408|DEVICE|Cool B70 Treatment Coil - Active Only|The treatment will be the same as the left dl-PFC accel-TMS dl-PFC except that the Cool B70 Treatment coil only has an active treatment coil.
48024917|NCT02606136|DRUG|Pamrevlumab|Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
48182229|NCT00373451|DRUG|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
48182230|NCT05891145|DRUG|Remimazolam|Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
48182231|NCT05891145|DRUG|midazolam|Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
48182232|NCT00519545|BEHAVIORAL|Prayer|Data collection on physiological biomarkers
48182233|NCT02503826|DRUG|Sufentanil|low dose
48182234|NCT02503826|DRUG|Sufentanil|moderate dose
48182235|NCT02503826|DRUG|Sufentanil|high dose
48519900|NCT00080145|BEHAVIORAL|Behavior Therapy|
48519901|NCT03167268|DRUG|Lycopene|
48519902|NCT03167268|OTHER|Placebo|
48519903|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
48024918|NCT02462395|DEVICE|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
48519904|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
48024919|NCT00058890|DRUG|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
48024920|NCT00058890|DRUG|Placebo|
48024921|NCT01343056|BEHAVIORAL|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
48024922|NCT01343056|BEHAVIORAL|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
48024923|NCT01343056|BEHAVIORAL|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
48024924|NCT01343056|BEHAVIORAL|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
48024925|NCT02006030|DRUG|ADI-PEG 20|
48024926|NCT02006030|DRUG|Transarterial chemoembolization|
48024927|NCT05778981|DIAGNOSTIC_TEST|FMD - Troponin measurement|Echographic FMD evaluation. Pre and post-operative troponin measurements.
48024928|NCT04949230|OTHER|No Intervention Used|There is no intervention in this study
48519905|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
48519906|NCT00652561|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
48519907|NCT01627678|DRUG|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
48024929|NCT01485952|DRUG|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
48519908|NCT01627678|DRUG|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
48519909|NCT03394469|OTHER|collection|Blood, urinary and faecal samples
48720037|NCT02272179|BEHAVIORAL|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
48720038|NCT02272179|BEHAVIORAL|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
48024930|NCT01485952|DRUG|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
48024931|NCT01485952|DRUG|Placebo|Once daily administration (immediate release capsule)
48024932|NCT00659646|DRUG|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
48024933|NCT00659646|DRUG|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
48024934|NCT06066112|DRUG|Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.|Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
48024935|NCT02923037|PROCEDURE|Yoga|Complete guided and home yoga sessions
48024936|NCT02923037|OTHER|tape measurement of arm|Ancillary studies
48024937|NCT02923037|OTHER|Quality-of-Life Assessment|Ancillary studies
48024938|NCT02923037|OTHER|ldex measurement of arms|
48024939|NCT04344821|DIETARY_SUPPLEMENT|Curves Calcium|"Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)"
48024940|NCT04344821|DIETARY_SUPPLEMENT|Placebo|Dextrose Placebo
48182236|NCT02503826|DRUG|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
48182237|NCT02503826|DRUG|propofol|
48182238|NCT02503826|DRUG|cisatracurium|
48182239|NCT02638597|DRUG|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
48519910|NCT00367302|DRUG|buprenorphine|maintenance
48519911|NCT00367302|DRUG|methadone|maintenance
48519912|NCT04167553|DRUG|HM15136|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
48383484|NCT01539707|DRUG|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
48182240|NCT02638597|BEHAVIORAL|smoking cessation counseling|smoking cessation counseling
48383485|NCT04288739|DIAGNOSTIC_TEST|flow cytometric immunophenotyping|Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
48720039|NCT02272179|BEHAVIORAL|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
48720040|NCT01778920|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
48383486|NCT04288739|GENETIC|Xist gene by fluorescence insitu hybridization|"Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes."
48383487|NCT04137926|DIAGNOSTIC_TEST|MicRNAs battery|for MCI due to AD diagnosis
48720041|NCT06030492|DRUG|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
48028935|NCT06634511|OTHER|core stability exercises|"Group A: core stability exercise group:15 Patients assigned to this group will undergo a core stability exercises ts.2times per week /8weeksin addition to conventional therapy (Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes~Group B:(aerobic exercise group) 15 patients will receive aerobic exercise in the form of treadmill for 30 minutes2 session per week/8 weeks~Group C(conventional group): 15 patients will receive Infrared radiation (using BL 220 Infrared lamp, MT03009201 model) for 15 minutes, Transcutaneous Electrical Nerve stimulation (using model DX66053, pain modulation mode) for 10 minutes, Participants were treated twice weekly"
48182241|NCT04129047|DRUG|Omnichroma (one shade universal) composite by Tokuyama|Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
48182242|NCT04129047|DRUG|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA|a multiple shade universal composite that needs prior shade selection procedure
48383488|NCT01302639|DIETARY_SUPPLEMENT|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
48383489|NCT00285259|BIOLOGICAL|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
48720042|NCT06030492|DRUG|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
48383490|NCT00285259|OTHER|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
48383491|NCT06467292|DEVICE|continuous theta-burst stimulation (cTBS)|cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.
48383492|NCT06467292|BEHAVIORAL|Adaptation|Auditory adaptation in speech
48720043|NCT02159378|OTHER|Fructosamines|
48024941|NCT04506450|PROCEDURE|Peripheral nerve block|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected."
48024942|NCT04506450|PROCEDURE|Spinal anesthesia|"In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected."
48720044|NCT04353882|OTHER|Assess the difference in MOR-1 expression between healthy and tumor tissue|Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
48720045|NCT05280249|OTHER|both aerobic and resistance exercises in the green exercise concept|Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. Participants in this group will be given aerobic and resistance exercises in the open air.
48024943|NCT05520138|DRUG|Enzalutamide|As provided in real-world setting
48024944|NCT05520138|DRUG|Abiraterone acetate|As provided in real-world setting
48024945|NCT06346093|PROCEDURE|Fecal Microbiota Transplantation Capsules|FMT Capsules in Combination with Chemotherapy and Anti-PD-L1 Therapy
48024946|NCT06346093|PROCEDURE|Placebo|Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules
48383493|NCT06467292|DEVICE|Single pulse Transcranial magnetic stimulation (TMS)|TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.
48024947|NCT00618657|DRUG|Carboplatin|Given IV
48024948|NCT00618657|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
48024949|NCT00618657|DRUG|bevacizumab|Given IV
48024950|NCT00618657|DRUG|trastuzumab|Given IV
48024951|NCT00618657|PROCEDURE|magnetic resonance imaging|Optional correlative studies
48383494|NCT06467292|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
48519913|NCT04167553|DRUG|Placebo|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.
48720046|NCT02917720|OTHER|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
48024952|NCT00618657|PROCEDURE|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
48024953|NCT00510666|DRUG|Saline|Saline infusion adjunct to morphine PCA pump
48024954|NCT00510666|DRUG|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
48024955|NCT00510666|DRUG|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
48024956|NCT00510666|DRUG|Saline|Preemptive saline as a control group to tramadol one
48024957|NCT03908684|DEVICE|Ultrasound Imaging|Ultrasound Spectroscopy assess changes in five different ultrasound spectroscopic parameters over different times during treatment with radiotherapy as predictors of tumour shrinkage and pathologic complete response. Ultrasound parameters investigated will include mid-band fit (related to image intensity),spectroscopic slope (backscatter versus frequency), spectroscopic intercept, histogram fit size and shape parameters which can be used as estimates of scatterer size and concentration.
48519914|NCT00246324|DRUG|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
48720047|NCT02917720|DRUG|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
48024958|NCT04465994|PROCEDURE|gastrocnemius turn-down flaps|We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
48024959|NCT04836260|DRUG|SARS-CoV-2 convalescent plasma|Included patients will receive at least one unit of convalescent plasma with NTAB titer ≥1:160 at maximum 3-7 days after diagnosis by RT-PCR or symptom onset. A second unit of plasma from a different donor can be proposed 24h after the first unit if immunocompromised and/or the patient received less than 3-5ml/kg of plasma volume. Additional units can be exceptionnally infused, at the investigator discretion.
48720048|NCT05804149|DEVICE|acupuncture|study group take acupuncture Acupuncture was applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.
48024960|NCT05561998|DEVICE|TalkingMats|TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.
48024961|NCT05561998|OTHER|Usual conversation method|The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
48182243|NCT05044923|DEVICE|Targeted Epidural Spinal Stimulation|Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
48182244|NCT04988776|OTHER|ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m|patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
48182245|NCT04988776|OTHER|ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block|Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
48182246|NCT01076790|DRUG|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
48182247|NCT01076790|DRUG|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
48182248|NCT00455741|DRUG|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
48182249|NCT00455741|DRUG|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
48182250|NCT06171269|RADIATION|Radiation|Radiation to the prostate gland will be given daily (Mon-Friday) for 4 weeks.
48519915|NCT00763633|DRUG|vitamin B6|high dose of vitamin B6
48519916|NCT00763633|DRUG|vitamin B6|low vitamin B6
48519917|NCT03180281|DRUG|DPP4|sitagliptin phosphate 100mg qd
48519918|NCT03180281|DRUG|Insulin|Insulin Glargine or detemir 0.2U/kg qd
48519919|NCT03180281|DRUG|SU|Glimepiride 1-2mg qd
48519920|NCT04513301|DRUG|Sintilimab|Sintilimab (200 mg q3w ×2 cycle)
48519921|NCT04513301|RADIATION|Radiotherapy|RT 50-60Gy/25-30f
48519922|NCT03899246|DRUG|Eight Percent Topical Capsaicin|See arm description
48720049|NCT05804149|DRUG|Thyroxine|Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine
48720050|NCT05804149|DIETARY_SUPPLEMENT|low caloric diet|Each woman in both groups will follow a low caloric diet regime consisting of 1200 to 800Kcal/ day for 4 months. The regime will start with 1200 Kcal for the first month and 1100 for the second month then 900 Kcal for the third month until reach 800 Kcal in fourth month.
48720051|NCT00081133|DRUG|arsenic trioxide|
48720052|NCT00081133|DRUG|imatinib mesylate|
48720053|NCT00005056|DRUG|bryostatin 1|
48720054|NCT00262990|DRUG|EPO906 (Patupilone)|
48024962|NCT01554046|DRUG|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day."
48182251|NCT06171269|RADIATION|MRI|The study doctor will use an MRI scan to take pictures of the prostate gland. These images of the prostate gland will let the study doctor know which areas of the prostate contain cancer cells that need to be targeted with higher doses of radiation and which uninvolved areas to target with lower doses of radiation.
48182252|NCT06171269|OTHER|Androgen Deprivation Therapy|Treatment of treating physician choice will be given for 6-24 months.
48182253|NCT04945447|OTHER|Systematic pharmacist intervention|Already described in the arm group intervention group for patient level
48383495|NCT06571955|DEVICE|Implantation of LARS artificial grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial grafted ligament.
48383496|NCT06571955|DEVICE|Implantation of LARS artificial non-grafted ligament to treat ACL injury|Implantation procedure will be realized by a well-trained orthopaedic surgeon and will consist of ACL repair using LARS artificial non-grafted ligaments.
48383497|NCT04668326|DEVICE|Manual Standing Wheelchair|Mobile in seated position; Not mobile in standing position
48720055|NCT00262990|DRUG|doxorubicin|
48024963|NCT04157829|DEVICE|Scintilling lamp|Lamp with a standardized scintilling
48024964|NCT04157829|DEVICE|Classic lamp|Lamp without a scintilling
48024965|NCT01462344|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
48720056|NCT01020903|PROCEDURE|Aprepitant|40 mg po pre-op
48024966|NCT01462344|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
48720057|NCT01020903|DRUG|Placebo|Orally, pre-op
48024967|NCT01462344|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
48024968|NCT01462344|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
48024969|NCT05159752|DRUG|Afamelanotide|Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
48024970|NCT02676206|OTHER|Classical music|Classical music will be played over the headphones
48182254|NCT06475794|OTHER|Patients with osteoporosis group|Pain, Q angle, muscle strength and foot posture will be evaluated.
48182255|NCT06475794|OTHER|Patients with osteoarthritis group|Osteoarthritis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
48024971|NCT05167838|PROCEDURE|fresh embryo transfer|55 patients undergoing fresh embryo transfer after ovarian stimulation followed by luteal phase support
48182256|NCT00002145|DRUG|Foscarnet sodium|
48182257|NCT01445795|DRUG|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
48182258|NCT01445795|DRUG|Placebo QD Fasted|Placebo capsule QD fasted x7 days
48182259|NCT01445795|DRUG|100 mg INX-08189 QD|100 mg INX-08189 capsule QD x 7 days
48182260|NCT01445795|DRUG|Placebo QD|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
48182261|NCT01445795|DRUG|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
48182262|NCT01445795|DRUG|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
48182263|NCT01445795|DRUG|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
48024972|NCT05167838|PROCEDURE|Frozen embryo transfer|55 patients undergoing frozen embryo transfer after ovarian stimulation followed by cryopreservation of all embryos and transfer in another cycle.
48024973|NCT00043446|DRUG|intravenous T900607-sodium|
48024974|NCT01154634|DRUG|AZD2516, 5 mg|Capsule, oral
48024975|NCT01154634|DRUG|AZD2516, 16 mg|Capsule, oral
48182264|NCT01445795|DRUG|Placebo BID Fasted|Placebo BID fasted x7 days
48182265|NCT01445795|DRUG|ribavirin|
48182266|NCT02645123|DEVICE|TENS|Enraf-Nonius Sonopuls 692
48720058|NCT00637572|DRUG|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
48720059|NCT00637572|DRUG|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
48720060|NCT06430515|PROCEDURE|Intratumoral Injection of Chemotherapy|This project intends to investigate the clinical efficacy of intra-tumoural injection of chemotherapeutic agents (e.g. cisplatin, oxaliplatin, etc.)via fine needle aspiration guided by CT or ultrasound in patients with advanced solid cancers to validate the safety and efficacy.
48720061|NCT00114920|DRUG|Resiquimod|
48024976|NCT01154634|DRUG|AZD2516, 40 mg|Capsule, oral
48024977|NCT01154634|DRUG|Placebo|Capsule, oral
48024978|NCT06266221|DRUG|Prednisone 20 Mg|Oral corticosteriods
48182267|NCT02645123|PROCEDURE|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
48182268|NCT02645123|PROCEDURE|swedish type massage|petrissage, effleurage, tapotement
48182269|NCT02645123|PROCEDURE|static hamstring stretch|static hamstring stretching
48182270|NCT02645123|PROCEDURE|sham treatment|touching of the skin overlying the lumbar area
48182271|NCT04213677|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.
48182272|NCT04213677|DRUG|Placebo|Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
48182273|NCT00791193|DRUG|Paliperidone ER|
48182274|NCT05421767|PROCEDURE|nerve stimulation guided renal denervation procedure|RNS-in
48182275|NCT05519553|OTHER|Peer support|: 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
48720062|NCT05566262|DRUG|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
48720063|NCT01330966|DRUG|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
48720064|NCT03033563|PROCEDURE|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
48720065|NCT04052776|DRUG|Buspirone|40mg
48720066|NCT04052776|DRUG|Levodopa-Carbidopa|400mg/100mg
48720067|NCT04052776|DRUG|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
48720068|NCT04052776|DRUG|Placebo oral tablet|Non-active metabolite
48720069|NCT05400629|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.
48720070|NCT06508242|DRUG|Cholecalciferol|cholecalciferol
48024979|NCT06266221|DRUG|Oral Placebo|Oral placebo
48024980|NCT06266221|DRUG|Methylprednisolone 120 Mg|IV corticosteriods
48024981|NCT06266221|DRUG|IV Placebo|IV placebo
48024982|NCT00450424|OTHER|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
48182276|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
48182277|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
48182278|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
48182279|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
48182280|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
48182281|NCT04349007|DIETARY_SUPPLEMENT|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in after cooking
48182282|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, maize, and vitamin and minerals
48182283|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use plus Milk|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, non-fat dried milk and vitamin and minerals
48182284|NCT00448006|DEVICE|Allium Biliary Stent|device
48182285|NCT00448006|DEVICE|allium biliary stent|allium biliary stent
48182286|NCT01947322|DRUG|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
48182287|NCT02559310|DRUG|lefamulin|antibacterial agent
48182288|NCT02559310|DRUG|Moxifloxacin|antibacterial agent
48182289|NCT02559310|DRUG|Linezolid|antibacterial agent
48182290|NCT03017547|DRUG|IC14|Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
48182291|NCT03017547|OTHER|Placebo|sterile normal saline for infusion
48182292|NCT01229774|DRUG|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
48182293|NCT01229774|DRUG|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
48720071|NCT06508242|OTHER|Placebo|placebo
48720072|NCT03609476|PROCEDURE|Room temperature saline instillation|Saline is used as room temperature
48720073|NCT03609476|PROCEDURE|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
48720074|NCT03609476|PROCEDURE|No saline instillation|No saline is used prior to catheter removal
48182294|NCT03236532|DIETARY_SUPPLEMENT|Glutamine and exercise|
48182295|NCT03236532|DIETARY_SUPPLEMENT|Maltodextrin and exercise|
48182296|NCT04769375|OTHER|Evaluation of pain|The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
48182297|NCT04769375|OTHER|Application of pelvic girdle pain tests|The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
48182298|NCT04769375|OTHER|Application of pelvic girdle questionnaire|Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
48720075|NCT04628949|DEVICE|aScope™ Duodeno endoscope and aBox™ Duodeno|"The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope."
48024983|NCT00450424|OTHER|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
48182299|NCT05701241|DRUG|Somatostatin analog|Somatostatin analog treatment every 4 weeks
48182300|NCT05036954|DEVICE|EyeBrid Excel hybrid lenses|new lenses
48182301|NCT02038712|DIETARY_SUPPLEMENT|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
48182302|NCT02038712|DIETARY_SUPPLEMENT|Fasted condition|Subjects will consume 600mL plain water.
48182303|NCT02038712|PROCEDURE|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
48720076|NCT00340379|DRUG|Ziprasidone|Target dosage 120-160mg/day based on tolerance
48720077|NCT00340379|DRUG|Sertraline|Target dosage 150-200mg/day based on tolerance.
48720078|NCT00340379|DRUG|Haloperidol|Target dosage 6-8mg/day based on tolerance.
48182304|NCT02038712|BEHAVIORAL|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
48182305|NCT02038712|PROCEDURE|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
48182306|NCT00136279|BEHAVIORAL|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
48182307|NCT01518907|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
48182308|NCT03774147|DEVICE|24-hour Ambulatory Blood Pressure Monitoring (ABPM)|
48182309|NCT04368845|DEVICE|Telerehabilitation|The treatment arm will be given up to 1-hour breathing exercises, aerobic and resistive training exercises administered by a physiotherapist via a telerehabilitation device every 10 days for a six-month period.
48182310|NCT01937975|DRUG|Grazoprevir|100 mg oral tablet administered once a day for 10 days
48182311|NCT01937975|DRUG|Elbasvir|50 mg oral tablet administered once a day for 10 days
48182312|NCT02419417|DRUG|BMS-986158|Specified dose on specified days
48383498|NCT04668326|DEVICE|Mobile Manual Standing Wheelchair|Mobile in BOTH seated and standing positions
48720079|NCT00581360|DRUG|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
48720080|NCT06507124|OTHER|This is observational with no intervention|This is observational with no intervention
48720081|NCT05080634|OTHER|Patients who underwent POEM|chalasia patients were recruited from a single center. The pre- and postoperative assessments included Eckardt scores, GerdQ questionnaire, high-resolution esophageal manometry, esophagogastroscopy and pH monitoring.
48720082|NCT04476394|DRUG|[14C]-Anaprazole Sodium enteric-coated capsule|\[14C\]-Anaprazole Sodium enteric-coated capsule
48383499|NCT00444665|DRUG|Travatan-Z|
48383500|NCT04690946|BEHAVIORAL|Cognitive Behavioral Therapy|14-18 sessions of CBT
48383501|NCT04690946|BEHAVIORAL|Emotion-Focused Therapy|14-18 sessions of EFT
48383502|NCT05485506|OTHER|Multimodal exercise program|"Running technical drills: pogo, askip, dribble, scissor, etc. Exercises for lumbopelvic stabilization: mobility exercises, hip thrust, dead lift, lunge to skip.~Resisted sprints by using a sled: resistance leading to a 60% and 30% of optimal load (previously calculated)"
48024984|NCT06535997|OTHER|Questionnaire|For patients alive only at the time of inclusion, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
48182313|NCT02419417|BIOLOGICAL|Nivolumab|Specified dose on specified days
48182314|NCT01261247|DRUG|panobinostat|Given orally
48182315|NCT01261247|OTHER|laboratory biomarker analysis|Correlative studies
48182316|NCT01261247|GENETIC|western blotting|Correlative studies
48182317|NCT01261247|GENETIC|DNA analysis|Correlative studies
48182318|NCT01261247|OTHER|flow cytometry|Correlative studies
48182319|NCT01261247|OTHER|pharmacological study|Correlative studies
48720083|NCT04415996|OTHER|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
48720084|NCT04415996|OTHER|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 20 seconds each side.
48720085|NCT05661396|BEHAVIORAL|Serious game rehabilitation|Three patients received therapeutic serious game rehabilitation in addition to conventional rehabilitation. The serious game was proposed to be played three times per week for four weeks, for a total of 12 sessions, with 15 min per session (= 45 minutes per week).
48720086|NCT05320198|DRUG|DISC-0974|DISC-0974 is administered subcutaneously.
48720087|NCT03445221|DIETARY_SUPPLEMENT|IV Immunonutrition|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 3 days before surgery.
48024985|NCT05577897|OTHER|Education|"A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet COPD Guide on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method."
48024986|NCT00782613|DRUG|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
48024987|NCT00782613|DRUG|Placebo|Placebo in a cream formulation
48024988|NCT01525082|DRUG|Capecitabine|Capecitabine by mouth twice daily on Days 1 to 14
48024989|NCT01525082|DRUG|Temozolomide|Temozolomide by mouth daily on Days 10 to 14
48383503|NCT06651177|DRUG|Tirzepatide|Tirzepatide is available in single dose vials at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A study MC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed
48024990|NCT01525082|BIOLOGICAL|Bevacizumab|Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15
48383504|NCT06651177|OTHER|Placebo|"A matched placebo (containing saline) will be created for use in the trial. A study MC will administer the once-weekly SQ dose of saline. The process for deciding on dose increases will be the same for placebo and tirzepatide."
48383505|NCT06454695|BEHAVIORAL|Future-oriented imagery rescripting|In this pilot study, in the screening phase, negative or catastrophic future-oriented images will be explored for all patients, including ratings of distress. The future-oriented imagery rescripting consists of 3-5 sessions; each image will be treated in one session, starting with the image that causes highest distress. The protocol is largely based on Hackmann (1998), with minor adaptations from other protocols.
48383506|NCT06454695|OTHER|Treatment as Usual|Psychotherapy and/or medication
48024991|NCT00006508|PROCEDURE|Controlled hypoglycemia using insulin|
48024992|NCT00006508|PROCEDURE|formula meal|
48024993|NCT02819726|BIOLOGICAL|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
48024994|NCT02819726|BIOLOGICAL|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
48024995|NCT02819726|BIOLOGICAL|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
48024996|NCT04564352|DIETARY_SUPPLEMENT|Adansonia digitata|Juice of AD fruit
48024997|NCT02498665|DRUG|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
48024998|NCT02010385|DRUG|Octreotide|
48024999|NCT02010385|DRUG|Saline|
48025000|NCT05447169|DIAGNOSTIC_TEST|EBV antibodies test|ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma
48025001|NCT05447169|DIAGNOSTIC_TEST|EBV DNA test|quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
48025002|NCT02087800|BEHAVIORAL|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
48383507|NCT06647693|BEHAVIORAL|Motor Synchrony Games (MSG)|"The motor synchrony games (MSG) intervention uses fun but progressively more challenging gross motor and imitation games to promote behavioral self-regulation. Primary activities include: songs and fingerplays, stop and go games, and imitation games. These games get progressively more challenging over time by varying signal/modality. For example, going from a verbal and gestural paired stop and go signal to only a gestural stop signal. A fidelity checklist is used to ensure the intervention is appropriately used with the following criteria (uses \>10 imitation trials, \>10 Stop \& Go games, \>3 trials/min on average with \>5 trials/min preferred, use of progressive challenge, opportunities for Child Choice, environmental arrangement, and therapeutic strategies such as modeling)."
48383508|NCT05285527|DEVICE|MiSight 1 Day|Subjects will wear MiSight 1 day lenses for three years.
48720088|NCT03445221|DIETARY_SUPPLEMENT|Conventional Diet|patients will continue preoperative oral conventional diet.
48720089|NCT00003231|DRUG|cisplatin|
48720090|NCT00003231|DRUG|docetaxel|
48720091|NCT00003231|PROCEDURE|surgical procedure|
48720092|NCT00003231|RADIATION|radiation therapy|
48720093|NCT02122809|DRUG|Chiauranib|Take orally
48720094|NCT01259453|BIOLOGICAL|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
48720095|NCT04506515|DIAGNOSTIC_TEST|Psychological stress and adaptation at work score (PSAS)|completing a survey based on PSAS
48720096|NCT00487474|DEVICE|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
48025003|NCT02087800|BEHAVIORAL|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
48025004|NCT06573905|OTHER|no intervention|no intervention. this is observational study.
48720097|NCT04252495|DRUG|Aprocitentan|A single oral dose of 25 mg.
48720098|NCT04743960|DIETARY_SUPPLEMENT|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
48720099|NCT01930890|BIOLOGICAL|BIIB023|
48720100|NCT01930890|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
48720101|NCT01930890|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
48720102|NCT05768243|DRUG|Hyaluronic acid|hyaluronic acid is used as an adjunctive treatment to scaling and root planing
48720103|NCT05768243|PROCEDURE|red injectable platelet rich fibrin (i-prf)|injecting red i-prf into the pocket after scaling and root planing
48720104|NCT03177096|BEHAVIORAL|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
48519923|NCT00398424|DRUG|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.~On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.~Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
48383509|NCT02663999|DRUG|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
48383510|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 20 mg capsule
48383511|NCT01369836|DRUG|Tafamidis meglumin|A single oral dose of 40 mg capsule.
48720105|NCT03177096|BEHAVIORAL|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
48383512|NCT01369836|DRUG|Placebo|A single oral dose of matched placebo.
48383513|NCT06173674|OTHER|Music intervention|"The music intervention will consist of three components including:~1. Playlist composition Six music genres playlists will be offered to patients, including Classical Music, Country Music, Folk Music, Hymns and Reglious Music, Jazz and Swing Music, Popular/Easy Listening/RNB and Soundtrack Music. Patients can also add their favourite music to the list as well.~2. Music Intervention Delivery The general criteria for intervention delivery are:1) Each session lasts at least 20 minutes; 2) The music will be delivered by a comfortable, wireless, on/off switch noise-cancelling headphone; 3) The volume will be adjusted according to the patient's preference and controlled at 65dB or lower; 4) The order of music in the playlists will be decided by the patient; 5) Music will be delivered in inpatient room and/or waiting area before surgery/procedure.~3. Cleaning and infection of the equipment We will comply with guidelines on disinfection of materials in the hospital."
48519924|NCT03623503|OTHER|Observational study|
48519925|NCT03684577|BEHAVIORAL|Hypnotherapy for Agoraphobia|see description of the experimental arm
48519926|NCT00128401|DRUG|D-Cycloserine|
48519927|NCT00128401|DRUG|Placebo|
48519928|NCT06551194|OTHER|prevalence of difficult-to-treat IBD|To assess the prevalence and risk factors of difficult-to-treat IBD patients
48519929|NCT01306266|DRUG|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
48519930|NCT01306266|DRUG|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
48519931|NCT02885545|DEVICE|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
48519932|NCT02885545|DRUG|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
48519933|NCT04942678|BEHAVIORAL|10-minute visit with therapy dog and child life specialist handler|A visit from a therapy dog and child life specialist will occur which will last for approximately 10 minutes. Parents and patients will be asked to sanitize their hand prior to the visit. The child life specialist will be instructed to have ad lib conversation with the family. The dog will remain on a leash during the visit. The patient will be free to pet the therapy dog if they wish.
48519934|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where we associate a sound with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, we want to accelerate the remission of nightmares.
48720106|NCT03177096|BEHAVIORAL|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
48720107|NCT05826977|BEHAVIORAL|CASI-Plus|See arm description
48025005|NCT06152094|OTHER|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
48025006|NCT06152094|OTHER|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
48383514|NCT05381025|DIETARY_SUPPLEMENT|Kava (Piper methysticum) extract|Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
48519935|NCT05237778|BEHAVIORAL|Imagery Rehearsal Therapy|These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without any association with a sound.
48519936|NCT01875328|OTHER|Telemedicine|Post stroke follow up in home using telemedicine.
48519937|NCT01875328|OTHER|Clinic|Post stroke clinic group follow up
48519938|NCT01546428|DRUG|INC280|
48519939|NCT00064987|PROCEDURE|Testicular biopsy|Outpatient surgical procedure.
48720108|NCT00530920|DRUG|tipranavir|
48720109|NCT00530920|DRUG|ritonavir|
48720110|NCT04588090|PROCEDURE|The concurrent 3 weeks TP regimen|paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
48720111|NCT04588090|PROCEDURE|The concurrent weekly TP regimen|paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
48519940|NCT00064987|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
48383515|NCT03506724|DRUG|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
48383516|NCT03506724|DRUG|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
48519941|NCT00064987|DRUG|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
48519942|NCT01979991|PROCEDURE|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
48519943|NCT03223350|DRUG|Capsaicin 0.1% Cream|Topical application
48519944|NCT03223350|DRUG|Placebos|placebo cream
48519945|NCT05829655|DRUG|Drug A (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
48519946|NCT05829655|DRUG|Drug B (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
48519947|NCT05829655|DRUG|Drug C (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
48720112|NCT04588090|RADIATION|External radiation plus intraluminal after-loading irradiation|External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
48720113|NCT02544334|PROCEDURE|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
48720114|NCT02544334|OTHER|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
48720115|NCT02544334|OTHER|Saliva Collection|All participants will have a saliva collection.
48720116|NCT00120055|DRUG|Atorvastatin (Lipitor)|
48720117|NCT04533230|BEHAVIORAL|Educational intervention with prescription feedback|Educational intervention and targeted feedback on prescription of benzodiazepines and benzodiazepine-like hypnotics
48720118|NCT04533230|BEHAVIORAL|Information on treatment guidelines|Written information on treatment guidelines.
48720119|NCT03434314|PROCEDURE|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
48720120|NCT00499746|DRUG|tramadol|oral dose, once per day
48025007|NCT00688805|DRUG|Propranolol|40 mg given as a single oral administration in an opaque capsule
48025008|NCT00688805|DRUG|Placebo|matching capsule containing no active medication
48025009|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
48025010|NCT03748745|DRUG|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
48383517|NCT04732884|DEVICE|Smartsens, Gelenic AG; with biofeedback|The Smartsens is a CE certified 4-cell load sensor integrated in an insole that can be placed in any orthosis or cast. A threshold (10-50kg) can be defined at which - if higher loads are measured - an audio signal warns the patient of overloading (biofeedback). The device additionally registers loads from 0-100kg continuously.
48383518|NCT04732884|DEVICE|Smartsens, Gelenic AG; without biofeedback|Patients will not be warned by an audio signal in case of overloading. The device registers loads from 0-100kg continuously.
48025011|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
48383519|NCT02921646|OTHER|Measure of resting energetic expenditure|measure of resting energetic expenditure
48383520|NCT00864084|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
48383521|NCT01814917|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
48383522|NCT01814917|DRUG|CBPB|
48383523|NCT05560802|OTHER|WHOs Labour care guide|Guidelines for monitoring labor progress, the WHOs LCG
48383524|NCT04705896|BIOLOGICAL|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
48383525|NCT04705896|OTHER|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
48383526|NCT06652659|OTHER|Non-union|Observational study looking prospectively at many different factors that may affect non-union of midshaft clavicle fractures.
48383527|NCT06651021|DRUG|balcinrenone/dapagliflozin|"Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days."
48383528|NCT04775953|DRUG|Cefazolin|Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)
48383529|NCT04775953|DRUG|Dalbavancin|A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species
48383530|NCT04775953|DRUG|Daptomycin|Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks
48383531|NCT04775953|DRUG|Nafcillin|Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)
48383532|NCT04775953|DRUG|Oxacillin|Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks
48383533|NCT04775953|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)
48383534|NCT06017973|DIAGNOSTIC_TEST|MRI scan including arterial spin labelling of the brain|Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
48383535|NCT06017973|DIAGNOSTIC_TEST|CT perfusion scan of the brain|Siemens Naeotom Alpha with quantum technology (photon-counting)
48383536|NCT06017973|DIAGNOSTIC_TEST|FDG-PET scan of the brain|An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
48383537|NCT02894060|OTHER|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
48720121|NCT00499746|DRUG|placebo|oral dose, once per day
48720122|NCT00499746|DRUG|Hydromorphone|oral dose, once per day
48025012|NCT03748745|DRUG|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
48383538|NCT02135276|DRUG|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
48383539|NCT04143568|OTHER|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
48383540|NCT02206256|DRUG|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
48383541|NCT02206256|BEHAVIORAL|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
48383542|NCT02361801|DRUG|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
48519948|NCT05829655|DRUG|Drug D (Blinded Drug)|Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
48519949|NCT05829655|DRUG|Suvorexant (20mg/day)|Double blind administration of suvorexant once per day during residential stay until discharge.
48720123|NCT00499746|DRUG|Methylphenidate|oral dose, once per day
48383543|NCT02361801|DRUG|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
48720124|NCT00721175|DEVICE|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
48720125|NCT00721175|DEVICE|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
48720126|NCT02610933|DRUG|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
48720127|NCT02610933|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 supplementation
48720128|NCT01186107|DEVICE|Endeavor Resolute stent|zotarolimus-eluting stent
48720129|NCT01186107|DEVICE|Cypher stent|sirolimus-eluting stent
48720130|NCT06038994|OTHER|No intervention|This is an obvertional study, and there is no intervention.
48720131|NCT00636259|DRUG|Bicalutamide (Casodex)|150mg
48720132|NCT01608503|PROCEDURE|lung deflation|lung was deflated during respiration cycle
48720133|NCT01608503|PROCEDURE|lung inflation|lung was inflated during respiratory cycle
48383544|NCT04190251|OTHER|Inteprofessional medication adherence support program (IMAP)|In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.
48519950|NCT05829655|DRUG|Placebo|Double blind administration of placebo once per day during residential stay until discharge.
48519951|NCT00144729|PROCEDURE|Bone marrow transplant|
48519952|NCT02501928|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
48720134|NCT03645304|DRUG|Ropivacaine|"Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics."
48720135|NCT03645304|DRUG|0.9% saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
48025013|NCT01145079|DEVICE|Zotarolimus-eluting stent|Zotarolimus-eluting stent
48025014|NCT01145079|DEVICE|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
48025015|NCT01145079|DEVICE|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
48025016|NCT01145079|DEVICE|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
48025017|NCT00209313|DRUG|Acyclovir|Acyclovir 800 mg twice daily or placebo
48383545|NCT00157040|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
48383546|NCT06650956|OTHER|Integrated HPV and SRH Service Package|"1. Integrated Service Package combines HPV vaccination with sexual and reproductive health (SRH) education. The vaccine in the intervention package is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.;~2. The package will be delivered through multiple touch-points such as school-based programs, health facility services, and community outreach. i) In school, the intervention incorporates Comprehensive Sexuality Education, empowering boys and girls with knowledge about their bodies, health, and rights. This goes beyond simply providing information about HPV and vaccination. ii) At health facilities, the intervention package will also be delivered in adolescent-friendly ways, ensuring that boys and girls feel comfortable accessing SRH information. iii) Since not all boys and girls attend school, the intervention includes community outreach that ensures wider reach and accessibility for adolescents aged 10-13, including those not enrolled in school."
48383547|NCT06650956|BIOLOGICAL|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.
48383548|NCT01438346|BEHAVIORAL|Substance Abuse Education|10 weeks of usual care for substance abuse.
48519953|NCT02501928|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
48519954|NCT02501928|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
48519955|NCT02501928|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
48519956|NCT04258176|OTHER|Multidisciplinary outpatient pathway|Coordinators, assigned to improve the care flow, review and align the patient's appointments and tests in agreement with the patient's wishes. Outpatient consultations are arranged to take place the same day and schedules for care providers are coordinated. The patients' attendance in outpatient clinics are planned sequentially where the delivering specialty writes a summary to the subsequent specialty. Afterwards, the involved physicians and nurses attend an interdisciplinary conference, resulting in a joint treatment plan, with feedback and notice of modifications, which is delivered to the patient and general practice.
48519957|NCT01870089|DEVICE|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
48519958|NCT01605851|DEVICE|Closure, Foramen Ovale|
48519959|NCT02836925|DRUG|Ledipasvir+Sofosbuvir|"Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~* 12 weeks in previously untreated infected patients~* 24 weeks for previously treated patients with uncertain subsequent retreatment options"
48519960|NCT02836925|DRUG|Sofosbuvir+Velpatasvir|"Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment"
48519961|NCT00395161|DRUG|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
48720136|NCT03645304|DEVICE|ON-Q Painbuster Silver Soaker|ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
48720137|NCT04304885|DIAGNOSTIC_TEST|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
48025018|NCT00871481|BIOLOGICAL|ipilimumab|Given IV
48025019|NCT00871481|DRUG|cyclophosphamide|Given IV
48025020|NCT00871481|PROCEDURE|biopsy|Optional correlative studies
48025021|NCT00871481|BIOLOGICAL|aldesleukin|Given SC
48383549|NCT01438346|BEHAVIORAL|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
48383550|NCT04945980|DIETARY_SUPPLEMENT|Ground beef|Ground beef naturally low in monounsaturated fatty acids or naturally high in monounsaturated fatty acids
48519962|NCT00395161|DRUG|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)
48519963|NCT00395161|DIETARY_SUPPLEMENT|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
48519964|NCT00395161|DRUG|Selenium|one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)
48519965|NCT00395161|OTHER|saline|equivalent volume of intravenous saline
48720138|NCT03103035|OTHER|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
48720139|NCT05690620|BEHAVIORAL|laughter yoga|Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
48720140|NCT05690620|OTHER|Control|"The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied."
48720141|NCT02030288|BEHAVIORAL|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
48720142|NCT05403697|PROCEDURE|Individualized MAP|Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
48720143|NCT04311827|OTHER|Serratus Anterior Plane Block|Injection of bupivacaine 75mg above the serratus anterior facial plane in the anterior axillary line
48720144|NCT02986932|DEVICE|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
48720145|NCT00204867|OTHER|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
48720146|NCT04687423|DRUG|FCN-011|FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
48720147|NCT04366557|OTHER|Manual therapy, exercises and education program|a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor
48720148|NCT04366557|OTHER|Education program|education about pelvic floor
48720149|NCT00864851|BIOLOGICAL|Replagal|Intravenous (IV) infusion for 12 months
48720150|NCT00416715|DRUG|letrozole|Given PO
48720151|NCT00416715|DIETARY_SUPPLEMENT|calcium carbonate|Given PO
48383551|NCT02007512|DRUG|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
48383552|NCT02007512|DRUG|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
48519966|NCT00395161|OTHER|sterile water|equivalent volume of sterile water
48383553|NCT02007512|DRUG|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
48383554|NCT02007512|DRUG|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
48383555|NCT06278532|DIAGNOSTIC_TEST|Brief Negative Symptoms Scale|The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).
48519967|NCT00395161|OTHER|selenium|equivalent volume of sterile water
48519968|NCT00395161|DIETARY_SUPPLEMENT|whey-protein|one enteral dose daily of whey-protein
48519969|NCT03022916|DRUG|Nail Polish + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish
48519970|NCT03022916|OTHER|Nail polish|Application of nail polish only to both big toe nails
48519971|NCT03022916|DRUG|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
48519972|NCT03022916|DRUG|Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
48519973|NCT00965887|DRUG|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
48720152|NCT00416715|OTHER|laboratory biomarker analysis|Optional correlative studies
48720153|NCT00416715|DIETARY_SUPPLEMENT|calcium citrate|Given PO
48720154|NCT00416715|DIETARY_SUPPLEMENT|calcium glucarate|Given PO
48720155|NCT00416715|DRUG|calcium gluconate|Given PO
48720156|NCT00416715|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
48720157|NCT00416715|PROCEDURE|assessment of therapy complications|Ancillary studies
48720158|NCT00416715|PROCEDURE|musculoskeletal complications management/prevention|Correlative studies
48720159|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
48720160|NCT03476161|DEVICE|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
48720161|NCT03506919|DRUG|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
48720162|NCT06384664|DEVICE|Atricure's crysoSPHERE probe|Cryoablation is a procedure that is used to freeze and burn away tissue cells via a device called a cryosphere which emits a freezing gas.
48720163|NCT06384664|PROCEDURE|Standard of Care|An intercostal nerve block involves injecting anesthetic medications into nerves around the thoracic incision to provide temporary longer term pain relief after surgery.
48720164|NCT02198794|DRUG|SD-809|SD-809 will be administered per dose and schedule specified in the arm.
48720165|NCT02198794|DRUG|Placebo|Placebo matching to SD-809 will be administered per schedule specified in the arm.
48720166|NCT04254029|DIETARY_SUPPLEMENT|MOROLSTEVER1|The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
48720167|NCT01576185|OTHER|laboratory biomarker analysis|Correlative studies
48720168|NCT01576185|DRUG|quizartinib|Via gavage
48720169|NCT01576185|DRUG|sorafenib tosylate|Via gavage
48720170|NCT04659694|OTHER|Wellness programme provided by Oomph! Wellness company|The Oomph! wellness programme empowers older adults to lead a full life for life. It focuses on building an individual-centred programme that consists of a varied exercise and activity plans including days out. All of these, aims in improving the physical and psychosocial wellness in older adults. This intervention is a three day training session for care home staff to understand and learn how to facilitate care activities within their care home.
48720171|NCT04454593|OTHER|no intervention|This is an observation study,with no intervention
48720172|NCT00237380|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
48720173|NCT01443130|DRUG|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
48025022|NCT00871481|OTHER|immunohistochemistry staining method|Correlative studies
48025023|NCT00871481|GENETIC|polymerase chain reaction|Correlative studies
48025024|NCT00871481|OTHER|immunoenzyme technique|Correlative studies
48383556|NCT06278532|DIAGNOSTIC_TEST|The Calgary Depression Scale for Schizophrenia|The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.
48383557|NCT06278532|DIAGNOSTIC_TEST|The Schizophrenia Cognition Rating Scale|The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.
48383558|NCT02552329|OTHER|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
48383559|NCT06402513|DRUG|Ravagalimab|Subcutaneous Injection
48720174|NCT01443130|DRUG|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
48720175|NCT01345383|PROCEDURE|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
48720176|NCT02967939|DRUG|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
48720177|NCT02967939|DRUG|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
48720178|NCT02976103|DEVICE|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
48720179|NCT02976103|OTHER|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
48720180|NCT04113460|OTHER|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
48720181|NCT01756443|DRUG|2% lidocaine/adrenaline and 0.5% bupivacaine|
48720182|NCT02707393|DRUG|Fludarabine|infusion
48025025|NCT00871481|BIOLOGICAL|therapeutic cytotoxic T lymphocytes|Given IV
48025026|NCT03411226|PROCEDURE|re-TREPP|repeated hernia repair via the TREPP technique
48025027|NCT05649657|OTHER|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25\~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2\~3 sessions per week and about 70 sessions in total.
48720183|NCT02707393|DRUG|Thiotepa|infusion
48720184|NCT02707393|DRUG|Melphalan|infusion
48720185|NCT02707393|DRUG|ATG|infusion
48720186|NCT02707393|DRUG|Cyclosporine A|infusion, orally if possible
48182320|NCT01261247|OTHER|immunohistochemistry staining method|Optional correlative studies
48182321|NCT01921647|DRUG|YH4808|
48383560|NCT06047964|DEVICE|DCB|Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
48182322|NCT01921647|DRUG|Nexium|
48383561|NCT06047964|DEVICE|POBA|Intracranial PTA balloon catheter
48383562|NCT03710759|OTHER|Assistive autogenic Drainage|Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
48383563|NCT03687580|DEVICE|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
48383564|NCT03687580|DEVICE|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
48383565|NCT06162624|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
48519974|NCT00965887|DRUG|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
48519975|NCT02893085|BIOLOGICAL|bile sample analysis|tumor mutation profile tumor genotype
48519976|NCT02893085|BIOLOGICAL|biochemical markers, VEGF and MMPs, in bile samples|
48519977|NCT06366763|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (CIVIQ-14 and VCSS scores )
48720187|NCT02707393|DRUG|Mycophenolate mofetil|infusion
48519978|NCT00631592|DRUG|GSK1349572|
48519979|NCT00537849|DEVICE|Sonablate 500(SB-500)|
48519980|NCT02756130|DRUG|Birinapant|Given IV
48519981|NCT02756130|DRUG|Carboplatin|Given IV
48519982|NCT02756130|OTHER|Laboratory Biomarker Analysis|Correlative studies
48519983|NCT02756130|OTHER|Pharmacological Study|Correlative studies
48519984|NCT01090414|DRUG|Idelalisib|Idelalisib tablets or capsules administered orally
48519985|NCT05081050|OTHER|Only Follow-up|No intervention is planned.
48519986|NCT01640249|DRUG|Placebo|Capsules administered orally
48025028|NCT00009737|DRUG|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
48025029|NCT00009737|DRUG|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
48025030|NCT00009737|DRUG|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
48025031|NCT04491500|BEHAVIORAL|High attitude environment|The participants will go to 4000m altitude to work for two weeks.
48519987|NCT01640249|DRUG|LY3006072|Capsules administered orally
48720188|NCT02707393|BIOLOGICAL|bone marrow or peripheral blood stem cells|infusion
48025032|NCT00608712|DRUG|Esomeprazole|Esomeprazole 20mg oral tablet
48025033|NCT00587145|DRUG|S-1,Docetaxel|"* S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
48025034|NCT02088996|DEVICE|longwave diathermy on high power and interferential therapy|
48025035|NCT02088996|DEVICE|longwave diathermy on low power|
48025036|NCT01717235|DRUG|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
48025037|NCT01351805|DRUG|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
48025038|NCT01351805|DIETARY_SUPPLEMENT|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
48025039|NCT01351805|OTHER|placebo pill|placebo
48025040|NCT04544046|OTHER|Supportive Oncology Care at Home|Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.
48025041|NCT04544046|OTHER|Usual Care|Standard care arm will receive standard oncology care and attend regular clinic visits.
48025042|NCT03251703|PROCEDURE|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
48025043|NCT00426023|DRUG|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
48025044|NCT00426023|DRUG|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
48028936|NCT04444154|BEHAVIORAL|Control group|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.
48519988|NCT02367976|DRUG|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
48519989|NCT03688633|DRUG|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
48519990|NCT03688633|OTHER|Usual care|patients will be followed as usual
48720189|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles."
48383566|NCT06162624|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"As control condition, CBT book Feeling Good Self-Help Book will be used"
48383567|NCT00002949|DRUG|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
48383568|NCT00002949|DRUG|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
48383569|NCT00002949|RADIATION|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
48383570|NCT00144859|DRUG|SB681323|
48383571|NCT06593574|PROCEDURE|Robotic laminectomy|Surgical robots are used to assist with laminectomy
48383572|NCT06593574|PROCEDURE|Traditional laminectomy|Instead of relying on a surgical robot, doctors perform the laminectomy themselves with an ultrasonic osteotome
48519991|NCT05625074|PROCEDURE|Conventional surgery for great saphenous vein insufficiency|Arch ligation and stripping of great saphenous vein. Prophilatic anticoagulation - Low molecular weight heparin vs DOACs Antibiotics Non-steoridal anti-inflamatory drugs
48519992|NCT05311189|DRUG|HLX10, Trastuzumab and Chemotherapy|HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
48519993|NCT00442871|DRUG|eltrombopag|eltrombopag 50 mg oral
48519994|NCT06581302|DEVICE|Magnetic seizure therapy by Magnetic stimulator|The seizure is induced by Magnetic stimulator of MagPro MST(XP)，MagVenture A/S, Farum, Denmark. It is administered in combinations with antipsychotic medications
48519995|NCT06581302|DRUG|Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)|It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.
48519996|NCT03138408|DRUG|SC-004|Intravenous
48025045|NCT00298233|DRUG|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
48383573|NCT03074916|DEVICE|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
48519997|NCT03138408|DRUG|ABBV-181|Intravenous
48519998|NCT03266796|BEHAVIORAL|goal setting process|goal setting process during the first consultation
48025046|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 4 g/day|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
48383574|NCT05042128|DRUG|LSTA1|LSTA1 is a novel cyclic tumour-penetrating peptide iRGD (internalizing Arginylglycylaspartic acid) which may overcome poor drug delivery by activation of a complex trans-tissue transport pathway, providing an opportunity to overcome this mechanism of resistance in PDAC
48383575|NCT05042128|DRUG|Gemcitabine Injection|Chemotherapy drug provided as solution to be administered via IV infusion.
48383576|NCT05042128|DRUG|Nab paclitaxel|Chemotherapy drug provided as solution to be administered via IV infusion.
48519999|NCT02166255|BIOLOGICAL|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
48520000|NCT02166255|OTHER|laboratory biomarker analysis|Correlative studies
48520001|NCT02561117|DRUG|Metronidazole|Administration once daily
48520002|NCT05970224|DRUG|Ir-CPI|Participants receive a single intravenous dose of Ir-CPI during 48 hours
48520003|NCT04133857|OTHER|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
48520004|NCT03198338|DRUG|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
48520005|NCT03198338|DRUG|Normal Saline|0.9% Normal Saline
48383577|NCT02353572|DRUG|Melphalan|Given IV
48383578|NCT02353572|DRUG|Bortezomib|Given IV
48383579|NCT02353572|DRUG|Dexamethasone|Given IV
48383580|NCT02353572|PROCEDURE|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
48520006|NCT03198338|DEVICE|Ultrasound|Ultrasound guided TAP block
48520007|NCT02370238|DRUG|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
48520008|NCT02370238|DRUG|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
48182323|NCT01921647|DRUG|Amoxicillin|
48383581|NCT06538402|PROCEDURE|10 cm pouch|A 10 cm pouch will be constructed
48383582|NCT06538402|PROCEDURE|15 cm pouch|A 15 cm pouch will be constructed
48520009|NCT02370238|DRUG|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
48520010|NCT04481555|DRUG|Azithromycin|Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
48520011|NCT04481555|DRUG|ICS|All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
48520012|NCT01519310|OTHER|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
48520013|NCT02245412|BIOLOGICAL|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
48520014|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
48520015|NCT02245412|BIOLOGICAL|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
48025047|NCT01047683|DRUG|AMR101 (ethyl icosapentate) - 2 g/day|AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
48025048|NCT01047683|DRUG|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
48025049|NCT02985658|DRUG|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
48025050|NCT02985658|DRUG|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
48025051|NCT02985658|DRUG|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
48025052|NCT05267301|DIETARY_SUPPLEMENT|AlmegaPL (FDA NDIN # 826)|The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.
48025053|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
48182324|NCT01921647|DRUG|clarithromycin|
48182325|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Ketamine
48182326|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Normal Saline
48383583|NCT01924572|PROCEDURE|cord clamping at 2 minutes|
48383584|NCT01924572|PROCEDURE|cord clamping at 5 minutes|
48383585|NCT01924572|PROCEDURE|cord milking|
48520016|NCT03309098|DIAGNOSTIC_TEST|Ligmaster Arthrometer Assessment|Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
48520017|NCT05695209|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
48520018|NCT02879344|OTHER|Blood draw|
48182327|NCT01239784|BEHAVIORAL|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
48182328|NCT04510298|DRUG|SP-624|Oral Capsule
48383586|NCT05070507|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
48383587|NCT05070507|DIETARY_SUPPLEMENT|Placebo lozenge|Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
48520019|NCT05820464|DIAGNOSTIC_TEST|DDA Doppler|A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.
48520020|NCT02371382|DEVICE|Arthroplasty hip|Hip replacement
48520021|NCT03409588|DRUG|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
48520022|NCT00734058|DEVICE|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
48720190|NCT05980338|PROCEDURE|genicular nerve ablation by thermal radiofrequency plus alcohol neurolysis|"radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves of the knee.~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radio-frequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view. After the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve Then remove the needles."
48720191|NCT00895687|DRUG|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
48720192|NCT00895687|DRUG|Bortezomib|Beginning dose of 1. mg/m\^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
48720193|NCT05104541|OTHER|Weight loss|"In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts."
48720194|NCT01563016|DIETARY_SUPPLEMENT|glucose drink|participants will receive a drink rich in glucose
48720195|NCT06125691|BIOLOGICAL|ARCT-2138|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
48182329|NCT04510298|DRUG|Placebo|Oral Capsule
48720196|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for younger adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
48720197|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for older adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
48720198|NCT05970094|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
48383588|NCT00618800|BEHAVIORAL|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
48383589|NCT00618800|OTHER|Written Materials|Participants receive written information about falls prevention.
48720199|NCT06380894|DEVICE|Virtual Reality Cognitive Training|"Participants who were assigned to the VRCT intervention group underwent 60 minutes of weekly VRCT sessions over a 10-week intervention period. The program consisted of two components: (1) psychoeducation on cognitive functioning and ways to maintain cognitive health, (2) VR multi-domain cognitive training tasks that target cognitive domains of attention, memory, and executive functioning.~The VR experiences were administered through a head-mounted Oculus Go Screen V7. The VR system runs on a software developed by Dancing Mind Pte Ltd. The software specifications and service provided by Dancing Mind Pte Ltd include: MindGym System Functions: System Setup (Processor Setup, Password Changing etc) and Data Centre (Memory Care Therapy Data Analytics Report Querying and Printing Functions). The MindGym cognitive training content was developed based on the Singaporean culture, with visual stimuli reflecting familiar local environments."
48720200|NCT06380894|BEHAVIORAL|Active Control|Participants who were assigned to the active control group were provided treatment-as-usual, which included: (1) psychoeducation on MCI, cognitive functioning, and compensatory strategies, and (2) brain training cognitive stimulation booklet which consisted of weekly homework activities focusing on attention, memory, and executive functioning. Control participants were reviewed for 3 sessions monthly to follow up on their progress on the cognitive stimulation activity booklet.
48720201|NCT05547165|DEVICE|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
48025054|NCT02908269|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
48025055|NCT02908269|BIOLOGICAL|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
48025056|NCT03237689|DRUG|Hydrocortisone|Low dose hydrocortisone (10mg)
48182330|NCT00440245|DRUG|salbutamol|200 micrograms salbutamol from MDI
48383590|NCT06540352|DRUG|4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride|The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
48383591|NCT06540352|DRUG|Mannitol|Placebo in tablets
48182331|NCT02270671|BEHAVIORAL|ABMT|Attention Bias Modification Training
48383592|NCT02508649|DRUG|selepressin|
48383593|NCT02508649|DRUG|placebo|
48383594|NCT04274101|OTHER|Clinical Manifestations|Clinical manifestations in patients treated with Nifurtimox and Benznidazole
48025057|NCT03237689|DRUG|Placebo Oral Tablet|capsules of starch 1500 powder
48025058|NCT02061631|DRUG|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
48025059|NCT02061631|DRUG|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
48025060|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
48025061|NCT02061631|DRUG|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
48025062|NCT02251535|DEVICE|ATTUNE® Knee System|
48025063|NCT02251535|DEVICE|PFC® SIGMA® Knee System|
48383595|NCT04274101|DIAGNOSTIC_TEST|Serologic response|Serologic response in patients treated with Nifurtimox and Benznidazole
48383596|NCT04274101|DIAGNOSTIC_TEST|Direct method|Direct method tests in patients treated with Nifurtimox and Benznidazole
48720202|NCT05547165|COMBINATION_PRODUCT|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
48383597|NCT04274101|BEHAVIORAL|Adverse events|Adverse events in patients treated with Nifurtimox and Benznidazole
48520023|NCT02107924|PROCEDURE|APPI of TKR-Stimulan|
48720203|NCT05547165|DIAGNOSTIC_TEST|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
48720204|NCT00214929|BEHAVIORAL|treatment at home|
48720205|NCT01800318|DEVICE|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
48720206|NCT01800318|BEHAVIORAL|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
48182332|NCT02270671|OTHER|Placebo|Placebo Training
48383598|NCT00310869|BEHAVIORAL|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
48520024|NCT04805112|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
48520025|NCT05181046|DEVICE|Nanodropper adaptor|The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
48520026|NCT05181046|OTHER|Original eyedrop bottle/No Nanodropper|The original eyedrop bottle dispenses standard eyedrops.
48720207|NCT01800318|DEVICE|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
48720208|NCT01800318|BEHAVIORAL|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
48720209|NCT00724113|PROCEDURE|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
48520027|NCT01168427|DEVICE|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
48520028|NCT01200069|DRUG|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
48520029|NCT01200069|DRUG|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
48720210|NCT00724113|PROCEDURE|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
48720211|NCT01713556|DRUG|Propranolol|
48720212|NCT01713556|OTHER|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
48720213|NCT01713556|DRUG|placebo|
48720214|NCT05226585|BEHAVIORAL|In-Person Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi). CBTi contains the following well-validated components of cognitive behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
48025064|NCT01415505|DRUG|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
48025065|NCT05043077|DRUG|Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (6.5 μL) for 3 doses with 5-minute intervals
48025066|NCT05043077|DRUG|Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (28-34 μL) for 3 doses with 5-minute intervals
48182333|NCT01292304|DRUG|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
48383599|NCT00040001|DRUG|DTI-0009|
48720215|NCT05226585|BEHAVIORAL|Telehealth Cognitive Behavioral Therapy for Insomnia|Telehealth cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi) conducted via audio-video communication. tCBTi contains the following well-validated components of cognitive-behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
48720216|NCT05226585|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia|Sleep Healthy Using The Internet (SHUTi; aka iCBTi) is a self-guided, fully automated, online CBTi program that includes interactive features: personalized goal setting, graphical feedback based on inputted data, animations/illustrations to enhance comprehension, patient vignettes, and video-based expert explanations.
48720217|NCT00645905|DRUG|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
48720218|NCT00645905|DRUG|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
48720219|NCT05953012|DRUG|PMC-403|PMC-403 will be administered Intravitreal.
48720220|NCT00446186|DRUG|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
48720221|NCT00446186|DRUG|Comparator: placebo / Duration of Treatment: 2 Weeks|
48720222|NCT03518268|DRUG|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
48025067|NCT03265028|BEHAVIORAL|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
48720223|NCT03518268|DRUG|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
48720224|NCT04474041|DEVICE|EyeQue Insight|The Insight will be used to measure visual acuity and compared with a standard ETDRS eye chart.
48720225|NCT01384032|DIETARY_SUPPLEMENT|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
48025068|NCT01081977|PROCEDURE|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
48025069|NCT01081977|PROCEDURE|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
48383600|NCT05480904|OTHER|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
48025070|NCT05853094|PROCEDURE|Ileostomy|Protective loop ileostomy after low anterior resection
48182334|NCT01948076|DEVICE|resident with GE vscan|resident with GE vscan
48383601|NCT05480904|DIAGNOSTIC_TEST|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
48383602|NCT05480904|OTHER|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
48383603|NCT05480904|DIAGNOSTIC_TEST|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
48383604|NCT05480904|DIAGNOSTIC_TEST|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
48720226|NCT01384032|DIETARY_SUPPLEMENT|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
48720227|NCT01384032|DIETARY_SUPPLEMENT|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
48720228|NCT00560495|DRUG|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
48720229|NCT00560495|OTHER|immunoenzyme technique|
48720230|NCT00560495|OTHER|laboratory biomarker analysis|
48720231|NCT00560495|RADIATION|Tc 99m sestamibi|
48720232|NCT00560495|RADIATION|radiation therapy|once daily, 5 days a week, for 6-7 weeks
48720233|NCT06026995|DRUG|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
48720234|NCT06026995|DRUG|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
48025071|NCT05853094|PROCEDURE|Transverse colostomy|Protective loop transverse colostomy after low anterior resection
48025072|NCT06531746|OTHER|Extracorporeal shock wave|"participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an~EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number:~EM12681015\], Italy, shock wave generator."
48182335|NCT00683059|DRUG|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
48720235|NCT03226977|DEVICE|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
48720236|NCT03226977|DEVICE|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
48025073|NCT06531746|OTHER|Selected physical therapy program|Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles
48025074|NCT00725894|DEVICE|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
48182336|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete expressive disclosure writing
48182337|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete benefit finding writing
48182338|NCT02339870|OTHER|Questionnaire Administration|Ancillary studies
48182339|NCT02339870|OTHER|Sham Intervention|Complete writing on an emotionally neutral topic
48383605|NCT05480904|DEVICE|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
48383606|NCT05480904|DIAGNOSTIC_TEST|Physical Function|This is a test of how your heart and lungs respond to exercise.
48383607|NCT02198209|DRUG|Liraglutide|"1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
48520030|NCT02435524|BEHAVIORAL|A&T infant and young child feeding intervention|"1. Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:~   * Increase mother's knowledge about optimal breastfeeding and its benefits~  * Increase mother's self-efficacy related to breastfeeding~  * Improve mother's perceptions about social norms relating to breastfeeding~2. Community mobilisation activities to:~   - Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers~3. Enhanced training of government health workers in infant and young child feeding to:~   * Improve their ability to support mothers and provide timely information about infant feeding"
48720237|NCT04730427|DRUG|GX-I7|Recombinant human interleukin-7 hybrid Fc
48025075|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
48025076|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
48025077|NCT05581693|DRUG|L04TD2|1 tablet of L04TD2
48025078|NCT05581693|DRUG|L04RD1|1 tablet of L04RD1
48182340|NCT04699760|DIETARY_SUPPLEMENT|Fish Oil|8 weeks, 2.2 G EPA/day
48182341|NCT04699760|DIETARY_SUPPLEMENT|Placebo|Placebo
48182342|NCT03513068|DEVICE|Portable Oxygen Concentrator (POC)|COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
48182343|NCT02071680|OTHER|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
48720238|NCT04730427|DRUG|GX-I7 vehicle|Formulation buffer of recombinant human interleukin-7 hybrid Fc
48720239|NCT00062608|BEHAVIORAL|Written self-disclosure|
48025079|NCT02966080|DRUG|HEP-IV|
48025080|NCT05507268|OTHER|no intervention|no intervention
48025081|NCT03738150|BIOLOGICAL|Sotatercept|Sotatercept injection
48025082|NCT03738150|OTHER|SOC|SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
48025083|NCT03421197|DRUG|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg tablet once per day
48025084|NCT03421197|DRUG|PPC-06 400 mg BID|Tepilamide Fumarate tablets 400 mg twice per day
48025085|NCT03421197|DRUG|PPC-06 600 mg|Tepilamide Fumarate tablets 600 mg twice per day
48182344|NCT01656213|DEVICE|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
48182345|NCT06385925|DRUG|TSN1611|TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
48383608|NCT02801201|DRUG|Midazolam|
48383609|NCT02801201|DRUG|Bupivacaine|
48383610|NCT03236337|BEHAVIORAL|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
48720240|NCT01281228|DRUG|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
48720241|NCT01281228|DRUG|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
48720242|NCT01281228|DRUG|placebo|saline infusion
48025086|NCT03421197|DRUG|Placebo|white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
48025087|NCT04895397|DEVICE|ultrasound guided Nerve Block procedure|"In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane."
48025088|NCT03936244|DEVICE|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
48025089|NCT00767546|DRUG|Botulinum toxin|60- 100 units Local injection to the rash area
48182346|NCT05406336|OTHER|Predicted uncontrolled BP status (yes/no) at follow up visit, derived using a machine learning algorithm|The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit. The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
48182347|NCT04470947|DIAGNOSTIC_TEST|Next generation functional drug screening|High-throughput image based in-vitro drug screening on primary patient tumor cells
48182348|NCT04470947|DIAGNOSTIC_TEST|Comprehensive genomic profiling|Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
48182349|NCT03805477|DRUG|Nintedanib|Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
48520031|NCT00248872|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
48182350|NCT02552459|DRUG|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
48182351|NCT02552459|DRUG|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
48182352|NCT02552459|DRUG|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
48182353|NCT02552459|DRUG|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
48182354|NCT01465945|PROCEDURE|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
48182355|NCT01465945|PROCEDURE|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
48182356|NCT06239415|OTHER|observation|Observation for 1 year of patients suffering from symptomatic peripheral atherosclerotic disease of the lower limb, with or without chronic ischemic heart disease, and indication for treatment with rivaroxaban 2.5 mg bid and acetylsalicylic acid 100 mg.
48182357|NCT05832879|BEHAVIORAL|OUD Telehealth Platform|The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
48182358|NCT01035853|DRUG|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
48182359|NCT03836573|BEHAVIORAL|Smoking Cessation iPad Decision Aid Tool|Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
48520032|NCT00707616|OTHER|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
48520033|NCT02308995|PROCEDURE|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
48182360|NCT03362034|DEVICE|double transfer trays|double trays one soft and one hard
48182361|NCT03362034|DEVICE|single transfer tray|single soft tray
48720243|NCT00499655|DRUG|erlotinib hydrochloride|Given orally
48720244|NCT00499655|DRUG|celecoxib|Given orally
48720245|NCT00499655|OTHER|placebo|Given orally
48720246|NCT00499655|OTHER|laboratory biomarker analysis|Correlative studies
48720247|NCT00499655|OTHER|immunohistochemistry staining method|Correlative studies
48720248|NCT00499655|GENETIC|fluorescence in situ hybridization|Correlative studies
48182362|NCT05616377|OTHER|Surgery or Radiotherapy|Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group
48182363|NCT05616377|OTHER|before or after target therapy|Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
48182364|NCT05655923|BIOLOGICAL|ozonized olive oil|ozonized oil will be mixed with xenograft in group II and Group III
48182365|NCT05655923|BIOLOGICAL|xenograft bone substitute|Xenograft bone substitutes in all Groups
48182366|NCT05198726|DEVICE|alpha tACS|2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)
48182367|NCT05198726|BEHAVIORAL|Speed of Processing Training|SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)
48182368|NCT00375531|BEHAVIORAL|Mindfulness Meditation (MfM)|
48182369|NCT01341249|DRUG|Experimental DW224aa|DW224aa tablet, single dose
48182370|NCT01341249|DRUG|Experimental DW224a|DW224a capsule, single dose
48182371|NCT01246089|DRUG|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
48182372|NCT03042364|OTHER|Pipelle de Cornier|RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
48720249|NCT00499655|GENETIC|mutation analysis|Correlative studies
48720250|NCT00499655|GENETIC|protein expression analysis|Correlative studies
48025090|NCT06534073|DEVICE|Socks|Plantar orthotic elements will be designed, according to the participants' previous baropodometric pattern, to alleviate pathological plantar pressure. These elements will be integrated into commonly worn items by patients, such as stockings or socks.
48383611|NCT04218175|OTHER|neuromobilization exercises|Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
48383612|NCT05566730|BEHAVIORAL|CT-MICART App|App designed with the goal of treating CUD in African American adults
48720251|NCT00499655|GENETIC|gene expression analysis|Correlative studies
48720252|NCT04485572|DIAGNOSTIC_TEST|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
48720253|NCT04485572|DIAGNOSTIC_TEST|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
48720254|NCT04485572|DIAGNOSTIC_TEST|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
48720255|NCT04485572|DIAGNOSTIC_TEST|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
48720256|NCT04485572|DIAGNOSTIC_TEST|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
48720257|NCT04438460|BIOLOGICAL|Blood test|"For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery."
48025091|NCT06534073|DEVICE|Standard device|Removable device of digital alignment to stabilize and unload the affected metatarsophalangeal joint. They do not require frequent replacement as they are washable and reusable elements.
48025092|NCT06534073|DEVICE|Foot orthoses|Custom-made foot orthoses.
48025093|NCT04255862|DRUG|Bimekizumab|Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
48025094|NCT01871298|OTHER|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
48025095|NCT06299202|DIAGNOSTIC_TEST|Diagnostic test|"* Inclusion visit (V1) Initial baseline CESM (V2) 15 days after inclusion~* First chemotherapy treatment (V3) 28 days after V2.~* Unilateral follow-up CESM (V4) 4 to 6 weeks after the first course of chemotherapy.~* Surgery (V5):~  3 to 6 weeks later at the end of the complete treatment with primary chemotherapy~* End of research visit (V6) It corresponds to the histological analysis on the surgical specimen after the complete treatment with neoadjuvant or primary chemotherapy."
48025096|NCT03239652|DEVICE|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
48025097|NCT02995668|OTHER|Strength-Function|Preoperative functional and strength capabilities training.
48025098|NCT02995668|OTHER|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
48025099|NCT02929576|DRUG|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
48025100|NCT02929576|DRUG|Placebo|
48025101|NCT02929576|DRUG|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
48025102|NCT03023735|OTHER|None. This is an observational study|
48025103|NCT01591681|DEVICE|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
48025104|NCT00002408|DRUG|Crofelemer|
48025105|NCT04589065|DEVICE|Selective Cytopheretic Device|SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
48025106|NCT02086591|DRUG|Doxycycline|
48025107|NCT05809570|DIAGNOSTIC_TEST|Clinical examination|"A total of 1057 individuals who applied to Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology and agreed to participate in the study were clinically and radiologically examined.~An intraoral scanner was utilized to capture direct optical intraoral data of a patient."
48025108|NCT05928325|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessments
48025109|NCT05928325|BEHAVIORAL|Health Education|Receive survivorship care education
48025110|NCT05928325|OTHER|Medical Device Usage and Evaluation|Wear activity tracking device
48025111|NCT05928325|OTHER|Supportive Care|Receive geriatric assessment-guided interventions
48182373|NCT00999739|BIOLOGICAL|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
48182374|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by HCL acid and inserted as demineralized dentin block graft in the socket
48025112|NCT02233712|BIOLOGICAL|G17DT|
48182375|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non restorable tooth, then the autogenous bone block graft will be harvested from the maxillary tuberosity and reshaped and inserted into the socket
48182376|NCT05518474|OTHER|Self-proning|Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.
48182377|NCT02523547|DRUG|Cavir|0.5mg/day
48182378|NCT02523547|DRUG|Baraclude|0.5mg/day
48182379|NCT03850275|DIETARY_SUPPLEMENT|Intervention/treatment|Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
48025113|NCT05955638|DEVICE|MiSight contact lenses|Contact lens for myopia management.
48182380|NCT02872012|DEVICE|Cryoanesthesia device|The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.
48182381|NCT02872012|DRUG|Lidocaine|Lidocaine applied to the non-cryoanesthesia eye.
48182382|NCT00786643|DRUG|5-Fluorouracil|5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
48383613|NCT05566730|BEHAVIORAL|Control|App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
48025114|NCT05955638|DEVICE|Proclear contact lenses|Single vision contact lens as control
48182383|NCT00786643|DRUG|Leucovorin (LV)|Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.
48383614|NCT04968912|OTHER|Placebo|Placebo infusion will be administered intravenously.
48383615|NCT04968912|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.
48383616|NCT04968912|DRUG|Standard of Care Treatment|Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.
48025115|NCT02842398|BEHAVIORAL|Balance Master|
48025116|NCT02842398|BEHAVIORAL|Customary Care|
48025117|NCT05035979|DRUG|BaidI Quzhi granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
48182384|NCT00786643|DRUG|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
48383617|NCT05494151|DIAGNOSTIC_TEST|Investigation of the metabolic substrate|A blood sample will be received from each patient to assess novel metabolomic biomarkers' levels at the time of acute myocardial infraction
48383618|NCT03744494|PROCEDURE|Bilateral simple orchidectomy (BSO)|
48383619|NCT03744494|PROCEDURE|Bilateral Subcapsular Orchidectomy|
48383620|NCT03744494|PROCEDURE|Bilateral Epididymal-sparing Orchidectomy|
48383621|NCT01915498|DRUG|Enasidenib|Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
48383622|NCT06474260|BEHAVIORAL|"One All Intervention"|"One-all is a Three-year curriculum targeted at specific outcomes for each yearfacilitated by young people from the community. The facilitators are inducted througha rigorous facilitators programme of three to five months' length. The facilitators areencouraged to adapt the program to their needs and provide the programme incustomized forms appropriate and as required for the communities. The interventionhas thus far been provided to the fishermen communities in Chennai and anecdotalfield evidence suggest, gains in the intended goals. After these experiences theintervention was being tried amongst the tribal adolescents in Gudalur. One-alltargets to provide the undermentioned skills to achieve the mentioned Goals andSkills:~* self-management • understanding feelings~* social awareness • conflict resolution~* relationship skills • empathy building~* self-awareness Skills •nurturing interpersonal relationships~* identity building • awareness about gender stereotypes"
48383623|NCT06357208|OTHER|Breathing Control and Retention|4 appointments with training of Breathing Control and Retention
48025118|NCT05035979|DRUG|Ju Yin cream|Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
48025119|NCT05035979|DRUG|Baidi Quzhi placebo granule|Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
48025120|NCT05035979|DRUG|Ju Yin placebo cream|Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
48025121|NCT01164059|DRUG|Olanzapine|Olanzapine 10, 15, or 20 mg / day
48025122|NCT01164059|DRUG|Flupentixol|Flupentixol 6, 9, or 12 mg / day
48025123|NCT01164059|DRUG|Quetiapine|Quetiapine 400, 600, or 800 mg / day
48025124|NCT01164059|DRUG|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
48025125|NCT01164059|DRUG|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
48025126|NCT01267071|DRUG|A|GSK962040 (50 mg, SD, oral)
48025127|NCT01267071|DRUG|B|14C GSK962040 (100 μg, SD, iv)
48383624|NCT01351194|PROCEDURE|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
48520034|NCT02308995|PROCEDURE|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
48520035|NCT02308995|DEVICE|V-Loc (Covidien, Mansfield, MA)|
48720258|NCT02356887|DIAGNOSTIC_TEST|Jugular venous ultrasound|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions at rest, jugular occlusion and valsalva maneuver. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
48720259|NCT03128190|OTHER|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
48720260|NCT03002311|DEVICE|Epharmix/CareSignal eHealth|The self-scheduling text and phone messaging system was built by Epharmix/CareSignal. Participants in the intervention group began receiving text or voice messages (for landlines) starting 1 hour following ED discharge if during normal business hours, or at 1000 the next business morning. Automated messages were sent up to 3 days in a row or until the participant responded or opted out. The phone system would ultimately connect them directly to their referral provider or clinic to schedule an appointment. Once participants hung up with the referral clinic, the intervention texted or called back to solicit the appointment date. If a date was entered, the system sent reminders at 14 days, 7 days, 3 days, and 1 day before the appointment. After the appointment, the intervention texted or called participants to confirm if they attended.
48720261|NCT05489900|DRUG|Dexmedetomidine Hydrochloride|"Dexmedetomidine is a specific and potent α2-adrenergic agonist. By acting directly on the sympathetic nervous system, they can exert beneficial effects on the immune system through neuroimmune interactions. Its administration can induce an anti-inflammatory response due to different central (increase parasympathetic tone, promoting control of the inflammatory condition) and peripheral effects (stimulating innate immunity).(MILLER, 2015).~Venous blood samples were collected at three times (T1, T2 and T3): Before anesthetic induction with collection in the preoperative environment on the day of surgery or during venoclysis before anesthetic induction (sample 1, T1); 6 hours after starting orifice closure and completion of drug or placebo infusion (sample 2, T2); and the last blood sample will be collected by me on the morning after the postoperative period, close to hospital discharge - 24h (sample 3, T3)."
48720262|NCT00308074|DRUG|Aripiprazole|open-label, flexible-dosing
48720263|NCT04391166|OTHER|Non invasive visual acuity testing|This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.
48720264|NCT03031392|DIAGNOSTIC_TEST|Sensitivity test|Routine clinical and radiographic examination
48720265|NCT00798317|DRUG|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
48720266|NCT00798317|DRUG|Placebo|Intravitreal injection placebo.
48720267|NCT01114360|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
48025128|NCT05185024|DIETARY_SUPPLEMENT|Ferrous Sulfate Capsules|Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
48720268|NCT01114360|DRUG|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
48720269|NCT02603445|DRUG|BCL201|
48720270|NCT02603445|DRUG|Idelalisib|
48025129|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Capsules|Once daily dose of one \>Your\< Iron Forte Capsule for 12 weeks in total.
48025130|NCT05185024|DIETARY_SUPPLEMENT|>Your< Iron Forte Liquid|Once daily dose of 5 ml of \>Your\< Iron Forte Liquid for 12 weeks in total.
48025131|NCT05185024|OTHER|Blank Capsules|Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
48025132|NCT05185024|OTHER|Blank Liquid|Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
48025133|NCT03634579|DEVICE|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
48025134|NCT02177344|DRUG|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
48025135|NCT02177344|DRUG|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
48025136|NCT02177344|DRUG|Atrovent|Two puffs, 4 times daily by oral inhalation
48025137|NCT02177344|DRUG|Placebo|
48520036|NCT02308995|DEVICE|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
48720271|NCT03052140|DEVICE|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
48182385|NCT00786643|DRUG|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
48182386|NCT03959852|DRUG|Fentanyl|1 mg/kg of Fentanyl IV administered over at least 1 minute
48182387|NCT03959852|COMBINATION_PRODUCT|Fentanyl and Ketamine|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
48182388|NCT03959852|DRUG|Ketamine|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
48182389|NCT04229810|PROCEDURE|STD-02|Conventional standardized ventilatory approach.
48182390|NCT04229810|PROCEDURE|iOLA-iHFNC|Indivudualized perioperative open lung ventilatory approach.
48182391|NCT01749098|DRUG|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
48720272|NCT03052140|DEVICE|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
48720273|NCT03883113|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
48720274|NCT03883113|BIOLOGICAL|Saline|Sodium Chloride Placebo
48720275|NCT03883113|BIOLOGICAL|H3N2 (A/Belgium/2417/2015)|Challenge Agent
48720276|NCT03973905|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
48720277|NCT01750359|DRUG|curcumin|500 mg/day for 6 week
48720278|NCT00842101|DEVICE|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
48720279|NCT06256991|DRUG|Patiromer 8400 MG [Veltassa]|Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.
48720280|NCT06256991|DRUG|Placebo|Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
48720281|NCT04724330|BEHAVIORAL|Healthy for Two/Healthy for You|\~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.
48720282|NCT00131456|DRUG|Venlafaxine|375mg/day
48720283|NCT00131456|DRUG|Placebo|Placebo
48182392|NCT01749098|DRUG|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
48182393|NCT01749098|DRUG|Placebo|Placebo capsule orally administered on Days 1 - 5
48182394|NCT01749098|DRUG|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
48182395|NCT02043834|OTHER|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
48182396|NCT02744339|DRUG|Riociguat|Adempas up-titrated to max. 1.5mg TID
48182397|NCT02744339|DRUG|Placebo|Placebo sham-titrated TID
48182398|NCT00205647|DRUG|Oral N-acetycystein (NAC)|
48182399|NCT01844713|BEHAVIORAL|Workbook|Subjects will read a workbook about sun protection
48720284|NCT04035746|OTHER|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
48520037|NCT06301074|DRUG|HS-10509|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
48520038|NCT06301074|DRUG|Placebo|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
48520039|NCT02521415|DRUG|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
48520040|NCT02521415|DRUG|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
48520041|NCT02521415|DRUG|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
48383625|NCT01351194|PROCEDURE|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
48025138|NCT05077267|BIOLOGICAL|ABNCoV2 100ug|IM injection 100ug dose
48383626|NCT05725473|DEVICE|Eso-Flip|Dilatation with Eso-FLIP
48383627|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS|The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
48383628|NCT06648499|OTHER|Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls|The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
48383629|NCT03622775|BIOLOGICAL|Daratumumab|Given IV
48383630|NCT06650488|DRUG|Clopidogrel|Patients will change from aspirin to clopidogrel (without loading dose)
48520042|NCT00534950|RADIATION|5 vs 6 weekly fraction of RT|Chemotherapy
48520043|NCT04407273|DRUG|observational|observational study
48520044|NCT06404918|PROCEDURE|Erector spinae plane group|The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.
48520045|NCT06404918|PROCEDURE|Serratus anterior plane group|Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.
48025139|NCT05077267|BIOLOGICAL|ABNCoV2 50ug|IM injection 50ug dose
48025140|NCT02399267|PROCEDURE|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
48383631|NCT06650488|DRUG|Aspirin|Patients will continue their existing aspirin.
48383632|NCT05688137|PROCEDURE|Abdominal drainage|The patients with intervention will take an abdominal drainage.
48383633|NCT06260358|OTHER|Survey|"MRI examinations will be performed on 1.5T or 3T scanners, with protocol according to ESUR guidelines.The contextual structured report will be generated by the investigators in consensus.~In every centre, one report (structured or narrative) will be generated from various radiologists experienced in gynaecologic imaging during clinical practice. Two radiologists in consensus, will develop the second version (narrative or structured report)."
48520046|NCT03586089|DRUG|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
48520047|NCT03586089|DRUG|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
48720285|NCT04794660|DIAGNOSTIC_TEST|HPV DNA Test|Screening for HPV using a HPV DNA test
48720286|NCT04794660|DIAGNOSTIC_TEST|VIA triage test|"VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device.~After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer"
48383634|NCT06650969|OTHER|Naturalistic observation|Naturalistic observation
48182400|NCT04714398|BEHAVIORAL|Opt-In Recruitment|Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.
48383635|NCT06650475|PROCEDURE|Using low or standart pressure|Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).
48383636|NCT03300726|DIAGNOSTIC_TEST|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
48383637|NCT03300726|RADIATION|Functional MRI|Functional MRI during resting state and semantic memory task activation
48383638|NCT05570214|OTHER|Virtual Reality|Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
48383639|NCT00616304|DRUG|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
48520048|NCT05708716|BEHAVIORAL|Modified ketogenic diet using an exogenous ketogenic formula|Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
48720287|NCT04794660|PROCEDURE|Treatment by ablative treatment|Cryotherapy or Thermal Ablation are performed on the cervix.
48720288|NCT04794660|PROCEDURE|Colposcopy|Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.
48720289|NCT01547091|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
48720290|NCT01547091|DRUG|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
48720291|NCT01547091|BIOLOGICAL|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
48720292|NCT01908166|PROCEDURE|ultrasound elasticity imaging|Undergo ultrasound elastography
48720293|NCT00733057|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
48720294|NCT00733057|DRUG|Placebo (200 mg/day)|
48720295|NCT05356338|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC|"A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors"
48720296|NCT01951313|OTHER|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (\< 2g) and low carotenoid (\< 2000µg) meal as the 2nd meal.
48720297|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
48720298|NCT01009749|BEHAVIORAL|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
48720299|NCT06421272|BEHAVIORAL|APP-based emotion recognition intervention|ASD children were asked to play emotion recognition-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
48720300|NCT06421272|BEHAVIORAL|APP-based memory intervention|ASD children were asked to play memory-related games for eight weeks using iPAD. Two 15-minsute sessions each day was required.
48720301|NCT00784485|DRUG|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
48720302|NCT05693454|DRUG|Infiltration with NaCl|Local wound infiltration at the end of spine surgery with NaCl
48720303|NCT05693454|DRUG|Infiltration with Ropivacain|Local wound infiltration at the end of spine surgery with Ropivacain
48720304|NCT05693454|DRUG|Infiltration with a combination of Levobupivacaine and Tramadol|Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
48720305|NCT01233388|OTHER|Text message surveillance|Text message surveillance for vaccine adverse events
48720306|NCT00468988|DRUG|Travatan® Z|
48720307|NCT00468988|DRUG|Xalatan®|
48720308|NCT01297400|DRUG|Investigational Drug, MW-III|Topical application, twice a day
48720309|NCT01297400|DRUG|Silvadene® Cream 1% [Silver Sulfadiazine]|Topical application, twice a day
48383640|NCT00616304|OTHER|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
48182401|NCT04714398|BEHAVIORAL|Opt-Out Recruitment|Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
48720310|NCT05086055|BEHAVIORAL|Kinematic movement analysis|moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.
48720311|NCT03481491|OTHER|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
48720312|NCT03263780|DRUG|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)
48720313|NCT06053736|DEVICE|REVIVE Contact Lens|REVIVE Contact Lens
48720314|NCT04369508|RADIATION|permanent brachytherapy|"Briefly, the patient had a general anesthesia and PPB was performed by using the real-time intraoperative planning method guided by TRUS. The radioactive seeds were inserted transperineally according to a modified peripherally loaded Seattle technique 17. I-125 was used for all implants with a mean seed activity of 0.45 mCi per seed. All procedures were completed by a single surgeon."
48720315|NCT05178784|DEVICE|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
48720316|NCT01355796|DRUG|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
48182402|NCT06072976|DIETARY_SUPPLEMENT|Standard of Care|Standard of care arm: Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age.
48720317|NCT01355796|DRUG|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
48383641|NCT05104450|BEHAVIORAL|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
48383642|NCT06537973|OTHER|İndividualized care education|A single session of training will be given to the mothers in the experimental group. In addition, the mother will be provided with counseling by the researcher at any time she wishes. The aim is to increase the mother-infant bonding levels and self-efficacy of the mothers, who will be supported by the care plans that will be created based on Swanson\&#39;s Theory of Care, and to adapt more easily to the role of motherhood, by evaluating them with the help of check-lists after the observations.
48383643|NCT05552391|DRUG|Bupivacaine|Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
48383644|NCT05552391|DRUG|Ketamine Hydrochloride|Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).
48383645|NCT05552391|DRUG|Dexmedetomidine Hydrochloride|Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
48383646|NCT02558075|BEHAVIORAL|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
48383647|NCT06569017|OTHER|1) Artificial intelligence supported working group|Pregnant women will be a personal information form, breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa infant nutrition attitude scale and Edinburgh postpartum depression scale. Pregnant women in the artificial intelligence-supported study group were aged 32-37. Starting from the first week of pregnancy, a mobile breastfeeding consultancy application supported by IOS and Android will be installed on smart phones. Pregnant women will be expected to use this application actively until birth and submit their questions about breastfeeding to this artificial intelligence-supported mobile application and receive instant answers. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
48520049|NCT05708716|BEHAVIORAL|Online cognitive training|Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
48720318|NCT02918708|BIOLOGICAL|Synflorix|10-valent pneumococcal conjugate vaccine
48520050|NCT02890602|DRUG|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
48520051|NCT02890602|DRUG|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
48520052|NCT04077944|DIAGNOSTIC_TEST|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
48720319|NCT02918708|BIOLOGICAL|Prevenar13|13-valent pneumococcal conjugate vaccine
48720320|NCT03344198|BEHAVIORAL|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
48720321|NCT05583149|DRUG|ACALABRUTINIB|Oral, twice daily, timing and dosage per protocol
48720322|NCT05583149|DRUG|LISOCABTAGENE MARALEUCEL|via IV timings and dosage per protocol
48720323|NCT05583149|DRUG|Lymphodepleting chemotherapy|lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
48720324|NCT05824936|BEHAVIORAL|Pilot study arm for technology-enhanced asthma intervention|Participants will be enrolled in a remote monitoring program using monthly remote study visits which will include the use of a mobile spirometer (device for testing lung function). Participants will complete monthly remote study visits visits using telehealth platform and will complete lung function testing during the visit using a mobile spirometer as well as remote study measures.
48720325|NCT05490108|BIOLOGICAL|ZR202-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)
48720326|NCT05490108|BIOLOGICAL|ZR202a-CoV|SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
48720327|NCT05490108|BIOLOGICAL|Comirnaty®|Comirnaty® (Pfizer-BioNTech)
48720328|NCT01665989|BEHAVIORAL|Group Lifestyle Program|
48720329|NCT01665989|BEHAVIORAL|Usual Care|Visits with a dietitian at nutrition services at MGH
48720330|NCT03131596|PROCEDURE|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
48720331|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
48720332|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
48182403|NCT06072976|DIETARY_SUPPLEMENT|Exclusive Human Milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
48182404|NCT01708434|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
48520053|NCT01261897|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
48520054|NCT01261897|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
48520055|NCT03032627|PROCEDURE|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
48520056|NCT01705379|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
48720333|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide|High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
48720334|NCT05332418|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, Educational postural correction, and Home neck exercise program for patient
48520057|NCT04789837|DRUG|Cilostazol 50 MG|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
48520058|NCT04789837|DRUG|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
48520059|NCT02091024|DIETARY_SUPPLEMENT|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
48520060|NCT02091024|DIETARY_SUPPLEMENT|Placebo|Placebo 200mg, twice a day
48520061|NCT01687894|DRUG|Vasopressins|Vasopressins propofol vasopressins sevoflurane
48520062|NCT01687894|DRUG|Placebo|Placebo propofol \& placebo sevoflurane
48520063|NCT01687894|DRUG|propofol|vasopressin propofol \& placebo propofol
48520064|NCT01687894|DRUG|sevoflurane|vasopressins sevoflurane placebo sevoflurane
48520065|NCT01795950|DRUG|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
48520066|NCT01598961|OTHER|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
48520067|NCT01598961|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
48520068|NCT01598961|OTHER|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
48520069|NCT01595685|DRUG|Telbivudine|Telbivudine 600 mg Daily Oral
48520070|NCT01595685|DRUG|Entecavir|Entecavir 0.5 mg Daily Oral
48182405|NCT04236687|DEVICE|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
48520071|NCT06325605|DRUG|Bifidobacterium|3 capsules, 3 times a day, for 8 consecutive weeks
48720335|NCT05332418|DEVICE|Electromagenetic Field therapy|Magnetotherapy application the device will be adjusted around the neck and shoulder area at low frequency (50 Hz), with intensity of 2.5 MT, field shape and applicator type rectangular csl60/csp60) , and the application time (10 minutes)
48720336|NCT00077844|DRUG|Enoxaparin sodium|
48720337|NCT05772078|OTHER|Assess compliance rate and demographics|Records to evaluate attendance rate
48720338|NCT03535285|PROCEDURE|Periodontal ligament distraction|decrease the bony resistant during canine retration
48720339|NCT05848765|DRUG|Epcoritamab|Bispecific antibody
48720340|NCT05848765|DRUG|Lenalidomide|Immunomodulatory agent
48720341|NCT05848765|DRUG|Rituximab|Monoclonal antibody
48720342|NCT05848765|DRUG|Obinutuzumab|Monoclonal antibody
48720343|NCT05848765|DRUG|Bendamustine|Alkylating agent (chemotherapy drug)
48720344|NCT05848765|DRUG|Vincristine|Antineoplastic, Vinca Alkaloid
48720345|NCT05848765|DRUG|Doxorubicin|Anthracycline
48720346|NCT05848765|DRUG|Cyclophosphamide|Alkylating agent (chemotherapy drug)
48720347|NCT05848765|DRUG|Prednisone|Corticosteroid
48720348|NCT05848765|DRUG|Investigation agent 2|The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
48720349|NCT05848765|DRUG|Investigation agent 3|The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
48720350|NCT05729139|DRUG|Cemiplimab-Rwlc|350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
48720351|NCT05729139|DRUG|PEG-IFN alfa-2a|"Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established."
48720352|NCT02427724|DRUG|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
48720353|NCT02427724|DRUG|lidocaine 7%/tetracaine 7% topical anesthetic|
48720354|NCT02427724|DRUG|placebo vehicle|
48720355|NCT02427724|DEVICE|Q-switched 532nm Laser|
48720356|NCT02831790|OTHER|Fontan Education Videos|"The intervention will consist of three brief (\~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~1. Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~2. Anticoagulation~3. Prolonged pleural drainage"
48720357|NCT05262686|DRUG|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
48720358|NCT05262686|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
48720359|NCT02975752|GENETIC|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
48025141|NCT02399267|PROCEDURE|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
48025142|NCT02399267|PROCEDURE|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
48025143|NCT02399267|PROCEDURE|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
48720360|NCT01051206|DRUG|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
48720361|NCT05342337|OTHER|Telerehabilitation Group|"The Telerehabilitation program includes a Biopsychosocial Exercise Therapy (BETY) approach.~BETY approach includes patient education on pain, functional body stabilization exercises (mind-body information management), dance therapy authentic movement (emotion-state information management), and sexual information management.~Telerehabilitation group participate in the sessions that last for one and a half hours, 3 days a week for 12 weeks, video conference over the Zoom program. The investigator, who provides supervision during the sessions, also participates in the exercises simultaneously."
48720362|NCT05342337|OTHER|Control group|The control group participants include those who do not want to receive exercise treatment with telerehabilitation and take their routine medications during the 12 weeks period.
48025144|NCT01931839|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
48025145|NCT01931839|DRUG|Ivacaftor|Film-coated tablet, oral use
48025146|NCT04864015|DEVICE|Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable|Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
48720363|NCT05307432|BEHAVIORAL|SPI+ Delivered by ED Staff|ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
48025147|NCT04365036|DRUG|Toripalimab|toripalimab 240mg, d1, intravenous drip
48025148|NCT04365036|DRUG|Pegaspargase|pegaspargase, 2000U/m2, d1, intravenous drip
48025149|NCT04365036|DRUG|Gemcitabine|gemcitabine, 1000mg/m2, d1,d8, intravenous drip
48025150|NCT04365036|DRUG|Oxaliplatin|oxaliplatin, 130mg/m2, d1, intravenous drip,
48025151|NCT04365036|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
48182406|NCT04236687|PROCEDURE|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate
48383648|NCT06569017|OTHER|Online breastfeeding counseling group led by a nurse|The forms that will be applied to pregnant women in all three groups at the first meeting will also be applied to this group. 32-37 in the nurse-led online breastfeeding counseling group. Primiparous pregnant women at the gestational age will be offered 1.5 hours of breastfeeding counseling by one of the researchers, between the 32nd and 37th weeks of pregnancy, with the participation of small groups of five pregnant women in each interactive session. Pregnant women in this group will receive only one session of breastfeeding training. These trainings, which will be given by the nurse, will be carried out online via video call via WhatsApp application. After these applications, the breastfeeding diagnosis and evaluation scale, postnatal breastfeeding self-efficacy scale, Lowa baby nutrition attitude scale and Edinburgh postpartum depression scale will be applied again to pregnant women on the first postpartum day, sixth day, third week and third month.
48720364|NCT05307432|BEHAVIORAL|SPI+ Delivered by SPCC Clinicians|The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
48520072|NCT06325605|DEVICE|High-frequency rTMS|"In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks."
48383649|NCT00677170|DRUG|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
48383650|NCT03431285|DRUG|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
48520073|NCT06325605|DRUG|Escitalopram Oxalate|Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
48720365|NCT02858752|OTHER|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
48520074|NCT03888846|DRUG|Pentoxifylline|Topical gel version of pentoxifylline to be administered intraorally.
48520075|NCT03888846|DRUG|Colchicine|Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
48720366|NCT02858752|OTHER|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, ...). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
48720367|NCT02858752|OTHER|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
48025152|NCT00637546|OTHER|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
48025153|NCT02426632|DRUG|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
48720368|NCT02858752|OTHER|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
48720369|NCT02858752|OTHER|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
48720370|NCT02759315|DRUG|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
48720371|NCT02759315|DRUG|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
48720372|NCT04957758|DRUG|OC-01 (varenicline) nasal spray 1.2 mg/ml|OC-01
48025154|NCT02426632|DRUG|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
48025155|NCT02426632|DRUG|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
48025156|NCT02426632|DRUG|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
48025157|NCT02426632|DRUG|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
48025158|NCT02426632|DRUG|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
48025159|NCT02426632|DRUG|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
48025160|NCT02426632|DRUG|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
48383651|NCT03431285|DRUG|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
48383652|NCT03431285|OTHER|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
48182407|NCT02968823|OTHER|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
48025161|NCT02426632|DRUG|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
48182408|NCT02968823|OTHER|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
48182409|NCT01705899|DRUG|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
48182410|NCT01177761|PROCEDURE|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
48182411|NCT05251675|BEHAVIORAL|Physician Led Professional Coaching|This is a one-on-one intervention between a physician coach and an individual physician. This is meant to help coaches attain valued professional or personal development.
48182412|NCT05251675|BEHAVIORAL|Delayed Physician Led Professional Coaching|This intervention will include professional one-on-one professional coaching delayed from the active comparator group.
48182413|NCT02399397|PROCEDURE|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
48720373|NCT04957758|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle)
48720374|NCT01495520|DRUG|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
48720375|NCT01495520|DRUG|Placebo|os, pill, b.i.d., 30 days
48720376|NCT01913704|DEVICE|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
48025162|NCT02426632|DRUG|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
48025163|NCT02426632|DRUG|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
48025164|NCT02426632|DRUG|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
48025165|NCT00352534|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiotherapy
48025166|NCT00352534|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48025167|NCT00352534|PROCEDURE|Chest Radiography|Undergo chest X-ray
48025168|NCT00352534|PROCEDURE|Computed Tomography|Undergo CT
48025169|NCT00352534|BIOLOGICAL|Dactinomycin|Given IV
48025170|NCT00352534|DRUG|Doxorubicin Hydrochloride|Given IV
48383653|NCT05156164|DEVICE|Kinesio Tape Group|The application of the KT consists of 6 strips of I-shaped tape adhered to the skin areas of the shoulder
48383654|NCT05156164|DEVICE|Control Group|KT application on the deltoid but without support function
48025171|NCT00352534|PROCEDURE|Echocardiography|Undergo echocardiography
48025172|NCT00352534|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48025173|NCT00352534|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48025174|NCT00352534|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
48025175|NCT00352534|DRUG|Vincristine Sulfate|Given IV
48025176|NCT00824109|DEVICE|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
48383655|NCT05661825|OTHER|phase II cardiac rehabilitation|Phase II cardiac rehabilitation was provided in the the department of physical medicine and rehabilitation in Wan Fang Hospital. The programs are two times a week, one session for 30 minutes (30 sessions in total). The training programs are focused on aerobic training with bicycles. The training intensity is calculated with 40% to 80% oxygen consumption reserve from the result of cardiopulmonary exercise test. In case of safety, heart rate, blood pressure, EKG and rate of perceived exertion will be monitored during training.
48383656|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
48025177|NCT03855189|DRUG|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
48025178|NCT03855189|DRUG|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
48025179|NCT03855189|DRUG|Placebo|Placebo nasal spray administered for 4 weeks.
48025180|NCT02211833|DRUG|BI 2536|
48025181|NCT02211833|DRUG|Pemetrexed|
48025182|NCT00734305|DRUG|MM-121|Dose escalation Frequency - once weekly
48025183|NCT04744363|DRUG|Stelara PFS|Pre filled syringes filled with AVT04 and Stelara
48025184|NCT00499889|DRUG|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
48025185|NCT00499889|DRUG|Fludarabine (Fludara)|40 mg/m\^2 by vein daily for 4 Days
48025186|NCT00499889|DRUG|Busulfan|130 mg/m\^2 by vein daily for 2 Days
48383657|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
48383658|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 30min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 30 minutes on Days (D) 1 and 15 of each 28-day cycle.
48383659|NCT03345485|DRUG|Tinostamustine 60mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 60mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
48383660|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
48383661|NCT03345485|DRUG|Tinostamustine 100mg/m2 over 60min|Tinostamustine as a single agent was administered at doses of 100mg/m2 by intravenous infusion over 60 minutes on Days (D) 1 and 15 of each 28-day cycle.
48383662|NCT03345485|DRUG|Tinostamustine 80mg/m2 over 80min|Tinostamustine as a single agent was administered at doses of 80mg/m2 by intravenous infusion over 80 minutes on Days (D) 1 and 15 of each 28-day cycle.
48720377|NCT04701203|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
48383663|NCT02392312|DRUG|ATF-Fresenius S|intravenous
48383664|NCT05041179|DIETARY_SUPPLEMENT|Pruvin R|Combination of N-acetylcysteine an glycine
48383665|NCT05041179|OTHER|Isomaltulose|Placebo as comparator to intervention
48383666|NCT03910439|BIOLOGICAL|Avelumab|Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
48383667|NCT03910439|RADIATION|External beam radiotherapy|5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
48720378|NCT04701203|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
48720379|NCT02966015|DEVICE|Coloplast test catheter|This is a newly developed catheter
48720380|NCT05108805|PROCEDURE|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, HR, RR, SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
48720381|NCT05108805|PROCEDURE|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
48720382|NCT05108805|PROCEDURE|Out-Patient Clinic Visit|Physical exam and review of all available data
48720383|NCT05108805|PROCEDURE|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
48720384|NCT03700814|DRUG|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
48720385|NCT01739803|BEHAVIORAL|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
48720386|NCT00548717|DRUG|Sirolimus|
48720387|NCT00548717|DRUG|Mycophenolate mofetil|
48383668|NCT00240786|DRUG|acetaminophen extended release|
48383669|NCT04513873|DEVICE|Equipment to divert the focus of children|The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
48383670|NCT01145573|DIETARY_SUPPLEMENT|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
48383671|NCT04206072|DRUG|D-0316 Capsule|"The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316."
48720388|NCT00548717|DRUG|Bortezomib|
48720389|NCT01513681|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
48720390|NCT01513681|DRUG|Lamictal®|Lamictal® 200 mg Tablets
48383672|NCT04206072|DRUG|Icotinib Hydrochloride Tablets|"Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316)."
48720391|NCT05414955|DEVICE|Neuromodulation|Neuromodulation
48720392|NCT02699372|DRUG|Placebo|
48720393|NCT02699372|DRUG|RO6889450|
48720394|NCT04215432|DEVICE|Gel containing propolis extract, nanovitamin C and nanovitamin E|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis. during 1 month.
48720395|NCT04215432|DEVICE|Placebo|The patient had to use the gel as a toothpaste and apply it with an interdental brush in mesial and distal aspects of the implant with peri-implant mucositis.
48720396|NCT04966923|OTHER|No intervention in this study|Analyses of pathogenic variant TP53 and variants in genetic test
48720397|NCT03460548|DEVICE|Remogen|instil 1 drop of the product in each eye, 4 times per day
48025187|NCT00499889|DRUG|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
48182414|NCT02399397|PROCEDURE|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
48182415|NCT02399397|PROCEDURE|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
48720398|NCT03460548|DEVICE|Cationorm|instil 1 drop of the product in each eye, 4 times per day
48182416|NCT02399397|DRUG|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
48720399|NCT02757794|OTHER|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
48182417|NCT02399397|PROCEDURE|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
48182418|NCT02386839|DRUG|rhIGF-1/rhIGFBP-3|"Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study."
48182419|NCT02069197|OTHER|Ketogenic diet|ketogenic diet will consist of 3:1\[fat\]:\[protein+carbohydrate\]weight ratio with 1600 kcal restriction. Diet will last 9 months.
48182420|NCT02069197|DRUG|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
48182421|NCT02069197|OTHER|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
48182422|NCT00760513|DRUG|OMACOR|4 grammes daily, oral capsule
48182423|NCT00760513|DRUG|Placebo oral capsule|4 grammes daily, oral capsule (olive oil)
48182424|NCT03251092|DRUG|PTI-808|Active
48182425|NCT03251092|DRUG|Placebo|Placebo
48720400|NCT02757794|OTHER|standard remediation|A speech therapy and / or academic support is realized.
48720401|NCT03645317|DIAGNOSTIC_TEST|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
48720402|NCT00712582|DRUG|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
48720403|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
48720404|NCT00712582|DRUG|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
48720405|NCT03859921|DRUG|Dydrogesterone|Progesterone
48182426|NCT03251092|DRUG|PTI-428|Active
48182427|NCT03251092|DRUG|PTI-801|Active
48182428|NCT00884897|DRUG|Oxytocin|Oxytocin given as 20 IU BID
48182429|NCT00884897|DRUG|Placebo|Placebo given as 20 IU BID
48182430|NCT01639742|DEVICE|New texture round breast implants|Breast implant surgery
48182431|NCT02469883|DRUG|Sinotecean|
48182432|NCT06508892|BEHAVIORAL|risk of fall|Gather information that will assist in determining risk of fall. The researchers will ask the subjects to perform several motor tests and study-related questionnaires.
48182433|NCT03722511|DIETARY_SUPPLEMENT|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
48182434|NCT01796054|BEHAVIORAL|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
48182435|NCT01796054|BEHAVIORAL|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
48182436|NCT06252012|BEHAVIORAL|Mobile application|The mobile application will be designed as a health assistant for women aged between 30-65 to encourage healthy choices and positively develop their behaviors regarding the prevention of cancer. Within the scope of the mobile application, information modules on cervical cancer screening tests, cervical cancer risk factors, ways to prevent cervical cancer, types of HPV, and HPV vaccine will be provided. A parallel-group pretest-posttest randomized controlled trial design will be used in the second stage of the study
48720406|NCT03859921|DRUG|Placebo|Placebo with appearance similar to Dydrogesterone
48720407|NCT01071616|DRUG|Cannabis Cigarette|
48182437|NCT04288349|PROCEDURE|perineal block with usage of one of solutions|Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.
48182438|NCT04288349|DRUG|epinephrine + ropivacaine +saline|epinephrine + ropivacaine +saline
48182439|NCT04288349|DRUG|epinephrine + saline|epinephrine + saline
48383673|NCT06436690|BEHAVIORAL|Diagnosis Mandate and Feedback|The intervention consists of: a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
48720408|NCT05302622|OTHER|There is no intervention planning|There is no intervention planning
48720409|NCT02530996|DRUG|BH4|BH4 10 mg/kg/day given once to a total of 12 SSc patients
48720410|NCT02530996|DIAGNOSTIC_TEST|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
48383674|NCT06411782|DEVICE|Foam roller|In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.
48383675|NCT06411782|DEVICE|Inspiratory muscle training|Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
48383676|NCT04708782|DRUG|Placebo|Placebo administered QID
48383677|NCT04708782|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
48383678|NCT04708782|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
48720411|NCT02530996|DRUG|Placebo|On the experimental days, patients reported to the laboratory after having consumed a standardized breakfast and oral BH4 (10mg/kg) or placebo five hours prior to their arrival. All measurements were taken at the same time of day to eliminate any diurnal effects. All participants abstained from alcohol, caffeine, and exercise for ≥12 hours prior to the study. Additionally, vasodilatory medications were discontinued 12 hours prior to study visit. In premenopausal women, measurements were performed during the early follicular phase of the menstrual cycle. All measurements were made under quiet, comfortable, ambient (\~22°C) laboratory conditions.
48720412|NCT03969511|PROCEDURE|direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
48720413|NCT03969511|PROCEDURE|standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
48720414|NCT04764344|DRUG|Haloperidol|2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
48383679|NCT00665366|DRUG|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
48720415|NCT04764344|DRUG|Ondansetron|Ondansetron
48720416|NCT02092402|OTHER|Fecal transplantation|
48720417|NCT04808193|OTHER|Survey|Participants will fill in the survey
48720418|NCT05462808|DRUG|High viscosity glass ionomer cement|High viscosity glass ionomer cement
48025188|NCT00499889|DRUG|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
48025189|NCT00499889|DRUG|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
48025190|NCT00499889|PROCEDURE|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after \>4 weeks of imatinib.
48383680|NCT00665366|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
48383681|NCT00665366|DRUG|Lithium|Participant's ongoing dose
48025191|NCT00499889|PROCEDURE|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
48025192|NCT05003921|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
48383682|NCT00665366|DRUG|Valproate|Participant's ongoing dose
48383683|NCT04185259|OTHER|Acupuncture|The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
48383684|NCT04185259|OTHER|Sham acupuncture|Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, \~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
48383685|NCT04486573|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
48720419|NCT05462808|DEVICE|Stainless steel crown|Stainless steel crown
48720420|NCT02400944|BEHAVIORAL|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
48720421|NCT02400944|OTHER|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
48025193|NCT01746823|DRUG|Cyclosporins|
48720422|NCT05683873|PROCEDURE|Electrocardiogram|Inclusion visit, V1, V2 and V3
48720423|NCT05683873|PROCEDURE|transthoracic echocardiography|V1, V2 and V3
48182440|NCT05475275|PROCEDURE|pancreaticojejunostomy|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
48182441|NCT03344068|RADIATION|Radiotherapy|Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
48182442|NCT03344068|DRUG|Chemotherapy|Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
48182443|NCT03344068|DIETARY_SUPPLEMENT|Nutren® Optimum|Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
48383686|NCT05237674|BEHAVIORAL|The TEACHOUT intervention|"The core component of the Intervention is a two-day training course on EOtC given to elementary school teachers followed by the teachers committing to apply EOtC for at least five hours a week, delivered in 1-2 weekly sessions for one school year (in this study, August 2022 to June 2023).~In the training course knowledge and understanding of the practice and theory of EOtC is facilitated in presentations and talks supplemented by illustrative examples in workshops and plenum discussions on local implementation. The 1-2 weekly EOtC sessions during the school year 2022-2023 may be delivered by one or more teachers simultaneously in various school subjects, at various places outside the school buildings."
48520076|NCT05929859|BEHAVIORAL|Speech Motor Chaining|Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
48520077|NCT04435912|DRUG|Hydrocortisone 200mg IV|single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
48520078|NCT02665221|OTHER|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
48520079|NCT02665221|DRUG|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
48520080|NCT04364776|DRUG|Durvalumab|In this observational study, durvalumab will be administered according to current indications (PACIFIC phase III trial).
48182444|NCT00777634|OTHER|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
48182445|NCT02701062|DEVICE|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
48182446|NCT02701062|DRUG|Anticoagulation Therapy|Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
48182447|NCT01957540|DRUG|Ticagrelor|
48182448|NCT01957540|DRUG|Prasugrel|
48182449|NCT02493842|DEVICE|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
48182450|NCT02646787|BEHAVIORAL|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
48182451|NCT02646787|BEHAVIORAL|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
48182452|NCT04467047|BIOLOGICAL|Mesenchymal Stromal Cells infusion|Intravenous 1\*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
48520081|NCT05744687|DRUG|SPH4336 Tablets 400mg|"SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
48520082|NCT05744687|DRUG|SPH4336 Tablets Placebo|"SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle"
48182453|NCT01689363|DRUG|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
48182454|NCT01689363|DRUG|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
48720424|NCT05683873|BIOLOGICAL|standard biology|Inclusion visit
48720425|NCT05683873|BIOLOGICAL|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
48720426|NCT05683873|BIOLOGICAL|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
48720427|NCT05683873|OTHER|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
48720428|NCT05683873|OTHER|72-hour continuous Holter-ECG recording|V1
48720429|NCT06416293|OTHER|Questionnaire patients|Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.
48720430|NCT06416293|OTHER|Questionnaire physicians|Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
48720431|NCT02880813|OTHER|Infusion|infusion of nutrients
48028937|NCT04444154|BEHAVIORAL|Group with active participation|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
48720432|NCT05065567|DRUG|Droperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
48182455|NCT01689363|DRUG|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
48720433|NCT05065567|DRUG|Haloperidol|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
48720434|NCT05065567|DRUG|Ondansetron 8mg|Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
48520083|NCT03369769|OTHER|Activity|10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
48520084|NCT03417778|DRUG|Filgotinib|100 mg tablet administered orally
48520085|NCT04534452|DRUG|Phenylephrine HCl (Sinus Comfort, BAY112476)|30 mg Extended Release Tablets, single oral dose
48520086|NCT05629715|DEVICE|ROSA Knee System|The Zimmer Biomet ROSA Knee System is a commercially available, FDA approved robotic assistant for performing TKA. It uses preoperative x-rays to create a three-dimensional image of the patient's knee anatomy which is used to create a preoperative template of the implants to be used and provides intraoperative guidance for bone cuts during the TKA. The robotic system also assesses the soft tissue envelope around the knee and can assist with the soft tissue balancing of the knee arthroplasty. Alternatively, it can also be used in an imageless mode where bone cuts are performed based on intra-operative mapping using anatomic landmarks.
48720435|NCT02723955|DRUG|feladilimab (GSK3359609)|
48720436|NCT02723955|DRUG|GSK3174998|
48720437|NCT02723955|DRUG|Pembrolizumab|
48720438|NCT02723955|DRUG|Docetaxel|
48720439|NCT02723955|DRUG|Pemetrexed|
48720440|NCT02723955|DRUG|Paclitaxel plus Carboplatin|
48720441|NCT02723955|DRUG|Gemcitabine plus Carboplatin|
48720442|NCT02723955|DRUG|Fluorouracil (5-FU) plus carboplatin or cisplatin|
48028938|NCT04444154|BEHAVIORAL|Group with video and quizz|oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
48720443|NCT02723955|DRUG|Dostarlimab|
48720444|NCT02723955|DRUG|Cobolimab|
48720445|NCT02723955|DRUG|Bintrafusp alfa|
48720446|NCT03308149|DRUG|infiltration with triamcinolone and bupivacaine|facet joint infiltration
48720447|NCT06075992|OTHER|experimental group|An experimental application will not be made to premature babies in this group.
48720448|NCT03579212|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
48720449|NCT05545644|BEHAVIORAL|Brief Family-Involved Treatment for Alcohol Use Disorder|Up to 3 sessions of counseling involving a patient with alcohol use disorder and a concerned family member
48720450|NCT02297165|BEHAVIORAL|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
48720451|NCT01462877|DRUG|fenofibrate|Fenofibrate Capsule 200mg qd orally
48720452|NCT01498185|DRUG|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
48720453|NCT01498185|DRUG|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
48720454|NCT02008409|DEVICE|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
48028939|NCT04741568|BEHAVIORAL|Parental psychoeducational Intervention|"The psychoeducation intervention for parents will focus on providing skills, knowledge and support motivation for caregivers of children with diabetes.~A brief (one-day or two half days) workshop, and a website with downloadable content will be made available to review and refresh any skills and techniques."
48028940|NCT01605617|DRUG|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
48028941|NCT01605617|DRUG|Placebo|PTNS + placebo for 12 weeks
48028942|NCT01605617|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
48028943|NCT03953027|OTHER|Survey Administration|Ancillary studies
48028944|NCT01834417|DEVICE|TexiMat|
48028945|NCT02707055|DRUG|PF-05190457|Ghrelin Receptor Inverse Agonist
48028946|NCT02707055|OTHER|Placebo|Placebo
48028947|NCT03829904|DRUG|VGH-BPH1|A scientific Chinese granule powder
48028948|NCT03829904|DRUG|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
48028949|NCT04644354|DRUG|Nifedipine 10 mg|For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
48028950|NCT03607383|DRUG|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
48720455|NCT03689075|DRUG|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
48720456|NCT00005048|DRUG|estramustine phosphate sodium|
48182456|NCT02353416|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
48182457|NCT02353416|OTHER|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
48182458|NCT03814304|OTHER|Personalized tDCS|The participant will receive 20, 20-minute sessions of personalized tDCS on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
48182459|NCT03814304|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
48182460|NCT01759147|PROCEDURE|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
48182461|NCT06146556|PROCEDURE|catheter based ablation|electrophysiological catheter based ablation of ventricular arrhythmia
48182462|NCT06292442|OTHER|traditional physical therapy|This group received conventional physical therapy treatment including Range of Motion (ROM) exercises for the affected hip, knee, and ankle joints, as well as stretching exercises for tight lower limb muscles, administered 3 times per week for 4 weeks, with each session lasting approximately 20-30 minutes.
48182463|NCT06292442|OTHER|High intensity interval training|This group received High Intensity interval training along with conventional treatment for lower limb muscles, performed 3 times per week fr 4 weeks.
48182464|NCT03542110|DRUG|Alirocumab 150 MG/ML subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
48182465|NCT03542110|DRUG|Matching Placebo subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
48182466|NCT05906797|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
48182467|NCT02420249|BEHAVIORAL|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong \[in Chinese\]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
48182468|NCT02758743|DRUG|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
48720457|NCT00005048|DRUG|paclitaxel|
48720458|NCT05485883|DRUG|Tislelizumab Lenvatinib|Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
48720459|NCT05831995|DRUG|ABM-168|Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
48720460|NCT04287686|DRUG|Recombinant human angiotensin-converting enzyme 2 (rhACE2)|In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
48025194|NCT02440152|DEVICE|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
48182469|NCT02758743|DRUG|Placebo|Placebo with no active substance will not have the effect on intervention device.
48182470|NCT01807182|BIOLOGICAL|Aldesleukin|Given IV
48182471|NCT01807182|DRUG|Cyclophosphamide|Given IV
48182472|NCT01807182|DRUG|Fludarabine Phosphate|Given IV
48182473|NCT01807182|OTHER|Laboratory Biomarker Analysis|Correlative studies
48182474|NCT01807182|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
48182475|NCT02281123|OTHER|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
48720461|NCT05748314|OTHER|Questionnaire|KINDL-R; Morisky Medication Adherence Scale;
48025195|NCT00600964|DRUG|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
48182476|NCT00987662|DRUG|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg.
48182477|NCT00987662|DRUG|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg
48182478|NCT00333905|PROCEDURE|Ischemic exercise training|
48720462|NCT00002177|DRUG|Hydroxyurea|
48182479|NCT05988242|OTHER|Primrose oil|group A will take primrose oil
48182480|NCT05988242|OTHER|Lavender oil|group B will take lavender oil
48720463|NCT00002177|DRUG|Nelfinavir mesylate|
48720464|NCT00002177|DRUG|Stavudine|
48720465|NCT00002177|DRUG|Didanosine|
48720466|NCT05455801|DEVICE|negative preassure wound therapy|wound treated with negative pressure therapy dressing
48720467|NCT04496375|OTHER|Survey|Self-completed questionnaires
48720468|NCT04124614|DRUG|Brexpiprazole|Up to 3 mg pill
48720469|NCT04124614|DRUG|Sertraline|Up to 150 mg pill
48720470|NCT04124614|OTHER|Placebo|Pill
48720471|NCT05453695|DRUG|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
48720472|NCT01908088|BIOLOGICAL|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
48720473|NCT00127335|DRUG|cellulose placebo vs. atorvastatin|drug
48720474|NCT02759536|RADIATION|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
48383687|NCT03788239|OTHER|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
48383688|NCT01516060|DRUG|Efavirenz|400mg qd; 2 x 200mg
48383689|NCT01516060|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
48383690|NCT01513759|DRUG|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
48383691|NCT01513759|DEVICE|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
48383692|NCT02890966|DRUG|SHR4640|Day1\~Day7:oral administration
48383693|NCT02890966|DRUG|placebo|Day1\~Day7:oral administration
48383694|NCT02729727|DEVICE|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
48383695|NCT06520735|DEVICE|Transcutaneous electrical nerve stimulation|The pregnant women with emesis gravidarum will be treated by transcutaneous electrical nerve stimulation (TENS) on p6 acupuncture point for 30 minutes daily for 5 consecutive days.
48383696|NCT06520735|OTHER|Capsicum plaster|The pregnant women with emesis gravidarum will be treated with capsicum plaster on p6 acupuncture point for 12 hours per day for 5 consecutive days.
48383697|NCT06099886|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate 30-45mg/day
48383698|NCT01565655|DRUG|peficitinib|oral
48520087|NCT05629715|DEVICE|KneeAlign Computer Assisted Navigation System|The OrthAlign KneeAlign computer assisted navigation system is a commercially available device that uses gyroscopic limb position sensing technology mounted to intramedullary and extramedullary jigs to measure bone resection cuts in TKA that ultimately dictate implant position.
48520088|NCT00442208|DRUG|PN 200|
48520089|NCT06398379|OTHER|Fecal Virome Transplantation|The primary steps of the production of fecal virome transplantation capsules is the same as when producing fecal microbiota transplantation capsules. Through an subsequent proces of filtering bacterial parts of the material are removed. The material, now called fecal virome transplanation material, has then been moved to capsules and stored in -80c untill use.
48520090|NCT06398379|OTHER|Fecal microbiota Transplantation|Donor fecal material is mixed with cryoprotectant and NaCl. Following processing the material transfered to capsules and is stored at -80c prior to use.
48025196|NCT00600964|DRUG|GX15-070MS|GX15-070MS at various doses and schedules
48182481|NCT05988242|OTHER|placcebo|this is the comparator group who will take the same bottle of oil which dosnt contain the active substances but have the sampe shape, same oder, same color
48520091|NCT00302861|BIOLOGICAL|MyVax|
48520092|NCT01602068|DRUG|Dexamethasone Phosphate Ophthalmic|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
48520093|NCT01602068|DRUG|100 mM Sodium Citrate Buffer|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
48520094|NCT00323050|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
48520095|NCT03573154|OTHER|administration of the liquid 1 and then the liquid 2|The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
48182482|NCT01936467|DEVICE|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
48383699|NCT01565655|DRUG|Placebo|oral
48025197|NCT02546245|BEHAVIORAL|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
48025198|NCT02546245|BEHAVIORAL|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
48025199|NCT04289649|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
48025200|NCT04289649|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
48383700|NCT05572944|OTHER|LDCT lung cancer screen, immediately|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test and chest X ray~5. Arrenge chest CT right away, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~6. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
48383701|NCT05572944|OTHER|LDCT lung cancer screen, later|"Participants will receive the following things in sequence~1. Non-smoker lung cancer prediction model among Taiwanese population by questionnaire~2. Check autoantibodies against p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2 in the blood of recruited patients and detect 133 SNPs and 11 mitochondrial mutations which are highly correlated with never-smoking lung cancer in our preliminary data~3. Check total bilirubin, urinary heavy metals, serum tumor marker, including CEA, alpha-fetal protein, etc.~4. Check pulmonary function test.~5. Arrange AI-asisted chest X-ray right away.~6. Arrange chest CT three years later, and detection, classification, prediction of lung cancer risk in CT using deep learning and radiomics~7. Optimization and validation of lung cancer risk and probability prediction model: prospective multicenter clinical study."
48383702|NCT02799485|OTHER|Laboratory Biomarker Analysis|Correlative studies
48383703|NCT02799485|OTHER|Pharmacological Study|Correlative studies
48383704|NCT02799485|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
48520096|NCT03573154|OTHER|administration of the liquid 2 and then the liquid 1|The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
48720475|NCT04346121|OTHER|GPs reports of potential patient safety incidents, non-COVID-19 related|GPs reports of potential patient safety incidents, non-COVID-19 related
48025201|NCT04289649|DRUG|K-924 LD Placebo|Pitavastain 2 mg
48720476|NCT04082013|OTHER|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~* The subject will be instructed to maintain 90° hip flexion in the supine position.~* Then asked to actively extend the knee joint.~* The degree of achieving active knee extension will be measured using a universal goniometer.~* The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~  * the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
48383705|NCT02799485|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
48025202|NCT04289649|DRUG|K-924 HD Placebo|Pitavastain 4 mg
48025203|NCT02013323|DRUG|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
48520097|NCT02223988|PROCEDURE|subglottic secretion removal|
48720477|NCT02537405|DRUG|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
48720478|NCT02537405|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
48720479|NCT05108597|DRUG|Misoprostol|400ug misoprostol will be administered through rectal route, 1 hour before surgery to assess its effect on intra-operative blood loss during myomectomy
48720480|NCT02488746|DEVICE|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
48720481|NCT02877498|OTHER|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
48720482|NCT02877498|OTHER|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
48720483|NCT04576078|DRUG|Oral nefopam|Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.
48720484|NCT04576078|DRUG|Placebo|Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
48720485|NCT04679909|BIOLOGICAL|AdCOVID|Administered intranasally
48720486|NCT04679909|OTHER|Placebo|Administered intranasally
48025204|NCT02013323|DRUG|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
48025205|NCT03702829|DRUG|Inotersen|Open Label Study
48025206|NCT00701389|DRUG|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
48025207|NCT00701389|DRUG|sumatriptan|single oral dose of 100 mg sumatriptan
48025208|NCT00701389|DRUG|sumatriptan placebo|single oral dose
48025209|NCT00701389|DRUG|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
48025210|NCT06533839|PROCEDURE|Permanent colostomy|A long-term (permanent) colostomy will be performed in the diseased colon or rectum.
48025211|NCT01621750|DRUG|Clopidogrel|Clopidogrel Tablets 300 mg
48025212|NCT02564198|DRUG|Ramucirumab|Administered IV
48025213|NCT00125632|PROCEDURE|Eccentric Viewing Training for Reading|
48025214|NCT06389812|OTHER|Dual-task exercise traning|To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
48025215|NCT04144400|BEHAVIORAL|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
48025216|NCT04144400|BEHAVIORAL|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
48025217|NCT00467181|DRUG|Fenoldopam|
48025218|NCT04943289|BIOLOGICAL|DUOC-01|DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
48025219|NCT04092634|DEVICE|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
48383706|NCT05770362|OTHER|lifestyle questionnaire|The changes in lifestyle by lifestyle questionnaire during and after home isolation
48383707|NCT00602927|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
48520098|NCT03308214|DRUG|Imipenem|Imipenem 1.0 q 8h
48520099|NCT00545714|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
48520100|NCT00545714|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
48720487|NCT00439452|OTHER|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
48720488|NCT00439452|OTHER|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
48025220|NCT04092634|DEVICE|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
48182483|NCT01936467|DEVICE|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
48383708|NCT00602927|DRUG|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
48383709|NCT06543056|DRUG|ES014|ES014 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 24 months.
48720489|NCT04268550|DRUG|Selpercatinib|Given PO
48383710|NCT05871853|BEHAVIORAL|Improved breastfeeding support|Cross-sectoral intervention to improve breastfeeding support among women giving birth at Slagelse Hospital, Region Zealand, Denmark
48720490|NCT01762995|DRUG|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
48025221|NCT00723801|DRUG|Atenolol|Atenolol 50mg PO QD
48025222|NCT00723801|DRUG|Losartan|Losartan 100mg PO QD
48025223|NCT02899728|DRUG|Carboplatin|Given IV
48025224|NCT02899728|DRUG|Cediranib|Given PO
48383711|NCT05062161|BEHAVIORAL|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
48383712|NCT05062161|BEHAVIORAL|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
48383713|NCT05384184|PROCEDURE|Tumor /metastases removal|Tumor /metastases removal
48383714|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
48720491|NCT01762995|DRUG|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
48720492|NCT01762995|DRUG|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
48025225|NCT02899728|DRUG|Cediranib Maleate|Given PO
48182484|NCT05328024|DRUG|Immunotherapy|anti-PD1
48182485|NCT04476212|OTHER|Topical antibiotic prophylaxis|The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
48025226|NCT02899728|DRUG|Cisplatin|Given IV
48025227|NCT02899728|DRUG|Etoposide|Given IV
48182486|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
48025228|NCT02899728|DRUG|Olaparib|Given PO
48720493|NCT06197087|OTHER|cross-sectional observational survey study|Patients' pain intensity (with VAS), quality of life (with SF-12), sleep quality (with Pittsburgh sleep quality scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspect of pain (with Pain Catastrophizing Scale), presence of central sensitization (with the central sensitization scale), functional status (with the Fibromyalgia impact questionnaire), and chronotype preferences will be evaluated with the Morningness and Eveningness Questionnaire.
48720494|NCT00596583|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
48720495|NCT00596583|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
48720496|NCT04445376|OTHER|Physical Exercises|Aerobic Training and Breathing Exercises.
48383715|NCT00938392|BIOLOGICAL|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
48383716|NCT04051658|DEVICE|Transcranial direct current stimulation|tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
48383717|NCT05946629|DEVICE|PCI with SELUTION SLR DCB|After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.
48383718|NCT05946629|DEVICE|"PCI with FDA approved -limus DES"|"For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B."
48383719|NCT05267639|DEVICE|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
48520101|NCT00545714|DRUG|Rituximab|Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
48520102|NCT04187755|DRUG|Ceftazidime Injection|Ceftazidime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 6 hourly)
48520103|NCT04187755|DRUG|Cefepime Injection|Cefepime was administered intravenously with usual standard dose for serious infection (50 mg/kgBW/dose, 8 hourly)
48720497|NCT05173935|PROCEDURE|Percutaneous endoscopic gastrostomy|Gastrostomy tube placement using an endoscopic camera inserted via the mouth into the stomach to place the tube.
48182487|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
48182488|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
48520104|NCT03929068|DRUG|carbidopa-levodopa|Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
48520105|NCT03929068|DRUG|Placebo Oral Tablet|Placebo will be given to maintain blinding of participants and study team.
48520106|NCT02666443|DRUG|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
48520107|NCT02666443|DRUG|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
48720498|NCT05173935|PROCEDURE|Radiologically-inserted gastrostomy|Gastrostomy tube placement using a temporary nasogastric tube placed from nose to stomach and fluoroscopy (x-rays).
48720499|NCT03134183|DRUG|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E
48720500|NCT03134183|DRUG|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E
48720501|NCT02955459|DRUG|VNRX-5133|
48720502|NCT02955459|DRUG|Placebo|
48720503|NCT03266172|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
48720504|NCT03266172|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
48383723|NCT03611920|PROCEDURE|Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
48383724|NCT03611920|PROCEDURE|Dexamethasone|Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
48383725|NCT06651814|BEHAVIORAL|Supervised Exercise Group|A supervised exercise program will consists of 10 sessions. The 1st exercise station will be a 5-minute warming up of the jaw with a heat lamp. The 2nd station will involve jaw opening-closing movements (TMJ rotation) with the mandible in a slightly protruded position for 6 minutes. The 3rd and 4th exercise stations will comprised of jaw opening and jaw protrusion, respectively, against resistance for 4 minutes each. Measurements will be done before the trial started and after 3 months.
48520108|NCT02666443|DRUG|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
48520109|NCT01662778|DRUG|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
48520110|NCT01662778|DRUG|6 microns at 50mg|STAG generated monodisperse 6 micron particles
48520111|NCT01662778|DRUG|Placebo Comparator|No drug just solvent
48520112|NCT01662778|DRUG|MDI FP|
48720505|NCT04469348|DIAGNOSTIC_TEST|nasal swab|nasal swab will be performed to analysis biological markers at every visit.
48720506|NCT02776592|OTHER|Cow's milk-based formula with added nutrients|
48720507|NCT02776592|OTHER|Cow's milk-based formula|
48720508|NCT04788862|BIOLOGICAL|P. falciparum infected erythrocytes|Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
48720509|NCT05362474|DRUG|Montelukast|10mg orally once a day
48182489|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
48182490|NCT06507423|DEVICE|Septicyte Lab Test pre operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
48383726|NCT06651814|BEHAVIORAL|Home Exercise Group|Patients will received a home regime of jaw exercises. They will be instructed to do two different trainings. The 1st type of exercise will be jaw opening and closing movements daily for 5 minutes after each meal with the mandible and the head of the TMJ in a slightly protruded position. This exercise should not produce any clicking sounds. The 2nd type of exercise will be isometric exercises; this entailed jaw opening and jaw protrusion against resistance with their hand for 10 seconds with 10 repetitions each daily. All the patients will receive a training brochure with photos of the exercises and detailed information on frequency and exercise time. The brochure will include a diary. After 6 weeks, the subject and the assistant will check the performance of the exercise and the diary
48383727|NCT02206100|DRUG|PER977|reversal of edoxaban-induced anticoagulation
48383728|NCT02206100|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
48720510|NCT06507384|OTHER|AI-Based Risk Assessment Model|Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
48720511|NCT05825625|DRUG|Atezolizumab|Atezolizumab 1,200 mg by IV infusion Q3W.
48720512|NCT05825625|DRUG|Tiragolumab|Tiragolumab by IV infusion Q3W.
48720513|NCT06179316|PROCEDURE|Robot Assisted Radical Prostatectomy|Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
48720514|NCT06237556|OTHER|Placebo|Patients in the control group will receive placebo.
48720515|NCT06237556|DRUG|Melatonin 5 MG|Three days before the operation patients will receive 5 mg of melatonin (Melatonin, Nature Made, Canada, and USA) one hour before assigned sleep time until the time of discharge from hospital.
48720516|NCT02800590|DRUG|ABP-700|
48720517|NCT05885737|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
48383729|NCT02206100|DRUG|enoxaparin|
48383730|NCT06110338|DRUG|placebo|placebo iv. once.
48383731|NCT06110338|DRUG|IBI355|IBI355 iv. once.
48383732|NCT04130009|PROCEDURE|Tourniquet use|Use of Tourniquet in The TKA
48383733|NCT05602025|BIOLOGICAL|Depemokimab|Depemokimab will be administered via a SSD or autoinjector.
48383734|NCT00110084|DRUG|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
48383735|NCT00110084|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
48383736|NCT05570175|BEHAVIORAL|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
48720518|NCT05885737|DRUG|Placebo Injection|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
48720519|NCT03327064|DRUG|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
48720520|NCT03327064|DRUG|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
48720521|NCT01756859|PROCEDURE|MRI Scan|
48720522|NCT05205655|BEHAVIORAL|collection of odour samples|Odours will be collected by participants by putting sterile compresses under the armpits for at least 4 h.
48720523|NCT06095167|DRUG|without concurrent cisplatin chemotherapy|IMRT without concurrent cisplatin chemotherapy
48720524|NCT06095167|DRUG|with concurrent cisplatin chemotherapy|IMRT with concurrent cisplatin chemotherapy
48720525|NCT04167865|OTHER|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
48720526|NCT05118490|DRUG|Daily rifapentine and isoniazid for 4 weeks|Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)
48720527|NCT05118490|DRUG|Weekly rifapentine and isoniazid for 12 weeks|Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
48720528|NCT03048591|DEVICE|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
48720529|NCT00112177|DRUG|Itopride Hydrochloride|
48383737|NCT06652620|OTHER|Cola|regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
48383738|NCT01237704|BEHAVIORAL|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
48383739|NCT01237704|BEHAVIORAL|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
48383740|NCT05087173|DEVICE|Chatbot|An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.
48383741|NCT00171899|DRUG|imatinib mesylate|
48383742|NCT06124001|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
48720530|NCT02965690|PROCEDURE|Zimmer Biomet NexGen CR|Total Knee Replacement
48720531|NCT02965690|PROCEDURE|Medacta International GMK Sphere|Total Knee Replacement
48720532|NCT02973568|OTHER|Observational Study|
48720533|NCT06506890|OTHER|Use of C-Polar coated HVAC Filter versus conventional HVAC Filter|comparing the difference in reduction of bioaerosols between HVAC filters.
48720534|NCT02190890|PROCEDURE|Dry needling|
48720535|NCT02190890|PROCEDURE|Control|
48720536|NCT06184958|DRUG|Lidocaine group|Group A: Lidocaine group( 25 patients) will receive 5 mg/Kg lidocaine in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
48720537|NCT06184958|DRUG|Ketamine group|Group B:Ketamine group(25 patients) will receive 0.5 mg/Kg ketamine sulphate in 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks.
48720538|NCT06184958|DRUG|Placebo group|Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
48720539|NCT03901404|PROCEDURE|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
48720540|NCT04799691|PROCEDURE|Invasive ventilation strategy|Use of an invasive ventilatory support strategy
48720541|NCT04799691|PROCEDURE|Non-invasive ventilation strategies|Use of non-invasive ventilatory support strategies
48720542|NCT05190861|DIAGNOSTIC_TEST|droplet digital PCR method|The droplet digital PCR method can detect nucleic acids from the most common pathogens (approximately 90%) responsible for BSIs according to Chinet2020 and takes about 4 hours to perform, reporting within the first 24h of suspected sepsis/septic shock.
48720543|NCT05190861|DIAGNOSTIC_TEST|blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling.
48720544|NCT03147794|DEVICE|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
48182491|NCT06507423|DEVICE|Septicyte Lab Test post operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
48720545|NCT01120925|BIOLOGICAL|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
48720546|NCT01120925|BIOLOGICAL|CD133|5-15 X 106 cells in 20ML suspension IPV
48720547|NCT01120925|BIOLOGICAL|Control|Injection of 20 ml Normal saline via IPV
48182492|NCT05638347|DRUG|HRS-7085 tablets|Single oral administration
48182493|NCT05638347|DRUG|Placebo tablet|Single oral administration
48182494|NCT00251706|DRUG|amiodarone|
48720548|NCT03166644|DEVICE|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
48720549|NCT02303106|DRUG|Lamotrigine|
48720550|NCT00434356|DRUG|bevacizumab|Intravenous repeating dose
48720551|NCT00434356|DRUG|sunitinib|Oral repeating dose
48720552|NCT00434356|DRUG|paclitaxel|Intravenous repeating dose
48720553|NCT01777945|DRUG|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
48720554|NCT01777945|DRUG|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
48182495|NCT03708796|DIAGNOSTIC_TEST|SIRS, qSOFA, NEWS, RETTS scores evaluation|Simple data collection from regular vital signs recordings during the initial phase of care management in the emergency department. Missing data is then possibly completed by the physician when made available during the regular medical management of the patient.
48182496|NCT04947319|DRUG|Tirabrutinib|Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.
48720555|NCT05219669|DRUG|Nalmefene Hydrochloride|30 mg/mL solution
48383743|NCT06124001|DRUG|camrelizumab for Injection|Administered once at 3 mg/kg intravenously on Days 8 of each cycle.
48383744|NCT03394404|DEVICE|ECG-I mapping and PVI|ECG-I mapping and PVI
48383745|NCT02696304|OTHER|Adipose tissu repartition|absorptiometry,
48720556|NCT04569812|PROCEDURE|Cardiopulmonary Resuscitation|flowchart-assisted standard resuscitation or chest compressions-only resuscitation for 5min
48720557|NCT04427449|BIOLOGICAL|CD44v6-specific CAR gene-engineered T cells|4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
48720558|NCT03695952|DRUG|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
48720559|NCT02705274|DRUG|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
48720560|NCT02705274|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
48182497|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
48182498|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
48182499|NCT05641779|DEVICE|pigtail|pigtail catheter insertion in chest in the pleural cavity
48182500|NCT02964702|DEVICE|Thrombectomy Device T-01|
48182501|NCT05360628|DRUG|D-0120 in combination with Allopurinol|noted above
48182502|NCT03450499|DRUG|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
48383746|NCT02696304|OTHER|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
48383747|NCT02696304|OTHER|Preadipocyte quantification and adipose tissue inflamation|biopsy
48720561|NCT04176120|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
48720562|NCT04176120|OTHER|Standard Care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
48720563|NCT04314219|DRUG|Cyclophosphamide 50mg|Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
48720564|NCT04314219|DRUG|Methotrexate|Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
48720565|NCT00514020|DRUG|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
48720566|NCT00514020|DRUG|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
48720567|NCT00514020|DRUG|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
48720568|NCT00514020|GENETIC|gene expression analysis|Blood collection
48720569|NCT00514020|GENETIC|polymorphism analysis|Blood collection
48182503|NCT03450499|DRUG|Placebo|the analgesic requirement will be calculated in placebo group.
48383748|NCT02696304|OTHER|Inflamation blood markers quantification|blood drawn,
48383749|NCT02288650|OTHER|early refeeding|
48383750|NCT02288650|OTHER|refeeding only in the recovery room (usual practice).|
48383751|NCT01389700|DRUG|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
48383752|NCT01389700|DRUG|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
48383753|NCT04754529|OTHER|Quality-of-Life Assessment|Ancillary studies
48383754|NCT04754529|OTHER|Survey Administration|Ancillary studies
48383755|NCT04754529|OTHER|Yoga|Receive yoga intervention
48720570|NCT00514020|GENETIC|protein expression analysis|Blood collection
48720571|NCT00514020|OTHER|pharmacological study|Blood collection
48720572|NCT02418988|DRUG|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
48720573|NCT02418988|DRUG|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
48720574|NCT02097342|DRUG|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
48720575|NCT02097342|DRUG|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
48720576|NCT02097342|DRUG|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
48182505|NCT06544603|DEVICE|Multiwave Locked System (MLS) laser|Laser probe directly contacts with skin of the all the acupoints. The probe was fixed on each point for 1 min. In this study, the laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm)
48182506|NCT05773911|DEVICE|4% chitosan gel (pH 3.48).|Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).
48182507|NCT05773911|DEVICE|Reciprocal Chitosan brush|Reciprocal Chitosan brush
48182508|NCT05521711|OTHER|Food|Commercially available powders or liquids
48182509|NCT06241781|BIOLOGICAL|GT101 injection|GT101 injection to treat cervical cancer
48182510|NCT06241781|DRUG|Gemcitabine injection|Gemcitabine injection to treat cervical cancer
48182511|NCT04649671|BEHAVIORAL|Mobile health|"Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening).~Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit"
48383756|NCT00595946|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
48383757|NCT00595946|DRUG|Placebo|0 mcg capsules twice daily (BID)
48383758|NCT06022666|OTHER|Geriatric assessment|Geriatric assessment through PATH clinic which includes an evaluation of comorbidities, health trajectory and baseline frailty as well as conducting an in-depth discussion with the patient on how frailty stage impacts decision-making about surgery in order to co-develop a care plan.
48025229|NCT03869229|BIOLOGICAL|Intra-articular injection of ADMSC|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
48025230|NCT00582582|DRUG|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
48025231|NCT00582582|DRUG|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
48025232|NCT05903560|PROCEDURE|endovascular recanalization via radial approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach
48025233|NCT05903560|PROCEDURE|endovascular recanalization via femoral approach|Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach
48025234|NCT02879838|OTHER|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
48025235|NCT06069154|DEVICE|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
48025236|NCT06069154|PROCEDURE|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
48182512|NCT04325633|DRUG|1: Naproxen|Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
48182513|NCT04325633|DRUG|2: Standard of care|Standard of care
48182514|NCT06240429|DIETARY_SUPPLEMENT|Collagen|Daily doses of 10 g collagen peptide supplementation
48182515|NCT03883464|OTHER|Diet|Restriction in postoperative fat diet
48182516|NCT04088864|DRUG|Fludarabine|Fludarabine is a purine antagonist antimetabolite
48182517|NCT04088864|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative alkylating agent
48383759|NCT01157065|DRUG|AL-78898A|Investigational treatment
48383760|NCT01157065|DRUG|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
48182518|NCT04088864|DRUG|Autologous CD22 CAR T|Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
48182519|NCT03993275|DEVICE|MindMotion GO|Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
48182520|NCT00517842|DRUG|ViNeuro|
48182521|NCT05175196|DIAGNOSTIC_TEST|CandyCollect|The CandyCollect device is a novel, micro-engineered, lollipop-inspired platform. It has functionalized open microchannels for pathogen capture and concentration. It also has time-controlled flavoring release to make the platform more patient-centric.
48182522|NCT05175196|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Child participants are instructed to suck on the swab for 10 seconds, as they would suck on a lollipop. Participant will be asked to take this test twice."
48182523|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
48182524|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
48182525|NCT00005637|DRUG|carmustine|
48182526|NCT00005637|DRUG|temozolomide|
48182527|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
48520113|NCT04529135|DRUG|Dexmedetomidine|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
48720577|NCT02721108|BEHAVIORAL|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
48720578|NCT02721108|BEHAVIORAL|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
48720579|NCT04104880|DEVICE|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
48720580|NCT01123473|DRUG|capecitabine|
48720581|NCT01123473|DRUG|cisplatin|
48720582|NCT01123473|DRUG|epirubicin hydrochloride|
48720583|NCT01123473|DRUG|fluorouracil|
48720584|NCT01123473|DRUG|lapatinib ditosylate|
48720585|NCT01256762|DRUG|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
48720586|NCT01256762|DRUG|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
48720587|NCT01256762|DRUG|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
48720588|NCT02782767|OTHER|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
48720589|NCT02782767|OTHER|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
48720590|NCT02878044|OTHER|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
48720591|NCT03075124|DEVICE|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
48720592|NCT00496132|DRUG|PRO131921|Escalating doses by IV infusion
48720593|NCT01051401|DRUG|rosuvastatin|Given PO
48720594|NCT01051401|OTHER|placebo|Given PO
48720595|NCT01051401|OTHER|survey administration|Correlative study
48720596|NCT01051401|PROCEDURE|management of therapy complications|
48720597|NCT01969721|DRUG|fluticasone propionate|low dose
48720598|NCT01969721|DRUG|salmeterol|
48720599|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
48720600|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
48720601|NCT01969721|DRUG|tiotropium|tiotropium high dose
48720602|NCT01969721|DRUG|olodaterol|
48720603|NCT01969721|DRUG|olodaterol|
48720604|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
48720605|NCT01969721|DRUG|placebo|placebo/dummy for blinding purposes
48720606|NCT01969721|DRUG|tiotropium|tiotropium low dose
48182528|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment control exercise|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
48182529|NCT00416598|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
48388037|NCT05786794|BEHAVIORAL|Patient Navigation Program for Hearing Health Care|Patients presenting for routine office visits will be invited to participate in the study and informed consent procedures and study enrollment will be conducted by a research assistant. Participants will then undergo baseline assessment. Following baseline measures, participants who screen positive for hearing loss will be contacted by the Patient Navigator (PN) to begin the intervention. The navigator will contact participants every 2 weeks to focus on addressing key aspects of Hearing Health Care (HHC): education, screening, diagnosis, and treatment. PNs will assist the patient to undergo a formal audiogram with the 12 months following enrollment. Each PN session will likely last between 10-30 minutes. Post-intervention data collection also administered by a trained interviewer, will occur following a diagnostic audiogram with an audiologist or at 12 months following enrollment.
48720607|NCT01969721|DRUG|fluticasone propionate|low dose
48720608|NCT01969721|DRUG|salmeterol|
48720609|NCT02489812|BEHAVIORAL|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
48720610|NCT03503981|OTHER|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
48720611|NCT00211952|DRUG|celecoxib|
48720612|NCT03562234|DIAGNOSTIC_TEST|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
48720613|NCT03562234|DIAGNOSTIC_TEST|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
48720614|NCT02584920|DRUG|HLX01|
48720615|NCT02584920|DRUG|Rituximab|
48182530|NCT00416598|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
48182531|NCT00416598|DRUG|Busulfan|Given IV
48182532|NCT00416598|DRUG|Cytarabine|Given IV
48720616|NCT02223481|DRUG|Terbogrel low dose|
48720617|NCT02223481|DRUG|Terbogrel high dose|
48720618|NCT02223481|DRUG|Placebo|
48720619|NCT01813123|BEHAVIORAL|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
48182533|NCT00416598|DRUG|Daunorubicin Hydrochloride|Given IV
48182534|NCT00416598|DRUG|Decitabine|Given IV
48182535|NCT00416598|DRUG|Etoposide|Given IV
48720620|NCT03972410|BEHAVIORAL|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
48182536|NCT00416598|BIOLOGICAL|Filgrastim|Given SC
48182537|NCT00416598|OTHER|Laboratory Biomarker Analysis|Correlative studies
48182538|NCT00416598|OTHER|Pharmacological Study|Correlative studies
48182539|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
48720621|NCT03972410|BEHAVIORAL|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
48182540|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
48182541|NCT02563548|DRUG|PEGPH20|PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
48182542|NCT02563548|DRUG|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
48182543|NCT03689634|DEVICE|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
48182544|NCT00751322|OTHER|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
48182545|NCT00751322|OTHER|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
48182546|NCT00430742|DRUG|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
48182547|NCT00430742|DRUG|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
48182548|NCT01889069|DRUG|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
48182549|NCT01889069|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
48182550|NCT01889069|DRUG|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
48182551|NCT01889069|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
48182552|NCT01889069|DRUG|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
48720622|NCT06436586|OTHER|No intervention|No intervention
48720623|NCT02880995|DEVICE|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
48720624|NCT02880995|BEHAVIORAL|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
48720625|NCT02880995|DRUG|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
48720626|NCT00038779|PROCEDURE|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
48720627|NCT03836677|COMBINATION_PRODUCT|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
48720628|NCT03836677|COMBINATION_PRODUCT|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
48182553|NCT01889069|DRUG|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
48182554|NCT02737813|DRUG|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
48182555|NCT02737813|DRUG|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
48182556|NCT00759122|DRUG|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
48383761|NCT06651320|OTHER|The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery|"The patients in the interventional arm will be introduced to video will be introduced to a concise, animated video explaining the steps they are about to undergo in the department, the OR, recovery and discharge. How to prepare for the procedure, what to expect during and after the procedure and what are the possible follow up scenarios.~In order to overcome language berries videos would be available in basic 6th grader language and translated into English, Arabic and Russian for the non-Hebrew speaking population.~There would be one staff member aware of the patient's allocation the international Vs nonintervention arm while the rest of the staff would be masked to the research arm the patient was allocated to.~Once they have watched the video they would be asked to fill up a questionnaire their anxiety level concerning the procedure (STAI-S)."
48520114|NCT04529135|DRUG|Remifentanil|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
48520115|NCT02436161|BEHAVIORAL|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
48520116|NCT02189837|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
48520117|NCT02189837|DRUG|Atorvastatin|Administered by mouth
48720629|NCT06054854|BIOLOGICAL|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
48520118|NCT02189837|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
48520119|NCT02189837|DRUG|Placebo to Atorvastatin|Administered by mouth
48720630|NCT02410577|DRUG|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
48720631|NCT02410577|DEVICE|PET/CT Scan|
48720632|NCT02410577|DEVICE|MRI|
48720633|NCT02410577|OTHER|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
48720634|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
48720635|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
48182557|NCT00759122|DRUG|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
48182558|NCT05141227|PROCEDURE|Two-stage Open reduction and internal fixation ( ORIF) using plates & screws|Two stage ORIF using initially temporary spanning fixator then conversion to plates \& screws
48383762|NCT02619370|BEHAVIORAL|Conversation card game|
48383763|NCT02619370|BEHAVIORAL|Active Control|
48388038|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 native powder|
48388039|NCT02944097|DIETARY_SUPPLEMENT|Vineatrol 30 micelles|
48520120|NCT03098160|DRUG|Evofosfamide|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
48520121|NCT03098160|DRUG|Ipilimumab|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
48520122|NCT03362814|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
48720636|NCT05672355|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48720637|NCT05672355|BIOLOGICAL|mRNA COVID-19 Vaccine|Given IM
48720638|NCT05672355|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
48720639|NCT06004375|DIETARY_SUPPLEMENT|Neomune|Neomune containing 4.8 g arginine and 2 g glutamine
48520123|NCT03362814|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
48520124|NCT03362814|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
48520125|NCT03362814|DRUG|Ribavirin 100 MG|Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 1000mg and ≥75kg = 1200mg)
48520126|NCT03362814|DRUG|Ravidasvir Placebo|Ravidasvir Placebo tablet administered orally once daily
48383764|NCT00816166|DEVICE|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
48383765|NCT00816166|DRUG|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone \[Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)\]
48383766|NCT06565650|DRUG|Miebo|100% perfluorohexyloctane
48383767|NCT06565650|DRUG|Saline|0.6% sodium chloride solution
48383768|NCT03253159|BEHAVIORAL|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
48720640|NCT05932602|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.
48720641|NCT05932602|DEVICE|Dual Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
48720642|NCT01916850|DRUG|LX4211 400 mg|
48720643|NCT01916850|DRUG|LX4211 800 mg|
48720644|NCT01916850|DRUG|LX4211 Placebo|
48720645|NCT00357383|DRUG|Azithromycin (T1225)|
48720646|NCT04454541|PROCEDURE|Ultrasound-guided nerve block for headache management|The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
48720647|NCT01164553|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
48720648|NCT01855152|OTHER|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
48720649|NCT01855152|OTHER|Treatment as usual|Treatment delivered as usual in the care home
48025237|NCT06069154|DEVICE|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
48383769|NCT06650371|DRUG|Fentanyl infusion|opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
48383770|NCT06650371|DRUG|Dexamedomedine and ketamine infusion|Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
48720650|NCT06318611|OTHER|sleep, chronotype|Our objectives were to compare sleep health composite dimensions, and chronotype in children and adolescents with and without T1D, and to explore relationship between sleep and glycemic variability in T1D.
48720651|NCT01669213|DRUG|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
48720652|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
48720653|NCT01669213|DRUG|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
48720654|NCT01669213|DRUG|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
48720655|NCT05613582|DEVICE|Transcranial Direct Current Stimulation|The flow of DC electric current 1 mA for 20 minutes. The position of the electrode placement follows the international EEG 10/20 system.
48720656|NCT06506799|OTHER|Training Given to Intensive Care Nurses on the Use of Physical Fixation|"Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test."
48028951|NCT03607383|DRUG|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
48383771|NCT03564678|DIETARY_SUPPLEMENT|Levocarnitine|Given IV
48383772|NCT03564678|DRUG|Vitamin B Complex|Given PO
48383773|NCT05673759|DEVICE|Electroencephalogram (EEG) system|An FDA 510(k) approved EEG/ERP device designed by G-Tec ™ intended for the acquisition, display, analysis, storage, reporting and management of EEG and auditory evoked potentials (AEP) information and uses Bluetooth technology to securely transmit EEG signals to a computer. The device is patient-friendly, and no serious adverse events have occurred to-date in any research or clinical study or in clinical use.
48388040|NCT04520594|OTHER|Resistant Starch|7.5 g resistant starch/m2 oral consumption
48720657|NCT06013436|DRUG|Autologous serum tears combined with 0.05% cyclosporin eye drop|All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
48720658|NCT05589883|BEHAVIORAL|EMPOWER-Latinx|EMPOWER-Latinx will be delivered in Spanish by videoconferencing (i.e., Zoom, WebEx) with a trained study interventionist. Intervention modules will be audio- and video-recorded (videorecording optional).
48720659|NCT00906958|DEVICE|Nexus Flow Generator|The modified device to be assessed in this study will act in a similar way to the existing device, VPAP Auto, but utilises an improved algorithm which should maintain or enhance the effectiveness of the treatment.
48383774|NCT05673759|BEHAVIORAL|Standard Neuropsychological Testing|Prior to the EEG session, neuropsychological testing will be done to establish a baseline measurement. We administer a full standard neuropsychological battery (45 mins) for all participants which includes the following tests: MOCA (only for older participants), MMSE, CERAD, Phonemic Test and the Category Fluency test, Trails Making Test A and B, BNT, BAI, BDI, PANAS, Ishihara Color Blindness test, and the Snellen Eye Chart.
48383775|NCT05673759|BEHAVIORAL|Additional neuropsychological tests|Younger participants will receive additional testing along with the standard neuropsychological battery including Pittsburgh Sleep Quality Index (PSQI) \[37\] for sleep quality measures, the Test of Memory Malingering (TOMM) for effort measure, Ohio State Traumatic Brain Injury Identification Method questionnaire (OSU-TBI) \[38\] to gather lifetime TBI history, and the Neurobehavioral Symptom Inventory (NBSI) \[39\] for post-concussive symptoms. These additional tests will add an extra fifteen minutes, making the total time for neuropsychological questionnaires 1 hour in younger participants.
48383776|NCT03393039|BEHAVIORAL|Negative Affect Task|fMRI stress task
48383777|NCT01895829|PROCEDURE|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
48520127|NCT03362814|DRUG|Danoprevir Placebo|Danoprevir Placebo tablet administered orally twice daily
48520128|NCT03362814|DRUG|Ritonavir Placebo|Ritonavir Placebo tablet administered orally twice daily
48520129|NCT03362814|DRUG|Ribavirin Placebo|Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)
48520130|NCT00814268|DRUG|Clopidogrel|75mg tablet, oral administration once daily
48720660|NCT00906958|DEVICE|VPAP Flow Generator 25|Exiting VPAP Auto 25 Flow Generator with A10 Algorithm
48720661|NCT03274804|BIOLOGICAL|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
48720662|NCT03274804|DRUG|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
48720663|NCT04464824|OTHER|no intervention|no intervention
48720664|NCT05558215|OTHER|Otago Exercise Program|"The Otago Exercise Program (OEP) is a CDC endorsed evidence-based falls prevention program for older adults. It has not been well studied with individuals with dementia. It is comprised of a brief warm up/flexibility series, lower extremity strengthening, and balance exercises. The same menu of exercises is used for all participants, but exercises are progressed based upon individual performance. For the purposes of this study, three 25-minute video recorded versions of OEP will be rotated for use, all of which include brief flexibility activities, strengthening, and balance exercises. Strengthening exercises will be limited to body weight resistance for ease of instruction, safety, and consistency. Balance exercises involve changes in base of support in static and dynamic contexts, with challenge progressively increased by decreasing arm support during training (from 2-hands, to 1-hand, to no hands)."
48720665|NCT05141656|OTHER|No intervention will be considered in this study.|No intervention will be considered in this study.
48720666|NCT03721809|BIOLOGICAL|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
48720667|NCT01788579|BEHAVIORAL|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
48720668|NCT01788579|BEHAVIORAL|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
48520131|NCT00814268|DRUG|Clopidogrel placebo|Matching tablet, oral administration once daily
48520132|NCT00814268|DRUG|Aspirin|100mg tablet, oral administration once daily
48520133|NCT00771498|DRUG|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
48720669|NCT02927275|BEHAVIORAL|Experimental: Standing Modality|Cognitive performance when standing
48720670|NCT02927275|BEHAVIORAL|Experimental: Biking Modality|Cognitive performance when biking slowly
48028952|NCT01103206|DRUG|cinacalcet|Intake of a single tablet of cinacalcet
48028953|NCT01103206|DRUG|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
48028954|NCT01103206|DRUG|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
48720671|NCT02927275|BEHAVIORAL|Experimental: Walking Modality|Cognitive performance when walking at 1mph
48720672|NCT02927275|BEHAVIORAL|No Intervention: Seated Modality|Cognitive performance when sitting.
48720673|NCT06230978|BEHAVIORAL|Habit workup|The patient and pharmacist will work together to specify a cue to help them take their medicine every day (e.g. brushing teeth, getting dressed, eating breakfast, making coffee, alarms, visual reminders etc).
48720674|NCT06230978|BEHAVIORAL|Standard Medication Counseling|The pharmacist provides standard counseling on the new medication
48720675|NCT05674253|DRUG|Dexmedetomidine + Hydrocortisone|Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
48720676|NCT00454584|DRUG|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
48720677|NCT00454584|DRUG|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
48720678|NCT00454584|DRUG|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
48720679|NCT01999218|DRUG|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
48720680|NCT01999218|DRUG|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
48720681|NCT01999218|DRUG|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
48720682|NCT01999218|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
48720683|NCT01999218|DRUG|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
48720684|NCT01999218|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
48720685|NCT01999218|DRUG|Sitagliptin|Open label, oral, once daily, rescue medication as required.
48720686|NCT03952715|DRUG|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
48720687|NCT03952715|DRUG|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
48182559|NCT05141227|PROCEDURE|single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed|Single stage Ex.Fix. Using illizarov \& minimal fixation of the articular surface using cannulated screws through mini open approaches
48182560|NCT04258683|DRUG|Pembrolizumab|Patients not progressing after 2 cycles of CyBorD treatment and achieving less than VGPR by IMWG criteria will be screened to receive pembrolizumab intravenously at 200mg at day 1 of every 3-week cycle for 8 cycles (24 weeks) starting Cycle 4 of CyBorD. CyBorD will be discontinued after 24 weeks and pembrolizumab will be administered as a single agent at the same dose for an additional 27 cycles (81 weeks).
48182561|NCT00312598|DRUG|Aripiprazole|
48182562|NCT04955899|DEVICE|Active Stimulation|The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
48720688|NCT01801852|BIOLOGICAL|NKT cells|
48720689|NCT05883046|OTHER|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
48720690|NCT05883046|OTHER|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
48720691|NCT05883046|OTHER|Baseline (Control)|No supplement conditions
48720692|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
48720693|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
48720694|NCT05705661|DEVICE|HIGH FREQUENCY CHEST WALL OSCILLATION|The HFCWO device used a triangular wave form which increases the airflow velocity more than other devices. Therefore, clearing sticky airway mucus and alveolar exudates and maintaining airway patency has become currently the most urgent issue in the ventilatory management of patients with severe COVID-19.
48182563|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Active|Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.
48182564|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Sham|Wearable device programmed to deliver sham stimulation.
48182565|NCT05225987|BEHAVIORAL|Postpartum Nurse Navigation Program based care|In addition to routine hospital care, the intervention group will receive navigation program-based nursing care that includes three home visits, three phone calls, and sending text messages at five different times.
48182566|NCT00458146|DRUG|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
48720695|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
48720696|NCT00999960|PROCEDURE|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
48720697|NCT02565810|DRUG|Adalimumab PFS and Pen|
48182567|NCT03091322|DEVICE|Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8|Assessment of the AV Opt and LV VectorOpt features
48182568|NCT01160237|BIOLOGICAL|PandemrixTM|One dose intramuscular injection
48720698|NCT01986959|PROCEDURE|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
48720699|NCT01986959|PROCEDURE|Without Periodontal dressing|The dressing was not inserted.
48182569|NCT01160237|BIOLOGICAL|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
48182570|NCT05224843|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
48182571|NCT01949181|PROCEDURE|Lung surgery|
48182572|NCT04041973|DRUG|Artemether-lumefantrine|"One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
48720700|NCT02578342|DEVICE|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
48720701|NCT01319721|PROCEDURE|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
48025238|NCT06069154|PROCEDURE|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
48182573|NCT04041973|DIETARY_SUPPLEMENT|Multivitamin|"One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
48720702|NCT01319721|PROCEDURE|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
48720703|NCT01319721|PROCEDURE|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
48720704|NCT02437604|DRUG|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
48720705|NCT02437604|DRUG|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
48720706|NCT02437604|DRUG|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
48720707|NCT02437604|DRUG|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
48720708|NCT02303860|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
48720709|NCT02303860|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
48025239|NCT04955626|BIOLOGICAL|BNT162b2|Intramuscular Injection
48025240|NCT04955626|OTHER|Placebo|Intramuscular Injection
48025241|NCT04955626|BIOLOGICAL|BNT162b2 OMI|Intramuscular Injection
48182574|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).
48720710|NCT02303860|DRUG|ORM-12741 IR|Immediately release formulation of ORM-12741
48025242|NCT04955626|BIOLOGICAL|Combination BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI~Intramuscular Injection"
48025243|NCT04955626|BIOLOGICAL|Combination (Bivalent) BNT162b2 and BNT162b2 OMI|"30-µg (15-µg each) or 60-µg (30-µg each)~Preformulated bivalent mixture (no dilution required) presented in a single vial~Intramuscular Injection"
48182575|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).
48182576|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
48182577|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
48720711|NCT01330654|DRUG|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
48720712|NCT02973776|DRUG|LEO 90100 aerosol foam|
48720713|NCT02973776|DRUG|Dermoval®/Dermovate®|
48720714|NCT02973776|DRUG|Diprosone|
48720715|NCT02973776|DRUG|Elocon|
48720716|NCT02973776|DRUG|Locoid|
48720717|NCT02973776|OTHER|LEO 90100 foam vehicle|
48182578|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).
48182579|NCT00133575|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
48025244|NCT04241939|BEHAVIORAL|Numberless BDS|Participants perform daily weighing using a numberless BDS with feedback from app (color codes, challenges), in conjunction with modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
48025245|NCT04241939|BEHAVIORAL|Digital Scale|Participants perform daily weighing using a digital scale (number readout), in conjunction with standard adolescent weight loss program
48182580|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
48182581|NCT03709108|OTHER|SI-Informed Bolus Calculator|The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission
48182582|NCT04140266|DRUG|Dapivirine (DPV) Vaginal Ring (VR)-004|Vaginal ring containing 25 mg of DPV
48182583|NCT04140266|DRUG|Truvada Tablet|Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
48025246|NCT04241939|BEHAVIORAL|Modified Motivational Interviewing|Modified motivational interviewing (clinic visits and weekly telephone calls), and the standard adolescent weight loss program.
48025247|NCT03211936|PROCEDURE|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
48182584|NCT03922607|DRUG|ABBV-157|ABBV-157 will be administered orally as capsule
48520134|NCT05630417|OTHER|Feet and Back Massage|"Foot massage: Feet are the most neglected organs of people and therefore cause many complaints. Foot massage is a massage applied to the back of the foot, toes, soles of the feet, the muscles between the thumb and little fingers, and the heel, where the muscles between the metatarsal bones are located.~Back massage: Back massage is a non-invasive nursing intervention that can be easily applied by nurses. In back massage application; A 10-minute back massage program applied by Çınar and Eşer (2012) will be applied."
48520135|NCT03617666|DRUG|Avelumab|Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
48025248|NCT03211936|DEVICE|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
48720718|NCT05996614|PROCEDURE|PRP in skin grafts|topical application of platelet rich plasma before resurfacing with STSG in Post burn raw areas
48720719|NCT05996614|PROCEDURE|conventional methods in skin grafts|fixation of the graft with stitches and staplers
48025249|NCT03211936|DEVICE|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
48025250|NCT03211936|OTHER|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
48025251|NCT03211936|OTHER|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
48025252|NCT04577144|OTHER|Online survey only|There are no interventions planned for this study. This is an observational study only.
48025253|NCT03843359|DRUG|GSK3745417|GSK3745417 will be administered.
48182585|NCT03922607|DRUG|Placebo for ABBV-157|Placebo for ABBV-157 will be administered orally as capsule
48182586|NCT04356625|DIAGNOSTIC_TEST|MEPic|"* patient in the supine position sitting 45° to 60°,~* closed suction catheter was removed~* a 90° elbow was placed and a bacterial filter in series with endotracheal tube~* adapter was also coupled to the aneroid pressure gauge~* in series an inspiratory unidirectional valve was placed that did not allow expiration~* 2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough"
48182587|NCT00131963|DRUG|cyclophosphamide|Given IV
48182588|NCT00131963|DRUG|doxorubicin|Given IV
48182589|NCT00131963|DRUG|paclitaxel|Given IV
48182590|NCT06296004|DEVICE|Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S|"Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US"
48720720|NCT00280345|PROCEDURE|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
48182591|NCT05961540|OTHER|Conventional care|"1. Instruct parents to follow up with the baby at the doctor's appointment.~2. Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight)."
48383778|NCT01895829|DRUG|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
48383779|NCT01969201|DRUG|Urofollitrophin|
48383780|NCT01969201|DRUG|Follitrophin alpha|
48720721|NCT00280345|PROCEDURE|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
48720722|NCT00280345|PROCEDURE|Cataract surgery|Removal of the cataract from the eye
48720723|NCT00001136|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
48720724|NCT06394453|OTHER|enteral feeding with mother milk or human donor breast milk|The experimental group will start enteral feeding with mother milk or human donor breast milk if mother milk is not accesible during the first day of therapeutic hypothermia.
48025254|NCT03843359|DRUG|Dostarlimab|Dostarlimab will be administered.
48025255|NCT01409694|DRUG|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
48388041|NCT04520594|OTHER|Placebo|Placebo oral consumption of food-grade cornstarch
48720725|NCT00918554|DRUG|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
48182592|NCT05961540|BEHAVIORAL|Breastfeeding behavioural intervention for mothers of infants with CHD|"Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~1. Evaluate signs of hunger and satiety in infants.~2. Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~3. Training methods for promoting breast milk secretion.~4. To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~5. Establish a breastfeeding promotion alliance.~6. Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~7. Assess and guide the growth and development of infants with CHD."
48383781|NCT06264765|OTHER|scalp block|The scalp block will be performed by the anesthesiologist 10 minutes before the pin head holder application (PHHA). Supraorbital and supratrochlear nerves will be blocked bilaterally with 6 ml of 0.5% bupivacaine injected vertically into the skin above the eyebrow midline. Auriculotemporal nerves will be blocked bilaterally by injecting 4 ml of 0.5% bupivacaine 1.5 cm anterior to the ear at the tragus level. The needle will be inserted perpendicular to the skin and the fascia will be injected deeply and superficially while the needle is withdrawn. Postauricular branches of the greater auricular nerves will be blocked bilaterally with 2 ml of 0.5% bupivacaine injected 1 cm posterior to the ear, between the bone and skin, at the level of the tragus. The greater, lesser, and third occipital nerves run along the upper nuchal line approximately halfway between the occipital prominence and the mastoid prominence.
48383782|NCT06264765|OTHER|Incisional infiltration|Incisional infiltration: 20 ml of 0.5% bupivacaine will be infiltrated by the surgeon into the PHHA points and surgical incision areas 10 minutes before PHHA. Two
48520136|NCT04505527|BEHAVIORAL|Lateral stepping|Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
48520137|NCT04505527|BEHAVIORAL|Forward walking|Subjects will have a typical forward walking
48520138|NCT06223802|BEHAVIORAL|biodex training|women group with a number of 29 women receiving 3-time biodex training per week, every time will be 10 minutes for 12 weeks
48520139|NCT04904133|OTHER|Low/No Calorie Sweeteners|LNCS powdered and then dissolved in water.
48520140|NCT04904133|OTHER|Placebo Group|Water
48520141|NCT05582070|OTHER|actigraphy|Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
48383783|NCT04067505|DRUG|Rivaroxaban|Dose: 15mg twice daily for three weeks, then 20mg once daily until six months after the operation. Application: oral
48025256|NCT01409694|DRUG|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
48383784|NCT04067505|DRUG|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
48383785|NCT04067505|DRUG|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
48520142|NCT02016183|DRUG|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
48520143|NCT04937881|DRUG|Tenofovir alafenamide|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)
48520144|NCT04937881|DRUG|Tenofovir Disoproxil Fumarate|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
48025257|NCT01409694|DRUG|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
48025258|NCT04494412|DRUG|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
48720726|NCT00918554|DRUG|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
48182593|NCT06270589|BEHAVIORAL|MF-HIIT|A single bout of 20-min MF-HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s mindful intervals), and finally a 2-min cool-down.
48182594|NCT06270589|BEHAVIORAL|MF-only|A single bout of 20-min intervention mindfulness intervention that includes 5 x 90s mindful intervals separated by sitting rest
48182595|NCT06270589|BEHAVIORAL|HIIT-only|A single bout of 20-min HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s rest intervals), and finally a 2-min cool-down.
48182596|NCT06270589|BEHAVIORAL|Sitting rest|Participants will sit in a comfortable chair, placed on the treadmill, while watching a HIIT video without mindfulness instructions for 20 minutes.
48182597|NCT00019695|DRUG|alendronate sodium|
48182598|NCT00019695|DRUG|ketoconazole|
48182599|NCT00374751|DRUG|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
48182600|NCT06064747|DEVICE|LF-rTMS|"LF-rTMS group: using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses);"
48182601|NCT06064747|DEVICE|Sham stimulation|Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days.
48383786|NCT05846152|DEVICE|Intervention|"Patient wounds will be examined:~* by eye by the principal investigator~* using a ruler by the principal investigator~* by WoundCare algorithms (AKA WoundTrack) using smartphone photography by the principal investigator~* by eye by a second investigator~* using a ruler by a second investigator~* by WoundCare (AKA WoundTrack) algorithms using smartphone photography by a second investigator."
48720727|NCT05332808|OTHER|questionnare|collecting data about treatment and quality of life
48720728|NCT03858504|OTHER|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
48720729|NCT00875173|DRUG|Selenium|selenium as a drug according to Brazilian regulation laws
48182602|NCT00504283|DRUG|Toradol|
48182603|NCT00504283|DRUG|Morphine|
48025259|NCT01977118|DRUG|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
48383787|NCT03870061|BEHAVIORAL|All Babies Are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
48520145|NCT05812534|DRUG|Cadonilimab|Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
48520146|NCT05484492|BIOLOGICAL|demineralized and mineralized combination putty bone allograft|Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
48520147|NCT05484492|BIOLOGICAL|calcium phosphosilicate putty alloplast graft|Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
48720730|NCT00875173|DRUG|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
48720731|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
48720732|NCT01763294|DEVICE|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
48720733|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
48720734|NCT01763294|DEVICE|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
48025260|NCT01977118|OTHER|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
48025261|NCT01657201|DRUG|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
48025262|NCT01657201|DRUG|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
48028955|NCT04782323|DRUG|aQII-1|Biological/Vaccine: Investigational aQII-1 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48720735|NCT01763294|DEVICE|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
48720736|NCT03475329|OTHER|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
48383788|NCT03492489|DRUG|cemiplimab|Intravenous (IV) administration
48383789|NCT03352544|BEHAVIORAL|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
48383791|NCT03312764|BEHAVIORAL|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
48383792|NCT03312764|BEHAVIORAL|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
48383793|NCT04155775|OTHER|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count \>50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
48383794|NCT06566235|BEHAVIORAL|Culturally adapted DBT-A-ST group|"The culturally adapted DBT-A-ST consists of 15 weekly group sessions, each lasting 120 minutes, including a 10-minute break. It maintains the core elements of standard DBT-A, including its philosophical foundation and treatment strategies.~Therapists focus on teaching DBT skills through various methods such as modeling, structured behavioral rehearsals, and feedback. Each session begins with a 40-minute group mindfulness exercise and homework review, followed by 60 minutes dedicated to skill-specific didactics and experiential activities, concluding with a 10-minute homework assignment. Two group leaders facilitate the sessions, and participants track their skill usage daily with diary cards, which are reviewed weekly."
48383795|NCT06566235|BEHAVIORAL|Activities-based support group (ASG)|ASG, based on principles of client-centered supportive therapy, is widely used by occupational therapists in mental health settings. ASG therapists aim to foster a sense of belongingness, maintain unconditional positive regard, provide empathy, psychoeducational and a treatment structure. Two group leaders held the sessions, teaching DBT skills and using cognitive behavioral strategies are prohibited. Each session starts with a review of their experiences over the last week (30 min), a support-building activity (30 min), and ends with an open group discussion about topics participants choose each week (50 min). For homework, participants will be asked to think about issues discussed and to track daily social support on diary cards.
48383796|NCT06651398|BEHAVIORAL|Lenient diet|The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.
48383797|NCT00003452|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48383798|NCT06651229|DRUG|JNJ-90189892|JNJ-90189892 will be administered.
48520148|NCT05119166|DIETARY_SUPPLEMENT|Vitamin B3|ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
48520149|NCT05119166|BIOLOGICAL|Azithromycin|"ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant."
48520150|NCT05119166|DIETARY_SUPPLEMENT|Fortified food supplement|"VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label)."
48520151|NCT02671838|BEHAVIORAL|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
48720737|NCT03562793|BEHAVIORAL|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
48720738|NCT02720640|DEVICE|Implant 'on' vs implant 'off'|Single group assignment
48520152|NCT02237092|PROCEDURE|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
48720739|NCT03571165|BEHAVIORAL|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
48720740|NCT02210091|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
48520153|NCT04038580|DEVICE|Laminated Socket|This is the currently prescribed socket the participant normally wears.
48720741|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
48720742|NCT02210091|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
48720743|NCT02599623|PROCEDURE|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
48028956|NCT04782323|DRUG|aQII-3 Investigational|Biological/Vaccine: Investigational aQII-3 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48383799|NCT05636475|OTHER|Manual hand massage after laparoscopic cholecystectomy surgery|Manual hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
48383800|NCT05636475|OTHER|Machine-based hand massage after laparoscopic cholecystectomy surgery|Machine-based hand massage is applied to a group of patients at 0, 4 and 8 hours after the patient returns from laparoscopic cholecystectomy surgery. It is applied to each hand for ten minutes.
48383801|NCT04761523|BEHAVIORAL|Dietary intervention: reduced fat diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
48383802|NCT04761523|BEHAVIORAL|Dietary intervention: standard healthy diet|Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
48720744|NCT02599623|PROCEDURE|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
48383803|NCT05427214|DEVICE|Halcyon 4.0 system|During each of the 1 or more imaging sessions, no more than 6 images total will be acquired. Only 5 images total across all of the imaging sessions will be used toward the study endpoint.
48383804|NCT04089150|RADIATION|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
48383805|NCT04089150|DRUG|mFOLFIRINOX|"* Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles"
48383806|NCT04089150|DRUG|Gemcitabine + Nab-paclitaxel|"* Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles"
48720745|NCT02235103|OTHER|Sperm Chromatin Dispersion Test|
48720746|NCT00053807|BIOLOGICAL|aldesleukin|
48383807|NCT04089150|DRUG|Gemcitabine + Capecitabine|"* Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles"
48383808|NCT04089150|PROCEDURE|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
48720747|NCT00053807|BIOLOGICAL|recombinant interferon alfa|
48383809|NCT03340246|PROCEDURE|Delayed sclerotherapy|See arm descriptions
48520154|NCT04038580|DEVICE|Quatro|The Quatro (Quorum) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
48520155|NCT04038580|DEVICE|Infinite Socket|The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
48520156|NCT04038580|DEVICE|CJ Socket|The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
48520157|NCT02180048|DIETARY_SUPPLEMENT|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
48520158|NCT02180048|DIETARY_SUPPLEMENT|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
48520159|NCT02180048|DIETARY_SUPPLEMENT|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
48720748|NCT00053807|DRUG|fluorouracil|
48720749|NCT00053807|PROCEDURE|adjuvant therapy|
48720750|NCT05978102|DRUG|STI-7349|Administered by intravenous infusion (IV)
48720751|NCT05978102|DRUG|Pembrolizumab|Administered by intravenous infusion (IV)
48720752|NCT05978102|DRUG|Standard treatment（SoC）|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
48720753|NCT00170989|DRUG|valsartan plus hydrochlorothiazide|
48720754|NCT03634267|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
48720755|NCT03634267|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
48720756|NCT05661266|DEVICE|Eye-Tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
48720757|NCT04527627|BEHAVIORAL|Nursing Empowerment Intervention|"Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU."
48720758|NCT01932775|DEVICE|GlucoTab System|
48383810|NCT03340246|PROCEDURE|Immediate phlebectomy|See arm description
48388042|NCT05779046|OTHER|HIT 1:1|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
48520160|NCT03065192|DRUG|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
48520161|NCT03415646|OTHER|Erector Spinae Plane Block|erector spinae plane block with double level injection will be administered before the surgery
48520162|NCT03415646|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
48520163|NCT00467974|PROCEDURE|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
48520164|NCT00467974|PROCEDURE|TACE|Transarterial chemoembolisation (TACE)
48383811|NCT04007393|BEHAVIORAL|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
48383812|NCT04007393|DRUG|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
48383813|NCT04007393|DRUG|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
48383814|NCT00583427|DRUG|Sulodexide|200 mg per day in an oral gelcap form
48383815|NCT02416089|DEVICE|Tampostat|
48383816|NCT02416089|DEVICE|Condom catheter tamponade|
48383817|NCT01503502|DRUG|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
48383818|NCT01503502|DRUG|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
48383819|NCT00405496|DRUG|Difluprednate Ophthalmic Emulsion|
48383820|NCT05444361|DEVICE|Cryoneurolysis|Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.
48383821|NCT05444361|DEVICE|Sham Comparator|Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
48720759|NCT00595933|OTHER|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
48720760|NCT00595933|OTHER|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
48720761|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
48720762|NCT00595933|OTHER|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
48720763|NCT00595933|DRUG|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
48720764|NCT00595933|DRUG|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
48028957|NCT04782323|DRUG|aQII-6 Investigational|Biological/Vaccine: Investigational aQII-6 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48383822|NCT05992207|OTHER|motor imaginary training|Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi#reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
48383823|NCT05992207|OTHER|physical therapy training|facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern
48720765|NCT01133015|DEVICE|Fractional flow reserve|Fractional flow reserve measured by pressure wire
48720766|NCT01133015|DEVICE|IVUS|intravascular ultrasound
48720767|NCT01621867|DRUG|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
48720768|NCT01621867|DRUG|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
48720769|NCT04373473|DRUG|PRIM-DJ2727|Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.
48720770|NCT04373473|DRUG|Placebos|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
48720771|NCT02072525|BIOLOGICAL|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
48720772|NCT02072525|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
48720773|NCT02072525|BIOLOGICAL|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
48720774|NCT02072525|BIOLOGICAL|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
48383824|NCT01069458|OTHER|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
48383825|NCT02511587|BIOLOGICAL|FSME-Immune vaccination|booster vaccination with FSME-Immune
48383826|NCT00423501|DRUG|Placebo|sc weekly
48383827|NCT00423501|DRUG|taspoglutide|20mg sc weekly
48383828|NCT00423501|DRUG|taspoglutide|10mg sc every 2 weeks
48383829|NCT00423501|DRUG|taspoglutide|5mg sc weekly
48720775|NCT00378248|BEHAVIORAL|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
48383830|NCT00423501|DRUG|taspoglutide|10mg sc weekly
48383831|NCT00423501|DRUG|taspoglutide|20mg sc every 2 weeks
48383832|NCT04572737|BEHAVIORAL|Activity plan to break up sitting time|This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.
48383833|NCT04279483|BEHAVIORAL|7-11|Assigned to make a small (\~$3.00) purchase from any 7-11 store(s) using a study-provided debit card during each retail environment visit
48383834|NCT04279483|BEHAVIORAL|CVS|Assigned to make a small (\~$3.00) purchase from any CVS store(s) using a study-provided debit card during each retail environment visit.
48383835|NCT00980460|DRUG|Cisplatin|Given IV
48383836|NCT00980460|DRUG|Dexrazoxane|Given IV
48383837|NCT00980460|DRUG|Doxorubicin Hydrochloride|Given IV
48383838|NCT00980460|DRUG|Fluorouracil|Given IV
48383839|NCT00980460|DRUG|Irinotecan Hydrochloride|Given IV
48383840|NCT00980460|OTHER|Laboratory Biomarker Analysis|Correlative studies
48383841|NCT00980460|PROCEDURE|Liver Transplantation|Undergo liver transplant
48383842|NCT00980460|DRUG|Temsirolimus|Given IV
48383843|NCT00980460|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48383844|NCT00980460|DRUG|Vincristine Sulfate|Given IV
48720776|NCT00378248|BEHAVIORAL|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
48720777|NCT04825431|DRUG|TAS-205, [14C]TAS-205|single oral administration under fasted conditions on day 1
48720778|NCT03616886|DRUG|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
48720779|NCT03616886|DRUG|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
48383845|NCT01851343|OTHER|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
48383846|NCT04937452|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
48383847|NCT04937452|DRUG|Rotigotine 6Mg/24Hrs Patch|Rotigotine 6 mg/24Hrs administration for 24 weeks
48383848|NCT04937452|DRUG|Placebo|Placebo administration for 24 weeks
48383849|NCT01073176|OTHER|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
48383850|NCT01815372|PROCEDURE|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
48720780|NCT03616886|DRUG|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
48720781|NCT03616886|DRUG|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
48720782|NCT02900755|DRUG|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
48720783|NCT05055882|OTHER|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|Comparison of Adult-Onset Still's disease phenotypes
48720784|NCT02674425|DEVICE|Dark Adaptometer|
48720785|NCT00409344|DRUG|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
48720786|NCT00409344|OTHER|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
48720787|NCT01804166|DRUG|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
48720788|NCT01804166|DRUG|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
48720789|NCT06304506|OTHER|Cross sectional study|Physiological testing, Sampling of blood and abdominal adipose tissue and respiratory measurements at rest and during exercise
48720790|NCT06232551|OTHER|EHR (electronic health record) alert|Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis
48720791|NCT06232551|OTHER|No EHR (electronic health record) alert|During the baseline phase while risk is assessed and stored, no alerting occurs
48720792|NCT05703451|OTHER|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
48720793|NCT00065806|DRUG|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
48383851|NCT01815372|PROCEDURE|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
48520165|NCT05248347|DEVICE|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
48720794|NCT00065806|DRUG|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
48720795|NCT04732104|DRUG|Lidocaine topical|intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia
48720796|NCT04732104|DRUG|Lidocaine Hydrochloride|injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
48720797|NCT03379142|BEHAVIORAL|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
48720798|NCT00272324|DRUG|Aspirin|
48383852|NCT05941845|DRUG|Peginterferon Alfa-2A 180 MCG/ML Injectable Solution|"Injections will be carried out on the Nephrology day hospitalization ward. The injections follows a personalized administration schedule: all enrolled patients will receive an injection of Pegasys® at Week 0.~Patients with a persistent Th17 profile (cytokine profile showing IL-17A levels greater than 73 pg/ml) at Week 2 will receive a new dose of Pegasys®, followed by a monthly cytokine profile. In the case of a persistent Th17 profile, 2 injections will be given two weeks apart.~In patients with no Th17 profile at Week 2, no Pegasys® injections will be performed at this time. Cytokine profiles will be performed monthly, and in the case of a persistent Th17 profile, 1 injection will be performed.~In total, patients will receive a minimum of one injection and a maximum of 13 injections of 180 µg (1 injection every two weeks for 24 weeks)."
48383853|NCT02829229|BEHAVIORAL|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials \& 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
48025263|NCT05522140|BEHAVIORAL|Nature-based social intervention (NBIS)|"Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu."
48025264|NCT05522140|BEHAVIORAL|Usual care + menu with nature based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
48025265|NCT05284045|OTHER|Detailed information|Subjects in this arm will receive usual information + detailed information on side effects
48025266|NCT00870779|DRUG|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
48025267|NCT06572670|OTHER|Progressive relaxation exercise before coronary angiography|Patients in the intervention group will undergo progressive relaxation before undergoing angiography.
48025268|NCT01479036|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
48720799|NCT00272324|DRUG|Folate|
48720800|NCT04039867|DRUG|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
48720801|NCT00547040|OTHER|no intervention|no intervention
48720802|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of beef|Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.
48025269|NCT01479036|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
48025270|NCT03156023|DRUG|Rozibafusp Alfa|Administered by subcutaneous injection once every 2 weeks.
48383854|NCT01626209|DRUG|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
48025271|NCT03156023|DRUG|Placebo|Administered by subcutaneous injection once every 2 weeks.
48383855|NCT00276458|DRUG|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
48383856|NCT00276458|DRUG|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
48383857|NCT00276458|DRUG|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
48383858|NCT00276458|DRUG|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
48383859|NCT03900481|PROCEDURE|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
48383860|NCT05218915|DRUG|Dulaglutide|Dulaglutide once weekly subcutaneous
48383861|NCT05218915|DRUG|Insulin Degludec|Insulin degludec once daily
48182604|NCT05005702|OTHER|Inspiratory Muscle training|"Patients received IMT for 30-minute per day, 3 days per week for 3 weeks using the Threshold Inspiratory Muscle training device (product Phillips). During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training.~Inspiratory muscle training diaries were checked weekly. The inspiratory load was set at 40%of maximal inspiratory pressure."
48720803|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of the vegatable protein source|Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
48720804|NCT00909597|DRUG|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
48025272|NCT03019952|BEHAVIORAL|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
48025273|NCT00724971|DRUG|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
48025274|NCT00724971|DRUG|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
48025275|NCT02258633|OTHER|Interactive interview and tailored family centered seatbelt safety intervention|
48182605|NCT06450236|DRUG|Perampanel 10 MG|1 tablet of Perampanel Tablets 10mg
48182606|NCT06450236|DRUG|Fycompa 10Mg Tablet|1 tablet of Perampanel Tablets 10mg
48383862|NCT05218915|DEVICE|Continuous glucose monitor|Dexcom G6 CGM system
48383863|NCT06326723|DRUG|Daridorexant|"25 mg group: Daridorexant group: strength 25 mg, administered at a dose of 25 mg; administered orally under fasting conditions, single dosing on Day1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~50 mg group: Daridorexant group: strength 50 mg, administered at a dose of 50 mg; administered orally under fasting conditions, single dosing on Day 1, and daily dosing on Day 4-8.~Placebo control group: administered in the same manner as the test drug.~Drug is to be administered at the same time every day, and the dosing window is recommended to be at 08:00 AM (±1 h) on the dosing day. Drinking water and other liquids should be avoided for 1 hour before and after dosing on the day of blood collection (except the water used to swallow the tablets.)."
48720805|NCT00909597|DRUG|taspoglutide|10mg sc once weekly
48720806|NCT00909597|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
48720807|NCT00774020|DRUG|Zoledronic acid|5mg, i.v. single dose
48720808|NCT05988190|BEHAVIORAL|Contextual Word Learning Intervention|Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
48720809|NCT00227513|DRUG|bortezomib|Given IV
48720810|NCT00227513|DRUG|vorinostat|Given orally
48720811|NCT03033342|DRUG|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
48720812|NCT03033342|DRUG|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
48025276|NCT04287062|DRUG|Suvorexant|Dual orexin receptor antagonist
48025277|NCT04287062|DRUG|Placebos|Weight and color matched placebo
48025278|NCT03539380|DRUG|TRx0237|Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)
48025279|NCT06067074|PROCEDURE|Volar Locking Plate|Surgery
48025280|NCT06067074|PROCEDURE|Plaster Cast|Non-operative treatment with a plaster cast
48720813|NCT03033342|DRUG|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
48720814|NCT03033342|DRUG|Oral single doses of placebo|Single doses of placebo to match MRX-4
48720815|NCT03033342|DRUG|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
48720816|NCT03033342|DRUG|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
48720817|NCT06256718|OTHER|Educational Intervention|Evidence-based strategy (PC TEACH)
48720818|NCT00559130|DEVICE|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
48720819|NCT06147687|DIAGNOSTIC_TEST|Self reported data collection|ML assessement of colleceted data
48028958|NCT04782323|OTHER|aQII-7 Investigational|Biological/Vaccine: Investigational aQII-7 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48028959|NCT04782323|DRUG|aQII-9 Investigational|Biological/Vaccine: Investigational aQII-9 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48182607|NCT06361862|DEVICE|Active alarms from WARD software|Wireless continuous vital sign monitoring with real time staff alerts
48383864|NCT04092491|OTHER|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)"
48383865|NCT04413357|OTHER|Balanced Nutritional Drink|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as Supplemental Nutrition.
48720820|NCT00709878|PROCEDURE|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
48720821|NCT02059954|PROCEDURE|Hysterectomy|
48720822|NCT00480259|BEHAVIORAL|hyperproteic nutrition|
48720823|NCT01864161|DRUG|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
48720824|NCT01864161|DRUG|Liposomal iron|Sideral forte 30 mg/die
48720825|NCT01454349|DRUG|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
48720826|NCT01454349|DRUG|Placebo|Single intraprostatic injection of matching placebo
48720827|NCT04831099|DRUG|Testosterone gel|The route of administration is transdermal.
48720828|NCT04831099|DRUG|Placebo|The route of administration is transdermal
48720829|NCT02610244|OTHER|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
48383866|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink (DMA)|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition available in retail setting.
48720830|NCT04419441|DRUG|Immune checkpoint inhibitor|concomitant administration of radiotherapy and immune checkpoint inhibitor
48720831|NCT05700253|DEVICE|Cooled Radiofrequency Ablation|Image-guided genicular nerve ablation will be performed with the Coolief System (COOLIEF\* CRFA; Avanos Medical).
48720832|NCT05700253|DEVICE|Hyaluronic Acid Injection|Synvisc-One (\[Hylan G-F 20\]; Sanofi) will be administered as a single intra-articular dose (6 mL).
48720833|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
48720834|NCT04386876|DRUG|Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet|Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
48720835|NCT01081639|DRUG|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
48720836|NCT01081639|DRUG|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
48720837|NCT02914561|DRUG|Filgotinib|Filgotinib tablets administered orally once daily.
48720838|NCT02914561|OTHER|Placebo|Placebo administered orally once daily.
48720839|NCT01852279|DEVICE|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
48720840|NCT01852279|DEVICE|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
48383867|NCT04413357|OTHER|Diabetes Specific, Balanced Nutritional Drink DMB|Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat, designed for people living with diabetes and intended for use as Supplemental Nutrition.
48720841|NCT02423122|DRUG|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
48720842|NCT02048410|DIETARY_SUPPLEMENT|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
48720843|NCT02048410|OTHER|low satured diet|
48720844|NCT01278082|DRUG|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
48720845|NCT01278082|DRUG|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
48025281|NCT05453305|PROCEDURE|Control group: Traditional venipuncture, on the stretcher.|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.
48025282|NCT05453305|PROCEDURE|Intervention group: DAK method venipuncture, simulating a hug|The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
48025283|NCT00522210|DRUG|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
48025284|NCT00522210|OTHER|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
48025285|NCT01112995|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
48025286|NCT01112995|DIETARY_SUPPLEMENT|Sugar pill (placebo)|placebo identical to the active product will be given
48720846|NCT02867774|BEHAVIORAL|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
48720847|NCT04552327|DEVICE|Solcera|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
48720848|NCT04552327|DEVICE|Placebo|Twice daily application for a duration of 4 weeks followed by another 4 weeks without treatment (up to 2 potential repetitions of this 8-week cycle)
48025287|NCT05681884|DRUG|Faricimab|Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
48025288|NCT06121713|DIETARY_SUPPLEMENT|GCE + Low ALA|Participants will consume a pill containing 200mg green coffee extract and 200mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
48025289|NCT06121713|DIETARY_SUPPLEMENT|GCE + High ALA|Participants will consume a pill containing 200mg green coffee extract and 400mg alpha-lipoic acid 30 minutes before a 75g oral glucose tolerance test
48383868|NCT06011499|OTHER|Internet-Based Exercise Intervention|Participate in online supervised, group resistance training sessions (iLIVE)
48720849|NCT04552327|DRUG|Solaraze|Twice daily application for a duration of 60 days
48025290|NCT06121713|DIETARY_SUPPLEMENT|Placebo|Participants will consume a placebo pill (500mg insoluble microcrystalline cellulose, 5mg magnesium stearate, 5mg silicon dioxide) prior to a 75g oral glucose tolerance test
48025291|NCT02670590|BEHAVIORAL|diet|diet
48025292|NCT03296189|DRUG|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
48025293|NCT03296189|DRUG|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
48025294|NCT03296189|DRUG|Placebos|10 mls normal saline
48025295|NCT01100463|DRUG|Cream|Twice daily lotion to prevent HFS
48025296|NCT01100463|DRUG|0.1% Uracil Cream|Twice daily lotion to prevent HFS
48025297|NCT03619694|DEVICE|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
48025298|NCT02137629|DRUG|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
48025299|NCT00476944|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
48025300|NCT04720417|DRUG|Defactinib Hydrochloride|Given PO
48025301|NCT04720417|DRUG|Raf/MEK Inhibitor VS-6766|Given PO
48025302|NCT04720417|PROCEDURE|Biopsy|Undergo tumor biopsy
48720850|NCT06507514|COMBINATION_PRODUCT|"blinatumomab and auto-HSCT sandwich  strategy"|The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
48720851|NCT00025623|DRUG|carboplatin|
48720852|NCT00025623|DRUG|cyclophosphamide|
48720853|NCT00025623|DRUG|doxorubicin hydrochloride|
48720854|NCT00025623|DRUG|etoposide|
48720855|NCT00025623|DRUG|vincristine sulfate|
48720856|NCT00025623|PROCEDURE|conventional surgery|
48720857|NCT01771614|BEHAVIORAL|Exercise|
48720858|NCT01771614|PROCEDURE|Hyperglycemia|
48720859|NCT03814434|PROCEDURE|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
48025303|NCT06173817|DEVICE|isocapnic hyperventilation|isocapnic hyperventilation (iHV) increases the elimination of methanol to the extent that it could replace haemodialysis for elimination purposes when haemodialysis is not required for the correction of acidosis, and alcohol dehydrogenase (ADH) is completely blocked by an antidote.
48025304|NCT02504645|DRUG|IPP-201101|
48025305|NCT02504645|DRUG|Placebo|
48025306|NCT02504645|OTHER|Standard of Care|
48025307|NCT02096835|DEVICE|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
48025308|NCT02096835|DEVICE|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
48025309|NCT02096835|DRUG|Tropisetron|will be given at the start of skin closure
48025310|NCT02096835|DRUG|Dexamethasone|will be given after induction
48025311|NCT04596878|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
48025312|NCT04596878|BIOLOGICAL|Placebo|Normal Saline 0.9%
48025313|NCT03753126|RADIATION|4-dimensional volume-rendered computed tomography|
48025314|NCT02401672|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
48025315|NCT04226638|DIAGNOSTIC_TEST|Dynamic ultrasound|Diagnosis was based on clinic suspicion and positive ultrasonography dynamic maneuvers by reproducing pain and slipping rib exam
48025316|NCT02149589|PROCEDURE|Mechanical ventilation|
48025317|NCT03037944|DRUG|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
48025318|NCT03037944|DEVICE|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
48182608|NCT04330651|PROCEDURE|ECLS|Emergency application of Extracorporeal Life Support in post-surgical patients
48720860|NCT03814434|PROCEDURE|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
48720861|NCT05562960|PROCEDURE|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
48720862|NCT03751514|BIOLOGICAL|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
48720863|NCT03751514|DRUG|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
48383869|NCT06011499|OTHER|Internet-Based Diet Intervention|Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)
48720864|NCT03751514|OTHER|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
48182609|NCT00797888|BEHAVIORAL|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
48182610|NCT04832295|OTHER|photo-supported conversations|"Sessions 1-4: Before each of the sessions, the client photographs that which is related to their well-being and send these to the therapist before the session. The therapist enlarges each of the photographs into the size of A4. The conversation departures from the photographs and the client is encouraged to talk about each of them and they ways it relates to their well-being. Potential strategies for everyday life are discussed.~Session 5-10: short virtual meetings of approximately 15-20 minutes with the aim to follow the client, confirm their process and support them towards increased well-being.~Session 11: reflecting upon all their previous photographs. Session 12: reflecting future everyday life upon their photographs."
48383870|NCT06011499|OTHER|Education Intervention|Receive usual care receiving educational information about diet and exercise for cancer survivors
48720865|NCT03411564|OTHER|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
48720866|NCT03913195|DRUG|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
48720867|NCT01492413|BEHAVIORAL|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
48720868|NCT00896649|OTHER|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
48720869|NCT00896649|PROCEDURE|digital mammography|standard screening mammogram
48720870|NCT00896649|PROCEDURE|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
48720871|NCT01945684|DRUG|Botulinum toxin type A|Maximum dose 360 U
48720872|NCT06194500|DRUG|[14C]-LY3549492|Administered as oral solution.
48720873|NCT06194500|DRUG|LY3549492|Administered orally.
48720874|NCT06194500|DRUG|[14C]-LY3549492|Administered as IV infusion.
48720875|NCT04664582|PROCEDURE|Sentinel Lymph Node Biopsy|see intervention group description
48720876|NCT05019391|DEVICE|transcranial doppler|it provides an accurate, noninvasive, and simple method for the diagnosis of VBI. Through the diagnosis results, it will be clear about the blood flow status of single vessel and vascular compliance, which is helpful for accurate reflection of the subtle changes of VBI
48720877|NCT04942223|DEVICE|guided bone regeneration|After local anesthesia, the surgery started with a mid-crestal incision with vertical releasing cuts followed by the full-thickness buccal and lingual/palatal flaps raising to expose the bone defect completely. The flaps were coronally extended to assure a complete closure with a passive suture above the titanium. Subsequently, an intra-oral mandibular ramus bone cortical block was harvested in the molar zone. The bone block was milled and mixed with freeze-dried. The particulate graft was put to fill the deficit above the mesh until its perfect stability and unity with the defect's borders. Two or three titanium mini-screws were used to stabilize the device , and the flaps were carefully sutured. Ceftriaxone was administered intravenously at a loading dose of 2 g; together with a non-steroidal analgesic, it was continued at two g/die per os beginning the day after surgery and continuing for six days.
48720878|NCT02290938|BEHAVIORAL|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
48720879|NCT02290938|OTHER|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
48182611|NCT04832295|OTHER|Care as usual|Medication, psychological treatment
48383871|NCT00886873|DRUG|Mifepristone|
48182612|NCT05987254|PROCEDURE|suprainguinal fascia iliaca block|ultrasound guided suprainguinal fascia iliaca block
48182613|NCT05987254|PROCEDURE|pericapsular nerve group block|ultrasound guided pericapsular nerve group block
48383872|NCT01308762|BIOLOGICAL|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
48520166|NCT05248347|DEVICE|The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
48025319|NCT02157311|DRUG|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
48025320|NCT02719405|DIETARY_SUPPLEMENT|Lactobacillus GG|Lactobacillus GG
48025321|NCT02719405|DIETARY_SUPPLEMENT|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
48025322|NCT02719405|DIETARY_SUPPLEMENT|Amino Acid Formula|Amino Acid Formula
48025323|NCT05437146|BEHAVIORAL|puppet|pain and fear during blood collection
48025324|NCT01449305|DEVICE|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
48720880|NCT05179499|DRUG|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
48182614|NCT04658563|OTHER|High Density Exercise Training Program - Yoga|A total of 8 weeks will be applied in our study, each session of the high-density yoga program will be started with 10 minute pranayama (breath) exercises as it is in classical yoga as a preliminary preparation for the participation of individuals; the program will be completed by applying 10-20 minutes warming-stretching movements, 40 minutes surya namaskar (SN) sets, 20-30 minutes dynamic yoga asanas and 10 minutes savasana. Participants will be encouraged to study the perceived difficulty levels between 14 and 17 using the Borg scale during the sessions
48182615|NCT05741190|DEVICE|Pentacam Imaging|Imaging of the corneal surface
48720881|NCT05179499|OTHER|Balanced Crystalloid|IV fluids administered as per standard care
48720882|NCT01102894|DEVICE|SmartPill|SmartPill
48720883|NCT02845531|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
48720884|NCT02845531|DRUG|Optimal Medical Therapy|
48182616|NCT02181907|DRUG|UH-AC 62 XX tablet|
48720885|NCT05571956|OTHER|Pancreatic ductal adenocarcinoma organoids and cancer-associated fibroblasts establishment group|Pancreatic masses were sampled using a 22-gauge FNB needle. If a sufficient visible core was obtained on macroscopic inspection, the tissue materials from the following one needle pass were placed into the transfer medium for organoid generation. Using a tiny portion (about 20%) of the FNB sample, we isolated CAFs
48720886|NCT05277038|DRUG|Clonidine 0.1mg pill|Routine prescription for insomnia
48720887|NCT05277038|DRUG|Clonidine 0.2mg pill|Routine prescription for insomnia
48720888|NCT05277038|DRUG|Zopiclone 3.75mg pill|Routine prescription for insomnia
48720889|NCT05277038|DRUG|Zopiclone 7.5mg pill|Routine prescription for insomnia
48720890|NCT05275322|BEHAVIORAL|Unified Protocol|The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
48720891|NCT01014455|BEHAVIORAL|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
48720892|NCT01014455|BEHAVIORAL|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
48025325|NCT02717949|DRUG|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
48025326|NCT02717949|DRUG|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
48720893|NCT01158209|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
48720894|NCT00430937|DRUG|Daptomycin|4 mg/kg intravenous once daily
48025327|NCT02717949|DRUG|Ribavirin|ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
48025328|NCT05419206|DIAGNOSTIC_TEST|CMV DNA analysis|CMV DNA quantitative viral load levels were studied
48025329|NCT05075252|PROCEDURE|laparoscopic lavage|This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
48182617|NCT02181907|DRUG|UH-AC 62 XX capsule|
48182618|NCT05247008|OTHER|Thyme honey|"* Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day."
48182619|NCT01561482|DRUG|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
48720895|NCT00430937|DRUG|Vancomycin|1 g intravenous twice daily
48025330|NCT01898195|DRUG|Varenicline|Varenicline will be provided for three months.
48025331|NCT01898195|BEHAVIORAL|Text Message|Text messages will be developed twice daily for three months
48025332|NCT01898195|BEHAVIORAL|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
48025333|NCT00984269|PROCEDURE|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
48025334|NCT02439346|DRUG|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
48720896|NCT00430937|DRUG|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
48720897|NCT01918514|DRUG|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
48025335|NCT06222723|DRUG|Dexamethasone|Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
48025336|NCT06222723|DRUG|Ribavirin|Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
48025337|NCT04088981|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet and a portion-controlled diet
48025338|NCT00975975|DRUG|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
48025339|NCT05117606|DEVICE|LYNG by Ably Medical|Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.
48720898|NCT05788133|OTHER|treatment and screening by neuropsychological tests on humanoid robot|treatment and screening by neuropsychological tests on humanoid robot
48025340|NCT02023385|DEVICE|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
48025341|NCT02023385|DEVICE|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
48383873|NCT01308762|BIOLOGICAL|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
48025342|NCT03120975|OTHER|Computerized decision support and audit & feedback|"* suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~* mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~* suggestion of standard antimicrobial treatment duration according to indication"
48025343|NCT03120975|OTHER|Audit & Feedback|\* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
48025344|NCT03120975|OTHER|Standard antibiotic stewardship|"* Infectious diseases consultation on demand~* Review of positive blood cultures~* Availability of a antibiotic use guidelines (on paper and as PDF)"
48025345|NCT04173533|DRUG|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
48025346|NCT04173533|DRUG|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
48025347|NCT06573632|DIETARY_SUPPLEMENT|TPN-N7 Baxter|providing TPN to all malnutrition patients preoperatively as well as postoperatively.
48025348|NCT04134897|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
48025349|NCT04134897|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
48383874|NCT01308762|BIOLOGICAL|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
48720899|NCT06198335|OTHER|Modified Perichondral Approach Thoracoabdominal Nerve block|M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
48720900|NCT06198335|OTHER|Transversus Abdominal Plane block|TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
48720901|NCT03636607|DIAGNOSTIC_TEST|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
48720902|NCT01407796|DRUG|Endotoxin (E. coli O:113, Reference Endotoxin)|
48720903|NCT01407796|DRUG|[18F](+/-)NOS|
48720904|NCT05375864|OTHER|Absorption test|Paracetamol's administration (1 gram) - 48 hours after oseltamivir administration.
48720905|NCT04294771|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)
48720906|NCT05093803|BEHAVIORAL|CONTROL GROUP|Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.
48720907|NCT05093803|BEHAVIORAL|HEALTH APP GROUP|"Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators."
48720908|NCT05035589|DRUG|Tocilizumab|Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
48720909|NCT01958853|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
48383875|NCT05804123|DRUG|0.9% NaCl physiological saline Nasal-spraying|0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
48383876|NCT05804123|COMBINATION_PRODUCT|LiveSpo Navax®|In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
48720910|NCT03511469|OTHER|Control Group|Control Group: Standart rehabilitation
48720911|NCT03511469|OTHER|Isokinetic Group|Concentric group: Standart rehabilitation + isokinetic training
48720912|NCT00048113|DRUG|Alicaforsen|
48720913|NCT04350307|DEVICE|22-gauge needle|22-gauge Quincke needle used for epidural injection
48720914|NCT04350307|DEVICE|25-gauge needle|25-gauge Quincke needle used for epidural injection
48720915|NCT03333317|DRUG|Lumicitabine|Participants will receive oral administration of lumicitabine.
48720916|NCT03333317|DRUG|Placebo|Participants will receive oral administration of matching placebo.
48720917|NCT00619489|DRUG|vedolizumab|Vedolizumab for intravenous (IV) infusion
48720918|NCT00576576|DRUG|Atorvastatin|Atorvastatin 80 mg a day
48025350|NCT04134897|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
48025351|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
48720919|NCT02520739|DIETARY_SUPPLEMENT|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
48720920|NCT02520739|DIETARY_SUPPLEMENT|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
48383877|NCT05804123|DRUG|Augmentin 500Mg Tablet|Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
48383878|NCT05804123|DRUG|Acetylcysteine|Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
48383879|NCT05804123|DRUG|Xylometazoline Nasal|Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
48383880|NCT05804123|DRUG|Cefotaxime|Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
48025352|NCT04134897|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
48383881|NCT05804123|DRUG|Ciprofloxacin|Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
48383882|NCT06062758|BEHAVIORAL|ECT Simulation Training|Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.
48182620|NCT01561482|DRUG|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
48182621|NCT02367352|DRUG|Alisertib|Alisertib tablets
48182622|NCT02367352|DRUG|Paclitaxel|Paclitaxel intravenous solution
48182623|NCT04500028|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) inserted by the study nurse 4 hours before IUD insertion.
48720921|NCT02520739|DIETARY_SUPPLEMENT|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
48720922|NCT03496636|PROCEDURE|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
48720923|NCT03823846|DRUG|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
48720924|NCT03823846|DRUG|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
48720925|NCT03823846|DRUG|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
48720926|NCT03823846|DRUG|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
48025353|NCT04134897|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
48025354|NCT02322697|DRUG|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
48025355|NCT05829408|BEHAVIORAL|KOPPeling|KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
48025356|NCT06216626|DIETARY_SUPPLEMENT|myota's prebiotic fibre blend|"Each 10g daily serve of supplement contains the following fibres:~* Fructooligosaccharides~* Inulin~* Resistant dextrin~* Resistant maltodextrin~* Partially hydrolysed guar gum~* Guar gum"
48025357|NCT02754167|BIOLOGICAL|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
48025358|NCT02754167|BIOLOGICAL|PRS-080-Placebo#001|Placebo comparator
48025359|NCT00745732|DRUG|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
48025360|NCT00745732|RADIATION|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
48025361|NCT00761059|DRUG|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
48025362|NCT00761059|DRUG|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
48025363|NCT04177693|DIETARY_SUPPLEMENT|Epigallocatechin gallate (EGCG)|800 mg (4 capsules) of EGCG (green tea extract), taken orally on a daily basis for up to 2 months
48025364|NCT04177693|DRUG|Clomiphene Citrate|100 mg for 5 days
48025365|NCT04177693|DRUG|Letrozole|5 mg for 5 days
48025366|NCT02838602|RADIATION|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
48025367|NCT02838602|RADIATION|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
48025368|NCT06388018|OTHER|Clinical Observation|Undergo observation
48182624|NCT04500028|DRUG|Placebo Comparator|3 tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
48383883|NCT06652139|DRUG|selinexor combined with BEAM regimen|Selinexor: 60mg po D-10, D-7 and D-4 Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
48720927|NCT03823846|OTHER|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
48720928|NCT03823846|DRUG|normal analgesia pump administration|Dose of analgesia pump was added if needed.
48720929|NCT03823846|DRUG|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
48720930|NCT02920515|DRUG|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
48720931|NCT02920515|DRUG|Zhibo dihuang pills|Traditional Chinese Medicine
48720932|NCT02920515|DRUG|Dabu ying pills|Traditional Chinese Medicine
48720933|NCT03562416|DRUG|Nintedanib|Nintedanib (BIBF 1120, Ofev)
48720934|NCT03562416|DRUG|Placebo Oral Tablet|Placebo
48720935|NCT02469415|DRUG|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
48720936|NCT02469415|DRUG|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
48720937|NCT02469415|DRUG|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
48720938|NCT00509171|DEVICE|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
48025369|NCT06388018|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
48025370|NCT06388018|RADIATION|External Beam Radiation Therapy|Undergo EBRT
48025371|NCT06388018|PROCEDURE|High-Dose-Rate Vaginal Brachytherapy|Undergo vaginal brachytherapy
48025372|NCT06388018|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48025373|NCT06388018|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48182625|NCT03334253|DRUG|Atropine|Daily 0.01% atropine eyedrops
48182626|NCT03334253|OTHER|Placebo Eyedrops|Daily placebo eyedrops
48383884|NCT06652139|DRUG|BEAM regimen|Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
48383885|NCT04619004|DRUG|Patritumab Deruxtecan (Fixed dose)|Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
48383886|NCT04619004|DRUG|Patritumab Deruxtecan (Up-Titration)|Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
48383887|NCT03713125|BEHAVIORAL|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
48383890|NCT06634407|PROCEDURE|transcatheter closure|using transcatheter closure of PDA to detect outcome of patients with PDA
48383891|NCT01392469|DRUG|Imatinib|Film coated tablets, oral administration
48383892|NCT01392469|DRUG|Sildenafil|Oral Administration
48720939|NCT00937989|OTHER|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
48720940|NCT00937989|OTHER|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
48720941|NCT00937989|OTHER|medical chart review|Baseline, 3, 6 and 9 months after starting the study
48720942|NCT00937989|OTHER|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
48720943|NCT00937989|OTHER|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
48720944|NCT00937989|PROCEDURE|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
48720945|NCT02566733|DRUG|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
48720946|NCT02566733|DRUG|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
48720947|NCT02880527|OTHER|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
48025374|NCT06388018|OTHER|Questionnaire Administration|Ancillary studies
48383893|NCT01392469|DRUG|Bosentan|Oral Administration
48383894|NCT02195921|OTHER|single point Zhongwan(CV12) plus antiemetic drug|"All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
48383895|NCT02195921|OTHER|single point Zusanli(ST36) plus antiemetic drug|"A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle."
48383896|NCT02195921|OTHER|Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug|Stimulating both Zusanli(ST36)and Zhongwan(CV12)
48383897|NCT02195921|DRUG|only antiemetic drug|received routine antiemetic treatment
48720948|NCT00167661|DRUG|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
48720949|NCT06246071|DRUG|TYK-00540|TYK-00540 PO, BID
48720950|NCT02193113|DRUG|KVD001 Injection|A novel plasma kallikrein inhibitor
48720951|NCT04385225|OTHER|Longitudinal follow-up|Longitudinal hearing, vestibular and cognitive follow-up
48720952|NCT03386409|BEHAVIORAL|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
48720953|NCT03386409|BEHAVIORAL|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
48720954|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
48025375|NCT06388018|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
48025376|NCT02505646|OTHER|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
48025377|NCT03397901|PROCEDURE|Transverse colostomy|Transverse double-cavity colostomy
48182627|NCT05777109|DRUG|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
48720955|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
48720956|NCT01719003|DRUG|Empagliflozin low dose qd|Empagliflozin low dose once daily
48720957|NCT01719003|DRUG|Empagliflozin high dose qd|Empagliflozin high dose once daily
48720958|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
48720959|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
48720960|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
48720961|NCT01719003|DRUG|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
48720962|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
48720963|NCT01719003|DRUG|Metformin 500 mg bid|Metformin 500 mg twice daily
48720964|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
48720965|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
48720966|NCT01719003|DRUG|Metformin 1000 mg bid|Metformin 1000 mg twice daily
48720967|NCT01719003|DRUG|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
48720968|NCT02715726|DRUG|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
48720969|NCT02715726|DRUG|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
48720970|NCT02715726|DRUG|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
48720971|NCT02715726|DRUG|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
48720972|NCT02715726|DRUG|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
48720973|NCT02715726|DRUG|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
48720974|NCT02715726|DRUG|simvastatin|Pharmaceutical form:tablet Route of administration: oral
48025378|NCT05893108|DRUG|Ethosomal gel bearing losartan 5%|A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
48025379|NCT05893108|DRUG|triamcinolone acetonide 10 mg/ml|intralesional injection
48720975|NCT05059977|BIOLOGICAL|TAK-881|Participants will receive subcutaneous infusion of TAK-881 on Day 1.
48720976|NCT04780789|PROCEDURE|Transarterial Chemoembolization|A contrast agent (Xenetix350, Guerbet, France) was applied under local anaesthesia via the common femoral artery using a 5F sheath. Selective catheterization of the coeliac trunk and other arteries supplying the liver was then performed under fluoroscopic control. A pathological vascularization pattern was identified and chemoembolization material consisting of DC beads (BTG International Ltd) was injected by the treating angiographist using micro instrumentation. Follow-up CT or MRI was performed after 1-3 TACE sessions according to the extent of the lesion, 3 weeks following the last procedure. Patients with completed treatments were scheduled for an imaging follow-up every 3 months, allowing evaluation of the effect of treatment. In case of a positive response to the treatment another session of TACE was indicated. Chemoembolization sessions were performed as inpatient procedures with the mean hospitalization time of 4 days.
48720977|NCT00278330|DRUG|alvocidib|Given by infusion
48720978|NCT00278330|DRUG|vorinostat|Given orally
48720979|NCT06077097|GENETIC|Biological samples|This project also includes an auxiliary exploratory biological study of subcellular mechanisms, using high-throughput sequencing (Next Generation Sequencing, NGS) to identify gene expression variations in order to determine the resilience/vulnerability of the variables studied with respect to the DC experience (cytogenetics and transcriptome).
48720980|NCT05521633|DRUG|Metformin and Pioglitazone|Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
48720981|NCT06102772|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
48720982|NCT00007020|DRUG|Cholic Acids|10-15 mg/kg body weight/day taken orally.
48720983|NCT00397007|BEHAVIORAL|Biofeedback-based cognitive-behavioural intervention|
48720984|NCT02843191|DRUG|Chemotherapy|5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
48720985|NCT03158350|OTHER|Instructed Brushing Method|Stationary Bristle Technique
48720986|NCT03124212|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
48383898|NCT01827553|DRUG|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)
48383899|NCT01827553|RADIATION|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
48720987|NCT05117203|DEVICE|WB-EMS (Whole body electrostimulation)|Application of physical exercise and electrical stimulation on the abdominal muscles through the WB-EMS during 20 minutes training session with specific exercise (CORE)
48720988|NCT05117203|DEVICE|EMS|Application of physical exercise and electrical stimulation on the abdominal muscles through the EMS during 20 minutes training session with specific exercise (CORE)
48025380|NCT02193620|DRUG|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
48383900|NCT01827553|DRUG|Chemotherapy, gemcitabine|5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d
48383901|NCT01827553|DRUG|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
48383902|NCT01075126|DRUG|Depakote|
48720989|NCT05117203|DEVICE|WB-EMS off|Application of physical exercise without electrical stimulation on the abdominal muscles through the WB-EMS off during a 20 minutes training session with specific exercise (CORE).
48720990|NCT02261233|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
48720991|NCT05792306|DEVICE|The novel electrolyzed water spray|The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
48025381|NCT02193620|DRUG|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
48383903|NCT01075126|DRUG|Lithium|
48383904|NCT05471518|OTHER|No intervention|No intervention
48720992|NCT05792306|DEVICE|The saline spray|The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
48720993|NCT00848341|DEVICE|GUIDANT ICD SYSTEM|
48720994|NCT02431390|DEVICE|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
48025382|NCT02193620|DRUG|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
48720995|NCT02431390|BEHAVIORAL|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
48025383|NCT06149260|DRUG|Semaglutide Pen Injector|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
48025384|NCT04304690|OTHER|blood sample|2 blood samples at T0 and 3 months
48383905|NCT02980939|OTHER|iv fluid infusion|Intravenous isotonic saline infusion
48720996|NCT05742165|BEHAVIORAL|Time Restricted Eating (TRE)|TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
48720997|NCT06198088|OTHER|PNF techniques|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
48720998|NCT06198088|OTHER|Exercise therapy|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
48720999|NCT02314364|RADIATION|SBRT with protons or photons|
48721000|NCT00946322|BEHAVIORAL|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
48721001|NCT03790800|DRUG|urapidil|A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
48721002|NCT03765827|DRUG|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
48721003|NCT03765827|DRUG|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
48383906|NCT02825979|PROCEDURE|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
48721004|NCT05505526|OTHER|Electroacupuncture|BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
48383907|NCT02825979|DRUG|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
48383908|NCT03931902|DEVICE|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
48383909|NCT03931902|DEVICE|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
48182628|NCT05777109|DRUG|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
48182629|NCT00406406|DRUG|SKI-606|
48025385|NCT06572436|BEHAVIORAL|Multimedia information training|The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
48025386|NCT02449759|BEHAVIORAL|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
48025387|NCT03892824|DEVICE|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
48025388|NCT01223664|PROCEDURE|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
48025389|NCT01223664|DRUG|Conserved therapy|Oral or intravenous administration
48025390|NCT05378945|DRUG|Varenicline Tartrate Nasal Spray|Intranasal delivery of OC-01 (varenicline solution) 0.6 mg/mL twice a day (BID) for 28 days
48025391|NCT05378945|DRUG|Placebo (vehicle)|Intranasal delivery of placebo (vehicle) twice a day (BID) for 28 days
48025392|NCT05056246|DRUG|maridebart cafraglutide|Solution for injection
48025393|NCT04892134|OTHER|blood sample|40-50 ml of blood is taken
48025394|NCT00951600|DRUG|oxcarbazepine 300 mg/5mL oral suspension|
48182630|NCT05256862|OTHER|Data collection|"Data collection~* on the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) comparing the time period before implementation (01/2017-01/2020) and after implementation (02/2020-06/2022)~* on the performance of three novel tests as triage tool in the screening algorithm, QG-MPH, Prevo-check® and PT Monitor®"
48182631|NCT02659098|DRUG|CNTO 2476 3.0 x 10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
48182632|NCT02659098|DEVICE|Subretinal Delivery System|Participants will receive CNTO 2476 by using the Delivery System.
48182633|NCT01573949|DRUG|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
48182634|NCT05281497|BEHAVIORAL|Health platform|Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
48182635|NCT05281497|BEHAVIORAL|Social media|We built a LINE group to inspire the intervention group.
48025395|NCT03077282|DRUG|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
48182636|NCT05281497|OTHER|Exercise training|exercise including walk and an 18-minutes calisthenics
48182637|NCT02400008|PROCEDURE|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
48025396|NCT00347308|BEHAVIORAL|Eyebrow Position|Photography of brow positions
48025397|NCT05306652|OTHER|Supervised physical activity|patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
48025398|NCT05306652|OTHER|Unsupervised physical activity|patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
48025399|NCT01169324|OTHER|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
48025400|NCT05218252|PROCEDURE|Posterior interosseous artery flap|The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
48025401|NCT03405467|OTHER|general and specific data|General and specific data collected
48025402|NCT02952079|DEVICE|Blephex|Lid margin exfoliation
48025403|NCT02952079|DEVICE|MiboFlo|Lid warming treatment
48025404|NCT05309512|BIOLOGICAL|KN052|0.01mg/kg, 0.1mg/kg, 0.3mg/kg, 1mg/kg, 2mg/kg, 4mg/kg, 6mg/kg, 9mg/kg, RP2D once every two or three weeks intravenously
48025405|NCT03779386|OTHER|music|music during labor and delivery
48182638|NCT00020722|BIOLOGICAL|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
48383910|NCT01067729|DEVICE|AWBAT Wound Dressing|
48383911|NCT01067729|DEVICE|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
48383912|NCT01687777|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
48383913|NCT01687777|BIOLOGICAL|OrthADAPT|
48383914|NCT00759226|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
48520167|NCT05626842|OTHER|Total Diet Replacement (800kcal/day)|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly for a further 36 weeks. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks.
48520168|NCT00109460|BEHAVIORAL|Tobacco Use Disorder|
48520169|NCT05671588|PROCEDURE|Controlled combined exercise group|Patients will undergo protocol-defined combined aerobic-resistant therapy on a cycling ergometer and multifunctional fitness device
48025406|NCT03811912|DRUG|CTP-543|CTP-543 administered as 8 mg tablet.
48383915|NCT00759226|DRUG|Cisplatin|Cisplatin 30 mg/m2 (90 min)
48383916|NCT00759226|DRUG|5-FU|5-FU 750 mg/m2 (24h CI)
48520170|NCT05671588|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation.
48520171|NCT03877679|DRUG|Triamcinolone|Triamcenolone +napolycarboxylate
48520172|NCT03877679|DRUG|Turmeric paste|Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
48520173|NCT03807726|BEHAVIORAL|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
48520174|NCT00777582|DRUG|AZD2281|Oral single dose formulation
48025407|NCT03811912|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
48383917|NCT00759226|DRUG|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
48025408|NCT00650949|DRUG|CYT997|Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
48383918|NCT04785027|DRUG|PSORI-CM01 formula|PSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
48520175|NCT03330873|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter
48025409|NCT00650949|DRUG|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
48383919|NCT04785027|DRUG|Gu Ben Hua Yu formula|Gu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs
48383920|NCT04785027|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs (adipose-derived multipotent mesenchymal stem cells) will be infused intravenously at a dose of 2 million cells/kg
48383921|NCT05863351|PROCEDURE|Computed Tomography|Undergo CT
48383922|NCT05863351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48383923|NCT05863351|OTHER|Questionnaire Administration|Ancillary studies
48383924|NCT05863351|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SAbR
48383925|NCT05863351|PROCEDURE|Systemic Therapy|Given standard of care systemic therapy
48388043|NCT05779046|OTHER|HIT 1:2|The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
48388044|NCT04849858|DRUG|Bupivacaine|Participants in this group will receive a TAP block using the drug Bupivacaine.
48388045|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine.
48520176|NCT03330873|DEVICE|Foley catheter|Foley catheter can partly separate the sides of uterus wall.
48025410|NCT04543734|DEVICE|HemoScreen hematology analyzer|The use of HemoScreen for self-testing of blood values
48388046|NCT04849858|DRUG|Liposomal bupivacaine|Participants in this group will receive a TAP block using the drug Liposomal Bupivacaine followed by a re-dosing during their hospitalization
48520177|NCT03078686|PROCEDURE|tSVF by lipoaspiration|Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
48025411|NCT00816634|DRUG|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
48383926|NCT03885349|BEHAVIORAL|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
48383927|NCT03885349|BEHAVIORAL|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
48721005|NCT05505526|OTHER|Sham electroacupuncture|Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
48721006|NCT04515368|BIOLOGICAL|Immunization|Immunisation with one of four licensed vaccines
48721007|NCT00186277|DRUG|Oxaliplatin|Calculated per patient
48025412|NCT03845257|DIAGNOSTIC_TEST|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as \>300/µl (or \>150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
48520178|NCT03078686|PROCEDURE|PRP Concentration|Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
48721008|NCT00186277|DRUG|Taxotere|Calculated per patient
48383934|NCT04368117|BEHAVIORAL|Physical Therapy|Directed and prescribe physical therapy program for severely burned patients
48025413|NCT04923386|OTHER|None (not interventional)|This is not an intervention
48025414|NCT00856856|DEVICE|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
48383935|NCT06650644|OTHER|Placebo of Lactococcus lactis KD10|"* Food Name: Placebo of Lactococcus lactis KD10~* Ingredients: Natural pigment enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Dosage period and route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
48721009|NCT01983124|DRUG|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
48383936|NCT06650644|DIETARY_SUPPLEMENT|Lactococcus lactis KD10 (health food)|"* Food Name: Lactococcus lactis KD10 (health food)~* Ingredients: Freeze-dried Lactococcus lactis enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Administration Period and Route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
48520179|NCT03078686|PROCEDURE|Emulsification tSVF|Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
48721010|NCT04214639|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
48721011|NCT04214639|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
48721012|NCT06522685|DEVICE|transcranial direct current stimulation Soterix REMOTE 1x1 miniCT|Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
48721013|NCT01151761|PROCEDURE|Stereotactic Body Radiotherapy|Standard of care
48721014|NCT01151761|DRUG|Gemcitabine|100 mg/m2, IV
48721015|NCT01151761|DRUG|Cisplatin|25 mg/m2, IV
48721016|NCT01151761|DRUG|Carboplatin|AUC 2, based on Calvert formula, IV
48721017|NCT01151761|DRUG|Capecitabine|1000 mg/m2, PO
48721018|NCT01151761|DRUG|5FU|200 mg/m2
48721019|NCT01151761|PROCEDURE|Liver transplantation|
48721020|NCT04539860|DEVICE|Transdermal Optical Imaging|Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
48721021|NCT01395277|DIETARY_SUPPLEMENT|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
48721022|NCT01395277|DIETARY_SUPPLEMENT|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
48025415|NCT02291718|DRUG|Isovue|iodine contrast
48388047|NCT05245227|DRUG|Sublingual Misoprostol|Misoprostol 400 mcg sublingual
48388048|NCT05245227|DRUG|IV Oxytocin|40 units IV Oxytocin in 1000 mL normal saline
48520180|NCT03078686|PROCEDURE|cSVF isolation and concentration|Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
48520181|NCT03078686|PROCEDURE|cSVF in Normal Saline IV|cSVF + NS for IV Placement
48025416|NCT02445079|OTHER|This is an observational study only|Observational study only
48025417|NCT04572633|DEVICE|HistoSonics System|The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
48028960|NCT04782323|DRUG|aQII-10 Investigational|Biological/Vaccine: Investigational aQII-10 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48028961|NCT04782323|DRUG|aQII-11 Investigational|Biological/Vaccine: Investigational aQII-11 Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48721023|NCT03082352|DRUG|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
48721024|NCT03082352|DRUG|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
48721025|NCT06213285|DEVICE|Watchman FLX left atrial appendage occlusion|Early (30-120 days) CT follow-up after Watchman FLX LAAO
48721026|NCT06198855|DEVICE|QMon-20 device|Automatic Blood pressure measurement with QMon-20 device in the waiting room for 20 minutes every 5 minutes.
48721027|NCT00180167|DRUG|randomization between two established Chemotherapies|
48721028|NCT03055390|DRUG|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
48721029|NCT03055390|DRUG|placebo|2ml of saline intravenous
48721030|NCT00346645|DRUG|Bortezomid (VELCADE®)|
48721031|NCT05147714|DEVICE|Surgical Pleth Index (SPI)|SPI data were recorded at one-minute intervals during the last five minutes (6 times in total) until the entropy value reached 60
48721032|NCT06219395|PROCEDURE|Endoscopy|Patients will be examined with gastroscopy, colonoscopy and WCE and the diagnostic yield of combined gastroscopy/colonoscopy will be compared to WCE
48025418|NCT05310825|OTHER|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.
48028962|NCT04782323|DRUG|Licensed QII Active Comparator|Biological/Vaccine: Licensed QII Licensed Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
48383937|NCT05072977|PROCEDURE|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
48383938|NCT05072977|PROCEDURE|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
48383939|NCT00002680|BIOLOGICAL|filgrastim|
48383940|NCT00002680|DRUG|cyclophosphamide|
48383941|NCT00002680|DRUG|megestrol acetate|
48383942|NCT00002680|DRUG|melphalan|
48383943|NCT00002680|DRUG|tamoxifen citrate|
48383944|NCT00002680|DRUG|thiotepa|
48383945|NCT00002680|PROCEDURE|conventional surgery|
48383946|NCT00002680|PROCEDURE|peripheral blood stem cell transplantation|
48383947|NCT00002680|RADIATION|radiation therapy|
48383948|NCT02861534|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
48383949|NCT02861534|DRUG|Placebo for vericiguat|2.5, 5.0, or 10.0 mg orally once daily
48383950|NCT01655173|BEHAVIORAL|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
48383951|NCT01655173|BEHAVIORAL|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
48383952|NCT02911610|DEVICE|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
48383953|NCT02911610|DEVICE|Volar plate|surgery of wrist fractures with volar plate
48383954|NCT03707938|DRUG|Brigatinib|Given PO
48383955|NCT03707938|PROCEDURE|Local Consolidation Therapy|Undergo local consolidative therapy
48383956|NCT05229783|PROCEDURE|Electronic chromoendoscopy|Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
48383957|NCT05229783|PROCEDURE|White light endoscopy with Seattle protocol|Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
48721033|NCT01095354|DRUG|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: \>6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece \>9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects \>10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
48721034|NCT04033874|OTHER|kangaroo care|kangaroo care
48721035|NCT04033874|OTHER|holding on the mother's lap|holding on the mother's lap
48383958|NCT03296267|PROCEDURE|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
48383959|NCT06568042|DRUG|LY3848575|Administered SC
48383960|NCT06568042|DRUG|Placebo|Administered SC
48383961|NCT03626246|OTHER|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin."
48383962|NCT02861729|OTHER|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
48721036|NCT04033874|OTHER|white noise listening|white noise listening
48721037|NCT04033874|OTHER|ambient sound listening|ambient sound listening
48721038|NCT05216276|PROCEDURE|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
48721039|NCT05216276|PROCEDURE|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
48182639|NCT00020722|DRUG|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
48182640|NCT00020722|DRUG|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
48182641|NCT00020722|PROCEDURE|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
48182642|NCT00020722|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
48182643|NCT00497874|BEHAVIORAL|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
48383963|NCT02861729|OTHER|IPS e.max|lithium disilicate partial coverage restorations
48383964|NCT00116545|DRUG|troglitazone|
48383965|NCT05562739|DIETARY_SUPPLEMENT|Postbiotic|multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
48383966|NCT05562739|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 6 weeks.
48383967|NCT01958502|GENETIC|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
48383968|NCT03106740|DRUG|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
48383969|NCT03106740|DIAGNOSTIC_TEST|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
48383970|NCT03106740|OTHER|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
48383971|NCT05153655|PROCEDURE|Local ischemic post-conditioning|"Direct local ischemic post-conditioning will be applied after successful recanalization of the culprit middle cerebral artery. Local ischemic post-conditioning consists of briefly repeated 4 cycles of occlusion and reperfusion (equal duration) of the initially occluded culprit middle cerebral artery using a balloon. The schedule of advancing duration is 0  1  2  3  4  5 min."
48182644|NCT04360785|DRUG|Methotrexate|Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
48182645|NCT02926911|OTHER|Surgery|Surgery +/- radiation choice for endocrine therapy
48182646|NCT02926911|OTHER|Active Monitoring|Choice for endocrine therapy
48182647|NCT05142930|OTHER|Intermittent ultrasound|Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
48383972|NCT00719407|DRUG|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
48383973|NCT04491188|DIETARY_SUPPLEMENT|Bacillus subtilis DE111|1 x10-9 CFU Bacillus subtilis DE111 probiotic
48383974|NCT04491188|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
48028963|NCT03243526|OTHER|fluid therapy|fluid resuscitation guided by CVP or PPV
48028964|NCT00158743|DRUG|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
48028965|NCT00158743|OTHER|sodium chloride|
48028966|NCT06264921|DRUG|NKT3447|Oral CDK2 inhibitor
48383975|NCT03931707|GENETIC|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
48383976|NCT04793958|DRUG|MRTX849|28 Day Cycle
48383977|NCT04793958|BIOLOGICAL|Cetuximab|28 Day Cycle
48383978|NCT04793958|DRUG|mFOLFOX6 Regimen|"* Fluorouracil~* Oxaliplatin~* Folinic acid"
48383979|NCT04793958|DRUG|FOLFIRI Regimen|"* Fluorouracil~* Irinotecan~* Folinic acid"
48383980|NCT06207656|DRUG|EBC|"Patients will receive the following per 28-day cycle:~* Encorafenib: 300 mg (4 × 75 mg oral capsule) daily (QD)~* Binimetinib: 45 mg (3 × 15 mg oral tablet) twice daily (BID)~* Cetuximab: 500 mg/m2 every 2 weeks as per standard institutional practice."
48383981|NCT01503086|PROCEDURE|Cognitive Assessment|Ancillary studies
48383982|NCT01503086|OTHER|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
48520182|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
48721040|NCT00220207|BEHAVIORAL|Internet co-management module|
48028967|NCT05907668|DRUG|IMVT-1401 (batoclimab)|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.
48028968|NCT02878993|DEVICE|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
48383983|NCT01503086|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
48383984|NCT01503086|OTHER|Quality-of-Life Assessment|Ancillary studies
48383985|NCT01503086|OTHER|Questionnaire Administration|Ancillary studies
48383986|NCT00843739|DEVICE|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
48721041|NCT04454736|BEHAVIORAL|"Amateur Group Singing"|45-minute singing session led by a professional choirmaster without a therapeutic background once a week
48721042|NCT04454736|BEHAVIORAL|"Professional Group Singing"|120-minute singing session led by a professional choirmaster without a therapeutic background three times a week. Assessments take place twice a week.
48721043|NCT05514249|DRUG|CRD-TMH-001|Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
48383987|NCT00843739|DEVICE|sham EMST|Four week sham device training program
48383988|NCT03715335|OTHER|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
48383989|NCT03715335|OTHER|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
48383990|NCT06171165|DIAGNOSTIC_TEST|Yale Swallow Protocol|"All the participants will receive the two swallow screenings, i.e., Yale Swallow Protocol and Speech-language therapist, to classify the participants into either try swallow or NPO status."
48721044|NCT00815828|OTHER|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
48721045|NCT02704611|DEVICE|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
48028969|NCT02093299|DRUG|Clopidogrel|a blood sample is drawn on all patients to determine responder status
48028970|NCT06367374|DRUG|Sonrotoclax|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
48028971|NCT06367374|DRUG|Zanubrutinib|"Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then."
48028972|NCT00970502|DRUG|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
48028973|NCT05930093|DIETARY_SUPPLEMENT|Placebo|Placebo matching LivPhcD cap.
48028974|NCT05930093|DIETARY_SUPPLEMENT|2 cap.LivPhcD/per day|2 caps. LivPhcD cap. after meal, once a day
48028975|NCT05930093|DIETARY_SUPPLEMENT|4 cap.LivPhcD/per day|4 caps. LivPhcD cap. after meal, BID
48028976|NCT05930093|DIETARY_SUPPLEMENT|6 cap.LivPhcD/per day|6 caps. LivPhcD cap. after meal, TID
48028977|NCT06163105|PROCEDURE|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~1. Topical anesthesia by Tetracaine 0.5%~2. Clean the eyelids by gauzes with commercial available foam~3. Warm the eyelids by Blephasteam machine for 10 minutes~4. Instill Tetracaine 0.5% again~5. Use Mastrota paddle and Q-tip to squeeze the gland~6. Clean the lid margin by commercial available foam~7. Use Moxifloxacin 0.5% eyedrop"
48520183|NCT00591773|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
48520184|NCT00591773|DRUG|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
48520185|NCT01290549|DRUG|Polatuzumab Vedotin|Participants will receive escalating intravenous dose of polatuzumab vedotin.
48520186|NCT01290549|DRUG|Rituximab|Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.
48520187|NCT01152372|PROCEDURE|Insulin, glucose and staple isotopes|
48520188|NCT03532152|DEVICE|Pure Purr VR technology|"The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate."
48520189|NCT03532152|DEVICE|Sham VR technology|The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
48025419|NCT05310825|OTHER|Traditional Body Wiping Bath|"The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated"
48025420|NCT05745740|DRUG|RC48-ADC|RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
48182648|NCT05142930|OTHER|Continuous ultrasound|Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
48182649|NCT01912989|BEHAVIORAL|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
48182650|NCT01791413|DRUG|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
48182651|NCT05997342|DRUG|TQB3912 tablets|TQB3912 is a small molecule Phosphorylated protein kinase inhibitor. Activation of the pathway plays an important role in cell survival, proliferation, migration, and differentiation.
48182652|NCT06470776|BEHAVIORAL|Chatbot counselling|Access to a chatbot that provides smoking cessation counselling based on the 5A's (Ask, Advice, Assess, Assist, Arrange follow-up) and 5R's (Risk, Relevance, Rewards, Relevance, Roadblocks, Repetition) tobacco intervention models from baseline to 3-month post-baseline.
48383991|NCT05390853|PROCEDURE|Active tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
48383992|NCT05390853|PROCEDURE|Sham tDCS|"tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode.~Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents.~Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes.~During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb.~In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice."
48520190|NCT06405594|BEHAVIORAL|Language Condition|The intervention involves asking participants to speak and understand words and sentences with different linguistic manipulations such as morphological, semantic, phonological priming, predictability of the subject and object nouns associated with verbs, naming of verbs and nouns, production of sentences with past, future or present tense. Accuracy, response times and brain activity are the outcome measures.
48520191|NCT04786847|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
48520192|NCT04767399|BEHAVIORAL|protaper next|rotary systems used on patients need root canal treatment
48520193|NCT02039193|BEHAVIORAL|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
48520194|NCT01847404|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
48721046|NCT02704611|DEVICE|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
48721047|NCT02577185|DRUG|Botulinum Toxin Type A|
48721048|NCT02577185|DRUG|Sodium chloride 9 mg/ml|
48721049|NCT04294550|OTHER|Naloxegol|28 days of therapy with 25 mg/day of Naloxegol on cancer patients using opioids and suffering for opioids induced constipation not relieved by first-line laxatives.
48721050|NCT00803972|DRUG|rHuPH20|recombinant human hyaluronidase PH20
48721051|NCT00803972|DRUG|Insulin Human Injection|injection
48721052|NCT00803972|DRUG|Insulin Lispro Injection|injection
48721053|NCT01484379|PROCEDURE|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
48721054|NCT04591925|DEVICE|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
48721055|NCT04591925|DEVICE|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
48721056|NCT00046930|BIOLOGICAL|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
48025421|NCT05745740|DRUG|Pyrotinib|Pyrotinib 400 mg by oral once a day.
48025422|NCT05422911|DRUG|Abiraterone acetate|YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
48721057|NCT00046930|BIOLOGICAL|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
48025423|NCT05422911|DRUG|Apalutamide|Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
48383993|NCT03819465|DRUG|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
48383994|NCT03819465|DRUG|Danvatirsen|Danvatirsen IV Loading dose Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 1 Day 5 then once a week (q1w) starting at Cycle 1 Day 8
48383995|NCT03819465|DRUG|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at Cycle 3 Day 1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at Cycle 5 Day 1
48383996|NCT03819465|DRUG|MEDI5752|MEDI5752 IV Every 3 weeks (q3w)
48383997|NCT03819465|DRUG|Pemetrexed|Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either every 3 weeks (q3w) or every 4 weeks (q4w) (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study
48025424|NCT05422911|DRUG|Enzalutamide|Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
48025425|NCT01592630|DRUG|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
48025426|NCT01592630|DRUG|Saline|On-Q pumps containing saline to be attached to TAP catheters
48025427|NCT01886547|OTHER|Prostate health screening|
48182653|NCT06470776|BEHAVIORAL|Peer counselling|Usual treatment provided by the Youth Quitline, i.e., telephone counselling for smoking cessation based on the 5As and 5Rs models delivered by trained peer counsellors at baseline and 1 week, 1 month and 3 months post-baseline
48182654|NCT00770588|DRUG|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
48182655|NCT00770588|DRUG|Placebo|To match Gefitinib
48182656|NCT04426435|DRUG|honey based (HB) syrup|"honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO)."
48182657|NCT01103921|OTHER|Glucose|25% dose at 2-week intervention assigned to subjects.
48182658|NCT01103921|OTHER|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
48721058|NCT00046930|DRUG|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
48025428|NCT03468439|OTHER|Femoral nerve block with phenol|
48025429|NCT00001022|DRUG|Zidovudine|
48721059|NCT00046930|DRUG|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
48721060|NCT00046930|DRUG|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
48721061|NCT00046930|DRUG|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
48721062|NCT02189408|BIOLOGICAL|Platelet rich plasma|
48721063|NCT05097300|OTHER|Suboccipital inhibition|The therapist will place his hands under the patient's head, making contact with the suboccipital muscles in the region of the posterior arch of the atlas, applying progressive and deep pressure. This pressure will be maintained for 10 minutes
48721064|NCT05097300|OTHER|Ischemic pressure|"Pressures will be made on the temporal, superior trapezius, masseter and sternocleidomastoid muscles. Physical therapist will apply gradual sustained finger pressure to the muscle's active trigger points for 5-15 seconds. The therapist will begin with light firm pressure and gradually increase the pressure until the patient feels a moderate but bearable level of pain (corresponding to a level 7 on a pain scale of 1 to 10 levels where 1 indicates no pain and 10 is excruciating pain). Pressure will remain at this level until pain levels decrease to level 3. The therapist will repeat this procedure approximately 3-4 times over a 90 second period."
48721065|NCT05097300|OTHER|Passive stretching|Passive stretches will be applied to each muscle 2 times for 30 seconds, they will be performed slowly at the rate of the patient's normal breathing and checking that no compensations appear.
48721066|NCT05097300|OTHER|Diaphragmatic breathing exercice|To perform diaphragmatic breaths, there will first be an education on how to do them. The patient will lie supine, with the hips and knees semi-flexed. The therapist will ask you to place one hand on your chest and one on your abdomen. Successively, it will ask you to take a few deep breaths, inhaling through your nose for 2 seconds and exhaling through your mouth, with your lips pursed (almost closed) for 4 seconds, helping you to maintain the rhythm of your breath by counting out loud. The patient should note that during inspiration his hand on top of the chest does not rise (the chest remains still) and during expiration that his hand on top of the abdomen goes down (the abdomen sinks).
48721067|NCT00002742|DRUG|amphotericin B deoxycholate|
48721068|NCT00002742|DRUG|nystatin|
48721069|NCT03144869|BEHAVIORAL|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
48721070|NCT02545816|DEVICE|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
48721071|NCT04425785|OTHER|Physical Exercise Program|A structured exercise program
48721072|NCT04425785|BEHAVIORAL|Cognitive Behavioural Therapy|A structured cognitive behavioural therapy program
48721073|NCT00081211|BIOLOGICAL|PV701|Given intratumorally
48025430|NCT00001022|DRUG|Zalcitabine|
48025431|NCT00001022|DRUG|Didanosine|
48025432|NCT02207829|DRUG|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
48025433|NCT02207829|DRUG|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
48025434|NCT02207829|DRUG|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
48025435|NCT02207829|DRUG|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
48182659|NCT01103921|OTHER|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
48383998|NCT03819465|DRUG|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
48383999|NCT03819465|DRUG|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
48384000|NCT03819465|DRUG|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
48384001|NCT03819465|DRUG|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
48384002|NCT03819465|DRUG|AZD2936|AZD2936 IV
48721074|NCT00724906|DRUG|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
48721075|NCT00002239|DRUG|Enfuvirtide|
48721076|NCT00002239|DRUG|Ritonavir|
48721077|NCT00002239|DRUG|Abacavir sulfate|
48721078|NCT00002239|DRUG|Amprenavir|
48182660|NCT01103921|OTHER|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
48182661|NCT04978090|DEVICE|3D printed EAF management device|Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
48721079|NCT00002239|DRUG|Efavirenz|
48721080|NCT05833451|OTHER|Reiki|Reiki, one of integrative practices, is an energy therapy involving the use of energy that flows naturally from the hands of the practitioner to strengthen the body's ability to heal itself in order to increase well-being. Reiki improves well-being in many areas, ensures that blood and lymph circulation is maintained properly, regulates blood pressure and pulse rate by stimulating the autonomic nervous system, increases comfort, reduces depression and anxiety levels. In this way, Reiki facilitates physical and mental relaxation and promotes health
48721081|NCT00111904|DRUG|paclitaxel-loaded polymeric micelle|
48182662|NCT04789343|OTHER|Root canal treatment|The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
48182663|NCT06421987|DEVICE|Near Infrared Spectroscopy (NIRS)|NIRS is a portable, non-invasive, brain imaging device.
48520195|NCT01847404|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
48520196|NCT01847404|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
48520197|NCT01847404|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
48520198|NCT00494702|PROCEDURE|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
48520199|NCT00494702|PROCEDURE|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
48520200|NCT05237492|DRUG|Tramadol|Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
48520201|NCT03897634|DEVICE|Remote Microphone|Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
48721082|NCT03052556|PROCEDURE|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
48721083|NCT05612360|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
48721084|NCT00436254|BIOLOGICAL|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
48721085|NCT00436254|BIOLOGICAL|sargramostim|Given intradermally
48721086|NCT00436254|OTHER|flow cytometry|Correlative studies
48721087|NCT00436254|OTHER|immunologic technique|Correlative studies
48384003|NCT01946204|DRUG|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
48721088|NCT00436254|OTHER|immunoenzyme technique|Undergo ELIspot (correlative studies)
48721089|NCT00436254|GENETIC|protein expression analysis|Undergo ELISA (correlative studies)
48721090|NCT00436254|PROCEDURE|biopsy|Undergo punch biopsy (correlative studies)
48025436|NCT01641887|OTHER|Decision Aid|Patients will use a decision aid administered on a computer.
48025437|NCT03286959|PROCEDURE|PCR with calcium hydroxide|
48025438|NCT03286959|PROCEDURE|PCR with RMGIC|
48025439|NCT03286959|PROCEDURE|PCR with direct composite|
48384004|NCT01946204|DRUG|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
48721091|NCT02451891|BIOLOGICAL|MVA-EBO Z|
48721092|NCT02451891|BIOLOGICAL|ChAd3-EBO Z|
48721093|NCT06137768|DRUG|HRS-5965|HRS-5965
48520202|NCT04511260|DEVICE|NuEra Tight VRF Handpiece|"The VRF is a Model that belongs to the NuEra Tight RF Family, specific for the treatment of small areas.~The NuEra is FDA cleared (K151296) for a wide range of indications including but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. The system and its accessories, are intended to be use for a wide range of indications including, but not limited to:~· Provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation of soft tissue."
48520203|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Dose: 1 x 10\^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)
48520204|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)|Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)
48520205|NCT05317819|DRUG|ADI-PEG20|Treatment for hepatocellular carcinoma
48520206|NCT05317819|OTHER|Placebo|Treatment for hepatocellular carcinoma
48520207|NCT01926431|OTHER|Exercise|
48025440|NCT02842775|OTHER|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
48182664|NCT04195347|DRUG|CM4620|IV
48182665|NCT02990468|DRUG|BMX-001|Subcutaneous injection.
48384005|NCT04471766|OTHER|Certified cloth face mask plus preventive information|Provision of two face masks sewed locally following a certified model tested for FORCE in the laboratory per residents \> 10 years old
48520208|NCT01926431|OTHER|Rest|
48520209|NCT05894837|DRUG|Serplulimab+Regorafenib|Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
48520210|NCT05894837|DRUG|Hepatic Artery Bicarbonate Infusion|hepatic artery bicarbonate infusion: once every four weeks
48520211|NCT00101634|DRUG|Paliperidone palmitate|
48520212|NCT01092858|DRUG|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
48520213|NCT01092858|DRUG|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
48025441|NCT05490459|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
48025442|NCT06529497|DRUG|Racecadotril|The intervention group will receive racecadotril+ORS+Zinc
48025443|NCT03901248|OTHER|No Intervention|Observational study
48025444|NCT01083030|DEVICE|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
48025445|NCT01083030|COMBINATION_PRODUCT|DCB|Drug Coated Balloon Angioplasty
48025446|NCT06107218|OTHER|Bioactive Glass Air Abrasion Particles.|Finishing of cavity walls by AquaCare Air Abrasion Device using Bioactive Glass Air Abrasion Particles.
48520214|NCT02020278|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
48025447|NCT06107218|OTHER|Diamond Stone.|Finishing of cavity walls using Diamond Stone.
48025448|NCT02405455|PROCEDURE|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
48182666|NCT02990468|RADIATION|Radiation Therapy|Patients will receive standard dose intensity modulated radiation therapy (IMRT).
48182667|NCT02990468|DRUG|Cisplatin|Cisplatin will be administered per institution's standard of care practice.
48182668|NCT03469726|DIAGNOSTIC_TEST|Contrast-enhanced Diffusion-weighted MRI|An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
48182669|NCT02209844|DRUG|BI 44847|
48182670|NCT02209844|DRUG|Placebo|
48182671|NCT02476942|DRUG|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
48384006|NCT04471766|BEHAVIORAL|Preventive information|Advice on how to prevent COVID-19 according to the government´ policy
48384007|NCT04259307|DRUG|Omapone Peri 724mL or Winuf Peri 654mL|Additional intravenous nutrition of 500 kcal per day for 3 weeks
48384008|NCT06653348|DRUG|Ticagrelor 60 + Aspirin|Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 3.
48384009|NCT06653348|DRUG|Ticagrelor 90 + aspirin|ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
48384010|NCT00103155|PROCEDURE|conventional surgery|
48520215|NCT04981418|DEVICE|customised pelvic support shorts|"These apply targeted compressive forces to the pelvic girdle through selective precisely positioned reinforced lycra panels that aim to stabilize and align body segments to improve function and reduce unwanted movements. The construction material (Nylon and Elastane) is durable and breathable, and its mechanical properties enable it to provide dynamic stability and support (rather than the rigid support provided by off-the-shelf belts) during movement/functional activities. This aims to optimise comfort and movement to increase wear compliance, which is crucial as any benefits gained rely upon this."
48520216|NCT04981418|OTHER|Exercise|Women will be provided with up to a maximum of 4 exercises from a pre-defined list of exercises. Suggested dosages are referred to in the protocol. The exercise programme contains a range of exercise focused around the pelvic girdle and hips (including movement control and strengthening
48721094|NCT06137768|DRUG|Placebo|Placebo.
48721095|NCT04729231|PROCEDURE|Nasalis Sling Flap|The nasalis sling flap involves alteration of the nasalis muscle to create a myocutaneous pedicle flap that will be used to fill in the wound.
48721096|NCT04729231|PROCEDURE|Lobed Transposition Flap|Lobed flap reconstruction involves the use of cutaneous tissue located adjacent to the nasal tip to fill in the wound. The flap will undergo a 90-degree arc to approximate the desired position.
48721097|NCT00702494|BIOLOGICAL|TB-403|Multiple IV
48721098|NCT05668663|DIAGNOSTIC_TEST|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
48721099|NCT04226040|BEHAVIORAL|DOW and illness perception|Acutely ill patients are exposed to a survey regarding their degree of worry and illness perception
48721100|NCT00185601|BEHAVIORAL|Internet Diabetes Self-Management Program|
48721101|NCT03082014|DRUG|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
48721102|NCT03082014|DRUG|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
48721103|NCT03082014|DRUG|Atenolol|blood pressure lowering agent - beta-blocker
48721104|NCT02310997|OTHER|Umbilical Cord Blood Transplant|
48721105|NCT02310997|DRUG|Cyclophosphamide|
48721106|NCT02310997|RADIATION|Total body irradiation|
48721107|NCT02310997|DRUG|Busulfan|
48721108|NCT02310997|DRUG|Melphalan|
48721109|NCT02310997|DRUG|Fludarabine|
48721110|NCT04033094|DRUG|MorphaBond ER|This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
48721111|NCT04033094|DRUG|Comparator Drug|This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
48721112|NCT01989611|DRUG|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
48721113|NCT06506539|DRUG|Placental Extract|add placental extract gel as a local delivery drug in periodontal pocket
48025449|NCT02405455|DEVICE|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
48025450|NCT02268773|DRUG|Asasantin®|
48025451|NCT02268773|DRUG|Acetylsalicylic acid low dose|
48025452|NCT02268773|DRUG|Acetylsalicylic acid high dose|
48025453|NCT04638010|BEHAVIORAL|Cancer control navigation (CNN)|Cancer Control Navigators (CNNs) housed at 2-1-1 call centers aid callers. CNNs receive electronic summary profiles of participants assigned to navigation. Navigators call the participant, build a collaborative relationship with them, identify their needs, work with them to identify barriers to services and coordinate solutions, and provide logistic (e.g., making appointments) and emotional support. Navigation services are provided by telephone only.
48384011|NCT00103155|PROCEDURE|radiofrequency ablation|
48721114|NCT02455076|DRUG|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
48388049|NCT06091527|BEHAVIORAL|Yoga practice|90-minute group yoga classes twice weekly for 12 weeks.
48721115|NCT02455076|DRUG|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~1. FBG \>180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~2. FBG \>140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~3. FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~4. FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~5. FBG or RBG \< 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~6. FBG or RBG \< 40 mg/dl, decrease dose of glargine by 30%."
48721116|NCT02455076|DRUG|Rapid-acting insulin analogs|"If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units."
48721117|NCT01779505|BIOLOGICAL|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
48721118|NCT00521664|BIOLOGICAL|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
48025454|NCT04638010|BEHAVIORAL|General referral (usual care)|Information Specialists at the 2-1-1 call center provide cancer control referrals specific to participant's screening or prevention needs.
48025455|NCT03888144|DRUG|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
48025456|NCT03888144|DRUG|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
48520217|NCT04981418|OTHER|advice|standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource.
48025457|NCT00564083|PROCEDURE|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
48384012|NCT03187899|DRUG|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
48520218|NCT01488773|DRUG|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
48520219|NCT01488773|DRUG|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
48520220|NCT00026065|BEHAVIORAL|Biofeedback|
48721119|NCT00521664|BIOLOGICAL|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
48721120|NCT02180477|DRUG|UHAC 62 XX - TF1 tablet|
48721121|NCT02180477|DRUG|UHAC 62 XX - TF2 tablet|
48721122|NCT02180477|DRUG|UHAC 62 XX - capsules|
48384013|NCT03187899|DRUG|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
48384014|NCT06650020|OTHER|synchronous online learning|Each participant in this cohort selected a suitable and peaceful learning environment, characterized by ample lighting and strong network connectivity. Equipped with laptops, participants logged into the Tencet conference software ten minutes prior to the session, entered their authentic names, completed the sign-in process five minutes before the course started, and kept their cameras activated throughout the session. During the instructional phase, both the teacher and control group were physically present. While the teacher instructed the control group, screen sharing through Tencet conference software allowed trainees in the experimental group to have clear visual access to instructional materials while audibly receiving instruction through microphones.
48384015|NCT06650020|OTHER|the traditional offline model of centralized training|The control group adhered to the traditional offline model of centralized training, which involved a training facility spanning 100 square meters and accommodating seating for 150 participants. The front section of the training room was equipped with various amenities, such as a projection screen, podium, computer, and microphone, all available for use by the instructors. Throughout the training period, the lecturer provided in-person instruction on-site, allowing trainees to engage in real-time interaction by raising their queries.
48384016|NCT05140239|OTHER|No Intervention|Non Interventional
48384017|NCT00870415|PROCEDURE|quality-of-life assessment|
48384018|NCT00870415|PROCEDURE|therapeutic conventional surgery|
48025458|NCT02066298|DRUG|Mometasone 220mcg BID|Mometasone is an ICS
48025459|NCT02066298|DRUG|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
48384019|NCT02765958|DEVICE|portable ECG devise|
48721123|NCT00351182|DRUG|Telithromycin|
48025460|NCT02066298|DRUG|Placebo|
48025461|NCT02395354|DEVICE|Placing a self-expanding metallic stent|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks."
48025462|NCT02395354|DEVICE|A balloon dilatation|"* Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required\> 2 expansions."
48025463|NCT00144573|DRUG|MRA(Tocilizumab)|
48025464|NCT02755493|BEHAVIORAL|Sleep deprivation|
48384020|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
48384021|NCT00633009|BIOLOGICAL|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
48520221|NCT05259527|DRUG|Ergocalciferol Capsules|Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
48520222|NCT05259527|DIETARY_SUPPLEMENT|Cholecalciferol Capsules|Vitamin D3 5,000IU by mouth daily
48520223|NCT02834325|PROCEDURE|mechanical ventilation|
48520224|NCT00248261|DRUG|ziprasidone, sertraline|
48721124|NCT00351182|DRUG|Doxycycline|
48721125|NCT04569994|DRUG|NNC0363-0845|A single dose administered s.c. (subcutaneously, under the skin)
48721126|NCT04569994|DRUG|Placebo (NNC0363-0845)|A single dose administered s.c.
48721127|NCT04569994|DRUG|Insulin degludec|A single dose administered s.c.
48721128|NCT04098978|OTHER|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
48721129|NCT02074813|OTHER|Inspiratory muscle training|Inspiratory muscle training
48721130|NCT01395407|RADIATION|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume \> 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume \> 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~1. 21 18 15~2. 23 20 17~3. 25 22 19"
48384022|NCT05695456|OTHER|personalized exclusion diet based on CLE|personalized exclusion diet based on CLE
48384023|NCT05695456|OTHER|empiric exclusion diet|exclusion diet with milk or gluten-containing grains
48384024|NCT06581146|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
48384025|NCT00209235|BEHAVIORAL|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
48384026|NCT03681561|DRUG|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
48384027|NCT03681561|DRUG|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
48384028|NCT05322200|RADIATION|A computerized tomography (CT) coronary angiogram|Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.
48384029|NCT05322200|PROCEDURE|Vicorder (Skidmore medical, UK)|Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.
48384030|NCT05322200|OTHER|Blood tests for inflammation and oxidative stress markers|All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
48384031|NCT03128775|BEHAVIORAL|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
48384032|NCT03128775|BEHAVIORAL|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
48384033|NCT03128775|BEHAVIORAL|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
48384034|NCT00002767|BIOLOGICAL|Detox-B adjuvant|
48384035|NCT00002767|BIOLOGICAL|recombinant interferon alfa|
48384036|NCT06539962|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL-6)|Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients
48384037|NCT06085586|OTHER|Early Weight Bearing|Full weight bearing (100%) initiated at 4 weeks postoperatively
48384038|NCT06085586|OTHER|Normal Weight Bearing|Full weight bearing (100%) initiated at 6 weeks postoperatively
48384039|NCT05698693|BEHAVIORAL|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
48384040|NCT05698693|BEHAVIORAL|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
48384041|NCT02159534|OTHER|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
48384042|NCT05792020|DEVICE|Focused Ultrasound Stimulation|This aim will test whether motor tFUS parameters thought to be excitatory (50% duty cycle) vs. inhibitory (5% duty cycle) elicit their predicted effects on MEPs before and after each of three stimulation blocks, using 50 MEPs at each time point.
48388050|NCT06091527|BEHAVIORAL|Education|90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
48025465|NCT02618473|OTHER|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
48388051|NCT00442338|DRUG|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
48025466|NCT04123639|PROCEDURE|PTA|Percutaneous transluminal angioplasty
48025467|NCT00585949|PROCEDURE|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
48025468|NCT00585949|PROCEDURE|Angiography|Angiography is an imaging technique to see coronary blood vessels.
48384043|NCT05846503|BEHAVIORAL|1. Quality and info management system|"1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines.~2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion.~3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP.~4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic.~5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values."
48384044|NCT04856488|DRUG|Iodine-Potassium Iodide 5%-10% Oral and Topical Solution|Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
48721131|NCT02517632|BEHAVIORAL|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
48721132|NCT02517632|BEHAVIORAL|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
48721133|NCT04367467|OTHER|Kidney Function Test|Cystatin-C measurement
48384045|NCT04382599|BEHAVIORAL|Text warning with square background|The warning message is in white text on a black square background
48384046|NCT04382599|BEHAVIORAL|Text warning with octagon background|The warning message is in white text on a black octagon background
48384047|NCT04382599|BEHAVIORAL|Icon warning|The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
48384048|NCT04382599|BEHAVIORAL|Graphic warning|The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
48384049|NCT05388526|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
48384050|NCT03144219|DIAGNOSTIC_TEST|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
48384051|NCT03144219|DIAGNOSTIC_TEST|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
48520225|NCT01320501|DRUG|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
48721134|NCT06137872|OTHER|Music Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. In the music group, the pregnant woman, who was assigned to the next group according to randomization during the non-stress test, was allowed to listen to music with disposable headphones for at least 20 minutes until the procedure was completed. At the same time, the mother will be asked to close her eyes and be relaxed. Headphones used to prevent infection were given to the pregnant woman as a gift at the end of the procedure.
48721135|NCT06137872|OTHER|Control Group|Pregnant women who came to the hospital for non-stress testing were met and informed about the study. The procedure was applied for non-stress testing. During the non-stress test, routine non-stress test was performed on the pregnant control group, which was assigned to the next group according to randomization.
48721136|NCT01818440|OTHER|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
48721137|NCT01818440|OTHER|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
48721138|NCT05644093|DRUG|SPL026 IV|IV dosing
48721139|NCT05644093|DRUG|SPL026 IM|IM dosing
48384052|NCT01900353|OTHER|brushing methods|
48384053|NCT05019872|BEHAVIORAL|(Components of) pasta meal|Samples will be provided one by one in cups labeled with an unique code.
48384054|NCT00747110|DRUG|budesonide|3x 3mg budesonide capsules once daily
48384055|NCT00747110|DRUG|mesalazine|3x 1000mg mesalazine onc daily
48384056|NCT00337727|DRUG|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
48384057|NCT00337727|DRUG|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
48384058|NCT00337727|DRUG|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
48520226|NCT04248530|DEVICE|Renal denervation|DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
48384059|NCT00337727|DRUG|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
48384060|NCT00337727|DRUG|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
48384061|NCT00337727|DRUG|Comparator; Placebo (unspecified)|Aprepitant 80 mg \& 125 mg Pbo capsules.
48384062|NCT06415305|DRUG|Winlevi (clascoterone) 1% cream|Dosed twice daily (BID)
48025469|NCT02239523|PROCEDURE|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
48025470|NCT02239523|PROCEDURE|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
48025471|NCT01405157|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
48025472|NCT01405157|DRUG|methylprednisolone|tablets 16 mg single dose
48025473|NCT06059469|DIAGNOSTIC_TEST|Ga-PSMA PET/CT|Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
48721140|NCT04833959|DRUG|89Zr-panitumumab|Imaging Agent
48721141|NCT03199521|OTHER|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
48721142|NCT02471781|DEVICE|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
48721143|NCT06508359|DRUG|Norepinephrine|Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
48721144|NCT06508359|DRUG|Phenylephrine|Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
48721145|NCT02145871|OTHER|standard fluid management|
48025474|NCT03606642|DRUG|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
48025475|NCT03606642|DEVICE|The Synergy® stent|IVUS guided stent
48025476|NCT02640729|DRUG|Nelotanserin|once daily, oral, 20-mg tablets
48025477|NCT02640729|DRUG|Placebo|once daily, oral, matching tablets
48025478|NCT06397794|OTHER|Quantitative surveys and qualitative interview|All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
48721146|NCT02145871|OTHER|fluid management guided by the EV1000|
48721147|NCT00915655|DRUG|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
48721148|NCT00915655|DRUG|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
48721149|NCT00915655|DRUG|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
48721150|NCT00915655|DRUG|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
48721151|NCT00915655|DRUG|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
48721152|NCT04480034|PROCEDURE|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
48721153|NCT01329744|DRUG|mecasermin|a subcutaneous injection twice a day
48721154|NCT01329744|DRUG|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
48721155|NCT03757754|DRUG|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
48721156|NCT03757754|DRUG|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
48721157|NCT03757754|DRUG|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
48721158|NCT03757754|DRUG|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
48721159|NCT03757754|DRUG|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
48025479|NCT03971643|DRUG|vilobelimab|IV infusions of vilobelimab diluted in sodium chloride.
48025480|NCT05982743|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota fermented milk|Participants will take one bottle (65 ml) of Yakult® drink daily, containing at least 6.5 x 10\^9 CFU of Lactobacillus casei strain Shirota, for a period of 4 weeks. Subsequently, there will be a two-week follow-up period.
48025481|NCT03063229|DEVICE|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
48025482|NCT03063229|OTHER|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
48182672|NCT02476942|DRUG|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
48721160|NCT03757754|DRUG|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
48721161|NCT04763187|PROCEDURE|Tooth extraction|Tooth extraction and alveolus regeneration with autologous blood concentrate.
48721162|NCT06171074|BIOLOGICAL|CM310|CM310 injection
48721163|NCT02335060|DRUG|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
48721164|NCT02335060|DRUG|N-acetylcysteine|A pill given orally.
48721165|NCT02335060|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
48721166|NCT02335060|DRUG|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
48721167|NCT03062241|PROCEDURE|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
48721168|NCT00889200|DRUG|eszopiclone|6 weeks standard oral therapy
48182673|NCT06294197|OTHER|Pelvic Floor Exercises|In the intervention types, women are given training on pelvic floor exercises, that they can perform in the form of home exercises for 12 weeks. Before starting pelvic floor exercises therapy, a physiotherapist who specializes in pelvic floor compatibility will provide information about the location of the pelvic floor muscles through anatomical models and their effect on healthy, vaginal and sexual function. The effects of pelvic floor exercises on this system will be explained on an individual basis, and normal palpation is required to demonstrate their correct execution of contraction of the pelvic floor muscles. Participants will be taught how to contract and contract different muscles, such as the abdominal muscles, hip muscles, and gluteal muscles, or how to avoid pelvic tilt during contraction, and how to perform both rapid and sustained contractions.
48721169|NCT03756831|DIAGNOSTIC_TEST|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
48721170|NCT01401712|PROCEDURE|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
48721171|NCT01401712|PROCEDURE|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
48721172|NCT06107972|BEHAVIORAL|Launching! to Adulthood (¡Iniciando! la Adultez) program|The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.
48721173|NCT04375397|DRUG|Ibrutinib|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
48721174|NCT04375397|DRUG|Placebo|Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
48721175|NCT02645435|PROCEDURE|hip replacement|Total hip replacement
48721176|NCT05156268|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
48721177|NCT05156268|DRUG|Olaparib|Olaparib will be administered orally at 300 mg every 12 hours.
48182674|NCT04112706|DRUG|CPP-ACP|CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
48721178|NCT05012007|OTHER|Reminder Phone|Standard reminder via phone (audiocare)
48182675|NCT03452683|BEHAVIORAL|Movn Mobile App|Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
48182676|NCT04556409|DEVICE|low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises.|Ultrasonic irradiation was employed with parameters of current use in clinical practice, including lower potency (0.16 W/cm2), which is more adequate for stimulation of nerve regeneration, according to results obtained in investigations in which the irradiation was applied at the lesion site 32, 33.
48721179|NCT05012007|OTHER|Reminder Text|reminder via text (VEText)
48721180|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
48721181|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
48721182|NCT04856254|PROCEDURE|Trial of labor after cesarean section|The pregnant females with history of previous cesarean section will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS \[TOLAC\]or not suitable for \[TOLAC\] so undergo from the beginning to elective repeated cesarean section.
48721183|NCT00987701|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
48721184|NCT00987701|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
48182677|NCT04556409|DEVICE|low level LASER plus static abdominal and pelvic floor exercises.|Application of laser irradiation (Ga-As laser) in the site of the anastomosis inhibits the degeneration process, accelerate remyelination, and nerve function recovery 27, 28
48182678|NCT04556409|OTHER|static abdominal and pelvic floor exercises only.|static abdominal and pelvic floor exercises., 3 times/week for 4 weeks.
48182679|NCT05784610|DEVICE|Monitorage by TOF/PTC|Installation of TOFscan® and monitoring by MAR appreciation on one of the patient's wrists and installation of TOFscan® and monitoring by ATP mode (MAR blind) on the other wrist Installation of TOFscan® and monitoring by ATP mode
48182680|NCT05784610|DEVICE|Monitorage by ATP|Installation of TOFscan® and monitoring by ATP mode on one of the patient's wrists
48182681|NCT04517240|OTHER|endoscopy|upper and lower endoscopy and fecal calprotectin test
48182682|NCT01262092|DRUG|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
48182683|NCT01512797|DRUG|Sitagliptin phosphate|100 mg/day orally
48182684|NCT01512797|OTHER|Placebo|1 Placebo Pill per day
48182685|NCT05603364|COMBINATION_PRODUCT|100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose|Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
48520227|NCT04459234|DRUG|Ketamine use in CLCC sites (indication and administration protocol)|"Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~2. Administration protocol: route, posology, duration, administration sequence, premedication~3. Antalgic efficacy~4. Tolerance profile~5. Quality of life, anxiety and depression evaluations"
48520228|NCT00062530|BIOLOGICAL|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
48520229|NCT06322784|DIETARY_SUPPLEMENT|Oat bran (dietary fiber)|"Dietary fiber, known as the seventh type of nutrients, refers to carbohydrate polymers that have health benefits for the human body, mainly derived from plant cell walls such as grains, fruits, and vegetables.Mediterranean cuisine is a dietary pattern"
48520230|NCT02524847|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
48520231|NCT02524847|PROCEDURE|Extracorporeal Photopheresis (ECP)|
48721185|NCT01119677|DRUG|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
48721186|NCT00370513|DRUG|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
48721187|NCT03532217|BIOLOGICAL|PROSTVAC-V|-Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)
48721188|NCT03532217|BIOLOGICAL|PROSTVAC-F|-Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.
48721189|NCT03532217|DRUG|Nivolumab|-Nivolumab is a human monoclonal antibody (mAb)
48721190|NCT03532217|DRUG|Ipilimumab|-Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
48721191|NCT03532217|BIOLOGICAL|Neoantigen DNA vaccine|Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.
48721192|NCT03532217|DEVICE|TriGrid Delivery System|-Electroporation device
48721193|NCT03532217|PROCEDURE|Tumor biopsy|-Pre-treatment, post-treatment A (optional), and end of treatment
48721194|NCT03532217|PROCEDURE|Peripheral blood|-At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)
48721195|NCT03532217|PROCEDURE|Fecal samples|-Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B
48721196|NCT03532217|PROCEDURE|Leukapheresis|"* Post-treatment A/pre-treatment B~* Mid-Treatment B, after Cycle 9 Day 1 and prior to Cycle 10 Day 1~* End of treatment"
48721197|NCT00584129|OTHER|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
48721198|NCT00584129|OTHER|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
48182686|NCT05603364|OTHER|Routine feeding|Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
48182687|NCT02412579|OTHER|None - Standard of Care|
48182688|NCT02019862|DEVICE|TRJ® Total Hip Arthroplasty|
48384063|NCT01137643|OTHER|biologic sample preservation procedure|All samples collected during routine clinical care.
48384064|NCT01137643|OTHER|cytology specimen collection procedure|All Samples collected during routine clinical care.
48384065|NCT03676439|DEVICE|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
48520232|NCT03288714|DEVICE|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
48520233|NCT03288714|DEVICE|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
48721199|NCT03255564|OTHER|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
48384066|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation|"In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold."
48388052|NCT00442338|DRUG|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
48388053|NCT00442338|DRUG|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
48388054|NCT02856282|DRUG|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
48721200|NCT03674879|OTHER|Text Message|Patient contact attempted with text message.
48721201|NCT00230152|DEVICE|Imaging|
48721202|NCT04845191|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
48721203|NCT04547361|DRUG|E2511|E2511 tablets.
48721204|NCT04547361|DRUG|E2511 Matched Placebo|Placebo tablets matching E2511 tablets.
48721205|NCT00587847|DRUG|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
48721206|NCT03234231|BEHAVIORAL|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
48520234|NCT04005001|OTHER|HindSight|HindSight will examine the dynamic trends of clinical measurements taken from a patient's EHR and analyzes correlations between vital signs to alert for the onset of sepsis.This machine learning based tool is optimized by encoder and utilizes periodic retraining to improve its performance over time.
48520235|NCT04005001|OTHER|InSight|Compared to the ability of the InSight software's recognition of sepsis onset to HindSight's performance. The study determines if the HindSight software has equivalent or better performance than the InSight software.
48520236|NCT03346096|DRUG|Thiotepa|fixed dose 5mg/kg on days -7-6
48388055|NCT05887973|BEHAVIORAL|The T.R.I.G.G.E.R Project|"The T.R.I.G.G.E.R Project includes the following core components to address root causes of gun violence:~* Summer Employment~* Social and Emotional Learning~* Future Orientation~* Adult and Peer Support~* Critical Consciousness~* Civic Efficacy and Engagement"
48388056|NCT00345826|DRUG|dasatinib|
48520237|NCT03337061|OTHER|Mindfulness Meditation|Mindfulness Meditation delivered through a mobile application
48520238|NCT01043692|OTHER|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
48520239|NCT03917251|DIAGNOSTIC_TEST|Coronary flow and pressure measurement in patients with ventricular pacing|Coronary flow and pressure measurement in patients with ventricular pacing
48721207|NCT03234231|BEHAVIORAL|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
48721208|NCT00259688|DEVICE|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
48721209|NCT05124379|DEVICE|Hemoclin Gel|Non sterile gel for intra-rectal use
48182689|NCT03099252|OTHER|Parent-targeted BSweet2Babies video|The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
48721210|NCT04240314|BIOLOGICAL|scAAV9.U7.ACCA|A single dose of scAAV9.U7.ACCA will be systemically delivered via a peripheral vein injection.
48025483|NCT03063229|PROCEDURE|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U\&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
48025484|NCT03063229|DEVICE|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
48384067|NCT05883631|DEVICE|Electrographic Flow (EGF) mapping (no ablation)|"In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter.~EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation."
48384068|NCT03879135|BIOLOGICAL|rVWF|Recombinant von Willebrand factor
48384069|NCT03879135|BIOLOGICAL|rFVIII|Recombinant Factor VIII
48384070|NCT03673124|DRUG|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
48384071|NCT03673124|DRUG|Letrozole|2.5 mg by mouth daily
48384072|NCT06308107|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
48520240|NCT04251247|DIAGNOSTIC_TEST|D-dimer/fibrinogen ratio|The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
48520241|NCT06582992|OTHER|RRBS|Measure of genomic regions with differentially methylated profiles and differentially expressed protein
48721211|NCT06129110|BEHAVIORAL|Diet Weight Loss|Low calorie diet of meal replacement shakes
48721212|NCT05292937|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
48721213|NCT04065594|PROCEDURE|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
48025485|NCT03063229|PROCEDURE|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
48182690|NCT00398281|DRUG|dutasteride|Given orally
48384073|NCT04554225|DRUG|Oxygen gas|Oxygen administered to a patient using ambulatory oxygen
48520242|NCT02321059|DEVICE|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
48721214|NCT04065594|PROCEDURE|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
48721215|NCT05546255|DRUG|Eribulin Mesylate|The recommended dose of Eribulin is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1
48721216|NCT05546255|DRUG|Lobaplatin|The recommended dose of lobaplatin is 25mg/m2 administered intravenously over on Days 1
48025486|NCT03063229|OTHER|Food Diary|Participants will keep a 7 day weighed food diary.
48025487|NCT03063229|DEVICE|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
48025488|NCT03063229|OTHER|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
48025489|NCT03063229|PROCEDURE|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
48182691|NCT00398281|OTHER|placebo|Given orally
48384074|NCT04190056|BIOLOGICAL|Pembrolizumab|Given IV
48384075|NCT04190056|DRUG|Tamoxifen|Given PO
48384076|NCT04190056|DRUG|Vorinostat|Given PO
48384077|NCT01079169|DIETARY_SUPPLEMENT|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
48384078|NCT04475731|DRUG|Ponatinib|"Ponatinib 45 mg/day x 4 weeks x 3 courses.~+/- chemotherapy:~* vincristine or~* L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)"
48384079|NCT04706494|DIETARY_SUPPLEMENT|AlphaWave® LTheanine|200 mg of AlphaWave® LTheanine
48384080|NCT04706494|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
48388057|NCT05451407|DRUG|TQB2618 injection|Humanized IgG4 mab targeting TIM-3
48721217|NCT00930436|DRUG|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
48384081|NCT03890159|BEHAVIORAL|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
48384082|NCT03890159|BEHAVIORAL|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
48025490|NCT03063229|PROCEDURE|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
48520243|NCT03241992|BEHAVIORAL|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
48384083|NCT02194959|BEHAVIORAL|Peer PN|Navigation by Peer Patient Navigators
48384084|NCT02194959|BEHAVIORAL|Pro PN|Navigation by Standard Hospital Navigators
48520244|NCT02750137|DRUG|Tetracaine|Application of Ametop prior to intravenous cannulation
48520245|NCT00551512|DRUG|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
48520246|NCT05919719|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Fluid expansion will be delayed while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard).~Our index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline, During abdominal compression, After the 10 to 20ml/kg crystalloid fluid expansion Abdominal compression : a sphygmomanometer will be inflated to a pressure of less than 10 mmHg and will be applied to the center of the patient's abdomen. Then, a gentle compression on the sphygmomanometer will be performed, calibrated at 22 - 26 mmHg according to the sphygmomanometer. The echocardiographic assessments will take place between 10 and 60 seconds after the start of the compression, which will therefore last less than a minute."
48520247|NCT05840055|BEHAVIORAL|Acceptance and Commitment Therapy|"Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis."
48520248|NCT05113745|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
48520249|NCT05113745|DRUG|Placebo|Placebo tablets, taken twice daily
48520250|NCT06103578|DIAGNOSTIC_TEST|GCF and saliva analysis|ELISA
48520251|NCT04834609|PROCEDURE|Injection of autologous adipose tissue in anal fistula|
48520252|NCT01808547|DRUG|ISV-303|0.075% bromfenac in DuraSite dosed BID
48520253|NCT01808547|OTHER|DuraSite Vehicle|DuraSite vehicle dosed BID
48520254|NCT05888857|DRUG|MEDI5752|A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
48520255|NCT03764618|DRUG|Fostamatinib disodium|"Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed."
48520256|NCT03764618|DRUG|Placebo|Placebo
48520257|NCT06488534|DIETARY_SUPPLEMENT|Fermentable Oligo-, Di- Monosaccharides And Polyols (FODMAPs)|A FODMAP solution of 200 mL will be infused in the colon for over 20 min. via the lumen of the solid-state catheter for high-resolution colonic manometry.
48025491|NCT03063229|DRUG|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
48025492|NCT03063229|DRUG|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
48025493|NCT05104658|OTHER|Patient-targeted rehabilitation offers|In addition to usual rehabilitation services, patients in the intervention arm will receive patient-targeted rehabilitation offers to support the patients' participation and completion of their heart rehabilitation course.
48025494|NCT06167447|OTHER|questionnaire and examination|Demographic data of all participants, height, weight, body mass index, occupation, marriage status, education level, comorbidities, medications used, duration of illness and subtype will be recorded by the researcher. Questionnaires to be filled by patients. On the same day, the musculoskeletal system and neurological examination of the participants will be evaluated by the researcher.
48025495|NCT00147186|DEVICE|Hylan G-F 20|
48384085|NCT06122779|DRUG|BMS-986435|Specified dose on specified days
48384086|NCT06122779|OTHER|Placebo|Specified dose on specified days
48384087|NCT04170569|BEHAVIORAL|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
48384088|NCT05061459|GENETIC|circANKRD36 as a new biomarker|expression levels of circANKRD36 in the development and progression of DN
48384089|NCT02903095|DRUG|TD-1439|
48384090|NCT02903095|DRUG|Placebo|
48384091|NCT06649695|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
48384092|NCT05870566|DEVICE|Corneal Crosslinking|"Riboflavin isotonic, 0,1 % Vitamin B2, with Dextran 20,0%, for epi-off procedure or Riboflavin isotonic 0,1% (Vitamin B2), 1,1% HPMC without Dextran for epi-off) 0.1% riboflavin-5-phosphate and 20% dextran T-500) will be applied to the cornea after epithelial debridement every 2 min for 10 minutes before irradiation and every 2 minutes during the course of a 10 minute exposure to 365 nm UV-A with an irradiance rate of 9 mW/cm2. This dose, mode and scheme of the intervention follows the internationally recognized accelerated CXL protocol (Elbaz et al. 2014). The data existing shows equivalent outcome regarding efficacy and safety compared to the standard protocol. To avoid any damage to the limbal stem cells, the limbus will not be irradiated during the procedure, as a CXL device (with maximal diameter of 11 mm) will be used. Furthermore, the limbal area will additionally be protected by a custom-cut LSC protection shield. (Protocol V04_0 Page 45-46)"
48384093|NCT06651671|PROCEDURE|Myofascial release|THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.
48384094|NCT06651671|PROCEDURE|Sham (No Treatment)|The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
48384095|NCT05805293|DEVICE|High-Velocity Nasal Insufflation Therapy|"Parameter settings for the HVNI apparatus are as follows:~1. The flow of HVNI will initially be set at 30-40 L/min, and inspiratory flow rate could be increased to 45-60 L/min.~2. FIO2 will be adjusted to maintain a SaO2 more than 90 % and relative humidity of 30-34%.~3. Temperature range of 35-37°C."
48384096|NCT05805293|DEVICE|Non-Invasive Ventilation|Patients will be put on inspiratory/expiratory pressure 10/5 cmH2O (11). The inspiratory and expiratory pressures will be titrated with increments of 2 cmH2O based on improvement of oxygen saturation by continuous pulse oximetry and arterial blood gases values, alleviation of dyspnea and a decrease of respiratory rate and heart rate. The maximum allowed inspiratory pressure was 20 cm H2O. The maximum allowed expiratory pressure was 10 cm H2O.
48721218|NCT02340390|DEVICE|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
48721219|NCT02340390|DEVICE|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
48721220|NCT03832608|OTHER|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
48721221|NCT00160654|DRUG|Levetiracetam|"* Pharmaceutical form: oral tablets~* Concentration: 500 mg~* Route of administration: Oral use"
48721222|NCT05378295|DIETARY_SUPPLEMENT|Fermentable oligosaccharide|Supplementation period 12 weeks
48025496|NCT00726531|BEHAVIORAL|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
48025497|NCT00726531|BEHAVIORAL|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
48025498|NCT00726531|OTHER|Treatment As Usual|Treatment as usual by the general practitioner
48025499|NCT02852213|DRUG|AAV2-hAADC|Initially, subjects will be enrolled sequentially into 2 dose groups. 3 subjects will be enrolled in Cohort 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as infusate volume of up to 160μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Cohort 2 may commence after the last subject in Cohort 1 is treated and followed through Month 3 post-op, with approval of the data safety monitoring board (DSMB). Cohort 2 will receive a higher dose (4.2 x 10\^11 vg, 160 uL). Upon DSMB review of Cohort 1/2 results, Cohort 3 (4-12 yo) and 4 (aged \>/= 13 yo) will be dosed (1.6 x 10\^12 vg, 60uL) in 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 will follow (aged 24-47 months) at 1.3 x 10\^12 vg, 500uL. Final safety and clinical outcome assessments will be performed 1 year post-surgery. Follow-up analysis will be performed for 2 years post-op. Subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.
48025500|NCT02199847|DRUG|Pharmaton® Caplets|
48025501|NCT02199847|DRUG|Placebo|
48025502|NCT04018027|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
48025503|NCT04018027|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
48025504|NCT04018027|DRUG|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
48025505|NCT04018027|DRUG|Placebo|Oral Placebo administered twice daily
48384097|NCT03771391|DIETARY_SUPPLEMENT|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
48721223|NCT05378295|DIETARY_SUPPLEMENT|Personalized fiber mixture|Supplementation period 12 weeks
48721224|NCT05335902|DIAGNOSTIC_TEST|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
48384098|NCT00860054|DIETARY_SUPPLEMENT|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
48384099|NCT06445725|BEHAVIORAL|Acceptance Based Coping (ABaCo)|The educational ABaCo protocol consists of core Acceptance \& Commitment Therapy (ACT) interventions, culturally and contextually-tailored for this population, and in accordance with clinician-led versions of ACT for diabetes to include (a) identification of patient values, (b) teaching acceptance and brief mindfulness skills, and (c) techniques for engaging in valued activities while coping with difficult experiences (e.g., sugar cravings, distress). It is delivered by a community health worker (promotor/a) over 6 consecutive weeks over the phone, followed by a booster call at week 10.
48384100|NCT03895827|BEHAVIORAL|Recovery Initiation and Management after Overdose (RIMO)|RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.
48384101|NCT03895827|OTHER|Passive Referral to Treatment Control|Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
48384102|NCT01433029|OTHER|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
48384103|NCT01433029|OTHER|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
48384104|NCT01371981|DRUG|Asparaginase|Given IM
48520258|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
48520259|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
48520260|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
48520261|NCT01289483|DRUG|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
48520262|NCT00145951|BEHAVIORAL|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
48520263|NCT02312414|DRUG|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
48520264|NCT02257281|DEVICE|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
48384105|NCT01371981|DRUG|Bortezomib|Given IV
48520265|NCT02257281|DEVICE|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
48028978|NCT01136291|OTHER|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
48384106|NCT01371981|DRUG|Cytarabine|Given IT or IV
48384107|NCT01371981|DRUG|Daunorubicin Hydrochloride|Given IV
48384108|NCT01371981|DRUG|Etoposide|Given IV
48384109|NCT01371981|OTHER|Laboratory Biomarker Analysis|Correlative studies
48384110|NCT01371981|DRUG|Mitoxantrone Hydrochloride|Given IV
48384111|NCT01371981|OTHER|Pharmacological Study|Correlative studies
48028979|NCT05369234|DIETARY_SUPPLEMENT|100% Aloe Vera Juice|George's 100% Aloe Vera Liquid Supplement
48028980|NCT05369234|COMBINATION_PRODUCT|Magic Mouthwash|Magic Mouthwash
48384112|NCT01371981|OTHER|Quality-of-Life Assessment|Ancillary studies
48384113|NCT01371981|OTHER|Questionnaire Administration|Ancillary studies
48384114|NCT01371981|DRUG|Sorafenib Tosylate|Given PO
48388058|NCT05451407|DRUG|Toripalimab injection|Monoclonal antibody against Programmed death factor receptor 1
48388059|NCT03147040|DRUG|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
48520266|NCT03093701|DRUG|TLC399 (ProDex)|2-vial system: TLC399-DSP and TLC399-Lipid
48520267|NCT04389372|BEHAVIORAL|Mindfulness|Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
48520268|NCT00987532|BEHAVIORAL|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
48520269|NCT00987532|BEHAVIORAL|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
48520270|NCT01807065|BIOLOGICAL|sipuleucel-T|Given IV
48721225|NCT05335902|DIAGNOSTIC_TEST|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
48721226|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
48721227|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
48721228|NCT00996346|DRUG|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
48721229|NCT05474534|DEVICE|Neurofeedback (MUSE 2)|During each at-home treatment session, mothers will place the MUSE 2 on their heads and connect it to the app on their personal device. Their brain activity is monitored by the MUSE 2 and is represented on the app through audio-based feedback (e.g., birds chirping, sounds of waves lapping on the beach) that mothers will listen to with earbuds as they direct their focus on maintaining a calm state of mind during the session; when a calm state is maintained, they are rewarded with calming sounds. The goal is to gain increased conscious control over their own brain activity. The audio feedback, primarily composed of nature-based sounds, is meant to guide their brain activity into a calm state. The session will begin, and the MUSE 2 will provide audio feedback in real time to guide their brainwave activity into an optimal frequency bandwidth range (e.g., as their brain activity reaches the target state, sounds of wind would subside to peaceful waves or other rewarding audio feedback).
48721230|NCT04517838|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tumor tissue samples
48721231|NCT00906269|DRUG|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
48721232|NCT00906269|DRUG|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
48721233|NCT02559414|DRUG|Aspirin|
48182692|NCT04530604|DRUG|Defibrotide|"All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~* Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~* Patients who have not responded to study therapy by day 7 of therapy, evidenced by \<20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~* Patients who have evidence of a partial pulmonary response by day 7 (\>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course)."
48721234|NCT02559414|DRUG|Clopidogrel|
48721235|NCT04403243|DRUG|Colchicine|0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.
48721236|NCT04403243|DRUG|Ruxolitinib 5 MG|Ruxolitinib - 5mg twice a day per os for ten days
48721237|NCT04403243|DRUG|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Secukinumab - 300mg subcutaneously singly
48384116|NCT06634680|PROCEDURE|Procedure: Selection of parent(mother or father) according to children preference|Children will choose the parent who will accompany them.
48384117|NCT06634680|PROCEDURE|Procedure: Both parents will accompany the children.|Both parents will accompany the children.
48384118|NCT06653530|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed using polyglycolic acido thread. Needles have a gauge size of 23G, a shaft length of 60mm, and a thread length of 50mm, folded in half, and are applied to fourteen acupoints, including Zhongwan (CV12), Qihai (CV6), bilateral Tianshu (ST 25), bilateral Wailing (ST 26), bilateral Daheng (SP 15), bilateral Zusanli (ST 36), bilateral Pishu (BL 20), and bilateral Weishu (BL 21). After the thread is inserted into the body, the needle will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
48384119|NCT06653530|OTHER|Sham thread embedding acupuncture|The protocol includes the same duration and frequency of sessions as for thread embedding acupuncture, but the treatment will be delivered superficially at non-acupuncture points 10mm from the lateral of the corresponding acupuncture and not above a meridian line. Needles without threads have a gauge size of 23G, and a shaft length of 60mm will be used. After the needle is inserted into the body, it will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
48384120|NCT00869726|DRUG|dirucotide|500mg, intravenous, dosed once every six months for 18 months
48384121|NCT00869726|DRUG|Placebo|intravenous, once every six months for 18 months
48721238|NCT04403243|OTHER|standard therapy|standard therapy for COVID 19
48520271|NCT01807065|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
48721239|NCT04921059|DIAGNOSTIC_TEST|Active Stand|The participant is asked to lie down for 10 mins without moving or speaking. A heart rate monitor is attached while the participant is lying down. They are then asked to stand up as quickly as possible and to remain standing unassisted for 3 minutes. The participant will be asked to describe any symptoms at 1 and 3 minutes after standing. Blood pressure and heart rate will be monitored constantly throughout the test.
48520272|NCT01807065|OTHER|laboratory biomarker analysis|Correlative studies
48721240|NCT00158912|DEVICE|Implantable Cardioverter Defibrillator|
48721241|NCT06077370|DEVICE|deep TMS|Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
48182693|NCT03387813|DEVICE|CardioMEMS™ HF System|The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
48384122|NCT04698252|RADIATION|Radiotherapy|Radiation therapy for oligometastatic sites
48384123|NCT04698252|PROCEDURE|Surgery|Surgery for oligometastatic sites
48384124|NCT04698252|OTHER|Radiofrequency ablation|Radiofrequency ablation for oligometastatic sites
48025506|NCT04352010|BEHAVIORAL|Res-Up!|Res-Up! is an internet-based intervention focusing on patients' strengths and positive experiences that have effects on distress, protective factors and quality of life. The intervention is based on the Personal Model of Resilience (PMR; Padesky and Mooney, 2012), which is a positive intervention that utilizes patients' strengths to overcome problems.The PMR activates resilient emotions, thoughts, metaphors, images and behaviors in four steps during five sessions about the aquisition of resilient strategies and their use in daily life. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Positive Therapy etc.) are integrated in the program. Participants should work through one module per week. The intervention is conducted as I-CBT via the platform Minddistrict.Res-Up! is administered as a standalone or an add-on treatment to psychotherapy.
48384125|NCT00327080|PROCEDURE|MRI|
48384126|NCT00327080|DRUG|L-NMMA|
48384127|NCT00327080|DRUG|Acetylcholine|
48384128|NCT04298008|DRUG|AZD6738|AZD6738 (240 ) mg bid on D15-D28 Every 4 weeks
48520273|NCT00379392|BEHAVIORAL|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
48520274|NCT00379392|PROCEDURE|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
48520275|NCT05675098|DRUG|Methylphenidate|This medication is a psychostimulant medication and is usually prescribed for individuals with Attention-Deficit/Hyperactivity Disorder to manage ADHD behavioral symptoms
48520276|NCT05675098|DRUG|Modafinil|This medication is a Central Nervous System stimulant and is usually used to treat neurological conditions, including Narcolepsy
48721242|NCT06077370|DEVICE|Sham TMS|Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
48721243|NCT00491920|DRUG|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~+ calcium 500 mg/cholecalciferol 400 IU x2/d"
48025507|NCT04352010|BEHAVIORAL|REMOTION|REMOTION is an internet-based intervention aimed at transdiagnostically reducing symptom severity and improving emotion regulation of psychotherapy patients. The structure of REMOTION is based on the idea of an extended process model of emotion regulation as postulated by J.J. Gross (2015). The program includes the following modules: introduction, psychoeducation, identification, selection, implementation and modification. A variety of elements based on different psychotherapy approaches (Cognitive Behavioral Therapy, Emotion Focused Therapy, Dialectical Behavior Therapy etc.) are integrated in the program. Participants should work through one module per week. REMOTION is administered as a standalone or an add-on treatment to psychotherapy.
48025508|NCT04352010|OTHER|Wait-Control Group|In the waiting control group participants will answer questionnaires and they will gain access to either REMOTION or Res-Up! after twelve weeks.
48520277|NCT05675098|OTHER|Placebo|Participant will receive placebo tablets (Methylphenidate and Modafinil shape)
48721244|NCT00491920|DRUG|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
48182694|NCT01514851|DRUG|Lanthanum carbonate (BAY77-1931)|
48182695|NCT01514851|DRUG|Calcium carbonate|
48182696|NCT04901832|OTHER|Intradialytic stretching exercises|Exercises performed actively and passively to reduce or prevent muscle cramps during hemodialysis procedure.
48182697|NCT02704013|DRUG|Oxybutynin|Anticholinergic
48384129|NCT04298008|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
48384130|NCT01408836|PROCEDURE|Plasma exchange|Plasma exchange
48384131|NCT01408836|DRUG|Intravenous methyl prednisolone|Intravenous methyl prednisolone
48721245|NCT02700165|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device will be used to perform the treatments.
48721246|NCT00277394|DRUG|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
48384132|NCT01408836|DRUG|Methyl prednisolone|methyl prednisolone
48384133|NCT05467748|DRUG|Tulmimetostat|combination of oral tazemetostat and intravenous pembrolizumab treatment for patients with advanced non-small cell lung cancer
48384134|NCT01650142|OTHER|No intervention|No intervention
48384135|NCT05251779|DRUG|Volatile Oil of Cang-Ai|The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation
48384136|NCT05251779|DRUG|Bergamot essential oils|The control group will be given Bergamot essential oils for inhalation.
48384137|NCT04205292|PROCEDURE|hysteroscopic|Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
48520278|NCT03995277|DIETARY_SUPPLEMENT|Biotin|Daily intake of 10 mg or 50 µg per day
48721247|NCT00277394|DRUG|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
48721248|NCT04772144|BEHAVIORAL|behavioural and cessation aids|information, motivational interview, refferal to healty life-centers, free cessation aids
48721249|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
48721250|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
48721251|NCT01278589|DIETARY_SUPPLEMENT|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
48721252|NCT01278589|DIETARY_SUPPLEMENT|Placebo|Liquid (80g) without Plantago asiatica L. extract
48721253|NCT02753634|BEHAVIORAL|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
48721254|NCT00490022|DRUG|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
48520279|NCT00836407|DRUG|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
48520280|NCT00836407|BIOLOGICAL|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
48721255|NCT00490022|DRUG|Placebo gel|Placebo gel for one month
48721256|NCT04867694|BEHAVIORAL|BCC|Behavior change communication on Nutrition, Health \& Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.
48721257|NCT04867694|DIETARY_SUPPLEMENT|Preventive supplement|Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to \[6-11\] months old children diagnosed as non-wasted (green MUAC); or children \[12-59\] months old for 6 months after discharge from a CMAM treatment or consolidation program.
48721258|NCT04867694|DIETARY_SUPPLEMENT|MNP|Delivery of micronutrient powders to \[12-23\] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).
48721259|NCT04867694|OTHER|Water purification input|Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with \[6-11\] months old children, or children \[12-59\] months old enrolled in a CMAM treatment program and for 6 months after discharge.
48721260|NCT04867694|BEHAVIORAL|Family MUAC|"One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with \[6-59\] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family.~Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary."
48721261|NCT04867694|BEHAVIORAL|Screening by care group|"Monthly screening by the care group volunteers of the children they follow, using the MUAC.~Referral to the health center of \[6-59\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled"
48721262|NCT04867694|BEHAVIORAL|CMAM compliance|"Weekly follow-up of \[6-59\] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits.~They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day)."
48721263|NCT03606772|OTHER|Questionanniare|Filling printed questionnaire + Pelvic examination
48721264|NCT02554708|DEVICE|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
48721265|NCT04464525|DRUG|Omecamtiv mecarbil|Film-coated tablet administered orally.
48721266|NCT02195804|DRUG|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
48721267|NCT02195804|DRUG|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
48721268|NCT02195804|DRUG|Ranitidine hydrochloride|
48721269|NCT03899792|DRUG|LOXO-292|Oral LOXO-292
48721270|NCT02478580|DRUG|Nuvigil|Patients will receive Nuvigil before the surgery
48025509|NCT04118621|DEVICE|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
48025510|NCT06529328|OTHER|core stability|"In this study the experimental group will perform core stability exercises 3 times per week for an 8-week period and each session of 30 to 45 minutes, the core stability exercises will work on abdominals and trunk muscles with challenges.Subjects received 25 min conventional therapy in addition to 30 30-minute trunk stabilization exercise program conducted for 3 days\\week on non-consecutive days.~Passive stretching exercises are applied to all tight muscles, including the hamstrings and calf muscles in the lower limb. It is performed five times initially, building up to ten repetitions, stretching for 5 times, and then allowing relaxation for 5time. Strengthening exercises for back, hip, and knee extensor muscles (for 10 minutes)."
48025511|NCT02348216|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
48025512|NCT02348216|DRUG|Fludarabine|Administered according to package insert
48025513|NCT02348216|DRUG|Cyclophosphamide|Administered according to package insert
48025514|NCT02348216|DRUG|Levetiracetam|Administered according to package insert
48025515|NCT02348216|DRUG|Tocilizumab|Administered according to package insert
48025516|NCT02348216|DRUG|Dexamethasone|Administered according to package insert
48025517|NCT02348216|DRUG|High-dose methylprednisolone|Administered according to package insert
48182698|NCT01795599|DRUG|Mifegyne ®|
48520281|NCT05883124|DRUG|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
48721271|NCT02478580|DRUG|Placebo|Placebo will be given before surgery
48721272|NCT02481713|BEHAVIORAL|motivational interviewing|motivational interviewing
48721273|NCT02481713|BEHAVIORAL|learning style interviews|interview and feedback about learning style
48721274|NCT04516551|BIOLOGICAL|anti-CD19 allo-CAR-T cells|The T cells collected from haploidentical donors have been manufactured to express CAR to binding CD19 on B-cell leukemia.
48721275|NCT03968783|OTHER|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
48721276|NCT03968783|OTHER|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
48025518|NCT02348216|DRUG|Bendamustine|Administered according to package insert
48721277|NCT03825159|DEVICE|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
48721278|NCT03825159|DEVICE|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
48721279|NCT02613169|DRUG|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
48721280|NCT01307293|BEHAVIORAL|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
48721281|NCT05530889|DEVICE|TEST Lens|ACUVUE® Theravision® with Ketotifen
48182699|NCT01795599|DRUG|Gymiso®|
48520282|NCT05883124|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
48520283|NCT05574361|DEVICE|Hypothermic Machine Perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
48520284|NCT05987852|DEVICE|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
48721282|NCT05530889|DEVICE|CONTROL Lens|1-DAY ACUVUE® MOIST.
48721283|NCT04001972|BEHAVIORAL|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
48721284|NCT04001972|DRUG|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette \<30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette \>30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
48025519|NCT02348216|DRUG|Rituximab|Administered according to package insert
48025520|NCT02348216|DRUG|Doxorubicin|Administered according to package insert
48025521|NCT02348216|DRUG|Prednisone|Administered according to package insert
48025522|NCT02348216|DRUG|Vincristine|Administered according to package insert
48025523|NCT02348216|DRUG|Ifosfamide|Administered according to package insert
48025524|NCT02348216|DRUG|Carboplatin|Administered according to package insert
48721285|NCT04001972|BEHAVIORAL|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
48520285|NCT05987852|OTHER|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
48721286|NCT04001972|BEHAVIORAL|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
48721287|NCT00754091|DEVICE|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
48721288|NCT05018741|PROCEDURE|liver transplantation|liver transplantation for chronic liver disease or acute liver failure
48721289|NCT04927793|DRUG|EDP-938|\[14C\]EDP-938
48721290|NCT01448005|DEVICE|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
48721291|NCT03848767|DEVICE|AID System|AID System
48721292|NCT03848767|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
48721293|NCT01055483|DRUG|panobinostat/LBH589B|
48721294|NCT04140981|DEVICE|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
48721295|NCT03908827|BIOLOGICAL|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
48721296|NCT05297526|BEHAVIORAL|Culturally adapted children's book|Tribe-specific children's book celebrating tribal culture with an embedded oral health message
48721297|NCT05297526|BEHAVIORAL|Standard informational brochure on children's oral health|Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
48721298|NCT04400929|DRUG|Sargramostim|Dosage for IV Leukine® injection: 125mcg/m2/day over a 4-hour period for up to 5 days.
48721299|NCT04400929|OTHER|Normal Saline 0.9%|IV normal saline 0.9% for 5 days
48721300|NCT05869500|DEVICE|Left Bundle Branch Area Pacemaker|Implantation of Medtronic 3830 lead for left bundle branch area pacing
48721301|NCT05869500|DEVICE|Right Ventricular Pacemaker|Implantation of a conventional right ventricular pacemaker lead
48721302|NCT00708760|BEHAVIORAL|paper based training|read selected material, test skills learned in simulator lab
48721303|NCT00708760|BEHAVIORAL|web based training|read and view selected web based material, test skills learned in simulator lab
48721304|NCT00076518|DRUG|Fenofibrate|
48721305|NCT00076518|DRUG|Fish Oil|
48721306|NCT05549375|DEVICE|MyHand System Hand Rehabilitation|15 1-hour patient specific sessions using the MyHand System to help improve Hand function in the affected hand of stroke survivors
48721307|NCT04246723|DRUG|Narlaprevir|100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
48721308|NCT04246723|DRUG|Ritonavir|100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
48721309|NCT04246723|DRUG|Sofosbuvir|"400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle."
48721310|NCT04186247|DRUG|Azithromycin|Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
48721311|NCT04186247|DRUG|Metronidazole|Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
48721312|NCT04186247|OTHER|Standard of Care|SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
48721313|NCT00697294|DIETARY_SUPPLEMENT|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
48721314|NCT04578925|BEHAVIORAL|Happy, Healthy, Loved|A text message based, mobile-device delivered intervention that provides educational information to primiparous mothers and their partners about breast-feeding and coping with stress.
48721315|NCT00664326|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
48721316|NCT01370759|OTHER|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
48721317|NCT02901652|DEVICE|noninvasive respiratory support devices|
48721318|NCT03987386|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48721319|NCT03987386|OTHER|Quality-of-Life Assessment|Ancillary studies
48721320|NCT03987386|OTHER|Questionnaire Administration|Ancillary studies
48721321|NCT03987386|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
48721322|NCT02963701|DRUG|Ibuprofen|Fixed dose combination
48721323|NCT02963701|DRUG|Pseudoephedrine-HCl|Fixed dose combination
48721324|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
48721325|NCT03840343|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
48721326|NCT00435526|BIOLOGICAL|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
48721327|NCT01264614|BEHAVIORAL|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
48721328|NCT06508879|COMBINATION_PRODUCT|Aquacel Ag Surgical®|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
48721329|NCT06508879|OTHER|Standard Care (sterile gauze and adhesive tape)|Presurgical preparation was identical in both groups and no further intervention in patient treatment was made. See descpription of arms.
48721330|NCT01300988|DRUG|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
48721331|NCT01300988|DRUG|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
48721332|NCT03623061|DIAGNOSTIC_TEST|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
48721333|NCT02418104|DRUG|CHS-1701|
48721334|NCT02418104|DRUG|Pegfilgrastim (Neulasta)|
48721335|NCT03224065|DIAGNOSTIC_TEST|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
48721336|NCT01207089|DRUG|AZD8329|AZD8329 Oral Solution 20mg/ml
48721337|NCT01207089|DRUG|Placebo|Placebo AZD8329 Oral Solution
48721338|NCT02134288|DRUG|Belatacept|
48721339|NCT02134288|DRUG|Everolimus|
48721340|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - ALS|"ALS patients will be administered the following TBCS tests:~* ALS Cognitive Behavioral Screen-Phone Version;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~This group will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Caregiver Behavioral Questionnaire;~* ECAS-Carer Interview."
48721341|NCT06337578|BEHAVIORAL|Telephone-based neuropsychological assessment - AD, LBD, FTD and CVD|"AD, DLB, FTD and CVD patients will be administered the following TBCS tests:~* Telephone Interview for Cognitive Status;~* Telephone-based Frontal Assessment Battery;~* Telephone Language Screener;~* Telephone-based Verbal Fluency Battery;~These groups will also undergo a telephone-based, caregiver-reported behavioral and functional assessment via the following scales:~* Activities of Daily Living;~* Instrumental Activities of Daily Living;~* Amsterdam IADL Questionnaire - Short Version;~* Neuropsychiatric Inventory;~* Frontal Behavioural Inventory."
48721342|NCT06337578|BEHAVIORAL|Telephone-based and in-person cognitive screening - NIs|"NIs will undergo the Telephone Interview for Cognitive Status over the telephone and will be additionally administered, in person, the following cognitive screeners:~* Mini-Mental State Examination~* Montreal Cognitive Assessment~* In-Person Telephone Interview for Cognitive Status in person."
48721343|NCT05827601|DIAGNOSTIC_TEST|respiratory specimen|participants will perform self-sampling with a nasopharyngeal swab
48025525|NCT02348216|DRUG|Etoposide|Administered according to package insert
48025526|NCT02348216|DRUG|Gemcitabine|Administered according to package insert
48025527|NCT02348216|DRUG|Oxaliplatin|Administered according to package insert
48025528|NCT02348216|DRUG|Cisplatin|Administered according to package insert
48025529|NCT02348216|DRUG|Methylprednisolone|Administered according to package insert
48025530|NCT03171025|DRUG|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
48025531|NCT00131157|PROCEDURE|expert support for interpretation of spirometry|
48025532|NCT05748028|OTHER|Rehabilitation|All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.
48025533|NCT05748028|OTHER|Administration of Clinical scales|All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.
48721344|NCT05827601|DIAGNOSTIC_TEST|serum|participants will be invited to get a blood sample taken by a general practitioner or to perform a self sampling of capillary blood
48721345|NCT01699074|DIETARY_SUPPLEMENT|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
48721346|NCT01699074|DIETARY_SUPPLEMENT|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
48721347|NCT01699074|DIETARY_SUPPLEMENT|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
48384138|NCT06396247|BEHAVIORAL|Functional Activity Strength Training|FAST consists of five exercises (stepping on a step, chair stands, push-ups, rows, walking), for 30 seconds each, performed daily, with 30 seconds of rest between.
48384139|NCT02058264|DRUG|BBI-4000|
48721348|NCT01699074|DIETARY_SUPPLEMENT|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
48721349|NCT01699074|DIETARY_SUPPLEMENT|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
48721350|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
48721351|NCT01120795|DRUG|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
48721352|NCT03897530|BEHAVIORAL|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
48721353|NCT03897530|OTHER|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
48025534|NCT00977041|BEHAVIORAL|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
48384140|NCT02105207|OTHER|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
48384141|NCT02105207|OTHER|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
48384142|NCT06586658|BIOLOGICAL|anti-CD70-CAR-T cells|The subjects received infusions of anti-CD70 CART cells following completion of lymphodepleting preconditioning chemotherapy. Dosage: 3×10\^6 cells/Kg; 1×10\^7 cells/Kg; 2×10\^7 cells/Kg.
48721354|NCT03897530|OTHER|Questionnaire Administration|Ancillary studies
48721355|NCT02299076|BEHAVIORAL|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
48721356|NCT02299076|OTHER|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
48721357|NCT02435706|PROCEDURE|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
48025535|NCT04481256|RADIATION|External beam radiotherapy|External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy
48384143|NCT01854125|BIOLOGICAL|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
48384144|NCT01854125|BIOLOGICAL|autologous bone marrow msenchymal stem cells transplantation|
48388060|NCT03147040|DRUG|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
48721358|NCT02435706|PROCEDURE|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
48721359|NCT02435706|DEVICE|Implant and temporary crown|Both groups receive this intervention
48721360|NCT04548362|OTHER|Meat arm|Randomised sequence of pork, beef, chicken meat, and an egg white/pea combination
48721361|NCT04548362|OTHER|Starchy foods arm|Randomised sequence of boiled potato, fried potato, potato crisps, and boiled white rice
48721362|NCT05130476|PROCEDURE|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
48721363|NCT02196428|OTHER|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
48384145|NCT06468007|DRUG|Methylprednisolone Tablet|Patients receiving equipotent doses of methylprednisolone or prednisolone . Dosages will be determined at the discretion of the treating physician, customized for the specific clinical need in accordance with local guidelines.
48721364|NCT00544622|PROCEDURE|structured therapeutic chain of stroke treatment|
48384146|NCT04650178|OTHER|Quality-of-Life Assessment|Ancillary studies
48721365|NCT05454826|OTHER|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
48721366|NCT05454826|OTHER|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
48384147|NCT04650178|OTHER|Questionnaire Administration|Complete questionnaire
48721367|NCT05377736|GENETIC|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
48721368|NCT02938273|DRUG|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
48721369|NCT02938273|RADIATION|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
48721370|NCT02938273|DRUG|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
48384148|NCT01114386|PROCEDURE|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography"
48721371|NCT01480011|DRUG|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
48721372|NCT03826823|DEVICE|HSG cannula|a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
48025536|NCT04481256|DRUG|Bintrafusp alfa|Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.
48025537|NCT04481256|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
48025538|NCT04481256|DRUG|Carboplatin|Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.
48025539|NCT05902195|BEHAVIORAL|Personal Resource Building and Inclusive Volunteering Intervention (PVI)|PVI is a 6-week virtual programme aimed at building up young stroke survivors' personal resources for work through engaging in inclusive volunteering activities.
48025540|NCT05902195|OTHER|Usual care|Usual stroke care services include medical and health services offered by the hospitals or community-based organisations.
48025541|NCT03058731|DEVICE|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
48025542|NCT03058731|DEVICE|Control|Paraesophageal hernia repair with other biologic mesh
48025543|NCT02761564|OTHER|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
48025544|NCT02761564|OTHER|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
48025545|NCT02992639|BEHAVIORAL|Control group|The participants who included in control group did not receive any treatment.
48384149|NCT02628821|OTHER|Preterm Infants treated with non-invasive ventilation.|
48384150|NCT05517707|DEVICE|Nasogastric Tube|Temperature and impedance data will be collected from sensors embedded within the feeding tube wall.
48520286|NCT05015829|DIAGNOSTIC_TEST|Dobutamine Stress Echocardiography|Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.
48520287|NCT03295955|DRUG|Amoxicillin Clavulanate|"Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery"
48520288|NCT04151680|DRUG|Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive intermittent treatment with a novel oral anticoagulant drug
48520289|NCT04151680|DRUG|Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive chronic treatment with a novel oral anticoagulant drug
48520290|NCT04338360|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
48025546|NCT02992639|BEHAVIORAL|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
48384151|NCT05898022|DRUG|Furosemide (plus potassium chloride)|Furosemide is a loop diuretic that inhibits the reabsorption of sodium and chloride in the proximal and distal tubules as well as the loop of Henle. Participants will receive 2 mg/kg enteral furosemide daily during treatment periods when they receive study drug. To prevent hypokalemia and hypochloremia associated with furosemide use, participants will also receive 1 mg/kg of potassium chloride enterally twice per day when receiving furosemide. Each patient will have 14 days of total exposure to furosemide over the 28-day N-of-1 trial.
48384152|NCT05898022|DRUG|Placebo (plus placebo electrolyte solution)|During treatment periods when participants receive placebo, they will receive a volume of sterile water equivalent to the study drug dose. Participants will also receive a placebo electrolyte solution equivalent to the volume of potassium chloride that would be given.
48384153|NCT02352116|OTHER|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
48384154|NCT02352116|OTHER|Standard of care management|Current standard of care at a major U.S. teaching hospital.
48384155|NCT00449761|DRUG|LBH589|
48384156|NCT02098707|OTHER|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
48384157|NCT06164886|OTHER|Waiting list|patient on the waiting list for scheduled surgical admissions
48384158|NCT06615635|DEVICE|DaRT seeds|Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients
48721373|NCT05351268|RADIATION|Radioactive seed brachytherapy|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
48384159|NCT06035094|BEHAVIORAL|Exercise Intervention to improve overall Brain Health|"During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session."
48384160|NCT06647576|DEVICE|Spinal Cord Stimulation - In Clinic|Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.
48520291|NCT04352101|DRUG|Bupropion XL|Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
48520292|NCT04352101|DRUG|Escitalopram|Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
48520293|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
48520294|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
48520295|NCT06028295|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
48721374|NCT03837288|PROCEDURE|Cerclage|Cervical cerclage under effect of spinal anaesthesia
48721375|NCT03891914|DRUG|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
48721376|NCT03891914|DRUG|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
48721377|NCT01906112|PROCEDURE|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
48025547|NCT01762761|DRUG|eltrombopag|TPO-R agonist
48025548|NCT01762761|DRUG|placebo|placebo
48025549|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a phospholipid|A shake with 3000 mg choline added as a phospholipid
48520296|NCT00422110|DRUG|Seletracetam|
48520297|NCT01439581|DEVICE|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
48520298|NCT01439581|DEVICE|Non-Mapping System|Standard ICU bed with no mapping system
48520299|NCT02573961|DEVICE|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
48520300|NCT02573961|BEHAVIORAL|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
48520301|NCT02573961|BEHAVIORAL|low caloric diet|Tailored balanced low caloric diet
48721378|NCT02090790|DRUG|iv dexamethasone|2 ml 8 mg iv dexamethasone
48384161|NCT06647576|DEVICE|Spinal Cord Stimulation - Neurosphere|Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
48384162|NCT03988049|DEVICE|1,550 fracionated photothermolysis laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
48721379|NCT02090790|DRUG|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
48721380|NCT02090790|DRUG|serum physiologic|2 ml iv serum physiologic
48721381|NCT03079856|BEHAVIORAL|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a \~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
48721382|NCT04087161|OTHER|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
48721383|NCT05088668|OTHER|Augmented reality|"The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement."
48721384|NCT05088668|OTHER|Scapular repositioning exercise|Subjects will perform scapular repositioning exercises for improving scapular movement.
48721385|NCT02125565|OTHER|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
48721386|NCT05218226|DRUG|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
48721387|NCT01030614|DRUG|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
48721388|NCT01030614|DRUG|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
48721389|NCT05729906|OTHER|psychological and physical tests|"Once included (T0), participants will be reviewed at 6 (T1), and 12 (T2) months. At the three measurement times, research professionals (belonging to the PAVeA laboratory) will carry out, within the nursing home the physical and psychological measurements (classic standardized tests for the population). These measurements will be carried out in parallel with the routine biological explorations performed in the institution.~At each visit, the remaining blood sampled in routine will be frozen in 2 aliquots for metabolomic and spectrometric analyses at the end of the study by the iBrain and Research Center for Respiratory Diseases laboratories."
48721390|NCT00903331|DRUG|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
48721391|NCT00903331|DRUG|Placebo|matching placebo, once daily
48384163|NCT03988049|DEVICE|755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
48384164|NCT02714140|BEHAVIORAL|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
48384165|NCT02714140|BEHAVIORAL|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
48384166|NCT02714140|BEHAVIORAL|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
48384167|NCT02714140|BEHAVIORAL|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
48384168|NCT02714140|BEHAVIORAL|SMS Reminder|Participants will receive an SMS reminder to test.
48520302|NCT04914169|DEVICE|ICRS|The ICRS enables a stationary bike to automatically adjust the pedaling resistance (i.e. training intensity) according to the subject's heart rate. The training intensity is determined by monitoring whether the subject is able to maintain a 50-70 cycles/min cadence with 60-80% HRR. Subjects heart rate was detected by a wearable device for heart rate, synching with the stationary bike.
48721392|NCT05039658|DRUG|IBI110 plus sintilimab|Sintilimab is a NMPA approved high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
48025550|NCT03822169|DIETARY_SUPPLEMENT|Choline added as a salt|A shake with 3000 mg choline added as a salt
48025551|NCT02396641|OTHER|Best Supportive Care Checklist|
48025552|NCT04382794|DRUG|Retrospective case-control analysis|Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
48721393|NCT05039658|DRUG|IBI110|BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
48721394|NCT00106574|DRUG|Placebo|iv every 4 weeks
48721395|NCT00106574|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
48182700|NCT05796154|DEVICE|ear blood pressure monitor|The ear blood pressure monitor is a biometric monitoring device that collects blood pressure non-invasively from the ear.
48025553|NCT03731494|BIOLOGICAL|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
48025554|NCT00171977|DRUG|Imatinib Mesylate|
48182701|NCT04648826|DEVICE|AeroEclipse II Breath Actuated Nebulizer|Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.
48721396|NCT01818492|BIOLOGICAL|NI-0501|
48721397|NCT04463849|DIAGNOSTIC_TEST|Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection|"All participants will be subjected to the collection of glycemic data through continuous professional retrospective monitoring of blood glucose for seven days, positioned on the day the test will be performed. During the entire recording period, parameters such as mean glucose, estimated glycosylated hemoglobin, peak glucose and nadir, blood sugar levels above the limit of 140 mg / dL, average glucose values at 60 and 120 minutes after meals, standard deviation and variability coefficient.~The evaluation of insulin secretion will be evaluated by performing the stimulus test with arginine infusion according to validated protocols."
48721398|NCT02282904|DRUG|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
48025555|NCT03295201|OTHER|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
48025556|NCT03295201|OTHER|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
48025557|NCT03209908|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
48028981|NCT05369234|COMBINATION_PRODUCT|Salt and Baking soda rinse|Mouth rinse made with salt and baking soda
48182702|NCT04648826|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
48182703|NCT04648826|DRUG|Azacytidine|Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
48721399|NCT02282904|BIOLOGICAL|Donor peripheral blood stem cells.|Infuse donor graft.
48721400|NCT02282904|DRUG|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
48721401|NCT02282904|RADIATION|Total body 200cGy|Day -1
48182704|NCT02263040|BIOLOGICAL|Fluzone High-Dose|Influenza vaccine
48182705|NCT02263040|BIOLOGICAL|Fluzone (standard dose)|Influenza vaccine
48182706|NCT04670445|OTHER|Educational Video and QPL List|The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.
48182707|NCT04670445|OTHER|Usual Care|Surveys
48182708|NCT03180944|DRUG|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
48182709|NCT03180944|DRUG|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
48182710|NCT03180944|DRUG|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
48182711|NCT03180944|DRUG|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
48182712|NCT03180944|DRUG|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
48721402|NCT02282904|DRUG|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
48721403|NCT02282904|DRUG|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
48721404|NCT02282904|DRUG|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
48721405|NCT04897607|BEHAVIORAL|Standard Care|Participants will be advised to quit smoking and offered a choice of nicotine replacement patches or varenicline. Participants are free to decline medication.
48182713|NCT04417205|OTHER|Carbohydrate Rich Breakfast|Participants will be asked to consume the provided carbohydrate rich breakfast before 1000h daily for 28 days.
48182714|NCT04417205|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|Participants will be asked to consume the provided whey protein enriched breakfast before 1000h daily for 28 days.
48182715|NCT05980169|DEVICE|SensoniQ Treatment Station|The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
48721406|NCT04897607|BEHAVIORAL|Precision pharmacotherapy|Participants will be advised to quit smoking and provided a medication recommendation on the basis of their nicotine metabolite ratio (NMR) test (i.e., nicotine replacement patches for slower metabolizers, varenicline for faster metabolizers). Participants are free to choose either medication or decline any medication.
48721407|NCT03235219|DRUG|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
48721408|NCT03235219|DRUG|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
48721409|NCT05751148|DRUG|Hyperbaric bupivacaïne|Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution
48721410|NCT05751148|DRUG|Hyperbaric prilocaïne|Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne
48721411|NCT03710304|DRUG|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
48182716|NCT00824330|BEHAVIORAL|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
48384169|NCT06357065|OTHER|Active transport educational program based on the ecological model|The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
48384170|NCT03264001|BEHAVIORAL|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
48721412|NCT03710304|DRUG|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
48721413|NCT03710304|DRUG|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
48721414|NCT02741037|BEHAVIORAL|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
48721415|NCT02741037|BEHAVIORAL|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
48721416|NCT02741037|OTHER|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
48721417|NCT05556213|PROCEDURE|laparoscopic examination|laparoscopic examination for staging of endometriosis
48721418|NCT05556213|DIAGNOSTIC_TEST|Blood sampling|Blood sample to detect endometriosis
48025558|NCT03210506|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
48025559|NCT01748994|DRUG|Pioglitazone|30mg per day for four months
48025560|NCT01748994|DRUG|Placebo|
48025561|NCT00772174|DRUG|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
48028982|NCT05369234|DRUG|Carafate|Carafate taken as a slurry
48182717|NCT02605746|DRUG|ceritinib 750mg|
48182718|NCT00583271|DRUG|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
48182719|NCT00583271|DRUG|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
48182720|NCT01359839|BEHAVIORAL|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
48182721|NCT06444490|BEHAVIORAL|General Approach Instruction|Oral health instruction focused more broadly on the different topics of oral diseases and oral hygiene care.
48182722|NCT06444490|BEHAVIORAL|Personalised Technique Instruction|Oral health instruction based on the specific needs of each participant.
48721419|NCT02850900|BEHAVIORAL|Internet Survey|Weekly survey will be emailed, subjects should complete them
48721420|NCT05910333|OTHER|observation|To compare the effect of the mandibular implant retained OVD using quadrilateral distribution (QD) versus linear distribution (LD) on posterior mandibular ridge resorption (PMandRR), anterior maxillary ridge resorption (AMaxRR), and changes to the crestal bone level around implants after 10 years of function.
48721421|NCT00865085|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
48721422|NCT00865085|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
48721423|NCT02207257|DRUG|PER977|Reversal of edoxaban-induced anticoagulation
48182723|NCT03527498|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
48182724|NCT03527498|BEHAVIORAL|Physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
48520303|NCT04119362|OTHER|Quality of live questionnaires|EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
48721424|NCT02207257|DRUG|Placebo|Reversal of edoxaban-induced anticoagulation
48721425|NCT02207257|DRUG|Edoxaban|
48182725|NCT02960971|PROCEDURE|Thoracic surgery for lung cancer|Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
48182726|NCT03158909|DEVICE|Eyemask and earplugs|Eyemask and earplugs for use during the night, to improve sleep.
48182727|NCT03158909|OTHER|Orientation about space and time|Information and orientation about space and time, given every night.
48182728|NCT05683145|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
48182729|NCT04135612|OTHER|Smartphone based communication|Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
48182730|NCT02221999|DRUG|Paclitaxel|
48182731|NCT02221999|DRUG|Cisplatin|
48182732|NCT02221999|DRUG|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
48182733|NCT02221999|DRUG|Letrozole|
48182734|NCT02689453|BIOLOGICAL|IL-15 plus|Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.
48182735|NCT02689453|BIOLOGICAL|alemtuzumab|Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
48182736|NCT01164111|OTHER|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
48182737|NCT01498315|OTHER|Ultrasound examination|Ultrasound examination following hysterectomy
48182738|NCT04513353|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to total knee arthroplasty post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 3 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 3 to 12 weeks post surgery."
48182739|NCT04513353|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
48182740|NCT01453023|DRUG|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
48182741|NCT01453023|DRUG|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
48182742|NCT00575042|DRUG|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
48520304|NCT04119362|OTHER|Optional translational project|Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
48520305|NCT03719027|DIAGNOSTIC_TEST|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
48721426|NCT05771038|PROCEDURE|socket preservation using sodium alendronate gel|"sockets will be preserved by sodium alendronate gel before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
48721427|NCT05771038|PROCEDURE|socket preservation using sticky bone|"sockets will be preserved by sticky bone as mentioned before then Patients will be evaluated after 3 days and weekly thereafter for the first month and then once monthly for signs of soft tissue irritation.~After 3 months post-operative CBCT scans will be done to evaluate the bone density, alveolar crest bone height will be measured and core biopsy will be taken for Histomorphological study at the same visit where implant will be placed"
48721428|NCT01608373|DRUG|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
48721429|NCT01608373|DRUG|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
48721430|NCT01608373|DRUG|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
48721431|NCT03765203|DIAGNOSTIC_TEST|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
48721432|NCT03765203|OTHER|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
48384171|NCT04478188|OTHER|Measuring Pressure Volume Loop Pre and Post Device Placement|To measure simultaneous pressure and volume of the heart (pressure volumes loops) before and after ventricular assist device placement for cardiogenic shock (a severe form of heart failure) and before and after device removal.
48721433|NCT01113346|DRUG|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
48721434|NCT01113346|DRUG|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
48721435|NCT02759224|DRUG|BRI-1501|
48721436|NCT02759224|DRUG|Lafutidine|
48721437|NCT02759224|DRUG|Irsogladine maleate|
48721438|NCT02555605|DRUG|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg-1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg-1•h-1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg-1•h-1. In addition, propofol 0.5 mg.kg-1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
48721439|NCT04627285|DRUG|Lacosamide|"* Pharmaceutical form: Oral-solution~* Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period."
48721440|NCT02263261|OTHER|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
48721441|NCT03943849|OTHER|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
48721442|NCT03943849|OTHER|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
48721443|NCT03943849|OTHER|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
48721444|NCT03943849|OTHER|Suture|Resorbable or non-resorbable suture material
48721445|NCT01181024|DRUG|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
48520306|NCT01221207|DEVICE|Total Contact Cast|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
48520307|NCT01221207|DEVICE|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
48721446|NCT01181024|DRUG|RO5303253|Cohorts receiving single ascending doses
48520308|NCT01221207|DEVICE|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
48520309|NCT02342301|BEHAVIORAL|Standing Desk|Participants will be provided with a standing desk for 3 months
48721447|NCT01181024|DRUG|RO5303253|Single dose
48721448|NCT01181024|DRUG|RO5303253|Multiple doses
48182743|NCT05785065|DRUG|Mycophenolate Mofetil|"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
48384174|NCT03427827|DRUG|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
48384175|NCT01991600|DIETARY_SUPPLEMENT|ferrous sulphate|
48384176|NCT01991600|DIETARY_SUPPLEMENT|ferric iron oxide-organic acid (Fe-OA)|
48384177|NCT04182412|PROCEDURE|ARD|surgical reconstruction with laparoscopic technique
48384178|NCT02959372|OTHER|lung ultrasound|
48384179|NCT02959372|OTHER|placebo|lung ultrasound. The attending physician will not know the result
48520310|NCT02342301|BEHAVIORAL|Traditional Desk|Participants will use a traditional seated desk for 3 months
48520311|NCT04565574|DRUG|E7090|Oral tablet.
48520312|NCT04565574|DRUG|Rabeprazole 20 mg|Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
48520313|NCT04565574|DRUG|Rifampin 600 mg|Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
48721449|NCT01248871|DRUG|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
48721450|NCT01248871|DRUG|volatile agent only during reperfusion|Active Comparator
48721451|NCT01248871|DRUG|propofol-remifentanil/sufentanil|Active Comparator
48721452|NCT01070108|DRUG|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
48721453|NCT01070108|DRUG|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
48721454|NCT01070108|DRUG|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
48721455|NCT06287307|OTHER|Placebo|The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
48721456|NCT06287307|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
48721457|NCT06321939|DIAGNOSTIC_TEST|EBV-DNA next generation sequencing|EBV-DNA next generation sequencing
48721458|NCT04024423|OTHER|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
48721459|NCT02077543|DEVICE|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
48721460|NCT04670783|PROCEDURE|Surgery|Orthopedic surgery (i.e. tenotomy, tendon transfer) or percutaneous neuroablative procedures (i.e. cryoneurotomy) which will be done for upper limb refractory spasticity after being triaged by DNB.
48721461|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
48721462|NCT01071629|OTHER|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
48384180|NCT00581334|PROCEDURE|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
48384181|NCT00581334|PROCEDURE|Open sacrocolpopexy|mesh augmented repair for post-hysterectomy prolapse performed via open laparotomy
48384182|NCT01175408|OTHER|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
48384183|NCT01175408|OTHER|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
48384184|NCT01175408|OTHER|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
48384185|NCT01175408|OTHER|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
48384186|NCT05527288|DRUG|Drug: [18F]florbetaben|All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.
48384187|NCT04874701|DRUG|Capsimax|Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg
48384188|NCT04874701|OTHER|Energy restriction|Personalised diet plan targeting a 500 kcal/day energy restriction
48384189|NCT05590182|DEVICE|Angiography|"Randomization either in the study arm (CO2) or in the control arm (iodine-CM) occurs right before angiography. Stenosis graduation and length are measured after diagnostic angiography and before intervention. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.~A pain protocol to the current pain-situation is led by the present medical-laboratory assistant after administration of CO2 and iodine-CM during intervention."
48384190|NCT05488340|DRUG|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
48520314|NCT00379314|PROCEDURE|TVT and TVT-O minimally invasive surgical procedures|
48520315|NCT00379314|PROCEDURE|Surgery for female stress urinary incontinence|
48721463|NCT01290900|DRUG|NXL104|IV Solution
48721464|NCT01290900|DRUG|Ceftaroline|IV Solution
48721465|NCT01290900|DRUG|Placebo Infusion|IV Saline
48721466|NCT01290900|DRUG|Ceftazidime|IV Solution
48721467|NCT01290900|DRUG|Moxifloxacin|Tablet (1)
48721468|NCT00096330|DIETARY_SUPPLEMENT|dietary intervention|oral folic acid supplementation once daily on days 57-84
48721469|NCT00096330|DIETARY_SUPPLEMENT|folic acid|oral folic acid supplementation once daily on days 1-56.
48182744|NCT05785065|OTHER|Placebo|"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"
48182745|NCT02904785|DEVICE|Extracorporeal Shock Waves|
48721470|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
48721471|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
48721472|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
48721473|NCT01196845|DEVICE|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
48721474|NCT04248335|DRUG|Pantoprazole|single-dose administration
48721475|NCT04248335|DRUG|Midazolam injection|single-dose administration
48721476|NCT02643823|BIOLOGICAL|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
48721477|NCT02643823|DRUG|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
48721478|NCT02567045|PROCEDURE|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
48182746|NCT02904785|DEVICE|Sham Extracorporeal Shock Waves|
48721479|NCT02567045|PROCEDURE|colonoscopy with sedation|One-time Colonoscopy with sedation.
48721480|NCT01859845|OTHER|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
48721481|NCT00262847|BIOLOGICAL|Bevacizumab|Given IV
48025562|NCT00772174|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
48384191|NCT05488340|DRUG|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
48721482|NCT00262847|DRUG|Carboplatin|Given IV
48721483|NCT00262847|OTHER|Laboratory Biomarker Analysis|Correlative studies
48721484|NCT00262847|DRUG|Paclitaxel|Given IV
48721485|NCT00262847|OTHER|Placebo|Given IV
48721486|NCT00262847|OTHER|Quality-of-Life Assessment|Ancillary studies
48721487|NCT02881528|DRUG|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
48721488|NCT02881528|DRUG|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
48721489|NCT03783494|DRUG|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
48721490|NCT02580513|BEHAVIORAL|Circadian Misalignment|
48025563|NCT03508557|BEHAVIORAL|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
48520316|NCT04269993|DRUG|Cannabis: placebo and medium THC/medium CBD|Vaporized cannabis: placebo and medium THC/medium CBD
48520317|NCT04239755|DRUG|Doxycycline 100 MG Oral Tablet|doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
48025564|NCT06057051|DEVICE|iStent Infinite|iStent Infinite Trabecular Micro-Bypass System
48025565|NCT01927445|OTHER|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
48520318|NCT04239755|OTHER|placebo|placebo in addition to the standard treatment.
48721491|NCT02557984|DRUG|Placebo|Placebo Pill
48025566|NCT00023673|DRUG|carboplatin|
48721492|NCT02557984|DRUG|Amisulpride|400 mg Amisulpride
48025567|NCT00023673|DRUG|paclitaxel|
48025568|NCT00023673|RADIATION|three-dimensional conformal radiation therapy|
48721493|NCT02557984|DRUG|Naltrexone|50 mg Naltrexone
48721494|NCT02475616|DRUG|PCO371|
48721495|NCT02475616|DRUG|Placebo|
48721496|NCT04199819|DRUG|entecavir|Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
48721497|NCT01150643|GENETIC|gene expression analysis|
48721498|NCT01150643|GENETIC|microarray analysis|
48721499|NCT01150643|GENETIC|polymerase chain reaction|
48721500|NCT01150643|GENETIC|polymorphism analysis|
48721501|NCT01150643|OTHER|immunohistochemistry staining method|
48721502|NCT01150643|OTHER|laboratory biomarker analysis|
48721503|NCT01727791|DRUG|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
48721504|NCT03654001|BIOLOGICAL|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
48721505|NCT03654001|OTHER|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
48721506|NCT05809804|DRUG|Esketamine|The initial dose of esketamine was set as 0.06 mg / kg, and the injection time of esketamine was 5 s. One minute after injection of esketamine, sufentanil 0.4 μg / kg was injected within 5 s, and the number of coughs within 1 min after injection was recorded. According to the evaluation of sufentanil-induced cough, the dose of esketamine was adjusted. If the patient had no cough ( negative reaction ), the dose of esketamine in the next patient was reduced until the cough reaction occurred. If the patient had a cough reaction ( positive reaction ), the dose of esketamine in the next patient was increased until the cough disappeared. The dose ratio of adjacent esketamine was 1.1. Each group was selected from the previous patient with positive reaction until the 7 groups of positive and negative reactions appeared alternately, and the test was completed.
48721507|NCT04662372|OTHER|Description|description of the cognitive and behavioral profile of stroke mimics patients, without evidence of neurological disease.
48721508|NCT00002254|DRUG|Alovudine|
48721509|NCT04761484|PROCEDURE|Vascular access on admission|PIVC insertion
48721510|NCT01198509|DRUG|doxycycline|doxycycline - 100 mg twice per day, for 2 months
48721511|NCT01198509|DRUG|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
48721512|NCT05883618|OTHER|Exposure|Human Development Index of Country
48721513|NCT04064346|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
48721514|NCT04064346|DRUG|Placebo|Matching placebo
48721515|NCT01066351|DRUG|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
48721516|NCT01066351|DRUG|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
48721517|NCT04391452|DIETARY_SUPPLEMENT|Stress Resist® (oral dietary supplement)|Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
48721518|NCT04980365|BEHAVIORAL|Mindfulness|Participants will be asked to use the app Mindfulness Coach daily for 10 minutes. Participants will follow app instructions for brief guided meditation sessions for 14 days.
48721519|NCT04980365|BEHAVIORAL|Gratitude|Participants will be asked to use the app Grateful daily for 10 minutes. Participants will follow app instructions and will be answering to prompts related to gratitude provided by the app daily, for 10 minutes for 14 days.
48721520|NCT04980365|BEHAVIORAL|Food Journal|Participants will be asked to use the app Day One daily for 10 minutes. Participants will be writing a daily journal entry describing what they ate during the previous day for 14 days.
48721521|NCT05302362|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)
48721522|NCT05529966|DEVICE|NGENUITY|Device for 3-D viewing during placement of micro-stent placement.
48025569|NCT01748435|DRUG|Qutenza|Single treatment with Qutenza
48182747|NCT02904785|OTHER|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
48520319|NCT00000947|DRUG|Azithromycin|
48520320|NCT02493660|DEVICE|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
48520321|NCT02493660|PROCEDURE|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
48025570|NCT03165045|DRUG|Spiolto® Respimat®|6 weeks
48025571|NCT01046110|DRUG|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
48025572|NCT01046110|DRUG|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
48025573|NCT01044810|DRUG|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
48520322|NCT06319040|OTHER|Muscle strength measurement|Muscle strength of both legs, maximal reciprocal concentric isokinetic knee extension (quadriceps) and flexion (hamstring) at 60°/s, 90°/s and 180°/s speeds were evaluated
48721523|NCT05529966|DEVICE|Conventional microscope|Device for stereoscopic viewing during placement of micro-stent placement.
48721524|NCT03256786|BEHAVIORAL|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
48721525|NCT05303688|DRUG|iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)|The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
48721526|NCT05303688|DRUG|Steril Salin (control)|30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
48721527|NCT05052619|DRUG|Preventive use of advanced antibiotics|Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
48025574|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
48025575|NCT01016795|DRUG|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
48025576|NCT01016795|DRUG|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
48025577|NCT05235880|OTHER|Virtual reality based games|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes virtual reality based games aiming improvement on upper extremities, trunk and cognitive functions.
48025578|NCT05235880|OTHER|Conventional exercises|In an hour physiotherapy session first 40 minutes of session includes conventional physiotherapy program tailored to patient's needs. Last 20 minutes of session includes conventional physiotherapy approaches aiming improvement on upper extremities, trunk and cognitive functions.
48025579|NCT00081588|DRUG|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
48025580|NCT03793192|OTHER|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
48182748|NCT05442450|DRUG|oral semaglutide|Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
48721528|NCT05052619|OTHER|Routine|Treat patients in this group with routine preventive usage of antibiocs: Cefmetazole 1g q12h, in postoperative days 1-3.
48721529|NCT02893124|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
48721530|NCT00130923|DRUG|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
48721531|NCT00130923|DRUG|oral risperidone|0.50-6.00 mg oral risperidone daily
48721532|NCT01926769|DRUG|Metformin|
48721533|NCT06354374|DIAGNOSTIC_TEST|volume survey|All subjects will receive oral hygiene instructions and, if needed. A dental cleaning of plaque and calculus. After calibration using digital photographs and digital intraoral scans, CBCT scans will be taken as a prerequisite for dental implant treatment protocol. one dentist who will not be involved in the screening phase will obtain all clinical parameters (gingival biotype, probing depth, gingival thickness, gingival width) to avoid any bias. After finishing data collection, a customized treatment plan for each patient will be performed and dental implant treatment will be completed for each patient.
48721534|NCT03216759|PROCEDURE|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
48721535|NCT03216759|DRUG|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
48721536|NCT03216759|PROCEDURE|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
48721537|NCT01410708|DRUG|Dasatinib|
48025581|NCT01490060|DRUG|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
48025582|NCT01490060|DRUG|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
48025583|NCT01490060|DRUG|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
48025584|NCT01490060|DRUG|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
48025585|NCT01490060|DRUG|Doxorubicin|25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
48384192|NCT05488340|DRUG|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
48721538|NCT05046691|BEHAVIORAL|8-week mindfulness program|The .b Foundations course is an 8-week mindfulness program developed by Mindfulness in Schools Project (MiSP) for school teachers and personnel. It includes a taster session and 8 weekly sessions. Each session lasts for 1.5 hours with a specific theme (e.g. Lesson 1 waking up from autopilot). Formal and informal mindfulness practices (e.g. mindful eating, body scan, mindful walking, habit releaser etc.), psychoeducation, cognitive exercises, inquiry, and home practice are involved.
48182749|NCT00420875|DEVICE|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
48182750|NCT00603083|DRUG|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
48182751|NCT00603083|DRUG|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
48182752|NCT02403518|DEVICE|Freedom Spinal Cord Stimulator System|
48721539|NCT03028987|BIOLOGICAL|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
48721540|NCT03028987|BIOLOGICAL|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
48721541|NCT00499902|DRUG|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
48721542|NCT02358915|DEVICE|FastStart neuromuscular electrical stimulator|
48182753|NCT01594827|DRUG|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
48182754|NCT01594827|DRUG|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
48384193|NCT05488340|DRUG|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
48384194|NCT05488340|DRUG|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
48384195|NCT05488340|DRUG|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
48384196|NCT05254015|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.
48384197|NCT05254015|BEHAVIORAL|Case Management|Case management includes linking to resources, monitoring health, and safety hazards.
48025586|NCT01490060|DRUG|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m\^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m\^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m\^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
48025587|NCT01490060|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m\^2).
48721543|NCT04523090|DRUG|Nitazoxanide|Nitazoxanide (NTZ) is licensed in the USA for treatment of diarrhoea caused by Cryptosporidium parvum and Giardia lamblia. NTZ is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae. NTZ was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. In vitro studies evaluating tizoxanide, the active circulating metabolite of NTZ, inhibits the replication of broad range of influenza A and B, HIN1, H3N2, H3N2V, H3N8, H5N9, H7N1 and oseltamivir resistant strain and coronaviruses . It has been shown to have anti-viral activity against several viruses including Ebola, hepatitis B and C, rotavirus and norovirus.
48721544|NCT04523090|DRUG|Placebo|Placebo pills with no active ingredient.
48721545|NCT06064773|DIAGNOSTIC_TEST|thoracic USG|the confirmation of double lumen tube placement with thoracic USG in thoracic surgery operations with one lung ventilation.
48721546|NCT06182163|BEHAVIORAL|Sedentary time intervention|Tests the effect of a multi-component mobile health (mHealth) intervention on reducing sedentary behavior among adolescents with ALL during maintenance therapy. The intervention includes an app-based peer support group for study participants via WhatsApp, individualized coaching sessions with study staff, and prompts to move delivered via a Fitbit wearable fitness tracker.
48721547|NCT00491881|BEHAVIORAL|no added salt diet|
48721548|NCT01112111|DRUG|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
48721549|NCT02412709|DEVICE|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
48721550|NCT04250597|DRUG|GNX102|Dose Escalation
48721551|NCT04250597|DRUG|GNX102|Expansion Phase
48721552|NCT03867682|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
48721553|NCT03867682|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
48520323|NCT06319040|OTHER|Knee joint proprioception|Knee joint proprioception was assessed by joint position sense. Joint position sense was measured by the previously taught ability to actively find joint position (EPAB)
48520324|NCT06319040|OTHER|Balance|The patients and healthy individuals participating in our study were evaluated with the General Stability Index (GSI) for general balance ability, Anterior-Posterior Stability Index (APSI) for anterior-posterior balance ability, Medial-Lateral Stability Index (MLSI) for lateral balance ability and Fall Risk Index (DRI) and Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk. High values obtained indicate deterioration in balance and increased risk of falling.
48520325|NCT06319040|OTHER|Fall risk test|Biodex Balance System (Biodex Inc., Shirley, New York, USA) for fall risk
48721554|NCT03867682|DRUG|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
48721555|NCT05332093|DIAGNOSTIC_TEST|skin biopsy|4mm skin biopsy
48721556|NCT05332093|DIAGNOSTIC_TEST|venous blood sample (plasma, PBMC, WB)|venous blood sample to acquire plasma, PBMCs and whole blood
48721557|NCT05332093|GENETIC|venous blood sample (HLA)|venous blood sample used for HLA typing
48721558|NCT05332093|GENETIC|skin slit|genome sequencing of parasite DNA that is extracted from the skin slit
48721559|NCT00921310|DRUG|Pemetrexed|
48721560|NCT00921310|DRUG|Temsirolimus|
48025588|NCT01490060|DRUG|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
48025589|NCT05734313|BEHAVIORAL|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
48182755|NCT01594827|DRUG|Rifampin|"Oral Rifampin by mouth for 28 days~1. \>45 kg: 600 mg by mouth daily~2. 35-45 kg : 450 mg by mouth daily~3. 25-34.9 kg: 300 mg by mouth daily"
48721561|NCT02544373|DEVICE|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
48721562|NCT06088160|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
48721563|NCT05670509|DRUG|administration of Nasal midazolam in home group as a rescue medication for seizure control.|Children from home group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
48182756|NCT01594827|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|"Oral trimethoprim/sulfamethoxazole (DS-160/800)~1. \>45 kg: two DS tablets twice a day by mouth (320/1600)~2. 25-45 kg: one DS tablet twice a day by mouth (160/800)"
48182757|NCT01594827|DRUG|Doxycycline|"If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. \>45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day"
48721564|NCT05670509|DRUG|administration of Buccal midazolam in home group as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
48721565|NCT05670509|DRUG|administration of intramuscular midazolam in homegroup as a rescue medication for seizure control.|Children from home group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
48721566|NCT05670509|DRUG|administration of Nasal midazolam in ER group as a rescue medication for seizure control.|Children from the ER group assigned to receive treatment with intranasal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via a metered dose sprayer at 0.1 mL/spray (i.e. 0.5 mg/spray). If the volume to be administered exceeded 1 mL, the dose was divided between both nostrils to avoid runoff and swallowing
48721567|NCT05670509|DRUG|administration of Buccal midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with buccal midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) via dripping between the cheek and the gum per side using insulin syringe
48721568|NCT05670509|DRUG|administration of intramuscular midazolam in ER group as a rescue medication for seizure control.|Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
48721569|NCT05023148|PROCEDURE|Electroacupuncture|Stimulating acupoints using electric stimulator
48721570|NCT05023148|PROCEDURE|Thread embedded acupuncture|Stimulating acupoints using thread embedded
48721571|NCT02312778|OTHER|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
48721572|NCT04185415|DRUG|bepranemab|"bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous"
48721573|NCT04185415|DRUG|Placebo|"* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9% w/v sodium chloride aqueous solution~* Route of Administration: Intravenous"
48721574|NCT04323293|OTHER|Cold Water Bath|immersion of the hand for 2-5min in 2-10°C water
48721575|NCT04323293|OTHER|Neutral Water Bath|immersion of the hand for 2-5min in 32±2°C water
48721576|NCT05484284|PROCEDURE|two-stage primary total knee arthroplasty with low-dose antibiotics|Briefly, investigators completely debrided all necrotic soft tissue in the first stage of the operation. The surgical site was flushed twice with hydrogen peroxide, iodine, and saline solutions. Then, the antibiotic-loaded cement spacer was inserted. After surgery, a 10-day course of intravenous organism-specific antibiotics or vancomycin was administered, followed by oral antibiotic therapy. Second-stage reimplantation was performed once there was no sign of infection. The spacer was removed and the new prosthesis was implanted without the use of antibiotic-containing bone cement.
48721577|NCT02484924|DRUG|Ticagrelor|No intervention- purely observational
48721578|NCT04109833|DRUG|ABT|any antibiotic therapy in the first week of life
48025590|NCT05734313|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
48025591|NCT05358145|BEHAVIORAL|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
48182758|NCT01594827|DRUG|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
48182759|NCT01594827|DRUG|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
48182760|NCT00827554|DRUG|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
48182761|NCT00827554|PROCEDURE|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
48721579|NCT04330781|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
48721580|NCT04330781|OTHER|No intraoral stent|Radiotherapy without intraoral stent
48721581|NCT03095820|BEHAVIORAL|Supportive therapy|
48721582|NCT03095820|BEHAVIORAL|Multidomain intervention|
48721583|NCT00052312|DRUG|cisplatin|
48721584|NCT00052312|DRUG|doxorubicin hydrochloride|
48721585|NCT00052312|DRUG|paclitaxel|
48025592|NCT05358145|BEHAVIORAL|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
48520326|NCT06319040|OTHER|Tegner Activity Level|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
48520327|NCT06319040|OTHER|Lysholm Knee Scoring Scale|Tegner Activity Level and the Turkish version of the Lysholm Knee Scoring Scale by Çelik et al. were used to subjectively determine the functional level in individuals undergoing ACL reconstruction surgery.
48721586|NCT01167166|DRUG|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
48721587|NCT00549770|DRUG|LCZ696|
48721588|NCT00549770|DRUG|Valsartan|
48721589|NCT00549770|DRUG|AHU377|
48721590|NCT00549770|DRUG|Placebo|
48721591|NCT04807803|DIAGNOSTIC_TEST|Assessment of Minimal hepatic encephalopathy (MHE)|Assessment of MHE at the inclusion and 6 months after treatment if diagnosed with MHE: Serum ammonia analysis, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT) and evaluation of abdominal imaging, liver and splenic transient elastography, gastroscopy
48721592|NCT03670784|OTHER|No intervention|No intervention, epidemiological investigation
48721593|NCT04039152|OTHER|locally adapted neonatal sepsis treatment protocol|the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
48721594|NCT04595162|BIOLOGICAL|GC019F|GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.
48721595|NCT05818514|DRUG|[11C]AZ14132516|Injection of radioligand for PET examinations
48721596|NCT01186640|DRUG|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
48721597|NCT01186640|DRUG|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
48721598|NCT04081272|DRUG|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
48721599|NCT02203955|DRUG|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
48721600|NCT02203955|DRUG|Maltodextrin|4 chews (maltodextrin) daily for 12 months
48721601|NCT00300365|DRUG|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
48182762|NCT02075619|DRUG|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
48721602|NCT00300365|OTHER|Placebo|Pioglitazone placebo
48721603|NCT00300365|DRUG|Niacin ER|Niacin ER 2.0 g/day
48721604|NCT00300365|DRUG|Aspirin|asprin 325 mg/day
48520328|NCT03087500|OTHER|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
48721605|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
48025593|NCT05358145|BEHAVIORAL|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
48182763|NCT02075619|DRUG|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
48520329|NCT01727752|PROCEDURE|Decompression|
48520330|NCT02225431|DRUG|sodium chloride infusion|
48721606|NCT01579630|DRUG|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
48721607|NCT05389189|BEHAVIORAL|Intervention Arm|"The MITIG.RA program incorporates the following key topics during the 8 weeks of intervention (1st phase):~(i) Psychoeducation on RA, sleep hygiene, exercise, and general nutritional recommendations (promote behavioural change and self-care, boost the sense of self-worth and self-efficacy) (ii) Activity engagement and pacing (iii) The functioning of the mind and its problematic patterns (iv) Focusing on the 'here and now' (mindfulness) (v) Learning new ways of self-relating - self-compassion (vi) Making room for suffering (acceptance); and (vii) Moving towards what matters (identification of valued life directions and promotion of consistent values and goals-directed behaviour)."
48721608|NCT00870194|DRUG|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
48721609|NCT00870194|DRUG|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
48025594|NCT05904964|DRUG|Disitamab vedotin|Disitamab Vedotin 2mg/kg was injected every 2 weeks,
48025595|NCT05904964|OTHER|Endocrine therapy|Doctors choose endocrine therapy independently
48025596|NCT04837365|OTHER|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
48025597|NCT03299595|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
48025598|NCT06489808|DRUG|Linperlisib|Linperlisib RP2D D1-14
48025599|NCT06489808|DRUG|Rituximab|rituximab 375 mg/m2 D0
48025600|NCT06489808|DRUG|Gemcitabine|gemcitabine per regimen dosage
48025601|NCT06489808|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1
48025602|NCT06489808|DRUG|Ifosfamide|Ifosfamide 5g/m2 D2
48025603|NCT06489808|DRUG|Carboplatin|Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
48025604|NCT06489808|DRUG|Etoposide|Etoposide 100mg/m2 D1-3
48025605|NCT06489808|DRUG|Dexamethasone|Dexamethasone 40mg D1-4
48025606|NCT06489808|DRUG|Cisplatin|Cisplatin 100mg/m2 D1, continuous intravenous infusion
48025607|NCT06489808|DRUG|Ara-C|Ara-C 2g/m2 q12h D2
48025608|NCT06489808|DRUG|Vinorelbine|Vinorelbine 20mg/m2 D1
48025609|NCT06489808|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 18mg/m2 D1
48025610|NCT00917046|BEHAVIORAL|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
48025611|NCT00917046|BEHAVIORAL|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
48025612|NCT00917046|BEHAVIORAL|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
48025613|NCT06038773|DIAGNOSTIC_TEST|Diagnosis|"Baseline data were presented with descriptive statistics. Sociodemographic information, pregnancy status, surgical history, exercise habits, gynecologic, obstetric, urologic and gastrointestinal history of the patients were evaluated with the Patient Information Form.Pain intensity was evaluated with the McGill pain questionnaire short form. At the same time, the patients drew the areas where they felt the most pain with the pain maps scale. Pain intensity during sexual intercourse was evaluated with the Visual Analog Scale (VAS).Sexual Abuse Items on the Questionnaire (Modified from Badgley)."
48025614|NCT00575848|DIETARY_SUPPLEMENT|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
48025615|NCT00575848|DIETARY_SUPPLEMENT|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
48182764|NCT02075619|DRUG|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
48025616|NCT01389973|DRUG|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
48025617|NCT01389973|DRUG|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
48025618|NCT01389973|DRUG|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
48025619|NCT01389973|DRUG|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
48025620|NCT03103282|DEVICE|PuraStat®|Synthetic haemostatic material
48025621|NCT03669081|DRUG|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
48182765|NCT01550055|DRUG|CMAB009 plus Irinotecan|Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
48025622|NCT03669081|DRUG|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
48025623|NCT03669081|DRUG|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
48025624|NCT03669081|DRUG|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
48025625|NCT00465166|PROCEDURE|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
48025626|NCT06574204|DRUG|Erythromycin|The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
48025627|NCT06574204|DRUG|Azithromycin|The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
48520331|NCT01281605|BEHAVIORAL|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).
48520332|NCT01281605|BEHAVIORAL|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\>=110mg/dL, and by 4 IU/day if the FPG\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
48721610|NCT02618551|PROCEDURE|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
48384198|NCT05899933|PROCEDURE|Non-surgical peri-implant therapy|"2 weeks after baseline examination, non surgical therapy will be applied in implants diagnosed with peri-implantitis prior to enrollment in surgical therapy.~Firstly, participants will be instructed in oral hygiene. Professional supragingival and subgingival debridement of implants/ teeth, including the selected for the study implants, will be performed. Local anesthesia will be performed, when needed. Targeted implants will be treated with PEEK-coating ultrasonic tips (Instrument PI; EMS), titanium curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), rubber cup and polishing paste. Possible adjustments to implant-borne prostheses will be considered, whenever possible. Re-evaluation of non-surgical therapy will be performed after 6 weeks.~At the 6-week reevaluation, participants with peri-implant probing pocket depth ≥5 mm and bleeding on probing and/or suppuration in patients with full mouth plaque score ≤20% will proceed to surgical therapy."
48520333|NCT04731571|RADIATION|CBCT-guided Adaptive Radiotherapy|The aim is to deliver adaptive radiotherapy using a CBCT-based radiotherapy delivery system.
48721611|NCT00667290|BEHAVIORAL|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
48721612|NCT05442177|PROCEDURE|Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment|
48520334|NCT00070551|BIOLOGICAL|GTI-2040|Given IV
48520335|NCT00070551|DRUG|cytarabine|Given IV
48721613|NCT03758690|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
48721614|NCT06380010|OTHER|Mediterranean diet group|Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
48721615|NCT03572790|DRUG|Prucalopride|1mg prucalopride capsule, once daily for seven days
48721616|NCT03572790|OTHER|Placebo|Lactose placebo capsule, once daily for seven days
48721617|NCT00398203|DEVICE|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
48721618|NCT06206811|DRUG|OD-07656|innate immune modulator
48721619|NCT01522261|OTHER|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
48721620|NCT01522261|OTHER|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
48721621|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
48721622|NCT02189707|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
48721623|NCT02189707|OTHER|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
48025628|NCT06574204|OTHER|physiological saline|The researchers injected 10-20 μl of physiological saline into the inner left wrist of the subjects, which is a liquid dosage form.
48520336|NCT00070551|OTHER|pharmacological study|Optional correlative studies
48721624|NCT04771325|BEHAVIORAL|Support from a trained companion|Birth companions trained on how to effectively support women during labor
48721625|NCT04752345|OTHER|Pharmacoinvasive strategy|Pharmacoinvasive treatment \[full-dose fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI (3 to 24 hours, in case of successful fibrinolysis)
48025629|NCT05218655|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
48520337|NCT00070551|OTHER|laboratory biomarker analysis|Optional correlative studies
48025630|NCT03143829|OTHER|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
48025631|NCT04101799|BEHAVIORAL|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
48025632|NCT04101799|OTHER|Active control|Participating in everyday activities that may include parenting activities in the control prisons
48384199|NCT05899933|PROCEDURE|Implantoplasty|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy) and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implantoplasty will be applied using tungsten carbide burs of various shapes and sizes (Peri-implantitis Kit; Meisinger) followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
48384200|NCT05899933|PROCEDURE|Erythritol Air-abrasive device|"Screw-retained supraconstructions and, when possible, cement-retained restorations will be removed.~Following local anesthesia, intrasulcular incisions will be performed and full-thickness flaps will be elevated on the buccal and lingual aspects of affected implants. Granulation tissue will be removed, and titanium-coated curettes (IMPM11/12T, IMPM13/14T; Hu-Friedy), and NiTi brushes (NEGRIN IN DENTAL) will be applied to remove hard deposits on implants. Osseous recontouring will be performed when indicated followed by irrigations with saline. Implant surface decontamination with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS) will be applied followed by irrigations with saline. Flaps will be readjusted and closed with sutures in order to allow a non-submerged healing. Supraconstructions will be reconnected after the surgery."
48384201|NCT05899933|PROCEDURE|Prophylaxis|Supramucosal biofilm removal of implants/ teeth will be performed at, 3, 6, 9 and 12 months after surgical therapy for the Implantoplasty group and the Erythritol Air-abrasive device group and at 2 weeks, 3, 6, 9 and 12 months after baseline examination for the control group. Targeted implants will be treated with an air-abrasive device (AIRFLOW® MAX, AIRFLOW® Prophylaxis Master; EMS) with erythritol powder (AIRFLOW® Plus Powder; EMS). During these appointments, patients will be re-motivated and re-instructed to oral-hygiene measures.
48384202|NCT01939834|DEVICE|Overnight CLC|Overnight Closed-Loop Control (CLC) is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the CLC and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
48384203|NCT01939834|DEVICE|Sensor-Augmented Pump Therapy (SAP)|The subject will be on their home insulin pump (UVA) or study pump (Italy) and using a CGM per their usual care.
48721626|NCT04752345|OTHER|Reduced-dose facilitated PCI strategy|Reduced-dose facilitated PCI\[reduced-dose fibrinolysis,simultaneously transfer,immediate coronary angiography and andioplasty when arrived at PCI center(\<3 hours)\]
48721627|NCT01345565|DRUG|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
48721628|NCT02479776|BIOLOGICAL|stem cell injection|Injection of autologous bone marrow derived stem cells
48721629|NCT00507273|OTHER|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
48721630|NCT05170789|DRUG|Elotuzumab, Selinexor, and Dexamethasone (ESd)|This is a single-arm, interventional, phase II clinical trial, in which the anticipated 18 enrolled patients will receive the trial drug, a combination of Elotuzumab, Selinexor, and Dexamethasone in monthly cycles. The study tests the theory of synergy between these drugs, as detailed in the study description above.
48025633|NCT04864808|BEHAVIORAL|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
48025634|NCT06127069|DEVICE|chitosan brush|debridement of periodontal pockets with ultrasonic scaler first and after with chitosan brush for 2 minutes
48025635|NCT06127069|DEVICE|ultrasonic scaler|debridement of periodontal pockets only with ultrasonic scaler
48025636|NCT04409964|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus followed by the infusion of 0.1-1 ug/kg/hr during general anesthesia
48025637|NCT04409964|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5 mg/kg/hr during general anesthesia
48025638|NCT04409964|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
48025639|NCT04483453|OTHER|EXPL feeding regimen|EXPL FUF (lower protein and 100% lactose) + EXPL IC (whole grains and legumes)
48025640|NCT04483453|OTHER|CTRL feeding regimen|CTRL FUF (standard protein content and carbohydrate profile) + CTRL IC (refined grains)
48025641|NCT05884034|OTHER|Telerehabilitation|Subjects will participate in a six-week self-care education program with weekly synchronous meetings using Google Meet or WhatsApp and an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with a schedule for weekly organization.
48025642|NCT05884034|OTHER|Education|Participants will receive an informative booklet containing guidelines for performing physical activities at home and information on healthy eating, mental health and routine management, with orientations on the importance of reading and implementing the guidelines described in the booklet.
48025643|NCT05253703|OTHER|Virtual reality bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
48025644|NCT06534736|PROCEDURE|Electrotherapy and physical agents|It will comprise of hot pack for 10 minutes, Tens for 10 minutes.
48025645|NCT06534736|PROCEDURE|Post Facilitation Stretch|Participants will be instructed to maintain the contraction for 6 to 10 seconds and then relax the muscles as quickly as possible.The stretch will be held for 15 seconds in an attempt to lengthen the shortened facscial structures.The muscles which will be targeted are Levator Scapular Upper Trapezius Sternocleidomastoid scalene Pectoralis Muscles
48025646|NCT06534736|PROCEDURE|Scapular Stabilization Exercise|Scapular Stabilization exercises protocol will consist of scapular wall slide exercise, scapular retraction, wall Ball Circle exercises, scapula squeeze, wall press ups. Exercise program 3 sets of 5 - 10 repetition for 10 seconds hold a 20 second break between each sets. The intervention will be applied 2 weeks 3 times a week and 30 min per session. Post Facilitation stretch of the targeted muscles also will be carried out during the sessions
48025647|NCT05975658|DEVICE|Gabi SmartCare Pediarity System [Gabi Band, Gabi Monitor App, Gabi Analytics]|Gabi SmartCare has created a monitoring system named Pediarity System that obtains pediatric vitals data through non-invasive means through a Gabi band. When paired with a proprietary algorithm and software - Gabi Analytics - the cloud-based platform measures blood oxygen levels, pulse rate (and variability), respiratory rate, actigraphy, inter-beat interval, and tracking for the time the device is worn (or not worn by the child). Three LEDs on the monitor are used for capturing this information. Peak wavelengths for the red, infrared, and green LEDs operate at 660nm, 950nm, and 526nm respectively. The Gabi band features an optical front end coupled with an analog front end using 24 bits. Bluetooth data transmission is utilized on a mobile phone application with a tablet-based system in a CSV format for the purpose of offline data processing.
48025648|NCT02266238|DEVICE|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
48025649|NCT02266238|DEVICE|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
48025650|NCT02266238|PROCEDURE|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
48025651|NCT02199782|OTHER|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
48721631|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
48025652|NCT05367453|DIETARY_SUPPLEMENT|Tropical juice with probiotics (B.coagulans)|Once a day during all the intervention phase, volunteers with lactose intolerance should allow the spore-forming ability of B. coagulans in order to digest lactase from dairy products through regular consumption of Tropical juice with probiotics (B.coagulans)
48025653|NCT05367453|OTHER|a Tropical juice with no probiotics|Once a day during all the intervention phase, volunteers with lactose intolerance should consume a Tropical juice with no probiotics
48025654|NCT05367453|OTHER|lactase tablet|lactase tablet
48025655|NCT05367453|OTHER|placebo tablet (cornstarch)|placebo tablet (cornstarch)
48025656|NCT03299049|DRUG|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
48025657|NCT03299049|DRUG|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
48025658|NCT03299049|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
48721632|NCT04033068|BIOLOGICAL|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~2. V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
48721633|NCT04033068|BIOLOGICAL|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~1. V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~2. V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
48182766|NCT01550055|DRUG|Irinotecan-only and sequential-CMAB009|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
48721634|NCT04033068|OTHER|Two placebo injection|"In this arm of the study, 8 participants will receive:~1. V1= day 0; placebo treatment~2. V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
48721635|NCT03181295|BEHAVIORAL|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
48721636|NCT05623111|DRUG|Incobotulinumtoxin-A 100 UNIT Injection|Perineural injection
48721637|NCT05623111|DRUG|Saline|Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
48721638|NCT01893359|DRUG|riboflavin ophthalmic solution, 0% dextran|
48721639|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
48721640|NCT01893359|DEVICE|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
48721641|NCT01893359|PROCEDURE|Laser-assisted in situ keratomileusis|
48721642|NCT02671565|DRUG|Hyaluronic Acid injections|
48721643|NCT00190047|DRUG|DP-b99|
48721644|NCT03218579|DIETARY_SUPPLEMENT|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
48721645|NCT03218579|BIOLOGICAL|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
48721646|NCT03974412|DIAGNOSTIC_TEST|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
48721647|NCT03974412|DEVICE|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
48721648|NCT03143998|DRUG|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
48721649|NCT03970616|DRUG|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
48721650|NCT03970616|DRUG|Durvalumab|1500mg every 28 days
48721651|NCT02142036|DRUG|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
48721652|NCT03963102|DRUG|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
48721653|NCT01608451|DRUG|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
48025659|NCT03299049|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
48025660|NCT03855215|DIAGNOSTIC_TEST|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
48025661|NCT01059617|BIOLOGICAL|GSK Biologicals' FluLaval®|Intramuscular injection
48025662|NCT01059617|BIOLOGICAL|Placebo (saline)|Intramuscular injection
48182767|NCT03453723|PROCEDURE|Magic glove hypnosis technique|Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.
48721654|NCT01608451|DRUG|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
48721655|NCT06174909|DRUG|Calcium Hydroxide|After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement
48721656|NCT06174909|DRUG|Triple Antibiotic paste|After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
48721657|NCT05248503|BEHAVIORAL|Complex Care Training of Hereditary Epidermolysis Bullosa|Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
48721658|NCT00328250|BEHAVIORAL|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
48721659|NCT02068560|DRUG|dDAVP infusion|
48721660|NCT02763436|PROCEDURE|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
48721661|NCT00514345|GENETIC|gene expression analysis|
48721662|NCT00514345|GENETIC|polymorphism analysis|
48721663|NCT00514345|PROCEDURE|management of therapy complications|
48384204|NCT04936009|BEHAVIORAL|Transcranial Magnetic Stimulation (TMS)|Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
48025663|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
48721664|NCT05601661|DEVICE|Active VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0.8 mA)
48721665|NCT05601661|DEVICE|Sham VNS|An implantable system consisting of an implantable neurostimulator (model 1001 Implantable Pulse Generator (IPG)) and an implantable lead and electrode (Model 30000 VNS lead) will be used. An external system consisting of an external controller (Model 2000 Wireless Transmitter) and an external software system (computer and Model 4001 Microtransponder SAPS® software) will provide clinical control of settings for the implantable pulse generator (IPG) . All VNS devices (Vivistim System® ) will be provided as a donation by Microtransponder Inc. The device is programmed to stimulate for 0.5s on each button push. After surgical recovery, participants will receive five stimulations in reducing strength (starting at 0.8mA and then reducing to 0.1mA each step) at the beginning of each therapy session, followed by stimulation (0 mA)
48721666|NCT05601661|OTHER|Arm rehabilitation|. The rehabilitation therapy involves arm and hand exercises with objects. The therapist will select these exercises based on movement abilities. Tasks will be selected from six functional task categories: reach and grasp, gross movement, object flipping, simulated eating tasks, inserting objects, and opening containers. Approximately 30-50 repetitions will be performed in each category. On average, 300-500 repetitions will be performed during each session within 1.5-2hours.
48721667|NCT01606787|DRUG|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
48721668|NCT01606787|OTHER|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
48721669|NCT03233035|DRUG|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
48721670|NCT03233035|DRUG|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
48721671|NCT04487171|OTHER|Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.
48721672|NCT00651963|DRUG|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
48721673|NCT02564328|GENETIC|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
48721674|NCT01027260|DRUG|Itopride HCI 50 mg|Variable dosing
48721675|NCT01027260|DRUG|Itopride HCI 100 mg|Variable dosing
48025664|NCT01059617|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
48721676|NCT01027260|DRUG|Placebo|Variable dosing
48721677|NCT01295970|PROCEDURE|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
48721678|NCT01295970|PROCEDURE|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
48721679|NCT00189501|DRUG|Sensipar®|
48721680|NCT04229355|DRUG|DEB-TACE plus Sorafenib|Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
48721681|NCT04229355|DRUG|DEB-TACE plus Lenvatinib|Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
48721682|NCT04229355|DRUG|DEB-TACE plus PD-1 inhibitor|Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor
48721683|NCT03530670|OTHER|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
48721684|NCT03530670|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
48721685|NCT03530670|OTHER|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
48721686|NCT01378429|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
48721687|NCT01378429|DRUG|Placebo|Placebo
48721688|NCT04147936|DIETARY_SUPPLEMENT|AXA1665|Dietary supplement: AXA1665
48721689|NCT04147936|DIETARY_SUPPLEMENT|Placebo|Placebo
48721690|NCT02539511|DRUG|CI-581a|
48721691|NCT02539511|DRUG|CI-581b|
48721692|NCT02539511|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
48721693|NCT02492256|DEVICE|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
48721694|NCT02492256|DEVICE|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
48721695|NCT02492256|DEVICE|ILR implantation|Implantation the ECG loop recorder according to standard procedure
48721696|NCT03106285|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938
48721697|NCT03106285|DIETARY_SUPPLEMENT|Placebo|5 drops of placebo drops
48721698|NCT06414161|DIETARY_SUPPLEMENT|mix of (green tea and peppermint)|"Dried green tea leaves (100 gm) will be soaked into 500 ml of methanol solution for two days. The solution obtained will then be strained by a strainer and shifted to a glass plate. The plates will be left at room temperature from three to four days. Scraping out of the crystal powder of the extract from the plates will be carried out \[27\].~The peppermint mouth rinse that was used in this study had 1% peppermint base, 10% xylisorb, 5% glycerin, 1% Tween 20%, 5% alcohol 96%, 0/18% methyl paraben, and 0/02% propyl paraben \[28\].~Similarly, green tea plus peppermint mouthwash will be prepared at the same way but by adding 50% green tea leaves and 50% peppermint in the extract."
48721699|NCT02413411|BEHAVIORAL|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
48721700|NCT02413411|BEHAVIORAL|an educational program (an NIH-developed booklet)|
48721701|NCT05428813|BEHAVIORAL|art therapy techniques|Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
48721702|NCT06334757|DRUG|Serplulimab|300 mg，IV，Q3W
48721703|NCT06334757|DRUG|Bevacizumab Biosimilar HLX04|7.5 mg/kg，Q3W
48721704|NCT06334757|DRUG|Pemetrexed|500 mg/m2，IV，Q3W
48721705|NCT06334757|DRUG|Carboplatin|AUC=5，IV，Q3W
48721706|NCT06547060|OTHER|Exercise leggings|The participants will wear two types of leggings (i.e., control leggings vs. leggings with shortened resistance bands) while performing the same exercise on two different days, respectively.
48721707|NCT02355951|OTHER|blood draw|
48721708|NCT04893499|BEHAVIORAL|Chios mastic water|Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
48721709|NCT04893499|BEHAVIORAL|Placebo water|Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
48025665|NCT02641080|DRUG|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
48384205|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
48384206|NCT01279265|DIETARY_SUPPLEMENT|Nutramigen A+|Hypoallergenic formula without lactobacillus
48721710|NCT04893499|BEHAVIORAL|Chios mastic fruit juice|Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
48721711|NCT04893499|BEHAVIORAL|Placebo fruit juice|Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months. Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
48721712|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
48721713|NCT02108691|DIETARY_SUPPLEMENT|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
48721714|NCT02108691|DIETARY_SUPPLEMENT|Placebo|Placebo (2.5g/day)
48721715|NCT05643586|DRUG|Ticagrelor|Patient treated with 180 mg ticagrelor 12 hours before the procedure
48721716|NCT05643586|DRUG|Prasugrel|Patient treated with 60 mg prasugrel 12 hours before the procedure
48721717|NCT02076906|DEVICE|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
48721718|NCT03063190|DRUG|Vitamin D|patients will receive vitamin D supplementation according to guidelines
48721719|NCT03063190|DRUG|Placebo Oral Tablet|patients will receive placebo oral tablets
48721720|NCT05478291|OTHER|Vitamin D supplementation|Appropriate diet and physical activity counselling to both groups. Supplementation with Vitamin D and oral Calcium-Doses of cholecalciferol (commercial name, Calcirol) 60,000 IU (sachets, dissolved in half glass milk) once per week for eight weeks for the intervention group and placebo (Lactose granules) to the placebo group according to the random numbers generated by the computer. After every 24 weeks blood 25 (OH) D levels will be assessed. If the subjects are found to be still deficient then supplementation of cholecalciferol 60,000 IU per week for eight weeks will be repeated.If the 25 (OH) D levels are normal, then cholecalciferol supplementation in doses of 200 IU per day will be given as a maintenance dose. Equal doses of calcium carbonate (1gm per day, commercial name Calcal) will be given to both the groups.
48025666|NCT02641080|DEVICE|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
48025667|NCT00483522|BEHAVIORAL|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
48025668|NCT06342544|DRUG|immediate treatment with corticosteroids|Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
48025669|NCT06342544|DRUG|addition of rituximab if recurrence|rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
48721721|NCT03871660|DEVICE|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
48721722|NCT00238914|DRUG|Naltrexone|50mg of oral naltrexone daily
48025670|NCT04148079|OTHER|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
48025671|NCT04640051|PROCEDURE|LAAO|LAAO by use of 3D in silico simulation by FEops HEARTguide as part of the pre-procedural assessment and device size selection
48025672|NCT03933293|DRUG|AK102|450mg, Q4W, subcutaneous injection
48182768|NCT03453723|DRUG|lidocaine|intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
48182769|NCT04226092|DEVICE|GPSkin Barrier Pro|This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
48721723|NCT00238914|BEHAVIORAL|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
48721724|NCT00238914|BEHAVIORAL|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
48721725|NCT05585515|BEHAVIORAL|Sleep deprivation|Total sleep deficit of consecutive 8 hours
48721726|NCT05585515|BEHAVIORAL|Sleep restriction|Total sleep deficit of cumulative 8 hours
48721727|NCT02086201|BEHAVIORAL|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
48721728|NCT02086201|BEHAVIORAL|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
48182770|NCT04226092|DEVICE|Aquaflux AF200|This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
48025673|NCT03933293|DRUG|Statins|Lipid-lowering therapies
48025674|NCT03933293|DRUG|Ezetimibe|Lipid-lowering therapies
48025675|NCT01750567|DRUG|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
48025676|NCT00335907|PROCEDURE|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
48182771|NCT03404544|DRUG|Carbetocin bolus|Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
48182772|NCT03404544|DRUG|Carbetocin infusion|Carbetocin 100 mcg intravenous as a 10 minutes infusion
48182773|NCT03543605|BEHAVIORAL|PROA Experimental|PROA Control plus clinical advice
48182774|NCT03543605|OTHER|PROA Control|PROA Control
48025677|NCT02721589|BIOLOGICAL|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
48721729|NCT06252441|DRUG|Rectal Diclofenac|100 mg Rectal Diclofenac Before ERCP
48721730|NCT06252441|DRUG|Oral N-acetyl cysteine|1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
48721731|NCT04487561|DEVICE|hemopatch|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
48721732|NCT04487561|PROCEDURE|Aspirative drainage|The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
48025678|NCT00288496|DRUG|polyethylene glycol bowel lavage solution|
48025679|NCT01690650|DRUG|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
48721733|NCT00819494|PROCEDURE|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
48721734|NCT02182765|DRUG|Nevirapine|
48025680|NCT00142974|DRUG|Tegaserod|
48025681|NCT00948831|BIOLOGICAL|Osteocel Plus|biologic
48025682|NCT02753751|OTHER|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
48384207|NCT03277859|BEHAVIORAL|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
48721735|NCT02182765|DRUG|Amprenavir|
48721736|NCT02182765|DRUG|Abacavir|
48721737|NCT02383771|DRUG|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
48721738|NCT02383771|DRUG|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
48721739|NCT02383771|DRUG|Control|No Anti-platelet Therapy
48025683|NCT02129179|DRUG|Glucagon-Like Peptide 1|
48025684|NCT03299140|BEHAVIORAL|Family Focused Therapy|
48025685|NCT02977546|DEVICE|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
48025686|NCT02977546|DEVICE|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
48025687|NCT02873169|OTHER|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
48025688|NCT01914848|OTHER|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
48025689|NCT01914848|OTHER|Control Group|A routine care discharge planning with the social service
48025690|NCT04191902|BEHAVIORAL|orientation|patients will be oriented
48384208|NCT06537505|DRUG|Adebrelimab|Q3W,IV
48384209|NCT06537505|DRUG|Apatinib|QoD
48384210|NCT06537505|PROCEDURE|microwave ablation|microwave ablation
48384211|NCT06537479|OTHER|Buteyko breathing technique|Participants will be advised to sit in a comfortable and relaxed position and take a shallow breath through nose, partially filling the lungs. Hold breath for 2-3 seconds and exhale slowly through the nose and emptying the lungs.
48721740|NCT02383771|DRUG|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
48721741|NCT01348555|DRUG|Bronchodilatator|
48721742|NCT01348555|DRUG|Bronchodilatator|
48721743|NCT04634942|DEVICE|Cryos REF 0971 Cold Spray|Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
48522748|NCT04768192|PROCEDURE|Physical Rehabilitation with Lokomat|"The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games."
48721744|NCT04634942|DEVICE|ShotBlocker BIONIX Press Firmly USA|ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
48721745|NCT03032445|OTHER|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
48721746|NCT03032445|OTHER|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
48721747|NCT01800656|PROCEDURE|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
48721748|NCT01800656|PROCEDURE|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
48721749|NCT05204056|DRUG|iced normal saline|Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
48721750|NCT05204056|DRUG|Tranexamic acid injection|20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
48721751|NCT05204056|OTHER|Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion|Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
48721752|NCT01123824|DRUG|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
48721753|NCT01123824|DRUG|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
48721754|NCT05202821|DRUG|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
48721755|NCT05202821|DRUG|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
48721756|NCT05202821|DRUG|MI paste|Third group will be receiving MI paste
48721757|NCT02758301|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
48721758|NCT05883254|DIAGNOSTIC_TEST|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
48721759|NCT05551624|DRUG|Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet|Oral tablets administered daily, atorvastatin once a day and N-acetylcysteine every 8 hours
48721760|NCT05265507|DRUG|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
48721761|NCT05265507|DRUG|Ondansetron|Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
48721762|NCT01840254|DRUG|dexmedetomidine|
48721763|NCT01840254|DRUG|normal saline|
48721764|NCT01013415|DRUG|HAART|
48721765|NCT01013415|BIOLOGICAL|T cells|
48721766|NCT04489121|DRUG|Omalizumab|For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
48721767|NCT03022981|DRUG|SOF/VEL|SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
48721768|NCT03022981|DRUG|SOF/VEL|SOF/VEL FDC 200/50 mg oral granules
48721769|NCT05622214|DIETARY_SUPPLEMENT|Else nutrition formula|Plant based nutrition from almond and buckwheat
48721770|NCT03976284|BEHAVIORAL|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
48721771|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
48721772|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
48721773|NCT00574548|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
48721774|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
48721775|NCT00574548|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
48721776|NCT05275790|DEVICE|Vestal device|Battery powered non-invasive neurostimulation device
48721777|NCT05275790|BEHAVIORAL|Lifestyle intervention|All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
48384212|NCT06537479|OTHER|Chest Wall Mobilization|It started with positioning, sitting or standing with good posture, and relaxing shoulders and arms. Hands were placed on the chest with fingers wide and thumbs on side of ribcage. Inhale deep breaths with expansion of chest and hands move outward. Exhale slowly allowed the chest to drop and the hands to move inward.
48384213|NCT06064110|BEHAVIORAL|Pictou County Person Empowerment Program|The 6 month home-based program focuses on aerobic and strength training, meditation/relaxation techniques, social connection, and overall healthy lifestyle practices supported with daily email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily, the meditation/relaxation practice is 10 minutes daily, the intimacy and connection component consists of engaging in at least one form of intimacy practice prescribed, per day. Optional social connection components will be offered, such as pairing participants up with peers from the study, monthly Zoom videoconferences, and monthly in-person events in Pictou County to further promote healthy lifestyle habits.
48384214|NCT04813653|DRUG|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
48384215|NCT03184376|DIETARY_SUPPLEMENT|Prebiotic oligofructose|Powder format
48384216|NCT03184376|DIETARY_SUPPLEMENT|Placebo maltodextrin|Powder format
48384217|NCT05639894|BIOLOGICAL|RSV vaccine candiate formulation 1|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
48384218|NCT05639894|BIOLOGICAL|RSV vaccine candidate formulation 2|Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
48384219|NCT05639894|OTHER|Placebo|Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
48384220|NCT05752396|OTHER|Conditioned Pain Modulation|Conditioned pain modulation (CPM) procedure evaluates the change in mechanical and heat pain sensitivity by a contralateral conditioning stimulus (cold immersion). This psychophysical paradigm investigates inhibitory pain modulation processes.
48384221|NCT05752396|OTHER|Offset Analgesia|Offset analgesia (OFA) procedure evaluates the disproportionate change in heat pain sensitivity after a slight decrease in stimulus intensity. This psychophysical paradigm investigates inhibitory pain modulation processes.
48384222|NCT05752396|OTHER|Spatial Summation|Spatial summation (SS) procedure evaluates the change in heat pain sensitivity when applying two painful stimuli simultaneously compared to one stimulus alone. This psychophysical paradigm investigates facilitatory pain modulation processes.
48384223|NCT05752396|OTHER|Temporal Summation|Temporal summation (TS) procedure evaluates the change in mechanical pain sensitivity after exposure to a series of noxious stimuli of the same intensity. This psychophysical paradigm investigates facilitatory pain modulation processes.
48384224|NCT00769132|DRUG|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
48384225|NCT00769132|DRUG|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
48384226|NCT00769132|DRUG|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
48721778|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive a second cycle of vaccination
48384227|NCT00769132|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
48384228|NCT06562556|DEVICE|the breather device|investigate the effect of the breather device on ventilatory effort and in patients with myogenic temporomandibular joint disorders
48522749|NCT06143280|OTHER|Data collection|Data collection using entries in the medical records of the respective patients (surgery reports, progress notes, consultation reports, imaging and pathology reports) who underwent surgery with the new dynamic technique for soft palate reconstruction.
48721779|NCT01884415|BIOLOGICAL|HBV vaccine|Patients receive vaccination according to the guidelines.
48721780|NCT02796885|OTHER|no intervention - observational study|
48721781|NCT01137019|DEVICE|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
48721782|NCT01137019|DEVICE|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
48025691|NCT00387218|BEHAVIORAL|Exercise, Physical therapy|
48025692|NCT00377195|RADIATION|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
48721783|NCT03410342|OTHER|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
48721784|NCT03410342|OTHER|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
48721785|NCT03410342|OTHER|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
48721786|NCT03208439|DEVICE|lower-limb cycling system|patients will receive 30-minute cycling exercise
48721787|NCT00773890|DRUG|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
48721788|NCT00773890|DRUG|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
48721789|NCT03364413|OTHER|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
48721790|NCT04190797|DEVICE|Photobiomodulation + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
48721791|NCT04190797|DEVICE|Placebo + patiente controled anaethesia (PCA)|Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
48721792|NCT04542720|PROCEDURE|Observational: Decompression|Patients will undergo decompression alone of the supradjacent level. The surgical technique will be surgeon dependent. All surgeons will be encouraged to avoid damaging facet joints above the fusion mass, retaining 50% of the pars of the decompressed level and performing as minimal of a medial facetectomy as necessary.
48721793|NCT04542720|PROCEDURE|Observational: Extension Fusion|Patients will undergo decompression and extension of posterior instrumentation and fusion. This may or may not include exchange of pre-existing instrumentation. The use of interbody cages will be left to the discretion of the treating surgeon. The purpose of introducing this heterogeneity is to increase the generalizability of the trial results. The fusion cohort will not utilize bone morphogenetic protein products.
48721794|NCT04343014|DEVICE|Tongue Root Retractor|Fibroptic endutracheal intubation will be performed with tongue root retractor.
48182775|NCT06546722|PROCEDURE|Transversus Thoracic Plane Block|The Transversus Thoracic Plane Block is a recent regional anesthesia technique. It provides analgesia for the anterior cutaneous branches of the intercostal nerves T2-6 to the medial anterior chest wall via a single injection of local anesthesia between the internal intercostal muscle and the transversus thoracic muscle located between the third and fourth (or fourth and fifth) intercostal space. It is noteworthy that the TTPB can consequently reduce pulmonary morbidity and the need for high-dose opioids.
48182776|NCT02907437|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
48182777|NCT02907437|DRUG|Placebo|(200 mg/day)
48182778|NCT02907437|OTHER|Probiotics|(450 mg/day)
48182779|NCT00104767|DRUG|celecoxib|
48384229|NCT06562556|OTHER|conventional exercise program|"-Therapeutic Ultrasound (US): Ultrasound therapy will be applied at the site of pain over the TMJ area with Frequency: 1 MHz, Mode: continuous, Duration: 6 min. each session 2-Myofascial release for masticatory muscles 3-The self-exercise Self exercise: include simplified myo-functional therapy. 10 repetitions, three: five times per day 4-Techniques to correct deglutition: swallowing a small amount of water and speaking while holding a semi-hard small object between the dental arches 5-Relaxation exercise of Masticator Muscle:10 repetitions, three.~6-Strain-counterstain (SCS): applied on the tender or trigger points of neck muscles on improving pain and pressure pain sensitivity in neck muscles"
48384230|NCT02192307|DEVICE|Potassium oxalate|
48384231|NCT03353415|DEVICE|Dexcom CGM masked|"The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
48721795|NCT04343014|DEVICE|Conventional Fibroscope|Fibroptic endutracheal intubation will be performed in conventional way.
48721796|NCT04943692|DRUG|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
48721797|NCT04943692|DRUG|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
48721798|NCT02598128|DEVICE|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
48721799|NCT02598128|DEVICE|Placebo|Sham device
48721800|NCT05948618|BEHAVIORAL|Embodied Conversational Agent|The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
48721801|NCT05948618|BEHAVIORAL|REDCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
48721802|NCT01744314|DRUG|Indomethacin and Pantoprazole|
48721803|NCT01744314|DRUG|microcrystalline cellulose powder tablets|
48721804|NCT02619721|DEVICE|PINS SNS|
48721805|NCT04762524|OTHER|CVVH vs CVVHD|Patients are initiated on CRRT in either the CVVH or CVVHD modality
48721806|NCT00554658|DRUG|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
48721807|NCT04714021|OTHER|CO2|to insufflate CO2 into the stomach instead of air during the PEG
48721808|NCT04714021|OTHER|air|to insufflate air into the stomach instead of CO2 during the PEG
48721809|NCT00829491|BEHAVIORAL|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
48721810|NCT01072825|OTHER|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
48721811|NCT01072825|BIOLOGICAL|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if\> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
48520338|NCT04932421|BEHAVIORAL|Emotion Detectives: Unified protocol for transdiagnostic treatment of emotional disorders in children (UP-C)|"UP-C is a transdiagnostic and emotion-focused cognitive-behavioral group intervention for children aged 6-13 years old with emotions disorders (i.e., anxious and/or mood disorders) and their parents. UP-C unifies cognitive-behavioral, contextual (eg. mindfulness) and parental training techniques aiming to reduce the intensity and frequency of children's clinical symptomatology.~The intervention consists of 15 weekly group sessions (90 minutes per session; 5-8 children and parents per group) conducted by at least two clinical psychologists trained in the UP-C. The sessions start with the parents and children together (15 minutes); then, one psychologist conduct the session with the group of children while the other psychologist conduct the session with the group of parents, simultaneously (60 minutes); finally, the session ends with the group together (15 minutes). This is a structured and manualized intervention with a manual for the therapist and a workbook for the child and parents."
48721812|NCT01072825|OTHER|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
48721813|NCT01072825|OTHER|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
48721814|NCT01072825|OTHER|Bone evaluation|PQCT scanner, BMD assessment
48384232|NCT03353415|DEVICE|Dexcom CGM unmasked|"During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation)."
48721815|NCT01107782|DRUG|sildenafil|50 mg TDS orally until birth
48721816|NCT01107782|DRUG|placebo|50mg tid
48721817|NCT05547789|DRUG|non steroidal anti inflammatory drugs|effect of non steroidal anti inflammatory drugs on macular changes
48721818|NCT03764267|DRUG|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
48025693|NCT06387251|OTHER|30 day wellness program|30 days and will evaluate the effects of sponsor-designed 30-day wellness program consisting of 3 supplement and functional food products, recommended diet, physical activity, hydration and mindfulness activities.
48025694|NCT03736200|OTHER|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (1/day)
48384233|NCT02723786|BIOLOGICAL|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
48025695|NCT03736200|OTHER|Physiotherapy|Physiotherapy 4-week-long.
48025696|NCT03736200|OTHER|Exergaming group 2/day|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/day)
48025697|NCT00105027|OTHER|Standard Care|CRVO: observation; BRVO: standard care
48025698|NCT00105027|DRUG|intravitreal triamcinolone injection|1 mg dose
48025699|NCT00105027|DRUG|intravitreal triamcinolone injection|4 mg
48025700|NCT00297453|BEHAVIORAL|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
48384234|NCT02723786|DRUG|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
48025701|NCT00297453|BEHAVIORAL|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
48025702|NCT00297453|BEHAVIORAL|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
48025703|NCT05914610|DRUG|Envolimab|Envolizumab 300mg, D1, ih, Q3W 4-6cycles
48025704|NCT05914610|DRUG|Fruquintinib|Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
48520339|NCT04932421|OTHER|ABC of Emotions|"ABC of Emotions is a psychoeducational group intervention for children with anxiety and/or mood disorders, aged between 6 to 13 years. ABC of Emotions consists of 5 group psychoeducation sessions (about 90 minutes per session; 5-8 children per group). This is a structured and manualized intervention, with a manual for the therapist and a workbook for the child.~The contents of the sessions were developed by the researchers of this study and are based on classic psychoeducational cognitive-behavioral therapies (CBT) strategies. Since anxiety disorders are more frequent in childhood than mood disorders (e.g., Merikangas et al., 2009), this program is essentially based on psychoeducation materials focused on emotions such as anxiety and fear. However, the same materials are available in an attachment, adapted for use with children to whom the main emotion is not fear/anxiety, but sadness (as in mood disorders)."
48384235|NCT02404675|DRUG|icotinib|
48384236|NCT06454955|DRUG|[68Ga] B7H3 Affibody-BCH|An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.
48520340|NCT02198937|OTHER|Blood sample|
48520341|NCT03340090|DEVICE|Medical Device Hemopatch-PEG-coated collagen patch|Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
48520342|NCT04932512|DRUG|ION224|ION224 will be administered by SC injection.
48520343|NCT04932512|OTHER|Placebo|ION224-matching placebo solution will be administered by SC injection.
48384237|NCT06005740|DRUG|TORL-4-500|antibody drug conjugate
48384238|NCT06161038|DEVICE|LASER|LLLT with a 685-nm wavelength and an output of 30 mW (BTL-5000 Laser, BTL, Stevenage, UK) at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
48384239|NCT06161038|DEVICE|Ultrasound|1 MHz therapeutic ultrasound for 5 min at a frequency of 4-6 times two week at the painful upper trapezius muscle.
48384240|NCT06161038|DRUG|Prolotherapy|Hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
48384241|NCT05153629|DEVICE|TENS|TENS device used four times a day for 60 minutes each time
48384242|NCT04725214|DRUG|Anlotinib|Anlotinib With STUPP Regimen
48384243|NCT01922635|OTHER|Valadation of the metrological properties of questionnaire of quality of life|
48384244|NCT02122939|DRUG|Escitalopram|
48384245|NCT06384534|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
48520344|NCT03878212|OTHER|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
48520345|NCT03878212|OTHER|mHealth application|a mHealth device
48025705|NCT05914610|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
48520346|NCT04081909|DRUG|Fentanyl，Remifentanil|Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
48520347|NCT04081909|DRUG|Ketamine,Dexmedetomidine|Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
48520348|NCT00929461|DRUG|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
48520349|NCT00003080|DRUG|endocrine-modulating drug therapy|
48384246|NCT06384534|OTHER|6-minute walk distance test with supplemental oxygen|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
48520350|NCT00003080|DRUG|melphalan|
48520351|NCT00003080|DRUG|mitoxantrone hydrochloride|
48025706|NCT05914610|DRUG|Tegafur|Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles
48025707|NCT01296568|DRUG|LY2603618|Administered intravenously
48025708|NCT01296568|DRUG|Pemetrexed|Administered intravenously
48025709|NCT01296568|DRUG|Gemcitabine|Administered intravenously
48025710|NCT02800044|DEVICE|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
48520352|NCT00003080|DRUG|tamoxifen citrate|
48520353|NCT00003080|DRUG|thiotepa|
48520354|NCT00003080|PROCEDURE|peripheral blood stem cell transplantation|
48520355|NCT05516186|OTHER|Scapular-focused exercise protocol with EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol with the aid of the electromyographic biofeedback
48520356|NCT05516186|OTHER|Control Therapy|manual and exercise therapy
48520357|NCT05516186|OTHER|Scapular-focused exercise protocol without EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol
48520358|NCT04814173|OTHER|One-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the one-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the maxillary arch between the roots of 2nd premolar and 1st molar and closer to the molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals).
48520359|NCT04814173|OTHER|Two-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
48520360|NCT04814173|OTHER|en-mass retraction|A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
48721819|NCT03764267|DRUG|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
48520361|NCT00054405|BIOLOGICAL|recombinant interleukin-12|Given IV
48520362|NCT00054405|BIOLOGICAL|aldesleukin|Given IV
48520363|NCT05008211|OTHER|Information-Motivation-Behavioral skills (IMB) model-based intervention|A six-week programme
48520364|NCT05008211|OTHER|Control - usual care|he nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems
48520365|NCT00681343|DRUG|Thymoglobulin|Induction
48520366|NCT00681343|DRUG|Campath-1H|Induction
48520367|NCT00681343|DRUG|Daclizumab|Induction
48520368|NCT00932672|BEHAVIORAL|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
48520369|NCT02190370|BEHAVIORAL|Resources activation|
48520370|NCT04428034|BEHAVIORAL|Learning Skills Together|Information provided in arm/group description.
48520371|NCT04583735|BIOLOGICAL|TEPEZZA|Intravenous infusion
48520372|NCT04583735|DRUG|Placebo|Intravenous infusion
48520373|NCT02245516|DRUG|KPI-121 0.25% Ophthalmic Suspension|KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
48520374|NCT02245516|DRUG|KPI-121 1.0% Ophthalmic Suspension|KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
48520375|NCT00829725|DEVICE|screws-internal fixation|3-4-screws-internal fixation
48721820|NCT03300297|OTHER|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
48721821|NCT03300297|OTHER|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
48721822|NCT03300297|OTHER|Home Program|therapeutic exercise program and education
48721823|NCT03300297|OTHER|Suboccipital Release|suboccipital soft tissue mobilization
48520376|NCT00829725|DEVICE|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
48721824|NCT06473935|OTHER|Questionnaires and focus groups|"Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes."
48721825|NCT06543927|DIAGNOSTIC_TEST|serum creatinine|Detection of renal impairment in patients receiving anticoagulants
48721826|NCT06543927|DIAGNOSTIC_TEST|INR|Detection of bleeding in patients with choronic kidney disease receiving anticoagulants
48721827|NCT03105648|OTHER|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
48721828|NCT06508034|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
48721829|NCT06508034|DIETARY_SUPPLEMENT|Live Freeze-Dried Lactic Acid Bacteria Probiotic|Given PO
48721830|NCT06508034|OTHER|Questionnaire Administration|Ancillary studies
48721831|NCT03217799|DEVICE|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
48520377|NCT00723502|DRUG|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
48520378|NCT00723502|DRUG|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
48520379|NCT03412695|DEVICE|MyFood|Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
48721832|NCT05325294|DEVICE|MiniMed 780G System|MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
48721833|NCT01494519|PROCEDURE|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
48721834|NCT01494519|PROCEDURE|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
48721835|NCT05570890|DEVICE|electrical noise stimulation|The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.
48721836|NCT05570890|DEVICE|Sham stimulation|Participants will not receive stimulation.
48721837|NCT05570890|DEVICE|Foam|The foam will be used to make an unstable surface.
48721838|NCT04784468|OTHER|No intervention|Case-control design, one single investigation
48721839|NCT00512291|DRUG|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
48721840|NCT00424411|DRUG|Inhaled human insulin (EXUBERA™)|
48721841|NCT01475162|DRUG|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
48721842|NCT01415804|DEVICE|endoprosthesis|Thoracic aortic stentgraft
48721843|NCT04167072|PROCEDURE|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
48721844|NCT02903394|DEVICE|mLCI Device|imaging of cervical epithelium using mLCI device
48721845|NCT04826016|DRUG|POL6326|POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
48721846|NCT04826016|DRUG|Eribulin|Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
48721847|NCT04826016|DRUG|Nab paclitaxel|Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
48721848|NCT06428812|OTHER|Experimental: perineal package application group|This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
48025711|NCT04504877|DRUG|Cannabidiol|Cannabidiol 300 mg daily for 4 weeks
48025712|NCT05054335|OTHER|Functional Assessment|Undergo walking function assessment with optical motion capture
48520380|NCT04168892|DRUG|150 IU of HMG in patients with age ≤ 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
48721849|NCT04453176|OTHER|Patient Satisfaction|Patient satisfaction evaluated with EVAN G questionnaire
48721850|NCT02179541|OTHER|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
48721851|NCT02920723|OTHER|Training|
48721852|NCT02920723|OTHER|Control|
48025713|NCT05054335|PROCEDURE|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
48520381|NCT04168892|DRUG|225 IU of HMG in patients with age > 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
48721853|NCT06475040|DEVICE|transcranial magnetic stimulation|non-invasive form of brain stimulation accelerated intermittent theta burst stimulation (aiTBS)
48721854|NCT01458834|BEHAVIORAL|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
48721855|NCT01458834|BEHAVIORAL|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (\< or \>). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
48721856|NCT03828474|DRUG|Acetazolamide Pill|Acetazolamide pill
48025714|NCT06395285|DRUG|DF-003|140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
48721857|NCT02342379|DRUG|Bevacizumab|10mg/kg
48721858|NCT02342379|DRUG|TH-302|670mg/m2
48721859|NCT05549154|DRUG|High-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
48721860|NCT05549154|DRUG|low-dose vitamin D2 softgels|5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
48721861|NCT05549154|DRUG|placebo|placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
48520382|NCT05063474|DIAGNOSTIC_TEST|No Intervention-Clinical Assessments only|No Intervention. Clinical Assessments include: vital signs, near infrared spectrometry, general leg strength, and 6-minute walking test.
48520383|NCT02044263|BEHAVIORAL|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
48721862|NCT02098889|DRUG|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
48721863|NCT02098889|DRUG|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
48721864|NCT04225819|DIETARY_SUPPLEMENT|Vitamin D3|Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water
48721865|NCT04225819|OTHER|Placebo|Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
48721866|NCT04758520|DEVICE|FLOAT upper limb exoskeleton|The FLOAT device is composed by a wearable exoskeleton assembled on a poly-articulated arm that, in turn, is mounted on a support base with unlockable wheels. The exoskeleton includes 5 motors arranged in a way that, when generating movement, ensures the optimal involvement of all the articulations of the shoulder complex, particularly the glenohumeral and the scapulothoracic joints. According to the chosen modality of use of the exoskeleton, the device allows patient's passive or active-assisted mobilization. The poly-articulated arm supporting the exoskeleton is capable to compensate exoskeleton weight in every configuration and, if configured appropriately, permits exoskeleton use both in seated and standing positions. The support base of the device has unlockable wheels that, if unlocked, permit the free movement of the patient in the workspace, enabling the performance of more complex functional activities while assisted by the exoskeleton.
48721867|NCT02680470|DEVICE|Virtual observed therapy|Virtual Observation of participants taking their medication
48721868|NCT01179061|DRUG|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
48721869|NCT01179061|DRUG|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
48721870|NCT05164146|DRUG|propofol|during the induction, remimazolam dose was controlled according to sedline (Psi target 40)
48384247|NCT06116292|DEVICE|The mobile application ESTOI for Asthmatic patients|"The mobile application ESTOI have various sections that can be managed and customized by the researchers to meet each patient's needs:~1. SYMPTOM CONTROL, it will record the ACT, TAI, the number of exacerbations, weight, and, depending on the case, symptom control for comorbidities.~2. RECOMMENDATIONS, it will provide patients with information needed to understand their condition, how to control it, and what to do in case of worsening symptoms.~3. YOUR TREATMENT, it will display personalized and update information about the patient's current asthma medication, including dosages and frequencies. There will be explanatory videos on how to administer the therapy and includes an action plan.~4. PEAK FLOW, the patient can record measurements using a Peak Flow Meter at home.~5. NUTRITIONAL PLAN, it will provide a daily dietary guide to enable individuals to adapt these tools and recommendations to their specific needs.~6. MESSAGING, it is a bidirectional contact area."
48384248|NCT03125564|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
48384249|NCT03125564|PROCEDURE|Sham|Infusion of sham
48384250|NCT03125564|PROCEDURE|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
48520384|NCT02044263|BEHAVIORAL|face-to-face CBT-i|
48520385|NCT02102113|DRUG|Placebo|placebo
48520386|NCT02102113|DRUG|Very Low Dose THC|Subjects will receive 0.010mg/kg.
48520387|NCT02102113|DRUG|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
48025715|NCT01294839|DEVICE|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
48025716|NCT02912533|DRUG|JR-131|
48025717|NCT03952247|DEVICE|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
48025718|NCT03952247|DEVICE|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
48384251|NCT03770481|BEHAVIORAL|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
48384252|NCT04438980|DRUG|Methylprednisolone|-A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión
48025719|NCT04193813|OTHER|Observational|Observational study
48182780|NCT06544850|OTHER|experimental group|Oswestry Low Back Pain Questionnaire will be used to assess functional limitations in daily life activities of patients with low back pain. Recognize mobile application will be used to assess lateralization performance. Evaluation will be made with hand, foot and back modules of this application. Reaction time and accuracy given at the end of the application will be recorded. The most accurate response instruction will be given in the shortest possible time. Visual Analog Scale (VAS) will be used to measure general pain status of patients. Tampa Kinesiophobia Scale will be used to assess fear of movement. Pain catastrophizing level will be assessed with Pain Catastrophizing Scale. Two-point discrimination device will be used to assess two-point discrimination. Central Sensitization Inventory will be used for central sensitization findings.
48384253|NCT04438980|OTHER|Placebo|-An infusion bag of 100 mL of 0.9% saline
48384254|NCT01583400|OTHER|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
48384255|NCT01583400|OTHER|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
48384256|NCT02069145|DRUG|OMP-54F28 with Sorafenib|
48384257|NCT03037918|DIETARY_SUPPLEMENT|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
48384258|NCT00312936|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|8 week program
48025720|NCT01850160|DRUG|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
48025721|NCT01850160|DRUG|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
48182781|NCT06544850|OTHER|control group|Healthy volunteer participants who meet the inclusion criteria will be evaluated with the tests applied to the experimental group
48182782|NCT06545318|DEVICE|Density Gradient Centrifugation|Sperm separation with density gradients
48025722|NCT01850160|DRUG|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
48025723|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
48182783|NCT06545318|DEVICE|CA0 chamber|Sperm separation with a novel device
48025724|NCT01070875|DRUG|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
48025725|NCT04028375|OTHER|No intervention|No intervention
48025726|NCT03070522|DRUG|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
48025727|NCT03070522|DRUG|Placebos|Placebo
48025728|NCT05968612|DRUG|Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet|Film-coated tablet administered orally.
48025729|NCT05968612|DRUG|Lumacaftor 200 mg Film-Coated Tablet Formulation|Film-coated tablet administered orally.
48384259|NCT02018601|PROCEDURE|BRILMA|
48384260|NCT02018601|PROCEDURE|paravertebral block|
48384261|NCT02018601|DRUG|dexketoprofen|
48384262|NCT02018601|DRUG|paracetamol|
48520388|NCT02042118|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
48520389|NCT02042118|DEVICE|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
48025730|NCT02861781|OTHER|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
48520390|NCT02497586|RADIATION|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
48182784|NCT03278743|OTHER|Cognitive performance and cognitive decline|Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
48182785|NCT01613690|DRUG|NVA237|NVA237 is administered via a BREEZHALER device
48384263|NCT03930901|OTHER|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), \& nail clipper).
48721871|NCT05164146|DRUG|remimazolam|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
48721872|NCT00797680|OTHER|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
48182786|NCT03333161|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
48182787|NCT01782521|PROCEDURE|No primer|Primer not used when bonding orthodontic brackets
48182788|NCT06099119|DRUG|creon 35.000 Ph.U (R)|Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.
48182789|NCT06099119|OTHER|Best Standarard of Care|Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month
48384264|NCT02127788|DRUG|Micafungin|intravenous
48182790|NCT00989547|OTHER|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
48182791|NCT00709501|BEHAVIORAL|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
48182792|NCT00709501|BEHAVIORAL|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
48182793|NCT01263249|PROCEDURE|Catheter Anterior to the Femoral Nerve|Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
48384265|NCT05661071|OTHER|Modified Mini Mental Test:|To assess the cognitive function of children
48384266|NCT05661071|OTHER|The Controlled Oral Word Association Test|To assess the cognitive function of children
48384267|NCT05661071|OTHER|The Central Nervous System Vital Signs|To assess the cognitive function of children
48182794|NCT01263249|PROCEDURE|Catheter Posterior to the Femoral Nerve|Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
48182795|NCT02323568|OTHER|Gynecological consultation|
48182796|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
48384268|NCT05661071|OTHER|Conners' Parent Rating Scale-48 (Parent Report)|To assess attention-deficit/hyperactivity disorder
48384269|NCT05661071|OTHER|Child Behavior Checklist 6-18 ages (Parent Report)|To assesses both child adaptive behaviors and problem behaviors.
48384270|NCT05661071|OTHER|Strengths and Difficulties Questionnaire (Self-Reported)|It is a brief emotional and behavioural screening questionnaire for children and young people.
48520391|NCT04747470|DRUG|GS-3583|Administered as an intravenous (IV) infusion
48520392|NCT04747470|DRUG|Zimberelimab|Administered as an IV infusion
48520393|NCT04747470|DRUG|Cisplatin|Administered as an IV infusion
48520394|NCT04747470|DRUG|Carboplatin|Administered as an IV infusion
48520395|NCT04747470|DRUG|5-Fluorouracil|Administered as an IV infusion
48721873|NCT00797680|OTHER|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
48721874|NCT01207245|OTHER|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
48721875|NCT03631277|DEVICE|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
48721876|NCT03631277|DRUG|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
48721877|NCT00295932|BIOLOGICAL|rituximab|Given IV
48721878|NCT00295932|DRUG|bortezomib|Given IV
48721879|NCT00295932|DRUG|cyclophosphamide|Given IV
48721880|NCT00295932|DRUG|prednisone|Given orally
48721881|NCT04871594|DRUG|Nivolumab|On day 1, 22, and 43 240mg
48721882|NCT01221194|BEHAVIORAL|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
48721883|NCT01221194|DEVICE|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
48721884|NCT06050798|DIAGNOSTIC_TEST|Von willebrand antigen|Von willebrand antigen change and hematological disorder in patients with angiodysplasia
48721885|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
48721886|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
48721887|NCT04847557|DRUG|Tirzepatide|Administered SC
48721888|NCT04847557|OTHER|Placebo|Administered SC
48721889|NCT01595191|OTHER|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
48721890|NCT01595191|OTHER|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
48721891|NCT00119665|DRUG|MF101|
48721892|NCT06459882|BEHAVIORAL|progressive relaxation exercises|Patients in the intervention group received 30-minute progressive relaxation exercises for 6 weeks
48721893|NCT02177838|BIOLOGICAL|cetuximab|Given IV
48721894|NCT02177838|DRUG|cisplatin|Given IV
48721895|NCT02177838|RADIATION|external beam radiation therapy|Undergo EBRT
48025731|NCT05642572|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48025732|NCT05642572|DRUG|Capmatinib|Given PO
48025733|NCT05642572|PROCEDURE|Computed Tomography|Undergo CT scan
48182797|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
48384271|NCT05661071|OTHER|Brooke Lower Extremity Functional Classification|To determine the functional status of the lower extremity
48384272|NCT05661071|OTHER|Motor Function Measurement-32 Items|To assessment of motor function and progression of weakness in neuromuscular disorders
48025734|NCT05642572|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48025735|NCT05642572|DRUG|Osimertinib|Given PO
48025736|NCT05642572|BIOLOGICAL|Ramucirumab|Given IV
48025737|NCT06574100|DRUG|Cannabidiol|Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.
48182798|NCT00524186|DRUG|fluorouracil|Given IV
48182799|NCT00524186|DRUG|irinotecan hydrochloride|Given IV
48182800|NCT00524186|DRUG|leucovorin calcium|Given IV
48182801|NCT00524186|DRUG|sunitinib malate|Taken Orally
48182802|NCT00524186|OTHER|flow cytometry|Correlative Study
48182803|NCT00524186|OTHER|pharmacological study|Correlative Study
48182804|NCT02337621|OTHER|No intervention|
48520396|NCT04747470|DRUG|Docetaxel|Administered as an IV infusion
48721896|NCT02177838|OTHER|laboratory biomarker analysis|Correlative studies
48721897|NCT04408768|OTHER|standard protocol for stroke patients|Standard protocol for stroke patients
48721898|NCT05275530|BEHAVIORAL|Active FIT Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a FIT, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
48721899|NCT05275530|BEHAVIORAL|Active Colonoscopy Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about colonoscopy as a screening strategy. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with a colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
48721900|NCT05275530|BEHAVIORAL|Active Dual Choice|The investigators will send randomized participants a message via MyChart indicating the benefits of CRC screening, along with tailored information about FIT Kit and Colonoscopy screening. At the end of the message, participants will complete a survey asking them to indicate if they would like to be screened for CRC with either a FIT or Colonoscopy, or if they prefer no screening whatsoever. The investigators will then ask follow-up questions to better understand the reason patients made their respective choices.
48721901|NCT02999152|OTHER|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
48721902|NCT03630744|OTHER|Fluid therapy|"* Analyze the type of fluid administered:~  * crystalloids:~    * Saline serum 0.9% ....... ml~   * Ringer Lactate ........ ml~   * Isofundin ® ........ ml~   * Plasmalyte® ... ... ml~   * Glucose Serum 5% ....... ml~   * Glucose serum 10% ........ ml~ * Glucosaline serum ........ ml~ * colloids:~    * Hydroxyethyl starch 130 / 0.4 ... ... ml~   * Hydroxyethyl alimdon 130 / 0.42 ... .... ml~   * Gelatins ... ....... ml~   * Albumin 5% .......... ml~ * Albumin 20% .......... ml.~* Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~* Analyze the form of administration:~  * Standard~ * Standard with dosimeters~ * on pump"
48721903|NCT02286323|DEVICE|Bonfils|Bonfils Intubation Fiberoscope
48721904|NCT02286323|DEVICE|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
48721905|NCT04430647|PROCEDURE|combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)|performing ultrasound ciliary plasty then performing standard phacoemulsification
48721906|NCT04430647|PROCEDURE|Phacoemulsification alone|standard phacoemulsification for catarct extraction
48721907|NCT00049595|BIOLOGICAL|bleomycin sulfate|
48721908|NCT00049595|BIOLOGICAL|filgrastim|
48721909|NCT00049595|BIOLOGICAL|pegfilgrastim|
48721910|NCT00049595|DRUG|ABVD regimen|
48721911|NCT00049595|DRUG|BEACOPP regimen|
48721912|NCT00049595|DRUG|cyclophosphamide|
48721913|NCT00049595|DRUG|dacarbazine|
48721914|NCT00049595|DRUG|doxorubicin hydrochloride|
48721915|NCT00049595|DRUG|etoposide|
48721916|NCT00049595|DRUG|prednisone|
48721917|NCT00049595|DRUG|procarbazine hydrochloride|
48721918|NCT00049595|DRUG|vinblastine sulfate|
48721919|NCT00049595|DRUG|vincristine sulfate|
48721920|NCT06265623|OTHER|No active intervention, but observational follow-up|Patients remain in usual care by their pulmonary medicine specialists and are being observed during annual follow-up investigations during up to 3 years
48721921|NCT05876247|OTHER|Electromagnetic Articulography|Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
48721922|NCT03825237|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
48721923|NCT00862472|DRUG|DuoTrav APS|DuoTrav APS QD AM
48721924|NCT00862472|DRUG|DuoTrav|DuoTrav QD AM
48721925|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (English)|completing the English version of the AGPM and validated health literacy and numeracy instruments
48721926|NCT06386861|OTHER|Attitudes Toward Genomics and Precision Medicine (Spanish)|completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
48721927|NCT04191785|DIAGNOSTIC_TEST|plasmatic NGAl and MRI|Determination of plasma NGAL protein during routine blood test Realization of a reno vesical MRI at 48 hours of inclusion
48182805|NCT03132506|OTHER|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
48384273|NCT05661071|OTHER|Four Square Step Test|A test of dynamic balance and coordination that clinically assesses the participant's ability to step over objects forward, sideways, and backwards.
48025738|NCT06574100|DRUG|Cannabidiol|Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
48025739|NCT06397404|DIAGNOSTIC_TEST|Venous excess ultrasound score (VExUS) protocol|All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.
48025740|NCT00709722|DRUG|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
48025741|NCT04905680|DEVICE|CGM lifestyle tracking and coaching|"Participants in the experimental group will go through a total of 5 lifestyle tracking sessions (including baseline), of which 1 will include CGM tracking. For this CGM lifestyle tracking session, experimental group participants will receive real-time feedback through the study applications, which will display the CGM trace.~The data collected during the lifestyle tracking sessions will be discussed with the participants during 3 face-to-face coaching and 2 tele-coaching sessions, where the participants will develop and implement lifestyle change action plans."
48721928|NCT02881619|DRUG|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
48721929|NCT02881619|DRUG|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
48721930|NCT05671796|GENETIC|Mesenchymal stem cell transplantation|Patients will undergo two autologous bone marrow stem cell transplantation into the lesion area
48721931|NCT05671796|OTHER|Placebo|Patients will undergo two subcutaneous injections of 1 ml of glycophysiological solution into the lesion area by sham procedure
48721932|NCT05373693|DEVICE|Single vision lens|Wear single vision lens
48721933|NCT05373693|DEVICE|+2D PDL|Wear Peripheral defocus lense with +2D
48721934|NCT05373693|DEVICE|+3D PDL|Wear Peripheral defocus lense with +3D
48721935|NCT05373693|DEVICE|+4D PDL|Wear Peripheral defocus lense with +4D
48721936|NCT00002112|DRUG|Nystatin|
48721937|NCT00002112|DRUG|Fluconazole|
48721938|NCT06526156|DRUG|Bupivacaine injection|A 3 mL hypobaric (0.33%) solution of bupivacaine, prepared by mixing 2 mL of isobaric (0.5%) bupivacaine with 1 mL of sterile water. Dural puncture will be performed using a 25 or 27G (gauge) spinal needle at the L5-S1 intervertebral space, and the 3 mL of 0.33% bupivacaine will be injected into the intrathecal space.
48721939|NCT05223387|DEVICE|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
48721940|NCT05223387|DEVICE|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
48721941|NCT03773107|DRUG|Carfilzomib|Irreversible proteasome inhibitor
48721942|NCT03773107|DRUG|Ruxolitinib|Oral JAK inhibitor
48721943|NCT03773107|DRUG|Dexamethasone|glucocorticoid
48721944|NCT02782026|DEVICE|Exhaled Breath Olfactory Signature (Artificial Nose)|
48721945|NCT00030277|PROCEDURE|high-intensity focused ultrasound ablation|
48721946|NCT05992194|OTHER|multimodal oculomotor measurements|"* Visual assessment to ensure that the subject meets the inclusion and non-inclusion criteria, including anamnesis and the following visual tests: Lang stereotest, H-test ocular motility, convergence, masking and accommodative rock.~* Evaluation by experimenter A (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR headset~* Evaluation by experimenter B (60 min)~  * Neuro-ophthalmological tests on screen~ * Neuro-ophthalmological tests in VR helmet The sequence of experimenters A-B or B-A will be randomized."
48182806|NCT00624013|DRUG|sertraline|50 mg up to 100 mg daily for 6 months
48025742|NCT02687334|DRUG|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
48721947|NCT04300803|BIOLOGICAL|Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression|Expanded Access Program, Non-Interventional Study
48721948|NCT01848470|DRUG|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
48025743|NCT02258477|DIETARY_SUPPLEMENT|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
48025744|NCT02258477|DIETARY_SUPPLEMENT|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
48025745|NCT02258477|DIETARY_SUPPLEMENT|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
48025746|NCT02258477|DIETARY_SUPPLEMENT|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
48025747|NCT06535074|OTHER|Detecting changes in lung volume with hypoxemia episodes|"Electrical impedance tomography (EIT) will be used to assess changes in lung aeration prior and during hypoxemia episodes to classify them into four different subtypes.~FE subtype: Defined as HEs preceded by reduction in EELI below the baseline.~Apnea subtype: Defined as HEs not meeting the criteria for FE subtype and preceded by cessation of breathing.~Mixed subtype: Defined as HEs meeting the criteria for both FE and apnea subtypes.~Unclassified: Defined as HEs not categorized into any of the above parameters."
48025748|NCT06208618|OTHER|Education and Motivational Interviews|"The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in Illness~Motivational interviews will consist of the following stages:~* First Meeting - Pre-awareness (Pre-contemplation)~* Second Meeting - Awareness (Contemplation)~* Third Meeting - Preparation~* Fourth Meeting - Taking Action (Action)~* Fifth Meeting - Maintenance~* Sixth Meeting - Termination or Review"
48025749|NCT00931021|DRUG|Varenicline (Chantix)|2 mg
48025750|NCT00931021|DRUG|Nicotine Patch|21 mg
48025751|NCT04806815|OTHER|A survey of 60 questions was created through the internet-based 'Google Forms surveys' site.|"The following tests will be used together with the survey;~* Menstrual Symptom Questionnaire~* Fatigue Severity Scale~* Short Form Of Coronavirus Anxiety Scale"
48025752|NCT00003498|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
48025753|NCT00990223|DRUG|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
48182807|NCT00624013|DRUG|Placebo|50 mg up to 100 mg daily for 6 months
48182808|NCT05297344|PROCEDURE|direct pulp capping|direct pulp capping
48182809|NCT05297344|PROCEDURE|pulpotomy|pulpotomy
48182810|NCT06486337|DRUG|CMOP±R|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
48182811|NCT04597346|DEVICE|Bronchoscopic Transparenchymal Nodule Access|Bronchoscopic Transparenchymal Nodule Access (BTPNA) is locating the lesion in the lung tissue guided by the bronchoscope navigation system (LungPro) in the natural lumen (bronchus), and automatically calculates the best point of entry (POE) and the best route to avoid blood vessels. An opening is made from the POE under the endoscope, and is extended with a balloon dilator. Combined with X-ray fluoroscopy, a sheath with a blunt-tip core is used in the lung parenchyma to reach the lesion site, and then biopsy diagnosis or treatment.
48721949|NCT01848470|DRUG|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
48721950|NCT01848470|DRUG|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
48721951|NCT01848470|DRUG|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
48721952|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
48721953|NCT01848470|DRUG|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
48721954|NCT01848470|DRUG|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
48721955|NCT01848470|DRUG|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
48721956|NCT03550768|OTHER|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
48721957|NCT04872998|BEHAVIORAL|Step Count Reduction|Subjects reduce daily step counts by approximately 70% through monitoring and recording from step-count monitor
48721958|NCT05986617|DEVICE|InBody Band 2|Wearable bioimpediance monitor similar to a fitness watch.
48721959|NCT00024011|DRUG|bortezomib|Given IV
48721960|NCT00024011|OTHER|laboratory biomarker analysis|Correlative studies
48025754|NCT05668195|PROCEDURE|systematic aerobic exercise and intelligent monitoring system in executive skill training|This is a closed-loop training initially developed by the research team in conjunction with other teams, adding a systematic aerobic exercise and intelligent monitoring system to the typical executive skill training, and is being further explored in training.
48721961|NCT00071448|DRUG|insulin human|
48721962|NCT00071448|DRUG|insulin lispro|
48721963|NCT00071448|DRUG|insulin aspart|
48721964|NCT03695965|PROCEDURE|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
48721965|NCT03399656|DIETARY_SUPPLEMENT|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
48721966|NCT03399656|DIETARY_SUPPLEMENT|Placebo tablets|MCC 90M Emcocel
48721967|NCT03369613|DEVICE|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
48721968|NCT04279158|BEHAVIORAL|"experience 1 The negative priming task"|The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
48025755|NCT05668195|PROCEDURE|executive skill training|The training program, based on Dawson and Guare's (2010) training of executive skills for children, aimed to improve the everyday performance of executive skills among children with ADHD. Qian Y and her team added some culturally adapted information, following the theory of cognitive behavioral therapy, to ensure that the concepts were acceptable to Chinese children.
48025756|NCT03176160|OTHER|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
48025757|NCT05156723|BIOLOGICAL|Subunit recombinant vaccine for the prevention of coronavirus infection|solution for intramuscular injection, 0.5 ml
48025758|NCT05156723|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
48025759|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
48025760|NCT03790982|DRUG|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
48025761|NCT03790982|DRUG|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
48025762|NCT03790982|DRUG|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
48182812|NCT03826524|DRUG|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
48182813|NCT05087251|BEHAVIORAL|Five Psycho-educational Session(s)|5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
48721969|NCT04279158|BEHAVIORAL|"experience 2 Stop signal task"|The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
48721970|NCT04279158|BEHAVIORAL|"experience 3 Anti-saccades"|The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
48721971|NCT02283307|OTHER|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
48721972|NCT02283307|OTHER|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
48721973|NCT00001909|DRUG|Soluble recombinantly produced IL-4R|
48721974|NCT06104956|DRUG|HFNO weaning protocol|Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
48721975|NCT06104956|DRUG|Standard of care|Weaning methods will be left to the free choice of the practitioner.
48721976|NCT04018742|OTHER|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
48721977|NCT02530736|OTHER|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
48721978|NCT01761773|DRUG|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
48721979|NCT01806649|DRUG|BKM120|
48721980|NCT05811117|DIAGNOSTIC_TEST|There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.|We will study patients that undergo autopsy after CAR T cell infusion.
48721981|NCT06164288|DRUG|Human Amniotic Epithelial Stem Cell Injection|"The dose escalation is carried out according to the 3+3 ascending principle, and a total of 3 dose levels are set:~1. Dose Level 1: 1×106 cells/kg;~2. Dose Level 2: 2×106 cells/kg;~3. Dose Level 3: 3×106 cells/kg; Note: In this study, if the maximum tolerated dose (MTD) is not explored at dose level 3 (3×106 cells/kg), it will be discussed by the Safety Review Committee (SRC) to decide whether to proceed with further dose escalation or expansion to 6 patients."
48520397|NCT00488189|DRUG|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
48025763|NCT03208387|DIAGNOSTIC_TEST|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
48384274|NCT05661071|OTHER|Six Minutes Walk Test|It evaluates the walking function and physical capacity of children at the submaximal level.
48384275|NCT05661071|OTHER|Timed Performance Test|10 meters Walk\& Run Test, Gower's(from a supine to a standing position), Right\& Left Leg Standing, Ascent/Descent of 4 Steps
48384276|NCT06027788|DEVICE|CardioGard Embolic Protection Cannula|The CardioGard embolic protection cannula is a device that combines the function of a standard aortic cannula with an added suction mechanism to capture debris that may result from cardiac surgery. The device is comprised of 2 hollow tubes. The first tube is the standard main forward-flow tube to return oxygenated blood to the patient's aorta. The second tube attached to an existing bypass vent port, is a novel element located posteriorly to the main tube; its function is to facilitate blood and particle suction by directing the blood back to the reservoir of the coronary bypass machine, while the retrieved embolic debris is eliminated through the filter of the venous reservoir.
48384277|NCT06027788|DEVICE|Standard Aortic Cannula|An aortic cannula is a device that is used routinely during cardiac surgery to return oxygenated blood from the cardiac bypass machine into the patient's aorta.
48384278|NCT05219032|BEHAVIORAL|Professional Medical Interpreter|A professional medical interpreter accompanies patient to each appointment.
48384279|NCT03083639|DRUG|Esomeprazole Capsule|Esomeprazole Capsule
48384280|NCT03083639|DRUG|Esomeprazole Tablet|Esomeprazole Tablet
48384281|NCT03620201|DRUG|Bintrafusp Alfa|Given IV
48384282|NCT01144988|DRUG|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
48384283|NCT02452008|DRUG|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
48384284|NCT02452008|DRUG|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
48384285|NCT06566391|DRUG|Ipilimumab|Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab
48520398|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily
48520399|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
48520400|NCT01197534|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
48520401|NCT01025089|DRUG|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
48520402|NCT06048952|BEHAVIORAL|Music Therapy|Huseyni maqam, Pentatonic music
48520403|NCT01541085|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
48520404|NCT01541085|DRUG|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
48520405|NCT04133987|BIOLOGICAL|Tetravalent live attenuated dengue vaccine admixture TV005|The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
48028983|NCT03932565|BIOLOGICAL|CAR-T therapy for nectin4-positive malignant solid tumor|The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
48520406|NCT04133987|BIOLOGICAL|Placebo|PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
48520407|NCT03354260|OTHER|Personalized adapted oral diet and nutritional education|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
48520408|NCT03234543|PROCEDURE|Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
48520409|NCT03234543|PROCEDURE|No Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
48721982|NCT04218396|DEVICE|Virtual Reality use during painful bedside procedure|Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
48721983|NCT04218396|DRUG|Standard Treatment during painful bedside procedure|Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
48721984|NCT02182271|DRUG|BI 201335 ZW - single rising dose|
48721985|NCT02182271|DRUG|Placebo|
48721986|NCT00129467|DRUG|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is \> 10 at day 18, the dose may be increased to 15 mg bid."
48721987|NCT00129467|DRUG|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
48721988|NCT00129467|DRUG|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
48721989|NCT04566146|OTHER|scapular muscle training, serratus anterior strength, scapular stabilization exercises|patients will be scheduled to attend physical therapy three sessions per week for one month. Three sets of 10 repetitions for each exercise were prescribed per session, with a 1-minute rest between sets.
48721990|NCT02032654|DRUG|Flucloxacillin|
48721991|NCT02032654|DRUG|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
48721992|NCT04903145|DIAGNOSTIC_TEST|REOM|To compare data generated by the REOM device with data from the tremoflo C-100 device
48721993|NCT02231268|DRUG|Gladem|
48721994|NCT02237482|DEVICE|Trilogy cup|
48721995|NCT02237482|DEVICE|Trabecular metal cup (TM)|
48721996|NCT02237482|DEVICE|ZCA cup|
48182814|NCT05087251|BEHAVIORAL|One Psycho-educational Session(s)|1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
48182815|NCT05781165|OTHER|Augmented reality|Step-by-step 3D models displayed with augmented reality guiding the self-test procedures
48182816|NCT02465151|OTHER|Protein-based beverage|protein-based beverage
48520410|NCT04688645|DRUG|Balanced crystalloid solution|Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
48520411|NCT04688645|DRUG|Normal saline|0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
48182817|NCT04554745|RADIATION|Ultrasound|ultrasound assessment of pregnant women
48182818|NCT04338789|OTHER|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
48182819|NCT00003564|DRUG|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
48721997|NCT05296980|BEHAVIORAL|REMINDER|The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
48721998|NCT05296980|BEHAVIORAL|Brain health Psychoeducation|Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
48721999|NCT00508612|BEHAVIORAL|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
48722000|NCT00508612|BEHAVIORAL|High school classes|The control group will attend regular high school classes.
48722001|NCT01266317|DRUG|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
48722002|NCT06064123|DIAGNOSTIC_TEST|Cell-free DNA|Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
48384286|NCT06279468|PROCEDURE|intervertebral disc release|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. The intervertebral discs on the convex side of the scoliosis, situated between the vertebrae that have undergone Ponte osteotomy, will be approached and incised parallel to the intervertebral space. The intervertebral disc and endplate cartilage were incised and separated using reamers. Subsequently, the intervertebral space was expanded and irrigated, and the fragments of the intervertebral disc were extracted using nucleus pulposus forceps. Impacting bone graft into the intervertebral space, thus sustaining the optimal height of intervertebral space.
48384287|NCT06279468|PROCEDURE|Ponte osteotomy|After standard posterior instrumentation and fusion in scoliosis cases, Ponte osteotomies are performed on vertebrae with a Nash-Moe classification of 1 degree or higher. Subsequent corrective procedures can be performed immediately following Ponte osteotomy completion. The deformity was corrected using the bilateral rod rotation and segmental derotation technique after inserting rods. Under fluoroscopic guidance, compression, distraction, and in situ bending maneuvers were implemented as needed. Allograft bone material was utilized for the purpose of bone fusion
48384288|NCT06561698|DRUG|Vonoprazan|Potassium competitive acid blocker
48384289|NCT06561698|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
48384290|NCT06561698|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
48384291|NCT06561698|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
48384292|NCT04427618|DRUG|Tranexamic acid|Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision
48384293|NCT04427618|DRUG|Normal saline|Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
48722003|NCT02971150|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|
48520412|NCT05247229|BEHAVIORAL|Middle school education program|The intervention assesses the impact of a middle school education program (implemented as an after school program in Sitka, AK and Juneau, AK and during school hours as an elective in Hoonah, AK) on shellfish and toxin knowledge and clam harvesting planned behaviors. The intervention takes place weekly during the school year. The curriculum centers around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices.
48520413|NCT00218712|BEHAVIORAL|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
48722004|NCT00267150|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
48722005|NCT03958708|DRUG|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
48722006|NCT04468074|DEVICE|Virtual Reality Therapy for Chronic Pain|"1. A 1 1/2 PowerPoint-based education session on the science behind chronic pain and a basic overview of the VR therapy~2. Virtual Reality Therapy: a virtual reality therapy consisting of different psychological training exercises"
48722007|NCT04702113|DIAGNOSTIC_TEST|Cipherome Lighthouse Pilot|Preemptive pharmacogenomic testing
48722008|NCT01537055|DRUG|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
48384294|NCT06565598|PROCEDURE|Single-layer robot-assisted transperitoneal retroperitoneal tubeless radical nephrectomy|Free through the single layer of the posterior abdominal cavity
48384295|NCT06561711|DRUG|Vonoprazan|Potassium competitive acid blocker
48722009|NCT01537055|DRUG|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
48722010|NCT01586455|DRUG|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
48722011|NCT04773990|DEVICE|Biodex Balance System|Subjects will receive several unique training modules using biodex
48722012|NCT04773990|OTHER|specific physical therapy exercise program|Subjects will receive recommended PT program
48182820|NCT00003564|DRUG|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
48384296|NCT06561711|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
48182821|NCT02155049|DRUG|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
48384297|NCT06561711|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
48384298|NCT06561711|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
48384299|NCT04843891|DRUG|[64]Cu Macrin|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
48384300|NCT01790139|DRUG|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
48384301|NCT03315325|BIOLOGICAL|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
48384302|NCT03614949|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
48384303|NCT03614949|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
48384304|NCT04028297|OTHER|Focus cardiac ultrasound (FoCUS)|
48520414|NCT00218712|BEHAVIORAL|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
48182822|NCT01238536|PROCEDURE|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
48182823|NCT01238536|PROCEDURE|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
48182824|NCT01238536|DRUG|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
48182825|NCT01238536|DRUG|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
48384305|NCT02716519|BIOLOGICAL|Santyl|Collagenase ointment applied topically once per day for up to six weeks
48384306|NCT02716519|OTHER|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
48384307|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
48384308|NCT01152931|DRUG|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
48384309|NCT01152931|DRUG|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
48384310|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
48520415|NCT02947360|OTHER|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
48520416|NCT05065580|PROCEDURE|Osteopathic Manipulative Treatment|Individuals will receive the following techniques during weekly OMT (osteopathic manipulative techniques) for a duration of 8 weeks: 1. Suboccipital release 2. Vault hold. 3. Soft tissue techniques at the cervical and shoulder region 4.There will be NO high velocity low amplitude (HVLA) techniques
48520417|NCT00154752|PROCEDURE|CCRT, Pelvic lymphadenoectomy.|
48520418|NCT06488859|BEHAVIORAL|Positive Affect Treatment|Sessions 1-8: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects
48182826|NCT03334877|DIAGNOSTIC_TEST|β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
48384311|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
48384312|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
48520419|NCT06488859|BEHAVIORAL|Positive Affect Treatment and Negative Affect Treatment|Sessions 1-4: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects Sessions 5-8: Exposure therapy to feared or avoided situations, sensations, or memories
48520420|NCT04279210|DEVICE|Platelet-rich plasma|The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
48384313|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
48384314|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
48384315|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
48384316|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
48384317|NCT01152931|DIETARY_SUPPLEMENT|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if \> 1year. 50ug daily for 4 days if \< 1 year.
48384318|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if \> 1 year.
48025764|NCT03208387|DIAGNOSTIC_TEST|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
48384319|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if \> 1 year. All administered orally.
48384320|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if \> 1 year.
48384321|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if \> 1 year. 50 ug orally daily for 4 days if \< 1 year.
48384322|NCT01152931|DIETARY_SUPPLEMENT|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if \> 1 year.
48384323|NCT06464536|OTHER|Compression|conventional surgical gloves that are commonly used in hospitals will be used for compression therapy of both hands
48384324|NCT05850260|DEVICE|Macintosh laryngoscope|During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
48722013|NCT03417986|DRUG|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
48384325|NCT05850260|DEVICE|Videolaryngoscope|During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
48384326|NCT06597760|DRUG|Enlicitide|Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
48384327|NCT06597760|DRUG|Digoxin|Participants will receive 0.25 mg digoxin orally on Day 1 Period 1 in Arm A and Day 1 Period 2 in Arm B. They also receive Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B coadministered with oral 20 mg enlicitide/180 mg sodium caprate.
48384328|NCT05958979|OTHER|Control Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
48384329|NCT05958979|OTHER|Experimental Marketing Strategies|Participants will self-administer experimenter-provided e-cigarettes
48384330|NCT06649825|DRUG|Vitamin B1|Vitamin B1 tablets, 100mg bid, taken orally for one year
48384331|NCT04719208|OTHER|Water (E) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
48384332|NCT04719208|OTHER|Chlorhexidine gluconate (A) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
48384333|NCT04719208|OTHER|Hydrogen peroxide (B) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
48028984|NCT05600608|DIETARY_SUPPLEMENT|Oral Stimulant Drink|please see description of the drink in the arm/ group section
48384334|NCT04719208|OTHER|Betadine (C) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
48384335|NCT04719208|OTHER|Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided|Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
48384336|NCT03725436|DRUG|MDM2/MDMX Inhibitor ALRN-6924|Given IV
48384337|NCT03725436|DRUG|Paclitaxel|Given IV
48384338|NCT06162117|DIAGNOSTIC_TEST|2- Minute Step Test|2- Minute Step Test will be administered to patients with traumatic meniscus tear
48384339|NCT01141569|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
48384340|NCT01141569|OTHER|Laboratory Biomarker Analysis|Correlative studies
48722014|NCT00819455|BEHAVIORAL|Experimental|Active Life style modification-motivation by I.T technology
48722015|NCT00819455|BEHAVIORAL|Control arm (usual care/standard care arm)|Life style modification only once
48384341|NCT02351297|DIETARY_SUPPLEMENT|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
48384342|NCT02351297|DIETARY_SUPPLEMENT|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
48722016|NCT02408809|BEHAVIORAL|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
48722017|NCT02408809|BEHAVIORAL|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
48722018|NCT05653440|BEHAVIORAL|Accuracy-maximized condition|Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
48384343|NCT02351297|DIETARY_SUPPLEMENT|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
48384344|NCT06111781|DRUG|Relugolix 120 MG [Orgovyx]|ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
48384345|NCT06111781|RADIATION|SBRT standard of care radiotherapy treatment|SBRT is a standard-of-care radiotherapy treatment for intermediate-risk prostate cancer.
48384346|NCT01659762|BIOLOGICAL|autologous mesenchymal stromal cell|
48384347|NCT06541756|PROCEDURE|Fibrine Clot-augmented Meniscal Repair|The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
48384348|NCT06541756|PROCEDURE|Conventional Meniscal Repair|Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
48384349|NCT03359473|DRUG|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
48384350|NCT03359473|DRUG|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
48384351|NCT03366142|DRUG|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
48520421|NCT02467140|DEVICE|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
48722019|NCT05653440|BEHAVIORAL|Effort-maximized condition|Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
48384352|NCT01265875|DRUG|Human Secretin|Dose Escalation
48384353|NCT06118099|DRUG|Amlitelimab|Injection solution SC injection
48384354|NCT06118099|DRUG|Placebo|Injection solution SC injection
48722020|NCT05653440|BEHAVIORAL|Effort-accuracy balanced condition|Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
48384355|NCT03114527|DRUG|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
48384356|NCT03114527|DRUG|Everolimus|mTOR inhibitor
48722021|NCT00437255|DRUG|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
48722022|NCT00437255|DRUG|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
48722023|NCT00676910|DRUG|JNJ-26854165|
48722024|NCT04963907|DEVICE|Active Alpha-Stim CES|Active Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
48722025|NCT04963907|DEVICE|Sham Alpha-Stim CES|Sham Alpha-Stim devices will be randomly assigned to participants for use daily for 8 weeks.
48722026|NCT04243928|OTHER|kinesio taping|apply kinesio taping on dorsi flexors muscles
48025765|NCT03208387|BEHAVIORAL|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
48025766|NCT03208387|BEHAVIORAL|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
48025767|NCT03208387|BEHAVIORAL|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
48025768|NCT03208387|BEHAVIORAL|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
48025769|NCT03208387|BEHAVIORAL|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
48384357|NCT06651580|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, urine or stool samples
48384358|NCT06651580|OTHER|Quality-of-Life Assessment|Complete QoL assessment
48384359|NCT06651580|OTHER|Questionnaire Administration|Complete questionnaire
48520422|NCT02467140|DEVICE|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
48520423|NCT02333942|DEVICE|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
48520424|NCT01960660|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|
48722027|NCT00884832|DRUG|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
48182827|NCT05803148|PROCEDURE|Cardioneuroablation|The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 4 times， amplitude ≥ 0.7mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
48182828|NCT05803148|DRUG|Midodrine Oral Tablet|Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
48182829|NCT05230719|PROCEDURE|Radial Artery Approach|dTRA or conventional TRA for radical artery approach
48182830|NCT03774290|DRUG|PBF-680|PBF-680 is an adenosine A1 receptor antagonist
48182831|NCT03774290|DRUG|Placebo oral capsule|Oral gelatine capsule
48182832|NCT00207753|DRUG|albendazole vs. combined albendazole/ivermectin treatment|
48182833|NCT01473992|DEVICE|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
48520425|NCT01296087|DRUG|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
48520426|NCT01296087|DRUG|Placebo|Matching placebo capsule given once daily on Days 1 to 28
48520427|NCT03229226|OTHER|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
48182834|NCT01473992|DEVICE|Otto Bock Genium|Study knee.
48182835|NCT02297685|DEVICE|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
48182836|NCT02297685|DEVICE|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
48182837|NCT02297685|DEVICE|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
48384360|NCT06542679|BEHAVIORAL|Mobile Application|A mobile health application based on Social Cognitive Theory (SCT) and the Information-Motivation-Behavioral Skills (IMB) model has been developed. The design of the mobile health application is grounded in SCT, the IMB model, and behavioral change interventions and techniques. The content of the mobile application is based on the 'Healthy Weight Gain Guide for Pregnancy.' The application offers a comprehensive program that provides evidence-based recommendations using self-monitoring, feedback, shaping information, goal setting, planning, and reward techniques for healthy nutrition, physical activity, and optimal gestational weight gain for pregnant women.
48384361|NCT06213441|OTHER|pecha kucha education|"Pecha kucha training to be given to the experimental arm will be given by the researcher.~The training content will be created in line with the literature and will be given before the patient is discharged."
48384362|NCT00594581|DRUG|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
48384363|NCT04259905|BEHAVIORAL|Active video game teleconference support group|12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
48384364|NCT04259905|BEHAVIORAL|Standard support group + pedometer|3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
48384365|NCT06649682|DRUG|68Ga-NYM096 PET/CT and 177Lu-NYM096|Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.
48520428|NCT06531278|DRUG|Irinotecan liposome|"* Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle.~* 27 days a cycle"
48520429|NCT06531278|DRUG|Adebrelimab|"* Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle.~* 27 days a cycle"
48520430|NCT06531278|DRUG|Oxaliplatin|"* Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle.~* 27 days a cycle"
48520431|NCT06531278|DRUG|Fluorouracil|"* Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle.~* 27 days a cycle"
48520432|NCT06531278|DRUG|Calcium folinate|"* Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle.~* 27 days a cycle"
48520433|NCT05098652|BEHAVIORAL|CuRB-IT|9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly
48520434|NCT04420845|BEHAVIORAL|Diabetes Self-Management and Support (DSMES) and Sleep Hygiene Education and Support (SHES)|SHES outlines the importance of sleep for people with type 2 diabetes mellitus and provide practical information and guidance about sleep habits. Specifically, the focus will be on: avoiding consumption of caffeine, nicotine, alcohol; avoiding use of light emitting devices before bedtime; avoiding excessive intake of fluids or heavy meals before bedtime; promoting regulation of light, noise, and temperature in the bedroom; timing of and importance of exercise; maintaining consistent sleep and wake times; establishing a pre-bedtime routine; and managing stress.
48520435|NCT03827889|PROCEDURE|WMP of fluoride varnish|Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found
48025770|NCT03208387|DIAGNOSTIC_TEST|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
48520436|NCT03827889|PROCEDURE|TWLP of fluoride varnish|application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis
48520437|NCT03827889|BEHAVIORAL|DHP (educational intervention)|The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices
48520438|NCT02271295|DRUG|Enoxaparine|Enoxaparine 4000UI/day during 24 months
48520439|NCT02731716|BEHAVIORAL|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
48384366|NCT03173937|BIOLOGICAL|Omidubicel (former CordIn)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn (TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn (TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
48384367|NCT03173937|DEVICE|Miltenyi CliniMACS(R) CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
48520440|NCT02731716|BEHAVIORAL|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
48025771|NCT03913364|DIETARY_SUPPLEMENT|Probiotic|B. bifidum 900791-containing ice cream
48384368|NCT05692739|DRUG|Insulin|see arm description
48384369|NCT05692739|DRUG|Cyclosporins|see arm description
48384370|NCT05692739|DRUG|Artificial tears|see arm description
48384371|NCT05473546|OTHER|ARTIFICIAL NUTRITION|ARTIFICIAL NUTRITION
48384372|NCT03413722|DRUG|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
48384373|NCT03413722|DRUG|Everolimus|The patient's physician will prescribe drug according to standard practice.
48384374|NCT05971732|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
48384375|NCT05971732|DRUG|Placebo|In the placebo group, patients will receive the equivalent number of normal saline injections.
48520441|NCT02731716|BEHAVIORAL|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
48520442|NCT03938909|GENETIC|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
48520443|NCT02333903|OTHER|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
48520444|NCT05047224|BEHAVIORAL|Tele-assessment + in-person assessment|Participants will complete a tele-assessment using the TAP. They will complete a traditional, in-person autism spectrum disorder assessment approximately two weeks later.
48520445|NCT05047224|BEHAVIORAL|Tele-assessment only|Participants will complete a tele-assessment using the TAP. They will complete a second, shorter tele-assessment approximately two weeks later.
48520446|NCT01868906|DRUG|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
48025772|NCT03913364|DIETARY_SUPPLEMENT|Placebo|Placebo ice-cream
48025773|NCT00512759|DRUG|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
48025774|NCT04445584|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI
48025775|NCT02507089|BEHAVIORAL|Tailored sleep health education materials.|Tailored sleep health materials.
48025776|NCT02507089|BEHAVIORAL|Generic sleep health education materials.|
48025777|NCT05507606|DRUG|Osimertinib|osimertinib 80mg/d
48025778|NCT05507606|DRUG|Bevacizumab Biosimilar IBI305|Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
48384376|NCT06242275|DIAGNOSTIC_TEST|Salivary Alpha-amylase|"Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab. The samples will be then stored at -70°C until analysis."
48384377|NCT02676271|PROCEDURE|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
48384378|NCT06455475|OTHER|Derm-Maxx|Derm-Maxx™ Dermal Matrix is an acellular human dermis graft sterilized using the Tutoplast® Tissue Sterilization Process.
48520447|NCT01868906|PROCEDURE|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
48520448|NCT01868906|DEVICE|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
48520449|NCT01868906|PROCEDURE|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
48520450|NCT01868906|RADIATION|Radiotherapy|Standard radiation therapy
48520451|NCT01868906|DRUG|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
48722028|NCT00884832|DRUG|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
48384379|NCT04692753|OTHER|Training and education|Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
48384380|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with a Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.
48520452|NCT03530683|DRUG|Maplirpacept (PF-07901801)|maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
48520453|NCT03530683|DRUG|Azacitidine|intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
48722029|NCT01725243|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
48722030|NCT06017934|BEHAVIORAL|Volunteer-led physical activity|Participants will be assessed by the therapy team who will prescribe tailored activity and then liaise with the mobility volunteers, who will deliver the intervention. Participants who can mobilise independently will be encouraged to perform walking exercises, progressing their walking distance over set markers in the hospital (e.g., to the end of the bed and back; to the doorway and back; to the toilet and back). Participants who require assistance in mobility will perform bed (e.g., hip abduction, static quads), or chair exercises (e.g., ankle pumps, knee extension, arm raise), and will be progressed to performing walking exercises when their physical function improves. Volunteers will check with nursing staff that participants are safe to exercise before each activity session. Participants will receive the mobility sessions twice daily, starting upon recruitment and continuing until the day of discharge from hospital.
48025779|NCT05507606|DRUG|Carboplatin|Carboplatin AUC5, d1; was stopped after 4 cycles
48025780|NCT05507606|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
48025781|NCT04906200|OTHER|Best Practice|Receive usual care
48384381|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with micro Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with multiple micro connective tissue graft harvested from the palate.
48384382|NCT06030947|DEVICE|Division of the Connective Tissue Graft into multiple micro Connective Tissue Grafts|The harvested connective tissue graft is divided in multiple micro connective tissue grafts with a scalpel blade before being placed on the recipient site.
48722031|NCT02283203|DRUG|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
48722032|NCT02283203|DRUG|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
48722033|NCT02201836|OTHER|One time music therapy|
48722034|NCT02201836|OTHER|Group music therapy|
48025782|NCT04906200|OTHER|Internet-Based Intervention|Receive access to YES portal
48025783|NCT04906200|OTHER|Survey Administration|Complete survey
48025784|NCT00861939|DRUG|Bupropion HCI 300 mg Extended-Release Tablets EON|
48025785|NCT00861939|DRUG|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
48384383|NCT05465122|PROCEDURE|Carotid Endarterectomy|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
48384384|NCT05465122|PROCEDURE|FDA-approved carotid stents|This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
48520454|NCT03530683|DRUG|Venetoclax|orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
48520455|NCT03530683|DRUG|Carfilzomib|Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
48722035|NCT01919736|BEHAVIORAL|Gait Retraining|
48722036|NCT02186704|DEVICE|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
48722037|NCT00000480|PROCEDURE|electrophysiology|
48722038|NCT00000480|DRUG|anti-arrhythmia agents|
48722039|NCT00000480|DEVICE|defibrillators, implantable|
48722040|NCT02024880|DEVICE|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
48722041|NCT02024880|DEVICE|Conventional catheter group|A standard embryo catheter
48722042|NCT05485142|PROCEDURE|prolotherapy|5% glucose 10ml local injection peripheral to posterior tibial nerve near ankle under ultrasound guidance once a week for 4 weeks.
48722043|NCT02170909|DRUG|BIBR 1048 MS low dose|
48722044|NCT02170909|DRUG|BIBR 1048 MS medium dose|
48722045|NCT02170909|DRUG|BIBR 1048 MS high dose|
48722046|NCT02365415|DRUG|Sirolimus|8 weeks oral sirolimus, following drug levels
48722047|NCT04212013|DRUG|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
48722048|NCT04212013|DRUG|Rituximab|Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1
48722049|NCT04212013|OTHER|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
48722050|NCT03545997|DRUG|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
48722051|NCT03545997|DRUG|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
48722052|NCT05632276|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
48722053|NCT03770104|PROCEDURE|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
48722054|NCT03770104|PROCEDURE|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
48722055|NCT05852821|OTHER|5STS remote assessment via videoconference|Patients will be asked to perform several times the 5STS test, from their home through videoconference, on 3 occasions (day 1, 24h later and 1month later).
48722056|NCT05910567|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST) Examination|A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
48722057|NCT05910567|OTHER|No Intervention: Standard of Care - Without the FAST Examination|Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
48722058|NCT02210832|BEHAVIORAL|Best practices|
48722059|NCT02210832|BEHAVIORAL|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
48722060|NCT03522727|BEHAVIORAL|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
48722061|NCT03522727|BEHAVIORAL|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
48722062|NCT03522727|BEHAVIORAL|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
48025786|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 2 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
48722063|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
48722064|NCT02153060|DRUG|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
48722065|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
48722066|NCT00853840|DRUG|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
48722067|NCT00853840|DRUG|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
48722068|NCT00853840|DRUG|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
48722069|NCT03677297|DRUG|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
48722070|NCT03959787|OTHER|Educational|Educational pamphlet will be given to intervention group.
48722071|NCT00034736|DRUG|Levofloxacin|
48025787|NCT04473404|DIETARY_SUPPLEMENT|Streptococcus salivarius DB-B5 - 10 billion CFU/day|The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.
48025788|NCT04473404|OTHER|Placebo|The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
48025789|NCT05209893|OTHER|Telerehabilitation|Application based video home exercise for the knee osteoarthritis
48025790|NCT05209893|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the knee osteoarthritis
48384385|NCT05465122|OTHER|Intensive Medical Management|INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
48384386|NCT03197506|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
48384387|NCT03197506|OTHER|Laboratory Biomarker Analysis|Correlative studies
48520456|NCT03530683|DRUG|Dexamethasone|starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
48025791|NCT04039516|DRUG|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
48722072|NCT02789891|PROCEDURE|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
48182838|NCT04225741|BEHAVIORAL|Training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
48182839|NCT00122486|DRUG|Tenofovir Disoproxil Fumarate|
48182840|NCT05271968|PROCEDURE|Global management of scabies|"For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes"
48182841|NCT02623998|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
48182842|NCT02623998|DRUG|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
48182843|NCT02623998|BEHAVIORAL|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
48182844|NCT01718951|DRUG|golimumab|golimumab
48025792|NCT04831125|OTHER|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
48025793|NCT05924646|DIETARY_SUPPLEMENT|Sodium Chloride Capsules|Table salt in slow release capsules.
48182845|NCT01718951|DRUG|Pamidronate|pamidronate
48384388|NCT03197506|BIOLOGICAL|Pembrolizumab|Given IV
48384389|NCT03197506|RADIATION|Radiation Therapy|Undergo radiation therapy
48182846|NCT02754193|OTHER|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
48182847|NCT05968651|DRUG|Oxytocin nasal spray|Single acute administration of 24 international units (IU) oxytocin
48182848|NCT06292923|DRUG|Foralumab|"Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare."
48182849|NCT06292923|OTHER|Placebo|Foralumab placebo nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).
48384390|NCT03197506|DRUG|Temozolomide|Given PO
48384391|NCT03197506|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
48722073|NCT02789891|PROCEDURE|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
48025794|NCT05924646|OTHER|Microcystalline Cellulose Capsules|Microcrystalline Cellulose Capsules (Placebo)
48028985|NCT01354821|PROCEDURE|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
48028986|NCT01354821|PROCEDURE|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
48384392|NCT04349501|OTHER|Restriction Spectrum Imaging Magnetic Resonance Imaging|RSI is a multicompartment model of diffusion MRI that uses data acquired at multiple b-values to distinguish varied diffusion speeds (restricted intracellular, hindered extracellular, and approximately free diffusion).
48384393|NCT04079972|BEHAVIORAL|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
48520457|NCT03530683|DRUG|Anti-CD20 Targeting agent|Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
48722074|NCT06522971|BEHAVIORAL|High-intensiy interval training|All participants undergo physical capacity tests before the onset of NAC and after the last course of NAC but before the breast cancer surgery. A treadmill protocol consisting of twenty-one 1-minute stages, with speed and/or grade increments at each stage, is used to obtain VO2 peak (the highest amount of oxygen consumed at peak exercise) data. The HIIT intervention consists of 2 to 3 exercise sessions per week for 6 months. The HIIT session starts with a 6-minute warm-up period at about 65-70% of maximal heart rate (HRmax) followed by 4 X 4-min high-intensity intervals (85%-95% of HRmax) combined with 3 min period of active recovery (55-70% of HRmax).
48384394|NCT04079972|BEHAVIORAL|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
48722075|NCT01985763|DRUG|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
48722076|NCT01551277|OTHER|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
48722077|NCT01551277|OTHER|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
48025795|NCT06048523|PROCEDURE|Patient cohort|"* For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation~* Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations~* Biological samples offered to patients in the context of research:~  * Annual blood sample~ * Annual urine sample~ * Collection of 1 skin biopsy at the inclusion visit (for 30 patients)~ * Cerebrospinal fluid sample at the inclusion visit (for 15 patients"
48025796|NCT06048523|PROCEDURE|Control cohort|"* controls without LP: 1 visit for blood, urine and optional skin biopsy~* controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up"
48384395|NCT06568874|COMBINATION_PRODUCT|Virtual Reality (VR) Therapy|"Intervention: Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
48722078|NCT03864913|DRUG|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
48384396|NCT06568874|DIAGNOSTIC_TEST|Conservative Treatment|"Intervention: Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
48384397|NCT04187937|DEVICE|Stereotactic image-guided resection|Stereotactic image-guided resection with an ultrasound-based image-guidance system.
48722079|NCT03864913|BEHAVIORAL|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
48384398|NCT02873195|DRUG|Atezolizumab|Given IV
48025797|NCT03734224|PROCEDURE|Adhesix mesh|Adhesix mesh
48182850|NCT02474849|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
48182851|NCT02884037|DRUG|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
48384399|NCT02873195|BIOLOGICAL|Bevacizumab|Given IV
48722080|NCT03864913|OTHER|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
48722081|NCT03864913|OTHER|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
48722082|NCT00316524|BIOLOGICAL|MVA-BN® (IMVAMUNE)|1x 10E8_TCID50
48722083|NCT00316524|BIOLOGICAL|Placebo|Tris-Buffer
48722084|NCT00219960|DRUG|North American Ginseng (Panax Quinquefolius)|
48722085|NCT00565799|PROCEDURE|Omentectomy|Removing the omentum
48722086|NCT00565799|OTHER|No intervention|Only LAGB without Omentectomy
48025798|NCT03734224|PROCEDURE|Progrip mesh|Progrip mesh
48182852|NCT01046045|DRUG|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
48182853|NCT06456476|DIAGNOSTIC_TEST|ERCP|ERCP used only if needed in some patients
48384400|NCT02873195|DRUG|Capecitabine|Given PO
48384401|NCT02873195|OTHER|Laboratory Biomarker Analysis|Correlative studies
48722087|NCT05374187|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
48722088|NCT05374187|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
48025799|NCT02451345|BEHAVIORAL|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
48182854|NCT06153992|DEVICE|Intelligent portable isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using intelligent portable isokinetic muscle strength test training system
48182855|NCT06153992|DEVICE|isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using isokinetic muscle strength test training system
48182856|NCT06153992|OTHER|without test training|Treatment was performed without using any isokinetic muscle strength test training system
48182857|NCT02498236|DRUG|Intranasal Oxytocin|
48182858|NCT00467415|BEHAVIORAL|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
48182859|NCT00467415|BEHAVIORAL|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
48182860|NCT00693979|DEVICE|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
48182861|NCT02830542|DRUG|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
48722089|NCT02265315|OTHER|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
48722090|NCT02265315|BEHAVIORAL|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
48722091|NCT04527939|PROCEDURE|three-dimensional endorectal ultrasonography|three-dimensional endorectal ultrasonography
48722092|NCT01918449|OTHER|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
48722093|NCT00438152|DRUG|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
48722094|NCT00438152|DRUG|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
48025800|NCT03324061|DRUG|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
48384402|NCT02873195|OTHER|Placebo|Given IV
48722095|NCT05839704|PROCEDURE|Bilateral Erector Spinae Plane Block|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the erector spinae plane at the level of T8.
48722096|NCT05839704|PROCEDURE|Abdominal Wall Blocks|Patient will receive local ropivacaine 0.75% with lignocaine 1% with adrenaline, administered under ultrasound into the subcostal transversus abdominus plane bilaterally and the serratus plane on the left side
48722097|NCT00541346|DRUG|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
48722098|NCT05597072|BEHAVIORAL|Intervention|Less people within the OR but longer waiting time.
48722099|NCT05597072|BEHAVIORAL|Control|More people in the OR but shorter waiting time
48722100|NCT03755583|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
48722101|NCT06382935|OTHER|Probin Pocket Depth reduction|Probin Pocket Depth reduction in millimetres before and after treatment
48722102|NCT03652519|BEHAVIORAL|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
48025801|NCT03324061|DRUG|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
48182862|NCT02830542|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
48182863|NCT01244165|DEVICE|Cytrix|
48182864|NCT01244165|OTHER|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
48182865|NCT00508495|DRUG|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
48722103|NCT03289949|DRUG|Psilocybine|Oral dose of psilocybine.
48722104|NCT03289949|DRUG|Ketanserin|Oral dose of ketanserin.
48722105|NCT01399216|DIETARY_SUPPLEMENT|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
48722106|NCT01399216|DIETARY_SUPPLEMENT|Placebo|for 8 weeks
48722107|NCT05575908|PROCEDURE|Digital expert team|A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
48722108|NCT00828789|DRUG|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
48722109|NCT01536808|OTHER|Cardiac RMI|Cardiac RMI
48025802|NCT06494111|DRUG|Pravastatin|Given by PO
48025803|NCT06494111|DRUG|Pentoxifylline|Given by PO
48025804|NCT06494111|DRUG|Tocopherol|Given by PO
48025805|NCT05413187|DRUG|Medical Grade Cannabis oil|MGC, 30% CBD and 1.5% Δ9-THC
48025806|NCT05413187|DRUG|Placebos|Olive oil and Chlorophyl
48025807|NCT05900024|OTHER|Funk It Cycle Bites|The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
48025808|NCT02696850|DRUG|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
48025809|NCT02696850|DRUG|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
48182866|NCT00508495|DRUG|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
48182867|NCT00508495|DRUG|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
48182868|NCT03750253|OTHER|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy will be used for pain-relief after arthroscopy for osteochondral lesions of the talus
48182869|NCT04539223|DRUG|Evolocumab|Autoinjector 1-mL deliverable volume of 140 mg/mL
48182870|NCT05474547|BEHAVIORAL|Meditation|Students will meditate for 30 min every day for 10 days
48182871|NCT01788475|DRUG|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
48025810|NCT05665218|DIAGNOSTIC_TEST|right heart catheterization|Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
48025811|NCT03870763|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
48722110|NCT01536808|OTHER|Analysis telomere|Analysis telomere
48722111|NCT01536808|OTHER|Stress test|Stress test
48182872|NCT04771377|DIETARY_SUPPLEMENT|Protein Supplementation|protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
48722112|NCT01536808|OTHER|echocardiography|echocardiography
48722113|NCT00663845|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
48722114|NCT00663845|DRUG|Placebo|Matching placebo
48722115|NCT00175409|PROCEDURE|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
48722116|NCT00175409|PROCEDURE|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
48722117|NCT06508476|BIOLOGICAL|Amnion Chorion membrane|it is a placental allograft.
48722118|NCT06508476|PROCEDURE|connective tissue graft|it is an autograft
48722119|NCT02153814|PROCEDURE|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
48722120|NCT02153814|PROCEDURE|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
48182873|NCT04853615|DRUG|Empagliflozin 25 MG|PAtient will receive empagliflozin 25 mg daily
48182874|NCT05104255|PROCEDURE|Spinal anesthesia|Twins delivered under under spinal anesthesia
48722121|NCT01477008|DEVICE|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
48722122|NCT01477008|PROCEDURE|Marrow Stimulation|Microfracture or Subchondral Drilling
48384403|NCT06149351|DIAGNOSTIC_TEST|Bio-fluid analysis for the implementation of a diagnostic test for sport related concussion|Saliva of participants will be sampled for analysis of biomarkers of interest (nucleic acids and proteins). The nucleic acids biomarkers will be quantified by reverse transcription followed by amplification (RT-PCR) and Next Generation Sequencing (NGS) techniques while enzymatic assay methods (ELISA) methods will be used to quantify protein biomarkers.
48722123|NCT02801890|BIOLOGICAL|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
48722124|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
48182875|NCT05104255|PROCEDURE|General anesthesia|Twins delivered under general anesthesia
48384404|NCT02875340|DRUG|VAL401|Risperidone formulated into a liquid lipid filled capsule
48722125|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + posterior wall box isolation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with posterior wall box isolation.
48722126|NCT05085912|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
48722127|NCT01998191|OTHER|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
48722128|NCT01998191|OTHER|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
48722129|NCT01998191|OTHER|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
48025812|NCT03870763|DRUG|Peginterferon Beta-1a|Administered as specified in the treatment arm.
48722130|NCT05025722|OTHER|Non Interventional|This is an observational study.
48025813|NCT03870763|DRUG|Placebo|Administered as specified in the treatment arm.
48025814|NCT04117932|DRUG|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
48025815|NCT01547650|OTHER|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
48384405|NCT01764594|BIOLOGICAL|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
48384406|NCT01764594|OTHER|Placebo|Placebo comparator
48384407|NCT01725100|DRUG|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
48384408|NCT01725100|DRUG|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
48722131|NCT02239146|DRUG|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
48722132|NCT02239146|DRUG|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
48384409|NCT02237885|DEVICE|NeuroSky MindWave Mobile|
48722133|NCT00244491|BEHAVIORAL|Care Transitions Intervention|
48722134|NCT05200689|DEVICE|Kinesiotaping (KT)|"Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin."
48722135|NCT00785174|DEVICE|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
48722136|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
48384410|NCT03843723|OTHER|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
48520458|NCT03530683|DRUG|Isatuximab|"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."
48722137|NCT00785174|DEVICE|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
48722138|NCT02759991|DRUG|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
48722139|NCT02759991|DRUG|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
48722140|NCT02391532|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
48722141|NCT02391532|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
48182876|NCT01368237|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
48182877|NCT03215953|DEVICE|cast shoe|ankle-high, custom-made, well-moulded cast shoe
48182878|NCT03215953|DEVICE|removable walker|Prefabricated especially designed for relieving load on the foot
48384411|NCT03899220|BEHAVIORAL|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
48722142|NCT01142024|DRUG|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
48722143|NCT01142024|DRUG|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
48722144|NCT06116695|DRUG|human treated dentin matrix|human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
48722145|NCT06116695|DRUG|Mineral Tri-Oxide Aggregate|mineral trioxide aggregate was used as control
48722146|NCT04886700|DRUG|SG001|Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
48722147|NCT05225259|DRUG|LOXO-260|Oral
48722148|NCT04870541|DRUG|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
48384412|NCT05490160|DRUG|Tranexamic acid|During the total knee arthroplasty, the patients received a 2-g retrograde injection of tranexamic acid through the drain after closure, with subsequent clamping of the drain for 6 hours.
48520459|NCT05010265|OTHER|Clinician Questionnaire|Surveys will serve to identify preferences, expectations and concerns among clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through investigative neurotechnologies which will then be systematically evaluated.
48722149|NCT04870541|DRUG|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
48722150|NCT04502368|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|FOB under full sedation (RASS sedation scale -5) and full paralysis.
48722151|NCT04502368|PROCEDURE|Bronchoalveolar Lavage (BAL)|BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.
48722152|NCT04502368|DIAGNOSTIC_TEST|Electrical Impedance Tomography (EIT)|Realtime thoracic impedance coupled with ventilation parameters recording.
48384413|NCT00399204|DRUG|Pioglitazone vs Metformin|
48722153|NCT04502368|DIAGNOSTIC_TEST|Arterial Blood Gas test (ABG)|Multiples Arterial Blood Gas test (ABG) via arterial catheter.
48722154|NCT02238015|PROCEDURE|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
48384414|NCT00350818|DRUG|Azacitidine|8 mg/m\^2 Subcutaneously Once Daily for 5 Days
48722155|NCT04043832|DIAGNOSTIC_TEST|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
48722156|NCT06547892|DRUG|Vasopressin|"To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour."
48722157|NCT06547892|OTHER|0,9% saline solution|Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
48722158|NCT03113604|OTHER|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
48722159|NCT04912752|GENETIC|Migraine CNV|Copy number variation effect on migraine disease
48722160|NCT04356079|DIAGNOSTIC_TEST|International Headache Society Test|Thorough History of Patients and families
48722161|NCT01606033|OTHER|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
48722162|NCT01606033|OTHER|questionnaire|understanding of the implications of participating in a clinical trial
48722163|NCT06301139|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Infant formula based on goat milk for 4 weeks at volume depending on the infant
48722164|NCT06301139|DIETARY_SUPPLEMENT|Cow's milk-based infant formula with probiotic drops|Infant formula based on cow's milk with probiotic Lactobacillus reuteri drops for 4 weeks at volume depending on the infant
48722165|NCT05746936|PROCEDURE|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
48722166|NCT05635474|DIETARY_SUPPLEMENT|Bacillus Coagulans|Bacillus coagulans is a Gram-positive bacterium belonging to the genus Bacillus and does not exist in the intestinal microbiota, because it has the characteristics of spore production and lactobacillus lactic acid production, and has the ability to maintain the health of intestinal bacteria, acid and alkali resistance, With the advantages of high temperature resistance and high stability, it is currently one of the commonly used probiotic strains.
48722167|NCT05635474|DIETARY_SUPPLEMENT|Placebo|The placebo was also administered in the form of capsules consisting of maltodextrin, silicon dioxide, and magnesium stearate.
48182879|NCT05666362|DRUG|benoxinate hydrochloride 0.4% group|They will receive benoxinate hydrochloride 0.4% immediately before fundus
48182880|NCT05666362|DRUG|saline 0.9% .|They will receive saline 0.9% before fundus examination in each eye .
48384415|NCT01544465|BEHAVIORAL|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
48384416|NCT01544465|BEHAVIORAL|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
48722168|NCT00812903|BEHAVIORAL|Exercise|Training exercises chosen with background in knowledge of intelligent training
48722169|NCT00905203|OTHER|exercise|exercise training
48182881|NCT04554537|BEHAVIORAL|SMART|A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
48182882|NCT04554537|BEHAVIORAL|Brain Health Workshop|A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
48182883|NCT00560144|DRUG|RG1507|3mg/kg iv weekly
48182884|NCT00560144|DRUG|RG1507|9mg/kg iv weekly
48182885|NCT00560144|DRUG|RG1507|Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
48182886|NCT02781805|DRUG|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
48182887|NCT01526837|DRUG|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
48384417|NCT06152653|DRUG|n-acetylcystine (NAC)+ albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
48384418|NCT06152653|DEVICE|AeroEclipse-VersaPAP System|The AeroEclipse-VersaPAP System combine continuous positive inspiratory pressure and nebulizer in one system.
48384419|NCT02860039|BIOLOGICAL|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
48182888|NCT05321849|OTHER|Echocardiography guide|Patients with PDA are percutaneously closed with echocardiography guide, without fluoroscopy like classical procedures
48182889|NCT04155034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48384420|NCT02860039|BIOLOGICAL|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
48384421|NCT02860039|OTHER|Laboratory Biomarker Analysis|Correlative studies
48384422|NCT05266807|DRUG|oral capsulized Fecal Microbiota Transplantation|FMT will be administered per os in the form of capsules containing faeces from a healthy donor. Capsules are manufactured at the CHUV pharmacy (University Hospital of Lausanne, Switzerland)
48384423|NCT05266807|DRUG|Vancomycin or Fidaxomicin|Vancomycin or Fidaxomicin per os as initially prescribed per SoC
48384424|NCT03464110|BEHAVIORAL|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
48722170|NCT04170270|DRUG|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
48025816|NCT03246360|DRUG|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
48025817|NCT01285375|DEVICE|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
48025818|NCT01285375|DEVICE|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
48025819|NCT05494879|BEHAVIORAL|microkinesitherapy treatment|"The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions."
48722171|NCT01530607|DRUG|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
48722172|NCT01530607|DRUG|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
48722173|NCT02483390|OTHER|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
48722174|NCT01948232|DRUG|Perindopril|Angiotensin converting enzyme inhibitor
48722175|NCT02133807|PROCEDURE|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
48722176|NCT02896270|DRUG|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
48025820|NCT05794217|BEHAVIORAL|This is a non-interventional study|This is a non-interventional study
48025821|NCT05207696|OTHER|retrospective data analysis|The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
48182890|NCT04155034|RADIATION|Prophylactic Cranial Irradiation|Undergo PCI
48722177|NCT03381027|PROCEDURE|Baby Massage|Structured massage of the baby
48722178|NCT02174653|DRUG|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
48182891|NCT03012243|PROCEDURE|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
48182892|NCT03012243|PROCEDURE|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
48182893|NCT05147337|DRUG|E2511|E2511 tablets.
48182894|NCT05147337|DRUG|Placebo|E2511 matched placebo tablets.
48722179|NCT02174653|DRUG|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
48722180|NCT01212614|PROCEDURE|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
48722181|NCT02703688|BEHAVIORAL|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
48722182|NCT02703688|OTHER|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
48182895|NCT04600986|OTHER|Repeated dose of GnRH agonist|0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
48182896|NCT04147195|DRUG|LYS006|5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
48520460|NCT05010265|OTHER|Semi Structured Interviews|Semi-structured interviews will further serve to identify preferences, expectations and concerns among patients, surrogates, clinicians and researchers surrounding data-sharing of uncertain diagnostic data generated through these investigative neurotechnologies which will then be systematically evaluated.
48520461|NCT02713685|PROCEDURE|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
48722183|NCT01287195|DRUG|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
48722184|NCT01287195|DRUG|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
48722185|NCT00997620|DRUG|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
48722186|NCT00997620|DRUG|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
48182897|NCT04147195|DRUG|Tropifexor|100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
48384425|NCT05434767|DEVICE|Mobile application|Participants will be instructed on the installation and use of the mobile application on their personal mobile phones. Participants will then have to perform the assigned exercises using the mobile application 3 times daily. Physiotherapists will still perform the required assessment/review, education, and intervention.
48520462|NCT02713685|PROCEDURE|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
48722187|NCT04465812|BEHAVIORAL|Self-monitoring and personalized feedback on smartphone app|"1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app"
48384426|NCT05434767|OTHER|Standard rehabilitation program|All participants will be seen by physiotherapists in the ward post-TKR surgery and undergo standard inpatient rehabilitation. Patients will be given instructions to perform assigned exercises 3 times daily. Physiotherapists will perform the required assessment/review, education, and intervention.
48384427|NCT04285983|DRUG|Trelagliptin|Trelagliptin tablets
48384428|NCT06653842|DRUG|QTORIN 3.9% rapamycin anhydrous gel|QTORIN 3.9% Rapamycin Anhydrous Gel
48384429|NCT03835312|PROCEDURE|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
48384430|NCT02279888|DEVICE|CardioMEMS HF System|Pulmonary artery pressure sensor
48182898|NCT00565266|DRUG|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
48384431|NCT03843905|OTHER|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
48384432|NCT04957316|DEVICE|Triple-effect blood purification filter|Blood purification using the oXiris filter to remove endotoxin, cytokines, and uremic toxins.
48384433|NCT05439135|OTHER|washed microbiota transplantation|Each patient will receive washed microbiota transplantation each day for three consecutive days. After WMT, participants will receive free diet plus home enteral nutrition (solution at a 750ml daily dosage that provides 750 kcal energy) at home for 8 weeks.
48384434|NCT06351540|DRUG|Cannabis|cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
48384435|NCT05406310|DEVICE|Ablation Index-guided ablation|Radiofrequency catheter ablation guided by Ablation Index software.
48384436|NCT05406310|DEVICE|High-power, short-duration ablation using QDOT Micro catheter|Radiofrequency catheter ablation guided by high-power, short-duration ablation using QDOT Micro catheter
48384437|NCT05270629|OTHER|Antegrade and retrograde anastomoses|Patients who had received both antegrade and retrograde anastomoses.
48384438|NCT05270629|OTHER|Antegrade-only anastomoses|Patients who had received antegrade-only anastomoses.
48722188|NCT00491608|BIOLOGICAL|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
48722189|NCT06201351|DEVICE|adaptive radiotherapy|MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
48722190|NCT02621073|DRUG|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
48722191|NCT02621073|DEVICE|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
48722192|NCT00895960|DRUG|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
48722193|NCT00895960|RADIATION|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
48722194|NCT00895960|DRUG|TMZ (Temozolomide)|75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
48722195|NCT01439178|DRUG|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
48722196|NCT01092793|DIETARY_SUPPLEMENT|Krill|Encapsulated oil from the antarctic crustacean Krill
48722197|NCT01092793|DIETARY_SUPPLEMENT|Fish oil|Encapsulated, raffined cod-oil
48722198|NCT04232215|DEVICE|HeraBEAT™|A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy
48722199|NCT04232215|DEVICE|Doppler fetal heart rate monitor|A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
48384439|NCT06437522|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
48384440|NCT06437522|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
48384441|NCT04950673|DEVICE|Cognivue|Computerized Cognitive Assessment Device
48722200|NCT03845595|DEVICE|(LF-rTMS) group|"The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ \*rTMS\* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous \*FDI\* muscle, while the patient is contracting his whole limb as much as possible ."
48722201|NCT03845595|OTHER|Control group|neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
48182899|NCT00565266|DRUG|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
48182900|NCT00565266|DRUG|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
48182901|NCT00272454|DRUG|Cilostazol|
48384442|NCT06541509|DRUG|Semaglutide|"10 overweight patients with heart failure will be enrolled, including 5 patients with heart failure with preserved ejection fraction (HFpEF) and 5 patients with heart failure with reduced ejection fraction (HFrEF). The diagnosis of HFpEF and HFrEF will be based on the most recent European Society of Cardiology guidelines for the diagnosis and treatment of heart failure.~After their baseline blood sample collections, all participants will receive once-weekly subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark) at a dose of 0.25 mg for 2 weeks, 0.5 mg for 2 weeks, and then 1.0 mg for a period of 12 weeks. At the end of the 3-month and 4-month period, blood sample collections will be repeated. All blood samples will be sent to Stanford Cardiovascular Institute for further analyses. At baseline, and again at 4 months transthoracic echocardiography, 6-minute walk test, and body composition assessment will be performed."
48384443|NCT04426188|PROCEDURE|Heading series|10 headers from machine-projected soccer balls at standardized speeds
48520463|NCT05718934|DRUG|Neostigmine and glycopyrrolate|See arm descriptions
48722202|NCT02749383|DRUG|PAC-14028 cream 0.3%|Topical application
48182902|NCT00272454|DRUG|Aspirin|
48722203|NCT02749383|DRUG|PAC-14028 cream 1.0%|Topical application
48722204|NCT02749383|DRUG|PAC-14028 cream vehicle|Topical application
48722205|NCT03699137|OTHER|No interventions|No interventions
48722206|NCT04731532|PROCEDURE|classical respiratory physiotherapy with thoracic vibration|Classical respiratory physiotherapy application: Patient is positioned, postural drainage application is operated by tapping and trifled .
48182903|NCT04652661|DRUG|Dexmedetomidine|30 children will be sedated with 2 μg/kg intranasal DEX.
48182904|NCT04652661|DRUG|Midazolam|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
48182905|NCT05295394|DRUG|Dolutegravir plus lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
48182906|NCT01910883|DRUG|Finafloxacin i.v. solution 200 mg|
48182907|NCT01910883|DRUG|Finafloxacin i.v. solution 400 mg|
48182908|NCT01910883|DRUG|Finafloxacin i.v. solution 600 mg|
48182909|NCT01910883|DRUG|Finafloxacin i.v. solution 800 mg|
48182910|NCT01910883|DRUG|Finafloxacin i.v. solution 1000 mg|
48182911|NCT01910883|DRUG|Placebo i.v. solution|
48182912|NCT03543553|OTHER|This is not an intervention study|This is not an intervention study
48384444|NCT04426188|DEVICE|Magnetic Resonance Imaging (MRI)|Brain MRI before and after a series
48722207|NCT03262116|DRUG|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
48722208|NCT03262116|DRUG|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
48722209|NCT03262116|DRUG|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
48722210|NCT03262116|DEVICE|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
48722211|NCT05529004|DRUG|Oral Capsule pregapalin|oral cap of pregapalin has been administration to patient before surgery to prvent PONV
48722212|NCT05529004|DEVICE|laparoscope device|general anesthesia with complete relaxation under laparoscopic cholecystectomy
48722213|NCT01581008|OTHER|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
48182913|NCT04626804|OTHER|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
48182914|NCT05109767|DEVICE|Virtual reality|The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
48384445|NCT04426188|OTHER|Cognitive computerized assessment|Cognitive evaluation carried out with two computerized tools
48384446|NCT04426188|PROCEDURE|Electrophysiological records|Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)
48384447|NCT04426188|DEVICE|Dynamometer|Measure of the strength of the neck muscles using a dynamometer
48384448|NCT06558526|DIETARY_SUPPLEMENT|Apple pectin (DE 57%)|Dietary intervention with apple pectin. Participants will orally take the supplement once a day, after dissolving it in 100 ml of water, for 6 months.
48384449|NCT06558526|DIETARY_SUPPLEMENT|Placebo|Dietary intervention with maltodextrin. Participants will orally take the placebo (maltodextrin) once a day, after dissolving it in 100ml of water, for 6 months.
48384450|NCT03327935|DIETARY_SUPPLEMENT|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
48384451|NCT01843660|DRUG|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
48384452|NCT02546180|OTHER|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
48384453|NCT02546180|OTHER|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
48520464|NCT05718934|DRUG|Sugammadex|See arm descriptions
48520465|NCT06193616|DRUG|Octreotide|All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.
48520466|NCT00297076|DRUG|GW873140|
48520467|NCT05193838|DRUG|Allopurinol Tablet|examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
48722214|NCT01581008|BEHAVIORAL|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
48722215|NCT06386341|PROCEDURE|Maxillomandibular Advancement Surgery|Surgery where the upper and lower jaw are repositioned.
48722216|NCT03353103|DRUG|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
48722217|NCT06267638|DRUG|Ketamine group|Participants will receive intraoperative ketamine during total knee arthroplasty
48722218|NCT06267638|DRUG|Placebo group|Participants will receive intraoperative normal saline during total knee arthroplasty
48722219|NCT00665236|OTHER|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
48722220|NCT00665236|PROCEDURE|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
48722221|NCT02273713|DRUG|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
48722222|NCT00201123|DRUG|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
48722223|NCT00201123|DRUG|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
48722224|NCT00201123|OTHER|Placebo|
48722225|NCT05539209|BEHAVIORAL|OKquit|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.
48722226|NCT05539209|BEHAVIORAL|Standard Helpline Care|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
48722227|NCT05499624|DEVICE|MicroTrend System|The hands-free device measures oral mucosal carbon dioxide pressure (POMCO2) and functions outside of the body and does not require a surgical procedure or any significant deviation from standard practice to operate.
48722228|NCT00558532|PROCEDURE|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
48722229|NCT05650671|DEVICE|instrumented wheelchair|Measurements of pressure, temperature and humidity at the subject/cushion interface
48722230|NCT04876612|PROCEDURE|Transforaminal epidural steroid injection (TFESI)|Well trained pain physician performs all the fluoroscopy-guided transforaminal epidural steroid injection (TFESI), who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For TFESI, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under fluoroscopy guidance at the patient's symptom complaining level. After confirming with a contrast medium, 3 ml of 0.1875% ropivacaine and 5 mg of dexamethasone are administered.
48722231|NCT05386212|DEVICE|web app healthcare instructions for relieving back pain|This study designed web-based dynamic pain relief instructions for women with spinal compression fractures.
48722232|NCT04397965|DEVICE|Cascade Continuous Glucose Monitor|Continuous Glucose Monitoring
48722233|NCT02698722|OTHER|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
48182915|NCT05109767|DEVICE|Smartphone|The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
48722234|NCT00536887|DRUG|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
48182916|NCT05428280|OTHER|Physiotherapy|Conventional treatment consisted of Transcutaneous Electrical Nerve Stimulation and Progressive Back Strengthening Exercise
48182917|NCT05428280|OTHER|Muscle Energy technique|Muscle Energy Technique (MET) is a technique that was developed in 1948 by Fred Mitchell, Sr, D.O\[1\]. It is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.
48182918|NCT05428280|OTHER|Myofacial mobilization|It is a type of gentle, constant massage that releases tightness and pain throughout your myofascial tissues
48182919|NCT03228147|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given PO
48182920|NCT03228147|OTHER|Questionnaire Administration|Ancillary studies
48182921|NCT00905047|DRUG|XELODA|"XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days"
48182922|NCT00905047|DRUG|TEGAFUR URACIL - FOLINIC ACID|"Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days."
48520468|NCT05509387|DEVICE|transcranial direct current stimulation and naming training|Participants will receive mild stimulation or no stimulation along with naming training
48520469|NCT02943980|DEVICE|CMAC Videolaryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
48025822|NCT04603989|DRUG|HNC042 for Injection|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg
48025823|NCT04603989|DRUG|Placebo Comparator|Placebo , Intravenous route , multiple ascending doses
48025824|NCT04121598|OTHER|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
48025825|NCT03582306|BEHAVIORAL|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
48025826|NCT03582306|BEHAVIORAL|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
48025827|NCT03956498|OTHER|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"* Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~* Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
48025828|NCT02824068|DRUG|glucosidase alfa|Long-term use in an observational study of licenced drug
48025829|NCT05117645|DIAGNOSTIC_TEST|Computed tomography|All patients will be examined by multislice CT scanner,Light speed 5X GE 8 detector elements scanner or GE Revolution Evo 128 multidetector elements scanner (GE Healthcare, Chicago, Illinois, United state) or Toshibe Alexion 16 detector elements scanner (Aplio 500, Toshiba Medical Systems, Otawara-shi, Tochigi 324-8550, Japan). Axial scanns will be done commences at 1 cm above the diaphragm and ending at lesser trochanters then coronal and sagittal reconstruction images will be exposed.
48025830|NCT05422118|DIAGNOSTIC_TEST|ascitic fluid calprotectin|ascitic fluid calprotectin
48025831|NCT01575340|DIETARY_SUPPLEMENT|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
48025832|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video and brochure
48025833|NCT01801059|OTHER|educational intervention|Receive patient activation intervention by educational video
48025834|NCT01801059|OTHER|questionnaire administration|Ancillary studies
48182923|NCT05869695|OTHER|OSPRO-ROS Questionnaire|Completion of questionnaires
48182924|NCT05869695|OTHER|OSPRO-YF Questionnaire|Completion of questionnaires
48182925|NCT00478205|DRUG|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
48182926|NCT00478205|DRUG|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
48722235|NCT04590209|OTHER|Blood sampling|Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
48384454|NCT05804201|PROCEDURE|EUS-guided hepatico-gastrostomy would be performed with Niti-S HOT Giob|(2) The EUS procedure will be performed with a therapeutic echoendoscope with a large working channel under guidance of ultrasound, endoscopy, and fluoroscopy. The echoendoscope will be positioned in the stomach or duodenum. Liver segment III, or sometimes segment II, will be punctured with an 19G needle. After puncture, a guidewire will be introduced in the dilated bile duct, and a Hot Giobor will be placed. All procedures will be performed with the patient and in the supine or prone position under monitored anesthesia.
48384455|NCT04176354|DRUG|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
48722236|NCT04590209|OTHER|Skin biopsy|Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
48182927|NCT01747863|OTHER|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
48384456|NCT04176354|DRUG|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
48384457|NCT04176354|DRUG|Letrozole|Letrozole monotherapy
48384458|NCT06292728|DEVICE|ENDOPLY System|One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.
48384459|NCT03533829|DEVICE|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
48384460|NCT03533829|BEHAVIORAL|Music|Music will be selected and listened to as a distraction before and during vaccination.
48384461|NCT05996601|BEHAVIORAL|Educational intervention|Educational materials would be given to all the participants. They would also be followed up by pharmacist.
48384462|NCT03976817|PROCEDURE|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
48384463|NCT05443256|DEVICE|Transcranial Magnetic Stimulation|Figure 8 coil stimulation
48384464|NCT05469776|PROCEDURE|bicruciate-retaining total knee arthroplasty|
48722237|NCT05404581|DEVICE|neuromodulation|"During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.~Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation."
48384465|NCT05469776|PROCEDURE|posterior-stabilized total knee arthroplasty|
48384466|NCT03861533|OTHER|survey|Cross-Reference
48384467|NCT03479515|DEVICE|Ultrasound|Ultrasound, ADP, bioimpedance measurements
48384468|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
48384469|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
48722238|NCT05435066|DIAGNOSTIC_TEST|Harbinger Health Test|This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year
48722239|NCT01360177|PROCEDURE|124 PET/CT imaging|Standard of Care
48722240|NCT01360177|DRUG|Na134I|25 to 150 mCi
48722241|NCT01360177|DRUG|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
48722242|NCT01360177|DRUG|Tri-iodothyronine|20 mg/day x 2
48722243|NCT00987493|BIOLOGICAL|rituximab|day 1 at a fixed dose of 375mg/m2
48722244|NCT00987493|DRUG|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
48384470|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
48384471|NCT05127707|BEHAVIORAL|Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
48384472|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
48520470|NCT02943980|DEVICE|Macintosh Laryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
48025835|NCT03892486|OTHER|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
48522750|NCT02120638|DRUG|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
48722245|NCT00987493|DRUG|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
48722246|NCT05951712|DRUG|Simethicone 150mg|Impact of simethicone on the mucosal visibility of stomach and duodenum
48722247|NCT05951712|DRUG|N Acetyl cysteine 600mg|Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
48722248|NCT05951712|DRUG|Simethicone 150mg plus N Acetyl cysteine 600 mg|Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
48722249|NCT05951712|OTHER|Placebo|Impact of water on the mucosal visibility of stomach and duodenum
48722250|NCT01665534|BEHAVIORAL|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
48722251|NCT00563823|DRUG|vatalanib|
48722252|NCT04524455|DRUG|Blinatumomab|Blinatumomab will be administered as a continuous intravenous infusion (cIV).
48025836|NCT01359735|BIOLOGICAL|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
48025837|NCT01359735|BIOLOGICAL|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
48722253|NCT04524455|DRUG|AMG 404|AMG 404 will be administered as an intravenous infusion (IV).
48722254|NCT04524455|DRUG|Dexamethasone Premedication|Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
48722255|NCT03874039|DEVICE|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
48722256|NCT03874039|DEVICE|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
48722257|NCT04906057|BEHAVIORAL|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
48722258|NCT04906057|BEHAVIORAL|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
48722259|NCT00498888|PROCEDURE|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
48722260|NCT00498888|PROCEDURE|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
48722261|NCT00498888|PROCEDURE|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
48722262|NCT00498888|PROCEDURE|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
48722263|NCT04014387|DRUG|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
48722264|NCT04014387|DRUG|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
48025838|NCT02773589|PROCEDURE|Peroral endoscopic myotomy|Peroral endoscopic myotomy
48722265|NCT04014387|DRUG|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
48722266|NCT05941260|DIAGNOSTIC_TEST|Computational fluid dynamics (CFD)|"- Video recording starts in an antegrade manner starting from the bladder neck through the prostatic urethra and ends after the verumontanum at the external sphincter. Videos were taken with a very slow movement of the endoscope to ensure the sharpness of the data and to prevent complications in post-processing.~The focal length and zoom of the endoscope camera were set at the beginning and maintained throughout the capturing, while the angle of the lens changes to capture the widest field possible for each targeted area.~* Computational fluid dynamics (CFD) can then be used to numerically model the behavior of the flow inside the urethra by solving the governing equations of the flow using the finite volume method.~* Through which we can develop a urodynamic computer model to simulate the bladder-urethral passage and predict the success of the resection undertaken by the surgeon. No extra intervention will be provided to our patients apart from their routine surgery."
48722267|NCT04631653|DEVICE|VeriSee®|Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®
48722268|NCT01238978|DRUG|Vildagliptin|
48722269|NCT01238978|DRUG|"Usual Care"|
48722270|NCT00166491|DRUG|Insulin|
48025839|NCT06559488|DRUG|Bevacizumab Injection [Avastin]|Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected at the completion of vitrectomy surgery.
48025840|NCT06559488|PROCEDURE|Pars Plana Vitrectomy|routine procedure of pars plana vitrectomy in vitreous hemorrhage for proliferative diabetic retinopathy patients
48182928|NCT02508597|OTHER|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
48722271|NCT05629910|DEVICE|O2Matic|During the interventional period the O2Matic will operate in automatic mode using the Neonatal Study Profile. O2Matic will continuously adjust the O2 flow to adjust SpO2 within range based on readings from the pulse oximeter connected to O2Matic, while AIRVO-2 will adjust the flow of ambient air to keep the total gas flow constant.
48722272|NCT04152213|BEHAVIORAL|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
48722273|NCT05340803|RADIATION|Ultrasonograghic optic nerve sheath diameter US-ONSD|To compare effect of sedation in 3 groups by follow up of intracranial pressure by US-ONSD
48722274|NCT05340803|DRUG|midazolam|midazolam
48722275|NCT05340803|DRUG|dexmedetomidine|dexmedetomidine
48722276|NCT05340803|DRUG|magnesium sulfate|magnesium sulfate
48722277|NCT02751528|BIOLOGICAL|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
48722278|NCT00307554|BIOLOGICAL|Pneumococcal (vaccine)|
48722279|NCT05110313|BIOLOGICAL|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
48722280|NCT02036762|OTHER|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
48722281|NCT03354390|BIOLOGICAL|cell infusion|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A\*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
48722282|NCT00885794|DRUG|Ranibizumab|3 intravitreal injection every 5 weeks
48722283|NCT05920408|DRUG|EXS21546|EXS21546 Granule in Capsule
48722284|NCT03303612|DEVICE|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
48722285|NCT03303612|DEVICE|Transcutaneous cardiac monitor|"Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include:~Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;"
48722286|NCT00443781|PROCEDURE|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
48722287|NCT00443781|PROCEDURE|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
48722288|NCT00612508|DRUG|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
48722289|NCT00612508|DRUG|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
48722290|NCT06419816|OTHER|"Physician-managed WellCheck use"|"Physician-managed WellCheck use"
48722291|NCT06419816|OTHER|"self-managed WellCheck use"|"self-managed WellCheck use"
48025841|NCT02810535|OTHER|Observation|"Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE"
48025842|NCT03396783|BIOLOGICAL|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
48025843|NCT03396783|OTHER|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
48025844|NCT04448184|DRUG|Tranexamic Acid|"Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously."
48025845|NCT06175728|DEVICE|S-Press|Leg Strengthening Device that can be used in supine and seated positions
48182929|NCT00943787|PROCEDURE|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
48182930|NCT05344677|OTHER|Trendelenburg Position|Group 1 (trendlenburg position group) in which the women will be positioned in a Trendelenburg position (20 °) once fully awake and cooperative in the recovery room and will remain in this posture for the first 24 hrs postoperatively. The maximum time allowed in a straight-up position will be three 15-min intervals over a 24-h period.
48722292|NCT03233438|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
48025846|NCT00034034|PROCEDURE|Acupuncture|
48182931|NCT05344677|OTHER|Warm Pad Application|• Group 2 (warm pad application group) in this group warm pad (38◦C -40◦C) will be applied on the shoulder after four hours postoperatively for a period of 5-10 minutes. Each woman will be asked to place heat pads when needed during the first 24 hours.
48182932|NCT05344677|BEHAVIORAL|Deep Breathing Exercise|• Group 3: (deep breathing group) the researcher will instruct women after the end of surgery and upon consciousness to take slowly deep breathing while observing her chest and hold her breath for about 5 seconds and then exhale slowly, repeating this deep breathing technique five times after full vigilance within the first 3 hours after surgery. Then, the process will be repeated 6, 12, and 24 h later. The patient will be instructed about this type of breathing before surgery by researchers.
48182933|NCT02454504|DRUG|sugammadex|
48182934|NCT02454504|DRUG|Neostigmine|
48182935|NCT02274779|DRUG|ELIGARD|"Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.~Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical."
48182936|NCT02675049|DRUG|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
48182937|NCT02675049|DRUG|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
48025847|NCT04177511|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
48182938|NCT02675049|DRUG|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
48182939|NCT02675049|DRUG|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
48182940|NCT06087471|DIETARY_SUPPLEMENT|Intervention snack|The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
48722293|NCT03233438|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
48722294|NCT03948919|DRUG|Fecal microbiota|Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
48722295|NCT03948919|OTHER|Placebo|Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
48722296|NCT06172400|DRUG|Mepivacaine, Combinations|Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
48722297|NCT00073281|PROCEDURE|Islet transplantation|
48722298|NCT05821725|DEVICE|Hyaluronic acid|Hyaluronic acid and hemostatic sponge
48722299|NCT05821725|DEVICE|Control|Hemostatic sponge
48722300|NCT05004129|DRUG|Tideglusib|All subjects will receive weight-adjusted 1000 mg tideglusib following a titration period of 2 weeks at a weight-adjusted dose of 400 mg and 2 weeks at a weight-adjusted dose of 600 mg tideglusib.
48722301|NCT02666794|DRUG|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
48722302|NCT02666794|DRUG|Epidural sufentanil|20 mcg
48722303|NCT02666794|PROCEDURE|Placement of the epidural catheter|Placement of the epidural catheter
48722304|NCT02666794|DRUG|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
48722305|NCT02666794|DRUG|Intrathecal morphine|60 mcg
48722306|NCT02666794|PROCEDURE|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
48025848|NCT02194621|DRUG|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
48025849|NCT02194621|DRUG|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
48025850|NCT02194621|DRUG|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
48025851|NCT02417246|DRUG|brand name metoprolol ER|This medication will be taken for 7 to 28 days
48025852|NCT02417246|DRUG|Generic A|This medication will be taken for 7 days
48025853|NCT02417246|DRUG|Generic B|This medication will be taken for 7 days
48722307|NCT02666794|DRUG|Intrathecal sufentanil|5 mcg
48722308|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
48722309|NCT01510899|DRUG|RO4917838|Single dose of RO4917838
48722310|NCT03612310|PROCEDURE|Skin biopsy/Urine Collection/Blood Sample Collection|"Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. Clinician will collect a 5-7mm section of skin, the area may be numbed beforehand and stitches may be used to close the wound when required. The wound will be dressed if deemed necessary by medical professional.~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or phlebotomost will use a disposable needle to remove a blood sample (normally 50ml but could be up to 320ml for adults).~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or other nominated member of the clinical team will provide a sterile urine collection vessel and direct the volunteer to a suitable private toilet area to provide the sample."
48722311|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
48722312|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
48722313|NCT00064402|DRUG|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
48722314|NCT00064402|DRUG|Salmeterol|Salmeterol MDI 42 mcg BID
48722315|NCT00064402|DRUG|Placebo|Placebo BID
48025854|NCT01173393|PROCEDURE|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:~* LMA/ Intubation and ventilation with 100% oxygen~* Measure temperature using tympanic probe and record~* Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~* If temperature \>34.5ºC, infuse further 10mL/kg stat~* After ROSC, infuse further (max 2 litres) ice-cold saline~* If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
48025855|NCT06384677|OTHER|M-Tapa Block|M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
48722316|NCT05160818|RADIATION|Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiotherapy radiosurgery (SRS)|intervention description see above
48722317|NCT02834286|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
48722318|NCT02834286|DRUG|Eltrombopag|Eltrombopag 50 mg PO days 1-28
48722319|NCT02834286|DRUG|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
48722320|NCT02526251|OTHER|observational|No intervention
48722321|NCT03829956|DEVICE|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
48722322|NCT01380704|DRUG|ABT-436|QD Days 1-7
48182941|NCT06087471|DIETARY_SUPPLEMENT|Control Snack|The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
48384473|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
48384474|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
48722323|NCT01380704|DRUG|Matching Placebo|QD Days 1-7
48722324|NCT03612050|BEHAVIORAL|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
48722325|NCT01944579|OTHER|Blackberries|Participants will receive blackberries as part of a controlled diet.
48722326|NCT01944579|OTHER|Control|Participants will receive a control food (jello) as part of a controlled diet.
48722327|NCT04004403|OTHER|Alternate day fasting|"The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
48722328|NCT04004403|OTHER|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
48722329|NCT00265018|DRUG|Adriamycin|
48722330|NCT00265018|DRUG|Bleomycin|
48722331|NCT00265018|DRUG|Vinblastine|
48722332|NCT00265018|DRUG|DTIC|
48722333|NCT00265018|RADIATION|30 Gy IF-RT|
48722334|NCT00265018|RADIATION|20 Gy IF-RT|
48025856|NCT02454426|DRUG|Vortioxetine|open label treatment
48722335|NCT05978141|OTHER|Optional Blood Sample and Nail Sample|Participants may provide optional research blood and nail samples for biobanking and future use
48722336|NCT02744417|BEHAVIORAL|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
48722337|NCT02744417|PROCEDURE|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
48722338|NCT02744417|DRUG|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
48722339|NCT02744417|DRUG|bupropion hydrochloride|bupropion hydrochloride 150mg
48722340|NCT02744417|DRUG|Varenicline|Varenicline 0,5mg
48722341|NCT06358404|BEHAVIORAL|PeersCOG|. The intervention will consist of 8 weekly video chats focused on emotional, appraisal, and informational support delivered by community-based older adult peer coaches to adults 60 years of age and older with subthreshold depression and SCD.
48025857|NCT03846843|DRUG|OCR-002 IR Oral Tablet|OCR-002 3 gram immediate release (IR) tablet for oral administration
48025858|NCT03846843|DRUG|OCR-002 Oral Solution|OCR-002 5 gram solution for oral administration
48025859|NCT03846843|DRUG|OCR-002 IV Solution|OCR-002 5 gram solution for intravenous (IV ) administration
48025860|NCT01459276|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
48025861|NCT01459276|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
48025862|NCT06496256|DEVICE|Barrigel|Barrigel is an absorbable gel based on Non-Animal Stabilized Hyaluronic Acid (NASHA™) that is injected into the peri-rectal space
48025863|NCT06496256|DEVICE|Transrectal Ultrasound|All subjects will have a transrectal ultrasound (TRUS) conducted. In the control subjects this will act as a sham procedure. For the investigational subjects, the TRUS will be used to visualize the placement of the needle
48025864|NCT03174886|DRUG|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
48025865|NCT03174886|DRUG|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
48025866|NCT03491735|OTHER|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
48025867|NCT00983229|PROCEDURE|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
48025868|NCT01476046|DRUG|GSK1995057 single dose|Single intravenous dose
48025869|NCT01476046|DRUG|Placebo|Single intravenous dose
48025870|NCT05173519|DEVICE|Omnibond Topical Skin Adhesive|Application of Omnibond topical skin adhesive to close incision following surgery
48025871|NCT05173519|DEVICE|Dermabond Advanced Topical Skin Adhesive|Application of Dermabond topical skin adhesive to close incision following surgery
48025872|NCT05244356|BEHAVIORAL|Health message exposure|Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
48025873|NCT02680600|DRUG|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
48025874|NCT02680600|OTHER|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
48520471|NCT03275142|DEVICE|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
48520472|NCT02174627|DRUG|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
48025875|NCT02680600|OTHER|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
48028987|NCT02842060|BEHAVIORAL|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
48722342|NCT03705975|OTHER|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
48384475|NCT05127707|BEHAVIORAL|Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)|Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
48384476|NCT05935618|BEHAVIORAL|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
48384477|NCT05227937|DRUG|Amikacin|patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
48722343|NCT02723175|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
48722344|NCT00003719|DRUG|irinotecan hydrochloride|
48025876|NCT02680600|OTHER|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R\&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
48384478|NCT06651203|OTHER|Follow-up|Clinical evaluation Blood sample Skin biopsy
48384479|NCT06262581|DRUG|Tisleizumab(BGB-A317)|200mg i.v. q3w
48384480|NCT00171080|DRUG|valsartan|
48384481|NCT00171080|DRUG|irbesartan|
48384482|NCT02250157|DRUG|Oratecan|
48384483|NCT06650410|OTHER|Virtual Intervention for Vertebral Fractures (VIVA)|VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. An exercise professional leads 1:1 once-weekly sessions (in person or virtual) over eight weeks. Sessions start with brief education on a topic, followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. The exercise professional prescribes resources using an app or that can be emailed or mailed. Exercises are tailored to the participant's abilities, and target balance, muscle strength, and endurance of back extensor muscles and scapular stabilizers.
48384484|NCT01711814|DRUG|peficitinib|oral
48384485|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3|2000 IU per day for 6 weeks (two capsules of 800 IU plus one capsule of 400 IU), followed by 800 IU (one capsule of 800 IU) per day for 6 weeks.
48722345|NCT00946907|DRUG|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
48722346|NCT00946907|DRUG|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
48722347|NCT03322813|DEVICE|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
48722348|NCT02191839|DRUG|Alpha 1-Antitrypsin|
48722349|NCT00667654|DRUG|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
48722350|NCT01751139|PROCEDURE|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
48722351|NCT01751139|OTHER|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
48722352|NCT01848847|PROCEDURE|Hysteroscopy|
48722353|NCT01086852|BIOLOGICAL|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
48722354|NCT03947528|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
48520473|NCT02174627|DRUG|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
48722355|NCT00786539|DEVICE|Diffuse Optical Spectroscopy|mitochondria
48520474|NCT01221701|BEHAVIORAL|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
48722356|NCT04083755|DRUG|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
48722357|NCT04083755|OTHER|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
48722358|NCT05385484|BEHAVIORAL|Receives mobile banking account with incentives to save|Participants will receive assistance in opening and using a mobile savings account, will be given education emphasizing saving practices and will be told about lottery-based incentives opportunities.
48722359|NCT03147638|DRUG|Warfarin, NOAC|duration of treatment
48722360|NCT06505538|DEVICE|NL-Mapp|Mobile applicaiton
48722361|NCT05850923|OTHER|speech competition training|Speech competition training include voice competition training twice a day in adjunction with drug treatment, and the patients will be required to perform voice-related tasks according to the instruction.
48520475|NCT03076632|DEVICE|Cervical plus transcranial stimulation|Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
48520476|NCT03076632|DEVICE|Cervical stimulation plus hand/wrist exercise|Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.
48520477|NCT03076632|DEVICE|Electromyographic (EMG)-triggered (closed-loop) stimulation|Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
48520478|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Low dose of ACI-35.030
48520479|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Medium dose of ACI-35.030
48520480|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a High dose of ACI-35.030
48520481|NCT04445831|OTHER|Placebo|Administration of Placebo
48722362|NCT05850923|OTHER|the soothing music|the soothing music
48722363|NCT04298424|OTHER|PLSM|The program was designed for implementation over 4 consecutive weeks, with groups of 6-8 people each attending one 60-90-minute class per week. Peer leaders lead the groups to promote interaction, sharing, and support, and assist in goal setting to address behavior-related health problems, and thereby the development and implementation of strategies to achieve suitable, sustainable, and feasible self-management behavior.
48722364|NCT02981966|DRUG|Dapagliflozin|dapagliflozin, 10mg tablet
48722365|NCT02981966|DRUG|Placebo|Placebo for dapagliflozin
48722366|NCT05632783|DRUG|Chondroitin Sulfate Sodium|Chondroitin sulfate 800 mg tablets
48722367|NCT05632783|OTHER|Placebo|Placebo tablets
48520482|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Low dose of JACI-35.054
48520483|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Medium dose of JACI-35.054
48384486|NCT06247930|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Three capsules for 6 weeks, followed by one capsule for 6 weeks.
48520484|NCT02288312|DRUG|BIA 2-093|
48182942|NCT04025268|BEHAVIORAL|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
48182943|NCT04025268|BEHAVIORAL|Standard of Care|Standard of prenatal care
48722368|NCT03705910|OTHER|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
48722369|NCT03705910|OTHER|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
48520485|NCT05416840|DRUG|Clonidine controlled-release patch|"Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
48182944|NCT00466609|DRUG|Clomipramine (fluoxetine plus clomipramine)|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
48182945|NCT00466609|DRUG|Quetiapine (fluoxetine plus quetiapine)|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
48025877|NCT02680600|OTHER|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
48182946|NCT00466609|DRUG|Placebo (fluoxetine plus placebo)|Placebo plus fluoxetine at maximum dosage of 80mg per day
48182947|NCT01275599|DRUG|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
48182948|NCT01275599|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
48520486|NCT05416840|DRUG|Amlodipine|"Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
48520487|NCT03345420|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
48182949|NCT01165177|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
48520488|NCT01410214|DRUG|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
48520489|NCT01410214|DRUG|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
48722370|NCT04161755|DRUG|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
48722371|NCT04161755|BIOLOGICAL|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
48182950|NCT01165177|BIOLOGICAL|Placebo|Intramuscular injection
48025878|NCT02680600|OTHER|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
48025879|NCT02680600|OTHER|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
48722372|NCT04161755|DRUG|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
48722373|NCT02102152|DRUG|Tobramycin|
48025880|NCT06429306|DRUG|Dexycu|5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
48722374|NCT02430324|OTHER|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
48722375|NCT00265265|DRUG|Atomoxetine|
48722376|NCT06262256|BEHAVIORAL|High-intensity interval training|supervised exercise conducted on stationary bikes after individualized intensity prescription.
48722377|NCT04345718|DRUG|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
48025881|NCT06429306|DRUG|Placebo|Acetyl triethyl citrate
48025882|NCT01084044|DRUG|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
48025883|NCT06050421|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a transdiagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as resistant depression, avoidant and obsessive-compulsive personality disorders, mood disorders, anorexia nervosa and autism spectrum disorder.
48025884|NCT06050421|OTHER|Treatment As Usual|he TAU condition will follow the standard treatment of the EDs Unit of the HSCSP for AN. This treatment consists of visits with a psychiatrist with a frequency decided according to the clinical situation and, in some cases, nursing follow-up and/or relapse prevention group that takes place twice per month
48025885|NCT06050421|OTHER|No intervention|All controls will complete data collection notebook and will undergo the same neuroimaging acquisition. There will not be follow-up for this group.
48182951|NCT05175469|DIAGNOSTIC_TEST|Flow cytometric analysis of neutrophil myeloperoxidase expression|"Performance of flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed on the same day of collection.~Blood samples will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8/12-color flow cytometer and analyzed using flow cytometry software. Myeloperoxidase expression in the peripheral blood neutrophil population within an individual subject will be expressed as intra-individual robust coefficient of variation (RCV)."
48520490|NCT05808101|OTHER|Neuro-QoL T-score determination|Neuro-Qol depression scale, using a T-score of 55 as a threshold
48182952|NCT00203034|DRUG|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
48520491|NCT03026491|OTHER|Chewing evaluation|Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
48520492|NCT03342885|BEHAVIORAL|Specific sleep ergonomics guidance|Participants receive a detailed instruction in sleep ergonomics. Participants are instructed to maintain either side lying or supine sleeping posture, depending on which is less painful. Neutral position of spine supported by specific placement of body pillow. Changing of posture during sleep is prevented. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
48722378|NCT04345718|DRUG|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
48722379|NCT03445390|DRUG|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
48722380|NCT03445390|DRUG|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
48722381|NCT06060860|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth."
48025886|NCT06300645|PROCEDURE|SPLATT|split tibialis anterior tendon transfer to peroneus brevis total tibialis anterior tendon transfer to lateral cuneiform
48025887|NCT00745927|OTHER|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
48025888|NCT02946736|BEHAVIORAL|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
48722382|NCT06060860|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
48722383|NCT02163785|PROCEDURE|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
48722384|NCT06273046|BEHAVIORAL|Biofeedback|Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.
48025889|NCT02946736|BEHAVIORAL|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
48025890|NCT04066218|OTHER|Interviews|"* Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
48520493|NCT03342885|BEHAVIORAL|General sleep ergonomics guidance|Participants are instructed find most comfortable sleeping posture by personal preference and to avoid painful posture. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
48722385|NCT06273046|BEHAVIORAL|Placebo|Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
48722386|NCT02925169|DEVICE|CT Scan|CT imaging
48722387|NCT02030990|DRUG|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
48722388|NCT02030990|DRUG|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
48722389|NCT00024375|DRUG|DHA-paclitaxel|
48722390|NCT03854539|OTHER|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
48722391|NCT01292564|DEVICE|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
48722392|NCT01292564|DEVICE|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
48722393|NCT04986280|DIAGNOSTIC_TEST|[18F]PSMA-1007|PSMA PET/CT using the intervention.
48722394|NCT03412604|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
48722395|NCT05856097|OTHER|kinesio taping with diaphragmatic breathing|.kinesio tape was applied on1st day of intervention with the 20 minutes session of diaphragmatic breathing 3 sessions were given
48722396|NCT05856097|OTHER|kinesio taping without diaphragmatic breathing|kinesio tape was applied day 1st of intervention. 3 sessions were given
48722397|NCT03661086|DEVICE|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
48722398|NCT00792532|PROCEDURE|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
48722399|NCT00792532|DEVICE|DBS electrodes|Deep brain stimulation (DBS) electrodes
48722400|NCT02424292|OTHER|Physical activity|Physical activity in a personalised program.
48722401|NCT04936347|PROCEDURE|cold knife|Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
48025891|NCT03544034|BEHAVIORAL|HomeTeam Toolkit|"A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge"
48025892|NCT05576467|BEHAVIORAL|MBCT-Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
48182953|NCT00203034|DRUG|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
48722402|NCT04936347|PROCEDURE|hot knife|Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
48182954|NCT00203034|OTHER|Placebo|oral placebo once daily
48522751|NCT02120638|DRUG|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
48722403|NCT00413010|DRUG|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
48182955|NCT00166946|PROCEDURE|foreskin from healthy adults for organotypic culture|
48182956|NCT02378636|DEVICE|600S|Monofocal Aspheric Intraocular Lens (IOL)
48182957|NCT04685447|PROCEDURE|Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
48384487|NCT06247930|BEHAVIORAL|Mental health education|The mental health education consists of providing a brochure with information about mental health problems. Additionally, participants will receive a set of 5 educational mental health videos regarding depression. Each of these videos is 15 minutes long.
48025893|NCT05576467|BEHAVIORAL|MBCT-Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
48520494|NCT04464850|DRUG|Intravenous iron|"Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose"
48520495|NCT04464850|DRUG|Oral iron|"1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate"
48722404|NCT00413010|DRUG|placebo|placebo + concurrent GAD treatment from the open-label study period
48722405|NCT00756951|DRUG|Placebo|Placebo
48722406|NCT00756951|DRUG|SCV-07|0.02 mg/kg
48722407|NCT00756951|DRUG|SCV-07|0.10 mg/kg
48722408|NCT01416428|DRUG|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
48722409|NCT02728531|DRUG|Bendamustine|
48025894|NCT05576467|BEHAVIORAL|Enhanced Usual Care (EUC)|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
48025895|NCT04756219|OTHER|Contact Video|No additional information necessary.
48025896|NCT04756219|OTHER|Contact Text|No additional information necessary.
48722410|NCT02728531|DRUG|Rituximab|
48722411|NCT02728531|DRUG|Cytarabine|
48025897|NCT04756219|OTHER|Education Video|No additional information necessary.
48025898|NCT04756219|OTHER|Education Text|No additional information necessary.
48025899|NCT02835534|DRUG|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
48025900|NCT02835534|DRUG|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
48722412|NCT02728531|DRUG|Pegfilgrastim|
48722413|NCT02728531|PROCEDURE|Leukapheresis|
48722414|NCT02728531|DRUG|Filgrastim|
48722415|NCT02728531|PROCEDURE|Autologous stem cell transplant|
48025901|NCT01316744|DRUG|ketamine hydrochloride|
48025902|NCT01316744|OTHER|pharmacogenomic studies|
48025903|NCT01316744|OTHER|questionnaire administration|
48025904|NCT01316744|PROCEDURE|assessment of therapy complications|
48025905|NCT01316744|PROCEDURE|quality-of-life assessment|
48182958|NCT04685447|PROCEDURE|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
48182959|NCT01146977|OTHER|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
48384488|NCT05423769|DRUG|Fingolimod|0.5 mg hard gelatine capsules
48384490|NCT05362669|BEHAVIORAL|SMS invitation|Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
48384491|NCT05362669|BEHAVIORAL|Phone call invitation|Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
48520496|NCT05477043|DIAGNOSTIC_TEST|Transabdominal ultrasound and cistoscopy|Ultrasound detection of the bilateral ureteral jets vs absence of the ureteral jet on one side compared with the presence of bilateral ureteral jet on cystoscopy vs absence on one side.
48520497|NCT04067050|DEVICE|comfilcon A asphere|Contact Lens
48520498|NCT04067050|DEVICE|Spectacles|Habitual spectacles
48384492|NCT05909007|PROCEDURE|thoracic epidural insertion|thoracic epidural for pain relief after major thoracic surgery and lung transplantation
48384493|NCT06653595|OTHER|Programme to Support Breastfeeding|The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
48520499|NCT05588700|BEHAVIORAL|Physical activity recommendations|At the baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population.
48520500|NCT05588700|BEHAVIORAL|Connected activity tracker|At baseline, all participants will receive a connected activity tracker to wear 24 hours a day during one year. Patients will be asked to download an application, dedicated to the study so that the physical activity data (ie. number of steps per day) will be synchronized in the application.
48520501|NCT05588700|BEHAVIORAL|Physical Activity (PA) Intervention|"The intervention will last 1 year and will have 2 phases. Phase 1: At each cycle of chemotherapy, patients will be proposed to perform 2-4 sessions per week. This program will be individual, supervised, performed at a moderate intensity. Between cycles, patients will be asked to perform 1-2 supervised collective live online physical activity sessions per week, proposed by a partner specialized in online PA.~Phase 2: After chemotherapy, patients will be asked to perform 2-3 PA sessions per week at a moderate intensity. Patients will be offered 2 options of PA practice: in the supervised collective live online PA session (as already performed in the phase 1), and/or in a fitness center (this practice will take place in a classic environment with a 9-month free access for patients thanks to a partnership).~In addition, patients will benefit from 4 individual motivational interviews, conducted by videoconference and/or by phone call with a professional."
48520502|NCT03861624|PROCEDURE|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
48520503|NCT03861624|PROCEDURE|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
48520504|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
48520505|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
48520506|NCT01802021|DRUG|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months"
48025906|NCT02649686|DRUG|Durvalumab|
48025907|NCT02649686|DRUG|Trastuzumab|
48025908|NCT00123240|BEHAVIORAL|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
48025909|NCT00123240|BEHAVIORAL|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
48025910|NCT05089396|OTHER|Maxillary protraction|A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
48384494|NCT06650826|DIAGNOSTIC_TEST|Determination of anti-platelet factor 4 antibodies in the blood|"The anti-platelet factor 4 antibodies in the blood are determined using latex agglutination and the chemiluminescence method in the coagulation laboratory of the CCB MVZ laboratory. In addition, the platelet factor 4-induced platelet activation test (PIPA test) and the heparin-induced platelet activation test (HIPA test) as well as an ELISA-based platelet factor 4 IgG antibody test (Prof. Greinacher, Greifswald University Hospital) will be performed as part of the routine work up.~In addition a new assay for heparin-independent anti-PF4 antibody detection provided by the company Werfen using chemiluminescence will be performed."
48520507|NCT03982290|OTHER|Probiotic, Lactobacillus plantarum PS128|PS128 capsules, 2 capsules per day
48025911|NCT06288815|DIETARY_SUPPLEMENT|Oral fluid|"Postoperation~* Off IV fluid immediately postoperative~* Allow patients drink oral fluid as protocol for 24hr"
48025912|NCT06288815|DIETARY_SUPPLEMENT|IV fluid|"Postoperation~* IV fluid replacement as protocol for 24hr~* Allow patients drink oral fluid as usual"
48025913|NCT06234345|DRUG|Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg|Participants randomized to this group will receive 1 capsule per inhalation twice a day
48025914|NCT06234345|DRUG|Comparator - Trimbow®|Participants randomized to this group will receive 2 triggering twice a day
48182960|NCT01146977|OTHER|Autologous HCT|"After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
48182961|NCT01606423|DRUG|Placebo|Administered orally, single dose
48182962|NCT01606423|DRUG|LY2409021|Administered orally, single dose
48384495|NCT06647966|DIAGNOSTIC_TEST|PET/CT|\[11C\]CH PET/CT
48384496|NCT03105076|OTHER|Decision aids|Shared decision making with decision aids
48384497|NCT06026514|BIOLOGICAL|B/HPIV3/S-6P|Intranasal vaccine.
48384498|NCT00871806|DRUG|Commercial tablet with water|40 mg tablet, given once to each subject
48384499|NCT00871806|DRUG|ODT #1 without water|40 mg tablet given once to each subject
48520508|NCT03982290|OTHER|Placebo, microcrystalline cellulose|Placebo capsules, 2 capsules per day
48520509|NCT04828174|DRUG|anti-TRBC1 CAR-T cell therapy|TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
48384500|NCT00871806|DRUG|ODT #2 without water|40 mg tablet given once to each subject
48384501|NCT00871806|DRUG|ODT #1 with water|40 mg tablet given once to each subject
48520510|NCT04650594|PROCEDURE|MUTARS® modular reconstruction prostheses|Patients with MUTARS® modular reconstruction prostheses following primary or secondary knee bone malignancy with minimal follow-up of one year
48520511|NCT05197543|DIAGNOSTIC_TEST|Biomechanical rupture risk assessment|3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
48520512|NCT01738347|DRUG|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
48520513|NCT06050928|DRUG|Oral EP262|Once daily
48520514|NCT02263287|OTHER|LeSCoD scale|LeSCoD is a clinical scale
48520515|NCT03399071|DRUG|FLOT-A|This is a single-arm study with all patients receiving combination FLOT-A
48520516|NCT05588479|DIETARY_SUPPLEMENT|Pomegranate extract|One capsule of pomegranate extract (500 mg) will be taken daily at any time of the day for a period of 12 weeks.
48520517|NCT05588479|DIETARY_SUPPLEMENT|Control|One capsule of containing no pomegranate extract will be taken daily at any time of the day for a period of 12 weeks.
48384502|NCT00871806|DRUG|ODT #2 with water|40 mg tablet given once to each subject
48384503|NCT00049010|GENETIC|comparative genomic hybridization|
48384504|NCT00049010|GENETIC|cytogenetic analysis|
48384505|NCT00049010|GENETIC|fluorescence in situ hybridization|
48384506|NCT00049010|OTHER|immunohistochemistry staining method|
48520518|NCT05812820|COMBINATION_PRODUCT|LiveSpo DIA30|LiveSpo® DIA 30 has a registration number: 6547/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
48520519|NCT05812820|COMBINATION_PRODUCT|LiveSpo CLAUSY|LiveSpo® CLAUSY has a registration number: 4071/2021/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
48384507|NCT05829265|BEHAVIORAL|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~* Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~* Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~* Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
48384508|NCT06031922|DEVICE|Microprocessor controlled knee|Microprocessor controlled knee
48384509|NCT03372772|DRUG|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
48384510|NCT05280613|BEHAVIORAL|Family Check-Up|See arm/group description
48384511|NCT05280613|BEHAVIORAL|Treatment as Usual|See arm/group description
48384512|NCT00993525|DRUG|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
48384513|NCT03788785|BEHAVIORAL|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
48384514|NCT03788785|OTHER|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
48520520|NCT05812820|OTHER|RO|"Aquafina's distilled water and reverse osmosis (RO) water, produce by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively.~The RO water ampoules are produced using a similar process as the LIVESPO DIA30/CLAUSY but contain 5ml of high-quality distilled water from Aquafina in an opaque plastic bottle"
48520521|NCT03457181|OTHER|music|effect of music on anxiety scores
48384515|NCT00147472|OTHER|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
48384516|NCT04827446|OTHER|Wearable Sensor|Patient is given a wearable device to wear for 12 weeks.
48520522|NCT03457181|OTHER|operating room noise|effect of operating room noise on anxiety scores
48025915|NCT03223818|OTHER|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
48722416|NCT05190055|DEVICE|bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
48025916|NCT04173221|OTHER|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
48025917|NCT04173221|OTHER|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
48025918|NCT05219877|DRUG|Pre-urodynamic Levofloxacin|Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
48025919|NCT05219877|DRUG|Post-urodynamic Levofloxacin|Administering once daily Levofloxacin 500 mg for 3 days after urodynamic study
48025920|NCT03294447|BEHAVIORAL|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
48025921|NCT05683340|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
48025922|NCT05683340|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
48025923|NCT00619021|DRUG|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
48520523|NCT00001271|DRUG|IgG-RFB4-SMPT-dgA|
48520524|NCT00685217|PROCEDURE|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
48025924|NCT06089304|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
48025925|NCT00614211|PROCEDURE|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
48025926|NCT00614211|PROCEDURE|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
48025927|NCT02529020|DEVICE|Mouthguard|Condition of wearing mouthguard
48025928|NCT02529020|DEVICE|No mouthguard|Condition without mouthguard
48520525|NCT00685217|PROCEDURE|TVT (Gynecare)|Sling procedure for stress urinary incontinence
48520526|NCT04317092|DRUG|Tocilizumab Injection|Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.
48520527|NCT03305848|DRUG|Nitrostat 0.4Mg Sublingual Tablet|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.
48520528|NCT02726659|DRUG|Celecoxib|Adjunct celecoxib
48520529|NCT02726659|DRUG|Placebo|Adjunct placebo
48520530|NCT04371107|OTHER|consultation|Patients are followed up by teleconsultation or remote follow-up until the end of symptoms and for a maximum of 2 months
48520531|NCT04371107|DRUG|Azithromycin|azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
48025929|NCT04770714|DIAGNOSTIC_TEST|Breast MRI|Standard of Care Breast MRI
48025930|NCT04770714|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Standard of Care Contrast Enhanced Mammography
48520532|NCT05898724|PROCEDURE|Blank group|include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
48520533|NCT05898724|PROCEDURE|Silver hydroxyapatite|include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
48520534|NCT05898724|PROCEDURE|Zinc oxide|include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
48722417|NCT05190055|DEVICE|wiltrom interbody fusion system/wiltrom spinal fixation system|After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
48025931|NCT03229330|PROCEDURE|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
48025932|NCT03229330|COMBINATION_PRODUCT|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
48520535|NCT06582082|OTHER|pulmonary rehabilitation|The study group will receive pulmonary rehabilitation
48520536|NCT06582082|OTHER|pursed lip breathing|the control group will stick to pursed lip breathing only
48722418|NCT00318331|DRUG|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
48722419|NCT04222855|DRUG|Diltiazem|Puerperal patients was administered (60 mg) orally every 8 hours with diltiazem (tables).
48384517|NCT04827446|OTHER|Blue-blocking glasses|Patient is given blue-blocking glasses to wear at instructed times.
48384518|NCT04827446|OTHER|Clear glasses|Patient is given glasses that block no visible light.
48520537|NCT01288079|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
48520538|NCT01288079|DRUG|Duloxetine|Capsule, oral, once daily
48520539|NCT01288079|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
48520540|NCT00100828|DRUG|irinotecan hydrochloride|
48520541|NCT04163965|DEVICE|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
48722420|NCT02668029|DRUG|oxygen|information already included in arm/group descriptions.
48722421|NCT02668029|DRUG|medical air|Placebo
48722422|NCT05568550|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
48722423|NCT05568550|DRUG|Olaparib|200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.
48722424|NCT05568550|DRUG|Androgen Deprivation Therapy|Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
48722425|NCT05568550|RADIATION|Radiation Therapy|Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
48182963|NCT03573193|OTHER|ridge preservation|"Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP)."
48520542|NCT05370105|OTHER|blood withdrawal|"10 ml of blood, two 5 ml tubes suitable for serum isolation. Given the nature and objectives of the study, there are no risks and / o inconveniences of particular importance for the patient since the blood samples will be performed according to the common procedure used in all analysis laboratories. At the end of the collection, in the area where the blood sample was taken, a small bruise may form which will disappear in the following hours, in any case during the collection particular attention will be paid to the subjects being treated with antiplatelet and anticoagulants.~The study does not include the execution of interventional treatments or therapies."
48520543|NCT03536884|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
48722426|NCT01280578|DEVICE|Transcatheter PFO Closure|Transcatheter PFO Closure
48722427|NCT01389999|OTHER|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
48722428|NCT06481085|DRUG|HDM1002 50 mg|HDM1002 tablets, 50 mg once daily, 12 weeks
48722429|NCT06481085|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 12 weeks
48722430|NCT06481085|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 12 weeks
48722431|NCT06481085|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 12 weeks
48722432|NCT06481085|DRUG|HDM1002 200 mg BID|HDM1002 tablets, 200 mg twice daily, 12 weeks
48520544|NCT03536884|DRUG|Secukinumab|Subjects will receive secukinumab at pre-specified time-points.
48520545|NCT03536884|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
48520546|NCT04353635|DEVICE|dolphin 3d|software
48722433|NCT06481085|DRUG|Placebo|Matching placebo will be provided
48520547|NCT01819870|DRUG|Dilatrend SR capsule 32mg|"* 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)"
48722434|NCT00569868|DRUG|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
48722435|NCT01731067|DRUG|Cocktail probe drugs|
48722436|NCT05661045|PROCEDURE|low-flow anesthesia|Changes in blood carboxyhemoglobin levels as a result of exposure to rebreathing during low-flow anaesthesia.
48520548|NCT01819870|DRUG|Dilatrend IR tablet 25mg|"* 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)"
48520549|NCT04967573|DRUG|Rivaroxaban|Rivaroxaban 20 mg or 10 mg for 3 months
48722437|NCT01597024|OTHER|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
48722438|NCT01597024|OTHER|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
48722439|NCT06407102|OTHER|Collection of nasal cells during programme surgery|During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.
48722440|NCT03522831|DRUG|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
48722441|NCT03522831|DRUG|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
48722442|NCT00618878|PROCEDURE|Electroacupuncture|twice a week for 26 treatments in total
48722443|NCT00618878|PROCEDURE|Laser Therapy|twice a week for a total of 26 treatments
48722444|NCT03639506|PROCEDURE|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
48722445|NCT03639506|COMBINATION_PRODUCT|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
48722446|NCT03639506|DRUG|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
48722447|NCT02488460|BEHAVIORAL|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
48722448|NCT01994993|DRUG|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
48722449|NCT01994993|DRUG|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
48722450|NCT01994993|DRUG|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
48182964|NCT01508663|DEVICE|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
48722451|NCT01994993|DRUG|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
48722452|NCT01994993|DRUG|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
48722453|NCT06546176|OTHER|End to end with Omega suture|After the rectum was divided with a linear stapler, the circular stapler was placed allowing the anvil rod to penetrate the rectal stump near the linear stapler line. An omega suture including both ends of the linear stapler line was placed. The linear stapler line was approximated around the anvil rod of the circular stapler in an omega shape fashion as the omega suture was tied. This technique resulted in a complete resection of linear stapler line by the circular stapler.
48722454|NCT06546176|OTHER|End to anterior rectal wall|"A burse string suture was applied over the anvil of the circular stapler at the transection point of the descending colon using prolene 2/0.~The circular stapler introduced though the anus and its rod directed toward the anterior rectal wall and colorectal anastomosis was performed."
48722455|NCT00527332|DRUG|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
48722456|NCT00527332|DRUG|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
48722457|NCT00527332|DRUG|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
48520550|NCT01542801|DRUG|Norfloxacin|Norfloxacin 400 mg per day
48520551|NCT01542801|DRUG|ciprofloxacin|Ciprofloxacin 750 mg per week
48182965|NCT01508663|DRUG|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
48182966|NCT01304498|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
48520552|NCT01588288|PROCEDURE|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
48722458|NCT00527332|DRUG|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
48722459|NCT00527332|DRUG|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
48722460|NCT00527332|DRUG|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
48722461|NCT00527332|DRUG|Morphine|5 mg is given IV (intravenously) before end of surgery
48722462|NCT06506929|OTHER|Task specific physical therapy|Physical Therapy based specifically on tasks that the participant os having difficulty with
48182967|NCT01304498|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
48384519|NCT04827446|OTHER|Full SYNC app|Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.
48384520|NCT04827446|OTHER|"Dummy SYNC app"|Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
48520553|NCT02023931|DRUG|Broccoli Sprout Extract (BSE)|"1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane."
48520554|NCT03337503|DRUG|THC and CDB in a 1 to 1 ratio|capsule containing cannabis oil
48520555|NCT03337503|DRUG|Experimental: THC and CBD in a 1 to 2 ratio|capsule containing cannabis oil
48520556|NCT03337503|DRUG|High CBD with trace THC oil|capsule containing cannabis oil
48520557|NCT03337503|OTHER|placebo|carrier oil capsule
48520558|NCT06581770|OTHER|Survey using a questionnaire.|It is a validity and reliability study that can evaluate digital health readiness.
48722463|NCT03328923|DIETARY_SUPPLEMENT|500mg brown seaweed powder|
48520559|NCT06581770|OTHER|Survey using a questionnaire.|This is a reliability and validity study.
48520560|NCT01851083|BIOLOGICAL|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10\^6 cells/kg or 10x10\^6 cells/kg weight.
48520561|NCT01851083|OTHER|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
48520562|NCT04767282|OTHER|Fruit and Vegetable Prescription|$15 voucher for fruit and vegetables
48520563|NCT00317629|DRUG|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
48722464|NCT03328923|DIETARY_SUPPLEMENT|Placebo|
48722465|NCT06507527|OTHER|Collection of variables|This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
48722466|NCT06448819|OTHER|Diet|Patients received Crohn's disease exclusion diet or Mediterranean diet
48722467|NCT02495493|DRUG|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
48722468|NCT05042180|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 14 treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations in virtual reality. VR-assisted gradual exposure therapy is integrated as a part of CBT. I.e. VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
48722469|NCT05042180|BEHAVIORAL|CBT|The active comparator receives 14 conventional cognitive behavioral therapy sessions with
48722470|NCT05674110|BEHAVIORAL|DSMES Intervention|This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
48722471|NCT04402541|DRUG|CB-5339|25mg and 75mg capsules
48722472|NCT03201159|DRUG|VLX103|150mg tablets
48384521|NCT06475105|DRUG|Oral Acetazolamide|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
48384522|NCT06475105|DRUG|Placebo|Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
48384523|NCT06282185|OTHER|Physiotherapy|supervised training program for twelve weeks + usual care + advice about exercise
48384524|NCT04619134|OTHER|NCSR Program|flexibility exercise,strengthening exercise,dynamic strengthening exercise,endurance training,counselling session
48384525|NCT04619134|OTHER|conventional physical therapy|hot pack,flexibility training,strengthening exercise.
48384526|NCT05813392|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
48520564|NCT00317629|DRUG|meglumine antimoniate|20mg/kg daily during 20 days
48520565|NCT03511027|DEVICE|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
48722473|NCT05895539|OTHER|An automated patient-reported outcome data collection and adverse event surveillance tool|Patients received a short prompt to provide information on treatment satisfaction and side effects
48384527|NCT00029107|DRUG|Rituximab|anti-CD20 monoclonal antibody
48722474|NCT00161525|PROCEDURE|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
48722475|NCT05391308|OTHER|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
48722476|NCT05391308|OTHER|Polysomnography measure|Apnea-Hypopnea Index
48722477|NCT05391308|OTHER|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
48722478|NCT02151331|BEHAVIORAL|External Facilitation|Non-responding sites randomized to receive external facilitation
48722479|NCT02151331|BEHAVIORAL|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
48722480|NCT04151277|DRUG|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
48722481|NCT04151277|DRUG|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
48722482|NCT04151277|DRUG|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
48722483|NCT02365571|DRUG|LY3154207|Administered orally
48722484|NCT02365571|DRUG|Placebo|Administered orally
48722485|NCT02365571|DRUG|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
48722486|NCT05707481|OTHER|Clinical Pharmacist-Led Educational Intervention|Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
48722487|NCT05429073|DRUG|RGLS8429|solution for subcutaneous injection
48384528|NCT03189199|OTHER|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
48520566|NCT03511027|OTHER|SME only|At discharge, participants will be provided with self-medication education.
48520567|NCT06263192|PROCEDURE|Intrauterine insemination|Intrauterine insemination with sperm donors
48722488|NCT05429073|DRUG|Placebo volume-matching RGLS8429 dose|solution for subcutaneous injection
48722489|NCT05605171|PROCEDURE|Posterior reconstruction urethrovesical anastomosis.|Rocco stitch.
48722490|NCT05605171|PROCEDURE|Conventional vesicourethral anastomosis.|Standard of care.
48722491|NCT00269204|DRUG|niacin (+) laropiprant|Duration of Treatment - 24 weeks
48722492|NCT00269204|DRUG|ER-niacin|Duration of Treatment - 24 weeks
48722493|NCT00473525|DRUG|Placebo|Placebo QD
48722494|NCT00473525|DRUG|PF-00734200 10 mg QD|10 mg QD
48182968|NCT00390078|BIOLOGICAL|MVA-mBN32|3 immunizations: 1x 10E8_TCID50 MVA-mBN32
48722495|NCT00473525|DRUG|PF-00734200 20 mg QD|20 mg QD
48722496|NCT00473525|DRUG|PF-00734200 5 mg QD|5 mg QD
48722497|NCT00473525|DRUG|PF-00734200 2 mg QD|2 mg QD
48722498|NCT00535821|DEVICE|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
48722499|NCT00535821|DEVICE|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
48182969|NCT00390078|BIOLOGICAL|IMVAMUNE|3 immunizations: 1x 10E8_TCID50 IMVAMUNE
48384529|NCT06652087|DRUG|Rifaximin|Rifaximin (Alfa Normix®, Alfa Wassermann S.P.A., Italy, registration number LS-001993, 08/31/2010) in standard doses of 200 mg 3 times a day for 7 days
48384530|NCT06652087|OTHER|Standard HFpEF treatment|diuretic, including an aldosterone antagonist; sodium-glucose cotransporter-2 inhibitor
48520568|NCT01174693|DRUG|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
48722500|NCT00740623|DRUG|Carisbamate|800 mg/day for 14 weeks
48722501|NCT00740623|DRUG|placebo|placebo for 14 weeks
48722502|NCT00740623|DRUG|Carisbamate|1,200 mg/day for 14 weeks
48722503|NCT05741047|OTHER|a2Milk skim milk powder|a2Milk skim milk powder (1L) containing A2 β-casein only
48384531|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
48722504|NCT05741047|OTHER|Yili skim milk powder|Yili skim milk powder (1L) containing A1 and A2 β-caseins
48182970|NCT03527641|BEHAVIORAL|CookingMatters|Nutrition education and hands-on cooking lessons for the whole family
48384532|NCT00926809|DRUG|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
48384533|NCT03389776|PROCEDURE|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
48384534|NCT00127296|DEVICE|FlexPen®|
48722505|NCT00131651|DRUG|ATN-161|
48384535|NCT00127296|DEVICE|vial and syringe|
48384536|NCT03867825|DEVICE|Non-invasive hemodynamic monitoring|Impedance cardiography
48384537|NCT02534467|DRUG|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
48520569|NCT01174693|DRUG|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
48722506|NCT05069753|PROCEDURE|Immediate sequential bilateral cataract surgery (ISBCS)|Surgery on both eyes will be performed on the same day as separate procedures: Once surgery on the first eye is completed, a new sterile procedure on the second eye will commence.
48182971|NCT03527641|BEHAVIORAL|Parent Education|Parenting, physical activity and nutrition education, and family health education for parents
48182972|NCT03527641|BEHAVIORAL|Physical Activity|Physical fitness activities for teens
48182973|NCT03527641|BEHAVIORAL|Health Education|Health knowledge curriculum for adolescents
48182974|NCT03527641|BEHAVIORAL|Mindfulness-based Stress Reduction|Adolescent mindfulness curriculum
48182975|NCT03527641|BEHAVIORAL|Brief Mindfulness Intervention|Parent-based education and experiential learning of mindfulness-based tools
48182976|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
48520570|NCT01284010|GENETIC|DNA analysis|
48520571|NCT01284010|GENETIC|fluorescence in situ hybridization|
48520572|NCT01284010|GENETIC|gene expression analysis|
48182977|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
48520573|NCT01284010|GENETIC|microarray analysis|
48520574|NCT01284010|GENETIC|mutation analysis|
48520575|NCT01284010|GENETIC|polymerase chain reaction|
48520576|NCT01284010|OTHER|laboratory biomarker analysis|
48722507|NCT05069753|PROCEDURE|Delayed sequential bilateral cataract surgery (DSBCS)|The group will undergo bilateral cataract surgery on two separate days with a time period of one week between the two procedures.
48722508|NCT02128945|OTHER|[18F] - Fludarabine PET/CT|\[18F\] - Fludarabine PET/CT before treatment
48384538|NCT02564172|DEVICE|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~* Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~* Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~* If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~* If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
48722509|NCT00330668|DRUG|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
48520577|NCT05697016|DRUG|Sivelestat Sodium for Injection|Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-\[2-\[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl\]amino-acetate tetrahydrate\]
48722510|NCT00988481|DRUG|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
48520578|NCT05697016|DRUG|The Placebo|Excipients used for the sivelestat sodium
48520579|NCT05075850|DEVICE|Neuroblate System|"All subjects will undergo comprehensive neuropsychological assessment post-LITT per standard of care practice.~Visual field testing will be conducted in a subset of enrolled patients."
48722511|NCT04363450|DRUG|Hydroxychloroquine|Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly
48520580|NCT01605747|DIETARY_SUPPLEMENT|Culturelle|one capsule 2x per day per feeding tube
48520581|NCT01605747|DIETARY_SUPPLEMENT|Placebo|one placebo 2x per day per feeding tube
48520582|NCT04539392|OTHER|Questionnaires on sexuality|Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
48520583|NCT02567630|BEHAVIORAL|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
48520584|NCT04078321|OTHER|Mollii ®|The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
48520585|NCT06099392|DEVICE|digital stimulators (SNM-FDC01, Ningbo MaidaMedical Device, Inc, Ningbo, China)|TEA at Zusanli(ST 36) 45 min when drinking Polyethylene Glycol Electrolytes Powder
48722512|NCT04363450|DRUG|Placebo|Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
48722513|NCT02107157|DEVICE|755nm Laser with Cap Array|
48722514|NCT01665352|DRUG|TTP054|Administered orally once daily for 12 weeks.
48722515|NCT01665352|DRUG|Placebo|Administered orally once daily for 12 weeks.
48520586|NCT02776943|BIOLOGICAL|umbilical cord mesenchymal stem cells|
48520587|NCT02776943|DEVICE|Hyaluronic acid|
48722516|NCT00840060|BEHAVIORAL|AMALS|Addressing multiple aspects of language simultaneously
48722517|NCT00840060|BEHAVIORAL|DTA|Discrete Trial Approach
48722518|NCT06276790|PROCEDURE|ultrasound-guided/hysteroscopic curettage|ultrasound-guided/hysteroscopic curettage
48182978|NCT01762332|OTHER|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
48722519|NCT06276790|PROCEDURE|Procedure/Surgery: laparoscopic removal of the pregnancy lesion|laparoscopic removal of the pregnancy lesion
48182979|NCT03563625|PROCEDURE|Caudal block|Caudal block/bupivacaine 0.25%
48182980|NCT03563625|PROCEDURE|Wound infiltration|Local anesthetic wound infiltration/bupivacaine 0.25%
48182981|NCT03563625|DRUG|Bupivacaine|bupivacaine
48025933|NCT01584063|BEHAVIORAL|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
48025934|NCT05972447|PROCEDURE|Immediate implant placement of Ultrawide diameter dental implants|immediate placement of ultrawide diameter dental implants in a fresh extraction socket of mandibular molar teeth
48025935|NCT03216174|PROCEDURE|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
48384539|NCT02564172|OTHER|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~* at effective dose, and minimal effective dose on the basis of adverse events and contraindications~* as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches...) will not be forbidden or contra-indicated."
48025936|NCT05703282|DRUG|AD-104-A|PO, Single-Dose, AD-104-A
48025937|NCT06532110|OTHER|Endoscopy/Colonoscopy|Esophagogastroduodenoscopy and colonoscopy with video recording and biopsy collection
48025938|NCT04793412|DEVICE|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
48384540|NCT02666768|DRUG|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
48025939|NCT00994916|DRUG|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
48025940|NCT02779179|PROCEDURE|Periodontal treatment|"* Mechanical debridement (scaling, root planning, subgingival curettage)~* Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~* Antiseptic mouthrinses, gel or dentifrice~* Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
48025941|NCT06533202|BEHAVIORAL|Psychoeducational Programme|The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.
48025942|NCT06533202|BEHAVIORAL|Education Programme|At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.
48025943|NCT00152295|DRUG|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
48182982|NCT05536206|DEVICE|Wireless and continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.
48384541|NCT01469845|DEVICE|3% hypertonic saline|4 ml dose to be administered every 6 hours
48384542|NCT00185107|DRUG|Colesevelam Hydrochloride|
48025944|NCT02175446|DRUG|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
48025945|NCT03354676|OTHER|MetS+|Data processing from Patient Medical Files
48025946|NCT03354676|OTHER|MetS-|Data processing from Patient Medical Files
48182983|NCT06292390|OTHER|Pet Therapy|Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy.
48182984|NCT06050447|PROCEDURE|Right hemicolectomy|Resection of the caecum and ascending colon is appropriate for patients with tumors located anywhere from caecum to the transverse colon
48384543|NCT00185107|DRUG|Ezetimibe|
48384544|NCT00185107|DRUG|Simvastatin|
48384545|NCT01383759|DRUG|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:~1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments."
48384546|NCT05943158|DRUG|myoinositol and folic acid|The pregnant women were given myoinositol+folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
48384547|NCT05943158|DRUG|folic acid|The pregnant women were given only folic acid starting from initial examination of pregnancy until 24-28 weeks of gestation (time of oral glucose tolerance test)
48722520|NCT04476927|DEVICE|DiaNose|"DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements."
48384548|NCT02108132|BIOLOGICAL|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
48722521|NCT03094559|DEVICE|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
48182985|NCT06050447|PROCEDURE|Left hemicolectomy|Resection of the sigmoid colon is appropriate for patients with tumors located anywhere from the distal transverse colon to the rectosigmoid junction.
48384549|NCT02108132|BIOLOGICAL|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
48722522|NCT06203977|DRUG|Colchicine|0.3mg and 0.6mg tablets
48722523|NCT03090347|OTHER|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
48722524|NCT05733728|OTHER|any therapy suitable|any therapy suitable
48722525|NCT01885910|DRUG|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
48722526|NCT01885910|DRUG|Aczone 5% gel|Aczone 5% gel twice daily
48384550|NCT00696059|DRUG|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
48384551|NCT04070534|OTHER|PALS|patient activated learning system
48384552|NCT06620016|DIAGNOSTIC_TEST|Circulating microRNAs.|Pre and post-surgery evaluation of peripheral blood circulating microRNAs levels.
48384553|NCT04185025|DRUG|Ceramides|"On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the Product Use Procedures, during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected."
48384554|NCT02435615|DEVICE|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
48722527|NCT05962359|BEHAVIORAL|Parent-Implemented Communication Treatment|The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
48722528|NCT00895661|DRUG|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
48384555|NCT04824573|DEVICE|Inspiratory Muscle Training|Inspiratory Muscle Training (IMT) was performed with Powerbreathe Classic-Light Resistance device. To determine the intensity of the training, MIP values were measured with the help of the respiratory pressure meter-RP Check (MD Diagnostics Ltd. RP Check MIP \& MEP) device before each training. The pressure corresponding to 50 percent of the MIP value in the Powerbreathe device was determined as training workload. It was applied two days a week for four weeks, with five-set and five repetitions, for 20 minutes with 30 seconds rest in between. This inspiratory muscle training program has previously been used by several studies to improve respiratory muscle strength.
48522752|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
48722529|NCT03951090|OTHER|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
48722530|NCT03951090|OTHER|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
48182986|NCT06050447|PROCEDURE|Sigmoid colon resection|Resection of the sigmoid colon is appropriate for patients with tumors located in the sigmoid colon
48182987|NCT06050447|PROCEDURE|Anterior resection of the rectum|AR is appropriate for tumors located in rectosigmoid junction and in the proximal rectum
48384556|NCT04824573|OTHER|Manual Therapy|"In the manual diaphragm release technique; While the participant was breathing in, the physiotherapist raised his hand slowly to accompany the rising movement of the ribs and deepened the contact during exhalation. The maneuver was performed in two sets of 10 deep breaths.~In thoracic mobilization application; The physiotherapist, standing behind the participant, wrapped the crossed arms from his right upper arm with his left hand and performed stretching, extension, lateral flexion, and thoracic rotation with his right hand.~In HVLA thoracic manipulation; the physiotherapist, with the support hand on the participant's elbows, applied HVLA thrust in the posterior-anterior and inferior-superior directions with the help of his body while the manipulating hand was on the transverse processes.~For cervical joint mobilization; the physiotherapist was applied using the right hand in flexion, extension, right-left rotation, and lateral flexion directions."
48384557|NCT01439776|DRUG|Vit D|800IU/day
48384558|NCT02787746|DRUG|Donepezil|Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.
48384559|NCT03979586|OTHER|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
48384560|NCT01898884|DRUG|VP 20629|
48384561|NCT01898884|DRUG|Placebo|
48384562|NCT00673712|DEVICE|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
48384563|NCT00673712|DRUG|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
48384564|NCT06537661|OTHER|Virtual reality|Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.
48384565|NCT06537661|OTHER|Traditional exercises|"Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)"
48384566|NCT03753893|OTHER|No intervention used|no intervention used
48384567|NCT06346080|OTHER|Survey|Discrete choice survey
48384568|NCT04477473|OTHER|Questionnaire-based observational study|"Questionnaire focusing on practical health care issues regarding respiratory support, health status and perception of the COVID-19 issue:~* Symptom score (related to noninvasive ventilation: NIV)~* Thymic disturbances (score of anxiety and depression)~* Compliance to treatment (assessed via tele-monitoring: routine procedure)"
48520588|NCT02269098|OTHER|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
48384569|NCT05615428|DIAGNOSTIC_TEST|LS-ratio|Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
48384570|NCT00878735|BEHAVIORAL|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
48520589|NCT04264325|OTHER|diaphragmatic ultrasound measure|patients with lung neoplasms and malignant pleural effusions who need a diagnostic or therapeutic thoracocentesis
48025947|NCT06262620|PROCEDURE|EBUS-TBNA|A 22G biopsy needle was insert into the lesion through tracheal-bronchial wall under real-time EBUS guided by bronchoscopist. Needle punctures were performed by using the jabbing method. Once it is confirmed that the puncture needle is within the target lesion, the puncture needle is moved back and forth while suction (An empty 50 ml syringe was connected to the port at the end of the puncture needle and aspirated to 20 ml maintained for 20 seconds.) is applied. Each lymph node was operated 5 times.
48182988|NCT06050447|PROCEDURE|Low anterior resection of the rectum|LAR is appropriate for tumors located in the middle and low rectum
48520590|NCT01569295|DRUG|Idelalisib|Idelalisib 150 mg administered orally twice daily
48520591|NCT01569295|DRUG|Rituximab|Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
48520592|NCT01569295|DRUG|Bendamustine|Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
48520593|NCT01569295|DRUG|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
48722531|NCT05077098|DRUG|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
48722532|NCT00820404|DRUG|BLI-489|
48722533|NCT00820404|DRUG|Placebo|
48182989|NCT06050447|PROCEDURE|Abdominoperineal resection|APR is appropriate for distal rectal cancers that invade the external sphincter or the levator muscles
48520594|NCT02297399|DRUG|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
48722534|NCT06234215|DEVICE|functional electrical stimulation|electrical stimulation during function
48182990|NCT06050447|PROCEDURE|Total Colectomy|Total abdominal colectomy may be indicated for patients with primary multiple cancer tumors
48182991|NCT00008281|DRUG|FOLFOX regimen|
48182992|NCT00008281|DRUG|fluorouracil|
48182993|NCT00008281|DRUG|leucovorin calcium|
48182994|NCT00008281|DRUG|oxaliplatin|
48182995|NCT06009042|DRUG|IVIG 20g/d|The dose of IVIG(intravenous immunoglobulin) is 20g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
48384571|NCT06400095|DIAGNOSTIC_TEST|Poccl, Time constant, driving pressure|Ventilatory parameters
48722535|NCT06234215|OTHER|functional task training|functional exercise
48722536|NCT03600454|DRUG|General anesthesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
48722537|NCT03600454|DRUG|Spinal anesthesia|The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
48722538|NCT03600454|DRUG|General anesthesia and epidural analgesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
48025948|NCT06262620|PROCEDURE|EBUS-TBMC via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Bronchus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
48182996|NCT06009042|DRUG|IVIG 10g/d|The dose of IVIG(intravenous immunoglobulin) is 10g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
48182997|NCT04698746|PROCEDURE|Pericapsular nerve group block|PENG block will be made with 15 ml 0.5% bupivacaine + 2 mg dexamethasone + 14.5 ml NaCl under US-guidance
48182998|NCT04698746|PROCEDURE|Intra-articular local anesthetic injection|Intra-articular local anesthetic injection will be made with 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml NaCl
48182999|NCT05864677|DRUG|Cerebrolysin|Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
48183000|NCT02296216|DEVICE|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
48183001|NCT04097847|DRUG|Pentoxifylline-Tocopherol-Clodronate|the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
48183002|NCT00848796|DRUG|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
48183003|NCT02799355|DRUG|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
48183004|NCT00717548|BEHAVIORAL|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
48183005|NCT01786304|PROCEDURE|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
48722539|NCT01032824|BEHAVIORAL|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
48722540|NCT01032824|OTHER|Group Arm|10-session didactic telephone group
48722541|NCT01032824|OTHER|Book Arm|Book only.
48722542|NCT01188057|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
48183006|NCT00307047|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
48722543|NCT01188057|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
48722544|NCT06288971|OTHER|Self-adaption web-based software for the rehabilitation of EF and visuo-spatial abilities|- Self-adaption web-based software integrated with neuropsychomotor activities in small groups to strengthen EF. The training will take place bi-weekly, for 3 months, for approximately 60 minutes per meeting. For the intervention will be used the Bee-bot, a robot to be programmed to achieve objectives set in space, allows to stimulate navigation, visuospatial working memory and planning skills (the activities will be taken from those already used in our previous studies in children with typical development and BES (Di Lieto et al., 2020)).
48183007|NCT00307047|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
48183008|NCT06486675|OTHER|education|breastfeeding consultant training
48183009|NCT00947232|BEHAVIORAL|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
48183010|NCT00947232|BEHAVIORAL|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
48183011|NCT01580904|BEHAVIORAL|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
48183012|NCT00002492|DRUG|cisplatin|
48183013|NCT00002492|DRUG|doxorubicin hydrochloride|
48183014|NCT00002492|DRUG|isolated limb perfusion|
48183015|NCT00002492|PROCEDURE|conventional surgery|
48183016|NCT00002492|RADIATION|brachytherapy|
48183017|NCT00002492|RADIATION|radiation therapy|
48183018|NCT04936685|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine|Liquid solution for injection Intramuscular
48183019|NCT00288951|DRUG|Travoprost 0.004% with and without BAK|
48183020|NCT00827398|BIOLOGICAL|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
48183021|NCT04191408|PROCEDURE|PEEP increase|PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
48183022|NCT03181347|PROCEDURE|RYGB|Roux-en-Y Gastric Bypass
48183023|NCT03181347|PROCEDURE|SG|Sleeve Gastrectomy
48183024|NCT03181347|BEHAVIORAL|Dietary and behavioral|Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
48183025|NCT03772769|DIAGNOSTIC_TEST|Target Enriched Multiplex PCR (TEM- PCR)|Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.
48183026|NCT03772769|DIAGNOSTIC_TEST|Microbial culture|Standard diagnosis by microbial culture.
48183027|NCT04610411|DEVICE|surgical navigation|surgical navigation for pedicle screw placement and rod beinding using AR-glasses and a specially developed software
48183028|NCT04610411|OTHER|standard surgical method|standard surgical method established at the institution
48183029|NCT03965676|OTHER|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia \< 360μmol/L (baseline DECT is in the domain of usual care).
48183030|NCT04787237|OTHER|VST and immediate implants|One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket . A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted after drilling to its pre-planned location 3-4 mm apical to socket base with adequate primary stability achieved using a torque wrench reaching 30 Ncm torque . A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
48183031|NCT04787237|OTHER|Buser technique and early implants placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks (depending on the size of the extracted tooth) was followed. Then an open flap implant surgery using a triangular flap design was cut. After preparing the implant bed, the site was irrigated using normal saline. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone. A non-cross liked membrane was then placed, after being soaked with BCM. Finally, the healing abutment was removed and the flap was released to allow for its suturing.
48183032|NCT01674322|DRUG|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
48183033|NCT00665093|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
48183034|NCT00665093|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
48183035|NCT04788342|DEVICE|pulse wave recording, echocardiography.|pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
48183036|NCT05859490|BIOLOGICAL|17D|Vaccine administration in subjects previously vaccinated with 17D.
48384572|NCT03029104|COMBINATION_PRODUCT|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
48384573|NCT04402944|DRUG|Pulmozyme|Pulmozyme 2.5 mg BID
48183037|NCT02641587|OTHER|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
48183038|NCT02641587|OTHER|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
48183039|NCT03000790|DEVICE|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
48384574|NCT04402944|DRUG|Placebo|Saline 2.5 mL BID
48384575|NCT03868176|OTHER|short message service|short message service
48522753|NCT01437839|DRUG|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
48384576|NCT02253199|DRUG|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
48384577|NCT04860752|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
48384578|NCT04195867|DRUG|Salmeterol Xinafoate|Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).
48384579|NCT04998188|PROCEDURE|Collagen|Patients will be treated with a single injection of collagen (2 ml) in the knee joint affected by osteoarthritis
48384580|NCT04998188|PROCEDURE|Placebo (saline solution)|Patients will be treated with a single injections of saline solution (2 ml) in the knee joint affected by osteoarthritis
48384581|NCT03541356|COMBINATION_PRODUCT|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device
48384582|NCT03541356|COMBINATION_PRODUCT|L-dopa 35 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
48384583|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
48384584|NCT03541356|COMBINATION_PRODUCT|L-dopa 140 mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
48384585|NCT03541356|COMBINATION_PRODUCT|L-dopa 70mg/carbidopa 7mg|Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
48384586|NCT05149989|DEVICE|Proning Pillow System|Participants will be asked to lie on the proning pillows in prone position for no more than 5 minutes. Each participant will then be asked to lie on standard hospital pillows for no more than 5 minutes.
48384587|NCT06351501|DRUG|hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months|4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)
48384588|NCT06351501|DRUG|Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months|2 years of hormonal treatment from 16 to 18 years old.
48384589|NCT05732012|BEHAVIORAL|Sexual Health Psychoeducation Program|"62 adolescents were included in the study. Adolescents were assigned to intervention and control groups by randomization using simple numbers table. The intervention group was divided into 3 groups of 10 and included in a six-week psychoeducation program that lasted for one hour once a week, and 55 adolescents completed the program. The data on the sociodemographic characteristics of the adolescents constituting the sample were collected with the Participant Information Form. Data on the effectiveness of the psychoeducation program on sexual health knowledge and attitudes were collected with the Sexual Health Knowledge and Attitude Inventory before the psychoeducation, at the end of the training and at the 3rd month of follow-up."
48384590|NCT05250609|OTHER|"Endocrown composite."|It is a type of restoration has been shown a great success in adult and recently has been suggested for children
48384591|NCT01041807|DRUG|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
48384592|NCT05046275|OTHER|Data analysis|No intervention, data analysis only
48384593|NCT03725358|BEHAVIORAL|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
48384594|NCT03725358|BEHAVIORAL|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
48722545|NCT06288971|OTHER|Tele-rehabilitation of EF and specific cognitive processes underlying academic skills|- Tele-rehabilitation intervention on FE (RuntheRAN and MemoRAN). The training will be conducted at home, with periodic meetings with the clinician, for 3 months, for approximately 4/5 days a week for approximately 30/40 minutes per day. An adult (e.g. a family member) will support the child in the treatment and ensure that the exercises are carried out adequately at home. One of the following tele-rehabilitation software will be used: RuntheRAN (RidiNet, Coopertiva Sociale Anastasis), a software that aims to strengthen the prerequisites of reading by requiring the timed and progressively faster naming of colour matrices or black and white figures. MemoRAN (RidiNet, Cooperativa Sociale Anastasis), which involves rapid naming exercises of stimuli (figures and colors) presented in matrices, within tasks that require inhibition, cognitive flexibility and updating in working memory.
48384595|NCT03725358|BEHAVIORAL|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
48522754|NCT02635984|DRUG|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
48183040|NCT03494465|PROCEDURE|PHACOEMULSIFICATION|"Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group"
48520595|NCT02297399|DRUG|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
48520596|NCT05153993|OTHER|Fascia stretch|"Stretch of the fascia plantaris during 3x30, 5x/week, 6 weeks"
48520597|NCT05624918|DRUG|Nab paclitaxel|125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
48520598|NCT05624918|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
48520599|NCT05624918|DEVICE|NovoTTF-200T(P)|Worn \> 18 hr /day starting C1D1 until completion of cycle 3
48520600|NCT05965752|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
48520601|NCT05965752|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
48520602|NCT05965752|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
48520603|NCT05965752|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
48520604|NCT05965752|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
48520605|NCT04789551|OTHER|Blood Sample|a blood sample will be collected
48520606|NCT04910594|DRUG|recombinant human erythropoietin|To determine the efficacy and safety of recombinant human erythropoietin in improving anemia in patients with lymphoma, and to improve the quality of life and the efficacy of chemotherapy in patients with lymphoma.
48520607|NCT00347984|OTHER|Systane Lubricant eye drops|
48520608|NCT04253665|BEHAVIORAL|Nursing discharge teaching|Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
48522755|NCT02635984|DRUG|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
48522756|NCT06198816|OTHER|ultrasound accelerated thrombolysis and venoplasty|IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
48183041|NCT03494465|DRUG|MEDICAL GLAUCOMA TREATMENT|The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
48183042|NCT05592184|OTHER|Exercise|The experimental protocol begins with the assessment of self-perceived pain intensity and perceived exertion when using different intensities of elastic resistance, during wrist flexion and extension, at a controlled speed of 1.5sec/ phase. To assess the intensity at which they will work, participants will perform 2 repetitions and will be allowed a rest of 60s between sets until they obtain a score of 3 on the Borg CR10 scale. Exercises should be performed with the subject's available ROM. Participants are asked to move their body and trunk as little as possible and to perform the exercise smoothly, without stopping or accelerating. The exercise will be performed in a seated position, with the back supported by the backrest and the forearm resting on a table, with the shoulders and elbows bent at 90o, leaving the wrist free, with the elastic bands held under the feet (stepping on them).
48522757|NCT01132833|OTHER|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
48522758|NCT01132833|OTHER|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
48025949|NCT06262620|PROCEDURE|EBUS-TBFB via a tunnel|Firstly, a tunnel to reach the lymph node is established by making use of a puncture dilation catheter, and a 1.5mm biopsy forceps is pushed into the lymph node through the working channel of the ultrasound bronchoscope. After entering the lymph node, the biopsy forceps were opened proximally to the lymph node, the biopsy forceps were advanced, and then the biopsy forceps were closed distally to the lymph node for each specimen. Each lymph node was operated 5 times.
48025950|NCT06006182|OTHER|Grape Powder|Freeze-dried grape powder
48025951|NCT05101187|DRUG|Olorofim|Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
48025952|NCT05101187|DRUG|AmBisome®|Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
48025953|NCT04538014|DRUG|Lu AF88434|Oral solution
48025954|NCT04538014|DRUG|[11C]-Lu AF88434|\[11C\]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection
48183043|NCT04565262|DRUG|NAs+IFN-α|NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
48183044|NCT05227781|DIETARY_SUPPLEMENT|L-Citrulline|8 weeks of L-Citrulline supplementation (10 grams/day)
48183045|NCT05227781|DIETARY_SUPPLEMENT|Placebo|8 weeks of Placebo (maltodextrin; 10 grams/day)
48183046|NCT02325362|DRUG|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
48520609|NCT01459783|BEHAVIORAL|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
48520610|NCT00908544|OTHER|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
48025955|NCT00889122|BEHAVIORAL|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
48183047|NCT02325362|DRUG|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
48520611|NCT00908544|OTHER|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
48722546|NCT06288971|OTHER|Game-based tools for the rehabilitation of EF and motor planning|- MondoELLI intervention (Cooperativa Sociale Anastasis) integrated with neuropsychomotor activities. The game-based app involves activities in small groups to strengthen various components of EF (interference control, inhibition, working memory, flexibility). The activities are organized with increasing difficulty, according to the self-adaptive algorithm, and within a narrative context.
48722547|NCT04058548|DIAGNOSTIC_TEST|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
48722548|NCT02246608|DEVICE|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
48025956|NCT01213017|DRUG|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
48025957|NCT06116773|OTHER|Training|"Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds."
48183048|NCT04198571|DRUG|Zinforo (ceftaroline fosamil)|IV Solution
48183049|NCT01913262|BEHAVIORAL|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
48183050|NCT01854606|DRUG|AEB071|a Protein Kinase C Inhibitor
48183051|NCT01854606|DRUG|Everolimus|mTOR inhibitor
48183052|NCT00000685|DRUG|Zidovudine|
48183053|NCT00160277|DRUG|Moxonidine|
48520612|NCT01841684|DRUG|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
48722549|NCT02246608|DEVICE|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
48722550|NCT00869401|DRUG|dasatinib|Given orally
48025958|NCT06116773|OTHER|Control|"Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~* Breathing exercises~* Moderate intensity (RPE 4-6) walking (150 min/week).~* Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~* They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position."
48025959|NCT04907240|DEVICE|GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)|Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
48025960|NCT05780645|DRUG|ALXN2050 MR Prototype Tablet|Participants will receive various doses of the MR Prototype Tablet orally.
48025961|NCT05780645|DRUG|ALXN2050 Immediate Release (IR) Tablet|Participants will receive a single dose IR (ALXN2050 Film Coated Tablet) tablet orally.
48025962|NCT05780645|DRUG|ALXN2050 MR Prototype Mini-Tablet|Participants will receive various doses of the MR Prototype Mini-Tablet orally.
48025963|NCT03925636|DIETARY_SUPPLEMENT|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
48025964|NCT02073968|DRUG|Carboplatin|Given IV
48025965|NCT02073968|PROCEDURE|Computed Tomography|Undergo PET-adjusted IMRT
48025966|NCT02073968|RADIATION|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
48025967|NCT02073968|DRUG|Paclitaxel|Given IV
48722551|NCT00869401|DRUG|temozolomide|Given orally
48722552|NCT00869401|OTHER|placebo|Given orally
48722553|NCT00869401|RADIATION|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
48722554|NCT00563043|PROCEDURE|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
48722555|NCT00875940|OTHER|Diagnostic imaging procedures.|
48722556|NCT04593407|PROCEDURE|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
48025968|NCT02073968|PROCEDURE|Positron Emission Tomography|Undergo PET-adjusted IMRT
48722557|NCT04593407|PROCEDURE|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
48520613|NCT01841684|DRUG|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
48520614|NCT05608876|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
48520615|NCT00005985|BIOLOGICAL|filgrastim|
48183054|NCT05488288|PROCEDURE|Mesh repair|Abdominal ventral hernia (VH) repair with mesh during bariatric surgery. the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.
48520616|NCT00005985|DRUG|carmustine|
48520617|NCT00005985|DRUG|cyclophosphamide|
48520618|NCT00005985|DRUG|cytarabine|
48520619|NCT00005985|DRUG|dexamethasone|
48520620|NCT00005985|DRUG|etoposide|
48722558|NCT01411384|PROCEDURE|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
48722559|NCT01411384|DEVICE|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
48722560|NCT03418558|DRUG|Trastuzumab emtansine|
48722561|NCT03774342|PROCEDURE|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
48722562|NCT03052530|DEVICE|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
48722563|NCT03001778|OTHER|Usability Testing|"Usability testing of ready made workouts in a group format."
48520621|NCT00005985|DRUG|mitoxantrone hydrochloride|
48520622|NCT00005985|PROCEDURE|peripheral blood stem cell transplantation|
48520623|NCT00005985|RADIATION|radiation therapy|
48520624|NCT01545518|DRUG|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
48183055|NCT05488288|PROCEDURE|Suture repair|The hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.
48183056|NCT02806843|DEVICE|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
48183057|NCT01372007|DRUG|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
48520625|NCT01907256|PROCEDURE|inverted V incision|It is a type of incision
48520626|NCT01907256|PROCEDURE|stair step incisions|It is a type of incision
48520627|NCT00934687|DRUG|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
48520628|NCT00934687|OTHER|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
48520629|NCT05843669|DRUG|Guafenesin tablets|During the 12-week period of receiving treatment, patient participants will take Mucinex® 12h, 2 x 600 mg (1200 mg total) twice daily.
48722564|NCT01676623|BEHAVIORAL|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
48722565|NCT01676623|BEHAVIORAL|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
48722566|NCT01676623|BEHAVIORAL|Mass media campaign|Alive \& Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
48722567|NCT00495755|DRUG|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
48722568|NCT05781646|DIAGNOSTIC_TEST|Xpert MTB/RIF|CSF samples was centrifuged at 3,000 - 4,000 X g for 15 minutes. Supernatant was removed to leave a 1-ml precipitate, which was then used for Ziehl-Neelsen AFB staining (100 μl), inoculation of MGIT culture (100 μl), and Xpert MTB/RIF testing (800 μl).
48722569|NCT05738720|DEVICE|Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)|Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
48722570|NCT05738720|OTHER|Exercise Programme|"Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test."
48722571|NCT05503888|DRUG|Almonertinib combined with SHR-1701|"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"
48722572|NCT05503888|DRUG|Almonertinib|"Phase Ⅱ:~Almonertinib: tablets, oral"
48722573|NCT06523062|DEVICE|blood pressure measurement|automated blood pressure measurement on 3 occasions at each consultation, twice with one month apart
48722574|NCT01268215|DRUG|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
48722575|NCT01268215|DRUG|Pulmicort|Endotracheal instillation, once per week for three weeks
48025969|NCT02073968|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
48025970|NCT05483426|OTHER|semi-structured Interviews|semi-structured interview conducted by a psychiatrist
48025971|NCT04946240|OTHER|Supervised (BRACE) Group|Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.
48025972|NCT04946240|OTHER|Conventional Balance Exercises Group|The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
48025973|NCT01911364|DRUG|BDP/FF/GB|Superiority over Tiotropium
48025974|NCT01911364|DRUG|Tiotropium|Superiority of CHF5993 over Tiotropium
48025975|NCT01911364|DRUG|BDP/FF + Tiotropium|non inferiority vs CHF5993
48384596|NCT06652282|OTHER|Pilates exercises|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
48384597|NCT06652282|OTHER|proprioceptive neuromuscular facilitation|Before starting the training program, patients will learn key Pilates elements, including diaphragmatic breathing, neutral position, rib cage placement, shoulder placement, and head and neck placement. The exercise program includes Pilates-based mat exercises and Pilates-based theraband exercises, with patients placed in supine, prone, and kneeling positions to perform exercises for the affected shoulder. The patient will be placed in various positions for optimal results.
48384598|NCT06652282|OTHER|The conventional program|Each patient was in the supine position and will receive stretching exercise for the flexors and adductors, and strengthening for the extensors, abductors and scapular stabilizers of the affected shoulder
48384599|NCT06652607|DRUG|Enzalutamide|The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
48384600|NCT06652607|DRUG|Apalutamide (Erleada™) 60 mg or 240 mg tablets|The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
48384601|NCT06652607|DRUG|Darolutamide (Nubeqa®) 300 mg tablets|The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
48384602|NCT06652607|DRUG|Taxotere (docetaxel)|The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
48384603|NCT06652607|DRUG|Abiraterone acetate + Prednisone or Prednisolone|The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
48384604|NCT03612830|PROCEDURE|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
48384605|NCT03612830|PROCEDURE|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
48384606|NCT05927532|DEVICE|Argyle Safety Fistula Cannula with Anti-Reflux Valve|The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula
48722576|NCT01268215|OTHER|Sham|None instilled through the endotracheal tube
48722577|NCT00167388|OTHER|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
48384607|NCT00604734|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
48384608|NCT01497860|DRUG|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
48722578|NCT02925741|OTHER|Silk-Like Linens|Synthetic moisture-wicking fabric
48722579|NCT00089947|DRUG|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
48722580|NCT01977690|DEVICE|Clavicle Brace|
48722581|NCT06269237|DEVICE|M22|"Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL"
48384609|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts|The connective tissue graft will be harvested from the palate.
48722582|NCT06269237|DEVICE|sham M22|Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
48722583|NCT00558272|DRUG|AZD0530|Daily oral dose
48722584|NCT00558272|DRUG|Zoledronic Acid|
48722585|NCT03336385|DIETARY_SUPPLEMENT|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
48025976|NCT00214136|RADIATION|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
48025977|NCT00404157|DRUG|Rituximab|
48025978|NCT03457259|DEVICE|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
48025979|NCT03457259|DEVICE|Midline|Pt. will receive midline
48384610|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts|The connective tissue graft will be harvested from the maxillary tuberosity.
48722586|NCT03336385|DIETARY_SUPPLEMENT|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
48722587|NCT03336385|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
48722588|NCT01013363|OTHER|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
48722589|NCT04630717|OTHER|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
48025980|NCT02334735|BIOLOGICAL|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10\^6 cells)"
48025981|NCT02334735|BIOLOGICAL|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
48025982|NCT02334735|BIOLOGICAL|Poly-ICLC|1.4 mg
48025983|NCT02809495|OTHER|use of app in smartphone|
48025984|NCT06240312|DEVICE|Images of eye at 2 eye pressures|subject images of the eye's optic nerve head are studied
48025985|NCT03155750|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
48384611|NCT05762796|DEVICE|tDCS in Youth with mild traumatic brain injury|The safety and tolerability of tDCS have been established in children with mTBI (1). A recent study of 13-18 year youths post-mTBI showed that three sessions of 1.5 mA anodal tDCS over the left DLPFC, positively influenced prolonged working memory deficits. (2) Additionally, rodent studies show the effectiveness of tDCS in improving cognitive-motor (motor planning and balance/gait) function in rats with mTBI. (3)
48384612|NCT01371006|DRUG|low dose|efavirenz single dosing once daily
48384613|NCT01371006|DRUG|normal dose|efavirenz once daily
48384614|NCT01371006|DRUG|low dose|Efavirenz single dosing once daily
48384615|NCT06015711|DRUG|Maxigesic administration|Preoperative Maxigesic IV administration
48384616|NCT01900925|PROCEDURE|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
48384617|NCT01900925|PROCEDURE|Pragmatic low back pain treatment|"1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities."
48722590|NCT04630717|OTHER|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
48722591|NCT00576472|DRUG|Methylphenidate|Please see detailed description for dosing information and study design.
48025986|NCT03155750|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
48025987|NCT05516199|BEHAVIORAL|Antenatal breastmilk expression|Stimulation of the breast by hand/handexpression of breastmilk during pregnancy from week 34
48722592|NCT05538546|DIAGNOSTIC_TEST|Complete blood count|Complete blood count will be conducted at 12th month and 24th month from baseline.
48722593|NCT05538546|DIAGNOSTIC_TEST|Transient elastrography|Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.
48025988|NCT05516199|BEHAVIORAL|Breastfeeding consultation|60 min standardized breastfeeding consultation with a trained midwife, with focus on practical breastfeeding skills
48722594|NCT05538546|DIAGNOSTIC_TEST|Endoscopy|Endoscopy will be conducted at 12th month and 24th month from baseline.
48722595|NCT06316440|DEVICE|Wear noise-cancelling earphones|Intervention of wearing noise-canceling earphones after general anesthesia
48722596|NCT00053547|DRUG|paricalcitol injection|
48025989|NCT06045624|DRUG|OR-101 (Single ascending dose)|SAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 150mg, 450mg, 900mg, 1500mg OR-101 in dose escalating manner in cohorts 1-6.
48025990|NCT06045624|DRUG|OR-101 (Food effect)|Food effect participants (8 subjects in 9 cohorts) will only receive OR-101with a high fat meal prior to administration and subjects in corresponding dose under fasted condition will serve as their reference group
48025991|NCT06045624|DRUG|OR-101 (Multiple ascending dose)|MAD participants will receive either placebo or one of planned doses levels of 15mg, 45mg, 135mg, 270mg, 540mg and 900mg OR-101 in dose escalating manner in cohorts 1-6. Total dosage of cohort 7 and 8 will be decided based on Safety review committe's input where cohort 8 will receive this daily for 7 days
48025992|NCT06045624|DRUG|Placebo|Participants will receive matching placebo across Part A and C of the study
48025993|NCT06567912|BEHAVIORAL|TEE simulation curriculum|The curriculum comprised of one-hour lecture and 3-hour hands-on training on a simulation model.
48384618|NCT04678700|OTHER|Chest physiotherapy post-covid19|"The sessions are divided into the following modules;~* Directed abdominal-diaphragmatic ventilation (10 times).~* Costal expansion exercises with the help of flexion and abduction of the upper limbs. (10 times)(1).~* Self-passive stretching of the ribcage and neck muscles, accessory to inspiration. The purpose of the stretching will be to increase the flexibility of the muscles to improve the vital capacity as has already been evidenced in other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (25)(26).~Relaxation time;Jacobson's progressive relaxation; we scan the body's condition.~Post-session evaluation by taking the respiratory frequency/ min and the Borg's dyspnea index, and level oxigen after the exercises."
48384619|NCT04361006|DEVICE|Radiofrequency (RF)|Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
48384620|NCT04361006|DEVICE|Cryotherapy (CRYO)|Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
48722597|NCT01536548|PROCEDURE|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
48722598|NCT01536548|PROCEDURE|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
48722599|NCT01410812|BEHAVIORAL|Control|Receive weekly emails asking participants about their exercise and receive cash.
48722600|NCT01410812|BEHAVIORAL|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
48520630|NCT02647801|BEHAVIORAL|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
48722601|NCT01410812|BEHAVIORAL|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
48722602|NCT00427882|DRUG|ALFUZOSIN|
48722603|NCT05687006|PROCEDURE|Colour Doppler Ultrasound|The main perforators were examined using a LOGIQ S8/V1 CDU device (GE Healthcare, Chalfont St Giles, Great Britain) with a linear transducer of frequency 4-11 MHz. Measured parameters were: 1) calibre of artery and vein; 2) Peak systolic velocity (PSV) of blood in the artery \[cm/s\]; 3) blood velocity in the perforator vein \[cm/s\]; 2) the thickness of the subcutaneous tissue of the lower abdomen measured 4 cm caudal and lateral to the umbilicus. Any additional perforators were marked nor have CTA deducted XY coordinates of marked perforators changed based on the CDU examination. The same sonography surgeon performed all CDU examinations. The time duration of the CDU examination was measured.
48722604|NCT04294914|OTHER|Cold Pressor Test|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.
48384621|NCT06653322|DRUG|HR-1703|HR-1703 will be administered by SC injection.
48384622|NCT06653322|DRUG|Placebo|Matching Placebo will be administered by the SC injection.
48384623|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
48384624|NCT00491322|DIETARY_SUPPLEMENT|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
48384625|NCT02244086|DRUG|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
48384626|NCT01856296|PROCEDURE|Biopsy|
48384627|NCT04962958|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48384628|NCT04962958|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
48384629|NCT04962958|DRUG|Donafenib|administration of Donafenib
48520631|NCT02962986|DRUG|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
48722605|NCT04294914|OTHER|Cold Pressor Test + Virtual Reality|The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
48722606|NCT03038893|DIAGNOSTIC_TEST|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
48722607|NCT03038893|DIAGNOSTIC_TEST|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
48722608|NCT01008462|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
48722609|NCT01008462|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
48183058|NCT01372007|DRUG|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
48183059|NCT01649557|DRUG|OPC-34712|oral administered once daily
48384630|NCT06650384|DRUG|Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin|Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
48384631|NCT06650384|DRUG|Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin|Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
48520632|NCT02962986|DRUG|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
48384632|NCT02269800|DRUG|Benzalkonium chloride solution|Tid, 7 days
48384633|NCT02269800|DRUG|Normal saline|Tid, 7 days
48384634|NCT06650683|BEHAVIORAL|Pediatric HAH|Pediatric HAH nursing support for home nursery care provided by parents as part of their child's disease.
48520633|NCT04863443|DEVICE|Ultrasound|ultrasound scanner to collect sonographic imaging data from the breast
48722610|NCT01008462|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
48722611|NCT01008462|PROCEDURE|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
48722612|NCT01008462|DRUG|Carmustine|Given IV
48722613|NCT01008462|DRUG|Cyclophosphamide|Given IV
48722614|NCT01008462|DRUG|Cytarabine|Given IV
48722615|NCT01008462|DRUG|Etoposide|Given IV
48522759|NCT01132833|OTHER|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
48522760|NCT00580450|DRUG|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
48722616|NCT01008462|DRUG|Fludarabine Phosphate|Given IV
48722617|NCT01008462|OTHER|Laboratory Biomarker Analysis|Correlative study
48722618|NCT01008462|DRUG|Melphalan|Given IV
48722619|NCT01008462|DRUG|Mycophenolate Mofetil|Given PO
48722620|NCT01008462|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
48722621|NCT01008462|DRUG|Tacrolimus|Given IV or PO
48722622|NCT01008462|RADIATION|Total-Body Irradiation|Undergo TBI
48384635|NCT04826952|PROCEDURE|Orchiectomy|Childhood testicular tumors deserve special diagnostic attention from the therapeutic point of view. A testicular tumor should be considered malignant until proven otherwise. In cases with suspicion of testicular tumors, the inguinal approach is preferred to the scrotal approach for scrotal violation.
48520634|NCT04108299|BEHAVIORAL|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
48722623|NCT04082286|OTHER|Yttrium-90 labelled monoclonal antibody against CD66|
48722624|NCT01729494|DRUG|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
48722625|NCT01729494|DRUG|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
48722626|NCT01729494|DRUG|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
48183060|NCT01012947|BEHAVIORAL|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
48722627|NCT01729494|DRUG|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
48722628|NCT01729494|DRUG|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
48025994|NCT04198779|DEVICE|APPLI|The support with the digital application is including a 10-minutes training about the use of the digital application at the beginning of the study. Patient will have to register information about their Heart failure disease (weight, shortness of breath, fatigue, mood, cardiologist appointments, blood results, ...). During each routine consultation, patients will be encouraged to use the digital app, and the obstacles encountered will be explored and resolved. In addition, participants will receive an email containing relevant information and, every three months, an email reminder of the use of the application.
48025995|NCT06328699|PROCEDURE|Spiritual Therapy|Undergo chaplain led compassionate centered spiritual health sessions
48183061|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
48183062|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
48183063|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
48183064|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
48384636|NCT06652503|BEHAVIORAL|online mental health coaching|SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency
48384637|NCT02766686|RADIATION|Radiotherapy with protons|
48384638|NCT02766686|RADIATION|Radiotherapy with photons|
48384639|NCT03672201|BEHAVIORAL|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
48522761|NCT04880486|OTHER|Education|Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.
48025996|NCT06328699|OTHER|Best Practice|Receive a traditional chaplain consultation and will receive care upon request
48025997|NCT04031339|PROCEDURE|Standard treatment|e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
48183065|NCT03084276|OTHER|High-fat meal|High-fat meal
48183066|NCT03084276|OTHER|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
48183067|NCT05716568|OTHER|Contrast dose reduction, CT-angiography|Contrast dose reduction for CT-angiography in pre-operative aorta
48183068|NCT04224168|DIETARY_SUPPLEMENT|Green Beans|Please see arm group Green beans for description
48183069|NCT04224168|DIETARY_SUPPLEMENT|Liquid Pectin|Please see arm group liquid pectin for description
48722629|NCT01729494|DRUG|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
48025998|NCT01063205|DRUG|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
48025999|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
48026000|NCT01063205|DRUG|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
48026001|NCT04772716|PROCEDURE|operation|The intervention was not decided by the investigator but studied following emergency or elective surgeries undergoing in the system
48522762|NCT04880486|OTHER|Supervision upper limb weight training exercise with VR|Participant is supervised by physical therapist to conduct upper limb weight training exercise with VR.
48722630|NCT04498351|DRUG|Control Test|"Spermatic cord block by18ml levobupivacaine 0.5% plus 2 ml normal saline in total volume of 20 ml.~The procedure is repeated on the contralateral side."
48026002|NCT03752164|BEHAVIORAL|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
48026003|NCT02021279|DEVICE|MatriStem Pelvic Floor Matrix|
48026004|NCT02021279|PROCEDURE|native tissue repair|
48026005|NCT05869812|DRUG|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
48722631|NCT04498351|DRUG|Dexmedetomidine|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
48026006|NCT05869812|DIETARY_SUPPLEMENT|CaLa|Comparative placebo
48026007|NCT04954365|DRUG|Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)|Rescue Post-Operative Nausea and Vomiting (PONV) treatment
48026008|NCT04954365|DRUG|Amisulpride|Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
48026009|NCT05954871|DRUG|GDC-1971|GDC-1971 capsules or tablets will be administered as specified in each treatment arm.
48026010|NCT05954871|DRUG|Osimertinib|Osimertinib tablets will be administered as specified in each treatment arm.
48026011|NCT05954871|DRUG|Cetuximab|Cetuximab, solution for infusion will be administered as specified in each treatment arm.
48026012|NCT05571943|DRUG|Difamilast|Difamilast Ointment 1%
48026013|NCT02394743|RADIATION|18FDG-PET|
48183070|NCT01774136|BEHAVIORAL|Enhanced HIV and MCH training for CHW|
48722632|NCT04498351|DRUG|Dexmedetomidine and magnesium sulphate|"Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side."
48722633|NCT04498351|DRUG|magnesium sulphate|Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
48722634|NCT01399268|DRUG|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
48722635|NCT01399268|DRUG|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
48722636|NCT03629912|BEHAVIORAL|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
48722637|NCT04384627|RADIATION|Delineating the GTV according to the pretreatment or post-IC tumor extension|Delineating the GTV according to the pretreatment or post-IC tumor extension
48722638|NCT06414330|BIOLOGICAL|Ringer acetate based Del Nido cardioplegia|All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.
48722639|NCT06414330|BIOLOGICAL|HTK|Giving HTK instead of Del Nido
48722640|NCT00634790|DRUG|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
48722641|NCT02694952|BIOLOGICAL|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
48722642|NCT02694952|BIOLOGICAL|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
48722643|NCT06025812|BIOLOGICAL|Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
48722644|NCT06025812|BIOLOGICAL|Recombinant novel coronavirus protein vaccine (CHO cells)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells).
48722645|NCT05188495|DRUG|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy|trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
48722646|NCT05940818|BEHAVIORAL|the intensive oral care|the intensive oral care
48722647|NCT00552760|DRUG|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
48722648|NCT00552760|DRUG|Placebo|one tablet at bedtime for up to 6 months
48722649|NCT02438345|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCr5
48026014|NCT03666676|OTHER|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
48183071|NCT05625347|DRUG|single dose (100 mg) of ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
48183072|NCT05625347|DRUG|single dose (162 mg) of non-enteric-coated chewable aspirin tablets|orally administered
48183073|NCT06269159|OTHER|Concept mapping: brainstorm|"Group health care providers:~* Duration: 1.5 hour for HCP via zoom session~* Brainstorm question: what would help your clients to change their sedentary behavior into more physical activity?~Group adults with overweight and obesity~* Duration: online survey (REDCAP) of approx. 10 minutes~* Brainstorm question via an online survey. What would help you to change your sedentary behavior into more physical activity?"
48520635|NCT04108299|BEHAVIORAL|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
48722650|NCT02968147|DEVICE|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
48722651|NCT02968147|DEVICE|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
48722652|NCT02552862|DRUG|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
48183074|NCT06269159|OTHER|Concept mapping: clustering and rating|"The same participant of the brainstorm session are asked to join session 2 to complete the clustering and rating). All interested adults will get access to the online cluster and rate tool described below.~* Duration: flexible use of the online tool (available for two weeks)~* The clustering and rating of all needs mentioned in session 1 will be done online and individually via a web application. In this online tool, the final list of 'needs' generated in session 1 will be presented.~* Individually sort the 'needs' into groups and give the group a theme. In addition, each need will be scored on effectiviness, feasibility, modifiability. Thhe participants have unlimited access for two weeks."
48183075|NCT00349466|DRUG|CF101|Orally CF101 1mg
48183076|NCT00349466|DRUG|Placebo|Orally matching Placebo
48183077|NCT00127842|DRUG|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
48183078|NCT03214445|PROCEDURE|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
48183079|NCT03214445|PROCEDURE|Sealing margins with seal|Seal the margin of restoration with sealant without filler
48183080|NCT00491621|PROCEDURE|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
48026015|NCT03939273|DRUG|Vancomycin Oral|500 mg thrice per day for seven days
48026016|NCT03939273|DRUG|Metronidazole Oral|500 mg thrice per day for seven days
48026017|NCT03939273|DRUG|Ciprofloxacin Pill|500 mg twice per day for seven days
48026018|NCT03939273|DRUG|Fluconazole Oral Product|200 mg once per day for six days
48026019|NCT03939273|DRUG|Placebos|seven day course of placebo tablets and capsules identical in appearance and number to active treatment
48026020|NCT00765908|DEVICE|Angioplasty balloon|90 second balloon inflation x 2
48026021|NCT00765908|DEVICE|Angioplasty balloon|30 seconds or less balloon inflations x 2
48384640|NCT03672201|OTHER|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
48183081|NCT00205595|DEVICE|Positron Emission Tomography|
48183082|NCT01760798|DRUG|Teriparatide|
48384641|NCT05420064|BEHAVIORAL|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
48026022|NCT02512718|DRUG|Omegaven|Comparison of FOLE vs. SOLE
48026023|NCT02512718|DRUG|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
48384642|NCT05420064|BEHAVIORAL|MyGene Portal|Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.
48384643|NCT05420064|BEHAVIORAL|Standard of Care|Participants will received appropriate clinical care as outline by standard of care guidelines
48384644|NCT01615822|DRUG|OZ439 100mg|OZ439 100mg oral suspension, single dose
48384645|NCT01615822|DRUG|OZ439 400mg|OZ439 400mg oral suspension, single dose
48384646|NCT01615822|DRUG|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
48384647|NCT01615822|DRUG|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
48384648|NCT01615822|DRUG|Placebo|
48384649|NCT02159651|DRUG|tacrolimus|oral
48384650|NCT03192631|OTHER|Financial incentive|Incentive of $15 Canadian
48384651|NCT06026449|DIETARY_SUPPLEMENT|Gluten-free diet|After initial fase of habitual diet (6 months), patients will start Gluten-free diet for a period of 12 months
48026024|NCT04502160|PROCEDURE|Vascular Access Creation|arteriovenous fistula creation
48026025|NCT03600285|DEVICE|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
48384652|NCT05915299|DEVICE|OCS Heart|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
48722653|NCT02552862|DRUG|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
48722654|NCT02270255|PROCEDURE|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
48722655|NCT02270255|DRUG|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
48722656|NCT02270255|PROCEDURE|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
48026026|NCT01230697|DRUG|Sorafenib|Sorafenib 800mg/die oral
48026027|NCT00746954|DRUG|Acetazolamide|Cabonic Anhydrase inhibitor
48026028|NCT00746954|DRUG|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
48026029|NCT02235766|OTHER|Echocardiographic assessment|
48026030|NCT04427280|DIAGNOSTIC_TEST|Throat/nose swabs|Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.
48026031|NCT04427280|DIAGNOSTIC_TEST|Saliva collection|Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5mL) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.
48026032|NCT04427280|DIAGNOSTIC_TEST|Blood collection|Approximately 30mL of blood will be taken at each study visit.
48026033|NCT06390735|BEHAVIORAL|Mommy ReachOut Intervention|The momy reachOut intervention is a web-based psycho-education with 4 sessions, released over a two week period.
48026034|NCT05831098|DEVICE|Reveal TP (Syphilis) Antibody Test|All subjects tested with both investigational devices and conventional syphilis serology tests.
48026035|NCT06535919|BEHAVIORAL|Treatment as Usual|Individuals will receive residential level of care followed by treatment at their partial hospitalization program.
48026036|NCT06529666|BEHAVIORAL|Didatic Session 1: Core Foundation Course|A 45-minute foundational presentation covering key Weight Management Counseling (WMC) concepts, obesity bias, and cultural humility facilitated by a trained clinician-educator at the residency program delivered at baseline.
48183083|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
48183084|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
48384653|NCT00641810|BEHAVIORAL|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
48384654|NCT06568757|OTHER|Wet Cupping|Wet cupping therapy will be applied once using disposable plastic vacuum cups to a total of 4 areas, which are recommended areas for headaches; cervical spine C7 (DU14 acupuncture point), bilateral T2-4 lateral spine (BL41-42 acupuncture point) and suboccipital region (FengFu DU-16 acupuncture point).
48722657|NCT02270255|DRUG|1% Xylocaine|5ml of 1% Xylocaine
48722658|NCT05579769|DRUG|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
48722659|NCT05579769|DRUG|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
48722660|NCT05579769|DRUG|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
48722661|NCT05579769|DRUG|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
48026037|NCT06529666|BEHAVIORAL|The 3Ps Program|"6 email modules delivered over months 2-8). Each 3P module will allow the resident to:~(1) Prepare: Review relevant concepts and demonstration videos sent via an email to prepare for completing the VCA vignettes; (2) Practice: Respond to brief vignettes of various 5As WMC challenging scenarios by audio recording their spoken response on the VCA tool; and (3) Process: Reflect on actionable expert and crowdsourced analogue patient feedback on the quality of their responses to each VCA vignette."
48722662|NCT05579769|DRUG|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
48722663|NCT05579769|DRUG|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
48026038|NCT06529666|BEHAVIORAL|Didactic session 2|(months 8-10): This 45-minute session will discuss key barriers to WMC adoption in clinical practice using real-world cases captured from residents facilitated by a trained clinician-educator at the residency program.
48183085|NCT05656612|OTHER|Written, Oral and Visual Education|"Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale."
48183086|NCT01620970|DRUG|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
48183087|NCT02250599|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
48384655|NCT06568757|OTHER|No intervention|No treatment will be applied to individuals and the routine medical treatment program will continue.
48384656|NCT06130839|OTHER|Rocker board training|Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.
48384657|NCT06130839|OTHER|Stable surface training|the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
48384658|NCT05649059|DRUG|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
48384659|NCT05649059|DRUG|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
48520636|NCT05846035|DIAGNOSTIC_TEST|Triphasic C.T abdomen and pelvis|for cirrhotic patients to ensure hepatocellular carcinoma
48520637|NCT00477048|DRUG|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
48520638|NCT04319354|DIAGNOSTIC_TEST|Analysis of cfDNA|Analysis of cfDNA through liquid biopsy
48183088|NCT02250599|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
48183089|NCT02250599|DRUG|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
48183090|NCT00820261|OTHER|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
48183091|NCT05332678|DRUG|SLS-005 - Once Weekly|Please see Arm description.
48183092|NCT05332678|DRUG|SLS-005 - Twice Weekly|Please see Arm description.
48183093|NCT02266342|DEVICE|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
48183094|NCT04318106|DEVICE|Precision tinted spectacle lenses|Precision tinted spectacles lenses (Cerium Technologies TM)
48026039|NCT06529666|BEHAVIORAL|Email reinforcement|2 emails in months 10-12 covering key concepts in the preceding components.
48026040|NCT06529666|BEHAVIORAL|PowerPoint of the foundational course|Residents will receive a core foundation slides on weight management counselling
48183095|NCT04072705|DRUG|General principles of care and judgement of researcher|Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
48384660|NCT05705349|DRUG|DOR/ISL|Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
48384661|NCT05705349|DRUG|BIC/FTC/TAF|Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
48384662|NCT05705349|DRUG|Placebo to DOR/ISL|Placebo tablet matched to DOR/ISL tablet taken by mouth.
48384663|NCT05705349|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
48520639|NCT03379337|DIAGNOSTIC_TEST|Dental imaging|The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
48520640|NCT03593395|OTHER|Peer Mentoring [PM]|Virtual Peer Mentoring
48520641|NCT03593395|OTHER|Structured Education Based Transition Program STE|Education-based program
48520642|NCT03122886|DIETARY_SUPPLEMENT|Fat Emulsion|Given IV
48520643|NCT03122886|OTHER|Placebo|Given IV
48026041|NCT03754023|DIAGNOSTIC_TEST|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
48520644|NCT00028171|DRUG|Tacrolimus|
48520645|NCT02665156|PROCEDURE|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
48722664|NCT05579769|DRUG|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
48722665|NCT05579769|RADIATION|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be \< 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
48722666|NCT05579769|DRUG|Bone marrow infusion|Day 0
48722667|NCT05579769|DRUG|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
48026042|NCT06057896|DIETARY_SUPPLEMENT|inositol, phytoestrogens, cocoa polyphenols|myo-inositol, soy isoflavones and cocoa polyphenols
48384664|NCT04045834|DEVICE|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
48384665|NCT06576752|OTHER|Digital follow-up and uptitration of medications at home after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
48384666|NCT06576752|OTHER|Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
48384667|NCT04027777|DEVICE|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
48722668|NCT05579769|DRUG|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
48722669|NCT05296993|DIETARY_SUPPLEMENT|Extracts found in the Extended Longevity supplements|Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.
48384668|NCT03254407|OTHER|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
48384669|NCT01689922|OTHER|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
48384670|NCT02771340|BIOLOGICAL|ICON-1|Intravitreal injection of ICON-1
48026043|NCT03783169|OTHER|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
48026045|NCT05860036|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
48722670|NCT02871089|DEVICE|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~* Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~* Dana R or RS insulin pump~* Dexcom G6 real-time CGM~* CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
48722671|NCT02871089|OTHER|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
48722672|NCT06284330|OTHER|Enhanced cascade testing|Direct mailed at-home genetic testing kit to probands' relatives.
48384671|NCT06566027|OTHER|Skeletal, dental, soft tissue index changes in Activator group|After being interviewed and provided by a doctor with two kinds of appliances (Activator and EF class II standard) for treating class II malocclusion, the patients choose their appliance. The patients were separated into two groups (30 in each). Group 1 was treated with an Activator appliance (Activator group), whereas Group 2 was treated with an EF class II standard appliance (EF line group)
48384672|NCT01330407|PROCEDURE|cryopreserved skin allografts.|
48384673|NCT01330407|PROCEDURE|Cultured Epidermal Autografts|
48384674|NCT03996694|DRUG|Belbuca 300 µg|Belbuca 300 µg buccal film
48384675|NCT03996694|DRUG|Belbuca 600 µg|Belbuca 600 µg buccal film
48384676|NCT03996694|DRUG|Belbuca 900 µg|Belbuca 900 µg buccal film
48384677|NCT03996694|DRUG|Oxycodone 30 mg|Oxycodone 30 mg capsule
48026046|NCT05860036|DRUG|VRd|Bortezomib, Lenalidomide and Dexamethasone
48026047|NCT01463605|DRUG|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
48026048|NCT03561779|DRUG|YYD302 2ml|YYD302 2ml
48026049|NCT03561779|DRUG|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
48026050|NCT04109989|DEVICE|HominisTM Surgical System|Trans-vaginal gynecological procedures
48384678|NCT03996694|DRUG|Oxycodone 60 mg|Oxycodone 60 mg capsule
48384679|NCT03996694|DRUG|Placebo|placebo buccal film and oral placebo
48384680|NCT06562075|DEVICE|Decoria Intense Strong|"Decoria® Intense Strong is a HA-based, BDDE-crosslinked dermal filler. Decoria® Intense Strong dermal fillers are injected into dermal tissue to improve and define contouring of jawline profile, supporting overlying tissue to shape facial contours to desired level of correction.~Appropriate injection volume for the jawline will be determined by the Treating investigator according to IFU"
48384681|NCT00231530|DRUG|topiramate|
48384682|NCT03918980|DRUG|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
48384683|NCT03918980|DRUG|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
48722673|NCT03782922|OTHER|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
48722674|NCT04066634|DEVICE|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
48722675|NCT02974569|DEVICE|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
48722676|NCT04852510|DRUG|Metformin Versus a combination of Metformin and Thymoquinone (TQ)|Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
48722677|NCT02851823|DEVICE|Periodontal curettes|
48722678|NCT02851823|DEVICE|Er-YAG+Nd-YAG lasers|
48722679|NCT02667756|OTHER|Non-interventional|
48722680|NCT05977166|DEVICE|hyperbaric oxygen therapy|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
48722681|NCT05977166|DEVICE|breathing exercise|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
48722682|NCT05977166|DRUG|medical treatment|All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
48722683|NCT03436823|OTHER|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
48722684|NCT03436823|OTHER|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music \& relaxation with eyes closed sessions are set up
48722685|NCT06438796|DRUG|Blinatumomab|Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation
48026051|NCT03415620|PROCEDURE|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before, during and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
48722686|NCT02805595|DRUG|23.4% Hypertonic saline|Saline Injections
48183096|NCT04253847|PROCEDURE|Radical antegrade modular pancreatosplenectomy|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
48722687|NCT05618093|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
48722688|NCT01117935|RADIATION|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
48722689|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term \[ST\], 42 months long term \[LT\])
48722690|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
48722691|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
48722692|NCT00121641|DRUG|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
48722693|NCT00121641|DRUG|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
48722694|NCT00121641|DRUG|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
48722695|NCT00121641|DRUG|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
48722696|NCT00121641|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
48722697|NCT02411370|BEHAVIORAL|phonetic tests|
48722698|NCT05816213|DEVICE|Portable low-field MRI|"Three FDA-approved low-field (LF) portable MRI commercialized by Hyperfine Research Inc. (www.hyperfine.io) will be employed. Patients will undergo LF-MRI in the CT suite during the downtime of preparation which usually occurs after urgent imaging in the CT suite (mean time, as calculated basing on the current door to imaging time: \~20-25 minutes), thus not delaying the conventional diagnostic processes and treatment administration. LF-MRI will be also repeated by the study staff at predefined time-points: 24 h, 72 h, at the discharge and 4 weeks after the event.~A prespecified acquisition of Fast-Spin Echo (Fast-SE) essential stroke sequences will be performed, starting with diffusion weighted imaging (DWI) + apparent diffusion coefficient (ADC) mapping and fluid attenuated inversion recovery (FLAIR)."
48026052|NCT02796326|DEVICE|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
48026053|NCT04277598|BIOLOGICAL|APO-2|APO-2: dose adjusted gel for topical administration.
48026054|NCT04277598|OTHER|Placebo|Placebo gel for topical administration.
48026055|NCT01462994|OTHER|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
48026056|NCT06531720|DRUG|Chlorhexidine Gluconate|topical preparation applied on oral mucosa lesion containing 0,2% CHX
48026057|NCT06531720|DRUG|Choline Salicylate 8.7 % Oral Gel|topical preparation applied on oral mucosa lesion containing, ethanol-based
48026058|NCT06531720|OTHER|control group|no medication has been prescribed
48026059|NCT02121847|DRUG|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
48026060|NCT02121847|DRUG|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
48026061|NCT02789787|PROCEDURE|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
48026062|NCT02789787|PROCEDURE|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
48026063|NCT04000451|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
48026064|NCT04000451|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
48520646|NCT05392218|BEHAVIORAL|motivational interviewing|consisted of six sessions (twice each week) up to 30 minutes of individual sessions. Each session contained a different component and topic that included substance abuse, physical activity, healthy sleep, stress management, nutrition and social support. The components in order were randomized for each participant.
48722699|NCT00568113|DRUG|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
48520647|NCT05392218|BEHAVIORAL|general health education|rceived the same amount of virtual session equivalent to MI form. However, the structure of the sessions consisted of brief advice to promote healthy lifestyle delivered by different therapists
48722700|NCT02067494|OTHER|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
48722701|NCT02067494|OTHER|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
48722702|NCT02916147|DRUG|Sevoflurane|
48722703|NCT02916147|DRUG|Propofol|
48722704|NCT02163213|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
48722705|NCT05855343|OTHER|BIDI Stick e-cigarette|The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.
48722706|NCT05538351|DEVICE|Body Composition Monitor (BCM)|The hydration status of each participant from the clinical assessment and the patient reported signs and symptoms will be compared with the readings from bioimpedance (BCM machine).
48722707|NCT00478309|OTHER|counseling intervention|
48722708|NCT00478309|OTHER|educational intervention|
48722709|NCT03288363|DEVICE|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
48722710|NCT00760838|DRUG|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
48722711|NCT00760838|DRUG|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
48722712|NCT01831817|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
48722713|NCT01831817|DRUG|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
48722714|NCT01831817|DRUG|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
48722715|NCT01831817|DRUG|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
48026065|NCT04000451|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
48026066|NCT02060890|OTHER|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
48026067|NCT04321837|DIETARY_SUPPLEMENT|Coral Complex 3|Coral-derived calcium supplement fortified with vitamin D3
48026068|NCT04321837|DRUG|Ibandronate|Bisphosphonate
48026069|NCT04321837|DIETARY_SUPPLEMENT|Vitamin D3|Oral vitamin D3
48026070|NCT06536296|OTHER|Music|Arm 1: Music only
48026071|NCT06536296|OTHER|Music and parent voice|Arm 2: Music and parent voice
48026072|NCT06536296|OTHER|Standard Care|Standard Care
48026073|NCT05274945|RADIATION|Radiotherapy|radiotherapy 45 Gy/ 25 fractions then boost 5.4 Gy/3 fractions with concurrent bolus 5-fluorouracil
48026074|NCT05274945|DRUG|consolidation chemotherapy|6 cycles of FOLFOX or CAPOX
48026075|NCT05274945|PROCEDURE|TME or APR|total mesorectal excision or abdominoperineal resection
48026076|NCT00949026|DRUG|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
48026077|NCT01098448|OTHER|scaling and root planing|scaling and root planing as a single therapy
48026078|NCT01098448|DRUG|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm
48026079|NCT01098448|DRUG|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
48026080|NCT01098448|OTHER|surgery|periodontal surgery in residual pockets of \>4mm
48026081|NCT01098448|DRUG|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
48026082|NCT01098448|OTHER|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets \>5mm and periodontal surgery in residual pockets of \>4mm
48520648|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
48722716|NCT00196053|DEVICE|Archimedes Constant Flow Implantable Pump|
48722717|NCT03861156|DRUG|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
48722718|NCT03228485|DEVICE|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
48722719|NCT02274545|BIOLOGICAL|H7N9 Anhui 2013/AA ca|10\^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
48722720|NCT02274545|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|30 mcg
48384684|NCT02566460|OTHER|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
48384685|NCT05433376|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) System C2|lithotripsy-enabled, low-pressure dilatation balloon to modify severely calcified lesions
48520649|NCT02291991|DRUG|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
48722721|NCT03315377|PROCEDURE|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
48722722|NCT03315377|PROCEDURE|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
48722723|NCT03472690|BIOLOGICAL|QBECO-SSI|Subcutaneous injection
48384686|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with \[18F\]-FDOPA
48384687|NCT03998852|DRUG|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with \[18F\]-FEOBV
48722724|NCT03472690|OTHER|Placebo|Subcutaneous injection
48722725|NCT03385330|OTHER|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
48722726|NCT03385330|OTHER|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
48520650|NCT05927870|PROCEDURE|pigtail|placing a small amount of local anaesthetic subcutaneously at the site of the gallbladder, a skin incision was made through which the catheter was introduced. A 7-Fr pigtail catheter was used in all cases . If possible, the catheter was introduced into the gallbladder after passing through the liver. The catheter was thereafter fixed, either by an internal locking device or by means of a suture to the skin. The catheter was rinsed with saline solution daily in order to prevent clogging.
48520651|NCT04649944|DIAGNOSTIC_TEST|Serological test and phone interview|"Families are interviewed by telephone to gather information about the family cluster (i.e. age and number of cohabitants, their symptoms and swab results, if performed), the subject who tested positive (i.e.sex, age, course of the disease, symptoms suggestive of COVID-19) and children aged between 4 and 16 y.o. (i.e. sex, age, drug therapy and/or chronic diseases, symptoms suggestive of COVID-19).~Children, young adults and the cohabitant who previously tested positive to the swab undergo a serological test for the detection of IgG and IgM antibodies for Sars-Cov-2."
48520652|NCT01491360|PROCEDURE|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
48520653|NCT01810302|DRUG|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
48520654|NCT01810302|DRUG|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
48520655|NCT04070261|OTHER|iOS application usability test|user tasks, questionnaires, semi-structured interviews
48520656|NCT03523455|DIETARY_SUPPLEMENT|Iron Aid IPS (Iron Protein Succinylate)|Taken orally in capsule form
48520657|NCT03523455|OTHER|Sugar Pill|Taken orally in capsule form
48520658|NCT01848600|BEHAVIORAL|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
48183097|NCT04253847|PROCEDURE|Standard retrograde pancreatosplenectomy|"Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
48183098|NCT00873327|DRUG|piperacillin-tazobactam|"6 doses intravenously at the following doses:~Infants \<32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6~Infants ≥32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q6~≥ 14 days PNA 100 mg/kg Q6"
48384688|NCT03998852|DEVICE|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the \[18F\]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
48384689|NCT03998852|OTHER|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
48520659|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy followed by Exercise Training|6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
48520660|NCT05543083|BEHAVIORAL|Exercise Training followed by Cognitive-Behavioral Therapy|6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
48722727|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Premeal Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
48722728|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Total Daily Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.
48722729|NCT05843318|BEHAVIORAL|Water Intake and weight control in older adults - hypocaloric diet alone|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
48722730|NCT06387641|BEHAVIORAL|Life review|Life review is a process that involves a thorough examination and reflection on one's past experiences, memories, and life events. This process often involves the identification and examination of significant themes, patterns, and lessons learned throughout one's lifespan. Through life review, individuals can gain a deeper understanding of their own identity, values, and beliefs, and how these have shaped their present circumstances and future outlooks. It can serve as a tool for personal growth, self-discovery, and the promotion of a sense of meaning and purpose in life.
48384690|NCT00268385|OTHER|Laboratory Biomarker Analysis|Correlative studies
48384691|NCT00268385|OTHER|Pharmacological Study|Correlative studies
48384692|NCT00268385|DRUG|Temozolomide|Given orally
48384693|NCT00268385|DRUG|Vorinostat|Given orally
48384694|NCT02325401|DRUG|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
48384695|NCT02325401|DRUG|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
48384696|NCT02325401|RADIATION|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
48384697|NCT05666648|OTHER|Sitz Bath|Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
48520661|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy Only|6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
48520662|NCT05543083|BEHAVIORAL|Exercise Training Only|6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
48520663|NCT06497582|OTHER|zhan-zhuang|zhan-zhuang as a fundamental type of qigong
48722731|NCT06387641|BEHAVIORAL|Routine community health services|"Routine community health services refer to a comprehensive health care service system that is government-led, community-participated, and guided by superior health institutions. It focuses on grass-roots health institutions and is staffed with general practitioners as the backbone. By rationally utilizing community resources, it provides a series of comprehensive health care services to community residents. These services center on human health, target families as the unit, cover the entire community, and aim to meet the basic health service needs of community residents.~Specifically, routine community health services include the following aspects: Health Education, Prevention and Control, Health Care Services and so on."
48722732|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)|vaccination
48722733|NCT02387294|BIOLOGICAL|Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)|vaccination
48026083|NCT01098448|OTHER|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets \>4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
48026084|NCT01098448|OTHER|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets \>4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets \>5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
48026085|NCT05739058|DEVICE|Violet-Blue Light Treatment / FlashHeal Device|"FlashHeal illuminates an area of 10 cm in diameter, located at 6-7 cm distance of the wound.~Wounds larger than 10 cm in diameter, will receive enough treatments to cover the wound bed.~To obtain full coverage the circular treatment area is relocated to cover the remaining wound field.~The wavelength is 405 nm, Full Width Half Maximum at (FWHM) 400-415 nm. Device irradiances are adjusted to the total fluences required for the Low, Medium and High group, the treatment will last 15 minutes at all dosages. Light is emitted with 1000 Hz."
48384698|NCT05753085|DEVICE|Conavi Medical Novasight Hybrid System intervention|Patients for a coronary angiogram who meet the inclusion criteria and none of the exclusion criteria are enrolled. Participants are prepared for angiography and PCI procedure in the usual way. Radial or femoral artery cannulation is done under local anaesthetic and the angiogram performed as per standard practice. IVUS-OCT imaging of the culprit vessel using the Novasight Hybrid system is then performed. If image quality of the IVUS-OCT is suboptimal it will be repeated. If the IVUS-OCT catheter cannot cross the lesion, pre-dilatation is performed. The acquired IVUS-OCT images can be used to optimise PCI. Following PCI, angiography is repeated and if the findings are optimal, IVUS-OCT imaging is repeated. If the PCI results are suboptimal further stent optimisation is performed and IVUS-OCT imaging repeated; The procedure is then completed as clinically indicated. The participant will then receive conventional post PCI care
48520664|NCT06497582|OTHER|self-acupressure|Self-acupressure as a common type of traditional Chinese medicine therapies
48520665|NCT01551771|DRUG|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
48520666|NCT01551771|DRUG|GW824575 matched-placebo|Placebo
48520667|NCT06509113|BEHAVIORAL|The online HIV-related stigma training|The intervention is an online HIV-related stigma training that takes 6 hours in 4 weeks to be completed.
48520668|NCT06509113|BEHAVIORAL|The online HIV epidemiology training with no specific content on stigma|Nursing students will be trained in an online HIV epidemiology training with no specific content on stigma. It will take 6 hours in 4 weeks to complete the training.
48520669|NCT03959969|OTHER|Educational video|An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.
48722734|NCT01711593|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
48722735|NCT01711593|PROCEDURE|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
48722736|NCT05041569|OTHER|MRI sequences|perform additional sequences added by research
48722737|NCT02506686|DRUG|Meropenem|Meropenem i.v.
48722738|NCT01008124|OTHER|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
48722739|NCT01008124|OTHER|Placebo maneuver|3 cycles placebo maneuver initial session.
48722740|NCT02004977|BEHAVIORAL|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
48384699|NCT06540833|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
48722741|NCT06335355|DRUG|Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin|Adebrelimab,1200mg; SHR-8068, 1.0 mg/kg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
48722742|NCT06335355|DRUG|Camrelizumab + Pemetrexed + Carboplatin|Camrelizumab,200mg;Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
48722743|NCT06335355|DRUG|Adebrelimab + Pemetrexed + Carboplatin|Adebrelimab,1200mg; Pemetrexed, 500mg/m2; Carboplatin, AUC 5 mg/mL/min
48722744|NCT04705948|DRUG|Magnesium sulfate versus ketamine|Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
48722745|NCT00724529|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
48722746|NCT04989647|RADIATION|No adjuvant therapy|Patients will not receive any type of adjuvant therapy.
48722747|NCT04989647|RADIATION|Adjuvant radiotherapy|Patients will receive adjuvant treatment composed of either pelvic radiotherapy external beam radiotherapy ± brachytherapy or concomitant chemoradiotherapy (pelvic radiotherapy + chemotherapy).
48722748|NCT00007644|PROCEDURE|Radical prostatectomy|Surgical removal of the prostate
48722749|NCT03153488|RADIATION|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
48722750|NCT06297473|BEHAVIORAL|Telephone-/video follow-up|"The yearly routine review of patients takes place by using a telephone or video interview rather than in-person interview in the endocrine outpatient department.~All other assessments, e.g. biochemical, MRI, is conducted as usual."
48722751|NCT06297473|BEHAVIORAL|In-person follow-up|The yearly routine review on patients takes place at the endocrine outpatient department
48384700|NCT06540833|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
48384701|NCT06182748|OTHER|Training on eccentric ergocycle|Subjects will train on eccentric ergocycles. In eccentric cycling, pedals push against the user's feet in the opposite direction, user has to slow down pedals and quadriceps muscles lengthen during contraction.
48384702|NCT06182748|OTHER|Training on concentric ergocycle|Subjects will train on regular concentric ergocycles. In concentric cycling, quadriceps contract to push pedals.
48722752|NCT01896271|DRUG|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
48722753|NCT01896271|RADIATION|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
48722754|NCT00800410|BEHAVIORAL|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
48722755|NCT05301036|DEVICE|Diadem prototype|Diadem prototype device delivers personalized low-intensity transcranial focused ultrasound stimulation
48183099|NCT06509360|DEVICE|Feelee app|Adolescents uses the Feelee app for 4-weeks in addition to treatment as usual in the forensic outpatient setting. The use of Feelee involves: submitting one emoji every day and allow the Feelee app to read the following passive data from the health app on the smartphone: number of steps and number of hours of sleep. The collected Feelee data will be presented in a dashboard in the Feelee app itself which will be discussed by the clinician in the weekly treatment session (in case the adolescents agreed to show the Feelee data to the clinician).
48384703|NCT06652685|DRUG|D5-PBCR(-) IA arm|"Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
48384704|NCT06652685|DRUG|D5-PBCR(+) IA+Venetoclax arm|"Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status."
48384705|NCT01757418|DRUG|Immune Globulin Intravenous (IVIG)|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
48722756|NCT02454153|DEVICE|REMStar Positive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
48722757|NCT02454153|BEHAVIORAL|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
48722758|NCT02514005|OTHER|Manual therapy|- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
48722759|NCT02514005|DEVICE|Dry needling|"* Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~* Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
48722760|NCT00846716|DRUG|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
48026086|NCT05402267|PROCEDURE|Adenoidectomy|Adenoidectomy will be conducted in OA and CA groups
48026087|NCT01828502|BEHAVIORAL|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
48026088|NCT01828502|BEHAVIORAL|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
48026089|NCT02509624|DRUG|Selonsertib|6 mg tablets administered orally in fed state
48722761|NCT00846716|DRUG|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
48026090|NCT05917730|BEHAVIORAL|Emotional Regulation and Interpersonal Abilities group Therapy (MERITA)|"Therapy sessions Block 1. Recognition and verbalization of emotions: Session 1: Presentation, framing, and beginning of identification and denomination of emotions. Session 2: Recognition and differentiation of emotions. Session 3 and 4: Effects of traumatic experiences.~Block 2. Learning to manage emotions: Session 5: Managing unpleasant emotions, coping Abilities in body, mind, and behavior. Session 6: New coping skills, self-esteem. Session 7: New coping skills, self-care. Session 8: Skills for clear communication. Session 9: Assertiveness and reciprocity. Session 10: Save card and the good relations game/negotiation skills. Session 11: Social skills and confidence recovery. Session 12: Consolidation and farewell."
48026091|NCT06534359|OTHER|Transpyloric tube feeding|Tube feeding into the small bowel
48026092|NCT06534359|OTHER|Gastric tube feeding|Tube feeding into the stomach
48026093|NCT00844454|PROCEDURE|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
48722762|NCT04889482|OTHER|No intervention|No intervention
48722763|NCT06120894|DIAGNOSTIC_TEST|Central visual acuity|Measurement of central visual acuity using Snellen optotype chart.
48722764|NCT06120894|DIAGNOSTIC_TEST|Intraocular pressure measurement|Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.
48722765|NCT06120894|DIAGNOSTIC_TEST|Slit lamp examination|Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).
48722766|NCT06120894|DIAGNOSTIC_TEST|Refraction and keratometry|Measurement of refraction and keratometry using refractometer Nidek ARK-1a.
48722767|NCT06120894|DIAGNOSTIC_TEST|Optical biometry|Measurement of optical biometry using biometer Argos (Barrett or SRK/T formula).
48722768|NCT06120894|DIAGNOSTIC_TEST|Strip meniscometry (SM)|Strip meniscometry examination using strip meniscometry tube.
48722769|NCT06120894|DIAGNOSTIC_TEST|Lid Parallel Conjunctival Folds test (LIPCOF)|Evaluation of lid parallel conjunctival folds using slit lamp examination.
48722770|NCT06120894|DIAGNOSTIC_TEST|Staining of the ocular surface with fluorescein|Evaluation of ocular surface fluorescein staining using Oxford scheme.
48722771|NCT06120894|DIAGNOSTIC_TEST|Tear break up time test (TBUT)|Evaluation of tear break up time using slit lamp examination.
48722772|NCT06120894|OTHER|Ocular Surface Disease Index questionnaire (OSDI)|Evaluation of Ocular Surface Disease Index using Ocular Surface Disease Index questionnaire.
48026094|NCT00844454|PROCEDURE|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
48026095|NCT04710797|PROCEDURE|Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~* The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve"
48183100|NCT01862068|OTHER|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
48384706|NCT01757418|OTHER|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
48183101|NCT01862068|OTHER|Blood sample|Blood sample will be performed at inclusion from all healthy patients
48183102|NCT01341847|PROCEDURE|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
48520670|NCT03959969|OTHER|Standard of care|The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.
48183103|NCT01341847|PROCEDURE|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
48183104|NCT00021047|DRUG|capecitabine|
48183105|NCT00021047|DRUG|carboplatin|
48384707|NCT00143416|DRUG|Pegvisomant|
48520671|NCT03959969|DRUG|Ibuprofen|Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
48520672|NCT03959969|DRUG|Oxycodone|Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
48722773|NCT05883722|PROCEDURE|Catheter ablation|The ablation approach includes: pulmonary vein isolation, left side linear ablation, left side driver ablation and right atrial driver ablation
48722774|NCT00651625|DEVICE|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
48722775|NCT00651625|DEVICE|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
48722776|NCT01934309|BEHAVIORAL|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
48026096|NCT04710797|PROCEDURE|Comprehensive staging surgery with no Lymphadenectomy|"* open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes"
48026097|NCT05081414|BEHAVIORAL|Program for Teaching Self-Care in HF (PEAC-IC)|As described previously
48026098|NCT04100447|DRUG|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
48183106|NCT00021047|DRUG|epirubicin hydrochloride|
48722777|NCT02388542|BEHAVIORAL|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
48722778|NCT05153707|BEHAVIORAL|Discharge Education Program|medication reconciliation, medication review, individually prepared patient medicine (pill) card, patient education (based on Health Belief Model by using written material and video, and verbally \[by using Teach back method especially for patients with low health literacy\]) and counseling (using behavior change techniques based on The Capability, Opportunity, and Motivation Behavior model).
48722779|NCT04934436|OTHER|sleeping glasses and earplug|In this study, the effect of the chronotype-appropriate nursing care on the intervention group will be examined.
48722780|NCT00951756|OTHER|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
48722781|NCT02404649|DEVICE|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
48722782|NCT02404649|DEVICE|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
48722783|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with or without a boost of 10 Gy in 5 fractions to the cavity.
48722784|NCT05528133|RADIATION|Genomically Guided Radiation Therapy|Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
48722785|NCT02380898|DRUG|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
48722786|NCT02380898|DRUG|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
48722787|NCT04025177|DRUG|Indomethacin Injection|The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
48722788|NCT02179814|DRUG|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
48026099|NCT05637463|OTHER|No intervention|no intervention was made
48722789|NCT02179814|DRUG|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
48722790|NCT02179814|DRUG|Placebo|Placebo at the second, third and fourth medication intake time point
48722791|NCT04276974|OTHER|Organic diet|Organic plant-rich foods (2000kcal for women, 2500kcal for men)
48183107|NCT05525247|DRUG|SLC-3010|Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
48183108|NCT05525247|COMBINATION_PRODUCT|Gemcitabine|1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
48722792|NCT04276974|OTHER|Non-organic diet|Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
48722793|NCT04564872|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
48722794|NCT04564872|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
48183109|NCT04266444|DEVICE|Exergaming in virtual environment|"The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty."
48722795|NCT04564872|DRUG|Linagliptin 5 mg QD|Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
48722796|NCT02970526|DRUG|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
48722797|NCT03166111|DRUG|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
48722798|NCT03166111|DRUG|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
48722799|NCT05527886|OTHER|AAROM|AAROM with knee to wall exercise, 3x30 reps
48722800|NCT05527886|OTHER|Slow Load|Single leg heel raise, 3x10 reps
48722801|NCT05527886|OTHER|Plyometric|Double leg 5 inch wall hops, 3x10 sec
48722802|NCT02337725|DRUG|TVP-1012|TVP-1012 1mg Tablets
48722803|NCT02337725|DRUG|Placebo|Placebo tablets
48722804|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/CT|Imaging scan
48722805|NCT04800068|DIAGNOSTIC_TEST|[Ga-68] PSMA-11 PET/MR|Imaging scan
48384708|NCT04512976|OTHER|Control (no cooling modalities)|Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modality.
48384709|NCT04512976|OTHER|Water Spray Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the skin wetting modality.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
48384710|NCT04512976|OTHER|Fan Only|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to the fan cooling modality.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout."
48384711|NCT04512976|OTHER|Water Spray and Fan|"Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to both the skin wetting and fan cooling modalities.~The fan will be a commercially available fan will be directed to the research subject throughout the exercise bout.~Skin wetting will be performed by spraying water onto the skin throughout the exercise bout."
48722806|NCT06081192|PROCEDURE|Implant placement surgery|Placement of six mini implants in the edentulous maxilla using a partially-guided protocol
48722807|NCT04055454|BIOLOGICAL|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
48722808|NCT04055454|OTHER|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
48722809|NCT02718014|OTHER|scaling and root planing (srp)|
48722810|NCT01762813|PROCEDURE|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
48722811|NCT01452503|DEVICE|Path Women's Condom|comparison between 3 types of female condoms
48722812|NCT01452503|DEVICE|FC2 female condom|comparison between 3 types of female condoms
48722813|NCT01452503|DEVICE|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
48722814|NCT02098811|DEVICE|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
48722815|NCT02098811|DEVICE|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
48722816|NCT03222414|DEVICE|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
48722817|NCT03222414|DEVICE|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
48722818|NCT03222414|OTHER|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
48722819|NCT02047097|DRUG|dimethyl fumarate|Provided under routine clinical care
48384712|NCT03231423|OTHER|Drainage|Using drain after operation
48384713|NCT04875637|DIAGNOSTIC_TEST|WAI-MEMR|Using wideband acoustic reflectance for middle-ear muscle reflex.
48520673|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Treatment Team|The trained professionals (the Digital Navigators) support the treatment teams in the study centers in the selection and integration of suitable apps and digital health applications (DiGAs).
48520674|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Patients|The trained professionals (the Digital Navigators) accompany and support the selected patients to find a suitable app for them and integrate it into their treatment.
48722820|NCT03890328|PROCEDURE|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
48722821|NCT01058941|DRUG|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
48722822|NCT01058941|DRUG|Placebo|Placebo LA and placebo oil capsules for 18 months
48722823|NCT00758641|DEVICE|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
48722824|NCT00758641|DRUG|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
48722825|NCT03423524|DEVICE|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
48722826|NCT03404622|DRUG|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
48722827|NCT02345330|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
48520675|NCT06575582|BEHAVIORAL|Training for Digital Navigators|The training takes place in the six study centers and is preferably aimed at medical assistants.
48520676|NCT05716126|DRUG|[14C]Iruplinalkib (WX-0593)|Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1
48026100|NCT05527028|OTHER|Occupational Therapy Services|Investigators will complete an initial assessment based on a thorough chart review and observation of the participants activities of daily living during week one. The resident will receive approximately 30 minutes a day of direct student OT service delivery. Additional intervention may be delivered through an indirect, collaborative, or consultative service delivery model. Students will use a workload measurement tool to track the amount of time and types of intervention provided to these residents. The intervention will be delivered by two pairs of OT students under the direction of a registered OT. Student OTs will have access to Point Click Care and will document daily and will be required to document indirect and non-direct time for each resident.
48520677|NCT04196647|OTHER|Home titration|Patients have their initial dosage titration of duodopa done in their own home, supported by one visit from nursing staff, and one video consultation a day
48520678|NCT04685512|DRUG|tenofovir disoproxil and emtricitabine|Experimental drugs administration of 7-day short course TDF/FTC
48520679|NCT04128930|DEVICE|PAP titration at home|Fixed CPAP or APAP titration at home
48722828|NCT02345330|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
48722829|NCT01291277|DEVICE|Endoscopic Variceal Ligation|Ligation of esophageal varices
48722830|NCT03645109|DIETARY_SUPPLEMENT|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
48722831|NCT03645109|OTHER|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
48722832|NCT04057885|DEVICE|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
48722833|NCT06246812|BEHAVIORAL|Deans' Fit Family Challenge|An annual 8-week physical activity and weight loss competition between VCOM-Auburn, AU College of Nursing, and AU Harrison School of Pharmacy
48722834|NCT06246812|BEHAVIORAL|Text message|Three text messages per week to promote and motive physical activity
48722835|NCT01076621|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
48722836|NCT03580928|DRUG|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
48722837|NCT03580928|DRUG|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
48520680|NCT00380835|DRUG|Amrubicin|
48722838|NCT03580928|DRUG|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
48722839|NCT03626545|DRUG|Canakinumab|Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
48722840|NCT03626545|DRUG|Docetaxel|Docetaxel 75mg/m\^2, intravenous, administered on Day 1 of each 21-day cycle
48722841|NCT03626545|OTHER|Placebo|Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
48722842|NCT03877653|DEVICE|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
48026101|NCT03585647|PROCEDURE|hip arthroplasty|Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
48183110|NCT06017908|DEVICE|Optokinetic stimulation through Virtual Reality|The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.
48520681|NCT05756582|DIAGNOSTIC_TEST|Prevalence of Latent Tuberculosis Infection|The prevalence of Latent Tuberculosis Infection \[LTBI\] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
48520682|NCT00842192|DRUG|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
48520683|NCT05469295|DEVICE|CGM MB-1701 device treatment|This is a pre-approved motorized traction device.
48520684|NCT05469295|DEVICE|CGM MB-1701 Sham device treatment|It is manufactured in the same way as the test device and the operation pattern. However, the actual effect of the massage is minimized.
48520685|NCT04789993|OTHER|No intervention.|There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
48722843|NCT06362122|OTHER|identification anatomo-clinico-biological profiles|to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature
48384714|NCT06651528|BEHAVIORAL|TBRI|The adapted TBRI WRA (Prison Only Component) will consist of an individual introductory module (1 hour) and a series of group modules (a minimum of 4 sessions, approximately 1-2 hours in length, delivered over the course of 3 months, with the final number and frequency to be determined in R61) focused on the core components of TBRI. The original TBRI approach includes a focus on group skills training; similarly, it is anticipated that R61 phase adaptations will meet the need for tailored skills training reflected by anticipated differences in the target population of women - including how their early attachment and trauma histories influence their current self-image and behavior (which likely has a tremendous impact on their relational attachments as adults). Group sessions will provide opportunities to build skills for regulating emotions and building healthy connections.
48384715|NCT06651528|BEHAVIORAL|TAU + TBRI + Re-entry Recovery Support|This condition includes the proposed adapted TBRI as well as on-going re-entry recovery support with the Safe Support Person (SPP). The SSP will be identified by the study participant as someone who will provide prosocial support during re-entry (e.g., support towards abstinence, establishing healthy recovery support relationships, rebuilding relationships with family and children) and in most cases will involve a close family member (mother, grandmother) or friend at the woman's identified home placement. This individual will be identified by the study participant as someone who is not involved in active substance use nor has a current legal system status (e.g., on probation).
48384716|NCT06651528|OTHER|Treatment as Usual (TAU)|Women in the TAU condition will not receive TBRI intervention services, but will receive traditional in-prison SUD treatment over 6 months as usual in the four targeted prison sites. The programs are separate units with the prisons and emphasize participation by all program members in the overall goal of addressing substance use and criminal thinking. Although trauma and violence are addressed as part of the holistic group process approach in these programs, these topics are not addressed from an on-going systematic or relational perspective and are not specifically addressed as part of re-entry planning.
48384717|NCT04098666|DRUG|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
48384718|NCT04098666|DRUG|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
48384719|NCT00391118|DRUG|enzastaurin|
48384720|NCT00391118|DRUG|carboplatin|
48722844|NCT03518346|BEHAVIORAL|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
48722845|NCT03518346|BEHAVIORAL|Standard of Care|Books, movies, TV
48722846|NCT06324695|BEHAVIORAL|HautKompass|The HautKompass program is a structured self-guided online psychosocial intervention designed to reduce self-stigma in people with visible chronic skin diseases. It combines educational content and practical exercises based on cognitive-behavioral therapy (CBT), namely cognitive restructuring of negative automatic thoughts and cultivating self-compassionate thinking and behavior. The program consists of eight skin-generic modules (on average, 15-20 minutes per module, one module per week).
48722847|NCT01375465|DEVICE|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
48722848|NCT02947399|RADIATION|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
48384721|NCT00391118|DRUG|paclitaxel|
48384722|NCT00391118|DRUG|placebo|
48384723|NCT03519386|COMBINATION_PRODUCT|G2-TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
48722849|NCT00442325|DRUG|Atorvastatin (Lipitor)|
48722850|NCT00946673|DRUG|Vorinostat|Orally up to 400 mg
48722851|NCT00946673|PROCEDURE|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
48384724|NCT03519386|DRUG|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
48384725|NCT03469141|DEVICE|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
48384726|NCT02162381|DRUG|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
48384727|NCT02162381|OTHER|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
48384728|NCT00160446|DRUG|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
48384729|NCT00160446|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
48384730|NCT00160446|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
48384731|NCT00160446|DRUG|Placebo|Tablet, oral Daily for 12 weeks
48384732|NCT00902486|DRUG|INCB028050|4 mg capsules QD
48384733|NCT00902486|DRUG|INCB028050|7 mg capsules QD
48384734|NCT00902486|DRUG|INCB028050|10 mg capsule QD
48384735|NCT00902486|DRUG|Placebo|Placebo matching INCB028050 QD
48384736|NCT00030602|BIOLOGICAL|PSA prostate cancer vaccine|
48384737|NCT00030602|BIOLOGICAL|incomplete Freund's adjuvant|
48722852|NCT02054884|DRUG|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
48384738|NCT05923320|BEHAVIORAL|training|The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
48384739|NCT06652698|OTHER|Cow's milk formula [CMF]|At least 10 ml daily of cow's milk formula (Bebiko 1 NUTRIFlor Expert®, Nutricia; formula with galactooligosaccharides and without probiotics); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
48384740|NCT06652698|OTHER|Amino-acid formula [AAF]|At least 10 ml daily of amino-acid formula (Nutramigen Pureamino®, Reckitt Benckiser Group PLC); and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
48384741|NCT06652698|OTHER|Donor human milk [DHM]|At least 10 ml daily of donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided.
48384742|NCT06652698|OTHER|"High-pressure processed pascalized donor human milk [DHM-P]"|"At least 10 ml daily of high-pressure processed pascalized donor human milk; and if additional supplementation will be needed (i.e., insufficient, partial, or discontinuation of breastfeeding), the randomly assigned nutritional intervention until the end of 4 months of age will be provided."
48384743|NCT05234619|DRUG|Group one ( lidocaine or control LE ) Early deflation|"This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction"
48384744|NCT05234619|DRUG|Group two ( lidocaine , ketorolac LKE ) Early deflation|As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
48722853|NCT02054884|DRUG|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
48722854|NCT01317511|DIETARY_SUPPLEMENT|Protein|Protein drink
48722855|NCT02662179|OTHER|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
48026102|NCT05257525|OTHER|Esophageal manometry catheter at various PEEP levels and tidal volumes|Participants will undergo placement of an esophageal manometry catheter before planned sternal closure. This catheter will be used to measure esophageal pressure which is a surrogate for pleural (intrathoracic) pressure. Esophageal pressure will then be used to estimate changes in respiratory system mechanics and hemodynamics following sternal closure and across different levels of positive end-expiratory pressure (PEEP) and tidal volumes.
48722856|NCT02662179|OTHER|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
48026103|NCT06104735|PROCEDURE|Synaptic Pairing Interval|Optimize interstimulus pairing between brain and spinal cord stimulation.
48384745|NCT05234619|DRUG|Group three ( lidocaine or control LL ) Late deflation|As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
48384746|NCT05234619|DRUG|Group four ( lidocaine , ketorolac LKL ) Late deflation|As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
48520686|NCT00512122|OTHER|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
48520687|NCT00512122|DRUG|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
48722857|NCT02662179|OTHER|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
48384747|NCT03940742|DRUG|Tirzepatide|Administered SC
48520688|NCT03282500|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
48520689|NCT04400162|BEHAVIORAL|Usability of the CCT|Evaluation of the usability of the provided training.
48520690|NCT04400162|BEHAVIORAL|Changes in regards to the depressive disorder|Evaluation of depressive symptoms and whether they change in regards to the provided training.
48722858|NCT02662179|OTHER|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
48384748|NCT05940571|DRUG|MBF-362|Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
48384749|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
48384750|NCT00320801|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
48384751|NCT01139242|BEHAVIORAL|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
48384752|NCT01139242|BEHAVIORAL|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
48384753|NCT06650267|BEHAVIORAL|Fathers for Change (F4C)|Defining features of F4C delivered over 18 sessions: 1) focus on the fathers model of fatherhood as a motivator for change, 2) focus on understanding and identifying feelings, teaching skills to identify and change emotional dysregulation that lead to both SU and FV, 3) co-parent communication skills to reduce stress and improve problem solving, 4) restorative parenting (see Table 1 and figure 1)127. F4C focuses on reflective understanding of emotional experiences, how that impacts thoughts and behaviors related to SU, FV, co-parenting/parenting each session. Through greater self-awareness, the father is better able to apply coping, communication and parenting skills introduced to reduce SU and FV.
48384754|NCT06650267|BEHAVIORAL|Individual Drug Counseling (IDC)|IDC is an individual evidence-based SU treatment84 that incorporates two elements: endorsement of the disease model and the spiritual dimensions of recovery. These elements differentiate the approach from F4C. IDC is influenced by 12-step recovery philosophy and participation in 12-step groups like NA are encouraged. The model places focus on the individual in recovery without a focus on fatherhood or co-parenting. IDC will be offered in an 18-session format.
48384755|NCT06652425|OTHER|Low temperature (16°C) group|The exposure group will be exposed to low temperature (16°C) in a chamber for about 2 hours, resting during the whole periods.
48384756|NCT06652425|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
48520691|NCT00934167|BIOLOGICAL|heparin sodium - Hipolabor|5.000 UI/0,25mL
48520692|NCT00934167|BIOLOGICAL|Heparin sodium - APP|5.000 USP/mL
48520693|NCT06351111|DEVICE|Active VNS|Subjects will receive active VNS paired with either of the three rehabilitation trainings
48520694|NCT04838730|DEVICE|Surgical procedure|Standard cataract extraction procedure will be performed under local anesthesia (at physician discretion) and CleaRing device will be implanted together with SeeLens AF IOL.
48520695|NCT00392366|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
48522763|NCT03124277|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
48522764|NCT03124277|OTHER|Control Group|Best local diet
48722859|NCT02440789|DRUG|Sirolimus|"Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks.~Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks."
48722860|NCT02653716|BEHAVIORAL|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
48722861|NCT02653716|BEHAVIORAL|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
48722862|NCT01131741|DRUG|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
48722863|NCT01131741|DRUG|Control|This group receives 3 mL of saline IV during operation.
48722864|NCT01986972|OTHER|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
48722865|NCT01986972|OTHER|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
48384757|NCT05738083|DIAGNOSTIC_TEST|Machine Leaning Models|"Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model."
48522765|NCT00289848|DRUG|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
48026104|NCT06104735|PROCEDURE|Frequency|Compare 2 Hz continuous to intermittent theta burst frequency
48026105|NCT06104735|PROCEDURE|Bouts|Compare effects of 1, 2, or 4 bouts of SCAP
48026106|NCT06104735|PROCEDURE|Spacing|Compare 6 versus 12 minutes of rest in between bouts of SCAP
48722866|NCT04063787|DEVICE|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
48384758|NCT06564272|DRUG|KC1036|For patients weighing between 30 kg and less than 50 kg, administer 40 mg QD of KC1036. For patients weighing between 50 kg and less than 70 kg, administer 50 mg QD of KC1036. For patients weighing 70 kg or more, administer 60 mg QD of KC1036. 4 weeks as a cycle.
48384759|NCT05812131|BEHAVIORAL|COPEWeb online training|COPE training delivered via online COPEWEb to providers
48520696|NCT00956423|BEHAVIORAL|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
48722867|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low carbohydrate diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
48722868|NCT06373887|DIETARY_SUPPLEMENT|plant-based Low low fat diet|In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
48722869|NCT05094817|OTHER|Brain Health Assessment|BHA is a free, self-administered online cognitive screening test developed in Toronto at Baycrest (www.cogniciti.com). BHA has been validated against a gold standard neuropsychological assessment for detecting amnestic MCI (aMCI) - the most common type of MCI - in community dwelling older adults. BHA has high sensitivity (.78), specificity (.78), PPV (.82), NPV (.74), and was better than MoCA for identifying aMCI. ROC curves showed an AUC of 0.75 for detecting aMCI from normal subjects. BHA measures memory and executive attention processes sensitive to subtle cognitive changes associated with normal aging and MCI. BHA can be completed from a patient's home or can be self-administered in hospital.
48722870|NCT05094817|OTHER|Demographics questionnaire|To compare the sociodemographic characteristics of patients completing Cogniciti's BHA vs. those who are not able to complete the BHA.
48384760|NCT05812131|BEHAVIORAL|COPE In Person|COPE training provided in person to providers
48384761|NCT06567054|DEVICE|Measurements with the POROUS R3C ultrasound device at the midshaft tibia|The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
48520697|NCT00956423|BEHAVIORAL|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
48520698|NCT02729571|BIOLOGICAL|MTBVAC|Live-attenuated tuberculosis vaccine
48520699|NCT02729571|BIOLOGICAL|BCG|Commercially available live-attenuated tuberculosis vaccine
48520700|NCT03709043|DRUG|Standardized kudzu|Standardized kudzu
48520701|NCT03709043|OTHER|Placebo|Placebo
48026107|NCT06104735|PROCEDURE|Exercise|Task-oriented hand exercises
48026108|NCT06104735|PROCEDURE|SCAP plus Exercise|Compare interleaved versus serial bouts of SCAP and exercise.
48384762|NCT06567054|DEVICE|DXA measurement of the hip and lumbar spine|"The following DXA measurements are to be performed:~* Spine L1-4~* Hip left~* Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan."
48384763|NCT06567054|DEVICE|DXA-based Vertebral Fracture Assessment (VFA)|DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.
48722871|NCT05094817|OTHER|PHQ-2|PHQ-2 is a shortened version of PHQ-9 which is originally a component of the longer Patient Health Questionnaire. The tool incorporates DSM-IV depression criteria and other leading major depressive symptoms into brief self-reported instruments. PHQ-2 inquires about the degree to which an individual experiences depression and anhedonia (inability to feel pleasure) over the past two weeks. The tool is not for final diagnosis of depression or monitoring its severity but only for the purpose of screening for the condition.The questionnaire comprises of the first two questions from PHQ-9, each item is scored 0-3. Therefore, the PHQ-2 score ranges from 0-6.
48722872|NCT05094817|OTHER|AFT|AFT is a free, rapid cognitive assessment commonly used to assess semantic language ability. Language is one of the earliest functions affected by AD and naming and semantical knowledge seems to be particularly affected. The identification of language deficits may pick up signs of neurological decline preceding the appearance of clinical symptoms. Milder forms of cognitive impairment such as MCI may also show language deficits if language is one of the domains affected.
48722873|NCT05094817|OTHER|GAI-SF|GAI-SF is a 5-item questionnaire derived from the original 20-item Geriatric Anxiety Inventory (GAI).In the population of community dwelling older women GAI-SF was developed in, a cut-off score of 3 yields a specificity of 87% and sensitivity of 75%. This highly accessible questionnaire is suitable for everyday use in a range of health-care settings. It has been employed amongst older adults in primary care settings, nursing homes, geriatric psychiatry patients and amongst clinical geriatric participants with co-morbid anxiety and unipolar mood disorder and their controls.
48722874|NCT05094817|OTHER|pain VAS|The VAS is a unidimensional measure of pain intensity. The VAS tries to measure a continuous characteristic or attitude signifying the intensity or frequency of symptoms. The scale ranges from 0-10, with 0 = no pain to 10 = worst pain.
48722875|NCT05094817|OTHER|IADL|Instrumental activities such as preparing meals or managing finances allow individuals to maintain their health while living on their own. The IADL measures the ability of older adults to manage their daily activities, as well as the impact, if any, cognitive decline would have on these activities. Scores range from 0-5 for men, and 0-8 for women, with higher sores being more independent and higher functioning.
48520702|NCT03709043|DIAGNOSTIC_TEST|Sexually transmitted infection testing:|At baseline and month 3 visits, all participants will be tested for syphilis (serum RPR), Neisseria gonorrhea and Chlamydia trachomatis (urine, pharyngeal swab, and rectal swab nucleic acid amplification \[NAAT\]) through an established protocol that has been validated by our Public Health Laboratory (PHL) and others.145-149
48026109|NCT00370162|DRUG|lactoserum|
48026110|NCT02065128|OTHER|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
48026111|NCT05636540|DRUG|[18F]FluorThanatrace ([18F]FTT)|A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
48522766|NCT00289848|DRUG|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
48026112|NCT02200822|DRUG|beta blockers|
48026113|NCT02200822|DRUG|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
48026114|NCT03839238|BIOLOGICAL|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
48026115|NCT06535529|DRUG|Acetazolamide|Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
48026116|NCT06535529|DRUG|Dapagliflozin 10mg|patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
48026117|NCT02553330|DRUG|Placebo Cream|
48722876|NCT05094817|OTHER|FAM CAM|FAM-CAM was derived from the CAM instrument in order to screen for delirium by interviewing family members or caregivers of the patient. They are asked specific questions about any new or sudden changes in the patient's activity, behavioural or cognitive status. FAM-CAM showed good sensitivity and specificity in the original study where caregivers of elderly patients with pre-existing cognitive impairment were interviewed.
48722877|NCT05094817|OTHER|4AT|The 4AT is a rapid tool for delirium detection that has previously been used in a surgical setting. The 4Ats test for the patient's alertness, mental state, attention, and signs of acute change. Across 17 studies, the pooled sensitivity and specificity of 4AT was 0.86 and 0.89. The 4AT will be administered after the patient has completed surgery, prior to discharge.
48384764|NCT06567054|DEVICE|Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)|Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
48384765|NCT00916617|DRUG|bapineuzumab|5 mg/week subcutaneous bapineuzumab
48384766|NCT04936334|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET Scan|Patients will undergo injection of 68Ga-PSMA-11 at the time of their pre treatment PSMA PET scan and followed until 12 months post surgery.
48384767|NCT02312752|DEVICE|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
48722878|NCT05094817|OTHER|BHA Usability Survey|The survey aims to assess system usability and acceptability based on standard questions adapted from the validated System Usability Scale. The questions evaluate satisfaction, experience with technology, and comfort level, as well as questions targeting usability concerns typically experienced by older adults, such as typeface and font size, consistent navigation, and writing style.
48026118|NCT02553330|DRUG|Ruxolitinib Phosphate Cream|
48026119|NCT04558346|DRUG|Ghrelin (OXE-103)|40ug/kg twice daily by self-injection
48026120|NCT04558346|DRUG|Placebo|40ug/kg twice daily by self-injection
48384768|NCT06652945|OTHER|Uterine artery embolization|Uterine artery embolization under fluoroscopy
48722879|NCT05094817|OTHER|Clinical Frailty Scale|CFS is a 9-item scale that uses clinical descriptors and pictographs and is an easily applicable tool to stratify older adults according to level of vulnerability. The CFS divides patients into 9 classes from very fit (CFS = 1) to terminally ill (CFS = 9). It is easy to use and may readily be administered in a clinical setting, an advantage over the tools previously developed. The scale helps in objective early identification of older adults with frailty in acute care units and helps to target interventions to prevent complications and to implement effective discharge planning.
48722880|NCT05400421|DEVICE|System & Method for Monitoring Aortic Pulse Wave Velocity & Blood Pressure|Carotid-femoral aortic pulse wave velocity will be compared against values collected from the oximeter system. The former is assessed by placing piezoelectric pressure sensors at three locations: the right common carotid artery, the right common femoral artery (groin), and the right superficial femoral artery (thigh). The oximeter will be secured on the right index finger. Simultaneous data collection will occur for both methods, with each trail lasting 60 seconds.
48722881|NCT03813381|BEHAVIORAL|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
48522767|NCT04618731|DIAGNOSTIC_TEST|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
48522768|NCT00269230|DEVICE|Pacing Lead|Left ventricular pacing lead
48722882|NCT03556020|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
48384769|NCT05196230|DEVICE|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
48722883|NCT01392287|DRUG|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
48722884|NCT02517671|DEVICE|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
48026121|NCT03893513|DEVICE|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
48026122|NCT03893513|DEVICE|Pulse Contour Analysis|Invasive hemodynamic monitor
48384770|NCT05196230|DEVICE|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
48384771|NCT05007106|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
48384772|NCT05007106|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered via IV infusion Q3W.
48026123|NCT05490667|DRUG|Anlotinib|Anlotinib combined with chemotherapy for desmoid tumors
48026124|NCT06319885|BEHAVIORAL|Text messaging|Participants receive text messages related to their alcohol consumption.
48026125|NCT00987207|DRUG|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
48026126|NCT00987207|OTHER|No injection|No cyclosporine A is administered before aortic cross-declamping.
48026127|NCT02940990|RADIATION|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
48026128|NCT02940990|DRUG|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
48026129|NCT05950802|DRUG|Cyclophosphamide|Higher dose than traditional conditioning chemo
48722885|NCT05879575|BEHAVIORAL|weight training|Pregnant women assigned to the intervention group will receive online weight training sessions twice a week, for 60 minutes per session, from the 16th to the 36th week of pregnancy. The Pelvic Girdle Questionnaire will be used to assess the condition of pelvic girdle pain during pregnancy, and to analyze whether weight training can improve this problem. Pelvic floor muscle structure will also be analyzed by pelvic ultrasound to determine whether it has been altered by weight training, leading to an improvement in pain.
48722886|NCT04955418|DEVICE|Epi-No®|evaluation, 10 sessions (twice a week for 5 weeks) of perineal preparation with the Epi-No device and revaluation six months after delivery.
48722887|NCT04955418|DIAGNOSTIC_TEST|Evaluation|evaluation (anamnesis, childbirth data, perineometry, International Consultation on Incontinence Questionnaire - Short Form, Female Sexual Function Index) six months after vaginal delivery.
48722888|NCT00940485|DRUG|entecavir|0.5mg po daily for 8 weeks
48183111|NCT06417762|BEHAVIORAL|Science Communication Curriculum Cohort 1|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
48183112|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 2|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
48384773|NCT05007106|DRUG|Lenvatinib|Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
48384774|NCT05007106|DRUG|5-Fluorouracil|5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
48384775|NCT05007106|DRUG|Cisplatin|Cisplatin administered via IV infusion
48384776|NCT05007106|DRUG|Paclitaxel|Paclitaxel administered via IV infusion at investigator's choice of dose
48384777|NCT05007106|DRUG|Gemcitabine|Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity
48384778|NCT05007106|DRUG|Carboplatin|Carboplatin administered via IV infusion at investigator's choice of dose and frequency
48384779|NCT05007106|DRUG|Docetaxel|For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles
48384780|NCT05007106|DRUG|Bevacizumab|Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles
48722889|NCT00940485|DRUG|entecavir|0.5mg po daily for 48 weeks
48722890|NCT00940485|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
48722891|NCT01378611|DEVICE|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
48722892|NCT03715296|DRUG|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2-6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5\*\[GFR(ml/min)+25\]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
48384781|NCT05007106|DRUG|Capecitabine|Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
48384782|NCT05007106|DRUG|Oxaliplatin|Oxaliplatin administered via IV infusion Q3W up to 35 cycles
48384783|NCT00890409|DEVICE|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
48384784|NCT03099616|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
48384785|NCT03099616|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
48384786|NCT06455774|DEVICE|Wearable Postural Feedback Device|The postural feedback wearable device we will use in the study is programmed to vibrate when hunched postures are detected (based on changes in the curvature and curvature of the spine), alerting users to changes in their body position.
48722893|NCT06221748|DRUG|Disitamab Vedotin Injection|Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
48722894|NCT06221748|DRUG|Cadonilimab Injection|Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
48722895|NCT06221748|DRUG|Paclitaxel Injection|Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
48722896|NCT05490966|OTHER|isometric trunk extensor muscles fatigue|Participants will perform three sets of intermittent isometric efforts between 50 and 60 percents of their maximal isometric strength. A padded force sensor will be placed approximately at the level of the 7th thoracic vertebrae. The first two sets will last six minutes each, while the third set will last three minutes. Between each set participants will rest for two minutes.
48722897|NCT00428207|DRUG|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
48722898|NCT00428207|DRUG|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
48722899|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
48722900|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
48722901|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
48722902|NCT01490294|DRUG|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
48722903|NCT04054999|DRUG|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
48722904|NCT04054999|DRUG|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
48722905|NCT04475484|OTHER|Online questionnaire|"Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress."
48722906|NCT05606991|OTHER|CPAP Withdrawal|Complete withdrawal of continuous positive airway pressure (CPAP) therapy for a 2-week period.
48722907|NCT00031460|DRUG|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
48722908|NCT00031460|DRUG|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
48722909|NCT04462939|DIETARY_SUPPLEMENT|Elevit Breastfeeding & Postnatal Care|Multi-micronutrients, lutein and DHA soft gel capsules; one capsule daily, oral
48722910|NCT04462939|DRUG|Placebo|No active ingredients except of 225 μg iodine; One capsule daily, oral
48722911|NCT01300455|DRUG|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
48384787|NCT06455774|OTHER|Exercise|Trapezius, Sternocleidomastoid (SCM), Scalene, pectoral muscles will be targeted for stretching exercises and deep neck flexors, Trapezius, Levator Scapula, Rhomboids will be targeted for strengthening exercises. The intensity of the exercises will be increased according to the weeks. Stretching exercises will be performed as a single set at the pain limit, maintaining the position of the muscle groups in the longest tolerable position for 30 seconds. In strengthening exercises, participants will hold the position for 5-10 seconds at the end of the movement. Moderate resistance elastic bands and free weights will be used for resistance exercises. In the following weeks, progression will be made in all exercises according to the patient's condition.
48384788|NCT05217901|DRUG|14C-labeled ASP0367|Oral
48384789|NCT01761617|BEHAVIORAL|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
48722912|NCT01300455|DRUG|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
48722913|NCT01650740|DRUG|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
48722914|NCT01650740|DRUG|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
48722915|NCT01650740|OTHER|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
48722916|NCT00208520|DRUG|Carbamazepine|
48722917|NCT00208520|DRUG|Lamotrigine|
48722918|NCT00208520|DRUG|Levetiracetam|
48722919|NCT02861911|OTHER|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
48722920|NCT02861911|DEVICE|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
48722921|NCT05086510|PROCEDURE|Radiofrequency ablation|Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.
48722922|NCT04983797|DEVICE|OPTRELL Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation using OPTRELL mapping catheter for the management of Atrial procedure (Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation) and Ventricular procedures (Ventricular Tachycardia, Premature Ventricular Complex).
48722923|NCT01389323|DRUG|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
48722924|NCT01389323|DRUG|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
48722925|NCT01389323|DRUG|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
48722926|NCT02752464|BEHAVIORAL|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
48722927|NCT02752464|BEHAVIORAL|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
48722928|NCT01927042|BEHAVIORAL|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
48722929|NCT01927042|BEHAVIORAL|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
48722930|NCT00336557|PROCEDURE|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
48722931|NCT00102713|DRUG|Divalproex Sodium (Depakote Sprinkle Capsules)|
48722932|NCT03762447|DRUG|INCB086550|INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
48722933|NCT00380419|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
48722934|NCT00837603|BEHAVIORAL|Training|Controlled home ergometer training
48722935|NCT05919485|PROCEDURE|tDCS|"0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC"
48722936|NCT04029818|BIOLOGICAL|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
48722937|NCT04029818|BIOLOGICAL|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
48722938|NCT02502981|DRUG|Spironolactone|25mg orally once a day for 40 weeks
48722939|NCT02502981|DRUG|Chlortalidone|25mg orally once a day for 40 weeks
48722940|NCT02048371|DRUG|Regorafenib|Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
48722941|NCT02048371|DRUG|Placebo|21 days on and 7 days off
48183113|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 3|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
48183114|NCT02818998|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
48384790|NCT01761617|BEHAVIORAL|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
48384791|NCT06485596|DEVICE|XVIVO Heart Assist Transport System|Direct procurement of donor hearts from DCD donation
48384792|NCT02867592|DRUG|Cabozantinib|Given PO
48384793|NCT02867592|DRUG|Cabozantinib S-malate|"Given PO~Note: Capsule formulation (Cometriq) not used in this trial."
48722942|NCT04115982|DRUG|Cholecalciferol|One vial every 15 days during 2 months
48722943|NCT04115982|DRUG|Placebos|One vial every 15 days during 2 months
48722944|NCT01722656|DRUG|Aflibercept|
48722945|NCT00324233|DEVICE|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
48384794|NCT02867592|OTHER|Pharmacological Study|Correlative studies
48384795|NCT00986609|BIOLOGICAL|MUC-1 peptide vaccine|Given subcutaneously
48722946|NCT00324233|DEVICE|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
48722947|NCT03250572|DIAGNOSTIC_TEST|serum ferritin|serum samples and ferritin ELISA test
48722948|NCT06540989|BEHAVIORAL|Immediate treatment|Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
48722949|NCT06540989|BEHAVIORAL|Deferred treatment|This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
48722950|NCT04893421|DEVICE|MOLLI Localization|Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
48722951|NCT03030339|OTHER|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
48722952|NCT03030339|OTHER|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
48722953|NCT03030339|OTHER|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
48722954|NCT03436485|DRUG|ODM-208|co-administered with glucocorticoid and fludrocortisone, orally daily
48722955|NCT03436485|DRUG|Midazolam|orally
48722956|NCT00422994|DRUG|ropinirole dosing for up to 28 days|
48722957|NCT00054028|DRUG|suramin|Given IV
48722958|NCT00054028|DRUG|paclitaxel|Given IV
48722959|NCT00054028|OTHER|pharmacological study|Correlative studies
48722960|NCT03481140|DEVICE|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
48722961|NCT00747409|DRUG|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
48722962|NCT00747409|DRUG|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
48722963|NCT04881747|DRUG|Lasmiditan|Administered orally.
48722964|NCT06477419|DRUG|Sacituzumab govitecan-hziy|After enrollment, participants will receive SG until disease progression or intolerable toxicity.
48722965|NCT05998135|DRUG|Atovaquone|Given PO
48722966|NCT05998135|PROCEDURE|Biopsy|Undergo biopsy
48183115|NCT05571826|BEHAVIORAL|telerehabilitation|No specific treatments will be applied. The persons who experienced telerehabilitation interventions will be included.
48722967|NCT05998135|PROCEDURE|Computed Tomography|Undergo CT
48722968|NCT05998135|PROCEDURE|Paracentesis|Undergo paracentesis
48722969|NCT00506194|DRUG|Insulin|
48722970|NCT00506194|DRUG|OAD|Gliclazide-MR, Metformin, Glimepiride
48183116|NCT04217772|DEVICE|Optical Coherence Tomography Angiography|A device testing the vascular density in the retina
48183117|NCT05078177|DRUG|Rituximab|All patients receive AHSCT with RIC (Cyclophosphamide, Antithymocyte globulin/Rituximab). After resolution of cytopenia (approximately from about D+12 to D+14 AHSCT), patients will receive intrathecal Rituximab.
48722971|NCT02915185|PROCEDURE|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
48722972|NCT02915185|DEVICE|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
48722973|NCT03551756|OTHER|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
48722974|NCT03300778|BEHAVIORAL|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
48722975|NCT03300778|BEHAVIORAL|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
48722976|NCT04607122|DRUG|Landiolol|Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.
48183118|NCT02775305|BEHAVIORAL|Frail|"Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques."
48384796|NCT00986609|BIOLOGICAL|poly ICLC|Given intramuscularly
48722977|NCT04607122|DRUG|Saline|Continuous infusion of saline solution at the same rate as landiolol infusion.
48722978|NCT05245188|OTHER|Chocolate milk shakes - Product 1|11.3 glucose
48722979|NCT05245188|OTHER|Chocolate milk shakes - Product 2|8.84 glucose
48722980|NCT05245188|OTHER|Chocolate milk shakes - Product 3|4.24 glucose
48722981|NCT05245188|OTHER|Chocolate milk shakes - Product 4|4.36 glucose
48722982|NCT01954316|DRUG|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
48722983|NCT05157139|DRUG|Oral Capsule|Oral Capsule of vanillin \& wheat germ oil
48722984|NCT01420666|DRUG|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
48722985|NCT01420666|DRUG|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
48722986|NCT01420666|DRUG|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
48722987|NCT01420666|DRUG|Placebo|placebo, three tablets four times a day, orally, with food
48722988|NCT01820052|DRUG|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
48722989|NCT01820052|DRUG|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
48722990|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
48722991|NCT01213823|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
48722992|NCT00933894|DRUG|Telaprevir; Escitalopram|
48722993|NCT04578561|PROCEDURE|Prophylactic mesh use|After laparotomy sutured clousur the abdominal wall wound is reinforced using a suprafascial synthetic mesh.
48183119|NCT05859438|OTHER|Communication aid support|Support to use voice input voice output communication aids
48384797|NCT00986609|BIOLOGICAL|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
48384798|NCT00986609|OTHER|laboratory biomarker analysis|Correlative studies
48026130|NCT05950802|RADIATION|TLI|radiation given with conditioning chemo
48026131|NCT04906018|DEVICE|Ultrasound scans|Each subject will be randomly allocated to an ultrasound machine and an expert scanner who will perform the ultrasound scans of all supported anatomical regions.
48026132|NCT01118390|DEVICE|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
48026133|NCT01118390|OTHER|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
48722994|NCT01345552|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
48722995|NCT04133714|DEVICE|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
48722996|NCT04133714|DEVICE|single-channel tDCS|single-channel transcranial direct current stimulation
48722997|NCT05276895|DIETARY_SUPPLEMENT|Quercetin and Fisetin tab.|1250 mg/day quercetin + 1000mg/day Fisetin for 3 consecutive days every 3 weeks over 15 weeks .
48722998|NCT05276895|DIETARY_SUPPLEMENT|Quercetin Cap/Tab,Fisetin Cap/tab and Glycyrrhizin capsules|quercetin + Fisetin for 3 consecutive days followed by 100mg/day glycyrrhizin for one week every 3 weeks over 15 weeks
48722999|NCT05276895|OTHER|Placebo|Placebo capsule for one week every 3 weeks over 15 weeks
48723000|NCT04031872|DRUG|LY3200882|Combination treatment with LY3200882 and capecitabine
48723001|NCT00073463|GENETIC|tgAAVCF|
48723002|NCT06140459|DEVICE|Conventional Toothbrushes|Oral-B Stages 3
48723003|NCT06140459|DEVICE|Pulsating Toothbrushes|Oral-B Pulsar, Colgate 360º Micro Sonic Power
48026134|NCT03615157|OTHER|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
48183120|NCT06062524|DEVICE|Aorta Vascular Plug System|The Aorta Vascular Plug System for false lumen is composed of a vascular plug system and an adjustable bend conveyor. The plug system is composed of a patch and a conveying steel cable. The plug is pre-installed on the conveying steel cable.
48183121|NCT06544681|PROCEDURE|Coronary stenting with planned drug eluting stent (DES).|Stenting will be performed with OCT guidance according to the algorithm described in the protocol. A deep learning-based OCT system was used to measure the adherence of coronary stents.
48026135|NCT03950193|OTHER|Questionnaires to evaluate psychic development of the child|Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
48026136|NCT04634487|OTHER|No intervention|No intervention
48183122|NCT03107507|DRUG|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
48183123|NCT03107507|DRUG|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
48183124|NCT01443923|DRUG|Boceprevir|
48723004|NCT01816555|DIETARY_SUPPLEMENT|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
48723005|NCT06120101|BEHAVIORAL|Reflexology Massage|The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
48723006|NCT00249613|BEHAVIORAL|Women-Only|Gender-responsive treatment for women only
48723007|NCT01241071|OTHER|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
48026137|NCT06191705|DIAGNOSTIC_TEST|QuickDASH|Participants will be administered Urdu version of QuickDASH to collect data regarding Disabilities of Arm, Shoulder \& Hand twice with a time interval of 72 hours to determine validity and reliability.
48026138|NCT00198640|PROCEDURE|Antibiotic use|
48026139|NCT03636152|PROCEDURE|MRI carotid|To assess the carotid atherosclerotic plaques
48026140|NCT03636152|PROCEDURE|APWV|Doppler measurement of the APWV
48026141|NCT03636152|DRUG|Hydroxychloroquine|Active Drug
48026142|NCT03636152|DRUG|Matching Placebo|Matching Placebo for the control group.
48026143|NCT03365765|DRUG|Apatinib|Apatinib tablet
48026144|NCT03365765|DRUG|Oxaliplatin|Oxaliplatin Intravenous
48723008|NCT01241071|OTHER|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
48723009|NCT04969536|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
48723010|NCT04969536|OTHER|Placebo|Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
48723011|NCT00240604|DRUG|Rosiglitazone|4 mg rosiglitazone per day
48723012|NCT00006455|DRUG|cyclophosphamide|
48723013|NCT00006455|DRUG|cytarabine|
48520703|NCT03709043|BEHAVIORAL|Medical Management (MM) counseling for alcohol use:|MM has been used in a targeted pharmacotherapy trial98 and our team has successfully used MM in AUD trials. MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist.
48723014|NCT00006455|DRUG|dexamethasone|
48384799|NCT00986609|OTHER|enzyme-linked immunosorbent assay|Correlative studies
48723015|NCT00006455|DRUG|doxorubicin hydrochloride|
48723016|NCT00006455|DRUG|etoposide|
48026145|NCT03365765|DRUG|5-fluorouracil|5-fluorouracil Intravenous
48026146|NCT04474184|PROCEDURE|Biospecimen Collection|Receive vaginal kit for biospecimen collection
48384800|NCT00986609|OTHER|flow cytometry|Correlative studies
48384801|NCT02080273|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
48723017|NCT00006455|DRUG|ifosfamide|
48723018|NCT00006455|DRUG|leucovorin calcium|
48723019|NCT00006455|DRUG|methotrexate|
48723020|NCT00006455|DRUG|therapeutic hydrocortisone|
48384802|NCT02080273|DRUG|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
48384803|NCT02080273|DRUG|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
48723021|NCT00006455|DRUG|vinblastine sulfate|
48723022|NCT00129961|DRUG|sirolimus|
48723023|NCT00129961|DRUG|cyclosporine or tacrolimus|
48723024|NCT01171209|DRUG|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
48723025|NCT00316420|DRUG|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
48723026|NCT00316420|DRUG|Gemcitabine|750 mg/m2 IV Days 1 \& 8 q 21 days
48723027|NCT00094432|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
48723028|NCT00094432|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
48723029|NCT02982083|DRUG|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
48723030|NCT02982083|DRUG|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
48723031|NCT04969315|DRUG|TT-10|TT-10 orally administered BID starting at 10 mg and will be increased to 200 mg (additional dose levels maybe explored, if appropriate based on emerging safety, PK or PD data).
48026147|NCT04474184|BEHAVIORAL|Focus Group|Attend focus group
48026148|NCT04474184|OTHER|Survey Administration|Ancillary studies
48026149|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1mg, tid
48026150|NCT01569516|DRUG|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
48026151|NCT01569516|DRUG|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
48723032|NCT06412952|DRUG|68Ga-RM26|Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
48723033|NCT03656081|DRUG|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
48723034|NCT03656081|DRUG|inhaled placebo|inhaled isotonic saline
48723035|NCT03656081|DRUG|Itraconazole|Itraconazole tablet
48723036|NCT01833234|OTHER|Interviews and questionnaires|
48723037|NCT05094830|PROCEDURE|Stomach Intestinal Pylorus-Sparing (SIPS) Procedure|The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
48723038|NCT00888641|PROCEDURE|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
48723039|NCT03281304|DRUG|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
48183125|NCT01443923|DRUG|Peg-Interferon-alfa 2B|
48183126|NCT01443923|DRUG|Ribavirin|
48183127|NCT02471456|OTHER|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
48384804|NCT05726409|OTHER|Mobile application|Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
48183128|NCT02471456|OTHER|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
48183129|NCT00268372|DRUG|cisplatin|
48183130|NCT00268372|DRUG|docetaxel|
48183131|NCT00268372|DRUG|5-fluorouracil|
48183132|NCT00268372|PROCEDURE|surgery|
48183133|NCT00268372|RADIATION|radiation therapy|
48183134|NCT04429282|DRUG|ibuprofen|Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
48183135|NCT04429282|DRUG|Placebo|Placebo
48183136|NCT00000897|DRUG|Zidovudine|
48183137|NCT03002142|DEVICE|Hearing aids|Phonak Audéo B-R (Target V 5.0)
48183138|NCT03002142|DEVICE|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
48183139|NCT03616795|DRUG|LY3154207|Administered orally
48183140|NCT03616795|DRUG|[14C]-LY3154207|Administered orally
48183141|NCT05631743|BEHAVIORAL|VR-CBT|The therapy is focused on emotion regulation through guided learning in virtual reality. The manual is a modified conventional cognitive behavioral therapy to include these aspects and the suggestions of an advisory committee of Inuit and non-Inuit health service providers (e.g., cultural adaptation).
48384805|NCT04631055|DEVICE|drug coated balloon|paclitaxel coated balloon catheter for intracranial PTA treatment
48723040|NCT03281304|DRUG|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
48723041|NCT06492473|DEVICE|ECHO|type and size of ventricular septal defect
48723042|NCT00877721|DEVICE|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
48723043|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
48723044|NCT01423474|RADIATION|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
48026152|NCT01569516|DRUG|Placebo|0mg, tid
48026153|NCT00364858|DRUG|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
48026154|NCT00931177|OTHER|weight|weight and dehydration scores
48026155|NCT00931177|OTHER|weight and dehydration score|weight and dehydration score
48026156|NCT00558675|BIOLOGICAL|AlloStim|single intravenous infusion of 1 x 10\^9 AlloStim cells
48183142|NCT05631743|BEHAVIORAL|Self-management|The previously developed commercial VR program involves guided relaxation and meditation techniques.
48183143|NCT04160806|DEVICE|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
48026157|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7
48026158|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14
48026159|NCT00558675|BIOLOGICAL|AlloStim|Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
48026160|NCT06534567|OTHER|Mediterranean Diet|Mediterranean diet adherence
48026161|NCT06534567|OTHER|Physical activity|Physical activity level
48026162|NCT01617291|OTHER|Induced therapeutic hypothermia|induced therapeutic hypothermia
48026163|NCT04735133|DEVICE|pNBYT|pNPWT device (80mm Hg) was placed in the pNPWT group for seven days The incision area was evaluated during the first seven days, and on the 15th, 21st, and 30th days postoperatively for the presence of hematoma, seroma, wound dehiscence/evisceration, and SSI.
48026164|NCT00881725|DRUG|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
48026165|NCT02513017|BEHAVIORAL|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
48026166|NCT04989270|PROCEDURE|General Anesthesia|General anesthesia with intubation, ventilation, intravenous and inhalational anesthetics, opioids and muscle paralysis
48183144|NCT02888379|DRUG|TOP1288|
48183145|NCT02888379|DRUG|Placebo (for TOP1288)|
48384806|NCT04631055|DEVICE|stent system|The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
48384807|NCT03035500|OTHER|Educational Intervention|Receive health education
48723045|NCT03239938|BEHAVIORAL|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
48723046|NCT03239938|BEHAVIORAL|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
48384808|NCT03035500|OTHER|Laboratory Biomarker Analysis|Correlative studies
48384809|NCT03035500|OTHER|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
48384810|NCT03035500|OTHER|Quality-of-Life Assessment|Ancillary studies
48384811|NCT03035500|OTHER|Questionnaire Administration|Ancillary studies
48384812|NCT05308654|DRUG|ABBV-453|Oral; Tablet
48384813|NCT05308654|DRUG|Dexamethasone|Oral Tablet
48723047|NCT01950091|BEHAVIORAL|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
48723048|NCT01950091|OTHER|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
48723049|NCT04274803|DRUG|Intralipid, 20% Intravenous Emulsion|intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
48723050|NCT04274803|DRUG|Conventional therapy of antiphospholipis syndrome|the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
48723051|NCT00445276|DRUG|Diacerein|
48723052|NCT00504374|BEHAVIORAL|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
48723053|NCT01283542|DRUG|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
48723054|NCT03743064|DRUG|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
48723055|NCT03743064|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
48723056|NCT05565768|DRUG|HZN-457|HZN-457 will be given in one subcutaneous administration
48723057|NCT05565768|DRUG|Placebo|Placebo will be given in one subcutaneous administration
48723058|NCT00885781|DRUG|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
48723059|NCT01189305|BEHAVIORAL|Behavioral Couples Therapy|Behavioral Couples Therapy
48723060|NCT01189305|BEHAVIORAL|Individual Drug Counseling|Individual Drug Counseling
48723061|NCT00332553|DRUG|Raloxifene|
48723062|NCT00332553|DRUG|medroxyprogesterone acetate|
48723063|NCT00332553|DRUG|estrogen|
48723064|NCT00332553|DRUG|17 beta estradiol|
48723065|NCT01060436|DEVICE|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
48723066|NCT03465787|DRUG|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
48723067|NCT03465787|DRUG|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
48183146|NCT04766255|PROCEDURE|Soft Tissue graft augmentation|"Donor site:~SCTG group: The SCTG will be harvested in the palat,In order to extract the same thickness in each grafts a double-bladed knife (separated by 1,5mm) will be used. The donor area will be sutured.~Recipient site:~SCTG group: the connective tissue graft will be trimmed to the correct dimensions (10mm height, 12mm length and 1,5mm thick) and placed and secured at the recipient site with a resorbable 5-0 suture CM group: The CM graft (Geistlich Fibro-gide) will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture PADM Group: the ADM (NovoMatrix, Biohorizons, Birmingham AL) graft will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture"
48183147|NCT04766255|PROCEDURE|Implant Placement|A crestal incision will be made in the implant reception area, extending from the distal of the most mesial tooth to the mesial of the most distal tooth. A mucoperiosteal flap will be elevated in the most crestal part of the ridge. The receptor bed will be prepared following the established drilling protocol for the placement of a BioHorizons Tapered Pro Implant (Biohorizons, Birmingham AL). The diameter and length of the implant will be previously established during the implant study. Later a healing abutment will be placed.
48183148|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
48183149|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
48183150|NCT02414126|OTHER|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~1. st period: Spontaneous breathing for 10 minutes~2. nd period: CPAP for 10 minutes~3. rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~* oesogastric pressures~* air flow~* gas exchange~* right and left cardiac function~Patients \> 6 years old will assess their dyspnea on a visual analogue scale"
48183151|NCT02414126|DEVICE|CPAP|
48384814|NCT05308654|DRUG|Daratumumab|Subcutaneous Injection
48384815|NCT05308654|DRUG|Lenalidomide|Oral Capsule
48723068|NCT05903859|DRUG|Probenecid 500 Milligrams (mg)|Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
48026167|NCT04989270|PROCEDURE|Regional Anesthesia|Spinal Anesthesia, Epidural Anesthesia
48183152|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid|
48183153|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid formulation|
48183154|NCT02209103|DIETARY_SUPPLEMENT|Identical looking placebo|
48183155|NCT00547053|DRUG|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
48183156|NCT03313141|DIAGNOSTIC_TEST|Ultrasound|Volitional and non volitional respiratory tasks
48183157|NCT04820998|OTHER|Families|Families's interviews about their precarious situation of living and the consequences on their autistic child care
48183158|NCT04820998|OTHER|professionals|Interviews so as to know how the specifics of precarious situations are identified and taken into account by the professionals
48183159|NCT02623660|DEVICE|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
48384816|NCT05929040|BEHAVIORAL|mindful cognitive intervention|Mindfulness based cognitive intervention based on the behavioural change techniques taxonomy
48384817|NCT04846075|BEHAVIORAL|Ramadan fasting, praying, and welfare for poor|Abstaining from food, drink, smoking, and sexual activity duirng daytime; ritualistic praying at specific time of a day for five or more times; volunteering for communities or donation
48384818|NCT03252756|OTHER|Placebo|Saline taken by mouth (PO)
48384819|NCT03252756|DRUG|Phytocannabinoid cannabidiol (CBD)|CBD taken by mouth (PO)
48723069|NCT05903859|DRUG|probenecid 250 Milligrams (mg)|Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
48723070|NCT05903859|DRUG|Placebo|Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
48026168|NCT02219932|DRUG|fampridine|
48026169|NCT02219932|DRUG|Placebo|Matched placebo
48026170|NCT02405286|OTHER|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
48026171|NCT04957602|OTHER|Blood collection|Blood collection (4\*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
48026172|NCT00418535|DRUG|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
48026173|NCT02239510|DRUG|Senna|1 capsule (50 mg) Senna daily for 12 weeks
48520704|NCT03709043|DIAGNOSTIC_TEST|Urinalysis for novel alcohol biochemical markers for recent alcohol use:|Urine samples will be collected at Enrollment, Month 1, Month 2 and Month 3 visits and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption in the past three days. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours.
48723071|NCT05833178|BEHAVIORAL|Drawn Blood Volume|Hemoglobine Changes
48723072|NCT05235919|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|30 minutes rTMS session 5 days/week for 3 weeks.
48723073|NCT05235919|OTHER|Sham stimulation|30 minutes sham stimulation 5 days/week for 3 weeks.
48723074|NCT00474461|BIOLOGICAL|Treatment group|Intracoronary injection of cardiac stem cells
48183160|NCT02623660|OTHER|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
48183161|NCT02623660|DEVICE|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
48183162|NCT05890937|DIAGNOSTIC_TEST|Oral and practical exam|Oral and practical exam that performed at the end of the semester
48183163|NCT05585645|BIOLOGICAL|Stimus (NNG-DEPO)|Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
48384820|NCT04807881|DRUG|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
48723075|NCT00189904|BIOLOGICAL|IMVAMUNE (MVA-BN)|
48026174|NCT02239510|DRUG|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
48384821|NCT02271100|DEVICE|ultrasound guidance|use of ultrasound for entry position estimation
48384822|NCT02271100|DEVICE|palpation guidance|use of palpation for position estimation
48384823|NCT04969991|DRUG|Varespladib|250 mg immediate-release oblong, white, film-coated tablet for oral administration
48384824|NCT04969991|DRUG|Placebo|Oral formulation matched to the oral varespladib tablet
48384825|NCT04534296|OTHER|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
48384826|NCT04534296|OTHER|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
48026175|NCT00522249|DRUG|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
48026176|NCT00522249|DRUG|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
48183164|NCT04278586|BEHAVIORAL|Live-Online M-ROCC|"1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
48384827|NCT04625907|DRUG|Irinotecan|antineoplastic enzyme inhibitor
48384828|NCT04625907|DRUG|Actinomycin D|Antineoplastic agent that is a polypeptide antibiotic
48384829|NCT04625907|DRUG|Doxorubicin|An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
48723076|NCT01471210|DRUG|Urelumab (BMS-663513)|
48723077|NCT04334564|DRUG|Ginkgo biloba capsule|Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
48723078|NCT04334564|DRUG|Placebos|Placebos were controls.
48723079|NCT01875718|DRUG|UC1010|
48723080|NCT01875718|DRUG|Placebo|
48723081|NCT03762798|DEVICE|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
48723082|NCT04452773|DIETARY_SUPPLEMENT|Manremyc|Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli
48723083|NCT04452773|DIETARY_SUPPLEMENT|Placebo|Same excipients than active arm without bacilli.
48026177|NCT00522249|DRUG|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
48026178|NCT01017172|OTHER|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
48026179|NCT01782131|DRUG|Posaconazole|POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
48026180|NCT01782131|DRUG|Voriconazole|VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
48026181|NCT01782131|DRUG|Placebo|Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
48026182|NCT01988818|DEVICE|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
48026183|NCT01988818|DEVICE|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
48723084|NCT01178424|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
48723085|NCT01178424|BEHAVIORAL|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
48026184|NCT03503942|BEHAVIORAL|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
48026185|NCT03503942|DRUG|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
48026186|NCT03503942|OTHER|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
48026187|NCT02520934|DRUG|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
48026188|NCT02520934|DRUG|ERT|enzyme replacement therapy
48026189|NCT02138214|PROCEDURE|Thyroidectomy|Undergo total thyroidectomy
48384830|NCT04625907|DRUG|Ifosfamide|chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
48520705|NCT03709043|DIAGNOSTIC_TEST|Dried Blood Spot (DBS) Testing for PEth:|DBS samples will be collected at enrollment, weeks 12, and post-treatment visits at month 3. Samples will be dried overnight using standardized methods. PEth testing of DBS samples will be conducted at the United States Drug Testing Laboratories in Des Plaines, IL using liquid chromatography-tandem mass spectrometry system following extraction into methanol.
48723086|NCT05747417|OTHER|prismatic glasses|prism glasses ranging from 4-10 prism diopters
48723087|NCT04054466|BEHAVIORAL|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
48723088|NCT04054466|BEHAVIORAL|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
48723089|NCT03633669|DIAGNOSTIC_TEST|Fecal calprotectin|Testing every 3 months
48026190|NCT02138214|PROCEDURE|entral lymph node dissection (CLND)|Undergo total thyroidectomy with ipsilateral prophylactic CND
48026191|NCT02138214|OTHER|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
48384831|NCT04625907|DRUG|Vincristine|anti neoplastic vinca alkaloid agent
48384832|NCT04625907|DRUG|Vinorelbine|vinca alkaloid with a role as an antineoplastic agent
48384833|NCT04625907|DRUG|Cyclophosphamide|Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
48384834|NCT04625907|DRUG|Temozolomide|oral antineoplastic alkylating agent
48384835|NCT04625907|RADIATION|radiotherapy|Ionising radiation
48520706|NCT03709043|BEHAVIORAL|Behavioral survey measurements:|Standardized and validated behavioral measures will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection.152,153 To minimize potential social desirability bias, staff will not have access to data during the trial. The draft of the ACASI survey instrument is included in the appendix.
48723090|NCT03633669|OTHER|Routine care|As per treating gastroenterologist
48723091|NCT02576808|DRUG|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
48723092|NCT02576808|DRUG|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
48723093|NCT01304407|OTHER|Calcium stable isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
48723094|NCT00002299|DRUG|Interferon beta-1b|
48723095|NCT00002299|DRUG|Ganciclovir|
48723096|NCT03778463|OTHER|Synovectomy|Removal of the synovium during total knee arthroplasty
48026192|NCT03867734|DRUG|Aztreonam|2g IM Aztreonam
48026193|NCT06141798|OTHER|Hemodialysis|Number of weekly hemodialysis treatment
48384836|NCT04625907|DRUG|Regorafenib|Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
48384837|NCT06652555|OTHER|Group 1|without Intervention
48384838|NCT06651723|DEVICE|Toothbrush type|The participants will use either an electric soft brush (test) and soft manual brush (control).
48384839|NCT04559776|OTHER|gait analysis|gait analysis with 3D optoelectronic system and surface EMG
48520707|NCT03709043|BEHAVIORAL|Ecological Momentary Assessment procedure:|Participants will receive daily SMS texts to collect data on alcohol consumption, number of drinks on drinking days, targeted medication administration prior to anticipated drinking sessions, and sexual risk behaviors
48723097|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
48723098|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
48026194|NCT03091751|DRUG|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
48026195|NCT05588518|COMBINATION_PRODUCT|desensitizing agents -10% Propolis|"10% propolis was prepared after mixing with 70% ethanol and distilled water based on the method described previously. Propolis and ethanol mixture was allowed to stay in dark place for two weeks. The mixture was stirred everyday intermittently for two weeks. Later the mixture was strained twice using filter paper to remove impurities.~Propolis in general are fairly stable without losing its antibacterial properties for over 12 months when stored without direct sunlight and at cool temperatures. Alcohol based extracts will have extended shelf life and hence ethanol-extracted propolis prepared was stored in dark amber colored bottle without any preservatives."
48026196|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
48026197|NCT04034641|DRUG|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
48026198|NCT02806739|DIETARY_SUPPLEMENT|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
48026199|NCT02806739|DIETARY_SUPPLEMENT|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
48026200|NCT03867331|BIOLOGICAL|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
48026201|NCT03867331|BIOLOGICAL|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
48026202|NCT03867331|BIOLOGICAL|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
48026203|NCT03867331|OTHER|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
48026204|NCT01181934|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
48026205|NCT01181934|DRUG|placebo|placebo - three times daily during each treatment period
48026206|NCT01181934|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
48026207|NCT05684887|OTHER|Digital based contact tracing|"* Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~* Immediate access to the contact list in Mamal Pro once validated by the health care worker.~* Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~* Contacts will be invited to go to the nearest testing facilities/units to get tested.~* Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~* Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module."
48026208|NCT00333593|DEVICE|Large pore dialyser|
48026209|NCT00333593|DEVICE|Standard dialyser|
48026210|NCT03087266|PROCEDURE|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
48026211|NCT03087266|PROCEDURE|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
48026212|NCT03981003|DIAGNOSTIC_TEST|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain and GFAP levels
48026213|NCT02290665|OTHER|Thermosensitive gel rectal formulation|
48026214|NCT02290665|OTHER|Saline enema|
48026215|NCT00186303|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
48026216|NCT00186303|PROCEDURE|ablative allogeneic hematopoietic cell transplant|
48026217|NCT05093517|DRUG|REMD-477|A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1
48026218|NCT05093517|DRUG|Placebo Subcutaneous injection|Placebo for REMD-477 to which subjects will be randomized 1:2.
48026219|NCT02169934|DRUG|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
48723099|NCT01504347|BIOLOGICAL|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
48026220|NCT05909189|OTHER|LEADing Dementia End-of-Life Planning Conversations|The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
48026221|NCT05009563|RADIATION|FDG-PET/CT|whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
48026222|NCT00824681|BEHAVIORAL|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
48026223|NCT00824681|OTHER|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
48026224|NCT06387043|OTHER|Balance exercises with Virtual Reality Glasses|Balance exercises with Virtual Reality Glasses
48026225|NCT06387043|OTHER|Balance Exercises with Stroboscopic Glasses|Balance Exercises with Stroboscopic Glasses
48026226|NCT06387043|OTHER|Balance Exercises with Visual-Based Metaphor Training|Balance Exercises with Visual-Based Metaphor Training
48026227|NCT06387043|OTHER|Traditional Balance Exercises|Traditional Balance Exercises
48723100|NCT06504069|BEHAVIORAL|Prosocial VR intervention|A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
48723101|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
48723102|NCT00658307|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
48384840|NCT05427370|PROCEDURE|Revascularization by PCI|"Contemporary, State-of-the-art PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated."
48520708|NCT05091970|PROCEDURE|Manualized cognitive rehabilitation for mild traumatic brain injury (mTBI)|Three 60-minute sessions per week with a minimum of 6 sessions and a maximum of 10 sessions. This intervention is to be delivered by trained Occupational Therapists (OTs) and Speech-Language Pathologists (SLPs), and includes training in compensatory strategies, direct training of cognitive subskills (e.g., attention training), and assigned homework to practice skills learned in treatment.
48026228|NCT03112044|DRUG|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
48026229|NCT03112044|DEVICE|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
48520709|NCT05212077|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
48520710|NCT05212077|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
48520711|NCT05778578|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
48520712|NCT06581380|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.
48723103|NCT00658307|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
48723104|NCT02473276|DRUG|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
48026230|NCT05298085|DRUG|Oxytocin nasal spray|Study treatment will be administered intranasally daily for 12 weeks. The daily dose of OT will be adapted according to age at the beginning of the study
48026231|NCT05298085|DRUG|Placebo|Study treatment will be administered intranasally daily for 12 weeks.
48723105|NCT02473276|DRUG|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
48723106|NCT02326766|DIETARY_SUPPLEMENT|KRG|5g Korea red ginseng (KRG)
48026232|NCT03436979|DEVICE|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
48026233|NCT05075317|BEHAVIORAL|Standard cardiac rehabilitation|Standard, multi-dimensional cardiac rehabilitation program.
48723107|NCT02326766|DIETARY_SUPPLEMENT|Placebo|5g placebo
48723108|NCT02698371|DEVICE|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
48723109|NCT02698371|DEVICE|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
48723110|NCT02698371|DEVICE|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
48723111|NCT02698371|DEVICE|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
48723112|NCT02698371|DEVICE|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
48723113|NCT02698371|DEVICE|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
48026234|NCT05075317|BEHAVIORAL|Time-Restricted Eating|Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
48026235|NCT00671281|DRUG|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
48026236|NCT00671281|DRUG|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
48026237|NCT04391231|DRUG|Pentoxifylline Oral Product|Blinded Pentoxifylline (in suspension with SyrSpend SF)
48026238|NCT04391231|DRUG|Placebo|Placebo (SyrSpend SF only)
48026239|NCT02962830|DRUG|Sufentanil|intra-amniotic injection of 10 micrograms of Sufentanil
48026240|NCT00548821|DRUG|Cisplatin|
48026241|NCT03297879|DRUG|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
48026242|NCT02983955|DEVICE|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
48026243|NCT02873923|DRUG|undefined|Chemotherapy drug (meta-analyses of randomized trials)
48026244|NCT02076464|BEHAVIORAL|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
48026245|NCT01194115|DRUG|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
48520713|NCT06581380|DRUG|Topotecan|Topotecan will be administered per drug label.
48723114|NCT04182061|BEHAVIORAL|The AMTE protocol|The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
48723115|NCT01457846|DRUG|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
48723116|NCT01457846|DRUG|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
48723117|NCT03802045|PROCEDURE|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
48723118|NCT03802045|DEVICE|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
48723119|NCT03802045|DEVICE|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
48723120|NCT03713541|OTHER|No intervention|Survey during normal supply.
48723121|NCT03189966|PROCEDURE|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
48026246|NCT01194115|DRUG|placebo|placebo representing standard of care
48026247|NCT04599881|DRUG|PTR-01|IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
48026248|NCT05209113|OTHER|Education|A self-management module was applied to the study group. This module includes informing the patient verbally and in writing about MS disease, the importance of drug compliance, and monitoring of disease symptoms.
48026249|NCT01682837|DRUG|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
48026250|NCT01682837|DRUG|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
48183165|NCT04278586|BEHAVIORAL|Live-Online Control|A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
48183166|NCT02294851|DRUG|BMS-986168|
48183167|NCT02294851|DRUG|BMS-986168 Placebo|
48723122|NCT03189966|PROCEDURE|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
48723123|NCT00708734|BEHAVIORAL|functional exercise training|twice weekly group sessions for 5 weeks
48723124|NCT01096511|DRUG|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
48026251|NCT01682837|DRUG|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
48026252|NCT01682837|DRUG|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
48026253|NCT05447546|DRUG|HT-6184|Oral capsule
48183168|NCT00580489|DRUG|either fentanyl or morphine|either morphine 4mg IV or fentanyl 50mcg IV
48183169|NCT04592081|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
48026254|NCT05447546|DRUG|HT-6184 Placebo|Oral capsule
48026255|NCT00835406|DRUG|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
48026256|NCT00835406|DRUG|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
48026257|NCT01764100|GENETIC|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
48026258|NCT05951322|DEVICE|Shockwave therapy|Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.
48026259|NCT05951322|DEVICE|Phonophoresis|Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
48026260|NCT05662501|DEVICE|Pleioflow-RF|Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
48183170|NCT00942747|DRUG|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
48183171|NCT03343093|BEHAVIORAL|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
48183172|NCT03343093|BEHAVIORAL|Control|usual care, surveys every 3 months
48723125|NCT01192828|DRUG|taurine|Take Taurine for 4 1/2 days, two doses per day
48723126|NCT01110382|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
48384841|NCT05427370|PROCEDURE|Revascularization by CABG|The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
48723127|NCT01110382|DRUG|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
48723128|NCT01110382|DRUG|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
48723129|NCT01110382|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
48723130|NCT01110382|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
48723131|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
48723132|NCT01084681|DEVICE|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
48026261|NCT05793905|COMBINATION_PRODUCT|Buffered lidocaine in inferior alveolar nerve block injection|Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars
48384842|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
48384843|NCT01615757|DRUG|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
48384844|NCT02723760|DRUG|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
48384845|NCT06555952|DRUG|MegaNatural-BP SR 150Mg Tablet|GSE MegaNatural BP
48520714|NCT05469334|BEHAVIORAL|DeStress for Health Program Participants|Behavioral: DeStress for Health Program The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals, with an additional class five as a check in that will be used for survey completion. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
48520715|NCT00005884|DRUG|eflornithine|
48520716|NCT04089449|DRUG|PRT811|PRT811 will be administered orally
48723133|NCT06106269|DEVICE|Rectal Artery Embolization|Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.
48723134|NCT01659255|DRUG|Tirabrutinib|Capsules administered orally
48723135|NCT03536026|PROCEDURE|Conventional bronchoscopy|-Standard of care
48723136|NCT03536026|DEVICE|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
48723137|NCT03536026|PROCEDURE|Biopsy|-Standard of care
48723138|NCT02582047|BIOLOGICAL|Influenza vaccination with PPV23|GCflu and Pneumovax-23
48723139|NCT02582047|BIOLOGICAL|Influenza vaccination with PCV13|GCflu and Prevenar-13
48723140|NCT05518526|DRUG|Liposomal Annamycin (L-Annamycin)|Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
48723141|NCT01875042|DEVICE|TENS|Transcutaneous electrical nerve stimulation
48723142|NCT01875042|DEVICE|Sham TENS|Sham Transcutaneous electrical nerve stimulation
48723143|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
48723144|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
48723145|NCT00813891|DRUG|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
48183173|NCT03124654|BEHAVIORAL|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
48183174|NCT05573581|DRUG|Botox|Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
48183175|NCT00909532|DRUG|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
48183176|NCT00909532|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
48183177|NCT01197612|DRUG|pulmicort|applied to nasal packing after surgery
48183178|NCT02313337|OTHER|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
48723146|NCT03187808|OTHER|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
48723147|NCT03187808|OTHER|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
48183179|NCT02313337|OTHER|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
48183180|NCT02313337|OTHER|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
48183181|NCT02313337|OTHER|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
48183182|NCT02313337|DRUG|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
48183183|NCT02313337|PROCEDURE|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
48183184|NCT02313337|DRUG|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
48384846|NCT06555952|OTHER|Placebo Capsule|given in place of GSE MegaNatural BP
48384847|NCT03157934|OTHER|not applicable (observational study)|Observational study without study related intervention
48723148|NCT06271330|DRUG|Faricimab|switch from previous anti-VEGF agents to faricimab
48183185|NCT05931445|OTHER|e-PRO monitoring|"The e-PRO monitoring will concern treatment of each predefined type of cancer or characteristic symptoms of the condition. PRO-CTCAE (Patient-Reported Outcome-Common Terminology Criteria for Adverse Events) will be used as the scale for monitoring symptoms. The patient and (sub)investigator will share the monitoring results during examinations and use them to determine treatment strategies, etc. Threshold values will be predefined for a diagnosis of severe for individual symptoms. When it is reported that a threshold value has been exceeded, an alert notification will be sent to the study staff member assigned to the patient. The (sub)investigator who receives the notification will assess the information in the notification and take the best course of action."
48183186|NCT00890292|DRUG|JNJ-31001074|
48183187|NCT05438836|RADIATION|online adaptive radiotherapy|Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
48723149|NCT02502162|DRUG|LDN|
48723150|NCT02502162|DRUG|Placebo|Sugar pill
48723151|NCT04556318|DEVICE|Ion Mobility Spectrometry (IMS)|Two breathing gas samples will be taken from each study participant using ion mobility spectrometry with an ultrasound-based spirometer. The total sampling time is 1 minute (at least 5-7 breath takes) following an analysis time of 5-12 minutes.
48723152|NCT02560298|DRUG|Capecitabine|
48723153|NCT02560298|DRUG|Carboplatin|Given IV
48183188|NCT05574751|OTHER|Titanium tacker|Mesh fixation with Titanium tacker
48183189|NCT05574751|OTHER|Polypropylene 0|Mesh was sutured and fixed with polypropylene 0
48384848|NCT03500237|BEHAVIORAL|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
48520717|NCT03856801|OTHER|Exercise|Whole-body vibration training in hypoxia and normoxia condition
48723154|NCT02560298|DRUG|Cisplatin|Given IV
48520718|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase I|Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)
48723155|NCT02560298|DRUG|Fluorouracil|Given IV
48723156|NCT02560298|OTHER|Laboratory Biomarker Analysis|Correlative studies
48723157|NCT02560298|DRUG|Paclitaxel|Given IV
48723158|NCT02560298|OTHER|Quality-of-Life Assessment|Ancillary studies
48183190|NCT06490601|DRUG|thalidomide and hydroxyurea|"Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity."
48183191|NCT06490601|DRUG|Thalidomide|"Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor -alpha , Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Investigating the impact of thalidomide on transfusion-dependent beta thalassemia patients is essential for discerning its therapeutic efficacy and safety profile."
48183192|NCT04157322|DIAGNOSTIC_TEST|prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study|Blood draw
48026262|NCT05793905|DRUG|lidocaine 2% in inferior alveolar nerve block injection|Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
48026263|NCT05372601|DIETARY_SUPPLEMENT|Relax+|Prebiotics, daily administered
48026264|NCT05372601|DIETARY_SUPPLEMENT|Maltodextrin|Placebo, daily administered
48183193|NCT00197795|BIOLOGICAL|"Meningococcal outer membrane vesicle vaccine MenBVac"|
48183194|NCT03682198|DEVICE|NIRS measurements on skin, skull and dura|During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.
48183195|NCT03682198|DRUG|Phenylephrine's effect on brain oxygenation|With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
48183196|NCT03682198|DRUG|Normal vs. high inspired oxygen|By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
48183197|NCT01814072|BEHAVIORAL|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
48183198|NCT01814072|BEHAVIORAL|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
48183199|NCT01814072|BEHAVIORAL|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
48520719|NCT03411161|DRUG|Paclitaxel|Paclitaxel (IV) at 80 mg/m²/week
48520720|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase II|S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
48723159|NCT05135962|DEVICE|orthodontic - rapid maxillary expansion|Rapid expansion: when RME was in situ, patients started the screw activation of one-quarter turn a day until overcorrection was achieved and RME was kept on teeth as a passive retainer and removed after one year from its application.
48723160|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with leaf expander|Leaf expander: The screw delivers a maximum expansion of 6 or 9 mm by activating (compressing) the spring, which generates a light (450g or 900g) and constant force. The leaves are preactivated in the laboratory to deliver 3mm of expansion. Reactivation is performed in the office by 10 quarter-turns (leaf 450g) or 15 quarter-turns (leaf 900g) of the screw per month until expansion has been completed. After active expansion the Leaf Expander is maintained passively in place for retention period. Leaf expander was kept on teeth as a passive retainer and removed after one year from its application.
48723161|NCT05135962|DEVICE|orthodontic - slow maxillary expansion with self leaf expander|Leaf self expander: similar to Leaf expander with no need for reactivation or patient compliance.
48723162|NCT04806802|DEVICE|APIOC Sphere and APIOC Astigmatism|Single Vision Contact Lenses
48026265|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3 + K2-MK7|Combined supplementation
48026266|NCT05689632|DIETARY_SUPPLEMENT|Placebo|MCT
48520721|NCT00784108|DEVICE|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
48520722|NCT00784108|OTHER|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
48520723|NCT05973799|OTHER|Fasting|Subjects remain fasted prior to insulin-induced hypoglycemia.
48520724|NCT05973799|OTHER|Feeding|Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
48723163|NCT00881504|DRUG|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay \> 4 weeks
48026267|NCT05689632|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 - 7000 IU
48026268|NCT00440765|DRUG|bortezomib|dose as determined (observational study) by treating physician
48026269|NCT03765437|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
48026270|NCT02266628|BIOLOGICAL|RSV-F Vaccine|
48026271|NCT02266628|BIOLOGICAL|Saline Placebo|
48026272|NCT02755389|DRUG|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
48520725|NCT00699426|DRUG|nexium|40 mg once daily is tested together with Yoghurt
48520726|NCT00699426|DRUG|nexium|nexium and placebo are tested
48520727|NCT00699426|DIETARY_SUPPLEMENT|Yoghurt|Yoghurt
48520728|NCT00699426|DRUG|placebo+placebo|placebo and placebo are tested.
48520729|NCT06295276|OTHER|teletherapy-guided exercise programme|"Exercise program guided by online sessions. Subjects perform this exercise program three times a week at home, so that they complete four sessions per week for six weeks. The duration of a session is approximately twenty minutes. There are six exercises with three sets and about fifteen repetitions. Subjects in the treatment group also receive an instructional video. The subjects keep a diary in which they record their adherence to the treatment protocol at home.~At the beginning of the intervention and after the sixth week, participants are assessed with ODI, NDI and SF36-Short and NRS-11 scales. At the end, we use the Global Rating Scale."
48723164|NCT03469024|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
48026273|NCT02755389|DRUG|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
48026274|NCT02755389|DRUG|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
48026275|NCT03912259|DRUG|Dupilumab|"Pharmaceutical form: solution,~Route of administration: SC"
48026276|NCT03912259|DRUG|Placebo|"Pharmaceutical form: solution,~Route of administration: SC"
48026277|NCT03912259|DRUG|Emollient (moisturizer)|"Pharmaceutical form: cream,~Route of administration: topical use"
48026278|NCT01123759|OTHER|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
48026279|NCT04534829|PROCEDURE|Fluoroscopic-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under fluoroscopic-guidance
48026280|NCT04534829|PROCEDURE|Ultrasound-guided Radiofrequency Ablation|Radiofrequency ablation of the posterior SIJ complex under ultrasound-guidance
48026281|NCT04837638|BEHAVIORAL|Diet|No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
48026282|NCT04002752|DRUG|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
48026283|NCT04002752|DRUG|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
48026284|NCT04287920|DRUG|Acomprosate|Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
48026285|NCT02663817|DEVICE|CT Scan|
48026286|NCT00507793|DRUG|Sirolimus|
48026287|NCT00507793|DRUG|Cyclosporine|
48026288|NCT00032292|DRUG|Visilizumab|
48026289|NCT04844424|DRUG|Milvexian|Milvexian will be administered orally or via nasogastric route as tablets or capsules.
48026290|NCT06074926|BEHAVIORAL|Associative Conditioning|There will be 3 planned activities per week (9 total) within play kits provided to families. Children will first taste their assigned target vegetable and then complete an activity with their parent following provided instructions. Activity instructions will include positive parenting skills adapted from evidence-based parenting programs (i.e., Parent-Child Interaction Therapy (PCIT) and Triple-P) designed to promote positive parent-child interactions.
48026291|NCT06074926|BEHAVIORAL|Repeated Exposure|There will be 3 planned exposures per week (9 total). Exposures will include only individual tastes of the child's assigned target vegetable.
48026292|NCT01515085|PROCEDURE|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
48026293|NCT02566395|RADIATION|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
48026294|NCT02566395|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
48026295|NCT02566395|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
48026296|NCT02566395|BIOLOGICAL|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
48026297|NCT03251469|DRUG|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
48026298|NCT03251469|DRUG|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
48026299|NCT04462328|DRUG|Durvalumab|Durvalumab will be administered over 60 minutes
48026300|NCT04462328|DRUG|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
48183200|NCT01814072|BEHAVIORAL|Text Messages|Participants will receive regular text messages
48183201|NCT01814072|BEHAVIORAL|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
48183202|NCT01814072|BEHAVIORAL|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
48183203|NCT02432833|DRUG|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
48183204|NCT02432833|DRUG|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
48183205|NCT02432833|DRUG|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
48183206|NCT03088774|OTHER|Information material|Online web-application developed together with patients with low back pain
48183207|NCT01833689|DIETARY_SUPPLEMENT|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
48183208|NCT02165995|PROCEDURE|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
48183209|NCT02165995|PROCEDURE|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
48183210|NCT01592812|DEVICE|electrical muscle stimulation|Duration of the stimulation 20 minutes
48183211|NCT05701904|OTHER|Local mechanical vibration|Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.
48183212|NCT05701904|OTHER|Shotblocker group|It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
48183213|NCT01632189|DRUG|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
48183214|NCT05802927|OTHER|DSF|Diabetes-specific formula
48723165|NCT03469024|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
48723166|NCT02618668|DRUG|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
48723167|NCT02618668|DRUG|Propofol|2 mg/kg I.V
48723168|NCT05577637|DRUG|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily|0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
48723169|NCT01877577|DIETARY_SUPPLEMENT|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
48723170|NCT03420105|OTHER|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
48723171|NCT03420105|DRUG|Hormonotherapy|Adjuvant hormone therapy
48183215|NCT05802927|OTHER|Breakfast 1|Noodle Soup
48183216|NCT05802927|OTHER|Breakfast 2|Glutinous rice
48183217|NCT03117764|DEVICE|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
48723172|NCT05592132|OTHER|Virtual reality headset|Each patient in this treatment group will use a virtual reality headset during 3 procedures. During each procedure, the pain level will be assessed and compared with the assessed group.
48723173|NCT05031078|BIOLOGICAL|Gardasil|"Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap."
48183218|NCT03117764|BEHAVIORAL|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
48183219|NCT03117764|DEVICE|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
48183220|NCT03621605|BIOLOGICAL|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
48723174|NCT05031078|DRUG|Lidocaine injections|"1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg."
48026301|NCT03153917|OTHER|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
48723175|NCT01028170|DRUG|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
48183221|NCT03621605|DRUG|Placebos|Placebo administered by slow IV infusion or SC injection.
48183222|NCT04073342|GENETIC|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
48183223|NCT00475228|DRUG|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D\&E procedure and for arm 2 at 3-6 weeks post-procedurem
48183224|NCT04669769|OTHER|interview|telephone interview
48183225|NCT02039245|DRUG|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
48183226|NCT03940690|DRUG|Anti-VEGF injections of bevacizumab|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)
48723176|NCT01028170|DRUG|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
48723177|NCT03744520|PROCEDURE|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
48723178|NCT04326816|PROCEDURE|Rehabilitation of severely worn dentitions using minimally invasive composite restorations (Estenia C&B or Clearfil AP-X, Kuraray, Osaka, Japan)|
48723179|NCT01571856|DRUG|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
48723180|NCT01571856|OTHER|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
48723181|NCT02393053|PROCEDURE|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
48723182|NCT02393053|PROCEDURE|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
48026302|NCT05146791|PROCEDURE|Inlay Bristow|A modified Bristow procedure
48183227|NCT03940690|DEVICE|Laser|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
48183228|NCT00127361|BEHAVIORAL|doula training|
48183229|NCT02719288|OTHER|CLARIX® CORD 1K graft|
48183230|NCT05921669|BEHAVIORAL|Provide breastfeeding education|Providing breastfeeding education within the first 24 hours after birth
48183231|NCT03338647|DRUG|DEB|Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery
48183232|NCT03338647|RADIATION|SBRT|High precision radiation therapy to the liver tumor(s)
48183233|NCT02738528|OTHER|Mental practice and brushing guidance in patients with Parkinson Disease|
48183234|NCT04678778|BEHAVIORAL|Physical and Cognitive Activity|There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
48183235|NCT04501393|OTHER|Clear liquid intake|Clear oral fluid including water, pulp-free juice and tea or coffee without milk
48183236|NCT00098397|DRUG|romidepsin|Given IV
48723183|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
48183237|NCT00098397|OTHER|laboratory biomarker analysis|Optional correlative studies
48183238|NCT03024892|PROCEDURE|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
48723184|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
48723185|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
48723186|NCT01508845|DIETARY_SUPPLEMENT|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
48183239|NCT03024892|PROCEDURE|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
48723187|NCT05044624|PROCEDURE|retroperitoneal mass excision|retroperitoneal mass excision
48723188|NCT02587546|PROCEDURE|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
48723189|NCT02587546|PROCEDURE|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
48723190|NCT02587546|PROCEDURE|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
48026303|NCT05146791|PROCEDURE|Bristow|Traditional Bristow procedure
48723191|NCT03150732|DRUG|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
48183240|NCT03024892|PROCEDURE|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
48183241|NCT03024892|PROCEDURE|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
48723192|NCT03150732|DRUG|Local nalbuphine|Patients will receive local nalbuphine 10 mg
48723193|NCT06256653|DIETARY_SUPPLEMENT|Freeze-dried blueberries|"* Participants will be supplied with an 8-week supply of Study Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Study Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Study Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
48723194|NCT06256653|DIETARY_SUPPLEMENT|Placebo|"* Participants will be supplied with an 8-week supply of Placebo Product and instructions of dosing.~* Participants will be instructed to mix one sachet of the Placebo Product either to breakfast, or dessert, or mixed with yoghurt daily for the next 56 days, starting on the same day, Day 1.~* Additional product will be supplied in case of delay of study visit or loss of Placebo Product.~* Participants will be provided with a stool collection kit and instructions for collecting and storing. Participants will collect stool samples at home, within 48 hours prior to their visit but preferably the morning, of their scheduled visit and bring it to the clinic.~* Participants will be provided with a urine collection kit and instructions for collecting and storing."
48026304|NCT06534190|RADIATION|89Zr-Df-crefmirlimab PET scan|"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."
48183242|NCT05515783|DRUG|68Ga-FAP-RGD|The dose will be 4-7mCi given intravenously.
48183243|NCT05515783|DRUG|68Ga-FAP-RGD|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
48183244|NCT05828836|DRUG|Allopurinol Tablet|allopurinol300mg once daily
48723195|NCT04070495|DRUG|KW-6356|A single oral dose will be administered at Day 1 and 15
48723196|NCT04070495|DRUG|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
48723197|NCT04070495|DRUG|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
48723198|NCT01283685|OTHER|breathing helium-hyperoxia|40% O2, 60% He
48723199|NCT01283685|OTHER|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
48723200|NCT05058846|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and saliva collection
48026305|NCT06534190|DRUG|Nivolumab|Immunotherapy treatment with Nivolumab
48026306|NCT06534190|DRUG|Cetrelimab|Immunotherapy treatment with cetrelimab
48183245|NCT05828836|DRUG|Placebo|placebo once daily
48183246|NCT04428008|DRUG|Thymalfasin|Synthetic 28 amino acid peptide
48183247|NCT01013961|BIOLOGICAL|alemtuzumab|Given IV
48183248|NCT01013961|BIOLOGICAL|rituximab|Given IV
48183249|NCT00003337|PROCEDURE|immunoscintigraphy|
48723201|NCT05058846|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRCP
48723202|NCT05058846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48183250|NCT00003337|RADIATION|technetium Tc 99m epratuzumab|
48183251|NCT03792347|DRUG|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
48183252|NCT04120376|BEHAVIORAL|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
48183253|NCT01115608|OTHER|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
48723203|NCT05058846|PROCEDURE|Endoscopic ultrasound|Undergo endoscopic ultrasound
48723204|NCT05058846|OTHER|Questionnaires|Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
48723205|NCT05996029|COMBINATION_PRODUCT|Digital Smoking Cessation|The core technology of the study is a smoking cessation assistance practice service driven by a machine learning algorithm. The small programs used by the intervention group in this study included smoking cessation service packages based on cognitive behavioral therapy and online guidance from medical staff on staff, and more digital smoking cessation tools.
48723206|NCT01177969|BEHAVIORAL|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
48723207|NCT01177969|BEHAVIORAL|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
48723208|NCT04946123|DIETARY_SUPPLEMENT|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
48026307|NCT06534190|OTHER|zirconium Zr 89 crefmirlimab berdoxam|89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later
48026308|NCT06108063|DRUG|Losartan|12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
48026309|NCT06108063|DRUG|Placebo - Losartan|Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
48026310|NCT00681317|DRUG|AZD6280|oral
48026311|NCT02661906|OTHER|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
48026312|NCT04968067|DEVICE|App group|In addition to the usual care, the participant will receive a health talk related to CHD care, a CHD app and a briefing from a trained research nurse (A). The app provides features such as structured e-educational contents and supportive features such as knowledge platform and member area.
48183254|NCT00333190|DEVICE|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
48183255|NCT05605639|DRUG|Bupivacaine|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
48723209|NCT04877769|DRUG|AT-527|administered twice daily (BID) for 2.5 days (5 doses in total)
48723210|NCT01379300|DRUG|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
48520730|NCT06295276|OTHER|Waiting list/control intervention/delayed teletherapy intervention|Subjects in the control group will be advised to maintain their daily routine but will be asked to refrain from other treatments to avoid co-interventions during the 6-week study period. However, the use of painkillers such as non-steroidal anti-inflammatory analgesics (NSAIDs) taken by study participants in all groups for more than 3 months is allowed and will be documented (taking a pragmatic approach). Any change in medication will be monitored and documented by the PT at each visit.
48183256|NCT05605639|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
48183257|NCT02405897|DEVICE|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
48183258|NCT02405897|DEVICE|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
48183259|NCT00594022|DEVICE|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
48520731|NCT02486237|OTHER|None, observational study|None, it is an observational study
48723211|NCT01379300|DRUG|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
48723212|NCT00002020|DRUG|Zidovudine|
48723213|NCT01805388|DRUG|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
48723214|NCT01805388|PROCEDURE|Control Non-Study Drug Group|Endodontic RTC with no study drug
48183260|NCT00594022|DEVICE|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
48384849|NCT03500237|BEHAVIORAL|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
48384850|NCT02559778|DRUG|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
48520732|NCT00525980|BEHAVIORAL|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
48520733|NCT00525980|BEHAVIORAL|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
48520734|NCT00525980|OTHER|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
48384851|NCT02559778|DRUG|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
48520735|NCT00525980|BEHAVIORAL|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
48520736|NCT01689051|OTHER|human glucagon-like peptide 1 (7-36)amide|
48520737|NCT01689051|OTHER|human glucagon-like peptide 1 (9-36)amide|
48520738|NCT01207583|OTHER|Non-interventional observational study|Non-interventional observational study
48384852|NCT02559778|DRUG|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
48520739|NCT05627843|DIETARY_SUPPLEMENT|Curcumin capsules 1 gm|Dietary supplement
48520740|NCT05627843|DIETARY_SUPPLEMENT|Placebo capsule|placebo corn starch
48520741|NCT02938143|PROCEDURE|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
48723215|NCT03281889|RADIATION|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
48723216|NCT05933590|DIAGNOSTIC_TEST|Cervical Joint Repositioning Error Assessment|The cervical joint repositioning error assessment is a non-invasive diagnostic test used to measure the ability of an individual to accurately reproduce a specific head position in different orientations (flexion, neutral position, 50% range of motion of left rotation, and 50% range of motion of right rotation). Participants in both the chronic migraine group and the control group will undergo this assessment using a digital inclinometer. The primary outcome of this study is the difference between the initial and repositioned cervical joint angles, measured in degrees.
48723217|NCT03726931|DIAGNOSTIC_TEST|18F-Fluorestradiol PET/CT scan|\[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
48723218|NCT05121324|DRUG|Standardized seizure protocol|The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
48384853|NCT02559778|DRUG|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
48384854|NCT02559778|DRUG|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
48723219|NCT05121324|DRUG|Conventional seizure protocol|"The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg)."
48723220|NCT04683458|DEVICE|Drug-coated device|The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
48384855|NCT02085798|OTHER|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
48384856|NCT05477940|DEVICE|Absorbable zinc alloy drug eluting coronary stent system|"Absorbable zinc alloy drug eluting coronary stent system (hereinafter referred to as stent system) consists of delivery system and drug stent (hereinafter referred to as stent) pressed on the balloon end of the delivery system"
48520742|NCT02938143|PROCEDURE|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
48723221|NCT00214084|DRUG|Allopurinol|
48723222|NCT00751855|BEHAVIORAL|Prolonged Exposure therapy|10 weekly sessions
48723223|NCT00751855|DRUG|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
48723224|NCT00751855|DRUG|placebo|placebo
48723225|NCT03703323|OTHER|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
48723226|NCT06191575|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
48723227|NCT06191575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
48384857|NCT03280563|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
48384858|NCT03280563|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
48384859|NCT03280563|DRUG|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21-day cycle.
48384860|NCT03280563|DRUG|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
48723228|NCT06191575|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
48723229|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.
48723230|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.
48723231|NCT00712803|BIOLOGICAL|rDEN3-3'D4delta30|Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.
48723232|NCT00418587|DRUG|Cholecalciferol|800 IU oral daily
48723233|NCT00418587|DRUG|Cholecalciferol|2000 IU oral daily
48723234|NCT00418587|DRUG|Cholecalciferol|4000 IU oral daily
48384861|NCT03280563|DRUG|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
48384862|NCT03280563|DRUG|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
48384863|NCT03280563|DRUG|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
48384864|NCT03280563|DRUG|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
48384865|NCT05753215|DRUG|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
48384866|NCT05753215|DRUG|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
48384867|NCT06651879|DIAGNOSTIC_TEST|techniques of ultrasound examination of the airway|two different techniques of ultrasound. The techniques are the two views and the five views
48384868|NCT05301894|DRUG|NBI-827104|T-type calcium channel blocker.
48520743|NCT03853031|PROCEDURE|LVEDA cm2 guided intraoperative fluid in TEE /Study Group|Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
48723235|NCT01038713|DEVICE|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
48723236|NCT00542061|DEVICE|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
48723237|NCT02845076|OTHER|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
48723238|NCT01722292|DRUG|LY2940680|Administered orally
48723239|NCT01722292|DRUG|Carboplatin|Administered IV
48723240|NCT01722292|DRUG|Etoposide|Administered IV
48723241|NCT01722292|DRUG|Placebo|Administered orally
48723242|NCT05383534|DRUG|Propofol Injection|propofol injections were used for the induction of anesthesia according to the body weight of the patients.
48723243|NCT02033239|DRUG|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
48723244|NCT02033239|DRUG|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
48723245|NCT03343600|DRUG|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
48723246|NCT03343600|DRUG|Placebo|Placebos 2 tablets daily
48723247|NCT04246814|DEVICE|LG1|Application of LASER AsGa 904nm 10 J/cm².
48723248|NCT04246814|DEVICE|LG2|Application of LASER AsGa 904nm 8 J/cm².
48723249|NCT04246814|DEVICE|LG3|Application of LASER AsGa 904nm 4 J/cm².
48723250|NCT04246814|DEVICE|CC|Application of placebo LASER.
48723251|NCT04246814|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
48723252|NCT05389215|DRUG|DWN12088|DWN12088 Xmg Tablet (BID)
48723253|NCT05389215|DRUG|Placebo|Placebo 0mg Tablet (BID)
48723254|NCT02220114|DRUG|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"* first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~* second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
48723255|NCT01716104|DRUG|Afalaza|Safety and Efficacy
48723256|NCT01716104|DRUG|Placebo|Safety and Efficacy
48723257|NCT00060580|PROCEDURE|Raman scattering spectroscopy|
48723258|NCT02786680|BEHAVIORAL|stroop test in condition DBS off|Patients were evaluated in DBS Off
48723259|NCT02786680|BEHAVIORAL|stroop test in condition DBS on|Patients were evaluated in DBS On
48723260|NCT01733433|PROCEDURE|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
48723261|NCT06259682|BEHAVIORAL|Paradoxical Intention|Paradoxical intention (PI). PI is described as instructing patients with sleep onset insomnia to try to remain awake for as long as possible rather than to focus on trying to fall asleep
48723262|NCT03394690|DIETARY_SUPPLEMENT|green coffee|2 capsuls
48723263|NCT03394690|OTHER|control|2 capsuls
48723264|NCT05678452|PROCEDURE|HOLEP for treating BPH|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.
48723265|NCT04123613|DRUG|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
48723266|NCT03769311|DRUG|Cetuximab|Monoclonal antibody against epidermal growth factor receptor (EGFR)
48723267|NCT01458028|DRUG|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
48723268|NCT01458028|DRUG|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
48723269|NCT03358940|OTHER|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
48723270|NCT02060032|DRUG|1.2% Atorvastatin local drug delivery|
48723271|NCT02060032|DRUG|1.2% simvastatin local drug delivery|
48723272|NCT02060032|DRUG|Placebo local drug delivery|
48723273|NCT00975143|DRUG|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
48723274|NCT00975143|DRUG|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
48723275|NCT04253457|DRUG|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
48026313|NCT04968067|DEVICE|Nursing telephone advice (NTA) group|All subjects will continue their usual care with prescribed medical treatments and follow-ups if any. By appointment, a trained nurse will provide a health talk related to the CHD care. In addition to the above usual care, three monthly 20-minute telephone follow-ups supplemented by take home leaflet will be provided by a trained research nurse for up to 3 months. Patients can ask about their related health problems, if any. The team has set up a telephone advice guide to support the research nurse in giving phone advice and text messages. .In summary, all two groups will receive from a nurse similar educational content as that related to their CHD and care. The only difference will be the re-enforcement and continual support provided through an app, telephone nursing advice and leaflet.
48384869|NCT06061848|DRUG|SLIT Grazax ALK Nordic 75 000 SQ-T|Daily sublingual grass allergen tablets
48384870|NCT06061848|DRUG|ILIT + Vitamin D|1 mL of Vicotrat D3, Heyl Pharma, 100 000 IU/mL, as intramuscular injection. Followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
48384871|NCT06061848|DRUG|ILIT + placebo|1 ml of Sodium chloride solution 9 mg/mL as intramuscular injection followed by 0,1 mL of Alutard SQ timothy, ALK Nordic, 10 000 SQ-U/mL as three intralymphatic injections
48183261|NCT04952480|RADIATION|Dose-escalated adaptive radiotherapy|Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk.
48384872|NCT05281328|DRUG|CAM2029|SC injection using a pre-filled pen
48723276|NCT05164588|OTHER|Statistics|Study and analyze the medicolegal aspects of different eye trauma cases ( patterns of injuries, mechanisms, causes, site of trauma and outcome)
48723277|NCT02078648|DRUG|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated)."
48723278|NCT02078648|DRUG|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
48723279|NCT02078648|DRUG|SL-701 + GM-CSF|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site."
48723280|NCT02078648|DRUG|Imiquimod|Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
48723281|NCT03879421|PROCEDURE|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
48723282|NCT02526108|OTHER|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
48723283|NCT02184832|DRUG|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
48723284|NCT02184832|OTHER|Low tryptophan diet|
48026314|NCT00278707|DRUG|GTA: Glyceryltriacetate|
48026315|NCT02945865|OTHER|Pain assessment|Pain assessment with assessment tools
48183262|NCT04952480|DRUG|Chemotherapy|Concurrent standard of care platinum doublet based therapy
48183263|NCT03327831|DRUG|Aminolevulinic Acid|Topical application followed by activation by ambient sunlight
48183264|NCT04232267|DEVICE|MEB-001|Software medical device used to aid in the screening of patients with potential depressive burden symptoms.
48384873|NCT05281328|DRUG|Placebo|SC injection using a pre-filled pen
48723285|NCT02184832|OTHER|High tryptophan diet|
48384874|NCT02246855|BIOLOGICAL|Gammaplex® (Human Normal Immunoglobulin)|
48384875|NCT04163328|DRUG|HydroEye®|This is an omega-3 fatty acids supplement.
48384876|NCT03972709|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
48183265|NCT01607541|BEHAVIORAL|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
48384877|NCT03972709|DRUG|Sham Control|Sham control
48384878|NCT06425601|DEVICE|SIL drain|Silicone chest tube used for pleural space drainage after VATS lobectomy
48384879|NCT06425601|DEVICE|PVC drain|Polyvinyl chloride chest tube used for pleural space drainage after VATS lobectomy
48384880|NCT05397119|BIOLOGICAL|BW-1014: 25 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
48384881|NCT05397119|BIOLOGICAL|BW-1014: 50 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
48384882|NCT05397119|BIOLOGICAL|BW-1014: 100 µg rH5 in 20% NE - pipette - IN|20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
48183266|NCT01607541|BEHAVIORAL|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
48183267|NCT01915797|OTHER|blood and tumor samples|all tumor pathology associated with anomaly of development
48723286|NCT05922241|OTHER|Costophrenic assisted cough|Therapist places the hands on the costophrenic angles of the patient's rib cage. During the patient's inspiration, the therapist applies a series of three repeated quick-stretch contractions down and in to encourage maximal inspiration. At the end of expiration, the therapist applies a quick stretch down and in on the patient's lower chest to facilitate a stronger diaphragmatic and intercostal muscle contraction. While instructing the patient to cough, the therapist applies strong pressure through the hands in toward the central tendon of the patient's diaphragm
48183268|NCT04199468|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
48183269|NCT04199468|DRUG|Placebo Delta-9-THC|A placebo dose given intravenously (IV)
48183270|NCT04199468|DRUG|Active Ketamine|Active Ketamine (0.2 mg/kg) given intravenously (IV)
48183271|NCT04199468|DRUG|Placebo Ketamine|A placebo dose given intravenously (IV)
48183272|NCT04199286|PROCEDURE|symmetrical and asymmetrical horizontal strabismus surgery|surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
48183273|NCT01896726|DRUG|Baricitinib|Administered orally
48183274|NCT01896726|DRUG|Microgynon|Administered orally
48183275|NCT00102024|DRUG|Unconjugated IDEC-159|
48384883|NCT05397119|BIOLOGICAL|rH5 (100 µg) control - pipette - IN|100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
48384884|NCT05397119|BIOLOGICAL|Saline (Placebo) - pipette - IN|Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart
48723287|NCT05922241|OTHER|Anterior chest compression|The therapist puts one arm across the patient's pectoral region to stabilize or compress the upper chest while the other arm is placed either parallel on the lower chest or abdomen below the xiphoid process
48723288|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
48723289|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
48723290|NCT00228865|PROCEDURE|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
48723291|NCT00228865|PROCEDURE|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
48183276|NCT00102024|DRUG|111In-IDEC-159|
48520744|NCT03853031|PROCEDURE|CVP guided intraoperative fluid in CVP / Control group|Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
48520745|NCT02087657|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
48520746|NCT00676702|DIETARY_SUPPLEMENT|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
48183277|NCT00102024|DRUG|90Y-IDEC-159|
48520747|NCT00676702|DRUG|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
48520748|NCT05857683|PROCEDURE|cextension pin block|this is the technique for mallet finger where 2 pins are used, one for the extension block and other intramedullary for the extension posture
48183278|NCT04011007|PROCEDURE|vitrectomy with or without inverted ILM flap technique|vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
48183279|NCT01932476|DIETARY_SUPPLEMENT|Gluten Challenge|Three-day gluten containing dietary challenge.
48183280|NCT01932476|DIETARY_SUPPLEMENT|Sham Challenge|Three-day sham (gluten free) dietary challenge
48183281|NCT02191904|OTHER|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
48183282|NCT04099654|OTHER|Core-Stabilization Exercise|A program consisting of core stabilization exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
48183283|NCT04099654|OTHER|Counseling of physical activity|Only physical activity counseling will be given to the subjects in this group.
48183284|NCT05490212|OTHER|Single Molecule Array (SiMoA)|The Single Molecule Array (SiMoA), capable of quantifying multiple salivary cytokines from a single sample source at a femtoscale level. The SiMoA platform has been adapted to detect up to nine inflammatory biomarkers, including CRP, PCT, tumor necrosis factor α (TNF α) and ILs 1ß, 6, and 8 in neonatal saliva.
48183285|NCT02595372|DRUG|Omeprazole|
48384885|NCT05397119|BIOLOGICAL|H5N1 IIV - IM|90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization
48520749|NCT05857683|PROCEDURE|pin orthosis- extension block pin|this is the technique for mallet finger where only 1 pin is used for extension block and an orthosis is applied for the extension posture
48520750|NCT01105364|DRUG|antiangiogenesis therapy|
48520751|NCT01105364|DRUG|stabilized sulphur hexafluoride microbubble-based contrast agent|
48520752|NCT01105364|OTHER|imaging biomarker analysis|
48520753|NCT01105364|OTHER|pharmacological study|
48520754|NCT01105364|PROCEDURE|computed tomography|
48520755|NCT01105364|PROCEDURE|magnetic resonance imaging|
48520756|NCT05365802|DRUG|68Ga-FAPi-46|Radiopharmaceutical will be administered via IV
48520757|NCT05365802|PROCEDURE|Computed Tomography|As part of PET/CT scan
48520758|NCT05365802|PROCEDURE|Positron Emission Tomography|As part of PET/CT scan
48723292|NCT04566406|PROCEDURE|Laparoscopic adrenalectomy|Preoperative staging in all cases consisted of computed tomography or/and magnetic resonance imaging. Prior to surgery, a routine panel of laboratory tests was carried out. The catecholamines metabolites (metanephrine, normetanephrine, and methoxytyramine) were measured from 24-hour urine collection. All patients were preoperatively treated with phenoxybenzamine or alternative doxazosin.Additionally, beta-blockers in case of coexisting tachycardia were given. In the morning of the operation, preinduction blood pressure was measured. Pneumoperitoneum was achieved by insufflating CO2 gas to an intraperitoneal pressure of 12 mmHg. The operative method in our department was laparoscopic transperitoneal lateral total adrenalectomy. Intraoperatively SBP and diastolic blood pressure (DBP) were measured and recorded every 10 minutes. To treat hypertensive and hypotensive episodes, intravenous doses of urapidil, ephedrine, nitrates, MgSO4, norepinephrine, or ß-blockers were administered.
48723293|NCT02929082|RADIATION|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
48723294|NCT03433534|OTHER|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
48723295|NCT03051594|DEVICE|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
48723296|NCT03051594|OTHER|caries detector dye|dye used to detect the residual caries.
48723297|NCT03051594|DIAGNOSTIC_TEST|visual tactile assessment|method usually used to detect the residual caries.
48026316|NCT06019650|BEHAVIORAL|ECMAP|The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
48026317|NCT00725426|DRUG|Bosutinib|
48026318|NCT04091399|DRUG|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
48026319|NCT00882674|DRUG|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
48026320|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
48183286|NCT03653000|PROCEDURE|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
48026321|NCT00898677|DRUG|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
48026322|NCT00898677|DRUG|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
48026323|NCT00898677|DRUG|Comparator: Placebo|placebo to rizatriptan
48026324|NCT06381479|DIETARY_SUPPLEMENT|probiotics|each capsule contains Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, 2 caps daily use
48026325|NCT06381479|DIETARY_SUPPLEMENT|placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
48183287|NCT03653000|DRUG|local anaesthetic injection|Local anesthetic injection (ropivacaine) at this new site
48183288|NCT00577135|DRUG|Furosemide-Q12 hour bolus|Q12 hours bolus
48026326|NCT04069572|DEVICE|Vibrotactile Stimulation|Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
48026327|NCT04069572|DEVICE|Sham Stimulation|Low-frequency sham of VCR stimulation
48026328|NCT01024127|OTHER|Laboratory Biomarker Analysis|Correlative studies
48026329|NCT05451303|DEVICE|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
48183289|NCT00577135|DRUG|Furosemide-Continuous Infusion|Continuous infusion
48723298|NCT06507475|DRUG|Semaglutide|Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
48723299|NCT04845139|DRUG|Nivolumab|Nivolumab given intraventricularly
48723300|NCT02663141|DRUG|Losartan|
48723301|NCT02663141|DRUG|Intravitreal bevacizumab|
48723302|NCT02663141|DRUG|Placebo|
48723303|NCT02790814|DEVICE|Moyo strap-on|Continous measurements
48723304|NCT02790814|DEVICE|Hand-held fetoscope|Intermittent measurements
48723305|NCT04797806|DRUG|Anlotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle.
48384886|NCT02964910|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
48384887|NCT02449109|PROCEDURE|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
48723306|NCT04797806|DRUG|Icotinib|Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
48520759|NCT05365802|PROCEDURE|High Resolution Computed Tomography|Will be conducted immediately after FAPI PET/CT
48520760|NCT04320823|DEVICE|Updated Plasma Collection Feature|Plasma collection using a novel, patented system that supports a more individualized collection approach.
48520761|NCT04320823|DEVICE|Current Plasma Collection Approach|Plasma collection using the current collection approach.
48723307|NCT04455945|PROCEDURE|Open Rectal cancer surgery|Open sphincter preserving surgery for rectal cancer
48723308|NCT04455945|PROCEDURE|Laparoscopic Rectal cancer surgery|Laparoscopic sphincter preserving surgery for rectal cancer
48384888|NCT06568315|DIETARY_SUPPLEMENT|Concurrent multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement providing 30 mg elemental iron and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate together every morning from enrollment through the end of pregnancy
48520762|NCT03225417|DRUG|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
48520763|NCT03225417|DRUG|Tacrolimus|Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
48520764|NCT03225417|DRUG|Sirolimus|Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
48520765|NCT03225417|DRUG|Any prophylaxis for GVHD|Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
48520766|NCT06036186|DEVICE|BaroPacing treatment|BaroPacing for the first 3 weeks (day 8 to day 28) and then crossover to standard treatment for another 3 weeks (day 29 to day 49).
48520767|NCT06036186|DEVICE|Standard treatment|Individual Standard treatment as prescribed by the Physician to each subject for the first 3 weeks (day 8 to day 28) and then crossover to BaroPacing for another 3 weeks (day 29 to day 49).
48520768|NCT03788343|DIETARY_SUPPLEMENT|Phenylalanine|The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
48723309|NCT02672592|DRUG|Anakinra|Anakinra 100mg s.c. bid
48723310|NCT02672592|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
48384889|NCT06568315|DIETARY_SUPPLEMENT|Separate multiple micronutrient and calcium supplementation|Participants counseled to take United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) multiple micronutrient supplement (MMS) providing 30 mg elemental iron every morning and calcium supplement providing 500 mg elemental calcium as 1250 mg calcium carbonate every evening from enrollment through the end of pregnancy
48723311|NCT02099305|OTHER|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
48723312|NCT04499911|DRUG|Isotonic dextrose 5% in water solution|The isotonic dextrose 5% in water solution (a total volume of about 5 ml). Subcutaneous perineural injection of dextrose (5%) in sterile water was given once. The injection was administered by using the Lyftgot technique of neural prolotherapy on the lateral aspect of the thigh along the tender areas.
48723313|NCT04228432|OTHER|Dedicated and coordinated monitoring|"* Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6."
48723314|NCT04608162|OTHER|Pulsed Electromagnetic Field (PEMF)|PEMF was administered to the whole body using a 1.8×0.6m mat
48723315|NCT04608162|OTHER|Exercise Program|Exercise program to facilitate bone health
48026330|NCT02346565|PROCEDURE|Exercise ECG|
48026331|NCT02346565|PROCEDURE|Stress Echocardiography|
48026332|NCT05051241|DRUG|GFH018|Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
48026333|NCT00353275|DRUG|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
48026334|NCT00353275|DRUG|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
48723316|NCT04608162|OTHER|Placebo PEMF|Patients received placebo PEMF
48723317|NCT00594594|OTHER|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
48723318|NCT00850941|BEHAVIORAL|Questionnaire|Information collection.
48723319|NCT04336527|BEHAVIORAL|Home Treatment with Peer Support|After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.
48723320|NCT04336527|BEHAVIORAL|Home Treatment without Peer Support|After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).
48723321|NCT03546335|DRUG|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
48183290|NCT00577135|DRUG|Furosemide-Low Intensification|1x oral dose
48723322|NCT04874090|OTHER|Acupuncture|Investigator will apply the acupuncture treatment to the first group to the neck area. BL-15, BL-18, BL-23, BL-25, KB-4, Du-20, GB-20, CV-14, KB-10, Ex-26, Yin Tang, Ah-shi points will be used. 0.25x25 mm, sterile, steel, disposable, acupuncture needle will be used for acupuncture points and painful trigger points. The treatment will be applied twice a week, on average 10 sessions. Dry needling treatment will be applied to the patients by a certified physician. All patient will be performed the neck exercises program
48723323|NCT04874090|OTHER|Exercises|Patient will perform neck exercises
48723324|NCT02035722|BEHAVIORAL|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
48723325|NCT02035722|BEHAVIORAL|Video|AMD-related information is presented as in the form of a video
48723326|NCT01657760|DRUG|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
48723327|NCT04302064|DRUG|Eplontersen|Eplontersen administered SC
48723328|NCT04302064|DRUG|Placebo|Eplontersen-matching placebo administered SC
48026335|NCT03965052|DRUG|PRO 179|"* Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
48723329|NCT02498990|BEHAVIORAL|Low calorie diet followed by life style intervention|"1. Low calorie diet of 800 kcal/day for 7 weeks.~2. Life style intervention for the remaining study period"
48723330|NCT00351962|PROCEDURE|Fractionated Stereotactic Radiotherapy|
48723331|NCT03233126|DRUG|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
48723332|NCT02025439|DEVICE|rTMS|
48723333|NCT02025439|DRUG|Amantadine|
48723334|NCT06020443|PROCEDURE|Low Dose chest CT Scan for Lung Cancer Screening|Low dose CT scans will be performed for three years
48723335|NCT02258529|DRUG|Idelalisib|150 tablets administered orally twice daily
48723336|NCT02258529|BIOLOGICAL|Rituximab|375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
48723337|NCT00787215|OTHER|observational: no treatment involved|observational: no treatment involved
48723338|NCT06066073|DRUG|Lavender Oil|Twenty drops of lavender oil was added the distal water which fill the vaporizer which were placed in the waiting room. The patients inhaled the vapors of the lavender oil 20 minutes before starting the dental procedures
48723339|NCT06066073|DRUG|Distal Water|The patients inhaled vapors of the distal water in the waiting room 20 minutes before starting dental procedures
48723340|NCT00689793|DRUG|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
48723341|NCT00689793|DRUG|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
48026336|NCT03965052|DRUG|Travatan 0.004 % Ophthalmic Solution|"* Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe."
48026337|NCT06347419|OTHER|Physiotherapy evaluation|In the physiotherapy evaluation, patients' spinal stability, rotary stability, and body awareness will be assessed.
48183291|NCT00577135|DRUG|Furosemide-High Intensification|2.5x oral dose
48384890|NCT06429891|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
48723342|NCT00845065|DRUG|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
48723343|NCT00845065|OTHER|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
48723344|NCT00845065|BIOLOGICAL|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
48723345|NCT00845065|DRUG|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
48723346|NCT00994994|DRUG|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
48723347|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
48723348|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
48723349|NCT00605891|DRUG|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
48723350|NCT00605891|DRUG|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
48723351|NCT00605891|DRUG|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
48723352|NCT04942990|OTHER|calisthenic exercises|these exercises are a kind of exercise for increasing cardiovascular endurance
48723353|NCT03127423|PROCEDURE|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
48723354|NCT03127423|PROCEDURE|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
48723355|NCT02496923|DEVICE|High flow nasal oxygen therapy (Optiflow™)|
48723356|NCT02496923|DEVICE|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
48723357|NCT03664804|OTHER|No Study Drug was Administered in this Study|No study drug was administered in this study
48723358|NCT05363540|PROCEDURE|pre-incisional parasternal intercostal block|LA will be administrated by the anesthesiologist under ultrasound guidance and before surgical incision On either side of thorax, 2 cm lateral to sternal edge from 2nd to 6th intercostal space, A volume of (4 mL) of 0.25% bupivacaine will be used
48384891|NCT04796168|PROCEDURE|Splinting (plaster of paris)|Placing stockinette followed by cotton rolls and 10-12 layer of posterior ankle splint made of plaster of paris
48723359|NCT05363540|PROCEDURE|post-incisional parasternal intercostal block|LA will be administered by the cardiac surgeon before the sternal closure. injection will introduced 2 cm lateral to sternal edge from 2nd to 6th intercostal space and volume (4 mL) of 0.25% bupivacaine will be used.
48723360|NCT02570880|OTHER|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products - Determination of the glycaemic index (GI) and recommendation for food classification
48723361|NCT05141955|OTHER|Group Erector Spinae Plane Block (ESPB)|"Patients will receive general anesthesia initially then bilateral ESPB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed (not exceeding toxic dose) 150 mg "
48723362|NCT05141955|OTHER|Group Quadratus Lumborum Block (QLB)|"Patients will receive general anesthesia initially then bilateral QLB with a total volume of (0.3-0.4 ml/kg LBW) of bupivacaine 0.25% will be performed not exceeding toxic dose150 mg "
48723363|NCT05141955|OTHER|Group (C) (Control group)|Where patients will be operated under general anesthesia.
48723364|NCT03850002|OTHER|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
48723365|NCT05105815|BIOLOGICAL|IPM001|IPM001 will be used against tumor cells
48723366|NCT03886155|PROCEDURE|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
48723367|NCT05728281|OTHER|Recommended time after hysterectomy|Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
48723368|NCT05002387|DEVICE|NanoScope™ Operative Arthroscopy (Arthrex, Inc)|Needle arthroscopy will be performed in the operating room to visual the medial, lateral, and patellofemoral compartments prior to undergoing either unicompartmental or total knee arthroplasty
48723369|NCT02950844|OTHER|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
48723370|NCT06295705|BEHAVIORAL|Hip-Hop Dance|"I. Week 1 - Session 1~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Hip-Hop~4. Cool-Down: Deep Breathing~5. Debrief Check-In~II. Week 2 - Session 2~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Locking~4. Cool-Down: Instructed Yoga~5. Debrief Check-In~III. Week 3 - Session 3~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Breaking~4. Cool-Down: Sensory Time~5. Debrief Check-In~IV. Week 4 - Session 4~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Popping~4. Cool-Down: Animal Deep Breathing~5. Debrief Check-In~V. Week 5 - Session 5~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Learn Showcase Routine~4. Cool-Down: Animal Instructed Yoga~5. Debrief Check-In~VI. Week 6 - Session 6~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Review Showcase Routine~4. Cool-Down: Sensory Time~5. Debrief Check-In~VII. Week 7 - Dance Showcase"
48723371|NCT02739516|DRUG|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
48723372|NCT02739516|DRUG|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
48723373|NCT02739516|DRUG|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
48384892|NCT06054750|DRUG|Ropivacaine|800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)
48384893|NCT06054750|DRUG|Normal saline|400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
48384894|NCT03004430|BEHAVIORAL|Mantra Meditation|Silent mantra meditation with spiritual mantra
48384895|NCT03004430|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation
48384896|NCT05671991|DRUG|Empagliflozin 25 mg vs Placebo|Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
48026338|NCT03549689|DRUG|Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)|Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
48026339|NCT03549689|DRUG|Current tenofovir alafenamide (TAF)-containing ART regimen|Continuation of current TAF-containing ART for 96 weeks.
48026340|NCT02699281|DRUG|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
48026341|NCT02699281|DRUG|Placebo|um-PEA like placebo twice a day
48723374|NCT06267066|DRUG|Betamethasone Valerate 0.1% Cream|Moderate potency
48723375|NCT06267066|DEVICE|SmartXide® fractional carbon dioxide laser|Ablative
48723376|NCT06267066|DRUG|Vaseline Topical Product|Emollient
48723377|NCT03528005|BEHAVIORAL|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
48723378|NCT01498016|DRUG|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
48723379|NCT00084656|BIOLOGICAL|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
48723380|NCT00084656|BIOLOGICAL|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A\*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
48723381|NCT05327504|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.
48723382|NCT05327504|BEHAVIORAL|Neutral Topic Writing|Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
48026342|NCT04125693|DRUG|Rogaratinib (BAY1163877)|Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
48026343|NCT04125693|DRUG|Combination drug|Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
48026344|NCT01806480|BEHAVIORAL|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
48026345|NCT00533390|DRUG|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
48026346|NCT00010517|PROCEDURE|Acupuncture|
48723383|NCT00958737|DRUG|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
48723384|NCT00958737|DRUG|CAPOX|4 or 8 cycles
48723385|NCT02504931|DRUG|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
48723386|NCT02504931|DRUG|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
48026347|NCT02790385|DEVICE|Negative Pressure Wound Therapy|
48026348|NCT02790385|OTHER|Standard Gauze Treatment|
48026349|NCT05234398|BIOLOGICAL|Blood and saliva samplings|At each protocol visits, on the occasion of a care collection, additional blood and saliva samples will be taken specifically for the study, with a total volume of blood of 38 mL, and a saliva sample of 1.5 to 2 mL per visit (inclusion, month 1, month 4, month 6, month 9 and month 12), corresponding to routine care.
48026350|NCT01462734|PROCEDURE|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
48026351|NCT00005853|BIOLOGICAL|anti-thymocyte globulin|
48026352|NCT00005853|BIOLOGICAL|etanercept|
48026353|NCT04889560|OTHER|Experimental group|Home-based version of a computerized cognitive training (CoRe)
48026354|NCT04889560|OTHER|Control group|Computerized cognitive training (CoRe)
48723387|NCT06337591|PROCEDURE|VI-RADS|Patients with suspected bladder cancer underwent multiparametric magnetic resonance imaging (mMRI) and vescical imaging reporting and data system (VI-RADS) score calculation. After trans-urethral resection of bladder (TURB), the results of biopsy were compared to the VI-RADS score to verify their concordance.
48723388|NCT04195386|PROCEDURE|Dental Restoration with Chemically activated Composite resin Alkasite|Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
48723389|NCT04195386|PROCEDURE|Dental Restoration with Resin-Modified Glass ionomer Cement|Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
48723390|NCT01533922|DRUG|Placebo|placebo matching tiotropium + olodaterol FDC
48384897|NCT05671991|DRUG|Empagliflozin 10 MG|Chronic Study- Empagliflozin 10 mg for 8 weeks
48384898|NCT06575348|DEVICE|YouControl-A-Fib mHealth Application|Participants will use the app for 3 months, includes 1 month phone call with Health Coach
48723391|NCT01533922|DRUG|Tiotropium|Tiotropium 5 mcg once daily
48723392|NCT01533922|DRUG|Olodaterol|Olodaterol 5 mcg once daily
48723393|NCT01533922|DRUG|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
48384899|NCT02601326|PROCEDURE|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
48723394|NCT01533922|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
48384900|NCT02601326|PROCEDURE|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
48384901|NCT06650319|BIOLOGICAL|intravenous LY-M003|The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.
48384902|NCT02133911|DRUG|Ranolazine|
48384903|NCT06179290|OTHER|Ploom HTP Menthol HTS; MX3 (681)|Menthol heated tobacco product
48384904|NCT06179290|OTHER|Ploom HTP Tobacco HTS; R8 (120)|Non-menthol heated tobacco product
48384905|NCT06179290|OTHER|Smoking Abstinence (menthol)|No smoking or other tobacco product use for duration of the study, menthol group comparator
48384906|NCT06179290|OTHER|Smoking Abstinence (non-menthol)|No smoking or other tobacco product use for duration of the study, non-menthol group comparator
48723395|NCT01533922|DEVICE|Respimat|Respimat inhaler
48723396|NCT02887547|PROCEDURE|micro-osteoperforation|
48723397|NCT05026853|BEHAVIORAL|PRO Integration into Clinical Practice|HCPs will document their discussion and recommendations/referrals in MiChart (Epic EMR)
48723398|NCT04512508|DIAGNOSTIC_TEST|Self test sample|Self test sample, DNA analysis, Biopsy and Anoscopy
48723399|NCT05322330|DRUG|Selinexor|40-60mg QW,w-3～d-3,PO
48723400|NCT05322330|DRUG|Flu|25-30 mg/m2，d-5 ～d-3，qd，ivgtt
48723401|NCT05322330|DRUG|CTX|250-500 mg/m2，d-5 ～d-3，qd，ivgtt
48026355|NCT03732092|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
48026356|NCT01673334|DEVICE|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
48026357|NCT05392634|DRUG|Meropenem 1000 mg|Group B: prolonged antibiotic prophylaxis \>72 hours (5 days) from the moment of the skin incision in accordance with the selected clinic drug + correction of the appointment based on clinical events after 5 days.
48026358|NCT05392634|DRUG|Amoxicillin+clavulanic acid 1200 mg or Cefuroksim 1500mg|Group A: antibiotic prophylaxis within 24 hours from the moment of skin incision according to local clinical practice;
48026359|NCT01594905|DRUG|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
48026360|NCT00813930|BEHAVIORAL|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
48026361|NCT05275777|DRUG|ADG106|Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
48026362|NCT05275777|DRUG|Doxorubicin|Administered as an intravenous infusion.
48026363|NCT05275777|DRUG|Cyclophosphamide|Administered as an intravenous infusion.
48026364|NCT05275777|DRUG|Paclitaxel|Administered as an intravenous infusion.
48183292|NCT06402942|OTHER|Gamified occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
48183293|NCT06402942|OTHER|Classic occupational therapy programme|Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
48183294|NCT05020145|BIOLOGICAL|BNT162b2 (Tozinameran)|Covid-19 Vaccine
48183295|NCT03502577|BIOLOGICAL|BCMA-specific CAR-expressing T Lymphocytes|Receive CAR T infusion
48183296|NCT03502577|DRUG|Cyclophosphamide|Given IV
48183297|NCT03502577|DRUG|Fludarabine|Given IV
48183298|NCT03502577|DRUG|Gamma-Secretase Inhibitor LY3039478|Given PO
48723402|NCT05322330|DRUG|CAR-T|2-5×10\^6 CAR-T/kg，ivgtt。
48723403|NCT01105455|OTHER|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
48723404|NCT00899158|OTHER|immunologic technique|
48723405|NCT00899158|OTHER|laboratory biomarker analysis|
48384907|NCT03231709|DRUG|Trelagliptin|Trelagliptin tablets
48384908|NCT03231709|DRUG|Alogliptin|Alogliptin tablets
48384909|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
48384910|NCT06156761|DRUG|Capecitabine|Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
48384911|NCT06156761|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.
48384912|NCT06156761|DRUG|Capecitabine|Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
48723406|NCT00899158|PROCEDURE|biopsy|
48723407|NCT05469139|DIAGNOSTIC_TEST|Portable MRI acquisition|Patients on ECMO will undergo a portable MRI of the brain
48723408|NCT02367404|DRUG|Duloxetine|Duloxetine 60mg OD for 3 months
48723409|NCT02367404|BEHAVIORAL|Pelvic Floor Muscle Training|PMFT weekly for 3 months
48723410|NCT01364740|DEVICE|PMP-300E|Data collected from Level 3 device
48723411|NCT01364740|DEVICE|In-lab PSG|Data collected from Type I In-Lab Polysomnography
48723412|NCT03489512|DRUG|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
48723413|NCT03489512|DRUG|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
48723414|NCT03576313|DRUG|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
48723415|NCT03576313|DRUG|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
48723416|NCT03576313|OTHER|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
48183299|NCT03502577|OTHER|Laboratory Biomarker Analysis|Correlative studies
48723417|NCT03120377|OTHER|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
48183300|NCT03502577|OTHER|Pharmacokinetic Study|Correlative studies
48384913|NCT05146609|BEHAVIORAL|Screening HCV. HR-HOSPITAL|Screening HCV in high risk population by themselves or at referral hospital.
48384914|NCT05146609|BEHAVIORAL|Screening HCV. HR-DDP|Screening HCV in high risk population by themselves or at drug dependence center.
48384915|NCT05146609|BEHAVIORAL|Screening HCV. GP-HOSPITAL|Screening HCV in general population by themselves or at referral hospital.
48520769|NCT03788343|DRUG|Placebo|Placebo capsules are indistinguishable in their appearance from Phe capsules
48723418|NCT03120377|OTHER|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
48723419|NCT03976999|OTHER|Biological collection|"* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
48723420|NCT05011799|BEHAVIORAL|Cancer Educational Materials|Receive prostate cancer educational materials
48723421|NCT05011799|OTHER|Questionnaire Administration|Ancillary studies
48384916|NCT05146609|BEHAVIORAL|Screening HCV. GP-PCC|Screening HCV in general population by themselves or at primary care center.
48520770|NCT04080466|RADIATION|Low-dose CT Scan|"Low dose computed tomography, also known as qCT, is sensitive to the mineral content within bone tissue, and can assess bone mineral density, a strong predictor of bone strength and stiffness, which can influence the health of the cartilage. Participants will undergo a low dose CT scan of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
48723422|NCT05011799|OTHER|Educational Intervention|Attend peer-led education sessions
48723423|NCT04325230|DEVICE|Arterial Spin Labeling sequence|ASL sequence added to the usual care brain MRI
48723424|NCT03969017|DRUG|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg \<0.05IU/ml, with a maximum duration of 48 weeks.
48723425|NCT03969017|DRUG|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
48723426|NCT00909740|DRUG|MEGF0444A|Intravenous escalating dose
48723427|NCT01057485|PROCEDURE|AF ablation and AV node ablation|AF ablation and AV node ablation
48723428|NCT01057485|PROCEDURE|AV node ablation|AV node ablation
48723429|NCT05781360|DRUG|SIM0237|SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
48723430|NCT03693911|BEHAVIORAL|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
48723431|NCT03922178|DEVICE|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
48723432|NCT03922178|DEVICE|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
48723433|NCT03922178|DEVICE|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
48723434|NCT00205816|DRUG|Tigecycline|
48723435|NCT00625638|BEHAVIORAL|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
48723436|NCT00625638|OTHER|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
48723437|NCT04161781|DRUG|18F-BMS-986229 Injection|Single injection prior to scan
48723438|NCT04161781|DRUG|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
48723439|NCT04161781|DIAGNOSTIC_TEST|PET/CT Scan|Whole-body PET/CT (80 mA)
48723440|NCT04094584|DRUG|Vivitrol (Extended Release Naltrexone)|Monthly Injections of 380mg Extended-Release Naltrexone, case management services as needed tailored to the individual participant
48723441|NCT00498121|DEVICE|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
48723442|NCT00388284|DEVICE|Arterial Sealing|
48723443|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with in person meetings.
48723444|NCT03389737|BEHAVIORAL|Counseling|Counseling on healthy behaviors with emails.
48026365|NCT00811083|DRUG|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
48723445|NCT05364762|DRUG|Cyclophosphamide|Given IV
48723446|NCT05364762|DRUG|Itacitinib|Given PO
48723447|NCT05364762|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell infusion
48723448|NCT05364762|OTHER|Quality-of-Life Assessment|Ancillary studies
48723449|NCT05364762|DRUG|Tacrolimus|Given IV or PO
48723450|NCT00003711|DRUG|irinotecan hydrochloride|
48723451|NCT00003711|DRUG|pemetrexed disodium|
48723452|NCT02519569|OTHER|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
48026366|NCT03089190|DIETARY_SUPPLEMENT|DC7-2|Effects on appetite
48026367|NCT03089190|DIETARY_SUPPLEMENT|DC7-2 + potato protein isolate|Effects on appetite
48026368|NCT03089190|DIETARY_SUPPLEMENT|Potato protein isolate|Effects on appetite
48026369|NCT03089190|DIETARY_SUPPLEMENT|Placebo|Inactive whey protein, not expected to affect appetite.
48026370|NCT01551862|PROCEDURE|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
48384917|NCT05518565|OTHER|No intervention|No intervention
48384918|NCT06564961|DRUG|Clomiphene Citrate|50 mg tab once daily
48384919|NCT06564961|DRUG|Placebo|1 tab once daily
48384920|NCT03162016|PROCEDURE|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
48723453|NCT04566692|BIOLOGICAL|IGSC 20%|SC infusion pump.
48723454|NCT00683969|DRUG|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
48723455|NCT00683969|DRUG|placebo|po bid for 36 weeks
48723456|NCT06491810|OTHER|Arm crank exercise|The arm ergometer exercise will be the only intervention implemented during the study.
48723457|NCT06027021|DIAGNOSTIC_TEST|18F-Fluoromisonidazole PET|Imaging of hypoxia before radioembolization with 18F-Fluoromisonidazole PET.
48723458|NCT06219421|OTHER|Clinical data reuse|Clinical data reuse
48723459|NCT03016923|DEVICE|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
48384921|NCT05545449|BEHAVIORAL|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
48384922|NCT00058045|BIOLOGICAL|aldesleukin|
48384923|NCT00058045|BIOLOGICAL|recombinant human stem cell factor|
48723460|NCT00521222|DRUG|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
48723461|NCT00521222|DRUG|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
48723462|NCT00521222|DRUG|Ipratropium HFA|Primary as-needed rescue medication in all treatment groups
48723463|NCT00521222|DRUG|Albuterol HFA|Secondary as-needed rescue medication in all treatment groups
48723464|NCT00006094|DRUG|oxaliplatin|Given IV
48723465|NCT00006094|DRUG|fluorouracil|Given IV
48026371|NCT03765879|OTHER|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of themselves receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
48026372|NCT03765879|OTHER|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of themselves receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
48026373|NCT00210834|DRUG|epoetin alfa|
48026374|NCT05888376|DEVICE|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
48026375|NCT02099006|DRUG|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
48026376|NCT02099006|DRUG|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
48026377|NCT02099006|DRUG|Ketoprofen|To be applied topically at a 10% concentration
48026378|NCT02099006|DRUG|Ketamine|To be applied topically at a 10% concentration
48026379|NCT02099006|DRUG|Loperamide|To be applied topically at a 5% concentration
48723466|NCT00006094|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
48723467|NCT01493856|DRUG|Cresto|tablet, rosuvastatin 20mg
48723468|NCT01493856|DRUG|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
48723469|NCT01493856|DRUG|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
48384924|NCT01906931|DEVICE|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
48723470|NCT03462953|PROCEDURE|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~1. Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~2. Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
48723471|NCT01274429|DRUG|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
48384925|NCT01906931|DEVICE|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
48723472|NCT01589913|BEHAVIORAL|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~1. Introduction to participants and online system~2. Knowledge regarding ICDs~3. Strategies for behavior change~4. Psychological models for anxiety and depression~5. Strategies to cope with avoidance, anxiety and depression~6. Resume, evaluation, resolution of open questions, goal setting, good bye"
48723473|NCT03570346|DRUG|Hemay005|Subjects will be randomized into 3 dose groups orally twice daily.
48723474|NCT03570346|DRUG|Placebo|Subjects will be randomized into 3 dose groups orally twice daily.
48723475|NCT03143751|DRUG|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (\<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ \< 145 mmol/L; 7.5 g if 145 \< Na+ \< 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+\< 150 mmol/L, reduced to 0.5 g/L if 150 \< Na+ \< 155 mmol/L, Discontinuation when 155 mmol/L\<Na+"
48723476|NCT01442805|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
48723477|NCT01442805|BEHAVIORAL|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
48723478|NCT01714258|PROCEDURE|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
48723479|NCT03150784|OTHER|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
48723480|NCT04023617|DRUG|Nivolumab|Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
48723481|NCT00468403|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
48723482|NCT00468403|BIOLOGICAL|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
48026380|NCT02099006|DRUG|Gabapentin|To be applied topically at a 6% concentration
48384926|NCT06622824|DRUG|KX-826 0.5% BID|0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
48723483|NCT00468403|BIOLOGICAL|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
48026381|NCT02099006|DRUG|placebo|Compounding base to be used alone as a placebo
48384927|NCT06622824|DRUG|KX-826 1.0% BID|1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
48026382|NCT02599168|DRUG|Propofol|
48026383|NCT02599168|DRUG|Dexmedetomidine|
48026384|NCT02599168|DRUG|Placebo (normal saline)|
48026385|NCT04991753|OTHER|Placebo|Placebo infusion will be administered intravenously.
48026386|NCT04991753|DRUG|Nipocalimab|Nipocalimab infusions will be administered intravenously.
48026387|NCT03778736|OTHER|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
48026388|NCT01591746|DRUG|Botulinum Toxin Type A|
48026389|NCT01591746|DRUG|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
48026390|NCT06475157|OTHER|No intervention|No intervention is applied.
48026391|NCT00019682|BIOLOGICAL|Aldesleukin|Given IV
48026392|NCT00019682|BIOLOGICAL|gp100 Antigen|Given SC
48026393|NCT00019682|DRUG|Montanide ISA 51 VG|Given SC
48026394|NCT00019682|OTHER|Quality-of-Life Assessment|Ancillary studies
48384928|NCT06622824|DRUG|Vehicle (Placebo) applied BID|Matching placebo applied topically to scalp twice daily for 24 weeks
48723484|NCT00468403|DRUG|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
48183301|NCT02694042|BEHAVIORAL|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
48723485|NCT00468403|DRUG|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
48723486|NCT00468403|PROCEDURE|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant\[s\]) will occur intraportally.
48384931|NCT04513925|DRUG|Atezolizumab|Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
48384932|NCT04513925|DRUG|Tiragolumab|Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
48384933|NCT04513925|DRUG|Durvalumab|Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.
48384935|NCT06652815|BEHAVIORAL|Suicide ideation or suicide attempt|Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
48384936|NCT02049931|DEVICE|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
48384937|NCT02049931|DEVICE|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
48384938|NCT02049931|DEVICE|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
48384939|NCT02780115|DRUG|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
48384940|NCT02780115|DRUG|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
48384941|NCT02780115|DRUG|AGN-199201 Vehicle|Vehicle to AGN-199201
48384942|NCT02780115|DRUG|AGN-190584 Vehicle|Vehicle to AGN-190584
48384943|NCT06651710|OTHER|Zynamite|Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.
48384944|NCT01445236|OTHER|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
48384945|NCT01096862|DRUG|peficitinib|oral
48384946|NCT01096862|DRUG|Placebo|oral
48723487|NCT00872729|DRUG|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
48723488|NCT00872729|DRUG|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
48723489|NCT02447809|DRUG|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)\* 12 month.
48723490|NCT02447809|DRUG|acetylsalicylic acid (ASA)|
48183302|NCT06133634|DIETARY_SUPPLEMENT|Fisetin|Fisetin dietary supplement
48384947|NCT05888649|BEHAVIORAL|Community Clusters|Assessment of the determinants for community preparedness to EVD outbreaks and acceptance of EVD vaccines.
48723491|NCT02605317|OTHER|WhatsApp|Consultations used WhatsApp Messenger
48384948|NCT00544349|BIOLOGICAL|cetuximab|
48384949|NCT00544349|DRUG|fluorouracil|
48384950|NCT00544349|DRUG|leucovorin calcium|
48384951|NCT00544349|DRUG|oxaliplatin|
48384952|NCT00989807|DRUG|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
48384953|NCT01294709|DRUG|telcagepant|
48384954|NCT01294709|DRUG|Placebo to telcagepant|
48384955|NCT02191930|DRUG|B-CAP|
48723492|NCT00768482|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
48723493|NCT00768482|DRUG|Sublingual Buprenorphine|16 mg/day, QD
48723494|NCT00795288|DRUG|Simvastatin, 80 mg/day for 21 days|Active treatment group
48183303|NCT06133634|OTHER|Placebo|Placebo capsules identical in appearance to fisetin capsules
48384956|NCT02191930|DRUG|Brentuximab Vedotin|
48384957|NCT05163548|DEVICE|PerQseal Plus Device|Percutaneous closure of femoral artery access site created by 14 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing Percutaneous Transcatheter procedures.
48384958|NCT03388528|DIETARY_SUPPLEMENT|Low Residue Diet Intervention|All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
48384959|NCT02008552|GENETIC|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
48384960|NCT03906929|DEVICE|buried intramedullary K-wire|Using of buried kirschner wire in pediatric forearm fixation
48384961|NCT03906929|DEVICE|exposed intramedullary K-wire|Using of exposed kirschner wire in pediatric forearm fixation
48723495|NCT00795288|DRUG|placebo|Control group
48026395|NCT00019682|OTHER|Questionnaire Administration|Ancillary studies
48026396|NCT00019682|OTHER|Laboratory Biomarker Analysis|Correlative studies
48026397|NCT03203213|PROCEDURE|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
48026398|NCT04425083|OTHER|no intervention|no intervention
48026399|NCT03342534|DEVICE|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
48384962|NCT04092257|PROCEDURE|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
48384963|NCT06568523|DIAGNOSTIC_TEST|MAGENTIQ-COLO.|This is a diagnostic performance study; no randomization will be conducted. All subjects will undergo the same study procedures. The endoscopist performing the examinations cannot be blinded for the output of the investigational device in this study. Due to the nature of the intervention, it is not guaranteed that the patient is not awake during the procedure, therefore blinding for the patient is also not feasible.
48384964|NCT03434873|OTHER|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
48384965|NCT04724070|GENETIC|NGS, PDO/PDX establishment|Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
48384966|NCT01003470|OTHER|acupuncture|Xing Nao Kai Qiao Acupuncture
48384967|NCT01003470|BEHAVIORAL|rehabilitation|Kinesitherapy
48384968|NCT01003470|OTHER|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
48384969|NCT03519152|DRUG|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
48026400|NCT01979653|DRUG|dexmedetomidine alone or dexmedetomidine + midazolam|
48026401|NCT01337089|DRUG|Nabiximols|
48026402|NCT01504438|DEVICE|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
48026403|NCT01504438|DEVICE|STAR Total Ankle Replacement|STAR Total Ankle Replacement
48384970|NCT04962659|BEHAVIORAL|Mindfulness-Based Music and Songwriting|The Mindfulness-Based Music and Songwriting (MBMS) program involves up to 8 weekly sessions (\~1 hour each) delivered via telehealth. During sessions, the participant works with a therapist (e.g., board-certified music therapist) to learn and apply mindfulness practices via music-based meditations and mindful songwriting. Supported by the therapist, participants write two songs during the program.
48384971|NCT01965015|DEVICE|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
48384972|NCT05378269|DRUG|Tamoxifen|Tamoxifen vaginal insert
48384973|NCT05378269|OTHER|Placebo|Placebo vaginal insert
48384974|NCT05959824|DEVICE|OR-AT0222|Topical viscous gel containing tamarind seed polysaccharide and isolated pea proteins will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
48026404|NCT00426075|DEVICE|Elastic stockings|
48026405|NCT04660357|OTHER|survey study|survey study
48384975|NCT05959824|OTHER|Placebo|Topical placebo viscous gel will be used 3 times a day away from the main meals (breakfast lunch and dinner) for 7 days.
48384976|NCT05326997|DEVICE|Photobiomodulation group|Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.
48723496|NCT01657708|OTHER|Shared Decision Making|
48723497|NCT02858921|DRUG|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
48723498|NCT02858921|DRUG|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
48026406|NCT01219738|DRUG|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
48026407|NCT01219738|DRUG|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
48026408|NCT01219738|DRUG|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
48026409|NCT01219738|DRUG|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
48026410|NCT01219738|DRUG|Placebo|A single inhaled dose of placebo from a DPI.
48026411|NCT02813031|OTHER|Functional meat products|
48026412|NCT02813031|OTHER|Traditional meat products|
48384977|NCT05326997|OTHER|Group control (Tranexamic acid)|Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
48384978|NCT04365907|DRUG|Zafatek tablets|Once weekly new anti-diabetic drug approved only in Japan
48384979|NCT01153685|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
48384980|NCT04546737|OTHER|Magnetic Resonance Spectroscopy (MRS).|This is a Nuclear Magnetic Resonance (NMR) technique which can detect the NMR signal allowing to measure under curves areas, amplitudes, ratios and concentrations of various metabolites contained in a biological tissue, in addition to water and lipids. This offers the possibility, in addition to the contribution of MRI imaging, to better characterize pathological processes (inflammatory, infectious, etc.) through spectral and metabolic changes that can be quantitatively evaluated. Spectroscopic measurements will be carried out with a mono-voxel spectroscopy using a PRESS \[Point RESolved Spectroscopy\] sequence with a short Echo Time (TE) of 35 ms, an intermediate TE of 144 ms and a long TE of 288 ms.
48384981|NCT03881605|DIAGNOSTIC_TEST|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
48384982|NCT02651974|BEHAVIORAL|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
48384983|NCT02651974|BEHAVIORAL|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
48384984|NCT02651974|BEHAVIORAL|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
48384985|NCT06626568|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4
48384986|NCT06626568|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.
48384987|NCT06626568|OTHER|Normal Saline as Placebo (ultrasound-guided subacromial injection)|ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.
48384988|NCT06626568|OTHER|Normal Saline as Placebo (gluteal muscle inection)|gluteal injection of 5 ml normal saline at week 0,2,4.
48384989|NCT06626568|BEHAVIORAL|home exercise|The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.
48384990|NCT03003793|DIAGNOSTIC_TEST|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
48384991|NCT06505213|OTHER|no intervention|no intervention
48384992|NCT03953157|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary intervention
48384993|NCT03953157|BEHAVIORAL|Exercise Intervention|Receive exercise intervention
48723499|NCT02858921|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
48026413|NCT06402435|DRUG|Lvonescimab (AK112)|8Gy\*3 SBRT (continuous irradiation) to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT (continuous irradiation) irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK112 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, Q3W) were administered, followed by four cycles of sequential Doxorubicin 50mg/m2 (Q3W) + Cyclophosphamide 600mg/m2 (Q3W) for 4 cycles.The immunotherapy drug used was Lvonescimab (AK112).
48723500|NCT00005875|DRUG|rubitecan|
48723501|NCT02760810|DEVICE|Marketed Contact Lens|Narafilcon A
48026414|NCT00472667|PROCEDURE|Procalcitonin guided strategy|Procalcitonin guided strategy
48026415|NCT02448784|DRUG|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
48384994|NCT03953157|OTHER|Questionnaire Administration|Ancillary studies
48384995|NCT04188678|OTHER|Bone Marrow Transplant (BMT)|Bone marrow transplantation will be conducted according to the investigators' institution's standard of care, or else according to research protocol (if applicable).Study visits that include the performance of assessments will occur prior to the start of conditioning chemotherapy and at 1 month and 6 months post-BMT. All dates are +/- 7 days. The initial study visit will take place during standard of care pre-transplant evaluations, which typically span 3-4 days. The post-BMT visits will take place before or after regularly-scheduled BMT follow up.
48384996|NCT06649864|DRUG|Autologous adipose derived mesenchymal stromal cells (AMSC)|Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.
48384997|NCT00249600|BEHAVIORAL|Contingency management|
48384998|NCT01950325|BIOLOGICAL|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
48723502|NCT06260969|DEVICE|balloon dilatation|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
48723503|NCT06522399|PROCEDURE|TAMIS mucosectomy|internal Delorme's procedure using TAMIS
48183304|NCT05090189|OTHER|Exercise Training|"The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week blocks, which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period."
48183305|NCT01199978|RADIATION|Fractionated proton radiation|Given daily for approximately 5.5 weeks
48183306|NCT01199978|DRUG|Losartan|25mg or 50mg daily, oral administration, for approximately 6 months.
48183307|NCT03624387|OTHER|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
48183308|NCT01972997|DEVICE|SENSIMED Triggerfish|
48183309|NCT00854204|DRUG|TMC114; TMC41629|
48520771|NCT04080466|OTHER|Blood/Urine Collection|"Collection of blood and urine allows the researchers to look for a biomarker in the blood and urine that might help to predict the evolution of disease/hip osteoarthritis. Identifying a marker in the blood and urine that could be used for early detection of individuals with cam deformity that are at-risk of hip degeneration could greatly improve patient care.~Participants in the Cam Group will undergo the blood and urine collection twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo a blood and urine collection once as part of the study."
48520772|NCT04080466|OTHER|Patient Reported Questionnaires|"The purpose of the questionnaires is to assess how much trouble the participant is having with their hip and how it affects their quality of life.~Participants in the Cam Group will complete the questionnaires twice; once before surgery and once 2-years post-operative. Participants in the Control Group will complete the questionnaires once as part of the study."
48520773|NCT04080466|RADIATION|EOS Scan|"The EOS® uses a new imaging technique that allows precise measurement of the hip and pelvis geometry and structure. This innovative x-ray technique exposes participants to 2-10 times less radiation than a routine x-ray and can capture multiple images at once.~Participants in the Cam Group will undergo the EOS scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
48723504|NCT01130090|DEVICE|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
48723505|NCT05087719|COMBINATION_PRODUCT|experimental group|patients will receive the hot pack initially for 15 minutes .Then for proprioception training of graphesthesia for 15 mints,stereognosis will be of 15 minutes. For motor training patients will practice 15 mints motor tasks
48723506|NCT05087719|COMBINATION_PRODUCT|conventional treatment|patients will receive the baseline treatment of hot pack for 15 minutes. The patients in this group will get muscle strengthening exercise of the hand, Range of motion, and stretching of the hand muscles, 3 sets of 8 repetitions were given to the patient, gap of 2 minutes will be given between regimes. For 20 minutes this session will be given to patient by the therapist.
48723507|NCT00000713|DRUG|Ampligen|
48723508|NCT00671437|PROCEDURE|FDG-PET/CT|
48723509|NCT00671437|DRUG|Cetuximab|
48723510|NCT03987906|BEHAVIORAL|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
48723511|NCT00162266|DRUG|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
48723512|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
48723513|NCT00162266|DRUG|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
48183310|NCT00884650|DRUG|oral analgesic|per clinical standard of care
48183311|NCT00884650|DRUG|intravenous analgesic per pump|per clinical standard of care
48723514|NCT00162266|DRUG|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
48723515|NCT05628207|OTHER|Observational|There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
48723516|NCT05628207|OTHER|Observational-control|There is no intervention, the hospitals will not use the CDS system.
48026416|NCT03359096|DEVICE|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
48723517|NCT01062061|BIOLOGICAL|VARIVAX™|Attenuated live varicella vaccine
48026417|NCT03359096|DEVICE|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
48520774|NCT04080466|RADIATION|PET-MRI|"Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that allows physicians to examine bone and cartilage at the molecular level.~Participants in the Cam Group will undergo the scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
48520775|NCT04080466|OTHER|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Participants in the Cam Group will undergo the Motion Analysis session twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the Motion Analysis session once as part of the study."
48520776|NCT04080466|RADIATION|3T MRI|"Participants will undergo a 3-Tesla (3T) Magnetic Resonance Imaging (MRI) of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
48520777|NCT06188221|DRUG|Lidocaine|The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
48520778|NCT06188221|DRUG|Corticoids|The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
48520779|NCT03159247|BEHAVIORAL|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
48520780|NCT06441123|BIOLOGICAL|Blood Sampling|20 ml of blood (5 tubes of 4 ml) will be collected once.
48520781|NCT02495662|DRUG|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
48520782|NCT02495662|DRUG|Placebo|0.9% normal saline
48520783|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48520784|NCT06237296|BIOLOGICAL|RSV/hMPV mRNA LNP 2|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48520785|NCT06237296|BIOLOGICAL|RSV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48520786|NCT06237296|BIOLOGICAL|hMPV mRNA LNP 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
48026418|NCT04317300|DRUG|Varenicline|Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
48026419|NCT04317300|OTHER|brief behavioral therapy|brief behavioral therapy
48183312|NCT02422680|PROCEDURE|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
48520787|NCT02277535|OTHER|Feedback/Reminder email.|
48520788|NCT01894087|BEHAVIORAL|TBI - Cohort 1|
48520789|NCT01894087|BEHAVIORAL|TBI - Cohort 2|
48723518|NCT01655147|DRUG|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
48723519|NCT01655147|DRUG|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
48723520|NCT03843801|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.
48723521|NCT03204422|OTHER|No intervention|no any other intervention
48723522|NCT03787992|DRUG|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
48723523|NCT03787992|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
48520790|NCT02502032|DRUG|Cisatracurium|Different groups received different pretreatments of cisatracurium.
48520791|NCT02636218|DRUG|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
48520792|NCT02636218|DRUG|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
48384999|NCT02187939|OTHER|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
48385000|NCT04035993|OTHER|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycaemic state (5.0-8.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level between 2.0-2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at the hypoglycaemic level for 30 minutes. Thereafter, it will be raised again and kept stable for another 30 minutes at an euglycaemic level between 5.0-8.0mmol/L. During the procedure, we will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, an eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
48385001|NCT05538663|DRUG|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
48385002|NCT05538663|DRUG|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
48385003|NCT05538663|DRUG|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
48385004|NCT01019109|DEVICE|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
48520793|NCT05327933|PROCEDURE|Surgery plus endovascular MMA embolization|A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.
48520794|NCT05327933|PROCEDURE|Surgery alone|Evacuation of cSDH
48520795|NCT02748148|OTHER|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
48520796|NCT03963193|DRUG|Etoposide|Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.
48520797|NCT03963193|DRUG|Irinotecan|Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
48520798|NCT04891757|DRUG|FHD-286|FHD-286 administered orally
48520799|NCT04891757|DRUG|Low Dose Cytarabine|LDAC administered subcutaneously (SC)
48520800|NCT04891757|DRUG|Decitabine|Decitabine administered intravenously
48520801|NCT05800886|OTHER|Early mobilization and tea consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
48723524|NCT03787992|DRUG|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
48723525|NCT03787992|DRUG|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
48026420|NCT05492136|PROCEDURE|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
48026421|NCT03330834|BIOLOGICAL|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
48026422|NCT04857359|DRUG|Dipraglurant|Oral 50mg and 100mg tablet
48026423|NCT04857359|DRUG|Placebo|Oral matching placebo tablet
48385005|NCT04203888|OTHER|Swedish Massage|60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.
48385006|NCT04203888|OTHER|Yoga|"60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005)."
48385007|NCT00132600|DRUG|bacitracin (allergen)|
48723526|NCT04713332|DIETARY_SUPPLEMENT|Vitamin E|Members of the vitamin E family are hydrophobic fat-soluble compounds found in a variety of food sources such as vegetable oils, fruits, and vegetables consumed through diet. Vitamin E exists in 8 isoforms, a, b, g, d-tocopherol, and a, b, g, d-tocotrienol. The recommended daily allowance for adults is 15 mg per day for alpha-tocopherol, an amount which is easily met by dietary sources, and 30 mg per day for synthetic all-rac-alpha-tocopherol. The upper limit for intake is 1,000 mg per day. Very often, the dosage of vitamin E is given in international units (IU) as capsules, with a typical dose being 400 IU per day, which is above the recommended daily allowance. The health benefits of consuming vitamin E through diet or supplementation are believed to be for its antioxidant properties as a peroxyl radical scavenger. Vitamin E protects cells from cell damage caused by free radicals that damage cell membranes through lipid oxidation leading to DNA damage and cancer development.
48723527|NCT04713332|DIETARY_SUPPLEMENT|Hydrogen rich water|Molecular hydrogen is a new medical gas that can be dissolved in water and administered through drinking, inhalation, baths, intravenous drip. A growing body of evidence indicates that hydrogen, as a novel antioxidant, scavenges hydroxyl radical and peroxynitrite. In contrast to other antioxidants, gaseous molecular hydrogen efficiently penetrates cytoplasmic membranes and targets intracellular organelles, largely owing to its small size and neutral electricity. Thus, hydrogen has been suggested as a suitable candidate for the therapeutic strategies for various diseases, including certain types of cancer. Hydrogen has emerged as a promising cancer remedy as a preventative agent or in combined therapy with anticancer drugs. Hydrogen water consumption might mitigate the side effects of anticancer drugs by decreasing oxidative stress and ameliorating metamorphosis due to decreased apoptosis.
48723528|NCT04713332|DIETARY_SUPPLEMENT|placebo|Placebo containing gelatin is made by cooking down the protein collagen found in the skin, hooves, connective tissues, and bones of animals. The cooking process breaks down the bonds between proteins to make smaller, more bioavailable building blocks that your body can easily absorb. Like collagen, gelatin is packed with beneficial amino acids, especially the anti-aging superstar's glycine and proline, which are lacking in the standard Western diet. These amino acids make gelatin especially powerful for healing skin, gut, and joint damage. Because collagen and gelatin come from the same source, they have identical amino acid profiles
48723529|NCT00213096|DRUG|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
48723530|NCT04030247|DRUG|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
48723531|NCT05245214|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Muscle analysis by Magnetic Resonance Imaging
48723532|NCT03678233|DRUG|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
48723533|NCT03492931|DRUG|Ticagrelor|Patients will receive a single dose of ticagrelor
48723534|NCT06334614|DEVICE|iReach|The iReach Device group will take part in playful multisensory motor and spatial activities for one month both at the clinic and at home with the medical device iReach.
48723535|NCT04049929|DRUG|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (\>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
48723536|NCT00721539|DEVICE|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
48723537|NCT00721539|PROCEDURE|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
48183313|NCT00294411|PROCEDURE|elective cesarean section|
48183314|NCT03530137|BEHAVIORAL|Healthy Home|An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The
48385008|NCT06653400|PROCEDURE|paracervical block|paracervical block with office hysteroscopy
48520802|NCT05800886|OTHER|Early mobilization and coffee consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
48723538|NCT01836081|OTHER|Volume expansion|
48723539|NCT01640665|DRUG|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
48520803|NCT05800886|OTHER|Early mobilization and warm water consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
48385009|NCT06653400|DRUG|Lidocaine|Dosage: 20 mL of 1% lidocaine
48520804|NCT05800886|OTHER|Ongoing treatment|The first mobilization and oral intake of the patients in the control group started at the 8th hour.
48385010|NCT06653400|DRUG|ketorolac|Dosage: 2 mL (30 mg) of ketorolac
48385011|NCT05312801|DRUG|BAFF CAR-T|Autologous CAR-T cell therapy expressing the BAFF-ligand.
48385012|NCT04275830|BEHAVIORAL|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
48723540|NCT01640665|DRUG|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
48723541|NCT00771615|BIOLOGICAL|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
48723542|NCT04395287|BEHAVIORAL|Leisure screen time|Questionnaire-based assessment of typical amount of time per week spent using screen-based media devices during leisure, assessed at two time points. Continuously scaled in main analyses; a difference is computed (18-month follow-up value minus baseline value). Additionally, screen time amount at the two time points will be scaled categorically, according to being classified as low or high according to WHO criteria for preschool children (Low (recommended): \<=1 hour/day, high: \>1 hour/day): High-high, high-low, low-high, and low-low.
48723543|NCT02412059|DRUG|Prednisolone acetate|
48723544|NCT05822050|DRUG|Selinexor|XPO1 inhibitor
48520805|NCT02926066|DRUG|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
48723545|NCT02887755|DEVICE|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
48026424|NCT03910335|DIAGNOSTIC_TEST|LSS Screen|Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
48026425|NCT00003457|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
48026426|NCT04621448|BEHAVIORAL|Moving Together|"Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being."
48026427|NCT01455441|OTHER|Training and liraglutide|
48026428|NCT01455441|OTHER|Training and placebo|
48026429|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 1
48183315|NCT03530137|BEHAVIORAL|Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).|ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.
48520806|NCT06033937|DEVICE|PFO occlusion|Patients in PFO occlusion group received PFO closure using devices.
48520807|NCT00168779|DRUG|telmisartan 80 mg / hydrochlorothiazide 25 mg|
48520808|NCT00168779|DRUG|valsartan 160 mg / hydrochlorothiazide 25 mg|
48520809|NCT00168779|DRUG|placebo|
48723546|NCT03809910|DEVICE|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
48723547|NCT03809910|DEVICE|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
48723548|NCT03809910|DEVICE|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
48026430|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 2
48026431|NCT01363323|DRUG|Methylnaltrexone (MNTX)|Dose 3
48723549|NCT03809910|DEVICE|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
48385013|NCT04275830|BEHAVIORAL|Heart rate variability biofeedback|"Participants randomized to the intervention arm will receive exactly the same four digital stories via REDCap, a standardized HRV sensor and accompanying smart phone app, and a 30-minute HRVB training to use the biofeedback signals to generate a resonant frequency pattern of HRV (coherence) after collecting data at baseline in person. Participants will be given a take-home manual and specifically asked to practice their HRVB skills at home for 5 minutes prior to viewing stories once each week and upload a log of their time practiced to the cloud. The main purpose of adding HRVB practice as a priming experience (i.e., to teach participants to practice HRV prior to viewing stories) is to optimize results by focusing patients' and caregivers' skills and experience on HRV as a mechanism of improved emotion regulation, and then combine this achieved coherent pattern with DS intervention."
48520810|NCT00842673|DRUG|ST101|30 mg; administered once/day
48723550|NCT05296031|DEVICE|Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
48723551|NCT05296031|DEVICE|Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions|Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
48723552|NCT03959982|DEVICE|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
48723553|NCT03959982|DIAGNOSTIC_TEST|Spirometry|Pre and post spirometry using albuterol.
48723554|NCT03959982|DIAGNOSTIC_TEST|6-minute walk|6-minute walk
48723555|NCT03959982|DIAGNOSTIC_TEST|CT scan|CT scan
48520811|NCT00842673|DRUG|ST101|90 mg; administered once/day
48520812|NCT00842673|DRUG|ST101|180 mg; administered once/day
48520813|NCT00842673|DRUG|Placebo|placebo to match ST101 tablets
48723556|NCT03959982|OTHER|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
48723557|NCT03959982|OTHER|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
48723558|NCT03959982|OTHER|COPD Assessment Test (CAT)|CAT questionnaire
48723559|NCT03959982|OTHER|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
48723560|NCT03959982|OTHER|CASA-Q|CASA-Q questionnaire
48723561|NCT03959982|OTHER|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
48723562|NCT00745797|RADIATION|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
48723563|NCT05538390|OTHER||
48026432|NCT01363323|DRUG|Placebo|
48026433|NCT01363323|DRUG|Moxifloxacin|
48723564|NCT03199391|DEVICE|BioWick SureLock Implant|The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
48723565|NCT00086411|DRUG|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
48723566|NCT00086411|DRUG|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
48723567|NCT00086411|BEHAVIORAL|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
48723568|NCT00086411|BEHAVIORAL|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
48723569|NCT00086411|DRUG|placebo patch|placebo patch containing no nicotine
48026434|NCT01895465|DEVICE|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
48520814|NCT06582199|OTHER|Blood sample|Plasma, DNA, RNA and PBMC Sampling
48520815|NCT06582199|BEHAVIORAL|Neuropsychological battery tests|"* Short term memory: Digit span (forward and backward)~* Long term memory: Free and Cued selective reminding Test~* Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40)~* Praxis~* Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test~* Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB)~* Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL)~* Mood and anxiety: Hospital Anxiety and Depression Scale (HADS)~* Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)"
48520816|NCT01088230|OTHER|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
48520817|NCT01088230|OTHER|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
48723570|NCT00086411|DRUG|placebo bupropion|placebo pills
48723571|NCT06344260|PROCEDURE|human Neural Stem Cells (hNSC)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
48723572|NCT06344260|PROCEDURE|Saline (Placebo)|The patient is placed on a regular operating room table with or without rigid head fixation. Procedure will be performed whether under general anesthesia or sedation and local anesthesia. Image guidance will be registered using the frameless stereotactic AxiEM system. Image guidance will be used to perform ventricular cannulation with the catheter passed over an electromagnetic-tipped stylet, which is recognized and tracked by the navigation system. The correct placement of the catheter is verified by the egress of CSF. Finally the electromagnetic stylet will be removed and a Rickam reservoir connect to ventricular catheter. Operative time will be about 30 minute. A post-operative CT scan will be obtained in all patients to confirm the catheter position.
48723573|NCT06264284|PROCEDURE|epidural anesthesia|Emergency cesarean section (red code) with epidural anesthesia
48723574|NCT06264284|PROCEDURE|general anesthesia|Emergency cesarean section (red code) with general anesthesia
48723575|NCT05683015|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.
48026435|NCT04908891|OTHER|Clinical Scapular protocol (ClinScaP)|the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.
48026436|NCT04908891|OTHER|the prevalence of trunk, scapula and upper limb impairments.|To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
48026437|NCT04908891|OTHER|the interaction between trunk, scapula and upper limb impairments.|To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
48723576|NCT05683015|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
48723577|NCT04844086|BIOLOGICAL|RPM CD19-mbIL15-CAR-T cells|"Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion"
48723578|NCT03444012|DRUG|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
48520818|NCT02456740|DRUG|Erenumab|Administered by subcutaneous injection once a month
48520819|NCT02456740|DRUG|Placebo|Administered by subcutaneous injection once a month
48520820|NCT00054795|DRUG|Motexafin Gadolinium|
48520821|NCT06281951|DRUG|Fentanyl - Inhalation by facial nebulization|3 administrations based on a weight-dependent threshold (40 µg per administration for a weight \< 70kg and 50 µg per administration for a weight ≥ 70kg).
48520822|NCT06281951|DRUG|Fentanyl - Nebulisation|3 administrations based on a weight-dependent threshold (20 µg/administration and for a weight \< 70kg and 30 µg/administration for a weight ≥ 70kg). The dose of each bolus will be distributed at equivalent volume in both nasal pits
48723579|NCT05614921|OTHER|ultrasound guided external oblique intercostal plane block|ultrasound guided external oblique intercostal plane block 30 ml local anesthetic each side
48723580|NCT05614921|OTHER|Wound infiltration|5 ml local anesthetic for each trocar side
48723581|NCT02406729|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
48723582|NCT02406729|OTHER|Placebo|Route:subcutaneous
48026438|NCT01410838|OTHER|Broth|200 mL of sodium chloride containing broth, consumed three times per day
48026439|NCT01410838|OTHER|Broth|200 mL of MSG containing broth consumed three times per day
48026440|NCT06268912|PROCEDURE|Cold Mepivacaine|change the temperature, 3% at 5ºC
48026441|NCT06268912|PROCEDURE|Mepivacaine at room temperature|no change the temperature of anesthesia
48026442|NCT02632578|BIOLOGICAL|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
48026443|NCT06293937|BEHAVIORAL|Numerical label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
48026444|NCT06293937|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
48723583|NCT04896372|OTHER|ACT comprehensive of standard care|"The proposed intervention was designed by the authors of the study. It was developed following the main ACT-based manuals, with adjustments according to the users and the context of the study implementation.~Specifically, we developed a practical and interactive intervention, which comprises practical activities such as roleplay and writing activities and imaginative activities supported by metaphors. The sessions are based on the use of age-appropriate language to convey the most complex therapeutic processes easily. According to Strosahl and colleagues' model, sessions will respectively target the components of openness, awareness, and engagement."
48723584|NCT04896372|OTHER|TAU only|adolescents will be assessed by a staff dietician and placed on an individualized hy-pocaloric balanced Mediterranean diet. They will also follow a nutritional counselling aimed at promoting the adoption of a healthy lifestyle. Moreover, they will attend a physical activity program consisting of five training sessions per week lasting one hour each with trainers; In addition, they will be involved in psychological counselling pro-vided once a week by a clinical psychologist, aimed to address psychological factors related to dysfunctional lifestyle habits.
48520823|NCT03422614|DIAGNOSTIC_TEST|Diagnostic Test|Characterisation of cellular and functional phenotype in different PIDs
48026445|NCT06293937|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
48026446|NCT06293937|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
48520824|NCT00408525|DRUG|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
48723585|NCT01551524|BIOLOGICAL|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
48520825|NCT06383455|PROCEDURE|Non-surgical periodontal therapy|An ultrasonic device (Cavitron Plus, Dentsply®, Duisburg, Germany) and periodontal hand instruments (periodontal curettes; Chicago, IL) were used for non-surgical periodontal treatment. The treatment procedure also included detailed oral hygiene instructions and full-mouth scaling and root planing. Scaling and root planing (SRP) was applied to all four quadrants under local anesthesia in a single appointment. No medication or mouthwash was prescribed to the patients.
48520826|NCT00017693|BIOLOGICAL|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
48723586|NCT04753021|OTHER|Exercise|Progressively increasing training load
48723587|NCT03615014|OTHER|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
48723588|NCT03839758|PROCEDURE|TSA standard|Glenoid preparation will be done with 2D CT-Scan
48723589|NCT03839758|PROCEDURE|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
48723590|NCT03839758|PROCEDURE|TSA Blueprint|Glenoid preparation will be done with Blueprint software
48723591|NCT03839758|PROCEDURE|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
48723592|NCT02913768|DRUG|Ondansetron|
48723593|NCT02913768|DRUG|Normal saline|
48723594|NCT04515524|OTHER|Non-Interventional|No study treatment will be administered in this study
48723595|NCT05633329|PROCEDURE|single level|injection of 40 ml bupivacaine 0.25 at T8 (20 ml on each side)
48723596|NCT05633329|PROCEDURE|dual level|injection of 40 ml of bupivacaine 0.25 at two level T7 and T9 (10 ml on each level of both side)
48723597|NCT04295863|DRUG|Nivolumab Standard|For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
48723598|NCT04295863|DRUG|Pembrolizumab Standard|For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
48520827|NCT00017693|BIOLOGICAL|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
48026447|NCT03531593|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
48026448|NCT01705457|DRUG|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
48026449|NCT01705457|DRUG|placebo|
48026450|NCT04994366|OTHER|Thank you card|A card thanking the patient for choosing NYU and entrusting us with their care. The card notifies the patient that they may receive a patient satisfaction survey after discharge.
48026451|NCT03434717|OTHER|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
48026452|NCT03434717|OTHER|Care as usual|Patients will get care as usual
48026453|NCT04755595|DRUG|Botox Cosmetic Injectable Product|Acetylcholine release inhibitor and a neuromuscular blocking agent
48026454|NCT04755595|DEVICE|Juvéderm Voluma XC|Gel implants consisting of cross-linked hyaluronic acid
48520828|NCT02177461|DRUG|Telmisartan|
48520829|NCT02177461|DRUG|Enalapril|
48026455|NCT04755595|DEVICE|Juvéderm Volbella XC|Gel implants consisting of cross-linked hyaluronic acid
48520830|NCT02177461|DRUG|Clonidine|
48723599|NCT04295863|DRUG|Nivolumab Extended|For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
48723600|NCT04295863|DRUG|Pembrolizumab Extended|For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
48723601|NCT05025696|OTHER|Blacksoap(R)|Blacksoap(R)
48723602|NCT00861016|DRUG|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
48723603|NCT03698565|OTHER|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
48723604|NCT03668405|DRUG|Lu AF20513|Injection
48723605|NCT00641082|DRUG|Clevudine|30mg for 48 weeks
48723606|NCT00641082|DRUG|Adefovir dipivoxil|10mg for 48 weeks
48723607|NCT03442582|BIOLOGICAL|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
48723608|NCT03013049|PROCEDURE|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
48723609|NCT03013049|PROCEDURE|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
48026456|NCT03102099|PROCEDURE|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
48026457|NCT03102099|PROCEDURE|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
48183316|NCT03530137|BEHAVIORAL|HealthySteps|Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
48385014|NCT04275830|BEHAVIORAL|Heart rate variability waitlist and Digital storytelling Control intervention|Four Digital Stories Intervention (4 patient stories about hematopoietic cell transplantation (HCT) over the course of 2 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each). The 4 digital stories patients produced contained the following content: (1) a leukemia patient expressed and controlled her depression and anxiety and described how she dealt with the intensive treatment and recovery through a positive attitude and active coping; (2) a mother of 3 children, who was experiencing severe pain due to MS, coped with HCT through family support and positive reframing; (3) a lymphoma patient coped with the HCT procedures by praying during the treatment; and (4) a father of young twins had a HCT twice, and his wife helped him cope with emotional distress through open communication and expressing emotions.Participants will receive a 30-minute HRVB training session at T2.
48385015|NCT02141373|DEVICE|Glubran 2|
48385016|NCT06259760|DRUG|Nitroglycerin|during surgery, the patient received nitroglycerin infusion or nitroglycerin with labetalol to decrease blood pressure and to decrease blood loss. During the procedures and management, patients were executed of continuously monitoring of arterial blood pressure, hemodynamic changes such as cardiac output, stroke volume variation, peripheral oxygen saturation, and cerebral oximeter.
48723610|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
48723611|NCT00440830|DRUG|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
48723612|NCT00440830|DRUG|placebo|placebo patch applied to smokers
48723613|NCT00440830|DRUG|placebo|placebo patch applied to nonsmokers
48026458|NCT06329635|DRUG|Intrathecal Nicardipine|First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
48026459|NCT06329635|OTHER|No intervention|"A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel."
48183317|NCT00250432|DRUG|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.
48183318|NCT04568863|DRUG|Melatonin intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
48385017|NCT06653374|BEHAVIORAL|Infant, Premature|This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment
48723614|NCT00252616|BEHAVIORAL|trophic enteral feeds|10cc/hr
48723615|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea containing L-arabinose and indigestible dextrin|
48723616|NCT00880646|DIETARY_SUPPLEMENT|Oolong tea (Placebo)|
48723617|NCT03648216|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
48385018|NCT06565884|DEVICE|Home radiofrequency skin treatment instrument|Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
48723618|NCT03968185|OTHER|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
48723619|NCT03968185|OTHER|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
48723620|NCT06181370|DRUG|AGMB-447|AGMB-447 inhaled drug
48723621|NCT06181370|OTHER|placebo|placebo inhaled drug
48723622|NCT01019837|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
48520831|NCT05523115|DIETARY_SUPPLEMENT|Heights Smart Supplement|"The ingredient list of the product includes the following:~Algae oil Blueberry Extract Methylcobalamin (Vitamin B12) Cholecalciferol (Vitamin D3) Ascorbic acid (Vitamin C) Retinol acetate (Vitamin A) Calcium L-methylfolate (Folic Acid) D-biotin Pyridoxine hydrochloride (Vitamin B6) Calcium pantothenate (Vitamin B5) Nicotinamide (Vitamin B3) Riboflavin (Vitamin B2) Thiamine hydrochloride (Vitamin B1) D-Alpha tocopheryl acetate (Vitamin E) Chromium picolinate Potassium iodide Iron Citrate Sodium selenite Zinc citrate"
48520832|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate~Intra muscular"
48520833|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate~Intramuscular injection"
48723623|NCT05647668|PROCEDURE|Laparoscopic fundoplication|Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
48026460|NCT01601301|DEVICE|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
48026461|NCT02921412|DEVICE|fanfilcon A|contact lens
48520834|NCT01006681|BIOLOGICAL|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
48520835|NCT02421055|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
48520836|NCT02421055|PROCEDURE|Laparoscopic Sleeve Gastrectomy|
48723624|NCT04863690|BEHAVIORAL|Meditation|Participants will be asked to use either the Muse Mind Meditation, Muse Sleep Journeys, Go to Sleep Soundscapes or Go to Sleep Guidance each evening as part of their bedtime routine to help them prepare to sleep. In addition, participants may use any part of the Muse App (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations, as often as they like to help them fall asleep, go back to sleep, or as a meditation practice during the daytime. All Participants will also be asked to do the Muse Mind meditation for a minimum of 5 minutes per day, a minimum of 5 days per week, for 6 weeks. If they also wish to use the Muse system more frequently (day or night), they will be encouraged to do so and will be able to choose between several styles of available meditation (Mind, Heart, Breath, Body, Guided or Go to Sleep meditations). Participants will be asked to also wear their Muse device while they sleep, as often as they like in order to track their sleep.
48723625|NCT04863690|BEHAVIORAL|Digital Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation.
48723626|NCT04863690|BEHAVIORAL|Digital Coaching plus Human Coaching|All participants will work through the content in the Muse S Sleep Coaching course, and implement the sleep hygiene and habit changes recommended through the course that they find reasonable and effective for their situation. All participants will also be asked to join regular online coaching sessions. Participants will be divided into 9 cohorts of 10 people per cohort. Each cohort will be offered group coaching once per week. Coaches will be versed in Mindfulness, and how to use Muse and how to support sleep. Coaching will take place virtually using Interaxon's Zoom account.
48723627|NCT04190524|OTHER|Application of cricoid pressure|The study first involves recording a baseline image of the neck anatomy using ultrasound, which is a non-invasive, non-irradiating, non-painful imaging modality. Once the baseline anatomy has been imaged, conventional cricoid pressure will be applied with fingers and/or with the ultrasound probe itself and an image will be recorded. The force applied to the cricoid cartilage will be 30 newtons, as determined by a thin force measurement sensor (Tekscan flexiforce sensor) placed in between the patient's skin and the finger (or ultrasound probe).
48723628|NCT04190524|OTHER|Application of Left lateral paratracheal pressure|Next, left lateral paralaryngeal pressure will be applied at the level of the cricoid cartilage with fingers and/or the ultrasound probe itself, and the image will again be recorded. Left lateral paralaryngeal pressure will be 30 newtons, as determined by a thin force measurement sensor placed in between the patient's skin and the finger (or ultrasound probe).
48723629|NCT05257369|DEVICE|Blue-Green LED photoherapy|Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
48723630|NCT02168985|BEHAVIORAL|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
48723631|NCT02313883|DRUG|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
48723632|NCT05361642|DRUG|Bupivacaine HCl 0.5% Injectable Solution|using nasal block including sphenopalatine ganglion block with general anesthesia to optimize surgical field
48723633|NCT05361642|DRUG|Dexmedetomidine|using dexmedetomidine with induction of general anesthesia to optimize surgical field
48723634|NCT04445623|DRUG|Prasugrel Hydrochloride 10 MG Oral Tablet|administration of prasugrel daily for 15 days
48723635|NCT04445623|DRUG|Placebo|administration of placebo daily for 15 days
48723636|NCT01569230|PROCEDURE|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
48026462|NCT06293963|BEHAVIORAL|Guideline Daily Amounts label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
48026463|NCT06293963|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
48026464|NCT06293963|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
48026465|NCT06293963|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
48183319|NCT04568863|DRUG|Placebo intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
48183320|NCT02119338|DRUG|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
48723637|NCT01569230|PROCEDURE|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
48026466|NCT03868436|DRUG|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
48026467|NCT03176693|DRUG|Phenoxybenzamine|Non-selective alpha blocker
48026468|NCT03176693|DRUG|Doxazosin|Selective alpha blocker
48026469|NCT02703935|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
48723638|NCT01569230|PROCEDURE|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
48723639|NCT01569230|OTHER|Waiting|No interventions were applied to the patients in this group.
48723640|NCT00042666|DRUG|LY317615|500 mg, oral, QD, up to six 28 day cycles
48723641|NCT00387647|DRUG|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
48723642|NCT03187223|DRUG|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
48723643|NCT03187223|DRUG|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
48723644|NCT03412383|DRUG|Pyrotinib|Pyrotinib 400mg/day
48026470|NCT02703935|BEHAVIORAL|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
48026471|NCT01079221|BEHAVIORAL|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at \< 90 % of peak power, 3 days/week for 6 weeks
48026472|NCT01627392|BEHAVIORAL|Smoking abstinence|6 hour smoking abstinence
48026473|NCT06052969|DEVICE|Pulse NanoMED System|The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.
48026474|NCT01952340|DIETARY_SUPPLEMENT|Flaxseed|Milled flaxseed
48026475|NCT01952340|DIETARY_SUPPLEMENT|Placebo|Wheat germ/wheat bran and mixed dietary oils
48026476|NCT05668182|PROCEDURE|TRUMATCH Graft Cage|TRUMATCH Graft Cage for surgical repair of segmental long bone defect
48026477|NCT04087057|OTHER|Interview|Participate in interview
48026478|NCT04087057|OTHER|Medical Chart Review|Patients' medical records are reviewed
48026479|NCT04087057|BEHAVIORAL|Questionnaire|Complete questionnaires
48723645|NCT04924478|BIOLOGICAL|Mepolizumab|Patients will be receiving this treatment as part of their standard clinical care
48723646|NCT04958746|DRUG|Ciprofol|intravenous bolus
48723647|NCT04958746|DRUG|Propofol|intravenous bolus
48723648|NCT05776628|DEVICE|Plenum® Tissue ortho membrane (polydioxanone membrane)|Membrane addition after flavectomy and spinal nerve and dura mater manipulation.
48723649|NCT02754960|DRUG|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
48723650|NCT02754960|DRUG|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
48723651|NCT03234491|DEVICE|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
48723652|NCT03234491|DRUG|Afrezza low dose|Afrezza inhaled insulin low dose.
48026480|NCT04095377|OTHER|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
48026481|NCT04592757|DEVICE|Virtual mirror therapy via VR headset|Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
48026482|NCT01606982|DRUG|MDV3100|oral
48183321|NCT01496365|DRUG|DS-5565 tablet|5mg and 10mg tablets
48723653|NCT03234491|DRUG|Afrezza high dose|Afrezza inhaled insulin high dose.
48723654|NCT00238368|BIOLOGICAL|filgrastim|
48723655|NCT00238368|BIOLOGICAL|rituximab|
48723656|NCT00238368|DRUG|busulfan|
48183322|NCT01496365|DRUG|pregabalin capsule|75mg and 150mg over-encapsulated
48183323|NCT01496365|DRUG|Placebo tablet|
48723657|NCT00238368|DRUG|cisplatin|
48723658|NCT00238368|DRUG|cyclophosphamide|
48723659|NCT00238368|DRUG|cytarabine|
48723660|NCT00238368|DRUG|doxorubicin hydrochloride|
48723661|NCT00238368|DRUG|etoposide|
48723662|NCT00238368|DRUG|methylprednisolone|
48723663|NCT00238368|DRUG|prednisone|
48723664|NCT00238368|DRUG|vincristine sulfate|
48723665|NCT00238368|PROCEDURE|autologous bone marrow transplantation|
48723666|NCT00238368|PROCEDURE|peripheral blood stem cell transplantation|
48723667|NCT00238368|PROCEDURE|positron emission tomography|
48723668|NCT00238368|RADIATION|fludeoxyglucose F 18|
48723669|NCT00238368|RADIATION|radiation therapy|
48723670|NCT02718040|DEVICE|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
48723671|NCT00399100|PROCEDURE|HBO - hyperbaric oxygen treatment|
48723672|NCT04878692|DRUG|Application of Onco-Rash cream|"The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
48723673|NCT04878692|DRUG|Application of Onco-Neutre cream|"The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage."
48026483|NCT03866174|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
48026484|NCT03866174|DRUG|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
48026485|NCT03866174|OTHER|Set and Setting (SaS) Protocol|The SaS Protocol prescribes 6-8 hours of preparatory meetings with two facilitators prior to dosing, a 7-10 hour dosing session in a comfortable room under the supervision of the same two facilitators, and 4 hours of post-dose integration sessions with facilitators. During the dosing session participants are encouraged to wear eyeshades and listen to a curated playlist on headphones.
48183324|NCT01496365|DRUG|placebo capsule|
48183325|NCT04872023|OTHER|Blood and bone marrow sampling|Blood and bone marrow sampling
48723674|NCT06013189|OTHER|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
48723675|NCT03562468|DIETARY_SUPPLEMENT|300 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
48183326|NCT00223275|DRUG|Naltrexone|
48723676|NCT03562468|DIETARY_SUPPLEMENT|1000 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
48723677|NCT03562468|DIETARY_SUPPLEMENT|Placebo|Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
48723678|NCT00001410|DRUG|Lysodase|
48723679|NCT05004948|OTHER|Exercise training|The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
48183327|NCT00798434|DRUG|Placebo|placebo administered orally in the morning or evening.
48183328|NCT00798434|DRUG|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
48183329|NCT01114490|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
48183330|NCT00421629|BEHAVIORAL|After-sales service and supportive supervision (AfterSS)|
48183331|NCT00421629|BEHAVIORAL|Prospective reimbursement (PR)|
48183332|NCT00421629|BEHAVIORAL|Both (AfterSS and PR)|
48183333|NCT04547777|DRUG|D2C7-IT|D2C7-IT intratumoral infusion
48385019|NCT06565884|OTHER|Ultrasonic coupler for medical purposes|In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
48026486|NCT03566641|DEVICE|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
48026487|NCT03566641|OTHER|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
48026488|NCT05826236|DEVICE|Periarticular compression|Periarticular knee compression using a sphygmomanometer.
48183334|NCT04547777|DRUG|2141-V11|2141-11 intratumoral infusion
48183335|NCT05764551|DIAGNOSTIC_TEST|Serum DNA methylation|Serum DNA methylation
48183336|NCT05675462|DRUG|Oncorine|a modified human recombinant type 5 adenovirus with genetic modifications
48183337|NCT05675462|DRUG|Tislelizumab|PD-1inhibitor
48183338|NCT05675462|DRUG|Lenvatinib|TKI
48183339|NCT01653600|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
48723680|NCT06437912|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
48723681|NCT02103413|DEVICE|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
48723682|NCT02103413|DEVICE|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
48026489|NCT00968604|GENETIC|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
48723683|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
48723684|NCT00975663|DRUG|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
48723685|NCT05308927|DRUG|Norditropin|Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
48723686|NCT02943616|DEVICE|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
48026490|NCT03346759|DEVICE|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
48026491|NCT03346759|DEVICE|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
48026492|NCT03662945|OTHER|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
48026493|NCT02886572|RADIATION|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
48183340|NCT01653600|DEVICE|LifeStent|same to SMART STENT
48026494|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training With Visual and Auditory Cues|Comparison of Effects of Treadmill Training With Visual and Auditory Cues
48723687|NCT06130982|BEHAVIORAL|Health Qigong·Yijinjing|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Yijinjing:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
48385020|NCT00057330|BIOLOGICAL|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
48385021|NCT00057330|BIOLOGICAL|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
48385022|NCT06159686|DRUG|Hemp|The application of the hemp-containing cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
48026495|NCT05854147|DIAGNOSTIC_TEST|Treadmill Training Without Visual and Auditory Cues|Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
48026496|NCT03899870|PROCEDURE|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
48385023|NCT06159686|DRUG|Placebo|The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
48385024|NCT03784755|RADIATION|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
48385025|NCT03784755|OTHER|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
48385026|NCT04391686|DIAGNOSTIC_TEST|indirect calorimetry|to determine and compare the resting energy expenditure of each group
48385027|NCT01518296|DEVICE|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
48385028|NCT04192747|DEVICE|Percutaneous Coronary Intervention|Percutaneous coronary intervention of de novo native coronary artery lesions
48183341|NCT06288347|DEVICE|GGON mobile app.|The intervention will be done through an app named GGON, which is used to work on the dysfunctional beliefs that are associated with orthorexia nervosa. The app is made up of a series of levels comprising the topics based in cognitive-conductual perspective that are related to Orthorexia Nervosa. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
48183342|NCT02441868|BEHAVIORAL|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
48183343|NCT02903303|OTHER|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~* 1st session : contact with the therapist, body scan, basic suggestions~* 2nd session : hypnosis induction followed by suggestions tu build a safe place~* 3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~* 4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
48385029|NCT00960232|DRUG|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
48385030|NCT00960232|DRUG|placebo|placebo
48385031|NCT01655784|PROCEDURE|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
48520837|NCT01553357|DRUG|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
48520838|NCT00003744|DRUG|gemcitabine|
48520839|NCT04759196|DRUG|Topamax|TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
48723688|NCT06130982|BEHAVIORAL|Health Qigong·Wuqinxi|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Wuqinxi:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
48026497|NCT03899870|DRUG|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil \[5-FU\] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
48026498|NCT03899870|DRUG|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
48026499|NCT02398097|BIOLOGICAL|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
48183344|NCT02931305|DRUG|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
48183345|NCT02931305|DRUG|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
48385032|NCT01655784|PROCEDURE|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
48385033|NCT03978806|BEHAVIORAL|Active Comparator: peer navigator|The intervention is aimed to provide support with social challenges and adherence. The peer navigator will meet with patients to provide support with social challenges and use motivational interviewing to provide support with adherence.
48385034|NCT03978806|OTHER|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients.
48026500|NCT02398097|BIOLOGICAL|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
48026501|NCT02398097|BIOLOGICAL|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
48026502|NCT00382343|DRUG|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
48520840|NCT04759196|DRUG|Levetiracetam|LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
48520841|NCT03170934|BEHAVIORAL|Psychotherapy skills class|Rapid access, large-scale, psychotherapy classes that are open format and delivered in lecture style. One class - Managing Difficult Emotions (MDE) - is an 8-session, DBT-informed program. The other class - Mindfulness-Based Cognitive Behavioral Therapy (CBTm) - is a 4-session program.
48723689|NCT06130982|BEHAVIORAL|Health Qigong·Baduanjin|1-2weeks:learning stage, the frequency is 1 time/day, 5times/week,30 min /time,the total duration controlled within 50 minutes,and includes 4 intervention contents.Warm up activity:take a slow walk around the track and field to activate body and activate small joints (5min).Basic Skills learning of HQ·Baduanjin:breathing exercises,hand exercises,trunk exercises,step exercises,stake exercises(10min).Learning a single action of a routine (30min).Cool down (5min).3-8weeks:practice stage,the frequency and duration of intervention remain unchanged, and the intervention components still include 4 parts.Based on the first two weeks,the intervention content emphasizes more on the practice of complete routine movements, as well as learning and experience the theories and functions of movements.8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
48723690|NCT06130982|BEHAVIORAL|Walking|1-8weeks:While the experimental group received intervention, the control group underwent walking exercise. The intervention frequency is the same as the experimental group: 1 time/day, 5times/week,30 minutes/time, the total duration controlled within 50 minutes, and includes 3 contents.Warm up activity:head movements,neck movements,shoulder movements, chest expansion exercise,waist rotation,body rotation, lunge movements,leg movements,knee joint movements,ankle movements(15 min).Walk around the track and field (30 min).Cool down (5min) 8-12weeks:stop intervention phase,the subjects resume their daily activities and stop intervention. After this, the final data measurement and collection are conducted again.
48723691|NCT00114088|PROCEDURE|hysterectomy|
48723692|NCT00114088|PROCEDURE|endometrial ablation|
48723693|NCT00343707|DRUG|vestipitant|
48723694|NCT00343707|DRUG|paroxetine|
48723695|NCT01156168|GENETIC|DNA analysis|
48723696|NCT01156168|GENETIC|gene expression analysis|
48723697|NCT01156168|GENETIC|polymorphism analysis|
48723698|NCT01156168|GENETIC|protein expression analysis|
48723699|NCT01156168|OTHER|immunohistochemistry staining method|
48183346|NCT06258213|DRUG|ABP-745|0.5, 5 or 25 mg tablet
48183347|NCT06258213|DRUG|Placebo|Placebo tablet
48385035|NCT00648583|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fed
48385036|NCT00648583|DRUG|Zofran® Tablets 24 mg|24mg, single dose fed
48385037|NCT06538428|GENETIC|DNA methylation profiling|measurement of methylation levels of MGMT, NUPR1,NDRG2,and GLI1 gene
48385038|NCT03469882|DIETARY_SUPPLEMENT|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.2 grams/kg/day of protein.
48520842|NCT03899909|DRUG|GLPG3121 SAD|GLPG3121 oral suspension, single ascending doses
48520843|NCT03899909|DRUG|Placebo SAD|Placebo oral suspension
48520844|NCT03899909|DRUG|GLPG3121 MAD|GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
48520845|NCT03899909|DRUG|Placebo MAD|Placebo oral suspension, daily for 13 days
48520846|NCT02548832|DRUG|Berberine|"Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner."
48723700|NCT01156168|OTHER|laboratory biomarker analysis|
48723701|NCT00548899|DRUG|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
48723702|NCT03637712|DEVICE|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
48723703|NCT06242223|OTHER|Multimodal HIIT|multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
48723704|NCT06242223|OTHER|conventional HIIT|conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
48723705|NCT01746173|DRUG|Cyclophosphamide|
48723706|NCT01746173|DRUG|Doxorubicin|
48723707|NCT01746173|DRUG|Vincristine|
48723708|NCT01746173|DRUG|Etoposide|
48723709|NCT01746173|DRUG|Prednisone|
48723710|NCT01746173|DRUG|Filgrastim|
48723711|NCT01746173|DRUG|Plerixafor|
48723712|NCT01746173|PROCEDURE|Stem Cell Collection|
48723713|NCT01746173|DRUG|Palifermin|
48520847|NCT02548832|DRUG|Bezafibrate|"Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
48026503|NCT05204524|DRUG|Temozolomide for injection combined with epirubicin|Temozolomide for injection, according to the requirements of GCP, the test drug should be sealed, kept away from light and kept at 2-8℃, with a valid period of 24 months.
48520848|NCT02548832|DRUG|Berberine plus Bezafibrate|"Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
48723714|NCT01746173|DRUG|Gemcitabine|
48026504|NCT06182670|DEVICE|Gingival Former Abutment|"GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the one abutment one time concept and should prevent bone loss and transmucosal tunnel."
48026505|NCT06182670|PROCEDURE|Subcrestal Implant|Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.
48520849|NCT05234801|DEVICE|DARCO™ Headed Cannulated Screw|The DARCO™ Headed Cannulated Screw is a multi-size screw system designed to be used over a guide pin or wire with instrumentation to provide interfragmentary compression and stability for bone fracture/fragment fixation.
48723715|NCT01746173|DRUG|Busulfan|
48723716|NCT01746173|DRUG|Melphalan|
48723717|NCT01746173|PROCEDURE|Stem Cell Transplant|
48723718|NCT05986903|DRUG|Tumor necrosis factor (TNF)-alpha inhibitors|"Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml."
48723719|NCT03334383|DEVICE|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
48723720|NCT02726945|DEVICE|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
48723721|NCT02726945|OTHER|Placebo|Placebo Control
48723722|NCT01325714|BEHAVIORAL|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
48520850|NCT05234801|DEVICE|ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|A multi-indication foot reconstruction solution providing indication specific implants and instruments designed to address the unique demands of the forefoot and midfoot.
48385039|NCT03469882|DEVICE|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
48385040|NCT03469882|OTHER|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
48520851|NCT05234801|DEVICE|ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|A comprehensive fixation system consisting of a wide variety of plate options, created with the purpose of stabilization and fixation of fractures, revision procedures, joint fusion and reconstruction of small bones of the feet.
48520852|NCT00918424|DRUG|Oxcarbazepine Extended Release|OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
48520853|NCT05758870|PROCEDURE|surgical stabilization of low rib fratures|surgical stabiliazation of rib fractures by internal fixation
48520854|NCT05758870|OTHER|converstive treatment of low rib fratures|chest wall fixation band
48520855|NCT03911830|OTHER|Exercise followed cold water immersion|Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
48520856|NCT01410903|DEVICE|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
48520857|NCT03171376|PROCEDURE|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
48520858|NCT02513225|BEHAVIORAL|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
48520859|NCT02513225|OTHER|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
48520860|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
48520861|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF with fTCP|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
48520862|NCT01289678|DRUG|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
48520863|NCT04177407|PROCEDURE|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
48520864|NCT04599647|BIOLOGICAL|PVSRIPO|PVSRIPO (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
48183348|NCT00406614|BEHAVIORAL|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
48385041|NCT03911817|DRUG|Midodrine|The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
48385042|NCT05218096|DRUG|ALXN2050|Oral tablet.
48385043|NCT05218096|DRUG|Placebo|Oral tablet.
48385044|NCT01711034|DRUG|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
48520865|NCT02754050|DEVICE|Tandem Snare|
48520866|NCT00019773|DRUG|capecitabine|
48520867|NCT00019773|DRUG|oxaliplatin|
48520868|NCT05778461|DRUG|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
48520869|NCT05778461|DRUG|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
48520870|NCT04311294|DRUG|ANS-6637 Low Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
48520871|NCT04311294|DRUG|ANS-6637 High Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
48723723|NCT01325714|BEHAVIORAL|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
48723724|NCT04450329|DRUG|SB15 (Proposed aflibercept biosimilar)|Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
48723725|NCT04450329|DRUG|Eylea (Aflibercept)|Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
48723726|NCT03764930|OTHER|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
48723727|NCT05304312|DEVICE|Kegel Exercises guidebook|The Kegel exercises book is consisted of basic explanation about stress urinary incontinence and Kegel exercises, how to do Kegel exercises, table for them to write how many session they did in a day, and lastly their report progress (UDI-6, IIQ-7, periineometer, and 1-hour pad test) that we updated every four weeks
48723728|NCT05369481|DRUG|Sildenafil 2%|Patients with male androgenic alopecia will be given topical Sildenafil 2% to apply twice daily for 6 consecutive months and then follow up.
48723729|NCT05369481|DRUG|Minoxidil 5 %|Patients with male androgenic alopecia will be given topical Minoxidil 5 % to apply twice daily for 6 consecutive months and then follow up.
48723730|NCT00028886|BIOLOGICAL|filgrastim|
48723731|NCT00028886|BIOLOGICAL|recombinant interferon alfa|
48723732|NCT00028886|DRUG|cyclophosphamide|
48723733|NCT00028886|DRUG|dexamethasone|
48723734|NCT00028886|DRUG|doxorubicin hydrochloride|
48723735|NCT00028886|DRUG|melphalan|
48026506|NCT06182670|DEVICE|Healing Abutment|A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.
48026507|NCT06182670|DEVICE|Prosthetic Crown|A zirconia prosthetic crown finalizes the implant rehabilitation.
48026508|NCT06182670|PROCEDURE|Crestal Implant|Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.
48026509|NCT02700646|BEHAVIORAL|Developmental recommendations|
48026510|NCT02700646|BEHAVIORAL|Standard care|standard care
48026511|NCT02747940|DRUG|flunarizine and/or pregabalin|
48026512|NCT06532487|OTHER|Critical Time Medical-Legal Partnership Intervention|Utilizing a hybrid type II effectiveness-implementation trial with a cluster randomized design in six predominantly Latino-serving federally qualified health centers (FQHCs) in three major urban settings, we are examining whether integrating legal services into existing health clinics that serve Latinx and recent migrant communities can improve engagement in care and improve the health of Latinx/Hispanic and recent migrants.
48026513|NCT01265953|DRUG|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
48026514|NCT01265953|DIETARY_SUPPLEMENT|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
48026515|NCT05548790|BEHAVIORAL|Spielberger State Anxiety Inventory (STAI-S)|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
48183349|NCT00814411|BEHAVIORAL|group family planning counseling|group family planning counseling for gynecological patients with unmet need
48723736|NCT00028886|DRUG|thalidomide|
48723737|NCT00028886|DRUG|vincristine sulfate|
48723738|NCT00028886|PROCEDURE|bone marrow ablation with stem cell support|
48723739|NCT00028886|PROCEDURE|peripheral blood stem cell transplantation|
48723740|NCT05498116|DRUG|Montelukast|10mg daily
48723741|NCT05498116|OTHER|Placebo|1 capsule daily
48723742|NCT02725190|BEHAVIORAL|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
48723743|NCT02725190|BEHAVIORAL|Normal sleep night|Normal sleep at home before trial.
48723744|NCT05642507|DRUG|AC01|AC01 microtablets
48026516|NCT05548790|BEHAVIORAL|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
48183350|NCT00814411|BEHAVIORAL|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
48385045|NCT06039956|PROCEDURE|Sentinel lymph Node Biopsy|The SLNB will be performed with 5 ml of undiluted methylene blue injected in equal aliquots, peri-tumoral, followed by a 5-minute massage prior to skin incision. Sentinel nodes will be defined as those that have uptake / visible blue staining or suspicious palpable nodes at the discretion of the operating surgeon. Sentinel nodes will be placed in formalin and sent separately. This will be followed by an immediate completion ALND, which will be similarly placed in formalin and sent separately from the SLNB specimen. Specimen radiographs will be performed on all specimens to confirm location of clip within SLNB vs. ALND specimens.
48385046|NCT04443426|DIETARY_SUPPLEMENT|Oral 3-hydroxybutyrate salts|Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.
48520872|NCT04311294|DRUG|Matched Placebo|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
48520873|NCT01626690|DEVICE|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
48520874|NCT01626690|DEVICE|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
48520875|NCT06297421|PROCEDURE|Fecal Microbiota Transplantation|Oral Fecal Microbiota Transplantation Capsule
48520876|NCT06297421|PROCEDURE|Placebo|Oral Placebo Capsule
48520877|NCT03829605|OTHER|Measurement of hydrogen sulfide|Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
48520878|NCT05335824|OTHER|The platelet-rich plasma (PRP)|"Twenty ml of venous blood was drawn from each patient with the use of PRP tubes that contain anticoagulant citrate dextrose. The double-spin technique was used to prepare the PRP. The injection areas were anesthetized with lidocaine 2% with epinephrine 1/80000 and left for 10 minutes. 15 units (0. 15 mL) of PRP were injected interaligamentlly in the middle, distobuccal, and distopalatal areas of the distal surface of the upper canines (5 units in each area) together with submucosal injections buccally and palatally (100 units and 50 units~, respectively)."
48520879|NCT05335824|OTHER|The injectable platelet-rich fibrin (I-PRF) group|"Twenty ml of venous blood was drawn from each patient in this experimental group.~I-PRF was prepared with the use of 20 ml of blood drawn from the patient in dry sterile tubes without anticoagulant (quickly before coagulation starts) by following the centrifugation protocol requires one cycle only (700 RPM for 3 minutes) Injection procedures, sites, and time were similar to the PRP group."
48723745|NCT04183088|DRUG|Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.|"There will be no dose reduction for tislelizumab in this study. In the part 1(safety cohort), if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles (6 weeks) of treatment, the dosage of regorafenib may be escalated. For subjects who escalate the regorafenib dosage to Level 2, if the subjects do not experience grade 2 or greater regorafenib-related adverse events after 2 cycles of study drug treatment, the dosage of regorafenib may be further escalated to Level 3.~During study drug treatment, dose delay/ interruption of regorafenib will be done depending on the occurrence and severity of regorafenib-related adverse events. After dose reduction of regorafenib, if the subjects tolerate the reduced dose of regorafenib well, the investigators may consider re-escalation of regorafenib to the previous dose level, depending on the types and severity of adverse events that led to dose reduction."
48723746|NCT01424228|DRUG|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
48723747|NCT01424228|DRUG|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4"
48723748|NCT00086099|DRUG|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
48723749|NCT00086099|DRUG|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
48723750|NCT05047575|OTHER|REASSURE|REASSURE utilizes remote patient-reported outcomes assessments to comprehensively assess symptoms, promotes practice change by providing feedback reports to oncologists and engaging primary care providers (PCPs) in survivorship care, and reduces the burden of follow-up by substituting an oncology visit for thriving survivors with reassurance messaging and encouragement to pursue preventive care.
48723751|NCT01548742|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
48723752|NCT01548742|BEHAVIORAL|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
48723753|NCT00119171|DRUG|Ispinesib|
48723754|NCT00119171|DRUG|Capecitabine|
48723755|NCT00523497|DEVICE|Non invasive mechanical ventilation|
48723756|NCT04316000|OTHER|Initial Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.
48723757|NCT04316000|PROCEDURE|Endoscopic band ligation without resection of the subpetihelial tumour.|Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.
48723758|NCT04316000|OTHER|1-2 Months Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.
48723759|NCT04316000|OTHER|1 Year Anxiety and Fear of Cancer Test|Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.
48723760|NCT02483949|BEHAVIORAL|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
48723761|NCT01610986|DIETARY_SUPPLEMENT|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
48520880|NCT05335824|DEVICE|The control group|NiTi closed-coil springs (American Orthodontics, Sheboygan, WI) were used to impose 150 g force from the first molar band hook to the bracket of canine on each side on 0.019\*0.025-in SS archwire Patients' follow-up appointments were two weeks intervals; at each visit, the force produced by the coil was checked and readjusted when needed in order to keep it at 150-g level and the appliances were examined for any deformation or change in the position because of chewing. Canine retraction continued until achieving Class I canine relationship.
48520881|NCT01522209|PROCEDURE|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
48723762|NCT01610986|DIETARY_SUPPLEMENT|Water|Only water intake during training
48723763|NCT05192213|DRUG|Vitamin C|Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
48385047|NCT04443426|DIETARY_SUPPLEMENT|Carbohydrate Placebo|Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.
48385048|NCT04443426|DIETARY_SUPPLEMENT|Ketone Monoester|Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
48385049|NCT06315530|DRUG|Telitacicept|160mg once a week for 48 weeks
48385050|NCT06315530|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
48385051|NCT02259413|BEHAVIORAL|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
48385052|NCT00845377|BEHAVIORAL|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
48385053|NCT04462354|PROCEDURE|Blumgart Anastomosis|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
48385054|NCT04462354|PROCEDURE|Pancreatogastric anastomosis.|Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
48385055|NCT06222502|OTHER|Planning, Reminders, and Micro-Incentives|Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.
48385056|NCT06222502|OTHER|Health Education|"Participants in this group will receive health education tips during weekly phone calls with study staff."
48385057|NCT06112756|DRUG|Elinzanetant|Oral
48520882|NCT01522209|DEVICE|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
48520883|NCT01522209|RADIATION|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
48520884|NCT01522209|RADIATION|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
48520885|NCT01594255|DRUG|sotrastaurin|
48520886|NCT01594255|DRUG|sotrastaurin|
48520887|NCT01594255|DRUG|placebo to sotrastaurin|
48385058|NCT06112756|OTHER|Placebo|Oral
48385059|NCT00055159|PROCEDURE|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
48385060|NCT01592968|OTHER|Cognitive Assessment|Ancillary studies
48385061|NCT01592968|OTHER|Quality-of-Life Assessment|Ancillary studies
48385062|NCT01592968|RADIATION|Stereotactic Radiosurgery|Undergo SRS
48385063|NCT01592968|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
48520888|NCT01594255|DRUG|Avelox|
48520889|NCT01777503|DRUG|prasugrel|prasugrel 5 mg o.d.
48520890|NCT01777503|DRUG|Clopidogrel|75 mg o.d.
48385064|NCT03461653|OTHER|Telemedicine counselling|women on web counselling
48385065|NCT06565585|PROCEDURE|Glans-sparing surgery|Patients who underwent glans-sparing surgery
48385066|NCT05053737|DRUG|Atezolizumab|One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
48385067|NCT05053737|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
48385068|NCT04206436|DRUG|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
48385069|NCT05527301|DRUG|Lactobacillus Fermentum|Lactobacillus Fermentum
48385070|NCT05527301|DRUG|Placebo|Placebo
48385071|NCT02682069|DEVICE|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
48385072|NCT03280628|PROCEDURE|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
48385073|NCT03280628|PROCEDURE|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
48520891|NCT04468685|DRUG|Ondansetron|Interperitoneal administration in the gall bladder bed
48723764|NCT05192213|OTHER|Placebo|Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
48723765|NCT02345096|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|
48723766|NCT02345096|DIETARY_SUPPLEMENT|Placebo|
48723767|NCT01985360|PROCEDURE|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
48385074|NCT03280628|PROCEDURE|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
48385075|NCT05644899|PROCEDURE|Interlaminar ultrasound-assisted intrathecal administration of nusinersen|All procedures were performed with patients either seated or placed in a lateral decubitus. After skin disinfection with 2% chlorhexidine in 70% alcohol, using a convex array, the L3-4 or L4-5 intervertebral space was identified and a left paramedian sagittal oblique view was obtained; the probe was rotated 90° into a transverse orientation, centered on the neuraxial midline, and moved in either the cephalad or caudal direction to obtain a transverse interlaminar view; the intersection between the two markings of the spinal midline and interspinous space was identified as the spinal entry point of the needle. After local anesthesia (LA) with lidocaine 2%, a 25-gauge non-traumatic 90 mm Whitacre spinal needle or a traumatic 90 mm Quincke spinal needle was used to access the subarachnoid space. After confirmation of cerebrospinal fluid (CSF) flow, 5 mL of CSF were removed. Subsequently, nusinersen was administered intrathecally over 1-3 min.
48520892|NCT04468685|DRUG|Normal saline|Interperitoneal administration in the gall bladder bed
48723768|NCT01985360|PROCEDURE|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
48520893|NCT00101426|DRUG|ranirestat, (AS-3201)|
48026517|NCT05548790|BEHAVIORAL|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
48520894|NCT03197623|DRUG|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
48520895|NCT03197623|DRUG|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
48520896|NCT04456088|COMBINATION_PRODUCT|150 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.
48520897|NCT04456088|COMBINATION_PRODUCT|80 ppm Nitric Oxide delivered through LungFit Delivery System|Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.
48026518|NCT05548790|BEHAVIORAL|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
48520898|NCT01761383|OTHER|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
48520899|NCT01385774|PROCEDURE|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
48183351|NCT04361383|OTHER|control group|the patient will receive general anesthesia
48723769|NCT01985360|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
48723770|NCT01985360|BEHAVIORAL|Lifestyle|Diet, physical activity, smoking cessation
48723771|NCT01985360|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
48723772|NCT03716661|PROCEDURE|ORIF|Open Reduction Internal Fixation
48723773|NCT02392403|DEVICE|Nucleus CI532 cochlear implant|
48723774|NCT04759365|DRUG|ASN51|ASN51 formulation for oral capsule
48723775|NCT04759365|DRUG|Placebo|Placebo formulation for oral capsule
48385076|NCT05644899|PROCEDURE|Landmark-based intrathecal administration of nusinersen|All procedures were performed with patients placed in their most comfortable position (either seated or placed in a lateral decubitus). After skin disinfection with 2% chlorhexidine in 70% alcohol, conventional palpation of the superior aspect of iliac crest was performed and the palpated intercristal line was assumed to cross the spine at L4 vertebral body or L4-L5 interspace. The skin was marked with horizontal and vertical lines at the L3-L4 or L2-L3 interspaces and was referred as entry point of the needle. The procedure was then completed in the same fashion as for US-assisted technique.
48385077|NCT06466057|BEHAVIORAL|Metacognitive Therapy|A one-on-one face-to-face dialogue format will be used to conduct psychotherapy with each participant, and the treatment protocol will be based on the treatment manual for metacognitive therapy.
48385078|NCT06466057|OTHER|General mental health promotion|A general mental health mission will be conducted, not covering any metacognitive therapy related content, set for 8-15 weeks, 1 time per week
48385079|NCT06124846|BEHAVIORAL|CB-Abst|incentivized, biochemically verified abstinence via contingency management
48385080|NCT06124846|BEHAVIORAL|CB-Mon|monitoring with no required abstinence
48385081|NCT06652763|OTHER|Minnesota Living with Heart Failure Questionnaire|Self-administered, validated questionnaire to assess symptoms of heart failure
48385082|NCT06652763|DIAGNOSTIC_TEST|Echocardiogram|Resting transthoracic echocardiogram to exclude valvular pathology and the assess indices of systolic and diastolic function and speckle tracking for strain
48385083|NCT06652763|DIAGNOSTIC_TEST|Six-minute walk test|Standardised, objective assessment of exercise capacity
48385084|NCT06652763|DIAGNOSTIC_TEST|Manganese-enhanced MRI and 31-P magnetic resonance spectroscopy|Using a 3-Tesla scanner, 31P magnetic resonance spectroscopy will be performed to obtain information regarding cardiac energetics. An intravenous infusion of manganese dipyridoxyl diphosphate (mangafodipir, MnDPDP) will be commenced at a rate of 1mL/min using a dose of 5µmol/kg (0.1mL/kg).
48385085|NCT06652763|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan|Scan including adenosine stress perfusion
48385086|NCT06652763|DIAGNOSTIC_TEST|Blood tests|Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses
48385087|NCT05672394|PROCEDURE|Continuous Serratus anterior plane block|in lateral position a linear transducer (10-12MHz, M-Turbo) will be used, The 5th rib is identified in the mid-axillary line. The following muscles are overlying the rib latissimusdorsi ,teres major, and serratus muscle.The needle (22G, 50-mm Tuohy needle) is introduced in-plane targeting the plane superficial to serratus muscle. local anesthetic is injected then a catheter is threaded and . Ultrasound-guided SAPB was done using a serratus anterior catheter Group DL (n=20) received a bolus of 30 mL of 0.25% bupivacaine followed by a continuous infusion of 0.125% bupivacaine at a rate of 7-12 ml/hr according to patient response upon ICU arrival after the stabilization of the clinical status. The infusion was continued until the end of the 1st 24 hours postoperatively .
48385088|NCT05672394|PROCEDURE|Thoracic Epidural|A thoracic epidural catheter was done to the patient while sitting. Tuohy needles are used. Epidural space can be identified by loss of resistance. Injection begins with a negative aspiration and a test dose (3 ccs of 1.5% lidocaine with 1:200,000 epinephrine) .A Continuous epidural technique through the placement of a catheter 3-5 cm beyond the needle is applied. Injection in 5ml increments of 0.25% bupivacaine is used until the block of the required segments achieved ( 10 to 15ml). sensory testing is via pinprick and cold test to detect sympathetic block . Throughout the technique hourly injection of 5 ml 0.25% bupivacaine for maintenance.
48385089|NCT05672394|DRUG|Bupivacaine|bupivacaine
48385090|NCT05672394|DRUG|lidocaine with epinephrine|3 ccs of 1.5% lidocaine with 1:200,000 epinephrine
48520900|NCT01385774|OTHER|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
48520901|NCT05437263|DRUG|Brepocitinib|Oral Brepocitinib
48520902|NCT05437263|DRUG|Placebo|Oral Placebo
48723776|NCT05571774|OTHER|collection data|collection data
48723777|NCT00464659|DEVICE|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
48723778|NCT00464659|DEVICE|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
48183352|NCT04361383|PROCEDURE|quadratus lumborum block type 3|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
48520903|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with Alt-RAMEC protocol.|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by Alt-RAMEC protocol.
48723779|NCT05938036|DRUG|ALT-100 mAb|Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.
48723780|NCT05938036|DRUG|ALT-100 (Placebo)|Normal saline solution via IV solution
48183353|NCT04361383|PROCEDURE|erector spinae plane block|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
48183354|NCT05345730|DIAGNOSTIC_TEST|3 DImensional Late Enhanced Gadolinium cardiac MRI scan|A cardiac MRI scan is made using late gadolinium enhancement to detect atrial fibrosis in the left atrium.
48183355|NCT00021138|BEHAVIORAL|smoking cessation intervention|
48183356|NCT00021138|DRUG|nicotine|
48723781|NCT01147900|BIOLOGICAL|Boostrix™|Intramuscular, single dose
48723782|NCT01147900|BIOLOGICAL|Boostrix™-US formulation|Intramuscular, single dose
48723783|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
48723784|NCT01071824|PROCEDURE|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
48723785|NCT03070821|OTHER|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
48520904|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with conventional protocol|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by conventional protocol
48520905|NCT03442439|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.
48520906|NCT03442439|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
48520907|NCT05813886|OTHER|biodex balance system|The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.
48520908|NCT02126826|DRUG|BI 1026706|Multiple Rising Doses (oral solution, tablet)
48723786|NCT03070821|DEVICE|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
48026519|NCT05359042|OTHER|Electronic Patient Reported Outcomes platform|The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
48026520|NCT05359042|OTHER|Health Related Quality of Life Surveys|Surveys will be administered to participants
48520909|NCT02126826|DRUG|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
48520910|NCT00768248|DRUG|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
48520911|NCT00768248|DRUG|normal saline (placebo)|the basal rate will be set at 7 mL/h
48520912|NCT04902001|BEHAVIORAL|Multidisciplinary weight loss|The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
48520913|NCT01034878|DRUG|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
48026521|NCT03574220|DRUG|Pembrolizumab|200mg IV every 21 days over 6 months
48026522|NCT03574220|RADIATION|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
48522769|NCT03021681|OTHER|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
48723787|NCT03223623|DEVICE|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
48723788|NCT03223623|DEVICE|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
48723789|NCT03223623|DEVICE|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
48723790|NCT04216407|PROCEDURE|Remote ischemic preconditioning|An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
48723791|NCT00206882|DRUG|corticosteroids|
48723792|NCT03549559|DRUG|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
48723793|NCT03549559|DEVICE|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
48723794|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~4. Trilaciclib: 240mg/m2, d1, d2, d8 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
48723795|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
48723796|NCT02390180|OTHER|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
48723797|NCT02841241|DRUG|Esmolol|Esmolol infusion
48723798|NCT06531031|DIAGNOSTIC_TEST|InfectID-BSI (Bloodstream Infection) qPCR Assay|"InfectID-BSI technology targets nucleic acid sequences unique to the target analyte. The qPCR raw data collected from InfectID-BSI's 9 assay tubes is analysed by Microbio's InfectID-Client (InfectID-BSI-associated software) and the result is reported as an analyte-detection if the unique target analyte is present or no result if the unique target analyte is absent.~InfectID-BSI is carried out with whole blood from a venous puncture (EDTA). DNA is extracted from a sample of the collected blood using a validated DNA extraction instrument according to the manufacturer's instructions. The extracted DNA is then added to the InfectID-BSI qPCR reagent panel which consists of 9 reaction tubes (6 for bacteria, and 3 for yeast species). The panel is subjected to real-time qPCR using a process of Melt Curve analysis using the Rotor-Gene Q MDx qPCR instrument. The assay report identifies the species present in the sample upon completion. Results are generated within 3 hours."
48723799|NCT00665769|OTHER|Hypercapnia|transcutaenous CO2 50-60 mm Hg
48723800|NCT00665769|OTHER|Normocapnia|transcutaneous CO2 35-45 mm Hg
48723801|NCT02471638|DEVICE|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
48723802|NCT04589143|DRUG|Agomelatine|Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
48723803|NCT04589143|DRUG|Placebos|Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
48723804|NCT02476136|DRUG|paroxetine, duloxetine, fluoxetine or venlafaxine|
48723805|NCT03480009|DRUG|Dextromethorphan Hydrobromide|Dextromethorphan capsule
48026523|NCT02612012|RADIATION|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
48026524|NCT01713595|DRUG|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
48723806|NCT03480009|DRUG|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
48723807|NCT03480009|DRUG|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
48026525|NCT06431919|DRUG|Simvastatin 20mg|Simvastatin fixed dose of 20 mg per day
48026526|NCT06431919|DRUG|Carvedilol 3.125 mg|Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate
48026527|NCT04088786|DRUG|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
48723808|NCT02648217|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
48723809|NCT02648217|DRUG|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
48723810|NCT06340490|BIOLOGICAL|RJMty19 (CD19-CAR-DNT cells)|Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
48723811|NCT01424280|DRUG|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
48723812|NCT01424280|DRUG|Placebo|Single dose of matching placebo tablets
48723813|NCT05320159|DRUG|Secukinumab|Included all the patients treated with secukinumab
48723814|NCT05522569|DRUG|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
48723815|NCT00734071|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
48723816|NCT00734071|DRUG|Placebo|Vortioxetine placebo-matching capsules
48723817|NCT03331523|DRUG|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
48723818|NCT03331523|DRUG|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
48723819|NCT03331523|DRUG|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
48723820|NCT00255775|DIETARY_SUPPLEMENT|broccoli sprout extract|
48026528|NCT05792553|DEVICE|bonded tongue tamers|Enamel surface will be treated initially with 37% phosphoric acid for 30 seconds then tongue tamers will be bonded to the palatal/lingual surface of upper and lower central incisors
48026529|NCT05792553|DEVICE|customized bonded spurs|Composite restoration will be used to fabricate the customized bonded spurs with sharp ends and 3 mm in length.
48026530|NCT05792553|DEVICE|conventional fixed palatal spurs|conventional fixed palatal spurs will be fabricated by taking impression after band selection, then the spurs appliance will be fabricated from 0.9 mm stainless steel wire and soldered to the bands bilaterally.
48026531|NCT01319318|PROCEDURE|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
48026532|NCT03403725|DRUG|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
48183357|NCT03806465|OTHER|Feasibility survey|A survey questionnaire will be administered at each household. At the baseline household survey, each child aged less than 5 years will be tested for malaria using a rapid malaria test.
48385091|NCT05173922|BEHAVIORAL|Safety in Dementia|Safety in Dementia is an online tool that, in a stepwise fashion, guides a caregiver individual through decisions related to firearm access for a person with dementia. It includes information and a comparison of the options and their risks and benefits. It guides the caregiver through clarification of personal feelings and values and identifying their decision/plan. The control group will view national Institute on Aging Home Safety Checklist.
48385092|NCT00448929|DEVICE|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
48385093|NCT04014296|BEHAVIORAL|High Protein Diet|16 week group-based weight loss program with high protein diet. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine the HP diet with supervised resistance training counseling (2 days per week) or add a protein supplement.
48723821|NCT00255775|PROCEDURE|complementary or alternative medicine procedure|
48385094|NCT04014296|BEHAVIORAL|Resistance Training|16 week weight loss program with normal protein diet and resistance training counseling. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:20%:26%. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed after 8 weeks. Non-responders will be randomized to either combine resistance training with HP/protein supplement or add supervised sessions with a personal trainer (2 days per week) to the resistance training regimen.
48385095|NCT06652009|OTHER|Radical nephroureterectomy|Radical nephroureterectomy
48723822|NCT02420548|BEHAVIORAL|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
48723823|NCT02420548|BEHAVIORAL|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
48723824|NCT01381536|DRUG|GSK1550188 1mg/kg or 10mg/kg|IV one shot
48026533|NCT02509689|BEHAVIORAL|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
48026534|NCT06447038|DIAGNOSTIC_TEST|albumin creatinine ratio|Albumin creatinine ratio, this test is routinely performed in urine.
48723825|NCT00290498|DRUG|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
48723826|NCT00290498|DRUG|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m\^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
48723827|NCT00290498|DRUG|Doxorubicin|Arm A: Doxorubicin 50 mg/m\^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
48026535|NCT02546544|DRUG|Linsitinib|
48026536|NCT00390390|DRUG|Lansoprazole|
48026537|NCT04402333|PROCEDURE|Robotic Interval Debulking Surgery|Interval debulking surgery carried out in a minimally invasive manner using the Da Vinci Robot.
48183358|NCT03806465|OTHER|Sentinel hospital surveillance|Cerebrospinal samples will be collected from all children hospitalised and suspected of having meningitis.
48183359|NCT03806465|OTHER|Community mortality surveillance|A verbal autopsy will be performed
48385096|NCT06652009|RADIATION|Radical radiotherapy|Radical radiotherapy with stereotactic body radiation therapy (SBRT) or moderately segmented radiotherapy
48385097|NCT06087029|PROCEDURE|TEVAR|Thoracic endovascular aortic repair
48385098|NCT06087029|OTHER|Guideline directed medical therapy and surveillance of dissection|Routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
48385099|NCT05518409|BIOLOGICAL|Detection of cytof in peripheral PBMC|Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.
48723828|NCT00290498|DRUG|Vincristine|"Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
48522770|NCT04913558|OTHER|Aerobic exercise|"The exercise will be performed by using the treadmill as the following:~- The first stage (warming up): It consists of 5 minutes warming up with the treadmill speed set at 1.0 mile per hour.~- The second stage (active stage): It consists of 20 minutes with the treadmill speed set at 3.0 miles per hour.~- Third stage (cooling down): It consists of 5 minutes of cooling down with the treadmill speed set at 1.0 miles per hour."
48723829|NCT00290498|DRUG|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
48723830|NCT00290498|DRUG|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
48723831|NCT00290498|DRUG|Cytarabine|Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
48723832|NCT00290498|DRUG|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
48723833|NCT00212706|DRUG|ONO-8025 (KRP-197)|
48723834|NCT04349033|BEHAVIORAL|Emotional Disclosure and Brain Education|Patients are interviewed about a number of aspects of their lives (stress, other illnesses, personality, adverse childhood experiences), and these are explored as part of education of the brain's role in their pain.
48723835|NCT04349033|BEHAVIORAL|Emotional Disclosure Only|Patients are interviewed about a number of aspects of their lives, but without brain education
48723836|NCT04349033|BEHAVIORAL|Pain Information Control|Patients are interviewed about their pain history and other basic, non-disclosure information about their health.
48723837|NCT03403023|DEVICE|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
48723838|NCT03403023|DRUG|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
48723839|NCT03525132|PROCEDURE|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
48026538|NCT05095584|DIAGNOSTIC_TEST|3 meter backward walk test|validity and reliability of 3-meter backward walk test in lower limb amputation group
48026539|NCT01681082|BEHAVIORAL|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
48026540|NCT05604729|DRUG|Botulinum toxin type A|Botulinum Neurotoxin type A
48026541|NCT05604729|DRUG|Placebo|Saline solution
48026542|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
48385100|NCT05518409|DRUG|Donepezil for patients with AD and DLB|The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
48385101|NCT02555254|PROCEDURE|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
48723840|NCT02102399|BEHAVIORAL|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
48723841|NCT02102399|BEHAVIORAL|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
48723842|NCT01176565|DRUG|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
48723843|NCT00226070|PROCEDURE|interview and advising|
48723844|NCT00226070|BEHAVIORAL|3 follow up interviews and personal advising|
48723845|NCT00226070|PROCEDURE|interview SF-36 self rated health|
48723846|NCT00251251|DEVICE|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
48723847|NCT00251251|DEVICE|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
48723848|NCT02087722|DRUG|KI1001|
48723849|NCT02087722|DRUG|Placebo|
48723850|NCT04129385|PROCEDURE|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
48723851|NCT02014584|DRUG|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
48723852|NCT02014584|DRUG|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
48723853|NCT03684694|DRUG|Loncastuximab Tesirine|Intravenous (IV) infusion.
48723854|NCT03684694|DRUG|Ibrutinib|Oral capsule.
48723855|NCT01798030|OTHER|Vitamin D|N/A, frozen specimen study
48723856|NCT04466527|DEVICE|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
48723857|NCT00175266|DRUG|alemtuzumab|
48723858|NCT00175266|PROCEDURE|islet transplant|
48385102|NCT02555254|PROCEDURE|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
48385103|NCT05961371|OTHER|Resistance Training|Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
48026543|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
48385104|NCT02773641|DRUG|Botulinum Toxin Type A|
48385105|NCT02773641|DRUG|Sterile Saline Solution|
48385106|NCT03793309|DRUG|Vitamin D|Oral vitamin D
48520914|NCT01614873|DEVICE|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
48520915|NCT00137150|PROCEDURE|Placement of implants|
48520916|NCT00657189|DRUG|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
48183360|NCT02229227|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
48183361|NCT02229227|DRUG|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
48183362|NCT05038540|PROCEDURE|Scaling and root planing|Phase 1 periodontal therapy
48385107|NCT06652724|BEHAVIORAL|Dynamic interpersonal therapy (DIT)|"Dynamic interpersonal therapy (DIT) is a dynamically oriented brief psychotherapeutic intervention based on attachment and mentalization theory that views symptoms of depression and anxiety as responses to interpersonal difficulties.~This intervention helps patients to understand the connection between their symptoms and their relationships by identifying a core, non-conscious, repetitive pattern of relating. Previous studies have shown positive results: significant reductions have been observed for the variables somatic symptom severity, depression, anxiety, and general psychiatric symptoms.~It consists of 16 sessions (one per week) for a total of 4 months."
48385108|NCT06652724|BEHAVIORAL|technique of expressive writing (TSE)|"The expressive writing technique created by Pennebaker has shown beneficial health effects in different contexts since, through writing, it is possible to mentally reorganize a difficult event, allowing the mind to find meaning to what has happened or is happening. This technique can be a resource that can promote activation from the ability to recognize, express, and process the unspoken emotional, psychological, and relational, helping to achieve emotional and physiological feedback. Although the application of expressive writing in patients with fibromyalgia is an under-explored area of investigation in the international literature, several studies have shown its effectiveness in some chronic syndromes.~It consists of 8 meetings (one every fortnight) for a total of 4 months."
48520917|NCT00657189|DRUG|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
48520918|NCT00657189|DRUG|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
48520919|NCT00657189|DRUG|MEDI-545|100 mg every week × 13 doses
48723859|NCT00175266|DRUG|infliximab|
48723860|NCT03031067|DEVICE|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
48520920|NCT00657189|DRUG|Placebo|SC Placebo every week × 13 doses
48026544|NCT00701051|BEHAVIORAL|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
48026545|NCT00701051|BEHAVIORAL|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
48183363|NCT00150618|DRUG|SPD503 (1 mg)|
48183364|NCT00150618|DRUG|SPD503 (2 mg)|
48183365|NCT00150618|DRUG|SPD503 (3 mg)|
48183366|NCT00150618|DRUG|SPD503 (4 mg)|
48183367|NCT00150618|DRUG|Placebo|
48183368|NCT00673907|OTHER|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
48183369|NCT02968238|BEHAVIORAL|Cognitive-behavioral therapy|10 weekly sessions of cognitive-behavioral therapy
48183370|NCT02968238|BEHAVIORAL|Yoga|10 weeks of biweekly yoga sessions (N = 20)
48522771|NCT04913558|OTHER|Traditional Treatment|"1. General advice for reducing fatigue and stress~2. Fluid and diet advice~3. Carrying the Baby~4. While Breastfeeding in a sitting position~5. Selecting Clothing"
48522772|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
48522773|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
48522774|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
48723861|NCT01826435|BEHAVIORAL|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
48520921|NCT06486870|DRUG|Gonadotropin|Human menopausal gonadotrophin (hMG) is given starting on cycle day three in a dose of 75 IU alternate days. The aim of treatment is to achieve mono-ovulation. Monitoring of treatment is achieved by serial transvaginal ultrasound scanning every other day starting from cycle day nine. Size and number of follicles is recorded in patients follow up sheets. The dose of hMG is reviewed around stimulation day 10 and if follicular development is unsatisfactory, the dose is increased to 75 IU daily .If a good response is not achieved day16 ; the cycle is cancelled. A new cycle is commenced with a higher starting dose of hMG (75 IU per day). When one follicle reached a size of \> =18 mm a single dose of 10,000 IU human chorionic gonadotrophin (hCG, Pregnyl, Epifasi, Choriomon) is given.
48723862|NCT04337008|OTHER|blood draw|20 mL blood draw will be performed at J1 et J7
48723863|NCT05006508|BEHAVIORAL|Lifestyle tool|Regular use of the digital Lifestyle tool
48723864|NCT03930992|DRUG|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
48723865|NCT03930992|DRUG|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
48385109|NCT06652724|OTHER|Treatment as Usual (TAU)|The usual treatment involves two contacts by a rheumatologist/neurologist (depending on the clinical condition of the patient) during a four-month period, lasting about 10-15 minutes each, in which patients will be followed up medically. This treatment represents the active control group, planned to monitor specific aspects of the psychotherapeutic intervention, which aims to equate a good standard of primary care.
48385110|NCT01231880|DRUG|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
48385111|NCT01231880|DRUG|Monthly IPT using DP|Given every month
48385112|NCT01231880|DRUG|Placebo given every month|No active ingredient
48385113|NCT01281176|DRUG|Carboplatin|Given IV
48385114|NCT01281176|OTHER|Laboratory Biomarker Analysis|Correlative studies
48385115|NCT01281176|DRUG|Paclitaxel|Given IV
48385116|NCT01281176|OTHER|Pharmacological Study|Correlative studies
48520922|NCT06486870|DRUG|Letrozole|5 mg LE oral tablets are administered on the fifth day of menses and then every day for 5 days. Treatment is repeated for up to six cycles
48520923|NCT06486870|PROCEDURE|laparoscopic ovarian drilling|"Laparoscopic ovarian drilling will be done according to the following:~Electrocautery using a mixed current in monopolar electrosurgical needle will be into introduced through the ovarian ipsilateral parts and applied up to 4 point cauterisation of the ovarian capsule, each for 4 second, at 40 W and for a diameter of 3mm and a depth of 4 mm in the antimesentric surface . (Amer et al 2003, Sawant S et al 2019) ,the procedure will be applied for one ovary .~The patient under the study will be followed up to six months of continuous marital life after the procedure"
48520924|NCT02071030|PROCEDURE|Third molar removal|Surgically removing the third molar in the lower jaw
48520925|NCT05576090|BEHAVIORAL|Mindfulness Meditation|The mindful awareness practices (MAPS) for Sleep intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA. This intervention includes educational and behavioral content related to sleep, including the importance of regularity of sleep schedules, minimizing noise and light, and reducing caffeine use later in the day. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for questions and group discussion. Home practice is a key component of MAPs and is particularly important for addressing sleep disturbance. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes, with practice prior to bedtime, and to practice at night if they awake and cannot return to sleep.
48723866|NCT03930992|DRUG|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
48723867|NCT03930992|DRUG|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
48385117|NCT01281176|DRUG|Vorinostat|Given PO
48385118|NCT04794595|PROCEDURE|CBP|continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines
48385119|NCT06314009|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL) and other Magnetic Resonance (MR) sequences
48385120|NCT04024722|PROCEDURE|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
48183371|NCT01356771|OTHER|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~* Current and past skin cancer screening practices~* Current and past sun protection practices~* Attitudes about skin cancer and sun protection~* Knowledge of melanoma"
48183372|NCT04350099|OTHER|quetionnary|Participants will complete self-questionnaires at different times during the epidemic
48183373|NCT02788266|PROCEDURE|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
48183374|NCT02788266|PROCEDURE|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
48183375|NCT02788266|PROCEDURE|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
48183376|NCT05803681|DEVICE|Capacitive Coupled Electric Fields (CCEF)|In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.
48183377|NCT05803681|OTHER|Calssic clinical protocol|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
48183378|NCT06216652|OTHER|downhill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the first group performed downhill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
48183379|NCT06216652|OTHER|uphill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the second group performed uphill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
48183380|NCT06216652|OTHER|walking with no incline|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the third group performed walking with no incline walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
48183381|NCT01806012|DEVICE|Sealing tissue with the Enseal device|
48723868|NCT02737384|BIOLOGICAL|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
48723869|NCT06102109|PROCEDURE|Pars plana vitrectomy|25gauge pars plana vitrectomy: to remove the vitreous if present
48723870|NCT06102109|PROCEDURE|IOL explantation|Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity
48723871|NCT06102109|PROCEDURE|Scleral IOL fixation Yamane Technique|Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.
48723872|NCT06102109|PROCEDURE|"Scleral IOL fixation 4-flanged Technique"|Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.
48723873|NCT01299402|DIETARY_SUPPLEMENT|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
48183382|NCT01806012|PROCEDURE|Conventional supracervical hysterectomy|
48183383|NCT00980590|DEVICE|Airway Scope|Tracheal intubation by Airway Scope
48723874|NCT01299402|DIETARY_SUPPLEMENT|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
48723875|NCT06508008|PROCEDURE|continuous negative pressure suction|(1) Open the mouth with a tongue depressor; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) Insert a suction tube into the mouth to aspirate phlegm.
48723876|NCT06508008|PROCEDURE|Intermittent negative pressure sputum suction through oral pharyngeal airway|(1) Insert the oropharyngeal airway parallel into the oral cavity; (2) Apply paraffin oil to the front end of the sputum suction tube; (3) The suction tube is inserted into the deep oral cavity through the middle lumen of the oropharyngeal airway; (4) Intermittent negative pressure for suction and suction of sputum
48723877|NCT04971252|DIAGNOSTIC_TEST|Hematologic tests for patients with diabetes mellitus and chronic kidney disease|Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease
48723878|NCT04795700|BEHAVIORAL|MSC intervention|Patients in the intervention group had access to conventional care, in addition to receiving the 8 weeks MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The intervention is mainly out-of-hospital intervention, supplemented by short-term in-hospital intervention. Among them, the first and second weeks of the intervention project in the hospital phase focus on guiding the research subjects to understand the content of mindful self-compassion and emotions, and carry out basic mindful self-compassion training; the content of the 3-8th week of the intervention program outside the hospital, Focus on the maintenance of mindful self-compassion training and the promotion of mindful life. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
48183384|NCT00980590|DEVICE|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
48723879|NCT02073851|DEVICE|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
48723880|NCT01264419|DEVICE|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
48183385|NCT05291377|OTHER||
48183386|NCT04492813|DRUG|Pharmacokinetic of propofol and remifentanil|Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
48723881|NCT05703594|DIAGNOSTIC_TEST|performance based balance test|Performance based balance test; 360° Turn Test, Alternative Step Test, Pen Pickup Test,5 Repetitive Stand Up and Sit Test, 10 Meter Walk Test Lower extremity strengthening exercises; Quadriceps femoris strengthening exercise Hamstring strengthening exercise Gluteus medius muscle strengthening exercise Strengthening exercise for hip adductor muscles Balance exercises; Standing tandem walk Standing side walks Standing cross walks Standing back walking
48723882|NCT02139904|DRUG|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
48723883|NCT02139904|OTHER|Active Symptom Control|
48723884|NCT01158690|OTHER|resource card|the intervention group receives an envelop with resource card
48723885|NCT01158690|OTHER|no resource card|the control group receives an envelop without resource card
48723886|NCT00544284|DRUG|bortezomib|
48183387|NCT04312542|PROCEDURE|Measurement of Biomarkers|Participants will have blood drawn at a 9-month and 12-month visit for the measurement of biomarkers.
48183388|NCT02683499|PROCEDURE|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
48183389|NCT03091816|DEVICE|Computed Tomography Perfusion Imaging|Undergo DPCT
48183390|NCT03091816|OTHER|Laboratory Biomarker Analysis|Correlative studies
48183391|NCT03091816|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
48183392|NCT04036851|BEHAVIORAL|Peer support intervention|Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
48522775|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
48723887|NCT00544284|DRUG|temozolomide|
48723888|NCT00544284|OTHER|pharmacological study|
48723889|NCT01431885|PROCEDURE|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
48723890|NCT01431885|PROCEDURE|Cervical change|Diagnosis will be made by digital examination of cervical change
48723891|NCT02149017|RADIATION|SNUBH-NM-333(18F)|5-10 mCi
48723892|NCT00016549|BIOLOGICAL|Bevacizumab|
48723893|NCT03801434|DRUG|Ruxolitinib|Given PO
48026546|NCT03165201|DEVICE|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
48183393|NCT04484389|OTHER|Telerehabilitation|Exercise protocol according to Ipaq will be prepared for 30 patients with chronic disease . Exercise protocol; warm-up exercises include, stretching exercises, postural exercises, aerobic exercise and cooling exercises. People will practice the exercises 3 days a week for 6 weeks. People will need to reserve 30 minutes a day for this study.
48183394|NCT04484389|OTHER|Exercise brochure|General exercise protocol will be prepared and given to the control group as a brochure
48183395|NCT03367598|GENETIC|rs662799 (APOA5 -1131T>C)|Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism.
48183396|NCT00652509|BEHAVIORAL|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
48522776|NCT00810147|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
48522777|NCT01368497|DRUG|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
48723894|NCT02006069|DEVICE|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
48385121|NCT03094949|PROCEDURE|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
48385122|NCT03094949|PROCEDURE|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
48385123|NCT03558607|DRUG|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~* If Age \< 55 years and ECOG PS \< 2 : 7+3 regimen~* If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
48385124|NCT02286726|OTHER|Laboratory Biomarker Analysis|Correlative studies
48385125|NCT02286726|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
48385126|NCT06646536|OTHER|Anti-gravity treadmill training|Patients will participate to anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
48520926|NCT05576090|BEHAVIORAL|Sleep Education|The Sleep Education intervention provides education and behavioral content based on the National Institutes of Health and National Sleep Foundation tips for better sleep (e.g., changing poor sleep habits and establishing a bedtime routine). Each session provides didactic instruction, review of behavioral techniques, and opportunity for questions. Homework includes practicing sleep hygiene and weekly reading. Key components of the intervention include information about sleep biology, characteristics of healthy and unhealthy sleep, sleep problems, stress biology and stress reduction, self-monitoring of sleep behavior, relaxation methods for improving sleep, and weekly behavioral sleep hygiene strategies.
48522778|NCT06392854|DRUG|Insulin|2 dose insulin infusion 4 hours
48723895|NCT00002077|DRUG|Fluconazole|
48723896|NCT01075984|DRUG|Posaconazole|
48026547|NCT00099983|DRUG|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
48723897|NCT01075984|DRUG|Dextrose 5% in water|
48723898|NCT05587166|OTHER|ultrasound guided adductor canal block|ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
48723899|NCT05257343|DIETARY_SUPPLEMENT|Liquid Placebo Supplementation|8-weeks of supplementing with a visually identical liquid placebo supplement.
48723900|NCT05257343|DIETARY_SUPPLEMENT|Liquid Iron Supplement (Blood Builder ®)|8-weeks of supplementing with a liquid iron supplement (Blood Builder ®)
48723901|NCT01732913|DRUG|Placebo|Tablets administered orally twice daily
48723902|NCT01732913|DRUG|Rituximab|375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
48026548|NCT00099983|DRUG|Placebo|Placebo
48026549|NCT01175226|DRUG|BTA798|BTA798 twice daily
48723903|NCT01732913|DRUG|Idelalisib|150 mg tablets administered orally twice daily
48723904|NCT02774304|DEVICE|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
48723905|NCT02774304|DEVICE|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
48723906|NCT02648672|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
48723907|NCT02648672|DRUG|Placebo|
48723908|NCT01436266|DRUG|Misoprostol|400 mcg buccally 2 hours prior to procedure
48026550|NCT01175226|DRUG|Placebo|Placebo twice daily
48183397|NCT00652509|BEHAVIORAL|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
48183398|NCT01988298|DRUG|Ibuprofen|Ibuprofen 400 mg each 8 hours
48183399|NCT01988298|DRUG|Acetaminophen|Control group
48723909|NCT01436266|OTHER|Folic acid|2mg buccally 2 hours prior to procedure
48026551|NCT00661492|DRUG|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
48183400|NCT00358644|DRUG|Decitabine|20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
48183401|NCT05167084|DRUG|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
48183402|NCT05167084|DRUG|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
48723910|NCT01624090|DRUG|Mithramycin|30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
48723911|NCT05649592|DIAGNOSTIC_TEST|Magnetic Resonance Hydrolipid Separation Imaging|"MRHS was used to measure different muscle percent fat of core muscles. MRHS, also called Dixon imaging, mainly used the different resonant frequency between the hydrogen nuclei in water and in fat to perform the data acquisition at different echo times (TE). The Dixon sequence basically acquires two images, one image with water and fat signals in-phase and the other with water and fat signals out-of-phase: the sum and subtraction of the two images allow the production of a water-only image and a fat-only image. Scanning equipment: 3.0T superconducting Siemens Skyra Scanner.~Scanning parameters: TR5.36ms, TE1.24ms, Flip Angle 9°, number of layers was 44-60, thickness of layer was 5.0 mm, layer interval 1.0mm, FOV50cm×50cm, the scanning time was 12s×5."
48385127|NCT06646536|OTHER|Conventional treadmill training|Patients will participate to walking program on a standard treadmill in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
48385128|NCT06646536|OTHER|Standard physiotherapy and rehabilitation program|Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
48385129|NCT03039686|DRUG|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
48385130|NCT03039686|DRUG|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
48520927|NCT06052137|DEVICE|Active TBS-DLPFC|"Participants will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
48522779|NCT00136227|BEHAVIORAL|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
48026552|NCT00661492|DRUG|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
48026553|NCT03137862|OTHER|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
48026554|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
48026555|NCT03137862|DIETARY_SUPPLEMENT|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
48026556|NCT01992536|BIOLOGICAL|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
48026557|NCT01992536|BIOLOGICAL|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
48026558|NCT01992536|BIOLOGICAL|Placebo|Saline solution for injection (0.5mL)
48026559|NCT06141642|DEVICE|Self-adaptive serious game|A self-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
48026560|NCT06141642|DEVICE|Non-adaptive serious game|A non-adaptive serious game in immersive virtual reality using the device MetaQuest 1 or 2
48026561|NCT02056301|DRUG|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
48385131|NCT05037409|DRUG|PF-06823859|low dose or high dose intravenous infusion
48385132|NCT05037409|DRUG|Placebo|Intravenous infusion
48385133|NCT06652269|OTHER|Psychopharmacology intervention|Psychotherapy with horses
48723912|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
48723913|NCT02184429|DRUG|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
48723914|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
48723915|NCT02184429|DRUG|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
48183403|NCT05167084|DRUG|Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8 in a total daily dose of 19.9mg
48183404|NCT05167084|DRUG|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8
48183405|NCT04201899|DIETARY_SUPPLEMENT|No intervention - pure observation|Phosphate administration (yes or no)
48183406|NCT00751660|OTHER|laboratory biomarker analysis|
48723916|NCT02184429|DRUG|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
48385134|NCT01198990|BEHAVIORAL|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
48385135|NCT01198990|BEHAVIORAL|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
48183407|NCT00751660|OTHER|screening questionnaire administration|
48183408|NCT00751660|PROCEDURE|bronchoscopic and lung imaging studies|
48183409|NCT00751660|PROCEDURE|computed tomography|
48183410|NCT00751660|PROCEDURE|endoscopic biopsy|
48183411|NCT00751660|PROCEDURE|quality-of-life assessment|
48183412|NCT04834713|OTHER|clinical classification of HFRS|Based upon clinical classification of HFRS , the patients were classified into four types
48385136|NCT05774431|OTHER|There was no intervention necessary.|There was no intervention necessary.
48385137|NCT04232696|DEVICE|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
48385138|NCT04286438|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration.~In subjects with potential drug interaction from recent concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36g infusion.~In patients presenting with intracranial hemorrhage (ICH), brain imaging within 2 hours of initiation of study drug and at least one follow-up brain imaging performed 12-24 hours post completion of PB2452."
48723917|NCT02184429|DRUG|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
48723918|NCT02184429|DRUG|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
48723919|NCT03672630|DRUG|Azithromycin|Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
48723920|NCT03672630|DRUG|Ethambutol|Ethambutol 25 mg/kg \[MYAMBUTOL\]
48723921|NCT03672630|DRUG|Rifampin|Rifampin 600 MG \[RIFADIN\]
48723922|NCT00710385|DRUG|Heroin|Heroin (25 mg)
48723923|NCT00710385|DRUG|Naloxone|.4 mg
48723924|NCT00710385|DRUG|Low Bup Dose|4 and 8 mg
48723925|NCT00710385|DRUG|High Bup Dose|8mg and 16 mg
48723926|NCT00710385|DRUG|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
48723927|NCT00710385|DRUG|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
48723928|NCT00710385|DRUG|Placebo (PCB)|Placebo control administration
48723929|NCT05010447|DEVICE|Virtual Coach App|The avatar-guided app aims to deepen the user's understanding of Acceptance and Commitment Therapy (ACT) and promote application of ACT skills in every-day-life. Event-Sampling-Methodology (ESM) is used to capture the user's progress as it unfolds.
48385139|NCT03790020|DRUG|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
48520928|NCT06052137|DEVICE|TBS-DMPFC|"Participants will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
48520929|NCT06291896|DEVICE|MammoWave|"Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study.~A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts.~The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave.~When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm."
48520930|NCT02474277|OTHER|30 sec chair stand test|diagnostic test for functional impairment
48520931|NCT00651274|DRUG|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
48520932|NCT00651274|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
48520933|NCT06486714|PROCEDURE|Total knee arthroplasty|All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.
48520934|NCT00181558|DRUG|Atrasentan|
48520935|NCT00181558|DRUG|Zoledronic Acid (Zometa)|
48520936|NCT00165555|DRUG|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
48520937|NCT00165555|DRUG|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
48385140|NCT04507646|OTHER|True auricular acupuncture|The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.
48385141|NCT04507646|OTHER|sham auricular acupuncture|The participant in control group will receive acupuncture on ineffective point at ear.
48183413|NCT04578288|PROCEDURE|INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION|The individual target range is defined as: bSBP ± 10 mmHg. The lowest possible SBP target range is 100-120 mmHg. The highest SBP target range is determined on the basis of whether patients receive concurrent IV fibrinolytic therapy or not. In patients where IV fibrinolytic therapy is applied, the highest SBP range is 160-180 mmHg, in patients without concurrent fibrinolytic therapy the highest SBP range is 180-200 mmHg.
48183414|NCT01642433|DRUG|Placebo|Placebo capsules, 3x daily
48183415|NCT01642433|DRUG|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
48183416|NCT06474065|PROCEDURE|Myomectomy|Patients submitted to operation of fibroids removal
48385142|NCT02388659|DEVICE|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
48385143|NCT04059484|DRUG|Amcenestrant|"Pharmaceutical form: Capsule~Route of administration: Oral"
48385144|NCT04059484|DRUG|Fulvestrant|"Pharmaceutical form: Solution for injection~Route of administration: Intramuscular"
48385145|NCT04059484|DRUG|Anastrozole|"Pharmaceutical form:Tablets or capsules~Route of administration: Oral"
48385146|NCT04059484|DRUG|Letrozole|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
48385147|NCT04059484|DRUG|Exemestane|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
48385148|NCT04059484|DRUG|Tamoxifen|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
48385149|NCT06149988|DRUG|THC/CBD S.E powder|A single dose of THC/CBD S.E powder- 500 mg, given orally.
48385150|NCT06149988|DRUG|THC/CBD oil|Followed by a 30-day washout- A single dose of THC/CBD oil- 8 mg, given orally (equivalent dose to the powder).
48385151|NCT01067339|DRUG|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
48385152|NCT01067339|DRUG|placebo|placebo, by mouth, once daily for six months
48385153|NCT06429033|DRUG|PEP (Purified Exosome Product)|Injection of PEP into hypodermis of abdomen
48385154|NCT03337776|OTHER|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
48520938|NCT05494073|PROCEDURE|ACL Reconstruction with Hybrid Remnant Repair|The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
48520939|NCT05494073|PROCEDURE|ACL Reconstruction without Hybrid Remnant Repair|ACL reconstruction without preservation or incorporation of host ACL remnant
48183417|NCT05196971|DRUG|HS-10345 84mg|6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
48385155|NCT03337776|OTHER|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
48385156|NCT00713830|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48385157|NCT00713830|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
48385158|NCT00713830|DEVICE|Pen auto-injector|
48522780|NCT00399126|DRUG|Perifosine|Perifosine oral dose
48522781|NCT00399126|DRUG|Paclitaxel|Paclitaxel IV
48183418|NCT05196971|DRUG|Placebo|6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
48723930|NCT00328471|BEHAVIORAL|care management|
48723931|NCT06007625|OTHER|Machine learning-based prediction model|This model will utilize patient characteristics and disease features to determine the disease's prognosis. The scoring system will also include management information to facilitate prediction of clinical outcomes of different management strategies and potential management that would yield the best prognosis.
48723932|NCT03959202|BEHAVIORAL|ELDERFITNESS|In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
48723933|NCT03959202|OTHER|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
48723934|NCT05511350|DRUG|TJ210001|
48723935|NCT03855852|PROCEDURE|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
48723936|NCT03855852|PROCEDURE|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
48723937|NCT01569386|BEHAVIORAL|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
48723938|NCT01569386|BEHAVIORAL|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
48723939|NCT05648682|OTHER|Salin|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use. SF solution was obtained from the medical company as 500 ml separately for each patient.
48723940|NCT05648682|OTHER|Sodium bicarbonate|Patients were told that they should gargle using approximately two tablespoons of the solution given for each use. The 500 ml distilled water bottle to be used for the SB solution was obtained from the medical company, separately for each patient.
48723941|NCT05648682|OTHER|Thyme honey|Patients were told that they should gargle using approximately 2 tablespoons of the solution given for each use.
48723942|NCT05648682|OTHER|Control|The patients continued to use the antifungal solution containing the active ingredient nystatin, which was prescribed routinely in the clinical procedure, 3 times a day.
48520940|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
48723943|NCT01065311|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
48723944|NCT01065311|BEHAVIORAL|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
48385159|NCT00713830|DRUG|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
48520941|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
48385160|NCT00713830|DRUG|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
48183419|NCT02392104|DRUG|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
48385161|NCT00740532|GENETIC|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
48183420|NCT01115686|DRUG|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks."
48520942|NCT02079740|PROCEDURE|Biopsy|Undergo biopsy
48520943|NCT02079740|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48520944|NCT02079740|PROCEDURE|Computed Tomography|Undergo conventional CT or PET/CT
48520945|NCT02079740|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48520946|NCT02079740|BIOLOGICAL|Navitoclax|Given PO
48520947|NCT02079740|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48520948|NCT02079740|DRUG|Trametinib|Given PO
48520949|NCT05066360|DIAGNOSTIC_TEST|serum antimullerian hormone|serum antimullerian hormone will be analyzed for all participants
48723945|NCT01065311|BIOLOGICAL|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
48723946|NCT00164957|DEVICE|continuous pump feeding|
48723947|NCT00164957|OTHER|intermittent bolus feeding|
48723948|NCT04056780|OTHER|Sample collection study|Sample collection and collection of laboratory values
48723949|NCT06360614|OTHER|Hand massage application|2 sessions of hand massage every day, 2 days a week (Monday and Friday) for 4 weeks
48723950|NCT06360614|OTHER|routine monitoring and nursing care|Routine monitoring and nursing care for 4 weeks
48723951|NCT03470363|DRUG|Sevoflurane Volatile Liquid|
48723952|NCT03470363|DRUG|Bupivacaine / SUFentanil|
48723953|NCT02780973|OTHER|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
48723954|NCT01387724|GENETIC|RNA analysis|
48723955|NCT01387724|GENETIC|polymerase chain reaction|
48723956|NCT01387724|GENETIC|protein expression analysis|
48723957|NCT01387724|GENETIC|proteomic profiling|
48520950|NCT00200902|DRUG|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
48522782|NCT06331169|DRUG|Anlotinib|Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
48522783|NCT06331169|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
48183421|NCT01115686|DRUG|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks."
48183422|NCT03478137|BEHAVIORAL|CPAP intervention|Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
48183423|NCT00304772|DRUG|Fluconazole|400mg/day
48183424|NCT00304772|DRUG|Micafungin|150mg/day
48183425|NCT04187859|BEHAVIORAL|Education Session|Participants will receive an education session from their District Nurse, advising on how to improve their hydration.
48183426|NCT04187859|DEVICE|Prompting Cup|The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink
48723958|NCT01387724|GENETIC|western blotting|
48723959|NCT01387724|OTHER|enzyme-linked immunosorbent assay|
48723960|NCT01387724|OTHER|immunohistochemistry staining method|
48723961|NCT01387724|OTHER|laboratory biomarker analysis|
48723962|NCT01387724|OTHER|liquid chromatography|
48723963|NCT01387724|OTHER|mass spectrometry|
48723964|NCT05241925|OTHER|Rehabilitation, exercise|"Combined training (continuous aerobic + resistance) The protocol will consist of supervised exercise lasting 1h10min each session (5 min of warm-up, 30 min of aerobic exercise, 30 min of resistance exercise and 5 min of cool-down/relaxation).~Combined training (high-intensity interval (IAI) + resistance) - Supervised exercise lasting 30 min each session (5 min warm-up, 20 min IAI and 5 min cool-down/relaxation).~And Resistance Training~- Resistance exercise will be performed at 70-80% of one repetition maximum (1-RM); 2 to 3 sets of 8 to 12 repetitions. The main muscle groups will be trained using training equipment with free weights and body mass of the participants. Exercises included leg extension, seated bicep curl, squat, seated triceps extension, sit-up, seated shoulder press, and standing pulldown"
48723965|NCT00110461|DRUG|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
48723966|NCT00110461|DRUG|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
48723967|NCT00110461|DRUG|placebo|Placebo tablet
48723968|NCT04214678|PROCEDURE|Underwater clip closure|Closure of post-resection defect with endoscopic clips by underwater technique
48723969|NCT04214678|PROCEDURE|Conventional clip closure|Closure of post-resection defect with endoscopic clip by conventional technique
48723970|NCT02024126|OTHER|Exercise therapy|Exercise therapy
48723971|NCT02272218|PROCEDURE|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
48723972|NCT00149019|DRUG|Cell therapy with bispecific antibodies|
48522784|NCT06582290|DIAGNOSTIC_TEST|Oxford Virtual Autism Assessment Tool (OVAAT)|The OVAAT is an online ASD diagnostic tool that has been designed to identify both the external/observable features of autism but also the internal/experiential features of autism.
48723973|NCT06115356|DIAGNOSTIC_TEST|Vitamin D Plasma Level|Blood test measured in ng/ml
48723974|NCT06115356|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis (BIA) technique|Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.
48723975|NCT06115356|DIAGNOSTIC_TEST|Ferritin|Ferritin plasma levels were measured in μg/L
48723976|NCT06115356|DIAGNOSTIC_TEST|C reactive protein (CRP)|CRP plasma levels were measured in mg/L
48723977|NCT06115356|DIAGNOSTIC_TEST|Inflammation-based prognostic scores|Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results
48723978|NCT06115356|OTHER|Liver biopsy|A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification
48723979|NCT02266212|PROCEDURE|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
48723980|NCT00235950|DRUG|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
48723981|NCT00115895|DRUG|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
48723982|NCT04246957|BEHAVIORAL|general quality of life questionary|Every patient will have to fill out a general quality of life questionary : DLQI (Dermatology Life Quality Index)
48723983|NCT04246957|BEHAVIORAL|specific quality of life questionary|Every patient will have to fill out a specific quality of life questionary : Hair Specific Skindex 29.
48723984|NCT02706665|OTHER|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
48385162|NCT05144958|DEVICE|Totally thoracoscopic LAAO - ATRICLIP|The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.
48723985|NCT01397604|DRUG|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
48723986|NCT01397604|DRUG|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
48723987|NCT01397604|OTHER|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
48723988|NCT03048760|OTHER|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
48723989|NCT06530134|OTHER|Driving situation and video feedback|At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation using video feedback.
48723990|NCT06530134|OTHER|Driving situation and usual recommendations (without video feedback)|"At the end of the driving situation, 35 patients will be asked to express themselves and analyze 4 driving situations resulting from the course of the driving situation without video feedback, according to the usual recommendations.~Comparison of responses to all questionnaires and interview grids sent before and after driving, to patients and professionals will determine whether video feedback promotes awareness of the difficulties of driving post-stroke patients."
48723991|NCT02228096|BIOLOGICAL|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10\^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10\^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg).
48723992|NCT01302054|DRUG|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
48026562|NCT02056301|DRUG|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
48723993|NCT01302054|DRUG|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
48026563|NCT03575130|DRUG|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
48723994|NCT03893877|DEVICE|nasal cannula|experimental group will be applied nasal cannula
48026564|NCT03575130|DRUG|Optive eye drops|Artificial tears (placebo)
48723995|NCT03893877|DEVICE|nasal mask|active comparator group will be applied nasal mask
48723996|NCT00037154|DRUG|Saw Palmetto|
48723997|NCT01820312|RADIATION|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
48723998|NCT02706379|OTHER|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
48723999|NCT05102968|BEHAVIORAL|Home-based rehabilitation supporting with the mobile application|For patients with mobile application supportive rehabilitation, patients managed rehabilitation exercise by themselves after the surgery without supervision. Rehabilitation protocol and exercise instruction video were available in the application. Patient could communicate with the physician and therapist via the application.
48724000|NCT05102968|BEHAVIORAL|Supervised rehabilitation by the therapist|For patients with therapist supervised rehabilitation, patients attended one-on-one instructions with a therapist (once a week at post-operative 2nd\~12th week and once two weeks at post-operative 13th\~24th week; totally 16 sessions in the 6-month rehabilitation program) and exercised under supervision at hospital. Subjects would receive additional sessions based on the rehabilitation progress. Subjects could cancel scheduled sessions by personal reasons. We provided telephone consultation without APP communication for subjects in the supervised group.
48724001|NCT04093986|OTHER|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
48724002|NCT04093986|OTHER|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
48385163|NCT05144958|DEVICE|Percutaneous LAAO - WATCHMAN|Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.
48385164|NCT05144958|DEVICE|Hybrid- minimally invasive LAAO - LARIAT|LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
48385165|NCT04496765|PROCEDURE|Total mesorectal excision|Radical resection of rectal cancer and draining lymph nodes
48385166|NCT06137339|OTHER|Avocado Group|Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
48385167|NCT03951701|OTHER|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
48385168|NCT04117048|DEVICE|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
48522785|NCT01153828|DRUG|Retapamulin|Prescription for retapamulin
48522786|NCT01153828|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
48522787|NCT01153828|DRUG|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
48724003|NCT01973556|OTHER|Pharmacist-Physician Collaborative Medication Therapy Management|
48724004|NCT05479890|OTHER|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
48724005|NCT04448353|DIAGNOSTIC_TEST|vascuCAP|adverse event and phenotype classification model
48724006|NCT04180085|DRUG|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
48724007|NCT06298201|OTHER|E-Based Physical Exercise Intervention|The intervention comprises a 6-months home-based resistance training for the lower extremities, conducted twice weekly.
48724008|NCT03481621|DEVICE|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
48724009|NCT03481621|OTHER|Standard care|PT, pain medications, nerve block, etc
48724010|NCT01554514|BIOLOGICAL|rituximab|rituximab intravenously 100 mg every week for four doses
48724011|NCT01936493|GENETIC|DNA analysis|At a future time DNA analysis will be performed
48724012|NCT01936493|OTHER|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
48724013|NCT04777266|BEHAVIORAL|Music therapy and treatment as usual|The session-based intervention programme was designed with an integrated and multimodal perspective of music therapy \[37\], which allows the combination of active and passive activities together with focuses and perspectives based on empirical evidence \[38\]. It was implemented using a process-based approach, adapting content to different phases in the process: initial contact, managing resistance, confidence building, relationships, awareness, and closure. The central focus is on the patient and to adapt and remain flexible in the sessions in accordance with the capabilities and needs of the group members. Different perspectives are integrated via nonverbal communication. The layout and any changes to the setting are made in a gradual way in keeping with the process to foster feelings of security and belonging. Sessions begin with a brief period of breathing which then moves into warming-up and free-expression using instruments, followed by the central activity and the closure.
48183427|NCT03060018|DEVICE|Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor|The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
48724014|NCT03400631|DRUG|Dextrose 0|Dextrose injection at time 0
48724015|NCT03400631|DRUG|Aspiration 0|Aspiration only at time 0
48724016|NCT03400631|DRUG|Dextrose 1|Dextrose injection at week 1
48724017|NCT03400631|DRUG|Aspiration 1|Aspiration only at week 1
48724018|NCT00359723|DRUG|methylphenidate|
48183428|NCT02335905|DRUG|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
48183429|NCT05026268|PROCEDURE|intracorporeal anastomosis|"intracorporeal stapled side-to-side isoperistaltic anastomosis"
48183430|NCT00692549|DEVICE|ultrasound|
48183431|NCT05999890|DRUG|Tapentadol Hydrochloride|Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia
48183432|NCT04402697|OTHER|Dietary and physical activity intervention|"OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling."
48183433|NCT02432651|DRUG|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
48385169|NCT00819091|DRUG|BI 1356|5mg orally (po) tablet qd
48724019|NCT02980627|BEHAVIORAL|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
48724020|NCT01132586|DRUG|Lenalidomide|Given PO
48724021|NCT01132586|DRUG|Cytarabine|Given IV
48724022|NCT01132586|DRUG|Idarubicin|Given IV
48724023|NCT01132586|OTHER|Pharmacological Study|Correlative studies
48724024|NCT01132586|OTHER|Laboratory Biomarker Analysis|Correlative studies
48724025|NCT02984449|BEHAVIORAL|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
48724026|NCT02984449|BEHAVIORAL|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
48724027|NCT00002580|DRUG|cyclophosphamide|
48724028|NCT00002580|DRUG|fluorouracil|
48724029|NCT00002580|DRUG|goserelin acetate|
48724030|NCT00002580|DRUG|leuprolide acetate|
48724031|NCT00002580|DRUG|methotrexate|
48724032|NCT00002580|DRUG|tamoxifen citrate|
48724033|NCT00002580|PROCEDURE|conventional surgery|
48724034|NCT00002580|PROCEDURE|laparoscopic surgery|
48724035|NCT00002580|PROCEDURE|oophorectomy|
48724036|NCT00002580|RADIATION|radiation therapy|
48724037|NCT00275756|DRUG|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
48724038|NCT00275756|DRUG|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
48724039|NCT00275756|DRUG|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
48724040|NCT00275756|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
48724041|NCT00275756|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
48724042|NCT00275756|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
48724043|NCT06285123|BEHAVIORAL|REP|"REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance."
48724044|NCT06285123|BEHAVIORAL|Facillitation|Facilitation is a process of interactive problem-solving via a supportive consultation relationship. Facilitation is delivered by an expert who meets regularly with site quality improvement leaders to support interactive problem-solving to address local barriers and unanticipated implementation challenges. In contrast to the group-based, brief technical assistance in REP, facilitation is individualized consultation with the site clinical champion that generates highly customized, local solutions that can potentially be sustained by the local providers and champions.
48724045|NCT01331967|DRUG|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
48724046|NCT04358159|DEVICE|Ventralex|Repair of the hernia by a Ventralex patch in sublay position
48724047|NCT04358159|DEVICE|Progrip|Repair of the hernia by a Progrip mesh in onlay position
48724048|NCT01088854|DEVICE|CPAP|unique session of 30-minute of continuous airway positive pressure
48724049|NCT06275308|OTHER|Ventilation manipulation|Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
48724050|NCT02623504|DRUG|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
48724051|NCT02623504|DRUG|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
48724052|NCT05618418|OTHER|No intervention|No intervention
48724053|NCT02008357|DRUG|Placebo|Administered IV
48724054|NCT02008357|DRUG|Solanezumab|Administered IV
48724055|NCT06380127|BEHAVIORAL|Exercise training|The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
48026565|NCT03575130|PROCEDURE|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
48183434|NCT02432651|DRUG|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
48183435|NCT02432651|DRUG|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
48724056|NCT04953624|DIAGNOSTIC_TEST|Appetite rating scale CNAQ|Chinese version of Appetite rating scale CNAQ
48724057|NCT03628729|OTHER|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
48724058|NCT03628729|OTHER|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
48385170|NCT00819091|DRUG|Placebo|Placebo matching BI 1356 5mg one tablet daily
48522788|NCT05255731|RADIATION|Low frequency laser activated photobiomodulation|"Protocol description Infrared: analgesia, biostimulation of tissues, edema and hyperemia (hard and soft tissues). There will be 11 laser application points, 3 intra-oral and 8 extra-oral, with a total dose of 33J.~Intraoral: one point in the region of the mandibular lingula (point of submersion of the mandibular nerve), one vestibular point and one lingual point in relation to the alveolus of the extracted wisdom tooth.~Extraoral: for muscle relaxation, five points on the masseter muscle; for oedema drainage, one point in each lymph node region: parotid, submandibular and buccal."
48724059|NCT03408210|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
48183436|NCT02432651|DRUG|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
48183437|NCT00305344|PROCEDURE|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
48385171|NCT05026879|BIOLOGICAL|Inactivated COVID-19 vaccine (CoronaVac)|The adverse events due to an inactivated COVID-19 vaccine.
48385172|NCT05656430|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. The 20 modules that the intervention consists of include psycho-educational texts as well as examples and exercises.
48385173|NCT05823194|PROCEDURE|Fertility sparing surgery|Sparing the uterus and/or ovaries of the patients suffering from gynecologic malignancies to keep the patients' fertility
48026566|NCT02240082|BEHAVIORAL|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
48183438|NCT00305344|BIOLOGICAL|Cord blood|Develop Cord blood vaccine
48026567|NCT05276570|DRUG|ARO-RAGE|single or multiple doses of ARO-RAGE by inhalation of nebulized solution
48026568|NCT05276570|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
48026569|NCT02326103|DRUG|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
48026570|NCT02326103|DRUG|Placebo|
48183439|NCT00004146|RADIATION|radiation therapy|Undergo radiotherapy
48183440|NCT00004146|DRUG|carboxyamidotriazole|Given orally
48183441|NCT00004146|OTHER|pharmacological study|Correlative studies
48183442|NCT04719299|BEHAVIORAL|Tell-Play-Do|Using smart phone application
48385174|NCT01348659|DRUG|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
48385175|NCT01348659|DRUG|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
48522789|NCT05255731|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
48520951|NCT00200902|OTHER|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
48520952|NCT00200902|BEHAVIORAL|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
48520953|NCT06392529|DRUG|Voriconazole Powder|The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
48520954|NCT02910804|DRUG|68Ga-BBN-IRDye800CW|
48520955|NCT02910804|DEVICE|PET/NIRF|
48520956|NCT02910804|PROCEDURE|PET/NIR fluorescent imaging-guided surgery|
48520957|NCT01215773|DRUG|Placebo|Matching to HEA 200 mg tablet, oral administration
48520958|NCT01215773|DRUG|BI 671800|High dose oral administration
48520959|NCT01215773|DRUG|BI 671800|Medium dose oral administration
48520960|NCT01864707|OTHER|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
48520961|NCT01864707|OTHER|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
48520962|NCT01864707|OTHER|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
48520963|NCT01226030|DRUG|M2ES 7.5mg|M2ES 7.5mg
48724060|NCT03408210|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
48724061|NCT04185506|BEHAVIORAL|DBT+BWL|DBT skills include a focus on emotion regulation, distress tolerance, and mindfulness techniques. BWL includes a focus on monitoring of food intake, calorie reduction, and dietary and physical activity education.
48724062|NCT03168360|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
48520964|NCT01226030|DRUG|M2ES 15mg|M2ES 15mg
48520965|NCT01226030|DRUG|M2ES 30mg|M2ES 30mg
48520966|NCT01226030|DRUG|M2ES 60mg|M2ES 60mg
48520967|NCT05323708|BIOLOGICAL|Bmab 1000|60mg/ml Prefilled syringe single dose
48520968|NCT05323708|BIOLOGICAL|Prolia®|60mg/ml Prefilled syringe single dose
48520969|NCT05938114|OTHER|Bonalive|Bonalive® is a bioactive glass synthetic bone substitute material that has been shown to have a low substitution rate and antibacterial properties. It has been used successfully in the orthopaedics, craniofacial and ear nose and throat (ENT) specialities for the treatment of osteomyelitis, sinusitis and bony cyst cavities. There have also been a few maxillofacial surgery case reports on its usage in the jaws.
48520970|NCT05938114|OTHER|Bio-Oss®|Bio-Oss® is a bovine xenogeneic bone graft substitute that is widely used in regenerative dentistry. Bio-Oss® is very similar to human bone in its structure and chemical make-up. The material's porosity allows for vascularisation and new bone formation.
48520971|NCT03044028|DEVICE|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
48520972|NCT04090125|BEHAVIORAL|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
48520973|NCT04090125|BEHAVIORAL|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
48520974|NCT04459039|DRUG|1000 mL 0.9% sterile saline|Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
48724063|NCT06530888|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
48724064|NCT06530888|OTHER|Routine practice (r-PT)|Intervention planning as usual.
48724065|NCT01940393|DRUG|Cetirizine|Drug administration
48724066|NCT01940393|DRUG|Desloratadine|Drug Administration
48183443|NCT04719299|BEHAVIORAL|Tell-Show-Do|Using traditional behavior management technique
48183444|NCT03747887|BEHAVIORAL|Daily Report Card|Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
48183445|NCT03747887|OTHER|School as Usual|The Individualized Education Program will be implemented as usual, with no additional study-related supports.
48026571|NCT00229008|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
48026572|NCT00229008|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
48183446|NCT02847481|PROCEDURE|fecal microbiota transplantation|fecal microbiota transplantation
48183447|NCT02847481|DRUG|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
48183448|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
48183449|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
48183450|NCT02614690|PROCEDURE|No Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
48183451|NCT02614690|PROCEDURE|Univalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
48385176|NCT01849029|BEHAVIORAL|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
48385177|NCT06652672|PROCEDURE|Organ-sparing surgery|Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.
48385178|NCT06652672|PROCEDURE|Standard of care segmental resection|Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
48385179|NCT05465044|OTHER|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
48385180|NCT05465044|OTHER|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
48385181|NCT04179578|PROCEDURE|Crura plastic|Closure of hiatus with a running suture
48385182|NCT04859699|BEHAVIORAL|COVID-19 Health Education Comic Books and Videos|Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
48385183|NCT06137729|DRUG|PF-07899895|Participants will receive oral ascending doses.
48385184|NCT06137729|DRUG|Placebo|Participants will receive matching placebo.
48385185|NCT01212926|DEVICE|Echographic analysis of myocardial deformation in 2D strain|
48520975|NCT04459039|DRUG|250 mL 0.9% sterile saline|Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.
48520976|NCT04364178|BIOLOGICAL|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
48026573|NCT04455919|OTHER|Wait-list group|The wait-list group benefit from a 8-week yoga program after the interventional group
48026574|NCT04455919|OTHER|Yoga group|During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
48026575|NCT02607579|DRUG|Exparel|
48026576|NCT02607579|DRUG|Ropivacaine|
48026577|NCT00801827|DRUG|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
48026578|NCT03799562|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
48026579|NCT03799562|DRUG|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
48026580|NCT03647501|DEVICE|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
48026581|NCT03647501|DEVICE|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
48520977|NCT04364178|BIOLOGICAL|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
48520978|NCT02814344|DEVICE|Electrohysterography|
48724067|NCT01940393|DRUG|Fexofenadine|Drug administration
48724068|NCT01940393|DRUG|Ebastine|Drug administration
48724069|NCT01940393|DRUG|Bilastine|Drug administration
48724070|NCT01263015|DRUG|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
48724071|NCT01263015|DRUG|Atripla|Atripla once daily on an empty stomach
48724072|NCT01263015|DRUG|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
48724073|NCT01263015|DRUG|Abacavir/Lamivudine Placebo|matching placebo taken once daily
48724074|NCT01263015|DRUG|Dolutegravir placebo|matching placebo taken once daily
48520979|NCT03173157|OTHER|Value Feedback Email|a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
48724075|NCT01263015|DRUG|Atripla placebo|matching placebo taken once daily on an empty stomach
48520980|NCT01942421|PROCEDURE|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
48724076|NCT03681613|OTHER|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
48724077|NCT03681613|OTHER|NEMEX program|The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.
48724078|NCT05099159|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
48724079|NCT05099159|DRUG|Placebo|Matching placebo orally once daily
48724080|NCT05583760|PROCEDURE|Experimental: Osteopathic manipulation TUG for scaphoid bone|The sequence of execution of the scaphoid TUG technique shall be applied as follows. Patient in the supine position. The inner hand of the intervener makes contact with the pisiform through the hypothenar eminence and ulnar border of the hand over the scaphoid tubercle, the outer hand reinforces the contact. The thumbs are directed to the sole of the patient's foot. The parameters are sought by bringing the sole of the foot into eversion, thus bringing the scaphoid into internal rotation (the direction of correction). In order to reduce the slack, the operator drops his body weight backwards while increasing the internal rotation parameter of the scaphoid. The manipulation is performed by associating a rapid traction movement with an increase of the correction parameter towards the internal rotation of the scaphoid.
48724081|NCT05583760|PROCEDURE|Sham group: Sham osteopathic manipulation TUG for scaphoid bone|The intervention will be performed in the same way as the intervention group, without actually performing the TUG manipulation on the scaphoid bone, only placing it in tension.
48724082|NCT02062203|DRUG|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
48183452|NCT02614690|PROCEDURE|Bivalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
48724083|NCT02062203|DRUG|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
48724084|NCT02062203|DRUG|Placebo|Single oral dose of placebo
48026582|NCT01902849|OTHER|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~* T0- before the induction of anesthesia (venous cannula insertion time)~* T1- after induction but before starting surgery~  * In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~ * In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~* T2, T3- at 2 and 24 hours after surgery"
48183453|NCT03573869|PROCEDURE|Cryoballoon ablation|Left atrial ablation using cryoballoon to achieve pulmonary vein isolation
48183454|NCT03655457|DEVICE|group 1 Poractant alfa|Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
48183455|NCT03655457|DEVICE|group 2 beractant|lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
48183456|NCT02717182|OTHER|interviews|interviews
48183457|NCT02609542|OTHER|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
48026583|NCT00059475|DRUG|Glycoprotein 100 (GP100): 209-217 (210M)|
48385186|NCT06565533|BEHAVIORAL|Retrogressive imagery (RETI)|"Week 1-2: Participants were asked to imagine a complete version of the FT imagery script included: a) Visualizing the court lines, the basket, and themselves standing at the free-throw line, focusing on their shooting technique. b) Imagining teammates and opponents positioned around the key, noting the main colors in the scene c) Imagining the coach standing on the sideline encouraging them, and paying attention to the sounds of the audience and the cheers from a close friend in the stands. d) Visualizing a high-pressure situation, experiencing the emotions felt during a real game with one second left on the clock, trailing by one point, with the game's outcome depending on their FT shot. Week 3-4: The exception of content dfrom the full script. Week 5-6: The exception of content cdfrom the full script. Week 7-8: The exception of content bcdfrom the full script."
48522790|NCT02960009|DEVICE|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
48522791|NCT00567008|DRUG|varenicline|1.0 mg BID for 8 weeks
48522792|NCT00567008|DRUG|placebo|placebo BID for 8 weeks
48724085|NCT02062203|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
48724086|NCT01009086|DRUG|Placebo|SC injections
48724087|NCT01009086|DRUG|Ustekinumab 45 mg|SC injections
48724088|NCT01009086|DRUG|Ustekinumab 90 mg|SC injections
48724089|NCT03066167|OTHER|Validation of different dysphagia scores|
48026584|NCT00059475|DRUG|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
48026585|NCT00059475|DRUG|Montanide ISA 51|
48026586|NCT00059475|DRUG|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
48183458|NCT01602510|DRUG|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
48183459|NCT01602510|DRUG|Placebo|Placebo
48522793|NCT06158893|DRUG|Salbutamol|inhalation anaesthesia
48522794|NCT06158893|DRUG|Budesonide|inhalation anaesthesia
48522795|NCT06158893|OTHER|Saline|saline
48522796|NCT01720225|DRUG|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
48522797|NCT01720225|DRUG|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
48724090|NCT01410188|DRUG|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
48724091|NCT01410188|DRUG|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
48026587|NCT00059475|DRUG|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
48026588|NCT00059475|DRUG|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
48026589|NCT01383070|BEHAVIORAL|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
48724092|NCT01410188|DRUG|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
48724093|NCT00963768|DRUG|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
48724094|NCT00963768|DRUG|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
48724095|NCT03847909|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
48026590|NCT04944342|OTHER|No intervention.|No intervention.
48026591|NCT05857046|DRUG|Melatonin 10 MG|Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
48026592|NCT05857046|OTHER|Placebo|Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
48026593|NCT05776485|OTHER|Progressive resistance training|Only the control group: 3 exercise bouts within the study period. Comparison between exercised and non-exercised leg.
48026594|NCT05776485|OTHER|Cross-sectional comparison between healthy and tendinopathic group|Comparison of primary and secondary outcomes.
48026595|NCT05847777|RADIATION|CBCT|cone beam computer tomography
48026596|NCT02233660|OTHER|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
48026597|NCT02233660|PROCEDURE|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
48026598|NCT02378142|DRUG|Pazopanib|
48026599|NCT04596566|OTHER|Therapeutic diet Intervention|The CD-TDI will incorporate global principles of the Mediterranean Diet (MD) refined to inform specific food choices based on our pilot data results and published literature reported mechanisms of mitigating inflammation in IBD. Patient compliance will be measured in three ways: 1) Mediterranean diet score checklists completed every 3 weeks at the face-to-face visits; 2) goal attainment scores captured weekly to identify the goals set, and the goals attained 47; and 3) fatty acids profiled from red blood cells to identify if fat intake reflects CD-TDI fat recommendations: 35% total calories from fat, 15% from MUFA, 13% from SFA and 6% from PUFA with a 8 n6:n:3 ratio of 8:1
48026600|NCT02157558|DRUG|Fexofenadine|All subjects will receive 180 mg fexofenadine
48026601|NCT02157558|DRUG|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
48026602|NCT00803634|DRUG|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
48026603|NCT00803634|DRUG|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
48026604|NCT06170333|DRUG|8% sulphur and A. vera soap|Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
48026605|NCT02559908|DEVICE|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
48026606|NCT02408614|OTHER|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
48026607|NCT02408614|OTHER|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
48026608|NCT02408614|OTHER|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
48026609|NCT02408614|DEVICE|Treadmill|
48388061|NCT05723042|OTHER|EMS with CIMT|The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
48522798|NCT04166201|PROCEDURE|double mesh hernioplasty with modified chevrel's technique|hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
48522799|NCT05850325|OTHER|Group 1 Elbow Flexed at 90 Degrees|subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.
48026610|NCT01028209|DRUG|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
48724096|NCT03847909|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
48724097|NCT06079151|DEVICE|Nasal high-flow|Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen if necessary
48724098|NCT03346967|COMBINATION_PRODUCT|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
48520981|NCT05816109|DIAGNOSTIC_TEST|superficial cervical block|After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
48520982|NCT05816109|DIAGNOSTIC_TEST|without superficial cervical block|patients who underwent anterior cervical surgery and did not undergo superficial cervical block
48520983|NCT00876330|OTHER|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
48520984|NCT00876330|OTHER|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
48724099|NCT06194071|OTHER|Completion of questionnaires and on-site visits during an 18 months follow-up after TBI|"We will evaluate the same outcomes and use the same questionnaires at 6, 12 and 18 months post-TBI.~For patients we will evaluate:~* Functional Outcome (GOS-Extended)~* Health-related Quality of Life (QOLIBRI)~* Neurocognitive tests (MoCA)~* Independence (Barthel Index)~* Daily issues (BICOQ)~* Anxiety and depression symptoms (HADS)~* Medico-economic evaluation (EQ5D-5L)~For Relatives we will evaluate:~* Symptoms of anxiety and depression (HADS)~* The appreciation of the patient's daily issues from their point of view (dedicated Bicoq for relatives)~* Burden of care (ZARIT)~Throughout the follow-up we will nest a qualitative research programs which will focus on several aspects:~* feasibility of such follow-up (6 months is the primary endpoint) defined as the drop-out rate, complete or incomplete completion of scales and their reasons~* factors that may lead to drop-out or the contrary that solidifies the follow-up"
48724100|NCT01583816|DRUG|Resiquimod 0.03%|topical application
48724101|NCT01583816|DRUG|Resiquimod 0.01%|topical application
48724102|NCT01583816|DRUG|placebo|topical application
48724103|NCT05946512|BEHAVIORAL|yoga|yoga breathing techniques for dysfunctional breathing
48520985|NCT00876330|OTHER|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
48520986|NCT00876330|OTHER|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
48520987|NCT01364012|DRUG|Bevacizumab|Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
48520988|NCT01364012|DRUG|Carboplatin|Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
48520989|NCT01364012|DRUG|Paclitaxel|Paclitaxel will be administered at 175 milligrams per square meter (mg/m\^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
48520990|NCT01364012|DRUG|Placebo|Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
48724104|NCT05946512|BEHAVIORAL|social contact|social contact as active comparator
48724105|NCT00279812|DIETARY_SUPPLEMENT|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
48724106|NCT00279812|DIETARY_SUPPLEMENT|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
48724107|NCT00279812|DIETARY_SUPPLEMENT|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
48724108|NCT00279812|DIETARY_SUPPLEMENT|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
48724109|NCT00279812|DIETARY_SUPPLEMENT|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
48724110|NCT00279812|OTHER|Placebo|Placebo supplement for 12 weeks
48724111|NCT02625870|DRUG|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
48520991|NCT03806673|DRUG|marcaine|epidural block
48520992|NCT01153425|OTHER|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
48520993|NCT01153425|DRUG|Teriparatide|Participants are clinically indicated for treatment.
48520994|NCT01153425|DRUG|Zoledronic Acid|Participants are clinically indicated for treatment.
48520995|NCT00580788|DRUG|PTHrP (1-36)|IND # 49,175
48724112|NCT02625870|DRUG|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
48724113|NCT01874938|BIOLOGICAL|LY2875358|Administered IV
48520996|NCT04877847|DEVICE|Low-frequency therapeutic ultrasound (LOTUS)|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.
48724114|NCT01688908|PROCEDURE|Endoscopic Screening|"1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
48724115|NCT05515289|DRUG|SHR6390|SHR6390 tablet single dose, and subjects will take the SHR6390 on Day 1.
48724116|NCT00386555|DRUG|docetaxel|
48520997|NCT04877847|DEVICE|LOTUS System with Ultrasound Disabled|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.
48724117|NCT00386555|DRUG|CP-868,596 + docetaxel|
48724118|NCT00386555|DRUG|AG-013736 + docetaxel|
48724119|NCT00386555|DRUG|CP-868,596 + AG-013736 + docetaxel|
48385187|NCT06565533|BEHAVIORAL|Virtual Reality (VR)|Standing on a lifelike full-sized basketball court, they observe smooth flooring and clear markings. Teammates and opponents don variously colored uniforms, while referees stand ready at the sidelines. Referees position teammates and opponents around the basket as participants feel the texture and weight of the basketball in their hands, as if gripping it for real. The sounds of cheering spectators and encouraging shouts from teammates and coaches further enhance their focus. Participants adjust their stance, noticing beads of sweat trickling down their arms as they prepare for the FT. With bent knees, they ready themselves for the shot, exerting every ounce of their strength as the ball leaves their hands and soars towards the basket. As the ball accurately swishes through the net, the crowd erupts into thunderous applause, and the scoreboard's change in score brings an overwhelming sense of joyous victory.
48385188|NCT03747939|DRUG|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
48385189|NCT03747939|OTHER|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
48385190|NCT04074356|OTHER|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
48385191|NCT04074356|DIAGNOSTIC_TEST|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
48385192|NCT04074356|DIAGNOSTIC_TEST|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
48385193|NCT04074356|DIAGNOSTIC_TEST|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
48385194|NCT05338671|DRUG|Local anesthetic|Patients will receive inferior alveolar nerve block injection following endodontic treatment.
48385195|NCT01649999|DRUG|peficitinib|oral
48385196|NCT01649999|DRUG|Placebo|oral
48385197|NCT04757402|OTHER|Counselling with NSQIP Surgical risk calculator|Use of NSQIP surgical risk calculator to check for patient satisfaction regarding pre operative counseling.
48520998|NCT00369941|DRUG|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
48520999|NCT00369941|DRUG|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
48521000|NCT00369941|DRUG|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
48385198|NCT04197882|BIOLOGICAL|OrienX010 Combination with Toripalimab injection|OrienX010 Produced by Oriengene Biotechnology Co.,Ltd. Strength: 1.0 mL/vial. Toripalimab infusion Produced by Junshi Biosciences Co., Ltd. Strength: 240 mg/6 mL/vial; Sterile water injection dosage form; Expiry date: 24 months; Date of manufacture: Based on the date of manufacture indicated in the product package.
48521001|NCT00369941|DRUG|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
48521002|NCT00369941|DRUG|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
48521003|NCT02535403|BEHAVIORAL|ICBT|
48521004|NCT05260294|PROCEDURE|Epidural space identification with cervical epidural steroid injection employing CST and LORT.|Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
48521005|NCT05943717|DEVICE|lung ultrasound and electrical cardiometry|: B-lines of lung ultrasound and the parameters of cardiometry will be measured at the mid-week HD session before starting the session by 30 min then every 30min during HD session for 180 min and then after the end of the session of HD by 30 min and then The specificity and sensitivity of both techniques will be compared to each other
48521006|NCT05592457|DIAGNOSTIC_TEST|MSCT|multislice computed tomography
48521007|NCT02862015|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
48521008|NCT02862015|DRUG|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
48521009|NCT05292027|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
48521010|NCT02088801|DEVICE|Airtraq, blade without channel for tracheal tube intubation|Intubation
48521011|NCT02088801|DEVICE|KingVision , blade without channel for tracheal tube intubation|
48521012|NCT02088801|DEVICE|A.P. Advance, blade without channel for tracheal tube intubation|
48521013|NCT02088801|DEVICE|Macintosh|
48521014|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally|Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
48724120|NCT03442296|BEHAVIORAL|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
48724121|NCT03442296|DEVICE|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
48385199|NCT06576167|BEHAVIORAL|IMPROVE|IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
48385200|NCT03003858|DEVICE|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
48724122|NCT05055310|DIAGNOSTIC_TEST|MicRNAs test|plasma micRNAs concentration
48724123|NCT02717130|DRUG|Aripiprazole|
48724124|NCT01310829|BEHAVIORAL|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
48724125|NCT01310829|BEHAVIORAL|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
48724126|NCT01310829|BEHAVIORAL|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
48724127|NCT02486250|OTHER|Validation Study|
48724128|NCT05245877|DRUG|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
48724129|NCT02713659|BEHAVIORAL|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
48724130|NCT02713659|BEHAVIORAL|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
48385201|NCT05744219|DRUG|Ferric carboxymaltose|Active drug
48385202|NCT05744219|DRUG|Placebo|Placebo
48724131|NCT01600092|BIOLOGICAL|RotaTeq™ experimental formulation|
48724132|NCT01600092|BIOLOGICAL|RotaTeq™ existing formulation|
48724133|NCT01399008|DRUG|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
48385203|NCT05436834|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
48385204|NCT05436834|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
48521015|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
48521016|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)|Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
48724134|NCT01399008|DRUG|Allopurinol|Allopurinol 300 mg as active comparator
48724135|NCT01399008|DRUG|Colchicine|0.6 mg colchicine daily as flare prophylaxis
48724136|NCT01399008|DRUG|Placebo|Placebo
48724137|NCT02419170|PROCEDURE|Standard of care surgery|
48385205|NCT00661960|DRUG|raltegravir|400mg tablet twice daily by mouth for nine months
48385206|NCT00661960|DRUG|efavirenz|600mg capsule once daily by mouth without regard to food
48724138|NCT02419170|PROCEDURE|Apheresis|
48724139|NCT02419170|DRUG|Cyclophosphamide|
48724140|NCT02419170|BIOLOGICAL|Personalized mature dendritic cell vaccine|
48724141|NCT02257203|BEHAVIORAL|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
48521017|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days|Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.
48521018|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
48724142|NCT02257203|BEHAVIORAL|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
48183460|NCT04214327|BEHAVIORAL|Strengthening Families Program Online eLearning Game|Families (parent/caregiver and children) are to play-test a highly interactive online gamified version of the Strengthening Families Program called SFP Online, with 10 lessons that utilize three 10-minute mini-sessions and games that teach parents evidence-based parenting and family relationship skills and teach youth social, life, and alcohol and drug refusal skills. Skills are reinforced through gaming. Game points are achieved by right answers to self-correcting mini-quizzes for low-stakes failure and through actual reported home practice of the skills. The SFP parenting skills have been shown to reduce risk factors and increase protective factors that prevent youth substance abuse.
48385207|NCT05925764|DIAGNOSTIC_TEST|Whole Slide Image based Deep Learning|Whole Slide Image Based Deep Learning for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
48385208|NCT04639635|OTHER|No intervention, this is a natural history progression study|The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
48385209|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using laryngeal mask
48724143|NCT01137253|DRUG|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
48724144|NCT01137253|DRUG|Placebo|Response to intrabrachial vasodilators during IV saline infusion
48724145|NCT04645745|DIETARY_SUPPLEMENT|myo-inositol, alpha-lactalbumin, folic acid|Evaluating the improvement vs the baseline after three and six months of treatment
48724146|NCT02532985|OTHER|Negative Control|No added fiber beverage
48724147|NCT02532985|OTHER|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
48724148|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
48724149|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
48385210|NCT04311723|PROCEDURE|Anesthesia Procedure|Receive anesthesia using endotracheal tube
48724150|NCT02532985|OTHER|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
48724151|NCT04474314|DRUG|IMR-687|Oral administration of once daily IMR-687
48183461|NCT04214327|BEHAVIORAL|SFP Home-use DVD|Family views an 11-session SFP video series online or at home using a DVD that contains the same program and lesson content as the online condition; however, the lesson material is more static without the interaction required in the gamified version of SFP Online.
48724152|NCT04474314|DRUG|Placebo|Oral administration of once daily Placebo
48724153|NCT04607876|OTHER|Technological Facilitator|See Enhanced Intervention Arm for full description.
48724154|NCT04607876|OTHER|Standard of Care|Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
48724155|NCT02644382|OTHER|qualitative data collection|qualitative data collection
48385211|NCT04311723|PROCEDURE|Bronchoscopy|Undergo standard of care bronchoscopy
48385212|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
48385213|NCT01537809|DIETARY_SUPPLEMENT|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
48385214|NCT02712359|OTHER|Blood sample collection|A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
48385215|NCT05353816|DEVICE|Corheart 6 Left Ventricular Assist System|Implantation of the Corheart 6 Left Ventricular Assist Device for mechanical circulatory support.
48385216|NCT04715321|OTHER|CT perfusion examination|CT perfusion was performed with a 64-section multidetector CT scanner. The following CT parameters were used to acquire dynamic data: blood flow (BF), blood volume (BV), mean transit time (MTT), permeability-surface area product (PS), hepatic artery ejection fraction (HAF), hepatic artery perfusion (HAP), and hepatic portal vein perfusion (PVP). And we used these parameters to predict the vascular pattern.
48385217|NCT03302130|BEHAVIORAL|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
48521019|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
48724156|NCT02644382|OTHER|survey|survey pre and post-surgical consult
48724157|NCT02644382|OTHER|decision aid|web-based decision aid post-surgical consult
48724158|NCT05807984|RADIATION|Carbon ion radiation therapy DT: 74Gy/20 fractions|patients with unresectable local recurrent rectal cancer will be treated with carbon ion radiation therapy as re-irradiation
48724159|NCT00209898|PROCEDURE|Fast initiation procedure|
48724160|NCT02694497|OTHER|Chlamydia care as usual|
48724161|NCT02602665|PROCEDURE|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
48724162|NCT02602665|PROCEDURE|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
48724163|NCT02917915|OTHER|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
48183462|NCT04214327|BEHAVIORAL|Wait-Listed Control|Families receive no active intervention for 22 weeks; however, during this wait time, participants receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. Following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention
48521020|NCT02591524|OTHER|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
48521021|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 10mcg|BNT162b2 Low/Mid-Dose (10mcg) level
48724164|NCT02917915|OTHER|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
48026611|NCT03177993|DRUG|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
48026612|NCT03177993|DRUG|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
48026613|NCT03177993|DRUG|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies"
48183463|NCT02503098|BEHAVIORAL|Recovery Record adaptive smartphone application|
48183464|NCT02503098|BEHAVIORAL|Recovery Record standard smartphone application|
48183465|NCT05317442|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks"
48385218|NCT03302130|DEVICE|Arterial spin labeling MRI|Single PLD PCASL
48385219|NCT03302130|DEVICE|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
48385220|NCT06049004|OTHER|Activities of Daily Living Protocol|The protocol is a performance-based objective measurement method based on repetition of daily activities. Participants are asked to perform the activities defined in the protocol at the same speed they do at home. The Londrina Protocol includes 5 stations: Station 1 Arranging Objects on the Table, Station 2 Walking with Bags, Station 3 Organizing Shelves, Station 4 Clothesline Task, Station 5 Walking. The completion time of the protocol is recorded.
48385221|NCT01035229|DRUG|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
48385222|NCT01035229|DRUG|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
48385223|NCT01035229|OTHER|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
48385224|NCT01892813|DRUG|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48385225|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48385226|NCT01892813|DRUG|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48385227|NCT01892813|DRUG|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48385228|NCT01892813|DRUG|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48724165|NCT05726890|BEHAVIORAL|bedtime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime. These changes are expected to foster the infant's ability to fall asleep independently at bedtime. It is also expected that after 1-2 weeks, these changes would lead to self-soothing also during the night.
48724166|NCT05726890|BEHAVIORAL|bedtime and nighttime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime and during the night. These changes are expected to foster the infant's ability to fall asleep independently at bedtime and to resume sleep independently during the night.
48385229|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48385230|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48385231|NCT01892813|DRUG|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
48385232|NCT01892813|BEHAVIORAL|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
48385233|NCT01892813|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
48385234|NCT01892813|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
48385235|NCT01892813|BEHAVIORAL|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
48026614|NCT05933915|OTHER|group-based laughter yoga|"Midwives in the intervention group of the research will apply 8 sessions of laughter yoga, 2 sessions a week. Laughter yoga will be practiced by researchers with leadership certification. Each session will take an average of 45 minutes. Laughter Yoga sessions will be held on the web through the Zoom program. Each session will consist of groups of 8 people."
48026615|NCT02970344|BEHAVIORAL|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
48026616|NCT01206335|DRUG|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
48028988|NCT02842060|BEHAVIORAL|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
48385236|NCT01892813|BEHAVIORAL|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
48385237|NCT05053750|DRUG|Paclitaxel/Bev (control)|Given by PO
48724167|NCT06055660|GENETIC|Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma|Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
48724168|NCT01932255|PROCEDURE|prophylactic spinal tap|
48724169|NCT01932255|PROCEDURE|no prophylactic spinal tap|
48385238|NCT05053750|DRUG|Paclitaxel/Bev + ZA (experimental)|Given by PO
48521022|NCT04816643|BIOLOGICAL|BNT162b2 20mcg|BNT162b2 Mid-Dose (20mcg) level
48385239|NCT06653296|DRUG|ENX-102|Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
48385240|NCT06653296|DRUG|Placebo|Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
48385241|NCT06242977|DRUG|Eutectic mixture of local anesthetics (EMLA; Astra Pharmaceutical Products Inc., Westborough, MA)|The intervention is the utilization of EMLA cream, a topical anesthetic to determine if this reduces pain with local anesthesia infiltration, and for overall procedural pain
48028989|NCT05759234|DRUG|HS248 pieces|The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
48521023|NCT04816643|BIOLOGICAL|BNT162b2 30mcg|BNT162b2 High-Dose (30mcg) level
48385242|NCT06242977|OTHER|Control cream|This intervention will be for the control group, a simple lotion cream.
48385243|NCT03299088|BIOLOGICAL|Pembrolizumab|Given IV
48385244|NCT03299088|DRUG|Trametinib|Given PO
48385248|NCT03902600|RADIATION|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
48385249|NCT05440175|OTHER|EMS, Mirror therapy & exercises|EMS will be applied with frequency between 20-100 Hz and pulse width between 20 to 450us and Mirror therapy for 30 minutes and four days per week for a total duration of 12 weeks. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
48385250|NCT05440175|OTHER|CIMT & exercises|Constraint induced movement therapy will be applied for 30 minutes and four days per week for a total duration of 12 weeks, it is a form of rehabilitation therapy that improves upper limb movement, it claims to improve the arm motor ability and the functional use of a paretic arm- hand. Exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
48385251|NCT05440175|OTHER|Mirror therapy & exercises|Mirror therapy will be given for 30 minutes and four days per week for a total duration of 12 weeks. The exercises include the flexion, extension of the wrist and elbow, ulnar and radial deviations , place any cylindrical object in patients palm and ask to lift the object off the table. other exercises includes external and internal rotations with different task orientations.
48385252|NCT00000227|DRUG|Buprenorphine|
48385253|NCT00530621|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
48521024|NCT04816643|OTHER|Placebo|Intramuscular injection
48521025|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 3mcg|BNT162b2 Low-Dose (3mcg) level
48521026|NCT01949402|OTHER|Computed Tomography|"The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit."
48724170|NCT02135978|OTHER|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
48385254|NCT00530621|DRUG|placebo|oral, daily
48385255|NCT00530621|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
48385256|NCT06651736|BEHAVIORAL|Low Vision Rehabilitation (LVR)|"The initial session will be with an LVR specialist that will recommend vision-enhancing devices and techniques to improve participant's vision and mobility functionality depending on needs. The devices will be given at no cost and include, but are not limited to: magnifiers that participants can hold or wear, glasses attachments that help filter out light to see better, or items that help with glare or seeing color. This session will be followed by at least one session with an occupational therapist, that will train participants to use the devices (take home and use) and recommend/teach ways to achieve functional goals.~Most participants will be asked to attend 2-4 visits, but additional visits may be needed depending on needs and progress toward functional goals. Additional visits if orientation and mobility training is also recommended. Participants will be asked to share experiences approximately 1-week after all visits."
48724171|NCT05484323|OTHER|Glucose as reference food|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
48724172|NCT05484323|OTHER|White bread|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
48724173|NCT05484323|DIAGNOSTIC_TEST|Cookie containing 0 g spirulina|Thirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
48385257|NCT06651736|BEHAVIORAL|Emotion Regulation Therapy (ERT)|There will be ten 1-hour weekly sessions of specialized psychotherapy with an ERT-trained therapist. These are typically done virtually but may be able to provide in-person sessions to those where this is needed. At the beginning of each session, the therapist will give participant's several questionnaires to learn about participant's experience with ERT. Questionnaires will also be completed after all sessions are completed.
48724174|NCT05484323|OTHER|Cookie containing 2.5 g spirulina|TThirteen healthy participants (male: 4, female: 9) after 10-14h fast, consumed 50 g available carbohydrates from D-glucose, in different visits as reference food, tested two times; and 50 g available carbohydrates from white bread, tested two times; and 50 g available carbohydrates from cookies containing 0 and 2.5g spirulina, tested once, in different visits, along with 250 mL water. There was a washout period of at least two days between visits. Fingertip capillary blood glucose and salivary insulin samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose and salivary insulin sample were taken exactly 15 min after the first bite of food or drink.
48522800|NCT05850325|OTHER|Group 2 Elbow Fully Flexed|subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
48724175|NCT06061107|BEHAVIORAL|Handbook for Geriatric Prearranged Medical Care Consultation|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
48724176|NCT03679455|DRUG|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
48724177|NCT06040281|BEHAVIORAL|intensive individual support in nutrition and exercise|"Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)"
48724178|NCT06040281|BEHAVIORAL|Usual Care|Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
48724179|NCT00337792|DRUG|oxycodone + lorazepam versus fentanyl + midazolam|
48026617|NCT05009849|OTHER|Yoga Exercises|The exercises in the Exercise I arm (Yoga and conventional exercises) will be upgraded to Phase II. Patients will be allowed to attend a minimum of four out of seven days in Phase I and II. Patients will be assessed at 6-9 months for compliance to phase II exercises. Only if patients are fulfilling the criteria for accuracy, sequence and duration of phase II exercises, will they be taught phase III exercises. Patients who are unable to do phase II exercises accurately or demonstrate non compliance to the exercise routine at first follow up visit/ 6-9 months will be re taught phase II exercises. These patients will be upgraded to phase III only if able to perform phase II adequately at assessment. Six months after completion of phase III exercises, patients will be assessed for compliance to phase III exercises. These women's will be assessed at the subsequent 6-9 month follow up and compliance will be evaluated.
48724180|NCT00847015|DRUG|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
48724181|NCT00847015|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m\^2
48724182|NCT00847015|DRUG|cisplatin|cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
48724183|NCT04330027|BIOLOGICAL|Growth factors|A new patented product named lyophilized Growth Factors that is an advanced and refined form of conventional platelet-rich plasma
48724184|NCT04330027|OTHER|Saline|0.9% Sodium Chloride
48724185|NCT03957876|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
48724186|NCT05220332|BEHAVIORAL|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
48385258|NCT02256202|OTHER|Interview|Monitoring interviews to show medical and economic advantages of given therapy
48385259|NCT02393066|DRUG|Propofol|Sedation
48385260|NCT02393066|DRUG|Dexmedetomidine|Sedation
48385261|NCT05000931|DEVICE|Osia 2 System|Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
48724187|NCT05220332|BEHAVIORAL|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
48385262|NCT02263118|OTHER|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
48521027|NCT01949402|OTHER|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
48521028|NCT01949402|OTHER|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
48724188|NCT03664583|BEHAVIORAL|ACHRU-Community Partnership Program (CPP)|The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
48724189|NCT02254395|DEVICE|Deep Brain Stimulation|
48521029|NCT01949402|OTHER|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
48724190|NCT00820872|BIOLOGICAL|trastuzumab|
48724191|NCT00820872|DRUG|carboplatin|
48724192|NCT00820872|DRUG|docetaxel|
48724193|NCT00820872|DRUG|lapatinib ditosylate|
48724194|NCT00046553|DRUG|RU-486 (Mifepristone)|
48724195|NCT02733653|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
48724196|NCT00025155|DRUG|ixabepilone|Given IV
48183466|NCT04561947|PROCEDURE|Tunnel technique|After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
48183467|NCT04561947|PROCEDURE|Connective tissue graft|CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
48385263|NCT02263118|DEVICE|Feature phone|Participants were given a feature phone.
48724197|NCT01755650|RADIATION|18F FPM|
48385264|NCT02263118|OTHER|Virtual communities|Exposure to virtual community communication via SMS
48385265|NCT02263118|OTHER|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
48385266|NCT06541561|DEVICE|transcutaneous electrical acupoint stimulation|"Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS) or the sham groups. In the TEAS group, the acupoints are bilateral neiguan (PC6) and Zusanli(ST 36) acupoints.~Patients will receive 30min TEAS before anesthesia until be discharged from the post anaesthesia care unit (PACU). The same treatment for 30 min will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient."
48385267|NCT06541561|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
48521030|NCT02389179|DRUG|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
48724198|NCT03753399|PROCEDURE|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
48724199|NCT02391493|DEVICE|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
48724200|NCT02616770|DRUG|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
48724201|NCT02616770|DRUG|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
48724202|NCT02616770|DRUG|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
48724203|NCT02616770|DRUG|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
48724204|NCT02616770|DRUG|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
48724205|NCT02616770|DRUG|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
48724206|NCT01975610|DRUG|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
48724207|NCT01975610|DRUG|Placebo|Twice daily for 28 days
48724208|NCT02198235|DRUG|Dexamethasone|
48724209|NCT02198235|DRUG|Buprenorphine|
48724210|NCT05794828|DRUG|Bupivacaine Injection|Bucivacaine will be administered intramuscularly according to package insert directions after first numbing the area with lidocaine subcutaneously
48724211|NCT03191253|OTHER|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
48724212|NCT00252772|DRUG|Tesaglitazar|
48385268|NCT05560594|DEVICE|Coloplast SpeediCath CH12 standard male intermittent catheter|Drainage of the bladder through the urethra when using the SpeediCath standard male intermittent catheter.
48724213|NCT00252772|BEHAVIORAL|Dietary and Lifestyle counseling|
48026618|NCT04703881|DIETARY_SUPPLEMENT|AYMES ActaGain|AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.
48724214|NCT02349490|DEVICE|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
48026619|NCT03971617|DRUG|Hydrogen|each hydrogen tablet contains 80mg magnesium
48026620|NCT03971617|DRUG|Placebo oral tablet|matching placebo tablet
48026621|NCT03357601|BEHAVIORAL|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
48385269|NCT03587740|DRUG|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
48385270|NCT03700515|DRUG|Erythropoietin|Subjects receive weekly infusions of EPO
48385271|NCT03700515|DRUG|Placebo|Subjects receive weekly infusions of saline
48521031|NCT04552795|DRUG|3TC|12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
48724215|NCT05348486|RADIATION|Dose escalation|Dose escalation 75,9 - 79,2 Gy in 33 fractions for GTV hypoxic or any hypoxic LN \> 2cm
48724216|NCT04124003|DRUG|rosuvastatin|Specified dose on specified days
48724217|NCT04124003|DRUG|BMS-963272|Specified dose on specified days
48724218|NCT00001088|BIOLOGICAL|APL 400-047|
48724219|NCT00001088|DRUG|Bupivacaine hydrochloride|
48724220|NCT05718037|BIOLOGICAL|Recombinant Zoster Vaccine|0.5mL, Intramuscular
48724221|NCT05718037|BIOLOGICAL|Placebo|0.5mL, Intramuscular
48026622|NCT03357601|BEHAVIORAL|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
48026623|NCT04968548|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
48026624|NCT03822923|OTHER|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
48385272|NCT04794049|DRUG|Lactulose|In experiment cohort, patients do not use standard bowel preparation regimen, they totally drink 300ml lactulose.
48521032|NCT06435689|OTHER|Sampling|Blood and surgical specimen sampling the day of surgery
48724222|NCT05718037|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|0.5mL, Intramuscular
48724223|NCT00164411|BIOLOGICAL|Tetanus-diphtheria toxoids (Td)|
48724224|NCT00164411|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
48724225|NCT00164411|BIOLOGICAL|23-valent polysaccharide vaccine|
48724226|NCT04106102|DEVICE|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
48724227|NCT04106102|DEVICE|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
48724228|NCT04420260|DIETARY_SUPPLEMENT|Group A: oropharygeal spray and immunostimulant emulsion|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.~Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus."
48026625|NCT03822923|OTHER|Control group|Conventional treatment
48026626|NCT01732367|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
48026627|NCT01732367|DRUG|Tenofovir|Tenofovir 300mg QD for 96 weeks
48385273|NCT04794049|DRUG|Polyethylene Glycol (PEG)|In control cohort, patients use the standard split-dose bowel preparation regimen,
48385274|NCT04014413|PROCEDURE|Fecal Microbiota Transplantation|Fecal microbiota transplantation
48521033|NCT03855449|BEHAVIORAL|eDECIDE Web-based Intervention Group|"Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention"
48521034|NCT01436955|DRUG|Placebo|multiple oral doses
48385275|NCT04352621|DRUG|intranasal ketamine|Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .
48385276|NCT04352621|DEVICE|rTMS treatment|patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
48385277|NCT01064869|BEHAVIORAL|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~1. A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~2. Motivational interviewing based on stages of change model to encourage change and adherence~3. Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
48385278|NCT04476654|BEHAVIORAL|YouTube Video Arm|Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
48385279|NCT06019533|COMBINATION_PRODUCT|LVDS|Levonorgestrel Vaginal Delivery System
48724229|NCT04420260|DIETARY_SUPPLEMENT|Group D:Placebo oropharyngeal spray + Placebo taken PO|"Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.~Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds"
48385280|NCT06652958|BIOLOGICAL|VH4527079|VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.
48521035|NCT01436955|DRUG|RG1662|Cohorts receiving multiple oral doses
48521036|NCT02130908|OTHER|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
48521037|NCT02130908|OTHER|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
48521038|NCT02130908|OTHER|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
48724230|NCT05777239|PROCEDURE|Dental Implant Approach for Crestal Sinus Elevation|Crestal Sinus Elevation by elevating the sinus membrane with a blunt ended dental implant approach
48521039|NCT03952182|OTHER|Spinal Orthosis (LSO, TLSO)|spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
48724231|NCT00967759|DRUG|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
48724232|NCT00967759|DRUG|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
48724233|NCT00967759|DRUG|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
48026628|NCT06417281|DRUG|5 Aminolevulinic Acid|3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
48026629|NCT02641548|DEVICE|Sock of silicone|
48026630|NCT02641548|OTHER|Heel cream|
48026631|NCT06533618|DIAGNOSTIC_TEST|Continuous glucose monitoring system|All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.
48026632|NCT03931434|DIETARY_SUPPLEMENT|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
48026633|NCT03931434|DIETARY_SUPPLEMENT|Placebo|Placebo
48026634|NCT01732393|DRUG|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
48026635|NCT01732393|DRUG|Placebo|
48026636|NCT03882125|BEHAVIORAL|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
48026637|NCT06171113|DRUG|GSK4024484C|Doses administrated orally with 240 mL of water.
48026638|NCT06171113|DRUG|Placebo|Doses administrated orally with 240 mL of water.
48026639|NCT06276543|DEVICE|antibiotic-impregnated catheter|Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
48026640|NCT03059173|DIETARY_SUPPLEMENT|Myo-Inositol + Levomefolic acid|Dietary supplement Gynositol® MTHF containing myo-inositol (4 g) and Levomefolic acid on glucosamine salts(0.736 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
48026641|NCT03059173|DRUG|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
48026642|NCT03059173|DIETARY_SUPPLEMENT|placebo|a placebo containing only 0.736 mg of 5-MTHF, glucosamine salts
48028990|NCT00125216|BEHAVIORAL|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
48028991|NCT01502501|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
48028992|NCT00435370|DRUG|Tropisetron|10 mg/day
48028993|NCT00435370|DRUG|Placebo|placebo
48028994|NCT00435370|DRUG|Risperidone|6mg/day
48028995|NCT04773587|DRUG|Roflumilast Cream 0.15%|Roflumilast Cream 0.15% - Active
48385281|NCT03514173|DEVICE|Remote Patient Monitoring|Use of remote patient monitoring
48385282|NCT05591547|RADIATION|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
48385283|NCT02554331|RADIATION|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
48385284|NCT02554331|BEHAVIORAL|neuropsychological evaluation|"Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory"
48385285|NCT02554331|OTHER|Gait recording with sensors|Gait recording with sensors
48385286|NCT06567223|PROCEDURE|Vibration Therapy|will receive the whole body vibration therapy. Patient will be ask to stand on the vibration plate in semi flexed knee position will 3 minute time of rest and therapy. It will be given for four weeks three days per week. Acceleration will be 18.0 meter per second square and frequency will be from 30 to 40 Hz. Intensity of the therapy will increase throughout all the sessions
48385287|NCT06567223|COMBINATION_PRODUCT|Rhythmic auditory stimulation therapy.|will receive rhythmic auditory stimulation therapy. Rhythmic auditory stimulation will be given for 90 minutes along with 30 minutes of conventional physiotherapy. It will consist of 15 minutes of general body warming metronome rhythm which proceed towards RAS music based exercise of 60 minutes. This period also ends up with 15 minutes of relaxation exercise. Relaxing Music was provided through headphones having voice cancellation property for 15 min. The total session will be given three days per week for four weeks. Exercises such as lateral walking military march, anterior walking, one toe and one heel walking along with posterior walking through progression with the speed of the rhythm is done
48385288|NCT03963960|DEVICE|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
48521040|NCT03952182|OTHER|No orthosis|no orthotic given for spinal fracture. These patient's will be given a bending restriction
48385289|NCT03963960|DEVICE|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
48385290|NCT01920698|DEVICE|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
48385291|NCT01920698|OTHER|control|
48385292|NCT02504463|DRUG|Samidorphan IV|Single IV administration
48521041|NCT03757858|DEVICE|Thermotron RF-8|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
48521042|NCT03757858|BIOLOGICAL|Adoptive cellular Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
48521043|NCT03757858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
48028996|NCT04773587|DRUG|Vehicle Cream|Cream - Vehicle
48028997|NCT06471101|DIAGNOSTIC_TEST|clusters|clustering
48028998|NCT02544906|DRUG|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
48028999|NCT02544906|DRUG|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
48029000|NCT06532682|DRUG|dapagliflozin|dapagliflozin 5 MG/10 MG once daily
48029001|NCT06532682|DRUG|ACE inhibitor|ACE inhibitor
48029002|NCT05108194|BEHAVIORAL|SMS Personalized Sleep Intervention|"All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions."
48029003|NCT06470672|DRUG|SHR-A1921|Anti-TROP-2 ADC
48029004|NCT06470672|DRUG|Adebrelimab|PD-L1 inhibitor
48385293|NCT02504463|DRUG|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
48385294|NCT02504463|DRUG|[14c]-Samidorphan oral|Single oral administration containing radiolabel
48183468|NCT04561947|OTHER|Concentrated growth factor membrane|Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
48385295|NCT05138614|OTHER|Medication for Opioid Use Disorder|medication management
48385296|NCT05138614|BEHAVIORAL|MISSION Critical Time Intervention|offering intensive community-based services that decrease in intensity over time
48385297|NCT05138614|BEHAVIORAL|MISSION Peer Support|including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders
48385298|NCT05138614|BEHAVIORAL|MISSION Dual Recovery Therapy|comprised of 13 structured co-occurring disorders treatment sessions
48521044|NCT03757858|DRUG|Chemotherapy|Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
48026643|NCT05718765|BEHAVIORAL|PACES intervention|"The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE."
48026644|NCT05718765|OTHER|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
48385299|NCT03166670|DIAGNOSTIC_TEST|stool examination|collection of stool specimen and microscopic examination for parasites
48385300|NCT03166670|DIAGNOSTIC_TEST|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
48385301|NCT00706927|DRUG|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
48385302|NCT00706927|DRUG|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
48385303|NCT03833531|BEHAVIORAL|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
48385304|NCT03833531|BEHAVIORAL|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
48521045|NCT05124470|OTHER|cognitive remediation by musical training sessions|"The musical learning method Diapason \& Metronome is unprecedented. It was specially created by Florent Cholat. It aims an apprenticeship of a musical practice adapted to subjects with schizophrenia. The method does not require the handling of a musical instrument; it is based on the voice and the body. It is built on the three essential dimensions of music, which are rhythm, single sound and harmony. Rhythm concerns the division and management of time. The single sound allows work on the representation of a sound object as a singularity. Harmony allows you to work on the positioning of a sound in the globality of the chord to which it belongs and in the collective polyphony exercises."
48724234|NCT01869660|BEHAVIORAL|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
48385305|NCT00293605|PROCEDURE|Total Hip Replacement|Implantation of one of 3 stem designs
48385306|NCT00032825|DRUG|Ketaconazole|
48385307|NCT00032825|DRUG|Docetaxel|
48385308|NCT06516653|DEVICE|VasQ|External support implant for the arteriovenous fistula
48385309|NCT06516653|PROCEDURE|Arteriovenous fistula creation for dialysis vascular access|End to side fistula creation in the arm for dialysis vascular access
48385310|NCT01456351|DRUG|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
48385311|NCT01456351|DRUG|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
48385312|NCT03570307|OTHER|medical VS surgical evacuation of the uterus|mentioned above
48385313|NCT06644729|PROCEDURE|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
48521046|NCT02513862|DEVICE|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
48521047|NCT02166567|PROCEDURE|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
48521048|NCT02166567|PROCEDURE|Swim-up|Semen processing will be carried out with the conventional swim-up method.
48521049|NCT05778201|BIOLOGICAL|Baby Drink group|1 packge (20 ml)/ day for 1 month
48521050|NCT04446247|DIAGNOSTIC_TEST|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
48521051|NCT05207891|DEVICE|Intervention mattress|The intervention mattress, Tidewave, will be compared to the regular care mattress, CuroCell 4AD. Primary outcome will be change in pressure injury occurence, assessed according to the NPIAP 2019 Clinical Guidance, and marked up on pressure injury body-map figures. Secondary outcomes will be experienced quality of life, assessed with the Spinal Cord Injury Quality of Life Basic Data Set. Further mattress comfort, assessed with the Mattress Comfort Scale, sleep-wellness, assessed with the Insomnia Severity Index, and pain, assessed with the Brief Pain Inventory. Satisfaction in the participants and in the nursing staff will be assessed with custom made Likert scales. Resource use and experienced stain in the nursing staff will be assessed with custom made forms asking for number of persons needed in position change, number of position changes needed during bed-rest, and experienced strain related to the position changes.
48521052|NCT04964102|BEHAVIORAL|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills|Workshop of Enhancing Interpersonal Effectiveness, Emotional Regulation and Clinical Communication Skills
48521053|NCT04139824|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
48521054|NCT04139824|DRUG|nonsteroidal anti-inflammatory drug|Naproxen 500mg BID
48724235|NCT06124820|DEVICE|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
48724236|NCT06124820|DEVICE|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
48183469|NCT05347472|OTHER|Smartphone application|the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.
48183470|NCT05347472|OTHER|Sham Smartphone application|ham application that includes information and general advice about UI only
48385314|NCT00348049|PROCEDURE|Laser in Situ Keratomileusis (LASIK)|
48385315|NCT00348049|PROCEDURE|Photorefractive Keratectomy (PRK)|
48385316|NCT05345418|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency|Patients will receive two administrations at a dose of 1.5 million cells/kg patient bodyweight via the IV route with a 3-month intervening interval. A validated umbilical cord blood mesenchymal stem cells (UC-MSC) line was selected from the Vinmec Tissue Bank and cultured under xeno-free, serum-free and antibiotic-free conditions as previously described. To prepare UC-MSCs for therapy, aliquots of Passage 3 (P3) UC-MSCs will be thawed and cultured to P5 to get approximately 500 million cells and dispensed to 10 million UC-MSCs/ml/vial for cryopreservation. Upon request from the clinical team, aliquots of P5 UC-MSCs will be thawed in a temperature control water bath or incubator on the infusion day. The UC-MSCs will be washed and suspended in Ringer Lactate.
48385317|NCT06334601|DIAGNOSTIC_TEST|Tests of upper airway collapsibility and muscle responsiveness.|"Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit.~Polysomnography"
48385318|NCT02102217|PROCEDURE|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
48385319|NCT00477620|BEHAVIORAL|Wearing of reading glasses during prolonged near work|
48385320|NCT06535828|DEVICE|AI and mechanic modeling|The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.
48385321|NCT04785651|DRUG|Tibial osteotomy with Tranexamic acid|"Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure."
48385322|NCT04785651|PROCEDURE|Tibial osteotomy without Tranexamic acid|Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
48385323|NCT05669924|DRUG|Methylphenidate|0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.
48385324|NCT05669924|DRUG|Placebo|Placebo for methylphenidate
48385325|NCT05745441|BEHAVIORAL|Early Dinner|Dinner before DLMO
48385326|NCT05745441|BEHAVIORAL|Late Dinner|Dinner after DLMO
48385327|NCT05745441|DRUG|Early Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
48385328|NCT05745441|DRUG|Late Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
48385329|NCT06652789|BEHAVIORAL|Sleep hygiene|"The intervention will be conducted over 6 weeks, and consist of engaging patients (and caregivers) in two 60-minute face to face sessions 3 weeks apart, and twice weekly telephonic follow ups lasting for 20 minutes each during the 6-week period.~The 2 Direct face to face sessions in local language will focus on health education about sleep. (After taking consent)~1. st session (60 mins) Information will be given about lifestyles that can affect sleep positively or negatively- adequate sleep time required for health, healthy and unhealthy sleep habits~2. nd session Participants will be asked to indicate how many of the sleep hygiene techniques they were able to successfully implement since the previous session Successes and barriers will be discussed. provide solutions for standard difficulties faced Twice a week telephone calls. The participants will be followed up through telephonic conversation twice weekly with a gap of three to four days in between each call."
48388062|NCT05723042|OTHER|EMS|this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
48385330|NCT00636922|DRUG|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
48026645|NCT01716247|OTHER|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
48026646|NCT01965067|DRUG|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
48026647|NCT01882634|DEVICE|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
48026648|NCT00045994|DRUG|ALT-711|
48026649|NCT00710424|DRUG|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
48026650|NCT00710424|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
48026651|NCT03812458|BEHAVIORAL|website and brochure|website and brochure
48026652|NCT02695238|PROCEDURE|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
48026653|NCT04598152|DEVICE|TDCS - transcranial direct current stimulation|TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
48026654|NCT04823598|PROCEDURE|Coached pushing and Finnish manual perineal protection|"Pushing technique: Rest will be encouraged between uterine contractions. With the onset of uterine contraction, women will be instructed to breathe normally. They will then be instructed to take a deep breath and hold (closed-glottis), and push down strongly for as long as possible (up to 10 seconds). After pushing effort, normal breathing will be encouraged, then the same pushing instruction will be repeated again.~Fetal expulsion: The expulsion rate of the fetal head will be controlled by light pressure applied on the fetal occiput. Simultaneously, the thumb and index finger of the dominant hand will be used to support the perineum, while the bent middle finger will grasp the baby's chin. Once a good grip is achieved, the investigator slowly assists in the expulsion of the fetal head from the vaginal introitus. When most of the fetal head is out, the perineal ring will be pushed under the baby's chin."
48026655|NCT04823598|PROCEDURE|Uncoached pushing and Hands-poised perineal protection|Women will not be given any instructions regarding straining and breathing, and will be allowed to follow their own pushing impulses. During the expulsion of the fetal head, the hands of the researcher will be kept in the air and ready for the intervention, but pressure will not be applied to the fetal head or perineum unless necessary (fetal hypoxic appearance, strain detection with a risk of spontaneous laceration towards the anus in the midline).
48026656|NCT05868083|DRUG|SNC-109 CAR-T Cells|SNC-109 CAR-T Cells, first dose from 2×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
48026657|NCT03697291|DEVICE|PS wire|The wiring connection used to convey ECG signal from inside the body
48026658|NCT04827199|DEVICE|Artificial Urinary Sphincter implantation|"Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~* Perineal approach and bulbar urethral dissection~* Inguinal approach~* Cuff implantation around the urethra~* Transmission cable passing~* Surgery test procedure~* Implantation of the Control Unit~* Closure of the inguinal incision~* Closure of the perineal incision~* Implant disabled mode activation"
48026659|NCT03509935|OTHER|Intervention Ultrasound Group|"Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
48026660|NCT04870801|DRUG|Respirogen Micro-Oxygen|Enteral (rectal) delivery of Respirogen Micro-Oxygen
48183471|NCT02356627|OTHER|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
48183472|NCT06117228|OTHER|Data collection|Data collection
48724237|NCT02998034|DEVICE|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
48521055|NCT03357185|PROCEDURE|Femoral eversion|"The purpose of this database is to compile the data of patients followed at the René Dubos Hospital Center with symptomatic lower extremity arterial disease (AOMI) (Rutherford 2 to 5) who were operated on by the femoral tripod eversion technique.~The database will include data on the operation, possible complications, clinical course of patients and medical and surgical follow-up."
48521056|NCT01068483|DRUG|BKM120|
48521057|NCT06280521|OTHER|fGQ-ASC|French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)
48026661|NCT03736525|BEHAVIORAL|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
48026662|NCT03736525|BEHAVIORAL|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
48183473|NCT01114451|PROCEDURE|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
48521058|NCT04981717|DRUG|REGN1908-1909|Subcutaneous (SC) for a total of 5 administrations
48521059|NCT04981717|DRUG|Matching Placebo|SC for a total of 5 administrations
48521060|NCT02251899|BEHAVIORAL|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
48724238|NCT02998034|DEVICE|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
48026663|NCT05436782|OTHER|core strengthening exercises|•Group B (experimental group) received routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in the lower extremity in D1 flexion pattern and D1 extension pattern up to the patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks. The outcome measure was measured at baseline and 6th-week interval
48724239|NCT05006144|OTHER|sequenced trunk co-activation exercises|"* Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises."
48724240|NCT05006144|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
48724241|NCT05006144|OTHER|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
48724242|NCT03914677|DRUG|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
48724243|NCT03495791|OTHER|YouTube Video|Educational Video
48724244|NCT03005808|DRUG|Ropivacaine|Surgery for appendicitis
48724245|NCT03908476|DEVICE|Burst-capable SCS system|Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.
48724246|NCT03908476|DEVICE|DRG Stimulator|Subjects will be implanted with a market-released Abbott DRG stimulation system.
48724247|NCT03852979|DRUG|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
48724248|NCT03852979|DRUG|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
48724249|NCT03852979|PROCEDURE|conisation|if tumor is reduced to \<2 cm, patients will be treated with a conisation
48724250|NCT01393938|OTHER|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
48724251|NCT04857411|BEHAVIORAL|Peers LEAD plus HLWD|Combined Peers LEAD and Healthy Living with Diabetes is a culturally-appropriate program to increase medication adherence
48724252|NCT03046979|DRUG|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
48724253|NCT02342080|OTHER|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
48724254|NCT02342080|DEVICE|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
48724255|NCT00057408|DRUG|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
48724256|NCT00057408|DRUG|Placebo|Matching Placebo
48724257|NCT01973504|DRUG|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
48724258|NCT01973504|DRUG|Control|Crystalloid solution IV infusion drip to keep vein open
48724259|NCT02411929|DRUG|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
48724260|NCT02411929|DRUG|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
48724261|NCT02411929|DRUG|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
48724262|NCT02058394|PROCEDURE|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
48724263|NCT00677755|DRUG|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
48026664|NCT05436782|OTHER|Routine physical therapy|•Group A (control group) will receive routine physical therapy involving muscle strengthening exercises, range of motion exercises, and stretching exercises up to the patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, and wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks
48521061|NCT03003195|DRUG|P10s-PADRE|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
48521062|NCT02446041|OTHER|Non-Interventional Study|Non-Interventional Study
48521063|NCT03658044|OTHER|Participation in the internet forum|Active participation in the forum with encouragement to participate on a weekly basis
48521064|NCT03658044|OTHER|Placebo|No intervention performed. Patients are offered to read the open pages on the website
48521065|NCT02810925|PROCEDURE|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
48521066|NCT02810925|PROCEDURE|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
48521067|NCT02810925|DIETARY_SUPPLEMENT|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
48521068|NCT02810925|DIETARY_SUPPLEMENT|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
48521069|NCT02997293|OTHER|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
48521070|NCT06126497|DRUG|Ropanicant|Tablet
48724264|NCT00677755|DRUG|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
48724265|NCT03898076|DEVICE|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
48724266|NCT03898076|OTHER|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
48724267|NCT03898076|OTHER|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
48026665|NCT05779267|DRUG|NRX-101|D-cycloserine/lurasidone fixed dose combination
48026666|NCT06077006|OTHER|questionnaires Only|questionnaires Only
48521071|NCT02271347|DRUG|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
48521072|NCT06455813|DRUG|Bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
48521073|NCT06455813|DRUG|Macrogol 3350 and electrolytes|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
48521074|NCT06455813|DRUG|A combination of macrogol 3350 and electrolytes and bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
48026667|NCT04257318|OTHER|Vibrating Relaxation Tool|Use of a Vibrating Relaxation Tool in case of pain during pregnancy
48521075|NCT04540653|BIOLOGICAL|Standard vaccination schedule|Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.
48521076|NCT04540653|BIOLOGICAL|Reinforced vaccination schedule|Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
48521077|NCT05177679|DIETARY_SUPPLEMENT|Active supplement|Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.
48521078|NCT05177679|DIETARY_SUPPLEMENT|Placebo control|Placebo control supplement
48521079|NCT06267989|PROCEDURE|Extraction of the primary canine teeth|Extraction of the primary teeth has show to be successful in some cases.
48724268|NCT02355444|DIETARY_SUPPLEMENT|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
48724269|NCT02355444|DIETARY_SUPPLEMENT|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
48724270|NCT05327764|OTHER|Work to rest cycles of 40:20 minutes|Walking in a hot environment for 2 hours with repeated 40 minutes of work and 20 minutes of rest
48026668|NCT01888315|DEVICE|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
48026669|NCT01888315|DEVICE|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
48026670|NCT01888315|DEVICE|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
48026671|NCT01888315|DEVICE|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
48521080|NCT06267989|PROCEDURE|Expansion|Expansion of the maxilla with rapid maxillary expander with no extractions
48521081|NCT06581445|BEHAVIORAL|Birdsongs|The participants listened to a clip of birdsongs from laughing thrushes.
48521082|NCT06581445|BEHAVIORAL|Music|The participants listened to a cheerful Cuckoo Waltz music.
48521083|NCT04177082|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
48724271|NCT05327764|OTHER|Work to rest cycles of 20:10 minutes|Walking in a hot environment for 2 hours with repeated 20 minutes of work and 10 minutes of rest
48724272|NCT03041363|DRUG|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
48724273|NCT01270256|DRUG|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
48724274|NCT01270256|DRUG|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
48724275|NCT02785419|BEHAVIORAL|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
48724276|NCT01170078|DRUG|Epoetin Hospira|IV dose 3 times a week.
48724277|NCT01170078|DRUG|Epogen|IV dose 3 times a week
48724278|NCT01343732|DEVICE|Deep TMS|deep transcranial magnetic stimulation
48724279|NCT05749952|DEVICE|Symphonie Aqua Digital System|We will digitally capture (via computer) the shape of your limb, which will create a digital file (computer file) of what the internal shape of your socket should be. This file will then be used with a computer software program to optimize the fit of your prosthesis. This image will be used to create a check socket (temporary socket) to confirm a correct anatomical and comfortable socket. Then the check socket (temporary socket) will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
48724280|NCT05749952|DEVICE|Symphonie Aqua System (Non-Digital)|A non-digital weight-bearing socket will be used to create the check socket (temporary socket), which will be used to create a laminated final socket for home use and research outcomes. The check socket is temporarily used; whereas, the final socket is for long-term use.
48724281|NCT01600053|DRUG|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
48724282|NCT02986113|BEHAVIORAL|MAPS tailored multimedia patient activation program|
48724283|NCT02986113|BEHAVIORAL|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
48724284|NCT02986113|BEHAVIORAL|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
48724285|NCT02986113|BEHAVIORAL|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
48724286|NCT03848949|DEVICE|Evenup|Orthotic which increases effective leg length.
48724287|NCT05294458|DRUG|cotadutide solution for injection|cotadutide solution for injection
48026672|NCT03498183|DRUG|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
48026673|NCT04209660|DRUG|Lenvatinib|Lenvatinib 20mg daily (two 10mg lenvatinib capsules) taken orally will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day.
48026674|NCT04209660|DRUG|Pembrolizumab|Pembrolizumab (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes are acceptable on C1D1.
48026675|NCT00931151|DIETARY_SUPPLEMENT|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
48026676|NCT04561570|DEVICE|Vivity ACRYSOF IQ IOL Group|Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens
48026677|NCT04561570|DEVICE|ACRYSOF IQ IOL Control Group|Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
48026678|NCT05387291|BEHAVIORAL|Intervention group|The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.
48026679|NCT05387291|BEHAVIORAL|Control group|The control group will receive the usual intervention of the center.
48026680|NCT06110312|BEHAVIORAL|NavCare-EU|NavCare-EU is a person- and family-centered intervention in which navigators collaborate with older persons and their close family caregivers across the continuum of supportive, palliative, and end-of-life care,. NavCare-EU is based on the existing and successfully tested Nav-CARE intervention from Canada. Navigators focus on connecting clients to social supports, both formal and informal, advocating for clients in meeting their quality-of-life goals, resourcing by identifying needs and negotiating access to meeting those needs, and engaging clients in what is most meaningful to them. Navigators are selected, trained, and mentored volunteers or professionals. NavCare-EU is based on the existing and successfully tested Nav-CARE(c) intervention from Canada.
48026681|NCT05331183|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
48026682|NCT05331183|DRUG|IVA|Tablets for oral administration.
48183474|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
48724288|NCT00431119|DRUG|Azathioprine or Mycophenolate mofetil|
48724289|NCT05685056|BEHAVIORAL|Text messages|Texts with detailed information focusing on nutrition and iodine rich foods specifically, every 3-5 days.
48724290|NCT02816619|BEHAVIORAL|Personalized Physical Activity coaching program|
48724291|NCT02816619|BEHAVIORAL|Free practice of physical activity|
48724292|NCT00895453|DRUG|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
48724293|NCT00895453|DRUG|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
48724294|NCT00895453|DRUG|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
48724295|NCT04014127|DIAGNOSTIC_TEST|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
48724296|NCT04014127|DIAGNOSTIC_TEST|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
48724297|NCT04014127|DIAGNOSTIC_TEST|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
48724298|NCT04014127|OTHER|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
48724299|NCT04014127|OTHER|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
48724300|NCT05701891|COMBINATION_PRODUCT|Physiotherapy with integrated Virtual Reality|A 12-week personalised, VR-integrated physiotherapy intervention.
48724301|NCT05701891|OTHER|Physiotherapy (usual care)|A 12-week usual physiotherapy care intervention.
48724302|NCT06065592|DRUG|Palbociclib|Palbociclib will be administered at a dose of 125 mg oral on a 21/7 cycle.
48724303|NCT06065592|DRUG|Rivaroxaban|Rivaroxaban will be administered at a dosage of 15 mg intravenously twice a day for 21 days, followed by 20 mg once daily for the subsequent 21 days.
48724304|NCT06065592|GENETIC|SNP|diagnostics of patients' carriers or not of the risk allele(s)
48724305|NCT00849862|DRUG|Levetiracetam|750 mg Tablet
48724306|NCT00849862|DRUG|Keppra®|750 mg Tablet
48724307|NCT04736615|DEVICE|SAFEWATER systems for drinking water disinfection|A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
48724308|NCT04736615|BEHAVIORAL|Behavior change interventions|Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
48183475|NCT00922688|DRUG|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
48724309|NCT02288988|PROCEDURE|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
48183476|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
48183477|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (Low dose)|One Capsule to be consumed twice a day
48183478|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (High Dose)|One Capsule to be consumed twice a day
48183479|NCT05825222|DIETARY_SUPPLEMENT|Placebo|One Capsule to be consumed twice a day
48724310|NCT01274910|DIETARY_SUPPLEMENT|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
48724311|NCT01274910|DIETARY_SUPPLEMENT|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
48724312|NCT01927055|DRUG|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
48724313|NCT01927055|DRUG|Placebo|Placebo to match droxidopa capsules and strength designations
48724314|NCT06525987|BEHAVIORAL|Physical activity|Randomization to a 24-week physical exercise program
48724315|NCT03171818|DRUG|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
48724316|NCT03171818|DRUG|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
48724317|NCT04397458|DRUG|Saline|0.9% saline on each side
48724318|NCT04397458|DRUG|Bupivacaine|0.25% bupivacaine (50mg) on each side
48724319|NCT04397458|DRUG|Dexamethasone|3mg preservative-free dexamethasone on each side
48724320|NCT03399955|DRUG|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
48724321|NCT03399955|DRUG|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
48724322|NCT03399955|DRUG|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
48724323|NCT02414620|DEVICE|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
48724324|NCT02378207|BIOLOGICAL|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
48724325|NCT02378207|BIOLOGICAL|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
48724326|NCT02378207|BIOLOGICAL|BCG|
48724327|NCT02378207|BIOLOGICAL|Control Sodium Chloride 0.9%|
48724328|NCT01992562|DRUG|Ziconotide|
48724329|NCT01992562|DRUG|placebo|
48724330|NCT00169221|DRUG|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
48385331|NCT06648915|DIAGNOSTIC_TEST|Lipoprotein(a)|Measurement of Lp(a) was performed at the time of entry to the registry. Lp(a) level was measured using immunenephelometric assay
48385332|NCT02309541|DEVICE|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
48724331|NCT00169221|RADIATION|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
48724332|NCT04922905|OTHER|NEURO +|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)~Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed."
48724333|NCT04922905|OTHER|NEURO -|"The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score :~* The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005)~* the Peri traumatic distress inventory (Jehel et al., 2005)~* and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)"
48724334|NCT03563365|OTHER|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
48724335|NCT03563365|DRUG|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
48724336|NCT05258539|OTHER|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~* Lifestyle follow-up questionnaire.~* Satisfaction questionnaire."
48724337|NCT03664765|OTHER|UA and RMT|daily oropharyngeal and respiratory muscle exercises
48724338|NCT03664765|OTHER|Sham exercise|Daily sham exercises
48724339|NCT00304005|DRUG|laromustine|
48724340|NCT01943552|DRUG|placebo|normal saline
48724341|NCT01943552|DRUG|ipratropium bromide|ipratropium bromide
48724342|NCT01375608|DRUG|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
48724343|NCT01953900|GENETIC|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied."
48724344|NCT01953900|BIOLOGICAL|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
48724345|NCT01953900|DRUG|Fludarabine|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
48026683|NCT01889420|DRUG|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
48026684|NCT01817205|PROCEDURE|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
48026685|NCT02665000|PROCEDURE|Structured training programme|Participants will undergo 5-days training sessions
48026686|NCT01542775|BEHAVIORAL|Aerobic Exercise Group|12 weeks Aerobic exercise
48026687|NCT01542775|BEHAVIORAL|Control Group|maintaining usual activities
48183480|NCT01240538|BIOLOGICAL|wild-type reovirus|Given IV
48183481|NCT01240538|DRUG|cyclophosphamide|Given PO
48183482|NCT01240538|OTHER|laboratory biomarker analysis|Correlative studies
48183483|NCT01240538|OTHER|pharmacological study|Correlative studies
48183484|NCT00379769|DRUG|Rosiglitazone|Rosiglitazone maximum 8 mg per day
48385333|NCT06567756|PROCEDURE|CSPO|The distal rectum is freed to the entrance of the internal and external sphincter space, and then an oblique resection line is designed under direct vision according to the tumor site and shape, ensuring that the distal and lateral margins are not less than 1 cm, and preserving the contralateral dentate line and the intestinal wall as much as possible, and the anastomosis is completed manually or with instruments.
48724346|NCT01953900|DRUG|Cyclophosphamide|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
48385334|NCT06567756|PROCEDURE|ISR|Partial, subtotal, or total excision of the internal sphincter and/or a portion of the longitudinal rectal muscle, expansion of the distal rectal excision margin into the anal canal or to the anal verge, and completion of the colo-anal anastomosis manually or instrumentally.
48724347|NCT04712552|PROCEDURE|deep brain stimulation|"On the day of surgery, under general anesthesia, a Fischer ZD frame will be attached to the skull. A T1-weighted 3D MRI with gadolinium will be performed.~Investigators will plan on this MRI, anatomical targets and deep brain trajectories using the NeuroInspire surgical planning software.~The patient will be attached to the base of the robot through the frame. Registration will be performed using the Neurolocate method after the acquisition of 3D CT images using the O-arm. The Neurolocate recording is based on radiographic images.The 3D MRI will be merged with the 3D tomography images taken with the O-arm to co-register the trajectories planned on the MRI in the robot space The surgical procedure will be performed as usual by milling the bone at the entry point and inserting under robotic guidance an electrode through a guide tube to the intended target."
48724348|NCT04576689|DRUG|IBE-814 70ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
48724349|NCT04576689|DRUG|IBE-814 140ug|Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
48724350|NCT03042130|OTHER|Standard of care|standard of care
48724351|NCT03042130|DRUG|Iron Carboxymaltose|Two IV doses
48724352|NCT01067365|DRUG|Androxal|12.5 mg once daily
48521084|NCT05578274|RADIATION|SBRT + LDRT|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."
48521085|NCT05578274|RADIATION|SBRT alone|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."
48724353|NCT01067365|DRUG|Androxal|25 mg once daily
48724354|NCT05637892|OTHER|No intervention|This is a prospective observational study with no intervention
48724355|NCT04891107|DEVICE|Walking Program with a Music-based, Rhythm-modulating Wearable Sensor System|Participants will walk using the music-based, rhythm-modulating wearable sensor system (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 5 times a week for 4 weeks.
48026688|NCT05045521|OTHER|plyometric warm up group|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~During the plyometric intervention, subjects will perform the 2 \* 8 squat jumps, 2 \* 8 scissor jumps, and 2 \* 8 double leg bounds (2 sets of 8 repetitions) as a part of warm-up, and will have 60 s to recover between each set. Prior to the intervention, participants will be shown the technique to be used during jumping through use of three videos."
48026689|NCT05045521|OTHER|resistance warm up|"participants will be asked to do 10 minutes self-paced jog on motorized treadmill.~After the jog participants will perform the 6\*10s strides with the 15% of the weight. Velocity of the strides will be controlled by the participants.~Warmup will be followed by the 10minutes rest"
48724356|NCT02686502|BEHAVIORAL|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
48724357|NCT01803867|DRUG|rHIgM22|Administered via IV infusion
48724358|NCT02014779|BEHAVIORAL|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
48026690|NCT05045521|OTHER|control warm up group|"participants will be asked to do 10 minutes self-paced jog on a motorized treadmill.~After the jog participants will perform the 6\*10s strides without the weight. Velocity of the strides will be controlled by the participants. Warmup will be followed by the 10minutes rest The total amount of time spended in each of the three warm-up protocols will be recorded. Participants will be instructed to wear the same pair of running shoes during the three tests."
48026691|NCT02628119|PROCEDURE|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
48026692|NCT02628119|PROCEDURE|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
48026693|NCT01924325|DRUG|Apixaban|orally active direct factor Xa inhibitor
48026694|NCT01924325|DRUG|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
48385335|NCT04993339|DRUG|OOC|The OOC will be mixed with autologous 5cc of platelet rich plasma (PRP), and then injected using a syringe into both tibia and femoral tunnels
48385336|NCT00268775|BEHAVIORAL|training and follow-up of pharmacists|
48385337|NCT00268775|BEHAVIORAL|patient-directed discontinuation letter|
48385338|NCT05125822|OTHER|Meal replacement and lifestyle modification|Meal replacement and lifestyle modification
48385339|NCT06249035|DIAGNOSTIC_TEST|Transoesophageal echocardiography (TEE)|TEE is a diagnostic modality in which an ultrasound probe is inserted via the oesophagus in order to visualize the heart.
48385340|NCT06651918|BEHAVIORAL|yoga practise|For the experimental study, the researcher will contact the participants to be included in the study and the intervention (yoga group) and control groups will be randomly created. The participants will be informed about the study by the researcher and their voluntary consent will be obtained. The researcher will provide information about the Identifying Characteristics Form for Children Diagnosed with Cancer and Their Families, the Quality of Life Scale for Children (PedsQL) and the Memorial Symptom Assessment Scale to be used in the study. The survey and scales will be applied to each participant individually one day before yoga. Then, the Yoga Group will be applied 3 sessions per week, 3 weeks in a row, each session will be 30 minutes. The researcher will repeat the survey and scale questions that he asked the participants before they started yoga at the end of the 3 weeks.
48385341|NCT01523301|DRUG|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
48385342|NCT01523301|DRUG|Placebo|"Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
48385343|NCT05310604|PROCEDURE|Blood withdrawal|Single blood withdrawal for determination of immunoglobulin levels
48385344|NCT06653335|BEHAVIORAL|Education Support Programme via Text Message|All students to be included in the study will be pre-tested via Google Form's. After the pre-test, the students in the experimental group will be sent images created by the researchers via text message for 4 weeks (22 days) and consisting of the information given in the Basic Principles and Practices in Midwifery Course. Each visual will contain one piece of information. The researchers will send 6 visuals to the students in the experimental group via text message every day for 4 weeks, except Saturdays and Sundays. The post-test will be applied immediately after the end of the implementation process. The messages will be short and contain a single piece of information.
48388063|NCT05110625|BEHAVIORAL|preDIABE-TEXT|Participants will receive text messages (three per week) in their mobile phones during six months.
48521086|NCT02286843|RADIATION|89Zr-trastuzumab|
48521087|NCT02286843|DEVICE|PET/CT scan|
48724359|NCT02014779|BEHAVIORAL|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
48724360|NCT06504186|DRUG|Blinatumomab|"* Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles."
48724361|NCT00801021|DRUG|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
48724362|NCT04477057|DRUG|HS-10241|HS-10241 is a tablet in the form of 100 mg, oral, once daily.
48724363|NCT00550901|DRUG|cisplatin|
48724364|NCT00550901|DRUG|dexrazoxane hydrochloride|
48724365|NCT00550901|OTHER|high performance liquid chromatography|
48026695|NCT01924325|DRUG|Aspirin|a non-steroidal anti-inflammatory drug
48026696|NCT01924325|DRUG|placebo|
48026697|NCT04376541|DRUG|Fentanyl|amount of fentanyl used in both groups
48026698|NCT01287585|DRUG|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
48724366|NCT00550901|OTHER|laboratory biomarker analysis|
48724367|NCT00550901|OTHER|mass spectrometry|
48724368|NCT00550901|OTHER|pharmacological study|
48724369|NCT03874390|OTHER|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
48385345|NCT01077167|DRUG|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
48724370|NCT05167903|OTHER|Normal Diet|All praticipants in ND will perform supervised and monitored RT three time per week for the 10 weeks of intervention. The ND group will consume all meals between 6 am - 10 pm (16 h eating window with 8 h of fasting, ad-libitum).
48724371|NCT05167903|BEHAVIORAL|Time-restricted eating|All participants in TRE will perform supervised and monitored RT three time per week for the 10 weeks of intervention. Participants in the TRE group will be instructed to consume all meals between 12pm to 8pm, and to avoid consumption of food or caloric drinks during the fasting period (8 h eating window with 16 h of fasting).
48026699|NCT01287585|DRUG|Placebo|weekly, intramuscular, until disease progression or toxicity.
48026700|NCT01287585|OTHER|Best Supportive Care|treatment of disease-related symptoms throughout the study.
48385346|NCT05335759|OTHER|Coaching programme for improvement and development of teaching skills in preceptorship|Training program An intervention based on coaching. The strategies of this program consisted of three 6-hour sessions using case studies and role-playing for motivation towards the development of the teaching role in the preceptorship of undergraduate nursing students and debriefing and a 4-hour booster session seven months later.
48385347|NCT04210882|BEHAVIORAL|Moderate-Intensity Exercise|See description of study arm.
48385348|NCT04889378|OTHER|prehabilitation|very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
48385349|NCT06652776|OTHER|Pharmacological treatment|"Pharmacological and non pharmacological treatments will be assessed and monitored during the retrospective and prospective phase, and will include:~* bronchodilators, inhaled steroids and their combinations~* mucolytics~* biologic therapies for COPD~* roflumilast~* pulmonary rehabilitation"
48385350|NCT06652776|OTHER|Pharmacological treatment|"All pharmacological and non pharmacological treatments for COPD will be assessed and monitored during the retrospective and prospective phase of the study, and will include:~* inhaled bronchodilators (long term beta-2 agonists and cholinergic antagonists), inhaled corticosteroids and their combinations~* mucolytics~* biologics for COPD (monoclonal antibodies)~* roflumilast~* chronic oral azythromicin~* pulmonary rehabilitation~* oxygen therapy~* non invasive/invasive ventilation"
48385351|NCT05429112|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
48385352|NCT05429112|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with a endotracheal tube + stylet.
48724372|NCT04059432|DIAGNOSTIC_TEST|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
48724373|NCT01651091|OTHER|Meditation Awareness Training|Psychotherapy Intervention
48724374|NCT01651091|OTHER|Treatment as usual|
48026701|NCT05187377|DRUG|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
48026702|NCT05187377|DRUG|Saline|Placebo (saline) will be administered subcutaneously once daily.
48724375|NCT03025178|PROCEDURE|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
48724376|NCT00989781|RADIATION|3-D Ultrasound|One time pelvic ultrasound
48724377|NCT00989781|DRUG|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
48724378|NCT00989781|DRUG|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
48724379|NCT00989781|DRUG|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
48026703|NCT04634357|DRUG|ET140203 T Cells|"Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct"
48026704|NCT03349710|BIOLOGICAL|Nivolumab|Specified dose on specified day
48385353|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
48385354|NCT02406937|DIETARY_SUPPLEMENT|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
48026705|NCT03349710|DRUG|Cetuximab|Specified dose on specified day
48026706|NCT03349710|DRUG|Cisplatin|Specified dose on specified day
48385355|NCT02406937|DIETARY_SUPPLEMENT|Breast Feeding|Oral intake of breast milk
48385356|NCT01502267|DRUG|High dose IVIG and B cell depleting agents|"1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
48724380|NCT00989781|DRUG|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
48724381|NCT00989781|DRUG|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
48724382|NCT05583032|DEVICE|ScanNav Anatomy PNB|AI-powered device that highlights anatomy of interest during ultrasound scans.
48724383|NCT00860834|BEHAVIORAL|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
48724384|NCT00860834|BEHAVIORAL|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
48724385|NCT06546488|BEHAVIORAL|Assessments|A standardized assessment battery will be administered. It will consist of cognitive, functional and motor assessments.
48724386|NCT00958217|BEHAVIORAL|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
48724387|NCT00958217|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
48026707|NCT03349710|RADIATION|Radiotherapy|Specified dose on specified day
48026708|NCT05571917|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)|This intervention is an integrated psychosocial treatment of two established treatments for chronic pain and Opioid Use Disorder (OUD). This intervention focuses on reducing pain interference and preventing relapse to opioid misuse.
48724388|NCT02467842|BIOLOGICAL|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
48026709|NCT05571917|BEHAVIORAL|Enhance Usual Care (EUC)|This intervention consists of psychoeducational materials about chronic pain treatment resources, signs and management of opioid overdose and overdose prevention. This intervention also consists of a brief, remote visit with a study therapist, lasting approximately 15 minutes.
48026710|NCT04690608|DRUG|Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1|suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion
48724389|NCT02467842|BIOLOGICAL|NBP607-Y|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
48724390|NCT02467842|BIOLOGICAL|NBP607-V|Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
48724391|NCT01272869|DEVICE|SenSura|The ostomy bag filter will be tested for a period of 14 days
48724392|NCT01272869|DEVICE|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
48026711|NCT01573702|PROCEDURE|Stereotactic Radiosurgery|21 Gy daily for 5 days
48026712|NCT01573702|DRUG|Erlotinib|150mg once daily
48026713|NCT05643066|DRUG|0.1 mg/kg esketamine|Esketamine 0.1 mg/kg was intravenously injected first.
48385357|NCT05722275|DIAGNOSTIC_TEST|Peritoneal metastasis status ascertainment|Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
48385358|NCT04973748|BEHAVIORAL|Conditioned open-label placebo (COLP)|"Placebo oxycodone will be formulated to have the same physical appearance as liquid oxycodone and will be dispensed by the inpatient pharmacy and administered by the nursing staff. At all times that oxycodone or placebo medication is administered on post-operative day (POD) 1-5, the patient will undergo conditioning via exposure to a clove oil scent:~1. Conditioning (i.e. exposure to clove oil scent) with each dose of oxycodone medication on POD 1-5.~2. Scheduled placebo oxycodone medication paired with conditioning (i.e. exposure to clove oil scent) 3 times per day on POD 2-5."
48385359|NCT04973748|BEHAVIORAL|Surveys about pain, opioid use and depression symptoms|"Surveys before surgery: Within 1 week prior to surgery, patients complete surveys about pain levels, opioid consumption, understanding of placebo effect and symptoms of depression.~Surveys after surgery: Through 6-months after surgery, patients complete surveys about pain levels, opioid consumption, side effects of opioids and symptoms of depression."
48385360|NCT06389825|OTHER|Healthy diet|28-day fully controlled dietary intervention during which participants will receive a diet that reflects the recommendations of Canada's Food Guide.
48385361|NCT02987114|DRUG|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
48385362|NCT04204135|PROCEDURE|LLIF or ALIF procedures|LLIF or ALIF procedures
48521088|NCT02286843|RADIATION|89Zr-pertuzumab|
48521089|NCT02188810|BIOLOGICAL|PAL|Single dose administered intramuscularly.
48521090|NCT02188810|BIOLOGICAL|TIV|Single dose administered intramuscularly .
48521091|NCT00000846|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
48521092|NCT00000846|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
48521093|NCT05646459|DRUG|cannabidiol|This group will locally apply cannabidiol to a posterior, localized 6-9 mm bleeding periodontal pocket.
48521094|NCT05646459|DEVICE|floss|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
48385363|NCT05454488|OTHER|Focal Cryoablation|Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area
48385364|NCT05454488|OTHER|Standard of Care|Participants will receive a prostate biopsy.
48385365|NCT05454488|OTHER|Quality-of-life Questionnaires|Participants will fill out questionnaires.
48026714|NCT05643066|DRUG|0.2 mg/kg esketamine|Esketamine 0.2 mg/kg was intravenously injected first.
48026715|NCT05643066|DRUG|0.9% saline|0.9% saline was intravenously injected first.
48026716|NCT05643066|DRUG|Propofol|Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
48385366|NCT05131893|DRUG|Tamoxifen|endocrine therapy
48385367|NCT05131893|DRUG|Goserelin|endocrine therapy
48385368|NCT05131893|DRUG|Letrozole 2.5Mg Tab|endocrine therapy
48385369|NCT05131893|DRUG|Epirubicin|chemotherapy
48385370|NCT05131893|DRUG|cyclophosphamide|chemotherapy
48385371|NCT05131893|DRUG|Docetaxel|chemotherapy
48026717|NCT00855829|DEVICE|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~1. The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~2. Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
48026718|NCT00855829|DEVICE|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
48026719|NCT05471973|OTHER|Multidisciplinary Team|Multidisciplinary team will be established that will define gaps in care, monitor ongoing data, identify barriers to guideline-directed care, and develop and implement multifaceted intervention to address the barriers
48385372|NCT05131893|DRUG|paclitaxel|chemotherapy
48385373|NCT05131893|DRUG|trastuzumab|biological treatment
48385374|NCT05131893|DRUG|pertuzumab|biological treatment
48385375|NCT05131893|DRUG|Capecitabine|chemotherapy
48385376|NCT05043961|PROCEDURE|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
48385377|NCT04082533|DRUG|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
48385378|NCT04082533|DRUG|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
48385379|NCT00119080|BIOLOGICAL|meningococcal conjugate vaccine (Menactra)|
48385380|NCT06401317|DRUG|Saline Hypertonic Solution|Ultrasound-guided intra-articular injection of 0.25ml of 0.9% saline solution.
48385381|NCT06401317|DRUG|Triamcinolone Acetonide|Ultrasound-guided intra-articular injection 0.25ml (10 mg) of triamcinolone.
48385382|NCT03544567|DRUG|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
48385383|NCT03777800|BEHAVIORAL|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
48385384|NCT03777800|BEHAVIORAL|Treatment as usual|Standard treatment
48385385|NCT05309993|DEVICE|PTNS|See arm description
48385386|NCT05309993|DEVICE|TENS|See arm description
48385388|NCT04466436|OTHER|tryptophan|measurement of tryptophan in serum
48385389|NCT06385873|DRUG|RC48|RC48: 2.5 mg/kg, intravenous infusion, on day 1, every 3 weeks (Q3W);
48385390|NCT06385873|DRUG|Adebrelimab|Adebrelimab：1200 mg, intravenous infusion, on day 1, every 3 weeks (Q3W);
48385391|NCT06385873|DRUG|Apatinib|Apatinib: 250mg, oral administration, once daily (qd), every 3 weeks (Q3W);
48385392|NCT06385873|DRUG|S-1|S-1：For patients with a body surface area (BSA) ≤1.5m², use 50mg each time; for patients with BSA \>1.5m², use 60mg each time, oral administration, twice daily (bid), on days 1-14, every 3 weeks (Q3W);
48026720|NCT05471973|OTHER|Outreach Visits|An outreach visit consulting group from the coordinating center and trial leadership will provide external guidance on reviewing data, defining barriers, and implementing interventions
48385393|NCT02765139|BEHAVIORAL|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
48385394|NCT02765139|OTHER|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
48385395|NCT00489008|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
48385396|NCT00761761|DRUG|Sensoril|
48521095|NCT05646459|DEVICE|proxabrush|This group will use floss alone at the test site (posterior, localized 6-9 mm bleeding periodontal pocket).
48521096|NCT00143442|DRUG|[S,S]-Reboxetine|
48521097|NCT05267106|DRUG|Pemigatinib|13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
48521098|NCT00577863|DRUG|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
48026721|NCT05471973|OTHER|Multifaceted Intervention|These interventions are not limited to targeted engagement with non-extractors, electronic health record (EHR) decision support, creation of OR block time, use of opinion leaders, and development of clinical pathways. In addition, once patients are identified and referred to extraction centers, clinical pathways are needed to provide prompt care without clinical delay
48183485|NCT00379769|DRUG|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
48385397|NCT00761761|OTHER|Placebo|
48724393|NCT05116696|PROCEDURE|For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery|"For chronic limb-threatening ischemia (CLTI) patients that represents one of the revascularisation methods (endovascular, open surgery, hybrid).~For the colorectal liver metastasis (CRLM) patients that represents liver resection with adjuvant chemo- or radiotherapy"
48026722|NCT05471973|OTHER|Measurement and Feedback|The coordinating center will provide ongoing feedback related to the site's data. This will include time to diagnosis, treatment, and outcomes related to the device infection.
48026723|NCT04793321|DEVICE|Baby carrier|"* It is made in china.~* It is made of Cotton-Polyester.~* It has 3 belts - 2 shoulder belts and one waist belt for superior lumbar support. Shoulder straps are padded and adjustable for the parent's comfort. It has webbing straps for shoulder and waist strap adjustment.~* It is suitable for newborn to 12-months baby~* It is available online at babyshopstores https://www.babyshopstores.com/"
48026724|NCT04793321|DEVICE|Biodex Balance System|"* The Biodex Balance System SD (The Biodex Balance System SD Model 945-300, 115 VAC, Shirley, NY, USA) is used to assess the balance in this study.~* It is an objective device that measures dynamic postural stability. It uses a circular platform that allows up to 20˚of of platform tilt in a 360˚ range of motion.~* The measures of postural stability score for BBS are the Overall Stability Index (OSI), Medial-Lateral Stability Index (MLSI), and Anterior-Posterior Stability Index (APSI). These indices are standard deviations that assess the path of sway around the zero point from the center of the platform and are measured in degrees. A high score in these stability indices indicates poor balance."
48026725|NCT04793321|OTHER|Infant mannequin|The mannequin infant has 3 Kg which corresponds to the infant's age from birth until 1month. This weight is selected as it corresponds to the age at which the infants are frequently carried by the mother .
48026726|NCT04793321|DEVICE|Biodex gait trainer 2 TM|"Gait Trainer 2™ ( model number:950-385, 115 VAC 50/60 Hz, made in the USA) is used for participants to walk on as walking is one of the most common daily life activities. because caregivers commonly walk while carrying their infants as it has a calming effect on crying infants~It consists of :~* Display: Use Audio and Visual Biofeedback - real-time biofeedback prompts patients into a proper gait pattern.~* Heart Rate Monitoring~* Handrail~* Open Platform"
48026727|NCT01312909|DRUG|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
48026728|NCT01312909|DRUG|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
48026729|NCT01312909|DRUG|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
48026730|NCT01925183|DRUG|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
48026731|NCT01925183|DRUG|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally
48026732|NCT01925183|DRUG|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
48183486|NCT00379769|DRUG|Metformin|Metformin maximum permitted daily dose .
48385398|NCT01984970|DEVICE|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
48521099|NCT04222426|OTHER|89Zr-atezolizumab PET scans|Patients receive a total amount of 10 mg unlabeled atezolizumab, this will be added to the tracer to prevent rapid clearance during imaging. A labeled dose of 37 Megabequerell (MBq) 89Zr-atezolizumab (±10%; 1 Millicurie) will then be administered. The tracer will be administered intravenously (i.v.). All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. After each tracer injection, 89Zr-atezolizumab PET scans will be performed on day 4 (96 ± 6h after tracer administration).
48521100|NCT00469430|DRUG|cefotaxim and metronidazol|iv administration for at least 24 h
48521101|NCT03182777|PROCEDURE|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
48521102|NCT06378515|OTHER|Physical activity, postural changes and cognitive tasks|"1. Measuring while patients are sitting in rest for 5 minutes.~2. Supine to stand test: lying down (5 min) standing up (5 min)~3. Repeated sit stand test: sitting (10 sec) ↔ standing (10 sec), changing position every 10 seconds for 5 minutes.~4. Paced breathing in sitting position: letting patients breath 6 breaths/minute (0.1Hz) for 5 minutes.~5. Breath hold manoeuvre in sitting position: 60s normal breathing, then 32s breath hold + 88s normal breathing repeated 3 times.~6. Arithmetic stress test by giving the subject single digit addition. To give the pressure, subject needs to do as many as possible calculation within 1 minute with 1 minute break. This is repeated 3 times."
48724394|NCT06089902|PROCEDURE|unroofing or other surgery if needed|unroofing of coronary artery
48183487|NCT02638883|DEVICE|Hybrid SRW cochlear implant|Subjects will be implanted with the Hybrid SRW
48183488|NCT06035081|DRUG|Prednisolone|see arm description
48183489|NCT06035081|OTHER|Placebo|Placebo similar to prednisolone
48183490|NCT03384303|OTHER|Standardized meal test|Preoperatively and postoperatively standardized meal test
48183491|NCT00337753|BEHAVIORAL|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
48183492|NCT00337753|BEHAVIORAL|Wait-list|subjects assigned to wait-list condition for six-weeks
48385399|NCT05446116|PROCEDURE|partial splenic artery embolization|embolization of the splenic artery for the treatment of hypersplenism
48385400|NCT00024557|DRUG|IL13-PE38QQR|
48385401|NCT00024557|PROCEDURE|targeted fusion protein therapy|
48385402|NCT00024557|PROCEDURE|surgery|
48385403|NCT00080925|BIOLOGICAL|filgrastim|
48385404|NCT00080925|BIOLOGICAL|graft-versus-tumor induction therapy|
48521103|NCT04884139|DRUG|Dolutegravir/Lamivudine as a single pill|- Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.
48521104|NCT04884139|DRUG|Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.|"* Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~* Route of adminstration: oral~* Schedule of administration: once a day for 96 weeks."
48385405|NCT00080925|BIOLOGICAL|rituximab|
48385406|NCT00080925|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48385407|NCT00080925|DRUG|cyclophosphamide|
48385408|NCT00080925|DRUG|cyclosporine|
48385409|NCT00080925|DRUG|cytarabine|
48385410|NCT00080925|DRUG|doxorubicin hydrochloride|
48385411|NCT00080925|DRUG|etoposide|
48521105|NCT06239077|OTHER|Non Invasive Prenatal Test via blood sample|Maternal - blood draw, Paternal - blood draw/Saliva sample
48521106|NCT02741414|DEVICE|The result of H pylori culture based on gram staining and enzyme activity testing|This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
48521107|NCT02741414|DEVICE|The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole|The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
48521108|NCT02741414|DEVICE|The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing|The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
48521109|NCT04584684|OTHER|0.9% w/v NaCL Saline|saline placebo rinse
48521110|NCT04584684|DRUG|1.5% w/v Hydrogen Peroxide|Over-the-counter antiseptic mouth rinse
48521111|NCT04584684|DRUG|0.12% Chlorohexidine Gluconate|Dentist prescribed antimicrobial mouth rinse
48385412|NCT00080925|DRUG|fludarabine phosphate|
48521112|NCT04584684|DRUG|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
48385413|NCT00080925|DRUG|prednisone|
48385414|NCT00080925|DRUG|vincristine sulfate|
48385415|NCT00080925|PROCEDURE|peripheral blood stem cell transplantation|
48385416|NCT05162326|BIOLOGICAL|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
48385417|NCT01823250|BEHAVIORAL|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
48385418|NCT01823250|BEHAVIORAL|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
48026733|NCT03897608|BEHAVIORAL|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
48026734|NCT00057915|BIOLOGICAL|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
48026735|NCT02523534|PROCEDURE|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
48026736|NCT02523534|PROCEDURE|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
48724395|NCT03150277|BEHAVIORAL|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
48385419|NCT01823250|BEHAVIORAL|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
48026737|NCT02062502|BIOLOGICAL|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
48026738|NCT02062502|BIOLOGICAL|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
48026739|NCT02062502|BIOLOGICAL|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
48385420|NCT01823250|BEHAVIORAL|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
48026740|NCT00670124|DEVICE|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
48026741|NCT06082180|PROCEDURE|prophylactic central neck dissection|prophylactic central neck dissection was performed for the ipsilateral lesion
48026742|NCT00002912|DRUG|etoposide|
48183493|NCT05250765|DEVICE|Twistflex retainer|twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
48385421|NCT02257736|DRUG|Apalutamide|Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
48385422|NCT02257736|DRUG|Abiraterone acetate|Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
48385423|NCT02257736|DRUG|Prednisone|Participants will receive 5 mg tablet of prednisone twice daily orally.
48385424|NCT02257736|DRUG|Placebo|Participants will receive matching placebo to apalutamide once daily orally.
48026743|NCT00002912|DRUG|mitoxantrone hydrochloride|
48026744|NCT00002912|DRUG|valspodar|
48026745|NCT05622981|BEHAVIORAL|Age-specific educational materials and monitoring|Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
48026746|NCT06310213|DEVICE|Non-Invasive Pressure Monitor|Modified smart soft contact lens and cap with reader coil
48183494|NCT05250765|DEVICE|Orthoflex retainer|Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
48183495|NCT01712061|DRUG|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
48183496|NCT01712061|DRUG|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
48183497|NCT05115292|BIOLOGICAL|BJ-005|dosed with intravenous infusion
48183498|NCT03673995|DIETARY_SUPPLEMENT|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
48183499|NCT02738905|DRUG|Rifaximin|One 550 mg tablet taken orally two times a day.
48521113|NCT04584684|DRUG|0.5% w/v Povidone-iodide|Over-the-counter antiseptic mouth rinse
48521114|NCT04584684|DRUG|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
48724396|NCT03150277|BEHAVIORAL|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
48724397|NCT03594214|DIAGNOSTIC_TEST|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
48724398|NCT06507800|OTHER|Observational cohort|Cancer incidence after AHSCT for an autoimmune indication.
48026747|NCT02890381|BIOLOGICAL|RSV LID cp ΔM2-2 Vaccine|10\^5 plaque-forming units (PFUs); administered as nose drops
48026748|NCT02890381|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
48026749|NCT05401292|DRUG|Hibiclens|antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
48026750|NCT05401292|DRUG|Isopropyl Alcohol 70% Topical Application Solution|First aid antiseptic
48026751|NCT00788840|DRUG|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
48026752|NCT00788840|DRUG|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
48026753|NCT06458361|PROCEDURE|Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis|Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
48026754|NCT02866682|DRUG|Prograf|Brand Drug for the duration of the study.
48026755|NCT02866682|DRUG|Tacrolimus|Generic
48026756|NCT05234346|DRUG|150 mg 5-ALAPhosphate + SFC|2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
48026757|NCT05234346|OTHER|Placebo|No Description for the intervention
48183500|NCT01425905|OTHER|The Blues Program|
48183501|NCT01425905|OTHER|Hey Durham|
48521115|NCT01927575|DEVICE|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
48026758|NCT04711265|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|Intramuscular injection with 3 doses of QHPV
48026759|NCT00958919|DRUG|naloxone|10 mg naloxone in 25 ml total volume
48026760|NCT00958919|DRUG|normal saline|25 ml
48026761|NCT00279123|DRUG|pantoprazole infusion|
48026762|NCT00279123|DRUG|pantoprazole bolus|
48026763|NCT00279123|DRUG|no treatment|
48026764|NCT04591834|OTHER|Observational|An observational study in subjects with the severe form of MPS II.
48026765|NCT04818411|OTHER|Routine physical therapy treatment with the Stabilization exercises|The program was based on specific training of the transversely oriented abdominal muscles with coactivation of the lumbar multifidus at the lumbosacral region, training of the gluteus maximus, the latissimus dorsi, the oblique abdominal muscles, the erector spinae, the quadratus lumborum, and the hip adductors and abductors. Initially, we focused on the specific contraction of the transversely oriented abdominal muscles. After approximately 2 weeks, loading was progressively increased throughout the intervention period. The women were required to exercise for 30 to 60 minutes, 3 days a week, for 3-4 weeks.
48026766|NCT04818411|OTHER|Routine physical therapy treatment + High-velocity thrust manipulation|: For high-velocity thrust technique, a modified Chicago technique was used. For this procedure, the lumbopelvic region was targeted. The side to be treated was chosen, based on the subject's report of her most symptomatic side. The physical therapist, performed passively side bend the subject toward the painful side, rotate the upper body in the direction opposite to the side bending, and then deliver a quick posterior and inferior thrust at a grade V including a small-amplitude/high-velocity therapeutic movement. A maximum of 2 attempts per side was permitted if no pop was heard following the first attempt. If the subject showed improvement of 50% or less after the first treatment, the intervention was categorized as a failure, the examination and intervention were repeated, and the subjects were asked to return 2 to 4 days later. If the subject showed greater than 50% improvement, the intervention was categorized as a success, and study participation was concluded.
48026767|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
48026768|NCT03926182|DRUG|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
48026769|NCT06533163|DEVICE|Oncomagnetic device|OncoMAGNETX has developed a portable wearable noninvasive magnetic device (Oncomagnetic device) for the treatment of GBM.
48385425|NCT00761566|OTHER|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
48385426|NCT00761566|OTHER|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
48026770|NCT05947513|DRUG|Curcumin|Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
48026771|NCT05947513|RADIATION|Palliative radiotherapy|As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
48183502|NCT05989594|BEHAVIORAL|Home-based mobile guided exercise-based cardiac rehabilitation|Discharge preparation, telerehabilitation, scheduled onsite follow-ups, telephone follow-ups, self-reporting, health education, online communication, family and peer support, mailing letters, institutional referrals, and security management.
48183503|NCT05989594|BEHAVIORAL|Routine Care|Discharge preparation, scheduled onsite follow-ups, telephone follow-ups
48183504|NCT00493740|PROCEDURE|chocolate cake|
48385427|NCT00199095|DRUG|Adriamycin|
48385428|NCT00199095|DRUG|Cyclophosphamide|
48026772|NCT02021435|DIETARY_SUPPLEMENT|salt substitute|Free salt substitute provided
48385429|NCT00199095|DRUG|Cytarabine|
48385430|NCT00199095|DRUG|Dexamethasone|
48385431|NCT00199095|DRUG|Idarubicin|
48385432|NCT00199095|DRUG|Ifosfamide|
48385433|NCT00199095|DRUG|Methotrexate|
48385434|NCT00199095|DRUG|Mercaptopurine|
48026773|NCT02341300|DEVICE|Cast Iron Pot|Cast iron pot
48026774|NCT02341300|DEVICE|Alumnium Pot|Aluminum Skillet
48026775|NCT02981394|PROCEDURE|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
48183505|NCT02577003|DRUG|Ipragliflozin|50 mg tablet administered orally
48183506|NCT02577003|DRUG|Placebo|Placebo to ipragliflozin tablet administered orally
48385435|NCT00199095|DRUG|VM26|
48385436|NCT00199095|DRUG|Vincristine|
48385437|NCT04059861|DIAGNOSTIC_TEST|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
48724399|NCT05764915|DRUG|RGT-264 phosphate tablets|RGT-264 phosphate tablets will be administered orally once daily (QD).
48385438|NCT01637064|DRUG|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
48385439|NCT05937230|DEVICE|Drug-coated balloon|Paclitaxel is a pharmacologically active substance for anti-neointima.
48385440|NCT05937230|DEVICE|Drug-eluting stents|Drug-eluting stent is composed of a metal stent, primer, and drug coating.
48385441|NCT01948011|DRUG|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
48385442|NCT01948011|DRUG|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
48385443|NCT00885937|DRUG|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
48385444|NCT00885937|DRUG|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
48385445|NCT00885937|DEVICE|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
48385446|NCT04583592|DRUG|Camostat Mesilate|Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
48385447|NCT04583592|DRUG|Placebo|Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
48385448|NCT05409157|DRUG|BMS-986166|Specified dose on specified days
48385449|NCT05409157|DRUG|Bisacodyl|Specified dose on specified days
48385450|NCT05665530|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion once weekly.
48385451|NCT05665530|DRUG|Zanubrutinib|Zanubrutinib will be provided in capsules for oral administration once or twice daily.
48385452|NCT05665530|DRUG|Venetoclax|Venetoclax will be provided in tablet for oral administration once daily
48385453|NCT06023758|DRUG|KN026|KN026：30 mg/kg Q3W
48385454|NCT06023758|DRUG|KN046|KN046：5 mg/kg Q3W
48385455|NCT06023758|DRUG|XELOX|Oxaliplatin 130mg/m2 d1，Capecitabine 1000mg/m2 d1-14，Q3W
48385456|NCT05246150|BEHAVIORAL|nursing care practices|To determine the effect of nursing care practices on Near Infrared Spectroscopy (NIRS) levels in premature babies
48385457|NCT05508321|DIAGNOSTIC_TEST|Nasal brushing|Nasal brushing to harvest nasal cells and perform staining experiments
48385458|NCT05508321|DIAGNOSTIC_TEST|Sniffin' Sticks|Assessment of olfactory function
48385459|NCT03814213|OTHER|CGA|Multi-level Health assessment
48385460|NCT03814213|OTHER|tailored care|Tailored care based on problems identified by CGA
48385461|NCT02940392|DEVICE|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
48385462|NCT05654649|DRUG|0.9%sodium chloride|Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
48385463|NCT05654649|DRUG|Dexamethasone|Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
48385464|NCT06306573|DEVICE|CardioMEMS HF System|The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
48385465|NCT06341270|DEVICE|transcutaneous electrical acupoint stimulation|transcutaneous electrical acupoint stimulation Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30min before anesthesia until be discharged from the postanaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery.The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
48385466|NCT06341270|DEVICE|sham transcutaneous electrical acupoint stimulation|Patients in the sham group will receive electrode attachment but without stimulation.
48724400|NCT06341010|PROCEDURE|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis|Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis
48183507|NCT02577003|DRUG|Sitagliptin|Background medication; 50 mg tablet administered orally
48183508|NCT01907269|BEHAVIORAL|Video-based Intervention|Video clips delivered by DVD and Internet
48521116|NCT01927575|DEVICE|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
48183509|NCT04041830|BEHAVIORAL|Visit 1|the participants will fill in the LFPQ questionnaire before and after a lunch test meal
48183510|NCT04041830|BEHAVIORAL|Visit 2|this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
48385467|NCT03607552|DEVICE|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
48385468|NCT03607552|DEVICE|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
48385469|NCT02187406|PROCEDURE|Modified ankle athletic taping|
48385470|NCT02187406|PROCEDURE|Traditional ankle athletic taping|
48385471|NCT06650605|DRUG|123I-ATT001|123I-ATT001
48521117|NCT01927575|DEVICE|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
48521118|NCT01759602|DRUG|C1-esterase inhibitor (Cinryze)|
48521119|NCT00017095|BIOLOGICAL|filgrastim|
48521120|NCT00017095|DRUG|cyclophosphamide|
48521121|NCT00017095|DRUG|docetaxel|
48521122|NCT00017095|DRUG|epirubicin hydrochloride|
48521123|NCT00017095|DRUG|fluorouracil|
48521124|NCT00017095|GENETIC|microarray analysis|
48724401|NCT04494308|OTHER|biomarker identification|flow cytometric analysis of eosinophils membrane molecules
48521125|NCT00017095|OTHER|immunohistochemistry staining method|
48521126|NCT00017095|OTHER|laboratory biomarker analysis|
48521127|NCT00017095|PROCEDURE|biopsy|
48521128|NCT00017095|PROCEDURE|conventional surgery|
48724402|NCT04157283|DIAGNOSTIC_TEST|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"1. Neurophysiological Evaluation:~   Visual Evoked Potential (VEP).~2. Imaging Evaluation:~   Conventional MRI.~3. Cerebrospinal Fluid (CSF):~4. Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~5. Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~6. Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
48026776|NCT05205135|BEHAVIORAL|SHARE Programme|"SHARE is Singapore's first 'Hospital-to-Home' programme to screen, identify and provide targeted interventions for caregivers at-risk of caregiver burden. Our interventions include psychosocial and emotional preparation of caregivers' mental resilience, and long-term engagement initiatives to connect caregivers into an integrated network of peers and community support services, delivered by programme facilitators and care support nurses.~Key stakeholders essential for the success of share include ward nurses and clinicians who refer caregivers to SHARE and community partners and hospital leaders.~This study seeks to recruit all of these individuals to better understand their experience of SHARE and the facilitators and barriers to its successful rollout to better evaluate the feasibility of SHARE in the hospital to home setting."
48183511|NCT06201078|RADIATION|Stereotactic Body Radiotherapy|"Salvage SBRT will be performed in three subgroups of patients with local recurrence:~Group A - after conventionally fractionated definitive radiotherapy; Group B - after prostatectomy and postoperative radiotherapy; Group C - after ultrahypofractionated definitive SBRT~Target volumes:~GTV- tumour visible on MRI and PET-CT; CTV- 1-3 mm margin around GTV PTV- 3 mm around CTV\*~\*- in cases in which very high accuracy and reproducibility of SBRT are ensured, and the margin overlaps the rectum and/or bladder, it is possible to reduce the margin from these organs to 1 mm.~Dose constrains:~The criteria for limiting the dose in nearby organs are not well-defined for repeated irradiation - the following doses should be aimed:~* Maximum rectal dose ≤103% of the prescribed dose (optimal ≤100%)~* Maximum bladder dose ≤105% of the prescribed dose (optimal ≤103%)~Dose-volume constrains:~Rectum:~• D30% \<15Gy~Bladder:~• D30% \< 15 Gy"
48183512|NCT02901769|OTHER|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
48183513|NCT00061425|DRUG|radiolabeled epratuzumab|
48183514|NCT06078098|OTHER|Clinical Information|We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
48521129|NCT00017095|PROCEDURE|neoadjuvant therapy|
48521130|NCT00017095|RADIATION|radiation therapy|
48521131|NCT04574570|DEVICE|High Tibial Osteotomy|Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
48521132|NCT06371625|PROCEDURE|Transeversus Thoracic Plane Block (TTPB) and Pectoral Nerves (PECS) Block|The TTP block will be performed in a supine position before general anesthesia. First, a high linear probe of the ultrasound system will be attached at sagittal plane to the sternum and counted from T2 near the clavicle to T5. Then the linear probe will be rotated by 90° and attached between the forth and the fifth costal cartilages connecting at the sternum near nipple. Then, the transversus thoracic muscle and the internal intercostal muscle will be identified. A total of 15 mL of 0.25% bupivacaine will be injected into the interfascial plane, between the transversus thoracic muscle and the internal intercostal muscle between the fourth and fifth costal cartilages connecting at the sternum. Pleural downward displacement will be used as an ultrasound endpoint.
48521133|NCT06371625|PROCEDURE|Pectoral Nerves (PECS) Block|Patients positioned supine with the ipsilateral arm abducted and externally rotated. The infra-clavicular and axillary regions will be cleaned with chlorhexidine. The skin point of and once the structures are identified with ultrasound, the probe will be positioned under the lateral third of the clavicle. After locating the subclavian artery, the axillary artery and the axillary vein we will move the probe distally towards the axilla, until the pectorals major muscle is identified. We will start counting the ribs, from 1st rib under the axillary artery and maintaining the pectorals major. Serratus anterior muscle cover 2nd, 3rd, 4th rib, this point being the entrance into the anterior axillary line we will use atraumatic needle with extension line and electrode for nerve stimulator (Stimuplex D). We will inject 10ml of 0.25% bupivacaine between the pectorals muscles first, then inject 20ml of 0.25% bupivacaine.
48521134|NCT03657225|DEVICE|Utilization of the mini CPB circuit|Comparison of the mini CPB circuit to conventional circuit
48521135|NCT03657225|DRUG|Utilization of the conventional circuit|Comparison of the mini CPB circuit to conventional circuit
48724403|NCT00578630|OTHER|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
48724404|NCT04491760|OTHER|Inspiratory Muscle Training|The inspiratory muscle training (IMT) will be carried out with a load of 30% of maximal inspiratory pressure (MIP) using a threshold inspiratory muscle trainer (c-type, Shengchang medical equipment factory, Yuyao city, China) at the beginning. During the hospital period, the resistance will increase incrementally, based on the rate of perceived exertion scored on the Borg scale (Borg, 1982). If the rate of perceived exertion less than 5, the resistance of the inspiratory threshold trainer will then be increase incrementally by 5%. The load for home-based IMT training will be set as the highest training load in the hospital. All patients will be required in sitting position during training, wearing nose-clips.
48724405|NCT03459053|BEHAVIORAL|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
48724406|NCT06520007|DRUG|Doxycyclin|The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
48724407|NCT05701046|PROCEDURE|Interbody fusion surgery|Interbody fusion surgery
48521136|NCT05590364|DEVICE|Profhilo® Body|Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
48521137|NCT01883466|OTHER|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
48521138|NCT06147648|DRUG|Tacrolimus Sustained-release Capsules|Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
48521139|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 180mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
48521140|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 120mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
48521141|NCT05582798|DRUG|Sodium chloride|Sodium chloride 09.% intravenous infusion
48521142|NCT02499848|DRUG|PRX302|Single prostate cancer lesion injected with PRX302.
48724408|NCT01804309|PROCEDURE|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
48724409|NCT03088553|DRUG|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
48724410|NCT01143987|DRUG|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
48724411|NCT01435837|DRUG|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
48724412|NCT01435837|DRUG|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
48724413|NCT01435837|DRUG|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
48026777|NCT01474603|DIETARY_SUPPLEMENT|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
48026778|NCT05219318|DRUG|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response beween the end of the 11th month and the end of the 13th month of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
48521143|NCT03261505|DEVICE|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
48521144|NCT05575882|OTHER|Skin hydration|Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
48521145|NCT05575882|OTHER|Barrier function measurement|TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
48521146|NCT05575882|OTHER|Potential of hydrogen measurement (pH)|pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
48521147|NCT05575882|OTHER|Clinical evaluation of atopic dermatitis|EASI score on each visit. Non invasive technique.
48521148|NCT05575882|OTHER|Quality of life assessment|Cardiff questionnaires to assess quality of life of subjects and their family members.
48026779|NCT05219318|OTHER|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
48026780|NCT02323191|DRUG|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
48026781|NCT02323191|DRUG|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
48724414|NCT01435837|DRUG|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
48724415|NCT05381285|OTHER|No intervention|Non-interventional study
48724416|NCT03566121|OTHER|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
48724417|NCT04807387|DEVICE|Vaginal Stent A|Ring stent
48724418|NCT04807387|DEVICE|Vaginal Stent B|Flower stent
48724419|NCT04807387|DEVICE|Vaginal Stent|Vaginal stent chosen from A or B that is the most comfortable
48724420|NCT06507917|DIAGNOSTIC_TEST|anal swabbing|anal swabbing
48724421|NCT02894450|OTHER|blood test|bioassay xaban
48724422|NCT05831254|OTHER|Health education:Interactive group training|"1. To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~2. Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes."
48724423|NCT05831254|OTHER|Health education: Individually training|To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
48026782|NCT06151262|DRUG|Trilaciclib+mFOLFIRINOX|This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
48183515|NCT01714167|GENETIC|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
48521149|NCT05575882|OTHER|Assessment of the effect on itching and sleep disturbances|Visual analogue scale from 0 to 10
48521150|NCT05575882|OTHER|Assessment of the tolerance of the study product or placebo|By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
48724424|NCT02659319|BEHAVIORAL|Family Lifestyle (FL)|12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
48724425|NCT02659319|BEHAVIORAL|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
48724426|NCT02659319|BEHAVIORAL|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
48724427|NCT04145674|DRUG|D-methadone|Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
48724428|NCT04145674|OTHER|Placebo|Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
48724429|NCT03305393|DEVICE|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
48724430|NCT02155530|DRUG|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
48724431|NCT02155530|DRUG|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
48724432|NCT00513955|DRUG|bortezomib|
48724433|NCT00513955|DRUG|cyclophosphamide|
48724434|NCT00513955|DRUG|doxorubicin hydrochloride|
48521151|NCT00754650|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
48521152|NCT03765450|DRUG|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
48724435|NCT00513955|DRUG|prednisolone|
48724436|NCT00513955|DRUG|vincristine sulfate|
48724437|NCT00513955|OTHER|questionnaire administration|
48724438|NCT00513955|PROCEDURE|quality-of-life assessment|
48724439|NCT02687516|BEHAVIORAL|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
48724440|NCT02687516|BEHAVIORAL|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
48724441|NCT01447303|OTHER|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
48183516|NCT05416567|PROCEDURE|Endovascular embolization|Therapeutic endovascular embolization in general anesthesia
48385472|NCT06450522|OTHER|Pharmacist co-management of HF medication optimization|"In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HFrEF as outlined by the 2021 CCS HF guidelines, and for HFmrEF/HFpEF as outlined by the 2022 ACC/AHA HF guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF: Where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF: We will target ACEI/ARB/ARNI+BB+MRA+SGLT2i. For HFpEF: We will target SGLT2i+MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF."
48385473|NCT06450522|OTHER|Usual care|Usual care
48385474|NCT06651359|BEHAVIORAL|Surveys for Quality of Life|This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL).
48385475|NCT06651359|BEHAVIORAL|Surveys and mHealth App access|"This group will take scheduled electronic surveys (at the beginning of the study, months 3, 6, 9, and 12) to assess the overall impact of prostate cancer on quality of life (QoL). Additionally, they will have a brief initial study visit, in-person or virtually, to review the app use. This arm of participants will use the mobile application at home for 12 months. During the first 12 weeks, the application will send daily surveys about symptoms, dietary and physical activities, weekly surveys about their mood, and an assessment of their overall QoL every 3 months. The app will provide tailored educational content, including short readings, videos, and audio recordings, to help users learn more about managing symptoms and improving their functioning. After 12 months of app use, an interview will be conducted to gather feedback about their experiences with the app. The information collected from these interviews will be analyzed to further enhance and improve the app's functionality."
48385476|NCT03601923|DRUG|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
48385477|NCT00887965|DRUG|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
48385478|NCT03724305|BEHAVIORAL|Mindfulness-Based Therapy for Insomnia|Mindfulness-based therapy for insomnia (MBTI) will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia.
48385479|NCT00000667|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
48385480|NCT04038307|DRUG|paracetamol|1gm
48385481|NCT04038307|DRUG|Saline Solution|100ml
48385482|NCT02756169|OTHER|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
48385483|NCT04512105|DRUG|Pitavastatin|Given PO
48385484|NCT04512105|DRUG|Venetoclax|Given PO
48385485|NCT04854421|DEVICE|VBC|Body Composition will be measured using the VBC system that takes under 60 seconds per scan. Image capture for VBC will include taking a series of four photos using a smartphone camera. Data from the camera will be downloaded to a local computer and then securely sent to the cloud for automated analysis and results generation. We will conduct two consecutive scans (image captures) for each research participant.
48385486|NCT05808907|OTHER|Questionnaire|A novel TAVI PROMs questionnaire will be created by us and used for this study.
48183517|NCT00399841|DEVICE|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
48183518|NCT03308175|DEVICE|flat fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females
48183519|NCT03308175|DEVICE|modified inclined fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
48183520|NCT05764135|BEHAVIORAL|SCI-Lynx Mobile Application|. The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
48385487|NCT05859269|DRUG|Methylprednisolone|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
48183521|NCT06102447|DRUG|Netopitam Palonosetron capsules and dexamethasone|On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.
48183522|NCT00709397|OTHER|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
48724442|NCT04285489|DEVICE|Hakim Shunt Programmable System|patient accept Hakim Shunt Programmable System due to HCP
48724443|NCT06132737|DRUG|[90Y]Y-PentixaTher|\[90Y\]Y-PTT i.v. injection
48724444|NCT06505759|DRUG|Bromelain gel|bromelain gel is prepared from bromelain capsules in laboratory
48724445|NCT06505759|DRUG|chlorhexidine gel|chlorhexidine gel is prepared from mouth wash
48724446|NCT06505759|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
48724447|NCT02178267|DIETARY_SUPPLEMENT|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
48724448|NCT03483298|OTHER|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
48724449|NCT00243984|DRUG|topiramate|
48724450|NCT01612455|BEHAVIORAL|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
48724451|NCT04570189|DEVICE|Auscul-X|The Auscul-X System (AusculSciences Canada, Inc.), is novel, professional grade, touch free, multichannel, touch-free electronic stethoscope with disposable elements designed to protect HCPs from exposure to infection diseases by allowing them to auscultate patients from a safe distance (10 feet away). The sensors can stay in place and enable providers to listen on-demand to a patient's heart and lungs over an extended period of time. This practice of distancing in the workplace is a key CDC and PHAC recommendation to protect the frontline HCP from exposure risk to the highly contagious COVID- 19 virus and other communicable diseases. The Auscul-X not only has the potential to better protect HCPs from infection, but also eliminates the potential transmission of pathogens through the use of conventional stethoscopes. In addition, the Auscul-X allows multiple HCPs to listen to the patient's heart and lung sounds simultaneously
48724452|NCT01455220|DRUG|Tysabri ® (Natalizumab)|IV, monthly
48724453|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
48388064|NCT05110625|OTHER|Online Education|Primary healthcare workers will receive an online educacion about prediabetes. This intervention will aim at: 1) raising awareness about the importance of T2DM prevention; 2) increasing knowledge about effective strategies for diabetes prevention; 3) improving knowledge about brief counselling techniques; and, 4) enhancing communication skills.
48724454|NCT03966131|DEVICE|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
48724455|NCT01731093|DRUG|AT-001|
48724456|NCT01731093|DRUG|Placebo|
48724457|NCT05587374|DRUG|Cadonilimab|Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
48724458|NCT05587374|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
48724459|NCT05587374|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
48724460|NCT05587374|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
48183523|NCT02811718|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
48724461|NCT03039894|OTHER|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
48724462|NCT04911179|OTHER|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
48724463|NCT04816604|DRUG|GB002 (seralutinib)|Capsule containing GB002 (seralutinib)
48724464|NCT04816604|DEVICE|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 (seralutinib) delivery
48724465|NCT02174744|OTHER|numeric pain rating scale|
48724466|NCT05623215|RADIATION|Radiographs of the knee for radiostereometric analysis (RSA)|RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
48724467|NCT00317590|DEVICE|Rapid Diagnostic Test for Malaria (Paracheck®)|
48724468|NCT03133312|DRUG|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
48724469|NCT03133312|DRUG|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
48724470|NCT05441956|DRUG|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
48724471|NCT06088836|DRUG|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
48724472|NCT06088836|DRUG|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
48026783|NCT03171233|OTHER|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
48026784|NCT03171233|OTHER|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
48026785|NCT00432380|BIOLOGICAL|Rotarix™|oral doses
48724473|NCT06256705|OTHER|Simultaneous 68Ga-DOTATOC PET-MRI|on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
48724474|NCT00215514|DRUG|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
48724475|NCT00215514|DRUG|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
48724476|NCT00215514|DRUG|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
48724477|NCT00215514|PROCEDURE|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> One-week rest --\> External Beam Radiation Therapy plus 5-FU CI --\> Four-week rest --\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--\> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
48724478|NCT00003842|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
48026786|NCT00432380|BIOLOGICAL|Placebo|oral dose
48026787|NCT02972840|DRUG|Acalabrutinib|Administered orally (PO)
48026788|NCT02972840|DRUG|Bendamustine|Administered intravenously (IV)
48026789|NCT02972840|DRUG|Rituximab|Administered intravenously (IV)
48183524|NCT02811718|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
48724479|NCT00003842|DRUG|isolated perfusion|
48724480|NCT00003842|PROCEDURE|surgical procedure|
48026790|NCT02972840|DRUG|Placebo|Placebo comparator
48026791|NCT05264376|BEHAVIORAL|Diabetes Body Project|The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
48183525|NCT02765789|DEVICE|Immunoadsorption (Immunosorba)|Immunoadsorption as an alternative to plasma exchange
48385488|NCT05859269|OTHER|Standard of Care|"Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care."
48724481|NCT02136056|BEHAVIORAL|Self-management program (SMP)|A self-management course
48724482|NCT04151849|DRUG|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
48724483|NCT04151849|DRUG|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
48724484|NCT03258060|PROCEDURE|Temporary pacing study|
48724485|NCT03258060|RADIATION|Body Surface Mapping|
48724486|NCT01581619|RADIATION|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
48724487|NCT06383468|DRUG|AK120|300mg Q2W subcutaneous injection thereafter until week 50.
48724488|NCT00083486|DRUG|epoetin alfa|
48724489|NCT03057470|DRUG|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
48724490|NCT03057470|DRUG|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
48724491|NCT03057470|DRUG|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
48724492|NCT03057470|OTHER|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
48724493|NCT05109260|DIAGNOSTIC_TEST|Point-of-Care Immunoassay device|2 POC Immunoassay devices will be used. One will measure D-dimer levels in capillary blood, the other will measure venous.
48724494|NCT06208566|BEHAVIORAL|Conversational Agent Zenny|The intervention group involves a newly developed conversational agent self-care program. This program consists of 40 separate modules based on empirically supported techniques. Modules include the following core sections: cognitive behavioral skills, interpersonal relationships, positive psychological growth, relaxation, goal setting, and emotional regulation skills. The modules focus on cognitive-behavioral skills for reducing emotional distress, improving behavioral activation and healthy behaviors, and problem-solving skills. The intervention was delivered via a decision-tree based conversational agent in WhatsApp messenger.
48026792|NCT05264376|BEHAVIORAL|Educational Control|We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
48029005|NCT01072682|DEVICE|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
48385489|NCT02428491|BIOLOGICAL|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
48385490|NCT05193578|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide, 1.34 mg/mL
48385491|NCT05193578|OTHER|Placebo|Semaglutide-Placebo
48521153|NCT04273191|DRUG|Brexanolone|Brexanolone will be initiated and administered per the USPI and the associated REMS.
48521154|NCT00491712|PROCEDURE|Glaucoma drainage implant with/without triamcinolone|
48724495|NCT06208566|BEHAVIORAL|Web-based Wellness Resources|"The control group involved referral to a menu of freely-available evidence-based wellness resources linked from the study website, Your Healthiest Self: Wellness Toolkits, Doing What Matters in Times of Stress, and How Right Now. These website choices involved self-selection of relevant modules for improving mood, reducing stress and anxiety, addressing relationship problems, and other wellness topics. These programs required only access to the websites and could be completed in a self-help format by participants at their own pace."
48724496|NCT02262754|DRUG|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
48724497|NCT02262754|DRUG|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
48724498|NCT02262754|DRUG|Naproxen|500 mg BID for 4 weeks
48724499|NCT03464916|BIOLOGICAL|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
48724500|NCT00566254|DRUG|Zonisamide|8mg/kg per day for approximately 24 weeks.
48724501|NCT00566254|DRUG|Placebo|
48724502|NCT03328416|DEVICE|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
48724503|NCT02271945|DRUG|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
48385492|NCT06653088|BEHAVIORAL|Physical Education program|"A four-month intervention will be implemented, led by the PE teacher, with three sessions per week. These sessions will last 45 minutes each (Koolwikh et al., 2023), divided into 5 minutes of warm-up, 35 minutes of intervention content, and 5 minutes of return to calm.~The program content of the intervention group will contemplate a warm-up with several activities, such as dancing or games. The intervention part will be composed of circuit-based exercises with several stations and games involving locomotion skills, namely run, gallop, slide, skip, jump, hop, etc.; games that integrate manipulative skills, such as throwing, catching, kicking, punting, striking, rolling and bouncing/dribbling; balance games involving swinging, turning, pulling, etc. Games involving perceptual motor skills, such as body schema, laterality, temporality, and spatiality, and games focused on PA. The return to calm will include activities such as yoga, meditation, and flexibility."
48385493|NCT05401773|OTHER|Real-time Quaking-Induced Conversion (RT-QuIC)|RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies.
48385494|NCT04688489|DIETARY_SUPPLEMENT|Carbloading and maltodextrin|The intervention is a dietary intervention that consists of a supplement of maltodextrin and added dietary carbohydrates. The supplement (20 g for women and 30 g for men) will be given to patients before and after a scheduled training, while the carbohydrates are given with meals. The extra carbohydrates given at meal time consists of extra potatoes, rice, bread, fruit, juice or other carbohydrate-rich food items.
48385495|NCT01053169|BIOLOGICAL|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
48385496|NCT01053169|BIOLOGICAL|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
48385497|NCT01053169|OTHER|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
48385498|NCT05649423|OTHER|POSTURAL DRAINAGE WITH PERCUSSION|"Each position should be held for a minimum of five minutes. In each position, your chest should be lower than your hips to allow mucus to drain. On your back: Patient's chest should be lower than his hips, which you can achieve by lying on a slanted surface up about 18 to 20 inches. On your sides: With pillows under your hips, lie on one side. To clear congestion from the right and left lobes. On your stomach: Drape patient's body over a stack of pillows, this is best in clearance of mucus from the lower back area of the lungs.~Percussion The equipment required here is cupped hands of caregiver to deliver the force required to drain the thick secretions. Patient should be in a comfortable position to enhance the effect. This loosens the thick, sticky secretions from the walls of the lung allowing them to into the larger airways, The sound heard must be hollow. The force applied must be equal."
48385499|NCT05649423|OTHER|Postural drainage|"* Each position should be held for a minimum of five minutes.~* In each position, your chest should be lower than your hips to allow mucus to drain On your back: Patient's chest should be lower than your hips, which you can achieve by lying on a slanted surface or propping patient's hips up about 18 to 20 inches~* This position is best for draining the bottom front parts of your lungs. On your sides: With pillows under your hips, lie on one side so that your chest is lower than your hips. To clear congestion from the bottom part of the right lung, lie on your left side. To clear congestion from the bottom part of your left lung, lie on your right side.~On your stomach: Drape patient's body over a stack of pillows or other object, and rest his arms by his head, with his chest lower than his hips. This position is best for clearing mucus in the lower back area of the lungs."
48385500|NCT05782140|DEVICE|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
48385501|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
48385502|NCT05925803|DRUG|Placebo (blinded)|matched placebo delivered subcutaneously, once weekly for 52 weeks
48385503|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
48724504|NCT02271945|DRUG|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
48724505|NCT02271945|DRUG|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
48724506|NCT04293367|OTHER|High Intensity Interval Training (HIIT)|"HIIT involves exercising in blocks of time (typically 4-5 minutes) where a small percentage of the time (typically 1 minute) is spent above the anaerobic (lactate) threshold (the work interval) followed by the remainder of the time at a sub-anaerobic threshold (active recovery)."
48724507|NCT00901810|DEVICE|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
48724508|NCT00901810|DEVICE|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
48029006|NCT02385448|DRUG|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
48724509|NCT04122170|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
48724510|NCT04122170|DRUG|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
48724511|NCT04122170|DRUG|Bentracimab (PB2452) Infusion|"Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration~In subjects with potential drug interaction from concomitant use of moderate or strong CYP3A inhibitors with ticagrelor, the active treatment period may be 24 hours and 10 min if receiving the 36 g infusion."
48724512|NCT04122170|DRUG|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
48724513|NCT04654260|BEHAVIORAL|Behavioral Therapy for Irritability in Autism|The child-focused components of BTIA are organized in modules dedicated to emotion regulation, problem solving and practice of planned steps to prevent or resolve conflicts. Each session contains a set of six to seven goals, and each goal contains a menu of techniques and activities that can be used to attain this goal. In order to administer the treatment in a flexible yet reliable manner, the therapist works collaboratively with the child and his or her parents to select activities that are perceived as relevant for attaining the session's goal. The parent-focused components of BTIA include include education about the effects of antecedents and consequences on disruptive behavior, developing strategies for reducing or altering antecedent events that may lead to disruptive reactions and helping parents to use reinforcement of competent and calm responses in potentially frustrating situations.
48026793|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
48029007|NCT02385448|DRUG|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
48724514|NCT04654260|BEHAVIORAL|Psychoeducation and Supportive Therapy (PST)|Each PST session will start with a review of events of the past week and include queries of topics such as school, interests, hobbies, and family with an overarching goal of enhancing subjective well-being. A major objective is to enables the participant to discuss his or her concerns with a therapist toward a goal of enhancing overall psychological wellbeing. Education about autism diagnosis and services is also provided to families as part of PST.
48724515|NCT04370379|DRUG|IBI302 (the first dose level)|q4week (3 injections) followed by PRN dosing
48026794|NCT04060940|BEHAVIORAL|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
48183526|NCT01808677|OTHER|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
48183527|NCT00648687|BEHAVIORAL|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
48385504|NCT03829020|DRUG|Bortezomib|Given SC
48385505|NCT03829020|DRUG|Metformin Hydrochloride|Given PO
48724516|NCT04370379|DRUG|IBI302 (the second dose level)|q4week (3 injections) followed by PRN dosing
48724517|NCT04370379|DRUG|Aflibercept|2mg, q4week (3 injections) followed by q8week
48724518|NCT04921332|DEVICE|Bright Light Therapy (BLT) Lamp|With its built in automatic timer shut-off function, the bedside registered nurse (RN) would not need to return to the room to turn off this lamp after 30 minutes because the lamp will automatically shut off on its own.
48724519|NCT02460341|DRUG|ondansetron|Ondansetron 8mg, 16mg, 24mg
48724520|NCT02460341|DRUG|placebo|placebo pill
48724521|NCT00778895|BIOLOGICAL|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
48724522|NCT00778895|BIOLOGICAL|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
48724523|NCT01566487|DRUG|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
48724524|NCT05833724|DRUG|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
48724525|NCT03006224|OTHER|One Lung Ventilation|
48724526|NCT05772910|BEHAVIORAL|EDUcation|The education intervention will consist of an individualized educative program based on intrinsic capacity optimization through lifestyle changes. To develop the program, the program creation team will be multidisciplinary (psychologists, medical doctor, dietitian...) and will discuss goal setting, the education strategy, and retention of motivation. The experts are required to create the education program such that the participants can manage their health by themselves. The goal will be self-management of dietary habits and increases in physical activity levels for each individual case. The education program will be in Spanish or in English; as it will consist in personal counselling, even with a low level of the language the communication will be possible. The nutritional education program will be conducted every 2 weeks for 10 consecutive weeks, with 20-min counselling sessions by an expert.
48724527|NCT05772910|OTHER|EXERcise|The intervention period will have 10 weeks, in which the EXER group will carry out 2-3 sessions a week (total of 20-30 sessions). In this concurrent program, exercises of the lower extremities (leg press, abduction and plantar flexion) will be performed mainly on weight training machines. Intensity in each exercise will be individualized for each participant through a test to determine muscle power. In addition, in the last part of each session the participants will perform an endurance training type high insensitive interval training on a cycle ergometer (60-80 rpm). The intensity will be individualized to each patient through an incremental stress test until volitional exhaustion, and the subjects will alternate intervals of 30 seconds at 90% of the maximum workload, with intervals of 90 seconds at 40% of the maximum. Each session is estimated to have a total duration of 30-50 minutes.
48724528|NCT05772910|OTHER|EDU-EXER|This group will carry out the same two previous interventions together.
48724529|NCT05772910|OTHER|CONtrol|CONtrol group will continue the usual clinical treatment and their normal life
48724530|NCT03891628|BEHAVIORAL|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
48724531|NCT03891628|BEHAVIORAL|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
48724532|NCT00003027|BIOLOGICAL|aldesleukin|
48724533|NCT00003027|BIOLOGICAL|filgrastim|
48724534|NCT00003027|BIOLOGICAL|recombinant interferon alfa|
48724535|NCT00003027|DRUG|cisplatin|
48724536|NCT00003027|DRUG|dacarbazine|
48724537|NCT00003027|DRUG|vinblastine|
48724538|NCT00327990|DRUG|Ibandronate|
48724539|NCT00327990|DRUG|Alendronate|
48724540|NCT03329261|DRUG|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
48724541|NCT06347250|PROCEDURE|Nerve Block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48724542|NCT06347250|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
48724543|NCT06347250|BEHAVIORAL|routine therapy|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
48724544|NCT06347250|PROCEDURE|placebo block|the patients were provided with normal saline. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
48724545|NCT06470750|OTHER|Non-Interventional Study|Non-interventional study
48724546|NCT01342614|DRUG|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
48724547|NCT01342614|DRUG|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
48724548|NCT04208048|DEVICE|FLXfit 15TM device|In order to implant the FLXfit 15TM device properly, your study doctor will first prepare the space between the low back bones (vertebrae) and then remove your damaged disc. The FLXfit 15TM device will then be placed into the space between the low backbones, using specific medical instruments, where the damaged disc was removed.
48724549|NCT00757692|DRUG|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
48724550|NCT00757692|DRUG|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
48724551|NCT02105545|OTHER|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
48724552|NCT02320344|BEHAVIORAL|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
48724553|NCT03108508|DIETARY_SUPPLEMENT|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
48724554|NCT03108508|DIETARY_SUPPLEMENT|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
48724555|NCT03108508|DIETARY_SUPPLEMENT|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
48724556|NCT02265796|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
48724557|NCT02265796|DRUG|Sugar pill|"1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
48724558|NCT06177093|RADIATION|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
48724559|NCT05178862|DRUG|SCY-078|Oral ibrexafungerp (SCY-078) as step-down therapy.
48724560|NCT05178862|DRUG|Fluconazole|Oral fluconazole (SCY-078) as step-down therapy.
48724561|NCT05178862|DRUG|Echinocandin|Intravenous echinocandin
48724562|NCT03107988|DRUG|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
48724563|NCT03107988|DRUG|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
48724564|NCT03107988|DRUG|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
48724565|NCT03107988|DRUG|Filgrastim/pegfilgrastim|"Filgrastim is to be given with each course beginning 24-48 hours following completion of cyclophosphamide and topotecan and continued through post-nadir count recovery with an ANC \> 2000/mm\^3 at 5mcg/kg/day. Filgrastim must be discontinued at least 24 hours prior to the start of the next course of therapy.~Pegfilgrastim (100mcg/kg; 6mg maximum dose) may be substituted and is given one time at 24-48 hours from completion of cyclophosphamide and topotecan."
48724566|NCT02208349|DEVICE|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
48724567|NCT02208349|DEVICE|traditional direct laryngoscopy (DL)|
48385506|NCT03829020|DRUG|Nelfinavir Mesylate|Given PO
48385507|NCT06653036|PROCEDURE|Dural puncture epidural|The Dural puncture epidural technique is done by assessing the epidural space using the Touhy needle and puncturing the dura matter with a finer needle.
48385508|NCT06653036|PROCEDURE|Standard Epidural Technique|The Standard Epidural Technique is usually performed by identifying the epidural space using the loss of resistance technique and threading the epidural catheter in the epidural space for administration of analgesic drugs.
48385509|NCT06652165|DRUG|zanubrutinib combined with BEAM|zanubrutinib：160mg oral bid D-8-D-2 camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
48385510|NCT06652165|DRUG|BEAM|camustine: 300mg/m2 vgtt qd D-8 etoposide: 100mg/m2/d vgtt q12h D-7-D-4 cytarabine: 200mg/m2/d vgtt q12h D-7-D-4 melphalan: 140mg/m2 vgtt qd D3-D-2
48026795|NCT02575664|DRUG|Buprenorphine|Buprenorphine 5 microg/h/7 days
48026796|NCT02575664|DRUG|Placebo|Placebo patch
48385511|NCT02789241|BIOLOGICAL|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
48385512|NCT02789241|OTHER|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
48724568|NCT01364701|DRUG|Sildenafil 100 mg|4 tablets for on demand use
48724569|NCT01364701|DRUG|Tadalafil 20 mg|4 tablets on demand
48724570|NCT01364701|DRUG|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
48724571|NCT03598751|DRUG|BCD-085|120 mg / 2 mL subcutaneously
48724572|NCT03598751|DRUG|Placebo|2 mL
48724573|NCT03805516|BEHAVIORAL|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
48724574|NCT03805516|BEHAVIORAL|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
48724575|NCT02544997|DRUG|Poziotinib|12mg P.O. for 2wks q21days
48724576|NCT03009318|OTHER|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
48724577|NCT02107872|DRUG|REGN1500|
48724578|NCT02107872|DRUG|placebo|
48724579|NCT02452203|BEHAVIORAL|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
48724580|NCT03529279|DRUG|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA \> 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
48724581|NCT03529279|DRUG|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
48026797|NCT04425226|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
48026798|NCT04425226|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
48724582|NCT03529279|RADIATION|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
48026799|NCT01273831|DRUG|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
48026800|NCT01273831|DRUG|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
48026801|NCT03108339|OTHER|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
48026802|NCT06536036|DRUG|SIM0270|Use according to the prescribed protocol
48026803|NCT02678546|OTHER|Other|case review of diagnosed disease
48029008|NCT01794325|OTHER|Trans-radial|Coronary angiography performed through trans-radial access
48385513|NCT05584202|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
48026804|NCT06325098|DIAGNOSTIC_TEST|Anti-nephrin antibodies|Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
48026805|NCT06325098|DIAGNOSTIC_TEST|u-RPC cultures|Urine sample collection for u-RPC cultures
48026806|NCT02106338|OTHER|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
48026807|NCT02106338|DRUG|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
48026808|NCT01993524|DIETARY_SUPPLEMENT|probiotic|antibiotic plus probiotic
48026809|NCT01993524|OTHER|placebo|antibiotic plus placebo
48026810|NCT01987713|BEHAVIORAL|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
48026811|NCT03200522|OTHER|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
48385514|NCT05584202|OTHER|Placebo|0.9% sodium chloride
48385515|NCT03099161|DRUG|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
48385516|NCT03099161|BIOLOGICAL|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
48385517|NCT05887102|BEHAVIORAL|PACHA Program|Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
48385518|NCT00755573|DRUG|Pregabalin|Pregabalin 300 mg - 600 mg BID
48385519|NCT00755573|DRUG|placebo|Regime as described for pregabalin
48026812|NCT03200522|OTHER|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
48026813|NCT04877912|DIAGNOSTIC_TEST|MRI Abbreviated Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
48026814|NCT04877912|DIAGNOSTIC_TEST|Abbreviated MRI Scan|"All subjects will be receiving an MRI scan, up to 15 minutes long that includes an injection of contrast agent. This contrast agent will be injected into the arm and will help the doctors to read the MRI more effectively. If there is a lesion (abnormality) in the breast, the contrast agent will go to the lesion first and we will be able to see it better.~The examination table will then move subject into the magnet, which is a long tube with a diameter of about 3 feet. Subject will be asked to lie in the magnet for about 15 minutes. During the periods when we are taking pictures, we will ask subject to be as still as possible."
48026815|NCT06454513|PROCEDURE|general anesthesia|Different anesthesia methods
48029009|NCT01794325|OTHER|Trans-femoral|Coronary angiography performed through trans-femoral access
48183528|NCT01666093|PROCEDURE|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
48385520|NCT03179488|DEVICE|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
48385521|NCT03179488|DEVICE|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
48385522|NCT00758225|DRUG|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
48521155|NCT06458465|DIETARY_SUPPLEMENT|Curcumin|- Curcumin capsules 500 mg twice daily for 6 months
48521156|NCT06458465|DRUG|Pentoxifylline 400 MG|- Pentoxifylline 400 mg twice daily for 6 months.
48183529|NCT01781832|DEVICE|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
48183530|NCT03943641|OTHER|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
48183531|NCT00460395|PROCEDURE|Surgery|
48183532|NCT00460395|PROCEDURE|Stereotactic radiosurgery|
48183533|NCT04923308|OTHER|Triage results disclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will be communicated to the specialist using a standardized clinical note, prior to the patient's consultation and without further discussion.
48183534|NCT04923308|OTHER|Triage results undisclosed|Following the chiropractor triage assessment, the working diagnosis and risk stratification or referral need will not be communicated to the specialist.
48183535|NCT01508338|DIETARY_SUPPLEMENT|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
48183536|NCT01508338|DIETARY_SUPPLEMENT|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
48183537|NCT01508338|DIETARY_SUPPLEMENT|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
48026816|NCT05036629|DEVICE|MRI Protocol|"Eye-tracker Eyelink (eye movements) BIOPAC : (electrodermal resistance) INVIVO Precess : breathing, arterial pressure, pulse,~* NIRS Oxymon artinis medical system~* tES (transcranial electrical stimulation, Neuroelectrics)"
48385523|NCT06271798|OTHER|Life style modification advice|The lifestyle modification advice involves several key elements: reducing daily standing periods, avoiding excessive flexion of the knee joint during sitting, weight reduction, addressing cardio-respiratory conditions, incorporating venotonic agents, and utilizing below-knee elastic compression devices. These measures collectively aim to mitigate the development and progression of varicose veins, potentially preventing complications such as deep venous thrombosis and improving overall circulatory health.
48385524|NCT06271798|OTHER|Resistive exercise|Participants in group A will perform resistive exercise. The patients will be instructed to do seated toe raises exercise or standing toe raise exercise. The exercise will be performed for 30 minutes, three times per week for six weeks.
48026817|NCT05289102|OTHER|Two postpartum visits.|Group 1 serves as an intervention group (experimental). All enrolled women in the intervention group were in connection with the inclusion given two pre-booked postpartum care visits. One early at 3 weeks and one later at 7 weeks postpartum.
48385525|NCT06271798|OTHER|Aerobic exercises|Participants in group B will perform aerobic exercise. Each session will begin with 10 min of low-intensity treadmill walking for a warm-up. The subsequent aerobic component will involve incline treadmill walking for 20 min at a perceived exertion of 6-7 (i.e., somewhat hard) on Borg's 3-10 scale followed by 10 min of low-intensity treadmill walking for cool down. The exercise will be performed for 30 minutes, three times per week for six weeks.
48026818|NCT05289102|OTHER|One postpartum visit.|Group 2 serves as a control group (active comparator). All enrolled women in the control group were in connection with the inclusion given one pre-booked postpartum care visit at 7 weeks postpartum according to the traditional postpartum care.
48026819|NCT04848285|OTHER|Early Mobilization|Additional 2 or more sessions of out-of-bed activity to the standard stroke care, focused in active sitting, standing and walking assisted by physiotherapists
48026820|NCT04848285|OTHER|Standard care|Standard protocol of mobilization in acute stroke patients admitted to the Stroke Unit at the discretion of the nursing and physiotherapy staff
48183538|NCT01508338|DIETARY_SUPPLEMENT|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
48183539|NCT00504075|BIOLOGICAL|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
48183540|NCT06327776|OTHER|Serum and saliva biomarkers|2x5mL blood samples and saliva samples will be used to determine the performance of different blood based and saliva biomarkers for determining diagnostic management and prognosis in mTBI patients.
48183541|NCT04583644|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion Surgery|"Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation."
48183542|NCT06239233|PROCEDURE|Laparoscopic cholecystectomy|"The surgeon makes small incisions in the abdominal wall, usually around the navel.~Trocars (hollow tubes) are inserted through these incisions to provide access for the laparoscope and specialized instruments.~A laparoscope, a thin tube with a light and camera, is inserted through one of the trocars. It allows the surgical team to visualize the abdominal cavity on a monitor.~The surgeon carefully identifies the gallbladder and the cystic duct, which connects the gallbladder to the common bile duct.~The cystic duct and artery are clipped and cut to disconnect the gallbladder from the biliary system. This step ensures the safe removal of the gallbladder.~The surgeon gently detaches the gallbladder from the liver bed and removes it through one of the small incisions.~Any bleeding vessels are sealed, and the small incisions are closed with stitches or surgical glue."
48385526|NCT02658500|DIETARY_SUPPLEMENT|Infant Formula|
48026821|NCT01242488|BIOLOGICAL|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
48026822|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
48026823|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
48026824|NCT01242488|BIOLOGICAL|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
48026825|NCT01242488|BIOLOGICAL|CDP6038|60 mg sc at Weeks 0, 4 and 8
48026826|NCT01242488|BIOLOGICAL|CDP6038|240 mg sc at Weeks 0, 4 and 8
48026827|NCT01242488|BIOLOGICAL|CDP6038|120 mg sc at Weeks 0, 4 and 8
48026828|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
48026829|NCT01242488|OTHER|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
48026830|NCT01242488|OTHER|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
48026831|NCT00693992|OTHER|Laboratory Biomarker Analysis|Correlative studies
48026832|NCT00693992|OTHER|Placebo|Given PO
48385527|NCT02658500|DIETARY_SUPPLEMENT|breast milk|
48385528|NCT05262894|OTHER|extreme hypercapnia induced by ventilation insufficiency|Re-breathing of gas by breathing into the simulated avalanche snow
48385529|NCT06367998|DRUG|Pregabalin|Pregabalin oral intake from the day before surgery to six weeks postoperatively
48385530|NCT01940731|DRUG|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
48385531|NCT00210925|DRUG|topiramate|
48385532|NCT05855473|OTHER|Auricular acupuncture|The NADA protocol used in this study uses five specific points on the ear: Shen men, sympathetic autonomic, lung, liver, and kidney. Using this protocol, semi-permanent needles and seeds were placed unilaterally at five specific points in the ear by a specialist physician certified in acupuncture.
48385533|NCT06653062|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|"Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients.~Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence."
48385534|NCT06651372|BIOLOGICAL|The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons|Serological tests detecting IgM and IgG
48385535|NCT04707833|DIAGNOSTIC_TEST|Serological testing for COVID-19 infection|"The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)"
48385536|NCT00823680|DRUG|Placebo|po bid for 4 weeks
48385537|NCT00823680|DRUG|RO5027838|200mg po qd for 4 weeks
48724583|NCT03529279|RADIATION|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
48724584|NCT06423560|RADIATION|Computed tomography|Follow-up computed tomography at 3-6 months and 12 months
48026833|NCT00693992|OTHER|Quality-of-Life Assessment|Ancillary studies
48026834|NCT00693992|DRUG|Sunitinib Malate|Given PO
48724585|NCT00859742|PROCEDURE|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
48724586|NCT00086645|DRUG|citalopram hydrobromide|10mg/5ml solution
48724587|NCT00086645|OTHER|placebo|up to equivalent of 20 mg of active comparator daily
48724588|NCT00462748|DRUG|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
48724589|NCT00462748|DRUG|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
48026835|NCT03927885|OTHER|Placebo Administration|Given open labeled placebo PO
48026836|NCT03927885|OTHER|Quality-of-Life Assessment|Ancillary studies
48026837|NCT03927885|OTHER|Questionnaire Administration|Ancillary studies
48026838|NCT03927885|OTHER|Waiting List|Assigned to a waiting list
48026839|NCT04532892|DIETARY_SUPPLEMENT|Meta 18.06 Day and Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
48026840|NCT04532892|DIETARY_SUPPLEMENT|Placebo Meta 18.06 Day and Placebo Meta 18.06 Night|5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
48026841|NCT05281692|DIAGNOSTIC_TEST|Enhanced Preservation Media (EPM-IX)|EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
48026842|NCT01954706|OTHER|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
48026843|NCT01954706|OTHER|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
48026844|NCT01672632|OTHER|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
48026845|NCT00911365|BIOLOGICAL|autologous mesenchymal stem cells|"4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-\> Total four times"
48026846|NCT00911365|BIOLOGICAL|normal saline|saline
48724590|NCT00462748|DRUG|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
48385538|NCT00823680|DRUG|RO5027838|50mg po bid for 4 weeks
48385539|NCT00823680|DRUG|RO5093151|400mg po bid for 4 weeks
48385540|NCT00823680|DRUG|RO5093151|10mg po bid for 4 weeks
48724591|NCT04001595|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
48724592|NCT02684188|BEHAVIORAL|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
48724593|NCT00075738|DRUG|cisplatin|
48026847|NCT05601531|PROCEDURE|Autologous Tooth Root|An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.
48385541|NCT06653101|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)
48385542|NCT06653101|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)
48385543|NCT00888472|PROCEDURE|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
48385544|NCT01836094|DRUG|Methylene Blue (USP grade, 280mg oral)|
48385545|NCT01836094|DRUG|Placebo|oral, one time
48385548|NCT06565767|OTHER|cardiopulmonary resuscitation quality|variability in compression depth among different age groups, taking into account physical attributes, through an active learning approach and game-based learning framework
48385549|NCT02701049|OTHER|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
48385550|NCT02304302|DRUG|Memantine|Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
48385551|NCT02304302|DRUG|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
48385552|NCT03311386|DRUG|Actilyse|thrombolytic therapy
48385553|NCT02204527|DIETARY_SUPPLEMENT|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
48385554|NCT02204527|DIETARY_SUPPLEMENT|placebo pill|Placebo
48385555|NCT06303687|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
48724594|NCT00075738|DRUG|fluorouracil|
48724595|NCT00075738|DRUG|irinotecan hydrochloride|
48724596|NCT00075738|DRUG|leucovorin calcium|
48724597|NCT02904655|OTHER|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
48724598|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
48183543|NCT05202054|OTHER|mindfulness stress reduction program|Before the program is implemented, in case women forget, they will be called and reminded of the training time, and they will be invited to the program. The women in the experimental group will be administered 150 minutes of BFSAP once a week, lasting 8 weeks, and consisting of 8 times in total. Afterwards, the women will be given an intermediate test. After the midterm test, women will be asked to individually repeat their BFSAP administration in their own home for 8 weeks (weeks 8-16).
48385556|NCT01143610|PROCEDURE|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
48385557|NCT01143610|OTHER|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
48724599|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
48724600|NCT03298399|BIOLOGICAL|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
48724601|NCT00865839|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
48724602|NCT00865839|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
48724603|NCT01313962|DRUG|Flufirvitide-3 0.05 mg single dose|Nasal Spray
48724604|NCT01313962|DRUG|Flufirvitide-3, 0.1 mg single dose|Nasal spray
48724605|NCT01313962|DRUG|Flufirvitide-3, 0.2 mg single dose|nasal spray
48724606|NCT01313962|DRUG|Flufirvitide-3, 0.4 mg single dose|Nasal spray
48724607|NCT01313962|OTHER|Placebo|Nasal spray
48724608|NCT06307236|BEHAVIORAL|Emotional Freedom Techniques|Emotional Freedom Technique (EFT), which is included in the energy psychotherapy similar to the cognitive behavioral therapy method, is an easily applicable method that is used to relieve mental problems such as anxiety and stress and has positive results, which has just started to be used in the world and in our country. EFT can be applied safely to all ages and groups.
48724609|NCT02522442|DEVICE|CPAP|Continuous positive airway pressure
48724610|NCT02522442|DEVICE|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
48724611|NCT01616979|PROCEDURE|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
48385558|NCT06642350|OTHER|Whole-body electrostimulation|10 weeks of WB-EMS 1.5x 20 min/week
48385559|NCT06642350|OTHER|Medical Training Therapy|10 weeks of MTT 2x 45 min/week
48385560|NCT01293682|DRUG|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
48385561|NCT06568276|PROCEDURE|Additional deep deltoid ligament suture|The deep deltoid ligament will be sutured through a curved incision lifting the tibialis posterior tendon out to be sutured back after tying the ligament to an anchor in the talus.
48385562|NCT01598740|DRUG|CLP|Oral administration
48385563|NCT01598740|DRUG|Spironolactone|oral administration
48385564|NCT03107416|PROCEDURE|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
48385565|NCT03107416|DRUG|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
48385566|NCT04511923|DRUG|Nebulised heparin|Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
48724612|NCT01030874|OTHER|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
48724613|NCT01030874|OTHER|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
48724614|NCT01030874|OTHER|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
48724615|NCT01030874|OTHER|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
48388065|NCT04540315|BEHAVIORAL|MobiMD|MobiMD is a mobile app. This is an app available to IOS and Android devices only. The app provides a digitized version of the discharge instructions and provides push notifications to remind the participant of important instructions. In addition, the app allows participants (and their care teams) to record and track relevant clinical data.
48521157|NCT02199964|DRUG|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
48521158|NCT02199964|DRUG|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
48521159|NCT00270244|BEHAVIORAL|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions-one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
48724616|NCT01030874|OTHER|Drug Recommendations|The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
48385567|NCT06110767|DEVICE|non-immersive virtual reality|Non-Immersive Virtual Reality Based Physical Activity Application: Application will be carried out 3 days a week, 30 minutes a day, for 4 weeks. Kinect Adventures and Kinect Sports game packages will be used using the Microsoft Kinect Xbox 360 game console. It is planned that the participants will engage in physical activity with these game packages.
48521160|NCT00270244|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
48521161|NCT03264807|PROCEDURE|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
48521162|NCT03264807|PROCEDURE|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
48521163|NCT04852523|DRUG|18F-fluciclovine|18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
48521164|NCT05107947|OTHER|Biocentric light|Light that changes in intensity and spectral distribution during the day to mimick daylight. High in intensity and high circadian stimulus during daytime and low intensity and low circadian stimulus during late afternoon and night.
48521165|NCT04019171|BEHAVIORAL|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
48724617|NCT03286179|OTHER|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
48729812|NCT06525090|OTHER|no intervention-child-administered questionnaires|The implementation of the research was started after getting approval from Mugla Sıtkı Kocman University Health Sciences Ethics Committee and TR Ministry of National Education Research, Competition and Social Activity. The purpose of the study was explained by the researchers to the administrators of the schools where the study was conducted and planning was made with the school administration. The data were collected in 15-20 minutes from the students who agreed to participate in the study during the course hours deemed appropriate by the administration. The purpose of the study and how to fill in the measurement tools was explained to the students, and it was stated that the research data would be kept confidential and used only by the researcher. The self-administered questionnaires were filled out on the paper. Verbal consent was obtained from the students participating in the study and written informed consent was obtained from their parents.
48729813|NCT00490074|BIOLOGICAL|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
48385568|NCT06110767|BEHAVIORAL|Healty Diet Programme|Healthy nutrition program: It will be implemented for 4 weeks.Healthy Nutrition Program: Türkiye Ministry of Health nutrition program will be prepared based on the recommendations of the Turkey Nutrition Guide published by the Ministry of Health in 2016 (TÜBER-2016). A personalized healthy nutrition program will be created in line with this guide, taking into account the age, gender and physical activity status of healthy individuals.
48385569|NCT06567977|OTHER|Trimbow|Trimbow® is a fixed triple therapy containing a long-acting muscarinic antago-nist (LAMA, Glycopyrronium), a long-acting beta-adrenergic agonist (LABA, Formoterol) and an inhaled corticosteroid (ICS, beclomethasone). Trimbow® has an extra-fine formulation delivered as a controlled dosage aerosol. Trim-bow® is to be applied in accordance with its current marketing authorisation and the guidance specified in the summary of product characteristics (SmPC) in each country.
48521166|NCT00408512|DRUG|thiazides|Up to 25 mg per day
48521167|NCT00408512|PROCEDURE|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
48521168|NCT00344448|DRUG|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
48729814|NCT00490074|BIOLOGICAL|NYVAC-C|NYVAC-C 1 ml IM
48026848|NCT05601531|DRUG|Vit.D3|Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
48521169|NCT05484414|DRUG|SRP-3D (diethylamide)|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
48521170|NCT05484414|DRUG|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
48724618|NCT03468582|COMBINATION_PRODUCT|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
48385570|NCT00822601|DEVICE|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
48385571|NCT00822601|DEVICE|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
48385572|NCT01708252|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
48385573|NCT06006416|DRUG|Fenugreek Fibre|Daily dose of 2 x 10g per day with/in food
48724619|NCT05892640|OTHER|Low-Salt Diet|Low-salt diet (LS diet) according to DASH eating plan, with sodium intake of 1500 mg (3.75 g of salt), within the period of 14 days
48385574|NCT04795973|BEHAVIORAL|time-restricted fasting for 4 weeks|eat ad libitum from 7am to 5pm and fast in other time
48385575|NCT04795973|BEHAVIORAL|5:2 regimen for 4 weeks|chose two non-consecutive days per week to eat very little and eat ad libitum the other 5 days of the week
48724620|NCT01341717|DRUG|Sitagliptin|100 mg once daily for 6 months
48724621|NCT01341717|DRUG|Glimepiride|1 mg/2 mg/3 mg once daily
48724622|NCT01341717|DRUG|Metformin|\>=1000 mg twice daily
48385576|NCT05916963|DRUG|Furosemide 40 mg|Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.
48385577|NCT04406272|DRUG|VB11|Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
48521171|NCT06581497|DRUG|ICIs|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines.
48385578|NCT04406272|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
48385579|NCT04406272|OTHER|Placebo|Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
48385580|NCT04406272|DRUG|Bevacizumab|A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
48385581|NCT00421811|DRUG|ADH-1|4 gm IV Days 1 and 8
48385582|NCT00421811|DRUG|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
48521172|NCT06581497|PROCEDURE|ICIs+MWA|ICIs mainly refer to PD-1 drug therapy, including pembrolizumab, camrizumab, toripalimab, tislelizumab, and sintilimab. The dosage and duration of ICIs comply with the manufacturer's guidelines. All patients, except for those enrolled in ICIs, should also undergo MWA treatment.
48521173|NCT05495243|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
48521174|NCT05495243|DRUG|Placebo|Isotonic saline (0.9%)
48521175|NCT00330317|DRUG|letrozole|2.5mg letrozole once-daily
48724623|NCT01341717|DRUG|Insulin|TDD \> 10 IU once/twice daily
48724624|NCT05282420|PROCEDURE|intravitreal injection of Ranibizumab|intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)
48026849|NCT05601531|OTHER|bone graft|Selecting bone materials for alveolar ridge preservation according to treatment needs
48026850|NCT02066935|OTHER|kidney transplant patient|kidney transplanted patients for at least one year
48385583|NCT00408005|DRUG|Asparaginase|Given IM or IV
48521176|NCT04149652|DIAGNOSTIC_TEST|Lung Elastosonography|Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
48521177|NCT00742209|DRUG|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
48521178|NCT00742209|DRUG|Placebo|Placebo-control
48521179|NCT04213495|OTHER|Anesthesia|Patients undergoing anesthesia from the cooperating Anesthesia center
48521180|NCT04133012|OTHER|Samplings|"* blood samples~* rectal biopsies~* nodes biopsies~* cutaneous fat tissues biopsies~* semen sample"
48521181|NCT00495573|DRUG|acyclovir|400 mg acyclovir, orally three times a day for 5 days
48724625|NCT05282420|PROCEDURE|intravitreal injection of Aflipercept|intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)
48724626|NCT05282420|DRUG|Ranibizumab|Ranibizumab
48724627|NCT05282420|DRUG|Aflibercept|Aflipercept
48724628|NCT01802307|RADIATION|Brachytherapy|
48724629|NCT00541853|DRUG|Candesartan|Candesartan upto 8mg
48724630|NCT00541853|DRUG|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
48724631|NCT00541853|DRUG|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
48724632|NCT04882787|DEVICE|BTE hearing aid|Amplification
48724633|NCT01629472|BEHAVIORAL|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
48724634|NCT01890668|OTHER|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility...) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
48724635|NCT01890668|OTHER|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture...) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
48724636|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular
48724637|NCT04841369|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular
48724638|NCT04506801|DIETARY_SUPPLEMENT|Probalans senior|Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
48724639|NCT04506801|OTHER|Placebo|Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
48724640|NCT03297125|DEVICE|Standard Magnetic Resonance Imaging (MRI)|Standard MRI.
48724641|NCT03297125|DEVICE|Advanced MRI.|Perfusion and diffusion MRI.
48724642|NCT00952614|DEVICE|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
48724643|NCT02800265|DIETARY_SUPPLEMENT|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
48724644|NCT02477553|BEHAVIORAL|DA - Quantitative|
48724645|NCT02477553|BEHAVIORAL|DA - Verbal|
48385584|NCT00408005|DRUG|Cyclophosphamide|Given IV
48385585|NCT00408005|DRUG|Cytarabine|Given IT, IV, or SC
48026851|NCT05286918|PROCEDURE|The intervention (CRP-guided) group|"The attending doctor will use the CRP level to inform their decision to continue antibiotics around 3 hours from blood taking. These doctors will be provided pre-study training on CRP interpretation.~Every day from randomization, serum CRP testing will be encouraged to take. Once CRP has declined to \<5mg/dL and the patient has remained afebrile for past 48 hours, antibiotic treatment will be reviewed for discontinuation. Otherwise, antibiotic treatment will be continued. A switch on the administration route, or a change of antibiotics due to adverse effect, allergy, or suggestion from culture result, is permitted according to in-patient physician's decisions. CRP will continue to be monitored daily upon discharge from that hospital (up to 28 days)."
48385586|NCT00408005|DRUG|Daunorubicin Hydrochloride|Given IV
48724646|NCT00991783|DRUG|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
48724647|NCT05969132|PROCEDURE|Fully digital guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement.~3. Oral hygiene instructions (OHI)~4. Presurgical intraoral scanning using an intraoral scanner (IOS)~5. Fabrication of the Gingivectomy guide:~   * Convert (DICOM) file to STL file then merged to STL file corresponding oral soft tissues 3D data obtained by IOS using software of surgical planning.~  * Digital waxing up with new desired positions of gingival margins and zenith points performed.~  * Designing Gingivectomy guide then exported to a 3D printer and mill a transparent resin gingivectomy guide.~6. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~7. Postoperative care"
48724648|NCT05969132|PROCEDURE|Convectional guided gingivectomy procedure|"1. Full history with clinical and radiographic examination (CBCT) to aid in patient's selection.~2. Supra- and sub-gingival debridement with OHI~3. Gingivectomy guide fabrication:~   * Impressions and casts obtained.~  * Waxing-up included new positions of gingival margins and zenith points.~  * Silicone index with condensation silicone impression materials made with pressure on the cast to reproduce the details of the wax, then filled after setting with resin material and placed in the patient's mouth.~  * Resin mock-up trimmed with blade to define the correct new gingival level.~  * After the patient accept the mock-up design will used as Gingivectomy guide.~4. Surgical Procedure: anesthetized the patient using local anesthesia, Surgical incision using 15c blade following CEJ anatomy will be made at each tooth using the Gingivectomy guide as reference to new gingival level and being careful to preserve the gingival papillae without involving the palatal surfaces.~5. Postoperative care"
48724649|NCT01009866|BIOLOGICAL|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
48385587|NCT00408005|DRUG|Dexamethasone|Given IV or PO
48385588|NCT00408005|DRUG|Doxorubicin Hydrochloride|Given IV
48385589|NCT00408005|OTHER|Laboratory Biomarker Analysis|Correlative studies
48385590|NCT00408005|DRUG|Leucovorin Calcium|Given PO
48724650|NCT03672786|DIETARY_SUPPLEMENT|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
48724651|NCT02161926|OTHER|dietary restrictions|Dietary restrictions during 8 weeks
48724652|NCT00861718|DRUG|AZD7268|Capsule, Oral, QD
48724653|NCT00861718|DRUG|AZD7268|Capsule, Oral, BID
48724654|NCT00861718|DRUG|Placebo|Capsule, Oral BID
48724655|NCT05492981|BEHAVIORAL|Enhanced (intervention) education|See arm description
48724656|NCT05115513|DRUG|Medium THC|Marijuana flower with medium THC
48724657|NCT05115513|DRUG|Placebo THC|Marijuana flower with no THC
48724658|NCT04476875|OTHER|Open Outpatient Clinic Programme|
48724659|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 8 weeks with specific exercises to target low back pain.
48724660|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 4 weeks with specific exercises to mitigate persistent post mastectomy pain ahead of the surgery.
48724661|NCT04607460|DEVICE|JOGO Digital Therapeutics EMG Biofeedback for Migraine|Use of the JOGO Digital Therapeutics EMG Biofeedback device for 6 weeks with specific exercises to target migraine pain.
48724662|NCT03148015|OTHER|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
48724663|NCT01416480|DRUG|Theobromine 300mg|Capsule, b.i.d.
48724664|NCT01416480|DRUG|Levodropropizine 10mg|Syrup, t.i.d.
48724665|NCT00772681|DRUG|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
48724666|NCT02874027|OTHER|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
48724667|NCT06377709|OTHER|ProACTive™|ProACTive™ intervention, a talking therapy utilising acceptance and commitment therapy (ACT) techniques.
48724668|NCT00675896|DRUG|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
48724669|NCT00675896|DRUG|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
48724670|NCT00483041|OTHER|PLACEBO|Placebo administered as a single intravenous infusion
48724671|NCT00483041|BIOLOGICAL|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
48724672|NCT00875342|DRUG|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
48385591|NCT00408005|DRUG|Mercaptopurine|Given PO
48724673|NCT00875342|OTHER|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
48724674|NCT00242307|DRUG|Roflumilast|
48724675|NCT04079881|DRUG|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
48724676|NCT01759823|BIOLOGICAL|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
48724677|NCT01759823|OTHER|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
48724678|NCT01759823|BIOLOGICAL|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
48724679|NCT00825721|DRUG|LiquiTears|4 drops applied daily for 360 days
48724680|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
48724681|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
48724682|NCT00825721|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
48724683|NCT01297205|BIOLOGICAL|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
48729815|NCT04565795|DEVICE|Uriprene® Degradable Temporary Ureteral Stent|Assess adequate intervention-free drainage during use and the time to complete degradation or the passage of stent fragments/segments from the urinary system by radiological assessment.
48385592|NCT00408005|DRUG|Methotrexate|Given IT or PO
48385593|NCT00408005|DRUG|Nelarabine|Given IV
48385594|NCT00408005|DRUG|Pegaspargase|Given IM or IV
48385595|NCT00408005|DRUG|Prednisone|Given IV or PO
48729816|NCT02207218|DRUG|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
48729817|NCT02353728|DRUG|Nilotinib|
48729818|NCT01835730|DRUG|PE0139 Injection|
48729819|NCT01835730|DRUG|Placebo|
48724684|NCT04294446|DEVICE|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
48183544|NCT01672593|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
48724685|NCT01595594|DRUG|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
48183545|NCT01672593|DRUG|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
48183546|NCT01672593|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
48183547|NCT01672593|PROCEDURE|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
48183548|NCT06089915|BEHAVIORAL|Standard occupational therapy|Standard occupational therapy as part of inpatient rehabilitation
48183549|NCT06089915|DEVICE|Robot-assisted exercise using Amadeo device and Armeo Spring exoskeleton|Exercise for fingers and hand using Amadeo device plus gross-motor exercise using Armeo Spring exoskeleton
48183550|NCT02145845|DEVICE|Injectable SIS|Injectable SIS
48385596|NCT00408005|RADIATION|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
48385597|NCT00408005|DRUG|Thioguanine|Given PO
48385598|NCT00408005|DRUG|Vincristine Sulfate|Given IV
48385599|NCT04278872|DRUG|SJX-653|administered orally once daily
48385600|NCT04278872|DRUG|Placebo|administered orally once daily
48385601|NCT03751852|BEHAVIORAL|Exercise Coaching|28 classes in 16 weeks
48385602|NCT03751852|BEHAVIORAL|Psychoeducation|28 classes in 16 weeks
48724686|NCT01595594|DRUG|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
48724687|NCT03500588|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
48385603|NCT06539208|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1
48724688|NCT03500588|DEVICE|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
48724689|NCT04237246|DRUG|Tacrolimus|"24 hour long acting advegraf"
48724690|NCT01858753|BIOLOGICAL|Autologous fibroblasts|
48724691|NCT01858753|BIOLOGICAL|placebo sterile saline|
48026852|NCT06178666|BIOLOGICAL|BCG|Three dose levels of intradermal BCG
48026853|NCT02011841|DRUG|Rifaximin|rifaximin 1200 mg/day orally for 6 months
48026854|NCT02011841|DRUG|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
48026855|NCT00217698|DRUG|cisplatin|
48183551|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
48183552|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
48183553|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
48183554|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
48183555|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
48183556|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
48183557|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
48385604|NCT05010915|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation
48385605|NCT03506776|DEVICE|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
48385606|NCT03506776|OTHER|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
48729820|NCT01660503|DIETARY_SUPPLEMENT|0 grams SCF|Given in snack foods (muffins and flavored beverage)
48729821|NCT01660503|DIETARY_SUPPLEMENT|10 grams SCF|Given in snack foods (muffins and flavored beverage)
48026856|NCT00217698|DRUG|gefitinib|
48026857|NCT00217698|DRUG|gemcitabine hydrochloride|
48026858|NCT00572572|DRUG|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
48026859|NCT00572572|DRUG|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
48385607|NCT03888898|OTHER|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
48724692|NCT06203587|RADIATION|[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347|The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.
48385608|NCT03888898|OTHER|Control fit test evaluation|control comparator for fit testing time threshold
48385609|NCT05563142|PROCEDURE|deploying vascular closure device versus manual compression|patients will be randomized to either group 1 or group 2 in a 1:1 ratio:
48385610|NCT06567483|DEVICE|ELISIO21HX|Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
48724693|NCT01191346|OTHER|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
48724694|NCT05546073|OTHER|Advanced point-of-care technology|"The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea"
48724695|NCT00313859|DRUG|simvastatin|
48724696|NCT06264297|PROCEDURE|Radiofrequency|Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.
48724697|NCT01699711|DIETARY_SUPPLEMENT|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
48724698|NCT04928729|OTHER|Pursed Lip Breathing|PLB with frequency of three times daily for First 3 days of week for a duration of 5-10 mins is perform.
48724699|NCT04928729|OTHER|Pursed Lip Breathing +DB|PLB+DB with frequency of three times daily for Last three days of week for a duration of 10-15 mins is perform.
48724700|NCT04928729|OTHER|Conservative care|Participants will be having different dose as per tolerance 5 times daily.
48724701|NCT00307866|PROCEDURE|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
48724702|NCT00616694|DRUG|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
48385611|NCT04095975|DIETARY_SUPPLEMENT|Baking Soda|Standard baking soda that can be bought from stores.
48385612|NCT04095975|DIETARY_SUPPLEMENT|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
48385613|NCT01898117|DRUG|Carbo/cyclo|
48385614|NCT01898117|DRUG|Carbo/cyclo + atezolizumab|
48385615|NCT01898117|DRUG|Paclitaxel|
48385616|NCT01898117|DRUG|Paclitaxel + Atezolizumab|
48724703|NCT03519061|DRUG|Budesonide|Nasal saline irrigations with budesonide
48724704|NCT06054256|BEHAVIORAL|Group CBT-I|The group-based intervention will consist of 6 weekly sessions (90-min, 5-8 pregnant women in each group). The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia with the followings: psycho-education about sleep and sleep hygiene (e.g., psychoeducation about sleep during pregnancy and normal development and patterns of infant sleep, psychoeducation on ways of improving infant sleep, strategies to limit the development of unwanted sleep associations, etc.), stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
48385617|NCT04980391|BIOLOGICAL|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
48385618|NCT04980391|DRUG|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
48385619|NCT01035112|PROCEDURE|MRI|
48385620|NCT03632837|DEVICE|Hemoadsorption|see arm description
48724705|NCT06054256|BEHAVIORAL|App-based CBT-I|The smartphone app-based intervention will consist of 6 weekly sessions. The app-based intervention will involve a self-paced, fully automated digital programme with interactive components. The structure of the app involves six sequential modules (comparable to the six treatment sessions delivered in groups) with different elements to engage the users, such as animated videos, case vignettes, narration, quizzes, and homework assignment. Each module will be unlocked and released to the participants every week after the previous module has been completed. Personalised feedback will be provided by the app following the completion of sleep diary each week. Automated messages will be sent to the participants regularly via phone to remind them of implementing learned strategies after each module, as well as timely completing the treatment modules and sleep diaries.
48729822|NCT01660503|DIETARY_SUPPLEMENT|20 grams SCF|Given in snack foods (muffins and flavored beverage)
48385621|NCT06650540|DRUG|Levofloxacin Plus Metronidazole Suppositories|Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
48385622|NCT06650540|BIOLOGICAL|Levofloxacin co-administered with Metronidazole tablets|Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
48385623|NCT06333041|DRUG|Epidiolex|Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
48385624|NCT06333041|DRUG|Placebo|Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
48724706|NCT06054256|OTHER|Health related psychoeducation|The control group will receive 6 sessions of group-based health-related psychoeducation, a format that has been adopted in the previous research, in order to provide the credibility of the intervention to the participants, and to control for the potential effects of attention and nonspecific components.
48724707|NCT01455194|DRUG|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
48724708|NCT00897624|GENETIC|gene expression analysis|
48724709|NCT00897624|GENETIC|reverse transcriptase-polymerase chain reaction|
48724710|NCT00897624|OTHER|laboratory biomarker analysis|
48724711|NCT05349383|DRUG|Antibody-Drug Conjugate|"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
48724712|NCT05349383|DRUG|Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate|We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
48724713|NCT01545973|OTHER|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
48724714|NCT00366327|DRUG|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
48724715|NCT00383396|DRUG|Topical Cyclosporine|
48724716|NCT03544307|BEHAVIORAL|Taekwondo training|Exercise group
48724717|NCT01524081|DRUG|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. - Cefuroxime in 100ml saline~2. - Metronidazole in 500ml saline"
48385625|NCT04593589|OTHER|Submandibular Gland Stem Cell Transplantation|Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
48385626|NCT04587856|OTHER|bone marrow withdrawal|bone marrow samples evaluation
48724718|NCT01524081|DRUG|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. - 2x amoxicillin in 100ml saline~2. - Fluconazole in 500ml saline"
48724719|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution"
48385627|NCT03015207|DRUG|NNC0194-0499|
48385628|NCT03015207|DRUG|Placebo|
48385629|NCT06652997|DRUG|SPH3348|Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
48385630|NCT02626273|RADIATION|weight loss|
48724720|NCT01524081|DRUG|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 2x 100ml saline solution~2. - 500ml saline solution"
48724721|NCT05059964|OTHER|Circuit Training program|"The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs"
48724722|NCT05059964|OTHER|Continuous aerobic exercise Group|Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
48724723|NCT03731260|DRUG|Avapritinib|Avapritinib tablet
48183558|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
48385631|NCT03489239|DRUG|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
48385632|NCT06650397|OTHER|Biofortified maize|Maize that has been grown to have higher amounts of iron and zinc.
48385633|NCT06650397|OTHER|Placebo|Traditional maize
48385634|NCT01905007|DEVICE|Defibrillation testing|Defibrillation testing at initial ICD implantation
48724724|NCT03731260|DRUG|Placebo|Placebo tablet
48724725|NCT05423392|PROCEDURE|Tooth extraction of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Tooth extraction will be following up with the methodological procedures in order to define the effectiveness of anesthetics during indicated dental procedure.
48724726|NCT05423392|PROCEDURE|Endodontic dental treatment of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Endodontic dental treatment will be following up with the methodological procedures in order to define the effectiveness of anesthetics during dental treatment.
48724727|NCT05423392|PROCEDURE|Conservative tooth restoration of deciduous and permanent molars in children aged 5-18 years and mandibular premolars in children aged 10-18 years|Conservative tooth restoration will be following up with the methodological procedures in order to define the effectiveness of anesthetics during conservative tooth restoration.
48724728|NCT00575874|DRUG|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
48724729|NCT00575874|DRUG|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
48724730|NCT00575874|DRUG|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
48724731|NCT00575874|DRUG|pioglitazone HCl|30 mg capsules once daily for 12 weeks
48026860|NCT04497701|DRUG|PEG-rhG-CSF group|Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight. Peg-rhG-CSF can be used prophylactically only when the interval between two chemotherapy regimens is no less than 12 days.
48026861|NCT04497701|DRUG|rhG-CSF group|Patients received 5μg/kg/d of rhG-CSF, on the basis of actual body weight.
48026862|NCT06169917|BEHAVIORAL|Paced Resonance Frequency Breathing|Participants are required to pace their breathing to their pre-determined individual resonance frequency.
48724732|NCT00575874|DRUG|placebo|matching tablets or capsule once daily for 12 weeks
48724733|NCT00468975|DRUG|PF-610,355|
48183559|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
48183560|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
48183561|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
48183562|NCT02922205|DEVICE|Endoscopic Linear Cutter Stapler and reloads|Endoscopic Linear Cutter Stapler and reloads
48385635|NCT03586778|OTHER|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
48385636|NCT03586778|OTHER|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
48385637|NCT03586778|OTHER|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
48026863|NCT06169917|BEHAVIORAL|Paced Breathing at Natural Frequency|Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
48183563|NCT01894997|DEVICE|Neuromuscular electrical stimulator|
48183564|NCT01894997|DEVICE|AV Impulse System Model 6000|
48385638|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
48026864|NCT06169917|OTHER|Heat Stimulations|Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
48026865|NCT05517239|DRUG|Gemcitabine, Oxaliplatin|Gemcitabine 1,000 mg/m2 infusion for 30minutes and followed by oxaliplatin 100mg/m2 infusion for 2hours on day1. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
48183565|NCT04586166|DEVICE|RP Sling|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
48183566|NCT04586166|DEVICE|SIS|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
48183567|NCT01371708|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
48385639|NCT02460861|PROCEDURE|RPVE|Open Radical prostatovesiculectomy in Magdeburg
48385640|NCT02460861|PROCEDURE|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
48385641|NCT02460861|PROCEDURE|CE|Open cystectomy in Magdeburg/Gronau
48385642|NCT02460861|PROCEDURE|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
48724734|NCT00468975|DRUG|Salmeterol|
48724735|NCT04135846|DRUG|Doxazosin|16 mg or maximum tolerated dose (MTD)
48724736|NCT04135846|DRUG|Placebo|Matching placebo
48183568|NCT04970290|DEVICE|Definisse threads free floating and definisse threads double needle|Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
48183569|NCT05253599|DEVICE|Isokinetic training|The knees were flexed slightly at 15 degrees, and the fixation straps were tied around the popliteus, thigh, pelvis, chest and scapula to prevent the tricky movements.
48385643|NCT06395389|BEHAVIORAL|Health Education (HealthEdu)|The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about stress and social connection.
48521182|NCT03293537|DIAGNOSTIC_TEST|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
48724737|NCT00288314|PROCEDURE|Magnetic Resonance Imaging, Functional|Structural and functional MRI
48724738|NCT04041245|DEVICE|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~   They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
48026866|NCT01617629|BIOLOGICAL|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
48183570|NCT05253599|DEVICE|Virtual reality training|"Training was given in the sitting position which provides challenges to the balance activities of the participant. The game which was used in the current study was a shooting game, which consists of the subject sitting on the virtual platform and visualizing the game on the display screen. The game was executed and controlled by moving the trunk back and forth and left and right according to the signs. Participants can perform all the six movements of their spine within their pain limits.~The level of difficulty of the exercises was increased by graded activity, in which the activities were gradually getting difficult and harder as participants required more muscle activity and movement."
48183571|NCT05253599|OTHER|Exercises|They performed these exercises 10-15 reps/day for 5 days per week for 4 weeks. Stretching was focused on each muscle group for 3 repetitions for 10 seconds per muscle group (Hamstring, Hip flexors and Lumbar Extensors).7 A home-based exercise protocol was prescribed to all the subjects to perform at home. All the subjects in three groups were undergone hot pack therapy for 20 mins and ultrasound with a frequency of 1 Mhz and intensity of 1.5 W/cm2 in continuous form for five minutes.
48183572|NCT05262751|DRUG|Ofev®|Ofev®
48724739|NCT01814670|BIOLOGICAL|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
48183573|NCT05262751|DRUG|Nintedanib formulation 1|Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).
48183574|NCT05262751|DRUG|Nintedanib formulation 2|Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).
48183575|NCT05502822|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
48724740|NCT06231433|DEVICE|CO2 Vaginal Laser|CO2 Vaginal laser
48724741|NCT02942654|DRUG|LY900014|Administered subcutaneously (SC)
48183576|NCT05502822|DEVICE|sham high definition transcranial alternating current stimulation|. In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
48183577|NCT04067843|PROCEDURE|Photodynamic treatment|Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
48385644|NCT06395389|BEHAVIORAL|Values in Action (VIA)|VIA is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.
48385645|NCT03059940|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
48724742|NCT02942654|DRUG|Insulin Lispro|Administered SC
48724743|NCT01511809|DRUG|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
48026867|NCT00003801|PROCEDURE|management of therapy complications|
48026868|NCT00003801|PROCEDURE|quality-of-life assessment|
48521183|NCT06345911|BEHAVIORAL|Experimental group|The animal characters were shown to the child before the bloodletting procedure. The child was asked to choose one of them and the one chosen by the child was attached to the vacutainer. The child and their parents were taken to the blood collection room. During the bloodletting procedure, the child was asked to focus on the animal character they had chosen.
48724744|NCT04129450|OTHER|Group medical visits with mindfulness-based stress reduction|Eight weekly 90 minute sessions of mindfulness-based stress reduction in group medical visits
48724745|NCT04129450|OTHER|Usual PCP care|Usual one on one PCP care for chronic lower back pain
48724746|NCT02746185|DRUG|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
48724747|NCT02746185|DRUG|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
48724748|NCT00007267|BEHAVIORAL|Cognitive behavioral therapy|
48724749|NCT00007267|BEHAVIORAL|Disease/health education|
48724750|NCT00007267|BEHAVIORAL|Self-help cognitive behavioral intervention facilitated by a psychologist|
48724751|NCT01642758|DRUG|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
48724752|NCT06026501|DRUG|PE0116,PE0105|"1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug"
48724753|NCT02211313|DEVICE|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
48026869|NCT06529367|OTHER|Snellen chart|"Patients will be asked to use the 5 feet distance for standardization, which allows for visual acuity assessment from 20/16 to 20/200.~Patients will be asked to wear their current corrective lens for distance, to take the test at home in a place with good lighting and to test each eye separately.~Office-based vision testing will be performed by a trained ophthalmic technician in a dimmed room with the Snellen chart illuminated on a screen. Patients will be asked to wear their current corrective lens for distance and an eye occluder will be used to test each eye separately."
48026870|NCT06532903|OTHER|Selective muscle electrostimulation with exponential current|An electroevaluation will be performed, with an exponential current generator equipment, using Meditea® brand Neuromatic 700 equipment, which consists of a first application of the current, the pulse width (in milliseconds) in which a contraction is achieved will be sought. frank, visible and selective of the facial muscle that is being stimulated. The purpose is to identify the pulse width and the lowest intensity to obtain a frank, visible and selective contraction, understood as the best quality.
48026871|NCT06532903|OTHER|Facial muscle reeducation in front of the mirror|"Muscle re-education: Symmetrical facial movements will be requested, activating the muscles of the affected side, avoiding the participation of the unaffected side. We will work with the patient sitting in front of a mirror, asking him to perform the following actions or gestures: raise his eyebrows, frown, close his eyes (tightly and blink), smell an unpleasant odor, show his fangs, blow a kiss, blow , fake smile (lip corner pulled back horizontally), frank smile (lip corner pulled back and up, showing teeth), kiss and pout. The functional capacity of the mouth will be trained, inflating the cheekbones and moving the air from one side to the other, avoiding compensations. Depending on the degree of facial dysfunction and its condition, the kinesiologist will perform a stretch reflex, facilitation of movement and/or inhibition of it. Three series of five repetitions of each gesture described will be done."
48026872|NCT04278326|PROCEDURE|Vaginal Biopsy|"1. Vaginal biopsies~2. Additional cervical and vaginal biopsies~3. Non invasive cervico-vaginal swab like a smear"
48026873|NCT03889717|DIETARY_SUPPLEMENT|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
48026874|NCT03050476|DRUG|RESCAP®|intravenous application before, during, and for 24 or 96 hours after heart surgery
48026875|NCT03050476|DRUG|placebo|intravenous application before, during, and for 24 or 96 hours after heart surgery
48026876|NCT04443218|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|The Edwards PASCAL Valve Repair System is indicated for the percutaneous reconstruction of an insufficient mitral valve.
48026877|NCT05754320|DEVICE|Tension band wire fixation|Tension band wire fixation
48026878|NCT05754320|DEVICE|Plate fixation|Tension band wire fixation
48724754|NCT00548236|BEHAVIORAL|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
48724755|NCT04458415|OTHER|Traxi Panniculus Retractor (TPR)|Surgeon uses the Traxi Panniculus Retractor (TPR) surgical retraction device to retract the panniculus during C-Section.
48724756|NCT04458415|OTHER|Silk Tape|Surgeon uses silk tape to retract the panniculus during C-Section.
48026879|NCT01577394|OTHER|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
48026880|NCT05919537|DRUG|HMBD-001|HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
48026881|NCT05919537|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV once every 3 weeks
48026882|NCT05919537|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
48026883|NCT05919537|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
48026884|NCT04624698|DEVICE|iStent Inject Implantation|Subjects will be implanted with the iStent Injection Micro-Bypass device
48026885|NCT02889549|DRUG|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
48026886|NCT02889549|DRUG|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
48385646|NCT03059940|PROCEDURE|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
48724757|NCT05231707|BEHAVIORAL|A couples-focused intervention for HIV prevention and care in South Africa|From a sample of 272 male-female couples (544 individuals, 272 men and 272 women) recruited from rural KaZulu-Natal, South Africa, couples will be randomized to receive either individual a package of dyadic counseling and testing (intervention arm) or an attention matched control.
48724758|NCT04067778|DIAGNOSTIC_TEST|Intervention Group|Standard colonoscopy with targeted biopsies only
48521184|NCT05920837|DEVICE|MyotonPRO|Muscles' viscoelastic properties assess with myotonPRO.
48724759|NCT04067778|DIAGNOSTIC_TEST|Control Group|Standard colonoscopy with random AND targeted biopsies
48724760|NCT03191370|OTHER|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
48724761|NCT03191370|DRUG|Local Anesthetics,Topical|Anesthetic spray
48026887|NCT02696005|OTHER|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
48026888|NCT04133935|PROCEDURE|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
48026889|NCT04133935|PROCEDURE|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
48026890|NCT05058911|BEHAVIORAL|Internet-delivered exposure-based cognitive behavior therapy|The primary treatment component is exposure to stimuli (situations and activities) that give rise to pain, distress, and unwanted emotional responses. The treatment proceeds in accordance with functional analysis. Exercises are tailored for the patient so that, for example, individuals whose main coping strategy is to be overly active (i.e., persistence behavior) are encouraged to sit down and observe pain and other aversive bodily sensations as they arise. The protocol also includes regular exercises where the participant is encouraged to observe and name physical sensations without acting on them.
48026891|NCT05058911|BEHAVIORAL|Internet-delivered traditional cognitive behavior therapy|This treatment is based on components typical of T-CBT for FM, such as relaxation, activity planning or pacing, cognitive restructuring techniques and stress management strategies.
48026892|NCT04589819|DRUG|Teriparatide|Teriparatide, an injectable synthetic parathyroid hormone, will be tested to evaluate its efficacy for decreasing the convalescence after a diaphyseal tibial stress fracture, a specific bone stress injury.
48521185|NCT05920837|OTHER|Box and Block Test|Upper extremity's functionality assess with Box and Block Test.
48521186|NCT03710980|DEVICE|Oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
48521187|NCT04610853|DIAGNOSTIC_TEST|rotational thromboelastometry|ROTEM will be conducted and DIC score calculated within 24 hours after the diagnosis of Sepsis as well as on day 3 and 5 of ICU stay
48724762|NCT02108665|RADIATION|Radiographic hysterosalpingography|
48724763|NCT02108665|RADIATION|Magnetic resonance imaging hysterosalpingography|
48724764|NCT03514563|DIAGNOSTIC_TEST|MRI imaging|MRI recordings of the craniofacial region
48724765|NCT03514563|DIAGNOSTIC_TEST|Optical scan|Optical intraoral scans
48724766|NCT03514563|DIAGNOSTIC_TEST|3D photography|Facial stereophotogrammetry
48724767|NCT05597332|OTHER|Care bundle for AKI|To maintain mean arterial pressure (MAP) ≥ 65 mmHg; to keep the patient euvolemic; to avoid nephrotoxic drugs; to adjust dose of medication for kidney function; to exclude urinary obstruction; to monitor urine output and serum creatinine levels.
48724768|NCT03882645|OTHER|CHH-diet|"This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period."
48724769|NCT03882645|OTHER|local usual diet|The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
48724770|NCT03020017|OTHER|Laboratory Biomarker Analysis|Correlative studies
48724771|NCT03020017|OTHER|Pharmacological Study|Correlative studies
48724772|NCT03020017|DRUG|Targeted Molecular Therapy|Given NU-0129 IV
48724773|NCT02915913|BEHAVIORAL|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
48724774|NCT02915913|BEHAVIORAL|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
48724775|NCT02915913|BEHAVIORAL|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
48026893|NCT04589819|DRUG|Placebos|Placebo will be a sugar solution of the manufacturer's design.
48026894|NCT01273272|BEHAVIORAL|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
48724776|NCT02915913|OTHER|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
48724777|NCT01152177|DEVICE|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
48724778|NCT03346577|DEVICE|stent or balloon|Endovascular treatment with stent or balloon according to current practice
48724779|NCT03197909|OTHER|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
48724780|NCT02951429|DRUG|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
48724781|NCT02951429|DRUG|Placebo|Placebo matched with sildenafil.
48724782|NCT02951429|DRUG|Sildenafil|Sildenafil will be given as 20 mg, TID.
48724783|NCT04764110|DIETARY_SUPPLEMENT|Cyplexinol|partially hydrolyzed Collagen and its associated proteins including Bone Morphogenetic Proteins (BMPs)
48724784|NCT04764110|OTHER|Placebo|Maltodextrin
48724785|NCT03377933|OTHER|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
48385647|NCT03059940|OTHER|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
48385648|NCT03059940|BEHAVIORAL|Cessation Counseling|Brief cessation counseling given by LDCT provider.
48385649|NCT03059940|BEHAVIORAL|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
48385650|NCT03059940|BEHAVIORAL|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
48724786|NCT06377891|OTHER|Emotional Resilience training|Primiparous pregnant women in the experimental group will be given emotional resilience training in the last trimester.
48724787|NCT03511456|PROCEDURE|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
48724788|NCT05906355|DEVICE|the wearable filtrating artificial Kidney Device|the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients
48026895|NCT01273272|BEHAVIORAL|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
48026896|NCT02479984|PROCEDURE|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
48026897|NCT02479984|DEVICE|Laparoscopic ultrasound|
48026898|NCT01271335|BIOLOGICAL|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
48026899|NCT02441452|OTHER|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
48026900|NCT03586635|OTHER|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
48385651|NCT03059940|DRUG|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
48385652|NCT03059940|DRUG|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
48385653|NCT03059940|BEHAVIORAL|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
48385654|NCT03059940|OTHER|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
48521188|NCT00065156|DRUG|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
48724789|NCT05906355|DEVICE|traditional hemodialysis machine|the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
48729823|NCT04420663|DIAGNOSTIC_TEST|Pleural Manometry|Recording pleural pressure during therapeutic thoracocentesis using a simple water manometer.
48385655|NCT06650553|PROCEDURE|Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.|This clinical trial is divided into three stages: the screening phase, the treatment phase, and the follow-up phase. During the screening phase, patient enrollment must be completed, and baseline conditions must be recorded. In the treatment phase, the transplantation treatment process for patients in the HLA-matched HSCT group and the umbilical cord blood-supported haplo-HSCT group must be completed, and treatment conditions must be recorded. In the follow-up phase, outcome evaluation indicators must be collected according to the follow-up plan, ensuring data quality.
48385656|NCT06364410|DRUG|Azenosertib|Given PO
48724790|NCT01850355|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
48724791|NCT01704456|BEHAVIORAL|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
48724792|NCT01704456|BEHAVIORAL|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
48724793|NCT02491424|DEVICE|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
48385657|NCT06364410|PROCEDURE|Biopsy|Undergo biopsy
48385658|NCT06364410|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
48385659|NCT06364410|PROCEDURE|Computed Tomography|Undergo CT
48385660|NCT06364410|PROCEDURE|Echocardiography|Undergo ECHO
48385661|NCT06364410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
48385662|NCT06364410|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
48724794|NCT00459472|BEHAVIORAL|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
48724795|NCT06020755|DRUG|Toripalimab|200mg q2w intravenous
48724796|NCT06020755|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
48724797|NCT02562807|DRUG|TAS-303 18mg single-dose|
48724798|NCT02562807|DRUG|Placebo 18mg single-dose|
48724799|NCT02562807|DRUG|TAS-303 9mg single-dose|
48724800|NCT02562807|DRUG|Placebo 9mg single-dose|
48724801|NCT05716204|OTHER|High force lateral distraction|High force lateral distraction on the affected hip.
48026901|NCT02057055|OTHER|Soap 300000027003|
48026902|NCT02057055|OTHER|Soap 300000029240|
48026903|NCT00001402|DEVICE|PET scan|
48026904|NCT02091804|BEHAVIORAL|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
48385663|NCT06364410|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
48521189|NCT04012788|DIETARY_SUPPLEMENT|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
48724802|NCT05716204|OTHER|Placebo distraction group|Placebo lateral distraction on the affected hip.
48724803|NCT05285306|BEHAVIORAL|PEACE Program|This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.
48724804|NCT00006268|BIOLOGICAL|cintredekin besudotox|
48724805|NCT00006268|DRUG|isolated perfusion|
48724806|NCT00006268|PROCEDURE|conventional surgery|
48724807|NCT01753401|DRUG|Acthar|Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
48724808|NCT01753401|DRUG|Placebo|Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
48724809|NCT01753401|DRUG|Steroid Drug|The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
48724810|NCT03467672|OTHER|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
48724811|NCT00640367|OTHER|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
48026905|NCT02091804|BEHAVIORAL|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (\~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
48026906|NCT04606953|BEHAVIORAL|Attention Process Training (APT-II)|The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
48026907|NCT00397423|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd\*5 days,3 months interval for 4 times
48026908|NCT00397423|DRUG|NS|NS 1ml iH Qd\*5 days, 3 months interval for 4 times
48026909|NCT04541381|OTHER|Availability of clinical decision support based on pharmacogenomic results.|Availability of clinical decision support based on pharmacogenomic results. These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
48521190|NCT04012788|OTHER|Placebo comparator|Placebo powder
48724812|NCT00640367|DRUG|Alteplase IV|intravenous recombinant tissue plasminogen activator
48724813|NCT05115916|BEHAVIORAL|MyChart Priming Message|In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
48026910|NCT00709384|PROCEDURE|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
48385664|NCT01757873|DRUG|Z160|
48385665|NCT01757873|DRUG|Placebo|
48521191|NCT04762004|BEHAVIORAL|Maternal speech|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
48521192|NCT04762004|BEHAVIORAL|Maternal singing|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
48521193|NCT04762004|BEHAVIORAL|Standard care|the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
48521194|NCT02754843|DEVICE|Phonak's equivalent newly developped power BTE|
48521195|NCT02754843|DEVICE|Equivalent competitor device|
48724814|NCT00752726|DRUG|Orlistat|Weight loss treatment
48724815|NCT00752726|DRUG|Placebo|Inactive
48724816|NCT01793259|DRUG|methotrexate prefilled pen|
48724817|NCT01793259|DRUG|methotrexate prefilled syringe|
48724818|NCT03087526|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
48724819|NCT00859157|PROCEDURE|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
48724820|NCT06128122|PROCEDURE|Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels|"Step one: 30 mL of 12.5%/0.1% lidocaine will be injected into the knee using an inferomedial approach. Using ultrasound guidance, a 20-gauge 2-inch I.V. catheter will be placed in the suprapatellar pouch, by which samples of synovial fluid from the pouch will be withdrawn and analyzed for glucose level.~Step two: 3 mL of D5W will be injected into a marked spot on the back of the upper arm. A sensor/transmitter (Dexcom G7 Dexcom) is placed at the site of injection. The sensor/transmitter will begin providing dextrose levels at 5 minute intervals beginning one-half hour after placement of the sensor/transmitter, transmitted to a paired smart phone."
48724821|NCT02066129|DRUG|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
48724822|NCT02066129|DRUG|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
48724823|NCT02772770|OTHER|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
48724824|NCT02772770|PROCEDURE|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
48724825|NCT02772770|PROCEDURE|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
48724826|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
48724827|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
48724828|NCT04190277|DEVICE|Open-loop condition|Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
48724829|NCT04190277|DEVICE|Closed-loop condition|Closed-loop algorithm system paired with continuous glucose monitoring sensor
48724830|NCT02434965|DRUG|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
48724831|NCT02434965|DRUG|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
48724832|NCT04496453|OTHER|Childhood vaccination decision support tool|Participants receive childhood vaccination decision support tool
48724833|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 1"
48724834|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 2"
48724835|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 3"
48724836|NCT00697281|DRUG|OC000459|"Tablets twice daily for 8 days~Dose level 4"
48724837|NCT00697281|DRUG|Placebo|"Tablets twice daily for 8 days~Dose level 5"
48724838|NCT05284916|BEHAVIORAL|liver diseases admissions|The different patterns of liver disease related admissions after the era of DAAS
48724839|NCT00188903|PROCEDURE|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
48724840|NCT01067469|DRUG|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
48724841|NCT01067469|DRUG|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
48724842|NCT01067469|DRUG|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
48724843|NCT01165970|DRUG|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
48724844|NCT01165970|DEVICE|Saliva natura|Saliva substitute without restriction to be used
48724845|NCT06544759|BEHAVIORAL|Aa educational Documentry|"The Gift of Life: Become an Organ Donor, Transform the Future! is an informative and captivating documentary that delves into the world of organ transplantation and the powerful implications of organ donation. This documentary aims to dispel common misconceptions about organ donation and shares a heartwarming real-life story that highlights the life-saving potential of organ transplants. Through its comprehensive exploration of the subject and engaging storytelling, the documentary not only educates but also inspires profoundly. The documentary challenges preconceptions and aims to cultivate a culture of empathy, generosity, and life-saving commitment through its meticulous examination of the topic. The documentary serves as a powerful tool to raise awareness about the importance of organ donation and its potential to make a positive change in the world."
48724846|NCT01704703|DRUG|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
48724847|NCT01704703|DRUG|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
48729824|NCT05718960|OTHER|Reassurance-alone|To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia
48026911|NCT01032941|DRUG|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
48026912|NCT00112073|DRUG|bapineuzumab|IV, Q13w
48026913|NCT00112073|OTHER|placebo|IV Q13w
48026914|NCT04267172|BEHAVIORAL|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
48026915|NCT04267172|OTHER|No intervention: Surgical Resident Control Group|Control Group
48026916|NCT04267172|OTHER|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
48385666|NCT01211613|PROCEDURE|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
48385667|NCT01211613|DEVICE|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
48521196|NCT00390637|BEHAVIORAL|High or low Glycemic Index and high or low Protein Diet|
48385668|NCT01211613|OTHER|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
48385669|NCT02844088|OTHER|Meningococcus C conjugate vaccine|
48521197|NCT00835302|PROCEDURE|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
48521198|NCT05941312|PROCEDURE|autologous products|After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.
48521199|NCT03154125|DRUG|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
48521200|NCT06124898|DEVICE|Alcohol-related mobile health technologies|Participants will be asked to use the three mobile technologies as they choose while drinking for a two-week period.
48521201|NCT06124898|BEHAVIORAL|Motivational interview and psychoeducation on blood/breath alcohol concentration|Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.
48521202|NCT06124898|BEHAVIORAL|Lower tech facilitation|Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.
48724848|NCT03514901|OTHER|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
48724849|NCT03514901|DRUG|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
48724850|NCT05363826|COMBINATION_PRODUCT|photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)|"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"
48724851|NCT00036101|DRUG|aripiprazole|
48724852|NCT03775564|OTHER|REMEDRUGBY PROGRAM|"* 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby"
48724853|NCT03775564|OTHER|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
48724854|NCT03775564|OTHER|TAU|Treatment as usual
48724855|NCT03083184|DRUG|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
48724856|NCT03083184|DRUG|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
48724857|NCT00439881|DRUG|SB-681323|
48724858|NCT05298800|BIOLOGICAL|Vaccine|Different arms were administrated different vaccines
48026917|NCT03152305|OTHER|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
48385670|NCT06566547|DRUG|GR1803 injection|D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
48521203|NCT06124898|DEVICE|Higher tech facilitation|Participants will use an app developed during the study that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.
48521204|NCT06124898|BEHAVIORAL|Attention control psychoeducation|Brief 25/30-minute psychoeducation on a topic not related to alcohol use that will be developed in the course of the study.
48521205|NCT06124898|DEVICE|Attention control technology|App or other form of technology that will be developed in the course of the study to deliver information not related to alcohol use
48521206|NCT00652054|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
48724859|NCT01979939|DRUG|DCV/ASV/BMS-791325|
48724860|NCT02869698|PROCEDURE|Spectral Dynamic Imaging|
48724861|NCT02869698|DEVICE|Hybride electrode|
48724862|NCT02869698|DEVICE|Macro electrode|
48385671|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls POTS patients|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
48724863|NCT04029571|DRUG|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
48724864|NCT04029571|OTHER|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
48724865|NCT04598269|DRUG|ATI-1777|ATI-1777 topical solution 2.0% w/w
48724866|NCT04598269|DRUG|Vehicle|Vehicle topical solution containing no ATI-1777
48724867|NCT05837104|DRUG|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
48724868|NCT05837104|DRUG|Placebo|Placebo tablet, three times daily for four weeks.
48724869|NCT01267175|DEVICE|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
48724870|NCT05071430|DRUG|HB-01|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
48724871|NCT05071430|DRUG|Placebo|HB-1 matched placebo
48724872|NCT04828005|DRUG|Nalmefene hydrochloride|3mg Nasal spray
48724873|NCT04828005|DRUG|Naloxone hydrochloride|4mg Nasal Spray
48724874|NCT01583660|DRUG|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
48724875|NCT01583660|DRUG|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
48724876|NCT06487728|DIAGNOSTIC_TEST|Urinary titin|Urinary titin and skeletal muscle index as predictor of muscle wasting in critically ill patient
48724877|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with normal saline|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with normal saline and to compared with those smeared with exosomes after laser treatment.
48724878|NCT06221787|PROCEDURE|microneedles combined with hUCMSC-Exos|the hUCMSC-Exos were applied while rolling a microneedle roller and to compared with those used 1565 nm non-ablative fractional laser or PBASM combined with hUCMSC-Exos.
48385672|NCT05375968|DIAGNOSTIC_TEST|Measurement of Splanchnic venous capacitance(SVC)done at Baseline and after 90 min of 75 g glucose in Healthy Controls|While segmental bioimpedance is monitored, continuous positive airway pressure (CPAP) will be applied sequentially at 0, 4, 8, 12, and 16 cm H2O for about 30 seconds each. This positive airway pressure will increase the intrathoracic pressure, which is transmitted to the venous circulation. Pressure (CPAP pressure, X axis) - volume (splanchnic vascular volume measured by segmental impedance and expressed as % change from baseline, Y axis) relationships are then constructed to assess for splanchnic venous capacitance
48385673|NCT05375968|DRUG|Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
48521207|NCT04944173|DRUG|Durvalumab|Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
48724879|NCT06221787|PROCEDURE|1565 nm non-ablative fractional laser combined with hUCMSC-Exos|After 1565 nm non-ablative fractional laser treatment, patients with melasma were smeared with hUCMSC-Exos and to compared with those smeared with normal saline after laser treatment.What's more,compared with those used microneedles or PBASM combined with hUCMSC-Exos.
48724880|NCT06221787|PROCEDURE|PBASM combined with hUCMSC-Exos|a plasma named Peninsula Blue Aurora Shumin Master (PBASM) rolling each area for 8-10 min before applying the hUCMSC-Exos in the entire face. And to compared with those used 1565 nm non-ablative fractional laser or microneedles combined with hUCMSC-Exos.
48724881|NCT06546072|OTHER|MRI|
48724882|NCT00875862|PROCEDURE|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
48724883|NCT03254355|PROCEDURE|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
48724884|NCT00828152|BEHAVIORAL|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
48724885|NCT00828152|BEHAVIORAL|On line discussion group|Placebo. On line discussion group.
48724886|NCT06507683|RADIATION|simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib|"A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).~ripretinib: oral 150mg QD"
48724887|NCT02606357|DRUG|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
48724888|NCT02083887|BIOLOGICAL|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu
48729825|NCT05718960|BEHAVIORAL|Traditional dietary advice|To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre
48521208|NCT04944173|RADIATION|Stereotactic Body Radiotherapy|Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
48026918|NCT05350293|OTHER|Molded abutment|"The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner."
48026919|NCT05350293|OTHER|3D printed abutment|A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
48026920|NCT02991209|DRUG|Testosterone|
48521209|NCT04944173|DIAGNOSTIC_TEST|Circulating Tumor DNA assay|After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
48026921|NCT02991209|DRUG|Placebos|
48026922|NCT00932893|DRUG|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
48026923|NCT00932893|DRUG|Pemetrexed|Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
48026924|NCT00932893|DRUG|Docetaxel|Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
48026925|NCT04410692|OTHER|Prediction Market|"Participants bet on likely future outcomes using a prediction market"
48385674|NCT05375968|DRUG|Compare change is SVC and SMA flow due to saline|Participants with POTS will be randomize to either saline versus GIP(3-30)NH2 acute infusion. We will measure changes in their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hr. Notably, we will assess changes in venous capacitance using segmental impedance to measure the effect of graded positive airway pressure (CPAP) on splanchnic blood volume.
48521210|NCT00042601|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
48521211|NCT00042601|DRUG|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
48026926|NCT01427244|DRUG|trastuzumab|monoclonal antibody
48026927|NCT03781518|PROCEDURE|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
48026928|NCT03443466|DEVICE|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
48026929|NCT03443466|DEVICE|Loss of resistance (LOR)|Using loss of resistance technique only
48521212|NCT03815825|DRUG|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
48521213|NCT03815825|DRUG|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
48385675|NCT02792400|DRUG|LY2403021|Glucagon receptor antagonist
48026930|NCT02706457|OTHER|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
48026931|NCT04221516|DRUG|Camrelizumab|Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
48724889|NCT01172574|OTHER|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
48026932|NCT01099319|DIETARY_SUPPLEMENT|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
48026933|NCT01099319|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
48724890|NCT05329207|BEHAVIORAL|Experimental group|Web Based Adolescent Health Promotion Education Program
48724891|NCT03125694|DRUG|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
48724892|NCT03125694|DRUG|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
48724893|NCT01224444|OTHER|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
48724894|NCT05407415|OTHER|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~* ECG noise filtering,~* heart rate measurement from ECGs,~* detection of noisy ECGs, and~* ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
48724895|NCT00434798|BIOLOGICAL|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10\^6-10\^9 CFU
48724896|NCT00002140|DRUG|Ethambutol hydrochloride|
48026934|NCT00129987|BEHAVIORAL|Self management education|
48026935|NCT03038373|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
48026936|NCT01392352|DRUG|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
48724897|NCT00002140|DRUG|Clarithromycin|
48724898|NCT00002140|DRUG|Azithromycin|
48183578|NCT03089996|PROCEDURE|Piezocision|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
48729826|NCT02191813|DRUG|Seresis®|
48729827|NCT02191813|DRUG|Placebo|
48026937|NCT03756558|DEVICE|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
48729828|NCT00238238|BIOLOGICAL|rituximab|Given IV
48026938|NCT03049124|BEHAVIORAL|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than \< 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than \< 60% of heart rate reserve) component.
48026939|NCT01774903|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
48026940|NCT03230279|PROCEDURE|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
48026941|NCT03230279|PROCEDURE|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
48026942|NCT00847873|BEHAVIORAL|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
48385676|NCT02792400|DRUG|LY2403021 placebo|
48385677|NCT02792400|PROCEDURE|Standardised liquid meal|
48385678|NCT02792400|DRUG|Linagliptin|DPP-4-inhibitor
48385679|NCT02792400|DRUG|Linagliptin placebo|
48026943|NCT00847873|BEHAVIORAL|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
48385680|NCT02792400|DRUG|Empagliflozin|SGLT2-inhibitor
48385681|NCT02792400|DRUG|Empagliflozin placebo|
48385682|NCT00230217|DRUG|Rasburicase (SR29142)|
48385683|NCT06536595|OTHER|Scales|Participants were asked to complete the HAnDE-T, MHISS, SF-36 and HAQ when they first came. After 1 week, they were asked to complete HAnDE-T for re-test.
48385684|NCT06554678|PROCEDURE|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）|Transnasal humidified rapid insufflation ventilatory exchange（THRIVE）
48724899|NCT02160444|BEHAVIORAL|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
48026944|NCT01466816|DIETARY_SUPPLEMENT|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
48026945|NCT06237283|BEHAVIORAL|Early shower|Start shower after drain removal
48026946|NCT01881451|DRUG|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
48026947|NCT01881451|PROCEDURE|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
48385685|NCT06554678|PROCEDURE|conventional oxygen mask|conventional oxygen mask
48385686|NCT01414062|BEHAVIORAL|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
48385687|NCT01414062|BEHAVIORAL|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the New York City (NYC)-based not-for-profit, God's Love We Deliver
48724900|NCT01031862|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
48724901|NCT01054521|PROCEDURE|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
48724902|NCT01054521|DEVICE|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
48026948|NCT03113539|OTHER|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
48026949|NCT06151249|COMBINATION_PRODUCT|Meritup oral solution|chemotherapy + Meritup
48026950|NCT05302765|OTHER|Normal Saline Intravenous Fluids|Administration of normal saline intravenous fluids (20 milliliters/kilogram).
48385688|NCT04177472|BEHAVIORAL|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
48724903|NCT02886559|DRUG|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
48724904|NCT02209623|BIOLOGICAL|TDAP|
48724905|NCT01912534|DRUG|Valsartan|40, 80 and 160 mg tablets of Valsartan
48026951|NCT06303765|OTHER|Practice Resource for Driving After Stroke (PReDAS)|"1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)"
48026952|NCT03659552|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
48026953|NCT04093934|BEHAVIORAL|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
48183579|NCT03089996|PROCEDURE|Corticotomy|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
48385689|NCT04177472|BEHAVIORAL|Obesity Prevention Group + Food Boxes|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.
48729829|NCT00238238|DRUG|lenalidomide|Given orally
48183580|NCT03089996|DEVICE|Control Side|The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
48724906|NCT01912534|DRUG|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
48724907|NCT03155308|DEVICE|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
48724908|NCT04365933|DRUG|EYP001a|Oral tablets
48724909|NCT04365933|DRUG|Entecavir|Oral tablets
48385690|NCT04177472|BEHAVIORAL|Infant Safety and Injury Prevention Group|Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
48724910|NCT04365933|DRUG|Pegylated interferon alpha2a|Subcutaneous
48724911|NCT04280874|DRUG|Dinoprostone 0.5 MG|0.5mg dinoprostone applied intracervically
48724912|NCT04280874|DRUG|Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly|2mg dinoprostone applied intravaginally
48724913|NCT05985096|DIAGNOSTIC_TEST|Virtual reality group|Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
48724914|NCT02408523|DRUG|Lacosamide Tablet|"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
48026954|NCT04244461|BEHAVIORAL|Personalized Normative Feedback|The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
48026955|NCT00924950|DRUG|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
48385691|NCT05911763|DRUG|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
48385692|NCT00879762|BIOLOGICAL|IMVAMUNE® High Dose|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10\^8 TCID50 (5×10\^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
48385693|NCT00879762|DRUG|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
48385694|NCT00879762|BIOLOGICAL|IMVAMUNE® Standard Dose|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10\^8 tissue culture infectious dose 50 \[TCID50\] per 0.5 mL dose)
48385695|NCT01220037|BEHAVIORAL|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
48385696|NCT06224504|BEHAVIORAL|routine health education|guided the diet of patients, and introduced the knowledge of the disease in detail
48521214|NCT06358768|OTHER|teamwork job improvement overall|increase of teamwork capacities and skills improvement
48724915|NCT02408523|DRUG|Lasosamide Oral Solution|"* Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
48724916|NCT02408523|OTHER|Placebo Tablet|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use"
48724917|NCT02408523|OTHER|Placebo Oral Solution|"* Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use"
48724918|NCT04166760|DIETARY_SUPPLEMENT|speWHE|25 gram of a specific whey fraction (confidential)
48026956|NCT00924950|DRUG|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
48724919|NCT04166760|DIETARY_SUPPLEMENT|WHE|25 gram protein of a regular whey compound
48724920|NCT05876845|OTHER|Combined pre-, pro-, and post-biotic supplement|Participants will take 2 capsules daily with water, with their first meal of the day.
48724921|NCT02342262|DIETARY_SUPPLEMENT|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
48724922|NCT02342262|OTHER|Placebo|similar appearance as the probiotic product, but without bacteria
48724923|NCT02399514|OTHER|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
48724924|NCT04691856|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
48729830|NCT04552106|DIETARY_SUPPLEMENT|3 caps x3/day|3 capsules 3 times daily for 28 days
48385697|NCT06224504|BEHAVIORAL|psychological nursing|hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
48385698|NCT06224504|BEHAVIORAL|MBSR therapy|Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans
48521215|NCT06358768|OTHER|teamwork job improvement in actor scenario vs mannequin scenario|increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning
48521216|NCT03524651|DRUG|Ferrous Sulfate|Blisters of 10 capsules containing 150 mg of ferrous sulfate.
48521217|NCT03524651|DRUG|Fe-ASP|Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.
48724925|NCT04691856|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
48724926|NCT04691856|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
48724927|NCT04691856|DRUG|Morphine|All patients were instructed to use intravenous patient-controlled analgesia (IV PCA). All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
48724928|NCT05583994|OTHER|Optim Park Intervention|For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
48724929|NCT02001337|OTHER|medical chart review|baseline, quarterly follow-up for 24 months
48724930|NCT02001337|OTHER|survey administration|baseline
48724931|NCT02001337|OTHER|Specimen collection|baseline
48724932|NCT03106467|PROCEDURE|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
48729831|NCT04552106|DIETARY_SUPPLEMENT|3 caps x2/day|3 capsules 2 times daily for 28 days
48729832|NCT04552106|DIETARY_SUPPLEMENT|2 caps x3/day|2 capsules 3 times daily for 28 days
48385699|NCT06224504|BEHAVIORAL|exercise therapy|Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
48729833|NCT04552106|DIETARY_SUPPLEMENT|2 caps x2/day|2 capsules 2 times daily for 28 days
48385700|NCT04501809|PROCEDURE|compare misoprostol with combined oxytocin and cervical foly catheter|we will compare using misoprostol alone in one group with oxytocin and cervical catheter in the other group
48385701|NCT01995409|BEHAVIORAL|No smoking material provided in households with newborn infants|
48385702|NCT02159573|BIOLOGICAL|natalizumab|Administered as per routine clinical practice
48385703|NCT02159573|DRUG|dimethyl fumarate|Administered as per routine clinical practice
48385704|NCT04827576|DRUG|Magrolimab|Administered intravenously
48385705|NCT04827576|DRUG|Docetaxel|Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle
48385706|NCT00397904|BIOLOGICAL|cetuximab|
48385707|NCT00397904|DRUG|cisplatin|
48385708|NCT00397904|DRUG|irinotecan hydrochloride|
48385709|NCT00397904|OTHER|immunohistochemistry staining method|
48385710|NCT00397904|OTHER|laboratory biomarker analysis|
48521218|NCT03524651|DRUG|Ferrous Sulfate|Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.
48521219|NCT03524651|DRUG|Fe-ASP|Blisters of 10 capsules containing inactive ingredients of Microfer.
48521220|NCT05291338|DRUG|Doxorubicin|no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size
48385711|NCT00397904|PROCEDURE|biopsy|
48385712|NCT06006169|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
48385713|NCT06006169|DRUG|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
48385714|NCT01021696|DRUG|Paracetamol|Paracetamol Max. dose: 3g/d
48385715|NCT01021696|DRUG|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
48385716|NCT01021696|DRUG|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
48385717|NCT01021696|DRUG|Pregabalin|25mgx1/d; max 300mg/d
48385718|NCT02342574|DRUG|F901318|Administration of active compound
48385719|NCT02342574|DRUG|Placebo|Administration of placebo
48521221|NCT05291338|DRUG|Lipiodol|Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
48521222|NCT03452943|DRUG|TEV-50717|6, 9, 12, 15, and 18 mg oral tablets
48521223|NCT03452943|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
48183581|NCT03089996|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations will be performed only once time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations will be performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations will be controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations will be aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation will be performed between the two central incisors. The first perforation will be performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
48385720|NCT01833897|DRUG|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
48724933|NCT03106467|PROCEDURE|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
48724934|NCT00187070|DRUG|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
48724935|NCT00187070|PROCEDURE|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
48724936|NCT00187070|RADIATION|Radiation Therapy|See Detailed Description section for details of treatment interventions.
48521224|NCT03958929|OTHER|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q\&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
48724937|NCT00870298|DRUG|Trimethoprim/Sulfamethoxazole and Warfarin|
48724938|NCT06544031|BEHAVIORAL|Healthy Nutrition Education Program|The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
48724939|NCT06249906|DEVICE|Commercial bone implant product Group|Commercial bone implant product Group with a smooth surface （without particular microstructures）.
48724940|NCT06249906|DEVICE|Mirco-structured Bioceramic Group|β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
48724941|NCT00588094|DRUG|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is \> 100kg. Leukapheresis will continue."
48724942|NCT03256253|DRUG|Pregabalin|pregabalin up to 600 mg/day
48724943|NCT00056446|DRUG|Vatalanib|
48183582|NCT01821105|PROCEDURE|PET Scan|All patients will receive whole body PET scans (chest-abdomen-pelvis).
48724944|NCT01571232|DRUG|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
48521225|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
48521226|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
48521227|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
48521228|NCT00615199|DRUG|Placebo|administration via oral route twice daily
48724945|NCT01571232|DRUG|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
48724946|NCT04382417|OTHER|Observational study|Not required
48724947|NCT02821364|OTHER|Advanced Life Support|IV FLUIDS, INTUBATION
48724948|NCT04563013|DEVICE|Transcutaneous vagus nerve stimulation|the transcutaneous vagus nerve stimulation was conducted by ear clip with cathode and anode placed at the tragus for 30 min.
48724949|NCT05065450|DEVICE|Intracranial Stimulation|Electrodes localized to the BLA will be stimulated with either active-BLAES (0.5-3.5 mA, theta-modulated gamma burst) electrical stimulation for a 1-sec duration immediately following item image presentation or sham-BLAES (zero-amplitude). At later stages of the project, stimulation parameters and timing will be varied and triggered not at random, but by real-time closed-loop analysis of memory biomarkers in the medial temporal lobe.
48724950|NCT02541786|DRUG|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
48521229|NCT02885402|OTHER|MRI Sodium ( 23Na )|
48521230|NCT04908592|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
48724951|NCT02541786|DRUG|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
48183583|NCT01821105|PROCEDURE|CT Scan|All patients will receive CT scans of the abdomen and pelvis with contrast.
48183584|NCT01821105|RADIATION|fludeoxyglucose F 18|Given IV
48385721|NCT01833897|DRUG|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
48385722|NCT01833897|DRUG|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
48385723|NCT06652295|OTHER|Complex decongestive physiotherapy (CDP)|CDP consists of patient education, manual lymph drainage, short traction bandaging, skin/nail care and exercise. The applications of all modalities of the CDP programme were performed by the physiotherapist.
48385724|NCT06652295|OTHER|Self-administered Complex Decongestive Physiotherapy (CDP)|The self-administered CDP programme consisted of patient education, self-manual lymph drainage, self-short traction bandage application, self-skin/nail care and exercise. Participants were given one session of patient education before the self-administered CDP programme and patients were given practical information about all applications. Additionally, each component of the self-administered CDP programme was presented to the participants with a patient booklet and a video prepared by the researchers. Patients in the self-CDP group were followed up once a week with a patient follow-up diary.
48385725|NCT05051384|DIAGNOSTIC_TEST|Doppler technology|The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors
48385726|NCT06646003|OTHER|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke|Evaluation of 6-minute walking distance and related factors in patients with chronic stroke.
48724952|NCT03966885|BEHAVIORAL|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
48724953|NCT03966885|BEHAVIORAL|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
48026957|NCT01918345|BEHAVIORAL|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
48183585|NCT01821105|PROCEDURE|computer-aided detection/diagnosis|Undergo computer-aided detection/diagnosis during surgery
48183586|NCT02802397|OTHER|Self-administered questionnaire and blood and urine samples|Self-administered questionnaire and blood and urine samples
48724954|NCT04329494|PROCEDURE|Biopsy|Undergo biopsy
48724955|NCT04329494|DRUG|Cisplatin|Given via PIPAC
48724956|NCT04329494|DRUG|Doxorubicin|Given via PIPAC
48724957|NCT04329494|DRUG|Fluorouracil|Given IV
48724958|NCT04329494|DEVICE|Intraperitoneal Chemotherapy|Undergo PIPAC
48724959|NCT04329494|DRUG|Irinotecan|Given IV
48724960|NCT04329494|DRUG|Leucovorin|Given IV
48724961|NCT04329494|DRUG|Mitomycin|Given via PIPAC
48724962|NCT04329494|DRUG|Oxaliplatin|Given via PIPAC
48724963|NCT04329494|OTHER|Quality-of-Life Assessment|Ancillary studies
48724964|NCT04329494|OTHER|Questionnaire Administration|Ancillary studies
48183587|NCT02108769|BEHAVIORAL|Yogic Breathing|"1. Chanting Om~   1. Sharp deep inhalation through nostrils~  2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~2. Yogic Breathing:~   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~  2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~  3. Hold breath in this position for about 16 seconds.~  4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~  5. Go to step a)."
48724965|NCT02090361|PROCEDURE|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
48724966|NCT03437707|DRUG|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
48724967|NCT03437707|DRUG|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
48724968|NCT03437707|DRUG|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
48724969|NCT00624754|DRUG|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
48724970|NCT00624754|DRUG|lactose|Lactose 2 puffs b.i.d for 1 month
48385727|NCT06214780|DEVICE|advanced hybrid closed-loop|"An advanced hybrid closed-loop system is a type of insulin delivery system that uses an algorithm to automatically adjust insulin delivery based on glucose levels. It combines an insulin pump with a continuous glucose monitor (CGM) and uses a closed-loop algorithm to adjust insulin doses based on real-time glucose readings. The hybrid aspect refers to the fact that the system still requires some user input, such as entering meal information, but the algorithm takes over the majority of insulin dosing decisions."
48724971|NCT05948046|BEHAVIORAL|Visual training in hospital|Completion of 1 session of standardized visual training
48724972|NCT03046524|OTHER|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
48183588|NCT02108769|BEHAVIORAL|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
48183589|NCT01544634|DRUG|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
48183590|NCT01544634|DRUG|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
48724973|NCT05014568|DRUG|tapinarof cream, 1%|applied topically once daily
48724974|NCT05014568|DRUG|Vehicle cream|applied topically once daily
48724975|NCT04956588|COMBINATION_PRODUCT|surgical robot|The surgical robot completed the screw placement according to the surgical plan, and the researchers closely monitored the screw placement process.
48724976|NCT04956588|COMBINATION_PRODUCT|controlled approach|The screw placement was performed using a controlled approach according to the surgical plan.
48724977|NCT02280447|BIOLOGICAL|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
48724978|NCT02280447|BIOLOGICAL|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
48724979|NCT02280447|BIOLOGICAL|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
48724980|NCT02280447|BIOLOGICAL|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
48724981|NCT05042973|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
48724982|NCT05042973|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling.
48183591|NCT01544634|DRUG|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
48183592|NCT01544634|DRUG|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
48724983|NCT06503120|BEHAVIORAL|Mediterranean-diet intervention group|Dietitian-guided Nutritionist Education Process
48724984|NCT06503120|BEHAVIORAL|Standard care|A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
48724985|NCT00490620|DRUG|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
48724986|NCT00490620|DRUG|Placebo|placebo BID for 6 months
48724987|NCT01365624|DRUG|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
48724988|NCT03755908|DEVICE|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
48026958|NCT01918345|BEHAVIORAL|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
48183593|NCT03274115|DEVICE|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
48724989|NCT01641822|DRUG|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
48724990|NCT01641822|DRUG|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
48724991|NCT01641822|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
48724992|NCT03420404|OTHER|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
48724993|NCT01657734|OTHER|MR imaging|MR imaging
48026959|NCT04266977|DRUG|Dexamethasone|restrictive use of DEX, based on standardized clinical and radiological criteria.
48026960|NCT01153594|BEHAVIORAL|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
48183594|NCT00458588|OTHER|physiologic testing|
48183595|NCT00458588|OTHER|questionnaire administration|
48183596|NCT00458588|PROCEDURE|breast imaging study|
48183597|NCT00458588|PROCEDURE|dual x-ray absorptometry|
48183598|NCT00458588|PROCEDURE|evaluation of cancer risk factors|
48183599|NCT00458588|PROCEDURE|magnetic resonance imaging|
48385728|NCT04945460|DRUG|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
48385729|NCT04945460|DRUG|Placebo|Administered by subcutaneous injection
48521231|NCT04908592|OTHER|Placebo|Patients will receive 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
48724994|NCT04583956|OTHER|Placebo|Risankizumab placebo will be given at an equal volume at the same schedule.
48724995|NCT04583956|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
48724996|NCT04583956|BIOLOGICAL|Risankizumab|Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
48724997|NCT01792518|DRUG|Placebo|
48724998|NCT01792518|DRUG|Linagliptin 5mg|
48724999|NCT02134678|BEHAVIORAL|self-system therapy|
48725000|NCT02134678|BEHAVIORAL|cognitive therapy|
48725001|NCT05494372|OTHER|safety precautions|Nursing safety precautions on CPB
48725002|NCT05273541|BIOLOGICAL|Coronavirus vaccination|Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
48725003|NCT01252979|DIETARY_SUPPLEMENT|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
48725004|NCT02072395|PROCEDURE|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
48725005|NCT00982202|DRUG|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months
48725006|NCT00982202|DRUG|Placebo|1 to 3 tablets daily for \~18 months
48725007|NCT01354366|OTHER|Infant formula|
48725008|NCT03729245|BIOLOGICAL|bempegaldesleukin|Specified dose on specified days
48725009|NCT03729245|DRUG|sunitinib|Specified dose on specified days
48725010|NCT03729245|BIOLOGICAL|nivolumab|Specified dose on specified days
48725011|NCT03729245|DRUG|cabozantinib|Specified dose on specified days
48725012|NCT00659503|DRUG|Ciclesonide|200µg Ciclesonide versus Placebo
48725013|NCT00659503|DRUG|Placebo|placebo
48725014|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
48385730|NCT04945460|DRUG|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
48385731|NCT00000705|DRUG|Zidovudine|
48385732|NCT05560230|DRUG|Clonidine|A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
48521232|NCT03169088|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~* survey like FFQ, IPAQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
48725015|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
48725016|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
48385733|NCT05560230|DRUG|Isotonic saline|A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
48385734|NCT06625047|BEHAVIORAL|Assessment|Complete in-person assessment visits
48521233|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
48725017|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
48725018|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
48725019|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
48725020|NCT06356688|DRUG|paclitaxel polymer micelles and cisplatin combined with Cadonilimab|Paclitaxel polymer micelles:Cycle 1: 230mg/m2, IV ≥3 hours; Cycles 2-4: If the patient has a neutrophil nadir ≥1.0 x 109/L along with a platelet nadir ≥80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV ≥3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 375mg, IV drip, d3, q3w;
48725021|NCT03455608|BEHAVIORAL|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
48725022|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
48725023|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
48725024|NCT03007095|BEHAVIORAL|Evaluation of the children's social cognitive development|standardized neuropsychological tests
48725025|NCT02115360|DRUG|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
48385735|NCT06625047|OTHER|Questionnaire Administration|Ancillary studies
48725026|NCT02115360|DRUG|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
48385736|NCT06625047|OTHER|Telemedicine Visit|Complete telehealth assessment visits
48385737|NCT06625047|DRUG|Temozolomide|Given PO
48385738|NCT04274426|DRUG|Carboplatin|Carboplatin will administered by intravenous route
48725027|NCT05173701|DIETARY_SUPPLEMENT|Probiotics|Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.
48725028|NCT05173701|DIETARY_SUPPLEMENT|Placebo|A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
48725029|NCT03332160|DEVICE|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
48725030|NCT03332160|OTHER|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
48725031|NCT00351273|DRUG|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
48385739|NCT04274426|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
48725032|NCT00351273|DRUG|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
48725033|NCT00351273|DRUG|Placebo|Methylcellulose
48725034|NCT03301467|DRUG|Avacopan|Orally administered
48725035|NCT03301467|DRUG|Avacopan Matching Placebo|avacopan matching placebo
48725036|NCT04734587|DIAGNOSTIC_TEST|Blood serum Neuron-specific Enolase measurement|The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.
48725037|NCT04117698|DRUG|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group."
48725038|NCT04117698|DRUG|Ethambutol|Ethambutol
48385740|NCT04274426|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous route
48385741|NCT04274426|DRUG|Paclitaxel|Paclitaxel will be administered by intravenous route
48385742|NCT04274426|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
48385743|NCT02066688|DRUG|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
48385744|NCT02066688|DRUG|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
48385745|NCT02066688|DRUG|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
48385746|NCT03143205|BEHAVIORAL|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
48385747|NCT03143205|BEHAVIORAL|Writing tasks|Writing sessions to explore daily activities.
48385748|NCT03763539|PROCEDURE|SWL|Shock wave lithotripsy
48385749|NCT06565169|BEHAVIORAL|Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training|Included in arm/group descriptions
48385750|NCT06565169|BEHAVIORAL|Care as Usual|Included in arm/group descriptions
48385751|NCT01145872|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
48385752|NCT01145872|BEHAVIORAL|Health Enhancement Program|
48385753|NCT03265483|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
48385754|NCT03265483|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
48521234|NCT01037452|DRUG|Lansoprazole|Tablet
48521235|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide|Tablet
48183600|NCT05030051|DEVICE|SkinPen Precision System|Microneedling is a relatively new, minimally invasive technique originally developed for skin rejuvenation. Controlled micro-injury to the dermis via the application of several small needles connected to a motorized device stimulates the wound healing process, resulting in the formation of new tissue and blood vessels. The SkinPen by Crown Laboratories is an FDA-cleared microneedling device proven to improve the appearance of acne scars This study evaluates the clinical performance of the SkinPen device for the treatment of signs of aging on the back of the hand. We hypothesize that the SkinPen device will produce a significant improvement in dorsal hand appearance at 3 month post treatment visit, when compared with baseline scores. The assessments will be based on the Clinician's Global Aesthetic Improvement Scale, and the Subject's Global Aesthetic Improvement Scale at the 3 month post treatment visit.
48183601|NCT05735665|DIAGNOSTIC_TEST|bowel ultrasound|Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.
48183602|NCT05735665|DIAGNOSTIC_TEST|colonoscopy|Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
48183603|NCT04060199|DRUG|Viltolarsen|IV infusion
48183604|NCT04060199|DRUG|Placebo|IV infusion
48385755|NCT04690959|OTHER|neural mobilization|Neural mobilization, or neurodynamics, is a movement-based intervention aimed at restoring the homeostasis in and around the nervous system.
48385756|NCT04690959|OTHER|Sham intervention|it is faked neural mobilization that mimic the neural mobilization treatment but believed not to stress the neural tissues in the upper extremity.
48521236|NCT01037452|DRUG|Placebo|Tablet
48521237|NCT04691427|DEVICE|Virtual Eye Rotation Vision Exercises (VERVE)|A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).
48521238|NCT02860546|DRUG|TAS-102|One Arm Only (of TAS 102 plus nivolumab)
48521239|NCT02860546|DRUG|nivolumab|One Arm Only (of TAS 102 plus nivolumab)
48385757|NCT06566352|PROCEDURE|Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine|intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution
48385758|NCT06566352|PROCEDURE|traditional laparoscopic myomectomy|traditional laparoscopic myomectomy
48385759|NCT06566352|PROCEDURE|laparoscopic myomectomy with temporary bilateral uterine artery occlusion|Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
48385760|NCT06566352|DRUG|injection of epinephrine 1mg diluted in 200mg of NaCl|injection of epinephrine 1mg diluted in 200mg of NaCl
48385761|NCT04865887|DRUG|Pembrolizumab|200mg, every 3 weeks, IV infusion
48521240|NCT06437015|DIAGNOSTIC_TEST|Constraint-Induced Movement Therapy|patient's unaffected hand is tied with a triangular bandage or splint and the patient asks to perform the exercise through the affected hand. for up to 6 hours a day for 5days week /4 weeks and the patient nonparetic arm restrained from the use by having the patient placing a mitt on the hand or a sling on the unaffected hand, forcing the use of the affected limb to promote purposeful movements when performing functional tasks.
48521241|NCT06437015|OTHER|Mirror Therapy|In this group training was given for 45min a day for 5 days a week for 4 weeks. Mirror box which was of 18×24inch \[was placed on the learning table and exercises were carried out by the patient looking into the mirror where an unaffected limb is placed in front of the mirror, through looking into the mirror patient assumes the reflection of the unaffected limb as the paretic limb. Exercises performed were hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation
48521242|NCT03642197|BEHAVIORAL|Attendance|The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
48521243|NCT06107569|OTHER|Fecal microbiota transplant (Promicrobioma)|Fecal microbiota transplant with Promicrobioma (freeze-dried isolated microbiota)
48521244|NCT06107569|DRUG|Antibiotic|Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.
48521245|NCT06132373|BEHAVIORAL|Peer delivered problem solving therapy|PST uses a straightforward approach amenable to use in new settings given its focus on idiographic problems, therefore session content is driven by the adolescent's presenting problem causing the most distress or impairment. We will use the standardized, core steps of PST and existing manualized protocols including from the Friendship Bench study and the WHO protocol for Problem Management Plus. The peers will deliver PST through 5 structured counseling sessions of 30-60 minutes over a 4-6 week period. There are 5 core components of PST which including problem listing and identification, problem exploration, developing an action plan, implementation, and follow up. The components will be introduced in the first session and be reviewed in an iterative process across the session to help participants use this model for different problems.
48521246|NCT04977804|OTHER|Exercise|The interventions are a form or exercise, specifically resistance exercise.
48385762|NCT04865887|DRUG|Lenvatinib|20 mg (2 capsules x10mg), daily, orally
48385763|NCT03660007|PROCEDURE|Fresh or frozen embryo transfer IVF|
48385764|NCT03361527|OTHER|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
48385765|NCT05570058|DRUG|RXC007|RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
48385766|NCT05570058|DRUG|Placebo|The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
48521247|NCT04977804|OTHER|Eccentric plus blood-flow restriction|Eccentric plus blood-flow restriction
48521248|NCT05611983|BEHAVIORAL|sensory relearning|feasibility of early sensory relearning
48521249|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs."
48521250|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
48725039|NCT04117698|DRUG|RIFINAH ©|RIFINAH ©
48521251|NCT02074150|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
48183605|NCT06265324|DEVICE|Angioplasty|Drug-coated balloons angioplasty for treatment of de novo and in-stent restenosis lesions
48183606|NCT01338376|BEHAVIORAL|Structured Education|"All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~* Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~* Physician Activity: frequent insulin titration"
48385767|NCT06197698|DIAGNOSTIC_TEST|F18-FDG, Tc-99m TRODAT-1|In this project, 18F-FDG PET is used as an imaging marker of gut microbiota composition evaluation in PD patients, and the nigrostriatal dopamine system is assessed by Tc-99m TRODAT-1 SPECT.
48385768|NCT03312881|DIAGNOSTIC_TEST|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
48385769|NCT03312881|DIAGNOSTIC_TEST|neuroimaging|magnetic resonance imaging (MRI)
48385770|NCT03312881|OTHER|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
48521252|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521253|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521254|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521255|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521256|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521257|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521258|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521259|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48725040|NCT00450034|PROCEDURE|drug - oriented multifaceted intervention|oriented multifaceted intervention
48725041|NCT06422637|DIAGNOSTIC_TEST|Liquid Biopsy Early Screening|An early screening model for lung cancer aids in identifying individuals with early-stage lung cancer. Those with positive indications of lung cancer will subsequently undergo confirmatory clinical assessments using Low-Dose Computed Tomography (LDCT) in sequence. Ultimately, a definitive diagnosis of lung cancer is established through surgical and pathological examination.
48725042|NCT00940784|DRUG|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
48725043|NCT00940784|DRUG|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
48725044|NCT00940784|DRUG|Aspirin|81-100 mg qd
48725045|NCT04506203|DIAGNOSTIC_TEST|Air test|Patients will breathe 0.21 \< FiO2 \< 0.25 during 5 min and have a lung ultrasound perfomed at the end of the 5 min trial.
48725046|NCT05684185|BIOLOGICAL|Intramuscular (IM) rabies post-exposure prophylaxis|one-site, 0.5 mL at Day 0, D3, D7 and D14
48725047|NCT05684185|BIOLOGICAL|Intradermal (ID) rabies post-exposure prophylaxis|two-site, 0.1 mL at Day 0, D3 and D7
48183607|NCT01338376|BEHAVIORAL|Conventional Diabetes Education|"The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~* Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~* Physician Activity: less frequent insulin titration"
48183608|NCT01338376|DRUG|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
48183609|NCT01611961|DRUG|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
48183610|NCT01611961|DRUG|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
48385771|NCT05393830|BEHAVIORAL|Sleep Restriction|Three nights of sleep restricted to 4 hours per night.
48385772|NCT06225401|OTHER|Simcapture PRE|Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom
48385773|NCT06225401|OTHER|Simcapture POST|Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
48385774|NCT06470087|DEVICE|SOC and Type-I Collagen-based Skin Substitute|Arm 1 -The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
48385775|NCT06470087|OTHER|SOC and Human Amnion/Chorion Membrane|Arm 2: The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
48385776|NCT00326339|DRUG|R788|R788 50 mg, 100 mg, or 150 mg PO bid
48385777|NCT00326339|DRUG|Placebo|Placebo PO bid
48385778|NCT06318975|BEHAVIORAL|Brief Alcohol Intervention|All Airmen will receive a standard BAI during the 4th week of Technical Training, the last week of enforced abstinence. The BAI is a group-based, one-hour session which includes the following components: Interactive discussion of the positives and negatives of drinking during training and heavy vs. moderate drinking; Discussion of USAF rules on alcohol use and penalties for violations; Discussion of impact of alcohol on military readiness; effects of alcohol and hangover on performance; Review of standard drinks, blood alcohol levels and tolerance; and normative feedback on the Airmen's drinking level compared to others. We will engage in a conversation about whether they have observed concerning patterns of alcohol misuse among other USAF personnel, and how to handle this, along with harm reduction and alcohol refusal strategies.
48385779|NCT06318975|BEHAVIORAL|Automated and Targeted Text Messages|All messages are pre-written, and their timing is pre-planned - All Airmen will start receiving 3-5 text messages per week starting the Monday after they received the Brief Alcohol Intervention and lasting for six weeks. The intervention is also targeted to age, with some messaging differing for Airmen less than 21 years and those already 21 years old or who will turn 21 during the intervention period. All Airmen randomized to the text message arm will be enroll into the supplemental program, and may opt out at any time. Messages reinforce content of the BAI and provide additional, actionable advice on reducing or avoiding alcohol in more detail and specificity than time typically allows for during the BAI. Messages are sent on days and at times that were indicated as being preferred during formative development of the intervention. Messages are designed to maintain or enhance skill building. No drinking behavior is collected as part of the text messaging intervention
48385780|NCT06250972|DRUG|Gemcitabine, Nab-paclitaxel, Irinotecan|continuing chemotherapy using the previous regimen until disease progression
48385781|NCT06250972|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Receive Intensity-Modulated Radiation Therapy (IMRT) after about 2\~6 cycles of chemotherapy.
48385782|NCT06605157|BEHAVIORAL|AMUSED|Delivered live by a board-certified music therapist (MT-BC) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. A Multimodal mUSic therapy intervention for Engaging persons with severe Dementia (AMUSED) uses live participant-preferred music and progressively layers singing, touch, and rhythmic instrument playing concurrent with participant behavioral responses. Follows the Clinical Practice Model for Persons with Dementia and implementation strategies that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. Each small group works with the same music therapist throughout the study.
48725048|NCT04736134|BIOLOGICAL|BMS-986326|Specified dose on specified days
48725049|NCT04736134|OTHER|Placebo matching BMS-986326|Specified dose on specified days
48725050|NCT04736134|BIOLOGICAL|Multiple Ascending Dose SC|Specified dose on specified days
48725051|NCT04736134|OTHER|Multiple Ascending Dose Placebo|Specified dose on specified days
48725052|NCT05823272|OTHER|ONS|oral nutritional supplement
48725053|NCT05856565|OTHER|Photo|Photography intake
48725054|NCT02463864|OTHER|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
48725055|NCT02463864|OTHER|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
48725056|NCT05152810|OTHER|Transcranial Magnetic Stimulation sessions|"* 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase"
48026961|NCT06534203|OTHER|Investigation - Observational Study|In this study, there will be no intervention, instead, it will be an observational study aimed at identifying the specific physical demands of caregivers working in long-term care facilities. This information will inform future interventions that can help reduce the occurrence of work-related musculoskeletal injuries.
48026962|NCT00280332|PROCEDURE|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
48725057|NCT05152810|OTHER|Evaluations|"Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI."
48729834|NCT04552106|DIETARY_SUPPLEMENT|3 caps x1/day|3 capsules 1 times daily for 28 days
48729835|NCT06155539|OTHER|No intervention|No intervention
48026963|NCT05864339|BEHAVIORAL|A designed empathy intervention|Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.
48026964|NCT05864339|BEHAVIORAL|Smoking cessation counseling tutorial|Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
48183611|NCT06109610|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment will be offered to participants free of charge. Cognitive Behavioral Therapy (CBT) sessions will be delivered in a group therapy format and the sessions will be offered in successive weeks. The protocol will be then administered to the intervention group (in 8 groups over a period of six months, eight sessions, each of 30 minutes' length).
48183612|NCT01327846|DRUG|Canakinumab|
48183613|NCT01327846|DRUG|Placebo|
48183614|NCT01327846|DRUG|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
48183615|NCT00038480|DRUG|Lopinavir/Ritonavir|
48183616|NCT02714712|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
48183617|NCT05445063|BIOLOGICAL|Autologous iPSC-derived RPE|Autologous transplantation of iPSC-derived RPE
48183618|NCT03436303|DRUG|CEE 0.625 mg/MP 100mg|CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
48183619|NCT03436303|DRUG|CEE 0.3 mg/MP 100mg|CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
48183620|NCT03436303|DRUG|CEE 0.625mg/dydrogesterone|CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
48725058|NCT06531317|DEVICE|transcranial Direct Current Stimulation|The treatment follows an approved neuromodulation protocol at our center (approved on Nov. 4 2021, valid until Nov. 4 2024). tDCS will be administered with a battery-powered DC stimulator (Sooma tDCS, Helsinki, Finland), using saline-saturated circular electrodes with a diameter of 6 cm². The anode will be positioned over C3 to stimulate the primary motor cortex (M1), and the cathode over the contralateral supraorbital area (FP2). For asymmetric pain, stimulation targets the M1 contralateral to the more painful side, and for symmetric pain, the dominant hemisphere (C3) is stimulated. The maximum current is 2 mA (current density: 0.06 mA/cm²). Each session lasts 30 minutes, conducted daily for two weeks (Monday to Friday), totaling 10 sessions. All stimulation parameters adhere to general safety guidelines for transcranial electrical stimulation (Bikson et al., 2016).
48725059|NCT06531317|DIAGNOSTIC_TEST|Electroencephalography|64-channel active-electrode EEG with impedances kept \~5KOhm
48725060|NCT05859750|DRUG|AK104|AK104 (6mg/kg) on day 1, IV, Q2W
48183621|NCT01001390|DEVICE|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
48183622|NCT00799955|PROCEDURE|Placebo block|100 micrograms of spinal morphine
48183623|NCT00799955|PROCEDURE|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
48183624|NCT00209664|DRUG|irinotecan|
48183625|NCT00209664|DRUG|S-1|
48183626|NCT00847522|DRUG|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
48388066|NCT06101719|DIAGNOSTIC_TEST|Enteral contrast challenge|Contrast agent, volume of contrast, and contrast dilution were not standardized across sites due to the differences in hospital specific formularies; otherwise, the protocol was standardized across sites. Diatrizoate meglumine (osmolality of 1940 mOsm/kg) was used preferentially at eight sites and Ioversol (702 mOms/kg) at one site. Patients received 30-200ml (based on age or weight depending on site) of enteral contrast followed by X-rays at 8-12 hours and 24 hours after contrast administration.
48725061|NCT05859750|DRUG|AK104|AK104 (10mg/kg) on day 1, IV, Q2W
48725062|NCT05859750|DRUG|Gemcitabine|Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
48725063|NCT05859750|DRUG|Nab-Paclitaxel|Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
48725064|NCT06301750|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
48183627|NCT04403542|DEVICE|Lehfilcon A contact lens|Investigational silicone hydrogel contact lens
48183628|NCT04403542|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
48183629|NCT05457166|DEVICE|KASPARD system for fall prevention in nursing homes|"All subjects will be monitored for 2 periods of 100 nights each. Recordings will be made continuously at night for the duration of the study Period 0: set-up, adjustment, recording (without alarm); This is a preparatory phase which is part of the usual use of the device.~Duration: 10 days Before period: The BEFORE period runs for 100 nights during which the device alarm is not activated, but the device records events.~After period: The AFTER period is 100 nights during which the device alarm is activated: Monitoring with recording + alarm activated (usual care + action if alarm is triggered)"
48183630|NCT04569019|OTHER|Vacciantion status in health care workers|Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
48183631|NCT01938053|OTHER|Call when test results are ready|Patients are called when the test results are ready
48183632|NCT01938053|OTHER|Text message when test results are ready|Patients receive a text message when results are ready
48725065|NCT06301750|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
48385783|NCT06605157|BEHAVIORAL|Reading Aloud|"Delivered live by a trained research assistant (interventionist) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. The interventionist will read aloud from age-appropriate books (Chicken Soup for the Golden Soul by Jack Canfield; World of Wonders by Aimee Nezhukumatathil) selected to have sufficient material for all sessions, contain short stories to accommodate for attention span and session length, and offer choice. Follows implementation strategies identical to the music therapy arm (i.e., within the Clinical Practice Model for Persons with Dementia) that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. However, no music (including musical references) is used. Each small group works with the same reading interventionist throughout the study."
48521260|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521261|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
48521262|NCT02074150|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
48725066|NCT06301750|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
48725067|NCT03149029|DRUG|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
48725068|NCT03149029|DRUG|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
48725069|NCT03149029|DRUG|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
48725070|NCT00240383|DRUG|Muraglitazar|
48725071|NCT02859896|DRUG|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
48725072|NCT02859896|DRUG|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
48026965|NCT01381172|DEVICE|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
48026966|NCT01381172|OTHER|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
48026967|NCT01777919|DRUG|Temozolomide|
48026968|NCT01777919|DRUG|Disulfiram|
48026969|NCT01777919|DRUG|Copper|
48026970|NCT00650468|DRUG|tacrolimus|Oral
48026971|NCT00650468|DRUG|CellCept|IV or Oral
48026972|NCT00650468|DRUG|steroids (methylprednisone or prednisone)|IV or Oral
48026973|NCT05542368|DIAGNOSTIC_TEST|Thyroid tests|Thyroid function test TSH ,T3,T4 Thyroid antibody test anti TPO,antithyroglobulin
48026974|NCT02376907|PROCEDURE|Biliary drainage|EUS-BD or ERCP
48026975|NCT04896489|DRUG|Hydrocortisone 20 MG|Participants receive Hydrocortisone 20 MG
48026976|NCT04896489|OTHER|Placebo|Participants receive placebo
48026977|NCT06627504|BEHAVIORAL|Sleep Health and Circadian Timing Intervention|Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
48026978|NCT01954654|DEVICE|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
48026979|NCT01954654|OTHER|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
48026980|NCT00345774|DRUG|PRX-08066|
48026981|NCT06115759|BEHAVIORAL|T-REX Twente precautions|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
48385784|NCT03130777|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
48385785|NCT05678101|DEVICE|transcutaneous electrical nerve stimulation (TENS)|Chattanooga Physio TENS (DJO Global, Vista, CA)
48521263|NCT02074150|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
48521264|NCT03487471|DIAGNOSTIC_TEST|Real-time elastography|Breast ultrasound with real-time elastography
48521265|NCT03487471|DIAGNOSTIC_TEST|Shear wave elastography|Breast ultrasound with shear wave elastography
48521266|NCT05573958|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban 2.5 mg oral tablet will be administered twice daily
48725073|NCT00471887|BIOLOGICAL|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
48725074|NCT06106763|OTHER|Mandala coloring|Mandala coloring page
48725075|NCT04520724|DIETARY_SUPPLEMENT|plant fiber|The patients with NAFLD (study and control group) will receive low-processed rolls with an 12 g plant fiber content twice daily, which would be a convenient for easy replenishment of the amount of vegetable fiber (act as prebiotic) in the diet. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
48725076|NCT04520724|DIETARY_SUPPLEMENT|maltodextrin bar|The patients with NAFLD (placebo group) will receive maltodextrin bars twice daily, which would be a convenient and easy-to-eat snack replacing the second breakfast and afternoon tea. The bars must be eaten with 180 ml of water or unsweetened liquid. The intervention will be preceded by a 21 day wash-out period during which subjects will be asked to avoid foods containing large amount of fiber.
48725077|NCT00410306|DRUG|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
48725078|NCT05432479|DIETARY_SUPPLEMENT|Probiotic|Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks
48725079|NCT05432479|DIETARY_SUPPLEMENT|Placebo|Placebo
48725080|NCT01896583|DRUG|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
48725081|NCT01896583|DRUG|Placebo|
48725082|NCT02441556|DEVICE|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
48725083|NCT02441556|OTHER|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
48725084|NCT01409369|DRUG|RO4995819|single oral dose
48725085|NCT01409369|DRUG|activated charcoal|orally 3 times daily, Days 1-7
48725086|NCT00317408|BIOLOGICAL|anti-thymocyte globulin|
48725087|NCT00317408|DRUG|busulfan|
48725088|NCT00317408|DRUG|carboplatin|
48385786|NCT05678101|DEVICE|Sham transcutaneous electrical nerve stimulation (TENS)|Sham treatment with Chattanooga Physio TENS (DJO Global, Vista, CA)
48725089|NCT00317408|DRUG|carmustine|
48725090|NCT00317408|DRUG|cyclosporine|
48725091|NCT00317408|DRUG|cytarabine|
48725092|NCT00317408|DRUG|dexamethasone|
48725093|NCT00317408|DRUG|etoposide phosphate|
48725094|NCT00317408|DRUG|idarubicin|
48725095|NCT00317408|DRUG|ifosfamide|
48725096|NCT00317408|DRUG|leucovorin calcium|
48725097|NCT00317408|DRUG|lomustine|
48725098|NCT00317408|DRUG|melphalan|
48725099|NCT00317408|DRUG|methotrexate|
48725100|NCT00317408|DRUG|mitoxantrone hydrochloride|
48385787|NCT06652633|GENETIC|GLPG CAR T-cell therapy|No investigational products will be administered to participants in this study.
48385788|NCT04613310|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
48385789|NCT02952300|PROCEDURE|neolix|single rotation file
48385790|NCT02952300|PROCEDURE|wave one|single reciprocation file
48521267|NCT05573958|DRUG|Clopidogrel tablet|Clopidogrel 75 mg once daily orally
48521268|NCT05573958|DRUG|Aspirin tablet|Aspirin 81 mg tablet once daily
48521269|NCT05475314|DIETARY_SUPPLEMENT|ReFerm(R)|Enemas of approx 250 mL twice daily
48521270|NCT05881824|BEHAVIORAL|MDG intervention|6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
48521271|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
48725101|NCT00317408|DRUG|prednisolone|
48725102|NCT00317408|DRUG|thiotepa|
48725103|NCT00317408|DRUG|vinblastine sulfate|
48725104|NCT00317408|DRUG|vindesine|
48725105|NCT00317408|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
48725106|NCT00317408|PROCEDURE|autologous hematopoietic stem cell transplantation|
48725107|NCT00317408|PROCEDURE|peripheral blood stem cell transplantation|
48725108|NCT00317408|RADIATION|total-body irradiation|
48725109|NCT00599508|DIETARY_SUPPLEMENT|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
48725110|NCT00599508|DIETARY_SUPPLEMENT|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
48026982|NCT06115759|BEHAVIORAL|Usual (restrictive) sternal precautions|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
48026983|NCT04858737|BEHAVIORAL|e-predictD-Work intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
48026984|NCT04858737|OTHER|Brief psychoeducational messages|The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
48026985|NCT05015894|DRUG|NNC0480-0389|"A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days"
48026986|NCT03022851|DEVICE|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
48026987|NCT05707234|DEVICE|VRH|The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
48725111|NCT00599508|DIETARY_SUPPLEMENT|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
48725112|NCT00599508|DIETARY_SUPPLEMENT|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
48725113|NCT00599508|DIETARY_SUPPLEMENT|berry placebo powder|berry placebo powder administered daily for 16 weeks
48725114|NCT00309062|BIOLOGICAL|Recombinant birch pollen|
48026988|NCT05707234|DRUG|Midazolam sedation|During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
48026989|NCT04780204|DRUG|Treatment|Tenofovir Alafenamide 25 mg oral once daily
48183633|NCT01938053|OTHER|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
48183634|NCT01044927|OTHER|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
48183635|NCT01044927|OTHER|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
48385791|NCT05920031|OTHER|Cross-education|Participants will perform resistance exercises at 60% of their 1 repetition maximum (1RM) with the less affected limb. The intervention will be performed three times per week for 8 weeks. Each session will consist of three sets of 15 repetitions of bicep curls, tricep extensions, and wrist flexion/extension exercises with a 1-minute rest period between sets. The exercises will be performed in a seated position, with the participant's forearm resting on a table and the therapist providing manual resistance. The therapist will be positioned in front of the participant.
48521272|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
48521273|NCT01047514|BEHAVIORAL|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
48521274|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
48521275|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
48521276|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
48521277|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
48725115|NCT03407885|OTHER|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
48183636|NCT00913523|DEVICE|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
48521278|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
48725116|NCT05546671|DIAGNOSTIC_TEST|Hand grip strength measurement|"Preoperative hand grip strength will be measured in kilograms using a digital hand dynamometer (Baseline Smedley Digital Hand Dynamometer, Model 12-0286, Baseline Evaluation Instruments, China). Participants will be instructed to grip the hand dynamometer for 5 seconds with their dominant hand 3 times. They will be allowed to rest for 20 second between each grip. The highest measurement of 3 attempts will be recorded. Participants will be categorized as strong grippers or weak grippers according to Fried criteria as previously defined by Linda P. Fried and colleagues. A weak grip will be defined as follows:~For men:~BMI ≤24: hand grip strength ≤29 kg; BMI =24.1 to 28: hand grip strength ≤30 kg; BMI \>28: hand grip strength ≤32 kg~For women:~BMI ≤23: hand grip strength ≤17 kg; BMI =23.1 to 26: hand grip strength ≤17.3 kg; BMI =26.1 to 29: hand grip strength ≤18 kg; BMI \>29: hand grip strength ≤21 kg"
48725117|NCT06160830|DIETARY_SUPPLEMENT|synbiotic|Two capsules of synbiotic per day, each containing 500 mg of synbiotic
48725118|NCT06160830|OTHER|placebo|Two capsules of placebo containing maltodextrin per day
48725119|NCT00257660|BIOLOGICAL|Botulinum toxin type A|500 units
48725120|NCT00257660|DRUG|Placebo|500 units
48725121|NCT04809155|BEHAVIORAL|Girl2Girl|The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
48725122|NCT05523375|BEHAVIORAL|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
48725123|NCT06172946|DEVICE|powerbreath|Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise. (Gandullo et al., 2022)
48725124|NCT06172946|DEVICE|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness. A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS. (Hsin et al., 2022)
48725125|NCT03927404|DEVICE|Active vacuum test prosthesis|The adaptive vacuum prosthesis is sold as a commercial device by the company Willow Wood with suggested U.S. L-Code L5781. The device is designated as a Class 1 Medical Device and 510(K) Exempt. This category is part of a low or moderate risk to patient safety and health. The Prosthetic socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
48725126|NCT05512013|DRUG|Ibuprofen 800 mg|Ibuprofen taken orally 2 hours prior to exercise
48725127|NCT05512013|DRUG|Celecoxib 200mg|Celebrex taken orally 2 hours prior to exercise
48725128|NCT05512013|DRUG|Flurbiprofen 100 mg|Flurbiprofen taken orally 2 hours prior to exercise
48725129|NCT05512013|DRUG|Placebo|Inert placebo taken orally 2 hours prior to exercise
48725130|NCT04787185|RADIATION|Valutation of toxicity|"Observation of toxicity~All patient with Brain metastases from NSCLC who are candidates for RS or HFSRT in course of immunotherapy"
48725131|NCT01252524|DRUG|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
48725132|NCT01252524|DRUG|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
48725133|NCT01230138|DRUG|Placebo|Placebo tablets
48725134|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 250mg TID
48725135|NCT01230138|DRUG|FP187|High daily dose of 750mg administered as 375mg BID
48725136|NCT01230138|DRUG|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
48725137|NCT01230138|DRUG|FP187|Oral tablets, up to 3 times daily for 20 weeks.
48725138|NCT00885300|DRUG|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
48725139|NCT00885300|DRUG|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
48725140|NCT00953563|DEVICE|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
48725141|NCT00604617|PROCEDURE|Interferon-Gamma Release Assay|IGRAs
48183637|NCT00913523|DEVICE|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
48725142|NCT00604617|DRUG|RT-23|TST - tuberculin skin test
48183638|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
48183639|NCT01648153|OTHER|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
48521279|NCT04447040|DRUG|Placebo|Placebo tablets administered as a single two-tablet dose.
48725143|NCT03289117|DEVICE|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
48725144|NCT03289117|DEVICE|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
48725145|NCT04915417|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Patients will receive 27-30 Gy in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost to the metabolically active areas of the gross tumor volume (GTV) to a maximum of 45 Gy. Patients will be treated every other day.
48725146|NCT06166329|OTHER|chair lift test|repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
48725147|NCT03429257|OTHER|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
48725148|NCT00519662|DRUG|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
48725149|NCT06050486|BEHAVIORAL|Mentalization-based treatment for children (MBT-C)|MBT-C is a time-limited intervention designed to resolve the child's emotional or behavioral problems and to promote resilience, by promoting the child's and parent's mentalizing capacities. It is composed by 1) an assessment phase, composed of 3 to 4 sessions, with the family, the child and the parent(s), 2) an intervention phase, composed of a minimum block of 12 individual sessions with the child and parallel sessions for the parent(s), that can be repeated up to three times (i.e., maximum of 36 sessions), and 3) a booster session 3 to 12 months after the last session. In this clinical trial, MBT-C will be composed of: 3 assessment sessions; 12 individual sessions with the child, plus 6 parallel individual sessions with the parent with BPD; 1 booster family session, 3 months after the last session.
48026990|NCT06446635|DEVICE|Semiflex Dome Catheter System|"Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter."
48026991|NCT04553952|OTHER|Measurement of gingival display|"All individuals were instructed to sit on a dental chair and the measurements were made by using a millimetric ruler. Next, the patients were grouped according to Liebart's classification by gingival display at maximum smile as follows:~Class 1.Excessive gingival display (Gummy smile): ≥ 3mm gingival display Class 2.High smile line: 0-2 mm of gingival display Class 3. Average smile line: Dental papilla is visible. Class 4. Low smile line: Gingival margin, dental papilla is not visible at all."
48521280|NCT01036854|DRUG|EUR-1025|orally, 24 mg, daily for 6 days
48026992|NCT06100926|DEVICE|software|virtual reality scene
48026993|NCT03956303|DRUG|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
48026994|NCT03956303|DRUG|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
48026995|NCT03956303|DRUG|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
48026996|NCT03956303|DRUG|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
48026997|NCT03021382|OTHER|data collection, non-intervention|
48026998|NCT02473614|DEVICE|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimum of 3 hours per week.
48521281|NCT01036854|DRUG|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
48521282|NCT01036854|DRUG|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
48521283|NCT01036854|DRUG|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
48521284|NCT02698163|DEVICE|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
48521285|NCT02698163|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
48521286|NCT06150248|OTHER|Education Intervention|"This intervention is based on the Social Cognitive Theory (SCT) and The Health Belief Model (HBM) to improve knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
48521287|NCT06150248|OTHER|No intervention|They will have their regular curriculums and normal physical activity routine.
48521288|NCT05664269|DIETARY_SUPPLEMENT|drink ingestion|drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
48026999|NCT02473614|OTHER|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimum of 3 hours per week.
48027000|NCT06536309|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titrated to maximally targeted dose
48027001|NCT06536309|DRUG|Valsartan|Valsartan titrated to maximally targeted dose
48027002|NCT00127608|PROCEDURE|Collection of clinical samples|"The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
48183640|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
48521289|NCT05664269|BEHAVIORAL|resistance-type exercise|Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
48183641|NCT00612118|DRUG|GSK256066|200mcg bd
48183642|NCT00612118|DRUG|azelastine hydrochloride|140mcg
48725150|NCT02472613|DEVICE|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
48725151|NCT02472613|DRUG|placebo|Placebo was given for 12 consecutive weeks.
48725152|NCT02472613|DEVICE|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
48725153|NCT02472613|DRUG|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
48725154|NCT05563467|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
48725155|NCT05553418|DEVICE|In-clinic wear first|Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection
48725156|NCT05553418|DEVICE|Home wear first|Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
48725157|NCT03597061|BEHAVIORAL|Healthy Start to Feeding|The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
48183643|NCT02379143|OTHER|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
48183644|NCT00903825|PROCEDURE|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (\< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
48385792|NCT05920031|OTHER|Mirror therapy|Participants will perform bilateral upper limb movements while observing the reflection of the less affected limb in a mirror. The intervention will be performed three times per week for 8 weeks. Each session will consist of 10 minutes of mirror therapy, with the participant seated in front of a mirror. The participant will perform various upper limb movements, such as reaching and grasping, while observing the mirror reflection of the less affected limb. The therapist will be positioned beside the participant, providing verbal cues and feedback as necessary.
48521290|NCT00419497|BEHAVIORAL|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
48385793|NCT05920031|OTHER|Conventional Physical Therapy|articipants will receive conventional rehabilitation for post-stroke upper limb motor impairments, which may include exercises such as range of motion, stretching, and strengthening of the affected limb, as well as other therapies such as electrical stimulation or constraint-induced movement therapy. The intervention will be individualized for each participant and will be performed three times per week for 8 weeks. The frequency, duration, and intensity of the exercises will be gradually increased over the course of the intervention, based on the participant's progress. The exercises may be performed in a seated or standing position, depending on the participant's ability and preference. The therapist will be positioned in front of or beside the participant, providing verbal cues and feedback as necessary.
48385794|NCT02980029|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
48385795|NCT02980029|OTHER|Placebo|Placebo
48183645|NCT00903825|PROCEDURE|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
48183646|NCT01275781|DRUG|[14C]-AZD9742|1000 mg intravenous over 2 hours
48385796|NCT06335511|PROCEDURE|microsurgical decompression|decompression of neurological structures
48385797|NCT06335511|PROCEDURE|decompression and instrumented fusion|decompression of neurological structures and spine stabilization
48385798|NCT04484805|DEVICE|ICE Condition|Experimental socket integrated with a heat spreader. An ICE Unit (includes TEC) is attached to the socket.
48183647|NCT02347995|OTHER|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
48385799|NCT04484805|DEVICE|Sham Condition|Experimental socket integrated with a heat spreader. A Sham Unit (excludes TEC) is attached to the socket.
48385800|NCT03914625|DRUG|Asparaginase Erwinia chrysanthemi|Given IV or IM
48385801|NCT03914625|BIOLOGICAL|Blinatumomab|Given IV
48183648|NCT02347995|OTHER|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
48183649|NCT01031498|DRUG|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
48385802|NCT03914625|DRUG|Cyclophosphamide|Given IV
48385803|NCT03914625|DRUG|Cytarabine|Given IT or IV
48385804|NCT03914625|DRUG|Dexamethasone|Given PO or IV
48725158|NCT06506877|BEHAVIORAL|Implementation of Cognitive Risk Calculator (RC) and Brief Assessment of Cognitive Health (BACH)|Enrolled providers will have access to two cognitive screening tools during the active phase. The first tool is a Cognitive Risk-Calculator (RC), integrated into the Electronic Health Record, to help providers identify patients who are at high risk of exhibiting cognitive decline. The second tool is a computerized cognitive screening tool, the Brief Assessment of Cognitive Health (BACH), which patients complete independently. Results are automatically entered into the patient's medical record, along with patient-specific flags for concerns about depression and/or sleep disorder. The purpose of these tools is to facilitate cognitive screening and treatment for factors that may be contributing to cognitive decline.
48725159|NCT05591716|PROCEDURE|Bilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis.The ureteroscope was extracted together with the case with the ureteral revision: there was no damage to the ureter.Next, this procedure is performed from the other side. Urine was excreted from the bladder using a Nelaton catheter.
48725160|NCT05591716|PROCEDURE|Unilateral same-session flexible ureterorenoscopy|The patient was in the lithotomic position. A semi-rigid ureteroscope was passed into the bladder, then a roadrunner was placed. A flexible urethroscope is guided along the roadrunner to the kidney. In the kidney, the concrement is fragmented with laser energy. The fragments were extracted using a basket. Then a revision of the kidney is performed using a flexible urethroscope. A ureteral stent was placed in the pelvis. The ureteroscope was extracted together with the body with revision of the ureter: there was no damage to the ureter. Urine was excreted from the bladder using a Nelaton catheter.
48183650|NCT01031498|DRUG|Palonosetron|"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."
48183651|NCT00776022|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
48183652|NCT00494468|DRUG|Zolpidem|
48385805|NCT03914625|DRUG|Doxorubicin Hydrochloride|Given IV
48385806|NCT03914625|DRUG|Leucovorin Calcium|Given PO or IV
48385807|NCT03914625|DRUG|Mercaptopurine|Given PO
48385808|NCT03914625|DRUG|Mercaptopurine Oral Suspension|Given PO
48385809|NCT03914625|DRUG|Methotrexate|Given IT or IV
48385810|NCT03914625|DRUG|Pegaspargase|Given IV or IM
48385811|NCT03914625|DRUG|Prednisolone|Given PO or IV
48385812|NCT03914625|DRUG|Prednisone|Given PO or IV
48385813|NCT03914625|RADIATION|Radiation Therapy|Undergo cranial radiation therapy
48385814|NCT03914625|RADIATION|Radiation Therapy|Undergo testicular radiation therapy
48385815|NCT03914625|DRUG|Thioguanine|Given PO
48725161|NCT01675362|DRUG|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
48725162|NCT01675362|DRUG|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
48725163|NCT01675362|DRUG|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
48183653|NCT04394195|OTHER|measurement of circulating sFlt1 concentration|blood circulating sFlt1 concentration will be determined
48183654|NCT02328586|OTHER|Group Acupuncture|
48183655|NCT02349945|DRUG|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage \> 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
48183656|NCT02322086|DRUG|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
48183657|NCT03689777|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
48183658|NCT03689777|PROCEDURE|gastric bypass|gastric bypass
48183659|NCT05371106|OTHER|exposure to mycotoxins|self-report eating questionnaire
48183660|NCT04642547|DRUG|Lenvatinib and Gefitinib|"First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral."
48183661|NCT05654233|DRUG|Sulodexide|The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
48183662|NCT01828086|BIOLOGICAL|CJM112|Monoclonal antibody
48183663|NCT01828086|BIOLOGICAL|Secukinumab|Monoclonal antibody
48183664|NCT01828086|OTHER|Placebo|Liquid for subcutaneous injection without active drug.
48521291|NCT03438838|PROCEDURE|Laparoscopic Heller's myotomy|"Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach"
48521292|NCT03438838|PROCEDURE|Anterior Fundoplication|The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
48521293|NCT00461916|DRUG|Half-Dose Depot Triptorelin|
48521294|NCT00461916|DRUG|Reduced-Dose Daily Buserelin|
48521295|NCT04443972|OTHER|PD VitalOs cement®|PD VitalOs cement®\* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery
48521296|NCT04443972|OTHER|Hydroxyapatite bone graft|a bioceramic bone substitute, providing a scaffold for bone deposition
48725164|NCT01675362|DRUG|Placebo|They will receive placebo
48725165|NCT03688555|DRUG|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
48725166|NCT03688555|DRUG|Placebo|Matching placebo hard gelatin capsules
48725167|NCT02258113|DEVICE|Ocusweep|A novel reaction-time based visual field device.
48183665|NCT02711319|DEVICE|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
48183666|NCT02711319|DEVICE|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
48183667|NCT03219762|DRUG|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
48183668|NCT01240915|DRUG|placebo|once every 7 days for 1- 3 doses
48183669|NCT01240915|DRUG|MultiStem low dose|1-3 doses
48183670|NCT01240915|DRUG|placebo|Single dose at week 8
48183671|NCT01240915|DRUG|MultiStem low dose|Single dose at week 8
48183672|NCT01240915|DRUG|placebo|Single dose Day 1
48183673|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
48183674|NCT01240915|DRUG|placebo|Single dose at week 8
48183675|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
48183676|NCT01240915|DRUG|placebo|Single dose Day 1
48725168|NCT02258113|DEVICE|Ocusweep OcuRT|Vision based choice reaction time test method
48725169|NCT04379778|OTHER|Aerobic exercise|Progressive moderate to high intensity aerobic exercise.
48183677|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
48183678|NCT01240915|DRUG|placebo|Single dose at week 8
48521297|NCT04443972|OTHER|biodegardable collagen membrane|provide efficacious barriers that were interposed between the flap and root surface.
48521298|NCT04696536|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
48725170|NCT00763945|OTHER|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
48725171|NCT05654701|DRUG|Palopegteriparatide (TransCon PTH)|The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
48725172|NCT04918355|OTHER|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
48725173|NCT04556422|OTHER|Aerobic exercise|15 minutes of aerobic exercise using stationary bicycle
48725174|NCT04556422|OTHER|Sauna bathing|Passive heat exposure
48725175|NCT01339117|OTHER|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
48725176|NCT01339117|OTHER|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
48183679|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
48183680|NCT01256671|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
48385816|NCT03914625|DRUG|Vincristine Sulfate|Given IV
48725177|NCT01043588|PROCEDURE|TURP|TransUrethral Resection of the Prostate
48725178|NCT01043588|PROCEDURE|PVP|Photo selective Vaporization of the Prostate
48725179|NCT03032549|DIETARY_SUPPLEMENT|RTD|Ready to Drink Supplement
48725180|NCT03032549|DIETARY_SUPPLEMENT|Placebo|Placebo
48027003|NCT01056744|DEVICE|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
48027004|NCT02667912|PROCEDURE|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
48027005|NCT02667912|PROCEDURE|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
48027006|NCT03871387|DRUG|Deep Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 \& PTC= 1\~2 (TOF = train-of-four. PTC = post-tetanic count)~* TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
48183681|NCT00807703|PROCEDURE|Select Stim|Select Stim: see summary
48385817|NCT06636682|BIOLOGICAL|FK-PC101|Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).
48385818|NCT06636682|BIOLOGICAL|Standard of Care (SOC)|Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
48385819|NCT04868877|DRUG|MCLA-129|full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
48385820|NCT04868877|DRUG|Osimertinib|Approved, 3rd-generation EGFR-TKI
48385821|NCT04868877|DRUG|Chemotherapy|administrated by IV infusion
48385822|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
48385823|NCT02107807|BIOLOGICAL|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
48725181|NCT05740865|PROCEDURE|open posterior instrumented thoracolumbar surgery|Both group previously received open posterior instrumented thoracolumbar surgery in 4 centers
48725182|NCT00619099|DRUG|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
48725183|NCT00619099|DRUG|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
48725184|NCT04969198|DRUG|Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)|Nicotine patch and mini-lozenge dosing will be based off the 2008 Public Health Services (PHS) Clinical Practice Guideline and package insert with adjustments to account for the delayed start 1-week post-TQD. All participants will receive 2mg mini-lozenge due to the superior palatability of the 2mg lozenges. Participants are encouraged to use at least 5 mini-lozenges per day for the full 8 weeks. Participants who report any smoking or nicotine use (e.g., even a cigarette puff, e-cigarette use) in the 3 days before C-NRT distribution will receive 4 weeks of 14mg and 4 weeks of 7mg nicotine patches. Participants who report complete abstinence from smoking and nicotine in the 3 days before C-NRT distribution will receive 8 weeks of 7mg nicotine patches.
48725185|NCT01636349|OTHER|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
48725186|NCT03380767|PROCEDURE|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
48725187|NCT02773654|OTHER|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
48725188|NCT02773654|OTHER|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
48725189|NCT03474783|BEHAVIORAL|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
48725190|NCT00843154|DRUG|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
48725191|NCT00843154|DRUG|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
48725192|NCT02961491|DRUG|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
48725193|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
48725194|NCT00895544|BIOLOGICAL|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
48725195|NCT06507150|OTHER|AI-assisted migraine education (AIME)|AIME Group will undergo the established migraine education plus AI-assisted education.
48725196|NCT05847413|DRUG|Verapamil|Subjects will receive oral verapamil for 12 weeks
48725197|NCT00537407|DRUG|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
48725198|NCT00537407|DRUG|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
48725199|NCT00537407|DRUG|Ribavirin|Ribavirin supplied as 200 mg tablets
48725200|NCT03596450|DRUG|Semaglutide|Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
48725201|NCT03596450|DRUG|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
48027007|NCT03871387|DRUG|Control Group|"* Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~* Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1\~2~* TOF and PTC are assessed by acceleromyograph (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~* At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme \[MSD\], Oss, the Netherlands) injection to reverse muscle relaxation.~* Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF \< 2"
48027008|NCT05273164|DEVICE|Computerized Cognitive Training|Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
48725202|NCT01723540|PROCEDURE|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
48385824|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
48385825|NCT02107807|BIOLOGICAL|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
48725203|NCT00684827|DRUG|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI"
48725204|NCT00684827|DRUG|Racemic Albuterol followed by levalbuterol HFA MDI|"1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI"
48725205|NCT00455208|DRUG|Cura-100|
48725206|NCT05574465|DEVICE|High resolution solid state manometry|The use of esophageal manometry device during removal of endotracheal tube by anesthesia
48725207|NCT00000643|DRUG|Pyrimethamine|
48725208|NCT00000643|DRUG|Leucovorin calcium|
48725209|NCT01181674|DRUG|insulin glargine|sc injection
48725210|NCT01181674|DRUG|metformin|oral administration
48027009|NCT02843789|DRUG|Tocilizumab|
48027010|NCT06177639|DEVICE|WiSLO|Imaging with the research WiSLO device in non-contact mode (4 images from each eye)
48385826|NCT04094818|DIAGNOSTIC_TEST|TriVerity|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection and sputum/ BAL sample collection
48385827|NCT03073642|OTHER|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
48385828|NCT03073642|OTHER|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
48725211|NCT01181674|DRUG|acarbose|oral administration
48027011|NCT06177639|DEVICE|Volk Pictor Plus™|Imaging with the commercial handheld fundus camera, Volk Pictor Plus™ (4 images from each eye)
48385829|NCT06058598|OTHER|Exercise Training|6-months supervised exercise training + 6 months unsupervised exercise training
48385830|NCT06058598|OTHER|Lifestyle Counselling|12-months of lifestyle counselling
48385831|NCT01982045|DEVICE|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
48725212|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
48521299|NCT04696536|OTHER|American Dental Association (ADA) Referenced Toothbrush|Participants will brush teeth at least one minute with provided toothbrush twice daily.
48183682|NCT05144399|OTHER|Accelerated antibiotic treatment|"E. faecalis uncomplicated: 4 weeks.~E. faecalis complicated: 4 weeks.~S. aureus uncomplicated: 2 weeks.~S. aureus complicated: 4 weeks.~Streptococci spp. NVE: 2 weeks.~Streptococci spp. PVE or abscess: 3 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
48385832|NCT01982045|OTHER|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
48521300|NCT04696536|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
48521301|NCT04696536|OTHER|REACH Dental Floss|Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
48725213|NCT01181674|DRUG|insulin glargine|sc injection
48725214|NCT01181674|DRUG|metformin|oral administration
48725215|NCT01181674|DRUG|acarbose|oral administration
48027012|NCT02893215|OTHER|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
48027013|NCT02370654|BEHAVIORAL|Tai chi|
48027014|NCT02370654|BEHAVIORAL|Conventional exercise|
48027015|NCT06221605|DIETARY_SUPPLEMENT|Probiotic|The intervention lasted for 6 months and 3 visits (at 0 month, 3rd and 6th month respectively).
48027016|NCT06535191|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|ASSET program is a manualized, theory-driven, 10-week soft skills intervention for autistic individuals, who seek employment or who wish to maintain employment by improving work-related social skills. Throughout a 10-week curriculum offered in a school-based group setting, ASSET addresses the following competencies for workplace success: Communication, Networking, Enthusiasm and Attitude, Teamwork, Problem-Solving and Critical Thinking, Professionalism, Mental Health and Stress Management, and Awareness of Self and Others.
48385833|NCT04991116|DRUG|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
48385834|NCT06566001|PROCEDURE|control group|socket shield technique and allogenic bone graft
48521302|NCT04696536|OTHER|Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)|Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
48725216|NCT01181674|BEHAVIORAL|lifestyle therapy|diet and exercise
48725217|NCT01181674|OTHER|Standard glycemic care|as informed by the current clinical practice guidelines
48725218|NCT03972956|OTHER|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
48725219|NCT00438334|DEVICE|Programmable directional/omni-directional hearing aid|
48385836|NCT00308230|PROCEDURE|Six minute walk test|
48385837|NCT00308230|BEHAVIORAL|Minnesota Living with Heart Failure Questionnaire|
48385838|NCT05007652|DRUG|KRN125(pegfilgrastim), PLR001(plerixafor)|7.2 mg of KRN125 in Day 1 Single subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
48385839|NCT05007652|DRUG|KRN8601(filgrastim), PLR001(plerixafor)|400 ug/m2 of KRN8601 from Day 1 to the end date of the Apheresis Once daily subcutaneous administration The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg when meets the criteria. The dosing period is 12-9 hours before apheresis on the following day.
48385840|NCT03144115|DRUG|Oxytocin|
48385841|NCT03144115|DRUG|Placebos|
48385842|NCT06379139|OTHER|•Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube|Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm
48385843|NCT06412666|DRUG|Aficamten|Oral Tablet
48385844|NCT06412666|DRUG|Placebo|Oral Tablet
48385845|NCT00397293|DRUG|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
48385846|NCT00397293|DRUG|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
48725220|NCT05629507|DEVICE|Virtual Reality|"The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.~The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios)."
48725221|NCT02839694|DRUG|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
48385847|NCT00068770|RADIATION|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
48385848|NCT00068770|DRUG|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
48385849|NCT04043052|OTHER|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
48385850|NCT04043052|OTHER|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; SSQ ; Physical activity (IPAQ)
48385851|NCT04043052|BIOLOGICAL|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
48385852|NCT04043052|OTHER|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
48385853|NCT05753592|DRUG|Part 1; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
48385854|NCT05753592|DRUG|Part 2; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
48385855|NCT02143479|DRUG|Tacrolimus|oral
48385856|NCT00380458|DEVICE|Coblation (radiofrequency-based device)|
48385857|NCT06538935|DRUG|adbelimumab|adbelimumab：1200mg iv d1 q3w
48385858|NCT06538935|PROCEDURE|SBRT|SBRT: SBRT: 8-30Gy/1-6F（dose is determined according to the tumor diameter）; tumor thrombus dose 30Gy /5-6F;
48385859|NCT06538935|DRUG|apatinib|apatinib：250mg po, qd
48385860|NCT04163991|DRUG|VIB4920|liquid for IV infusion following dilution in normal saline
48385861|NCT04163991|DRUG|Placebo|0.9% saline for IV infusion
48385862|NCT04757675|DRUG|S-ketamine 0.3|0.3 μg/kg intravenous injection s-ketamin
48385863|NCT04757675|DRUG|S-ketamine 0.5|0.5 μg/kg intravenous injection s-ketamin
48385864|NCT04757675|DRUG|S-ketamine 2|2 μg/kg intranasal s-ketamin
48725222|NCT02839694|DRUG|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
48725223|NCT02839694|DRUG|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
48725224|NCT01274520|DEVICE|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
48725225|NCT02273960|DRUG|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
48725226|NCT02273960|DRUG|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
48725227|NCT02273960|DRUG|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
48725228|NCT02273960|DRUG|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
48027017|NCT03548844|PROCEDURE|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
48385865|NCT04757675|DRUG|S-ketamine 1+Dexmedetomidine 1|1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
48385866|NCT04757675|DRUG|S-ketamine 0.5 +Dexmedetomidine 2|0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
48385867|NCT03242707|BIOLOGICAL|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
48385868|NCT03242707|DRUG|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
48385869|NCT04692103|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
48385870|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
48385871|NCT04692103|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
48027018|NCT03548844|PROCEDURE|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
48027019|NCT02687880|PROCEDURE|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
48385872|NCT04692103|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
48385873|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
48385874|NCT04692103|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
48385875|NCT04692103|OTHER|Laboratory Biomarker Analysis|Correlative studies
48385876|NCT05451849|BIOLOGICAL|TC-510|TC-510
48385877|NCT05451849|DRUG|Fludarabine|Fludarabine
48385878|NCT05451849|DRUG|Cyclophosphamide|Cyclophosphamide
48385879|NCT03597620|DRUG|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
48385880|NCT01023815|DRUG|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
48725229|NCT05035433|PROCEDURE|First lithotripsy and then EPBD|After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.
48725230|NCT05035433|PROCEDURE|First EPBD and then lithotripsy|After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
48725231|NCT03164330|BEHAVIORAL|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
48725232|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
48725233|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, \& waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); \& (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
48725234|NCT03164330|BEHAVIORAL|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
48725235|NCT03164330|BEHAVIORAL|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
48725236|NCT03164330|BEHAVIORAL|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
48725237|NCT01502163|DEVICE|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
48725238|NCT01502163|DEVICE|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
48725239|NCT03067376|DRUG|[14C]-CORT125134|
48725240|NCT06001619|DRUG|Prostate hyperplasia medication|The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
48725241|NCT06001619|DRUG|LhRH-antagonist|The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
48725242|NCT06188299|OTHER|Restricted Fluid Administration|Restrictive fluid administration generally consists of partial or no replacement for the intravascular expansion from anesthesia, in which case vasopressors are usually administered, no replacement for the third space loss, and only partial replacement for deficits from preoperative fasting.
48725243|NCT01919216|DRUG|Citalopram|
48725244|NCT03083223|OTHER|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
48725245|NCT03961412|BEHAVIORAL|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
48027020|NCT02362880|RADIATION|Florbetaben|single dose of Florbetaben followed by PET scan
48725246|NCT03961412|BEHAVIORAL|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
48725247|NCT02100306|BEHAVIORAL|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
48385881|NCT01023815|DRUG|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
48521303|NCT03348332|BEHAVIORAL|Exercise pregnant women|A supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
48725248|NCT02100306|BEHAVIORAL|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
48725249|NCT00685737|DRUG|1-MNA|Capsule
48385882|NCT01023815|DRUG|Prednison (continuous steroids)|continuous steroids
48385883|NCT05909904|DRUG|Tislelizumab|Administered intravenously
48521304|NCT02601014|BIOLOGICAL|Ipilimumab|Given 1 mg/kg IV
48725250|NCT00685737|DRUG|Placebo|Capsule
48725251|NCT02228447|BEHAVIORAL|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
48725252|NCT02968628|OTHER|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
48521305|NCT02601014|BIOLOGICAL|Nivolumab|Given 3 mg/kg IV
48521306|NCT02601014|DRUG|Enzalutamide|given orally per standard of care
48725253|NCT02968628|OTHER|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
48725254|NCT02968628|OTHER|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
48027021|NCT04410432|BIOLOGICAL|Blood sample collection|"Additional blood volumes taken during a routine care blood test:~* 1 dry tube 5 mL for isolation and freezing of serum~* 1 x 5 mL EDTA tube to isolate and freeze plasma~* 8 heparinized 6 mL tubes for flow cytometry study"
48725255|NCT02968628|OTHER|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
48725256|NCT04189029|OTHER|Extensive phenotyping|Prospective assessment of physical evaluation, biomarkers and omics, cardiac and vascular imaging and telemonitoring of cardiovascular parameters for 14 days.
48725257|NCT03429543|DRUG|Metformin|At least 1000 mg/day or up to a maximal tolerated dose.
48725258|NCT03429543|DRUG|Insulin|Basal or multiple dose injection.
48027022|NCT02161718|DRUG|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
48385884|NCT05909904|DRUG|BGB-A425|Administered intravenously
48385885|NCT05909904|DRUG|LBL-007|Administered intravenously
48385886|NCT02988310|OTHER|No intervention|
48385887|NCT00432367|DRUG|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
48385888|NCT02092584|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
48385889|NCT02092584|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
48385890|NCT04928794|PROCEDURE|Erector Spinae Plane Block|Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
48385891|NCT04928794|PROCEDURE|Paravertebral Block|Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
48385892|NCT04384731|DRUG|poractant alfa|Patient receiving surfactant (3 mL/kg of a poractant alpha solution diluted to 16 mg/mL, resulting in a total dose of 48mg/kg) administred by bronchial fibroscopy. The total volume will be divided in each of the five lobar bronchi.
48385893|NCT03668379|BEHAVIORAL|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
48385894|NCT03668379|BEHAVIORAL|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
48385895|NCT03668379|BEHAVIORAL|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT \& mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
48521307|NCT03606616|PROCEDURE|no further ALND arm|Patients meeting the Z0011 inclusion criteria to receive no additional ALND
48521308|NCT00601887|DRUG|Meloxicam|
48027023|NCT02161718|DRUG|Placebo + olanzapine|Oral tablet, taken once daily
48385896|NCT03668379|BEHAVIORAL|Augment w/BAT & mHealth|"Non-responders to the BAT \& mHealth intervention may be re-randomized to receive an additional dose of BAT \& mHealth in the form of an additional session of BAT."
48385897|NCT04824612|DEVICE|Photobiomodulation with blue led|Preoperative: every two weeks for 30 days. Postoperative: Immediately after surgery, weekly for 4 weeks, every two weeks for another 4 weeks, and one session in 3rd month. blue LED (470 nm, 0,4W, 24J per point on 10 linear points, total 240J).
48385898|NCT04824612|DRUG|Triamcinolone Hexacetonide|intralesional injection of 20 mg/ml. two injections in the preoperative period with a two-week interval between injections and a monthly injection for three months in the postoperative period. The injections will be intralesional and will not surpass the dermis. The drug will be diluted with the same quantity of 2% lidocaine. The scar will be divided into equal parts of 1 cm² and the drug will be distributed equally, respecting the total dose per session of 20 mg for the face and 40 mg for other topographies.
48385899|NCT04824612|DEVICE|Sham LED|A blue LED without power and biologic effect.
48521309|NCT03528616|DRUG|adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.|drugs used for treatment of supraventricular tachycardia
48521310|NCT03106324|DRUG|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
48725259|NCT03429543|DRUG|Placebo|1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
48725260|NCT03429543|DRUG|Linagliptin|1 film-coated tablet Linagliptin once daily, until end of treatment.
48725261|NCT03429543|DRUG|Empagliflozin|1 film-coated tablet of Empagliflozin once daily, until end of treatment.
48027024|NCT05421598|DRUG|Amlitelimab|Injection solution Subcutaneous injection
48027025|NCT05421598|DRUG|Placebo|Injection solution Subcutaneous injection
48183683|NCT05144399|OTHER|Standard treatment length|"E. faecalis uncomplicated: 6 weeks.~E. faecalis complicated: 6 weeks.~S. aureus uncomplicated: 4 weeks.~S. aureus complicated: 6 weeks.~Streptococci spp. NVE: 4 weeks.~Streptococci spp. PVE or abscess: 6 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
48385900|NCT01444469|DRUG|Zithromax|250mg \* 2 capsules once daily for three days
48385901|NCT01444469|DRUG|Placebo|Lactose powder
48385902|NCT01232075|DRUG|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
48385903|NCT01232075|DRUG|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
48385904|NCT06567418|DRUG|alirocumab 75mg/2week|patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference
48385905|NCT06567418|DRUG|statin ± ezetimibe|patients will be censored at initiation of alirocumab during the follow up visit
48725262|NCT00494910|BEHAVIORAL|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
48183684|NCT03752086|PROCEDURE|greater omentum binding|Bind pancreatic stump using greater omentum after distal pancreatectomy
48183685|NCT03752086|PROCEDURE|Pancreatic stump exposed without omentum binding|Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
48725263|NCT00494910|BEHAVIORAL|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
48521311|NCT01268462|OTHER|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
48725264|NCT06523257|DIAGNOSTIC_TEST|Spirometry|"Spirometry is a simple test used to diagnose and monitor lung diseases by measuring how much air a person can breathe out in one forced breath.~After the baseline spirometry, and only if there is clear evidence of an airflow limitation/obstruction, i.e., if the FEV1/FVC (forced expiratory volume in the first second/forced vital capacity) ratio is less than 70% or less than the 5th percentile of the distribution of values measured in the reference population, a bronchodilator test will be performed using standardised post-bronchodilator spirometry (200 µg salbutamol), in order to identify persistent airflow limitation/obstruction."
48725265|NCT01760590|PROCEDURE|Manual Manipulation|A grade 5 thrust to the thoracic spine
48725266|NCT01760590|PROCEDURE|Mobilization|A grade 1-4 mobilization directed at thoracic spine
48725267|NCT01694108|BIOLOGICAL|BCG-vaccine (SSI)|
48725268|NCT00257972|DRUG|aripiprazole|
48725269|NCT03841760|DIAGNOSTIC_TEST|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
48725270|NCT04094675|DRUG|Sirolimus|Use of sirolimus 2 mg by mouth daily for 1 year
48725271|NCT01856621|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
48725272|NCT01856621|DRUG|Seretide Diskus|2 inhalations as a single dose
48725273|NCT01856621|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
48725274|NCT01856621|DRUG|SF Easyhaler|2 inhalations as a single dose
48725275|NCT02924909|DRUG|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
48521312|NCT01268462|OTHER|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
48521313|NCT01268462|OTHER|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
48521314|NCT01268462|OTHER|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
48521315|NCT04627792|BEHAVIORAL|IUSECAMH Parent Intervention (Waitlist)|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
48725276|NCT04827303|OTHER|Kinesio taping|A 10-15 cm sized I band was applied to the trapezius muscles of the first group patients with the patient's neck in lateral flexion. Then, while the patient's neck is flexed, a Y-shaped 15-20 cm tape will be affixed between C1-7 with the arms of the Y up, and I tape of 5-10 cm is attached on the arms. In group 2 patients, 1 cc lidocaine diluted with 4 cc saline (SF) was applied to the trigger points palpated manually in the trapezius muscles. After the trigger point was squeezed between the thumb and index finger, a few cc of local anesthetic mixture was applied into the trigger point with the injector and exited. In the 3rd group patients, a few cc local anesthetic mixture will be applied intradermally over the trigger point without entering into the trigger points palpated manually in the trapezius muscles. Patients were checked 72 hours and 1 week after the first applications.
48725277|NCT00483002|DRUG|varenicline|As prescribed by physician in usual clinical practice.
48725278|NCT04927572|DRUG|FMX114|Active Comparator
48725279|NCT04927572|OTHER|Vehicle|Placebo Comparator
48725280|NCT04451473|PROCEDURE|Enhanced Recovery After Surgery (ERAS )|the treatment of procedure according to Guidelines for enhanced recovery after lung surgery: recommendations of the ERAS Society and the ESTS
48725281|NCT04451473|PROCEDURE|Traditional perioperative management without Enhanced Recovery After Surgery (ERAS )|the treatment of procedure not abiding Guidelines for enhanced recovery after lung surgery
48725282|NCT06277648|PROCEDURE|PENG block|PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic as 30 mL 0.375% bupivacaine was injected between the periosteum and psoas tendon following negative aspiration.
48027026|NCT05123209|BIOLOGICAL|IM83 CAR-T cells|3×10\^9 CAR-T cells
48027027|NCT05123209|COMBINATION_PRODUCT|The second-line treatment of liver cancer|approved by NMPA
48027028|NCT05810922|OTHER|arbutus berry|consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
48027029|NCT02176148|DRUG|fluocinonide 0.05% cream|
48027030|NCT00761839|BEHAVIORAL|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
48027031|NCT00761839|BEHAVIORAL|Control group|Patients in the control group will receive usual counseling for self-management.
48027032|NCT02732535|PROCEDURE|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
48027033|NCT03874000|BIOLOGICAL|Sintilimab|Given IV
48027034|NCT03874000|DRUG|Metformin Hydrochloride|Given PO
48027035|NCT04182022|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions and verified abstinence from alcohol.
48027036|NCT04182022|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on- time breathalyzer submissions only with no contingency on alcohol use.
48027037|NCT00363766|DRUG|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
48027038|NCT04155931|OTHER|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
48027039|NCT03351023|OTHER|no intervention-this was an observational study|
48027040|NCT01316822|DRUG|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
48027041|NCT01024387|DRUG|AMG 479|
48027042|NCT04057495|OTHER|further fasting|2 hours of fasting
48027043|NCT04057495|OTHER|white bread consumption|113 grams of white bread consumption
48027044|NCT04057495|OTHER|mango consumption|330 grams of mango consumption
48521316|NCT01838850|DRUG|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
48725283|NCT06277648|PROCEDURE|SIFIB|The high-frequency linear probe was placed medial to the anterosuperior iliac spine in a parasagittal orientation to visualize the bow tie appearance formed by the sartorius's internal oblique and iliacus muscles. The needle tip was placed under fascia iliaca through an in-plane approach, and local anaesthetic as 30 mL 0.375% bupivacaine was injected from the caudad to the cephalic direction.
48725284|NCT01873690|DRUG|Ciprofloxacin|Once, 400 mg IV
48725285|NCT01873690|DRUG|Placebo|5% Dextrose in water
48725286|NCT06216249|PROCEDURE|Computed Tomography|Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT
48725287|NCT06216249|OTHER|Gallium Ga 68 Gozetotide|Given IV
48725288|NCT06216249|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
48725289|NCT06216249|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
48725290|NCT06216249|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
48725291|NCT06216249|OTHER|Questionnaire Administration|Ancillary studies
48725292|NCT06216249|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
48725293|NCT02943915|DEVICE|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
48725294|NCT02943915|DEVICE|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
48725295|NCT04900285|DEVICE|Delta Dental Oral Device|"The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described."
48725296|NCT00607399|DRUG|SGX523 Capsules|This is a dose escalation study
48725297|NCT03860467|OTHER|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
48725298|NCT04684992|DEVICE|GEBT Telehealth Administration Usability|Establish the usability of a telehealth platform for the administration of GEBT
48725299|NCT03892135|OTHER|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
48725300|NCT03892135|OTHER|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
48725301|NCT03892135|OTHER|Interviews with Physicians|Interviews with Physicians
48725302|NCT01105585|DEVICE|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
48725303|NCT01105585|DEVICE|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
48725304|NCT04349956|DRUG|UBX0101 or placebo|This is an observational study. No intervention is administered.
48385906|NCT04655339|DRUG|Bilateral abdominal Lap-TAP|A total of 30ml of anesthetic (0.25% Bupivacaine HCL), 0.25% Liposomal Bupivacaine (Exparel®) or control will be injected into the transversus abdominis plane bilaterally. A long spinal needle attached to a 30cc syringe with the TAP block solution or control will be used to inject the patient. The needle puncture will be halfway between the subcostal margin and anterior superior iliac spine at the midclavicular line. With laparoscopic guidance, needle will enter through the skin, external oblique and internal oblique. Once the needle is in place, injection of 30 ml on each side will be applied between the internal oblique and transversus abdominis muscle. The injection of bupivacaine into this abdominal wall induces an observable bulge, indicating accuracy of the procedure. These steps will be repeated on the contralateral side of the abdomen. All patients will receive 10 ml bupivacaine 0.25% pre-incision infiltration.
48725305|NCT04186507|COMBINATION_PRODUCT|Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)|"To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat."
48725306|NCT01990456|DEVICE|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
48725307|NCT01990456|DEVICE|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
48725308|NCT03806075|BEHAVIORAL|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
48725309|NCT03806075|BEHAVIORAL|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
48725310|NCT02742311|PROCEDURE|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
48725311|NCT03759470|DIAGNOSTIC_TEST|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
48725312|NCT01447121|DEVICE|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
48725313|NCT01697943|PROCEDURE|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
48725314|NCT02983994|DEVICE|TURBUHALER®|
48725315|NCT02983994|DEVICE|SPIROMAX®|
48725316|NCT00001696|DRUG|Genistein|
48725317|NCT01528761|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
48027045|NCT03814447|DRUG|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
48027046|NCT03814447|DRUG|Fludarabine|Dose: 30mg/m2/d
48027047|NCT03814447|DRUG|Cyclophosphamide|Dose: 300mg/m2/d
48027048|NCT04059926|OTHER|insert apossing lumen metal stent|insert apossing lumen metal stent
48027049|NCT02063789|DRUG|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
48027050|NCT02565641|DRUG|Capecitabine|Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
48385907|NCT04361552|OTHER|Best Practice|Receive standard of care
48385908|NCT04361552|BIOLOGICAL|Tocilizumab|Given IV
48385909|NCT05117294|DRUG|Bocidelpar|Oral
48027051|NCT02565641|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m\^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
48027052|NCT03309436|DRUG|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
48027053|NCT03309436|PROCEDURE|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
48725318|NCT01528761|OTHER|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
48725319|NCT00273156|BEHAVIORAL|Telephone quitline|
48183686|NCT06344468|OTHER|Early Mobilization|Essentially, early mobilization practices consist of two parts: in-bed and out-of-bed. In-bed mobilization; Active-passive joint range of motion (ROM) Exercises include raising the head in bed, turning in bed, in-bed exercises and sitting at the end of the bed. Out-of-bed mobilization includes the process of transferring from bed to chair, standing up, and returning to bed after standing up. In studies conducted on cardiac surgery, the early mobilization period is the first 12 hours.
48725320|NCT05161689|BEHAVIORAL|HUG-M+|A multicomponent, multi-level, community mobilization, combination intervention (HUG-M+) to address the entire HIV Continuum of Prevention and Care.
48725321|NCT00911573|DRUG|Tigecycline|50 mg IV every 12 hours up to 14 days
48725322|NCT00911573|DRUG|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
48725323|NCT04804150|DEVICE|Vacuum suspension system active or inactive|The device will be plugged in, or won't be plugged in, depending of the randomization. The patient and the investigator will not know whether the device is plugged in or not, and if the medical device is active or not
48725324|NCT03255876|DIETARY_SUPPLEMENT|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
48725325|NCT03255876|DIETARY_SUPPLEMENT|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
48725326|NCT00036257|DRUG|CP-461|
48725327|NCT02772900|OTHER|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
48725328|NCT02772900|OTHER|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
48725329|NCT00718341|DRUG|AF056|
48385910|NCT05645562|BEHAVIORAL|Pain neuroscience education program|"1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)"
48725330|NCT00718341|DRUG|Placebo|
48725331|NCT04387266|RADIATION|modified reduce-volume target IMRT|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
48521317|NCT01838850|DRUG|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
48725332|NCT05989659|OTHER|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
48725333|NCT01277315|DRUG|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
48725334|NCT00235287|DRUG|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
48725335|NCT00235287|DRUG|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
48725336|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
48385911|NCT05645562|BEHAVIORAL|Self-care education program|"1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training"
48385912|NCT00006014|DRUG|semaxanib|
48725337|NCT00235287|DRUG|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
48725338|NCT05771961|DIAGNOSTIC_TEST|coronary pressure/temperature sensor-tipped guidewire|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire will be first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
48725339|NCT05771961|DIAGNOSTIC_TEST|Angiography-derived index of microcirculatory resistance (IMRangio)|Angiography-derived index of microcirculatory resistance (IMRangio) will be calculated by an anticipated software
48725340|NCT05614648|DRUG|Clonidine Micropellets|0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
48725341|NCT05614648|DEVICE|Tuohy epidural needle|18-gauge Tuohy epidural needle using a custom-built injector
48725342|NCT04572750|BEHAVIORAL|EMPOWER-ED|An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.
48521318|NCT04370678|BEHAVIORAL|Change in preference to surgery under COVID-19 pandemic.|Under the COVID-19 pandemic all arthroscopic procedures were cancelled. We wished to describe if patients experienced a change in preference to surgery under this period.
48725343|NCT06386705|DRUG|TSN084|TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
48385913|NCT05349760|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
48385914|NCT05349760|DRUG|Placebo|Saline/D5W
48385915|NCT04639310|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
48183687|NCT05260099|DEVICE|LPS Adsorber|LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
48385916|NCT04639310|DRUG|Placebo|Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child TID.
48385917|NCT05589246|DEVICE|regional analgesia with cryolesia|The regional analgesia (erector spine plane block) will be added to intraoperative cryolesia of intercostal nerves
48385918|NCT03699956|COMBINATION_PRODUCT|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
48385919|NCT03699956|DRUG|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
48385920|NCT04649892|DRUG|Naltrexone|Patients will receive daily doses of Naltrexone, starting at 50mg and increasing 25mg per week until reaching 200mg or the maximum tolerated by the patient
48385921|NCT04649892|DRUG|Placebo|Patients will receive daily doses placebo matching tablets for the 12 weeks of the study. Throughout this period, possible adverse effects will be monitored weekly.
48725344|NCT06464523|BEHAVIORAL|Face to face education|In addition to the standard cervical cancer screening programme service, participants in this group received individual face-to-face health education on HPV and cervical cancer prevention through home visits and were given educational brochures. Participants in this group were interviewed a total of four times (four times face-to-face) during the research period.
48725345|NCT06464523|BEHAVIORAL|Online education|In addition to the standard cervical cancer screening programme service, participants in this group received individual health education on HPV and cervical cancer prevention online via video call via WhatsApp application and were given a digital education brochure. Participants in this group were interviewed a total of four times (four times remotely) during the research process.
48725346|NCT04867460|PROCEDURE|Ultrasound guided venous access|Access of the axillary vein using ultrasound guidance.
48725347|NCT05644275|OTHER|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
48385922|NCT04649892|BEHAVIORAL|Psychoeducational|Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8
48385923|NCT04649892|DEVICE|Eye-tracking|"The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo."
48385924|NCT04625634|OTHER|2 days of work heat stress|2 consecutive days of identical simulated structural firefighting tasks.
48385925|NCT05773053|DRUG|NT 201|Clostridium botulinum neurotoxin type A (150 kiloDalton \[kD\], free of complexing proteins) powder for solution for injection.
48385926|NCT05773053|DRUG|NT 201 Placebo|NT 201 Matching-placebo.
48385927|NCT02297724|OTHER|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
48521319|NCT00316290|BEHAVIORAL|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
48385928|NCT05496634|BEHAVIORAL|Sedantary|An informative presentation
48521320|NCT00316290|BEHAVIORAL|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
48385929|NCT05496634|BEHAVIORAL|Exercise therapy|Pilates exercise therapy
48385930|NCT01508286|DRUG|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
48385931|NCT01508286|DRUG|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
48521321|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
48521322|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
48521323|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
48183688|NCT01932268|DRUG|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
48725348|NCT03404856|DRUG|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
48725349|NCT03586115|DEVICE|Critical flicker frequency assessment|All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
48725350|NCT01175395|DRUG|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
48725351|NCT03169257|BEHAVIORAL|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
48725352|NCT05934331|DRUG|LM302+Toripalimab|LM-302 in combination with Toripalimab.
48725353|NCT01124981|DRUG|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
48385932|NCT01508286|DRUG|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
48385933|NCT04045665|DRUG|Antiplatelet-only strategy|Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
48385934|NCT04045665|DRUG|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
48385935|NCT00307138|DRUG|hetastarch|
48385936|NCT00891527|DRUG|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
48385937|NCT06567067|DEVICE|Pulsenmore ES home ultrasound|Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched
48385938|NCT00170456|BIOLOGICAL|rPA vaccine containing alhydrogel|
48385939|NCT04269031|DRUG|AZD2373 subcutaneous injection|Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
48521324|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
48725354|NCT01124981|DRUG|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
48725355|NCT03414294|DRUG|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
48725356|NCT03414294|DRUG|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
48725357|NCT03414294|DRUG|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
48725358|NCT03414294|DRUG|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
48725359|NCT03414294|DRUG|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
48183689|NCT01163474|OTHER|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
48725360|NCT03414294|DRUG|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
48725361|NCT03414294|DRUG|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
48183690|NCT05924945|DEVICE|Bridge™ active device|Bridge is a percutaneous nerve field stimulation device
48183691|NCT05924945|DEVICE|Bridge™ sham device|The sham device has the same appearance and will require the same placement technique as the Bridge (active) device but will not deliver electrical impulses.
48183692|NCT02395419|DEVICE|Orotracheal intubation with Totaltrack|
48183693|NCT02395419|DEVICE|Orotracheal intubation with Airtraq|
48385940|NCT04269031|DRUG|Placebo|Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
48385941|NCT01016184|DIETARY_SUPPLEMENT|Vitamin D|Oral vitamin D 100,000 IU
48385942|NCT01016184|DIETARY_SUPPLEMENT|Placebo|Placebo
48385943|NCT06538961|OTHER|Collection of blood samples|the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture from individuals where the amount of blood does not exceed allowable amounts (see help).
48385944|NCT06538961|OTHER|Data Collection|Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.
48385945|NCT06538961|OTHER|Urine Sample|Post-transplant monthly urine sample collection for 6 months
48183694|NCT03193463|DRUG|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
48385946|NCT02845037|DRUG|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
48385947|NCT02845037|DRUG|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
48725362|NCT03414294|DRUG|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
48725363|NCT05650853|OTHER|Transrectal ultrasound|Examinations for observation of the pre, per and post-ejaculatory phases
48183695|NCT03193463|DRUG|Topotecan (>8cc)|In predominantly enhancing mass with a volume of \> 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
48183696|NCT03193463|DEVICE|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
48183697|NCT03193463|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
48183698|NCT03193463|DRUG|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
48183699|NCT04399343|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
48385948|NCT02896621|DRUG|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
48385949|NCT02896621|DRUG|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
48725364|NCT05650853|OTHER|Urethroscopy|Examinations for observation of the pre, per and post-ejaculatory phases
48725365|NCT00275977|PROCEDURE|Coronary catherization and stem cell infusion|
48725366|NCT01260545|DRUG|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
48725367|NCT03688243|DEVICE|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
48725368|NCT02334397|BEHAVIORAL|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
48725369|NCT01009177|DRUG|Bosentan|Bosentan 500 mg bid
48725370|NCT01009177|DRUG|Placebo|Placebo
48385950|NCT06653452|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan|Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
48385951|NCT00265460|DRUG|Oliwer Twist smokeless tobacco (tobacco)|
48725371|NCT05790980|DEVICE|Abdominal ultrasound|Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction
48385952|NCT05086627|DRUG|Tislelizumab|Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
48385953|NCT05086627|RADIATION|Short-course radiotherapy|Patients were treated with short-course neoadjuvant radiotherapy
48385954|NCT05086627|DRUG|Capecitabine+Oxaliplatin|Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
48385955|NCT05217537|DRUG|Omadacycline Injection [Nuzyra]|Single dose of 100 mg omadacycline IV in 100 mL of normal saline
48385956|NCT05217537|DRUG|Omadacycline Oral Tablet|Single dose of 300 mg omadacycline PO (2 x 150 mg tablets)
48385957|NCT02263222|DRUG|MDT-10013|
48385958|NCT06652334|PROCEDURE|Spinal anesthesia|20 patients undergoing spinal anesthesia
48385959|NCT06652334|PROCEDURE|Erector spinae plane block|20 patients undergoing erector spinae plane block
48385960|NCT03320031|DRUG|Linagliptin|Take linagliptin 5mg a day.
48385961|NCT03320031|DRUG|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
48385962|NCT05242107|DIETARY_SUPPLEMENT|Omega-3 supplement group|35 Neonates were given Omega 3 in a dose of 40mg/kg/day (8), after establishment of full-feeding and for 2 weeks duration. Omega-300 (Montana pharmaceutical industry) capsule was used which contains 1000mg Omega 3 fatty acids.
48521325|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
48521326|NCT01371747|DRUG|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
48521327|NCT01371747|DRUG|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
48521328|NCT01371747|DRUG|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
48521329|NCT00197171|BIOLOGICAL|Combined Hepatitis A and B vaccine|
48521330|NCT04159246|DEVICE|Optical coherence tomography angiography|"Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~* Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~* The patient will be examined before and after finishing the treatment course"
48521331|NCT04159246|DRUG|Sofosbuvir (Sovaldi)|Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
48521332|NCT02499796|DEVICE|Hygrovent Gold|
48725372|NCT00787501|DRUG|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
48385963|NCT05242107|OTHER|Full feeding without receiving any supplementation group|35 full term Growth Restriction( IUGR) neonates who were followed up to full feeding without receiving any supplementation.
48385964|NCT01102608|DRUG|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
48521333|NCT02499796|DEVICE|Heated and moisture exchanger (HME)|
48521334|NCT02499796|DEVICE|Heated humidifier (HH)|
48521335|NCT02335697|BEHAVIORAL|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
48521336|NCT02335697|OTHER|No intervention|
48725373|NCT00787501|BEHAVIORAL|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
48725374|NCT02133365|BEHAVIORAL|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
48385965|NCT04925531|DRUG|Antibiotics|to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
48385966|NCT06170528|DEVICE|AURA_ALZ|AURA_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
48385967|NCT05351437|DRUG|MTx-COVAB36|MTx-COVAB36 is a fully human monoclonal IgG1 antibody derived from the memory B cells of convalescent COVID-19 donors and directed against SARS-CoV-2 spike protein with potent virus neutralising activity.
48385968|NCT05351437|DRUG|Placebo|0.9% saline
48385969|NCT05589701|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
48385970|NCT00440193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
48385971|NCT00440193|DRUG|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
48725375|NCT03668990|OTHER|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
48725376|NCT01364909|OTHER|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
48725377|NCT01364909|OTHER|Usual practice|These patients will not receive exercise early in their intensive care admission
48725378|NCT04133194|DRUG|Mesalazine|1600 mg Asacol \[mesalazine\]
48725379|NCT04133194|DRUG|Mesalazine|800 mg Asacol \[mesalazine\]
48725380|NCT01833000|DEVICE|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
48725381|NCT05679063|OTHER|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
48725382|NCT05679063|OTHER|Sham, Control|Talks about healthy habits
48725383|NCT01635803|DRUG|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
48725384|NCT01635803|DRUG|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
48385972|NCT03522155|BEHAVIORAL|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
48385973|NCT03070327|BIOLOGICAL|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
48385974|NCT03070327|DRUG|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
48385975|NCT03070327|DRUG|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
48385976|NCT06649643|DIAGNOSTIC_TEST|Inborn errors of immunity|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6. Complement assay (CH"
48385977|NCT06649643|DIAGNOSTIC_TEST|A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B|"A. Routine~.1CBC with blood film.~.2Liver Function Test.~.3Kidney Function Test.~4. Inflamatory marker ESR, CRP~B.Immunology~1. Immunoglobulins IgG, IgM, IgA, IgE~2. Flow cytometric assessment: B Cell (CD19), T cells (CD3,CD4, CD8) anc NK Cells (CD16+56) and other markers whenever needed (e.g. CD40, CD40L for cases of hyper IGM)~3. Chest x-ray to assess thymus and any abnormality~4. DHR123 whenever needed (e.g. chronic granulomatous disease).~5. LAD panel (CD11b CD15-CD18) whenever needed.~6. Complement assay (CH"
48385978|NCT06416930|DRUG|Cadonilimab Combined with chemotherapy|Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks.
48385979|NCT03338907|DRUG|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
48385980|NCT06651502|DEVICE|dental implant placement and immediate provisionalization|dental implant placement and immediate temporization
48385981|NCT05782309|DRUG|Flavanol|Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
48521337|NCT05825443|DRUG|Camrelizumab|Patients received four 21-day cycles of chemotherapy (decided by the researcher) combined with camrelizumab (200 mg in day 1), followed by maintenance with camrelizumab (200 mg in day 1, q3w), until one year or the disease progressed or unacceptable toxicity.
48521338|NCT03671161|DEVICE|Insulin Pump and flash glucose monitoring|Adults with type 1 diabetes, HbA1c \>9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
48725385|NCT06371534|DRUG|QL2109|subcutaneous injection 3-5 min D1 (Day 1, single dose)
48725386|NCT06371534|DRUG|DARZALEX FASPRO®|subcutaneous injection 3-5 min D1 (Day 1, single dose)
48725387|NCT05378074|DRUG|Maxipost|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
48725388|NCT05378074|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
48725389|NCT00472966|DRUG|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
48725390|NCT03372005|BEHAVIORAL|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
48385982|NCT05782309|DRUG|Placebo|Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
48385983|NCT02823587|OTHER|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
48385984|NCT02823587|OTHER|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
48385985|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in first three days
48385986|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the first three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in first three days
48385987|NCT04460092|DEVICE|5-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 5mm to inject insulin in second three days
48385988|NCT04460092|DEVICE|8-mm 32-gauge Insulin needles in the last three days of Intervention|32-gauge needles with a length of 8mm to inject insulin in second three days
48385989|NCT06048198|OTHER|No intervention|No intervention
48385990|NCT02010307|OTHER|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
48385991|NCT00803530|DRUG|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
48385992|NCT00637598|RADIATION|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
48385993|NCT05874518|OTHER|warm needling combined with electroacupuncture|Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.
48183700|NCT04399343|DRUG|Normal saline|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
48183701|NCT03532503|DEVICE|Foley catheter|Transcervical foley catheter will be applied
48183702|NCT00513162|DRUG|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
48183703|NCT00513162|DRUG|Etoposide|25 - 50 mg/m\^2 By Mouth Daily
48385994|NCT05874518|DRUG|The treatment with letrozole tablets was started on the fifth day of the menstrual cycle|Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
48385995|NCT02539329|OTHER|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
48183704|NCT03044977|DRUG|90Y-DOTA-3-Tyr-Octreotide|Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.
48385996|NCT04520711|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
48385997|NCT04520711|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
48385998|NCT04520711|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
48385999|NCT01585896|OTHER|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
48386000|NCT00537056|PROCEDURE|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
48386001|NCT00537056|PROCEDURE|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
48386002|NCT00537056|DRUG|F-18 Fluoro-deoxi-glucose|15 mCi iv
48183705|NCT03044977|DRUG|131I-MIBG|Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.
48183706|NCT05508269|GENETIC|quantitative polymerase chain reaction(QPCR) for four genes|quantitative polymerase chain reaction(QPCR) for four genes
48183707|NCT05508269|PROCEDURE|Cardiac biopsy, blood sampling|In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
48386003|NCT00537056|DRUG|Gadolinium-DTPA|0.1 mmol/kg iv
48386004|NCT00537056|DRUG|Sunitinib|50 mg/day po
48386005|NCT03205163|BIOLOGICAL|Advate (Low Dose)|Participants received a single IV low dose of Advate 25 IU/kg.
48386006|NCT03205163|BIOLOGICAL|Advate (High Dose)|Participants received a single IV high dose of Advate 65 IU/kg.
48725391|NCT05805644|DEVICE|Robot mediated upper limb therapy|"The OR is classified as a Class A device with the Health Sciences Authority. The OR is capable of delivering RMIT as well as RMTT. It can provide zero, partial or full assistance to the patient to complete the movement or task. Its teach-and-follow mode allows a movement to be performed by the therapist, with the device then replaying the movement at either zero, partial or full assistance for the patient.~Impairment oriented training will focus on the following movements:~1. Diagonal movement~2. Shoulder abduction~3. Shoulder adduction~4. Shoulder flexion~5. Shoulder extension~6. Elbow flexion~7. Elbow extension~Task-specific training will focus on the following activities:~1. Picking up a cup/glass by the side and drink~2. Brushing hair~3. Cleaning unaffected upper limb (hand to arm)~4. Wiping table~5. Wiping wall~6. Sliding card on table to a designated location~7. Clipping a clothe peg"
48725392|NCT02343705|DEVICE|Latella Knee Implant System|
48725393|NCT02553538|BEHAVIORAL|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
48725394|NCT02954666|DEVICE|radio-frequency ablation|"Patients will undergo a tailored 'radio-frequency ablation' of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval \< 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval \< 600 ms after 5 minute of waiting time; 5 radiofrequency applications \> 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
48183708|NCT03223051|OTHER|Motor assessment|An occupational therapist install the patient sitting in front of the test board and tell him the instructions
48183709|NCT00002107|DRUG|Aldesleukin|
48183710|NCT03792490|DRUG|Fasudil|Fasudil hydrochloride hydrate IV solution
48183711|NCT03792490|DRUG|Placebo|Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
48183712|NCT06114992|DEVICE|Servo-n HFOV modes|Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
48183713|NCT01508637|OTHER|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
48183714|NCT01508637|OTHER|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
48183715|NCT01508637|DRUG|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
48183716|NCT01508637|DRUG|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
48183717|NCT05893589|OTHER|test group|Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks
48183718|NCT03067545|OTHER|Step rate increase|increase the step rate during running by 10% steps per minute
48183719|NCT05335200|DIAGNOSTIC_TEST|(S)-[18F]FBFP PET/CT|Patients will be intravenously injected with 185-370MBq (S)-\[18F\]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
48183720|NCT04016116|DRUG|Pembrolizumab|Pembrolizumab IV every 3 weeks
48386007|NCT03205163|BIOLOGICAL|BIVV001 (Low Dose)|Participants received single IV low dose of BIVV001 25 IU/kg.
48386008|NCT03205163|BIOLOGICAL|BIVV001 (High Dose)|Participants received single IV high dose of BIVV001 65 IU/kg.
48386009|NCT00006092|DRUG|Arsenic Trioxide|
48386010|NCT05878600|OTHER|kendall's exercise|comparative effect of targeted cervical spine strengthening versus kendalls exercise will be analyzed
48386011|NCT05878600|OTHER|cervical spine strengthening|sole effect of cervical spine strengthening will be analyzed
48386012|NCT06566976|OTHER|Exercise Intervention|Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.
48386013|NCT06566976|OTHER|VAPAHCS Rehabilitation Core Components|The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
48386014|NCT06437353|DRUG|Paclitaxel|"First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily."
48725395|NCT05352763|DRUG|simufilam|simufilam 100 mg oral tablets
48725396|NCT03610373|BEHAVIORAL|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
48725397|NCT03243175|DRUG|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
48725398|NCT03243175|DEVICE|left atrial appendage closure|left atrial appendage closure
48027054|NCT04917679|DRUG|Eltrombopag plus diacerein|In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
48183721|NCT04016116|DRUG|Ruxolitinib|Ruxolitinib po days 1-21
48183722|NCT00263211|DRUG|Plavix|
48183723|NCT00263211|DRUG|Aspirin|
48183724|NCT00980746|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
48386015|NCT05268718|DRUG|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel|Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel was excited by NIR laser to release functional silver ions, copper ions and ROS.
48521339|NCT06581887|BEHAVIORAL|Classical conditioning task|To evaluate the neurophysiological and physiological response to a classical conditioning task, which is comparable to findings that have been made in the mdx dystrophic mouse (deficient in Dp427). The investigators will assess correlations between the specific DMD/BMD genotype and susceptibility to conditioning, as well as the relationship between conditioning and behavioural/emotional characteristics of the syndrome.
48725399|NCT03299361|OTHER|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
48725400|NCT02263911|DRUG|Baricitinib|Administered orally
48725401|NCT04465968|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV, day 1
48725402|NCT04465968|DRUG|S1|80 - 120 mg/day, PO, day 1-14
48725403|NCT04465968|RADIATION|concurrent radiotherapy|66 Gy/33 Fr
48725404|NCT04465968|DRUG|Durvalumab|preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
48183725|NCT00980746|DRUG|Placebo|oral route
48183726|NCT05693077|BIOLOGICAL|10E4 NTCD spores|in capsule for oral ingestion.
48183727|NCT05693077|BIOLOGICAL|10E7 NTCD spores|in capsule for oral ingestion.
48183728|NCT05693077|OTHER|placebo|in capsule for oral ingestion.
48183729|NCT05693077|DRUG|Vancomycin Oral Capsule|4 times a day 250mg
48183730|NCT02453243|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
48183731|NCT02453243|BEHAVIORAL|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean."
48386016|NCT05268718|DRUG|Voriconazole eye drops|Voriconazole eye drops (1%) were administrated to infectious eye very frequently (once half an hour)
48183732|NCT01084226|DIETARY_SUPPLEMENT|Rye-2008|
48386017|NCT05268718|OTHER|Normal saline|To be placebo, normal saline were administrated to infectious eye
48386018|NCT04633187|DRUG|EDP-938|"EDP-938 800mg~Dose adjustments were made for subjects taking azole antifungals."
48386019|NCT04633187|DRUG|Placebo|Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
48725405|NCT04465968|PROCEDURE|Surgery|Surgery will be performed between day 15 and day 42 of the second course of preoperative durvalumab therapy after confirming that all surgical operation criteria are met.
48725406|NCT04465968|DRUG|Durvalumab|"(For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1"
48183733|NCT01578213|DRUG|Imatinib mesylate|"* Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~* Total dosage per day: 800 mg~* Oral use"
48386020|NCT03356769|DRUG|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
48725407|NCT04379999|DRUG|Atorvastatin 20mg|No history of colorectal cancer and no colorectal adenomas within 5 years.
48725408|NCT04379999|DRUG|Atorvastatin 20mg AND Aspirin 325 mg|History of colorectal cancer and/or history of colorectal adenomas within 5 years.
48725409|NCT01739543|DEVICE|Hem-Avert|Application of Hem-Avert
48725410|NCT04999527|DRUG|DISC-0974|DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
48725411|NCT04999527|DRUG|Placebo|Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
48725412|NCT01873248|DRUG|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
48725413|NCT05518708|DRUG|BI 3032950|BI 3032950
48521340|NCT04413019|OTHER|Clinical follow up|"Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~* Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~* Penicillin may be used in patients who can't tolerate erythromycin~* In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection."
48386021|NCT03356769|DRUG|AED|maintain the dosages and the drugs throughout the 3-month observation time
48725414|NCT05518708|DRUG|Placebo|Placebo
48725415|NCT04268745|BEHAVIORAL|Balance training|Progressive balance training within virtual environments
48386022|NCT03356769|DRUG|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
48386023|NCT05784714|BEHAVIORAL|NOLA GEM|This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
48386024|NCT03954899|DIETARY_SUPPLEMENT|melatonin|5mg of melatonin-otc 30 minutes before sleep
48386025|NCT03954899|OTHER|placebo|placebo 30 minutes before sleep
48521341|NCT01047254|DRUG|Elontril|flexible dose of Bupropion 150-300 mg
48521342|NCT01047254|DRUG|placebo|
48521343|NCT01648530|OTHER|No Treatment|No Treatment
48521344|NCT02159313|DRUG|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
48521345|NCT03659214|BEHAVIORAL|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
48027055|NCT04917679|DRUG|Eltrombopag|In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
48027056|NCT01428960|DIETARY_SUPPLEMENT|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
48386026|NCT01218386|DRUG|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
48386027|NCT06163209|DIAGNOSTIC_TEST|Nasal Ultrasonography|"Ultrasonography of the external nose will be performed with the use of a high-resolution transducer (Clarius L20HD3 8-20 MHz) and a 3mm-thick disposable gel pad, according to the following protocol:~1. Sagittal plane, along the most prominent part of nasal dorsum.~2. Transverse plane, level of nasion.~3. Transverse plane, level of intercanthal line.~4. Transverse plane, level of rhinion.~5. Along inferior border of the right nasal bone.~6. Along inferior border of the left nasal bone.~7. Along medial part of the right orbital rim below frontomaxillary suture.~8. Along medial part of the right orbital rim below frontomaxillary suture.~9. Along the line connecting right frontomaxillary suture and the tip of the nose.~10. Along the line connecting left frontomaxillary suture and the tip of the nose.~At each location the transducer position will be adjusted until it is held perpendicular to the bone surface and a single image will be saved for further assessment."
48386028|NCT06163209|DIAGNOSTIC_TEST|Computed Tomography Scan of the Face|"A standard computed tomography scan of the face will be performed and the following areas will be assessed by an experienced radiologist:~1. Bony part of the nasal septum~2. Left nasal bone - part proximal to the intercanthal line~3. Right nasal bone - part proximal to the intercanthal line~4. Left nasal bone - part distal to the intercanthal line~5. Right nasal bone - part distal to the intercanthal line~6. Frontal process of the left maxilla~7. Frontal process of the right maxilla"
48386029|NCT05366725|DRUG|Avelumab|As provided in real world practice
48521346|NCT00156403|DRUG|amlodipine (drug)|
48521347|NCT06190392|OTHER|MODS Modified simplified diagnostic strategy|"The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.~In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.~If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied."
48521348|NCT01756027|DEVICE|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
48521349|NCT01756027|DEVICE|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
48521350|NCT03439956|PROCEDURE|Transvaginal specimen extraction|Previous transvaginal specimen extraction through posterior colpotomy.
48521351|NCT01551030|DRUG|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
48521352|NCT03290378|DRUG|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
48521353|NCT03290378|OTHER|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
48725416|NCT04268745|BEHAVIORAL|Traditional Vestibular Rehabilitation|Progressive balance training and gaze stability exercises
48725417|NCT02162966|DRUG|High Dose Colistin|High Dose Colistin
48725418|NCT02162966|DRUG|Standard Dose Colistin|Standard Dose Colistin
48725419|NCT02882386|OTHER|Strength Training|
48725420|NCT02882386|DIETARY_SUPPLEMENT|Milk 1%|
48725421|NCT02882386|DIETARY_SUPPLEMENT|Whey protein concentrate 80 (WPC-80)|
48725422|NCT02882386|DIETARY_SUPPLEMENT|Microparticulated whey|
48725423|NCT02882386|DIETARY_SUPPLEMENT|Hydrolyzed whey|
48725424|NCT02882386|DIETARY_SUPPLEMENT|Native whey|
48183734|NCT00919204|DRUG|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
48183735|NCT00616824|PROCEDURE|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
48183736|NCT00616824|PROCEDURE|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
48183737|NCT05955274|BEHAVIORAL|Mobile Behavioral Parent Training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
48183738|NCT05955274|BEHAVIORAL|Just-in-time intervention: Parenting Strategies|Parents will receive prompts via phone that provide parenting suggestions and parenting feedback when they are interacting with their child.
48183739|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
48386030|NCT04027907|OTHER|Flowcytometry|detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
48386031|NCT06568380|OTHER|Oyster consumption|Volunteers consume one of the four panel of oysters (Noro+Phage+, Noro+Phage-, Noro-Phage+ and Noro-Phage-).
48386032|NCT02351206|RADIATION|x-ray, MRI|
48386033|NCT05663333|OTHER|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy|Dynamic full-field optical coherence tomography analysis of temporal artery biopsy in the dermatology department before conventional histopathological analysis
48386034|NCT05878405|OTHER|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
48386035|NCT05878405|OTHER|Methylene Blue Oral Rinse|Given PO
48725425|NCT01700010|DRUG|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
48725426|NCT00265031|DRUG|Cyclophosphamide|
48725427|NCT00265031|DRUG|Adriamycin|
48725428|NCT00265031|DRUG|Etoposide|
48725429|NCT00265031|DRUG|Procarbazine|
48183740|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
48183741|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
48183742|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
48183743|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
48183744|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
48183745|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
48183746|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
48183747|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
48183748|NCT02019186|DIETARY_SUPPLEMENT|Vitamin C|\<30 kg 250 mg 30-60 kg 500 mg \>60 kg 750 mg
48183749|NCT02019186|DIETARY_SUPPLEMENT|Vitamin E|\<30 kg 100 IU, 30-60 kg 200 IU, \>60 kg 300 IU
48183750|NCT00707499|DRUG|BMS747158|Single dose administration.
48183751|NCT02274090|DRUG|Placebo gel|Placebo gel consist of drug without the active component.
48183752|NCT02274090|DRUG|1% Metformin gel|Metformin gel consist of active component.
48183753|NCT04990778|DRUG|Eprenetapopt|Given IV
48183754|NCT04990778|DRUG|Venetoclax|Given PO
48386036|NCT03187873|BEHAVIORAL|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
48386037|NCT04819932|DRUG|DWJ1451|DWC202008 DWC202009
48725430|NCT00265031|DRUG|Prednisone|
48725431|NCT00265031|DRUG|Vincristine|
48725432|NCT00265031|DRUG|Bleomycin|
48725433|NCT00265031|PROCEDURE|radiation therapy|
48725434|NCT02803996|DRUG|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
48725435|NCT02803996|DRUG|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
48725436|NCT05660447|DRUG|Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]|One drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
48521354|NCT02015728|DEVICE|Tumor biology testing|"Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide."
48521355|NCT02015728|DRUG|Temozolomide|"Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
48521356|NCT02015728|DRUG|Etoposide|"Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
48521357|NCT02015728|DRUG|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
48725437|NCT05660447|DRUG|Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud|Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56
48725438|NCT00003552|DRUG|allogeneic lymphocytes|
48386038|NCT05688800|DEVICE|conventional therapy|Participants in control group will receive conventional physical therapy treatment including Conventional TENS high frequency (90-130hz) low intensity according to the patient sensation for 30-45 min(Gozani, 2019) , continuous ultrasound with frequency 1 MHz and intensity 0.8 W/cm 2 will be applied by slow circular perpendicular movements with slightly deep pressure. Application time was 5 minutes at each side of the level of C7_T4 along the medial borders of the scapulae width, infra-red radiation will be four 15 minutes and directed perpendicular to the inter-scapular area, centered at the level of C7_T4 long and between the 2 medial borders of the scapulae width . Also combined stretching and strengthening exercise will be added due to its greater pain-relieving effect
48521358|NCT02015728|DRUG|Everolimus|Everolimus is an mTOR pathway inhibitor.
48521359|NCT02015728|DRUG|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
48521360|NCT02015728|DRUG|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
48521361|NCT04470063|DRUG|DDO-3055 tablets|Multi-dose for DDO-3055 tablets
48521362|NCT04470063|DRUG|Placebo|Multi-dose for Placebo
48521363|NCT05584189|DEVICE|Rapid SARS-CoV-2 Antigen Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person.
48521364|NCT05215444|DIAGNOSTIC_TEST|some prognostic factors|cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count
48521365|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
48521366|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
48725439|NCT00003552|DRUG|anti-thymocyte globulin|
48725440|NCT00003552|DRUG|cyclophosphamide|
48725441|NCT00003552|DRUG|fludarabine|
48521367|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
48521368|NCT05522127|OTHER|Colonoscopy|Colonoscopy
48521369|NCT05522127|OTHER|Sedoanalgesia|Ketamine, fentanil, midazolam, propofol
48521370|NCT03552380|DRUG|Entinostat|RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
48386039|NCT05688800|OTHER|Experimental group 1 : pressure release technique|Participants who are assigned to this group will receive conventionalphysical therapy treatment in addition to pressure release technique. the participant will be positioned either sitting or prone position according to his preferred position, the researcher will apply the pressure release procedure by a pressure below the PPT dependent onsoft tissue release. When the researcher detected a reduction in soft tissue resistance, the amount of compression will be increased. The pressure should -33- be nonpainful, applied at slow rate, and will maintained until release of tissue barrier. Further pressure was increased to reach a new barrier. The pressure will last 60 seconds. With the thumb or the second and third fingers, the non-painful manual therapy approach was applied to the active MTrPs of therhomboid muscle
48386040|NCT05688800|OTHER|Experimental group 2: thoracic spine manipulation|Thoracic spine manipulation will be performed as screw thrust manipulation technique; the vertebral transverse processes will beforced from posterior to anterior direction. The direction of the manipulation should be identified by applying springing test to the adjacent spinous process to determine the painful and stiff segment. Patient will be prone and researcher hand placement will be positioned as the following one pisiform on the right facet of the above, and the other pisiform on the left facet of the below vertebrae.A slack will be taken up. The thrust applied directly toward the patient once
48386041|NCT01438827|DRUG|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
48386042|NCT01438827|DRUG|Placebo|Suspension for Injection, Every 6 weeks for one year
48386043|NCT00301925|BIOLOGICAL|pegfilgrastim|
48386044|NCT00301925|DRUG|capecitabine|
48386045|NCT00301925|DRUG|cyclophosphamide|
48386046|NCT00301925|DRUG|epirubicin hydrochloride|
48386047|NCT00301925|DRUG|fluorouracil|
48386048|NCT00301925|DRUG|methotrexate|
48386049|NCT00301925|PROCEDURE|adjuvant therapy|
48386050|NCT04337359|DRUG|Ruxolitinib|5 mg. Tablet
48386051|NCT03657576|BIOLOGICAL|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
48386052|NCT01243307|DRUG|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
48386053|NCT04766970|BEHAVIORAL|ADOS-2 Module 4|Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.
48386054|NCT04766970|BEHAVIORAL|Adapted Telehealth ADOS-2 Module 4|Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
48386055|NCT00685711|BIOLOGICAL|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
48386056|NCT05134545|DEVICE|Genoss® DCB|Peripheral Drug Coated Balloon
48386057|NCT05134545|DEVICE|IN.PACT Admiral® DCB|Peripheral Drug Coated Balloon
48386058|NCT06538779|DIAGNOSTIC_TEST|elastography,usg|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
48725442|NCT03891368|OTHER|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
48725443|NCT03891368|OTHER|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
48386059|NCT06304688|OTHER|Yoga and Mediterranean Diet intervention|"It will last 12 weeks with a frequency of 2 sessions per week and each lasting 50 minutes.~* Warm-up phase (10 minutes): Conscious and gentle breathing. Gentle movements of the neck, shoulders, arms and legs to increase blood circulation and flexibility.~* Training phase (30 minutes): Series of gentle postures adapted to the needs of older adults. Includes standing, sitting and lying postures for relaxation and stretching. It will begin with basic postures and breathing techniques and will gradually advance as participants gain confidence.~* Return to calm (10 minutes): Deep relaxation in a lying position to integrate the benefits of the practice and promote total relaxation of the body and mind.~The Mediterranean diet consisted of: i) carbohydrates constitute 50% of the daily intake; ii) fats represented 35%; and iii) proteins represented 15%."
48386060|NCT06519799|OTHER|Menstrual hygiene products|The influence on the intimate health of each product will be evaluated. As you can't not use a menstrual product during menstruation, no control group is included
48386061|NCT04483570|PROCEDURE|Redo-tethering operation|
48386062|NCT04794725|PROCEDURE|Blood sampling|blood samples from venepuncture (10mL)
48725444|NCT05787106|OTHER|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
48725445|NCT03584555|PROCEDURE|SMILE using 120μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
48725446|NCT03584555|PROCEDURE|SMILE using 140μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
48725447|NCT03225924|DRUG|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
48725448|NCT03225924|DRUG|Rituximab|cycles of 21 days - 375mg/m²
48725449|NCT03225924|DRUG|Cyclophosphamide|cycles of 21 days - 750 mg/m²
48725450|NCT03225924|DRUG|Doxorubicin|cycles of 21 days - 50mg/m²
48725451|NCT03225924|DRUG|Vincristine|cycles of 21 days - 1.4mg/m²
48725452|NCT03225924|DRUG|Prednisone|cycles of 21 days - 40mg/m²
48183755|NCT03030313|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
48386068|NCT04501159|OTHER|blood sample pre, during and post HD|Assessment of ABG pre, during and post HD
48386069|NCT04501159|DEVICE|Non invasive cardiac output assessment|Four ECG style electrodes are placed on the thorax which indirectly measures cardiac output.
48386070|NCT06563440|OTHER|Digital app and information system|A custom digital app and information system that consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures point of care test image, interprets, and transmits results to the central ministry of health data center; (3) Education module - stores and plays back short educational videos for pre- and post-screening counseling; (4) SCD e-Passport module - entry and display of child's salient clinical information.
48386071|NCT00991211|DRUG|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
48386072|NCT00991211|DRUG|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
48725453|NCT01238965|DRUG|panobinostat|Given orally
48386073|NCT05146700|DRUG|Restrictive oxygen|Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
48386074|NCT05146700|DRUG|Liberal oxygen|15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
48521371|NCT03552380|DRUG|Nivolumab|Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
48521372|NCT03552380|DRUG|Ipilimumab|Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
48521373|NCT03301649|DRUG|Generic Ivermectin Lotion 0.5%|Topical lotion, generic formulation of the brand product.
48521374|NCT03301649|DRUG|Sklice® (Ivermectin) Lotion 0.5%|Topical lotion, brand product.
48521375|NCT03301649|DRUG|Vehicle Lotion|Topical lotion, placebo. Has no active ingredient.
48725454|NCT01238965|DRUG|fluorouracil|Given IV
48725455|NCT01238965|DRUG|leucovorin calcium|Given IV
48725456|NCT01238965|PROCEDURE|biopsy|Correlative studies
48725457|NCT01238965|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
48725458|NCT01238965|GENETIC|western blotting|Correlative studies
48725459|NCT01238965|OTHER|laboratory biomarker analysis|Correlative studies
48725460|NCT01238965|GENETIC|gene expression analysis|Correlative studies
48725461|NCT01238965|GENETIC|RNA analysis|Correlative studies
48725462|NCT01238965|GENETIC|polymorphism analysis|Correlative studies
48725463|NCT05024136|DEVICE|Limon essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of Limon essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
48725464|NCT05024136|DEVICE|Vetiver essential oil aromatherapy|Subjects receive three times 30 mins aromatherapy of vetiver essential oil per time for the month. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), autonomic nerve parameters including a. SDNN (standard deviation of all normal to normal intervals index); b. HRV（heart rate variability）; c. LF（0.04-0.15 Hz）and HF（0.15-0.4 Hz）were measured every week. PSQI（Pittsburgh sleep quality index）and HADS (Hospital Anxiety and Depression Scale) were measured initial and ten ends.
48386075|NCT05043779|PROCEDURE|Awake Airway Nasoendoscopy|Preoperative Awake Airway Nasoendoscopy of upper airway
48725465|NCT01639755|DEVICE|new texture shaped breast implants|breast implant surgery
48725466|NCT03141541|BEHAVIORAL|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
48725467|NCT00547950|DRUG|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid\*1year.
48386076|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
48386077|NCT00605397|RADIATION|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
48725468|NCT05462639|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
48725469|NCT06169852|DEVICE|Neuromodulation eXperiment Testbed system (NEXT) stimulation|Initial studies in this aim will use NEXT to stimulate and record neural activity at clinically effective sites.
48725470|NCT04343716|BEHAVIORAL|Low-carbohydrate diet|A diet low in daily carbohydrates (\<40 grams/day) provided as prepared meals.
48027057|NCT05768308|BEHAVIORAL|Internet CBT-UP intervention iCBT-UP|The self-helped internet intervention for students experiencing emotional difficulties, especially adjustment disorder. This intervention is based on transdiagnostic cbt principles - unified protocol (Barlow et al., 2018). It is a modular intervention consisting of six modules teaching different skills of dealing with emotions. Intervention is interactive and contains of video materials, quizes, texts and audio materials.
48521376|NCT04599478|DRUG|Naltrexone and Bupropion medication|NB medication will be taken daily in pill form.
48521377|NCT04599478|BEHAVIORAL|Behavioral Weight Loss|Behavioral Weight Loss (BWL) counseling includes weekly sessions.
48521378|NCT04599478|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
48521379|NCT04662814|OTHER|shock wave therapy|Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.
48725471|NCT00247455|DRUG|Low fibre breakfast cereal (puffed rice/cornflakes)|
48725472|NCT00247455|DRUG|High fibre cereal (All Bran/Bran Flakes)|
48725473|NCT00678548|BEHAVIORAL|Pleasant guided imagery|CD with pleasant guided imagery
48725474|NCT00678548|BEHAVIORAL|Pain diary|Filling out a pain diary
48725475|NCT00002961|DRUG|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
48725476|NCT00002961|DRUG|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
48725477|NCT00002961|DRUG|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
48725478|NCT00002961|DRUG|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is \>2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
48725479|NCT00002961|PROCEDURE|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
48725480|NCT00002961|RADIATION|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) \[200 cGy twice a day (BID)\].
48521380|NCT04662814|OTHER|dietary modification|Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
48386084|NCT04611152|DRUG|KSI-301|Intravitreal Injection
48386085|NCT04611152|DRUG|Aflibercept|Intravitreal Injection
48386086|NCT04611152|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
48386087|NCT01666067|DRUG|placebo|
48386088|NCT01666067|DRUG|vytorin|
48386089|NCT01666067|DRUG|simvastatin|
48386090|NCT05844995|DRUG|Acetaminophen/Naproxen Sodium|Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
48386091|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
48386092|NCT04838132|PROCEDURE|Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline|A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
48386093|NCT06224387|DRUG|CTS2190 capsules|4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
48386094|NCT04997369|DEVICE|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
48386095|NCT05567562|COMBINATION_PRODUCT|dual anti-platelet therapy|dual anti-platelet therapy
48386096|NCT05567562|DRUG|Placebo|Placebo
48386097|NCT00897507|OTHER|Laboratory Biomarker Analysis|Correlative studies
48386098|NCT02217657|DEVICE|Thermocool Smart Touch Catheter|Physician informed to contact force
48521381|NCT00150605|DRUG|Extended-release carbamazepine|
48521382|NCT01280643|DRUG|fluorouracil|Given IV
48521383|NCT01280643|DRUG|leucovorin calcium|Given IV
48521384|NCT01280643|DRUG|oxaliplatin|Given IV
48521385|NCT01280643|DRUG|irinotecan hydrochloride|Given IV
48521386|NCT01280643|BIOLOGICAL|bevacizumab|Given IV
48521387|NCT01280643|BIOLOGICAL|cetuximab|Given IV
48521388|NCT01280643|DRUG|capecitabine|Given PO
48521389|NCT01280643|GENETIC|mutation analysis|Correlative studies
48725481|NCT00002961|DRUG|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients \</= 20kg to receive busulfan 1.0 mg/kg/dose IV\*\*Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients \>20kg and 1.25 mg/kg/dose by mouth (po) for patients \</= 20 kg."
48725482|NCT00002961|DRUG|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
48725483|NCT00002961|RADIATION|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) \>/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses \>3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
48725484|NCT06398925|DRUG|OCT461201 50 mg|Oral capsule
48725485|NCT06398925|DRUG|OCT461201 100 mg|Oral capsule
48725486|NCT06398925|DRUG|OCT461201 150 mg|Oral capsule
48521390|NCT01280643|GENETIC|gene expression analysis|Correlative studies
48521391|NCT01280643|OTHER|laboratory biomarker analysis|Correlative studies
48521392|NCT01280643|OTHER|immunohistochemistry staining method|Correlative studies
48521393|NCT01280643|GENETIC|nucleic acid sequencing|Correlative studies
48725487|NCT06398925|DRUG|OCT461201 450 mg|Oral capsule
48725488|NCT06398925|DRUG|Placebo|Placebo capsule
48027058|NCT05768308|BEHAVIORAL|Internet Progressive Muscle Realxation Training (iPMR)|Participants from the active control group will receive progressive muscle relaxation training (iPMR) (Bernstein, Borkovec, Hazlett-Stevens, 2000). It is also a modular intervention and, similar to the i-cbt condition, consists of 5 modules. During the intervention, participants learn how to progressively tighten and relax different muscle groups.The first module is planned for two weeks and the rest of them for one week each. Intervention consists of video materials and audio guided relaxations. Participants are encouraged to train these relaxations once a day.
48027059|NCT03112616|OTHER|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
48027060|NCT02032901|DRUG|Daclatasvir|
48521394|NCT01280643|GENETIC|protein expression analysis|Correlative studies
48521395|NCT01280643|GENETIC|polymerase chain reaction|Correlative studies
48521396|NCT01280643|GENETIC|DNA analysis|Correlative studies
48521397|NCT02449278|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).~Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
48725489|NCT03156439|DRUG|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
48725490|NCT00206934|DRUG|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
48725491|NCT00206934|DRUG|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
48725492|NCT06150794|DEVICE|Excimer laser|Excimer laser will be started at a dose of 300 mj/cm2 and increases 50-100 mj/cm2 each session. The aim of treatment is to deliver a dose that induces visible redness in the psoriatic lesion (supra-erythematous dose), but not induce a blister.
48521398|NCT02449278|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).~Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
48521399|NCT02449278|DRUG|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
48521400|NCT02449278|DRUG|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
48521401|NCT02449278|DRUG|vincristine|Patients in both arms will be given vincristine chemotherapy
48521402|NCT02449278|DRUG|prednisone|Patients in both arms will be given prednisone chemotherapy
48521403|NCT01522456|DRUG|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
48725493|NCT06150794|DRUG|Methotrexate Injection|A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
48725494|NCT00718770|DRUG|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
48725495|NCT06213181|OTHER|Mindfulness intervention|It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
48725496|NCT02337166|DEVICE|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
48725497|NCT02337166|PROCEDURE|Periodontal flap surgery|
48725498|NCT04084821|OTHER|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
48725499|NCT00584207|PROCEDURE|radiofrequency ablation|Intraoperative RFA of uterine fibroids
48386099|NCT05912608|PROCEDURE|Conservative TAAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
48386100|NCT05912608|PROCEDURE|Extensive TAAAD-R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
48386101|NCT03574818|DRUG|Necitumumab-Gemcitabine-Cisplatin|"* Gemcitabine 1250mg/m2 IV on D1, D8~* Cisplatin 75mg / m2 IV on D1~* Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
48521404|NCT01522456|DRUG|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
48521405|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based physical activity|Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.
48521406|NCT05758857|BEHAVIORAL|Experimental: Guidelines-based healthy eating|One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.
48725500|NCT03706300|DRUG|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
48725501|NCT04665531|PROCEDURE|Erector Spinae Catheter|Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
48725502|NCT04665531|PROCEDURE|Intercostal block|Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
48027061|NCT02032901|DRUG|Sofosbuvir|
48521407|NCT05758857|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
48725503|NCT04665531|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
48725504|NCT05172674|DIAGNOSTIC_TEST|ultrasound according routine antenatal care|ultrasound examinations at 11-14, 19-22 and 33-35 weeks
48725505|NCT01363934|DRUG|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
48725506|NCT01363934|DRUG|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
48725507|NCT02095509|DRUG|Enoxaparin|Drug class: Low-molecular weight heparin
48725508|NCT03102567|DRUG|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
48725509|NCT03102567|DRUG|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
48027062|NCT06415201|OTHER|Interactive Artificial Intelligence|scenario based AI to assess, classify, explain and conduct supportive interviews
48027063|NCT04495712|DRUG|spironolactone|aldosterone blocker
48027064|NCT04495712|DRUG|placebo|identical in appearance to spironolactone study drug
48027065|NCT05235529|PROCEDURE|Aortic valve replacement|Surgery replacement od the aortic valve
48027066|NCT05235529|DEVICE|TAVI|Transcatheter aortic valve implantation
48386102|NCT03574818|DIAGNOSTIC_TEST|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
48725510|NCT03102567|DRUG|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
48725511|NCT05106010|OTHER|Balance Flow Yoga|The yoga class is based on hatha yoga which includes physical poses and mindful movement integrated with breath. Conducted in a local yoga studio for 75 minutes duration, twice per week and also open to the public. The specific yoga techniques reflect the objectives of our study and focus on addressing some of the physical, mental and emotional factors that potentially contribute to falls such as balance, balance confidence, strength, coordination, proprioception, core training strategies, and breathing techniques integrated with mindfulness practices and yoga philosophy. The practices will incorporate a combination of seated, kneeling, standing and lying postures and transitions between positions with individual modifications provided on an as-needed basis. The yoga classes will be co-designed by registered yoga teachers and taught by two trained and experienced and yoga teachers blinded to study testing measures.
48725512|NCT04716920|OTHER|Tai Chi|Attend Tai Chi exercise classes
48725513|NCT04716920|DEVICE|FitBit|Wear FitBit
48183756|NCT02592915|DRUG|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
48386103|NCT04898790|BEHAVIORAL|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
48386104|NCT02983773|DRUG|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
48386105|NCT02983773|DRUG|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
48386106|NCT02983773|DRUG|Placebo|1 smoked placebo marijuana cigarette
48386107|NCT00244881|DRUG|cediranib maleate|Given orally
48386108|NCT00244881|OTHER|laboratory biomarker analysis|Correlative studies
48386109|NCT06033963|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
48386110|NCT06033963|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
48386111|NCT00170898|DRUG|Lumiracoxib|
48386112|NCT03455530|OTHER|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
48386113|NCT05722938|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
48386114|NCT05722938|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
48386115|NCT02395536|OTHER|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
48386116|NCT02395536|OTHER|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
48386117|NCT01264328|DRUG|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
48386118|NCT05694169|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
48386119|NCT04913311|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
48386120|NCT04913311|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with BAL
48386121|NCT04913311|OTHER|Chemoradiotherapy|Undergo concurrent chemoradiation per standard of care
48386122|NCT04913311|PROCEDURE|Computed Tomography|Undergo computed tomography scan
48521408|NCT01107691|OTHER|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
48725514|NCT04716920|OTHER|Support Group Therapy|Join Tai4Chijoint group
48725515|NCT04716920|OTHER|Questionnaire Administration|Ancillary studies
48725516|NCT04716920|OTHER|Quality-of-Life Assessment|Ancillary studies
48725517|NCT03517462|DRUG|Ivermectin 3Mg Tab|ivermectin tablet
48725518|NCT00444067|DEVICE|Spinal Sealant|Spinal Sealant System
48725519|NCT00444067|OTHER|Standard of Care|Standard of Care
48725520|NCT03312205|BIOLOGICAL|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
48386123|NCT04913311|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
48386124|NCT04913311|DRUG|Immune Checkpoint Inhibitor|Receive CPI per standard of care
48725521|NCT05241145|DRUG|IVMED-80|Good Manufacturing Practices-grade copper (ІІ) sulfate pentahydrate (CuSO4 #5H2O MW 249.69) was dissolved in a vehicle solution comprised of a balanced salt solution (BSS) with osmolality of approximately 500 mOsm/L. Copper sulfate was concentrated to 0.15 mg/mL. The drops were manufactured on prior to the study at a compounding pharmacy in Salt Lake City, Utah.
48725522|NCT05241145|OTHER|Placebo|This was identical to the IVMED-80 product, but without the active ingredient, copper sulfate.
48725523|NCT04591236|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to Parkinson patients.
48725524|NCT04591236|DEVICE|Treadmill gait training|Treadmill gait training was applied to Parkinson patients.
48725525|NCT00004245|DRUG|sodium salicylate|
48725526|NCT03922165|PROCEDURE|Adenotonsillectomy|Routine AT per clinical care.
48725527|NCT01441700|PROCEDURE|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
48386125|NCT04913311|PROCEDURE|Nasal Wash and Collection|Undergo nasal wash
48521409|NCT03212235|RADIATION|Hypofractionated radiation therapy|Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
48521410|NCT06581510|PROCEDURE|esthetic dental crowns|Minimal Preparation of esthetic dental crown
48521411|NCT06581510|PROCEDURE|control group|Nuu smile ready-made zirconia crown with its well-known reduction
48725528|NCT01601210|DRUG|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
48725529|NCT03057080|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
48725530|NCT00005859|DRUG|tipifarnib|
48725531|NCT02421679|DRUG|TNX-102 SL|TNX-102 Sublingual tablets
48725532|NCT02373514|DRUG|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
48725533|NCT02373514|DRUG|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
48725534|NCT04755452|PROCEDURE|Low intra-abdominal pressure|7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
48521412|NCT04632576|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
48521413|NCT02297256|PROCEDURE|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
48521414|NCT02297256|PROCEDURE|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
48521415|NCT00034138|DRUG|oregovomab|
48725535|NCT04755452|PROCEDURE|High (standard) intra-abdominal pressure|12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
48521416|NCT06079892|PROCEDURE|radiofrequency|haemorrhoidal removal using radiofrequency
48521417|NCT06275438|OTHER|The delivery being performed via cesarean section surgery rather than natural childbirth|At Kars Harakani State Hospital and Kafkas University, 16 placentas were collected, with 8 obtained from induced deliveries and 8 from spontaneous deliveries, between 09:00-21:00. Nulliparity and multiparity were not distinguished among the expectant mothers. Placentas were obtained hours before delivery from mothers admitted to the gynecology service, whose eligibility was determined based on exclusion criteria, after obtaining signed informed consent forms, with assurances given that no interventional procedures would be performed on the mother or the baby. The method of cesarean section (spinal or general anesthesia) in the case group was recorded, ensuring that the anesthetic agents used contained the same active ingredients. Placentas from births involving different anesthetic drugs were not included in the study, aiming to standardize the procedure.
48521418|NCT02254980|DEVICE|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
48386126|NCT04913311|OTHER|Quality-of-Life Assessment|Ancillary studies
48386127|NCT04913311|OTHER|Questionnaire Administration|Ancillary studies
48386128|NCT04913311|PROCEDURE|Spirometry|Under lung spirometry tests
48386129|NCT03715816|BEHAVIORAL|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
48386130|NCT01394120|DRUG|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~* Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~* TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~* TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~* TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~* TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~* TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
48386131|NCT01394120|DRUG|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
48386132|NCT01578603|DIETARY_SUPPLEMENT|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
48027067|NCT06350019|PROCEDURE|Penile revascularızation|The importance of resistive index in the preoperative evaluation of vascular-induced erectile dysfunction, predicting the success of penile revascularization surgery, and postoperative patient management was investigated.
48183757|NCT02592915|OTHER|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
48521419|NCT02254980|DEVICE|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
48725536|NCT00820222|DRUG|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
48725537|NCT00820222|DRUG|lapatinib|oral medication; daily dose taken once a day
48725538|NCT00820222|DRUG|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
48725539|NCT05897697|OTHER|Interview|Structured interview
48725540|NCT04159584|OTHER|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
48725541|NCT01079936|DRUG|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
48725542|NCT01079936|DRUG|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
48725543|NCT01079936|PROCEDURE|Stem Cell Infusion|Stem cell infusion on Day 0.
48725544|NCT05899296|DEVICE|dental syringe ( NumBee)|assess the capability of NumBee to reduce anxiety and pain during injection
48725545|NCT05899296|DEVICE|Traditional dental syringe|compare the level of anxiety of the traditional dental syringe and the Number dental syringe
48725546|NCT00301288|PROCEDURE|Autologous stem cell transplant|
48725547|NCT06368934|PROCEDURE|sub-lobectomy|Combined with previous research and our team's precise neurosurgery concept, we define the surgical strategy based on lobectomy and further preserving the brain parenchyma in functional areas according to anatomical landmarks and electrophysiological boundaries as sub-lobectomy.
48725548|NCT06368934|PROCEDURE|imaging total resection|Imaging total resection (T1-enhanced borders) will met the RANO criteria
48725549|NCT02437084|DRUG|Atorvastatin|Study subjects will receive atorvastatin 40 mg for 10 weeks.
48725550|NCT01754792|DIETARY_SUPPLEMENT|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
48725551|NCT01026740|DRUG|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
48725552|NCT00915551|DRUG|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
48725553|NCT00915551|DRUG|Vehicle Gel|once daily for 3 consecutive days
48725554|NCT06135610|DIAGNOSTIC_TEST|Postive SAR-CoV-2 PCR nasopharyngeal swab|Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
48725555|NCT01851785|BEHAVIORAL|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
48725556|NCT02259855|DRUG|Tipranavir|
48725557|NCT02259855|DRUG|Ritonavir|
48725558|NCT02259855|DRUG|Pegylated interferon|
48725559|NCT02259855|DRUG|Ribavirin|
48027068|NCT00664612|DEVICE|AirTraq|Laryngoscopy with AirTraq
48027069|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain Plus dexamethasone|Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side
48183758|NCT04420039|DEVICE|Endoscopic biliary transmural drainage|"Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent."
48027070|NCT06292273|PROCEDURE|Transversus Abdominis Plane Block with bupivacain|plain bupivacaine 0.25%, 25 ml bilaterally
48027071|NCT00345397|DEVICE|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
48183759|NCT00914745|DRUG|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
48183760|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 15g/d|Supplementation with 15g/day of SPF or Comparator
48521420|NCT00124748|DRUG|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
48521421|NCT02655497|BEHAVIORAL|Cognitive training|
48027072|NCT04098627|BEHAVIORAL|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
48027073|NCT00648869|DRUG|metformin tablet, metformin gum|500 mg, 250 mg
48027074|NCT02451748|OTHER|Lab Work|Lab work to measure IL-7 and IL-7R
48183761|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 7.5g/d|Supplementation with 7.5g/d of SPF ou comparator
48183762|NCT04710199|DRUG|Maraviroc experimental group|300-milligram dose of the drug two times daily , oral way. During 14 days.
48725560|NCT03259815|PROCEDURE|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
48725561|NCT03259815|DIAGNOSTIC_TEST|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
48725562|NCT01609413|DIETARY_SUPPLEMENT|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
48725563|NCT01609413|DIETARY_SUPPLEMENT|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
48725564|NCT06393634|DRUG|Testosterone injection|A single injection of testosterone
48725565|NCT06393634|DRUG|Testosterone gel|A daily dose of testosterone gel
48725566|NCT06393634|DRUG|Testosterone Oral|A twice-daily pill of testosterone pill to swallow
48386133|NCT01578603|DIETARY_SUPPLEMENT|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
48386134|NCT05552430|DEVICE|RelieveVRx|Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.
48386135|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
48521422|NCT02655497|BEHAVIORAL|Psychosocial education|
48027075|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
48386136|NCT01861431|BEHAVIORAL|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
48386137|NCT02131753|DRUG|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
48386138|NCT02332655|DRUG|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
48386139|NCT05112263|DRUG|Tofacitinib|For the tofacitinib the dose of 10 mg BD will be administered for 8 weeks (10 mg TDS for initial three days) and then reduced to 5 mg BD for the period of study
48521423|NCT01910818|DEVICE|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
48521424|NCT01910818|OTHER|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
48521425|NCT02492867|RADIATION|Response-driven Adaptive Radiation Therapy|
48521426|NCT02492867|DRUG|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
48725567|NCT05726474|BEHAVIORAL|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
48027076|NCT02451748|DRUG|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or is provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg is given every 2 weeks. Treatment is performed through subcutaneous injection."
48027077|NCT02451748|DRUG|Hydroxychloroquine|some patients are on 400mg/day of hydroxychloroquine.
48027078|NCT02451748|DRUG|Sulfasalazine|some patients are on 300 mg/day and some patients are on 1000 mg/day dose of sulfasalazine
48027079|NCT02451748|DRUG|Medrol|some patients are on 8mg/day of medrol
48027080|NCT02451748|DRUG|Prednisone|some patients are on 10mg /day, some patients are on 20 mg/day, some patients are on 2.5 mg/day, some patients are on 30 mg/day, and some patients are on 5 mg/day of prednisone
48027081|NCT02451748|DRUG|Triamcinolone|some patients are on Triamcinolone 40-80mg IM monthly (received 40mg dose 1 week before blood draw, off enbrel 50mg weekly and SSZ 1000mg bid for \~ 3 months) some patients are on Triamcinolone 40mg IM monthly
48027082|NCT02451748|DRUG|Naproxen|some patients are on 1000 mg/day of naproxen
48027083|NCT02451748|DRUG|Leflunomide|some patients are on 20mg/day of leflunomide
48027084|NCT02451748|DRUG|Methotrexate|some patients are on 20mg weekly, some patients are on 25mg weekly, some patients are on 17.5 mg, some patients are on 15 mg weekly, some patients are on 7.5 mg weekly, and some patients are on 15 mg weekly dose of methotrexate
48027085|NCT02451748|DRUG|humira|some patients are on Humira 40mg q2weeks
48027086|NCT02826226|DEVICE|multiple-breath-washout test|
48027087|NCT02826226|DRUG|Bronchodilator Agents|
48027088|NCT00337714|PROCEDURE|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
48027089|NCT00337714|PROCEDURE|CVC cannulation|placement of conventional trilumen CVCs
48027090|NCT03566719|OTHER|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
48027091|NCT00987298|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
48027092|NCT05319678|OTHER|evaluation with Meludia music software|"Measurement instruments:~1. - MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests"
48027093|NCT01859455|DRUG|LGT209 50 mg|Active experimental drug
48521427|NCT02492867|DRUG|Paclitaxel|40 mg/m\^2 IV concurrent with RT; 200 mg/m\^2 during consolidation. Given IV
48521428|NCT02492867|DEVICE|FDG-PET|
48521429|NCT02492867|DEVICE|V/Q SPECT|
48521430|NCT02492867|DRUG|Durvalumab|10 mg/kg during consolidation. Given IV
48521431|NCT00549432|DEVICE|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
48725568|NCT05726474|BEHAVIORAL|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
48725569|NCT00348647|BEHAVIORAL|physical training program to prevent injuries|
48725570|NCT00709410|BIOLOGICAL|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
48725571|NCT01412385|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
48386140|NCT05112263|DRUG|Cyclosporine|: Intravenous Cyclosporine 2 mg/kg continuous infusion for 5-7 days and then shifted to oral cyclosporine 4 mg/kg/day in two divided doses for 12 weeks.Those who respond with intravenous cyclosporine will be shifted to oral cyclosporine 4 mg/kg for 12 weeks while the thiopurine dose is adjusted to the patient's weight
48386141|NCT03875716|RADIATION|Radiation therapy|Radiation therapy
48386142|NCT03092115|DEVICE|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
48725572|NCT01412385|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
48386143|NCT02163278|DRUG|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
48386144|NCT02163278|DRUG|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
48386145|NCT04837274|DIETARY_SUPPLEMENT|Placebo|Dextrose (480 mg)
48386146|NCT04837274|DIETARY_SUPPLEMENT|Active|Tary Cherry (480 mg)
48725573|NCT01412385|BIOLOGICAL|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
48725574|NCT00518297|DRUG|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
48725575|NCT00518297|DRUG|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
48725576|NCT00518297|DRUG|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
48725577|NCT02387489|BEHAVIORAL|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
48725578|NCT02387489|BEHAVIORAL|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
48725579|NCT06459336|OTHER|Intensive constraint-induced movement therapy|Intensive protocol of CIMT will be given for 6hrs for 6 days to make total of 36 hours
48027094|NCT01859455|DRUG|LGT209 300 mg|Active experimental drug
48027095|NCT01859455|DRUG|Placebo|Placebo comparator
48027096|NCT01859455|DRUG|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
48027097|NCT03494257|DRUG|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
48027098|NCT01141361|PROCEDURE|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
48027099|NCT03778216|BEHAVIORAL|Family Based Treatment|
48027100|NCT04100226|DIETARY_SUPPLEMENT|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
48027101|NCT05688813|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and sacral erector spinae blocks were administered
48027102|NCT05052970|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
48027103|NCT05052970|DRUG|Bortezomib for Injection|Bortezomib (1.3 mg/m\^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
48027104|NCT05052970|DRUG|Dexamethasone Acetate Tablets|Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
48027105|NCT03907501|DIETARY_SUPPLEMENT|Synbiotic|an herbal prebiotic plus probiotic
48027106|NCT03907501|DIETARY_SUPPLEMENT|Probiotic|Triphala alone
48027107|NCT03907501|DIETARY_SUPPLEMENT|Placebo|Inert capsule
48027108|NCT02212223|DIETARY_SUPPLEMENT|Vitamin D3|
48027109|NCT01806337|DRUG|Alemtuzumab|Consolidation after CHOP induction
48027110|NCT06095414|DIAGNOSTIC_TEST|MRI|MRI based assessment of tumor microenvironment in breast cancer mass
48027111|NCT04880941|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
48027112|NCT00030550|DRUG|thalidomide|
48027113|NCT03136068|DRUG|Digoxin|Trans-abdominal injection
48027114|NCT03136068|DRUG|Placebo|Trans-abdominal injection
48027115|NCT00786357|BEHAVIORAL|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
48027116|NCT00786357|BEHAVIORAL|Sleep Enhancement Training System|4 week program of readings and relaxation programs
48027117|NCT01193556|DEVICE|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
48027118|NCT01193556|DEVICE|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
48027119|NCT05409417|DRUG|Experimental drug|Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
48027120|NCT05694624|DRUG|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
48027121|NCT00975234|PROCEDURE|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
48027122|NCT00975234|PROCEDURE|Revascularisation|Revascularisation surgery
48183763|NCT04710199|OTHER|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
48725580|NCT06459336|OTHER|Distributed constraint-induced movement therapy|Distributed protocol of CIMT will be given for 2.25hrs two times a week for 8 weeks making total of 36 hours
48725581|NCT04038762|PROCEDURE|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
48725582|NCT02215343|DIETARY_SUPPLEMENT|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).
48725583|NCT02215343|DIETARY_SUPPLEMENT|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
48386147|NCT05714150|BEHAVIORAL|Complex Balance Tasks|The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform.
48521432|NCT03472781|OTHER|No intervention. A retrospective case review|No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
48521433|NCT01153100|DRUG|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
48521434|NCT02115607|DRUG|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
48521435|NCT02807337|DRUG|Caphosol|
48521436|NCT02807337|DRUG|0,9% NaCl|
48725584|NCT04640974|DEVICE|Cingal|Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
48725585|NCT02186717|DIETARY_SUPPLEMENT|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
48725586|NCT06152549|BEHAVIORAL|Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge|The first group (N=250) will receive the Maltreatment and Abuse Chronology of Exposure (MACE) scale first, to assess early life adversity, followed by the standardized test questions. A POMS will be administered before each challenge.
48725587|NCT06152549|BEHAVIORAL|Standardized Maths and Verbal Questions such as the ones used in SATs|The second group (N=250) will be presented with the standardized test questions (Math/Verbal) to assess their stress level, measured through POMS, followed by the Maltreatment and Abuse Chronology of Exposure (MACE) scale.
48725588|NCT06152549|BEHAVIORAL|Chronology of Perceived Discrimination Scale (CPDS)|The group will also receive the Chronology of Perceived Discrimination Scale (CPDS) to assess type and timing of perceived discrimination during the first 18 years of life. A POMS will be administered before and after the intervention/challenge.
48725589|NCT06152549|BEHAVIORAL|International Personality Item Pool (IPIP-NEO)|Participants in both groups will be presented with the abbreviated version of the IPIP-NEO a personality questionnaire that provides ratings on the Five Factor Personality Model. The research team sees this task as non-stressful and even potentially soothing and envisions that it will help to restore an individual's mood before taking the next stressful test and again at the completion of the online session.
48725590|NCT05849519|DRUG|Coenzyme I for Injection + conventional treatment|The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
48725591|NCT05849519|DRUG|Conventional treatment|The control group was treated with conventional treatment
48725592|NCT02112734|DRUG|Vitamin D|400 IU/daily until age 12 months
48725593|NCT02112734|DRUG|placebo|identical placebo daily
48725594|NCT01964677|DEVICE|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
48725595|NCT00504894|DRUG|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
48725596|NCT00504894|DRUG|Propofol|A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
48725597|NCT00504894|DRUG|Thiopental|A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
48386148|NCT00958698|OTHER|Communication Intervention|Ancillary studies
48725598|NCT04119102|DRUG|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
48725599|NCT01120990|OTHER|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
48725600|NCT03841136|DRUG|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1\~D3
48386149|NCT00958698|OTHER|Educational Intervention|Ancillary studies
48386150|NCT00958698|OTHER|Internet-Based Intervention|Ancillary studies
48386151|NCT00958698|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
48386152|NCT00958698|OTHER|Quality-of-Life Assessment|Ancillary studies
48386153|NCT00958698|OTHER|Questionnaire Administration|Ancillary studies
48386154|NCT04400175|DEVICE|Valved ergonomic teat|Administration of milk with a feeding system with a valved ergonomic teat in late preterm newborns.
48725601|NCT01946126|OTHER|No Intervention|There is no intervention in this study.
48725602|NCT03579173|DIAGNOSTIC_TEST|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
48725603|NCT03579173|DIAGNOSTIC_TEST|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
48386155|NCT04400175|DEVICE|Standard silicon teat|Administration of milk with a feeding system with a standard silicon teat
48521437|NCT03135717|DIETARY_SUPPLEMENT|Nutritional care|"* Diagnosis of protein energy wasting : anthropometry, calculation of the nutrient intakes, evaluation of appetite, evaluation of gastrointestinal syndromes, hand grip test and bioimpedancemetry~* Treatment of protein energy wasting : estimation of nutritional requirements, prescription of oral nutritional supplement or artificial nutrition, physical rehabilitation~* Multidisciplinary approach (nephrologists, dieticians, physiotherapists, nurses)~* Evaluation of the nutritional treatment (plasma albumin and prealbumin, weight evolution, muscle strength and body composition)"
48725604|NCT03579173|DIAGNOSTIC_TEST|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
48725605|NCT02093338|DIETARY_SUPPLEMENT|Lactobacillus fermentum CECT5716|
48725606|NCT02093338|OTHER|Placebo Comparator: maltodextrin|Placebo
48725607|NCT00017290|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
48725608|NCT00017290|BIOLOGICAL|keyhole limpet hemocyanin|
48725609|NCT00017290|BIOLOGICAL|sargramostim|
48725610|NCT00017290|DRUG|cyclophosphamide|
48725611|NCT00017290|DRUG|prednisone|
48725612|NCT00017290|DRUG|vincristine sulfate|
48725613|NCT05753163|COMBINATION_PRODUCT|HAIC-FOLFOX combined with Sintilimab and Regorafenib|HAIC (FOLFOX: oxaliplatin 85mg/m2, 5- fluorouracil 2500mg/m2, calcium folinate 400mg/m2) was given every 4-6 weeks for 2-4 cycles depending on pts' health status, in combination with Sintilimab (200mg, iv, d1) and regorafenib (80mg, po, d1-21) every 3 weeks for up to 6 months .
48521438|NCT05089591|DEVICE|Intense Pulsed Light therapy|The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.
48521439|NCT05089591|DEVICE|Sham Treatment|The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
48521440|NCT05780060|BEHAVIORAL|Standard of care, RPM and digital feedback|Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.
48725614|NCT01939366|DRUG|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
48725615|NCT01939366|DRUG|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
48725616|NCT01939366|DRUG|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
48725617|NCT01939366|DRUG|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
48725618|NCT01939366|DRUG|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
48725619|NCT01286103|DRUG|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
48725620|NCT01286103|DRUG|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
48725621|NCT04197388|DEVICE|Inspiratory muscle training device|Inspiratory muscle training, 6 cycles of 30 breaths for 12 weeks.
48725622|NCT01895309|DRUG|Enbrel (etanercept)|
48725623|NCT01895309|DRUG|SB4 (proposed biosimilar to etanercept)|
48725624|NCT01106274|RADIATION|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
48725625|NCT00892138|BEHAVIORAL|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
48725626|NCT02540291|DRUG|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
48725627|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System|The LX2.3 Laser and LED Photobiomodulation system by THOR Photomedicine Ltd is a CE marked product and has a long track record of safety, usability, and effectiveness.
48725628|NCT06258096|DEVICE|LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting|The sham setting consists of light of the same colour (white light with a red filter), applied in the same way as in the experimental group.
48027123|NCT03830671|DRUG|18-month regimen containing 6 anti-TB drugs|Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
48183764|NCT03186586|DRUG|Ulipristal acetate|5mg/day/five days
48725629|NCT04699461|DRUG|Loncastuximab Tesirine|IV infusion
48183765|NCT03186586|DRUG|Placebo|Placebo one pill a day for 5 days at the bleeding episode
48725630|NCT04699461|DRUG|Idelalisib|Oral tablet
48725631|NCT00654459|DIETARY_SUPPLEMENT|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
48725632|NCT03044808|DRUG|Lidocaine|
48027124|NCT06037759|DIAGNOSTIC_TEST|Cardiac Biomarkers|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
48725633|NCT03044808|DRUG|Saline|
48386156|NCT06548529|RADIATION|HER2 expression of PET imaging|Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
48725634|NCT05806866|BEHAVIORAL|Cognition scores, cognitive instrumental activities of daily living scores|A detailed neuropsychological test battery will be applied. The Functional Activitites Questionnaire (FAQ) subscores will be used to define cognitive and motor instrumental activities of daily living function
48386157|NCT05927194|BEHAVIORAL|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
48725635|NCT00006026|DRUG|rubitecan|
48725636|NCT01997190|BIOLOGICAL|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
48027125|NCT06037759|DIAGNOSTIC_TEST|Lipidomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
48386158|NCT01354015|DEVICE|DRMS|USE OF TEXT MESSAGING SYSTEM
48386159|NCT06271226|OTHER|acupressure|With acupressure, massage or pressure is applied to certain points on the body with fingers, hands or palms. The pressed points are the points on the skin that are sensitive to bioelectrical impulses and can easily transmit them.
48386160|NCT06271226|OTHER|placebo acupressure|n the placebo group, the preparations and forms applied to the experimental group will be applied in the same way, but in accordance with the literature, an area 1.5 cm away from the acupressure point that has no connection with the acupressure point will be selected and the application will be made in the form of light touch
48386161|NCT06271226|OTHER|control group|During the study, pain and physiological parameters will be monitored and recorded twice a day (morning and evening) for 2 days, without any application (other than the routine treatment given by the physician).
48027126|NCT06037759|DIAGNOSTIC_TEST|Proteomics|Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
48386162|NCT06566651|OTHER|Emotion Discrimination Task (EDT)|It estimates the subjective bias and sensitivity in discriminating between happy and angry facial expressions of different intensities of emotional expression
48027127|NCT01813240|DRUG|Minocycline|
48027128|NCT01813240|DRUG|placebo|
48386163|NCT03934242|OTHER|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
48386164|NCT01004575|DEVICE|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
48386165|NCT00745459|DRUG|NPO-11|20 mL NPO-11
48725637|NCT05676216|DRUG|Diphenhydramine|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
48725638|NCT05676216|DRUG|Sodium Bicarbonate|Sodium bicarbonate 66.4 mEq in 100 mL normal saline intravenous dripping when vertigo patients visit Emergency Department
48725639|NCT05676216|DRUG|Diphenhydramine + Sodium Bicarbonate|Diphenhydramine 30 mg in 100 mL normal saline intravenous dripping with Sodium bicarbonate 66.4 mEq intravenous push when vertigo patients visit Emergency Department
48725640|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
48725641|NCT02526225|DRUG|Ginkgo diterpene lactone meglumine injection simulation|5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
48725642|NCT06465745|DEVICE|AltaValve System.|Transcatheter Mitral Valve Replacement.
48725643|NCT03574428|DRUG|GNbAC1|Monoclonal Antibody infused i.v.
48725644|NCT03574428|OTHER|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
48725645|NCT03412253|PROCEDURE|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
48725646|NCT05835583|BEHAVIORAL|The theory based integrated program|The theory-based integrated program is administered by a nurse trained in motivational interviewing.In the 12-hour intervention, this program uses motivational interviewing skills to increase the patient's attitude towards medication, enhance the support of significant others around them, and increase the patient's control over their own behavior.
48725647|NCT03888209|DEVICE|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
48725648|NCT04943432|BEHAVIORAL|Behavioral Activation|8 sessions of harm reduction-focused Behavioral Activation for Substance Use
48725649|NCT04772781|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuflex®
48725650|NCT04772781|DRUG|Ibuflex®|Ibuflex® + placebo of S (+) - Ibuprofen
48725651|NCT02561559|RADIATION|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
48725652|NCT00337584|PROCEDURE|Pre-surgical screening|
48027129|NCT04971382|DRUG|Curcumin|Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
48386166|NCT02032446|BIOLOGICAL|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~1. 3 patients → 3 infusions of 1x106 cells /kg~2. 3 patients → 3 infusions of 2x106 cells /kg~3. 3 patients → 3 infusions of 3x106 cells /kg"
48386167|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo HF-WBI
48386168|NCT01266642|RADIATION|External Beam Radiation Therapy|Undergo CF-WBI
48027130|NCT06485778|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Patients will receive bilateral cervical nodal irradiation with the primary post operative site excluded (30 fractions).
48027131|NCT06485778|OTHER|Life questionnaire's|EORTC QLQ C30/HN 35 and MDADI
48027132|NCT03999619|BEHAVIORAL|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
48027133|NCT02524704|DEVICE|CT scan|Applied only when part of the patient's standard care
48027134|NCT04258696|DEVICE|diode laser|using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken
48027135|NCT04258696|DEVICE|ultrapak Knitted retraction cord|using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
48027136|NCT01027910|DRUG|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
48027137|NCT01027910|DRUG|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
48386169|NCT01266642|RADIATION|Hypofractionated Radiation Therapy|Undergo HF-WBI
48386170|NCT01266642|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
48725653|NCT05196685|DIAGNOSTIC_TEST|Carotid Doppler USG|All Doppler ultrasonography measurements will be made in a dimly lit room at room temperature, with the patient in the supine position, the head slightly hyperextended, the patient looking to the left when measuring the right side, and the patient looking to the right when measuring the left side. In all patients, common carotid artery (CCA), internal carotid artery (ICA) and vertebral artery (VA) gray scale and color Doppler ultrasonography wşll be performed using the GE 9L Linear Probe. Color Doppler examination will be performed with a frequency of 4.0/8.0 MHz.
48725654|NCT06175169|DEVICE|Information of Appendix (IA) model|Deep learning model
48027138|NCT01027910|DRUG|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
48027139|NCT03397446|DRUG|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
48027140|NCT02249572|RADIATION|gamma knife radiosurgery|Leksell Perfection model gamma knife.
48725655|NCT02603848|DRUG|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
48027141|NCT05515302|OTHER|Audio Clip|Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
48386171|NCT01266642|OTHER|Quality-of-Life Assessment|Ancillary studies
48725656|NCT02603848|DRUG|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
48725657|NCT05229250|OTHER|Cycling test|RAMP and MULTI-STAGE test
48027142|NCT05404529|DRUG|Tavapadon|Oral tablets
48725658|NCT05229250|OTHER|Occlusion tests|Occlusion test before and after exercise
48725659|NCT05229250|DEVICE|NIRS during cycling|NIRS devices measuring oxygenation during exercise
48027143|NCT00029835|DRUG|Rimonabant (SR141716)|
48183766|NCT01191554|DRUG|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
48386172|NCT01266642|OTHER|Questionnaire Administration|Ancillary studies
48386173|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo HF-WBI
48386174|NCT01266642|RADIATION|Whole Breast Irradiation|Undergo CF-WBI
48725660|NCT05229250|DEVICE|CPET|Cardiopulmonary exercise testing (heart rate, pulmonary gas exchange) during exercise
48725661|NCT05229250|DEVICE|Echo-Doppler examination|Peak systolic velocity and vascular stiffness measurements in the iliac-aortic tract
48725662|NCT05548985|DRUG|Midodrine Oral Tablet|oral midodrine tablet (5 mg) 90 min before performing spinal block
48386175|NCT02511873|DRUG|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
48386176|NCT02511873|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
48386177|NCT01456598|PROCEDURE|Laparoscopic gastrectomy|"* After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
48521441|NCT05780060|BEHAVIORAL|Standard of care and RPM only|Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
48521442|NCT00198055|DRUG|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
48725663|NCT05548985|DRUG|Metoclopramide|oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
48725664|NCT03754829|BEHAVIORAL|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
48725665|NCT01422668|OTHER|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
48725666|NCT05018026|BEHAVIORAL|Nutri-Grade labels|All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
48725667|NCT05184933|OTHER|At-home Polysomnography|Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
48725668|NCT05184933|OTHER|Circadian Protocol|Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
48027144|NCT01605045|OTHER|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
48386178|NCT01456598|PROCEDURE|Open gastrectomy|"* After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
48386179|NCT02181634|DRUG|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
48386180|NCT00870714|DRUG|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
48386181|NCT00870714|DRUG|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
48521443|NCT03848494|PROCEDURE|Surgery|Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
48725669|NCT05184933|OTHER|Rested Wakefulness Trial|Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
48725670|NCT05184933|OTHER|Overnight Sleep Trial|Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
48725671|NCT05184933|BEHAVIORAL|Regularized Sleep Schedule|All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
48725672|NCT05656781|OTHER|Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)|Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
48725673|NCT00013169|BEHAVIORAL|Strong Patient Focus|
48725674|NCT02785614|DRUG|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
48725675|NCT02785614|DRUG|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
48725676|NCT02831322|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
48386182|NCT03635060|PROCEDURE|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
48386183|NCT03635060|PROCEDURE|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
48521444|NCT03208686|BEHAVIORAL|Intervention Group|A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology - a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
48725677|NCT04597840|PROCEDURE|Incisional hernia repair with reinforcement of biosynthetic mesh|The biosynthetic mesh (Phasix or Bio-A meshes) will be placed as a sublay in the retromuscular position to reinforce midline fascial closure. All the surgical procedure (including placement and fixation of the mesh) will be performed according to a standardized protocol.
48725678|NCT04597840|PROCEDURE|Incisional hernia repair with simple suture or synthetic mesh reinforcement.|Based on the discretion of the surgeon, the incisional hernia repair will be done by simple suture or by synthetic mesh reinforcement. All the surgical procedure (including placement and fixation of the mesh if applicable) will be performed according to a standardized protocol.
48725679|NCT04354272|OTHER|Questionnaire|Questionnaire for the satisfaction of patients consulting the odontological emergencies of the GHPS during COVID 19.
48725680|NCT00898391|OTHER|laboratory biomarker analysis|Correlative studies
48521445|NCT00618111|DRUG|Granisetron|
48521446|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 1|2-week ad libitum use of the RELX ENDS tobacco flavor 1
48521447|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 2|2-week ad libitum use of the RELX ENDS tobacco flavor 2
48027145|NCT01605045|OTHER|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
48027146|NCT00775918|DRUG|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
48027147|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
48027148|NCT05827224|DEVICE|Lotrafilcon B spherical soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
48027149|NCT05827224|DEVICE|Lotrafilcon B toric soft contact lenses with comfort additive|Commercially available silicone hydrogel contact lenses
48027150|NCT05827224|DEVICE|Comfilcon A spherical soft contact lenses|Commercially available silicone hydrogel contact lenses
48521448|NCT05134415|OTHER|RELX ENDS Menthol Flavor 1|2-week ad libitum use of the RELX ENDS menthol flavor 1
48521449|NCT05134415|OTHER|RELX ENDS Menthol Flavor 2|2-week ad libitum use of the RELX ENDS menthol flavor 2
48725681|NCT00898391|GENETIC|polymerase chain reaction|Correlative studies
48725682|NCT00898391|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
48725683|NCT00898391|GENETIC|DNA analysis|Correlative studies
48725684|NCT04314076|OTHER|Rhythmic auditory stimulation|RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.
48027151|NCT05827224|DEVICE|Comfilcon A toric soft contact lenses|Commercially available silicone hydrogel contact lenses
48027152|NCT00697749|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
48725685|NCT04314076|OTHER|Gait Training|Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.
48027153|NCT00697749|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
48725686|NCT01691976|DRUG|Oestrogen Patches|
48725687|NCT01691976|DRUG|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
48725688|NCT01196962|DEVICE|Central venous catheter|Central venous catheter insertion to subclavian vein
48027154|NCT02012829|BEHAVIORAL|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
48027155|NCT02459067|BIOLOGICAL|ImmuniCell®|Autologous γδ T Lymphocytes
48027156|NCT03917290|BEHAVIORAL|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
48725689|NCT00727558|DEVICE|nelfilcon A|spherical soft contact lens
48725690|NCT00727558|DEVICE|narafilcon A|spherical soft contact lens
48725691|NCT04690244|OTHER|Tai Chi Chuan trainings|10 weeks of Tai Chi Chuan practice by 6-year experienced training teacher, 2 times per week, 60 min per session.
48725692|NCT00094107|DRUG|Axitinib [AG-013736]|VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
48725693|NCT01276002|PROCEDURE|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
48725694|NCT02924012|OTHER|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
48027157|NCT03542643|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
48027158|NCT03542643|DIETARY_SUPPLEMENT|Placebo|Olive oil ethyl esters
48027159|NCT03738865|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
48027160|NCT03738865|DRUG|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
48027161|NCT01303627|DRUG|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
48027162|NCT01539291|DRUG|Idelalisib|Idelalisib tablet(s) administered orally twice daily
48725695|NCT02924012|OTHER|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
48027163|NCT02201602|DRUG|Gliclazide|
48027164|NCT02201602|DRUG|Glibenclamide|
48027165|NCT05297045|DRUG|RGT001-075|Oral GLP1 Receptor Agonist
48027166|NCT05297045|OTHER|Placebo|Placebo comparator
48027167|NCT02973958|DRUG|Bupivacaine|See active comparator description
48027168|NCT02973958|DRUG|Sevoflurane|See active comparator description
48725696|NCT02924012|OTHER|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
48725697|NCT06043609|OTHER|This is an observational cohort study|This is an observational cohort study
48725698|NCT03086902|DEVICE|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
48725699|NCT03086902|DEVICE|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
48725700|NCT05760534|DRUG|Remimazolam|0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
48725701|NCT03035682|OTHER|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
48725702|NCT03035682|OTHER|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
48725703|NCT06014281|BEHAVIORAL|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~* Close your eyes very gently, in a relaxed way, as you do when we go to sleep~* Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~* Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~* Mentally repeat the (chosen) calming word~* Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
48725704|NCT00354666|DRUG|GSK159797|
48725705|NCT01107613|BEHAVIORAL|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
48183767|NCT02595320|DRUG|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
48725706|NCT01807377|DRUG|PF-05175157|200 mg tablet administered twice per day for 14 days
48725707|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
48725708|NCT01807377|OTHER|Placebo|Placebo administered twice per day for 14 days
48725709|NCT01807377|DRUG|Midazolam|2mg administered as single doses on Days 0 and 11
48725710|NCT06543680|OTHER|Dental restoration|Each patient will randomly receive one cervical restoration with one of the tested restorative systems
48725711|NCT02995798|OTHER|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
48386184|NCT06496360|DIAGNOSTIC_TEST|Artificial Intelligence|The model employs machine learning algorithms to analyze CT imaging data of patients with non-small cell lung cancer. It focuses on the identification and assessment of features of the mediastinal fourth group lymph nodes, including size, shape, margins, and density. By extracting features related to lymph node metastasis, the model assists doctors in making more accurate diagnoses.
48386185|NCT05336318|BEHAVIORAL|Peer support|patients were supported by a mentor
48386186|NCT04981782|OTHER|No study specific intervention, regular care.|Chiropractic care (regular care)
48521450|NCT06331481|OTHER|Fullicular fluid for cytology and biocemical analysis|"The fullicular fluid in the oocyte retrieval process is consider to medical waste. This fluid contains a verity of proteins, mitochondria and verity of cells.~The investigators using this fluid to learn about the evironment of the oocyte and its quality."
48521451|NCT01495000|DRUG|denosumab|60mg subcutaneous injection, single dose
48521452|NCT01495000|DRUG|placebo|placebo subcutaneous injection, single dose
48725712|NCT00259207|PROCEDURE|Pulmonary valve insertion|Pulmonary valve insertion
48725713|NCT00259207|PROCEDURE|medical surgery hybride|medical surgery hybride
48725714|NCT01515046|DRUG|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
48386187|NCT02772003|BIOLOGICAL|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
48386188|NCT02772003|BIOLOGICAL|HCV DNA Vaccine INO-8000|Given IM
48386189|NCT02772003|OTHER|Laboratory Biomarker Analysis|Correlative studies
48725715|NCT03173768|PROCEDURE|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
48725716|NCT04238169|DRUG|Bevacizumab|7.5mg/kg once every three weeks
48725717|NCT04238169|DRUG|Toripalimab|240 mg once every three weeks
48725718|NCT04238169|RADIATION|SBRT|30-50Gy/5F（2-4 lesions）
48725719|NCT00586976|DRUG|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
48725720|NCT00586976|DRUG|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
48725721|NCT00551291|DRUG|Mycophenolate mofetil|1 gm twice daily orally until end of study.
48183768|NCT00953732|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
48183769|NCT01726569|BEHAVIORAL|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
48386190|NCT02772003|OTHER|Quality-of-Life Assessment|Ancillary studies
48386191|NCT02772003|BIOLOGICAL|Rocakinogene Sifuplasmid|Given IM
48521453|NCT00998504|DIETARY_SUPPLEMENT|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
48521454|NCT00998504|DIETARY_SUPPLEMENT|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
48521455|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ lower dose (10\^8 TU) at weeks 0, 8 and 16.
48521456|NCT01428596|BIOLOGICAL|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
48521457|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ higher dose (10\^9 TU) at weeks 0, 8 and 16.
48521458|NCT04931693|DRUG|paracetamol|iv post operative analgesia
48521459|NCT04931693|PROCEDURE|modifiedPECs block|sonar guided pectoral nerve block
48725722|NCT00551291|DRUG|Prednisone|10 mg/day orally until end of study.
48725723|NCT00551291|DRUG|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
48725724|NCT03599323|DRUG|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
48725725|NCT00556413|BIOLOGICAL|cetuximab|
48725726|NCT00556413|DRUG|fluorouracil|
48725727|NCT00556413|DRUG|irinotecan hydrochloride|
48725728|NCT00556413|DRUG|leucovorin calcium|
48725729|NCT00556413|DRUG|oxaliplatin|
48725730|NCT03553082|DRUG|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
48725731|NCT03553082|DRUG|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
48725732|NCT05710276|OTHER|abdominal infrared radiation|In a specific room (controlled temperature and humidity) with a patient lying on his back, we will determine the abdominal infrared radiation with a FLIR® thermal camera (without contact) and quantify the thermal signal by spectral analysis (in degrees Celsius).
48725733|NCT01761500|OTHER|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
48725734|NCT00296153|DRUG|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
48725735|NCT02784600|DEVICE|Bioinductive implant|
48027169|NCT02973958|DRUG|Acetaminophen|See active comparator description
48027170|NCT02973958|DRUG|Ibuprofen|See active comparator description
48725736|NCT00258466|RADIATION|radiation therapy|
48725737|NCT05749393|DRUG|Heparin sodium|Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
48725738|NCT04171232|OTHER|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
48725739|NCT04171232|OTHER|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
48725740|NCT04171232|OTHER|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
48725741|NCT02557022|OTHER|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
48725742|NCT03101085|DRUG|S-equol and Placebo|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
48725743|NCT03101085|DRUG|Placebo and S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
48725744|NCT00536952|DRUG|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
48027171|NCT02973958|DRUG|Ketorolac|See experimental arm description
48027172|NCT06280365|OTHER|Mulligan Mobilization with Movement Technique|Mobilization Technique
48725745|NCT00536952|DRUG|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
48027173|NCT01798550|DRUG|Enoxaparin|Twice daily dosing
48027174|NCT00001663|DEVICE|Magstim Super Rapid Stimulator|
48183770|NCT01726569|OTHER|traditional counseling|Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
48725746|NCT00536952|RADIATION|Radiation Therapy|5 days per week for 4 weeks
48027175|NCT05413538|BEHAVIORAL|Mindfulness training|The intervention recordings will teach the basic concepts of mindfulness through simple guided meditations with content supported by science. Each recording has the same format that included (1) a daily theme, (2) a meditation exercise echoing the theme, (3) a suggested exercise for practice, and (4) an invitation for participants to give a short response to their meditation experience at the end of the recording.
48027176|NCT00606424|DRUG|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
48027177|NCT00002872|BIOLOGICAL|bleomycin sulfate|
48027178|NCT00002872|DRUG|doxycycline|
48027179|NCT00002872|OTHER|talc|
48027180|NCT06193993|DRUG|Abiraterone Acetate|Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
48027181|NCT00004327|DRUG|octreotide|
48725747|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
48725748|NCT05191953|PROCEDURE|Bilateral ultrasound-guided ESPB and superficial PIPB|"Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit."
48027182|NCT00097812|DRUG|zoledronic acid|
48386192|NCT01988337|DEVICE|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactures´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
48386193|NCT01988337|OTHER|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentially, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
48386194|NCT03125707|OTHER|Registry study|
48386195|NCT03022799|DRUG|KM-819|
48386196|NCT03022799|DRUG|Placebo|
48521460|NCT03125798|DEVICE|LigaSure™|LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.
48521461|NCT03125798|DEVICE|Monopolar electrocautery|Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
48521462|NCT02346656|DEVICE|Implantation with the commercially available Axium neurostimulator|
48521463|NCT05615727|DRUG|Dexmedetomidine|2 mcg/kg of undiluted dexmedetomidine \[= 0.02 ml/kg\] and oral placebo tablet
48521464|NCT05615727|DRUG|Zolpidem|zolpidem 10 mg and intranasal saline 0.02 ml/kg
48521465|NCT05615727|OTHER|Placebo|a placebo oral tablet and intranasal saline at 0.02 ml/kg
48521466|NCT03188796|DRUG|Cholecalciferol|oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
48521467|NCT03188796|DRUG|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
48521468|NCT04951869|DRUG|Protescal gel|Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
48521469|NCT04515134|DIAGNOSTIC_TEST|assessment of follicular level of coenzyme Q10 in the ovaries in females undergoing ICSI|human coenzyme Q10 (CoQ10) ELISA kit
48521470|NCT02532686|DRUG|DAAOI-2|500-2000mg/d, oral, for 6 weeks
48725749|NCT03984656|DRUG|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
48521471|NCT02532686|DRUG|placebo|oral, for 6 weeks
48521472|NCT00280735|DRUG|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
48521473|NCT00280735|DRUG|docetaxel|75 mg/m² intravenously, once, every 3 weeks
48521474|NCT03353701|BEHAVIORAL|Contingency Management (CM)|A reinforcement delivery method that involves financial incentive to participants for sustained alcohol abstinence. CM will start after the participants complete the baseline measures and last for at least 30 days and up to 90 days.
48521475|NCT04146103|DRUG|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
48027183|NCT03757559|DRUG|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
48027184|NCT03757559|DRUG|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
48027185|NCT03757559|DRUG|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
48027186|NCT03757559|DRUG|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
48521476|NCT02251600|DRUG|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
48521477|NCT01651117|BEHAVIORAL|Peer Mentoring|Patients will receive peer mentoring.
48521478|NCT06342687|PROCEDURE|High compliance with ERAS protocol|Patients were categorized into two groups based on their adherence to the ERAS protocol: group 1 with a compliance rate below 80% and group 2 with a compliance rate of 80% or above.
48725750|NCT03984656|DRUG|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
48725751|NCT05418491|OTHER|No intervention is used in the current study. Interventions were given in the original A.R.T. study|The current study is a post-intervention study; interventions were given in the original A.R.T. study
48725752|NCT03870425|OTHER|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
48725753|NCT04196673|DEVICE|Alcon SN60WF|Implantation of an intraocular lens Alcon SN60WF
48725754|NCT04196673|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
48725755|NCT06533930|OTHER|Transorbital Sonography|OND and ONSD of participants in the MS patient group and healthy control group were measured by TOS.
48725756|NCT06533930|OTHER|Orbita Magnetic Resonance Imaging|OND and ONSD of participants in the MS patient group were measured by orbita MRI.
48725757|NCT06533930|OTHER|Visual Evoked Potentials|P100 amplitude and P100 latency values of participants in the MS patient group were measured by VEP.
48386197|NCT06539585|PROCEDURE|Meiotic spindle status observation in polarized light|In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.
48183771|NCT01389089|BEHAVIORAL|ice gel pack|ice gel pack combined with elevation
48183772|NCT01389089|OTHER|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
48725758|NCT06533930|OTHER|Optical Coherence Tomography|pRNFL thickness of participants in the MS patient group were measured by OCT.
48725759|NCT04437992|GENETIC|NIPT|The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
48725760|NCT04288700|DRUG|oral propranolol|oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
48725761|NCT04288700|DRUG|Oral Captopril|A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
48386198|NCT06539585|PROCEDURE|ICSI|ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.
48725762|NCT04288700|DRUG|intralesional propranolol injection|intralesional propranolol injection 1 mg/mL
48725763|NCT04288700|DRUG|topical Timolol maleate 0.5% eye drops|To be Applied on the surface of the lesions three times daily
48725764|NCT03582696|BEHAVIORAL|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
48725765|NCT01141478|RADIATION|Proton Beam Radiotherapy|Fifteen consecutive sessions
48725766|NCT01141478|DRUG|Sorafenib|400 mg po bid
48027187|NCT03757559|DRUG|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
48027188|NCT02617589|DRUG|Nivolumab|
48183773|NCT01389089|DEVICE|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
48183774|NCT00013247|BEHAVIORAL|Prostate Cancer Screening Education|
48725767|NCT02708355|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
48725768|NCT02708355|DRUG|Placebo|Placebo capsules
48027189|NCT02617589|DRUG|Temozolomide|
48027190|NCT02617589|RADIATION|Radiotherapy|
48027191|NCT03471689|BEHAVIORAL|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
48027192|NCT03471689|BEHAVIORAL|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
48027193|NCT00822029|DRUG|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
48725769|NCT03134339|DRUG|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
48725770|NCT03134339|DRUG|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
48725771|NCT03134339|DRUG|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
48725772|NCT03134339|DRUG|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
48725773|NCT05556538|PROCEDURE|Transforaminal Epidural Steroid Injection|Patients are placed in the prone position, with a pillow under their abdomen (to reduce lumbar lordosis) and taken to the operating table. The procedure area is cleaned 3 times with povidone-iodine antiseptic and covered with a sterile cover. In order to view the foramen to be processed, the fluoroscopy arm is evaluated at AP-oblique / cranial or caudal angles to obtain an optimal image. Local anesthetic (3 cc 2% prilocaine) is injected into the skin and subcutaneous tissue. The spinal Quincke 21-gauge 90 mm needle is advanced by targeting the relevant foramen under the guidance of fluoroscopy image. Needle position is confirmed by taking a lateral view. Needle aspiration is checked for blood. 1-2 ml of contrast material is injected to confirm that there is no vascular distribution and that it is in the epidural space. When distribution without vascular invasion is observed, an injection of a mixture of 10 mg dexamethasone, 1 cc saline and 1 cc (0.5%) bupivacaine is performed.
48725774|NCT06329024|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
48725775|NCT06329024|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
48725776|NCT04343118|PROCEDURE|Hardware Removal|elective removal of plate osteosynthesis at the clavicle
48725777|NCT00613093|DRUG|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
48725778|NCT03869476|DIAGNOSTIC_TEST|Non-invasive diagnosis score|"* spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells"
48725779|NCT01972789|DRUG|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
48725780|NCT02796508|BEHAVIORAL|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
48725781|NCT02796508|BEHAVIORAL|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
48725782|NCT05827315|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
48725783|NCT05827315|DIAGNOSTIC_TEST|T1 Cardiovascular Magnetic Resonance|T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
48725784|NCT05827315|DIAGNOSTIC_TEST|Right heart catheterisation and coronary sinus blood sampling|10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
48725785|NCT05934864|GENETIC|84-gene penal|84-gene penal was targeted sequenced in 1000 PTCL patients to investigate their mutation profile and molecular subtypes.
48725786|NCT00185874|BIOLOGICAL|Intratumoral Dendritic Cell Immunotherapy|
48725787|NCT00185874|BIOLOGICAL|autologous dendritic cells|
48725788|NCT06280885|BEHAVIORAL|Exercise|Participants will be randomised to either the FIERCE exercise programme involving supervised exercise prescription
48725789|NCT06280885|BEHAVIORAL|Health Behaviour Change (Pedometer)|Participants in both arms will be provided with a pedometer as a health behaviour change intervention
48725790|NCT02707796|PROCEDURE|Hemicolectomy|
48725791|NCT00004274|DRUG|Estrogen|
48725792|NCT05097352|BEHAVIORAL|High Intensity Interval Training (HIIT)|Twenty minutes of HIIT will be completed three days a week for six weeks.
48027194|NCT00822029|OTHER|PLACEBO|patient receiving one tablet (oral use) placebo by week
48027195|NCT04475601|DRUG|Enzalutamide Pill|The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
48027196|NCT00687258|DEVICE|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
48183775|NCT05677386|DIAGNOSTIC_TEST|Primary preventive treatment guided by CTCA|Computed tomography coronary angiography (CTCA)
48386199|NCT01233349|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
48521479|NCT03321149|OTHER|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
48521480|NCT04730583|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion
48521481|NCT04730583|DEVICE|1064nm laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
48521482|NCT04730583|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
48521483|NCT00501995|DRUG|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
48521484|NCT05560490|DEVICE|FibroFix Cartilage P Knee Implantation|The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
48521485|NCT02423200|DRUG|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
48027197|NCT01197040|DRUG|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
48386200|NCT01233349|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
48386201|NCT03191435|DEVICE|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
48521486|NCT00172029|DRUG|Zoledronic acid|
48521487|NCT03233893|OTHER|light activated calcium silicate|"for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration."
48521488|NCT00505830|OTHER|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
48521489|NCT01848925|BIOLOGICAL|SANGUINATE™|40 mg/mL intravenous infusion.
48521490|NCT01848925|DRUG|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
48521491|NCT00127114|DRUG|Amantadine|
48521492|NCT00127114|DRUG|Placebo|
48725793|NCT05097352|OTHER|Waitlist|Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
48725794|NCT03131882|DRUG|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
48027198|NCT01197040|DRUG|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
48386202|NCT03191435|DEVICE|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
48386203|NCT02139930|BEHAVIORAL|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
48386204|NCT02139930|BEHAVIORAL|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
48386205|NCT02139930|BEHAVIORAL|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
48386206|NCT02831478|DRUG|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
48386207|NCT02831478|DRUG|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
48521493|NCT00556244|PROCEDURE|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
48521494|NCT04020523|OTHER|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
48521495|NCT04641104|DRUG|Thiamine 500 MG|A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
48725795|NCT03131882|DRUG|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
48725796|NCT03903939|DRUG|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
48725797|NCT03903939|DRUG|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
48725798|NCT04487457|OTHER|Blood samples|Blood samples
48725799|NCT04671992|DEVICE|Out of-Plane Technique and In-Plane on|A comparison of out of-plane technique and in-plane
48725800|NCT01057524|DEVICE|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
48725801|NCT01057524|OTHER|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
48725802|NCT06106919|OTHER|surveys (Fertiqol and WHOQOL-BREF)|surveys (Fertiqol and WHOQOL-BREF)
48725803|NCT01560455|DEVICE|single stent|single stent
48183776|NCT05677386|OTHER|Cardiovascular risk Score|Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
48183777|NCT05397847|BEHAVIORAL|Education|"Rational Drug Use in Elderly Individuals~1. Training: Through home visits, an average of 30 minutes of training will be given to elderly individuals (drugs, rational drug use, the importance of rational drug use, and what the elderly should do for rational drug use). Question-answer method and visual materials will be used in the training.~2. Training: An average of 20 minutes of training will be given, including a brief repetition of the topics covered in the first training, via a home visit. Visual materials will be used in the training."
48725804|NCT01560455|DEVICE|two stent|culotte
48725805|NCT03964792|GENETIC|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
48725806|NCT05893472|COMBINATION_PRODUCT|combination of venetoclax and HAA regimen|Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
48183778|NCT05397847|OTHER|Rational Drug Use Guide|At the end of the first training, a rational drug use guide will be given to elderly individuals, including the topics explained.
48183779|NCT05397847|OTHER|Medicine Box|Elderly individuals will be given a medicine box large enough to be carried in the pocket when appropriate, so that the elderly people do not forget their medicines and use them regularly, with a 7-day medicine compartment that organizes their medicines and a daily (morning, noon, evening and night) medicine box.
48386208|NCT02545868|BIOLOGICAL|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
48386209|NCT02545868|BIOLOGICAL|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
48725807|NCT00861328|DRUG|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
48725808|NCT00861328|DRUG|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
48725809|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
48725810|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
48725811|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
48386210|NCT02545868|BIOLOGICAL|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
48725812|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
48725813|NCT01981681|DRUG|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
48725814|NCT01981681|DRUG|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
48725815|NCT03802903|DEVICE|Remo-Wax|topical treatment
48725816|NCT05717023|BEHAVIORAL|Online guided self-help intervention for sexual distress following sexual assault|4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
48725817|NCT02647346|DEVICE|Daily use of podimetrics smart-foot mat|
48725818|NCT06530719|DRUG|Osimertinib mesylate|Osimertinib mesylate , 80mg QD，until the duration of treatment reaches 3 years, the disease progresses, or other treatment termination criteria are met
48725819|NCT03750643|DRUG|LY3454738|Administered IV
48725820|NCT03750643|DRUG|LY3454738|Administered SC
48725821|NCT03750643|DRUG|Placebo|Administered IV
48725822|NCT06303856|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
48725823|NCT02990507|OTHER|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
48725824|NCT02990507|OTHER|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
48386211|NCT02545868|BIOLOGICAL|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
48386212|NCT02545868|DRUG|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
48386213|NCT02545868|BIOLOGICAL|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
48386214|NCT03150433|BEHAVIORAL|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
48386215|NCT03150433|OTHER|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
48386216|NCT06542224|PROCEDURE|Deep Brain stimulation|All subjects will receive bilateral surgical implantation of DBS system.
48386217|NCT05894382|DEVICE|Double Helix Design Defocus Lens Spectacle (RACE)|Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.
48386218|NCT05894382|DEVICE|single-vision spetacle lens|single-vision spetacle lens wearing more than 10h/day.
48725825|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
48725826|NCT02990507|OTHER|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
48725827|NCT04546542|OTHER|Parallel Assignment|We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
48725828|NCT03583827|OTHER|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
48725829|NCT03583827|OTHER|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
48725830|NCT01472744|BEHAVIORAL|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
48725831|NCT01472744|BEHAVIORAL|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
48725832|NCT01472744|BEHAVIORAL|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
48725833|NCT01472744|BEHAVIORAL|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
48725834|NCT02654665|BEHAVIORAL|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
48725835|NCT02654665|DRUG|Liraglutide|GLP-1 agonist
48725836|NCT00304863|DRUG|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
48725837|NCT03307031|OTHER|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
48725838|NCT03307031|OTHER|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
48725839|NCT03307031|OTHER|Control Group|Did not exercise, during 10 weeks.
48725840|NCT00538993|BEHAVIORAL|Stage based counseling|
48725841|NCT03855683|BEHAVIORAL|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
48725842|NCT05891158|DRUG|Fazirsiran|Fazirsiran SC injection
48725843|NCT02319135|DRUG|Azacitadine|
48725844|NCT02319135|DRUG|Fludarabine|
48725845|NCT02319135|DRUG|Cytarabine|
48725846|NCT02319135|DRUG|Lenograstim|
48725847|NCT02319135|DRUG|Filgastrim|
48725848|NCT03911024|BEHAVIORAL|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
48725849|NCT03911024|BEHAVIORAL|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating \>= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
48386219|NCT05472363|DIAGNOSTIC_TEST|Electroencephalogram|A routine test that involves attaching small wires to the head to read the electrical activity of the brain
48386220|NCT05472363|PROCEDURE|Transcranial Magnetic Stimulation|Noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. An electromagnetic coil is placed against the scalp near the forehead. The electromagnet painlessly delivers repetitive magnetic pulses to simulate nerve cells in the brain.
48725850|NCT01966445|BIOLOGICAL|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
48725851|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
48725852|NCT03696095|DRUG|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
48386221|NCT05472363|PROCEDURE|Transcranial Direct Current Stimulation|Noninvasive procedure that uses direct electrical currents to stimulate the brain. A constant, low intensity current is passed through two electrodes that are place on the head.
48386222|NCT06105008|DRUG|Disitamab Vedotin|2.0 mg/kg intravenous (lV) infusion every 2 weeks
48386223|NCT06105008|DRUG|Toripalimab|3.0 mg/kg intravenous (lV) infusion every 2 weeks
48386224|NCT06069427|BEHAVIORAL|Sprint interval training (SIT)|The SIT protocol consists of 4 repeated 30-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 4-minute warm-up consisting of unloaded pedalling. Each sprint will be followed by 4 minutes of unloaded pedalling.
48725853|NCT04732949|DRUG|SNG001|SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
48725854|NCT04732949|DRUG|Placebo|Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
48386225|NCT06069427|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT|The REHIT protocol consists of 2 repeated 20-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 2-minute warm-up consisting of unloaded pedalling. The first sprint will be followed by 3 minutes of unloaded pedalling, and the second sprint will be followed by 4 minutes of unloaded pedalling.
48386226|NCT06069427|BEHAVIORAL|No-exercise control (CON)|The control condition will involve seated rest for a period equivalent to the other interventions.
48386227|NCT04420000|BEHAVIORAL|Mindfulness|Mindfulness based programme
48386228|NCT04420000|OTHER|Control|Treatment as usual
48386229|NCT05643625|OTHER|Pilates exercise and myofascial release|Pilates exercise and myofascial relaxation technique will be applied to the experimental group and pilates exercise will be applied to the control group.
48725855|NCT05037058|OTHER|Quality improvement activities|Quality improvement activities
48725856|NCT02450968|DRUG|Dexamethasone|
48725857|NCT02450968|DRUG|Placebo|
48521496|NCT04641104|DRUG|Placebo|100 ml of NaCl 0.9% will be administered in the placebo group.
48386230|NCT05819645|BEHAVIORAL|Fluid intake not as per standard guidlines|The participant will be randomized into two arms. After the randomization one arm will get the per os fluid intake before the standard time frame.
48386231|NCT02962115|BEHAVIORAL|Decision Aid Invitation|electronic invitation to complete web-based decision aid
48386232|NCT01845194|DRUG|Codeine|"Treatment period 2:~5 mg Codeine once"
48386233|NCT01845194|DRUG|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
48386234|NCT01845194|DRUG|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
48386235|NCT01845194|DRUG|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
48386236|NCT01845194|DRUG|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
48386237|NCT01845194|DRUG|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
48386238|NCT01845194|DRUG|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
48386239|NCT00131326|DEVICE|Synvisc (hylan G-F 20)|
48386240|NCT04294498|DRUG|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
48386241|NCT04831502|DRUG|TAK-906|TAK-906 Tablets.
48386242|NCT04831502|DRUG|TAK-906|TAK-906 Capsules.
48386243|NCT01964391|DRUG|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
48386244|NCT01964391|DRUG|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
48386245|NCT01964391|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
48521497|NCT05898971|OTHER|Robotic|Patients receive robotic training (grasp and grip)
48521498|NCT05898971|OTHER|Mirror|Patients receive mirror therapy
48521499|NCT05898971|OTHER|Traditional Physical Therapy|Traditional exercise and Neurophysiological approaches
48521500|NCT00318890|DRUG|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
48521501|NCT00318890|DRUG|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
48521502|NCT00318890|PROCEDURE|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
48521503|NCT00318890|DRUG|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
48386246|NCT01964391|DRUG|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
48386247|NCT01964391|DRUG|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
48386248|NCT01964391|DRUG|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
48725858|NCT02029794|PROCEDURE|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
48725859|NCT02029794|PROCEDURE|visual inspection with acetic acid (VIA)|
48725860|NCT02029794|DRUG|3-5% acetic acid|
48725861|NCT04785599|BEHAVIORAL|Exercices|An exercise program. Seven days after lymph node removal, participants began this program at the physiotherapy department. They attended two weekly sessions of 60 minutes each. The sessions at the centre continued for 12 weeks. The program consisted of aerobic exercise, in combination with resistance and stretching exercises.
48521504|NCT01968772|OTHER|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
48725862|NCT04785599|BEHAVIORAL|Informative talk|An informative talk: Patients attended a one-hour long talk about lymphedema. The topics covered were a description of the condition, the risks, and preventive measures to include in their daily life. The recommended measures were those from the general consensus of the International Lymphedema Society, the Spanish Rehabilitation Society and The National Breast and Ovarian Cancer Center
48725863|NCT04785599|DEVICE|Compression garment|"Wearing a flat knit compression garment (CG), class 1. Participants were recommended to wear this CG for an average of 8 hours during the daytime for the first 3 months after surgery, and to remove it at night.~From the fourth month onwards, use of the garment was reduced to 2 hours a day, coinciding with exercises and physical activity."
48725864|NCT01116973|OTHER|PICC|Peripheral inserted catheter placement to take the reading
48725865|NCT03680872|DEVICE|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
48725866|NCT04320108|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
48725867|NCT05013970|OTHER|Clinical assessment|Clinical assessment including Visual Analog Scale (VAS) for Knee Pain, and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire
48725868|NCT05013970|OTHER|Radiographic imaging|MRI of the knee
48725869|NCT04341688|DRUG|Gargle/Mouthwash|"There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period."
48725870|NCT01993563|OTHER|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
48725871|NCT01993563|OTHER|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
48725872|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
48725873|NCT00908466|DRUG|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
48725874|NCT01620528|DRUG|elagolix|oral tablet
48725875|NCT01620528|OTHER|placebo|oral tablet
48521505|NCT02037425|DRUG|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
48725876|NCT06047496|BEHAVIORAL|Time restricted eating|Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
48725877|NCT05293678|DRUG|REGN15160 (IV)|Administered in single intravenous (IV) dose
48725878|NCT05293678|DRUG|Matching Placebo (IV)|Administered in single IV dose
48725879|NCT05293678|DRUG|REGN15160 (SC)|Administered in single subcutaneous (SC) dose
48725880|NCT05293678|DRUG|Matching Placebo (SC)|Administered in single SC dose
48725881|NCT00075556|DRUG|capecitabine|
48725882|NCT00075556|PROCEDURE|conventional surgery|
48725883|NCT00075556|PROCEDURE|neoadjuvant therapy|
48725884|NCT00075556|RADIATION|radiation therapy|
48725885|NCT01976260|DEVICE|Fractional Radiofrequency|
48725886|NCT01976260|DEVICE|1550-nm Fractional Photothermolysis|
48386249|NCT01964391|DRUG|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
48386250|NCT01816334|DRUG|methylprednisolone|
48386251|NCT01816334|DRUG|Ketoprofen|
48725887|NCT02797158|PROCEDURE|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
48725888|NCT02713867|BIOLOGICAL|Nivolumab|
48386252|NCT01816334|DRUG|Sodium Chloride|
48725889|NCT03090672|DRUG|Normal Saline|Normal Saline IV delivery
48386253|NCT06566573|OTHER|Pain|The relationship between the degree of stenosis and pain in patients with lumbar spinal stenosis will be evaluated with a visual analogue scale.
48386254|NCT06566573|OTHER|Normal Range of Motion|CROM will be used for normal range of motion (ROM) of the cervical region. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
48725890|NCT03090672|PROCEDURE|Tissue Stromal Vascular Fraction|tSVF
48725891|NCT03090672|BIOLOGICAL|Platelet Rich Plasma|PRP
48725892|NCT03090672|PROCEDURE|Cellular Stromal Vascular Fraction|cSVF
48725893|NCT02166541|PROCEDURE|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
48725894|NCT02166541|PROCEDURE|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
48725895|NCT02166541|PROCEDURE|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
48725896|NCT01443832|DIETARY_SUPPLEMENT|Fe57 and Fe58-FeSO4 stable isotopes|\[57Fe\] and \[58Fe\]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
48725897|NCT02423980|DRUG|Glucagon|
48725898|NCT02880917|DEVICE|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
48725899|NCT02880917|DEVICE|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
48725900|NCT02880917|OTHER|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
48725901|NCT00290667|BIOLOGICAL|pegfilgrastim|
48725902|NCT00290667|BIOLOGICAL|rituximab|
48725903|NCT00290667|DRUG|cyclophosphamide|
48725904|NCT00290667|DRUG|doxorubicin hydrochloride|
48725905|NCT00290667|DRUG|prednisone|
48725906|NCT00290667|DRUG|vincristine sulfate|
48725907|NCT00290667|OTHER|pharmacological study|
48725908|NCT00290667|RADIATION|radiation therapy|
48521506|NCT01439412|PROCEDURE|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
48521507|NCT01439412|OTHER|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
48521508|NCT01805843|OTHER|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
48521509|NCT01749202|DIETARY_SUPPLEMENT|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
48521510|NCT01749202|DIETARY_SUPPLEMENT|EPA softgels|3 x 500 mg softgel capsules/day
48521511|NCT01749202|OTHER|Sunflower Oil Food|3 servings/day
48521512|NCT01749202|OTHER|SDA soybean Oil Food|3 servings/day
48521513|NCT04342819|DRUG|SGLT2 inhibitor|Sodium-Glucose Like Transporter 2 Inhibitor
48521514|NCT05191004|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
48725909|NCT06203418|BEHAVIORAL|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
48725910|NCT05074420|DRUG|Baricitinib|Given Orally
48725911|NCT00351325|DRUG|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
48725912|NCT00849108|DRUG|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
48725913|NCT00626405|BIOLOGICAL|bevacizumab|Given IV over 30-90 minutes
48386255|NCT06566573|OTHER|Proprioceptive Sense|CROM will be used for cervical proprioception. Measurements will be made separately for flexion, extension, right rotation, left rotation, right and left lateral flexion.
48386256|NCT03311217|BEHAVIORAL|Healthy retail strategies|
48386257|NCT03671135|OTHER|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
48386258|NCT01029769|DRUG|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
48386259|NCT00897039|OTHER|flow cytometry|
48386260|NCT00897039|OTHER|immunohistochemistry staining method|
48386261|NCT05876039|DRUG|Initial remifentanil effect-site concentration|Different initial remifentanil effect-site concentration
48386262|NCT01224769|DRUG|bendamustine +/- rituximab|
48521515|NCT05191004|DRUG|Fulvestrant|Fulvestrant
48725914|NCT00626405|DRUG|carboplatin|Given IV over 30 minutes
48725915|NCT00626405|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
48725916|NCT00626405|DRUG|temozolomide|Oral temozolomide on days 1-5
48725917|NCT00127309|DRUG|Glutathione|
48725918|NCT00495378|DRUG|epoetin alfa|
48725919|NCT06065436|DRUG|Collagenase Clostridium Histolyticum|Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
48386263|NCT02707718|BIOLOGICAL|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
48386264|NCT06417749|BEHAVIORAL|Control arm|Participants will receive a copy of the Chinese Dietary Guidelines leaflet at baseline.
48521516|NCT06582251|BEHAVIORAL|High-intensity functional training|Participants assigned to this group will undergo 8 weeks of high-intensity functional training.
48521517|NCT06582251|BEHAVIORAL|Traditional resistance training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training.
48521518|NCT06582251|BEHAVIORAL|Concurrent training|Participants assigned to this group will undergo 8 weeks of traditional strength and hypertrophy training followed by high-intensity interval aerobic training.
48521519|NCT00254709|DRUG|Sirolimus|
48521520|NCT05488093|DEVICE|X-sens sensor|"the procedure will include:~* 7 to 8 sensors (Foot, leg, thigh, pelvis and chest possibly).~* 5 movements/exercises for the patients, each exercise performed 3 times except walking~* Analysis of 20m walking cycle (normal speed, most natural arm movement, 4 return trips of 20m):~* Climbing up and down stairs (using the public stairs of the rheumatology access department, 6 steps of 20 cm height, at normal speed, without using the handrail)~* Getting up from a chair without the help of hands (start standing, then the patient sits, leans and stands up, feet together, without taking the feet off the floor, using one and the same chair for each patient with a height of 50 cm)"
48725920|NCT06065436|DEVICE|Storz Duolith LiSWT|Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
48521521|NCT04759807|DRUG|Placebo Comparator|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
48521522|NCT04759807|DRUG|PUR1800 250 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
48725921|NCT00500760|DRUG|Cisplatin|Administered intravenously (IV; in a vein)
48725922|NCT00500760|RADIATION|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
48725923|NCT00500760|DRUG|Panitumumab|Administered intravenously
48725924|NCT00945230|PROCEDURE|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
48725925|NCT05023278|DRUG|Venlafaxine 37.5 MG|venlafaxine 37.5mg daily for 7 consecutive days.
48725926|NCT05023278|DRUG|Placebo|placebo filled pill daily for 7 consecutive days.
48725927|NCT05732883|DRUG|Dexamethasone|Dexamethasone injection
48725928|NCT05732883|DRUG|Normal saline|Placebo
48725929|NCT04368793|BEHAVIORAL|Remote pulmonary rehabilitation|The pulmonary rehabilitation intervention includes respiratory exercise, barehanded aerobic training, exercise prescription of elastic band impedance training, respiratory muscle strength training, etc.
48725930|NCT03222947|GENETIC|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
48725931|NCT04619355|DEVICE|NIRS-IVUS|Near-infrared spectroscopy-intravascular ultrasound can be implemented in parallel with intravascular ultrasound and provides important information for predicting prognosis by measuring the lipid component of atherosclerotic plaques.
48725932|NCT01085032|DRUG|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
48725933|NCT01085032|DRUG|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
48725934|NCT05450627|DRUG|Pancreatic Enzyme|Registry of pancreatic enzyme therapy prescribed to included patients
48725935|NCT04108806|PROCEDURE|Endovascular therapy|Ballon dialtation of the diseased artery
48725936|NCT00358839|DRUG|CGRP|
48725937|NCT06087978|DRUG|14C RPT193|Radiolabelled RPT193
48725938|NCT00057369|DRUG|dalbavancin|
48725939|NCT04594928|DRUG|GLPG3667|GLPG3667 capsules
48725940|NCT04594928|DRUG|Placebo|Matching placebo capsules
48725941|NCT05269030|DRUG|Ivermectin Topical|Ivermectin 1% in a dose of two drops per nostril twice daily.
48725942|NCT05269030|DRUG|Budesonide Nasal|64 µg per puff in a dose of 1 puff for each nostril twice daily.
48725943|NCT04356040|DEVICE|TactiFlex SE|Radiofrequency ablation with the TactiFlex SE ablation catheter. The procedure should be performed according to the TactiFlex SE investigational Instructions for Use document using the recommended ablation parameters as noted in the document.
48183780|NCT05397847|BEHAVIORAL|Counseling|After the training, counseling services will be given to elderly individuals regarding rational drug use. Within the scope of the counseling service, it will be ensured that the drugs used by the elderly person are regulated and their questions about rational drug use will be answered.
48725944|NCT04356040|DEVICE|TactiFlex SE - High Standard Power|Radiofrequency ablation with the TactiFlex SE ablation catheter. Subjects in the High Standard Power Substudy are to undergo the same study procedures as subjects in the main study, except that ablation power settings of 40-50 Watts are to be used in the left atrium, unless there is a medical reason to use a lower power.
48725945|NCT04621487|DRUG|Amoxicillin|14 days 1 gr bid
48725946|NCT04621487|DRUG|Metronidazole|14 days 500 mg bid
48725947|NCT04621487|DRUG|Clarithromycin|14 days 500 mg bid
48725948|NCT04621487|DRUG|Pantoprazole 40mg|40 mg bid 14 days
48725949|NCT04621487|DRUG|according to antibiogram|according to antibiogram
48725950|NCT00016965|DRUG|ixabepilone|
48725951|NCT04794881|OTHER|24 hours|Performing a lumbar puncture at 24 hours after a traumatic lumbar puncture
48725952|NCT04794881|OTHER|48 hours|Performing a lumbar puncture at 48 hours after a traumatic lumbar puncture
48725953|NCT01987583|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
48725954|NCT01987583|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
48725955|NCT05323097|OTHER|Drowning-related OHCA|Drowning-related out-of-hospital cardiac arrest (OHCA): YES
48725956|NCT02364440|DEVICE|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
48725957|NCT05136261|DEVICE|Ceradan ® Advanced Cream|Ceradan ® Advanced Cream
48725958|NCT05136261|DEVICE|Basic cream|Basic cream
48725959|NCT02458183|BIOLOGICAL|DTaP-IPV combination vaccine|0.5-mL IM
48725960|NCT02458183|BIOLOGICAL|DTaP vaccine and IPV vaccine|0.5-mL IM
48725961|NCT01369186|DRUG|Morphine|i.v. bolus injection
48725962|NCT01369186|DRUG|Placebo|i.v. bolus injection
48725963|NCT05807685|BEHAVIORAL|laughter therapy|Description: Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researchers who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
48725964|NCT03561935|DRUG|Propafenone|prescribing propafenone for the management of premature ventricular complex
48725965|NCT03561935|DRUG|Indenol|prescribing indenol for the management of premature ventricular complex
48725966|NCT04070066|OTHER|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
48027199|NCT04434404|DRUG|L-Carnitine 500Mg Oral Tablet|"eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months."
48027200|NCT02053233|DEVICE|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
48027201|NCT02053233|DEVICE|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
48027202|NCT06019104|OTHER|Task-oriented training|"Task-oriented training is defined as an approach based on movement science and motor learning, where the patient makes functional movements specific to a certain task and receives feedback. Task-oriented training focuses on improving performance on functional tasks through targeted practice and repetition."
48027203|NCT06019104|OTHER|Control group|Gaze stabilization exercises included head-fixed right-left eye movements, head-fixed up-down eye movements, eye fixed right-left head movements, and eye fixed up-down head movements.
48027204|NCT01199081|DRUG|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
48027205|NCT00001101|DRUG|ceftriaxone|
48027206|NCT00001101|DRUG|doxycycline|
48027207|NCT05866757|OTHER|Discontinuation of maintenance treatment|The discontinuation of maintenance treatment in multiple myeloma. Classed as interventional due to treatment being taken away.
48027208|NCT03701555|OTHER|PvP001 placebo|placebo
48027209|NCT03701555|DRUG|PvP001 100 mg|PvP001 100 mg
48027210|NCT03701555|DRUG|PvP001 300 mg|PvP001 300 mg
48027211|NCT03701555|DRUG|PvP001 900 mg|PvP001 900 mg
48027212|NCT03701555|DRUG|Maximum Feasible Dose (MFD) of PvP002|MFD of PvP002
48027213|NCT03701555|DRUG|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
48027214|NCT03701555|DRUG|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
48027215|NCT03701555|OTHER|PvP002 placebo|Placebo
48027216|NCT03701555|DRUG|PvP001 600 mg|PvP001 600 mg
48027217|NCT03701555|DRUG|PvP003 placebo|Placebo tablet orally.
48027218|NCT03701555|DRUG|PvP003|PvP003 tablet orally.
48027219|NCT03701555|DRUG|PvP003 150 mg|PvP003 150 mg
48027220|NCT05388448|DRUG|Sanfetrinem Cilexetil|"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"
48027221|NCT05388448|DRUG|Amoxicillin/clavulanic acid|Amx/CA will be administered orally as Amx/CA 250/125 mg, 1 tablet twice daily for 14 days alongside with sanfetrinem cilexetil.
48027222|NCT05388448|DRUG|Rifampicin|Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
48027223|NCT03783923|DRUG|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the arm.
48725967|NCT04070066|OTHER|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
48725968|NCT00367276|DRUG|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
48725969|NCT01220180|DRUG|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
48725970|NCT01220180|DRUG|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
48386265|NCT06417749|BEHAVIORAL|Intervention arm|Participants will be given three MIND diet education videos on different topics at baseline and during follow-up. In addition, each participant will receive a MIND diet education brochure at baseline and some food supply during follow-up.
48386266|NCT00863239|DRUG|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.
48521523|NCT04759807|DRUG|PUR1800 500 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
48027224|NCT01149304|DRUG|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
48027225|NCT01149304|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
48386267|NCT00863239|DRUG|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
48386268|NCT00863239|DRUG|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
48386269|NCT06286813|OTHER|Plant (natural) oils|Using 10 ml of plant(natural) oil once a day for daily skin care of newborns
48386270|NCT05430308|PROCEDURE|Chlorhexidine scrub|Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes
48386271|NCT05430308|PROCEDURE|Povidone-iodine|The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
48386272|NCT02689986|DRUG|Bendamustine, Rituximab|Bendamustine, Rituximab
48725971|NCT01220180|DRUG|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
48386273|NCT06563128|OTHER|Clearfil Majesty Posterior|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
48386274|NCT06563128|OTHER|Omnichroma Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
48386275|NCT06563128|OTHER|Zen Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
48521524|NCT06030375|DRUG|KAND567|Continuous intravenous infusion for 6 hours
48521525|NCT06030375|OTHER|Placebo|Continuous intravenous infusion for 6 hours
48521526|NCT06582069|DEVICE|Bleaching|Bleaching
48027226|NCT01149304|DRUG|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
48725972|NCT04608422|OTHER|Electrical stimulation|A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
48725973|NCT05713539|OTHER|Metal block|Small sheet of copper will be used when cooled to the designated temperature
48725974|NCT02652468|DRUG|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
48725975|NCT02652468|DRUG|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
48725976|NCT02652468|DRUG|Cyclophosphamide|Given IV for 2 days
48725977|NCT02652468|RADIATION|Total nodal irradiation|Undergo total lymphoid irradiation
48027227|NCT02095262|OTHER|reactive auditory training|
48027228|NCT02095262|OTHER|Interactive auditory training|
48027229|NCT00504829|DRUG|LCP-AtorFen|40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
48027230|NCT00504829|DRUG|atorvastatin|dyslipidemia and mixed dyslipidemia
48183781|NCT02103114|DRUG|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level\*%) X body weight)/1.4~* expressed as a % normal level based on functional ATIII assay"
48183782|NCT02103114|OTHER|Placebo|Normal saline placebo
48725978|NCT02652468|BIOLOGICAL|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
48725979|NCT02652468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
48725980|NCT02652468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
48183783|NCT00000367|DRUG|Treatment of depression|
48386276|NCT06563128|OTHER|Vittra Aps Unique Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
48725981|NCT02652468|DRUG|Mycophenolate Mofetil|Given PO
48725982|NCT02652468|DRUG|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient
48183784|NCT00000367|BEHAVIORAL|Suicide prevention intervention|
48183785|NCT00000367|DRUG|Suicide prevention treatment|
48183786|NCT00362375|BEHAVIORAL|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
48183787|NCT00362375|BEHAVIORAL|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
48183788|NCT01871688|BEHAVIORAL|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
48183789|NCT00455845|DEVICE|Levonorgestrel IUD|levonorgestrel IUD
48183790|NCT02397447|DRUG|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
48183791|NCT02397447|DRUG|Placebo|Placebo: 2000 mg per day for three months
48386277|NCT06563128|OTHER|Charisma Diamond Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
48725983|NCT02652468|BIOLOGICAL|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
48725984|NCT03481426|OTHER|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
48725985|NCT01631916|DRUG|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
48725986|NCT00450073|DRUG|ergocalciferol (vitamin D2)|50,000 IU weekly
48725987|NCT00450073|DEVICE|Sperti Del Sol Lamp|5 times a week for 12 weeks
48725988|NCT00450073|DRUG|Vitamin D3|50,000 IU weekly
48725989|NCT06312033|DRUG|Estradiol Valerate|To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)
48725990|NCT06312033|DRUG|Placebo|Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
48725991|NCT01404455|OTHER|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
48725992|NCT00076232|DRUG|Acyclovir|400 mg tablet taken orally twice daily
48725993|NCT00076232|DRUG|Acyclovir placebo|Oral tablet taken twice daily
48725994|NCT04267185|BEHAVIORAL|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
48725995|NCT04901091|OTHER|Not Provided|Not Provided
48725996|NCT03443427|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
48725997|NCT03443427|BIOLOGICAL|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
48725998|NCT05423912|BEHAVIORAL|Couple in Control (CiC) Program|MCI dyads engaging in the pilot testing aim of the CiC Program meet in virtual intervention group meetings lasting 90 to 120 minutes over the course of 8-9 consecutive weeks. Participants are asked to take part in structured quantitative interviews at baseline and 4 and 8 weeks post-intervention. A subsample of participants will be interviewed virtually via videoconference for a 30 to 60 minute discussion on their experiences in and perceptions of the intervention.
48725999|NCT00516035|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
48726000|NCT06028360|OTHER|Progressive Muscle Relaxation|Intervention will be applied for 15-20 minutes 3 consecutive days a week for 1 week
48726001|NCT06028360|DEVICE|Virtual Reality Therapy|Therapy through VR will be given for 8 minutes 3 times a week on consecutively for 1 week
48183792|NCT05775783|PROCEDURE|Transvenous lead extraction|Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
48183793|NCT02367430|BEHAVIORAL|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
48183794|NCT00335101|DRUG|Iodixanol, Ioversol, Iopromide|
48183795|NCT02536742|DRUG|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
48183796|NCT02536742|DRUG|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
48183797|NCT06487663|PROCEDURE|TACE with ICI|Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors
48183798|NCT01782729|DRUG|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
48183799|NCT05570812|DRUG|Placebo|(4-week ramp, 4-week steady dosing)
48183800|NCT05570812|DRUG|Pregnenolone|(4-week ramp, 4-week steady dosing)
48183801|NCT03473210|DRUG|Antibiotics|ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
48183802|NCT03473210|DRUG|Corticosteroid|dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
48183803|NCT03473210|PROCEDURE|Amniopatch|a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
48183804|NCT05834192|OTHER|Backward treadmill walking|Backward Treadmill walking will be given to this group. Speed settings of treadmill will be established based on the previous motor function of participants. All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down.
48183805|NCT05834192|OTHER|Lower extremity cross training|"For cross-training, a strong resistance will be applied by the therapist until a response will be achieved on the contralateral lower extremity at the end range of motion. Resistance will be consistently applied for 10 seconds once a response will be achieved.~All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down."
48386278|NCT06653517|DRUG|Dabrafenib|"Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
48386279|NCT06653517|DRUG|Trametinib|"Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule."
48386280|NCT05219513|DRUG|RO7443904|RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
48386281|NCT05219513|DRUG|Glofitamab|Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).
48027231|NCT00504829|DRUG|fenofibrate|dyslipidemia and mixed dyslipidemia
48521527|NCT05483790|BEHAVIORAL|the multimodal intervention|"The in-person training course included 25 minutescognitive training activities were conducted for , followed by a 15-minute healthy lifestyle education. After a 10-minute break, physical exercise training was administered for 15 minutes. Finally, 15 minutes wrap-up session.~The cognitive training encompassed memory-related training and attention-related training. The physical exercise included finger exercises, elastic band exercises, Tai Chi/ Baduanjin with guidance. The healthy lifestyle education included guidance on nutrition, sleep, stress management, and mood adjustment by teaching problem-solving skills. Additionally, the intervention provided information and support to facilitate lifestyle changes and included discussions and practical exercises, such as tools for assessing dietary behavior."
48027232|NCT06381908|OTHER|Calorie-restriction with low carbohydrate|Calorie-restriction and low carbohydrate availability
48027233|NCT06381908|OTHER|Calorie-restriction with moderate carbohydrate|Calorie-restriction and moderate carbohydrate availability
48027234|NCT00663312|BEHAVIORAL|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
48027235|NCT00668460|DRUG|Lactic acid (Dermacid)|
48027236|NCT01564225|DRUG|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
48027237|NCT03094689|OTHER|Cold water immersion|
48027238|NCT03094689|OTHER|Water immersion|
48027239|NCT01610323|OTHER|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
48027240|NCT01610323|OTHER|Standard Care|
48183806|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
48183807|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
48183808|NCT00950482|PROCEDURE|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
48726002|NCT04851756|DEVICE|CRet|In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min F.M with CRet on capacitive mode (180-250VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (110-140W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (180-250VA) on the mentioned area. A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes.
48726003|NCT04851756|DEVICE|Sham CRet|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min Functional Massage (F.M) with passive anckle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area. In supine position, a 5 min F.M with passive knee flexion and CRet on resistive mode (0W) will be performed on the rectus femoris, followed by a 4 min F.M with passive knee flexion and CRet on capacitive mode (0VA) on the mentioned area.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes."
48726004|NCT00440310|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
48183809|NCT00950482|OTHER|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
48183810|NCT00950482|OTHER|WC|Waiting Group
48183811|NCT04171349|DRUG|Articaine|Vial
48183812|NCT04171349|DRUG|Dexmedetomidine|Vial
48183813|NCT00458276|DRUG|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
48386282|NCT05219513|DRUG|Obinutuzumab|Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).
48386283|NCT05219513|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
48386284|NCT01692470|DRUG|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
48386285|NCT01425515|BEHAVIORAL|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
48386286|NCT00672308|OTHER|Benefiber|
48386287|NCT00672308|OTHER|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
48386288|NCT00672308|OTHER|Benefiber with ORS|
48386289|NCT00672308|OTHER|Benefiber with ORS|
48386290|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
48386291|NCT00672308|OTHER|the reduced-osmolarity WHO-ORS without added Benefiber|
48521528|NCT05346042|OTHER|duration infectiousness|is the probability and the duration of being infectious in hospitalized COVID-19 patients, consequently influencing the decision on cessation of isolation
48521529|NCT01379846|BIOLOGICAL|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
48183814|NCT00458276|DRUG|placebo|Placebo (i.e., normal saline) for i.v. use.
48183815|NCT06082570|DRUG|c610 injection|Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
48183816|NCT02522728|DEVICE|Triathlon CR|Implantation of Knee Prosthesis
48183817|NCT02522728|DEVICE|Triathlon PS|Implantation of Knee Prosthesis
48183818|NCT00398190|BEHAVIORAL|Control|Standard anti-tobacco programming
48183819|NCT00398190|BEHAVIORAL|Media Literacy|Anti-smoking media literacy curriculum intervention
48183820|NCT02431052|DRUG|Olumacostat Glasaretil|
48183821|NCT02431052|OTHER|Vehicle|
48183822|NCT00844597|DRUG|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
48183823|NCT00369096|DRUG|bemiparin 3500 IU/day|
48183824|NCT05203341|DRUG|Placebo|Matching placebo tablets
48386292|NCT05029167|OTHER|Restrictive PaO2|Patients are randomized to a PaO2 target of 9-10 kPa (open-label).
48386293|NCT05029167|OTHER|Low normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
48386294|NCT05029167|OTHER|Liberal PaO2|Patients are randomized to a PaO2 target of 13-14 kPa (open-label).
48726005|NCT00440310|PROCEDURE|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
48726006|NCT00440310|DEVICE|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
48183825|NCT05203341|DRUG|NBI-1065845|NBI-1065845 tablets
48521530|NCT01379846|BIOLOGICAL|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
48521531|NCT00218933|BEHAVIORAL|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
48521532|NCT00218933|BEHAVIORAL|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
48521533|NCT01959061|DRUG|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
48726007|NCT00440310|DRUG|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
48726008|NCT00440310|DRUG|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
48726009|NCT03990506|PROCEDURE|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
48726010|NCT03990506|PROCEDURE|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; \> 50D, 15 J/cm2.
48726011|NCT02846012|OTHER|CSCM2|
48726012|NCT05505604|PROCEDURE|PENG|patients will receive an ultrasound-guided Pericapsular Nerve Group Block with 20mL of 0.25% bupivacaine (not to exceed 2mg/kg)
48726013|NCT05505604|PROCEDURE|FICB|Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block with 20 mL of 0.25% bupivacaine (not to exceed 2 mg/kg) diluted to total volume of 40 mL of injectate
48726014|NCT03880344|DEVICE|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
48726015|NCT03880344|COMBINATION_PRODUCT|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
48726016|NCT01420822|DRUG|Fluticasone|Collection of safety data
48726017|NCT05774847|OTHER|No intervention|No intervention
48726018|NCT05607706|BEHAVIORAL|Exposure to maternal odor|Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
48726019|NCT06299176|OTHER|Whole Heart Radiation Therapy|Radiation to the whole heart in one treatment with a prescribed dose of 5 Gy.
48726020|NCT03527719|OTHER|Village-doctor-led multifaceted intervention|"* Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support"
48726021|NCT04022980|DRUG|Nivolumab|HD-MTX containing induction chemotherapy (per standard of care) followed by Nivolumab consolidation.
48386295|NCT05029167|OTHER|High normal MAP|The patients are randomized to receive a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
48386296|NCT06213961|OTHER|pecha kucha education|Basic life support training to be given to students will be given by the pecha kucha presentation method.
48386297|NCT03458039|BEHAVIORAL|In-person CETA|The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
48521534|NCT01959061|DRUG|Oxaliplatin|100\~150mg, every 4 weeks, transhepatic arterial infusion
48521535|NCT01959061|DRUG|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
48521536|NCT01358214|BEHAVIORAL|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
48521537|NCT03544723|DRUG|Ad-p53|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
48521538|NCT03385889|PROCEDURE|Cervical Spine Mobilization|C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
48027241|NCT03850119|PROCEDURE|Nanofat injection|Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
48027242|NCT04529577|DEVICE|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
48386298|NCT03458039|BEHAVIORAL|Telephone CETA|"For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors."
48521539|NCT03385889|PROCEDURE|Cervical Spine Manipulation|C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
48521540|NCT03532529|OTHER|not applicable, it is an observational study|not applicable, it is an observational study
48521541|NCT05314231|DRUG|ALXN1720|All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
48521542|NCT03670615|OTHER|tDCS|All study participants randomized to tDCS will receive active tDCS.
48521543|NCT03670615|OTHER|Exercise|Participants will exercise at TRI according to an individualized exercise prescription.
48521544|NCT03670615|OTHER|Exercise Education|Exercise education/ treatment as usual will include routine advice about physical activity for older adults.
48027243|NCT05923281|DRUG|K-877 0.2 mg/day (once daily)|K-877 0.2mg tablet
48521545|NCT03670615|OTHER|Sham tDCS|The same procedure for tDCS will be used for the sham condition, except without active current.
48521546|NCT01001650|BIOLOGICAL|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
48521547|NCT05462041|OTHER|DBD Donor Heart Transplantation|A technique of donor heart procurement.
48521548|NCT05462041|DEVICE|DCD Donor Heart Transplantation|A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
48521549|NCT04451148|OTHER|Obese with or without metabolic syndromesubjects|Children with obesity and with or without metabolic syndrome
48521550|NCT05009017|DRUG|Bevacizumab|Patients with colorectal cancer or lung cancer who use originator or biosimilar of bevacizumab
48521551|NCT00604682|DRUG|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
48521552|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
48726022|NCT06499883|BEHAVIORAL|Pocket Ark|Pocket Ark (PA) is a mobile e-learning and assessment platform for use by flood remediation workers in the field. The purpose of this mobile application is to provide workers with real-time data to assist with making safe decisions during the planning phase in the flooded zone and provide a communications platform to improve logistics between operational bases and workers during and after the deployment to the flooded zone. Pocket Ark incorporates an action planner, scenario-based PPE training content, assessments (both knowledge and health-risk), personal security protection, and resource location features for workers involved in disaster rescue and recovery. Individual construction worker's readiness to be safely deployed to flooded and post-flood environments will be assessed.
48726023|NCT03446417|DRUG|ZN-e4|Oral dose, tablet, daily dosing
48521553|NCT01709825|DIETARY_SUPPLEMENT|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
48521554|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
48521555|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
48726024|NCT04506333|DEVICE|A&D UA-651 Blood Pressure Monitor|Test device to be validated.
48027244|NCT05923281|DRUG|K-877 0.4 mg/day (once daily)|K-877 0.2mg tablet
48027245|NCT05923281|DRUG|Placebo (once daily)|Placebo tablet
48726025|NCT04506333|DEVICE|ADC 740-N Manual Sphygmomanometer|Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
48027246|NCT04262999|OTHER|effect of sodium valproate on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
48027247|NCT04262999|OTHER|effect of levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
48726026|NCT05037513|BEHAVIORAL|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
48726027|NCT05037513|BEHAVIORAL|CDC-PrEP|1 session PrEP education following CDC guidelines
48726028|NCT04628065|BEHAVIORAL|#BabyLetsMove|This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (\<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
48726029|NCT03908970|DRUG|1% OPA-15406|Twice daily
48726030|NCT03908970|DRUG|Placebos|Twice daily
48521556|NCT02550301|OTHER|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
48726031|NCT01765725|BEHAVIORAL|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
48726032|NCT02925728|OTHER|Finger-Food|Finger-Food at lunch and having diner
48726033|NCT02925728|OTHER|Without Finger-Food|Without finger-food
48726034|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
48726035|NCT00453973|DRUG|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
48726036|NCT03688100|BEHAVIORAL|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
48027248|NCT04262999|OTHER|effect of sodium valproate+levetiracetam on alveolar bone level|Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
48027249|NCT04262999|OTHER|control group|Control group individuals will be systemically healthy.
48027250|NCT05706727|DRUG|Intravenous bolus dose of Mephentermine and mephentermine|intravenous bolus dose of mephenteramine 6mg
48027251|NCT05706727|DRUG|intravenous bolus dose of phenylephrine 50 mcg|intravenous bolus dose of phenylephrine 50 mcg
48027252|NCT01971398|BEHAVIORAL|Positive FASD education brochure|Exposure to a positive FASD education brochure
48027253|NCT01971398|BEHAVIORAL|Negative FASD education brochure|Exposure to a negative FASD education brochure
48027254|NCT01971398|BEHAVIORAL|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
48027255|NCT05450874|PROCEDURE|hepatectomy|
48027256|NCT06491004|DIAGNOSTIC_TEST|PTX3 assay|PTX3 dosage by the in vitro medical device in evaluation.
48521557|NCT04435834|DRUG|Propofol or Sevoflurane|Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
48521558|NCT02604095|DIETARY_SUPPLEMENT|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
48027257|NCT05152979|BEHAVIORAL|Verb Network Strengthening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
48027258|NCT06386666|DEVICE|Disposable fibrous ring sutures|A new disposable fibrous ring suture device developed and produced by 2020 (Beijing) Medical Technology Co., Ltd
48027259|NCT05947448|DRUG|Azilsartan Medoxomil Potassium Tablet|Azilsartan Medoxomil Potassium Tablet，80mg，qd，lasts six month
48027260|NCT05947448|DRUG|Nifedipine Sustained -release Tablets|Nifedipine Sustained -release Tablets，qd，The maximum clinical dose，lasts six months；
48027261|NCT05947448|DRUG|Levoamlodipine Maleate Table|Levoamlodipine Maleate Table，qd，The maximum clinical dose，lasts six months；
48027262|NCT00966316|DRUG|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
48726037|NCT03688100|DRUG|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
48726038|NCT00805064|DRUG|triamcinolone and bevacizumab|
48726039|NCT00716742|DRUG|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
48726040|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Unified protocol|"Treatment condition:~The cognitive, behavioral treatment Unified protocol is a transdiagnostic treatment for anxiety and depression. Participants are taught five techniques in order to find new and more helpful ways to react to hindering thoughts and feelings: mindfulness, cognitive flexibility, identify and reduce behavioral avoidance, increase willingness to experience physiological sensations and exposure. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week."
48386299|NCT03458039|BEHAVIORAL|Treatment as Usual (TAU)|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
48386300|NCT01187615|DRUG|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
48386301|NCT01187615|DRUG|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
48386302|NCT06000839|DEVICE|(D0) Intradermal injection - micropapula technique|First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
48386303|NCT06000839|DEVICE|(D14) Intradermal injection - micropapula technique|Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
48386304|NCT06000839|DEVICE|(D28) Intradermal injection - micropapula technique|Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
48386305|NCT04751786|DRUG|PRECIOUS-01|Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
48386306|NCT01501071|DEVICE|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
48386307|NCT06566859|OTHER|NRS 0. hour|Numerical rating scala
48386308|NCT06566859|OTHER|NRS 6. Hour|Numerical rating scala
48027263|NCT03344991|OTHER|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
48027264|NCT03344991|OTHER|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
48183826|NCT04201587|OTHER|Henna application|Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
48726041|NCT05016843|BEHAVIORAL|Treatment condition: Internet-administered Affect phobia treatment|The aim of psychodynamic Affect phobia treatment is for the patient to reach an intellectual and emotional understanding of his/hers problems. The goal of the treatment is for participants to decrease emotional avoidance and start to approach emotions and increase emotional awareness. Participants are taught this through linking their symptoms to their emotional avoidance, observe frequent and maladaptive patterns in relationships and see how these are linked to emotional avoidance. The intervention is delivered online through a secure platform. Modules consist of text and the participants can work with the material whenever they wish to. Participants gain access to a new treatment modul every week.
48726042|NCT05016843|OTHER|Treatment condition: Waitlist control|The waitlist condition is a control condition without any intervention.
48726043|NCT05016843|OTHER|Treatment length: 8 weeks|Participants will partake in their treatment condition for 8 weeks.
48726044|NCT05016843|OTHER|Treatment length: 16 weeks|Participants will partake in their treatment condition for 16 weeks.
48726045|NCT05016843|OTHER|Access to a moderated forum|During their treatment, participants will have access to a discussion forum moderated by a clinician. Participants are encouraged to discuss questions and experiences related to their treatment condition.
48386309|NCT06566859|OTHER|NRS 12. Hour|Numerical rating scala
48521559|NCT01068145|DRUG|SCH 527123|Very low dose SCH 527123, once daily for 7 days
48521560|NCT01068145|DRUG|SCH 527123|Low dose SCH 527123, once daily for 7 days
48521561|NCT01068145|DRUG|SCH 527123|Medium dose SCH 527123, once daily for 7 days
48726046|NCT05016843|OTHER|No access to a moderated forum|Participants will not have access to a moderated forum, hence their treatment is self-guided.
48726047|NCT01423916|DRUG|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
48027265|NCT02882802|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
48027266|NCT02882802|BEHAVIORAL|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
48027267|NCT04257370|DEVICE|Kerecis™ Omega3 Wound|Kerecis™ Omega3 Wound is decellularised, intact fish skin from North Atlantic cod fish. Kerecis™ Omega3 Wound is FDA approved and EU cleared for the treatment of diabetic ulcers, chronic vascular ulcers, venous ulcers, trauma wounds (including abrasions, lacerations, and skin tears), acute surgical wounds (including debridement, amputation, and donor sites), surgical wounds (dehiscence or failed healing after surgery), imminent failure of STSG, and post-injection necrosis.
48027268|NCT04257370|OTHER|Standard of care|Standard of care wound treatment as defined by the local site, including debridement of the wound, standard wound dressing, and proper offloading of the wound site.
48027269|NCT03011216|BEHAVIORAL|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
48027270|NCT03011216|BEHAVIORAL|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
48027271|NCT06535360|BIOLOGICAL|Platelet transfusion|platelet administration through intravenous access
48183827|NCT04593823|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
48386310|NCT06566859|OTHER|NRS 24. Hour|Numerical rating scala
48386311|NCT04426552|DRUG|dexmedetomidine|will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
48521562|NCT01068145|DRUG|SCH 527123|High dose SCH 527123, once daily for 7 days
48726048|NCT01423916|DRUG|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
48726049|NCT01423916|DRUG|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
48726050|NCT01423916|DRUG|Placebo|OPC-34712 placebo
48726051|NCT02392936|PROCEDURE|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
48726052|NCT04890314|OTHER|Patient-reported questionnaire|Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
48027272|NCT05336240|BEHAVIORAL|Physician Communication 2 Virtual (PCOM2-virtual)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. While this provider communication technique previously showed success in increasing HPV vaccination uptake, it is neither easy to disseminate nor sustainable due to it's nature of direct, intensive in-person training. Therefore, the intervention is to compare the standard-PCOM intervention to a new, PCOM2 intervention, that will be adapted virtually.
48027273|NCT05336240|BEHAVIORAL|Physician Communication Standard (PCOM-standard)|The PCOM-standard intervention is based off of a provider communication training that utilizes presumptive technique when initiating the vaccine discussion followed by motivational interviewing if a parent continues to show hesitation. PCOM-standard will be conducted in-person with providers.
48027274|NCT04378933|DEVICE|Amber Glasses|Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
48027275|NCT04378933|DEVICE|Clear Lens Glasses|Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
48183828|NCT04169191|DRUG|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
48726053|NCT01614171|BIOLOGICAL|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
48726054|NCT06158113|DRUG|Baricitinib 4 milligram Oral Tablet|4 milligrams once daily
48027276|NCT06103981|OTHER|Acute Liver Injury|To evaluate the impact of acute liver injury in patients with pneumonia on hospital stay and outcome.
48027277|NCT03286023|RADIATION|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
48027278|NCT03906058|DRUG|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
48027279|NCT05927129|DRUG|Antidepressant|Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
48027280|NCT05927129|OTHER|Psychotherapy IPT|The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
48027281|NCT05927129|OTHER|The combination of antidepressant and IPT|The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
48027282|NCT00952653|DRUG|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
48183829|NCT01173978|BEHAVIORAL|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
48183830|NCT01173978|OTHER|No intervention|
48183831|NCT06067607|OTHER|eye gaze technology|eye gaze technology and software activities
48726055|NCT01836393|DRUG|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
48726056|NCT05277428|DIETARY_SUPPLEMENT|GTB1|2 capsule/day
48726057|NCT05277428|DIETARY_SUPPLEMENT|Placebo|2 capsule/day
48726058|NCT05521438|DRUG|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
48726059|NCT05521438|DRUG|QRX003-4% Lotion QAM|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
48183832|NCT04489108|DRUG|Tranexamic acid|Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours
48183833|NCT04489108|OTHER|Standard Medical Treatment|Standard Medical Treatment
48183834|NCT04489108|OTHER|Placebo|isotonic solution (saline)
48726060|NCT05521438|DRUG|Vehicle|Vehicle Lotion
48726061|NCT05521438|DRUG|QRX003-4% Lotion BID|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
48726062|NCT01662947|DEVICE|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
48726063|NCT01662947|DEVICE|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
48726064|NCT03712111|DRUG|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
48726065|NCT03712111|DRUG|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
48183835|NCT00240214|DRUG|sirolimus|Tablet, dosage is determined by trough level
48521563|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
48726066|NCT03712111|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
48726067|NCT03712111|DRUG|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
48726068|NCT00149175|OTHER|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
48726069|NCT00348894|DRUG|[S,S]-Reboxetine|\[S,S\]-reboxetine
48726070|NCT00348894|DRUG|Any|Any standard of care treatment for DPN
48027283|NCT00952653|DRUG|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
48027284|NCT03571295|DEVICE|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
48027285|NCT03571295|DEVICE|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
48027286|NCT00908440|BEHAVIORAL|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
48027287|NCT03961594|OTHER|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
48027288|NCT00680407|OTHER|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
48027289|NCT00680407|DRUG|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
48027290|NCT00680407|DRUG|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
48183836|NCT00725543|BIOLOGICAL|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
48183837|NCT02567305|OTHER|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
48183838|NCT00132678|DRUG|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
48726071|NCT03922087|OTHER|No intervention|No intervention
48726072|NCT02495454|DRUG|Ga101|
48027291|NCT05581446|DIAGNOSTIC_TEST|Visual Analogue Scale|pain type severity determination and quality of life assessment
48183839|NCT00132678|DRUG|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
48386312|NCT04426552|DRUG|sevoflurane|preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
48521564|NCT01068145|DRUG|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
48521565|NCT01068145|DRUG|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
48521566|NCT01068145|DRUG|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
48521567|NCT01068145|DRUG|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
48521568|NCT03705429|DRUG|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
48521569|NCT00428272|DRUG|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
48726073|NCT05701436|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
48726074|NCT05701436|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
48027292|NCT01243333|RADIATION|[F-18]fluorodeoxyglucose|Undergo PET scans with \[F-18\]fluorodeoxyglucose
48027293|NCT01243333|RADIATION|[F-18]fluorothymidine|Undergo PET scans with fluorine \[F-18\]fluorothymidine
48027294|NCT01243333|PROCEDURE|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
48027295|NCT01243333|RADIATION|Water O-15|Undergo PET scans with water O-15 tracers
48521570|NCT00428272|DRUG|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
48726075|NCT05701436|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
48726076|NCT05701436|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
48027296|NCT02633384|OTHER|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
48386313|NCT06567353|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
48386314|NCT06567353|DEVICE|Radiofrequency ablation therapeutic apparatus|All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.
48386315|NCT01017731|BIOLOGICAL|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
48386316|NCT01017731|DRUG|Moxifloxacin|Administered orally
48386317|NCT01017731|DRUG|Diphenhydramine|Administered IV
48386318|NCT06649357|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
48386319|NCT06649357|PROCEDURE|BiTURP|Patients with an indication for surgery for BPH viaEEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
48386320|NCT03867500|DRUG|Niacin|Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)
48386321|NCT03867500|DRUG|Saline|Intravenous infusion of 0.9% Sodium chloride (NaCl)
48726077|NCT05701436|DRUG|Oxaliplatin, Leucovorin, fluorouracil|Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
48726078|NCT05701436|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
48726079|NCT02198690|OTHER|Mammography decision aid|
48726080|NCT02198690|OTHER|Home safety pamphlet|
48726081|NCT03871972|DRUG|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
48726082|NCT02212678|DRUG|N-acetylcysteine capsule|N-acetylcysteine capsule
48726083|NCT02547051|OTHER|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
48027297|NCT02633384|OTHER|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
48027298|NCT01181921|DRUG|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
48027299|NCT02948179|PROCEDURE|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
48027300|NCT00788554|PROCEDURE|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
48726084|NCT00629798|DRUG|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients \> or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
48726085|NCT01443663|BIOLOGICAL|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
48726086|NCT03009968|OTHER|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
48726087|NCT01914653|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
48726088|NCT05210426|OTHER|Pilates exercises|The Pilates Group completed a 10-week Pilates program. The intervention was performed in 20 sessions. In the first session, introduction and explanations regarding the principles and benefits of Pilates was made in a language that preschool children can understand. Exercises were supervised, and they were taught via gamification. In addition, the participation of the children was encouraged and stickers were given to increase their motivation at the end of the sessions. No adverse events occurred during intervention. The exercise program was created based on books and from the booklet acquired in the APPI Pilates Method training courses. Since the study was in preschool children, the basic level of Pilates was performed. Each exercise was performed 5 times for 30 minutes each twice a week.
48726089|NCT01435967|OTHER|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
48726090|NCT01294163|DRUG|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
48726091|NCT01294163|DRUG|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
48027301|NCT00788554|PROCEDURE|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
48027302|NCT06281691|DIAGNOSTIC_TEST|Xpert® Bladder Cancer Detection Test|A urine sample is analyzed with the Xpert® Bladder Cancer Detection Test
48027303|NCT02775383|OTHER|Therapeutic|Observational Study
48386322|NCT02291172|BEHAVIORAL|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
48386323|NCT05879692|PROCEDURE|focused ultrasound|"focused ultra sound cavitation using a device of Mabel6 DUO Ultra Cavitation Technology system produced by DAEYANG MEDICAL COMPANY, KOREA will be applied on the abdominal region which extending bilaterally from the line extending from mid axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crest below.~the session of Focused Ultra Sound will take 25- 30 minutes, twice/week and with about three day intervals for 12 weeks."
48386324|NCT05879692|BEHAVIORAL|Low Caloric Diet (LCD) and a low (FODMAPs) diet|"The Low caloric diet (LCD) diet will be an equilibrated diet that had a caloric value 10% below the total metabolic expenditure (total energy expenditure) of each individual.~The low FODMAPs diet (LFD) is a diet low in fermentable oligo-, di-, mono- saccharides and polyols (FODMAPs)."
48386325|NCT05879692|OTHER|aerobic exercise|aerobic exercise program under direct supervision at a frequency of 3 times/week for 12 weeks, in the form of walking on a treadmill for 30 minutes with moderate intensity (12-14) according to The Borg Rating of Perceived Exertion (RPE) scale.
48386326|NCT00374465|DRUG|Verapamil|
48726092|NCT01294163|DRUG|Propofol|Hourly dose of 2-4 mg/kg
48726093|NCT02505568|DRUG|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
48726094|NCT03578887|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
48726095|NCT03578887|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
48027304|NCT04916639|DEVICE|Device: Physiomer undiluted seawater nasal spray|"In this study, subjects are asked to adhere to the following dosage during the 3 weeks of the study:~* Nasal wash four times every day~* These washes are to be carried out in each nostril~* By continuously pressing the spray for 3 seconds in each nostril~* Subjects are recommended to distribute the 4 nasal washes as follows:~  * 1st : morning~ * 2nd : midday~ * 3rd : afternoon~ * 4th : evening Subjects will be instructed to maintain daily nasal wash over the 3 weeks study period even in case of earlier nasal symptoms resolution, in order to assess the impact of nasal wash on viral load and other symptoms."
48027305|NCT02863991|DRUG|ONC201|375 mg or 625 mg ONC201
48027306|NCT02863991|DRUG|Dexamethasone|20 mg dexamethasone
48386327|NCT00374465|DRUG|Carvedilol|
48726096|NCT02093910|DRUG|Monosialotetrahexosylganglioside|
48726097|NCT01331291|DRUG|bosutinib|Taken orally
48726098|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
48726099|NCT05334277|DRUG|Furmonertinib|Furmonertinib 80mg QD
48027307|NCT04209582|DEVICE|measurement of TcPO2 with skin electrode|measurement of TcPO2 with skin electrode
48521571|NCT00428272|DRUG|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
48521572|NCT00428272|DRUG|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
48521573|NCT00295997|BIOLOGICAL|anti-thymocyte globulin|
48521574|NCT00295997|BIOLOGICAL|filgrastim|
48521575|NCT00295997|BIOLOGICAL|graft-versus-tumor induction therapy|
48521576|NCT00295997|BIOLOGICAL|therapeutic allogeneic lymphocytes|
48521577|NCT00295997|DRUG|busulfan|
48521578|NCT00295997|DRUG|cyclophosphamide|
48726100|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
48726101|NCT05334277|DRUG|Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab|Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
48726102|NCT03477058|OTHER|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
48726103|NCT00552409|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU by mouth daily for one year
48726104|NCT00552409|DIETARY_SUPPLEMENT|Placebo|One softgel daily for one year
48726105|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
48726106|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
48726107|NCT01143194|DIETARY_SUPPLEMENT|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
48726108|NCT01143194|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo twice a day
48726109|NCT05052593|OTHER|compressive myofascial release|Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.
48726110|NCT05052593|OTHER|conventional treatment group|Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
48726111|NCT05737719|BEHAVIORAL|Rehabilitation before knee surgery (prehab)|Physiotherapy strategies for preparing the patient awaiting the surgical procedure
48027308|NCT05363345|DEVICE|bile duct stone removal|Common bile duct stones (≧ 10 mm) are removed by using Vortic Catch V basket catheter or ordinary basket catheter following endoscopic papillary large balloon dilation.
48027309|NCT01563861|GENETIC|RNA analysis|
48027310|NCT01563861|GENETIC|gene expression analysis|
48027311|NCT01563861|OTHER|immunohistochemistry staining method|
48027312|NCT01563861|OTHER|laboratory biomarker analysis|
48027313|NCT02632149|DEVICE|PINS Vagus Nerve Stimulator|
48521579|NCT00295997|DRUG|fludarabine phosphate|
48521580|NCT00295997|DRUG|methotrexate|
48521581|NCT00295997|DRUG|mycophenolate mofetil|
48521582|NCT00295997|DRUG|tacrolimus|
48521583|NCT00295997|PROCEDURE|allogeneic bone marrow transplantation|
48521584|NCT00295997|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
48521585|NCT00295997|PROCEDURE|peripheral blood stem cell transplantation|
48521586|NCT05482217|BEHAVIORAL|Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)|"The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks."
48521587|NCT00842166|OTHER|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
48726112|NCT05737719|BEHAVIORAL|Post-surgery rehabilitation|Physiotherapy strategies to manage post-surgery recovery
48726113|NCT02291926|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
48726114|NCT05458856|DRUG|Triptorelin embonate 22.5 mg|A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
48726115|NCT04435990|BIOLOGICAL|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
48726116|NCT04435990|BIOLOGICAL|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
48726117|NCT04435990|BIOLOGICAL|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
48726118|NCT03507075|BEHAVIORAL|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
48726119|NCT03507075|BEHAVIORAL|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
48183840|NCT05244369|OTHER|Only TENS|Rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and application of transcutaneous electrical nerve stimulation (TENS) to the tip of the stump
48183841|NCT05244369|PROCEDURE|Acupuncture+TENS|acupuncture application twice a week - a total of 8 sessions, rehabilitation program consisting of exercises 5 days a week for 4 weeks and transcutaneous electrical nerve stimulation (TENS) to the stump tip.
48726120|NCT00043927|DRUG|topotecan/cisplatin|
48726121|NCT00043927|DRUG|etoposide/cisplatin|
48726122|NCT02266576|BEHAVIORAL|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the San Jose State Timpany Center is the Group Lifestyle Balance™ DPP, which has previously been tailored for urban American Indians and Alaska Natives by the Indian Health Service. Standard DPP components consist of 16 group classes, 4 visits with a lifestyle coach and access to a therapeutic swimming pool and gym.
48726123|NCT02266576|BEHAVIORAL|Enhanced DPP|Enhanced DPP components consist of access to a mental health counselor, active referrals to mental health services, and traditional healing workshops such as the use of talking circles, a modified photo voice and digital storytelling to address specific psychosocial issues that are a result of historical trauma, stress, and grief.
48726124|NCT00647114|BIOLOGICAL|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
48726125|NCT00647114|BIOLOGICAL|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
48726126|NCT06033872|COMBINATION_PRODUCT|Focused education, medication adjustment and telemonitoring|"1. Focused diabetes education session for Ramadan fasting~   Participants will be taught to record~  1. Meal plans~  2. Physical activities~  3. Blood glucose monitoring, and~  4. Monitoring for diabetes complications. Then perform a trial fasting day prior to Ramadan when control is not optimal or medication with risk of hypoglycemia.~2. Medication adjustment for Ramadan fasting Participants will be provided regimen modified for Ramadan fasting.~3. Telemonitoring~Participants will be taught to perform blood glucose monitoring 4 times daily using a glucometer and upload recordings of glucose levels onto the data software."
48726127|NCT00628147|DEVICE|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
48726128|NCT05216627|DIAGNOSTIC_TEST|Self-administered saliva-based viral testing|Participants will be instructed on how to inactivate the virus and bring their sample to their laboratory's central PCR machine, where they will take an assay test. They will be instructed to collect saliva into a 1.5 milliliter (mL) collection tube containing inactivation buffer (TCEP and EDTA) using a small funnel and inactivate at 95°C for 10 minutes. Participants will then transfer 6ul of saliva into 2 PCR tubes containing amplification master mix and primers, put tubes in a heat block or PCR machine at 65°C for 45 minutes and assess fluorescence using a simple battery-powered fluorescence viewer. Once they assess their sample, they will be instructed to dispose of the saliva sample safely and in accordance with best laboratory practices. No saliva samples will be collected by the research team at any time as part of this study.
48027314|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
48027315|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
48027316|NCT01226745|DRUG|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
48027317|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
48027318|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
48183842|NCT01507649|BEHAVIORAL|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
48386328|NCT06652191|PROCEDURE|Direct catheterization with non-dilation|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, place the catheter into the vessel directly along the guide wire without using an dilator to expand the skin
48386329|NCT06652191|PROCEDURE|Catheterization after expanding the skin with a dilator|Under the guidance of real-time ultrasound, the right internal jugular vein was punctured and a guide wire was inserted, after the skin is expanded with a dilator, the catheter is inserted into the vessel along the guide wire
48521588|NCT05593484|OTHER|Standard Referral|Schools in the control condition will use standard referral, as determined by the school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
48521589|NCT05593484|OTHER|Specialty Telemedicine Access for Referrals (STAR)|The STAR intervention will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the STAR intervention and send the information asynchronously to an audiologist for review.
48521590|NCT01811472|DRUG|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
48521591|NCT01811472|DRUG|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
48521592|NCT03162874|DRUG|Placebo oral capsule|BID
48521593|NCT03162874|DRUG|PXT002331 - dose 1|Oral
48726129|NCT05976009|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
48726130|NCT00681993|OTHER|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
48521594|NCT03162874|DRUG|PXT002331 - dose 2|Oral
48521595|NCT03335826|PROCEDURE|Combined epidural-general anesthesia|Combined epidural-general anesthesia and postoperative epidural analgesia.
48521596|NCT03335826|PROCEDURE|General anesthesia|General anesthesia and postoperative intravenous analgesia.
48726131|NCT00681993|OTHER|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
48183843|NCT01896557|DRUG|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
48386330|NCT01211873|DRUG|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
48386331|NCT01211873|DRUG|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
48386332|NCT00157573|DRUG|GM-CSF, sargramostim|GM-CSF subcutaneous injection
48386333|NCT06401993|PROCEDURE|"The dao qi tong luo group"|"The dao qi tong luo group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. Among them, the dao qi tong luo group will make patients feel qi."
48386334|NCT06401993|PROCEDURE|The acupuncture group|The acupuncture group will accept acpuncture. Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu) and etc. The acupuncture group will not feel qi.
48386335|NCT06569030|BIOLOGICAL|spinal orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
48386336|NCT04362761|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
48386337|NCT04362761|DRUG|IVA|Tablet for oral administration.
48521597|NCT03610230|DRUG|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
48521598|NCT03610230|DRUG|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
48521599|NCT03514095|OTHER|Individual Cognitive Stimulation Therapy Program|"This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program."
48521600|NCT02477956|DIETARY_SUPPLEMENT|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
48521601|NCT02477956|DIETARY_SUPPLEMENT|vitamin D|
48521602|NCT03288064|DIETARY_SUPPLEMENT|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
48521603|NCT03288064|DIETARY_SUPPLEMENT|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
48521604|NCT03288064|DIETARY_SUPPLEMENT|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
48726132|NCT00681993|OTHER|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
48726133|NCT00681993|OTHER|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
48726134|NCT00681993|OTHER|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
48726135|NCT01033318|DRUG|MK1809|single oral doses of MK1809
48726136|NCT01033318|DRUG|Comparator: Losartan|single oral doses of 100 mg Losartan
48726137|NCT01033318|DRUG|Comparator: Placebo|Placebo to MK1809
48726138|NCT04062097|DRUG|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
48726139|NCT04062097|DRUG|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
48726140|NCT04062097|DRUG|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
48726141|NCT03048604|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
48726142|NCT02276417|OTHER|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
48726143|NCT02276417|OTHER|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
48183844|NCT01896557|DRUG|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
48183845|NCT01896557|DRUG|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
48183846|NCT03566979|DRUG|Test naproxen sodium tablet|Single dose of 2 test naproxen sodium 220 mg tablets
48386338|NCT05926739|DEVICE|Electrical stimulation and biofeedback with Phenix Liberty medical device|"12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.~The patient will undergo 12 therapeutic functional reeducation sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care.~Overall, the functional rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 12 sessions between 6 and 8 weeks~* 1 end visit, within the week after the 12th session"
48386339|NCT05959564|BEHAVIORAL|Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
48386340|NCT05959564|BEHAVIORAL|Non-Personalized Chatbot Intervention|In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
48726144|NCT02276417|OTHER|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
48726145|NCT02276417|OTHER|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
48726146|NCT02276417|OTHER|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
48726147|NCT02276417|OTHER|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
48726148|NCT02276417|OTHER|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
48726149|NCT02445573|OTHER|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
48726150|NCT02445573|OTHER|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
48726151|NCT03996317|OTHER|Room air|Avoidance of hyperoxygenation
48183847|NCT03566979|DRUG|Commercial naproxen sodium tablet|Single dose of 2 naproxen sodium 220 mg tablets
48183848|NCT03566979|DRUG|Commercial naproxen sodium liquid gels capsule|Single dose of 2 naproxen sodium 220 mg liquid gel capsules
48183849|NCT03566979|DRUG|Placebo tablet|2 placebo tablets
48183850|NCT02344589|DRUG|Lidocaine|used for the active blocks
48183851|NCT02344589|DRUG|Saline|used for the placebo-block
48726152|NCT02325297|OTHER|Letter of condolence|
48726153|NCT04496024|DRUG|ofloxacin|ofloxacin treatment in patients with bone and joint infections
48726154|NCT04496024|OTHER|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
21587754|NCT06578130|DEVICE|StypCel™ Absorbable Hemostat|The StypCel™ Absorbable Hemostat is used during neurosurgery to control bleeding. It is applied directly to the bleeding site to achieve hemostasis within a few minutes. The study will observe its effectiveness and any related complications during and after surgery.
48726155|NCT04496024|BIOLOGICAL|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
48726156|NCT06026956|OTHER|Tele-Assessment|Tele-Assessment
48726157|NCT05764174|BEHAVIORAL|Factual messages|Messages with descriptive data on COVID-19 vaccines
48726158|NCT05764174|BEHAVIORAL|Narrative message|Messages with emotional descriptions on COVID-19 vaccines
48726159|NCT05764174|BEHAVIORAL|Mixed message|Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
48726160|NCT05242094|PROCEDURE|Pulmonary Rehabilitation Program|An in-patients 3-week high intensity rehabilitation program, five times a week, was used as the intervention treatment. The author's pulmonary rehabilitation program was programmed based on previous experience in patients with COPD. A holistic pulmonary rehabilitation program with combined treatment focused on increasing exercise capacity, restoring lung function, and supporting mental health, developed by a multidisciplinary team, was introduced. Based on the patient's submaximal exercise tolerance test results, the qualification for one of the respiratory physiotherapy models differing in therapy intensity was performed. Rehabilitation models included exercise capacity training on a cycle ergometer, breathing exercises, general fitness exercises, resistance training, and relaxation.
48726161|NCT02092766|DRUG|artesunate|
48726162|NCT02092766|DRUG|quinine|
48726163|NCT00506168|DRUG|Irinotecan, Capecitabine|
48726164|NCT00098306|DRUG|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
48726165|NCT00098306|DRUG|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
48726166|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
48726167|NCT00098306|DRUG|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
48726168|NCT00098306|DRUG|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
48726169|NCT06325319|OTHER|Community engagement using M-MAMA Champions to improve awareness on obstetric danger signs, bith preparedness and complication readiness among pregnant women|Community engagement using M-MAMA Champions to improve awareness of obstetric danger signs, birth preparedness, and complication readiness among pregnant women. The empowered M-MAMA Champions will deliver the intervention to pregnant women in their communities. A total of three (3) sessions will be held, whereby each will take two (2) hours. The sensitization will take place at one of the study participant's residential area, where women will gather up and be sensitized on the subject by the M-MAMA Champion as a facilitator using a well-prepared brochure (package).
48726170|NCT05386316|OTHER|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
48726171|NCT05386316|OTHER|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
48726172|NCT00154362|DRUG|Oxcarbazepine|
48183852|NCT03560570|BIOLOGICAL|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
48183853|NCT03560570|OTHER|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
48183854|NCT05201053|DIAGNOSTIC_TEST|Exploratory for different markers|Test biomarkers for development of mild, moderate or severe disease
48726173|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
48726174|NCT03499327|DIETARY_SUPPLEMENT|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
48183855|NCT03298269|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
48183856|NCT03298269|BEHAVIORAL|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
48183857|NCT02769442|DEVICE|Terumo SurFlash Plus catheter|
48386341|NCT05959564|BEHAVIORAL|No Chatbot Control|In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.
48386342|NCT01856257|BIOLOGICAL|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
48386343|NCT01856257|BIOLOGICAL|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
48386344|NCT01856257|DRUG|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
48386345|NCT01856257|BIOLOGICAL|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
48386346|NCT01856257|DRUG|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
48386347|NCT01856257|DRUG|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
48386348|NCT05770778|OTHER|Inclined Backwalk|They will receive inclined backward treadmill gait training exercise for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child, three times weekly, over three months.
48386349|NCT05770778|OTHER|Knee Walk|They will receive kneel walk exercise programme for thirty minutes with 2 interval break for 5min every 10 minutes for three times per week over three successive months with a specifically designed physical therapy program according to child need for one hour for each child , three times weekly, over three months.
48386350|NCT01257737|DRUG|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
48386351|NCT04285736|DRUG|Ivabradine|Ivabradine (5mg twice daily)
48386352|NCT04285736|DRUG|Conventional Treatment|
48386353|NCT04642131|DIETARY_SUPPLEMENT|Caffeine supplementation|Participants will wear standard insoles and ingest caffeine in liquid form (3mg/kg) with carbohydrates.
48386354|NCT04642131|DEVICE|Personalized insoles|Participants will wear personalized insoles and ingest a drink of carbohydrates without caffeine
48386355|NCT04642131|OTHER|Control condition|Participants will wear standard insoles and ingest a drink of carbohydrates without caffeine
48386356|NCT05063149|DRUG|Broncho-Vaxom|Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
48726175|NCT03175146|RADIATION|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
48386357|NCT05063149|OTHER|Placebo|Placebo powder from a capsule will be given, which will be indistinguishable from the active study drug.
48386358|NCT06224764|OTHER|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
48386359|NCT00962013|DEVICE|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
48726176|NCT01853956|DRUG|Alprazolam 0.25 mg|Reference product
48726177|NCT01853956|DRUG|Alprazolam 0.25 mg|Test product
48726178|NCT01420419|OTHER|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
48521605|NCT05514223|OTHER|Biomaterial collection for observational purpose|The semen will be collected to measure the free radical concentration in seminal plasma and sperm together with the diversity of microbiota. Both males with a normal semen analysis (SA) and abnormal SA according to the WHO guidelines (2010) will be included. Blood plasma will be collected to measure systemic radical concentration and all outcomes will be related to lifestyle factors and food intake acquired through hospital charts and routinely conducted questionnaires together with a food frequency Questionnaire (FFQ).
48521606|NCT04958655|BEHAVIORAL|Tetris Task|a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen
48521607|NCT04958655|BEHAVIORAL|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
48521608|NCT02321111|DRUG|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
48521609|NCT02321111|DRUG|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
48521610|NCT04888832|OTHER|Work requirement exemption months|Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
48386360|NCT04419701|PROCEDURE|periarticular infiltration|"The cocktail will be injected at the following 7 anatomical zones as follows:~Zone 1: medial retinaculum Zone 2: medial collateral ligament and medial meniscus capsular attachment Zone 3: posterior capsule Zone 4: lateral collateral ligament and lateral meniscus capsular attachment Zone 5: lateral retinaculum Zone 6: patellar tendon and fat pad Zone 7: cut ends of quadriceps muscle and tendon Injection at zones 2, 3, and 4 will be administered after making the tibial and femoral cuts and ligament balancing. At zones 1, 5, 6, and 7, the injection will be administered after implant placement."
48386361|NCT04419701|PROCEDURE|genicular nerve block|The genicular arteries will be identified near the periosteal areas, which are the junctions of the epicondyle and the shafts of the femur and tibia, and confirmed by color Doppler ultrasound. genicular nerve block target points should be next to each genicular artery because the superior lateral, superior medial, and inferior medial genicular artery traveled along each genicular nerve.After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view.
48386362|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy ONCE|"rESWT application ONCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
48521611|NCT04519073|BIOLOGICAL|V-306 candidate vaccine|"Each V-306 monomer consists of the following elements:~1. A Lipopeptide Building Block that contains an optimized, artificially designed coiled-coil domain, which self-assembles into highly stable trimers.~2. A 'universal' T-helper epitope fused at the C-terminus of the coiled-coil domain.~3. A lipid component di-palmitoyl-S-glyceryl cysteine (Pam2C), fused at the N-terminus.~4. A mimetic of the Palivizumab epitope, referred to RSV F-protein site II antigen mimetic (FsIIm), which is coupled near the C-terminus of the Lipopeptide Building Block via a short maleimide-PEG-oxime linker."
48521612|NCT05711420|BEHAVIORAL|Gamification method group|Gamification method group
48521613|NCT05711420|BEHAVIORAL|Flipped learning group|Flipped learning group
48521614|NCT03309501|DRUG|Tong-Luo-Qu-Tong Plaster|for 14 days as two period of treatment, daily 1 time.
48521615|NCT03309501|DRUG|Qi-Zheng-Xiao-Tong Plaster|for 14 days as two period of treatment, daily 1 time
48521616|NCT06208137|BEHAVIORAL|Health monitoring and regular return follow-up reminders|Health monitoring \& reminders for blood tests and follow-up visits until 1 year post-transplant
48521617|NCT06490367|BEHAVIORAL|Time-Restricted Eating Diet|Participants engage in a time-restricted eating diet, specifically maintaining a 6-8-hour eating window every day for 12 weeks. Participants are allowed to self-select the timing of the eating window, but once selected, they are asked to maintain that schedule daily. Outside of that window, for the remaining 16-18 hours of day/night, participants are asked not to consume calorie-containing food or drink. Beverages without calories are allowed.
48521618|NCT00182325|BEHAVIORAL|personalized web prenatal information|
48521619|NCT00182325|BEHAVIORAL|general web prenatal information|
48386363|NCT06126523|DEVICE|Radial Extracorporeal Shock Wave Therapy TWİCE|"rESWT application TWİCE The points where rESWT will be applied will be determined under ultrasonography guidance. The pressure pulses will be focused on the injection site in the medial and lateral heads of the gastrocnemius muscle and the soleus muscle.~A total of 2 sessions of rESWT will be applied on the same day after BTX-A injection and on the 7th day after BTX-A.~Number of pulses: 1500 pulses Frequency: 6 Hz Energy level/Pressure: 2.2 bar air pressure Duration: 12 minutes~Device to be used in research ELMED VIBROLITH ESWT SW. Give. 3.3 It is based on the principle that currents produced outside the body spread in the tissue in the form of sound waves."
48183858|NCT02769442|DEVICE|BD Insyte Autoguard catheter|
48183859|NCT04737837|DRUG|lacosamide|lacosamide as first add on therapy
48027319|NCT01226745|DRUG|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
48726179|NCT01420419|OTHER|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, 